PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
2891263-0	1987	Taxol inhibits N-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced human neutrophil polarization and H2O2 production while decreasing [3H]FMLP binding.	Paclitaxel	0-5	formyl peptide receptor 1	Homo sapiens	56-60
3131325-1	1988	Limited chymotryptic digestion of whole tau proteins produced a fragment of Mr 14,000 (CT14), which was able to bind to microtubules reconstituted from tubulin alone in the presence of taxol.	Paclitaxel	185-190	sarcoma antigen 1	Homo sapiens	87-91
2900046-9	1988	In 14 cases taxol was rinsed out and the concentration of nerve growth factor was increased 10x, 11/14 neurites retracted within the next hour.	Paclitaxel	12-17	nerve growth factor	Gallus gallus	58-77
2891263-0	1987	Taxol inhibits N-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced human neutrophil polarization and H2O2 production while decreasing [3H]FMLP binding.	Paclitaxel	0-5	formyl peptide receptor 1	Homo sapiens	141-145
2891263-1	1987	We have studied the effect of taxol on two N-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced neutrophil functions and the possible mechanism by which it inhibits these functions.	Paclitaxel	30-35	formyl peptide receptor 1	Homo sapiens	84-88
2891263-2	1987	Taxol inhibited FMLP-induced human neutrophil polarization (a characteristic change in neutrophil shape in response to a chemotactic stimulus) and H2O2 generation.	Paclitaxel	0-5	formyl peptide receptor 1	Homo sapiens	16-20
2891263-3	1987	Taxol also decreased the specific binding of [3H]FMLP to human neutrophils at 4 degrees C. The decreased binding of FMLP to its receptor may be responsible for the inhibition by taxol of FMLP-induced polarization and H2O2 generation.	Paclitaxel	178-183	formyl peptide receptor 1	Homo sapiens	49-53
2891263-3	1987	Taxol also decreased the specific binding of [3H]FMLP to human neutrophils at 4 degrees C. The decreased binding of FMLP to its receptor may be responsible for the inhibition by taxol of FMLP-induced polarization and H2O2 generation.	Paclitaxel	178-183	formyl peptide receptor 1	Homo sapiens	116-120
2891263-3	1987	Taxol also decreased the specific binding of [3H]FMLP to human neutrophils at 4 degrees C. The decreased binding of FMLP to its receptor may be responsible for the inhibition by taxol of FMLP-induced polarization and H2O2 generation.	Paclitaxel	178-183	formyl peptide receptor 1	Homo sapiens	116-120
6376120-2	1984	When insoluble cell fractions were prepared by incubation of isotonic cell extracts with 20 microM taxol, polypeptides co-migrating with MAP-1 and MAP-2 upon gel electrophoresis were observed in virtually all cases examined.	Paclitaxel	99-104	microtubule-associated protein 2	Mus musculus	147-152
2863145-4	1985	By contrast, when microtubules were polymerized with taxol after isotonic cell lysis a considerable enrichment of MAP-1 and MAP-2 was achieved; again, plectin co-distributed only partially.	Paclitaxel	53-58	plectin	Rattus norvegicus	151-158
6489451-9	1984	Moreover, stabilization of cytoplasmic microtubules with taxol has been found to block microtubule disassembly and initiation of DNA synthesis by colchicine and to inhibit thrombin- and EGF-stimulated DNA synthesis under serum-free conditions.	Paclitaxel	57-62	coagulation factor II, thrombin	Homo sapiens	172-180
6145157-0	1984	Antagonism by taxol of effects of microtubule-disrupting agents on lymphocyte cAMP metabolism and cell function.	Paclitaxel	14-19	cathelicidin antimicrobial peptide	Homo sapiens	78-82
6145157-4	1984	Taxol also antagonized the enhancement of cAMP increases by colchicine in lymphocytes stimulated by 2-chloroadenosine, isoproterenol, and cholera toxin.	Paclitaxel	0-5	cathelicidin antimicrobial peptide	Homo sapiens	42-46
6384236-8	1984	After taxol-induced polymerization, the MAP 4 triplet was preferentially associated with the microtubule pellet whereas band 4 remained in the supernatant.	Paclitaxel	6-11	microtubule-associated protein 4	Mus musculus	40-45
6120766-0	1981	Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor.	Paclitaxel	29-34	coagulation factor II	Mus musculus	75-83
6120766-3	1981	Pretreatment of quiescent cultures of mouse embryo cells with 10 microgram/ml taxol inhibited up to 60% of the thrombin-stimulated and 47% of the EGF-stimulated DNA synthesis.	Paclitaxel	78-83	coagulation factor II	Mus musculus	111-119
6120766-11	1981	These results confirm that taxol was not nonspecifically affecting transport or metabolism required for DNA synthesis and indicate that thrombin and EGF may initiate cell proliferation through a gradual microtubule depolymerization or rearrangement that is necessary to commit cells to a replicative cycle.	Paclitaxel	27-32	coagulation factor II	Mus musculus	136-144
6111398-10	1981	Furthermore, pretreatment of cultures with taxol (5 micrograms/ml) inhibited approximately 30% of the stimulation of thymidine incorporation by thrombin.	Paclitaxel	43-48	coagulation factor II, thrombin	Homo sapiens	144-152
34056794-0	2021	RIP3/MLKL pathway-regulated necroptosis: A new mechanism of paclitaxel-induced peripheral neuropathy.	Paclitaxel	60-70	mixed lineage kinase domain like pseudokinase	Rattus norvegicus	5-9
33848578-8	2021	Also, green tea and PTX combination induced apoptosis in ovarian cancer cells by blocking the phosphorylation of Akt and the expression of Bcl-2 while inducing Bax, Cyt-C, cleaved-caspase 3, and cleaved-caspase 9.	Paclitaxel	20-23	AKT serine/threonine kinase 1	Homo sapiens	113-116
33848578-8	2021	Also, green tea and PTX combination induced apoptosis in ovarian cancer cells by blocking the phosphorylation of Akt and the expression of Bcl-2 while inducing Bax, Cyt-C, cleaved-caspase 3, and cleaved-caspase 9.	Paclitaxel	20-23	BCL2 apoptosis regulator	Homo sapiens	139-144
33848578-8	2021	Also, green tea and PTX combination induced apoptosis in ovarian cancer cells by blocking the phosphorylation of Akt and the expression of Bcl-2 while inducing Bax, Cyt-C, cleaved-caspase 3, and cleaved-caspase 9.	Paclitaxel	20-23	BCL2 associated X, apoptosis regulator	Homo sapiens	160-163
33848578-8	2021	Also, green tea and PTX combination induced apoptosis in ovarian cancer cells by blocking the phosphorylation of Akt and the expression of Bcl-2 while inducing Bax, Cyt-C, cleaved-caspase 3, and cleaved-caspase 9.	Paclitaxel	20-23	cytochrome c, somatic	Homo sapiens	165-170
33894420-8	2021	Meanwhile, CCT combined with taxol caused significant ER stress through improving phosphorylated PERK, eukaryotic translation initiation factor 2alpha (eIF2alpha), C/EBP homologous protein (CHOP) and glucose-regulated protein 78 (GRP78).	Paclitaxel	29-34	DNA damage inducible transcript 3	Homo sapiens	164-188
33894420-8	2021	Meanwhile, CCT combined with taxol caused significant ER stress through improving phosphorylated PERK, eukaryotic translation initiation factor 2alpha (eIF2alpha), C/EBP homologous protein (CHOP) and glucose-regulated protein 78 (GRP78).	Paclitaxel	29-34	DNA damage inducible transcript 3	Homo sapiens	190-194
33894420-8	2021	Meanwhile, CCT combined with taxol caused significant ER stress through improving phosphorylated PERK, eukaryotic translation initiation factor 2alpha (eIF2alpha), C/EBP homologous protein (CHOP) and glucose-regulated protein 78 (GRP78).	Paclitaxel	29-34	heat shock protein family A (Hsp70) member 5	Homo sapiens	200-228
33894420-8	2021	Meanwhile, CCT combined with taxol caused significant ER stress through improving phosphorylated PERK, eukaryotic translation initiation factor 2alpha (eIF2alpha), C/EBP homologous protein (CHOP) and glucose-regulated protein 78 (GRP78).	Paclitaxel	29-34	heat shock protein family A (Hsp70) member 5	Homo sapiens	230-235
33770618-8	2021	Carboplatin-paclitaxel showed the most favorable profile with a decrease in immunosuppressive cells in the peritoneal cavity and an increase of interferon-gamma in serum.	Paclitaxel	12-22	interferon gamma	Mus musculus	144-160
34056794-8	2021	PTX application also increased RIP3 and MLKL protein levels in DRG, which were primarily in neurons.	Paclitaxel	0-3	mixed lineage kinase domain like pseudokinase	Rattus norvegicus	40-44
34048126-6	2021	We observed elevated expression of Notch1 in HeLa-229PTR cells compared with their parental HeLa-229 cells, indicating its potential involvement in the EMT phenotype of the paclitaxel-resistant cells.	Paclitaxel	173-183	notch receptor 1	Homo sapiens	35-41
34047951-9	2021	Additionally, MCF-7/Wnt5a (+) cells displayed reduced sensitivity to the metabolic substrates of CYP, tamoxifen (P < 0.001), paclitaxel (P < 0.001), and cyclophosphamide (P < 0.001).	Paclitaxel	125-135	Wnt family member 5A	Homo sapiens	20-25
34047951-11	2021	CONCLUSIONS: In ER-positive breast cancer, Wnt5a upregulates the CYP metabolic pathway and suppresses tamoxifen, paclitaxel, and cyclophosphamide resistance, all of the three, standard treatment methods for ER-positive breast cancer.	Paclitaxel	113-123	estrogen receptor 1	Homo sapiens	16-18
34047951-11	2021	CONCLUSIONS: In ER-positive breast cancer, Wnt5a upregulates the CYP metabolic pathway and suppresses tamoxifen, paclitaxel, and cyclophosphamide resistance, all of the three, standard treatment methods for ER-positive breast cancer.	Paclitaxel	113-123	Wnt family member 5A	Homo sapiens	43-48
34048126-0	2021	Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial-mesenchymal transition process.	Paclitaxel	91-101	notch receptor 1	Homo sapiens	18-23
34048126-7	2021	Furthermore, silencing of the NOTCH1 gene, as well as treatment with a gamma-secretase inhibitor (DAPT) partially reversed the EMT phenotype and significantly enhanced the sensitivity of HeLa-229PTR cells to paclitaxel.	Paclitaxel	208-218	notch receptor 1	Homo sapiens	30-36
34048126-10	2021	Thus, inhibition of Notch1 signaling can be a strategy for the reversal of the EMT phenotype and may increase the sensitivity of cervical cancer cells to treatment with paclitaxel.	Paclitaxel	169-179	notch receptor 1	Homo sapiens	20-26
34041901-5	2021	Hybrid albumin nanoparticles were assembled via the disulfide reprogramming method and encapsulated paclitaxel (PTX) to formulate PSN-HSA-PTX-IR780.	Paclitaxel	100-110	albumin	Homo sapiens	7-14
34041901-5	2021	Hybrid albumin nanoparticles were assembled via the disulfide reprogramming method and encapsulated paclitaxel (PTX) to formulate PSN-HSA-PTX-IR780.	Paclitaxel	112-115	albumin	Homo sapiens	7-14
34041901-5	2021	Hybrid albumin nanoparticles were assembled via the disulfide reprogramming method and encapsulated paclitaxel (PTX) to formulate PSN-HSA-PTX-IR780.	Paclitaxel	138-141	albumin	Homo sapiens	7-14
34046939-0	2021	CircMYBL2 regulates the resistance of cervical cancer cells to paclitaxel via miR-665-dependent regulation of EGFR.	Paclitaxel	63-73	epidermal growth factor receptor	Homo sapiens	110-114
34046939-11	2021	CircMYBL2 played a positive role in the PTX resistance and malignant activities of PTX-sensitive and PTX-resistant CC cells by regulating the miR-665/EGFR network, providing a novel therapeutic strategy for the treatment of CC patients resistant to PTX.	Paclitaxel	83-86	epidermal growth factor receptor	Homo sapiens	150-154
34050450-7	2021	Also, significant downregulation of several genes like MUC1 and MKI67 in MCF-7 cells treated with doxorubicin showed much lower gene expression (- 37.63, - 10.88 folds) when compared with cells treated with paclitaxel (- 2.47, - 2.05 folds) or the combination treatment (- 18.99, - 2.81 folds), respectively.	Paclitaxel	207-217	marker of proliferation Ki-67	Homo sapiens	64-69
34051575-0	2021	GDI2 is a target of paclitaxel that affects tumorigenesis of prostate cancer via the p75NTR signaling pathway.	Paclitaxel	20-30	nerve growth factor receptor (TNFR superfamily, member 16)	Mus musculus	85-91
34046939-11	2021	CircMYBL2 played a positive role in the PTX resistance and malignant activities of PTX-sensitive and PTX-resistant CC cells by regulating the miR-665/EGFR network, providing a novel therapeutic strategy for the treatment of CC patients resistant to PTX.	Paclitaxel	83-86	epidermal growth factor receptor	Homo sapiens	150-154
34046939-11	2021	CircMYBL2 played a positive role in the PTX resistance and malignant activities of PTX-sensitive and PTX-resistant CC cells by regulating the miR-665/EGFR network, providing a novel therapeutic strategy for the treatment of CC patients resistant to PTX.	Paclitaxel	83-86	epidermal growth factor receptor	Homo sapiens	150-154
34031188-8	2021	Finally, the highest eribulin IC50 quartile (>~1 nM) exhibited significantly elevated mRNA expression of the drug pump, ABCB1, a defined resistance mechanism to eribulin and paclitaxel.	Paclitaxel	174-184	ATP binding cassette subfamily B member 1	Homo sapiens	120-125
34023418-6	2021	Silencing GABRP induced down-regulation of EGFR signaling, which hindered cell stemness and enhanced sensitivity to chemotherapies, including paclitaxel, doxorubicin, and cisplatin.	Paclitaxel	142-152	epidermal growth factor receptor	Homo sapiens	43-47
34022909-6	2021	TPP promoted the targeting of the DA-P-SS-T/PTX nanomicelles to the mitochondrial outer membrane to decrease the membrane potential and ATP level, resulting in inhibition of P-glycoprotein and suppression of drug resistance and cancer metastasis.	Paclitaxel	44-47	ATP binding cassette subfamily B member 1	Homo sapiens	174-188
34022910-0	2021	Circular RNA circ_0006168 enhances Taxol resistance in esophageal squamous cell carcinoma by regulating miR-194-5p/JMJD1C axis.	Paclitaxel	35-40	microRNA 1945	Mus musculus	104-114
34022910-11	2021	RESULTS: Circ_0006168 and JMJD1C were upregulated and miR-194-5p was downregulated in ESCC tissues, ESCC cells, and Taxol-resistant cells.	Paclitaxel	116-121	microRNA 1945	Mus musculus	54-64
34022910-17	2021	CONCLUSION: Circ_0006168 facilitated Taxol resistance in ESCC by regulating miR-194-5p/JMJD1C axis, providing a promising therapeutic target for ESCC chemotherapy.	Paclitaxel	37-42	microRNA 1945	Mus musculus	76-86
34011375-1	2021	BACKGROUND: Paclitaxel (PTX) has been suggested to be a promising front-line drug for gastric cancer (GC), while P-glycoprotein (P-gp) could lead to drug resistance by pumping PTX out of GC cells.	Paclitaxel	176-179	ATP binding cassette subfamily B member 1	Homo sapiens	113-127
34011375-1	2021	BACKGROUND: Paclitaxel (PTX) has been suggested to be a promising front-line drug for gastric cancer (GC), while P-glycoprotein (P-gp) could lead to drug resistance by pumping PTX out of GC cells.	Paclitaxel	176-179	ATP binding cassette subfamily B member 1	Homo sapiens	129-133
34011375-5	2021	With near infrared (NIR)-irradiation, PTX@GO-PEG-OSA could generate excessive reactive oxygen species (ROS), attack mitochondrial respiratory chain complex enzyme, reduce adenosine-triphosphate (ATP) supplement for P-gp, and effectively inhibit P-gp"s efflux pump function.	Paclitaxel	38-41	ATP binding cassette subfamily B member 1	Homo sapiens	215-219
34011375-5	2021	With near infrared (NIR)-irradiation, PTX@GO-PEG-OSA could generate excessive reactive oxygen species (ROS), attack mitochondrial respiratory chain complex enzyme, reduce adenosine-triphosphate (ATP) supplement for P-gp, and effectively inhibit P-gp"s efflux pump function.	Paclitaxel	38-41	ATP binding cassette subfamily B member 1	Homo sapiens	245-249
34000456-7	2021	Several target glycoproteins bearing suppressed levels of multi-antennary branching structures were identified, and ERK signaling pathway was strongly suppressed in PTX resistant MCF7 cells.	Paclitaxel	165-168	mitogen-activated protein kinase 1	Homo sapiens	116-119
34003380-9	2021	IF staining revealed that TLR4, TRPV1, and microglial activation were all upregulated in PAC-injected rats and exhibited early and significant downregulation in SHBOT-treated rats.	Paclitaxel	89-92	toll-like receptor 4	Rattus norvegicus	26-30
33985619-3	2022	c-Src-mediated Caspase-8 phosphorylation essential for EMT in lung adenocarcinoma cell lines preferentially occurs in cells with the mesenchymal phenotype, resulting in chemoresistance to cisplatin plus paclitaxel inpatients with resectable lung adenocarcinoma and a significantly worse 5-year PFS.	Paclitaxel	203-213	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-5
33985619-7	2022	Dasatinib mitigated c-Src-mediated phosphorylation of Caspase-8-induced EMT and enhanced necroptosis in mesenchymal-like lung adenocarcinoma cells treated with paclitaxel, while c-FLIP knockdown predominantly sensitized the mesenchymal-like lung adenocarcinoma cells to paclitaxel+dasatinib.	Paclitaxel	160-170	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	20-25
33985619-8	2022	c-Src-Caspase-8 interaction initiates EMT and chemoresistance viaCaspase-8 phosphorylation and lncCRLA expression, to which the dasatinib/paclitaxel liposome+siFLIP regimen was lethal.	Paclitaxel	138-148	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-5
33985619-7	2022	Dasatinib mitigated c-Src-mediated phosphorylation of Caspase-8-induced EMT and enhanced necroptosis in mesenchymal-like lung adenocarcinoma cells treated with paclitaxel, while c-FLIP knockdown predominantly sensitized the mesenchymal-like lung adenocarcinoma cells to paclitaxel+dasatinib.	Paclitaxel	270-280	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	20-25
33960504-1	2021	BACKGROUND AND PURPOSE: Paclitaxel is a widely used anti-neoplastic agent but has low oral bioavailability due to gut extrusion by P-glycoprotein (P-gp).	Paclitaxel	24-34	ATP binding cassette subfamily B member 1	Homo sapiens	131-145
33964142-0	2021	Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy.	Paclitaxel	73-83	sterile alpha and HEAT/Armadillo motif containing 1	Mus musculus	16-21
33964142-9	2021	In a mouse paclitaxel model of CIPN we determined that Sarm1 KO mice prevented loss of axonal function, assessed by sensory nerve action potential (SNAP) amplitudes of the tail nerve, in a gene dosage-dependent manner.	Paclitaxel	11-21	sterile alpha and HEAT/Armadillo motif containing 1	Mus musculus	55-60
33964142-10	2021	In that CIPN model, the irreversible SARM1 inhibitors prevented loss of intraepidermal nerve fibers induced by paclitaxel and provided partial protection of axonal function assessed by SNAP amplitude and mechanical allodynia.	Paclitaxel	111-121	sterile alpha and HEAT/Armadillo motif containing 1	Mus musculus	37-42
33960504-1	2021	BACKGROUND AND PURPOSE: Paclitaxel is a widely used anti-neoplastic agent but has low oral bioavailability due to gut extrusion by P-glycoprotein (P-gp).	Paclitaxel	24-34	ATP binding cassette subfamily B member 1	Homo sapiens	147-151
34026617-2	2021	In this review, we first summarize the molecular mechanisms of chemotherapy resistance that occur during the treatment with cisplatin, 5-fluorouracil, and docetaxel/paclitaxel, including DNA/RNA damage repair, drug efflux, apoptosis inhibition, and epidermal growth factor receptor/focal adhesion kinase/nuclear factor-kappaB activation.	Paclitaxel	165-175	epidermal growth factor receptor	Homo sapiens	249-281
33749060-11	2021	Moreover, PTX prevented TAA-induced elevation of transforming growth factor-beta1 (TGF-beta1), platelet-derived growth factor-BB (PDGF-BB), and tissue inhibitor of metalloproteinase 1 (TIMP-1) levels in liver tissues.	Paclitaxel	10-13	transforming growth factor, beta 1	Rattus norvegicus	49-81
33992968-9	2021	The Co(III) complexes of fluoro and bromo derivatives of ligands have displayed remarkable results with roughly two fold increase in their activity in correlation to the standard drug, Paclitaxel.	Paclitaxel	185-195	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	4-11
33585999-3	2021	We aimed to identify the recommended phase 2 dose (RP2D) of ruxolitinib in combination with paclitaxel in patients with HER2-negative metastatic breast cancer (MBC).	Paclitaxel	92-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
33965541-1	2021	The high expression of multidrug resistance-associated protein 1 (MRP1) in cancer cells caused serious multidrug resistance (MDR), which limited the effectiveness of paclitaxel (PTX) in non-small cell lung cancer (NSCLC) chemotherapy.	Paclitaxel	166-176	ATP binding cassette subfamily C member 1	Homo sapiens	23-64
33965541-1	2021	The high expression of multidrug resistance-associated protein 1 (MRP1) in cancer cells caused serious multidrug resistance (MDR), which limited the effectiveness of paclitaxel (PTX) in non-small cell lung cancer (NSCLC) chemotherapy.	Paclitaxel	166-176	ATP binding cassette subfamily C member 1	Homo sapiens	66-70
33965541-1	2021	The high expression of multidrug resistance-associated protein 1 (MRP1) in cancer cells caused serious multidrug resistance (MDR), which limited the effectiveness of paclitaxel (PTX) in non-small cell lung cancer (NSCLC) chemotherapy.	Paclitaxel	178-181	ATP binding cassette subfamily C member 1	Homo sapiens	23-64
33965541-1	2021	The high expression of multidrug resistance-associated protein 1 (MRP1) in cancer cells caused serious multidrug resistance (MDR), which limited the effectiveness of paclitaxel (PTX) in non-small cell lung cancer (NSCLC) chemotherapy.	Paclitaxel	178-181	ATP binding cassette subfamily C member 1	Homo sapiens	66-70
33749060-11	2021	Moreover, PTX prevented TAA-induced elevation of transforming growth factor-beta1 (TGF-beta1), platelet-derived growth factor-BB (PDGF-BB), and tissue inhibitor of metalloproteinase 1 (TIMP-1) levels in liver tissues.	Paclitaxel	10-13	transforming growth factor beta 1	Homo sapiens	83-92
33749060-11	2021	Moreover, PTX prevented TAA-induced elevation of transforming growth factor-beta1 (TGF-beta1), platelet-derived growth factor-BB (PDGF-BB), and tissue inhibitor of metalloproteinase 1 (TIMP-1) levels in liver tissues.	Paclitaxel	10-13	TIMP metallopeptidase inhibitor 1	Homo sapiens	185-191
33749060-12	2021	These findings suggest that the low dose of PTX prevented TAA-induced liver fibrosis in rats, possibly by inhibiting the expression of TGF-beta1 and PDGF-BB and subsequently suppressing the apoptosis and the expression of TIMP-1.	Paclitaxel	44-47	transforming growth factor, beta 1	Rattus norvegicus	135-144
33987090-6	2021	The reduction of DHX36 level de-sensitises the proliferation response of lung cancer cells to chemotherapeutic drugs such as paclitaxel with cell dependence.	Paclitaxel	125-135	DEAH-box helicase 36	Homo sapiens	17-22
33894017-1	2021	Veliparib (ABT-888) is a poly (ADP-ribose) polymerase (PARP) inhibitor in development for treatment of high-grade ovarian cancer or BRCA-mutated breast cancer in combination with carboplatin and paclitaxel.	Paclitaxel	195-205	poly(ADP-ribose) polymerase 1	Homo sapiens	55-59
33893626-10	2021	Furthermore, E-cadherin protein concentration increased while N-cadherin and Vimentin decreased due to increasing PTX treatments.	Paclitaxel	114-117	cadherin 1	Homo sapiens	13-23
33764366-11	2021	In summary, our results showed that nab-paclitaxel increased the expression of CCL26 in CAFs, and CCL26 enhanced the invasive potential of pancreatic cancer cells by activating the PI3K/AKT/mTOR axis.	Paclitaxel	40-50	AKT serine/threonine kinase 1	Homo sapiens	186-189
33764366-11	2021	In summary, our results showed that nab-paclitaxel increased the expression of CCL26 in CAFs, and CCL26 enhanced the invasive potential of pancreatic cancer cells by activating the PI3K/AKT/mTOR axis.	Paclitaxel	40-50	mechanistic target of rapamycin kinase	Homo sapiens	190-194
33848959-8	2021	For glial differentiation, taxol significantly reduced oligodendrogenesis as observed by immunostaining for Olig2 and O4.	Paclitaxel	27-32	oligodendrocyte transcription factor 2	Mus musculus	108-113
33846536-2	2021	Herein, we found that USP24 not only repressed DNA-damage repair (DDR) activity by decreasing Rad51 expression to cause the tumor genomic instability and cancer stemness, but also increased the levels of the ATP-binding cassette (ABC) transporters P-gp, ABCG2, and ezrin to enhance the pumping out of Taxol from cancer cells, thus resulted in drug resistance during cancer therapy.	Paclitaxel	301-306	ubiquitin specific peptidase 24	Homo sapiens	22-27
33729781-1	2021	Many chemotherapeutics, such as paclitaxel, are administered intravenously as they suffer from poor oral bioavailability, partly because of efflux mechanism of P-glycoprotein in the intestinal epithelium.	Paclitaxel	32-42	ATP binding cassette subfamily B member 1	Homo sapiens	160-174
33608316-4	2021	Following multiple intraperitoneal injections of paclitaxel in mice, galectin-3 levels were elevated in Schwann cells within the sciatic nerve but not in other peripheral organs or cells expressing galectin-3.	Paclitaxel	49-59	lectin, galactose binding, soluble 3	Mus musculus	69-79
33608316-4	2021	Following multiple intraperitoneal injections of paclitaxel in mice, galectin-3 levels were elevated in Schwann cells within the sciatic nerve but not in other peripheral organs or cells expressing galectin-3.	Paclitaxel	49-59	lectin, galactose binding, soluble 3	Mus musculus	198-208
33608316-5	2021	Consistent with this, paclitaxel treatment of primary cultures of rat Schwann cells induced upregulation and secretion of galectin-3.	Paclitaxel	22-32	galectin 3	Rattus norvegicus	122-132
33608316-7	2021	In addition, perineural administration of galectin-3 to the sciatic nerve of naive mice mimicked paclitaxel-induced macrophage infiltration and mechanical hypersensitivity.	Paclitaxel	97-107	lectin, galactose binding, soluble 3	Mus musculus	42-52
33608316-9	2021	Deficiency (galectin-3-/- mice) or pharmacological inhibition of galectin-3 inhibited paclitaxel-induced macrophage infiltration and mechanical hypersensitivity.	Paclitaxel	86-96	lectin, galactose binding, soluble 3	Mus musculus	12-22
33608316-9	2021	Deficiency (galectin-3-/- mice) or pharmacological inhibition of galectin-3 inhibited paclitaxel-induced macrophage infiltration and mechanical hypersensitivity.	Paclitaxel	86-96	lectin, galactose binding, soluble 3	Mus musculus	65-75
33863546-0	2021	Blocking miR-27a-3p sensitises Taxol resistant osteosarcoma cells through targeting Fbxw7.	Paclitaxel	31-36	F-box and WD repeat domain containing 7	Homo sapiens	84-89
33863546-12	2021	Particularly, results from rescue experiments by inhibiting Fbxw7 expressions in miR-23a-3p-blocked OS cells demonstrated the miR-27a-3p-mediated Taxol resistance was through direct targeting Fbxw7.	Paclitaxel	146-151	F-box and WD repeat domain containing 7	Homo sapiens	60-65
33863546-12	2021	Particularly, results from rescue experiments by inhibiting Fbxw7 expressions in miR-23a-3p-blocked OS cells demonstrated the miR-27a-3p-mediated Taxol resistance was through direct targeting Fbxw7.	Paclitaxel	146-151	F-box and WD repeat domain containing 7	Homo sapiens	192-197
33863546-13	2021	In summary, our findings report a new molecular mechanism for the miR-27a-3p-mediated Taxol resistance via targeting tumour suppressor, Fbxw7 in osteosarcoma.	Paclitaxel	86-91	F-box and WD repeat domain containing 7	Homo sapiens	136-141
33797754-8	2021	Notably, treating with the beta-catenin/CBP inhibitor PRI-724 induced an enhancement of chemotherapeutic response of paclitaxel in BOP1-overexpressing TNBC cells.	Paclitaxel	117-127	CREB binding protein	Homo sapiens	40-43
33880384-2	2021	The shell consisted of a human serum albumin- (HSA-) paclitaxel (PTX) layer, which extended the blood circulation time and ensured the effectiveness of the chemotherapy.	Paclitaxel	53-63	albumin	Homo sapiens	31-44
33880384-2	2021	The shell consisted of a human serum albumin- (HSA-) paclitaxel (PTX) layer, which extended the blood circulation time and ensured the effectiveness of the chemotherapy.	Paclitaxel	65-68	albumin	Homo sapiens	31-44
33917510-12	2021	Our results suggest that: (i) miR-877-3p is a potential therapeutic target whose inhibition improves paclitaxel effects; (ii) the expression and location of its target ZNF177 could be diagnostic biomarkers between HSIL and SCCC; and (iii) cytoplasmic ZNF177 is a poor-prognosis biomarker in SCCC.	Paclitaxel	101-111	zinc finger protein 177	Homo sapiens	168-174
33797754-8	2021	Notably, treating with the beta-catenin/CBP inhibitor PRI-724 induced an enhancement of chemotherapeutic response of paclitaxel in BOP1-overexpressing TNBC cells.	Paclitaxel	117-127	BOP1 ribosomal biogenesis factor	Homo sapiens	131-135
33556340-5	2021	Both the TLR4 activator taxol and IL-6 can induce AKT phosphorylation, whereas TLR4 knockdown or inhibition of the IL-6 signal transducer GP130 abrogates AKT activation.	Paclitaxel	24-29	AKT serine/threonine kinase 1	Homo sapiens	154-157
33556340-6	2021	Furthermore, expression of AR and IL-6 is downregulated in TLR4-knockdown, taxol-resistant cells.	Paclitaxel	75-80	androgen receptor	Homo sapiens	27-29
33556340-0	2021	TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.	Paclitaxel	108-113	interleukin 6	Homo sapiens	5-9
33556340-6	2021	Furthermore, expression of AR and IL-6 is downregulated in TLR4-knockdown, taxol-resistant cells.	Paclitaxel	75-80	interleukin 6	Homo sapiens	34-38
33556340-0	2021	TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.	Paclitaxel	108-113	interferon regulatory factor 1	Homo sapiens	10-14
33556340-0	2021	TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.	Paclitaxel	108-113	androgen receptor	Homo sapiens	35-52
33556340-8	2021	On the other hand, nuclear translocation of AR is induced by IL-6 treatment, whereas knockdown of endogenous IL-6 reduces AR and TLR4 expression in taxol-resistant ovarian cancer cells.	Paclitaxel	148-153	interleukin 6	Homo sapiens	109-113
33556340-4	2021	Based on transcriptomic analysis, we show that IL-6 functions as a hub gene among the upregulated genes in taxol-treated TLR4-overexpressing ovarian cancer cells.	Paclitaxel	107-112	interleukin 6	Homo sapiens	47-51
33556340-5	2021	Both the TLR4 activator taxol and IL-6 can induce AKT phosphorylation, whereas TLR4 knockdown or inhibition of the IL-6 signal transducer GP130 abrogates AKT activation.	Paclitaxel	24-29	AKT serine/threonine kinase 1	Homo sapiens	50-53
33556340-8	2021	On the other hand, nuclear translocation of AR is induced by IL-6 treatment, whereas knockdown of endogenous IL-6 reduces AR and TLR4 expression in taxol-resistant ovarian cancer cells.	Paclitaxel	148-153	androgen receptor	Homo sapiens	122-124
33556340-11	2021	Moreover, analysis of clinical samples indicates that high IL-6 expression correlates with poor progression-free survival in ovarian cancer patients treated with taxol.	Paclitaxel	162-167	interleukin 6	Homo sapiens	59-63
33556340-12	2021	Overall, our findings indicate that the TLR4/IL-6/IRF1 signaling axis represents a potential therapeutic target to overcome AR-based taxol resistance in ovarian cancer.	Paclitaxel	133-138	interleukin 6	Homo sapiens	45-49
33732454-1	2021	Nanoparticle albumin-bound (nab)-paclitaxel is a 130-nm formulation containing human serum albumin (HSA).	Paclitaxel	33-43	albumin	Homo sapiens	85-98
33732454-1	2021	Nanoparticle albumin-bound (nab)-paclitaxel is a 130-nm formulation containing human serum albumin (HSA).	Paclitaxel	33-43	albumin	Homo sapiens	100-103
33556340-12	2021	Overall, our findings indicate that the TLR4/IL-6/IRF1 signaling axis represents a potential therapeutic target to overcome AR-based taxol resistance in ovarian cancer.	Paclitaxel	133-138	interferon regulatory factor 1	Homo sapiens	50-54
33732454-3	2021	The high pressure employed during the manufacture of nab-paclitaxel HSA (nab HSA) may influence its conformation and/or oligomerization, and ultimately its affinity for HSA.	Paclitaxel	57-67	albumin	Homo sapiens	68-71
33732454-3	2021	The high pressure employed during the manufacture of nab-paclitaxel HSA (nab HSA) may influence its conformation and/or oligomerization, and ultimately its affinity for HSA.	Paclitaxel	57-67	albumin	Homo sapiens	77-80
33732454-3	2021	The high pressure employed during the manufacture of nab-paclitaxel HSA (nab HSA) may influence its conformation and/or oligomerization, and ultimately its affinity for HSA.	Paclitaxel	57-67	albumin	Homo sapiens	77-80
33732454-4	2021	Therefore, studies are required to evaluate whether the affinity of paclitaxel for nab HSA is similar to that of generic HSA (control HSA).	Paclitaxel	68-78	albumin	Homo sapiens	87-90
33732454-5	2021	In the present study, nab HSA was isolated from nab-paclitaxel by gel filtration, and the binding affinities (KDs) were determined by surface plasmon resonance.	Paclitaxel	52-62	albumin	Homo sapiens	26-29
33732454-7	2021	Paclitaxel showed KDs of 8.93+-8.60 and 7.39+-5.81 microM for nab HSA and control HSA, respectively, whereas the corresponding KDs for docetaxel were 44.3+-9.50 and 55.9+-2.28 microM, respectively.	Paclitaxel	0-10	albumin	Homo sapiens	66-69
33732454-7	2021	Paclitaxel showed KDs of 8.93+-8.60 and 7.39+-5.81 microM for nab HSA and control HSA, respectively, whereas the corresponding KDs for docetaxel were 44.3+-9.50 and 55.9+-2.28 microM, respectively.	Paclitaxel	0-10	albumin	Homo sapiens	82-85
33556340-12	2021	Overall, our findings indicate that the TLR4/IL-6/IRF1 signaling axis represents a potential therapeutic target to overcome AR-based taxol resistance in ovarian cancer.	Paclitaxel	133-138	androgen receptor	Homo sapiens	124-126
33795638-7	2021	Significantly, UTD1 exhibited stronger effect on inducing apoptosis than paclitaxel and 5-FU, especially in HCT15 cells which is ABCB1 high-expression.	Paclitaxel	73-83	ATP binding cassette subfamily B member 1	Homo sapiens	129-134
33710778-0	2021	Knockout of vasohibin-2 reduces tubulin carboxypeptidase activity and increases paclitaxel sensitivity in ovarian cancer.	Paclitaxel	80-90	vasohibin 2	Homo sapiens	12-23
33710778-4	2021	Paclitaxel (PTX), an effective chemotherapeutic agent that is widely used to treat ovarian cancer, inhibits microtubule depolymerization and may interact with VASH2.	Paclitaxel	0-10	vasohibin 2	Homo sapiens	159-164
33710778-4	2021	Paclitaxel (PTX), an effective chemotherapeutic agent that is widely used to treat ovarian cancer, inhibits microtubule depolymerization and may interact with VASH2.	Paclitaxel	12-15	vasohibin 2	Homo sapiens	159-164
33710778-8	2021	The knockout of VASH2 significantly increased chemosensitivity to PTX, but not to cisplatin in ovarian cancer cell lines.	Paclitaxel	66-69	vasohibin 2	Homo sapiens	16-21
33710778-9	2021	The knockout of VASH2 reduced TCP activity and increased cyclin B1 expression, resulting in increased PTX chemosensitivity in ovarian cancer cells.	Paclitaxel	102-105	vasohibin 2	Homo sapiens	16-21
33446524-6	2021	Moreover, the hydroxylation of paclitaxel was evaluated using recombinant CYP3A4 and CYP3A5.	Paclitaxel	31-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-80
33446524-6	2021	Moreover, the hydroxylation of paclitaxel was evaluated using recombinant CYP3A4 and CYP3A5.	Paclitaxel	31-41	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	85-91
33717236-0	2021	Interleukin-1beta weakens paclitaxel sensitivity through regulating autophagy in the non-small cell lung cancer cell line A549.	Paclitaxel	26-36	interleukin 1 beta	Homo sapiens	0-17
33867704-0	2021	Amelioration of Combination of Paclitaxel and Di Allyl Sulfide on the Alterations of Bcl2, P53 and Apoptosis Changes Against 7,12 Di Methyl Benz (A) Anthracene Induced Skin Cancer in Experimental Animals.	Paclitaxel	31-41	BCL2, apoptosis regulator	Rattus norvegicus	85-89
33867704-7	2021	The levels of Bcl2 gene expression were significantly decreased and P53gene expression were markedly increased in Paclitaxel and Di allyl sulfide treated animals when compared with cancer bearing animals.	Paclitaxel	114-124	BCL2, apoptosis regulator	Rattus norvegicus	14-18
33867704-8	2021	The treatment with combination of Paclitaxel and Di allyl sulfide effectively reduced Bcl2 protein expression and also increased P53gene expression.	Paclitaxel	34-44	BCL2, apoptosis regulator	Rattus norvegicus	86-90
33732454-10	2021	In conclusion, the binding affinities of paclitaxel and docetaxel for nab HSA and control HSA were found to be comparable.	Paclitaxel	41-51	albumin	Homo sapiens	74-77
33732454-10	2021	In conclusion, the binding affinities of paclitaxel and docetaxel for nab HSA and control HSA were found to be comparable.	Paclitaxel	41-51	albumin	Homo sapiens	90-93
33548860-0	2021	Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial.	Paclitaxel	27-37	albumin	Homo sapiens	13-20
33756128-0	2021	MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer.	Paclitaxel	62-72	tumor protein p53 inducible nuclear protein 1	Homo sapiens	88-96
33756128-12	2021	Furthermore, the overexpression of the target gene, TP53INP1, contributed to the re-sensitivity of drug-resistant cells to paclitaxel.	Paclitaxel	123-133	tumor protein p53 inducible nuclear protein 1	Homo sapiens	52-60
33756128-13	2021	The subsequent combination of the knockdown of miR-155-5p and the overexpression of TP53INP1 conferred paclitaxel sensitivity in resistant cells.	Paclitaxel	103-113	tumor protein p53 inducible nuclear protein 1	Homo sapiens	84-92
33548860-3	2021	nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel that improves drug delivery into tumor compared to paclitaxel.	Paclitaxel	4-14	albumin	Homo sapiens	33-40
33740022-7	2021	The most prominent difference observed was the significant increase of octanoylcarnitine in cells treated with solvent-based paclitaxel, which was found to be associated with significant decrease of medium-chain acyl-CoA dehydrogenase (MCAD).	Paclitaxel	125-135	acyl-CoA dehydrogenase medium chain	Homo sapiens	199-234
33548860-3	2021	nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel that improves drug delivery into tumor compared to paclitaxel.	Paclitaxel	62-72	albumin	Homo sapiens	33-40
33548860-3	2021	nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel that improves drug delivery into tumor compared to paclitaxel.	Paclitaxel	62-72	albumin	Homo sapiens	33-40
33422634-7	2021	Moreover, the data suggests that the synergistic effect of CG and PTX played a role in a mitochondrial intrinsic pathway through the apoptotic gene expression of Bax, caspase-9 and caspase-3.	Paclitaxel	66-69	BCL2 associated X, apoptosis regulator	Homo sapiens	162-165
33422634-7	2021	Moreover, the data suggests that the synergistic effect of CG and PTX played a role in a mitochondrial intrinsic pathway through the apoptotic gene expression of Bax, caspase-9 and caspase-3.	Paclitaxel	66-69	caspase 3	Homo sapiens	181-190
33739080-3	2021	We revealed that beta-tubulin III, androgen receptor, and CXCR4 expressions were significantly increased in LNCaP/PTX cells and directly contributed to PTX resistance and EMT.	Paclitaxel	114-117	androgen receptor	Homo sapiens	17-52
33739080-3	2021	We revealed that beta-tubulin III, androgen receptor, and CXCR4 expressions were significantly increased in LNCaP/PTX cells and directly contributed to PTX resistance and EMT.	Paclitaxel	152-155	androgen receptor	Homo sapiens	17-52
33740022-7	2021	The most prominent difference observed was the significant increase of octanoylcarnitine in cells treated with solvent-based paclitaxel, which was found to be associated with significant decrease of medium-chain acyl-CoA dehydrogenase (MCAD).	Paclitaxel	125-135	acyl-CoA dehydrogenase medium chain	Homo sapiens	236-240
33996222-0	2021	Anti-HER2 PLGA-PEG polymer nanoparticle containing gold nanorods and paclitaxel for laser-activated breast cancer detection and therapy.	Paclitaxel	69-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
33737682-0	2021	Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer.	Paclitaxel	88-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-123
33737682-1	2021	Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined.	Paclitaxel	9-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
33758505-0	2021	Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis.	Paclitaxel	118-128	mechanistic target of rapamycin kinase	Homo sapiens	71-75
33758505-10	2021	Moreover, NE-PTX+BEZ235 treatment increased apoptosis, decreased Pgp and ABCC1 expression, and reduced tumor weights compared to the single drug treatment and the control group.	Paclitaxel	13-16	ATP binding cassette subfamily C member 1	Homo sapiens	73-78
33690190-0	2021	Nanostructured lipid carrier co-delivering paclitaxel and doxorubicin restrains the proliferation and promotes apoptosis of glioma stem cells via regulating PI3K/Akt/mTOR signaling.	Paclitaxel	43-53	thymoma viral proto-oncogene 1	Mus musculus	162-165
33721913-9	2021	Results from combinatorial screening in ESCC cells expressing lower phosphorylation level of EGFR showed that paclitaxel and afatinib presented a significant synergistic inhibitory effect (P < 0.001).	Paclitaxel	110-120	epidermal growth factor receptor	Homo sapiens	93-97
33721913-10	2021	Molecular analysis revealed that paclitaxel sentisized afatinib by activating EGFR, and afatinib in combination with paclitaxel effectively blocked MAPK pathway, induced G2/M cell arrest and apoptosis which is an indicator of mitotic catastrophe.	Paclitaxel	33-43	epidermal growth factor receptor	Homo sapiens	78-82
33721913-12	2021	And for patients with lower p-EGFR in tumors, paclitaxel in combination with afatinib might be a promising therapeutic strategy in ESCC.	Paclitaxel	46-56	epidermal growth factor receptor	Homo sapiens	30-34
33690190-11	2021	Mechanistic investigations evidenced that PTX-DOX-NLC inhibited tumor progression by suppressing the PI3K/AKT/mTOR signaling in vitro and in vivo.	Paclitaxel	42-45	thymoma viral proto-oncogene 1	Mus musculus	106-109
33289076-8	2021	Hence, FA-PTX co-loaded, RGD-functionalized PAMAM G4.5 dendrimers may be considered as an effective therapeutic strategy to induce apoptosis in P-gp-overexpressing, multidrug-resistant cells.	Paclitaxel	10-13	ATP binding cassette subfamily B member 1	Homo sapiens	144-148
33688210-9	2021	The resistance rates to paclitaxel were different between the patients with high VCAM-1 expression and those with low VCAM-1 expression.	Paclitaxel	24-34	vascular cell adhesion molecule 1	Homo sapiens	81-87
33688210-9	2021	The resistance rates to paclitaxel were different between the patients with high VCAM-1 expression and those with low VCAM-1 expression.	Paclitaxel	24-34	vascular cell adhesion molecule 1	Homo sapiens	118-124
33328427-11	2021	Paclitaxel also suppressed stiffness-induced alpha-SMA mRNA expression and the number of HSCs, but mildly reduced that of Col1alpha mRNA.	Paclitaxel	0-10	actin alpha 1, skeletal muscle	Homo sapiens	45-54
33655494-0	2021	Overexpressed COL5A1 is correlated with tumor progression, paclitaxel resistance, and tumor-infiltrating immune cells in ovarian cancer.	Paclitaxel	59-69	collagen type V alpha 1 chain	Homo sapiens	14-20
33655494-3	2021	The association of COL5A1 with paclitaxel (PTX)-resistance and stemness in OC was also studied and the multidatabase and big data analyses of the prognostic value, coexpression network, genetic alterations, and tumor-infiltrating immune cells of COL5A1 were elucidated.	Paclitaxel	31-41	collagen type V alpha 1 chain	Homo sapiens	19-25
33655494-3	2021	The association of COL5A1 with paclitaxel (PTX)-resistance and stemness in OC was also studied and the multidatabase and big data analyses of the prognostic value, coexpression network, genetic alterations, and tumor-infiltrating immune cells of COL5A1 were elucidated.	Paclitaxel	43-46	collagen type V alpha 1 chain	Homo sapiens	19-25
33655494-6	2021	Further study also showed that COL5A1 was overexpressed in PTX-resistant OC cells compared to respective PTX-sensitive cells.	Paclitaxel	59-62	collagen type V alpha 1 chain	Homo sapiens	31-37
33655494-6	2021	Further study also showed that COL5A1 was overexpressed in PTX-resistant OC cells compared to respective PTX-sensitive cells.	Paclitaxel	105-108	collagen type V alpha 1 chain	Homo sapiens	31-37
33655494-8	2021	Silencing COL5A1 expression decreased the OC cell resistance to PTX and inhibited the ability of OC-spheroid formation.	Paclitaxel	64-67	collagen type V alpha 1 chain	Homo sapiens	10-16
33655494-11	2021	Taken together, our data demonstrate that COL5A1 is a biomarker to predict OC progression and PTX-resistance and represents a promising target for OC treatment.	Paclitaxel	94-97	collagen type V alpha 1 chain	Homo sapiens	42-48
33738259-9	2021	Furthermore, Hsp90 enhanced the AKT/GSK3beta signaling, and AKT signaling played a critical role in Hsp90-induced accumulation and transcriptional activity of beta-catenin, as well as multi-drug resistance to paclitaxel and cisplatin.	Paclitaxel	209-219	AKT serine/threonine kinase 1	Homo sapiens	32-35
33738259-9	2021	Furthermore, Hsp90 enhanced the AKT/GSK3beta signaling, and AKT signaling played a critical role in Hsp90-induced accumulation and transcriptional activity of beta-catenin, as well as multi-drug resistance to paclitaxel and cisplatin.	Paclitaxel	209-219	AKT serine/threonine kinase 1	Homo sapiens	60-63
33788730-3	2021	MATERIALS AND METHODS: Metformin with trametinib and paclitaxel was tested for effects on cell viability, signaling molecules in MAPK and mTOR pathways, factors involved in epithelial-mesenchymal transition (EMT), and cell motility.	Paclitaxel	53-63	mitogen-activated protein kinase 1	Homo sapiens	129-133
33788730-3	2021	MATERIALS AND METHODS: Metformin with trametinib and paclitaxel was tested for effects on cell viability, signaling molecules in MAPK and mTOR pathways, factors involved in epithelial-mesenchymal transition (EMT), and cell motility.	Paclitaxel	53-63	mechanistic target of rapamycin kinase	Homo sapiens	138-142
33788730-4	2021	RESULTS: The combination of metformin with trametinib and paclitaxel showed differential growth inhibitory effects; synergistic effects were observed in a cell line in which metformin suppresses ERK activity, whereas the combination showed antagonistic effects in a cell line with metformin-induced ERK activation.	Paclitaxel	58-68	mitogen-activated protein kinase 1	Homo sapiens	195-198
33788730-4	2021	RESULTS: The combination of metformin with trametinib and paclitaxel showed differential growth inhibitory effects; synergistic effects were observed in a cell line in which metformin suppresses ERK activity, whereas the combination showed antagonistic effects in a cell line with metformin-induced ERK activation.	Paclitaxel	58-68	mitogen-activated protein kinase 1	Homo sapiens	299-302
33289076-0	2021	PAMAM G4.5 dendrimers for targeted delivery of ferulic acid and paclitaxel to overcome P-glycoprotein-mediated multidrug resistance.	Paclitaxel	64-74	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
33289076-1	2021	In this study, we prepared ferulic acid (FA) and paclitaxel (PTX) co-loaded polyamidoamine (PAMAM) dendrimers conjugated with arginyl-glycyl-aspartic acid (RGD) to overcome P-glycoprotein (P-gp)-mediated multidrug resistance (MDR).	Paclitaxel	49-59	ATP binding cassette subfamily B member 1	Homo sapiens	173-187
33289076-1	2021	In this study, we prepared ferulic acid (FA) and paclitaxel (PTX) co-loaded polyamidoamine (PAMAM) dendrimers conjugated with arginyl-glycyl-aspartic acid (RGD) to overcome P-glycoprotein (P-gp)-mediated multidrug resistance (MDR).	Paclitaxel	49-59	ATP binding cassette subfamily B member 1	Homo sapiens	189-193
33289076-1	2021	In this study, we prepared ferulic acid (FA) and paclitaxel (PTX) co-loaded polyamidoamine (PAMAM) dendrimers conjugated with arginyl-glycyl-aspartic acid (RGD) to overcome P-glycoprotein (P-gp)-mediated multidrug resistance (MDR).	Paclitaxel	61-64	ATP binding cassette subfamily B member 1	Homo sapiens	173-187
33289076-1	2021	In this study, we prepared ferulic acid (FA) and paclitaxel (PTX) co-loaded polyamidoamine (PAMAM) dendrimers conjugated with arginyl-glycyl-aspartic acid (RGD) to overcome P-glycoprotein (P-gp)-mediated multidrug resistance (MDR).	Paclitaxel	61-64	ATP binding cassette subfamily B member 1	Homo sapiens	189-193
33289076-3	2021	FA improved intracellular availability of PTX via P-gp modulation in drug-resistant cells.	Paclitaxel	42-45	ATP binding cassette subfamily B member 1	Homo sapiens	50-54
33434562-0	2021	Targeting Peroxisome Proliferator-Activated Receptor-alpha (PPAR- alpha) to Reduce Paclitaxel-Induced Peripheral Neuropathy.	Paclitaxel	83-93	peroxisome proliferator activated receptor alpha	Mus musculus	10-58
33434562-0	2021	Targeting Peroxisome Proliferator-Activated Receptor-alpha (PPAR- alpha) to Reduce Paclitaxel-Induced Peripheral Neuropathy.	Paclitaxel	83-93	peroxisome proliferator activated receptor alpha	Mus musculus	60-71
33434562-12	2021	Our results indicate that suppression of paclitaxel-induced hypersensitivity by fibrates involves the regulation of PPAR-  expression and decrease neuroinflammation in DRG.	Paclitaxel	41-51	peroxisome proliferator activated receptor alpha	Mus musculus	116-120
33574940-7	2021	These results demonstrated synergy between paclitaxel and HDAC6-selective inhibitors, providing further impetus for clinical trials of combination therapy using HDAC6-selective inhibitors, not only in ovarian cancer but also in other tumors.	Paclitaxel	43-53	histone deacetylase 6	Homo sapiens	161-166
33875073-4	2021	The drug-loaded micelles increased the chemosensitivity of MDR tumor cells (MDA-MB-231/MDR1) to PTX and activated mitochondria-dependent apoptotic pathways (the IC50 was 2.22-fold lower than that of PTX alone).	Paclitaxel	96-99	ATP binding cassette subfamily B member 1	Homo sapiens	87-91
33549629-9	2021	Similarly, treatment with 3HF suppressed the paclitaxel-induced increase in mRNA expression of several inflammatory cytokines including tumor necrosis factor -alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), CGRP, and Substance P. However, the daily treatment of 3HF did not affect the motor behaviors of rats.	Paclitaxel	45-55	tumor necrosis factor	Rattus norvegicus	136-164
33549629-9	2021	Similarly, treatment with 3HF suppressed the paclitaxel-induced increase in mRNA expression of several inflammatory cytokines including tumor necrosis factor -alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), CGRP, and Substance P. However, the daily treatment of 3HF did not affect the motor behaviors of rats.	Paclitaxel	45-55	tumor necrosis factor	Rattus norvegicus	166-175
33549629-9	2021	Similarly, treatment with 3HF suppressed the paclitaxel-induced increase in mRNA expression of several inflammatory cytokines including tumor necrosis factor -alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), CGRP, and Substance P. However, the daily treatment of 3HF did not affect the motor behaviors of rats.	Paclitaxel	45-55	interleukin 1 beta	Rattus norvegicus	178-195
33549629-9	2021	Similarly, treatment with 3HF suppressed the paclitaxel-induced increase in mRNA expression of several inflammatory cytokines including tumor necrosis factor -alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), CGRP, and Substance P. However, the daily treatment of 3HF did not affect the motor behaviors of rats.	Paclitaxel	45-55	interleukin 1 alpha	Rattus norvegicus	197-205
33549629-9	2021	Similarly, treatment with 3HF suppressed the paclitaxel-induced increase in mRNA expression of several inflammatory cytokines including tumor necrosis factor -alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), CGRP, and Substance P. However, the daily treatment of 3HF did not affect the motor behaviors of rats.	Paclitaxel	45-55	interleukin 6	Rattus norvegicus	212-225
33549629-9	2021	Similarly, treatment with 3HF suppressed the paclitaxel-induced increase in mRNA expression of several inflammatory cytokines including tumor necrosis factor -alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), CGRP, and Substance P. However, the daily treatment of 3HF did not affect the motor behaviors of rats.	Paclitaxel	45-55	interleukin 6	Rattus norvegicus	227-231
33613708-0	2021	Paclitaxel increases the sensitivity of lung cancer cells to lobaplatin via PI3K/Akt pathway.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	81-84
33156701-0	2021	lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-kappaB Signaling Pathway.	Paclitaxel	20-30	SIRT1 regulating lncRNA tumor promoter	Homo sapiens	0-11
33156701-0	2021	lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-kappaB Signaling Pathway.	Paclitaxel	20-30	nuclear factor kappa B subunit 1	Homo sapiens	85-94
33326171-0	2021	GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.	Paclitaxel	95-105	ATP binding cassette subfamily B member 1	Homo sapiens	10-15
33574940-0	2021	HDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells.	Paclitaxel	57-67	histone deacetylase 6	Homo sapiens	0-5
33574940-3	2021	In the present study, a second generation HDAC6-selective inhibitor, ACY-241 (citarinostat), and a novel inhibitor, A452, exhibited synergistic anticancer effects with paclitaxel in AT-rich interaction domain 1A-mutated ovarian cancer in vitro.	Paclitaxel	168-178	histone deacetylase 6	Homo sapiens	42-47
33650658-0	2021	Circadian clock protein CRY1 prevents paclitaxel-induced senescence of bladder cancer cells by promoting p53 degradation.	Paclitaxel	38-48	tumor protein p53	Homo sapiens	105-108
33649523-5	2021	The heterozygous genotype of CYP3A4*22 showed a trend of association with skin reactions in pts treated with paclitaxel and nab-paclitaxel (RR = 6.92; 95% CI 0.47, 99.8; p = 0.0766).	Paclitaxel	109-119	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-35
33650658-11	2021	These data suggested that the accumulated CRY1 in cisplatin-resistant cells could prevent PTX-induced senescence by promoting p53 degradation.	Paclitaxel	90-93	tumor protein p53	Homo sapiens	126-129
33649523-9	2021	Despite the population was heterogeneous, CYP3A4*22 and CYP2C8 SNPs may influence paclitaxel and nab-paclitaxel toxicity and ABCB1 c.3435 may affect taxanes effectiveness, even if any statistically significant was found.	Paclitaxel	101-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48
33649523-5	2021	The heterozygous genotype of CYP3A4*22 showed a trend of association with skin reactions in pts treated with paclitaxel and nab-paclitaxel (RR = 6.92; 95% CI 0.47, 99.8; p = 0.0766).	Paclitaxel	128-138	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-35
33649523-9	2021	Despite the population was heterogeneous, CYP3A4*22 and CYP2C8 SNPs may influence paclitaxel and nab-paclitaxel toxicity and ABCB1 c.3435 may affect taxanes effectiveness, even if any statistically significant was found.	Paclitaxel	82-92	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48
33602685-0	2021	Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer.	Paclitaxel	90-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-108
33602685-17	2021	CONCLUSIONS: Alpelisib plus nab-paclitaxel combination was well-tolerated and shows encouraging efficacy, especially in patients with PIK3CA-mutated tumor/ctDNA.	Paclitaxel	32-42	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	134-140
33670464-2	2021	Here, we designed a dual-targeting drug delivery system by conjugating paclitaxel (PTX)-loaded poly(ethylene glycol)-poly(lactic acid) nanoparticles (NPs) with a cyclic peptide (CNPs-PTX) with a special affinity with platelet-derived growth factor/platelet-derived growth factor receptor (PDGFR-beta) overexpressed on both CAFs and myeloma cells.	Paclitaxel	71-81	platelet derived growth factor receptor alpha	Homo sapiens	289-299
33670464-2	2021	Here, we designed a dual-targeting drug delivery system by conjugating paclitaxel (PTX)-loaded poly(ethylene glycol)-poly(lactic acid) nanoparticles (NPs) with a cyclic peptide (CNPs-PTX) with a special affinity with platelet-derived growth factor/platelet-derived growth factor receptor (PDGFR-beta) overexpressed on both CAFs and myeloma cells.	Paclitaxel	83-86	platelet derived growth factor receptor alpha	Homo sapiens	289-299
33597970-7	2021	mRNA expression analysis using The Cancer Genome Atlas database revealed that RPGRIP1L was highly expressed in several cancer types, especially in pancreatic adenocarcinoma, and correlated with patient survival and sensitivity to paclitaxel, probably through the TGF-beta signaling pathway.	Paclitaxel	230-240	RPGRIP1 like	Homo sapiens	78-86
33681555-6	2021	Relative to the controls, there were also significant fold change differences in palmitic and linoleic acid levels in the cell lysates, mitochondrial CPT1 activities, and mitochondrial medium-chain acyl-CoA dehydrogenase (MCAD) protein levels in the A549 cells subjected to the nab-paclitaxel and solvent-based paclitaxel formulations.	Paclitaxel	282-292	acyl-CoA dehydrogenase medium chain	Homo sapiens	222-226
33681555-6	2021	Relative to the controls, there were also significant fold change differences in palmitic and linoleic acid levels in the cell lysates, mitochondrial CPT1 activities, and mitochondrial medium-chain acyl-CoA dehydrogenase (MCAD) protein levels in the A549 cells subjected to the nab-paclitaxel and solvent-based paclitaxel formulations.	Paclitaxel	311-321	acyl-CoA dehydrogenase medium chain	Homo sapiens	222-226
33577833-0	2021	Validated HPLC method for paclitaxel determination in PLGA submicron particles conjugated with alpha-fetoprotein third domain: sample preparation case study.	Paclitaxel	26-36	alpha fetoprotein	Homo sapiens	95-112
33587352-0	2021	Nuclear Her2 contributes to paclitaxel resistance in breast cancer cells.	Paclitaxel	28-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	8-12
33587352-2	2021	Here, we tested whether nuclear Her2 contributes to paclitaxel resistance in Her2-overexpressing breast cancer cells.	Paclitaxel	52-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-36
33587352-5	2021	Paclitaxel-resistant breast cancer cell was also developed and nuclear Her2 expression was tested.	Paclitaxel	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
33360797-7	2021	Mechanism studies indicated that compound 10c increased the accumulation of P-glycoprotein (P-gp) substrates rhodamine 123 and Flutax1 in KBV cells and MCF-7T (paclitaxel-resistant breast carcinoma) cells, that is to say, compound 10c exerted the reversal effect of tumor MDR by inhibiting the efflux function of P-gp.	Paclitaxel	160-170	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
33360797-7	2021	Mechanism studies indicated that compound 10c increased the accumulation of P-glycoprotein (P-gp) substrates rhodamine 123 and Flutax1 in KBV cells and MCF-7T (paclitaxel-resistant breast carcinoma) cells, that is to say, compound 10c exerted the reversal effect of tumor MDR by inhibiting the efflux function of P-gp.	Paclitaxel	160-170	ATP binding cassette subfamily B member 1	Homo sapiens	92-96
33541289-9	2021	Patients treated with nab-paclitaxel had better event-free survival (EFS; HR = 0.69, 95%CI: 0.57-0.85, P < 0.001) than with sb-taxanes.	Paclitaxel	26-36	nuclear receptor subfamily 4 group A member 1	Homo sapiens	74-76
33401943-7	2021	Expert opinion: Paclitaxel pharmacokinetics is a major determinant of PN.	Paclitaxel	16-26	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	70-72
33597376-0	2021	[A Case of HER2-Positive Metastatic Breast Cancer Achieved a Complete Response to Paclitaxel and Trastuzumab in Combination with Pertuzumab in Fifth Therapy].	Paclitaxel	82-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
33597376-1	2021	We report a case of HER2-positive metastatic breast cancer achieved a complete response(CR)to paclitaxel(PTX) and trastuzumab(HER) in combination with pertuzumab(PER) in 5th therapy.	Paclitaxel	94-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-24
33594306-5	2021	This study aimed to explore the regulatory effect of FMNT/miR-199a-3p/mTOR pathway on Taxol resistance and autophagy in breast cancer (BC).	Paclitaxel	86-91	mechanistic target of rapamycin kinase	Homo sapiens	70-74
33594306-6	2021	MiR-199a-3p, mTOR, LC3 and other autophagy related proteins were detected in Taxol sensitive and Taxol resistant TNBC cell lines, which were MDA-MB-231 and MDA-MB-231/Taxol, respectively.	Paclitaxel	77-82	mechanistic target of rapamycin kinase	Homo sapiens	13-17
33594306-14	2021	Moreover, oral administration of FMNT and Taxol suppressed autophagy and Taxol resistance by restoring mTOR protein level to that of the parent MDA-MB-231, suggesting that miR-199a-3p can severe as a new target to overcome Taxol resistance in TNBC.	Paclitaxel	42-47	mechanistic target of rapamycin kinase	Homo sapiens	103-107
33594306-14	2021	Moreover, oral administration of FMNT and Taxol suppressed autophagy and Taxol resistance by restoring mTOR protein level to that of the parent MDA-MB-231, suggesting that miR-199a-3p can severe as a new target to overcome Taxol resistance in TNBC.	Paclitaxel	73-78	mechanistic target of rapamycin kinase	Homo sapiens	103-107
33594306-14	2021	Moreover, oral administration of FMNT and Taxol suppressed autophagy and Taxol resistance by restoring mTOR protein level to that of the parent MDA-MB-231, suggesting that miR-199a-3p can severe as a new target to overcome Taxol resistance in TNBC.	Paclitaxel	73-78	mechanistic target of rapamycin kinase	Homo sapiens	103-107
33587352-6	2021	Then, correlation between nuclear Her2 and resistance to paclitaxel were analyzed.	Paclitaxel	57-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
33587352-8	2021	RESULTS: We found that Her2 overexpression increases Her2 nuclear expression and cells resistance to paclitaxel in MCF-7 cells.	Paclitaxel	101-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
33587352-9	2021	In the paclitaxel resistant cell (SK-BR-3/R), nuclear Her2 expression is upregulated compared with parental SK-BR-3 cells.	Paclitaxel	7-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
33587352-10	2021	Increased expression of nuclear Her2 after short-time (48 h) treatment of paclitaxel was also observed in SK-BR-3 cells.	Paclitaxel	74-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-36
33587352-11	2021	Further downregulation of Her2 nuclear expression through blocking expression of importin beta1 sensitizes the cells to paclitaxel.	Paclitaxel	120-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-30
33587352-12	2021	The analysis showed that the Her2 nuclear expression increases the survivin expression which leads to resistance to paclitaxel.	Paclitaxel	116-126	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
33587352-13	2021	Her2 nuclear expression decreases paclitaxel-induced apoptosis.	Paclitaxel	34-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
33587352-15	2021	CONCLUSION: We show for the first time that nuclear Her2 contributes to paclitaxel resistance in breast cancer cells which suggests that nuclear Her2 as a potential target to sensitize breast cancers to paclitaxel treatment.	Paclitaxel	72-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
33587352-15	2021	CONCLUSION: We show for the first time that nuclear Her2 contributes to paclitaxel resistance in breast cancer cells which suggests that nuclear Her2 as a potential target to sensitize breast cancers to paclitaxel treatment.	Paclitaxel	72-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	145-149
33587352-15	2021	CONCLUSION: We show for the first time that nuclear Her2 contributes to paclitaxel resistance in breast cancer cells which suggests that nuclear Her2 as a potential target to sensitize breast cancers to paclitaxel treatment.	Paclitaxel	203-213	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
33587352-15	2021	CONCLUSION: We show for the first time that nuclear Her2 contributes to paclitaxel resistance in breast cancer cells which suggests that nuclear Her2 as a potential target to sensitize breast cancers to paclitaxel treatment.	Paclitaxel	203-213	erb-b2 receptor tyrosine kinase 2	Homo sapiens	145-149
33545700-2	2021	Cabazitaxel, a second-generation taxane, exhibits greater anticancer activity than paclitaxel and docetaxel and has low affinity for the P-glycoprotein (P-gp) efflux pump because of its structure.	Paclitaxel	83-93	ATP binding cassette subfamily B member 1	Homo sapiens	153-157
33555529-8	2021	The obtained results demonstrated that miR-424-5p repressed BC cell proliferation and sensitized these cells to Taxol treatment through the induction of apoptosis.	Paclitaxel	112-117	microRNA 424	Homo sapiens	39-46
33002289-0	2021	Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line.	Paclitaxel	48-58	BCL2 associated X, apoptosis regulator	Homo sapiens	97-100
33002289-0	2021	Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line.	Paclitaxel	48-58	tumor protein p53	Homo sapiens	105-108
33172975-10	2021	Inhibition of RhoA also enhanced paclitaxel cytotoxicity in TNBC cells, including in a taxane-refractory TNBC model.	Paclitaxel	33-43	ras homolog family member A	Homo sapiens	14-18
33183411-4	2021	To investigate the effect of NGR-SWCNTs-Paclitaxel on isolated cells, and to observe the antitumor effect of NGR-SWCNTs-Paclitaxel on S180 colon cancer mice in vivo, we provide theoretical and experimental basis for targeted cancer treatment.	Paclitaxel	120-130	reticulon 4 receptor	Mus musculus	109-112
33506275-0	2021	Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells.	Paclitaxel	77-87	ATP binding cassette subfamily B member 1	Homo sapiens	27-32
33506275-0	2021	Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells.	Paclitaxel	77-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	34-39
33555529-12	2021	Overall, the upregulation of miR-424-5p was indicated to upregulate the sensitivity of BC cells to treatment with Taxol.	Paclitaxel	114-119	microRNA 424	Homo sapiens	29-36
33506275-6	2021	We demonstrated that ABCB1 and ABCG2 expressions gradually elevated and reached a maximum level in Taxol 8x cells.	Paclitaxel	99-104	ATP binding cassette subfamily B member 1	Homo sapiens	21-26
33506275-6	2021	We demonstrated that ABCB1 and ABCG2 expressions gradually elevated and reached a maximum level in Taxol 8x cells.	Paclitaxel	99-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	31-36
33300063-8	2021	The apoptosis-inducing role of WWOX was also confirmed by flow cytometry after WWOX overexpression was induced in PTX-treated A2780 cells.	Paclitaxel	114-117	WW domain containing oxidoreductase	Homo sapiens	79-83
33506275-9	2021	Our findings suggest that higher expressions of ABCB1, ABCG2, and KLF4 might be considered as putative indicators for paclitaxel resistance in LSCC patients.	Paclitaxel	118-128	ATP binding cassette subfamily B member 1	Homo sapiens	48-53
33506275-9	2021	Our findings suggest that higher expressions of ABCB1, ABCG2, and KLF4 might be considered as putative indicators for paclitaxel resistance in LSCC patients.	Paclitaxel	118-128	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	55-60
33300063-0	2021	WWOX promotes apoptosis and inhibits autophagy in paclitaxel-treated ovarian carcinoma cells.	Paclitaxel	50-60	WW domain containing oxidoreductase	Homo sapiens	0-4
33300063-3	2021	In the present study, the role of WWOX was demonstrated using PTX-treated EOC cells.	Paclitaxel	62-65	WW domain containing oxidoreductase	Homo sapiens	34-38
33300063-12	2021	PTX was also shown to inhibit mTOR signaling, indicated by a decreased level of p-mTOR and increased expression of eukaryotic translation initiation factor 4E-binding protein 1.	Paclitaxel	0-3	mechanistic target of rapamycin kinase	Homo sapiens	30-34
33300063-5	2021	WWOX and phosphorylated (p)-WWOX were highly expressed in PTX-treated sensitive EOC cells (A2780), which was accompanied by activation of the apoptosis-related proteins caspase-3 and poly (ADP-ribose) polymerase (PARP).	Paclitaxel	58-61	WW domain containing oxidoreductase	Homo sapiens	0-4
33300063-5	2021	WWOX and phosphorylated (p)-WWOX were highly expressed in PTX-treated sensitive EOC cells (A2780), which was accompanied by activation of the apoptosis-related proteins caspase-3 and poly (ADP-ribose) polymerase (PARP).	Paclitaxel	58-61	WW domain containing oxidoreductase	Homo sapiens	28-32
33300063-12	2021	PTX was also shown to inhibit mTOR signaling, indicated by a decreased level of p-mTOR and increased expression of eukaryotic translation initiation factor 4E-binding protein 1.	Paclitaxel	0-3	mechanistic target of rapamycin kinase	Homo sapiens	82-86
33300063-5	2021	WWOX and phosphorylated (p)-WWOX were highly expressed in PTX-treated sensitive EOC cells (A2780), which was accompanied by activation of the apoptosis-related proteins caspase-3 and poly (ADP-ribose) polymerase (PARP).	Paclitaxel	58-61	caspase 3	Homo sapiens	169-178
33300063-5	2021	WWOX and phosphorylated (p)-WWOX were highly expressed in PTX-treated sensitive EOC cells (A2780), which was accompanied by activation of the apoptosis-related proteins caspase-3 and poly (ADP-ribose) polymerase (PARP).	Paclitaxel	58-61	poly(ADP-ribose) polymerase 1	Homo sapiens	183-211
33300063-14	2021	These data indicated that WWOX may serve a critical role in PTX-induced apoptosis and could suppress autophagy by downregulating essential autophagic effectors in EOC cells via mTOR signaling.	Paclitaxel	60-63	WW domain containing oxidoreductase	Homo sapiens	26-30
33300063-5	2021	WWOX and phosphorylated (p)-WWOX were highly expressed in PTX-treated sensitive EOC cells (A2780), which was accompanied by activation of the apoptosis-related proteins caspase-3 and poly (ADP-ribose) polymerase (PARP).	Paclitaxel	58-61	poly(ADP-ribose) polymerase 1	Homo sapiens	213-217
33300063-6	2021	Conversely, PTX-resistant EOC cells (A2780/T) were characterized by reduced WWOX expression and constant phosphorylation levels, as well as undetectable levels of activated caspase-3 and PARP when cells were treated with PTX.	Paclitaxel	12-15	WW domain containing oxidoreductase	Homo sapiens	76-80
33300063-14	2021	These data indicated that WWOX may serve a critical role in PTX-induced apoptosis and could suppress autophagy by downregulating essential autophagic effectors in EOC cells via mTOR signaling.	Paclitaxel	60-63	mechanistic target of rapamycin kinase	Homo sapiens	177-181
33300063-6	2021	Conversely, PTX-resistant EOC cells (A2780/T) were characterized by reduced WWOX expression and constant phosphorylation levels, as well as undetectable levels of activated caspase-3 and PARP when cells were treated with PTX.	Paclitaxel	12-15	caspase 3	Homo sapiens	173-182
33300063-6	2021	Conversely, PTX-resistant EOC cells (A2780/T) were characterized by reduced WWOX expression and constant phosphorylation levels, as well as undetectable levels of activated caspase-3 and PARP when cells were treated with PTX.	Paclitaxel	12-15	poly(ADP-ribose) polymerase 1	Homo sapiens	187-191
33300063-8	2021	The apoptosis-inducing role of WWOX was also confirmed by flow cytometry after WWOX overexpression was induced in PTX-treated A2780 cells.	Paclitaxel	114-117	WW domain containing oxidoreductase	Homo sapiens	31-35
33503955-2	2021	Previously, we found that inhibition of SIK2 enhanced sensitivity of ovarian cancer cells to paclitaxel.	Paclitaxel	93-103	salt inducible kinase 2	Homo sapiens	40-44
33665229-0	2021	Molecular subtyping and functional validation of TTK, TPX2, UBE2C, and LRP8 in sensitivity of TNBC to paclitaxel.	Paclitaxel	102-112	ubiquitin conjugating enzyme E2 C	Homo sapiens	60-65
33665229-0	2021	Molecular subtyping and functional validation of TTK, TPX2, UBE2C, and LRP8 in sensitivity of TNBC to paclitaxel.	Paclitaxel	102-112	LDL receptor related protein 8	Homo sapiens	71-75
33491578-6	2021	CYP3A4 liver enzymes are responsible for the metabolism of fifty percent of the drugs and are major metabolizing enzyme for paclitaxel.	Paclitaxel	124-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
33519462-0	2020	CPEB4-Promoted Paclitaxel Resistance in Ovarian Cancer In Vitro Relies on Translational Regulation of CSAG2.	Paclitaxel	15-25	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	0-5
33552547-2	2021	Materials & methods: We analyzed the efficacy of treatment with bevacizumab plus paclitaxel in 43 patients with hormone receptor-positive and HER2-negative metastatic breast cancer.	Paclitaxel	81-91	nuclear receptor subfamily 4 group A member 1	Homo sapiens	112-128
33087331-2	2021	Previous studies demonstrate that caveolin-1 (Cav-1) expression is critical for nab-paclitaxel uptake into tumors and correlates with response.	Paclitaxel	84-94	caveolin 1	Homo sapiens	34-44
33087331-2	2021	Previous studies demonstrate that caveolin-1 (Cav-1) expression is critical for nab-paclitaxel uptake into tumors and correlates with response.	Paclitaxel	84-94	caveolin 1	Homo sapiens	46-51
33087331-3	2021	Gemcitabine increases nab-paclitaxel uptake by increasing Cav-1 expression.	Paclitaxel	26-36	caveolin 1	Homo sapiens	58-63
33087331-8	2021	Cav-1 silencing reduced the uptake of albumin and therapeutic advantage observed when cells were pre-treated with gemcitabine prior to nab-paclitaxel.	Paclitaxel	139-149	caveolin 1	Homo sapiens	0-5
33087331-8	2021	Cav-1 silencing reduced the uptake of albumin and therapeutic advantage observed when cells were pre-treated with gemcitabine prior to nab-paclitaxel.	Paclitaxel	139-149	albumin	Homo sapiens	38-45
33519462-8	2020	Mechanistically, CPEB4 binds with the taxol (paclitaxel)-resistance-associated gene-3 (TRAG-3/CSAG2) mRNAs and induces its expression at a translational level.	Paclitaxel	45-55	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	17-22
33519462-9	2020	Moreover, CSAG2 expression is upregulated in paclitaxel-resistant ovarian carcinoma and cancer cell lines, and more importantly, siRNA-mediated CSAG2 knockdown overtly attenuates CPEB4-mediated paclitaxel resistance.	Paclitaxel	45-55	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	179-184
33519462-9	2020	Moreover, CSAG2 expression is upregulated in paclitaxel-resistant ovarian carcinoma and cancer cell lines, and more importantly, siRNA-mediated CSAG2 knockdown overtly attenuates CPEB4-mediated paclitaxel resistance.	Paclitaxel	194-204	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	179-184
33519462-10	2020	Conclusion: This study suggests that the drug-resistant protein CSAG2 is translationally induced by CPEB4, which underlies CPEB4-promoted paclitaxel resistance in ovarian cancer in vitro.	Paclitaxel	138-148	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	100-105
33519462-10	2020	Conclusion: This study suggests that the drug-resistant protein CSAG2 is translationally induced by CPEB4, which underlies CPEB4-promoted paclitaxel resistance in ovarian cancer in vitro.	Paclitaxel	138-148	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	123-128
33519462-11	2020	Thus, interfering CPEB4/CSAG2 axis might be of benefit to overcome paclitaxel-resistant ovarian cancer.	Paclitaxel	67-77	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	18-23
33513992-6	2021	The addition of RTV can inhibit the P-gp and CYP3A4-mediated metabolism of PTX, thus aiding in reversing MDR and sensitizing the cells toward PTX.	Paclitaxel	75-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
33513992-6	2021	The addition of RTV can inhibit the P-gp and CYP3A4-mediated metabolism of PTX, thus aiding in reversing MDR and sensitizing the cells toward PTX.	Paclitaxel	142-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
33519462-6	2020	Results: CPEB4 is elevated in paclitaxel-resistant ovarian cancer cells and recurrent ovarian tumors treated with paclitaxel-based chemotherapy.	Paclitaxel	30-40	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	9-14
33519462-7	2020	In addition, CPEB4 overexpression promotes paclitaxel resistance in ovarian cancer cells in vitro, and vice versa, CPEB4 knockdown restores paclitaxel sensitivity, indicating that CPEB4 confers paclitaxel resistance in ovarian cancer cells.	Paclitaxel	43-53	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	13-18
33519462-7	2020	In addition, CPEB4 overexpression promotes paclitaxel resistance in ovarian cancer cells in vitro, and vice versa, CPEB4 knockdown restores paclitaxel sensitivity, indicating that CPEB4 confers paclitaxel resistance in ovarian cancer cells.	Paclitaxel	140-150	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	115-120
33519462-7	2020	In addition, CPEB4 overexpression promotes paclitaxel resistance in ovarian cancer cells in vitro, and vice versa, CPEB4 knockdown restores paclitaxel sensitivity, indicating that CPEB4 confers paclitaxel resistance in ovarian cancer cells.	Paclitaxel	140-150	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	115-120
33519462-7	2020	In addition, CPEB4 overexpression promotes paclitaxel resistance in ovarian cancer cells in vitro, and vice versa, CPEB4 knockdown restores paclitaxel sensitivity, indicating that CPEB4 confers paclitaxel resistance in ovarian cancer cells.	Paclitaxel	140-150	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	115-120
33519462-7	2020	In addition, CPEB4 overexpression promotes paclitaxel resistance in ovarian cancer cells in vitro, and vice versa, CPEB4 knockdown restores paclitaxel sensitivity, indicating that CPEB4 confers paclitaxel resistance in ovarian cancer cells.	Paclitaxel	140-150	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	115-120
33519462-8	2020	Mechanistically, CPEB4 binds with the taxol (paclitaxel)-resistance-associated gene-3 (TRAG-3/CSAG2) mRNAs and induces its expression at a translational level.	Paclitaxel	38-43	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	17-22
33393480-13	2021	CONCLUSION: We found that the addition of trastuzumab to carboplatin/paclitaxel was a cost-effective treatment strategy for patients with advanced/recurrent Her2/neu-positive UPSC.	Paclitaxel	69-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	157-161
33166086-0	2021	Hydroxyapatite-Bovine Serum Albumin-Paclitaxel Nanoparticles for Locoregional Treatment of Osteosarcoma.	Paclitaxel	36-46	albumin	Homo sapiens	22-35
33218896-7	2021	Among all coumarins tested, 4-trifluoromethyl-6,7-dihydroxycoumarin (Cpd 4) displayed the most potent inhibitory activity towards Mcl-1 (Ki = 0.21 +- 0.02 muM, IC50 = 1.21 +- 0.56 muM, respectively), for which the beneficial effect on taxol resistance was also validated in A549 cells.	Paclitaxel	235-240	inositol polyphosphate-5-phosphatase E	Homo sapiens	69-74
32715420-1	2021	PURPOSE: To investigate the effectiveness and safety of bevacizumab-paclitaxel combination therapy as first- or second-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer in daily clinical practice.	Paclitaxel	68-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-145
33506900-16	2021	Finally, the increased levels of MDR1 were significantly reversed following with adding DDX53 si-DDX53-CNE1-TR exosomes, and the increased IC50 to Taxol was obviously reversed.	Paclitaxel	147-152	ATP binding cassette subfamily B member 1	Homo sapiens	33-37
33506900-18	2021	The transferred DDX53 could upregulate the expression of MDR1 in NPC cells to promote the resistant capacity to Taxol, which provided a novel insight for understanding NPC and might be a potential therapeutic target for NPC.	Paclitaxel	112-117	ATP binding cassette subfamily B member 1	Homo sapiens	57-61
33443463-17	2021	On the other hand, siRNAs were respectively implemented to inhibit the expression of endogenous Beclin1 and Atg5, two important autophagy-related genes, in BCa cells, which significantly increased 5637R cells death upon taxol exposing.	Paclitaxel	220-225	autophagy related 5	Homo sapiens	108-112
33436648-8	2021	Subsequent cDNA array analysis confirmed multiple PI3K-AKT pathway members such as AKT2, PIK3R3, CDKN1A, CCND2 and FGF2 to be upregulated in PTX-resistant cells.	Paclitaxel	141-144	AKT serine/threonine kinase 1	Homo sapiens	55-58
33436648-8	2021	Subsequent cDNA array analysis confirmed multiple PI3K-AKT pathway members such as AKT2, PIK3R3, CDKN1A, CCND2 and FGF2 to be upregulated in PTX-resistant cells.	Paclitaxel	141-144	cyclin dependent kinase inhibitor 1A	Homo sapiens	97-103
33436648-8	2021	Subsequent cDNA array analysis confirmed multiple PI3K-AKT pathway members such as AKT2, PIK3R3, CDKN1A, CCND2 and FGF2 to be upregulated in PTX-resistant cells.	Paclitaxel	141-144	cyclin D2	Homo sapiens	105-110
33436648-8	2021	Subsequent cDNA array analysis confirmed multiple PI3K-AKT pathway members such as AKT2, PIK3R3, CDKN1A, CCND2 and FGF2 to be upregulated in PTX-resistant cells.	Paclitaxel	141-144	fibroblast growth factor 2	Homo sapiens	115-119
33091526-3	2021	As evidenced by the success of paclitaxel-bound albumin nanoparticles (AbraxaneTM), serum protein-based nanoparticles have gained attractive attentions for precise biological design and potential clinical application.	Paclitaxel	31-41	albumin	Homo sapiens	48-55
33429062-5	2021	In vitro studies of these formulations and fluorescent nanoparticle analogs demonstrate that Genexol-PM allows paclitaxel to overcome P-glycoprotein efflux, but Abraxane behaves as a free drug formulation.	Paclitaxel	93-103	ATP binding cassette subfamily B member 1	Homo sapiens	134-148
32988253-10	2021	TFs such as FOXA2, NFE2L2, as well as miRNAs like has-miR-508-3p and has-miR-584 also played role in the paclitaxel treatment.	Paclitaxel	105-115	forkhead box A2	Homo sapiens	12-17
33391403-0	2021	Downregulation of CDH11 Promotes Metastasis and Resistance to Paclitaxel in Gastric Cancer Cells.	Paclitaxel	62-72	cadherin 11	Homo sapiens	18-23
33391403-8	2021	Immunohistochemistry (IHC) staining and western blot were performed to confirm the expression of CDH11 in the PTX-resistant tissues and MKN45P-PR cells.	Paclitaxel	110-113	cadherin 11	Homo sapiens	97-102
33391403-10	2021	Results: CDH11 expression was downregulated in the relapsed PTX-resistant ascites, tissues and the PTX-resistant cell line MKN45P-PR.	Paclitaxel	60-63	cadherin 11	Homo sapiens	9-14
33391403-10	2021	Results: CDH11 expression was downregulated in the relapsed PTX-resistant ascites, tissues and the PTX-resistant cell line MKN45P-PR.	Paclitaxel	99-102	cadherin 11	Homo sapiens	9-14
33391403-11	2021	Inhibition of CDH11 expression promoted the invasion, migration and PTX resistance of MKN45P cells, while overexpression of CDH11 repressed these biological functions.	Paclitaxel	68-71	cadherin 11	Homo sapiens	14-19
33391403-13	2021	Conclusions: Our results reveal that CDH11 is inhibited in the relapsed PTX-resistant patients and the downregulated CDH11 expression promotes GC cell invasion, migration and PTX resistance.	Paclitaxel	72-75	cadherin 11	Homo sapiens	37-42
33391403-13	2021	Conclusions: Our results reveal that CDH11 is inhibited in the relapsed PTX-resistant patients and the downregulated CDH11 expression promotes GC cell invasion, migration and PTX resistance.	Paclitaxel	175-178	cadherin 11	Homo sapiens	117-122
33391403-14	2021	CDH11 may have the potential to serve as a predictable marker for the occurrence of PTX resistance in GC patients with peritoneal metastasis.	Paclitaxel	84-87	cadherin 11	Homo sapiens	0-5
33051852-0	2021	CREB Participates in Paclitaxel-Induced Neuropathic Pain Genesis Through Transcriptional Activation of Dnmt3a in Primary Sensory Neurons.	Paclitaxel	21-31	cAMP responsive element binding protein 1	Mus musculus	0-4
33051852-0	2021	CREB Participates in Paclitaxel-Induced Neuropathic Pain Genesis Through Transcriptional Activation of Dnmt3a in Primary Sensory Neurons.	Paclitaxel	21-31	DNA methyltransferase 3A	Mus musculus	103-109
33051852-3	2021	Here, we showed that systemic administration of the chemotherapeutic drug paclitaxel significantly and time-dependently increased the levels of cyclic AMP response element-binding protein (CREB) in dorsal root ganglion (DRG) neurons.	Paclitaxel	74-84	cAMP responsive element binding protein 1	Mus musculus	144-187
33051852-6	2021	Mechanically, paclitaxel-induced increase of DRG CREB protein augmented Dnmt3a promoter activity and participated in the paclitaxel-induced upregulation of DNMT3a protein in the DRG.	Paclitaxel	14-24	DNA methyltransferase 3A	Mus musculus	72-78
33051852-6	2021	Mechanically, paclitaxel-induced increase of DRG CREB protein augmented Dnmt3a promoter activity and participated in the paclitaxel-induced upregulation of DNMT3a protein in the DRG.	Paclitaxel	14-24	DNA methyltransferase 3A	Mus musculus	156-162
33051852-6	2021	Mechanically, paclitaxel-induced increase of DRG CREB protein augmented Dnmt3a promoter activity and participated in the paclitaxel-induced upregulation of DNMT3a protein in the DRG.	Paclitaxel	121-131	DNA methyltransferase 3A	Mus musculus	156-162
32985928-0	2021	Co-administration of Paclitaxel and 2-Methoxyestradiol using folate-conjugated human serum albumin nanoparticles for improving drug resistance and antitumor efficacy.	Paclitaxel	21-31	albumin	Homo sapiens	85-98
32985928-2	2021	This research aims to co-encapsulate Paclitaxel (PTX) and the chemosensitizer 2-Methoxyestradiol (2-ME) into folate-conjugated human serum albumin nanoparticles (FA-HSANPs) to reduce multiple drug resistance and improve anti-tumor efficiency.	Paclitaxel	37-47	albumin	Homo sapiens	133-146
32985928-2	2021	This research aims to co-encapsulate Paclitaxel (PTX) and the chemosensitizer 2-Methoxyestradiol (2-ME) into folate-conjugated human serum albumin nanoparticles (FA-HSANPs) to reduce multiple drug resistance and improve anti-tumor efficiency.	Paclitaxel	49-52	albumin	Homo sapiens	133-146
33089875-6	2021	OBJECTIVES: In the present study, we determined whether a single administration of paclitaxel induces glutamatergic alterations and whether mGluR7 activation blocks paclitaxel-induced neuropathic pain by suppressing glial reactivity in the spinal cord.	Paclitaxel	165-175	glutamate receptor, ionotropic, kainate 3	Mus musculus	140-146
33089875-7	2021	RESULTS: A single paclitaxel injection dose-dependently induced acute mechanical and thermal hypersensitivity, and was associated with increased glutamate level accompanied by reduction in mGluR7 expression in the spinal cord.	Paclitaxel	18-28	glutamate receptor, ionotropic, kainate 3	Mus musculus	189-195
33089875-8	2021	Selective activation of mGluR7 by its positive allosteric modulator, AMN082, blocked the development of paclitaxel-induced acute mechanical and thermal hypersensitivity, without affecting the normal pain behavior of control rats.	Paclitaxel	104-114	glutamate receptor, ionotropic, kainate 3	Mus musculus	24-30
33383736-12	2020	Our results indicate that suppression of paclitaxel-induced pain by fenofibrate involves the regulation of PPAR-alpha expression through reduction in neuroinflammation.	Paclitaxel	41-51	peroxisome proliferator activated receptor alpha	Mus musculus	107-117
33473256-9	2020	Moreover, combination treatment of erlotinib (ERL) or paclitaxel (PAC) with miR-708-5p enhances COX-2 and mPGES-1 protein suppression.	Paclitaxel	54-64	prostaglandin-endoperoxide synthase 2	Homo sapiens	96-101
33473256-9	2020	Moreover, combination treatment of erlotinib (ERL) or paclitaxel (PAC) with miR-708-5p enhances COX-2 and mPGES-1 protein suppression.	Paclitaxel	66-69	prostaglandin-endoperoxide synthase 2	Homo sapiens	96-101
33280384-2	2020	In this work, we reported the structure-based design of triazolo[1,5-a]pyrimidines as new ABCB1 modulators, of which WS-691 significantly increased sensitization of ABCB1-overexpressed SW620/Ad300 cells to paclitaxel (PTX) (IC50 = 22.02 nM).	Paclitaxel	206-216	ATP binding cassette subfamily B member 1	Homo sapiens	165-170
33280384-2	2020	In this work, we reported the structure-based design of triazolo[1,5-a]pyrimidines as new ABCB1 modulators, of which WS-691 significantly increased sensitization of ABCB1-overexpressed SW620/Ad300 cells to paclitaxel (PTX) (IC50 = 22.02 nM).	Paclitaxel	218-221	ATP binding cassette subfamily B member 1	Homo sapiens	165-170
33393480-13	2021	CONCLUSION: We found that the addition of trastuzumab to carboplatin/paclitaxel was a cost-effective treatment strategy for patients with advanced/recurrent Her2/neu-positive UPSC.	Paclitaxel	69-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-165
33437383-0	2020	The inhibition of BRAF activity sensitizes chemoresistant human ovarian cancer cells to paclitaxel-induced cytotoxicity and tumor growth inhibition.	Paclitaxel	88-98	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	18-22
33323915-16	2020	Paclitaxel alleviated the expression levels of the antioxidant molecules, Nrf-2, HO-1, SOD-1, and SOD-2.	Paclitaxel	0-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	74-79
33323915-16	2020	Paclitaxel alleviated the expression levels of the antioxidant molecules, Nrf-2, HO-1, SOD-1, and SOD-2.	Paclitaxel	0-10	heme oxygenase 1	Mus musculus	81-85
33323915-16	2020	Paclitaxel alleviated the expression levels of the antioxidant molecules, Nrf-2, HO-1, SOD-1, and SOD-2.	Paclitaxel	0-10	superoxide dismutase 1, soluble	Mus musculus	87-92
33323915-16	2020	Paclitaxel alleviated the expression levels of the antioxidant molecules, Nrf-2, HO-1, SOD-1, and SOD-2.	Paclitaxel	0-10	superoxide dismutase 2, mitochondrial	Mus musculus	98-103
33323915-17	2020	The paclitaxel effects were accompanied by inhibition of the inflammatory cytokines, MCP-1, TNF-alpha, TNF-R2, and TLR4, as well as attenuation of the apoptosis markers, Bax, Bcl-2, and Caspase-3.	Paclitaxel	4-14	mast cell protease 1	Mus musculus	85-90
33323915-17	2020	The paclitaxel effects were accompanied by inhibition of the inflammatory cytokines, MCP-1, TNF-alpha, TNF-R2, and TLR4, as well as attenuation of the apoptosis markers, Bax, Bcl-2, and Caspase-3.	Paclitaxel	4-14	tumor necrosis factor	Mus musculus	92-101
33323915-17	2020	The paclitaxel effects were accompanied by inhibition of the inflammatory cytokines, MCP-1, TNF-alpha, TNF-R2, and TLR4, as well as attenuation of the apoptosis markers, Bax, Bcl-2, and Caspase-3.	Paclitaxel	4-14	toll-like receptor 4	Mus musculus	115-119
33323915-17	2020	The paclitaxel effects were accompanied by inhibition of the inflammatory cytokines, MCP-1, TNF-alpha, TNF-R2, and TLR4, as well as attenuation of the apoptosis markers, Bax, Bcl-2, and Caspase-3.	Paclitaxel	4-14	B cell leukemia/lymphoma 2	Mus musculus	175-180
33437383-6	2020	Here, we investigated whether BRAF inhibitors (BRAFi) could sensitize PTX-resistant ovarian cancer cells to PTX, and thus would overcome the resistance to chemotherapies.	Paclitaxel	70-73	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	30-34
33437383-7	2020	We found that BRAF and several members of the RAS/MAPK pathways were upregulated upon PTX treatment in ovarian cancer cells, and that BRAF expression was significantly elevated in the PTX-resistant ovarian cancer cells.	Paclitaxel	86-89	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	14-18
32852145-2	2020	Here, hypoxia-activated self-immolative paclitaxel prodrug (PTX 2 -Azo) was synthesized and combined with photodynamic therapy (PDT) to prepare light-boosted PTX nanoparticle (Ce6/PTX 2 -Azo NP) by encapsulation PTX 2 -Azo into photosensitizer chlorine (Ce6) decorated peptide copolymer.	Paclitaxel	40-50	paired like homeodomain 2	Homo sapiens	60-65
33320289-9	2022	Immunohistochemistry and western blot results indicated that PTX and MTX reduce the expression rate of IL-6 and IL-1beta and downregulate TLR4 and p-NF-kappaBp65 protein expression.	Paclitaxel	61-64	interleukin 6	Rattus norvegicus	103-107
33320289-9	2022	Immunohistochemistry and western blot results indicated that PTX and MTX reduce the expression rate of IL-6 and IL-1beta and downregulate TLR4 and p-NF-kappaBp65 protein expression.	Paclitaxel	61-64	interleukin 1 alpha	Rattus norvegicus	112-120
33320289-9	2022	Immunohistochemistry and western blot results indicated that PTX and MTX reduce the expression rate of IL-6 and IL-1beta and downregulate TLR4 and p-NF-kappaBp65 protein expression.	Paclitaxel	61-64	toll-like receptor 4	Rattus norvegicus	138-142
32852145-2	2020	Here, hypoxia-activated self-immolative paclitaxel prodrug (PTX 2 -Azo) was synthesized and combined with photodynamic therapy (PDT) to prepare light-boosted PTX nanoparticle (Ce6/PTX 2 -Azo NP) by encapsulation PTX 2 -Azo into photosensitizer chlorine (Ce6) decorated peptide copolymer.	Paclitaxel	40-50	paired like homeodomain 2	Homo sapiens	180-185
32852145-2	2020	Here, hypoxia-activated self-immolative paclitaxel prodrug (PTX 2 -Azo) was synthesized and combined with photodynamic therapy (PDT) to prepare light-boosted PTX nanoparticle (Ce6/PTX 2 -Azo NP) by encapsulation PTX 2 -Azo into photosensitizer chlorine (Ce6) decorated peptide copolymer.	Paclitaxel	40-50	paired like homeodomain 2	Homo sapiens	180-185
33363381-15	2020	Furthermore, reversed regulation of Fos and P53 based on UBE2N reduction could reverse paclitaxel sensitivity, respectively.	Paclitaxel	87-97	tumor protein p53	Homo sapiens	44-47
33363381-0	2020	UBE2N Regulates Paclitaxel Sensitivity of Ovarian Cancer via Fos/P53 Axis.	Paclitaxel	16-26	tumor protein p53	Homo sapiens	65-68
33319669-5	2021	PTX resistance pathways that involve major regulatory proteins/RNAs like RNF8/Twist/ROR1, TLR, ErbB3/ErbB2, BRCA1-IRIS, MENA, LIN9, MiRNA, FoxM1 and IRAK1 have expanded the complexity of resistance mechanisms, and brought newer insights for development of drug targets.	Paclitaxel	0-3	twist family bHLH transcription factor 1	Homo sapiens	78-83
33319669-5	2021	PTX resistance pathways that involve major regulatory proteins/RNAs like RNF8/Twist/ROR1, TLR, ErbB3/ErbB2, BRCA1-IRIS, MENA, LIN9, MiRNA, FoxM1 and IRAK1 have expanded the complexity of resistance mechanisms, and brought newer insights for development of drug targets.	Paclitaxel	0-3	receptor tyrosine kinase like orphan receptor 1	Homo sapiens	84-88
33319669-5	2021	PTX resistance pathways that involve major regulatory proteins/RNAs like RNF8/Twist/ROR1, TLR, ErbB3/ErbB2, BRCA1-IRIS, MENA, LIN9, MiRNA, FoxM1 and IRAK1 have expanded the complexity of resistance mechanisms, and brought newer insights for development of drug targets.	Paclitaxel	0-3	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-106
33319669-5	2021	PTX resistance pathways that involve major regulatory proteins/RNAs like RNF8/Twist/ROR1, TLR, ErbB3/ErbB2, BRCA1-IRIS, MENA, LIN9, MiRNA, FoxM1 and IRAK1 have expanded the complexity of resistance mechanisms, and brought newer insights for development of drug targets.	Paclitaxel	0-3	ENAH actin regulator	Homo sapiens	120-124
33363381-16	2020	Conclusion: Our study suggests that UBE2N could be used as a therapeutic agent for paclitaxel-resistant ovarian cancer through Fos/P53 pathway.	Paclitaxel	83-93	tumor protein p53	Homo sapiens	131-134
32064933-6	2020	Six genes (KANK1, ALDH3A1, GALNT14, PIK3R3, LRG1, WEE2), which may be related to paclitaxel resistance in lung adenocarcinoma, were identified.	Paclitaxel	81-91	leucine rich alpha-2-glycoprotein 1	Homo sapiens	44-48
33322698-0	2020	CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study.	Paclitaxel	88-98	cyclin dependent kinase inhibitor 2A	Homo sapiens	0-6
33322698-6	2020	Chemosensitivity profiling of PDAC cell lines and patient-derived organoids found that CDKN2A inactivation was associated with the increased sensitivity to paclitaxel and SN-38 (the active metabolite of irinotecan).	Paclitaxel	156-166	cyclin dependent kinase inhibitor 2A	Homo sapiens	87-93
33322698-7	2020	However, only paclitaxel can mimic the effect of CDKN2A restoration, and its drug sensitivity was correlated with genes related to estrogen response.	Paclitaxel	14-24	cyclin dependent kinase inhibitor 2A	Homo sapiens	49-55
33322698-8	2020	Therefore, our study suggested that CDKN2A-inactivated PDAC patients could benefit from the precision treatment with paclitaxel, whose albumin-stabilized nanoparticle formulation (nab-paclitaxel) has been approved for treating PDAC.	Paclitaxel	117-127	cyclin dependent kinase inhibitor 2A	Homo sapiens	36-42
33322698-8	2020	Therefore, our study suggested that CDKN2A-inactivated PDAC patients could benefit from the precision treatment with paclitaxel, whose albumin-stabilized nanoparticle formulation (nab-paclitaxel) has been approved for treating PDAC.	Paclitaxel	184-194	cyclin dependent kinase inhibitor 2A	Homo sapiens	36-42
33414996-9	2020	DHX36 KD also desensitized the cytotoxic cellular response to paclitaxel and cisplatin.	Paclitaxel	62-72	DEAH (Asp-Glu-Ala-His) box polypeptide 36	Mus musculus	0-5
32064933-6	2020	Six genes (KANK1, ALDH3A1, GALNT14, PIK3R3, LRG1, WEE2), which may be related to paclitaxel resistance in lung adenocarcinoma, were identified.	Paclitaxel	81-91	WEE2 oocyte meiosis inhibiting kinase	Homo sapiens	50-54
33188992-1	2020	PURPOSE: Combining bevacizumab with paclitaxel significantly improves progression-free survival (PFS) versus paclitaxel alone in HER2-negative metastatic breast cancer (MBC).	Paclitaxel	36-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
33113434-9	2020	Furthermore, paclitaxel could upregulate the Bax / Bcl-2 ratio by inhibiting HSP27 expression, and in turn, promoting apoptosis due to hyperthermia.	Paclitaxel	13-23	BCL2 associated X, apoptosis regulator	Homo sapiens	45-48
33113434-9	2020	Furthermore, paclitaxel could upregulate the Bax / Bcl-2 ratio by inhibiting HSP27 expression, and in turn, promoting apoptosis due to hyperthermia.	Paclitaxel	13-23	BCL2 apoptosis regulator	Homo sapiens	51-56
33121324-11	2020	Moreover, the impact of miR-4513 inhibitor on cell progression and PTX-resistance was overturned by MEG3 deficiency.	Paclitaxel	67-70	microRNA 4513	Homo sapiens	24-32
33121324-12	2020	Interestingly, miR-4513 mimic could abolish the role of PBLD upregulation in cell behaviors and PTX-resistance in MCF-7 and MDA-MB-231 cells.	Paclitaxel	96-99	microRNA 4513	Homo sapiens	15-23
33121324-14	2020	MEG3/miR-4513/PBLD axis modulated PTX-resistance and the development of breast cancer cells, which might provide a promising therapeutic strategy for breast cancer.	Paclitaxel	34-37	microRNA 4513	Homo sapiens	5-13
33008871-1	2020	Paclitaxel-associated peripheral neuropathy (PN), a major dose-limiting toxicity, significantly impacts patients" quality of life/treatment outcome.	Paclitaxel	0-10	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	45-47
32920426-2	2020	In this article, a quinazolinone derivative (36b) as a NOD1/2 dual antagonist was identified that significantly sensitizes B16 tumor-bearing mice to paclitaxel treatment by inhibiting both nuclear factor kappaB (NF-kappaB) and mitogen-activated protein kinase inflammatory signaling that mediated by NOD1/2.	Paclitaxel	149-159	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	212-221
32562308-4	2020	Treatment of oocytes with the reagents taxol or nocodazole disturbed the distribution of PRC1 in metaphase II oocytes.	Paclitaxel	39-44	protein regulator of cytokinesis 1	Mus musculus	89-93
32711612-0	2020	Study on the Effect of Nano Albumin Paclitaxel Combined with Carboplatin in the Treatment of Lung Squamous Cell Carcinoma.	Paclitaxel	36-46	albumin	Homo sapiens	28-35
32711612-1	2020	This study aims to compare the efficacy and side effects of albumin-binding paclitaxel plus carboplatin (NAB PC) and paclitaxel plus carboplatin (PC) in the first-line treatment of advanced non-small cell lung cancer (NSCLC).	Paclitaxel	76-86	albumin	Homo sapiens	60-67
32711612-2	2020	A total of 60 patients with advanced NSCLC diagnosed by histopathology or cytology were randomly divided into nab PC group (albumin-binding paclitaxel 130 mg/mL, D1, D; carboplatin AUC = 6, D1) and PC group (paclitaxel 175 mg/mL, D1; carboplatin AUC = 6, D1), one cycle every three weeks.	Paclitaxel	140-150	albumin	Homo sapiens	124-131
32489129-5	2020	Released APA effectively inhibited the function of the P-glycoprotein (P-gp) drug pump and improved the sensitivity of MDR cells to chemotherapeutic agents, leading to the recovery of PTX chemosensitivity in MDR cells.	Paclitaxel	184-187	ATP binding cassette subfamily B member 1	Homo sapiens	71-75
33008871-10	2020	Significance Statement Characterization of risk factors of paclitaxel-associated peripheral neuropathy (PN) typically involves time-independent comparison of PN odds in patient subpopulations, concealing the impact of time-dependent factors e.g. changing paclitaxel exposure required to comprehensively characterise PN.	Paclitaxel	59-69	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	104-106
33008871-10	2020	Significance Statement Characterization of risk factors of paclitaxel-associated peripheral neuropathy (PN) typically involves time-independent comparison of PN odds in patient subpopulations, concealing the impact of time-dependent factors e.g. changing paclitaxel exposure required to comprehensively characterise PN.	Paclitaxel	59-69	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	158-160
33008871-10	2020	Significance Statement Characterization of risk factors of paclitaxel-associated peripheral neuropathy (PN) typically involves time-independent comparison of PN odds in patient subpopulations, concealing the impact of time-dependent factors e.g. changing paclitaxel exposure required to comprehensively characterise PN.	Paclitaxel	59-69	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	158-160
33008871-10	2020	Significance Statement Characterization of risk factors of paclitaxel-associated peripheral neuropathy (PN) typically involves time-independent comparison of PN odds in patient subpopulations, concealing the impact of time-dependent factors e.g. changing paclitaxel exposure required to comprehensively characterise PN.	Paclitaxel	255-265	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	104-106
33008871-11	2020	We developed a parametric time-to-event model describing the time-course in risk of clinically-relevant paclitaxel-associated PN, identifying the highest risk in older, male, smokers with higher paclitaxel AUCcycle The developed framework enabled quantification of patient"s risk of PN for clinically-relevant paclitaxel dosing schedules, facilitating future dosing decisions.	Paclitaxel	104-114	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	126-128
33008871-11	2020	We developed a parametric time-to-event model describing the time-course in risk of clinically-relevant paclitaxel-associated PN, identifying the highest risk in older, male, smokers with higher paclitaxel AUCcycle The developed framework enabled quantification of patient"s risk of PN for clinically-relevant paclitaxel dosing schedules, facilitating future dosing decisions.	Paclitaxel	104-114	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	283-285
33008871-11	2020	We developed a parametric time-to-event model describing the time-course in risk of clinically-relevant paclitaxel-associated PN, identifying the highest risk in older, male, smokers with higher paclitaxel AUCcycle The developed framework enabled quantification of patient"s risk of PN for clinically-relevant paclitaxel dosing schedules, facilitating future dosing decisions.	Paclitaxel	195-205	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	126-128
33008871-11	2020	We developed a parametric time-to-event model describing the time-course in risk of clinically-relevant paclitaxel-associated PN, identifying the highest risk in older, male, smokers with higher paclitaxel AUCcycle The developed framework enabled quantification of patient"s risk of PN for clinically-relevant paclitaxel dosing schedules, facilitating future dosing decisions.	Paclitaxel	195-205	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	126-128
33256016-7	2020	Sitagliptin induced apoptosis by caspase 3/7 activation in paclitaxel-treated SKOV-3 and OVCAR-3 cells.	Paclitaxel	59-69	caspase 3	Homo sapiens	33-44
32998017-10	2020	SIGNIFICANCE: Paclitaxel could protect against LPS-induced AKI via the regulation of lnc-MALAT1/miR-370-3p/HMGB1 axis and the expression of TNF-alpha, IL-6 and IL-1beta, revealing that paclitaxel might act as a therapy drug in reducing sepsis-associated AKI.	Paclitaxel	14-24	tumor necrosis factor	Homo sapiens	140-149
32998017-10	2020	SIGNIFICANCE: Paclitaxel could protect against LPS-induced AKI via the regulation of lnc-MALAT1/miR-370-3p/HMGB1 axis and the expression of TNF-alpha, IL-6 and IL-1beta, revealing that paclitaxel might act as a therapy drug in reducing sepsis-associated AKI.	Paclitaxel	14-24	interleukin 6	Homo sapiens	151-155
32805372-9	2020	Moreover, the inhibitory effect of YAN on PI3K/Akt activity was involved in the regulation of P-gp, MRP1 and AIF in A549/Taxol cells.	Paclitaxel	121-126	AKT serine/threonine kinase 1	Homo sapiens	47-50
32031060-2	2020	METHODS: The patient was given chemotherapy again, with albumin-bound paclitaxel, etoposide capsules, apatinib, and other treatment.	Paclitaxel	70-80	albumin	Homo sapiens	56-63
33256016-8	2020	Sitagliptin maintained paclitaxel influence on ERK and Akt signaling pathways.	Paclitaxel	23-33	mitogen-activated protein kinase 1	Homo sapiens	47-50
33256016-8	2020	Sitagliptin maintained paclitaxel influence on ERK and Akt signaling pathways.	Paclitaxel	23-33	AKT serine/threonine kinase 1	Homo sapiens	55-58
33256016-12	2020	SKOV-3 cells co-treated with sitagliptin and paclitaxel decreased concentrations of MMP-1, MMP-2, MMP-7, MMP-10, TIMP-1, TIMP-2.	Paclitaxel	45-55	TIMP metallopeptidase inhibitor 1	Homo sapiens	113-119
33200709-0	2020	Paclitaxel Priming of TRAIL Expressing Mesenchymal Stromal Cells (MSCs-TRAIL) Increases Antitumor Efficacy of Their Secretome.	Paclitaxel	0-10	TNF superfamily member 10	Homo sapiens	22-27
33283132-0	2020	Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer.	Paclitaxel	136-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
33283132-4	2020	In this phase Ib trial, we present safety and tolerability for PU-H71 plus nab-paclitaxel in HER2-negative patients with metastatic breast cancer (MBC) and the utility of PU-PET as a noninvasive predictive biomarker.	Paclitaxel	79-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
33292283-0	2020	Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer.	Paclitaxel	23-33	AKT serine/threonine kinase 1	Homo sapiens	73-76
33292283-0	2020	Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer.	Paclitaxel	23-33	mechanistic target of rapamycin kinase	Homo sapiens	77-81
33198652-0	2020	Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.	Paclitaxel	57-67	albumin	Homo sapiens	43-50
33198652-1	2020	BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-PTX) has shown non-inferiority to paclitaxel (PTX) as second-line therapy for advanced gastric cancer (AGC) with fewer infusion-related reactions.	Paclitaxel	39-49	albumin	Homo sapiens	25-32
33198652-1	2020	BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-PTX) has shown non-inferiority to paclitaxel (PTX) as second-line therapy for advanced gastric cancer (AGC) with fewer infusion-related reactions.	Paclitaxel	55-58	albumin	Homo sapiens	25-32
33207738-6	2020	Furthermore, combination treatment with the mitotic kinase PLK1 inhibitor volasertib and the USP7 inhibitor P22077 showed a strong synergism through down-regulation of MDR1/ABCB1 in paclitaxel-resistant lung cancer.	Paclitaxel	182-192	ATP binding cassette subfamily B member 1	Homo sapiens	168-172
33207738-6	2020	Furthermore, combination treatment with the mitotic kinase PLK1 inhibitor volasertib and the USP7 inhibitor P22077 showed a strong synergism through down-regulation of MDR1/ABCB1 in paclitaxel-resistant lung cancer.	Paclitaxel	182-192	ATP binding cassette subfamily B member 1	Homo sapiens	173-178
33299650-8	2020	The basal-like and HER2+ breast cancer primary cells showed chemosensitivities to paclitaxel and epirubicin with significant differences compared with luminal breast cancer primary cells (P < 0.05).	Paclitaxel	82-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
33200709-0	2020	Paclitaxel Priming of TRAIL Expressing Mesenchymal Stromal Cells (MSCs-TRAIL) Increases Antitumor Efficacy of Their Secretome.	Paclitaxel	0-10	TNF superfamily member 10	Homo sapiens	71-76
33200709-3	2020	The purpose of this study was to verify the ability of MSCs-TRAIL to uptake and release paclitaxel (PTX) by providing an increased antitumor efficacy.	Paclitaxel	88-98	TNF superfamily member 10	Homo sapiens	60-65
33200709-3	2020	The purpose of this study was to verify the ability of MSCs-TRAIL to uptake and release paclitaxel (PTX) by providing an increased antitumor efficacy.	Paclitaxel	100-103	TNF superfamily member 10	Homo sapiens	60-65
33200709-6	2020	RESULTS: MSCs-TRAIL were resistant to PTX and able to incorporate and then release the drug.	Paclitaxel	38-41	TNF superfamily member 10	Homo sapiens	14-19
33200709-7	2020	The secretion of s-TRAIL by PTX loaded MSCs-TRAIL was not inhibited and the PTX delivery together with s-TRAIL secretion resulted into an increased antitumor efficacy of cell secretoma as tested in vitro on human pancreatic carcinoma (CFPAC-1) and glioblastoma (U87-MG).	Paclitaxel	28-31	TNF superfamily member 10	Homo sapiens	19-24
33200709-7	2020	The secretion of s-TRAIL by PTX loaded MSCs-TRAIL was not inhibited and the PTX delivery together with s-TRAIL secretion resulted into an increased antitumor efficacy of cell secretoma as tested in vitro on human pancreatic carcinoma (CFPAC-1) and glioblastoma (U87-MG).	Paclitaxel	28-31	TNF superfamily member 10	Homo sapiens	44-49
33200709-7	2020	The secretion of s-TRAIL by PTX loaded MSCs-TRAIL was not inhibited and the PTX delivery together with s-TRAIL secretion resulted into an increased antitumor efficacy of cell secretoma as tested in vitro on human pancreatic carcinoma (CFPAC-1) and glioblastoma (U87-MG).	Paclitaxel	28-31	TNF superfamily member 10	Homo sapiens	44-49
32721635-2	2020	Herein, three paclitaxel dimers (named as PTX2-R, R = S, Se and Te) bridged with alkyl sulfide, selenide or telluride are synthesized.	Paclitaxel	14-24	paired like homeodomain 2	Homo sapiens	42-46
33200709-9	2020	If confirmed in vivo, this could potentiate the efficacy of MSCs-TRAIL and strongly contribute to reduce the toxicity due to the systemic treatment of PTX.	Paclitaxel	151-154	TNF superfamily member 10	Homo sapiens	65-70
33165766-0	2020	Paclitaxel-Loaded Colloidal Silica and TPGS-Based Solid Self-Emulsifying System Interferes Akt/mTOR Pathway in MDA-MB-231 and Demonstrates Anti-tumor Effect in Syngeneic Mammary Tumors.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	91-94
33336070-4	2020	Based on the results, several impressive drugs have been approved to benefit patients with TNBC, including the PARP inhibitors olaparib and talazoparib for germline BRCA mutation-associated breast cancer (gBRCAm-BC) and immunotherapy using the checkpoint inhibitor atezolizumab in combination with nab-paclitaxel for programmed cell death-ligand 1-positive (PD-L1+) advanced TNBC.	Paclitaxel	302-312	poly(ADP-ribose) polymerase 1	Homo sapiens	111-115
33165766-0	2020	Paclitaxel-Loaded Colloidal Silica and TPGS-Based Solid Self-Emulsifying System Interferes Akt/mTOR Pathway in MDA-MB-231 and Demonstrates Anti-tumor Effect in Syngeneic Mammary Tumors.	Paclitaxel	0-10	mechanistic target of rapamycin kinase	Homo sapiens	95-99
32959525-4	2020	Bicompartmental nanoparticles delivering a synergistic combination of lapatinib and paclitaxel result in increased activity against HER2+ breast cancer cells.	Paclitaxel	84-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
32776291-16	2020	The subgroup analysis among different molecular subtypes found that in triple negative (TN) and HER-2 positive (HER2+) subgroup, the apCR in liposomal paclitaxel group was significantly higher than those in PTX and docetaxel group (all p < 0.05).	Paclitaxel	151-161	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-101
33269821-0	2020	Paclitaxel inhibits proliferation and invasion and promotes apoptosis of breast cancer cells by blocking activation of the PI3K/AKT signaling pathway.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	128-131
33269821-8	2020	In the PTX group, the apoptosis rate, the number of cells arrested in the G2/M phase and the expression levels of Cleaved caspase-3 and Bax were increased, but the number of invasive cells and the expression levels of Bcl-2, MMP-9, vascular endothelial growth factor (VEGF), p-AKT (Thr308), and p-AKT (Ser473) were decreased.	Paclitaxel	7-10	BCL2 associated X, apoptosis regulator	Homo sapiens	136-139
33269821-8	2020	In the PTX group, the apoptosis rate, the number of cells arrested in the G2/M phase and the expression levels of Cleaved caspase-3 and Bax were increased, but the number of invasive cells and the expression levels of Bcl-2, MMP-9, vascular endothelial growth factor (VEGF), p-AKT (Thr308), and p-AKT (Ser473) were decreased.	Paclitaxel	7-10	BCL2 apoptosis regulator	Homo sapiens	218-223
33269821-8	2020	In the PTX group, the apoptosis rate, the number of cells arrested in the G2/M phase and the expression levels of Cleaved caspase-3 and Bax were increased, but the number of invasive cells and the expression levels of Bcl-2, MMP-9, vascular endothelial growth factor (VEGF), p-AKT (Thr308), and p-AKT (Ser473) were decreased.	Paclitaxel	7-10	vascular endothelial growth factor A	Homo sapiens	232-266
33269821-8	2020	In the PTX group, the apoptosis rate, the number of cells arrested in the G2/M phase and the expression levels of Cleaved caspase-3 and Bax were increased, but the number of invasive cells and the expression levels of Bcl-2, MMP-9, vascular endothelial growth factor (VEGF), p-AKT (Thr308), and p-AKT (Ser473) were decreased.	Paclitaxel	7-10	vascular endothelial growth factor A	Homo sapiens	268-272
33269821-8	2020	In the PTX group, the apoptosis rate, the number of cells arrested in the G2/M phase and the expression levels of Cleaved caspase-3 and Bax were increased, but the number of invasive cells and the expression levels of Bcl-2, MMP-9, vascular endothelial growth factor (VEGF), p-AKT (Thr308), and p-AKT (Ser473) were decreased.	Paclitaxel	7-10	AKT serine/threonine kinase 1	Homo sapiens	277-280
33269821-8	2020	In the PTX group, the apoptosis rate, the number of cells arrested in the G2/M phase and the expression levels of Cleaved caspase-3 and Bax were increased, but the number of invasive cells and the expression levels of Bcl-2, MMP-9, vascular endothelial growth factor (VEGF), p-AKT (Thr308), and p-AKT (Ser473) were decreased.	Paclitaxel	7-10	AKT serine/threonine kinase 1	Homo sapiens	297-300
33269821-10	2020	CONCLUSIONS: Paclitaxel could inhibit MCF-7 cell proliferation and invasion, and promote MCF-7 cell apoptosis by downregulating the expression of p-AKT (Thr308) and p-AKT (Ser473) in the PI3K/AKT signaling pathway.	Paclitaxel	13-23	AKT serine/threonine kinase 1	Homo sapiens	148-151
33269821-10	2020	CONCLUSIONS: Paclitaxel could inhibit MCF-7 cell proliferation and invasion, and promote MCF-7 cell apoptosis by downregulating the expression of p-AKT (Thr308) and p-AKT (Ser473) in the PI3K/AKT signaling pathway.	Paclitaxel	13-23	AKT serine/threonine kinase 1	Homo sapiens	167-170
33269821-10	2020	CONCLUSIONS: Paclitaxel could inhibit MCF-7 cell proliferation and invasion, and promote MCF-7 cell apoptosis by downregulating the expression of p-AKT (Thr308) and p-AKT (Ser473) in the PI3K/AKT signaling pathway.	Paclitaxel	13-23	AKT serine/threonine kinase 1	Homo sapiens	167-170
32776291-16	2020	The subgroup analysis among different molecular subtypes found that in triple negative (TN) and HER-2 positive (HER2+) subgroup, the apCR in liposomal paclitaxel group was significantly higher than those in PTX and docetaxel group (all p < 0.05).	Paclitaxel	151-161	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116
32776291-25	2020	Therefore, we suggested the application of liposome paclitaxel in the NAT setting, especially for cN+ patients with TN and HER2 + disease.	Paclitaxel	52-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-127
33138677-0	2020	LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.	Paclitaxel	46-56	arylsulfatase B	Mus musculus	13-16
33138677-0	2020	LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.	Paclitaxel	92-102	arylsulfatase B	Mus musculus	13-16
32815403-9	2020	Paclitaxel exposure reduced IL-8 levels in cancer cell lines, whilst no cytotoxic effect was observed in all cell lines at treatment concentration levels (<= 0.1% (w/v) paclitaxel in silicone).	Paclitaxel	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	28-32
32989391-10	2020	Furthermore, the knockdown of TC2N improved the sensitivity of AGS cells to cisplatin, paclitaxel and 5-fluorouracil, and downregulated the protein expression levels of P-gp.	Paclitaxel	87-97	tandem C2 domains, nuclear	Homo sapiens	30-34
32963602-9	2020	In CD1133+ cells treated with PTX, a dose-dependent reduction in the expression levels of the key glycolytic enzymes GLUT1, PKM and LDHA was observed at both the mRNA and protein levels.	Paclitaxel	30-33	lactate dehydrogenase A	Homo sapiens	132-136
32706146-0	2020	Experiences of trastuzumab plus paclitaxel combination therapy in metastatic human epidermal growth factor receptor 2-positive extramammary Paget"s disease: Four cases and a review.	Paclitaxel	32-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-117
32998859-17	2020	In the sub-group of HER2 positive disease, weekly paclitaxel-trastuzumab appears to be active and safe, and may be considered a therapeutic option in these patients.	Paclitaxel	50-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-24
32706146-4	2020	Here, we report cases of HER2-positive metastatic extramammary Paget"s disease identified by both immunohistochemistry and in situ hybridization, and the patients were treated with HER2 inhibitor (trastuzumab) and paclitaxel combination chemotherapy.	Paclitaxel	214-224	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-29
33136246-0	2020	Alterations in the matrix metalloproteinase-3 promoter methylation after common chemotherapeutics: in vitro study of paclitaxel, cisplatin and methotrexate in the MCF-7 and SH-SY5Y cell lines.	Paclitaxel	117-127	matrix metallopeptidase 3	Homo sapiens	19-45
32574131-6	2020	In the metastatic setting, compared with before the emergency, fewer oncologists adopted first-line weekly paclitaxel for HER2-positive disease (41.8% v 53.9%) or CDK4/6 inhibitors for luminal tumors with less-aggressive characteristics (55.8% v 80.0%) during the COVID-19 outbreak.	Paclitaxel	107-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
32806261-0	2020	Anti-PSMA monoclonal antibody increases the toxicity of paclitaxel carried by carbon nanotubes.	Paclitaxel	56-66	folate hydrolase 1	Homo sapiens	5-9
32806261-5	2020	Analysis of cytotoxicity revealed that both prostate (PSMA+) and colorectal cancer cells (PSMA-) were more susceptible to PTX complexed with CNTs than to pure PTX or CNTs alone, while the incorporation of anti-PSMA (CNT-PTX-PSMA) improved the toxicity on LNCaP cells but not on PSMA- targets.	Paclitaxel	122-125	folate hydrolase 1	Homo sapiens	54-58
32806261-5	2020	Analysis of cytotoxicity revealed that both prostate (PSMA+) and colorectal cancer cells (PSMA-) were more susceptible to PTX complexed with CNTs than to pure PTX or CNTs alone, while the incorporation of anti-PSMA (CNT-PTX-PSMA) improved the toxicity on LNCaP cells but not on PSMA- targets.	Paclitaxel	122-125	folate hydrolase 1	Homo sapiens	90-94
32806261-5	2020	Analysis of cytotoxicity revealed that both prostate (PSMA+) and colorectal cancer cells (PSMA-) were more susceptible to PTX complexed with CNTs than to pure PTX or CNTs alone, while the incorporation of anti-PSMA (CNT-PTX-PSMA) improved the toxicity on LNCaP cells but not on PSMA- targets.	Paclitaxel	122-125	folate hydrolase 1	Homo sapiens	90-94
32806261-5	2020	Analysis of cytotoxicity revealed that both prostate (PSMA+) and colorectal cancer cells (PSMA-) were more susceptible to PTX complexed with CNTs than to pure PTX or CNTs alone, while the incorporation of anti-PSMA (CNT-PTX-PSMA) improved the toxicity on LNCaP cells but not on PSMA- targets.	Paclitaxel	122-125	folate hydrolase 1	Homo sapiens	90-94
32806261-5	2020	Analysis of cytotoxicity revealed that both prostate (PSMA+) and colorectal cancer cells (PSMA-) were more susceptible to PTX complexed with CNTs than to pure PTX or CNTs alone, while the incorporation of anti-PSMA (CNT-PTX-PSMA) improved the toxicity on LNCaP cells but not on PSMA- targets.	Paclitaxel	122-125	folate hydrolase 1	Homo sapiens	90-94
33136246-9	2020	As a result, methotrexate and paclitaxel treatment significantly methylated the MMP-3 promoter; however, cisplatin caused MMP-3 promoter unmethylation in MCF-7 and SH-SY5Y cells.	Paclitaxel	30-40	matrix metallopeptidase 3	Homo sapiens	80-85
33000256-0	2020	Knockdown of SERPINE1 reverses resistance of triple-negative breast cancer to paclitaxel via suppression of VEGFA.	Paclitaxel	78-88	vascular endothelial growth factor A	Homo sapiens	108-113
32730778-8	2020	Taken together, our results demonstrate that the novel taxane, DFV-OTX, can effectively overcome PTX-resistance in MDA-MB-231R cells, wherein the drug resistance was attributed to ABCB1/ABCG2 upregulation and a distinct mode of action in MCF-7R cells.	Paclitaxel	97-100	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	186-191
33183015-0	2021	A heavily pre-treated adenocarcinoma patient with EGFR exon 20 insertion mutation responded to pembrolizumab plus nab-paclitaxel/bevacizumab: a case report.	Paclitaxel	118-128	epidermal growth factor receptor	Homo sapiens	50-54
33218396-15	2020	Paclitaxel decreased the expression levels of PI3K, p-PI3K and p-AKT.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	65-68
33218396-16	2020	Compared with paclitaxel alone, the combination significantly promoted the reduction of PI3K, p-PI3K and p-AKT expressions (P < 0.05).	Paclitaxel	14-24	AKT serine/threonine kinase 1	Homo sapiens	107-110
32505840-0	2020	Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules.	Paclitaxel	30-40	nuclear receptor subfamily 1 group I member 2	Homo sapiens	72-91
32505840-12	2020	The synergetic effect was played by Xiaoaiping injection inhibiting paclitaxel-induced PXR and CAR expression, which subsequently inhibited CYP450 enzymes CYP2C8 and CYP3A4, transporter P-gp and anti-apoptotic proteins Bcl-2 and Bcl-xl in SK-OV-3 cells.	Paclitaxel	68-78	nuclear receptor subfamily 1 group I member 2	Homo sapiens	87-90
32505840-12	2020	The synergetic effect was played by Xiaoaiping injection inhibiting paclitaxel-induced PXR and CAR expression, which subsequently inhibited CYP450 enzymes CYP2C8 and CYP3A4, transporter P-gp and anti-apoptotic proteins Bcl-2 and Bcl-xl in SK-OV-3 cells.	Paclitaxel	68-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	166-172
32505840-12	2020	The synergetic effect was played by Xiaoaiping injection inhibiting paclitaxel-induced PXR and CAR expression, which subsequently inhibited CYP450 enzymes CYP2C8 and CYP3A4, transporter P-gp and anti-apoptotic proteins Bcl-2 and Bcl-xl in SK-OV-3 cells.	Paclitaxel	68-78	BCL2 apoptosis regulator	Homo sapiens	219-224
32505840-12	2020	The synergetic effect was played by Xiaoaiping injection inhibiting paclitaxel-induced PXR and CAR expression, which subsequently inhibited CYP450 enzymes CYP2C8 and CYP3A4, transporter P-gp and anti-apoptotic proteins Bcl-2 and Bcl-xl in SK-OV-3 cells.	Paclitaxel	68-78	BCL2 like 1	Homo sapiens	229-235
32811645-0	2020	Neferine sensitized Taxol-resistant nasopharygeal carcinoma to Taxol by inhibiting EMT via downregulating miR-130b-5p.	Paclitaxel	20-25	microRNA 130b	Homo sapiens	106-114
33097020-8	2020	CONCLUSIONS: The model, consistent with the observed reduction in the Bcl2/BAX ratio, suggests that BRP-induced apoptosis of mitotically-arrested cells is a major contributor to the synergy between BRP and PTX.	Paclitaxel	206-209	BCL2 apoptosis regulator	Homo sapiens	70-74
33097020-8	2020	CONCLUSIONS: The model, consistent with the observed reduction in the Bcl2/BAX ratio, suggests that BRP-induced apoptosis of mitotically-arrested cells is a major contributor to the synergy between BRP and PTX.	Paclitaxel	206-209	BCL2 associated X, apoptosis regulator	Homo sapiens	75-78
32811645-0	2020	Neferine sensitized Taxol-resistant nasopharygeal carcinoma to Taxol by inhibiting EMT via downregulating miR-130b-5p.	Paclitaxel	63-68	microRNA 130b	Homo sapiens	106-114
32811645-7	2020	Further through Microarray based analysis, we found that miR-130b-5p was stably down-regulated after treating 5-8F/Taxol with NEF.	Paclitaxel	115-120	microRNA 130b	Homo sapiens	57-65
32811645-8	2020	Later we verified that up-regulation of miR-130b-5p could not only promote the EMT-related migration/invasion, but also impair the inhibition effects of NEF on the EMT-associated metastatic ability and the chemotherapy resistance to Taxol.	Paclitaxel	233-238	microRNA 130b	Homo sapiens	40-48
32682904-3	2020	With Pluronic F127 as the surfactant and hydrophobic paclitaxel (PTX) as the spacer, such HBP molecule would self-assemble to form surfactant-stripped HBP/PTX micelles with absorption peak red-shifted to 1012 nm and intrinsic NIR-II fluorescence negligibly disturbed.	Paclitaxel	53-63	signal transducing adaptor molecule (SH3 domain and ITAM motif) 2	Mus musculus	90-93
33998863-5	2021	Our laboratory recently reported that the G protein-biased CB2 cannabinoid receptor agonist LY2828360 suppressed chemotherapy-induced neuropathic nociception and attenuated both morphine tolerance and physical dependence in paclitaxel-treated mice.	Paclitaxel	224-234	cannabinoid receptor 2 (macrophage)	Mus musculus	59-62
33070779-0	2020	NFATc2-dependent epigenetic upregulation of CXCL14 is involved in the development of neuropathic pain induced by paclitaxel.	Paclitaxel	113-123	C-X-C motif chemokine ligand 14	Rattus norvegicus	44-50
33070779-8	2020	Also, knockdown of CXCL14 in dorsal horn significantly attenuated mechanical allodynia induced by paclitaxel.	Paclitaxel	98-108	C-X-C motif chemokine ligand 14	Rattus norvegicus	19-25
33070779-9	2020	CONCLUSION: These results suggested that enhanced interaction between p300 and NFATc2 mediated the epigenetic upregulation of CXCL14 in the spinal dorsal horn, which contributed to the chemotherapeutic paclitaxel-induced chronic pain.	Paclitaxel	202-212	C-X-C motif chemokine ligand 14	Rattus norvegicus	126-132
33087151-13	2020	TAOK3 inhibitor, CP43, and shRNA of NF-kappaB both reduced the paclitaxel resistance in TAOK3 overexpressed cells.	Paclitaxel	63-73	nuclear factor kappa B subunit 1	Homo sapiens	36-45
32682904-3	2020	With Pluronic F127 as the surfactant and hydrophobic paclitaxel (PTX) as the spacer, such HBP molecule would self-assemble to form surfactant-stripped HBP/PTX micelles with absorption peak red-shifted to 1012 nm and intrinsic NIR-II fluorescence negligibly disturbed.	Paclitaxel	53-63	signal transducing adaptor molecule (SH3 domain and ITAM motif) 2	Mus musculus	151-154
32682904-3	2020	With Pluronic F127 as the surfactant and hydrophobic paclitaxel (PTX) as the spacer, such HBP molecule would self-assemble to form surfactant-stripped HBP/PTX micelles with absorption peak red-shifted to 1012 nm and intrinsic NIR-II fluorescence negligibly disturbed.	Paclitaxel	65-68	signal transducing adaptor molecule (SH3 domain and ITAM motif) 2	Mus musculus	90-93
32682904-3	2020	With Pluronic F127 as the surfactant and hydrophobic paclitaxel (PTX) as the spacer, such HBP molecule would self-assemble to form surfactant-stripped HBP/PTX micelles with absorption peak red-shifted to 1012 nm and intrinsic NIR-II fluorescence negligibly disturbed.	Paclitaxel	65-68	signal transducing adaptor molecule (SH3 domain and ITAM motif) 2	Mus musculus	151-154
32682904-3	2020	With Pluronic F127 as the surfactant and hydrophobic paclitaxel (PTX) as the spacer, such HBP molecule would self-assemble to form surfactant-stripped HBP/PTX micelles with absorption peak red-shifted to 1012 nm and intrinsic NIR-II fluorescence negligibly disturbed.	Paclitaxel	155-158	signal transducing adaptor molecule (SH3 domain and ITAM motif) 2	Mus musculus	90-93
32682904-4	2020	We found that such HBP/PTX micelles can be utilized as a bimodal NIR-II nano-probe to enable real-time tracking of lymph nodes and tumors under an NIR-II fluorescence imaging system, as well as clear visualization of tumor microvasculatures under an NIR-II photoacoustic imaging system.	Paclitaxel	23-26	signal transducing adaptor molecule (SH3 domain and ITAM motif) 2	Mus musculus	19-22
32682904-5	2020	Furthermore, together with 1064 nm laser exposure, such HBP/PTX micelles would synergistically suppress the growth of tumors grown on the mice upon tumor accumulation.	Paclitaxel	60-63	signal transducing adaptor molecule (SH3 domain and ITAM motif) 2	Mus musculus	56-59
32643224-4	2020	This PTX-chemogene conjugate can self-assemble into spherical nucleic acid (SNA)-like micellular nanoparticle as a carrier-free DDS, which effectively knocks down the expression of P-glycoprotein first and subsequently releases the FdU and PTX to exert a synergistic antitumor effect and greatly inhibit the tumor growth.	Paclitaxel	5-8	ATP binding cassette subfamily B member 1	Homo sapiens	181-195
33163405-3	2020	Sapitinib significantly increased the efficacy of paclitaxel and doxorubicin in ABCB1 overexpressing cells without altering the expression or the subcellular location of the ABCB1 transporter.	Paclitaxel	50-60	ATP binding cassette subfamily B member 1	Homo sapiens	80-85
33050126-4	2020	Moreover, the A549/T CM-HNPs sensitized MDR cells to PTX by suppressing P-glycoprotein (P-gp) activity by 3.2-fold and induced effective apoptosis (70%) in homologous A549/T cells.	Paclitaxel	53-56	ATP binding cassette subfamily B member 1	Homo sapiens	72-86
33050126-4	2020	Moreover, the A549/T CM-HNPs sensitized MDR cells to PTX by suppressing P-glycoprotein (P-gp) activity by 3.2-fold and induced effective apoptosis (70%) in homologous A549/T cells.	Paclitaxel	53-56	ATP binding cassette subfamily B member 1	Homo sapiens	88-92
33023532-13	2020	Treatment with cisplatin or paclitaxel significantly elevated the expression of TIMP-2 in Cont cells but not in T2-KD cells, consistent with significantly elevated expression of chemoresistance and CSC markers and activation of STAT3.	Paclitaxel	28-38	signal transducer and activator of transcription 3	Homo sapiens	228-233
32643224-4	2020	This PTX-chemogene conjugate can self-assemble into spherical nucleic acid (SNA)-like micellular nanoparticle as a carrier-free DDS, which effectively knocks down the expression of P-glycoprotein first and subsequently releases the FdU and PTX to exert a synergistic antitumor effect and greatly inhibit the tumor growth.	Paclitaxel	240-243	ATP binding cassette subfamily B member 1	Homo sapiens	181-195
33006481-0	2020	CircEXOC6B Suppresses the Proliferation and Motility and Sensitizes Ovarian Cancer Cells to Paclitaxel Through miR-376c-3p/FOXO3 Axis.	Paclitaxel	92-102	forkhead box O3	Homo sapiens	123-128
33006481-17	2020	CircEXOC6B accelerated the PTX sensitivity of ovarian cancer cells through acting as a decoy of miR-376c-3p to upregulate FOXO3 in vivo.	Paclitaxel	27-30	forkhead box O3	Homo sapiens	122-127
31993881-0	2020	The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy.	Paclitaxel	51-56	caspase 1	Homo sapiens	12-21
33019717-0	2020	Specific c-Jun N-Terminal Kinase Inhibitor, JNK-IN-8 Suppresses Mesenchymal Profile of PTX-Resistant MCF-7 Cells through Modulating PI3K/Akt, MAPK and Wnt Signaling Pathways.	Paclitaxel	87-90	mitogen-activated protein kinase 8	Homo sapiens	44-47
33019717-3	2020	The aim of the study was to investigate the functional role of PTX resistance on MCF-7 cell survival and proliferation related to PI3K/Akt and MAPK pathways.	Paclitaxel	63-66	AKT serine/threonine kinase 1	Homo sapiens	135-138
33019717-5	2020	PTX-res MCF-7 cells exhibited increased motility profile with EMT, PI3K/Akt, and MAPK pathway induction.	Paclitaxel	0-3	AKT serine/threonine kinase 1	Homo sapiens	72-75
33019717-6	2020	According to the significant SAPK/JNK activation in PTX-res MCF-7 cells, specific c-Jun N-terminal kinase inhibitor, JNK-IN-8 is shown to suppress the migration potential of cells.	Paclitaxel	52-55	mitogen-activated protein kinase 9	Homo sapiens	29-33
33019717-6	2020	According to the significant SAPK/JNK activation in PTX-res MCF-7 cells, specific c-Jun N-terminal kinase inhibitor, JNK-IN-8 is shown to suppress the migration potential of cells.	Paclitaxel	52-55	mitogen-activated protein kinase 8	Homo sapiens	34-37
33019717-8	2020	However, the JNK inhibitor further downregulated Wnt signaling members in PTX-res MCF-7 cells.	Paclitaxel	74-77	mitogen-activated protein kinase 8	Homo sapiens	13-16
33019717-9	2020	Therefore, the JNK inhibitor JNK-IN-8 might be used as a potential therapy model to reverse PTX-resistance related to Wnt signaling.	Paclitaxel	92-95	mitogen-activated protein kinase 8	Homo sapiens	15-18
33019717-9	2020	Therefore, the JNK inhibitor JNK-IN-8 might be used as a potential therapy model to reverse PTX-resistance related to Wnt signaling.	Paclitaxel	92-95	mitogen-activated protein kinase 8	Homo sapiens	29-32
33024904-9	2021	Significant differences between sirolimus and paclitaxel NPs in anti-proliferation effect under normoxia and hypoxia may due to the different inhibitory effects on HIF-1alpha expression and glycolysis.	Paclitaxel	46-56	hypoxia inducible factor 1 subunit alpha	Homo sapiens	164-174
32930844-8	2020	Simulation based on the developed PK/PD model showed a substantial impact of age and serum albumin level on the time course of neutrophil counts after nab-paclitaxel administration.	Paclitaxel	155-165	albumin	Homo sapiens	91-98
32930844-10	2020	CONCLUSION: We have developed a novel PK/PD model for nab-paclitaxel in which age and serum albumin level were considered clinically important covariate factors.	Paclitaxel	58-68	albumin	Homo sapiens	92-99
31993881-5	2020	In this study, we observed that Taxol treatment caused pyroptotic cell death, along with activation of Caspase-1 and maturation of IL-1beta, as well as cleavage of GSDMD, which is the canonical pyroptosis executor.	Paclitaxel	32-37	caspase 1	Homo sapiens	103-112
31993881-6	2020	Furthermore, Taxol-induced pyroptotic cell death could be suppressed by Caspase-1 inhibitor (Z-YVAD-FMK) and GSDMD knockout.	Paclitaxel	13-18	caspase 1	Homo sapiens	72-81
31993881-7	2020	Moreover, NPC parental cells demonstrated higher levels of pyroptosis than Taxol-resistant cells, and pyroptosis mediated by Caspase-1/GSDMD suppression induced by a Caspase-1 inhibitor and GSDMD knockout could induce a Taxol-resistant phenotype in vitro and in vivo.	Paclitaxel	75-80	caspase 1	Homo sapiens	125-134
31993881-7	2020	Moreover, NPC parental cells demonstrated higher levels of pyroptosis than Taxol-resistant cells, and pyroptosis mediated by Caspase-1/GSDMD suppression induced by a Caspase-1 inhibitor and GSDMD knockout could induce a Taxol-resistant phenotype in vitro and in vivo.	Paclitaxel	220-225	caspase 1	Homo sapiens	125-134
31993881-8	2020	By transfecting an siRNA targeting Beclin-1 into NPC Taxol-resistant cells, we discovered that autophagy could negatively regulate pyroptosis by inhibiting Caspase-1/GSDMD activation.	Paclitaxel	53-58	caspase 1	Homo sapiens	156-165
31993881-9	2020	Taken together, our results indicated that Caspase-1/GSDMD mediated Taxol-induced pyroptosis and a Taxol-resistant phenotype in NPC cell lines, which may be regulated by autophagy.	Paclitaxel	68-73	caspase 1	Homo sapiens	43-52
31993881-9	2020	Taken together, our results indicated that Caspase-1/GSDMD mediated Taxol-induced pyroptosis and a Taxol-resistant phenotype in NPC cell lines, which may be regulated by autophagy.	Paclitaxel	99-104	caspase 1	Homo sapiens	43-52
32447047-8	2020	Intriguingly, paclitaxel stimulation activated the TLR4-NF-kappaB signaling, which was reversed after hyperoside administration.	Paclitaxel	14-24	nuclear factor kappa B subunit 1	Homo sapiens	56-65
32564116-0	2020	ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers.	Paclitaxel	97-107	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
32564116-9	2020	The risk association between ABCB1 c.1236C>T and moderate-to-severe nephrotoxicity following paclitaxel/carboplatin chemotherapy was also present among non-diabetic patients (ORadjusted 2.16; 95% CI 1.22-3.82).	Paclitaxel	93-103	ATP binding cassette subfamily B member 1	Homo sapiens	29-34
32564116-11	2020	CONCLUSIONS: ABCB1 c.1236C>T and ERCC1 c.118C>T might serve as potential biomarkers for the risk of moderate-to-severe toxicities to carboplatin/paclitaxel chemotherapy of gynecological cancers.	Paclitaxel	145-155	ATP binding cassette subfamily B member 1	Homo sapiens	13-18
32447047-9	2020	Concomitantly, hyperoside also attenuated paclitaxel-mediated anti-apoptotic Bcl-2 expression, but enhanced the effects of paclitaxel on pro-apoptotic Bax expression, and pro-inflammatory cytokine IL-6 and IL-6 levels in MDA-MB-231 cells.	Paclitaxel	42-52	BCL2 apoptosis regulator	Homo sapiens	77-82
32447047-9	2020	Concomitantly, hyperoside also attenuated paclitaxel-mediated anti-apoptotic Bcl-2 expression, but enhanced the effects of paclitaxel on pro-apoptotic Bax expression, and pro-inflammatory cytokine IL-6 and IL-6 levels in MDA-MB-231 cells.	Paclitaxel	123-133	BCL2 associated X, apoptosis regulator	Homo sapiens	151-154
32961775-9	2020	ITGBL1-overexpressing cells were significantly more resistant to cisplatin and paclitaxel, major drugs used in OC treatment.	Paclitaxel	79-89	integrin subunit beta like 1	Homo sapiens	0-6
32847971-0	2020	Dysregulation of EAAT2 and VGLUT2 spinal glutamate transports via histone deacetylase 2 (HDAC2) contributes to paclitaxel-induced painful neuropathy.	Paclitaxel	111-121	solute carrier family 1 member 2	Rattus norvegicus	17-22
32847971-3	2020	Paclitaxel (2 mg/kg, i.p., cumulative dose 8mg/kg) induced long-lasting mechanical allodynia (> 28days) with increased glutamate concentration and decreased EAAT2 expression with no changes in GABA/glycine or VGAT (vesicular GABA transporter) in rat spinal dorsal horn.	Paclitaxel	0-10	solute carrier family 1 member 2	Rattus norvegicus	157-162
32594311-12	2020	Multiple comparisons confirmed that PARP expression results in a significant difference in PFS and OS achieved by first-line Taxol-carboplatin chemotherapy.	Paclitaxel	125-130	poly(ADP-ribose) polymerase 1	Homo sapiens	36-40
33061425-0	2020	Paclitaxel Suppresses Hepatocellular Carcinoma Tumorigenesis Through Regulating Circ-BIRC6/miR-877-5p/YWHAZ Axis.	Paclitaxel	0-10	microRNA 877	Homo sapiens	91-98
33061425-12	2020	Paclitaxel treatment inhibited the expression of circ-BIRC6 and YWHAZ while promoted the expression of miR-877-5p.	Paclitaxel	0-10	microRNA 877	Homo sapiens	103-110
33061425-17	2020	Conclusion: Paclitaxel limited HCC tumorigenesis via modulating circ-BIRC6/miR-877-5p/YWHAZ axis, providing a novel therapeutic approach for the treatment of HCC.	Paclitaxel	12-22	microRNA 877	Homo sapiens	75-82
32847971-6	2020	Inhibition or knockdown of HDAC2 expression by valproic acid (VPA), BRD6688 or HDAC2 siRNA (small interfering RNA) not only attenuated paclitaxel-induced mechanical allodynia but also suppressed HDAC2 upregulation, glutamate accumulation and the corresponding changes in EAAT2/VGLUT/synaptophysin expression and HDAC2/YY1 interaction.	Paclitaxel	135-145	solute carrier family 1 member 2	Rattus norvegicus	271-276
32847971-7	2020	These findings indicate that loss of the balance between glutamate release and reuptake due to dysregulation EAAT2/VGLUT2/synaptophysin cascade in the spinal dorsal horn plays an important role in the development of paclitaxel-induced neuropathic pain.	Paclitaxel	216-226	solute carrier family 1 member 2	Rattus norvegicus	109-114
32863924-4	2020	The present study observed that CHL1 was significantly downregulated in cisplatin (DDP)-resistant cells (A549/DDP) and paclitaxel (PTX)-resistant cells (A549/PTX) compared with A549 cells.	Paclitaxel	119-129	cell adhesion molecule L1 like	Homo sapiens	32-36
32863924-4	2020	The present study observed that CHL1 was significantly downregulated in cisplatin (DDP)-resistant cells (A549/DDP) and paclitaxel (PTX)-resistant cells (A549/PTX) compared with A549 cells.	Paclitaxel	131-134	cell adhesion molecule L1 like	Homo sapiens	32-36
32863924-4	2020	The present study observed that CHL1 was significantly downregulated in cisplatin (DDP)-resistant cells (A549/DDP) and paclitaxel (PTX)-resistant cells (A549/PTX) compared with A549 cells.	Paclitaxel	158-161	cell adhesion molecule L1 like	Homo sapiens	32-36
32863924-5	2020	When treated with or without DDP and PTX, silencing of CHL1 in A549 cells promoted the cell survival rate and clone formation, and decreased apoptosis.	Paclitaxel	37-40	cell adhesion molecule L1 like	Homo sapiens	55-59
33024896-6	2021	Subsequently, anti-HER2 antibody conjugated paclitaxel-loaded liposomes were used for HER2-targeted drug delivery.	Paclitaxel	44-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
33024896-6	2021	Subsequently, anti-HER2 antibody conjugated paclitaxel-loaded liposomes were used for HER2-targeted drug delivery.	Paclitaxel	44-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
32251770-2	2020	After verifying combination of chemotherapy drug paclitaxel (PTX) and TRAIL could significantly enhance their anti-melanoma effects, we developed a liposomal melanoma target-delivery system with tumor microenvironment responsiveness (TRAIL-[Lip-PTX]C18-TR) to co-deliver TRAIL and PTX.	Paclitaxel	61-64	TNF superfamily member 10	Homo sapiens	234-239
32603693-0	2020	JTC-801 alleviates mechanical allodynia in paclitaxel-induced neuropathic pain through the PI3K/Akt pathway.	Paclitaxel	43-53	AKT serine/threonine kinase 1	Rattus norvegicus	96-99
32603693-6	2020	Using Western blot analysis and immunohistochemistry, we found that paclitaxel increased the expression of phosphatidylinositol 3-kinase (PI3K) and phospho-Akt (p-Akt) in the DRG.	Paclitaxel	68-78	AKT serine/threonine kinase 1	Rattus norvegicus	156-159
32603693-6	2020	Using Western blot analysis and immunohistochemistry, we found that paclitaxel increased the expression of phosphatidylinositol 3-kinase (PI3K) and phospho-Akt (p-Akt) in the DRG.	Paclitaxel	68-78	AKT serine/threonine kinase 1	Rattus norvegicus	163-166
32603693-9	2020	The data suggest that JTC-801 alleviates mechanical allodynia associated with paclitaxel-induced neuropathic pain via the PI3K/Akt pathway.	Paclitaxel	78-88	AKT serine/threonine kinase 1	Rattus norvegicus	127-130
32928102-6	2020	Escalated expression of OLA1 resulted in a reduced ability of metastasis in highly metastatic cells, and enhanced its sensitivity to the paclitaxel treatment.	Paclitaxel	137-147	Obg like ATPase 1	Homo sapiens	24-28
32251770-2	2020	After verifying combination of chemotherapy drug paclitaxel (PTX) and TRAIL could significantly enhance their anti-melanoma effects, we developed a liposomal melanoma target-delivery system with tumor microenvironment responsiveness (TRAIL-[Lip-PTX]C18-TR) to co-deliver TRAIL and PTX.	Paclitaxel	49-59	TNF superfamily member 10	Homo sapiens	234-239
32251770-2	2020	After verifying combination of chemotherapy drug paclitaxel (PTX) and TRAIL could significantly enhance their anti-melanoma effects, we developed a liposomal melanoma target-delivery system with tumor microenvironment responsiveness (TRAIL-[Lip-PTX]C18-TR) to co-deliver TRAIL and PTX.	Paclitaxel	49-59	TNF superfamily member 10	Homo sapiens	234-239
32251770-2	2020	After verifying combination of chemotherapy drug paclitaxel (PTX) and TRAIL could significantly enhance their anti-melanoma effects, we developed a liposomal melanoma target-delivery system with tumor microenvironment responsiveness (TRAIL-[Lip-PTX]C18-TR) to co-deliver TRAIL and PTX.	Paclitaxel	61-64	TNF superfamily member 10	Homo sapiens	234-239
32251770-2	2020	After verifying combination of chemotherapy drug paclitaxel (PTX) and TRAIL could significantly enhance their anti-melanoma effects, we developed a liposomal melanoma target-delivery system with tumor microenvironment responsiveness (TRAIL-[Lip-PTX]C18-TR) to co-deliver TRAIL and PTX.	Paclitaxel	245-248	TNF superfamily member 10	Homo sapiens	70-75
32251770-5	2020	TRAIL-[Lip-PTX]C18-TR displayed significantly better in vitro half-maximal inhibitory concentration (IC50) than other formulations, and an in vivo tumor inhibition rate of 93.8%.	Paclitaxel	10-14	TNF superfamily member 10	Homo sapiens	0-5
33072537-0	2020	Restoring of miR-193a-5p Sensitizes Breast Cancer Cells to Paclitaxel through P53 Pathway.	Paclitaxel	59-69	tumor protein p53	Homo sapiens	78-81
32911509-5	2020	The addition of carbachol or arecaidine propargyl ester, a non-selective or a selective subtype 2 muscarinic receptor agonist respectively, plus paclitaxel reduces cell viability involving a down-regulation in the expression of ATP "binding cassette" G2 drug transporter and epidermal growth factor receptor.	Paclitaxel	145-155	epidermal growth factor receptor	Homo sapiens	275-307
32943934-8	2020	Moxibustion combined with paclitaxel increased the number of white blood cells, thymus index, and spleen index, and enhanced immune function by upregulating interferon-gamma and interleukin-2 and downregulating interleukin-10 and transforming growth factor-beta1.	Paclitaxel	26-36	interferon gamma	Mus musculus	157-173
32943934-8	2020	Moxibustion combined with paclitaxel increased the number of white blood cells, thymus index, and spleen index, and enhanced immune function by upregulating interferon-gamma and interleukin-2 and downregulating interleukin-10 and transforming growth factor-beta1.	Paclitaxel	26-36	interleukin 10	Mus musculus	211-225
32943934-9	2020	Notably, moxibustion combined with paclitaxel inhibited the angiogenesis of tumors through the downregulation of CD34, HIF-1alpha, and VEGFA, and overcame the immunosuppressive microenvironment by inhibiting the PD-1/PD-L1 signaling pathway.	Paclitaxel	35-45	programmed cell death 1	Mus musculus	212-216
32943934-9	2020	Notably, moxibustion combined with paclitaxel inhibited the angiogenesis of tumors through the downregulation of CD34, HIF-1alpha, and VEGFA, and overcame the immunosuppressive microenvironment by inhibiting the PD-1/PD-L1 signaling pathway.	Paclitaxel	35-45	CD274 antigen	Mus musculus	217-222
33042272-9	2020	By contrast, pharmacological inhibition of JAK1/2 by ruxolitinib reversed paclitaxel resistance both in vitro and in vivo.	Paclitaxel	74-84	Janus kinase 1	Homo sapiens	43-49
32887626-4	2020	GA not only overcame the multidrug resistance of PTX by inhibiting P-glycoprotein (P-gp) activity in MCF-7/ADR cells, but also inhibited MDA-MB-231 cells migration and invasion, playing a crucial role in preventing and treating the lung metastasis of breast cancer caused by PTX; meanwhile, the synergistic anti-tumor effect of GA and PTX has also been verified in vitro and in vivo experiments.	Paclitaxel	49-52	ATP binding cassette subfamily B member 1	Homo sapiens	67-81
32887626-4	2020	GA not only overcame the multidrug resistance of PTX by inhibiting P-glycoprotein (P-gp) activity in MCF-7/ADR cells, but also inhibited MDA-MB-231 cells migration and invasion, playing a crucial role in preventing and treating the lung metastasis of breast cancer caused by PTX; meanwhile, the synergistic anti-tumor effect of GA and PTX has also been verified in vitro and in vivo experiments.	Paclitaxel	49-52	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
33072537-4	2020	Therefore, the aim of this study was to evaluate the potential function of miR-193a-5p and paclitaxel in the apoptosis induction by targeting P53 in BC cells.	Paclitaxel	91-101	tumor protein p53	Homo sapiens	142-145
32535388-0	2020	PPARgamma activation mitigates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of Nrf2/HO-1 signaling pathway.	Paclitaxel	55-65	NFE2 like bZIP transcription factor 2	Rattus norvegicus	108-112
32569926-3	2020	These P-gp inhibitors were dramatically effective than verapamil in sensitizing the human ABCB1-overexpressing ABCB1/Flp-In -293 cells and MDR KBvin cells to a series of chemotherapeutic agents, including vincristine and paclitaxel, as manifested by multi-fold decreases in the respective IC50 values to therapeutically attainable levels.	Paclitaxel	221-231	ATP binding cassette subfamily B member 1	Homo sapiens	6-10
32768937-10	2020	Specifically we found the expression of E-cadherin was significantly increased in A549 cultures pretreated with AUY922 prior to exposure to paclitaxel, while expression of the drug transporters ABCB1 and ABCC1 was significantly reduced under similar conditions.	Paclitaxel	140-150	cadherin 1	Homo sapiens	40-50
31548657-0	2020	Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer.	Paclitaxel	83-93	CEA cell adhesion molecule 3	Homo sapiens	46-49
31548657-11	2020	Our results suggest that the CEA promoter is an excellent candidate for directing E gene expression specifically towards lung cancer cells, and may be used to enhance the effectiveness of PTX against this type of tumor.	Paclitaxel	188-191	CEA cell adhesion molecule 3	Homo sapiens	29-32
32275773-0	2020	P-glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Cancer Patients.	Paclitaxel	38-48	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
32275773-2	2020	The role of P-glycoprotein (P-gp) in the neuronal efflux of paclitaxel was assessed using a translational approach.	Paclitaxel	60-70	ATP binding cassette subfamily B member 1	Homo sapiens	12-26
32275773-2	2020	The role of P-glycoprotein (P-gp) in the neuronal efflux of paclitaxel was assessed using a translational approach.	Paclitaxel	60-70	ATP binding cassette subfamily B member 1	Homo sapiens	28-32
32275773-5	2020	Paclitaxel neurotoxicity was exacerbated with concomitant P-gp inhibition by valspodar and verapamil, consistent with increased intracellular accumulation of paclitaxel.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
32275773-6	2020	Cancer patients treated with paclitaxel and P-gp inhibitors had a 2.4-fold (95% confidence interval (CI): 1.3-4.3) increased risk of peripheral neuropathy-induced dose modification, a 4.7-fold (95% CI: 1.9-11.9) increased risk for patients treated with strong P-gp inhibitors and a 7.0-fold (95% CI: 2.3-21.5) increased risk in patients treated with atorvastatin.	Paclitaxel	29-39	ATP binding cassette subfamily B member 1	Homo sapiens	260-264
32569926-3	2020	These P-gp inhibitors were dramatically effective than verapamil in sensitizing the human ABCB1-overexpressing ABCB1/Flp-In -293 cells and MDR KBvin cells to a series of chemotherapeutic agents, including vincristine and paclitaxel, as manifested by multi-fold decreases in the respective IC50 values to therapeutically attainable levels.	Paclitaxel	221-231	ATP binding cassette subfamily B member 1	Homo sapiens	90-95
32671412-2	2020	Here, we found that the endogenous expression of TNFSF13 in a panel of TNBC cell lines highly correlates with paclitaxel (PTX) and doxorubicin IC50 concentrations.	Paclitaxel	110-120	TNF superfamily member 13	Homo sapiens	49-56
32427586-4	2020	Paclitaxel induces HIF-1-dependent expression of S100A10, which forms a complex with ANXA2 that interacts with histone chaperone SPT6 and histone demethylase KDM6A.	Paclitaxel	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	19-24
32427586-4	2020	Paclitaxel induces HIF-1-dependent expression of S100A10, which forms a complex with ANXA2 that interacts with histone chaperone SPT6 and histone demethylase KDM6A.	Paclitaxel	0-10	S100 calcium binding protein A10	Homo sapiens	49-56
32427586-4	2020	Paclitaxel induces HIF-1-dependent expression of S100A10, which forms a complex with ANXA2 that interacts with histone chaperone SPT6 and histone demethylase KDM6A.	Paclitaxel	0-10	lysine demethylase 6A	Homo sapiens	158-163
32401077-7	2020	PTX + SPS-NEs increased the release of NO, IL-6 and TNF-alpha, and the expression of p-p65 NF-kappaB, p-I-kappaB, TLR4.	Paclitaxel	0-3	interleukin 6	Mus musculus	43-47
32401077-7	2020	PTX + SPS-NEs increased the release of NO, IL-6 and TNF-alpha, and the expression of p-p65 NF-kappaB, p-I-kappaB, TLR4.	Paclitaxel	0-3	tumor necrosis factor	Mus musculus	52-61
32401077-7	2020	PTX + SPS-NEs increased the release of NO, IL-6 and TNF-alpha, and the expression of p-p65 NF-kappaB, p-I-kappaB, TLR4.	Paclitaxel	0-3	toll-like receptor 4	Mus musculus	114-118
32401077-8	2020	In addition, PTX + SPS-NEs significantly inhibited tumor growth by 72.82% and increased the secretion of serum IL-2, TNF-alpha and IFN-gamma.	Paclitaxel	13-16	tumor necrosis factor	Mus musculus	117-126
32671412-2	2020	Here, we found that the endogenous expression of TNFSF13 in a panel of TNBC cell lines highly correlates with paclitaxel (PTX) and doxorubicin IC50 concentrations.	Paclitaxel	122-125	TNF superfamily member 13	Homo sapiens	49-56
32401077-8	2020	In addition, PTX + SPS-NEs significantly inhibited tumor growth by 72.82% and increased the secretion of serum IL-2, TNF-alpha and IFN-gamma.	Paclitaxel	13-16	interferon gamma	Mus musculus	131-140
32401077-9	2020	Conclusions: SPS-NEs can regulate immunity through TLR4/NF-kappaB signaling pathways, which enhances the anti-tumor effect of PTX.	Paclitaxel	126-129	toll-like receptor 4	Mus musculus	51-55
32671412-3	2020	Whereas knocking down TNFSF13 enhances PTX effectiveness in PTX-insensitive MDA-MB231 cells, recombinant TNFSF13 (recTNFSF13) desensitizes PTX-sensitive HCC1806 cells to PTX treatment.	Paclitaxel	39-42	TNF superfamily member 13	Homo sapiens	22-29
32671412-7	2020	Significantly, the pharmaceutical inhibition of autophagy activity restores the therapeutic effectiveness of PTX in TNFSF13-treated HCC1806 cells.	Paclitaxel	109-112	TNF superfamily member 13	Homo sapiens	116-123
32872293-5	2020	We found that HL156A inhibited the expression of MDR1 by inhibiting the HOXC6-mediated ERK1/2 signaling pathway and increased the sensitivity to paclitaxel or doxorubicin in MDR cells.	Paclitaxel	145-155	ATP binding cassette subfamily B member 1	Homo sapiens	49-53
32333719-3	2020	Here, we show that LIN28A is SUMOylated in vivo and in vitro at K15, which is increased by hypoxia but reduced by chemotherapy drugs such as Cisplatin and Paclitaxel.	Paclitaxel	155-165	lin-28 homolog A	Homo sapiens	19-25
32705214-0	2020	A small molecule STAT3 inhibitor, LLL12, enhances cisplatin- and paclitaxel-mediated inhibition of cell growth and migration in human ovarian cancer cells.	Paclitaxel	65-75	signal transducer and activator of transcription 3	Homo sapiens	17-22
32705214-3	2020	As previously reported, persistent STAT3 signaling is associated with resistance to cisplatin and paclitaxel.	Paclitaxel	98-108	signal transducer and activator of transcription 3	Homo sapiens	35-40
32705214-4	2020	To investigate whether the STAT3 small molecule inhibitor LLL12 can enhance the treatment effect of cisplatin and paclitaxel in ovarian cancer cells, A2780, SKOV3, CAOV-3 and OVCAR5 cells were treated with LLL12, cisplatin and paclitaxel, alone or combination, and cell viability, cell migration, cell growth and protein expression levels were then evaluated.	Paclitaxel	114-124	signal transducer and activator of transcription 3	Homo sapiens	27-32
32705214-9	2020	Combining LLL12 with cisplatin or paclitaxel may be a viable therapeutic approach in the treatment of patients with ovarian cancer exhibiting persistent STAT3 signaling.	Paclitaxel	34-44	signal transducer and activator of transcription 3	Homo sapiens	153-158
32843422-1	2020	A 44-year-old woman diagnosed with a HER2 positive early breast cancer, receiving neoadjuvant treatment with paclitaxel and targeted agents, trastuzumab together with pertuzumab, presented to the emergency room with gait instability and upper right limb weakness.	Paclitaxel	109-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-41
32984343-3	2020	Previous, we uncovered that the Bruton"s tyrosine kinase (BTK) inhibitor ibrutinib is a potent reversal agent to overcomes paclitaxel resistance in ABCB1-overexpressing cells and tumors.	Paclitaxel	123-133	ATP binding cassette subfamily B member 1	Homo sapiens	148-153
32984343-5	2020	We found that RN486 significantly increased the efficacy of paclitaxel and doxorubicin in both drug-selected carcinoma cells and transfected cells overexpressing ABCB1.	Paclitaxel	60-70	ATP binding cassette subfamily B member 1	Homo sapiens	162-167
32829374-0	2020	Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.	Paclitaxel	11-21	mitogen-activated protein kinase 14	Homo sapiens	66-102
32829374-0	2020	Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.	Paclitaxel	41-51	mitogen-activated protein kinase 14	Homo sapiens	66-102
32829374-0	2020	Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.	Paclitaxel	137-142	mitogen-activated protein kinase 14	Homo sapiens	66-102
32829374-8	2020	RESULTS Octreotide-paclitaxel conjugate inhibited phosphorylation of the p38MAPK signal pathway, decreased the expression of downstream VEGF, and increased the apoptosis of drug-resistant cancer cells.	Paclitaxel	19-29	vascular endothelial growth factor A	Homo sapiens	136-140
32848392-5	2020	We designed a dual-functional targeting delivery system by modifying paclitaxel (PTX)-loaded PEGylation bovine serum albumin (BSA) nanoparticles (NPs) with AMD3100 (AMD-NP-PTX), which can not only achieve specific tumor-targeting efficiency but also enhance the therapeutic outcomes.	Paclitaxel	69-79	albumin	Homo sapiens	111-124
32663002-4	2020	The final two sp3 C-H oxidations at C-1 and C-7 were attained by dioxirane-mediated C-H oxidation and an oxidation relay based on judicious substrate design, culminating in a two-phase synthesis of Taxol .	Paclitaxel	198-203	Sp3 transcription factor	Homo sapiens	14-17
32497533-8	2020	Therapeutically, co-treatment with LCL161 at low cytotoxic concentrations restored the sensitivity to the known ABCB1 substrate, paclitaxel, in ABCB1-expressing cancer cells and increased the sensitivity to tamoxifen in MCF7-TamC3 cells.	Paclitaxel	129-139	ATP binding cassette subfamily B member 1	Homo sapiens	112-117
32497533-8	2020	Therapeutically, co-treatment with LCL161 at low cytotoxic concentrations restored the sensitivity to the known ABCB1 substrate, paclitaxel, in ABCB1-expressing cancer cells and increased the sensitivity to tamoxifen in MCF7-TamC3 cells.	Paclitaxel	129-139	ATP binding cassette subfamily B member 1	Homo sapiens	144-149
32806533-7	2020	Key glycolytic enzymes such as hexokinase, lactate dehydrogenase, and enolase are upregulated, thereby conferring resistance towards drugs such as cisplatin, paclitaxel, tamoxifen, and doxorubicin.	Paclitaxel	158-168	hexokinase 1	Homo sapiens	31-41
32848392-5	2020	We designed a dual-functional targeting delivery system by modifying paclitaxel (PTX)-loaded PEGylation bovine serum albumin (BSA) nanoparticles (NPs) with AMD3100 (AMD-NP-PTX), which can not only achieve specific tumor-targeting efficiency but also enhance the therapeutic outcomes.	Paclitaxel	81-84	albumin	Homo sapiens	111-124
32848392-13	2020	We also confirmed that AMD-NP-PTX worked through targeting CXCL12/CXCR4 axis, thereby disturbing its downstream signaling pathways including epithelial-mesenchymal transition (EMT) processes and nuclear factor kappaB (NF-kappaB) pathway.	Paclitaxel	30-33	nuclear factor kappa B subunit 1	Homo sapiens	218-227
32203087-0	2020	Nrf2 activation ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain.	Paclitaxel	52-62	NFE2 like bZIP transcription factor 2	Rattus norvegicus	0-4
32903706-5	2020	In ABCB1-overexpressing cells, nontoxic dose of peptide HX-12C inhibited drug resistance and increased the effective intracellular concentration of paclitaxel and other ABCB1 substrate drugs.	Paclitaxel	148-158	ATP binding cassette subfamily B member 1	Homo sapiens	3-8
32632453-4	2020	Here, we established two paclitaxel (PTX)-resistant TNBC cancer cell lines using an intermittent and stepwise method and found that long non-coding RNA long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT) was significantly decreased in PTX-resistant cancer cells.	Paclitaxel	25-35	tumor protein p53	Homo sapiens	191-194
32632453-4	2020	Here, we established two paclitaxel (PTX)-resistant TNBC cancer cell lines using an intermittent and stepwise method and found that long non-coding RNA long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT) was significantly decreased in PTX-resistant cancer cells.	Paclitaxel	37-40	tumor protein p53	Homo sapiens	191-194
32601971-2	2020	Here, we identified the role of an RNA-binding protein, CUG-BP Elav-like family member 6 (CELF6), in the TNBC development and paclitaxel (PTX) chemoresistance.	Paclitaxel	126-136	CUGBP Elav-like family member 6	Homo sapiens	56-88
31967866-0	2020	Reversal of P-Glycoprotein-Mediated Multidrug Resistance by Novel Curcumin Analogues in Paclitaxel-resistant Human Breast Cancer Cells.	Paclitaxel	88-98	ATP binding cassette subfamily B member 1	Homo sapiens	12-26
32535103-7	2020	Interestingly, we found that the upregulation of G6PD in paclitaxel-resistant cells was due to the decreased expression of protein arginine methyltransferase 6 (PRMT6), which targets the promoter of G6PD.	Paclitaxel	57-67	protein arginine methyltransferase 6	Homo sapiens	123-159
32535103-7	2020	Interestingly, we found that the upregulation of G6PD in paclitaxel-resistant cells was due to the decreased expression of protein arginine methyltransferase 6 (PRMT6), which targets the promoter of G6PD.	Paclitaxel	57-67	protein arginine methyltransferase 6	Homo sapiens	161-166
32354736-0	2020	Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis.	Paclitaxel	0-10	small NF90 (ILF3) associated RNA E	Homo sapiens	74-79
32601971-2	2020	Here, we identified the role of an RNA-binding protein, CUG-BP Elav-like family member 6 (CELF6), in the TNBC development and paclitaxel (PTX) chemoresistance.	Paclitaxel	126-136	CUGBP Elav-like family member 6	Homo sapiens	90-95
32601971-2	2020	Here, we identified the role of an RNA-binding protein, CUG-BP Elav-like family member 6 (CELF6), in the TNBC development and paclitaxel (PTX) chemoresistance.	Paclitaxel	138-141	CUGBP Elav-like family member 6	Homo sapiens	56-88
32601971-2	2020	Here, we identified the role of an RNA-binding protein, CUG-BP Elav-like family member 6 (CELF6), in the TNBC development and paclitaxel (PTX) chemoresistance.	Paclitaxel	138-141	CUGBP Elav-like family member 6	Homo sapiens	90-95
32601971-7	2020	Additionally, the PTX resistant cell line was established to determine the role of CELF6 in PTX resistance.	Paclitaxel	92-95	CUGBP Elav-like family member 6	Homo sapiens	83-88
32743678-0	2020	HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.	Paclitaxel	16-26	checkpoint kinase 1	Homo sapiens	52-57
32601971-11	2020	Moreover, CELF6 overexpression increased the sensitivity to PTX treatment.	Paclitaxel	60-63	CUGBP Elav-like family member 6	Homo sapiens	10-15
32743678-12	2020	Strikingly, our results also revealed that HOTAIR plays a regulatory role in the expression of checkpoint kinase 1 (CHEK1), and that the restored paclitaxel sensitivity through knockdown of HOTAIR can be weakened by CHEK1 up-regulation.	Paclitaxel	146-156	checkpoint kinase 1	Homo sapiens	95-114
32501121-0	2020	Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients.	Paclitaxel	27-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
32743678-12	2020	Strikingly, our results also revealed that HOTAIR plays a regulatory role in the expression of checkpoint kinase 1 (CHEK1), and that the restored paclitaxel sensitivity through knockdown of HOTAIR can be weakened by CHEK1 up-regulation.	Paclitaxel	146-156	checkpoint kinase 1	Homo sapiens	116-121
32743678-12	2020	Strikingly, our results also revealed that HOTAIR plays a regulatory role in the expression of checkpoint kinase 1 (CHEK1), and that the restored paclitaxel sensitivity through knockdown of HOTAIR can be weakened by CHEK1 up-regulation.	Paclitaxel	146-156	checkpoint kinase 1	Homo sapiens	216-221
32743678-13	2020	Consistently, in vivo data confirmed that the therapeutic efficacy of paclitaxel can be enhanced through down-regulation of HOTAIR, and that CHEK1 is the down-stream target of HOTAIR in inducing paclitaxel resistance.	Paclitaxel	195-205	checkpoint kinase 1	Homo sapiens	141-146
32743678-14	2020	CONCLUSION: HOTAIR confers paclitaxel resistance in epithelial ovarian cancer by increasing the protein level of CHEK1.	Paclitaxel	27-37	checkpoint kinase 1	Homo sapiens	113-118
32594651-0	2020	Paclitaxel induces apoptosis through the TAK1-JNK activation pathway.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	46-49
32594651-2	2020	PTX-induced apoptosis is associated with p38 MAPK, ERK, NF-kappaB and JNK/ SAPK pathway.	Paclitaxel	0-3	mitogen-activated protein kinase 1	Homo sapiens	51-54
32594651-2	2020	PTX-induced apoptosis is associated with p38 MAPK, ERK, NF-kappaB and JNK/ SAPK pathway.	Paclitaxel	0-3	nuclear factor kappa B subunit 1	Homo sapiens	56-65
32594651-2	2020	PTX-induced apoptosis is associated with p38 MAPK, ERK, NF-kappaB and JNK/ SAPK pathway.	Paclitaxel	0-3	mitogen-activated protein kinase 8	Homo sapiens	70-73
32353410-7	2020	Besides, we found that FNDC5 increased paclitaxel chemosensitivity in paclitaxel-sensitive or resistant NSCLCs cell lines via downregulating multidrug resistance protein 1 (MDR1).	Paclitaxel	70-80	ATP binding cassette subfamily B member 1	Homo sapiens	173-177
32353410-9	2020	FNDC5 promotes paclitaxel sensitivity of NSCLCs cells via inhibiting NF-kappaB/MDR1 signaling, and FNDC5 might be a novel therapeutic target for the treatment of NSCLCs.	Paclitaxel	15-25	ATP binding cassette subfamily B member 1	Homo sapiens	79-83
32594651-8	2020	CRISPR-editing of the tak1 gene upon PTX treatment resulted in lower phospho-JNK and PARP cleavage levels than in cells transfected with the control or the TAK1- or TAB1 + TAK1-containing plasmids.	Paclitaxel	37-40	mitogen-activated protein kinase 8	Homo sapiens	77-80
32594651-8	2020	CRISPR-editing of the tak1 gene upon PTX treatment resulted in lower phospho-JNK and PARP cleavage levels than in cells transfected with the control or the TAK1- or TAB1 + TAK1-containing plasmids.	Paclitaxel	37-40	poly(ADP-ribose) polymerase 1	Homo sapiens	85-89
32594651-10	2020	We conclude that PTX induces HEK293 and 8305C cell apoptosis through the TAK1-JNK activation pathway, potentially highlighting TAK1"s role in chemosensitivity.	Paclitaxel	17-20	mitogen-activated protein kinase 8	Homo sapiens	78-81
32652877-0	2020	LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPbeta.	Paclitaxel	19-29	long intergenic non-protein coding RNA 160	Homo sapiens	0-9
32211849-7	2020	Mechanically, SDHAP1 upregulated the expression of EIF4G2 by sponging miR-4465 and thus facilitated the PTX-induced apoptosis in ovarian cancer cells.	Paclitaxel	104-107	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	51-57
32211849-8	2020	The regulation network involving SDHAP1, miR-4465 and EIF4G2 could be a potential therapy target for the PTX-resistant ovarian cancer.	Paclitaxel	105-108	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	54-60
32211849-0	2020	LncRNA SDHAP1 confers paclitaxel resistance of ovarian cancer by regulating EIF4G2 expression via miR-4465.	Paclitaxel	22-32	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	76-82
32652877-0	2020	LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPbeta.	Paclitaxel	19-29	trefoil factor 3	Homo sapiens	94-98
32652877-0	2020	LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPbeta.	Paclitaxel	19-29	CCAAT enhancer binding protein alpha	Homo sapiens	124-133
32652877-2	2020	This study aimed to probe the roles of LINC00160 in paclitaxel- and doxorubicin-resistant BC cells.	Paclitaxel	52-62	long intergenic non-protein coding RNA 160	Homo sapiens	39-48
32652877-5	2020	Correlation between LINC00160 expression and clinical response to paclitaxel in BC patients was examined.	Paclitaxel	66-76	long intergenic non-protein coding RNA 160	Homo sapiens	20-29
32652877-9	2020	Consequently, up-regulated LINC00160 led to poor clinical response to paclitaxel in BC patients.	Paclitaxel	70-80	long intergenic non-protein coding RNA 160	Homo sapiens	27-36
33132430-0	2020	Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study.	Paclitaxel	117-127	albumin	Homo sapiens	103-110
33132430-3	2020	Nanoparticle albumin-bound paclitaxel (nab-PTX) is a solvent-free formulation that can be delivered to cancer cells at higher doses than conventional PTX.	Paclitaxel	27-37	albumin	Homo sapiens	13-20
33132430-3	2020	Nanoparticle albumin-bound paclitaxel (nab-PTX) is a solvent-free formulation that can be delivered to cancer cells at higher doses than conventional PTX.	Paclitaxel	43-46	albumin	Homo sapiens	13-20
32700738-0	2020	LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a.	Paclitaxel	26-31	AKT serine/threonine kinase 1	Homo sapiens	92-95
32700738-7	2020	Besides, HOTAIR knockdown impaired Taxol-resistance in HCC by accommodating Akt phosphorylation and Wnt/beta-catenin signaling via interacting with miR-34a.	Paclitaxel	35-40	AKT serine/threonine kinase 1	Homo sapiens	76-79
32720079-0	2020	Correction to: EGFR Targeted Paclitaxel and Piperine Co-loaded Liposomes for the Treatment of Triple Negative Breast Cancer.	Paclitaxel	29-39	epidermal growth factor receptor	Homo sapiens	15-19
32760845-9	2020	Results: Application of formulated dermal gel to paclitaxel-treated rats significantly improved paw-withdrawal latency responses during noxious stimulus testing, reduced the levels of TBARS, TNF-alpha, IL-6 and elevated the levels of reduced GSH as compared to paclitaxel treated rats.	Paclitaxel	49-59	tumor necrosis factor	Rattus norvegicus	191-200
32536602-3	2020	We previously reported that TEC resist paclitaxel treatment via upregulation of ABCB1.	Paclitaxel	39-49	ATP binding cassette subfamily B member 1	Homo sapiens	80-85
32536602-10	2020	In vivo, the ABCB1 inhibitor combined with paclitaxel reduced tumor growth and metastasis compared with paclitaxel alone.	Paclitaxel	104-114	ATP binding cassette subfamily B member 1	Homo sapiens	13-18
32722340-0	2020	TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy.	Paclitaxel	124-134	tumor protein p53	Homo sapiens	0-4
32722340-6	2020	In the Ramucirumab/Paclitaxel group, 29/48 (60.4%) patients had TP53 mutations.	Paclitaxel	19-29	tumor protein p53	Homo sapiens	64-68
32704014-6	2020	The alpelisib and paclitaxel combination demonstrated synergistic anti-proliferative effects, preferentially on PIK3CA-mutant cells, resulting in increased DNA damage response and apoptosis.	Paclitaxel	18-28	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	112-118
32704014-7	2020	In addition, alpelisib and paclitaxel combination potentiated anti-migratory activity in PIK3CA-mutant cells.	Paclitaxel	27-37	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	89-95
32704014-11	2020	Our data suggest promising anti-tumor efficacy of alpelisib alone or in combination with paclitaxel in PIK3CA-mutant GC cells.	Paclitaxel	89-99	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Mus musculus	103-109
32707710-4	2020	In this article, we investigated several novel antimicrobial peptides to see if they could sensitize ABCB1-overexpressing cells to the anticancer drugs paclitaxel and doxorubicin, which are transported by ABCB1.	Paclitaxel	152-162	ATP binding cassette subfamily B member 1	Homo sapiens	101-106
32707710-4	2020	In this article, we investigated several novel antimicrobial peptides to see if they could sensitize ABCB1-overexpressing cells to the anticancer drugs paclitaxel and doxorubicin, which are transported by ABCB1.	Paclitaxel	152-162	ATP binding cassette subfamily B member 1	Homo sapiens	205-210
32707710-5	2020	It was found that peptide XH-14C increased the intracellular accumulation of ABCB1 substrate paclitaxel, which demonstrated that XH-14C could reverse ABCB1-mediated MDR.	Paclitaxel	93-103	ATP binding cassette subfamily B member 1	Homo sapiens	77-82
32707710-5	2020	It was found that peptide XH-14C increased the intracellular accumulation of ABCB1 substrate paclitaxel, which demonstrated that XH-14C could reverse ABCB1-mediated MDR.	Paclitaxel	93-103	ATP binding cassette subfamily B member 1	Homo sapiens	150-155
32760845-9	2020	Results: Application of formulated dermal gel to paclitaxel-treated rats significantly improved paw-withdrawal latency responses during noxious stimulus testing, reduced the levels of TBARS, TNF-alpha, IL-6 and elevated the levels of reduced GSH as compared to paclitaxel treated rats.	Paclitaxel	49-59	interleukin 6	Rattus norvegicus	202-206
32278794-0	2020	Role of the TLR4-androgen receptor axis and genistein in taxol-resistant ovarian cancer cells.	Paclitaxel	57-62	androgen receptor	Homo sapiens	17-34
33463352-7	2020	In summary, the results of this study revealed that US-MB-mediated codelivery of SIK2 siRNA, and anti-miR21 encapsulated in a folate-lipid-PLGA hybrid polymer nanoparticle could significantly improve the sensitivity of EOC tumors to PTX and is a highly effective approach for treating EOC in complementary experiments.	Paclitaxel	233-236	salt inducible kinase 2	Homo sapiens	81-85
32733972-11	2020	Further, SHP enhanced the stimulation efficiency of PTX on TLR4 and its downstream cytokines, as well as on IL-1beta in intestinal cells.	Paclitaxel	52-55	toll-like receptor 4	Mus musculus	59-63
32733972-13	2020	Hence, these results provide evidence that SHP alleviates PTX-induced constipation and intestinal morphological damage but augments the effects of PTX on the expression of cytokines in the TLR4 pathway and IL-1beta.	Paclitaxel	147-150	toll-like receptor 4	Mus musculus	189-193
32724476-11	2020	However, this antitumor immunity was hampered by highly expressed PD-1 on tumor-infiltrating CD8+ T cells and upregulated PD-L1 on both immune cells and tumor cells after nano-PTX treatment.	Paclitaxel	176-179	CD274 molecule	Sus scrofa	122-127
32724476-13	2020	Conclusions: Our results provide systemic insights into the immune-regulation ability of PTX to induce ICD, which acts as an inducer of endogenous vaccines through ICD effects, and also provides an experimental basis for clinical combination therapy with nano-PTX and PD-1 antibodies.	Paclitaxel	89-92	MHC class I antigen 1	Sus scrofa	268-272
32278794-8	2020	We also observed that genistein inhibits AR activation, leading to suppression of AR-driven genes and reduced taxol resistance in ovarian cancer cells.	Paclitaxel	110-115	androgen receptor	Homo sapiens	41-43
32278794-9	2020	Overall, we identified six TLR4- and AR-regulated genes involved in taxol resistance.	Paclitaxel	68-73	androgen receptor	Homo sapiens	37-39
32278794-4	2020	Accordingly, AR expression was induced in taxol-resistant SKOV3 cells overexpressing TLR4, whereas depletion of TLR4 by shRNA repressed AR expression.	Paclitaxel	42-47	androgen receptor	Homo sapiens	13-15
32278794-10	2020	Our results reveal that the TLR4/AR axis plays a critical role in taxol resistance and that genistein is a candidate compound to limit chemoresistance and improve cancer treatment in ovarian cancer.	Paclitaxel	66-71	androgen receptor	Homo sapiens	33-35
32278794-6	2020	We found that expression of DCDC2, ANKRD18B, ALDH1A1, c14orf105, ITGBL1 and NEB was overexpressed in taxol-resistant cells, suggesting the involvement of these AR-related genes in taxol resistance.	Paclitaxel	101-106	integrin subunit beta like 1	Homo sapiens	65-71
32278794-6	2020	We found that expression of DCDC2, ANKRD18B, ALDH1A1, c14orf105, ITGBL1 and NEB was overexpressed in taxol-resistant cells, suggesting the involvement of these AR-related genes in taxol resistance.	Paclitaxel	101-106	androgen receptor	Homo sapiens	160-162
32278794-6	2020	We found that expression of DCDC2, ANKRD18B, ALDH1A1, c14orf105, ITGBL1 and NEB was overexpressed in taxol-resistant cells, suggesting the involvement of these AR-related genes in taxol resistance.	Paclitaxel	180-185	integrin subunit beta like 1	Homo sapiens	65-71
32278794-6	2020	We found that expression of DCDC2, ANKRD18B, ALDH1A1, c14orf105, ITGBL1 and NEB was overexpressed in taxol-resistant cells, suggesting the involvement of these AR-related genes in taxol resistance.	Paclitaxel	180-185	androgen receptor	Homo sapiens	160-162
33102192-0	2020	Induction of apoptosis and role of paclitaxel-loaded hyaluronic acid-crosslinked nanoparticles in the regulation of AKT and RhoA.	Paclitaxel	35-45	AKT serine/threonine kinase 1	Homo sapiens	116-119
32452013-11	2020	To sum up, IL-22 may mediate the chemosensitivity of lung adenocarcinoma cells to paclitaxel through inhibiting the AKT signaling pathways.	Paclitaxel	82-92	AKT serine/threonine kinase 1	Homo sapiens	116-119
32611325-7	2020	After the removal of the metastasis, we started first line therapy for metastatic HER2 positive cancer with trastuzumab and paclitaxel.	Paclitaxel	124-134	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
32779438-10	2020	Overexpression of GATA5 also promoted Paclitaxel to inhibit expression of reprogramming genes, such as Nanog, EpCAM, c-Myc and Sox2 in Bel7402 and PLC/PRF/5 cells.	Paclitaxel	38-48	epithelial cell adhesion molecule	Homo sapiens	110-115
33102192-0	2020	Induction of apoptosis and role of paclitaxel-loaded hyaluronic acid-crosslinked nanoparticles in the regulation of AKT and RhoA.	Paclitaxel	35-45	ras homolog family member A	Homo sapiens	124-128
31650338-0	2020	LncRNA HEIH Enhances Paclitaxel-Tolerance of Endometrial Cancer Cells via Activation of MAPK Signaling Pathway.	Paclitaxel	21-31	hepatocellular carcinoma up-regulated EZH2-associated long non-coding RNA	Homo sapiens	0-11
32173323-3	2020	HCC827 lung cancer cells overexpressing the transcription factor Snail showed increased Rhodamine123 efflux and increased paclitaxel resistance, reflecting increased P-gp activity.	Paclitaxel	122-132	snail family transcriptional repressor 1	Homo sapiens	65-70
32485058-6	2020	Paclitaxel induced overexpression of C-C motif chemokine ligand 2 (CCL2), tumour necrosis alpha (TNFalpha) and interleukin-6 (IL-6) in DRGs, where the presence of macrophages was demonstrated.	Paclitaxel	0-10	tumor necrosis factor	Homo sapiens	97-105
32485058-6	2020	Paclitaxel induced overexpression of C-C motif chemokine ligand 2 (CCL2), tumour necrosis alpha (TNFalpha) and interleukin-6 (IL-6) in DRGs, where the presence of macrophages was demonstrated.	Paclitaxel	0-10	interleukin 6	Homo sapiens	111-124
32485058-6	2020	Paclitaxel induced overexpression of C-C motif chemokine ligand 2 (CCL2), tumour necrosis alpha (TNFalpha) and interleukin-6 (IL-6) in DRGs, where the presence of macrophages was demonstrated.	Paclitaxel	0-10	interleukin 6	Homo sapiens	126-130
31650338-1	2020	This study aimed to investigate the function of lncRNA HEIH on promoting endometrial cancer cells" tolerance of paclitaxel (PTX).	Paclitaxel	112-122	hepatocellular carcinoma up-regulated EZH2-associated long non-coding RNA	Homo sapiens	48-59
31650338-1	2020	This study aimed to investigate the function of lncRNA HEIH on promoting endometrial cancer cells" tolerance of paclitaxel (PTX).	Paclitaxel	124-127	hepatocellular carcinoma up-regulated EZH2-associated long non-coding RNA	Homo sapiens	48-59
31650338-6	2020	Then, differential genes in PTX-resistant and HEIH-knock-down PTX-resistant endometrial cancer cells were screened out by microarray analysis.	Paclitaxel	62-65	hepatocellular carcinoma up-regulated EZH2-associated long non-coding RNA	Homo sapiens	46-50
31650338-8	2020	LncRNA HEIH, the dysregulation of which involved in production of drug-resistance, was overexpressed in PTX-resistant endometrial cancer cells.	Paclitaxel	104-107	hepatocellular carcinoma up-regulated EZH2-associated long non-coding RNA	Homo sapiens	0-11
31650338-10	2020	Down-regulating lncRNA HEIH expression reversed the PTX-resistance of endometrial cancer cells through MAPK signaling pathway.	Paclitaxel	52-55	hepatocellular carcinoma up-regulated EZH2-associated long non-coding RNA	Homo sapiens	16-27
32445273-0	2020	Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.	Paclitaxel	27-37	E2F transcription factor 3	Homo sapiens	79-83
32445273-2	2020	Here, we aimed to explore the role of circ-RNF111 in paclitaxel (PTX) resistance of BC.	Paclitaxel	53-63	ring finger protein 111	Homo sapiens	43-49
32445273-2	2020	Here, we aimed to explore the role of circ-RNF111 in paclitaxel (PTX) resistance of BC.	Paclitaxel	65-68	ring finger protein 111	Homo sapiens	43-49
32445273-15	2020	CONCLUSIONS: Circ-RNF111 improved PTX resistance of BC by upregulating E2F3 via sponging miR-140-5p.	Paclitaxel	34-37	E2F transcription factor 3	Homo sapiens	71-75
32600444-7	2020	RESULTS: Enhanced expression of PRKCQ is sufficient to suppress apoptosis triggered by paclitaxel or doxorubicin treatment.	Paclitaxel	87-97	protein kinase C theta	Homo sapiens	32-37
32522979-8	2020	Experiments with HCC xenograft models revealed that restoring SHQ1 levels enhanced the anti-tumor activity of the endoplasmic reticulum (ER) stress inducer tunicamycin (TM) and common chemotherapy drug paclitaxel (PTX).	Paclitaxel	202-212	SHQ1, H/ACA ribonucleoprotein assembly factor	Homo sapiens	62-66
32634713-5	2020	Our results demonstrate that breast cancer cells grown in 3D bone-mimetic scaffolds exhibited altered physiological and biochemical properties, including tumoroids formation, elevated levels of cytokine such as IL-6, and its downstream effector-mediated inhibition of apoptosis and upregulation of multidrug transporters proteins, leading to drug resistance against paclitaxel.	Paclitaxel	366-376	interleukin 6	Homo sapiens	211-215
32169451-7	2020	Molecular docking analysis disclosed that the binding of PTX and RES to bovine serum albumin (BSA) was noncompetitive but the binding free energy of BSA/PTX dockings was significantly lower than BSA/RES dockings, which resulted in high encapsulation efficiency and sustained drug release profiles of PTX.	Paclitaxel	57-60	albumin	Homo sapiens	79-92
32169451-7	2020	Molecular docking analysis disclosed that the binding of PTX and RES to bovine serum albumin (BSA) was noncompetitive but the binding free energy of BSA/PTX dockings was significantly lower than BSA/RES dockings, which resulted in high encapsulation efficiency and sustained drug release profiles of PTX.	Paclitaxel	153-156	albumin	Homo sapiens	79-92
32169451-7	2020	Molecular docking analysis disclosed that the binding of PTX and RES to bovine serum albumin (BSA) was noncompetitive but the binding free energy of BSA/PTX dockings was significantly lower than BSA/RES dockings, which resulted in high encapsulation efficiency and sustained drug release profiles of PTX.	Paclitaxel	153-156	albumin	Homo sapiens	79-92
32522979-8	2020	Experiments with HCC xenograft models revealed that restoring SHQ1 levels enhanced the anti-tumor activity of the endoplasmic reticulum (ER) stress inducer tunicamycin (TM) and common chemotherapy drug paclitaxel (PTX).	Paclitaxel	214-217	SHQ1, H/ACA ribonucleoprotein assembly factor	Homo sapiens	62-66
32547883-0	2020	Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-kappaB and ERK pathways.	Paclitaxel	38-48	nuclear factor kappa B subunit 1	Homo sapiens	84-93
32502055-0	2020	First-line albumin-bound paclitaxel/carboplatin plus apatinib in advanced pulmonary sarcomatoid carcinoma: A case series and review of the literature.	Paclitaxel	25-35	albumin	Homo sapiens	11-18
32502055-7	2020	Therefore, first-line albumin-bound paclitaxel (nab-paclitaxel, 260 mg/m of the body surface area) and carboplatin (area under curve 5) combined with oral apatinib (425 mg, daily) were administered empirically.	Paclitaxel	36-46	albumin	Homo sapiens	22-29
32547883-0	2020	Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-kappaB and ERK pathways.	Paclitaxel	38-48	mitogen-activated protein kinase 1	Homo sapiens	98-101
32547883-15	2020	Conclusion: Our study demonstrates that GPT can resensitize TNBC PTX resistant cells to PTX by inhibiting the IRAK1/NF-kappaB and ERK pathways and reducing stem cell characteristics.	Paclitaxel	88-91	nuclear factor kappa B subunit 1	Homo sapiens	116-125
32581554-0	2020	Long Non-Coding RNA CRNDE Promotes Colorectal Carcinoma Cell Progression and Paclitaxel Resistance by Regulating miR-126-5p/ATAD2 Axis.	Paclitaxel	77-87	ATPase family AAA domain containing 2	Homo sapiens	124-129
32581554-14	2020	Conclusion: Our data suggested that CRNDE regulated CRC cell development and PTX resistance by modulating miR-126-5p/ATAD2 axis, providing the theoretical basis for the treatment of CRC patients.	Paclitaxel	77-80	ATPase family AAA domain containing 2	Homo sapiens	117-122
32024940-0	2020	Correction: Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer.	Paclitaxel	95-105	CEA cell adhesion molecule 3	Homo sapiens	58-61
32647677-13	2020	Tan-I combination with Paclitaxel promotes apoptosis of cancer cells by promoting Bax expression and Bcl-2 expression.	Paclitaxel	23-33	BCL2 associated X, apoptosis regulator	Homo sapiens	82-85
32647677-13	2020	Tan-I combination with Paclitaxel promotes apoptosis of cancer cells by promoting Bax expression and Bcl-2 expression.	Paclitaxel	23-33	BCL2 apoptosis regulator	Homo sapiens	101-106
32647677-14	2020	Besides, Tan-I treatment can notably increase Paclitaxel-inducing cell senescence by promoting DNA damage and senescence-associated proteins such as p21 and p16.	Paclitaxel	46-56	cyclin dependent kinase inhibitor 2A	Homo sapiens	157-160
32238452-0	2020	Duloxetine attenuates paclitaxel-induced peripheral nerve injury by inhibiting p53-related pathways.	Paclitaxel	22-32	tumor protein p53	Homo sapiens	79-82
32273207-9	2020	CONCLUSION: Treatment with nab-paclitaxel in first- or further-line of metastatic HR-positive/HER2-negative breast cancer resulted in similar effectiveness and safety, irrespective of age.	Paclitaxel	31-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-98
31883148-8	2020	Furthermore, transport of cationic drugs, metformin and paclitaxel in HepG2 cells was blunted by OCT inhibitors, suggesting that hOCT1 and hOCT3 expressed in HepG2 cells exhibit notable impacts on cationic drug actions.	Paclitaxel	56-66	solute carrier family 22 member 1	Homo sapiens	129-134
32470092-0	2020	Retraction: miR-23a Targets Interferon Regulatory Factor 1 and Modulates Cellular Proliferation and Paclitaxel-Induced Apoptosis in Gastric Adenocarcinoma Cells.	Paclitaxel	100-110	interferon regulatory factor 1	Homo sapiens	28-58
32068666-0	2020	Targeting interleukin-20 alleviates paclitaxel-induced peripheral neuropathy.	Paclitaxel	36-46	interleukin 20	Homo sapiens	10-24
32068666-2	2020	Here we studied the contribution of interleukin-20 (IL-20) to the development of paclitaxel-induced peripheral neuropathy.	Paclitaxel	81-91	interleukin 20	Homo sapiens	36-50
32068666-2	2020	Here we studied the contribution of interleukin-20 (IL-20) to the development of paclitaxel-induced peripheral neuropathy.	Paclitaxel	81-91	interleukin 20	Homo sapiens	52-57
31503379-10	2020	Oral paclitaxel also downregulated the intratumoral expression of cyclin D1 and inhibited cell proliferation.	Paclitaxel	5-15	cyclin D1	Canis lupus familiaris	66-75
32897218-7	2020	miR-485-3p was identified as the target of MALAT1, and inhibiting miR-485-3p significantly reverse the effect of MALAT1 silencing on IC50 of paclitaxel and the expressions of P-gp, Bcl-2 and Bax in SK-BR-3/PR cells (P < 0.05).	Paclitaxel	141-151	BCL2 apoptosis regulator	Homo sapiens	181-186
32897218-7	2020	miR-485-3p was identified as the target of MALAT1, and inhibiting miR-485-3p significantly reverse the effect of MALAT1 silencing on IC50 of paclitaxel and the expressions of P-gp, Bcl-2 and Bax in SK-BR-3/PR cells (P < 0.05).	Paclitaxel	141-151	BCL2 associated X, apoptosis regulator	Homo sapiens	191-194
32897218-8	2020	CONCLUSIONS: MALAT1 can modulate paclitaxel resistance in breast cancer cells possibly by targeting miR-485-3p to down-regulate P-gp and Bcl-2 and up-regulate Bax.	Paclitaxel	33-43	BCL2 apoptosis regulator	Homo sapiens	137-142
32897218-8	2020	CONCLUSIONS: MALAT1 can modulate paclitaxel resistance in breast cancer cells possibly by targeting miR-485-3p to down-regulate P-gp and Bcl-2 and up-regulate Bax.	Paclitaxel	33-43	BCL2 associated X, apoptosis regulator	Homo sapiens	159-162
32220496-4	2020	Here we report that the use of apigenin can suppress the HIF-1alpha expression in hypoxic tumors through the simultaneous inhibition of the AKT/p-AKT pathway and HSP90, which is beneficial for enhancing the anticancer activity of the co-administered paclitaxel.	Paclitaxel	250-260	hypoxia inducible factor 1 subunit alpha	Homo sapiens	57-67
32086692-0	2020	The Effects of Paclitaxel in the Combination of Diamond Nanoparticles on the Structure of Human Serum Albumin (HSA) and Their Antiproliferative Role on MDA-MB-231cells.	Paclitaxel	15-25	albumin	Homo sapiens	96-109
32457290-3	2020	Paclitaxel- and doxorubicin-resistant cancer cells showed higher expression of MDR1 and HSF1.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	79-83
32343559-3	2020	Inspired by the discovery of a strong affinity between a photosensitizer sinoporphyrin sodium (DVDMS) and human serum albumin (HSA), a clinically used albumin-paclitaxel (HSA-PTX) nanoparticle is utilized as a "nanoglue" to load a large amount of DVDMS by simple mixing.	Paclitaxel	159-169	albumin	Homo sapiens	112-125
32343559-3	2020	Inspired by the discovery of a strong affinity between a photosensitizer sinoporphyrin sodium (DVDMS) and human serum albumin (HSA), a clinically used albumin-paclitaxel (HSA-PTX) nanoparticle is utilized as a "nanoglue" to load a large amount of DVDMS by simple mixing.	Paclitaxel	159-169	albumin	Homo sapiens	118-125
32547059-7	2020	The patient then received late-line treatment with trastuzumab and albumin-bound paclitaxel.	Paclitaxel	81-91	albumin	Homo sapiens	67-74
32440910-0	2020	EGFR Targeted Paclitaxel and Piperine Co-loaded Liposomes for the Treatment of Triple Negative Breast Cancer.	Paclitaxel	14-24	epidermal growth factor receptor	Homo sapiens	0-4
32440910-2	2020	The combination of paclitaxel (PTX) and piperine (PIP) may improve the bioavailability of paclitaxel for cancer therapy.	Paclitaxel	90-100	prolactin induced protein	Homo sapiens	50-53
32440910-9	2020	Indeed, combining PIP with PTX control has improved the cytotoxicity of PTX control, which proved the synergistic anticancer effect of PIP.	Paclitaxel	27-30	prolactin induced protein	Homo sapiens	135-138
32440910-9	2020	Indeed, combining PIP with PTX control has improved the cytotoxicity of PTX control, which proved the synergistic anticancer effect of PIP.	Paclitaxel	72-75	prolactin induced protein	Homo sapiens	18-21
32440910-9	2020	Indeed, combining PIP with PTX control has improved the cytotoxicity of PTX control, which proved the synergistic anticancer effect of PIP.	Paclitaxel	72-75	prolactin induced protein	Homo sapiens	135-138
32551021-0	2020	ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.	Paclitaxel	79-89	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	21-30
32419122-0	2020	An NMR Protocol for In Vitro Paclitaxel Release from an Albumin-Bound Nanoparticle Formulation.	Paclitaxel	29-39	albumin	Homo sapiens	56-63
32419122-1	2020	The paclitaxel protein-bound particles for injectable suspension (marketed under the brand name Abraxane ) contains nanosized complexes of paclitaxel and albumin.	Paclitaxel	4-14	albumin	Homo sapiens	154-161
32419122-7	2020	In addition, 2D diffusion ordered NMR spectroscopy (DOSY) results revealed that the released paclitaxel experiencing slightly slowed diffusion rates than free paclitaxel, which was attributed to paclitaxel in equilibrium with albumin-bound states.	Paclitaxel	93-103	albumin	Homo sapiens	226-233
32419122-7	2020	In addition, 2D diffusion ordered NMR spectroscopy (DOSY) results revealed that the released paclitaxel experiencing slightly slowed diffusion rates than free paclitaxel, which was attributed to paclitaxel in equilibrium with albumin-bound states.	Paclitaxel	159-169	albumin	Homo sapiens	226-233
32419122-7	2020	In addition, 2D diffusion ordered NMR spectroscopy (DOSY) results revealed that the released paclitaxel experiencing slightly slowed diffusion rates than free paclitaxel, which was attributed to paclitaxel in equilibrium with albumin-bound states.	Paclitaxel	159-169	albumin	Homo sapiens	226-233
32440550-3	2020	Here, we report development of the FX@HP nanocomplex composed of fluorinated polymerized CXCR4 antagonism (FX) and paclitaxel-loaded human serum albumin (HP) for pulmonary delivery of anti-PD-L1 small interfering RNA (siPD-L1) to treat orthotopic lung tumors.	Paclitaxel	115-125	albumin	Homo sapiens	139-152
32348030-6	2020	The combination of PTX and IL-12 activates T lymphocytes and NK cells to release IFN-gamma, selectively inhibits regulatory T cells and induces M1-type differentiation of tumor-related macrophages, thereby improving tumor immunosuppressive microenvironments.	Paclitaxel	19-22	interferon gamma	Mus musculus	81-90
32477959-11	2020	Finally, upregulated expression of heparanase resulted in increased resistance to radiotherapy, whereas high expression of enzymatically inactive heparanase promoted chemoresistance to paclitaxel and cisplatin.	Paclitaxel	185-195	heparanase	Homo sapiens	146-156
32494162-11	2020	Moreover, overexpression of miR-153-5p prominently increased PTX-induced cell cycle arrest at G2/M phase in MDA-MB-231/PTX cells via downregulation of CDK1, cyclin B1 and p-Akt.	Paclitaxel	61-64	AKT serine/threonine kinase 1	Homo sapiens	173-176
32321829-9	2020	Furthermore, BCL2L14-ETV6 fusions prime partial epithelial-mesenchymal transition and endow resistance to paclitaxel treatment.	Paclitaxel	106-116	ETS variant transcription factor 6	Homo sapiens	21-25
32461977-2	2020	This study is aimed at evaluating the efficacy of epirubicin/cyclophosphamide with weekly paclitaxel-trastuzumab as neoadjuvant chemotherapies in HER2+ BC patients.	Paclitaxel	90-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-150
31883395-7	2020	Adriyamicin/cyclophosphamide and Paclitaxel resistant MDA-MB-231 cells activated NRP-1/TNC/Integrin beta3/FAK/NF-kappaBp65 axis and displayed a decrease in breast cancer resistant protein (BCRP/ABCB2).	Paclitaxel	33-43	integrin subunit beta 3	Homo sapiens	91-105
31883395-7	2020	Adriyamicin/cyclophosphamide and Paclitaxel resistant MDA-MB-231 cells activated NRP-1/TNC/Integrin beta3/FAK/NF-kappaBp65 axis and displayed a decrease in breast cancer resistant protein (BCRP/ABCB2).	Paclitaxel	33-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	189-193
31883395-7	2020	Adriyamicin/cyclophosphamide and Paclitaxel resistant MDA-MB-231 cells activated NRP-1/TNC/Integrin beta3/FAK/NF-kappaBp65 axis and displayed a decrease in breast cancer resistant protein (BCRP/ABCB2).	Paclitaxel	33-43	transporter 1, ATP binding cassette subfamily B member	Homo sapiens	194-199
32114508-2	2020	This study aimed to elucidate in vivo inhibition potency of paclitaxel against OATP1B1 and OATP1B3 using endogenous OATP1B biomarkers.	Paclitaxel	60-70	solute carrier organic anion transporter family member 1B3	Homo sapiens	91-98
32154964-7	2020	We found that PTX/Fol-c1 -beta-CyD killed not only FRalpha-expressing cells but also FRalpha-negative cells.	Paclitaxel	14-17	rabaptin, RAB GTPase binding effector protein 2	Mus musculus	51-58
32154964-8	2020	In the FRalpha-negative A2780 cells, knockdown of proton-coupled folate transporter (PCFT) significantly decreased the cytotoxicity of PTX/Fol-c1 -beta-CyD, whereas knockdown of FRalpha did not.	Paclitaxel	135-138	rabaptin, RAB GTPase binding effector protein 2	Mus musculus	7-14
32154964-9	2020	By contrast, knockdown of either FRalpha or proton-coupled folate transporter (PCFT) decreased the cytotoxicity of PTX/Fol-c1 -beta-CyD in FRalpha-expressing SK-OV-3 cells.	Paclitaxel	115-118	rabaptin, RAB GTPase binding effector protein 2	Mus musculus	139-146
32154964-11	2020	In mice intraperitoneally inoculated with FRalpha-expressing or PCFT-expressing EOC cells, intraperitoneal administration of PTX/Fol-c1 -beta-CyD significantly suppressed the growth of both types of EOC cells relative to PTX alone, without inducing a significant change in the neutrophil/white blood cell ratio.	Paclitaxel	125-128	rabaptin, RAB GTPase binding effector protein 2	Mus musculus	42-49
32012482-5	2020	Like taxol, however, all of the probes disrupted the F-actin cytoskeleton at higher concentrations.	Paclitaxel	5-10	Actin 79B	Drosophila melanogaster	53-60
32488780-1	2020	Paclitaxel in a single MTD of 40 mg/kg caused chromosome aberrations and genome changes (polyploidy) in the bone marrow cells of mice early and 3 months after the injection.	Paclitaxel	0-10	BCL2-related ovarian killer	Mus musculus	23-26
32488780-3	2020	Injection of paclitaxel in the MTD caused the development of bone marrow hypoplasia during the early period of observation (up to 14 days) and 3 months after injection.	Paclitaxel	13-23	BCL2-related ovarian killer	Mus musculus	31-34
32114508-3	2020	Paclitaxel is an inhibitor of OATP1B1 and OATP1B3 with Ki of 0.579 +- 0.107 microM and 5.29 +- 3.87 microM, respectively.	Paclitaxel	0-10	solute carrier organic anion transporter family member 1B3	Homo sapiens	42-49
32114508-11	2020	In this study, we could elucidate a significant increment of the plasma concentrations of OATP1B endogenous biomarkers following a 3-h infusion (200 mg/m2) of paclitaxel, an inhibitor causing time-dependent inhibition of OATP1B1 and OATP1B3, in patients.	Paclitaxel	159-169	solute carrier organic anion transporter family member 1B3	Homo sapiens	233-240
31912682-6	2020	The cell counting kit-8 results revealed that APOA1 was overexpressed in both the paclitaxel- and carboplatin- resistant SiHa cells compared with the control cells.	Paclitaxel	82-92	apolipoprotein A1	Homo sapiens	46-51
32237067-0	2020	PBK attenuates paclitaxel-induced autophagic cell death by suppressing p53 in H460 non-small cell lung cancer cells.	Paclitaxel	15-25	PDZ binding kinase	Homo sapiens	0-3
32237067-0	2020	PBK attenuates paclitaxel-induced autophagic cell death by suppressing p53 in H460 non-small cell lung cancer cells.	Paclitaxel	15-25	tumor protein p53	Homo sapiens	71-74
32237067-2	2020	However, it remains unclear how PBK regulates paclitaxel-induced cancer cell death.	Paclitaxel	46-56	PDZ binding kinase	Homo sapiens	32-35
32237067-3	2020	Here, we demonstrate that PBK hinders paclitaxel-mediated autophagic cell death in H460 non-small cell lung cancer cells.	Paclitaxel	38-48	PDZ binding kinase	Homo sapiens	26-29
32237067-4	2020	PBK knockdown increased apoptosis, autophagy, p53 level and LC3 puncta upon paclitaxel treatment.	Paclitaxel	76-86	PDZ binding kinase	Homo sapiens	0-3
32237067-5	2020	Moreover, p53 expression facilitated an increase in the LC3-II/ LC3-I ratio in response to paclitaxel, and PBK knockdown augmented paclitaxel-mediated p53 transcriptional activity.	Paclitaxel	91-101	tumor protein p53	Homo sapiens	10-13
32237067-5	2020	Moreover, p53 expression facilitated an increase in the LC3-II/ LC3-I ratio in response to paclitaxel, and PBK knockdown augmented paclitaxel-mediated p53 transcriptional activity.	Paclitaxel	131-141	PDZ binding kinase	Homo sapiens	107-110
32237067-5	2020	Moreover, p53 expression facilitated an increase in the LC3-II/ LC3-I ratio in response to paclitaxel, and PBK knockdown augmented paclitaxel-mediated p53 transcriptional activity.	Paclitaxel	131-141	tumor protein p53	Homo sapiens	151-154
32237067-6	2020	Meanwhile, paclitaxel induced PBK-mediated p53 nuclear export and its subsequent ubiquitination in control cells, but not in PBK knockdown cells.	Paclitaxel	11-21	PDZ binding kinase	Homo sapiens	30-33
32237067-6	2020	Meanwhile, paclitaxel induced PBK-mediated p53 nuclear export and its subsequent ubiquitination in control cells, but not in PBK knockdown cells.	Paclitaxel	11-21	tumor protein p53	Homo sapiens	43-46
32237067-7	2020	We conclude that PBK hampers paclitaxel-induced autophagic cell death by suppressing p53, suggesting a potential role of PBK in p53-mediated H460 cell death.	Paclitaxel	29-39	PDZ binding kinase	Homo sapiens	17-20
32237067-7	2020	We conclude that PBK hampers paclitaxel-induced autophagic cell death by suppressing p53, suggesting a potential role of PBK in p53-mediated H460 cell death.	Paclitaxel	29-39	tumor protein p53	Homo sapiens	85-88
32237067-7	2020	We conclude that PBK hampers paclitaxel-induced autophagic cell death by suppressing p53, suggesting a potential role of PBK in p53-mediated H460 cell death.	Paclitaxel	29-39	tumor protein p53	Homo sapiens	128-131
31912682-7	2020	Immunohistochemistry showed that APOA1 was highly expressed in the paclitaxel- and carboplatin- resistant squamous cell carcinoma of the cervix.	Paclitaxel	67-77	apolipoprotein A1	Homo sapiens	33-38
31912682-10	2020	Moreover, these findings indicate that the APOA1 protein could serve as a potential marker for monitoring and predicting paclitaxel and carboplatin resistance levels.	Paclitaxel	121-131	apolipoprotein A1	Homo sapiens	43-48
31856423-7	2020	Western blotting was performed to investigate changes in the expression levels of YAP, TAZ, Bcl-2, and EGFR in U87 and U251 cells treated with BPD, cisplatin, and paclitaxel, both as monotherapies and in combination.	Paclitaxel	163-173	BCL2 apoptosis regulator	Homo sapiens	92-97
32156786-9	2020	Finally, taxol-resistant breast cancer cells expressing high levels of multidrug resistance transporter ABCB1 remained sensitive to decitabine, suggesting that the drug could be used as second-line treatment for chemoresistant patients.	Paclitaxel	9-14	ATP binding cassette subfamily B member 1	Homo sapiens	104-109
31856423-7	2020	Western blotting was performed to investigate changes in the expression levels of YAP, TAZ, Bcl-2, and EGFR in U87 and U251 cells treated with BPD, cisplatin, and paclitaxel, both as monotherapies and in combination.	Paclitaxel	163-173	epidermal growth factor receptor	Homo sapiens	103-107
32431514-8	2020	In addition, PTX-induced apoptosis in SKOV3/PTX cells was significantly enhanced by the treatment of TET via upregulating the levels of Bax and cleaved caspase 3, and downregulating the expression of Bcl-2.	Paclitaxel	13-16	BCL2 associated X, apoptosis regulator	Homo sapiens	136-139
32194209-0	2020	Prediction of paclitaxel pharmacokinetic based on in vitro studies: Interaction with membrane models and human serum albumin.	Paclitaxel	14-24	albumin	Homo sapiens	111-124
32190895-0	2020	Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.	Paclitaxel	50-60	microRNA 27a	Homo sapiens	33-40
32190895-10	2020	The expression of the miR-27a was obviously up-regulated under hypoxia and involved in hypoxia-induced paclitaxel resistance.	Paclitaxel	103-113	microRNA 27a	Homo sapiens	22-29
32190895-11	2020	Follow-up experiments portray that miR-27a improved paclitaxel resistance by restraining the expression of APAF1 in OC.	Paclitaxel	52-62	microRNA 27a	Homo sapiens	35-42
32190895-11	2020	Follow-up experiments portray that miR-27a improved paclitaxel resistance by restraining the expression of APAF1 in OC.	Paclitaxel	52-62	apoptotic peptidase activating factor 1	Homo sapiens	107-112
32431514-8	2020	In addition, PTX-induced apoptosis in SKOV3/PTX cells was significantly enhanced by the treatment of TET via upregulating the levels of Bax and cleaved caspase 3, and downregulating the expression of Bcl-2.	Paclitaxel	13-16	caspase 3	Homo sapiens	152-161
32431514-8	2020	In addition, PTX-induced apoptosis in SKOV3/PTX cells was significantly enhanced by the treatment of TET via upregulating the levels of Bax and cleaved caspase 3, and downregulating the expression of Bcl-2.	Paclitaxel	13-16	BCL2 apoptosis regulator	Homo sapiens	200-205
32166948-6	2020	Thus, the efficient tumor accumulation and cell transfection of the polyplexes loaded with the tumor suicide gene tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) give rise to potent antitumor activity similar to that of the first-line chemotherapy drug paclitaxel but with much less adverse effects.	Paclitaxel	269-279	TNF superfamily member 10	Homo sapiens	114-169
32176509-7	2020	Tariquidar release from this nanocarrier suppressed the P-gp function of MCF-7/Taxol cells and significantly increased the intracellular paclitaxel level (p < 0.01 versus the PTX group).	Paclitaxel	79-84	ATP binding cassette subfamily B member 1	Homo sapiens	56-60
32161199-14	2020	Six courses of adjuvant chemotherapy with paclitaxel and carboplatin were given following radical surgery to prevent the recurrence of malignant transformation of MCTO.	Paclitaxel	42-52	MAF bZIP transcription factor B	Homo sapiens	163-167
32368142-3	2020	We utilized a specific inhibitor of PIK3CG combined with paclitaxel (PTX) to treat CLBC cells in vitro and in vivo.	Paclitaxel	57-67	A-kinase anchoring protein 13	Homo sapiens	83-87
32368142-3	2020	We utilized a specific inhibitor of PIK3CG combined with paclitaxel (PTX) to treat CLBC cells in vitro and in vivo.	Paclitaxel	69-72	A-kinase anchoring protein 13	Homo sapiens	83-87
32368142-9	2020	Targeting PIK3CG potentiated CLBC cells growth inhibition in 2D and 3D cultures by PTX.	Paclitaxel	83-86	A-kinase anchoring protein 13	Homo sapiens	29-33
32368142-10	2020	Inhibition of PIK3CG activation could enhance CLBC cells apoptosis and migration suppression induced by PTX.	Paclitaxel	104-107	A-kinase anchoring protein 13	Homo sapiens	46-50
32368142-12	2020	Using CLBC xenograft mice model, we found that CLBC tumors in vivo could be well treated by combined drugs of PIK3CG inhibitor and PTX.	Paclitaxel	131-134	A-kinase anchoring protein 13	Homo sapiens	6-10
32368142-13	2020	Conclusion: We demonstrated that PIK3CG was a potential target for the therapy of CLBC and inhibition of PIK3CG activation could reinforce the therapeutic effect of this aggressive disease by PTX.	Paclitaxel	192-195	A-kinase anchoring protein 13	Homo sapiens	82-86
32313566-0	2020	The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.	Paclitaxel	118-128	solute carrier family 17 member 5	Homo sapiens	4-11
32313566-3	2020	In the present study we investigated the AST/ALT ratio as a possible predictor of treatment response and disease outcome in patients with advanced PDAC treated with first-line gemcitabine/nab-paclitaxel.	Paclitaxel	192-202	solute carrier family 17 member 5	Homo sapiens	41-44
32313566-10	2020	Conclusions: The pretreatment serum AST/ALT ratio predicts poor disease outcome and response rate in patients with advanced PDAC treated with gemcitabine/nab-paclitaxel and might represent a novel and inexpensive marker for individual risk assessment in the treatment of pancreatic cancer.	Paclitaxel	158-168	solute carrier family 17 member 5	Homo sapiens	36-39
32268876-0	2020	Shikonin suppresses NEAT1 and Akt signaling in treating paclitaxel-resistant non-small cell of lung cancer.	Paclitaxel	56-66	AKT serine/threonine kinase 1	Homo sapiens	30-33
32268876-6	2020	Shikonin induced apoptotic cell death of paclitaxel-resistant NSCLC cell lines and suppressed the level of NEAT1 and Akt signaling of paclitaxel-resistant NSCLC cell lines and xenograft tumors.	Paclitaxel	134-144	AKT serine/threonine kinase 1	Homo sapiens	117-120
32166948-6	2020	Thus, the efficient tumor accumulation and cell transfection of the polyplexes loaded with the tumor suicide gene tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) give rise to potent antitumor activity similar to that of the first-line chemotherapy drug paclitaxel but with much less adverse effects.	Paclitaxel	269-279	TNF superfamily member 10	Homo sapiens	171-176
32273769-0	2020	Circ-ABCB10 Contributes to Paclitaxel Resistance in Breast Cancer Through Let-7a-5p/DUSP7 Axis.	Paclitaxel	27-37	ATP binding cassette subfamily B member 10	Homo sapiens	5-11
32259780-2	2020	This report describes a patient with HER2-positive metastatic breast cancer with an exceptional response to trastuzumab and nab-paclitaxel who remains in complete remission several years after cessation of therapy.	Paclitaxel	128-138	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-41
31848297-3	2020	In multiple human prostate cancer cell lines under hypoxia taxol treatment induces the degradation of HIF-1a and this response is abrogated by knockdown of CHIP, but not by E3 ligase VHL or RACK1.	Paclitaxel	59-64	hypoxia inducible factor 1 subunit alpha	Homo sapiens	102-108
31848297-5	2020	CHIP-dependent HIF-1a degradation also occurs in cells arrested in mitosis by nocodazole instead of taxol.	Paclitaxel	100-105	hypoxia inducible factor 1 subunit alpha	Homo sapiens	15-21
31848297-6	2020	Mitotic kinase Aurora B activity is required for taxol-induced HIF-1a degradation.	Paclitaxel	49-54	hypoxia inducible factor 1 subunit alpha	Homo sapiens	63-69
31873051-3	2020	Herein, paclitaxel (PTX)-loaded poly(lactide-co-glycolide) (PLGA) NBs are prepared as drug carriers with covalently conjugated herceptin (anti-HER2 monoclonal antibody) on the surface to guide the target.	Paclitaxel	8-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
31873051-3	2020	Herein, paclitaxel (PTX)-loaded poly(lactide-co-glycolide) (PLGA) NBs are prepared as drug carriers with covalently conjugated herceptin (anti-HER2 monoclonal antibody) on the surface to guide the target.	Paclitaxel	20-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
32683880-6	2020	CASE: A 70-year-old patient with lung adenocarcinoma, sensitive mutation in exon 19 of epidermal growth factor receptor gene, clinical-stage IV (according to the 7th edition of TNM classification), demonstrating long-term stable disease on erlotinib treatment after first-line gefitinib failure and second-line carboplatin-bevacizumab-paclitaxel combination chemotherapy failure.	Paclitaxel	335-345	epidermal growth factor receptor	Homo sapiens	87-119
32342732-4	2020	We also examined the synergistic cytotoxic effect of paclitaxel on A-kinase anchor protein 4 downregulated triple-negative breast cancer cells.	Paclitaxel	53-63	A-kinase anchoring protein 4	Homo sapiens	67-92
32342732-6	2020	Interestingly, we also observed enhanced cell death in A-kinase anchor protein 4 downregulated cells treated with paclitaxel.	Paclitaxel	114-124	A-kinase anchoring protein 4	Homo sapiens	55-80
32342732-11	2020	These data together suggest that A-kinase anchor protein 4 downregulation inhibits various malignant properties and enhances the cytotoxic effect of paclitaxel, and this combinatorial approach could be useful for triple-negative breast cancer treatment.	Paclitaxel	149-159	A-kinase anchoring protein 4	Homo sapiens	33-58
32258043-14	2020	The overexpression of BCRP among SP cells may be the cause of resistance to Taxol, progestin and radiotherapy, which may be related to apoptosis and autophagic activity.	Paclitaxel	76-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	22-26
32269999-0	2020	A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy.	Paclitaxel	106-116	estrogen receptor 1	Homo sapiens	77-79
32269999-1	2020	For estrogen receptor (ER)-negative breast cancer patients, paclitaxel (P), doxorubicin (A) and cyclophosphamide (C) neoadjuvant chemotherapy (NAC) is the standard therapeutic regimen.	Paclitaxel	60-70	estrogen receptor 1	Homo sapiens	4-21
32269999-1	2020	For estrogen receptor (ER)-negative breast cancer patients, paclitaxel (P), doxorubicin (A) and cyclophosphamide (C) neoadjuvant chemotherapy (NAC) is the standard therapeutic regimen.	Paclitaxel	60-70	estrogen receptor 1	Homo sapiens	23-25
32202508-0	2020	Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT/FoxO1 pathway.	Paclitaxel	35-45	AKT serine/threonine kinase 1	Homo sapiens	111-114
32202508-0	2020	Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT/FoxO1 pathway.	Paclitaxel	35-45	forkhead box O1	Homo sapiens	115-120
32202508-7	2020	We also found that ITGA2 regulated the phosphorylation of forkhead box O1 (FoxO1) by mediating AKT phosphorylation, which provided a reasonable explanation for ITGA2"s role in ovarian cancer"s resistance to albumin paclitaxel.	Paclitaxel	215-225	forkhead box O1	Homo sapiens	58-73
32202508-7	2020	We also found that ITGA2 regulated the phosphorylation of forkhead box O1 (FoxO1) by mediating AKT phosphorylation, which provided a reasonable explanation for ITGA2"s role in ovarian cancer"s resistance to albumin paclitaxel.	Paclitaxel	215-225	forkhead box O1	Homo sapiens	75-80
32202508-7	2020	We also found that ITGA2 regulated the phosphorylation of forkhead box O1 (FoxO1) by mediating AKT phosphorylation, which provided a reasonable explanation for ITGA2"s role in ovarian cancer"s resistance to albumin paclitaxel.	Paclitaxel	215-225	AKT serine/threonine kinase 1	Homo sapiens	95-98
31919136-11	2020	CONCLUSIONS: The inflammatory cytokine IL6 may be predictive of therapeutic benefit from bevacizumab when combined with carboplatin and paclitaxel.	Paclitaxel	136-146	interleukin 6	Homo sapiens	39-42
31899273-12	2020	This increased intracellular delivery also translated to a more potent nanomedicine against HER2-positive cells; incorporation of the chemotherapeutic paclitaxel into this targeted carrier enhanced cytotoxicity over untargeted polymer-drug conjugate.	Paclitaxel	151-161	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-96
32166458-10	2020	Furthermore, free PTX resulted in significant increase in the levels of AST and ALT while PD-PTLP insignificantly different compared to that of control indicating the safety index.	Paclitaxel	18-21	solute carrier family 17 member 5	Homo sapiens	72-75
31901301-0	2020	Retraction notice to "STAT3-dependent TXNDC17 expression mediates Taxol resistance through inducing autophagy in human colorectal cancer cells" [GENE 584 (1) (2016) 75-82].	Paclitaxel	66-71	signal transducer and activator of transcription 3	Homo sapiens	22-27
32132628-0	2020	Paclitaxel-induced peripheral neuropathy is caused by epidermal ROS and mitochondrial damage through conserved MMP-13 activation.	Paclitaxel	0-10	matrix metallopeptidase 13a	Danio rerio	111-117
32395375-0	2020	Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers.	Paclitaxel	96-106	protein phosphatase, Mg2+/Mn2+ dependent 1H	Homo sapiens	0-22
32395375-2	2020	The aim of this study was to examine the role of protein phosphatase 1H (PPM1H) in paclitaxel resistance in breast cancer patients.	Paclitaxel	83-93	protein phosphatase, Mg2+/Mn2+ dependent 1H	Homo sapiens	49-71
32395375-2	2020	The aim of this study was to examine the role of protein phosphatase 1H (PPM1H) in paclitaxel resistance in breast cancer patients.	Paclitaxel	83-93	protein phosphatase, Mg2+/Mn2+ dependent 1H	Homo sapiens	73-78
32395375-3	2020	Methods: To investigate the function of PPM1H in paclitaxel treatment, we conducted in vitro assays and molecular experiments using a stable cell line (MDA-MB-231) in which PPM1H is overexpressed.	Paclitaxel	49-59	protein phosphatase, Mg2+/Mn2+ dependent 1H	Homo sapiens	40-45
32395375-6	2020	Results: We investigated whether PPM1H was associated with paclitaxel resistance in breast cancer.	Paclitaxel	59-69	protein phosphatase, Mg2+/Mn2+ dependent 1H	Homo sapiens	33-38
32395375-7	2020	PPM1H expression was upregulated in breast cancer cells treated with paclitaxel.	Paclitaxel	69-79	protein phosphatase, Mg2+/Mn2+ dependent 1H	Homo sapiens	0-5
32395375-8	2020	We also observed that overexpression of PPM1H in breast cancer cells resulted in increased sensitivity to paclitaxel in vitro.	Paclitaxel	106-116	protein phosphatase, Mg2+/Mn2+ dependent 1H	Homo sapiens	40-45
32395375-9	2020	Additionally, paclitaxel treatment induced dephosphorylation of cyclin-dependent kinase (CDK) inhibitor p27 (p27), which was more evident in PPM1H-overexpressing cells.	Paclitaxel	14-24	dynactin subunit 6	Homo sapiens	104-107
32395375-9	2020	Additionally, paclitaxel treatment induced dephosphorylation of cyclin-dependent kinase (CDK) inhibitor p27 (p27), which was more evident in PPM1H-overexpressing cells.	Paclitaxel	14-24	protein phosphatase, Mg2+/Mn2+ dependent 1H	Homo sapiens	141-146
32395375-10	2020	To understand how upregulation of PPM1H increases paclitaxel sensitivity, we determined the levels of p27, phospho-p27, and CDK2, since CDK2 exerts antagonistic effects against PPM1H on p27 phosphorylation.	Paclitaxel	50-60	protein phosphatase, Mg2+/Mn2+ dependent 1H	Homo sapiens	34-39
31945729-0	2020	circCELSR1 (hsa_circ_0063809) Contributes to Paclitaxel Resistance of Ovarian Cancer Cells by Regulating FOXR2 Expression via miR-1252.	Paclitaxel	45-55	forkhead box R2	Mus musculus	105-110
31945729-14	2020	In this study, we explored the specific mechanisms of PTX resistance and tumor progress of ovarian cancer due to circCELSR1; presented the circCELSR1-miR-1252-FOXR2 axis and its role in ovarian cancer drug sensitivity and progression; and suggest that the results may provide an experimental basis for clinical application.	Paclitaxel	54-57	forkhead box R2	Mus musculus	159-164
32132628-10	2020	Finally, we show that MMP-13 dysregulation also underlies paclitaxel-induced peripheral neuropathy in mammals, indicating that epidermal mitochondrial H2O2 and its effectors could be targeted for therapeutic interventions.	Paclitaxel	58-68	matrix metallopeptidase 13a	Danio rerio	22-28
32239987-8	2020	In stage I HER2+ breast cancer, there are excellent outcomes with paclitaxel plus trastuzumab or T-DM1 alone.	Paclitaxel	66-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
32108588-1	2020	P-glycoprotein (P-gp) and betaIII-tubulin overexpression-mediated drug resistance leads to clinical therapy failure for paclitaxel.	Paclitaxel	120-130	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
31633500-0	2020	Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models.	Paclitaxel	32-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-137
32521853-0	2020	Efficacy of albumin-bound paclitaxel in the treatment of advanced refractory breast cancer and its effect on serum resistin.	Paclitaxel	26-36	albumin	Homo sapiens	12-19
32521853-1	2020	PURPOSE: This study aimed to investigate the efficacy of albumin-bound paclitaxel (nab-paclitaxel) in the treatment of advanced refractory breast cancer (BC) and its effect on serum resistin.	Paclitaxel	71-81	albumin	Homo sapiens	57-64
32521853-1	2020	PURPOSE: This study aimed to investigate the efficacy of albumin-bound paclitaxel (nab-paclitaxel) in the treatment of advanced refractory breast cancer (BC) and its effect on serum resistin.	Paclitaxel	87-97	albumin	Homo sapiens	57-64
31883360-6	2020	The knockout and the induction of ABCC1 significantly increased and decreased the sensitivity of melanoma cells to paclitaxel.	Paclitaxel	115-125	ATP binding cassette subfamily C member 1	Homo sapiens	34-39
32108588-1	2020	P-glycoprotein (P-gp) and betaIII-tubulin overexpression-mediated drug resistance leads to clinical therapy failure for paclitaxel.	Paclitaxel	120-130	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
32108588-4	2020	EM-E-11-4 was able to recover the effects of paclitaxel in inducing arrest at G2/M phase and apoptosis in both A549/Tax (P-gp overexpression) and Hela/betaIII (betaIII-tubulin overexpression) cells, respectively, at a non-cytotoxic dose.	Paclitaxel	45-55	ATP binding cassette subfamily B member 1	Homo sapiens	121-125
32106859-9	2020	Importantly, cisplatin and paclitaxel promote miR-522 secretion from CAFs by activating USP7/hnRNPA1 axis, leading to ALOX15 suppression and decreased lipid-ROS accumulation in cancer cells, and ultimately result in decreased chemo-sensitivity.	Paclitaxel	27-37	arachidonate 15-lipoxygenase	Homo sapiens	118-124
32121130-3	2020	We developed NT4 directly conjugated with one, two, or three units of paclitaxel and an NT4-based nanosystem, using NIR-emitting quantum dots, loaded with the NT4 tumor-targeting agent and conjugated with paclitaxel, to obtain a NT4-QD-PTX nanodevice designed to simultaneously detect and kill tumor cells.	Paclitaxel	70-80	neurotrophin 4	Homo sapiens	13-16
32121130-3	2020	We developed NT4 directly conjugated with one, two, or three units of paclitaxel and an NT4-based nanosystem, using NIR-emitting quantum dots, loaded with the NT4 tumor-targeting agent and conjugated with paclitaxel, to obtain a NT4-QD-PTX nanodevice designed to simultaneously detect and kill tumor cells.	Paclitaxel	205-215	neurotrophin 4	Homo sapiens	13-16
31816351-6	2020	Out of the 27 Micro protransfersome formulations, PTX-loaded LMH powder formulations F3, F6 and F9 (i.e. 1:25 w/w lipid phase to carrier ratio) exhibited excellent powder flowability via angle of repose (AOR) and good compressibility index due to associated smaller and uniform particle size and shape of LMH.	Paclitaxel	50-53	ATP synthase peripheral stalk subunit F6	Homo sapiens	85-98
32092870-11	2020	Furthermore, WYE-354 increased the intracellular accumulation of paclitaxel in the ABCB1-mediated MDR cell line, without affecting the corresponding parental cell line, which indicated that WYE-354 could compete with other chemotherapeutic drugs for the ABCB1 transporter substrate binding site.	Paclitaxel	65-75	ATP binding cassette subfamily B member 1	Homo sapiens	83-88
31286496-7	2020	Furthermore, we investigated the role of the antiapoptotic BCL-2 family member MCL-1 in determining the fate of ovarian cancer cells lines with CCNE1 amplification that are challenged with clinically relevant dose of paclitaxel.	Paclitaxel	217-227	BCL2 apoptosis regulator	Homo sapiens	59-64
32080166-6	2020	We further identified that STAT3 functions to promote the transcription of the activating transcription factor 6 (ATF6), which induces endoplasmic reticulum stress to promote cellular autophagy, granting cancer cell resistance to both cisplatin and paclitaxel treatment.	Paclitaxel	249-259	signal transducer and activator of transcription 3	Homo sapiens	27-32
32110051-11	2020	Furthermore, it was found that when activated by 740Y-P, PI3K/Akt signaling pathway could resist the effects of FOXO6 knockdown on the cytotoxicity and glycolysis of paclitaxel in HCC cells.	Paclitaxel	166-176	AKT serine/threonine kinase 1	Homo sapiens	62-65
31816351-14	2020	Moreover, PTX-loaded F3, F6 and F9 tablet formulations (10%) exhibited toxicity (60, 68 and 67% cell viability) to cancer MRC-5 SV2 (i.e. immortalized human lung cells) while safe to MRC-5 (normal lung fibroblast cells) cell lines.	Paclitaxel	10-13	ATP synthase peripheral stalk subunit F6	Homo sapiens	21-34
32083171-0	2020	Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms.	Paclitaxel	29-39	epidermal growth factor receptor	Homo sapiens	55-59
32194871-9	2020	The mechanistic studies confirmed that E7 knockdown sensitized HeLa cells to PTX chemotherapy, mainly by inhibiting PTX-induced AKT pathway activation.	Paclitaxel	77-80	AKT serine/threonine kinase 1	Homo sapiens	128-131
32194871-9	2020	The mechanistic studies confirmed that E7 knockdown sensitized HeLa cells to PTX chemotherapy, mainly by inhibiting PTX-induced AKT pathway activation.	Paclitaxel	116-119	AKT serine/threonine kinase 1	Homo sapiens	128-131
31841354-12	2020	CONCLUSION: Addition of the AKT inhibitor capivasertib to first-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS.	Paclitaxel	69-79	AKT serine/threonine kinase 1	Homo sapiens	28-31
32083171-4	2020	Using resistance selection and small-scale pharmacological screens, we find that cancer cells with primary acquired resistance to the microtubule-stabilizing drug paclitaxel often develop tolerance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), leading to formation of more stable resistant cell populations.	Paclitaxel	163-173	epidermal growth factor receptor	Homo sapiens	262-266
32083171-5	2020	We show that paclitaxel-resistant cancer cells follow distinct selection paths under EGFR-TKIs by enriching the stemness program, developing a highly glycolytic adaptive stress response, and rewiring an apoptosis control pathway.	Paclitaxel	13-23	epidermal growth factor receptor	Homo sapiens	85-89
32083171-6	2020	Collectively, our work demonstrates the alterations in cellular state stemming from paclitaxel failure that result in collateral resistance to EGFR-TKIs and points to new exploitable vulnerabilities during resistance evolution in the second-line treatment setting.	Paclitaxel	84-94	epidermal growth factor receptor	Homo sapiens	143-147
31846802-8	2020	MDR1-siRNA can knock down MDR1, promoting the accumulation of PTX in cells, and thus is expected to achieve an efficient inhibitory effect against highly PTX-resistant cancer cells.	Paclitaxel	62-65	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
31846802-8	2020	MDR1-siRNA can knock down MDR1, promoting the accumulation of PTX in cells, and thus is expected to achieve an efficient inhibitory effect against highly PTX-resistant cancer cells.	Paclitaxel	62-65	ATP binding cassette subfamily B member 1	Homo sapiens	26-30
31846802-8	2020	MDR1-siRNA can knock down MDR1, promoting the accumulation of PTX in cells, and thus is expected to achieve an efficient inhibitory effect against highly PTX-resistant cancer cells.	Paclitaxel	154-157	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
31846802-8	2020	MDR1-siRNA can knock down MDR1, promoting the accumulation of PTX in cells, and thus is expected to achieve an efficient inhibitory effect against highly PTX-resistant cancer cells.	Paclitaxel	154-157	ATP binding cassette subfamily B member 1	Homo sapiens	26-30
32005098-5	2020	Tumors from mice treated with stampidine or stampidine plus paclitaxel displayed unique changes of a signature protein cassette comprised of BRCA1, p21, Bax, and Bcl-2.Conclusion: Stampidine has potent chemopreventive activity and is as effective as the standard chemotherapy drug paclitaxel in the chemical carcinogenesis model of DMBA-induced murine breast cancer.	Paclitaxel	60-70	B cell leukemia/lymphoma 2	Mus musculus	162-167
31512793-5	2020	Moreover, treatment with Taxol reduced cell survival with an increase in mRNA expression of metastasis-related genes caspase-3 and caspase-9, whereas miR-193a transfection alone didn"t significantly influence cell viability and apoptosis induction.	Paclitaxel	25-30	caspase 3	Homo sapiens	117-126
31388880-0	2020	Thiamine, riboflavin, and nicotinamide inhibit paclitaxel-induced allodynia by reducing TNF-alpha and CXCL-1 in dorsal root ganglia and thalamus and activating ATP-sensitive potassium channels.	Paclitaxel	47-57	tumor necrosis factor	Homo sapiens	88-97
31545524-10	2020	Significant reduction in IL-6 was seen with three-weekly paclitaxel-carboplatin (from median 81.3 [range 8.6, 1006] pg/mL to 51.8 [11.4, 99.5] pg/mL; P = .025).	Paclitaxel	57-79	interleukin 6	Homo sapiens	25-29
31545524-11	2020	C-reactive protein levels reduced with weekly nab-paclitaxel (P = .043).	Paclitaxel	50-60	C-reactive protein	Homo sapiens	0-18
32099448-0	2020	Electroacupuncture Treatment Attenuates Paclitaxel-Induced Neuropathic Pain in Rats via Inhibiting Spinal Glia and the TLR4/NF-kappaB Pathway.	Paclitaxel	40-50	toll-like receptor 4	Rattus norvegicus	119-123
31695151-6	2020	Stable HNF4alpha knockdown not only could promote cell proliferation and suppress doxorubicin (Dox)-induced cellular senescence in prostate cancer cells, but also confer resistance to paclitaxel treatment and enhance colony formation capacity and in vivo tumorigenicity of prostate cancer cells.	Paclitaxel	184-194	hepatocyte nuclear factor 4 alpha	Homo sapiens	7-16
31884406-10	2020	Notably, Nrf2 and phosphorylation of AKT/ERK expression in MDR tumor tissues were significantly inhibited by giving nobiletin and PTX together.	Paclitaxel	130-133	NFE2 like bZIP transcription factor 2	Rattus norvegicus	9-13
31884406-10	2020	Notably, Nrf2 and phosphorylation of AKT/ERK expression in MDR tumor tissues were significantly inhibited by giving nobiletin and PTX together.	Paclitaxel	130-133	AKT serine/threonine kinase 1	Rattus norvegicus	37-40
31884406-10	2020	Notably, Nrf2 and phosphorylation of AKT/ERK expression in MDR tumor tissues were significantly inhibited by giving nobiletin and PTX together.	Paclitaxel	130-133	Eph receptor B1	Rattus norvegicus	41-44
31704732-0	2020	EZH2 loss drives resistance to carboplatin and paclitaxel in serous ovarian cancers expressing ATM.	Paclitaxel	47-57	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	0-4
31990457-4	2020	Antitumor immunity can be activated by PTX-induced immunogenic cell death (ICD), while aPD-1 blocks the PD-1/PD-L1 axis to suppress the immune escape due to PTX-induced PD-L1 up-regulation, thus resulting in a synergistic antitumor chemoimmunotherapy.	Paclitaxel	157-160	CD274 antigen	Mus musculus	109-114
31990457-4	2020	Antitumor immunity can be activated by PTX-induced immunogenic cell death (ICD), while aPD-1 blocks the PD-1/PD-L1 axis to suppress the immune escape due to PTX-induced PD-L1 up-regulation, thus resulting in a synergistic antitumor chemoimmunotherapy.	Paclitaxel	157-160	CD274 antigen	Mus musculus	169-174
32158279-0	2020	TGF-beta-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel.	Paclitaxel	106-116	prostate transmembrane protein, androgen induced 1	Homo sapiens	17-23
32158279-10	2020	Further, in TMEPAI-KO cells, we found a significant reduction of IC50 for doxorubicin and paclitaxel, and minimal effects were seen for cisplatin and bicalutamide.	Paclitaxel	90-100	prostate transmembrane protein, androgen induced 1	Homo sapiens	12-18
32158279-11	2020	Our findings suggest that TGF-beta-induced TMEPAI attenuates the response of TNBC to doxorubicin and paclitaxel, but not to cisplatin and bicalutamide.	Paclitaxel	101-111	prostate transmembrane protein, androgen induced 1	Homo sapiens	43-49
32158279-12	2020	Conclusion: TGF-beta induced TMEPAI contributes to the reduced response of TNBC treatment to doxorubicin and paclitaxel, but minimal on cisplatin and bicalutamide.	Paclitaxel	109-119	prostate transmembrane protein, androgen induced 1	Homo sapiens	29-35
31937780-3	2020	Organotypic cultures of primary human breast tumors and patient-derived xenografts sensitive to paclitaxel exhibit gene expression signatures typical of type I IFN and TNFalpha exposure.	Paclitaxel	96-106	tumor necrosis factor	Homo sapiens	153-176
31993509-5	2020	Cellular uptake of rhodamine 123 and calcein-acetoxymethyl ester (calcein-AM), P-glycoprotein substrates, decreased in paclitaxel- or eribulin-treated LS174T cells.	Paclitaxel	119-129	ATP binding cassette subfamily B member 1	Homo sapiens	79-93
31969184-0	2020	Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.	Paclitaxel	72-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	172-176
31969555-0	2020	Blockade of IL-6 signaling prevents paclitaxel-induced neuropathy in C57Bl/6 mice.	Paclitaxel	36-46	interleukin 6	Mus musculus	12-16
31969555-4	2020	We observed that paclitaxel exposure induced IL-6 synthesis in cultured sensory neurons from postnatal Wistar rats, which could be prevented by co-treatment with a calpain inhibitor.	Paclitaxel	17-27	interleukin 6	Rattus norvegicus	45-49
31969555-6	2020	We demonstrate that adult C57BL/6 mice deficient in IL-6 are protected from developing functional and histological changes of paclitaxel-induced neuropathy.	Paclitaxel	126-136	interleukin 6	Mus musculus	52-56
31969555-7	2020	Furthermore, pretreatment with an IL-6-neutralizing antibody resulted in the prevention of paclitaxel-induced neuropathy in C57BL/6 mice.	Paclitaxel	91-101	interleukin 6	Mus musculus	34-38
31969555-10	2020	Our findings demonstrate that IL-6 plays a pivotal role in the pathophysiology of paclitaxel-induced neuropathy per se and that pharmacological or genetic interference with this signaling pathway prevents the development of this potentially debilitating adverse effect.	Paclitaxel	82-92	interleukin 6	Homo sapiens	30-34
31969555-11	2020	These findings provide a rationale for a clinical trial with IL-6 neutralizing antibodies to prevent dose-limiting neurotoxic adverse effects of paclitaxel chemotherapy.	Paclitaxel	145-155	interleukin 6	Homo sapiens	61-65
31937590-8	2020	The most discriminatory miRNA, with the highest  fold change , was miR-451a, which regulates the expression of the drug-transporter protein P-glycoprotein, potentially promoting paclitaxel resistance.	Paclitaxel	178-188	ATP binding cassette subfamily B member 1	Homo sapiens	140-154
31993509-1	2020	This study examined the effects of microtubule-targeting anticancer drugs (paclitaxel, cabazitaxel, and eribulin) on the expression of drug efflux transporter P-glycoprotein, which is encoded by MDR1.	Paclitaxel	75-85	ATP binding cassette subfamily B member 1	Homo sapiens	159-173
31993509-1	2020	This study examined the effects of microtubule-targeting anticancer drugs (paclitaxel, cabazitaxel, and eribulin) on the expression of drug efflux transporter P-glycoprotein, which is encoded by MDR1.	Paclitaxel	75-85	ATP binding cassette subfamily B member 1	Homo sapiens	195-199
31993509-2	2020	Paclitaxel and eribulin induced MDR1 promoter activity in a concentration-dependent manner, while cabazitaxel had little effect in human intestinal epithelial LS174T cells.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	32-36
31993509-3	2020	Overexpression of the nuclear receptor pregnane X receptor (PXR) gene (NR1I2) enhanced paclitaxel- and eribulin-induced MDR1 activation, but expression of the nuclear receptor co-repressor silencing mediator for retinoid and thyroid receptors (SMRT) gene (NCOR2) repressed MDR1 activation.	Paclitaxel	87-97	nuclear receptor subfamily 1 group I member 2	Homo sapiens	60-63
31993509-3	2020	Overexpression of the nuclear receptor pregnane X receptor (PXR) gene (NR1I2) enhanced paclitaxel- and eribulin-induced MDR1 activation, but expression of the nuclear receptor co-repressor silencing mediator for retinoid and thyroid receptors (SMRT) gene (NCOR2) repressed MDR1 activation.	Paclitaxel	87-97	nuclear receptor subfamily 1 group I member 2	Homo sapiens	71-76
31993509-3	2020	Overexpression of the nuclear receptor pregnane X receptor (PXR) gene (NR1I2) enhanced paclitaxel- and eribulin-induced MDR1 activation, but expression of the nuclear receptor co-repressor silencing mediator for retinoid and thyroid receptors (SMRT) gene (NCOR2) repressed MDR1 activation.	Paclitaxel	87-97	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
31907045-8	2020	DSF/SPC-NSps groups administered via intravenous injections exhibited better antitumor efficacy compared to the commercial paclitaxel injection (PTX injection) and had a dose-dependent effect in vivo.	Paclitaxel	123-133	sparse coat	Mus musculus	4-7
31918714-6	2020	Subsequently, TPH/PTX caused mitochondrial outer membrane permeabilization (MOMP) by inhibiting antiapoptotic Bcl-2, leading to cytochrome C release and activation of caspase-3 and caspase-9.	Paclitaxel	18-21	B cell leukemia/lymphoma 2	Mus musculus	110-115
32002126-0	2020	Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer.	Paclitaxel	115-125	C-reactive protein	Homo sapiens	44-62
32002126-9	2020	Low levels of NLR and CRP at baseline were significantly associated with improved prognosis in patients treated with bevacizumab plus paclitaxel.	Paclitaxel	134-144	C-reactive protein	Homo sapiens	22-25
31207400-2	2020	METHODS: A retrospective review of all patients with Rutherford stage 5 and 6 limb ischemia undergoing endovascular revascularization with paclitaxel-related technology, both PES and PCB, was carried out over a 4-year period.	Paclitaxel	139-149	pyruvate carboxylase	Homo sapiens	183-186
31628941-0	2020	Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug resistance by curcumin and vitamin D3 increases sensitivity to paclitaxel in breast cancer.	Paclitaxel	140-150	ATP binding cassette subfamily B member 1	Homo sapiens	43-57
31628941-10	2020	Combining CUR and 1,25(OH)2D3 to PAX caused a downregulation in both MDR-1 and ALDH-1 gene expression in MCF-7 besides a decrease in their protein levels.	Paclitaxel	33-36	ATP binding cassette subfamily B member 1	Homo sapiens	69-74
31628941-14	2020	Overall, the present study showed that PAX, as a monotherapy, demonstrated acquired resistance possibly by increasing MDR-1 expression and enriching CSCs population, as evidenced by increased ALDH-1.	Paclitaxel	39-42	ATP binding cassette subfamily B member 1	Homo sapiens	118-123
32407275-9	2020	CONCLUSION: These results indicated that the sodium channel Nav1.7 in the DRG exerted an important function in paclitaxel-induced neuropathy, which was associated with ERK phosphorylation in neurons.	Paclitaxel	111-121	Eph receptor B1	Rattus norvegicus	168-171
32364081-0	2020	Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells.	Paclitaxel	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-67
31093891-3	2020	METHODS: U14 cervical cancer cells and xenograft mouse tumors were treated with PTX-miR-34a-MBs.	Paclitaxel	80-83	microRNA 34a	Mus musculus	84-91
31093891-4	2020	RESULTS: Levels of miR-34a increased in vitro and vivo after treatment with ultrasound-mediated PTX-miR-34a-MBs.	Paclitaxel	96-99	microRNA 34a	Mus musculus	19-26
31093891-4	2020	RESULTS: Levels of miR-34a increased in vitro and vivo after treatment with ultrasound-mediated PTX-miR-34a-MBs.	Paclitaxel	96-99	microRNA 34a	Mus musculus	100-107
31093891-8	2020	CONCLUSIONS: These results indicate that ultrasound-mediated PTX-miR-34a-MBs synergistically inhibit the growth of cervical cancer via the upregulation of miR-34a and downregulation of Bcl-2 and CDK6.	Paclitaxel	61-64	microRNA 34a	Mus musculus	65-72
31093891-8	2020	CONCLUSIONS: These results indicate that ultrasound-mediated PTX-miR-34a-MBs synergistically inhibit the growth of cervical cancer via the upregulation of miR-34a and downregulation of Bcl-2 and CDK6.	Paclitaxel	61-64	microRNA 34a	Mus musculus	155-162
31093891-8	2020	CONCLUSIONS: These results indicate that ultrasound-mediated PTX-miR-34a-MBs synergistically inhibit the growth of cervical cancer via the upregulation of miR-34a and downregulation of Bcl-2 and CDK6.	Paclitaxel	61-64	B cell leukemia/lymphoma 2	Mus musculus	185-190
31093891-9	2020	Thus, PTX-miR-34a-MBs in combination with ultrasound microbubbles are a promising anticancer delivery strategy for treating cervical cancer.	Paclitaxel	6-9	microRNA 34a	Mus musculus	10-17
31783010-0	2020	Overcoming Taxol-resistance in A549 Cells: A Comprehensive Strategy of Targeting P-gp transporter, AKT/ERK Pathways, and Cytochrome P450 Enzyme CYP1B1 by 4-hydroxyemodin.	Paclitaxel	11-16	AKT serine/threonine kinase 1	Homo sapiens	99-102
31783010-0	2020	Overcoming Taxol-resistance in A549 Cells: A Comprehensive Strategy of Targeting P-gp transporter, AKT/ERK Pathways, and Cytochrome P450 Enzyme CYP1B1 by 4-hydroxyemodin.	Paclitaxel	11-16	mitogen-activated protein kinase 1	Homo sapiens	103-106
32401925-0	2020	Treatment with beta-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-kappaB pathway.	Paclitaxel	42-52	nuclear factor kappa B subunit 1	Homo sapiens	162-171
32401925-4	2020	Results demonstrated that beta-elemene+paclitaxel induced apoptosis of SKOV3 cells, down-regulated anti-apoptotic Bcl-2 and Bcl-xl gene expression and up-regulated pro-apoptotic P53 and Apaf1 gene expression in SKOV3 cells.	Paclitaxel	39-49	BCL2 apoptosis regulator	Homo sapiens	114-119
32401925-4	2020	Results demonstrated that beta-elemene+paclitaxel induced apoptosis of SKOV3 cells, down-regulated anti-apoptotic Bcl-2 and Bcl-xl gene expression and up-regulated pro-apoptotic P53 and Apaf1 gene expression in SKOV3 cells.	Paclitaxel	39-49	BCL2 like 1	Homo sapiens	124-130
32401925-4	2020	Results demonstrated that beta-elemene+paclitaxel induced apoptosis of SKOV3 cells, down-regulated anti-apoptotic Bcl-2 and Bcl-xl gene expression and up-regulated pro-apoptotic P53 and Apaf1 gene expression in SKOV3 cells.	Paclitaxel	39-49	tumor protein p53	Homo sapiens	178-181
32401925-4	2020	Results demonstrated that beta-elemene+paclitaxel induced apoptosis of SKOV3 cells, down-regulated anti-apoptotic Bcl-2 and Bcl-xl gene expression and up-regulated pro-apoptotic P53 and Apaf1 gene expression in SKOV3 cells.	Paclitaxel	39-49	apoptotic peptidase activating factor 1	Homo sapiens	186-191
32401925-5	2020	Administration of beta-elemene+paclitaxel arrested SKOV3 cell cycle at S phase and down-regulated CDK1, cyclin-B1, and P27 gene expression and apoptotic-related resistant gene expression of MDR1, LRP, and TS in SKOV3 cells.	Paclitaxel	31-41	dynactin subunit 6	Homo sapiens	119-122
32401925-5	2020	Administration of beta-elemene+paclitaxel arrested SKOV3 cell cycle at S phase and down-regulated CDK1, cyclin-B1, and P27 gene expression and apoptotic-related resistant gene expression of MDR1, LRP, and TS in SKOV3 cells.	Paclitaxel	31-41	ATP binding cassette subfamily B member 1	Homo sapiens	190-194
32401925-5	2020	Administration of beta-elemene+paclitaxel arrested SKOV3 cell cycle at S phase and down-regulated CDK1, cyclin-B1, and P27 gene expression and apoptotic-related resistant gene expression of MDR1, LRP, and TS in SKOV3 cells.	Paclitaxel	31-41	LDL receptor related protein 1	Homo sapiens	196-199
32401925-9	2020	In conclusion, the data suggested that beta-elemene+paclitaxel can inhibit ovarian cancer growth via down-regulation of the STAT3-NF-kappaB signaling pathway, which may be a potential therapeutic strategy for ovarian cancer therapy.	Paclitaxel	52-62	signal transducer and activator of transcription 3	Homo sapiens	124-129
32401925-9	2020	In conclusion, the data suggested that beta-elemene+paclitaxel can inhibit ovarian cancer growth via down-regulation of the STAT3-NF-kappaB signaling pathway, which may be a potential therapeutic strategy for ovarian cancer therapy.	Paclitaxel	52-62	nuclear factor kappa B subunit 1	Homo sapiens	130-139
31778258-9	2020	CONCLUSIONS: Targeting the activation of Stat3 may be a potential therapeutic approach for EOC by acting synergistically with paclitaxel.	Paclitaxel	126-136	signal transducer and activator of transcription 3	Homo sapiens	41-46
32047545-0	2020	Long non-coding RNA TCL6 enhances preferential toxicity of paclitaxel to renal cell carcinoma cells.	Paclitaxel	59-69	T cell leukemia/lymphoma 6	Homo sapiens	20-24
31648639-6	2020	Ag@PTX induced A549 cells apoptosis was confirmed by nuclear condensation, DNA fragmentation, and activation of caspase-3.	Paclitaxel	3-6	caspase 3	Homo sapiens	112-121
32016960-13	2020	Silencing of SIK2 could hinder the PTX resistance and suppress the progression of PTX-resistant OC cells, while miR-654-5p inhibitor could invert this inhibitory effect.	Paclitaxel	35-38	salt inducible kinase 2	Homo sapiens	13-17
32016960-13	2020	Silencing of SIK2 could hinder the PTX resistance and suppress the progression of PTX-resistant OC cells, while miR-654-5p inhibitor could invert this inhibitory effect.	Paclitaxel	82-85	salt inducible kinase 2	Homo sapiens	13-17
31648639-7	2020	Furthermore, Ag@PTX enhanced the anti-canceractivity of A549 cells through ROS-mediated p53 and AKT signalling pathways.	Paclitaxel	16-19	tumor protein p53	Homo sapiens	88-91
31648639-7	2020	Furthermore, Ag@PTX enhanced the anti-canceractivity of A549 cells through ROS-mediated p53 and AKT signalling pathways.	Paclitaxel	16-19	AKT serine/threonine kinase 1	Homo sapiens	96-99
32554905-8	2020	Analysis of cell cycle phases followed by apoptotic markers also showed that miR-214 overexpression along with Paclitaxel treatment caused an increase in PARP and decline of PI-3 kinase/Akt levels.	Paclitaxel	111-121	poly(ADP-ribose) polymerase 1	Homo sapiens	154-158
32554905-8	2020	Analysis of cell cycle phases followed by apoptotic markers also showed that miR-214 overexpression along with Paclitaxel treatment caused an increase in PARP and decline of PI-3 kinase/Akt levels.	Paclitaxel	111-121	AKT serine/threonine kinase 1	Homo sapiens	186-189
32047545-2	2020	In this report, we investigate the effect of T-cell leukemia lymphoma 6 (TCL6) on paclitaxel (PTX)-induced apoptosis in Renal cell carcinoma (RCC) cells.	Paclitaxel	82-92	T cell leukemia/lymphoma 6	Homo sapiens	45-71
32047545-2	2020	In this report, we investigate the effect of T-cell leukemia lymphoma 6 (TCL6) on paclitaxel (PTX)-induced apoptosis in Renal cell carcinoma (RCC) cells.	Paclitaxel	82-92	T cell leukemia/lymphoma 6	Homo sapiens	73-77
32047545-2	2020	In this report, we investigate the effect of T-cell leukemia lymphoma 6 (TCL6) on paclitaxel (PTX)-induced apoptosis in Renal cell carcinoma (RCC) cells.	Paclitaxel	94-97	T cell leukemia/lymphoma 6	Homo sapiens	45-71
32047545-2	2020	In this report, we investigate the effect of T-cell leukemia lymphoma 6 (TCL6) on paclitaxel (PTX)-induced apoptosis in Renal cell carcinoma (RCC) cells.	Paclitaxel	94-97	T cell leukemia/lymphoma 6	Homo sapiens	73-77
32047545-12	2020	After PTX treatment, a time-dependent decrease in cell viability was observed in TCL6-overexpressed RCC cells and an increase in cell viability was observed in TCL6-silenced cells compared to control cells.	Paclitaxel	6-9	T cell leukemia/lymphoma 6	Homo sapiens	81-85
32047545-12	2020	After PTX treatment, a time-dependent decrease in cell viability was observed in TCL6-overexpressed RCC cells and an increase in cell viability was observed in TCL6-silenced cells compared to control cells.	Paclitaxel	6-9	T cell leukemia/lymphoma 6	Homo sapiens	160-164
32047545-13	2020	Apoptosis induced by PTX was significantly increased in TCL6-overexpressed cells.	Paclitaxel	21-24	T cell leukemia/lymphoma 6	Homo sapiens	56-60
32047545-16	2020	Conclusions: TCL6 effectively sensitizes RCC to PTX mainly through downregulation of miR-221.	Paclitaxel	48-51	T cell leukemia/lymphoma 6	Homo sapiens	13-17
31662022-4	2020	During cytokinesis induced by treatment with taxol, the epithelial barrier was maintained and the tricellular tight junction molecules LSR and tricellulin were concentrated at the flank of the acetylated tubulin-positive midbody and in gamma-tubulin-positive centrosomes with the dynein adaptor Hook2, whereas the other molecules were localized there as well.	Paclitaxel	45-50	MARVEL domain containing 2	Homo sapiens	143-154
31562256-10	2020	In vivo, LY2090314 plus nab-paclitaxel significantly prolonged mice survival duration.Our study demonstrates a unique role for TAK1 in controlling YAP/TAZ in pancreatic cancer.	Paclitaxel	28-38	tafazzin, phospholipid-lysophospholipid transacylase	Mus musculus	151-154
31906029-9	2019	A cross-activation of JNK and PERK by TAX and NOC leading to anti-CRC actions including apoptosis and G2/M arrest was first demonstrated herein.	Paclitaxel	38-41	mitogen-activated protein kinase 8	Homo sapiens	22-25
32187596-2	2020	METHODS: The process of HER2-negative locally recurrent or metastatic breast cancer treated with bevacizumab combined with paclitaxel or bevaciz-umab combined with capecitabine made up the decision model in our analysis.	Paclitaxel	123-133	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
33095154-0	2020	Siwei Jianbu decoction improves painful paclitaxel-induced peripheral neuropathy in mouse model by modulating the NF-kappaB and MAPK signaling pathways.	Paclitaxel	40-50	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	114-123
31490328-3	2020	Our work in male rodents using paclitaxel, oxaliplatin and bortezomib showed robust inhibition of CINP with either S1PR1 antagonists or A3AR agonists.	Paclitaxel	31-41	sphingosine-1-phosphate receptor 1	Rattus norvegicus	115-120
31490328-5	2020	Our findings reveal that S1PR1 antagonists and A3AR agonists mitigate paclitaxel and oxaliplatin CINP in female and male rodents, but failed to block or reverse bortezomib-induced neuropathic pain (BINP) in females.	Paclitaxel	70-80	adenosine A3 receptor	Mus musculus	47-51
31906029-5	2019	Application of the c-Jun N-terminal kinase (JNK) inhibitors SP600125 (SP) and JNK inhibitor V (JNKI) significantly reduced TAX- and NOC-induced apoptosis and G2/M arrest of human colon cancer cells.	Paclitaxel	123-126	mitogen-activated protein kinase 8	Homo sapiens	19-42
31844042-6	2019	Circ_0002483 was demonstrated to inhibit NSCLC progression in vitro and in vivo and enhanced the sensitivity of NSCLC cells to Taxol by sponging miR-182-5p to release the inhibition on GRB2, FOXO1, and FOXO3 mRNAs.	Paclitaxel	127-132	microRNA 1825	Homo sapiens	145-155
31906029-5	2019	Application of the c-Jun N-terminal kinase (JNK) inhibitors SP600125 (SP) and JNK inhibitor V (JNKI) significantly reduced TAX- and NOC-induced apoptosis and G2/M arrest of human colon cancer cells.	Paclitaxel	123-126	mitogen-activated protein kinase 8	Homo sapiens	44-47
31906029-5	2019	Application of the c-Jun N-terminal kinase (JNK) inhibitors SP600125 (SP) and JNK inhibitor V (JNKI) significantly reduced TAX- and NOC-induced apoptosis and G2/M arrest of human colon cancer cells.	Paclitaxel	123-126	mitogen-activated protein kinase 8	Homo sapiens	78-81
31906029-6	2019	Interestingly, TAX- and NOC-induced pPERK (Tyr980) protein expression was inhibited by adding the JNK inhibitors, SP and JNKI, and application of the PERK inhibitor GSK2606414 (GSK) significantly reduced apoptosis and G2/M arrest by TAX and NOC, with decreased pPERK (Tyr980) and pJNK, phosphorylated Cdc25C, and Cyc B1 protein expressions in human colon cancer cells.	Paclitaxel	15-18	mitogen-activated protein kinase 8	Homo sapiens	98-101
31906029-6	2019	Interestingly, TAX- and NOC-induced pPERK (Tyr980) protein expression was inhibited by adding the JNK inhibitors, SP and JNKI, and application of the PERK inhibitor GSK2606414 (GSK) significantly reduced apoptosis and G2/M arrest by TAX and NOC, with decreased pPERK (Tyr980) and pJNK, phosphorylated Cdc25C, and Cyc B1 protein expressions in human colon cancer cells.	Paclitaxel	233-236	mitogen-activated protein kinase 8	Homo sapiens	98-101
31906029-8	2019	Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI.	Paclitaxel	139-142	BCL2 apoptosis regulator	Homo sapiens	70-87
31906029-8	2019	Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI.	Paclitaxel	139-142	BCL2 apoptosis regulator	Homo sapiens	89-94
31844042-6	2019	Circ_0002483 was demonstrated to inhibit NSCLC progression in vitro and in vivo and enhanced the sensitivity of NSCLC cells to Taxol by sponging miR-182-5p to release the inhibition on GRB2, FOXO1, and FOXO3 mRNAs.	Paclitaxel	127-132	growth factor receptor bound protein 2	Homo sapiens	185-189
31844042-6	2019	Circ_0002483 was demonstrated to inhibit NSCLC progression in vitro and in vivo and enhanced the sensitivity of NSCLC cells to Taxol by sponging miR-182-5p to release the inhibition on GRB2, FOXO1, and FOXO3 mRNAs.	Paclitaxel	127-132	forkhead box O1	Homo sapiens	191-196
31844042-6	2019	Circ_0002483 was demonstrated to inhibit NSCLC progression in vitro and in vivo and enhanced the sensitivity of NSCLC cells to Taxol by sponging miR-182-5p to release the inhibition on GRB2, FOXO1, and FOXO3 mRNAs.	Paclitaxel	127-132	forkhead box O3	Homo sapiens	202-207
31819016-0	2019	Posttranscriptional regulation of AKT by circular RNA angiomotin- like 1 mediates chemoresistance against paclitaxel in breast cancer cells.	Paclitaxel	106-116	AKT serine/threonine kinase 1	Homo sapiens	34-37
31934276-0	2019	BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway.	Paclitaxel	36-46	AKT serine/threonine kinase 1	Homo sapiens	103-106
31908478-10	2019	Furthermore, miR-7-induced sensitization of breast cancer to paclitaxel/carboplatin is markedly reversed by restoration of MRP1 and BCL2.	Paclitaxel	61-71	ATP binding cassette subfamily C member 1	Homo sapiens	123-127
31908478-10	2019	Furthermore, miR-7-induced sensitization of breast cancer to paclitaxel/carboplatin is markedly reversed by restoration of MRP1 and BCL2.	Paclitaxel	61-71	BCL2 apoptosis regulator	Homo sapiens	132-136
31934276-0	2019	BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway.	Paclitaxel	36-46	mechanistic target of rapamycin kinase	Homo sapiens	107-111
31934276-4	2019	In vitro results showed that paclitaxel, combined with BEZ235, inhibited HCC cell proliferation and migration, arrested the cell cycle in the G2/M phase, and promoted cell apoptosis by decreasing PI3K/Akt/mTOR activity.	Paclitaxel	29-39	AKT serine/threonine kinase 1	Homo sapiens	201-204
31934276-4	2019	In vitro results showed that paclitaxel, combined with BEZ235, inhibited HCC cell proliferation and migration, arrested the cell cycle in the G2/M phase, and promoted cell apoptosis by decreasing PI3K/Akt/mTOR activity.	Paclitaxel	29-39	mechanistic target of rapamycin kinase	Homo sapiens	205-209
31934276-5	2019	In vivo experiments confirmed that BEZ235 enhances the anti-tumor effect of paclitaxel by reducing PI3K/Akt/mTOR activity.	Paclitaxel	76-86	AKT serine/threonine kinase 1	Homo sapiens	104-107
31934276-5	2019	In vivo experiments confirmed that BEZ235 enhances the anti-tumor effect of paclitaxel by reducing PI3K/Akt/mTOR activity.	Paclitaxel	76-86	mechanistic target of rapamycin kinase	Homo sapiens	108-112
31934276-7	2019	We conclude that BEZ235 enhanced the sensitivity of HCC to paclitaxel, and inhibition of PI3K/Akt/mTOR signaling might be a therapeutic strategy against paclitaxel-resistant HCC.	Paclitaxel	153-163	AKT serine/threonine kinase 1	Homo sapiens	94-97
31934276-7	2019	We conclude that BEZ235 enhanced the sensitivity of HCC to paclitaxel, and inhibition of PI3K/Akt/mTOR signaling might be a therapeutic strategy against paclitaxel-resistant HCC.	Paclitaxel	153-163	mechanistic target of rapamycin kinase	Homo sapiens	98-102
31149728-5	2019	Subsequently, we examined the effects of CYC1 on proliferation, glycolysis and chemosensitivity to paclitaxel, which is one of the most common chemotherapeutic agents in breast cancer, in ER-positive breast carcinoma cells (MCF7 and T47D).	Paclitaxel	99-109	cytochrome c1	Homo sapiens	41-45
31819079-8	2019	SAC imposed by paclitaxel was dramatically reversed by Cdc7 inhibition, similar to the effect of Aurora B inhibition under the similar situation.	Paclitaxel	15-25	cell division cycle 7	Homo sapiens	55-59
31867270-10	2019	In order to test this, we generated a paclitaxel-resistant TNBC cell line which demonstrated an elevated level of eIF4A along with increased levels of cancer stemness markers (ALDH activity and CD44), pluripotency transcription factors (SOX2, OCT4, and NANOG) and drug transporters (ABCB1, ABCG2, and ABCC1).	Paclitaxel	38-48	eukaryotic translation initiation factor 4A1	Homo sapiens	114-119
31867270-10	2019	In order to test this, we generated a paclitaxel-resistant TNBC cell line which demonstrated an elevated level of eIF4A along with increased levels of cancer stemness markers (ALDH activity and CD44), pluripotency transcription factors (SOX2, OCT4, and NANOG) and drug transporters (ABCB1, ABCG2, and ABCC1).	Paclitaxel	38-48	ATP binding cassette subfamily B member 1	Homo sapiens	283-288
31867270-10	2019	In order to test this, we generated a paclitaxel-resistant TNBC cell line which demonstrated an elevated level of eIF4A along with increased levels of cancer stemness markers (ALDH activity and CD44), pluripotency transcription factors (SOX2, OCT4, and NANOG) and drug transporters (ABCB1, ABCG2, and ABCC1).	Paclitaxel	38-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	290-295
31867270-10	2019	In order to test this, we generated a paclitaxel-resistant TNBC cell line which demonstrated an elevated level of eIF4A along with increased levels of cancer stemness markers (ALDH activity and CD44), pluripotency transcription factors (SOX2, OCT4, and NANOG) and drug transporters (ABCB1, ABCG2, and ABCC1).	Paclitaxel	38-48	ATP binding cassette subfamily C member 1	Homo sapiens	301-306
31797089-9	2019	Paclitaxel significantly up-regulated the expression of interleukin-6.	Paclitaxel	0-10	interleukin 6	Homo sapiens	56-69
30829071-0	2019	Plastin 3 down-regulation augments the sensitivity of MDA-MB-231 cells to paclitaxel via the p38 MAPK signalling pathway.	Paclitaxel	74-84	mitogen-activated protein kinase 14	Homo sapiens	93-96
30829071-4	2019	Further study revealed that p38 MAPK signalling was responsible for the increased sensitivity to paclitaxel in these cells, as the p38 MAPK inhibitor SB203580 impaired the changes mediated by PLS3 down-regulation in response to paclitaxel.	Paclitaxel	97-107	mitogen-activated protein kinase 14	Homo sapiens	28-31
30829071-4	2019	Further study revealed that p38 MAPK signalling was responsible for the increased sensitivity to paclitaxel in these cells, as the p38 MAPK inhibitor SB203580 impaired the changes mediated by PLS3 down-regulation in response to paclitaxel.	Paclitaxel	97-107	mitogen-activated protein kinase 14	Homo sapiens	131-134
30829071-4	2019	Further study revealed that p38 MAPK signalling was responsible for the increased sensitivity to paclitaxel in these cells, as the p38 MAPK inhibitor SB203580 impaired the changes mediated by PLS3 down-regulation in response to paclitaxel.	Paclitaxel	228-238	mitogen-activated protein kinase 14	Homo sapiens	28-31
30829071-4	2019	Further study revealed that p38 MAPK signalling was responsible for the increased sensitivity to paclitaxel in these cells, as the p38 MAPK inhibitor SB203580 impaired the changes mediated by PLS3 down-regulation in response to paclitaxel.	Paclitaxel	228-238	mitogen-activated protein kinase 14	Homo sapiens	131-134
30829071-5	2019	Therefore, our study identifies PLS3 as a potential target for enhancing the p38 MAPK-mediated apoptosis induced by paclitaxel.	Paclitaxel	116-126	mitogen-activated protein kinase 14	Homo sapiens	77-80
31432702-5	2019	Mechanism studies indicated that the DQA modified paclitaxel plus ligustrazine micelles could down-regulate the expressions of VEGF, MMP2, TGF-beta1 and E-cadherin in A549 cells.	Paclitaxel	50-60	vascular endothelial growth factor A	Homo sapiens	127-131
31432702-5	2019	Mechanism studies indicated that the DQA modified paclitaxel plus ligustrazine micelles could down-regulate the expressions of VEGF, MMP2, TGF-beta1 and E-cadherin in A549 cells.	Paclitaxel	50-60	transforming growth factor beta 1	Homo sapiens	139-148
31432702-5	2019	Mechanism studies indicated that the DQA modified paclitaxel plus ligustrazine micelles could down-regulate the expressions of VEGF, MMP2, TGF-beta1 and E-cadherin in A549 cells.	Paclitaxel	50-60	cadherin 1	Homo sapiens	153-163
31553933-6	2019	The results indicated that the paclitaxel-loaded Fru-RGD-Lip had the strongest growth inhibition against GLUT5 and alphavbeta3 overexpressed MDA-MB-231 and 4T1 cells.	Paclitaxel	31-41	solute carrier family 2 member 5	Homo sapiens	105-110
31149728-5	2019	Subsequently, we examined the effects of CYC1 on proliferation, glycolysis and chemosensitivity to paclitaxel, which is one of the most common chemotherapeutic agents in breast cancer, in ER-positive breast carcinoma cells (MCF7 and T47D).	Paclitaxel	99-109	estrogen receptor 1	Homo sapiens	188-190
31149728-9	2019	In in vitro experiments, MCF7 and T47D cells transfected specific siRNA for CYC1 significantly increased cell proliferation activity, L-lactate production and cell viability after paclitaxel treatment.	Paclitaxel	180-190	cytochrome c1	Homo sapiens	76-80
31149728-10	2019	CONCLUSION: These results suggest that CYC1 inhibits cell proliferation, glycolytic activity and increases chemosensitivity to paclitaxel in ER-positive breast carcinoma cells and that CYC1 status is a potent favorable prognostic factor in ER-positive breast cancer patients.	Paclitaxel	127-137	cytochrome c1	Homo sapiens	39-43
31149728-10	2019	CONCLUSION: These results suggest that CYC1 inhibits cell proliferation, glycolytic activity and increases chemosensitivity to paclitaxel in ER-positive breast carcinoma cells and that CYC1 status is a potent favorable prognostic factor in ER-positive breast cancer patients.	Paclitaxel	127-137	estrogen receptor 1	Homo sapiens	141-143
30782035-0	2019	NEAT1 mediates paclitaxel-resistance of non-small cell of lung cancer through activation of Akt/mTOR signalling pathway.	Paclitaxel	15-25	AKT serine/threonine kinase 1	Homo sapiens	92-95
30782035-0	2019	NEAT1 mediates paclitaxel-resistance of non-small cell of lung cancer through activation of Akt/mTOR signalling pathway.	Paclitaxel	15-25	mechanistic target of rapamycin kinase	Homo sapiens	96-100
31546458-11	2019	In vitro and in vivo studies using MDA-MB-231 breast cancer cells (GRPr-positive) demonstrated a 177Lu-BN-PLGA(PTX) specific uptake and a significantly higher cytotoxic effect for the radiolabeled nanosystem than the unlabeled BN-PLGA(PTX) nanoparticles.	Paclitaxel	111-114	gastrin releasing peptide receptor	Homo sapiens	67-71
31546458-11	2019	In vitro and in vivo studies using MDA-MB-231 breast cancer cells (GRPr-positive) demonstrated a 177Lu-BN-PLGA(PTX) specific uptake and a significantly higher cytotoxic effect for the radiolabeled nanosystem than the unlabeled BN-PLGA(PTX) nanoparticles.	Paclitaxel	235-238	gastrin releasing peptide receptor	Homo sapiens	67-71
31488699-9	2019	Furthermore, the PI3K/Akt pathway inhibitor MK-2206 reversed the resistance to paclitaxel and inhibited the migration and invasion of breast cancer cells.	Paclitaxel	79-89	AKT serine/threonine kinase 1	Homo sapiens	22-25
31536779-6	2019	Molecular and pharmacological targeting of ABCB1/P-gp did not modify its cytotoxic effect in NCI-H295R cells, while it increased the paclitaxel-induced toxicity.	Paclitaxel	133-143	ATP binding cassette subfamily B member 1	Homo sapiens	43-48
31488699-10	2019	These findings indicate that Transgelin 2 promotes paclitaxel resistance and the migration and invasion of breast cancer by directly interacting with PTEN and activating the PI3K/Akt/GSK-3beta pathway.	Paclitaxel	51-61	AKT serine/threonine kinase 1	Homo sapiens	179-182
31855118-0	2019	Transferrin/alpha-tocopherol modified poly(amidoamine) dendrimers for improved tumor targeting and anticancer activity of paclitaxel.	Paclitaxel	122-132	transferrin	Homo sapiens	0-11
31855118-1	2019	Aim: Transferrin anchored, poly(ethylene glycol) (PEG) and alpha-tocopheryl succinate (alpha-TOS) conjugated generation 4 dendrimer has been prepared in order to develop a tumor targeted delivery system of a hydrophobic chemotherapeutic agent, paclitaxel (PTX).	Paclitaxel	244-254	transferrin	Homo sapiens	5-16
31855118-1	2019	Aim: Transferrin anchored, poly(ethylene glycol) (PEG) and alpha-tocopheryl succinate (alpha-TOS) conjugated generation 4 dendrimer has been prepared in order to develop a tumor targeted delivery system of a hydrophobic chemotherapeutic agent, paclitaxel (PTX).	Paclitaxel	256-259	transferrin	Homo sapiens	5-16
31772161-5	2019	In this context, MUC1 induces CSCs enrichment in paclitaxel-resistant cells via activation of EGFR, which directly enhances IL-6 transcription through cAMP response element-binding protein (CREB) and glucocorticoid receptor beta (GRbeta).	Paclitaxel	49-59	epidermal growth factor receptor	Homo sapiens	94-98
31801248-4	2019	In this study, tetrandrine showed synergistic cytotoxic activity in combinational use with chemotherapeutic drugs, such as Doxorubicin, Vincristine, and Paclitaxel, in both drug-induced and MDR1 gene-transfected cancer cells that over-expressed ABCB1/P-glycoprotein.	Paclitaxel	153-163	ATP binding cassette subfamily B member 1	Homo sapiens	190-194
31852648-0	2019	[Golgi phosphoprotein 3 overexpression inhibits paclitaxel-induced apoptosis in HeLa cells by promoting autophagy].	Paclitaxel	48-58	golgi phosphoprotein 3	Homo sapiens	1-23
31852648-1	2019	OBJECTIVE: To investigate the effect of Golgi phosphoprotein 3 (Golph3) on paclitaxel- induced apoptosis and autophagy in HeLa cells.	Paclitaxel	75-85	golgi phosphoprotein 3	Homo sapiens	40-62
31852648-1	2019	OBJECTIVE: To investigate the effect of Golgi phosphoprotein 3 (Golph3) on paclitaxel- induced apoptosis and autophagy in HeLa cells.	Paclitaxel	75-85	golgi phosphoprotein 3	Homo sapiens	64-70
31852648-8	2019	The cell apoptosis induced by paclitaxel was significantly decreased in Golph3-overexpressing HeLa cells and increased in the cells with Golph3 knockdown (P>0.01).	Paclitaxel	30-40	golgi phosphoprotein 3	Homo sapiens	72-78
31852648-8	2019	The cell apoptosis induced by paclitaxel was significantly decreased in Golph3-overexpressing HeLa cells and increased in the cells with Golph3 knockdown (P>0.01).	Paclitaxel	30-40	golgi phosphoprotein 3	Homo sapiens	137-143
31852648-9	2019	Treatment with 3-MA alone did not obviously affect HeLa cell apoptosis, but in cells with Golph3 knockdown, 3-MA significantly enhanced paclitaxel-induced apoptosis (P>0.01).	Paclitaxel	136-146	golgi phosphoprotein 3	Homo sapiens	90-96
31852648-10	2019	CONCLUSIONS: Up-regulation of Golph3 promotes autophagy and inhibits paclitaxel-induced apoptosis, whereas suppression of Golph3 inhibits autophagy and enhances paclitaxel- induced apoptosis in HeLa cells.	Paclitaxel	69-79	golgi phosphoprotein 3	Homo sapiens	30-36
31852648-10	2019	CONCLUSIONS: Up-regulation of Golph3 promotes autophagy and inhibits paclitaxel-induced apoptosis, whereas suppression of Golph3 inhibits autophagy and enhances paclitaxel- induced apoptosis in HeLa cells.	Paclitaxel	161-171	golgi phosphoprotein 3	Homo sapiens	122-128
31692005-12	2019	The regimens of paclitaxel + bevacizumab + capecitabine, docetaxel + gemcitabine, and paclitaxel + gemcitabine may be superior to other regimens for treatment of HER2-negative MBC.	Paclitaxel	16-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-166
31692005-12	2019	The regimens of paclitaxel + bevacizumab + capecitabine, docetaxel + gemcitabine, and paclitaxel + gemcitabine may be superior to other regimens for treatment of HER2-negative MBC.	Paclitaxel	86-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-166
31772161-9	2019	Collectively, our work has demonstrated that the MUC1-EGFR-CREB/GRbeta axis stimulates IL-6 expression to induce CSCs enrichment and importantly, this effect can be abrogated by erlotinib, uncovering a novel strategy to treat paclitaxel-resistant cervical cancer.	Paclitaxel	226-236	epidermal growth factor receptor	Homo sapiens	54-58
31772161-9	2019	Collectively, our work has demonstrated that the MUC1-EGFR-CREB/GRbeta axis stimulates IL-6 expression to induce CSCs enrichment and importantly, this effect can be abrogated by erlotinib, uncovering a novel strategy to treat paclitaxel-resistant cervical cancer.	Paclitaxel	226-236	interleukin 6	Homo sapiens	87-91
31772161-5	2019	In this context, MUC1 induces CSCs enrichment in paclitaxel-resistant cells via activation of EGFR, which directly enhances IL-6 transcription through cAMP response element-binding protein (CREB) and glucocorticoid receptor beta (GRbeta).	Paclitaxel	49-59	interleukin 6	Homo sapiens	124-128
31752957-8	2019	Moreover, such EMT reversion can be induced by drug targeting of WDR5 as well, leading to BC cell sensitization to chemotherapy and enhancement of paclitaxel-dependent effects.	Paclitaxel	147-157	WD repeat domain 5	Homo sapiens	65-69
31819616-0	2019	Low-Concentration PTX And RSL3 Inhibits Tumor Cell Growth Synergistically By Inducing Ferroptosis In Mutant p53 Hypopharyngeal Squamous Carcinoma.	Paclitaxel	18-21	tumor protein p53	Homo sapiens	108-111
31819616-3	2019	Recent findings showed low-concentration paclitaxel (PTX) could inhibit cell death by upregulating p53 expression; downregulating glutaminolysis-related genes.	Paclitaxel	41-51	tumor protein p53	Homo sapiens	99-102
31819616-3	2019	Recent findings showed low-concentration paclitaxel (PTX) could inhibit cell death by upregulating p53 expression; downregulating glutaminolysis-related genes.	Paclitaxel	53-56	tumor protein p53	Homo sapiens	99-102
31499197-3	2019	Due to the dense surrounding stroma and the high autophagy in pancreatic cancer, integrin alphavbeta3 targeting, acid environmental sensitive, TR peptide-modified liposomal platforms loaded with combined autophagy inhibiting hydroxychloroquine (HCQ), and cytotoxic paclitaxel (PTX) were designed (TR-PTX/HCQ-Lip) to accomplish the aim of synergistically killing tumor cells while inhibiting stroma fibrosis.	Paclitaxel	265-275	coagulation factor II thrombin receptor	Homo sapiens	143-145
31775332-9	2019	These results demonstrated that EA alleviates paclitaxel-induced peripheral neuropathic pain via mechanisms possibly involving suppressing TLR4 signaling and TRPV1 upregulation in DRG neurons, which further result in reduced spinal glia activation.	Paclitaxel	46-56	toll-like receptor 4	Rattus norvegicus	139-143
31775332-0	2019	Electroacupuncture Alleviates Paclitaxel-Induced Peripheral Neuropathic Pain in Rats via Suppressing TLR4 Signaling and TRPV1 Upregulation in Sensory Neurons.	Paclitaxel	30-40	toll-like receptor 4	Rattus norvegicus	101-105
31775332-5	2019	Mechanistically, TLR4 (Toll-Like Receptor 4) and downstream signaling MyD88 (Myeloid Differentiation Primary Response 88) and TRPV1 (Transient Receptor Potential Vallinoid 1) were upregulated in dorsal root ganglion (DRGs) of paclitaxel-treated rats, whereas EA reduced their overexpression.	Paclitaxel	226-236	toll-like receptor 4	Rattus norvegicus	17-21
31476282-5	2019	Further mechanism studies demonstrated that 479 increased the accumulation of paclitaxel and mitoxantrone in cancer cells by interrupting the efflux function of transporters and stimulating ABCB1/ABCG2 ATPase activity.	Paclitaxel	78-88	ATP binding cassette subfamily B member 1	Homo sapiens	190-195
31476282-5	2019	Further mechanism studies demonstrated that 479 increased the accumulation of paclitaxel and mitoxantrone in cancer cells by interrupting the efflux function of transporters and stimulating ABCB1/ABCG2 ATPase activity.	Paclitaxel	78-88	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	196-201
31712703-4	2019	In paclitaxel-treated mice, increased fatigue and decreased cognitive performance occurred in parallel with reduced microglia immunoreactivity, increased circulating chemokine expression (CXCL1), as well as transient increases in pro-inflammatory cytokine/chemokine (Il-1beta, Tnfalpha, Il-6, and Cxcl1) gene expression in the brain.	Paclitaxel	3-13	chemokine (C-X-C motif) ligand 1	Mus musculus	188-193
31712703-4	2019	In paclitaxel-treated mice, increased fatigue and decreased cognitive performance occurred in parallel with reduced microglia immunoreactivity, increased circulating chemokine expression (CXCL1), as well as transient increases in pro-inflammatory cytokine/chemokine (Il-1beta, Tnfalpha, Il-6, and Cxcl1) gene expression in the brain.	Paclitaxel	3-13	tumor necrosis factor	Mus musculus	277-285
31712703-4	2019	In paclitaxel-treated mice, increased fatigue and decreased cognitive performance occurred in parallel with reduced microglia immunoreactivity, increased circulating chemokine expression (CXCL1), as well as transient increases in pro-inflammatory cytokine/chemokine (Il-1beta, Tnfalpha, Il-6, and Cxcl1) gene expression in the brain.	Paclitaxel	3-13	interleukin 6	Mus musculus	287-291
31712703-4	2019	In paclitaxel-treated mice, increased fatigue and decreased cognitive performance occurred in parallel with reduced microglia immunoreactivity, increased circulating chemokine expression (CXCL1), as well as transient increases in pro-inflammatory cytokine/chemokine (Il-1beta, Tnfalpha, Il-6, and Cxcl1) gene expression in the brain.	Paclitaxel	3-13	chemokine (C-X-C motif) ligand 1	Mus musculus	297-302
31707979-0	2019	Paclitaxel-activated astrocytes produce mechanical allodynia in mice by releasing tumor necrosis factor-alpha and stromal-derived cell factor 1.	Paclitaxel	0-10	tumor necrosis factor	Mus musculus	82-109
31707979-8	2019	Cultured astrocytes were activated by paclitaxel with significant increases in protein levels for tumor necrosis factor-alpha (TNF-alpha) and stromal-derived cell factor 1 (SDF-1).	Paclitaxel	38-48	tumor necrosis factor	Mus musculus	98-125
31707979-8	2019	Cultured astrocytes were activated by paclitaxel with significant increases in protein levels for tumor necrosis factor-alpha (TNF-alpha) and stromal-derived cell factor 1 (SDF-1).	Paclitaxel	38-48	tumor necrosis factor	Mus musculus	127-136
31707979-9	2019	Importantly, intrathecal injection of paclitaxel-activated astrocytes produced mechanical allodynia that was reversed by TNF-alpha and SDF-1 neutralizing antibodies.	Paclitaxel	38-48	tumor necrosis factor	Mus musculus	121-130
31707979-10	2019	CONCLUSION: Our results suggest for the first time that paclitaxel can directly activate astrocytes, which are sufficient to produce acute pain by releasing TNF-alpha and SDF-1.	Paclitaxel	56-66	tumor necrosis factor	Mus musculus	157-166
31499197-3	2019	Due to the dense surrounding stroma and the high autophagy in pancreatic cancer, integrin alphavbeta3 targeting, acid environmental sensitive, TR peptide-modified liposomal platforms loaded with combined autophagy inhibiting hydroxychloroquine (HCQ), and cytotoxic paclitaxel (PTX) were designed (TR-PTX/HCQ-Lip) to accomplish the aim of synergistically killing tumor cells while inhibiting stroma fibrosis.	Paclitaxel	277-280	coagulation factor II thrombin receptor	Homo sapiens	143-145
31499197-3	2019	Due to the dense surrounding stroma and the high autophagy in pancreatic cancer, integrin alphavbeta3 targeting, acid environmental sensitive, TR peptide-modified liposomal platforms loaded with combined autophagy inhibiting hydroxychloroquine (HCQ), and cytotoxic paclitaxel (PTX) were designed (TR-PTX/HCQ-Lip) to accomplish the aim of synergistically killing tumor cells while inhibiting stroma fibrosis.	Paclitaxel	300-303	coagulation factor II thrombin receptor	Homo sapiens	143-145
31037647-8	2019	Paclitaxel significantly increased, and losartan subsequently decreased, the expression levels of inflammatory cytokines, including IL-1beta and tumor necrosis factor alpha (TNF-alpha), in the lumbar DRG.	Paclitaxel	0-10	interleukin 1 alpha	Rattus norvegicus	132-140
31445322-1	2019	We have constructed Herceptin-conjugated, paclitaxel (PTX) loaded, PCL-PEG worm-like nanocrystal micelles (PTX@PCL-PEG-Herceptin) for the combinatorial therapy of HER2-positive breast cancer that exploit the specific targeting of Herceptin to HER2-positive breast cancer cells.	Paclitaxel	54-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	163-167
31445322-1	2019	We have constructed Herceptin-conjugated, paclitaxel (PTX) loaded, PCL-PEG worm-like nanocrystal micelles (PTX@PCL-PEG-Herceptin) for the combinatorial therapy of HER2-positive breast cancer that exploit the specific targeting of Herceptin to HER2-positive breast cancer cells.	Paclitaxel	54-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	243-247
31445322-4	2019	This study shows PTX@PCL-PEG-Herceptin remained relatively stable in the circulation and in the tumor microenvironment, and rapidly targeted and entered into the HER2-overexpressing tumor cells while sparing normal tissues from the toxic effects.	Paclitaxel	17-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-166
31445322-6	2019	Mechanistic studies showed that PTX@PCL-PEG-Herceptin entered into the HER2-positive tumor cells through the caveolin-mediated pathway.	Paclitaxel	32-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
31675995-8	2019	Arr2 attenuated the promotion of caspase-3 and caspase-9 by paclitaxel and mediated the increase of TLR2 and several inflammatory cytokines.	Paclitaxel	60-70	arrestin beta 2	Homo sapiens	0-4
31675995-8	2019	Arr2 attenuated the promotion of caspase-3 and caspase-9 by paclitaxel and mediated the increase of TLR2 and several inflammatory cytokines.	Paclitaxel	60-70	caspase 3	Homo sapiens	33-42
31675995-10	2019	CONCLUSION: Arr2 overexpression was associated with the increase of TLR2 and several inflammatory factors, meanwhile inhibited paclitaxel-induced anti-tumor effect on human EC heterotransplants.	Paclitaxel	127-137	arrestin beta 2	Homo sapiens	12-16
31983136-0	2019	Some concerns about adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer.	Paclitaxel	29-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-121
31363957-0	2019	G protein-coupled receptor kinase 5 modifies cancer cell resistance to paclitaxel.	Paclitaxel	71-81	G protein-coupled receptor kinase 5	Homo sapiens	0-35
31363957-3	2019	In this report, we show that cervical cancer HeLa cells and breast cancer MDA MB 231 cells with reduced GRK5 expression display increased sensitivity to the apoptotic effects of paclitaxel (Taxol).	Paclitaxel	178-188	G protein-coupled receptor kinase 5	Homo sapiens	104-108
31363957-3	2019	In this report, we show that cervical cancer HeLa cells and breast cancer MDA MB 231 cells with reduced GRK5 expression display increased sensitivity to the apoptotic effects of paclitaxel (Taxol).	Paclitaxel	190-195	G protein-coupled receptor kinase 5	Homo sapiens	104-108
31363957-4	2019	This effect in cancer cells with low GRK5 levels could be because of blunted histone deacetylase 6 (HDAC6) activity that leads to an increase in alpha-tubulin acetylation levels, which augments paclitaxel sensitivity.	Paclitaxel	194-204	G protein-coupled receptor kinase 5	Homo sapiens	37-41
31363957-4	2019	This effect in cancer cells with low GRK5 levels could be because of blunted histone deacetylase 6 (HDAC6) activity that leads to an increase in alpha-tubulin acetylation levels, which augments paclitaxel sensitivity.	Paclitaxel	194-204	histone deacetylase 6	Homo sapiens	77-98
31363957-4	2019	This effect in cancer cells with low GRK5 levels could be because of blunted histone deacetylase 6 (HDAC6) activity that leads to an increase in alpha-tubulin acetylation levels, which augments paclitaxel sensitivity.	Paclitaxel	194-204	histone deacetylase 6	Homo sapiens	100-105
31363957-7	2019	Therefore, the GRK5-HDAC6 interaction may contribute to paclitaxel resistance in cancer cells.	Paclitaxel	56-66	G protein-coupled receptor kinase 5	Homo sapiens	15-19
31363957-7	2019	Therefore, the GRK5-HDAC6 interaction may contribute to paclitaxel resistance in cancer cells.	Paclitaxel	56-66	histone deacetylase 6	Homo sapiens	20-25
31098863-7	2019	Combination therapy with CX-4945 and paclitaxel exerted synergistic antiproliferative effects and inhibited the downregulation of phosphatidylinositol 3-kinase/AKT signaling in SNU-1 cells.	Paclitaxel	37-47	AKT serine/threonine kinase 1	Homo sapiens	160-163
31037647-8	2019	Paclitaxel significantly increased, and losartan subsequently decreased, the expression levels of inflammatory cytokines, including IL-1beta and tumor necrosis factor alpha (TNF-alpha), in the lumbar DRG.	Paclitaxel	0-10	tumor necrosis factor	Rattus norvegicus	145-172
31037647-8	2019	Paclitaxel significantly increased, and losartan subsequently decreased, the expression levels of inflammatory cytokines, including IL-1beta and tumor necrosis factor alpha (TNF-alpha), in the lumbar DRG.	Paclitaxel	0-10	tumor necrosis factor	Rattus norvegicus	174-183
31571407-11	2019	For non-small cell lung cancer (NSCLC) patients, those harboring ABCB1 2677 and 3435 site wild-type patients had longer median progression-free survival (PFS) in the paclitaxel subgroup (3435 site: TT 3.87 vs. TC 9.50 vs. CC 14.13 months; P &lt; 0.001; 2677 site: TT 4.37 vs. TG 9.73 vs. GG 12.1 months; P = 0.013).	Paclitaxel	166-176	ATP binding cassette subfamily B member 1	Homo sapiens	65-70
31462500-8	2019	Conversely, specific inhibitors of BCL-XL, MCL1, or BCL-XL/BCL-2, but not BCL-2 alone, enhanced cell death when combined with cisplatin or paclitaxel.	Paclitaxel	139-149	BCL2 like 1	Homo sapiens	35-41
31462500-8	2019	Conversely, specific inhibitors of BCL-XL, MCL1, or BCL-XL/BCL-2, but not BCL-2 alone, enhanced cell death when combined with cisplatin or paclitaxel.	Paclitaxel	139-149	BCL2 like 1	Homo sapiens	52-58
31462500-8	2019	Conversely, specific inhibitors of BCL-XL, MCL1, or BCL-XL/BCL-2, but not BCL-2 alone, enhanced cell death when combined with cisplatin or paclitaxel.	Paclitaxel	139-149	BCL2 apoptosis regulator	Homo sapiens	59-64
31611995-13	2019	Additionally, transketolase family genes served a role in predicting PFS in patients with ovarian cancer treated with platinum and/or taxol.	Paclitaxel	134-139	transketolase	Homo sapiens	14-27
31467112-0	2019	Breast cancer risk-associated SNPs in the mTOR promoter form de novo KLF5 and ZEB1 binding sites that influence the cellular response to paclitaxel.	Paclitaxel	137-147	mechanistic target of rapamycin kinase	Homo sapiens	42-46
31467112-4	2019	At the cellular level, compared to Ht1, Ht2 exhibits a much stronger effect on promoting mTOR expression, leading to enhanced tumor cell growth and strengthened resistance to PTX treatment.	Paclitaxel	175-178	mechanistic target of rapamycin kinase	Homo sapiens	89-93
31467112-5	2019	Mechanistically, the -141T allele of Ht2 creates a novel ZEB1 binding site; meanwhile, the -78C allele of Ht1 exists as an emerging KLF5 binding site, which synergistically induces promote/inhibit mTOR expression, cell proliferation and excretion of cytotoxic drugs through the ZEB1/KLF5-mTOR-CCND1/ABCB1 cascade, thereby affecting the response to PTX treatment in vivo and in vitro.	Paclitaxel	348-351	mechanistic target of rapamycin kinase	Homo sapiens	197-201
31467112-5	2019	Mechanistically, the -141T allele of Ht2 creates a novel ZEB1 binding site; meanwhile, the -78C allele of Ht1 exists as an emerging KLF5 binding site, which synergistically induces promote/inhibit mTOR expression, cell proliferation and excretion of cytotoxic drugs through the ZEB1/KLF5-mTOR-CCND1/ABCB1 cascade, thereby affecting the response to PTX treatment in vivo and in vitro.	Paclitaxel	348-351	mechanistic target of rapamycin kinase	Homo sapiens	288-292
31467112-5	2019	Mechanistically, the -141T allele of Ht2 creates a novel ZEB1 binding site; meanwhile, the -78C allele of Ht1 exists as an emerging KLF5 binding site, which synergistically induces promote/inhibit mTOR expression, cell proliferation and excretion of cytotoxic drugs through the ZEB1/KLF5-mTOR-CCND1/ABCB1 cascade, thereby affecting the response to PTX treatment in vivo and in vitro.	Paclitaxel	348-351	ATP binding cassette subfamily B member 1	Homo sapiens	299-304
31467112-6	2019	Our results suggest the existence of a ZEB1/KLF5-mTOR-CCND1/ABCB1 axis in human cells that could be involved in PTX response pathways and functionally regulate inter-individualized breast cancer susceptibility and prognosis.	Paclitaxel	112-115	mechanistic target of rapamycin kinase	Homo sapiens	49-53
31467112-6	2019	Our results suggest the existence of a ZEB1/KLF5-mTOR-CCND1/ABCB1 axis in human cells that could be involved in PTX response pathways and functionally regulate inter-individualized breast cancer susceptibility and prognosis.	Paclitaxel	112-115	ATP binding cassette subfamily B member 1	Homo sapiens	60-65
31467112-7	2019	Implications: The current study highlights the function of haplotypes of mTOR -78C/-141G and -78G/-141T, in affecting breast cancer susceptibility and PTX response regulated by ZEB1/KLF5-mTOR-CCND1/ABCB1 axis.	Paclitaxel	151-154	mechanistic target of rapamycin kinase	Homo sapiens	73-77
31467112-7	2019	Implications: The current study highlights the function of haplotypes of mTOR -78C/-141G and -78G/-141T, in affecting breast cancer susceptibility and PTX response regulated by ZEB1/KLF5-mTOR-CCND1/ABCB1 axis.	Paclitaxel	151-154	mechanistic target of rapamycin kinase	Homo sapiens	187-191
31467112-7	2019	Implications: The current study highlights the function of haplotypes of mTOR -78C/-141G and -78G/-141T, in affecting breast cancer susceptibility and PTX response regulated by ZEB1/KLF5-mTOR-CCND1/ABCB1 axis.	Paclitaxel	151-154	ATP binding cassette subfamily B member 1	Homo sapiens	198-203
31023863-9	2019	Among the seven polymorphisms selected for genotyping, the variant alleles of EPHA5-rs7349683, EPHA6-rs301927, and EPHA8-rs209709 were associated with an increased risk of paclitaxel-induced neuropathy.	Paclitaxel	172-182	EPH receptor A6	Homo sapiens	95-100
31023863-9	2019	Among the seven polymorphisms selected for genotyping, the variant alleles of EPHA5-rs7349683, EPHA6-rs301927, and EPHA8-rs209709 were associated with an increased risk of paclitaxel-induced neuropathy.	Paclitaxel	172-182	EPH receptor A8	Homo sapiens	115-120
31772741-5	2019	Given the HER2 overexpression, she was treated with trastuzumab, paclitaxel and cisplatin.	Paclitaxel	65-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-14
31623606-11	2019	In addition, AKT inhibitor MK-2206 could block the tumor-promoting effect of circPLEKHM3 depletion, and potentiate Taxol-induced growth inhibition of ovarian cancer cells.	Paclitaxel	115-120	AKT serine/threonine kinase 1	Homo sapiens	13-16
31762812-9	2019	Ovarian cancer cells with SIK3 knockdown display increased chemoresistance to Taxol plus cisplatin treatment, which is associated with the upregulation of the ABCG2 transporter.	Paclitaxel	78-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	159-164
31762817-0	2019	Lin28b is involved in curcumin-reversed paclitaxel chemoresistance and associated with poor prognosis in hepatocellular carcinoma.	Paclitaxel	40-50	lin-28 homolog B	Homo sapiens	0-6
31762817-3	2019	In this study, we found that overexpression of Lin28B significantly increased the paclitaxel chemoresistance in two different HCC cells lines while silencing Lin28B reduced the chemoresistance in paclitaxel-resistance HCC cells.	Paclitaxel	82-92	lin-28 homolog B	Homo sapiens	47-53
31762817-3	2019	In this study, we found that overexpression of Lin28B significantly increased the paclitaxel chemoresistance in two different HCC cells lines while silencing Lin28B reduced the chemoresistance in paclitaxel-resistance HCC cells.	Paclitaxel	196-206	lin-28 homolog B	Homo sapiens	158-164
31762817-4	2019	Curcumin, a natural anti-cancer agent, increased the sensitivity of HCC cells to paclitaxel through inhibiting NF-kappaB stimulated Lin28B expression both in vitro and in vivo.	Paclitaxel	81-91	lin-28 homolog B	Homo sapiens	132-138
31762748-7	2019	Here we describe a case of TKI refractory EGFR-mutant NSCLC successfully treated with carboplatin, paclitaxel, atezolizumab and bevacizumab combination with remarkable prompt tumor response.	Paclitaxel	99-109	epidermal growth factor receptor	Homo sapiens	42-46
31581131-5	2019	Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel.	Paclitaxel	87-97	small nucleolar RNA host gene 22	Homo sapiens	13-19
31720085-0	2019	The resistance of esophageal cancer cells to paclitaxel can be reduced by the knockdown of long noncoding RNA DDX11-AS1 through TAF1/TOP2A inhibition.	Paclitaxel	45-55	DEAD/H-box helicase 11	Homo sapiens	110-115
31749880-7	2019	Oocyte-specific genes such as growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) were more suppressed in the paclitaxel group than in the cisplatin group.	Paclitaxel	139-149	bone morphogenetic protein 15	Homo sapiens	73-102
31570440-0	2019	Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter.	Paclitaxel	18-28	ATP binding cassette subfamily B member 1	Homo sapiens	97-102
31570440-9	2019	RESULTS: A549/PTX cells had significant resistance to PTX and higher expression of ABCB1 compared to A549 cells.	Paclitaxel	14-17	ATP binding cassette subfamily B member 1	Homo sapiens	83-88
31570440-12	2019	Apatinib-PTX combination inhibited AKT and ERK pathways.	Paclitaxel	9-12	AKT serine/threonine kinase 1	Homo sapiens	35-38
31570440-12	2019	Apatinib-PTX combination inhibited AKT and ERK pathways.	Paclitaxel	9-12	mitogen-activated protein kinase 1	Homo sapiens	43-46
31570440-13	2019	CONCLUSION: Apatinib reverses the drug resistance to PTX in A549 PTX-resistant cells through inhibiting the function of ABCB1 and resumes anti-cancer effects.	Paclitaxel	53-56	ATP binding cassette subfamily B member 1	Homo sapiens	120-125
31570440-13	2019	CONCLUSION: Apatinib reverses the drug resistance to PTX in A549 PTX-resistant cells through inhibiting the function of ABCB1 and resumes anti-cancer effects.	Paclitaxel	65-68	ATP binding cassette subfamily B member 1	Homo sapiens	120-125
31720085-3	2019	The present study aims to define the role of the long noncoding RNA (lncRNA) DDX11-AS1 in the progression of EC with the involvement of PTX-resistant EC cells.	Paclitaxel	136-139	DEAD/H-box helicase 11	Homo sapiens	77-82
31720085-8	2019	DDX11-AS1 could promote TOP2A transcription via TAF1, and the knockdown of TOP2A or DDX11-AS1 could increase the sensitivity of EC cells to PTX.	Paclitaxel	140-143	DEAD/H-box helicase 11	Homo sapiens	0-5
31720085-8	2019	DDX11-AS1 could promote TOP2A transcription via TAF1, and the knockdown of TOP2A or DDX11-AS1 could increase the sensitivity of EC cells to PTX.	Paclitaxel	140-143	DEAD/H-box helicase 11	Homo sapiens	84-89
31720085-9	2019	The effect of DDX11-AS1 on the growth of PTX-inhibited tumors was confirmed using a tumor formation assay in nude mice.	Paclitaxel	41-44	DEAD/H box helicase 11	Mus musculus	14-19
31720085-9	2019	The effect of DDX11-AS1 on the growth of PTX-inhibited tumors was confirmed using a tumor formation assay in nude mice.	Paclitaxel	41-44	arylsulfatase B	Mus musculus	20-23
31720085-11	2019	In conclusion, our findings suggest that DDX11-AS1 knockdown results in reduced resistance of EC cells to PTX by inhibiting TOP2A transcription via TAF1.	Paclitaxel	106-109	DEAD/H-box helicase 11	Homo sapiens	41-46
31749880-7	2019	Oocyte-specific genes such as growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) were more suppressed in the paclitaxel group than in the cisplatin group.	Paclitaxel	139-149	bone morphogenetic protein 15	Homo sapiens	104-109
31350703-1	2019	We previously reported that anti-paclitaxel-resistant ovarian carcinoma cells characteristically expressed the MDR1 (multidrug resistance 1) gene with enhanced synthesis of glycolipids, i.e., LacCer, Gb3Cer, Leb and GM3, and that anti-cisplatin-resistant cells lost GM3.	Paclitaxel	33-43	ATP binding cassette subfamily B member 1	Homo sapiens	111-115
31545250-0	2019	High Notch1 expression affects chemosensitivity of head and neck squamous cell carcinoma to paclitaxel and cisplatin treatment.	Paclitaxel	92-102	notch receptor 1	Homo sapiens	5-11
31545250-6	2019	RESULTS: High Notch1 expression was significantly associated with paclitaxel resistance (P &lt; 0.01).	Paclitaxel	66-76	notch receptor 1	Homo sapiens	14-20
31545250-10	2019	CONCLUSION: Taken together, our findings may provide some evidence to partially support the predictive value of Notch1 expression in the therapeutic response to paclitaxel and cisplatin.	Paclitaxel	161-171	notch receptor 1	Homo sapiens	112-118
31783991-2	2019	METHODS: To describe topological features of the MTAs networks associated to intrinsic apoptosis induction in p53-null prostate cancer cells, we predicted and compared the interactomes and topological properties of Paclitaxel and Vincristine, and thus, the essential nodes corresponding with the pro- and anti-apoptotic proteins and their kinetics were subjected to experimental analysis in PC-3 cell line.	Paclitaxel	215-225	tumor protein p53	Homo sapiens	110-113
31783991-3	2019	RESULTS: The essential nodes of the apoptotic pathways, TP53, and CASP3, were identified in both, Paclitaxel and Vincristine networks, but the intrinsic pathway markers BCL2, BAX, and BCL2L1 were identified as hub nodes only in the Paclitaxel network.	Paclitaxel	98-108	tumor protein p53	Homo sapiens	56-60
31783991-3	2019	RESULTS: The essential nodes of the apoptotic pathways, TP53, and CASP3, were identified in both, Paclitaxel and Vincristine networks, but the intrinsic pathway markers BCL2, BAX, and BCL2L1 were identified as hub nodes only in the Paclitaxel network.	Paclitaxel	98-108	caspase 3	Homo sapiens	66-71
31783991-3	2019	RESULTS: The essential nodes of the apoptotic pathways, TP53, and CASP3, were identified in both, Paclitaxel and Vincristine networks, but the intrinsic pathway markers BCL2, BAX, and BCL2L1 were identified as hub nodes only in the Paclitaxel network.	Paclitaxel	232-242	tumor protein p53	Homo sapiens	56-60
31783991-3	2019	RESULTS: The essential nodes of the apoptotic pathways, TP53, and CASP3, were identified in both, Paclitaxel and Vincristine networks, but the intrinsic pathway markers BCL2, BAX, and BCL2L1 were identified as hub nodes only in the Paclitaxel network.	Paclitaxel	232-242	caspase 3	Homo sapiens	66-71
31464090-8	2019	Conversely, activation of IFN/JAK2 and ER stress response pathways in NPC cells reduced paclitaxel resistance and increased apoptosis.	Paclitaxel	88-98	interferon alpha 1	Homo sapiens	26-29
31350703-3	2019	The MDR1 gene was only detected in RMG-1 cells, in which the amounts of Gb4Cer, Leb and GM3 were higher than in the other cells, which reflected their much higher resistance to paclitaxel and docetaxel compared to the other cells.	Paclitaxel	177-187	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
31350703-6	2019	Thus, MDR1, and increased amounts of Gb4Cer, Leb and GM3 were suggested to be involved in the anticancer drug-resistance to hydrophobic paclitaxel and docetaxel, and GM3 was to basic cisplatin.	Paclitaxel	136-146	ATP binding cassette subfamily B member 1	Homo sapiens	6-10
31350703-1	2019	We previously reported that anti-paclitaxel-resistant ovarian carcinoma cells characteristically expressed the MDR1 (multidrug resistance 1) gene with enhanced synthesis of glycolipids, i.e., LacCer, Gb3Cer, Leb and GM3, and that anti-cisplatin-resistant cells lost GM3.	Paclitaxel	33-43	ATP binding cassette subfamily B member 1	Homo sapiens	117-139
31898651-6	2019	Results: Compared with parental HeLa cells, HeLa/Taxol with Taxol resistance had the following biological characteristics: first, they had a lower growth velocity; second, the expression of P-glycoprotein and glutathione S-transferases was significantly increased; Third, the expression of antiapoptotic protein Bcl-2 and apoptosis inhibitor protein survivin was prominently increased.	Paclitaxel	49-54	BCL2 apoptosis regulator	Homo sapiens	312-317
30367323-5	2019	In the in vivo model, placental tissues isolated from pregnant cancer patients treated with paclitaxel were analyzed to assess the protein expression of ABCB1/P-gp and ABCG2/BCRP.	Paclitaxel	92-102	ATP binding cassette subfamily B member 1	Homo sapiens	153-158
30367323-5	2019	In the in vivo model, placental tissues isolated from pregnant cancer patients treated with paclitaxel were analyzed to assess the protein expression of ABCB1/P-gp and ABCG2/BCRP.	Paclitaxel	92-102	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	168-173
30367323-7	2019	Results In the in vitro model, the expression of twelve drug-transporters genes was found to be significantly down-regulated after exposure to paclitaxel, including ABCC10, SLC28A3, SLC29A2, and ATP7B (involved in the transport of taxanes, antimetabolites, and cisplatin, respectively).	Paclitaxel	143-153	solute carrier family 29 member 2	Homo sapiens	182-189
30367323-8	2019	The protein expression of ABCB1/P-gp increased by 1.3-fold after paclitaxel administration.	Paclitaxel	65-75	ATP binding cassette subfamily B member 1	Homo sapiens	26-31
30367323-9	2019	Finally, the protein expression of ABCB1/P-gp and ABCG2/BCRP was higher in cotyledons from mothers treated with multiple doses of paclitaxel during pregnancy than in cotyledons perfused with a single dose of paclitaxel.	Paclitaxel	130-140	ATP binding cassette subfamily B member 1	Homo sapiens	35-40
30367323-9	2019	Finally, the protein expression of ABCB1/P-gp and ABCG2/BCRP was higher in cotyledons from mothers treated with multiple doses of paclitaxel during pregnancy than in cotyledons perfused with a single dose of paclitaxel.	Paclitaxel	130-140	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	50-55
30367323-9	2019	Finally, the protein expression of ABCB1/P-gp and ABCG2/BCRP was higher in cotyledons from mothers treated with multiple doses of paclitaxel during pregnancy than in cotyledons perfused with a single dose of paclitaxel.	Paclitaxel	130-140	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	56-60
30367323-9	2019	Finally, the protein expression of ABCB1/P-gp and ABCG2/BCRP was higher in cotyledons from mothers treated with multiple doses of paclitaxel during pregnancy than in cotyledons perfused with a single dose of paclitaxel.	Paclitaxel	208-218	ATP binding cassette subfamily B member 1	Homo sapiens	35-40
30367323-9	2019	Finally, the protein expression of ABCB1/P-gp and ABCG2/BCRP was higher in cotyledons from mothers treated with multiple doses of paclitaxel during pregnancy than in cotyledons perfused with a single dose of paclitaxel.	Paclitaxel	208-218	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	50-55
30367323-9	2019	Finally, the protein expression of ABCB1/P-gp and ABCG2/BCRP was higher in cotyledons from mothers treated with multiple doses of paclitaxel during pregnancy than in cotyledons perfused with a single dose of paclitaxel.	Paclitaxel	208-218	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	56-60
31401198-2	2019	In this report, we designed and developed a new multifunctional nanocarrier based on anti-epidermal growth factor receptor antibody-conjugated and paclitaxel loaded-thiol chitosan-layered gold nanoshells (anti-EGFR-PTX-TCS-GNSs) as a theranostic agent for the first time used for fluorescence/photoacoustic dual-modal imaging-guided chemophotothermal synergistic therapy.	Paclitaxel	147-157	epidermal growth factor receptor	Homo sapiens	210-214
31898651-6	2019	Results: Compared with parental HeLa cells, HeLa/Taxol with Taxol resistance had the following biological characteristics: first, they had a lower growth velocity; second, the expression of P-glycoprotein and glutathione S-transferases was significantly increased; Third, the expression of antiapoptotic protein Bcl-2 and apoptosis inhibitor protein survivin was prominently increased.	Paclitaxel	60-65	BCL2 apoptosis regulator	Homo sapiens	312-317
31382032-6	2019	Furthermore, the combination of NLG919/HP-beta-CD with paclitaxel (PTX) significantly improved anti-tumour chemotherapy compared to PTX alone.	Paclitaxel	67-70	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	42-49
31382032-7	2019	In summary, NLG919/HP-beta-CD is shown to highly enhance the aqueous solubility of NLG919 with activity unaffected, greatly facilitating the intravenous use of this small molecule immunotherapeutic to improve the efficacy of PTX.	Paclitaxel	225-228	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	22-29
31898651-7	2019	Conclusions: The drug-resistance in HeLa/Taxol is mainly associated with the high expression of multidrug resistance genes, antiapoptotic protein Bcl-2, and apoptosis inhibitor protein survivin as an important reason for the failure of chemotherapy of tumor tissue.	Paclitaxel	41-46	BCL2 apoptosis regulator	Homo sapiens	146-151
31601301-0	2019	Downregulation of iASPP Expression Suppresses Proliferation, Invasion and Increases Chemosensitivity to Paclitaxel of Head and Neck Squamous Cell Carcinoma In Vitro.	Paclitaxel	104-114	protein phosphatase 1 regulatory subunit 13 like	Homo sapiens	18-23
31308076-7	2019	In concert with these results, we show that MUC1-C and TWIST1 also drive EMT and stemness in association with acquired paclitaxel (PTX) resistance.	Paclitaxel	119-129	twist family bHLH transcription factor 1	Homo sapiens	55-61
31308076-7	2019	In concert with these results, we show that MUC1-C and TWIST1 also drive EMT and stemness in association with acquired paclitaxel (PTX) resistance.	Paclitaxel	131-134	twist family bHLH transcription factor 1	Homo sapiens	55-61
31308076-8	2019	Of potential therapeutic importance, targeting MUC1-C and thereby TWIST1 reverses the PTX refractory phenotype as evidenced by synergistic activity with PTX against drug-resistant cells.	Paclitaxel	86-89	twist family bHLH transcription factor 1	Homo sapiens	66-72
31308076-8	2019	Of potential therapeutic importance, targeting MUC1-C and thereby TWIST1 reverses the PTX refractory phenotype as evidenced by synergistic activity with PTX against drug-resistant cells.	Paclitaxel	153-156	twist family bHLH transcription factor 1	Homo sapiens	66-72
31579409-11	2019	Furthermore, the inhibitory effect of miR-23a and Taxol therapy, which reduced SIX1 expression in endometrial cancer, was demonstrated in vivo.	Paclitaxel	50-55	sine oculis-related homeobox 1	Mus musculus	79-83
31601301-10	2019	The survival rate of shRNA-iASPP cells administrated with paclitaxel was highly decreased, compared with CON cells and shRNA-NC cells (F=634.841, P=0.000).	Paclitaxel	58-68	protein phosphatase 1 regulatory subunit 13 like	Homo sapiens	27-32
31482205-2	2019	In the present study, we developed and synthesised two PAMAM dendrimer-trastuzumab conjugates that carried docetaxel or paclitaxel, specifically targeted to cells which overexpressed HER-2.	Paclitaxel	120-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	183-188
31579626-0	2019	Efficacy of Paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer.	Paclitaxel	12-22	epidermal growth factor receptor	Homo sapiens	59-63
31391192-0	2019	6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.	Paclitaxel	79-89	tumor protein p53	Homo sapiens	64-68
31492947-2	2019	Longitudinal alterations in cell confluence are reported for an in vitro model of BT474 HER2+ breast cancer cells following various dosages and timings of paclitaxel and trastuzumab combination regimens.	Paclitaxel	155-165	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
31569625-6	2019	Results of the 177Lu-DOTA-DN(PTX)-BN effect on T47D cell viability (1.3%, compared with 10.9% of 177Lu-DOTA-DN-BN and 14.0% of DOTA-DN-(PTX)-BN) demonstrated the concomitant radiotherapeutic and chemotherapeutic properties of the polymeric nanosystem as a potential agent for the treatment of GRPr-positive tumors.	Paclitaxel	29-32	gastrin releasing peptide receptor	Homo sapiens	293-297
31576113-0	2019	Paclitaxel alleviated sepsis-induced acute lung injury by activating MUC1 and suppressing TLR-4/NF-kappaB pathway.	Paclitaxel	0-10	toll-like receptor 4	Mus musculus	90-95
31576113-0	2019	Paclitaxel alleviated sepsis-induced acute lung injury by activating MUC1 and suppressing TLR-4/NF-kappaB pathway.	Paclitaxel	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	96-105
31576113-12	2019	We also found paclitaxel could attenuate TLR 4-NF-kappaB/p65 activation both in lung tissues of septic mice and LPS-stimulated lung type II epithelial cell line A549.	Paclitaxel	14-24	toll-like receptor 4	Mus musculus	41-46
31576113-12	2019	We also found paclitaxel could attenuate TLR 4-NF-kappaB/p65 activation both in lung tissues of septic mice and LPS-stimulated lung type II epithelial cell line A549.	Paclitaxel	14-24	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	47-56
31576113-14	2019	The inhibitory effects of paclitaxel on TLR 4-NF-kappaB/p65 activation were reversed in lung tissues of septic mice pre-treated with MUC1 inhibitor and in MUC1-knockdown A549 cells.	Paclitaxel	26-36	toll-like receptor 4	Mus musculus	40-45
31576113-14	2019	The inhibitory effects of paclitaxel on TLR 4-NF-kappaB/p65 activation were reversed in lung tissues of septic mice pre-treated with MUC1 inhibitor and in MUC1-knockdown A549 cells.	Paclitaxel	26-36	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	46-55
31576113-16	2019	Conclusion: Collectively, these results indicated paclitaxel could significantly alleviate acute lung injury in CLP-induced septic mice and LPS-stimulated lung type II epithelial cell line A549 by activating MUC1 and suppressing TLR-4/NF-kappaB pathway.	Paclitaxel	50-60	toll-like receptor 4	Mus musculus	229-234
31576113-16	2019	Conclusion: Collectively, these results indicated paclitaxel could significantly alleviate acute lung injury in CLP-induced septic mice and LPS-stimulated lung type II epithelial cell line A549 by activating MUC1 and suppressing TLR-4/NF-kappaB pathway.	Paclitaxel	50-60	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	235-244
31660072-0	2019	CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1/P50.	Paclitaxel	28-38	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	83-89
31660072-0	2019	CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1/P50.	Paclitaxel	28-38	nuclear factor kappa B subunit 1	Homo sapiens	90-93
31660072-13	2019	Consistently, inhibiting p300/CBP substantially decreased CapG-dependent upregulation of PIK3R1/P50 and subsequent PI3K/Akt activation, resulting in increased sensitivity to paclitaxel treatment in breast cancer cells.	Paclitaxel	174-184	CREB binding protein	Homo sapiens	30-33
31660072-13	2019	Consistently, inhibiting p300/CBP substantially decreased CapG-dependent upregulation of PIK3R1/P50 and subsequent PI3K/Akt activation, resulting in increased sensitivity to paclitaxel treatment in breast cancer cells.	Paclitaxel	174-184	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	89-95
31660072-13	2019	Consistently, inhibiting p300/CBP substantially decreased CapG-dependent upregulation of PIK3R1/P50 and subsequent PI3K/Akt activation, resulting in increased sensitivity to paclitaxel treatment in breast cancer cells.	Paclitaxel	174-184	nuclear factor kappa B subunit 1	Homo sapiens	96-99
31660072-13	2019	Consistently, inhibiting p300/CBP substantially decreased CapG-dependent upregulation of PIK3R1/P50 and subsequent PI3K/Akt activation, resulting in increased sensitivity to paclitaxel treatment in breast cancer cells.	Paclitaxel	174-184	AKT serine/threonine kinase 1	Homo sapiens	120-123
31506466-5	2019	Importantly, these inhibitory effects on glucose metabolism were enhanced by palbociclib/paclitaxel sequential combination; the superior efficacy of such combination was ascribed to the ability of paclitaxel to inhibit palbociclib-mediated induction of AKT and to further down-regulate the Rb/E2F/c-myc signaling.	Paclitaxel	197-207	AKT serine/threonine kinase 1	Homo sapiens	253-256
31484456-6	2019	On 4T1 cells, siRNAs against AKT and ERBB2 plus paclitaxel or docetaxel resulted in the largest increase in anti-cancer effects compared to CA/paclitaxel or CA/docetaxel.	Paclitaxel	143-153	thymoma viral proto-oncogene 1	Mus musculus	29-32
31484456-9	2019	Interestingly, synergistic interactions in target protein knock down with combinations of CA/AKT/paclitaxel, CA/ERBB2/docetaxel were documented via western blotting.	Paclitaxel	97-107	thymoma viral proto-oncogene 1	Mus musculus	93-96
31477168-1	2019	BACKGROUND: Neoadjuvant dual human epidermal growth factor receptor (HER2) blockade with trastuzumab and pertuzumab plus paclitaxel leads to an overall pathologic complete response (pCR) rate of 46%.	Paclitaxel	121-131	epidermal growth factor receptor	Homo sapiens	35-67
31477168-2	2019	Dual HER2 blockade with ado-trastuzumab emtansine (T-DM1) and lapatinib plus nab-paclitaxel has shown efficacy in patients with metastatic HER2-positive breast cancer.	Paclitaxel	81-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
31179749-6	2019	We observed that the most sensitive marker was alpha-MHC in the case of both Dox and Pac, and the order of sensitivity of the various prediction assays was MMP > protein expression by FC > gene expression by qRT-PCR > cell viability by PI staining.	Paclitaxel	85-88	myosin heavy chain 6	Homo sapiens	47-56
31786845-12	2019	CONCLUSIONS: Inhibitor PD98059 combined with paclitaxel can affect the expression of ERK1/2 in ERK1/2 signaling pathway, effectively inhibit the proliferation and invasive abilities of CRC cells, increase the apoptotic ability of CRC cells, and is expected to become a potential drug for clinical treatment of CRC.	Paclitaxel	45-55	mitogen-activated protein kinase 3	Homo sapiens	85-91
31786845-12	2019	CONCLUSIONS: Inhibitor PD98059 combined with paclitaxel can affect the expression of ERK1/2 in ERK1/2 signaling pathway, effectively inhibit the proliferation and invasive abilities of CRC cells, increase the apoptotic ability of CRC cells, and is expected to become a potential drug for clinical treatment of CRC.	Paclitaxel	45-55	mitogen-activated protein kinase 3	Homo sapiens	95-101
30577988-11	2019	CONCLUSION: Buparlisib plus weekly paclitaxel might be a new treatment option for patients with metastatic MCB harboring a PIK3CA mutation.	Paclitaxel	35-45	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	123-129
31211507-3	2019	When exposed to paclitaxel, cancer cells activated the EIF2AK3/EIF2AK4-pEIF2S1-ATF4 axis and maintained redox homoeostasis by inducing expression of the major antioxidant enzymes HMOX1, SHMT2 and SLC7A11.	Paclitaxel	16-26	eukaryotic translation initiation factor 2 alpha kinase 4	Mus musculus	63-70
31211507-3	2019	When exposed to paclitaxel, cancer cells activated the EIF2AK3/EIF2AK4-pEIF2S1-ATF4 axis and maintained redox homoeostasis by inducing expression of the major antioxidant enzymes HMOX1, SHMT2 and SLC7A11.	Paclitaxel	16-26	activating transcription factor 4	Mus musculus	79-83
31211507-3	2019	When exposed to paclitaxel, cancer cells activated the EIF2AK3/EIF2AK4-pEIF2S1-ATF4 axis and maintained redox homoeostasis by inducing expression of the major antioxidant enzymes HMOX1, SHMT2 and SLC7A11.	Paclitaxel	16-26	heme oxygenase 1	Mus musculus	179-184
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	353-356	signal transducer and activator of transcription 3	Homo sapiens	0-50
31452796-9	2019	In summary, shikonin can sensitize esophageal cancer cells to paclitaxel-treatment by promoting cell mitotic arrest and reinforcing the susceptibility of esophageal cancer cells to apoptosis induced by paclitaxel, which is potentially associated with altered levels of Bcl-2 and p53.	Paclitaxel	62-72	BCL2 apoptosis regulator	Homo sapiens	269-274
31452796-9	2019	In summary, shikonin can sensitize esophageal cancer cells to paclitaxel-treatment by promoting cell mitotic arrest and reinforcing the susceptibility of esophageal cancer cells to apoptosis induced by paclitaxel, which is potentially associated with altered levels of Bcl-2 and p53.	Paclitaxel	62-72	tumor protein p53	Homo sapiens	279-282
31077613-0	2019	Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer.	Paclitaxel	130-140	signal transducer and activator of transcription 3	Homo sapiens	117-122
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	353-356	signal transducer and activator of transcription 3	Homo sapiens	52-57
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	102-112	signal transducer and activator of transcription 3	Homo sapiens	0-50
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	102-112	signal transducer and activator of transcription 3	Homo sapiens	52-57
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	102-112	signal transducer and activator of transcription 3	Homo sapiens	321-326
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	114-117	signal transducer and activator of transcription 3	Homo sapiens	0-50
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	114-117	signal transducer and activator of transcription 3	Homo sapiens	52-57
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	114-117	signal transducer and activator of transcription 3	Homo sapiens	321-326
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	353-356	signal transducer and activator of transcription 3	Homo sapiens	321-326
31416135-6	2019	The paclitaxel-combined XAV939 treatment induced apoptosis by suppressing Bcl-2 and by increasing the cleavage of caspases-3 and PARP.	Paclitaxel	4-14	BCL2 apoptosis regulator	Homo sapiens	74-79
31506155-1	2019	OBJECTIVE: To study the effect of low-concentration paclitaxel (PTX) on transforming growth factor-beta1 (TGF-beta1)-induced collagen deposition outside rat pulmonary artery smooth muscle cells (PASMCs) and related mechanism.	Paclitaxel	52-62	transforming growth factor, beta 1	Rattus norvegicus	72-104
31270160-9	2019	Paclitaxel treatment also upregulated TNF and CXCL1 in macrophage cultures and DRG tissues in both sexes, but these changes were compromised by Tlr9 mutation in male animals.	Paclitaxel	0-10	tumor necrosis factor	Mus musculus	38-41
31270160-9	2019	Paclitaxel treatment also upregulated TNF and CXCL1 in macrophage cultures and DRG tissues in both sexes, but these changes were compromised by Tlr9 mutation in male animals.	Paclitaxel	0-10	chemokine (C-X-C motif) ligand 1	Mus musculus	46-51
31506155-1	2019	OBJECTIVE: To study the effect of low-concentration paclitaxel (PTX) on transforming growth factor-beta1 (TGF-beta1)-induced collagen deposition outside rat pulmonary artery smooth muscle cells (PASMCs) and related mechanism.	Paclitaxel	52-62	transforming growth factor, beta 1	Rattus norvegicus	106-115
31506155-1	2019	OBJECTIVE: To study the effect of low-concentration paclitaxel (PTX) on transforming growth factor-beta1 (TGF-beta1)-induced collagen deposition outside rat pulmonary artery smooth muscle cells (PASMCs) and related mechanism.	Paclitaxel	64-67	transforming growth factor, beta 1	Rattus norvegicus	72-104
31506155-1	2019	OBJECTIVE: To study the effect of low-concentration paclitaxel (PTX) on transforming growth factor-beta1 (TGF-beta1)-induced collagen deposition outside rat pulmonary artery smooth muscle cells (PASMCs) and related mechanism.	Paclitaxel	64-67	transforming growth factor, beta 1	Rattus norvegicus	106-115
31506155-13	2019	CONCLUSIONS: Low-concentration PTX exerts a marked inhibitory effect on TGF-beta1-induced collagen deposition outside PASMCs, possibly by regulating the phosphorylation of Smad3 protein.	Paclitaxel	31-34	transforming growth factor, beta 1	Rattus norvegicus	72-81
31506155-13	2019	CONCLUSIONS: Low-concentration PTX exerts a marked inhibitory effect on TGF-beta1-induced collagen deposition outside PASMCs, possibly by regulating the phosphorylation of Smad3 protein.	Paclitaxel	31-34	SMAD family member 3	Rattus norvegicus	172-177
31480338-6	2019	We found that the phosphorylation of AKT was suppressed by eribulin, a microtubule depolymerizing agent, but activated by paclitaxel, a microtubule stabilizing agent.	Paclitaxel	122-132	AKT serine/threonine kinase 1	Homo sapiens	37-40
31248772-0	2019	Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates.	Paclitaxel	54-64	folate hydrolase 1	Homo sapiens	39-43
31248772-5	2019	In this study we describe the development of Glu-urea-Lys based PSMA-targeting conjugates with paclitaxel.	Paclitaxel	95-105	folate hydrolase 1	Homo sapiens	64-68
31248772-6	2019	A series of new PSMA targeting conjugates with paclitaxel was designed and synthesized.	Paclitaxel	47-57	folate hydrolase 1	Homo sapiens	16-20
31123858-3	2019	OBJECTIVE: To evaluate the role of ABCB1 1236C&gt;T, 3435C&gt;T; CYP2C8*3; CYP3A5*3C variants on paclitaxel/carboplatin toxicities.	Paclitaxel	97-107	ATP binding cassette subfamily B member 1	Homo sapiens	35-40
31331172-3	2019	The theranostic nanoparticle, DHP, consisting of a disulfide-bond-linked hydroxyethyl starch paclitaxel conjugate (HES-SS-PTX) and a near-infrared (NIR) cyanine fluorophore DiR, is prepared with a simple one-step dialysis method.	Paclitaxel	93-103	dihydropyrimidinase	Homo sapiens	30-33
31199661-7	2019	Importantly, PTX/CAP-loaded micelles exhibited superior in vivo antitumor activity on the inhibition rate of tumor growth than other treatments (70.5% tumor growth reduction in PTX/CAP micelle-treated mice vs 57.8, 43.3, and 23.8% of tumor growth inhibition rate in PTX/PEG-Fmoc-OA2 micelles, Taxol, and PEG-Fmoc-CAP2 micelle-treated mice, respectively).	Paclitaxel	13-16	CAP, adenylate cyclase-associated protein, 2 (yeast)	Mus musculus	313-317
31199661-8	2019	Thus, the dual-functional PEG-Fmoc-CAP2 polymeric prodrug micelles are a promising co-delivery nanosystem for achieving synergistic antitumor efficacy of PTX and CAP.	Paclitaxel	154-157	CAP, adenylate cyclase-associated protein, 2 (yeast)	Mus musculus	35-39
31404980-9	2019	Furthermore, the number of colonies formed from EMT cells and paclitaxel-treated EMT cells after passing through a constriction were found to be 95 +- 10 and 79 +- 4, respectively, confirming that the EMT cells were more drug resistant with a concomitant two-fold higher expression of the multi-drug resistance (MDR1) gene.	Paclitaxel	62-72	ATP binding cassette subfamily B member 1	Homo sapiens	312-316
31123858-3	2019	OBJECTIVE: To evaluate the role of ABCB1 1236C&gt;T, 3435C&gt;T; CYP2C8*3; CYP3A5*3C variants on paclitaxel/carboplatin toxicities.	Paclitaxel	97-107	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	75-81
31423204-5	2019	Upregulation of PDCD4 significantly enhanced the sensitivity of CRC cells to Taxol, by partially contributing to pro-apoptosis and anti-invasion pathways, both through upregulation of the apoptosis-associated protein Bax, and downregulation of the anti-apoptosis protein Bcl-2 and invasion-associated proteins MMP-9.	Paclitaxel	77-82	BCL2 associated X, apoptosis regulator	Homo sapiens	217-220
31486484-0	2019	DANCR sponges miR-135a to regulate paclitaxel sensitivity in prostate cancer.	Paclitaxel	35-45	differentiation antagonizing non-protein coding RNA	Homo sapiens	0-5
31486484-3	2019	Our experiment aims to clarify the role of DANCR in paclitaxel sensitivity of prostate cancer.	Paclitaxel	52-62	differentiation antagonizing non-protein coding RNA	Homo sapiens	43-48
31486484-6	2019	Moreover, DANCR silence enhanced the effect of paclitaxel on cell proliferation and apoptosis in prostate cancer cells.	Paclitaxel	47-57	differentiation antagonizing non-protein coding RNA	Homo sapiens	10-15
31486484-9	2019	miR-135a inhibition reversed the promoting effect of DANCR silence on paclitaxel sensitivity in prostate cancer cells.	Paclitaxel	70-80	differentiation antagonizing non-protein coding RNA	Homo sapiens	53-58
31486484-10	2019	CONCLUSIONS: Downregulation of DANCR increased paclitaxel sensitivity in prostate cancer cells by negatively regulating the expression of miR-135a.	Paclitaxel	47-57	differentiation antagonizing non-protein coding RNA	Homo sapiens	31-36
30939096-1	2019	PURPOSE: The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)-positive breast cancer.	Paclitaxel	22-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-152
30939096-1	2019	PURPOSE: The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)-positive breast cancer.	Paclitaxel	22-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-158
31127007-7	2019	In silico docking of compounds 3 and 8 was performed using the recently solved atomic structure of paclitaxel (Taxol)-bound human P-gp.	Paclitaxel	99-109	ATP binding cassette subfamily B member 1	Homo sapiens	130-134
31127007-7	2019	In silico docking of compounds 3 and 8 was performed using the recently solved atomic structure of paclitaxel (Taxol)-bound human P-gp.	Paclitaxel	111-116	ATP binding cassette subfamily B member 1	Homo sapiens	130-134
31273338-0	2019	The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway.	Paclitaxel	76-86	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	111-114
31273338-2	2019	In this study, lncRNA array of CNE-1 and HNE-2 paclitaxel-resistant cells and their parental strains revealed that the paclitaxel-resistant strains had significantly lower MRVI1-AS1 (murine retrovirus integration site 1 homolog antisense RNA 1) expression than the parental strains, and that MRVI1-AS1 overexpression in vitro and in vivo increased paclitaxel chemosensitivity.	Paclitaxel	119-129	arylsulfatase B	Mus musculus	298-301
31273338-2	2019	In this study, lncRNA array of CNE-1 and HNE-2 paclitaxel-resistant cells and their parental strains revealed that the paclitaxel-resistant strains had significantly lower MRVI1-AS1 (murine retrovirus integration site 1 homolog antisense RNA 1) expression than the parental strains, and that MRVI1-AS1 overexpression in vitro and in vivo increased paclitaxel chemosensitivity.	Paclitaxel	119-129	arylsulfatase B	Mus musculus	298-301
31273338-3	2019	Further, MRVI1-AS1 upregulated ATF3 (activating transcription factor 3) by simultaneously inhibiting miR-513a-5p (microRNA-513a-5p) and miR-27b-3p expression levels to increase NPC paclitaxel chemosensitivity.	Paclitaxel	181-191	arylsulfatase B	Mus musculus	15-18
31273338-6	2019	The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide) assay and flow cytometry showed that the decreased TAZ increased NPC cell paclitaxel chemosensitivity.	Paclitaxel	145-155	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	122-125
31273338-7	2019	Overall, the results indicate that the MRVI1-AS1/ATF3 signaling pathway can increase NPC paclitaxel chemosensitivity by modulating the Hippo-TAZ signaling pathway.	Paclitaxel	89-99	arylsulfatase B	Mus musculus	45-48
31273338-7	2019	Overall, the results indicate that the MRVI1-AS1/ATF3 signaling pathway can increase NPC paclitaxel chemosensitivity by modulating the Hippo-TAZ signaling pathway.	Paclitaxel	89-99	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	141-144
31197964-7	2019	Moreover, Pect-MCP synergized with PTX to kill SKOV3 MCTS through abrogation of STAT3 activity and reduced expression of its downstream target HIF-1alpha, reduced integrin mRNA levels, and subsequently decreased AKT activity.	Paclitaxel	35-38	signal transducer and activator of transcription 3	Homo sapiens	80-85
31197964-7	2019	Moreover, Pect-MCP synergized with PTX to kill SKOV3 MCTS through abrogation of STAT3 activity and reduced expression of its downstream target HIF-1alpha, reduced integrin mRNA levels, and subsequently decreased AKT activity.	Paclitaxel	35-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	143-153
31197964-7	2019	Moreover, Pect-MCP synergized with PTX to kill SKOV3 MCTS through abrogation of STAT3 activity and reduced expression of its downstream target HIF-1alpha, reduced integrin mRNA levels, and subsequently decreased AKT activity.	Paclitaxel	35-38	AKT serine/threonine kinase 1	Homo sapiens	212-215
31197964-9	2019	Together, these results revealed for the first time that Pect-MCP could be considered as a potential drug to enhance the PTX effect on ovarian cancer cells MCTS through inhibition of STAT3 activity.	Paclitaxel	121-124	CD46 molecule	Homo sapiens	62-65
31370861-0	2019	Cathepsin L-mediated resistance of paclitaxel and cisplatin is mediated by distinct regulatory mechanisms.	Paclitaxel	35-45	cathepsin L	Homo sapiens	0-11
31370861-5	2019	RESULTS: TGF-beta and smad3 were overexpressed only in A549/TAX cells, silencing TGF-beta or smad3 in A549/TAX cells decreased the expression of CTSL and enhanced their sensitivity to paclitaxel.	Paclitaxel	184-194	transforming growth factor beta 1	Homo sapiens	81-89
31370861-5	2019	RESULTS: TGF-beta and smad3 were overexpressed only in A549/TAX cells, silencing TGF-beta or smad3 in A549/TAX cells decreased the expression of CTSL and enhanced their sensitivity to paclitaxel.	Paclitaxel	184-194	cathepsin L	Homo sapiens	145-149
31370861-11	2019	CONCLUSION: CTSL-mediated drug resistance to paclitaxel and cisplatin may be modulated by different mechanisms.	Paclitaxel	45-55	cathepsin L	Homo sapiens	12-16
31088908-0	2019	HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.	Paclitaxel	96-106	tumor protein p53	Homo sapiens	20-23
31088908-12	2019	TPT-mediated downregulation of HIF1alpha in hypoxic cells required TOPO1 resident on HIF1alpha mRNA, restored p53 transcriptional activity, downregulated ABCB1/ABCB5 cell surface expression, and reversed hypoxia-related cisplatin and paclitaxel resistance.	Paclitaxel	234-244	hypoxia inducible factor 1 subunit alpha	Homo sapiens	31-40
30602614-1	2019	BACKGROUND: Favorable progression-free survival (PFS) and overall survival (OS) results were previously reported on a phase II trial of patients with human epidermal growth receptor 2 (HER2)-positive metastatic breast cancer (MBC), treated with weekly paclitaxel in combination with trastuzumab and pertuzumab in the first- and second-line setting, with a median follow-up of 33 months.	Paclitaxel	252-262	erb-b2 receptor tyrosine kinase 2	Homo sapiens	185-189
30602614-12	2019	IMPLICATIONS FOR PRACTICE: The combination of weekly paclitaxel, trastuzumab, and pertuzumab has been endorsed by the National Comprehensive Cancer Network as one of the first-line treatment options in patients with human epidermal growth receptor 2 (HER2)-positive metastatic breast cancer (MBC).	Paclitaxel	53-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	251-255
31423204-5	2019	Upregulation of PDCD4 significantly enhanced the sensitivity of CRC cells to Taxol, by partially contributing to pro-apoptosis and anti-invasion pathways, both through upregulation of the apoptosis-associated protein Bax, and downregulation of the anti-apoptosis protein Bcl-2 and invasion-associated proteins MMP-9.	Paclitaxel	77-82	BCL2 apoptosis regulator	Homo sapiens	271-276
31170432-7	2019	Furthermore, alpha-SMA protein expression in cells arrested at S- and G2/M-phases by MTX and paclitaxel (PTX) was significantly higher than that in cells at G1.	Paclitaxel	93-103	actin alpha 1, skeletal muscle	Homo sapiens	13-22
31170432-7	2019	Furthermore, alpha-SMA protein expression in cells arrested at S- and G2/M-phases by MTX and paclitaxel (PTX) was significantly higher than that in cells at G1.	Paclitaxel	105-108	actin alpha 1, skeletal muscle	Homo sapiens	13-22
31317744-0	2019	Antitumor Activity of 1,18-Octadecanedioic Acid-Paclitaxel Complexed with Human Serum Albumin.	Paclitaxel	48-58	albumin	Homo sapiens	80-93
31163384-5	2019	Specifically, SGK1 affects paclitaxel sensitivity in RKO colon carcinoma cells by modulating the specificity protein 1 (SP1)-dependent expression of Ran-specific GTPase-activating protein (RANBP1), a member of the GTP-binding nuclear protein Ran (RAN) network that is required for the organization and function of the mitotic spindle.	Paclitaxel	27-37	Sp1 transcription factor	Homo sapiens	97-118
31317744-2	2019	This 1,18-octadecanedioic acid-PTX (ODDA-PTX) prodrug readily forms a noncovalent complex with human serum albumin (HSA).	Paclitaxel	31-34	albumin	Homo sapiens	101-114
31367191-11	2019	By establishing Taxol resistant breast cancer cell line, we found Taxol resistant cells exhibit upregulated LDHA and MCT1 expressions.	Paclitaxel	66-71	solute carrier family 16 member 1	Homo sapiens	117-121
31367191-16	2019	Importantly, based on in vitro and in vivo results, inhibition of MCT1 significantly sensitized Taxol resistant cells.	Paclitaxel	96-101	solute carrier family 16 member 1	Homo sapiens	66-70
31367191-0	2019	Interfering cellular lactate homeostasis overcomes Taxol resistance of breast cancer cells through the microRNA-124-mediated lactate transporter (MCT1) inhibition.	Paclitaxel	51-56	solute carrier family 16 member 1	Homo sapiens	146-150
31367191-17	2019	Finally, rescue experiments showed restoration of MCT1 in miR-124 overexpressing cells promoted Taxol resistance.	Paclitaxel	96-101	solute carrier family 16 member 1	Homo sapiens	50-54
31367191-4	2019	Materials and methods: In this study, Human breast cancer cells, BT474, SKBR3 and MCF7 were used to study the causal relationship between the lactate exporter, MCT1 (SLC16A1)-modulated glucose metabolism and Taxol resistance of breast cancer cells.	Paclitaxel	208-213	solute carrier family 16 member 1	Homo sapiens	160-164
31367191-4	2019	Materials and methods: In this study, Human breast cancer cells, BT474, SKBR3 and MCF7 were used to study the causal relationship between the lactate exporter, MCT1 (SLC16A1)-modulated glucose metabolism and Taxol resistance of breast cancer cells.	Paclitaxel	208-213	solute carrier family 16 member 1	Homo sapiens	166-173
31367191-18	2019	Conclusions: This study reveals a possible role of miRNA-214-mediated Taxol resistance, contributing to identify novel therapeutic targets against chemoresistant breast cancers.	Paclitaxel	70-75	microRNA 214	Homo sapiens	51-60
31367191-10	2019	Results: Low toxic Taxol treatments promoted cellular glucose metabolism and intracellular lactate accumulation with upregulated lactate dehydrogenase-A (LDHA) and MCT1 expressions.	Paclitaxel	19-24	lactate dehydrogenase A	Homo sapiens	129-152
31367191-10	2019	Results: Low toxic Taxol treatments promoted cellular glucose metabolism and intracellular lactate accumulation with upregulated lactate dehydrogenase-A (LDHA) and MCT1 expressions.	Paclitaxel	19-24	lactate dehydrogenase A	Homo sapiens	154-158
31315040-4	2019	Our top hit was 10-Deacetyl-baccatin-III (DAB), a chemical precursor in the synthesis of Taxol, which selects for haploid cells in HAP1 and mouse haploid embryonic stem cultures.	Paclitaxel	89-94	huntingtin-associated protein 1	Mus musculus	131-135
31367191-10	2019	Results: Low toxic Taxol treatments promoted cellular glucose metabolism and intracellular lactate accumulation with upregulated lactate dehydrogenase-A (LDHA) and MCT1 expressions.	Paclitaxel	19-24	solute carrier family 16 member 1	Homo sapiens	164-168
31367191-11	2019	By establishing Taxol resistant breast cancer cell line, we found Taxol resistant cells exhibit upregulated LDHA and MCT1 expressions.	Paclitaxel	16-21	lactate dehydrogenase A	Homo sapiens	108-112
31367191-11	2019	By establishing Taxol resistant breast cancer cell line, we found Taxol resistant cells exhibit upregulated LDHA and MCT1 expressions.	Paclitaxel	16-21	solute carrier family 16 member 1	Homo sapiens	117-121
31367191-11	2019	By establishing Taxol resistant breast cancer cell line, we found Taxol resistant cells exhibit upregulated LDHA and MCT1 expressions.	Paclitaxel	66-71	lactate dehydrogenase A	Homo sapiens	108-112
31336860-5	2019	Pre-exposure of paclitaxel-resistant ovarian cancer cells to gliotoxin inhibited the expression of multidrug resistant-associated proteins (MDR1 and MRP1-3), disrupted the mitochondrial membrane potential, and induced caspase-dependent apoptosis through autophagy induction after subsequent treatment with paclitaxel.	Paclitaxel	16-26	ATP binding cassette subfamily B member 1	Homo sapiens	140-144
31406477-7	2019	Moreover, the expression levels of Bcl-2, survivin, CDK2 and MMP-2 significantly decreased in SCLC cells treated with paclitaxel targeting nanobubbles, whereas the expression of caspase-3 and Rb were increased.	Paclitaxel	118-128	BCL2 apoptosis regulator	Homo sapiens	35-40
31406477-7	2019	Moreover, the expression levels of Bcl-2, survivin, CDK2 and MMP-2 significantly decreased in SCLC cells treated with paclitaxel targeting nanobubbles, whereas the expression of caspase-3 and Rb were increased.	Paclitaxel	118-128	caspase 3	Homo sapiens	178-187
31336860-6	2019	Gene silencing of DAPK1 prevented TAp63-mediated downregulation of MDR1 and MRP1-3 and autophagic cell death after sequential treatment with gliotoxin and then paclitaxel.	Paclitaxel	160-170	death associated protein kinase 1	Homo sapiens	18-23
31103263-9	2019	Increased drug sensitivity was observed with Pgp silencing or inhibition as determined by drug IC50s of paclitaxel-response of silenced Pgp and doxorubicin-response of inhibited Pgp, respectively.	Paclitaxel	104-114	ATP binding cassette subfamily B member 1	Homo sapiens	45-48
31295843-9	2019	Moreover, combination therapy significantly enhanced drug sensitivity and apoptosis through the activation of Bax, and cleavage of poly-(ADP-ribose) polymerase compared with paclitaxel alone.	Paclitaxel	174-184	poly(ADP-ribose) polymerase 1	Homo sapiens	131-159
31299200-6	2019	Accordingly, expression of cGAS and IRF3 in cancer cells makes mouse xenograft tumors responsive to the anti-mitotic agent Taxol.	Paclitaxel	123-128	cyclic GMP-AMP synthase	Mus musculus	27-31
31413745-0	2019	SphK1 functions downstream of IGF-1 to modulate IGF-1-induced EMT, migration and paclitaxel resistance of A549 cells: A preliminary in vitro study.	Paclitaxel	81-91	insulin like growth factor 1	Homo sapiens	48-53
31413745-6	2019	The results showed that, IGF-1 treatment of A549 cells stimulated the expression of SphK1, the activation of ERK and AKT, the cell migration, and the expression of EMT hallmark proteins, while inhibition of SphK1 by its specific inhibitor SKI-II suppressed all the above changes and increased the sensitivity of A549 cells to paclitaxel.	Paclitaxel	326-336	insulin like growth factor 1	Homo sapiens	25-30
31413745-7	2019	Our data demonstrate that SphK1 acts as a downstream effector of IGF-1 and plays a critical role in IGF-1-induced EMT, cell migration and paclitaxel resistance of A549 cells, suggesting that SphK1 might be a potential therapeutic target for NSCLC.	Paclitaxel	138-148	insulin like growth factor 1	Homo sapiens	65-70
31413745-7	2019	Our data demonstrate that SphK1 acts as a downstream effector of IGF-1 and plays a critical role in IGF-1-induced EMT, cell migration and paclitaxel resistance of A549 cells, suggesting that SphK1 might be a potential therapeutic target for NSCLC.	Paclitaxel	138-148	insulin like growth factor 1	Homo sapiens	100-105
31103263-9	2019	Increased drug sensitivity was observed with Pgp silencing or inhibition as determined by drug IC50s of paclitaxel-response of silenced Pgp and doxorubicin-response of inhibited Pgp, respectively.	Paclitaxel	104-114	ATP binding cassette subfamily B member 1	Homo sapiens	136-139
31103263-9	2019	Increased drug sensitivity was observed with Pgp silencing or inhibition as determined by drug IC50s of paclitaxel-response of silenced Pgp and doxorubicin-response of inhibited Pgp, respectively.	Paclitaxel	104-114	ATP binding cassette subfamily B member 1	Homo sapiens	136-139
31333464-11	2019	Notably, PTX-induced mechanical allodynia was fully developed in Trpv1 or Trpa1 knockout mice, showing no sex differences.	Paclitaxel	9-12	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	65-70
31379992-10	2019	Also, the analysis correlated with induced cell death elucidated that concurrent treatment of polysaccharide plus paclitaxel had a further anti-cancer effect against A2780cp cells mainly through restoration of p53 and mitochondrial apoptosis cell death induction.	Paclitaxel	114-124	tumor protein p53	Homo sapiens	210-213
31261957-7	2019	RESULTS: In comparison with free paclitaxel:beta-cyclodextrins complexes, the developed conjugated nanovehicle presented specificity for the treatment of HER2-overpressing cells, in which it was internalized by endocytosis.	Paclitaxel	33-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-158
31140859-0	2019	EZH2 Confers Sensitivity of Breast Cancer Cells to Taxol by Attenuating p21 Expression Epigenetically.	Paclitaxel	51-56	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	0-4
31140859-4	2019	In the present study, we showed the negative relationship between EZH2 and chemoresistance to taxol in breast cancer cells.	Paclitaxel	94-99	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	66-70
31140859-5	2019	EZH2 interference was capable of decreasing while overexpression increasing apoptosis of breast cancer cells challenged with taxol.	Paclitaxel	125-130	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	0-4
31140859-8	2019	Collectively, EZH2 attenuates chemoresistance of breast cancer cells to taxol by dampening p21 epigenetically.	Paclitaxel	72-77	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	14-18
31196356-2	2019	However, many drugs, especially most anticancer drugs such as paclitaxel (PTX), are not orally bioavailable, which is attributed to low aqueous solubility, poor intestinal permeability, and the high level of P-glycoprotein (P-gp) efflux.	Paclitaxel	62-72	ATP binding cassette subfamily B member 1	Homo sapiens	208-222
31196356-2	2019	However, many drugs, especially most anticancer drugs such as paclitaxel (PTX), are not orally bioavailable, which is attributed to low aqueous solubility, poor intestinal permeability, and the high level of P-glycoprotein (P-gp) efflux.	Paclitaxel	62-72	ATP binding cassette subfamily B member 1	Homo sapiens	224-228
31196356-2	2019	However, many drugs, especially most anticancer drugs such as paclitaxel (PTX), are not orally bioavailable, which is attributed to low aqueous solubility, poor intestinal permeability, and the high level of P-glycoprotein (P-gp) efflux.	Paclitaxel	74-77	ATP binding cassette subfamily B member 1	Homo sapiens	208-222
31196356-2	2019	However, many drugs, especially most anticancer drugs such as paclitaxel (PTX), are not orally bioavailable, which is attributed to low aqueous solubility, poor intestinal permeability, and the high level of P-glycoprotein (P-gp) efflux.	Paclitaxel	74-77	ATP binding cassette subfamily B member 1	Homo sapiens	224-228
31047896-13	2019	CDK6 knockdown attenuated the effects of miR-29c inhibition on paclitaxel cytotoxicity in breast cancer cells.	Paclitaxel	63-73	cyclin dependent kinase 6	Homo sapiens	0-4
31047896-15	2019	SIGNIFICANCE: LINC00511 knockdown enhanced paclitaxel cytotoxicity in breast cancer cells via regulating miR-29c/CDK6 axis.	Paclitaxel	43-53	cyclin dependent kinase 6	Homo sapiens	113-117
30904013-2	2019	Our recent study showed that impairment of Nrf2-antioxidant response element (Nrf2-ARE) and upregulation of oxidative signals in the dorsal root ganglion (DRG) of rats with treatment of paclitaxel result in neuropathic pain.	Paclitaxel	186-196	NFE2 like bZIP transcription factor 2	Rattus norvegicus	43-47
30904013-2	2019	Our recent study showed that impairment of Nrf2-antioxidant response element (Nrf2-ARE) and upregulation of oxidative signals in the dorsal root ganglion (DRG) of rats with treatment of paclitaxel result in neuropathic pain.	Paclitaxel	186-196	NFE2 like bZIP transcription factor 2	Rattus norvegicus	78-82
30904013-3	2019	The purpose of this study was to examine the beneficial role played by electroacupuncture (EA) in modifying neuropathic pain evoked by paclitaxel via Nrf2-ARE and oxidative mechanisms.	Paclitaxel	135-145	NFE2 like bZIP transcription factor 2	Rattus norvegicus	150-154
30904013-6	2019	Our data showed that paclitaxel increased mechanical and thermal sensitivity and this was accompanied with impaired Nrf2-ARE and SOD in the DRG and amplified products of oxidative stress (i.e. 8-isoprostaglandin F2alpha and 8-hydroxy-2"-deoxyguanosine).	Paclitaxel	21-31	NFE2 like bZIP transcription factor 2	Rattus norvegicus	116-120
30904013-8	2019	In conclusion, we revealed specific signaling pathways leading to paclitaxel-evoked neuropathic pain, including impairment of Nrf2-ARE and heightened oxidative signals.	Paclitaxel	66-76	NFE2 like bZIP transcription factor 2	Rattus norvegicus	126-130
30979740-9	2019	An increased response to nab-paclitaxel was observed only in PIK3CAwt breast cancer, with univariate significance for the complete cohort (P = 0.009) and the TNBC (P = 0.013) and multivariate significance in the HER2pos subcohort (test for interaction P = 0.0074).	Paclitaxel	29-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	212-216
30701373-10	2019	The mitochondrial dysfunction evoked by paclitaxel was also remarkably improved in evodiamine-treated rats, evidenced by restoration of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), uncoupling protein 2 (UCP2), and superoxide dismutase 2 (SOD2) expression.	Paclitaxel	40-50	PPARG coactivator 1 alpha	Rattus norvegicus	136-204
30701373-11	2019	In in vitro studies, we found that evodiamine prevented paclitaxel-induced the loss of mitochondrial membrane potential and PGC-1alpha, UCP2 and SOD2 expression in DRG cells.	Paclitaxel	56-66	PPARG coactivator 1 alpha	Rattus norvegicus	124-134
30433798-7	2019	Paclitaxel also impaired Nrf2-ARE and SOD in the DRG and amplified products of oxidative stress, namely 8-isoprostaglandin F2alpha and 8-hydroxy-2"-deoxyguanosine.	Paclitaxel	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	25-29
31261957-3	2019	To solve these handicaps, a novel paclitaxel-trastuzumab targeted transport nanosystem has been developed and characterized in this work to specifically treat cancer cells that overexpress the human epidermal growth factor receptor-2 (HER2).	Paclitaxel	34-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	193-233
31261957-3	2019	To solve these handicaps, a novel paclitaxel-trastuzumab targeted transport nanosystem has been developed and characterized in this work to specifically treat cancer cells that overexpress the human epidermal growth factor receptor-2 (HER2).	Paclitaxel	34-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	235-239
31261957-8	2019	CONCLUSIONS: It seems that potentially avoiding the conventional adverse effects of paclitaxel treatment could be possible with the use of the proposed mixed nanovehicle, which improves its bioavailability and targets HER2-positive cancer cells.	Paclitaxel	84-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	218-222
31141661-6	2019	The released CXB not only acted on cyclooxygenase-2 (COX-2) to suppress the production of pro-inflammatory PGE2 in multiple cell types but also suppressed the expression of the anti-apoptotic Bcl-2 gene to sensitize cancer cells to chemotherapy, thus resulting in a synergistic anticancer effect of PTX and CXB.	Paclitaxel	299-302	prostaglandin-endoperoxide synthase 2	Homo sapiens	35-51
31141661-6	2019	The released CXB not only acted on cyclooxygenase-2 (COX-2) to suppress the production of pro-inflammatory PGE2 in multiple cell types but also suppressed the expression of the anti-apoptotic Bcl-2 gene to sensitize cancer cells to chemotherapy, thus resulting in a synergistic anticancer effect of PTX and CXB.	Paclitaxel	299-302	prostaglandin-endoperoxide synthase 2	Homo sapiens	53-58
31141661-6	2019	The released CXB not only acted on cyclooxygenase-2 (COX-2) to suppress the production of pro-inflammatory PGE2 in multiple cell types but also suppressed the expression of the anti-apoptotic Bcl-2 gene to sensitize cancer cells to chemotherapy, thus resulting in a synergistic anticancer effect of PTX and CXB.	Paclitaxel	299-302	BCL2 apoptosis regulator	Homo sapiens	192-197
31293426-6	2019	Furthermore, we found that combined treatment of TMP and PTX suppressed angiogenesis by inhibiting both ERK1/2 and Akt pathways and promoted apoptosis of tumor cells compared to TMP or PTX treatment alone.	Paclitaxel	57-60	mitogen-activated protein kinase 3	Homo sapiens	104-110
31293426-6	2019	Furthermore, we found that combined treatment of TMP and PTX suppressed angiogenesis by inhibiting both ERK1/2 and Akt pathways and promoted apoptosis of tumor cells compared to TMP or PTX treatment alone.	Paclitaxel	57-60	AKT serine/threonine kinase 1	Homo sapiens	115-118
31248184-5	2019	The tested compounds were found to increase the intracellular accumulation of Rho 123, and to enhance the efficacy of paclitaxel in P-gp overexpressing cells.	Paclitaxel	118-128	ATP binding cassette subfamily B member 1	Homo sapiens	132-136
31249607-4	2019	In the presence of nocodazole or taxol combined with M2I-1 cell death is triggered by the premature degradation of Cyclin B1, the perturbation of the microtubule network, and an increase in the level of the pro-apoptotic protein MCL-1s combined with a marginal increase in the level of NOXA.	Paclitaxel	33-38	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	286-290
31160603-0	2019	EPHB6 mutation induces cell adhesion-mediated paclitaxel resistance via EPHA2 and CDH11 expression.	Paclitaxel	46-56	cadherin 11	Homo sapiens	82-87
31181850-7	2019	Highly metastatic MDA-hyb1 breast tumors were induced in NODscid mice, and systemic intravenous application of MSC-derived taxol exosomes revealed a more than 60% reduction of subcutaneous primary tumors.	Paclitaxel	123-128	musculin	Mus musculus	111-114
31166995-0	2019	Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.	Paclitaxel	31-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93
31166995-1	2019	OBJECTIVES: Adjuvant paclitaxel and trastuzumab has been shown to be an effective regimen with low risk of cancer recurrence and treatment-related toxicities in early-stage node-negative, HER2-positive breast cancer.	Paclitaxel	21-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	188-192
31171918-6	2019	Results: Our results revealed that the highest cytotoxic effect, the highest induction of apoptosis and significant elevation in P53 and Caspase 3 levels was seen in Paclitaxel/Gallic acid combination.	Paclitaxel	166-176	tumor protein p53	Homo sapiens	129-132
31171918-6	2019	Results: Our results revealed that the highest cytotoxic effect, the highest induction of apoptosis and significant elevation in P53 and Caspase 3 levels was seen in Paclitaxel/Gallic acid combination.	Paclitaxel	166-176	caspase 3	Homo sapiens	137-146
31160603-5	2019	EPHB6 mutation-induced paclitaxel resistance was mediated by an interaction with EPHA2, which promotes c-Jun N-terminal kinase (JNK)-mediated cadherin 11 (CDH11) expression.	Paclitaxel	23-33	mitogen-activated protein kinase 8	Homo sapiens	103-126
31160603-5	2019	EPHB6 mutation-induced paclitaxel resistance was mediated by an interaction with EPHA2, which promotes c-Jun N-terminal kinase (JNK)-mediated cadherin 11 (CDH11) expression.	Paclitaxel	23-33	mitogen-activated protein kinase 8	Homo sapiens	128-131
31160603-5	2019	EPHB6 mutation-induced paclitaxel resistance was mediated by an interaction with EPHA2, which promotes c-Jun N-terminal kinase (JNK)-mediated cadherin 11 (CDH11) expression.	Paclitaxel	23-33	cadherin 11	Homo sapiens	142-153
31160603-5	2019	EPHB6 mutation-induced paclitaxel resistance was mediated by an interaction with EPHA2, which promotes c-Jun N-terminal kinase (JNK)-mediated cadherin 11 (CDH11) expression.	Paclitaxel	23-33	cadherin 11	Homo sapiens	155-160
31160603-7	2019	Targeted inhibition of EPHA2 or CDH11 reversed the acquired paclitaxel resistance, suggesting its potential clinical utility.	Paclitaxel	60-70	cadherin 11	Homo sapiens	32-37
31160603-8	2019	The present results suggest that the EPHB6 mutation and its downstream EPHA2/JNK/CDH11/RhoA/FAK signaling axis are novel diagnostic and therapeutic targets for overcoming paclitaxel resistance in cancer patients.	Paclitaxel	171-181	mitogen-activated protein kinase 8	Homo sapiens	77-80
31160603-8	2019	The present results suggest that the EPHB6 mutation and its downstream EPHA2/JNK/CDH11/RhoA/FAK signaling axis are novel diagnostic and therapeutic targets for overcoming paclitaxel resistance in cancer patients.	Paclitaxel	171-181	cadherin 11	Homo sapiens	81-86
31160603-8	2019	The present results suggest that the EPHB6 mutation and its downstream EPHA2/JNK/CDH11/RhoA/FAK signaling axis are novel diagnostic and therapeutic targets for overcoming paclitaxel resistance in cancer patients.	Paclitaxel	171-181	ras homolog family member A	Homo sapiens	87-91
31285951-0	2019	Genome-scale CRISPR activation screening identifies a role of ELAVL2-CDKN1A axis in paclitaxel resistance in esophageal squamous cell carcinoma.	Paclitaxel	84-94	cyclin dependent kinase inhibitor 1A	Homo sapiens	69-75
31285951-8	2019	We then found that overexpression of CDKN1A, ELAVL2 or TSPAN4 in ESCC cell lines significantly promoted the resistance to PTX by inhibiting cell apoptosis.	Paclitaxel	122-125	cyclin dependent kinase inhibitor 1A	Homo sapiens	37-43
30701575-0	2019	SMAD3 inducing the transcription of  STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.	Paclitaxel	126-136	SMAD family member 3	Rattus norvegicus	0-5
30825187-0	2019	Diosmetin induces apoptosis and enhances the chemotherapeutic efficacy of paclitaxel in non-small cell lung cancer cells via Nrf2 inhibition.	Paclitaxel	74-84	nuclear factor, erythroid derived 2, like 2	Mus musculus	125-129
31136990-8	2019	Furthermore, decrease of survivin by inhibition of PI3K/AKT pathway significantly inhibits the effect of PTX in Caki-1PTX cells.	Paclitaxel	105-108	AKT serine/threonine kinase 1	Homo sapiens	56-59
30624616-0	2019	Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.	Paclitaxel	90-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-108
31321352-5	2019	However, paclitaxel induced the activation of ERK/mitogen-activated protein kinase (MAPK) pathway, a cell signaling pathway implicated in cell survival and proliferation.	Paclitaxel	9-19	mitogen-activated protein kinase 1	Homo sapiens	46-49
31321352-5	2019	However, paclitaxel induced the activation of ERK/mitogen-activated protein kinase (MAPK) pathway, a cell signaling pathway implicated in cell survival and proliferation.	Paclitaxel	9-19	mitogen-activated protein kinase 1	Homo sapiens	84-88
30701575-1	2019	OBJECTIVE: To figure out the relationship between SMAD3 and serine-threonine tyrosine kinase (STYK1) in ovarian carcinoma cell"s paclitaxel resistance.	Paclitaxel	129-139	SMAD family member 3	Rattus norvegicus	50-55
30701575-12	2019	CONCLUSION: SMAD3 combined with the promoter region of STYK1 to promote the transcription process of STYK1, thereby promoting the EMT process and paclitaxel resistance of ovarian cancer cells.	Paclitaxel	146-156	SMAD family member 3	Rattus norvegicus	12-17
31146485-3	2019	The current study goal is to study the in vivo fate of human epidermal factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) dual-targeted PTX+EVER-loaded NPs (Dual-NPs) in an MDA-MB-231-H2N BC tumor-bearing mouse model.	Paclitaxel	154-157	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-88
30760861-7	2019	Reduction of FBP levels in cancer cells by the ectopic expression of ALDOB disrupted redox homeostasis, arrested cancer proliferation, and sensitized ccRCC cells to a chemotherapy agent (paclitaxel).	Paclitaxel	187-197	aldolase, fructose-bisphosphate B	Homo sapiens	69-74
30991054-0	2019	Spinal blockage of CXCL1 and its receptor CXCR2 inhibits paclitaxel-induced peripheral neuropathy in mice.	Paclitaxel	57-67	chemokine (C-X-C motif) ligand 1	Mus musculus	19-24
30991054-4	2019	Herein, we sought to evaluate the possible involvement of CXCL1 and CXCR2 in the pathogenesis of PTX-induced neuropathic pain in mice.	Paclitaxel	97-100	chemokine (C-X-C motif) ligand 1	Mus musculus	58-63
30991054-5	2019	PTX treatment led to increased levels of CXCL1 in both dorsal root ganglion and spinal cord samples.	Paclitaxel	0-3	chemokine (C-X-C motif) ligand 1	Mus musculus	41-46
30991054-10	2019	treatment with anti-CXCL1 (1 ng/site) or SB225002 (10 mug/site) consistently inhibited the nociceptive responses of PTX-treated mice.	Paclitaxel	116-119	chemokine (C-X-C motif) ligand 1	Mus musculus	20-25
30991054-13	2019	Overall, the data indicates that the up-regulation of CXCL1 is important for the development and maintenance of PTX-induced neuropathic pain in mice.	Paclitaxel	112-115	chemokine (C-X-C motif) ligand 1	Mus musculus	54-59
30991054-14	2019	Therefore, the spinal blockage of CXCL1/CXCR2 signalling might be a new innovative therapeutic approach to treat this clinical side effect of PTX.	Paclitaxel	142-145	chemokine (C-X-C motif) ligand 1	Mus musculus	34-39
30720585-8	2019	Moreover, adoptive transfer of cisplatin-educated CD8 T cells to Rag2 mice prevented CIPN development induced by either cisplatin or paclitaxel, indicating that the activity of the educated CD8 T is not cisplatin specific.	Paclitaxel	133-143	recombination activating gene 2	Mus musculus	65-69
30317630-0	2019	Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells.	Paclitaxel	110-115	androgen receptor	Homo sapiens	0-17
30317630-0	2019	Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells.	Paclitaxel	110-115	ATP binding cassette subfamily B member 1	Homo sapiens	78-83
30317630-1	2019	We report here that the androgen receptor (AR) and ABCB1 are upregulated in a model of acquired taxol resistance (txr) in ovarian carcinoma cells.	Paclitaxel	96-101	androgen receptor	Homo sapiens	24-41
30317630-1	2019	We report here that the androgen receptor (AR) and ABCB1 are upregulated in a model of acquired taxol resistance (txr) in ovarian carcinoma cells.	Paclitaxel	96-101	androgen receptor	Homo sapiens	43-45
30317630-1	2019	We report here that the androgen receptor (AR) and ABCB1 are upregulated in a model of acquired taxol resistance (txr) in ovarian carcinoma cells.	Paclitaxel	96-101	ATP binding cassette subfamily B member 1	Homo sapiens	51-56
30317630-2	2019	AR silencing sensitizes txr cells to taxol threefold, whereas ectopic AR expression in AR-null HEK293 cells induces resistance to taxol by 1.7-fold.	Paclitaxel	37-42	androgen receptor	Homo sapiens	0-2
30317630-2	2019	AR silencing sensitizes txr cells to taxol threefold, whereas ectopic AR expression in AR-null HEK293 cells induces resistance to taxol by 1.7-fold.	Paclitaxel	130-135	androgen receptor	Homo sapiens	70-72
30317630-2	2019	AR silencing sensitizes txr cells to taxol threefold, whereas ectopic AR expression in AR-null HEK293 cells induces resistance to taxol by 1.7-fold.	Paclitaxel	130-135	androgen receptor	Homo sapiens	70-72
30317630-3	2019	AR activation using the agonist dihydrotestosterone (DHT) or sublethal taxol treatment upregulates ABCB1 expression in both txr cells and AR-expressing HEK293 cells.	Paclitaxel	71-76	androgen receptor	Homo sapiens	0-2
30317630-3	2019	AR activation using the agonist dihydrotestosterone (DHT) or sublethal taxol treatment upregulates ABCB1 expression in both txr cells and AR-expressing HEK293 cells.	Paclitaxel	71-76	ATP binding cassette subfamily B member 1	Homo sapiens	99-104
30317630-3	2019	AR activation using the agonist dihydrotestosterone (DHT) or sublethal taxol treatment upregulates ABCB1 expression in both txr cells and AR-expressing HEK293 cells.	Paclitaxel	71-76	androgen receptor	Homo sapiens	138-140
30317630-4	2019	In contrast, AR inactivation using the antagonist bicalutamide downregulates ABCB1 expression and enhances cytotoxicity to taxol.	Paclitaxel	123-128	androgen receptor	Homo sapiens	13-15
30317630-7	2019	Notably, DHT- or taxol-activated AR potentiates binding of the AR to ARE4 as revealed by the chromatin immunoprecipitation.	Paclitaxel	17-22	androgen receptor	Homo sapiens	33-35
30317630-7	2019	Notably, DHT- or taxol-activated AR potentiates binding of the AR to ARE4 as revealed by the chromatin immunoprecipitation.	Paclitaxel	17-22	androgen receptor	Homo sapiens	63-65
30317630-9	2019	AR/H3K9ac and AR/H3K14ac complexes bind specifically to ARE4 in response to taxol.	Paclitaxel	76-81	androgen receptor	Homo sapiens	0-2
30317630-12	2019	While the phosphatidylinositol 3-kinase (PI3K)/serine/threonine protein kinase (AKT) pathway is significantly activated by taxol, taxol-induced ABCB1 expression, histone posttranslational modifications, and p300 binding to ARE4 are suppressed following inhibition of the PI3K/AKT cellular pathway.	Paclitaxel	130-135	ATP binding cassette subfamily B member 1	Homo sapiens	144-149
30317630-13	2019	These results demonstrate that the AKT/p300/AR axis can be activated to target ABCB1 gene expression in response to taxol, thus revealing a new treatment target to counter taxol resistance.	Paclitaxel	116-121	androgen receptor	Homo sapiens	44-46
30317630-13	2019	These results demonstrate that the AKT/p300/AR axis can be activated to target ABCB1 gene expression in response to taxol, thus revealing a new treatment target to counter taxol resistance.	Paclitaxel	116-121	ATP binding cassette subfamily B member 1	Homo sapiens	79-84
30317630-13	2019	These results demonstrate that the AKT/p300/AR axis can be activated to target ABCB1 gene expression in response to taxol, thus revealing a new treatment target to counter taxol resistance.	Paclitaxel	172-177	androgen receptor	Homo sapiens	44-46
30317630-13	2019	These results demonstrate that the AKT/p300/AR axis can be activated to target ABCB1 gene expression in response to taxol, thus revealing a new treatment target to counter taxol resistance.	Paclitaxel	172-177	ATP binding cassette subfamily B member 1	Homo sapiens	79-84
31206033-8	2019	In addition, miR-107 may prominently enhance PTX induced reduction of cell viability and the promotion of cell apoptosis in breast cancer, and the variation could be reversed by co-transfected with pcDNA3.1-TPD52.	Paclitaxel	45-48	tumor protein D52	Homo sapiens	207-212
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	126-129	tumor protein D52	Homo sapiens	66-71
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	126-129	Wnt family member 1	Homo sapiens	73-77
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	126-129	tumor protein D52	Homo sapiens	194-199
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	126-129	tumor protein D52	Homo sapiens	194-199
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	268-271	tumor protein D52	Homo sapiens	66-71
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	268-271	Wnt family member 1	Homo sapiens	73-77
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	268-271	tumor protein D52	Homo sapiens	194-199
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	268-271	tumor protein D52	Homo sapiens	194-199
31142317-9	2019	Knockdown of TM4SF1 substantially inhibited tumor cell growth, migration, and invasion, and enhanced the chemo-sensitivity of the lung cancer cell lines A549 and H1299 to cisplatin and paclitaxel.	Paclitaxel	185-195	transmembrane 4 superfamily member 1	Mus musculus	13-19
31146485-3	2019	The current study goal is to study the in vivo fate of human epidermal factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) dual-targeted PTX+EVER-loaded NPs (Dual-NPs) in an MDA-MB-231-H2N BC tumor-bearing mouse model.	Paclitaxel	154-157	epidermal growth factor receptor	Homo sapiens	100-132
31146485-3	2019	The current study goal is to study the in vivo fate of human epidermal factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) dual-targeted PTX+EVER-loaded NPs (Dual-NPs) in an MDA-MB-231-H2N BC tumor-bearing mouse model.	Paclitaxel	154-157	epidermal growth factor receptor	Homo sapiens	134-138
31118065-16	2019	MTDH reversed the sensitivity of miR-let-7b and miR-let-7c to paclitaxel in vitro.	Paclitaxel	62-72	metadherin	Homo sapiens	0-4
31156650-2	2019	In addition to its antitumor effect, paclitaxel is also known to promote Toll-like receptor (TLR) 4-dependent inflammatory responses, which may lower its chemotherapeutic efficacy.	Paclitaxel	37-47	toll-like receptor 4	Mus musculus	93-96
31190887-0	2019	Mitochondria P-glycoprotein confers paclitaxel resistance on ovarian cancer cells.	Paclitaxel	36-46	ATP binding cassette subfamily B member 1	Homo sapiens	13-27
31190887-14	2019	Conclusion: P-gp is highly expressed in mitochondria of taxol-resistant ovarian cancer cells and ovarian cancer tissues and mediates the drug efflux, which probably protect cancer cells from chemotherapy.	Paclitaxel	56-61	ATP binding cassette subfamily B member 1	Homo sapiens	12-16
31334335-0	2019	FoxM1 Induced Paclitaxel Resistance via Activation of the FoxM1/PHB1/RAF-MEK-ERK Pathway and Enhancement of the ABCA2 Transporter.	Paclitaxel	14-24	mitogen-activated protein kinase kinase 7	Homo sapiens	73-76
31334335-0	2019	FoxM1 Induced Paclitaxel Resistance via Activation of the FoxM1/PHB1/RAF-MEK-ERK Pathway and Enhancement of the ABCA2 Transporter.	Paclitaxel	14-24	mitogen-activated protein kinase 1	Homo sapiens	77-80
31334335-5	2019	FoxM1 contributed to the PHB1/C-RAF interaction and phosphorylation of ERK1/2 kinases, thus promoting paclitaxel resistance.	Paclitaxel	102-112	mitogen-activated protein kinase 3	Homo sapiens	71-77
31334335-7	2019	Besides, we identified that ABCA2 promoted paclitaxel resistance under the regulation of FoxM1/PHB1/RAF-MEK-ERK.	Paclitaxel	43-53	mitogen-activated protein kinase kinase 7	Homo sapiens	104-107
31334335-7	2019	Besides, we identified that ABCA2 promoted paclitaxel resistance under the regulation of FoxM1/PHB1/RAF-MEK-ERK.	Paclitaxel	43-53	mitogen-activated protein kinase 1	Homo sapiens	108-111
31334335-11	2019	It was regulated by FoxM1 to maintain phosphorylation of ERK1/2 in drug-resistant cells, and FoxM1 simultaneously enhanced the function of ABCA2, which collectively contributed to paclitaxel resistance.	Paclitaxel	180-190	mitogen-activated protein kinase 3	Homo sapiens	57-63
31156650-8	2019	Mechanistically, paclitaxel treatment induced robust activation of the TLR4 signaling cascade, including phosphorylation of IkappaB and JNK and upregulation of proinflammatory cytokine mRNA levels in a TLR4-dependent manner.	Paclitaxel	17-27	toll-like receptor 4	Mus musculus	71-75
31156650-8	2019	Mechanistically, paclitaxel treatment induced robust activation of the TLR4 signaling cascade, including phosphorylation of IkappaB and JNK and upregulation of proinflammatory cytokine mRNA levels in a TLR4-dependent manner.	Paclitaxel	17-27	toll-like receptor 4	Mus musculus	202-206
31156650-11	2019	This suggestion was supported by the observations that paclitaxel treatment caused robust IL-1beta production in macrophages in the presence of cell-free medium derived from growth of injured cells and also in the spleen of mice.	Paclitaxel	55-65	interleukin 1 beta	Mus musculus	90-98
31156720-0	2019	Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer.	Paclitaxel	79-89	androgen receptor	Homo sapiens	21-38
31156720-8	2019	Results: Treatment with Plk1 inhibitors markedly reduced the expression of MDR1, MRP1, and Plk1 in the paclitaxel-resistant cancer.	Paclitaxel	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	75-79
31156720-9	2019	Among Plk1 inhibitors, genistein, recently found as a direct Plk1 inhibitor, tended to be more effective in the paclitaxel-resistant prostate cancer than the parental cancer cells, which was related to the suppression of the AR, as well as inhibition of Plk1 activity.	Paclitaxel	112-122	androgen receptor	Homo sapiens	225-227
31156720-8	2019	Results: Treatment with Plk1 inhibitors markedly reduced the expression of MDR1, MRP1, and Plk1 in the paclitaxel-resistant cancer.	Paclitaxel	103-113	ATP binding cassette subfamily C member 1	Homo sapiens	81-85
31156720-12	2019	Conclusions: We suggest that cotargeting Plk1 and AR would be effective in advanced chemoresistant prostate cancer cells to overcome the limitations associated with paclitaxel.	Paclitaxel	165-175	androgen receptor	Homo sapiens	50-52
30387134-0	2019	Toll-like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3-UNC93B1-IFN-beta signaling axis in paclitaxel-resistant colon cancer.	Paclitaxel	135-145	unc-93 homolog B1, TLR signaling regulator	Homo sapiens	100-107
30230544-3	2019	ClC-3 was highly expressed in the P-glycoprotein (P-gp)-dependent human lung adenocarcinoma cell line (A549)/paclitaxel (PTX) and the human breast carcinoma cell line (MCF-7)/doxorubicin (DOX) resistant cells.	Paclitaxel	109-119	ATP binding cassette subfamily B member 1	Homo sapiens	50-54
30230544-5	2019	Double transgenic MMTV-PyMT/CLCN3 mice with spontaneous mammary cancer and ClC-3 overexpression demonstrated drug resistance to PTX and DOX.	Paclitaxel	128-131	chloride channel, voltage-sensitive 3	Mus musculus	75-80
30387134-6	2019	In addition, when TLR3 was overexpressed in HCT-8/PTX cells, we found that TLR3 contributed to the production of IFN-beta that reduced cell viability, and poly I:C preferentially activated the TLR3-UNC93B1 signaling pathway to mediate this effect.	Paclitaxel	50-53	unc-93 homolog B1, TLR signaling regulator	Homo sapiens	198-205
31424664-0	2019	The efficacy and reliability of sequential adjuvant anthracycline-based chemotherapy and weekly paclitaxel regimen in human epidermal growth factor receptor 2 negative breast cancer: A retrospective analysis of a multicentre study.	Paclitaxel	96-106	erb-b2 receptor tyrosine kinase 2	Homo sapiens	124-158
30387134-7	2019	Moreover, cotreatment of poly I:C and PTX acted synergistically to induce cell apoptosis of HCT-8/PTX via upregulating the expression of TLR3 and its molecular chaperone UNC93B1, assisting in the secretion of IFN-beta.	Paclitaxel	38-41	unc-93 homolog B1, TLR signaling regulator	Homo sapiens	170-177
31424664-13	2019	CONCLUSIONS: This multicentric retrospective study confirmed that sequential adjuvant therapy with anthracycline-based chemotherapy and paclitaxel for HER2 negative breast cancer is an effective and reliable regimen.	Paclitaxel	136-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	151-155
30387134-7	2019	Moreover, cotreatment of poly I:C and PTX acted synergistically to induce cell apoptosis of HCT-8/PTX via upregulating the expression of TLR3 and its molecular chaperone UNC93B1, assisting in the secretion of IFN-beta.	Paclitaxel	98-101	unc-93 homolog B1, TLR signaling regulator	Homo sapiens	170-177
30387134-9	2019	In conclusion, our studies demonstrate that poly I:C reinforces the potency of cytotoxic chemotherapeutics in PTX-resistant cell line through the TLR3-UNC93B1-IFN-beta signaling pathway, which supplies a novel mechanism of poly I:C for the chemotherapy sensitizing effect in a PTX-resistant tumor.	Paclitaxel	110-113	unc-93 homolog B1, TLR signaling regulator	Homo sapiens	151-158
30471427-5	2019	Consistently, MMP9 protein levels are increased in DRG neurons in vivo and in vitro after paclitaxel treatment, and it is demonstrated, for the first time, that intrathecal injections of exogenous TIMP1 or a monoclonal antibody targeting MMP9 (MMP9 mAb) significantly prevented and reversed paclitaxel-induced mechanical allodynia in male and female mice.	Paclitaxel	291-301	tissue inhibitor of metalloproteinase 1	Mus musculus	197-202
30782852-2	2019	In the past decade, OATPs, primarily OATP1A2, OATP1B1, and OATP1B3, have emerged as potential mediators of chemotherapy disposition, including drugs such as methotrexate, doxorubicin, paclitaxel, docetaxel, irinotecan and its important metabolite 7-ethyl-10-hydroxycamptothecin, and certain tyrosine kinase inhibitors.	Paclitaxel	184-194	solute carrier organic anion transporter family member 1B3	Homo sapiens	59-66
30414958-7	2019	Paclitaxel induced the expression of CB2 receptors and production of interleukin (IL)-6 in microglia in the dorsal horn.	Paclitaxel	0-10	interleukin 6	Rattus norvegicus	69-87
30414958-10	2019	Paclitaxel also upregulated the expression of glutamate receptor subunits GluR1 and NR2B, decreased the expression of K+-Cl- cotransporter, and induced mechanical allodynia in rats.	Paclitaxel	0-10	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	74-79
30471427-4	2019	Here, we report that paclitaxel-induced mechanical allodynia is associated with transcriptional increase in matrix metalloproteinase (MMP) 2 and 9 and decrease in metallopeptidase inhibitor 1 (TIMP1), a strong endogenous MMP9 inhibitor.	Paclitaxel	21-31	tissue inhibitor of metalloproteinase 1	Mus musculus	193-198
30942454-8	2019	In conclusion, the data suggested that elevated miR-302a levels, in part, mediate sensitivity to paclitaxel in prostate cancer through the aberrant regulation of its downstream targets, AOF2, BCRP and permeability glycoprotein 1.	Paclitaxel	97-107	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	192-196
30707920-3	2019	In this study, we investigated the inhibitory effects of bazedoxifene alone or in combination with paclitaxel on several estrogen receptor positive and TNBC cells.	Paclitaxel	99-109	estrogen receptor 1	Homo sapiens	121-138
30705408-11	2019	Moreover, Aurora A"s activation correlates with microtubule stabilization induced by the microtubule stabilizer paclitaxel, implicating that stabilized microtubules caused by RITA depletion could also account for increased active Aurora A.	Paclitaxel	112-122	RBPJ interacting and tubulin associated 1	Mus musculus	175-179
30942454-7	2019	Gene and protein expression analyses suggested that the miR-302a target gene breast cancer resistance protein (BCRP) may mediate chemo-resistance to paclitaxel in PC-3PR cells.	Paclitaxel	149-159	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	77-109
30942454-7	2019	Gene and protein expression analyses suggested that the miR-302a target gene breast cancer resistance protein (BCRP) may mediate chemo-resistance to paclitaxel in PC-3PR cells.	Paclitaxel	149-159	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	111-115
30714183-14	2019	Combined Zn and PTX inhibited prostate cancer cell invasion and migration by downregulating the expression of TWIST1.	Paclitaxel	16-19	twist family bHLH transcription factor 1	Homo sapiens	110-116
30714183-15	2019	Furthermore, knockdown of TWIST1 increased the sensitivity of prostate cancer cells to PTX.	Paclitaxel	87-90	twist family bHLH transcription factor 1	Homo sapiens	26-32
30714183-17	2019	CONCLUSIONS: Our results demonstrated that Zn and PTX combined therapy inhibits EMT by reducing the expression of TWIST1, which reduces the invasion and migration of prostate cancer cells.	Paclitaxel	50-53	twist family bHLH transcription factor 1	Homo sapiens	114-120
30810041-3	2019	Research has suggested that the upregulation of ERK signaling by the anticancer agent paclitaxel leads to acquired resistance of cells to this compound.	Paclitaxel	86-96	mitogen-activated protein kinase 1	Homo sapiens	48-51
30810041-7	2019	Plumbagin was shown to decrease levels of phosphorylated ERK in breast cancer cells and abrogated paclitaxel-induced ERK phosphorylation.	Paclitaxel	98-108	mitogen-activated protein kinase 1	Homo sapiens	117-120
30810041-8	2019	The role of ERK in plumbagin-mediated sensitization of breast cancer cells to paclitaxel was shown through the enhancement of the synergistic effect between compounds in cells with decreased ERK expression.	Paclitaxel	78-88	mitogen-activated protein kinase 1	Homo sapiens	12-15
30810041-8	2019	The role of ERK in plumbagin-mediated sensitization of breast cancer cells to paclitaxel was shown through the enhancement of the synergistic effect between compounds in cells with decreased ERK expression.	Paclitaxel	78-88	mitogen-activated protein kinase 1	Homo sapiens	191-194
30810041-10	2019	These results imply that plumbagin inhibits ERK activation in breast cancer cells, which plays a role in the sensitization of cells to paclitaxel-induced cell death.	Paclitaxel	135-145	mitogen-activated protein kinase 1	Homo sapiens	44-47
31027318-7	2019	Results: The results showed a decreased level of PTPRK expression in ovarian cancer cell lines resistant to cisplatin (CIS), paclitaxel (PAC), doxorubicin (DOX), topotecan (TOP), vincristine (VIN) and methotrexate (MTX).	Paclitaxel	125-135	protein tyrosine phosphatase receptor type K	Homo sapiens	49-54
31027318-7	2019	Results: The results showed a decreased level of PTPRK expression in ovarian cancer cell lines resistant to cisplatin (CIS), paclitaxel (PAC), doxorubicin (DOX), topotecan (TOP), vincristine (VIN) and methotrexate (MTX).	Paclitaxel	137-140	protein tyrosine phosphatase receptor type K	Homo sapiens	49-54
31106148-6	2019	Glesatinib suppressed the efflux function of P-gp to [3H]-paclitaxel and it didn"t impact both the expression and cellular localization of P-gp based on Western blot and immunofluorescent analysis.	Paclitaxel	58-68	ATP binding cassette subfamily B member 1	Homo sapiens	45-49
31006192-0	2019	[Role and mechanism of the regulation of nuclear factor-kappaB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].	Paclitaxel	145-155	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	41-62
31006192-1	2019	Objective: To investigate the role and mechanism of the regulation of nuclear factor-kappaB (NF-kappaB) by heparin binding-epidermal growth factor-like growth factor (HB-EGF) in paclitaxel resistance of ovarian cancer in vitro and in vivo.	Paclitaxel	178-188	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	70-91
31006192-1	2019	Objective: To investigate the role and mechanism of the regulation of nuclear factor-kappaB (NF-kappaB) by heparin binding-epidermal growth factor-like growth factor (HB-EGF) in paclitaxel resistance of ovarian cancer in vitro and in vivo.	Paclitaxel	178-188	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	93-102
31281722-9	2019	Myosin light chain (MLC) 2 phosphorylation and RhoA activity were upregulated by doxorubicin and downregulated by paclitaxel.	Paclitaxel	114-124	ras homolog family member A	Homo sapiens	47-51
31006192-2	2019	Methods: (1) The detection of NF-kappaB expression: parental (A2780) and paclitaxel-resistant (A2780/Taxol) ovarian carcinoma cells were divided into four groups, named A2780 group, A2780+cross-reacting material 197 (CRM197, HB-EGF inhibitor) group, A2780/Taxol group and A2780/Taxol+CRM197 group.	Paclitaxel	73-83	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	30-39
31006192-10	2019	The expression level of HB-EGF, EGFR and NF-kappaB protein between A2780 and A2780/Taxol groups in vivo and in vitro were higher than these in A2780+CRM197 and A2780/Taxol+CRM197 group, while the expression level of HB-EGF, EGFR and NF-kappaB protein in A2780 group were lower than those in A2780/Taxol groups in vivo and in vitro (P&lt;0.05).	Paclitaxel	83-88	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	41-50
31006192-10	2019	The expression level of HB-EGF, EGFR and NF-kappaB protein between A2780 and A2780/Taxol groups in vivo and in vitro were higher than these in A2780+CRM197 and A2780/Taxol+CRM197 group, while the expression level of HB-EGF, EGFR and NF-kappaB protein in A2780 group were lower than those in A2780/Taxol groups in vivo and in vitro (P&lt;0.05).	Paclitaxel	83-88	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	233-242
31006192-13	2019	Conclusions: The expression of NF-kappaB may contributes to the paclitaxel resistance to ovarian cancer.	Paclitaxel	64-74	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	31-40
31006192-14	2019	HB-EGF may induce the paclitaxel resistance of ovarian cancer by the regulation of EGFR/NF-kappaB/P-gp pathway.	Paclitaxel	22-32	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	88-97
31044156-0	2019	Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types.	Paclitaxel	14-24	BCL2 apoptosis regulator	Homo sapiens	66-70
31044156-4	2019	Since paclitaxel is known to target BCL2 and TUBB1, we used pan-cancer genomic data from hundreds of patients to show that a single-nucleotide variant in the BCL2 sequence can predict a patient"s response to paclitaxel.	Paclitaxel	6-16	BCL2 apoptosis regulator	Homo sapiens	36-40
31044156-4	2019	Since paclitaxel is known to target BCL2 and TUBB1, we used pan-cancer genomic data from hundreds of patients to show that a single-nucleotide variant in the BCL2 sequence can predict a patient"s response to paclitaxel.	Paclitaxel	6-16	BCL2 apoptosis regulator	Homo sapiens	158-162
31044156-4	2019	Since paclitaxel is known to target BCL2 and TUBB1, we used pan-cancer genomic data from hundreds of patients to show that a single-nucleotide variant in the BCL2 sequence can predict a patient"s response to paclitaxel.	Paclitaxel	208-218	BCL2 apoptosis regulator	Homo sapiens	36-40
31044156-4	2019	Since paclitaxel is known to target BCL2 and TUBB1, we used pan-cancer genomic data from hundreds of patients to show that a single-nucleotide variant in the BCL2 sequence can predict a patient"s response to paclitaxel.	Paclitaxel	208-218	BCL2 apoptosis regulator	Homo sapiens	158-162
30790579-4	2019	Five flavonoids, including tangeretin, sinensetin, isosinensetin, sciadopitysin and oroxylin A exhibited significant inhibition on P-gp in MDR1-MDCKIIcells, which reduced the P-gp-mediated efflux of paraquat and taxol and consequently increased their cell toxicity.	Paclitaxel	212-217	ATP binding cassette subfamily B member 1	Homo sapiens	131-135
30999914-0	2019	Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer.	Paclitaxel	46-56	eosinophil granule ontogeny transcript	Homo sapiens	10-14
30999914-0	2019	Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer.	Paclitaxel	46-56	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	90-95
30999914-6	2019	Moreover, the mechanism of EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions was investigated in detail.	Paclitaxel	63-73	eosinophil granule ontogeny transcript	Homo sapiens	27-31
30999914-8	2019	Finally, clinical breast specimens in our cohort, TCGA and ICGC were applied to validate the role of EGOT in enhancing of paclitaxel sensitivity.	Paclitaxel	122-132	eosinophil granule ontogeny transcript	Homo sapiens	101-105
30999914-9	2019	RESULTS: EGOT enhances autophagosome accumulation via the up-regulation of ITPR1 expression, thereby sensitizing cells to paclitaxel toxicity.	Paclitaxel	122-132	eosinophil granule ontogeny transcript	Homo sapiens	9-13
30999914-13	2019	Finally, EGOT expression enhances paclitaxel sensitivity via assessment of cancer specimens.	Paclitaxel	34-44	eosinophil granule ontogeny transcript	Homo sapiens	9-13
30999914-15	2019	Proper regulation of EGOT may be a novel synergistic strategy for enhancing paclitaxel sensitivity in cancer therapy.	Paclitaxel	76-86	eosinophil granule ontogeny transcript	Homo sapiens	21-25
30790579-4	2019	Five flavonoids, including tangeretin, sinensetin, isosinensetin, sciadopitysin and oroxylin A exhibited significant inhibition on P-gp in MDR1-MDCKIIcells, which reduced the P-gp-mediated efflux of paraquat and taxol and consequently increased their cell toxicity.	Paclitaxel	212-217	ATP binding cassette subfamily B member 1	Homo sapiens	175-179
31008009-0	2019	Synthesis and Feasibility Evaluation of a new Trastuzumab Conjugate Integrated with Paclitaxel and 89Zr for Theranostic Application Against HER2-Expressing Breast Cancers.	Paclitaxel	84-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	140-144
31013972-8	2019	There are 12, 10 and 11 paclitaxel biosynthesis genes promoters that could be activated by MYC2, MYC3 and MYC4.	Paclitaxel	24-34	Basic helix-loop-helix (bHLH) DNA-binding family protein	Arabidopsis thaliana	106-110
31114158-9	2019	In addition, we found that emodin significantly enhanced PTX-induced apoptosis in A549 cells via increasing the expressions of Bax and active caspase 3 and decreasing the levels of Bcl-2, p-Akt and p-ERK.	Paclitaxel	57-60	BCL2 associated X, apoptosis regulator	Homo sapiens	127-130
31114158-9	2019	In addition, we found that emodin significantly enhanced PTX-induced apoptosis in A549 cells via increasing the expressions of Bax and active caspase 3 and decreasing the levels of Bcl-2, p-Akt and p-ERK.	Paclitaxel	57-60	caspase 3	Homo sapiens	142-151
31114158-9	2019	In addition, we found that emodin significantly enhanced PTX-induced apoptosis in A549 cells via increasing the expressions of Bax and active caspase 3 and decreasing the levels of Bcl-2, p-Akt and p-ERK.	Paclitaxel	57-60	BCL2 apoptosis regulator	Homo sapiens	181-186
31114158-9	2019	In addition, we found that emodin significantly enhanced PTX-induced apoptosis in A549 cells via increasing the expressions of Bax and active caspase 3 and decreasing the levels of Bcl-2, p-Akt and p-ERK.	Paclitaxel	57-60	mitogen-activated protein kinase 1	Homo sapiens	200-203
33405563-0	2019	Antitumor Effect and Toxicity of an Albumin-Paclitaxel Nanocarrier System Constructed via Controllable Alkali-Induced Conformational Changes.	Paclitaxel	44-54	albumin	Homo sapiens	36-43
33405563-2	2019	In this work, a compound comprising albumin-paclitaxel nanoparticles (NPs-PTX) with a drug loading efficiency of 21% was constructed via manipulation of alkali induced conformation changes and hydrophilic-hydrophobicity transition.	Paclitaxel	44-54	albumin	Homo sapiens	36-43
30982496-0	2019	miR-205-5p contributes to paclitaxel resistance and progression of endometrial cancer by downregulating FOXO1.	Paclitaxel	26-36	forkhead box O1	Homo sapiens	104-109
31008009-5	2019	Furthermore, DFO-trastuzumab-PTX displayed comparable cytotoxicity with PTX and 89Zr-DFO-trastuzumab-PTX exhibited HER2 receptor-mediated binding on HER2-positive MDA-MB-231 breast cancer cells.	Paclitaxel	29-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-119
31008009-5	2019	Furthermore, DFO-trastuzumab-PTX displayed comparable cytotoxicity with PTX and 89Zr-DFO-trastuzumab-PTX exhibited HER2 receptor-mediated binding on HER2-positive MDA-MB-231 breast cancer cells.	Paclitaxel	29-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-153
30710195-0	2019	Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation.	Paclitaxel	17-27	caspase 3	Homo sapiens	105-114
30959904-8	2019	We suggest that PTX/LAP micelles can be applicable not only for the therapy of HER-2-positive, but also HER-2-negative breast cancers.	Paclitaxel	16-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-84
30959904-8	2019	We suggest that PTX/LAP micelles can be applicable not only for the therapy of HER-2-positive, but also HER-2-negative breast cancers.	Paclitaxel	16-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-109
31205528-0	2019	P16 Methylation Leads to Paclitaxel Resistance of Advanced Non-Small Cell Lung Cancer.	Paclitaxel	25-35	cyclin dependent kinase inhibitor 2A	Homo sapiens	0-3
31205528-3	2019	This study aimed to investigate whether P16 methylation could be used to predict paclitaxel chemosensitivity of NSCLC.	Paclitaxel	81-91	cyclin dependent kinase inhibitor 2A	Homo sapiens	40-43
31205528-7	2019	The association between P16 methylation and the sensitivity of paclitaxel in cell lines was determined by in vitro assay using a P16-specific DNA demethylase (P16-TET) and methyltransferase (P16-Dnmt).	Paclitaxel	63-73	cyclin dependent kinase inhibitor 2A	Homo sapiens	24-27
31205528-7	2019	The association between P16 methylation and the sensitivity of paclitaxel in cell lines was determined by in vitro assay using a P16-specific DNA demethylase (P16-TET) and methyltransferase (P16-Dnmt).	Paclitaxel	63-73	cyclin dependent kinase inhibitor 2A	Homo sapiens	129-132
31205528-7	2019	The association between P16 methylation and the sensitivity of paclitaxel in cell lines was determined by in vitro assay using a P16-specific DNA demethylase (P16-TET) and methyltransferase (P16-Dnmt).	Paclitaxel	63-73	cyclin dependent kinase inhibitor 2A	Homo sapiens	129-132
31205528-7	2019	The association between P16 methylation and the sensitivity of paclitaxel in cell lines was determined by in vitro assay using a P16-specific DNA demethylase (P16-TET) and methyltransferase (P16-Dnmt).	Paclitaxel	63-73	cyclin dependent kinase inhibitor 2A	Homo sapiens	129-132
31205528-8	2019	The total response rate of the low-dose paclitaxel-based chemo-radiotherapy was significantly lower in P16 methylation-positive NSCLCs than that in the P16 methylation-negative NSCLCs (2/15 vs. 16/30: adjusted OR=0.085; 95%CI, 0.012-0.579).	Paclitaxel	40-50	cyclin dependent kinase inhibitor 2A	Homo sapiens	103-106
31205528-8	2019	The total response rate of the low-dose paclitaxel-based chemo-radiotherapy was significantly lower in P16 methylation-positive NSCLCs than that in the P16 methylation-negative NSCLCs (2/15 vs. 16/30: adjusted OR=0.085; 95%CI, 0.012-0.579).	Paclitaxel	40-50	cyclin dependent kinase inhibitor 2A	Homo sapiens	152-155
31205528-9	2019	Results revealed that P16 demethylation significantly decreased paclitaxel resistance of lung cancer H1299 cells (IC50 values decreased from 2.15 to 1.13 microg/ml, P&lt;0.001).	Paclitaxel	64-74	cyclin dependent kinase inhibitor 2A	Homo sapiens	22-25
31205528-10	2019	In contrast, P16-specific methylation by P16-Dnmt significantly increased paclitaxel resistance of lung cancer HCC827 cells and gastric cancer BGC823 cells (IC50 values increased from 18.2 to 24.0 ng/ml and 0.18 to 0.81 microg/ml, respectively; P=0.049 and &lt;0.001, respectively).	Paclitaxel	74-84	cyclin dependent kinase inhibitor 2A	Homo sapiens	13-16
31205528-10	2019	In contrast, P16-specific methylation by P16-Dnmt significantly increased paclitaxel resistance of lung cancer HCC827 cells and gastric cancer BGC823 cells (IC50 values increased from 18.2 to 24.0 ng/ml and 0.18 to 0.81 microg/ml, respectively; P=0.049 and &lt;0.001, respectively).	Paclitaxel	74-84	cyclin dependent kinase inhibitor 2A	Homo sapiens	41-44
31205528-11	2019	The present results suggest that P16 methylation may lead to paclitaxel resistance and be a predictor of paclitaxel chemosensitivity of NSCLC.	Paclitaxel	61-71	cyclin dependent kinase inhibitor 2A	Homo sapiens	33-36
31205528-11	2019	The present results suggest that P16 methylation may lead to paclitaxel resistance and be a predictor of paclitaxel chemosensitivity of NSCLC.	Paclitaxel	105-115	cyclin dependent kinase inhibitor 2A	Homo sapiens	33-36
30753274-2	2019	In this study, we aimed to characterize the immune microenvironment of small HER2-positive breast cancers included in the Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer (APT) trial and to correlate the immune markers with pathological and molecular tumor characteristics.	Paclitaxel	131-141	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
30753274-3	2019	PATIENTS AND METHODS: The APT trial was a multicenter, single-arm, phase II study of paclitaxel and trastuzumab in patients with node-negative HER2-positive breast cancer.	Paclitaxel	85-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
30986993-0	2019	Increase Paclitaxel Sensitivity to Better Suppress Serous Epithelial Ovarian Cancer via Ablating Androgen Receptor/Aryl Hydrocarbon Receptor-ABCG2 Axis.	Paclitaxel	9-19	androgen receptor	Homo sapiens	97-114
30986993-0	2019	Increase Paclitaxel Sensitivity to Better Suppress Serous Epithelial Ovarian Cancer via Ablating Androgen Receptor/Aryl Hydrocarbon Receptor-ABCG2 Axis.	Paclitaxel	9-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	141-146
30986993-4	2019	METHODS: To elucidate AR-related paclitaxel sensitivity, co-IP, luciferase reporter assay and ChIP assay were performed to identify that AR direct-regulated ABCG2 expression under paclitaxel treatment.	Paclitaxel	33-43	androgen receptor	Homo sapiens	22-24
30986993-4	2019	METHODS: To elucidate AR-related paclitaxel sensitivity, co-IP, luciferase reporter assay and ChIP assay were performed to identify that AR direct-regulated ABCG2 expression under paclitaxel treatment.	Paclitaxel	33-43	androgen receptor	Homo sapiens	137-139
30986993-4	2019	METHODS: To elucidate AR-related paclitaxel sensitivity, co-IP, luciferase reporter assay and ChIP assay were performed to identify that AR direct-regulated ABCG2 expression under paclitaxel treatment.	Paclitaxel	33-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	157-162
30986993-4	2019	METHODS: To elucidate AR-related paclitaxel sensitivity, co-IP, luciferase reporter assay and ChIP assay were performed to identify that AR direct-regulated ABCG2 expression under paclitaxel treatment.	Paclitaxel	180-190	androgen receptor	Homo sapiens	22-24
30986993-4	2019	METHODS: To elucidate AR-related paclitaxel sensitivity, co-IP, luciferase reporter assay and ChIP assay were performed to identify that AR direct-regulated ABCG2 expression under paclitaxel treatment.	Paclitaxel	180-190	androgen receptor	Homo sapiens	137-139
30986993-4	2019	METHODS: To elucidate AR-related paclitaxel sensitivity, co-IP, luciferase reporter assay and ChIP assay were performed to identify that AR direct-regulated ABCG2 expression under paclitaxel treatment.	Paclitaxel	180-190	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	157-162
30986993-6	2019	AR degradation enhancer (ASC-J9) was used to examine paclitaxel-associated and paclitaxel-resistant cytotoxicity in vitro and in vivo.	Paclitaxel	53-63	androgen receptor	Homo sapiens	0-2
30986993-6	2019	AR degradation enhancer (ASC-J9) was used to examine paclitaxel-associated and paclitaxel-resistant cytotoxicity in vitro and in vivo.	Paclitaxel	79-89	androgen receptor	Homo sapiens	0-2
30986993-8	2019	Molecular mechanism study showed that paclitaxel activated AR transactivity and bound to alternative ARE in the ABCG2 proximal promoter region.	Paclitaxel	38-48	androgen receptor	Homo sapiens	59-61
30986993-8	2019	Molecular mechanism study showed that paclitaxel activated AR transactivity and bound to alternative ARE in the ABCG2 proximal promoter region.	Paclitaxel	38-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	112-117
30986993-9	2019	To identify AR as a potential therapeutic target, the ASC-J9 was used to re-sensitize paclitaxel-resistant EOC tumors upon paclitaxel treatment in vitro and in vivo.	Paclitaxel	86-96	androgen receptor	Homo sapiens	12-14
30986993-9	2019	To identify AR as a potential therapeutic target, the ASC-J9 was used to re-sensitize paclitaxel-resistant EOC tumors upon paclitaxel treatment in vitro and in vivo.	Paclitaxel	123-133	androgen receptor	Homo sapiens	12-14
30229430-8	2019	We propose that 5-DMN cooperates with PTX to induce apoptosis via the caspase pathway (by modulating caspase-3, caspase-8, and caspase-9 activities).	Paclitaxel	38-41	caspase 3	Homo sapiens	101-110
30952749-1	2019	AIM: This study was conducted in order to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus trastuzumab followed by 5-fluorouracil/ epirubicin/cyclophosphamide (FEC) in a neoadjuvant chemotherapy (NAC) setting for patients with human epidermal growth factor receptor 2 (HER2)-positive operable breast cancer.	Paclitaxel	105-115	erb-b2 receptor tyrosine kinase 2	Homo sapiens	280-314
30952749-1	2019	AIM: This study was conducted in order to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus trastuzumab followed by 5-fluorouracil/ epirubicin/cyclophosphamide (FEC) in a neoadjuvant chemotherapy (NAC) setting for patients with human epidermal growth factor receptor 2 (HER2)-positive operable breast cancer.	Paclitaxel	105-115	erb-b2 receptor tyrosine kinase 2	Homo sapiens	316-320
30952749-9	2019	CONCLUSION: Nab-paclitaxel plus trastuzumab followed by FEC in patients with HER2-positive operable breast cancer is considerably effective and well tolerated.	Paclitaxel	16-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
30314995-8	2019	Further, we found that HER2 inhibition increased drastically the sensitivity of ovarian cancer cells to doxorubicin (DOX) or paclitaxel (PTX).	Paclitaxel	125-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
30421506-0	2019	Potentiation of paclitaxel effect by resveratrol in human breast cancer cells by counteracting the 17beta-estradiol/estrogen receptor alpha/neuroglobin pathway.	Paclitaxel	16-26	estrogen receptor 1	Homo sapiens	116-139
30421506-2	2019	Here, the possibility that resveratrol (Res), an anticancer plant polyphenol, could increase the susceptibility of breast cancer cells to paclitaxel (Pacl) by affecting E2/ERalpha/NGB pathway has been evaluated.	Paclitaxel	150-154	estrogen receptor 1	Homo sapiens	172-179
30802327-4	2019	Taxol, a beta-tubulin binding and MT stabilizing drug, was found to abolish this CXCL1- and fMLP-stimulated MT polymerization.	Paclitaxel	0-5	formyl peptide receptor 1	Homo sapiens	92-96
30802327-8	2019	Nevertheless, and consistent with its ability to suppress MT polymerization induced by soluble CXCL1 and fMLP, taxol treatment inhibited neutrophil chemotaxis toward both chemotactic peptides.	Paclitaxel	111-116	formyl peptide receptor 1	Homo sapiens	105-109
30802327-9	2019	Taxol treatment also suppressed CXCL1- and fMLP-triggered elastase-dependent neutrophil invasion through collagen I barriers.	Paclitaxel	0-5	formyl peptide receptor 1	Homo sapiens	43-47
30739035-0	2019	Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.	Paclitaxel	115-125	fatty acid amide hydrolase	Homo sapiens	44-70
30739035-0	2019	Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.	Paclitaxel	229-239	fatty acid amide hydrolase	Homo sapiens	44-70
30739035-5	2019	Each FAAH inhibitor suppressed the development of paclitaxel-induced neuropathic pain and reduced the maintenance of already established allodynia with sustained efficacy.	Paclitaxel	50-60	fatty acid amide hydrolase	Homo sapiens	5-9
30739035-14	2019	Our results suggest that FAAH inhibitors reduce paclitaxel-induced allodynia without the occurrence of CB1-dependence in vivo and may, in fact, enhance the anti-tumor actions of paclitaxel in vitro.	Paclitaxel	48-58	fatty acid amide hydrolase	Homo sapiens	25-29
30739035-14	2019	Our results suggest that FAAH inhibitors reduce paclitaxel-induced allodynia without the occurrence of CB1-dependence in vivo and may, in fact, enhance the anti-tumor actions of paclitaxel in vitro.	Paclitaxel	178-188	fatty acid amide hydrolase	Homo sapiens	25-29
30520096-0	2019	A four-gene signature predicts the efficacy of paclitaxel-based neoadjuvant therapy in human epidermal growth factor receptor 2-negative breast cancer.	Paclitaxel	47-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-127
30520096-2	2019	The current study aimed to define the predictive biomarkers for paclitaxel (PTX) response in NAC of HER2-negative BC.	Paclitaxel	64-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
30520096-2	2019	The current study aimed to define the predictive biomarkers for paclitaxel (PTX) response in NAC of HER2-negative BC.	Paclitaxel	76-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
30520096-4	2019	Through logistic regression, COX regression, and correlation analysis with bootstrapping, we found that four genes (CDK8, FAM64A, MARC2, and OCEL1) were associated with drug sensitivity of PTX.	Paclitaxel	189-192	cyclin dependent kinase 8	Homo sapiens	116-120
30520096-4	2019	Through logistic regression, COX regression, and correlation analysis with bootstrapping, we found that four genes (CDK8, FAM64A, MARC2, and OCEL1) were associated with drug sensitivity of PTX.	Paclitaxel	189-192	PICALM interacting mitotic regulator	Homo sapiens	122-128
30520096-9	2019	The current study demonstrated the promising potential of the novel four-gene signature as a predictive biomarker for pathological complete response of HER2-negative BC patients and indicated the drug sensitivity of PTX.	Paclitaxel	216-219	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-156
31068300-10	2019	RRM1 silencing significantly inhibited the proliferation (P &amp;lt; 0.01) and enhanced the apoptosis-inducing effect of paclitaxel in MCF-7/R cells (P &amp;lt; 0.001); RRM1 silencing also resulted in obviously reduced Akt phosphorylation, suppressed Bcl-2 expression and promoted the expression of p53 protein in MCF-7/R cells.	Paclitaxel	121-131	BCL2 apoptosis regulator	Homo sapiens	251-256
31068300-10	2019	RRM1 silencing significantly inhibited the proliferation (P &amp;lt; 0.01) and enhanced the apoptosis-inducing effect of paclitaxel in MCF-7/R cells (P &amp;lt; 0.001); RRM1 silencing also resulted in obviously reduced Akt phosphorylation, suppressed Bcl-2 expression and promoted the expression of p53 protein in MCF-7/R cells.	Paclitaxel	121-131	tumor protein p53	Homo sapiens	299-302
30911062-5	2019	Hence, we hypothesized that HER2/beta-catenin mediates paclitaxel resistance in breast cancer and suppression of HER2/beta-catenin signaling could overcome paclitaxel resistance.	Paclitaxel	55-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
30911062-5	2019	Hence, we hypothesized that HER2/beta-catenin mediates paclitaxel resistance in breast cancer and suppression of HER2/beta-catenin signaling could overcome paclitaxel resistance.	Paclitaxel	156-166	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
30911062-10	2019	Taken together our results demonstrate a novel role of HER2/beta-catenin in paclitaxel resistance and open up new avenues for application of PFL as a therapeutic option for overcoming paclitaxel resistance.	Paclitaxel	76-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
30894541-6	2019	MDR1 inhibition in a fusion positive ovarian cancer cell line increased sensitivity to paclitaxel more than 50-fold.	Paclitaxel	87-97	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
30314995-8	2019	Further, we found that HER2 inhibition increased drastically the sensitivity of ovarian cancer cells to doxorubicin (DOX) or paclitaxel (PTX).	Paclitaxel	137-140	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
30767506-3	2019	Based on the strong intermolecular interactions between indomethacin (IDM, a COX-2 inhibitor) and paclitaxel (PTX, a chemotherapy drug), we herein successfully engineered a novel kind of carrier-free nanomedicines that organized as IDM-induced PTX nanocrystal aggregates via one-pot self-assembly without any nonactive excipients.	Paclitaxel	98-108	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	77-82
30911326-14	2019	Conclusions: These results reveal a P-gp-independent mechanism through ROS generation for the SKN/PTX combination to overcome MDR in ovarian cancer.	Paclitaxel	98-101	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
30911326-0	2019	Combination of shikonin with paclitaxel overcomes multidrug resistance in human ovarian carcinoma cells in a P-gp-independent manner through enhanced ROS generation.	Paclitaxel	29-39	ATP binding cassette subfamily B member 1	Homo sapiens	109-113
30770442-5	2019	Systemic in vivo administration of paclitaxel promotes PD-L1 accumulation on the surface of TAMS in a mouse model of TNBC, consistent with in vitro results.	Paclitaxel	35-45	CD274 antigen	Mus musculus	55-60
30866433-5	2019	TSA induced synergistic cytotoxicity, when combined with paclitaxel (combination index &lt; 1), resulted in concomitant suppression of paclitaxel-induced activation of phospho-extracellular signal-regulated kinase (ERK) 1/2.	Paclitaxel	135-145	mitogen-activated protein kinase 1	Homo sapiens	215-218
30840584-3	2019	We also examined the effects of pretreatment with menthol on the cytotoxic activity of paclitaxel (PAC) and vincristine (VIN), which are substrates of CYP3A4, in the cells.	Paclitaxel	87-97	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	151-157
30770442-6	2019	Combinatorial treatment with paclitaxel and an anti-mouse PD-L1 blocking antibody significantly improved the therapeutic efficacy of paclitaxel by reducing tumor burden and increasing the number of tumor-associated cytotoxic T cells.	Paclitaxel	133-143	CD274 antigen	Mus musculus	58-63
30660004-5	2019	In this study, we designed a nanocomposite by using ND conjugated with paclitaxel (PTX) and cetuximab (Cet) for targeting therapy on the EGFR-positive TNBC cells.	Paclitaxel	71-81	epidermal growth factor receptor	Homo sapiens	137-141
30881098-0	2019	Resveratrol inhibits paclitaxel-induced neuropathic pain by the activation of PI3K/Akt and SIRT1/PGC1alpha pathway.	Paclitaxel	21-31	AKT serine/threonine kinase 1	Rattus norvegicus	83-86
30881098-0	2019	Resveratrol inhibits paclitaxel-induced neuropathic pain by the activation of PI3K/Akt and SIRT1/PGC1alpha pathway.	Paclitaxel	21-31	sirtuin 1	Rattus norvegicus	91-96
30881098-0	2019	Resveratrol inhibits paclitaxel-induced neuropathic pain by the activation of PI3K/Akt and SIRT1/PGC1alpha pathway.	Paclitaxel	21-31	PPARG coactivator 1 alpha	Rattus norvegicus	97-106
30881098-11	2019	The expressions of p-Akt, SIRT1, and PGC1alpha were decreased in paclitaxel-induced neuropathic rats; however, the expressions of p-Akt, SIRT1, and PGC1alpha were significantly increased after RES treatment (P&lt;0.05).	Paclitaxel	65-75	AKT serine/threonine kinase 1	Rattus norvegicus	21-24
30881098-11	2019	The expressions of p-Akt, SIRT1, and PGC1alpha were decreased in paclitaxel-induced neuropathic rats; however, the expressions of p-Akt, SIRT1, and PGC1alpha were significantly increased after RES treatment (P&lt;0.05).	Paclitaxel	65-75	sirtuin 1	Rattus norvegicus	26-31
30881098-11	2019	The expressions of p-Akt, SIRT1, and PGC1alpha were decreased in paclitaxel-induced neuropathic rats; however, the expressions of p-Akt, SIRT1, and PGC1alpha were significantly increased after RES treatment (P&lt;0.05).	Paclitaxel	65-75	PPARG coactivator 1 alpha	Rattus norvegicus	37-46
30881098-11	2019	The expressions of p-Akt, SIRT1, and PGC1alpha were decreased in paclitaxel-induced neuropathic rats; however, the expressions of p-Akt, SIRT1, and PGC1alpha were significantly increased after RES treatment (P&lt;0.05).	Paclitaxel	65-75	AKT serine/threonine kinase 1	Rattus norvegicus	132-135
30881098-11	2019	The expressions of p-Akt, SIRT1, and PGC1alpha were decreased in paclitaxel-induced neuropathic rats; however, the expressions of p-Akt, SIRT1, and PGC1alpha were significantly increased after RES treatment (P&lt;0.05).	Paclitaxel	65-75	sirtuin 1	Rattus norvegicus	137-142
30881098-11	2019	The expressions of p-Akt, SIRT1, and PGC1alpha were decreased in paclitaxel-induced neuropathic rats; however, the expressions of p-Akt, SIRT1, and PGC1alpha were significantly increased after RES treatment (P&lt;0.05).	Paclitaxel	65-75	PPARG coactivator 1 alpha	Rattus norvegicus	148-157
30881098-14	2019	RES prevented paclitaxel-induced mitochondrial damage by PI3K/Akt.	Paclitaxel	14-24	AKT serine/threonine kinase 1	Rattus norvegicus	62-65
30881098-18	2019	Conclusion: Our results suggest that RES may inhibit paclitaxel-induced neuropathic pain via PI3K/Akt and SIRT1/PGC1alpha pathways.	Paclitaxel	53-63	AKT serine/threonine kinase 1	Rattus norvegicus	98-101
30881098-18	2019	Conclusion: Our results suggest that RES may inhibit paclitaxel-induced neuropathic pain via PI3K/Akt and SIRT1/PGC1alpha pathways.	Paclitaxel	53-63	sirtuin 1	Rattus norvegicus	106-111
30881098-18	2019	Conclusion: Our results suggest that RES may inhibit paclitaxel-induced neuropathic pain via PI3K/Akt and SIRT1/PGC1alpha pathways.	Paclitaxel	53-63	PPARG coactivator 1 alpha	Rattus norvegicus	112-121
30660004-0	2019	Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.	Paclitaxel	85-95	epidermal growth factor receptor	Homo sapiens	10-14
30660004-5	2019	In this study, we designed a nanocomposite by using ND conjugated with paclitaxel (PTX) and cetuximab (Cet) for targeting therapy on the EGFR-positive TNBC cells.	Paclitaxel	83-86	epidermal growth factor receptor	Homo sapiens	137-141
30660004-9	2019	ND-PTX-Cet could specifically bind to EGFR and enhanced the anticancer effects including drug uptake levels, mitotic catastrophe, and apoptosis in the EGFR-expressed MDA-MB-231 cells but not in the EGFR-negative MCF-7 cells.	Paclitaxel	3-6	epidermal growth factor receptor	Homo sapiens	38-42
30660004-9	2019	ND-PTX-Cet could specifically bind to EGFR and enhanced the anticancer effects including drug uptake levels, mitotic catastrophe, and apoptosis in the EGFR-expressed MDA-MB-231 cells but not in the EGFR-negative MCF-7 cells.	Paclitaxel	3-6	epidermal growth factor receptor	Homo sapiens	151-155
30660004-9	2019	ND-PTX-Cet could specifically bind to EGFR and enhanced the anticancer effects including drug uptake levels, mitotic catastrophe, and apoptosis in the EGFR-expressed MDA-MB-231 cells but not in the EGFR-negative MCF-7 cells.	Paclitaxel	3-6	epidermal growth factor receptor	Homo sapiens	151-155
30660004-12	2019	Taken together, these results demonstrated that ND-PTX-Cet nanocomposite enhanced mitotic catastrophe and apoptosis by targeting EGFR of TNBC cells, which can provide a feasible strategy for TNBC therapy.	Paclitaxel	50-54	epidermal growth factor receptor	Homo sapiens	129-133
30660004-15	2019	Here, we have designed a nanocomposite by targeting on the EGFR of TNBC to enhance therapeutic efficacy by ND-conjugated PTX and Cet (ND-PTX-Cet).	Paclitaxel	121-124	epidermal growth factor receptor	Homo sapiens	59-63
30660004-16	2019	Interestingly, we found that the co-delivery of Cet and PTX by ND enhanced the apoptosis, mitotic catastrophe and tumor inhibition in the EGFR-expressed TNBC in vitro and in vivo.	Paclitaxel	56-59	epidermal growth factor receptor	Homo sapiens	138-142
30660004-17	2019	Consequently, this nanocomposite ND-PTX-Cet can be applied for targeting EGFR of human TNBC therapy.	Paclitaxel	36-40	epidermal growth factor receptor	Homo sapiens	73-77
30578561-0	2019	Interleukin-1beta released by microglia initiates the enhanced glutamatergic activity in the spinal dorsal horn during paclitaxel-associated acute pain syndrome.	Paclitaxel	119-129	interleukin 1 beta	Homo sapiens	0-17
30899303-0	2019	Mir-26b inhibits growth and resistance to paclitaxel chemotherapy by silencing the CDC6 gene in gastric cancer.	Paclitaxel	42-52	cell division cycle 6	Homo sapiens	83-87
30899303-13	2019	Moreover, CDC6 knockdown inhibited chemotherapy resistance to paclitaxel, IC50 to paclitaxel decreased from 153.17 +-0.49 mug/l to 39.81 +-0.28 mug/l (p &lt; 0.05).	Paclitaxel	62-72	cell division cycle 6	Homo sapiens	10-14
30899303-13	2019	Moreover, CDC6 knockdown inhibited chemotherapy resistance to paclitaxel, IC50 to paclitaxel decreased from 153.17 +-0.49 mug/l to 39.81 +-0.28 mug/l (p &lt; 0.05).	Paclitaxel	82-92	cell division cycle 6	Homo sapiens	10-14
30899303-14	2019	Conclusions: miR-26b inhibits growth and resistance to paclitaxel chemotherapy by silencing the CDC6 gene in the gastric cancer cell line SGC7901.	Paclitaxel	55-65	cell division cycle 6	Homo sapiens	96-100
30562553-4	2019	Silencing of PKCeta by siRNA attenuated apoptosis induced by doxorubicin and paclitaxel in both MCF-7 and T47D breast cancer cells.	Paclitaxel	77-87	protein kinase C eta	Homo sapiens	13-19
30563934-0	2019	Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.	Paclitaxel	95-105	AKT serine/threonine kinase 1	Homo sapiens	48-51
30578561-7	2019	TLR4 activation in microglia by paclitaxel caused microglia to rapidly release interleukin-1beta (IL-1beta) but not tumor necrosis factor alpha, IL-6, or interferon-gamma.	Paclitaxel	32-42	interleukin 1 beta	Homo sapiens	79-96
30578561-7	2019	TLR4 activation in microglia by paclitaxel caused microglia to rapidly release interleukin-1beta (IL-1beta) but not tumor necrosis factor alpha, IL-6, or interferon-gamma.	Paclitaxel	32-42	interleukin 1 beta	Homo sapiens	98-106
30132865-8	2019	Finally, drug combination experiments showed that cell-penetrant B1R antagonists can cooperate with suboptimal doses of chemotherapeutic agents (doxorubicin and paclitaxel) to promote TNBC death.	Paclitaxel	161-171	bradykinin receptor B1	Homo sapiens	65-68
30471295-2	2019	Recently spinal Toll-like receptor 4 (TLR4) and the transient receptor potential cation channel subfamily V member 1 (TRPV1) were identified to be involved in the pro-nociceptive effect of paclitaxel.	Paclitaxel	189-199	toll-like receptor 4	Rattus norvegicus	16-36
31165698-9	2019	More importantly, PNLS combined with PTX (Paclitaxel) showed antitumor effects and high MDR1 gene silencing efficiency in the tumor-bearing nude mice.	Paclitaxel	37-40	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	88-92
31165698-9	2019	More importantly, PNLS combined with PTX (Paclitaxel) showed antitumor effects and high MDR1 gene silencing efficiency in the tumor-bearing nude mice.	Paclitaxel	42-52	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	88-92
30606772-0	2019	Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel.	Paclitaxel	73-83	claudin 4	Homo sapiens	33-42
30606772-9	2019	Results show that claudin-4 expression reduced epithelial ovarian cancer (EOC) cell apoptotic response to paclitaxel.	Paclitaxel	106-116	claudin 4	Homo sapiens	18-27
30606772-12	2019	In conclusion, we demonstrate that claudin-4 reduces the ovarian tumor cell response to microtubule-targeting paclitaxel and disrupting claudin-4 with CMP can restore apoptotic response.	Paclitaxel	110-120	claudin 4	Homo sapiens	35-44
30606772-13	2019	IMPLICATIONS: These results suggest that claudin-4 expression may provide a biomarker for paclitaxel response and can be a target for new therapeutic strategies to improve response.	Paclitaxel	90-100	claudin 4	Homo sapiens	41-50
30471295-2	2019	Recently spinal Toll-like receptor 4 (TLR4) and the transient receptor potential cation channel subfamily V member 1 (TRPV1) were identified to be involved in the pro-nociceptive effect of paclitaxel.	Paclitaxel	189-199	toll-like receptor 4	Rattus norvegicus	38-42
30628717-8	2019	Further experiments validated that p53 enhanced the sensitivity of NCI-H1299 cells to Taxol through initiating the caspase-3 and -9 intrinsic death pathways, and resulted in cell cycle arrest at the G1/S phases.	Paclitaxel	86-91	tumor protein p53	Homo sapiens	35-38
30592293-0	2019	Bromodomain-containing protein 7 sensitizes breast cancer cells to paclitaxel by activating Bcl2-antagonist/killer protein.	Paclitaxel	67-77	BCL2 apoptosis regulator	Homo sapiens	92-96
30628717-8	2019	Further experiments validated that p53 enhanced the sensitivity of NCI-H1299 cells to Taxol through initiating the caspase-3 and -9 intrinsic death pathways, and resulted in cell cycle arrest at the G1/S phases.	Paclitaxel	86-91	caspase 3	Homo sapiens	115-131
30830867-6	2019	Fbxw7-deficient DTCs were significantly depleted by treatment with paclitaxel, suggesting that cell proliferation induced by Fbxw7 ablation sensitized DTCs to chemotherapy.	Paclitaxel	67-77	F-box and WD-40 domain protein 7	Mus musculus	0-5
30668434-11	2019	Furthermore, PTX plus curcumin most impressively activated caspase-3, effector of apoptosis pathways, and reduced the expression of the anti-apoptotic protein Bcl-2.	Paclitaxel	13-16	BCL2, apoptosis regulator	Rattus norvegicus	159-164
30747829-10	2019	Notably, the survival rate on day 80 in the Pan2MmLuc mouse model was 100% for the NK105 group and 0% for the paclitaxel group.	Paclitaxel	110-120	PAN2 poly(A) specific ribonuclease subunit	Mus musculus	44-48
31031868-14	2019	We further display that MSI-1 effectively protects OC cells from paclitaxel-induced apoptosis by increasing the expression of p-Bcl-2 through ERK signaling pathway activation.	Paclitaxel	65-75	BCL2 apoptosis regulator	Homo sapiens	128-133
31031868-14	2019	We further display that MSI-1 effectively protects OC cells from paclitaxel-induced apoptosis by increasing the expression of p-Bcl-2 through ERK signaling pathway activation.	Paclitaxel	65-75	mitogen-activated protein kinase 1	Homo sapiens	142-145
30863067-12	2019	Finally, we found PTX treatment suppressed the production of tumor necrosis factor alpah (TNF-alpha), interleukin 6 (IL-6) and transforming growth factor beta (TGF-beta) and inhibited the expression of alpha smooth muscle actin (alpha-SMA) and collagen I in HKFs.	Paclitaxel	18-21	tumor necrosis factor	Homo sapiens	90-99
30863067-12	2019	Finally, we found PTX treatment suppressed the production of tumor necrosis factor alpah (TNF-alpha), interleukin 6 (IL-6) and transforming growth factor beta (TGF-beta) and inhibited the expression of alpha smooth muscle actin (alpha-SMA) and collagen I in HKFs.	Paclitaxel	18-21	interleukin 6	Homo sapiens	102-115
30863067-12	2019	Finally, we found PTX treatment suppressed the production of tumor necrosis factor alpah (TNF-alpha), interleukin 6 (IL-6) and transforming growth factor beta (TGF-beta) and inhibited the expression of alpha smooth muscle actin (alpha-SMA) and collagen I in HKFs.	Paclitaxel	18-21	interleukin 6	Homo sapiens	117-121
30863067-12	2019	Finally, we found PTX treatment suppressed the production of tumor necrosis factor alpah (TNF-alpha), interleukin 6 (IL-6) and transforming growth factor beta (TGF-beta) and inhibited the expression of alpha smooth muscle actin (alpha-SMA) and collagen I in HKFs.	Paclitaxel	18-21	transforming growth factor beta 1	Homo sapiens	127-158
30863067-12	2019	Finally, we found PTX treatment suppressed the production of tumor necrosis factor alpah (TNF-alpha), interleukin 6 (IL-6) and transforming growth factor beta (TGF-beta) and inhibited the expression of alpha smooth muscle actin (alpha-SMA) and collagen I in HKFs.	Paclitaxel	18-21	transforming growth factor beta 1	Homo sapiens	160-168
30863067-13	2019	The activation of protein kinase B (AKT)/glycogen synthase kinase 3 beta (GSK3beta) signaling pathway also blocked by PTX in cultured HKFs and keloid tissues.	Paclitaxel	118-121	AKT serine/threonine kinase 1	Homo sapiens	36-39
30830867-6	2019	Fbxw7-deficient DTCs were significantly depleted by treatment with paclitaxel, suggesting that cell proliferation induced by Fbxw7 ablation sensitized DTCs to chemotherapy.	Paclitaxel	67-77	F-box and WD-40 domain protein 7	Mus musculus	125-130
30673276-5	2019	Herein, the formation of reduced bovine serum albumin (rBSA) and glycol chitosan (GC) nanoparticles (rBG-NPs) stabilized by hydrophobic interactions and disulfide bonds was demonstrated for paclitaxel (PTX) delivery.	Paclitaxel	190-200	albumin	Homo sapiens	40-53
30791462-3	2019	This study investigated the association between paclitaxel-mediated Src activation (p-Src) and CSC populations in driving ovarian cancer progression.	Paclitaxel	48-58	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	68-71
30791462-3	2019	This study investigated the association between paclitaxel-mediated Src activation (p-Src) and CSC populations in driving ovarian cancer progression.	Paclitaxel	48-58	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	86-89
30791462-7	2019	Dasatinib in combination with paclitaxel significantly suppressed p-Src in ovarian cancer cell lines and xenografts but had no effect on the expression of CSC markers.	Paclitaxel	30-40	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	68-71
30673276-5	2019	Herein, the formation of reduced bovine serum albumin (rBSA) and glycol chitosan (GC) nanoparticles (rBG-NPs) stabilized by hydrophobic interactions and disulfide bonds was demonstrated for paclitaxel (PTX) delivery.	Paclitaxel	202-205	albumin	Homo sapiens	40-53
30744578-9	2019	CONCLUSIONS: The analysis indicated that the combination of bevacizumab plus paclitaxel is likely to be cost-effective compared with paclitaxel alone for the first-line treatment of HER2-negative metastatic breast cancer in specialized oncology centers in France.	Paclitaxel	77-87	erb-b2 receptor tyrosine kinase 2	Homo sapiens	182-186
30863062-12	2019	Meanwhile, Bax mRNA and protein expression was upregulated, while Bcl-2 mRNA and protein expression was downregulated after PTX-NPs treatment in vivo.	Paclitaxel	124-127	BCL2 apoptosis regulator	Homo sapiens	66-71
30765569-2	2019	We determined the 3.5-angstrom cryo-electron microscopy structure of substrate-bound human ABCB1 reconstituted in lipidic nanodiscs, revealing a single molecule of the chemotherapeutic compound paclitaxel (Taxol) bound in a central, occluded pocket.	Paclitaxel	194-204	ATP binding cassette subfamily B member 1	Homo sapiens	91-96
30765569-2	2019	We determined the 3.5-angstrom cryo-electron microscopy structure of substrate-bound human ABCB1 reconstituted in lipidic nanodiscs, revealing a single molecule of the chemotherapeutic compound paclitaxel (Taxol) bound in a central, occluded pocket.	Paclitaxel	206-211	ATP binding cassette subfamily B member 1	Homo sapiens	91-96
30383888-0	2019	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.	Paclitaxel	66-76	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	94-98
33405800-2	2019	In this manuscript, an injectable hydrogel-encapsulating paclitaxel-loaded red blood cell membrane nanoparticles (PRNP-gel) is designed on the basis of temperature-induced phase transition of polyethylene-glycol-modified bovine serum albumin (PEG-BSA).	Paclitaxel	57-67	prion protein	Homo sapiens	114-118
30601011-0	2019	Exploring the Binding Interaction Mechanism of Taxol in beta-Tubulin and Bovine Serum Albumin: A Biophysical Approach.	Paclitaxel	47-52	albumin	Homo sapiens	80-93
30601011-1	2019	In this present study on understanding the taxol (PTX) binding interaction mechanism in both the beta-tubulin and bovine serum albumin (BSA) molecule, various optical spectroscopy and computational techniques were used.	Paclitaxel	43-48	albumin	Homo sapiens	121-149
30711936-0	2019	AS602801 Sensitizes Ovarian Cancer Stem Cells to Paclitaxel by Down-regulating MDR1.	Paclitaxel	49-59	ATP binding cassette subfamily B member 1	Homo sapiens	79-83
30711936-7	2019	Knockdown of MDR1 sensitized the cells to paclitaxel, but not to carboplatin or cisplatin.	Paclitaxel	42-52	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
30711936-8	2019	CONCLUSION: AS602801 chemosensitized ovarian CSCs to paclitaxel by reducing the expression of MDR1.	Paclitaxel	53-63	ATP binding cassette subfamily B member 1	Homo sapiens	94-98
30500985-7	2019	In response to Bcl-2 homology 3 (BH3)-only protein Bmf stress, Bcl-2 phosphorylation switched from diminishing to enhancing the Bcl-2 anti-apoptotic ability with increased phosphorylation of Bcl-2, and the turning point was 50% Bcl-2 phosphorylation induced by 0.2 muM paclitaxel treatment.	Paclitaxel	269-279	BCL2 apoptosis regulator	Homo sapiens	63-68
30500985-7	2019	In response to Bcl-2 homology 3 (BH3)-only protein Bmf stress, Bcl-2 phosphorylation switched from diminishing to enhancing the Bcl-2 anti-apoptotic ability with increased phosphorylation of Bcl-2, and the turning point was 50% Bcl-2 phosphorylation induced by 0.2 muM paclitaxel treatment.	Paclitaxel	269-279	BCL2 apoptosis regulator	Homo sapiens	63-68
30881589-0	2019	Alphalipoic Acid Prevents Oxidative Stress and Peripheral Neuropathy in Nab-Paclitaxel-Treated Rats through the Nrf2 Signalling Pathway.	Paclitaxel	76-86	NFE2 like bZIP transcription factor 2	Rattus norvegicus	112-116
30778300-3	2019	When mouse MG6 cells were stimulated with the TLR4 ligands lipopolysaccharide (LPS) and paclitaxel, we found that interferon regulatory factor 1 (IRF1) protein expression and activation was upregulated, transcription of interferon-beta (IFN-beta) was accelerated, induction/activation of STAT1 and activation of STAT3 were promoted, and subsequently iNOS expression was upregulated.	Paclitaxel	88-98	toll-like receptor 4	Mus musculus	46-50
30778300-3	2019	When mouse MG6 cells were stimulated with the TLR4 ligands lipopolysaccharide (LPS) and paclitaxel, we found that interferon regulatory factor 1 (IRF1) protein expression and activation was upregulated, transcription of interferon-beta (IFN-beta) was accelerated, induction/activation of STAT1 and activation of STAT3 were promoted, and subsequently iNOS expression was upregulated.	Paclitaxel	88-98	signal transducer and activator of transcription 3	Mus musculus	312-317
30778300-3	2019	When mouse MG6 cells were stimulated with the TLR4 ligands lipopolysaccharide (LPS) and paclitaxel, we found that interferon regulatory factor 1 (IRF1) protein expression and activation was upregulated, transcription of interferon-beta (IFN-beta) was accelerated, induction/activation of STAT1 and activation of STAT3 were promoted, and subsequently iNOS expression was upregulated.	Paclitaxel	88-98	nitric oxide synthase 2, inducible	Mus musculus	350-354
30460489-0	2019	Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project.	Paclitaxel	90-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-118
30500985-7	2019	In response to Bcl-2 homology 3 (BH3)-only protein Bmf stress, Bcl-2 phosphorylation switched from diminishing to enhancing the Bcl-2 anti-apoptotic ability with increased phosphorylation of Bcl-2, and the turning point was 50% Bcl-2 phosphorylation induced by 0.2 muM paclitaxel treatment.	Paclitaxel	269-279	BCL2 apoptosis regulator	Homo sapiens	15-20
30500985-7	2019	In response to Bcl-2 homology 3 (BH3)-only protein Bmf stress, Bcl-2 phosphorylation switched from diminishing to enhancing the Bcl-2 anti-apoptotic ability with increased phosphorylation of Bcl-2, and the turning point was 50% Bcl-2 phosphorylation induced by 0.2 muM paclitaxel treatment.	Paclitaxel	269-279	BCL2 apoptosis regulator	Homo sapiens	63-68
30383888-11	2019	CONCLUSIONS: The combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity, predominantly in patients with advanced melanoma and BRAFV600 mutations, regardless of prior treatment with BRAF and/or MEK inhibitors.	Paclitaxel	62-72	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	183-187
30383888-11	2019	CONCLUSIONS: The combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity, predominantly in patients with advanced melanoma and BRAFV600 mutations, regardless of prior treatment with BRAF and/or MEK inhibitors.	Paclitaxel	62-72	mitogen-activated protein kinase kinase 7	Homo sapiens	250-253
30322860-0	2019	UNC-45A Is a Novel Microtubule-Associated Protein and Regulator of Paclitaxel Sensitivity in Ovarian Cancer Cells.	Paclitaxel	67-77	unc-45 myosin chaperone A	Homo sapiens	0-7
30391357-8	2019	The combination of IPI-549 with paclitaxel showed that IPI-549 potentiates the anti-tumor effects of paclitaxel in P-gp-overexpressing MDR SW620/Ad300 xenograft tumors.	Paclitaxel	32-42	ATP binding cassette subfamily B member 1	Homo sapiens	115-119
30391357-8	2019	The combination of IPI-549 with paclitaxel showed that IPI-549 potentiates the anti-tumor effects of paclitaxel in P-gp-overexpressing MDR SW620/Ad300 xenograft tumors.	Paclitaxel	101-111	ATP binding cassette subfamily B member 1	Homo sapiens	115-119
30679989-7	2019	Following PTX intervention, the expression levels of Ki67 and cyclin B1 were significantly reduced when compared with the model group (P&lt;0.01), while p27Kip1 expression was significantly increased (P&lt;0.01).	Paclitaxel	10-13	cyclin B1	Rattus norvegicus	62-71
30679989-9	2019	These effects of PTX may be associated with increased expression of p27Kip1 and decreased expression of cyclin B1.	Paclitaxel	17-20	cyclin B1	Rattus norvegicus	104-113
30322860-3	2019	Using in vitro biophysical reconstitution and total internal reflection fluorescence microscopy analysis, we reveal that UNC-45A directly binds to taxol-stabilized MTs in the absence of any additional cellular cofactors or other MT-associated proteins and acts as an ATP-independent MT destabilizer.	Paclitaxel	147-152	unc-45 myosin chaperone A	Homo sapiens	121-128
30322860-5	2019	UNC-45A is overexpressed in human clinical specimens from chemoresistant ovarian cancer and that UNC-45A-overexpressing cells resist chromosome missegregation and aneuploidy when treated with clinically relevant concentrations of paclitaxel.	Paclitaxel	230-240	unc-45 myosin chaperone A	Homo sapiens	0-7
30322860-5	2019	UNC-45A is overexpressed in human clinical specimens from chemoresistant ovarian cancer and that UNC-45A-overexpressing cells resist chromosome missegregation and aneuploidy when treated with clinically relevant concentrations of paclitaxel.	Paclitaxel	230-240	unc-45 myosin chaperone A	Homo sapiens	97-104
30322860-6	2019	Lastly, UNC-45A depletion exacerbates paclitaxel-mediated stabilizing effects on mitotic spindles and restores sensitivity to paclitaxel.	Paclitaxel	38-48	unc-45 myosin chaperone A	Homo sapiens	8-15
30322860-6	2019	Lastly, UNC-45A depletion exacerbates paclitaxel-mediated stabilizing effects on mitotic spindles and restores sensitivity to paclitaxel.	Paclitaxel	126-136	unc-45 myosin chaperone A	Homo sapiens	8-15
30322860-7	2019	IMPLICATIONS: These findings reveal novel and significant roles for UNC-45A in regulation of cytoskeletal dynamics, broadening our understanding of the basic mechanisms regulating MT stability and human cancer susceptibility to paclitaxel, one of the most widely used chemotherapy agents for the treatment of human cancers.	Paclitaxel	228-238	unc-45 myosin chaperone A	Homo sapiens	68-75
30202098-7	2019	Furthermore, a microtubule-stabilizing drug paclitaxel could prevent KIAA1199-induced microtubule destabilization, and inhibit cell migration and invasion in vitro and tumor metastasis in vivo in colorectal cancer.	Paclitaxel	44-54	cell migration inducing hyaluronidase 1	Homo sapiens	69-77
30661182-6	2019	Bag-1 knockdown by shRNA or siRNA transfection sensitized MCF-7 cells to apoptosis induced by cisplatin or paclitaxel.	Paclitaxel	107-117	BAG cochaperone 1	Homo sapiens	0-5
30661182-9	2019	These results overall indicated that Bag-1 silencing enhanced cisplatin- or paclitaxel-induced cytotoxicity through multiple pathways.	Paclitaxel	76-86	BAG cochaperone 1	Homo sapiens	37-42
30622051-0	2019	MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.	Paclitaxel	79-89	signal transducer and activator of transcription 3	Homo sapiens	48-53
30761271-8	2019	Thirdly, B-cell lymphoma-2 (Bcl2) and Multidrug Resistance-Associated Protein 4 (MRP4) genes were target genes of miR-125a-5p, which modulated paclitaxel resistance of Ishikawa/PA and HEC1A/PA cells through targeted silencing Bcl2 and MRP4.	Paclitaxel	143-153	BCL2 apoptosis regulator	Homo sapiens	9-26
30389744-2	2019	Here we report a case of Takotsubo cardiomyopathy associated with the use of dual anti-HER2 therapy in a 63-year-old woman who presented to the emergency department with an 8- to 10-hour history of progressive dyspnea after completing her third cycle of pertuzumab plus trastuzumab in addition to nab-paclitaxel chemotherapy.	Paclitaxel	301-311	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-91
30592172-14	2019	CONCLUSION: Paclitaxel can significantly repress cell proliferation and induce apoptosis of HS 737.T cells through activating Caspase-3, PARP1, p53, and TP53INP1.	Paclitaxel	12-22	caspase 3	Homo sapiens	126-135
30592172-14	2019	CONCLUSION: Paclitaxel can significantly repress cell proliferation and induce apoptosis of HS 737.T cells through activating Caspase-3, PARP1, p53, and TP53INP1.	Paclitaxel	12-22	poly(ADP-ribose) polymerase 1	Homo sapiens	137-142
30592172-14	2019	CONCLUSION: Paclitaxel can significantly repress cell proliferation and induce apoptosis of HS 737.T cells through activating Caspase-3, PARP1, p53, and TP53INP1.	Paclitaxel	12-22	tumor protein p53	Homo sapiens	144-147
30592172-14	2019	CONCLUSION: Paclitaxel can significantly repress cell proliferation and induce apoptosis of HS 737.T cells through activating Caspase-3, PARP1, p53, and TP53INP1.	Paclitaxel	12-22	tumor protein p53 inducible nuclear protein 1	Homo sapiens	153-161
30522045-3	2019	This study aimed to investigate the involvement of mitochondrial cytochrome c-dependent apoptosis in the mechanism of action of a combination of paclitaxel, sorafenib, and RT in RCC and breast cancer.	Paclitaxel	145-155	cytochrome c, somatic	Homo sapiens	65-77
30522045-7	2019	Our results suggest that paclitaxel, sorafenib, and RT synergistically decreased the viability of RCC and breast cancer cells and significantly induced their apoptosis, as shown by caspase-3 cleavage.	Paclitaxel	25-35	caspase 3	Homo sapiens	181-190
32123828-6	2019	Additionally, proteins namely VASP, coronin-1A, stathmin, and suprabasin were confidently identified in ovarian chemotherapy subjects, possibly in response to combined paclitaxel and carboplatin drug therapy to ovarian cancer.	Paclitaxel	168-178	coronin 1A	Homo sapiens	36-46
30761140-3	2019	Here we showed that paclitaxel pre-treatment greatly enhanced ATP- or nigericin-induced NLRP3 inflammasome activation as indicated by increased release of cleaved caspase-1 and mature IL-1beta, enhanced formation of ASC speck, and increased gasdermin D cleavage and pyroptosis.	Paclitaxel	20-30	interleukin 1 beta	Mus musculus	184-192
30761140-6	2019	Concurrently, the paclitaxel-mediated enhancement of NLRP3 inflammasome activation was significantly suppressed by resveratrol, NAD+, or MEC-17 knockdown, indicating the involvement of paclitaxel-induced alpha-tubulin acetylation in the augmentation of NLRP3 inflammasome activation.	Paclitaxel	18-28	alpha tubulin acetyltransferase 1	Mus musculus	137-143
30761140-6	2019	Concurrently, the paclitaxel-mediated enhancement of NLRP3 inflammasome activation was significantly suppressed by resveratrol, NAD+, or MEC-17 knockdown, indicating the involvement of paclitaxel-induced alpha-tubulin acetylation in the augmentation of NLRP3 inflammasome activation.	Paclitaxel	185-195	alpha tubulin acetyltransferase 1	Mus musculus	137-143
30761140-8	2019	Consistent with the in vitro results, intraperitoneal administration of paclitaxel significantly increased serum IL-1beta levels, reduced bacterial burden, dampened infiltration of inflammatory cells in the liver, and improved animal survival in a mouse model of bacterial infection.	Paclitaxel	72-82	interleukin 1 beta	Mus musculus	113-121
30761271-0	2019	Long Non-coding RNA CDKN2B Antisense RNA 1 Gene Contributes to Paclitaxel Resistance in Endometrial Carcinoma.	Paclitaxel	63-73	cyclin dependent kinase inhibitor 2B	Homo sapiens	20-26
30592172-0	2019	Paclitaxel Induce Apoptosis of Giant Cells Tumor of Bone via TP53INP1 Signaling.	Paclitaxel	0-10	tumor protein p53 inducible nuclear protein 1	Homo sapiens	61-69
30592172-9	2019	RNA-seq and bioinformatics analysis showed that apoptosis, death receptor signaling pathway, TNF signaling pathway, and TP53 regulated transcription of cell death genes pathway were closely associated with paclitaxel in the treatment of GCTB.	Paclitaxel	206-216	tumor protein p53	Homo sapiens	120-124
30592172-10	2019	Western bolt results revealed that paclitaxel induced cleavage of Caspase-3 and PARP1, and increased the phosphorylation level of p53 in HS 737.T cells.	Paclitaxel	35-45	caspase 3	Homo sapiens	66-75
30592172-10	2019	Western bolt results revealed that paclitaxel induced cleavage of Caspase-3 and PARP1, and increased the phosphorylation level of p53 in HS 737.T cells.	Paclitaxel	35-45	poly(ADP-ribose) polymerase 1	Homo sapiens	80-85
30592172-10	2019	Western bolt results revealed that paclitaxel induced cleavage of Caspase-3 and PARP1, and increased the phosphorylation level of p53 in HS 737.T cells.	Paclitaxel	35-45	tumor protein p53	Homo sapiens	130-133
30592172-12	2019	In addition, we found that the inhibitory ratios of paclitaxel on HS737.T cells deficient in TP53INP1 were less than in HS737.T cells with empty vector (19.88 and 40.60%, respectively).	Paclitaxel	52-62	tumor protein p53 inducible nuclear protein 1	Homo sapiens	93-101
30592172-13	2019	Hence, our data revealed that TP53INP1 regulated paclitaxel-driven apoptosis in HS737.T cells.	Paclitaxel	49-59	tumor protein p53 inducible nuclear protein 1	Homo sapiens	30-38
30761271-8	2019	Thirdly, B-cell lymphoma-2 (Bcl2) and Multidrug Resistance-Associated Protein 4 (MRP4) genes were target genes of miR-125a-5p, which modulated paclitaxel resistance of Ishikawa/PA and HEC1A/PA cells through targeted silencing Bcl2 and MRP4.	Paclitaxel	143-153	BCL2 apoptosis regulator	Homo sapiens	28-32
30761271-8	2019	Thirdly, B-cell lymphoma-2 (Bcl2) and Multidrug Resistance-Associated Protein 4 (MRP4) genes were target genes of miR-125a-5p, which modulated paclitaxel resistance of Ishikawa/PA and HEC1A/PA cells through targeted silencing Bcl2 and MRP4.	Paclitaxel	143-153	BCL2 apoptosis regulator	Homo sapiens	226-230
30761271-9	2019	In conclusion, high-expression of CDKN2B-AS is associated with a poor response to paclitaxel of EC patients, and knockdown of CDKN2B-AS inhibits paclitaxel resistance through miR-125a-5p-Bcl2/MRP4 pathway in EC patients.	Paclitaxel	145-155	BCL2 apoptosis regulator	Homo sapiens	187-191
30635009-11	2019	CONCLUSIONS: These results suggest circumstances where nintedanib plus PTX may be potentially effective in treating TNBC, and nintedanib with PTX may improve PD-L1 therapy of metastatic TNBC.	Paclitaxel	142-145	CD274 antigen	Mus musculus	158-163
30675689-8	2019	IC50 values of PTX-NLCs and Intaxel  after 24-h exposure were found to be 4.19 muM and 11.2 muM.	Paclitaxel	15-18	latexin	Homo sapiens	79-82
30675689-8	2019	IC50 values of PTX-NLCs and Intaxel  after 24-h exposure were found to be 4.19 muM and 11.2 muM.	Paclitaxel	15-18	latexin	Homo sapiens	92-95
30366077-0	2019	PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment.	Paclitaxel	44-54	CD274 antigen	Mus musculus	0-5
30366077-4	2019	Here, we demonstrated that PTX mediated the Cancer-Immunity Cycle could be enhanced by PD-L1 knockdown (KD) and followed mTOR pathway inhibition in tumor cells.	Paclitaxel	27-30	CD274 antigen	Mus musculus	87-92
30682083-7	2019	RESULTS: Twelve of the tested drug combinations addressed a synthetic lethal interaction with the anti-VEGF inhibitor bevacizumab in combination with paclitaxel being the most studied drug combination addressing the synthetic lethal pair between VEGFA and BCL2.	Paclitaxel	150-160	vascular endothelial growth factor A	Homo sapiens	246-251
30431082-0	2019	ERp57-small interfering RNA silencing can enhance the sensitivity of drug-resistant human ovarian cancer cells to paclitaxel.	Paclitaxel	114-124	protein disulfide isomerase family A member 3	Homo sapiens	0-5
30666203-7	2018	Together, these results suggested that puerarin may preferentially block beta1 subunit of Nav1.8 in sensory neurons contributed to its anti-paclitaxel induced neuropathic pain effect.	Paclitaxel	140-150	sodium voltage-gated channel alpha subunit 10	Rattus norvegicus	90-96
31328624-5	2019	Here, we extended our previous findings and show that UNC45A is variably expressed across a spectrum of cell lines with the highest level being found in HeLa cells and in ovarian cancer cells inherently paclitaxel-resistant.	Paclitaxel	203-213	unc-45 myosin chaperone A	Homo sapiens	54-60
31328624-7	2019	In sum, we report alteration of UNC45A localization in the setting of chemotherapeutic treatment of cells with paclitaxel, and localization of UNC45A to MTs both in vitro and in vivo.	Paclitaxel	111-121	unc-45 myosin chaperone A	Homo sapiens	32-38
30365045-10	2019	These results demonstrated that exosomal delivery of miR-155-5p may induce EMT and chemoresistant phenotypes from paclitaxel-resistant gastric cancer cells to the sensitive cells, which may be mediated by GATA3 and TP53INP1 suppression.	Paclitaxel	114-124	tumor protein p53 inducible nuclear protein 1	Homo sapiens	215-223
30662353-0	2019	Calpain-2 Enhances Non-Small Cell Lung Cancer Progression and Chemoresistance to Paclitaxel via EGFR-pAKT Pathway.	Paclitaxel	81-91	calpain 2	Homo sapiens	0-9
30662353-0	2019	Calpain-2 Enhances Non-Small Cell Lung Cancer Progression and Chemoresistance to Paclitaxel via EGFR-pAKT Pathway.	Paclitaxel	81-91	epidermal growth factor receptor	Homo sapiens	96-100
30662353-4	2019	This study aims to explore the bio-function of Calpain-2 on NSCLC and chemoresistance to paclitaxel.	Paclitaxel	89-99	calpain 2	Homo sapiens	47-56
30662353-12	2019	Meanwhile, knockdown of Calpain-2 down-regulated EGFR and pAKT expression, which weakened the chemoresistance of NSCLC cells to paclitaxel by suppressing cell proliferation and inducing apoptosis, and even enhanced the paclitaxel-mediated downregulation of EGFR and pAKT level.	Paclitaxel	128-138	calpain 2	Homo sapiens	24-33
30662353-12	2019	Meanwhile, knockdown of Calpain-2 down-regulated EGFR and pAKT expression, which weakened the chemoresistance of NSCLC cells to paclitaxel by suppressing cell proliferation and inducing apoptosis, and even enhanced the paclitaxel-mediated downregulation of EGFR and pAKT level.	Paclitaxel	128-138	epidermal growth factor receptor	Homo sapiens	49-53
30662353-12	2019	Meanwhile, knockdown of Calpain-2 down-regulated EGFR and pAKT expression, which weakened the chemoresistance of NSCLC cells to paclitaxel by suppressing cell proliferation and inducing apoptosis, and even enhanced the paclitaxel-mediated downregulation of EGFR and pAKT level.	Paclitaxel	219-229	calpain 2	Homo sapiens	24-33
30662353-13	2019	To conclude, Calpain-2 might activate EGFR/pAKT pathway to promote NSCLC progression and contributes to the chemoresistance to paclitaxel, which might be a therapeutic target to prevent or postpone the progression of NSCLC.	Paclitaxel	127-137	calpain 2	Homo sapiens	13-22
30124494-0	2019	Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer.	Paclitaxel	46-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-96
30124494-2	2019	We evaluated the efficacy and safety of weekly paclitaxel plus Tmab as second-line chemotherapy for HER2-positive gastric cancer patients.	Paclitaxel	47-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
30866697-3	2019	The results showed that p-SRC can be highly expressed in most human and mouse pancreatic cancer cell lines compared with normal human cell lines and can be induced by paclitaxel or gemcitabine in HPAC cells.	Paclitaxel	167-177	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	26-29
30866697-5	2019	Dasatinib with paclitaxel combination exhibits statistically greater inhibition of the cell migration ability than single agent alone, paclitaxel with gemcitabine or FOLFIRINOX (combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin) in HAPC, PANC-1, and BXPC-3 human pancreatic cancer cell lines as well as 8-285 APR and 8-365 APR mouse pancreatic cancer cell lines.	Paclitaxel	15-25	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	328-331
30866697-5	2019	Dasatinib with paclitaxel combination exhibits statistically greater inhibition of the cell migration ability than single agent alone, paclitaxel with gemcitabine or FOLFIRINOX (combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin) in HAPC, PANC-1, and BXPC-3 human pancreatic cancer cell lines as well as 8-285 APR and 8-365 APR mouse pancreatic cancer cell lines.	Paclitaxel	15-25	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	342-345
30866697-8	2019	Dasatinib with paclitaxel or gemcitabine combination also inhibits p-SRC, p-STAT3, p-AKT, and/or p-ERK in these pancreatic cancer cells.	Paclitaxel	15-25	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	69-72
30866697-8	2019	Dasatinib with paclitaxel or gemcitabine combination also inhibits p-SRC, p-STAT3, p-AKT, and/or p-ERK in these pancreatic cancer cells.	Paclitaxel	15-25	signal transducer and activator of transcription 3	Homo sapiens	76-81
30866697-8	2019	Dasatinib with paclitaxel or gemcitabine combination also inhibits p-SRC, p-STAT3, p-AKT, and/or p-ERK in these pancreatic cancer cells.	Paclitaxel	15-25	AKT serine/threonine kinase 1	Homo sapiens	85-88
30866697-8	2019	Dasatinib with paclitaxel or gemcitabine combination also inhibits p-SRC, p-STAT3, p-AKT, and/or p-ERK in these pancreatic cancer cells.	Paclitaxel	15-25	mitogen-activated protein kinase 1	Homo sapiens	99-102
29956630-4	2019	Also, many studies have proved that paclitaxel is a substrate of the membrane-bound drug efflux pump P-glycoprotein (P-gp), therefore it often shows limited efficacy against the resistant tumors and oral absorption or uptake.	Paclitaxel	36-46	ATP binding cassette subfamily B member 1	Homo sapiens	101-115
29956630-4	2019	Also, many studies have proved that paclitaxel is a substrate of the membrane-bound drug efflux pump P-glycoprotein (P-gp), therefore it often shows limited efficacy against the resistant tumors and oral absorption or uptake.	Paclitaxel	36-46	ATP binding cassette subfamily B member 1	Homo sapiens	117-121
30431082-11	2019	Notably, ERp57-siRNA and 100 nM paclitaxel co-treatment downregulated Bcl-2, Bcl-xl, MMP2, MMP9, TUBB3 and P-gp expression levels and upregulated the expression of Bax protein.	Paclitaxel	32-42	BCL2 apoptosis regulator	Homo sapiens	70-75
30431082-11	2019	Notably, ERp57-siRNA and 100 nM paclitaxel co-treatment downregulated Bcl-2, Bcl-xl, MMP2, MMP9, TUBB3 and P-gp expression levels and upregulated the expression of Bax protein.	Paclitaxel	32-42	BCL2 like 1	Homo sapiens	77-83
30431082-11	2019	Notably, ERp57-siRNA and 100 nM paclitaxel co-treatment downregulated Bcl-2, Bcl-xl, MMP2, MMP9, TUBB3 and P-gp expression levels and upregulated the expression of Bax protein.	Paclitaxel	32-42	BCL2 associated X, apoptosis regulator	Homo sapiens	164-167
30431082-14	2019	The present study implies that ERp57 is a potential therapeutic target for the treatment of paclitaxel-resistant human ovarian cancer.	Paclitaxel	92-102	protein disulfide isomerase family A member 3	Homo sapiens	31-36
30431082-6	2019	ERp57 was highly expressed in the paclitaxel-resistant SKOV3/tax cells, and experimental results concluded that the paclitaxel-resistance phenotype was due primarily to the activation of the STAT3 signaling pathway.	Paclitaxel	34-44	protein disulfide isomerase family A member 3	Homo sapiens	0-5
30431082-6	2019	ERp57 was highly expressed in the paclitaxel-resistant SKOV3/tax cells, and experimental results concluded that the paclitaxel-resistance phenotype was due primarily to the activation of the STAT3 signaling pathway.	Paclitaxel	34-44	signal transducer and activator of transcription 3	Homo sapiens	191-196
30431082-6	2019	ERp57 was highly expressed in the paclitaxel-resistant SKOV3/tax cells, and experimental results concluded that the paclitaxel-resistance phenotype was due primarily to the activation of the STAT3 signaling pathway.	Paclitaxel	116-126	protein disulfide isomerase family A member 3	Homo sapiens	0-5
30431082-6	2019	ERp57 was highly expressed in the paclitaxel-resistant SKOV3/tax cells, and experimental results concluded that the paclitaxel-resistance phenotype was due primarily to the activation of the STAT3 signaling pathway.	Paclitaxel	116-126	signal transducer and activator of transcription 3	Homo sapiens	191-196
30431082-7	2019	ERp57 overexpression by lentiviral particle infection decreased the sensitivity of SKOV3 cells to paclitaxel.	Paclitaxel	98-108	protein disulfide isomerase family A member 3	Homo sapiens	0-5
30431082-8	2019	Furthermore, ERp57-siRNA silencing restored paclitaxel sensitivity of SKOV3/tax cells.	Paclitaxel	44-54	protein disulfide isomerase family A member 3	Homo sapiens	13-18
30431082-10	2019	Additionally, co-treatment of ERp57-siRNA silencing and paclitaxel could inhibit the STAT3 signaling pathway and downregulate the expression levels of downstream proteins.	Paclitaxel	56-66	protein disulfide isomerase family A member 3	Homo sapiens	30-35
30431082-10	2019	Additionally, co-treatment of ERp57-siRNA silencing and paclitaxel could inhibit the STAT3 signaling pathway and downregulate the expression levels of downstream proteins.	Paclitaxel	56-66	signal transducer and activator of transcription 3	Homo sapiens	85-90
30809279-4	2019	Paclitaxel exerts anti-cancer effects but, paradoxically, exacerbates cancer metastasis and drug resistance by increasing the expression of apoptotic B-cell lymphoma-2 protein (BCL-2).	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	150-175
31939438-0	2019	Efficacy and safety of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy in HER2-negative breast cancer.	Paclitaxel	50-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-96
30788785-6	2019	We also describe the measurement of the activity of the cytochrome P450 expressed by taking the example of cytochrome P450 2J2, the primary P450 expressed in the human heart and CYP725A4, the primary cytochrome P450 expressed in the first step of taxol synthesis.	Paclitaxel	247-252	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
30320402-4	2019	Furthermore, the expression levels of caspase-3 and -8, and sensitivity to Taxol were increased.	Paclitaxel	75-80	caspase 3	Homo sapiens	38-54
30431158-4	2019	Here we show that paclitaxel treatment in rats increases the alpha2delta-1 expression level in the dorsal root ganglion and spinal cord and the mRNA levels of GluN1, GluN2A, and GluN2B in the spinal cord.	Paclitaxel	18-28	glutamate ionotropic receptor NMDA type subunit 2A	Rattus norvegicus	166-172
30788785-6	2019	We also describe the measurement of the activity of the cytochrome P450 expressed by taking the example of cytochrome P450 2J2, the primary P450 expressed in the human heart and CYP725A4, the primary cytochrome P450 expressed in the first step of taxol synthesis.	Paclitaxel	247-252	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	107-122
30325723-3	2019	The purposes of this study were to examine (1) the effects of blocking mammalian target of rapamycin (mTOR) on mechanical and thermal hypersensitivity evoked by paclitaxel; and (2) the underlying mechanisms responsible for the role of mTOR in regulating paclitaxel-induced neuropathic pain.	Paclitaxel	161-171	mechanistic target of rapamycin kinase	Homo sapiens	71-100
30325723-3	2019	The purposes of this study were to examine (1) the effects of blocking mammalian target of rapamycin (mTOR) on mechanical and thermal hypersensitivity evoked by paclitaxel; and (2) the underlying mechanisms responsible for the role of mTOR in regulating paclitaxel-induced neuropathic pain.	Paclitaxel	161-171	mechanistic target of rapamycin kinase	Homo sapiens	102-106
30325723-3	2019	The purposes of this study were to examine (1) the effects of blocking mammalian target of rapamycin (mTOR) on mechanical and thermal hypersensitivity evoked by paclitaxel; and (2) the underlying mechanisms responsible for the role of mTOR in regulating paclitaxel-induced neuropathic pain.	Paclitaxel	254-264	mechanistic target of rapamycin kinase	Homo sapiens	102-106
30325723-7	2019	Paclitaxel also amplified the expression of p-mTOR, mTOR-mediated phosphorylation of p70 ribosomal S6 protein kinase 1 (p-S6K1), 4E-binding protein 1 (p-4E-BP1) in the DRG.	Paclitaxel	0-10	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	153-159
30655858-9	2019	Additionally, it was observed that, when compared with Taxol treatment, the combination of Taxol and antagomiR-1207-5p induced a sharp decrease in B-cell lymphoma 2 (Bcl-2) and phosphorylated-protein kinase B expression accompanied by an increase in the Bcl-2-associated X protein expression.	Paclitaxel	91-96	BCL2 apoptosis regulator	Homo sapiens	147-164
30655858-9	2019	Additionally, it was observed that, when compared with Taxol treatment, the combination of Taxol and antagomiR-1207-5p induced a sharp decrease in B-cell lymphoma 2 (Bcl-2) and phosphorylated-protein kinase B expression accompanied by an increase in the Bcl-2-associated X protein expression.	Paclitaxel	91-96	BCL2 apoptosis regulator	Homo sapiens	166-171
30655858-9	2019	Additionally, it was observed that, when compared with Taxol treatment, the combination of Taxol and antagomiR-1207-5p induced a sharp decrease in B-cell lymphoma 2 (Bcl-2) and phosphorylated-protein kinase B expression accompanied by an increase in the Bcl-2-associated X protein expression.	Paclitaxel	91-96	BCL2 apoptosis regulator	Homo sapiens	254-259
31045551-5	2019	Bcl-2 and Caspase-3 in vascular smooth muscle and endothelial cells (VSMC, EC) were significantly down-regulated and up-regulated after the cells were treated with gefitinib and paclitaxel.	Paclitaxel	178-188	BCL2, apoptosis regulator	Rattus norvegicus	0-5
31045551-8	2019	In gefitinib- and paclitaxel-coated balloon group, the expression of PI3K/AKT was significantly down-regulated.	Paclitaxel	18-28	AKT serine/threonine kinase 1	Rattus norvegicus	74-77
30359947-4	2019	Here we describe a novel part of a signaling route in which c-Myc enhances paclitaxel sensitivity through upregulation of miR-203b-3p and miR-203a-3p; two clustered antiapoptosis protein Bcl-xL controlling microRNAs.	Paclitaxel	75-85	microRNA 203b	Homo sapiens	122-130
30359947-4	2019	Here we describe a novel part of a signaling route in which c-Myc enhances paclitaxel sensitivity through upregulation of miR-203b-3p and miR-203a-3p; two clustered antiapoptosis protein Bcl-xL controlling microRNAs.	Paclitaxel	75-85	BCL2 like 1	Homo sapiens	187-193
30359947-6	2019	Notably, overexpression of the miR-203b-3p changed the fate of paclitaxel-treated breast and ovarian cancer cells from mitotic slippage to cell death.	Paclitaxel	63-73	microRNA 203b	Homo sapiens	31-39
30359947-0	2019	MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells.	Paclitaxel	70-80	microRNA 203b	Homo sapiens	12-20
30809279-4	2019	Paclitaxel exerts anti-cancer effects but, paradoxically, exacerbates cancer metastasis and drug resistance by increasing the expression of apoptotic B-cell lymphoma-2 protein (BCL-2).	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	177-182
30563080-3	2018	Obatoclax, a BH3 mimetic of the Bcl-2 family of proteins, antagonizes Mcl-1 and hence may reverse paclitaxel resistance in Mcl-1-overexpressing tumors.	Paclitaxel	98-108	BCL2 apoptosis regulator	Homo sapiens	32-37
30774541-12	2019	These preliminary data suggest that a cocktail of 131I-anti-EpCAM (9C4), paclitaxel, and doxorubicin may be suitable for treating breast cancers with high expression of EpCAM.	Paclitaxel	73-83	epithelial cell adhesion molecule	Homo sapiens	169-174
30420976-3	2018	In particular, both the tumor hypoxic microenvironment and the increase in hydrogen peroxide (H2O2) levels via paclitaxel stimulation primarily mediate the resistance to chemotherapy, where multiple drug resistance proteins such as P-gp and tumor invasion-related cytokines such as VEGF are continuously activated to pump out chemical drugs and aggravate tumor metastasis, respectively.	Paclitaxel	111-121	vascular endothelial growth factor A	Homo sapiens	282-286
30553276-7	2018	The association between c-Src-mediated DMAP1 phosphorylation and paclitaxel activity in vivo and clinicopathologic characteristics were analyzed.	Paclitaxel	65-75	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	24-29
30544991-6	2018	DRAIC was also investigated in the Oncomine database and we found that DRAIC expression predicted patients" response to paclitaxel and FEC as well as lapatinib, which are commonly used therapy options for breast cancer.	Paclitaxel	120-130	downregulated RNA in cancer, inhibitor of cell invasion and migration	Homo sapiens	0-5
30544991-6	2018	DRAIC was also investigated in the Oncomine database and we found that DRAIC expression predicted patients" response to paclitaxel and FEC as well as lapatinib, which are commonly used therapy options for breast cancer.	Paclitaxel	120-130	downregulated RNA in cancer, inhibitor of cell invasion and migration	Homo sapiens	71-76
30521500-0	2018	LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1.	Paclitaxel	20-30	ATP binding cassette subfamily C member 1	Homo sapiens	93-98
30521500-10	2018	CONCLUSIONS LINC01118 acted as an oncogene and modulated EOC paclitaxel sensitivity by regulating miR-134/ABCC1.	Paclitaxel	61-71	ATP binding cassette subfamily C member 1	Homo sapiens	106-111
30401501-6	2018	The cellular thermal shift assay (CETSA) showed that WS-10 was able to bind to ABCB1, which could be responsible for the reversal effect of WS-10 toward paclitaxel and doxorubicin in SW620/Ad300 cells.	Paclitaxel	153-163	ATP binding cassette subfamily B member 1	Homo sapiens	79-84
30613365-3	2018	In this study, we demonstrate that the Brn-3b transcription factor was increased in different ovarian cancer cells including SKOV3 and A2780 following treatment with cis and pax.	Paclitaxel	174-177	POU class 4 homeobox 2	Homo sapiens	39-45
30487062-10	2018	Overexpression of Cav1 and anti-miR-1246 treatment significantly sensitized OC cells to paclitaxel.	Paclitaxel	88-98	caveolin 1	Homo sapiens	18-22
30505814-9	2018	The flavonoid either alone or in combination with paclitaxel therapy resulted in an increase in tumor suppressor PTEN (phosphatase and tensin homolog deleted on chromosome 10) protein expression and decrease in nuclear factor-kappaB p50 protein level in DU145 cells.	Paclitaxel	50-60	nuclear factor kappa B subunit 1	Homo sapiens	233-236
30275151-2	2018	We compared efficacies of brain-permeant and -impermeant inhibitors of fatty acid amide hydrolase (FAAH) in suppressing neuropathic pain induced by the chemotherapeutic agent paclitaxel.	Paclitaxel	175-185	fatty acid amide hydrolase	Homo sapiens	71-97
30275151-2	2018	We compared efficacies of brain-permeant and -impermeant inhibitors of fatty acid amide hydrolase (FAAH) in suppressing neuropathic pain induced by the chemotherapeutic agent paclitaxel.	Paclitaxel	175-185	fatty acid amide hydrolase	Homo sapiens	99-103
30275151-6	2018	URB937, a brain-impermeant FAAH inhibitor, suppressed paclitaxel-induced allodynia through a CB1 mechanism only.	Paclitaxel	54-64	fatty acid amide hydrolase	Homo sapiens	27-31
30275151-6	2018	URB937, a brain-impermeant FAAH inhibitor, suppressed paclitaxel-induced allodynia through a CB1 mechanism only.	Paclitaxel	54-64	cannabinoid receptor 1	Homo sapiens	93-96
30275151-8	2018	Thus, URB937 suppressed paclitaxel-induced allodynia through a mechanism that was dependent upon peripheral CB1 receptor activation only.	Paclitaxel	24-34	cannabinoid receptor 1	Homo sapiens	108-111
30175868-8	2018	TRIM59 overexpression promoted cell proliferation, invasion, migration, cell cycle transition, and paclitaxel resistance, whereas TRIM59 depletion showed the opposite results.	Paclitaxel	99-109	tripartite motif containing 59	Homo sapiens	0-6
30478403-3	2018	In the present study, a variety of thermodynamic, spectroscopic, computational, and cellular techniques were applied to assess alpha-lactalbumin potential as a carrier for doxorubicin and paclitaxel.	Paclitaxel	188-198	lactalbumin alpha	Homo sapiens	127-144
30478403-7	2018	Based on Pace analysis to determine protein thermal stability, doxorubicin and paclitaxel induced higher and lower thermal stability in alpha-lactalbumin, respectively.	Paclitaxel	79-89	lactalbumin alpha	Homo sapiens	136-153
30478403-8	2018	Besides, fluorescence lifetime measurements reflected that the interaction between alpha-lactalbumin with doxorubicin or paclitaxel was of static nature.	Paclitaxel	121-131	lactalbumin alpha	Homo sapiens	83-100
30478403-4	2018	According to isothermal titration calorimetry data, the interaction between alpha-lactalbumin and doxorubicin or paclitaxel is spontaneous and the K (M-1) value for the interaction of alpha-lactalbumin and paclitaxel is higher than that for doxorubicin.	Paclitaxel	113-123	lactalbumin alpha	Homo sapiens	76-93
30478403-9	2018	Therefore, the authors hypothesized that alpha-lactalbumin could serve as a carrier for doxorubicin and paclitaxel by reducing cytotoxicity and apoptosis which was demonstrated during our in vitro cell studies.	Paclitaxel	104-114	lactalbumin alpha	Homo sapiens	41-58
30478403-4	2018	According to isothermal titration calorimetry data, the interaction between alpha-lactalbumin and doxorubicin or paclitaxel is spontaneous and the K (M-1) value for the interaction of alpha-lactalbumin and paclitaxel is higher than that for doxorubicin.	Paclitaxel	113-123	lactalbumin alpha	Homo sapiens	184-201
30478403-4	2018	According to isothermal titration calorimetry data, the interaction between alpha-lactalbumin and doxorubicin or paclitaxel is spontaneous and the K (M-1) value for the interaction of alpha-lactalbumin and paclitaxel is higher than that for doxorubicin.	Paclitaxel	206-216	lactalbumin alpha	Homo sapiens	76-93
30478403-5	2018	Differential scanning calorimetry and anisotropy results indicated formation of alpha-lactalbumin complexes with doxorubicin or paclitaxel.	Paclitaxel	128-138	lactalbumin alpha	Homo sapiens	80-97
30322886-8	2018	Furthermore, overexpression of Sab in chemoresistant cells enhanced apoptotic priming and restored cellular vulnerability to a combination treatment of cisplatin and paclitaxel.	Paclitaxel	166-176	SH3 domain binding protein 5	Homo sapiens	31-34
30429459-2	2018	Here we uncovered that either sulforaphane-cysteine (SFN-Cys) or sulforaphane-N-acetyl-cysteine (SFN-NAC) induced apoptosis via phosphorylated ERK1/2-mediated upregulation of 26 S proteasome and Hsp70, and downregulation of betaIII-tubulin, XIAP, Tau, Stathmin1 and alpha-tubulin causing microtubule disruption in human PTX-resistant non-small cell lung cancer (NSCLC) cells.	Paclitaxel	320-323	mitogen-activated protein kinase 3	Homo sapiens	143-149
29844129-2	2018	MEK inhibition targets tumors harboring MAPK pathway alterations and enhances paclitaxel-induced apoptosis in EOC.	Paclitaxel	78-88	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
30429459-7	2018	The combination of PTX with SFN metabolites decreased the resistance to PTX, and doses of both PTX and SFN metabolites, and enhanced apoptosis resulting from activated Caspase-3-caused microtubule degradation.	Paclitaxel	19-22	caspase 3	Homo sapiens	168-177
30405089-11	2018	Calreticulin expression in tumors also increased upon the co-delivery of PTX and GMP.	Paclitaxel	73-76	calreticulin	Homo sapiens	0-12
30307008-0	2018	Anti-EGFR lipid micellar nanoparticles co-encapsulating quantum dots and paclitaxel for tumor-targeted theranosis.	Paclitaxel	73-83	epidermal growth factor receptor	Homo sapiens	5-9
30307008-8	2018	These results suggest that the anti-EGFR immuno-PTX-QDMs and anti-EGFR aptamo-PTX-QDMs could be utilized as a tumor-targeted theranostic delivery system for cancer treatment in the clinic.	Paclitaxel	48-51	epidermal growth factor receptor	Homo sapiens	36-40
30307008-8	2018	These results suggest that the anti-EGFR immuno-PTX-QDMs and anti-EGFR aptamo-PTX-QDMs could be utilized as a tumor-targeted theranostic delivery system for cancer treatment in the clinic.	Paclitaxel	78-81	epidermal growth factor receptor	Homo sapiens	66-70
30408068-0	2018	Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer.	Paclitaxel	19-29	epidermal growth factor receptor	Homo sapiens	5-9
30408068-2	2018	The aim of the present study is to analyze the viability of anti-EGFR anchored immunonanoparticle (INP) bearing Paclitaxel (PTX) to specifically bind the EGFR protein on the TNBC cells.	Paclitaxel	112-122	epidermal growth factor receptor	Homo sapiens	65-69
30408068-2	2018	The aim of the present study is to analyze the viability of anti-EGFR anchored immunonanoparticle (INP) bearing Paclitaxel (PTX) to specifically bind the EGFR protein on the TNBC cells.	Paclitaxel	112-122	epidermal growth factor receptor	Homo sapiens	154-158
30408068-2	2018	The aim of the present study is to analyze the viability of anti-EGFR anchored immunonanoparticle (INP) bearing Paclitaxel (PTX) to specifically bind the EGFR protein on the TNBC cells.	Paclitaxel	124-127	epidermal growth factor receptor	Homo sapiens	65-69
30408068-2	2018	The aim of the present study is to analyze the viability of anti-EGFR anchored immunonanoparticle (INP) bearing Paclitaxel (PTX) to specifically bind the EGFR protein on the TNBC cells.	Paclitaxel	124-127	epidermal growth factor receptor	Homo sapiens	154-158
30408068-8	2018	Based on these reports, we recommend that anti-EGFR anchored PTX loaded NP may have the ability to target the TNBC cells and improve the therapeutic action and subsidize the side effects of PTX for the treatment of TNBC.	Paclitaxel	61-64	epidermal growth factor receptor	Homo sapiens	47-51
30408068-8	2018	Based on these reports, we recommend that anti-EGFR anchored PTX loaded NP may have the ability to target the TNBC cells and improve the therapeutic action and subsidize the side effects of PTX for the treatment of TNBC.	Paclitaxel	190-193	epidermal growth factor receptor	Homo sapiens	47-51
28884602-13	2018	Expression analysis by real-time PCR showed the significant up-regulation of two tumour suppressor genes, P53 and P21 in response to combination of silibinin and paclitaxel.	Paclitaxel	162-172	tumor protein p53	Homo sapiens	106-109
30151731-10	2018	H-NMR and FTIR analysis done on PSMA-coupled paclitaxel-loaded PBNM showed peaks characteristic of the drug (paclitaxel) and the polymer, confirming the successful encapsulation.	Paclitaxel	45-55	folate hydrolase 1	Homo sapiens	32-36
30151731-10	2018	H-NMR and FTIR analysis done on PSMA-coupled paclitaxel-loaded PBNM showed peaks characteristic of the drug (paclitaxel) and the polymer, confirming the successful encapsulation.	Paclitaxel	109-119	folate hydrolase 1	Homo sapiens	32-36
29299936-6	2018	Both in vitro and in vivo antitumor results demonstrated that the sustained-release PTX could induce the microtubules assembly and the over-expression of Bax and Cyclin B1 proteins, resulting in the microtubule dynamics disruption, G2/M phase arrest, and cell apoptosis accordingly.	Paclitaxel	84-87	BCL2 associated X, apoptosis regulator	Homo sapiens	154-157
30179775-0	2018	Endogenous albumin-mediated delivery of redox-responsive paclitaxel-loaded micelles for targeted cancer therapy.	Paclitaxel	57-67	albumin	Homo sapiens	11-18
30179775-3	2018	Herein, a novel redox-responsive paclitaxel-loaded micelle system with the modification of ABD035, which specifically and strongly binds to albumin, is designed to combine the strengths of albumin and micelles together for antitumor drug biomimetic delivery.	Paclitaxel	33-43	albumin	Homo sapiens	140-147
30179775-3	2018	Herein, a novel redox-responsive paclitaxel-loaded micelle system with the modification of ABD035, which specifically and strongly binds to albumin, is designed to combine the strengths of albumin and micelles together for antitumor drug biomimetic delivery.	Paclitaxel	33-43	albumin	Homo sapiens	189-196
30388386-0	2018	Enhancement of radiotherapeutic efficacy for esophageal cancer by paclitaxel-loaded red blood cell membrane nanoparticles modified by the recombinant protein anti-EGFR-iRGD.	Paclitaxel	66-76	epidermal growth factor receptor	Homo sapiens	163-167
29777024-7	2018	The brain-to-plasma ratios of P-gp substrates in hMDR1-MAC mice were much lower than those in Mdr1a/1b-knockout mice, and the brain-to-plasma ratio of paclitaxel was significantly increased by pretreatment with a P-gp inhibitor in hMDR1-MAC mice.	Paclitaxel	151-161	ATP binding cassette subfamily B member 1	Homo sapiens	213-217
29777024-7	2018	The brain-to-plasma ratios of P-gp substrates in hMDR1-MAC mice were much lower than those in Mdr1a/1b-knockout mice, and the brain-to-plasma ratio of paclitaxel was significantly increased by pretreatment with a P-gp inhibitor in hMDR1-MAC mice.	Paclitaxel	151-161	ATP binding cassette subfamily B member 1	Homo sapiens	231-236
30265158-6	2018	CONCLUSION: The present study revealed paclitaxel may reverse the trastuzumab resistance by JUN, which possibly in turn regulated DUSP1 and DUSP1-related signaling pathways.	Paclitaxel	39-49	dual specificity phosphatase 1	Homo sapiens	130-135
30265158-6	2018	CONCLUSION: The present study revealed paclitaxel may reverse the trastuzumab resistance by JUN, which possibly in turn regulated DUSP1 and DUSP1-related signaling pathways.	Paclitaxel	39-49	dual specificity phosphatase 1	Homo sapiens	140-145
30388386-2	2018	In this study, we constructed a novel nano-radiosensitizer, anti-EGFR-iRGD-conjugated (iE)-PRNPs, by conjugating the recombinant protein anti-epidermal growth factor receptor (EGFR)-internalizing arginine-glycine-aspartic (iRGD) to the surface of paclitaxel-loaded red blood cell membrane nanoparticles (PRNPs).	Paclitaxel	247-257	epidermal growth factor receptor	Homo sapiens	65-69
30388386-2	2018	In this study, we constructed a novel nano-radiosensitizer, anti-EGFR-iRGD-conjugated (iE)-PRNPs, by conjugating the recombinant protein anti-epidermal growth factor receptor (EGFR)-internalizing arginine-glycine-aspartic (iRGD) to the surface of paclitaxel-loaded red blood cell membrane nanoparticles (PRNPs).	Paclitaxel	247-257	epidermal growth factor receptor	Homo sapiens	142-174
29991529-0	2018	Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.	Paclitaxel	0-5	nuclear receptor subfamily 3 group C member 1	Homo sapiens	80-82
30179299-6	2018	Meanwhile, E2 could promote ERalpha expression to render ER+ breast cancer cells resistant to paclitaxel.	Paclitaxel	94-104	estrogen receptor 1	Homo sapiens	28-35
30179299-7	2018	Furthermore, we established paclitaxel-resistant breast cancer cell lines and determined the function of ERalpha in the enhancement of paclitaxel resistance via the regulation of CD44 transcription.	Paclitaxel	28-38	estrogen receptor 1	Homo sapiens	105-112
30179299-7	2018	Furthermore, we established paclitaxel-resistant breast cancer cell lines and determined the function of ERalpha in the enhancement of paclitaxel resistance via the regulation of CD44 transcription.	Paclitaxel	135-145	estrogen receptor 1	Homo sapiens	105-112
30221728-12	2018	These results suggested that exposure to pristimerin induced autophagic cell death, whereas a combination treatment of pristimerin and paclitaxel resulted in an additive effect on ERK-dependent autophagic cell death.	Paclitaxel	135-145	mitogen-activated protein kinase 1	Homo sapiens	180-183
30221728-0	2018	Combination of pristimerin and paclitaxel additively induces autophagy in human breast cancer cells via ERK1/2 regulation.	Paclitaxel	31-41	mitogen-activated protein kinase 3	Homo sapiens	104-110
30375371-0	2018	Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-beta1-induced EMT and confers paclitaxel resistance in ovarian cancer.	Paclitaxel	99-109	ST6 beta-galactoside alpha-2,6-sialyltransferase 2	Homo sapiens	0-17
30221728-10	2018	Pristimerin and paclitaxel inhibited extracellular signal-regulated kinase (ERK)1/2/p90RSK signaling, consistent with autophagy indicators, namely p62 degradation and beclin 1 expression.	Paclitaxel	16-26	mitogen-activated protein kinase 1	Homo sapiens	37-83
30221728-11	2018	In addition, ERK activator ceramide C6 treatment suppressed the LC3-II levels induced by a combination of paclitaxel and pristimerin.	Paclitaxel	106-116	mitogen-activated protein kinase 1	Homo sapiens	13-16
30348118-0	2018	Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial.	Paclitaxel	50-64	caveolin 1	Homo sapiens	0-10
30425998-7	2018	Sensitivity to paclitaxel was also measured and was found to inversely correlate to bcl-2 status.	Paclitaxel	15-25	BCL2 apoptosis regulator	Homo sapiens	84-89
29902299-4	2018	Design, Setting, and Participants: In the NeoALTTO trial, HER2-positive patients recruited between January 5, 2008, and May 27, 2010, were treated with paclitaxel plus either lapatinib or trastuzumab or both as neoadjuvant therapy.	Paclitaxel	152-162	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-62
30348118-10	2018	Higher tumor Cav-1 level and lower stromal Cav-1 level were significantly associated with longer PFS of nab-paclitaxel and gemcitabine.	Paclitaxel	104-118	caveolin 1	Homo sapiens	13-18
30348118-10	2018	Higher tumor Cav-1 level and lower stromal Cav-1 level were significantly associated with longer PFS of nab-paclitaxel and gemcitabine.	Paclitaxel	104-118	caveolin 1	Homo sapiens	43-48
30348118-12	2018	Tumor/stromal Cav-1 level may be a good predictor for the efficacy of nab-paclitaxel and gemcitabine.	Paclitaxel	70-84	caveolin 1	Homo sapiens	14-19
30333474-11	2018	The patient was started on paclitaxel and carboplatin chemotherapy regimen as a last resort, despite failure of prior TCF treatment, and the patient responded, this time with complete remission in 4 months.	Paclitaxel	27-37	hepatocyte nuclear factor 4 alpha	Homo sapiens	118-121
30240955-12	2018	Herein, we successfully developed a light-controllable and HER2 targeted theranostic nanoparticels (PFH-PTX@PLGA/SPIO-Her) as a specific drug delivery nanoplatform to overcome the low accuracy of tumor detection and the low specificity of traditional chemo-therapeutic protocols.	Paclitaxel	104-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
30084832-7	2018	Dual knockdown of IKBKB/STK39 or EDN2/TBK1 enhanced paclitaxel sensitivity more than silencing single kinases.	Paclitaxel	52-62	serine/threonine kinase 39	Homo sapiens	24-29
30084832-10	2018	Knockdown of IKBKB/STK39 or EDN2/TBK1 enhanced paclitaxel sensitivity in two ovarian xenograft models.Conclusions: Sequential knockdown of dual kinases increased microtubule stability by decreasing p38-mediated phosphorylation of MAP4 and enhanced response to paclitaxel in ovarian cancer cell lines and xenografts, suggesting a strategy to improve primary therapy.	Paclitaxel	47-57	serine/threonine kinase 39	Homo sapiens	19-24
30084832-10	2018	Knockdown of IKBKB/STK39 or EDN2/TBK1 enhanced paclitaxel sensitivity in two ovarian xenograft models.Conclusions: Sequential knockdown of dual kinases increased microtubule stability by decreasing p38-mediated phosphorylation of MAP4 and enhanced response to paclitaxel in ovarian cancer cell lines and xenografts, suggesting a strategy to improve primary therapy.	Paclitaxel	47-57	mitogen-activated protein kinase 14	Homo sapiens	198-201
30084832-10	2018	Knockdown of IKBKB/STK39 or EDN2/TBK1 enhanced paclitaxel sensitivity in two ovarian xenograft models.Conclusions: Sequential knockdown of dual kinases increased microtubule stability by decreasing p38-mediated phosphorylation of MAP4 and enhanced response to paclitaxel in ovarian cancer cell lines and xenografts, suggesting a strategy to improve primary therapy.	Paclitaxel	260-270	serine/threonine kinase 39	Homo sapiens	19-24
30104241-0	2018	Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner.	Paclitaxel	0-10	toll-like receptor 4	Mus musculus	100-104
30104241-4	2018	In vitro, paclitaxel reprogrammed M2-polarized macrophages to the M1-like phenotype in a TLR4-dependent manner, similarly to LPS.	Paclitaxel	10-20	toll-like receptor 4	Mus musculus	89-93
30104241-6	2018	In mice selectively lacking TLR4 on myeloid cells, for example, macrophages (LysM-Cre+/-/TLR4fl/fl), the antitumor effect of paclitaxel was attenuated.	Paclitaxel	125-135	toll-like receptor 4	Mus musculus	28-32
30104241-6	2018	In mice selectively lacking TLR4 on myeloid cells, for example, macrophages (LysM-Cre+/-/TLR4fl/fl), the antitumor effect of paclitaxel was attenuated.	Paclitaxel	125-135	lysozyme 2	Mus musculus	77-81
30104241-6	2018	In mice selectively lacking TLR4 on myeloid cells, for example, macrophages (LysM-Cre+/-/TLR4fl/fl), the antitumor effect of paclitaxel was attenuated.	Paclitaxel	125-135	toll-like receptor 4	Mus musculus	89-93
30104241-7	2018	Gene expression analysis of tumor samples from patients with ovarian cancer before and after treatment with paclitaxel detected an enrichment of genes linked to the M1 macrophage activation profile (IFNgamma-stimulated macrophages).	Paclitaxel	108-118	interferon gamma	Homo sapiens	199-207
30243650-0	2018	Paclitaxel alleviates liver fibrosis induced by bile duct ligation in rats: Role of TGF-beta1, IL-10 and c-Myc.	Paclitaxel	0-10	transforming growth factor, beta 1	Rattus norvegicus	84-93
30104241-8	2018	These findings indicate that paclitaxel skews TAMs toward an immunocompetent profile via TLR4, which might contribute to the antitumor effect of paclitaxel and provide a rationale for new combination regimens comprising paclitaxel and immunotherapies as an anticancer treatment.Significance: This study provides new evidence that the antitumor effect of paclitaxel occurs in part via reactivation of the immune response against cancer, guiding tumor-associated macrophages toward the M1-like antitumor phenotype.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/20/5891/F1.large.jpg Cancer Res; 78(20); 5891-900.	Paclitaxel	29-39	toll-like receptor 4	Mus musculus	89-93
30104241-8	2018	These findings indicate that paclitaxel skews TAMs toward an immunocompetent profile via TLR4, which might contribute to the antitumor effect of paclitaxel and provide a rationale for new combination regimens comprising paclitaxel and immunotherapies as an anticancer treatment.Significance: This study provides new evidence that the antitumor effect of paclitaxel occurs in part via reactivation of the immune response against cancer, guiding tumor-associated macrophages toward the M1-like antitumor phenotype.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/20/5891/F1.large.jpg Cancer Res; 78(20); 5891-900.	Paclitaxel	145-155	toll-like receptor 4	Mus musculus	89-93
30104241-8	2018	These findings indicate that paclitaxel skews TAMs toward an immunocompetent profile via TLR4, which might contribute to the antitumor effect of paclitaxel and provide a rationale for new combination regimens comprising paclitaxel and immunotherapies as an anticancer treatment.Significance: This study provides new evidence that the antitumor effect of paclitaxel occurs in part via reactivation of the immune response against cancer, guiding tumor-associated macrophages toward the M1-like antitumor phenotype.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/20/5891/F1.large.jpg Cancer Res; 78(20); 5891-900.	Paclitaxel	145-155	toll-like receptor 4	Mus musculus	89-93
30104241-8	2018	These findings indicate that paclitaxel skews TAMs toward an immunocompetent profile via TLR4, which might contribute to the antitumor effect of paclitaxel and provide a rationale for new combination regimens comprising paclitaxel and immunotherapies as an anticancer treatment.Significance: This study provides new evidence that the antitumor effect of paclitaxel occurs in part via reactivation of the immune response against cancer, guiding tumor-associated macrophages toward the M1-like antitumor phenotype.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/20/5891/F1.large.jpg Cancer Res; 78(20); 5891-900.	Paclitaxel	145-155	toll-like receptor 4	Mus musculus	89-93
30326563-0	2018	BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.	Paclitaxel	40-50	fibroblast growth factor receptor 1	Homo sapiens	91-96
30326563-3	2018	Epithelial-to-mesenchymal transition (EMT) induced by fibroblast growth factor receptor (FGFR)1 signaling has been proposed as a mechanism of PTX resistance, but it is unclear whether this can be overcome by FGFR1 inhibition.	Paclitaxel	142-145	fibroblast growth factor receptor 1	Homo sapiens	89-95
30326563-7	2018	Additionally, PTX+BGJ398 synergistically suppressed UC cell migration and colony formation via regulation of EMT-associated factors, while FGFR1 knockdown enhanced the antitumor effect of PTX.	Paclitaxel	188-191	fibroblast growth factor receptor 1	Homo sapiens	139-144
30326563-8	2018	These findings provide a basis for development of effective strategies for overcoming PTX resistance in UC through inhibition of FGFR1 signaling.	Paclitaxel	86-89	fibroblast growth factor receptor 1	Homo sapiens	129-134
30243650-2	2018	It has been shown that low dose paclitaxel (PTX) can stabilize microtubules and inhibit the profibrotic transforming growth factor-beta 1 (TGF-beta1) signaling pathway.	Paclitaxel	32-42	transforming growth factor, beta 1	Rattus norvegicus	104-137
30243650-2	2018	It has been shown that low dose paclitaxel (PTX) can stabilize microtubules and inhibit the profibrotic transforming growth factor-beta 1 (TGF-beta1) signaling pathway.	Paclitaxel	32-42	transforming growth factor, beta 1	Rattus norvegicus	139-148
30243650-2	2018	It has been shown that low dose paclitaxel (PTX) can stabilize microtubules and inhibit the profibrotic transforming growth factor-beta 1 (TGF-beta1) signaling pathway.	Paclitaxel	44-47	transforming growth factor, beta 1	Rattus norvegicus	104-137
30243650-2	2018	It has been shown that low dose paclitaxel (PTX) can stabilize microtubules and inhibit the profibrotic transforming growth factor-beta 1 (TGF-beta1) signaling pathway.	Paclitaxel	44-47	transforming growth factor, beta 1	Rattus norvegicus	139-148
30243650-8	2018	This antifibrotic effect of PTX was further examined through its inhibitory effect on TGF-beta1 mRNA and protein expression in addition to c-Myc mRNA expression.	Paclitaxel	28-31	transforming growth factor, beta 1	Rattus norvegicus	86-95
30243650-10	2018	In conclusion, this study suggests that PTX at low dose has the potential to treat BDL-induced liver fibrosis in rats possibly through suppression of TGF-beta1 and c-Myc and activation of IL-10 pathways.	Paclitaxel	40-43	transforming growth factor, beta 1	Rattus norvegicus	150-159
30300579-3	2018	Therapeutic inhibition of C5aR1 via the peptide antagonist PMX-53 improved efficacy of paclitaxel chemotherapy associated with increased presence and cytotoxic properties of CXCR3+ effector memory CD8+ T cells in carcinomas, dependent on both macrophage transcriptional programming and IFNgamma.	Paclitaxel	87-97	complement C5a receptor 1	Homo sapiens	26-31
30110619-7	2018	Overall, the surface-modified PLGA-PEG nanoparticles with the CEA-targeting antibody were successfully developed as nanocarriers for paclitaxel and interacted with CEA expressing cells.	Paclitaxel	133-143	CEA cell adhesion molecule 3	Homo sapiens	62-65
30301218-0	2018	FBXL7 Upregulation Predicts a Poor Prognosis and Associates with a Possible Mechanism for Paclitaxel Resistance in Ovarian Cancer.	Paclitaxel	90-100	F-box and leucine rich repeat protein 7	Homo sapiens	0-5
30301218-4	2018	We found that FBXL7 was downregulated in OVSAHO (PTX-sensitive) but upregulated in KURAMOCHI (PTX-resistant) cells after PTX treatment at cytotoxic concentrations.	Paclitaxel	49-52	F-box and leucine rich repeat protein 7	Homo sapiens	14-19
30301218-4	2018	We found that FBXL7 was downregulated in OVSAHO (PTX-sensitive) but upregulated in KURAMOCHI (PTX-resistant) cells after PTX treatment at cytotoxic concentrations.	Paclitaxel	94-97	F-box and leucine rich repeat protein 7	Homo sapiens	14-19
30301218-4	2018	We found that FBXL7 was downregulated in OVSAHO (PTX-sensitive) but upregulated in KURAMOCHI (PTX-resistant) cells after PTX treatment at cytotoxic concentrations.	Paclitaxel	94-97	F-box and leucine rich repeat protein 7	Homo sapiens	14-19
30301218-5	2018	Moreover, our data showed that the fold change of FBXL7 expression post-treatment with PTX was causally correlated with the 50% inhibitory concentrations (IC50) of PTX in a panel of ovarian cancer cell lines.	Paclitaxel	87-90	F-box and leucine rich repeat protein 7	Homo sapiens	50-55
30301218-5	2018	Moreover, our data showed that the fold change of FBXL7 expression post-treatment with PTX was causally correlated with the 50% inhibitory concentrations (IC50) of PTX in a panel of ovarian cancer cell lines.	Paclitaxel	164-167	F-box and leucine rich repeat protein 7	Homo sapiens	50-55
30301218-6	2018	In assessments of progression-free survival probability, high levels of FBXL7 transcript strongly predicted a poor prognosis and unfavorable response to PTX-based chemotherapy in patients with ovarian cancer.	Paclitaxel	153-156	F-box and leucine rich repeat protein 7	Homo sapiens	72-77
30301218-7	2018	The knockdown of FBXL7 predominantly enhanced the cytotoxic effectiveness of PTX on the PTX-resistant KURAMOCHI cells.	Paclitaxel	77-80	F-box and leucine rich repeat protein 7	Homo sapiens	17-22
30301218-7	2018	The knockdown of FBXL7 predominantly enhanced the cytotoxic effectiveness of PTX on the PTX-resistant KURAMOCHI cells.	Paclitaxel	88-91	F-box and leucine rich repeat protein 7	Homo sapiens	17-22
30301218-8	2018	FBXL7 may be a useful biomarker for predicting complete pathologic response in ovarian cancer patients who decide to receive post-operative PTX therapy.	Paclitaxel	140-143	F-box and leucine rich repeat protein 7	Homo sapiens	0-5
30179591-3	2018	RAGE or CXCR4 antagonists, ethyl pyruvate or minocycline, known to inhibit HMGB1 release from macrophages, and liposomal clodronate, a macrophage depletor, prevented the paclitaxel-induced allodynia.	Paclitaxel	170-180	MOK protein kinase	Mus musculus	0-4
30096559-5	2018	In mice bearing human Her-2-positive breast cancer xenografts, high-payload paclitaxel encapsulated in 25 nm (diameter) micellesomes kills more cancer cells than paclitaxel in standard clinical formulation, as evidenced by the enhanced apparent diffusion coefficient of water determined by in vivo MR imaging.	Paclitaxel	76-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-27
30150104-6	2018	The cellular thermal shift assay (CETSA) showed that WS-10 was able to bind to ABCB1, which could be responsible for the reversal effect of WS-10 toward paclitaxel and doxorubicin in SW620/Ad300 cells.	Paclitaxel	153-163	ATP binding cassette subfamily B member 1	Homo sapiens	79-84
29349598-0	2018	Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.	Paclitaxel	146-156	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-179
30179591-4	2018	Paclitaxel caused upregulation of RAGE and CXCR4 in the dorsal root ganglia and macrophage accumulation in the sciatic nerve.	Paclitaxel	0-10	MOK protein kinase	Mus musculus	34-38
30179591-6	2018	Paclitaxel increased accumulation of reactive oxygen species (ROS) and phosphorylation of p38MAPK, NF-kappaB p65 and I-kappaB in RAW264.7 cells.	Paclitaxel	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	99-108
30179591-9	2018	Our data indicate that HMGB1 released from macrophages through the ROS/p38MAPK/NF-kappaB/HAT pathway participates in the paclitaxel-induced peripheral neuropathy in mice, and unveils an emerging therapeutic avenue targeting a neuroimmune crosstalk in CIPN.	Paclitaxel	121-131	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	79-88
29935185-6	2018	The results demonstrate that the inhibition of miR-16 renders resistance to paclitaxel in vitro and in vivo by targeting IKBKB via NF-kappaB signaling pathway, suggesting that miR-16 may be a meaningful therapeutic potential to overcome drug resistance in HCC.	Paclitaxel	76-86	glycerophosphodiester phosphodiesterase 1	Homo sapiens	47-53
30173893-0	2018	Paclitaxel promotes lung cancer cell apoptosis via MEG3-P53 pathway activation.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	56-59
30173893-10	2018	PTX significantly inhibited the proliferation of NSCLC cells and increased the expressions of MEG3 and P53.	Paclitaxel	0-3	tumor protein p53	Homo sapiens	103-106
30173893-13	2018	Our results suggest that the MEG3-P53 pathway is involved in the apoptosis of A549 cells induced by PTX.	Paclitaxel	100-103	tumor protein p53	Homo sapiens	34-37
30227879-0	2018	Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro.	Paclitaxel	63-73	metadherin	Homo sapiens	42-46
30429875-6	2018	Results: On-demand designed paclitaxel dimeric prodrug could co-precipitate with amphiphilic copolymers to form ultra-stable uPA-PTXD NPs with high drug loading capacity.	Paclitaxel	28-38	proline rich acidic protein 1	Homo sapiens	125-128
30191515-0	2018	Antiproliferative and Apoptosis Triggering Potential of Paclitaxel-Based Targeted-Lipid Nanoparticles with Enhanced Cellular Internalization by Transferrin Receptors-a Study in Leukemia Cells.	Paclitaxel	56-66	transferrin	Homo sapiens	144-155
30191515-3	2018	In this study, transferrin-decorated paclitaxel-loaded lipid nanoparticle (TPLN) was prepared with an aim to increase the chemotherapeutic efficacy in the leukemia cells.	Paclitaxel	37-47	transferrin	Homo sapiens	15-26
30066930-6	2018	The results indicated that curcumin and paclitaxel induced apoptosis and necrosis, which was demonstrated through multiple methods, including assays of caspase-3/7 activity, Annexin V, poly(ADP-ribose) polymerase-1 activation and protein expression of caspase-3, nuclear factor (NF)-kappaB transcription factor and proliferating cell nuclear antigen.	Paclitaxel	40-50	caspase 3	Homo sapiens	152-161
30066930-6	2018	The results indicated that curcumin and paclitaxel induced apoptosis and necrosis, which was demonstrated through multiple methods, including assays of caspase-3/7 activity, Annexin V, poly(ADP-ribose) polymerase-1 activation and protein expression of caspase-3, nuclear factor (NF)-kappaB transcription factor and proliferating cell nuclear antigen.	Paclitaxel	40-50	poly(ADP-ribose) polymerase 1	Homo sapiens	185-214
30066930-6	2018	The results indicated that curcumin and paclitaxel induced apoptosis and necrosis, which was demonstrated through multiple methods, including assays of caspase-3/7 activity, Annexin V, poly(ADP-ribose) polymerase-1 activation and protein expression of caspase-3, nuclear factor (NF)-kappaB transcription factor and proliferating cell nuclear antigen.	Paclitaxel	40-50	caspase 3	Homo sapiens	252-261
30235479-3	2018	RESULTS:  In freshly isolated human RBCs, paclitaxel induced thrombin generation through PS exposure and MV release, whereas either coagulation factors or platelets were unaffected.	Paclitaxel	42-52	coagulation factor II, thrombin	Homo sapiens	61-69
30254439-7	2018	Results: Paclitaxel (PTX)-loaded anti-EGFR-iRGD-modified erythrocyte membrane nano-system (anti-EGFR-iRGD-RBCm-PTX, abbreviated to PRP) were manufactured.	Paclitaxel	9-19	epidermal growth factor receptor	Homo sapiens	38-42
30254439-7	2018	Results: Paclitaxel (PTX)-loaded anti-EGFR-iRGD-modified erythrocyte membrane nano-system (anti-EGFR-iRGD-RBCm-PTX, abbreviated to PRP) were manufactured.	Paclitaxel	9-19	epidermal growth factor receptor	Homo sapiens	96-100
30254439-7	2018	Results: Paclitaxel (PTX)-loaded anti-EGFR-iRGD-modified erythrocyte membrane nano-system (anti-EGFR-iRGD-RBCm-PTX, abbreviated to PRP) were manufactured.	Paclitaxel	9-19	prion protein	Homo sapiens	131-134
30254439-7	2018	Results: Paclitaxel (PTX)-loaded anti-EGFR-iRGD-modified erythrocyte membrane nano-system (anti-EGFR-iRGD-RBCm-PTX, abbreviated to PRP) were manufactured.	Paclitaxel	21-24	epidermal growth factor receptor	Homo sapiens	38-42
30254439-7	2018	Results: Paclitaxel (PTX)-loaded anti-EGFR-iRGD-modified erythrocyte membrane nano-system (anti-EGFR-iRGD-RBCm-PTX, abbreviated to PRP) were manufactured.	Paclitaxel	21-24	epidermal growth factor receptor	Homo sapiens	96-100
30254439-7	2018	Results: Paclitaxel (PTX)-loaded anti-EGFR-iRGD-modified erythrocyte membrane nano-system (anti-EGFR-iRGD-RBCm-PTX, abbreviated to PRP) were manufactured.	Paclitaxel	21-24	prion protein	Homo sapiens	131-134
30254439-8	2018	PRP was spheroid, uniformly size, about 171.7+-4.7 nm in average, could be stable in vitro for 8 days, and released PTX in a biphasic pattern.	Paclitaxel	116-119	prion protein	Homo sapiens	0-3
30254455-0	2018	Low-frequency ultrasound enhances chemotherapy sensitivity and induces autophagy in PTX-resistant PC-3 cells via the endoplasmic reticulum stress-mediated PI3K/Akt/mTOR signaling pathway.	Paclitaxel	84-87	AKT serine/threonine kinase 1	Homo sapiens	160-163
30254455-0	2018	Low-frequency ultrasound enhances chemotherapy sensitivity and induces autophagy in PTX-resistant PC-3 cells via the endoplasmic reticulum stress-mediated PI3K/Akt/mTOR signaling pathway.	Paclitaxel	84-87	mechanistic target of rapamycin kinase	Homo sapiens	164-168
30254455-3	2018	This study aimed to investigate the effects of low-frequency ultrasound on autophagy and drug-resistance of paclitaxel (PTX)-resistant PC-3 cells via the endoplasmic reticulum stress (ERs)-mediated PI3K/AT/mTOR signaling pathway.	Paclitaxel	108-118	mechanistic target of rapamycin kinase	Homo sapiens	206-210
30254455-3	2018	This study aimed to investigate the effects of low-frequency ultrasound on autophagy and drug-resistance of paclitaxel (PTX)-resistant PC-3 cells via the endoplasmic reticulum stress (ERs)-mediated PI3K/AT/mTOR signaling pathway.	Paclitaxel	120-123	mechanistic target of rapamycin kinase	Homo sapiens	206-210
30254455-13	2018	Conclusion: Results indicated that ultrasound induces autophagy by ERs-mediated PI3K/AKT/mTOR signaling pathway in PTX-resistant PC-3 cells; this autophagy acts as a cytoprotector during low-frequency ultrasound-mediated reversal of drug resistance.	Paclitaxel	115-118	AKT serine/threonine kinase 1	Homo sapiens	85-88
30254455-13	2018	Conclusion: Results indicated that ultrasound induces autophagy by ERs-mediated PI3K/AKT/mTOR signaling pathway in PTX-resistant PC-3 cells; this autophagy acts as a cytoprotector during low-frequency ultrasound-mediated reversal of drug resistance.	Paclitaxel	115-118	mechanistic target of rapamycin kinase	Homo sapiens	89-93
29885837-3	2018	We investigated whether inhibiting TKTL1 in OC3/TAX300 cells could re-sensitize paclitaxel-resistant cells to paclitaxel and proposed a mechanism of action.	Paclitaxel	80-90	one cut homeobox 3	Homo sapiens	44-47
29885837-3	2018	We investigated whether inhibiting TKTL1 in OC3/TAX300 cells could re-sensitize paclitaxel-resistant cells to paclitaxel and proposed a mechanism of action.	Paclitaxel	110-120	one cut homeobox 3	Homo sapiens	44-47
29885837-7	2018	A 2.2-fold increase in the ROS level and an obvious increase in the cell apoptosis rate were observed in the si-TKTL1+paclitaxel group compared with those in the negative si-TKTL1+paclitaxel and OC3/Tax300 + paclitaxel groups.	Paclitaxel	118-128	one cut homeobox 3	Homo sapiens	195-198
29885837-11	2018	Collectively, TKTL1 down-regulation sensitized paclitaxel-resistant OC3/Tax300 ovarian cancer cells to paclitaxel.	Paclitaxel	47-57	one cut homeobox 3	Homo sapiens	68-71
29885837-11	2018	Collectively, TKTL1 down-regulation sensitized paclitaxel-resistant OC3/Tax300 ovarian cancer cells to paclitaxel.	Paclitaxel	103-113	one cut homeobox 3	Homo sapiens	68-71
29935185-6	2018	The results demonstrate that the inhibition of miR-16 renders resistance to paclitaxel in vitro and in vivo by targeting IKBKB via NF-kappaB signaling pathway, suggesting that miR-16 may be a meaningful therapeutic potential to overcome drug resistance in HCC.	Paclitaxel	76-86	glycerophosphodiester phosphodiesterase 1	Homo sapiens	176-182
29504705-0	2018	ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients.	Paclitaxel	92-102	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
29909520-10	2018	The phosphorylated EGFR and HER2 as well as the activation of downstream molecules MAPKs and AKT significantly decreased when exposed to lapatinib and paclitaxel.	Paclitaxel	151-161	epidermal growth factor receptor	Homo sapiens	19-23
28968698-6	2018	Taxol application dampened microtubule hyperdynamics and suppressed axon overbranching and overgrowth in MEC-17-deficient neurons.	Paclitaxel	0-5	alpha tubulin acetyltransferase 1	Mus musculus	105-111
30015868-10	2018	Furthermore, the ectopic expression of their target gene myeloid differentiation primary response gene 88 (MYD88) or tumor protein 53-induced nuclear protein 1 (TP53INP1) combined with NT21MP enhanced the sensitivity of the breast cancer cells to paclitaxel.	Paclitaxel	247-257	tumor protein p53 inducible nuclear protein 1	Homo sapiens	117-159
30015868-10	2018	Furthermore, the ectopic expression of their target gene myeloid differentiation primary response gene 88 (MYD88) or tumor protein 53-induced nuclear protein 1 (TP53INP1) combined with NT21MP enhanced the sensitivity of the breast cancer cells to paclitaxel.	Paclitaxel	247-257	tumor protein p53 inducible nuclear protein 1	Homo sapiens	161-169
30015868-11	2018	Taken together, these findings suggested that miR-155-3p/5p and their target genes MYD88 and TP53INP1 may serve as novel biomarkers for NT21MP therapy through the CXCR4 pathway for improving sensitivity to paclitaxel in breast cancer.	Paclitaxel	206-216	tumor protein p53 inducible nuclear protein 1	Homo sapiens	93-101
29909520-10	2018	The phosphorylated EGFR and HER2 as well as the activation of downstream molecules MAPKs and AKT significantly decreased when exposed to lapatinib and paclitaxel.	Paclitaxel	151-161	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
30249901-0	2018	Four-and-a-half LIM protein 1 promotes paclitaxel resistance in hepatic carcinoma cells through the regulation of caspase-3 activation.	Paclitaxel	39-49	caspase 3	Homo sapiens	114-123
29971911-0	2018	Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.	Paclitaxel	37-47	microRNA 206	Homo sapiens	84-91
30249901-8	2018	Moreover, knockdown of FHL1 promoted the activation of caspase-3 and caspase-9, which were induced by paclitaxel.	Paclitaxel	102-112	caspase 3	Homo sapiens	55-64
30249901-5	2018	Caspase activity assay was performed to explore the activation of caspase-3 and caspase-9 in paclitaxel treated FHL1-knockdown HepG2 cells.	Paclitaxel	93-103	caspase 3	Homo sapiens	66-75
29971911-0	2018	Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.	Paclitaxel	37-47	ATP binding cassette subfamily B member 1	Homo sapiens	92-97
29971911-8	2018	In summary, our results reveal the potential regulatory mechanism of FTH1P3 on breast cancer paclitaxel resistance through miR-206/ABCB1, providing a novel insight for the breast cancer chemoresistance.	Paclitaxel	93-103	microRNA 206	Homo sapiens	123-130
29388151-5	2018	Afterwards, the expression of P16 was knocked down in BC cell line BT-549 and the effect on the cell proliferation, sensitivity to paclitaxel (TAX), apoptosis, migration, and invasion abilities was assessed using CCK-8, Edu, flow cytometry, scratch, and transwell assays, respectively.	Paclitaxel	131-141	cyclin dependent kinase inhibitor 2A	Homo sapiens	30-33
29971911-8	2018	In summary, our results reveal the potential regulatory mechanism of FTH1P3 on breast cancer paclitaxel resistance through miR-206/ABCB1, providing a novel insight for the breast cancer chemoresistance.	Paclitaxel	93-103	ATP binding cassette subfamily B member 1	Homo sapiens	131-136
30570890-0	2018	Adding anthracycline plus cyclophosphamide to adjuvant paclitaxel plus trastuzumab might be more reasonable in stage I hormone receptor negative HER-2 positive breast cancer patients.	Paclitaxel	55-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	145-150
30066948-0	2018	Knockdown of miR-935 increases paclitaxel sensitivity via regulation of SOX7 in non-small-cell lung cancer.	Paclitaxel	31-41	microRNA 935	Homo sapiens	13-20
30181335-0	2018	Retraction: Potentiation of Paclitaxel Activity by the HSP90 Inhibitor 17-allylamino-17-demethoxygeldanamycin in Human Ovarian Carcinoma Cell Lines with High Levels of Activated AKT.	Paclitaxel	28-38	AKT serine/threonine kinase 1	Homo sapiens	178-181
30066948-8	2018	The findings of the present study validate miR-935 as a predictor of paclitaxel sensitivity in NSCLC.	Paclitaxel	69-79	microRNA 935	Homo sapiens	43-50
30066948-6	2018	In addition, the inhibition of miR-935 enhanced the anticancer effect of paclitaxel, i.e., induced cell growth arrest and apoptosis in A549 cells.	Paclitaxel	73-83	microRNA 935	Homo sapiens	31-38
30066948-7	2018	It was further observed that the inhibition of miR-935 decreased the B cell lymphoma (Bcl)-2 and phosphorylated-RAC-alpha serine/threonine-protein kinase (AKT) protein levels and increased the Bcl-2 associated X, apoptosis regulator protein levels, without affecting the AKT levels in the presence of paclitaxel within A549 cells.	Paclitaxel	301-311	microRNA 935	Homo sapiens	47-54
30127274-8	2018	Moreover, Sp17high (PD-L1+MHCII-) cell populations showed significantly enhanced resistance to Paclitaxel-induced cell death in vitro compared to Sp17low (PD-L1-MHCII+) cells, which was associated in turn with increased STAT3 expression.	Paclitaxel	95-105	CD274 antigen	Mus musculus	20-25
30158588-8	2018	Taking advantage of the difference between transformed and non-transformed cells, we developed a rational strategy by combining the chemotherapeutic agent paclitaxel, which decreases c-FLIP expression, with TLR3 ligand.	Paclitaxel	155-165	CASP8 and FADD like apoptosis regulator	Homo sapiens	183-189
30127274-8	2018	Moreover, Sp17high (PD-L1+MHCII-) cell populations showed significantly enhanced resistance to Paclitaxel-induced cell death in vitro compared to Sp17low (PD-L1-MHCII+) cells, which was associated in turn with increased STAT3 expression.	Paclitaxel	95-105	signal transducer and activator of transcription 3	Mus musculus	220-225
29790111-0	2018	Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.	Paclitaxel	64-74	mechanistic target of rapamycin kinase	Homo sapiens	22-26
30175145-11	2018	Conclusion: Paclitaxel can inhibit Ishikawa and Ishikawa-TAX cell via PI3K/Akt/mTOR signaling pathway.	Paclitaxel	12-22	AKT serine/threonine kinase 1	Homo sapiens	75-78
30175145-11	2018	Conclusion: Paclitaxel can inhibit Ishikawa and Ishikawa-TAX cell via PI3K/Akt/mTOR signaling pathway.	Paclitaxel	12-22	mechanistic target of rapamycin kinase	Homo sapiens	79-83
30061586-0	2018	Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment.	Paclitaxel	16-26	epidermal growth factor receptor	Homo sapiens	44-48
30061586-0	2018	Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment.	Paclitaxel	16-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
30061586-0	2018	Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment.	Paclitaxel	16-26	epidermal growth factor receptor	Homo sapiens	102-106
30061586-3	2018	METHODS: A single arm phase II study was performed to study the safety and efficacy of trastuzumab and paclitaxel treatment in patients with a sensitising EGFR mutation who show HER2 expression in a tumour biopsy (IHC &gt;= 1) after progression on EGFR TKI treatment.	Paclitaxel	103-113	epidermal growth factor receptor	Homo sapiens	155-159
30061586-3	2018	METHODS: A single arm phase II study was performed to study the safety and efficacy of trastuzumab and paclitaxel treatment in patients with a sensitising EGFR mutation who show HER2 expression in a tumour biopsy (IHC &gt;= 1) after progression on EGFR TKI treatment.	Paclitaxel	103-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	178-182
30061586-15	2018	CONCLUSIONS: Trastuzumab-paclitaxel induces objective tumour responses in 46% of EGFR TKI pretreated patients with an activating EGFR mutation and HER2 expression.	Paclitaxel	25-35	epidermal growth factor receptor	Homo sapiens	81-85
30061586-15	2018	CONCLUSIONS: Trastuzumab-paclitaxel induces objective tumour responses in 46% of EGFR TKI pretreated patients with an activating EGFR mutation and HER2 expression.	Paclitaxel	25-35	epidermal growth factor receptor	Homo sapiens	129-133
30061586-15	2018	CONCLUSIONS: Trastuzumab-paclitaxel induces objective tumour responses in 46% of EGFR TKI pretreated patients with an activating EGFR mutation and HER2 expression.	Paclitaxel	25-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-151
30093840-7	2018	Concurrent expression of miR-125a and miR-205 via the miRNA cluster transfection significantly enhanced trastuzumab-mediated growth inhibition and cell cycle G1 arrest in BT474 cells and markedly increased paclitaxel-induced apoptosis in another HER2-overexpressing breast cancer cell line HCC1954.	Paclitaxel	206-216	erb-b2 receptor tyrosine kinase 2	Homo sapiens	246-250
30093840-9	2018	This novel approach targeting of HER3 was able to enhance the therapeutic efficacy of trastuzumab and paclitaxel against HER2-overexpressing breast cancer.	Paclitaxel	102-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
30076255-0	2018	Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappa B and the serine/threonine kinase Akt and is independent of tubulin polymerization.	Paclitaxel	17-22	AKT serine/threonine kinase 1	Homo sapiens	136-139
29980405-5	2018	Upon introduction of the WT-TP53 gene into the MIA-PaCa-2 pancreatic cancer cell line, the sensitivity to drugs used to treat pancreatic cancer cells such as: gemcitabine, fluorouracil (5FU), cisplatin, irinotecan, oxaliplatin, and paclitaxel increased significantly.	Paclitaxel	232-242	tumor protein p53	Homo sapiens	28-32
29902349-0	2018	Nab-paclitaxel interrupts cancer-stromal interaction through C-X-C motif chemokine 10-mediated interleukin-6 downregulation in vitro.	Paclitaxel	4-14	interleukin 6	Homo sapiens	95-108
30087850-0	2018	nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2.	Paclitaxel	4-14	taste 2 receptor member 64 pseudogene	Homo sapiens	76-79
30008912-5	2018	Anti-apoptosis B-cell lymphoma (Bcl)-2 and Bcl-w genes were downregulated and pro-apoptotic Bcl-2-associated agonist of cell death and caspase-3 genes were upregulated in U-2OS cells following treatment with beta-elemene-paclitaxel.	Paclitaxel	221-231	BCL2 apoptosis regulator	Homo sapiens	92-97
30008912-6	2018	Treatment of beta-elemene-paclitaxel arrested the cell cycle and decreased cyclin-dependent kinase, cyclin-B1, P21 and P27 expression levels and decreased resistant genes alterations of ATP binding cassette subfamily B member 1, LDL receptor related protein and TS in U-2OS cells.	Paclitaxel	26-36	ATP binding cassette subfamily B member 1	Homo sapiens	186-227
30008912-7	2018	Results demonstrated that beta-elemene-paclitaxel decreased G-protein coupled receptor 124 (GPR124), vascular endothelial growth factor receptor, matrix metallopeptidase (MMP)-3, MMP-9 expression levels and increased endostatin, TIMP metallopeptidase inhibitor (TIMP)-1, TIMP-2 expression in U-2OS cells.	Paclitaxel	39-49	adhesion G protein-coupled receptor A2	Homo sapiens	60-90
30008912-7	2018	Results demonstrated that beta-elemene-paclitaxel decreased G-protein coupled receptor 124 (GPR124), vascular endothelial growth factor receptor, matrix metallopeptidase (MMP)-3, MMP-9 expression levels and increased endostatin, TIMP metallopeptidase inhibitor (TIMP)-1, TIMP-2 expression in U-2OS cells.	Paclitaxel	39-49	adhesion G protein-coupled receptor A2	Homo sapiens	92-98
30008912-7	2018	Results demonstrated that beta-elemene-paclitaxel decreased G-protein coupled receptor 124 (GPR124), vascular endothelial growth factor receptor, matrix metallopeptidase (MMP)-3, MMP-9 expression levels and increased endostatin, TIMP metallopeptidase inhibitor (TIMP)-1, TIMP-2 expression in U-2OS cells.	Paclitaxel	39-49	matrix metallopeptidase 3	Homo sapiens	146-177
30008912-7	2018	Results demonstrated that beta-elemene-paclitaxel decreased G-protein coupled receptor 124 (GPR124), vascular endothelial growth factor receptor, matrix metallopeptidase (MMP)-3, MMP-9 expression levels and increased endostatin, TIMP metallopeptidase inhibitor (TIMP)-1, TIMP-2 expression in U-2OS cells.	Paclitaxel	39-49	TIMP metallopeptidase inhibitor 1	Homo sapiens	229-269
30008912-9	2018	Immunostaining demonstrated that beta-elemene-paclitaxel treatment increased apoptotic bodies, GPR124 and increased endostatin, TIMP-1 and TIMP-2 expression in tumor tissues.	Paclitaxel	46-56	adhesion G protein-coupled receptor A2	Homo sapiens	95-101
30008912-9	2018	Immunostaining demonstrated that beta-elemene-paclitaxel treatment increased apoptotic bodies, GPR124 and increased endostatin, TIMP-1 and TIMP-2 expression in tumor tissues.	Paclitaxel	46-56	TIMP metallopeptidase inhibitor 1	Homo sapiens	128-134
29978708-5	2018	LbL miR708/PTX-MTNst strongly inhibited c-FLIP expression and resulted in increased expression of proapoptotic proteins.	Paclitaxel	11-14	CASP8 and FADD like apoptosis regulator	Homo sapiens	40-46
30008912-0	2018	beta-elemene enhances anticancer bone neoplasms efficacy of paclitaxel through regulation of GPR124 in bone neoplasms cells.	Paclitaxel	60-70	adhesion G protein-coupled receptor A2	Homo sapiens	93-99
29635751-7	2018	Furthermore, combined treatment of Dox, Pac, or Vcr with Que significantly inhibited nuclear translocation of YB-1.	Paclitaxel	40-43	Y-box binding protein 1	Homo sapiens	110-114
29791145-10	2018	In view of the great pharmaceutical importance of taxadiene, a detailed understanding of the TXS mechanism can provide important clues toward a synthetic strategy for Taxol manufacturing.	Paclitaxel	167-172	thromboxane A synthase 1	Homo sapiens	93-96
29660518-7	2018	These findings revealed that HOXB4 knockdown enhanced the cytotoxic effects of Taxol and DDP by downregulating ABC transporters via inhibiting the PI3K/Akt pathway in ovarian cancer cells.	Paclitaxel	79-84	AKT serine/threonine kinase 1	Homo sapiens	152-155
30013393-3	2018	The purpose of this study was to identify the effect of HIF-1alpha and PKM1 expression on the development of acquired chemoresistance using a paclitaxel (PTX)-resistant gastric cancer cell line.	Paclitaxel	142-152	hypoxia inducible factor 1 subunit alpha	Homo sapiens	56-66
30013393-3	2018	The purpose of this study was to identify the effect of HIF-1alpha and PKM1 expression on the development of acquired chemoresistance using a paclitaxel (PTX)-resistant gastric cancer cell line.	Paclitaxel	154-157	hypoxia inducible factor 1 subunit alpha	Homo sapiens	56-66
30013393-8	2018	Expression of nuclear factor kappa B and HIF-1alpha was increased in rMKN45-PTX cells compared with the parent cells.	Paclitaxel	76-79	hypoxia inducible factor 1 subunit alpha	Homo sapiens	41-51
30013393-9	2018	Expression of Bax and caspase-3 was significantly downregulated, whereas expression of Bcl-xL, P-glycoprotein, multidrug resistance-associated protein and VEGF was increased in rMKN45-PTX.	Paclitaxel	184-187	BCL2 associated X, apoptosis regulator	Homo sapiens	14-17
30013393-9	2018	Expression of Bax and caspase-3 was significantly downregulated, whereas expression of Bcl-xL, P-glycoprotein, multidrug resistance-associated protein and VEGF was increased in rMKN45-PTX.	Paclitaxel	184-187	BCL2 like 1	Homo sapiens	87-93
30013393-9	2018	Expression of Bax and caspase-3 was significantly downregulated, whereas expression of Bcl-xL, P-glycoprotein, multidrug resistance-associated protein and VEGF was increased in rMKN45-PTX.	Paclitaxel	184-187	vascular endothelial growth factor A	Homo sapiens	155-159
29777711-0	2018	UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.	Paclitaxel	13-23	ATP binding cassette subfamily B member 1	Homo sapiens	69-74
29777711-6	2018	Mechanistically, UCA1 silencing induced PTX sensitivity of SKOV3/PTX and HeyA-8/PTX cells by de-repressing ABCB1 through sponging miR-129.	Paclitaxel	40-43	ATP binding cassette subfamily B member 1	Homo sapiens	107-112
29777711-7	2018	Collectively, our study elaborated a novel UCA1/miR-129/ABCB1 regulatory axis underlying PTX resistance of OC cells, providing a potential therapeutic target for OC.	Paclitaxel	89-92	ATP binding cassette subfamily B member 1	Homo sapiens	56-61
30094097-8	2018	In conclusion, we demonstrated that the disruption of this pathway by MEK inhibitors suppresses oxaliplatin-, paclitaxel-, vincristine-, and bortezomib-induced neuropathy.	Paclitaxel	110-120	mitogen-activated protein kinase kinase 7	Homo sapiens	70-73
30019863-9	2018	CONCLUSIONS: Our results confirmed a better response of HER2-overexpressing breast cancer to paclitaxel at the miRNA level.	Paclitaxel	93-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
30094097-7	2018	In addition, treatment with oxaliplatin, paclitaxel, vincristine, or bortezomib enhanced ERK1/2 and c-Jun N-terminal kinase (JNK) phosphorylation in the spinal cord lumbar segments 4-6, and when combined with trametinib, can prevent chemotherapy-induced neuropathy via the suppression of ERK1/2 activation, but does not affect JNK activation.	Paclitaxel	41-51	mitogen-activated protein kinase 3	Homo sapiens	89-95
30094097-7	2018	In addition, treatment with oxaliplatin, paclitaxel, vincristine, or bortezomib enhanced ERK1/2 and c-Jun N-terminal kinase (JNK) phosphorylation in the spinal cord lumbar segments 4-6, and when combined with trametinib, can prevent chemotherapy-induced neuropathy via the suppression of ERK1/2 activation, but does not affect JNK activation.	Paclitaxel	41-51	mitogen-activated protein kinase 8	Homo sapiens	100-123
30094097-7	2018	In addition, treatment with oxaliplatin, paclitaxel, vincristine, or bortezomib enhanced ERK1/2 and c-Jun N-terminal kinase (JNK) phosphorylation in the spinal cord lumbar segments 4-6, and when combined with trametinib, can prevent chemotherapy-induced neuropathy via the suppression of ERK1/2 activation, but does not affect JNK activation.	Paclitaxel	41-51	mitogen-activated protein kinase 8	Homo sapiens	125-128
30094097-7	2018	In addition, treatment with oxaliplatin, paclitaxel, vincristine, or bortezomib enhanced ERK1/2 and c-Jun N-terminal kinase (JNK) phosphorylation in the spinal cord lumbar segments 4-6, and when combined with trametinib, can prevent chemotherapy-induced neuropathy via the suppression of ERK1/2 activation, but does not affect JNK activation.	Paclitaxel	41-51	mitogen-activated protein kinase 3	Homo sapiens	288-294
29445928-13	2018	CONCLUSIONS: This study confirmed the therapeutic impact of lapatinib, trastuzumab, and paclitaxel therapy for each ER- and ER+ subgroup of HER2+ patients.	Paclitaxel	88-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	140-144
30094097-7	2018	In addition, treatment with oxaliplatin, paclitaxel, vincristine, or bortezomib enhanced ERK1/2 and c-Jun N-terminal kinase (JNK) phosphorylation in the spinal cord lumbar segments 4-6, and when combined with trametinib, can prevent chemotherapy-induced neuropathy via the suppression of ERK1/2 activation, but does not affect JNK activation.	Paclitaxel	41-51	mitogen-activated protein kinase 8	Homo sapiens	327-330
29970562-9	2018	Adv-siSurv infection reduced survivin, procaspase-9, and procaspase-3 levels in paclitaxel-treated MCF-7 cells.	Paclitaxel	80-90	caspase 3	Homo sapiens	57-69
29683800-12	2018	Western blot analysis indicated that P-gp, Bcl-2, and PARP protein were more abundant in MGC803/PTX and SW620/PTX cells compared with MGC803 and SW620 cells, whereas Bax protein levels were lower in resistant cells.	Paclitaxel	96-99	BCL2 apoptosis regulator	Homo sapiens	43-48
29683800-12	2018	Western blot analysis indicated that P-gp, Bcl-2, and PARP protein were more abundant in MGC803/PTX and SW620/PTX cells compared with MGC803 and SW620 cells, whereas Bax protein levels were lower in resistant cells.	Paclitaxel	110-113	BCL2 apoptosis regulator	Homo sapiens	43-48
29635137-5	2018	The complex between Ptx and Peps (Ptx-Peps) was prepared by mixing an ethanol solution of Ptx and an aqueous solution of Peps, followed by lyophilization.	Paclitaxel	20-23	leucine aminopeptidase 3	Homo sapiens	28-32
29744672-0	2018	Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study.	Paclitaxel	107-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-166
29550143-4	2018	Moreover, paclitaxel is a substrate for p-glycoprotein, which shows a decreased accumulation of drug within the cancer cell expressed by a p-glycoprotein.	Paclitaxel	10-20	ATP binding cassette subfamily B member 1	Homo sapiens	40-54
29550143-4	2018	Moreover, paclitaxel is a substrate for p-glycoprotein, which shows a decreased accumulation of drug within the cancer cell expressed by a p-glycoprotein.	Paclitaxel	10-20	ATP binding cassette subfamily B member 1	Homo sapiens	139-153
29550143-5	2018	Therefore, the purpose of this study is to prepare a paclitaxel-loaded liposome and evaluate the effect of d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) as an inhibitor of p-glycoprotein on the paclitaxel-loaded liposome.	Paclitaxel	53-63	ATP binding cassette subfamily B member 1	Homo sapiens	187-201
29635137-5	2018	The complex between Ptx and Peps (Ptx-Peps) was prepared by mixing an ethanol solution of Ptx and an aqueous solution of Peps, followed by lyophilization.	Paclitaxel	20-23	leucine aminopeptidase 3	Homo sapiens	34-42
29635137-5	2018	The complex between Ptx and Peps (Ptx-Peps) was prepared by mixing an ethanol solution of Ptx and an aqueous solution of Peps, followed by lyophilization.	Paclitaxel	20-23	leucine aminopeptidase 3	Homo sapiens	38-42
29635137-5	2018	The complex between Ptx and Peps (Ptx-Peps) was prepared by mixing an ethanol solution of Ptx and an aqueous solution of Peps, followed by lyophilization.	Paclitaxel	34-37	leucine aminopeptidase 3	Homo sapiens	28-32
29635137-5	2018	The complex between Ptx and Peps (Ptx-Peps) was prepared by mixing an ethanol solution of Ptx and an aqueous solution of Peps, followed by lyophilization.	Paclitaxel	34-37	leucine aminopeptidase 3	Homo sapiens	38-42
29727353-11	2018	Only paclitaxel-treated ovarian cancer cells showed decrease in expression of p53.	Paclitaxel	5-15	tumor protein p53	Homo sapiens	78-81
29738245-8	2018	In an intraperitoneal tumor xenograft model mimicking late-stage metastatic cervical cancer, the LPQDEA/DNA vector with TRAIL suicide gene exerted strong tumor inhibition as effective as paclitaxel, the first-line anticancer drug, but gave much less tumor relapse and much longer survival than the clinical chemotherapy drugs, irinotecan and paclitaxel.	Paclitaxel	342-352	TNF superfamily member 10	Homo sapiens	120-125
29540562-5	2018	Complementary genetic and pharmacologic approaches revealed that the antiallodynic effects of each drug require both cannabinoid receptors, CB1 and CB2 MJN110 reduced paclitaxel-mediated increased expression of monocyte chemoattractant protein-1 (MCP-1, CCL2) and phospho-p38 MAPK in dorsal root ganglia as well as MCP-1 in spinal dorsal horn.	Paclitaxel	167-177	cannabinoid receptor 2 (macrophage)	Mus musculus	148-151
29938948-5	2018	In vivo release and the pharmacokinetics study in mice showed that the elimination half-life ( t1/2 beta ) and area under curve (AUC) of PTX/NMs were significantly higher than those of PTX/polyoxyethylene castor oil (PTX/PCO), and less clearance (CL) of PTX/NMs was also observed.	Paclitaxel	137-140	brachyury, T-box transcription factor T	Mus musculus	95-104
29715459-0	2018	Mesenchymal stem cells drive paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells via paracrine of neuregulin 1.	Paclitaxel	29-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-59
29715459-1	2018	We had previously demonstrated that increased expression of ErbB3 is required for ErbB2-mediated paclitaxel resistance in breast cancer cells.	Paclitaxel	97-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-87
29715459-2	2018	In the present study, we have explored the possible role of mesenchymal stem cells (MSCs) in regulating the paclitaxel-sensitivity of ErbB2/ErbB3-coexpressing breast cancer cells.	Paclitaxel	108-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-139
29715459-4	2018	Coculture or treatment with conditioned medium of MSCs not only decreases the anti-proliferation effect of paclitaxel on ErbB2/ErbB3-coexpressing breast cancer cells, but also significantly inhibits paclitaxel-induced apoptosis.	Paclitaxel	107-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-126
29715459-5	2018	We further demonstrate that this MSCs-drived paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells could be attributed to upregulation of Survivin via paracrine effect of NRG-1/ErbB3/PI-3K/Akt signaling, as either specific knockdown expression of ErbB3, or blocking of downstream PI-3K/Akt signaling, or specific inhibition of Survivin can completely reverse this effect.	Paclitaxel	45-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-75
29715459-5	2018	We further demonstrate that this MSCs-drived paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells could be attributed to upregulation of Survivin via paracrine effect of NRG-1/ErbB3/PI-3K/Akt signaling, as either specific knockdown expression of ErbB3, or blocking of downstream PI-3K/Akt signaling, or specific inhibition of Survivin can completely reverse this effect.	Paclitaxel	45-55	AKT serine/threonine kinase 1	Homo sapiens	205-208
29715459-5	2018	We further demonstrate that this MSCs-drived paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells could be attributed to upregulation of Survivin via paracrine effect of NRG-1/ErbB3/PI-3K/Akt signaling, as either specific knockdown expression of ErbB3, or blocking of downstream PI-3K/Akt signaling, or specific inhibition of Survivin can completely reverse this effect.	Paclitaxel	45-55	AKT serine/threonine kinase 1	Homo sapiens	302-305
29715459-6	2018	Moreover, targeted knockdown of NRG-1 expression in MSCs abrogates theirs effect on paclitaxel sensitivity of ErbB2/ErbB3-coexpressing breast cancer cells.	Paclitaxel	84-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-115
29715459-7	2018	Taken together, our study indicate that paracrine of NRG-1 by MSCs induces paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells through PI-3K/Akt signaling-dependent upregulation of Survivin.	Paclitaxel	75-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-105
29715459-7	2018	Taken together, our study indicate that paracrine of NRG-1 by MSCs induces paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells through PI-3K/Akt signaling-dependent upregulation of Survivin.	Paclitaxel	75-85	AKT serine/threonine kinase 1	Homo sapiens	159-162
29715459-8	2018	Our findings suggest that simultaneously targeting mesenchymal stem cells in tumor microenvironment may be a novel strategy to overcome paclitaxel resistance in patients with ErbB2/ErbB3-coexpressing breast cancer.	Paclitaxel	136-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-180
29549161-7	2018	Istiratumab (MM-141), a novel bispecific antibody that blocks IGF-1R and ErbB3, restored the activity of paclitaxel and gemcitabine in the presence of IGF-1 and HRG in vitro Dual IGF-1R/ErbB3 blocking enhanced chemosensitivity through inhibition of AKT phosphorylation and promotion of IGF-1R and ErbB3 degradation.	Paclitaxel	105-115	insulin like growth factor 1	Homo sapiens	62-67
29766327-13	2018	The resistant cell lines demonstrated less accumulation of intracellular doxorubicin, and were cross-resistant to other Pgp client drugs: bortezomib, doxorubicin, and paclitaxel, but not cisplatin.	Paclitaxel	167-177	ATP binding cassette subfamily B member 1	Homo sapiens	120-123
29641982-2	2018	However, the effectiveness of PTX is limited by resistance mechanisms mediated in part by upregulation of the anti-apoptotic BCL-2 and P-glycoprotein (P-gp).	Paclitaxel	30-33	B cell leukemia/lymphoma 2	Mus musculus	125-130
29577893-2	2018	Thus far, evidence has suggested that transient receptor potential vanilloid-1 (TRPV1) has a key role in the chronic neuropathy induced by paclitaxel.	Paclitaxel	139-149	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	38-78
29577893-2	2018	Thus far, evidence has suggested that transient receptor potential vanilloid-1 (TRPV1) has a key role in the chronic neuropathy induced by paclitaxel.	Paclitaxel	139-149	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	80-85
29577893-9	2018	In addition, TRPV1-positive sensory fibre ablation (using resiniferatoxin, 200 microg/kg, s.c.) reduced visceral nociception and mechanical or heat hypersensitivity caused by paclitaxel injection.	Paclitaxel	175-185	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	13-18
29577893-10	2018	Similarly, TRPV1 deficient mice showed a pronounced reduction in mechanical allodynia to paclitaxel acute injection and did not develop heat hypersensitivity.	Paclitaxel	89-99	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	11-16
29577893-11	2018	Moreover, 24 h after its injection, paclitaxel induced chemical hypersensitivity to capsaicin (a TRPV1 agonist, 0.01 nmol/site) and increased TRPV1 immunoreactivity in the dorsal root ganglion and sciatic nerve.	Paclitaxel	36-46	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	97-102
29577893-11	2018	Moreover, 24 h after its injection, paclitaxel induced chemical hypersensitivity to capsaicin (a TRPV1 agonist, 0.01 nmol/site) and increased TRPV1 immunoreactivity in the dorsal root ganglion and sciatic nerve.	Paclitaxel	36-46	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	142-147
29577893-12	2018	In conclusion, TRPV1 is involved in mechanical and heat hypersensitivity and spontaneous-pain behaviour induced 24 h after a single paclitaxel injection.	Paclitaxel	132-142	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	15-20
29396664-9	2018	CONCLUSIONS: Eighty percent of HR-negative, HER2-positive breast cancers achieve pCR with paclitaxel/FEC neoadjuvant chemotherapy administered concomitantly with pertuzumab and trastuzumab.	Paclitaxel	90-100	nuclear receptor subfamily 4 group A member 1	Homo sapiens	31-33
29396664-9	2018	CONCLUSIONS: Eighty percent of HR-negative, HER2-positive breast cancers achieve pCR with paclitaxel/FEC neoadjuvant chemotherapy administered concomitantly with pertuzumab and trastuzumab.	Paclitaxel	90-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
29532357-4	2018	The advantage of this DDDS is that the bulk incorporation of fluorescein diacetate (FDAc) (model drug for paclitaxel (PTX)) via spray coating enhanced the subsequent cleavable surface coupling of vascular endothelial growth factor (VEGF) via the crosslinker bissulfosuccinimidyl suberate (BS3).	Paclitaxel	106-116	vascular endothelial growth factor A	Homo sapiens	196-230
29532357-4	2018	The advantage of this DDDS is that the bulk incorporation of fluorescein diacetate (FDAc) (model drug for paclitaxel (PTX)) via spray coating enhanced the subsequent cleavable surface coupling of vascular endothelial growth factor (VEGF) via the crosslinker bissulfosuccinimidyl suberate (BS3).	Paclitaxel	106-116	vascular endothelial growth factor A	Homo sapiens	232-236
29532357-4	2018	The advantage of this DDDS is that the bulk incorporation of fluorescein diacetate (FDAc) (model drug for paclitaxel (PTX)) via spray coating enhanced the subsequent cleavable surface coupling of vascular endothelial growth factor (VEGF) via the crosslinker bissulfosuccinimidyl suberate (BS3).	Paclitaxel	118-121	vascular endothelial growth factor A	Homo sapiens	196-230
29567488-4	2018	In this study, we showed that activation of nuclear factor-kappaB (NF-kappaB) is significantly higher in therapy-resistant EOC cells compared to chemosensitive counterparts, which was positively associated with resistance to cisplatin, carboplatin, paclitaxel and erlotinib.	Paclitaxel	249-259	nuclear factor kappa B subunit 1	Homo sapiens	44-65
29567488-4	2018	In this study, we showed that activation of nuclear factor-kappaB (NF-kappaB) is significantly higher in therapy-resistant EOC cells compared to chemosensitive counterparts, which was positively associated with resistance to cisplatin, carboplatin, paclitaxel and erlotinib.	Paclitaxel	249-259	nuclear factor kappa B subunit 1	Homo sapiens	67-76
29620264-0	2018	Pegylated liposomal-paclitaxel induces ovarian cancer cell apoptosis via TNF-induced ERK/AKT signaling pathway.	Paclitaxel	20-30	tumor necrosis factor	Mus musculus	73-76
29620264-0	2018	Pegylated liposomal-paclitaxel induces ovarian cancer cell apoptosis via TNF-induced ERK/AKT signaling pathway.	Paclitaxel	20-30	mitogen-activated protein kinase 1	Mus musculus	85-88
29620264-0	2018	Pegylated liposomal-paclitaxel induces ovarian cancer cell apoptosis via TNF-induced ERK/AKT signaling pathway.	Paclitaxel	20-30	thymoma viral proto-oncogene 1	Mus musculus	89-92
29658612-6	2018	Markedly, an increased expression of let-7d-3p (also known as let-7d-3*) was associated with positive response to carboplatin/paclitaxel treatment in ovarian cancer patients.	Paclitaxel	126-136	microRNA let-7d	Homo sapiens	37-43
29658612-6	2018	Markedly, an increased expression of let-7d-3p (also known as let-7d-3*) was associated with positive response to carboplatin/paclitaxel treatment in ovarian cancer patients.	Paclitaxel	126-136	microRNA let-7d	Homo sapiens	62-68
29658612-12	2018	In summary, our findings showed that inhibition of let-7d-3 activates apoptosis and that its upregulation is associated with a positive response of ovarian cancer patients to carboplatin/paclitaxel chemotherapy.	Paclitaxel	187-197	microRNA let-7d	Homo sapiens	51-57
29928353-12	2018	The expression levels of two proteins associated with paclitaxel resistance, Plxdc2 and CK7, were further validated by western blotting, which revealed that they were upregulated in the paclitaxel-resistant tissues.	Paclitaxel	54-64	plexin domain containing 2	Homo sapiens	77-83
29928353-12	2018	The expression levels of two proteins associated with paclitaxel resistance, Plxdc2 and CK7, were further validated by western blotting, which revealed that they were upregulated in the paclitaxel-resistant tissues.	Paclitaxel	54-64	keratin 7	Homo sapiens	88-91
29928353-12	2018	The expression levels of two proteins associated with paclitaxel resistance, Plxdc2 and CK7, were further validated by western blotting, which revealed that they were upregulated in the paclitaxel-resistant tissues.	Paclitaxel	186-196	plexin domain containing 2	Homo sapiens	77-83
29928353-12	2018	The expression levels of two proteins associated with paclitaxel resistance, Plxdc2 and CK7, were further validated by western blotting, which revealed that they were upregulated in the paclitaxel-resistant tissues.	Paclitaxel	186-196	keratin 7	Homo sapiens	88-91
29928353-14	2018	Plxdc2 and CK7 may be potential makers for distinguishing patients with paclitaxel-resistant EOC from those with paclitaxel-sensitive EOC.	Paclitaxel	72-82	plexin domain containing 2	Homo sapiens	0-6
29928353-14	2018	Plxdc2 and CK7 may be potential makers for distinguishing patients with paclitaxel-resistant EOC from those with paclitaxel-sensitive EOC.	Paclitaxel	72-82	keratin 7	Homo sapiens	11-14
29928353-14	2018	Plxdc2 and CK7 may be potential makers for distinguishing patients with paclitaxel-resistant EOC from those with paclitaxel-sensitive EOC.	Paclitaxel	113-123	plexin domain containing 2	Homo sapiens	0-6
29928353-14	2018	Plxdc2 and CK7 may be potential makers for distinguishing patients with paclitaxel-resistant EOC from those with paclitaxel-sensitive EOC.	Paclitaxel	113-123	keratin 7	Homo sapiens	11-14
29684847-5	2018	RESULTS: Cell lines and tumor cells p53+, p53- revealed a significant decrease in cell survival after camptothecin, paclitaxel, cisplatin treatment, compared to the control group (p &lt; 0.01).	Paclitaxel	116-126	tumor protein p53	Homo sapiens	42-45
29684847-6	2018	In p53+ group, the expression of Ser20 significantly increased after camptothecin and paclitaxel (p &lt; 0.05).	Paclitaxel	86-96	tumor protein p53	Homo sapiens	3-6
29219949-0	2018	A miRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial-mesenchymal transition.	Paclitaxel	50-60	cathepsin L	Homo sapiens	13-24
29219949-4	2018	A549/TAX cells were paclitaxel-resistant A549 cells overexpressing CTSL and characterized by epithelial-mesenchymal transition (EMT).	Paclitaxel	20-30	cathepsin L	Homo sapiens	67-71
29219949-7	2018	Overexpression of CTSL in A549 cells significantly decreased the expression of miRNA-200c, and reduced their sensitivity to paclitaxel and induced EMT, but these effects were reversed by miRNA-200c, whereas knockdown of CTSL in A549/TAX cells attenuated paclitaxel resistance and remarkably inhibited EMT, but the inhibition of miRNA-200c could reverse these effects.	Paclitaxel	124-134	cathepsin L	Homo sapiens	18-22
29219949-7	2018	Overexpression of CTSL in A549 cells significantly decreased the expression of miRNA-200c, and reduced their sensitivity to paclitaxel and induced EMT, but these effects were reversed by miRNA-200c, whereas knockdown of CTSL in A549/TAX cells attenuated paclitaxel resistance and remarkably inhibited EMT, but the inhibition of miRNA-200c could reverse these effects.	Paclitaxel	254-264	cathepsin L	Homo sapiens	18-22
29219949-8	2018	Therefore, miRNA-200c may be involved in regulating paclitaxel resistance through CTSL-mediated EMT in A549 cells, and CTSL and miRNA-200c are reciprocally linked in a feedback loop.	Paclitaxel	52-62	cathepsin L	Homo sapiens	82-86
29917187-3	2018	This study aimed to explore the mechanism of paclitaxel on the inhibition of bladder cancer cell proliferation by applying paclitaxel combined with miR-448 on bladder cancer cells.	Paclitaxel	45-55	microRNA 448	Homo sapiens	148-155
29917187-12	2018	The expression of Bcl-2 protein in paclitaxel group and miR-448 mimic group was significantly lower than that in control group and higher than paclitaxel combined with miR-448 mimic group (p<0.05).	Paclitaxel	35-45	BCL2 apoptosis regulator	Homo sapiens	18-23
29917187-12	2018	The expression of Bcl-2 protein in paclitaxel group and miR-448 mimic group was significantly lower than that in control group and higher than paclitaxel combined with miR-448 mimic group (p<0.05).	Paclitaxel	143-153	BCL2 apoptosis regulator	Homo sapiens	18-23
29917187-13	2018	CONCLUSIONS: Paclitaxel combined with miR-448 promoted EJ cell apoptosis and inhibited cell proliferation by suppressing Bcl-2 gene expression.	Paclitaxel	13-23	BCL2 apoptosis regulator	Homo sapiens	121-126
29696771-5	2018	Serum albumin (P = .002), paclitaxel dose (P = .001), and body surface area (P = .006) were statistically significantly associated with a positive rTNS change (worsening neuropathy).	Paclitaxel	26-36	tensin 1	Rattus norvegicus	147-151
29693189-0	2018	Gallic acid sensitizes paclitaxel-resistant human ovarian carcinoma cells through an increase in reactive oxygen species and subsequent downregulation of ERK activation.	Paclitaxel	23-33	mitogen-activated protein kinase 1	Homo sapiens	154-157
29693189-4	2018	Taken together, these results indicate that GA sensitizes PTX-resistant ovarian carcinoma cells via the ROS-mediated inactivation of ERK, and suggest that GA could represent a useful co-adjuvant to PTX in ovarian carcinoma treatment.	Paclitaxel	58-61	mitogen-activated protein kinase 1	Homo sapiens	133-136
29684847-5	2018	RESULTS: Cell lines and tumor cells p53+, p53- revealed a significant decrease in cell survival after camptothecin, paclitaxel, cisplatin treatment, compared to the control group (p &lt; 0.01).	Paclitaxel	116-126	tumor protein p53	Homo sapiens	36-39
29660653-8	2018	The increased levels of IL-1beta or TBARS induced by pretreatment with PTX or PSNL were reduced by rosuvastatin.	Paclitaxel	71-74	interleukin 1 beta	Mus musculus	24-32
29861445-6	2018	The self-assemblies were capable of solubilising up to 0.698 mg/mL of paclitaxel (700-fold improvement) with 0.012 mg/mL of cytochrome C also attached onto the hybrid iron oxide-gold nanoparticles (HNPs) within the hydrophobic core.	Paclitaxel	70-80	cytochrome c, somatic	Homo sapiens	124-136
29910679-5	2018	The PTX resistant cells showed stronger cell proliferation ability by exhibiting the upregulation of CENPF, CDC6, MCM3, CLSPN and SMC1A expression.	Paclitaxel	4-7	centromere protein F	Homo sapiens	101-106
29899826-9	2018	This conclusion is supported by data showing that BI6727/paclitaxel-co-treatment stabilizes FBW7, a component of SCF-type ubiquitin ligases that bind and regulate key modulators of cell division and growth including MCL-1 and Cyclin E. This identification of a novel synthetic lethality of PLK1 inhibitors and a microtubule-stabilizing drug has important implications for developing PLK1 inhibitor-based combination treatments in CCNE1-amplified HGSOC cells.	Paclitaxel	57-67	F-box and WD repeat domain containing 7	Homo sapiens	92-96
29899843-4	2018	In this study, we found that pro-survival protein Bcl-2 is upregulated in paclitaxel resistant cells, potentially contributing to chemotherapy resistance.	Paclitaxel	74-84	BCL2 apoptosis regulator	Homo sapiens	50-55
29899843-6	2018	The Nur77 derived peptide preferentially induced apoptosis in paclitaxel-resistant cancer cells with high expression of Bcl-2.	Paclitaxel	62-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	4-9
29899843-6	2018	The Nur77 derived peptide preferentially induced apoptosis in paclitaxel-resistant cancer cells with high expression of Bcl-2.	Paclitaxel	62-72	BCL2 apoptosis regulator	Homo sapiens	120-125
29899843-8	2018	The Nur77 peptide strongly suppressed the growth of paclitaxel-resistant lung cancer cells in a zebrafish xenograft tumor model.	Paclitaxel	52-62	nuclear receptor subfamily 4, group A, member 1	Danio rerio	4-9
29861863-4	2018	Further, high salt induced P-glycoprotein (P-gp) mediated paclitaxel drug resistance in breast cancer cells.	Paclitaxel	58-68	ATP binding cassette subfamily B member 1	Homo sapiens	27-41
29861863-4	2018	Further, high salt induced P-glycoprotein (P-gp) mediated paclitaxel drug resistance in breast cancer cells.	Paclitaxel	58-68	ATP binding cassette subfamily B member 1	Homo sapiens	43-47
29910679-5	2018	The PTX resistant cells showed stronger cell proliferation ability by exhibiting the upregulation of CENPF, CDC6, MCM3, CLSPN and SMC1A expression.	Paclitaxel	4-7	cell division cycle 6	Homo sapiens	108-112
29910679-6	2018	Furthermore, DUSP1 and DUSP5 expression was significantly downregulated in PTX resistant cells.	Paclitaxel	75-78	dual specificity phosphatase 1	Homo sapiens	13-18
29808798-5	2018	Subsequently, we used SIRT1 siRNA to knockdown the expression of SIRT1, and then measured cell proliferation, cell apoptosis rate, cell cycle distribution, and expression levels of Bcl-2 and Bax in PTX-sensitive Hela cell line, PTX-resistant Hela and Sila-resistant cell lines.	Paclitaxel	198-201	BCL2 apoptosis regulator	Homo sapiens	181-186
29808798-5	2018	Subsequently, we used SIRT1 siRNA to knockdown the expression of SIRT1, and then measured cell proliferation, cell apoptosis rate, cell cycle distribution, and expression levels of Bcl-2 and Bax in PTX-sensitive Hela cell line, PTX-resistant Hela and Sila-resistant cell lines.	Paclitaxel	198-201	BCL2 associated X, apoptosis regulator	Homo sapiens	191-194
29723165-10	2018	Moreover, the results showed that p-JNK and Caspase 3 expression were significantly increased in IL-22 knockdown A549/PTX cells, while Bcl-2 expression was significantly decreased.	Paclitaxel	118-121	caspase 3	Homo sapiens	44-53
29760419-0	2018	PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.	Paclitaxel	82-92	ATP binding cassette subfamily B member 1	Homo sapiens	33-37
29760419-0	2018	PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.	Paclitaxel	82-92	BCL2 apoptosis regulator	Homo sapiens	42-46
29760419-6	2018	Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively.	Paclitaxel	159-169	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
29760419-6	2018	Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively.	Paclitaxel	159-169	BCL2 apoptosis regulator	Homo sapiens	63-67
29760419-6	2018	Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively.	Paclitaxel	191-201	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
29760419-6	2018	Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively.	Paclitaxel	191-201	BCL2 apoptosis regulator	Homo sapiens	63-67
29608845-0	2018	Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.	Paclitaxel	84-94	folate hydrolase 1	Homo sapiens	0-34
29608845-6	2018	Herein, a novel DUPA-PTX conjugate is developed using DUPA as the targeting ligand to deliver PTX specifically for treatment of PSMA expressing PCa.	Paclitaxel	21-24	folate hydrolase 1	Homo sapiens	128-132
29608845-6	2018	Herein, a novel DUPA-PTX conjugate is developed using DUPA as the targeting ligand to deliver PTX specifically for treatment of PSMA expressing PCa.	Paclitaxel	94-97	folate hydrolase 1	Homo sapiens	128-132
29608845-7	2018	The targeting ligand DUPA enhances the transport capability and selectivity of PTX to tumor cells via PSMA mediated endocytosis.	Paclitaxel	79-82	folate hydrolase 1	Homo sapiens	102-106
29608845-9	2018	The DUPA-PTX conjugate exhibits potent cytotoxicity in PSMA expressing cell lines and induces a complete cessation of tumor growth with no obvious toxicity.	Paclitaxel	9-12	folate hydrolase 1	Homo sapiens	55-59
29723165-0	2018	Interleukin-22 (IL-22) Regulates Apoptosis of Paclitaxel-Resistant Non-Small Cell Lung Cancer Cells Through C-Jun N-Terminal Kinase Signaling Pathway.	Paclitaxel	46-56	mitogen-activated protein kinase 8	Homo sapiens	108-131
29723165-10	2018	Moreover, the results showed that p-JNK and Caspase 3 expression were significantly increased in IL-22 knockdown A549/PTX cells, while Bcl-2 expression was significantly decreased.	Paclitaxel	118-121	mitogen-activated protein kinase 8	Homo sapiens	36-39
29723165-11	2018	CONCLUSIONS IL-22 is involved in A549 cell resistance to PTX through regulating cell apoptosis via the JNK signaling pathway.	Paclitaxel	57-60	mitogen-activated protein kinase 8	Homo sapiens	103-106
28509576-0	2018	HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines.	Paclitaxel	54-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
29616103-0	2018	Paclitaxel increases the sensitivity of lung cancer cells to lobaplatin via PI3K/Akt pathway.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	81-84
29565447-0	2018	CAFs enhance paclitaxel resistance by inducing EMT through the IL-6/JAK2/STAT3 pathway.	Paclitaxel	13-23	interleukin 6	Homo sapiens	63-67
29771413-9	2018	Subsequently, we detected decreased expression of Notch1 in PER3 over-expressed paclitaxel-resistant cell lines by Western blot; this attenuated resistance in paclitaxel-resistant cell lines.	Paclitaxel	80-90	notch receptor 1	Homo sapiens	50-56
29771413-9	2018	Subsequently, we detected decreased expression of Notch1 in PER3 over-expressed paclitaxel-resistant cell lines by Western blot; this attenuated resistance in paclitaxel-resistant cell lines.	Paclitaxel	159-169	notch receptor 1	Homo sapiens	50-56
29771413-10	2018	CONCLUSIONS: PER3 can induce sensitivity of paclitaxel-resistant cell lines to paclitaxel by inhibiting the expression of Notch1.	Paclitaxel	44-54	notch receptor 1	Homo sapiens	122-128
29771413-10	2018	CONCLUSIONS: PER3 can induce sensitivity of paclitaxel-resistant cell lines to paclitaxel by inhibiting the expression of Notch1.	Paclitaxel	79-89	notch receptor 1	Homo sapiens	122-128
29660811-0	2018	Natural Borneol Enhances Paclitaxel-Induced Apoptosis of ESCC Cells by Inactivation of the PI3K/AKT.	Paclitaxel	25-35	AKT serine/threonine kinase 1	Homo sapiens	96-99
29660811-6	2018	The molecular mechanism by western blotting elucidated that combination treatment with PTX and NB significantly activated apoptotic pathway by triggering upregulation of cleaved caspase-3 expression and downregulation of survivin and P-AKT expression.	Paclitaxel	87-90	AKT serine/threonine kinase 1	Homo sapiens	236-239
29660811-7	2018	These results demonstrated that NB could strongly potentiate PTX-induced apoptosis in ESCC cells through suppressing PI3K/AKT pathway.	Paclitaxel	61-64	AKT serine/threonine kinase 1	Homo sapiens	122-125
29874151-1	2018	AIM: This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer.	Paclitaxel	98-108	epidermal growth factor receptor	Homo sapiens	56-60
29874151-1	2018	AIM: This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer.	Paclitaxel	110-113	epidermal growth factor receptor	Homo sapiens	56-60
29565447-0	2018	CAFs enhance paclitaxel resistance by inducing EMT through the IL-6/JAK2/STAT3 pathway.	Paclitaxel	13-23	signal transducer and activator of transcription 3	Homo sapiens	73-78
29565447-22	2018	These results demonstrated that CAFs highly secreted IL-6 and promoted beta-TGF-mediated EMT in ovarian cancer via the JAK2/STAT3 pathway, leading to inhibited apoptosis and subsequent paclitaxel resistance.	Paclitaxel	185-195	interleukin 6	Homo sapiens	53-57
29616103-1	2018	The effect of paclitaxel combined with lobaplatin on the sensitivity of lung cancer cell line NCI-H446 through influencing the phosphatidylinositol 3-kinase (PI3K)/Akt pathway was investigated.	Paclitaxel	14-24	AKT serine/threonine kinase 1	Homo sapiens	164-167
29616103-4	2018	Finally, the effect of paclitaxel on PI3K/Akt pathway was detected via western blotting.	Paclitaxel	23-33	AKT serine/threonine kinase 1	Homo sapiens	42-45
29616103-13	2018	Moreover, paclitaxel can enhance the effect of lobaplatin on lung cancer cells and reduce the drug resistance through inhibiting PI3K/Akt pathway.	Paclitaxel	10-20	AKT serine/threonine kinase 1	Homo sapiens	134-137
29409974-0	2018	Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.	Paclitaxel	118-128	microRNA 542	Homo sapiens	19-26
29369966-5	2018	We demonstrate that global Epac1-knockout (Epac1-/-) male and female mice are protected against paclitaxel-induced mechanical allodynia.	Paclitaxel	96-106	Rap guanine nucleotide exchange factor (GEF) 3	Mus musculus	27-32
29369966-5	2018	We demonstrate that global Epac1-knockout (Epac1-/-) male and female mice are protected against paclitaxel-induced mechanical allodynia.	Paclitaxel	96-106	Rap guanine nucleotide exchange factor (GEF) 3	Mus musculus	43-48
29369966-8	2018	Notably, mice with cell-specific deletion of Epac1 in Nav1.8-positive neurons (N-Epac1-/-) also show reduced paclitaxel-induced mechanical allodynia, astrocyte activation, and IENF loss, indicating that CIPN develops downstream of Epac1 activation in nociceptors.	Paclitaxel	109-119	Rap guanine nucleotide exchange factor (GEF) 3	Mus musculus	45-50
29369966-8	2018	Notably, mice with cell-specific deletion of Epac1 in Nav1.8-positive neurons (N-Epac1-/-) also show reduced paclitaxel-induced mechanical allodynia, astrocyte activation, and IENF loss, indicating that CIPN develops downstream of Epac1 activation in nociceptors.	Paclitaxel	109-119	sodium channel, voltage-gated, type X, alpha	Mus musculus	54-60
29369966-9	2018	The Epac-inhibitor ESI-09 reversed established paclitaxel-induced mechanical allodynia in wild-type mice even when dosing started 10 days after completion of paclitaxel treatment.	Paclitaxel	47-57	Rap guanine nucleotide exchange factor (GEF) 3	Mus musculus	4-8
29369966-9	2018	The Epac-inhibitor ESI-09 reversed established paclitaxel-induced mechanical allodynia in wild-type mice even when dosing started 10 days after completion of paclitaxel treatment.	Paclitaxel	158-168	Rap guanine nucleotide exchange factor (GEF) 3	Mus musculus	4-8
29409974-10	2018	Thus, miR-542-3p-replacement therapy is an excellent approach to overcome HER3-mediated paclitaxel resistance and significantly enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.	Paclitaxel	163-173	microRNA 542	Homo sapiens	6-13
29409974-10	2018	Thus, miR-542-3p-replacement therapy is an excellent approach to overcome HER3-mediated paclitaxel resistance and significantly enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.	Paclitaxel	163-173	erb-b2 receptor tyrosine kinase 2	Homo sapiens	182-186
29409974-0	2018	Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.	Paclitaxel	118-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
29410067-9	2018	In addition, the Taxol-R cells that acquired the resistance to paclitaxel through induction were characterized with higher expressions of proteasomes but a lower expression of HIF-1 signaling genes.	Paclitaxel	17-22	hypoxia inducible factor 1 subunit alpha	Homo sapiens	176-181
29410067-9	2018	In addition, the Taxol-R cells that acquired the resistance to paclitaxel through induction were characterized with higher expressions of proteasomes but a lower expression of HIF-1 signaling genes.	Paclitaxel	63-73	hypoxia inducible factor 1 subunit alpha	Homo sapiens	176-181
29410067-10	2018	Furthermore, we showed that carfilzomib (CFZ), a proteasome inhibitor, could attenuate the paclitaxel resistance in Taxol-R cancer cells through activating the HIF-1 signaling.	Paclitaxel	91-101	hypoxia inducible factor 1 subunit alpha	Homo sapiens	160-165
29409974-6	2018	Consistently, miR-542-3p mimic was much more effective than miR-203 mimic not only in inhibition of Survivin, but also in enhancement of paclitaxel-induced apoptosis in HER2-overexpressing breast cancer cells.	Paclitaxel	137-147	microRNA 542	Homo sapiens	14-21
29410067-10	2018	Furthermore, we showed that carfilzomib (CFZ), a proteasome inhibitor, could attenuate the paclitaxel resistance in Taxol-R cancer cells through activating the HIF-1 signaling.	Paclitaxel	116-121	hypoxia inducible factor 1 subunit alpha	Homo sapiens	160-165
29454064-9	2018	Further studies showed that the Paclitaxel loaded RNA micelles induced cancer cell apoptosis in a Caspase-3 dependent manner but RNA micelles alone exhibited low cytotoxicity.	Paclitaxel	32-42	caspase 3	Homo sapiens	98-107
29409974-6	2018	Consistently, miR-542-3p mimic was much more effective than miR-203 mimic not only in inhibition of Survivin, but also in enhancement of paclitaxel-induced apoptosis in HER2-overexpressing breast cancer cells.	Paclitaxel	137-147	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-173
29409974-7	2018	Moreover, the combination of miR-542-3p mimic and paclitaxel, as compared with either agent alone, significantly inhibited in vivo tumor growth of HER2-overexpressing breast cancer cells.	Paclitaxel	50-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-151
29701902-6	2018	Interestingly, paclitaxel significantly inhibits cell invasion and migration, decreases Snail and increases E-cadherin mRNA expression levels at the indicated low doses.	Paclitaxel	15-25	cadherin 1	Homo sapiens	108-118
29409974-10	2018	Thus, miR-542-3p-replacement therapy is an excellent approach to overcome HER3-mediated paclitaxel resistance and significantly enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.	Paclitaxel	88-98	microRNA 542	Homo sapiens	6-13
29373839-4	2018	Here, we demonstrate NgBR as a potential therapeutic target for ERalpha positive breast cancer patients to attenuate paclitaxel resistance.	Paclitaxel	117-127	estrogen receptor 1	Homo sapiens	64-71
29701706-16	2018	In conclusion, mansorin-II synergizes the anticancer effect of paclitaxel in colorectal cancer cells, which might be partially attributed to enhancing its cellular entrapment via inhibiting P-gp efflux pump.	Paclitaxel	63-73	ATP binding cassette subfamily B member 1	Homo sapiens	190-194
29643394-0	2018	Author Correction: Kanglaite sensitizes colorectal cancer cells to Taxol via NF-kappaBeta inhibition and connexin 43 upregulation.	Paclitaxel	67-72	nuclear factor kappa B subunit 1	Homo sapiens	77-89
29649113-8	2018	Short-term exposure to PAC led to increased expression of the MDR1 and BCRP genes in the A2780 and W1 cell lines.	Paclitaxel	23-26	ATP binding cassette subfamily B member 1	Homo sapiens	62-66
29373839-5	2018	NgBR knockdown enhanced paclitaxel-induced cell apoptosis by modulating expression of p53 and survivin in ERalpha positive breast cancer cells via NgBR-mediated PI3K/Akt and MAPK/ERK signaling pathways.	Paclitaxel	24-34	tumor protein p53	Homo sapiens	86-89
29373839-5	2018	NgBR knockdown enhanced paclitaxel-induced cell apoptosis by modulating expression of p53 and survivin in ERalpha positive breast cancer cells via NgBR-mediated PI3K/Akt and MAPK/ERK signaling pathways.	Paclitaxel	24-34	estrogen receptor 1	Homo sapiens	106-113
29373839-5	2018	NgBR knockdown enhanced paclitaxel-induced cell apoptosis by modulating expression of p53 and survivin in ERalpha positive breast cancer cells via NgBR-mediated PI3K/Akt and MAPK/ERK signaling pathways.	Paclitaxel	24-34	AKT serine/threonine kinase 1	Homo sapiens	166-169
29373839-8	2018	In summary, our data suggest that NgBR expression is essential to promoting ERalpha positive breast cancer cell resistance to paclitaxel.	Paclitaxel	126-136	estrogen receptor 1	Homo sapiens	76-83
29632436-13	2018	In addition, the blockage of miR-144-3p forced the anti-tumor effect delivered by X-ray exposure or paclitaxel.	Paclitaxel	100-110	microRNA 144	Homo sapiens	29-36
29333945-0	2018	Remarkable response with pembrolizumab plus albumin-bound paclitaxel in 2 cases of HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy.	Paclitaxel	58-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
29333945-6	2018	The results indicate that regimen of pembrolizumab combination with albumin-bound paclitaxel might produce response in patients with HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy.	Paclitaxel	82-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-137
29333945-6	2018	The results indicate that regimen of pembrolizumab combination with albumin-bound paclitaxel might produce response in patients with HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy.	Paclitaxel	82-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	202-206
29367764-0	2018	Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer.	Paclitaxel	62-72	insulin	Homo sapiens	12-19
29282807-7	2018	RESULTS: Compared with control rats, plasma levels of IL-1alpha, IL-1beta, IL-6, TNF-alpha, INF-gamma and MCP-1 were significantly upregulated in paclitaxel-treated rats.	Paclitaxel	146-156	interleukin 1 alpha	Rattus norvegicus	54-63
29282807-7	2018	RESULTS: Compared with control rats, plasma levels of IL-1alpha, IL-1beta, IL-6, TNF-alpha, INF-gamma and MCP-1 were significantly upregulated in paclitaxel-treated rats.	Paclitaxel	146-156	interleukin 1 beta	Rattus norvegicus	65-73
29282807-7	2018	RESULTS: Compared with control rats, plasma levels of IL-1alpha, IL-1beta, IL-6, TNF-alpha, INF-gamma and MCP-1 were significantly upregulated in paclitaxel-treated rats.	Paclitaxel	146-156	interleukin 6	Rattus norvegicus	75-79
29282807-7	2018	RESULTS: Compared with control rats, plasma levels of IL-1alpha, IL-1beta, IL-6, TNF-alpha, INF-gamma and MCP-1 were significantly upregulated in paclitaxel-treated rats.	Paclitaxel	146-156	tumor necrosis factor	Rattus norvegicus	81-90
29556305-6	2018	The present data indicate that Taxol may enhance the pro-apoptotic effects of TRAIL overexpression in HeLa cells by increasing cleaved caspase-3 and DR5 expression levels and decreasing Bcl-2 expression levels.	Paclitaxel	31-36	BCL2 apoptosis regulator	Homo sapiens	186-191
29556305-7	2018	Furthermore, the findings suggest a possible novel treatment option for cervical cancer and uncovers a potential mechanism of the enhancing effects of Taxol on TRAIL-induced apoptosis.	Paclitaxel	151-156	TNF superfamily member 10	Homo sapiens	160-165
29556305-6	2018	The present data indicate that Taxol may enhance the pro-apoptotic effects of TRAIL overexpression in HeLa cells by increasing cleaved caspase-3 and DR5 expression levels and decreasing Bcl-2 expression levels.	Paclitaxel	31-36	TNF superfamily member 10	Homo sapiens	78-83
29517223-0	2018	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of beta-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.	Paclitaxel	0-5	ATP binding cassette subfamily B member 1	Homo sapiens	127-141
29682172-3	2018	We demonstrate that paclitaxel treatment enhanced JAK2/STAT3 activation which resulted in the enrichment of cancer stem cell (CSC)-like phenotype in the surviving ovarian cancer cells in vitro and in in vivo mouse xenografts.	Paclitaxel	20-30	signal transducer and activator of transcription 3	Mus musculus	55-60
29682172-4	2018	Combined treatment with paclitaxel and momelotinib inhibited paclitaxel-induced JAK2/STAT3 activation and CSC-like development in mice xenografts, and consequently reduced the tumor burden significantly greater than that achieved by paclitaxel-treatment alone.	Paclitaxel	24-34	signal transducer and activator of transcription 3	Mus musculus	85-90
29682172-4	2018	Combined treatment with paclitaxel and momelotinib inhibited paclitaxel-induced JAK2/STAT3 activation and CSC-like development in mice xenografts, and consequently reduced the tumor burden significantly greater than that achieved by paclitaxel-treatment alone.	Paclitaxel	61-71	signal transducer and activator of transcription 3	Mus musculus	85-90
29682172-4	2018	Combined treatment with paclitaxel and momelotinib inhibited paclitaxel-induced JAK2/STAT3 activation and CSC-like development in mice xenografts, and consequently reduced the tumor burden significantly greater than that achieved by paclitaxel-treatment alone.	Paclitaxel	61-71	signal transducer and activator of transcription 3	Mus musculus	85-90
29517223-1	2018	Several next-generation taxanes have been reported to possess high potency against Taxol-resistant cancer cell lines overexpressing betaIII-tubulin and/or P-glycoprotein (P-gp), both of which are involved in drug resistance.	Paclitaxel	83-88	ATP binding cassette subfamily B member 1	Homo sapiens	155-169
29517223-1	2018	Several next-generation taxanes have been reported to possess high potency against Taxol-resistant cancer cell lines overexpressing betaIII-tubulin and/or P-glycoprotein (P-gp), both of which are involved in drug resistance.	Paclitaxel	83-88	ATP binding cassette subfamily B member 1	Homo sapiens	171-175
29517223-7	2018	The mechanisms involved in drug resistance are multifactorial, and the effectiveness of new Taxol analogues depends on the interaction between the drugs and all possible targets; in this case the two major cellular targets are beta-tubulin and P-gp.	Paclitaxel	92-97	ATP binding cassette subfamily B member 1	Homo sapiens	244-248
29636883-4	2018	We found that the embryonic transcription factor Brachyury inhibits Paclitaxel induced apoptosis in different cells, including PCH1 and U2OS cells.	Paclitaxel	68-78	VRK serine/threonine kinase 1	Homo sapiens	127-131
29155559-8	2018	This approach lead us to a potential octapeptide, which strongly binds to the taxol pocket of beta-tubulin, serves as an excellent microtubule stabilizer, increases the expression of acetylated tubulin, and acts as an Abeta aggregation inhibitor and neuroprotective agent.	Paclitaxel	78-83	amyloid beta precursor protein	Homo sapiens	218-223
29636883-8	2018	We further showed that CA9 is responsible for Paclitaxel resistance in PCH1 cell.	Paclitaxel	46-56	VRK serine/threonine kinase 1	Homo sapiens	71-75
29540677-11	2018	Collectively, our results suggest that SUMOylation positively regulates FOXK2 transcriptional activity and has a role in mediating the cytotoxic response to paclitaxel through the tumour suppressor FOXO3.	Paclitaxel	157-167	forkhead box O3	Homo sapiens	198-203
29358095-5	2018	In this paper we found that the effect of paclitaxel can be significantly improved when used in combination with FEN1 inhibitor SC13, suggesting a synergistic mechanism between the two compounds.	Paclitaxel	42-52	cystatin 11	Homo sapiens	128-132
29522490-9	2018	Furthermore, EEAC enhanced chemosensitivity of A549 to paclitaxel by reducing the protein levels of caveolin-1.	Paclitaxel	55-65	caveolin 1	Homo sapiens	100-110
29411964-0	2018	Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Co-delivered with MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR/ERK pathway Activation for Ovarian Cancer Therapy.	Paclitaxel	38-48	epidermal growth factor receptor	Homo sapiens	125-129
29411964-0	2018	Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Co-delivered with MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR/ERK pathway Activation for Ovarian Cancer Therapy.	Paclitaxel	106-116	epidermal growth factor receptor	Homo sapiens	125-129
29411964-3	2018	Paclitaxel (PTX) is one of the first-line chemotherapy drugs for ovarian cancer, and it induces the activation of the epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (ERK) pathway that leads to tumor cell proliferation, survival, invasion, and drug resistance.	Paclitaxel	0-10	epidermal growth factor receptor	Homo sapiens	118-150
29411964-3	2018	Paclitaxel (PTX) is one of the first-line chemotherapy drugs for ovarian cancer, and it induces the activation of the epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (ERK) pathway that leads to tumor cell proliferation, survival, invasion, and drug resistance.	Paclitaxel	0-10	epidermal growth factor receptor	Homo sapiens	152-156
29411964-3	2018	Paclitaxel (PTX) is one of the first-line chemotherapy drugs for ovarian cancer, and it induces the activation of the epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (ERK) pathway that leads to tumor cell proliferation, survival, invasion, and drug resistance.	Paclitaxel	12-15	epidermal growth factor receptor	Homo sapiens	118-150
29411964-3	2018	Paclitaxel (PTX) is one of the first-line chemotherapy drugs for ovarian cancer, and it induces the activation of the epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (ERK) pathway that leads to tumor cell proliferation, survival, invasion, and drug resistance.	Paclitaxel	12-15	epidermal growth factor receptor	Homo sapiens	152-156
29411964-7	2018	The chemotherapeutic efficacy of PTX is prominently enhanced in vitro and in vivo via the inhibition of PTX-induced EGFR/ERK pathway activation by miR-7.	Paclitaxel	33-36	epidermal growth factor receptor	Homo sapiens	116-120
29411964-7	2018	The chemotherapeutic efficacy of PTX is prominently enhanced in vitro and in vivo via the inhibition of PTX-induced EGFR/ERK pathway activation by miR-7.	Paclitaxel	104-107	epidermal growth factor receptor	Homo sapiens	116-120
29358095-7	2018	Our work also revealed that paclitaxel demonstrates stronger synergistic effect with SC13 than other common used chemical drugs such as doxorubicin, carboplatin or camptothecin on cervical cancer cells.	Paclitaxel	28-38	cystatin 11	Homo sapiens	85-89
28771725-8	2018	Consistent with these results, ectopic expression of TLR4 in taxol-sensitive SKOV3 cells enhanced ABCB1 expression and conferred resistance to taxol.	Paclitaxel	61-66	ATP binding cassette subfamily B member 1	Homo sapiens	98-103
29456682-5	2018	The present study demonstrated that overexpressing L1CAM promoted paclitaxel resistance and regulated paclitaxel resistance-associated microRNA expression in HEC-1A cells.	Paclitaxel	66-76	L1 cell adhesion molecule	Homo sapiens	51-56
29456682-5	2018	The present study demonstrated that overexpressing L1CAM promoted paclitaxel resistance and regulated paclitaxel resistance-associated microRNA expression in HEC-1A cells.	Paclitaxel	102-112	L1 cell adhesion molecule	Homo sapiens	51-56
28771725-0	2018	TLR4 and NFkappaB signaling is critical for taxol resistance in ovarian carcinoma cells.	Paclitaxel	44-49	nuclear factor kappa B subunit 1	Homo sapiens	9-17
28771725-9	2018	The protective effect of exogenous TLR4 expression against taxol was reduced by treatment with NFkappaB inhibitor in these cells.	Paclitaxel	59-64	nuclear factor kappa B subunit 1	Homo sapiens	95-103
28771725-1	2018	We report here that toll-like receptor 4 (TLR4) and ABCB1 are upregulated in SKOV3 ovarian carcinoma cells that acquired resistance to the anticancer drug taxol.	Paclitaxel	155-160	ATP binding cassette subfamily B member 1	Homo sapiens	52-57
28771725-3	2018	A sub-lethal dose of taxol induced ABCB1 protein expression in taxol-resistant SKOV3 cells.	Paclitaxel	21-26	ATP binding cassette subfamily B member 1	Homo sapiens	35-40
28771725-10	2018	These results demonstrate that taxol activates the TLR4-NFkappaB pathway which in turn induces ABCB1 gene expression.	Paclitaxel	31-36	nuclear factor kappa B subunit 1	Homo sapiens	56-64
28771725-3	2018	A sub-lethal dose of taxol induced ABCB1 protein expression in taxol-resistant SKOV3 cells.	Paclitaxel	63-68	ATP binding cassette subfamily B member 1	Homo sapiens	35-40
28771725-10	2018	These results demonstrate that taxol activates the TLR4-NFkappaB pathway which in turn induces ABCB1 gene expression.	Paclitaxel	31-36	ATP binding cassette subfamily B member 1	Homo sapiens	95-100
28771725-6	2018	Notably, the NFkappaB pathway was significantly activated by taxol, and inhibition of this pathway suppressed TLR4-regulated ABCB1 expression.	Paclitaxel	61-66	nuclear factor kappa B subunit 1	Homo sapiens	13-21
28771725-6	2018	Notably, the NFkappaB pathway was significantly activated by taxol, and inhibition of this pathway suppressed TLR4-regulated ABCB1 expression.	Paclitaxel	61-66	ATP binding cassette subfamily B member 1	Homo sapiens	125-130
28771725-7	2018	Furthermore, taxol-induced NFkappaB signaling was reduced following TLR4 silencing in taxol-resistant SKOV3 cells.	Paclitaxel	13-18	nuclear factor kappa B subunit 1	Homo sapiens	27-35
28771725-7	2018	Furthermore, taxol-induced NFkappaB signaling was reduced following TLR4 silencing in taxol-resistant SKOV3 cells.	Paclitaxel	86-91	nuclear factor kappa B subunit 1	Homo sapiens	27-35
29328489-0	2018	Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer.	Paclitaxel	92-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-167
29327055-4	2018	Objective: To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.	Paclitaxel	36-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-139
28283888-1	2018	Kinin B1 (B1R) and B2 receptors (B2R) and the transient receptor potential vanilloid 4 (TRPV4) channel are known to play a critical role in the peripheral neuropathy induced by paclitaxel (PTX) in rodents.	Paclitaxel	177-187	bradykinin receptor, beta 1	Mus musculus	0-13
28283888-1	2018	Kinin B1 (B1R) and B2 receptors (B2R) and the transient receptor potential vanilloid 4 (TRPV4) channel are known to play a critical role in the peripheral neuropathy induced by paclitaxel (PTX) in rodents.	Paclitaxel	189-192	bradykinin receptor, beta 1	Mus musculus	0-13
28283888-7	2018	The selective kinin B1R (des-Arg9-[Leu8]-bradykinin) and B2R (HOE 140) antagonists reduced the mechanical hyperalgesia induced by PTX, with efficacies and time response profiles similar to those observed for the TRPV4 antagonist (HC-067047).	Paclitaxel	130-133	bradykinin receptor, beta 1	Mus musculus	20-23
29328489-11	2018	In conclusion, trastuzumab/nab-paclitaxel could mediate targeted therapy and enhance antitumor efficacy, which could represent a novel therapeutic agent for HER2-positive GC.	Paclitaxel	31-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	157-161
29456735-0	2018	Metadherin contributes to epithelial-mesenchymal transition and paclitaxel resistance induced by acidic extracellular pH in nasopharyngeal carcinoma.	Paclitaxel	64-74	metadherin	Homo sapiens	0-10
29482988-5	2018	In the current study, we identified that the combination of FH535 and miR-200a with taxol had potent growth-inhibitory and pro-apoptotic effects.	Paclitaxel	84-89	microRNA 200a	Homo sapiens	70-78
29456735-8	2018	Furthermore, the silencing of MTDH expression reversed EMT molecular marker expression and sensitized NPC cells to paclitaxel.	Paclitaxel	115-125	metadherin	Homo sapiens	30-34
29456735-9	2018	Taken together, the results of the present study provide evidence to support an association between acidic pHe-induced paclitaxel resistance and MTDH-mediated EMT in NPC cells.	Paclitaxel	119-129	metadherin	Homo sapiens	145-149
29482988-7	2018	Collectively, miR-200a and FH535 can enhance the inhibitory effect of taxol on cell proliferation and moderate the invasion of human gastric cancer.	Paclitaxel	70-75	microRNA 200a	Homo sapiens	14-22
29339567-10	2018	The experimental results demonstrate that EpCam-RPAuNs can effectively generate hyperthermia and precisely deliver the antitumor drug PTX to targeted cells.	Paclitaxel	134-137	epithelial cell adhesion molecule	Mus musculus	42-47
29641777-9	2018	CONCLUSION: Paclitaxel combined with avastin decreased MPE volume and increased survival rate of NSCLC patients via inhibiting vascular endothelial growth factor expression.	Paclitaxel	12-22	vascular endothelial growth factor A	Homo sapiens	127-161
29204706-0	2018	MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1.	Paclitaxel	36-46	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	71-75
29204706-12	2018	YES1 was a target of miR-199a, and overexpression of YES1 reversed the effect of miR-199a in suppressing PTX resistance.	Paclitaxel	105-108	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	0-4
29204706-12	2018	YES1 was a target of miR-199a, and overexpression of YES1 reversed the effect of miR-199a in suppressing PTX resistance.	Paclitaxel	105-108	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	53-57
29204706-15	2018	YES1 mediates the regulation of miR-199a in prostate cancer PTX resistance.	Paclitaxel	60-63	YES proto-oncogene 1, Src family tyrosine kinase	Homo sapiens	0-4
29486738-7	2018	The apoptotic cells after adding PTX alone or in combination with CpdA were detected by caspase-3/7 assay.	Paclitaxel	33-36	caspase 3	Homo sapiens	88-97
29486738-10	2018	IL-6, IL-8 and XIAP showed increased expressions in PTX-treated cells and this over-production effect was inhibited in TLR4-transient knockdown cells.	Paclitaxel	52-55	interleukin 6	Homo sapiens	0-4
29486738-10	2018	IL-6, IL-8 and XIAP showed increased expressions in PTX-treated cells and this over-production effect was inhibited in TLR4-transient knockdown cells.	Paclitaxel	52-55	C-X-C motif chemokine ligand 8	Homo sapiens	6-10
29486738-14	2018	CONCLUSIONS: The acquired TLR4-mediated PTX resistance in BCA and melanoma is explained partly by the paracrine effect of IL-6 and IL-8 released into the tumor microenvironment and over-production of anti-apoptotic protein, XIAP, in BCA cells and importantly CpdA could reduce this effect and sensitize PTX-induced apoptosis in a synergistic manner.	Paclitaxel	40-43	interleukin 6	Homo sapiens	122-126
29486738-14	2018	CONCLUSIONS: The acquired TLR4-mediated PTX resistance in BCA and melanoma is explained partly by the paracrine effect of IL-6 and IL-8 released into the tumor microenvironment and over-production of anti-apoptotic protein, XIAP, in BCA cells and importantly CpdA could reduce this effect and sensitize PTX-induced apoptosis in a synergistic manner.	Paclitaxel	40-43	C-X-C motif chemokine ligand 8	Homo sapiens	131-135
29486738-14	2018	CONCLUSIONS: The acquired TLR4-mediated PTX resistance in BCA and melanoma is explained partly by the paracrine effect of IL-6 and IL-8 released into the tumor microenvironment and over-production of anti-apoptotic protein, XIAP, in BCA cells and importantly CpdA could reduce this effect and sensitize PTX-induced apoptosis in a synergistic manner.	Paclitaxel	303-306	interleukin 6	Homo sapiens	122-126
29054579-0	2018	Relevance of the CYP3A4*20 variant as a predictor of paclitaxel-induced neuropathy in the Spanish population.	Paclitaxel	53-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	17-23
29681766-11	2018	Also, paclitaxel treatment increased the expression levels of TNF-alpha and IL-1beta in the hippocampus tissue.	Paclitaxel	6-16	tumor necrosis factor	Rattus norvegicus	62-71
29681766-11	2018	Also, paclitaxel treatment increased the expression levels of TNF-alpha and IL-1beta in the hippocampus tissue.	Paclitaxel	6-16	interleukin 1 beta	Rattus norvegicus	76-84
29681766-12	2018	In addition, the TNF-alpha synthesis inhibitor thalidomide significantly attenuated the number of paclitaxel-induced TUNEL-positive neurons in the hippocampus and restored the impaired spatial learning and memory function in paclitaxel-treated rats.	Paclitaxel	98-108	tumor necrosis factor	Rattus norvegicus	17-26
29681766-12	2018	In addition, the TNF-alpha synthesis inhibitor thalidomide significantly attenuated the number of paclitaxel-induced TUNEL-positive neurons in the hippocampus and restored the impaired spatial learning and memory function in paclitaxel-treated rats.	Paclitaxel	225-235	tumor necrosis factor	Rattus norvegicus	17-26
29681766-13	2018	These data suggest that TNF-alpha is critically involved in the paclitaxel-induced impairment of learning and memory function.	Paclitaxel	64-74	tumor necrosis factor	Rattus norvegicus	24-33
29251928-5	2018	Selected compounds were shown to reverse paclitaxel resistance in HEK293 cells overexpressing P-gp and were selective toward P-gp over CYP3A4.	Paclitaxel	41-51	ATP binding cassette subfamily B member 1	Homo sapiens	94-98
29408042-5	2018	Interestingly, siRNA knockdown of MDR1 further sensitized the cytotoxic activity of paclitaxel when co-administrated with H6.	Paclitaxel	84-94	ATP binding cassette subfamily B member 1	Homo sapiens	34-38
29334216-2	2018	The particle size and the zeta potential of PTX-DODAB/p53-rHDL nanoparticles were 177.2 nm and -20.06 mV, respectively.	Paclitaxel	44-47	tumor protein p53	Homo sapiens	54-57
29251928-5	2018	Selected compounds were shown to reverse paclitaxel resistance in HEK293 cells overexpressing P-gp and were selective toward P-gp over CYP3A4.	Paclitaxel	41-51	ATP binding cassette subfamily B member 1	Homo sapiens	125-129
29251928-5	2018	Selected compounds were shown to reverse paclitaxel resistance in HEK293 cells overexpressing P-gp and were selective toward P-gp over CYP3A4.	Paclitaxel	41-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	135-141
29208281-5	2018	Thanks to the cationic nanoparticle complex formation ability and high transfection efficiency to express Bcl-2 conversion proteins, PHB-PDMAEMA/PTX@polyplex could partially impair P-glycoprotein induced PTX efflux and activate the apoptotic function of previous prosurvival Bcl-2 protein.	Paclitaxel	145-148	BCL2 apoptosis regulator	Homo sapiens	106-111
29445301-7	2018	Patients receiving nab-paclitaxel vs. paclitaxel had significantly longer TTD (median 4.2 vs. 2.8 months, P&lt;0.0001) and TTNT (median 6.0 vs. 4.2 months, P&lt;0.0001); similar outcomes were observed for patients with hormone receptor-positive/human epidermal growth factor receptor 2 negative disease.	Paclitaxel	23-33	erb-b2 receptor tyrosine kinase 2	Homo sapiens	251-285
29367423-4	2018	Here, we report that treatment of human or murine TNBC cells with carboplatin, doxorubicin, gemcitabine, or paclitaxel induces the coordinate transcriptional induction of CD47, CD73, and PDL1 mRNA and protein expression, leading to a marked increase in the percentage of CD47+CD73+PDL1+ breast cancer cells.	Paclitaxel	108-118	CD274 antigen	Mus musculus	187-191
29367423-4	2018	Here, we report that treatment of human or murine TNBC cells with carboplatin, doxorubicin, gemcitabine, or paclitaxel induces the coordinate transcriptional induction of CD47, CD73, and PDL1 mRNA and protein expression, leading to a marked increase in the percentage of CD47+CD73+PDL1+ breast cancer cells.	Paclitaxel	108-118	CD274 antigen	Mus musculus	281-285
29441192-0	2018	Knockdown of LncRNA MAPT-AS1 inhibites proliferation and migration and sensitizes cancer cells to paclitaxel by regulating MAPT expression in ER-negative breast cancers.	Paclitaxel	98-108	MAPT antisense RNA 1	Homo sapiens	20-28
29441192-7	2018	MAPT-AS1 is correlated with the cell growth, invasiveness and paclitaxel resistance by regulating its natural comparable sense transcripts MAPT in ER-negative breast cancer cells.	Paclitaxel	62-72	MAPT antisense RNA 1	Homo sapiens	0-8
29441192-13	2018	MAPT-AS1 is correlated with the cell growth, invasiveness and paclitaxel resistance in ER-negative breast cancer cells through antisense pairing with MAPT.	Paclitaxel	62-72	MAPT antisense RNA 1	Homo sapiens	0-8
29396402-8	2018	This work provides a rationale for inhibiting FER-mediated CRMP2 phosphorylation to enhance paclitaxel on-target activity for cancer therapy.	Paclitaxel	92-102	dihydropyrimidinase like 2	Homo sapiens	59-64
29176398-0	2018	The role of the globular heads of the C1q receptor in paclitaxel-induced human ovarian cancer cells apoptosis by a mitochondria-dependent pathway.	Paclitaxel	54-64	CD93 molecule	Homo sapiens	38-50
29056557-0	2018	AKAP150 involved in paclitaxel-induced neuropathic pain via inhibiting CN/NFAT2 pathway and downregulating IL-4.	Paclitaxel	20-30	interleukin 4	Homo sapiens	107-111
29056557-5	2018	Paclitaxel decreased the expression of anti-inflammatory cytokine interleukin-4 (IL-4), and intrathecal injections of IL-4 effectively alleviated paclitaxel-induced hypersensitivity and the frequency of dorsal root ganglion (DRG) neurons action potential.	Paclitaxel	0-10	interleukin 4	Homo sapiens	66-79
29056557-5	2018	Paclitaxel decreased the expression of anti-inflammatory cytokine interleukin-4 (IL-4), and intrathecal injections of IL-4 effectively alleviated paclitaxel-induced hypersensitivity and the frequency of dorsal root ganglion (DRG) neurons action potential.	Paclitaxel	0-10	interleukin 4	Homo sapiens	81-85
29056557-5	2018	Paclitaxel decreased the expression of anti-inflammatory cytokine interleukin-4 (IL-4), and intrathecal injections of IL-4 effectively alleviated paclitaxel-induced hypersensitivity and the frequency of dorsal root ganglion (DRG) neurons action potential.	Paclitaxel	146-156	interleukin 4	Homo sapiens	118-122
29056557-8	2018	Overexpression of NFAT2 by intrathecal injection of the AAV5-NFAT2-GFP virus alleviated the pain behavior induced by paclitaxel via increasing the expression of IL-4.	Paclitaxel	117-127	interleukin 4	Homo sapiens	161-165
29056557-10	2018	Our results indicated that regulation of IL-4 via the CN/NFAT2 pathway mediated by AKAP150 could be a pivotal treatment target for paclitaxel-induced neuropathic pain and or other neuropsychiatric disorders.	Paclitaxel	131-141	interleukin 4	Homo sapiens	41-45
29345283-10	2018	Among the anticancer drugs conventionally used in the treatment of patients with HNSCC, paclitaxel increased MMP-13 expression in R/M HNSCC cells (HOC313 cells) co-cultured without/with dendritic cells (DCs).	Paclitaxel	88-98	matrix metallopeptidase 13	Homo sapiens	109-115
29369007-0	2018	Combination therapy Eve and Pac to induce apoptosis in cervical cancer cells by targeting PI3K/AKT/mTOR pathways.	Paclitaxel	28-31	AKT serine/threonine kinase 1	Homo sapiens	95-98
29369007-0	2018	Combination therapy Eve and Pac to induce apoptosis in cervical cancer cells by targeting PI3K/AKT/mTOR pathways.	Paclitaxel	28-31	mechanistic target of rapamycin kinase	Homo sapiens	99-103
29242937-22	2018	Patients with VEGFA CC genotype may be more resistant to weekly paclitaxel than those with the AC or AA genotype, with 1 of 14 (7%), 3 of 15 (20%), and 4 of 8 (50%) responding, respectively.	Paclitaxel	64-74	vascular endothelial growth factor A	Homo sapiens	14-19
29208281-5	2018	Thanks to the cationic nanoparticle complex formation ability and high transfection efficiency to express Bcl-2 conversion proteins, PHB-PDMAEMA/PTX@polyplex could partially impair P-glycoprotein induced PTX efflux and activate the apoptotic function of previous prosurvival Bcl-2 protein.	Paclitaxel	145-148	ATP binding cassette subfamily B member 1	Homo sapiens	181-195
29208281-5	2018	Thanks to the cationic nanoparticle complex formation ability and high transfection efficiency to express Bcl-2 conversion proteins, PHB-PDMAEMA/PTX@polyplex could partially impair P-glycoprotein induced PTX efflux and activate the apoptotic function of previous prosurvival Bcl-2 protein.	Paclitaxel	145-148	BCL2 apoptosis regulator	Homo sapiens	275-280
29208281-5	2018	Thanks to the cationic nanoparticle complex formation ability and high transfection efficiency to express Bcl-2 conversion proteins, PHB-PDMAEMA/PTX@polyplex could partially impair P-glycoprotein induced PTX efflux and activate the apoptotic function of previous prosurvival Bcl-2 protein.	Paclitaxel	204-207	BCL2 apoptosis regulator	Homo sapiens	106-111
29208281-5	2018	Thanks to the cationic nanoparticle complex formation ability and high transfection efficiency to express Bcl-2 conversion proteins, PHB-PDMAEMA/PTX@polyplex could partially impair P-glycoprotein induced PTX efflux and activate the apoptotic function of previous prosurvival Bcl-2 protein.	Paclitaxel	204-207	ATP binding cassette subfamily B member 1	Homo sapiens	181-195
29208281-5	2018	Thanks to the cationic nanoparticle complex formation ability and high transfection efficiency to express Bcl-2 conversion proteins, PHB-PDMAEMA/PTX@polyplex could partially impair P-glycoprotein induced PTX efflux and activate the apoptotic function of previous prosurvival Bcl-2 protein.	Paclitaxel	204-207	BCL2 apoptosis regulator	Homo sapiens	275-280
29374144-0	2018	Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.	Paclitaxel	76-86	mechanistic target of rapamycin kinase	Homo sapiens	10-14
29257268-7	2018	Inhibition of TGF-beta expression led to an inhibition of growth, migration and invasion, in addition to a promotion of apoptosis, in ovarian carcinoma cells treated with paclitaxel.	Paclitaxel	171-181	transforming growth factor beta 1	Homo sapiens	14-22
29251630-5	2018	siRNA-mediated LPP silencing in ovarian tumor-bearing mice improved paclitaxel delivery to cancer cells by decreasing intratumoral microvessel leakiness.	Paclitaxel	68-78	LIM domain containing preferred translocation partner in lipoma	Mus musculus	15-18
29374144-0	2018	Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.	Paclitaxel	76-86	AKT serine/threonine kinase 1	Homo sapiens	131-134
29374144-0	2018	Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.	Paclitaxel	76-86	mechanistic target of rapamycin kinase	Homo sapiens	135-139
29374144-6	2018	In vitro data suggested that targeting these pathways were sufficient to elicit antitumor responses in PTX-resistant GC, in which the dual PI3K/mTOR inhibitor BEZ235 displayed higher therapeutic efficiency than the mTOR inhibitor everolimus or the MEK inhibitor AZD6244.	Paclitaxel	103-106	mechanistic target of rapamycin kinase	Homo sapiens	144-148
29374144-6	2018	In vitro data suggested that targeting these pathways were sufficient to elicit antitumor responses in PTX-resistant GC, in which the dual PI3K/mTOR inhibitor BEZ235 displayed higher therapeutic efficiency than the mTOR inhibitor everolimus or the MEK inhibitor AZD6244.	Paclitaxel	103-106	mechanistic target of rapamycin kinase	Homo sapiens	215-219
29374144-6	2018	In vitro data suggested that targeting these pathways were sufficient to elicit antitumor responses in PTX-resistant GC, in which the dual PI3K/mTOR inhibitor BEZ235 displayed higher therapeutic efficiency than the mTOR inhibitor everolimus or the MEK inhibitor AZD6244.	Paclitaxel	103-106	mitogen-activated protein kinase kinase 7	Homo sapiens	248-251
29374144-8	2018	Thus, these data suggest that PI3K/Akt/mTOR and MAPK pathway inhibition, especially PI3K/mTOR dual blockade, might be a promising therapeutic strategy against PTX-resistant GC.	Paclitaxel	159-162	AKT serine/threonine kinase 1	Homo sapiens	35-38
29374144-8	2018	Thus, these data suggest that PI3K/Akt/mTOR and MAPK pathway inhibition, especially PI3K/mTOR dual blockade, might be a promising therapeutic strategy against PTX-resistant GC.	Paclitaxel	159-162	mechanistic target of rapamycin kinase	Homo sapiens	39-43
29374144-8	2018	Thus, these data suggest that PI3K/Akt/mTOR and MAPK pathway inhibition, especially PI3K/mTOR dual blockade, might be a promising therapeutic strategy against PTX-resistant GC.	Paclitaxel	159-162	mechanistic target of rapamycin kinase	Homo sapiens	89-93
29141899-2	2018	Though distinct in their mechanisms of action, doxorubicin, paclitaxel, and 5-FU all induce rapid and robust upregulation of atypical G protein Gbeta5 in the myocardium correlating with oxidative stress, myocyte apoptosis, and the accumulation of proinflammatory and profibrotic cytokines.	Paclitaxel	60-70	G protein subunit beta 5	Homo sapiens	144-150
29403275-0	2018	Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo.	Paclitaxel	47-57	vascular endothelial growth factor A	Homo sapiens	33-37
29403275-2	2018	PTX absorbed on GO nanosheets as cores were coated with human serum albumin (HSA), following surface conjugation with monoclonal antibodies (mAb) against vascular endothelial growth factor (VEGF; denoted as mAbVEGF) via polyethylene glycol linker to form targeted nanoparticles (PTX-GHP-VEGF).	Paclitaxel	0-3	vascular endothelial growth factor A	Homo sapiens	210-214
29403275-5	2018	The mechanism of thermal-triggered drug release was also investigated preliminarily, in which the heat generated by GO induced swelling of PTX-GHP-VEGF nanoparticles which released the drugs.	Paclitaxel	139-142	vascular endothelial growth factor A	Homo sapiens	147-151
29403275-6	2018	In vitro studies found that PTX-GHP-VEGF can efficiently target human SW-13 adrenocortical carcinoma cells as evaluated by confocal fluorescence microscopy as well as transmission electron microscopy, and showed an obvious thermal-triggered antitumor effect, mediated by apoptosis.	Paclitaxel	28-31	vascular endothelial growth factor A	Homo sapiens	36-40
29403275-7	2018	Moreover, PTX-GHP-VEGF combined with near infrared irradiation showed specific tumor suppression effects with high survival rate after 100 days of treatment.	Paclitaxel	10-13	vascular endothelial growth factor A	Homo sapiens	18-22
29403275-8	2018	PTX-GHP-VEGF also demonstrated high biosafety with no adverse effects on normal tissues and organs.	Paclitaxel	0-3	vascular endothelial growth factor A	Homo sapiens	8-12
29403275-9	2018	These results highlight the remarkable potential of PTX-GHP-VEGF in photothermal controllable tumor treatment.	Paclitaxel	52-55	vascular endothelial growth factor A	Homo sapiens	60-64
29084921-6	2018	In addition, the REDD1-mediated proliferation, apoptosis, and autophagy are found to be negatively regulated by miR-22 in vitro, which intensify the paclitaxel sensitivity via inhibition of the well-acknowledged REDD1-EEF2K-autophagy axis.	Paclitaxel	149-159	microRNA 22	Homo sapiens	112-118
29084921-8	2018	Finally, the inhibited REDD1 expression by either RNAi or miR-22 sensitizes BUC tumor cells to paclitaxel in a subcutaneous transplant carcinoma model in vivoConclusions: REDD1 is confirmed as an oncogene in BUC, and antagonizing REDD1 could be a potential therapeutic strategy to sensitize BUC cells to paclitaxel.	Paclitaxel	95-105	microRNA 22	Homo sapiens	58-64
29332931-0	2018	Proteasome Inhibitor Carbobenzoxy-L-Leucyl-L-Leucyl-L-Leucinal (MG132) Enhances Therapeutic Effect of Paclitaxel on Breast Cancer by Inhibiting Nuclear Factor (NF)-kappaB Signaling.	Paclitaxel	102-112	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	144-170
29192128-4	2018	Here we show that locally injected zinc markedly reduces neuropathic pain in male and female mice induced by paclitaxel, a chemotherapy drug, in a TRPV1-dependent manner.	Paclitaxel	109-119	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	147-152
29324735-0	2018	Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.	Paclitaxel	44-54	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	13-18
29324735-2	2018	To date, the role of c-Src, a member of SRC family kinase, in resistance to paclitaxel in human ovarian cancer cells under hypoxia has not been investigated.	Paclitaxel	76-86	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	21-26
29324735-3	2018	In the present study, we discovered that hypoxic environment suppressed paclitaxel-induced G2/M phase arrest and blockade of c-Src improved ovarian cancer cells" sensitivity to paclitaxel.	Paclitaxel	177-187	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	125-130
29324735-4	2018	FV-429, a derivative of natural flavonoid wogonin, could suppress gene expression and activation of c-Src, followed by deteriorated Stat3 nuclear translocation and its binding to HIF-1alpha, resulting in paclitaxel resistance reversal through G2/M arrest potentiation.	Paclitaxel	204-214	hypoxia inducible factor 1 subunit alpha	Homo sapiens	179-189
29324735-5	2018	Our study demonstrated that c-Src contributed to hypoxic microenvironment-rendered paclitaxel resistance in human epithelial ovarian cancer cells by G2/M phase arrest deterioration, and through c-Src suppression, FV-429 was capable of reversing the resistance by blocking c-Src/Stat3/HIF-1alpha pathway.	Paclitaxel	83-93	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	28-33
29324735-5	2018	Our study demonstrated that c-Src contributed to hypoxic microenvironment-rendered paclitaxel resistance in human epithelial ovarian cancer cells by G2/M phase arrest deterioration, and through c-Src suppression, FV-429 was capable of reversing the resistance by blocking c-Src/Stat3/HIF-1alpha pathway.	Paclitaxel	83-93	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	194-199
29324735-5	2018	Our study demonstrated that c-Src contributed to hypoxic microenvironment-rendered paclitaxel resistance in human epithelial ovarian cancer cells by G2/M phase arrest deterioration, and through c-Src suppression, FV-429 was capable of reversing the resistance by blocking c-Src/Stat3/HIF-1alpha pathway.	Paclitaxel	83-93	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	194-199
29324735-5	2018	Our study demonstrated that c-Src contributed to hypoxic microenvironment-rendered paclitaxel resistance in human epithelial ovarian cancer cells by G2/M phase arrest deterioration, and through c-Src suppression, FV-429 was capable of reversing the resistance by blocking c-Src/Stat3/HIF-1alpha pathway.	Paclitaxel	83-93	signal transducer and activator of transcription 3	Homo sapiens	278-283
29324735-5	2018	Our study demonstrated that c-Src contributed to hypoxic microenvironment-rendered paclitaxel resistance in human epithelial ovarian cancer cells by G2/M phase arrest deterioration, and through c-Src suppression, FV-429 was capable of reversing the resistance by blocking c-Src/Stat3/HIF-1alpha pathway.	Paclitaxel	83-93	hypoxia inducible factor 1 subunit alpha	Homo sapiens	284-294
29156532-11	2018	Furthermore, paclitaxel treatment significantly decreased the expression of NF-kappaB p65, but increased inhibitor of nuclear factor-kappaB-alpha (IkappaBalpha) protein levels in septic mice, suggesting the inactivation of NF-kappaB signaling pathway.	Paclitaxel	13-23	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	147-159
28681330-0	2018	Antiproliferative Activity and VEGF Expression Reduction in MCF7 and PC-3 Cancer Cells by Paclitaxel and Imatinib Co-encapsulation in Folate-Targeted Liposomes.	Paclitaxel	90-100	vascular endothelial growth factor A	Homo sapiens	31-35
29416920-1	2018	Our previous study showed that 5-aza-2-deoxycytidine (5-aza-dC) could inhibit tumor growth by enhancing the susceptibility of ovarian clear cell carcinoma (OCCC) to paclitaxel through decreasing AKT/mTOR expressions.	Paclitaxel	165-175	AKT serine/threonine kinase 1	Homo sapiens	195-198
29416920-1	2018	Our previous study showed that 5-aza-2-deoxycytidine (5-aza-dC) could inhibit tumor growth by enhancing the susceptibility of ovarian clear cell carcinoma (OCCC) to paclitaxel through decreasing AKT/mTOR expressions.	Paclitaxel	165-175	mechanistic target of rapamycin kinase	Homo sapiens	199-203
29416920-9	2018	Activation of phospho-AKT ser473 and PIK3IP1 was observed in RAD001-treated paclitaxel-sensitive and resistant OCCC cells.	Paclitaxel	76-86	AKT serine/threonine kinase 1	Homo sapiens	22-25
29416920-10	2018	In contrast, inhibition of phospho-AKT ser473 and EZH2 was observed with RAD001 following 5-aza-dC treatment of paclitaxel-sensitive and resistant OCCC cells.	Paclitaxel	112-122	AKT serine/threonine kinase 1	Homo sapiens	35-38
29416920-10	2018	In contrast, inhibition of phospho-AKT ser473 and EZH2 was observed with RAD001 following 5-aza-dC treatment of paclitaxel-sensitive and resistant OCCC cells.	Paclitaxel	112-122	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	50-54
29872625-0	2018	Substance P-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma.	Paclitaxel	67-77	tachykinin precursor 1	Homo sapiens	0-11
29872625-3	2018	Here we characterize PTX-loaded human serum albumin (HSA) NPs stabilized with intramolecular disulfide bonds and modified with substance P (SP) peptide as the targeting ligand.	Paclitaxel	21-24	tachykinin precursor 1	Homo sapiens	127-138
29277798-0	2018	Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.	Paclitaxel	59-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
29914005-0	2018	Targeted regulationof STAT3 by miR-29a in mediating Taxol resistance of nasopharyngeal carcinoma cell line CNE-1.	Paclitaxel	52-57	signal transducer and activator of transcription 3	Homo sapiens	22-27
29914005-13	2018	MiR-29a down-regulation is correlated with drug resistance of nasopharyngeal carcinoma cell line CNE-1 and MiR-29a up-regulation decreases Taxol resistance of nasopharyngeal carcinoma CNE-1 cells possibly via inhibiting STAT3 and Bcl-2 expression.	Paclitaxel	139-144	signal transducer and activator of transcription 3	Homo sapiens	220-225
29914005-13	2018	MiR-29a down-regulation is correlated with drug resistance of nasopharyngeal carcinoma cell line CNE-1 and MiR-29a up-regulation decreases Taxol resistance of nasopharyngeal carcinoma CNE-1 cells possibly via inhibiting STAT3 and Bcl-2 expression.	Paclitaxel	139-144	BCL2 apoptosis regulator	Homo sapiens	230-235
30001527-12	2018	MRP1 depletion increased the sensitivity of MCF-7/ADR cells to ADR, VCR and PTX, and this effect was attenuated following miR-199a inhibition or linc00518 overexpression.	Paclitaxel	76-79	ATP binding cassette subfamily C member 1	Homo sapiens	0-4
30282072-0	2018	MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.	Paclitaxel	24-34	notch receptor 1	Homo sapiens	102-108
30064123-12	2018	Furthermore, CA increased the PTX-induced activation of Bax, Bid, and downstream cleaved PARP, and phosphorylation of extracellular signal regulated kinase1/2 and c-Jun NH2-terminal protein kinase1/2.	Paclitaxel	30-33	BCL2 associated X, apoptosis regulator	Homo sapiens	56-59
30064123-12	2018	Furthermore, CA increased the PTX-induced activation of Bax, Bid, and downstream cleaved PARP, and phosphorylation of extracellular signal regulated kinase1/2 and c-Jun NH2-terminal protein kinase1/2.	Paclitaxel	30-33	BH3 interacting domain death agonist	Homo sapiens	61-64
30064123-12	2018	Furthermore, CA increased the PTX-induced activation of Bax, Bid, and downstream cleaved PARP, and phosphorylation of extracellular signal regulated kinase1/2 and c-Jun NH2-terminal protein kinase1/2.	Paclitaxel	30-33	mitogen-activated protein kinase 3	Homo sapiens	118-158
30282072-17	2018	By regulating the JAG1/Notch1 axis, miR-34a or its target genes JAG1 or Notch1 might serve as potential predictive biomarkers of response to paclitaxel-based chemotherapy and/or therapeutic targets that will help to overcome chemoresistance at the mCRPC stage.	Paclitaxel	141-151	notch receptor 1	Homo sapiens	23-29
30282072-17	2018	By regulating the JAG1/Notch1 axis, miR-34a or its target genes JAG1 or Notch1 might serve as potential predictive biomarkers of response to paclitaxel-based chemotherapy and/or therapeutic targets that will help to overcome chemoresistance at the mCRPC stage.	Paclitaxel	141-151	notch receptor 1	Homo sapiens	72-78
29486476-8	2018	RESULTS: Voruciclib significantly potentiated the effect of paclitaxel and doxorubicin in ABCB1-overexpressing cells, as well as mitoxantrone and SN-38 in ABCG2-overexpressing cells.	Paclitaxel	60-70	ATP binding cassette subfamily B member 1	Homo sapiens	90-95
30355931-12	2018	CONCLUSION: The paclitaxel+hirudin compound promotes MyD88 degradation in the TLR4/MyD88/NF-kappaB pathway to reduce the activity of TLR4 and NF-kappaB p65 and to weaken the LPS-initiated inflammatory reactions of IL-1beta, IL-6, and TNF-alpha.	Paclitaxel	16-26	nuclear factor kappa B subunit 1	Homo sapiens	89-98
30355931-12	2018	CONCLUSION: The paclitaxel+hirudin compound promotes MyD88 degradation in the TLR4/MyD88/NF-kappaB pathway to reduce the activity of TLR4 and NF-kappaB p65 and to weaken the LPS-initiated inflammatory reactions of IL-1beta, IL-6, and TNF-alpha.	Paclitaxel	16-26	nuclear factor kappa B subunit 1	Homo sapiens	142-151
30355931-12	2018	CONCLUSION: The paclitaxel+hirudin compound promotes MyD88 degradation in the TLR4/MyD88/NF-kappaB pathway to reduce the activity of TLR4 and NF-kappaB p65 and to weaken the LPS-initiated inflammatory reactions of IL-1beta, IL-6, and TNF-alpha.	Paclitaxel	16-26	interleukin 1 beta	Homo sapiens	214-222
30355931-12	2018	CONCLUSION: The paclitaxel+hirudin compound promotes MyD88 degradation in the TLR4/MyD88/NF-kappaB pathway to reduce the activity of TLR4 and NF-kappaB p65 and to weaken the LPS-initiated inflammatory reactions of IL-1beta, IL-6, and TNF-alpha.	Paclitaxel	16-26	interleukin 6	Homo sapiens	224-228
30355931-12	2018	CONCLUSION: The paclitaxel+hirudin compound promotes MyD88 degradation in the TLR4/MyD88/NF-kappaB pathway to reduce the activity of TLR4 and NF-kappaB p65 and to weaken the LPS-initiated inflammatory reactions of IL-1beta, IL-6, and TNF-alpha.	Paclitaxel	16-26	tumor necrosis factor	Homo sapiens	234-243
30355931-3	2018	This study aimed to explore the anti-inflammatory and anti-restenosis mechanisms of paclitaxel+hirudin with regard to the TLR4/MyD88/NF-kappaB pathway.	Paclitaxel	84-94	nuclear factor kappa B subunit 1	Homo sapiens	133-142
30355931-6	2018	After MyD88 knockdown and selective blocking of MyD88 degradation with epoxomicin, the effects of paclitaxel+hirudin stenting on key sites of the TLR4/MyD88/NF-kappaB pathway were detected using ELISA, Q-PCR, and western blot analysis.	Paclitaxel	98-108	nuclear factor kappa B subunit 1	Homo sapiens	157-166
29031923-0	2018	DEAE-Dextran coated paclitaxel nanoparticles act as multifunctional nano system for intranuclear delivery to triple negative breast cancer through VEGF and NOTCH1 inhibition.	Paclitaxel	20-30	vascular endothelial growth factor A	Homo sapiens	147-151
29577869-1	2018	BACKGROUND: Membrane transport protein organic anion transporting polypeptide (OATP) 1B3 mediates the cellular uptake of many clinically important drugs including anti-cancer drugs (e.g., paclitaxel).	Paclitaxel	188-198	solute carrier organic anion transporter family member 1B3	Homo sapiens	39-88
29031923-0	2018	DEAE-Dextran coated paclitaxel nanoparticles act as multifunctional nano system for intranuclear delivery to triple negative breast cancer through VEGF and NOTCH1 inhibition.	Paclitaxel	20-30	notch receptor 1	Homo sapiens	156-162
29483955-8	2018	In vitro analysis of cell viability, apoptosis and cell cycle revealed that Abra/anti-HER2 NPs showed more anti-tumor efficacy against HER2(+) SK-BR-3 cells than Abraxane  at equivalent PTX concentration.	Paclitaxel	186-189	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
29940750-0	2018	Alpha1,2-fucosyl transferase gene, the key enzyme of Lewis y synthesis, promotes Taxol resistance of ovarian carcinoma through apoptosis-related proteins.	Paclitaxel	81-86	fucosyltransferase 2	Homo sapiens	0-28
28581827-4	2018	When loaded with paclitaxel, FCD-1 nanoparticles, which have smaller particle size, neutral zeta potential, high encapsulation efficiency and better loading capacity for controlled release, emerged as an effective formulation in terms of cytotoxicity and high cellular uptake.	Paclitaxel	17-27	FECD2	Homo sapiens	29-34
28581827-7	2018	Both paclitaxel-loaded FCD-1 and FCD-2 significantly reduced tumour burden while FCD-1 significantly improved the survival.	Paclitaxel	5-15	FECD2	Homo sapiens	23-28
29623757-0	2018	Icariin, a flavonoid with anti-cancer effects, alleviated paclitaxel-induced neuropathic pain in a SIRT1-dependent manner.	Paclitaxel	58-68	sirtuin 1	Rattus norvegicus	99-104
29623757-11	2018	Paclitaxel treatment also induced NF-kappaB(p65) activation and upregulation of proinflammatory factors (TNF-alpha, IL-1beta, and IL-6).	Paclitaxel	0-10	synaptotagmin 1	Rattus norvegicus	44-47
29623757-11	2018	Paclitaxel treatment also induced NF-kappaB(p65) activation and upregulation of proinflammatory factors (TNF-alpha, IL-1beta, and IL-6).	Paclitaxel	0-10	tumor necrosis factor	Rattus norvegicus	105-114
29623757-11	2018	Paclitaxel treatment also induced NF-kappaB(p65) activation and upregulation of proinflammatory factors (TNF-alpha, IL-1beta, and IL-6).	Paclitaxel	0-10	interleukin 1 beta	Rattus norvegicus	116-124
29623757-11	2018	Paclitaxel treatment also induced NF-kappaB(p65) activation and upregulation of proinflammatory factors (TNF-alpha, IL-1beta, and IL-6).	Paclitaxel	0-10	interleukin 6	Rattus norvegicus	130-134
29623757-14	2018	Furthermore, icariin treatment dosage-dependently reversed paclitaxel-induced SIRT1 downregulation and H4 acetylation.	Paclitaxel	59-69	sirtuin 1	Rattus norvegicus	78-83
29623757-16	2018	Conclusions This meant that spinal SIRT1 activation was involved in icariin-induced effects in paclitaxel-induced neuropathic pain rats.	Paclitaxel	95-105	sirtuin 1	Rattus norvegicus	35-40
29203914-2	2018	Our objective was to engender synthetic lethality to paclitaxel (PTX), the frontline treatment for endometrial cancer, in tumours with mutant p53 and enhance the therapeutic efficacy using polymeric nanoparticles (NPs).	Paclitaxel	53-63	tumor protein p53	Homo sapiens	142-145
29203914-2	2018	Our objective was to engender synthetic lethality to paclitaxel (PTX), the frontline treatment for endometrial cancer, in tumours with mutant p53 and enhance the therapeutic efficacy using polymeric nanoparticles (NPs).	Paclitaxel	65-68	tumor protein p53	Homo sapiens	142-145
29203914-6	2018	Together, our data provide compelling evidence for future studies of BIBF- and PTX-loaded NPs as a therapeutic opportunity for LOF p53 cancers.	Paclitaxel	79-82	tumor protein p53	Homo sapiens	131-134
29169081-2	2018	Transcriptome profiling was conducted for different tissues of the ZD1 and WT to illustrate the regulation mechanism of paclitaxel biosynthesis.	Paclitaxel	120-130	ZD1	Homo sapiens	67-70
29399166-7	2018	It was identified that the expression levels of Twist, TOPO IIalpha, MRP and P-gp were upregulated and LRP was downregulated in human breast cancer tissues, which was consistent with the expression of these proteins in the Taxol -resistant MCF-7 cell model.	Paclitaxel	223-228	ATP binding cassette subfamily C member 1	Homo sapiens	69-72
29399166-7	2018	It was identified that the expression levels of Twist, TOPO IIalpha, MRP and P-gp were upregulated and LRP was downregulated in human breast cancer tissues, which was consistent with the expression of these proteins in the Taxol -resistant MCF-7 cell model.	Paclitaxel	223-228	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
29169081-3	2018	It was observed that average contents of paclitaxel and 10-DABIII in ZD1 were 4 folds and 32 folds higher than those in WT, respectively.	Paclitaxel	41-51	ZD1	Homo sapiens	69-72
29169081-4	2018	More significant elevations of differential expressed genes (DEGs) from paclitaxel biosynthesis pathway were revealed in ZD1 rather than WT, which should be responsible for the higher contents of paclitaxel and 10-DABIII in the ZD1.	Paclitaxel	72-82	ZD1	Homo sapiens	121-124
29169081-4	2018	More significant elevations of differential expressed genes (DEGs) from paclitaxel biosynthesis pathway were revealed in ZD1 rather than WT, which should be responsible for the higher contents of paclitaxel and 10-DABIII in the ZD1.	Paclitaxel	72-82	ZD1	Homo sapiens	228-231
29169081-4	2018	More significant elevations of differential expressed genes (DEGs) from paclitaxel biosynthesis pathway were revealed in ZD1 rather than WT, which should be responsible for the higher contents of paclitaxel and 10-DABIII in the ZD1.	Paclitaxel	196-206	ZD1	Homo sapiens	121-124
29169081-4	2018	More significant elevations of differential expressed genes (DEGs) from paclitaxel biosynthesis pathway were revealed in ZD1 rather than WT, which should be responsible for the higher contents of paclitaxel and 10-DABIII in the ZD1.	Paclitaxel	196-206	ZD1	Homo sapiens	228-231
29169081-5	2018	Special tissues-dependent expression patterns of paclitaxel biosynthesis DEGs in ZD1 compared to WT were unraveled.	Paclitaxel	49-59	ZD1	Homo sapiens	81-84
29169081-6	2018	The relative higher expressions of paclitaxel biosynthesis genes in needles than other tissues supported the higher content of paclitaxel and 10-DABIII content in needles of ZD1.	Paclitaxel	35-45	ZD1	Homo sapiens	174-177
29169081-6	2018	The relative higher expressions of paclitaxel biosynthesis genes in needles than other tissues supported the higher content of paclitaxel and 10-DABIII content in needles of ZD1.	Paclitaxel	127-137	ZD1	Homo sapiens	174-177
29054369-10	2017	Additional model simulations indicate that within clinically achievable PTX concentrations, the contribution of exosomes to active drug efflux increased with drug concentration and exceeded the p-glycoprotein efflux when the latter was saturated.	Paclitaxel	72-75	ATP binding cassette subfamily B member 1	Homo sapiens	194-208
30384806-0	2018	MicroRNA-22 Suppresses Breast Cancer Cell Growth and Increases Paclitaxel Sensitivity by Targeting NRAS.	Paclitaxel	63-73	microRNA 22	Homo sapiens	0-11
30384806-8	2018	Moreover, microRNA-22 sensitized breast cancer cells to paclitaxel by regulation of NRAS.	Paclitaxel	56-66	microRNA 22	Homo sapiens	10-21
29416635-0	2018	OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer.	Paclitaxel	48-58	OTU deubiquitinase 7B	Homo sapiens	0-6
29435178-0	2018	Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.	Paclitaxel	47-57	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
29435178-0	2018	Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.	Paclitaxel	47-57	mitogen-activated protein kinase 1	Homo sapiens	22-25
29416635-9	2018	In silico analysis suggested that OTUD7B regulation, probably owing to miR-1180 downregulation, may negatively regulate the NF-kappaB-Lin28 axis which in turn triggers Let-7 microRNA-mediated caspase-3 downregulation, thereby conferring paclitaxel resistance in TNBCs.	Paclitaxel	237-247	lin-28 homolog A	Homo sapiens	134-139
29416635-4	2018	We found that OTUD7B was downregulated in HCC38 but upregulated in MDA-MB436 cells after paclitaxel treatment at cytotoxic concentrations.	Paclitaxel	89-99	OTU deubiquitinase 7B	Homo sapiens	14-20
29416635-9	2018	In silico analysis suggested that OTUD7B regulation, probably owing to miR-1180 downregulation, may negatively regulate the NF-kappaB-Lin28 axis which in turn triggers Let-7 microRNA-mediated caspase-3 downregulation, thereby conferring paclitaxel resistance in TNBCs.	Paclitaxel	237-247	caspase 3	Homo sapiens	192-201
29416635-10	2018	These findings suggest that OTUD7B may be a useful biomarker for predicting the anti-cancer effectiveness of paclitaxel and could serve as a new drug target for enhancing the canceridal efficiency of paclitaxel against TNBCs.	Paclitaxel	109-119	OTU deubiquitinase 7B	Homo sapiens	28-34
29416635-5	2018	Moreover, our data showed that OTUD7B expression causally correlated with IC50 of paclitaxel in a panel of TNBC cell lines.	Paclitaxel	82-92	OTU deubiquitinase 7B	Homo sapiens	31-37
29416635-10	2018	These findings suggest that OTUD7B may be a useful biomarker for predicting the anti-cancer effectiveness of paclitaxel and could serve as a new drug target for enhancing the canceridal efficiency of paclitaxel against TNBCs.	Paclitaxel	200-210	OTU deubiquitinase 7B	Homo sapiens	28-34
29416635-8	2018	In assessments of recurrence/metastasis-free survival probability, high-levels of OTUD7B transcripts strongly predicted a poor prognosis and unfavorable response to paclitaxel-based chemotherapy in patients with TNBCs.	Paclitaxel	165-175	OTU deubiquitinase 7B	Homo sapiens	82-88
29416635-9	2018	In silico analysis suggested that OTUD7B regulation, probably owing to miR-1180 downregulation, may negatively regulate the NF-kappaB-Lin28 axis which in turn triggers Let-7 microRNA-mediated caspase-3 downregulation, thereby conferring paclitaxel resistance in TNBCs.	Paclitaxel	237-247	OTU deubiquitinase 7B	Homo sapiens	34-40
29371916-0	2017	The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.	Paclitaxel	59-69	mitogen-activated protein kinase 3	Homo sapiens	113-119
29255417-7	2017	Paclitaxel significantly increased the expression of inflammatory cytokines including tumor necrosis factor-alpha (2.2 times) and interleukin-1beta (2.7 times) in the lumbar dorsal root ganglion, and rolipram significantly decreased it.	Paclitaxel	0-10	tumor necrosis factor	Rattus norvegicus	86-113
29255417-7	2017	Paclitaxel significantly increased the expression of inflammatory cytokines including tumor necrosis factor-alpha (2.2 times) and interleukin-1beta (2.7 times) in the lumbar dorsal root ganglion, and rolipram significantly decreased it.	Paclitaxel	0-10	interleukin 1 beta	Rattus norvegicus	130-147
29255417-8	2017	In addition, phosphodiesterase-4 and interleukin-1beta were expressed in the dorsal root ganglion neurons and satellite cells and paclitaxel significantly increased the intensity of interleukin-1beta (2 times) and rolipram significantly decreased it.	Paclitaxel	130-140	interleukin 1 beta	Rattus norvegicus	182-199
28832946-7	2017	The combination of Cis-DDP and PTX demonstrates a synergistic effect against MDA-MB-231 cell line assigned to three different mechanisms of action, including denaturation of DNA strands, stabilization of microtubules, and amplification of intracellular reactive oxygen species (ROS) and activation of caspase-3 pathways.	Paclitaxel	31-34	caspase 3	Homo sapiens	301-310
29270012-6	2017	The results of in vitro studies show that, compared to the control group, the DSF and PTX co-loaded micelles with charge reversal exhibits more effective cellular uptake and significantly increased cytotoxicity of PTX to MCF-7/ADR cells which may be due to the inhibitory effect of DSF on the efflux function of P-gp.	Paclitaxel	86-89	ATP binding cassette subfamily B member 1	Homo sapiens	312-316
29285378-0	2017	Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin-bound paclitaxel for human epidermal growth factor receptor 2-negative breast cancer.	Paclitaxel	85-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-140
29619192-3	2017	The first synthesis of poly(1,2-glycerol carbonate)-graft-succinic acid-paclitaxel (PGC-PTX) is described, and its use enables high, controlled PTX loadings of up to 74 wt%.	Paclitaxel	88-91	progastricsin (pepsinogen C)	Mus musculus	84-87
29619192-5	2017	When formulated as nanoparticles (NPs), PGC-PTX NPs exhibit PTX concentrations &gt;15 mg mL-1, sub-100 nm diameters, narrow dispersity, storage stability for up to 6 months, and sustained and controlled PTX release kinetics over an extended period of 70 days.	Paclitaxel	44-47	progastricsin (pepsinogen C)	Mus musculus	40-43
29619192-5	2017	When formulated as nanoparticles (NPs), PGC-PTX NPs exhibit PTX concentrations &gt;15 mg mL-1, sub-100 nm diameters, narrow dispersity, storage stability for up to 6 months, and sustained and controlled PTX release kinetics over an extended period of 70 days.	Paclitaxel	60-63	progastricsin (pepsinogen C)	Mus musculus	40-43
29619192-5	2017	When formulated as nanoparticles (NPs), PGC-PTX NPs exhibit PTX concentrations &gt;15 mg mL-1, sub-100 nm diameters, narrow dispersity, storage stability for up to 6 months, and sustained and controlled PTX release kinetics over an extended period of 70 days.	Paclitaxel	60-63	progastricsin (pepsinogen C)	Mus musculus	40-43
29619192-6	2017	A safely administered single dose of PGC-PTX NPs contains more PTX than the median lethal dose of standard PTX.	Paclitaxel	41-44	progastricsin (pepsinogen C)	Mus musculus	37-40
29619192-6	2017	A safely administered single dose of PGC-PTX NPs contains more PTX than the median lethal dose of standard PTX.	Paclitaxel	63-66	progastricsin (pepsinogen C)	Mus musculus	37-40
29619192-6	2017	A safely administered single dose of PGC-PTX NPs contains more PTX than the median lethal dose of standard PTX.	Paclitaxel	63-66	progastricsin (pepsinogen C)	Mus musculus	37-40
29619192-7	2017	In murine models of peritoneal carcinomatosis, in which the clinical implementation of multi-dose intraperitoneal (IP) treatment regimens is limited by catheter-related complications, PGC-PTX NPs exhibit improved safety at high doses, tumor localization, and efficacy even after a single IP injection, with comparable curative effect to PTX administered as a multi-dose IP treatment regimen.	Paclitaxel	188-191	progastricsin (pepsinogen C)	Mus musculus	184-187
29619192-7	2017	In murine models of peritoneal carcinomatosis, in which the clinical implementation of multi-dose intraperitoneal (IP) treatment regimens is limited by catheter-related complications, PGC-PTX NPs exhibit improved safety at high doses, tumor localization, and efficacy even after a single IP injection, with comparable curative effect to PTX administered as a multi-dose IP treatment regimen.	Paclitaxel	337-340	progastricsin (pepsinogen C)	Mus musculus	184-187
28978720-5	2017	On an extended panel of 31 NSCLC cell lines, 25 of which were adenocarcinoma, the synergy between BMS-906024 and paclitaxel was significantly greater in KRAS- and BRAF-wildtype than KRAS- or BRAF-mutant cells (mean CI, 0.43 vs. 0.90, respectively; P = 0.003).	Paclitaxel	113-123	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	163-167
28978720-5	2017	On an extended panel of 31 NSCLC cell lines, 25 of which were adenocarcinoma, the synergy between BMS-906024 and paclitaxel was significantly greater in KRAS- and BRAF-wildtype than KRAS- or BRAF-mutant cells (mean CI, 0.43 vs. 0.90, respectively; P = 0.003).	Paclitaxel	113-123	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	191-195
28978720-6	2017	Paclitaxel-induced Notch1 activation was associated with synergy between BMS-906024 and paclitaxel in the KRAS- or BRAF-mutant group.	Paclitaxel	0-10	notch receptor 1	Homo sapiens	19-25
28978720-6	2017	Paclitaxel-induced Notch1 activation was associated with synergy between BMS-906024 and paclitaxel in the KRAS- or BRAF-mutant group.	Paclitaxel	0-10	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	115-119
28978720-6	2017	Paclitaxel-induced Notch1 activation was associated with synergy between BMS-906024 and paclitaxel in the KRAS- or BRAF-mutant group.	Paclitaxel	88-98	notch receptor 1	Homo sapiens	19-25
28978720-6	2017	Paclitaxel-induced Notch1 activation was associated with synergy between BMS-906024 and paclitaxel in the KRAS- or BRAF-mutant group.	Paclitaxel	88-98	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	115-119
29031225-0	2017	Cube-shaped theranostic paclitaxel prodrug nanocrystals with surface functionalization of SPC and MPEG-DSPE for imaging and chemotherapy.	Paclitaxel	24-34	proline rich protein gene cluster	Homo sapiens	90-93
29031225-9	2017	Moreover, in comparison with free PTX-NBD and the sphere-shaped PTX-NBD nanocrystals with surface functionalization of SPC and MPEG-DSPE (PTX-NBD@PC-PEG NSs), PTX-NBD@PC-PEG NCs remarkably reduced burst release and improved cellular uptake efficiency and in vitro cancer cell killing ability.	Paclitaxel	64-67	proline rich protein gene cluster	Homo sapiens	119-122
29031225-9	2017	Moreover, in comparison with free PTX-NBD and the sphere-shaped PTX-NBD nanocrystals with surface functionalization of SPC and MPEG-DSPE (PTX-NBD@PC-PEG NSs), PTX-NBD@PC-PEG NCs remarkably reduced burst release and improved cellular uptake efficiency and in vitro cancer cell killing ability.	Paclitaxel	64-67	proline rich protein gene cluster	Homo sapiens	119-122
28815582-3	2017	Small interfering RNA-mediated reduction in COL11A1 protein levels increased the chemosensitivity to cisplatin and paclitaxel via downregulated TWIST1 expression.	Paclitaxel	115-125	twist family bHLH transcription factor 1	Homo sapiens	144-150
27844290-0	2017	Potentiation of Paclitaxel-Induced Pain Syndrome in Mice by Angiotensin I Converting Enzyme Inhibition and Involvement of Kinins.	Paclitaxel	16-26	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	60-73
27844290-10	2017	Because hypertension is the most frequent comorbidity affecting cancer patients, treatment of hypertension with ACE inhibitors in patients undergoing paclitaxel chemotherapy should be reviewed, since this could enhance the P-APS and P-CPN.	Paclitaxel	150-160	angiotensin I converting enzyme	Homo sapiens	112-115
28991240-6	2017	Consistent with YB1 signaling being known to cause taxol resistance, combination of ceritinib with paclitaxel displayed strong synergy, particularly in cells expressing high FAK autophosphorylation, which we show to be prevalent in lung cancer.	Paclitaxel	51-56	Y-box binding protein 1	Homo sapiens	16-19
28991240-6	2017	Consistent with YB1 signaling being known to cause taxol resistance, combination of ceritinib with paclitaxel displayed strong synergy, particularly in cells expressing high FAK autophosphorylation, which we show to be prevalent in lung cancer.	Paclitaxel	99-109	Y-box binding protein 1	Homo sapiens	16-19
29290962-10	2017	After adjusting for multiple clinical covariates, SNPs on the LPHN2, ROBO1, SNTG1, and GRIK1 genes were significant independent predictors of poor tumor response (tumor growth) despite paclitaxel treatment.	Paclitaxel	185-195	adhesion G protein-coupled receptor L2	Homo sapiens	62-67
29209558-3	2017	The combined application of pertuzumab, trastuzumab and paclitaxel has been suggested as a standard therapy for HER2 positive advanced breast cancer.	Paclitaxel	56-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116
29162114-0	2017	A computational study of the inhibition mechanisms of P-glycoprotein mediated paclitaxel efflux by kinase inhibitors.	Paclitaxel	78-88	ATP binding cassette subfamily B member 1	Homo sapiens	54-68
29162114-2	2017	One P-gp substrate is the widely used chemotherapy drug paclitaxel.	Paclitaxel	56-66	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
29162114-3	2017	Co-administration of paclitaxel and another drug that inhibits P-gp may enhance the therapeutic effectiveness of paclitaxel by preventing its efflux from tumor cells.	Paclitaxel	21-31	ATP binding cassette subfamily B member 1	Homo sapiens	63-67
29162114-3	2017	Co-administration of paclitaxel and another drug that inhibits P-gp may enhance the therapeutic effectiveness of paclitaxel by preventing its efflux from tumor cells.	Paclitaxel	113-123	ATP binding cassette subfamily B member 1	Homo sapiens	63-67
29162114-4	2017	RESULTS: Here we present a computational approach that combines docking studies with mass action kinetic modeling to investigate how kinase inhibitors may inhibit P-gp mediated paclitaxel efflux.	Paclitaxel	177-187	ATP binding cassette subfamily B member 1	Homo sapiens	163-167
29162114-6	2017	The relative scales of these two competitions are TKI dependent and determined by the relative affinities of paclitaxel and TKIs to the SBD and NBD of P-gp, and their membrane partition coefficients.	Paclitaxel	109-119	ATP binding cassette subfamily B member 1	Homo sapiens	151-155
29180320-7	2017	lncRNA-GAS5 expression was also significantly lowered in paclitaxel-resistant breast cancer cells and showed a positive correlation with P21 expression and a negative correlation with CDK6.	Paclitaxel	57-67	cyclin dependent kinase 6	Homo sapiens	184-188
29039556-0	2017	Huaier extract enhances the treatment efficacy of paclitaxel in breast cancer cells via the NF-kappaB/IkappaBalpha pathway.	Paclitaxel	50-60	NFKB inhibitor alpha	Homo sapiens	102-114
29039556-8	2017	Furthermore, the results of real-time PCR and western blotting revealed that Huaier extract decreased p65 and c-Met expression and increased IkappaBalpha expression, while paclitaxel increased p65 expression and reduced IkappaBalpha and c-Met expression.	Paclitaxel	172-182	NFKB inhibitor alpha	Homo sapiens	220-232
29039556-8	2017	Furthermore, the results of real-time PCR and western blotting revealed that Huaier extract decreased p65 and c-Met expression and increased IkappaBalpha expression, while paclitaxel increased p65 expression and reduced IkappaBalpha and c-Met expression.	Paclitaxel	172-182	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	237-242
29179722-10	2017	The caspase-9 and caspase-3 cascade was activated by the AG-PEG-SS-PLA/PTX nanomicelles through upregulation of the pro-apoptotic proteins Bax and Bid and suppression of the anti-apoptotic protein Bcl-2, thereby increasing apoptosis.	Paclitaxel	71-74	B cell leukemia/lymphoma 2	Mus musculus	197-202
29290962-10	2017	After adjusting for multiple clinical covariates, SNPs on the LPHN2, ROBO1, SNTG1, and GRIK1 genes were significant independent predictors of poor tumor response (tumor growth) despite paclitaxel treatment.	Paclitaxel	185-195	glutamate ionotropic receptor kainate type subunit 1	Homo sapiens	87-92
29291021-7	2017	We then determined the epitope recognition of GRP78 autoantibodies and showed that treatment with paclitaxel-loaded nanoparticles coated with anti-GRP78 antibodies significantly decreased tumor development in chick embryo culture of ovarian cancer cell tumors compared to paclitaxel treatment alone.	Paclitaxel	98-108	heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)	Gallus gallus	46-51
29291021-7	2017	We then determined the epitope recognition of GRP78 autoantibodies and showed that treatment with paclitaxel-loaded nanoparticles coated with anti-GRP78 antibodies significantly decreased tumor development in chick embryo culture of ovarian cancer cell tumors compared to paclitaxel treatment alone.	Paclitaxel	98-108	heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)	Gallus gallus	147-152
29291021-7	2017	We then determined the epitope recognition of GRP78 autoantibodies and showed that treatment with paclitaxel-loaded nanoparticles coated with anti-GRP78 antibodies significantly decreased tumor development in chick embryo culture of ovarian cancer cell tumors compared to paclitaxel treatment alone.	Paclitaxel	272-282	heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)	Gallus gallus	147-152
28756208-3	2017	Compared to control cells caspase-3/7 activation by paclitaxel was lower in MDA-2J2 cells, while cell proliferation and colony formation following paclitaxel treatment were increased.	Paclitaxel	52-62	caspase 3	Homo sapiens	26-35
29061836-0	2017	Evaluation of Efficacy and Safety of Upfront Weekly Nanoparticle Albumin-bound Paclitaxel for HER2-negative Breast Cancer.	Paclitaxel	79-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-98
29061836-2	2017	This study aimed to evaluate the efficacy of upfront weekly nanoparticle albumin-bound paclitaxel (Nab-PTX; 100 mg/m2) for human epidermal growth factor 2 (HER2)-negative breast cancer.	Paclitaxel	87-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	156-160
29061836-2	2017	This study aimed to evaluate the efficacy of upfront weekly nanoparticle albumin-bound paclitaxel (Nab-PTX; 100 mg/m2) for human epidermal growth factor 2 (HER2)-negative breast cancer.	Paclitaxel	99-106	erb-b2 receptor tyrosine kinase 2	Homo sapiens	156-160
29163177-5	2017	Methods: An extensive panel of five polymorphisms on four candidate genes (ABCB1, CYP2C8*3, CYP3A4*1B, XRCC3), previously validated as significant markers related to paclitaxel and Docetaxel toxicity, are analyzed and discussed.	Paclitaxel	166-176	ATP binding cassette subfamily B member 1	Homo sapiens	75-80
29348852-8	2017	Knockdown of FBXW7 in vitro enhanced cell proliferation, and migration, and invasion abilities and promoted gemcitabine and nab-paclitaxel chemoresistance in pancreatic cancer cells.	Paclitaxel	128-138	F-box and WD repeat domain containing 7	Homo sapiens	13-18
28950656-8	2017	Mechanistically, the combination treatment was more efficient than paclitaxel monotherapy in reducing ATP, MDA, TNF-alpha and Il-17 contents in SEC.	Paclitaxel	67-77	tumor necrosis factor	Mus musculus	112-121
28946186-0	2017	Cryptotanshinone sensitizes antitumor effect of paclitaxel on tongue squamous cell carcinoma growth by inhibiting the JAK/STAT3 signaling pathway.	Paclitaxel	48-58	signal transducer and activator of transcription 3	Homo sapiens	122-127
28946186-5	2017	Furthermore, we found that the combination treatment of Cryptotanshinone and paclitaxel more effectively inhibited TSCC cell proliferation and migration, and induced apoptosis via the inhibition of STAT3 signaling pathway.	Paclitaxel	77-87	signal transducer and activator of transcription 3	Homo sapiens	198-203
28946186-6	2017	In brief, we provided the new evidence that Cryptotanshinone could enhance the efficacy of paclitaxel on TSCC cells in vitro and demonstrated that STAT3 signaling pathway played an important role in Cryptotanshinone-induced anticancer effects in human TSCC.	Paclitaxel	91-101	signal transducer and activator of transcription 3	Homo sapiens	147-152
28869866-3	2017	In order to overcome these limitations, an oncolytic Ad expressing a p53 variant (oAd-vp53) that is resistant to p53 inactivation in the tumor microenvironment was complexed with PEGylated and PTX-conjugated polymeric micelle (APP).	Paclitaxel	193-196	tumor protein p53	Homo sapiens	69-72
28938519-11	2017	DTX and PTX caused significant decreases in absolute and relative weights of all reproductive organs, testosterone level, sperm motility, concentration, Bcl-2 anti-apoptotic immunopositive cell scores of testes and spermatozoa as well as catalase activity in epididymal tissue, superoxide dismutase and glutathione peroxidase activities of testicular and epididymal tissues when compared with the control group.	Paclitaxel	8-11	BCL2, apoptosis regulator	Rattus norvegicus	153-158
28856937-6	2017	In vivo, AP/PTX-SLNs were revealed to be much more effective in suppressing tumor growth in B16F10-bearing mice and in eliminating cancer cells in the lungs than single drug (AP or PTX)-loaded SLNs via a synergistic effect through reducing the Bcl-2/Bax ratio.	Paclitaxel	12-15	B cell leukemia/lymphoma 2	Mus musculus	244-249
28845572-2	2017	Here, we report the case of a 34-year-old woman with hormone-sensitive, HER-2/neu negative, metastatic breast cancer who develope a nasal septum perforation during the treatment with paclitaxel and bevacizumab.	Paclitaxel	183-193	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-77
28845572-2	2017	Here, we report the case of a 34-year-old woman with hormone-sensitive, HER-2/neu negative, metastatic breast cancer who develope a nasal septum perforation during the treatment with paclitaxel and bevacizumab.	Paclitaxel	183-193	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-81
28923854-7	2017	Cav-1 protein levels correlated positively with nab-paclitaxel sensitivity.	Paclitaxel	52-62	caveolin 1	Homo sapiens	0-5
28923854-8	2017	RNAi-mediated attenuation of Cav-1 expression reduced uptake of albumin and nab-paclitaxel in cancer cells and rendered them resistant to nab-paclitaxel-induced apoptosis.	Paclitaxel	80-90	caveolin 1	Homo sapiens	29-34
28923854-9	2017	Conversely, Cav-1 overexpression enhanced sensitivity to nab-paclitaxel.	Paclitaxel	61-71	caveolin 1	Homo sapiens	12-17
28923854-10	2017	Selection for cellular resistance to nab-paclitaxel in cell culture correlated with a loss of Cav-1 expression.	Paclitaxel	41-51	caveolin 1	Homo sapiens	94-99
28923854-12	2017	Overall, our findings suggest Cav-1 as a predictive biomarker for the response to nab-paclitaxel and other albumin-based cancer therapeutic drugs.	Paclitaxel	86-96	caveolin 1	Homo sapiens	30-35
28923573-0	2017	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).	Paclitaxel	44-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-74
31271140-11	2017	In addition, we revealed that free paclitaxel treatment resulted in higher levels of IL-6, IL-10, PDL-1, TGF-beta1, TNF-alpha and VEGF, while the expression levels of these inflammatory factors were much lower in the other two groups, especially in the Nano-PTX-GEL treated groups.	Paclitaxel	35-45	interleukin 6	Homo sapiens	85-89
31271140-11	2017	In addition, we revealed that free paclitaxel treatment resulted in higher levels of IL-6, IL-10, PDL-1, TGF-beta1, TNF-alpha and VEGF, while the expression levels of these inflammatory factors were much lower in the other two groups, especially in the Nano-PTX-GEL treated groups.	Paclitaxel	35-45	transforming growth factor beta 1	Homo sapiens	105-114
31271140-11	2017	In addition, we revealed that free paclitaxel treatment resulted in higher levels of IL-6, IL-10, PDL-1, TGF-beta1, TNF-alpha and VEGF, while the expression levels of these inflammatory factors were much lower in the other two groups, especially in the Nano-PTX-GEL treated groups.	Paclitaxel	35-45	tumor necrosis factor	Homo sapiens	116-125
31271140-11	2017	In addition, we revealed that free paclitaxel treatment resulted in higher levels of IL-6, IL-10, PDL-1, TGF-beta1, TNF-alpha and VEGF, while the expression levels of these inflammatory factors were much lower in the other two groups, especially in the Nano-PTX-GEL treated groups.	Paclitaxel	35-45	vascular endothelial growth factor A	Homo sapiens	130-134
28701571-15	2017	IMPLICATIONS FOR PRACTICE: The pathological response rate (residual cancer burden [RCB]; Symmans criteria) of nanoparticle albumin-bound paclitaxel administered as neoadjuvant treatment for early estrogen receptor-positive, human epidermal growth factor receptor 2-negative disease was evaluated.	Paclitaxel	137-147	erb-b2 receptor tyrosine kinase 2	Homo sapiens	230-264
29181166-0	2017	Successful and long-term response to trastuzumab plus paclitaxel combination therapy in human epidermal growth factor receptor 2-positive extramammary Paget"s disease: A case report and review of the literature.	Paclitaxel	54-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-128
29181166-3	2017	As pathological examination indicated that the lesion was positive for human epidermal growth factor receptor 2 (HER2) on immunohistochemical staining, the patient was treated with trastuzumab plus paclitaxel.	Paclitaxel	198-208	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-111
29181166-3	2017	As pathological examination indicated that the lesion was positive for human epidermal growth factor receptor 2 (HER2) on immunohistochemical staining, the patient was treated with trastuzumab plus paclitaxel.	Paclitaxel	198-208	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
29037225-12	2017	GCCSysm-4 (G-4), a YAP and COX-2 inhibitor, effectively inhibited both YAP and COX-2 activation, induced apoptosis and decreased viability in Taxol-resistant cells.	Paclitaxel	142-147	chromosome 6 open reading frame 47	Homo sapiens	0-14
29072615-0	2017	The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells.	Paclitaxel	94-104	signal transducer and activator of transcription 3	Homo sapiens	109-114
29072615-0	2017	The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells.	Paclitaxel	94-104	ATP binding cassette subfamily B member 1	Homo sapiens	125-129
29072615-0	2017	The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells.	Paclitaxel	94-104	ATP binding cassette subfamily C member 1	Homo sapiens	134-138
29072615-8	2017	Collectively, our data show that LSS-11 is a potent naphthalimide-based chemosensitizer that could enhance cell death in paclitaxel-resistant lung cancer cells through the DR5/PARP1 pathway and STAT3/MDR1/MRP1 STAT3 inhibition.	Paclitaxel	121-131	ATP binding cassette subfamily B member 1	Homo sapiens	200-204
29083340-1	2017	Taxanes, including paclitaxel and docetaxel, are one of the most active cytotoxic agents in breast cancer  treatment  including  Her-2  positive  subtype characterized  by  aggressive  clinical  and pathological features since the early stage.	Paclitaxel	19-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-134
29066719-6	2017	We further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.	Paclitaxel	198-208	insulin like growth factor 2 mRNA binding protein 2	Homo sapiens	93-100
29066719-6	2017	We further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.	Paclitaxel	198-208	kelch domain containing 9	Homo sapiens	122-128
28581516-4	2017	Although the drug targeting inactivation of tumor suppressors by DNA methylation had little effect, the inhibition of Mek, a K-Ras effector, in combination with the standard of care (chemotherapy consisting of gemcitabine/Nab-paclitaxel), reduced the growth of three out of five PC-PDXs and impaired metastasis.	Paclitaxel	226-236	mitogen-activated protein kinase kinase 7	Homo sapiens	118-121
29024661-0	2017	Paclitaxel Reduces Axonal Bclw to Initiate IP3R1-Dependent Axon Degeneration.	Paclitaxel	0-10	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	43-48
29024661-4	2017	Here we show that the chemotherapeutic agent paclitaxel triggers CIPN by altering IP3 receptor phosphorylation and intracellular calcium flux, and activating calcium-dependent calpain proteases.	Paclitaxel	45-55	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	82-94
29024661-5	2017	Concomitantly paclitaxel impairs axonal trafficking of RNA-granules and reduces synthesis of Bclw (bcl2l2), a Bcl2 family member that binds IP3R1 and restrains axon degeneration.	Paclitaxel	14-24	BCL2 apoptosis regulator	Homo sapiens	110-114
29024661-5	2017	Concomitantly paclitaxel impairs axonal trafficking of RNA-granules and reduces synthesis of Bclw (bcl2l2), a Bcl2 family member that binds IP3R1 and restrains axon degeneration.	Paclitaxel	14-24	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	140-145
28991260-7	2017	We demonstrate that TIS Cal51 cells treated with 75 nM PTX for 7 days became senescent (senescence-associated beta-galactosidase (SA-beta-Gal) positive, Ki67-negative, increased p21 and p16, G2/M cell cycle arrest) and released significantly more EVs (P=0.0002) and exosomes (P=0.0007) than non-senescent control cells.	Paclitaxel	55-58	cyclin dependent kinase inhibitor 2A	Homo sapiens	186-189
29190954-0	2017	Cyclooxygenase-2 mediated synergistic effect of ursolic acid in combination with paclitaxel against human gastric carcinoma.	Paclitaxel	81-91	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-16
29190954-7	2017	Combined delivery of UA and PTX synergistically reduced cell proliferation and induced apoptosis in these cells by lowering COX-2, PCNA, and Bcl-2 expression and by increasing Bax expression.	Paclitaxel	28-31	prostaglandin-endoperoxide synthase 2	Homo sapiens	124-129
29190954-7	2017	Combined delivery of UA and PTX synergistically reduced cell proliferation and induced apoptosis in these cells by lowering COX-2, PCNA, and Bcl-2 expression and by increasing Bax expression.	Paclitaxel	28-31	BCL2 apoptosis regulator	Homo sapiens	141-146
29190954-7	2017	Combined delivery of UA and PTX synergistically reduced cell proliferation and induced apoptosis in these cells by lowering COX-2, PCNA, and Bcl-2 expression and by increasing Bax expression.	Paclitaxel	28-31	BCL2 associated X, apoptosis regulator	Homo sapiens	176-179
29190954-8	2017	These results indicate that the synergistic inhibition of proliferation and induction of apoptosis by UA and PTX may be induced by reducing COX-2 expression in gastric cancer cells.	Paclitaxel	109-112	prostaglandin-endoperoxide synthase 2	Homo sapiens	140-145
27840167-2	2017	Herein, a unique type of biocompatible nanoscale delivery system is fabricated by utilizing a chemotherapeutic drug, paclitaxel (PTX), to induce co-assembly of catalase and human serum albumin (HSA), the latter of which is pre-modified with chlorine e6 (Ce6), forming smart multifunctional HSA-Ce6-Cat-PTX nanoparticles via a rather simple one-step method.	Paclitaxel	117-127	catalase	Homo sapiens	160-168
27840167-2	2017	Herein, a unique type of biocompatible nanoscale delivery system is fabricated by utilizing a chemotherapeutic drug, paclitaxel (PTX), to induce co-assembly of catalase and human serum albumin (HSA), the latter of which is pre-modified with chlorine e6 (Ce6), forming smart multifunctional HSA-Ce6-Cat-PTX nanoparticles via a rather simple one-step method.	Paclitaxel	117-127	albumin	Homo sapiens	179-192
27840167-2	2017	Herein, a unique type of biocompatible nanoscale delivery system is fabricated by utilizing a chemotherapeutic drug, paclitaxel (PTX), to induce co-assembly of catalase and human serum albumin (HSA), the latter of which is pre-modified with chlorine e6 (Ce6), forming smart multifunctional HSA-Ce6-Cat-PTX nanoparticles via a rather simple one-step method.	Paclitaxel	129-132	catalase	Homo sapiens	160-168
27840167-2	2017	Herein, a unique type of biocompatible nanoscale delivery system is fabricated by utilizing a chemotherapeutic drug, paclitaxel (PTX), to induce co-assembly of catalase and human serum albumin (HSA), the latter of which is pre-modified with chlorine e6 (Ce6), forming smart multifunctional HSA-Ce6-Cat-PTX nanoparticles via a rather simple one-step method.	Paclitaxel	129-132	albumin	Homo sapiens	179-192
27840167-2	2017	Herein, a unique type of biocompatible nanoscale delivery system is fabricated by utilizing a chemotherapeutic drug, paclitaxel (PTX), to induce co-assembly of catalase and human serum albumin (HSA), the latter of which is pre-modified with chlorine e6 (Ce6), forming smart multifunctional HSA-Ce6-Cat-PTX nanoparticles via a rather simple one-step method.	Paclitaxel	302-305	catalase	Homo sapiens	160-168
28581516-9	2017	Together with the gemcitabine/Nab-paclitaxel backbone, Mek inhibition could be effective in treatment of PC.	Paclitaxel	34-44	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
28961834-1	2017	Background: Activating events along the PI3K/mTOR pathway are common in head and neck squamous cell carcinomas (HNSCC), and preclinical studies suggest additive or synergistic effects when combining mTORC1 inhibitors with carboplatin and paclitaxel chemotherapy.	Paclitaxel	238-248	mechanistic target of rapamycin kinase	Homo sapiens	45-49
29212208-6	2017	Mechanistically, we demonstrated that Taxol induced expression of stress and stemness markers including GRP78 and CD133 was significantly reduced by addition of Ruxolitinib.	Paclitaxel	38-43	heat shock protein family A (Hsp70) member 5	Homo sapiens	104-109
28829143-2	2017	NADP(H) quinone oxidoreductase 1 (NQO1) inhibitors, such as beta-lapachone (LPC) and tanshinone IIA (THA), are structurally and pharmacologically similar molecules that are poorly water-soluble, crystallize extremely fast, and demonstrate synergistic anticancer effect when used together with paclitaxel (PTX).	Paclitaxel	293-303	NAD(P)H quinone dehydrogenase 1	Homo sapiens	0-32
28829143-2	2017	NADP(H) quinone oxidoreductase 1 (NQO1) inhibitors, such as beta-lapachone (LPC) and tanshinone IIA (THA), are structurally and pharmacologically similar molecules that are poorly water-soluble, crystallize extremely fast, and demonstrate synergistic anticancer effect when used together with paclitaxel (PTX).	Paclitaxel	293-303	NAD(P)H quinone dehydrogenase 1	Homo sapiens	34-38
28829143-2	2017	NADP(H) quinone oxidoreductase 1 (NQO1) inhibitors, such as beta-lapachone (LPC) and tanshinone IIA (THA), are structurally and pharmacologically similar molecules that are poorly water-soluble, crystallize extremely fast, and demonstrate synergistic anticancer effect when used together with paclitaxel (PTX).	Paclitaxel	305-308	NAD(P)H quinone dehydrogenase 1	Homo sapiens	0-32
28829143-2	2017	NADP(H) quinone oxidoreductase 1 (NQO1) inhibitors, such as beta-lapachone (LPC) and tanshinone IIA (THA), are structurally and pharmacologically similar molecules that are poorly water-soluble, crystallize extremely fast, and demonstrate synergistic anticancer effect when used together with paclitaxel (PTX).	Paclitaxel	305-308	NAD(P)H quinone dehydrogenase 1	Homo sapiens	34-38
28726078-0	2017	Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis.	Paclitaxel	124-134	CEA cell adhesion molecule 3	Homo sapiens	18-21
28779263-0	2017	Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.	Paclitaxel	24-34	thymoma viral proto-oncogene 1	Mus musculus	80-83
28779263-1	2017	PURPOSE: Paclitaxel has been reported to upregulate both AKT and MAPK signaling pathways and thereby compromises its antitumor efficacy.	Paclitaxel	9-19	thymoma viral proto-oncogene 1	Mus musculus	57-60
28779263-13	2017	Western blotting analysis confirmed that tunicamycin decreased paclitaxel-induced upregulation of survival signal pathways such as AKT and MAPK.	Paclitaxel	63-73	thymoma viral proto-oncogene 1	Mus musculus	131-134
28779263-14	2017	CONCLUSION: These results revealed that tunicamycin synergistically enhanced the antitumor effects of paclitaxel through potentiating apoptosis via inhibiting paclitaxel-induced elevation of AKT and MAPK pathways.	Paclitaxel	102-112	thymoma viral proto-oncogene 1	Mus musculus	191-194
28779263-14	2017	CONCLUSION: These results revealed that tunicamycin synergistically enhanced the antitumor effects of paclitaxel through potentiating apoptosis via inhibiting paclitaxel-induced elevation of AKT and MAPK pathways.	Paclitaxel	159-169	thymoma viral proto-oncogene 1	Mus musculus	191-194
28768217-1	2017	BACKGROUND: The GENEVIEVE study compared the pathological complete response (pCR) rate (ypT0/is ypN0/+) in patients with operable human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) treated with either cabazitaxel or paclitaxel.	Paclitaxel	241-251	erb-b2 receptor tyrosine kinase 2	Homo sapiens	172-176
28849180-0	2017	Silencing Aurora A leads to re-sensitization of breast cancer cells to Taxol through downregulation of SRC-mediated ERK and mTOR pathways.	Paclitaxel	71-76	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	103-106
29093604-9	2017	Secretion of the cytokines CCL5, CCL2 and IL-6 increased after paclitaxel treatment in several endometrial cancer cell lines, but no general effect on cytokine secretion was detected after heparin treatment.	Paclitaxel	63-73	interleukin 6	Homo sapiens	42-46
29093604-11	2017	Conclusion: Further in-depth studies are needed to investigate the functions of cytokines CCL2, CCL5 and IL-6 in endometrial cancer cells treated with paclitaxel.	Paclitaxel	151-161	interleukin 6	Homo sapiens	105-109
29552052-11	2017	Furthermore, combinational treatment of paclitaxel and noscapine showed significant decrease in the mRNA expression of B-cell CLL/Lymphoma (Bcl-2) and increase in the mRNA expression of Bcl-2-associated X protein (Bax(, and Bax/Bcl-2 ratio in LNCaP and PC-3 cells (P&lt;0.05.	Paclitaxel	40-50	BCL2 apoptosis regulator	Homo sapiens	140-145
29552052-11	2017	Furthermore, combinational treatment of paclitaxel and noscapine showed significant decrease in the mRNA expression of B-cell CLL/Lymphoma (Bcl-2) and increase in the mRNA expression of Bcl-2-associated X protein (Bax(, and Bax/Bcl-2 ratio in LNCaP and PC-3 cells (P&lt;0.05.	Paclitaxel	40-50	BCL2 associated X, apoptosis regulator	Homo sapiens	186-212
29552052-11	2017	Furthermore, combinational treatment of paclitaxel and noscapine showed significant decrease in the mRNA expression of B-cell CLL/Lymphoma (Bcl-2) and increase in the mRNA expression of Bcl-2-associated X protein (Bax(, and Bax/Bcl-2 ratio in LNCaP and PC-3 cells (P&lt;0.05.	Paclitaxel	40-50	BCL2 associated X, apoptosis regulator	Homo sapiens	214-217
29552052-11	2017	Furthermore, combinational treatment of paclitaxel and noscapine showed significant decrease in the mRNA expression of B-cell CLL/Lymphoma (Bcl-2) and increase in the mRNA expression of Bcl-2-associated X protein (Bax(, and Bax/Bcl-2 ratio in LNCaP and PC-3 cells (P&lt;0.05.	Paclitaxel	40-50	BCL2 associated X, apoptosis regulator	Homo sapiens	224-227
29552052-11	2017	Furthermore, combinational treatment of paclitaxel and noscapine showed significant decrease in the mRNA expression of B-cell CLL/Lymphoma (Bcl-2) and increase in the mRNA expression of Bcl-2-associated X protein (Bax(, and Bax/Bcl-2 ratio in LNCaP and PC-3 cells (P&lt;0.05.	Paclitaxel	40-50	BCL2 apoptosis regulator	Homo sapiens	186-191
29552052-12	2017	( The mRNA expression of androgen receptor (AR) and prostate specific antigen (PSA) decreased in paclitaxel and noscapine combination-treated of LNCaP cells (P&lt;0.05).	Paclitaxel	97-107	androgen receptor	Homo sapiens	25-42
29552052-12	2017	( The mRNA expression of androgen receptor (AR) and prostate specific antigen (PSA) decreased in paclitaxel and noscapine combination-treated of LNCaP cells (P&lt;0.05).	Paclitaxel	97-107	androgen receptor	Homo sapiens	44-46
28639112-8	2017	The co-treatment with PTX and KJ dramatically decreased the level of survivin and markedly induced cleavage of PARP and caspase-3, which are apoptotic-induced molecules.	Paclitaxel	22-25	poly(ADP-ribose) polymerase 1	Homo sapiens	111-115
28639112-8	2017	The co-treatment with PTX and KJ dramatically decreased the level of survivin and markedly induced cleavage of PARP and caspase-3, which are apoptotic-induced molecules.	Paclitaxel	22-25	caspase 3	Homo sapiens	120-129
28729222-9	2017	BCP attenuated the established mechanical allodynia induced by PTX (p &lt; 0.0001) in a CB2-dependent manner.	Paclitaxel	63-66	cannabinoid receptor 2 (macrophage)	Mus musculus	88-91
28729222-11	2017	Spinal cord immunohistochemistry revealed that preventive treatment with BCP reduced p38 MAPK and NF-kappaB activation, as well as the increased Iba-1 and IL-1beta immunoreactivity promoted by PTX.	Paclitaxel	193-196	interleukin 1 beta	Mus musculus	155-163
28849180-6	2017	Silencing of Aurora A reduced the activity of SRC and downregulated the ERK and Akt/mTOR pathways, which led to re-sensitization of the resistant MCF-7/T cells to Taxol in vitro.	Paclitaxel	163-168	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	46-49
28849180-6	2017	Silencing of Aurora A reduced the activity of SRC and downregulated the ERK and Akt/mTOR pathways, which led to re-sensitization of the resistant MCF-7/T cells to Taxol in vitro.	Paclitaxel	163-168	mitogen-activated protein kinase 1	Homo sapiens	72-75
28849180-6	2017	Silencing of Aurora A reduced the activity of SRC and downregulated the ERK and Akt/mTOR pathways, which led to re-sensitization of the resistant MCF-7/T cells to Taxol in vitro.	Paclitaxel	163-168	AKT serine/threonine kinase 1	Homo sapiens	80-83
28849180-6	2017	Silencing of Aurora A reduced the activity of SRC and downregulated the ERK and Akt/mTOR pathways, which led to re-sensitization of the resistant MCF-7/T cells to Taxol in vitro.	Paclitaxel	163-168	mechanistic target of rapamycin kinase	Homo sapiens	84-88
28849180-7	2017	These results suggested that the activation of Aurora A and the subsequent upregulation of ERK and Akt through SRC induced Taxol-resistance in breast cancer cells, and inhibiting Aurora A and the related SRC/EKT/Akt pathway could restore the sensitivity of breast cancer cells to Taxol.	Paclitaxel	123-128	mitogen-activated protein kinase 1	Homo sapiens	91-94
28849180-7	2017	These results suggested that the activation of Aurora A and the subsequent upregulation of ERK and Akt through SRC induced Taxol-resistance in breast cancer cells, and inhibiting Aurora A and the related SRC/EKT/Akt pathway could restore the sensitivity of breast cancer cells to Taxol.	Paclitaxel	123-128	AKT serine/threonine kinase 1	Homo sapiens	99-102
28849180-7	2017	These results suggested that the activation of Aurora A and the subsequent upregulation of ERK and Akt through SRC induced Taxol-resistance in breast cancer cells, and inhibiting Aurora A and the related SRC/EKT/Akt pathway could restore the sensitivity of breast cancer cells to Taxol.	Paclitaxel	123-128	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	111-114
28849180-7	2017	These results suggested that the activation of Aurora A and the subsequent upregulation of ERK and Akt through SRC induced Taxol-resistance in breast cancer cells, and inhibiting Aurora A and the related SRC/EKT/Akt pathway could restore the sensitivity of breast cancer cells to Taxol.	Paclitaxel	123-128	AKT serine/threonine kinase 1	Homo sapiens	212-215
28849180-7	2017	These results suggested that the activation of Aurora A and the subsequent upregulation of ERK and Akt through SRC induced Taxol-resistance in breast cancer cells, and inhibiting Aurora A and the related SRC/EKT/Akt pathway could restore the sensitivity of breast cancer cells to Taxol.	Paclitaxel	280-285	mitogen-activated protein kinase 1	Homo sapiens	91-94
28849180-7	2017	These results suggested that the activation of Aurora A and the subsequent upregulation of ERK and Akt through SRC induced Taxol-resistance in breast cancer cells, and inhibiting Aurora A and the related SRC/EKT/Akt pathway could restore the sensitivity of breast cancer cells to Taxol.	Paclitaxel	280-285	AKT serine/threonine kinase 1	Homo sapiens	99-102
28849180-7	2017	These results suggested that the activation of Aurora A and the subsequent upregulation of ERK and Akt through SRC induced Taxol-resistance in breast cancer cells, and inhibiting Aurora A and the related SRC/EKT/Akt pathway could restore the sensitivity of breast cancer cells to Taxol.	Paclitaxel	280-285	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	111-114
28849180-7	2017	These results suggested that the activation of Aurora A and the subsequent upregulation of ERK and Akt through SRC induced Taxol-resistance in breast cancer cells, and inhibiting Aurora A and the related SRC/EKT/Akt pathway could restore the sensitivity of breast cancer cells to Taxol.	Paclitaxel	280-285	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	204-207
28849180-7	2017	These results suggested that the activation of Aurora A and the subsequent upregulation of ERK and Akt through SRC induced Taxol-resistance in breast cancer cells, and inhibiting Aurora A and the related SRC/EKT/Akt pathway could restore the sensitivity of breast cancer cells to Taxol.	Paclitaxel	280-285	AKT serine/threonine kinase 1	Homo sapiens	212-215
29085518-9	2017	The TxR cells also exhibited an increased expression of MDR-related proteins including MDR1 and MRP-1, which led to a substantial increase (5.4-fold) of the paclitaxel efflux from TxR-cells.	Paclitaxel	157-167	ATP binding cassette subfamily B member 1	Homo sapiens	87-91
29085518-9	2017	The TxR cells also exhibited an increased expression of MDR-related proteins including MDR1 and MRP-1, which led to a substantial increase (5.4-fold) of the paclitaxel efflux from TxR-cells.	Paclitaxel	157-167	ATP binding cassette subfamily C member 1	Homo sapiens	96-101
28849180-0	2017	Silencing Aurora A leads to re-sensitization of breast cancer cells to Taxol through downregulation of SRC-mediated ERK and mTOR pathways.	Paclitaxel	71-76	mitogen-activated protein kinase 1	Homo sapiens	116-119
28849180-0	2017	Silencing Aurora A leads to re-sensitization of breast cancer cells to Taxol through downregulation of SRC-mediated ERK and mTOR pathways.	Paclitaxel	71-76	mechanistic target of rapamycin kinase	Homo sapiens	124-128
28982309-0	2017	TWIST mediates resistance to paclitaxel by regulating Akt and Bcl-2 expression in gastric cancer cells.	Paclitaxel	29-39	twist family bHLH transcription factor 1	Homo sapiens	0-5
27573201-0	2017	Knockdown of Hypoxia-Inducible Factor 1alpha Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts.	Paclitaxel	106-116	hypoxia inducible factor 1 subunit alpha	Homo sapiens	13-44
27573201-4	2017	Our study aimed to investigate whether knockdown of hypoxia-inducible factor-1alpha expression in tumor cell could facilitate low-dose metronomic therapy with paclitaxel for human colon cancer.	Paclitaxel	159-169	hypoxia inducible factor 1 subunit alpha	Homo sapiens	52-83
27573201-7	2017	All these data indicated that the combination of paclitaxel low-dose metronomic therapy with hypoxia-inducible factor-1alpha knockdown might provide a potent battle against colon cancer.	Paclitaxel	49-59	hypoxia inducible factor 1 subunit alpha	Homo sapiens	93-124
28982309-0	2017	TWIST mediates resistance to paclitaxel by regulating Akt and Bcl-2 expression in gastric cancer cells.	Paclitaxel	29-39	AKT serine/threonine kinase 1	Homo sapiens	54-57
28982309-0	2017	TWIST mediates resistance to paclitaxel by regulating Akt and Bcl-2 expression in gastric cancer cells.	Paclitaxel	29-39	BCL2 apoptosis regulator	Homo sapiens	62-67
28982309-4	2017	Our study showed that overexpression of TWIST not only increased cell migration and invasion but also induced resistance to the anti-cancer drug paclitaxel in gastric cancer.	Paclitaxel	145-155	twist family bHLH transcription factor 1	Homo sapiens	40-45
28982309-5	2017	Paclitaxel increased gastric cancer cell death in dose-dependent manner; this was decreased following TWIST overexpression.	Paclitaxel	0-10	twist family bHLH transcription factor 1	Homo sapiens	102-107
28982309-6	2017	Furthermore, treatment with paclitaxel decreased Akt phosphorylation and Bcl-2 expression, whereas these effects were suppressed by TWIST overexpression.	Paclitaxel	28-38	AKT serine/threonine kinase 1	Homo sapiens	49-52
28982309-6	2017	Furthermore, treatment with paclitaxel decreased Akt phosphorylation and Bcl-2 expression, whereas these effects were suppressed by TWIST overexpression.	Paclitaxel	28-38	BCL2 apoptosis regulator	Homo sapiens	73-78
28982309-6	2017	Furthermore, treatment with paclitaxel decreased Akt phosphorylation and Bcl-2 expression, whereas these effects were suppressed by TWIST overexpression.	Paclitaxel	28-38	twist family bHLH transcription factor 1	Homo sapiens	132-137
28982309-7	2017	Treatment of cells with Akt inhibitor or small interfering RNA targeting for Bcl-2 led to increased paclitaxel-induced cell death, indicating that TWIST elicits resistance to paclitaxel via the regulation of the Akt and Bcl-2 pathway.	Paclitaxel	100-110	AKT serine/threonine kinase 1	Homo sapiens	24-27
28982309-7	2017	Treatment of cells with Akt inhibitor or small interfering RNA targeting for Bcl-2 led to increased paclitaxel-induced cell death, indicating that TWIST elicits resistance to paclitaxel via the regulation of the Akt and Bcl-2 pathway.	Paclitaxel	100-110	BCL2 apoptosis regulator	Homo sapiens	77-82
28982309-7	2017	Treatment of cells with Akt inhibitor or small interfering RNA targeting for Bcl-2 led to increased paclitaxel-induced cell death, indicating that TWIST elicits resistance to paclitaxel via the regulation of the Akt and Bcl-2 pathway.	Paclitaxel	100-110	twist family bHLH transcription factor 1	Homo sapiens	147-152
28982309-7	2017	Treatment of cells with Akt inhibitor or small interfering RNA targeting for Bcl-2 led to increased paclitaxel-induced cell death, indicating that TWIST elicits resistance to paclitaxel via the regulation of the Akt and Bcl-2 pathway.	Paclitaxel	100-110	AKT serine/threonine kinase 1	Homo sapiens	212-215
28982309-7	2017	Treatment of cells with Akt inhibitor or small interfering RNA targeting for Bcl-2 led to increased paclitaxel-induced cell death, indicating that TWIST elicits resistance to paclitaxel via the regulation of the Akt and Bcl-2 pathway.	Paclitaxel	100-110	BCL2 apoptosis regulator	Homo sapiens	220-225
28982309-7	2017	Treatment of cells with Akt inhibitor or small interfering RNA targeting for Bcl-2 led to increased paclitaxel-induced cell death, indicating that TWIST elicits resistance to paclitaxel via the regulation of the Akt and Bcl-2 pathway.	Paclitaxel	175-185	BCL2 apoptosis regulator	Homo sapiens	77-82
28982309-7	2017	Treatment of cells with Akt inhibitor or small interfering RNA targeting for Bcl-2 led to increased paclitaxel-induced cell death, indicating that TWIST elicits resistance to paclitaxel via the regulation of the Akt and Bcl-2 pathway.	Paclitaxel	175-185	twist family bHLH transcription factor 1	Homo sapiens	147-152
28982309-7	2017	Treatment of cells with Akt inhibitor or small interfering RNA targeting for Bcl-2 led to increased paclitaxel-induced cell death, indicating that TWIST elicits resistance to paclitaxel via the regulation of the Akt and Bcl-2 pathway.	Paclitaxel	175-185	AKT serine/threonine kinase 1	Homo sapiens	212-215
28980921-6	2017	The microtubule depolymerizer colchicine promoted cell surface recovery of CD71 but inhibited that of GPA; the microtubule stabilizer paclitaxel inhibited cell surface recovery of CD71 but promoted that of GPA; the microfilament depolymerizer cytochalasin D had no effect on cell surface recovery of CD71 and GPA; the microfilament stabilizer phalloidin inhibited cell surface recovery of GPA.	Paclitaxel	134-144	glycophorin A (MNS blood group)	Homo sapiens	206-209
28982309-7	2017	Treatment of cells with Akt inhibitor or small interfering RNA targeting for Bcl-2 led to increased paclitaxel-induced cell death, indicating that TWIST elicits resistance to paclitaxel via the regulation of the Akt and Bcl-2 pathway.	Paclitaxel	175-185	BCL2 apoptosis regulator	Homo sapiens	220-225
28980921-6	2017	The microtubule depolymerizer colchicine promoted cell surface recovery of CD71 but inhibited that of GPA; the microtubule stabilizer paclitaxel inhibited cell surface recovery of CD71 but promoted that of GPA; the microfilament depolymerizer cytochalasin D had no effect on cell surface recovery of CD71 and GPA; the microfilament stabilizer phalloidin inhibited cell surface recovery of GPA.	Paclitaxel	134-144	glycophorin A (MNS blood group)	Homo sapiens	206-209
28980921-6	2017	The microtubule depolymerizer colchicine promoted cell surface recovery of CD71 but inhibited that of GPA; the microtubule stabilizer paclitaxel inhibited cell surface recovery of CD71 but promoted that of GPA; the microfilament depolymerizer cytochalasin D had no effect on cell surface recovery of CD71 and GPA; the microfilament stabilizer phalloidin inhibited cell surface recovery of GPA.	Paclitaxel	134-144	glycophorin A (MNS blood group)	Homo sapiens	206-209
28982309-8	2017	Our results suggest an underlying mechanism for TWIST-mediated paclitaxel resistance and indicate that TWIST represents a potential target for overcoming paclitaxel resistance in gastric cancer cells.	Paclitaxel	63-73	twist family bHLH transcription factor 1	Homo sapiens	48-53
28982309-8	2017	Our results suggest an underlying mechanism for TWIST-mediated paclitaxel resistance and indicate that TWIST represents a potential target for overcoming paclitaxel resistance in gastric cancer cells.	Paclitaxel	154-164	twist family bHLH transcription factor 1	Homo sapiens	48-53
28982309-8	2017	Our results suggest an underlying mechanism for TWIST-mediated paclitaxel resistance and indicate that TWIST represents a potential target for overcoming paclitaxel resistance in gastric cancer cells.	Paclitaxel	154-164	twist family bHLH transcription factor 1	Homo sapiens	103-108
28849826-0	2017	Multifunctional nanoparticles for co-delivery of paclitaxel and carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis.	Paclitaxel	49-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
29033584-12	2017	Sensitivity to adriamycin was significantly correlated with ploidy (P=0.03), whereas sensitivity to taxol was correlated with SPF (P=0.04).	Paclitaxel	100-105	SEC14 like lipid binding 2	Homo sapiens	126-129
29158820-2	2017	This study was aimed at improving the anti-cancer effect of the chemotherapeutic agent paclitaxel (PTX) on the drug resistant and metastatic breast cancer by co-delivering PTX and a siRNA, siAkt, directed at silencing the Akt expression.	Paclitaxel	87-97	thymoma viral proto-oncogene 1	Mus musculus	191-194
29158820-2	2017	This study was aimed at improving the anti-cancer effect of the chemotherapeutic agent paclitaxel (PTX) on the drug resistant and metastatic breast cancer by co-delivering PTX and a siRNA, siAkt, directed at silencing the Akt expression.	Paclitaxel	99-102	thymoma viral proto-oncogene 1	Mus musculus	191-194
28117030-0	2017	Three Combined Treatments, a Novel HDAC Inhibitor OBP-801/YM753, 5-Fluorouracil, and Paclitaxel, Induce G2 Phase Arrest Through the p38 Pathway in Human Ovarian Cancer Cells.	Paclitaxel	85-95	mitogen-activated protein kinase 14	Homo sapiens	132-135
28687352-8	2017	In conclusion, we found that nAb-PTX treatment of gem-resistant PDAC can be enhanced by (1) gem through up-regulation of caveolin-1 and (2) MSV through increasing accumulation of nAb-PTX in the tumor.	Paclitaxel	29-36	caveolin 1	Homo sapiens	121-131
29156771-10	2017	Depletion of BOK suppressed caspase-3 activation in the presence of paclitaxel and in turn protected cells from paclitaxel-induced apoptosis.	Paclitaxel	68-78	BCL2 family apoptosis regulator BOK	Homo sapiens	13-16
29156771-10	2017	Depletion of BOK suppressed caspase-3 activation in the presence of paclitaxel and in turn protected cells from paclitaxel-induced apoptosis.	Paclitaxel	68-78	caspase 3	Homo sapiens	28-37
29156771-10	2017	Depletion of BOK suppressed caspase-3 activation in the presence of paclitaxel and in turn protected cells from paclitaxel-induced apoptosis.	Paclitaxel	112-122	BCL2 family apoptosis regulator BOK	Homo sapiens	13-16
28753317-2	2017	Herein, vascular endothelial growth factor specific siRNA (siVEGF) and paclitaxel (PTX) were introduced as therapeutic companions and coencapsulated into naturally mimic high-density lipoproteins (rHDL/siVEGF-PTX), so that various mechanisms of treatment can occur simultaneously.	Paclitaxel	209-212	vascular endothelial growth factor A	Homo sapiens	8-42
28753317-7	2017	Moreover, in vivo results further demonstrated that rHDL/siVEGF-PTX performed enhanced tumor growth inhibition via natural targeting pathway, accompanied by remarkable inhibition of neovascularization in situ caused by siVEGF silencing in down-regulation of VEGF proteins.	Paclitaxel	64-67	vascular endothelial growth factor A	Homo sapiens	59-63
28689298-10	2017	Furthermore, augmented C-reactive protein and creatine kinase fraction MB were found to be significantly higher in paclitaxel-treated patients in comparison with healthy controls.	Paclitaxel	115-125	C-reactive protein	Homo sapiens	23-41
28322937-6	2017	Although Western blot analysis showed that P-gp expression levels were similar in Mock and Snail-overexpressing cells, the results of P-gp functional assays with P-gp substrates rhodamine123 and paclitaxel indicated that P-gp is activated in Snail-overexpressing cells.	Paclitaxel	195-205	ATP binding cassette subfamily B member 1	Homo sapiens	134-138
28604143-4	2017	NLG919 increased the cytotoxic activity of paclitaxel toward B16-F10 cells in the presence of pretreatment with interferon (IFN)-gamma in vitro.	Paclitaxel	43-53	interferon gamma	Mus musculus	112-134
28411377-0	2017	miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression.	Paclitaxel	74-79	microRNA 495	Homo sapiens	0-7
28411377-0	2017	miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression.	Paclitaxel	74-79	ATP binding cassette subfamily B member 1	Homo sapiens	94-98
28411377-5	2017	The results indicated that the expression of MDR1 in the above cells or tumours was suppressed and that subsequently the drug accumulation in the MDR cells was decreased, cell death was increased, and tumour growth was inhibited after treatment with taxol-doxorubicin, demonstrating increased drug sensitivity.	Paclitaxel	250-255	ATP binding cassette subfamily B member 1	Homo sapiens	45-49
28322937-6	2017	Although Western blot analysis showed that P-gp expression levels were similar in Mock and Snail-overexpressing cells, the results of P-gp functional assays with P-gp substrates rhodamine123 and paclitaxel indicated that P-gp is activated in Snail-overexpressing cells.	Paclitaxel	195-205	ATP binding cassette subfamily B member 1	Homo sapiens	134-138
28322937-6	2017	Although Western blot analysis showed that P-gp expression levels were similar in Mock and Snail-overexpressing cells, the results of P-gp functional assays with P-gp substrates rhodamine123 and paclitaxel indicated that P-gp is activated in Snail-overexpressing cells.	Paclitaxel	195-205	ATP binding cassette subfamily B member 1	Homo sapiens	134-138
28485482-3	2017	In this study, we show that mice lacking the Sarm1 gene are resistant to distal axonal degeneration in a model of chemotherapy induced peripheral neuropathy caused by paclitaxel and a model of high fat diet induced putative metabolic neuropathy.	Paclitaxel	167-177	sterile alpha and HEAT/Armadillo motif containing 1	Mus musculus	45-50
28322937-7	2017	Indeed, Snail-overexpressing cells showed greater viability than Mock cells in the presence of paclitaxel.	Paclitaxel	95-105	snail family transcriptional repressor 1	Homo sapiens	8-13
28852020-5	2017	Conjugation of ND-PTX with Cet (ND-PTX-Cet) was specifically binding to the EGFR-positive CRC cells and enhanced the mitotic catastrophe and apoptosis induction.	Paclitaxel	18-21	epidermal growth factor receptor	Homo sapiens	76-80
28883751-0	2017	Resveratrol raises in vitro anticancer effects of paclitaxel in NSCLC cell line A549 through COX-2 expression.	Paclitaxel	50-60	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	93-98
28852020-6	2017	Besides, ND-PTX-Cet markedly decreased tumor size in the xenograft EGFR-expressed human CRC tumors of nude mice.	Paclitaxel	12-15	epidermal growth factor receptor	Homo sapiens	67-71
28852020-7	2017	Moreover, ND-PTX-Cet induced the mitotic marker protein phospho-histone 3 (Ser10) and apoptotic protein active-caspase 3 for mitotic catastrophe and apoptosis.	Paclitaxel	13-16	caspase 3	Homo sapiens	111-120
28839165-7	2017	We validated the increase of caspase-6 (CASP6) in small-sized DRG neurons and its functional role in SNI- and paclitaxel-induced neuropathic pain.	Paclitaxel	110-120	caspase 6	Rattus norvegicus	29-38
28843263-5	2017	The IC50 values for silibinin, paclitaxel and cisplatin were160 +- 22.2 muM, 33.7 +- 4.2 nM and 3.2 +- 0.5 muM, respectively.	Paclitaxel	31-41	latexin	Homo sapiens	72-75
28843263-5	2017	The IC50 values for silibinin, paclitaxel and cisplatin were160 +- 22.2 muM, 33.7 +- 4.2 nM and 3.2 +- 0.5 muM, respectively.	Paclitaxel	31-41	latexin	Homo sapiens	107-110
28839165-7	2017	We validated the increase of caspase-6 (CASP6) in small-sized DRG neurons and its functional role in SNI- and paclitaxel-induced neuropathic pain.	Paclitaxel	110-120	caspase 6	Rattus norvegicus	40-45
28835684-11	2017	This study eventually established that SOX2 silencing of CSCs along with paclitaxel treatment reduced SOX2-ABCG2-TWIST1 expression, disrupted sphere forming capacity and also reduced invasiveness by retaining epithelial-like properties of the cells, thereby suggesting a more comprehensive therapy for TNBC patients in future.	Paclitaxel	73-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	107-112
28835684-11	2017	This study eventually established that SOX2 silencing of CSCs along with paclitaxel treatment reduced SOX2-ABCG2-TWIST1 expression, disrupted sphere forming capacity and also reduced invasiveness by retaining epithelial-like properties of the cells, thereby suggesting a more comprehensive therapy for TNBC patients in future.	Paclitaxel	73-83	twist family bHLH transcription factor 1	Homo sapiens	113-119
29137317-5	2017	Mcl-1 is shown to be stabilized in Taxol -resistant gastric cancer cells because of the hyper-activation of the PI3K/Akt signaling pathway.	Paclitaxel	35-40	AKT serine/threonine kinase 1	Homo sapiens	117-120
28671455-6	2017	The strong anticancer activity of paclitaxel-incorporated siRNA micelles can be attributed to the synergistic effect of Bcl-2 siRNA and paclitaxel.	Paclitaxel	34-44	BCL2 apoptosis regulator	Homo sapiens	120-125
29245917-8	2017	In an animal model, mice injected with ZEB1-silencing PTX-resistant cells survived for longer than the control cell-injected mice.	Paclitaxel	54-57	zinc finger E-box binding homeobox 1	Mus musculus	39-43
28796259-8	2017	Moreover, co-administration of the inhibitors of MUC1-EGFR-ABCB1 with paclitaxel significantly blocked not only tumor growth but also relapse in xenograft mouse model.	Paclitaxel	70-80	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	59-64
29137317-7	2017	Furthermore, inhibition of Mcl-1 or PI3K/Akt pathway significantly reversed the resistant phenotype of Taxol-resistant human gastric cancer cells.	Paclitaxel	103-108	AKT serine/threonine kinase 1	Homo sapiens	41-44
29137317-8	2017	Taken together, our findings broaden the view of PI3K/Akt pathway as an important regulator in Taxol acquired resistance, and implicate Mcl-1 as a specific therapeutic target for the treatment of Taxol-resistant human gastric cancer.	Paclitaxel	95-100	AKT serine/threonine kinase 1	Homo sapiens	54-57
29137317-8	2017	Taken together, our findings broaden the view of PI3K/Akt pathway as an important regulator in Taxol acquired resistance, and implicate Mcl-1 as a specific therapeutic target for the treatment of Taxol-resistant human gastric cancer.	Paclitaxel	196-201	AKT serine/threonine kinase 1	Homo sapiens	54-57
28769027-9	2017	Concomitant treatment with paclitaxel and GSI or siRNA downregulated Bcl-2 expression and upregulated Bax expression levels.	Paclitaxel	27-37	BCL2 apoptosis regulator	Homo sapiens	69-74
28664915-7	2017	Advanced tumours with low relative activation of the metabolic signature and increased FOXO1 T24/FOXO3 T32 phosphorylation (P=0.041) were associated with carboplatin-paclitaxel resistance.	Paclitaxel	166-176	forkhead box O1	Homo sapiens	87-92
28664915-7	2017	Advanced tumours with low relative activation of the metabolic signature and increased FOXO1 T24/FOXO3 T32 phosphorylation (P=0.041) were associated with carboplatin-paclitaxel resistance.	Paclitaxel	166-176	forkhead box O3	Homo sapiens	97-102
28664915-8	2017	CONCLUSIONS: If validated in a larger cohort of patients, the decreased AMPK-AKT-mTOR activation and phosphorylation of FOXO1 T24/FOXO3 T32 may help identify carboplatin-paclitaxel-resistant EOC patients.	Paclitaxel	170-180	AKT serine/threonine kinase 1	Homo sapiens	77-80
28664915-8	2017	CONCLUSIONS: If validated in a larger cohort of patients, the decreased AMPK-AKT-mTOR activation and phosphorylation of FOXO1 T24/FOXO3 T32 may help identify carboplatin-paclitaxel-resistant EOC patients.	Paclitaxel	170-180	mechanistic target of rapamycin kinase	Homo sapiens	81-85
28664915-8	2017	CONCLUSIONS: If validated in a larger cohort of patients, the decreased AMPK-AKT-mTOR activation and phosphorylation of FOXO1 T24/FOXO3 T32 may help identify carboplatin-paclitaxel-resistant EOC patients.	Paclitaxel	170-180	forkhead box O1	Homo sapiens	120-125
28576551-0	2017	Free paclitaxel-loaded E-selectin binding peptide modified micelle self-assembled from hyaluronic acid-paclitaxel conjugate inhibit breast cancer metastasis in a murine model.	Paclitaxel	5-15	selectin, endothelial cell	Mus musculus	23-33
28576551-0	2017	Free paclitaxel-loaded E-selectin binding peptide modified micelle self-assembled from hyaluronic acid-paclitaxel conjugate inhibit breast cancer metastasis in a murine model.	Paclitaxel	103-113	selectin, endothelial cell	Mus musculus	23-33
28769027-9	2017	Concomitant treatment with paclitaxel and GSI or siRNA downregulated Bcl-2 expression and upregulated Bax expression levels.	Paclitaxel	27-37	BCL2 associated X, apoptosis regulator	Homo sapiens	102-105
28315766-5	2017	Consistent with in vitro assays, migration potential and BMP4 expression were increased in EC109/Taxol nude mice.	Paclitaxel	97-102	bone morphogenetic protein 4	Mus musculus	57-61
28296507-9	2017	Both PVT1 and miR-195 could inhibit paclitaxel (PTX) induced epithelial-to-mesenchymal transition (EMT) and also sensitize CaSki cells to PTX.	Paclitaxel	36-46	microRNA 195	Homo sapiens	14-21
28296507-9	2017	Both PVT1 and miR-195 could inhibit paclitaxel (PTX) induced epithelial-to-mesenchymal transition (EMT) and also sensitize CaSki cells to PTX.	Paclitaxel	48-51	microRNA 195	Homo sapiens	14-21
28296507-9	2017	Both PVT1 and miR-195 could inhibit paclitaxel (PTX) induced epithelial-to-mesenchymal transition (EMT) and also sensitize CaSki cells to PTX.	Paclitaxel	138-141	microRNA 195	Homo sapiens	14-21
28296507-11	2017	In addition, the PVT1/miR-195 axis can modulate responses of the cancer cells to PTX via regulating EMT.	Paclitaxel	81-84	microRNA 195	Homo sapiens	22-29
28487996-0	2017	miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression.	Paclitaxel	20-30	BCL2 apoptosis regulator	Homo sapiens	91-96
28487996-7	2017	In addition, miR-30a-5p increases paclitaxel sensitivity by promoting chemotherapy-induced apoptosis via downregulating BCL-2, a key apoptosis regulator.	Paclitaxel	34-44	BCL2 apoptosis regulator	Homo sapiens	120-125
28487996-13	2017	miR-30a-5p sensitizes NSCLC cells to paclitaxel by inducing apoptosis through BCL-2 inhibition.	Paclitaxel	37-47	BCL2 apoptosis regulator	Homo sapiens	78-83
29254147-7	2017	In conclusion, Bcl-2 negative, HER2-positive and smaller (&lt;=2 cm) tumor sizes are independent predictors of pCR in ER-positive patients treated with dose-dense (biweekly) paclitaxel/carboplatin NCT.	Paclitaxel	174-184	estrogen receptor 1	Homo sapiens	32-34
28758908-10	2017	The results of our study show that treatment with paclitaxel, cabazitaxel and docetaxel is able to enhance the apoptosis induced by TRAIL even in prostate cancer stem cells.	Paclitaxel	50-60	TNF superfamily member 10	Homo sapiens	132-137
28751630-13	2017	PKC zeta co-immunoprecipitated with beta-tubulin at different intervals upon insulin stimulus, and the activation of PKC zeta was affected by paclitaxel and nocodazole.	Paclitaxel	142-152	insulin	Homo sapiens	77-84
28758908-6	2017	The aim of this work was to analyze the enhancement of the anticancer effect of TRAIL by paclitaxel, cabazitaxel and docetaxel in the whole population of PC3 and DU145 prostate cancer cells, but also in CD44+/CD24- prostate cancer stem cells.	Paclitaxel	89-99	TNF superfamily member 10	Homo sapiens	80-85
28758908-6	2017	The aim of this work was to analyze the enhancement of the anticancer effect of TRAIL by paclitaxel, cabazitaxel and docetaxel in the whole population of PC3 and DU145 prostate cancer cells, but also in CD44+/CD24- prostate cancer stem cells.	Paclitaxel	89-99	CD24 molecule	Homo sapiens	209-213
29254147-0	2017	Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy.	Paclitaxel	141-151	estrogen receptor 1	Homo sapiens	71-88
29254147-1	2017	The aim of this study was to determine the predictive value of the clinical and histopathological characteristics of estrogen receptor (ER)-positive patients treated with dose-dense paclitaxel/carboplatin neoadjuvant chemotherapy (NCT).	Paclitaxel	182-192	estrogen receptor 1	Homo sapiens	117-134
29254147-1	2017	The aim of this study was to determine the predictive value of the clinical and histopathological characteristics of estrogen receptor (ER)-positive patients treated with dose-dense paclitaxel/carboplatin neoadjuvant chemotherapy (NCT).	Paclitaxel	182-192	estrogen receptor 1	Homo sapiens	136-138
29254147-7	2017	In conclusion, Bcl-2 negative, HER2-positive and smaller (&lt;=2 cm) tumor sizes are independent predictors of pCR in ER-positive patients treated with dose-dense (biweekly) paclitaxel/carboplatin NCT.	Paclitaxel	174-184	BCL2 apoptosis regulator	Homo sapiens	15-20
29254147-7	2017	In conclusion, Bcl-2 negative, HER2-positive and smaller (&lt;=2 cm) tumor sizes are independent predictors of pCR in ER-positive patients treated with dose-dense (biweekly) paclitaxel/carboplatin NCT.	Paclitaxel	174-184	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-35
28749468-0	2017	WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response.	Paclitaxel	40-50	WW domain containing oxidoreductase	Homo sapiens	0-4
28749468-4	2017	Here, we examine the role of WWOX (WW domain containing oxidoreductase), a gene frequently lost in several cancers, in mediating paclitaxel response.	Paclitaxel	129-139	WW domain containing oxidoreductase	Homo sapiens	29-33
28749468-4	2017	Here, we examine the role of WWOX (WW domain containing oxidoreductase), a gene frequently lost in several cancers, in mediating paclitaxel response.	Paclitaxel	129-139	WW domain containing oxidoreductase	Homo sapiens	35-70
28749468-5	2017	We examine the ER stress-mediated apoptotic response to paclitaxel in WWOX-transfected epithelial ovarian cancer (EOC) cells and following siRNA knockdown of WWOX.	Paclitaxel	56-66	WW domain containing oxidoreductase	Homo sapiens	70-74
28749468-6	2017	We show that WWOX-induced apoptosis following exposure of EOC cells to paclitaxel is related to ER stress and independent of the antimitotic action of taxanes.	Paclitaxel	71-81	WW domain containing oxidoreductase	Homo sapiens	13-17
28749468-8	2017	We report that paclitaxel treatment activates both the IRE-1 and PERK kinases and that the increase in paclitaxel-mediated cell death through WWOX is dependent on active ER stress pathway.	Paclitaxel	15-25	WW domain containing oxidoreductase	Homo sapiens	142-146
28749468-8	2017	We report that paclitaxel treatment activates both the IRE-1 and PERK kinases and that the increase in paclitaxel-mediated cell death through WWOX is dependent on active ER stress pathway.	Paclitaxel	103-113	WW domain containing oxidoreductase	Homo sapiens	142-146
28729624-6	2017	By contrast, paclitaxel led to dedifferentiation of Schwann cells into an immature state, characterized by increased expression of p75 and galectin-3.	Paclitaxel	13-23	galectin 3	Rattus norvegicus	139-149
28749468-10	2017	High WWOX mRNA expression predicted longer OS and PFS in patients treated with paclitaxel, but not in patients who were treated with only cisplatin.	Paclitaxel	79-89	WW domain containing oxidoreductase	Homo sapiens	5-9
28749468-11	2017	The association of WWOX and survival was dependent on the expression level of glucose-related protein 78 (GRP78), a key ER stress marker in paclitaxel-treated patients.	Paclitaxel	140-150	WW domain containing oxidoreductase	Homo sapiens	19-23
28749468-11	2017	The association of WWOX and survival was dependent on the expression level of glucose-related protein 78 (GRP78), a key ER stress marker in paclitaxel-treated patients.	Paclitaxel	140-150	heat shock protein family A (Hsp70) member 5	Homo sapiens	78-104
28749468-11	2017	The association of WWOX and survival was dependent on the expression level of glucose-related protein 78 (GRP78), a key ER stress marker in paclitaxel-treated patients.	Paclitaxel	140-150	heat shock protein family A (Hsp70) member 5	Homo sapiens	106-111
28749468-12	2017	We conclude that WWOX sensitises EOC to paclitaxel via ER stress-induced apoptosis, and predicts clinical outcome in patients.	Paclitaxel	40-50	WW domain containing oxidoreductase	Homo sapiens	17-21
28743247-1	2017	BACKGROUND: We conducted an open-label, randomized, two-arm multi-center study to assess the efficacy and safety of paclitaxel versus paclitaxel + sorafenib in patients with locally advanced or metastatic HER2-negative breast cancer.	Paclitaxel	116-126	erb-b2 receptor tyrosine kinase 2	Homo sapiens	205-209
31305693-0	2017	Erratum: Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report: Erratum.	Paclitaxel	32-42	epidermal growth factor receptor	Homo sapiens	46-50
28748102-4	2017	METHODS: Paclitaxel-treated PC12 cells were assessed for neurite length and performed Western blot analysis for growth-associated protein-43 (GAP-43) and light neurofilament protein (NF-L) levels in the presence of nerve growth factor (NGF); they were re-assessed, with additional testing for acetylcholinesterase levels, after application of one of the kampo.	Paclitaxel	9-19	neurofilament light chain	Rattus norvegicus	160-181
28748102-4	2017	METHODS: Paclitaxel-treated PC12 cells were assessed for neurite length and performed Western blot analysis for growth-associated protein-43 (GAP-43) and light neurofilament protein (NF-L) levels in the presence of nerve growth factor (NGF); they were re-assessed, with additional testing for acetylcholinesterase levels, after application of one of the kampo.	Paclitaxel	9-19	neurofilament light chain	Rattus norvegicus	183-187
28729624-7	2017	Consistent with in vitro findings, repeated injection of paclitaxel increased expression of p75 and galectin-3 in Schwann cells within the mouse sciatic nerve.	Paclitaxel	57-67	nerve growth factor receptor (TNFR superfamily, member 16)	Mus musculus	92-95
28729624-7	2017	Consistent with in vitro findings, repeated injection of paclitaxel increased expression of p75 and galectin-3 in Schwann cells within the mouse sciatic nerve.	Paclitaxel	57-67	lectin, galactose binding, soluble 3	Mus musculus	100-110
28738964-1	2017	BACKGROUND: Albumin-bound paclitaxel is a novel paclitaxel formulation formed by the combination of paclitaxel and human serum albumin (HSA) to improve the efficacy of paclitaxel and reduce its adverse reactions.	Paclitaxel	48-58	albumin	Homo sapiens	121-134
28502672-0	2017	DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.	Paclitaxel	65-75	ATP binding cassette subfamily B member 1	Homo sapiens	90-104
28718813-0	2017	Suppression of Nrf2 Activity by Chestnut Leaf Extract Increases Chemosensitivity of Breast Cancer Stem Cells to Paclitaxel.	Paclitaxel	112-122	NFE2 like bZIP transcription factor 2	Homo sapiens	15-19
28718813-8	2017	These findings suggest that the chestnut leaf extract or its constituents could increase the susceptibility of breast CSCs to an anticancer drug, paclitaxel, through inhibition of the Nrf2 signaling pathway, and could be utilized as an adjuvant for chemotherapy.	Paclitaxel	146-156	NFE2 like bZIP transcription factor 2	Homo sapiens	184-188
28738964-1	2017	BACKGROUND: Albumin-bound paclitaxel is a novel paclitaxel formulation formed by the combination of paclitaxel and human serum albumin (HSA) to improve the efficacy of paclitaxel and reduce its adverse reactions.	Paclitaxel	26-36	albumin	Homo sapiens	121-134
28738964-1	2017	BACKGROUND: Albumin-bound paclitaxel is a novel paclitaxel formulation formed by the combination of paclitaxel and human serum albumin (HSA) to improve the efficacy of paclitaxel and reduce its adverse reactions.	Paclitaxel	48-58	albumin	Homo sapiens	121-134
28738964-1	2017	BACKGROUND: Albumin-bound paclitaxel is a novel paclitaxel formulation formed by the combination of paclitaxel and human serum albumin (HSA) to improve the efficacy of paclitaxel and reduce its adverse reactions.	Paclitaxel	48-58	albumin	Homo sapiens	121-134
28187446-6	2017	Gene expression profiling of paclitaxel-residual, -resistant and naive MDA-MB-231 cells demonstrated that paclitaxel-residual, as opposed to -resistant cells, were characterized by an apoptotic signature, with downregulation of anti-apoptotic genes (BCL2, BIRC5), induction of apoptosis inducers (IL24, PDCD4), and enrichment of TNFalpha/NF-kappaB pathway, including upregulation of TNFSF15, coupled with cell-cycle arrest.	Paclitaxel	106-116	BCL2 apoptosis regulator	Homo sapiens	250-254
28187446-6	2017	Gene expression profiling of paclitaxel-residual, -resistant and naive MDA-MB-231 cells demonstrated that paclitaxel-residual, as opposed to -resistant cells, were characterized by an apoptotic signature, with downregulation of anti-apoptotic genes (BCL2, BIRC5), induction of apoptosis inducers (IL24, PDCD4), and enrichment of TNFalpha/NF-kappaB pathway, including upregulation of TNFSF15, coupled with cell-cycle arrest.	Paclitaxel	106-116	tumor necrosis factor	Homo sapiens	329-337
28187446-6	2017	Gene expression profiling of paclitaxel-residual, -resistant and naive MDA-MB-231 cells demonstrated that paclitaxel-residual, as opposed to -resistant cells, were characterized by an apoptotic signature, with downregulation of anti-apoptotic genes (BCL2, BIRC5), induction of apoptosis inducers (IL24, PDCD4), and enrichment of TNFalpha/NF-kappaB pathway, including upregulation of TNFSF15, coupled with cell-cycle arrest.	Paclitaxel	106-116	TNF superfamily member 15	Homo sapiens	383-390
28604448-0	2017	MAP2K6-FP Enhances the Sensitiveness of Paclitaxel for Ovarian Cancer via Inducing Autophagy.	Paclitaxel	40-50	mitogen-activated protein kinase kinase 6	Homo sapiens	0-6
27669706-7	2017	Moreover, V-ATPase siRNA or esomeprazole followed by paclitaxel significantly increased the expression of active caspase-3 in these cells compared to cells treated with paclitaxel alone (both, p &lt; 0.05).	Paclitaxel	53-63	caspase 3	Homo sapiens	113-122
27669706-7	2017	Moreover, V-ATPase siRNA or esomeprazole followed by paclitaxel significantly increased the expression of active caspase-3 in these cells compared to cells treated with paclitaxel alone (both, p &lt; 0.05).	Paclitaxel	169-179	caspase 3	Homo sapiens	113-122
28534969-6	2017	Co-treatment with purvalanol A and taxol weakened the expression of Bcl-2 and activated the extrinsic cell death pathway through the activation of caspase-3 and caspase-8.	Paclitaxel	35-40	BCL2 apoptosis regulator	Homo sapiens	68-73
28534969-6	2017	Co-treatment with purvalanol A and taxol weakened the expression of Bcl-2 and activated the extrinsic cell death pathway through the activation of caspase-3 and caspase-8.	Paclitaxel	35-40	caspase 3	Homo sapiens	147-156
28604448-5	2017	In this study, we investigated the effect of MAP2K6-FP on HO8910 cells treated with paclitaxel.	Paclitaxel	84-94	mitogen-activated protein kinase kinase 6	Homo sapiens	45-51
28604448-11	2017	Furthermore, either MAP2K6-FP alone or in combination with paclitaxel increased the ratio of expressions of Beclin-1/Bcl-2, another autophagy-related markers, compared with paclitaxel alone.	Paclitaxel	59-69	BCL2 apoptosis regulator	Homo sapiens	117-122
28604448-11	2017	Furthermore, either MAP2K6-FP alone or in combination with paclitaxel increased the ratio of expressions of Beclin-1/Bcl-2, another autophagy-related markers, compared with paclitaxel alone.	Paclitaxel	173-183	mitogen-activated protein kinase kinase 6	Homo sapiens	20-26
28604448-12	2017	CONCLUSIONS: MAP2K6-FP enhanced the sensitiveness of paclitaxel for ovarian cancer via inducing autophagy.	Paclitaxel	53-63	mitogen-activated protein kinase kinase 6	Homo sapiens	13-19
28693250-0	2017	Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death.	Paclitaxel	78-88	BCL2 apoptosis regulator	Homo sapiens	0-5
27008163-0	2017	Binary-copolymer system base on low-density lipoprotein-coupled N-succinyl chitosan lipoic acid micelles for co-delivery MDR1 siRNA and paclitaxel, enhances antitumor effects via reducing drug.	Paclitaxel	136-146	ATP binding cassette subfamily B member 1	Homo sapiens	121-125
28404507-0	2017	Paclitaxel inhibits the activity and membrane localization of PKCalpha and PKCbetaI/II to elicit a decrease in stimulated calcitonin gene-related peptide release from cultured sensory neurons.	Paclitaxel	0-10	protein kinase C alpha	Homo sapiens	62-70
28404507-0	2017	Paclitaxel inhibits the activity and membrane localization of PKCalpha and PKCbetaI/II to elicit a decrease in stimulated calcitonin gene-related peptide release from cultured sensory neurons.	Paclitaxel	0-10	calcitonin related polypeptide alpha	Homo sapiens	122-153
28404507-9	2017	Under stimulatory conditions, paclitaxel attenuated the membrane translocation of phosphorylated PKC alpha, betaI and betaII, providing a rationale for the attenuation in PDBu- and capsaicin-stimulated release.	Paclitaxel	30-40	protein kinase C alpha	Homo sapiens	97-124
28693250-0	2017	Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death.	Paclitaxel	78-88	BCL2 like 1	Homo sapiens	6-12
28693250-3	2017	The present study analyzed the effect of the B-cell lymphoma-2 (Bcl-2)/B-cell lymphoma extra-large (Bcl-xL) inhibitor, ABT-737, on paclitaxel-induced PDA cell death.	Paclitaxel	131-141	BCL2 apoptosis regulator	Homo sapiens	45-62
28693250-3	2017	The present study analyzed the effect of the B-cell lymphoma-2 (Bcl-2)/B-cell lymphoma extra-large (Bcl-xL) inhibitor, ABT-737, on paclitaxel-induced PDA cell death.	Paclitaxel	131-141	BCL2 apoptosis regulator	Homo sapiens	64-69
28693250-3	2017	The present study analyzed the effect of the B-cell lymphoma-2 (Bcl-2)/B-cell lymphoma extra-large (Bcl-xL) inhibitor, ABT-737, on paclitaxel-induced PDA cell death.	Paclitaxel	131-141	BCL2 like 1	Homo sapiens	100-106
28693250-9	2017	Knockdown of Bcl-xL lowered the IC50 of paclitaxel, but knockdown of TUBB3 did not.	Paclitaxel	40-50	BCL2 like 1	Homo sapiens	13-19
28485901-0	2017	Synthesis of a Fluorescent Analogue of Paclitaxel That Selectively Binds Microtubules and Sensitively Detects Efflux by P-Glycoprotein.	Paclitaxel	39-49	ATP binding cassette subfamily B member 1	Homo sapiens	120-134
28473236-8	2017	Moreover, Ptx-SA significantly attenuates the expression of p-Akt and increases the expression of cleaved PARP and Caspase-3 compared to the equivalent dose of free Ptx, which demonstrates the enhanced apoptosis-inducing effect of Ptx-SA.	Paclitaxel	10-13	poly(ADP-ribose) polymerase 1	Homo sapiens	106-110
28473236-8	2017	Moreover, Ptx-SA significantly attenuates the expression of p-Akt and increases the expression of cleaved PARP and Caspase-3 compared to the equivalent dose of free Ptx, which demonstrates the enhanced apoptosis-inducing effect of Ptx-SA.	Paclitaxel	10-13	caspase 3	Homo sapiens	115-124
28541685-3	2017	In this article, we describe for the first time a 1,4-benzodiazepine-2,5-dione (BZD) derivative (26bh) that acts as a dual NOD1/NOD2 antagonist and inhibits both nuclear factor kappaB (NF-kappaB) and mitogen-activated protein kinase (MAPK) inflammatory signaling, thereby sensitizing PTX to suppress Lewis lung carcinoma (LLC) growth.	Paclitaxel	284-287	nuclear factor kappa B subunit 1	Homo sapiens	177-183
28428276-1	2017	Treatment of prostate cancer with paclitaxel often fails due to the development of chemoresistance caused by downregulation of the tumor suppressor gene miR-34a.	Paclitaxel	34-44	microRNA 34a	Mus musculus	153-160
28428276-2	2017	In this study, we demonstrate that codelivery of paclitaxel and 2"-hydroxy-2,4,4",5,6"-pentamethoxychalcone (termed rubone) drives upregulation of miR-34a and chemosensitizes paclitaxel-resistant prostate cancer cells, killing both cancer stem-like cells (CSC) and bulk tumor cells.	Paclitaxel	49-59	microRNA 34a	Mus musculus	147-154
28428276-2	2017	In this study, we demonstrate that codelivery of paclitaxel and 2"-hydroxy-2,4,4",5,6"-pentamethoxychalcone (termed rubone) drives upregulation of miR-34a and chemosensitizes paclitaxel-resistant prostate cancer cells, killing both cancer stem-like cells (CSC) and bulk tumor cells.	Paclitaxel	175-185	microRNA 34a	Mus musculus	147-154
28428276-7	2017	Delivery of miR-34a and rubone decreased PC3-TXR cell viability with increasing paclitaxel concentration.	Paclitaxel	80-90	microRNA 34a	Mus musculus	12-19
28428276-10	2017	Systemic administration of micelles carrying paclitaxel and rubone inhibited orthotopic prostate tumor growth in nude mice, compared with monotherapy, by reversing the expression of miR-34a, SIRT1, cyclin D1, and E-cadherin.	Paclitaxel	45-55	microRNA 34a	Mus musculus	182-189
28428276-10	2017	Systemic administration of micelles carrying paclitaxel and rubone inhibited orthotopic prostate tumor growth in nude mice, compared with monotherapy, by reversing the expression of miR-34a, SIRT1, cyclin D1, and E-cadherin.	Paclitaxel	45-55	cadherin 1	Mus musculus	213-223
28428276-11	2017	In summary, our results showed how rubone acts as an efficient small-molecule modulator of miR-34a to reverse chemoresistance and further enhance the therapeutic efficacy of paclitaxel in paclitaxel-resistant prostate cancer.	Paclitaxel	174-184	microRNA 34a	Mus musculus	91-98
28428276-11	2017	In summary, our results showed how rubone acts as an efficient small-molecule modulator of miR-34a to reverse chemoresistance and further enhance the therapeutic efficacy of paclitaxel in paclitaxel-resistant prostate cancer.	Paclitaxel	188-198	microRNA 34a	Mus musculus	91-98
28415580-11	2017	Together, these results indicated that CXCR4 overexpression drives acquired paclitaxel resistance, partly by activating the PDGFA and PDGFB/PDGFRalpha autocrine signaling loops that activate AKT and ERK1/2.	Paclitaxel	76-86	platelet derived growth factor receptor alpha	Homo sapiens	140-150
28415580-11	2017	Together, these results indicated that CXCR4 overexpression drives acquired paclitaxel resistance, partly by activating the PDGFA and PDGFB/PDGFRalpha autocrine signaling loops that activate AKT and ERK1/2.	Paclitaxel	76-86	AKT serine/threonine kinase 1	Homo sapiens	191-194
28415580-11	2017	Together, these results indicated that CXCR4 overexpression drives acquired paclitaxel resistance, partly by activating the PDGFA and PDGFB/PDGFRalpha autocrine signaling loops that activate AKT and ERK1/2.	Paclitaxel	76-86	mitogen-activated protein kinase 3	Homo sapiens	199-205
28302530-5	2017	The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1.	Paclitaxel	107-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-126
28302530-5	2017	The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1.	Paclitaxel	107-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-126
28302530-5	2017	The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1.	Paclitaxel	107-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	121-126
28441715-4	2017	Our findings show that downregulation of Bcl-2, Bcl-XL and Mcl-1 can significantly promote EC109/PTX cell apoptosis and reduce the EC109/PTX cell resistance index (RI).	Paclitaxel	97-100	BCL2 like 1	Homo sapiens	48-54
28552909-3	2017	In this study, we synthesized transferrin (Tf)-modified poly(D,L-lactic-co-glycolic acid) nanoparticles (PLGA NPs) loaded with paclitaxel (PTX) and superparamagnetic nanoparticle (MNP) using a solid-in-oil-in-water solvent evaporation method, followed by Tf adsorption on the surface of NPs.	Paclitaxel	127-137	transferrin	Homo sapiens	30-41
28552909-3	2017	In this study, we synthesized transferrin (Tf)-modified poly(D,L-lactic-co-glycolic acid) nanoparticles (PLGA NPs) loaded with paclitaxel (PTX) and superparamagnetic nanoparticle (MNP) using a solid-in-oil-in-water solvent evaporation method, followed by Tf adsorption on the surface of NPs.	Paclitaxel	139-142	transferrin	Homo sapiens	30-41
28441715-0	2017	Targeting the Bcl-2 family and P-glycoprotein reverses paclitaxel resistance in human esophageal carcinoma cell line.	Paclitaxel	55-65	BCL2 apoptosis regulator	Homo sapiens	14-19
28441715-0	2017	Targeting the Bcl-2 family and P-glycoprotein reverses paclitaxel resistance in human esophageal carcinoma cell line.	Paclitaxel	55-65	ATP binding cassette subfamily B member 1	Homo sapiens	31-45
28260803-1	2017	P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a major obstacle in achieving the therapeutic benefits of paclitaxel (PTX) in the treatment of human ovarian carcinoma.	Paclitaxel	119-129	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
28260803-1	2017	P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a major obstacle in achieving the therapeutic benefits of paclitaxel (PTX) in the treatment of human ovarian carcinoma.	Paclitaxel	119-129	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
28260803-1	2017	P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a major obstacle in achieving the therapeutic benefits of paclitaxel (PTX) in the treatment of human ovarian carcinoma.	Paclitaxel	131-134	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
28260803-1	2017	P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a major obstacle in achieving the therapeutic benefits of paclitaxel (PTX) in the treatment of human ovarian carcinoma.	Paclitaxel	131-134	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
28260803-4	2017	PTX-loaded PSST micelles (PTX/PSST-M) designed to display synergistic functions, including reversible inhibition of P-gp, intracellular redox-sensitive release and potent anticancer activities.	Paclitaxel	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	116-120
28404373-1	2017	In this work, a glutamic acid linked paclitaxel (PTX) dimer (Glu-PTX2) with high PTX content of 88.9wt% was designed and synthesized.	Paclitaxel	37-47	paired like homeodomain 2	Homo sapiens	65-69
28404373-1	2017	In this work, a glutamic acid linked paclitaxel (PTX) dimer (Glu-PTX2) with high PTX content of 88.9wt% was designed and synthesized.	Paclitaxel	49-52	paired like homeodomain 2	Homo sapiens	65-69
28404373-2	2017	Glu-PTX2 could self-assemble into nanoparticles (Glu-PTX2 NPs) in aqueous solution to increase the water solubility of PTX.	Paclitaxel	4-7	paired like homeodomain 2	Homo sapiens	53-57
28441715-2	2017	In this study, we investigated the changes of Bcl-2 family members in the moderate paclitaxel-resistance of esophageal carcinoma EC109/PTX cells both in vitro and in vivo.	Paclitaxel	83-93	BCL2 apoptosis regulator	Homo sapiens	46-51
28441715-2	2017	In this study, we investigated the changes of Bcl-2 family members in the moderate paclitaxel-resistance of esophageal carcinoma EC109/PTX cells both in vitro and in vivo.	Paclitaxel	135-138	BCL2 apoptosis regulator	Homo sapiens	46-51
28441715-4	2017	Our findings show that downregulation of Bcl-2, Bcl-XL and Mcl-1 can significantly promote EC109/PTX cell apoptosis and reduce the EC109/PTX cell resistance index (RI).	Paclitaxel	97-100	BCL2 apoptosis regulator	Homo sapiens	41-46
28441715-4	2017	Our findings show that downregulation of Bcl-2, Bcl-XL and Mcl-1 can significantly promote EC109/PTX cell apoptosis and reduce the EC109/PTX cell resistance index (RI).	Paclitaxel	137-140	BCL2 apoptosis regulator	Homo sapiens	41-46
28441715-4	2017	Our findings show that downregulation of Bcl-2, Bcl-XL and Mcl-1 can significantly promote EC109/PTX cell apoptosis and reduce the EC109/PTX cell resistance index (RI).	Paclitaxel	137-140	BCL2 like 1	Homo sapiens	48-54
28441715-6	2017	These results suggest that targeting of the Bcl-2 family and P-gp is capable of reversing the resistance in EC109/PTX cells and the two-inhibitor combination may be a novel treatment strategy for resistant esophageal cancer.	Paclitaxel	114-117	BCL2 apoptosis regulator	Homo sapiens	44-49
28434806-0	2017	Fibronectin-adherent peripheral blood derived mononuclear cells as Paclitaxel carriers for glioblastoma treatment: An in vitro study.	Paclitaxel	67-77	fibronectin 1	Homo sapiens	0-11
28447211-0	2017	Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	71-76
28341962-15	2017	Importantly, two key genes in apoptosis and stemness, BCL2 and ABCG2, were also upregulated in EP300-knockout colon carcinoma cells and their paclitaxel-resistant derivatives.	Paclitaxel	142-152	BCL2 apoptosis regulator	Homo sapiens	54-58
28341962-15	2017	Importantly, two key genes in apoptosis and stemness, BCL2 and ABCG2, were also upregulated in EP300-knockout colon carcinoma cells and their paclitaxel-resistant derivatives.	Paclitaxel	142-152	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	63-68
28332162-12	2017	The expression of bcl-2 anti-apoptotic gene, in contrast to bax pro-apoptotic gene, significantly decreased after treatment by standard and fungal taxols.	Paclitaxel	147-153	BCL2 apoptosis regulator	Homo sapiens	18-23
28332162-12	2017	The expression of bcl-2 anti-apoptotic gene, in contrast to bax pro-apoptotic gene, significantly decreased after treatment by standard and fungal taxols.	Paclitaxel	147-153	BCL2 associated X, apoptosis regulator	Homo sapiens	60-63
28434806-6	2017	MCs were cultured and the adherent population on fibronectin (FN-MCs), after immunocytochemistry and flow cytometry characterization, was loaded with Paclitaxel (FN-MCs-PTX).	Paclitaxel	150-160	fibronectin 1	Homo sapiens	49-60
28204229-8	2017	As CD24 is hPRL-regulated and has been implicated in drug resistance in EC, we further showed that CD24 is a critical mediator of hPRL-stimulated reduced sensitivity to doxorubicin and paclitaxel in EC cells.	Paclitaxel	185-195	CD24 molecule	Homo sapiens	99-103
28204229-8	2017	As CD24 is hPRL-regulated and has been implicated in drug resistance in EC, we further showed that CD24 is a critical mediator of hPRL-stimulated reduced sensitivity to doxorubicin and paclitaxel in EC cells.	Paclitaxel	185-195	prolactin	Homo sapiens	130-134
28204229-6	2017	In addition, forced expression of hPRL decreased sensitivity of EC cells to chemotherapeutic drugs (i.e., doxorubicin and paclitaxel), both in vitro and in vivo.	Paclitaxel	122-132	prolactin	Homo sapiens	34-38
28204229-8	2017	As CD24 is hPRL-regulated and has been implicated in drug resistance in EC, we further showed that CD24 is a critical mediator of hPRL-stimulated reduced sensitivity to doxorubicin and paclitaxel in EC cells.	Paclitaxel	185-195	CD24 molecule	Homo sapiens	3-7
27941877-3	2017	Here, we show that HuR cleavage associated with active caspase-3 in oral cancer cells treated with ionizing radiation and chemotherapeutic drug, paclitaxel.	Paclitaxel	145-155	caspase 3	Homo sapiens	55-64
28265007-0	2017	The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.	Paclitaxel	50-60	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	75-80
28265007-3	2017	The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major membrane protein transporters responsible for the efflux of paclitaxel, constituting one of the most important mechanisms of paclitaxel resistance.	Paclitaxel	183-193	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-45
28265007-3	2017	The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major membrane protein transporters responsible for the efflux of paclitaxel, constituting one of the most important mechanisms of paclitaxel resistance.	Paclitaxel	183-193	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-52
28440494-5	2017	The ability of PTX to stimulate intranuclear translocation of NF-kappaB was determined by evaluating the expression of the p65 subunit of NF-kappaB.	Paclitaxel	15-18	nuclear factor kappa B subunit 1	Homo sapiens	62-71
28257810-0	2017	Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.	Paclitaxel	45-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
28257810-11	2017	Cell studies showed increased cytotoxicity of PTX/RAP for the immunoliposome, compared to the control liposomes in SKBR3 cells, which could be attributed to enhanced uptake mediated through HER2 binding.	Paclitaxel	46-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	190-194
27861874-0	2017	A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.	Paclitaxel	48-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
28265007-3	2017	The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major membrane protein transporters responsible for the efflux of paclitaxel, constituting one of the most important mechanisms of paclitaxel resistance.	Paclitaxel	248-258	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-45
28265007-3	2017	The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major membrane protein transporters responsible for the efflux of paclitaxel, constituting one of the most important mechanisms of paclitaxel resistance.	Paclitaxel	248-258	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	47-52
28265007-4	2017	Here, we demonstrated that the Bruton tyrosine kinase inhibitor, ibrutinib, significantly enhanced the antitumor activity of paclitaxel by antagonizing the efflux function of ABCB1 and ABCC10 in cells overexpressing these transporters.	Paclitaxel	125-135	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	175-180
28265007-8	2017	Importantly, ibrutinib could effectively enhance paclitaxel-induced inhibition on the growth of ABCB1- and ABCC10-overexpressing tumors in nude athymic mice.	Paclitaxel	49-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	96-101
28265007-9	2017	These results demonstrate that the combination of ibrutinib and paclitaxel can effectively antagonize ABCB1- or ABCC10-mediated paclitaxel resistance that could be of great clinical interest.	Paclitaxel	64-74	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	102-107
28265007-9	2017	These results demonstrate that the combination of ibrutinib and paclitaxel can effectively antagonize ABCB1- or ABCC10-mediated paclitaxel resistance that could be of great clinical interest.	Paclitaxel	128-138	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	102-107
28487984-0	2017	Induction of cell cycle arrest by increasing GTP-RhoA levels via Taxol-induced microtubule polymerization in renal cell carcinoma.	Paclitaxel	65-70	ras homolog family member A	Homo sapiens	49-53
28487984-3	2017	The present study revealed that Taxol-induced microtubule (MT) polymerization causes cell cycle arrest and an increase in guanosine triphosphate-Ras homology gene family, member A (GTP-RhoA) protein expression.	Paclitaxel	32-37	ras homolog family member A	Homo sapiens	185-189
28487984-4	2017	Disruption of Taxol-induced MT polymerization reversed GTP-RhoA expression and cell cycle arrest.	Paclitaxel	14-19	ras homolog family member A	Homo sapiens	59-63
28487984-7	2017	Taken together, Taxol-induced MT polymerization regulated the protein expression levels of GTP-RhoA and cell cycle arrest.	Paclitaxel	16-21	ras homolog family member A	Homo sapiens	95-99
28487984-8	2017	However, the alteration in GTP-RhoA expression did not influence MT arrangement, suggesting that GTP-RhoA serves a pivotal role in Taxol-induced MT polymerization and cell cycle arrest in RCC.	Paclitaxel	131-136	ras homolog family member A	Homo sapiens	101-105
28588737-4	2017	The multidrug resistance (MDR)-1/P-glycoprotein has previously been demonstrated to be associated with the acquisition of paclitaxel resistance in certain ovarian tumors.	Paclitaxel	122-132	ATP binding cassette subfamily B member 1	Homo sapiens	4-32
28588737-4	2017	The multidrug resistance (MDR)-1/P-glycoprotein has previously been demonstrated to be associated with the acquisition of paclitaxel resistance in certain ovarian tumors.	Paclitaxel	122-132	ATP binding cassette subfamily B member 1	Homo sapiens	33-47
28440494-6	2017	In THP-1 macrophages, low-dose PTX (1 and 5 nM) inhibited the expression of CD204, enhanced the expression of NOS2, and significantly suppressed the phosphorylation of Stat3, which is essential for the M2 phenotype.	Paclitaxel	31-34	GLI family zinc finger 2	Homo sapiens	3-8
28440494-6	2017	In THP-1 macrophages, low-dose PTX (1 and 5 nM) inhibited the expression of CD204, enhanced the expression of NOS2, and significantly suppressed the phosphorylation of Stat3, which is essential for the M2 phenotype.	Paclitaxel	31-34	nitric oxide synthase 2	Homo sapiens	110-114
28440494-6	2017	In THP-1 macrophages, low-dose PTX (1 and 5 nM) inhibited the expression of CD204, enhanced the expression of NOS2, and significantly suppressed the phosphorylation of Stat3, which is essential for the M2 phenotype.	Paclitaxel	31-34	signal transducer and activator of transcription 3	Homo sapiens	168-173
28440494-8	2017	PTX treatment of THP-1 macrophages for 1 h induced marked intranuclear translocation of NF-kappaB p65.	Paclitaxel	0-3	GLI family zinc finger 2	Homo sapiens	17-22
28440494-8	2017	PTX treatment of THP-1 macrophages for 1 h induced marked intranuclear translocation of NF-kappaB p65.	Paclitaxel	0-3	nuclear factor kappa B subunit 1	Homo sapiens	88-97
28599410-7	2017	It was indicated that cell lines overexpressing ABCB1 exhibited similar resistance profiles to nab-paclitaxel and paclitaxel.	Paclitaxel	95-109	ATP binding cassette subfamily B member 1	Homo sapiens	48-53
28599410-7	2017	It was indicated that cell lines overexpressing ABCB1 exhibited similar resistance profiles to nab-paclitaxel and paclitaxel.	Paclitaxel	99-109	ATP binding cassette subfamily B member 1	Homo sapiens	48-53
28599410-8	2017	Cabozantinib and crizotinib sensitized tumor cells to nab-paclitaxel and paclitaxel in the same dose-dependent manner in cell lines overexpressing ABCB1, without altering the downstream signaling of tyrosine kinases.	Paclitaxel	73-83	ATP binding cassette subfamily B member 1	Homo sapiens	147-152
28588737-9	2017	It was also determined that the pre-incubation of ovarian cancer cells with a lower dose of myricetin was able to increase the cytotoxicity of paclitaxel, due to the significant downregulation of MDR-1 in these cells.	Paclitaxel	143-153	ATP binding cassette subfamily B member 1	Homo sapiens	196-201
28599410-0	2017	Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells.	Paclitaxel	41-51	ATP binding cassette subfamily B member 1	Homo sapiens	67-72
28599410-9	2017	These results suggest that the overexpression of ABCB1 confers resistance to nab-paclitaxel in urothelial cancer cells.	Paclitaxel	81-91	ATP binding cassette subfamily B member 1	Homo sapiens	49-54
27941877-4	2017	We determined that oral cancer cells overexpressing cyclooxygenase-2 (COX-2) limited the cleavage of caspase-3 and HuR, which reduced the rate of cell death in paclitaxel resistant oral cancer cells.	Paclitaxel	160-170	prostaglandin-endoperoxide synthase 2	Homo sapiens	52-68
27941877-4	2017	We determined that oral cancer cells overexpressing cyclooxygenase-2 (COX-2) limited the cleavage of caspase-3 and HuR, which reduced the rate of cell death in paclitaxel resistant oral cancer cells.	Paclitaxel	160-170	prostaglandin-endoperoxide synthase 2	Homo sapiens	70-75
27941877-4	2017	We determined that oral cancer cells overexpressing cyclooxygenase-2 (COX-2) limited the cleavage of caspase-3 and HuR, which reduced the rate of cell death in paclitaxel resistant oral cancer cells.	Paclitaxel	160-170	caspase 3	Homo sapiens	101-110
28599444-4	2017	In addition, treatment with SFN and paclitaxel resulted in downregulation of the nuclear factor kappa B signaling pathway, and reduced protein expression of apoptosis regulator Bcl-2 and phosphorylated AKT serine/threonine kinase.	Paclitaxel	36-46	AKT serine/threonine kinase 1	Homo sapiens	202-205
28599444-5	2017	Furthermore, SFN-paclitaxel-induced apoptosis was inhibited by overexpression of Bcl-2.	Paclitaxel	17-27	BCL2 apoptosis regulator	Homo sapiens	81-86
27941877-5	2017	Specific inhibition of COX-2 by celecoxib, promoted apoptosis through activation of caspase-3 and cleavage of HuR in paclitaxel-resistant oral cancer cells, both in vitro and in vivo.	Paclitaxel	117-127	prostaglandin-endoperoxide synthase 2	Homo sapiens	23-28
28599444-3	2017	Combined treatment of breast cancer cells with SFN and paclitaxel resulted in increased activation of apoptotic signaling pathway members, including caspase-3, -8 and -9, and cytochrome c, compared with treatment with SFN or paclitaxel alone.	Paclitaxel	55-65	caspase 3	Homo sapiens	149-169
27941877-10	2017	Altogether, our observations support the use of the COX-2 inhibitor celecoxib, in combination with paclitaxel, for the management of paclitaxel resistant oral cancer cells.	Paclitaxel	133-143	prostaglandin-endoperoxide synthase 2	Homo sapiens	52-57
28599444-3	2017	Combined treatment of breast cancer cells with SFN and paclitaxel resulted in increased activation of apoptotic signaling pathway members, including caspase-3, -8 and -9, and cytochrome c, compared with treatment with SFN or paclitaxel alone.	Paclitaxel	55-65	cytochrome c, somatic	Homo sapiens	175-187
28599444-4	2017	In addition, treatment with SFN and paclitaxel resulted in downregulation of the nuclear factor kappa B signaling pathway, and reduced protein expression of apoptosis regulator Bcl-2 and phosphorylated AKT serine/threonine kinase.	Paclitaxel	36-46	BCL2 apoptosis regulator	Homo sapiens	177-182
28277162-7	2017	Similarly, 1 muM and 10 muM caffeine protected cells against paclitaxel-induced toxicity and mitochondrial ROS production.	Paclitaxel	61-71	latexin	Homo sapiens	24-27
29108309-11	2017	Neoadjuvant chemotherapy by weekly paclitaxel and cisplatin combination was highly effective and tolerated in this study, especially in the triple negative and HER2 positive tumors.	Paclitaxel	35-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	160-164
28507307-4	2017	Senescence occurred following cisplatin- or Taxol-treatment in cell lines from both cancer types and was associated with decreased histone 3 (H3) acetylation and increased Bcl-xL expression: the latter a biomarker of senescence and target of anti-senescence therapeutics, or senolytics.	Paclitaxel	44-49	H3 clustered histone 14	Homo sapiens	131-144
28507307-4	2017	Senescence occurred following cisplatin- or Taxol-treatment in cell lines from both cancer types and was associated with decreased histone 3 (H3) acetylation and increased Bcl-xL expression: the latter a biomarker of senescence and target of anti-senescence therapeutics, or senolytics.	Paclitaxel	44-49	BCL2 like 1	Homo sapiens	172-178
28350442-5	2017	The results demonstrated that the engineered Tf variant polymer conjugates formed better-defined self-assembled nanoparticles than the nonselectively derivatized conjugates and showed greater efficacy in paclitaxel delivery.	Paclitaxel	204-214	transferrin	Homo sapiens	45-47
28277162-7	2017	Similarly, 1 muM and 10 muM caffeine protected cells against paclitaxel-induced toxicity and mitochondrial ROS production.	Paclitaxel	61-71	latexin	Homo sapiens	13-16
28254410-3	2017	We demonstrate that paclitaxel or docetaxel treatment induces IL-6 secretion and results in expansion of CSCs in TNBC cell lines.	Paclitaxel	20-30	interleukin 6	Mus musculus	62-66
28320862-6	2017	IRS-2 colocalization with tubulin is enhanced upon Taxol-mediated microtubule stabilization, which, together with the signaling data, suggests that the microtubule cytoskeleton may facilitate access of IRS-2 to downstream effectors such as AKT.	Paclitaxel	51-56	AKT serine/threonine kinase 1	Homo sapiens	240-243
29029411-0	2017	Nestin expression involves invasiveness of esophageal carcinoma and its downregulation enhances paclitaxel sensitivity to esophageal carcinoma cell apoptosis.	Paclitaxel	96-106	nestin	Homo sapiens	0-6
29029411-4	2017	To further elucidate whether nestin inhibition could enhance paclitaxel sensitivity to esophageal carcinoma cells, we applied nestin siRNA in esophageal squamous cell carcinoma Eca-109 cells.	Paclitaxel	61-71	nestin	Homo sapiens	29-35
29029411-5	2017	Flow cytometry and TUNEL staining both showed that combination of paclitaxel treatment and nestin knockdown resulted in greater induction of apoptosis of esophageal carcinoma cells as compared with the cells transfected with control siRNA (also treated with paclitaxel).	Paclitaxel	258-268	nestin	Homo sapiens	91-97
29029411-6	2017	This study indicates that nestin knockdown enhances chemotherapeutic sensitivity of paclitaxel to esophageal carcinoma, and suggests that silencing of nestin could be a valuble therapeutic approach for enhancing drug sensitivity and thereby improving the treatment outcome of esophageal carcinoma patients.	Paclitaxel	84-94	nestin	Homo sapiens	26-32
29069726-8	2017	However, although RPE-20 cells displayed enhanced TUBB3 levels, we find that simultaneous up-regulation of the P-glycoprotein (P-gP) drug-efflux pump is responsible for the resistance to taxol.	Paclitaxel	187-192	ATP binding cassette subfamily B member 1	Homo sapiens	111-125
29069726-8	2017	However, although RPE-20 cells displayed enhanced TUBB3 levels, we find that simultaneous up-regulation of the P-glycoprotein (P-gP) drug-efflux pump is responsible for the resistance to taxol.	Paclitaxel	187-192	ATP binding cassette subfamily B member 1	Homo sapiens	127-131
28423731-3	2017	The faster release of curcumin from the folate-conjugated curcumin and paclitaxel-loaded lipid nanoparticles enables sufficient p-glycoprotein inhibition, which allows increased cellular uptake and cytotoxicity of paclitaxel.	Paclitaxel	71-81	ATP binding cassette subfamily B member 1	Homo sapiens	128-142
28470171-3	2017	In this co-delivery system, PTX was covalently conjugated to poly (D,L-lactide-co-glycolide) polymeric core by redox-sensitive disulfide bond, while TET was physically capsulated spontaneously for the aim to suppress P-gp in advance by the earlier released TET in cancer cells.	Paclitaxel	28-31	ATP binding cassette subfamily B member 1	Homo sapiens	217-221
28522974-11	2017	Up-regulation of p53 and p21 in colorectal carcinoma cells treated with low-dose PTX also contributed to inhibition of tumor cell growth.	Paclitaxel	81-84	tumor protein p53	Homo sapiens	17-20
28423731-4	2017	In western blot assay, curcumin can efficiently inhibit the expression of p-glycoprotein, conformed the enhancement of cytotoxicity by paclitaxel.	Paclitaxel	135-145	ATP binding cassette subfamily B member 1	Homo sapiens	74-88
28231544-0	2017	Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-kappaB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.	Paclitaxel	41-51	BCL2 associated X, apoptosis regulator	Homo sapiens	106-109
28231544-0	2017	Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-kappaB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.	Paclitaxel	41-51	BCL2 apoptosis regulator	Homo sapiens	110-115
28231544-10	2017	Ginsenoside Rg3 combined Paclitaxel inhibited NF-kappaB activation, decreased NF-kappaB p65 and Bcl-2 protein expressions, increased Bax and Caspase-3 protein expressions.	Paclitaxel	25-35	BCL2 apoptosis regulator	Homo sapiens	96-101
28231544-10	2017	Ginsenoside Rg3 combined Paclitaxel inhibited NF-kappaB activation, decreased NF-kappaB p65 and Bcl-2 protein expressions, increased Bax and Caspase-3 protein expressions.	Paclitaxel	25-35	BCL2 associated X, apoptosis regulator	Homo sapiens	133-136
28231544-10	2017	Ginsenoside Rg3 combined Paclitaxel inhibited NF-kappaB activation, decreased NF-kappaB p65 and Bcl-2 protein expressions, increased Bax and Caspase-3 protein expressions.	Paclitaxel	25-35	caspase 3	Homo sapiens	141-150
28231544-11	2017	The ratio of Bax/Bcl-2 was significantly enhanced by the Ginsenoside Rg3 to Paclitaxel.	Paclitaxel	76-86	BCL2 associated X, apoptosis regulator	Homo sapiens	13-16
28231544-11	2017	The ratio of Bax/Bcl-2 was significantly enhanced by the Ginsenoside Rg3 to Paclitaxel.	Paclitaxel	76-86	BCL2 apoptosis regulator	Homo sapiens	17-22
28231544-12	2017	Ginsenoside Rg3 promotes cytotoxicity and apoptosis of Paclitaxel by inhibiting NF-kappaB signaling and modulating Bax/Bcl-2 expression on TNBC.	Paclitaxel	55-65	BCL2 associated X, apoptosis regulator	Homo sapiens	115-118
28235687-9	2017	In spleens, IM+PTX therapy elevated proportion of whole lymphocytes in the account of myelo-monocytic cells characteristic with low expression of CD11c+ and bearing Fc receptor (CD16/32) as well as T-lymphocytes, NK cells and dendritic cells.	Paclitaxel	15-18	Fc receptor, IgG, low affinity III	Mus musculus	178-182
27689412-0	2017	Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box-Behnken design.	Paclitaxel	107-117	transferrin	Homo sapiens	32-43
29145976-3	2017	Upon repeated or even single dose treatment of cultured tumor cells or tumors in vivo with anti-tumor agents such as paclitaxel and doxorubicin, increased ABCB1 copy number has been demonstrated, resulting from chromosomal amplification events at 7q11.2-21 locus, leading to marked P-glycoprotein overexpression, and multidrug resistance (MDR).	Paclitaxel	117-127	ATP binding cassette subfamily B member 1	Homo sapiens	155-160
29145976-3	2017	Upon repeated or even single dose treatment of cultured tumor cells or tumors in vivo with anti-tumor agents such as paclitaxel and doxorubicin, increased ABCB1 copy number has been demonstrated, resulting from chromosomal amplification events at 7q11.2-21 locus, leading to marked P-glycoprotein overexpression, and multidrug resistance (MDR).	Paclitaxel	117-127	ATP binding cassette subfamily B member 1	Homo sapiens	282-296
28158579-1	2017	Background: In the double-blind placebo-controlled randomized Phase III MERiDiAN trial (ClinicalTrials.gov NCT01663727), adding bevacizumab to paclitaxel for HER2-negative metastatic breast cancer (mBC) significantly improved progression-free survival (PFS; stratified hazard ratio [HR] 0.68, 99% confidence interval [CI], 0.51-0.91).	Paclitaxel	143-153	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
28538405-0	2017	Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.	Paclitaxel	23-33	epidermal growth factor receptor	Homo sapiens	37-41
28256066-0	2017	Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.	Paclitaxel	33-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
27689412-2	2017	The purpose of this study was to develop transferrin-conjugated nanostructured lipid carriers (Tf-NLCs) for brain delivery of paclitaxel (PTX).	Paclitaxel	126-136	transferrin	Homo sapiens	41-52
27689412-2	2017	The purpose of this study was to develop transferrin-conjugated nanostructured lipid carriers (Tf-NLCs) for brain delivery of paclitaxel (PTX).	Paclitaxel	138-141	transferrin	Homo sapiens	41-52
27689412-4	2017	Optimized PTX-NLC was coupled with transferrin as targeting ligand and in vitro cytotoxicity of it was investigated against U-87 brain cancer cell line.	Paclitaxel	10-13	transferrin	Homo sapiens	35-46
27689412-7	2017	Following conjugation of optimized PTX-NLCs with transferrin, coupling efficiency was 21.3 mg transferrin per mmol of stearylamine; PS and MRT were increased while ZP, EE and DL decreased non-significantly.	Paclitaxel	35-38	transferrin	Homo sapiens	49-60
27689412-7	2017	Following conjugation of optimized PTX-NLCs with transferrin, coupling efficiency was 21.3 mg transferrin per mmol of stearylamine; PS and MRT were increased while ZP, EE and DL decreased non-significantly.	Paclitaxel	35-38	transferrin	Homo sapiens	94-105
28069192-10	2017	Studies on normal lung cells, MRC-5 and nasopharyngeal cancer cells, HK-1 supported the biocompatibility of RGO-Ptx towards normal cell line.	Paclitaxel	112-115	hexokinase 1	Homo sapiens	69-73
28455529-7	2017	Kanglaite inhibited the expression of nuclear factor (NF)-kappaBeta and upregulated that of connexin 43, both of which sensitized cancer cells to Taxol.	Paclitaxel	146-151	gap junction protein, alpha 1	Mus musculus	92-103
27189791-2	2017	Drug efflux by P-glycoprotein (P-gp) is a common resistance mechanism of breast cancer cells to paclitaxel, the primary chemotherapy in breast cancer.	Paclitaxel	96-106	phosphoglycolate phosphatase	Rattus norvegicus	31-35
27189791-4	2017	Therefore, we assessed whether KRG alters P-gp mediated paclitaxel efflux, and therefore paclitaxel efficacy in in vitro and vivo models.	Paclitaxel	56-66	phosphoglycolate phosphatase	Rattus norvegicus	42-46
27189791-7	2017	In female rats with mammary tumor, the combination of paclitaxel with KRG showed the greater reduction of tumor volumes, lower P-gp protein expression and higher paclitaxel distribution in tumors, and greater oral bioavailability of paclitaxel than paclitaxel alone.	Paclitaxel	54-64	phosphoglycolate phosphatase	Rattus norvegicus	127-131
27189791-9	2017	From these results, KRG increased systemic circulation of oral paclitaxel and its distribution to tumors via P-gp inhibition in rats and under the current study conditions.	Paclitaxel	63-73	phosphoglycolate phosphatase	Rattus norvegicus	109-113
28427190-0	2017	Pygopus2 inhibits the efficacy of paclitaxel-induced apoptosis and induces multidrug resistance in human glioma cells.	Paclitaxel	34-44	pygopus family PHD finger 2	Homo sapiens	0-8
28903364-4	2017	Our results showed that KIF7-CC but not KIF7-MD significantly attenuated proliferation and colony formation, impeded migration and invasion, induced apoptosis and sensitized PCa cells to paclitaxel.	Paclitaxel	187-197	kinesin family member 7	Homo sapiens	24-28
28427190-5	2017	In this study, we report that over-expression of Pygo2 inhibited the efficacy of PTX and contributed to cell multidrug resistance in two different ways.	Paclitaxel	81-84	pygopus family PHD finger 2	Homo sapiens	49-54
28427190-6	2017	First, over-expression of Pygo2 inhibited the PTX-induced phosphorylation of B-cell lymphoma 2 (Bcl-2), suppressing the proteolytic cleavage of procaspase-8/9 and further inhibiting the activation of caspase-3, which also inhibits the activation of the JNK/SAPK pathway, ultimately inhibiting cell apoptosis.	Paclitaxel	46-49	pygopus family PHD finger 2	Homo sapiens	26-31
28427190-6	2017	First, over-expression of Pygo2 inhibited the PTX-induced phosphorylation of B-cell lymphoma 2 (Bcl-2), suppressing the proteolytic cleavage of procaspase-8/9 and further inhibiting the activation of caspase-3, which also inhibits the activation of the JNK/SAPK pathway, ultimately inhibiting cell apoptosis.	Paclitaxel	46-49	BCL2 apoptosis regulator	Homo sapiens	77-94
28427190-6	2017	First, over-expression of Pygo2 inhibited the PTX-induced phosphorylation of B-cell lymphoma 2 (Bcl-2), suppressing the proteolytic cleavage of procaspase-8/9 and further inhibiting the activation of caspase-3, which also inhibits the activation of the JNK/SAPK pathway, ultimately inhibiting cell apoptosis.	Paclitaxel	46-49	BCL2 apoptosis regulator	Homo sapiens	96-101
28427190-6	2017	First, over-expression of Pygo2 inhibited the PTX-induced phosphorylation of B-cell lymphoma 2 (Bcl-2), suppressing the proteolytic cleavage of procaspase-8/9 and further inhibiting the activation of caspase-3, which also inhibits the activation of the JNK/SAPK pathway, ultimately inhibiting cell apoptosis.	Paclitaxel	46-49	caspase 3	Homo sapiens	200-209
28427190-7	2017	Second, over-expression of Pygo2 facilitated the expression of P-glycoprotein, which acts as a drug efflux pump, by promoting the transcription of Multi-drug resistance 1 (MDR1) at the MDR1 promoter loci, resulting in acceleration of the efflux of PTX.	Paclitaxel	248-251	pygopus family PHD finger 2	Homo sapiens	27-32
28427190-7	2017	Second, over-expression of Pygo2 facilitated the expression of P-glycoprotein, which acts as a drug efflux pump, by promoting the transcription of Multi-drug resistance 1 (MDR1) at the MDR1 promoter loci, resulting in acceleration of the efflux of PTX.	Paclitaxel	248-251	ATP binding cassette subfamily B member 1	Homo sapiens	63-77
28427190-7	2017	Second, over-expression of Pygo2 facilitated the expression of P-glycoprotein, which acts as a drug efflux pump, by promoting the transcription of Multi-drug resistance 1 (MDR1) at the MDR1 promoter loci, resulting in acceleration of the efflux of PTX.	Paclitaxel	248-251	ATP binding cassette subfamily B member 1	Homo sapiens	147-170
28427190-7	2017	Second, over-expression of Pygo2 facilitated the expression of P-glycoprotein, which acts as a drug efflux pump, by promoting the transcription of Multi-drug resistance 1 (MDR1) at the MDR1 promoter loci, resulting in acceleration of the efflux of PTX.	Paclitaxel	248-251	ATP binding cassette subfamily B member 1	Homo sapiens	172-176
28378801-0	2017	Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma.	Paclitaxel	18-28	keratin 20	Homo sapiens	71-75
28417924-10	2017	Investigation with real time quantitative PCR analysis revealed the limiting expression of chemo-resistant genes (ABCG2 and MDR1) after applying PLGA NPs as a drug delivery system for PTX.	Paclitaxel	184-187	malic enzyme complex, mitochondrial	Mus musculus	124-128
28258248-6	2017	Moreover, HGF in CAF matrix attenuated paclitaxel (PAC)-caused inhibition of cell proliferation and increase in cell apoptosis through activating c-Met/PI3K/Akt and GRP78 pathways in SKOV3 and HO-8910 cells.	Paclitaxel	39-49	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	146-151
28258248-6	2017	Moreover, HGF in CAF matrix attenuated paclitaxel (PAC)-caused inhibition of cell proliferation and increase in cell apoptosis through activating c-Met/PI3K/Akt and GRP78 pathways in SKOV3 and HO-8910 cells.	Paclitaxel	39-49	AKT serine/threonine kinase 1	Homo sapiens	157-160
28258248-6	2017	Moreover, HGF in CAF matrix attenuated paclitaxel (PAC)-caused inhibition of cell proliferation and increase in cell apoptosis through activating c-Met/PI3K/Akt and GRP78 pathways in SKOV3 and HO-8910 cells.	Paclitaxel	39-49	heat shock protein family A (Hsp70) member 5	Homo sapiens	165-170
28258248-6	2017	Moreover, HGF in CAF matrix attenuated paclitaxel (PAC)-caused inhibition of cell proliferation and increase in cell apoptosis through activating c-Met/PI3K/Akt and GRP78 pathways in SKOV3 and HO-8910 cells.	Paclitaxel	51-54	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	146-151
28258248-6	2017	Moreover, HGF in CAF matrix attenuated paclitaxel (PAC)-caused inhibition of cell proliferation and increase in cell apoptosis through activating c-Met/PI3K/Akt and GRP78 pathways in SKOV3 and HO-8910 cells.	Paclitaxel	51-54	AKT serine/threonine kinase 1	Homo sapiens	157-160
28258248-6	2017	Moreover, HGF in CAF matrix attenuated paclitaxel (PAC)-caused inhibition of cell proliferation and increase in cell apoptosis through activating c-Met/PI3K/Akt and GRP78 pathways in SKOV3 and HO-8910 cells.	Paclitaxel	51-54	heat shock protein family A (Hsp70) member 5	Homo sapiens	165-170
29069857-0	2017	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer.	Paclitaxel	75-85	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	23-26
28399902-11	2017	CONCLUSIONS: The efficacy and safety of everolimus plus trastuzumab and paclitaxel as first-line treatment for HER2+ advanced breast cancer in the Asian subset was consistent with that reported previously in the overall population.	Paclitaxel	72-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
28380350-7	2017	MEK inhibition blocked the protective capacity of TAMs and phenocopied the effects of TAM depletion on Taxol treatment.	Paclitaxel	103-108	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
28190247-6	2017	Cells also displayed varying sensitivities to anti-neoplastic drugs, although all cells with PIK3CA mutations showed a relative increased sensitivity to paclitaxel.	Paclitaxel	153-163	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	93-99
28423567-0	2017	CXCR1/2 pathways in paclitaxel-induced neuropathic pain.	Paclitaxel	20-30	C-X-C motif chemokine receptor 1	Rattus norvegicus	0-5
27868228-3	2017	THE PATIENT: A 77-year-old woman with a history of hypertension, hyperlipidemia, and palpitations, managed with amiodarone, was treated for HER2-positive invasive ductal breast cancer with paclitaxel and trastuzumab as an adjunct to surgery.	Paclitaxel	189-199	erb-b2 receptor tyrosine kinase 2	Homo sapiens	140-144
28614779-10	2017	Doxorubicin, PTX and DTX induced OS, DNA damage and changes in expression of TNF-alpha, nNOS and PARP-1 in the rat brain.	Paclitaxel	13-16	tumor necrosis factor	Rattus norvegicus	77-86
28106938-0	2017	Vascular endothelial growth factor-targeted paclitaxel-loaded liposome microbubbles and inhibition of human epidermoid-2 cell proliferation.	Paclitaxel	44-54	vascular endothelial growth factor A	Homo sapiens	0-34
28106938-2	2017	The purpose of this study was to evaluate the inhibitory effect of VEGF-targeted paclitaxel (PTX)-loaded liposome microbubbles (VTPLLMs) on the proliferation of human epidermoid (Hep-2) laryngeal squamous cell carcinoma (SCC).	Paclitaxel	81-91	vascular endothelial growth factor A	Homo sapiens	67-71
28106938-2	2017	The purpose of this study was to evaluate the inhibitory effect of VEGF-targeted paclitaxel (PTX)-loaded liposome microbubbles (VTPLLMs) on the proliferation of human epidermoid (Hep-2) laryngeal squamous cell carcinoma (SCC).	Paclitaxel	93-96	vascular endothelial growth factor A	Homo sapiens	67-71
27599706-4	2017	METHODS: This study predicted the magnitude of the DDI between efavirenz, an inducer of CYP3A4 and inhibitor of CYP2C8, and dual CYP3A4/CYP2C8 substrates (repaglinide, montelukast, pioglitazone, paclitaxel) using a physiologically based pharmacokinetic (PBPK) modeling approach integrating concurrent effects on CYPs.	Paclitaxel	195-205	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135
28260091-5	2017	The cells treated with paclitaxel alone eventually acquired MDR along with the overexpression of and highly activated P-glycoprotein (Pgp), while the cells treated with the paclitaxel-TET combination were sensitive to chemotherapeutic drugs and expressed decreased levels of Pgp and less Pgp activity.	Paclitaxel	23-33	ATP binding cassette subfamily B member 1	Homo sapiens	118-132
28260091-5	2017	The cells treated with paclitaxel alone eventually acquired MDR along with the overexpression of and highly activated P-glycoprotein (Pgp), while the cells treated with the paclitaxel-TET combination were sensitive to chemotherapeutic drugs and expressed decreased levels of Pgp and less Pgp activity.	Paclitaxel	23-33	ATP binding cassette subfamily B member 1	Homo sapiens	134-137
28260091-5	2017	The cells treated with paclitaxel alone eventually acquired MDR along with the overexpression of and highly activated P-glycoprotein (Pgp), while the cells treated with the paclitaxel-TET combination were sensitive to chemotherapeutic drugs and expressed decreased levels of Pgp and less Pgp activity.	Paclitaxel	23-33	ATP binding cassette subfamily B member 1	Homo sapiens	275-278
28260091-5	2017	The cells treated with paclitaxel alone eventually acquired MDR along with the overexpression of and highly activated P-glycoprotein (Pgp), while the cells treated with the paclitaxel-TET combination were sensitive to chemotherapeutic drugs and expressed decreased levels of Pgp and less Pgp activity.	Paclitaxel	23-33	ATP binding cassette subfamily B member 1	Homo sapiens	275-278
28260091-5	2017	The cells treated with paclitaxel alone eventually acquired MDR along with the overexpression of and highly activated P-glycoprotein (Pgp), while the cells treated with the paclitaxel-TET combination were sensitive to chemotherapeutic drugs and expressed decreased levels of Pgp and less Pgp activity.	Paclitaxel	173-183	ATP binding cassette subfamily B member 1	Homo sapiens	275-278
28260091-5	2017	The cells treated with paclitaxel alone eventually acquired MDR along with the overexpression of and highly activated P-glycoprotein (Pgp), while the cells treated with the paclitaxel-TET combination were sensitive to chemotherapeutic drugs and expressed decreased levels of Pgp and less Pgp activity.	Paclitaxel	173-183	ATP binding cassette subfamily B member 1	Homo sapiens	275-278
28260091-6	2017	The promoter activities of MDR gene 1 (MDR1) and nuclear factor (NF)-kappaB, and the expression levels of NF-kappaB and p-IkappaB-alpha were all enhanced in the cells cultured with paclitaxel alone.	Paclitaxel	181-191	ATP binding cassette subfamily B member 1	Homo sapiens	27-37
28260091-6	2017	The promoter activities of MDR gene 1 (MDR1) and nuclear factor (NF)-kappaB, and the expression levels of NF-kappaB and p-IkappaB-alpha were all enhanced in the cells cultured with paclitaxel alone.	Paclitaxel	181-191	ATP binding cassette subfamily B member 1	Homo sapiens	39-43
28260091-6	2017	The promoter activities of MDR gene 1 (MDR1) and nuclear factor (NF)-kappaB, and the expression levels of NF-kappaB and p-IkappaB-alpha were all enhanced in the cells cultured with paclitaxel alone.	Paclitaxel	181-191	nuclear factor kappa B subunit 1	Homo sapiens	49-75
28260091-6	2017	The promoter activities of MDR gene 1 (MDR1) and nuclear factor (NF)-kappaB, and the expression levels of NF-kappaB and p-IkappaB-alpha were all enhanced in the cells cultured with paclitaxel alone.	Paclitaxel	181-191	nuclear factor kappa B subunit 1	Homo sapiens	106-115
28260091-7	2017	NF-kappaB DNA-binding activity and the binding ability of NF-kappaB to the MDR1 promoter were also enhanced in the cells cultured with paclitaxel alone compared to the control cells.	Paclitaxel	135-145	nuclear factor kappa B subunit 1	Homo sapiens	0-9
28260091-7	2017	NF-kappaB DNA-binding activity and the binding ability of NF-kappaB to the MDR1 promoter were also enhanced in the cells cultured with paclitaxel alone compared to the control cells.	Paclitaxel	135-145	nuclear factor kappa B subunit 1	Homo sapiens	58-67
28260091-7	2017	NF-kappaB DNA-binding activity and the binding ability of NF-kappaB to the MDR1 promoter were also enhanced in the cells cultured with paclitaxel alone compared to the control cells.	Paclitaxel	135-145	ATP binding cassette subfamily B member 1	Homo sapiens	75-79
28260091-8	2017	However, the expression and activity of NF-kappaB were significantly decreased in the paclitaxel-TET combination-treated group as compared with the cells treated with paclitaxel alone.	Paclitaxel	86-96	nuclear factor kappa B subunit 1	Homo sapiens	40-49
28260091-8	2017	However, the expression and activity of NF-kappaB were significantly decreased in the paclitaxel-TET combination-treated group as compared with the cells treated with paclitaxel alone.	Paclitaxel	167-177	nuclear factor kappa B subunit 1	Homo sapiens	40-49
28260091-9	2017	On the whole, our findings suggest that TET prevents paclitaxel-induced MDR by inhibiting Pgp overexpression through a mechanism that may involve the inhibition of NF-kappaB signaling in osteosarcoma.	Paclitaxel	53-63	ATP binding cassette subfamily B member 1	Homo sapiens	90-93
28260091-9	2017	On the whole, our findings suggest that TET prevents paclitaxel-induced MDR by inhibiting Pgp overexpression through a mechanism that may involve the inhibition of NF-kappaB signaling in osteosarcoma.	Paclitaxel	53-63	nuclear factor kappa B subunit 1	Homo sapiens	164-173
28350087-3	2017	In this study, we found that paclitaxel-induced apoptosis by increasing the relevant apoptosis protein expression and the release of cytochrome c via downregulation of signal transducer and activator of transcription 3 (STAT3) and phospho-STAT3 (Ser727).	Paclitaxel	29-39	signal transducer and activator of transcription 3	Homo sapiens	220-225
28350087-0	2017	Paclitaxel induces apoptosis of esophageal squamous cell carcinoma cells by downregulating STAT3 phosphorylation at Ser727.	Paclitaxel	0-10	signal transducer and activator of transcription 3	Homo sapiens	91-96
28413662-0	2017	Phase I study of nanoparticle albumin-bound paclitaxel, carboplatin and trastuzumab in women with human epidermal growth factor receptor 2-overexpressing breast cancer.	Paclitaxel	44-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-138
28454434-0	2017	F10, a novel hydatidiform mole-associated gene, inhibits the paclitaxel sensitivity of A549 lung cancer cells by downregulating BAX and caspase-3.	Paclitaxel	61-71	BCL2 associated X, apoptosis regulator	Homo sapiens	128-131
28454434-0	2017	F10, a novel hydatidiform mole-associated gene, inhibits the paclitaxel sensitivity of A549 lung cancer cells by downregulating BAX and caspase-3.	Paclitaxel	61-71	caspase 3	Homo sapiens	136-145
28454476-0	2017	PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis.	Paclitaxel	55-65	poly(ADP-ribose) polymerase 1	Homo sapiens	0-4
28454476-6	2017	These results indicate that the inhibition of PARP with PJ34 sensitizes endometrial cancer cells to cytotoxic treatment with paclitaxel.	Paclitaxel	125-135	poly(ADP-ribose) polymerase 1	Homo sapiens	46-50
28072604-5	2017	In addition, paclitaxel and vincristine both could increase the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and the acetylation of histone H4 in the CXCL12-expressing neurons.	Paclitaxel	13-23	signal transducer and activator of transcription 3	Mus musculus	83-133
28072604-5	2017	In addition, paclitaxel and vincristine both could increase the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and the acetylation of histone H4 in the CXCL12-expressing neurons.	Paclitaxel	13-23	signal transducer and activator of transcription 3	Mus musculus	135-140
28350087-3	2017	In this study, we found that paclitaxel-induced apoptosis by increasing the relevant apoptosis protein expression and the release of cytochrome c via downregulation of signal transducer and activator of transcription 3 (STAT3) and phospho-STAT3 (Ser727).	Paclitaxel	29-39	cytochrome c, somatic	Homo sapiens	133-145
28350087-3	2017	In this study, we found that paclitaxel-induced apoptosis by increasing the relevant apoptosis protein expression and the release of cytochrome c via downregulation of signal transducer and activator of transcription 3 (STAT3) and phospho-STAT3 (Ser727).	Paclitaxel	29-39	signal transducer and activator of transcription 3	Homo sapiens	168-218
28350087-3	2017	In this study, we found that paclitaxel-induced apoptosis by increasing the relevant apoptosis protein expression and the release of cytochrome c via downregulation of signal transducer and activator of transcription 3 (STAT3) and phospho-STAT3 (Ser727).	Paclitaxel	29-39	signal transducer and activator of transcription 3	Homo sapiens	239-244
28350087-6	2017	In conclusion, our findings reveal that paclitaxel induced apoptosis in both EC-1 and Eca-109 cells through the reduction of STAT3 and phospho-STAT3 (Ser727) level, and suggest that paclitaxel may be of therapeutic potential in the treatment of ESCC through the induction of mitochondrial apoptosis in ESCC cells.	Paclitaxel	40-50	signal transducer and activator of transcription 3	Homo sapiens	125-130
28350087-6	2017	In conclusion, our findings reveal that paclitaxel induced apoptosis in both EC-1 and Eca-109 cells through the reduction of STAT3 and phospho-STAT3 (Ser727) level, and suggest that paclitaxel may be of therapeutic potential in the treatment of ESCC through the induction of mitochondrial apoptosis in ESCC cells.	Paclitaxel	40-50	signal transducer and activator of transcription 3	Homo sapiens	143-148
28314310-0	2017	First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.	Paclitaxel	27-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
28356132-13	2017	In particular, the sensitivity to paclitaxel was reactivated in E-cadherin-overexpressing PC3-TxR and DU145-TxR cells.	Paclitaxel	34-44	cadherin 1	Homo sapiens	64-74
28356132-14	2017	When E-cadherin expression was silenced in parental PC3 and DU145 cells, the expression of Vimentin and Snail was up-regulated, and, particularly, the sensitivity to paclitaxel was decreased.	Paclitaxel	166-176	cadherin 1	Homo sapiens	5-15
28356132-16	2017	The use of gamma-secretase inhibitor, a Notch signaling pathway inhibitor, significantly increased the sensitivity of chemoresistant cells to paclitaxel.	Paclitaxel	142-152	notch receptor 1	Homo sapiens	40-45
28145547-0	2017	Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-kappaB/Twist1 signaling pathways in a mouse 4T1 breast tumor model.	Paclitaxel	43-48	phospholipase A2, group VI	Mus musculus	86-91
28145547-0	2017	Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-kappaB/Twist1 signaling pathways in a mouse 4T1 breast tumor model.	Paclitaxel	43-48	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	96-105
28145547-13	2017	The synergistic antitumor and anti-metastasis effects were enhanced primarily through the induction of Taxol-stimulated G2/M phase arrest and the inhibition of caspase-3/cytosolic Ca2+-independent phospholipase A2 (iPLA2) and nuclear factor-kappaB (NF-kappaB)/Twist-related protein 1 (Twist1) drive downstream events including tumor cell repopulation, survival, inflammation, angiogenesis, invasion, and EMT.	Paclitaxel	103-108	phospholipase A2, group VI	Mus musculus	215-220
28145547-13	2017	The synergistic antitumor and anti-metastasis effects were enhanced primarily through the induction of Taxol-stimulated G2/M phase arrest and the inhibition of caspase-3/cytosolic Ca2+-independent phospholipase A2 (iPLA2) and nuclear factor-kappaB (NF-kappaB)/Twist-related protein 1 (Twist1) drive downstream events including tumor cell repopulation, survival, inflammation, angiogenesis, invasion, and EMT.	Paclitaxel	103-108	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	249-259
28137584-0	2017	Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via oxidative stress-mediated mTOR inhibition.	Paclitaxel	89-99	mechanistic target of rapamycin kinase	Homo sapiens	130-134
28150932-5	2017	Here, PTX was incorporated in nontoxic and endogenous material, human serum albumin (HSA), via an innovative disulfide reduction method to construct HSA-based PTX nanoparticle (HSA-PTX NP) to not only realize redox-responsive drug release but also improve in vivo stability.	Paclitaxel	6-9	albumin	Homo sapiens	70-83
28108630-5	2017	The macropinocytic uptake of nab-paclitaxel induced macrophage immunostimulatory (M1) cytokine expression and synergized with IFNgamma to promote inducible nitric oxide synthase expression in a TLR4-dependent manner.	Paclitaxel	33-43	interferon gamma	Homo sapiens	126-134
27582484-5	2017	Variation-/gene-based analyses were used to compare variant frequencies among neuropathy groups, and Cox regression models were used to analyze neuropathy along treatment.Results: Gene-based analysis identified EPHA6 as the gene most significantly associated with paclitaxel-induced neuropathy.	Paclitaxel	264-274	EPH receptor A6	Homo sapiens	211-216
28038747-0	2017	Efficient delivery of paclitaxel into ASGPR over-expressed cancer cells using reversibly stabilized multifunctional pullulan nanoparticles.	Paclitaxel	22-32	asialoglycoprotein receptor 1	Homo sapiens	38-43
28335887-11	2017	CONCLUSION: An anthracycline-free neo-adjuvant regimen of weekly paclitaxel, trastuzumab and carboplatin is highly effective in HER2-positive breast cancer with manageable toxicity.	Paclitaxel	65-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-132
27718638-0	2017	SET protein overexpression contributes to paclitaxel resistance in MCF-7/S cells through PI3K/Akt pathway.	Paclitaxel	42-52	AKT serine/threonine kinase 1	Homo sapiens	94-97
28104295-0	2017	Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.	Paclitaxel	111-121	mechanistic target of rapamycin kinase	Homo sapiens	90-94
28104295-7	2017	A combination of either dasatinib or an mTOR-inhibitor everolimus with paclitaxel resulted in synergistic inhibition of AGCT cell viability.	Paclitaxel	71-81	mechanistic target of rapamycin kinase	Homo sapiens	40-44
27718638-3	2017	The different expressions of SET, ATP-binding cassette (ABC) transporters and PI3K/Akt pathway between paclitaxel sensitive MCF-7/S and paclitaxel resistant MCF-7/PTX cells were identified using western blotting.	Paclitaxel	103-113	AKT serine/threonine kinase 1	Homo sapiens	83-86
27616277-0	2017	The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles.	Paclitaxel	100-110	transferrin	Homo sapiens	114-125
27718638-3	2017	The different expressions of SET, ATP-binding cassette (ABC) transporters and PI3K/Akt pathway between paclitaxel sensitive MCF-7/S and paclitaxel resistant MCF-7/PTX cells were identified using western blotting.	Paclitaxel	136-146	AKT serine/threonine kinase 1	Homo sapiens	83-86
27616277-1	2017	In this study, a transferrin (Tf)-modified polyethylene glycol-phosphatidyl ethanolamine (PEG-PE)-based micellar delivery system containing paclitaxel (PTX) and tariquidar (TRQ), a potent third generation P-gp inhibitor, was prepared.	Paclitaxel	140-150	transferrin	Homo sapiens	17-28
28178652-3	2017	On the other hand, miR-17-5p induced apoptosis in breast cancer cells, and overexpression of miR-17-5p sensitized MCF-7 cells to paclitaxel-induced apoptosis via STAT3.	Paclitaxel	129-139	signal transducer and activator of transcription 3	Homo sapiens	162-167
27616277-1	2017	In this study, a transferrin (Tf)-modified polyethylene glycol-phosphatidyl ethanolamine (PEG-PE)-based micellar delivery system containing paclitaxel (PTX) and tariquidar (TRQ), a potent third generation P-gp inhibitor, was prepared.	Paclitaxel	152-155	transferrin	Homo sapiens	17-28
27902567-7	2017	Paclitaxel-induced behavioral hypersensitivity to mechanical stimuli in rats was prevented but not reversed by spinal administration of ML218 hydrochloride or intravenous injection of the TLR4 antagonist TAK242.	Paclitaxel	0-10	toll-like receptor 4	Rattus norvegicus	188-192
27902567-10	2017	In summary, Cav3.2 in concert with TLR4 in DRG neurons appears to contribute to paclitaxel-induced neuropathy.	Paclitaxel	80-90	toll-like receptor 4	Rattus norvegicus	35-39
28178652-4	2017	Overexpression of STAT3 in MCF-7 cells decreased paclitaxel-induced apoptosis, but STAT3 knockout abolished the miR-17-5p-induced increases in apoptosis.	Paclitaxel	49-59	signal transducer and activator of transcription 3	Homo sapiens	18-23
28182729-0	2017	Rikkunshito prevents paclitaxel-induced peripheral neuropathy through the suppression of the nuclear factor kappa B (NFkappaB) phosphorylation in spinal cord of mice.	Paclitaxel	21-31	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	93-115
28253574-10	2017	The expression level of EGFR protein (0.71+-0.25) and P-gp protein (0.82+-0.19) in A2780/Taxol+CRM197 group was significantly lower than EGFR protein (1.87+-0.31) and P-gp protein (1.84+-0.27) of A2780/Taxol group (P&lt;0.05).	Paclitaxel	89-94	epidermal growth factor receptor	Homo sapiens	24-28
28253574-10	2017	The expression level of EGFR protein (0.71+-0.25) and P-gp protein (0.82+-0.19) in A2780/Taxol+CRM197 group was significantly lower than EGFR protein (1.87+-0.31) and P-gp protein (1.84+-0.27) of A2780/Taxol group (P&lt;0.05).	Paclitaxel	89-94	epidermal growth factor receptor	Homo sapiens	137-141
28253574-10	2017	The expression level of EGFR protein (0.71+-0.25) and P-gp protein (0.82+-0.19) in A2780/Taxol+CRM197 group was significantly lower than EGFR protein (1.87+-0.31) and P-gp protein (1.84+-0.27) of A2780/Taxol group (P&lt;0.05).	Paclitaxel	202-207	epidermal growth factor receptor	Homo sapiens	24-28
28253574-11	2017	Compared with A2780/Taxol group (1.78+-0.27) , MDR1 mRNA was significantly down-regulated in A2780/Taxol+CRM197 group (0.79+-0.13, P&lt;0.05).	Paclitaxel	20-25	ATP binding cassette subfamily B member 1	Homo sapiens	47-51
28253574-14	2017	(3) In vivo, the expression scores of EGFR protein in A2780/Taxol+CRM197 tumors (4.4+-1.4) were lower than that in A2780/Taxol tumors (10.2+-3.1, P&lt;0.05).	Paclitaxel	60-65	epidermal growth factor receptor	Homo sapiens	38-42
28253574-16	2017	Conclusion: CRM197 reverses the resistance of ovarian cancer to paclitaxel by increasing caspase-3 activity to advance apoptosis via EGFR/MDR1/P-gp pathway.	Paclitaxel	64-74	caspase 3	Homo sapiens	89-98
28253574-16	2017	Conclusion: CRM197 reverses the resistance of ovarian cancer to paclitaxel by increasing caspase-3 activity to advance apoptosis via EGFR/MDR1/P-gp pathway.	Paclitaxel	64-74	ATP binding cassette subfamily B member 1	Homo sapiens	138-142
28181548-4	2017	TTT-28 reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1 overexpressing cells by selectively blocking the efflux function of ABCB1, but not interfering with the expression level and localization of ABCB1.	Paclitaxel	78-88	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-97
28181548-4	2017	TTT-28 reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1 overexpressing cells by selectively blocking the efflux function of ABCB1, but not interfering with the expression level and localization of ABCB1.	Paclitaxel	78-88	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-97
28181548-4	2017	TTT-28 reversed the ABCB1-mediated MDR and increased the accumulation of [3H]-paclitaxel in ABCB1 overexpressing cells by selectively blocking the efflux function of ABCB1, but not interfering with the expression level and localization of ABCB1.	Paclitaxel	78-88	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	92-97
28181548-9	2017	Furthermore, the strategy that co-administer MDR-ABCB1 inhibitor to overcome the resistance of one FDA approved, widely used chemotherapeutic paclitaxel, may be promising direction for the field of adjuvant chemotherapy.	Paclitaxel	142-152	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	49-54
28182729-0	2017	Rikkunshito prevents paclitaxel-induced peripheral neuropathy through the suppression of the nuclear factor kappa B (NFkappaB) phosphorylation in spinal cord of mice.	Paclitaxel	21-31	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	117-125
28182729-6	2017	Thus, RKT may attenuate paclitaxel-induced peripheral neuropathy by inhibiting phosphorylated NFkappaB (pNFkappaB) in the spinal cord.	Paclitaxel	24-34	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	94-102
28182729-8	2017	Paclitaxel increased the protein levels of spinal pNFkappaB, but not those of spinal NFkappaB.	Paclitaxel	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	51-59
28182729-9	2017	NFkappaB inhibitor attenuated paclitaxel-induced mechanical hyperalgesia suggesting that the activation of NFkappaB mediates paclitaxel-induced hyperalgesia.	Paclitaxel	30-40	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	0-8
28182729-9	2017	NFkappaB inhibitor attenuated paclitaxel-induced mechanical hyperalgesia suggesting that the activation of NFkappaB mediates paclitaxel-induced hyperalgesia.	Paclitaxel	30-40	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	107-115
28182729-9	2017	NFkappaB inhibitor attenuated paclitaxel-induced mechanical hyperalgesia suggesting that the activation of NFkappaB mediates paclitaxel-induced hyperalgesia.	Paclitaxel	125-135	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	0-8
28182729-9	2017	NFkappaB inhibitor attenuated paclitaxel-induced mechanical hyperalgesia suggesting that the activation of NFkappaB mediates paclitaxel-induced hyperalgesia.	Paclitaxel	125-135	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	107-115
28182729-13	2017	Taken together, the present study indicates that RKT exerts an antihyperalgesic effect in paclitaxel-induced neuropathic pain by suppressing the activation of spinal NFkappaB.	Paclitaxel	90-100	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	166-174
27803006-3	2017	Patients and methods: BELLE-4 was a 1:1 randomized, double-blind, placebo-controlled, adaptive phase II/III study investigating the combination of buparlisib or placebo with paclitaxel in women with human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with no prior chemotherapy for advanced disease.	Paclitaxel	174-184	erb-b2 receptor tyrosine kinase 2	Homo sapiens	205-239
28077325-12	2017	This data indicates that 14-3-3sigma contributes to P-gp overexpression through interaction with PXR with rifampin and paclitaxel treatment.	Paclitaxel	119-129	ATP binding cassette subfamily B member 1	Homo sapiens	52-56
28077325-0	2017	Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR.	Paclitaxel	64-74	ATP binding cassette subfamily B member 1	Homo sapiens	43-47
28237486-0	2017	Targeted inhibition of Notch1 gene enhances the killing effects of paclitaxel on triple negative breast cancer cells.	Paclitaxel	67-77	notch receptor 1	Homo sapiens	23-29
28237486-1	2017	OBJECTIVE: To study the influence of targeted inhibition of Notch1 gene on the killing effects of paclitaxel on triple negative breast cancer cells.	Paclitaxel	98-108	notch receptor 1	Homo sapiens	60-66
28237486-4	2017	CONCLUSIONS: Targeted inhibition of Notch1 gene may enhance the killing effects of paclitaxel on triple negative breast cancer cells by up-regulating the expression of Caspase-3 and Caspase-9 and inhibiting the expression of Bcl-2.	Paclitaxel	83-93	notch receptor 1	Homo sapiens	36-42
28237486-4	2017	CONCLUSIONS: Targeted inhibition of Notch1 gene may enhance the killing effects of paclitaxel on triple negative breast cancer cells by up-regulating the expression of Caspase-3 and Caspase-9 and inhibiting the expression of Bcl-2.	Paclitaxel	83-93	caspase 3	Homo sapiens	168-177
28237486-4	2017	CONCLUSIONS: Targeted inhibition of Notch1 gene may enhance the killing effects of paclitaxel on triple negative breast cancer cells by up-regulating the expression of Caspase-3 and Caspase-9 and inhibiting the expression of Bcl-2.	Paclitaxel	83-93	BCL2 apoptosis regulator	Homo sapiens	225-230
27832973-0	2017	Neutralization of TNFalpha in tumor with a novel nanobody potentiates paclitaxel-therapy and inhibits metastasis in breast cancer.	Paclitaxel	70-80	tumor necrosis factor	Homo sapiens	18-26
27832973-9	2017	Drug administration of the combination of paclitaxel with the TNFalpha nanobody in vivo significantly enhanced the efficacy against 4T-1 breast tumor proliferation and lung metastasis; meanwhile, E-cadherin tumor epithelial marker expression was upregulated, supporting the anti-tumor therapeutic relevance of paclitaxel and the TNFalpha nanobody on EMT.	Paclitaxel	42-52	tumor necrosis factor	Homo sapiens	62-70
27832973-9	2017	Drug administration of the combination of paclitaxel with the TNFalpha nanobody in vivo significantly enhanced the efficacy against 4T-1 breast tumor proliferation and lung metastasis; meanwhile, E-cadherin tumor epithelial marker expression was upregulated, supporting the anti-tumor therapeutic relevance of paclitaxel and the TNFalpha nanobody on EMT.	Paclitaxel	42-52	cadherin 1	Homo sapiens	196-206
27832973-9	2017	Drug administration of the combination of paclitaxel with the TNFalpha nanobody in vivo significantly enhanced the efficacy against 4T-1 breast tumor proliferation and lung metastasis; meanwhile, E-cadherin tumor epithelial marker expression was upregulated, supporting the anti-tumor therapeutic relevance of paclitaxel and the TNFalpha nanobody on EMT.	Paclitaxel	42-52	tumor necrosis factor	Homo sapiens	329-337
27832973-9	2017	Drug administration of the combination of paclitaxel with the TNFalpha nanobody in vivo significantly enhanced the efficacy against 4T-1 breast tumor proliferation and lung metastasis; meanwhile, E-cadherin tumor epithelial marker expression was upregulated, supporting the anti-tumor therapeutic relevance of paclitaxel and the TNFalpha nanobody on EMT.	Paclitaxel	310-320	tumor necrosis factor	Homo sapiens	62-70
27832973-9	2017	Drug administration of the combination of paclitaxel with the TNFalpha nanobody in vivo significantly enhanced the efficacy against 4T-1 breast tumor proliferation and lung metastasis; meanwhile, E-cadherin tumor epithelial marker expression was upregulated, supporting the anti-tumor therapeutic relevance of paclitaxel and the TNFalpha nanobody on EMT.	Paclitaxel	310-320	cadherin 1	Homo sapiens	196-206
28077325-0	2017	Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR.	Paclitaxel	64-74	nuclear receptor subfamily 1 group I member 2	Homo sapiens	112-115
28077325-1	2017	In this study, we presented the role of 14-3-3sigma to activate CK2-Hsp90beta-PXR-MDR1 pathway on rifampin and paclitaxel treated LS174T cells and in vivo LS174T cell-xenografted nude mouse model.	Paclitaxel	111-121	nuclear receptor subfamily 1 group I member 2	Homo sapiens	78-81
28077325-1	2017	In this study, we presented the role of 14-3-3sigma to activate CK2-Hsp90beta-PXR-MDR1 pathway on rifampin and paclitaxel treated LS174T cells and in vivo LS174T cell-xenografted nude mouse model.	Paclitaxel	111-121	ATP binding cassette subfamily B member 1	Homo sapiens	82-86
28077325-2	2017	Following several in vitro and in vivo experiments, rifampin and paclitaxel were found to be stimulated the CK2-Hsp90beta-PXR-MDR1 pathway.	Paclitaxel	65-75	nuclear receptor subfamily 1 group I member 2	Homo sapiens	122-125
28077325-2	2017	Following several in vitro and in vivo experiments, rifampin and paclitaxel were found to be stimulated the CK2-Hsp90beta-PXR-MDR1 pathway.	Paclitaxel	65-75	ATP binding cassette subfamily B member 1	Homo sapiens	126-130
28077325-7	2017	On the other hand, PXR was found to be localized in nucleus after rifampin and paclitaxel treatment by using cell fractionation assay.	Paclitaxel	79-89	nuclear receptor subfamily 1 group I member 2	Homo sapiens	19-22
28077325-10	2017	P-gp overexpression was induced only when 14-3-3sigma transfected LS174T cells were treated with rifampin and paclitaxel, whereas 14-3-3sigma inhibition by nonpeptidic inhibitor, BV02 and 14-3-3sigma siRNA reduced rifampin induced PXR and P-gp expression.	Paclitaxel	110-120	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
27854072-5	2017	Here, we investigated an inhibition effect of SH003 on MDR1 activity in paclitaxel-resistant MCF-7/PAX breast cancer cells.	Paclitaxel	72-82	ATP binding cassette subfamily B member 1	Homo sapiens	55-59
27854072-10	2017	We also found that a combinatorial treatment of SH003 and paclitaxel in paclitaxel-resistant MCF-7 cells caused apoptosis in synergistic manner, which was due to SH003 inhibition of MDR1 expression.	Paclitaxel	58-68	ATP binding cassette subfamily B member 1	Homo sapiens	182-186
27854072-10	2017	We also found that a combinatorial treatment of SH003 and paclitaxel in paclitaxel-resistant MCF-7 cells caused apoptosis in synergistic manner, which was due to SH003 inhibition of MDR1 expression.	Paclitaxel	72-82	ATP binding cassette subfamily B member 1	Homo sapiens	182-186
27887867-10	2017	RESULTS: PTX induced apoptosis, decreased the proliferation and cell migration rates of ASCs and inhibited ASCs multipotent differentiation in both in vitro human ASC populations and ex vivo rat ASC populations with PTX treatment.	Paclitaxel	9-12	PYD and CARD domain containing	Homo sapiens	88-91
28212993-7	2017	Consistent with investigator-assessed results, in patients with EGFR mutation-positive NSCLC: PFS (hazard ratio 0.54; 95% confidence interval [CI] 0.38, 0.79; p=0.0012) and ORR (odds ratio 3.00; 95% CI 1.63, 5.54; p=0.0004) were significantly longer with gefitinib versus carboplatin/paclitaxel.	Paclitaxel	284-294	epidermal growth factor receptor	Homo sapiens	64-68
27854072-7	2017	Paclitaxel-resistant MCF-7 cells showed an increase of MDR1 activity, which was confirmed by measuring an amount of accumulated rhodamine 123 in the cells.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	55-59
27854072-8	2017	Also, qRT-PCR and Western blot assays confirmed that paclitaxel-resistant MCF-7 cells exhibited high MDR1 expression level.	Paclitaxel	53-63	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
27854072-9	2017	Furthermore, paclitaxel-resistant MCF-7 cells showed mesenchymal morphology with alterations of EMT markers, and acquired tamoxifen resistance with a decrease of ERalpha expression.	Paclitaxel	13-23	estrogen receptor 1	Homo sapiens	162-169
28356971-12	2017	Thus, identification of miR-125b may be a potential molecular biomarker for the prediction of clinical outcomes in breast cancer patients, particularly HER2-positive cases that will receive paclitaxel-based neoadjuvant chemotherapy.	Paclitaxel	190-200	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-156
28167568-0	2017	Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.	Paclitaxel	91-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	151-155
27932243-0	2017	Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma.	Paclitaxel	90-100	mechanistic target of rapamycin kinase	Homo sapiens	14-18
27123551-10	2017	Our results demonstrate SSA could increase the chemosensitivity of P-gp overexpressing HepG2/ADM and MCF-7/ADR cells to doxorubicin (DOX), vincristine (VCR) and paclitaxel.	Paclitaxel	161-171	tripartite motif containing 21	Homo sapiens	24-27
27123551-10	2017	Our results demonstrate SSA could increase the chemosensitivity of P-gp overexpressing HepG2/ADM and MCF-7/ADR cells to doxorubicin (DOX), vincristine (VCR) and paclitaxel.	Paclitaxel	161-171	ATP binding cassette subfamily B member 1	Homo sapiens	67-71
28125674-11	2017	We also found that PTX induced up-regulation of several inflammatory cytokines and chemokines (TNF-alpha, IFN-gamma, CCL11, CCL4, CCL3, IL-12p70 and GM-CSF) in the spinal cord.	Paclitaxel	19-22	tumor necrosis factor	Mus musculus	95-104
28125674-11	2017	We also found that PTX induced up-regulation of several inflammatory cytokines and chemokines (TNF-alpha, IFN-gamma, CCL11, CCL4, CCL3, IL-12p70 and GM-CSF) in the spinal cord.	Paclitaxel	19-22	interferon gamma	Mus musculus	106-115
28125674-11	2017	We also found that PTX induced up-regulation of several inflammatory cytokines and chemokines (TNF-alpha, IFN-gamma, CCL11, CCL4, CCL3, IL-12p70 and GM-CSF) in the spinal cord.	Paclitaxel	19-22	chemokine (C-C motif) ligand 11	Mus musculus	117-122
27932243-3	2017	In this work, we show that ribavirin, an anti-viral drug, effectively augments sensitivity of OTSCC cells to paclitaxel via inhibiting mTOR/eIF4E signaling pathway.	Paclitaxel	109-119	mechanistic target of rapamycin kinase	Homo sapiens	135-139
27435393-0	2017	Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.	Paclitaxel	81-91	epidermal growth factor receptor	Homo sapiens	18-22
28104912-0	2017	Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	59-64
28104912-0	2017	Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation.	Paclitaxel	0-10	forkhead box O3	Homo sapiens	137-143
28138318-9	2016	Paclitaxel increased the levels of phosphorylated protein kinase C, phosphorylated nuclear factor kappaB, phosphodiesterase 4D (PDE4D), IL-1beta, and monocyte chemoattractant protein-1 in the lumbar dorsal root ganglia; however, tempol decreased these levels.	Paclitaxel	0-10	interleukin 1 beta	Rattus norvegicus	136-144
27435393-6	2017	Finally, a xenograft animal assay was used to examine the abilities of gefitinib and S3I-201 (a STAT3 inhibitor) to reverse CDDP and paclitaxel sensitivity.	Paclitaxel	133-143	signal transducer and activator of transcription 3	Homo sapiens	96-101
27435393-0	2017	Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.	Paclitaxel	81-91	signal transducer and activator of transcription 3	Homo sapiens	23-28
28255354-4	2017	Interestingly, as revealed by in vivo photoacoustic imaging and ex vivo immunofluorescence staining, PTX delivered into the tumor by HSA-nanoparticle transportation can remarkably enhance the tumor local oxygen level and suppress the expression of HIF-1alpha, leading to greatly relieved tumor hypoxia.	Paclitaxel	101-104	hypoxia inducible factor 1 subunit alpha	Homo sapiens	248-258
27716527-8	2017	The PTX-M remarkably increased the upregulation of Bax, caspase-3, caspase-9, and PARP-1 expression and downregulated the Bcl-2 expression in K562 cancer cells.	Paclitaxel	4-7	BCL2 associated X, apoptosis regulator	Homo sapiens	51-54
28086946-13	2017	Finally, we proved the inhibiting effect of miR-1307 ASO and Taxol therapy by increasing the ING5 expression against ovarian cancer through xenografts assay in vivo.	Paclitaxel	61-66	inhibitor of growth family member 5	Homo sapiens	93-97
27702691-3	2017	We demonstrate that paclitaxel and etoposide, but not cisplatin, confer ASMase-mediated endothelial injury within minutes.	Paclitaxel	20-30	sphingomyelin phosphodiesterase 1	Homo sapiens	72-78
28647734-0	2017	MiR-4673 Modulates Paclitaxel-Induced Oxidative Stress and Loss of Mitochondrial Membrane Potential by Targeting 8-Oxoguanine-DNA Glycosylase-1.	Paclitaxel	19-29	microRNA 4673	Homo sapiens	0-8
28647734-1	2017	BACKGROUND: Our previous study identified a novel microRNA, miR-4673, which is upregulated in A549 cells exposed to paclitaxel (PTX).	Paclitaxel	116-126	microRNA 4673	Homo sapiens	60-68
28647734-1	2017	BACKGROUND: Our previous study identified a novel microRNA, miR-4673, which is upregulated in A549 cells exposed to paclitaxel (PTX).	Paclitaxel	128-131	microRNA 4673	Homo sapiens	60-68
28647734-2	2017	In this study, we investigated the role of miR-4673 in PTX-induced cytotoxicity.	Paclitaxel	55-58	microRNA 4673	Homo sapiens	43-51
28647734-5	2017	RESULTS: Enforced expression of miR-4673 decreased cell viability and increased PTX-induced apoptosis, MMP loss and reactive oxygen species (ROS) generation in A549 and H1299 cells.	Paclitaxel	80-83	microRNA 4673	Homo sapiens	32-40
28647734-10	2017	Moreover, enforced expression of OGG1 compromised promoting effects of miR-4673 on PTX-induced apoptosis, MMP loss and ROS generation.	Paclitaxel	83-86	microRNA 4673	Homo sapiens	71-79
28647734-11	2017	CONCLUSION: miR-4673 modulates PTX-induced apoptosis, MMP loss and ROS generation by targeting OGG1.	Paclitaxel	31-34	microRNA 4673	Homo sapiens	12-20
27885439-0	2017	Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.	Paclitaxel	7-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
27716527-8	2017	The PTX-M remarkably increased the upregulation of Bax, caspase-3, caspase-9, and PARP-1 expression and downregulated the Bcl-2 expression in K562 cancer cells.	Paclitaxel	4-7	caspase 3	Homo sapiens	56-65
27716527-8	2017	The PTX-M remarkably increased the upregulation of Bax, caspase-3, caspase-9, and PARP-1 expression and downregulated the Bcl-2 expression in K562 cancer cells.	Paclitaxel	4-7	poly(ADP-ribose) polymerase 1	Homo sapiens	82-88
27716527-8	2017	The PTX-M remarkably increased the upregulation of Bax, caspase-3, caspase-9, and PARP-1 expression and downregulated the Bcl-2 expression in K562 cancer cells.	Paclitaxel	4-7	BCL2 apoptosis regulator	Homo sapiens	122-127
27811011-0	2017	MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer.	Paclitaxel	27-37	ENAH actin regulator	Homo sapiens	0-4
27810470-5	2017	The functional role of P-gp in limiting the permeability of the anticancer drug paclitaxel (Ptx) was assessed in MDA-MB-436 cells.	Paclitaxel	80-90	ATP binding cassette subfamily B member 1	Homo sapiens	23-27
27810470-5	2017	The functional role of P-gp in limiting the permeability of the anticancer drug paclitaxel (Ptx) was assessed in MDA-MB-436 cells.	Paclitaxel	92-95	ATP binding cassette subfamily B member 1	Homo sapiens	23-27
28883885-0	2017	Synergistic Antitumor Effects of Berbamine and Paclitaxel through ROS/Akt Pathway in Glioma Cells.	Paclitaxel	47-57	AKT serine/threonine kinase 1	Homo sapiens	70-73
27521503-0	2017	Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naive patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102).	Paclitaxel	66-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
27521503-12	2017	In conclusion, trastuzumab combined with paclitaxel was well tolerated and was a promising regimen for patients with HER2-positive, previously treated, advanced or recurrent gastric cancer.	Paclitaxel	41-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
27811011-6	2017	We find that both MENA and MENAINV confer resistance to the taxane paclitaxel, but not to the widely used DNA-damaging agents doxorubicin or cisplatin.	Paclitaxel	67-77	ENAH actin regulator	Homo sapiens	18-22
27811011-8	2017	Mechanistically, MENA isoform expression alters the ratio of dynamic and stable microtubule populations in paclitaxel-treated cells.	Paclitaxel	107-117	ENAH actin regulator	Homo sapiens	17-21
27811011-9	2017	MENA expression also increases MAPK signaling in response to paclitaxel treatment.	Paclitaxel	61-71	ENAH actin regulator	Homo sapiens	0-4
27811011-10	2017	Decreasing ERK phosphorylation by co-treatment with MEK inhibitor restored paclitaxel sensitivity by driving microtubule stabilization in MENA isoform-expressing cells.	Paclitaxel	75-85	mitogen-activated protein kinase kinase 7	Homo sapiens	52-55
27811011-10	2017	Decreasing ERK phosphorylation by co-treatment with MEK inhibitor restored paclitaxel sensitivity by driving microtubule stabilization in MENA isoform-expressing cells.	Paclitaxel	75-85	ENAH actin regulator	Homo sapiens	138-142
28031414-7	2017	Intracellular concentrations of known P-gp and BCRP substrates [(3H)-paclitaxel and (3H)-prazosin, respectively] were significantly higher (indicating less efflux) in NIH-3T3-MDR1 and MDCK-BCRP cells in the presence of 6-OH-BDE-47, but not BDE-47.	Paclitaxel	69-79	ATP binding cassette subfamily B member 1	Homo sapiens	175-179
28714351-0	2017	Activation of NLRP3 inflammasome in peripheral nerve contributes to paclitaxel-induced neuropathic pain.	Paclitaxel	68-78	NLR family, pyrin domain containing 3	Rattus norvegicus	14-19
28714351-3	2017	Growing evidences have supported that peripheral interleukin-1beta is critical in enhancing paclitaxel-induced neuropathic pain.	Paclitaxel	92-102	interleukin 1 beta	Rattus norvegicus	49-66
28714351-4	2017	However, whether activation of NLRP3 inflammasome in peripheral nerve contributes to paclitaxel-induced neuropathic pain is still unclear.	Paclitaxel	85-95	NLR family, pyrin domain containing 3	Rattus norvegicus	31-36
28714351-6	2017	Paclitaxel resulted in expression of NLRP3 and activated fragments of caspase-1 and interleukin-1beta in L4-6 dorsal root ganglia and sciatic nerve three weeks after injection, indicating activation of NLRP3 inflammasome.	Paclitaxel	0-10	NLR family, pyrin domain containing 3	Rattus norvegicus	37-42
28714351-6	2017	Paclitaxel resulted in expression of NLRP3 and activated fragments of caspase-1 and interleukin-1beta in L4-6 dorsal root ganglia and sciatic nerve three weeks after injection, indicating activation of NLRP3 inflammasome.	Paclitaxel	0-10	interleukin 1 beta	Rattus norvegicus	84-101
28714351-6	2017	Paclitaxel resulted in expression of NLRP3 and activated fragments of caspase-1 and interleukin-1beta in L4-6 dorsal root ganglia and sciatic nerve three weeks after injection, indicating activation of NLRP3 inflammasome.	Paclitaxel	0-10	NLR family, pyrin domain containing 3	Rattus norvegicus	202-207
28714351-7	2017	The expression of NLRP3 was located in CD68-labeled macrophages infiltrating in L4-6 dorsal root ganglia and sciatic nerve, and paclitaxel increased the expression of NLRP3 in macrophage.	Paclitaxel	128-138	NLR family, pyrin domain containing 3	Rattus norvegicus	18-23
28714351-7	2017	The expression of NLRP3 was located in CD68-labeled macrophages infiltrating in L4-6 dorsal root ganglia and sciatic nerve, and paclitaxel increased the expression of NLRP3 in macrophage.	Paclitaxel	128-138	NLR family, pyrin domain containing 3	Rattus norvegicus	167-172
28714351-10	2017	The administration of a non-specific reactive oxygen species scavenger, phenyl-N-tert-butylnitrone, markedly alleviated mechanical allodynia and inhibited the activation of NLRP3 inflammasome in L4-6 dorsal root ganglia and sciatic nerve of the paclitaxel-induced neuropathic pain model.	Paclitaxel	245-255	NLR family, pyrin domain containing 3	Rattus norvegicus	173-178
28714351-11	2017	Conclusions Paclitaxel induced mechanical allodynia and activation of NLRP3 inflammasome in infiltrated macrophages of L4-6 dorsal root ganglia and sciatic nerve.	Paclitaxel	12-22	NLR family, pyrin domain containing 3	Rattus norvegicus	70-75
28714351-12	2017	Paclitaxel elicited mitochondria damage and reactive oxygen species production may result in activation of NLRP3 inflammasome in peripheral nerve, which contributes to paclitaxel-induced neuropathic pain.	Paclitaxel	0-10	NLR family, pyrin domain containing 3	Rattus norvegicus	107-112
28714351-12	2017	Paclitaxel elicited mitochondria damage and reactive oxygen species production may result in activation of NLRP3 inflammasome in peripheral nerve, which contributes to paclitaxel-induced neuropathic pain.	Paclitaxel	168-178	NLR family, pyrin domain containing 3	Rattus norvegicus	107-112
28031414-7	2017	Intracellular concentrations of known P-gp and BCRP substrates [(3H)-paclitaxel and (3H)-prazosin, respectively] were significantly higher (indicating less efflux) in NIH-3T3-MDR1 and MDCK-BCRP cells in the presence of 6-OH-BDE-47, but not BDE-47.	Paclitaxel	69-79	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
28031414-7	2017	Intracellular concentrations of known P-gp and BCRP substrates [(3H)-paclitaxel and (3H)-prazosin, respectively] were significantly higher (indicating less efflux) in NIH-3T3-MDR1 and MDCK-BCRP cells in the presence of 6-OH-BDE-47, but not BDE-47.	Paclitaxel	69-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	47-51
27746331-2	2016	To reverse MDR and improve the chemotherapy effect of paclitaxel (PTX), we propose a new drug delivery system based on mixed micelles constructed with d-alpha-tocopheryl poly(ethylene glycol) 1000 succinate (TPGS) and the mPEG-SS-PTX conjugate with consideration that TPGS is a P-gp inhibitor that can block the cancer cell action of pumping drugs outside of cells and can enhance the anticancer effect.	Paclitaxel	66-69	ATP binding cassette subfamily B member 1	Homo sapiens	278-282
27992556-1	2016	BACKGROUND: Bevacizumab (BEV), a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, enhances the antitumor effectiveness of paclitaxel (PTX)-based chemotherapy in many metastatic cancers.	Paclitaxel	151-161	vascular endothelial growth factor A	Homo sapiens	43-82
27991556-6	2016	The treatment of oocytes with taxol and nocodazole demonstrated that KIF2A was co-localized with alpha-tubulin.	Paclitaxel	30-35	kinesin family member 2A	Mus musculus	69-74
27769712-9	2016	Moreover, we showed that Akt activation markedly increased resistance to microtubule-directed agents, including CWF-145, colchicine, and paclitaxel.	Paclitaxel	137-147	AKT serine/threonine kinase 1	Homo sapiens	25-28
27992556-1	2016	BACKGROUND: Bevacizumab (BEV), a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, enhances the antitumor effectiveness of paclitaxel (PTX)-based chemotherapy in many metastatic cancers.	Paclitaxel	151-161	vascular endothelial growth factor A	Homo sapiens	84-88
27992556-1	2016	BACKGROUND: Bevacizumab (BEV), a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, enhances the antitumor effectiveness of paclitaxel (PTX)-based chemotherapy in many metastatic cancers.	Paclitaxel	163-166	vascular endothelial growth factor A	Homo sapiens	43-82
27840408-0	2016	Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.	Paclitaxel	98-108	IL2 inducible T cell kinase	Mus musculus	33-36
27994465-6	2016	Ag@PEI@PTX-induced HepG2 cell apoptosis was confirmed by accumulation of the sub-G1 cells population, translocation of phosphatidylserine, depletion of mitochondrial membrane potential, DNA fragmentation, caspase-3 activation, and poly(ADP-ribose) polymerase cleavage.	Paclitaxel	7-10	caspase 3	Homo sapiens	205-214
27994465-6	2016	Ag@PEI@PTX-induced HepG2 cell apoptosis was confirmed by accumulation of the sub-G1 cells population, translocation of phosphatidylserine, depletion of mitochondrial membrane potential, DNA fragmentation, caspase-3 activation, and poly(ADP-ribose) polymerase cleavage.	Paclitaxel	7-10	poly(ADP-ribose) polymerase 1	Homo sapiens	231-258
27994465-7	2016	Furthermore, Ag@PEI@PTX enhanced cytotoxic effects on HepG2 cells and triggered intracellular reactive oxygen species; the signaling pathways of AKT, p53, and MAPK were activated to advance cell apoptosis.	Paclitaxel	20-23	tumor protein p53	Homo sapiens	150-153
27840408-16	2016	CONCLUSION: Cisplatin and paclitaxel resistance is associated with CTSL upregulation-induced EMT in A549 cells.	Paclitaxel	26-36	IL2 inducible T cell kinase	Mus musculus	93-96
27840408-17	2016	Thus, CTSL-mediated EMT may be exploited as a target to enhance the efficacy of cisplatin or paclitaxel against lung cancer and other types of malignancies.	Paclitaxel	93-103	IL2 inducible T cell kinase	Mus musculus	20-23
27978745-1	2016	A highly functionalized intermediate in the synthesis of Taxol has been synthesized, which features the tricyclic core and the required oxygen substituents at C1, C2, C7, C10, and C13.	Paclitaxel	57-62	homeobox C10	Homo sapiens	171-174
27994987-2	2016	Gamma-aminobutyric acid transporter-1 (GAT-1) whose expression is increased in the brain and spinal cord during paclitaxel-induced neuropathic pain (PINP) might be a potential therapeutic target for managing PINP.	Paclitaxel	112-122	solute carrier family 6 (neurotransmitter transporter, GABA), member 1	Mus musculus	0-44
28101033-2	2016	Here, we present the case of a 33-year-old female patient with extensive metastatic ER+/PR+/HER2- mucinous adenocarcinoma of the breast, who was started on doxorubicin/cyclophosphamide therapy after progressing on paclitaxel and ovarian suppressor goserelin with aromatase inhibitor exemestane.	Paclitaxel	214-224	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-96
27845892-5	2016	In the present study, the high expression of lncRNA H19 was identified as a powerful factor associated with paclitaxel (PTX) resistance in ERalpha-positive breast cancer cells, but not in ERalpha-negative breast cancer cells.	Paclitaxel	108-118	estrogen receptor 1	Homo sapiens	139-146
27845892-5	2016	In the present study, the high expression of lncRNA H19 was identified as a powerful factor associated with paclitaxel (PTX) resistance in ERalpha-positive breast cancer cells, but not in ERalpha-negative breast cancer cells.	Paclitaxel	120-123	estrogen receptor 1	Homo sapiens	139-146
27845892-6	2016	LncRNA H19 attenuated cell apoptosis in response to PTX treatment by inhibiting transcription of pro-apoptotic genes BIK and NOXA.	Paclitaxel	52-55	BCL2 interacting killer	Homo sapiens	117-120
27845892-6	2016	LncRNA H19 attenuated cell apoptosis in response to PTX treatment by inhibiting transcription of pro-apoptotic genes BIK and NOXA.	Paclitaxel	52-55	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	125-129
27779649-5	2016	Results indicated that curcumin combined with paclitaxel decreased c-Ha-Ras, Rho-A, p53 and Bcl-xL gene expression in comparison to control and substances alone in MCF-7 cell line.	Paclitaxel	46-56	ras homolog family member A	Homo sapiens	77-82
27881234-0	2016	DENSpm overcame Bcl-2 mediated resistance against Paclitaxel treatment in MCF-7 breast cancer cells via activating polyamine catabolic machinery.	Paclitaxel	50-60	BCL2 apoptosis regulator	Homo sapiens	16-21
27881234-2	2016	Conventional chemotherapeutics such as Paclitaxel, a commonly used in the treatment of metastatic breast cancer, is not sufficient to overcome Bcl-2 mediated drug resistance mechanism.	Paclitaxel	39-49	BCL2 apoptosis regulator	Homo sapiens	143-148
27881234-9	2016	Co-treatment of Paclitaxel (30nM) with DENSpm (20muM) further increased the cytoxicity of Paclitaxel (30nM) compared to alone Paclitaxel (30nM) treatment in MCF-7 Bcl-2+ breast cancer cells.	Paclitaxel	16-26	BCL2 apoptosis regulator	Homo sapiens	163-168
27881234-9	2016	Co-treatment of Paclitaxel (30nM) with DENSpm (20muM) further increased the cytoxicity of Paclitaxel (30nM) compared to alone Paclitaxel (30nM) treatment in MCF-7 Bcl-2+ breast cancer cells.	Paclitaxel	90-100	BCL2 apoptosis regulator	Homo sapiens	163-168
27881234-9	2016	Co-treatment of Paclitaxel (30nM) with DENSpm (20muM) further increased the cytoxicity of Paclitaxel (30nM) compared to alone Paclitaxel (30nM) treatment in MCF-7 Bcl-2+ breast cancer cells.	Paclitaxel	90-100	BCL2 apoptosis regulator	Homo sapiens	163-168
27878971-0	2016	Pregnane X receptors regulate CYP2C8 and P-glycoprotein to impact on the resistance of NSCLC cells to Taxol.	Paclitaxel	102-107	ATP binding cassette subfamily B member 1	Homo sapiens	41-55
27878971-3	2016	We aim to research the effect of PXR on Taxol-resistant non-small-cell lung cancer (NSCLC cells) via regulating CYP2C8 and P-gp.	Paclitaxel	40-45	nuclear receptor subfamily 1 group I member 2	Homo sapiens	33-36
27878971-3	2016	We aim to research the effect of PXR on Taxol-resistant non-small-cell lung cancer (NSCLC cells) via regulating CYP2C8 and P-gp.	Paclitaxel	40-45	ATP binding cassette subfamily B member 1	Homo sapiens	123-127
27878971-13	2016	Furthermore, the hydroxylation products of Taxol analyzed by HPLC were increased in comparison to the SR12813 untreated group, indicating that high expressions of CYP2C8 and P-gp enhanced the resistance of A549 cells to Taxol.	Paclitaxel	43-48	ATP binding cassette subfamily B member 1	Homo sapiens	174-178
27764550-0	2016	Paclitaxel-induced aberrant mitosis and mitotic slippage efficiently lead to proliferative death irrespective of canonical apoptosis and p53.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	137-140
27632697-0	2016	Transferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cells.	Paclitaxel	79-89	transferrin	Homo sapiens	0-11
27919976-0	2016	Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer.	Paclitaxel	31-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
27289016-0	2016	Silencing Op18/stathmin by RNA Interference Promotes the Sensitivity of Nasopharyngeal Carcinoma Cells to Taxol and High-Grade Differentiation of Xenografted Tumours in Nude Mice.	Paclitaxel	106-111	stathmin 1	Mus musculus	10-14
27289016-0	2016	Silencing Op18/stathmin by RNA Interference Promotes the Sensitivity of Nasopharyngeal Carcinoma Cells to Taxol and High-Grade Differentiation of Xenografted Tumours in Nude Mice.	Paclitaxel	106-111	stathmin 1	Mus musculus	15-23
27881234-10	2016	In addition, we determined that resistance against Paclitaxel-induced apoptotic cell death in Bcl-2 overexpressed MCF-7 cells was overcome due to activation of polyamine catabolic pathway, which caused depletion of polyamines.	Paclitaxel	51-61	BCL2 apoptosis regulator	Homo sapiens	94-99
27878971-13	2016	Furthermore, the hydroxylation products of Taxol analyzed by HPLC were increased in comparison to the SR12813 untreated group, indicating that high expressions of CYP2C8 and P-gp enhanced the resistance of A549 cells to Taxol.	Paclitaxel	220-225	ATP binding cassette subfamily B member 1	Homo sapiens	174-178
27878971-14	2016	For cells treated with PXR siRNA, cell viability, cell proliferation, and Taxol metabolites were significantly reduced after the Taxol treatment in comparison to the siRNA-negative group.	Paclitaxel	74-79	nuclear receptor subfamily 1 group I member 2	Homo sapiens	23-26
27878971-14	2016	For cells treated with PXR siRNA, cell viability, cell proliferation, and Taxol metabolites were significantly reduced after the Taxol treatment in comparison to the siRNA-negative group.	Paclitaxel	129-134	nuclear receptor subfamily 1 group I member 2	Homo sapiens	23-26
27878971-15	2016	The cell viability, cell proliferation, and Taxol metabolites were regulated by the expressions of PXR, P-gp, and CYP2C8.	Paclitaxel	44-49	nuclear receptor subfamily 1 group I member 2	Homo sapiens	99-102
27878971-15	2016	The cell viability, cell proliferation, and Taxol metabolites were regulated by the expressions of PXR, P-gp, and CYP2C8.	Paclitaxel	44-49	ATP binding cassette subfamily B member 1	Homo sapiens	104-108
27878971-16	2016	That is, PXR expression has an important effect on the resistance of NSCLC cells to Taxol via upregulating P-gp and CYP2C8.	Paclitaxel	84-89	nuclear receptor subfamily 1 group I member 2	Homo sapiens	9-12
27878971-16	2016	That is, PXR expression has an important effect on the resistance of NSCLC cells to Taxol via upregulating P-gp and CYP2C8.	Paclitaxel	84-89	ATP binding cassette subfamily B member 1	Homo sapiens	107-111
27840924-6	2016	DU145 cells were more sensitive to paclitaxel than PC-3 cells since the amount of cleaved poly(ADP-ribose) polymerase (PARP) reached its peak at 50 microM of paclitaxel in DU145 cells but at 100 microM in PC-3 cells.	Paclitaxel	35-45	poly(ADP-ribose) polymerase 1	Homo sapiens	90-117
27840924-6	2016	DU145 cells were more sensitive to paclitaxel than PC-3 cells since the amount of cleaved poly(ADP-ribose) polymerase (PARP) reached its peak at 50 microM of paclitaxel in DU145 cells but at 100 microM in PC-3 cells.	Paclitaxel	35-45	poly(ADP-ribose) polymerase 1	Homo sapiens	119-123
27840924-6	2016	DU145 cells were more sensitive to paclitaxel than PC-3 cells since the amount of cleaved poly(ADP-ribose) polymerase (PARP) reached its peak at 50 microM of paclitaxel in DU145 cells but at 100 microM in PC-3 cells.	Paclitaxel	158-168	poly(ADP-ribose) polymerase 1	Homo sapiens	90-117
27840924-6	2016	DU145 cells were more sensitive to paclitaxel than PC-3 cells since the amount of cleaved poly(ADP-ribose) polymerase (PARP) reached its peak at 50 microM of paclitaxel in DU145 cells but at 100 microM in PC-3 cells.	Paclitaxel	158-168	poly(ADP-ribose) polymerase 1	Homo sapiens	119-123
27840924-7	2016	In addition, the amount of cleaved PARP was decreased by DEC1 siRNA, while it was increased by DEC2 siRNA in the presence of paclitaxel.	Paclitaxel	125-135	poly(ADP-ribose) polymerase 1	Homo sapiens	35-39
27779649-5	2016	Results indicated that curcumin combined with paclitaxel decreased c-Ha-Ras, Rho-A, p53 and Bcl-xL gene expression in comparison to control and substances alone in MCF-7 cell line.	Paclitaxel	46-56	tumor protein p53	Homo sapiens	84-87
27779649-5	2016	Results indicated that curcumin combined with paclitaxel decreased c-Ha-Ras, Rho-A, p53 and Bcl-xL gene expression in comparison to control and substances alone in MCF-7 cell line.	Paclitaxel	46-56	BCL2 like 1	Homo sapiens	92-98
27779649-10	2016	Paclitaxel alone and combined increased IkappaBalpha and Stat-3.	Paclitaxel	0-10	NFKB inhibitor alpha	Homo sapiens	40-52
27779649-10	2016	Paclitaxel alone and combined increased IkappaBalpha and Stat-3.	Paclitaxel	0-10	signal transducer and activator of transcription 3	Homo sapiens	57-63
27779649-11	2016	Curcumin alone and combined with paclitaxel increased p53, Bid, caspase-3, caspase-8 and Bax gene expression in MDA-MB-231, whereas Bcl-xL decreased such expression in MDA-MB-231 cells.	Paclitaxel	33-43	tumor protein p53	Homo sapiens	54-57
27779649-11	2016	Curcumin alone and combined with paclitaxel increased p53, Bid, caspase-3, caspase-8 and Bax gene expression in MDA-MB-231, whereas Bcl-xL decreased such expression in MDA-MB-231 cells.	Paclitaxel	33-43	BH3 interacting domain death agonist	Homo sapiens	59-62
27779649-11	2016	Curcumin alone and combined with paclitaxel increased p53, Bid, caspase-3, caspase-8 and Bax gene expression in MDA-MB-231, whereas Bcl-xL decreased such expression in MDA-MB-231 cells.	Paclitaxel	33-43	caspase 3	Homo sapiens	64-73
29368881-0	2016	Targeting Therapy of Neuropilin-1 Receptors Overexpressed Breast Cancer by Paclitaxel-Loaded CK3-Conjugated Polymeric Micelles.	Paclitaxel	75-85	keratin 3	Homo sapiens	93-96
27779649-11	2016	Curcumin alone and combined with paclitaxel increased p53, Bid, caspase-3, caspase-8 and Bax gene expression in MDA-MB-231, whereas Bcl-xL decreased such expression in MDA-MB-231 cells.	Paclitaxel	33-43	BCL2 associated X, apoptosis regulator	Homo sapiens	89-92
29368881-5	2016	When paclitaxel (PTX) was loaded into micelles, CK3-PM-PTX induced the strongest inhibition and apoptosis against MDA-MB-231 cells in vitro and in vivo.	Paclitaxel	5-15	keratin 3	Homo sapiens	48-51
29368881-5	2016	When paclitaxel (PTX) was loaded into micelles, CK3-PM-PTX induced the strongest inhibition and apoptosis against MDA-MB-231 cells in vitro and in vivo.	Paclitaxel	17-20	keratin 3	Homo sapiens	48-51
29368881-5	2016	When paclitaxel (PTX) was loaded into micelles, CK3-PM-PTX induced the strongest inhibition and apoptosis against MDA-MB-231 cells in vitro and in vivo.	Paclitaxel	55-58	keratin 3	Homo sapiens	48-51
27779649-12	2016	When paclitaxel and curcumin were combined the expression of Bcl-2 protein was decreased.	Paclitaxel	5-15	BCL2 apoptosis regulator	Homo sapiens	61-66
28480395-6	2017	In addition, apoptosis-related genes caspase-3 and bax expressions were increased after paclitaxel treatment.	Paclitaxel	88-98	caspase 3	Homo sapiens	37-46
27889448-5	2016	This phospho-regulatory circuit is engaged by cancer therapeutics, such as rigosertib and paclitaxel/Taxol, that activate JNK through mitotic and oxidative stress as well as by physiological regulators of the JNK cascade and may function as a signaling checkpoint to suppress the Ras pathway during conditions of cellular stress.	Paclitaxel	90-100	mitogen-activated protein kinase 8	Homo sapiens	122-125
27889448-5	2016	This phospho-regulatory circuit is engaged by cancer therapeutics, such as rigosertib and paclitaxel/Taxol, that activate JNK through mitotic and oxidative stress as well as by physiological regulators of the JNK cascade and may function as a signaling checkpoint to suppress the Ras pathway during conditions of cellular stress.	Paclitaxel	90-100	mitogen-activated protein kinase 8	Homo sapiens	209-212
27889448-5	2016	This phospho-regulatory circuit is engaged by cancer therapeutics, such as rigosertib and paclitaxel/Taxol, that activate JNK through mitotic and oxidative stress as well as by physiological regulators of the JNK cascade and may function as a signaling checkpoint to suppress the Ras pathway during conditions of cellular stress.	Paclitaxel	101-106	mitogen-activated protein kinase 8	Homo sapiens	122-125
27889448-5	2016	This phospho-regulatory circuit is engaged by cancer therapeutics, such as rigosertib and paclitaxel/Taxol, that activate JNK through mitotic and oxidative stress as well as by physiological regulators of the JNK cascade and may function as a signaling checkpoint to suppress the Ras pathway during conditions of cellular stress.	Paclitaxel	101-106	mitogen-activated protein kinase 8	Homo sapiens	209-212
28105210-0	2016	Mammalian target of rapamycin inhibitor RAD001 sensitizes endometrial cancer cells to paclitaxel-induced apoptosis via the induction of autophagy.	Paclitaxel	86-96	mechanistic target of rapamycin kinase	Homo sapiens	0-29
27773824-8	2016	By contrast, cannabinoid CB1 and CB2 receptor antagonists partially attenuated the antinociceptive actions of desipramine in a manner that was restricted to the development phase of paclitaxel-induced neuropathic pain only.	Paclitaxel	182-192	cannabinoid receptor 1	Homo sapiens	25-28
27941276-5	2016	Moreover, we found that siRNA mediated ABCB1 knockdown successfully restored drug sensitivity in both paclitaxel and docetaxel resistant esophageal cancer cell lines.	Paclitaxel	102-112	ATP binding cassette subfamily B member 1	Homo sapiens	39-44
28480395-6	2017	In addition, apoptosis-related genes caspase-3 and bax expressions were increased after paclitaxel treatment.	Paclitaxel	88-98	BCL2 associated X, apoptosis regulator	Homo sapiens	51-54
27651326-1	2016	In this study, Paclitaxel (PTX) containing, bovine serum albumin (BSA) nanoparticles were fabricated via a simple approach.	Paclitaxel	15-25	albumin	Homo sapiens	51-64
27736846-0	2016	Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.	Paclitaxel	105-115	FYVE, RhoGEF and PH domain containing 4	Homo sapiens	24-28
27736846-10	2016	FGD4 c.2044-236 A-allele carriers had an increased risk of paclitaxel dose reduction (HR per A-allele=1.38, P=0.036) when adjusted for total cumulative paclitaxel dose.	Paclitaxel	59-69	FYVE, RhoGEF and PH domain containing 4	Homo sapiens	0-4
27736846-10	2016	FGD4 c.2044-236 A-allele carriers had an increased risk of paclitaxel dose reduction (HR per A-allele=1.38, P=0.036) when adjusted for total cumulative paclitaxel dose.	Paclitaxel	152-162	FYVE, RhoGEF and PH domain containing 4	Homo sapiens	0-4
27596118-8	2016	Mechanism research showed that PTX/BA NE could significantly increase the cellular reactive oxygen species (ROS), decrease cellular glutathione (GSH), and enhance caspase-3 activity in MCF-7/Tax cells.	Paclitaxel	31-34	caspase 3	Homo sapiens	163-172
27651326-1	2016	In this study, Paclitaxel (PTX) containing, bovine serum albumin (BSA) nanoparticles were fabricated via a simple approach.	Paclitaxel	27-30	albumin	Homo sapiens	51-64
27896032-6	2016	Thus, comparison in mRNA expression between untreated control, vehicle-treated and paclitaxel treated animals was done for Nav1.1, Nav1.2, Nav1.3, Nav1.6, Nax as well as Navbeta1-Navbeta4.	Paclitaxel	83-93	sodium channel, voltage-gated, type I, alpha	Mus musculus	123-129
27904705-11	2016	In addition, the levels of anti-CII antibodies as well as serum tumor necrosis factor (TNF)-alpha and vascular endothelial growth factor (VEGF) levels were remarkably lower in PTX group than those in 5% GS controls (p&lt;0.05).	Paclitaxel	176-179	tumor necrosis factor	Rattus norvegicus	64-97
27845771-0	2016	The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non-small-cell Lung Cancer Through Altering STAT3 Expression.	Paclitaxel	61-71	signal transducer and activator of transcription 3	Homo sapiens	131-136
27845771-10	2016	Furthermore, we identified that miR-9600 augmented paclitaxel and cisplatin sensitivity by downregulating STAT3 and promoting chemotherapy-induced apoptosis.	Paclitaxel	51-61	signal transducer and activator of transcription 3	Homo sapiens	106-111
28058139-1	2016	OBJECTIVE: Paclitaxel is used in the treatment of cancer, and it may cause interleukin-1 beta (IL-1beta)-related peripheral neuropathic pain.	Paclitaxel	11-21	interleukin 1 beta	Rattus norvegicus	75-93
28058139-1	2016	OBJECTIVE: Paclitaxel is used in the treatment of cancer, and it may cause interleukin-1 beta (IL-1beta)-related peripheral neuropathic pain.	Paclitaxel	11-21	interleukin 1 beta	Rattus norvegicus	95-103
27756602-0	2016	Synergistic effect of piperine and paclitaxel on cell fate via cyt-c, Bax/Bcl-2-caspase-3 pathway in ovarian adenocarcinomas SKOV-3 cells.	Paclitaxel	35-45	BCL2 associated X, apoptosis regulator	Homo sapiens	70-73
27756602-0	2016	Synergistic effect of piperine and paclitaxel on cell fate via cyt-c, Bax/Bcl-2-caspase-3 pathway in ovarian adenocarcinomas SKOV-3 cells.	Paclitaxel	35-45	BCL2 apoptosis regulator	Homo sapiens	74-79
27756602-0	2016	Synergistic effect of piperine and paclitaxel on cell fate via cyt-c, Bax/Bcl-2-caspase-3 pathway in ovarian adenocarcinomas SKOV-3 cells.	Paclitaxel	35-45	caspase 3	Homo sapiens	80-89
27896032-8	2016	Paclitaxel treatment significantly increased the mRNA expression of Nav1.1, Nav1.2, Nav1.6 and Nax, but not Nav1.3, sodium channel alpha subunits compared to vehicle-treated animals.	Paclitaxel	0-10	sodium channel, voltage-gated, type I, alpha	Mus musculus	68-74
27793920-6	2016	Neutralizing single-domain antibodies directed to catalase and SOD also caused a very strong synergistic effect with the established chemotherapeutic agent taxol, indicating an overlap of signaling pathways.	Paclitaxel	156-161	catalase	Homo sapiens	50-58
27933242-5	2016	CASE DESCRIPTION: A 43 year old lady with Her 2 neu 3+, estrogen and progesterone receptor positive, metastatic breast cancer was started on weekly transtuzumab and albumen bound paclitaxel.	Paclitaxel	179-189	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-51
27659528-0	2016	Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/PI3K/Akt pathway.	Paclitaxel	14-24	AKT serine/threonine kinase 1	Homo sapiens	147-150
27659528-7	2016	Mechanistic analysis revealed that administration of geridonin in combination with paclitaxel up-regulated the tumor suppressor PTEN and inhibited phosphorylation of Akt and MDM2.	Paclitaxel	83-93	AKT serine/threonine kinase 1	Homo sapiens	166-169
27920708-6	2016	CONCLUSION: A multidisciplinary approach to local control and attenuated doses of nab-paclitaxel and trastuzumab suggest a durable response to HER-2-positive breast cancer with cutaneous metastasis.	Paclitaxel	86-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-148
27655643-8	2016	Statistically significant interactions with treatment were found for DNA-dependent protein kinase (DNA-PK) and phosphorylated acetyl-coenzymeA carboxylase (pACC), both predicting worse outcome for patients receiving carboplatin/paclitaxel.	Paclitaxel	228-238	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	69-97
27655643-8	2016	Statistically significant interactions with treatment were found for DNA-dependent protein kinase (DNA-PK) and phosphorylated acetyl-coenzymeA carboxylase (pACC), both predicting worse outcome for patients receiving carboplatin/paclitaxel.	Paclitaxel	228-238	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	99-105
27655643-9	2016	CONCLUSION: These data show that in presence of DNA-PK or pACC overexpression, carboplatin/paclitaxel might be less effective than carboplatin/PLD as first line treatment of ovarian cancer patients.	Paclitaxel	91-101	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	48-54
27812204-9	2016	However, stratified by chemotherapy regimen, inverse correlation between high ABCB1 status and poor OS, PFS and TR were only found in patients underwent platinum-based chemotherapy but not in patients received standard platinum/paclitaxel-based chemotherapy.	Paclitaxel	228-238	ATP binding cassette subfamily B member 1	Homo sapiens	78-83
27793920-6	2016	Neutralizing single-domain antibodies directed to catalase and SOD also caused a very strong synergistic effect with the established chemotherapeutic agent taxol, indicating an overlap of signaling pathways.	Paclitaxel	156-161	superoxide dismutase 1	Homo sapiens	63-66
28133330-5	2016	S-1/irinotecan combination chemotherapy was administered as second-line chemotherapy, but he developed grade 3 diarrhea, and the S-1/irinotecan combination chemotherapy was immediately stopped.Weekly paclitaxel chemother- apy was administered as third-line chemotherapy, and S-1/docetaxel combination chemotherapy was administered as fourth-line chemotherapy.	Paclitaxel	200-210	proteasome 26S subunit, non-ATPase 1	Homo sapiens	0-3
27168024-3	2016	OBJECTIVES: The primary aim was to investigate the metabolic response to pazopanib monotherapy and pazopanib plus paclitaxel in patients with BRAF wild-type melanoma.	Paclitaxel	114-124	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	142-146
27749106-0	2016	DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.	Paclitaxel	11-21	transferrin	Homo sapiens	61-72
27749106-2	2016	Here, we developed dioleoyl phosphatidic acid (DOPA)-based paclitaxel (PTX)-loaded liposomes with modifications of alendronate and transferrin (Ald-/Tf-modified PTX-L), which were capable of bone affinity mediated by phosphate groups in DOPA and alendronate, and tumor targeting offered by transferrin.	Paclitaxel	59-69	transferrin	Homo sapiens	290-301
27749106-2	2016	Here, we developed dioleoyl phosphatidic acid (DOPA)-based paclitaxel (PTX)-loaded liposomes with modifications of alendronate and transferrin (Ald-/Tf-modified PTX-L), which were capable of bone affinity mediated by phosphate groups in DOPA and alendronate, and tumor targeting offered by transferrin.	Paclitaxel	71-74	transferrin	Homo sapiens	290-301
27882079-7	2016	In addition, the results of the present study demonstrated that downregulation of caveolin-1 promotes autophagy and induces osteosarcoma cell resistance to Taxol.	Paclitaxel	156-161	caveolin 1	Homo sapiens	82-92
27882079-8	2016	Notably, overexpression of CAV-1 resensitized drug-resistant cells to Taxol via declined autophagy.	Paclitaxel	70-75	caveolin 1	Homo sapiens	27-32
27882079-9	2016	In conclusion, CAV-1 was demonstrated to be downregulated in Taxol-resistant osteosarcoma cells, and overexpression of CAV-1 in human osteosarcoma cells suppressed Taxol resistance by attenuating PI3K-Akt-JNK-dependent autophagy.	Paclitaxel	61-66	caveolin 1	Homo sapiens	15-20
27882079-9	2016	In conclusion, CAV-1 was demonstrated to be downregulated in Taxol-resistant osteosarcoma cells, and overexpression of CAV-1 in human osteosarcoma cells suppressed Taxol resistance by attenuating PI3K-Akt-JNK-dependent autophagy.	Paclitaxel	164-169	caveolin 1	Homo sapiens	119-124
27882079-10	2016	The present findings suggest that further investigation into CAV-1"s role in Taxol resistance is warranted.	Paclitaxel	77-82	caveolin 1	Homo sapiens	61-66
27414207-0	2016	A Combination Therapy with Baicalein and Taxol Promotes Mitochondria-Mediated Cell Apoptosis: Involving in Akt/beta-Catenin Signaling Pathway.	Paclitaxel	41-46	AKT serine/threonine kinase 1	Homo sapiens	107-110
27414207-5	2016	The ovarian cancer cells were treated with 10 muM of baicalein combined with increasing concentration of taxol for 48 h, and the results demonstrated that combination therapy with baicalein and taxol had much higher antitumor effects compared with the monotherapy.	Paclitaxel	194-199	latexin	Homo sapiens	46-49
27414207-10	2016	In conclusion, our result revealed that baicalein combinated with taxol at low concentrations could exert synergistic antitumor effects in ovarian cancer cells through mitochondria-mediated cell apoptosis and Akt/beta-catenin signaling pathway.	Paclitaxel	66-71	AKT serine/threonine kinase 1	Homo sapiens	209-212
27882079-0	2016	Overexpression of caveolin-1 reduces Taxol resistance in human osteosarcoma cells by attenuating PI3K-Akt-JNK dependent autophagy.	Paclitaxel	37-42	caveolin 1	Homo sapiens	18-28
27882079-0	2016	Overexpression of caveolin-1 reduces Taxol resistance in human osteosarcoma cells by attenuating PI3K-Akt-JNK dependent autophagy.	Paclitaxel	37-42	AKT serine/threonine kinase 1	Homo sapiens	102-105
27882079-6	2016	The effect of caveolin-1 on autophagy was investigated, and the downregulation of caveolin-1 and increased autophagy was identified in Taxol-resistant osteosarcoma cells.	Paclitaxel	135-140	caveolin 1	Homo sapiens	14-24
27882079-6	2016	The effect of caveolin-1 on autophagy was investigated, and the downregulation of caveolin-1 and increased autophagy was identified in Taxol-resistant osteosarcoma cells.	Paclitaxel	135-140	caveolin 1	Homo sapiens	82-92
27654264-6	2016	RESULTS: Paclitaxel and DOX decreased cell viability and increased caspase-3 activity, and co-treatment with VPA enhanced this effect.	Paclitaxel	9-19	caspase 3	Homo sapiens	67-76
27664577-9	2016	Employing mRNA expression profiling of all known human ABC transporters and subsequent Western blot analysis of the expression of selected transporters, we demonstrated that only the ABCB1/PgP and ABCC3/MRP3 proteins were up-regulated in both paclitaxel-resistant sublines.	Paclitaxel	243-253	ATP binding cassette subfamily B member 1	Homo sapiens	183-188
27599579-8	2016	Of the cytotoxic agents, paclitaxel was the most effective for inhibiting the growth of OCCLs, and of various combinations of these drugs, only treatment with a combination of NVP-AEW541 and paclitaxel produced a synergistic or additive anti-proliferative effect in all three cell lines examined (i.e., SKOV3, Caov3, ES2).	Paclitaxel	191-201	ess-2 splicing factor homolog	Homo sapiens	317-320
27893676-9	2016	Incidence of adverse events for the 2 treatment approaches was similar in the patients.Intervention of Avastin enhances potency of paclitaxel in treatment of MPEs with the increased survival rate of the patients through inhibiting VEGF production and prolonging time of ongoing interaction between the chemotherapy drug and the tumor tissues.	Paclitaxel	131-141	vascular endothelial growth factor A	Homo sapiens	231-235
27664577-10	2016	We found up-regulation of ABCG2/BCRP and ABCC4 proteins only in paclitaxel-resistant SK-BR-3 cells.	Paclitaxel	64-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	26-31
27664577-10	2016	We found up-regulation of ABCG2/BCRP and ABCC4 proteins only in paclitaxel-resistant SK-BR-3 cells.	Paclitaxel	64-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	32-36
27664577-12	2016	Silencing of ABCB1 expression using specific siRNA increased significantly, but did not completely restore full sensitivity to both paclitaxel and doxorubicin.	Paclitaxel	132-142	ATP binding cassette subfamily B member 1	Homo sapiens	13-18
27664577-13	2016	Thus we showed a key, but not exclusive, role for ABCB1 in mechanisms of paclitaxel resistance.	Paclitaxel	73-83	ATP binding cassette subfamily B member 1	Homo sapiens	50-55
27798865-8	2016	Furthermore, through using microscopic observation, assessment of cleaved poly ADP ribose polymerase (C-PARP) and annexin V staining we determined that both COX-2 inhibitors strongly sensitized resistant KBV20C cells to vinblastine (VIB) or paclitaxel (PAC) treatment.	Paclitaxel	241-251	prostaglandin-endoperoxide synthase 2	Homo sapiens	157-162
27798187-10	2016	Inhibition of endogenous IL-10 signaling by intrathecal injection of anti-IL-10 to WT mice or Rag1-/- mice reconstituted with CD8+ T cells delayed recovery from paclitaxel-induced mechanical allodynia.	Paclitaxel	161-171	interleukin 10	Mus musculus	25-30
27798187-10	2016	Inhibition of endogenous IL-10 signaling by intrathecal injection of anti-IL-10 to WT mice or Rag1-/- mice reconstituted with CD8+ T cells delayed recovery from paclitaxel-induced mechanical allodynia.	Paclitaxel	161-171	interleukin 10	Mus musculus	74-79
27798187-12	2016	Conversely, administration of exogenous IL-10 attenuated paclitaxel-induced allodynia.	Paclitaxel	57-67	interleukin 10	Mus musculus	40-45
27798187-13	2016	In vitro, IL-10 suppressed abnormal paclitaxel-induced spontaneous discharges in DRG neurons.	Paclitaxel	36-46	interleukin 10	Mus musculus	10-15
27798187-14	2016	Paclitaxel increased DRG IL-10 receptor expression and this effect requires CD8+ T cells.	Paclitaxel	0-10	interleukin 10	Mus musculus	25-30
27798187-16	2016	We propose that CD8+ T cells increase DRG IL-10 receptor expression and that IL-10 suppresses the abnormal paclitaxel-induced spontaneous discharges by DRG neurons to promote recovery from CIPN.	Paclitaxel	107-117	interleukin 10	Mus musculus	77-82
27798187-20	2016	We identified a novel and critical role for CD8+ T cells and for endogenous IL-10 in recovery from paclitaxel-induced neuropathy in mice.	Paclitaxel	99-109	interleukin 10	Mus musculus	76-81
27568005-7	2016	In addition, the reconstitution of DAB2IP enhances the sensitivity of PCa cells to microtubule stabilizing drugs (paclitaxel, docetaxel) and Plk1 inhibitor (BI2536).	Paclitaxel	114-124	DAB2 interacting protein	Homo sapiens	35-41
27718127-7	2016	In addition, Rab14 overexpression increased paclitaxel resistance in SW626 cells while its depletion reduced drug resistance.	Paclitaxel	44-54	RAB14, member RAS oncogene family	Homo sapiens	13-18
27563006-8	2016	After paclitaxel treatment, GLT-1 was significantly down-regulated, and the phosphorylation of ERK1/2 and JNK were obviously up-regulated.	Paclitaxel	6-16	solute carrier family 1 member 2	Homo sapiens	28-33
27563006-8	2016	After paclitaxel treatment, GLT-1 was significantly down-regulated, and the phosphorylation of ERK1/2 and JNK were obviously up-regulated.	Paclitaxel	6-16	mitogen-activated protein kinase 3	Homo sapiens	95-101
27563006-8	2016	After paclitaxel treatment, GLT-1 was significantly down-regulated, and the phosphorylation of ERK1/2 and JNK were obviously up-regulated.	Paclitaxel	6-16	mitogen-activated protein kinase 8	Homo sapiens	106-109
27502704-8	2016	However, both subclones responded to carboplatin/paclitaxel, and although the KIT-wild-type subclone progressed after chemotherapy, it responded to subsequent re-administration of paclitaxel.	Paclitaxel	180-190	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	78-81
27798902-3	2016	We report the outcome in patients treated simultaneously with trastuzumab and paclitaxel for advanced or recurrent HER2-positive endometrial carcinoma and compared it to their microsatellite instability (MSI) status and PIK3CA mutational profiles.	Paclitaxel	78-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-119
27629142-0	2016	Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis.	Paclitaxel	47-57	H2A.X variant histone	Mus musculus	140-144
27687545-4	2016	Compared with PC3, PC3-PR exhibited some unique phenotypes that might be associated with PTX resistance, including decreased expression of acetylated alpha-tubulin and the cell cycle regulator p21, and increased expression of betaIII tubulin, histone deacetylase 6 (HDAC6), and the anti-apoptotic protein Bcl2.	Paclitaxel	89-92	histone deacetylase 6	Homo sapiens	266-271
27687545-4	2016	Compared with PC3, PC3-PR exhibited some unique phenotypes that might be associated with PTX resistance, including decreased expression of acetylated alpha-tubulin and the cell cycle regulator p21, and increased expression of betaIII tubulin, histone deacetylase 6 (HDAC6), and the anti-apoptotic protein Bcl2.	Paclitaxel	89-92	BCL2 apoptosis regulator	Homo sapiens	305-309
27588398-8	2016	Inhibition of ABCB1 partially restored paclitaxel and doxorubicin sensitivity.	Paclitaxel	39-49	ATP binding cassette subfamily B member 1	Homo sapiens	14-19
27770785-12	2016	Vimentin phosphorylation catalyzed by cell division cycle 2 (Cdc2) kinase was induced from Schwann cells in the sciatic nerves after taxol injection and crush injury, and phospho-vimentin levels were further upregulated by BGJTD treatment.	Paclitaxel	133-138	cyclin-dependent kinase 1	Rattus norvegicus	38-59
27770785-12	2016	Vimentin phosphorylation catalyzed by cell division cycle 2 (Cdc2) kinase was induced from Schwann cells in the sciatic nerves after taxol injection and crush injury, and phospho-vimentin levels were further upregulated by BGJTD treatment.	Paclitaxel	133-138	cyclin-dependent kinase 1	Rattus norvegicus	61-65
27757042-8	2016	Overexpression of miR-590-5p promoted cell proliferation and invasion and reduced the sensitivity of GC cells to cisplatin and paclitaxel.	Paclitaxel	127-137	microRNA 590	Homo sapiens	18-25
27798902-13	2016	This report underlines the low accuracy of HER2 positivity to predict response of endometrial cancer to combined targeted therapy using trastuzumab and paclitaxel.	Paclitaxel	152-162	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
27798865-8	2016	Furthermore, through using microscopic observation, assessment of cleaved poly ADP ribose polymerase (C-PARP) and annexin V staining we determined that both COX-2 inhibitors strongly sensitized resistant KBV20C cells to vinblastine (VIB) or paclitaxel (PAC) treatment.	Paclitaxel	253-256	prostaglandin-endoperoxide synthase 2	Homo sapiens	157-162
27431785-8	2016	This study demonstrates that the combination of NCS and PTX can potentiate the effect on survival and apoptosis of glioma cells via suppression of Akt, bcl-2, and activations of p53; Meanwhile, the in vivo studies also confirmed that the combination of NCS and PTX synergistically inhibit the gliom growth.	Paclitaxel	56-59	AKT serine/threonine kinase 1	Homo sapiens	147-150
27472162-7	2016	CendR-targeted polymersomes loaded with paclitaxel were more cytotoxic on NRP-1-positive cells than on NRP-1-negative cells.	Paclitaxel	40-50	neuropilin 1	Mus musculus	74-79
27472162-7	2016	CendR-targeted polymersomes loaded with paclitaxel were more cytotoxic on NRP-1-positive cells than on NRP-1-negative cells.	Paclitaxel	40-50	neuropilin 1	Mus musculus	103-108
27431785-8	2016	This study demonstrates that the combination of NCS and PTX can potentiate the effect on survival and apoptosis of glioma cells via suppression of Akt, bcl-2, and activations of p53; Meanwhile, the in vivo studies also confirmed that the combination of NCS and PTX synergistically inhibit the gliom growth.	Paclitaxel	56-59	BCL2 apoptosis regulator	Homo sapiens	152-157
27431785-8	2016	This study demonstrates that the combination of NCS and PTX can potentiate the effect on survival and apoptosis of glioma cells via suppression of Akt, bcl-2, and activations of p53; Meanwhile, the in vivo studies also confirmed that the combination of NCS and PTX synergistically inhibit the gliom growth.	Paclitaxel	56-59	tumor protein p53	Homo sapiens	178-181
27452985-0	2016	Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.	Paclitaxel	32-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-86
27565729-4	2016	With an increase in paclitaxel concentration from 0.1 muM to 10 muM, the critical nucleation concentration decreases by 89%.	Paclitaxel	20-30	latexin	Homo sapiens	64-67
27590579-5	2016	Expression of the isotype of the hGBP-1-interacting protein, PIM1, which may contribute to paclitaxel resistance when associated with hGBP-1, is different in breast and ovarian cancer cell lines.	Paclitaxel	91-101	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	61-65
27151564-5	2016	An in vivo study using xenograft mice bearing peritoneal human pancreatic carcinoma MIA PaCa-2 demonstrated that the MSN-paclitaxel formulation, compared to free paclitaxel, exhibited a 3.2-fold increase in peritoneal cavity residence time, slower absorption into the systemic circulation with one third systemic exposure, but a 6.5-fold increase in peritoneal tumor accumulation.	Paclitaxel	121-131	moesin	Homo sapiens	117-120
27151564-5	2016	An in vivo study using xenograft mice bearing peritoneal human pancreatic carcinoma MIA PaCa-2 demonstrated that the MSN-paclitaxel formulation, compared to free paclitaxel, exhibited a 3.2-fold increase in peritoneal cavity residence time, slower absorption into the systemic circulation with one third systemic exposure, but a 6.5-fold increase in peritoneal tumor accumulation.	Paclitaxel	162-172	moesin	Homo sapiens	117-120
27737687-13	2016	Molecular studies revealed that paclitaxel increased TNFalpha expression, thereby leading to the recruitment of various factors and the formation of the TRADD-TRAF2-RIP1-cIAP complex.	Paclitaxel	32-42	tumor necrosis factor	Homo sapiens	53-61
27737687-13	2016	Molecular studies revealed that paclitaxel increased TNFalpha expression, thereby leading to the recruitment of various factors and the formation of the TRADD-TRAF2-RIP1-cIAP complex.	Paclitaxel	32-42	TNFRSF1A associated via death domain	Homo sapiens	153-158
27619088-7	2016	PTX would perturb the anodic/cathodic responses of the cell-covered biosensor by binding phosphate groups to deformed proteins due to extracellular signal-regulated kinase (ERK(1/2)) pathway.	Paclitaxel	0-3	mitogen-activated protein kinase 3	Homo sapiens	134-180
27565729-4	2016	With an increase in paclitaxel concentration from 0.1 muM to 10 muM, the critical nucleation concentration decreases by 89%.	Paclitaxel	20-30	latexin	Homo sapiens	54-57
27565729-7	2016	Addition of 10 muM taxol resulted in reduced steady state length of microtubules by 37.5%.	Paclitaxel	19-24	latexin	Homo sapiens	15-18
27422607-9	2016	Collectively, these data indicated that DUSP1 may induce the resistance against paclitaxel through the p38 MAPK-mediated overexpression of p-glycoprotein in human ovarian cancer cells.	Paclitaxel	80-90	dual specificity phosphatase 1	Homo sapiens	40-45
27698563-9	2016	When coupling to Tmab and loading with paclitaxel or doxorubicin, they become efficient vehicles for the selective delivery of the drug to Tmab-resistant HER2-overexpressing breast cancer cells.	Paclitaxel	39-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-158
27458019-7	2016	Blocking GluN2A-containing, but not GluN2B-containing, NMDARs largely decreased the frequency of mEPSCs and the amplitude of evoked EPSCs of dorsal horn neurons in paclitaxel-treated rats.	Paclitaxel	164-174	glutamate ionotropic receptor NMDA type subunit 2A	Rattus norvegicus	9-15
27458019-9	2016	Paclitaxel treatment significantly increased the protein level of GluN2A and phosphorylated GluN1 in the dorsal root ganglion.	Paclitaxel	0-10	glutamate ionotropic receptor NMDA type subunit 2A	Rattus norvegicus	66-72
27611665-4	2016	Cdc6 depletion by RNAi or Norcantharidin inhibited PTX-induced Cdc6 up-regulation, maintained Cdk1 activity, and repressed Cohesin/Rad21 cleavage.	Paclitaxel	51-54	cell division cycle 6	Homo sapiens	0-4
27611665-4	2016	Cdc6 depletion by RNAi or Norcantharidin inhibited PTX-induced Cdc6 up-regulation, maintained Cdk1 activity, and repressed Cohesin/Rad21 cleavage.	Paclitaxel	51-54	cell division cycle 6	Homo sapiens	63-67
27611665-6	2016	Moreover, in synchronized cells, the role of Cdc6 in mitotic exit under PTX pressure was also confirmed.	Paclitaxel	72-75	cell division cycle 6	Homo sapiens	45-49
27611665-8	2016	Targeting of Cdc6 may serve as a promising strategy for enhancing the anticancer activity of PTX.	Paclitaxel	93-96	cell division cycle 6	Homo sapiens	13-17
27648001-9	2016	Specifically, treatment of paclitaxel (PTX) after down-regulating Akt gene expression using RNAi reduces the cell proliferation and increases apoptosis.	Paclitaxel	27-37	AKT serine/threonine kinase 1	Homo sapiens	66-69
27648001-9	2016	Specifically, treatment of paclitaxel (PTX) after down-regulating Akt gene expression using RNAi reduces the cell proliferation and increases apoptosis.	Paclitaxel	39-42	AKT serine/threonine kinase 1	Homo sapiens	66-69
27635041-0	2016	Commentary on "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" (A Follow Up).	Paclitaxel	103-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-46
27635041-0	2016	Commentary on "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" (A Follow Up).	Paclitaxel	103-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	138-142
27422607-0	2016	DUSP1 induces paclitaxel resistance through the regulation of p-glycoprotein expression in human ovarian cancer cells.	Paclitaxel	14-24	dual specificity phosphatase 1	Homo sapiens	0-5
27422607-0	2016	DUSP1 induces paclitaxel resistance through the regulation of p-glycoprotein expression in human ovarian cancer cells.	Paclitaxel	14-24	ATP binding cassette subfamily B member 1	Homo sapiens	62-76
27422607-2	2016	In this study, we investigated the role of dual-specificity phosphatase 1 (DUSP1) in the development of the resistance in human ovarian cancer cells against paclitaxel.	Paclitaxel	157-167	dual specificity phosphatase 1	Homo sapiens	43-73
27422607-2	2016	In this study, we investigated the role of dual-specificity phosphatase 1 (DUSP1) in the development of the resistance in human ovarian cancer cells against paclitaxel.	Paclitaxel	157-167	dual specificity phosphatase 1	Homo sapiens	75-80
27422607-4	2016	Consequently, HeyA8-DUSP1 cells are highly resistant to paclitaxel, with the resistance comparable to that of a multi-drug resistance cell line (HeyA8-MDR).	Paclitaxel	56-66	dual specificity phosphatase 1	Homo sapiens	20-25
27422607-6	2016	Pharmacological suppression of p38 MAPK activity prevents the up-regulation of p-glycoprotein expression and the consequent resistance against paclitaxel in HeyA8-DUSP1 cells.	Paclitaxel	143-153	mitogen-activated protein kinase 1	Homo sapiens	31-34
27422607-6	2016	Pharmacological suppression of p38 MAPK activity prevents the up-regulation of p-glycoprotein expression and the consequent resistance against paclitaxel in HeyA8-DUSP1 cells.	Paclitaxel	143-153	mitogen-activated protein kinase 3	Homo sapiens	35-39
27422607-6	2016	Pharmacological suppression of p38 MAPK activity prevents the up-regulation of p-glycoprotein expression and the consequent resistance against paclitaxel in HeyA8-DUSP1 cells.	Paclitaxel	143-153	dual specificity phosphatase 1	Homo sapiens	163-168
27422607-7	2016	By contrast, HeyA8-MDR cells expressed a significantly higher level of DUSP1, but treatment with small interference RNA against DUSP1 significantly suppressed the expression of p-glycoprotein and the resistance against paclitaxel in HeyA8-MDR cells.	Paclitaxel	219-229	dual specificity phosphatase 1	Homo sapiens	128-133
27422607-9	2016	Collectively, these data indicated that DUSP1 may induce the resistance against paclitaxel through the p38 MAPK-mediated overexpression of p-glycoprotein in human ovarian cancer cells.	Paclitaxel	80-90	mitogen-activated protein kinase 1	Homo sapiens	103-106
27422607-9	2016	Collectively, these data indicated that DUSP1 may induce the resistance against paclitaxel through the p38 MAPK-mediated overexpression of p-glycoprotein in human ovarian cancer cells.	Paclitaxel	80-90	mitogen-activated protein kinase 3	Homo sapiens	107-111
27422607-9	2016	Collectively, these data indicated that DUSP1 may induce the resistance against paclitaxel through the p38 MAPK-mediated overexpression of p-glycoprotein in human ovarian cancer cells.	Paclitaxel	80-90	ATP binding cassette subfamily B member 1	Homo sapiens	139-153
27262378-0	2016	Ferulic acid reverses ABCB1-mediated paclitaxel resistance in MDR cell lines.	Paclitaxel	37-47	ATP binding cassette subfamily B member 1	Homo sapiens	22-27
27072400-0	2016	A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.	Paclitaxel	57-67	Y-box binding protein 1	Homo sapiens	38-42
27262378-3	2016	The aim of this study was to investigate whether a naturally occurring diet-based phenolic acid, ferulic acid, could sensitize paclitaxel efficacy in ABCB1 overexpressing (P-glycoprotein) colchicine selected KB Ch(R)8-5 cell line.	Paclitaxel	127-137	ATP binding cassette subfamily B member 1	Homo sapiens	150-155
27262378-3	2016	The aim of this study was to investigate whether a naturally occurring diet-based phenolic acid, ferulic acid, could sensitize paclitaxel efficacy in ABCB1 overexpressing (P-glycoprotein) colchicine selected KB Ch(R)8-5 cell line.	Paclitaxel	127-137	ATP binding cassette subfamily B member 1	Homo sapiens	172-186
27262378-6	2016	Cytotoxicity assay reveals that ferulic acid decreased paclitaxel resistance in KBCh(R)8-5 and HEK293/ABCB1 cells, which indicates its chemosensitizing potential.	Paclitaxel	55-65	ATP binding cassette subfamily B member 1	Homo sapiens	102-107
27498772-10	2016	RESULTS: Pretreatment with quercetin (3, 10, 30 mumol/L) dose-dependently inhibited excessive histamine release from paclitaxel-stimulated RBL-2H3 cells in vitro, and quercetin administration significantly suppressed the high plasma histamine levels in paclitaxel-treated rats.	Paclitaxel	117-127	RB transcriptional corepressor like 2	Rattus norvegicus	139-144
27436849-0	2016	Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.	Paclitaxel	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-74
27436849-0	2016	Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.	Paclitaxel	31-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-74
27436849-10	2016	CONCLUSIONS: In this large-scale, real-life setting, patients with HER2-negative MBC who received paclitaxel plus bevacizumab as first-line chemotherapy had a significantly better OS and PFS than those receiving paclitaxel.	Paclitaxel	98-108	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
27436849-10	2016	CONCLUSIONS: In this large-scale, real-life setting, patients with HER2-negative MBC who received paclitaxel plus bevacizumab as first-line chemotherapy had a significantly better OS and PFS than those receiving paclitaxel.	Paclitaxel	212-222	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
26338546-0	2016	Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.	Paclitaxel	135-145	epidermal growth factor receptor	Homo sapiens	31-35
26338546-1	2016	OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions.	Paclitaxel	156-166	epidermal growth factor receptor	Homo sapiens	47-51
27416882-0	2016	New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.	Paclitaxel	28-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
27072400-5	2016	High levels of YB-1 have previously been associated with resistance to PTX in TNBCs.	Paclitaxel	71-74	Y-box binding protein 1	Homo sapiens	15-19
27072400-6	2016	In this study, we aimed to determine mechanisms by which YB-1 confers PTX resistance.	Paclitaxel	70-73	Y-box binding protein 1	Homo sapiens	57-61
27072400-11	2016	Given that PTX targets cycling cells, we propose a model whereby high YB-1 levels in some TNBC cells can lead to reduced levels of EGR1, which in turn promotes slow cell cycling and resistance to PTX.	Paclitaxel	11-14	Y-box binding protein 1	Homo sapiens	70-74
27072400-11	2016	Given that PTX targets cycling cells, we propose a model whereby high YB-1 levels in some TNBC cells can lead to reduced levels of EGR1, which in turn promotes slow cell cycling and resistance to PTX.	Paclitaxel	196-199	Y-box binding protein 1	Homo sapiens	70-74
27072400-12	2016	Therefore YB-1 and EGR1 levels are biologically linked and may provide a biomarker for TNBC response to PTX.	Paclitaxel	104-107	Y-box binding protein 1	Homo sapiens	10-14
27572875-4	2016	PXR agonists, phthalate and pregnenolone had significant positive effects on cytochrome P450 (CYP) 3A4 expression and PXR-mediated transcription through the CYP3A4 promoter, whereas MDR1 expression and PXR-mediated transcription though the MDR1 promoter were significantly increased in the presence of paclitaxel or cisplatin.	Paclitaxel	302-312	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-3
27572875-4	2016	PXR agonists, phthalate and pregnenolone had significant positive effects on cytochrome P450 (CYP) 3A4 expression and PXR-mediated transcription through the CYP3A4 promoter, whereas MDR1 expression and PXR-mediated transcription though the MDR1 promoter were significantly increased in the presence of paclitaxel or cisplatin.	Paclitaxel	302-312	nuclear receptor subfamily 1 group I member 2	Homo sapiens	118-121
27572875-4	2016	PXR agonists, phthalate and pregnenolone had significant positive effects on cytochrome P450 (CYP) 3A4 expression and PXR-mediated transcription through the CYP3A4 promoter, whereas MDR1 expression and PXR-mediated transcription though the MDR1 promoter were significantly increased in the presence of paclitaxel or cisplatin.	Paclitaxel	302-312	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	157-163
27572875-4	2016	PXR agonists, phthalate and pregnenolone had significant positive effects on cytochrome P450 (CYP) 3A4 expression and PXR-mediated transcription through the CYP3A4 promoter, whereas MDR1 expression and PXR-mediated transcription though the MDR1 promoter were significantly increased in the presence of paclitaxel or cisplatin.	Paclitaxel	302-312	nuclear receptor subfamily 1 group I member 2	Homo sapiens	118-121
27572875-5	2016	Downregulation of PXR suppressed the augmented MDR1 expression and PXR-mediated transcription by PXR ligands, and significantly enhanced cell growth inhibition and apoptosis in the presence of paclitaxel or cisplatin.	Paclitaxel	193-203	nuclear receptor subfamily 1 group I member 2	Homo sapiens	18-21
27572875-6	2016	Additionally, ketoconazole, a PXR antagonist, suppressed the augmented MDR1 expression and PXR-mediated transactivation by paclitaxel and cisplatin, and enhanced cell growth inhibition and apoptosis in their presence.	Paclitaxel	123-133	nuclear receptor subfamily 1 group I member 2	Homo sapiens	30-33
27572875-6	2016	Additionally, ketoconazole, a PXR antagonist, suppressed the augmented MDR1 expression and PXR-mediated transactivation by paclitaxel and cisplatin, and enhanced cell growth inhibition and apoptosis in their presence.	Paclitaxel	123-133	ATP binding cassette subfamily B member 1	Homo sapiens	71-75
27572875-6	2016	Additionally, ketoconazole, a PXR antagonist, suppressed the augmented MDR1 expression and PXR-mediated transactivation by paclitaxel and cisplatin, and enhanced cell growth inhibition and apoptosis in their presence.	Paclitaxel	123-133	nuclear receptor subfamily 1 group I member 2	Homo sapiens	91-94
27422809-0	2016	CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.	Paclitaxel	57-67	checkpoint kinase 1	Homo sapiens	0-4
27422809-11	2016	CHK1 may serve as a biomarker for identifying tumors likely to recur and, therefore, patients who may benefit from concomitant treatment with a CHK1 inhibitor and paclitaxel during radiotherapy.	Paclitaxel	163-173	checkpoint kinase 1	Homo sapiens	0-4
27059733-7	2016	Furthermore, exogenous galectin-3 boosted expression of TLR4, MyD88, and p-p65, as well as interleukin (IL)-6, IL-8, and vascular endothelial growth factor (VEGF) release induced by paclitaxel.	Paclitaxel	182-192	vascular endothelial growth factor A	Homo sapiens	121-155
27236538-0	2016	Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2).	Paclitaxel	37-47	salt inducible kinase 2	Homo sapiens	112-135
27236538-0	2016	Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2).	Paclitaxel	37-47	salt inducible kinase 2	Homo sapiens	137-141
27236538-0	2016	Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2).	Paclitaxel	49-54	salt inducible kinase 2	Homo sapiens	112-135
27236538-0	2016	Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2).	Paclitaxel	49-54	salt inducible kinase 2	Homo sapiens	137-141
27059733-10	2016	In summary, our study elucidated that exogenous galectin-3 might induce paclitaxel resistance through TLR4 signaling activation by inhibiting TLR4-Cav-1 interaction, revealing a novel insight into paclitaxel resistance induction.	Paclitaxel	72-82	caveolin 1	Homo sapiens	147-152
27059733-10	2016	In summary, our study elucidated that exogenous galectin-3 might induce paclitaxel resistance through TLR4 signaling activation by inhibiting TLR4-Cav-1 interaction, revealing a novel insight into paclitaxel resistance induction.	Paclitaxel	197-207	caveolin 1	Homo sapiens	147-152
27236538-4	2016	In this study, we report a miR-203-SIK2 axis that involves in the regulation of Taxol sensitivity in colon cancer cells.	Paclitaxel	80-85	salt inducible kinase 2	Homo sapiens	35-39
27059733-9	2016	In addition, overexpression of Cav-1 dampened the expression of MyD88 and p-p65 stimulated by galectin-3 and enhanced apoptosis in SKOV-3 cells under paclitaxel exposure.	Paclitaxel	150-160	caveolin 1	Homo sapiens	31-36
27236538-8	2016	Overexpression of miR-203 complementary pairs to the 3" untranslated region (UTR) of SIK2, leading to the sensitization of Taxol resistant cells.	Paclitaxel	123-128	salt inducible kinase 2	Homo sapiens	85-89
27236538-10	2016	Finally, we demonstrate recovery of SIK2 by overexpression of SIK2-desensitized Taxol-resistant cells, supporting the miR-203-mediated sensitization to Taxol, is through the inhibition of SIK2.	Paclitaxel	80-85	salt inducible kinase 2	Homo sapiens	36-40
28620450-8	2016	Minimum redundancy maximum relevance feature selection of a paclitaxel-based SVM classifier based on expression of genes  BCL2L1, BBC3, FGF2, FN1, and  TWIST1 was 81.1% accurate in 53 CT patients.	Paclitaxel	60-70	BCL2 like 1	Homo sapiens	122-128
27236538-10	2016	Finally, we demonstrate recovery of SIK2 by overexpression of SIK2-desensitized Taxol-resistant cells, supporting the miR-203-mediated sensitization to Taxol, is through the inhibition of SIK2.	Paclitaxel	80-85	salt inducible kinase 2	Homo sapiens	62-66
27236538-10	2016	Finally, we demonstrate recovery of SIK2 by overexpression of SIK2-desensitized Taxol-resistant cells, supporting the miR-203-mediated sensitization to Taxol, is through the inhibition of SIK2.	Paclitaxel	80-85	salt inducible kinase 2	Homo sapiens	62-66
27236538-10	2016	Finally, we demonstrate recovery of SIK2 by overexpression of SIK2-desensitized Taxol-resistant cells, supporting the miR-203-mediated sensitization to Taxol, is through the inhibition of SIK2.	Paclitaxel	152-157	salt inducible kinase 2	Homo sapiens	62-66
27236538-10	2016	Finally, we demonstrate recovery of SIK2 by overexpression of SIK2-desensitized Taxol-resistant cells, supporting the miR-203-mediated sensitization to Taxol, is through the inhibition of SIK2.	Paclitaxel	152-157	salt inducible kinase 2	Homo sapiens	62-66
28620450-8	2016	Minimum redundancy maximum relevance feature selection of a paclitaxel-based SVM classifier based on expression of genes  BCL2L1, BBC3, FGF2, FN1, and  TWIST1 was 81.1% accurate in 53 CT patients.	Paclitaxel	60-70	fibroblast growth factor 2	Homo sapiens	136-140
28620450-8	2016	Minimum redundancy maximum relevance feature selection of a paclitaxel-based SVM classifier based on expression of genes  BCL2L1, BBC3, FGF2, FN1, and  TWIST1 was 81.1% accurate in 53 CT patients.	Paclitaxel	60-70	fibronectin 1	Homo sapiens	142-145
28620450-8	2016	Minimum redundancy maximum relevance feature selection of a paclitaxel-based SVM classifier based on expression of genes  BCL2L1, BBC3, FGF2, FN1, and  TWIST1 was 81.1% accurate in 53 CT patients.	Paclitaxel	60-70	twist family bHLH transcription factor 1	Homo sapiens	152-158
27409838-12	2016	Also, FBXW7, MCL1 and PLK1 may be relevant predictive markers of tumor progression and response to paclitaxel treatment.	Paclitaxel	99-109	F-box and WD repeat domain containing 7	Homo sapiens	6-11
27195913-0	2016	Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src.	Paclitaxel	19-29	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	106-111
27195913-7	2016	Moreover, dasatinib, a c-Src inhibitor, dephosphorylated caspase-8 to facilitate necroptosis, rather than apoptosis, in paclitaxel-treated p-Casp8-expressing lung adenocarcinoma cells.	Paclitaxel	120-130	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	23-28
27409347-4	2016	ING5 transfection desensitized cells to the chemotherapy of MG132, paclitaxel, and SAHA, which paralleled with apoptotic alteration.	Paclitaxel	67-77	inhibitor of growth family member 5	Homo sapiens	0-4
27409838-0	2016	Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.	Paclitaxel	56-66	F-box and WD repeat domain containing 7	Homo sapiens	8-13
27409838-5	2016	We investigated the role of FBXW7 and their substrates MCL1 and PLK1 in regulating the apoptotic response to paclitaxel treatment in breast cancer cells and their expression in breast cancer tissues.	Paclitaxel	109-119	F-box and WD repeat domain containing 7	Homo sapiens	28-33
27409838-7	2016	Forced expression of FBXW7 or downregulation of MCL1 or PLK1 restored sensitivity to paclitaxel in MDA-MB-468R cells.	Paclitaxel	85-95	F-box and WD repeat domain containing 7	Homo sapiens	21-26
27409838-8	2016	By contrary, FBXW7-silenced MDA-MB-468 cells became resistant to paclitaxel.	Paclitaxel	65-75	F-box and WD repeat domain containing 7	Homo sapiens	13-18
27409838-10	2016	In breast cancer tissues, loss of FBXW7 correlated with adverse prognosis markers and loss of FBXW7 and MCL1 or PLK1 accumulation were associated with diminished disease-free survival in paclitaxel-treated patients.	Paclitaxel	187-197	F-box and WD repeat domain containing 7	Homo sapiens	94-99
27409838-11	2016	We conclude that FBXW7 regulates the response to paclitaxel by targeting MCL1 and PLK1 in breast cancer cells and thus targeting these substrates may be a valuable adjunct for paclitaxel treatment.	Paclitaxel	49-59	F-box and WD repeat domain containing 7	Homo sapiens	17-22
27409838-11	2016	We conclude that FBXW7 regulates the response to paclitaxel by targeting MCL1 and PLK1 in breast cancer cells and thus targeting these substrates may be a valuable adjunct for paclitaxel treatment.	Paclitaxel	176-186	F-box and WD repeat domain containing 7	Homo sapiens	17-22
27574448-0	2016	Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.	Paclitaxel	110-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-22
27328733-6	2016	Downregulation of nuclear S100A4 by low-dose paclitaxel was associated with a strong reduction in RhoA and Cdc42 GTPase activity, MT1-MMP expression, and MMP-9 secretion.	Paclitaxel	45-55	ras homolog family member A	Homo sapiens	98-102
27574448-0	2016	Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.	Paclitaxel	110-120	ATP binding cassette subfamily B member 1	Homo sapiens	27-32
27415012-0	2016	ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.	Paclitaxel	64-74	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
27415012-0	2016	ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.	Paclitaxel	64-74	ATP binding cassette subfamily B member 1	Homo sapiens	7-11
27415012-8	2016	Active efflux of paclitaxel, olaparib, doxorubicin and rucaparib was confirmed in drug-resistant cells and in ABCB1-expressing bacterial membranes.	Paclitaxel	17-27	ATP binding cassette subfamily B member 1	Homo sapiens	110-115
27415012-9	2016	CONCLUSIONS: We describe a common ABCB1-mediated mechanism of paclitaxel and olaparib resistance in ovarian cancer cells.	Paclitaxel	62-72	ATP binding cassette subfamily B member 1	Homo sapiens	34-39
27302171-5	2016	We found that HOXC10 promotes survival in cells treated with doxorubicin, paclitaxel, or carboplatin by suppressing apoptosis and upregulating NF-kappaB Overexpressed HOXC10 increases S-phase-specific DNA damage repair by homologous recombination (HR) and checkpoint recovery in cells at three important phases.	Paclitaxel	74-84	homeobox C10	Homo sapiens	14-20
27131064-6	2016	In particular, the compound 5a sensitized ABCB1/Flp-In -293 cells toward paclitaxel, vincristine, and doxorubicin by 16.1, 21.0, and 1.6-fold at 10 muM, respectively.	Paclitaxel	73-83	ATP binding cassette subfamily B member 1	Homo sapiens	42-47
27648354-0	2016	Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment.	Paclitaxel	0-10	vascular endothelial growth factor A	Homo sapiens	19-23
27295567-9	2016	Collectively, our data establish a hitherto unknown liaison among MDR1, BMI1 and TIP60 and provide mechanistic insights into cisplatin-induced MDR1 expression resulting in acquired cross-resistance against paclitaxel, doxorubicin and likely other drugs.	Paclitaxel	206-216	ATP binding cassette subfamily B member 1	Homo sapiens	143-147
27302171-5	2016	We found that HOXC10 promotes survival in cells treated with doxorubicin, paclitaxel, or carboplatin by suppressing apoptosis and upregulating NF-kappaB Overexpressed HOXC10 increases S-phase-specific DNA damage repair by homologous recombination (HR) and checkpoint recovery in cells at three important phases.	Paclitaxel	74-84	homeobox C10	Homo sapiens	167-173
27376707-2	2016	The replacement of the 3"-N-benzoyl group of paclitaxel with a ferrocenoyl moiety, in particular, led to formation of an analogue that was at least one order of magnitude more potent in terms of antiproliferative activity than the parent compound (IC50 values of 0.11 versus 1.11 mum, respectively), but still preserved the classical taxane mode of action, that is, microtubule stabilisation leading to mitotic arrest.	Paclitaxel	45-55	latexin	Homo sapiens	280-283
26873069-4	2016	Our aim was to evaluate the in vitro effects of some of the anticancer agents such as cetuximab, paclitaxel, etoposide, docetaxel, and ifosfamide on the activity of hPON1 in this study.	Paclitaxel	97-107	paraoxonase 1	Homo sapiens	165-170
26913996-9	2016	We guess that when cancer cell lines arrest in G2-M by anticancer drugs like paclitaxel, Akt activates mTOR to make cells continue living, then inhibiting mTOR can enhance anticancer effects.	Paclitaxel	77-87	AKT serine/threonine kinase 1	Homo sapiens	89-92
26913996-9	2016	We guess that when cancer cell lines arrest in G2-M by anticancer drugs like paclitaxel, Akt activates mTOR to make cells continue living, then inhibiting mTOR can enhance anticancer effects.	Paclitaxel	77-87	mechanistic target of rapamycin kinase	Homo sapiens	103-107
26913996-9	2016	We guess that when cancer cell lines arrest in G2-M by anticancer drugs like paclitaxel, Akt activates mTOR to make cells continue living, then inhibiting mTOR can enhance anticancer effects.	Paclitaxel	77-87	mechanistic target of rapamycin kinase	Homo sapiens	155-159
27312786-0	2016	Neuroglobin overexpression induced by the 17beta-Estradiol-Estrogen receptor-alpha Pathway reduces the sensitivity of MCF-7 Breast cancer cell to paclitaxel.	Paclitaxel	146-156	estrogen receptor 1	Homo sapiens	59-82
27312786-2	2016	In particular, there is a wide agreement on the low sensitivity of estrogen receptor (ER) alpha-positive breast cancer to paclitaxel treatment.	Paclitaxel	122-132	estrogen receptor 1	Homo sapiens	67-84
27312786-2	2016	In particular, there is a wide agreement on the low sensitivity of estrogen receptor (ER) alpha-positive breast cancer to paclitaxel treatment.	Paclitaxel	122-132	estrogen receptor 1	Homo sapiens	86-88
27312786-4	2016	Here, the effect of the E2/ERalpha-dependent upregulation of neuroglobin (NGB), an antiapoptotic globin, on the reduced sensitivity of breast cancer cells to paclitaxel-induced apoptosis has been evaluated in ERalpha-containing MCF-7 cells.	Paclitaxel	158-168	estrogen receptor 1	Homo sapiens	27-34
27312786-5	2016	The E2 pretreatment enhances the ERalpha activity and significantly impairs paclitaxel-induced apoptosis as evaluated by Annexin V assay and PARP-1 cleavage.	Paclitaxel	76-86	poly(ADP-ribose) polymerase 1	Homo sapiens	141-147
26820129-6	2016	Moreover, the anti-AFP-scFv also effectively sensitized the HepG2 cells to paclitaxel (PTX) at a lower concentration.	Paclitaxel	87-90	alpha fetoprotein	Homo sapiens	19-22
27311481-6	2016	By contrast, SIRT2 and HDAC6 acted similarly on the morphologically different, hyperacetylated microtubule structures induced by taxol, MAP2c overexpression or hyperosmotic stress.	Paclitaxel	129-134	histone deacetylase 6	Homo sapiens	23-28
26850595-8	2016	In summary, we demonstrated that overexpression of miR-873 increased the sensitivity of ovarian cancer cells to cisplatin and paclitaxel by targeting MDR1 expression.	Paclitaxel	126-136	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	150-154
27446381-0	2016	Harmine combined with paclitaxel inhibits tumor proliferation and induces apoptosis through down-regulation of cyclooxygenase-2 expression in gastric cancer.	Paclitaxel	22-32	prostaglandin-endoperoxide synthase 2	Homo sapiens	111-127
27446381-6	2016	The combination of HM and PTX exerted synergistic effects on proliferation inhibition and apoptosis induction in SGC-7901 cells, with down-regulation of COX-2, PCNA and Bcl-2 and up-regulation of Bax expression.	Paclitaxel	26-29	prostaglandin-endoperoxide synthase 2	Homo sapiens	153-158
27446381-6	2016	The combination of HM and PTX exerted synergistic effects on proliferation inhibition and apoptosis induction in SGC-7901 cells, with down-regulation of COX-2, PCNA and Bcl-2 and up-regulation of Bax expression.	Paclitaxel	26-29	BCL2 apoptosis regulator	Homo sapiens	169-174
27446381-6	2016	The combination of HM and PTX exerted synergistic effects on proliferation inhibition and apoptosis induction in SGC-7901 cells, with down-regulation of COX-2, PCNA and Bcl-2 and up-regulation of Bax expression.	Paclitaxel	26-29	BCL2 associated X, apoptosis regulator	Homo sapiens	196-199
26820129-0	2016	A novel anti-alpha-fetoprotein single-chain variable fragment displays anti-tumor effects in HepG2 cells as a single agent or in combination with paclitaxel.	Paclitaxel	146-156	alpha fetoprotein	Homo sapiens	13-30
26820129-6	2016	Moreover, the anti-AFP-scFv also effectively sensitized the HepG2 cells to paclitaxel (PTX) at a lower concentration.	Paclitaxel	75-85	alpha fetoprotein	Homo sapiens	19-22
26820129-6	2016	Moreover, the anti-AFP-scFv also effectively sensitized the HepG2 cells to paclitaxel (PTX) at a lower concentration.	Paclitaxel	75-85	immunglobulin heavy chain variable region	Homo sapiens	23-27
26820129-6	2016	Moreover, the anti-AFP-scFv also effectively sensitized the HepG2 cells to paclitaxel (PTX) at a lower concentration.	Paclitaxel	87-90	immunglobulin heavy chain variable region	Homo sapiens	23-27
26850595-7	2016	ABCB1 overexpression reduced sensitivities of ovarian cancer lines OVCAR3 and A2780 to cisplatin and paclitaxel, which can be reversed by miR-873 mimic transfection (P &lt; 0.05).	Paclitaxel	101-111	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
27467397-0	2016	Reducing Both Pgp Overexpression and Drug Efflux with Anti-Cancer Gold-Paclitaxel Nanoconjugates.	Paclitaxel	71-81	ATP binding cassette subfamily B member 1	Homo sapiens	14-17
27502138-10	2016	CONCLUSION: DCB with paclitaxel is safe in patients with PAD, and associated with reductions in LLL, restenosis and clinically driven TLR 6-month postoperative.	Paclitaxel	21-31	toll like receptor 6	Homo sapiens	134-139
27467397-6	2016	Compared with PTX, PGNPs did not induce the Pgp overexpression in drug-sensitive H460 cells after long-term treatment and also avoided being pumped out of cells by overexpressed Pgp molecules in H460PTX with a 17-fold lower EC50 compared to PTX.	Paclitaxel	199-202	ATP binding cassette subfamily B member 1	Homo sapiens	178-181
27191893-6	2016	However, when stratified by chemotherapy regimen, patients whose tumors had TP53 and HR mutations demonstrated a marked survival advantage when treated with platinum and paclitaxel vs. platinum +/- cyclophosphamide (median OS of 90 months (95% CI 50-NA) vs. 29.5 months (95% CI 17.7-50.5), p = 0.0005).	Paclitaxel	170-180	tumor protein p53	Homo sapiens	76-80
27282534-5	2016	Blank and paclitaxel loaded FCD-1 and FCD-2 nanoparticles remained within the range of 70-275nm and 125-185nm, respectively.	Paclitaxel	10-20	FECD2	Homo sapiens	28-33
27282534-5	2016	Blank and paclitaxel loaded FCD-1 and FCD-2 nanoparticles remained within the range of 70-275nm and 125-185nm, respectively.	Paclitaxel	10-20	FECD3	Homo sapiens	38-43
27332148-3	2016	In this study, we prepared a nanovehicle for codelivery of photosensitizer (pyropheophorbide-a, PPa) and chemo-drugs (paclitaxel, PTX) based on the synthesis of PPa-conjugated amphiphilic copolymer PPa-PLA-PEG-PLA-PPa.	Paclitaxel	118-128	preproenkephalin	Mus musculus	161-164
27454930-12	2016	CONCLUSIONS: The EndoTAG-1 and paclitaxel combination showed promising preliminary activity as preoperative treatment, especially in ER-/HER2- patients.	Paclitaxel	31-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
29599904-5	2018	BHPI increased sensitivity of MDR1 overexpressing multidrug resistant OVCAR-3 ovarian cancer cells to killing by paclitaxel by &gt;1,000 fold.	Paclitaxel	113-123	ATP binding cassette subfamily B member 1	Homo sapiens	30-34
26873489-10	2016	Moreover, CAT combination caused an antagonism in paclitaxel anticancer effect.	Paclitaxel	50-60	catalase	Homo sapiens	10-13
26883251-7	2016	Under different concentrations of 5-FU and paclitaxel in MDA-MB231 cell, E-cadherin mRNA and protein expressions increased gradually with the increase of concentrations, and Vimentin and N-cadherin mRNA and protein expressions decreased gradually with the decrease of concentrations (all P &lt; 0.05).	Paclitaxel	43-53	cadherin 1	Homo sapiens	73-83
27332148-3	2016	In this study, we prepared a nanovehicle for codelivery of photosensitizer (pyropheophorbide-a, PPa) and chemo-drugs (paclitaxel, PTX) based on the synthesis of PPa-conjugated amphiphilic copolymer PPa-PLA-PEG-PLA-PPa.	Paclitaxel	118-128	preproenkephalin	Mus musculus	161-164
27332148-3	2016	In this study, we prepared a nanovehicle for codelivery of photosensitizer (pyropheophorbide-a, PPa) and chemo-drugs (paclitaxel, PTX) based on the synthesis of PPa-conjugated amphiphilic copolymer PPa-PLA-PEG-PLA-PPa.	Paclitaxel	118-128	preproenkephalin	Mus musculus	161-164
27351223-3	2016	Cathepsin L (CTSL) is overexpressed in various cancers, however, the association between CTSL expression and paclitaxel resistance remains unclear.	Paclitaxel	109-119	cathepsin L	Homo sapiens	0-11
27150036-1	2016	Our recent finding that paclitaxel behaves as a peptidomimetic of the endogenous protein Nur77 inspired the design of two peptides (PEP1 and PEP2) reproducing the effects of paclitaxel on Bcl-2 and tubulin, proving the peptidomimetic nature of paclitaxel.	Paclitaxel	24-34	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
27150036-1	2016	Our recent finding that paclitaxel behaves as a peptidomimetic of the endogenous protein Nur77 inspired the design of two peptides (PEP1 and PEP2) reproducing the effects of paclitaxel on Bcl-2 and tubulin, proving the peptidomimetic nature of paclitaxel.	Paclitaxel	24-34	BCL2 apoptosis regulator	Homo sapiens	188-193
27150036-1	2016	Our recent finding that paclitaxel behaves as a peptidomimetic of the endogenous protein Nur77 inspired the design of two peptides (PEP1 and PEP2) reproducing the effects of paclitaxel on Bcl-2 and tubulin, proving the peptidomimetic nature of paclitaxel.	Paclitaxel	174-184	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
27150036-1	2016	Our recent finding that paclitaxel behaves as a peptidomimetic of the endogenous protein Nur77 inspired the design of two peptides (PEP1 and PEP2) reproducing the effects of paclitaxel on Bcl-2 and tubulin, proving the peptidomimetic nature of paclitaxel.	Paclitaxel	174-184	nuclear receptor subfamily 4 group A member 1	Homo sapiens	89-94
27216424-7	2016	It has been found that quercetin and rutin were the highly desirable flavonoids for the inhibition of P-gp transport function and they significantly reduced resistance in cytotoxicity assays to paclitaxel in P-gp overexpressing MDR cell lines.	Paclitaxel	194-204	ATP binding cassette subfamily B member 1	Homo sapiens	208-212
27351223-4	2016	In the present study, we investigated the role of CTSL in paclitaxel-resistant SKOV3/TAX cells by CTSL silencing.	Paclitaxel	58-68	cathepsin L	Homo sapiens	50-54
27351223-9	2016	Knocking-down of CTSL in ovarian cancer cells could decrease cell proliferation, migration, and invasion, and potentiate apoptosis induced by paclitaxel, suggesting CTSL may contribute to Paclitaxel resistance in ovarian cancer.	Paclitaxel	188-198	cathepsin L	Homo sapiens	17-21
27351223-9	2016	Knocking-down of CTSL in ovarian cancer cells could decrease cell proliferation, migration, and invasion, and potentiate apoptosis induced by paclitaxel, suggesting CTSL may contribute to Paclitaxel resistance in ovarian cancer.	Paclitaxel	188-198	cathepsin L	Homo sapiens	165-169
27351223-4	2016	In the present study, we investigated the role of CTSL in paclitaxel-resistant SKOV3/TAX cells by CTSL silencing.	Paclitaxel	58-68	cathepsin L	Homo sapiens	98-102
27351223-8	2016	Western blot analysis showed that the CTSL was overexpressed in SKOV3/TAX cells and weakly detectable in paclitaxel-sensitive SKOV3 cells.	Paclitaxel	105-115	cathepsin L	Homo sapiens	38-42
27351223-9	2016	Knocking-down of CTSL in ovarian cancer cells could decrease cell proliferation, migration, and invasion, and potentiate apoptosis induced by paclitaxel, suggesting CTSL may contribute to Paclitaxel resistance in ovarian cancer.	Paclitaxel	142-152	cathepsin L	Homo sapiens	17-21
27288915-3	2016	PURPOSE: This study aims to investigate the anti-cancer potential of alisol B 23-acetate (AB23), a protostane-type triterpene isolated from the Alismatis Rhizoma, in the parental and paclitaxel-resistant ovarian cancer cells.	Paclitaxel	183-193	NBPF member 1	Homo sapiens	69-88
27288915-3	2016	PURPOSE: This study aims to investigate the anti-cancer potential of alisol B 23-acetate (AB23), a protostane-type triterpene isolated from the Alismatis Rhizoma, in the parental and paclitaxel-resistant ovarian cancer cells.	Paclitaxel	183-193	NBPF member 1	Homo sapiens	90-94
27420038-6	2016	Homoharringtonine did not show any effects on microtubules and cell cycle, while the known microtubule-stabilizing agent paclitaxel was found to inhibit tubulin polymerization in the presence of MAPs in vitro with an IC50 value of 38.19 +- 3.33 muM.	Paclitaxel	121-131	latexin	Homo sapiens	245-248
27259248-0	2016	Study of single nucleotide polymorphisms of FBW7 and its substrate genes revealed a predictive factor for paclitaxel plus cisplatin chemotherapy in Chinese patients with advanced esophageal squamous cell carcinoma.	Paclitaxel	106-116	F-box and WD repeat domain containing 7	Homo sapiens	44-48
27259248-3	2016	This work was conducted to investigate the association of genetic polymorphisms in FBW7 and its substrate genes and the clinical response of paclitaxel.	Paclitaxel	141-151	F-box and WD repeat domain containing 7	Homo sapiens	83-87
27259248-6	2016	Statistical analysis revealed that patients with mTOR rs1057079 AG (ORadjusted: 4.59; 95% CI: 1.78-11.86) genotype had significant correlation with the clinical response of paclitaxel when compared with AA genotype after adjustment for sex, age, and chemotherapy cycle.	Paclitaxel	173-183	mechanistic target of rapamycin kinase	Homo sapiens	49-53
27304668-0	2016	Glaucarubinone sensitizes KB cells to paclitaxel by inhibiting ABC transporters via ROS-dependent and p53-mediated activation of apoptotic signaling pathways.	Paclitaxel	38-48	tumor protein p53	Homo sapiens	102-105
27091714-10	2016	An alternative regimen in a lower-risk, node-negative, HER2-positive population is paclitaxel and trastuzumab once per week for 12 cycles.	Paclitaxel	83-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
27305462-7	2016	After integrating paclitaxel into the structure, cell viability, cell cycle progression, and radiosensitivity studies demonstrate HER2/neu targeting polymers were most effective to inhibit cell proliferation.	Paclitaxel	18-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-134
27304668-3	2016	Our data showed that the administration of GLU pre-treatment significantly enhanced PTX anti-proliferative effect in ABCB1 over-expressing KB cells.	Paclitaxel	84-87	ATP binding cassette subfamily B member 1	Homo sapiens	117-122
27304668-9	2016	Importantly, GLU and/or PTX triggered apoptosis through the activation of pro-apoptotic proteins such as p53, Bax, and caspase-9.	Paclitaxel	24-27	tumor protein p53	Homo sapiens	105-108
27304668-9	2016	Importantly, GLU and/or PTX triggered apoptosis through the activation of pro-apoptotic proteins such as p53, Bax, and caspase-9.	Paclitaxel	24-27	BCL2 associated X, apoptosis regulator	Homo sapiens	110-113
27306421-0	2016	Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.	Paclitaxel	7-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
27130953-4	2016	F56 peptide-conjugated paclitaxel-loaded nanoparticles (F56-PTX-NP) were formulated from PEGylated polylactide using an oil in water emulsion approach.	Paclitaxel	23-33	DLEC1 cilia and flagella associated protein	Homo sapiens	0-3
27130953-4	2016	F56 peptide-conjugated paclitaxel-loaded nanoparticles (F56-PTX-NP) were formulated from PEGylated polylactide using an oil in water emulsion approach.	Paclitaxel	23-33	DLEC1 cilia and flagella associated protein	Homo sapiens	56-59
27306421-1	2016	We previously reported progression-free survival (PFS) results on a phase II trial of weekly paclitaxel, trastuzumab, and pertuzumab in patients with human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer (MBC) treated in the first- and second-line setting.	Paclitaxel	93-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	156-190
27306421-1	2016	We previously reported progression-free survival (PFS) results on a phase II trial of weekly paclitaxel, trastuzumab, and pertuzumab in patients with human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer (MBC) treated in the first- and second-line setting.	Paclitaxel	93-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	191-195
27166151-0	2016	Paclitaxel-induced increase in NCX activity in subpopulations of nociceptive afferents: A protective mechanism against chemotherapy-induced peripheral neuropathy?	Paclitaxel	0-10	solute carrier family 8 member A1	Rattus norvegicus	31-34
27060927-11	2016	CDX2 induced MDR1-dependent resistance to vincristine and paclitaxel, which was reversed by treatment with the MDR1-specific inhibitor verapamil.	Paclitaxel	58-68	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
27060927-11	2016	CDX2 induced MDR1-dependent resistance to vincristine and paclitaxel, which was reversed by treatment with the MDR1-specific inhibitor verapamil.	Paclitaxel	58-68	ATP binding cassette subfamily B member 1	Homo sapiens	111-115
27166151-6	2016	More interestingly, there was a paclitaxel-induced increase in NCX activity in putative nociceptive neurons innervating the thigh, neurons in which there is no evidence of a change in the depolarization-induced Ca(2+) transient, or a body site in which there was a change in nociceptive threshold.	Paclitaxel	32-42	solute carrier family 8 member A1	Rattus norvegicus	63-66
27166151-8	2016	These results suggest that a mechanism(s) other than NCX underlies the paclitaxel-induced decrease in the duration of the evoked Ca(2+) transient in putative nociceptive glabrous skin neurons.	Paclitaxel	71-81	solute carrier family 8 member A1	Rattus norvegicus	53-56
26979998-2	2016	Recent reports showed that paclitaxel treatment results in the activation of Toll-like receptor 4 (TLR4) signaling and increased expression of monocyte chemoattractant protein 1 (MCP-1) in dorsal root ganglion cells.	Paclitaxel	27-37	toll-like receptor 4	Mus musculus	77-97
27151574-6	2016	Moreover, DEX significantly enhanced cell resistance to the chemotherapeutic agent paclitaxel (PTX) by activating PI-3K-Akt pathway.	Paclitaxel	83-93	AKT serine/threonine kinase 1	Homo sapiens	120-123
27151574-6	2016	Moreover, DEX significantly enhanced cell resistance to the chemotherapeutic agent paclitaxel (PTX) by activating PI-3K-Akt pathway.	Paclitaxel	95-98	AKT serine/threonine kinase 1	Homo sapiens	120-123
27120977-6	2016	In vitro, BAG3 knockdown in ES2 clear ovarian cancer cells significantly increased the efficacy of paclitaxel in combination with the Mcl-1 antagonist MIM1, with or without the Bcl-2 family antagonist ABT737.	Paclitaxel	99-109	BAG cochaperone 3	Homo sapiens	10-14
27120977-6	2016	In vitro, BAG3 knockdown in ES2 clear ovarian cancer cells significantly increased the efficacy of paclitaxel in combination with the Mcl-1 antagonist MIM1, with or without the Bcl-2 family antagonist ABT737.	Paclitaxel	99-109	ess-2 splicing factor homolog	Homo sapiens	28-31
27120977-9	2016	In BAG3 knockdown ES2 clear ovarian cancer cells, combination with ABT737 and MIM1 enhanced the efficacy of paclitaxel.	Paclitaxel	108-118	BAG cochaperone 3	Homo sapiens	3-7
27120977-9	2016	In BAG3 knockdown ES2 clear ovarian cancer cells, combination with ABT737 and MIM1 enhanced the efficacy of paclitaxel.	Paclitaxel	108-118	ess-2 splicing factor homolog	Homo sapiens	18-21
27120977-9	2016	In BAG3 knockdown ES2 clear ovarian cancer cells, combination with ABT737 and MIM1 enhanced the efficacy of paclitaxel.	Paclitaxel	108-118	MER1 repeat containing imprinted transcript 1	Homo sapiens	78-82
26979998-2	2016	Recent reports showed that paclitaxel treatment results in the activation of Toll-like receptor 4 (TLR4) signaling and increased expression of monocyte chemoattractant protein 1 (MCP-1) in dorsal root ganglion cells.	Paclitaxel	27-37	toll-like receptor 4	Mus musculus	99-103
26979998-7	2016	Intrathecal treatment with the TLR4 antagonist lipopolysaccharide-RS (LPS-RS) blocked mechanical hypersensitivity, reduced MCP-1 expression, and blocked the infiltration of macrophages into the DRG in paclitaxel-treated rats.	Paclitaxel	201-211	toll-like receptor 4	Rattus norvegicus	31-35
26979998-9	2016	These results are the first to indicate a mechanistic link such that activation of TLR4 by paclitaxel leads to increased expression of MCP-1 by DRG neurons resulting in macrophage infiltration to the DRG that express inflammatory cytokines and the combination of these events results in IENF loss and the development of behavioral signs of CIPN.	Paclitaxel	91-101	toll-like receptor 4	Rattus norvegicus	83-87
27196755-7	2016	We also show that combined treatments with paclitaxel and Wnt/beta-catenin or Akt inhibitors improve the apoptotic response to paclitaxel, even in the absence of PKCdelta.	Paclitaxel	127-137	AKT serine/threonine kinase 1	Homo sapiens	78-81
26869361-0	2016	Low-dose paclitaxel ameliorates renal fibrosis by suppressing transforming growth factor-beta1-induced plasminogen activator inhibitor-1 signaling.	Paclitaxel	9-19	transforming growth factor, beta 1	Rattus norvegicus	62-94
26869361-8	2016	RESULTS: In the UUO kidneys, paclitaxel significantly attenuated tubular damage and interstitial collagen deposition, as well as alpha-smooth muscle actin (alpha-SMA), TGF-beta1 and PAI-1 protein expression.	Paclitaxel	29-39	serpin family E member 1	Rattus norvegicus	182-187
26869361-0	2016	Low-dose paclitaxel ameliorates renal fibrosis by suppressing transforming growth factor-beta1-induced plasminogen activator inhibitor-1 signaling.	Paclitaxel	9-19	serpin family E member 1	Rattus norvegicus	103-136
26869361-11	2016	In TGF-beta1-treated IMCD cells, treatment with 1 and 2 nM paclitaxel for 72 h reduced fibronectin, alpha-SMA and PAI-1 protein expression.	Paclitaxel	59-69	transforming growth factor, beta 1	Rattus norvegicus	3-12
26869361-11	2016	In TGF-beta1-treated IMCD cells, treatment with 1 and 2 nM paclitaxel for 72 h reduced fibronectin, alpha-SMA and PAI-1 protein expression.	Paclitaxel	59-69	serpin family E member 1	Rattus norvegicus	114-119
27462592-10	2016	And growth inhibition of OVCAR3 CD44(+)CD117(+) cells by paclitaxel combined with salinomycin was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay.	Paclitaxel	57-67	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	39-44
26869361-12	2016	Moreover, a 2 nM dose of paclitaxel for 24 h significantly inhibited the TGF-beta1-stimulated activation of Smad2/3, JNK and ERK1/2 in IMCD cells.	Paclitaxel	25-35	transforming growth factor, beta 1	Rattus norvegicus	73-82
26869361-13	2016	CONCLUSION: Paclitaxel at low non-cytotoxic doses ameliorates renal fibrosis by inhibiting multiple steps in the TGF-beta1-induced PAI-1 signaling including Smads and mitogen-activated protein kinases.	Paclitaxel	12-22	transforming growth factor, beta 1	Rattus norvegicus	113-122
26869361-13	2016	CONCLUSION: Paclitaxel at low non-cytotoxic doses ameliorates renal fibrosis by inhibiting multiple steps in the TGF-beta1-induced PAI-1 signaling including Smads and mitogen-activated protein kinases.	Paclitaxel	12-22	serpin family E member 1	Rattus norvegicus	131-136
27462592-12	2016	Treatment with a combination of paclitaxel and salinomycin demonstrated growth inhibition of OVCAR3 CD44(+)CD117(+) cells.	Paclitaxel	32-42	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	107-112
26810068-4	2016	Here, we showed that suppression of GRIM-19 by shRNA enhanced cell-type-dependent autophagy by activating extracellular regulated protein kinase (ERK) and hypoxia inducible factor-1a (HIF-1a) in a reactive oxygen species (ROS)-mediated manner, and thereby conferred resistance to paclitaxel.	Paclitaxel	280-290	mitogen-activated protein kinase 1	Homo sapiens	146-149
26810068-4	2016	Here, we showed that suppression of GRIM-19 by shRNA enhanced cell-type-dependent autophagy by activating extracellular regulated protein kinase (ERK) and hypoxia inducible factor-1a (HIF-1a) in a reactive oxygen species (ROS)-mediated manner, and thereby conferred resistance to paclitaxel.	Paclitaxel	280-290	hypoxia inducible factor 1 subunit alpha	Homo sapiens	184-190
27223427-0	2016	Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer.	Paclitaxel	166-176	erb-b2 receptor tyrosine kinase 2	Homo sapiens	200-205
27445484-1	2016	BACKGROUND: The combined therapy of bevacizumab (BEV) with taxane (paclitaxel or docetaxel) has shown an improvement on progression-free survival (PFS) and objective remission in Her2-negative patients with locally recurrent or metastatic breast cancer (LR/MBC).	Paclitaxel	67-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	179-183
27223427-2	2016	In the present study, we applied a pharmacometabolomics approach to identify biomarkers potentially associated with pathological complete response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer patients.	Paclitaxel	162-172	erb-b2 receptor tyrosine kinase 2	Homo sapiens	196-201
26976343-0	2016	STAT3-dependent TXNDC17 expression mediates Taxol resistance through inducing autophagy in human colorectal cancer cells.	Paclitaxel	44-49	signal transducer and activator of transcription 3	Homo sapiens	0-5
27336622-8	2016	Employing non-site-specific, amine-reactive chemistry, our novel biopharmaceutical theranostic is a monoclonal antibody specific for a carcinoembryonic antigen (CEA) biomarker conjugated to both paclitaxel and a near-infrared (NIR), polyethylene glycol modified (PEGylated) fluorophore (DyLight  680-4xPEG).	Paclitaxel	195-205	CEA cell adhesion molecule 3	Homo sapiens	135-159
27336622-8	2016	Employing non-site-specific, amine-reactive chemistry, our novel biopharmaceutical theranostic is a monoclonal antibody specific for a carcinoembryonic antigen (CEA) biomarker conjugated to both paclitaxel and a near-infrared (NIR), polyethylene glycol modified (PEGylated) fluorophore (DyLight  680-4xPEG).	Paclitaxel	195-205	CEA cell adhesion molecule 3	Homo sapiens	161-164
26976343-8	2016	Taxol exposure induced high levels of phospho-STAT3 (Tyr 705) and TXNDC17; and increase of basal autophagy in colorectal cancer cells.	Paclitaxel	0-5	signal transducer and activator of transcription 3	Homo sapiens	46-51
27277231-4	2016	Remarkably, mutant SOD1-triggered Golgi fragmentation and Golgi SNARE accumulation are recapitulated by Stathmin 1/2 overexpression but completely rescued by Stathmin 1/2 knockdown or the microtubule-stabilizing drug Taxol.	Paclitaxel	217-222	superoxide dismutase 1, soluble	Mus musculus	19-23
27284014-0	2016	Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation.	Paclitaxel	45-55	ATP binding cassette subfamily B member 1	Homo sapiens	144-149
27153547-7	2016	Additionally, ERRalpha knockdown sensitized cells to paclitaxel.	Paclitaxel	53-63	estrogen related receptor alpha	Homo sapiens	14-22
27284014-0	2016	Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation.	Paclitaxel	45-55	forkhead box O3	Homo sapiens	128-134
27284014-2	2016	The correlation of point mutations in class III beta-tubulin (TUBB3) and the prominent overexpression of ATP-binding cassette P-glycoprotein (ABCB1), a multidrug resistance gene, have been protruding mechanisms of resistance to microtubule disruptors such as paclitaxel (PTX) for many cancers.	Paclitaxel	259-269	ATP binding cassette subfamily B member 1	Homo sapiens	126-140
27284014-2	2016	The correlation of point mutations in class III beta-tubulin (TUBB3) and the prominent overexpression of ATP-binding cassette P-glycoprotein (ABCB1), a multidrug resistance gene, have been protruding mechanisms of resistance to microtubule disruptors such as paclitaxel (PTX) for many cancers.	Paclitaxel	259-269	ATP binding cassette subfamily B member 1	Homo sapiens	142-147
27284014-2	2016	The correlation of point mutations in class III beta-tubulin (TUBB3) and the prominent overexpression of ATP-binding cassette P-glycoprotein (ABCB1), a multidrug resistance gene, have been protruding mechanisms of resistance to microtubule disruptors such as paclitaxel (PTX) for many cancers.	Paclitaxel	271-274	ATP binding cassette subfamily B member 1	Homo sapiens	126-140
27284014-2	2016	The correlation of point mutations in class III beta-tubulin (TUBB3) and the prominent overexpression of ATP-binding cassette P-glycoprotein (ABCB1), a multidrug resistance gene, have been protruding mechanisms of resistance to microtubule disruptors such as paclitaxel (PTX) for many cancers.	Paclitaxel	271-274	ATP binding cassette subfamily B member 1	Homo sapiens	142-147
27284014-4	2016	We determined that our established PTX-resistant cancer cells display ABCB1/ABCC1-associated cross-resistance to chemically different drugs such as 5-fluorouracil, docetaxel, and cisplatin.	Paclitaxel	35-38	ATP binding cassette subfamily B member 1	Homo sapiens	70-75
27284014-4	2016	We determined that our established PTX-resistant cancer cells display ABCB1/ABCC1-associated cross-resistance to chemically different drugs such as 5-fluorouracil, docetaxel, and cisplatin.	Paclitaxel	35-38	ATP binding cassette subfamily C member 1	Homo sapiens	76-81
27284014-5	2016	We found that feedback activation of TUBB3 can be triggered through the FOXO3a-dependent regulation of ABCB1, which resulted in the accentuation of induced PTX resistance and encouraged multiplicity in acquired cross-resistance.	Paclitaxel	156-159	forkhead box O3	Homo sapiens	72-78
27284014-5	2016	We found that feedback activation of TUBB3 can be triggered through the FOXO3a-dependent regulation of ABCB1, which resulted in the accentuation of induced PTX resistance and encouraged multiplicity in acquired cross-resistance.	Paclitaxel	156-159	ATP binding cassette subfamily B member 1	Homo sapiens	103-108
27284014-9	2016	In addition, we found that secretome factors from PTX-resistant cancer cells with acquired cross-resistance support a P-gp-dependent association in multidrug resistance (MDR) development, which assisted the FOXO3a-mediated control of TUBB3 feedback.	Paclitaxel	50-53	ATP binding cassette subfamily B member 1	Homo sapiens	118-122
27284014-9	2016	In addition, we found that secretome factors from PTX-resistant cancer cells with acquired cross-resistance support a P-gp-dependent association in multidrug resistance (MDR) development, which assisted the FOXO3a-mediated control of TUBB3 feedback.	Paclitaxel	50-53	forkhead box O3	Homo sapiens	207-213
27272808-0	2016	Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.	Paclitaxel	128-138	vascular endothelial growth factor A	Homo sapiens	0-34
27255186-0	2016	Alpha fetoprotein antagonizes apoptosis induced by paclitaxel in hepatoma cells in vitro.	Paclitaxel	51-61	alpha fetoprotein	Homo sapiens	0-17
27255186-3	2016	HLE cells and L-02 cells resisted the cytotoxicity of paclitaxel when transfected with pcDNA3.1-afp vectors.	Paclitaxel	54-64	alpha fetoprotein	Homo sapiens	96-99
27255186-4	2016	However, Bel 7402 cell sensitivity to paclitaxel was increased when transfected with alpha fetoprotein (AFP)-siRNA.	Paclitaxel	38-48	alpha fetoprotein	Homo sapiens	85-102
27255186-4	2016	However, Bel 7402 cell sensitivity to paclitaxel was increased when transfected with alpha fetoprotein (AFP)-siRNA.	Paclitaxel	38-48	alpha fetoprotein	Homo sapiens	104-107
27255186-6	2016	Paclitaxel significantly inhibited growth and promoted apoptosis in HLE cells and L-02 cells by inducing fragmentation of caspase-3 and inhibiting the expression of Ras and Survivin, but pcDNA3.1-afp vectors prevented these effects.	Paclitaxel	0-10	caspase 3	Homo sapiens	122-131
27255186-6	2016	Paclitaxel significantly inhibited growth and promoted apoptosis in HLE cells and L-02 cells by inducing fragmentation of caspase-3 and inhibiting the expression of Ras and Survivin, but pcDNA3.1-afp vectors prevented these effects.	Paclitaxel	0-10	alpha fetoprotein	Homo sapiens	196-199
27255186-8	2016	Silenced expression of AFP may be synergistic with paclitaxel to restrain proliferation and induce apoptosis, enhance cleavage of caspase-3, and suppress the expression of Ras and Survivin.	Paclitaxel	51-61	alpha fetoprotein	Homo sapiens	23-26
27255186-8	2016	Silenced expression of AFP may be synergistic with paclitaxel to restrain proliferation and induce apoptosis, enhance cleavage of caspase-3, and suppress the expression of Ras and Survivin.	Paclitaxel	51-61	caspase 3	Homo sapiens	130-139
27255186-9	2016	Taken together, AFP may be an important molecule acting against paclitaxel-inhibited proliferation and induced apoptosis in HCC cells via repressing the activity of caspase-3 and stimulating the expression of Ras and Survivin.	Paclitaxel	64-74	alpha fetoprotein	Homo sapiens	16-19
27255186-9	2016	Taken together, AFP may be an important molecule acting against paclitaxel-inhibited proliferation and induced apoptosis in HCC cells via repressing the activity of caspase-3 and stimulating the expression of Ras and Survivin.	Paclitaxel	64-74	caspase 3	Homo sapiens	165-174
27255186-10	2016	Targeted inhibition of AFP expression after treatment with paclitaxel is an available strategy for the therapy of patients with HCC.	Paclitaxel	59-69	alpha fetoprotein	Homo sapiens	23-26
27100344-8	2016	Finally, we conjugated an EGFR-targeting peptide to obtain conjugates of paclitaxel, branched PEG, and EGFR-targeting peptide.	Paclitaxel	73-83	epidermal growth factor receptor	Homo sapiens	26-30
27338042-12	2016	CONCLUSIONS: MiR-18a upregulation results in enhanced autophagy via inhibiting mTOR signaling pathway in TNBC cells, which is a mechanism contributing to paclitaxel resistance.	Paclitaxel	154-164	mechanistic target of rapamycin kinase	Homo sapiens	79-83
27035628-6	2016	In this investigation we showed that intracellular delivery of c-ROS1-targeting siRNA using pH-sensitive inorganic nanoparticles of carbonate apatite sensitizes mouse breast cancer cells (4T1) to doxorubicin, but not to cisplatin or paclitaxel, with the highest enhancement in chemosensitivity obtained at 40 nM of the drug concentration.	Paclitaxel	233-243	Ros1 proto-oncogene	Mus musculus	63-69
26662632-1	2016	BACKGROUND: Substance P contributes to the hypersensitivity reaction (HSR) to paclitaxel in a rat model.	Paclitaxel	78-88	tachykinin precursor 1	Homo sapiens	12-23
26662632-2	2016	Aprepitant acts as an inhibitor of the binding of substance P to the neurokinin-1 receptor and, consequently, may reduce the frequency of paclitaxel-induced HSR.	Paclitaxel	138-148	tachykinin precursor 1	Homo sapiens	50-61
26547424-1	2016	BACKGROUND: The aim of this study was to explore whether a combination of S-1 and paclitaxel offers any benefit over paclitaxel alone to patients pretreated by S-1.	Paclitaxel	82-92	proteasome 26S subunit, non-ATPase 1	Homo sapiens	160-163
26961886-0	2016	CX3CR1-Mediated Akt1 Activation Contributes to the Paclitaxel-Induced Painful Peripheral Neuropathy in Rats.	Paclitaxel	51-61	AKT serine/threonine kinase 1	Rattus norvegicus	16-20
26961886-3	2016	Here, we found that paclitaxel treatment (3 x 8 mg/kg, cumulative dose 24 mg/kg) upregulated the expression of CX3CR1 and phosphorylated Akt1 in DRG and spinal dorsal horn.	Paclitaxel	20-30	AKT serine/threonine kinase 1	Rattus norvegicus	137-141
26961886-4	2016	Blocking of Akt1 pathway activation with different inhibitor (MK-2206 or LY294002) significantly attenuated mechanical allodynia and thermal hyperalgesia induced by paclitaxel.	Paclitaxel	165-175	AKT serine/threonine kinase 1	Rattus norvegicus	12-16
26961886-6	2016	This study suggested that CX3CR1/Akt1 signaling pathway may be a potential target for prevention and reversion of the painful peripheral neuropathy induced by paclitaxel.	Paclitaxel	159-169	AKT serine/threonine kinase 1	Rattus norvegicus	33-37
27313771-9	2016	Paclitaxel treatment downregulated the expression of CTSL in SKOV-3 but not in the paclitaxel-resistant SKOV3/TAX cells.	Paclitaxel	0-10	cathepsin L	Homo sapiens	53-57
27313771-10	2016	CTSL small hairpin RNA (shRNA) knockdown significantly potentiated apoptosis induced by paclitaxel compared with SKOV3/TAX cells transfected with control shRNA, suggesting that CTSL contributes to paclitaxel resistance in ovarian cancer cells and that CTSL silencing can enhance paclitaxel-mediated cell apoptosis.	Paclitaxel	88-98	cathepsin L	Homo sapiens	0-4
27313771-10	2016	CTSL small hairpin RNA (shRNA) knockdown significantly potentiated apoptosis induced by paclitaxel compared with SKOV3/TAX cells transfected with control shRNA, suggesting that CTSL contributes to paclitaxel resistance in ovarian cancer cells and that CTSL silencing can enhance paclitaxel-mediated cell apoptosis.	Paclitaxel	197-207	cathepsin L	Homo sapiens	0-4
27313771-10	2016	CTSL small hairpin RNA (shRNA) knockdown significantly potentiated apoptosis induced by paclitaxel compared with SKOV3/TAX cells transfected with control shRNA, suggesting that CTSL contributes to paclitaxel resistance in ovarian cancer cells and that CTSL silencing can enhance paclitaxel-mediated cell apoptosis.	Paclitaxel	197-207	cathepsin L	Homo sapiens	177-181
27313771-10	2016	CTSL small hairpin RNA (shRNA) knockdown significantly potentiated apoptosis induced by paclitaxel compared with SKOV3/TAX cells transfected with control shRNA, suggesting that CTSL contributes to paclitaxel resistance in ovarian cancer cells and that CTSL silencing can enhance paclitaxel-mediated cell apoptosis.	Paclitaxel	197-207	cathepsin L	Homo sapiens	177-181
27313771-10	2016	CTSL small hairpin RNA (shRNA) knockdown significantly potentiated apoptosis induced by paclitaxel compared with SKOV3/TAX cells transfected with control shRNA, suggesting that CTSL contributes to paclitaxel resistance in ovarian cancer cells and that CTSL silencing can enhance paclitaxel-mediated cell apoptosis.	Paclitaxel	197-207	cathepsin L	Homo sapiens	0-4
27313771-10	2016	CTSL small hairpin RNA (shRNA) knockdown significantly potentiated apoptosis induced by paclitaxel compared with SKOV3/TAX cells transfected with control shRNA, suggesting that CTSL contributes to paclitaxel resistance in ovarian cancer cells and that CTSL silencing can enhance paclitaxel-mediated cell apoptosis.	Paclitaxel	197-207	cathepsin L	Homo sapiens	177-181
27313771-10	2016	CTSL small hairpin RNA (shRNA) knockdown significantly potentiated apoptosis induced by paclitaxel compared with SKOV3/TAX cells transfected with control shRNA, suggesting that CTSL contributes to paclitaxel resistance in ovarian cancer cells and that CTSL silencing can enhance paclitaxel-mediated cell apoptosis.	Paclitaxel	197-207	cathepsin L	Homo sapiens	177-181
27313771-11	2016	Thus, CTSL should be explored as a candidate of therapeutic target for modulating paclitaxel sensitivity in ovarian cancer.	Paclitaxel	82-92	cathepsin L	Homo sapiens	6-10
27262815-7	2016	Moreover, PFKFB3 modulated toll like receptor 4 (TLR4) and MyD88 expression as well as interleukin (IL)-6 and IL-8 release from breast cancer cells in response to paclitaxel exposure.	Paclitaxel	163-173	C-X-C motif chemokine ligand 8	Homo sapiens	110-114
29879343-6	2016	This study suggests that olaparib is a representative of the PARP inhibitor that can enhance Taxol"s antitumor effect in the 4T1 ectopic breast tumor model, which sets the foundation for future study of the mechanism of olaparib action.	Paclitaxel	93-98	poly(ADP-ribose) polymerase 1	Homo sapiens	61-65
27313785-0	2016	Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.	Paclitaxel	156-166	nuclear receptor subfamily 4 group A member 1	Homo sapiens	32-48
27166255-0	2016	A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells.	Paclitaxel	73-83	annexin A4	Homo sapiens	34-44
27166255-1	2016	We recently reported that Fhit is in a molecular complex with annexin A4 (ANXA4); following to their binding, Fhit delocalizes ANXA4 from plasma membrane to cytosol in paclitaxel-resistant lung cancer cells, thus restoring their chemosensitivity to the drug.	Paclitaxel	168-178	annexin A4	Homo sapiens	62-72
27166255-1	2016	We recently reported that Fhit is in a molecular complex with annexin A4 (ANXA4); following to their binding, Fhit delocalizes ANXA4 from plasma membrane to cytosol in paclitaxel-resistant lung cancer cells, thus restoring their chemosensitivity to the drug.	Paclitaxel	168-178	annexin A4	Homo sapiens	74-79
27166255-1	2016	We recently reported that Fhit is in a molecular complex with annexin A4 (ANXA4); following to their binding, Fhit delocalizes ANXA4 from plasma membrane to cytosol in paclitaxel-resistant lung cancer cells, thus restoring their chemosensitivity to the drug.	Paclitaxel	168-178	annexin A4	Homo sapiens	127-132
27166255-4	2016	Interestingly, Fhit peptide also recapitulates the property of the native protein in inhibiting Annexin A4 translocation from cytosol to plasma membrane in A549 and Calu-2 lung cancer cells treated with paclitaxel.	Paclitaxel	203-213	annexin A4	Homo sapiens	96-106
27184621-4	2016	In addition, Braf conferred increased resistance to the microtubule-stabilizing drug Taxol in narrow confinement.	Paclitaxel	85-90	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	13-17
27313785-0	2016	Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.	Paclitaxel	156-166	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-98
27313785-9	2016	Nevertheless, the fact that CDK4/6 activation remained intact in paclitaxel-resistant cells indicates that patients who have HR-positive/HER2-negative residual disease after taxane-based neoadjuvant chemotherapy may still benefit from palbociclib in combination with other regimens, such as endocrine therapies, for adjuvant therapy.	Paclitaxel	65-75	nuclear receptor subfamily 4 group A member 1	Homo sapiens	125-127
27313785-9	2016	Nevertheless, the fact that CDK4/6 activation remained intact in paclitaxel-resistant cells indicates that patients who have HR-positive/HER2-negative residual disease after taxane-based neoadjuvant chemotherapy may still benefit from palbociclib in combination with other regimens, such as endocrine therapies, for adjuvant therapy.	Paclitaxel	65-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
27159676-0	2016	MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression.	Paclitaxel	18-28	signal transducer and activator of transcription 3	Homo sapiens	77-82
27082930-2	2016	By a three-round screening process, we identified novel tricyclic pyrido[2,3-b][1,4]benzothiazepines showing potent inhibitory activity against paclitaxel-resistant cell line H460TaxR (EC50 &lt; 1.0 muM), which exhibits much less toxicity toward normal cells (EC50 &gt; 100 muM against normal human fibroblasts).	Paclitaxel	144-154	latexin	Homo sapiens	199-202
27082930-2	2016	By a three-round screening process, we identified novel tricyclic pyrido[2,3-b][1,4]benzothiazepines showing potent inhibitory activity against paclitaxel-resistant cell line H460TaxR (EC50 &lt; 1.0 muM), which exhibits much less toxicity toward normal cells (EC50 &gt; 100 muM against normal human fibroblasts).	Paclitaxel	144-154	latexin	Homo sapiens	274-277
27050375-10	2016	Moreover, STOX2 accelerated OSCC cell growth, invasion, suppressed apoptosis, and enhanced resistance to paclitaxel, cisplatin, and 5-FU.	Paclitaxel	105-115	storkhead box 2	Homo sapiens	10-15
27152196-5	2016	Moreover, curcumin, an intracellularly cleaved product of PCDA, can effectively down regulate the expression of drug efflux transporters such as P-glycoprotein (P-gp) to increase PTX accumulation within target cancer cells, thereby enhancing PTX induced cytotoxicity and therapeutic efficacy against MCF-7/ADR cells.	Paclitaxel	179-182	ATP binding cassette subfamily B member 1	Homo sapiens	145-159
27152196-5	2016	Moreover, curcumin, an intracellularly cleaved product of PCDA, can effectively down regulate the expression of drug efflux transporters such as P-glycoprotein (P-gp) to increase PTX accumulation within target cancer cells, thereby enhancing PTX induced cytotoxicity and therapeutic efficacy against MCF-7/ADR cells.	Paclitaxel	179-182	ATP binding cassette subfamily B member 1	Homo sapiens	161-165
27152196-5	2016	Moreover, curcumin, an intracellularly cleaved product of PCDA, can effectively down regulate the expression of drug efflux transporters such as P-glycoprotein (P-gp) to increase PTX accumulation within target cancer cells, thereby enhancing PTX induced cytotoxicity and therapeutic efficacy against MCF-7/ADR cells.	Paclitaxel	242-245	ATP binding cassette subfamily B member 1	Homo sapiens	145-159
27152196-5	2016	Moreover, curcumin, an intracellularly cleaved product of PCDA, can effectively down regulate the expression of drug efflux transporters such as P-glycoprotein (P-gp) to increase PTX accumulation within target cancer cells, thereby enhancing PTX induced cytotoxicity and therapeutic efficacy against MCF-7/ADR cells.	Paclitaxel	242-245	ATP binding cassette subfamily B member 1	Homo sapiens	161-165
27123064-0	2016	Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature.	Paclitaxel	128-138	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-55
26883566-2	2016	We previously demonstrated that paclitaxel alters neuronal sensitivity, in vitro, in the presence of nerve growth factor (NGF).	Paclitaxel	32-42	nerve growth factor	Homo sapiens	101-120
26883566-2	2016	We previously demonstrated that paclitaxel alters neuronal sensitivity, in vitro, in the presence of nerve growth factor (NGF).	Paclitaxel	32-42	nerve growth factor	Homo sapiens	122-125
26883566-3	2016	Evidence in the literature suggests that NGF may modulate the neurotoxic effects of paclitaxel.	Paclitaxel	84-94	nerve growth factor	Homo sapiens	41-44
26883566-4	2016	Here, we examine whether NGF modulates changes in neuronal sensitivity and morphology induced by paclitaxel and EpoB.	Paclitaxel	97-107	nerve growth factor	Homo sapiens	25-28
26883566-8	2016	In the presence of NGF, EpoB mimicked the effects of paclitaxel: capsaicin-stimulated release was attenuated, potassium-stimulated release was slightly enhanced and the total peptide content was unchanged.	Paclitaxel	53-63	nerve growth factor	Homo sapiens	19-22
26883566-9	2016	In the absence of NGF, both paclitaxel and EpoB decreased capsaicin- and potassium-stimulated release and the total peptide content, suggesting that NGF may reverse MTA-induced hyposensitivity.	Paclitaxel	28-38	nerve growth factor	Homo sapiens	149-152
27210086-0	2016	[Efficacy and Safety of Neoadjuvant Chemotherapy Containing Nanoparticle Albumin-Bound Paclitaxel (NabPTX) in Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer].	Paclitaxel	87-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-159
27210086-0	2016	[Efficacy and Safety of Neoadjuvant Chemotherapy Containing Nanoparticle Albumin-Bound Paclitaxel (NabPTX) in Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer].	Paclitaxel	99-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-159
27210086-1	2016	The efficacy and safety of nanoparticle albumin-bound paclitaxel (nabPTX)-containing neoadjuvant chemotherapy (NAC) were investigated in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancers.	Paclitaxel	66-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	193-197
27210086-2	2016	Thirteen HER2-positive patients received NAC containing nabPTX or paclitaxel between June 2008 and December 2014.	Paclitaxel	56-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
27210086-2	2016	Thirteen HER2-positive patients received NAC containing nabPTX or paclitaxel between June 2008 and December 2014.	Paclitaxel	66-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
27210086-3	2016	Of 13 HER2-positive patients, those who received nabPTX-containing NAC showed an 85.7% (6/7) pathological complete response (pCR) rate, whereas those who received paclitaxel-containing NAC showed a pCR rate of 50.0% (3/6).	Paclitaxel	49-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-10
27123064-12	2016	The present study demonstrated that neoadjuvant FEC followed by weekly administration of paclitaxel and/or trastuzumab induces a high pathological response and a high pCR rate in patients with hormone receptor-negative breast cancer.	Paclitaxel	89-99	nuclear receptor subfamily 4 group A member 1	Homo sapiens	193-209
26036724-0	2016	Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma.	Paclitaxel	82-92	transferrin	Homo sapiens	21-32
26036724-2	2016	Liposomes modified with transferrin (Tf) and cell-penetrating peptide TAT was prepared, which encapsulated two kinds of chemotherapy drugs, paclitaxel and doxorubicin (Tf/TAT-PTX/DOX-LP).	Paclitaxel	140-150	transferrin	Homo sapiens	37-39
26986870-0	2016	Paclitaxel enhances tumoricidal potential of TRAIL via inhibition of MAPK in resistant gastric cancer cells.	Paclitaxel	0-10	TNF superfamily member 10	Homo sapiens	45-50
26986870-5	2016	We found combined administration of paclitaxel (PTX) markedly enhanced TRAIL-induced apoptosis in resistant cancer cells both in vitro and in vivo.	Paclitaxel	36-46	TNF superfamily member 10	Homo sapiens	71-76
26986870-5	2016	We found combined administration of paclitaxel (PTX) markedly enhanced TRAIL-induced apoptosis in resistant cancer cells both in vitro and in vivo.	Paclitaxel	48-51	TNF superfamily member 10	Homo sapiens	71-76
26986870-10	2016	Thus, PTX-induced suppression of MAPKs may contribute to restoring TRAIL senstitivity.	Paclitaxel	6-9	TNF superfamily member 10	Homo sapiens	67-72
26986870-11	2016	Collectively, our comprehensive analyses gave new insight into the role of PTX on enhancing TRAIL sensitivity, and provided theoretical references on the development of combination treatment in TRAIL-resistant gastric cancer.	Paclitaxel	75-78	TNF superfamily member 10	Homo sapiens	92-97
26596839-11	2016	Knockdown of MyD88 reduced the proliferation, migration, and invasion of MCF-7 cells and increased the sensitivity of MCF-7 cells to paclitaxel treatment through the inhibition of activation of NF-kappaB via PI3K/Akt.	Paclitaxel	133-143	nuclear factor kappa B subunit 1	Homo sapiens	194-203
27228525-11	2016	Paclitaxel increased the levels of the catalytic subunit alpha of protein kinase A, phosphorylated nuclear factor ;kappaB, TNF- alpha, and IL-1kappa in the lumbar dorsal root ganglia.	Paclitaxel	0-10	tumor necrosis factor	Rattus norvegicus	123-133
27228525-12	2016	Pentoxifylline decreased the paclitaxel-induced TNF- alpha and IL-1beta levels.	Paclitaxel	29-39	tumor necrosis factor	Rattus norvegicus	48-58
27228525-12	2016	Pentoxifylline decreased the paclitaxel-induced TNF- alpha and IL-1beta levels.	Paclitaxel	29-39	interleukin 1 beta	Rattus norvegicus	63-71
27228525-13	2016	In addition, IL-1beta was expressed in neurons and satellite cells in the lumbar dorsal root ganglia after paclitaxel.	Paclitaxel	107-117	interleukin 1 beta	Rattus norvegicus	13-21
26596839-11	2016	Knockdown of MyD88 reduced the proliferation, migration, and invasion of MCF-7 cells and increased the sensitivity of MCF-7 cells to paclitaxel treatment through the inhibition of activation of NF-kappaB via PI3K/Akt.	Paclitaxel	133-143	AKT serine/threonine kinase 1	Homo sapiens	213-216
26608370-5	2016	In this study, we explored the effect of MPT0B169 on apoptosis in AML HL60 and NB4 cells and MDR1-mediated taxol-resistant HL60/TaxR cells and the underlying mechanism.	Paclitaxel	107-112	ATP binding cassette subfamily B member 1	Homo sapiens	93-97
26608370-12	2016	Together, these results demonstrated that MPT0B169-induced apoptosis in nonresistant and MDR1-mediated taxol-resistant AML cells through Mcl-1 downregulation and a mitochondria-mediated pathway.	Paclitaxel	103-108	ATP binding cassette subfamily B member 1	Homo sapiens	89-93
27121110-0	2016	Rhus verniciflua Stokes (RVS) and butein induce apoptosis of paclitaxel-resistant SKOV-3/PAX ovarian cancer cells through inhibition of AKT phosphorylation.	Paclitaxel	61-71	AKT serine/threonine kinase 1	Homo sapiens	136-139
27171333-6	2016	Upon identification of an ERBB2 gene amplification within the NCT MASTER (Molecularly Aided Stratification for Tumor Eradication Research) exome sequencing program with resulting overexpression of HER2 in the tumors cells, the patient received a targeted therapy with the HER2 antibodies pertuzumab and trastuzumab in combination with nab-paclitaxel, which led to a durable remission for more than one year.	Paclitaxel	339-349	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-31
27035978-9	2016	Pharmacological inhibition of MMP-13, in contrast, largely rescued paclitaxel-induced epithelial damage and neurotoxicity, whereas MMP-13 overexpression in zebrafish embryos rendered the skin vulnerable to injury under mechanical stress conditions.	Paclitaxel	67-77	matrix metallopeptidase 13a	Danio rerio	30-36
26992213-0	2016	Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel.	Paclitaxel	148-158	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-77
26992213-1	2016	Bevacizumab plus weekly paclitaxel improves progression-free survival (PFS) in HER2-negative metastatic breast cancer (mBC), but its use has been questioned due to the absence of a predictive biomarker, lack of benefit in overall survival (OS) and increased toxicity.	Paclitaxel	24-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-83
26921339-9	2016	Functionally, we showed that HIF1A-AS2 and AK124454 promoted cell proliferation and invasion in TNBC cells and contributed there to paclitaxel resistance.	Paclitaxel	132-142	HIF1A antisense RNA 2	Homo sapiens	29-38
26980709-4	2016	Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERalpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells.	Paclitaxel	43-53	estrogen receptor 1	Homo sapiens	70-77
26980709-4	2016	Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERalpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells.	Paclitaxel	55-58	estrogen receptor 1	Homo sapiens	70-77
26980709-4	2016	Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERalpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells.	Paclitaxel	170-173	estrogen receptor 1	Homo sapiens	70-77
26993770-3	2016	Here, we showed that overexpression of miR-16 promoted Taxol-induced cytotoxicity and apoptosis in breast cancer cells.	Paclitaxel	55-60	glycerophosphodiester phosphodiesterase 1	Homo sapiens	39-45
26993770-6	2016	Moreover, miR-16 was highly expressed in Taxol-sensitive breast cancer tissues compared with Taxol-resistant tissues, and there was an inverse correlation between miR-16 expression and IKBKB expression in breast cancer tissues.	Paclitaxel	41-46	glycerophosphodiester phosphodiesterase 1	Homo sapiens	10-16
26993770-6	2016	Moreover, miR-16 was highly expressed in Taxol-sensitive breast cancer tissues compared with Taxol-resistant tissues, and there was an inverse correlation between miR-16 expression and IKBKB expression in breast cancer tissues.	Paclitaxel	93-98	glycerophosphodiester phosphodiesterase 1	Homo sapiens	10-16
26993770-8	2016	Taken together, our data demonstrates that miR-16 sensitizes breast cancer cells to Taxol through the suppression of IKBKB expression, and targeting miR-16/IKBKB axis will be a promising strategy for overcoming Taxol resistance in breast cancer.	Paclitaxel	84-89	glycerophosphodiester phosphodiesterase 1	Homo sapiens	43-49
26993770-8	2016	Taken together, our data demonstrates that miR-16 sensitizes breast cancer cells to Taxol through the suppression of IKBKB expression, and targeting miR-16/IKBKB axis will be a promising strategy for overcoming Taxol resistance in breast cancer.	Paclitaxel	211-216	glycerophosphodiester phosphodiesterase 1	Homo sapiens	149-155
27090655-8	2016	Mechanism of action molecular model representations of cisplatin and paclitaxel embed the very same signaling components, and specifically proteins afflicted with the activation status of the mTOR pathway become evident, including VEGFA.	Paclitaxel	69-79	mechanistic target of rapamycin kinase	Homo sapiens	192-196
27090655-9	2016	Analyzing mechanism of action interference of the mTOR inhibitor sirolimus shows specific impact on the drug resistance signature imposed by cisplatin and paclitaxel, further holding evidence for a synthetic lethal interaction to paclitaxel mechanism of action involving cyclin D1.	Paclitaxel	155-165	mechanistic target of rapamycin kinase	Homo sapiens	50-54
27090655-9	2016	Analyzing mechanism of action interference of the mTOR inhibitor sirolimus shows specific impact on the drug resistance signature imposed by cisplatin and paclitaxel, further holding evidence for a synthetic lethal interaction to paclitaxel mechanism of action involving cyclin D1.	Paclitaxel	230-240	mechanistic target of rapamycin kinase	Homo sapiens	50-54
26930229-0	2016	Paclitaxel inhibits cell proliferation and collagen lattice contraction via TGF-beta signaling pathway in human tenon"s fibroblasts in vitro.	Paclitaxel	0-10	transforming growth factor beta 1	Homo sapiens	76-84
26930229-5	2016	The results indicate that paclitaxel could apparently inhibit the cell viability, induces the elevation of S and G2/M phases of HTFs, and downregulates the expression of both TGF-beta1 and CTGF.	Paclitaxel	26-36	transforming growth factor beta 1	Homo sapiens	175-184
26930229-7	2016	Overall, paclitaxel could apparently inhibit the proliferation of HTFs and leads to cell cycle arrest at both S and G2/M phases, attenuates the generation of collagen and collagen lattice contraction, decreases the expressions of TGF-beta1, CTGF and fibronectin EDA.	Paclitaxel	9-19	transforming growth factor beta 1	Homo sapiens	230-239
26930229-8	2016	The inhibitory mechanism of paclitaxel on HTFs is involved in TGF-beta1 signaling pathway.	Paclitaxel	28-38	transforming growth factor beta 1	Homo sapiens	62-71
26989074-4	2016	We found that the expression level of miR-137 is down-regulated in the human lung cancer tissues and the resistant cells strains: A549/paclitaxel(A549/PTX) and A549/cisplatin (A549/CDDP) when compared with lung cancer A549 cells.	Paclitaxel	135-145	microRNA 137	Homo sapiens	38-45
26581245-8	2016	DUSP1 overexpression resulted in reduced paclitaxel-induced apoptosis in ovarian cancer cells compared with control; conversely, DUSP1 gene silencing resulted in increased apoptosis compared with control cells.	Paclitaxel	41-51	dual specificity phosphatase 1	Homo sapiens	0-5
27044816-7	2016	The increase of APOBEC3B expression in Docataxel resitant and Paclitaxel resistant MCF-7 cell lines was not very high.	Paclitaxel	62-72	apolipoprotein B mRNA editing enzyme catalytic subunit 3B	Homo sapiens	16-24
26454612-0	2016	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.	Paclitaxel	28-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
27173212-10	2016	Compared with the untreated group, paclitaxel liposome inhalation and intravenous injection significantly reduced the levels of collagen types I and III and TGF-beta1 expression equally.	Paclitaxel	35-45	transforming growth factor, beta 1	Rattus norvegicus	157-166
27043783-10	2016	CONCLUSIONS: The combined treatment using wilfortrine and paclitaxel can inhibit proliferation and invasion of liver cancer cells via down-regulating Bcl-2 and up-regulating Bax, with better efficacy than single use of either drug.	Paclitaxel	58-68	BCL2 apoptosis regulator	Homo sapiens	150-155
27043783-10	2016	CONCLUSIONS: The combined treatment using wilfortrine and paclitaxel can inhibit proliferation and invasion of liver cancer cells via down-regulating Bcl-2 and up-regulating Bax, with better efficacy than single use of either drug.	Paclitaxel	58-68	BCL2 associated X, apoptosis regulator	Homo sapiens	174-177
26842845-4	2016	The activation of NF-kappaB and its dependent genes, mediated by paclitaxel and vinblastine, was completely inhibited in Profilin overexpressing cells.	Paclitaxel	65-75	nuclear factor kappa B subunit 1	Homo sapiens	18-27
26581245-9	2016	DUSP1 gene silencing in vivo significantly enhanced response to paclitaxel and increased apoptosis.	Paclitaxel	64-74	dual specificity phosphatase 1	Homo sapiens	0-5
26995790-6	2016	RESULTS: Cancer cells and tumor-associated endothelial cells expressed activated forms of AKT and MAPK in vehicle- and paclitaxel-treated groups in both metastasis models, but these proteins were downregulated in metastases of mice that received macitentan.	Paclitaxel	119-129	thymoma viral proto-oncogene 1	Mus musculus	90-93
26858237-0	2016	Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.	Paclitaxel	109-119	nuclear receptor subfamily 3 group C member 1	Homo sapiens	28-51
26858237-6	2016	Ganetespib-associated GR degradation also sensitized TNBC cells to paclitaxel-induced cell death both in vitro and in vivo.	Paclitaxel	67-77	nuclear receptor subfamily 3 group C member 1	Homo sapiens	22-24
26858237-7	2016	The beneficial effect of the Hsp90 inhibitor on paclitaxel-induced cytotoxicity was reduced when GR was depleted in TNBC cells but could be recovered with GR overexpression.	Paclitaxel	48-58	nuclear receptor subfamily 3 group C member 1	Homo sapiens	97-99
26858237-7	2016	The beneficial effect of the Hsp90 inhibitor on paclitaxel-induced cytotoxicity was reduced when GR was depleted in TNBC cells but could be recovered with GR overexpression.	Paclitaxel	48-58	nuclear receptor subfamily 3 group C member 1	Homo sapiens	155-157
26858237-8	2016	These findings suggest that GR-regulated anti-apoptotic and pro-proliferative signaling networks in TNBC are disrupted by Hsp90 inhibitors, thereby sensitizing TNBC to paclitaxel-induced cell death.	Paclitaxel	168-178	nuclear receptor subfamily 3 group C member 1	Homo sapiens	28-30
26951122-0	2016	Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer.	Paclitaxel	66-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-112
26951122-18	2016	The combination of trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel should be considered for the treatment of HER2-overexpressing breast cancer.	Paclitaxel	85-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	138-142
27198186-7	2016	Bevacizumab (Bev, anti-VEGF monoclonal antibody) is considered as one of key agent with paclitaxel and carboplatin in SCC, but not for ADC.	Paclitaxel	88-98	vascular endothelial growth factor A	Homo sapiens	23-27
26995790-7	2016	The survival-related proteins Bcl2L1, Gsta5, and Twist1 that localized to cancer cells and tumor-associated endothelial cells in vehicle- and paclitaxel-treated tumors were suppressed by macitentan.	Paclitaxel	142-152	BCL2 like 1	Homo sapiens	30-36
26995790-7	2016	The survival-related proteins Bcl2L1, Gsta5, and Twist1 that localized to cancer cells and tumor-associated endothelial cells in vehicle- and paclitaxel-treated tumors were suppressed by macitentan.	Paclitaxel	142-152	glutathione S-transferase alpha 5	Homo sapiens	38-43
26995790-7	2016	The survival-related proteins Bcl2L1, Gsta5, and Twist1 that localized to cancer cells and tumor-associated endothelial cells in vehicle- and paclitaxel-treated tumors were suppressed by macitentan.	Paclitaxel	142-152	twist family bHLH transcription factor 1	Homo sapiens	49-55
26995790-11	2016	CONCLUSIONS: Dual antagonism of ETAR and ETBR signaling sensitizes experimental brain metastases to paclitaxel and may represent a new therapeutic option for patients with brain metastases.	Paclitaxel	100-110	endothelin receptor type B	Homo sapiens	41-45
26948879-6	2016	Interestingly, spindle misorientation and NuMA mislocalization were reversed by treatment with a low dose of the microtubule-stabilizing agent paclitaxel.	Paclitaxel	143-153	nuclear mitotic apparatus protein 1	Homo sapiens	42-46
26499946-11	2016	Following paclitaxel treatment, the level of Bax was slightly increased in both cell populations, whereas Poly (ADP-ribose) polymerase (PARP) cleavage was increased only in A7-nAChR-KD cells.	Paclitaxel	10-20	BCL2 associated X, apoptosis regulator	Homo sapiens	45-48
26898799-13	2016	ES2 spheroids were highly responsive with clear additive anti-viability effects with dual taxol or cisplatin when combined with SMIFH2 treatments.	Paclitaxel	90-95	ess-2 splicing factor homolog	Homo sapiens	0-3
26898799-15	2016	Our data indicate that mDia formin inhibition combined with taxol to drive enhanced and/or additive anti-viability effects targeting 3D EOC structures, including ES2 and Skov3 spheroids.	Paclitaxel	60-65	ess-2 splicing factor homolog	Homo sapiens	162-165
27021436-0	2016	Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1.	Paclitaxel	50-60	apoptotic peptidase activating factor 1	Homo sapiens	114-119
27066372-4	2016	The DUP1 modified PTX micelle significantly enhanced the cytotoxicity of paclitaxel to PSMA negative prostate tumor cells (PC-3 cell) as demonstrated by MTT (IC50 = 15.8 mug/mL compared to 68.7 mug/mL of free PTX).	Paclitaxel	18-21	folate hydrolase 1	Homo sapiens	87-91
27066372-4	2016	The DUP1 modified PTX micelle significantly enhanced the cytotoxicity of paclitaxel to PSMA negative prostate tumor cells (PC-3 cell) as demonstrated by MTT (IC50 = 15.8 mug/mL compared to 68.7 mug/mL of free PTX).	Paclitaxel	73-83	folate hydrolase 1	Homo sapiens	87-91
26964739-15	2016	By contrast, in the carboplatin-unresponsive HOX 424 xenograft, carboplatin only modulated expression of MLH1 while carboplatin-paclitaxel treatment modulated ESR1 and pMET.	Paclitaxel	128-138	estrogen receptor 1	Homo sapiens	159-163
26709987-3	2016	METHODS: This study evaluated Reolysin combined with paclitaxel and carboplatin in patients with metastatic/recurrent KRAS-mutated or epidermal growth factor receptor (EGFR)-mutated/amplified non-small cell lung cancer.	Paclitaxel	53-63	epidermal growth factor receptor	Homo sapiens	134-166
27065850-5	2016	His disease and associated KMS had progressed previously through paclitaxel and then through liposomal doxorubicin.	Paclitaxel	65-75	MKKS centrosomal shuttling protein	Homo sapiens	27-30
26840567-8	2016	KIT+CD11b+ cells decreased in response to paclitaxel with bevacizumab, but not paclitaxel alone.	Paclitaxel	42-52	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	0-3
26985944-5	2016	Exposure of cells to PTX at concentrations &gt;= 10 nM for 18 or 24 h resulted in a significant release of cytochrome c from mitochondria to the cytosol, cleavages of procaspase 3 and poly (ADP-ribose) polymerase (PARP), and JNK activation, leading to apoptosis.	Paclitaxel	21-24	caspase 3	Homo sapiens	167-212
26985944-5	2016	Exposure of cells to PTX at concentrations &gt;= 10 nM for 18 or 24 h resulted in a significant release of cytochrome c from mitochondria to the cytosol, cleavages of procaspase 3 and poly (ADP-ribose) polymerase (PARP), and JNK activation, leading to apoptosis.	Paclitaxel	21-24	poly(ADP-ribose) polymerase 1	Homo sapiens	214-218
26985944-5	2016	Exposure of cells to PTX at concentrations &gt;= 10 nM for 18 or 24 h resulted in a significant release of cytochrome c from mitochondria to the cytosol, cleavages of procaspase 3 and poly (ADP-ribose) polymerase (PARP), and JNK activation, leading to apoptosis.	Paclitaxel	21-24	mitogen-activated protein kinase 8	Homo sapiens	225-228
26985944-7	2016	Moreover, both pharmacological JNK inhibitors SP600125 and JNK siRNA dramatically blocked PTX-induced apoptosis, cytochrome c release, caspase 3, and PARP cleavage.	Paclitaxel	90-93	mitogen-activated protein kinase 8	Homo sapiens	31-34
26985944-7	2016	Moreover, both pharmacological JNK inhibitors SP600125 and JNK siRNA dramatically blocked PTX-induced apoptosis, cytochrome c release, caspase 3, and PARP cleavage.	Paclitaxel	90-93	mitogen-activated protein kinase 8	Homo sapiens	59-62
26985944-7	2016	Moreover, both pharmacological JNK inhibitors SP600125 and JNK siRNA dramatically blocked PTX-induced apoptosis, cytochrome c release, caspase 3, and PARP cleavage.	Paclitaxel	90-93	cytochrome c, somatic	Homo sapiens	113-125
26985944-7	2016	Moreover, both pharmacological JNK inhibitors SP600125 and JNK siRNA dramatically blocked PTX-induced apoptosis, cytochrome c release, caspase 3, and PARP cleavage.	Paclitaxel	90-93	caspase 3	Homo sapiens	135-144
26985944-7	2016	Moreover, both pharmacological JNK inhibitors SP600125 and JNK siRNA dramatically blocked PTX-induced apoptosis, cytochrome c release, caspase 3, and PARP cleavage.	Paclitaxel	90-93	poly(ADP-ribose) polymerase 1	Homo sapiens	150-154
26985944-8	2016	These findings demonstrate that JNK activation plays a critical role in the induction of apoptosis mediated by PTX in human leukemia cell lines and CLL patient-derived primary cancer cells, and this event is upstream of cytochrome c release, caspase 3, and PARP cleavage.	Paclitaxel	111-114	mitogen-activated protein kinase 8	Homo sapiens	32-35
26985944-8	2016	These findings demonstrate that JNK activation plays a critical role in the induction of apoptosis mediated by PTX in human leukemia cell lines and CLL patient-derived primary cancer cells, and this event is upstream of cytochrome c release, caspase 3, and PARP cleavage.	Paclitaxel	111-114	poly(ADP-ribose) polymerase 1	Homo sapiens	257-261
26887049-5	2016	LP117, the compound that exerted the strongest effect on ABCB1, interfered in the investigated concentrations of up to 2muM with the ABCB1-mediated transport of vincristine, vinorelbine, actinomycin D, paclitaxel, and calcein-AM but not of doxorubicin, rhodamine 123, or JC-1.	Paclitaxel	202-212	ATP binding cassette subfamily B member 1	Homo sapiens	57-62
26887049-5	2016	LP117, the compound that exerted the strongest effect on ABCB1, interfered in the investigated concentrations of up to 2muM with the ABCB1-mediated transport of vincristine, vinorelbine, actinomycin D, paclitaxel, and calcein-AM but not of doxorubicin, rhodamine 123, or JC-1.	Paclitaxel	202-212	ATP binding cassette subfamily B member 1	Homo sapiens	133-138
26985944-0	2016	Paclitaxel induces apoptosis in leukemia cells through a JNK activation-dependent pathway.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	57-60
26985944-3	2016	In this paper, we focused on the role of c-Jun N-terminal kinase (JNK) pathways in PTX-induced apoptosis and proliferation inhibition.	Paclitaxel	83-86	mitogen-activated protein kinase 8	Homo sapiens	41-64
26985944-3	2016	In this paper, we focused on the role of c-Jun N-terminal kinase (JNK) pathways in PTX-induced apoptosis and proliferation inhibition.	Paclitaxel	83-86	mitogen-activated protein kinase 8	Homo sapiens	66-69
26985944-4	2016	The effects of PTX were examined in human leukemia cell lines and patients" chronic lymphocytic leukemia (CLL) cells in relation to mitochondrial events, apoptosis, and perturbation of JNK activation using flow cytometry, siRNA, mitochondrial membrane potential determination, and western blotting.	Paclitaxel	15-18	mitogen-activated protein kinase 8	Homo sapiens	185-188
26985944-5	2016	Exposure of cells to PTX at concentrations &gt;= 10 nM for 18 or 24 h resulted in a significant release of cytochrome c from mitochondria to the cytosol, cleavages of procaspase 3 and poly (ADP-ribose) polymerase (PARP), and JNK activation, leading to apoptosis.	Paclitaxel	21-24	cytochrome c, somatic	Homo sapiens	107-119
27005608-6	2016	The best compound, with potent and selective cytotoxicity (IC50 = 12.51 muM in comparison with the value 10.84 muM of paclitaxel), contains a phenothiazine moiety on ring A and a thiophene heterocycle on ring B.	Paclitaxel	118-128	latexin	Homo sapiens	111-114
26898472-8	2016	Stabilization of midzone MTs with low amounts of Taxol rescues cytokinesis in INCENP actin-binding mutant-expressing cells.	Paclitaxel	49-54	Actin 79B	Drosophila melanogaster	85-90
26840567-8	2016	KIT+CD11b+ cells decreased in response to paclitaxel with bevacizumab, but not paclitaxel alone.	Paclitaxel	79-89	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	0-3
26641474-7	2016	Transport activities of oocyte that overexpress the SLCO1B3 c.699 G&gt;A variant showed a significantly decreased uptake of paclitaxel compared with the wild-type expressing oocytes.	Paclitaxel	124-134	solute carrier organic anion transporter family member 1B3	Homo sapiens	52-59
26881937-0	2016	Regulation of Oncoprotein 18/Stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells.	Paclitaxel	82-87	mitogen-activated protein kinase 1	Homo sapiens	51-54
26881937-5	2016	These findings suggest that ERK-mediated Op18/stathmin is involved in taxol resistance of tumors; blockage of ERK signal improves the sensitivity of tumor cells to taxol, which provides new clues for treating taxol-resistant carcinomas.	Paclitaxel	70-75	mitogen-activated protein kinase 1	Homo sapiens	28-31
26881937-5	2016	These findings suggest that ERK-mediated Op18/stathmin is involved in taxol resistance of tumors; blockage of ERK signal improves the sensitivity of tumor cells to taxol, which provides new clues for treating taxol-resistant carcinomas.	Paclitaxel	164-169	mitogen-activated protein kinase 1	Homo sapiens	28-31
26881937-5	2016	These findings suggest that ERK-mediated Op18/stathmin is involved in taxol resistance of tumors; blockage of ERK signal improves the sensitivity of tumor cells to taxol, which provides new clues for treating taxol-resistant carcinomas.	Paclitaxel	164-169	mitogen-activated protein kinase 1	Homo sapiens	110-113
26881937-5	2016	These findings suggest that ERK-mediated Op18/stathmin is involved in taxol resistance of tumors; blockage of ERK signal improves the sensitivity of tumor cells to taxol, which provides new clues for treating taxol-resistant carcinomas.	Paclitaxel	164-169	mitogen-activated protein kinase 1	Homo sapiens	28-31
26881937-5	2016	These findings suggest that ERK-mediated Op18/stathmin is involved in taxol resistance of tumors; blockage of ERK signal improves the sensitivity of tumor cells to taxol, which provides new clues for treating taxol-resistant carcinomas.	Paclitaxel	164-169	mitogen-activated protein kinase 1	Homo sapiens	110-113
26179145-0	2016	Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.	Paclitaxel	39-49	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	21-27
26179145-3	2016	This study investigated the relationship between CYP3A5 polymorphisms and paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.	Paclitaxel	74-84	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	49-55
26179145-10	2016	This is the first study to verify the influence of CYP3A5 polymorphisms on paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.	Paclitaxel	75-85	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	51-57
26179145-11	2016	Our findings suggest that interindividual variability in paclitaxel/carboplatin-induced myelosuppression can be predicted by CYP3A5*3 genotyping and that incorporation of CYP3A5*3 genetic data in treatment selection could help to reduce myelosuppression events, thereby individualizing paclitaxel/carboplatin pharmacotherapy.	Paclitaxel	57-67	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	125-131
26863629-4	2016	miR-217 and CAGE oppositely regulated the response to anti-cancer drugs such as taxol, gefitinib and trastuzumab, an inhibitor of HER2.	Paclitaxel	80-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-134
25234137-0	2016	Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting.	Paclitaxel	39-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
26900348-0	2016	Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy.	Paclitaxel	60-70	TSC complex subunit 1	Homo sapiens	0-16
26900348-8	2016	RESULTS: We identified 22 TSGs involved in PTX resistance, including BRCA1, TP53, PTEN, APC, CDKN1A, CDKN2A, HIN-1, RASSF1, YAP, ING4, PLK2, FBW7, BLU, LZTS1, REST, FADD, PDCD4, TGFBI, ING1, Bax, PinX1 and hEx.	Paclitaxel	43-46	F-box and WD repeat domain containing 7	Homo sapiens	141-145
26900348-8	2016	RESULTS: We identified 22 TSGs involved in PTX resistance, including BRCA1, TP53, PTEN, APC, CDKN1A, CDKN2A, HIN-1, RASSF1, YAP, ING4, PLK2, FBW7, BLU, LZTS1, REST, FADD, PDCD4, TGFBI, ING1, Bax, PinX1 and hEx.	Paclitaxel	43-46	BCL2 associated X, apoptosis regulator	Homo sapiens	191-194
26878391-0	2016	MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression.	Paclitaxel	18-28	signal transducer and activator of transcription 3	Homo sapiens	77-82
26799187-0	2016	p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.	Paclitaxel	42-52	mitogen-activated protein kinase 14	Homo sapiens	0-3
26799187-0	2016	p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.	Paclitaxel	42-52	tumor protein p53	Homo sapiens	72-75
26799187-0	2016	p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.	Paclitaxel	42-52	epidermal growth factor receptor	Homo sapiens	99-103
26799187-6	2016	The inhibition of p38 MAPK activity by SB203580 treatment or the transfection of dominant-negative p38 MAPK sensitized both cell lines to PTX treatment.	Paclitaxel	138-141	mitogen-activated protein kinase 14	Homo sapiens	18-21
26799187-6	2016	The inhibition of p38 MAPK activity by SB203580 treatment or the transfection of dominant-negative p38 MAPK sensitized both cell lines to PTX treatment.	Paclitaxel	138-141	mitogen-activated protein kinase 14	Homo sapiens	99-102
26799187-7	2016	Erlotinib, an EGFR inhibitor, also increased PTX-induced apoptosis in PTX resistant cells, which suggests a role for p38 MAPK and EGFR in the development of PTX resistance.	Paclitaxel	45-48	epidermal growth factor receptor	Homo sapiens	14-18
26799187-7	2016	Erlotinib, an EGFR inhibitor, also increased PTX-induced apoptosis in PTX resistant cells, which suggests a role for p38 MAPK and EGFR in the development of PTX resistance.	Paclitaxel	45-48	mitogen-activated protein kinase 14	Homo sapiens	117-120
26799187-7	2016	Erlotinib, an EGFR inhibitor, also increased PTX-induced apoptosis in PTX resistant cells, which suggests a role for p38 MAPK and EGFR in the development of PTX resistance.	Paclitaxel	45-48	epidermal growth factor receptor	Homo sapiens	130-134
26799187-7	2016	Erlotinib, an EGFR inhibitor, also increased PTX-induced apoptosis in PTX resistant cells, which suggests a role for p38 MAPK and EGFR in the development of PTX resistance.	Paclitaxel	70-73	mitogen-activated protein kinase 14	Homo sapiens	117-120
26799187-7	2016	Erlotinib, an EGFR inhibitor, also increased PTX-induced apoptosis in PTX resistant cells, which suggests a role for p38 MAPK and EGFR in the development of PTX resistance.	Paclitaxel	70-73	mitogen-activated protein kinase 14	Homo sapiens	117-120
26799187-9	2016	These results suggest for the first time that the p38 MAPK/p53/EGFR axis is crucial for the facilitation of PTX resistance in NSCLCs.	Paclitaxel	108-111	mitogen-activated protein kinase 14	Homo sapiens	50-53
26799187-9	2016	These results suggest for the first time that the p38 MAPK/p53/EGFR axis is crucial for the facilitation of PTX resistance in NSCLCs.	Paclitaxel	108-111	tumor protein p53	Homo sapiens	59-62
26799187-9	2016	These results suggest for the first time that the p38 MAPK/p53/EGFR axis is crucial for the facilitation of PTX resistance in NSCLCs.	Paclitaxel	108-111	epidermal growth factor receptor	Homo sapiens	63-67
26799187-11	2016	These results provide a foundation for the future development of potential therapeutic strategies to regulate the p38 MAPK/p53/EGFR pathway for the treatment of lung cancer patients with PTX resistance.	Paclitaxel	187-190	mitogen-activated protein kinase 14	Homo sapiens	114-117
26799187-11	2016	These results provide a foundation for the future development of potential therapeutic strategies to regulate the p38 MAPK/p53/EGFR pathway for the treatment of lung cancer patients with PTX resistance.	Paclitaxel	187-190	tumor protein p53	Homo sapiens	123-126
26799187-11	2016	These results provide a foundation for the future development of potential therapeutic strategies to regulate the p38 MAPK/p53/EGFR pathway for the treatment of lung cancer patients with PTX resistance.	Paclitaxel	187-190	epidermal growth factor receptor	Homo sapiens	127-131
26878391-7	2016	Moreover, we determined that miR-125a increased paclitaxel and cisplatin sensitivity by downregulating STAT3.	Paclitaxel	48-58	signal transducer and activator of transcription 3	Homo sapiens	103-108
26809267-4	2016	The PTX- and FK506-coloaded MPEG-PCL micelles (P-F/M) were prepared by a one-step solid dispersion method without any surfactants, toxic organic solvent, or severe experimental conditions.	Paclitaxel	4-7	msh homeobox 2	Homo sapiens	47-52
26838546-7	2016	Paclitaxel/MWE also retarded tumor growth in a TSGH 8301 xenograft model via activation of PTEN and Caspase 3.	Paclitaxel	0-10	caspase 3	Homo sapiens	100-109
26809267-6	2016	Compared with A2780s cells (PTX-sensitive human ovarian cancer cells), P-F/M showed a stronger cytotoxicity and an improving intracellular drug concentration of PTX than PTX-loaded micelles (PTX/M) in A2780/T cells (PTX-resistant human ovarian cancer cells).	Paclitaxel	28-31	msh homeobox 2	Homo sapiens	71-76
26809267-6	2016	Compared with A2780s cells (PTX-sensitive human ovarian cancer cells), P-F/M showed a stronger cytotoxicity and an improving intracellular drug concentration of PTX than PTX-loaded micelles (PTX/M) in A2780/T cells (PTX-resistant human ovarian cancer cells).	Paclitaxel	161-164	msh homeobox 2	Homo sapiens	71-76
26744318-0	2016	MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.	Paclitaxel	57-67	mechanistic target of rapamycin kinase	Homo sapiens	99-103
26809267-6	2016	Compared with A2780s cells (PTX-sensitive human ovarian cancer cells), P-F/M showed a stronger cytotoxicity and an improving intracellular drug concentration of PTX than PTX-loaded micelles (PTX/M) in A2780/T cells (PTX-resistant human ovarian cancer cells).	Paclitaxel	161-164	msh homeobox 2	Homo sapiens	71-76
26744318-8	2016	Rapamycin-mediated inhibition of the mammalian target of rapamycin (mTOR), a target of miR-100, also sensitized MCF-7 cells to paclitaxel.	Paclitaxel	127-137	mechanistic target of rapamycin kinase	Homo sapiens	37-66
26809267-6	2016	Compared with A2780s cells (PTX-sensitive human ovarian cancer cells), P-F/M showed a stronger cytotoxicity and an improving intracellular drug concentration of PTX than PTX-loaded micelles (PTX/M) in A2780/T cells (PTX-resistant human ovarian cancer cells).	Paclitaxel	161-164	msh homeobox 2	Homo sapiens	71-76
26744318-8	2016	Rapamycin-mediated inhibition of the mammalian target of rapamycin (mTOR), a target of miR-100, also sensitized MCF-7 cells to paclitaxel.	Paclitaxel	127-137	mechanistic target of rapamycin kinase	Homo sapiens	68-72
26809267-6	2016	Compared with A2780s cells (PTX-sensitive human ovarian cancer cells), P-F/M showed a stronger cytotoxicity and an improving intracellular drug concentration of PTX than PTX-loaded micelles (PTX/M) in A2780/T cells (PTX-resistant human ovarian cancer cells).	Paclitaxel	161-164	msh homeobox 2	Homo sapiens	71-76
26875185-2	2016	Preclinical studies demonstrate synergy between MK-2206, a selective allosteric Akt-inhibitor, with paclitaxel and trastuzumab.	Paclitaxel	100-110	AKT serine/threonine kinase 1	Homo sapiens	80-83
26446447-9	2016	In vitro, 30-min preincubation with 100 muM clopidogrel acyl-beta-D-glucuronide inhibited the depletion rate of 0.5 muM paclitaxel by 51% and the formation rate of 6-hydroxypaclitaxel by 77%.	Paclitaxel	120-130	latexin	Homo sapiens	40-43
26446447-9	2016	In vitro, 30-min preincubation with 100 muM clopidogrel acyl-beta-D-glucuronide inhibited the depletion rate of 0.5 muM paclitaxel by 51% and the formation rate of 6-hydroxypaclitaxel by 77%.	Paclitaxel	120-130	latexin	Homo sapiens	116-119
27051389-5	2016	In contrast, the 10-year follow-up data of the E1199/Intergroup trial no longer showed any superiority of weekly paclitaxel for ER-positive/HER2-negative patients; superiority was observed in the triple-negative subgroup only.	Paclitaxel	113-123	erb-b2 receptor tyrosine kinase 2	Homo sapiens	140-144
26936755-10	2016	Neoadjuvant biweekly paclitaxel plus carboplatin is a feasible therapy that achieved high pCR rates in patients with the HER2+, triple-negative, and luminal B (HER2+) cancer subtypes (NCT0205986).	Paclitaxel	21-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
26573761-5	2016	Paclitaxel resistance was also studied after experimental downregulation of EP300 or E-cadherin.	Paclitaxel	0-10	cadherin 1	Homo sapiens	85-95
26936755-10	2016	Neoadjuvant biweekly paclitaxel plus carboplatin is a feasible therapy that achieved high pCR rates in patients with the HER2+, triple-negative, and luminal B (HER2+) cancer subtypes (NCT0205986).	Paclitaxel	21-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	160-164
26668343-6	2016	He subsequently received four cycles of paclitaxel, ifosfamide, and cisplatin for relapse in the lungs and mediastinal nodes with a rising AFP level starting in January 2011.	Paclitaxel	40-50	alpha fetoprotein	Homo sapiens	139-142
26636714-5	2016	In non-small cell lung cancer A549 cells that harbor mutant KRAS, paclitaxel and let-7b mimic-loaded nanoassemblies (N-PTX/let-7b) markedly potentiated the cytotoxicity of paclitaxel, induced apoptosis, and diminished the invasiveness of tumor cells.	Paclitaxel	66-76	microRNA let7b	Mus musculus	123-129
26636714-5	2016	In non-small cell lung cancer A549 cells that harbor mutant KRAS, paclitaxel and let-7b mimic-loaded nanoassemblies (N-PTX/let-7b) markedly potentiated the cytotoxicity of paclitaxel, induced apoptosis, and diminished the invasiveness of tumor cells.	Paclitaxel	172-182	microRNA let7b	Mus musculus	81-87
26636714-5	2016	In non-small cell lung cancer A549 cells that harbor mutant KRAS, paclitaxel and let-7b mimic-loaded nanoassemblies (N-PTX/let-7b) markedly potentiated the cytotoxicity of paclitaxel, induced apoptosis, and diminished the invasiveness of tumor cells.	Paclitaxel	172-182	microRNA let7b	Mus musculus	123-129
27382749-9	2016	In conclusion, the MDR1 gene could be silenced by siRNA-PTX-SLNs, which could promote the growth inhibition efficiency of PTX on tumor cells, leading to synergetic effect on MDR tumor therapy.	Paclitaxel	56-59	ATP binding cassette subfamily B member 1	Homo sapiens	19-23
27382749-9	2016	In conclusion, the MDR1 gene could be silenced by siRNA-PTX-SLNs, which could promote the growth inhibition efficiency of PTX on tumor cells, leading to synergetic effect on MDR tumor therapy.	Paclitaxel	122-125	ATP binding cassette subfamily B member 1	Homo sapiens	19-23
26807857-9	2016	Doxorubicin and paclitaxel both increased apoB protein levels and paclitaxel also decreased low density lipoprotein receptor (LDLR) protein levels.	Paclitaxel	16-26	apolipoprotein B	Homo sapiens	42-46
26794658-4	2016	By contrast, knockdown of HDAC1, a primary isoform of HDAC, sensitized resistant cells to paclitaxel in vitro.	Paclitaxel	90-100	histone deacetylase 1	Homo sapiens	26-31
26794658-5	2016	Furthermore, we observed that overexpression of HDAC1 was associated with the downregulation of p21, a known HDAC target, in advanced NSCLC patients with paclitaxel treatment, and predicted chemotherapy resistance and bad outcome.	Paclitaxel	154-164	histone deacetylase 1	Homo sapiens	48-53
26779808-8	2016	The c-SRC protein, an activator of MUC1-C, was also overexpressed in A549/PTX.	Paclitaxel	74-77	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	4-9
26696550-0	2016	TP53 Codon 72 Polymorphism Predicts Efficacy of Paclitaxel Plus Capecitabine Chemotherapy in Advanced Gastric Cancer Patients.	Paclitaxel	48-58	tumor protein p53	Homo sapiens	0-4
26696550-1	2016	BACKGROUND AND AIMS: The present study analyzed the relationship between TP53 codon 72 polymorphisms and the clinical outcome of advanced gastric cancer patients receiving capecitabine plus paclitaxel chemotherapy.	Paclitaxel	190-200	tumor protein p53	Homo sapiens	73-77
26696550-5	2016	RESULTS: The Pro/Pro genotypes of TP53 codon 72 were significantly correlated with a lower response rate to capecitabine plus paclitaxel chemotherapy in patients with gastric cancer when compared to the Arg/Arg genotype (30.6 vs. 63.2%, p value 0.000).	Paclitaxel	126-136	tumor protein p53	Homo sapiens	34-38
26696550-7	2016	CONCLUSIONS: TP53 codon 72 polymorphisms was effective in predicting the response to chemotherapy and correlate with PFS and OS in patients with advanced gastric cancer treated with paclitaxel and capecitabine chemotherapy.	Paclitaxel	182-192	tumor protein p53	Homo sapiens	13-17
26773176-11	2016	In paclitaxel-resistant cells, there was a significant increase in Six1 and BCL-2 mRNA levels (p = 0.0007) with a marked decrease in pro-apoptotic Bax mRNA expression level (p = 0.03); however, there was no significant change in P53 expression (p = 0.025).	Paclitaxel	3-13	BCL2 apoptosis regulator	Homo sapiens	76-81
26246283-0	2016	Enhancement of paclitaxel-induced breast cancer cell death via the glycogen synthase kinase-3beta-mediated B-cell lymphoma 2 regulation.	Paclitaxel	15-25	BCL2 apoptosis regulator	Homo sapiens	107-124
26246283-2	2016	Here, we show that B-cell lymphoma 2 (Bcl-2), an anti-apoptotic protein, is regulated by GSK-3beta and that GSK-3beta-mediated regulation of Bcl-2 is crucial for mitochondrial-dependent cell death in paclitaxel-stimulated cells.	Paclitaxel	200-210	BCL2 apoptosis regulator	Homo sapiens	19-36
26246283-2	2016	Here, we show that B-cell lymphoma 2 (Bcl-2), an anti-apoptotic protein, is regulated by GSK-3beta and that GSK-3beta-mediated regulation of Bcl-2 is crucial for mitochondrial-dependent cell death in paclitaxel-stimulated cells.	Paclitaxel	200-210	BCL2 apoptosis regulator	Homo sapiens	38-43
26246283-2	2016	Here, we show that B-cell lymphoma 2 (Bcl-2), an anti-apoptotic protein, is regulated by GSK-3beta and that GSK-3beta-mediated regulation of Bcl-2 is crucial for mitochondrial-dependent cell death in paclitaxel-stimulated cells.	Paclitaxel	200-210	BCL2 apoptosis regulator	Homo sapiens	141-146
26246283-3	2016	We demonstrate that MCF7 GSK-3beta siRNA cells are more sensitive to cell death than MCF7 GFP control cells and that in the absence of GSK-3beta, Bcl-2 levels are reduced, a result enhanced by paclitaxel.	Paclitaxel	193-203	BCL2 apoptosis regulator	Homo sapiens	146-151
26773176-11	2016	In paclitaxel-resistant cells, there was a significant increase in Six1 and BCL-2 mRNA levels (p = 0.0007) with a marked decrease in pro-apoptotic Bax mRNA expression level (p = 0.03); however, there was no significant change in P53 expression (p = 0.025).	Paclitaxel	3-13	BCL2 associated X, apoptosis regulator	Homo sapiens	147-150
26246283-4	2016	Paclitaxel-induced JNK (c-Jun N-terminal kinase) activation is critical for Bcl-2 modulation.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	19-22
26246283-4	2016	Paclitaxel-induced JNK (c-Jun N-terminal kinase) activation is critical for Bcl-2 modulation.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	24-47
26773176-11	2016	In paclitaxel-resistant cells, there was a significant increase in Six1 and BCL-2 mRNA levels (p = 0.0007) with a marked decrease in pro-apoptotic Bax mRNA expression level (p = 0.03); however, there was no significant change in P53 expression (p = 0.025).	Paclitaxel	3-13	tumor protein p53	Homo sapiens	229-232
26246283-4	2016	Paclitaxel-induced JNK (c-Jun N-terminal kinase) activation is critical for Bcl-2 modulation.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	76-81
27095936-0	2016	Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel.	Paclitaxel	120-130	BCL2 apoptosis regulator	Homo sapiens	8-12
26246283-7	2016	Taken together, our data suggest that GSK-3beta-dependent regulation of Bcl-2 is crucial for mitochondria-dependent cell death in paclitaxel-mediated breast cancer therapy.	Paclitaxel	130-140	BCL2 apoptosis regulator	Homo sapiens	72-77
27185570-11	2016	The finding that newly designed coumarins can be exploited for inhibition of P-gp mediated efflux in order to enhance paclitaxel bioavailability and can inhibit breast cancer stem cell growth is significant for designing potent anticancer drugs.	Paclitaxel	118-128	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
27095936-11	2016	However, combined treatment of everolimus and paclitaxel significantly reduced BCL2 and CCND1 mRNA expression (p &lt; 0.05).	Paclitaxel	46-56	BCL2 apoptosis regulator	Homo sapiens	79-83
26575609-7	2016	The Fat4-silenced cells which were treated with 5-FU, Cisplatin, Oxaliplatin and Paclitaxel individually demonstrated less sensitivities to these chemotherapy drugs compared with the control cells.	Paclitaxel	81-91	FAT atypical cadherin 4	Homo sapiens	4-8
27185570-0	2016	Inhibition of P-Glycoprotein Mediated Efflux of Paclitaxel by Coumarin Derivatives in Cancer Stem Cells: An In Silico Approach.	Paclitaxel	48-58	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
27095936-3	2016	In this study, we aimed to investigate the effects of everolimus, gemcitabine, and paclitaxel in terms of cell viability and mRNA expression levels of GRP78, CCND1, CASP2, and BCL2 genes.	Paclitaxel	83-93	heat shock protein family A (Hsp70) member 5	Homo sapiens	151-156
27095936-13	2016	CONCLUSIONS: Down-regulation of CCND1 and BCL2 expression may be an important mechanism by which everolimus increases the therapeutic window of paclitaxel in cervical cancers.	Paclitaxel	144-154	BCL2 apoptosis regulator	Homo sapiens	42-46
27095936-3	2016	In this study, we aimed to investigate the effects of everolimus, gemcitabine, and paclitaxel in terms of cell viability and mRNA expression levels of GRP78, CCND1, CASP2, and BCL2 genes.	Paclitaxel	83-93	BCL2 apoptosis regulator	Homo sapiens	176-180
29943935-9	2016	At the same time, the expression of WTl, bcl-2 and WTI, mRNA were significantly decreased in the paclitaxel therapy group (p &lt; 0.05).	Paclitaxel	97-107	B cell leukemia/lymphoma 2	Mus musculus	41-46
27061550-13	2016	The expression level of MCM4 was remarkably decreased under eribulin treatment relative to paclitaxel.	Paclitaxel	91-101	minichromosome maintenance complex component 4	Homo sapiens	24-28
26636340-0	2015	Overexpression of Lin28 Decreases the Chemosensitivity of Gastric Cancer Cells to Oxaliplatin, Paclitaxel, Doxorubicin, and Fluorouracil in Part via microRNA-107.	Paclitaxel	95-105	lin-28 homolog A	Homo sapiens	18-23
26539793-0	2016	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.	Paclitaxel	55-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-106
26910068-0	2016	In Vitro Approaches to Study Regulation of Hepatic Cytochrome P450 (CYP) 3A Expression by Paclitaxel and Rifampicin.	Paclitaxel	90-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-75
26910068-4	2016	In this investigation, we tested the hypothesis that induction of cytochrome P450 (Cyp)3a11 gene by paclitaxel is downregulated by the inflammatory mediator, lipopolysaccharide (LPS), and that the pro-inflammatory cytokine, tumor necrosis factor (TNF)-alpha, attenuates human CYP3A4 gene induction by rifampicin.	Paclitaxel	100-110	tumor necrosis factor	Homo sapiens	224-257
26910068-4	2016	In this investigation, we tested the hypothesis that induction of cytochrome P450 (Cyp)3a11 gene by paclitaxel is downregulated by the inflammatory mediator, lipopolysaccharide (LPS), and that the pro-inflammatory cytokine, tumor necrosis factor (TNF)-alpha, attenuates human CYP3A4 gene induction by rifampicin.	Paclitaxel	100-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	276-282
26910068-7	2016	Induction and subsequent downregulation of CYP3A enzyme can impact paclitaxel treatment in cancer patients where inflammatory mediators are activated.	Paclitaxel	67-77	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-48
26531258-0	2016	Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-kappaB signaling pathway and the expression of NF-kappaB-regulated drug-resistant genes.	Paclitaxel	24-29	nuclear factor kappa B subunit 1	Homo sapiens	82-91
26531258-0	2016	Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-kappaB signaling pathway and the expression of NF-kappaB-regulated drug-resistant genes.	Paclitaxel	24-29	nuclear factor kappa B subunit 1	Homo sapiens	132-141
26673577-3	2015	nab-paclitaxel-based regimens (with gemcitabine or carboplatin+-bevacizumab) also demonstrated efficacy and safety in first-line phase II trials of human epidermal growth factor receptor 2-negative metastatic breast cancer.	Paclitaxel	4-14	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-188
26659127-2	2015	Preclinical studies showed that epidermal growth factor receptor (EGFR)-targeted, paclitaxel-loaded minicells (EGFRminicellsPac) have antitumor effects in xenograft models.	Paclitaxel	82-92	epidermal growth factor receptor	Homo sapiens	32-64
26659127-2	2015	Preclinical studies showed that epidermal growth factor receptor (EGFR)-targeted, paclitaxel-loaded minicells (EGFRminicellsPac) have antitumor effects in xenograft models.	Paclitaxel	82-92	epidermal growth factor receptor	Homo sapiens	66-70
26534836-0	2016	Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel.	Paclitaxel	109-119	mitogen-activated protein kinase 8	Homo sapiens	29-32
26534836-3	2016	In the present study, while investigating the mechanism underlying the chemoresistance of ovarian cancer, we found that JNK may have a key role in the resistance of ovarian cancer cells to cisplatin and paclitaxel.	Paclitaxel	203-213	mitogen-activated protein kinase 8	Homo sapiens	120-123
26534836-4	2016	Importantly, whereas simultaneous application of a JNK inhibitor and either of the chemotherapeutic agents had contrasting effects for cisplatin (enhanced cytotoxicity) and paclitaxel (decreased cytotoxicity), JNK inhibitor treatment prior to chemotherapeutic agent application invariably enhanced the cytotoxicity of both drugs, suggesting that the basal JNK activity is commonly involved in the chemoresistance of ovarian cancer cells to cisplatin and paclitaxel in contrast to drug-induced JNK activity which may have different roles for these two drugs.	Paclitaxel	173-183	mitogen-activated protein kinase 8	Homo sapiens	51-54
26534836-4	2016	Importantly, whereas simultaneous application of a JNK inhibitor and either of the chemotherapeutic agents had contrasting effects for cisplatin (enhanced cytotoxicity) and paclitaxel (decreased cytotoxicity), JNK inhibitor treatment prior to chemotherapeutic agent application invariably enhanced the cytotoxicity of both drugs, suggesting that the basal JNK activity is commonly involved in the chemoresistance of ovarian cancer cells to cisplatin and paclitaxel in contrast to drug-induced JNK activity which may have different roles for these two drugs.	Paclitaxel	454-464	mitogen-activated protein kinase 8	Homo sapiens	51-54
26404750-9	2015	In addition, RYBP expression was induced by paclitaxel, the first-line chemotherapeutic agent for NSCLC.	Paclitaxel	44-54	RING1 and YY1 binding protein	Homo sapiens	13-17
26689156-2	2015	Here we found that nobiletin, a citrus methoxyflavone, significantly sensitized ABCB1 overexpressing cells A2780/T and A549/T to chemotherapeutic agents such as paclitaxel (a 433-fold reversal of MDR to PTX at 9 muM), doxorubicin (DOX), docetaxel and dounorubicin.	Paclitaxel	161-171	ATP binding cassette subfamily B member 1	Homo sapiens	80-85
26636340-3	2015	In this study, we found that transfection of Lin28 into gastric cancer cells (MKN45 and MKN28) increased their resistance to the chemo-drugs oxaliplatin (OXA), paclitaxel (PTX), doxorubicin (ADM), and fluorouracil (5-Fu) compared with gastric cancer cells transfected with a control vector.	Paclitaxel	160-170	lin-28 homolog A	Homo sapiens	45-50
26633878-0	2015	Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice.	Paclitaxel	36-46	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	76-81
26636340-3	2015	In this study, we found that transfection of Lin28 into gastric cancer cells (MKN45 and MKN28) increased their resistance to the chemo-drugs oxaliplatin (OXA), paclitaxel (PTX), doxorubicin (ADM), and fluorouracil (5-Fu) compared with gastric cancer cells transfected with a control vector.	Paclitaxel	172-175	lin-28 homolog A	Homo sapiens	45-50
26637920-9	2015	CONCLUSION: First-line bevacizumab plus chemotherapy, mainly paclitaxel, is an effective and well-tolerated treatment option for HER2-negative MBC, particularly in more aggressive disease.	Paclitaxel	61-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
26626158-3	2015	In this paper we report the in vitro and in vivo activity of a new form of paclitaxel, modified for conjugation with a tumor-selective tetrabranched peptide carrier (NT4).	Paclitaxel	75-85	neurotrophin 4	Homo sapiens	166-169
26626158-6	2015	Using in vivo bioluminescence imaging, we found that conjugation of paclitaxel with the NT4 peptide led to increased therapeutic activity of the drug in vivo.	Paclitaxel	68-78	neurotrophin 4	Homo sapiens	88-91
26626158-7	2015	NT4-paclitaxel induced tumor regression, whereas treatment with unconjugated paclitaxel only produced a reduction in tumor growth.	Paclitaxel	4-14	neurotrophin 4	Homo sapiens	0-3
26626440-0	2015	MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1.	Paclitaxel	60-70	ATP binding cassette subfamily B member 1	Homo sapiens	98-103
26626440-12	2015	CONCLUSION: Our results are the first to demonstrate that miR-186 may sensitize ovarian cancer cell to paclitaxel and cisplatin by targeting ABCB1 and modulating the expression of GST-pi.	Paclitaxel	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	141-146
26573793-4	2015	In a mouse model of ovarian cancer, treatment with paclitaxel increased CD8(+) T-cell infiltration into the tumor site, upregulated PD-L1 expression, and activated NF-kappaB signaling.	Paclitaxel	51-61	CD274 antigen	Mus musculus	132-137
26426537-4	2015	The TPGS component was confirmed able to elevate the intracellular accumulation of PTX by inhibiting the P-gp efflux, and to facilitate the mitochondrial-targeting of the liposome.	Paclitaxel	83-86	ATP binding cassette subfamily B member 1	Homo sapiens	105-109
26573793-5	2015	In particular, tumor-bearing mice treated with a combination of paclitaxel and a PD-L1/PD-1 signal blockade survived longer than mice treated with paclitaxel alone.	Paclitaxel	147-157	CD274 antigen	Mus musculus	81-86
26573793-5	2015	In particular, tumor-bearing mice treated with a combination of paclitaxel and a PD-L1/PD-1 signal blockade survived longer than mice treated with paclitaxel alone.	Paclitaxel	147-157	programmed cell death 1	Mus musculus	87-91
26752929-2	2015	Here, we investigated whether HER2-positive breast cancers responded to sequential neoadjuvant anthracycline followed by paclitaxel plus carboplatin regimen in the absence of trastuzumab.	Paclitaxel	121-131	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
26752929-0	2015	Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer.	Paclitaxel	86-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-24
26356996-0	2015	Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells.	Paclitaxel	14-24	microRNA 183	Homo sapiens	73-80
26356996-8	2015	According to our data, cisplatin and paclitaxel strongly decreased T24 cells" viability, showing in parallel the ability to significantly down-regulate miR-143 levels, and up-regulate the expression levels of miR-145, miR-183, miR-96, and miR-182, which, in their total, demonstrated case-specific variations after recovery period.	Paclitaxel	37-47	microRNA 183	Homo sapiens	218-225
26356996-8	2015	According to our data, cisplatin and paclitaxel strongly decreased T24 cells" viability, showing in parallel the ability to significantly down-regulate miR-143 levels, and up-regulate the expression levels of miR-145, miR-183, miR-96, and miR-182, which, in their total, demonstrated case-specific variations after recovery period.	Paclitaxel	37-47	microRNA 96	Homo sapiens	227-233
26159849-0	2015	Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.	Paclitaxel	38-48	AKT serine/threonine kinase 1	Homo sapiens	91-94
26460148-8	2015	Further histopathology, immunohistochemical and western blot analysis (bax, cas-9 and bcl-2) of apoptotic markers in breast tissues clearly showed the anti-carcinogenic property of fungal taxol.	Paclitaxel	188-193	BCL2, apoptosis regulator	Rattus norvegicus	86-91
26415823-7	2015	Second, the combination of LPC/PTX demonstrates strong synergistic cytotoxicity effect against the NQO1 overexpressing cancer cells, including A549 NSCLC cells, and several pancreatic cancer cells (combination index &lt;1).	Paclitaxel	31-34	NAD(P)H quinone dehydrogenase 1	Homo sapiens	99-103
26469772-5	2015	Here, we report the utilization of biocompatible, biodegradable, small (~30 nm) and stable iron oxide NPs (IONPs) for targeted delivery of paclitaxel (PTX) to HER2/neu positive breast cancer cells using an anti-HER2/neu peptide (AHNP) targeting ligand.	Paclitaxel	139-149	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-167
26469772-5	2015	Here, we report the utilization of biocompatible, biodegradable, small (~30 nm) and stable iron oxide NPs (IONPs) for targeted delivery of paclitaxel (PTX) to HER2/neu positive breast cancer cells using an anti-HER2/neu peptide (AHNP) targeting ligand.	Paclitaxel	151-154	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-163
26469772-5	2015	Here, we report the utilization of biocompatible, biodegradable, small (~30 nm) and stable iron oxide NPs (IONPs) for targeted delivery of paclitaxel (PTX) to HER2/neu positive breast cancer cells using an anti-HER2/neu peptide (AHNP) targeting ligand.	Paclitaxel	151-154	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-167
26462028-6	2015	We confirmed that Snail is increased by paclitaxel-induced intracellular reactive oxygen species (ROS) and EW-7197 suppresses the paclitaxel-induced Snail and EMT by attenuating paclitaxel-induced intracellular ROS.	Paclitaxel	130-140	snail family transcriptional repressor 1	Homo sapiens	149-154
26462028-6	2015	We confirmed that Snail is increased by paclitaxel-induced intracellular reactive oxygen species (ROS) and EW-7197 suppresses the paclitaxel-induced Snail and EMT by attenuating paclitaxel-induced intracellular ROS.	Paclitaxel	130-140	snail family transcriptional repressor 1	Homo sapiens	149-154
26462028-7	2015	Knock-down of SNAI1 suppresses paclitaxel-induced EMT and CSC properties.	Paclitaxel	31-41	snail family transcriptional repressor 1	Homo sapiens	14-19
26462028-8	2015	These data together suggest that blocking the Snail-induced EMT with the ALK5 inhibitor attenuates metastasis after paclitaxel-therapy and that this combinatorial approach could prove useful in treating breast cancer.	Paclitaxel	116-126	snail family transcriptional repressor 1	Homo sapiens	46-51
26469772-0	2015	Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells.	Paclitaxel	83-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
26469772-0	2015	Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells.	Paclitaxel	83-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-13
26469772-5	2015	Here, we report the utilization of biocompatible, biodegradable, small (~30 nm) and stable iron oxide NPs (IONPs) for targeted delivery of paclitaxel (PTX) to HER2/neu positive breast cancer cells using an anti-HER2/neu peptide (AHNP) targeting ligand.	Paclitaxel	139-149	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-163
26462028-3	2015	Paclitaxel, one of the cytotoxic taxane-drugs such as docetaxel, increases mesenchymal markers (Vimentin and Fibronectin) and decreases an epithelial marker (Zo-1).	Paclitaxel	0-10	fibronectin 1	Homo sapiens	109-120
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	Paclitaxel	107-117	CD24 molecule	Homo sapiens	242-246
26462028-6	2015	We confirmed that Snail is increased by paclitaxel-induced intracellular reactive oxygen species (ROS) and EW-7197 suppresses the paclitaxel-induced Snail and EMT by attenuating paclitaxel-induced intracellular ROS.	Paclitaxel	40-50	snail family transcriptional repressor 1	Homo sapiens	18-23
26462148-6	2015	RESULTS: The expression and migration of ATF2 to the mitochondria accounted for paclitaxel stimuli and acquired resistance to BRAF inhibitors.	Paclitaxel	80-90	activating transcription factor 2	Mus musculus	41-45
26463651-12	2015	Dexamethasone and paclitaxel inversely regulated the activity of NFkappaB, which is essential to both paclitaxel-mediated apoptosis and dexamethasone-mediated rescue.	Paclitaxel	18-28	nuclear factor kappa B subunit 1	Homo sapiens	65-73
26463651-12	2015	Dexamethasone and paclitaxel inversely regulated the activity of NFkappaB, which is essential to both paclitaxel-mediated apoptosis and dexamethasone-mediated rescue.	Paclitaxel	102-112	nuclear factor kappa B subunit 1	Homo sapiens	65-73
26463651-13	2015	The transcriptional target of NFkappaB, Fas receptor, is inversely regulated by paclitaxel and dexamethasone and is a downstream target of paclitaxel-activated NFkappaB.	Paclitaxel	80-90	nuclear factor kappa B subunit 1	Homo sapiens	30-38
26463651-13	2015	The transcriptional target of NFkappaB, Fas receptor, is inversely regulated by paclitaxel and dexamethasone and is a downstream target of paclitaxel-activated NFkappaB.	Paclitaxel	80-90	nuclear factor kappa B subunit 1	Homo sapiens	160-168
26463651-13	2015	The transcriptional target of NFkappaB, Fas receptor, is inversely regulated by paclitaxel and dexamethasone and is a downstream target of paclitaxel-activated NFkappaB.	Paclitaxel	139-149	nuclear factor kappa B subunit 1	Homo sapiens	30-38
26463651-13	2015	The transcriptional target of NFkappaB, Fas receptor, is inversely regulated by paclitaxel and dexamethasone and is a downstream target of paclitaxel-activated NFkappaB.	Paclitaxel	139-149	nuclear factor kappa B subunit 1	Homo sapiens	160-168
26463651-14	2015	Dexamethasone antagonizes paclitaxel-mediated apoptosis through inhibition of NFkappaB transcription of Fas receptor.	Paclitaxel	26-36	nuclear factor kappa B subunit 1	Homo sapiens	78-86
26103952-12	2015	CONCLUSION: This study shows that trastuzumab-based adjuvant treatment of small HER2-positive breast cancer is mostly based on chemotherapy-mainly paclitaxel/docetaxel.	Paclitaxel	147-157	erb-b2 receptor tyrosine kinase 2	Homo sapiens	80-84
26123189-0	2015	Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.	Paclitaxel	83-97	caveolin 1	Homo sapiens	8-18
26123189-3	2015	Tumor-associated stromal caveolin-1 (Cav-1) expression was correlated with improved response rate and survival in NSCLC patients who received nab-paclitaxel in this phase II trial.	Paclitaxel	146-156	caveolin 1	Homo sapiens	25-35
26123189-3	2015	Tumor-associated stromal caveolin-1 (Cav-1) expression was correlated with improved response rate and survival in NSCLC patients who received nab-paclitaxel in this phase II trial.	Paclitaxel	146-156	caveolin 1	Homo sapiens	37-42
26397839-0	2015	Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1alpha and FOXO3a by AMPK signaling.	Paclitaxel	0-10	forkhead box O3	Homo sapiens	102-108
26360705-6	2015	OC3/TAX300 cells treated with JAK2-siRNA exhibited stalled growth, increased cell cycle arrest in G2/M phase, and enhanced apoptosis in response to paclitaxel.	Paclitaxel	148-158	one cut homeobox 3	Homo sapiens	0-3
26360705-10	2015	CONCLUSIONS: Collectively, we conclude that the JAK2-STAT3 pathway promotes the development of paclitaxel resistance via upregulating the expression of prosurvival and antiapoptotic genes.	Paclitaxel	95-105	signal transducer and activator of transcription 3	Homo sapiens	53-58
26397839-5	2015	In addition, paclitaxel increased the expression, as well as the phosphorylation of forkhead box O3a (FOXO3a).	Paclitaxel	13-23	forkhead box O3	Homo sapiens	102-108
26397839-6	2015	Phosphorylation of FOXO3a was suppressed in the presence of compound C, a specific AMPK inhibitor, suggesting the involvement of AMPK in paclitaxel-induced FOXO3a phosphorylation.	Paclitaxel	137-147	forkhead box O3	Homo sapiens	19-25
26397839-6	2015	Phosphorylation of FOXO3a was suppressed in the presence of compound C, a specific AMPK inhibitor, suggesting the involvement of AMPK in paclitaxel-induced FOXO3a phosphorylation.	Paclitaxel	137-147	forkhead box O3	Homo sapiens	156-162
26397839-7	2015	The induction and phosphorylation of FOXO3a by paclitaxel were not observed in EF1alpha and AMPK knockdown cells.	Paclitaxel	47-57	forkhead box O3	Homo sapiens	37-43
26397839-8	2015	Co-treatment with AICAR resulted in increased susceptibility of cancer cells to paclitaxel-induced suppression of their viability and further enhanced paclitaxel-induced FOXO3a phosphorylation.	Paclitaxel	151-161	forkhead box O3	Homo sapiens	170-176
26397839-9	2015	These results suggest that the antitumor effects of paclitaxel in breast cancer are mediated by activation of the AMPK/EF1alpha/FOXO3a signaling pathway.	Paclitaxel	52-62	forkhead box O3	Homo sapiens	128-134
26640594-4	2015	Either hTERT siRNA or BIBR1532 in combination with paclitaxel promoted a synergistic inhibitory effect on cell growth through induction of Annexin V expression and a remarkable reduction in cell invasion through reduction of protein expression of MMP9, MMP2, and MMP3.	Paclitaxel	51-61	matrix metallopeptidase 3	Homo sapiens	263-267
25154499-7	2015	In MCF-7 and MDA-MB-231 mammmosphere cells, the Nrf2-mediated cellular protective response is significantly elevated which is associated with increased resistance to taxol and anchorage-independent growth.	Paclitaxel	166-171	NFE2 like bZIP transcription factor 2	Homo sapiens	48-52
26665000-8	2015	Neural differentiation markers NFL (for neurons), beta III-tubulin (for neurons), GFAP (for astrocytes), and CNPase (for oligodendrocytes) were detected in the taxol-treated C6 cells.	Paclitaxel	160-165	neurofilament light chain	Rattus norvegicus	31-34
26282378-0	2015	Induction of oxidative stress by Taxol  vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA.	Paclitaxel	33-38	C-X-C motif chemokine ligand 8	Homo sapiens	84-97
26516138-9	2015	CONCLUSIONS: Increased miR-451 expression may negatively regulate Bcl-2 mRNA and protein expression, followed by affecting the protein expression of caspase 3, and accelerate the apoptosis in breast cancer, indicating that miR-451 might influence the drug resistances of the Paclitaxel-resistant breast cancer cell line.	Paclitaxel	275-285	BCL2 apoptosis regulator	Homo sapiens	66-71
26516138-9	2015	CONCLUSIONS: Increased miR-451 expression may negatively regulate Bcl-2 mRNA and protein expression, followed by affecting the protein expression of caspase 3, and accelerate the apoptosis in breast cancer, indicating that miR-451 might influence the drug resistances of the Paclitaxel-resistant breast cancer cell line.	Paclitaxel	275-285	caspase 3	Homo sapiens	149-158
26503059-5	2015	Pharmacologic inhibition of IRAK1 is able to reverse paclitaxel resistance by triggering massive apoptosis at least in part through inhibiting p38-MCL1 pro-survival pathway.	Paclitaxel	53-63	mitogen-activated protein kinase 14	Homo sapiens	143-146
26206775-3	2015	Knowing that histone deacetylase 1 (HDAC1) transcriptionally suppresses RhoB, we sought to extend our findings to other HDACs and to identify the HDAC inhibitor (HDACi) that optimally synergize with paclitaxel.	Paclitaxel	199-209	histone deacetylase 1	Homo sapiens	13-34
26375501-0	2015	Non-adherent culture induces paclitaxel resistance in H460 lung cancer cells via ERK-mediated up-regulation of betaIVa-tubulin.	Paclitaxel	29-39	mitogen-activated protein kinase 1	Homo sapiens	81-84
26375501-7	2015	qRT-PCR analysis showed that a paclitaxel-resistant beta-tubulin isotype, betaIVa-tubulin, was the most up-regulated gene compared with other beta-tubulin isotypes in H460 floating cells, concomitant with elevated ERK activation.	Paclitaxel	31-41	mitogen-activated protein kinase 1	Homo sapiens	214-217
26375501-8	2015	ERK inhibitor treatment could attenuate the up-regulation of betaIVa-tubulin, and decreased the paclitaxel resistance of H460 floating cells, even though other beta-tubulin isotypes were up-regulated when the ERK activation was blocked.	Paclitaxel	96-106	mitogen-activated protein kinase 1	Homo sapiens	0-3
26315118-0	2015	Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.	Paclitaxel	45-55	TNF superfamily member 10	Homo sapiens	30-35
26315118-2	2015	We developed a one-pot/one-step formulation of paclitaxel (PTX)-bound albumin nanoparticles with embedded tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/PTX HSA-NP) for the treatment of pancreatic cancer.	Paclitaxel	47-57	TNF superfamily member 10	Homo sapiens	163-168
26315118-4	2015	TRAIL/PTX HSA-NPs were spherical and became larger in size (170-230 nm) with increasing TRAIL amount (0.2-2.0%).	Paclitaxel	6-9	TNF superfamily member 10	Homo sapiens	88-93
26315118-5	2015	The loading efficiencies of PTX were in the range of ~86.4% and significantly low at 2.0% TRAIL (60.4%).	Paclitaxel	28-31	TNF superfamily member 10	Homo sapiens	90-95
26315118-6	2015	Specifically, the inhibitory concentrations (IC50) of TRAIL (1.0 or 2.0%)/PTX HSA-NPs were &gt;20-fold lower than that of plain PTX-HSA NP (0.032+-0.06, 0.022+-0.005, and 0.96+-0.15 ng/ml, respectively) in pancreatic Mia Paca-2 cells.	Paclitaxel	74-77	TNF superfamily member 10	Homo sapiens	54-59
26315118-9	2015	The loaded PTX and TRAIL were gradually released from the TRAIL(1.0%)/PTX HSA-NPs until ~24 h, which is considered to be a sufficient time for delivery to the tumor tissue.	Paclitaxel	11-14	TNF superfamily member 10	Homo sapiens	58-63
26315118-9	2015	The loaded PTX and TRAIL were gradually released from the TRAIL(1.0%)/PTX HSA-NPs until ~24 h, which is considered to be a sufficient time for delivery to the tumor tissue.	Paclitaxel	70-73	TNF superfamily member 10	Homo sapiens	19-24
26315118-12	2015	We believe that this TRAIL/PTX HSA-NP would have potential as a novel apoptosis-based anticancer agent.	Paclitaxel	27-30	TNF superfamily member 10	Homo sapiens	21-26
26359218-4	2015	Herein, we rationally designed a taxol derivative Fmoc-Phe-Phe-Lys(taxol)-Tyr(H2PO4)-OH (1) which could be subjected to alkaline phosphatase (ALP)-catalyzed self-assembly to form taxol nanofibers.	Paclitaxel	33-38	alkaline phosphatase, placental	Homo sapiens	120-140
26359218-4	2015	Herein, we rationally designed a taxol derivative Fmoc-Phe-Phe-Lys(taxol)-Tyr(H2PO4)-OH (1) which could be subjected to alkaline phosphatase (ALP)-catalyzed self-assembly to form taxol nanofibers.	Paclitaxel	33-38	alkaline phosphatase, placental	Homo sapiens	142-145
26359218-4	2015	Herein, we rationally designed a taxol derivative Fmoc-Phe-Phe-Lys(taxol)-Tyr(H2PO4)-OH (1) which could be subjected to alkaline phosphatase (ALP)-catalyzed self-assembly to form taxol nanofibers.	Paclitaxel	67-72	alkaline phosphatase, placental	Homo sapiens	120-140
26359218-4	2015	Herein, we rationally designed a taxol derivative Fmoc-Phe-Phe-Lys(taxol)-Tyr(H2PO4)-OH (1) which could be subjected to alkaline phosphatase (ALP)-catalyzed self-assembly to form taxol nanofibers.	Paclitaxel	67-72	alkaline phosphatase, placental	Homo sapiens	142-145
26065826-0	2015	MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy.	Paclitaxel	49-59	toll-like receptor 4	Rattus norvegicus	29-33
26065826-1	2015	Toll-like receptor 4 (TLR4) has been implicated as a locus for initiation of paclitaxel related chemotherapy induced peripheral neuropathy (CIPN).	Paclitaxel	77-87	toll-like receptor 4	Rattus norvegicus	0-20
26065826-1	2015	Toll-like receptor 4 (TLR4) has been implicated as a locus for initiation of paclitaxel related chemotherapy induced peripheral neuropathy (CIPN).	Paclitaxel	77-87	toll-like receptor 4	Rattus norvegicus	22-26
26065826-8	2015	The TLR4 antagonist LPS derived from Rhodobacter sphaeroides (LPS-RS) inhibited paclitaxel-induced phosphorylation of ERK1/2 and P38.	Paclitaxel	80-90	toll-like receptor 4	Rattus norvegicus	4-8
26065826-13	2015	These results implicate TLR4 signaling via MAP kinases and NFkappaB in the induction and maintenance of paclitaxel-related CIPN.	Paclitaxel	104-114	toll-like receptor 4	Rattus norvegicus	24-28
26497956-0	2015	Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.	Paclitaxel	32-42	OTU deubiquitinase 4	Homo sapiens	17-22
26497956-0	2015	Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.	Paclitaxel	32-42	AKT serine/threonine kinase 1	Homo sapiens	98-101
26497956-0	2015	Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.	Paclitaxel	32-42	mechanistic target of rapamycin kinase	Homo sapiens	102-106
26497956-3	2015	METHODS: In vitro flow cytometric analysis and evaluation of caspase-3/7 activity of paclitaxel-sensitive and resistant OCCC cell lines were performed.	Paclitaxel	85-95	caspase 3	Homo sapiens	61-70
26497956-8	2015	Methylation of HIN-1 was noted in paclitaxel-resistant OCCC cell lines and cancerous tissues.	Paclitaxel	34-44	OTU deubiquitinase 4	Homo sapiens	15-20
26497956-10	2015	Immunoblotting revealed that phospho-AKT473 and phospho-mTOR were significantly increased in HIN-1-methylated paclitaxel-resistant OCCC cell lines.	Paclitaxel	110-120	mechanistic target of rapamycin kinase	Homo sapiens	56-60
26497956-10	2015	Immunoblotting revealed that phospho-AKT473 and phospho-mTOR were significantly increased in HIN-1-methylated paclitaxel-resistant OCCC cell lines.	Paclitaxel	110-120	OTU deubiquitinase 4	Homo sapiens	93-98
26497956-12	2015	CONCLUSIONS: Demethylating agents can restore the HIN-1 expression in paclitaxel-resistant OCCC cells through the HIN-1-AKT-mTOR signaling pathway to inhibit tumor growth.	Paclitaxel	70-80	OTU deubiquitinase 4	Homo sapiens	50-55
26497956-12	2015	CONCLUSIONS: Demethylating agents can restore the HIN-1 expression in paclitaxel-resistant OCCC cells through the HIN-1-AKT-mTOR signaling pathway to inhibit tumor growth.	Paclitaxel	70-80	OTU deubiquitinase 4	Homo sapiens	114-119
26497956-12	2015	CONCLUSIONS: Demethylating agents can restore the HIN-1 expression in paclitaxel-resistant OCCC cells through the HIN-1-AKT-mTOR signaling pathway to inhibit tumor growth.	Paclitaxel	70-80	AKT serine/threonine kinase 1	Homo sapiens	120-123
26497956-12	2015	CONCLUSIONS: Demethylating agents can restore the HIN-1 expression in paclitaxel-resistant OCCC cells through the HIN-1-AKT-mTOR signaling pathway to inhibit tumor growth.	Paclitaxel	70-80	mechanistic target of rapamycin kinase	Homo sapiens	124-128
26206775-3	2015	Knowing that histone deacetylase 1 (HDAC1) transcriptionally suppresses RhoB, we sought to extend our findings to other HDACs and to identify the HDAC inhibitor (HDACi) that optimally synergize with paclitaxel.	Paclitaxel	199-209	histone deacetylase 1	Homo sapiens	36-41
26206775-10	2015	This study intimates that the combination of belinostat/vorinostat with paclitaxel may prove to be an effective therapeutic strategy via the novel observation that class II/(I) HDACi antagonize HDAC6-mediated suppression of RhoB and subsequent BIMEL, thereby promoting antitumor synergy.	Paclitaxel	72-82	histone deacetylase 6	Homo sapiens	194-199
26499139-5	2015	Combined chemotherapy of intravenous and intraperitoneal paclitaxel with oral S-1 has been confirmed by pharmacokinetic and pharmacodynamic studies to be well tolerated and well effective in gastric cancer patients with peritoneal metastasis.	Paclitaxel	57-67	proteasome 26S subunit, non-ATPase 1	Homo sapiens	78-81
26722421-9	2015	15 genes of 762 transcripts on this chromosome region were consistently up-regulated detected by cDNA microarray in three taxol resistant sub-lines, and functionally clustered into various groups, including genes related to vascular formation vascular formation (ANGPT1), apoptosis (MYC, TOP1MT), cell adhesion and cell cycle (PPP1R16A, SDC2, CA2, ANKRD46), gene regulation (HRSP12, ZNF696, SLC39A4, POP1), metabolism (PYCRL).	Paclitaxel	122-127	protein phosphatase 1 regulatory subunit 16A	Homo sapiens	327-335
26516582-7	2015	In the present study, we demonstrate that three of these compounds reversed P-gp-mediated multidrug resistance of cultured prostate cancer cells to restore sensitivity comparable to naive prostate cancer cells to the chemotherapeutic drug, paclitaxel.	Paclitaxel	240-250	ATP binding cassette subfamily B member 1	Homo sapiens	76-80
26318424-0	2015	Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor.	Paclitaxel	71-76	cripto, FRL-1, cryptic family 1	Homo sapiens	52-59
26318424-0	2015	Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor.	Paclitaxel	71-76	androgen receptor	Homo sapiens	138-155
26318424-10	2015	Individually silencing seven out of nine (78%) AR-regulated txr genes sensitized txr cells to taxol.	Paclitaxel	94-99	androgen receptor	Homo sapiens	47-49
26406239-5	2015	Pro-apoptotic Bcl-2 antagonist killer 1 (Bak) plays an important role in Taxol-induced apoptosis in breast cancer.	Paclitaxel	73-78	BCL2 apoptosis regulator	Homo sapiens	14-19
26309162-7	2015	Moreover, h-R3-dendriplexes for p53 delivery indicated efficient cell growth inhibition and potentiated paclitaxel-induced cell death.	Paclitaxel	104-114	tumor protein p53	Homo sapiens	32-35
25998561-4	2015	In this paper, we investigated the effects of anti-EGFR-iRGD in combination with chemotherapeutic drugs including PTX in epidermal growth factor receptor highly expressing gastric cancer.	Paclitaxel	114-117	epidermal growth factor receptor	Homo sapiens	121-153
26722421-9	2015	15 genes of 762 transcripts on this chromosome region were consistently up-regulated detected by cDNA microarray in three taxol resistant sub-lines, and functionally clustered into various groups, including genes related to vascular formation vascular formation (ANGPT1), apoptosis (MYC, TOP1MT), cell adhesion and cell cycle (PPP1R16A, SDC2, CA2, ANKRD46), gene regulation (HRSP12, ZNF696, SLC39A4, POP1), metabolism (PYCRL).	Paclitaxel	122-127	ankyrin repeat domain 46	Homo sapiens	348-355
26177978-6	2015	Chemotherapy according to paclitaxel/carboplatin protocol was more frequent in the patients with positive CD117 expression (70.9% vs 54.2%; P &lt; 0.05), while carboplatin monotherapy was more frequent in the patients with negative CD117 expression (18.0% vs 6.4%; P &lt; 0.05).	Paclitaxel	26-36	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	106-111
26177978-6	2015	Chemotherapy according to paclitaxel/carboplatin protocol was more frequent in the patients with positive CD117 expression (70.9% vs 54.2%; P &lt; 0.05), while carboplatin monotherapy was more frequent in the patients with negative CD117 expression (18.0% vs 6.4%; P &lt; 0.05).	Paclitaxel	26-36	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	232-237
26025631-3	2015	Lentiviral transfection of inhibitors of miR-200c or miR-141 in parental OVCAR-3 triggered EMT and rendered the cells resistant to paclitaxel and carboplatin.	Paclitaxel	131-141	microRNA 141	Homo sapiens	53-60
26025631-8	2015	MiR-200c and miR-141 mimics conferred resistance to carboplatin in MES-OV/TP cells, similar to OVCAR-3/TP, but sensitized MES-OV to paclitaxel.	Paclitaxel	132-142	microRNA 141	Homo sapiens	13-20
26622855-0	2015	Paclitaxel induces apoptosis and reduces proliferation by targeting epidermal growth factor receptor signaling pathway in oral cavity squamous cell carcinoma.	Paclitaxel	0-10	epidermal growth factor receptor	Homo sapiens	68-100
26622855-11	2015	Paclitaxel also enhanced oral cancer cell apoptosis via increased Bim and Bid protein expression.	Paclitaxel	0-10	BH3 interacting domain death agonist	Homo sapiens	74-77
26622855-13	2015	Paclitaxel inhibited the growth of the oral cancer cell line, tea8113 malignant proliferation and enhanced tea8113 cell apoptosis through inhibiting the EGFR signaling pathway.	Paclitaxel	0-10	epidermal growth factor receptor	Homo sapiens	153-157
26424893-4	2015	The number of TRPV1(+) neurons is increased in the dorsal root ganglia (DRG) in paclitaxel-treated rats and is colocalized with TLR4 in rat and human DRG neurons.	Paclitaxel	80-90	toll-like receptor 4	Rattus norvegicus	128-132
26424893-6	2015	Perfusion of paclitaxel or the archetypal TLR4 agonist LPS activated both rat DRG and spinal neurons directly and produced acute sensitization of TRPV1 in both groups of cells via a TLR4-mediated mechanism.	Paclitaxel	13-23	toll-like receptor 4	Rattus norvegicus	182-186
26314844-9	2015	These data suggest that PTX-NPs with ABCG2 McAb can be developed into potential treatment regimens for patients with relapsed/refractory MM.	Paclitaxel	24-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	37-42
26337085-0	2015	A novel mitosis-associated lncRNA, MA-linc1, is required for cell cycle progression and sensitizes cancer cells to Paclitaxel.	Paclitaxel	115-125	mitosis associated long intergenic non-coding RNA 1	Homo sapiens	35-43
26337085-7	2015	In agreement with its suggested role in M phase, inhibition of MA-linc1 enhances apoptotic cell death induced by the antimitotic drug, Paclitaxel and this enhancement of apoptosis is rescued by Puralpha knockdown.	Paclitaxel	135-145	mitosis associated long intergenic non-coding RNA 1	Homo sapiens	63-71
26406239-9	2015	Importantly, higher Bak expression predicted a favorable clinical outcome in the cases treated with Taxol indicated by a higher overall survival than that of patients with lower Bak expression especially in Luminal and HER2 subtypes.	Paclitaxel	100-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	219-223
25998561-0	2015	A tumor-penetrating recombinant protein anti-EGFR-iRGD enhance efficacy of paclitaxel in 3D multicellular spheroids and gastric cancer in vivo.	Paclitaxel	75-85	epidermal growth factor receptor	Homo sapiens	45-49
26287605-7	2015	Combination of tocilizumab with cisplatin or paclitaxel enhanced the inhibitory effect of chemotherapy on xenograft growth (P &lt; 0.05), time to failure (P &lt; 0.01), decreased vascular endothelial growth factor (VEGF) expression and tumor microvessel density (P &lt; 0.05) without added systemic toxicities.	Paclitaxel	45-55	vascular endothelial growth factor A	Homo sapiens	179-213
26396496-8	2015	Following miR-133b transfection, four cell lines showed increased sensitivity to paclitaxel and cisplatin, while anti-miR-133b transfection reduced cell sensitivity to paclitaxel and cisplatin.	Paclitaxel	81-91	microRNA 133b	Homo sapiens	10-18
26396496-8	2015	Following miR-133b transfection, four cell lines showed increased sensitivity to paclitaxel and cisplatin, while anti-miR-133b transfection reduced cell sensitivity to paclitaxel and cisplatin.	Paclitaxel	168-178	microRNA 133b	Homo sapiens	118-126
26296969-4	2015	In addition, ORA (3 muM) significantly increased the intracellular accumulation of [3H]-paclitaxel by suppressing the efflux function of ABCB1.	Paclitaxel	88-98	latexin	Homo sapiens	20-23
26296969-4	2015	In addition, ORA (3 muM) significantly increased the intracellular accumulation of [3H]-paclitaxel by suppressing the efflux function of ABCB1.	Paclitaxel	88-98	ATP binding cassette subfamily B member 1	Homo sapiens	137-142
26287605-7	2015	Combination of tocilizumab with cisplatin or paclitaxel enhanced the inhibitory effect of chemotherapy on xenograft growth (P &lt; 0.05), time to failure (P &lt; 0.01), decreased vascular endothelial growth factor (VEGF) expression and tumor microvessel density (P &lt; 0.05) without added systemic toxicities.	Paclitaxel	45-55	vascular endothelial growth factor A	Homo sapiens	215-219
26287605-9	2015	Collectively, these findings demonstrate that tocilizumab enhances the anti-tumor effect of conventional chemotherapy in preclinical models of mucoepidermoid carcinoma, and suggest that patients might benefit from combination therapy with an inhibitor of IL-6R signaling and chemotherapeutic agent such as paclitaxel.	Paclitaxel	306-316	interleukin 6 receptor	Homo sapiens	255-260
26135626-0	2015	Paclitaxel pretreatment overcomes hypoxia inducible factor-1alpha-induced radioresistance acquisition of human hepatoma and lung adenocarcinoma cells.	Paclitaxel	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	34-65
26344694-0	2015	Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer.	Paclitaxel	41-51	forkhead box O3	Homo sapiens	72-78
26344694-4	2015	Our data also showed that the activation of the tumour suppressor FOXO3a by paclitaxel and epirubicin is mediated through the induction of FOXK2, as depletion of FOXK2 by siRNA limits the induction of FOXO3a by these drugs in MCF-7 cells.	Paclitaxel	76-86	forkhead box O3	Homo sapiens	66-72
26344694-4	2015	Our data also showed that the activation of the tumour suppressor FOXO3a by paclitaxel and epirubicin is mediated through the induction of FOXK2, as depletion of FOXK2 by siRNA limits the induction of FOXO3a by these drugs in MCF-7 cells.	Paclitaxel	76-86	forkhead box O3	Homo sapiens	201-207
26329920-7	2015	The levels of DR4 and caspase-3 were significantly increased (P&lt;0.01) in MCF-7 cells treated with the tested sample compared to untreated cells and possessed a similar activity of paclitaxel in DR4 induction but lower induction in caspase-3.	Paclitaxel	183-193	caspase 3	Homo sapiens	22-31
25838353-6	2015	Most importantly, when combined with paclitaxel and small interfering RNA, the composite cationic liposome induced a great enhancement in the antitumor activity, which showed a significantly higher in vitro cytotoxicity in Bcap-37 cells than liposomal paclitaxel or small interfering RNA alone.	Paclitaxel	37-47	phosphoinositide-3-kinase adaptor protein 1	Homo sapiens	223-227
26232188-3	2015	Our aim was to determine the interaction between the ERalpha/ERbeta ratio and the response to cytotoxic treatments such as cisplatin (CDDP), paclitaxel (PTX) and tamoxifen (TAM).	Paclitaxel	141-151	estrogen receptor 1	Homo sapiens	53-60
26232188-3	2015	Our aim was to determine the interaction between the ERalpha/ERbeta ratio and the response to cytotoxic treatments such as cisplatin (CDDP), paclitaxel (PTX) and tamoxifen (TAM).	Paclitaxel	153-156	estrogen receptor 1	Homo sapiens	53-60
26135626-3	2015	The efficacy of PTX disruptions of hypoxia-inducible factor-1 alpha (HIF-1alpha) was assessed using Western blotting.	Paclitaxel	16-19	hypoxia inducible factor 1 subunit alpha	Homo sapiens	35-67
26135626-3	2015	The efficacy of PTX disruptions of hypoxia-inducible factor-1 alpha (HIF-1alpha) was assessed using Western blotting.	Paclitaxel	16-19	hypoxia inducible factor 1 subunit alpha	Homo sapiens	69-79
26135626-8	2015	SIGNIFICANCE: Our data clearly indicate that PTX pretreatment is an effective radiosensitizing procedure against HIF-1alpha-expressing hepatoma and HLAC cells, which are constitutively endowed with radioresistance.	Paclitaxel	45-48	hypoxia inducible factor 1 subunit alpha	Homo sapiens	113-123
26177745-3	2015	Paclitaxel and other microtubule inhibitors can inhibit the growth of different types of cancer cells and induce apoptosis which is believed to be p53-independent.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	147-150
25975261-0	2015	Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.	Paclitaxel	41-51	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	78-81
25975261-10	2015	p-Src expression increased in ovarian cancer cells following paclitaxel treatment.	Paclitaxel	61-71	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	2-5
25975261-15	2015	The effects of dasatinib and paclitaxel treatments on ovarian cancer cells appeared to be mediated by the Src pathway.	Paclitaxel	29-39	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	106-109
26004124-0	2015	MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3.	Paclitaxel	58-68	protein disulfide isomerase family A member 3	Homo sapiens	124-129
26004124-11	2015	Knockdown of PDIA3 significantly inhibited the proliferation and promoted the paclitaxel-induced apoptosis of the ovarian cancer cells, whereas overexpression of PDIA3 had the opposite effects.	Paclitaxel	78-88	protein disulfide isomerase family A member 3	Homo sapiens	13-18
26004124-12	2015	Therefore, the results of the present study suggested that miR-148a inhibited the proliferation and promoted the paclitaxel-induced apoptosis of ovarian cancer cells, and this may be partly attributed to direct targeting of PDIA3.	Paclitaxel	113-123	protein disulfide isomerase family A member 3	Homo sapiens	224-229
25980581-6	2015	Compared with the control, ING5 transfectants displayed drug resistance to triciribine, paclitaxel, cisplatin, SAHA, MG132 and parthenolide, which was positively related to their apoptotic induction and the overexpression of chemoresistance-related genes (MDR1, GRP78, GRP94, IRE, CD147, FBXW7, TOP1, TOP2, MLH1, MRP1, BRCP1 and GST-pi).	Paclitaxel	88-98	inhibitor of growth family member 5	Homo sapiens	27-31
26622726-8	2015	Individually PTX and HM were able to inhibit the migration and invasion of two human gastric cancer cells; however, the combination of PTX and HM exerted synergistic effects on migration and invasion inhibition, with downregulation of COX-2 and matrix metalloproteinase (MMP)-9.	Paclitaxel	135-138	prostaglandin-endoperoxide synthase 2	Homo sapiens	235-240
26622726-0	2015	Paclitaxel combined with harmine inhibits the migration and invasion of gastric cancer cells through downregulation of cyclooxygenase-2 expression.	Paclitaxel	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	119-135
26622726-8	2015	Individually PTX and HM were able to inhibit the migration and invasion of two human gastric cancer cells; however, the combination of PTX and HM exerted synergistic effects on migration and invasion inhibition, with downregulation of COX-2 and matrix metalloproteinase (MMP)-9.	Paclitaxel	13-16	prostaglandin-endoperoxide synthase 2	Homo sapiens	235-240
26525017-7	2015	The curative effect of paclitaxel and cisplatin combined therapy was promising, positive and was closely related with cervical cancer tissue LVD and MVD.	Paclitaxel	23-33	mevalonate diphosphate decarboxylase	Homo sapiens	149-152
26070258-8	2015	CONCLUSIONS: Thus, the mutation BRAF G469A in MM might be related to a weak effectiveness of therapy with BRAF inhibitors and a promising therapeutic approach may be with nab-paclitaxel.	Paclitaxel	175-185	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	32-36
26032505-7	2015	We found that elevating Sab levels in HeLa cells increased the efficacy of chemotherapeutic agents, paclitaxel and cisplatin, while silencing Sab decreased the sensitivity of cells towards these agents.	Paclitaxel	100-110	SH3 domain binding protein 5	Homo sapiens	24-27
26547077-7	2015	Chemotherapeutic drugs such as doxorubicin, paclitaxel, and bortezomib augmented the effect of both TRAIL variants, and the enhancing effect was more pronounced for DR5-B.	Paclitaxel	44-54	TNF superfamily member 10	Homo sapiens	100-105
25388329-7	2015	RESULTS: Paclitaxel treatment increased the expression and release of TNF-alpha in satellite glial cells and increased the expression of TRPA1 and TRPV4 in DRG neurons in animals.	Paclitaxel	9-19	tumor necrosis factor	Homo sapiens	70-79
25388329-8	2015	In vitro, paclitaxel enhanced the expression and release of TNF-alpha in enriched primary satellite glial cells, an effect that was blocked by an inhibitor of TLR-4.	Paclitaxel	10-20	tumor necrosis factor	Homo sapiens	60-69
25388329-11	2015	CONCLUSION: These results suggest that paclitaxel activation of TLR-4 to cause release of TNF-alpha from satellite glial cells increases the expression of TRPA1 and TRPV4 in DRG neurons to cause neuropathic pain.	Paclitaxel	39-49	tumor necrosis factor	Homo sapiens	90-99
26464635-0	2015	Caveolin-1 regulates cell apoptosis and invasion ability in paclitaxel-induced multidrug-resistant A549 lung cancer cells.	Paclitaxel	60-70	caveolin 1	Homo sapiens	0-10
25499884-9	2015	P-glycoprotein is the main mechanism of taxol resistance found in the UPN251 taxane-resistant sublines.	Paclitaxel	40-45	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
26464635-1	2015	The aim of the study was to investigate the effect and potential mechanism of caveolin-1 (Cav1) knockdown in paclitaxel-resistant lung cancer A549/Taxol cells.	Paclitaxel	109-119	caveolin 1	Homo sapiens	78-88
26464635-1	2015	The aim of the study was to investigate the effect and potential mechanism of caveolin-1 (Cav1) knockdown in paclitaxel-resistant lung cancer A549/Taxol cells.	Paclitaxel	109-119	caveolin 1	Homo sapiens	90-94
26464635-2	2015	The human paclitaxel-resistant lung cancer cell line A549/Taxol was transfected with a Cav1 shRNA lentiviral vector.	Paclitaxel	10-20	caveolin 1	Homo sapiens	87-91
26042692-10	2015	Bcl-2 expression of PTX and M(FA/PTX) groups was lower than control group (p&lt;0.05).	Paclitaxel	20-23	B cell leukemia/lymphoma 2	Mus musculus	0-5
25947567-11	2015	Paclitaxel caused a reduction of VEGF in MCF7.	Paclitaxel	0-10	vascular endothelial growth factor A	Homo sapiens	33-37
25858687-0	2015	Lentinan exerts synergistic apoptotic effects with paclitaxel in A549 cells via activating ROS-TXNIP-NLRP3 inflammasome.	Paclitaxel	51-61	thioredoxin interacting protein	Homo sapiens	95-100
25858687-0	2015	Lentinan exerts synergistic apoptotic effects with paclitaxel in A549 cells via activating ROS-TXNIP-NLRP3 inflammasome.	Paclitaxel	51-61	NLR family pyrin domain containing 3	Homo sapiens	101-106
25858687-5	2015	Co-treatment with paclitaxel and lentinan enhanced cell apoptosis rate by inducing caspase-3 activation.	Paclitaxel	18-28	caspase 3	Homo sapiens	83-92
25858687-6	2015	Furthermore, co-treatment with paclitaxel and lentinan significantly triggered reactive oxygen species (ROS) production, and increased thioredoxin-interacting protein (TXNIP) expression.	Paclitaxel	31-41	thioredoxin interacting protein	Homo sapiens	135-166
25858687-6	2015	Furthermore, co-treatment with paclitaxel and lentinan significantly triggered reactive oxygen species (ROS) production, and increased thioredoxin-interacting protein (TXNIP) expression.	Paclitaxel	31-41	thioredoxin interacting protein	Homo sapiens	168-173
25858687-7	2015	Moreover, co-treatment with paclitaxel and lentinan enhanced TXNIP-NLRP3 interaction, and activated NLRP3 inflammasome whereat interleukin-1beta levels were increased and cell apoptosis was induced.	Paclitaxel	28-38	thioredoxin interacting protein	Homo sapiens	61-66
25858687-7	2015	Moreover, co-treatment with paclitaxel and lentinan enhanced TXNIP-NLRP3 interaction, and activated NLRP3 inflammasome whereat interleukin-1beta levels were increased and cell apoptosis was induced.	Paclitaxel	28-38	NLR family pyrin domain containing 3	Homo sapiens	67-72
25858687-7	2015	Moreover, co-treatment with paclitaxel and lentinan enhanced TXNIP-NLRP3 interaction, and activated NLRP3 inflammasome whereat interleukin-1beta levels were increased and cell apoptosis was induced.	Paclitaxel	28-38	NLR family pyrin domain containing 3	Homo sapiens	100-105
25858687-7	2015	Moreover, co-treatment with paclitaxel and lentinan enhanced TXNIP-NLRP3 interaction, and activated NLRP3 inflammasome whereat interleukin-1beta levels were increased and cell apoptosis was induced.	Paclitaxel	28-38	interleukin 1 beta	Homo sapiens	127-144
25858687-8	2015	In addition, combination of paclitaxel and lentinan could activate apoptosis signal regulating kinase-1 (ASK1)/p38 mitogen-activated protein kinase (MAPK) signal which also contributed to cell apoptosis.	Paclitaxel	28-38	mitogen-activated protein kinase 14	Homo sapiens	111-114
25858687-9	2015	Taken together, co-treatment with paclitaxel and lentinan exerts synergistic apoptotic effects in A549 cells through inducing ROS production, and activating NLRP3 inflammasome and ASK1/p38 MAPK signal pathway.	Paclitaxel	34-44	NLR family pyrin domain containing 3	Homo sapiens	157-162
25858687-9	2015	Taken together, co-treatment with paclitaxel and lentinan exerts synergistic apoptotic effects in A549 cells through inducing ROS production, and activating NLRP3 inflammasome and ASK1/p38 MAPK signal pathway.	Paclitaxel	34-44	mitogen-activated protein kinase 14	Homo sapiens	185-188
26042692-10	2015	Bcl-2 expression of PTX and M(FA/PTX) groups was lower than control group (p&lt;0.05).	Paclitaxel	33-36	B cell leukemia/lymphoma 2	Mus musculus	0-5
26126538-11	2015	The down-regulation of HDAC6 conferred sensitivity to taxol.	Paclitaxel	54-59	histone deacetylase 6	Homo sapiens	23-28
25912549-0	2015	Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor.	Paclitaxel	58-68	cyclin dependent kinase inhibitor 1A	Homo sapiens	28-35
25912549-0	2015	Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor.	Paclitaxel	58-68	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	72-76
25912549-3	2015	Of the two BRAF inhibitor-resistant cell lines, A375P/Mdr cells harboring the BRAF V600E mutant were resistant and the wild-type BRAF SK-MEL-2 cells were sensitive to paclitaxel.	Paclitaxel	167-177	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	11-15
25912549-6	2015	In A375P cells, paclitaxel treatment resulted in a marked emergence of apoptotic cells after mitotic arrest, concomitant with a remarkable induction of p21(Cip1).	Paclitaxel	16-26	cyclin dependent kinase inhibitor 1A	Homo sapiens	152-155
25912549-6	2015	In A375P cells, paclitaxel treatment resulted in a marked emergence of apoptotic cells after mitotic arrest, concomitant with a remarkable induction of p21(Cip1).	Paclitaxel	16-26	cyclin dependent kinase inhibitor 1A	Homo sapiens	156-160
25912549-7	2015	However, paclitaxel only moderately increased the levels of p21(Cip1) in A375P/Mdr cells, which exhibited a strong resistance to paclitaxel.	Paclitaxel	9-19	cyclin dependent kinase inhibitor 1A	Homo sapiens	60-63
25912549-7	2015	However, paclitaxel only moderately increased the levels of p21(Cip1) in A375P/Mdr cells, which exhibited a strong resistance to paclitaxel.	Paclitaxel	9-19	cyclin dependent kinase inhibitor 1A	Homo sapiens	64-68
25912549-7	2015	However, paclitaxel only moderately increased the levels of p21(Cip1) in A375P/Mdr cells, which exhibited a strong resistance to paclitaxel.	Paclitaxel	129-139	cyclin dependent kinase inhibitor 1A	Homo sapiens	60-63
25912549-7	2015	However, paclitaxel only moderately increased the levels of p21(Cip1) in A375P/Mdr cells, which exhibited a strong resistance to paclitaxel.	Paclitaxel	129-139	cyclin dependent kinase inhibitor 1A	Homo sapiens	64-68
25912549-8	2015	The p21(Cip1) overexpression partially conferred paclitaxel sensitivity to A375P/Mdr cells.	Paclitaxel	49-59	cyclin dependent kinase inhibitor 1A	Homo sapiens	4-7
25912549-8	2015	The p21(Cip1) overexpression partially conferred paclitaxel sensitivity to A375P/Mdr cells.	Paclitaxel	49-59	cyclin dependent kinase inhibitor 1A	Homo sapiens	8-12
25912549-10	2015	Taken together, these results suggest that paclitaxel may be an effective anticancer agent through regulating the expression of p21(Cip1) for the treatment of BRAF mutant melanoma cells resistant to BRAF inhibitors.	Paclitaxel	43-53	cyclin dependent kinase inhibitor 1A	Homo sapiens	128-131
25912549-10	2015	Taken together, these results suggest that paclitaxel may be an effective anticancer agent through regulating the expression of p21(Cip1) for the treatment of BRAF mutant melanoma cells resistant to BRAF inhibitors.	Paclitaxel	43-53	cyclin dependent kinase inhibitor 1A	Homo sapiens	132-136
25912549-10	2015	Taken together, these results suggest that paclitaxel may be an effective anticancer agent through regulating the expression of p21(Cip1) for the treatment of BRAF mutant melanoma cells resistant to BRAF inhibitors.	Paclitaxel	43-53	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	159-163
25912549-10	2015	Taken together, these results suggest that paclitaxel may be an effective anticancer agent through regulating the expression of p21(Cip1) for the treatment of BRAF mutant melanoma cells resistant to BRAF inhibitors.	Paclitaxel	43-53	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	199-203
25888278-4	2015	More importantly, Ptx-induced expression of P-glycoprotein was repressed by the nanocombination both at the protein and gene levels.	Paclitaxel	18-21	ATP binding cassette subfamily B member 1	Homo sapiens	44-58
25801244-8	2015	The P-gp expression was assessed by the Western blot; it showed that SKOV3/PTX cells showed highly expressed P-gp protein, while their sensitive cells scarcely showed P-gp.	Paclitaxel	75-78	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
26622605-3	2015	Furthermore, application of the anticancer agent Taxol appeared to reduce nuclear RhoA localization, indicating an association between the nuclear translocation of RhoA and tumor progression.	Paclitaxel	49-54	ras homolog family member A	Homo sapiens	82-86
26622605-3	2015	Furthermore, application of the anticancer agent Taxol appeared to reduce nuclear RhoA localization, indicating an association between the nuclear translocation of RhoA and tumor progression.	Paclitaxel	49-54	ras homolog family member A	Homo sapiens	164-168
25801244-8	2015	The P-gp expression was assessed by the Western blot; it showed that SKOV3/PTX cells showed highly expressed P-gp protein, while their sensitive cells scarcely showed P-gp.	Paclitaxel	75-78	ATP binding cassette subfamily B member 1	Homo sapiens	109-113
25801244-8	2015	The P-gp expression was assessed by the Western blot; it showed that SKOV3/PTX cells showed highly expressed P-gp protein, while their sensitive cells scarcely showed P-gp.	Paclitaxel	75-78	ATP binding cassette subfamily B member 1	Homo sapiens	109-113
25801244-10	2015	This study indicated that GQ-ODNs could effectively reverse P-gp-mediated PTX resistance by inhibiting the expression of P-gp and by the co-administration of GQ-ODNs and PTX that could increase the apoptosis of SKOV3/PTX cells.	Paclitaxel	74-77	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
25801244-10	2015	This study indicated that GQ-ODNs could effectively reverse P-gp-mediated PTX resistance by inhibiting the expression of P-gp and by the co-administration of GQ-ODNs and PTX that could increase the apoptosis of SKOV3/PTX cells.	Paclitaxel	74-77	ATP binding cassette subfamily B member 1	Homo sapiens	121-125
25801244-10	2015	This study indicated that GQ-ODNs could effectively reverse P-gp-mediated PTX resistance by inhibiting the expression of P-gp and by the co-administration of GQ-ODNs and PTX that could increase the apoptosis of SKOV3/PTX cells.	Paclitaxel	170-173	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
25801244-10	2015	This study indicated that GQ-ODNs could effectively reverse P-gp-mediated PTX resistance by inhibiting the expression of P-gp and by the co-administration of GQ-ODNs and PTX that could increase the apoptosis of SKOV3/PTX cells.	Paclitaxel	170-173	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
26219569-9	2015	Furthermore, we also observed that the growth-inhibitory effect of 17-DMAG was decreased in A549/PR and H460/PR cells generated to over-express P-gp by long-term exposure to paclitaxel, and these cells recovered their sensitivity to 17-DMAG through the inhibition of P-gp.	Paclitaxel	174-184	ATP binding cassette subfamily B member 1	Homo sapiens	144-148
26714597-13	2015	Estrogen and progesterone combined with paclitaxel show tumor suppressing or sensitizing effect through upregulated Drosha expression, and are associated with the estrogen receptor expression.	Paclitaxel	40-50	estrogen receptor 1	Homo sapiens	163-180
26223974-11	2015	After paclitaxel treatment, decreased apoptosis and G2 phase ratio, increased cell migration, increased level of Bcl-2, and decreased level of Bax were found in miRNA-149-down-regulated A2780 cells.	Paclitaxel	6-16	BCL2 apoptosis regulator	Homo sapiens	113-118
26223974-11	2015	After paclitaxel treatment, decreased apoptosis and G2 phase ratio, increased cell migration, increased level of Bcl-2, and decreased level of Bax were found in miRNA-149-down-regulated A2780 cells.	Paclitaxel	6-16	BCL2 associated X, apoptosis regulator	Homo sapiens	143-146
26158423-6	2015	Knockdown of IMP3 or Lin28B decreased cell proliferation, migration, and invasion, and increased the platinum sensitivity, but not taxol sensitivity, of ovarian cancer cells through increased expression of hCTR1, a copper transporter involved in platinum uptake.	Paclitaxel	131-136	IMP U3 small nucleolar ribonucleoprotein 3	Homo sapiens	13-17
25791937-9	2015	These data indicated that thiacremonone leads to increased apoptotic cell death in lung cancer cell lines through greater inhibition of NF-kappaB by the combination treatment with paclitaxel.	Paclitaxel	180-190	nuclear factor kappa B subunit 1	Homo sapiens	136-145
25956050-4	2015	The obtained nanoparticles, denoted as PTX/TET-CTAB@MSN, exhibited pH-responsive release property with more easily released in the weak acidic environment.	Paclitaxel	39-42	moesin	Homo sapiens	52-55
25956050-6	2015	Furthermore, the PTX/TET-CTAB@MSN suppressed tumor cells growth more efficiently than only delivery of PTX (PTX-CTAB@MSN) or the free PTX.	Paclitaxel	17-20	moesin	Homo sapiens	30-33
25956050-6	2015	Furthermore, the PTX/TET-CTAB@MSN suppressed tumor cells growth more efficiently than only delivery of PTX (PTX-CTAB@MSN) or the free PTX.	Paclitaxel	17-20	moesin	Homo sapiens	108-120
25956050-6	2015	Furthermore, the PTX/TET-CTAB@MSN suppressed tumor cells growth more efficiently than only delivery of PTX (PTX-CTAB@MSN) or the free PTX.	Paclitaxel	103-106	moesin	Homo sapiens	30-33
25956050-6	2015	Furthermore, the PTX/TET-CTAB@MSN suppressed tumor cells growth more efficiently than only delivery of PTX (PTX-CTAB@MSN) or the free PTX.	Paclitaxel	103-106	moesin	Homo sapiens	30-33
26146988-7	2015	In addition, CDK5 knockdown alone and in combination with paclitaxel induced G1 cell cycle arrest and caspase 3 dependent apoptotic cell death associated with post-translational upregulation and nuclear translocation of TP53 and p27(Kip1) as well as TP53-dependent transcriptional induction of p21(Cip1) in wild type TP53 cancer cells.	Paclitaxel	58-68	tumor protein p53	Homo sapiens	250-254
26146988-7	2015	In addition, CDK5 knockdown alone and in combination with paclitaxel induced G1 cell cycle arrest and caspase 3 dependent apoptotic cell death associated with post-translational upregulation and nuclear translocation of TP53 and p27(Kip1) as well as TP53-dependent transcriptional induction of p21(Cip1) in wild type TP53 cancer cells.	Paclitaxel	58-68	cyclin dependent kinase inhibitor 1A	Homo sapiens	294-297
26146988-7	2015	In addition, CDK5 knockdown alone and in combination with paclitaxel induced G1 cell cycle arrest and caspase 3 dependent apoptotic cell death associated with post-translational upregulation and nuclear translocation of TP53 and p27(Kip1) as well as TP53-dependent transcriptional induction of p21(Cip1) in wild type TP53 cancer cells.	Paclitaxel	58-68	cyclin dependent kinase inhibitor 1A	Homo sapiens	298-302
26146988-7	2015	In addition, CDK5 knockdown alone and in combination with paclitaxel induced G1 cell cycle arrest and caspase 3 dependent apoptotic cell death associated with post-translational upregulation and nuclear translocation of TP53 and p27(Kip1) as well as TP53-dependent transcriptional induction of p21(Cip1) in wild type TP53 cancer cells.	Paclitaxel	58-68	tumor protein p53	Homo sapiens	250-254
26146988-10	2015	CDK5 modulates paclitaxel sensitivity by regulating AKT activation, the cell cycle and caspase-dependent apoptosis.	Paclitaxel	15-25	AKT serine/threonine kinase 1	Homo sapiens	52-55
26182353-0	2015	Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp.	Paclitaxel	42-52	ATP binding cassette subfamily B member 1	Homo sapiens	100-104
26182353-1	2015	P-glycoprotein (P-gp) can actively pump paclitaxel (PTX) out of cells and induces drug resistance.	Paclitaxel	40-50	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
26182353-1	2015	P-glycoprotein (P-gp) can actively pump paclitaxel (PTX) out of cells and induces drug resistance.	Paclitaxel	40-50	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
26182353-1	2015	P-glycoprotein (P-gp) can actively pump paclitaxel (PTX) out of cells and induces drug resistance.	Paclitaxel	52-55	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
26182353-1	2015	P-glycoprotein (P-gp) can actively pump paclitaxel (PTX) out of cells and induces drug resistance.	Paclitaxel	52-55	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
26146988-0	2015	CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.	Paclitaxel	15-25	AKT serine/threonine kinase 1	Homo sapiens	76-79
26146988-6	2015	Knockdown of CDK5 with siRNAs inhibits activation of AKT which significantly correlates with decreased cell growth and enhanced paclitaxel sensitivity in ovarian cancer cell lines.	Paclitaxel	128-138	AKT serine/threonine kinase 1	Homo sapiens	53-56
26146988-7	2015	In addition, CDK5 knockdown alone and in combination with paclitaxel induced G1 cell cycle arrest and caspase 3 dependent apoptotic cell death associated with post-translational upregulation and nuclear translocation of TP53 and p27(Kip1) as well as TP53-dependent transcriptional induction of p21(Cip1) in wild type TP53 cancer cells.	Paclitaxel	58-68	tumor protein p53	Homo sapiens	220-224
25851250-2	2015	Here, degarelix [Ac-D-Nal-D-Cpa-D-Pal-Ser-Aph(L-Hor)-D-Aph(Cbm)-Leu-ILys-Pro-D-Ala-NH2], a gonadotropin-releasing hormone antagonist, was employed as a targeting moiety for paclitaxel (PTX).	Paclitaxel	173-183	acylaminoacyl-peptide hydrolase	Homo sapiens	42-45
26211584-4	2015	We have used Schrodinger suite 2014, to perform molecular docking of human CYP3A4, by Induced Fit Docking using gemcitabine, cisplatin, carboplatin, docetaxel and paclitaxel drugs.	Paclitaxel	163-173	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
25975389-7	2015	Metformin treatment was also found to augment its anti-proliferative effect in SKOV3 and taxol-resistant SKOV3/TR cells transfected with Axl and Tyro3 specific siRNAs, siAxl and siTyro3, respectively, suggesting that metformin might target Axl and Tyro3 RTKs to restrain cell proliferation.	Paclitaxel	89-94	TYRO3 protein tyrosine kinase	Homo sapiens	145-150
25975389-7	2015	Metformin treatment was also found to augment its anti-proliferative effect in SKOV3 and taxol-resistant SKOV3/TR cells transfected with Axl and Tyro3 specific siRNAs, siAxl and siTyro3, respectively, suggesting that metformin might target Axl and Tyro3 RTKs to restrain cell proliferation.	Paclitaxel	89-94	TYRO3 protein tyrosine kinase	Homo sapiens	180-185
25826750-0	2015	A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer.	Paclitaxel	44-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
25640606-6	2015	Inactivating these pathways using the PI3K/Akt pathway inhibitor LY294002 or the MAP kinase pathway inhibitor PD98059 renders the DU145-TxR cells more sensitive to paclitaxel.	Paclitaxel	164-174	AKT serine/threonine kinase 1	Homo sapiens	43-46
25851250-2	2015	Here, degarelix [Ac-D-Nal-D-Cpa-D-Pal-Ser-Aph(L-Hor)-D-Aph(Cbm)-Leu-ILys-Pro-D-Ala-NH2], a gonadotropin-releasing hormone antagonist, was employed as a targeting moiety for paclitaxel (PTX).	Paclitaxel	173-183	acylaminoacyl-peptide hydrolase	Homo sapiens	55-58
25851250-2	2015	Here, degarelix [Ac-D-Nal-D-Cpa-D-Pal-Ser-Aph(L-Hor)-D-Aph(Cbm)-Leu-ILys-Pro-D-Ala-NH2], a gonadotropin-releasing hormone antagonist, was employed as a targeting moiety for paclitaxel (PTX).	Paclitaxel	185-188	acylaminoacyl-peptide hydrolase	Homo sapiens	42-45
25851250-2	2015	Here, degarelix [Ac-D-Nal-D-Cpa-D-Pal-Ser-Aph(L-Hor)-D-Aph(Cbm)-Leu-ILys-Pro-D-Ala-NH2], a gonadotropin-releasing hormone antagonist, was employed as a targeting moiety for paclitaxel (PTX).	Paclitaxel	185-188	acylaminoacyl-peptide hydrolase	Homo sapiens	55-58
25815442-0	2015	Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.	Paclitaxel	77-82	TYRO3 protein tyrosine kinase	Homo sapiens	18-23
25777341-15	2015	In addition, the protein expression levels of caspase-3 were increased following treatment with a combination of CZEO and PTX.	Paclitaxel	122-125	caspase 3	Homo sapiens	46-55
25760096-0	2015	Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	125-128
25760096-11	2015	SET-induced paclitaxel resistance was found to be associated with the activation of the PI3K/Akt pathway.	Paclitaxel	12-22	AKT serine/threonine kinase 1	Homo sapiens	93-96
25760096-13	2015	Furthermore, paeonol significantly sensitized the MCF-7/PTX to paclitaxel via regulation of ABC transporters, B cell lymphoma-2 (Bcl-2) and Bcl-2-associated X protein.	Paclitaxel	63-73	BCL2 apoptosis regulator	Homo sapiens	140-145
25760096-14	2015	In addition, paeonol inhibited SET-mediated paclitaxel resistance by attenuating PI3K/Akt pathway activity in the MCF-7/PTX cells.	Paclitaxel	44-54	AKT serine/threonine kinase 1	Homo sapiens	86-89
25815442-14	2015	Taken together, the results of the present study demonstrated that the acquired taxol resistance of ovarian cancer cells was associated with ROS-dependent upregulation in the expression of Tyro3 RTK and the subsequent activation of Akt.	Paclitaxel	80-85	TYRO3 protein tyrosine kinase	Homo sapiens	189-194
25815442-10	2015	In addition, restoration of the level of Tyro3 by transfecting Tyro3-specific small interfering RNA into the SKOV3/TR cells reduced the proliferative capacity of the cells, indicating that upregulation of the expression of Tyro3 in SKOV3/TR cells may promote survival in the presence of taxol, which eventually resulted in the acquisition of resistance upon taxol treatment.	Paclitaxel	287-292	TYRO3 protein tyrosine kinase	Homo sapiens	41-46
25815442-14	2015	Taken together, the results of the present study demonstrated that the acquired taxol resistance of ovarian cancer cells was associated with ROS-dependent upregulation in the expression of Tyro3 RTK and the subsequent activation of Akt.	Paclitaxel	80-85	AKT serine/threonine kinase 1	Homo sapiens	232-235
25815442-10	2015	In addition, restoration of the level of Tyro3 by transfecting Tyro3-specific small interfering RNA into the SKOV3/TR cells reduced the proliferative capacity of the cells, indicating that upregulation of the expression of Tyro3 in SKOV3/TR cells may promote survival in the presence of taxol, which eventually resulted in the acquisition of resistance upon taxol treatment.	Paclitaxel	287-292	TYRO3 protein tyrosine kinase	Homo sapiens	63-68
25815442-10	2015	In addition, restoration of the level of Tyro3 by transfecting Tyro3-specific small interfering RNA into the SKOV3/TR cells reduced the proliferative capacity of the cells, indicating that upregulation of the expression of Tyro3 in SKOV3/TR cells may promote survival in the presence of taxol, which eventually resulted in the acquisition of resistance upon taxol treatment.	Paclitaxel	287-292	TYRO3 protein tyrosine kinase	Homo sapiens	63-68
25815442-10	2015	In addition, restoration of the level of Tyro3 by transfecting Tyro3-specific small interfering RNA into the SKOV3/TR cells reduced the proliferative capacity of the cells, indicating that upregulation of the expression of Tyro3 in SKOV3/TR cells may promote survival in the presence of taxol, which eventually resulted in the acquisition of resistance upon taxol treatment.	Paclitaxel	358-363	TYRO3 protein tyrosine kinase	Homo sapiens	41-46
25815442-10	2015	In addition, restoration of the level of Tyro3 by transfecting Tyro3-specific small interfering RNA into the SKOV3/TR cells reduced the proliferative capacity of the cells, indicating that upregulation of the expression of Tyro3 in SKOV3/TR cells may promote survival in the presence of taxol, which eventually resulted in the acquisition of resistance upon taxol treatment.	Paclitaxel	358-363	TYRO3 protein tyrosine kinase	Homo sapiens	63-68
25815442-10	2015	In addition, restoration of the level of Tyro3 by transfecting Tyro3-specific small interfering RNA into the SKOV3/TR cells reduced the proliferative capacity of the cells, indicating that upregulation of the expression of Tyro3 in SKOV3/TR cells may promote survival in the presence of taxol, which eventually resulted in the acquisition of resistance upon taxol treatment.	Paclitaxel	358-363	TYRO3 protein tyrosine kinase	Homo sapiens	63-68
25964202-0	2015	Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.	Paclitaxel	86-96	malic enzyme complex, mitochondrial	Mus musculus	25-30
25904556-0	2015	CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.	Paclitaxel	128-138	cannabinoid receptor 2 (macrophage)	Mus musculus	35-38
25904556-6	2015	suppressed paclitaxel-induced allodynia in WT and CB2KO mice, but not CB1KO mice.	Paclitaxel	11-21	cannabinoid receptor 2 (macrophage)	Mus musculus	50-53
25904556-10	2015	produced catalepsy in WT mice, which precluded determination of antiallodynic efficacy but produced sustained CB2-mediated suppression of paclitaxel-induced allodynia in CB1KO mice; these antiallodynic effects were blocked by the CB2 antagonist 6-iodopravadoline (AM630).	Paclitaxel	138-148	cannabinoid receptor 2 (macrophage)	Mus musculus	110-113
25904556-10	2015	produced catalepsy in WT mice, which precluded determination of antiallodynic efficacy but produced sustained CB2-mediated suppression of paclitaxel-induced allodynia in CB1KO mice; these antiallodynic effects were blocked by the CB2 antagonist 6-iodopravadoline (AM630).	Paclitaxel	138-148	cannabinoid receptor 2 (macrophage)	Mus musculus	230-233
25964202-11	2015	Although previous studies indicated that silencing of MDR-1 alone sensitized MDR ovarian cancer to paclitaxel only modestly, these data suggest that concurrent silencing of PKM-2 improves the efficacy of paclitaxel against MDR ovarian cancer.	Paclitaxel	99-109	malic enzyme complex, mitochondrial	Mus musculus	54-59
26068792-0	2015	SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.	Paclitaxel	97-102	mechanistic target of rapamycin kinase	Homo sapiens	121-125
26115510-0	2015	Cancer Associated Fibroblast-Derived Hepatocyte Growth Factor Inhibits the Paclitaxel-Induced Apoptosis of Lung Cancer A549 Cells by Up-Regulating the PI3K/Akt and GRP78 Signaling on a Microfluidic Platform.	Paclitaxel	75-85	AKT serine/threonine kinase 1	Homo sapiens	156-159
26115510-0	2015	Cancer Associated Fibroblast-Derived Hepatocyte Growth Factor Inhibits the Paclitaxel-Induced Apoptosis of Lung Cancer A549 Cells by Up-Regulating the PI3K/Akt and GRP78 Signaling on a Microfluidic Platform.	Paclitaxel	75-85	heat shock protein family A (Hsp70) member 5	Homo sapiens	164-169
26115510-7	2015	Furthermore, inhibition of PI3K or GRP78 enhanced spontaneous and paclitaxel-induced A549 cell apoptosis.	Paclitaxel	66-76	heat shock protein family A (Hsp70) member 5	Homo sapiens	35-40
26086592-3	2015	Here, we silenced the taxol-sensitizer genes identified (acrbp, atp6v0d2, fgd4, hs6st2, psma6, and tubgcp2) in nine other cancer cell types (including lung, cervical, ovarian, and hepatocellular carcinoma cell lines) that showed reduced cell viability in the presence of a sub-lethal concentration of taxol.	Paclitaxel	22-27	acrosin binding protein	Homo sapiens	57-62
26086592-3	2015	Here, we silenced the taxol-sensitizer genes identified (acrbp, atp6v0d2, fgd4, hs6st2, psma6, and tubgcp2) in nine other cancer cell types (including lung, cervical, ovarian, and hepatocellular carcinoma cell lines) that showed reduced cell viability in the presence of a sub-lethal concentration of taxol.	Paclitaxel	22-27	FYVE, RhoGEF and PH domain containing 4	Homo sapiens	74-78
26086592-3	2015	Here, we silenced the taxol-sensitizer genes identified (acrbp, atp6v0d2, fgd4, hs6st2, psma6, and tubgcp2) in nine other cancer cell types (including lung, cervical, ovarian, and hepatocellular carcinoma cell lines) that showed reduced cell viability in the presence of a sub-lethal concentration of taxol.	Paclitaxel	22-27	proteasome 20S subunit alpha 6	Homo sapiens	88-93
26086592-7	2015	Notably, four of the five inducible taxol-sensitizer genes tested (acrbp, atp6v0d2, psma6, and tubgcp2) were upregulated in a taxol-resistant ovarian cancer cell line.	Paclitaxel	36-41	acrosin binding protein	Homo sapiens	67-72
26086592-7	2015	Notably, four of the five inducible taxol-sensitizer genes tested (acrbp, atp6v0d2, psma6, and tubgcp2) were upregulated in a taxol-resistant ovarian cancer cell line.	Paclitaxel	36-41	proteasome 20S subunit alpha 6	Homo sapiens	84-89
26086592-7	2015	Notably, four of the five inducible taxol-sensitizer genes tested (acrbp, atp6v0d2, psma6, and tubgcp2) were upregulated in a taxol-resistant ovarian cancer cell line.	Paclitaxel	126-131	acrosin binding protein	Homo sapiens	67-72
26086592-7	2015	Notably, four of the five inducible taxol-sensitizer genes tested (acrbp, atp6v0d2, psma6, and tubgcp2) were upregulated in a taxol-resistant ovarian cancer cell line.	Paclitaxel	126-131	proteasome 20S subunit alpha 6	Homo sapiens	84-89
25715123-10	2015	The further functional assay revealed that VAV3 knockdown regulated CSC activation and ovarian cancer cell proliferation and sensitized paclitaxel (PTX)-resistant cancer cells to PTX treatment.	Paclitaxel	136-146	vav guanine nucleotide exchange factor 3	Homo sapiens	43-47
25715123-10	2015	The further functional assay revealed that VAV3 knockdown regulated CSC activation and ovarian cancer cell proliferation and sensitized paclitaxel (PTX)-resistant cancer cells to PTX treatment.	Paclitaxel	148-151	vav guanine nucleotide exchange factor 3	Homo sapiens	43-47
25715123-10	2015	The further functional assay revealed that VAV3 knockdown regulated CSC activation and ovarian cancer cell proliferation and sensitized paclitaxel (PTX)-resistant cancer cells to PTX treatment.	Paclitaxel	179-182	vav guanine nucleotide exchange factor 3	Homo sapiens	43-47
26555418-4	2015	The expression of Bax, Bcl-2 and miR-21 in parental and paclitaxel-resistant cells was detected by RT-PCR and Western blotting.	Paclitaxel	56-66	BCL2 associated X, apoptosis regulator	Homo sapiens	18-21
26115510-9	2015	Inhibition of PI3K or GRP78 attenuated the CAF matrix-mediated inhibition on paclitaxel-induced A549 cell apoptosis.	Paclitaxel	77-87	heat shock protein family A (Hsp70) member 5	Homo sapiens	22-27
26015406-6	2015	We further show that phospho-MARCKS acted upstream of Src activation upon paclitaxel exposure.	Paclitaxel	74-84	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	54-57
25891676-16	2015	Paclitaxel was also found to induce apoptosis and TNF-alpha was upregulated in paclitaxel-treated hASCs (P &lt; 0.001).	Paclitaxel	0-10	tumor necrosis factor	Homo sapiens	50-59
25891676-16	2015	Paclitaxel was also found to induce apoptosis and TNF-alpha was upregulated in paclitaxel-treated hASCs (P &lt; 0.001).	Paclitaxel	79-89	tumor necrosis factor	Homo sapiens	50-59
25891676-18	2015	Paclitaxel inhibits hASC proliferation, differentiation, and induces apoptosis, possibly through the TNF-alpha pathway.	Paclitaxel	0-10	tumor necrosis factor	Homo sapiens	101-110
25424246-5	2015	When using HL60, losartan and the CYP3A4-selective inhibitors, erythromycin and ketoconazole, caused a greater inhibition of the paclitaxel metabolism than quercetin, a CYP2C8-selective inhibitor.	Paclitaxel	129-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40
25928036-6	2015	Immunoprecipitation of PDCD4-RNA complexes and RT-PCR revealed that PDCD4 mediated PTX sensitivity acts through its interaction with mRNA of UBE2S, a ubiquitin K11 linkage conjugating enzyme critical for mitotic exit.	Paclitaxel	83-86	ubiquitin conjugating enzyme E2 S	Homo sapiens	141-146
25424246-6	2015	This demonstrated that the paclitaxel metabolism was mainly catalysed by CYP3A4 in HL60.	Paclitaxel	27-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-79
25424246-7	2015	There were no significant differences found for the inhibitory effects caused by the four inhibitors of the paclitaxel metabolism in HL54, indicating that both CYP2C8 and CYP3A4 play important roles in paclitaxel metabolism in HL54.	Paclitaxel	202-212	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	171-177
25900794-14	2015	In addition, resensitization to taxol was also observed in mouse tumor xenografts from cells over-expressing miR-218.	Paclitaxel	32-37	microRNA 218	Mus musculus	109-116
25424246-10	2015	The CYP2C8*3 allele carriers are likely susceptible to the interactions of losartan and CYP3A4 inhibitors to paclitaxel metabolism.	Paclitaxel	109-119	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
25579459-9	2015	The present study evaluated the activity and safety of nab-PTX as a neoadjuvant treatment of HER2(+) breast cancer.	Paclitaxel	59-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
25783790-8	2015	Furthermore, overexpression of miR-34a increased chemosensitivity of breast cancer cells to paclitaxel (PTX) by downregulating the Notch1 pathway.	Paclitaxel	92-102	notch receptor 1	Homo sapiens	131-137
25783790-8	2015	Furthermore, overexpression of miR-34a increased chemosensitivity of breast cancer cells to paclitaxel (PTX) by downregulating the Notch1 pathway.	Paclitaxel	104-107	notch receptor 1	Homo sapiens	131-137
25783790-10	2015	Taken together, our results indicate that miR-34a inhibited breast cancer stemness and increased the chemosensitivity to PTX partially by downregulating the Notch1 pathway, suggesting that miR-34a/Notch1 play an important role in regulating breast cancer stem cells.	Paclitaxel	121-124	notch receptor 1	Homo sapiens	157-163
25783790-10	2015	Taken together, our results indicate that miR-34a inhibited breast cancer stemness and increased the chemosensitivity to PTX partially by downregulating the Notch1 pathway, suggesting that miR-34a/Notch1 play an important role in regulating breast cancer stem cells.	Paclitaxel	121-124	notch receptor 1	Homo sapiens	197-203
25011497-1	2015	BACKGROUND: Based on previous results obtained with non-pegylated liposomal-encapsulated doxorubicin (TLC-D99) together with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer (BC), a similar regimen was evaluated in the neoadjuvant setting in a prospectively selected series of consecutive patients with clinical stage II-III BC.	Paclitaxel	125-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-209
25011497-1	2015	BACKGROUND: Based on previous results obtained with non-pegylated liposomal-encapsulated doxorubicin (TLC-D99) together with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer (BC), a similar regimen was evaluated in the neoadjuvant setting in a prospectively selected series of consecutive patients with clinical stage II-III BC.	Paclitaxel	125-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	211-215
25827582-9	2015	The paclitaxel-induced attenuation of GABAergic tonic inhibition was ameliorated by blocking GAT-1 but not GAT-3 transporters.	Paclitaxel	4-14	solute carrier family 6 member 1	Homo sapiens	93-98
25827582-0	2015	Blocking the GABA transporter GAT-1 ameliorates spinal GABAergic disinhibition and neuropathic pain induced by paclitaxel.	Paclitaxel	111-121	solute carrier family 6 member 1	Homo sapiens	30-35
25827582-9	2015	The paclitaxel-induced attenuation of GABAergic tonic inhibition was ameliorated by blocking GAT-1 but not GAT-3 transporters.	Paclitaxel	4-14	solute carrier family 6 member 13	Homo sapiens	107-112
25827582-10	2015	Paclitaxel-induced neuropathic pain was significantly attenuated by the intrathecal injection of a GAT-1 inhibitor.	Paclitaxel	0-10	solute carrier family 6 member 1	Homo sapiens	99-104
25827582-11	2015	These findings suggest that targeting GAT-1 transporters for reversing disinhibition in the spinal dorsal horn may be a useful approach for treating paclitaxel-induced neuropathic pain.	Paclitaxel	149-159	solute carrier family 6 member 1	Homo sapiens	38-43
25827582-13	2015	In this study, we demonstrated that animals treated with paclitaxel develop neuropathic pain, have enhancements of GABA transporter-1 protein expression and global GABA uptake, as well as suppression of GABAergic tonic inhibition in the spinal dorsal horn.	Paclitaxel	57-67	solute carrier family 6 member 1	Homo sapiens	115-133
25827582-14	2015	Pharmacological inhibition of GABA transporter-1 ameliorates the paclitaxel-induced suppression of GABAergic tonic inhibition and neuropathic pain.	Paclitaxel	65-75	solute carrier family 6 member 1	Homo sapiens	30-48
25827582-15	2015	Thus, targeting GAT-1 transporters for reversing GABAergic disinhibition in the spinal dorsal horn could be a useful approach for treating paclitaxel-induced neuropathic pain.	Paclitaxel	139-149	solute carrier family 6 member 1	Homo sapiens	16-21
25494456-8	2015	Chromatin immunoprecipitation further found that paclitaxel induced an increased recruitment of nuclear factor-kappaB (NF-kappaB)p65 to the Cx3cl1 promoter region.	Paclitaxel	49-59	synaptotagmin 1	Rattus norvegicus	129-132
25946136-6	2015	Combination of let-7b mimic with paclitaxel or gemcitabine diminished MEK/ERK and PI3K/AKT signaling concurrently, triggered the onset of apoptosis, and reverted the epithelial-mesenchymal transition in KRAS mutant tumor cells.	Paclitaxel	33-43	mitogen-activated protein kinase kinase 7	Homo sapiens	70-73
25946136-6	2015	Combination of let-7b mimic with paclitaxel or gemcitabine diminished MEK/ERK and PI3K/AKT signaling concurrently, triggered the onset of apoptosis, and reverted the epithelial-mesenchymal transition in KRAS mutant tumor cells.	Paclitaxel	33-43	mitogen-activated protein kinase 1	Homo sapiens	74-77
25946136-6	2015	Combination of let-7b mimic with paclitaxel or gemcitabine diminished MEK/ERK and PI3K/AKT signaling concurrently, triggered the onset of apoptosis, and reverted the epithelial-mesenchymal transition in KRAS mutant tumor cells.	Paclitaxel	33-43	AKT serine/threonine kinase 1	Homo sapiens	87-90
25887886-0	2015	Blocking IL1beta Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis.	Paclitaxel	35-45	interleukin 1 beta	Mus musculus	9-16
25887886-2	2015	Here, we show that the proinflammatory cytokine IL1beta is overexpressed in response to paclitaxel chemotherapy in macrophages, subsequently promoting the invasive properties of malignant cells.	Paclitaxel	88-98	interleukin 1 beta	Mus musculus	48-55
25887886-4	2015	Tumors from mice treated with combined therapy of paclitaxel and the IL1 receptor antagonist anakinra exhibit increased number of M2 macrophages and vessel leakiness when compared with paclitaxel monotherapy-treated mice, indicating a prometastatic role of M2 macrophages in the IL1beta-deprived microenvironment.	Paclitaxel	50-60	interleukin 1 beta	Mus musculus	279-286
25515492-7	2015	Additionally, HA-PEI/HA-PEG nanoparticles loaded with MDR1 siRNA efficiently down-regulated the expression of MDR1 and P-glycoprotein (Pgp), inhibited the functional activity of Pgp, and subsequently increased cell sensitivity to paclitaxel.	Paclitaxel	230-240	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
25515492-7	2015	Additionally, HA-PEI/HA-PEG nanoparticles loaded with MDR1 siRNA efficiently down-regulated the expression of MDR1 and P-glycoprotein (Pgp), inhibited the functional activity of Pgp, and subsequently increased cell sensitivity to paclitaxel.	Paclitaxel	230-240	ATP binding cassette subfamily B member 1	Homo sapiens	110-114
25515492-7	2015	Additionally, HA-PEI/HA-PEG nanoparticles loaded with MDR1 siRNA efficiently down-regulated the expression of MDR1 and P-glycoprotein (Pgp), inhibited the functional activity of Pgp, and subsequently increased cell sensitivity to paclitaxel.	Paclitaxel	230-240	ATP binding cassette subfamily B member 1	Homo sapiens	119-133
25515492-7	2015	Additionally, HA-PEI/HA-PEG nanoparticles loaded with MDR1 siRNA efficiently down-regulated the expression of MDR1 and P-glycoprotein (Pgp), inhibited the functional activity of Pgp, and subsequently increased cell sensitivity to paclitaxel.	Paclitaxel	230-240	ATP binding cassette subfamily B member 1	Homo sapiens	135-138
25515492-7	2015	Additionally, HA-PEI/HA-PEG nanoparticles loaded with MDR1 siRNA efficiently down-regulated the expression of MDR1 and P-glycoprotein (Pgp), inhibited the functional activity of Pgp, and subsequently increased cell sensitivity to paclitaxel.	Paclitaxel	230-240	ATP binding cassette subfamily B member 1	Homo sapiens	178-181
25494456-0	2015	Up-regulation of CX3CL1 via Nuclear Factor-kappaB-dependent Histone Acetylation Is Involved in Paclitaxel-induced Peripheral Neuropathy.	Paclitaxel	95-105	C-X3-C motif chemokine ligand 1	Rattus norvegicus	17-23
25494456-2	2015	However, whether CX3CL1 participates in the paclitaxel-induced painful peripheral neuropathy remains unknown.	Paclitaxel	44-54	C-X3-C motif chemokine ligand 1	Rattus norvegicus	17-23
25494456-3	2015	The aim of the current study was to elucidate the involvement of transcriptional factors nuclear factor-kappaB (NF-kappaB) and its causal interaction with CX3CL1 signaling in the paclitaxel-induced painful peripheral neuropathy.	Paclitaxel	179-189	C-X3-C motif chemokine ligand 1	Rattus norvegicus	155-161
25494456-6	2015	RESULTS: The application of paclitaxel induced an up-regulation of CX3CL1 expression in the spinal neurons, which is reduced significantly by NF-kappaB inhibitor ammonium pyrrolidinedithiocarbamate or p65 small interfering RNA.	Paclitaxel	28-38	C-X3-C motif chemokine ligand 1	Rattus norvegicus	67-73
25494456-6	2015	RESULTS: The application of paclitaxel induced an up-regulation of CX3CL1 expression in the spinal neurons, which is reduced significantly by NF-kappaB inhibitor ammonium pyrrolidinedithiocarbamate or p65 small interfering RNA.	Paclitaxel	28-38	synaptotagmin 1	Rattus norvegicus	201-204
25494456-7	2015	Blockade of either CX3CL1 (n = 12 each) or NF-kappaB (n = 12 each) signaling pathway attenuated mechanical allodynia induced by paclitaxel.	Paclitaxel	128-138	C-X3-C motif chemokine ligand 1	Rattus norvegicus	19-25
25494456-8	2015	Chromatin immunoprecipitation further found that paclitaxel induced an increased recruitment of nuclear factor-kappaB (NF-kappaB)p65 to the Cx3cl1 promoter region.	Paclitaxel	49-59	C-X3-C motif chemokine ligand 1	Rattus norvegicus	140-146
25494456-9	2015	Furthermore, an increased acetylation level of H4, but not H3, in Cx3cl1 promoter region in spinal neurons was detected after paclitaxel treatment, which was reversed by inhibition of NF-kappaB with ammonium pyrrolidinedithiocarbamate or p65 small interfering RNA.	Paclitaxel	126-136	C-X3-C motif chemokine ligand 1	Rattus norvegicus	66-72
25494456-9	2015	Furthermore, an increased acetylation level of H4, but not H3, in Cx3cl1 promoter region in spinal neurons was detected after paclitaxel treatment, which was reversed by inhibition of NF-kappaB with ammonium pyrrolidinedithiocarbamate or p65 small interfering RNA.	Paclitaxel	126-136	synaptotagmin 1	Rattus norvegicus	238-241
25494456-10	2015	CONCLUSIONS: These findings suggest that up-regulation of CX3CL1 via NF-kappaB-dependent H4 acetylation might be critical for paclitaxel-induced mechanical allodynia.	Paclitaxel	126-136	C-X3-C motif chemokine ligand 1	Rattus norvegicus	58-64
25708932-9	2015	Different doses of paclitaxel were required in the two ACC cell line to induce a block in the G2 phase, characterized by increased cyclin B1 levels and to induce apoptosis by pro-caspase-3 activation.	Paclitaxel	19-29	caspase 3	Homo sapiens	175-188
26054670-2	2015	Trastuzumab is a highly targeting protein to HER2 protein, and it is usually combined with paclitaxel or cisplatin for the treatment of HER2-overexpressing breast cancer.	Paclitaxel	91-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-140
26054673-3	2015	We found that tumorspheres generated from MCF-7 human breast cancer cells exhibited high proportions of quiescent cells and expressed MDR-1 at elevated levels, leading to resistance to 5-fluorouracil, paclitaxel, and doxorubicin.	Paclitaxel	201-211	ATP binding cassette subfamily B member 1	Homo sapiens	134-139
25684390-8	2015	Furthermore, in relation to a chemotherapeutic response, quantitative real-time polymerase chain reaction (qRT-PCR) analysis revealed that only PEO1 and PEO4 OC cells with the highest miR-433 expression survive paclitaxel treatment.	Paclitaxel	211-221	twinkle mtDNA helicase	Homo sapiens	144-148
25754234-5	2015	PG545 inhibited growth factor-mediated cell migration and reduced HB-EGF-induced phosphorylation of ERK, AKT and EGFR in vitro and significantly reduced tumour burden which was enhanced when combined with paclitaxel in an A2780 model or carboplatin in a SKOV-3 model.	Paclitaxel	205-215	mitogen-activated protein kinase 1	Homo sapiens	100-103
25779097-4	2015	Ganoderenic acid B, a lanostane-type triterpene isolated from Ganoderma lucidum, exhibited potent reversal effect on ABCB1-mediated multidrug resistance of HepG2/ADM cells to doxorubicin, vincristine and paclitaxel.	Paclitaxel	204-214	ATP binding cassette subfamily B member 1	Homo sapiens	117-122
25931810-3	2015	In this study, we hypothesized that low-dose paclitaxel may block the STAT3 (signal transducer and activator of transcription 3) signaling to attenuate fibrosis in a mouse model with unilateral ureteral obstruction.	Paclitaxel	45-55	signal transducer and activator of transcription 3	Mus musculus	70-75
26029934-3	2015	OBJECTIVE: To report on experience with nab-paclitaxel for human epidermal growth factor receptor 2 (HER2)-negative MBC and identify patient characteristics affecting nab-paclitaxel treatment patterns in the community practice setting.	Paclitaxel	44-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-99
26502701-0	2015	INHIBITOR OF THE TRANSCRIPTION FACTOR NF-kappaB, DHMEQ, ENHANCES THE EFFECT OF PACLITAXEL ON CELLS OF ANAPLASTIC THYROID CARCINOMA IN VITRO AND IN VIVO.	Paclitaxel	79-89	nuclear factor kappa B subunit 1	Homo sapiens	38-47
26502701-3	2015	Paclitaxel-induced activation of nuclear factor kappa B (NF-kappaB) leads to an increase of some antiapoptotic proteins expression such as survivin, cIAP, XIAP.	Paclitaxel	0-10	nuclear factor kappa B subunit 1	Homo sapiens	33-55
26502701-3	2015	Paclitaxel-induced activation of nuclear factor kappa B (NF-kappaB) leads to an increase of some antiapoptotic proteins expression such as survivin, cIAP, XIAP.	Paclitaxel	0-10	nuclear factor kappa B subunit 1	Homo sapiens	57-66
26502701-4	2015	A novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), was found to enhance cytotoxic effect of Ptx in anaplastic thyroid carcinoma cells.	Paclitaxel	110-113	nuclear factor kappa B subunit 1	Homo sapiens	8-17
26502701-7	2015	NF-kappaB inhibition also potentiates paclitaxel effect at tumors formed by xenotransplantation of FRO cells into mice.	Paclitaxel	38-48	nuclear factor kappa B subunit 1	Homo sapiens	0-9
26502701-9	2015	Thus, the combined use of paclitaxel and NF-kappaB inhibitor inhibits biochemical processes that contribute to the resistance of anaplastic thyroid carcinoma cells to paclitaxel action.	Paclitaxel	167-177	nuclear factor kappa B subunit 1	Homo sapiens	41-50
25769882-7	2015	The up-regulation of MDR1 protein and transcripts in EKVX cells was specifically associated with the expression of wild-type LKB1 and mainly responsible for the increased cellular resistance to paclitaxel.	Paclitaxel	194-204	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
25769882-10	2015	In contrast, in some NSCLC, the presence of LKB1 may facilitate increases in either MDR1 or class III beta-tubulin expression which can lead to paclitaxel resistance.	Paclitaxel	144-154	ATP binding cassette subfamily B member 1	Homo sapiens	84-88
25544595-7	2015	Taxol pretreatment significantly ameliorated the depolymerization of microtubules, improved Cx43 expression and redistribution, reduced the occurrence of VAs, ameliorated shortening of 90% repolarization action potential durations (APD)90 and improved APD dispersion during myocardial ischemia-reperfusion.	Paclitaxel	0-5	gap junction protein, alpha 1	Rattus norvegicus	92-96
25544595-8	2015	The present study demonstrated that taxol reduced ischemic VAs and its mechanism may be correlated with the preservation of Cx43 by stabilizing microtubules.	Paclitaxel	36-41	gap junction protein, alpha 1	Rattus norvegicus	124-128
25932632-7	2015	Moreover, two distinct trends were clearly expressed, where under the treatment of Disulfiram, paclitaxel, and MK-2206, the exponent coefficient of the frequency- modulus function remained almost unchanged, while with Celebrex, BAY, Totamine, TPA, and Vaproic acid, the exponential rate was significantly increased.	Paclitaxel	95-105	plasminogen activator, tissue type	Homo sapiens	243-246
25931813-14	2015	CONCLUSION: Our results showed that single-agent nab-paclitaxel 260 mg/m(2) every 3 weeks is an effective and well tolerated regimen as second-line chemotherapy in HER2-negative, taxane-pretreated MBC patients, and that it produced interesting values of objective response rate and progression-free survival without the concern of significant toxicity.	Paclitaxel	53-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	164-168
25931810-3	2015	In this study, we hypothesized that low-dose paclitaxel may block the STAT3 (signal transducer and activator of transcription 3) signaling to attenuate fibrosis in a mouse model with unilateral ureteral obstruction.	Paclitaxel	45-55	signal transducer and activator of transcription 3	Mus musculus	77-127
25931810-8	2015	Furthermore, paclitaxel also ameliorated renal fibrosis by down-regulating the expression of fibronectin, alpha-SMA, and collagen I, and suppressed the infiltration of macrophages and production of TNF-alpha, IL-1beta, TGF-beta, and ICAM-1 (intercellular adhesion molecule 1) by inhibition of STAT3 activity in obstructive nephropathy.	Paclitaxel	13-23	tumor necrosis factor	Rattus norvegicus	198-207
25931810-8	2015	Furthermore, paclitaxel also ameliorated renal fibrosis by down-regulating the expression of fibronectin, alpha-SMA, and collagen I, and suppressed the infiltration of macrophages and production of TNF-alpha, IL-1beta, TGF-beta, and ICAM-1 (intercellular adhesion molecule 1) by inhibition of STAT3 activity in obstructive nephropathy.	Paclitaxel	13-23	interleukin 1 beta	Rattus norvegicus	209-217
25931813-0	2015	Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.	Paclitaxel	27-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
25596561-1	2015	Paclitaxel is an alternative chemotherapeutic agent for chronic myelogenous leukemia (CML) when primary or secondary resistance of tyrosine kinase inhibitors (TKI) is emerging, because paclitaxel could bypass the apoptotic deficiencies linked to p53 and fas ligand pathways in CML.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	246-249
25867272-0	2015	The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.	Paclitaxel	40-50	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	100-104
25867272-16	2015	CONCLUSIONS: Axitinib followed by carboplatin and paclitaxel was well tolerated and effective in BRAF wild-type metastatic melanoma.	Paclitaxel	50-60	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	97-101
25596561-2	2015	However, high levels of Bcl-2 family proteins in CML could resist paclitaxel-induced apoptosis.	Paclitaxel	66-76	BCL2 apoptosis regulator	Homo sapiens	24-29
25596561-6	2015	By using Bcl-2 siRNA, Bcl-XL siRNA or Mcl-1 siRNA, we found although each of the three members exhibited activities to block paclitaxel-induced apoptosis, Mcl-1 was the determinant for the synergistic effect between paclitaxel and ABT-737 or S1.	Paclitaxel	125-135	BCL2 like 1	Homo sapiens	22-28
25643607-11	2015	CONCLUSIONS: Taken together, these results suggest that silencing DVL1 sensitized A2780/Taxol cells to paclitaxel, by down-regulating AKT/GSK-3beta/beta-catenin signalling, providing a novel strategy for chemosensitization of ovarian cancer to paclitaxel-induced cytotoxicity.	Paclitaxel	244-254	dishevelled segment polarity protein 1	Homo sapiens	66-70
24858045-8	2015	Moreover, p21 is dramatically stabilized in mitotic tumor cells upon treatment with mitotic agents like paclitaxel or mitotic kinase inhibitors.	Paclitaxel	104-114	cyclin dependent kinase inhibitor 1A	Homo sapiens	10-13
25578058-8	2015	On the other hand, the expression of GRP78 obviously increased, suggesting that ER stress was induced after paclitaxel treatment.	Paclitaxel	108-118	heat shock protein family A (Hsp70) member 5	Homo sapiens	37-42
25643607-0	2015	Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3beta/beta-catenin signalling.	Paclitaxel	35-45	dishevelled segment polarity protein 1	Homo sapiens	10-23
25643607-0	2015	Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3beta/beta-catenin signalling.	Paclitaxel	35-45	AKT serine/threonine kinase 1	Homo sapiens	87-90
25643607-2	2015	In this study, we aimed to explore the function of DVL1 in paclitaxel-resistant human ovarian cancer cells.	Paclitaxel	59-69	dishevelled segment polarity protein 1	Homo sapiens	51-55
25643607-3	2015	MATERIALS AND METHODS: The MTT assay was used to assess effects of DVL1 silencing on sensitivity of cells that were otherwise resistant to paclitaxel (Taxol).	Paclitaxel	139-149	dishevelled segment polarity protein 1	Homo sapiens	67-71
25960213-4	2015	We have used Schrodinger suite 2014, to perform homology modelling of human MDR1 based on Mouse MDR1, followed by Induced Fit Docking with Paclitaxel, Docetaxel, Gemcitabine, Carboplatin and Cisplatin drugs.	Paclitaxel	139-149	ATP binding cassette subfamily B member 1	Homo sapiens	76-80
25960213-9	2015	Our results suggest that, Paclitaxel or combination of Paclitaxel+Gemcitabine could serve as a suitable therapy against MDR1 in NSCLC patients.	Paclitaxel	26-36	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
25960213-9	2015	Our results suggest that, Paclitaxel or combination of Paclitaxel+Gemcitabine could serve as a suitable therapy against MDR1 in NSCLC patients.	Paclitaxel	55-65	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
25643607-5	2015	RESULTS: Dishevelled-1 was found to be over-expressed in a paclitaxel-resistant cell line derived from human ovarian cancer cell line A2780 (A2780/Taxol line) as well as parental A2780 cells.	Paclitaxel	59-69	dishevelled segment polarity protein 1	Homo sapiens	9-22
26122237-4	2015	In the present study, Real-time PCR and Western blot were used to detect the protein expression level of metadherin before and after transfecting MDA-MB-231 cells to identify the effect, while the sensitivity of MDA-MB-231 cells to 1 mg/L doxorubicin and 8mg/L taxol was measured by methylthiazolyldiphenyl-tetrazolium bromide (MTT).	Paclitaxel	261-266	metadherin	Homo sapiens	105-115
25643607-6	2015	Down-regulation of DVL1 (using the inhibitor 3289-8625 or siRNA (siDVL1) against DVL1) sensitized A2780/Taxol cells to paclitaxel.	Paclitaxel	119-129	dishevelled segment polarity protein 1	Homo sapiens	19-23
25643607-6	2015	Down-regulation of DVL1 (using the inhibitor 3289-8625 or siRNA (siDVL1) against DVL1) sensitized A2780/Taxol cells to paclitaxel.	Paclitaxel	119-129	dishevelled segment polarity protein 1	Homo sapiens	67-71
25643607-11	2015	CONCLUSIONS: Taken together, these results suggest that silencing DVL1 sensitized A2780/Taxol cells to paclitaxel, by down-regulating AKT/GSK-3beta/beta-catenin signalling, providing a novel strategy for chemosensitization of ovarian cancer to paclitaxel-induced cytotoxicity.	Paclitaxel	103-113	dishevelled segment polarity protein 1	Homo sapiens	66-70
25780454-0	2015	Curcumin improves the paclitaxel-induced apoptosis of HPV-positive human cervical cancer cells via the NF-kappaB-p53-caspase-3 pathway.	Paclitaxel	22-32	tumor protein p53	Homo sapiens	113-116
25780454-8	2015	The expression levels of p53 protein and cleaved caspase-3 were increased significantly in the curcumin plus paclitaxel-treated HeLa and CaSki cells compared with those in the cells treated with paclitaxel alone (P&lt;0.01).	Paclitaxel	109-119	tumor protein p53	Homo sapiens	25-28
25780454-8	2015	The expression levels of p53 protein and cleaved caspase-3 were increased significantly in the curcumin plus paclitaxel-treated HeLa and CaSki cells compared with those in the cells treated with paclitaxel alone (P&lt;0.01).	Paclitaxel	195-205	tumor protein p53	Homo sapiens	25-28
25780454-9	2015	Significant reductions in the levels of phosphorylation of IkappaBalpha and the p65-NF-kappaB subunit in CaSki cells treated with curcumin and paclitaxel were observed compared with those in cells treated with paclitaxel alone (P&lt;0.05).	Paclitaxel	143-153	NFKB inhibitor alpha	Homo sapiens	59-71
25780454-9	2015	Significant reductions in the levels of phosphorylation of IkappaBalpha and the p65-NF-kappaB subunit in CaSki cells treated with curcumin and paclitaxel were observed compared with those in cells treated with paclitaxel alone (P&lt;0.05).	Paclitaxel	210-220	NFKB inhibitor alpha	Homo sapiens	59-71
25780454-10	2015	This suggests that the combined effect of curcumin and paclitaxel was associated with the NF-kappaB-p53-caspase-3 pathway.	Paclitaxel	55-65	tumor protein p53	Homo sapiens	100-103
25780454-11	2015	In conclusion, curcumin has the ability to improve the paclitaxel-induced apoptosis of HPV-positive human cervical cancer cell lines via the NF-kappaB-p53-caspase-3 pathway.	Paclitaxel	55-65	tumor protein p53	Homo sapiens	151-154
25681684-2	2015	Among various molecular factors, presence of MyD88, a component of TLR-4/MyD88 mediated NF-kappaB signaling in EOC tumors is reported to cause intrinsic paclitaxel resistance and poor survival.	Paclitaxel	153-163	nuclear factor kappa B subunit 1	Homo sapiens	88-97
25681684-5	2015	Using isogenic cellular matrices of cisplatin, paclitaxel and platinum-taxol resistant MyD88(negative) A2780 ovarian cancer cells expressing a NF-kappaB reporter sensor, we showed that enhanced NF-kappaB activity was required for cisplatin but not for paclitaxel resistance.	Paclitaxel	47-57	nuclear factor kappa B subunit 1	Homo sapiens	194-203
25681684-5	2015	Using isogenic cellular matrices of cisplatin, paclitaxel and platinum-taxol resistant MyD88(negative) A2780 ovarian cancer cells expressing a NF-kappaB reporter sensor, we showed that enhanced NF-kappaB activity was required for cisplatin but not for paclitaxel resistance.	Paclitaxel	252-262	nuclear factor kappa B subunit 1	Homo sapiens	194-203
25681684-8	2015	In contrast, paclitaxel and the platinum-taxol resistant cells showed down regulation in NF-kappaB activity.	Paclitaxel	13-23	nuclear factor kappa B subunit 1	Homo sapiens	89-98
25681684-8	2015	In contrast, paclitaxel and the platinum-taxol resistant cells showed down regulation in NF-kappaB activity.	Paclitaxel	41-46	nuclear factor kappa B subunit 1	Homo sapiens	89-98
25681684-9	2015	Intriguingly, silencing of MyD88 in cisplatin resistant and MyD88(positive) TOV21G and SKOV3 cells showed enhanced NF-kappaB activity after cisplatin but not after paclitaxel or platinum-taxol treatments.	Paclitaxel	187-192	nuclear factor kappa B subunit 1	Homo sapiens	115-124
26310068-5	2015	Biotinylated alpha-fetoprotein (AFP) antibodies were linked to the micelle surface by a biotin-avidin reaction to form targeted Gd/PTX-loaded micelles (TGPM).	Paclitaxel	131-134	alpha fetoprotein	Homo sapiens	13-30
26310068-5	2015	Biotinylated alpha-fetoprotein (AFP) antibodies were linked to the micelle surface by a biotin-avidin reaction to form targeted Gd/PTX-loaded micelles (TGPM).	Paclitaxel	131-134	alpha fetoprotein	Homo sapiens	32-35
25498514-11	2015	Significantly enhanced conversion of PC-3 to caspase-3 was observed with PAC-1 paclitaxel combination (P &lt; 0.05).	Paclitaxel	79-89	caspase 3	Homo sapiens	45-54
25633416-10	2015	In addition, DIM significantly and dose-dependently inhibited phosphorylation of Akt and potentiated paclitaxel-induced inhibition of Akt function in gastric cancer cells.	Paclitaxel	101-111	AKT serine/threonine kinase 1	Homo sapiens	134-137
25677062-8	2015	RESULTS: Paclitaxel treated cells eventually developed MDR with overexpression of Pgp and MDR1, and with high activity of Pgp, while paclitaxel-NSC23925 co-treated cells remained sensitive to chemotherapeutic agents in both in vitro and in vivo models.	Paclitaxel	9-19	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	55-58
25677062-8	2015	RESULTS: Paclitaxel treated cells eventually developed MDR with overexpression of Pgp and MDR1, and with high activity of Pgp, while paclitaxel-NSC23925 co-treated cells remained sensitive to chemotherapeutic agents in both in vitro and in vivo models.	Paclitaxel	9-19	ATP binding cassette subfamily B member 1	Homo sapiens	90-94
25633416-11	2015	Therefore, our results indicate that DIM effectively potentiates the efficacy of chemotherapeutic agents such as paclitaxel by downregulation of the Akt/FOXM1 signaling cascade in gastric cancer cells.	Paclitaxel	113-123	AKT serine/threonine kinase 1	Homo sapiens	149-152
25789051-0	2015	Synergistic cytotoxicity of cisplatin and Taxol in overcoming Taxol resistance through the inhibition of LDHA in oral squamous cell carcinoma.	Paclitaxel	42-47	lactate dehydrogenase A	Homo sapiens	105-109
25789051-0	2015	Synergistic cytotoxicity of cisplatin and Taxol in overcoming Taxol resistance through the inhibition of LDHA in oral squamous cell carcinoma.	Paclitaxel	62-67	lactate dehydrogenase A	Homo sapiens	105-109
25633416-0	2015	3,3"-Diindolylmethane potentiates paclitaxel-induced antitumor effects on gastric cancer cells through the Akt/FOXM1 signaling cascade.	Paclitaxel	34-44	AKT serine/threonine kinase 1	Homo sapiens	107-110
25633416-7	2015	Treatment with DIM plus paclitaxel substantially increased apoptosis as indicated by increased levels of cleaved polyADP-ribose polymerase (PARP) and cleaved caspase-9 protein.	Paclitaxel	24-34	poly(ADP-ribose) polymerase 1	Homo sapiens	113-138
25789051-3	2015	The aim of this study was to identify whether LDHA was involved in oral cancer cell resistance to Taxol and whether the downregulation of LDHA, as a result of cisplatin treatment, may overcome Taxol resistance in human oral squamous cells.	Paclitaxel	98-103	lactate dehydrogenase A	Homo sapiens	46-50
25633416-7	2015	Treatment with DIM plus paclitaxel substantially increased apoptosis as indicated by increased levels of cleaved polyADP-ribose polymerase (PARP) and cleaved caspase-9 protein.	Paclitaxel	24-34	poly(ADP-ribose) polymerase 1	Homo sapiens	140-144
25789051-3	2015	The aim of this study was to identify whether LDHA was involved in oral cancer cell resistance to Taxol and whether the downregulation of LDHA, as a result of cisplatin treatment, may overcome Taxol resistance in human oral squamous cells.	Paclitaxel	193-198	lactate dehydrogenase A	Homo sapiens	138-142
25647149-7	2015	Paclitaxel increased p53 protein expression in 10A, 10AT, 10ATG3B and 10CA1a cells, by 87, 102, 812 and 84%, respectively.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	21-24
25789051-9	2015	By contrast, the Taxol-resistant cancer cells showed elevated LDHA expression levels.	Paclitaxel	17-22	lactate dehydrogenase A	Homo sapiens	62-66
25789051-10	2015	In addition, small interfering RNA-knockdown of LDHA sensitized the cells to Taxol, but desensitized them to CDDP treatment, while exogenous expression of LDHA sensitized the cells to CDDP, but desensitized them to Taxol.	Paclitaxel	77-82	lactate dehydrogenase A	Homo sapiens	48-52
25789051-10	2015	In addition, small interfering RNA-knockdown of LDHA sensitized the cells to Taxol, but desensitized them to CDDP treatment, while exogenous expression of LDHA sensitized the cells to CDDP, but desensitized them to Taxol.	Paclitaxel	215-220	lactate dehydrogenase A	Homo sapiens	48-52
25789051-10	2015	In addition, small interfering RNA-knockdown of LDHA sensitized the cells to Taxol, but desensitized them to CDDP treatment, while exogenous expression of LDHA sensitized the cells to CDDP, but desensitized them to Taxol.	Paclitaxel	215-220	lactate dehydrogenase A	Homo sapiens	155-159
25633416-9	2015	FOXM1 effector genes such as CDK4, p53 and cyclin D1 were downregulated in gastric cancer cells by combination treatment with DIM and paclitaxel.	Paclitaxel	134-144	tumor protein p53	Homo sapiens	35-38
25647149-11	2015	The effects of paclitaxel on the multidrug resistance 1 (MDR1), MRP1 and breast cancer resistance protein (BCRP) gene expression were not significant in the MCF10AT cell lineage.	Paclitaxel	15-25	ATP binding cassette subfamily B member 1	Homo sapiens	33-55
25789051-11	2015	The present study also revealed the synergistic cytotoxicity of CDDP and Taxol for killing oral cancer cells through the inhibition of LDHA.	Paclitaxel	73-78	lactate dehydrogenase A	Homo sapiens	135-139
25789051-12	2015	This study highlights LDHA as a novel therapeutic target for overcoming Taxol resistance in oral cancer patients using the combined treatments of Taxol and CDDP.	Paclitaxel	72-77	lactate dehydrogenase A	Homo sapiens	22-26
25789051-12	2015	This study highlights LDHA as a novel therapeutic target for overcoming Taxol resistance in oral cancer patients using the combined treatments of Taxol and CDDP.	Paclitaxel	146-151	lactate dehydrogenase A	Homo sapiens	22-26
25647149-11	2015	The effects of paclitaxel on the multidrug resistance 1 (MDR1), MRP1 and breast cancer resistance protein (BCRP) gene expression were not significant in the MCF10AT cell lineage.	Paclitaxel	15-25	ATP binding cassette subfamily C member 1	Homo sapiens	64-68
25647149-11	2015	The effects of paclitaxel on the multidrug resistance 1 (MDR1), MRP1 and breast cancer resistance protein (BCRP) gene expression were not significant in the MCF10AT cell lineage.	Paclitaxel	15-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	73-105
25647149-11	2015	The effects of paclitaxel on the multidrug resistance 1 (MDR1), MRP1 and breast cancer resistance protein (BCRP) gene expression were not significant in the MCF10AT cell lineage.	Paclitaxel	15-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	107-111
25647149-13	2015	The decreased responsiveness to paclitaxel observed in 10CA1a tumor cells was likely due, in part, to activation of the Akt signaling pathway and a high expression of wild-type p53 with lack of p21Waf1/Cip1.	Paclitaxel	32-42	tumor protein p53	Homo sapiens	177-180
25647149-13	2015	The decreased responsiveness to paclitaxel observed in 10CA1a tumor cells was likely due, in part, to activation of the Akt signaling pathway and a high expression of wild-type p53 with lack of p21Waf1/Cip1.	Paclitaxel	32-42	cyclin dependent kinase inhibitor 1A	Homo sapiens	202-206
25811469-6	2015	The results indicate that Bcl-xl has a protective role against paclitaxel-induced apoptosis in LNCaP and PC3 cells, and its overexpression causes the paclitaxel resistance seen in PC3 cells.	Paclitaxel	63-73	BCL2 like 1	Homo sapiens	26-32
25811469-6	2015	The results indicate that Bcl-xl has a protective role against paclitaxel-induced apoptosis in LNCaP and PC3 cells, and its overexpression causes the paclitaxel resistance seen in PC3 cells.	Paclitaxel	150-160	BCL2 like 1	Homo sapiens	26-32
25811469-4	2015	Knocking down Bcl-xl enhanced paclitaxel-induced apoptosis in LNCaP cells, while we were unable to knock down Bcl-xl efficiently in PC3 cells.	Paclitaxel	30-40	BCL2 like 1	Homo sapiens	14-20
25811469-7	2015	Interestingly, combined paclitaxel with ABT-263 to treat LNCaP and PC3 cells demonstrated synergistic apoptosis activation, indicating that ABT-263 could enhance paclitaxel-induced apoptosis in LNCaP cells and overcome Bcl-xl overexpression to trigger paclitaxel-induced apoptosis in PC3 cells.	Paclitaxel	24-34	BCL2 like 1	Homo sapiens	219-225
25811469-7	2015	Interestingly, combined paclitaxel with ABT-263 to treat LNCaP and PC3 cells demonstrated synergistic apoptosis activation, indicating that ABT-263 could enhance paclitaxel-induced apoptosis in LNCaP cells and overcome Bcl-xl overexpression to trigger paclitaxel-induced apoptosis in PC3 cells.	Paclitaxel	162-172	BCL2 like 1	Homo sapiens	219-225
25811469-7	2015	Interestingly, combined paclitaxel with ABT-263 to treat LNCaP and PC3 cells demonstrated synergistic apoptosis activation, indicating that ABT-263 could enhance paclitaxel-induced apoptosis in LNCaP cells and overcome Bcl-xl overexpression to trigger paclitaxel-induced apoptosis in PC3 cells.	Paclitaxel	162-172	BCL2 like 1	Homo sapiens	219-225
25788267-7	2015	Most importantly, when administered intraperitoneally, combination of BSN and paclitaxel significantly decreased the tumor development in a xenograft lung cancer mouse model associated with down-modulation of phospho-STAT3, Ki-67 and CD31.	Paclitaxel	78-88	signal transducer and activator of transcription 3	Mus musculus	217-222
25788267-8	2015	We suggest that BSN inhibits STAT3 signaling through modulation of PIAS-3 and SOCS-3, thereby attenuating tumor growth and increasing sensitivity to paclitaxel.	Paclitaxel	149-159	signal transducer and activator of transcription 3	Mus musculus	29-34
25853126-4	2015	We tested the microchamber device with HeLa cells over-expressing MDR1, an ATP-binding cassette transporter, and succeeded in detecting the transport of fluorescence-conjugated paclitaxel, the anti-cancer drug, at the single-cell level.	Paclitaxel	177-187	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
25618019-6	2015	Substrate uptake experiments performed in the presence of antineoplastic compounds showed that vinblastine and paclitaxel strongly interacted with the OATP1B1 with Ki values of 10.2 muM and 0.84 muM, respectively.	Paclitaxel	111-121	latexin	Homo sapiens	182-185
25834432-0	2015	Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab.	Paclitaxel	36-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-122
25834432-2	2015	In this study, trastuzumab (TMAB), which binds to human epidermal growth factor receptor 2 (HER2), was used as a targeting agent in a TMAB-polyamidoamine (PAMAM) conjugate carrying paclitaxel (PTX) specifically to cells overexpressing HER2.	Paclitaxel	181-191	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-90
25834432-2	2015	In this study, trastuzumab (TMAB), which binds to human epidermal growth factor receptor 2 (HER2), was used as a targeting agent in a TMAB-polyamidoamine (PAMAM) conjugate carrying paclitaxel (PTX) specifically to cells overexpressing HER2.	Paclitaxel	181-191	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-96
25834432-2	2015	In this study, trastuzumab (TMAB), which binds to human epidermal growth factor receptor 2 (HER2), was used as a targeting agent in a TMAB-polyamidoamine (PAMAM) conjugate carrying paclitaxel (PTX) specifically to cells overexpressing HER2.	Paclitaxel	193-196	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-96
25618019-6	2015	Substrate uptake experiments performed in the presence of antineoplastic compounds showed that vinblastine and paclitaxel strongly interacted with the OATP1B1 with Ki values of 10.2 muM and 0.84 muM, respectively.	Paclitaxel	111-121	latexin	Homo sapiens	195-198
25618019-7	2015	OATP1B3 showed highly significant interactions with a variety of antineoplastic compounds including chlorambucil, mitoxantrone, vinblastine, vincristine, paclitaxel and etoposide, with Ki values of 40.6 muM, 3.2 muM, 15.9 muM, 30.6 muM, 1.8 muM and 13.5 muM, respectively.	Paclitaxel	154-164	solute carrier organic anion transporter family member 1B3	Homo sapiens	0-7
25962593-3	2015	METHODS: We determined the effects of cabazitaxel, a novel tubulin-binding taxane, and paclitaxel on paclitaxel-resistant, ABCB1-overexpressing KB-C2 and LLC-MDR1-WT cells and paclitaxel-resistant, ABCC10-overexpressing HEK293/ABCC10 cells by calculating the degree of drug resistance and measuring ATPase activity of the ABCB1 transporter.	Paclitaxel	87-97	ATP binding cassette subfamily B member 1	Homo sapiens	123-128
25962593-5	2015	Moreover, cabazitaxel had low efficacy, whereas paclitaxel had high efficacy in stimulating the ATPase activity of ABCB1, indicating a direct interaction of both drugs with the transporter.	Paclitaxel	48-58	ATP binding cassette subfamily B member 1	Homo sapiens	115-120
24853387-0	2015	Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.	Paclitaxel	51-61	cannabinoid receptor 2 (macrophage)	Mus musculus	8-30
24853387-6	2015	RESULTS: Paclitaxel-induced mechanical and cold allodynia developed to an equivalent degree in CB1KO, CB2KO, and WT mice.	Paclitaxel	9-19	cannabinoid receptor 2 (macrophage)	Mus musculus	102-105
24853387-11	2015	Finally, both acute and chronic administration of AM1710 decreased messenger RNA levels of tumor necrosis factor-alpha and monocyte chemoattractant protein 1 in lumbar spinal cord of paclitaxel-treated WT mice.	Paclitaxel	183-193	tumor necrosis factor	Mus musculus	91-118
25544427-4	2015	Silencing of IL-6 using IL-6 siRNA was found to suppress IL-6 production, STAT3 and phosphoSTAT3 levels, which eventually reduced proliferation and clonogenicity of taxol-resistant SKOV3/TR cells.	Paclitaxel	165-170	interleukin 6	Homo sapiens	13-17
25721485-9	2015	EpoB and PTX mediate activation of both initiator caspases-8 and -9, leading to the appearance of caspase-3.	Paclitaxel	9-12	caspase 3	Homo sapiens	98-107
25483711-3	2015	Here we showed that Trx1 and FOXO1 were involved in paclitaxel (PTX)-induced drug resistance in ovarian cancer A2780 cells.	Paclitaxel	52-62	forkhead box O1	Homo sapiens	29-34
25483711-3	2015	Here we showed that Trx1 and FOXO1 were involved in paclitaxel (PTX)-induced drug resistance in ovarian cancer A2780 cells.	Paclitaxel	64-67	forkhead box O1	Homo sapiens	29-34
25483711-4	2015	PTX induced reactive oxygen species (ROS) and resulted in Trx1 and FOXO1 nuclear translocation.	Paclitaxel	0-3	forkhead box O1	Homo sapiens	67-72
25683304-0	2015	Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials.	Paclitaxel	51-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
25683304-8	2015	Paclitaxel significantly improves pCR versus docetaxel with a single HER2-inhibition by 6.7% (p=0.0012), with no difference if combined with a dual HER2-inhibition.	Paclitaxel	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
25544427-4	2015	Silencing of IL-6 using IL-6 siRNA was found to suppress IL-6 production, STAT3 and phosphoSTAT3 levels, which eventually reduced proliferation and clonogenicity of taxol-resistant SKOV3/TR cells.	Paclitaxel	165-170	interleukin 6	Homo sapiens	24-28
25544427-4	2015	Silencing of IL-6 using IL-6 siRNA was found to suppress IL-6 production, STAT3 and phosphoSTAT3 levels, which eventually reduced proliferation and clonogenicity of taxol-resistant SKOV3/TR cells.	Paclitaxel	165-170	interleukin 6	Homo sapiens	24-28
25544427-4	2015	Silencing of IL-6 using IL-6 siRNA was found to suppress IL-6 production, STAT3 and phosphoSTAT3 levels, which eventually reduced proliferation and clonogenicity of taxol-resistant SKOV3/TR cells.	Paclitaxel	165-170	signal transducer and activator of transcription 3	Homo sapiens	74-79
25544427-5	2015	In addition, stattic, a STAT3 inhibitor, was found to result in decrease of cell viability and clonogenicity of these cells, indicating that the elevated IL-6 and STAT3, phosphoSTAT3 levels are associated with the development of taxol resistance.	Paclitaxel	229-234	signal transducer and activator of transcription 3	Homo sapiens	24-29
25544427-5	2015	In addition, stattic, a STAT3 inhibitor, was found to result in decrease of cell viability and clonogenicity of these cells, indicating that the elevated IL-6 and STAT3, phosphoSTAT3 levels are associated with the development of taxol resistance.	Paclitaxel	229-234	interleukin 6	Homo sapiens	154-158
25544427-5	2015	In addition, stattic, a STAT3 inhibitor, was found to result in decrease of cell viability and clonogenicity of these cells, indicating that the elevated IL-6 and STAT3, phosphoSTAT3 levels are associated with the development of taxol resistance.	Paclitaxel	229-234	signal transducer and activator of transcription 3	Homo sapiens	163-168
25544427-10	2015	Taken together, our data suggest that inhibition of IL-6/STAT3 signaling pathway and downregulation of Axl and Tyro3 RTKs expression might be a therapeutic strategy to overcome taxol resistance in ovarian cancer cells.	Paclitaxel	177-182	interleukin 6	Homo sapiens	52-56
25544427-10	2015	Taken together, our data suggest that inhibition of IL-6/STAT3 signaling pathway and downregulation of Axl and Tyro3 RTKs expression might be a therapeutic strategy to overcome taxol resistance in ovarian cancer cells.	Paclitaxel	177-182	TYRO3 protein tyrosine kinase	Homo sapiens	111-116
25164250-9	2015	Here, paclitaxel was chosen as an apoptosis inducer in TGF-beta restored cells and confirmed its cytotoxic effects in radiation alone and thymoquinone sensitized irradiated cells.	Paclitaxel	6-16	transforming growth factor beta 1	Homo sapiens	55-63
25599995-9	2015	Carboplatin and paclitaxel treatment combined with carbon-ion beams increased TUNEL-positive cells and the expression of cleaved caspase-3 and Bax, indicating the enhancement of apoptosis.	Paclitaxel	16-26	BCL2 associated X, apoptosis regulator	Homo sapiens	143-146
25377161-8	2015	Further study revealed that patients with POMC-negative expression can benefit more from a regimen of paclitaxel and carboplatin chemotherapy than a regimen of vinorelbine and carboplatin compared to patients with POMC-positive expression.	Paclitaxel	102-112	proopiomelanocortin	Homo sapiens	42-46
25640195-0	2015	Replacing heme with paclitaxel to prepare drug-loaded globin nanoassembles for CD163 targeting.	Paclitaxel	20-30	CD163 antigen	Mus musculus	79-84
25640195-7	2015	The binding activity of Gb-NPs-PTX to CD163 was confirmed by cell uptake in CD163(+) Chinese hamster ovary cells.	Paclitaxel	31-34	CD163 antigen	Mus musculus	38-43
25640195-7	2015	The binding activity of Gb-NPs-PTX to CD163 was confirmed by cell uptake in CD163(+) Chinese hamster ovary cells.	Paclitaxel	31-34	CD163 antigen	Mus musculus	76-81
25640195-8	2015	Results in vivo also showed a CD163-dependent tissue accumulation of Gb-NPs-PTX in mice.	Paclitaxel	76-79	CD163 antigen	Mus musculus	30-35
25605244-0	2015	MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.	Paclitaxel	77-87	semaphorin 4C	Homo sapiens	67-73
25499080-3	2015	Silencing of p53 or KRAS in A549 or H358 cells either enhanced or attenuated the resistance of cells to cisplatin and taxol through promotion or suppression of the NF-kappaB p65 nuclear translocation.	Paclitaxel	118-123	tumor protein p53	Homo sapiens	13-16
25499080-3	2015	Silencing of p53 or KRAS in A549 or H358 cells either enhanced or attenuated the resistance of cells to cisplatin and taxol through promotion or suppression of the NF-kappaB p65 nuclear translocation.	Paclitaxel	118-123	nuclear factor kappa B subunit 1	Homo sapiens	164-173
25605244-7	2015	More importantly, overexpression of miR-125b or depletion of Sema4C sensitized PR cells to paclitaxel.	Paclitaxel	91-101	semaphorin 4C	Homo sapiens	61-67
25687880-0	2015	MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.	Paclitaxel	86-96	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
25081641-2	2015	GBP1:PIM1 binding initiates a signaling pathway that induces resistance to common chemotherapeutics such as paclitaxel.	Paclitaxel	108-118	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	5-9
25687880-5	2015	The goal of this study is to evaluate the ability of HA-PEI/HA-PEG to deliver MDR1 siRNA and the efficacy of the combination of HA-PEI/HA-PEG/MDR1 siRNA with paclitaxel to suppress growth of ovarian cancer.	Paclitaxel	158-168	ATP binding cassette subfamily B member 1	Homo sapiens	142-146
25081641-4	2015	It resulted that only GTP decreases the formation of the GBP1:PIM1 complex through an allosteric mechanism, putting the bases for the identification of new compounds potentially able to revert resistance to paclitaxel.	Paclitaxel	207-217	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	62-66
25547504-0	2015	Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.	Paclitaxel	18-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-144
25885449-12	2015	Overexpression of YY1 in the cells results in down-regulation of FEN1 and sensitization of the cancer cells to MMC or taxol.	Paclitaxel	118-123	YY1 transcription factor	Homo sapiens	18-21
25709444-3	2015	The aim of this study was to develop transferrin (Tf)-decorated NLC as multifunctional nanomedicine for co-delivery of paclitaxel (PTX) and enhanced green fluorescence protein plasmid.	Paclitaxel	119-129	transferrin	Homo sapiens	37-48
25709444-3	2015	The aim of this study was to develop transferrin (Tf)-decorated NLC as multifunctional nanomedicine for co-delivery of paclitaxel (PTX) and enhanced green fluorescence protein plasmid.	Paclitaxel	119-129	transferrin	Homo sapiens	50-52
25709444-3	2015	The aim of this study was to develop transferrin (Tf)-decorated NLC as multifunctional nanomedicine for co-delivery of paclitaxel (PTX) and enhanced green fluorescence protein plasmid.	Paclitaxel	131-134	transferrin	Homo sapiens	37-48
25709444-3	2015	The aim of this study was to develop transferrin (Tf)-decorated NLC as multifunctional nanomedicine for co-delivery of paclitaxel (PTX) and enhanced green fluorescence protein plasmid.	Paclitaxel	131-134	transferrin	Homo sapiens	50-52
25709444-9	2015	RESULTS: Tf-decorated PTX and DNA co-encapsulated NLC (Tf-PTX-DNA-NLC) were nano-sized particles with positive zeta potential.	Paclitaxel	22-25	transferrin	Homo sapiens	9-11
25709444-9	2015	RESULTS: Tf-decorated PTX and DNA co-encapsulated NLC (Tf-PTX-DNA-NLC) were nano-sized particles with positive zeta potential.	Paclitaxel	58-61	transferrin	Homo sapiens	9-11
25496994-6	2015	Treatment with taxol, a microtubule stabilizing agent, attenuates rotenone-induced phosphorylation and presumably activation of JNK.	Paclitaxel	15-20	mitogen-activated protein kinase 8	Homo sapiens	128-131
25678799-0	2015	Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases.	Paclitaxel	16-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
25678799-7	2015	Herein, we report a lengthy progression-free survival with the combination trastuzumab/nanoparticle albumin-bound (nab)-paclitaxel in a heavily pretreated HER2-positive BC patient with BM.	Paclitaxel	120-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	155-159
25678799-12	2015	In conclusion, weekly nab-paclitaxel plus trastuzumab may represent a valuable option in the treatment of HER2-positive MBC with BM after radiotherapy and is effective and associated with a good toxicity profile, even in heavily pretreated patients.	Paclitaxel	26-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
25399965-3	2015	Especially, compound exhibited the most potent activity (IC50 4.6 muM) against HGC-27 as compared with the reference compound, sindaxel (IC50 10.3 muM), and could be used as a lead compound to search new chiral thiosemicarbazone derivatives as antiproliferative agents.	Paclitaxel	127-135	latexin	Homo sapiens	66-69
25435430-0	2015	MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis.	Paclitaxel	24-34	glycerophosphodiester phosphodiesterase 1	Homo sapiens	0-6
25435430-0	2015	MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis.	Paclitaxel	24-34	BCL2 apoptosis regulator	Homo sapiens	15-20
25435430-6	2015	In this study, we showed that miR-16 was also significantly downregulated in paclitaxel resistant lung cancer cells.	Paclitaxel	77-87	glycerophosphodiester phosphodiesterase 1	Homo sapiens	30-36
25435430-7	2015	We demonstrated that anti-apoptotic protein Bcl-2 was directly targeted miR-16 in paclitaxel resistant lung cancer cells.	Paclitaxel	82-92	BCL2 apoptosis regulator	Homo sapiens	44-49
25435430-7	2015	We demonstrated that anti-apoptotic protein Bcl-2 was directly targeted miR-16 in paclitaxel resistant lung cancer cells.	Paclitaxel	82-92	glycerophosphodiester phosphodiesterase 1	Homo sapiens	72-78
25435430-8	2015	Moreover, in this report we showed that the combined overexpression of miR-16 and miR-17 and subsequent paclitaxel treatment greatly sensitized paclitaxel resistant lung cancer cells to paclitaxel by inducing apoptosis via caspase-3 mediated pathway.	Paclitaxel	104-114	caspase 3	Homo sapiens	223-232
25435430-8	2015	Moreover, in this report we showed that the combined overexpression of miR-16 and miR-17 and subsequent paclitaxel treatment greatly sensitized paclitaxel resistant lung cancer cells to paclitaxel by inducing apoptosis via caspase-3 mediated pathway.	Paclitaxel	144-154	glycerophosphodiester phosphodiesterase 1	Homo sapiens	71-77
25435430-8	2015	Moreover, in this report we showed that the combined overexpression of miR-16 and miR-17 and subsequent paclitaxel treatment greatly sensitized paclitaxel resistant lung cancer cells to paclitaxel by inducing apoptosis via caspase-3 mediated pathway.	Paclitaxel	144-154	caspase 3	Homo sapiens	223-232
25435430-8	2015	Moreover, in this report we showed that the combined overexpression of miR-16 and miR-17 and subsequent paclitaxel treatment greatly sensitized paclitaxel resistant lung cancer cells to paclitaxel by inducing apoptosis via caspase-3 mediated pathway.	Paclitaxel	144-154	glycerophosphodiester phosphodiesterase 1	Homo sapiens	71-77
25435430-8	2015	Moreover, in this report we showed that the combined overexpression of miR-16 and miR-17 and subsequent paclitaxel treatment greatly sensitized paclitaxel resistant lung cancer cells to paclitaxel by inducing apoptosis via caspase-3 mediated pathway.	Paclitaxel	144-154	caspase 3	Homo sapiens	223-232
25435430-10	2015	Our results indicated that though miR-17 and miR-16 had no common target, both miR-16 and miR-17 jointly played roles in the development of paclitaxel resistance in lung cancer.	Paclitaxel	140-150	glycerophosphodiester phosphodiesterase 1	Homo sapiens	79-85
25435430-11	2015	miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1, whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2.	Paclitaxel	123-133	glycerophosphodiester phosphodiesterase 1	Homo sapiens	104-110
25065563-5	2015	We hypothesized that the combination of neoadjuvant nab-paclitaxel followed by vinorelbine could represent a nonanthracycline-based treatment option for early-stage Her2-overexpressing breast cancer.	Paclitaxel	56-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	165-169
25399965-3	2015	Especially, compound exhibited the most potent activity (IC50 4.6 muM) against HGC-27 as compared with the reference compound, sindaxel (IC50 10.3 muM), and could be used as a lead compound to search new chiral thiosemicarbazone derivatives as antiproliferative agents.	Paclitaxel	127-135	latexin	Homo sapiens	147-150
25788055-0	2015	Combination chemotherapy with S-1 and docetaxel for cutaneous angiosarcoma resistant to paclitaxel.	Paclitaxel	88-98	proteasome 26S subunit, non-ATPase 1	Homo sapiens	30-33
25788055-5	2015	Therefore, we treated paclitaxel-resistant angiosarcoma patient with S-1/docetaxel chemotherapy.	Paclitaxel	22-32	proteasome 26S subunit, non-ATPase 1	Homo sapiens	69-72
25760537-5	2015	Pre-treatment with IL-6 enhanced the cytotoxic effects of gefitinib and paclitaxel.	Paclitaxel	72-82	interleukin 6	Homo sapiens	19-23
25788055-7	2015	Our data need to be confirmed in a large number of patients, but S-1/docetaxel chemotherapy as an additional regimen seems to be an effective treatment option for paclitaxel-resistant angiosarcoma.	Paclitaxel	163-173	proteasome 26S subunit, non-ATPase 1	Homo sapiens	65-68
25351378-0	2015	Biological characteristics of Taxol-resistant ovarian cancer cells and reversal of Taxol resistance by adenovirus expressing p53.	Paclitaxel	83-88	tumor protein p53	Homo sapiens	125-128
25973036-0	2015	Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1.	Paclitaxel	36-46	microRNA 877	Homo sapiens	17-24
25973036-4	2015	In the present study, our objective was to identify miR-877 associated with HCC cell lines response to paclitaxel and to evaluate these miRNAs as therapeutic targets to increase paclitaxel sensitivity.	Paclitaxel	103-113	microRNA 877	Homo sapiens	52-59
25973036-4	2015	In the present study, our objective was to identify miR-877 associated with HCC cell lines response to paclitaxel and to evaluate these miRNAs as therapeutic targets to increase paclitaxel sensitivity.	Paclitaxel	178-188	microRNA 877	Homo sapiens	52-59
25973036-5	2015	We measured the expression of miR-877 in paclitaxel-treated HCC cell lines.	Paclitaxel	41-51	microRNA 877	Homo sapiens	30-37
25973036-6	2015	We verified that miR-877 was up-regulated in paclitaxel-induced HCC cells by real-time PCR.	Paclitaxel	45-55	microRNA 877	Homo sapiens	17-24
25973036-8	2015	Over-expression of miR-877 in HCC cells partially restores paclitaxel sensitivity.	Paclitaxel	59-69	microRNA 877	Homo sapiens	19-26
25973036-13	2015	These results indicate that miR-877 could influence the sensitivity of paclitaxel treatment in hepatocellular carcinoma cell lines by targeting FOXM1.	Paclitaxel	71-81	microRNA 877	Homo sapiens	28-35
25553650-0	2015	A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).	Paclitaxel	67-77	epidermal growth factor receptor	Homo sapiens	158-190
25351620-0	2015	Ephrin type-A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3-kinase/Akt signalling pathway.	Paclitaxel	50-60	AKT serine/threonine kinase 1	Homo sapiens	123-126
25351620-6	2015	Furthermore, paclitaxel stimulation and EphA2 over-expression resulted in activation of the phosphoinositide 3-kinase (PI3K)/Akt signalling pathway in NPC cells.	Paclitaxel	13-23	AKT serine/threonine kinase 1	Homo sapiens	125-128
25351620-7	2015	Inhibition of the PI3K/Akt signalling pathway restored sensitivity to paclitaxel in 5-8F cells over-expressing EphA2, which indicated that the PI3K/Akt pathway is involved in EphA2-mediated paclitaxel sensitivity.	Paclitaxel	70-80	AKT serine/threonine kinase 1	Homo sapiens	23-26
25351620-7	2015	Inhibition of the PI3K/Akt signalling pathway restored sensitivity to paclitaxel in 5-8F cells over-expressing EphA2, which indicated that the PI3K/Akt pathway is involved in EphA2-mediated paclitaxel sensitivity.	Paclitaxel	70-80	AKT serine/threonine kinase 1	Homo sapiens	148-151
25542057-1	2015	BACKGROUND: We sought to determine the maximal tolerated dose of the MEK inhibitor trametinib with weekly paclitaxel, with a view to exploring the combination"s activity in melanoma lacking a BRAF V600 mutation.	Paclitaxel	106-116	mitogen-activated protein kinase kinase 7	Homo sapiens	69-72
26012295-4	2015	Expression of Survivin and MRP were detected in 31 patients of NPC with paclitaxel resistance and 20 patients of NPC without paclitaxel resistance.	Paclitaxel	72-82	ATP binding cassette subfamily C member 1	Homo sapiens	27-30
26012295-4	2015	Expression of Survivin and MRP were detected in 31 patients of NPC with paclitaxel resistance and 20 patients of NPC without paclitaxel resistance.	Paclitaxel	125-135	ATP binding cassette subfamily C member 1	Homo sapiens	27-30
26012295-16	2015	The positive of MRP were 87.1% (27/31) in NPC patients with paclitaxel resistance and 40.0% (8/20) in NPC patients without paclitaxel resistance, respectively.	Paclitaxel	60-70	ATP binding cassette subfamily C member 1	Homo sapiens	16-19
26012295-16	2015	The positive of MRP were 87.1% (27/31) in NPC patients with paclitaxel resistance and 40.0% (8/20) in NPC patients without paclitaxel resistance, respectively.	Paclitaxel	123-133	ATP binding cassette subfamily C member 1	Homo sapiens	16-19
26012295-18	2015	There were positive correlation between the expression of Survivin and MRP in NPC patients with Paclitaxel resistance.	Paclitaxel	96-106	ATP binding cassette subfamily C member 1	Homo sapiens	71-74
25351620-8	2015	The current study demonstrated that EphA2 mediates sensitivity to paclitaxel via the regulation of the PI3K/Akt signalling pathway in NPC.	Paclitaxel	66-76	AKT serine/threonine kinase 1	Homo sapiens	108-111
25398452-0	2015	Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy.	Paclitaxel	71-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
25656118-0	2015	[Association between ABCB1 G2677T/A polymorphisms and chemosensitivity of paclitaxel in advanced gastric cancer].	Paclitaxel	74-84	ATP binding cassette subfamily B member 1	Homo sapiens	21-26
25656118-1	2015	OBJECTIVE: To investigate the association between ABCB1 polymorphisms and chemosensitivity of paclitaxel in Chinese advanced gastric cancer(AGC) patients.	Paclitaxel	94-104	ATP binding cassette subfamily B member 1	Homo sapiens	50-55
25656118-9	2015	CONCLUSIONS: ABCB1 G2677T/A polymorphisms are associated with chemosensitivity of paclitaxel in gastric cancer.	Paclitaxel	82-92	ATP binding cassette subfamily B member 1	Homo sapiens	13-18
25510604-1	2015	Paclitaxel (PTX) has been used in the treatment of wide range of cancers but its entry into cancer cell is restricted by p-glycoprotein (p-gp).	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	121-135
25510604-1	2015	Paclitaxel (PTX) has been used in the treatment of wide range of cancers but its entry into cancer cell is restricted by p-glycoprotein (p-gp).	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	137-141
25510604-1	2015	Paclitaxel (PTX) has been used in the treatment of wide range of cancers but its entry into cancer cell is restricted by p-glycoprotein (p-gp).	Paclitaxel	12-15	ATP binding cassette subfamily B member 1	Homo sapiens	121-135
25510604-1	2015	Paclitaxel (PTX) has been used in the treatment of wide range of cancers but its entry into cancer cell is restricted by p-glycoprotein (p-gp).	Paclitaxel	12-15	ATP binding cassette subfamily B member 1	Homo sapiens	137-141
25351620-7	2015	Inhibition of the PI3K/Akt signalling pathway restored sensitivity to paclitaxel in 5-8F cells over-expressing EphA2, which indicated that the PI3K/Akt pathway is involved in EphA2-mediated paclitaxel sensitivity.	Paclitaxel	190-200	AKT serine/threonine kinase 1	Homo sapiens	23-26
25351620-7	2015	Inhibition of the PI3K/Akt signalling pathway restored sensitivity to paclitaxel in 5-8F cells over-expressing EphA2, which indicated that the PI3K/Akt pathway is involved in EphA2-mediated paclitaxel sensitivity.	Paclitaxel	190-200	AKT serine/threonine kinase 1	Homo sapiens	148-151
25514463-0	2015	The Na+/H+ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells.	Paclitaxel	61-71	solute carrier family 9 member A1	Homo sapiens	22-26
25514463-3	2015	Here, we investigated NHE1 as a co-adjuvant target in paclitaxel chemotherapy of metastatic breast cancer.	Paclitaxel	54-64	solute carrier family 9 member A1	Homo sapiens	22-26
25514463-7	2015	Loss of NHE1 expression also increased the susceptibility of knockout cells to paclitaxel-mediated cell death.	Paclitaxel	79-89	solute carrier family 9 member A1	Homo sapiens	8-12
25514463-9	2015	Our data suggest that NHE1 is critical in triple-negative breast cancer metastasis, and its chemical inhibition boosts the efficacy of paclitaxel in vitro, highlighting NHE1 as a novel, potential co-adjuvant target in breast cancer chemotherapy.	Paclitaxel	135-145	solute carrier family 9 member A1	Homo sapiens	169-173
25398452-9	2015	Relative to CYP3A4 wild-type patients, those carrying CYP3A4 defective variants had more severe neuropathy (2- and 1.3-fold higher risk of neuropathy for loss-of-function and missense variants, respectively, P = 0.045) and higher probability of neuropathy-induced paclitaxel treatment modifications (7- and 3-fold higher risk for loss-of-function and missense variants, respectively, P = 5.9 x 10(-5)).	Paclitaxel	264-274	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-60
25398452-11	2015	CYP3A4 defective variants may provide a basis for paclitaxel treatment individualization.	Paclitaxel	50-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
25583261-13	2015	CONCLUSIONS: In addition to driving TNBC tumor formation, BRCA1-IRIS overexpression drives their intrinsic and acquired paclitaxel resistance, partly by activating autocrine signaling loops EGF/EGFR-ErbB2 and NRG1/ErbB2-ErbB3.	Paclitaxel	120-130	epidermal growth factor receptor	Homo sapiens	194-198
25973302-7	2015	Then, we evaluated the sensitivity to cisplatin and paclitaxel in 5 ovarian cancer cell lines (ES2, A2870, HO-8910, SKOV3 and SW626), and ES2, the highest MK expression among those cell lines, show the most sensitive to paclitaxel and cisplatin.	Paclitaxel	220-230	ess-2 splicing factor homolog	Homo sapiens	138-141
25973302-8	2015	Further, we confirmed this correlation between MK and paclitaxel and/or cisplatin cytotoxicity with the gain- and lost- of function.	Paclitaxel	54-64	midkine	Homo sapiens	47-49
25973302-9	2015	Finally, we demonstrated that MK enhanced the cytotoxicity of paclitaxel and/or cisplatin by accumulated cisplatin and paclitaxel through inhibited the expression of multidrug resistance-associated protein 3 (MRP3).	Paclitaxel	62-72	midkine	Homo sapiens	30-32
25973302-9	2015	Finally, we demonstrated that MK enhanced the cytotoxicity of paclitaxel and/or cisplatin by accumulated cisplatin and paclitaxel through inhibited the expression of multidrug resistance-associated protein 3 (MRP3).	Paclitaxel	119-129	midkine	Homo sapiens	30-32
25973302-0	2015	Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy.	Paclitaxel	84-94	midkine	Homo sapiens	0-7
25973302-4	2015	We perform immunohistochemistry analysis to detect MK in EOC sample with postoperative platinum/paclitaxel combination therapy, we found that 71.4% (85 in 119 samples) of these samples were MK positive (&gt; 10% of the cells were stained), and the expression of MK was significantly associated with disease histology (P = 0.038) as well as differentiation grade (P &lt; 0.001).	Paclitaxel	96-106	midkine	Homo sapiens	51-53
25973302-5	2015	Moreover, MK positive samples show much more sensitive to cisplatin/paclitaxel combination therapy, compared with MK negative samples (P = 0.029).	Paclitaxel	68-78	midkine	Homo sapiens	10-12
25973302-6	2015	Those results indicated that MK expression might correlate with paclitaxel and/or cisplatin cytotoxicity in clinical therapy of EOC.	Paclitaxel	64-74	midkine	Homo sapiens	29-31
25419788-6	2015	The YPSMA-1-modified micelles were very effective in enhancing the cytotoxicity of paclitaxel by increasing the cellular uptake in PSMA-positive 22Rv1 cells, which was verified the correlation with PSMA expression in tumor cells by flow cytometric analysis and confocal microscopy.	Paclitaxel	83-93	folate hydrolase 1	Homo sapiens	5-9
25419788-6	2015	The YPSMA-1-modified micelles were very effective in enhancing the cytotoxicity of paclitaxel by increasing the cellular uptake in PSMA-positive 22Rv1 cells, which was verified the correlation with PSMA expression in tumor cells by flow cytometric analysis and confocal microscopy.	Paclitaxel	83-93	folate hydrolase 1	Homo sapiens	131-135
25583261-13	2015	CONCLUSIONS: In addition to driving TNBC tumor formation, BRCA1-IRIS overexpression drives their intrinsic and acquired paclitaxel resistance, partly by activating autocrine signaling loops EGF/EGFR-ErbB2 and NRG1/ErbB2-ErbB3.	Paclitaxel	120-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	199-204
25583261-13	2015	CONCLUSIONS: In addition to driving TNBC tumor formation, BRCA1-IRIS overexpression drives their intrinsic and acquired paclitaxel resistance, partly by activating autocrine signaling loops EGF/EGFR-ErbB2 and NRG1/ErbB2-ErbB3.	Paclitaxel	120-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	214-219
25564897-0	2015	Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.	Paclitaxel	9-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
26118713-0	2015	Mitogen-activated Protein Kinase Kinase 6-fusion Protein (MAP2K6-FP) Potentiates the Anti-tumor effects of Paclitaxel in Ovarian Cancer.	Paclitaxel	107-117	mitogen-activated protein kinase kinase 6	Homo sapiens	58-64
26118713-11	2015	Interestingly, the combination of MAP2K6-FP and paclitaxel had a synergistic antitumor effect on HO8910 cells, which induced apoptosis by increasing caspase-3 expression and decreasing VEGF expression.	Paclitaxel	48-58	caspase 3	Homo sapiens	149-158
26118713-11	2015	Interestingly, the combination of MAP2K6-FP and paclitaxel had a synergistic antitumor effect on HO8910 cells, which induced apoptosis by increasing caspase-3 expression and decreasing VEGF expression.	Paclitaxel	48-58	vascular endothelial growth factor A	Homo sapiens	185-189
25268938-7	2015	In NIH-3T3/MDR1 cells, propiconazole (1 and 10muM) led to decreased cellular resistance (chemosensitization) to paclitaxel, a chemotherapeutic drug and known MDR1 substrate.	Paclitaxel	112-122	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	158-162
25564897-11	2015	CONCLUSIONS: Among women with predominantly stage I HER2-positive breast cancer, treatment with adjuvant paclitaxel plus trastuzumab was associated with a risk of early recurrence of about 2%; 6% of patients withdrew from the study because of protocol-specified adverse events.	Paclitaxel	105-115	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
25921171-0	2015	Involvement of GRP78 in the Resistance of Ovarian Carcinoma Cells to Paclitaxel.	Paclitaxel	69-79	heat shock protein family A (Hsp70) member 5	Homo sapiens	15-20
25921171-8	2015	RESULTS: HO-8910 cells, with high basal levels of GRP78, exhibited low sensitivity to paclitaxel.	Paclitaxel	86-96	heat shock protein family A (Hsp70) member 5	Homo sapiens	50-55
25921171-9	2015	The mRNA and protein levels of GRP78 were dramatically decreased at 24h, 48h and 72h after transfection and the sensitivity to paclitaxel was increased when the GRP78 gene was disturbed by specific siRNA transfection.	Paclitaxel	127-137	heat shock protein family A (Hsp70) member 5	Homo sapiens	31-36
25921171-9	2015	The mRNA and protein levels of GRP78 were dramatically decreased at 24h, 48h and 72h after transfection and the sensitivity to paclitaxel was increased when the GRP78 gene was disturbed by specific siRNA transfection.	Paclitaxel	127-137	heat shock protein family A (Hsp70) member 5	Homo sapiens	161-166
25921171-10	2015	CONCLUSIONS: The results suggested that high GRP78 expression might be one of the molecular mechanisms causing resistance to paclitaxel, and therefore siRNA of GRP78 may be useful in tumor-specific gene therapy for ovarian cancer.	Paclitaxel	125-135	heat shock protein family A (Hsp70) member 5	Homo sapiens	45-50
26407111-3	2015	The activity of ABCB1 in Flp-In-293/ABCB1 cells were confirmed by typical substrates for ABCB1 (taxol and vinblastine) in MTT assay.	Paclitaxel	96-101	ATP binding cassette subfamily B member 1	Homo sapiens	16-21
25684511-5	2015	Treatment of SKMEL-28R cells with 100 nM paclitaxel resulted in increased apoptosis and decreased cellular proliferation, invasion and colony formation via reduction of expression levels of EGFR and pAKTs.	Paclitaxel	41-51	epidermal growth factor receptor	Homo sapiens	190-194
26407111-4	2015	Flp-In-293/ABCB1 cells were also resistant to the four guanidine alkaloids as well as taxol and vinblastine compared to Flp-In-293/Mock cells although the four guanidine alkaloids exhibited cytotoxicity against the two Flp-In-293 cells.	Paclitaxel	86-91	ATP binding cassette subfamily B member 1	Homo sapiens	11-16
26407111-3	2015	The activity of ABCB1 in Flp-In-293/ABCB1 cells were confirmed by typical substrates for ABCB1 (taxol and vinblastine) in MTT assay.	Paclitaxel	96-101	ATP binding cassette subfamily B member 1	Homo sapiens	36-41
26407111-3	2015	The activity of ABCB1 in Flp-In-293/ABCB1 cells were confirmed by typical substrates for ABCB1 (taxol and vinblastine) in MTT assay.	Paclitaxel	96-101	ATP binding cassette subfamily B member 1	Homo sapiens	36-41
25533622-6	2015	In addition, downregulation of SRC also abolished radiation-acquired resistance of breast cancer cells to anticancer agents such as cisplatin, etoposide, paclitaxel, and IR.	Paclitaxel	154-164	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	31-34
25542269-9	2015	The most frequent grade 3 and 4 adverse events during paclitaxel and pazopanib were neutropenia (27 %), diarrhea (5 %), ALT and AST elevations (each 5 %), and hypertension (5 %).	Paclitaxel	54-64	solute carrier family 17 member 5	Homo sapiens	128-131
26075272-0	2015	Ecdysteroids sensitize MDR and non-MDR cancer cell lines to doxorubicin, paclitaxel, and vincristine but tend to protect them from cisplatin.	Paclitaxel	73-83	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-26
25537644-0	2015	Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.	Paclitaxel	96-106	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-137
26605100-1	2015	Paclitaxel induced mild derangement of liver functions including bilirubin, alkaline phosphatase, and AST has been infrequently noticed in clinical trials.	Paclitaxel	0-10	solute carrier family 17 member 5	Homo sapiens	102-105
25835050-2	2015	Experimental evidences suggested a correlation between mutational status in B-RAF and melanoma cell susceptibility to drugs, such as paclitaxel, doxorubicin and temozolomide, which generate an accumulation of hydrogen peroxide (H2O2) in the cells.	Paclitaxel	133-143	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	76-81
25564714-0	2015	In vitro and in vivo conditional sensitization of hepatocellular carcinoma cells to TNF-induced apoptosis by taxol.	Paclitaxel	109-114	tumor necrosis factor	Homo sapiens	84-87
25564714-12	2015	Of interest, prior TAX administration could also sensitize to TNF-induced apoptosis in the Yoshida AH-130 hepatoma transplanted in mice.	Paclitaxel	19-22	tumor necrosis factor	Mus musculus	62-65
26775347-0	2015	Cytoplasmic p21 is responsible for paclitaxel resistance in ovarian cancer A2780 cells.	Paclitaxel	35-45	cyclin dependent kinase inhibitor 1A	Homo sapiens	12-15
24670093-0	2015	EGFR-targeted poly(ethylene glycol)-distearoylphosphatidylethanolamine micelle loaded with paclitaxel for laryngeal cancer: preparation, characterization and in vitro evaluation.	Paclitaxel	91-101	epidermal growth factor receptor	Homo sapiens	0-4
24670093-9	2015	Our results suggested that GE11-PEG-DSPE micelle could be a promising strategy for enhancing paclitaxel"s chemotherapeutic effects on EGFR over-expressed cancer cells.	Paclitaxel	93-103	epidermal growth factor receptor	Homo sapiens	134-138
26775347-2	2015	This study was conducted to investigate the role of p21 in the paclitaxel (PTX) resistance of ovarian cancer.	Paclitaxel	63-73	cyclin dependent kinase inhibitor 1A	Homo sapiens	52-55
26775347-2	2015	This study was conducted to investigate the role of p21 in the paclitaxel (PTX) resistance of ovarian cancer.	Paclitaxel	75-78	cyclin dependent kinase inhibitor 1A	Homo sapiens	52-55
25855930-4	2015	Detection of effects of paclitaxel, rAd-p53, and drug combination on the expression of VEGF of HeLa cells by Western blotting.	Paclitaxel	24-34	vascular endothelial growth factor A	Homo sapiens	87-91
26775347-5	2015	RESULTS: Induction of p21 translocation into the cytoplasm via constitutively active Akt2 transfection in A2780 enhanced the resistance to PTX, while inhibition of p21 translocation into the cytoplasm via Akt2 shRNA trans- fection in A2780 cells significantly increased PTX treatment sensitivity.	Paclitaxel	139-142	cyclin dependent kinase inhibitor 1A	Homo sapiens	22-25
26775347-5	2015	RESULTS: Induction of p21 translocation into the cytoplasm via constitutively active Akt2 transfection in A2780 enhanced the resistance to PTX, while inhibition of p21 translocation into the cytoplasm via Akt2 shRNA trans- fection in A2780 cells significantly increased PTX treatment sensitivity.	Paclitaxel	270-273	cyclin dependent kinase inhibitor 1A	Homo sapiens	22-25
26775347-6	2015	Furthermore, knockdown of cytoplasmic p21 by direct p21 siRNA transfection in Akt2 overexpressed A2780 cells notably increased PTX-induced apoptosis.	Paclitaxel	127-130	cyclin dependent kinase inhibitor 1A	Homo sapiens	38-41
26775347-6	2015	Furthermore, knockdown of cytoplasmic p21 by direct p21 siRNA transfection in Akt2 overexpressed A2780 cells notably increased PTX-induced apoptosis.	Paclitaxel	127-130	cyclin dependent kinase inhibitor 1A	Homo sapiens	52-55
26775347-7	2015	CONCLUSION: Cytoplasmic p21 may represent a potential therapeutic target for ovarian tumors that are resistant to PTX treatment.	Paclitaxel	114-117	cyclin dependent kinase inhibitor 1A	Homo sapiens	24-27
25310526-7	2015	p53 and Bax were upregulated and Bcl2 was downregulated in the EB1-depleted PTX-treated MCF-7 cells, indicating that the apoptosis occurs via a p53-dependent pathway.	Paclitaxel	76-79	tumor protein p53	Homo sapiens	0-3
25983747-8	2015	Paclitaxel from the PEM and its diffusion into the tumor inhibited angiogenesis, which involved suppression of mammalian target of rapamycin (mTOR) through regulation of hypoxia inducible factor (HIF-1) and increased apoptosis.	Paclitaxel	0-10	mechanistic target of rapamycin kinase	Homo sapiens	111-140
25983747-8	2015	Paclitaxel from the PEM and its diffusion into the tumor inhibited angiogenesis, which involved suppression of mammalian target of rapamycin (mTOR) through regulation of hypoxia inducible factor (HIF-1) and increased apoptosis.	Paclitaxel	0-10	mechanistic target of rapamycin kinase	Homo sapiens	142-146
25983747-8	2015	Paclitaxel from the PEM and its diffusion into the tumor inhibited angiogenesis, which involved suppression of mammalian target of rapamycin (mTOR) through regulation of hypoxia inducible factor (HIF-1) and increased apoptosis.	Paclitaxel	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	196-201
25552929-0	2015	Decrease of let-7f in low-dose metronomic Paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer.	Paclitaxel	42-52	thrombospondin 1	Homo sapiens	97-113
25552929-2	2015	Upregulation of anti-angiogenic factor Thrombospondin-1 (TSP-1) accords for therapeutic potency of LDM paclitaxel, but its molecular mechanism has not been elucidated yet.	Paclitaxel	103-113	thrombospondin 1	Homo sapiens	39-55
25552929-2	2015	Upregulation of anti-angiogenic factor Thrombospondin-1 (TSP-1) accords for therapeutic potency of LDM paclitaxel, but its molecular mechanism has not been elucidated yet.	Paclitaxel	103-113	thrombospondin 1	Homo sapiens	57-62
25552929-4	2015	Here, we hypothesize that miRNAs are involved in TSP-1 overexpression in paclitaxel LDM therapy of breast tumors.	Paclitaxel	73-83	thrombospondin 1	Homo sapiens	49-54
25552929-13	2015	Paclitaxel LDM therapy led to a decrease of let-7f and the elevation of TSP-1 protein expression in MCF-7 cells, while overexpression of let-7f may abolish LDM-induced the upregulation of TSP-1 in MCF-7 cells.	Paclitaxel	0-10	thrombospondin 1	Homo sapiens	72-77
25552929-13	2015	Paclitaxel LDM therapy led to a decrease of let-7f and the elevation of TSP-1 protein expression in MCF-7 cells, while overexpression of let-7f may abolish LDM-induced the upregulation of TSP-1 in MCF-7 cells.	Paclitaxel	0-10	thrombospondin 1	Homo sapiens	188-193
25552929-14	2015	In summary, let-7f inhibition contributed to the upregulation of TSP-1 in paclitaxel LDM therapy, independently of proliferation, cell cycle arrest and apoptosis of breast cancer.	Paclitaxel	74-84	thrombospondin 1	Homo sapiens	65-70
25700370-4	2015	Paclitaxel treatment resulted in thermal hyperalgesia and in increased GABA transporter-1 (GAT-1) mRNA expression, but not that of other GABA transporters or GABA(A) ergic enzymes in the ACC compared to vehicle treatment.	Paclitaxel	0-10	solute carrier family 6 (neurotransmitter transporter, GABA), member 1	Mus musculus	71-89
25700370-4	2015	Paclitaxel treatment resulted in thermal hyperalgesia and in increased GABA transporter-1 (GAT-1) mRNA expression, but not that of other GABA transporters or GABA(A) ergic enzymes in the ACC compared to vehicle treatment.	Paclitaxel	0-10	solute carrier family 6 (neurotransmitter transporter, GABA), member 1	Mus musculus	91-96
25700370-7	2015	In conclusion, these data show that during paclitaxel-induced neuropathic pain there is significant increase in GAT-1 expression in the ACC.	Paclitaxel	43-53	solute carrier family 6 (neurotransmitter transporter, GABA), member 1	Mus musculus	112-117
25700370-9	2015	GAT-1 is a potential therapeutic target for managing paclitaxel-induced neuropathic pain.	Paclitaxel	53-63	solute carrier family 6 (neurotransmitter transporter, GABA), member 1	Mus musculus	0-5
25310526-7	2015	p53 and Bax were upregulated and Bcl2 was downregulated in the EB1-depleted PTX-treated MCF-7 cells, indicating that the apoptosis occurs via a p53-dependent pathway.	Paclitaxel	76-79	BCL2 associated X, apoptosis regulator	Homo sapiens	8-11
25310526-7	2015	p53 and Bax were upregulated and Bcl2 was downregulated in the EB1-depleted PTX-treated MCF-7 cells, indicating that the apoptosis occurs via a p53-dependent pathway.	Paclitaxel	76-79	BCL2 apoptosis regulator	Homo sapiens	33-37
25310526-7	2015	p53 and Bax were upregulated and Bcl2 was downregulated in the EB1-depleted PTX-treated MCF-7 cells, indicating that the apoptosis occurs via a p53-dependent pathway.	Paclitaxel	76-79	tumor protein p53	Homo sapiens	144-147
25535473-5	2015	Moreover, SG significantly increased the mitochondrial accumulation of both Bax and Bak triggered by epirubicin or paclitaxel as well as the subsequent release of cytochrome c in the targeted cells.	Paclitaxel	115-125	BCL2 associated X, apoptosis regulator	Homo sapiens	76-79
26045195-1	2015	P-glycoprotein (P-gp) overexpression is the main mechanism involved in chemotherapy drug resistance such as paclitaxel resistance and therapy failure.	Paclitaxel	108-118	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
26045195-1	2015	P-glycoprotein (P-gp) overexpression is the main mechanism involved in chemotherapy drug resistance such as paclitaxel resistance and therapy failure.	Paclitaxel	108-118	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
26045195-3	2015	In this study, EM-E-11-4, a lathyrane-type diterpenoid isolated from Euphorbia micractina, was found to significantly increase paclitaxel uptake in Caco-2 cells, which functionally overexpressed P-gp.	Paclitaxel	127-137	ATP binding cassette subfamily B member 1	Homo sapiens	195-199
26045195-4	2015	In vitro transport experiments, carried out in the Caco-2 monolayer model, indicated that EM-E-11-4 significantly reduced the efflux ratio of paclitaxel transport by inhibiting P-gp function without affecting P-gp expression.	Paclitaxel	142-152	ATP binding cassette subfamily B member 1	Homo sapiens	177-181
26045195-6	2015	Hence, EM-E-11-4 is an effective potential agent to reverse P-gp-mediated paclitaxel resistance by inhibiting P-gp transport function and increasing the intracellular concentration of paclitaxel.	Paclitaxel	74-84	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
26045195-6	2015	Hence, EM-E-11-4 is an effective potential agent to reverse P-gp-mediated paclitaxel resistance by inhibiting P-gp transport function and increasing the intracellular concentration of paclitaxel.	Paclitaxel	74-84	ATP binding cassette subfamily B member 1	Homo sapiens	110-114
26045195-6	2015	Hence, EM-E-11-4 is an effective potential agent to reverse P-gp-mediated paclitaxel resistance by inhibiting P-gp transport function and increasing the intracellular concentration of paclitaxel.	Paclitaxel	184-194	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
25535473-4	2015	Results of the mechanism study highlighted the cooperation between SG and epirubicin or paclitaxel in activating caspase-3 and -9 but not caspase-8.	Paclitaxel	88-98	caspase 3	Homo sapiens	113-129
26004370-6	2015	In vitro cell proliferation test, IC50 showed the superior antiproliferative activity of paclitaxel-loaded VEGF-NPs over unconjugated nanoparticles and native paclitaxel due to higher cellular association on tumour cells.	Paclitaxel	89-99	vascular endothelial growth factor A	Homo sapiens	107-111
25421492-0	2015	A novel combined micellar system of lapatinib and Paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro.	Paclitaxel	50-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-145
25421492-1	2015	Lapatinib (LPT) could sensitize human epidermal growth factor receptor-2 (HER-2) positive breast cancer to paclitaxel (PTX) and induce synergetic action with PTX in preclinical test and phase II/III trial.	Paclitaxel	107-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-79
25989666-32	2015	CONCLUSION: Beclinl enhances paclitaxel-sensitivity by inhibition of PI3K/Akt pathway.	Paclitaxel	29-39	AKT serine/threonine kinase 1	Homo sapiens	74-77
26108226-0	2015	Paclitaxel-sensitization enhanced by curcumin involves down-regulation of nuclear factor-kappaB and Lin28 in Hep3B cells.	Paclitaxel	0-10	lin-28 homolog A	Homo sapiens	100-105
26108226-2	2015	Previously, we discovered that Lin28 was closely associated with resistance to paclitaxel in Hep3B cells.	Paclitaxel	79-89	lin-28 homolog A	Homo sapiens	31-36
26108226-5	2015	In this study, we reported that a combination of curcumin and paclitaxel exhibited synergistic anti-proliferative and pro-apoptosis effects on Hep3B cells, and curcumin down-regulated paclitaxel-induced enhanced expression of Lin28 and NF-kappaB activation.	Paclitaxel	62-72	lin-28 homolog A	Homo sapiens	226-231
26108226-5	2015	In this study, we reported that a combination of curcumin and paclitaxel exhibited synergistic anti-proliferative and pro-apoptosis effects on Hep3B cells, and curcumin down-regulated paclitaxel-induced enhanced expression of Lin28 and NF-kappaB activation.	Paclitaxel	62-72	nuclear factor kappa B subunit 1	Homo sapiens	236-245
26108226-5	2015	In this study, we reported that a combination of curcumin and paclitaxel exhibited synergistic anti-proliferative and pro-apoptosis effects on Hep3B cells, and curcumin down-regulated paclitaxel-induced enhanced expression of Lin28 and NF-kappaB activation.	Paclitaxel	184-194	lin-28 homolog A	Homo sapiens	226-231
26108226-5	2015	In this study, we reported that a combination of curcumin and paclitaxel exhibited synergistic anti-proliferative and pro-apoptosis effects on Hep3B cells, and curcumin down-regulated paclitaxel-induced enhanced expression of Lin28 and NF-kappaB activation.	Paclitaxel	184-194	nuclear factor kappa B subunit 1	Homo sapiens	236-245
25164962-0	2015	The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.	Paclitaxel	55-65	AKT serine/threonine kinase 1	Homo sapiens	4-7
25351906-6	2015	5-FU and paclitaxel treatment increased the number of SP cells and JNK phosphorylation, and decreased cell survival.	Paclitaxel	9-19	mitogen-activated protein kinase 8	Homo sapiens	67-70
25164962-0	2015	The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.	Paclitaxel	67-72	AKT serine/threonine kinase 1	Homo sapiens	4-7
25164962-3	2015	Here, we demonstrate the efficacy of an Akt inhibitor, MK-2206, in increasing the cytotoxic effect of either paclitaxel (Taxol) or cisplatin against the ovarian cancer cell lines SKOV3 (with constitutively active Akt) and ES2 (with inactive Akt).	Paclitaxel	109-119	AKT serine/threonine kinase 1	Homo sapiens	40-43
25164962-3	2015	Here, we demonstrate the efficacy of an Akt inhibitor, MK-2206, in increasing the cytotoxic effect of either paclitaxel (Taxol) or cisplatin against the ovarian cancer cell lines SKOV3 (with constitutively active Akt) and ES2 (with inactive Akt).	Paclitaxel	121-126	AKT serine/threonine kinase 1	Homo sapiens	40-43
25164962-4	2015	Sequential treatment of Taxol or cisplatin, followed by MK-2206, induced a synergistic inhibition of cell proliferation and effectively promoted cell death, either by inhibiting the phosphorylation of Akt and its downstream effectors 4E-BP1 and p70S6K in SKOV3 cells or by restoring p53 levels, which were downregulated after Taxol or cisplatin treatment, in ES2 cells.	Paclitaxel	24-29	AKT serine/threonine kinase 1	Homo sapiens	201-204
25997962-6	2015	Finally, we invalidated that miR-200a significantly enhanced the chemosensitivity of paclitaxel but not cisplatin in both adherent culture and sphere culture.	Paclitaxel	85-95	microRNA 200a	Homo sapiens	29-37
25164962-4	2015	Sequential treatment of Taxol or cisplatin, followed by MK-2206, induced a synergistic inhibition of cell proliferation and effectively promoted cell death, either by inhibiting the phosphorylation of Akt and its downstream effectors 4E-BP1 and p70S6K in SKOV3 cells or by restoring p53 levels, which were downregulated after Taxol or cisplatin treatment, in ES2 cells.	Paclitaxel	24-29	tumor protein p53	Homo sapiens	283-286
25164962-4	2015	Sequential treatment of Taxol or cisplatin, followed by MK-2206, induced a synergistic inhibition of cell proliferation and effectively promoted cell death, either by inhibiting the phosphorylation of Akt and its downstream effectors 4E-BP1 and p70S6K in SKOV3 cells or by restoring p53 levels, which were downregulated after Taxol or cisplatin treatment, in ES2 cells.	Paclitaxel	24-29	ess-2 splicing factor homolog	Homo sapiens	359-362
25164962-4	2015	Sequential treatment of Taxol or cisplatin, followed by MK-2206, induced a synergistic inhibition of cell proliferation and effectively promoted cell death, either by inhibiting the phosphorylation of Akt and its downstream effectors 4E-BP1 and p70S6K in SKOV3 cells or by restoring p53 levels, which were downregulated after Taxol or cisplatin treatment, in ES2 cells.	Paclitaxel	326-331	AKT serine/threonine kinase 1	Homo sapiens	201-204
25164962-6	2015	In addition, we discovered that Taxol/MK-2206 or cisplatin/MK-2206 combination treatment resulted in significant enhancement of intracellular reactive oxygen species (ROS) induced by MK-2206, in both SKOV3 and ES2 cells; however, MK-2206-induced growth inhibition was reversed by a ROS scavenger only in ES2 cells.	Paclitaxel	32-37	ess-2 splicing factor homolog	Homo sapiens	210-213
25164962-6	2015	In addition, we discovered that Taxol/MK-2206 or cisplatin/MK-2206 combination treatment resulted in significant enhancement of intracellular reactive oxygen species (ROS) induced by MK-2206, in both SKOV3 and ES2 cells; however, MK-2206-induced growth inhibition was reversed by a ROS scavenger only in ES2 cells.	Paclitaxel	32-37	ess-2 splicing factor homolog	Homo sapiens	304-307
25459393-1	2014	BACKGROUND: The addition of bevacizumab to paclitaxel or capecitabine has demonstrated improved progression-free survival (PFS) and objective response rate (ORR) as compared with chemotherapy alone in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC).	Paclitaxel	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	215-219
25550688-6	2014	Furthermore, the property of NF-kappaB activation shared by DOX and PTX was not identical.	Paclitaxel	68-71	nuclear factor kappa B subunit 1	Homo sapiens	29-38
25550688-7	2014	An attempt made in the present study demonstrated that the acquired resistance to DOX was via or partially via NF-kappaB activation but not its upstream receptor TLR4, while PTX can induce the drug resistance via TLR4-NF-kappaB pathway.	Paclitaxel	174-177	nuclear factor kappa B subunit 1	Homo sapiens	218-227
25550688-9	2014	The current study provides useful insight into the distinct ability of DOX and PTX to induce P-gp mediated MDR in breast cancer.	Paclitaxel	79-82	ATP binding cassette subfamily B member 1	Homo sapiens	93-97
25453096-4	2014	Here, we demonstrate that HIF expression and transcriptional activity are induced by treatment of MDA-MB-231, SUM-149, and SUM-159, which are human TNBC cell lines, as well as MCF-7, which is an ER(+)/PR(+) breast cancer line, with paclitaxel or gemcitabine.	Paclitaxel	232-242	estrogen receptor 1	Homo sapiens	195-197
25370413-6	2015	Cisplatin and paclitaxel significantly increased the expression of EGFR phosphorylation in the HCC827 cell line.	Paclitaxel	14-24	epidermal growth factor receptor	Homo sapiens	67-71
25370413-7	2015	However, only paclitaxel increased the expression of EGFR phosphorylation in the H1975 cell line.	Paclitaxel	14-24	epidermal growth factor receptor	Homo sapiens	53-57
25370413-8	2015	Cisplatin/paclitaxel followed by icotinib influenced the expression of p-EGFR and p-AKT, although the expression of p-ERK1/2 remained unchanged.	Paclitaxel	10-20	epidermal growth factor receptor	Homo sapiens	73-77
26267044-0	2015	Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.	Paclitaxel	96-106	solute carrier organic anion transporter family member 1B3	Homo sapiens	17-24
26267044-0	2015	Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.	Paclitaxel	96-106	nuclear receptor subfamily 1 group I member 2	Homo sapiens	29-34
26267044-5	2015	CONCLUSION: Our results revealed the importance of SLCO1B3 and NR1I2 in the sensitivity to carboplatin/paclitaxel thrombocytopenia.	Paclitaxel	103-113	solute carrier organic anion transporter family member 1B3	Homo sapiens	51-58
26267044-5	2015	CONCLUSION: Our results revealed the importance of SLCO1B3 and NR1I2 in the sensitivity to carboplatin/paclitaxel thrombocytopenia.	Paclitaxel	103-113	nuclear receptor subfamily 1 group I member 2	Homo sapiens	63-68
25459427-8	2014	Cytokine estimation study in macrophages showed that both PTX loaded nanoemulsion and blank nanoemulsion enhanced secretion of IL-12 and downregulated secretion of IL-4 and IL-10.	Paclitaxel	58-61	interleukin 4	Homo sapiens	164-168
25534230-7	2014	Suppressing ER by fulvestrant, paclitaxel and ER siRNA showed increased expression of E-cadherin, which is a crucial factor in diffuse-type carcinogenesis.	Paclitaxel	31-41	estrogen receptor 1	Homo sapiens	12-14
25534230-7	2014	Suppressing ER by fulvestrant, paclitaxel and ER siRNA showed increased expression of E-cadherin, which is a crucial factor in diffuse-type carcinogenesis.	Paclitaxel	31-41	cadherin 1	Homo sapiens	86-96
25550688-5	2014	Both PXR and NF-kappaB pathways took part in the PTX drug resistance acquisition, whereas DOX did not exert a significant effect on the PXR-mediated induction of P-gp.	Paclitaxel	49-52	nuclear receptor subfamily 1 group I member 2	Homo sapiens	5-8
25550688-5	2014	Both PXR and NF-kappaB pathways took part in the PTX drug resistance acquisition, whereas DOX did not exert a significant effect on the PXR-mediated induction of P-gp.	Paclitaxel	49-52	nuclear factor kappa B subunit 1	Homo sapiens	13-22
25512030-4	2014	METHODS: Stage II-III HER2-positive BC patients received 24 weeks paclitaxel and trastuzumab NC, followed by 1 year adjuvant trastuzumab +- hormonal and/or radio-therapy.	Paclitaxel	66-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-26
25512030-12	2014	CONCLUSIONS: In the absence of anthracyclines, trastuzumab and paclitaxel induced a high rate of pCR, exploiting the synergy between the immunomodulating properties of these drugs and the retained immunological proficiency of patients with HER2-overexpressing BC.	Paclitaxel	63-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	240-244
25460502-0	2014	Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response.	Paclitaxel	28-33	FKBP prolyl isomerase 5	Homo sapiens	76-81
25460502-0	2014	Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response.	Paclitaxel	28-33	androgen receptor	Homo sapiens	90-107
25460502-7	2014	Silencing of FKBP5 sensitized txr cells to taxol, whereas ectopic expression of FKBP5 increased resistance to the drug.	Paclitaxel	43-48	FKBP prolyl isomerase 5	Homo sapiens	13-18
25460502-9	2014	We observed that a panel of newly identified txr genes was trancriptionally regulated by FKBP5 and silencing of these genes sensitized cells to taxol.	Paclitaxel	144-149	FKBP prolyl isomerase 5	Homo sapiens	89-94
25460502-12	2014	These results indicate that the FKBP5/AR complex may affect cancer cell sensitivity to taxol by regulating expression of txr genes.	Paclitaxel	87-92	FKBP prolyl isomerase 5	Homo sapiens	32-37
25460502-12	2014	These results indicate that the FKBP5/AR complex may affect cancer cell sensitivity to taxol by regulating expression of txr genes.	Paclitaxel	87-92	androgen receptor	Homo sapiens	38-40
26116117-0	2014	Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model.	Paclitaxel	0-10	L1 cell adhesion molecule	Homo sapiens	25-30
25459393-14	2014	INTERPRETATION: In patients with HER2-negative LR/MBC, addition of capecitabine to paclitaxel and bevacizumab significantly improved PFS, ORR and response duration.	Paclitaxel	83-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-37
25230791-0	2014	Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-kappaB activity in human oral squamous cell carcinoma cell lines.	Paclitaxel	0-10	nuclear factor kappa B subunit 1	Homo sapiens	80-89
24752740-8	2014	Dysregulation of Tcf4-regulated ion transporters and increased cytosolic acidification were observed in HS3ST2-expressing MDA-MB-231 cells, which is a possible underlying cause of increased chemosensitivity towards doxorubicine and paclitaxel in these cells.	Paclitaxel	232-242	heparan sulfate-glucosamine 3-sulfotransferase 2	Homo sapiens	104-110
25230791-4	2014	Furthermore, PTX and cetuximab combination treatment reduced the expression of p65 (NF-kappaB) protein in OSCC cells.	Paclitaxel	13-16	nuclear factor kappa B subunit 1	Homo sapiens	84-93
25310235-0	2014	Sox2 is involved in paclitaxel resistance of the prostate cancer cell line PC-3 via the PI3K/Akt pathway.	Paclitaxel	20-30	AKT serine/threonine kinase 1	Homo sapiens	93-96
25521357-0	2014	Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.	Paclitaxel	119-129	C-X-C motif chemokine ligand 8	Homo sapiens	52-56
25242567-0	2014	A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways.	Paclitaxel	58-68	adenosine A3 receptor	Homo sapiens	0-21
25242567-4	2014	We recently reported that activation of the Gi/Gq-coupled A3 adenosine receptor (A3AR) with selective A3AR agonists (ie, IB-MECA) blocked the development of chemotherapy induced-neuropathic pain evoked by distinct agents, including paclitaxel, without interfering with anticancer effects.	Paclitaxel	232-242	adenosine A3 receptor	Homo sapiens	58-79
25242567-4	2014	We recently reported that activation of the Gi/Gq-coupled A3 adenosine receptor (A3AR) with selective A3AR agonists (ie, IB-MECA) blocked the development of chemotherapy induced-neuropathic pain evoked by distinct agents, including paclitaxel, without interfering with anticancer effects.	Paclitaxel	232-242	adenosine A3 receptor	Homo sapiens	81-85
25242567-4	2014	We recently reported that activation of the Gi/Gq-coupled A3 adenosine receptor (A3AR) with selective A3AR agonists (ie, IB-MECA) blocked the development of chemotherapy induced-neuropathic pain evoked by distinct agents, including paclitaxel, without interfering with anticancer effects.	Paclitaxel	232-242	adenosine A3 receptor	Homo sapiens	102-106
24793378-6	2014	Patients with NSCLCs harboring EGFR exon 19 deletions or the exon 21 L858R mutation were found to have a higher chance of response to platinum-paclitaxel (OR 9.67 [95 % CI 1.03-90.41], p = 0.047).	Paclitaxel	143-153	epidermal growth factor receptor	Homo sapiens	31-35
24793378-8	2014	EGFR mutations seem to be predictive of a response to platinum-paclitaxel, and additional studies are needed to confirm or refute this relationship.	Paclitaxel	63-73	epidermal growth factor receptor	Homo sapiens	0-4
25427200-7	2014	Furthermore, c-Met knockdown enhanced the anti-proliferative effects of 5-FU and Taxol but not cisplatin, irinotecan or sorafenib.	Paclitaxel	81-86	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	13-18
25473300-10	2014	CONCLUSION: Bevacizumab plus paclitaxel was effective in HER2-negative MBC.	Paclitaxel	29-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-61
25411964-8	2014	FOXM1 knockdown significantly inhibited migration and invasion of ovarian cancer cells and enhanced paclitaxel-mediated cell death and mitotic catastrophe in a p53-independent manner.	Paclitaxel	100-110	tumor protein p53	Homo sapiens	160-163
25546354-10	2014	Q-PCR showed the combination of Suberoylanilide hydroxamic acid and paclitaxel reduced intracellular bcl-2 and c-myc gene expression and increased bax gene expression more distinctly than the application of SAHA or paclitaxel alone.	Paclitaxel	68-78	BCL2 apoptosis regulator	Homo sapiens	101-106
25546354-10	2014	Q-PCR showed the combination of Suberoylanilide hydroxamic acid and paclitaxel reduced intracellular bcl-2 and c-myc gene expression and increased bax gene expression more distinctly than the application of SAHA or paclitaxel alone.	Paclitaxel	68-78	BCL2 associated X, apoptosis regulator	Homo sapiens	147-150
25546354-12	2014	Western blot analysis showed that Suberoylanilide hydroxamic acid alone or in combination with paclitaxel enhanced caspase-3 protein expression and degraded ID1 protein expression in OC3/P cells.	Paclitaxel	95-105	caspase 3	Homo sapiens	115-124
25332249-11	2014	CONCLUSION: The addition of trastuzumab to paclitaxel after doxorubicin and cyclophosphamide in early-stage HER2-positive breast cancer results in a substantial and durable improvement in survival as a result of a sustained marked reduction in cancer recurrence.	Paclitaxel	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-112
25667746-3	2014	The two anti-cancer drugs of interest were stochastically conjugated to a beta-sheet forming peptide (Sup35) and under physiologically-relevant conditions the dual DA could spontaneously associate into supramolecular filaments with a fixed 41% total drug loading (29% PTX and 12% CPT).	Paclitaxel	268-271	amyloid beta precursor protein	Homo sapiens	72-78
25454663-5	2014	In vitro cytotoxicity studies reveal that the NPs have excellent biocompatibility, and the presence of Tf enhance the activity of PTX to the targeted cells.	Paclitaxel	130-133	transferrin	Homo sapiens	103-105
25228695-6	2014	In contrast, the reconstitution of 14-3-3beta expression in miR-152(high) cells increased the expression of the anti-apoptotic BCL2 gene, enhances the proliferative activity in the presence of the cytostatic drug paclitaxel, and causes resistance to apoptosis induced by this drug.	Paclitaxel	213-223	BCL2 apoptosis regulator	Homo sapiens	127-131
23971495-5	2014	The presence of verapamil and Pluronic both improved the intestinal permeability of paclitaxel, which further certified the inhibition effect of thiolated Pluronic on P-gp.	Paclitaxel	84-94	phosphoglycolate phosphatase	Rattus norvegicus	167-171
25175786-8	2014	Following the paclitaxel treatment, a decreased apoptosis and G2 phase ratio, an increased cell migration ratio, and an increased production of IL-8 were found in MyD88-overexpressed A549 cells.	Paclitaxel	14-24	C-X-C motif chemokine ligand 8	Homo sapiens	144-148
25731503-0	2014	[A case of curative surgery for HER2-positive gastric cancer after chemotherapy using paclitaxel combined with trastuzumab].	Paclitaxel	86-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-36
25280517-9	2014	Our data offer the convincing evidence that combined expression of miR-133a and miR-133b may predict chemosensitivity of patients with ESCC undergoing paclitaxel-based chemotherapy, implying its importance in applying "personalized cancer medicine" in the clinical treatment of ESCC.	Paclitaxel	151-161	microRNA 133b	Homo sapiens	80-88
25985578-1	2014	The effects of ethanol extracts from Thai plants belonging to the families of Annonaceae, Rutaceae, and Zingiberaceae on P-glycoprotein (P-gp) function and multidrug resistance were examined in paclitaxel-resistant HepG2 (PR-HepG2) cells.	Paclitaxel	194-204	ATP binding cassette subfamily B member 1	Homo sapiens	137-141
25175513-2	2014	Paclitaxel-resistant ovarian carcinoma cell lines OC3/TAX300 and OC3/TAX50 and their parental cell lines were analyzed by comparative genomic hybridization, and the expression levels of hMSH2 in ovarian carcinoma cell lines and tissues were determined.	Paclitaxel	0-10	one cut homeobox 3	Homo sapiens	50-53
25175513-2	2014	Paclitaxel-resistant ovarian carcinoma cell lines OC3/TAX300 and OC3/TAX50 and their parental cell lines were analyzed by comparative genomic hybridization, and the expression levels of hMSH2 in ovarian carcinoma cell lines and tissues were determined.	Paclitaxel	0-10	one cut homeobox 3	Homo sapiens	65-68
25985578-2	2014	All the extracts tested, significantly increased the accumulation of [3H]paclitaxel, a P-gp substrate, in the cells.	Paclitaxel	73-83	ATP binding cassette subfamily B member 1	Homo sapiens	87-91
25181333-7	2014	In addition, caspase-6, caspase-8 and caspase-9 labeling was present in SGN treated with 30 muM paclitaxel for 48 h. These results suggest that caspase-dependent apoptotic pathways are involved in paclitaxel-induced damage of SGN, but not hair cells in cochlea.	Paclitaxel	96-106	caspase 6	Rattus norvegicus	13-22
25181333-7	2014	In addition, caspase-6, caspase-8 and caspase-9 labeling was present in SGN treated with 30 muM paclitaxel for 48 h. These results suggest that caspase-dependent apoptotic pathways are involved in paclitaxel-induced damage of SGN, but not hair cells in cochlea.	Paclitaxel	96-106	caspase 9	Rattus norvegicus	38-47
25181333-7	2014	In addition, caspase-6, caspase-8 and caspase-9 labeling was present in SGN treated with 30 muM paclitaxel for 48 h. These results suggest that caspase-dependent apoptotic pathways are involved in paclitaxel-induced damage of SGN, but not hair cells in cochlea.	Paclitaxel	197-207	caspase 6	Rattus norvegicus	13-22
25181333-7	2014	In addition, caspase-6, caspase-8 and caspase-9 labeling was present in SGN treated with 30 muM paclitaxel for 48 h. These results suggest that caspase-dependent apoptotic pathways are involved in paclitaxel-induced damage of SGN, but not hair cells in cochlea.	Paclitaxel	197-207	caspase 9	Rattus norvegicus	38-47
25330011-5	2014	Forced over-expression of miR-375 may suppress Ecadherin expression by a directly targeting pathway, which led to paclitaxel resistance.	Paclitaxel	114-124	cadherin 1	Homo sapiens	47-56
25688502-13	2014	CONCLUSIONS: Irinotecan and paclitaxel are an effective treatment for HCT 116 wt cells, whereas HCT 116 cells with p53 deficiency can be treated successfully with paclitaxel and gemcitabine.	Paclitaxel	163-173	tumor protein p53	Homo sapiens	115-118
25289099-11	2014	Pretreatment of miR-7 mimics enhanced the PTX-mediated downregulation of epidermal growth factor receptor (EGFR) in NSCLC cells.	Paclitaxel	42-45	epidermal growth factor receptor	Homo sapiens	73-105
25289099-11	2014	Pretreatment of miR-7 mimics enhanced the PTX-mediated downregulation of epidermal growth factor receptor (EGFR) in NSCLC cells.	Paclitaxel	42-45	epidermal growth factor receptor	Homo sapiens	107-111
25289099-12	2014	These results have identified miR-7 as a potential EGFR-targeting sensitizer in PTX therapy.	Paclitaxel	80-83	epidermal growth factor receptor	Homo sapiens	51-55
25342321-8	2014	SC-560 combined with taxol showed a greater inhibition on VEGF mRNA expression than SC-560 or taxol alone (p &lt; 0.05).	Paclitaxel	21-26	vascular endothelial growth factor A	Homo sapiens	58-62
25330011-3	2014	Here, we showed the association of paclitaxel-resistance with miR-375 over-expression and epithelial-mesenchymal transition inducement in cervical cancer.	Paclitaxel	35-45	microRNA 375	Homo sapiens	62-69
25330011-6	2014	Contrarily, re-expression of Ecadherin partly reversed epithelial-mesenchymal transition phenotype and miR-375 induced paclitaxel-resistance.	Paclitaxel	119-129	cadherin 1	Homo sapiens	29-38
25330011-4	2014	Using different cervical cancer cell models, we found that paclitaxel transiently induced up-regulation of miR-375 expression, proliferation inhibition, transition from epithelial to mesenchymal phenotype, and consequently impaired paclitaxel sensitivity.	Paclitaxel	59-69	microRNA 375	Homo sapiens	107-114
25330011-5	2014	Forced over-expression of miR-375 may suppress Ecadherin expression by a directly targeting pathway, which led to paclitaxel resistance.	Paclitaxel	114-124	microRNA 375	Homo sapiens	26-33
25330011-6	2014	Contrarily, re-expression of Ecadherin partly reversed epithelial-mesenchymal transition phenotype and miR-375 induced paclitaxel-resistance.	Paclitaxel	119-129	microRNA 375	Homo sapiens	103-110
25330011-7	2014	Our findings suggest that paclitaxel-induced miR-375 over-expression facilitates epithelial-mesenchymal transition process via directly targeting Ecadherin, proliferation inhibition, and consequently results in chemo-resistance in cervical cancer cells.	Paclitaxel	26-36	microRNA 375	Homo sapiens	45-52
25330011-7	2014	Our findings suggest that paclitaxel-induced miR-375 over-expression facilitates epithelial-mesenchymal transition process via directly targeting Ecadherin, proliferation inhibition, and consequently results in chemo-resistance in cervical cancer cells.	Paclitaxel	26-36	cadherin 1	Homo sapiens	146-155
25442283-3	2014	Western blotting and real-time quantitative polymerase chain reaction (qRT-PCR) indicated that transgelin 2 may mediate paclitaxel resistance by activating the phosphatidylinositol 3-kinase (PI3 K)/Akt signaling pathway to suppress MCF-7/PTX cells apoptosis.	Paclitaxel	120-130	AKT serine/threonine kinase 1	Homo sapiens	198-201
25128812-0	2014	Src inhibition potentiates antitumoral effect of paclitaxel by blocking tumor-induced angiogenesis.	Paclitaxel	49-59	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
25128812-8	2014	In conclusion, Src-inhibition could be an effective therapeutic strategy aimed at supporting the anti-angiogenic action of PTX in aggressive PCa.	Paclitaxel	123-126	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	15-18
25442283-0	2014	Salvianolic acid A reverses paclitaxel resistance in human breast cancer MCF-7 cells via targeting the expression of transgelin 2 and attenuating PI3 K/Akt pathway.	Paclitaxel	28-38	AKT serine/threonine kinase 1	Homo sapiens	152-155
25442283-6	2014	Taken together, SAA can reverse paclitaxel resistance through suppressing transgelin 2 expression by mechanisms involving attenuation of PI3 K/Akt pathway activation and ABC transporter up-regulation.	Paclitaxel	32-42	AKT serine/threonine kinase 1	Homo sapiens	143-146
23388565-2	2014	In 2008, the FDA approved bevacizumab with paclitaxel for the initial treatment of HER2-negative MBC.	Paclitaxel	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
25314641-2	2014	EXPERIMENTAL DESIGN: Placental growth factor was evaluated at baseline and study week 4 (after 3 weeks treatment) in an exploratory analysis of data from a randomized phase 2 study of motesanib 125 mg once daily plus carboplatin/paclitaxel and in a prespecified analysis of data from a randomized, double-blind phase 3 study of motesanib 125 mg once daily plus carboplatin/paclitaxel vs placebo plus carboplatin/paclitaxel (MONET1).	Paclitaxel	229-239	placental growth factor	Homo sapiens	21-44
25314641-2	2014	EXPERIMENTAL DESIGN: Placental growth factor was evaluated at baseline and study week 4 (after 3 weeks treatment) in an exploratory analysis of data from a randomized phase 2 study of motesanib 125 mg once daily plus carboplatin/paclitaxel and in a prespecified analysis of data from a randomized, double-blind phase 3 study of motesanib 125 mg once daily plus carboplatin/paclitaxel vs placebo plus carboplatin/paclitaxel (MONET1).	Paclitaxel	373-383	placental growth factor	Homo sapiens	21-44
25314641-2	2014	EXPERIMENTAL DESIGN: Placental growth factor was evaluated at baseline and study week 4 (after 3 weeks treatment) in an exploratory analysis of data from a randomized phase 2 study of motesanib 125 mg once daily plus carboplatin/paclitaxel and in a prespecified analysis of data from a randomized, double-blind phase 3 study of motesanib 125 mg once daily plus carboplatin/paclitaxel vs placebo plus carboplatin/paclitaxel (MONET1).	Paclitaxel	373-383	placental growth factor	Homo sapiens	21-44
25211704-3	2014	Once in the cytoskeleton, GBP1 binds to prosurvival kinases such as PIM1 and initiates a signaling pathway that induces resistance to paclitaxel.	Paclitaxel	134-144	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	68-72
25211704-4	2014	Therefore, the inhibition of the GBP1:PIM1 interaction could potentially revert resistance to paclitaxel.	Paclitaxel	94-104	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	38-42
23388565-6	2014	This study aimed to assess the cost-effectiveness of bevacizumab with paclitaxel for HER2-negative MBC.	Paclitaxel	70-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
25104330-3	2014	TNBC cell lines with NOTCH1 rearrangements associated with high levels of activated NOTCH1 (N1-ICD) were sensitive to the gamma-secretase inhibitor (GSI) MRK-003, both alone and in combination with paclitaxel, in vitro and in vivo, whereas cell lines with NOTCH2 rearrangements were resistant to GSI.	Paclitaxel	198-208	notch receptor 1	Homo sapiens	21-27
25275030-6	2014	Up-regulation of the MDR1 and CYP2C8 genes were shown to be potential mechanisms of paclitaxel resistance in the resistant cells.	Paclitaxel	84-94	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
25046000-4	2014	Seven of them (melphalan, cisplatin, vincristine, etoposide, paclitaxel, methotrexate, and cytarabine) caused the production of IL-1beta in cells pretreated with lipopolysaccharide.	Paclitaxel	61-71	interleukin 1 beta	Homo sapiens	128-136
25104330-3	2014	TNBC cell lines with NOTCH1 rearrangements associated with high levels of activated NOTCH1 (N1-ICD) were sensitive to the gamma-secretase inhibitor (GSI) MRK-003, both alone and in combination with paclitaxel, in vitro and in vivo, whereas cell lines with NOTCH2 rearrangements were resistant to GSI.	Paclitaxel	198-208	notch receptor 2	Homo sapiens	256-262
25016976-0	2014	The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors.	Paclitaxel	29-39	transferrin	Homo sapiens	56-67
25327563-9	2014	The increase in CD133+ cells resulting from ARID3B expression was accompanied by enhanced paclitaxel resistance.	Paclitaxel	90-100	AT-rich interaction domain 3B	Homo sapiens	44-50
25016976-7	2014	Both in monolayers and in spheroids, PCL cytotoxicity was significantly increased when co-delivered with CUR in non-targeted micelles or as single agent in TF-targeted micelles, whereas TF-modification of co-loaded micelles did not further enhance the cytotoxicity.	Paclitaxel	37-40	transferrin	Homo sapiens	156-158
24950257-1	2014	OBJECTIVES: The aim of this study was to develop the hexapeptide-conjugated active targeting micelles for delivery of doxorubicin (DOX) and paclitaxel (PTX) to EGFR high-expressed cancer cells.	Paclitaxel	140-150	epidermal growth factor receptor	Homo sapiens	160-164
24950257-1	2014	OBJECTIVES: The aim of this study was to develop the hexapeptide-conjugated active targeting micelles for delivery of doxorubicin (DOX) and paclitaxel (PTX) to EGFR high-expressed cancer cells.	Paclitaxel	152-155	epidermal growth factor receptor	Homo sapiens	160-164
25198583-0	2014	Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells.	Paclitaxel	96-106	insulin-like growth factor I receptor	Mus musculus	8-14
25111376-9	2014	CONCLUSIONS: Silencing Bcl-2 in PTEN-mutated prostate cancer cells enhances the apoptotic effects of combined starvation and taxol treatments, indicating that inhibition of Bcl-2 may be of significant value in PTEN-mutant tumor therapy.	Paclitaxel	125-130	BCL2 apoptosis regulator	Homo sapiens	23-28
24993095-0	2014	Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population.	Paclitaxel	10-20	ATP binding cassette subfamily B member 1	Homo sapiens	78-83
24993095-6	2014	We show that ABCB1 is the functioning ABC transporter in ovarian cancer cell lines, and expression of ABCB1 is associated with a paclitaxel-resistant phenotype.	Paclitaxel	129-139	ATP binding cassette subfamily B member 1	Homo sapiens	13-18
24993095-6	2014	We show that ABCB1 is the functioning ABC transporter in ovarian cancer cell lines, and expression of ABCB1 is associated with a paclitaxel-resistant phenotype.	Paclitaxel	129-139	ATP binding cassette subfamily B member 1	Homo sapiens	102-107
24993095-7	2014	Moreover, silencing of ABCB1 using a specific morpholino oligonucleotide results in an inhibition of the SP phenotype and a sensitising of ovarian cancer cell lines to paclitaxel.	Paclitaxel	168-178	ATP binding cassette subfamily B member 1	Homo sapiens	23-28
24510775-2	2014	In our study, paclitaxel-resistant ovarian cancer patients and cell lines had decreased miR-145 levels and expressed high levels of Sp1 and Cdk6.	Paclitaxel	14-24	cyclin dependent kinase 6	Homo sapiens	140-144
25264898-8	2014	Increase in cells expressing CSC markers and Notch1 signaling pathway in tumors exposed to CIS may explain recurrence of cancer in patients treated with carboplatin and paclitaxel.	Paclitaxel	169-179	notch receptor 1	Homo sapiens	45-51
25258543-5	2014	The lncRNA plasma-cytoma variant translocation 1 (PVT1) was found to exhibit higher expression in both gastric cancer tissues and the SGC7901 paclitaxel-resistant cell line.	Paclitaxel	142-152	sarcoglycan beta	Homo sapiens	134-137
25236161-10	2014	Inhibition of Src expression in U-2OSMR and KHOSR2 cell lines using lentiviral shRNA also resulted in increased doxorubicin and paclitaxel drug sensitivity.	Paclitaxel	128-138	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	14-17
24510775-0	2014	miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.	Paclitaxel	43-53	cyclin dependent kinase 6	Homo sapiens	75-79
25102234-3	2014	High cell cytotoxicity in PTX-resistant human ovarian cell line A2780/T was observed with enhanced PTX accumulation due to the P-gp inhibition by the TPGS moiety.	Paclitaxel	26-29	ATP binding cassette subfamily B member 1	Homo sapiens	127-131
24882083-2	2014	This study was directed to evaluate the inhibitory effects of cisplatin and paclitaxel on two CYP450 enzymes namely CYP2E1 and CYP3A1/2 in hepatic microsomes isolated from normal and turmeric pretreated rats.	Paclitaxel	76-86	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	116-122
24882083-5	2014	Addition of cisplatin or paclitaxel by (10, 50 and 100 muM) to hepatic microsomes from normal or turmeric pretreated rats caused a concentration dependent inhibition of CYP2E1, with an evidence of less inhibition in turmeric pretreated microsomes particularly at higher concentration.	Paclitaxel	25-35	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	169-175
24882083-6	2014	Both drugs at 100 muM displayed a mixed type of inhibition of CYP2E1 in normal or turmeric pretreated microsomes where paclitaxel was the most potent inhibitor.	Paclitaxel	119-129	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	62-68
24882083-11	2014	In conclusion, turmeric pretreatment attenuated the inhibitory influence of cisplatin and paclitaxel on CYP2E1 activity and magnified their inhibition on CYP3A1/2, thus the use of turmeric with drugs or other medications should raise concern for drugs-herb interactions.	Paclitaxel	90-100	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	104-110
25102234-1	2014	To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release.	Paclitaxel	104-114	ATP binding cassette subfamily B member 1	Homo sapiens	46-60
25102234-1	2014	To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release.	Paclitaxel	104-114	ATP binding cassette subfamily B member 1	Homo sapiens	62-66
25102234-1	2014	To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release.	Paclitaxel	104-114	ATP binding cassette subfamily B member 1	Homo sapiens	303-307
25102234-1	2014	To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release.	Paclitaxel	116-119	ATP binding cassette subfamily B member 1	Homo sapiens	46-60
25102234-1	2014	To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release.	Paclitaxel	116-119	ATP binding cassette subfamily B member 1	Homo sapiens	62-66
25356184-2	2014	In this article we report a case of male breast cancer with liver metastases, which showed a good response to a combined treatment of bevacizumb and paclitaxel, suggesting a useful option for the first-line treatment of patients with recurrent HER2-negative male breast cancer.	Paclitaxel	149-159	erb-b2 receptor tyrosine kinase 2	Homo sapiens	244-248
24877693-0	2014	Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance.	Paclitaxel	52-62	ATP binding cassette subfamily B member 1	Homo sapiens	34-48
24877693-0	2014	Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance.	Paclitaxel	118-128	ATP binding cassette subfamily B member 1	Homo sapiens	34-48
24877693-4	2014	Paclitaxel-resistant human ovarian cancer cells (A2780/PTX) readily formed and released P-gp-containing MVs into the extracellular space compared with the wild-type parental line (A2780/WT).	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	88-92
24877693-6	2014	MV-mediated transfer of P-gp led to redistribution of the chemotherapeutic drug adriamycin in recipient cells (A2780/WT), which displayed 5- and 5-fold higher resistance to adriamycin and paclitaxel, respectively.	Paclitaxel	188-198	ATP binding cassette subfamily B member 1	Homo sapiens	24-28
24882083-0	2014	Pretreatment with turmeric modulates the inhibitory influence of cisplatin and paclitaxel on CYP2E1 and CYP3A1/2 in isolated rat hepatic microsomes.	Paclitaxel	79-89	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	93-99
25102234-3	2014	High cell cytotoxicity in PTX-resistant human ovarian cell line A2780/T was observed with enhanced PTX accumulation due to the P-gp inhibition by the TPGS moiety.	Paclitaxel	99-102	ATP binding cassette subfamily B member 1	Homo sapiens	127-131
24167124-7	2014	Furthermore, pre-treatment of cancer cells with STAT3-siRNA formulation increased the cytotoxic effect of doxorubicin and paclitaxel in both wild type and drug resistant MDA-MB-435 cells.	Paclitaxel	122-132	signal transducer and activator of transcription 3	Homo sapiens	48-53
24974009-2	2014	In the present study, by taking advantage of the specific expression of fibronectin extra domain B (EDB) on both glioma neovasculature endothelial cells and glioma cells, we constructed EDB-targeted peptide APTEDB-modified PEG-PLA nanoparticles (APT-NP) for paclitaxel (PTX) loading to enable tumor neovasculature and tumor cells dual-targeting chemotherapy.	Paclitaxel	258-268	fibronectin 1	Homo sapiens	100-103
24974009-2	2014	In the present study, by taking advantage of the specific expression of fibronectin extra domain B (EDB) on both glioma neovasculature endothelial cells and glioma cells, we constructed EDB-targeted peptide APTEDB-modified PEG-PLA nanoparticles (APT-NP) for paclitaxel (PTX) loading to enable tumor neovasculature and tumor cells dual-targeting chemotherapy.	Paclitaxel	258-268	fibronectin 1	Homo sapiens	186-189
24974009-2	2014	In the present study, by taking advantage of the specific expression of fibronectin extra domain B (EDB) on both glioma neovasculature endothelial cells and glioma cells, we constructed EDB-targeted peptide APTEDB-modified PEG-PLA nanoparticles (APT-NP) for paclitaxel (PTX) loading to enable tumor neovasculature and tumor cells dual-targeting chemotherapy.	Paclitaxel	270-273	fibronectin 1	Homo sapiens	100-103
24974009-2	2014	In the present study, by taking advantage of the specific expression of fibronectin extra domain B (EDB) on both glioma neovasculature endothelial cells and glioma cells, we constructed EDB-targeted peptide APTEDB-modified PEG-PLA nanoparticles (APT-NP) for paclitaxel (PTX) loading to enable tumor neovasculature and tumor cells dual-targeting chemotherapy.	Paclitaxel	270-273	fibronectin 1	Homo sapiens	186-189
24893857-0	2014	Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.	Paclitaxel	104-114	interleukin 2	Homo sapiens	26-29
24893857-4	2014	F8-IL2 was shown to selectively localize at the tumor site in vivo, following intravenous administration, and to mediate tumor growth retardation, which was potentiated by the combination with paclitaxel or dacarbazine.	Paclitaxel	193-203	interleukin 2	Homo sapiens	3-6
24992675-8	2014	RESULTS: BAG3 knockdown increased the chemosensitivity to paclitaxel of ES2 ovarian clear cell carcinoma cells to a greater degree than AMOC2 serous adenocarcinoma cells.	Paclitaxel	58-68	BAG cochaperone 3	Homo sapiens	9-13
24992675-13	2014	This suggests that BAG3 is a key determinant of the responsiveness of ovarian cancer cells, especially clear cell carcinoma, to paclitaxel and that BAG3 may be a useful therapeutic target for the treatment of ovarian cancer.	Paclitaxel	128-138	BAG cochaperone 3	Homo sapiens	19-23
25102234-1	2014	To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release.	Paclitaxel	116-119	ATP binding cassette subfamily B member 1	Homo sapiens	303-307
25102234-1	2014	To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release.	Paclitaxel	217-220	ATP binding cassette subfamily B member 1	Homo sapiens	46-60
25102234-1	2014	To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release.	Paclitaxel	217-220	ATP binding cassette subfamily B member 1	Homo sapiens	62-66
25102234-1	2014	To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release.	Paclitaxel	234-242	ATP binding cassette subfamily B member 1	Homo sapiens	46-60
25102234-1	2014	To overcome the multidrug resistance (MDR) of P-glycoprotein (P-gp) substrate anticancer drugs, such as paclitaxel (PTX), a novel dual-functional prodrug, D-alpha-tocopherol polyethylene glycol succinate (TPGS) based PTX prodrug (TPGS-S-S-PTX), was synthesized here to fulfill the synergistic effect of P-gp inhibiting and intracellular redox-sensitive release.	Paclitaxel	234-242	ATP binding cassette subfamily B member 1	Homo sapiens	62-66
25153728-0	2014	The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1alpha and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.	Paclitaxel	35-45	hypoxia inducible factor 1 subunit alpha	Homo sapiens	80-90
24970027-4	2014	We found that the expression of Lin28 was closely associated with resistance to paclitaxel.	Paclitaxel	80-90	lin-28 homolog A	Homo sapiens	32-37
24970027-5	2014	The drug-resistant Hep3B cell line, which expresses high levels of Lin28, is more resistant to paclitaxel and other anticancer drugs than the parental cell line.	Paclitaxel	95-105	lin-28 homolog A	Homo sapiens	67-72
24676891-0	2014	Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.	Paclitaxel	32-42	proteasome 26S subunit, non-ATPase 1	Homo sapiens	48-51
25122429-1	2014	INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel.	Paclitaxel	268-278	vascular endothelial growth factor A	Homo sapiens	79-113
25216523-10	2014	HDAC6 inhibitor tubastatin-a demonstrated that microtubule effects are associated with hedgehog inhibition and sensitization to paclitaxel and LDE225.	Paclitaxel	128-138	histone deacetylase 6	Homo sapiens	0-5
25127716-8	2014	Paclitaxel-treated rats showed a significant increase in the expression of mRNAs for CCL3 and its receptor CCR5 in the SDH.	Paclitaxel	0-10	C-C motif chemokine receptor 5	Rattus norvegicus	107-111
25153728-0	2014	The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1alpha and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.	Paclitaxel	35-45	vascular endothelial growth factor A	Homo sapiens	95-99
25153728-6	2014	Treatment with sMEK1 and paclitaxel reduced phosphorylation of ribosomal S6 kinase (S6K) and 4E-binding protein (4E-BP), two critical downstream targets of the mTOR-signaling pathway.	Paclitaxel	25-35	mechanistic target of rapamycin kinase	Homo sapiens	160-164
25153728-7	2014	Furthermore, both sMEK1 and paclitaxel significantly inhibited the expression of signaling components downstream of S6K/4E-BP, such as hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF), both in vitro and in vivo.	Paclitaxel	28-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	135-166
25153728-7	2014	Furthermore, both sMEK1 and paclitaxel significantly inhibited the expression of signaling components downstream of S6K/4E-BP, such as hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF), both in vitro and in vivo.	Paclitaxel	28-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	168-178
25153728-7	2014	Furthermore, both sMEK1 and paclitaxel significantly inhibited the expression of signaling components downstream of S6K/4E-BP, such as hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF), both in vitro and in vivo.	Paclitaxel	28-38	vascular endothelial growth factor A	Homo sapiens	184-218
25118927-9	2014	Downregulation of HIF1-alpha by specific siRNA could decrease autophagy and resensitize HeLa-R cells to paclitaxel.	Paclitaxel	104-114	hypoxia inducible factor 1 subunit alpha	Homo sapiens	18-28
25118927-10	2014	Taken together, a possible Warburg effect activated HIF1-alpha-mediated signaling-induced autophagic pathway is proposed, which may provide new insight into paclitaxel chemoresistance.	Paclitaxel	157-167	hypoxia inducible factor 1 subunit alpha	Homo sapiens	52-62
25153728-7	2014	Furthermore, both sMEK1 and paclitaxel significantly inhibited the expression of signaling components downstream of S6K/4E-BP, such as hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF), both in vitro and in vivo.	Paclitaxel	28-38	vascular endothelial growth factor A	Homo sapiens	220-224
24712391-5	2014	The improvements in therapeutic response over either PTX-VE or 5-FU-TPGS therapy alone were demonstrated by the ability to effectively induce the apoptosis of tumor cells via up-regulation of tumor suppressor p53 and beta-tubulin and by the significant inhibition of cell cycle progression.	Paclitaxel	53-56	tumor protein p53	Homo sapiens	209-212
24681252-0	2014	CX3CL1-mediated macrophage activation contributed to paclitaxel-induced DRG neuronal apoptosis and painful peripheral neuropathy.	Paclitaxel	53-63	C-X3-C motif chemokine ligand 1	Homo sapiens	0-6
25089613-8	2014	Under hypoxia, downregulation of HIF-1alpha and upregulation of caspase-3, caspase-8, caspase-9, LC3 and Beclin-1 were observed when paclitaxel was combined with oxygen-CNT.	Paclitaxel	133-143	hypoxia inducible factor 1 subunit alpha	Homo sapiens	33-43
25089613-8	2014	Under hypoxia, downregulation of HIF-1alpha and upregulation of caspase-3, caspase-8, caspase-9, LC3 and Beclin-1 were observed when paclitaxel was combined with oxygen-CNT.	Paclitaxel	133-143	caspase 3	Homo sapiens	64-73
24318305-0	2014	Potentiation of paclitaxel activity by curcumin in human breast cancer cell by modulating apoptosis and inhibiting EGFR signaling.	Paclitaxel	16-26	epidermal growth factor receptor	Homo sapiens	115-119
24318305-3	2014	Treatment of MCF-7 cell lines with paclitaxel and curcumin induced the apoptosis of regulatory protein Bcl-2 but decreased Bax expression.	Paclitaxel	35-45	BCL2 apoptosis regulator	Homo sapiens	103-108
24318305-3	2014	Treatment of MCF-7 cell lines with paclitaxel and curcumin induced the apoptosis of regulatory protein Bcl-2 but decreased Bax expression.	Paclitaxel	35-45	BCL2 associated X, apoptosis regulator	Homo sapiens	123-126
24318305-4	2014	In addition, simultaneous treatment with paclitaxel and curcumin strongly inhibited paclitaxel-induced activities of EGFR signaling.	Paclitaxel	41-51	epidermal growth factor receptor	Homo sapiens	117-121
24318305-4	2014	In addition, simultaneous treatment with paclitaxel and curcumin strongly inhibited paclitaxel-induced activities of EGFR signaling.	Paclitaxel	84-94	epidermal growth factor receptor	Homo sapiens	117-121
24681252-3	2014	Here we showed that the clinically relevant dose of paclitaxel (3x8mg/kg, cumulative dose 24mg/kg) induced significant upregulation of the chemokine CX3CL1 in the A-fiber primary sensory neurons in vivo and in vitro and infiltration of macrophages into the dorsal root ganglion (DRG) in rats.	Paclitaxel	52-62	C-X3-C motif chemokine ligand 1	Rattus norvegicus	149-155
24681252-6	2014	Intrathecal or systemic injection of CX3CL1 neutralizing antibody blocked paclitaxel-induced macrophage recruitment and neuronal apoptosis in the DRG, and also attenuated paclitaxel-induced allodynia.	Paclitaxel	74-84	C-X3-C motif chemokine ligand 1	Homo sapiens	37-43
24681252-6	2014	Intrathecal or systemic injection of CX3CL1 neutralizing antibody blocked paclitaxel-induced macrophage recruitment and neuronal apoptosis in the DRG, and also attenuated paclitaxel-induced allodynia.	Paclitaxel	171-181	C-X3-C motif chemokine ligand 1	Homo sapiens	37-43
24681252-8	2014	Blocking CX3CL1 decreased activation of p38 MAPK in the macrophage, and inhibition of p38 MAPK activity blocked the neuronal apoptosis and development of mechanical allodynia induced by paclitaxel.	Paclitaxel	186-196	C-X3-C motif chemokine ligand 1	Homo sapiens	9-15
24681252-8	2014	Blocking CX3CL1 decreased activation of p38 MAPK in the macrophage, and inhibition of p38 MAPK activity blocked the neuronal apoptosis and development of mechanical allodynia induced by paclitaxel.	Paclitaxel	186-196	mitogen-activated protein kinase 14	Homo sapiens	86-89
24681252-9	2014	These findings provide novel evidence that CX3CL1-recruited macrophage contributed to paclitaxel-induced DRG neuronal apoptosis and painful peripheral neuropathy.	Paclitaxel	86-96	C-X3-C motif chemokine ligand 1	Homo sapiens	43-49
25056500-7	2014	In the PIK3CA wild-type subgroup, lapatinib plus paclitaxel reduced risk of progression compared with paclitaxel alone (HR = 0.44; 95% CI: 0.28, 0.69; P &lt;0.0001); progression-free survival (PFS) was not significantly improved within the PIK3CA mutation subgroup (P = 0.179).	Paclitaxel	49-59	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	7-13
24965002-7	2014	Interestingly, reminiscent of what is seen clinically in anti-HER2 treated individuals, several of the PTX/SA-treated long term survivors went on to develop late onset CNS metastasis.	Paclitaxel	103-106	erb-b2 receptor tyrosine kinase 2	Homo sapiens	62-66
24295377-4	2014	RESULTS: The results indicate that tivozanib can significantly reverse ABCB1-mediated resistance to paclitaxel, vinblastine and colchicine, as well as ABCG2-mediated resistance to mitoxantrone, SN-38 and doxorubicin.	Paclitaxel	100-110	ATP binding cassette subfamily B member 1	Homo sapiens	71-76
24786296-0	2014	ERalpha directly activated the MDR1 transcription to increase paclitaxel-resistance of ERalpha-positive breast cancer cells in vitro and in vivo.	Paclitaxel	62-72	estrogen receptor 1	Homo sapiens	0-7
24786296-0	2014	ERalpha directly activated the MDR1 transcription to increase paclitaxel-resistance of ERalpha-positive breast cancer cells in vitro and in vivo.	Paclitaxel	62-72	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
24786296-0	2014	ERalpha directly activated the MDR1 transcription to increase paclitaxel-resistance of ERalpha-positive breast cancer cells in vitro and in vivo.	Paclitaxel	62-72	estrogen receptor 1	Homo sapiens	87-94
24786296-8	2014	Knockdown of MDR1 restrained the effect of ERalpha in MCF-7 cells and sensitized the cells to paclitaxel.	Paclitaxel	94-104	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
24786296-9	2014	Treatment of ICI 182,780 that selectively suppressed ERalpha significantly decreased the MDR1 expression and increased the sensitivity of drug resistant breast cancer cells and xenograft tumors to paclitaxel.	Paclitaxel	197-207	estrogen receptor 1	Homo sapiens	53-60
24522815-0	2014	Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells.	Paclitaxel	68-78	transferrin	Homo sapiens	0-11
24522815-0	2014	Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells.	Paclitaxel	101-111	transferrin	Homo sapiens	0-11
24522815-3	2014	In this study, the therapeutic potential of transferrin (TF)-targeted mixed micelles, made of PEG-PE and vitamin E co-loaded with curcumin (CUR), a potent NF-kappaB inhibitor, and paclitaxel (PCL), was examined.	Paclitaxel	180-190	transferrin	Homo sapiens	44-55
24522815-3	2014	In this study, the therapeutic potential of transferrin (TF)-targeted mixed micelles, made of PEG-PE and vitamin E co-loaded with curcumin (CUR), a potent NF-kappaB inhibitor, and paclitaxel (PCL), was examined.	Paclitaxel	180-190	transferrin	Homo sapiens	57-59
24522815-3	2014	In this study, the therapeutic potential of transferrin (TF)-targeted mixed micelles, made of PEG-PE and vitamin E co-loaded with curcumin (CUR), a potent NF-kappaB inhibitor, and paclitaxel (PCL), was examined.	Paclitaxel	192-195	transferrin	Homo sapiens	44-55
24522815-3	2014	In this study, the therapeutic potential of transferrin (TF)-targeted mixed micelles, made of PEG-PE and vitamin E co-loaded with curcumin (CUR), a potent NF-kappaB inhibitor, and paclitaxel (PCL), was examined.	Paclitaxel	192-195	transferrin	Homo sapiens	57-59
24522815-5	2014	RESULTS: Our results indicated that the TF-targeted combination micelles were able to improve the net cytotoxic effect of CUR and PCL to clear synergistic one against the SK-OV-3 cells.	Paclitaxel	130-133	transferrin	Homo sapiens	40-42
24805866-8	2014	Twist1 overexpression decreased the sensitivity of cells to taxol as revealed by a significant increase in MDR1/P-gp and IC50 (P&lt;0.05).	Paclitaxel	60-65	twist family bHLH transcription factor 1	Homo sapiens	0-6
24347266-3	2014	EMT/6 murine-mammary carcinoma cells exposed to paclitaxel chemotherapy exhibited an increased number of TMPs and significantly altered their angiogenic properties.	Paclitaxel	48-58	IL2 inducible T cell kinase	Mus musculus	0-3
24347266-8	2014	However, when BMDCs from paclitaxel-treated mice were injected into wild-type EMT/6-bearing mice, a substantial increase in tumor growth and BMDC infiltration was detected compared to osteopontin-depleted EMT/6-bearing mice injected with BMDCs from paclitaxel-treated mice.	Paclitaxel	25-35	IL2 inducible T cell kinase	Mus musculus	78-81
25313764-0	2014	A novel series of di-fluorinated propanedione derivatives synergistically augment paclitaxel mediated caspase 3 activation in ovarian cancer cells.	Paclitaxel	82-92	caspase 3	Homo sapiens	102-111
25313764-4	2014	MATERIALS AND METHODS: A cellular model of paclitaxel resistance was developed in OAW42 cells stably expressing the caspase 3 sensor.	Paclitaxel	43-53	caspase 3	Homo sapiens	116-125
25313764-11	2014	Intriguingly, PR2 alone or in combination with Paclitaxel could induce a 2.5- to 2.9-fold increase in caspase-3 activity in Paclitaxel resistant cells.	Paclitaxel	47-57	caspase 3	Homo sapiens	102-111
25313764-11	2014	Intriguingly, PR2 alone or in combination with Paclitaxel could induce a 2.5- to 2.9-fold increase in caspase-3 activity in Paclitaxel resistant cells.	Paclitaxel	124-134	caspase 3	Homo sapiens	102-111
24569835-0	2014	Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.	Paclitaxel	38-48	AKT serine/threonine kinase 1	Homo sapiens	102-105
24569835-0	2014	Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.	Paclitaxel	38-48	mechanistic target of rapamycin kinase	Homo sapiens	106-110
24569835-1	2014	Ongoing clinical trials target the aberrant PI3K/Akt/mammalian target of rapamycin (mTOR) pathway in breast cancer through administration of rapamycin, an allosteric mTOR inhibitor, in combination with paclitaxel.	Paclitaxel	202-212	AKT serine/threonine kinase 1	Homo sapiens	49-52
24569835-1	2014	Ongoing clinical trials target the aberrant PI3K/Akt/mammalian target of rapamycin (mTOR) pathway in breast cancer through administration of rapamycin, an allosteric mTOR inhibitor, in combination with paclitaxel.	Paclitaxel	202-212	mechanistic target of rapamycin kinase	Homo sapiens	53-82
24569835-1	2014	Ongoing clinical trials target the aberrant PI3K/Akt/mammalian target of rapamycin (mTOR) pathway in breast cancer through administration of rapamycin, an allosteric mTOR inhibitor, in combination with paclitaxel.	Paclitaxel	202-212	mechanistic target of rapamycin kinase	Homo sapiens	84-88
24569835-6	2014	Simultaneous and preferential in vivo delivery of rapamycin and paclitaxel to tumors yielded mechanistic insights into synergy involving suppression of feedback loop Akt phosphorylation and its downstream targets.	Paclitaxel	64-74	AKT serine/threonine kinase 1	Homo sapiens	166-169
24347266-8	2014	However, when BMDCs from paclitaxel-treated mice were injected into wild-type EMT/6-bearing mice, a substantial increase in tumor growth and BMDC infiltration was detected compared to osteopontin-depleted EMT/6-bearing mice injected with BMDCs from paclitaxel-treated mice.	Paclitaxel	25-35	IL2 inducible T cell kinase	Mus musculus	205-208
24821111-6	2014	Furthermore, knockdown of P-gp expression in MDR cells with P-gp-siRNA reversed DPPE sensitivity and increased their sensitivity to doxorubicin and taxol but not to cisplatin.	Paclitaxel	148-153	glycerol-3-phosphate phosphatase	Cricetulus griseus	26-30
24821111-6	2014	Furthermore, knockdown of P-gp expression in MDR cells with P-gp-siRNA reversed DPPE sensitivity and increased their sensitivity to doxorubicin and taxol but not to cisplatin.	Paclitaxel	148-153	glycerol-3-phosphate phosphatase	Cricetulus griseus	60-64
25327865-3	2014	Then the effects of miR-200a on cytotoxicity of paclitaxel and cisplatin were investigated by methyl thiazolyl tetrazolium (MTT).	Paclitaxel	48-58	microRNA 200a	Homo sapiens	20-28
25327865-7	2014	MiR-200a enhanced the chemosensitivity of SKOV-3 and ES-2 to paclitaxel, but not to cisplatin.	Paclitaxel	61-71	microRNA 200a	Homo sapiens	0-8
25327865-10	2014	CONCLUSION: An over-expression of miR-200a may increase chemosensitivity to paclitaxel in ovarian cancer cells through negatively regulated chemoresistance associated ABC family.	Paclitaxel	76-86	microRNA 200a	Homo sapiens	34-42
24746965-5	2014	Consequently, the PTX treatment-inducible antiapoptosis in HepG2 cells was effectively suppressed by the codelivered siRNA targeting an antiapoptosis gene (BCL-2 siRNA) during chemotherapy.	Paclitaxel	18-21	BCL2 apoptosis regulator	Homo sapiens	156-161
24677792-2	2014	We recently described a new targeted delivery system based on specific EphA2-targeting peptides conjugated with the chemotherapeutic agent paclitaxel.	Paclitaxel	139-149	Eph receptor A2	Rattus norvegicus	71-76
24868024-1	2014	PURPOSE: In Asian countries, paclitaxel once per week is used as second-line treatment in advanced gastric cancer, including human epidermal growth factor receptor 2 (HER2) -positive tumors.	Paclitaxel	29-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-165
24868024-1	2014	PURPOSE: In Asian countries, paclitaxel once per week is used as second-line treatment in advanced gastric cancer, including human epidermal growth factor receptor 2 (HER2) -positive tumors.	Paclitaxel	29-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	167-171
24868024-12	2014	CONCLUSION: Lapatinib plus paclitaxel demonstrated activity in the second-line treatment of patients with HER2 FISH-positive IHC3+ advanced gastric cancer but did not significantly improve OS in the intent-to-treat population.	Paclitaxel	27-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
24805866-8	2014	Twist1 overexpression decreased the sensitivity of cells to taxol as revealed by a significant increase in MDR1/P-gp and IC50 (P&lt;0.05).	Paclitaxel	60-65	ATP binding cassette subfamily B member 1	Homo sapiens	107-111
24805866-11	2014	This study provided evidence that alterations of Twist1 expression modulates the chemosensitivity of FaDu cells to taxol.	Paclitaxel	115-120	twist family bHLH transcription factor 1	Homo sapiens	49-55
25289403-9	2014	Our present results showed that TAB could reverse Taxol resistance in MDA-MB-231/Taxol cells,mainly inhibiting the activity of P-gp and down-regulating the expression level of P-gp, and then enhancing the accumulation of chemotherapy agents.	Paclitaxel	50-55	ATP binding cassette subfamily B member 1	Homo sapiens	127-131
25289403-9	2014	Our present results showed that TAB could reverse Taxol resistance in MDA-MB-231/Taxol cells,mainly inhibiting the activity of P-gp and down-regulating the expression level of P-gp, and then enhancing the accumulation of chemotherapy agents.	Paclitaxel	50-55	ATP binding cassette subfamily B member 1	Homo sapiens	176-180
24715305-1	2014	: The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.	Paclitaxel	35-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
23912453-0	2014	Role of tumor necrosis factor alpha-induced protein 1 in paclitaxel resistance.	Paclitaxel	57-67	tumor necrosis factor, alpha-induced protein 1 (endothelial)	Mus musculus	8-53
23912453-4	2014	Here we report that increased expression of TNFAIP1 (tumor necrosis factor alpha-induced protein 1) confers acquired resistance to paclitaxel.	Paclitaxel	131-141	tumor necrosis factor, alpha-induced protein 1 (endothelial)	Mus musculus	44-51
23912453-4	2014	Here we report that increased expression of TNFAIP1 (tumor necrosis factor alpha-induced protein 1) confers acquired resistance to paclitaxel.	Paclitaxel	131-141	tumor necrosis factor, alpha-induced protein 1 (endothelial)	Mus musculus	53-98
23912453-5	2014	TNFAIP1 is shown to compete with paclitaxel for binding to beta-tubulin, thereby preventing paclitaxel-induced tubulin polymerization, cell cycle arrest and ultimate cell death.	Paclitaxel	33-43	tumor necrosis factor, alpha-induced protein 1 (endothelial)	Mus musculus	0-7
23912453-5	2014	TNFAIP1 is shown to compete with paclitaxel for binding to beta-tubulin, thereby preventing paclitaxel-induced tubulin polymerization, cell cycle arrest and ultimate cell death.	Paclitaxel	92-102	tumor necrosis factor, alpha-induced protein 1 (endothelial)	Mus musculus	0-7
23912453-7	2014	In a xenograft mouse model, increased expression of TNFAIP1 decreases, whereas knockdown of TNFAIP1 increases tumor response to paclitaxel.	Paclitaxel	128-138	tumor necrosis factor, alpha-induced protein 1 (endothelial)	Mus musculus	92-99
23912453-8	2014	Therefore, these results reveal tnfaip1 as a novel paclitaxel-resistance associated gene and suggest that TNFAIP1 may represent a valuable therapeutic target for the treatment of cancer.	Paclitaxel	51-61	tumor necrosis factor, alpha-induced protein 1 (endothelial)	Mus musculus	32-39
23912453-8	2014	Therefore, these results reveal tnfaip1 as a novel paclitaxel-resistance associated gene and suggest that TNFAIP1 may represent a valuable therapeutic target for the treatment of cancer.	Paclitaxel	51-61	tumor necrosis factor, alpha-induced protein 1 (endothelial)	Mus musculus	106-113
24704556-5	2014	Our results demonstrated that acerinol could increase the chemosensitivity of ABCB1-overexpressing HepG2/ADM and MCF-7/ADR cells to chemotherapeutic drugs, doxorubicin, vincristine and paclitaxel.	Paclitaxel	185-195	ATP binding cassette subfamily B member 1	Homo sapiens	78-83
24853187-8	2014	RESULTS: We observed that tumour cells selected with increasing concentrations of paclitaxel alone developed MDR with resistance to paclitaxel and other Pgp substrates, whereas cells cultured with paclitaxel-NSC23925 did not develop MDR and cells remained sensitive to chemotherapeutic agents.	Paclitaxel	82-92	ATP binding cassette subfamily B member 1	Homo sapiens	153-156
24680370-7	2014	It was found that transgelin 2 may mediate the resistance of MCF-7/PTX cells to paclitaxel by up-regulating the expressions of the adenosine-triphosphate binding cassette transporter proteins, including P-glycoprotein (P-gp), multidrug resistance associated protein 1 (MRP1), and breast cancer resistance protein (BCRP).	Paclitaxel	67-70	ATP binding cassette subfamily B member 1	Homo sapiens	203-217
24680370-9	2014	In addition, this study found that paeonol down-regulated the transgelin 2-mediated paclitaxel resistance by reducing the expressions of P-gp, MRP1, and BCRP in MCF-7/PTX cells.	Paclitaxel	84-94	ATP binding cassette subfamily B member 1	Homo sapiens	137-141
24680370-9	2014	In addition, this study found that paeonol down-regulated the transgelin 2-mediated paclitaxel resistance by reducing the expressions of P-gp, MRP1, and BCRP in MCF-7/PTX cells.	Paclitaxel	84-94	ATP binding cassette subfamily C member 1	Homo sapiens	143-147
24680370-9	2014	In addition, this study found that paeonol down-regulated the transgelin 2-mediated paclitaxel resistance by reducing the expressions of P-gp, MRP1, and BCRP in MCF-7/PTX cells.	Paclitaxel	84-94	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	153-157
24680370-9	2014	In addition, this study found that paeonol down-regulated the transgelin 2-mediated paclitaxel resistance by reducing the expressions of P-gp, MRP1, and BCRP in MCF-7/PTX cells.	Paclitaxel	167-170	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	153-157
24853187-9	2014	Paclitaxel-resistant cells showed high expression and activity of the Pgp, whereas paclitaxel-NSC23925-treated cells did not express Pgp.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	70-73
24749390-7	2014	The PTX-loaded PLA-PEG-PLL nanoparticles (PNP) and VEGF antibody modified PTX-loaded PLA-PEG-PLL nanoparticles (VPNP) were prepared using solvent diffusion methods.	Paclitaxel	74-77	vascular endothelial growth factor A	Homo sapiens	51-55
24959746-6	2014	Interestingly, the mCAR agonist TCPOBOP enhanced the expression of two tumor suppressor genes, namely WT1 and MGMT, which were additively enhanced in cells treated with CAR agonist in combination with paclitaxel.	Paclitaxel	201-211	WT1 transcription factor	Homo sapiens	102-105
24657178-8	2014	On the other hand, after 24h, PTX-infused rats showed reduced catalase activity and reduced metahemoglobin levels.	Paclitaxel	30-33	catalase	Rattus norvegicus	62-70
24729449-7	2014	RESULTS: Natural taxane paclitaxel from Taxus brevifolia activated the Raf-1/extracellular signal-regulated kinase (ERK) pathway, leading to an activation of ribosomal S6 kinases (RSK)/YB-1 signaling.	Paclitaxel	24-34	mitogen-activated protein kinase 1	Homo sapiens	116-119
24659394-0	2014	Combination of Cl-IB-MECA with paclitaxel is a highly  effective cytotoxic therapy causing mTOR-dependent autophagy  and mitotic catastrophe on human melanoma cells.	Paclitaxel	31-41	mechanistic target of rapamycin kinase	Homo sapiens	91-95
24939301-6	2014	The percentage of cells in G0-G1 and G2-M phases was reduced, and that in S phase increased after treatment for 72 h. The expression of cyclin D1 and B1, p27 and PCNA in VSMCs of paclitaxel-treated group was up-regulated, but that of p21 down-regulated as compared with VECs.	Paclitaxel	179-189	cyclin D1	Rattus norvegicus	136-152
24729449-7	2014	RESULTS: Natural taxane paclitaxel from Taxus brevifolia activated the Raf-1/extracellular signal-regulated kinase (ERK) pathway, leading to an activation of ribosomal S6 kinases (RSK)/YB-1 signaling.	Paclitaxel	24-34	ribosomal protein S6 kinase A2	Homo sapiens	180-183
24729449-7	2014	RESULTS: Natural taxane paclitaxel from Taxus brevifolia activated the Raf-1/extracellular signal-regulated kinase (ERK) pathway, leading to an activation of ribosomal S6 kinases (RSK)/YB-1 signaling.	Paclitaxel	24-34	Y-box binding protein 1	Homo sapiens	185-189
24729449-10	2014	YB-1 knockdown as well as RSK inhibition using RSK-specific siRNA or the small molecule inhibitor SL0101 successfully blocked activation of YB-1, leading to suppression of prostate cancer growth and sensitization to paclitaxel.	Paclitaxel	216-226	ribosomal protein S6 kinase A2	Homo sapiens	26-29
24729449-10	2014	YB-1 knockdown as well as RSK inhibition using RSK-specific siRNA or the small molecule inhibitor SL0101 successfully blocked activation of YB-1, leading to suppression of prostate cancer growth and sensitization to paclitaxel.	Paclitaxel	216-226	ribosomal protein S6 kinase A2	Homo sapiens	47-50
24886365-13	2014	CONCLUSION: AZD8931 single agent and in combination with paclitaxel demonstrated signal inhibition and antitumor activity in EGFR-overexpressed and HER2 non-amplified IBC models.	Paclitaxel	57-67	epidermal growth factor receptor	Homo sapiens	125-129
24886365-13	2014	CONCLUSION: AZD8931 single agent and in combination with paclitaxel demonstrated signal inhibition and antitumor activity in EGFR-overexpressed and HER2 non-amplified IBC models.	Paclitaxel	57-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
24810093-0	2014	Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	38-43
24800949-11	2014	Coadministration of pazopanib and lapatinib, weak inhibitors of CYP2C8 and CYP3A4, had an inhibitory effect on paclitaxel clearance.	Paclitaxel	111-121	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
24964007-6	2014	Among chemotherapy groups, HERV env gene expression was the lowest in the taxotere- or taxol-treated group, suggesting that taxotere and taxol can reduce HERVs env expression.	Paclitaxel	87-92	endogenous retrovirus group W member 1, envelope	Homo sapiens	32-35
24964007-6	2014	Among chemotherapy groups, HERV env gene expression was the lowest in the taxotere- or taxol-treated group, suggesting that taxotere and taxol can reduce HERVs env expression.	Paclitaxel	87-92	endogenous retrovirus group W member 1, envelope	Homo sapiens	160-163
24964007-6	2014	Among chemotherapy groups, HERV env gene expression was the lowest in the taxotere- or taxol-treated group, suggesting that taxotere and taxol can reduce HERVs env expression.	Paclitaxel	137-142	endogenous retrovirus group W member 1, envelope	Homo sapiens	32-35
24964007-6	2014	Among chemotherapy groups, HERV env gene expression was the lowest in the taxotere- or taxol-treated group, suggesting that taxotere and taxol can reduce HERVs env expression.	Paclitaxel	137-142	endogenous retrovirus group W member 1, envelope	Homo sapiens	160-163
24885658-9	2014	These trends predict sensitivity to agents such as paclitaxel (ABCB1 substrate) and imatinib (c-KIT inhibitor) would be altered with extended passage.	Paclitaxel	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	63-68
24864163-2	2014	Bevacizumab, a recombinant monoclonal antibody against vascular endothelial growth factor, has gained European Medicines Agency approval for the front-line treatment of advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer in combination with carboplatin and paclitaxel, and for the treatment of first recurrence of platinum-sensitive ovarian cancer in combination with carboplatin and gemcitabine.	Paclitaxel	292-302	vascular endothelial growth factor A	Homo sapiens	55-89
24853425-0	2014	SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.	Paclitaxel	97-102	mechanistic target of rapamycin kinase	Homo sapiens	121-125
24853425-6	2014	Under SPAG5 downregulation, the sensitivity of cervical cancer cells differed according to taxol dose, which correlated with mammalian target of rapamycin (mTOR) signaling pathway activity.	Paclitaxel	91-96	mechanistic target of rapamycin kinase	Homo sapiens	125-154
24853425-6	2014	Under SPAG5 downregulation, the sensitivity of cervical cancer cells differed according to taxol dose, which correlated with mammalian target of rapamycin (mTOR) signaling pathway activity.	Paclitaxel	91-96	mechanistic target of rapamycin kinase	Homo sapiens	156-160
24853425-7	2014	In general, SPAG5 upregulation relates to poor prognosis in cervical cancer patients, and SPAG5 is a regulator of mTOR activity during taxol treatment in cervical cancer.	Paclitaxel	135-140	mechanistic target of rapamycin kinase	Homo sapiens	114-118
24773054-5	2014	Compound 28 at 3 muM reduced resistance in cytotoxicity assay to paclitaxel in P-gp-expressing SW620/Ad300 and HEK/ABCB1 cell lines.	Paclitaxel	65-75	ATP binding cassette subfamily B member 1	Homo sapiens	79-83
24810093-1	2014	ABCB1 (adenosine triphosphate-binding cassette transporter B1) mediates cellular elimination of many chemotherapeutic agents including paclitaxel, which is commonly used to treat ovarian cancer.	Paclitaxel	135-145	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
24810093-3	2014	Variable paclitaxel clearance due to genotype specific differences in ABCB1 activity in cancer cells and/or normal tissues may underlie the association.	Paclitaxel	9-19	ATP binding cassette subfamily B member 1	Homo sapiens	70-75
24810093-5	2014	Close associations between ABCB1 expression, transporter function and paclitaxel sensitivity were found in lymphoblastoid cell lines, although we could not demonstrate an association with common SNPs.	Paclitaxel	70-80	ATP binding cassette subfamily B member 1	Homo sapiens	27-32
24810093-7	2014	These results suggest that ABCB1 related survival difference in ovarian cancer patients is more likely to be due to differential whole body paclitaxel clearance mediated by normal cells rather than a direct effect on cancer cells.	Paclitaxel	140-150	ATP binding cassette subfamily B member 1	Homo sapiens	27-32
24886434-5	2014	RESULTS: Treatment of isolated tumor cells from the ascites of ovarian cancer patients and HEY ovarian cancer cell line with paclitaxel resulted in a CSC-like residual population which coincided with the activation of Janus activated kinase 2 (JAK2) and signal transducer and activation of transcription 3 (STAT3) pathway in paclitaxel surviving cells.	Paclitaxel	125-135	signal transducer and activator of transcription 3	Homo sapiens	254-305
24886434-6	2014	Both paclitaxel-induced JAK2/STAT3 activation and CSC-like characteristics were inhibited by a low dose JAK2-specific small molecule inhibitor CYT387 (1 muM) in vitro.	Paclitaxel	5-15	signal transducer and activator of transcription 3	Homo sapiens	29-34
24886434-6	2014	Both paclitaxel-induced JAK2/STAT3 activation and CSC-like characteristics were inhibited by a low dose JAK2-specific small molecule inhibitor CYT387 (1 muM) in vitro.	Paclitaxel	5-15	latexin	Homo sapiens	153-156
24886434-5	2014	RESULTS: Treatment of isolated tumor cells from the ascites of ovarian cancer patients and HEY ovarian cancer cell line with paclitaxel resulted in a CSC-like residual population which coincided with the activation of Janus activated kinase 2 (JAK2) and signal transducer and activation of transcription 3 (STAT3) pathway in paclitaxel surviving cells.	Paclitaxel	125-135	signal transducer and activator of transcription 3	Homo sapiens	307-312
24886434-9	2014	These results were consistent with significantly reduced activation of JAK2 and STAT3 in paclitaxel and CYT387-treated cell-derived xenografts compared to paclitaxel only-treated cell derived xenografts.	Paclitaxel	89-99	signal transducer and activator of transcription 3	Homo sapiens	80-85
24637579-5	2014	The metabolism of paclitaxel is mediated primarily by the P450 cytochrome enzymes CYP2C8 and CYP3A, whereas docetaxel is only metabolized by CYP3A4.	Paclitaxel	18-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-98
24654922-6	2014	RESULTS: Patients on nab-paclitaxel + gemcitabine spent a significantly longer time in every state and experienced significantly greater overall Q-TWiST (+1.7 months [95% CI = 0.8, 2.7]) than those receiving gemcitabine alone (8.2 months [95% CI = 7.5, 8.9] vs 6.5 months [95% CI = 5.8, 7.0]), assuming base-case utilities of TOX/REL = 0.50.	Paclitaxel	25-35	twist family bHLH transcription factor 1	Homo sapiens	147-152
24462773-10	2014	Moreover, the AMP-activated protein kinase (AMPK)-dependent nuclear factor kappa B (NF-kappaB) pathway mediated paclitaxel-increased chemoresistance and survivin expression.	Paclitaxel	112-122	nuclear factor kappa B subunit 1	Homo sapiens	60-82
24462773-10	2014	Moreover, the AMP-activated protein kinase (AMPK)-dependent nuclear factor kappa B (NF-kappaB) pathway mediated paclitaxel-increased chemoresistance and survivin expression.	Paclitaxel	112-122	nuclear factor kappa B subunit 1	Homo sapiens	84-93
24787013-6	2014	EBV sensitized TP53-mutated BL cells to all spindle poisons tested, including vincristine and taxol, an effect that was systematically downmodulated by pretreatment of cells with inhibitors of p38 and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases.	Paclitaxel	94-99	tumor protein p53	Homo sapiens	15-19
24787013-6	2014	EBV sensitized TP53-mutated BL cells to all spindle poisons tested, including vincristine and taxol, an effect that was systematically downmodulated by pretreatment of cells with inhibitors of p38 and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases.	Paclitaxel	94-99	mitogen-activated protein kinase 14	Homo sapiens	193-196
24787013-6	2014	EBV sensitized TP53-mutated BL cells to all spindle poisons tested, including vincristine and taxol, an effect that was systematically downmodulated by pretreatment of cells with inhibitors of p38 and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases.	Paclitaxel	94-99	mitogen-activated protein kinase 8	Homo sapiens	226-229
24632038-0	2014	Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: II.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
24632038-2	2014	PURPOSE: The present studies evaluated the ability of paclitaxel (PTX) nanosuspension coated with TPGS to reverse drug-resistance of P-glycoprotein (P-gp)-overexpressing H460 human lung cancer cells.	Paclitaxel	54-64	ATP binding cassette subfamily B member 1	Homo sapiens	133-147
24632038-2	2014	PURPOSE: The present studies evaluated the ability of paclitaxel (PTX) nanosuspension coated with TPGS to reverse drug-resistance of P-glycoprotein (P-gp)-overexpressing H460 human lung cancer cells.	Paclitaxel	54-64	ATP binding cassette subfamily B member 1	Homo sapiens	149-153
24632038-2	2014	PURPOSE: The present studies evaluated the ability of paclitaxel (PTX) nanosuspension coated with TPGS to reverse drug-resistance of P-glycoprotein (P-gp)-overexpressing H460 human lung cancer cells.	Paclitaxel	66-69	ATP binding cassette subfamily B member 1	Homo sapiens	133-147
24632038-2	2014	PURPOSE: The present studies evaluated the ability of paclitaxel (PTX) nanosuspension coated with TPGS to reverse drug-resistance of P-glycoprotein (P-gp)-overexpressing H460 human lung cancer cells.	Paclitaxel	66-69	ATP binding cassette subfamily B member 1	Homo sapiens	149-153
24619482-3	2014	On the basis of glucose transporter (GLUT) overexpression on cancer cells, d-glucosamine-conjugated and paclitaxel-loaded poly(ethylene glycol)-co-poly(trimethylene carbonate) copolymer nanoparticles (DGlu-NP/PTX) were developed as potential tumor-targeting drug delivery system in this study.	Paclitaxel	104-114	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	16-35
24619482-3	2014	On the basis of glucose transporter (GLUT) overexpression on cancer cells, d-glucosamine-conjugated and paclitaxel-loaded poly(ethylene glycol)-co-poly(trimethylene carbonate) copolymer nanoparticles (DGlu-NP/PTX) were developed as potential tumor-targeting drug delivery system in this study.	Paclitaxel	104-114	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	37-41
24765145-0	2014	Inhibition of phosphoinositide 3-kinase/Akt pathway decreases hypoxia inducible factor-1alpha expression and increases therapeutic efficacy of paclitaxel in human hypoxic gastric cancer cells.	Paclitaxel	143-153	AKT serine/threonine kinase 1	Homo sapiens	40-43
24765145-8	2014	Under hypoxic conditions, the combined inhibition of the PI3K/Akt pathway with paclitaxel markedly reduced the proliferative activity and induced cell apoptosis in GC cells compared with the single treatment of PI3K inhibitor or paclitaxel (each P&lt;0.01), and was accompanied by a decreased expression of HIF-1alpha.	Paclitaxel	79-89	AKT serine/threonine kinase 1	Homo sapiens	62-65
24765145-8	2014	Under hypoxic conditions, the combined inhibition of the PI3K/Akt pathway with paclitaxel markedly reduced the proliferative activity and induced cell apoptosis in GC cells compared with the single treatment of PI3K inhibitor or paclitaxel (each P&lt;0.01), and was accompanied by a decreased expression of HIF-1alpha.	Paclitaxel	79-89	hypoxia inducible factor 1 subunit alpha	Homo sapiens	307-317
24765145-8	2014	Under hypoxic conditions, the combined inhibition of the PI3K/Akt pathway with paclitaxel markedly reduced the proliferative activity and induced cell apoptosis in GC cells compared with the single treatment of PI3K inhibitor or paclitaxel (each P&lt;0.01), and was accompanied by a decreased expression of HIF-1alpha.	Paclitaxel	229-239	AKT serine/threonine kinase 1	Homo sapiens	62-65
24765145-10	2014	The inhibition of the PI3K/Akt pathway enhanced the therapeutic efficacy of paclitaxel in GC cells under hypoxic conditions, suggesting that the PI3K/Akt/HIF-1alpha pathway may act as an important therapeutic target for paclitaxel treatment of GC.	Paclitaxel	76-86	AKT serine/threonine kinase 1	Homo sapiens	27-30
24765145-10	2014	The inhibition of the PI3K/Akt pathway enhanced the therapeutic efficacy of paclitaxel in GC cells under hypoxic conditions, suggesting that the PI3K/Akt/HIF-1alpha pathway may act as an important therapeutic target for paclitaxel treatment of GC.	Paclitaxel	76-86	AKT serine/threonine kinase 1	Homo sapiens	150-153
24765145-10	2014	The inhibition of the PI3K/Akt pathway enhanced the therapeutic efficacy of paclitaxel in GC cells under hypoxic conditions, suggesting that the PI3K/Akt/HIF-1alpha pathway may act as an important therapeutic target for paclitaxel treatment of GC.	Paclitaxel	76-86	hypoxia inducible factor 1 subunit alpha	Homo sapiens	154-164
24765145-10	2014	The inhibition of the PI3K/Akt pathway enhanced the therapeutic efficacy of paclitaxel in GC cells under hypoxic conditions, suggesting that the PI3K/Akt/HIF-1alpha pathway may act as an important therapeutic target for paclitaxel treatment of GC.	Paclitaxel	220-230	AKT serine/threonine kinase 1	Homo sapiens	27-30
24765145-10	2014	The inhibition of the PI3K/Akt pathway enhanced the therapeutic efficacy of paclitaxel in GC cells under hypoxic conditions, suggesting that the PI3K/Akt/HIF-1alpha pathway may act as an important therapeutic target for paclitaxel treatment of GC.	Paclitaxel	220-230	AKT serine/threonine kinase 1	Homo sapiens	150-153
24765145-10	2014	The inhibition of the PI3K/Akt pathway enhanced the therapeutic efficacy of paclitaxel in GC cells under hypoxic conditions, suggesting that the PI3K/Akt/HIF-1alpha pathway may act as an important therapeutic target for paclitaxel treatment of GC.	Paclitaxel	220-230	hypoxia inducible factor 1 subunit alpha	Homo sapiens	154-164
24774218-10	2014	And, in cervical SCC patients after treatment with Taxol chemotherapy, the expression level of miR-143 was higher and the positive expression of bcl-2 protein was lower.	Paclitaxel	51-56	BCL2 apoptosis regulator	Homo sapiens	145-150
24570182-1	2014	Although both bevacizumab and paclitaxel significantly improve the efficacy of chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative patients with metastatic breast cancer (MBC), little have changed with overall survival rates when they have been used alone or combined with other chemotherapy.	Paclitaxel	30-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-136
24570182-1	2014	Although both bevacizumab and paclitaxel significantly improve the efficacy of chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative patients with metastatic breast cancer (MBC), little have changed with overall survival rates when they have been used alone or combined with other chemotherapy.	Paclitaxel	30-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	138-142
24570182-7	2014	The meta-analysis confirms the benefits of bevacizumab-paclitaxel combination therapy in HER2 negative metastatic breast cancer, with an improvement in both progression free survival and objective response rate.	Paclitaxel	55-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93
24826054-9	2014	Pro-caspase-3 and PARP degradation was induced by paclitaxel and enhanced by olaparib in a dose-dependent manner.	Paclitaxel	50-60	caspase 3	Homo sapiens	0-13
24525192-7	2014	Moreover, immunoblotting analysis also showed that the co-administration of luteolin and paclitaxel activated caspase-8 and caspase-3 and increased the expression of Fas.	Paclitaxel	89-99	caspase 3	Homo sapiens	124-133
24782986-8	2014	The addition of CYT387 with paclitaxel resulted in the suppression of JAK2/STAT3 activation and abrogation of Oct4 and CD117 expression in mouse xenografts.	Paclitaxel	28-38	signal transducer and activator of transcription 3	Mus musculus	75-80
24525192-0	2014	Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3.	Paclitaxel	18-28	signal transducer and activator of transcription 3	Homo sapiens	99-104
24566868-4	2014	In addition, RSF1-overexpressing paclitaxel-resistant ovarian cancer cell lines were found to express elevated levels of genes regulated by NF-kappaB, including some involved with the evasion of apoptosis (CFLAR, XIAP, BCL2, and BCL2L1) and inflammation (PTGS2).	Paclitaxel	33-43	nuclear factor kappa B subunit 1	Homo sapiens	140-149
24566868-4	2014	In addition, RSF1-overexpressing paclitaxel-resistant ovarian cancer cell lines were found to express elevated levels of genes regulated by NF-kappaB, including some involved with the evasion of apoptosis (CFLAR, XIAP, BCL2, and BCL2L1) and inflammation (PTGS2).	Paclitaxel	33-43	CASP8 and FADD like apoptosis regulator	Homo sapiens	206-211
24566868-4	2014	In addition, RSF1-overexpressing paclitaxel-resistant ovarian cancer cell lines were found to express elevated levels of genes regulated by NF-kappaB, including some involved with the evasion of apoptosis (CFLAR, XIAP, BCL2, and BCL2L1) and inflammation (PTGS2).	Paclitaxel	33-43	BCL2 apoptosis regulator	Homo sapiens	219-223
24566868-4	2014	In addition, RSF1-overexpressing paclitaxel-resistant ovarian cancer cell lines were found to express elevated levels of genes regulated by NF-kappaB, including some involved with the evasion of apoptosis (CFLAR, XIAP, BCL2, and BCL2L1) and inflammation (PTGS2).	Paclitaxel	33-43	BCL2 like 1	Homo sapiens	229-235
24566868-4	2014	In addition, RSF1-overexpressing paclitaxel-resistant ovarian cancer cell lines were found to express elevated levels of genes regulated by NF-kappaB, including some involved with the evasion of apoptosis (CFLAR, XIAP, BCL2, and BCL2L1) and inflammation (PTGS2).	Paclitaxel	33-43	prostaglandin-endoperoxide synthase 2	Homo sapiens	255-260
24566868-7	2014	Moreover, pretreatment with NF-kappaB inhibitors or downregulation of NF-kappaB-regulated gene expression considerably enhanced paclitaxel sensitivity in RSF1-overexpressing OVCAR3 and/or RSF1-induced SKOV3 cells.	Paclitaxel	128-138	nuclear factor kappa B subunit 1	Homo sapiens	28-37
24566868-7	2014	Moreover, pretreatment with NF-kappaB inhibitors or downregulation of NF-kappaB-regulated gene expression considerably enhanced paclitaxel sensitivity in RSF1-overexpressing OVCAR3 and/or RSF1-induced SKOV3 cells.	Paclitaxel	128-138	nuclear factor kappa B subunit 1	Homo sapiens	70-79
24782986-4	2014	In the first approach, we demonstrate that a single intraperitoneal administration of paclitaxel in mice 7 days after subcutaneous transplantation of the HEY ovarian cancer cell line resulted in a significant increase in the expression of CA125, Oct4, and CD117 in mice xenografts compared to control mice xenografts which did not receive paclitaxel.	Paclitaxel	86-96	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	256-261
24782986-7	2014	At the molecular level, mouse tumors remaining after paclitaxel administration showed a significant increase in the expression of Oct4 and CD117 coinciding with a significant activation of the JAK2/STAT3 pathway compared to control tumors.	Paclitaxel	53-63	signal transducer and activator of transcription 3	Mus musculus	198-203
24625050-2	2014	Through a combination of computational modeling, reagent screening, and oxidation sequence analysis, the first three of eight C-H oxidations (at the allylic sites corresponding to C-5, C-10, and C-13) required to reach Taxol from taxadiene were accomplished.	Paclitaxel	219-224	homeobox C10	Homo sapiens	185-189
24826054-9	2014	Pro-caspase-3 and PARP degradation was induced by paclitaxel and enhanced by olaparib in a dose-dependent manner.	Paclitaxel	50-60	poly(ADP-ribose) polymerase 1	Homo sapiens	18-22
24632940-5	2014	Conversely, elevating microtubule acetylation by inhibiting the tubulin deacetylase, HDAC6, or stabilizing microtubules via Taxol stimulates IL-10 hyper-induction.	Paclitaxel	124-129	interleukin 10	Mus musculus	141-146
24476576-2	2014	Because paclitaxel is metabolized by CYP2C8 and CYP3A4, the possibility of drug-drug interactions mediated by enzyme inhibition may exist between the combining agents.	Paclitaxel	8-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
24476576-9	2014	The present results suggest that potent and pathway-dependent inhibition of CYP2C8 and/or CYP3A4 pathways by kinase inhibitors may alter the ratio of paclitaxel metabolites in vivo, and that such changes can be clinically relevant as differential metabolism has been linked to paclitaxel-induced neurotoxicity in cancer patients.	Paclitaxel	150-160	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
24476576-9	2014	The present results suggest that potent and pathway-dependent inhibition of CYP2C8 and/or CYP3A4 pathways by kinase inhibitors may alter the ratio of paclitaxel metabolites in vivo, and that such changes can be clinically relevant as differential metabolism has been linked to paclitaxel-induced neurotoxicity in cancer patients.	Paclitaxel	277-287	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
23640816-4	2014	Furthermore, paclitaxel and doxorubicin coencapsulated in the peptide beads were delivered to THP-1 monocytes, causing a decrease in cell viability due to the activity of the anticancer drugs.	Paclitaxel	13-23	GLI family zinc finger 2	Homo sapiens	94-99
24565839-0	2014	p53 down-regulates SETDB1 gene expression during paclitaxel induced-cell death.	Paclitaxel	49-59	tumor protein p53	Homo sapiens	0-3
24565839-0	2014	p53 down-regulates SETDB1 gene expression during paclitaxel induced-cell death.	Paclitaxel	49-59	SET domain bifurcated histone lysine methyltransferase 1	Homo sapiens	19-25
24565839-3	2014	In this study, we examine if PTX affects expression of SETDB1 HMTase during cell death.	Paclitaxel	29-32	SET domain bifurcated histone lysine methyltransferase 1	Homo sapiens	55-61
24565839-5	2014	PTX treatment induces the p53 protein, but down-regulates expression of SETDB1 at the transcriptional level as well as the protein level.	Paclitaxel	0-3	tumor protein p53	Homo sapiens	26-29
24565839-5	2014	PTX treatment induces the p53 protein, but down-regulates expression of SETDB1 at the transcriptional level as well as the protein level.	Paclitaxel	0-3	SET domain bifurcated histone lysine methyltransferase 1	Homo sapiens	72-78
24565839-6	2014	SETDB1 promoter activity is increased to approximately 30-fold in normal condition, but the activity is significantly inhibited in the PTX treated group.	Paclitaxel	135-138	SET domain bifurcated histone lysine methyltransferase 1	Homo sapiens	0-6
24565839-10	2014	This result demonstrates that PTX down-regulates SETDB1 gene expression in a p53 dependent manner, and p53 might participate in heterochromatic repression on the promoter regions of SETDB1.	Paclitaxel	30-33	SET domain bifurcated histone lysine methyltransferase 1	Homo sapiens	49-55
24565839-10	2014	This result demonstrates that PTX down-regulates SETDB1 gene expression in a p53 dependent manner, and p53 might participate in heterochromatic repression on the promoter regions of SETDB1.	Paclitaxel	30-33	tumor protein p53	Homo sapiens	77-80
24565839-10	2014	This result demonstrates that PTX down-regulates SETDB1 gene expression in a p53 dependent manner, and p53 might participate in heterochromatic repression on the promoter regions of SETDB1.	Paclitaxel	30-33	SET domain bifurcated histone lysine methyltransferase 1	Homo sapiens	182-188
24401928-0	2014	Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.	Paclitaxel	90-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-108
24817940-0	2014	AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.	Paclitaxel	72-82	AKT serine/threonine kinase 1	Homo sapiens	0-3
24817940-0	2014	AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.	Paclitaxel	72-82	mitogen-activated protein kinase 1	Homo sapiens	4-7
24817940-6	2014	Additionally, the AKT/ERK signaling pathway, which is the pathway downstream of ErbB, was predicted to be active in PTX-resistant GC cell lines.	Paclitaxel	116-119	AKT serine/threonine kinase 1	Homo sapiens	18-21
24817940-6	2014	Additionally, the AKT/ERK signaling pathway, which is the pathway downstream of ErbB, was predicted to be active in PTX-resistant GC cell lines.	Paclitaxel	116-119	mitogen-activated protein kinase 1	Homo sapiens	22-25
24817940-6	2014	Additionally, the AKT/ERK signaling pathway, which is the pathway downstream of ErbB, was predicted to be active in PTX-resistant GC cell lines.	Paclitaxel	116-119	epidermal growth factor receptor	Homo sapiens	80-84
24817940-7	2014	ErbB3 overexpression and AKT/ERK activation in PTX-resistant cell lines were validated, respectively, by quantitative PCR and immunoblotting.	Paclitaxel	47-50	AKT serine/threonine kinase 1	Homo sapiens	25-28
24817940-7	2014	ErbB3 overexpression and AKT/ERK activation in PTX-resistant cell lines were validated, respectively, by quantitative PCR and immunoblotting.	Paclitaxel	47-50	mitogen-activated protein kinase 1	Homo sapiens	29-32
23681836-6	2014	It was observed the terminal t 1/2 and MRT of paclitaxel were significantly (p = 0.002 and 0.001) reduced by MI, respectively, from 11.0 +- 2.2 and 5.6 +- 1.0 h to 7.7 +- 1.7 and 4.0 +- 0.3 h. Hematological toxicity indicated by platelet count and hepatic events marked with ALT, AST and gamma-GT were significant in both groups.	Paclitaxel	46-56	solute carrier family 17 member 5	Homo sapiens	280-283
24745277-0	2014	Dissipative particle dynamics simulation on paclitaxel loaded PEO-PPO-PEO block copolymer micelles.	Paclitaxel	44-54	protoporphyrinogen oxidase	Homo sapiens	66-69
24375949-4	2014	Furthermore, a significant increase in the ratios of glutathione peroxidase/glutathione reductase, superoxide dismutase/glutathione peroxidase, and superoxide dismutase/catalase in PTX-treated cells was observed, compared with control cells.	Paclitaxel	181-184	catalase	Homo sapiens	169-177
24362251-7	2014	Conversely, the transient transfection of CABYR-a/b-depleted cells with constitutively active Akt partially restored the resistance to cisplatin and paclitaxel and significantly decreased the activation of GSK-3beta and cleaved PARP.	Paclitaxel	149-159	calcium binding tyrosine phosphorylation regulated	Homo sapiens	42-47
24362251-7	2014	Conversely, the transient transfection of CABYR-a/b-depleted cells with constitutively active Akt partially restored the resistance to cisplatin and paclitaxel and significantly decreased the activation of GSK-3beta and cleaved PARP.	Paclitaxel	149-159	AKT serine/threonine kinase 1	Homo sapiens	94-97
24767644-5	2014	However, ability of migration and invasion of ES-2 cells was significantly decreased in either use of D-Lys(6) or paclitaxel and more apparent with the combination.	Paclitaxel	114-124	ess-2 splicing factor homolog	Homo sapiens	46-50
24431074-4	2014	In this study, we show that masitinib, a small molecule stem-cell growth factor receptor (c-Kit) tyrosine kinase inhibitor, at nontoxic concentrations, significantly attenuates paclitaxel resistance in HEK293 cells transfected with ABCC10.	Paclitaxel	177-187	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	90-95
24116978-10	2014	A decrease in TGFbeta1-induced SZP accumulation was also observed when the microtubule cytoskeleton was modified using paclitaxel.	Paclitaxel	119-129	transforming growth factor beta 1	Homo sapiens	14-22
24116978-10	2014	A decrease in TGFbeta1-induced SZP accumulation was also observed when the microtubule cytoskeleton was modified using paclitaxel.	Paclitaxel	119-129	proteoglycan 4	Homo sapiens	31-34
24469707-3	2014	Results showed that treatment of Taxol could increase the inhibition rate of tumour growth, positive expression levels of Caspase-3, Bax and decrease positive expression levels of Bcl-2 and Bcl-2/Bax, expression levels of HGF, MACC1 and C-met proteins and MACC1 mRNA in tumour tissue of CC mice.	Paclitaxel	33-38	B cell leukemia/lymphoma 2	Mus musculus	180-185
24469707-3	2014	Results showed that treatment of Taxol could increase the inhibition rate of tumour growth, positive expression levels of Caspase-3, Bax and decrease positive expression levels of Bcl-2 and Bcl-2/Bax, expression levels of HGF, MACC1 and C-met proteins and MACC1 mRNA in tumour tissue of CC mice.	Paclitaxel	33-38	B cell leukemia/lymphoma 2	Mus musculus	190-195
24469707-3	2014	Results showed that treatment of Taxol could increase the inhibition rate of tumour growth, positive expression levels of Caspase-3, Bax and decrease positive expression levels of Bcl-2 and Bcl-2/Bax, expression levels of HGF, MACC1 and C-met proteins and MACC1 mRNA in tumour tissue of CC mice.	Paclitaxel	33-38	metastasis associated in colon cancer 1	Mus musculus	227-232
24469707-3	2014	Results showed that treatment of Taxol could increase the inhibition rate of tumour growth, positive expression levels of Caspase-3, Bax and decrease positive expression levels of Bcl-2 and Bcl-2/Bax, expression levels of HGF, MACC1 and C-met proteins and MACC1 mRNA in tumour tissue of CC mice.	Paclitaxel	33-38	metastasis associated in colon cancer 1	Mus musculus	256-261
24469707-4	2014	It can be concluded that inhibitory activity of Taxol against tumour growth in CC mice is closely associated with its modulating positive expression of Bcl-2, Bax, Caspase-3, expression of HGF, MACC1, Caspase-3 and C-met proteins and MACC1 mRNA in tumour of CC mice.	Paclitaxel	48-53	B cell leukemia/lymphoma 2	Mus musculus	152-157
24469707-4	2014	It can be concluded that inhibitory activity of Taxol against tumour growth in CC mice is closely associated with its modulating positive expression of Bcl-2, Bax, Caspase-3, expression of HGF, MACC1, Caspase-3 and C-met proteins and MACC1 mRNA in tumour of CC mice.	Paclitaxel	48-53	metastasis associated in colon cancer 1	Mus musculus	194-199
24469707-4	2014	It can be concluded that inhibitory activity of Taxol against tumour growth in CC mice is closely associated with its modulating positive expression of Bcl-2, Bax, Caspase-3, expression of HGF, MACC1, Caspase-3 and C-met proteins and MACC1 mRNA in tumour of CC mice.	Paclitaxel	48-53	metastasis associated in colon cancer 1	Mus musculus	234-239
24527095-8	2014	It was found that lipopolysaccharide and Pac significantly increase the secretion of IL-6 and IL-8 in the SKOV3 cell line.	Paclitaxel	41-44	interleukin 6	Homo sapiens	85-89
24527095-8	2014	It was found that lipopolysaccharide and Pac significantly increase the secretion of IL-6 and IL-8 in the SKOV3 cell line.	Paclitaxel	41-44	C-X-C motif chemokine ligand 8	Homo sapiens	94-98
24527095-9	2014	Similarly, Pac resulted in a significant upregulation of IL-6 and IL-8 in OVCAR3 cells, but not in A2780 and 3AO cells.	Paclitaxel	11-14	interleukin 6	Homo sapiens	57-61
24527095-9	2014	Similarly, Pac resulted in a significant upregulation of IL-6 and IL-8 in OVCAR3 cells, but not in A2780 and 3AO cells.	Paclitaxel	11-14	C-X-C motif chemokine ligand 8	Homo sapiens	66-70
26766992-0	2014	Phase II trial of paclitaxel-carboplatin with intercalated gefitinib for untreated, epidermal growth factor receptor gene mutation status unknown non-small cell lung cancer.	Paclitaxel	18-28	epidermal growth factor receptor	Homo sapiens	84-116
24361916-0	2014	Spinal gene expression profiling and pathways analysis of a CB2 agonist (MDA7)-targeted prevention of paclitaxel-induced neuropathy.	Paclitaxel	102-112	interleukin 24	Rattus norvegicus	73-77
24361916-11	2014	CONCLUSION: The preventive effect of MDA7 on paclitaxel-induced peripheral allodynia in rats may be associated with genes involved in signal pathways in central sensitization, microglial activation, and neuroinflammation in the spinal cord.	Paclitaxel	45-55	interleukin 24	Rattus norvegicus	37-41
24361916-2	2014	We found that a novel selective cannabinoid CB2 receptor agonist (MDA7) prevents paclitaxel-induced mechanical allodynia in rats and mice.	Paclitaxel	81-91	interleukin 24	Rattus norvegicus	66-70
24361916-3	2014	Here we investigated gene expression profiling in the lumbar spinal cord after 14-day treatment of MDA7 in paclitaxel animals and analyzed possible signaling pathways underlying the preventive effect of MDA7 on paclitaxel-induced neuropathy.	Paclitaxel	107-117	interleukin 24	Rattus norvegicus	99-103
24361916-3	2014	Here we investigated gene expression profiling in the lumbar spinal cord after 14-day treatment of MDA7 in paclitaxel animals and analyzed possible signaling pathways underlying the preventive effect of MDA7 on paclitaxel-induced neuropathy.	Paclitaxel	211-221	interleukin 24	Rattus norvegicus	203-207
24361916-6	2014	MDA7 was administered at a dose of 15mg/kg 15min before paclitaxel and then continued daily for another 10days.	Paclitaxel	56-66	interleukin 24	Rattus norvegicus	0-4
24361916-8	2014	The Ingenuity pathway analysis was performed to determine the potential relevant canonical pathways responsible for the effect of MDA7 on paclitaxel-induced peripheral neuropathy.	Paclitaxel	138-148	interleukin 24	Rattus norvegicus	130-134
24591819-10	2014	Underexpressed miRNAs in Taxol-sensitive cells included miR-497, miR-187, miR-195, and miR-107.	Paclitaxel	25-30	microRNA 195	Homo sapiens	74-81
24495785-5	2014	The combination of PEITC and taxol also reduced expressions of cell cycle regulator Cdk1, and anti-apoptotic protein bcl-2, enhanced expression of Bax and cleavage of PARP proteins.	Paclitaxel	29-34	BCL2 apoptosis regulator	Homo sapiens	117-122
24549172-2	2014	Furthermore, the actions of paclitaxel attenuated Bcl-2 resistance to apoptosis through endoplasmic reticulum-mediated calcium release.	Paclitaxel	28-38	BCL2 apoptosis regulator	Homo sapiens	50-55
24420921-2	2014	The hexaacylated lipid A is an agonist of mouse (mTLR4) and human TLR4/MD-2, whereas the tetraacylated lipid IVa and paclitaxel activate only mTLR4/MD-2 and antagonize activation of the human receptor complex.	Paclitaxel	117-127	toll-like receptor 4	Mus musculus	142-147
24420921-4	2014	We show that each of the hydrophobic residues F438 and F461, which are located on the convex face of leucine-rich repeats 16 and 17 of the mTLR4 ectodomain, are essential for activation of with lipid IVa and paclitaxel, which, although not a structural analog of LPS, activates cells expressing mTLR4/MD-2.	Paclitaxel	208-218	toll-like receptor 4	Mus musculus	139-144
24420921-4	2014	We show that each of the hydrophobic residues F438 and F461, which are located on the convex face of leucine-rich repeats 16 and 17 of the mTLR4 ectodomain, are essential for activation of with lipid IVa and paclitaxel, which, although not a structural analog of LPS, activates cells expressing mTLR4/MD-2.	Paclitaxel	208-218	toll-like receptor 4	Mus musculus	295-300
24581301-10	2014	In contrast, paclitaxel was tended to regulate 27 pathways such as PI3K/AKT.	Paclitaxel	13-23	AKT serine/threonine kinase 1	Homo sapiens	72-75
24502656-11	2014	More importantly, combined treatment of anti-PD-1/GITR mAb and chemotherapeutic drugs (cisplatin or paclitaxel) further increased the antitumor efficacy with 80% of mice obtaining tumor-free long-term survival in murine ID8 ovarian cancer and 4 T1 breast cancer models.	Paclitaxel	100-110	programmed cell death 1	Mus musculus	45-49
24502656-11	2014	More importantly, combined treatment of anti-PD-1/GITR mAb and chemotherapeutic drugs (cisplatin or paclitaxel) further increased the antitumor efficacy with 80% of mice obtaining tumor-free long-term survival in murine ID8 ovarian cancer and 4 T1 breast cancer models.	Paclitaxel	100-110	tumor necrosis factor receptor superfamily, member 18	Mus musculus	50-54
24495785-5	2014	The combination of PEITC and taxol also reduced expressions of cell cycle regulator Cdk1, and anti-apoptotic protein bcl-2, enhanced expression of Bax and cleavage of PARP proteins.	Paclitaxel	29-34	BCL2 associated X, apoptosis regulator	Homo sapiens	147-150
24080340-5	2014	In the CD133(-) subpopulation, the exposure to taxol induced the activation of apoptosis signal-regulating kinase1 (ASK1)/c-jun-N-terminal kinase (JNK), p38, extracellular signal regulated kinase (ERK) pathways and Bax expression, while in CD133(+) cells taxol was able only to enhance the activity of the ERK pathway.	Paclitaxel	47-52	mitogen-activated protein kinase 1	Homo sapiens	153-156
24140176-0	2014	Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines.	Paclitaxel	45-55	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
23975319-12	2014	CONCLUSIONS: Salvage gastrectomy after chemotherapy of S-1 with IV and IP PTX is promising, even for patients with highly advanced gastric cancer and severe peritoneal metastasis and malignant ascites.	Paclitaxel	74-77	proteasome 26S subunit, non-ATPase 1	Homo sapiens	55-58
24117398-10	2014	CONCLUSIONS AND IMPLICATIONS: Our data suggest that CBD is protective against PAC-induced neurotoxicity mediated in part by the 5-HT(1A) receptor system.	Paclitaxel	78-81	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	128-145
24080340-5	2014	In the CD133(-) subpopulation, the exposure to taxol induced the activation of apoptosis signal-regulating kinase1 (ASK1)/c-jun-N-terminal kinase (JNK), p38, extracellular signal regulated kinase (ERK) pathways and Bax expression, while in CD133(+) cells taxol was able only to enhance the activity of the ERK pathway.	Paclitaxel	47-52	mitogen-activated protein kinase 1	Homo sapiens	306-309
24080340-6	2014	In CD133(+) cells, the direct gene transfer of Bax overcame the acquired resistance to taxol.	Paclitaxel	87-92	BCL2 associated X, apoptosis regulator	Homo sapiens	47-50
24080340-5	2014	In the CD133(-) subpopulation, the exposure to taxol induced the activation of apoptosis signal-regulating kinase1 (ASK1)/c-jun-N-terminal kinase (JNK), p38, extracellular signal regulated kinase (ERK) pathways and Bax expression, while in CD133(+) cells taxol was able only to enhance the activity of the ERK pathway.	Paclitaxel	47-52	mitogen-activated protein kinase 1	Homo sapiens	158-195
24080340-5	2014	In the CD133(-) subpopulation, the exposure to taxol induced the activation of apoptosis signal-regulating kinase1 (ASK1)/c-jun-N-terminal kinase (JNK), p38, extracellular signal regulated kinase (ERK) pathways and Bax expression, while in CD133(+) cells taxol was able only to enhance the activity of the ERK pathway.	Paclitaxel	47-52	mitogen-activated protein kinase 1	Homo sapiens	197-200
24080340-5	2014	In the CD133(-) subpopulation, the exposure to taxol induced the activation of apoptosis signal-regulating kinase1 (ASK1)/c-jun-N-terminal kinase (JNK), p38, extracellular signal regulated kinase (ERK) pathways and Bax expression, while in CD133(+) cells taxol was able only to enhance the activity of the ERK pathway.	Paclitaxel	47-52	BCL2 associated X, apoptosis regulator	Homo sapiens	215-218
24284783-4	2014	The incubation of KB-C2 cells overexpressing ABCB1 transporter with beta-elemene (100 microM) significantly augmented the antineoplastic efficacy of colchicine, vinblastine and paclitaxel when compared to KB-C2 cells incubated with these drugs alone.	Paclitaxel	177-187	ATP binding cassette subfamily B member 1	Homo sapiens	45-50
24284783-5	2014	In HEK293 cells overexpressing the ABCB1 transporter, beta-elemene significantly increased the cytotoxicity of paclitaxel.	Paclitaxel	111-121	ATP binding cassette subfamily B member 1	Homo sapiens	35-40
24180344-0	2014	Intravenous administration of high-dose Paclitaxel reduces gut-associated lymphoid tissue cell number and respiratory immunoglobulin A concentrations in mice.	Paclitaxel	40-50	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	118-134
24180344-12	2014	Respiratory tract IgA concentrations were lower in the high PTX than in the control group.	Paclitaxel	60-63	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	18-21
24472145-5	2014	METHODS: We evaluated the expression of HER-2/neu protein in gastric cell lines by FACS and then comparing the cytotoxicity in chemotherapeutics (doxorubicin, cisplatin, paclitaxel, 5-FU) alone and in combination with Herceptin according to the expression of HER-2/neu protein by MTT assay.	Paclitaxel	170-180	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-49
24652302-0	2014	Drug promiscuity of P-glycoprotein and its mechanism of interaction with paclitaxel and doxorubicin.	Paclitaxel	73-83	ATP binding cassette subfamily B member 1	Homo sapiens	20-34
24652302-5	2014	Results indicate that different drugs like paclitaxel and doxorubicin approach the putative binding site of P-gp, and the inner residues are found to be important in this process.	Paclitaxel	43-53	ATP binding cassette subfamily B member 1	Homo sapiens	108-112
25339026-0	2014	Sensitization of cervical carcinoma cells to paclitaxel by an IPP5 active mutant.	Paclitaxel	45-55	protein phosphatase 1 regulatory inhibitor subunit 1C	Homo sapiens	62-66
24252806-0	2014	Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel.	Paclitaxel	120-130	ATP binding cassette subfamily B member 1	Homo sapiens	53-67
25374178-0	2014	Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel.	Paclitaxel	86-96	BCL2 apoptosis regulator	Homo sapiens	13-18
24261922-3	2014	NOSC in a wide concentration range even above the critical micelle concentration showed an effective effect on inhibiting P-gp-mediated PTX efflux, which was remarkably different from the surfactants and the Pluronic copolymers.	Paclitaxel	136-139	ATP binding cassette subfamily B member 1	Homo sapiens	122-126
24261922-4	2014	Multiple mechanisms were involved in this effect of NOSC, such as stimulating P-gp ATPase, competitively impeding the binding of PTX with P-gp and reducing the fluidity of the cell membrane.	Paclitaxel	129-132	ATP binding cassette subfamily B member 1	Homo sapiens	78-82
24261922-4	2014	Multiple mechanisms were involved in this effect of NOSC, such as stimulating P-gp ATPase, competitively impeding the binding of PTX with P-gp and reducing the fluidity of the cell membrane.	Paclitaxel	129-132	ATP binding cassette subfamily B member 1	Homo sapiens	138-142
24261922-6	2014	Furthermore, it was demonstrated that most of PTX-M as an intact form was delivered at the tumor site, which ensures the synergetic effect of NOSC micelles on drug delivery and P-gp inhibition.	Paclitaxel	46-49	ATP binding cassette subfamily B member 1	Homo sapiens	177-181
25081695-0	2014	Expression and underlying roles of IGFBP-3 in paclitaxel-treated gastric cancer SGC-7901 cells.	Paclitaxel	46-56	sarcoglycan beta	Homo sapiens	80-83
25081695-1	2014	PURPOSE: To study the expression of insulin-like growth factor binding proteins (IGFBPs) in paclitaxel-treated gastric cancer SGC-7901 cells, and to further investigate underlying mechanisms.	Paclitaxel	92-102	sarcoglycan beta	Homo sapiens	126-129
25081695-2	2014	MATERIALS AND METHODS: Real time PCR and Western blot assays were applied to detect the mRNA and protein expression of IGFBP-2, -3 and -5 after paclitaxel (10 nM) treatment of SGC-7901 cells.	Paclitaxel	144-154	sarcoglycan beta	Homo sapiens	176-179
25081695-7	2014	Paclitaxel treatment caused cell cycle arrest and apoptosis via downregulating Bcl-2 expression.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	79-84
25081695-9	2014	CONCLUSIONS: IGFBP-3 exhibits anti-apoptotic effects on paclitaxel-treated SGC-7901 cells via elevating Bcl-2 expression.	Paclitaxel	56-66	sarcoglycan beta	Homo sapiens	75-78
25081695-9	2014	CONCLUSIONS: IGFBP-3 exhibits anti-apoptotic effects on paclitaxel-treated SGC-7901 cells via elevating Bcl-2 expression.	Paclitaxel	56-66	BCL2 apoptosis regulator	Homo sapiens	104-109
25339026-2	2014	In this study, we obtained evidence that the active mutant IPP5 (8-60hIPP5m), the latest member of the inhibitory molecules for protein phosphatase 1, sensitizes human cervix carcinoma cells HeLa more efficiently to the therapeutic effects of paclitaxel.	Paclitaxel	243-253	protein phosphatase 1 regulatory inhibitor subunit 1C	Homo sapiens	59-63
25339026-4	2014	Furthermore, our results revealed that 8-60hIPP5m enhances paclitaxel- induced G2/M arrest and apoptosis, and augments paclitaxel-induced activation of caspases and release of cytochrome C.	Paclitaxel	119-129	cytochrome c, somatic	Homo sapiens	176-188
25339026-6	2014	We noted that 8-60hIPP5m down- regulated the paclitaxel-induced NF-?B activation, I?Balpha degradation, PI3-K activity and phosphorylation of the serine/threonine kinase Akt, a survival signal which in many instances is regulated by NF-?B.	Paclitaxel	45-55	protein phosphatase 1 regulatory inhibitor subunit 1C	Homo sapiens	14-23
25339026-6	2014	We noted that 8-60hIPP5m down- regulated the paclitaxel-induced NF-?B activation, I?Balpha degradation, PI3-K activity and phosphorylation of the serine/threonine kinase Akt, a survival signal which in many instances is regulated by NF-?B.	Paclitaxel	45-55	AKT serine/threonine kinase 1	Homo sapiens	170-173
24596624-0	2014	Identification of p-glycoprotein and transport mechanism of Paclitaxel in syncytiotrophoblast cells.	Paclitaxel	60-70	ATP binding cassette subfamily B member 1	Homo sapiens	18-32
24189097-1	2014	For developing a multifunctional bioreducible targeted and synergistic co-delivery system for anticancer drug paclitaxel (PTX) and p53 gene for potential cancer therapy, supramolecular self-assembled inclusion complex was prepared from PTX and star-shaped cationic polymer containing gamma-cyclodextrin (gamma-CD) and multiple oligoethylenimine (OEI) arms with folic acid (FA) conjugated via a disulfide linker.	Paclitaxel	236-239	tumor protein p53	Homo sapiens	131-134
24189097-8	2014	Therefore, the multifunctional gamma-CD-OEI-SS-FA/PTX self-assembly system with the synergistic effects of redox-sensitive FA-targeted and PTX-enhanced p53 gene delivery may be promising for cancer therapeutic application.	Paclitaxel	50-53	tumor protein p53	Homo sapiens	152-155
24189097-8	2014	Therefore, the multifunctional gamma-CD-OEI-SS-FA/PTX self-assembly system with the synergistic effects of redox-sensitive FA-targeted and PTX-enhanced p53 gene delivery may be promising for cancer therapeutic application.	Paclitaxel	139-142	tumor protein p53	Homo sapiens	152-155
24332858-1	2014	A group of novel taxoids, with modifications at C-7, C-10, C-3" and C-14 positions of paclitaxel, was synthesized in order to improve their biological profile by decreasing their affinity with P-glycoprotein (P-gp) and increasing cellular permeability.	Paclitaxel	86-96	ATP binding cassette subfamily B member 1	Homo sapiens	193-207
24332858-1	2014	A group of novel taxoids, with modifications at C-7, C-10, C-3" and C-14 positions of paclitaxel, was synthesized in order to improve their biological profile by decreasing their affinity with P-glycoprotein (P-gp) and increasing cellular permeability.	Paclitaxel	86-96	ATP binding cassette subfamily B member 1	Homo sapiens	209-213
24332858-7	2014	It was thus clear that simultaneous modifications at the C-7, C-10 and C-3" positions of paclitaxel significantly impaired its interactions with P-gp and interfered with P-gp mediated efflux.	Paclitaxel	89-99	homeobox C10	Homo sapiens	62-66
24332858-7	2014	It was thus clear that simultaneous modifications at the C-7, C-10 and C-3" positions of paclitaxel significantly impaired its interactions with P-gp and interfered with P-gp mediated efflux.	Paclitaxel	89-99	ATP binding cassette subfamily B member 1	Homo sapiens	145-149
24332858-7	2014	It was thus clear that simultaneous modifications at the C-7, C-10 and C-3" positions of paclitaxel significantly impaired its interactions with P-gp and interfered with P-gp mediated efflux.	Paclitaxel	89-99	ATP binding cassette subfamily B member 1	Homo sapiens	170-174
24596624-7	2014	[(3)H]Paclitaxel uptake was markedly inhibited by cyclosporine and verapamil, well-known substrates of P-glycoprotein (P-gp) transporter.	Paclitaxel	6-16	ATP binding cassette subfamily B member 1	Homo sapiens	103-117
24596624-7	2014	[(3)H]Paclitaxel uptake was markedly inhibited by cyclosporine and verapamil, well-known substrates of P-glycoprotein (P-gp) transporter.	Paclitaxel	6-16	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
24596624-9	2014	These results suggest that P-gp may be involved in paclitaxel transport at the placenta.	Paclitaxel	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	27-31
24621501-1	2014	Functional analysis of a series of phosphorylation mutants reveals that Bcl-xL(Ser62Ala) influences cell entry into anaphase and mitotic exit in taxol-exposed cells compared with cells expressing wild-type Bcl-xL or a series of other phosphorylation mutants, an effect that appears to be independent of its anti-apoptotic activity.	Paclitaxel	145-150	BCL2 like 1	Homo sapiens	72-78
24520227-13	2014	CONCLUSION: OVCAR-3 cells were sensitized to paclitaxel-induced apoptosis by celecoxib through downregulation of NF-kappaB and Akt activation, suggesting that celecoxib may work synergistically with paclitaxel to inhibit different targets and ultimately produce anticancer effects.	Paclitaxel	45-55	AKT serine/threonine kinase 1	Homo sapiens	127-130
24520227-0	2014	Synergistic Effect of COX-2 Inhibitor on Paclitaxel-Induced Apoptosis in the Human Ovarian Cancer Cell Line OVCAR-3.	Paclitaxel	41-51	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	22-27
24520227-10	2014	Pretreatment with celecoxib also increased activation of caspase-9, -3 and cleaved PARP following paclitaxel-treatment.	Paclitaxel	98-108	poly(ADP-ribose) polymerase 1	Homo sapiens	83-87
24520227-11	2014	Exposure of OVCAR-3 cells to celecoxib in combination with paclitaxel resulted in downregulation of NF-kappaB activation and VEGF expression.	Paclitaxel	59-69	nuclear factor kappa B subunit 1	Homo sapiens	100-109
24520227-11	2014	Exposure of OVCAR-3 cells to celecoxib in combination with paclitaxel resulted in downregulation of NF-kappaB activation and VEGF expression.	Paclitaxel	59-69	vascular endothelial growth factor A	Homo sapiens	125-129
24520227-12	2014	Furthermore, combining celecoxib and paclitaxel inhibited phosphorylation of Akt.	Paclitaxel	37-47	AKT serine/threonine kinase 1	Homo sapiens	77-80
24520227-13	2014	CONCLUSION: OVCAR-3 cells were sensitized to paclitaxel-induced apoptosis by celecoxib through downregulation of NF-kappaB and Akt activation, suggesting that celecoxib may work synergistically with paclitaxel to inhibit different targets and ultimately produce anticancer effects.	Paclitaxel	45-55	nuclear factor kappa B subunit 1	Homo sapiens	113-122
25485509-6	2014	Both full-length and N-terminally truncated forms of the PRKAR2A gene product markedly increased survival of prostate cancer cells lines treated with Taxol and Taxotere.	Paclitaxel	150-155	protein kinase cAMP-dependent type II regulatory subunit alpha	Homo sapiens	57-64
24621501-1	2014	Functional analysis of a series of phosphorylation mutants reveals that Bcl-xL(Ser62Ala) influences cell entry into anaphase and mitotic exit in taxol-exposed cells compared with cells expressing wild-type Bcl-xL or a series of other phosphorylation mutants, an effect that appears to be independent of its anti-apoptotic activity.	Paclitaxel	145-150	BCL2 like 1	Homo sapiens	206-212
24621501-4	2014	In taxol- and nocodazole-exposed cells, phospho-Bcl-xL(Ser62) also binds to Cdc20- Mad2-, BubR1-, and Bub3-bound complexes, while Bcl-xL(Ser62Ala) does not.	Paclitaxel	3-8	BCL2 like 1	Homo sapiens	48-54
24621501-4	2014	In taxol- and nocodazole-exposed cells, phospho-Bcl-xL(Ser62) also binds to Cdc20- Mad2-, BubR1-, and Bub3-bound complexes, while Bcl-xL(Ser62Ala) does not.	Paclitaxel	3-8	BUB3 mitotic checkpoint protein	Homo sapiens	102-106
23430338-8	2014	MAGE-A5 was connected to a positive effect on treatment with paclitaxel within the first 24 h after application.	Paclitaxel	61-71	MAGE family member A5, pseudogene	Homo sapiens	0-7
24451948-0	2014	Inhibition of Notch1 increases paclitaxel sensitivity to human breast cancer.	Paclitaxel	31-41	notch receptor 1	Homo sapiens	14-20
24451948-10	2014	CONCLUSION: Notch1 expression has an effect on PAC sensitivity in breast cancer patients, and the inhibition of Notch1 increases paclitaxel sensitivity to human breast cancer.	Paclitaxel	129-139	notch receptor 1	Homo sapiens	112-118
25186575-0	2014	Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer.	Paclitaxel	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
24165483-7	2014	Mechanistic study of NSCLC cell lines with silenced FBXW7 revealed enhanced MS-275 sensitivity and taxol resistance.	Paclitaxel	99-104	F-box and WD repeat domain containing 7	Homo sapiens	52-57
23966347-6	2014	The micelleplexes are further exploited for co-delivery of siRNA-Bcl-2 and PTX to Bcl-2 overexpressing A549 lung cancer cells (A549-Bcl-2).	Paclitaxel	75-78	BCL2 apoptosis regulator	Homo sapiens	82-87
23966347-6	2014	The micelleplexes are further exploited for co-delivery of siRNA-Bcl-2 and PTX to Bcl-2 overexpressing A549 lung cancer cells (A549-Bcl-2).	Paclitaxel	75-78	BCL2 apoptosis regulator	Homo sapiens	82-87
23966347-7	2014	The experimental results show that the micelleplexes could sensitize A549-Bcl-2 cells to PTX via down-regulation of anti-apoptosis gene of Bcl-2, suggesting that PDMA-b-PDPA micelleplexes are promising nanovectors for siRNA and anti-cancer drug co-delivery to overcome cancer MDR.	Paclitaxel	89-92	BCL2 apoptosis regulator	Homo sapiens	74-79
23966347-7	2014	The experimental results show that the micelleplexes could sensitize A549-Bcl-2 cells to PTX via down-regulation of anti-apoptosis gene of Bcl-2, suggesting that PDMA-b-PDPA micelleplexes are promising nanovectors for siRNA and anti-cancer drug co-delivery to overcome cancer MDR.	Paclitaxel	89-92	BCL2 apoptosis regulator	Homo sapiens	139-144
25116401-5	2014	RESULTS: Nilotinib alone and in combination with carboplatin and paclitaxel significantly inhibited cell growth in PDGFR-alpha-positive ovarian cancer cell lines.	Paclitaxel	65-75	platelet derived growth factor receptor alpha	Homo sapiens	115-126
24247637-0	2014	Combination treatment with paclitaxel and doxorubicin inhibits growth of human esophageal squamous cancer cells by inactivation of Akt.	Paclitaxel	27-37	AKT serine/threonine kinase 1	Homo sapiens	131-134
24247637-5	2014	Increased p-cdc2, p-Wee1 and p53 protein levels were observed, while Akt activation was suppressed by combination treatment with paclitaxel and doxorubicin.	Paclitaxel	129-139	AKT serine/threonine kinase 1	Homo sapiens	69-72
24247637-6	2014	In addition, treatment with paclitaxel plus doxorubicin significantly increased apoptosis as indicated by increased cleaved poly(ADP-ribose) polymerase and cleaved caspase-7 and -9 levels.	Paclitaxel	28-38	poly(ADP-ribose) polymerase 1	Homo sapiens	124-151
24247637-7	2014	These results suggest that combination treatment with paclitaxel and doxorubicin induced G2/M cell cycle arrest and apoptosis in human ESCC cells by suppressing Akt activity.	Paclitaxel	54-64	AKT serine/threonine kinase 1	Homo sapiens	161-164
24173825-1	2014	Colorectal cancer (CRC) cells have been previously observed to be resistant to paclitaxel-induced apoptosis by activation of the mitogen-activated protein/extracellular signal-regulated kinase (MEK)/ERK signaling pathway and increased expression of glucose-regulated protein 78 (GRP78).	Paclitaxel	79-89	mitogen-activated protein kinase kinase 7	Homo sapiens	129-192
24173825-1	2014	Colorectal cancer (CRC) cells have been previously observed to be resistant to paclitaxel-induced apoptosis by activation of the mitogen-activated protein/extracellular signal-regulated kinase (MEK)/ERK signaling pathway and increased expression of glucose-regulated protein 78 (GRP78).	Paclitaxel	79-89	mitogen-activated protein kinase kinase 7	Homo sapiens	194-197
24173825-1	2014	Colorectal cancer (CRC) cells have been previously observed to be resistant to paclitaxel-induced apoptosis by activation of the mitogen-activated protein/extracellular signal-regulated kinase (MEK)/ERK signaling pathway and increased expression of glucose-regulated protein 78 (GRP78).	Paclitaxel	79-89	mitogen-activated protein kinase 1	Homo sapiens	199-202
24173825-1	2014	Colorectal cancer (CRC) cells have been previously observed to be resistant to paclitaxel-induced apoptosis by activation of the mitogen-activated protein/extracellular signal-regulated kinase (MEK)/ERK signaling pathway and increased expression of glucose-regulated protein 78 (GRP78).	Paclitaxel	79-89	heat shock protein family A (Hsp70) member 5	Homo sapiens	249-277
24173825-1	2014	Colorectal cancer (CRC) cells have been previously observed to be resistant to paclitaxel-induced apoptosis by activation of the mitogen-activated protein/extracellular signal-regulated kinase (MEK)/ERK signaling pathway and increased expression of glucose-regulated protein 78 (GRP78).	Paclitaxel	79-89	heat shock protein family A (Hsp70) member 5	Homo sapiens	279-284
24173825-5	2014	Pretreatment of CRC cells with caffeine significantly inhibited paclitaxel-induced cytotoxicity by increasing the levels of the antiapoptotic Bcl-2 family member, Mcl-1.	Paclitaxel	64-74	BCL2 apoptosis regulator	Homo sapiens	142-147
24173825-8	2014	Moreover, administration of caffeine may decrease chemotherapeutic responses to paclitaxel by the MEK-ERK mediated upregulation of Mcl-1.	Paclitaxel	80-90	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
24173825-8	2014	Moreover, administration of caffeine may decrease chemotherapeutic responses to paclitaxel by the MEK-ERK mediated upregulation of Mcl-1.	Paclitaxel	80-90	mitogen-activated protein kinase 1	Homo sapiens	102-105
24070631-3	2013	Two known critical spinal mechanisms underlying taxol-induced neuropathic pain are an increased production of pro-inflammatory cytokines including interleukin-1beta (IL-1beta) and suppressed glial glutamate transporter activities.	Paclitaxel	48-53	interleukin 1 beta	Homo sapiens	147-164
24376711-0	2013	Induction of paclitaxel resistance by ERalpha mediated prohibitin mitochondrial-nuclear shuttling.	Paclitaxel	13-23	estrogen receptor 1	Homo sapiens	38-45
24376711-5	2013	We found that small interfering RNA mediated knockdown of ERalpha lead to a decrease in E2 induced Paclitaxel resistance in androgen-independent cells.	Paclitaxel	99-109	estrogen receptor 1	Homo sapiens	58-65
24376711-6	2013	We also showed that ERalpha mediated the effects of estrogen, thereby suppressing androgen-independent cell proliferation and mediating Paclitaxel resistance.	Paclitaxel	136-146	estrogen receptor 1	Homo sapiens	20-27
24376711-8	2013	Additionally, restoration of Paclitaxel sensitivity by ERalpha knockdown could be overcome by PHB overexpression and, conversely, PHB knockdown decreased E2 induced Paclitaxel resistance.	Paclitaxel	29-39	estrogen receptor 1	Homo sapiens	55-62
24070631-8	2013	The taxol-induced increased GSK3beta activities and decreased AKT and mTOR activities in the spinal dorsal horn were also reversed by lithium.	Paclitaxel	4-9	AKT serine/threonine kinase 1	Homo sapiens	62-65
24070631-8	2013	The taxol-induced increased GSK3beta activities and decreased AKT and mTOR activities in the spinal dorsal horn were also reversed by lithium.	Paclitaxel	4-9	mechanistic target of rapamycin kinase	Homo sapiens	70-74
24070631-3	2013	Two known critical spinal mechanisms underlying taxol-induced neuropathic pain are an increased production of pro-inflammatory cytokines including interleukin-1beta (IL-1beta) and suppressed glial glutamate transporter activities.	Paclitaxel	48-53	interleukin 1 beta	Homo sapiens	166-174
24070812-8	2013	Paclitaxel significantly increased the mRNA expression of 5-HT1A receptor in the dorsal root ganglia, but not in the spinal dorsal horn.	Paclitaxel	0-10	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	58-73
24097825-7	2013	Importantly, binding of endogenous Bcl-2 to Bim also increased during mitosis, when Bcl-2 is endogenously phosphorylated, and disruption of this mitotic Bcl-2/Bim binding with navitoclax or ABT-199, like Bcl-2 downregulation, enhanced the cytotoxicity of paclitaxel.	Paclitaxel	255-265	BCL2 apoptosis regulator	Homo sapiens	35-40
24349321-12	2013	Paclitaxel, androgen, and inhibitors for PI3K/Akt, EGFR, Src, or Bcl-2 seem to be potential choices for treatment of advanced prostate cancers.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	46-49
24349321-12	2013	Paclitaxel, androgen, and inhibitors for PI3K/Akt, EGFR, Src, or Bcl-2 seem to be potential choices for treatment of advanced prostate cancers.	Paclitaxel	0-10	epidermal growth factor receptor	Homo sapiens	51-55
24349321-12	2013	Paclitaxel, androgen, and inhibitors for PI3K/Akt, EGFR, Src, or Bcl-2 seem to be potential choices for treatment of advanced prostate cancers.	Paclitaxel	0-10	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	57-60
24349321-12	2013	Paclitaxel, androgen, and inhibitors for PI3K/Akt, EGFR, Src, or Bcl-2 seem to be potential choices for treatment of advanced prostate cancers.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	65-70
23941826-7	2013	Yg-3-46a was found to be a poorer substrate of P-gp compared to paclitaxel, in both binding and ATPase experiments, which is likely responsible for its ability to circumvent P-gp mediated multidrug resistance (MDR).	Paclitaxel	64-74	ATP binding cassette subfamily B member 1	Homo sapiens	174-178
24219296-3	2013	In this study, protein levels of PDCD5 were found to be up-regulated in paclitaxel-treated MDA-MB-231 breast cancer cells.	Paclitaxel	72-82	programmed cell death 5	Homo sapiens	33-38
24100466-0	2013	Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor.	Paclitaxel	11-21	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	71-76
24141649-11	2013	SNU-1528 had an in-frame deletion of 42 base pairs of p53 gene and showed over 20-fold resistance for taxol compared to the other cell lines.	Paclitaxel	102-107	tumor protein p53	Homo sapiens	54-57
23870999-7	2013	Finally, piperine pretreatment enhanced sensitization to paclitaxel killing in HER2-overexpressing breast cancer cells.	Paclitaxel	57-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-83
24090921-8	2013	It seems that by using ibuprofen in concomitant with potent P-gp inhibitors before PCT solution, oral delivery of PCT could be promising.	Paclitaxel	114-117	phosphoglycolate phosphatase	Rattus norvegicus	60-64
24100466-2	2013	In the present study, we investigated the association between COX-2 and MDR1 expression in endometrial cancers and evaluated the effects of the COX-2 inhibitor, etodolac, in combination with paclitaxel on paclitaxel-resistant endometrial cancer cells.	Paclitaxel	205-215	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	144-149
24100466-11	2013	In OMC-2 cells, COX-2 and MDR1 mRNA levels were significantly upregulated by paclitaxel treatment and downregulated by co-administration with etodolac.	Paclitaxel	77-87	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	16-21
24100466-11	2013	In OMC-2 cells, COX-2 and MDR1 mRNA levels were significantly upregulated by paclitaxel treatment and downregulated by co-administration with etodolac.	Paclitaxel	77-87	ATP binding cassette subfamily B member 1	Homo sapiens	26-30
24100466-12	2013	In OMC-2P cells, COX-2 mRNA expression was also significantly upregulated by paclitaxel treatment and tended to be downregulated by co-administration with etodolac.	Paclitaxel	77-87	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	17-22
24100466-13	2013	Moreover, co-administration of paclitaxel and etodolac suppressed the induction of MDR1 mRNA.	Paclitaxel	31-41	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
24100466-17	2013	These findings suggest that paclitaxel resistance may be associated with COX-2 and MDR1 expression in cancer cells.	Paclitaxel	28-38	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	73-78
24100466-17	2013	These findings suggest that paclitaxel resistance may be associated with COX-2 and MDR1 expression in cancer cells.	Paclitaxel	28-38	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
24100466-18	2013	Co-administration of COX-2 inhibitors and paclitaxel may have a key role in modulating or overcoming paclitaxel resistance in endometrial cancers.	Paclitaxel	101-111	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	21-26
24260253-4	2013	Docetaxel (Doc) and paclitaxel (Pac) agents showed different effects on LNCaP and LNb4 evidenced by alteration in the protein and mRNA levels of c-jun, AR and PSA.	Paclitaxel	20-30	androgen receptor	Homo sapiens	152-154
24294361-10	2013	The first three pathways were predicted to be suppressed, while the last two pathways were predicted to be induced by paclitaxel, suggesting the combination therapy with mTOR inhibition and paclitaxel might be better than single one.	Paclitaxel	118-128	mechanistic target of rapamycin kinase	Homo sapiens	170-174
24223161-0	2013	Fhit delocalizes annexin a4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel.	Paclitaxel	96-106	annexin A4	Homo sapiens	17-27
24223161-4	2013	Here we report that overexpression of Fhit prevents Annexin A4 translocation from cytosol to plasma membrane in A549 lung cancer cells treated with paclitaxel.	Paclitaxel	148-158	annexin A4	Homo sapiens	52-62
23090204-7	2013	We developed anti-KDEL functionalized polymeric nanoparticles (NPs) loaded with paclitaxel (Tx) to specifically target prostate cancer cells expressing GRP78.	Paclitaxel	80-90	heat shock protein family A (Hsp70) member 5	Homo sapiens	152-157
24076228-0	2013	Encapsulation of paclitaxel into lauric acid-O-carboxymethyl chitosan-transferrin micelles for hydrophobic drug delivery and site-specific targeted delivery.	Paclitaxel	17-27	transferrin	Homo sapiens	70-81
24016618-10	2013	Mifepristone also antagonized GR-induced SGK1 and MKP1/DUSP1 gene expression while significantly augmenting paclitaxel-induced GR+ MDA-MB-231 xenograft tumor shrinkage in vivo.	Paclitaxel	108-118	nuclear receptor subfamily 3, group C, member 1	Mus musculus	30-32
24016618-10	2013	Mifepristone also antagonized GR-induced SGK1 and MKP1/DUSP1 gene expression while significantly augmenting paclitaxel-induced GR+ MDA-MB-231 xenograft tumor shrinkage in vivo.	Paclitaxel	108-118	nuclear receptor subfamily 3, group C, member 1	Mus musculus	127-129
24114859-5	2013	Furthermore, higher methylation within the ESR1 gene was associated with CA125 response (odds ratio, OR = 1.06, q = 0.04) and with neuropathy (HR = 0.95, q = 0.002), but only in the paclitaxel arm of the trial.	Paclitaxel	182-192	estrogen receptor 1	Homo sapiens	43-47
23735541-0	2013	Apoptosis induced by paclitaxel via Bcl-2, Bax and caspases 3 and 9 activation in NB4 human leukaemia cells is not modulated by ERK inhibition.	Paclitaxel	21-31	BCL2 apoptosis regulator	Homo sapiens	36-41
23735541-0	2013	Apoptosis induced by paclitaxel via Bcl-2, Bax and caspases 3 and 9 activation in NB4 human leukaemia cells is not modulated by ERK inhibition.	Paclitaxel	21-31	BCL2 associated X, apoptosis regulator	Homo sapiens	43-46
23735541-0	2013	Apoptosis induced by paclitaxel via Bcl-2, Bax and caspases 3 and 9 activation in NB4 human leukaemia cells is not modulated by ERK inhibition.	Paclitaxel	21-31	caspase 3	Homo sapiens	51-67
23735541-7	2013	When these cells were preincubated for 90min with 20muM PD98059, 2"-amino-3"-methoxyflavone, an inhibitor of ERK phosphorylation, a slight reduction of cell viability was observed in comparison to that produced by Ptx alone.	Paclitaxel	214-217	mitogen-activated protein kinase 1	Homo sapiens	109-112
23735541-10	2013	Decrease of p53 and Bcl-2, fragmentation of DNA, increase of Bax and, finally, activation of caspases 3 and 9 in NB4 leukaemia cells make the apoptotic process induced by Ptx irreversible.	Paclitaxel	171-174	tumor protein p53	Homo sapiens	12-15
23735541-10	2013	Decrease of p53 and Bcl-2, fragmentation of DNA, increase of Bax and, finally, activation of caspases 3 and 9 in NB4 leukaemia cells make the apoptotic process induced by Ptx irreversible.	Paclitaxel	171-174	BCL2 apoptosis regulator	Homo sapiens	20-25
23735541-10	2013	Decrease of p53 and Bcl-2, fragmentation of DNA, increase of Bax and, finally, activation of caspases 3 and 9 in NB4 leukaemia cells make the apoptotic process induced by Ptx irreversible.	Paclitaxel	171-174	BCL2 associated X, apoptosis regulator	Homo sapiens	61-64
24002547-16	2013	Bcl-2, Bax, Procaspase-3 and P-gp are involved in the resistance of cell lines to PTX, which are invaluable tools to study the resistance of anticancer drugs and to identify the methods to overcome resistance.	Paclitaxel	82-85	BCL2 apoptosis regulator	Homo sapiens	0-5
24002547-16	2013	Bcl-2, Bax, Procaspase-3 and P-gp are involved in the resistance of cell lines to PTX, which are invaluable tools to study the resistance of anticancer drugs and to identify the methods to overcome resistance.	Paclitaxel	82-85	BCL2 associated X, apoptosis regulator	Homo sapiens	7-10
24002547-16	2013	Bcl-2, Bax, Procaspase-3 and P-gp are involved in the resistance of cell lines to PTX, which are invaluable tools to study the resistance of anticancer drugs and to identify the methods to overcome resistance.	Paclitaxel	82-85	caspase 3	Homo sapiens	12-24
23917345-12	2013	CONCLUSIONS: Our findings suggest that Akt inhibition augments the efficacy of existing gastric cancer therapeutics (carboplatinum and paclitaxel); thus, MK-2206 is a promising agent to treat gastric cancer patients who receive these cytotoxic agents.	Paclitaxel	135-145	AKT serine/threonine kinase 1	Homo sapiens	39-42
23553437-6	2013	We show that specific blocking of IL-4 and IL-13-mediated STAT6 activation by either an IL-4-binding fusion protein APG598 or an IL-4R antagonist APG201 (R121D/Y124D) renders HL cells more prone to apoptotic killing by chemotherapeutic drugs such as Mitomycin C, 5-Fluorouracil, Etopside, Doxorubicin and Paclitaxel.	Paclitaxel	305-315	interleukin 4	Homo sapiens	34-38
23553437-6	2013	We show that specific blocking of IL-4 and IL-13-mediated STAT6 activation by either an IL-4-binding fusion protein APG598 or an IL-4R antagonist APG201 (R121D/Y124D) renders HL cells more prone to apoptotic killing by chemotherapeutic drugs such as Mitomycin C, 5-Fluorouracil, Etopside, Doxorubicin and Paclitaxel.	Paclitaxel	305-315	interleukin 13	Homo sapiens	43-48
23553437-6	2013	We show that specific blocking of IL-4 and IL-13-mediated STAT6 activation by either an IL-4-binding fusion protein APG598 or an IL-4R antagonist APG201 (R121D/Y124D) renders HL cells more prone to apoptotic killing by chemotherapeutic drugs such as Mitomycin C, 5-Fluorouracil, Etopside, Doxorubicin and Paclitaxel.	Paclitaxel	305-315	interleukin 4	Homo sapiens	88-92
24062525-0	2013	Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.	Paclitaxel	58-68	Y-box binding protein 1	Homo sapiens	44-48
24223926-6	2013	Additional modules from the HER2 transcriptome model, including ubiquitin-mediated proteolysis, TGF-beta signaling, RHO-family GTPase signaling, and M-phase progression, were linked to response to lapatinib and paclitaxel in vitro and/or risk of relapse in the N9831 dataset.	Paclitaxel	211-221	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
24255856-4	2013	Here, we showed that the overexpression of p31(comet) can abolish the Mad2-dependent SAC that is induced by anti-mitotic drugs, including nocodazole, taxol, and monastrol; these drugs, except monastrol, cause aneuploidy in HeLa cells.	Paclitaxel	150-155	ATPase H+ transporting V1 subunit E1	Homo sapiens	43-46
24255856-7	2013	Moreover, overexpression of p31(comet) led to resistance against apoptosis that was induced by nocodazole and taxol in human cells, and taxol resistance was dependent on the p31(comet)/Mad2 protein expression level ratio of in cancer cell lines.	Paclitaxel	110-115	ATPase H+ transporting V1 subunit E1	Homo sapiens	28-31
24255856-7	2013	Moreover, overexpression of p31(comet) led to resistance against apoptosis that was induced by nocodazole and taxol in human cells, and taxol resistance was dependent on the p31(comet)/Mad2 protein expression level ratio of in cancer cell lines.	Paclitaxel	136-141	ATPase H+ transporting V1 subunit E1	Homo sapiens	28-31
24255856-7	2013	Moreover, overexpression of p31(comet) led to resistance against apoptosis that was induced by nocodazole and taxol in human cells, and taxol resistance was dependent on the p31(comet)/Mad2 protein expression level ratio of in cancer cell lines.	Paclitaxel	136-141	ATPase H+ transporting V1 subunit E1	Homo sapiens	174-177
24022482-3	2013	In the present study, we examined the activity of purified CCP5 toward synthetic peptides as well as soluble alpha- and beta-tubulin and paclitaxel-stabilized microtubules using a combination of antisera and mass spectrometry to detect the products.	Paclitaxel	137-147	ATP/GTP binding protein-like 5	Mus musculus	59-63
23726937-0	2013	Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy.	Paclitaxel	120-130	C-C motif chemokine receptor 2	Homo sapiens	73-77
24101324-0	2013	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.	Paclitaxel	60-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
24101324-10	2013	These findings suggest that the combination of everolimus plus trastuzumab and paclitaxel is feasible, with promising activity in patients with highly resistant HER2-positive advanced breast cancer.	Paclitaxel	79-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	161-165
24062525-12	2013	CONCLUSIONS: We have identified a novel pathway whereby FAK inhibition with VS-6063 overcomes YB-1-mediated paclitaxel resistance by an AKT-dependent pathway.	Paclitaxel	108-118	Y-box binding protein 1	Homo sapiens	94-98
24062525-12	2013	CONCLUSIONS: We have identified a novel pathway whereby FAK inhibition with VS-6063 overcomes YB-1-mediated paclitaxel resistance by an AKT-dependent pathway.	Paclitaxel	108-118	AKT serine/threonine kinase 1	Homo sapiens	136-139
24137413-8	2013	The expression levels of miR-21 and P-gp were upregulated to a greater extent in the paclitaxel-resistant ovarian cancer A2780/taxol cell line compared with the parental A2780 cell line.	Paclitaxel	85-95	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
23921446-7	2013	However, knockdown of gp100/PMEL sensitized the cells to both paclitaxel and cisplatin.	Paclitaxel	62-72	premelanosome protein	Homo sapiens	22-27
23921446-7	2013	However, knockdown of gp100/PMEL sensitized the cells to both paclitaxel and cisplatin.	Paclitaxel	62-72	premelanosome protein	Homo sapiens	28-32
23900609-2	2013	Our previous results that a high amount of RhoA was detected in gastric cancer cell nucleus and application of anticancer drug Taxol could reduce RhoA nuclear localization, suggest a relationship between nuclear translocation of RhoA and tumor progression.	Paclitaxel	127-132	ras homolog family member A	Homo sapiens	43-47
23900609-2	2013	Our previous results that a high amount of RhoA was detected in gastric cancer cell nucleus and application of anticancer drug Taxol could reduce RhoA nuclear localization, suggest a relationship between nuclear translocation of RhoA and tumor progression.	Paclitaxel	127-132	ras homolog family member A	Homo sapiens	146-150
23900609-2	2013	Our previous results that a high amount of RhoA was detected in gastric cancer cell nucleus and application of anticancer drug Taxol could reduce RhoA nuclear localization, suggest a relationship between nuclear translocation of RhoA and tumor progression.	Paclitaxel	127-132	ras homolog family member A	Homo sapiens	146-150
24088129-2	2013	We determined the frequency of polymorphisms in the CYP2D6 gene associated with activation of tamoxifen, and those of the genes CYP2C8, CYP3A5 and DPYD associated with toxicity of paclitaxel and capecitabine.	Paclitaxel	180-190	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	136-142
24155780-1	2013	We examined the feasibility and safety of using paclitaxel and trastuzumab as maintenance therapy after high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (AHST) for patients with HER2-positive metastatic breast cancer.	Paclitaxel	48-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	214-218
24155780-17	2013	Our findings indicate that paclitaxel plus trastuzumab as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results.	Paclitaxel	27-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
23851981-6	2013	RESULTS: The sequential use of gefitinib and paclitaxel to treat EGFR over-expressing A431 cells in vitro decreased repopulation compared to chemotherapy alone, and there was greater cell kill compared to concurrent treatment.	Paclitaxel	45-55	epidermal growth factor receptor	Homo sapiens	65-69
23810466-14	2013	CONCLUSION: Weekly paclitaxel combined with S-1 is an active and well-tolerated regimen, supporting the view that S-1 can be an alternative for infusional 5-fluorouracil for advanced gastric cancer.	Paclitaxel	19-29	proteasome 26S subunit, non-ATPase 1	Homo sapiens	114-117
24137436-5	2013	The present study determined whether low-dose PTX was able to inhibit EMT in a human cholangiocarcinoma CCKS-1 cell line that had been treated with TGF-beta1.	Paclitaxel	46-49	transforming growth factor beta 1	Homo sapiens	148-157
23708960-0	2013	CARMA3 overexpression accelerates cell proliferation and inhibits paclitaxel-induced apoptosis through NF-kappaB regulation in breast cancer cells.	Paclitaxel	66-76	nuclear factor kappa B subunit 1	Homo sapiens	103-112
23851981-0	2013	Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor.	Paclitaxel	14-24	epidermal growth factor receptor	Homo sapiens	143-175
23861345-7	2013	The reduction of BCL-2 expression in endocrine-resistant cells lowered their apoptotic threshold to antimitotic agents: nocodazole, paclitaxel, and the PLK1 inhibitor BI2536.	Paclitaxel	132-142	BCL2 apoptosis regulator	Homo sapiens	17-22
23661607-4	2013	Significantly, it was recently found that the anti-tumor effect of paclitaxel in CRPC is due to its inhibition of AR activity via its inhibition of microtubule dynamics.	Paclitaxel	67-77	androgen receptor	Homo sapiens	114-116
23661607-7	2013	METHODS: We compared paclitaxel-mediated phenotypes (inhibition of the AR signaling, decrease of microtubule dynamics and cell death) of PCa cells expressing different forms of CLIP-170 and p150(Glued) with different Plk1 phosphorylation states.	Paclitaxel	21-31	androgen receptor	Homo sapiens	71-73
23978876-6	2013	Further, resistance to paclitaxel-induced cell death was associated with high gremlin-1 and slug expression.	Paclitaxel	23-33	gremlin 1, DAN family BMP antagonist	Homo sapiens	78-87
23978876-7	2013	Treatment of gremlin-1-silenced mesothelioma cells with paclitaxel or pemetrexed resulted in efficient loss of cell survival.	Paclitaxel	56-66	gremlin 1, DAN family BMP antagonist	Homo sapiens	13-22
23869765-8	2013	Finally, PI3K/AKT pathway inhibitor LY294002 reduced expressions of mesenchymal markers and stem-cell gene activity in spheroid cells, enhancing sensitivity of spheroid cells to paclitaxel treatment.	Paclitaxel	178-188	AKT serine/threonine kinase 1	Homo sapiens	14-17
23936348-6	2013	CONCLUSIONS: In light of the absence of treatment effect associated with sorafenib, the association found between FGF-R1 and VEGF-R1 expression and OS, PFS and response might reflect a predictive biomarker signature for carboplatin/paclitaxel-based therapy.	Paclitaxel	232-242	fibroblast growth factor receptor 1	Homo sapiens	114-120
23936348-6	2013	CONCLUSIONS: In light of the absence of treatment effect associated with sorafenib, the association found between FGF-R1 and VEGF-R1 expression and OS, PFS and response might reflect a predictive biomarker signature for carboplatin/paclitaxel-based therapy.	Paclitaxel	232-242	fms related receptor tyrosine kinase 1	Homo sapiens	125-132
23967091-0	2013	Low-dose paclitaxel ameliorates pulmonary fibrosis by suppressing TGF-beta1/Smad3 pathway via miR-140 upregulation.	Paclitaxel	9-19	transforming growth factor, beta 1	Rattus norvegicus	66-75
23967091-0	2013	Low-dose paclitaxel ameliorates pulmonary fibrosis by suppressing TGF-beta1/Smad3 pathway via miR-140 upregulation.	Paclitaxel	9-19	SMAD family member 3	Rattus norvegicus	76-81
23967091-0	2013	Low-dose paclitaxel ameliorates pulmonary fibrosis by suppressing TGF-beta1/Smad3 pathway via miR-140 upregulation.	Paclitaxel	9-19	microRNA 140	Rattus norvegicus	94-101
23967091-1	2013	Abnormal TGF-beta1/Smad3 activation plays an important role in the pathogenesis of pulmonary fibrosis, which can be prevented by paclitaxel (PTX).	Paclitaxel	129-139	transforming growth factor, beta 1	Rattus norvegicus	9-18
23967091-1	2013	Abnormal TGF-beta1/Smad3 activation plays an important role in the pathogenesis of pulmonary fibrosis, which can be prevented by paclitaxel (PTX).	Paclitaxel	129-139	SMAD family member 3	Rattus norvegicus	19-24
23967091-1	2013	Abnormal TGF-beta1/Smad3 activation plays an important role in the pathogenesis of pulmonary fibrosis, which can be prevented by paclitaxel (PTX).	Paclitaxel	141-144	transforming growth factor, beta 1	Rattus norvegicus	9-18
23967091-1	2013	Abnormal TGF-beta1/Smad3 activation plays an important role in the pathogenesis of pulmonary fibrosis, which can be prevented by paclitaxel (PTX).	Paclitaxel	141-144	SMAD family member 3	Rattus norvegicus	19-24
23967091-3	2013	PTX treatment resulted in phenotype reversion of epithelial-mesenchymal transition (EMT) in alveolar epithelial cells (AECs) with increase of miR-140.	Paclitaxel	0-3	microRNA 140	Rattus norvegicus	142-149
23967091-5	2013	Our results further demonstrated that PTX inhibited the effect of TGF-beta1 on regulating the expression of Smad3 and phosphorylated Smad3 (p-Smad3), and restored the levels of E-cadherin, vimentin and alpha-SMA.	Paclitaxel	38-41	transforming growth factor, beta 1	Rattus norvegicus	66-75
23967091-5	2013	Our results further demonstrated that PTX inhibited the effect of TGF-beta1 on regulating the expression of Smad3 and phosphorylated Smad3 (p-Smad3), and restored the levels of E-cadherin, vimentin and alpha-SMA.	Paclitaxel	38-41	SMAD family member 3	Rattus norvegicus	108-113
23967091-5	2013	Our results further demonstrated that PTX inhibited the effect of TGF-beta1 on regulating the expression of Smad3 and phosphorylated Smad3 (p-Smad3), and restored the levels of E-cadherin, vimentin and alpha-SMA.	Paclitaxel	38-41	SMAD family member 3	Rattus norvegicus	133-138
23967091-5	2013	Our results further demonstrated that PTX inhibited the effect of TGF-beta1 on regulating the expression of Smad3 and phosphorylated Smad3 (p-Smad3), and restored the levels of E-cadherin, vimentin and alpha-SMA.	Paclitaxel	38-41	SMAD family member 3	Rattus norvegicus	133-138
23967091-7	2013	Through decreasing Smad3/p-Smad3 expression and upregulating miR-140, PTX treatment could significantly reverse the EMT of AECs and prevent pulmonary fibrosis of rats.	Paclitaxel	70-73	SMAD family member 3	Rattus norvegicus	19-24
23967091-7	2013	Through decreasing Smad3/p-Smad3 expression and upregulating miR-140, PTX treatment could significantly reverse the EMT of AECs and prevent pulmonary fibrosis of rats.	Paclitaxel	70-73	microRNA 140	Rattus norvegicus	61-68
23967091-8	2013	The action of PTX to ameliorate TGF-beta1-induced EMT was promoted by miR-140, which increased E-cadherin levels and reduced the expression of vimentin, Smad3 and p-Smad3.	Paclitaxel	14-17	transforming growth factor, beta 1	Rattus norvegicus	32-41
23967091-8	2013	The action of PTX to ameliorate TGF-beta1-induced EMT was promoted by miR-140, which increased E-cadherin levels and reduced the expression of vimentin, Smad3 and p-Smad3.	Paclitaxel	14-17	microRNA 140	Rattus norvegicus	70-77
23967091-8	2013	The action of PTX to ameliorate TGF-beta1-induced EMT was promoted by miR-140, which increased E-cadherin levels and reduced the expression of vimentin, Smad3 and p-Smad3.	Paclitaxel	14-17	SMAD family member 3	Rattus norvegicus	153-158
23967091-8	2013	The action of PTX to ameliorate TGF-beta1-induced EMT was promoted by miR-140, which increased E-cadherin levels and reduced the expression of vimentin, Smad3 and p-Smad3.	Paclitaxel	14-17	SMAD family member 3	Rattus norvegicus	165-170
23967091-9	2013	Collectively, our results demonstrate that low-dose PTX prevents pulmonary fibrosis by suppressing the TGF-beta1/Smad3 pathway via upregulating miR-140.	Paclitaxel	52-55	transforming growth factor, beta 1	Rattus norvegicus	103-112
23967091-9	2013	Collectively, our results demonstrate that low-dose PTX prevents pulmonary fibrosis by suppressing the TGF-beta1/Smad3 pathway via upregulating miR-140.	Paclitaxel	52-55	SMAD family member 3	Rattus norvegicus	113-118
23967091-9	2013	Collectively, our results demonstrate that low-dose PTX prevents pulmonary fibrosis by suppressing the TGF-beta1/Smad3 pathway via upregulating miR-140.	Paclitaxel	52-55	microRNA 140	Rattus norvegicus	144-151
23967153-3	2013	Present study assessed a new use of GSP on the MDR reversal activity and its possible molecular mechanisms in MDR1-overpressing paclitaxel resistant ovarian cancer cells.	Paclitaxel	128-138	ATP binding cassette subfamily B member 1	Homo sapiens	110-114
23860537-14	2013	CONCLUSION: The MTD for lenvatinib with carboplatin/paclitaxel is 4 mg BID in advanced NSCLC patients.	Paclitaxel	52-62	BH3 interacting domain death agonist	Homo sapiens	71-74
23474915-7	2013	CONCLUSION: In the rat common carotid artery injury model, the short-term delivery of paclitaxel could effectively inhibit neointimal hyperplasia in the long term, with very little influence on the local expression of TF and PAI-1.	Paclitaxel	86-96	serpin family E member 1	Rattus norvegicus	225-230
23913603-0	2013	Long-term clinical performance of paclitaxel-eluting stents coated with a bioactive polymer (P-5) containing a triflusal derivative: results of the REWAC registry.	Paclitaxel	34-44	solute carrier family 10 member 5	Homo sapiens	93-96
24659938-5	2014	In an experimental model of lung cancer, the triterpenoids activated the Nrf2 pathway, as seen by induction of the cytoprotective enzyme NQO1, and reduced the toxicity of carboplatin and paclitaxel.	Paclitaxel	187-197	NFE2 like bZIP transcription factor 2	Homo sapiens	73-77
23802633-4	2013	On the other hand, the amount of BCL2, an anti-apoptotic protein, was well correlated with paclitaxel resistance.	Paclitaxel	91-101	BCL2 apoptosis regulator	Homo sapiens	33-37
23802633-5	2013	Treatment of the paclitaxel-resistant cell lines with ABT-737, an inhibitor of BCL2 and BCLxL, or simultaneous knock-down of BCL2 and BCLxL dramatically increased the cells" sensitivity, while knock-down of MCL1, another member of the BCL2 family, had only a minimal effect.	Paclitaxel	17-27	BCL2 apoptosis regulator	Homo sapiens	79-83
23802633-5	2013	Treatment of the paclitaxel-resistant cell lines with ABT-737, an inhibitor of BCL2 and BCLxL, or simultaneous knock-down of BCL2 and BCLxL dramatically increased the cells" sensitivity, while knock-down of MCL1, another member of the BCL2 family, had only a minimal effect.	Paclitaxel	17-27	BCL2 like 1	Homo sapiens	88-93
23802633-5	2013	Treatment of the paclitaxel-resistant cell lines with ABT-737, an inhibitor of BCL2 and BCLxL, or simultaneous knock-down of BCL2 and BCLxL dramatically increased the cells" sensitivity, while knock-down of MCL1, another member of the BCL2 family, had only a minimal effect.	Paclitaxel	17-27	BCL2 apoptosis regulator	Homo sapiens	125-129
23802633-5	2013	Treatment of the paclitaxel-resistant cell lines with ABT-737, an inhibitor of BCL2 and BCLxL, or simultaneous knock-down of BCL2 and BCLxL dramatically increased the cells" sensitivity, while knock-down of MCL1, another member of the BCL2 family, had only a minimal effect.	Paclitaxel	17-27	BCL2 like 1	Homo sapiens	134-139
23802633-5	2013	Treatment of the paclitaxel-resistant cell lines with ABT-737, an inhibitor of BCL2 and BCLxL, or simultaneous knock-down of BCL2 and BCLxL dramatically increased the cells" sensitivity, while knock-down of MCL1, another member of the BCL2 family, had only a minimal effect.	Paclitaxel	17-27	BCL2 apoptosis regulator	Homo sapiens	125-129
24137188-8	2013	CEA, CA 125 and CA 19-9 expression was only associated with a positive response in patients receiving paclitaxel, docetaxel, pemetrexed and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).	Paclitaxel	102-112	CEA cell adhesion molecule 3	Homo sapiens	0-3
23913603-2	2013	We evaluated clinical performance of paclitaxel-eluting stents coated with a new bioactive polymer system (P-5) based on a copolymer of an acrylic derivative of triflusal in patients with coronary artery disease.	Paclitaxel	37-47	solute carrier family 10 member 5	Homo sapiens	107-110
23913603-8	2013	CONCLUSION: Under routine clinical practice, the implantation of paclitaxel-eluting stents coated with P-5 is associated with favorable clinical outcomes in both the short and long term (2 years) in patients with coronary artery disease.	Paclitaxel	65-75	solute carrier family 10 member 5	Homo sapiens	103-106
22996305-1	2013	In our previous reports, Wuzhi tablet (an herbal preparation of ethanol extract of Wuweizi (Schisandra sphenanthera)) can significantly increase the blood concentration of tacrolimus and paclitaxel in rats by inhibiting the CYP3A-mediated metabolism and the P-gp-mediated efflux.	Paclitaxel	187-197	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	224-229
24137360-0	2013	Synergy of Taxol and rhein lysinate associated with the downregulation of ERK activation in lung carcinoma cells.	Paclitaxel	11-16	mitogen-activated protein kinase 1	Homo sapiens	74-77
24137360-8	2013	RHL potentiated Taxol-induced cell killing by reducing extracellular signal-regulated kinase (ERK) activity and increasing the levels of cleaved poly(ADP-ribose) polymerase (PARP) and caspase-3.	Paclitaxel	16-21	mitogen-activated protein kinase 1	Homo sapiens	55-92
24137360-8	2013	RHL potentiated Taxol-induced cell killing by reducing extracellular signal-regulated kinase (ERK) activity and increasing the levels of cleaved poly(ADP-ribose) polymerase (PARP) and caspase-3.	Paclitaxel	16-21	mitogen-activated protein kinase 1	Homo sapiens	94-97
24137360-8	2013	RHL potentiated Taxol-induced cell killing by reducing extracellular signal-regulated kinase (ERK) activity and increasing the levels of cleaved poly(ADP-ribose) polymerase (PARP) and caspase-3.	Paclitaxel	16-21	poly(ADP-ribose) polymerase 1	Homo sapiens	145-172
24137360-8	2013	RHL potentiated Taxol-induced cell killing by reducing extracellular signal-regulated kinase (ERK) activity and increasing the levels of cleaved poly(ADP-ribose) polymerase (PARP) and caspase-3.	Paclitaxel	16-21	poly(ADP-ribose) polymerase 1	Homo sapiens	174-178
24137360-8	2013	RHL potentiated Taxol-induced cell killing by reducing extracellular signal-regulated kinase (ERK) activity and increasing the levels of cleaved poly(ADP-ribose) polymerase (PARP) and caspase-3.	Paclitaxel	16-21	caspase 3	Homo sapiens	184-193
23778521-0	2013	miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer.	Paclitaxel	35-45	microRNA 375	Homo sapiens	0-7
23735077-8	2013	Furthermore, the ABCB1 inhibitor verapamil (10 muM) effectively reversed doxorubicin and paclitaxel resistance by 90- and 200-fold, respectively.	Paclitaxel	89-99	ATP binding cassette subfamily B member 1	Homo sapiens	17-22
23735077-8	2013	Furthermore, the ABCB1 inhibitor verapamil (10 muM) effectively reversed doxorubicin and paclitaxel resistance by 90- and 200-fold, respectively.	Paclitaxel	89-99	latexin	Homo sapiens	47-50
23684934-6	2013	Digoxin, vinblastine and paclitaxel, established P-gp substrates inhibited transport of NMQ with estimated K(i) values of 250, 0.1 and 0.6 muM, respectively.	Paclitaxel	25-35	latexin	Homo sapiens	139-142
23936594-1	2013	CYP3A4 is a key enzyme involved in the metabolism of numerous compounds, such as paclitaxel, and its activity shows an extensive inter-individual variation which can influence treatment response.	Paclitaxel	81-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
23936594-2	2013	The study"s purpose was to investigate the potential predictive role of a CYP3A4 profile (CYP3A4*1B, rs2740574 and CYP3A4*22, rs35599367) in serous ovarian cancer patients treated with first-line chemotherapy (paclitaxel and cisplatin or carboplatin), after cytoreductive surgery.	Paclitaxel	210-220	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-80
23799854-8	2013	We also demonstrated that BLT2-induced paclitaxel resistance was associated with the upregulation of P-glycoprotein.	Paclitaxel	39-49	ATP binding cassette subfamily B member 1	Homo sapiens	101-115
23585021-2	2013	Overexpression of tubulin-beta-III and p-glycoprotein has been linked to paclitaxel resistance in many cancers but has been undercharacterized among USCs.	Paclitaxel	73-83	ATP binding cassette subfamily B member 1	Homo sapiens	39-53
23778521-5	2013	We exogenously upregulated miR-375 expression in SiHa and Caski cells using a pre-miRNA lentiviral vector transfection and observed its impact on paclitaxel sensitivity using MTS.	Paclitaxel	146-156	microRNA 375	Homo sapiens	27-34
23778521-8	2013	Of those, miR-375 showed consistent high expression levels across paclitaxel-treated cervical cells and tissues.	Paclitaxel	66-76	microRNA 375	Homo sapiens	10-17
23778521-9	2013	Paclitaxel induced upregulated miR-375 expression in a clear dose-dependent manner.	Paclitaxel	0-10	microRNA 375	Homo sapiens	31-38
23778521-10	2013	Forced overexpression of miR-375 in cervical cancer cells decreased paclitaxel sensitivity in vitro and in vivo.	Paclitaxel	68-78	microRNA 375	Homo sapiens	25-32
23778521-11	2013	CONCLUSION: Collectively, our results suggest that miR-375 might be a therapeutic target in paclitaxel-resistant cervical cancer.	Paclitaxel	92-102	microRNA 375	Homo sapiens	51-58
23583215-12	2013	P-glycoprotein correlated with in vitro paclitaxel resistance, but not clinical outcome.	Paclitaxel	40-50	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
23389639-3	2013	Furthermore, paclitaxel was shown to downregulate VEGF and Ang-1 expression in tumor cells, and to increase the secretion of TSP-1 in the tumor microenvironment.	Paclitaxel	13-23	vascular endothelial growth factor A	Homo sapiens	50-54
23389639-3	2013	Furthermore, paclitaxel was shown to downregulate VEGF and Ang-1 expression in tumor cells, and to increase the secretion of TSP-1 in the tumor microenvironment.	Paclitaxel	13-23	thrombospondin 1	Homo sapiens	125-130
23682812-1	2013	To evaluate a nonanthracycline-containing regimen consisting of 24 weekly administrations of paclitaxel, carboplatin, and trastuzumab as neo-adjuvant therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer.	Paclitaxel	93-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	168-202
23582684-2	2013	In this study, MT1-AF7p peptide, which presents high binding affinity to membrane type-1 matrix metalloproteinase (MT1-MMP) that over-expressed on both angiogenic blood vessels and glioma cells, was employed to decorate the paclitaxel-loaded PEG-PLA nanoparticles (MT1-NP-PTX) to mediate glioblastoma targeting.	Paclitaxel	224-234	metallothionein 1	Mus musculus	15-18
23682812-1	2013	To evaluate a nonanthracycline-containing regimen consisting of 24 weekly administrations of paclitaxel, carboplatin, and trastuzumab as neo-adjuvant therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer.	Paclitaxel	93-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	204-208
23673445-7	2013	The observed reversal effect seems to be primarily due to the decreased active efflux of [3H]-paclitaxel in ABCB1 overexpressing cells observed in efflux assay.	Paclitaxel	94-104	ATP binding cassette subfamily B member 1	Homo sapiens	108-113
23682812-10	2013	A weekly carboplatin-paclitaxel-trastuzumab neo-adjuvant regimen is highly active in HER2-positive breast cancer with an acceptable toxicity profile.	Paclitaxel	21-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
23860928-0	2013	Increased expression of mitotic arrest deficient-like 1 (MAD1L1) is associated with poor prognosis and insensitive to Taxol treatment in breast cancer.	Paclitaxel	118-123	mitotic arrest deficient 1 like 1	Homo sapiens	57-63
23792647-10	2013	Combined CINK4 and paclitaxel produced synergistic anti-proliferative activity and increased apoptosis through reduced cyclin D1 and Bcl-2 in KRAS mutation-positive cancer cells.	Paclitaxel	19-29	BCL2 apoptosis regulator	Homo sapiens	133-138
22935677-1	2013	Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study.	Paclitaxel	98-108	ATP binding cassette subfamily B member 1	Homo sapiens	246-268
22935677-1	2013	Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study.	Paclitaxel	98-108	ATP binding cassette subfamily B member 1	Homo sapiens	270-274
22935677-1	2013	Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study.	Paclitaxel	98-108	ATP binding cassette subfamily B member 1	Homo sapiens	289-303
22935677-1	2013	Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study.	Paclitaxel	98-108	ATP binding cassette subfamily B member 1	Homo sapiens	305-309
23860928-6	2013	Furthermore, patients with high level of MAD1L1 expression (in nuclei) and undergone Taxol chemotherapy treatment have shorter overall survival than ones without Taxol treatment in this study (p = 0.026).	Paclitaxel	85-90	mitotic arrest deficient 1 like 1	Homo sapiens	41-47
23860928-6	2013	Furthermore, patients with high level of MAD1L1 expression (in nuclei) and undergone Taxol chemotherapy treatment have shorter overall survival than ones without Taxol treatment in this study (p = 0.026).	Paclitaxel	162-167	mitotic arrest deficient 1 like 1	Homo sapiens	41-47
23514751-7	2013	Further cell viability studies demonstrate that deletion of FOXO1/3/4 in MEFs can confer sensitivity to both paclitaxel and epirubicin, suggesting that SIRT6 reduces paclitaxel and epirubicin sensitivity, at least in part, through modulating FOXO acetylation and expression.	Paclitaxel	109-119	forkhead box O1	Homo sapiens	60-65
23541564-12	2013	INTERPRETATION: Neoadjuvant therapy with everolimus and paclitaxel for patients with HER2-negative disease unresponsive to EC with or without bevacizumab did not improve the pCR rate.	Paclitaxel	56-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
23514751-7	2013	Further cell viability studies demonstrate that deletion of FOXO1/3/4 in MEFs can confer sensitivity to both paclitaxel and epirubicin, suggesting that SIRT6 reduces paclitaxel and epirubicin sensitivity, at least in part, through modulating FOXO acetylation and expression.	Paclitaxel	166-176	forkhead box O1	Homo sapiens	60-65
23836994-11	2013	CONCLUSION: Bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed provided meaningful and comparable efficacy in advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation.	Paclitaxel	36-46	epidermal growth factor receptor	Homo sapiens	178-182
23852894-5	2013	MATERIALS AND METHODS: The paclitaxel sensitivity of ovarian cancer cell lines HO-8910PM, H0-8910, SKOV-3, OVCAR-3, COC1 and ES-2 were determined by MTT assays.	Paclitaxel	27-37	ess-2 splicing factor homolog	Homo sapiens	125-129
23480726-3	2013	When bound with biotinylated cetuximab these spores could specifically target to the epidermal growth factor receptor on HT 29 colon cancer cells, thereby delivered paclitaxel to the cells with 4-fold higher efficiency, as indicated by fluorescent intensity of paclitaxel Oregon Green 488 bound to HT29 cells.	Paclitaxel	165-175	epidermal growth factor receptor	Homo sapiens	85-117
23480726-4	2013	Based on real-time monitoring of cell index, the IC50 of growth of HT29 cells by paclitaxel-SA1-cetuximab was estimated to be 2.9 nM approximately 5-fold lower than water-soluble paclitaxel (14.5 nM).	Paclitaxel	81-91	stromal antigen 1	Homo sapiens	92-95
23480726-5	2013	Instability of DNA content was observed when cells were treated with 16 nM paclitaxel-SA1-cetuximab, resulting in a 2-fold enhancement in polyploidy cells.	Paclitaxel	75-85	stromal antigen 1	Homo sapiens	86-89
23875078-0	2013	Selective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expression.	Paclitaxel	45-55	ATP binding cassette subfamily B member 1	Homo sapiens	118-132
23875078-1	2013	OBJECTIVE: The purpose of this study was to investigate whether selective cyclooxygenase (COX) inhibitors promote paclitaxel-induced apoptosis in taxane-resistant ovarian cancer cells by suppressing MDR1/P-glycoprotein (P-gp) expression.	Paclitaxel	114-124	ATP binding cassette subfamily B member 1	Homo sapiens	199-203
23875078-1	2013	OBJECTIVE: The purpose of this study was to investigate whether selective cyclooxygenase (COX) inhibitors promote paclitaxel-induced apoptosis in taxane-resistant ovarian cancer cells by suppressing MDR1/P-glycoprotein (P-gp) expression.	Paclitaxel	114-124	ATP binding cassette subfamily B member 1	Homo sapiens	204-218
23875078-9	2013	Moreover, combined treatment with paclitaxel and selective COX inhibitors increased poly (ADP-ribose) polymerase (PARP) cleavage in taxane-resistant ovarian cancer cells.	Paclitaxel	34-44	poly(ADP-ribose) polymerase 1	Homo sapiens	114-118
23875078-11	2013	COX inhibitors could be potent therapeutic tools to promote paclitaxel sensitization of taxane-resistant ovarian cancers by suppressing MDR1/P-gp, which is responsible for the efflux of chemotherapeutic agents.	Paclitaxel	60-70	ATP binding cassette subfamily B member 1	Homo sapiens	136-140
23420555-18	2013	This study raises the possibility that erythropoietin might play a neuroprotective role when administered with paclitaxel.	Paclitaxel	111-121	erythropoietin	Homo sapiens	39-53
23466650-3	2013	Using the MTT assay, we found that DABB and DHBB could enhance the cytotoxicities of ABCB1 substrates doxorubicin, vincristine, and paclitaxel in ABCB1-overexpressing HepG2/ADM and MCF-7/ADR cells, whereas that of a non-ABCB1 substrate cisplatin was unaffected.	Paclitaxel	132-142	ATP binding cassette subfamily B member 1	Homo sapiens	85-90
23785404-6	2013	The ectopic expression of IRF1 markedly promoted paclitaxel-induced apoptosis and inhibited cell viability and colony formation ability, whereas the knockdown of IRF1 had the opposite effects.	Paclitaxel	49-59	interferon regulatory factor 1	Homo sapiens	26-30
23785404-7	2013	The restoration of IRF1 expression counteracted the effects of miR-23a on the paclitaxel-induced apoptosis and cell proliferation of gastric adenocarcinoma cells.	Paclitaxel	78-88	interferon regulatory factor 1	Homo sapiens	19-23
23785404-9	2013	Altogether, these results indicate that miR-23a suppresses paclitaxel-induced apoptosis and promotes cell viability and the colony formation ability of gastric adenocarcinoma cells by targeting IRF1 at the post-transcriptional level.	Paclitaxel	59-69	interferon regulatory factor 1	Homo sapiens	194-198
23761728-0	2013	Withdrawal: Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells.	Paclitaxel	89-99	epithelial cell adhesion molecule	Homo sapiens	59-64
23640974-0	2013	CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.	Paclitaxel	48-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
23640974-6	2013	Genetic variants of paclitaxel pharmacokinetics tested were CYP3A4*22, CYP2C8*3, CYP2C8*4, and ABCB1 3435 C&gt;T. The association between CYP3A4*22 and neurotoxicity observed in the exploratory cohort was validated in an independent patient cohort (n = 239).	Paclitaxel	20-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66
23640974-6	2013	Genetic variants of paclitaxel pharmacokinetics tested were CYP3A4*22, CYP2C8*3, CYP2C8*4, and ABCB1 3435 C&gt;T. The association between CYP3A4*22 and neurotoxicity observed in the exploratory cohort was validated in an independent patient cohort (n = 239).	Paclitaxel	20-30	ATP binding cassette subfamily B member 1	Homo sapiens	95-100
23640974-6	2013	Genetic variants of paclitaxel pharmacokinetics tested were CYP3A4*22, CYP2C8*3, CYP2C8*4, and ABCB1 3435 C&gt;T. The association between CYP3A4*22 and neurotoxicity observed in the exploratory cohort was validated in an independent patient cohort (n = 239).	Paclitaxel	20-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-144
23640974-13	2013	In this study, female CYP3A4*22 carriers had increased risk of developing severe neurotoxicity during paclitaxel therapy.	Paclitaxel	102-112	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-28
23762410-10	2013	BPR0L075 induced cell death in both parental and paclitaxel-resistant ovarian cancer cells proceed through caspase-3 independent mechanisms.	Paclitaxel	49-59	caspase 3	Homo sapiens	107-116
23466650-3	2013	Using the MTT assay, we found that DABB and DHBB could enhance the cytotoxicities of ABCB1 substrates doxorubicin, vincristine, and paclitaxel in ABCB1-overexpressing HepG2/ADM and MCF-7/ADR cells, whereas that of a non-ABCB1 substrate cisplatin was unaffected.	Paclitaxel	132-142	ATP binding cassette subfamily B member 1	Homo sapiens	146-151
23466650-3	2013	Using the MTT assay, we found that DABB and DHBB could enhance the cytotoxicities of ABCB1 substrates doxorubicin, vincristine, and paclitaxel in ABCB1-overexpressing HepG2/ADM and MCF-7/ADR cells, whereas that of a non-ABCB1 substrate cisplatin was unaffected.	Paclitaxel	132-142	ATP binding cassette subfamily B member 1	Homo sapiens	146-151
23782748-2	2013	Organic anion transporting polypeptide 1B3 (OATP1B3) and copper transporter 1 (CTR1) are critical for the uptake of paclitaxel and carboplatin, respectively.	Paclitaxel	116-126	solute carrier organic anion transporter family member 1B3	Homo sapiens	0-42
23782748-0	2013	Prognostic value of organic anion transporting polypeptide 1B3 and copper transporter 1 expression in endometrial cancer patients treated with paclitaxel and carboplatin.	Paclitaxel	143-153	solute carrier organic anion transporter family member 1B3	Homo sapiens	20-62
23782748-2	2013	Organic anion transporting polypeptide 1B3 (OATP1B3) and copper transporter 1 (CTR1) are critical for the uptake of paclitaxel and carboplatin, respectively.	Paclitaxel	116-126	solute carrier organic anion transporter family member 1B3	Homo sapiens	44-51
23500524-0	2013	ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.	Paclitaxel	61-71	notch receptor 1	Homo sapiens	16-22
23562605-3	2013	Paclitaxel-evoked cold hypernociception was assessed in mice by the unilateral cold plate test and the effects on cold hyperalgesia of the CCR2 antagonist RS 504393, the CCR1 antagonist J113863, the microglial inhibitor minocycline or an anti-CCL2 antibody were tested.	Paclitaxel	0-10	chemokine (C-C motif) receptor 1	Mus musculus	170-174
23496232-0	2013	Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.	Paclitaxel	11-21	BCL2 apoptosis regulator	Homo sapiens	90-95
23500524-5	2013	In this study, we confirmed that paclitaxel enriched breast CSCs (CD44+/CD24-) in a dose-dependent manner in MCF-7 human breast cancer cell line.	Paclitaxel	33-43	CD24 molecule	Homo sapiens	72-76
23563171-7	2013	The augmentation of PCX-induced apoptosis by 3-MA was accompanied by increase in the cytochrome c release from the mitochondria, caspase-3 activity and XIAP downregulation, which suggests that inhibiting autophagy further stimulates the PCX-induced mitochondrion-related (intrinsic) apoptotic pathway by provoking caspase-3 activation.	Paclitaxel	20-23	cytochrome c, somatic	Homo sapiens	85-97
23500524-6	2013	We then demonstrated that Notch1 was overexpressed in breast CSCs isolated from paclitaxel-treated MCF-7 cells compared to non-CSCs.	Paclitaxel	80-90	notch receptor 1	Homo sapiens	26-32
23563171-7	2013	The augmentation of PCX-induced apoptosis by 3-MA was accompanied by increase in the cytochrome c release from the mitochondria, caspase-3 activity and XIAP downregulation, which suggests that inhibiting autophagy further stimulates the PCX-induced mitochondrion-related (intrinsic) apoptotic pathway by provoking caspase-3 activation.	Paclitaxel	20-23	caspase 3	Homo sapiens	129-138
23563171-7	2013	The augmentation of PCX-induced apoptosis by 3-MA was accompanied by increase in the cytochrome c release from the mitochondria, caspase-3 activity and XIAP downregulation, which suggests that inhibiting autophagy further stimulates the PCX-induced mitochondrion-related (intrinsic) apoptotic pathway by provoking caspase-3 activation.	Paclitaxel	20-23	caspase 3	Homo sapiens	314-323
23500524-8	2013	The anti-apoptosis protein NF-kappaB was decreased significantly when treated with shRNA-Notch1, and this effect was sharply improved by combination with paclitaxel.	Paclitaxel	154-164	nuclear factor kappa B subunit 1	Homo sapiens	27-36
23500524-8	2013	The anti-apoptosis protein NF-kappaB was decreased significantly when treated with shRNA-Notch1, and this effect was sharply improved by combination with paclitaxel.	Paclitaxel	154-164	notch receptor 1	Homo sapiens	89-95
23500524-9	2013	Paclitaxel decreased CD44+/CD24- cell population in MCF-7 cells and reduced the size and number of primary mammospheres after down-regulating the Notch1.	Paclitaxel	0-10	CD24 molecule	Homo sapiens	27-31
23500524-9	2013	Paclitaxel decreased CD44+/CD24- cell population in MCF-7 cells and reduced the size and number of primary mammospheres after down-regulating the Notch1.	Paclitaxel	0-10	notch receptor 1	Homo sapiens	146-152
23500524-12	2013	These results suggest that Notch1 might play a critical role in the resistance to paclitaxel, and targeting Notch1 may have important clinical applications in cancer therapy.	Paclitaxel	82-92	notch receptor 1	Homo sapiens	27-33
23624503-3	2013	METHODS: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCT116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells).	Paclitaxel	60-70	CD24 molecule	Homo sapiens	81-85
23543364-12	2013	We found that reduced expression and possibly posttranslational modification of SCLIP following paclitaxel treatment impaired the microtubule-destabilizing effect of SCLIP, thereby promoting induction of mitotic arrest and apoptosis by paclitaxel.	Paclitaxel	96-106	stathmin 3	Homo sapiens	80-85
23543364-12	2013	We found that reduced expression and possibly posttranslational modification of SCLIP following paclitaxel treatment impaired the microtubule-destabilizing effect of SCLIP, thereby promoting induction of mitotic arrest and apoptosis by paclitaxel.	Paclitaxel	96-106	stathmin 3	Homo sapiens	166-171
23543364-12	2013	We found that reduced expression and possibly posttranslational modification of SCLIP following paclitaxel treatment impaired the microtubule-destabilizing effect of SCLIP, thereby promoting induction of mitotic arrest and apoptosis by paclitaxel.	Paclitaxel	236-246	stathmin 3	Homo sapiens	80-85
23543364-12	2013	We found that reduced expression and possibly posttranslational modification of SCLIP following paclitaxel treatment impaired the microtubule-destabilizing effect of SCLIP, thereby promoting induction of mitotic arrest and apoptosis by paclitaxel.	Paclitaxel	236-246	stathmin 3	Homo sapiens	166-171
23697602-11	2013	CONCLUSIONS: The dose-limiting toxicity of paclitaxel, trastuzumab, and lapatinib in first-line HER2-positive MBC was diarrhea.	Paclitaxel	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
23580645-7	2013	However, microtubule stabilization by paclitaxel attenuated TGF-beta-induced myofibroblast differentiation.	Paclitaxel	38-48	transforming growth factor beta 1	Homo sapiens	60-68
22797058-8	2013	In addition, cisplatin/paclitaxel, which killed non-OTICs, with c-Kit knockdown or imatinib revealed that this was critically required for intervening ovarian cancer progression and recurrence in vitro and in xenograft tumors in vivo.	Paclitaxel	23-33	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	64-69
23632474-0	2013	Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer.	Paclitaxel	36-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
23632482-1	2013	BACKGROUND: Paclitaxel has recently been reported by this laboratory to potentiate the high-LET radiation therapeutic (212)Pb-TCMC-trastuzumab, which targets HER2.	Paclitaxel	12-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
23628417-3	2013	BLU and paclitaxel induced cell cycle arrest in the G2/M phase through the reduction of cyclin dependent kinase 1, cyclin B1, while promoting both p16 and p27 expression.	Paclitaxel	8-18	cyclin dependent kinase inhibitor 2A	Homo sapiens	147-150
23628417-3	2013	BLU and paclitaxel induced cell cycle arrest in the G2/M phase through the reduction of cyclin dependent kinase 1, cyclin B1, while promoting both p16 and p27 expression.	Paclitaxel	8-18	dynactin subunit 6	Homo sapiens	155-158
23628417-4	2013	In addition, both BLU and paclitaxel enhanced the expression of the pro-apoptotic protein Bax together with the suppression of anti-apoptotic protein Bcl-2, a protein which is well-known for its function as a regulator in protecting cells from apoptosis.	Paclitaxel	26-36	BCL2 associated X, apoptosis regulator	Homo sapiens	90-93
23628417-4	2013	In addition, both BLU and paclitaxel enhanced the expression of the pro-apoptotic protein Bax together with the suppression of anti-apoptotic protein Bcl-2, a protein which is well-known for its function as a regulator in protecting cells from apoptosis.	Paclitaxel	26-36	BCL2 apoptosis regulator	Homo sapiens	150-155
23628417-5	2013	As expected, the Bax and p21 activities were enhanced by BLU or paclitaxel, while a combination of BLU and paclitaxel were additively promoted, whereas Bcl-xL and NF-kappaB including Bcl-2 activity were inactivated.	Paclitaxel	64-74	BCL2 associated X, apoptosis regulator	Homo sapiens	17-20
23628417-7	2013	Furthermore, both BLU and paclitaxel inhibited the phosphorylation of signaling components downstream of phosphoinositide 3-kinase, such as 3-phosphoinositide-dependent protein kinase 1, and Akt.	Paclitaxel	26-36	AKT serine/threonine kinase 1	Homo sapiens	191-194
23624503-8	2013	The sensitivity of CD44(+)CD24(+)p53wt cells to paclitaxel is associated with the downregulation of Bcl-2 expression, upregulation of Bax levels, and upregulation of caspase-3 activity.	Paclitaxel	48-58	CD24 molecule	Homo sapiens	26-30
23624503-8	2013	The sensitivity of CD44(+)CD24(+)p53wt cells to paclitaxel is associated with the downregulation of Bcl-2 expression, upregulation of Bax levels, and upregulation of caspase-3 activity.	Paclitaxel	48-58	BCL2 apoptosis regulator	Homo sapiens	100-105
23624503-8	2013	The sensitivity of CD44(+)CD24(+)p53wt cells to paclitaxel is associated with the downregulation of Bcl-2 expression, upregulation of Bax levels, and upregulation of caspase-3 activity.	Paclitaxel	48-58	BCL2 associated X, apoptosis regulator	Homo sapiens	134-137
23624503-8	2013	The sensitivity of CD44(+)CD24(+)p53wt cells to paclitaxel is associated with the downregulation of Bcl-2 expression, upregulation of Bax levels, and upregulation of caspase-3 activity.	Paclitaxel	48-58	caspase 3	Homo sapiens	166-175
23624503-9	2013	Silencing of Cdx1 expression and treatment with lysosomal inhibitor bafilomycin A increased paclitaxel-induced cytotoxicity in CD44(+)CD24(+)Cdx1(+) cells.	Paclitaxel	92-102	CD24 molecule	Homo sapiens	134-138
23463098-1	2013	PURPOSE: Combinations of trastuzumab with paclitaxel or capecitabine are effective therapies in human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC).	Paclitaxel	42-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
23463098-11	2013	CONCLUSIONS: Combination of trastuzumab and paclitaxel plus capecitabine is an effective and well-tolerated regimen in the first-line therapy for women with HER2-positive MBC.	Paclitaxel	44-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	157-161
24024333-3	2013	Immunocytochemistry, Reverse transcription-polymerase chain reaction and western blotting were used to analyze the expression of MAPK1 (mitogen-activated protein kinases 1) and cyclin D1 in response to siRNA (small interfering RNA) transfection and taxol treatment.	Paclitaxel	249-254	mitogen-activated protein kinase 1	Homo sapiens	129-134
23624503-3	2013	METHODS: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCT116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells).	Paclitaxel	60-70	CD24 molecule	Homo sapiens	139-143
23624503-3	2013	METHODS: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCT116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells).	Paclitaxel	60-70	CD24 molecule	Homo sapiens	139-143
23624503-3	2013	METHODS: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCT116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells).	Paclitaxel	60-70	CD24 molecule	Homo sapiens	139-143
23624503-6	2013	The isolated CD44(+)CD24(+)Cdx1(+) cells showed higher resistance to paclitaxel-induced cytotoxicity than CD44(+)CD24(+)p53wt cells.	Paclitaxel	69-79	CD24 molecule	Homo sapiens	20-24
23624503-7	2013	The resistance of CD44(+)CD24(+)Cdx1(+) cells to paclitaxel is associated with upregulation of Cdx1 and Bcl-2 expression, caspase-3 activity, and the ratio of LC3-II/LC3-I.	Paclitaxel	49-59	CD24 molecule	Homo sapiens	25-29
23624503-7	2013	The resistance of CD44(+)CD24(+)Cdx1(+) cells to paclitaxel is associated with upregulation of Cdx1 and Bcl-2 expression, caspase-3 activity, and the ratio of LC3-II/LC3-I.	Paclitaxel	49-59	BCL2 apoptosis regulator	Homo sapiens	104-109
23681233-0	2013	Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation.	Paclitaxel	20-25	mitogen-activated protein kinase 8	Homo sapiens	101-104
23624503-7	2013	The resistance of CD44(+)CD24(+)Cdx1(+) cells to paclitaxel is associated with upregulation of Cdx1 and Bcl-2 expression, caspase-3 activity, and the ratio of LC3-II/LC3-I.	Paclitaxel	49-59	caspase 3	Homo sapiens	122-131
23681233-8	2013	Autophagy induction is induced after taxol exposure via mechanistic target of rapamycin (mTOR) inhibition, which is more important in cells exposed to hypoxia.	Paclitaxel	37-42	mechanistic target of rapamycin kinase	Homo sapiens	56-87
23681233-8	2013	Autophagy induction is induced after taxol exposure via mechanistic target of rapamycin (mTOR) inhibition, which is more important in cells exposed to hypoxia.	Paclitaxel	37-42	mechanistic target of rapamycin kinase	Homo sapiens	89-93
23090875-13	2013	Mouse liver microsomes metabolized paclitaxel far less efficiently than human or CYP3A4-transgenic liver microsomes, revealing much lower efficiency of paclitaxel metabolism by mouse than by human CYP3As.	Paclitaxel	152-162	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87
23681233-9	2013	Taxol also induced c-Jun N-terminal kinase (JNK) activation and phosphorylation of its substrates B-cell CLL/lymphoma 2 (Bcl2) and BCL2-like 1 (BclXL) under normoxia and hypoxia very early after taxol exposure.	Paclitaxel	0-5	mitogen-activated protein kinase 8	Homo sapiens	19-42
23681233-9	2013	Taxol also induced c-Jun N-terminal kinase (JNK) activation and phosphorylation of its substrates B-cell CLL/lymphoma 2 (Bcl2) and BCL2-like 1 (BclXL) under normoxia and hypoxia very early after taxol exposure.	Paclitaxel	0-5	mitogen-activated protein kinase 8	Homo sapiens	44-47
23681233-9	2013	Taxol also induced c-Jun N-terminal kinase (JNK) activation and phosphorylation of its substrates B-cell CLL/lymphoma 2 (Bcl2) and BCL2-like 1 (BclXL) under normoxia and hypoxia very early after taxol exposure.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	121-125
23681233-9	2013	Taxol also induced c-Jun N-terminal kinase (JNK) activation and phosphorylation of its substrates B-cell CLL/lymphoma 2 (Bcl2) and BCL2-like 1 (BclXL) under normoxia and hypoxia very early after taxol exposure.	Paclitaxel	0-5	BCL2 like 1	Homo sapiens	131-142
23681233-9	2013	Taxol also induced c-Jun N-terminal kinase (JNK) activation and phosphorylation of its substrates B-cell CLL/lymphoma 2 (Bcl2) and BCL2-like 1 (BclXL) under normoxia and hypoxia very early after taxol exposure.	Paclitaxel	0-5	BCL2 like 1	Homo sapiens	144-149
23681233-9	2013	Taxol also induced c-Jun N-terminal kinase (JNK) activation and phosphorylation of its substrates B-cell CLL/lymphoma 2 (Bcl2) and BCL2-like 1 (BclXL) under normoxia and hypoxia very early after taxol exposure.	Paclitaxel	195-200	BCL2 apoptosis regulator	Homo sapiens	121-125
23681233-9	2013	Taxol also induced c-Jun N-terminal kinase (JNK) activation and phosphorylation of its substrates B-cell CLL/lymphoma 2 (Bcl2) and BCL2-like 1 (BclXL) under normoxia and hypoxia very early after taxol exposure.	Paclitaxel	195-200	BCL2 like 1	Homo sapiens	144-149
23681233-12	2013	The results showed that JNK activation promotes resistance against taxol-induced apoptosis under normoxia and hypoxia without being involved in induction of autophagy.	Paclitaxel	67-72	mitogen-activated protein kinase 8	Homo sapiens	24-27
23681233-13	2013	In conclusion, the resistance against taxol-induced cell death observed under hypoxia can be explained by a more effective autophagic flow activated via the classical mTOR pathway and by a mechanism involving JNK, which could be dependent on Bcl2 and BclXL phosphorylation but independent of JNK-induced autophagy activation.	Paclitaxel	38-43	mechanistic target of rapamycin kinase	Homo sapiens	167-171
23681233-13	2013	In conclusion, the resistance against taxol-induced cell death observed under hypoxia can be explained by a more effective autophagic flow activated via the classical mTOR pathway and by a mechanism involving JNK, which could be dependent on Bcl2 and BclXL phosphorylation but independent of JNK-induced autophagy activation.	Paclitaxel	38-43	mitogen-activated protein kinase 8	Homo sapiens	209-212
23681233-13	2013	In conclusion, the resistance against taxol-induced cell death observed under hypoxia can be explained by a more effective autophagic flow activated via the classical mTOR pathway and by a mechanism involving JNK, which could be dependent on Bcl2 and BclXL phosphorylation but independent of JNK-induced autophagy activation.	Paclitaxel	38-43	BCL2 apoptosis regulator	Homo sapiens	242-246
23681233-13	2013	In conclusion, the resistance against taxol-induced cell death observed under hypoxia can be explained by a more effective autophagic flow activated via the classical mTOR pathway and by a mechanism involving JNK, which could be dependent on Bcl2 and BclXL phosphorylation but independent of JNK-induced autophagy activation.	Paclitaxel	38-43	BCL2 like 1	Homo sapiens	251-256
23681233-13	2013	In conclusion, the resistance against taxol-induced cell death observed under hypoxia can be explained by a more effective autophagic flow activated via the classical mTOR pathway and by a mechanism involving JNK, which could be dependent on Bcl2 and BclXL phosphorylation but independent of JNK-induced autophagy activation.	Paclitaxel	38-43	mitogen-activated protein kinase 8	Homo sapiens	292-295
23090875-1	2013	Paclitaxel is avidly transported by P-glycoprotein (P-gp/MDR1/ABCB1).	Paclitaxel	0-10	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	57-61
23090875-1	2013	Paclitaxel is avidly transported by P-glycoprotein (P-gp/MDR1/ABCB1).	Paclitaxel	0-10	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	62-67
23090875-14	2013	Accordingly, ritonavir could enhance the oral bioavailability of paclitaxel in CYP3A4-humanized mice, despite the fact that these mice are P-gp-proficient.	Paclitaxel	65-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
23090875-15	2013	Our results show that CYP3A4 inhibition most likely underlies the boosting effect of ritonavir on oral paclitaxel bioavailability in humans.	Paclitaxel	103-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-28
23090875-16	2013	Furthermore, CYP3A4-humanized mice allow improved understanding of CYP3A4-mediated paclitaxel metabolism in humans.	Paclitaxel	83-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
23090875-16	2013	Furthermore, CYP3A4-humanized mice allow improved understanding of CYP3A4-mediated paclitaxel metabolism in humans.	Paclitaxel	83-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73
23590802-11	2013	PTX and dual drug micelles had a synergistic inhibition effect on HUVEC proliferation through the induction of apoptosis via caspase 3/7 activity.	Paclitaxel	0-3	caspase 3	Homo sapiens	125-134
23534449-7	2013	Tumor growth inhibition and prolonged survival time, accompanied by increased mIL-12 or interferon-gamma (IFN-gamma) expression levels in serum or tumor sites, were observed in mice treated with AL/Ad5-mIL-12/PTX, as compared with those treated with either AL/Ad5-mIL-12 or AL/PTX.	Paclitaxel	209-212	interferon gamma	Mus musculus	106-115
23698321-4	2013	Our results demonstrate that incubation of cells for 3 h with 10 muM of paclitaxel does not induce apoptosis in MCF-7 cells.	Paclitaxel	72-82	latexin	Homo sapiens	65-68
23610448-7	2013	However, when an antibody targeting the VEGF pathway (DC101) was tested, it showed a trend in modestly improving the efficacy of paclitaxel therapy, thus resembling to a degree prior phase III clinical results of bevacizumab plus paclitaxel in MBC.	Paclitaxel	129-139	vascular endothelial growth factor A	Homo sapiens	40-44
23610448-7	2013	However, when an antibody targeting the VEGF pathway (DC101) was tested, it showed a trend in modestly improving the efficacy of paclitaxel therapy, thus resembling to a degree prior phase III clinical results of bevacizumab plus paclitaxel in MBC.	Paclitaxel	230-240	vascular endothelial growth factor A	Homo sapiens	40-44
23422592-6	2013	The targeting paclitaxel liposomes could significantly enhance the cellular uptake, be selectively accumulated into the mitochondria, and cause the release of cytochrome C.	Paclitaxel	14-24	cytochrome c, somatic	Homo sapiens	159-171
23479137-8	2013	However, PXR activity tended to correlate with IC50 values of paclitaxel (p = 0.08).	Paclitaxel	62-72	nuclear receptor subfamily 1 group I member 2	Homo sapiens	9-12
23698321-5	2013	On the contrary, incubation for 30 min at a higher concentration (100 muM) of paclitaxel induces gradual release of the cytochrome c into the cytoplasm, indicating cell apoptosis via a caspase independent pathway.	Paclitaxel	78-88	latexin	Homo sapiens	70-73
23698321-5	2013	On the contrary, incubation for 30 min at a higher concentration (100 muM) of paclitaxel induces gradual release of the cytochrome c into the cytoplasm, indicating cell apoptosis via a caspase independent pathway.	Paclitaxel	78-88	cytochrome c, somatic	Homo sapiens	120-132
23434829-11	2013	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and rapamycin, which are also P-gp substrates.	Paclitaxel	83-93	ATP binding cassette subfamily B member 1	Homo sapiens	153-157
23674486-0	2013	Insights into the binding of paclitaxel to human serum albumin: multispectroscopic studies.	Paclitaxel	29-39	albumin	Homo sapiens	49-62
23674486-1	2013	The interaction of paclitaxel with human serum albumin (HSA) was studied using fluorescence, resonance light scattering, ultraviolet-visible, circular dichroism and Fourier transform infrared spectroscopy at pH 7.4.	Paclitaxel	19-29	albumin	Homo sapiens	41-54
23467907-0	2013	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.	Paclitaxel	66-76	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	8-13
23468530-8	2013	Moreover, we observed an increase in the expression of CXCL1, a CXCR2 ligand in paclitaxel and doxorubicin-treated mammary tumor cells, which were inhibited following CXCR2 knockdown.	Paclitaxel	80-90	chemokine (C-X-C motif) ligand 1	Mus musculus	55-60
23467907-13	2013	Furthermore, HGF/c-Met inhibition by MK8033 represents a promising new therapeutic avenue to increase OVCA sensitivity to carboplatin plus paclitaxel.	Paclitaxel	139-149	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	17-22
23590835-13	2013	We identified a set of eight genes (EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32 and NNMT) showing significant gene-drug correlation with paclitaxel, docetaxel, erlotinib, everolimus and dasatinib.	Paclitaxel	136-146	epidermal growth factor receptor	Homo sapiens	36-40
22689054-6	2013	GRP78 stabilized CLU protein and its hypoglycosylated forms, in particular after paclitaxel treatment.	Paclitaxel	81-91	heat shock protein family A (Hsp70) member 5	Homo sapiens	0-5
22689054-8	2013	GRP78 silencing reduced CLU protein, but not mRNA levels, and enhanced paclitaxel-induced cell apoptosis.	Paclitaxel	71-81	heat shock protein family A (Hsp70) member 5	Homo sapiens	0-5
23499109-2	2013	The objective of this study was to develop a drug delivery system comprising O-carboxymethyl chitosan (O-CMC) nanoparticles, surface-conjugated with Cetuximab (Cet) for targeted delivery of paclitaxel (PTXL) to Epidermal Growth Factor Receptor (EGFR) over-expressing cancer cells.	Paclitaxel	190-200	epidermal growth factor receptor	Homo sapiens	211-243
23499109-2	2013	The objective of this study was to develop a drug delivery system comprising O-carboxymethyl chitosan (O-CMC) nanoparticles, surface-conjugated with Cetuximab (Cet) for targeted delivery of paclitaxel (PTXL) to Epidermal Growth Factor Receptor (EGFR) over-expressing cancer cells.	Paclitaxel	190-200	epidermal growth factor receptor	Homo sapiens	245-249
23499109-6	2013	The selective uptake of Cet-PTXL-O-CMC nanoparticles by EGFR +VE cancer cells (A549, A431 and SKBR3) compared to EGFR -VE MIAPaCa-2 cells confirms the active targeting and delivery of PTXL via the targeted nanomedicine.	Paclitaxel	28-32	epidermal growth factor receptor	Homo sapiens	56-60
23474708-0	2013	Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel.	Paclitaxel	88-98	NDC80 kinetochore complex component	Homo sapiens	14-18
23474708-2	2013	The aim of this study was to explore the role and mechanism of action of Hec1 with respect to the cytotoxicity of paclitaxel in ovarian cancer.	Paclitaxel	114-124	NDC80 kinetochore complex component	Homo sapiens	73-77
23474708-9	2013	RESULTS: Hec1 expression was significantly higher in ovarian cancer samples than in normal ovarian samples, and was associated with paclitaxel-resistance and poor prognosis.	Paclitaxel	132-142	NDC80 kinetochore complex component	Homo sapiens	9-13
23474708-10	2013	Among the 6 ovarian cancer cell lines examined, Hec1 expression was highest in paclitaxel-resistant A2780/Taxol cells, and lowest in A2780 cells.	Paclitaxel	79-89	NDC80 kinetochore complex component	Homo sapiens	48-52
23474708-11	2013	Depleting Hec1 in A2780/Taxol cells with siRNA decreased the IC50 value of paclitaxel by more than 10-fold (from 590+-26.7 to 45.6+-19.4 nmol/L).	Paclitaxel	75-85	NDC80 kinetochore complex component	Homo sapiens	10-14
23474708-13	2013	In paclitaxel-treated A2780/Taxol cells, depleting Hec1 significantly increased the cleaved PARP and Bax protein levels, and decreased the Bcl-xL protein level.	Paclitaxel	3-13	NDC80 kinetochore complex component	Homo sapiens	51-55
23474708-13	2013	In paclitaxel-treated A2780/Taxol cells, depleting Hec1 significantly increased the cleaved PARP and Bax protein levels, and decreased the Bcl-xL protein level.	Paclitaxel	3-13	poly(ADP-ribose) polymerase 1	Homo sapiens	92-96
23474708-13	2013	In paclitaxel-treated A2780/Taxol cells, depleting Hec1 significantly increased the cleaved PARP and Bax protein levels, and decreased the Bcl-xL protein level.	Paclitaxel	3-13	BCL2 associated X, apoptosis regulator	Homo sapiens	101-104
23474708-13	2013	In paclitaxel-treated A2780/Taxol cells, depleting Hec1 significantly increased the cleaved PARP and Bax protein levels, and decreased the Bcl-xL protein level.	Paclitaxel	3-13	BCL2 like 1	Homo sapiens	139-145
23474708-15	2013	Inhibition of Hec1 expression can sensitize ovarian cancer cells to paclitaxel.	Paclitaxel	68-78	NDC80 kinetochore complex component	Homo sapiens	14-18
23590835-13	2013	We identified a set of eight genes (EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32 and NNMT) showing significant gene-drug correlation with paclitaxel, docetaxel, erlotinib, everolimus and dasatinib.	Paclitaxel	136-146	retinoic acid induced 14	Homo sapiens	55-60
23537287-1	2013	BACKGROUND: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines.	Paclitaxel	172-182	erb-b2 receptor tyrosine kinase 2	Homo sapiens	16-20
23380587-9	2013	Efficient autophagy by hypertonic stress required microtubule remodeling and was DYNC/dynein-dependent as autophagosome clustering was enhanced by paclitaxel-induced microtubule stabilization and was reduced by nocodazole-induced tubulin depolymerization as well as chemical (EHNA) or genetic [DCTN2/dynactin 2 (p50) overexpression] interference of DYNC activity.	Paclitaxel	147-157	nuclear factor kappa B subunit 1	Homo sapiens	312-315
23478574-2	2013	In the present study, we show that paclitaxel induces MDR1 expression in the MCF-7 breast cancer cell line in a MAPK/Egr-1-dependent manner.	Paclitaxel	35-45	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
23478574-3	2013	Paclitaxel exposure activated the Erk1/2/MAPK pathway and promoted the accumulation of the early response transcription factor Egr-1 in MCF-7 cells.	Paclitaxel	0-10	mitogen-activated protein kinase 3	Homo sapiens	34-40
23478574-5	2013	Loss of Egr-1 function in paclitaxel-resistant MCF-7 cells decreased MDR1 expression, whereas inhibiting Erk1/2 activity reduced both Egr-1 accumulation and MDR1 expression.	Paclitaxel	26-36	ATP binding cassette subfamily B member 1	Homo sapiens	69-73
23478574-6	2013	These findings suggest that Erk1/2-induced Egr-1 accumulation activates MDR1 transcription and thereby induces the drug resistance observed in paclitaxel-resistant MCF-7 cells.	Paclitaxel	143-153	mitogen-activated protein kinase 3	Homo sapiens	28-34
23478574-6	2013	These findings suggest that Erk1/2-induced Egr-1 accumulation activates MDR1 transcription and thereby induces the drug resistance observed in paclitaxel-resistant MCF-7 cells.	Paclitaxel	143-153	ATP binding cassette subfamily B member 1	Homo sapiens	72-76
23478574-8	2013	Indeed, our results suggest a novel pathway by which paclitaxel induces MDR1 expression, possibly illuminating a potential target pathway for the prevention of MDR1-mediated drug resistance.	Paclitaxel	53-63	ATP binding cassette subfamily B member 1	Homo sapiens	72-76
23478574-8	2013	Indeed, our results suggest a novel pathway by which paclitaxel induces MDR1 expression, possibly illuminating a potential target pathway for the prevention of MDR1-mediated drug resistance.	Paclitaxel	53-63	ATP binding cassette subfamily B member 1	Homo sapiens	160-164
23160625-5	2013	Nocodazole and taxol treatments showed that WHAMM was localized around the MI spindle.	Paclitaxel	15-20	WAS protein homolog associated with actin, golgi membranes and microtubules	Mus musculus	44-49
23443842-4	2013	The TGF-beta/Smad signalling pathway can be modulated by stabilising microtubules with paclitaxel (PTX).	Paclitaxel	87-97	transforming growth factor beta 1	Homo sapiens	4-12
23443842-4	2013	The TGF-beta/Smad signalling pathway can be modulated by stabilising microtubules with paclitaxel (PTX).	Paclitaxel	99-102	transforming growth factor beta 1	Homo sapiens	4-12
23443842-5	2013	Here, we investigated whether paclitaxel can modulate TGF-beta/Smad signalling in human peritoneal methothelial cells (HPMCs).	Paclitaxel	30-40	transforming growth factor beta 1	Homo sapiens	54-62
23443842-7	2013	The minimum concentration that caused significant inhibition of TGF-beta1-induced morphological changes in human peritoneal methothelial cells on pre-treatment with PTX was 5 nM at 48 h (cell viability: 87.1+-1.5%, P&lt;0.01).	Paclitaxel	165-168	transforming growth factor beta 1	Homo sapiens	64-73
23443842-9	2013	TGF-beta signalling induced morphological changes, alpha-SMA expression and collagen I synthesis in HPMCs and PTX treatment suppressed these EMT-like changes.	Paclitaxel	110-113	transforming growth factor beta 1	Homo sapiens	0-8
23443842-11	2013	These data suggest that at a low-dose, PTX can significantly suppress the TGF-beta/Smad signalling pathway by inhibiting Smad2 phosphorylation in the human peritoneum and that this can reduce stromal fibrosis.	Paclitaxel	39-42	transforming growth factor beta 1	Homo sapiens	74-82
23318472-5	2013	The beneficial effects of paclitaxel were accompanied by the downregulation of tumor necrosis factor-alpha, interleukin-1, and interleukin-6 production.	Paclitaxel	26-36	interleukin 6	Mus musculus	127-140
23318472-7	2013	At the upstream level, paclitaxel reduced LPS-induced association of myeloid differentiation protein-2 (MD-2) with Toll-like receptor 4 (TLR4).	Paclitaxel	23-33	toll-like receptor 4	Mus musculus	115-135
23318472-7	2013	At the upstream level, paclitaxel reduced LPS-induced association of myeloid differentiation protein-2 (MD-2) with Toll-like receptor 4 (TLR4).	Paclitaxel	23-33	toll-like receptor 4	Mus musculus	137-141
23318472-10	2013	Collectively, these results suggest that paclitaxel may bind MD-2 to block MD-2/TLR4 association during LPS treatment, resulting in the suppression of NF-kappaB activation and inhibition of proinflammatory cytokine production.	Paclitaxel	41-51	toll-like receptor 4	Mus musculus	80-84
23354756-8	2013	The HER2-positive breast cancer cells were also exposed to the targeted therapy             trastuzumab and dual exposure to trastuzumab and paclitaxel.	Paclitaxel	141-151	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
23318472-0	2013	Paclitaxel ameliorates lipopolysaccharide-induced kidney injury by binding myeloid differentiation protein-2 to block Toll-like receptor 4-mediated nuclear factor-kappaB activation and cytokine production.	Paclitaxel	0-10	toll-like receptor 4	Mus musculus	118-138
23318472-5	2013	The beneficial effects of paclitaxel were accompanied by the downregulation of tumor necrosis factor-alpha, interleukin-1, and interleukin-6 production.	Paclitaxel	26-36	tumor necrosis factor	Mus musculus	79-106
23415863-0	2013	Paclitaxel attenuates Bcl-2 resistance to apoptosis in breast cancer cells through an endoplasmic reticulum-mediated calcium release in a dosage dependent manner.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	22-27
23401453-7	2013	A first prospective biomarker study known as MERiDiAN, which will treat patients stratified for circulating levels of short VEGF-A isoforms with bevacizumab and paclitaxel, is planned and will hopefully provide us with new directions on how to treat patients more efficiently.	Paclitaxel	161-171	vascular endothelial growth factor A	Homo sapiens	124-130
23415863-5	2013	Depending upon dosage, a paclitaxel-induced stimulatory effect can overcome the Bcl-2-mediated inhibitory effect on endoplasmic reticulum calcium release, thus attenuating the resistance of Bcl-2 to apoptosis.	Paclitaxel	25-35	BCL2 apoptosis regulator	Homo sapiens	80-85
23415863-5	2013	Depending upon dosage, a paclitaxel-induced stimulatory effect can overcome the Bcl-2-mediated inhibitory effect on endoplasmic reticulum calcium release, thus attenuating the resistance of Bcl-2 to apoptosis.	Paclitaxel	25-35	BCL2 apoptosis regulator	Homo sapiens	190-195
23415863-6	2013	Our finding is the first to demonstrate that endoplasmic reticulum calcium plays a key role in the efficacy of paclitaxel in the presence of Bcl-2, thus providing insight into the complex but crucial paclitaxel-calcium-Bcl-2 relationship, which may impact breast cancer treatment.	Paclitaxel	111-121	BCL2 apoptosis regulator	Homo sapiens	141-146
23537295-6	2013	In addition, immunohistochemical studies on mouse tumors injected with cisplatin or paclitaxel treated residual cells displayed higher staining for the proliferative antigen Ki67, oncogeneic CA125, epithelial E-cadherin as well as cancer stem cell markers such as Oct4 and CD117, compared to mice injected with control untreated cells.	Paclitaxel	84-94	cadherin 1	Mus musculus	209-219
23415863-1	2013	To address the controversy regarding efficacy of paclitaxel in the presence of the anti-apoptotic protein Bcl-2, we investigated calcium stored in the endoplasmic reticulum as a potential factor.	Paclitaxel	49-59	BCL2 apoptosis regulator	Homo sapiens	106-111
23415863-6	2013	Our finding is the first to demonstrate that endoplasmic reticulum calcium plays a key role in the efficacy of paclitaxel in the presence of Bcl-2, thus providing insight into the complex but crucial paclitaxel-calcium-Bcl-2 relationship, which may impact breast cancer treatment.	Paclitaxel	111-121	BCL2 apoptosis regulator	Homo sapiens	219-224
23415863-6	2013	Our finding is the first to demonstrate that endoplasmic reticulum calcium plays a key role in the efficacy of paclitaxel in the presence of Bcl-2, thus providing insight into the complex but crucial paclitaxel-calcium-Bcl-2 relationship, which may impact breast cancer treatment.	Paclitaxel	200-210	BCL2 apoptosis regulator	Homo sapiens	141-146
23415863-6	2013	Our finding is the first to demonstrate that endoplasmic reticulum calcium plays a key role in the efficacy of paclitaxel in the presence of Bcl-2, thus providing insight into the complex but crucial paclitaxel-calcium-Bcl-2 relationship, which may impact breast cancer treatment.	Paclitaxel	200-210	BCL2 apoptosis regulator	Homo sapiens	219-224
23328075-3	2013	The aim of this study was to examine any modulations in the DDC mRNA levels in gastric cancer cells after their treatment with the chemotherapeutic agents 5-fluorouracil, leucovorin, irinotecan, etoposide, cisplatin, and taxol.	Paclitaxel	221-226	dopa decarboxylase	Homo sapiens	60-63
23313612-0	2013	The decrease of paclitaxel efflux by pretreatment of interferon-gamma and tumor necrosis factor-alpha after intracerebral microinjection.	Paclitaxel	16-26	interferon gamma	Homo sapiens	53-101
23313612-3	2013	Paclitaxel is known to be a substrate for P-glycoprotein (P-gp), so this transporter may be due to insufficient access of paclitaxel to the brain.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	42-56
23313612-3	2013	Paclitaxel is known to be a substrate for P-glycoprotein (P-gp), so this transporter may be due to insufficient access of paclitaxel to the brain.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
23313612-3	2013	Paclitaxel is known to be a substrate for P-glycoprotein (P-gp), so this transporter may be due to insufficient access of paclitaxel to the brain.	Paclitaxel	122-132	ATP binding cassette subfamily B member 1	Homo sapiens	42-56
23313612-3	2013	Paclitaxel is known to be a substrate for P-glycoprotein (P-gp), so this transporter may be due to insufficient access of paclitaxel to the brain.	Paclitaxel	122-132	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
23313612-6	2013	The elimination of [(3)H]paclitaxel was inhibited by unlabeled paclitaxel and verapamil, suggesting a carrier-mediated transport process via P-gp.	Paclitaxel	25-35	ATP binding cassette subfamily B member 1	Homo sapiens	141-145
23313612-7	2013	Furthermore, TNF-alpha and IFN-gamma induced significant decrease of paclitaxel efflux 1 and 24h pre-treatment.	Paclitaxel	69-79	tumor necrosis factor	Homo sapiens	13-22
23313612-7	2013	Furthermore, TNF-alpha and IFN-gamma induced significant decrease of paclitaxel efflux 1 and 24h pre-treatment.	Paclitaxel	69-79	interferon gamma	Homo sapiens	27-36
23313612-9	2013	Therefore, the distribution of P-gp dependant drugs including paclitaxel in the central nervous system can be modulated by neurological diseases.	Paclitaxel	62-72	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
23333498-0	2013	Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation.	Paclitaxel	84-94	BCL2 apoptosis regulator	Homo sapiens	144-149
23340303-0	2013	Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.	Paclitaxel	136-146	vascular endothelial growth factor A	Homo sapiens	41-75
23667401-10	2013	Results showed that circulating taxol (10nM) reduced PAEC polarity, NF-kappaB activation, gene expression of pro-inflammatory molecules (ICAM-1 and VCAM-1), and monocyte adhesion on the PAECs under high pulsatility flow.	Paclitaxel	32-37	vascular cell adhesion molecule 1	Homo sapiens	148-154
23436791-6	2013	A synergistic effect in the inhibition of cell proliferation by ATP-competitive and ATP-noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all Pim-1 inhibitors tested in showed synergism with the known anticancer agent, paclitaxel.	Paclitaxel	255-265	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	178-183
23391723-7	2013	The TGF-beta type I receptor kinase inhibitor LY2157299, a neutralizing TGF-beta type II receptor antibody, and SMAD4 siRNA all blocked paclitaxel-induced IL8 transcription and CSC expansion.	Paclitaxel	136-146	transforming growth factor beta 1	Homo sapiens	4-12
23293323-5	2013	TECs show resistance to paclitaxel through greater mRNA expression of multidrug resistance 1, which encodes P-glycoprotein, as compared with normal endothelial cells.	Paclitaxel	24-34	ATP binding cassette subfamily B member 1	Homo sapiens	70-92
22717660-6	2013	Blocking MT disruption by Taxol prevented such phenomena, proving that the redistribution of SEPT6 was due to the MT disruption.	Paclitaxel	26-31	septin 6	Rattus norvegicus	93-98
22864818-6	2013	Subsequent in vitro study in SiHa and C-33A human cervical squamous carcinoma cell lines revealed that knocking down galectin-7 or S100A9 enhanced tumor cell invasion and tumor cell viability against paclitaxel-induced apoptotic stress, likely through increasing the matrix metalloproteinase-9 expression and activating the phosphatidylinositol 3-kinase/Akt signaling pathway, respectively.	Paclitaxel	200-210	galectin 7	Homo sapiens	117-127
22864818-6	2013	Subsequent in vitro study in SiHa and C-33A human cervical squamous carcinoma cell lines revealed that knocking down galectin-7 or S100A9 enhanced tumor cell invasion and tumor cell viability against paclitaxel-induced apoptotic stress, likely through increasing the matrix metalloproteinase-9 expression and activating the phosphatidylinositol 3-kinase/Akt signaling pathway, respectively.	Paclitaxel	200-210	AKT serine/threonine kinase 1	Homo sapiens	354-357
23391723-7	2013	The TGF-beta type I receptor kinase inhibitor LY2157299, a neutralizing TGF-beta type II receptor antibody, and SMAD4 siRNA all blocked paclitaxel-induced IL8 transcription and CSC expansion.	Paclitaxel	136-146	C-X-C motif chemokine ligand 8	Homo sapiens	155-158
23283649-0	2013	Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience.	Paclitaxel	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
23283649-1	2013	The aim of our analysis was to report the outcome and safety of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2-negative metastatic breast cancer.	Paclitaxel	102-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-145
23364970-13	2013	Expressions of HIF-1alpha and TUBB3 were most decreased when AGS cells were treated with a combination of paclitaxel and anti-VEGFR-1.	Paclitaxel	106-116	hypoxia inducible factor 1 subunit alpha	Homo sapiens	15-25
23426648-8	2013	Moreover, the VEGF mRNA levels, MVD value and apoptotic index in the SC-560/Taxol group were significantly different from the celecoxib/Taxol group (P&lt;0.05, P&lt;0.05 and P&lt;0.001, respectively).	Paclitaxel	76-81	vascular endothelial growth factor A	Homo sapiens	14-18
23364970-15	2013	CONCLUSION: We suggest that blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in TUBB3-expressing gastric cancer cells.	Paclitaxel	69-79	fms related receptor tyrosine kinase 1	Homo sapiens	40-47
23364970-0	2013	Blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in gastric cancer cells.	Paclitaxel	41-51	fms related receptor tyrosine kinase 1	Homo sapiens	12-19
23364970-12	2013	Hypoxia-dependent upregulation of HIF-1alpha and TUBB3 was reduced in response to paclitaxel treatment.	Paclitaxel	82-92	hypoxia inducible factor 1 subunit alpha	Homo sapiens	34-44
23228696-8	2013	Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and paclitaxel as well as cell viability and DNA repair capacity.	Paclitaxel	153-163	mitogen-activated protein kinase kinase 6	Homo sapiens	45-49
23879997-8	2013	When DNA damage occurred in A375 cells exposed to paclitaxel, expression of P-EGFR, P-ERK and P-AKT proteins was increased.	Paclitaxel	50-60	epidermal growth factor receptor	Homo sapiens	78-82
23879997-8	2013	When DNA damage occurred in A375 cells exposed to paclitaxel, expression of P-EGFR, P-ERK and P-AKT proteins was increased.	Paclitaxel	50-60	AKT serine/threonine kinase 1	Homo sapiens	96-99
23879997-9	2013	When EGFR signaling pathway was blocked, paclitaxel did not activate MAPK signaling pathway or PI3K/AKT signaling pathway and did not change its effect on cell cycle in vitro.	Paclitaxel	41-51	epidermal growth factor receptor	Homo sapiens	5-9
23879997-10	2013	When EGFR was inhibited by 20 micromol/L tyrophostin AG1478, the 0.001 and 0.01 micromol/L paclitaxel-induced early apoptosis rate in A375 cells was increased by 1.73- and 1.80-fold, respectively.	Paclitaxel	91-101	epidermal growth factor receptor	Homo sapiens	5-9
23879997-11	2013	When the ERK signaling was blocked by 40 micromol/L PD98059, the 0.001 and 0.01 micromol/L paclitaxel-induced early apoptosis rate in A375 cells was increased by 2.73- and 2.25-fold, respectively.	Paclitaxel	91-101	mitogen-activated protein kinase 1	Homo sapiens	9-12
23879997-12	2013	When the AKT signaling was blocked by 10 micromol/L LY294002, the 0.001 and 0.01 micromol/L paclitaxel-induced early apoptosis rate in A375 cells was increased by 2.02- and 1.46-fold, respectively.	Paclitaxel	92-102	AKT serine/threonine kinase 1	Homo sapiens	9-12
23879997-13	2013	CONCLUSIONS: Human melanoma A375 cells produce resistance to paclitaxel (0.001 to 0.1 micromol/L) by activating MAPK signaling and PI3K/AKT signaling pathways.	Paclitaxel	61-71	mitogen-activated protein kinase 3	Homo sapiens	112-116
23879997-13	2013	CONCLUSIONS: Human melanoma A375 cells produce resistance to paclitaxel (0.001 to 0.1 micromol/L) by activating MAPK signaling and PI3K/AKT signaling pathways.	Paclitaxel	61-71	AKT serine/threonine kinase 1	Homo sapiens	136-139
23879997-14	2013	Targeting EGFR, ERK and AKT signaling pathways significantly enhances the cytotoxic effect of paclitaxel on human melanoma cells.	Paclitaxel	94-104	epidermal growth factor receptor	Homo sapiens	10-14
23879997-14	2013	Targeting EGFR, ERK and AKT signaling pathways significantly enhances the cytotoxic effect of paclitaxel on human melanoma cells.	Paclitaxel	94-104	mitogen-activated protein kinase 1	Homo sapiens	16-19
23879997-14	2013	Targeting EGFR, ERK and AKT signaling pathways significantly enhances the cytotoxic effect of paclitaxel on human melanoma cells.	Paclitaxel	94-104	AKT serine/threonine kinase 1	Homo sapiens	24-27
23228696-0	2013	Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.	Paclitaxel	194-204	mitogen-activated protein kinase 14	Homo sapiens	37-40
23228696-4	2013	In this current study, paclitaxel was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.	Paclitaxel	23-33	mitogen-activated protein kinase 14	Homo sapiens	135-138
23228696-5	2013	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).	Paclitaxel	10-20	mitogen-activated protein kinase 14	Homo sapiens	109-112
23228696-5	2013	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).	Paclitaxel	10-20	mitogen-activated protein kinase 14	Homo sapiens	134-137
23228696-5	2013	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).	Paclitaxel	10-20	mitogen-activated protein kinase 14	Homo sapiens	134-137
23228696-7	2013	Furthermore, metformin was able to not only decrease the paclitaxel-induced p38 MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.	Paclitaxel	57-67	mitogen-activated protein kinase 14	Homo sapiens	76-79
23856142-14	2013	CONCLUSION: Targeting to inhibit antiapoptotic mitochondrial gene Bcl-2 expression in A549 cells specifically decreased the mRNA of ERCC1, TYMS, and TOP2alpha genes, and significantly increased the sensitivities of A549 cells to chemotherapeutic agents such as etoposide, cisplatin, paclitaxel and navelbine.	Paclitaxel	283-293	BCL2 apoptosis regulator	Homo sapiens	66-71
23879997-0	2013	[Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].	Paclitaxel	46-56	epidermal growth factor receptor	Homo sapiens	106-110
23879997-1	2013	OBJECTIVE: To study the molecular mechanism of epidermal growth factor receptor (EGFR) signaling pathway in mediating paclitaxel-resistance and improving paclitaxel sensitivity in human melanoma A375 cells.	Paclitaxel	118-128	epidermal growth factor receptor	Homo sapiens	47-79
23879997-1	2013	OBJECTIVE: To study the molecular mechanism of epidermal growth factor receptor (EGFR) signaling pathway in mediating paclitaxel-resistance and improving paclitaxel sensitivity in human melanoma A375 cells.	Paclitaxel	118-128	epidermal growth factor receptor	Homo sapiens	81-85
23879997-1	2013	OBJECTIVE: To study the molecular mechanism of epidermal growth factor receptor (EGFR) signaling pathway in mediating paclitaxel-resistance and improving paclitaxel sensitivity in human melanoma A375 cells.	Paclitaxel	154-164	epidermal growth factor receptor	Homo sapiens	47-79
23879997-1	2013	OBJECTIVE: To study the molecular mechanism of epidermal growth factor receptor (EGFR) signaling pathway in mediating paclitaxel-resistance and improving paclitaxel sensitivity in human melanoma A375 cells.	Paclitaxel	154-164	epidermal growth factor receptor	Homo sapiens	81-85
23442791-7	2013	RESULTS: Using this approach we successfully identify genes involved in paclitaxel resistance in a variety of cancer cell lines, including the multidrug transporter ABCB1, a previously identified major paclitaxel resistance gene.	Paclitaxel	72-82	ATP binding cassette subfamily B member 1	Homo sapiens	165-170
23466962-10	2013	Interestingly, down-regulation of LINE-1 ORF-1p level by siRNA could promote the response of HepG2 cells to the paclitaxel.	Paclitaxel	112-122	ORF1	Homo sapiens	41-47
23228696-9	2013	Overall, our results suggest that inhibition of the p38 MAPK signaling by metformin coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.	Paclitaxel	97-107	mitogen-activated protein kinase 14	Homo sapiens	52-55
23255607-6	2013	Restoring the expression of Bak1 or depleting miR-125b re-sensitizes Snail-expressing cancer cells to Taxol, indicating that miR-125b is critical in Snail-induced chemoresistance.	Paclitaxel	102-107	snail family transcriptional repressor 1	Homo sapiens	69-74
23243220-2	2013	We aimed to determine the influence of the individual human OATP1B1, OATP1B3, and OATP1A2 transporters on the in vivo disposition of the anticancer drugs methotrexate and paclitaxel by using liver-specific humanized OATP1A/1B transgenic mice.	Paclitaxel	171-181	solute carrier organic anion transporter family member 1B3	Homo sapiens	69-76
23243220-5	2013	Furthermore, hepatic expression of OATP1B3 and OATP1A2, but not OATP1B1, resulted in increased liver uptake of paclitaxel (2 mg/kg).	Paclitaxel	111-121	solute carrier organic anion transporter family member 1B3	Homo sapiens	35-42
23255607-6	2013	Restoring the expression of Bak1 or depleting miR-125b re-sensitizes Snail-expressing cancer cells to Taxol, indicating that miR-125b is critical in Snail-induced chemoresistance.	Paclitaxel	102-107	snail family transcriptional repressor 1	Homo sapiens	149-154
23178957-3	2013	The aim of the present study was to evaluate whether expression of resistance genes (MDR1, MRP3 and LRP) can predict clinical outcome in NSCLC patients treated with paclitaxel and carboplatin.	Paclitaxel	165-175	ATP binding cassette subfamily B member 1	Homo sapiens	85-89
23393327-5	2013	RESULTS: Collagen I, collagen IV and fibronectin specifically increased the efficiency of 2-D colony formation through binding integrins alpha2beta1 and alpha5beta1, respectively, and provided resistance to paclitaxel-induced colony elimination and apoptosis.	Paclitaxel	207-217	fibronectin 1	Homo sapiens	37-48
23178957-3	2013	The aim of the present study was to evaluate whether expression of resistance genes (MDR1, MRP3 and LRP) can predict clinical outcome in NSCLC patients treated with paclitaxel and carboplatin.	Paclitaxel	165-175	LDL receptor related protein 1	Homo sapiens	100-103
23178957-6	2013	RESULTS: MDR1 expression levels in PMNs rose rapidly within 24 h post-administration of paclitaxel and carboplatin, whereas MRP and LRP expression levels remained unchanged.	Paclitaxel	88-98	ATP binding cassette subfamily B member 1	Homo sapiens	9-13
23178957-8	2013	CONCLUSIONS: Modulation of MDR1 gene expression in PMNs after lung cancer treatment with paclitaxel and carboplatin cannot be used as a prognosis marker in these patients.	Paclitaxel	89-99	ATP binding cassette subfamily B member 1	Homo sapiens	27-31
23161364-0	2013	p53 acetylation enhances Taxol-induced apoptosis in human cancer cells.	Paclitaxel	25-30	tumor protein p53	Homo sapiens	0-3
23174537-6	2013	RESULTS: We demonstrated that Akt1 and Akt2 downregulation by RNAi highly sensitizes KLE cells to cisplatin by inducing the activation of pro-apoptotic factors such as the cleavage of caspases-3, -6, -9 and PARP; downregulation of all Akt isoforms leads to increased sensitivity to doxorubicin while only Akt1-2 downregulation increases taxol sensitivity.	Paclitaxel	337-342	AKT serine/threonine kinase 1	Homo sapiens	30-33
23126604-5	2013	The presence of verapamil and Pluronic both improved the intestinal absorption of PTX, which further certified the effect of Pluronic on P-gp inhibition.	Paclitaxel	82-85	ATP binding cassette subfamily B member 1	Homo sapiens	137-141
23223572-5	2013	In mec-7 mutants, the ALM mechanosensory neuron forms a long ectopic neurite that extends posteriorly, a phenotype that can be mimicked in wild-type worms with a microtubule-stabilizing drug (paclitaxel), and suppressed by mutations in unc-33/CRMP2 and the kinesin-related gene, vab-8.	Paclitaxel	192-202	Kinesin-like protein vab-8	Caenorhabditis elegans	279-284
23168176-8	2013	Navitoclax enhanced the activation of caspase 3/7 induced by carboplatin and/or paclitaxel in Igrov-1 cells.	Paclitaxel	80-90	caspase 3	Homo sapiens	38-47
23174537-6	2013	RESULTS: We demonstrated that Akt1 and Akt2 downregulation by RNAi highly sensitizes KLE cells to cisplatin by inducing the activation of pro-apoptotic factors such as the cleavage of caspases-3, -6, -9 and PARP; downregulation of all Akt isoforms leads to increased sensitivity to doxorubicin while only Akt1-2 downregulation increases taxol sensitivity.	Paclitaxel	337-342	AKT serine/threonine kinase 1	Homo sapiens	30-34
23063650-3	2013	With no apparent toxicity observed in the above models, nilotinib attenuated tumor growth synergistically and increased paclitaxel concentrations in ABCB1-overexpressing tumors.	Paclitaxel	120-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	149-154
23161364-5	2013	p53 was upregulated upon Taxol treatment in p53 wild type cells and deletion of p53 diminished Taxol-induced apoptosis.	Paclitaxel	25-30	tumor protein p53	Homo sapiens	44-47
23161364-5	2013	p53 was upregulated upon Taxol treatment in p53 wild type cells and deletion of p53 diminished Taxol-induced apoptosis.	Paclitaxel	25-30	tumor protein p53	Homo sapiens	44-47
23161364-5	2013	p53 was upregulated upon Taxol treatment in p53 wild type cells and deletion of p53 diminished Taxol-induced apoptosis.	Paclitaxel	95-100	tumor protein p53	Homo sapiens	0-3
23161364-6	2013	p53 target proteins including MDM2, p21, BAX, and beta-isoform of PUMA were also upregulated by Taxol in p53 wild type cells.	Paclitaxel	96-101	tumor protein p53	Homo sapiens	0-3
23161364-4	2013	Here we investigated the function of p53 in Taxol-induced apoptosis using p53 wild type and p53 null cancer cell lines.	Paclitaxel	44-49	tumor protein p53	Homo sapiens	37-40
23161364-6	2013	p53 target proteins including MDM2, p21, BAX, and beta-isoform of PUMA were also upregulated by Taxol in p53 wild type cells.	Paclitaxel	96-101	tumor protein p53	Homo sapiens	105-108
23161364-7	2013	Conversely, when the wild type p53 was re-introduced into two different p53 null cancer cell lines, Taxol-induced apoptosis was enhanced.	Paclitaxel	100-105	tumor protein p53	Homo sapiens	31-34
23161364-5	2013	p53 was upregulated upon Taxol treatment in p53 wild type cells and deletion of p53 diminished Taxol-induced apoptosis.	Paclitaxel	25-30	tumor protein p53	Homo sapiens	0-3
23161364-7	2013	Conversely, when the wild type p53 was re-introduced into two different p53 null cancer cell lines, Taxol-induced apoptosis was enhanced.	Paclitaxel	100-105	tumor protein p53	Homo sapiens	72-75
23161364-8	2013	Among post-translational modifications that affect p53 stability and function, p53 acetylation, rather than phosphorylation, increased significantly in Taxol-treated cells.	Paclitaxel	152-157	tumor protein p53	Homo sapiens	51-54
23224144-0	2013	Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.	Paclitaxel	60-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
23161364-8	2013	Among post-translational modifications that affect p53 stability and function, p53 acetylation, rather than phosphorylation, increased significantly in Taxol-treated cells.	Paclitaxel	152-157	tumor protein p53	Homo sapiens	79-82
23161364-9	2013	When acetylation was enhanced by anti-Sirt1 siRNA or an HDAC inhibitor, Taxol-induced apoptosis was enhanced, which was not observed in p53 null cells.	Paclitaxel	72-77	tumor protein p53	Homo sapiens	136-139
23161364-11	2013	Thus, p53 plays a pro-apoptotic role in Taxol-induced apoptosis and acetylation of p53 contributes to this pro-apoptotic function in response to Taxol in several human cancer cell lines, suggesting that enhancing acetylation of p53 could have potential implication for increasing the sensitivity of cancer cells to Taxol.	Paclitaxel	40-45	tumor protein p53	Homo sapiens	6-9
23161364-11	2013	Thus, p53 plays a pro-apoptotic role in Taxol-induced apoptosis and acetylation of p53 contributes to this pro-apoptotic function in response to Taxol in several human cancer cell lines, suggesting that enhancing acetylation of p53 could have potential implication for increasing the sensitivity of cancer cells to Taxol.	Paclitaxel	145-150	tumor protein p53	Homo sapiens	83-86
23161364-11	2013	Thus, p53 plays a pro-apoptotic role in Taxol-induced apoptosis and acetylation of p53 contributes to this pro-apoptotic function in response to Taxol in several human cancer cell lines, suggesting that enhancing acetylation of p53 could have potential implication for increasing the sensitivity of cancer cells to Taxol.	Paclitaxel	145-150	tumor protein p53	Homo sapiens	83-86
23161364-11	2013	Thus, p53 plays a pro-apoptotic role in Taxol-induced apoptosis and acetylation of p53 contributes to this pro-apoptotic function in response to Taxol in several human cancer cell lines, suggesting that enhancing acetylation of p53 could have potential implication for increasing the sensitivity of cancer cells to Taxol.	Paclitaxel	145-150	tumor protein p53	Homo sapiens	83-86
23161364-11	2013	Thus, p53 plays a pro-apoptotic role in Taxol-induced apoptosis and acetylation of p53 contributes to this pro-apoptotic function in response to Taxol in several human cancer cell lines, suggesting that enhancing acetylation of p53 could have potential implication for increasing the sensitivity of cancer cells to Taxol.	Paclitaxel	145-150	tumor protein p53	Homo sapiens	83-86
24460334-4	2013	Treatment of cells with a non-effective dose of PTX (100nM) and 0.1% Pect-MCP in combination revealed synergistic cytotoxic effects with 75% reduced cell viability and subsequent 3.9-fold increase in caspase-3 activity.	Paclitaxel	48-51	caspase 3	Homo sapiens	200-209
24289639-2	2013	This study was conducted to establish paclitaxel-resistant breast cancer cell line and nude mice models to explore underlying mechanisms of MDR.	Paclitaxel	38-48	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	140-143
23286491-10	2013	Using Western blotting, we demonstrated that treatment with TSA/paclitaxel led to synergistic increase in acetylated tubulin, PARP, caspase-3, and reduced the expression of survivin.	Paclitaxel	64-74	poly(ADP-ribose) polymerase 1	Homo sapiens	126-130
24168763-0	2013	Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.	Paclitaxel	84-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-108
24168763-1	2013	INTRODUCTION: Elevated expression of erbB3 rendered erbB2-overexpressing breast cancer cells resistant to paclitaxel via PI-3 K/Akt-dependent upregulation of Survivin.	Paclitaxel	106-116	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-57
24168763-2	2013	It is unclear whether an erbB3-targeted therapy may abrogate erbB2-mediated paclitaxel resistance in breast cancer.	Paclitaxel	76-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-66
24168763-13	2013	MM-121 enhances paclitaxel-induced poly(ADP-ribose) polymerase (PARP) cleavage, activation of caspase-8 and -3, and apoptosis in both paclitaxel-sensitive and -resistant cells.	Paclitaxel	16-26	poly(ADP-ribose) polymerase 1	Homo sapiens	35-62
24168763-13	2013	MM-121 enhances paclitaxel-induced poly(ADP-ribose) polymerase (PARP) cleavage, activation of caspase-8 and -3, and apoptosis in both paclitaxel-sensitive and -resistant cells.	Paclitaxel	16-26	poly(ADP-ribose) polymerase 1	Homo sapiens	64-68
24168763-17	2013	CONCLUSIONS: The combinations of MM-121 and paclitaxel not only inhibit tumor cell proliferation, but also promote erbB2-overexpressing breast cancer cells to undergo apoptosis via downregulation of Survivin in vitro and in vivo, suggesting that inactivation of erbB3 with MM-121 enhances paclitaxel-mediated antitumor activity against erbB2-overexpressing breast cancers.	Paclitaxel	44-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-120
24168763-17	2013	CONCLUSIONS: The combinations of MM-121 and paclitaxel not only inhibit tumor cell proliferation, but also promote erbB2-overexpressing breast cancer cells to undergo apoptosis via downregulation of Survivin in vitro and in vivo, suggesting that inactivation of erbB3 with MM-121 enhances paclitaxel-mediated antitumor activity against erbB2-overexpressing breast cancers.	Paclitaxel	44-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	336-341
24168763-18	2013	Our data supports further exploration of the combinatorial regimens consisting of MM-121 and paclitaxel in breast cancer patients with erbB2-overexpressing tumors, particularly those resistant to paclitaxel.	Paclitaxel	93-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	135-140
23286491-10	2013	Using Western blotting, we demonstrated that treatment with TSA/paclitaxel led to synergistic increase in acetylated tubulin, PARP, caspase-3, and reduced the expression of survivin.	Paclitaxel	64-74	caspase 3	Homo sapiens	132-141
22907189-8	2013	Treatment with paclitaxel alone or coadministration with COL-3 increased CD11b transcript levels in the brain but not in the spinal cord.	Paclitaxel	15-25	integrin alpha M	Mus musculus	73-78
24601052-6	2013	p53 positive expression and Ki67 high expression were associated with high PTX (p = 0.01 and p &lt; 0.01, respectively) and CBDCA (p = 0.03 and p &lt; 0.01, respectively) sensitivity.	Paclitaxel	75-78	tumor protein p53	Homo sapiens	0-3
23215690-0	2013	2-Hydroxypropyl-beta-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.	Paclitaxel	50-60	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
23215690-1	2013	OBJECTIVES: This study aimed to evaluate the potential of solid lipid nanoparticles (SLNs) of paclitaxel (PTX) modified with a 2-hydroxypropyl-beta-cyclodextrin system to enhance cellular accumulation of PTX into p-glycoprotein (p-gp)-expressing cells.	Paclitaxel	94-104	ATP binding cassette subfamily B member 1	Homo sapiens	213-227
23215690-1	2013	OBJECTIVES: This study aimed to evaluate the potential of solid lipid nanoparticles (SLNs) of paclitaxel (PTX) modified with a 2-hydroxypropyl-beta-cyclodextrin system to enhance cellular accumulation of PTX into p-glycoprotein (p-gp)-expressing cells.	Paclitaxel	94-104	ATP binding cassette subfamily B member 1	Homo sapiens	229-233
23215690-1	2013	OBJECTIVES: This study aimed to evaluate the potential of solid lipid nanoparticles (SLNs) of paclitaxel (PTX) modified with a 2-hydroxypropyl-beta-cyclodextrin system to enhance cellular accumulation of PTX into p-glycoprotein (p-gp)-expressing cells.	Paclitaxel	106-109	ATP binding cassette subfamily B member 1	Homo sapiens	213-227
23215690-1	2013	OBJECTIVES: This study aimed to evaluate the potential of solid lipid nanoparticles (SLNs) of paclitaxel (PTX) modified with a 2-hydroxypropyl-beta-cyclodextrin system to enhance cellular accumulation of PTX into p-glycoprotein (p-gp)-expressing cells.	Paclitaxel	106-109	ATP binding cassette subfamily B member 1	Homo sapiens	229-233
23925664-1	2013	Vascular endothelial growth factor (VEGF) is involved in non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE), but little is known regarding the efficacy of bevacizumab (Bev) with carboplatin-paclitaxel (CP) for NSCLC with MPE.	Paclitaxel	212-222	vascular endothelial growth factor A	Homo sapiens	0-34
23925664-1	2013	Vascular endothelial growth factor (VEGF) is involved in non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE), but little is known regarding the efficacy of bevacizumab (Bev) with carboplatin-paclitaxel (CP) for NSCLC with MPE.	Paclitaxel	212-222	vascular endothelial growth factor A	Homo sapiens	36-40
22806547-3	2013	Chemoresistance due to paclitaxel-induced nuclear factor-kappa B (NF-kappaB) activation is an important cause of suboptimal therapeutic efficacy.	Paclitaxel	23-33	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	42-64
22806547-3	2013	Chemoresistance due to paclitaxel-induced nuclear factor-kappa B (NF-kappaB) activation is an important cause of suboptimal therapeutic efficacy.	Paclitaxel	23-33	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	66-75
22806547-11	2013	RESULTS: In the combination group, paclitaxel-induced NF-kappaB activation was inhibited and apoptosis was enhanced in comparison with those in the other groups both in vitro and in vivo.	Paclitaxel	35-45	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	54-63
22806547-15	2013	paclitaxel against gastric cancer with peritoneal dissemination by inhibiting NF-kappaB activation in mice.	Paclitaxel	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	78-87
23629743-5	2013	These results are consistent with those of molecular docking simulations, where paclitaxel could not access the CYP2C8 catalytic site in the presence of nilotinib, but the binding of midazolam, a substrate of CYP3A4, to the catalytic site of CYP3A4 was not affected by nilotinib.	Paclitaxel	80-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	209-215
23629743-5	2013	These results are consistent with those of molecular docking simulations, where paclitaxel could not access the CYP2C8 catalytic site in the presence of nilotinib, but the binding of midazolam, a substrate of CYP3A4, to the catalytic site of CYP3A4 was not affected by nilotinib.	Paclitaxel	80-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	242-248
22623106-8	2013	Importantly, saracatinib significantly enhanced the effect of paclitaxel against ABCB1-overexpressing HeLa/v200 cancer cell xenografts in nude mice.	Paclitaxel	62-72	ATP binding cassette subfamily B member 1	Homo sapiens	81-86
22907189-10	2013	The coadministration of COL-3 with paclitaxel significantly increased the transcript levels of IL-6 in the spleen and decreased CX3CL1 transcripts in the brain in comparison to treatment with paclitaxel alone.	Paclitaxel	35-45	interleukin 6	Mus musculus	95-99
22907189-9	2013	Treatment with paclitaxel reduced IL-6 transcript levels in the spinal cord but did not alter the transcript levels of other cytokines or chemokines in the brain, spinal cord or spleen.	Paclitaxel	15-25	interleukin 6	Mus musculus	34-38
23358890-3	2013	We show that Bcl-2-overexpressing lung and breast cancer cells were more sensitive to both paclitaxel and vinorelbine.	Paclitaxel	91-101	B cell leukemia/lymphoma 2	Mus musculus	13-18
23358890-4	2013	Bcl-2 over-expression also significantly potentiated in vivo efficacy of paclitaxel, in terms of tumor volume decrease and survival benefits, in models of nude mice bearing lung cancer xenografts.	Paclitaxel	73-83	B cell leukemia/lymphoma 2	Mus musculus	0-5
23505544-1	2013	BACKGROUND: Despite the promising anticancer efficacy observed in preclinical studies, paclitaxel and tanespimycin (17-AAG) combination therapy has yielded meager responses in a phase I clinical trial.	Paclitaxel	87-97	N-methylpurine-DNA glycosylase	Mus musculus	119-122
24381593-3	2013	We hypothesized that synthetic lethality can be achieved in endometrial cancer cells with mutant p53 by combining paclitaxel with agents to overcome G2/M arrest and induce mitotic catastrophe.	Paclitaxel	114-124	tumor protein p53	Homo sapiens	97-100
24381593-4	2013	The combination of BIBF1120, an investigational VEGFR, PDGFR, and FGFR multityrosine kinase inhibitor with established anti-angiogenic activity, with paclitaxel abrogated the G2/M checkpoint in p53-null endometrial cancer cells via modulation of G2/M checkpoint regulators followed by induction of mitotic cell death.	Paclitaxel	150-160	tumor protein p53	Homo sapiens	194-197
24381593-5	2013	In endometrial cancer cells harboring an oncogenic gain-of-function p53 mutation, synthetic lethality was created by combining paclitaxel with BIBF1120 and a histone deacetylase inhibitor, which serves to destabilize mutant p53.	Paclitaxel	127-137	tumor protein p53	Homo sapiens	68-71
24381593-5	2013	In endometrial cancer cells harboring an oncogenic gain-of-function p53 mutation, synthetic lethality was created by combining paclitaxel with BIBF1120 and a histone deacetylase inhibitor, which serves to destabilize mutant p53.	Paclitaxel	127-137	tumor protein p53	Homo sapiens	224-227
24060847-8	2013	The PI3K/Akt, mitogen-activated protein kinase (MAPK), TGF-beta, ErbB, p53, cell cycle, mammalian target of rapamycin, and Jak-STAT signaling pathways were involved in paclitaxel-induced apoptosis.	Paclitaxel	168-178	epidermal growth factor receptor	Homo sapiens	65-69
24060847-8	2013	The PI3K/Akt, mitogen-activated protein kinase (MAPK), TGF-beta, ErbB, p53, cell cycle, mammalian target of rapamycin, and Jak-STAT signaling pathways were involved in paclitaxel-induced apoptosis.	Paclitaxel	168-178	mechanistic target of rapamycin kinase	Homo sapiens	88-117
23635560-0	2013	Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.	Paclitaxel	7-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
23635560-1	2013	BACKGROUND: The efficacy and tolerability of two different schedules of paclitaxel, carboplatin, and trastuzumab (PCarH) for HER2-positive, locally aggressive (stage IIB-IIIC) breast cancers were evaluated in this phase II trial.	Paclitaxel	72-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
23505544-2	2013	One serious problem associated with paclitaxel/17-AAG combination therapy is the employment of large quantities of toxic organic surfactants and solvents for drug solubilization.	Paclitaxel	36-46	N-methylpurine-DNA glycosylase	Mus musculus	50-53
23505544-5	2013	Compared with the free drugs at equivalent doses, intravenous administration of paclitaxel/17-AAG-loaded micelles led to 3.5- and 1.7-fold increase in the tumor concentrations of paclitaxel and 17-AAG, respectively, without significant altering drug levels in normal organs.	Paclitaxel	80-90	N-methylpurine-DNA glycosylase	Mus musculus	94-97
23505544-5	2013	Compared with the free drugs at equivalent doses, intravenous administration of paclitaxel/17-AAG-loaded micelles led to 3.5- and 1.7-fold increase in the tumor concentrations of paclitaxel and 17-AAG, respectively, without significant altering drug levels in normal organs.	Paclitaxel	80-90	N-methylpurine-DNA glycosylase	Mus musculus	197-200
23441224-0	2013	The role of TLR4 in the paclitaxel effects on neuronal growth in vitro.	Paclitaxel	24-34	toll-like receptor 4	Mus musculus	12-16
23505544-5	2013	Compared with the free drugs at equivalent doses, intravenous administration of paclitaxel/17-AAG-loaded micelles led to 3.5- and 1.7-fold increase in the tumor concentrations of paclitaxel and 17-AAG, respectively, without significant altering drug levels in normal organs.	Paclitaxel	179-189	N-methylpurine-DNA glycosylase	Mus musculus	94-97
23441224-5	2013	The goal of this study was to analyze the concentration-dependent effect of Pac on isolated and cultured DRG neuronal cells from wild-type and TLR4 knockout mice.	Paclitaxel	76-79	toll-like receptor 4	Mus musculus	143-147
23441224-9	2013	In DRG from TLR4 knockout mice high concentrations of Pac showed a similar effect on the number of neurons which developed neurites and the length of neurites.	Paclitaxel	54-57	toll-like receptor 4	Mus musculus	12-16
23505544-8	2013	We found that paclitaxel/17-AAG-loaded micelles caused near-complete arrest of tumor growth, whereas the free drug-treated tumors experienced rapid growth shortly after the 3-week treatment period ended.	Paclitaxel	14-24	N-methylpurine-DNA glycosylase	Mus musculus	28-31
23441224-11	2013	Thus, our data showed that Pac in high concentrations has a significant damaging effect on axonal growth and that this effect is partially mediated through TLR4 pathways.	Paclitaxel	27-30	toll-like receptor 4	Mus musculus	156-160
23505544-10	2013	CONCLUSIONS/SIGNIFICANCE: We have demonstrated in the current wok a safe and efficacious nano-sized formulation for the combined delivery of paclitaxel and 17-AAG, and uncovered unique metabolomic signatures in the tumor that correlate with the favorable therapeutic response to paclitaxel/17-AAG combination therapy.	Paclitaxel	141-151	N-methylpurine-DNA glycosylase	Mus musculus	293-296
23534290-5	2013	Thus, in ATC cells the ionizing radiation and Ptx exhibited competitive effects upon phosphorylation of cell cycle controllers: p53, pRb, CHK2, cAbl and expression of Bax.	Paclitaxel	46-49	BCL2 associated X, apoptosis regulator	Homo sapiens	167-170
23349730-6	2013	We show here that overexpressing ILK in HeLa cells was associated with a shorter duration of mitosis and decreased sensitivity to paclitaxel, a chemotherapeutic agent that suppresses microtubule dynamics.	Paclitaxel	130-140	integrin linked kinase	Homo sapiens	33-36
23349730-7	2013	Measurement of interphase microtubule dynamics revealed that ILK overexpression favored microtubule depolymerization, suggesting that microtubule destabilization could be the mechanism behind the decreased sensitivity to paclitaxel, which is known to stabilize microtubules.	Paclitaxel	221-231	integrin linked kinase	Homo sapiens	61-64
23460921-5	2013	Nab-paclitaxel treatment increased expression of the mitotic-spindle associated phospho-stathmin irrespective of the baseline total or phosphorylated stathmin level, and induced mitotic cell death as confirmed through increased expression of cleaved-PARP and caspase-3.	Paclitaxel	4-14	poly(ADP-ribose) polymerase 1	Homo sapiens	250-254
23460921-5	2013	Nab-paclitaxel treatment increased expression of the mitotic-spindle associated phospho-stathmin irrespective of the baseline total or phosphorylated stathmin level, and induced mitotic cell death as confirmed through increased expression of cleaved-PARP and caspase-3.	Paclitaxel	4-14	caspase 3	Homo sapiens	259-268
23349819-9	2013	Importantly, BIRB796 also enhanced the effect of paclitaxel on the inhibition of growth of the ABCB1-overexpressing KBV200 cell xenografts in nude mice.	Paclitaxel	49-59	ATP binding cassette subfamily B member 1	Homo sapiens	95-100
23534290-5	2013	Thus, in ATC cells the ionizing radiation and Ptx exhibited competitive effects upon phosphorylation of cell cycle controllers: p53, pRb, CHK2, cAbl and expression of Bax.	Paclitaxel	46-49	tumor protein p53	Homo sapiens	128-131
23534290-6	2013	At the same time, the combined effect of radiation and Ptx enhanced antiapoptotic Bcl-2 phosphorylation, caspases activation and survivin expression.	Paclitaxel	55-58	BCL2 apoptosis regulator	Homo sapiens	82-87
22885806-1	2012	We have examined the relationship between chemotherapy-induced mitotic catastrophe and cell death by apoptosis in both wild-type and p53(-/-) HCT116 human colon carcinoma cells treated with nanomolar concentrations of paclitaxel (PTX), a drug that acts on tubulin altering the normal development of mitosis.	Paclitaxel	218-228	tumor protein p53	Homo sapiens	133-136
22885806-3	2012	In the presence of PTX, the percentage of polyploid cells observed was higher in p53-deficient cells, indicating that mitotic slippage was favored compared to wild-type cells, with the presence of large multinucleate cells.	Paclitaxel	19-22	tumor protein p53	Homo sapiens	81-84
22885806-5	2012	Lack of p53 facilitated endoreduplication and polyploidy in PTX-treated cells, but cells were still killed with similar efficacy through the same apoptotic-like mechanism in the absence of caspase activity.	Paclitaxel	60-63	tumor protein p53	Homo sapiens	8-11
22902993-2	2012	Human ovarian cancer SKOV3 cells (parental SKOV3) were treated with paclitaxel (1muM) for 2days, and the morphologic changes in the cells were monitored for more than 4months.	Paclitaxel	68-78	latexin	Homo sapiens	81-84
23443122-0	2012	Modulation of MDR1 and MRP3 gene expression in lung cancer cells after paclitaxel and carboplatin exposure.	Paclitaxel	71-81	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
23443122-4	2012	Our results showed that exposure of the three NSCLC lines to plasma concentrations of paclitaxel (5 muM) produced an increase in MDR1 expression, while MRP3 showed no alteration in expression.	Paclitaxel	86-96	latexin	Homo sapiens	100-103
23443122-4	2012	Our results showed that exposure of the three NSCLC lines to plasma concentrations of paclitaxel (5 muM) produced an increase in MDR1 expression, while MRP3 showed no alteration in expression.	Paclitaxel	86-96	ATP binding cassette subfamily B member 1	Homo sapiens	129-133
23443122-7	2012	Interestingly, the combination of both paclitaxel and carboplatin caused increased expression of the MDR1 drug resistance gene rather than the individual treatments.	Paclitaxel	39-49	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
23443122-8	2012	These results suggest that carboplatin and paclitaxel may induce drug resistance mediated by MDR1 and MRP3, which may be enhanced by the simultaneous use of both drugs.	Paclitaxel	43-53	ATP binding cassette subfamily B member 1	Homo sapiens	93-97
24808664-8	2012	CONCLUSION: The BCL2 protein of human origin showed a higher affinity toward the compound paclitaxel.	Paclitaxel	90-100	BCL2 apoptosis regulator	Homo sapiens	16-20
23027625-0	2012	Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFkappaB pathway.	Paclitaxel	24-34	AKT serine/threonine kinase 1	Homo sapiens	102-105
23027625-0	2012	Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFkappaB pathway.	Paclitaxel	24-34	nuclear factor kappa B subunit 1	Homo sapiens	110-118
23027625-4	2012	The combination of tectorigenin with paclitaxel resulted in a synergistic apoptosis compared with either agent alone through activation of caspases-3, -8 and -9.	Paclitaxel	37-47	caspase 3	Homo sapiens	139-160
23027625-6	2012	In addition, the tectorigenin-paclitaxel combination inhibited the phosphorylation of IkappaB and IKK and the activation of Akt in paclitaxel-resistant cancer cells.	Paclitaxel	30-40	AKT serine/threonine kinase 1	Homo sapiens	124-127
23027625-6	2012	In addition, the tectorigenin-paclitaxel combination inhibited the phosphorylation of IkappaB and IKK and the activation of Akt in paclitaxel-resistant cancer cells.	Paclitaxel	131-141	AKT serine/threonine kinase 1	Homo sapiens	124-127
23027625-7	2012	Moreover, tectorigenin-paclitaxel-induced cell growth inhibition was enhanced by pretreatment with the Akt inhibitor LY294002 or overexpression of the dominant negative Akt (Akt-DN), but reduced by overexpression of constitutively activated Akt (Akt-Myr).	Paclitaxel	23-33	AKT serine/threonine kinase 1	Homo sapiens	103-106
23027625-7	2012	Moreover, tectorigenin-paclitaxel-induced cell growth inhibition was enhanced by pretreatment with the Akt inhibitor LY294002 or overexpression of the dominant negative Akt (Akt-DN), but reduced by overexpression of constitutively activated Akt (Akt-Myr).	Paclitaxel	23-33	AKT serine/threonine kinase 1	Homo sapiens	169-172
23027625-7	2012	Moreover, tectorigenin-paclitaxel-induced cell growth inhibition was enhanced by pretreatment with the Akt inhibitor LY294002 or overexpression of the dominant negative Akt (Akt-DN), but reduced by overexpression of constitutively activated Akt (Akt-Myr).	Paclitaxel	23-33	AKT serine/threonine kinase 1	Homo sapiens	169-172
23027625-7	2012	Moreover, tectorigenin-paclitaxel-induced cell growth inhibition was enhanced by pretreatment with the Akt inhibitor LY294002 or overexpression of the dominant negative Akt (Akt-DN), but reduced by overexpression of constitutively activated Akt (Akt-Myr).	Paclitaxel	23-33	AKT serine/threonine kinase 1	Homo sapiens	169-172
23027625-7	2012	Moreover, tectorigenin-paclitaxel-induced cell growth inhibition was enhanced by pretreatment with the Akt inhibitor LY294002 or overexpression of the dominant negative Akt (Akt-DN), but reduced by overexpression of constitutively activated Akt (Akt-Myr).	Paclitaxel	23-33	AKT serine/threonine kinase 1	Homo sapiens	246-253
23027625-8	2012	Furthermore, we found that Akt-Myr, at least in part, reversed tectorigenin-paclitaxel-induced nuclear translocation of NFkappaB and the phosphorylation of IkappaB and IKK.	Paclitaxel	76-86	AKT serine/threonine kinase 1	Homo sapiens	27-34
23027625-8	2012	Furthermore, we found that Akt-Myr, at least in part, reversed tectorigenin-paclitaxel-induced nuclear translocation of NFkappaB and the phosphorylation of IkappaB and IKK.	Paclitaxel	76-86	nuclear factor kappa B subunit 1	Homo sapiens	120-128
23027625-9	2012	These data suggest that tectorigenin could sensitize paclitaxel-resistant human ovarian cancer cells through inactivation of the Akt/IKK/IkappaB/NFkappaB signaling pathway, and promise a new intervention to chemosensitize paclitaxel-induced cytotoxicity in ovarian cancer.	Paclitaxel	53-63	AKT serine/threonine kinase 1	Homo sapiens	129-132
23027625-9	2012	These data suggest that tectorigenin could sensitize paclitaxel-resistant human ovarian cancer cells through inactivation of the Akt/IKK/IkappaB/NFkappaB signaling pathway, and promise a new intervention to chemosensitize paclitaxel-induced cytotoxicity in ovarian cancer.	Paclitaxel	53-63	nuclear factor kappa B subunit 1	Homo sapiens	145-153
23038675-3	2012	Gb(3)Cer was increased in all resistant cells, irrespective of whether the resistance was to paclitaxel or cisplatin, and expression of the MDR1 gene and gangliosides was enhanced in paclitaxel-resistant cells, but gangliosides were absent in cisplatin-resistant cells.	Paclitaxel	183-193	ATP binding cassette subfamily B member 1	Homo sapiens	140-144
23336096-5	2012	We found that even in vitro cytotoxicity of P-SSMM-VIP was 2-fold higher that that of free paclitaxel (p&lt;0.05).	Paclitaxel	91-101	vasoactive intestinal peptide	Homo sapiens	51-54
23336096-6	2012	Given the unique attributes of P-SSMM and P-SSMM-VIP, most notable small hydrodynamic diameter (~15nm) and stealth properties, biodistribution of paclitaxel was significantly altered.	Paclitaxel	146-156	vasoactive intestinal peptide	Homo sapiens	49-52
23336096-7	2012	Accumulation of paclitaxel in breast tumor was highest for P-SSMM-VIP, followed by P-SSMM and Cremophor based paclitaxel (PTX).	Paclitaxel	16-26	vasoactive intestinal peptide	Homo sapiens	66-69
23336096-8	2012	Importantly, bone marrow accumulation of paclitaxel encapsulated in both SSMM-VIP and SSMM was significantly less than that of PTX.	Paclitaxel	41-51	vasoactive intestinal peptide	Homo sapiens	78-81
23336096-9	2012	Administration of clinically-relevant dose of paclitaxel (5mg/kg) as P-SSMM-VIP and P-SSMM eradicated carcinogen-induced orthotopic breast cancer in rats, whereas PTX decreased tumor size by only 45%.	Paclitaxel	46-56	vasoactive intestinal peptide	Homo sapiens	76-79
23336096-10	2012	In addition, a 5-fold lower dose (1mg/kg) of paclitaxel in actively targeted P-SSMM-VIP was associated with ~80% reduction in tumor size while the response to PTX and P-SSMM was significantly less.	Paclitaxel	45-55	vasoactive intestinal peptide	Homo sapiens	84-87
23336096-10	2012	In addition, a 5-fold lower dose (1mg/kg) of paclitaxel in actively targeted P-SSMM-VIP was associated with ~80% reduction in tumor size while the response to PTX and P-SSMM was significantly less.	Paclitaxel	159-162	vasoactive intestinal peptide	Homo sapiens	84-87
22993037-10	2012	Importantly, swainsonine             also potentiated the cytotoxic effects of paclitaxel in vitro and in vivo, in             part, by restricting the paclitaxel-induced nuclear accumulation of NF-kappaB.	Paclitaxel	79-89	nuclear factor kappa B subunit 1	Homo sapiens	195-204
22544540-0	2012	High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy.	Paclitaxel	90-100	TIMP metallopeptidase inhibitor 1	Homo sapiens	19-25
22544540-6	2012	Additionally, our previous study proved that TIMP-1 significantly decreased the sensitivity of breast cancer cells to paclitaxel-induced apoptosis by enhancing degradation of cyclin B1.	Paclitaxel	118-128	TIMP metallopeptidase inhibitor 1	Homo sapiens	45-51
22544540-8	2012	In this retrospective study, we investigated the association between expression levels of TIMP-1 protein in the primary tumor and objective response to paclitaxel-based chemotherapy in 99 patients with breast cancer.	Paclitaxel	152-162	TIMP metallopeptidase inhibitor 1	Homo sapiens	90-96
22544540-12	2012	Our data showed that elevated tumor tissue TIMP-1 levels were significantly associated with a poor response to paclitaxel-based chemotherapy, and TIMP-1 might be a potential biomarker for predicting response of breast cancer patients to paclitaxel-based chemotherapy.	Paclitaxel	111-121	TIMP metallopeptidase inhibitor 1	Homo sapiens	43-49
22544540-12	2012	Our data showed that elevated tumor tissue TIMP-1 levels were significantly associated with a poor response to paclitaxel-based chemotherapy, and TIMP-1 might be a potential biomarker for predicting response of breast cancer patients to paclitaxel-based chemotherapy.	Paclitaxel	237-247	TIMP metallopeptidase inhibitor 1	Homo sapiens	146-152
23023313-0	2012	Taxol-induced growth arrest and apoptosis is associated with the upregulation             of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells.	Paclitaxel	0-5	cyclin dependent kinase inhibitor 1A	Homo sapiens	112-124
23023313-3	2012	In this study, we used MCF-7 and MDA-MB-231 human breast carcinoma cells which             have different estrogen receptor (ER) and tumor suppressor p53 statuses to examine             the mechanisms of taxol-induced growth inhibition and apoptosis.	Paclitaxel	204-209	estrogen receptor 1	Homo sapiens	125-127
23023313-3	2012	In this study, we used MCF-7 and MDA-MB-231 human breast carcinoma cells which             have different estrogen receptor (ER) and tumor suppressor p53 statuses to examine             the mechanisms of taxol-induced growth inhibition and apoptosis.	Paclitaxel	204-209	tumor protein p53	Homo sapiens	150-153
23023313-5	2012	Furthermore, chromatin condensation,             DNA ladder formation and proteolytic cleavage of poly(ADP-ribose) polymerase (PARP)             in both cell lines were observed following treatment with taxol, indicating the             occurrence of apoptotic cell death.	Paclitaxel	203-208	poly(ADP-ribose) polymerase 1	Homo sapiens	98-125
23226802-0	2012	Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report.	Paclitaxel	70-80	proteasome 26S subunit, non-ATPase 1	Homo sapiens	146-149
23023313-5	2012	Furthermore, chromatin condensation,             DNA ladder formation and proteolytic cleavage of poly(ADP-ribose) polymerase (PARP)             in both cell lines were observed following treatment with taxol, indicating the             occurrence of apoptotic cell death.	Paclitaxel	203-208	poly(ADP-ribose) polymerase 1	Homo sapiens	127-131
22993037-10	2012	Importantly, swainsonine             also potentiated the cytotoxic effects of paclitaxel in vitro and in vivo, in             part, by restricting the paclitaxel-induced nuclear accumulation of NF-kappaB.	Paclitaxel	152-162	nuclear factor kappa B subunit 1	Homo sapiens	195-204
23023313-6	2012	Western blot analysis using whole cell lysates             from MCF-7 and MDA-MB-231 cells treated with taxol demonstrated that taxol treatment             inhibited expression of cyclin A and cyclin B1 proteins in a time-dependent manner.	Paclitaxel	104-109	cyclin A2	Homo sapiens	180-188
23023313-6	2012	Western blot analysis using whole cell lysates             from MCF-7 and MDA-MB-231 cells treated with taxol demonstrated that taxol treatment             inhibited expression of cyclin A and cyclin B1 proteins in a time-dependent manner.	Paclitaxel	128-133	cyclin A2	Homo sapiens	180-188
23146280-8	2012	High VEGF-C mRNA expression was predictive for benefit from adjuvant treatment with paclitaxel (E-T-CMF arm) for OS (test for interaction, Wald"s P = 0.038), while in multivariate analysis the interaction of VEGF-C with taxane treatment was significant for both OS (Wald"s P = 0.019) and DFS (P = 0.041) and continuous VEGF-B mRNA expression values for OS (P = 0.019).	Paclitaxel	84-94	vascular endothelial growth factor C	Homo sapiens	5-11
23023313-7	2012	The inhibitory effects of taxol on cell growth and apoptosis induced by taxol             were also associated with the downregulation of Wee1 kinase expression and a marked             induction in the activity of the cyclin-dependent kinase inhibitor, p21WAF/CIP1.	Paclitaxel	26-31	cyclin dependent kinase inhibitor 1A	Homo sapiens	261-265
23023313-7	2012	The inhibitory effects of taxol on cell growth and apoptosis induced by taxol             were also associated with the downregulation of Wee1 kinase expression and a marked             induction in the activity of the cyclin-dependent kinase inhibitor, p21WAF/CIP1.	Paclitaxel	72-77	cyclin dependent kinase inhibitor 1A	Homo sapiens	261-265
23023313-8	2012	Furthermore, taxol elevated p21 promoter activity in both cell lines.	Paclitaxel	13-18	cyclin dependent kinase inhibitor 1A	Homo sapiens	28-31
23023313-9	2012	These findings             suggest that taxol-induced G2/M arrest and apoptosis in human breast carcinoma             cells is mediated through the ER- and p53-independent upregulation of p21.	Paclitaxel	40-45	estrogen receptor 1	Homo sapiens	148-150
23023313-9	2012	These findings             suggest that taxol-induced G2/M arrest and apoptosis in human breast carcinoma             cells is mediated through the ER- and p53-independent upregulation of p21.	Paclitaxel	40-45	tumor protein p53	Homo sapiens	156-159
23023313-9	2012	These findings             suggest that taxol-induced G2/M arrest and apoptosis in human breast carcinoma             cells is mediated through the ER- and p53-independent upregulation of p21.	Paclitaxel	40-45	cyclin dependent kinase inhibitor 1A	Homo sapiens	188-191
23072999-6	2012	In addition, nek4, nek5, and nek6/ibo1 mutants were hypersensitive to microtubule inhibitors such as propyzamide and taxol.	Paclitaxel	117-122	Serine/Threonine kinase catalytic domain protein	Arabidopsis thaliana	19-23
23328431-0	2012	[Effects of modification of transferrin on cytotoxicity and intracellular delivery of paclitaxel loaded PLGA nanoparticles].	Paclitaxel	86-96	transferrin	Homo sapiens	28-39
22965228-5	2012	We show that when treated with Taxol, slippage-resistant HT29 colon carcinoma cells display robust Cdk1 activity and extensive Mcl-1/Bcl-x(L) phosphorylation and die in mitosis, whereas slippage-prone DLD-1 colon carcinoma cells display weak Cdk1 activity and partial and transient Mcl-1/Bcl-x(L) phosphorylation and die in subsequent interphase or survive.	Paclitaxel	31-36	BCL2 like 1	Homo sapiens	133-138
22965228-5	2012	We show that when treated with Taxol, slippage-resistant HT29 colon carcinoma cells display robust Cdk1 activity and extensive Mcl-1/Bcl-x(L) phosphorylation and die in mitosis, whereas slippage-prone DLD-1 colon carcinoma cells display weak Cdk1 activity and partial and transient Mcl-1/Bcl-x(L) phosphorylation and die in subsequent interphase or survive.	Paclitaxel	31-36	BCL2 like 1	Homo sapiens	288-293
23146280-8	2012	High VEGF-C mRNA expression was predictive for benefit from adjuvant treatment with paclitaxel (E-T-CMF arm) for OS (test for interaction, Wald"s P = 0.038), while in multivariate analysis the interaction of VEGF-C with taxane treatment was significant for both OS (Wald"s P = 0.019) and DFS (P = 0.041) and continuous VEGF-B mRNA expression values for OS (P = 0.019).	Paclitaxel	84-94	vascular endothelial growth factor C	Homo sapiens	208-214
23146280-9	2012	CONCLUSIONS: The present study reports, for the first time, that VEGF-C mRNA overexpression, as assessed by qRT-PCR, has a strong predictive value in high-risk early breast cancer patients undergoing adjuvant paclitaxel-containing treatment.	Paclitaxel	209-219	vascular endothelial growth factor C	Homo sapiens	65-71
23155247-5	2012	RESULTS: Doxycycline induced sustained NFkappaB activation, followed by desensitization to further NFkappaB activation by TNF-alpha -or paclitaxel, which was accompanied by decreased expression of TNF receptor p55, p75, and epidermal growth factor receptor.	Paclitaxel	136-146	nuclear factor kappa B subunit 1	Homo sapiens	99-107
23046348-7	2012	Importantly, BBA increased the inhibitory effect of paclitaxel in ABCB1 overexpressing KB-C2 cell xenografts in nude mice.	Paclitaxel	52-62	ATP binding cassette subfamily B member 1	Homo sapiens	66-71
22923148-1	2012	To investigate acquired paclitaxel (PTX) resistance in cancer cells, we             established five monoclonal PTX-resistant cell lines from HEC-1 human endometrial             adenocarcinoma cells by means of long-term PTX-exposed cultures and limiting dilution             cultures.	Paclitaxel	112-115	NDC80 kinetochore complex component	Homo sapiens	142-147
23155247-0	2012	Desensitization of NFkappaB for overcoming chemoresistance of pancreatic cancer cells to TNF-alpha or paclitaxel.	Paclitaxel	102-112	nuclear factor kappa B subunit 1	Homo sapiens	19-27
22713763-1	2012	The purpose of this study was to target ovarian cancer cells by coupling paclitaxel (Tx)-loaded nanoparticles (NPs-Tx) to antibodies against KDEL sequence, able to recognize GRP94 and GRP78 that are located at cell surface in cancer cells whereas they are in the endoplasmic reticulum in healthy cells.	Paclitaxel	73-83	heat shock protein family A (Hsp70) member 5	Homo sapiens	184-189
23268066-10	2012	Weekly paclitaxel (PTX; 3-week administration followed by 1-week withdrawal) was used together with doxifluridine(5"-DFUR; daily oral administration).	Paclitaxel	7-17	pentraxin 3	Homo sapiens	19-25
23268070-0	2012	[A case of unresectable HER2-positive advanced gastric cancer successfully treated by combination therapy with trastuzumab and paclitaxel].	Paclitaxel	127-137	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
23268070-7	2012	Trastuzumab and paclitaxel combination chemotherapy appears to be an effective treatment for HER2-positive advanced gastric cancer.	Paclitaxel	16-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
22923148-0	2012	Differential sensitivity to paclitaxel-induced apoptosis and growth             suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial             adenocarcinoma cells.	Paclitaxel	28-38	NDC80 kinetochore complex component	Homo sapiens	144-149
22923148-0	2012	Differential sensitivity to paclitaxel-induced apoptosis and growth             suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial             adenocarcinoma cells.	Paclitaxel	95-105	NDC80 kinetochore complex component	Homo sapiens	144-149
22936118-7	2012	Thus the pharmacokinetic changes of taxanes observed in the DMIS rats were attributed to changes in P-gp and Cyp3A, predominant factors that control the absorption of paclitaxel and docetaxel, respectively.	Paclitaxel	167-177	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	109-114
22847181-0	2012	Mitochondrial uncoupling protein 2 regulates the effects of paclitaxel on Stat3 activation and cellular survival in lung cancer cells.	Paclitaxel	60-70	signal transducer and activator of transcription 3	Homo sapiens	74-79
22847181-3	2012	We found that paclitaxel activated Stat3 in the human lung cancer cell lines PC14PE6AS2 (AS2) and H157, whereas it reduced Stat3 activation in A549 and H460 cells.	Paclitaxel	14-24	signal transducer and activator of transcription 3	Homo sapiens	35-40
22847181-3	2012	We found that paclitaxel activated Stat3 in the human lung cancer cell lines PC14PE6AS2 (AS2) and H157, whereas it reduced Stat3 activation in A549 and H460 cells.	Paclitaxel	14-24	signal transducer and activator of transcription 3	Homo sapiens	123-128
22847181-7	2012	Silencing high UCP-2 expression with small interfering RNA (siRNA) in A549 and H460 cells restored paclitaxel-induced Stat3 activation.	Paclitaxel	99-109	signal transducer and activator of transcription 3	Homo sapiens	118-123
22847181-8	2012	In addition, paclitaxel-induced Stat3 activation led to the upregulation of survivin and Mcl-1, which in turn facilitated cell survival.	Paclitaxel	13-23	signal transducer and activator of transcription 3	Homo sapiens	32-37
22847181-10	2012	Treatment with paclitaxel activated Stat3 in CL1-5 but not in CL1-0 cells, whereas in CL1-5 cells, the overexpression of UCP-2 with complementary DNA (cDNA) blocked Stat3 activation.	Paclitaxel	15-25	signal transducer and activator of transcription 3	Homo sapiens	36-41
22847181-10	2012	Treatment with paclitaxel activated Stat3 in CL1-5 but not in CL1-0 cells, whereas in CL1-5 cells, the overexpression of UCP-2 with complementary DNA (cDNA) blocked Stat3 activation.	Paclitaxel	15-25	signal transducer and activator of transcription 3	Homo sapiens	165-170
23023659-2	2012	P-gp regulates the absorption and elimination of a wide range of compounds, such as digoxin, paclitaxel, HIV protease inhibitors and psychotropic drugs.	Paclitaxel	93-103	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
23030458-10	2012	The human MDR1 gene-transfected and thus paclitaxel-resistant MDCKII-MDR1 P-gp overexpressing cells were used for cytotoxicity evaluation.	Paclitaxel	41-51	ATP binding cassette subfamily B member 1	Homo sapiens	69-73
23051955-13	2012	Taxol resistance in this cell could be related to overexpression of P-gp and the change of cell cycle profiles.	Paclitaxel	0-5	ATP binding cassette subfamily B member 1	Homo sapiens	68-72
22923148-1	2012	To investigate acquired paclitaxel (PTX) resistance in cancer cells, we             established five monoclonal PTX-resistant cell lines from HEC-1 human endometrial             adenocarcinoma cells by means of long-term PTX-exposed cultures and limiting dilution             cultures.	Paclitaxel	112-115	NDC80 kinetochore complex component	Homo sapiens	142-147
22760214-3	2012	The biological effects of UbcH10 on the cell proliferation, cell cycle, and chemosensitivity to gemcitabine or paclitaxel in SK-MES-1 cells were examined upon the UbcH10 silencing.	Paclitaxel	111-121	ubiquitin conjugating enzyme E2 C	Homo sapiens	26-32
22760214-7	2012	Suppression of UbcH10 expression in SK-MES-1 cells inhibited cell proliferation and increased chemosensitivity to gemcitabine or paclitaxel concomitant with decreased MDR1 gene expression.	Paclitaxel	129-139	ubiquitin conjugating enzyme E2 C	Homo sapiens	15-21
23033932-2	2012	Antagonizing PDGFR with imatinib may improve intra-tumoral delivery of paclitaxel, increasing response rate (RR).	Paclitaxel	71-81	platelet derived growth factor receptor beta	Homo sapiens	13-18
22549011-2	2012	We previously found that poly(ethylene glycol)-block-poly(D, L-lactic acid) (PEG-b-PLA) micelles can serve as a safe delivery platform for simultaneous delivery of paclitaxel (PTX), 17-allylamino-17-demethoxygeldanamycin (17-AAG), and rapamycin (RAP) to mice.	Paclitaxel	164-174	regulatory associated protein of MTOR, complex 1	Mus musculus	246-249
22549011-4	2012	In this study, it was shown that 3-in-1 PEG-b-PLA micelle delivering high doses of PTX, 17-AAG, and RAP (60, 60, and 30 mg/kg, respectively) significantly increased the values of the area under the plasma concentration-time curves (AUC) of PTX and RAP in mice compared to the drugs delivered individually, while the pharmacokinetic parameters of 17-AAG were similar in both 3-in-1 and single drug-loaded PEG-b-PLA micelle formulations.	Paclitaxel	83-86	regulatory associated protein of MTOR, complex 1	Mus musculus	248-251
22549011-4	2012	In this study, it was shown that 3-in-1 PEG-b-PLA micelle delivering high doses of PTX, 17-AAG, and RAP (60, 60, and 30 mg/kg, respectively) significantly increased the values of the area under the plasma concentration-time curves (AUC) of PTX and RAP in mice compared to the drugs delivered individually, while the pharmacokinetic parameters of 17-AAG were similar in both 3-in-1 and single drug-loaded PEG-b-PLA micelle formulations.	Paclitaxel	240-243	regulatory associated protein of MTOR, complex 1	Mus musculus	100-103
22506717-8	2012	Finally, human recombinant RANTES and thrombospondin-1 improved survival of Caco-2 cells challenged with paclitaxel.	Paclitaxel	105-115	thrombospondin 1	Homo sapiens	38-54
23060563-7	2012	Interference with ATF5 function in SW1990 cells resulted in down-regulation of BCL-2 and up-regulation of BAX, resulting in enhanced sensitivity to apoptosis induced by paclitaxel treatment.	Paclitaxel	169-179	BCL2 apoptosis regulator	Homo sapiens	79-84
23060563-7	2012	Interference with ATF5 function in SW1990 cells resulted in down-regulation of BCL-2 and up-regulation of BAX, resulting in enhanced sensitivity to apoptosis induced by paclitaxel treatment.	Paclitaxel	169-179	BCL2 associated X, apoptosis regulator	Homo sapiens	106-109
22923236-6	2012	Neutralizing antibodies against IL-6 and IL-8 partially reversed the drug resistance of MCF-7/R to paclitaxel and doxorubicin, while a neutralizing antibody against MCP-1 had no significant effect.	Paclitaxel	99-109	interleukin 6	Homo sapiens	32-36
22923236-6	2012	Neutralizing antibodies against IL-6 and IL-8 partially reversed the drug resistance of MCF-7/R to paclitaxel and doxorubicin, while a neutralizing antibody against MCP-1 had no significant effect.	Paclitaxel	99-109	C-X-C motif chemokine ligand 8	Homo sapiens	41-45
22945507-8	2012	In our efforts to induce cell surface GRP78, we subjected the cells to doxorubicin and taxol that increased significantly the percent of GRP78 positive population.	Paclitaxel	87-92	heat shock protein family A (Hsp70) member 5	Homo sapiens	38-43
22765290-3	2012	In this review, we focus on highlighting several representative plant natural compounds such as curcumin, resveratrol, paclitaxel, oridonin, quercetin and plant lectin - that may lead to cancer cell death - for regulation of some core autophagic pathways, involved in Ras-Raf signalling, Beclin-1 interactome, BCR-ABL, PI3KCI/Akt/mTOR, FOXO1 signalling and p53.	Paclitaxel	119-129	AKT serine/threonine kinase 1	Homo sapiens	326-329
22765290-3	2012	In this review, we focus on highlighting several representative plant natural compounds such as curcumin, resveratrol, paclitaxel, oridonin, quercetin and plant lectin - that may lead to cancer cell death - for regulation of some core autophagic pathways, involved in Ras-Raf signalling, Beclin-1 interactome, BCR-ABL, PI3KCI/Akt/mTOR, FOXO1 signalling and p53.	Paclitaxel	119-129	mechanistic target of rapamycin kinase	Homo sapiens	330-334
22765290-3	2012	In this review, we focus on highlighting several representative plant natural compounds such as curcumin, resveratrol, paclitaxel, oridonin, quercetin and plant lectin - that may lead to cancer cell death - for regulation of some core autophagic pathways, involved in Ras-Raf signalling, Beclin-1 interactome, BCR-ABL, PI3KCI/Akt/mTOR, FOXO1 signalling and p53.	Paclitaxel	119-129	forkhead box O1	Homo sapiens	336-341
22765290-3	2012	In this review, we focus on highlighting several representative plant natural compounds such as curcumin, resveratrol, paclitaxel, oridonin, quercetin and plant lectin - that may lead to cancer cell death - for regulation of some core autophagic pathways, involved in Ras-Raf signalling, Beclin-1 interactome, BCR-ABL, PI3KCI/Akt/mTOR, FOXO1 signalling and p53.	Paclitaxel	119-129	tumor protein p53	Homo sapiens	357-360
22945507-8	2012	In our efforts to induce cell surface GRP78, we subjected the cells to doxorubicin and taxol that increased significantly the percent of GRP78 positive population.	Paclitaxel	87-92	heat shock protein family A (Hsp70) member 5	Homo sapiens	137-142
22622430-4	2012	We generated a direct in vivo xenograft model, and demonstrated that SP cells were resistant to paclitaxel, a substrate of ABCB1, both in vitro and in vivo.	Paclitaxel	96-106	ATP binding cassette subfamily B member 1	Homo sapiens	123-128
23170132-1	2012	This study aimed to investigate the impact of the combined use of the nuclear factor-kappaB (NF-kappaB) inhibitors pyrrolidine dithiocarbamate (PDTC), bortezomib or SN50, and the chemotherapy agents arsenic acid (As(2)O(3)), fluorouracil (5FU), oxaliplatin or paclitaxel on the growth and apoptosis of HT-29 cells.	Paclitaxel	260-270	nuclear factor kappa B subunit 1	Homo sapiens	70-91
22895534-5	2012	Compared to AdLacZ plus paclitaxel, AdNEP plus paclitaxel significantly inhibited DU145 cell growth and increased apoptosis as determined by increased caspase-3 and PARP-1 proteolytic fragments.	Paclitaxel	47-57	caspase 3	Homo sapiens	151-160
22895534-5	2012	Compared to AdLacZ plus paclitaxel, AdNEP plus paclitaxel significantly inhibited DU145 cell growth and increased apoptosis as determined by increased caspase-3 and PARP-1 proteolytic fragments.	Paclitaxel	47-57	poly(ADP-ribose) polymerase 1	Homo sapiens	165-171
25893133-0	2012	Human GM3 Synthase Attenuates Taxol-Triggered Apoptosis Associated with Downregulation of Caspase-3 in Ovarian Cancer Cells.	Paclitaxel	30-35	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	6-18
25893133-2	2012	MATERIALS AND METHOD: The roles of GM3 synthase (alpha2,3-sialyltransferase, ST3Gal V) in attenuating Taxol-induced apoptosis and triggering drug resistance were determined by cloning and overexpressing this enzyme in the SKOV3 human ovarian cancer cell line, treating SKOV3 and the transfectants (SKOV3/GS) with Taxol and determining apoptosis, cell survival, clonogenic ability, and caspase-3 activation.	Paclitaxel	102-107	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	35-47
25893133-2	2012	MATERIALS AND METHOD: The roles of GM3 synthase (alpha2,3-sialyltransferase, ST3Gal V) in attenuating Taxol-induced apoptosis and triggering drug resistance were determined by cloning and overexpressing this enzyme in the SKOV3 human ovarian cancer cell line, treating SKOV3 and the transfectants (SKOV3/GS) with Taxol and determining apoptosis, cell survival, clonogenic ability, and caspase-3 activation.	Paclitaxel	102-107	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	77-85
25893133-2	2012	MATERIALS AND METHOD: The roles of GM3 synthase (alpha2,3-sialyltransferase, ST3Gal V) in attenuating Taxol-induced apoptosis and triggering drug resistance were determined by cloning and overexpressing this enzyme in the SKOV3 human ovarian cancer cell line, treating SKOV3 and the transfectants (SKOV3/GS) with Taxol and determining apoptosis, cell survival, clonogenic ability, and caspase-3 activation.	Paclitaxel	102-107	caspase 3	Homo sapiens	385-394
25893133-2	2012	MATERIALS AND METHOD: The roles of GM3 synthase (alpha2,3-sialyltransferase, ST3Gal V) in attenuating Taxol-induced apoptosis and triggering drug resistance were determined by cloning and overexpressing this enzyme in the SKOV3 human ovarian cancer cell line, treating SKOV3 and the transfectants (SKOV3/GS) with Taxol and determining apoptosis, cell survival, clonogenic ability, and caspase-3 activation.	Paclitaxel	313-318	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	35-47
25893133-3	2012	RESULTS: In this report, we demonstrated that Taxol treatment resulted in apoptosis which was associated with caspase-3 activation.	Paclitaxel	46-51	caspase 3	Homo sapiens	110-119
25893133-4	2012	Taxol treatment upregulated the expression of human GM3 synthase, an enzyme that transfers a sialic acid to lactosylceramide.	Paclitaxel	0-5	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	52-64
25893133-5	2012	Moreover, we cloned the full-length GM3 synthase gene and showed for the first time that forced expression of GM3 synthase attenuated Taxol-induced apoptosis and increased resistance to Taxol in SKOV3 cells.	Paclitaxel	134-139	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	36-48
25893133-5	2012	Moreover, we cloned the full-length GM3 synthase gene and showed for the first time that forced expression of GM3 synthase attenuated Taxol-induced apoptosis and increased resistance to Taxol in SKOV3 cells.	Paclitaxel	134-139	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	110-122
25893133-5	2012	Moreover, we cloned the full-length GM3 synthase gene and showed for the first time that forced expression of GM3 synthase attenuated Taxol-induced apoptosis and increased resistance to Taxol in SKOV3 cells.	Paclitaxel	186-191	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	36-48
25893133-5	2012	Moreover, we cloned the full-length GM3 synthase gene and showed for the first time that forced expression of GM3 synthase attenuated Taxol-induced apoptosis and increased resistance to Taxol in SKOV3 cells.	Paclitaxel	186-191	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	110-122
25893133-6	2012	CONCLUSIONS: GM3 synthase overexpression inhibited Taxol-triggered caspase-3 activation, revealing that upregulation of GM3 synthase prevents apoptosis and hence reduces the efficacy of Taxol therapy.	Paclitaxel	51-56	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	13-25
25893133-6	2012	CONCLUSIONS: GM3 synthase overexpression inhibited Taxol-triggered caspase-3 activation, revealing that upregulation of GM3 synthase prevents apoptosis and hence reduces the efficacy of Taxol therapy.	Paclitaxel	51-56	caspase 3	Homo sapiens	67-76
25893133-6	2012	CONCLUSIONS: GM3 synthase overexpression inhibited Taxol-triggered caspase-3 activation, revealing that upregulation of GM3 synthase prevents apoptosis and hence reduces the efficacy of Taxol therapy.	Paclitaxel	51-56	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	120-132
25893133-6	2012	CONCLUSIONS: GM3 synthase overexpression inhibited Taxol-triggered caspase-3 activation, revealing that upregulation of GM3 synthase prevents apoptosis and hence reduces the efficacy of Taxol therapy.	Paclitaxel	186-191	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	13-25
25893133-6	2012	CONCLUSIONS: GM3 synthase overexpression inhibited Taxol-triggered caspase-3 activation, revealing that upregulation of GM3 synthase prevents apoptosis and hence reduces the efficacy of Taxol therapy.	Paclitaxel	186-191	caspase 3	Homo sapiens	67-76
25893133-6	2012	CONCLUSIONS: GM3 synthase overexpression inhibited Taxol-triggered caspase-3 activation, revealing that upregulation of GM3 synthase prevents apoptosis and hence reduces the efficacy of Taxol therapy.	Paclitaxel	186-191	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	120-132
22116711-8	2012	In contrast, the IC(50)  values of three clinical anticancer drugs, etoposide, paclitaxel and vinblastine were significantly elevated in HER2 and/or P-glycoprotein overexpressing cells.	Paclitaxel	79-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
22855252-5	2012	We have shown before that NCI/ADR-RES cells were 1,000-fold less sensitive to paclitaxel than MDA-MB-435 cells in correspondence to P-glycoprotein overexpression and up to 20-fold lower uptake of the drug in the resistant cells.	Paclitaxel	78-88	ATP binding cassette subfamily B member 1	Homo sapiens	132-146
22855252-10	2012	Thus, structural modifications of taxanes resulting in their decreased P-glycoprotein-related transport probably caused their higher efficiency than paclitaxel in multidrug-resistant NCI/ADR-RES tumour cells.	Paclitaxel	149-159	ATP binding cassette subfamily B member 1	Homo sapiens	71-85
23205070-0	2012	Cyclin A overexpression is associated with chemosensitivity to paclitaxel-based chemotherapy in patients with esophageal squamous cell carcinoma.	Paclitaxel	63-73	cyclin A2	Homo sapiens	0-8
23205070-1	2012	The aim of this study was to investigate the correlation between cyclin A expression and efficacy of paclitaxel-based chemotherapy in patients with esophageal squamous cell carcinoma (ESCC).	Paclitaxel	101-111	cyclin A2	Homo sapiens	65-73
23205070-5	2012	Univariate and multivariate Cox analysis revealed that clinicopathological stage, degree of differentiation and expression of cyclin A were independent prognosis factors in patients with ESCC following paclitaxel-based chemotherapy.	Paclitaxel	202-212	cyclin A2	Homo sapiens	126-134
23205070-6	2012	ESCC patients with positive cyclin A expression demonstrated an increased sensitivity to paclitaxel-based chemotherapy, suggesting that cyclin A may be used as a marker to predict the treatment efficacy of paclitaxel in patients with ESCC.	Paclitaxel	89-99	cyclin A2	Homo sapiens	28-36
23205070-6	2012	ESCC patients with positive cyclin A expression demonstrated an increased sensitivity to paclitaxel-based chemotherapy, suggesting that cyclin A may be used as a marker to predict the treatment efficacy of paclitaxel in patients with ESCC.	Paclitaxel	89-99	cyclin A2	Homo sapiens	136-144
23205070-6	2012	ESCC patients with positive cyclin A expression demonstrated an increased sensitivity to paclitaxel-based chemotherapy, suggesting that cyclin A may be used as a marker to predict the treatment efficacy of paclitaxel in patients with ESCC.	Paclitaxel	206-216	cyclin A2	Homo sapiens	28-36
23205070-6	2012	ESCC patients with positive cyclin A expression demonstrated an increased sensitivity to paclitaxel-based chemotherapy, suggesting that cyclin A may be used as a marker to predict the treatment efficacy of paclitaxel in patients with ESCC.	Paclitaxel	206-216	cyclin A2	Homo sapiens	136-144
22549660-6	2012	Our findings indicated that by synergism with anticancer drugs, FLX modulation of apoptosis via targeting p53 and Bcl-2 expression, FLX reverse the breast cancer cell"s resistance and enhance the chemosensitivity to ADM and PTX.	Paclitaxel	224-227	tumor protein p53	Homo sapiens	106-109
22549660-6	2012	Our findings indicated that by synergism with anticancer drugs, FLX modulation of apoptosis via targeting p53 and Bcl-2 expression, FLX reverse the breast cancer cell"s resistance and enhance the chemosensitivity to ADM and PTX.	Paclitaxel	224-227	BCL2 apoptosis regulator	Homo sapiens	114-119
22971921-5	2012	SP cells are resistant to paclitaxel because of the upregulation of ABCB1 and ABCB5.	Paclitaxel	26-36	ATP binding cassette subfamily B member 1	Homo sapiens	68-73
24716145-3	2012	Both SB and PTX alone or SB+PTX treatment inhibited 4T1 cell migration and motility possibly through downregulation of the serpin protease nexin-1 (PN-1) and N-cadherin expression, inhibition of matrix metalloprotease (MMP)-9 activity, and upregulation of E-cadherin.	Paclitaxel	12-15	cadherin 1	Mus musculus	256-266
24716145-3	2012	Both SB and PTX alone or SB+PTX treatment inhibited 4T1 cell migration and motility possibly through downregulation of the serpin protease nexin-1 (PN-1) and N-cadherin expression, inhibition of matrix metalloprotease (MMP)-9 activity, and upregulation of E-cadherin.	Paclitaxel	28-31	cadherin 1	Mus musculus	256-266
22869527-7	2012	Indeed, we demonstrate that combining paclitaxel with a small-molecule inhibitor of the gametogenic and tumor cell mitotic protein TACC3 leads to enhanced centrosomal abnormalities, activation of death programs, and loss of anchorage-independent growth.	Paclitaxel	38-48	transforming acidic coiled-coil containing protein 3	Homo sapiens	131-136
23960813-2	2012	The specific indication that was withdrawn was for the use of bevacizumab in metastatic breast cancer, with paclitaxel for the treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer.	Paclitaxel	108-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	199-203
22851567-0	2012	Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma.	Paclitaxel	37-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-106
22116711-8	2012	In contrast, the IC(50)  values of three clinical anticancer drugs, etoposide, paclitaxel and vinblastine were significantly elevated in HER2 and/or P-glycoprotein overexpressing cells.	Paclitaxel	79-89	ATP binding cassette subfamily B member 1	Homo sapiens	149-163
22824824-10	2012	Six of them (DLC1, CHFR, ABCC5, PEG10, ERBB2, and GSTP1) were independently confirmed to contribute to taxol resistance by both methylation-specific PCR and quantitative real-time PCR.	Paclitaxel	103-108	DLC1 Rho GTPase activating protein	Homo sapiens	13-17
22843789-7	2012	CONCLUSIONS: A genome-wide association study has identified novel genetic markers of paclitaxel-induced sensory peripheral neuropathy, including a common polymorphism in FGD4, a congenital peripheral neuropathy gene.	Paclitaxel	85-95	FYVE, RhoGEF and PH domain containing 4	Homo sapiens	170-174
22950635-8	2012	The PI3K/Akt pathway and other pathways associated with cyclins, DNA replication and cell cycle/mitotic regulation were also associated with the synergy of DAC and PTX against RCC.	Paclitaxel	164-167	AKT serine/threonine kinase 1	Homo sapiens	9-12
22987486-1	2012	Recent studies have shown that the microtubule-stabilizing drug paclitaxel, which is commonly used for the treatment of prostate cancer, inhibits signaling from the androgen receptor by inhibiting its nuclear accumulation downstream of microtubule stabilization.	Paclitaxel	64-74	androgen receptor	Homo sapiens	165-182
22824824-10	2012	Six of them (DLC1, CHFR, ABCC5, PEG10, ERBB2, and GSTP1) were independently confirmed to contribute to taxol resistance by both methylation-specific PCR and quantitative real-time PCR.	Paclitaxel	103-108	paternally expressed 10	Homo sapiens	32-37
22824824-10	2012	Six of them (DLC1, CHFR, ABCC5, PEG10, ERBB2, and GSTP1) were independently confirmed to contribute to taxol resistance by both methylation-specific PCR and quantitative real-time PCR.	Paclitaxel	103-108	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-44
22717365-5	2012	Moreover, PTX and shRNA simultaneously delivered to SKOV-3 cells lead to efficient reduction in the survivin and Bcl-2 expression as well as synergistic cell apoptotic induction in the in vitro study.	Paclitaxel	10-13	BCL2 apoptosis regulator	Homo sapiens	113-118
22772380-13	2012	Primary therapy with concurrent trastuzumab plus paclitaxel-FEC for HER2-positive breast cancer in everyday practice is highly effective and safe confirming the results observed in a randomized trial stopped prematurely.	Paclitaxel	49-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-72
22743248-7	2012	We demonstrated that treatment of A375 cells with IS in combination with paclitaxel resulted in a significant decrease in the production of IL-8 and VEGF, compared with paclitaxel alone.	Paclitaxel	73-83	C-X-C motif chemokine ligand 8	Homo sapiens	140-144
22743248-7	2012	We demonstrated that treatment of A375 cells with IS in combination with paclitaxel resulted in a significant decrease in the production of IL-8 and VEGF, compared with paclitaxel alone.	Paclitaxel	73-83	vascular endothelial growth factor A	Homo sapiens	149-153
22743248-8	2012	Recent studies suggest that TLR4-MyD88-ERK signaling may be a novel target for reversing chemoresistance to paclitaxel.	Paclitaxel	108-118	mitogen-activated protein kinase 1	Homo sapiens	39-42
22743248-9	2012	Our flow cytometry and Western blot data showed that paclitaxel activated TLR4-MyD88-ERK signaling and that IS treatment could effectively inhibit this paclitaxel-induced activation of TLR4-MyD88-ERK signaling.	Paclitaxel	53-63	mitogen-activated protein kinase 1	Homo sapiens	85-88
22743248-9	2012	Our flow cytometry and Western blot data showed that paclitaxel activated TLR4-MyD88-ERK signaling and that IS treatment could effectively inhibit this paclitaxel-induced activation of TLR4-MyD88-ERK signaling.	Paclitaxel	53-63	mitogen-activated protein kinase 1	Homo sapiens	196-199
22743248-9	2012	Our flow cytometry and Western blot data showed that paclitaxel activated TLR4-MyD88-ERK signaling and that IS treatment could effectively inhibit this paclitaxel-induced activation of TLR4-MyD88-ERK signaling.	Paclitaxel	152-162	mitogen-activated protein kinase 1	Homo sapiens	196-199
23019416-8	2012	Paclitaxel and splitomicin promoted translocation into the nucleus--and hence activation--of FOXO3a, a negative regulator of cell motility.	Paclitaxel	0-10	forkhead box O3	Homo sapiens	93-99
22734651-3	2012	H23 and DLD-1 cells (human lung and colon adenocarcinoma cell lines) with acquired resistance to carfilzomib displayed marked cross-resistance to YU-101, a closely related proteasome inhibitor, and paclitaxel, a known substrate of Pgp.	Paclitaxel	198-208	ATP binding cassette subfamily B member 1	Homo sapiens	231-234
22742525-0	2012	Paclitaxel-loaded SCK nanoparticles: an investigation of loading capacity and cell killing abilities in vitro.	Paclitaxel	0-10	SHC adaptor protein 2	Homo sapiens	18-21
22734125-3	2012	Here, we provide unprecedented evidence that vascular endothelial growth factor receptor inhibitors trigger a painful neuropathy and aggravate paclitaxel-induced neuropathies in mice.	Paclitaxel	143-153	vascular endothelial growth factor A	Homo sapiens	45-79
22734125-5	2012	In vitro, vascular endothelial growth factor prevented primary dorsal root ganglion cultures from paclitaxel-induced neuronal stress and cell death by counteracting mitochondrial membrane potential decreases and normalizing hyperacetylation of alpha-tubulin.	Paclitaxel	98-108	vascular endothelial growth factor A	Homo sapiens	10-44
21920731-10	2012	In vitro response for Paclitaxel/Epirubicin was most frequently observed for cases in the basal category (40.3%) compared to HER2-like (25.8%) and luminal cases (28.6%).	Paclitaxel	22-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
22871047-7	2012	The HIN-1 gene was over-expressed in ES2 cells, a significant reduction in cell growth and induction of apoptosis, and increasing paclitaxel sensitivity by reducing phosphorylation of Akt were observed.	Paclitaxel	130-140	OTU deubiquitinase 4	Homo sapiens	4-9
22871047-7	2012	The HIN-1 gene was over-expressed in ES2 cells, a significant reduction in cell growth and induction of apoptosis, and increasing paclitaxel sensitivity by reducing phosphorylation of Akt were observed.	Paclitaxel	130-140	AKT serine/threonine kinase 1	Homo sapiens	184-187
22871047-9	2012	Ectopic expression of the HIN-1 gene increased paclitaxel sensitivity which is partly through Akt pathway.	Paclitaxel	47-57	OTU deubiquitinase 4	Homo sapiens	26-31
22871047-9	2012	Ectopic expression of the HIN-1 gene increased paclitaxel sensitivity which is partly through Akt pathway.	Paclitaxel	47-57	AKT serine/threonine kinase 1	Homo sapiens	94-97
22687601-9	2012	CONCLUSIONS: In metastatic breast cancer, metabolomics may play a role in sub selecting patients with HER2 positive disease with greater sensitivity to paclitaxel plus lapatinib.	Paclitaxel	152-162	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
22632055-5	2012	Importantly, CCT129202 increased the inhibitory effect of vincristine and paclitaxel on ABCB1 overexpressing KBv200 cell xenografts in nude mice and human esophageal cancer tissue overexpressing ABCB1 ex vivo, respectively.	Paclitaxel	74-84	ATP binding cassette subfamily B member 1	Homo sapiens	88-93
22632055-5	2012	Importantly, CCT129202 increased the inhibitory effect of vincristine and paclitaxel on ABCB1 overexpressing KBv200 cell xenografts in nude mice and human esophageal cancer tissue overexpressing ABCB1 ex vivo, respectively.	Paclitaxel	74-84	ATP binding cassette subfamily B member 1	Homo sapiens	195-200
22753724-8	2012	The expression of caspase-3 and -7 was induced in (5Z)-7-oxozeaenol treated HeLa cells, in comparison with those treated with paclitaxel.	Paclitaxel	126-136	caspase 3	Homo sapiens	18-34
22449053-4	2012	Using an IFNgamma ELISPOT assay, it was found that administration of 1 mg paclitaxel/kg in combination with the peptide vaccination strongly increased the frequencies of TRP-2 specific spleen T-cells as compared to levels due to the vaccination alone.	Paclitaxel	74-84	interferon gamma	Mus musculus	9-17
22534478-4	2012	RESULTS: p53 expression were associated with the significantly shorter disease-free survival (DFS) (p&lt;0.001) and overall survival (OS) (p=0.012) in the curatively resected advanced gastric cancer patients receiving capecitabine plus paclitaxel.	Paclitaxel	236-246	tumor protein p53	Homo sapiens	9-12
22534478-6	2012	CONCLUSIONS: p53 expression positive might predict prognosis in gastric cancer patients who underwent curative surgery followed by adjuvant capecitabine plus paclitaxel chemotherapy.	Paclitaxel	158-168	tumor protein p53	Homo sapiens	13-16
22534478-7	2012	A favorable effect of capecitabine plus paclitaxel might therefore be expected in patients that do not express p53.	Paclitaxel	40-50	tumor protein p53	Homo sapiens	111-114
22680343-7	2012	AIMS: To evaluate the use of rosiglitazone and the erythromycin breath test (ERMBT), as probes of CYP2C8 and CYP3A4, respectively, to explain inter-individual variability in paclitaxel exposure.	Paclitaxel	174-184	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	109-115
22543280-8	2012	Estrogen induced GRP78 expression, which was correlated with cell viability and resistance to paclitaxel and cisplatin.	Paclitaxel	94-104	heat shock protein family A (Hsp70) member 5	Homo sapiens	17-22
22543280-9	2012	Western blot analysis indicated that active caspase-3 and the 85-kDa protein poly (ADP-ribose) polymerase (PARP) were increased by incubation with either paclitaxel or cisplatin, suggesting that the apoptotic pathway was involved in cancer-drug-induced cell death.	Paclitaxel	154-164	caspase 3	Homo sapiens	44-53
22543280-9	2012	Western blot analysis indicated that active caspase-3 and the 85-kDa protein poly (ADP-ribose) polymerase (PARP) were increased by incubation with either paclitaxel or cisplatin, suggesting that the apoptotic pathway was involved in cancer-drug-induced cell death.	Paclitaxel	154-164	poly(ADP-ribose) polymerase 1	Homo sapiens	107-111
22283566-0	2012	Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner.	Paclitaxel	0-10	toll-like receptor 4	Mus musculus	107-111
22283566-6	2012	This effect of paclitaxel was TLR4-independent since it was not diminished in cell cultures originated from TLR4-/- mice.	Paclitaxel	15-25	toll-like receptor 4	Mus musculus	30-34
22449053-7	2012	Furthermore, in paclitaxel-treated mice, a significant augmentation of natural killer (NK) cell numbers in the bone marrow and their ability to produce IFNgamma were observed.	Paclitaxel	16-26	interferon gamma	Mus musculus	152-160
22469813-6	2012	On the other             hand, the number of apoptotic cells significantly increased in Ishikawa and Hec-1a             cells transfected with CHFR siRNA after treatment with taxol, which was associated             with cyclin B1 nuclear localization.	Paclitaxel	175-180	NDC80 kinetochore complex component	Homo sapiens	101-106
22261337-0	2012	Pim-1 knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers through inhibition of NHEJ DNA repair.	Paclitaxel	28-38	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	0-5
22437668-9	2012	A subset of SLC genes, namely SLC31A2, SLC43A1, SLC35A5, and SLC41A2, was associated with paclitaxel sensitivity and had regulating single nucleotide polymorphisms that were also associated with paclitaxel-induced cytotoxicity.	Paclitaxel	90-100	solute carrier family 41 member 2	Homo sapiens	61-68
22437668-9	2012	A subset of SLC genes, namely SLC31A2, SLC43A1, SLC35A5, and SLC41A2, was associated with paclitaxel sensitivity and had regulating single nucleotide polymorphisms that were also associated with paclitaxel-induced cytotoxicity.	Paclitaxel	195-205	solute carrier family 41 member 2	Homo sapiens	61-68
22437668-11	2012	Using RNA interference, we demonstrated increased paclitaxel susceptibility with knockdown of three SLC genes, SLC31A2, SLC35A5, and SLC41A2.	Paclitaxel	50-60	solute carrier family 41 member 2	Homo sapiens	133-140
22545578-0	2012	Up-regulation of P-glycoprotein is involved in the increased paclitaxel resistance in human esophageal cancer radioresistant cells.	Paclitaxel	61-71	ATP binding cassette subfamily B member 1	Homo sapiens	17-31
22545578-11	2012	CONCLUSIONS: These results suggested that up-regulation of P-gp is involved in the increased paclitaxel resistance but not cisplatin resistance in ionization radiation-induced human esophageal squamous cancer radioresistant cells.	Paclitaxel	93-103	ATP binding cassette subfamily B member 1	Homo sapiens	59-63
22757735-6	2012	At present, Phase III data are only available for the VEGF-targeted monoclonal antibody, bevacizumab, and that has demonstrated a progression-free survival benefit when used in combination with first-line paclitaxel/carboplatin and continued as maintenance therapy.	Paclitaxel	205-215	vascular endothelial growth factor A	Homo sapiens	54-58
22967465-9	2012	The Western blot analysis demonstrated that treatment with TSA/paclitaxel led to a synergistic increase of acetylated tubulin, PARP and caspase-3, and reduced the expression of survivin.	Paclitaxel	63-73	poly(ADP-ribose) polymerase 1	Homo sapiens	127-131
22967465-9	2012	The Western blot analysis demonstrated that treatment with TSA/paclitaxel led to a synergistic increase of acetylated tubulin, PARP and caspase-3, and reduced the expression of survivin.	Paclitaxel	63-73	caspase 3	Homo sapiens	136-145
22608923-6	2012	By contrast, depletion of Pin1 in cancer cells leads to elevated Fbw7 expression, which subsequently reduces Mcl-1 abundance, sensitizing cancer cells to Taxol.	Paclitaxel	154-159	F-box and WD repeat domain containing 7	Homo sapiens	65-69
22261337-4	2012	In the absence of Pim-1, the ability of DNA repair significantly decreases when exposed to paclitaxel, leading to severe DNA damage and apoptosis.	Paclitaxel	91-101	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	18-23
22642877-5	2012	RESULTS: Four days after treatment the lethality of cisplatin-paclitaxel was evidenced by reduced number of cells, increased hypodiploid DNA content, morphological features of apoptosis, DNA fragmentation, and cleavage of caspase-3, and of its downstream substrate PARP.	Paclitaxel	62-72	caspase 3	Homo sapiens	222-231
22642877-5	2012	RESULTS: Four days after treatment the lethality of cisplatin-paclitaxel was evidenced by reduced number of cells, increased hypodiploid DNA content, morphological features of apoptosis, DNA fragmentation, and cleavage of caspase-3, and of its downstream substrate PARP.	Paclitaxel	62-72	poly(ADP-ribose) polymerase 1	Homo sapiens	265-269
22709569-5	2012	RESULTS: Here we show that carbonate apatite-mediated delivery of siRNA against PLC-gamma-2 (PLCG2) and calmodulin 1 (CALM1) genes has led to the sensitization of a human cervical cancer cell line to doxorubicin- and paclitaxel depending on the dosage of the individual drug whereas no such enhancement in cell death was observed with cisplatin irrespective of the dosage following intracellular delivery of the siRNAs.	Paclitaxel	217-227	calmodulin 1	Homo sapiens	104-116
22716997-8	2012	Caspase-3 fluorescent assay was used to quantify caspase-3 activity of EC treated with everolimus or paclitaxel (10-5 M, 10-7 M) for 24 hours.	Paclitaxel	101-111	caspase 3	Sus scrofa	0-9
22716997-8	2012	Caspase-3 fluorescent assay was used to quantify caspase-3 activity of EC treated with everolimus or paclitaxel (10-5 M, 10-7 M) for 24 hours.	Paclitaxel	101-111	caspase 3	Sus scrofa	49-58
22716997-12	2012	In ECs, paclitaxel (10-5 M) significantly increased caspase-3 activity (p &lt; 0.05) while everolimus had no effect.	Paclitaxel	8-18	caspase 3	Sus scrofa	52-61
22709569-0	2012	Knockdown of PLC-gamma-2 and calmodulin 1 genes sensitizes human cervical adenocarcinoma cells to doxorubicin and paclitaxel.	Paclitaxel	114-124	calmodulin 1	Homo sapiens	29-41
22709569-5	2012	RESULTS: Here we show that carbonate apatite-mediated delivery of siRNA against PLC-gamma-2 (PLCG2) and calmodulin 1 (CALM1) genes has led to the sensitization of a human cervical cancer cell line to doxorubicin- and paclitaxel depending on the dosage of the individual drug whereas no such enhancement in cell death was observed with cisplatin irrespective of the dosage following intracellular delivery of the siRNAs.	Paclitaxel	217-227	calmodulin 1	Homo sapiens	118-123
22709569-6	2012	CONCLUSION: Thus, PLCG2 and CALM1 genes are two potential targets for gene knockdown in doxorubicin and paclitaxel-based chemotherapy of cervical cancer.	Paclitaxel	104-114	calmodulin 1	Homo sapiens	28-33
22076480-0	2012	Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction.	Paclitaxel	0-10	BCL2 like 1	Homo sapiens	98-104
22672901-3	2012	In vitro, recombinant human Fidgetin severs taxol-stabilized microtubules along their length and promotes depolymerization, primarily from their minus-ends.	Paclitaxel	44-49	fidgetin, microtubule severing factor	Homo sapiens	28-36
21909982-0	2012	Estrogen receptor-alpha directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.	Paclitaxel	58-68	estrogen receptor 1	Homo sapiens	0-23
21909982-5	2012	Next, we examined the effects of alterations in ERalpha expression levels on sensitivity to paclitaxel, a key drug in NAC, by stable expression of ERalpha in ER-negative SKBR3 cells and by siRNA-mediated down-regulation of ERalpha in ER-positive MCF-7 cells, and showed that ERalpha expression and sensitivity to paclitaxel showed an inverse correlation.	Paclitaxel	92-102	estrogen receptor 1	Homo sapiens	48-55
21909982-5	2012	Next, we examined the effects of alterations in ERalpha expression levels on sensitivity to paclitaxel, a key drug in NAC, by stable expression of ERalpha in ER-negative SKBR3 cells and by siRNA-mediated down-regulation of ERalpha in ER-positive MCF-7 cells, and showed that ERalpha expression and sensitivity to paclitaxel showed an inverse correlation.	Paclitaxel	92-102	estrogen receptor 1	Homo sapiens	147-154
22076480-8	2012	In breast cancer tissues, high Bcl-xL expression was correlated with a shorter time of disease-free survival in patients treated with a chemotherapeutic regimen that contains paclitaxel, in a statistically significant way.	Paclitaxel	175-185	BCL2 like 1	Homo sapiens	31-37
21909982-5	2012	Next, we examined the effects of alterations in ERalpha expression levels on sensitivity to paclitaxel, a key drug in NAC, by stable expression of ERalpha in ER-negative SKBR3 cells and by siRNA-mediated down-regulation of ERalpha in ER-positive MCF-7 cells, and showed that ERalpha expression and sensitivity to paclitaxel showed an inverse correlation.	Paclitaxel	92-102	estrogen receptor 1	Homo sapiens	147-154
21909982-5	2012	Next, we examined the effects of alterations in ERalpha expression levels on sensitivity to paclitaxel, a key drug in NAC, by stable expression of ERalpha in ER-negative SKBR3 cells and by siRNA-mediated down-regulation of ERalpha in ER-positive MCF-7 cells, and showed that ERalpha expression and sensitivity to paclitaxel showed an inverse correlation.	Paclitaxel	92-102	estrogen receptor 1	Homo sapiens	147-154
22764771-5	2012	Important examples include ketoconazole inhibition of hepatic CYP3A4 in order to increase systemic exposure to docetaxel, irinotecan and etoposide, and cyclosporine inhibition of intestinal ATP-binding cassette transporters in order to decrease the toxicity of irinotecan and increase the bioavailability of oral docetaxel, paclitaxel and topotecan.	Paclitaxel	324-334	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
21909982-8	2012	Finally, we demonstrate herein that ERalpha knockdown in MCF-7 cells prevents deacetylation of alpha-tubulin, thereby increasing sensitivity to paclitaxel.	Paclitaxel	144-154	estrogen receptor 1	Homo sapiens	36-43
21909982-9	2012	Taken together, these results suggest that ERalpha expression directly regulates sensitivity to paclitaxel in NAC for breast cancer via the effect on microtubule stability.	Paclitaxel	96-106	estrogen receptor 1	Homo sapiens	43-50
22472175-10	2012	Suppression of L1CAM expression in ATC cell lines increased chemosensitivity to gemcitabine or paclitaxel.	Paclitaxel	95-105	L1 cell adhesion molecule	Homo sapiens	15-20
23359770-7	2012	RESULTS: The IC50 of paclitaxel in MDR1shRNA-transfected group was significantly reduced (1.986+-0.153) mumol/ml as compared with that in negative control (5.246+-0.107) mumol/ml and empty vector-transfected group (5.212+-0.075) mumol/ml (P&lt;0.05).	Paclitaxel	21-31	ATP binding cassette subfamily B member 1	Homo sapiens	35-39
23359770-10	2012	CONCLUSION: The present study demonstrated that the eukaryotic expression plasmid of shRNA targeting on MDR1 inhibited the expression of MDR1 effectively, thus enhance the sensitivity of A2780/Taxol cells to paclitaxel.	Paclitaxel	208-218	ATP binding cassette subfamily B member 1	Homo sapiens	104-108
23359770-10	2012	CONCLUSION: The present study demonstrated that the eukaryotic expression plasmid of shRNA targeting on MDR1 inhibited the expression of MDR1 effectively, thus enhance the sensitivity of A2780/Taxol cells to paclitaxel.	Paclitaxel	208-218	ATP binding cassette subfamily B member 1	Homo sapiens	137-141
22635028-10	2012	Enhanced paclitaxel or cisplatin sensitivity was observed in A2780 cells or C13K cells treated with Wnt2B siRNA, respectively.	Paclitaxel	9-19	Wnt family member 2B	Homo sapiens	100-105
22422925-9	2012	In addition, GL and ILG inhibited NF-kappaB activation and IL-6 production induced by paclitaxel, a nonbacterial TLR4 ligand.	Paclitaxel	86-96	interleukin 6	Mus musculus	59-63
22422925-9	2012	In addition, GL and ILG inhibited NF-kappaB activation and IL-6 production induced by paclitaxel, a nonbacterial TLR4 ligand.	Paclitaxel	86-96	toll-like receptor 4	Mus musculus	113-117
22238053-0	2012	Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol.	Paclitaxel	189-194	BCL2 apoptosis regulator	Homo sapiens	64-68
21380780-2	2012	We present a case of a patient who suffered from metastatic SDC that was positive for human epidermal growth factor receptor-2 (HER-2) and attained complete objective response, as seen on PET-CT after combined treatment with paclitaxel, carboplatin, and trastuzumab.	Paclitaxel	225-235	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-126
22238053-11	2012	Treatment of AGS cells with 10 muM cisplatin, 0.5 muM etoposide and 10 nM taxol affected the BCL2, BAX and BCL2L12 mRNA levels, compared to the untreated cells.	Paclitaxel	74-79	BCL2 apoptosis regulator	Homo sapiens	93-97
22238053-11	2012	Treatment of AGS cells with 10 muM cisplatin, 0.5 muM etoposide and 10 nM taxol affected the BCL2, BAX and BCL2L12 mRNA levels, compared to the untreated cells.	Paclitaxel	74-79	BCL2 associated X, apoptosis regulator	Homo sapiens	99-102
22238053-13	2012	Moreover, taxol had an up-regulating effect on both BCL2 and BAX transcript levels after 48 h of incubation.	Paclitaxel	10-15	BCL2 apoptosis regulator	Homo sapiens	52-56
22238053-13	2012	Moreover, taxol had an up-regulating effect on both BCL2 and BAX transcript levels after 48 h of incubation.	Paclitaxel	10-15	BCL2 associated X, apoptosis regulator	Homo sapiens	61-64
22433870-4	2012	In estrogen receptor alpha-positive (ER(+)) breast cancer cells, phosphorylation of caveolin-1 (CAV1) on Tyr-14 facilitates mitochondrial apoptosis by increasing BCL2 phosphorylation in response to low dose paclitaxel (10 nM).	Paclitaxel	207-217	estrogen receptor 1	Homo sapiens	3-26
22640878-0	2012	ss3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.	Paclitaxel	84-94	SS3	Homo sapiens	0-3
22640878-7	2012	Suppression of ss3 integrin in SKOV3 cells increases resistance to paclitaxel-induced cell death while suppression of ss1 integrin has no effect.	Paclitaxel	67-77	SS3	Homo sapiens	15-18
22640878-8	2012	Furthermore, suppression of TGFBI expression stimulates a paclitaxel resistant phenotype while suppression of fibronectin expression, which primarily signals through a ss1 integrin-mediated pathway, increases paclitaxel sensitivity.	Paclitaxel	209-219	fibronectin 1	Homo sapiens	110-121
22433870-4	2012	In estrogen receptor alpha-positive (ER(+)) breast cancer cells, phosphorylation of caveolin-1 (CAV1) on Tyr-14 facilitates mitochondrial apoptosis by increasing BCL2 phosphorylation in response to low dose paclitaxel (10 nM).	Paclitaxel	207-217	caveolin 1	Homo sapiens	84-94
22433870-0	2012	Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).	Paclitaxel	69-79	caveolin 1	Homo sapiens	24-34
22433870-0	2012	Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).	Paclitaxel	69-79	BCL2 apoptosis regulator	Homo sapiens	94-98
22433870-4	2012	In estrogen receptor alpha-positive (ER(+)) breast cancer cells, phosphorylation of caveolin-1 (CAV1) on Tyr-14 facilitates mitochondrial apoptosis by increasing BCL2 phosphorylation in response to low dose paclitaxel (10 nM).	Paclitaxel	207-217	caveolin 1	Homo sapiens	96-100
22433870-0	2012	Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).	Paclitaxel	69-79	BCL2 like 1	Homo sapiens	103-108
22433870-0	2012	Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).	Paclitaxel	69-79	mitogen-activated protein kinase 8	Homo sapiens	122-145
22433870-4	2012	In estrogen receptor alpha-positive (ER(+)) breast cancer cells, phosphorylation of caveolin-1 (CAV1) on Tyr-14 facilitates mitochondrial apoptosis by increasing BCL2 phosphorylation in response to low dose paclitaxel (10 nM).	Paclitaxel	207-217	BCL2 apoptosis regulator	Homo sapiens	162-166
22433870-0	2012	Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).	Paclitaxel	69-79	mitogen-activated protein kinase 8	Homo sapiens	147-150
22433870-8	2012	We now show that CAV1 variants play distinct roles in paclitaxel-mediated cell death/survival.	Paclitaxel	54-64	caveolin 1	Homo sapiens	17-21
22433870-14	2012	Thus, we highlight novel roles for CAV1 variants in cell death; wtCAV1 promotes cell death, whereas CAV1beta promotes cell survival by preventing inactivation of BCL2 and BCLxL via JNK in paclitaxel-mediated apoptosis.	Paclitaxel	188-198	caveolin 1	Homo sapiens	35-39
22433870-14	2012	Thus, we highlight novel roles for CAV1 variants in cell death; wtCAV1 promotes cell death, whereas CAV1beta promotes cell survival by preventing inactivation of BCL2 and BCLxL via JNK in paclitaxel-mediated apoptosis.	Paclitaxel	188-198	BCL2 like 1	Homo sapiens	171-176
22433870-14	2012	Thus, we highlight novel roles for CAV1 variants in cell death; wtCAV1 promotes cell death, whereas CAV1beta promotes cell survival by preventing inactivation of BCL2 and BCLxL via JNK in paclitaxel-mediated apoptosis.	Paclitaxel	188-198	mitogen-activated protein kinase 8	Homo sapiens	181-184
22544328-6	2012	The higher level of ABCG2 efflux pump could explain increased resistance to taxol and VP16, and higher levels of genes involved in nucleotide excision repair partially explain the resistance to cisplatin.	Paclitaxel	76-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	20-25
22578285-8	2012	Indeed, these signatures were independently predictive of chemotherapy response after adjusting for standard clinic-pathological variables such as age, grade, and estrogen receptor status in a cohort of 488 breast cancer patients treated with adriamycin and taxotere/taxol.	Paclitaxel	267-272	estrogen receptor 1	Homo sapiens	163-180
22369858-8	2012	In the taxol resistant cell lines, the IC50 values of paclitaxel and parthenolide were 233nM and 32muM, respectively, while the combination had an IC(50) of 128nM.	Paclitaxel	7-12	latexin	Homo sapiens	99-102
22369858-8	2012	In the taxol resistant cell lines, the IC50 values of paclitaxel and parthenolide were 233nM and 32muM, respectively, while the combination had an IC(50) of 128nM.	Paclitaxel	54-64	latexin	Homo sapiens	99-102
21074392-5	2012	Moreover, taxol caused an increase in c-Jun NH(2)-terminal kinase (JNK) and p38 activities, two of the well known mediators of the stress activation pathways.	Paclitaxel	10-15	mitogen-activated protein kinase 8	Homo sapiens	38-65
22323130-0	2012	Resistance to paclitaxel in hepatoma cells is related to static JNK activation and prohibition into entry of mitosis.	Paclitaxel	14-24	mitogen-activated protein kinase 8	Homo sapiens	64-67
22323130-7	2012	In response to paclitaxel, Bcl-2 was highly phosphorylated in death-prone cells, whereas much less Bcl-2 was phosphorylated in death-reluctant cells.	Paclitaxel	15-25	BCL2 apoptosis regulator	Homo sapiens	27-32
22323130-10	2012	In death-reluctant cells, inbuild-phospho-JNK levels were high but no longer activated in response to paclitaxel.	Paclitaxel	102-112	mitogen-activated protein kinase 8	Homo sapiens	42-45
22392969-4	2012	METHODS: To explore the potential of CB(2) agonists for preventing paclitaxel-induced neuropathy, we designed and synthesized a novel CB(2)-selective agonist, namely, MDA7.	Paclitaxel	67-77	interleukin 24	Mus musculus	167-171
22392969-5	2012	The effect of MDA7 in preventing paclitaxel-induced allodynia was assessed in rats and in CB(2)(+/+) and CB(2)(-/-) mice.	Paclitaxel	33-43	interleukin 24	Rattus norvegicus	14-18
22392969-6	2012	We hypothesized that the CB(2) receptor functions in a negative-feedback loop and that early MDA7 administration can blunt the neuroinflammatory response to paclitaxel and prevent mechanical allodynia through interference with specific signaling pathways.	Paclitaxel	157-167	interleukin 24	Mus musculus	93-97
22392969-7	2012	RESULTS: We found that MDA7 prevents paclitaxel-induced mechanical allodynia in rats and mice in a dose- and time-dependent manner without compromising paclitaxel"s antineoplastic effect.	Paclitaxel	37-47	interleukin 24	Rattus norvegicus	23-27
22392969-9	2012	MDA7 treatment was found to interfere with early events in the paclitaxel-induced neuroinflammatory response as evidenced by relatively reduced toll-like receptor and CB(2) expression in the lumbar spinal cord, reduced levels of extracellular signal-regulated kinase 1/2 activity, reduced numbers of activated microglia and astrocytes, and reduced secretion of proinflammatory mediators in vivo and in in vitro models.	Paclitaxel	63-73	interleukin 24	Mus musculus	0-4
22489661-0	2012	Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.	Paclitaxel	10-20	tumor protein p53	Homo sapiens	34-37
22489661-11	2012	CONCLUSIONS: Our study suggested that a PTEN-PI3K-Akt-Bax signaling cascade is involved in the therapeutic effect of combined radiation/paclitaxel treatment in NSCLC without p53 expression.	Paclitaxel	136-146	BCL2 associated X, apoptosis regulator	Homo sapiens	54-57
21074392-5	2012	Moreover, taxol caused an increase in c-Jun NH(2)-terminal kinase (JNK) and p38 activities, two of the well known mediators of the stress activation pathways.	Paclitaxel	10-15	mitogen-activated protein kinase 8	Homo sapiens	67-70
21074392-5	2012	Moreover, taxol caused an increase in c-Jun NH(2)-terminal kinase (JNK) and p38 activities, two of the well known mediators of the stress activation pathways.	Paclitaxel	10-15	mitogen-activated protein kinase 14	Homo sapiens	76-79
21074392-7	2012	Furthermore, our data indicated that Bcl-2alpha was down-regulated in taxol-treated cells and its expression was modulated by ROS and JNK activity.	Paclitaxel	70-75	mitogen-activated protein kinase 8	Homo sapiens	134-137
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	Paclitaxel	75-80	mitogen-activated protein kinase 8	Homo sapiens	126-129
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	Paclitaxel	75-80	mitogen-activated protein kinase 8	Homo sapiens	238-241
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	Paclitaxel	159-164	mitogen-activated protein kinase 8	Homo sapiens	126-129
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	Paclitaxel	159-164	mitogen-activated protein kinase 8	Homo sapiens	238-241
21074392-9	2012	Taken together, these results indicate that taxol induces apoptosis in chronic myelogenous leukemia cells by inducing intracellular oxidative stress and JNK activation pathway.	Paclitaxel	44-49	mitogen-activated protein kinase 8	Homo sapiens	153-156
21855113-8	2012	Higher SCARA3 expression was found in disease recurrence postchemotherapy compared with primary diagnosis prechemotherapy OC effusions (P = .001), and this difference was significant for treatment with both platinum agents (P = .006) and paclitaxel (P = .002).	Paclitaxel	238-248	scavenger receptor class A member 3	Homo sapiens	7-13
22252099-0	2012	Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.	Paclitaxel	37-47	mechanistic target of rapamycin kinase	Homo sapiens	139-143
22094934-0	2012	Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.	Paclitaxel	31-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
22252099-6	2012	Western immunoblotting was performed to determine the effect of metformin/paclitaxel on the mTOR pathway.	Paclitaxel	74-84	mechanistic target of rapamycin kinase	Homo sapiens	92-96
22252099-15	2012	CONCLUSIONS: Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.	Paclitaxel	50-60	mechanistic target of rapamycin kinase	Homo sapiens	152-156
22359351-4	2012	In Caco-2 cells, which express P-gp, BCRP, and MRP2, FTC (1 microM) selectively inhibited the efflux of BCRP substrates estrone-3-sulfate and genistein; however, at 10 microM, FTC partially inhibited the efflux of P-gp substrates paclitaxel and digoxin.	Paclitaxel	230-240	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	104-108
21618519-2	2012	One of the resistance factors that protects cancer cells from Taxol-based therapy is multidrug resistance 1 (MDR1).	Paclitaxel	62-67	ATP binding cassette subfamily B member 1	Homo sapiens	85-107
21618519-2	2012	One of the resistance factors that protects cancer cells from Taxol-based therapy is multidrug resistance 1 (MDR1).	Paclitaxel	62-67	ATP binding cassette subfamily B member 1	Homo sapiens	109-113
21618519-6	2012	Introducing let-7g into ADR-RES cells expressing both IMP-1 and MDR1 reduced expression of both proteins rendering the cells more sensitive to treatment with either Taxol or vinblastine without affecting the sensitivity of the cells to carboplatin, a non-MDR1 substrate.	Paclitaxel	165-170	ATP binding cassette subfamily B member 1	Homo sapiens	64-68
22493354-1	2012	BACKGROUND/AIM: This study specifies a strategy to improve radiotherapy by partial synchronization of p53-deficient cancer cells (FaDu and H1299) in mitosis using taxol, with protecting p53 wild-type cells (A549) by the prior administration of cytostatic compounds.	Paclitaxel	163-168	tumor protein p53	Homo sapiens	102-105
21359953-10	2012	The combination of lapatinib and nab-paclitaxel was well tolerated and provided good efficacy in women with HER2 positive breast cancer.	Paclitaxel	37-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-112
22094934-2	2012	This study was designed to evaluate the efficacy and safety of preoperative paclitaxel, gemcitabine, and trastuzumab (PGH) combination for HER2-positive breast caner.	Paclitaxel	76-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-143
22179563-0	2012	Drug resistance to paclitaxel is not only associated with ABCB1 mRNA             expression but also with drug accumulation in intracellular compartments in human             lung cancer cell lines.	Paclitaxel	19-29	ATP binding cassette subfamily B member 1	Homo sapiens	58-63
22392081-0	2012	Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts.	Paclitaxel	0-10	fibronectin 1	Homo sapiens	77-88
22392081-2	2012	In this study, we show that the antibody F8, which recognizes perivascular and stromal EDA-fibronectin (EDA-Fn), when conjugated to interleukin-2 (F8-IL2) can effectively inhibit the growth of EDA-Fn-expressing melanomas in combination with paclitaxel.	Paclitaxel	241-251	fibronectin 1	Homo sapiens	91-102
22392081-2	2012	In this study, we show that the antibody F8, which recognizes perivascular and stromal EDA-fibronectin (EDA-Fn), when conjugated to interleukin-2 (F8-IL2) can effectively inhibit the growth of EDA-Fn-expressing melanomas in combination with paclitaxel.	Paclitaxel	241-251	interleukin 2	Homo sapiens	132-145
22392081-2	2012	In this study, we show that the antibody F8, which recognizes perivascular and stromal EDA-fibronectin (EDA-Fn), when conjugated to interleukin-2 (F8-IL2) can effectively inhibit the growth of EDA-Fn-expressing melanomas in combination with paclitaxel.	Paclitaxel	241-251	interleukin 2	Homo sapiens	150-153
22392081-5	2012	Paclitaxel also boosted the recruitment of F8-IL2-induced natural killer (NK) cells to the tumor, suggesting a host response as part of the observed therapeutic benefit.	Paclitaxel	0-10	interleukin 2	Homo sapiens	46-49
22392081-9	2012	Together, our findings offer a preclinical proof that by acting on the tumor stroma paclitaxel potentiates the antitumor activity elicited by a targeted delivery of IL2, thereby supporting the use of immunochemotherapy in the treatment of metastatic melanoma.	Paclitaxel	84-94	interleukin 2	Homo sapiens	165-168
22392081-0	2012	Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts.	Paclitaxel	0-10	interleukin 2	Homo sapiens	51-54
22842366-6	2012	The MDR1-shRNA2 transfected cells showed that the sensitivities to chemotherapy drugs were higher than other shRNAs transfected A2780 cells, and that the formed tumor in mice grew slower than those of other mice after paclitaxel was injected into tumor-bearing nude mice.	Paclitaxel	218-228	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-8
22316245-3	2012	In an in vitro system, we previously demonstrated that targeted drug delivery to cancer cells overexpressing epidermal growth factor receptor (EGFR+) can be achieved by poly(ethylene glycol)-functionalized carbon nanovectors simply mixed with a drug, paclitaxel, and an antibody that binds to the epidermal growth factor receptor, cetuximab.	Paclitaxel	251-261	epidermal growth factor receptor	Homo sapiens	109-141
22202118-0	2012	Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel.	Paclitaxel	113-123	solute carrier family 22 member 1	Homo sapiens	6-34
22202118-4	2012	Functionally, the antineoplastic agents irinotecan, mitoxantrone, and paclitaxel inhibited the uptake of the organic cation [(3)H]1-methyl-4-pyridinium iodide into OCT1-transfected Chinese hamster ovary model cells, with K(i) values of 1.7, 85, and 50 muM, respectively.	Paclitaxel	70-80	solute carrier family 22 member 1	Homo sapiens	164-168
22202118-5	2012	Correspondingly, OCT1-positive cell lines and transfectants exhibited significantly higher susceptibilities to the cytotoxic effects of irinotecan and paclitaxel compared with those of OCT1-negative controls.	Paclitaxel	151-161	solute carrier family 22 member 1	Homo sapiens	17-21
22800348-1	2012	OBJECTIVE: To investigate the expression of multidrug resistance gene ABCB1 and ABCG2 in FaDu cells (human hypopharyngeal carcinoma cell line) and the multidrug resistance (MDR) cell lines FaDu/T transformed from FaDu cells by taxol and underlying mechanisms of MDR.	Paclitaxel	227-232	ATP binding cassette subfamily B member 1	Homo sapiens	70-75
22800348-7	2012	JNK signal was inhibited in FaDu or FaDu/T cells and the inhibited JNK was reactivated by taxol or anisomycin (an activator for MAPK signal transduction pathways).	Paclitaxel	90-95	mitogen-activated protein kinase 8	Homo sapiens	0-3
22800348-7	2012	JNK signal was inhibited in FaDu or FaDu/T cells and the inhibited JNK was reactivated by taxol or anisomycin (an activator for MAPK signal transduction pathways).	Paclitaxel	90-95	mitogen-activated protein kinase 8	Homo sapiens	67-70
22226879-3	2012	Large amount of PTX up to 60-75%, depending on polymer composition, was possibly loaded into the C18/MPEG/API-g-PASPAMs nano-aggregates using a solvent-free protocol.	Paclitaxel	16-19	Bardet-Biedl syndrome 9	Homo sapiens	97-100
22258694-8	2012	Exposure to paclitaxel of slices of mouse esophagus released the sensory neuropeptide, calcitonin gene-related peptide (CGRP).	Paclitaxel	12-22	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	87-118
22258694-8	2012	Exposure to paclitaxel of slices of mouse esophagus released the sensory neuropeptide, calcitonin gene-related peptide (CGRP).	Paclitaxel	12-22	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	120-124
22316245-3	2012	In an in vitro system, we previously demonstrated that targeted drug delivery to cancer cells overexpressing epidermal growth factor receptor (EGFR+) can be achieved by poly(ethylene glycol)-functionalized carbon nanovectors simply mixed with a drug, paclitaxel, and an antibody that binds to the epidermal growth factor receptor, cetuximab.	Paclitaxel	251-261	epidermal growth factor receptor	Homo sapiens	143-148
22245726-4	2012	TECs were more resistant to paclitaxel with the up-regulation of multidrug resistance (MDR) 1 mRNA, which encodes the P-glycoprotein, compared with normal ECs.	Paclitaxel	28-38	ATP binding cassette subfamily B member 1	Homo sapiens	65-93
22477198-1	2012	Paclitaxel is a P-gp substrate and metabolized via CYP2C and 3A subfamily in rats.	Paclitaxel	0-10	phosphoglycolate phosphatase	Rattus norvegicus	16-20
23422737-10	2012	HM781-36B combined with 5-fluorouracil, cisplatin, paclitaxel, or gemcitabine showed a synergistic inhibitory effect on the HER2-amplified and on some of the HER2-nonamplified breast cancer cells.	Paclitaxel	51-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	124-128
23422737-10	2012	HM781-36B combined with 5-fluorouracil, cisplatin, paclitaxel, or gemcitabine showed a synergistic inhibitory effect on the HER2-amplified and on some of the HER2-nonamplified breast cancer cells.	Paclitaxel	51-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
22477198-6	2012	These results are consistent with that oral cysteine supplement on a single day did not considerably inhibit the metabolism of paclitaxel via hepatic and/or intestinal CYP3A subfamily and P-gp mediated efflux of paclitaxel in the liver and/or intestine both after intravenous and oral administration to rats.	Paclitaxel	212-222	phosphoglycolate phosphatase	Rattus norvegicus	188-192
22481432-3	2012	Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel.	Paclitaxel	130-140	vascular endothelial growth factor A	Homo sapiens	21-25
22177840-3	2012	We hypothesized that combination of Akt1-targeted therapy with conventional chemotherapy using paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel may have synergistic effects in cancer therapeutic efficiency compared with chemotherapy alone.	Paclitaxel	95-105	AKT serine/threonine kinase 1	Homo sapiens	36-40
22120505-0	2012	Anti-proliferative activity and suppression of P-glycoprotein by (-)-antofine, a natural phenanthroindolizidine alkaloid, in paclitaxel-resistant human lung cancer cells.	Paclitaxel	125-135	ATP binding cassette subfamily B member 1	Homo sapiens	47-61
22034016-0	2012	Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL-induced activation of NF-kappaB and ERK.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Mus musculus	149-152
22034016-7	2012	Furthermore, luciferase reporter gene assays and western blot analysis indicate that paclitaxel modulates key RANKL-induced activation pathways that are essential to osteoclast formation including NF-kappaB and ERK.	Paclitaxel	85-95	mitogen-activated protein kinase 1	Mus musculus	211-214
22177224-0	2012	Paclitaxel therapy potentiates cold hyperalgesia in streptozotocin-induced diabetic rats through enhanced mitochondrial reactive oxygen species production and TRPA1 sensitization.	Paclitaxel	0-10	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	159-164
22177224-6	2012	We hypothesized that paclitaxel might potentiate cold hyperalgesia by increasing mitochondrial injuries and TRPA1 activation.	Paclitaxel	21-31	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	108-113
22177224-13	2012	Paclitaxel potentiation of cold hyperalgesia in diabetes may result from the combination of increased mitochondrial ROS production and poor radical detoxification induced by paclitaxel treatment and diabetes-related overexpression of TRPA1.	Paclitaxel	0-10	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	234-239
22335738-11	2012	In addition, neutralizing interleukin-6 significantly enhanced the therapeutic efficacy of paclitaxel in mouse models of epithelial ovarian cancer.	Paclitaxel	91-101	interleukin 6	Mus musculus	26-39
20641391-0	2004	1-(9H-Carbazol-4-yloxy)-3-(2-(2-[(11)C]methoxyphenoxy)ethylamino)-propan-2-ol One of the mechanisms cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Taxol, is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2).	Paclitaxel	247-252	ATP binding cassette subfamily B member 1	Homo sapiens	321-335
20641391-0	2004	1-(9H-Carbazol-4-yloxy)-3-(2-(2-[(11)C]methoxyphenoxy)ethylamino)-propan-2-ol One of the mechanisms cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Taxol, is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2).	Paclitaxel	247-252	ATP binding cassette subfamily B member 1	Homo sapiens	337-341
20641391-0	2004	1-(9H-Carbazol-4-yloxy)-3-(2-(2-[(11)C]methoxyphenoxy)ethylamino)-propan-2-ol One of the mechanisms cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Taxol, is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2).	Paclitaxel	247-252	ATP binding cassette subfamily B member 1	Homo sapiens	391-396
20641916-0	2004	4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2).	Paclitaxel	15-25	ATP binding cassette subfamily B member 1	Homo sapiens	291-305
22172604-6	2012	Based on these results, we conclude that oral bioavailability of paclitaxel is significantly improved by co-administration with silymarin, an inhibitor of the P-gp efflux pump and by microemulsion formulation.	Paclitaxel	65-75	phosphoglycolate phosphatase	Rattus norvegicus	159-163
20641916-0	2004	4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2).	Paclitaxel	15-25	ATP binding cassette subfamily B member 1	Homo sapiens	307-311
20641916-0	2004	4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2).	Paclitaxel	15-25	ATP binding cassette subfamily B member 1	Homo sapiens	361-366
20641916-0	2004	4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2).	Paclitaxel	218-221	ATP binding cassette subfamily B member 1	Homo sapiens	291-305
20641916-0	2004	4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2).	Paclitaxel	218-221	ATP binding cassette subfamily B member 1	Homo sapiens	307-311
20641916-0	2004	4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2).	Paclitaxel	218-221	ATP binding cassette subfamily B member 1	Homo sapiens	361-366
20641759-0	2004	2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-[(11)C]methyl-amino]-2-propan-2-yl-pentanenitrile One of the mechanisms by which cells mitigate the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Paclitaxel, is to limit their presence inside the cells via the transmembrane protein P-glycoprotein (P-gp), which is encoded by the multidrug resistance (MDR-1) gene (1, 2).	Paclitaxel	279-289	ATP binding cassette subfamily B member 1	Homo sapiens	365-379
20641759-0	2004	2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-[(11)C]methyl-amino]-2-propan-2-yl-pentanenitrile One of the mechanisms by which cells mitigate the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Paclitaxel, is to limit their presence inside the cells via the transmembrane protein P-glycoprotein (P-gp), which is encoded by the multidrug resistance (MDR-1) gene (1, 2).	Paclitaxel	279-289	ATP binding cassette subfamily B member 1	Homo sapiens	381-385
20641759-0	2004	2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-[(11)C]methyl-amino]-2-propan-2-yl-pentanenitrile One of the mechanisms by which cells mitigate the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Paclitaxel, is to limit their presence inside the cells via the transmembrane protein P-glycoprotein (P-gp), which is encoded by the multidrug resistance (MDR-1) gene (1, 2).	Paclitaxel	279-289	ATP binding cassette subfamily B member 1	Homo sapiens	434-439
22309939-15	2012	Finally, whereas paclitaxel, doxorubicin, and 5-fluorouracil enriched the CD44high/CD24-/low population compared with control in SUM149, subsequent treatment with BI 2536 killed the emergent population, suggesting that it could potentially be used to prevent relapse.	Paclitaxel	17-27	CD24 molecule	Homo sapiens	83-87
22012632-3	2012	Bevacizumab is a monoclonal antibody against circulating vascular endothelial growth factor (VEGF), which was approved in 2008 by the US Food and Drug Administration (FDA), for first-line treatment of HER-2 negative MBC in combination with paclitaxel.	Paclitaxel	240-250	vascular endothelial growth factor A	Homo sapiens	57-91
21955855-11	2012	Variants in the drug transporter ABCB1 gene are possibly associated with the neutrophil suppressing effect of paclitaxel in patients with ovarian cancer.	Paclitaxel	110-120	ATP binding cassette subfamily B member 1	Homo sapiens	33-38
22118775-0	2012	Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles.	Paclitaxel	23-33	transferrin	Homo sapiens	83-94
22118775-2	2012	Herein, a novel hyperbranched amphiphilic poly[(amine-ester)-co-(D,L-lactide)]/1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer (HPAE-co-PLA/DPPE) with RGD peptide (cRGDfK) and transferrin (Tf) on the periphery was synthesized and used to prepare paclitaxel-loaded nanoparticles (NPs) for dual-targeting chemotherapy.	Paclitaxel	257-267	transferrin	Homo sapiens	187-198
22118775-2	2012	Herein, a novel hyperbranched amphiphilic poly[(amine-ester)-co-(D,L-lactide)]/1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer (HPAE-co-PLA/DPPE) with RGD peptide (cRGDfK) and transferrin (Tf) on the periphery was synthesized and used to prepare paclitaxel-loaded nanoparticles (NPs) for dual-targeting chemotherapy.	Paclitaxel	257-267	transferrin	Homo sapiens	200-202
22012632-3	2012	Bevacizumab is a monoclonal antibody against circulating vascular endothelial growth factor (VEGF), which was approved in 2008 by the US Food and Drug Administration (FDA), for first-line treatment of HER-2 negative MBC in combination with paclitaxel.	Paclitaxel	240-250	vascular endothelial growth factor A	Homo sapiens	93-97
22005523-11	2012	Demethylation with 5-aza-CdR led to reactivation of miR-130b expression in drug resistant ovarian cancer cell lines concomitant with increase of sensibility to cisplatin and taxol.	Paclitaxel	174-179	microRNA 130b	Homo sapiens	52-60
22969865-5	2012	The data demonstrated that the VEGF shRNA vector significantly knocked down VEGF expression, which synergistically sensitized U251 glioma cells to liposomal paclitaxel, radiation or liposomal paclitaxel plus radiation treatment in terms of cell viability, apoptosis, colony formation and morphological changes.	Paclitaxel	157-167	vascular endothelial growth factor A	Homo sapiens	31-35
22969865-5	2012	The data demonstrated that the VEGF shRNA vector significantly knocked down VEGF expression, which synergistically sensitized U251 glioma cells to liposomal paclitaxel, radiation or liposomal paclitaxel plus radiation treatment in terms of cell viability, apoptosis, colony formation and morphological changes.	Paclitaxel	157-167	vascular endothelial growth factor A	Homo sapiens	76-80
22969865-5	2012	The data demonstrated that the VEGF shRNA vector significantly knocked down VEGF expression, which synergistically sensitized U251 glioma cells to liposomal paclitaxel, radiation or liposomal paclitaxel plus radiation treatment in terms of cell viability, apoptosis, colony formation and morphological changes.	Paclitaxel	192-202	vascular endothelial growth factor A	Homo sapiens	31-35
22969865-5	2012	The data demonstrated that the VEGF shRNA vector significantly knocked down VEGF expression, which synergistically sensitized U251 glioma cells to liposomal paclitaxel, radiation or liposomal paclitaxel plus radiation treatment in terms of cell viability, apoptosis, colony formation and morphological changes.	Paclitaxel	192-202	vascular endothelial growth factor A	Homo sapiens	76-80
22206665-0	2012	ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression.	Paclitaxel	46-56	ATP binding cassette subfamily B member 1	Homo sapiens	130-134
22203732-1	2012	GRN1005 is a novel peptide-drug conjugate composed of paclitaxel covalently linked to a peptide, angiopep-2, that targets the low-density lipoprotein receptor-related protein 1.	Paclitaxel	54-64	LDL receptor related protein 1	Homo sapiens	126-176
22018777-1	2012	Association of estrogen receptor (ER), progesterone receptor (PR), HER2, Ki67 and 70-gene classifier (70-GC) with a response to paclitaxel (PAC) (n=79) or docetaxel (DOC) (n=55) was investigated in the neoadjuvant setting for breast cancer patients.	Paclitaxel	128-138	estrogen receptor 1	Homo sapiens	15-32
28920260-8	2012	In our case, positive immunohistochemical analysis for caveolin-1 in the tumor vascular endothelia suggests that the complete response may have been facilitated by enhanced transportation of paclitaxel through the tumor vascular barrier via caveolin-1, despite being negative for secreted protein acidic and rich in cysteine (SPARC) in tumor cells.	Paclitaxel	191-201	caveolin 1	Homo sapiens	55-65
28920260-8	2012	In our case, positive immunohistochemical analysis for caveolin-1 in the tumor vascular endothelia suggests that the complete response may have been facilitated by enhanced transportation of paclitaxel through the tumor vascular barrier via caveolin-1, despite being negative for secreted protein acidic and rich in cysteine (SPARC) in tumor cells.	Paclitaxel	191-201	caveolin 1	Homo sapiens	241-251
22206665-5	2012	In PC3PR cells, silencing of ETS1 expression by siRNAs inhibited the activity of the MDR1 promoter containing ETS binding sites, reduced the mRNA and protein levels of MDR1 and suppressed paclitaxel resistance.	Paclitaxel	188-198	ATP binding cassette subfamily B member 1	Homo sapiens	85-89
22206665-7	2012	Our results suggest that ETS1 promotes paclitaxel resistance and invasion in part by up-regulating MDR1 and MMP9 expression.	Paclitaxel	39-49	ATP binding cassette subfamily B member 1	Homo sapiens	99-103
22225778-3	2012	Paclitaxel has been shown to induce soluble tumor necrosis factor alpha (sTNF-alpha) production in macrophages, but the involvement of TNF production in taxane cytotoxicity or resistance in tumor cells has not been established.	Paclitaxel	0-10	tumor necrosis factor	Homo sapiens	44-71
22225778-3	2012	Paclitaxel has been shown to induce soluble tumor necrosis factor alpha (sTNF-alpha) production in macrophages, but the involvement of TNF production in taxane cytotoxicity or resistance in tumor cells has not been established.	Paclitaxel	0-10	tumor necrosis factor	Homo sapiens	74-77
23037162-2	2012	HuH-7/PTX cells expressed high levels of MDR-1 and efficiently exported calcein-acetoxymethylester (calcein-AM), which is a substrate of MDR-1, suggesting that HuH-7/PTX cells resist paclitaxel by overexpressing MDR-1.	Paclitaxel	183-193	ATP binding cassette subfamily B member 1	Homo sapiens	137-142
22156929-8	2012	Paclitaxel and nab-paclitaxel show in vitro inhibition of H295R and SW-13 cells at IC50 concentrations of 0.33 muM and 0.0078 muM for paclitaxel and 0.35 muM and 0.0087 muM for nab-paclitaxel compared with mitotane concentrations of 15.9 muM and 46.4 muM.	Paclitaxel	19-29	latexin	Homo sapiens	111-114
22156929-8	2012	Paclitaxel and nab-paclitaxel show in vitro inhibition of H295R and SW-13 cells at IC50 concentrations of 0.33 muM and 0.0078 muM for paclitaxel and 0.35 muM and 0.0087 muM for nab-paclitaxel compared with mitotane concentrations of 15.9 muM and 46.4 muM.	Paclitaxel	19-29	latexin	Homo sapiens	126-129
22156929-8	2012	Paclitaxel and nab-paclitaxel show in vitro inhibition of H295R and SW-13 cells at IC50 concentrations of 0.33 muM and 0.0078 muM for paclitaxel and 0.35 muM and 0.0087 muM for nab-paclitaxel compared with mitotane concentrations of 15.9 muM and 46.4 muM.	Paclitaxel	19-29	latexin	Homo sapiens	126-129
22156929-8	2012	Paclitaxel and nab-paclitaxel show in vitro inhibition of H295R and SW-13 cells at IC50 concentrations of 0.33 muM and 0.0078 muM for paclitaxel and 0.35 muM and 0.0087 muM for nab-paclitaxel compared with mitotane concentrations of 15.9 muM and 46.4 muM.	Paclitaxel	19-29	latexin	Homo sapiens	126-129
22156929-8	2012	Paclitaxel and nab-paclitaxel show in vitro inhibition of H295R and SW-13 cells at IC50 concentrations of 0.33 muM and 0.0078 muM for paclitaxel and 0.35 muM and 0.0087 muM for nab-paclitaxel compared with mitotane concentrations of 15.9 muM and 46.4 muM.	Paclitaxel	19-29	latexin	Homo sapiens	126-129
22156929-8	2012	Paclitaxel and nab-paclitaxel show in vitro inhibition of H295R and SW-13 cells at IC50 concentrations of 0.33 muM and 0.0078 muM for paclitaxel and 0.35 muM and 0.0087 muM for nab-paclitaxel compared with mitotane concentrations of 15.9 muM and 46.4 muM.	Paclitaxel	19-29	latexin	Homo sapiens	126-129
23037162-1	2012	Paclitaxel-resistant HuH-7 (HuH-7/PTX) cells were established by one-week exposure of HuH-7 cells to paclitaxel to analyze the effects of Kampo medicines on MDR-1-mediated multidrug resistance.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	157-162
21643015-5	2012	Rassf1/Daxx depletion or expression of Daxx-binding domain of Rassf1 elevates cyclin B stability and increases taxol resistance in cells and mouse xenograft models.	Paclitaxel	111-116	Ras association (RalGDS/AF-6) domain family member 1	Mus musculus	0-6
21643015-5	2012	Rassf1/Daxx depletion or expression of Daxx-binding domain of Rassf1 elevates cyclin B stability and increases taxol resistance in cells and mouse xenograft models.	Paclitaxel	111-116	Ras association (RalGDS/AF-6) domain family member 1	Mus musculus	62-68
22221539-12	2012	The real time RT-PCR analysis confirmed the activation of apoptosis as result of liberation of cytochrome c in the cells treated with the PTX loaded PU nanomicelles.	Paclitaxel	138-141	cytochrome c, somatic	Homo sapiens	95-107
21968419-7	2012	The three major MAPKs were rapidly activated by XRP44X, and extracellular signal-related kinases and p38 by PTX, whereas JNK did not quickly respond to PTX.	Paclitaxel	108-111	mitogen-activated protein kinase 14	Homo sapiens	101-104
23037162-2	2012	HuH-7/PTX cells expressed high levels of MDR-1 and efficiently exported calcein-acetoxymethylester (calcein-AM), which is a substrate of MDR-1, suggesting that HuH-7/PTX cells resist paclitaxel by overexpressing MDR-1.	Paclitaxel	183-193	ATP binding cassette subfamily B member 1	Homo sapiens	137-142
23037162-4	2012	Additionally, the sensitivity of HuH-7/PTX cells to paclitaxel was increased in combination with these Kampo medicines, indicating that takushato and goreisan overcame paclitaxel resistance in the cells by suppressing drug export by MDR-1.	Paclitaxel	52-62	ATP binding cassette subfamily B member 1	Homo sapiens	233-238
23037162-5	2012	We further clarified that Alismatis Rhizoma contained in both takushato and goreisan reversed paclitaxel resistance by preventing drug efflux by MDR-1 without affecting the expression levels of MDR-1.	Paclitaxel	94-104	ATP binding cassette subfamily B member 1	Homo sapiens	145-150
23037162-6	2012	Moreover, the principal components of Alismatis Rhizoma, Alisol A, Alisol B, and Alisol B acetate, were found to increase the sensitivity to paclitaxel in HuH-7/PTX by inhibiting drug export by MDR-1 without affecting the expression levels of MDR-1.	Paclitaxel	141-151	ATP binding cassette subfamily B member 1	Homo sapiens	194-199
23037162-6	2012	Moreover, the principal components of Alismatis Rhizoma, Alisol A, Alisol B, and Alisol B acetate, were found to increase the sensitivity to paclitaxel in HuH-7/PTX by inhibiting drug export by MDR-1 without affecting the expression levels of MDR-1.	Paclitaxel	141-151	ATP binding cassette subfamily B member 1	Homo sapiens	243-248
21982683-4	2012	Notably, P-glycoprotein-overexpressing KBV200 and K562/ADR cells, which are strongly resistant to colchicine, vinorelbine and paclitaxel, were sensitive to YHHU0895 both in vitro and in vivo.	Paclitaxel	126-136	ATP binding cassette subfamily B member 1	Homo sapiens	9-23
22754361-0	2012	Protective effect of caffeic acid on paclitaxel induced anti-proliferation and apoptosis of lung cancer cells involves NF-kappaB pathway.	Paclitaxel	37-47	nuclear factor kappa B subunit 1	Homo sapiens	119-128
23481572-8	2012	While 5-florouracil did not inhibit the VEGF secretion of HT-29 cell line, irinotecan, oxaliplatin, docetaxel and paclitaxel significantly decreased the levels of secreted VEGF.	Paclitaxel	114-124	vascular endothelial growth factor A	Homo sapiens	40-44
23481572-8	2012	While 5-florouracil did not inhibit the VEGF secretion of HT-29 cell line, irinotecan, oxaliplatin, docetaxel and paclitaxel significantly decreased the levels of secreted VEGF.	Paclitaxel	114-124	vascular endothelial growth factor A	Homo sapiens	172-176
21924351-3	2012	Here we show that treatment of cells with nocodazole or paclitaxel does cause phosphorylation of BIM(EL), which is independent of ERK1/2.	Paclitaxel	56-66	mitogen-activated protein kinase 3	Homo sapiens	130-136
22754361-9	2012	Our study suggested that the pro-survival effect of CA on PTX-treated lung cancer cells is mediated through a NF-kappaB signaling pathway.	Paclitaxel	58-61	nuclear factor kappa B subunit 1	Homo sapiens	110-119
22701315-4	2012	METHODS AND RESULTS: We report that carbonate apatite-mediated delivery of the siRNAs targeting ABCG2 and ABCB1 gene transcripts in human breast cancer cells which constitutively express both of the transporter genes dose-dependently enhanced chemosensitivity to doxorubicin, paclitaxel and cisplatin, the traditionally used chemotherapeutic agents.	Paclitaxel	276-286	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	96-101
22904633-8	2012	RESULTS: A549 and A549/T12 cells contain constitutively activated Stat3, and silencing Stat3 by siRNA made both cancer cells more sensitive to paclitaxel.	Paclitaxel	143-153	signal transducer and activator of transcription 3	Homo sapiens	87-92
22701315-4	2012	METHODS AND RESULTS: We report that carbonate apatite-mediated delivery of the siRNAs targeting ABCG2 and ABCB1 gene transcripts in human breast cancer cells which constitutively express both of the transporter genes dose-dependently enhanced chemosensitivity to doxorubicin, paclitaxel and cisplatin, the traditionally used chemotherapeutic agents.	Paclitaxel	276-286	ATP binding cassette subfamily B member 1	Homo sapiens	106-111
22745543-7	2012	The molar ratio of apolipoprotein A-I and paclitaxel was 1:55, suggesting that a single nanoparticle contained approximately 110 paclitaxel particles in a spherical structure with a 9.2 nm diameter.	Paclitaxel	129-139	apolipoprotein A1	Homo sapiens	19-37
22848173-6	2012	METHODS AND RESULTS: Intravenous administration of folate-targeted, paclitaxel-loaded micelles was demonstrated to be more efficient in inhibiting subcutaneous xenograft tumors and extending the survival rate of tumor-bearing nude mice than free paclitaxel and plain paclitaxel micelles at an equivalent paclitaxel dose of 20 mg/kg, which was further backed up by flow cytometry, TUNEL, and expression of apoptosis-related proteins, including Bax, Bcl2, and caspase 3 in this study.	Paclitaxel	68-78	B cell leukemia/lymphoma 2	Mus musculus	448-452
22915856-0	2012	Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner.	Paclitaxel	0-10	folate hydrolase 1	Homo sapiens	126-130
22915856-5	2012	Binding assays suggested that PSMA-targeted SPMs specifically bound to C4-2 human prostate cancer cells in vitro and released paclitaxel into the cells.	Paclitaxel	126-136	folate hydrolase 1	Homo sapiens	30-34
22915856-10	2012	Furthermore, mice injected with PSMA-targeted SPMs showed significantly more paclitaxel and platinum in tumors, compared with nontargeted SPM-injected and paclitaxel-injected mice.	Paclitaxel	77-87	folate hydrolase 1	Homo sapiens	32-36
21391217-5	2012	Furthermore, the activity of ERK1/2 was enhanced by the combination of K8 and paclitaxel, and an ERK1/2 inhibitor dramatically inhibited NAG-1 expression in human lung cancer cells.	Paclitaxel	78-88	mitogen-activated protein kinase 3	Homo sapiens	29-35
22517709-8	2012	CONCLUSION: Our findings support that with carboplatin/ paclitaxel combination chemotherapy, important parameters of the immune system (IFN-gamma, CD4, CD4/CD8) can be used as prognostic factors for survival, while others (IL-3) as indicators of toxicity.	Paclitaxel	56-66	interferon gamma	Homo sapiens	136-145
22517709-8	2012	CONCLUSION: Our findings support that with carboplatin/ paclitaxel combination chemotherapy, important parameters of the immune system (IFN-gamma, CD4, CD4/CD8) can be used as prognostic factors for survival, while others (IL-3) as indicators of toxicity.	Paclitaxel	56-66	CD4 molecule	Homo sapiens	147-150
22517709-8	2012	CONCLUSION: Our findings support that with carboplatin/ paclitaxel combination chemotherapy, important parameters of the immune system (IFN-gamma, CD4, CD4/CD8) can be used as prognostic factors for survival, while others (IL-3) as indicators of toxicity.	Paclitaxel	56-66	CD4 molecule	Homo sapiens	152-155
21391217-8	2012	In addition, treatment of nude mice with K8 combined with paclitaxel induced phospho-ERK1/2 and NAG-1 expression in vivo.	Paclitaxel	58-68	mitogen-activated protein kinase 3	Homo sapiens	85-91
21391217-10	2012	Our results reveal that activation of NAG-1 by K8 enhanced the therapeutic efficacy of paclitaxel in human lung cancer cells via the ERK1/2 signaling pathway.	Paclitaxel	87-97	mitogen-activated protein kinase 3	Homo sapiens	133-139
23028798-0	2012	Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.	Paclitaxel	90-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
22693671-7	2012	Loss of RASSF2 expression also confers resistance to taxol and cisplatin, two frontline therapeutics for the treatment of lung cancer.	Paclitaxel	53-58	Ras association domain family member 2	Homo sapiens	8-14
21900837-0	2012	Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.	Paclitaxel	141-151	epidermal growth factor receptor	Homo sapiens	0-32
22668020-10	2012	This chemosensitization effect could be a result of the intensification of pro-apoptotic JNK activation, and repression of anti-apoptotic p-ERK, p-Bad and p-IkappaBalpha expression stimulated by paclitaxel.	Paclitaxel	195-205	NFKB inhibitor alpha	Homo sapiens	157-169
22808086-0	2012	Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells.	Paclitaxel	15-25	lin-28 homolog A	Homo sapiens	0-5
23029028-0	2012	Effects of paclitaxel on EGFR endocytic trafficking revealed using quantum dot tracking in single cells.	Paclitaxel	11-21	epidermal growth factor receptor	Homo sapiens	25-29
22808086-4	2012	We found that the expression level of Lin28 was closely associated with the resistance to paclitaxel treatment.	Paclitaxel	90-100	lin-28 homolog A	Homo sapiens	38-43
22808086-5	2012	The T47D cancer cell line, which highly expresses Lin28, is more resistant to paclitaxel than the MCF7, Bcap-37 or SK-BR-3 cancer cell lines, which had low-level expression of Lin28.	Paclitaxel	78-88	lin-28 homolog A	Homo sapiens	50-55
22808086-6	2012	Knocking down of Lin28 in Lin28 high expression T47D cells increased the sensitivity to paclitaxel treatment, while stable expression of Lin28 in breast cancer cells effectively attenuated the sensitivity to paclitaxel treatment, resulting in a significant increase of IC50 values of paclitaxel.	Paclitaxel	88-98	lin-28 homolog A	Homo sapiens	17-22
22808086-7	2012	Transfection with Lin28 also significantly inhibited paclitaxel-induced apoptosis.	Paclitaxel	53-63	lin-28 homolog A	Homo sapiens	18-23
22808086-11	2012	Our results indicate that Lin28 expression might be one mechanism underlying paclitaxel resistance in breast cancer, and Lin28 could be a potential target for overcoming paclitaxel resistance in breast cancer.	Paclitaxel	77-87	lin-28 homolog A	Homo sapiens	26-31
22808086-11	2012	Our results indicate that Lin28 expression might be one mechanism underlying paclitaxel resistance in breast cancer, and Lin28 could be a potential target for overcoming paclitaxel resistance in breast cancer.	Paclitaxel	170-180	lin-28 homolog A	Homo sapiens	121-126
22349379-5	2012	The expression of 17 genes was increased or decreased more than 5 folds in CNE-1/taxol compared with CNE-1.Through analyzing documented drug-resistant genes, MDR1 expression was not detected in each group.	Paclitaxel	81-86	ATP binding cassette subfamily B member 1	Homo sapiens	158-162
22723956-4	2012	By combining in vitro and in silico approaches, we identified STAT3 and RAP1A as direct targets that mediate the effect of miR-337-3p on paclitaxel sensitivity.	Paclitaxel	137-147	signal transducer and activator of transcription 3	Homo sapiens	62-67
22655084-7	2012	Additionally, the U87MG cells pre-treated with PTX and followed by RGD peptides exhibited greater expression of caspases-3, -8 and -9 than those merely treated with single agent of PTX or RGD peptide.	Paclitaxel	47-50	caspase 3	Homo sapiens	112-133
22655084-7	2012	Additionally, the U87MG cells pre-treated with PTX and followed by RGD peptides exhibited greater expression of caspases-3, -8 and -9 than those merely treated with single agent of PTX or RGD peptide.	Paclitaxel	181-184	caspase 3	Homo sapiens	112-133
22723956-6	2012	The identification of a miR-337-3p as a modulator of cellular response to taxanes, and STAT3 and RAP1A as regulatory targets which mediate that response, defines a novel regulatory pathway modulating paclitaxel sensitivity in lung cancer cells, which may provide novel adjuvant strategies along with paclitaxel in the treatment of lung cancer and may also provide biomarkers for predicting paclitaxel response in NSCLC.	Paclitaxel	200-210	signal transducer and activator of transcription 3	Homo sapiens	87-92
22679488-12	2012	In the pre-trastuzumab era, the HER2-enriched subtype predicts favorable outcome following paclitaxel-containing treatment.	Paclitaxel	91-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-36
22349379-10	2012	TSP1 was obviously down-regulated in CNE- 1/taxol compared with CNE-1, and a more significant down-regulation of TSP1 was found when treated by taxol.	Paclitaxel	44-49	thrombospondin 1	Homo sapiens	0-4
22349379-10	2012	TSP1 was obviously down-regulated in CNE- 1/taxol compared with CNE-1, and a more significant down-regulation of TSP1 was found when treated by taxol.	Paclitaxel	144-149	thrombospondin 1	Homo sapiens	0-4
22349379-10	2012	TSP1 was obviously down-regulated in CNE- 1/taxol compared with CNE-1, and a more significant down-regulation of TSP1 was found when treated by taxol.	Paclitaxel	144-149	thrombospondin 1	Homo sapiens	113-117
22153075-6	2011	Interestingly, STARD9-depletion synergizes with the chemotherapeutic agent taxol to increase mitotic death, demonstrating that STARD9 is a mitotic kinesin and a potential antimitotic target.	Paclitaxel	75-80	StAR related lipid transfer domain containing 9	Homo sapiens	127-133
22044164-4	2011	Importantly, ATIs 5, 8, and 10 were more effective than vinorelbine, vinblastine, and paclitaxel as growth inhibitors of the P-glycoprotein-overexpressing cell line NCI/ADR-RES.	Paclitaxel	86-96	ATP binding cassette subfamily B member 1	Homo sapiens	125-139
21955049-9	2011	We think that all patients with GCC of stage Ib1 or more should undergo adjuvant chemotherapy of paclitaxel and carboplatin or other adjuvant therapies.	Paclitaxel	97-107	mitogen-activated protein kinase 8 interacting protein 1	Homo sapiens	45-48
21935570-6	2011	In addition, paclitaxel induced apoptosis through the activation of caspase-3 followed by PARP degradation.	Paclitaxel	13-23	caspase 3	Homo sapiens	68-77
21935570-6	2011	In addition, paclitaxel induced apoptosis through the activation of caspase-3 followed by PARP degradation.	Paclitaxel	13-23	poly(ADP-ribose) polymerase 1	Homo sapiens	90-94
21935570-7	2011	In conclusion, our results suggest that paclitaxel leads to mitotic cell cycle arrest following G2/M arrest and induces apoptosis via a caspase-3 pathway in SKGT4 cells.	Paclitaxel	40-50	caspase 3	Homo sapiens	136-145
22340335-2	2011	Bcl-2 antisense oligonucleotide (G3139) has shown its antitumor effects enhanced in preclinical models when combined with taxol-based chemotherapy.	Paclitaxel	122-127	BCL2 apoptosis regulator	Homo sapiens	0-5
21411308-1	2011	Protein engineering of cytochrome P450 monooxygenases (P450s) has been very successful in generating valuable non-natural activities and properties, allowing these powerful catalysts to be used for the synthesis of drug metabolites and in biosynthetic pathways for the production of precursors of artemisinin and paclitaxel.	Paclitaxel	313-323	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
21887460-1	2011	Trastuzumab has efficacy to improve the effect of cytotoxic drugs, such as paclitaxel and anthracyclin, against HER2-overexpressing breast cancer cells.	Paclitaxel	75-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116
22173491-0	2011	Preparation of anti-HER2 monoclonal antibody-paclitaxel immunoconjugate and its biological evaluation.	Paclitaxel	45-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-24
22173491-1	2011	Anti-HER2 monoclonal antibody (Sc7301)-paclitaxel (TAX) immunoconjugate was prepared and its specific binding to tumor cells was investigated in this study.	Paclitaxel	39-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
22060185-2	2011	Our data showed that paclitaxel can down-regulate the increased MLK3, JNK3, c-Jun, Bcl-2, and caspase-3 phosphorylation induced by ischemia injury.	Paclitaxel	21-31	BCL2 apoptosis regulator	Homo sapiens	83-88
20691985-5	2011	We blocked the expression of TGF-beta1 using paclitaxel and knocked down Smad2/3 by siRNA to explore the role of TGF-beta1/Smad2/3 pathway in the EMT of HIBEpiCs.	Paclitaxel	45-55	transforming growth factor beta 1	Homo sapiens	29-38
22060185-2	2011	Our data showed that paclitaxel can down-regulate the increased MLK3, JNK3, c-Jun, Bcl-2, and caspase-3 phosphorylation induced by ischemia injury.	Paclitaxel	21-31	caspase 3	Homo sapiens	94-103
20691985-8	2011	Paclitaxel inhibited the mRNA and protein expression of TGF-beta1 in vitro.	Paclitaxel	0-10	transforming growth factor beta 1	Homo sapiens	56-65
21903448-3	2011	We demonstrated that down-regulation of MRP1 in MC3/5FU, a drug-resistant MEC cell line, by RNA interference increased the drug sensitivity of the cells to 5-fluorouracil, doxorubicin, pharmorubicin, bleomycin-A5, cis-platinum and taxol.	Paclitaxel	231-236	ATP binding cassette subfamily C member 1	Homo sapiens	40-44
22019170-7	2011	Data revealed that paclitaxel induced an increase of Cdk1 activity and DR5 expression on the Golgi complex that was associated with increased cleavage of caspase-8, a DR5 downstream factor, and caspase-3 into catalytically active fragments.	Paclitaxel	19-29	caspase 3	Homo sapiens	194-203
21987172-4	2011	In response to endoplasmic reticulum stress inducers, including paclitaxel, YB-1 is translocated to the nucleus to transactivate clusterin.	Paclitaxel	64-74	Y-box binding protein 1	Homo sapiens	76-80
21987172-6	2011	Knockdown of either YB-1 or clusterin sensitized prostate cancer cells to paclitaxel, whereas their overexpression increased resistance to taxane.	Paclitaxel	74-84	Y-box binding protein 1	Homo sapiens	20-24
21987172-8	2011	Collectively, these data indicate that YB-1 transactivation of clusterin in response to stress is a critical mediator of paclitaxel resistance in prostate cancer.	Paclitaxel	121-131	Y-box binding protein 1	Homo sapiens	39-43
21801281-0	2011	Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.	Paclitaxel	82-92	estrogen receptor 1	Homo sapiens	166-183
21689642-7	2011	Regarding their sensitivity to anticancer treatments, we observed that cells overexpressing catalase were more sensitive to paclitaxel, etoposide and arsenic trioxide.	Paclitaxel	124-134	catalase	Homo sapiens	92-100
22077725-3	2011	We have examined potential alterations in p53 in response to 2-ME(2), E(2) and the microtubule disruptor taxol in T47D breast cancer cells.	Paclitaxel	105-110	tumor protein p53	Homo sapiens	42-45
22077725-8	2011	The observed upregulation of p53 induced by 2-ME(2) is inhibited by concurrent treatment with 1 microM taxol.	Paclitaxel	103-108	tumor protein p53	Homo sapiens	29-32
21775054-0	2011	Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition.	Paclitaxel	37-47	AKT serine/threonine kinase 1	Homo sapiens	122-125
21775054-2	2011	We found that co-administration perifosine with paclitaxel in human ovarian cancer cells led to the inhibition of AKT/mTOR complex 1 (mTORC1), a marked increase in ceramide and reactive oxygen species (ROS) production, and a striking increase in the activation of pro-apoptosis pathways, including caspase 3, c-Jun N-terminal kinases (JNK) and AMP-activated protein kinase (AMPK).	Paclitaxel	48-58	AKT serine/threonine kinase 1	Homo sapiens	114-117
21850373-5	2011	Furthermore, the microtubule-targeted anticancer drug Taxol triggered the translocation of RhoA from the nucleus toward the cytosol and membrane, and Lysophosphatidic acid (LPA) enhanced this translocation.	Paclitaxel	54-59	ras homolog family member A	Homo sapiens	91-95
21775054-2	2011	We found that co-administration perifosine with paclitaxel in human ovarian cancer cells led to the inhibition of AKT/mTOR complex 1 (mTORC1), a marked increase in ceramide and reactive oxygen species (ROS) production, and a striking increase in the activation of pro-apoptosis pathways, including caspase 3, c-Jun N-terminal kinases (JNK) and AMP-activated protein kinase (AMPK).	Paclitaxel	48-58	caspase 3	Homo sapiens	298-307
21742513-0	2011	Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells.	Paclitaxel	60-70	C-X-C motif chemokine ligand 8	Homo sapiens	24-37
21984124-3	2011	We hypothesized that paclitaxel may attenuate renal fibrosis in a rat model of remnant kidney disease by inhibiting TGF-beta induced-miRs.	Paclitaxel	21-31	transforming growth factor, beta 1	Rattus norvegicus	116-124
21984124-11	2011	In vitro, in tubular epithelial cells (NRK-52E), paclitaxel also inhibited TGF-beta1-induced Smad2/3 activation and normalized ILK, COL(I)A1, COL(IV)A2 and alpha-SMA expression.	Paclitaxel	49-59	transforming growth factor, beta 1	Rattus norvegicus	75-84
21984124-11	2011	In vitro, in tubular epithelial cells (NRK-52E), paclitaxel also inhibited TGF-beta1-induced Smad2/3 activation and normalized ILK, COL(I)A1, COL(IV)A2 and alpha-SMA expression.	Paclitaxel	49-59	collagen type I alpha 1 chain	Rattus norvegicus	132-140
21984124-12	2011	Furthermore, ChIP analyses indicated that Taxol suppressed Smad3-mediated miR-192 transcriptional activity.	Paclitaxel	42-47	SMAD family member 3	Rattus norvegicus	59-64
21984124-14	2011	These data suggest that low-dose paclitaxel ameliorates renal fibrosis via modulating miR-192 pathobiology and TGF-beta/Smad signalling.	Paclitaxel	33-43	transforming growth factor, beta 1	Rattus norvegicus	111-119
21594648-0	2011	Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells.	Paclitaxel	34-44	microRNA 22	Homo sapiens	18-24
21594648-0	2011	Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells.	Paclitaxel	34-44	tumor protein p53	Homo sapiens	109-112
21594648-4	2011	We further investigated the role of miR-22 on cytotoxicity of paclitaxel in both the p53-mutated and p53 wild-type colon cancer cells.	Paclitaxel	62-72	microRNA 22	Homo sapiens	36-42
21594648-4	2011	We further investigated the role of miR-22 on cytotoxicity of paclitaxel in both the p53-mutated and p53 wild-type colon cancer cells.	Paclitaxel	62-72	tumor protein p53	Homo sapiens	101-104
21911455-2	2011	Resistance to paclitaxel has been reported to occur in cells expressing low levels of the Forkhead transcription factor FOXO3a.	Paclitaxel	14-24	forkhead box O3	Homo sapiens	120-126
21911455-3	2011	In this article, we report that FOXO3a is critical for E1A-mediated chemosensitization to paclitaxel.	Paclitaxel	90-100	forkhead box O3	Homo sapiens	32-38
21911455-4	2011	RNA interference-mediated knockdown of FOXO3a abolished E1A-induced sensitivity to paclitaxel.	Paclitaxel	83-93	forkhead box O3	Homo sapiens	39-45
21926165-0	2011	iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.	Paclitaxel	57-67	protein phosphatase 1 regulatory subunit 13 like	Homo sapiens	0-5
21926165-2	2011	Herein, we provided the first report on the expression profile of iASPP in ovarian epithelial tumor and its effect on paclitaxel chemosensitivity.	Paclitaxel	118-128	protein phosphatase 1 regulatory subunit 13 like	Homo sapiens	66-71
21926165-4	2011	Changes in proliferation, mitotic catastrophe, apoptosis, and underlying mechanism in ovarian cancer cells of different p53 status following paclitaxel exposure were also analyzed.	Paclitaxel	141-151	tumor protein p53	Homo sapiens	120-123
21926165-6	2011	High iASPP expression was significantly associated with clear cell carcinoma subtype (P = 0.003), carboplatin and paclitaxel chemoresistance (P = 0.04), shorter overall (P = 0.003), and disease-free (P = 0.001) survival.	Paclitaxel	114-124	protein phosphatase 1 regulatory subunit 13 like	Homo sapiens	5-10
21926165-9	2011	iASPP overexpression in ovarian cancer cells conferred resistance to paclitaxel by reducing mitotic catastrophe in a p53-independent manner via activation of separase, whereas knockdown of iASPP enhanced paclitaxel-mediated mitotic catastrophe through inactivating separase.	Paclitaxel	69-79	protein phosphatase 1 regulatory subunit 13 like	Homo sapiens	0-5
21926165-9	2011	iASPP overexpression in ovarian cancer cells conferred resistance to paclitaxel by reducing mitotic catastrophe in a p53-independent manner via activation of separase, whereas knockdown of iASPP enhanced paclitaxel-mediated mitotic catastrophe through inactivating separase.	Paclitaxel	204-214	protein phosphatase 1 regulatory subunit 13 like	Homo sapiens	189-194
21660974-1	2011	Intestinal absorption and bioavailability of taxol are limited by its low solubility and P-glycoprotein (Pgp) activity.	Paclitaxel	45-50	ATP binding cassette subfamily B member 1	Homo sapiens	89-103
21660974-1	2011	Intestinal absorption and bioavailability of taxol are limited by its low solubility and P-glycoprotein (Pgp) activity.	Paclitaxel	45-50	ATP binding cassette subfamily B member 1	Homo sapiens	105-108
21660974-6	2011	In co-treatment with beta-cyclodextrins, the apical to basolateral taxol flux was 4 to 6 times greater than in untreated monolayers and it was also higher than in cells treated with Pgp inhibitor cyclosporin A.	Paclitaxel	67-72	ATP binding cassette subfamily B member 1	Homo sapiens	182-185
21594648-8	2011	Importantly, miR-22 overexpression enhanced the cytotoxic role of paclitaxel in p53-mutated HT-29 and HCT-15 cells, but not in p53 wild-type HCT-116 cell.	Paclitaxel	66-76	microRNA 22	Homo sapiens	13-19
21594648-8	2011	Importantly, miR-22 overexpression enhanced the cytotoxic role of paclitaxel in p53-mutated HT-29 and HCT-15 cells, but not in p53 wild-type HCT-116 cell.	Paclitaxel	66-76	tumor protein p53	Homo sapiens	80-83
22005063-0	2011	Paclitaxel induced B7-H1 expression in cancer cells via the MAPK pathway.	Paclitaxel	0-10	CD274 antigen	Mus musculus	19-24
21883677-1	2011	BACKGROUND AND OBJECTIVE: The adenosine triphosphate (ATP)-binding cassette, sub-family B, member 1 (ABCB1) gene encodes P-glycoprotein (Pgp), which plays an important role in drug disposition by limiting intracellular uptake of paclitaxel.	Paclitaxel	229-239	ATP binding cassette subfamily B member 1	Homo sapiens	30-99
21883677-1	2011	BACKGROUND AND OBJECTIVE: The adenosine triphosphate (ATP)-binding cassette, sub-family B, member 1 (ABCB1) gene encodes P-glycoprotein (Pgp), which plays an important role in drug disposition by limiting intracellular uptake of paclitaxel.	Paclitaxel	229-239	ATP binding cassette subfamily B member 1	Homo sapiens	101-106
21883677-1	2011	BACKGROUND AND OBJECTIVE: The adenosine triphosphate (ATP)-binding cassette, sub-family B, member 1 (ABCB1) gene encodes P-glycoprotein (Pgp), which plays an important role in drug disposition by limiting intracellular uptake of paclitaxel.	Paclitaxel	229-239	ATP binding cassette subfamily B member 1	Homo sapiens	121-135
21883677-1	2011	BACKGROUND AND OBJECTIVE: The adenosine triphosphate (ATP)-binding cassette, sub-family B, member 1 (ABCB1) gene encodes P-glycoprotein (Pgp), which plays an important role in drug disposition by limiting intracellular uptake of paclitaxel.	Paclitaxel	229-239	ATP binding cassette subfamily B member 1	Homo sapiens	137-140
21883677-3	2011	A panel of 17 non-small cell lung cancer (NSCLC) cell lines was used to investigate whether alterations in the ABCB1 gene or its mRNA expression correlated with in vitro chemosensitivity to paclitaxel.	Paclitaxel	190-200	ATP binding cassette subfamily B member 1	Homo sapiens	111-116
21883677-7	2011	RESULTS: The variant allele frequencies for four ABCB1 gene polymorphisms were 14.71% for 2677G&gt;T/A, 32.35% for 2734T&gt;C, 23.53% for 3396C&gt;T and 76.47% for 3435C&gt;T. There was a significant positive correlation between ABCB1 mRNA expression and half-maximal inhibitory concentration values for paclitaxel (r=0.5322, P=0.0279).	Paclitaxel	304-314	ATP binding cassette subfamily B member 1	Homo sapiens	49-54
21883677-9	2011	CONCLUSIONS: These in vitro results suggest that high ABCB1 mRNA expression may be a predictive biomarker for poor chemosensitivity to paclitaxel.	Paclitaxel	135-145	ATP binding cassette subfamily B member 1	Homo sapiens	54-59
22024163-3	2011	Chk1 kinase is essential for Ser331 phosphorylation during unperturbed prometaphase or during spindle disruption by taxol but not nocodazole.	Paclitaxel	116-121	checkpoint kinase 1	Homo sapiens	0-4
21552288-0	2011	miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo.	Paclitaxel	24-34	microRNA 615	Mus musculus	0-3
21552288-3	2011	We observed concordant upregulation of miR-135a in paclitaxel-resistant cell lines representing three human malignancies.	Paclitaxel	51-61	microRNA 615	Mus musculus	39-42
21552288-6	2011	In paclitaxel-resistant cell lines, established either in vitro or in vivo, blockage of miR-135a sensitized resistant cell lines to paclitaxel-induced cell death.	Paclitaxel	3-13	microRNA 615	Mus musculus	88-91
21552288-6	2011	In paclitaxel-resistant cell lines, established either in vitro or in vivo, blockage of miR-135a sensitized resistant cell lines to paclitaxel-induced cell death.	Paclitaxel	132-142	microRNA 615	Mus musculus	88-91
21552288-7	2011	We further demonstrated a correlation between paclitaxel response and miR-135a expression in paclitaxel-resistant subclones that were established in vivo.	Paclitaxel	46-56	microRNA 615	Mus musculus	70-73
21552288-7	2011	We further demonstrated a correlation between paclitaxel response and miR-135a expression in paclitaxel-resistant subclones that were established in vivo.	Paclitaxel	93-103	microRNA 615	Mus musculus	70-73
21552288-11	2011	Our results indicate that paclitaxel resistance is associated with upregulation of miR-135a, both in vitro and in vivo, and is in part determined by miR-135a-mediated downregulation of APC.	Paclitaxel	26-36	microRNA 615	Mus musculus	83-86
21552288-11	2011	Our results indicate that paclitaxel resistance is associated with upregulation of miR-135a, both in vitro and in vivo, and is in part determined by miR-135a-mediated downregulation of APC.	Paclitaxel	26-36	microRNA 615	Mus musculus	149-152
21965726-0	2011	Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.	Paclitaxel	39-49	TNF superfamily member 10	Homo sapiens	15-20
21965726-9	2011	CONCLUSION: The addition of TRAIL to PA can potentiate apoptosis in a relatively PA-resistant SCLC line (specifically 86M1 cells).	Paclitaxel	81-83	TNF superfamily member 10	Homo sapiens	28-33
21965726-10	2011	More importantly, we are the first to report an active method of resistance to paclitaxel in SCLC via BCL-xl up-regulation.	Paclitaxel	79-89	BCL2 like 1	Homo sapiens	102-108
21763756-7	2011	These results revealed specific cellular signaling pathways leading to paclitaxel-induced neuropathy, including the activation of PAR2 and downstream enzymes PLC, PKCepsilon, and PKA and resultant sensitization of TRPV1, TRPV4, and TRPA1.	Paclitaxel	71-81	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	214-219
21965779-4	2011	Some recent studies showed that COX-2 inhibitors, such as meloxicam, have the potential to enhance tumor suppression and reduce the severity of paclitaxel-induced neuropathy.	Paclitaxel	144-154	prostaglandin-endoperoxide synthase 2	Homo sapiens	32-37
21830159-0	2011	Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer.	Paclitaxel	30-40	proteasome 26S subunit, non-ATPase 1	Homo sapiens	76-79
21830159-9	2011	CONCLUSION: Although it remains unclear whether second-line chemotherapy contributes to survival in patients with URGC, the combination of PTX plus 5"-DFUR might be the treatment of choice for second-line chemotherapy in both elderly and nonelderly patients who have already received an S-1-based first-line treatment.	Paclitaxel	139-142	proteasome 26S subunit, non-ATPase 1	Homo sapiens	287-290
22005063-0	2011	Paclitaxel induced B7-H1 expression in cancer cells via the MAPK pathway.	Paclitaxel	0-10	mitogen-activated protein kinase 3	Homo sapiens	60-64
22005063-3	2011	Moreover, PTX treatment induced Erk1/2 phosphorylation in both cell lines.	Paclitaxel	10-13	mitogen-activated protein kinase 3	Homo sapiens	32-38
22005063-4	2011	PTX-increased B7-H1 mRNA expression was significantly blocked by MEK inhibitor U0126.	Paclitaxel	0-3	mitogen-activated protein kinase kinase 7	Homo sapiens	65-68
21638284-3	2011	No effects of ORM duplications on serum AGP levels at baseline or PK of PTX were observed, but close associations of ORM1 -559T &gt; A with the increases of AGP levels and area under the curve (AUC) of PTX metabolites were detected.	Paclitaxel	202-205	orosomucoid 1	Homo sapiens	117-121
21813412-0	2011	The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.	Paclitaxel	44-54	zinc ribbon domain containing 2	Homo sapiens	12-15
21702053-0	2011	Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.	Paclitaxel	38-48	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	10-16
21702053-2	2011	Recently, the genetic variants CYP2C8*3, CYP2C8-HapC, and CYP3A5*3 were associated with paclitaxel-induced neurotoxicity.	Paclitaxel	88-98	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	58-64
22010421-6	2011	PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir.	Paclitaxel	90-95	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-3
21868450-10	2011	In contrast, the microtubule stabilizers paclitaxel and epothilone B increased cytosolic Smad3 binding to beta2-tubulin and enhanced the inhibitory effect of cGMP on Smad3 nuclear translocation and PAI-1 expression in response to TGF-beta1.	Paclitaxel	41-51	transforming growth factor beta 1	Homo sapiens	230-239
21394739-8	2011	RESULTS: Expression of the TMPRSS2/ERG fusions in PC3 cells increased radiation sensitivity and decreased paclitaxel sensitivity.	Paclitaxel	106-116	transmembrane serine protease 2	Homo sapiens	27-34
21394739-8	2011	RESULTS: Expression of the TMPRSS2/ERG fusions in PC3 cells increased radiation sensitivity and decreased paclitaxel sensitivity.	Paclitaxel	106-116	ETS transcription factor ERG	Homo sapiens	35-38
22006582-7	2011	Furthermore, Matrigel assays indicated that low concentrations of propranolol (10 - 50 muM) potentiated the anti-angiogenic effects of 5-FU and paclitaxel.	Paclitaxel	144-154	latexin	Homo sapiens	87-90
21813412-13	2011	Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression.	Paclitaxel	133-143	zinc ribbon domain containing 2	Homo sapiens	114-117
21813412-4	2011	The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts.	Paclitaxel	65-75	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	41-44
21813412-7	2011	RESULTS: Src family and Abl kinases were identified as modulators of paclitaxel sensitivity in SKOv3 cells.	Paclitaxel	69-79	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	9-12
21813412-14	2011	CONCLUSION: Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.	Paclitaxel	94-104	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	26-29
21813412-8	2011	The siRNA knockdown of Src, Fyn, or Abl1 enhanced paclitaxel-mediated growth inhibition in ovarian cancer cells compared with a control siRNA.	Paclitaxel	50-60	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	23-26
21813412-14	2011	CONCLUSION: Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.	Paclitaxel	94-104	zinc ribbon domain containing 2	Homo sapiens	149-152
21813412-12	2011	The siRNA knockdown of p27(Kip1) decreased dasatinib- and paclitaxel-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017).	Paclitaxel	58-68	zinc ribbon domain containing 2	Homo sapiens	23-26
21726541-3	2011	In this study, the contribution of the redox partners cytochrome P450 reductase (CPR) and cytochrome b5 to the substrate dependent activity of CYP2C8.3 (R139K, K399R) was investigated in human liver microsomes (HLMs) and Escherichia coli expressed recombinant CYP2C8 proteins using amodiaquine, paclitaxel, rosiglitazone and cerivastatin as probe substrates.	Paclitaxel	295-305	cytochrome p450 oxidoreductase	Homo sapiens	54-79
21726541-3	2011	In this study, the contribution of the redox partners cytochrome P450 reductase (CPR) and cytochrome b5 to the substrate dependent activity of CYP2C8.3 (R139K, K399R) was investigated in human liver microsomes (HLMs) and Escherichia coli expressed recombinant CYP2C8 proteins using amodiaquine, paclitaxel, rosiglitazone and cerivastatin as probe substrates.	Paclitaxel	295-305	cytochrome p450 oxidoreductase	Homo sapiens	81-84
22135629-9	2011	Our findings may imply that trastuzumab plus paclitaxel combination therapy is useful for the treatment of advanced EMPD overexpressing HER2.	Paclitaxel	45-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-140
21868556-0	2011	Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.	Paclitaxel	79-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	160-164
21719246-5	2011	Kinetic analysis of paclitaxel uptake was characterized in both cell lines and in OATP-transfected Xenopus laevis oocytes.	Paclitaxel	20-30	solute carrier organic anion transporter family member 1A2 L homeolog	Xenopus laevis	82-86
21719246-9	2011	The higher mRNA levels for OATP1B1 and OATP1B3 found in SK-OV-3 cells correlated with higher initial uptake rates for paclitaxel.	Paclitaxel	118-128	solute carrier organic anion transporter family member 1B3	Homo sapiens	39-46
21719246-11	2011	CONCLUSIONS: Our results revealed OATP1B1 and OATP1B3 as high-affinity paclitaxel transporters expressed in ovarian cancer cell lines and tumor tissues, suggesting a role for these polypeptides in the disposition of paclitaxel during therapy.	Paclitaxel	71-81	solute carrier organic anion transporter family member 1B3	Homo sapiens	46-53
21511395-3	2011	Paclitaxel treatment could lead to the formation of acidic vesicular organelles (AVOs), the induction of Atg5, Beclin 1 and microtubule-associated protein 1 light chain 3 (LC3) expressions, and the increase of punctate fluorescent signals in A549 cells pre-transfected with green fluorescent protein (GFP)-tagged LC3.	Paclitaxel	0-10	autophagy related 5	Homo sapiens	105-109
21788566-1	2011	PURPOSE: To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.	Paclitaxel	88-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	163-197
21849404-3	2011	As a substrate of P-glycoprotein, a drug efflux pump associated with multidrug resistance, (18)F-fluoropaclitaxel may also be useful in identifying multidrug resistance and predicting tumor response for drugs other than paclitaxel.	Paclitaxel	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	18-32
21687948-2	2011	Recent studies have shown a correlation between the polymorphisms characterizing GSTM1-T1 detoxifying enzymes and poor outcome in advanced ovarian cancer patients treated with platinum/paclitaxel-based chemotherapy.	Paclitaxel	185-195	glutathione S-transferase mu 1	Homo sapiens	81-86
21687948-3	2011	Multidrug resistance 1 (mdr-1) polymorphisms were found to be associated with resistance to paclitaxel treatment.	Paclitaxel	92-102	ATP binding cassette subfamily B member 1	Homo sapiens	0-22
21687948-3	2011	Multidrug resistance 1 (mdr-1) polymorphisms were found to be associated with resistance to paclitaxel treatment.	Paclitaxel	92-102	ATP binding cassette subfamily B member 1	Homo sapiens	24-29
21514041-0	2011	Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer.	Paclitaxel	94-104	tumor protein p53	Homo sapiens	29-33
21514041-1	2011	PURPOSE: The aim of this study was to determine whether TP53 mutation status (MS) can predict response of breast cancer to paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (P-FEC).	Paclitaxel	123-133	tumor protein p53	Homo sapiens	56-60
21844414-2	2011	DESIGN: Oral squamous carcinoma cells were examined for nuclear factor-kappaB (NF-kappaB) activation and binding activity by paclitaxel, an agent currently used in head and neck cancer chemotherapy.	Paclitaxel	125-135	nuclear factor kappa B subunit 1	Homo sapiens	56-77
21728341-3	2011	This is accomplished with enhanced cellular accumulation and retention of paclitaxel (one of the most effective anticancer drugs in use today and a well-known P-glycoprotein (P-gp) substrate) in a P-gp-overexpressing cancer model.	Paclitaxel	74-84	ATP binding cassette subfamily B member 1	Homo sapiens	175-179
21728341-3	2011	This is accomplished with enhanced cellular accumulation and retention of paclitaxel (one of the most effective anticancer drugs in use today and a well-known P-glycoprotein (P-gp) substrate) in a P-gp-overexpressing cancer model.	Paclitaxel	74-84	ATP binding cassette subfamily B member 1	Homo sapiens	197-201
21728341-9	2011	These findings suggest that when the paclitaxel was delivered as an HFT-T nanoparticle, the drug is better retained within the P-gp-overexpressing cells than the free form of paclitaxel.	Paclitaxel	37-47	ATP binding cassette subfamily B member 1	Homo sapiens	127-131
21736358-5	2011	Here we show that by further mixing the drug-loaded nanoparticles with Cetuximab, a monoclonal antibody that recognizes the epidermal growth factor receptor (EGFR), paclitaxel is preferentially targeted to EGFR+ tumor cells in vitro.	Paclitaxel	165-175	epidermal growth factor receptor	Homo sapiens	124-156
21736358-5	2011	Here we show that by further mixing the drug-loaded nanoparticles with Cetuximab, a monoclonal antibody that recognizes the epidermal growth factor receptor (EGFR), paclitaxel is preferentially targeted to EGFR+ tumor cells in vitro.	Paclitaxel	165-175	epidermal growth factor receptor	Homo sapiens	158-162
21736358-5	2011	Here we show that by further mixing the drug-loaded nanoparticles with Cetuximab, a monoclonal antibody that recognizes the epidermal growth factor receptor (EGFR), paclitaxel is preferentially targeted to EGFR+ tumor cells in vitro.	Paclitaxel	165-175	epidermal growth factor receptor	Homo sapiens	206-210
21640715-5	2011	Conversely, stabilization of the microtubules by paclitaxel attenuated TG-evoked activation of SOCE and the interaction between STIM1 and the Ca(2+) channels Orai1 and TRPC1, altogether suggesting that the microtubules act as a negative regulator of SOCE.	Paclitaxel	49-59	stromal interaction molecule 1	Homo sapiens	128-133
21712253-6	2011	Furthermore, we found that HER2 overexpression led to an increased resistance of MCF7 cells to multiple antitumor drugs such as paclitaxel (Taxol), cisplatin (DDP), etoposide (VP-16), adriamycin (ADM), mitoxantrone (MX), and 5-fluorouracil (5-FU).	Paclitaxel	128-138	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
21712253-6	2011	Furthermore, we found that HER2 overexpression led to an increased resistance of MCF7 cells to multiple antitumor drugs such as paclitaxel (Taxol), cisplatin (DDP), etoposide (VP-16), adriamycin (ADM), mitoxantrone (MX), and 5-fluorouracil (5-FU).	Paclitaxel	140-145	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
21844414-2	2011	DESIGN: Oral squamous carcinoma cells were examined for nuclear factor-kappaB (NF-kappaB) activation and binding activity by paclitaxel, an agent currently used in head and neck cancer chemotherapy.	Paclitaxel	125-135	nuclear factor kappa B subunit 1	Homo sapiens	79-88
21844414-6	2011	RESULTS: Paclitaxel possessed the capacity to functionally activate NF-kappaB, as demonstrated by luciferase reporter gene assays and electromobility shift assay.	Paclitaxel	9-19	nuclear factor kappa B subunit 1	Homo sapiens	68-77
21844414-7	2011	Indomethacin was able to inhibit paclitaxel-mediated NF-kappaB activation and promote apoptosis of paclitaxel-treated cells at 24 hours.	Paclitaxel	33-43	nuclear factor kappa B subunit 1	Homo sapiens	53-62
21844414-9	2011	The dominant negative IkappaBalpha cell line exhibited increased chemosensitization to paclitaxel by 2- to 10-fold.	Paclitaxel	87-97	NFKB inhibitor alpha	Homo sapiens	22-34
21844414-10	2011	CONCLUSIONS: Paclitaxel has the capacity to activate NF-kappaB in oral squamous carcinoma cells.	Paclitaxel	13-23	nuclear factor kappa B subunit 1	Homo sapiens	53-62
21501865-8	2011	The extent of this increase in cancer cell specificity for encapsulated PTX was more for p160-decorated micelles than c(RGDfK)-decorated ones.	Paclitaxel	72-75	MYB binding protein 1a	Homo sapiens	89-93
21844414-12	2011	Treatment strategies that combine paclitaxel with indomethacin may have therapeutic benefits attributable to paclitaxel chemosensitization through NF-kappaB inhibition.	Paclitaxel	34-44	nuclear factor kappa B subunit 1	Homo sapiens	147-156
21546083-4	2011	Further studies revealed that paclitaxel (PTX)-loaded PEG-b-PLA micelles (M-PTX) increased the cellular accumulation of PTX in PTX-resistant human ovarian cell line A2780/T which resulted in more apoptosis as measured by flow cytometry and the cleavage of poly (ADP-ribose) polymerase (PARP) compared with free PTX.	Paclitaxel	30-40	poly(ADP-ribose) polymerase 1	Homo sapiens	256-284
21844414-12	2011	Treatment strategies that combine paclitaxel with indomethacin may have therapeutic benefits attributable to paclitaxel chemosensitization through NF-kappaB inhibition.	Paclitaxel	109-119	nuclear factor kappa B subunit 1	Homo sapiens	147-156
21546083-4	2011	Further studies revealed that paclitaxel (PTX)-loaded PEG-b-PLA micelles (M-PTX) increased the cellular accumulation of PTX in PTX-resistant human ovarian cell line A2780/T which resulted in more apoptosis as measured by flow cytometry and the cleavage of poly (ADP-ribose) polymerase (PARP) compared with free PTX.	Paclitaxel	30-40	poly(ADP-ribose) polymerase 1	Homo sapiens	286-290
21546083-4	2011	Further studies revealed that paclitaxel (PTX)-loaded PEG-b-PLA micelles (M-PTX) increased the cellular accumulation of PTX in PTX-resistant human ovarian cell line A2780/T which resulted in more apoptosis as measured by flow cytometry and the cleavage of poly (ADP-ribose) polymerase (PARP) compared with free PTX.	Paclitaxel	42-45	poly(ADP-ribose) polymerase 1	Homo sapiens	256-284
21546083-4	2011	Further studies revealed that paclitaxel (PTX)-loaded PEG-b-PLA micelles (M-PTX) increased the cellular accumulation of PTX in PTX-resistant human ovarian cell line A2780/T which resulted in more apoptosis as measured by flow cytometry and the cleavage of poly (ADP-ribose) polymerase (PARP) compared with free PTX.	Paclitaxel	42-45	poly(ADP-ribose) polymerase 1	Homo sapiens	286-290
21546083-4	2011	Further studies revealed that paclitaxel (PTX)-loaded PEG-b-PLA micelles (M-PTX) increased the cellular accumulation of PTX in PTX-resistant human ovarian cell line A2780/T which resulted in more apoptosis as measured by flow cytometry and the cleavage of poly (ADP-ribose) polymerase (PARP) compared with free PTX.	Paclitaxel	76-79	poly(ADP-ribose) polymerase 1	Homo sapiens	256-284
21546083-4	2011	Further studies revealed that paclitaxel (PTX)-loaded PEG-b-PLA micelles (M-PTX) increased the cellular accumulation of PTX in PTX-resistant human ovarian cell line A2780/T which resulted in more apoptosis as measured by flow cytometry and the cleavage of poly (ADP-ribose) polymerase (PARP) compared with free PTX.	Paclitaxel	76-79	poly(ADP-ribose) polymerase 1	Homo sapiens	286-290
21775090-8	2011	The secretion of vascular endothelial growth factor (VEGF) was inhibited by single PTX treatment of colon cancer and in continuous treatment of glioblastoma cell lines.	Paclitaxel	83-86	vascular endothelial growth factor A	Homo sapiens	17-51
21546083-4	2011	Further studies revealed that paclitaxel (PTX)-loaded PEG-b-PLA micelles (M-PTX) increased the cellular accumulation of PTX in PTX-resistant human ovarian cell line A2780/T which resulted in more apoptosis as measured by flow cytometry and the cleavage of poly (ADP-ribose) polymerase (PARP) compared with free PTX.	Paclitaxel	76-79	poly(ADP-ribose) polymerase 1	Homo sapiens	256-284
21546083-4	2011	Further studies revealed that paclitaxel (PTX)-loaded PEG-b-PLA micelles (M-PTX) increased the cellular accumulation of PTX in PTX-resistant human ovarian cell line A2780/T which resulted in more apoptosis as measured by flow cytometry and the cleavage of poly (ADP-ribose) polymerase (PARP) compared with free PTX.	Paclitaxel	76-79	poly(ADP-ribose) polymerase 1	Homo sapiens	286-290
21546083-4	2011	Further studies revealed that paclitaxel (PTX)-loaded PEG-b-PLA micelles (M-PTX) increased the cellular accumulation of PTX in PTX-resistant human ovarian cell line A2780/T which resulted in more apoptosis as measured by flow cytometry and the cleavage of poly (ADP-ribose) polymerase (PARP) compared with free PTX.	Paclitaxel	76-79	poly(ADP-ribose) polymerase 1	Homo sapiens	256-284
21546083-4	2011	Further studies revealed that paclitaxel (PTX)-loaded PEG-b-PLA micelles (M-PTX) increased the cellular accumulation of PTX in PTX-resistant human ovarian cell line A2780/T which resulted in more apoptosis as measured by flow cytometry and the cleavage of poly (ADP-ribose) polymerase (PARP) compared with free PTX.	Paclitaxel	76-79	poly(ADP-ribose) polymerase 1	Homo sapiens	286-290
21546083-4	2011	Further studies revealed that paclitaxel (PTX)-loaded PEG-b-PLA micelles (M-PTX) increased the cellular accumulation of PTX in PTX-resistant human ovarian cell line A2780/T which resulted in more apoptosis as measured by flow cytometry and the cleavage of poly (ADP-ribose) polymerase (PARP) compared with free PTX.	Paclitaxel	76-79	poly(ADP-ribose) polymerase 1	Homo sapiens	256-284
21775090-8	2011	The secretion of vascular endothelial growth factor (VEGF) was inhibited by single PTX treatment of colon cancer and in continuous treatment of glioblastoma cell lines.	Paclitaxel	83-86	vascular endothelial growth factor A	Homo sapiens	53-57
21546083-4	2011	Further studies revealed that paclitaxel (PTX)-loaded PEG-b-PLA micelles (M-PTX) increased the cellular accumulation of PTX in PTX-resistant human ovarian cell line A2780/T which resulted in more apoptosis as measured by flow cytometry and the cleavage of poly (ADP-ribose) polymerase (PARP) compared with free PTX.	Paclitaxel	76-79	poly(ADP-ribose) polymerase 1	Homo sapiens	286-290
21775090-9	2011	In conclusion, continuous PTX treatment caused the over-expression of P-gp and acquisition of MDR in colon cancer and glioblastoma cell lines, while some mechanisms of MDR and tumor progression such as GSH detoxification system and VEGF secretion were suppressed.	Paclitaxel	26-29	ATP binding cassette subfamily B member 1	Homo sapiens	70-74
21775090-9	2011	In conclusion, continuous PTX treatment caused the over-expression of P-gp and acquisition of MDR in colon cancer and glioblastoma cell lines, while some mechanisms of MDR and tumor progression such as GSH detoxification system and VEGF secretion were suppressed.	Paclitaxel	26-29	vascular endothelial growth factor A	Homo sapiens	232-236
21443462-5	2011	Several anti-cancer drugs like paclitaxel, imatinib, and doxorubicin activate FOXO3a by counteracting those oncogenic pathways which restrain FOXOs functions.	Paclitaxel	31-41	forkhead box O3	Homo sapiens	78-84
21482024-7	2011	Ki23057 increased the p53 expression level in OCUM-2M/SN38 and OCUM-2M/PTX, but not in OCUM-2M/VP16.	Paclitaxel	71-74	tumor protein p53	Homo sapiens	22-25
21693655-3	2011	PATIENTS AND METHODS: Epithelial p53 expression was evaluated using two immunohistochemical antibodies (DO7 and 1801) in formalin-fixed, paraffin-embedded tissue from patients with node-positive breast cancer who were randomized to four cycles of cyclophosphamide and one of three doses of doxorubicin (60, 75, or 90 mg/m(2); AC) and to receive four subsequent cycles of paclitaxel (T) or not.	Paclitaxel	371-381	tumor protein p53	Homo sapiens	33-36
21693655-9	2011	CONCLUSION: Nuclear staining of p53 by immunohistochemistry is associated with worse prognosis in node-positive patients treated with adjuvant doxorubicin-based chemotherapy but is not a useful predictor of benefit from doxorubicin dose escalation or the addition of paclitaxel.	Paclitaxel	267-277	tumor protein p53	Homo sapiens	32-35
21796700-4	2011	Paclitaxel is a substrate of the efflux transporter P-gp, and is mainly metabolized by CYP450 enzymes in the liver.	Paclitaxel	0-10	phosphoglycolate phosphatase	Rattus norvegicus	52-56
21305272-1	2011	OBJECTIVES: This study aimed to characterize the effects of bovine serum albumin (BSA) on the kinetics of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation in vitro; determine whether the addition of BSA to incubations improves the prediction of paclitaxel hepatic clearance via this pathway in vivo; and assess interindividual variability in predicted clearance.	Paclitaxel	123-133	albumin	Homo sapiens	67-80
21305272-1	2011	OBJECTIVES: This study aimed to characterize the effects of bovine serum albumin (BSA) on the kinetics of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation in vitro; determine whether the addition of BSA to incubations improves the prediction of paclitaxel hepatic clearance via this pathway in vivo; and assess interindividual variability in predicted clearance.	Paclitaxel	245-255	albumin	Homo sapiens	67-80
21190751-3	2011	Furthermore, the combination of paclitaxel and AVE1642 resulted in a sequence-dependent increase in the inhibition of cell proliferation, compared to each agent alone, which was associated with a dose-dependent increase in phosphorylated IGF-IR and Akt.	Paclitaxel	32-42	AKT serine/threonine kinase 1	Homo sapiens	249-252
21916570-3	2011	Bevacizumab, a monoclonal antibody against VEGF, increased survival in non-small-cell lung cancer (NSCLC) patients when added to standard carboplatin/paclitaxel chemotherapy.	Paclitaxel	150-160	vascular endothelial growth factor A	Homo sapiens	43-47
21917707-0	2011	Long-chain polyunsaturated fatty acids promote paclitaxel cytotoxicity via inhibition of the MDR1 gene in the human colon cancer Caco-2 cell line.	Paclitaxel	47-57	ATP binding cassette subfamily B member 1	Homo sapiens	93-97
21657271-4	2011	Long-term exposure of P-gp-expressing cells to 1 sensitized them to doxorubicin and paclitaxel, both P-gp substrates.	Paclitaxel	84-94	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
21657271-4	2011	Long-term exposure of P-gp-expressing cells to 1 sensitized them to doxorubicin and paclitaxel, both P-gp substrates.	Paclitaxel	84-94	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
21786301-6	2011	The administration of PKCepsilon AS, which has been shown to mediate cutaneous hyperalgesia in paclitaxel and ethanol models of neuropathic pain, also inhibited muscle hyperalgesia induced by these agents.	Paclitaxel	95-105	protein kinase C, epsilon	Rattus norvegicus	22-32
21670455-8	2011	A high proportion (64.3%) of EGFR mutation-positive patients randomly assigned to carboplatin/paclitaxel received subsequent EGFR tyrosine kinase inhibitors.	Paclitaxel	94-104	epidermal growth factor receptor	Homo sapiens	29-33
21317920-4	2011	We have previously shown that curcumin, a natural polyphenol, enhances paclitaxel-induced cytotoxicity in vitro through downregulation of nuclear factor (NF)-kappaB and Akt pathways.	Paclitaxel	71-81	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	138-164
21317920-4	2011	We have previously shown that curcumin, a natural polyphenol, enhances paclitaxel-induced cytotoxicity in vitro through downregulation of nuclear factor (NF)-kappaB and Akt pathways.	Paclitaxel	71-81	thymoma viral proto-oncogene 1	Mus musculus	169-172
21317920-8	2011	The results suggest that a suboptimal concentration of curcumin augments the antitumor action of paclitaxel by downregulating the activation and downstream signaling of antiapoptotic factors and survival signals such as NF-kappaB, Akt and mitogen-activated protein kinases that have significant roles in proliferation, survival, angiogenesis and metastasis.	Paclitaxel	97-107	thymoma viral proto-oncogene 1	Mus musculus	231-234
21482433-2	2011	We recently developed particle clusters coated with hyaluronan (termed gagomers; GAG), and showed that they can deliver the insoluble drug paclitaxel directly into CD44-over-expressing tumors in a mouse tumor model.	Paclitaxel	139-149	melanoma antigen	Mus musculus	81-84
21440934-6	2011	In the Caco-2 transport studies, the presence of verapamil and NOSC both improved the transport of Taxol( ), which further certified the effect of NOSC on P-gp inhibition, and PTX-M enhanced the permeability of PTX compared with Taxol( ).	Paclitaxel	99-104	ATP binding cassette subfamily B member 1	Homo sapiens	155-159
21440934-7	2011	The apparent permeability coefficient (Papp) of PTX-M decreased significantly at 4  C in comparison with at 37  C, which indicated a predominant active endocytic mechanism for the transport of PTX-M, a P-gp-independent way.	Paclitaxel	48-51	ATP binding cassette subfamily B member 1	Homo sapiens	202-206
21684102-4	2011	Our data demonstrated that overexpression of TIMP-1 could significantly decrease the sensitivity of MDA-435 breast cancer cells to epirubicin and paclitaxel.	Paclitaxel	146-156	TIMP metallopeptidase inhibitor 1	Homo sapiens	45-51
21928134-0	2011	Targeted delivery of paclitaxel-loaded recombinant alpha-fetoprotein fragment-conjugated nanoparticles to tumor cells.	Paclitaxel	21-31	alpha fetoprotein	Homo sapiens	51-68
21555371-3	2011	We show here that exposure of tumor cells to TGFbeta and TNFalpha induces EMT and, more importantly, generates cells with a stable BCSC phenotype which is shown by increased self-renewing capacity, greatly increased tumorigenicity, and increased resistance to oxaliplatin, etoposide, and paclitaxel.	Paclitaxel	288-298	transforming growth factor beta 1	Homo sapiens	45-52
21555371-3	2011	We show here that exposure of tumor cells to TGFbeta and TNFalpha induces EMT and, more importantly, generates cells with a stable BCSC phenotype which is shown by increased self-renewing capacity, greatly increased tumorigenicity, and increased resistance to oxaliplatin, etoposide, and paclitaxel.	Paclitaxel	288-298	tumor necrosis factor	Homo sapiens	57-65
21327421-2	2011	Paclitaxel is metabolized in the liver by CYP2C8 and CYP3A4 and transported by P-glycoprotein.	Paclitaxel	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-59
21822799-3	2011	Ectopic expression of the dominant negative Cdk2 (Cdk2-dn) and a specific Cdk2 inhibitor, p21( WAF1/CIP1 ), effectively suppresses the loss of MMP, the release of cytochrome c, and subsequent activation of caspase-3 in paclitaxel-treated cells.	Paclitaxel	219-229	cyclin dependent kinase inhibitor 1A	Homo sapiens	90-93
21822799-3	2011	Ectopic expression of the dominant negative Cdk2 (Cdk2-dn) and a specific Cdk2 inhibitor, p21( WAF1/CIP1 ), effectively suppresses the loss of MMP, the release of cytochrome c, and subsequent activation of caspase-3 in paclitaxel-treated cells.	Paclitaxel	219-229	cyclin dependent kinase inhibitor 1A	Homo sapiens	95-104
21684102-6	2011	Furthermore, the TIMP-1-induced attenuation of the effect of epirubicin and paclitaxel was reversed by the PI3K/Akt chemical inhibitor LY294002 and the NF-kB inhibitor pyrrolidine dithiocarbamate (PDTC), showing that the PI3K/Akt and NF-kB signaling pathway was involved in the TIMP-1-induced effect on chemoresistance.	Paclitaxel	76-86	TIMP metallopeptidase inhibitor 1	Homo sapiens	17-23
21684102-6	2011	Furthermore, the TIMP-1-induced attenuation of the effect of epirubicin and paclitaxel was reversed by the PI3K/Akt chemical inhibitor LY294002 and the NF-kB inhibitor pyrrolidine dithiocarbamate (PDTC), showing that the PI3K/Akt and NF-kB signaling pathway was involved in the TIMP-1-induced effect on chemoresistance.	Paclitaxel	76-86	AKT serine/threonine kinase 1	Homo sapiens	112-115
21684102-6	2011	Furthermore, the TIMP-1-induced attenuation of the effect of epirubicin and paclitaxel was reversed by the PI3K/Akt chemical inhibitor LY294002 and the NF-kB inhibitor pyrrolidine dithiocarbamate (PDTC), showing that the PI3K/Akt and NF-kB signaling pathway was involved in the TIMP-1-induced effect on chemoresistance.	Paclitaxel	76-86	AKT serine/threonine kinase 1	Homo sapiens	226-229
21684102-6	2011	Furthermore, the TIMP-1-induced attenuation of the effect of epirubicin and paclitaxel was reversed by the PI3K/Akt chemical inhibitor LY294002 and the NF-kB inhibitor pyrrolidine dithiocarbamate (PDTC), showing that the PI3K/Akt and NF-kB signaling pathway was involved in the TIMP-1-induced effect on chemoresistance.	Paclitaxel	76-86	TIMP metallopeptidase inhibitor 1	Homo sapiens	278-284
21502402-7	2011	Accordingly, the mammary epithelial cells expressing Twist1 exhibit much higher degrees of EMT and invasiveness on stimulation with TGF-beta or the active Ras and paclitaxel resistance compared with the same cells expressing the Ser 68A-Twist1 mutant.	Paclitaxel	163-173	twist family bHLH transcription factor 1	Homo sapiens	53-59
21469749-1	2011	Poly(ADP-ribose) polymerase (PARP) is regarded as a target protein for paclitaxel (PTX) to bind.	Paclitaxel	71-81	poly(ADP-ribose) polymerase 1	Homo sapiens	0-27
21469749-1	2011	Poly(ADP-ribose) polymerase (PARP) is regarded as a target protein for paclitaxel (PTX) to bind.	Paclitaxel	71-81	poly(ADP-ribose) polymerase 1	Homo sapiens	29-33
21469749-1	2011	Poly(ADP-ribose) polymerase (PARP) is regarded as a target protein for paclitaxel (PTX) to bind.	Paclitaxel	83-86	poly(ADP-ribose) polymerase 1	Homo sapiens	0-27
21469749-1	2011	Poly(ADP-ribose) polymerase (PARP) is regarded as a target protein for paclitaxel (PTX) to bind.	Paclitaxel	83-86	poly(ADP-ribose) polymerase 1	Homo sapiens	29-33
21469749-2	2011	An important issue is to identify the key residues as active sites for PTX interacting with PARP, which will help to understand the potential drug activity of PTX against cancer cells.	Paclitaxel	71-74	poly(ADP-ribose) polymerase 1	Homo sapiens	92-96
21469749-2	2011	An important issue is to identify the key residues as active sites for PTX interacting with PARP, which will help to understand the potential drug activity of PTX against cancer cells.	Paclitaxel	159-162	poly(ADP-ribose) polymerase 1	Homo sapiens	92-96
21469749-3	2011	Using docking method and MD simulation, we have constructed a refined structure of PTX docked on the catalytic function domain of PARP (PDB code: 1A26).	Paclitaxel	83-86	poly(ADP-ribose) polymerase 1	Homo sapiens	130-134
21469749-9	2011	The tight association of PTX with the catalytic fragment would inhibit PARP activation, suggesting a potential application of PTX as an effective antineoplastic agent.	Paclitaxel	25-28	poly(ADP-ribose) polymerase 1	Homo sapiens	71-75
21469749-9	2011	The tight association of PTX with the catalytic fragment would inhibit PARP activation, suggesting a potential application of PTX as an effective antineoplastic agent.	Paclitaxel	126-129	poly(ADP-ribose) polymerase 1	Homo sapiens	71-75
21518725-0	2011	B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.	Paclitaxel	26-36	signal transducer and activator of transcription 3	Mus musculus	68-73
20677914-0	2011	The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats.	Paclitaxel	73-83	reticulon 4 receptor	Rattus norvegicus	31-34
20677914-1	2011	Aminopeptidase N (APN), recognized by Asn-Gly-Arg (NGR) peptides, is expressed in the pericytes associated with the BBB, and the main objective of this study is to confirm the hypothesis that NGR-modified DSPE-PEG micelles containing paclitaxel (NGR-M-PTX) can bind to and kill brain tumor angiogenic blood vessels and penetrate into the brain tumor interstitial space, resulting in direct cell death.	Paclitaxel	234-244	reticulon 4 receptor	Rattus norvegicus	192-195
20677914-1	2011	Aminopeptidase N (APN), recognized by Asn-Gly-Arg (NGR) peptides, is expressed in the pericytes associated with the BBB, and the main objective of this study is to confirm the hypothesis that NGR-modified DSPE-PEG micelles containing paclitaxel (NGR-M-PTX) can bind to and kill brain tumor angiogenic blood vessels and penetrate into the brain tumor interstitial space, resulting in direct cell death.	Paclitaxel	234-244	reticulon 4 receptor	Mus musculus	192-195
21518725-5	2011	Next, we investigated the mechanisms behind B7-H3-mediated paclitaxel resistance and found that the level of Stat3 Tyr705 phosphorylation was decreased in B7-H3 knockdown cells along with the expression of its direct downstream targets Mcl-1 and survivin.	Paclitaxel	59-69	signal transducer and activator of transcription 3	Mus musculus	109-114
21518725-10	2011	Taken together, our data show that in breast cancer cells, B7-H3 induces paclitaxel resistance, at least partially by interfering with Jak2/Stat3 pathway.	Paclitaxel	73-83	signal transducer and activator of transcription 3	Mus musculus	140-145
21354697-3	2011	Importantly, miR-203 overexpression increased the cytotoxic role of paclitaxel in the p53-mutated colon cancer cells, but not in the p53 wild-type cells.	Paclitaxel	68-78	tumor protein p53	Homo sapiens	86-89
21350003-2	2011	We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (ddAC)   nanoparticle albumin-bound (nab)-paclitaxel in human epidermal growth factor receptor 2 normal early-stage breast cancer.	Paclitaxel	134-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-188
21262849-5	2011	Overexpression of P-gp also resulted in significantly decreased cell susceptibility to docetaxel, paclitaxel, and vinblastine.	Paclitaxel	98-108	ATP binding cassette subfamily B member 1	Homo sapiens	18-22
21272926-8	2011	ABCB1 was strongly expressed in the PTX-resistant cells, but not in their parental lines, which are sensitive to PTX.	Paclitaxel	36-39	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
21272926-8	2011	ABCB1 was strongly expressed in the PTX-resistant cells, but not in their parental lines, which are sensitive to PTX.	Paclitaxel	113-116	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
21262849-9	2011	This HEK-BCRP cell line demonstrated resistance to docetaxel, paclitaxel, vinblastine, and mitoxantrone, in comparison with the parental cell line (7.3, 4.3, 2.9, and 11.9 resistance factor, respectively).	Paclitaxel	62-72	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	9-13
21320484-6	2011	The results indicated that the upregulation of MDR1 gene is the dominating mechanism of the paclitaxel and vincristine drug resistance.	Paclitaxel	92-102	ATP binding cassette subfamily B member 1	Homo sapiens	47-51
21331447-15	2011	Moreover, higher expression of anti-apoptosis-related transcripts (BCL2L10, CFLAR, HIP1 and TRADD) in PANC-1 cells was observed upon combination treatment over PTX treatment alone.	Paclitaxel	160-163	BCL2 like 10	Homo sapiens	67-74
21331447-15	2011	Moreover, higher expression of anti-apoptosis-related transcripts (BCL2L10, CFLAR, HIP1 and TRADD) in PANC-1 cells was observed upon combination treatment over PTX treatment alone.	Paclitaxel	160-163	CASP8 and FADD like apoptosis regulator	Homo sapiens	76-81
21331447-15	2011	Moreover, higher expression of anti-apoptosis-related transcripts (BCL2L10, CFLAR, HIP1 and TRADD) in PANC-1 cells was observed upon combination treatment over PTX treatment alone.	Paclitaxel	160-163	huntingtin interacting protein 1	Homo sapiens	83-87
21331447-15	2011	Moreover, higher expression of anti-apoptosis-related transcripts (BCL2L10, CFLAR, HIP1 and TRADD) in PANC-1 cells was observed upon combination treatment over PTX treatment alone.	Paclitaxel	160-163	TNFRSF1A associated via death domain	Homo sapiens	92-97
21556366-0	2011	Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.	Paclitaxel	139-149	tumor protein p53	Homo sapiens	36-40
21556366-10	2011	Remarkably, TP53 mutations (p = 0.007) but also MDM2 309TG/GG genotype status (p = 0.012) were associated with a poor disease-specific survival among patients having paclitaxel but not patients having epirubicin first-line.	Paclitaxel	166-176	tumor protein p53	Homo sapiens	12-16
21556366-13	2011	In contrast, TP53 mutations and MDM2 309G allele status conferred poor disease-specific survival among patients treated with primary paclitaxel but not epirubicin monotherapy.	Paclitaxel	133-143	tumor protein p53	Homo sapiens	13-17
21490677-6	2011	The bidirectional regulation of raft-associated Akt signaling by aPPD enhanced the chemotoxicity of Paclitaxel or Vinblastine in U87MG cells but attenuated the excitotoxicity of N-methyl-D-aspartate in N2a cells.	Paclitaxel	100-110	AKT serine/threonine kinase 1	Homo sapiens	48-51
21402712-3	2011	In ABCB1-overexpressing cells, nontoxic doses of sildenafil inhibited resistance and increased the effective intracellular concentration of ABCB1 substrate drugs such as paclitaxel.	Paclitaxel	170-180	ATP binding cassette subfamily B member 1	Homo sapiens	3-8
21402712-3	2011	In ABCB1-overexpressing cells, nontoxic doses of sildenafil inhibited resistance and increased the effective intracellular concentration of ABCB1 substrate drugs such as paclitaxel.	Paclitaxel	170-180	ATP binding cassette subfamily B member 1	Homo sapiens	140-145
21290210-5	2011	RESULTS: Our results showed that PAC and DOX increased the intracellular expression of APM proteins, including calmodulin, LMP2, LMP7, TAP1 and tapasin.	Paclitaxel	33-36	calmodulin 1	Homo sapiens	111-121
21508398-0	2011	Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.	Paclitaxel	54-64	BCL2 apoptosis regulator	Homo sapiens	9-14
21508398-0	2011	Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.	Paclitaxel	54-64	ATP binding cassette subfamily B member 1	Homo sapiens	19-23
21508398-8	2011	CONCLUSION: BCL-2 and MDR1 overexpression may predict the inefficacy of paclitaxel-based chemoradiotherapy.	Paclitaxel	72-82	BCL2 apoptosis regulator	Homo sapiens	12-17
21508398-8	2011	CONCLUSION: BCL-2 and MDR1 overexpression may predict the inefficacy of paclitaxel-based chemoradiotherapy.	Paclitaxel	72-82	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
20864569-5	2011	Promising results were shown in phase II trials in which the anti-epidermal growth factor receptor monoclonal antibody cetuximab was added to induction therapy with TPF, docetaxel/cisplatin, or paclitaxel/carboplatin, and in some of these studies, to subsequent CRT.	Paclitaxel	194-204	epidermal growth factor receptor	Homo sapiens	66-98
21290210-5	2011	RESULTS: Our results showed that PAC and DOX increased the intracellular expression of APM proteins, including calmodulin, LMP2, LMP7, TAP1 and tapasin.	Paclitaxel	33-36	transporter 1, ATP binding cassette subfamily B member	Homo sapiens	135-139
21290210-5	2011	RESULTS: Our results showed that PAC and DOX increased the intracellular expression of APM proteins, including calmodulin, LMP2, LMP7, TAP1 and tapasin.	Paclitaxel	33-36	TAP binding protein	Homo sapiens	144-151
21327324-5	2011	Knockdown of DEC1 by siRNA decreased the amount of cleaved poly (ADP-ribose) polymerase (PARP), after treatment with paclitaxel, whereas DEC2 knockdown increased the amount of cleaved PARP in both the presence and absence of paclitaxel.	Paclitaxel	117-127	poly(ADP-ribose) polymerase 1	Homo sapiens	59-87
21223991-9	2011	We also found that gossypol suppresses NF-kappaB activation induced by a wide variety of agents, including taxol, okadaic acid, and phorbol myristate acetate.	Paclitaxel	107-112	nuclear factor kappa B subunit 1	Homo sapiens	39-48
21682141-5	2011	The validated 3D structure of tubulin beta-1 chain and Bcl-2 protein was taken to study their interaction with paclitaxel.	Paclitaxel	111-121	BCL2 apoptosis regulator	Homo sapiens	55-60
21682141-8	2011	It was also observed that CID_9919057 had glide score of -9.0, as compared to -8.24 of paclitaxel with Bcl-2 protein.	Paclitaxel	87-97	BCL2 apoptosis regulator	Homo sapiens	103-108
21327324-5	2011	Knockdown of DEC1 by siRNA decreased the amount of cleaved poly (ADP-ribose) polymerase (PARP), after treatment with paclitaxel, whereas DEC2 knockdown increased the amount of cleaved PARP in both the presence and absence of paclitaxel.	Paclitaxel	117-127	poly(ADP-ribose) polymerase 1	Homo sapiens	89-93
21247966-10	2011	CONCLUSIONS: EGFR copy number gain is associated with aggressive tumor biology and is a poor prognostic factor for tumor relapse in resected lung adenocarcinoma patients receiving adjuvant chemotherapy of paclitaxel and carboplatin.	Paclitaxel	205-215	epidermal growth factor receptor	Homo sapiens	13-17
21270667-10	2011	Furthermore, enforced expression of miR-101 or knockdown of EZH2 led to reduced NSCLC cell proliferation and invasion and sensitized cancer cells to paclitaxel-mediated apoptosis through inducing expression of the proapoptotic protein Bim.	Paclitaxel	149-159	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	60-64
21270667-11	2011	CONCLUSIONS: miR-101 inhibits cell proliferation and invasion and enhances paclitaxel-induced apoptosis in NSCLC cells, at least in part, by directly repressing EZH2 expression.	Paclitaxel	75-85	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	161-165
20212519-4	2011	We selected 13 relevant polymorphisms in genes encoding paclitaxel metabolizing enzymes (CYP2C8, CYP3A4 and CYP3A5) and transporters (organic anion transporting polypeptide (OATP) 1B1, OATP1B3 and P-glycoprotein) and genotyped them in 118 Spanish cancer patients treated with paclitaxel.	Paclitaxel	56-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103
20212519-4	2011	We selected 13 relevant polymorphisms in genes encoding paclitaxel metabolizing enzymes (CYP2C8, CYP3A4 and CYP3A5) and transporters (organic anion transporting polypeptide (OATP) 1B1, OATP1B3 and P-glycoprotein) and genotyped them in 118 Spanish cancer patients treated with paclitaxel.	Paclitaxel	56-66	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	108-114
21406114-0	2011	Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.	Paclitaxel	67-72	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	99-102
21163349-5	2011	Unfortunately, paclitaxel is a P-glycoprotein substrate and has poor blood-brain barrier permeability, making it unsuitable for the treatment of human tauopathies.	Paclitaxel	15-25	ATP binding cassette subfamily B member 1	Homo sapiens	31-45
21184150-10	2011	Paclitaxel-loaded PBCA as well as blank PBCA nanoparticles decreased P-gp function in a dose-dependent manner, suggesting the efficacy of the drug-loaded nanoparticle system on overcoming MDR.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	69-73
21184150-12	2011	CONCLUSIONS: Paclitaxel-loaded PBCA nanoparticles can enhance cytotoxicity and overcome MDR through a mechanism of the inhibition of P-gp function caused by the nanoparticles system.	Paclitaxel	13-23	ATP binding cassette subfamily B member 1	Homo sapiens	133-137
21223350-7	2011	Further study showed that the effect of PTX on TLR4-/- mice deficient in TLR4 signalling was similar to that on C57BL/6 mice both in vivo and in vitro.	Paclitaxel	40-43	toll-like receptor 4	Mus musculus	47-51
21223350-7	2011	Further study showed that the effect of PTX on TLR4-/- mice deficient in TLR4 signalling was similar to that on C57BL/6 mice both in vivo and in vitro.	Paclitaxel	40-43	toll-like receptor 4	Mus musculus	73-77
21565129-0	2011	Retraction: "Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells".	Paclitaxel	68-78	vascular endothelial growth factor A	Homo sapiens	114-148
20368717-1	2011	The primary purpose of this study was to evaluate the effect of CYP2C8*3 and three genetic ABCB1 variants on the elimination of paclitaxel.	Paclitaxel	128-138	ATP binding cassette subfamily B member 1	Homo sapiens	91-96
21563601-0	2011	[Retraction: Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells].	Paclitaxel	68-78	vascular endothelial growth factor A	Homo sapiens	114-148
21220478-2	2011	EXPERIMENTAL DESIGN: We treated a panel of NSCLC lines with a dose matrix of paclitaxel and navitoclax (formerly ABT-263), an inhibitor of Bcl-2, Bcl-x(L), and Bcl-w (1), and evaluated synergy.	Paclitaxel	77-87	BCL2 like 1	Homo sapiens	146-151
21406114-6	2011	The ATX-LPA axis activates LPA2, Akt, ERK and ELK-1 and also protects SGC7901 cells from apoptosis induced by Taxol treatment.	Paclitaxel	110-115	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	4-7
21406114-8	2011	In addition, OPN is required for the protective effects of ATX-LPA against Taxol-induced apoptosis and ATX-LPA-induced migration of SGC7901 cells.	Paclitaxel	75-80	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	59-62
21086124-0	2011	In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.	Paclitaxel	67-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-36
20883815-0	2011	Akt is upstream and MAPKs are downstream of NF-kappaB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism.	Paclitaxel	57-67	AKT serine/threonine kinase 1	Homo sapiens	0-3
20495920-8	2011	The sequence of paclitaxel followed by gefitinib resulted in greater anti-VEGF activity than did the reverse sequence.	Paclitaxel	16-26	vascular endothelial growth factor A	Homo sapiens	74-78
20883815-0	2011	Akt is upstream and MAPKs are downstream of NF-kappaB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism.	Paclitaxel	57-67	nuclear factor kappa B subunit 1	Homo sapiens	44-53
20883815-2	2011	Our earlier report has shown that cervical cancer cells can be sensitized by curcumin to paclitaxel-induced apoptosis through down-regulation of NF-kappaB and Akt.	Paclitaxel	89-99	nuclear factor kappa B subunit 1	Homo sapiens	145-154
20883815-2	2011	Our earlier report has shown that cervical cancer cells can be sensitized by curcumin to paclitaxel-induced apoptosis through down-regulation of NF-kappaB and Akt.	Paclitaxel	89-99	AKT serine/threonine kinase 1	Homo sapiens	159-162
24212635-10	2011	CONCLUSIONS: Zoledronic acid enhances fluvastatin and paclitaxel activity against T24 in a synergistic manner and this is mediated largely by inhibition of both the Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways via isoprenylation inhibition.	Paclitaxel	54-64	mitogen-activated protein kinase kinase 7	Homo sapiens	173-176
20883815-4	2011	The study has clearly proved that Akt and NF-kappaB function successively in the sequence of paclitaxel induced signaling events where Akt is upstream of NF-kappaB.	Paclitaxel	93-103	AKT serine/threonine kinase 1	Homo sapiens	34-37
20883815-4	2011	The study has clearly proved that Akt and NF-kappaB function successively in the sequence of paclitaxel induced signaling events where Akt is upstream of NF-kappaB.	Paclitaxel	93-103	nuclear factor kappa B subunit 1	Homo sapiens	42-51
20883815-4	2011	The study has clearly proved that Akt and NF-kappaB function successively in the sequence of paclitaxel induced signaling events where Akt is upstream of NF-kappaB.	Paclitaxel	93-103	AKT serine/threonine kinase 1	Homo sapiens	135-138
20883815-4	2011	The study has clearly proved that Akt and NF-kappaB function successively in the sequence of paclitaxel induced signaling events where Akt is upstream of NF-kappaB.	Paclitaxel	93-103	nuclear factor kappa B subunit 1	Homo sapiens	154-163
20883815-5	2011	While inhibition of NF-kappaB led to complete inhibition of the synergism of paclitaxel and curcumin, inhibition of Akt brought about only partial reduction of the same, suggesting that, apart from Akt, there are other pathways induced by paclitaxel leading to NF-kappaB activation, which are also down-regulated by curcumin.	Paclitaxel	77-87	nuclear factor kappa B subunit 1	Homo sapiens	20-29
20883815-5	2011	While inhibition of NF-kappaB led to complete inhibition of the synergism of paclitaxel and curcumin, inhibition of Akt brought about only partial reduction of the same, suggesting that, apart from Akt, there are other pathways induced by paclitaxel leading to NF-kappaB activation, which are also down-regulated by curcumin.	Paclitaxel	239-249	nuclear factor kappa B subunit 1	Homo sapiens	20-29
20883815-7	2011	Up-regulation of Cyclin-D1, Cox-2, XIAP and cIAP1 and phosphorylation of MAPKs, were completely inhibited on inactivation of NF-kappaB assigning a key regulatory role to NF-kappaB in the synergistic effect of paclitaxel and curcumin.	Paclitaxel	209-219	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	28-33
20883815-7	2011	Up-regulation of Cyclin-D1, Cox-2, XIAP and cIAP1 and phosphorylation of MAPKs, were completely inhibited on inactivation of NF-kappaB assigning a key regulatory role to NF-kappaB in the synergistic effect of paclitaxel and curcumin.	Paclitaxel	209-219	nuclear factor kappa B subunit 1	Homo sapiens	125-134
20883815-7	2011	Up-regulation of Cyclin-D1, Cox-2, XIAP and cIAP1 and phosphorylation of MAPKs, were completely inhibited on inactivation of NF-kappaB assigning a key regulatory role to NF-kappaB in the synergistic effect of paclitaxel and curcumin.	Paclitaxel	209-219	nuclear factor kappa B subunit 1	Homo sapiens	170-179
20883815-8	2011	While up-regulation of survivin by paclitaxel is regulated by Akt, independent of NF-kappaB, inactivation of neither Akt nor NF-kappaB produced any change in Bcl-2 level suggesting a distinct pathway for its action.	Paclitaxel	35-45	AKT serine/threonine kinase 1	Homo sapiens	62-65
21225235-8	2011	In HT-29 MCL, full penetration of PTX was obtained at 10 muM after 48 h, whereas only 80% was obtained at 1 muM.	Paclitaxel	34-37	latexin	Homo sapiens	57-60
21225235-9	2011	In DLD-1 MCLs, penetration of PTX was minimal, especially at 1 muM, showing penetration rates as low as 10 and 20% after 24 and 96 h, respectively.	Paclitaxel	30-33	latexin	Homo sapiens	63-66
21487460-0	2011	Transient effectiveness of an oral 5-Fluorouracil derivative, s-1, for epirubicin, cyclophosphamide and Paclitaxel refractory skin metastases from possible occult breast cancer in a male.	Paclitaxel	104-114	proteasome 26S subunit, non-ATPase 1	Homo sapiens	62-65
21487460-2	2011	We describe the case of a 76-year-old male showing transient effectiveness with an oral 5-fluorouracil derivative, S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate), for epirubicin, cyclophosphamide and paclitaxel refractory skin metastases from possible occult breast cancer.	Paclitaxel	221-231	proteasome 26S subunit, non-ATPase 1	Homo sapiens	115-118
21464539-0	2011	Effect of CD147 monoclonal antibody on paclitaxel resistance in HCE1 multicellular spheroids.	Paclitaxel	39-49	RNA guanylyltransferase and 5'-phosphatase	Homo sapiens	64-68
21464539-1	2011	OBJECTIVE: To investigate the effect of CD147 monoclonal antibody (mAb) on the natural resistance to paclitaxel (TAX) in the human cervical cancer line (HCE1) multicellular spheroid (HCE1/MCS) model and if CD147 mAb can reverse the HCE1/MCS resistance to TAX.	Paclitaxel	101-111	RNA guanylyltransferase and 5'-phosphatase	Homo sapiens	153-157
21154473-2	2011	Polyplexes formed between paclitaxel-loaded nanoparticles and TRAIL are stable with a size of  180 nm and a zeta potential at  75 mV.	Paclitaxel	26-36	TNF superfamily member 10	Homo sapiens	62-67
24212635-10	2011	CONCLUSIONS: Zoledronic acid enhances fluvastatin and paclitaxel activity against T24 in a synergistic manner and this is mediated largely by inhibition of both the Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways via isoprenylation inhibition.	Paclitaxel	54-64	mitogen-activated protein kinase 1	Homo sapiens	177-180
24212635-10	2011	CONCLUSIONS: Zoledronic acid enhances fluvastatin and paclitaxel activity against T24 in a synergistic manner and this is mediated largely by inhibition of both the Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways via isoprenylation inhibition.	Paclitaxel	54-64	AKT serine/threonine kinase 1	Homo sapiens	190-193
20942457-0	2011	Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.	Paclitaxel	72-82	epidermal growth factor receptor	Homo sapiens	15-19
20942457-7	2011	Treatment with a nanoparticle dose of 1 muM paclitaxel/10 muM lonidamine resulted in less than 10% cell viability for all hypoxic/MDR cell lines and less than 5% cell viability for all normoxic cell lines.	Paclitaxel	44-54	latexin	Homo sapiens	40-43
20942457-7	2011	Treatment with a nanoparticle dose of 1 muM paclitaxel/10 muM lonidamine resulted in less than 10% cell viability for all hypoxic/MDR cell lines and less than 5% cell viability for all normoxic cell lines.	Paclitaxel	44-54	latexin	Homo sapiens	58-61
20942457-8	2011	Comparatively, treatment with 1 muM paclitaxel alone was the approximate IC50 value of the MDR cells while treatment with lonidamine alone had very little effect.	Paclitaxel	36-46	latexin	Homo sapiens	32-35
20942457-11	2011	This nanocarrier system actively targets a MDR associated phenotype (EGFR receptor overexpression), further enhancing the therapeutic index of both drugs and potentiating the use of lonidamine/paclitaxel combination therapy in the treatment of MDR cancer.	Paclitaxel	193-203	epidermal growth factor receptor	Homo sapiens	69-73
21314952-10	2011	RESULTS: 43 SNPs were found significantly associated (FDR&lt;0.005) with paclitaxel response, with 10 belonging to protein-coding genes (CFTR, ROBO1, PTPRD, BTBD12, DCT, SNTG1, SGCD, LPHN2, GRIK1, ZNF607).	Paclitaxel	73-83	CF transmembrane conductance regulator	Homo sapiens	137-141
21314952-10	2011	RESULTS: 43 SNPs were found significantly associated (FDR&lt;0.005) with paclitaxel response, with 10 belonging to protein-coding genes (CFTR, ROBO1, PTPRD, BTBD12, DCT, SNTG1, SGCD, LPHN2, GRIK1, ZNF607).	Paclitaxel	73-83	adhesion G protein-coupled receptor L2	Homo sapiens	183-188
21314952-10	2011	RESULTS: 43 SNPs were found significantly associated (FDR&lt;0.005) with paclitaxel response, with 10 belonging to protein-coding genes (CFTR, ROBO1, PTPRD, BTBD12, DCT, SNTG1, SGCD, LPHN2, GRIK1, ZNF607).	Paclitaxel	73-83	glutamate ionotropic receptor kainate type subunit 1	Homo sapiens	190-195
21314952-10	2011	RESULTS: 43 SNPs were found significantly associated (FDR&lt;0.005) with paclitaxel response, with 10 belonging to protein-coding genes (CFTR, ROBO1, PTPRD, BTBD12, DCT, SNTG1, SGCD, LPHN2, GRIK1, ZNF607).	Paclitaxel	73-83	zinc finger protein 607	Homo sapiens	197-203
21056987-2	2011	This information may be important for understanding paclitaxel metabolism in vivo and in the investigation of the role of genetic polymorphisms in the metabolizing enzymes CYP2C8 and CYP3A4/CYP3A5 and the ABCB1 transporter.	Paclitaxel	52-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	183-189
21296416-0	2011	BRCA1 suppresses the expression of survivin and promotes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in human breast cancer cells.	Paclitaxel	72-82	calcium sensing receptor	Homo sapiens	95-119
21296416-0	2011	BRCA1 suppresses the expression of survivin and promotes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in human breast cancer cells.	Paclitaxel	72-82	calcium sensing receptor	Homo sapiens	121-125
21296416-1	2011	Both BRCA1 and CaSR have been shown to suppress the expression of survivin and promote sensitivity to paclitaxel in human breast cancer cells.	Paclitaxel	102-112	calcium sensing receptor	Homo sapiens	15-19
21296416-8	2011	In a final series of experiments, we show that ectopic expression of CaSR in either the BRCA1 knocked-down wild type or mutant cells suppressed the expression of survivin and promoted sensitivity to paclitaxel.	Paclitaxel	199-209	calcium sensing receptor	Homo sapiens	69-73
21296416-12	2011	We conclude, and report for the first time, that BRCA1 regulates the expression of CaSR and that it functions through CaSR in suppressing the expression of survivin and promoting sensitivity to paclitaxel.	Paclitaxel	194-204	calcium sensing receptor	Homo sapiens	118-122
21056987-2	2011	This information may be important for understanding paclitaxel metabolism in vivo and in the investigation of the role of genetic polymorphisms in the metabolizing enzymes CYP2C8 and CYP3A4/CYP3A5 and the ABCB1 transporter.	Paclitaxel	52-62	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	190-196
21056987-2	2011	This information may be important for understanding paclitaxel metabolism in vivo and in the investigation of the role of genetic polymorphisms in the metabolizing enzymes CYP2C8 and CYP3A4/CYP3A5 and the ABCB1 transporter.	Paclitaxel	52-62	ATP binding cassette subfamily B member 1	Homo sapiens	205-210
21056987-11	2011	The correlation of G2677T/A with 6alpha-hydroxypaclitaxel has not been described previously but supports other findings of the ABCB1 transporter playing a part in paclitaxel metabolism.	Paclitaxel	47-57	ATP binding cassette subfamily B member 1	Homo sapiens	127-132
20934246-3	2011	Herein, we have identified protein kinase D isoform 2 (PKD2) as an important regulator of MDR and P-gp expression in paclitaxel-treated breast cancer cell lines.	Paclitaxel	117-127	polycystin 2, transient receptor potential cation channel	Homo sapiens	27-53
21220510-5	2011	Microtubule perturbation by taxol (TX) and other microtubule-targeting drugs stalls HIF-1alpha mRNA transport and releases it from polysomes, suppressing its translation.	Paclitaxel	28-33	hypoxia inducible factor 1 subunit alpha	Homo sapiens	84-94
21115120-0	2011	Selective impairment of CD4+CD25+Foxp3+ regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis.	Paclitaxel	62-72	CD4 molecule	Homo sapiens	24-27
21115120-0	2011	Selective impairment of CD4+CD25+Foxp3+ regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis.	Paclitaxel	62-72	BCL2 apoptosis regulator	Homo sapiens	89-94
21115120-0	2011	Selective impairment of CD4+CD25+Foxp3+ regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis.	Paclitaxel	62-72	BCL2 associated X, apoptosis regulator	Homo sapiens	95-98
21115120-4	2011	We found that paclitaxel significantly decreased the percentage of Treg cells in CD4(+) cells and impaired their suppressive functions, but effector T (Teff) cells remained unaffected.	Paclitaxel	14-24	CD4 molecule	Homo sapiens	81-84
21115120-7	2011	Treg cells exposed to paclitaxel displayed downregulation of Bcl-2 and upregulation of Bax.	Paclitaxel	22-32	BCL2 apoptosis regulator	Homo sapiens	61-66
21115120-7	2011	Treg cells exposed to paclitaxel displayed downregulation of Bcl-2 and upregulation of Bax.	Paclitaxel	22-32	BCL2 associated X, apoptosis regulator	Homo sapiens	87-90
21115120-8	2011	Blocking the Bcl-2 pathway eliminated the difference between Treg and Teff cells responding to paclitaxel.	Paclitaxel	95-105	BCL2 apoptosis regulator	Homo sapiens	13-18
21115120-9	2011	These results suggest that Bcl-2 rather than tubulin contributes to the distinctive effect of paclitaxel on Treg cells.	Paclitaxel	94-104	BCL2 apoptosis regulator	Homo sapiens	27-32
20665703-1	2011	Chemotherapy employing paclitaxel and docetaxel is widely used for treating early-stage breast cancer and metastasis, which is frequently associated with overexpression of epidermal growth factor receptor (EGFR) and resistance to apoptosis.	Paclitaxel	23-33	epidermal growth factor receptor	Homo sapiens	172-204
20665703-1	2011	Chemotherapy employing paclitaxel and docetaxel is widely used for treating early-stage breast cancer and metastasis, which is frequently associated with overexpression of epidermal growth factor receptor (EGFR) and resistance to apoptosis.	Paclitaxel	23-33	epidermal growth factor receptor	Homo sapiens	206-210
20665703-4	2011	In order to improve the antineoplastic activity of paclitaxel, we presently investigated the effects of ZD6474 in combination with paclitaxel in EGFR and VEGFR expressing human breast cancer cell lines MCF-7 and MDA-MB-231.	Paclitaxel	131-141	epidermal growth factor receptor	Homo sapiens	145-149
20665703-7	2011	The combination of ZD6474 with paclitaxel versus either agent alone also more potently down-regulated the antiapoptotic bcl-2 protein, up-regulated pro-apoptotic signaling events involving expression of bax, activation of caspase-3 and caspase-7 proteins, and induced poly(ADP-ribose) polymerase resulting in apoptosis.	Paclitaxel	31-41	BCL2 apoptosis regulator	Homo sapiens	120-125
20665703-7	2011	The combination of ZD6474 with paclitaxel versus either agent alone also more potently down-regulated the antiapoptotic bcl-2 protein, up-regulated pro-apoptotic signaling events involving expression of bax, activation of caspase-3 and caspase-7 proteins, and induced poly(ADP-ribose) polymerase resulting in apoptosis.	Paclitaxel	31-41	BCL2 associated X, apoptosis regulator	Homo sapiens	203-206
20665703-7	2011	The combination of ZD6474 with paclitaxel versus either agent alone also more potently down-regulated the antiapoptotic bcl-2 protein, up-regulated pro-apoptotic signaling events involving expression of bax, activation of caspase-3 and caspase-7 proteins, and induced poly(ADP-ribose) polymerase resulting in apoptosis.	Paclitaxel	31-41	caspase 3	Homo sapiens	222-231
20665703-7	2011	The combination of ZD6474 with paclitaxel versus either agent alone also more potently down-regulated the antiapoptotic bcl-2 protein, up-regulated pro-apoptotic signaling events involving expression of bax, activation of caspase-3 and caspase-7 proteins, and induced poly(ADP-ribose) polymerase resulting in apoptosis.	Paclitaxel	31-41	poly(ADP-ribose) polymerase 1	Homo sapiens	268-295
20975605-10	2011	This was supported by data from three c-Kit-expressing human melanoma cell lines showing varying sensitization to paclitaxel by the kinase inhibitors.	Paclitaxel	114-124	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	38-43
21255411-0	2011	Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.	Paclitaxel	136-146	epidermal growth factor receptor	Homo sapiens	73-77
21255411-8	2011	Paclitaxel produced a dose-dependent increase in EGFR phosphorylation.	Paclitaxel	0-10	epidermal growth factor receptor	Homo sapiens	49-53
21255411-9	2011	Paclitaxel significantly increased EGFR phosphorylation compared with that in untreated controls (mean differences: +50% in Hcc827, + 56% in PC-9, + 39% in PC-9/GR, and + 69% in H1650 cells; p &lt; 0.05).	Paclitaxel	0-10	epidermal growth factor receptor	Homo sapiens	35-39
21255411-11	2011	Addition of a neutralizing anti-TGFalpha antibody abolished paclitaxel-induced activation of the EGFR pathway in PC-9 and H1650 cells.	Paclitaxel	60-70	epidermal growth factor receptor	Homo sapiens	97-101
21255411-13	2011	CONCLUSION: The data suggest that the sequence of paclitaxel followed by gefitinib is an appropriate treatment combination for NSCLC cell lines harboring EGFR mutations.	Paclitaxel	50-60	epidermal growth factor receptor	Homo sapiens	154-158
22393970-12	2011	When paclitaxel was used as a single-agent or in combinations, the protein expression of PI3K/AKT pathway totally abated, especially in HEC-1A cells, suggesting a role in chemoresistance.	Paclitaxel	5-15	AKT serine/threonine kinase 1	Homo sapiens	94-97
21289336-11	2011	CONCLUSION: The NF-kappaB inhibitor, parthenolide, may enhance chemosensitivity to paclitaxel in the treatment of patients with gastric cancer.	Paclitaxel	83-93	nuclear factor kappa B subunit 1	Homo sapiens	16-25
20934246-3	2011	Herein, we have identified protein kinase D isoform 2 (PKD2) as an important regulator of MDR and P-gp expression in paclitaxel-treated breast cancer cell lines.	Paclitaxel	117-127	polycystin 2, transient receptor potential cation channel	Homo sapiens	55-59
20934246-3	2011	Herein, we have identified protein kinase D isoform 2 (PKD2) as an important regulator of MDR and P-gp expression in paclitaxel-treated breast cancer cell lines.	Paclitaxel	117-127	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
20934246-7	2011	Treatment with paclitaxel was shown to induce both PKD2 phosphorylation and P-gp expression in a time-dependent manner.	Paclitaxel	15-25	polycystin 2, transient receptor potential cation channel	Homo sapiens	51-55
20934246-7	2011	Treatment with paclitaxel was shown to induce both PKD2 phosphorylation and P-gp expression in a time-dependent manner.	Paclitaxel	15-25	ATP binding cassette subfamily B member 1	Homo sapiens	76-80
20934246-8	2011	Importantly, shRNA-mediated knockdown of PKD2 in MDA-MB-231 cells resulted in a significant decrease in resistance to paclitaxel, evident as significant decreases in both the IC(50) value and the resistance index (RI).	Paclitaxel	118-128	polycystin 2, transient receptor potential cation channel	Homo sapiens	41-45
20934246-9	2011	Concurrent with the decrease in drug resistance, paclitaxel-induced expression of P-gp was also significantly reduced in PKD knockdown cells.	Paclitaxel	49-59	ATP binding cassette subfamily B member 1	Homo sapiens	82-86
20934246-10	2011	These results indicate that PKD2 is required for paclitaxel-induced MDR and expression of P-gp.	Paclitaxel	49-59	polycystin 2, transient receptor potential cation channel	Homo sapiens	28-32
20934246-10	2011	These results indicate that PKD2 is required for paclitaxel-induced MDR and expression of P-gp.	Paclitaxel	49-59	ATP binding cassette subfamily B member 1	Homo sapiens	90-94
21949561-5	2011	We found that microtubule stabilizers, such as paclitaxel, or microtubule inhibitors, such as vinorelbine, decrease the activating tyrosine phosphorylation of STAT3 in tumor cells and inhibit the expression of STAT3 target genes.	Paclitaxel	47-57	signal transducer and activator of transcription 3	Homo sapiens	159-164
21769295-6	2011	After surgery, the patients received six courses of carboplatin/paclitaxel chemotherapy, and the serum levels of AFP decreased to normal range.	Paclitaxel	64-74	alpha fetoprotein	Homo sapiens	113-116
21822381-3	2011	As proof of concept, the interaction of paclitaxel with partially unfolded states of human serum albumin was evaluated as a potential method for the preparation of water-soluble complexes of the taxane with albumin.	Paclitaxel	40-50	albumin	Homo sapiens	97-104
21822381-3	2011	As proof of concept, the interaction of paclitaxel with partially unfolded states of human serum albumin was evaluated as a potential method for the preparation of water-soluble complexes of the taxane with albumin.	Paclitaxel	40-50	albumin	Homo sapiens	207-214
21822381-4	2011	RESULTS: We found that paclitaxel readily binds to pH-induced partially unfolded albumin, leading to the formation of optically clear water-soluble complexes.	Paclitaxel	23-33	albumin	Homo sapiens	81-88
21822381-6	2011	It was also observed that the hydrodynamic radius of human serum albumin was only slightly increased after the cycle of pH changes, remaining in a monomeric state with a size according to paclitaxel binding.	Paclitaxel	188-198	albumin	Homo sapiens	65-72
22065926-0	2011	Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells.	Paclitaxel	77-87	epithelial cell adhesion molecule	Homo sapiens	47-52
22065926-1	2011	BACKGROUND: To specifically deliver paclitaxel (PTX) to retinoblastoma (RB) cells, the anionic surface-charged poly(lactic-co-glycolic acid) (PLGA) NPs loaded with paclitaxel were conjugated with epithelial cell adhesion molecule (EpCAM) antibody for enhancing site-specific intracellular delivery of paclitaxel against EpCAM overexpressing RB cells.	Paclitaxel	48-51	epithelial cell adhesion molecule	Homo sapiens	196-229
22065926-1	2011	BACKGROUND: To specifically deliver paclitaxel (PTX) to retinoblastoma (RB) cells, the anionic surface-charged poly(lactic-co-glycolic acid) (PLGA) NPs loaded with paclitaxel were conjugated with epithelial cell adhesion molecule (EpCAM) antibody for enhancing site-specific intracellular delivery of paclitaxel against EpCAM overexpressing RB cells.	Paclitaxel	48-51	epithelial cell adhesion molecule	Homo sapiens	231-236
22065926-1	2011	BACKGROUND: To specifically deliver paclitaxel (PTX) to retinoblastoma (RB) cells, the anionic surface-charged poly(lactic-co-glycolic acid) (PLGA) NPs loaded with paclitaxel were conjugated with epithelial cell adhesion molecule (EpCAM) antibody for enhancing site-specific intracellular delivery of paclitaxel against EpCAM overexpressing RB cells.	Paclitaxel	48-51	epithelial cell adhesion molecule	Homo sapiens	320-325
22065926-7	2011	Increased uptake of PTX-Np-EpCAM by the cells suggests that they were mainly taken up through EpCAM mediated endocytosis.	Paclitaxel	20-23	epithelial cell adhesion molecule	Homo sapiens	27-32
22065926-7	2011	Increased uptake of PTX-Np-EpCAM by the cells suggests that they were mainly taken up through EpCAM mediated endocytosis.	Paclitaxel	20-23	epithelial cell adhesion molecule	Homo sapiens	94-99
21034425-3	2011	Accordingly, some potent chemotherapeutic agents such as camptothecin (CPT), methotrexate (MTX), paclitaxel (PTX) and doxorubicin (DOX) have been coupled to SSTR2-preferential somatostatin (SST) analogs.	Paclitaxel	97-107	somatostatin receptor 2	Homo sapiens	157-162
21034425-3	2011	Accordingly, some potent chemotherapeutic agents such as camptothecin (CPT), methotrexate (MTX), paclitaxel (PTX) and doxorubicin (DOX) have been coupled to SSTR2-preferential somatostatin (SST) analogs.	Paclitaxel	109-112	somatostatin receptor 2	Homo sapiens	157-162
21196304-3	2011	In the present study, we found that the CD44(+)/CD24(-/low) CSCs, isolated from both human breast cell line MCF-7 and MDA-MB-231, were more resistant to thiotepa, paclitaxel and anthracycline, when compared with the non-breast cancer stem cell subset from the same cell lines, whereas the chemosensitivities were remarkably reversed by higher concentration of thiotepa and paclitaxel except for adriamycin.	Paclitaxel	163-173	CD24 molecule	Homo sapiens	48-52
21196304-3	2011	In the present study, we found that the CD44(+)/CD24(-/low) CSCs, isolated from both human breast cell line MCF-7 and MDA-MB-231, were more resistant to thiotepa, paclitaxel and anthracycline, when compared with the non-breast cancer stem cell subset from the same cell lines, whereas the chemosensitivities were remarkably reversed by higher concentration of thiotepa and paclitaxel except for adriamycin.	Paclitaxel	373-383	CD24 molecule	Homo sapiens	48-52
21694451-8	2011	Taxol, a microtubule stabilizer drug, was able to restore microtubule network and to prevent cell death induced by Abeta peptides.	Paclitaxel	0-5	amyloid beta precursor protein	Homo sapiens	115-120
22117968-3	2011	Transfection of these cells with small interfering RNA (siRNA) for XIAP blocked overexpression of the gene, suppressed cell proliferation, increased apoptosis and increased the cells" sensitivity to cisplatin and paclitaxel by preventing the binding of XIAP to caspase3 and  increasing the activity of this enzyme.	Paclitaxel	213-223	caspase 3	Homo sapiens	261-269
21949561-5	2011	We found that microtubule stabilizers, such as paclitaxel, or microtubule inhibitors, such as vinorelbine, decrease the activating tyrosine phosphorylation of STAT3 in tumor cells and inhibit the expression of STAT3 target genes.	Paclitaxel	47-57	signal transducer and activator of transcription 3	Homo sapiens	210-215
21949561-6	2011	Paclitaxel decreases the association between STAT3 and microtubules, and appears to decrease STAT3 phosphorylation through induction of a negative feedback regulator.	Paclitaxel	0-10	signal transducer and activator of transcription 3	Homo sapiens	45-50
21949561-6	2011	Paclitaxel decreases the association between STAT3 and microtubules, and appears to decrease STAT3 phosphorylation through induction of a negative feedback regulator.	Paclitaxel	0-10	signal transducer and activator of transcription 3	Homo sapiens	93-98
21949561-7	2011	The cytotoxic activity of paclitaxel in breast cancer cell lines correlates with its ability to decrease STAT3 phosphorylation.	Paclitaxel	26-36	signal transducer and activator of transcription 3	Homo sapiens	105-110
21949561-8	2011	However, consistent with the necessity for expression of a negative regulator, treatment of resistant MDA-MB-231 cells with the DNA demethylating agent 5-azacytidine restores the ability of paclitaxel to block STAT3-dependent gene expression.	Paclitaxel	190-200	signal transducer and activator of transcription 3	Homo sapiens	210-215
21949561-9	2011	Finally, the combination of paclitaxel and agents that directly target STAT3 has beneficial effects in killing STAT3-dependent cell lines.	Paclitaxel	28-38	signal transducer and activator of transcription 3	Homo sapiens	71-76
21949561-9	2011	Finally, the combination of paclitaxel and agents that directly target STAT3 has beneficial effects in killing STAT3-dependent cell lines.	Paclitaxel	28-38	signal transducer and activator of transcription 3	Homo sapiens	111-116
22140576-7	2011	Intriguingly, two main drugs for drug-eluting stent, paclitaxel or rapamycin, significantly exaggerated thrombin-induced TF expression, which was also effectively blocked by the PPAR-gamma agonist in all cell types.	Paclitaxel	53-63	coagulation factor II, thrombin	Homo sapiens	104-112
21109480-8	2011	In combination therapy, p53RA small molecules enhanced the anti-tumor activity of cisplatin, 5-fluorouracil, paclitaxel, and erlotinib against HNSCC cells.	Paclitaxel	109-119	tumor protein p53	Homo sapiens	24-27
22140576-7	2011	Intriguingly, two main drugs for drug-eluting stent, paclitaxel or rapamycin, significantly exaggerated thrombin-induced TF expression, which was also effectively blocked by the PPAR-gamma agonist in all cell types.	Paclitaxel	53-63	peroxisome proliferator activated receptor gamma	Homo sapiens	178-188
22140576-11	2011	Also, this PPAR-gamma agonist reversed the paclitaxel-induced aggravation of TF expression, which suggests a possibility that the benefits might outweigh its risks in a group of patients with paclitaxel-eluting stent implanted.	Paclitaxel	43-53	peroxisome proliferator activated receptor gamma	Homo sapiens	11-21
22140576-11	2011	Also, this PPAR-gamma agonist reversed the paclitaxel-induced aggravation of TF expression, which suggests a possibility that the benefits might outweigh its risks in a group of patients with paclitaxel-eluting stent implanted.	Paclitaxel	192-202	peroxisome proliferator activated receptor gamma	Homo sapiens	11-21
21647386-5	2011	We discovered that autotaxin strongly antagonizes the Taxol-induced killing of breast cancer and melanoma cells by converting the abundant extra-cellular lipid, lysophosphatidylcholine, into lysophosphatidate.	Paclitaxel	54-59	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	19-28
22194993-3	2011	In the present study we investigated the effect of paclitaxel in combination with two novel HDACi, ST2782 or ST3595, able to induce p53 and tubulin hyperacetylation.	Paclitaxel	51-61	tumor protein p53	Homo sapiens	132-135
22194993-4	2011	A synergistic effect of the paclitaxel/ST2782 (or ST3595) combination was found in wild-type p53 ovarian carcinoma cells, but not in a p53 mutant subline, in spite of a marked tubulin acetylation.	Paclitaxel	28-38	tumor protein p53	Homo sapiens	93-96
22194993-7	2011	In contrast to SAHA, which was substantially less effective in sensitizing cells to paclitaxel-induced apoptosis, ST2782 prevented up-regulation of p21(WAF1/Cip1) by paclitaxel, which has a protective role in response to taxanes, and caused p53 down-regulation, acetylation and mitochondrial localization of acetylated p53.	Paclitaxel	166-176	cyclin dependent kinase inhibitor 1A	Homo sapiens	152-156
22194993-7	2011	In contrast to SAHA, which was substantially less effective in sensitizing cells to paclitaxel-induced apoptosis, ST2782 prevented up-regulation of p21(WAF1/Cip1) by paclitaxel, which has a protective role in response to taxanes, and caused p53 down-regulation, acetylation and mitochondrial localization of acetylated p53.	Paclitaxel	166-176	cyclin dependent kinase inhibitor 1A	Homo sapiens	157-161
22194993-9	2011	Our results support the relevance of p53 modulation as a major determinant of the synergistic interaction observed between paclitaxel and novel HDACi and emphasize the therapeutic interest of this combination.	Paclitaxel	123-133	tumor protein p53	Homo sapiens	37-40
21931642-0	2011	Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.	Paclitaxel	35-45	epidermal growth factor receptor	Homo sapiens	64-68
21931642-3	2011	We exploit this expression through the development of EGFR-targeted, polymer blend nanocarriers for the treatment of MDR cancer using paclitaxel (a common chemotherapeutic agent) and lonidamine (an experimental drug; mitochondrial hexokinase 2 inhibitor).	Paclitaxel	134-144	epidermal growth factor receptor	Homo sapiens	54-58
21931642-9	2011	In addition, treatment with the EGFR-targeted lonidamine/paclitaxel nanoparticles decreased tumor density and altered the MDR phenotype of the tumor xenografts.	Paclitaxel	57-67	epidermal growth factor receptor	Homo sapiens	32-36
21647386-12	2011	CONCLUSIONS/SIGNIFICANCE: This work demonstrates a previously unknown consequence of lysophosphatidate action that explains why autotaxin and lysophosphatidate protect against Taxol-induced cell death and promote resistance to the action of this important therapeutic agent.	Paclitaxel	176-181	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	128-137
20673698-3	2010	Synergistic interactions were observed for RAD001 plus gemcitabine or paclitaxel in six NHL cell lines; enhanced gemcitabine- and paclitaxel-induced caspase-dependent apoptosis associated with down-regulation of mTOR signaling was detected.	Paclitaxel	130-140	mechanistic target of rapamycin kinase	Homo sapiens	212-216
20869436-6	2010	Similarly, 50muM paclitaxel (Pacl) increased UIC2 binding, and consequently reinstated the uptake of R123, DNR and (99m)Tc-MIBI into the Pgp(+) cells.	Paclitaxel	17-27	ATP binding cassette subfamily B member 1	Homo sapiens	137-140
20869436-6	2010	Similarly, 50muM paclitaxel (Pacl) increased UIC2 binding, and consequently reinstated the uptake of R123, DNR and (99m)Tc-MIBI into the Pgp(+) cells.	Paclitaxel	29-33	ATP binding cassette subfamily B member 1	Homo sapiens	137-140
21122157-10	2010	In AS2 derived cells, resistance to paclitaxel was positively correlated with Stat3 activation status and the expression of IL-6, which is commonly secreted in drug resistant cancer cells.	Paclitaxel	36-46	signal transducer and activator of transcription 3	Homo sapiens	78-83
20623213-8	2010	The effects of the Cys431Leu variation, due to MDR1 (GT1292-3TG) nucleotide transition, on P-gp-dependent intracellular substrate accumulation appeared to be substrate dependent where doxorubicin, vinblastine, and paclitaxel exhibit an increased accumulation (p &lt; 0.05), while verapamil and Hoechst33342 exhibit a decreased intracellular concentration compared with wild type (p &lt; 0.05).	Paclitaxel	214-224	ATP binding cassette subfamily B member 1	Homo sapiens	47-51
20623213-8	2010	The effects of the Cys431Leu variation, due to MDR1 (GT1292-3TG) nucleotide transition, on P-gp-dependent intracellular substrate accumulation appeared to be substrate dependent where doxorubicin, vinblastine, and paclitaxel exhibit an increased accumulation (p &lt; 0.05), while verapamil and Hoechst33342 exhibit a decreased intracellular concentration compared with wild type (p &lt; 0.05).	Paclitaxel	214-224	ATP binding cassette subfamily B member 1	Homo sapiens	91-95
21122157-10	2010	In AS2 derived cells, resistance to paclitaxel was positively correlated with Stat3 activation status and the expression of IL-6, which is commonly secreted in drug resistant cancer cells.	Paclitaxel	36-46	interleukin 6	Homo sapiens	124-128
20825984-9	2010	These data paralleled the findings of an increased expression of HDAC6 in the presence of PTX in PTX-resistant cell lines.	Paclitaxel	90-93	histone deacetylase 6	Homo sapiens	65-70
20935456-2	2010	Many anticancer chemotherapeutics (anthracyclines, Vinca alkaloids, paclitaxel, and fenretinide), as well as physiological stimuli such as tumor necrosis factor alpha (TNFalpha), stimulate ceramide accumulation and increase oxidative stress in malignant cells.	Paclitaxel	68-78	tumor necrosis factor	Homo sapiens	139-166
20847137-3	2010	In this study, catalytic activities of the two alleles found in East Asians, CYP3A4*16 (T185S) and CYP3A4*18 (L293P), were assessed using the following seven substrates: midazolam, carbamazepine, atorvastatin, paclitaxel, docetaxel, irinotecan, and terfenadine.	Paclitaxel	210-220	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-83
20847137-3	2010	In this study, catalytic activities of the two alleles found in East Asians, CYP3A4*16 (T185S) and CYP3A4*18 (L293P), were assessed using the following seven substrates: midazolam, carbamazepine, atorvastatin, paclitaxel, docetaxel, irinotecan, and terfenadine.	Paclitaxel	210-220	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
20847137-5	2010	CYP3A4.16 exhibited intrinsic clearances (V(max)/K(m)) that were lowered considerably (by 84-60%) for metabolism of midazolam, carbamazepine, atorvastatin, paclitaxel, and irinotecan compared with CYP3A4.1 due to increased K(m) with or without decreased V(max) values, whereas no apparent decrease in intrinsic clearance was observed for docetaxel.	Paclitaxel	156-166	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
20847137-6	2010	On the other hand, K(m) values for CYP3A4.18 were comparable to those for CYP3A4.1 for all substrates except terfenadine; but V(max) values were lower for midazolam, paclitaxel, docetaxel, and irinotecan, resulting in partially reduced intrinsic clearance values (by 34-52%).	Paclitaxel	166-176	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-41
20847137-6	2010	On the other hand, K(m) values for CYP3A4.18 were comparable to those for CYP3A4.1 for all substrates except terfenadine; but V(max) values were lower for midazolam, paclitaxel, docetaxel, and irinotecan, resulting in partially reduced intrinsic clearance values (by 34-52%).	Paclitaxel	166-176	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-80
20825984-9	2010	These data paralleled the findings of an increased expression of HDAC6 in the presence of PTX in PTX-resistant cell lines.	Paclitaxel	97-100	histone deacetylase 6	Homo sapiens	65-70
21119364-8	2010	The expected 5-year OS rate of those receiving paclitaxel-based chemotherapy was better than non-paclitaxel-based chemotherapy for those with positive E-cadherin immunoexpression (43% vs 0%, P = 0.01).	Paclitaxel	47-57	cadherin 1	Homo sapiens	151-161
20473628-0	2010	A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.	Paclitaxel	169-179	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-15
20473628-1	2010	We report a case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a complete response to trastuzumab and paclitaxel treatment.	Paclitaxel	157-167	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-25
21160270-0	2010	[A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock].	Paclitaxel	163-173	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
21160270-0	2010	[A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock].	Paclitaxel	163-173	nuclear factor I C	Homo sapiens	59-62
21119364-8	2010	The expected 5-year OS rate of those receiving paclitaxel-based chemotherapy was better than non-paclitaxel-based chemotherapy for those with positive E-cadherin immunoexpression (43% vs 0%, P = 0.01).	Paclitaxel	97-107	cadherin 1	Homo sapiens	151-161
21119364-10	2010	CONCLUSIONS: E-cadherin is a useful prognostic marker for OCCA patients, and paclitaxel-based chemotherapy can improve survival among patients with positive E-cadherin immunoreactivity.	Paclitaxel	77-87	cadherin 1	Homo sapiens	157-167
20125118-4	2010	Increased ABCB1 transcript expression coincident with acquisition of resistance to epirubicin or paclitaxel was temporally associated with hypomethylation of the ABCB1 downstream promoter in the absence of gene amplifications or changes in mRNA stability.	Paclitaxel	97-107	ATP binding cassette subfamily B member 1	Homo sapiens	10-15
20975068-14	2010	CONCLUSION: Everolimus combined with weekly paclitaxel and trastuzumab was generally well tolerated and had encouraging antitumor activity in patients with trastuzumab-pretreated and -resistant metastatic HER2-overexpressing breast cancer.	Paclitaxel	44-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	205-209
20125118-7	2010	Furthermore, our data suggest that allele-specific reductions in ABCB1 promoter methylation regulate promoter usage within paclitaxel-resistant cells.	Paclitaxel	123-133	ATP binding cassette subfamily B member 1	Homo sapiens	65-70
20858016-0	2010	Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells.	Paclitaxel	28-38	heterogeneous nuclear ribonucleoprotein A2/B1	Homo sapiens	61-69
20729911-0	2010	The centrosomal protein TACC3 controls paclitaxel sensitivity by modulating a premature senescence program.	Paclitaxel	39-49	transforming acidic coiled-coil containing protein 3	Homo sapiens	24-29
20729911-5	2010	Remarkably, the onset of senescence following TACC3 knockdown was strongly accelerated in the presence of non-toxic PTX concentrations.	Paclitaxel	116-119	transforming acidic coiled-coil containing protein 3	Homo sapiens	46-51
20858851-1	2010	PURPOSE: To characterize effects of combining radiofrequency (RF) ablation with proapoptotic intravenous liposome-encapsulated paclitaxel and doxorubicin on tumor destruction, apoptosis and heat-shock protein (HSP) production, intratumoral drug accumulation, and end-point survival.	Paclitaxel	127-137	selenoprotein K	Rattus norvegicus	210-213
20858851-11	2010	Paclitaxel substantially increased apoptosis and decreased HSP70 expression at coagulation margin.	Paclitaxel	0-10	selenoprotein K	Rattus norvegicus	59-64
20858851-13	2010	CONCLUSION: Selecting adjuvant liposomal chemotherapies (paclitaxel, doxorubicin) to target cellular apoptosis and HSP production effectively increases RF ablation-induced tumor coagulation and end-point survival, and combined multidrug approach results in even better outcomes.	Paclitaxel	57-67	selenoprotein K	Rattus norvegicus	115-118
20940192-5	2010	Minor allele carriers for SNP Lys940Arg in the poly (ADP-ribose) polymerase 1 (PARP1) gene showed a better response rate to the paclitaxel regimen (45.8%) than to the gemcitabine regimen (10.5%; P for interaction = .019).	Paclitaxel	128-138	poly(ADP-ribose) polymerase 1	Homo sapiens	47-77
20940192-5	2010	Minor allele carriers for SNP Lys940Arg in the poly (ADP-ribose) polymerase 1 (PARP1) gene showed a better response rate to the paclitaxel regimen (45.8%) than to the gemcitabine regimen (10.5%; P for interaction = .019).	Paclitaxel	128-138	poly(ADP-ribose) polymerase 1	Homo sapiens	79-84
21139994-2	2010	In the present study, we have used gene expression analysis to determine the molecular action of digitoxin on breast cancer cells and assessed digitoxin"s ability to synergize with the chemotherapy agent paclitaxel with respect to inhibition of cell proliferation MATERIALS AND METHODS: We treated (Her2 overexpressing, ER low) MDA-MB-453 human breast cancer cells with digitoxin at four doses {20 ng/ml (26 nM) to 1 mug/ml} and collected RNA at 6 h and 24 h for gene expression analysis.	Paclitaxel	204-214	erb-b2 receptor tyrosine kinase 2	Homo sapiens	299-303
21139994-7	2010	Western blot analysis confirmed induction of EGR1 protein at 1 h and ATF3 at 24 h. Paclitaxel, as well as digitoxin, inhibited the in vitro activity of the purified Na(+)-K(+)-ATPase; digitoxin enhanced the growth inhibitory effects of paclitaxel on Her2 overexpressing breast cancer cells.	Paclitaxel	83-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	250-254
20858016-9	2010	Our results suggest that hnRNP A2 and GDI 2 may represent potential biomarkers of the paclitaxel-resistant ovarian cancers for tailored cancer therapy.	Paclitaxel	86-96	heterogeneous nuclear ribonucleoprotein A2/B1	Homo sapiens	25-33
20549538-6	2010	In vitro experiments verified that CD44(+)CD24- cells were markedly resistant to carboplatin and paclitaxol.	Paclitaxel	97-107	CD24 molecule	Homo sapiens	42-46
20977456-8	2010	KEY RESULTS: N-desmethylimatinib formation was correlated with microsomal oxidation of the CYP3A4 substrates testosterone (rho= 0.60; P &lt; 0.01) and midazolam (rho= 0.46; P &lt; 0.05), and the CYP2C8 substrate paclitaxel (rho= 0.58; P &lt; 0.01).	Paclitaxel	212-222	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-97
20726858-9	2010	However, gemcitabine, paclitaxel, or cisplatin treatment enhanced the Akt activation, heterodimer formation of EGFR with HER3, and secretion of amphiregulin, indicating that the presence of gemcitabine promoted the activity of targeted molecules including amphiregulin, Akt, and HER3 for pancreatic cancer therapy.	Paclitaxel	22-32	AKT serine/threonine kinase 1	Homo sapiens	70-73
20726858-9	2010	However, gemcitabine, paclitaxel, or cisplatin treatment enhanced the Akt activation, heterodimer formation of EGFR with HER3, and secretion of amphiregulin, indicating that the presence of gemcitabine promoted the activity of targeted molecules including amphiregulin, Akt, and HER3 for pancreatic cancer therapy.	Paclitaxel	22-32	epidermal growth factor receptor	Homo sapiens	111-115
20726858-9	2010	However, gemcitabine, paclitaxel, or cisplatin treatment enhanced the Akt activation, heterodimer formation of EGFR with HER3, and secretion of amphiregulin, indicating that the presence of gemcitabine promoted the activity of targeted molecules including amphiregulin, Akt, and HER3 for pancreatic cancer therapy.	Paclitaxel	22-32	AKT serine/threonine kinase 1	Homo sapiens	270-273
20726858-10	2010	Combined treatment with an inhibitor for amphiregulin and gemcitabine, paclitaxel, or cisplatin induced synergistic antitumor effects, accompanied by the suppression of Akt and ERK activation.	Paclitaxel	71-81	AKT serine/threonine kinase 1	Homo sapiens	169-172
20726858-10	2010	Combined treatment with an inhibitor for amphiregulin and gemcitabine, paclitaxel, or cisplatin induced synergistic antitumor effects, accompanied by the suppression of Akt and ERK activation.	Paclitaxel	71-81	mitogen-activated protein kinase 1	Homo sapiens	177-180
20802016-8	2010	CONCLUSIONS: HVGGSSV-nab-paclitaxel was found to bind specifically to the tax-interacting protein-1 (TIP-1) receptor expressed in irradiated tumors, enhance bioavailability of paclitaxel, and significantly increase tumor growth delay as compared with controls in mouse models of lung cancer.	Paclitaxel	25-35	Tax1 (human T cell leukemia virus type I) binding protein 3	Mus musculus	74-99
20674962-8	2010	RESULTS: Nanomolar concentrations of EpoB, Taxol, discodermolide or vinblastine caused a marked increase in surface EpCAM expression in Hey cells.	Paclitaxel	43-48	epithelial cell adhesion molecule	Homo sapiens	116-121
20693278-4	2010	When treated with paclitaxel or vinorelbine, breast cancer cells with constitutive activation of STAT3 display a loss of STAT3 phosphorylation, and paclitaxel disrupts the interaction of STAT3 with tubulin.	Paclitaxel	18-28	signal transducer and activator of transcription 3	Homo sapiens	97-102
20693278-4	2010	When treated with paclitaxel or vinorelbine, breast cancer cells with constitutive activation of STAT3 display a loss of STAT3 phosphorylation, and paclitaxel disrupts the interaction of STAT3 with tubulin.	Paclitaxel	18-28	signal transducer and activator of transcription 3	Homo sapiens	121-126
20693278-4	2010	When treated with paclitaxel or vinorelbine, breast cancer cells with constitutive activation of STAT3 display a loss of STAT3 phosphorylation, and paclitaxel disrupts the interaction of STAT3 with tubulin.	Paclitaxel	18-28	signal transducer and activator of transcription 3	Homo sapiens	121-126
20693278-4	2010	When treated with paclitaxel or vinorelbine, breast cancer cells with constitutive activation of STAT3 display a loss of STAT3 phosphorylation, and paclitaxel disrupts the interaction of STAT3 with tubulin.	Paclitaxel	148-158	signal transducer and activator of transcription 3	Homo sapiens	97-102
20693278-5	2010	Paclitaxel also inhibits cytokine-induced STAT3 activation.	Paclitaxel	0-10	signal transducer and activator of transcription 3	Homo sapiens	42-47
20876799-9	2010	Importantly, apatinib significantly enhanced the effect of paclitaxel against the ABCB1-resistant KBv200 cancer cell xenografts in nude mice.	Paclitaxel	59-69	ATP binding cassette subfamily B member 1	Homo sapiens	82-87
21224536-0	2010	[The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer].	Paclitaxel	24-34	estrogen receptor 1	Homo sapiens	62-79
21224536-1	2010	Multidrug resistance proteins such as P-glycoprotein (P-gp) are potential targets for improving the efficacy of paclitaxel (PTX), a mitotic inhibitor used in cancer chemotherapy.	Paclitaxel	112-122	ATP binding cassette subfamily B member 1	Homo sapiens	38-52
21224536-1	2010	Multidrug resistance proteins such as P-glycoprotein (P-gp) are potential targets for improving the efficacy of paclitaxel (PTX), a mitotic inhibitor used in cancer chemotherapy.	Paclitaxel	112-122	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
21224536-1	2010	Multidrug resistance proteins such as P-glycoprotein (P-gp) are potential targets for improving the efficacy of paclitaxel (PTX), a mitotic inhibitor used in cancer chemotherapy.	Paclitaxel	124-127	ATP binding cassette subfamily B member 1	Homo sapiens	38-52
21224536-1	2010	Multidrug resistance proteins such as P-glycoprotein (P-gp) are potential targets for improving the efficacy of paclitaxel (PTX), a mitotic inhibitor used in cancer chemotherapy.	Paclitaxel	124-127	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
20878066-0	2010	Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent.	Paclitaxel	53-63	tumor protein p53	Homo sapiens	89-93
20878066-5	2010	In this report, using a cell line with knock-down p53 expression through siRNA, we found that amifostine enhancement of paclitaxel"s anticancer effect is p53 status-dependent.	Paclitaxel	120-130	tumor protein p53	Homo sapiens	50-53
20878066-5	2010	In this report, using a cell line with knock-down p53 expression through siRNA, we found that amifostine enhancement of paclitaxel"s anticancer effect is p53 status-dependent.	Paclitaxel	120-130	tumor protein p53	Homo sapiens	154-157
20878066-8	2010	Sensitivity to the therapeutic effect of paclitaxel in combination with amifostine was dependent upon the status of p53.	Paclitaxel	41-51	tumor protein p53	Homo sapiens	116-119
20878066-9	2010	A tumor with a nonsense TP53 mutation showed increased therapeutic response to paclitaxel and amifostine as measured by tumor weight compared to a tumor with wild- type TP53.	Paclitaxel	79-89	tumor protein p53	Homo sapiens	24-28
20878066-10	2010	Our study provides a rationale for a clinical trial of combined paclitaxel and amifostine in endometrial cancer patients whose tumors harbor TP53 mutations.	Paclitaxel	64-74	tumor protein p53	Homo sapiens	141-145
21078266-0	2010	[Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells].	Paclitaxel	56-66	vascular endothelial growth factor A	Homo sapiens	102-136
21078266-1	2010	OBJECTIVE: To investigate the effects of oxymatrine injection (OI) combined with low-dose paclitaxel on expressions of mRNAs and proteins of vascular endothelial growth factor (VEGF) and CXC chemokine receptor 4 (CXCR4) in human gastric carcinoma SGC-7901 cells.	Paclitaxel	90-100	vascular endothelial growth factor A	Homo sapiens	141-175
21078266-1	2010	OBJECTIVE: To investigate the effects of oxymatrine injection (OI) combined with low-dose paclitaxel on expressions of mRNAs and proteins of vascular endothelial growth factor (VEGF) and CXC chemokine receptor 4 (CXCR4) in human gastric carcinoma SGC-7901 cells.	Paclitaxel	90-100	vascular endothelial growth factor A	Homo sapiens	177-181
21078266-5	2010	The expressions of VEGF and CXCR4 mRNAs and proteins in the OI plus low-dose paclitaxel group were markedly lower than those in the low-dose paclitaxel group (P&lt;0.01).	Paclitaxel	77-87	vascular endothelial growth factor A	Homo sapiens	19-23
21078266-5	2010	The expressions of VEGF and CXCR4 mRNAs and proteins in the OI plus low-dose paclitaxel group were markedly lower than those in the low-dose paclitaxel group (P&lt;0.01).	Paclitaxel	141-151	vascular endothelial growth factor A	Homo sapiens	19-23
21078266-6	2010	CONCLUSION: OI combined with low-dose paclitaxel can inhibit VEGF and CXCR4 of gastric carcinoma SGC-7901 cells markedly, which may be one of its mechanisms of anti-angiogenic ability.	Paclitaxel	38-48	vascular endothelial growth factor A	Homo sapiens	61-65
20802016-8	2010	CONCLUSIONS: HVGGSSV-nab-paclitaxel was found to bind specifically to the tax-interacting protein-1 (TIP-1) receptor expressed in irradiated tumors, enhance bioavailability of paclitaxel, and significantly increase tumor growth delay as compared with controls in mouse models of lung cancer.	Paclitaxel	25-35	Tax1 (human T cell leukemia virus type I) binding protein 3	Mus musculus	101-106
20802016-8	2010	CONCLUSIONS: HVGGSSV-nab-paclitaxel was found to bind specifically to the tax-interacting protein-1 (TIP-1) receptor expressed in irradiated tumors, enhance bioavailability of paclitaxel, and significantly increase tumor growth delay as compared with controls in mouse models of lung cancer.	Paclitaxel	176-186	Tax1 (human T cell leukemia virus type I) binding protein 3	Mus musculus	74-99
20802016-8	2010	CONCLUSIONS: HVGGSSV-nab-paclitaxel was found to bind specifically to the tax-interacting protein-1 (TIP-1) receptor expressed in irradiated tumors, enhance bioavailability of paclitaxel, and significantly increase tumor growth delay as compared with controls in mouse models of lung cancer.	Paclitaxel	176-186	Tax1 (human T cell leukemia virus type I) binding protein 3	Mus musculus	101-106
20802016-9	2010	Here we show that targeting nab-paclitaxel to radiation-inducible TIP-1 results in increased tumor-specific drug delivery and enhanced biological efficacy in the treatment of cancer.	Paclitaxel	32-42	Tax1 (human T cell leukemia virus type I) binding protein 3	Mus musculus	66-71
20807808-10	2010	In vitro, exposure of prostate cancer cells to paclitaxel (1 mumol/L) or nocodazole (5 mug/mL) inhibited androgen-dependent AR nuclear translocation by targeting AR association with tubulin.	Paclitaxel	47-57	androgen receptor	Homo sapiens	124-126
20807808-10	2010	In vitro, exposure of prostate cancer cells to paclitaxel (1 mumol/L) or nocodazole (5 mug/mL) inhibited androgen-dependent AR nuclear translocation by targeting AR association with tubulin.	Paclitaxel	47-57	androgen receptor	Homo sapiens	162-164
21063845-5	2010	However, paclitaxel sensitivity assay showed that sensitivity to paclitaxel was reversed after the transfection in both cell lines in terms of number of cells arrested at G(2)/M phase and the expression of Bcl-2 was significantly changed.	Paclitaxel	9-19	BCL2 apoptosis regulator	Homo sapiens	206-211
20610805-4	2010	Subsequently, a functional study was conducted for comparison of paclitaxel-induced cytotoxicity and apoptosis between the BCL2 variant and the wild type in vitro.	Paclitaxel	65-75	BCL2 apoptosis regulator	Homo sapiens	123-127
20610805-8	2010	In addition, HeLa cells expressing the BCL2 Ala43Thr (G127A), similar to the control cells, were more sensitive to paclitaxel-induced cytotoxicity and apoptosis than those expressing wild-type BCL2.	Paclitaxel	115-125	BCL2 apoptosis regulator	Homo sapiens	39-43
20610805-9	2010	Consistently, the cleaved PARP and p-BCL2 proteins were subsequently increased after paclitaxel treatment, as also predicted by the bioinformatics analysis.	Paclitaxel	85-95	BCL2 apoptosis regulator	Homo sapiens	37-41
20876808-4	2010	From a pan-genomic small interfering RNA screen for modifiers of chemoresponsiveness, we identified the tumor antigen acrosin binding protein (ACRBP)/OY-TES-1 as a specifier of paclitaxel resistance.	Paclitaxel	177-187	acrosin binding protein	Homo sapiens	118-141
20876808-4	2010	From a pan-genomic small interfering RNA screen for modifiers of chemoresponsiveness, we identified the tumor antigen acrosin binding protein (ACRBP)/OY-TES-1 as a specifier of paclitaxel resistance.	Paclitaxel	177-187	acrosin binding protein	Homo sapiens	143-148
20876808-4	2010	From a pan-genomic small interfering RNA screen for modifiers of chemoresponsiveness, we identified the tumor antigen acrosin binding protein (ACRBP)/OY-TES-1 as a specifier of paclitaxel resistance.	Paclitaxel	177-187	acrosin binding protein	Homo sapiens	150-158
20876808-6	2010	We found that ACRBP is both necessary and sufficient for paclitaxel resistance in ovarian cancer cell lines and ovarian tumor explants.	Paclitaxel	57-67	acrosin binding protein	Homo sapiens	14-19
20876808-8	2010	We identified the mitotic spindle protein NuMA as an ACRBP-interacting protein that could account for the effects of ACRBP on paclitaxel sensitivity.	Paclitaxel	126-136	nuclear mitotic apparatus protein 1	Homo sapiens	42-46
20876808-8	2010	We identified the mitotic spindle protein NuMA as an ACRBP-interacting protein that could account for the effects of ACRBP on paclitaxel sensitivity.	Paclitaxel	126-136	acrosin binding protein	Homo sapiens	53-58
20876808-8	2010	We identified the mitotic spindle protein NuMA as an ACRBP-interacting protein that could account for the effects of ACRBP on paclitaxel sensitivity.	Paclitaxel	126-136	acrosin binding protein	Homo sapiens	117-122
20673976-5	2010	Compared to low-expressing cell lines, high HER-2/neu expressors were significantly more sensitive to patupilone than to paclitaxel (P&lt;0.0002).	Paclitaxel	121-131	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-53
20624637-7	2010	RESULTS: The expression levels of miR-27a and P-gp were up-regulated in paclitaxel-resistant ovarian cancer cell line A2780/Taxol as compared with its parental line A2780.	Paclitaxel	72-82	microRNA 27a	Homo sapiens	34-41
20624637-7	2010	RESULTS: The expression levels of miR-27a and P-gp were up-regulated in paclitaxel-resistant ovarian cancer cell line A2780/Taxol as compared with its parental line A2780.	Paclitaxel	72-82	ATP binding cassette subfamily B member 1	Homo sapiens	46-50
20624637-8	2010	Transfection of A2780/Taxol cells with the inhibitors of miR-27a decreased the expression of MDR1 mRNA and P-gp protein, increased HIPK2 protein expression, enhanced the sensitivity of A2780/taxol cells to paclitaxel, increased paclitaxel-induced apoptosis and the fluorescence intensity of intracellular Rh-123.	Paclitaxel	206-216	microRNA 27a	Homo sapiens	57-64
20624637-8	2010	Transfection of A2780/Taxol cells with the inhibitors of miR-27a decreased the expression of MDR1 mRNA and P-gp protein, increased HIPK2 protein expression, enhanced the sensitivity of A2780/taxol cells to paclitaxel, increased paclitaxel-induced apoptosis and the fluorescence intensity of intracellular Rh-123.	Paclitaxel	228-238	microRNA 27a	Homo sapiens	57-64
20624637-9	2010	Expression of MDR1 mRNA was increased while the sensitivity to paclitaxel was decreased in A2780 cells management with the mimics of miR-27a.	Paclitaxel	63-73	microRNA 27a	Homo sapiens	133-140
21063845-5	2010	However, paclitaxel sensitivity assay showed that sensitivity to paclitaxel was reversed after the transfection in both cell lines in terms of number of cells arrested at G(2)/M phase and the expression of Bcl-2 was significantly changed.	Paclitaxel	65-75	BCL2 apoptosis regulator	Homo sapiens	206-211
21063847-7	2010	Insulin plus paclitaxel (combination group) could significantly inhibit cell proliferation (69.38%+-2.32% vs 40.31%+-4.52% with Ishikawa; 64.11%+-6.33% vs 45.89%+-3.27% with Hec-1A) and increase cell apoptosis compared with treatment with paclitaxel alone (paclitaxel group).	Paclitaxel	239-249	insulin	Homo sapiens	0-7
21063847-7	2010	Insulin plus paclitaxel (combination group) could significantly inhibit cell proliferation (69.38%+-2.32% vs 40.31%+-4.52% with Ishikawa; 64.11%+-6.33% vs 45.89%+-3.27% with Hec-1A) and increase cell apoptosis compared with treatment with paclitaxel alone (paclitaxel group).	Paclitaxel	239-249	insulin	Homo sapiens	0-7
20687223-12	2010	Thus, in PC3PR cells, reduced expression of miR-34a confers paclitaxel resistance via up-regulating SIRT1 and Bcl2 expression.	Paclitaxel	60-70	BCL2 apoptosis regulator	Homo sapiens	110-114
20811685-10	2010	PTX combined with radiation maintained high expressions of Chk1 and MAD2 proteins for 24 h post-radiation and, in particular, MAD2 protein was strongly induced by PTX with high-dose radiation.	Paclitaxel	0-3	checkpoint kinase 1	Homo sapiens	59-63
20811685-10	2010	PTX combined with radiation maintained high expressions of Chk1 and MAD2 proteins for 24 h post-radiation and, in particular, MAD2 protein was strongly induced by PTX with high-dose radiation.	Paclitaxel	163-166	checkpoint kinase 1	Homo sapiens	59-63
20687223-13	2010	CONCLUSIONS: MiR-34a and its downstream targets SIRT1 and Bcl2 play important roles in the development of paclitaxel resistance, all of which can be useful biomarkers and promising therapeutic targets for the drug resistance in hormone-refractory prostate cancer.	Paclitaxel	106-116	BCL2 apoptosis regulator	Homo sapiens	58-62
20707381-6	2010	PTX-loaded composite nanocarriers are synthesized by conjugating anti-prostate specific membrane antigen (anti-PSMA) for targeting.	Paclitaxel	0-3	folate hydrolase 1	Homo sapiens	111-115
21089680-1	2010	This investigation was made with special reference to the effect of the combined use of nuclear factor-kappaB (NF-kappaB) inhibitor Pyrrolidine dithiocarbamate(PDTC) and Paclitaxel on the expression of Matrix metalloproteinases (MMP-9) and its inhibitor TIMP-1, and on the proliferation and invasion of human breast cancer cell line MCF-7.	Paclitaxel	170-180	TIMP metallopeptidase inhibitor 1	Homo sapiens	254-260
20959065-0	2010	[Paclitaxel blocks immunologic escape through up-regulating TAP-1, TAP-2 and eliminatiing Treg cells in 3LL-bearing mice].	Paclitaxel	1-11	transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	Mus musculus	60-65
20959065-9	2010	RESULTS: The expression of TAP-1 (5.68%+/-0.65%), TAP-2 (89.54%+/-4.8%) was remarkably higher in paclitaxel-pretreating 3LL group than that in 3LL bearing mice group with TAP-1 (1.93%+/-0.25%), TAP-2 (67.78%+/-5.08%), P=0.006, P=0.036 respectively.	Paclitaxel	97-107	transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	Mus musculus	27-32
20959065-9	2010	RESULTS: The expression of TAP-1 (5.68%+/-0.65%), TAP-2 (89.54%+/-4.8%) was remarkably higher in paclitaxel-pretreating 3LL group than that in 3LL bearing mice group with TAP-1 (1.93%+/-0.25%), TAP-2 (67.78%+/-5.08%), P=0.006, P=0.036 respectively.	Paclitaxel	97-107	transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	Mus musculus	171-176
20959065-12	2010	CONCLUSIONS: Paclitaxel may block immunologic escape in the treatment of 3LL bearing mice partly through up-regulation TAP-1, TAP-2 and eliminating Treg cells.	Paclitaxel	13-23	transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	Mus musculus	119-124
20862795-0	2004	6,7-Dimethoxy-2-{3-[4-[(11)C]methoxy-3,4-dihydro-2H-naphthalen-(1E)-ylidene]-propyl}-1,2,3,4-tetrahydro-isoquinoline One of the mechanisms of tumor cells to escape the cytotoxic effects of chemotherapeutic agents, such as adriamycin, vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel, is to limit their presence inside the cells by way of a multidrug resistance (MDR-1) protein (1, 2).	Paclitaxel	291-301	ATP binding cassette subfamily B member 1	Homo sapiens	381-401
20553861-5	2010	Based on detailed kinetic analysis, using liposomes to model paclitaxel diffusion through cell membranes, efflux slowdown can be attributed to reduction in the rate constant of drug diffusion through Pgp, and not to Pgp blockage.	Paclitaxel	61-71	ATP binding cassette subfamily B member 1	Homo sapiens	200-203
20553861-6	2010	Chemosensitization was consistently-better for paclitaxel (cytosol-operating) than for doxorubicin (nuclear-operating) implying linkage between P-glycoprotein localization and loci of drug action.	Paclitaxel	47-57	ATP binding cassette subfamily B member 1	Homo sapiens	144-158
20624405-1	2010	AIMS: the aims of the study are to investigate the additive effect of exogenous short-carbon chain phospholipids, C(2)-ceramide, on an anti-cancer drug paclitaxel (PTX)-induced senescence of human non-small cell lung cancer (NSCLC) cells deficient in functional p53 and p16, and to examine whether mitogen-activated protein kinase (MAPK) plays a role in ceramide-sensitized senescence of NSCLC cells.	Paclitaxel	152-162	tumor protein p53	Homo sapiens	262-265
20624405-1	2010	AIMS: the aims of the study are to investigate the additive effect of exogenous short-carbon chain phospholipids, C(2)-ceramide, on an anti-cancer drug paclitaxel (PTX)-induced senescence of human non-small cell lung cancer (NSCLC) cells deficient in functional p53 and p16, and to examine whether mitogen-activated protein kinase (MAPK) plays a role in ceramide-sensitized senescence of NSCLC cells.	Paclitaxel	152-162	cyclin dependent kinase inhibitor 2A	Homo sapiens	270-273
20624405-1	2010	AIMS: the aims of the study are to investigate the additive effect of exogenous short-carbon chain phospholipids, C(2)-ceramide, on an anti-cancer drug paclitaxel (PTX)-induced senescence of human non-small cell lung cancer (NSCLC) cells deficient in functional p53 and p16, and to examine whether mitogen-activated protein kinase (MAPK) plays a role in ceramide-sensitized senescence of NSCLC cells.	Paclitaxel	164-167	tumor protein p53	Homo sapiens	262-265
20624405-1	2010	AIMS: the aims of the study are to investigate the additive effect of exogenous short-carbon chain phospholipids, C(2)-ceramide, on an anti-cancer drug paclitaxel (PTX)-induced senescence of human non-small cell lung cancer (NSCLC) cells deficient in functional p53 and p16, and to examine whether mitogen-activated protein kinase (MAPK) plays a role in ceramide-sensitized senescence of NSCLC cells.	Paclitaxel	164-167	cyclin dependent kinase inhibitor 2A	Homo sapiens	270-273
20624405-5	2010	The additive effects of C(2)-ceramide and PTX resulted in proliferative inhibition, G(2)-phase arrest of cell cycle, activation of p38 and eventually premature senescence.	Paclitaxel	42-45	mitogen-activated protein kinase 14	Homo sapiens	131-134
20624405-7	2010	SIGNIFICANCE: our study demonstrates that the short-carbon chain C(2)-ceramide can effectively sensitize PTX-induced senescence of H1299 cells via both p21(waf1/cip1)- and p16(ink4)-independent pathways.	Paclitaxel	105-108	cyclin dependent kinase inhibitor 1A	Homo sapiens	152-165
20624405-7	2010	SIGNIFICANCE: our study demonstrates that the short-carbon chain C(2)-ceramide can effectively sensitize PTX-induced senescence of H1299 cells via both p21(waf1/cip1)- and p16(ink4)-independent pathways.	Paclitaxel	105-108	cyclin dependent kinase inhibitor 2A	Homo sapiens	172-175
20624405-7	2010	SIGNIFICANCE: our study demonstrates that the short-carbon chain C(2)-ceramide can effectively sensitize PTX-induced senescence of H1299 cells via both p21(waf1/cip1)- and p16(ink4)-independent pathways.	Paclitaxel	105-108	cyclin dependent kinase inhibitor 2A	Homo sapiens	176-180
20664599-0	2010	Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer.	Paclitaxel	49-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-19
20664599-8	2010	As the PI3K-AKT pathway is known to have crucial roles in anticancer drug sensitivity, we examined the involvement of HER-2 in sensitivity to paclitaxel.	Paclitaxel	142-152	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-123
20664599-9	2010	Short interfering RNA-based knockdown of HER-2 conferred increased sensitivity to paclitaxel in endometrial cancer cells, attenuating the induction of p-AKT on paclitaxel stimulation, which was cancelled by inactivating AKT by the introduction of a dominant-negative form.	Paclitaxel	82-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-46
20664599-9	2010	Short interfering RNA-based knockdown of HER-2 conferred increased sensitivity to paclitaxel in endometrial cancer cells, attenuating the induction of p-AKT on paclitaxel stimulation, which was cancelled by inactivating AKT by the introduction of a dominant-negative form.	Paclitaxel	82-92	AKT serine/threonine kinase 1	Homo sapiens	153-156
20664599-9	2010	Short interfering RNA-based knockdown of HER-2 conferred increased sensitivity to paclitaxel in endometrial cancer cells, attenuating the induction of p-AKT on paclitaxel stimulation, which was cancelled by inactivating AKT by the introduction of a dominant-negative form.	Paclitaxel	82-92	AKT serine/threonine kinase 1	Homo sapiens	220-223
20664599-9	2010	Short interfering RNA-based knockdown of HER-2 conferred increased sensitivity to paclitaxel in endometrial cancer cells, attenuating the induction of p-AKT on paclitaxel stimulation, which was cancelled by inactivating AKT by the introduction of a dominant-negative form.	Paclitaxel	160-170	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-46
20664599-9	2010	Short interfering RNA-based knockdown of HER-2 conferred increased sensitivity to paclitaxel in endometrial cancer cells, attenuating the induction of p-AKT on paclitaxel stimulation, which was cancelled by inactivating AKT by the introduction of a dominant-negative form.	Paclitaxel	160-170	AKT serine/threonine kinase 1	Homo sapiens	153-156
20664599-9	2010	Short interfering RNA-based knockdown of HER-2 conferred increased sensitivity to paclitaxel in endometrial cancer cells, attenuating the induction of p-AKT on paclitaxel stimulation, which was cancelled by inactivating AKT by the introduction of a dominant-negative form.	Paclitaxel	160-170	AKT serine/threonine kinase 1	Homo sapiens	220-223
20664599-10	2010	CONCLUSION: HER-2 is a significant prognostic factor of endometrioid-type endometrial cancer, as well as a key molecule that affects paclitaxel sensitivity by HER-2 interaction with the PI3K-AKT pathway.	Paclitaxel	133-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-17
20664599-10	2010	CONCLUSION: HER-2 is a significant prognostic factor of endometrioid-type endometrial cancer, as well as a key molecule that affects paclitaxel sensitivity by HER-2 interaction with the PI3K-AKT pathway.	Paclitaxel	133-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-164
20664599-10	2010	CONCLUSION: HER-2 is a significant prognostic factor of endometrioid-type endometrial cancer, as well as a key molecule that affects paclitaxel sensitivity by HER-2 interaction with the PI3K-AKT pathway.	Paclitaxel	133-143	AKT serine/threonine kinase 1	Homo sapiens	191-194
20736943-1	2010	BACKGROUND: Bevacizumab is an anti-vascular endothelial growth factor approved in association with paclitaxel or docetaxel as first line in patients (pts) with metastatic breast cancer.	Paclitaxel	99-109	vascular endothelial growth factor A	Homo sapiens	35-69
20957218-0	2010	Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles.	Paclitaxel	82-92	albumin	Homo sapiens	107-120
20957218-3	2010	In this study, targeted delivery of paclitaxel-loaded nanoparticles was prepared by a desolvation procedure, crosslinked on the wall material of bovine serum albumin, and subsequently decorated by folic acid.	Paclitaxel	36-46	albumin	Homo sapiens	152-165
20862794-0	2004	6,7-Dimethoxy-2-[3-(5-[(11)C]methoxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-propyl]-1,2,3,4-tetrahydro-isoquinoline One of the mechanisms of tumor cells to escape the cytotoxic effects of chemotherapeutic agents, such as adriamycin, vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel, is to limit their presence inside the cells by way of a multidrug resistance (MDR-1) gene protein (1, 2).	Paclitaxel	287-297	ATP binding cassette subfamily B member 1	Homo sapiens	377-402
20826658-8	2010	The Abeta-induced effects on microtubule and mitochondria depletion, Tau missorting, and loss of spines are prevented by taxol, indicating that Abeta-induced microtubule destabilization and corresponding traffic defects are key factors in incipient degeneration.	Paclitaxel	121-126	amyloid beta precursor protein	Homo sapiens	4-9
20826658-8	2010	The Abeta-induced effects on microtubule and mitochondria depletion, Tau missorting, and loss of spines are prevented by taxol, indicating that Abeta-induced microtubule destabilization and corresponding traffic defects are key factors in incipient degeneration.	Paclitaxel	121-126	amyloid beta precursor protein	Homo sapiens	144-149
20944098-7	2010	Phosphorylation of p21Cip/Waf1, but not change in total levels, correlated with the chemosensitizing effect of Akt inhibition to paclitaxel.	Paclitaxel	129-139	cyclin dependent kinase inhibitor 1A	Homo sapiens	26-30
20944098-7	2010	Phosphorylation of p21Cip/Waf1, but not change in total levels, correlated with the chemosensitizing effect of Akt inhibition to paclitaxel.	Paclitaxel	129-139	AKT serine/threonine kinase 1	Homo sapiens	111-114
20236757-0	2010	Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.	Paclitaxel	60-70	interleukin 6	Homo sapiens	24-37
20236757-3	2010	Here we demonstrate that both exogenous (a relatively short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells, while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) promotes the sensitivity of these cells to anticancer drugs.	Paclitaxel	201-211	interleukin 6	Homo sapiens	99-103
20236757-3	2010	Here we demonstrate that both exogenous (a relatively short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells, while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) promotes the sensitivity of these cells to anticancer drugs.	Paclitaxel	201-211	interleukin 6	Homo sapiens	120-124
20236757-3	2010	Here we demonstrate that both exogenous (a relatively short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells, while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) promotes the sensitivity of these cells to anticancer drugs.	Paclitaxel	201-211	interleukin 6	Homo sapiens	120-124
20236757-3	2010	Here we demonstrate that both exogenous (a relatively short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells, while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) promotes the sensitivity of these cells to anticancer drugs.	Paclitaxel	201-211	interleukin 6	Homo sapiens	120-124
20236757-3	2010	Here we demonstrate that both exogenous (a relatively short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells, while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) promotes the sensitivity of these cells to anticancer drugs.	Paclitaxel	201-211	interleukin 6	Homo sapiens	120-124
20236757-3	2010	Here we demonstrate that both exogenous (a relatively short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells, while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) promotes the sensitivity of these cells to anticancer drugs.	Paclitaxel	201-211	interleukin 6	Homo sapiens	120-124
20236757-3	2010	Here we demonstrate that both exogenous (a relatively short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells, while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) promotes the sensitivity of these cells to anticancer drugs.	Paclitaxel	201-211	interleukin 6	Homo sapiens	120-124
20699370-10	2010	Overexpression of CDX2 in HT-29 cells revealed increased resistance to the known substrate of MDR1, vincristine and paclitaxel, which was reversed by an MDR1 inhibitor, verapamil.	Paclitaxel	116-126	ATP binding cassette subfamily B member 1	Homo sapiens	153-157
20944127-2	2010	Treatment response to paclitaxel has been shown to correlate with ABCB1 gene polymorphisms.	Paclitaxel	22-32	ATP binding cassette subfamily B member 1	Homo sapiens	66-71
20944133-9	2010	CONCLUSION: We hypothesize that mTOR signalling may play a role in mediating paclitaxel resistance in ovarian cancer.	Paclitaxel	77-87	mechanistic target of rapamycin kinase	Homo sapiens	32-36
20944137-0	2010	Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro.	Paclitaxel	64-74	tumor protein p53	Homo sapiens	11-14
20944137-7	2010	A significant positive correlation between p53 protein concentration and cytotoxic response was demonstrated (R(2) for CDDP=0.823; R(2) for PAX=0.909; p&lt;0.001).	Paclitaxel	140-143	tumor protein p53	Homo sapiens	43-46
20944137-8	2010	CONCLUSION: Increasing intracellular p53 protein concentrations can augment the effect of CDDP and PAX in NSCLC, despite the baseline level of p53 protein expression.	Paclitaxel	99-102	tumor protein p53	Homo sapiens	37-40
20519133-5	2010	Results of the recent phase III IPASS trial showed that the EGFR-TKI gefitinib has a superior progression-free survival (PFS) to the most commonly used platinum-based doublet carboplatin-paclitaxel as the first-line chemotherapy for pulmonary lung adenocarcinoma among nonsmokers in East Asia.	Paclitaxel	187-197	epidermal growth factor receptor	Homo sapiens	60-64
20041327-7	2010	RESULTS: Our study showed that vincristine, tamoxifen, vinblastine, docetaxel, cyclophosphamide, flutamide, ifosfamide and paclitaxel activate PXR-mediated Pgp induction, and were additionally shown to affect the intracellular accumulation of the Pgp probe rhodamine 123.	Paclitaxel	123-133	nuclear receptor subfamily 1 group I member 2	Homo sapiens	143-146
20041327-7	2010	RESULTS: Our study showed that vincristine, tamoxifen, vinblastine, docetaxel, cyclophosphamide, flutamide, ifosfamide and paclitaxel activate PXR-mediated Pgp induction, and were additionally shown to affect the intracellular accumulation of the Pgp probe rhodamine 123.	Paclitaxel	123-133	ATP binding cassette subfamily B member 1	Homo sapiens	156-159
20041327-7	2010	RESULTS: Our study showed that vincristine, tamoxifen, vinblastine, docetaxel, cyclophosphamide, flutamide, ifosfamide and paclitaxel activate PXR-mediated Pgp induction, and were additionally shown to affect the intracellular accumulation of the Pgp probe rhodamine 123.	Paclitaxel	123-133	ATP binding cassette subfamily B member 1	Homo sapiens	247-250
21034557-0	2010	Inflammation inhibitory effects of sirolimus and paclitaxel-eluting stents on interleukin-1beta-induced coronary artery in-stent restenosis in pigs.	Paclitaxel	49-59	interleukin-1 beta	Sus scrofa	78-95
20837456-3	2010	The addition of bevacizumab, an antibody to vascular endothelial growth factor (VEGF), to paclitaxel and carboplatin improves survival compared with chemotherapy alone in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC).	Paclitaxel	90-100	vascular endothelial growth factor A	Homo sapiens	80-84
22993609-0	2010	Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells.	Paclitaxel	16-26	vascular endothelial growth factor A	Homo sapiens	54-88
20956191-6	2010	IPASS showed that EGFR mutation was the strongest predictor of improved progression-free survival (mutation-positive subgroup hazard ratio (HR) 0.48, 95% CI 0.36-0.64 (p&lt;0.001, n = 261); mutation-negative subgroup HR 2.85, 95% CI 2.05-3.98 (p&lt;0.001, n = 176); interaction test p&lt;0.001) with gefitinib versus carboplatin/paclitaxel as first-line therapy for advanced NSCLC.	Paclitaxel	329-339	epidermal growth factor receptor	Homo sapiens	18-22
22993609-3	2010	Paclitaxel inhibited the production of VEGF in A549 cells, while cisplatin and erlotinib did not.	Paclitaxel	0-10	vascular endothelial growth factor A	Homo sapiens	39-43
22993609-4	2010	Paclitaxel and gemcitabine inhibited deferoxamine (DFX) (known to mimic hypoxia)-induced VEGF production in A549 cells.	Paclitaxel	0-10	vascular endothelial growth factor A	Homo sapiens	89-93
22993609-6	2010	We subsequently examined the effect of the interaction between paclitaxel or gemcitabine and VEGF protein.	Paclitaxel	63-73	vascular endothelial growth factor A	Homo sapiens	93-97
22993609-8	2010	Since VEGF is known as one of the HIF-1 target genes, we examined the effect of paclitaxel and gemcitabine on HIF-1alpha levels induced by DFX in A549 cells.	Paclitaxel	80-90	hypoxia inducible factor 1 subunit alpha	Homo sapiens	110-120
22993609-9	2010	Paclitaxel and gemcitabine inhibited DFX-induced HIF-1alpha in A549 cells.	Paclitaxel	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	49-59
20637781-0	2010	Actin-sequestering protein, thymosin beta-4, induces paclitaxel resistance through ROS/HIF-1alpha stabilization in HeLa human cervical tumor cells.	Paclitaxel	53-63	thymosin beta 4 X-linked	Homo sapiens	28-43
20637781-0	2010	Actin-sequestering protein, thymosin beta-4, induces paclitaxel resistance through ROS/HIF-1alpha stabilization in HeLa human cervical tumor cells.	Paclitaxel	53-63	hypoxia inducible factor 1 subunit alpha	Homo sapiens	87-97
20637781-1	2010	AIMS: We investigated whether actin-sequestering protein, thymosin beta-4 (TB4)-induced reactive oxygen species (ROS) affect the stabilization of hypoxia-inducible transcription factor (HIF)-1alpha and paclitaxel-resistance induction.	Paclitaxel	202-212	thymosin beta 4 X-linked	Homo sapiens	58-73
20637781-1	2010	AIMS: We investigated whether actin-sequestering protein, thymosin beta-4 (TB4)-induced reactive oxygen species (ROS) affect the stabilization of hypoxia-inducible transcription factor (HIF)-1alpha and paclitaxel-resistance induction.	Paclitaxel	202-212	thymosin beta 4 X-linked	Homo sapiens	75-78
20637781-13	2010	Tumor cell death by paclitaxel was also increased by NAC treatment or the transfection with HIF-1alpha-siRNA.	Paclitaxel	20-30	hypoxia inducible factor 1 subunit alpha	Homo sapiens	92-102
20637781-15	2010	SIGNIFICANCE: These findings demonstrate that TB4-induced ROS and ROS-mediated HIF-1alpha stabilization could play a role in tumor cell resistance to anticancer agents like paclitaxel.	Paclitaxel	173-183	thymosin beta 4 X-linked	Homo sapiens	46-49
20637781-15	2010	SIGNIFICANCE: These findings demonstrate that TB4-induced ROS and ROS-mediated HIF-1alpha stabilization could play a role in tumor cell resistance to anticancer agents like paclitaxel.	Paclitaxel	173-183	hypoxia inducible factor 1 subunit alpha	Homo sapiens	79-89
19940992-4	2010	We observed very low levels of Nrf2 and of Nrf2-regulated detoxification proteins as a frequent phenotype in the more chemosensitive breast cancer, and when engineering increased Nrf2 levels, we found resistance to both doxorubicin and paclitaxel.	Paclitaxel	236-246	NFE2 like bZIP transcription factor 2	Homo sapiens	31-35
20708153-3	2010	Interference with the known SIK2 inhibitor PKA induced SIK2-dependent centrosome splitting in interphase while SIK2 depletion blocked centrosome separation in mitosis, sensitizing ovarian cancers to paclitaxel in culture and in xenografts.	Paclitaxel	199-209	salt inducible kinase 2	Homo sapiens	28-32
20481608-7	2010	Both Taxol and the construct appear to induce caspase 3-dependent apoptosis.	Paclitaxel	5-10	caspase 3	Homo sapiens	46-55
20420860-8	2010	Moreover, complementation experiments in Jurkat FADD-/- T cells indicated that: a) cells expressing FADD mutants in the CaM binding sites are protected from Taxol-induced G2/M cell cycle arrest; b) FADD/CaM interaction is not required for Fas receptor-mediated apoptosis although Fas and CaM might compete for binding to FADD.	Paclitaxel	157-162	calmodulin 1	Homo sapiens	120-123
19940992-4	2010	We observed very low levels of Nrf2 and of Nrf2-regulated detoxification proteins as a frequent phenotype in the more chemosensitive breast cancer, and when engineering increased Nrf2 levels, we found resistance to both doxorubicin and paclitaxel.	Paclitaxel	236-246	NFE2 like bZIP transcription factor 2	Homo sapiens	43-47
20309692-6	2010	However, MDR1 (2005T) cells were less resistant to paclitaxel (28.2 +/- 2.1 vs. 91.8 +/- 3.5 nM; P &lt; 0.05) and etoposide (119.7 +/- 6.5 vs. 546.8 +/- 9.5 nM; P &lt; 0.05).	Paclitaxel	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	9-13
19940992-4	2010	We observed very low levels of Nrf2 and of Nrf2-regulated detoxification proteins as a frequent phenotype in the more chemosensitive breast cancer, and when engineering increased Nrf2 levels, we found resistance to both doxorubicin and paclitaxel.	Paclitaxel	236-246	NFE2 like bZIP transcription factor 2	Homo sapiens	43-47
20647325-5	2010	Time-lapse microscopy revealed that cells entered mitosis with normal kinetics, but died after entry into mitosis in the presence of paclitaxel more rapidly when TP53RK was depleted.	Paclitaxel	133-143	TP53 regulating kinase	Homo sapiens	162-168
20547325-0	2010	Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide, HRAP.	Paclitaxel	15-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-51
20705560-0	2010	Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.	Paclitaxel	52-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-137
20705560-1	2010	PURPOSE: This multicenter phase II trial evaluated the efficacy and safety of weekly nanoparticle albumin-bound paclitaxel with carboplatin and weekly trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer (MBC).	Paclitaxel	112-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	200-204
20705560-13	2010	CONCLUSION: Weekly albumin-bound paclitaxel with carboplatin and trastuzumab is highly active in HER2-overexpressing MBC.	Paclitaxel	33-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-101
20596672-0	2010	Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and -resistant epithelial ovarian cancer cells: the involvement of specific conformational states of beta-actin.	Paclitaxel	93-103	protein disulfide isomerase family A member 3	Homo sapiens	65-70
20596672-3	2010	Recent data obtained by our group demonstrate that the disulphide isomerase ERp57 is strongly modulated in paclitaxel resistance suggesting that it may represent a chemoresistance biomarker in ovarian cancer.	Paclitaxel	107-117	protein disulfide isomerase family A member 3	Homo sapiens	76-81
20596672-5	2010	In particular, we show that the occurrence of the interaction of nuclear ERp57 with beta-actin is associated with paclitaxel resistance and that specific actin conformations modulate this complex.	Paclitaxel	114-124	protein disulfide isomerase family A member 3	Homo sapiens	73-78
20596672-6	2010	We propose the involvement of the nuclear ERp57 complex in mechanisms associated with chromosome segregation in which specific conformational states of actin play a role in the pathway involved in paclitaxel resistance.	Paclitaxel	197-207	protein disulfide isomerase family A member 3	Homo sapiens	42-47
20547325-1	2010	HRAP, a pentapeptide designed to bind with the pertuzumab interacting site in an extracellular domain of the HER2 molecule, enhanced the cytotoxicity of paclitaxel in HER2-overexpressing human breast cancer cell lines, BT474 and SKBR-3, but not in MDA-231 cells, which express lower levels of HER2.	Paclitaxel	153-163	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
20547325-1	2010	HRAP, a pentapeptide designed to bind with the pertuzumab interacting site in an extracellular domain of the HER2 molecule, enhanced the cytotoxicity of paclitaxel in HER2-overexpressing human breast cancer cell lines, BT474 and SKBR-3, but not in MDA-231 cells, which express lower levels of HER2.	Paclitaxel	153-163	erb-b2 receptor tyrosine kinase 2	Homo sapiens	167-171
20547325-1	2010	HRAP, a pentapeptide designed to bind with the pertuzumab interacting site in an extracellular domain of the HER2 molecule, enhanced the cytotoxicity of paclitaxel in HER2-overexpressing human breast cancer cell lines, BT474 and SKBR-3, but not in MDA-231 cells, which express lower levels of HER2.	Paclitaxel	153-163	erb-b2 receptor tyrosine kinase 2	Homo sapiens	167-171
20547325-4	2010	These results suggest that HRAP enhances paclitaxel-induced apoptosis in a manner dependent on the PTEN/Akt signal transduction pathway.	Paclitaxel	41-51	AKT serine/threonine kinase 1	Homo sapiens	104-107
20614491-0	2010	Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-beta/Smad activity.	Paclitaxel	0-10	transforming growth factor beta 1	Homo sapiens	76-84
20689763-7	2010	Forced expression of CD24 in endometrial carcinoma cells stimulated cell proliferation and oncogenicity, enhanced cell invasion, and decreased sensitivity to doxorubicin and paclitaxel.	Paclitaxel	174-184	CD24 molecule	Homo sapiens	21-25
20689763-8	2010	Depletion of CD24 in endometrial carcinoma cells abrogated ARTN-stimulated resistance to doxorubicin and paclitaxel.	Paclitaxel	105-115	CD24 molecule	Homo sapiens	13-17
20689763-9	2010	ARTN-stimulated resistance to doxorubicin and paclitaxel in endometrial carcinoma cells is therefore mediated by the specific regulation of CD24.	Paclitaxel	46-56	CD24 molecule	Homo sapiens	140-144
20642825-11	2010	The drug resistance index to Adriamycin (ADM), vincristine (VCR), paclitaxel (Taxol) and bleomycin (BLM) increased to19.8050, 9.0663, 9.7245, 3.5650 respectively for 4T1/HA117 and 24.2236, 11.0480, 11.3741, 0.9630 respectively for 4T1/MDR1 as compared to the control cells.	Paclitaxel	66-76	regulator of G protein signaling 6	Homo sapiens	170-175
20642825-11	2010	The drug resistance index to Adriamycin (ADM), vincristine (VCR), paclitaxel (Taxol) and bleomycin (BLM) increased to19.8050, 9.0663, 9.7245, 3.5650 respectively for 4T1/HA117 and 24.2236, 11.0480, 11.3741, 0.9630 respectively for 4T1/MDR1 as compared to the control cells.	Paclitaxel	66-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	235-239
20642825-11	2010	The drug resistance index to Adriamycin (ADM), vincristine (VCR), paclitaxel (Taxol) and bleomycin (BLM) increased to19.8050, 9.0663, 9.7245, 3.5650 respectively for 4T1/HA117 and 24.2236, 11.0480, 11.3741, 0.9630 respectively for 4T1/MDR1 as compared to the control cells.	Paclitaxel	78-83	regulator of G protein signaling 6	Homo sapiens	170-175
20642825-11	2010	The drug resistance index to Adriamycin (ADM), vincristine (VCR), paclitaxel (Taxol) and bleomycin (BLM) increased to19.8050, 9.0663, 9.7245, 3.5650 respectively for 4T1/HA117 and 24.2236, 11.0480, 11.3741, 0.9630 respectively for 4T1/MDR1 as compared to the control cells.	Paclitaxel	78-83	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	235-239
20614491-6	2010	CONCLUSION: These data indicate that 200 nmol/L paclitaxel ameliorates hepatic fibrosis via modulating TGF-beta signaling, and that paclitaxel may have some therapeutic value in humans with hepatic fibrosis.	Paclitaxel	48-58	transforming growth factor beta 1	Homo sapiens	103-111
20596630-5	2010	Overexpression of Rabl3 resulted in the enhancement of cell proliferation, inhibition of apoptosis and paclitaxel resistance in human cancer cell lines.	Paclitaxel	103-113	RAB, member of RAS oncogene family like 3	Homo sapiens	18-23
20498638-6	2010	The Ecad-lo subset contained more low-turnover cells, correlating with resistance to the conventional chemotherapeutic paclitaxel in vitro.	Paclitaxel	119-129	cadherin 1	Homo sapiens	4-8
20498641-0	2010	Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.	Paclitaxel	37-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	62-67
20498641-2	2010	In this study, we determine the role of erbB3 in erbB2-mediated paclitaxel resistance in breast cancer cells.	Paclitaxel	64-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	49-54
20498641-3	2010	The overexpression of exogenous erbB3 via either stable or transient transfection in erbB2-overexpressing, but not epidermal growth factor receptor (EGFR)-expressing, breast cancer cells significantly decreases paclitaxel-induced growth inhibition and apoptosis.	Paclitaxel	211-221	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-90
20498641-4	2010	Consistently, knockdown of erbB3 expression with a specific short hairpin RNA (shRNA) in breast cancer cells with coexpression of both erbB2 and erbB3 enhances paclitaxel-induced apoptosis evidenced by increased DNA fragmentation, poly (ADP-ribose) polymerase (PARP) cleavage and activation of caspase-3 and -8.	Paclitaxel	160-170	erb-b2 receptor tyrosine kinase 2	Homo sapiens	135-140
20498641-4	2010	Consistently, knockdown of erbB3 expression with a specific short hairpin RNA (shRNA) in breast cancer cells with coexpression of both erbB2 and erbB3 enhances paclitaxel-induced apoptosis evidenced by increased DNA fragmentation, poly (ADP-ribose) polymerase (PARP) cleavage and activation of caspase-3 and -8.	Paclitaxel	160-170	poly(ADP-ribose) polymerase 1	Homo sapiens	231-259
20498641-4	2010	Consistently, knockdown of erbB3 expression with a specific short hairpin RNA (shRNA) in breast cancer cells with coexpression of both erbB2 and erbB3 enhances paclitaxel-induced apoptosis evidenced by increased DNA fragmentation, poly (ADP-ribose) polymerase (PARP) cleavage and activation of caspase-3 and -8.	Paclitaxel	160-170	poly(ADP-ribose) polymerase 1	Homo sapiens	261-265
20498641-4	2010	Consistently, knockdown of erbB3 expression with a specific short hairpin RNA (shRNA) in breast cancer cells with coexpression of both erbB2 and erbB3 enhances paclitaxel-induced apoptosis evidenced by increased DNA fragmentation, poly (ADP-ribose) polymerase (PARP) cleavage and activation of caspase-3 and -8.	Paclitaxel	160-170	caspase 3	Homo sapiens	294-310
20498641-7	2010	Mechanistic studies indicate that the specific phosphoinositide 3-kinase (PI-3K), Akt and mammalian target of rapamycin (mTOR) inhibitors, but not the mitogen-activated protein kinase kinase (MEK) inhibitor, not only abrogate erbB3-mediated upregulation of Survivin, but also reinforce the erbB2/erbB3-coexpressing breast cancer cells to paclitaxel-induced growth inhibition.	Paclitaxel	338-348	AKT serine/threonine kinase 1	Homo sapiens	82-85
20498641-8	2010	These data demonstrate that heterodimerization of erbB2/erbB3 is a prerequisite for erbB2 tyrosine kinase activation; and elevated expression of erbB3 is required for erbB2-mediated paclitaxel resistance in breast cancer cells via PI-3K/Akt/mTOR signaling pathway-dependent upregulation of Survivin.	Paclitaxel	182-192	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-55
20498641-8	2010	These data demonstrate that heterodimerization of erbB2/erbB3 is a prerequisite for erbB2 tyrosine kinase activation; and elevated expression of erbB3 is required for erbB2-mediated paclitaxel resistance in breast cancer cells via PI-3K/Akt/mTOR signaling pathway-dependent upregulation of Survivin.	Paclitaxel	182-192	AKT serine/threonine kinase 1	Homo sapiens	237-240
20498641-8	2010	These data demonstrate that heterodimerization of erbB2/erbB3 is a prerequisite for erbB2 tyrosine kinase activation; and elevated expression of erbB3 is required for erbB2-mediated paclitaxel resistance in breast cancer cells via PI-3K/Akt/mTOR signaling pathway-dependent upregulation of Survivin.	Paclitaxel	182-192	mechanistic target of rapamycin kinase	Homo sapiens	241-245
19908232-3	2010	Here, for the first time, we investigated the effects and mechanisms of NF-kappaB inhibition by ursolic acid on chemotherapy treatment (Taxol or cisplatin) of cancer.	Paclitaxel	136-141	nuclear factor kappa B subunit 1	Homo sapiens	72-81
20657644-4	2010	METHODOLOGY/PRINCIPAL FINDINGS: A fluorescence microscopy-based in vitro assay was developed to screen compound libraries for molecules that prevented the binding of a recombinant human Ndc80 kinetochore complex to taxol-stabilized microtubules.	Paclitaxel	215-220	NDC80 kinetochore complex component	Homo sapiens	186-191
20626868-0	2010	Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia.	Paclitaxel	41-51	hypoxia inducible factor 1 subunit alpha	Homo sapiens	23-28
20626868-0	2010	Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia.	Paclitaxel	41-51	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	33-37
20530274-13	2010	CONCLUSION: Lapatinib monotherapy for 14 days followed by lapatinib plus paclitaxel for 12 weeks provided clinical benefit in IBC patients with HER2-overexpressing tumors without unexpected toxicity.	Paclitaxel	73-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-148
20460378-0	2010	MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.	Paclitaxel	63-73	BCL2 apoptosis regulator	Homo sapiens	111-116
21029701-0	2010	[Efficacy and safety assessment of neoadjuvant paclitaxel and trastuzumab in Chinese women with Her-2 positive operable breast cancer].	Paclitaxel	47-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-101
20427545-2	2010	We describe three cases of pregnant women with Stage Ib1 to IIa cervical cancer who were treated with paclitaxel plus platinum neoadjuvant chemotherapy followed by radical surgery.	Paclitaxel	102-112	mitogen-activated protein kinase 8 interacting protein 1	Homo sapiens	53-56
20514461-0	2010	c-Met antisense oligodeoxynucleotides increase sensitivity of human glioma cells to paclitaxel.	Paclitaxel	84-94	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	0-5
20514461-1	2010	Cell culture, tissue chemistry and flow cytometry were used to determine whether antisense c-Met oligodeoxynucleotides enhanced the sensitivity of human glioma cells to paclitaxel.	Paclitaxel	169-179	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	91-96
20514461-2	2010	A combination of paclitaxel with antisense c-Met oligodeoxynucleotides inhibited cell growth, induced apoptosis and induced c-Met protein expression in U251 and SHG44 human glioma cells more significantly than either paclitaxel or the oligodeoxynucleotides on their own (P&lt;0.01).	Paclitaxel	217-227	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	43-48
20514461-3	2010	Thus, c-Met antisense oligodeoxynucleotides increase the sensitivity of human glioma cells to paclitaxel.	Paclitaxel	94-104	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	6-11
21029701-1	2010	OBJECTIVE: To assess the efficacy and safety of neoadjuvant 3-weekly paclitaxel plus trastuzumab (TH) in Chinese women with Her-2 overexpressing operable breast cancer.	Paclitaxel	69-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	124-129
20434553-0	2010	Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice.	Paclitaxel	0-10	negative elongation factor complex member C/D, Th1l	Mus musculus	47-50
20479407-0	2010	Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.	Paclitaxel	50-60	AKT serine/threonine kinase 1	Homo sapiens	0-3
20479407-1	2010	PURPOSE: We tested the hypothesis that Akt-Ser473 phosphorylation (pAkt) predicts benefit from the sequential addition of paclitaxel to adjuvant doxorubicin plus cyclophosphamide (AC) chemotherapy in patients with node-positive breast cancer participating in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28 trial.	Paclitaxel	122-132	AKT serine/threonine kinase 1	Homo sapiens	39-42
20434553-0	2010	Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice.	Paclitaxel	0-10	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	87-96
20434553-9	2010	Incubation of a murine macrophage-like cell line with paclitaxel significantly increased TNF-alpha and -10 released from the cells and expression of microRNAs such as miR-155, miR-147, miR-146a and miR-132.	Paclitaxel	54-64	tumor necrosis factor	Mus musculus	89-106
20434553-10	2010	Therefore, paclitaxel activated both Th1 and Th2 responses.	Paclitaxel	11-21	negative elongation factor complex member C/D, Th1l	Mus musculus	37-40
20434553-11	2010	Considering its unique adjuvant effect demonstrated in this study and a safe record clinically used as an antineoplastic agent, paclitaxel could be an ideal adjuvant candidate when mixed Th1/Th2 immune responses are needed.	Paclitaxel	128-138	negative elongation factor complex member C/D, Th1l	Mus musculus	187-190
20436269-3	2010	When cytokine-dependent FL5.12 cells were cultured in the presence of IL-3, which stimulated multiple proliferation and anti-apoptotic cascades, MEK, PI3K and mTOR inhibitors transiently suppressed but did not totally inhibit cell cycle progression or induce apoptosis while chemotherapeutic drugs such as doxorubicin and paclitaxel were more effective in inducing cell cycle arrest and apoptosis.	Paclitaxel	322-332	interleukin 3	Mus musculus	70-74
20628434-5	2010	We found that the combination of zibotentan with cisplatinum as well as zibotentan with paclitaxel was more effective at inhibiting ovarian cancer HEY cell proliferation induced by endogenous ET-1 than were the single agents alone.	Paclitaxel	88-98	endothelin 1	Homo sapiens	192-196
20584694-1	2010	OBJECTIVE: To assess the value of serum carcinoembryonec antigen (CEA) in monitoring the response to biochemotherapy by Herceptin plus taxol (TAX) in patients with Her-2-positive advanced breast cancer.	Paclitaxel	135-140	CEA cell adhesion molecule 3	Homo sapiens	40-64
20584694-1	2010	OBJECTIVE: To assess the value of serum carcinoembryonec antigen (CEA) in monitoring the response to biochemotherapy by Herceptin plus taxol (TAX) in patients with Her-2-positive advanced breast cancer.	Paclitaxel	135-140	CEA cell adhesion molecule 3	Homo sapiens	66-69
22069634-3	2010	P-glycoprotein mediates resistance to various classes of anticancer drugs including vinblastine, daunorubicin, and paclitaxel, by actively extruding the drugs from the cells.	Paclitaxel	115-125	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
20822025-3	2010	Verapamil hydrochloride was adopted as the active control to investigate the bilateral transport activity of paclitaxel regulated by fangchinoline in MDR1-MDCK II cells.	Paclitaxel	109-119	ATP binding cassette subfamily B member 1	Homo sapiens	150-154
20822025-4	2010	RP-HPLC was applied to determine the concentration of paclitaxel in the transporting medium, which was used to calculate apparent permeability coefficient of paclitaxel across MDR1-MDCK I1 monolayer cells.	Paclitaxel	54-64	ATP binding cassette subfamily B member 1	Homo sapiens	176-180
20822025-4	2010	RP-HPLC was applied to determine the concentration of paclitaxel in the transporting medium, which was used to calculate apparent permeability coefficient of paclitaxel across MDR1-MDCK I1 monolayer cells.	Paclitaxel	158-168	ATP binding cassette subfamily B member 1	Homo sapiens	176-180
20100468-8	2010	Inhibition of mitotic arrest in the presence of paclitaxel blocks the phosphorylation of BNIP3, Bcl-2 and Bcl-xL, demonstrating that these proteins are phosphorylated by a mitochondrially active mitotic kinase.	Paclitaxel	48-58	BCL2 interacting protein 3	Homo sapiens	89-94
20100468-8	2010	Inhibition of mitotic arrest in the presence of paclitaxel blocks the phosphorylation of BNIP3, Bcl-2 and Bcl-xL, demonstrating that these proteins are phosphorylated by a mitochondrially active mitotic kinase.	Paclitaxel	48-58	BCL2 apoptosis regulator	Homo sapiens	96-101
20100468-8	2010	Inhibition of mitotic arrest in the presence of paclitaxel blocks the phosphorylation of BNIP3, Bcl-2 and Bcl-xL, demonstrating that these proteins are phosphorylated by a mitochondrially active mitotic kinase.	Paclitaxel	48-58	BCL2 like 1	Homo sapiens	106-112
20100569-3	2010	To validate the screen we showed that siRNA interfering with the apoptosis regulators FLIP and Bcl-X(L) conferred sensitivity to paclitaxel and carboplatin respectively.	Paclitaxel	129-139	BCL2 like 1	Homo sapiens	95-103
20404007-2	2010	EXPERIMENTAL DESIGN: The effect of Taxol treatment on AKT activation in A2780 ovarian carcinoma cells was evaluated using antibodies specific for phospho-AKT.	Paclitaxel	35-40	AKT serine/threonine kinase 1	Homo sapiens	54-57
20404007-2	2010	EXPERIMENTAL DESIGN: The effect of Taxol treatment on AKT activation in A2780 ovarian carcinoma cells was evaluated using antibodies specific for phospho-AKT.	Paclitaxel	35-40	AKT serine/threonine kinase 1	Homo sapiens	154-157
20404007-8	2010	RESULTS: Taxol-induced AKT phosphorylation required IGF1R tyrosine kinase activity and was associated with upregulation of IGF2.	Paclitaxel	9-14	AKT serine/threonine kinase 1	Homo sapiens	23-26
20428807-15	2010	Targeting Notch-1 through its enhancer Gl-1, should be significant for novel treatments to eliminate taxol-resistant cancer stem cells (CSC).	Paclitaxel	101-106	notch receptor 1	Homo sapiens	10-17
20822025-0	2010	[Transmembrane transport activity of paclitaxel regulated by fangchinoline in MDR1-mDCK II cells].	Paclitaxel	37-47	ATP binding cassette subfamily B member 1	Homo sapiens	78-82
20822025-1	2010	OBJECTIVE: To research the regulation of transmembrane transport activity of paclitaxel influenced by fangchinoline in MDR1-MDCK II cells.	Paclitaxel	77-87	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
20218616-7	2010	Finally, we showed that osthole could enhance paclitaxel-induced cytotoxicity in HER2-overexpressing cancer cells.	Paclitaxel	46-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	81-85
20358982-1	2010	A fluorescence susceptible water-soluble paclitaxel was synthesized by a condensation reaction between PEGylated paclitaxel (namely, PP7) and 1-pyrene butyric acid (PBA) in order to obtain a better understanding of the mechanism of action of paclitaxel as well as of the environment of the paclitaxel-binding site.	Paclitaxel	41-51	protein phosphatase with EF-hand domain 1	Homo sapiens	133-136
20358982-1	2010	A fluorescence susceptible water-soluble paclitaxel was synthesized by a condensation reaction between PEGylated paclitaxel (namely, PP7) and 1-pyrene butyric acid (PBA) in order to obtain a better understanding of the mechanism of action of paclitaxel as well as of the environment of the paclitaxel-binding site.	Paclitaxel	113-123	protein phosphatase with EF-hand domain 1	Homo sapiens	133-136
20358982-1	2010	A fluorescence susceptible water-soluble paclitaxel was synthesized by a condensation reaction between PEGylated paclitaxel (namely, PP7) and 1-pyrene butyric acid (PBA) in order to obtain a better understanding of the mechanism of action of paclitaxel as well as of the environment of the paclitaxel-binding site.	Paclitaxel	113-123	protein phosphatase with EF-hand domain 1	Homo sapiens	133-136
20358982-1	2010	A fluorescence susceptible water-soluble paclitaxel was synthesized by a condensation reaction between PEGylated paclitaxel (namely, PP7) and 1-pyrene butyric acid (PBA) in order to obtain a better understanding of the mechanism of action of paclitaxel as well as of the environment of the paclitaxel-binding site.	Paclitaxel	113-123	protein phosphatase with EF-hand domain 1	Homo sapiens	133-136
20386470-7	2010	LPS stimulation of DCs induced IL-10, IL-12p70, TNFalpha and IL-1beta secretion, and taxol pretreatment modified this response by down-regulating IL-1beta secretion whereas colchicine induced a proinflammatory cytokine profile with reduced IL-10 and increased IL-12p70 and TNFalpha secretion.	Paclitaxel	85-90	interleukin 1 beta	Homo sapiens	146-154
20386470-7	2010	LPS stimulation of DCs induced IL-10, IL-12p70, TNFalpha and IL-1beta secretion, and taxol pretreatment modified this response by down-regulating IL-1beta secretion whereas colchicine induced a proinflammatory cytokine profile with reduced IL-10 and increased IL-12p70 and TNFalpha secretion.	Paclitaxel	85-90	tumor necrosis factor	Homo sapiens	273-281
20395330-10	2010	The antiapoptotic marker Bcl-2 exhibited a biphasic pattern, with a maximum drop at 3 h, followed by return toward baseline levels at 6 h. CONCLUSION: These results define the time course of various biologic events taking place in this model of murine breast cancer after a proapoptotic insult (single-dose paclitaxel).	Paclitaxel	307-317	BCL2 apoptosis regulator	Homo sapiens	25-30
20372864-0	2010	Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells.	Paclitaxel	61-66	CASP8 and FADD like apoptosis regulator	Homo sapiens	14-20
20372864-4	2010	Our study disclosed that c-FLIP was overexpressed in HepG2 hepatocellular carcinoma cells and down-regulation of c-FLIP enhanced taxol-induced apoptosis.	Paclitaxel	129-134	CASP8 and FADD like apoptosis regulator	Homo sapiens	25-31
20372864-4	2010	Our study disclosed that c-FLIP was overexpressed in HepG2 hepatocellular carcinoma cells and down-regulation of c-FLIP enhanced taxol-induced apoptosis.	Paclitaxel	129-134	CASP8 and FADD like apoptosis regulator	Homo sapiens	113-119
20372864-5	2010	Taxol induction significantly decreased the protein level of c-FLIP.	Paclitaxel	0-5	CASP8 and FADD like apoptosis regulator	Homo sapiens	61-67
20372864-6	2010	While no decrease in c-FLIP mRNA level was observed, indicating taxol decreased c-FLIP expression through a post-transcriptional mechanism.	Paclitaxel	64-69	CASP8 and FADD like apoptosis regulator	Homo sapiens	80-86
20372864-7	2010	miR-512-3p was a predicted suppressor of c-FLIP and exhibited an opposite expression manner to c-FLIP before and after taxol induction.	Paclitaxel	119-124	CASP8 and FADD like apoptosis regulator	Homo sapiens	95-101
20372864-11	2010	In summary, our study disclosed a novel regulatory mechanism that down-regulation of c-FLIP by miR-512-3p contributed to taxol-induced apoptosis.	Paclitaxel	121-126	CASP8 and FADD like apoptosis regulator	Homo sapiens	85-91
20095796-1	2010	BACKGROUND: In a phase 3 randomized, multicenter, double-blind, placebo-controlled study, first-line therapy with lapatinib plus paclitaxel significantly improved clinical outcomes based on a pre-planned analysis of ErbB2+ metastatic breast cancer patients (GSK Study #EGF30001; ClinicalTrials.gov identifier: NCT00075270).	Paclitaxel	129-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	216-221
20051827-10	2010	An approximate seven-fold increase in TXR1 mRNA expression and an 8.9-fold decrease in TSP1 mRNA expression were observed in taxol-resistant cells compared with their parental cells.	Paclitaxel	125-130	thrombospondin 1	Homo sapiens	87-91
20051827-11	2010	An 8.7-fold increase in TSP1 mRNA expression was observed in CNE-1/taxol cells exposed to 590 nmol/l of cisplatin for 24 h. An increase in TSP1 protein expression was obtained in a dose-dependent manner after CNE-1/taxol cells were exposed to cisplatin.	Paclitaxel	67-72	thrombospondin 1	Homo sapiens	24-28
20051827-11	2010	An 8.7-fold increase in TSP1 mRNA expression was observed in CNE-1/taxol cells exposed to 590 nmol/l of cisplatin for 24 h. An increase in TSP1 protein expression was obtained in a dose-dependent manner after CNE-1/taxol cells were exposed to cisplatin.	Paclitaxel	67-72	thrombospondin 1	Homo sapiens	139-143
20051827-11	2010	An 8.7-fold increase in TSP1 mRNA expression was observed in CNE-1/taxol cells exposed to 590 nmol/l of cisplatin for 24 h. An increase in TSP1 protein expression was obtained in a dose-dependent manner after CNE-1/taxol cells were exposed to cisplatin.	Paclitaxel	215-220	thrombospondin 1	Homo sapiens	24-28
20051827-11	2010	An 8.7-fold increase in TSP1 mRNA expression was observed in CNE-1/taxol cells exposed to 590 nmol/l of cisplatin for 24 h. An increase in TSP1 protein expression was obtained in a dose-dependent manner after CNE-1/taxol cells were exposed to cisplatin.	Paclitaxel	215-220	thrombospondin 1	Homo sapiens	139-143
20332234-11	2010	Here, we show that paclitaxel induces P-YB-1(S102) expression, nuclear localization of activated YB-1, and CD44 expression.	Paclitaxel	19-29	Y-box binding protein 1	Homo sapiens	40-44
20332234-11	2010	Here, we show that paclitaxel induces P-YB-1(S102) expression, nuclear localization of activated YB-1, and CD44 expression.	Paclitaxel	19-29	Y-box binding protein 1	Homo sapiens	97-101
20332234-12	2010	The overexpression of WT YB-1 promotes mammosphere growth in the presence of paclitaxel.	Paclitaxel	77-87	Y-box binding protein 1	Homo sapiens	25-29
20332234-13	2010	Importantly, targeting YB-1 sensitized the CD44(High)/CD24(Low) cells to paclitaxel.	Paclitaxel	73-83	Y-box binding protein 1	Homo sapiens	23-27
20332234-13	2010	Importantly, targeting YB-1 sensitized the CD44(High)/CD24(Low) cells to paclitaxel.	Paclitaxel	73-83	CD24 molecule	Homo sapiens	54-58
20237434-3	2010	Microtubule-interacting agents such as Taxol and epothilone B (EpoB), at concentrations that induce mitotic arrest, transiently increase expression of CENP-E in a variety of cancer cell lines.	Paclitaxel	39-44	centromere protein E	Homo sapiens	151-157
20414030-0	2010	[Successful management with S-1 of recurrent gastric cancer after adjuvant chemotherapy with paclitaxel/UFT].	Paclitaxel	93-103	proteasome 26S subunit, non-ATPase 1	Homo sapiens	28-31
20198351-4	2010	Suppression of HER-2 expression by siRNA or shRNA pDNA caused significant reduction of proliferation by inducing apoptosis and enhancing the sensitivity for PTX in HER-2 positive KB cells.	Paclitaxel	157-160	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-20
20198351-4	2010	Suppression of HER-2 expression by siRNA or shRNA pDNA caused significant reduction of proliferation by inducing apoptosis and enhancing the sensitivity for PTX in HER-2 positive KB cells.	Paclitaxel	157-160	erb-b2 receptor tyrosine kinase 2	Homo sapiens	164-169
20198351-6	2010	Combination therapy by intratumoral injection of HER-2 siRNA or HER-2 shRNA pDNA with PTX significantly inhibited the tumor growth of xenografts compared with each therapy used individually.	Paclitaxel	86-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-69
20198351-8	2010	Collectively, these findings suggest that HER-2 shRNA-based combined therapy with PTX could be a novel strategy to inhibit the progression of HER-2-positive cancer.	Paclitaxel	82-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-47
20198351-8	2010	Collectively, these findings suggest that HER-2 shRNA-based combined therapy with PTX could be a novel strategy to inhibit the progression of HER-2-positive cancer.	Paclitaxel	82-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-147
20302610-9	2010	However, paclitaxel exposure reduced the endocytic capacity of DC but reduced the expression of key pro-inflammatory cytokines such as IL-12 and TNFalpha.	Paclitaxel	9-19	tumor necrosis factor	Homo sapiens	145-153
20009926-4	2010	RECENT FINDINGS: Bevacizumab, a mAb against the vascular endothelial growth factor, has been approved by the U.S. Food and Drug Administration for the treatment of patients with advanced stage nonsquamous NSCLC in combination with the carboplatin-paclitaxel regimen.	Paclitaxel	247-257	vascular endothelial growth factor A	Homo sapiens	48-82
19963269-9	2010	The combinatorial delivery of VEGF siRNA and paclitaxel showed an efficient knockdown of VEGF expression.	Paclitaxel	45-55	vascular endothelial growth factor A	Homo sapiens	89-93
19951750-8	2010	We focused on four glycoproteins (tumor rejection antigen (gp96) 1, triose phosphate isomerase, palmitoyl-protein thioesterase 1 precursor and ER-associated DNAJ) which were remarkably upregulated in A2780TC1 compared to A2780 cell line and which may represent biomarkers for paclitaxel resistance in ovarian cancer.	Paclitaxel	276-286	triosephosphate isomerase 1	Homo sapiens	34-94
20004970-0	2010	Anti-HIF-1alpha antibody-conjugated pluronic triblock copolymers encapsulated with Paclitaxel for tumor targeting therapy.	Paclitaxel	83-93	hypoxia inducible factor 1 subunit alpha	Homo sapiens	5-15
20004970-2	2010	Herein we reported the development of anti-HIF-1alpha antibody-conjugated unimolecular polymer nano micelles filled with Paclitaxel for cancer targeting therapy.	Paclitaxel	121-131	hypoxia inducible factor 1 subunit alpha	Homo sapiens	43-53
20004970-7	2010	In conclusion, unique anti-HIF-1alpha antibody-conjugated nano micelles filled with Paclitaxel can target and selectively kill cancer cells with over-expression of HIF-1alpha, and has great potential in clinical tumor targeting imaging and therapy.	Paclitaxel	84-94	hypoxia inducible factor 1 subunit alpha	Homo sapiens	27-37
20004970-7	2010	In conclusion, unique anti-HIF-1alpha antibody-conjugated nano micelles filled with Paclitaxel can target and selectively kill cancer cells with over-expression of HIF-1alpha, and has great potential in clinical tumor targeting imaging and therapy.	Paclitaxel	84-94	hypoxia inducible factor 1 subunit alpha	Homo sapiens	164-174
19688827-7	2010	Treatment with rapamycin and paclitaxel resulted in decreased phosphorylation of S6 and 4E-BP1, two critical downstream targets of the mTOR pathway.	Paclitaxel	29-39	mechanistic target of rapamycin kinase	Homo sapiens	135-139
20075745-6	2010	Cotreatment of paclitaxel with TNF-alpha markedly augmented the release of TF.	Paclitaxel	15-25	tumor necrosis factor	Homo sapiens	31-40
19760195-0	2010	Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.	Paclitaxel	16-26	hypoxia inducible factor 1 subunit alpha	Homo sapiens	67-98
19760195-10	2010	Interestingly, knockdown of endogenous HIF-1alpha significantly alleviates the chemoresistance and promotes G1/S transition with the increased sensitivity of A2780 cells to paclitaxel under each hypoxic condition.	Paclitaxel	173-183	hypoxia inducible factor 1 subunit alpha	Homo sapiens	39-49
19760195-12	2010	Eliminating hypoxic conditions or silencing HIF-1alpha by siRNA might provide a potent tool to enhance paclitaxel effectiveness in treatment of human ovarian cancer.	Paclitaxel	103-113	hypoxia inducible factor 1 subunit alpha	Homo sapiens	44-54
20075745-14	2010	These findings indicate that paclitaxel enhances TNF-alpha-induced release of TF, and downregulated thrombomodulin, increased protein nitration, which may subsequently favor prothrombotic intimal surface.	Paclitaxel	29-39	tumor necrosis factor	Homo sapiens	49-58
20142807-8	2010	The paclitaxel treatment markedly suppressed Smad2 and Smad3 phosphorylation.	Paclitaxel	4-14	SMAD family member 3	Rattus norvegicus	55-60
20150272-0	2010	Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.	Paclitaxel	14-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-61
20150272-1	2010	UNLABELLED: Our goal in this study was to elucidate the mechanisms by which methotrexate radiosensitizes HER2-positive human breast cancer cells to the Auger electron emitter (111)In-trastuzumab modified with nuclear-localization sequence peptides ((111)In-NLS-trastuzumab) and to compare these mechanisms with the potential sensitizing effects of paclitaxel and doxorubicin when combined with this radiopharmaceutical.	Paclitaxel	348-358	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
20150272-11	2010	CONCLUSION: Low-dose methotrexate, paclitaxel, or doxorubicin potently sensitized HER2-overexpressing human breast cancer cells, with and without acquired trastuzumab-resistance, to the Auger electron emissions from (111)In-NLS-trastuzumab through cell cycle distribution changes and in part through the inhibitory effects of these agents on DNA damage repair.	Paclitaxel	35-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
20178647-1	2010	BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC).	Paclitaxel	122-132	BCL2 apoptosis regulator	Homo sapiens	54-59
20178585-0	2010	Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment.	Paclitaxel	39-44	tumor protein p53	Homo sapiens	14-17
20178647-1	2010	BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC).	Paclitaxel	122-132	interferon alpha 1	Homo sapiens	112-115
20018861-0	2010	Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment.	Paclitaxel	73-83	cyclin dependent kinase inhibitor 1A	Homo sapiens	23-26
20170547-0	2010	Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study.	Paclitaxel	154-164	albumin	Homo sapiens	44-51
20170547-2	2010	The aim of this study was to associate malnutrition and albumin serum levels with the occurrence of chemotherapy-induced toxicity in cisplatin plus paclitaxel chemotherapy-treated NSCLC.	Paclitaxel	148-158	albumin	Homo sapiens	56-63
20018861-0	2010	Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment.	Paclitaxel	73-83	cyclin dependent kinase inhibitor 1A	Homo sapiens	27-31
20018861-0	2010	Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment.	Paclitaxel	73-83	cyclin dependent kinase inhibitor 1A	Homo sapiens	32-36
20018861-6	2010	Finally, we demonstrate that hGTSE-1 mediated-p21(CIP1/WAF1) stabilization is clearly involved in the ability of cells to counteract cytotoxicity induced by the microtubule poison paclitaxel.	Paclitaxel	180-190	cyclin dependent kinase inhibitor 1A	Homo sapiens	46-49
20018861-6	2010	Finally, we demonstrate that hGTSE-1 mediated-p21(CIP1/WAF1) stabilization is clearly involved in the ability of cells to counteract cytotoxicity induced by the microtubule poison paclitaxel.	Paclitaxel	180-190	cyclin dependent kinase inhibitor 1A	Homo sapiens	50-54
20018861-6	2010	Finally, we demonstrate that hGTSE-1 mediated-p21(CIP1/WAF1) stabilization is clearly involved in the ability of cells to counteract cytotoxicity induced by the microtubule poison paclitaxel.	Paclitaxel	180-190	cyclin dependent kinase inhibitor 1A	Homo sapiens	55-59
20144215-0	2010	Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol.	Paclitaxel	84-89	lactate dehydrogenase A	Homo sapiens	46-69
20145176-2	2010	This hypothesis was examined using the data from a phase III trial that randomized patients with HER2-negative or HER2-untested metastatic breast cancer to first-line therapy with paclitaxel along with either lapatinib or placebo.	Paclitaxel	180-190	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-118
20144215-0	2010	Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol.	Paclitaxel	116-121	lactate dehydrogenase A	Homo sapiens	46-69
20144215-4	2010	In this study we investigated the role of LDH-A in mediating Taxol resistance in human breast cancer cells.	Paclitaxel	61-66	lactate dehydrogenase A	Homo sapiens	42-47
20144215-6	2010	The increased expression and activity of LDH-A were detected in Taxol-resistant cells when compared with their parental cells.	Paclitaxel	64-69	lactate dehydrogenase A	Homo sapiens	41-46
20144215-7	2010	The downregulation of LDH-A by siRNA significantly increased the sensitivity of Taxol-resistant cells to Taxol.	Paclitaxel	80-85	lactate dehydrogenase A	Homo sapiens	22-27
20144215-7	2010	The downregulation of LDH-A by siRNA significantly increased the sensitivity of Taxol-resistant cells to Taxol.	Paclitaxel	105-110	lactate dehydrogenase A	Homo sapiens	22-27
20144215-10	2010	CONCLUSION: LDH-A plays an important role in Taxol resistance and inhibition of LDH-A re-sensitizes Taxol-resistant cells to Taxol.	Paclitaxel	45-50	lactate dehydrogenase A	Homo sapiens	12-17
20144215-10	2010	CONCLUSION: LDH-A plays an important role in Taxol resistance and inhibition of LDH-A re-sensitizes Taxol-resistant cells to Taxol.	Paclitaxel	100-105	lactate dehydrogenase A	Homo sapiens	12-17
20144215-10	2010	CONCLUSION: LDH-A plays an important role in Taxol resistance and inhibition of LDH-A re-sensitizes Taxol-resistant cells to Taxol.	Paclitaxel	100-105	lactate dehydrogenase A	Homo sapiens	80-85
20144215-10	2010	CONCLUSION: LDH-A plays an important role in Taxol resistance and inhibition of LDH-A re-sensitizes Taxol-resistant cells to Taxol.	Paclitaxel	100-105	lactate dehydrogenase A	Homo sapiens	12-17
20144215-10	2010	CONCLUSION: LDH-A plays an important role in Taxol resistance and inhibition of LDH-A re-sensitizes Taxol-resistant cells to Taxol.	Paclitaxel	100-105	lactate dehydrogenase A	Homo sapiens	80-85
20144215-12	2010	To our knowledge, this is the first report showing that the increased expression of LDH-A plays an important role in Taxol resistance of human breast cancer cells.	Paclitaxel	117-122	lactate dehydrogenase A	Homo sapiens	84-89
20332474-7	2010	This report suggests that combination therapy with epirubicin and cyclophosphamide followed by trastuzumab and paclitaxel was useful for HER2-positive IBC.	Paclitaxel	111-121	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
20103636-2	2010	In this study, we identified the NIMA kinase Nek4 in a genetic screen for mediators of the response to Taxol, a chemotherapeutic agent that stabilizes microtubules.	Paclitaxel	103-108	NIMA related kinase 4	Homo sapiens	45-49
19910452-10	2010	MDA-7/IL-24 toxicity was enhanced in a weak additive fashion by paclitaxel; paclitaxel enhanced MDA-7/IL-24 + cisplatin lethality in a greater than additive fashion via BAX.	Paclitaxel	76-86	BCL2 associated X, apoptosis regulator	Homo sapiens	169-172
19918793-2	2010	In this report, we further explored the relationship between taxol-induced cell death and vacuolization, and the roles of protein synthesis, mitogen-activated protein kinase kinases (MEK), c-jun N-terminal kinase (JNK) and P38 in taxol-induced paraptosis.	Paclitaxel	61-66	mitogen-activated protein kinase 14	Homo sapiens	223-226
19918798-0	2010	Paclitaxel and beta-lapachone synergistically induce apoptosis in human retinoblastoma Y79 cells by downregulating the levels of phospho-Akt.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	137-140
19918798-5	2010	PTX/LPC combination acted by favoring p53 stabilization through a lowering in p-Akt levels and in ps166-MDM2, the phosphorylated-MDM2 form that enters the nucleus and induces p53 export and degradation.	Paclitaxel	0-3	tumor protein p53	Homo sapiens	38-41
19918798-5	2010	PTX/LPC combination acted by favoring p53 stabilization through a lowering in p-Akt levels and in ps166-MDM2, the phosphorylated-MDM2 form that enters the nucleus and induces p53 export and degradation.	Paclitaxel	0-3	AKT serine/threonine kinase 1	Homo sapiens	80-83
19918798-5	2010	PTX/LPC combination acted by favoring p53 stabilization through a lowering in p-Akt levels and in ps166-MDM2, the phosphorylated-MDM2 form that enters the nucleus and induces p53 export and degradation.	Paclitaxel	0-3	tumor protein p53	Homo sapiens	175-178
19918798-6	2010	Treatment with wortmannin or transfection with a dominant negative form of Akt anticipated at 24 h the effects induced by PTX/LPC, suggesting a protective role against apoptosis played by Akt in Y79 cells.	Paclitaxel	122-125	AKT serine/threonine kinase 1	Homo sapiens	75-78
19918798-6	2010	Treatment with wortmannin or transfection with a dominant negative form of Akt anticipated at 24 h the effects induced by PTX/LPC, suggesting a protective role against apoptosis played by Akt in Y79 cells.	Paclitaxel	122-125	AKT serine/threonine kinase 1	Homo sapiens	188-191
19918798-8	2010	PTX/LPC treatment induced a weakness of Akt-MDM2-p53 complex and increased nuclear p53 levels.	Paclitaxel	0-3	AKT serine/threonine kinase 1	Homo sapiens	40-43
19918798-8	2010	PTX/LPC treatment induced a weakness of Akt-MDM2-p53 complex and increased nuclear p53 levels.	Paclitaxel	0-3	tumor protein p53	Homo sapiens	49-52
19918798-8	2010	PTX/LPC treatment induced a weakness of Akt-MDM2-p53 complex and increased nuclear p53 levels.	Paclitaxel	0-3	tumor protein p53	Homo sapiens	83-86
19918798-9	2010	Our results suggest that phospho-Akt lowering is at the root of the apoptotic action exerted by PTX/LPC combination and provide strong validation for a treatment approach that targets survival signals represented by phospho-Akt and inhibitor of apoptosis proteins.	Paclitaxel	96-99	AKT serine/threonine kinase 1	Homo sapiens	33-36
19918798-9	2010	Our results suggest that phospho-Akt lowering is at the root of the apoptotic action exerted by PTX/LPC combination and provide strong validation for a treatment approach that targets survival signals represented by phospho-Akt and inhibitor of apoptosis proteins.	Paclitaxel	96-99	AKT serine/threonine kinase 1	Homo sapiens	224-227
20145041-6	2010	In addition, hyperactive JNK attenuated the apoptosis of breast cancer cells treated by the chemotherapy drug paclitaxel, which is in contrast to the requirement for inducible JNK activity in response to cytotoxic chemotherapy.	Paclitaxel	110-120	mitogen-activated protein kinase 8	Homo sapiens	25-28
20113836-7	2010	Results showed that STAT3 decoy ODN inhibited cancer cell invasive power and enhanced sensitivity to paclitaxel for SKOV3 and OVCAR3 cells.	Paclitaxel	101-111	signal transducer and activator of transcription 3	Homo sapiens	20-25
20157422-12	2010	The four ascites with prosurvival activity against TRAIL had some inhibitory on cisplatin and/or paclitaxel.	Paclitaxel	97-107	TNF superfamily member 10	Homo sapiens	51-56
20113523-14	2010	Meanwhile, the expression of STAT3 and p-STAT3 decreased to relatively low levels after miR-21 inhibitor and taxol treatment.	Paclitaxel	109-114	signal transducer and activator of transcription 3	Homo sapiens	29-34
20113523-14	2010	Meanwhile, the expression of STAT3 and p-STAT3 decreased to relatively low levels after miR-21 inhibitor and taxol treatment.	Paclitaxel	109-114	signal transducer and activator of transcription 3	Homo sapiens	41-46
20113523-17	2010	A combination of miR-21 inhibitor and taxol could be an effective therapeutic strategy for controlling the growth of GBM by inhibiting STAT3 expression and phosphorylation.	Paclitaxel	38-43	signal transducer and activator of transcription 3	Homo sapiens	135-140
20157422-15	2010	CONCLUSIONS: The prosurvival activity of ascites against TRAIL is associated with shorter disease-free interval, which may be explained, at least in part, by ascites-induced cisplatin/paclitaxel resistance.	Paclitaxel	184-194	TNF superfamily member 10	Homo sapiens	57-62
21188093-6	2010	Retrospective analysis of a phase III, first-line MBC study confirmed incremental benefit from lapatinib and paclitaxel over paclitaxel alone in HER2-positive disease.	Paclitaxel	109-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	145-149
19609944-0	2010	Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1.	Paclitaxel	80-90	TIMP metallopeptidase inhibitor 1	Homo sapiens	0-39
19609944-6	2010	We hypothesized that TIMP-1 could reduce the sensitivity of breast cancer cells to PTX by inhibiting apoptosis.	Paclitaxel	83-86	TIMP metallopeptidase inhibitor 1	Homo sapiens	21-27
19609944-8	2010	Our data demonstrate that TIMP-1 could significantly decrease the sensitivity of MCF-7 cells to PTX-induced apoptosis, attenuate mitotic blockage in G(2)/M, and enhance the degradation of cyclin B1.	Paclitaxel	96-99	TIMP metallopeptidase inhibitor 1	Homo sapiens	26-32
19609944-9	2010	To further investigate whether the inhibitory effect of TIMP-1 on PTX-induced apoptosis is mediated by lowering levels of cyclin B1, a cyclin B1-expression plasmid was transfected into clone overexpressing TIMP-1.	Paclitaxel	66-69	TIMP metallopeptidase inhibitor 1	Homo sapiens	56-62
19609944-11	2010	The data showed that the TIMP-1-based decrease in PTX-induced apoptosis was reversed by cyclin B1.	Paclitaxel	50-53	TIMP metallopeptidase inhibitor 1	Homo sapiens	25-31
19609944-12	2010	Our data indicate that TIMP-1 can protect breast cancer cells from PTX-induced apoptosis by decreasing the stability of cyclin B1.	Paclitaxel	67-70	TIMP metallopeptidase inhibitor 1	Homo sapiens	23-29
20068074-3	2010	We hypothesize that SLPI may antagonize paclitaxel injury.	Paclitaxel	40-50	secretory leukocyte peptidase inhibitor	Homo sapiens	20-24
20068074-4	2010	EXPERIMENTAL DESIGN: Differential SLPI induction in response to paclitaxel and in response to stable forced expression of SLPI was shown in A2780-1A9 cells and their paclitaxel-resistant sublines, PTX10 and PTX22, and confirmed with HEY-A8 cells.	Paclitaxel	64-74	secretory leukocyte peptidase inhibitor	Homo sapiens	34-38
20068074-4	2010	EXPERIMENTAL DESIGN: Differential SLPI induction in response to paclitaxel and in response to stable forced expression of SLPI was shown in A2780-1A9 cells and their paclitaxel-resistant sublines, PTX10 and PTX22, and confirmed with HEY-A8 cells.	Paclitaxel	166-176	secretory leukocyte peptidase inhibitor	Homo sapiens	34-38
20068074-4	2010	EXPERIMENTAL DESIGN: Differential SLPI induction in response to paclitaxel and in response to stable forced expression of SLPI was shown in A2780-1A9 cells and their paclitaxel-resistant sublines, PTX10 and PTX22, and confirmed with HEY-A8 cells.	Paclitaxel	166-176	secretory leukocyte peptidase inhibitor	Homo sapiens	122-126
20068074-7	2010	RESULTS: SLPI expression was lower in A2780-1A9 ovarian cancer cells than in PTX10 and PTX22, and SLPI was induced by paclitaxel exposure.	Paclitaxel	118-128	secretory leukocyte peptidase inhibitor	Homo sapiens	98-102
20068074-9	2010	SLPI reduced the paclitaxel susceptibility of 1A9 and HEY-A8 cells (P &lt;or= 0.05), and SLPI expression did not increase the resistance of PTX10 and PTX22 cells.	Paclitaxel	17-27	secretory leukocyte peptidase inhibitor	Homo sapiens	0-4
20068074-10	2010	Both paclitaxel and SLPI overexpression induced ERK activation.	Paclitaxel	5-15	mitogen-activated protein kinase 1	Homo sapiens	48-51
20068074-11	2010	Inhibition of MAP/ERK kinase with U0126 increased paclitaxel injury and overcame SLPI-mediated cell protection.	Paclitaxel	50-60	mitogen-activated protein kinase 1	Homo sapiens	18-21
20068074-14	2010	CONCLUSIONS: A two-pronged approach confirmed that SLPI overcomes paclitaxel in part through activation of ERK1/2.	Paclitaxel	66-76	secretory leukocyte peptidase inhibitor	Homo sapiens	51-55
19826412-6	2010	The Tyr 1226/7 binds Shc, and the knockdown of Shc blocks the ability of ErbB2 to inhibit apoptosis and mediate paclitaxel resistance.	Paclitaxel	112-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-78
20576088-9	2010	The transforming growth factor beta (TGFbeta) receptor inhibitor, LY2109761, that targets the signaling pathway of another top scoring hit, TGFbeta1, was synergistic with paclitaxel when used in combination on select breast cancer cell lines grown in 3D culture.	Paclitaxel	171-181	transforming growth factor beta 1	Homo sapiens	4-35
19944065-7	2010	Real-time polymerase chain reaction (PCR) showed that thrombin and thrombin/paclitaxel-induced 3.0-fold and 4.6-fold TF mRNA expressions compared with the control.	Paclitaxel	76-86	coagulation factor II, thrombin	Homo sapiens	67-75
19944065-9	2010	The c-Jun terminal NH2 kinase (JNK) inhibitor SP600125 reduced thrombin/paclitaxel-induced TF expression.	Paclitaxel	72-82	mitogen-activated protein kinase 8	Homo sapiens	31-34
19944065-9	2010	The c-Jun terminal NH2 kinase (JNK) inhibitor SP600125 reduced thrombin/paclitaxel-induced TF expression.	Paclitaxel	72-82	coagulation factor II, thrombin	Homo sapiens	63-71
19944065-10	2010	Furthermore, EGCG significantly inhibited the phosphorylation of JNK to 49% of thrombin/paclitaxel-stimulated HAECs at 60min.	Paclitaxel	88-98	mitogen-activated protein kinase 8	Homo sapiens	65-68
19944065-10	2010	Furthermore, EGCG significantly inhibited the phosphorylation of JNK to 49% of thrombin/paclitaxel-stimulated HAECs at 60min.	Paclitaxel	88-98	coagulation factor II, thrombin	Homo sapiens	79-87
19238538-4	2010	Furthermore, when we transiently silenced Bcl-2, both cisplatin and paclitaxel induced apoptosis more than parental cells.	Paclitaxel	68-78	BCL2 apoptosis regulator	Homo sapiens	42-47
19944065-0	2010	(-)-Epigallocatechin-3-gallate decreases thrombin/paclitaxel-induced endothelial tissue factor expression via the inhibition of c-Jun terminal NH2 kinase phosphorylation.	Paclitaxel	50-60	coagulation factor II, thrombin	Homo sapiens	41-49
19944065-2	2010	This study investigates the effect of (-)-epigallocatechin-3-gallate (EGCG) on the expression of thrombin/paclitaxel-induced endothelial tissue factor (TF) expressions in human aortic endothelial cells (HAECs).	Paclitaxel	106-116	coagulation factor II, thrombin	Homo sapiens	97-105
19944065-5	2010	Thrombin and thrombin/paclitaxel-induced 2.6-fold and 2.9-fold increases in TF activity compared with the control.	Paclitaxel	22-32	coagulation factor II, thrombin	Homo sapiens	13-21
20078855-16	2010	EGCG overcame paclitaxel-induced GRP78 expression and potentiated paclitaxel-induced JNK phosphorylation in 4T1 cells both in vitro and in vivo.	Paclitaxel	14-24	heat shock protein 5	Mus musculus	33-38
20576088-9	2010	The transforming growth factor beta (TGFbeta) receptor inhibitor, LY2109761, that targets the signaling pathway of another top scoring hit, TGFbeta1, was synergistic with paclitaxel when used in combination on select breast cancer cell lines grown in 3D culture.	Paclitaxel	171-181	transforming growth factor beta 1	Homo sapiens	37-44
19860840-0	2010	Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo.	Paclitaxel	115-125	glypican 3	Mus musculus	18-28
19824995-7	2010	NF-kappaB was activated by paclitaxel; however, the activation of NF-kappaB was inhibited by alpha-TOS.	Paclitaxel	27-37	nuclear factor kappa B subunit 1	Homo sapiens	0-9
19824995-7	2010	NF-kappaB was activated by paclitaxel; however, the activation of NF-kappaB was inhibited by alpha-TOS.	Paclitaxel	27-37	nuclear factor kappa B subunit 1	Homo sapiens	66-75
19860840-4	2010	We show that the clear cell carcinoma cell line with silenced GPC3 expression (GPC3 [-]) was more sensitive to paclitaxel than GPC3 (+) cells.	Paclitaxel	111-121	glypican 3	Mus musculus	62-66
19860840-4	2010	We show that the clear cell carcinoma cell line with silenced GPC3 expression (GPC3 [-]) was more sensitive to paclitaxel than GPC3 (+) cells.	Paclitaxel	111-121	glypican 3	Mus musculus	79-83
19860840-4	2010	We show that the clear cell carcinoma cell line with silenced GPC3 expression (GPC3 [-]) was more sensitive to paclitaxel than GPC3 (+) cells.	Paclitaxel	111-121	glypican 3	Mus musculus	79-83
19860840-5	2010	In addition, the GPC3 silencing induced sensitization to paclitaxel was associated with the activation of an apoptosis pathway, as shown by flow cytometry.	Paclitaxel	57-67	glypican 3	Mus musculus	17-21
19860840-7	2010	Peritoneal metastases caused by GPC3 (-) were more sensitive to paclitaxel than those caused by GPC3 (+) cells.	Paclitaxel	64-74	glypican 3	Mus musculus	32-36
19860840-8	2010	These results indicate that increased GPC3 expression in a clear cell carcinoma cell line may play a protective role against apoptosis, and so the downregulation of GPC3 may be a potential target to increase sensitivity to paclitaxel-induced apoptosis in clear cell carcinoma.	Paclitaxel	223-233	glypican 3	Mus musculus	165-169
20357441-8	2010	Furthermore, paclitaxel and pirarubicin suppressed the expression of PCNA, cyclin D1, cyclin E and Bcl-2, and increased Bax expression.	Paclitaxel	13-23	BCL2 apoptosis regulator	Homo sapiens	99-104
20346445-0	2010	Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice.	Paclitaxel	0-10	toll-like receptor 4	Mus musculus	73-77
20346445-5	2010	Finally, PTX treatment results in enhanced antigen-specific, IFN-gamma-secreting CD8(+) T cells in vivo.	Paclitaxel	9-12	interferon gamma	Mus musculus	61-70
20357441-9	2010	CONCLUSION: These results suggest that the G2/M or G0/G1 cell cycle arrest and apoptosis induced by paclitaxel and pirarubicin are Bcl-2/Bax dependent, suggesting favorable effects of combination therapy with paclitaxel and pirarubicin in the treatment of osteosarcoma.	Paclitaxel	209-219	BCL2 apoptosis regulator	Homo sapiens	131-136
20357441-9	2010	CONCLUSION: These results suggest that the G2/M or G0/G1 cell cycle arrest and apoptosis induced by paclitaxel and pirarubicin are Bcl-2/Bax dependent, suggesting favorable effects of combination therapy with paclitaxel and pirarubicin in the treatment of osteosarcoma.	Paclitaxel	209-219	BCL2 associated X, apoptosis regulator	Homo sapiens	137-140
20357441-8	2010	Furthermore, paclitaxel and pirarubicin suppressed the expression of PCNA, cyclin D1, cyclin E and Bcl-2, and increased Bax expression.	Paclitaxel	13-23	BCL2 associated X, apoptosis regulator	Homo sapiens	120-123
20357441-9	2010	CONCLUSION: These results suggest that the G2/M or G0/G1 cell cycle arrest and apoptosis induced by paclitaxel and pirarubicin are Bcl-2/Bax dependent, suggesting favorable effects of combination therapy with paclitaxel and pirarubicin in the treatment of osteosarcoma.	Paclitaxel	100-110	BCL2 apoptosis regulator	Homo sapiens	131-136
20357441-9	2010	CONCLUSION: These results suggest that the G2/M or G0/G1 cell cycle arrest and apoptosis induced by paclitaxel and pirarubicin are Bcl-2/Bax dependent, suggesting favorable effects of combination therapy with paclitaxel and pirarubicin in the treatment of osteosarcoma.	Paclitaxel	100-110	BCL2 associated X, apoptosis regulator	Homo sapiens	137-140
20460821-0	2010	Effect of Thai plant extracts on P-glycoprotein function and viability in paclitaxel-resistant HepG2 cells.	Paclitaxel	74-84	ATP binding cassette subfamily B member 1	Homo sapiens	33-47
19924122-1	2010	Oral administration of the taxanes docetaxel and paclitaxel is hampered by their affinity for drug transporters, especially ABCB1 (P-glycoprotein, Pgp); extensive first-pass metabolism by cytochrome P450 3A (CYP3A); and poor drug solubility.	Paclitaxel	49-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	124-129
20661829-0	2010	Protection of p53 wild type cells from taxol by genistein in the combined treatment of lung cancer.	Paclitaxel	39-44	tumor protein p53	Homo sapiens	14-17
20814160-3	2010	Hydroxylation activities of mfCYP3A4 and mfCYP3A5 toward coumarin, paclitaxel, diclofenac, flurbiprofen, and S-mephenytoin were below detectable levels, as was also true for CYP3A4 and CYP3A5.	Paclitaxel	67-77	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36
20814160-3	2010	Hydroxylation activities of mfCYP3A4 and mfCYP3A5 toward coumarin, paclitaxel, diclofenac, flurbiprofen, and S-mephenytoin were below detectable levels, as was also true for CYP3A4 and CYP3A5.	Paclitaxel	67-77	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	43-49
20714087-4	2010	Our results showed that low concentration of taxol induced cell death dominantly in apoptotic fashion associated with nuclear fragmentation, protein synthesis, phosphatidylserine (PS) externalization, G2/M cell cycle arrest, Bax translocation into mitochondria and caspase-3 activation, whereas high concentration of this drug induced significant cytoplasm vacuolization, mitochondria swelling and paraptosis-like cell death form without protein synthesis that is necessary for paraptosis.	Paclitaxel	45-50	BCL2 associated X, apoptosis regulator	Homo sapiens	225-228
20714087-4	2010	Our results showed that low concentration of taxol induced cell death dominantly in apoptotic fashion associated with nuclear fragmentation, protein synthesis, phosphatidylserine (PS) externalization, G2/M cell cycle arrest, Bax translocation into mitochondria and caspase-3 activation, whereas high concentration of this drug induced significant cytoplasm vacuolization, mitochondria swelling and paraptosis-like cell death form without protein synthesis that is necessary for paraptosis.	Paclitaxel	45-50	caspase 3	Homo sapiens	265-274
20099200-1	2010	MCF-7/ADR cells, a doxorubicin-resistant human breast cancer cell line, acquires resistance to several chemotherapeutic agents, such as anthracylines and taxol, via overexpression of the multidrug resistance1 (MDR1) gene.	Paclitaxel	154-159	ATP binding cassette subfamily B member 1	Homo sapiens	187-208
20099200-1	2010	MCF-7/ADR cells, a doxorubicin-resistant human breast cancer cell line, acquires resistance to several chemotherapeutic agents, such as anthracylines and taxol, via overexpression of the multidrug resistance1 (MDR1) gene.	Paclitaxel	154-159	ATP binding cassette subfamily B member 1	Homo sapiens	210-214
19455332-3	2010	METHODS: Concurrent treatment with 4-OH-TAM and paclitaxel (Ptx) was investigated in estrogen receptor (ER)-positive breast cancer cells.	Paclitaxel	48-58	estrogen receptor 1	Homo sapiens	85-102
19455332-3	2010	METHODS: Concurrent treatment with 4-OH-TAM and paclitaxel (Ptx) was investigated in estrogen receptor (ER)-positive breast cancer cells.	Paclitaxel	48-58	estrogen receptor 1	Homo sapiens	104-106
19455332-3	2010	METHODS: Concurrent treatment with 4-OH-TAM and paclitaxel (Ptx) was investigated in estrogen receptor (ER)-positive breast cancer cells.	Paclitaxel	60-63	estrogen receptor 1	Homo sapiens	85-102
19455332-3	2010	METHODS: Concurrent treatment with 4-OH-TAM and paclitaxel (Ptx) was investigated in estrogen receptor (ER)-positive breast cancer cells.	Paclitaxel	60-63	estrogen receptor 1	Homo sapiens	104-106
19455332-5	2010	RESULTS: Concurrent treatment with 4-OH-TAM and Ptx yielded less than additive antitumor effects in ER-positive breast cancer cells, as observed with Dox in our previous study.	Paclitaxel	48-51	estrogen receptor 1	Homo sapiens	100-102
19820208-7	2010	Although disulfiram has been shown to inhibit multidrug resistance-1 P-glycoprotein (P-gp) in vitro, our data demonstrate that the known P-gp substrate paclitaxel is not affected by coadministration of disulfiram.	Paclitaxel	152-162	ATP binding cassette subfamily B member 1	Homo sapiens	137-141
20724802-8	2010	Using paclitaxel as a known P-gp substrate, erythromycin demonstrated only partial P-gp inhibitory capacity, maintaining an efflux ratio over 100.	Paclitaxel	6-16	ATP binding cassette subfamily B member 1	Homo sapiens	28-32
20419056-0	2010	Targeting the Androgen Receptor by Taxol in Castration-Resistant Prostate Cancer.	Paclitaxel	35-40	androgen receptor	Homo sapiens	14-31
20419056-3	2010	We have demonstrated recently that Taxol (paclitaxel and its semisynthetic analogue docetaxel) treatment of 22Rv1, a CRPC cell line that expresses the tumor suppressor gene PTEN, inhibits AR transcriptional activity.	Paclitaxel	35-40	androgen receptor	Homo sapiens	188-190
20419056-3	2010	We have demonstrated recently that Taxol (paclitaxel and its semisynthetic analogue docetaxel) treatment of 22Rv1, a CRPC cell line that expresses the tumor suppressor gene PTEN, inhibits AR transcriptional activity.	Paclitaxel	42-52	androgen receptor	Homo sapiens	188-190
20419056-6	2010	Further studies demonstrated that Taxol inhibition of the AR is mediated, at least in part, by Taxol-induced nuclear accumulation of FOXO1, a key downstream effector protein of PTEN and increased association of FOXO1 with the AR.	Paclitaxel	34-39	androgen receptor	Homo sapiens	58-60
20419056-6	2010	Further studies demonstrated that Taxol inhibition of the AR is mediated, at least in part, by Taxol-induced nuclear accumulation of FOXO1, a key downstream effector protein of PTEN and increased association of FOXO1 with the AR.	Paclitaxel	34-39	forkhead box O1	Homo sapiens	133-138
20419056-6	2010	Further studies demonstrated that Taxol inhibition of the AR is mediated, at least in part, by Taxol-induced nuclear accumulation of FOXO1, a key downstream effector protein of PTEN and increased association of FOXO1 with the AR.	Paclitaxel	34-39	forkhead box O1	Homo sapiens	211-216
20419056-6	2010	Further studies demonstrated that Taxol inhibition of the AR is mediated, at least in part, by Taxol-induced nuclear accumulation of FOXO1, a key downstream effector protein of PTEN and increased association of FOXO1 with the AR.	Paclitaxel	34-39	androgen receptor	Homo sapiens	226-228
20419056-6	2010	Further studies demonstrated that Taxol inhibition of the AR is mediated, at least in part, by Taxol-induced nuclear accumulation of FOXO1, a key downstream effector protein of PTEN and increased association of FOXO1 with the AR.	Paclitaxel	95-100	androgen receptor	Homo sapiens	58-60
20419056-6	2010	Further studies demonstrated that Taxol inhibition of the AR is mediated, at least in part, by Taxol-induced nuclear accumulation of FOXO1, a key downstream effector protein of PTEN and increased association of FOXO1 with the AR.	Paclitaxel	95-100	forkhead box O1	Homo sapiens	133-138
20419056-6	2010	Further studies demonstrated that Taxol inhibition of the AR is mediated, at least in part, by Taxol-induced nuclear accumulation of FOXO1, a key downstream effector protein of PTEN and increased association of FOXO1 with the AR.	Paclitaxel	95-100	forkhead box O1	Homo sapiens	211-216
20419056-6	2010	Further studies demonstrated that Taxol inhibition of the AR is mediated, at least in part, by Taxol-induced nuclear accumulation of FOXO1, a key downstream effector protein of PTEN and increased association of FOXO1 with the AR.	Paclitaxel	95-100	androgen receptor	Homo sapiens	226-228
21058190-3	2010	Although quercetin induced cell death in a dose-dependent manner, 12.5-50 muM quercetin inhibited the activity of both taxol and nocodazole to induce G2/M arrest in various cell lines.	Paclitaxel	119-124	latexin	Homo sapiens	74-77
19956892-0	2010	Association of the ABCB1 3435C&gt;T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy.	Paclitaxel	121-131	ATP binding cassette subfamily B member 1	Homo sapiens	19-24
19956892-10	2010	Our data suggest that the ABCB1 polymorphism at 3435 is associated with clinical outcomes after paclitaxel-based combined chemotherapy in advanced gastric cancer patients.	Paclitaxel	96-106	ATP binding cassette subfamily B member 1	Homo sapiens	26-31
20661829-1	2010	This study specifies the basic principles to selectively kill p53-deficient cells (H1299, FaDu) by taxol and to protect p53 wild type cells (A549) by the prior administration of structurally related flavonoids (apigenin, genistein, and quercetin).	Paclitaxel	99-104	tumor protein p53	Homo sapiens	62-65
20661829-7	2010	The proposed therapeutic strategy allows protection of p53 wild type cells from taxol and selectively increases apoptosis in p53-deficient cells.	Paclitaxel	80-85	tumor protein p53	Homo sapiens	55-58
21088439-0	2010	A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.	Paclitaxel	42-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
20661829-7	2010	The proposed therapeutic strategy allows protection of p53 wild type cells from taxol and selectively increases apoptosis in p53-deficient cells.	Paclitaxel	80-85	tumor protein p53	Homo sapiens	125-128
21088439-9	2010	CONCLUSIONS: First-line lapatinib plus paclitaxel for HER2-overexpressing MBC produced an encouraging ORR with manageable toxicities.	Paclitaxel	39-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
19747165-9	2009	Thus mesothelin can inhibit paclitaxel-induced cell death mainly by involving PI3K signalling in the regulation of Bcl-2 family expression.	Paclitaxel	28-38	BCL2 apoptosis regulator	Homo sapiens	115-120
22966279-4	2010	This study aimed to evaluate the impact of the MAGE-A antigen subgroups MAGE-A2, -A3, -A4 and -A6 on oral squamous cell carcinoma cell lines treated with docetaxel and paclitaxel.	Paclitaxel	168-178	MAGE family member A2	Homo sapiens	72-79
22966279-12	2010	MAGE-A4 has a statistically significant impact on the tumour response to docetaxel and paclitaxel in oral squamous cell carcinoma.	Paclitaxel	87-97	MAGE family member A4	Homo sapiens	0-7
22966274-3	2010	The purpose of this study was to evaluate the possible relationship between paclitaxel-induced neurotoxicity and the distribution of genetic variations with reported functional significance in the ABCB1, CYP2C8 and CYP3A4 genes that are all implicated in taxol metabolism.	Paclitaxel	76-86	ATP binding cassette subfamily B member 1	Homo sapiens	197-202
22966274-3	2010	The purpose of this study was to evaluate the possible relationship between paclitaxel-induced neurotoxicity and the distribution of genetic variations with reported functional significance in the ABCB1, CYP2C8 and CYP3A4 genes that are all implicated in taxol metabolism.	Paclitaxel	76-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	215-221
22966274-3	2010	The purpose of this study was to evaluate the possible relationship between paclitaxel-induced neurotoxicity and the distribution of genetic variations with reported functional significance in the ABCB1, CYP2C8 and CYP3A4 genes that are all implicated in taxol metabolism.	Paclitaxel	255-260	ATP binding cassette subfamily B member 1	Homo sapiens	197-202
22966274-3	2010	The purpose of this study was to evaluate the possible relationship between paclitaxel-induced neurotoxicity and the distribution of genetic variations with reported functional significance in the ABCB1, CYP2C8 and CYP3A4 genes that are all implicated in taxol metabolism.	Paclitaxel	255-260	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	215-221
19725034-12	2010	Then knockdown of actin and EGFR in PC-3-TxR cells recovered paclitaxel sensitivity, indicating that CTEN down-regulation mediates paclitaxel resistance through elevation of EGFR and actin expression.	Paclitaxel	61-71	epidermal growth factor receptor	Homo sapiens	28-32
19725034-12	2010	Then knockdown of actin and EGFR in PC-3-TxR cells recovered paclitaxel sensitivity, indicating that CTEN down-regulation mediates paclitaxel resistance through elevation of EGFR and actin expression.	Paclitaxel	131-141	epidermal growth factor receptor	Homo sapiens	174-178
20173382-0	2010	Successful treatment with paclitaxel/carboplatin chemotherapy in advanced adenocarcinoma of the urinary tract producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125.	Paclitaxel	26-36	CEA cell adhesion molecule 3	Homo sapiens	120-144
19699770-14	2009	CONCLUSIONS: In the present study a novel siRNA delivery carrier system with an MDR1-targeting siRNA (siMDR1) effectively reduced the expression of MDR1 in human colon CSCs (CD133+ enriched cell population), resulting in significantly increasing the chemosensitivity to paclitaxel.	Paclitaxel	270-280	ATP binding cassette subfamily B member 1	Homo sapiens	80-84
19699770-14	2009	CONCLUSIONS: In the present study a novel siRNA delivery carrier system with an MDR1-targeting siRNA (siMDR1) effectively reduced the expression of MDR1 in human colon CSCs (CD133+ enriched cell population), resulting in significantly increasing the chemosensitivity to paclitaxel.	Paclitaxel	270-280	ATP binding cassette subfamily B member 1	Homo sapiens	104-108
20641310-0	2004	[N-methyl-(11)C]4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-2,2-diphenyl-N-methyl-butanamide One of the mechanisms of tumor cells to escape the cytotoxic effects of chemotherapeutic agents, such as adriamycin, vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel, is to limit their presence inside the cells by a multidrug resistance (MDR-1) gene protein (1, 2).	Paclitaxel	270-280	ATP binding cassette subfamily B member 1	Homo sapiens	353-378
19826413-8	2009	In MyD88(+) SCOV3 cells, LPS or PTX binding to TLR4 induced IRAK4 activation and cJun phosphorylation, activated the NF-kappaB pathway and promoted interleukin (IL)-8, IL-6, vascular endothelial growth factor and monocyte chemotactic protein-1 production and resistance to drug-induced apoptosis.	Paclitaxel	32-35	nuclear factor kappa B subunit 1	Homo sapiens	117-126
19826413-8	2009	In MyD88(+) SCOV3 cells, LPS or PTX binding to TLR4 induced IRAK4 activation and cJun phosphorylation, activated the NF-kappaB pathway and promoted interleukin (IL)-8, IL-6, vascular endothelial growth factor and monocyte chemotactic protein-1 production and resistance to drug-induced apoptosis.	Paclitaxel	32-35	C-X-C motif chemokine ligand 8	Homo sapiens	148-166
19826413-8	2009	In MyD88(+) SCOV3 cells, LPS or PTX binding to TLR4 induced IRAK4 activation and cJun phosphorylation, activated the NF-kappaB pathway and promoted interleukin (IL)-8, IL-6, vascular endothelial growth factor and monocyte chemotactic protein-1 production and resistance to drug-induced apoptosis.	Paclitaxel	32-35	interleukin 6	Homo sapiens	168-172
19826413-10	2009	In PTX-sensitive, MyD88(neg) A2780 cells, TLR4 stimulation upregulated TRIF, and TLR4 silencing eliminated this effect.	Paclitaxel	3-6	TIR domain containing adaptor molecule 1	Homo sapiens	71-75
20062660-0	2009	Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report.	Paclitaxel	99-109	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
19847923-12	2009	Treatment with taxol resulted in accumulation of EcR in the cytoplasm and simultaneous depletion of EcR from the nucleus, suggesting that microtubules may be involved in targeted intracellular transport of EcR to the nucleus (genomic action) or may play a role in rapid ecdysone signal transduction in the extranuclear compartment, i.e., in non-genomic actions of ecdysone.	Paclitaxel	15-20	Ecdysone receptor	Drosophila melanogaster	49-52
19847923-12	2009	Treatment with taxol resulted in accumulation of EcR in the cytoplasm and simultaneous depletion of EcR from the nucleus, suggesting that microtubules may be involved in targeted intracellular transport of EcR to the nucleus (genomic action) or may play a role in rapid ecdysone signal transduction in the extranuclear compartment, i.e., in non-genomic actions of ecdysone.	Paclitaxel	15-20	Ecdysone receptor	Drosophila melanogaster	100-103
19847923-12	2009	Treatment with taxol resulted in accumulation of EcR in the cytoplasm and simultaneous depletion of EcR from the nucleus, suggesting that microtubules may be involved in targeted intracellular transport of EcR to the nucleus (genomic action) or may play a role in rapid ecdysone signal transduction in the extranuclear compartment, i.e., in non-genomic actions of ecdysone.	Paclitaxel	15-20	Ecdysone receptor	Drosophila melanogaster	100-103
20017221-10	2009	CONCLUSION: TWIST, which has a significantly decreased expression in response to paclitaxel in Hep-2 cells, may play a pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.	Paclitaxel	135-145	twist family bHLH transcription factor 1	Homo sapiens	12-17
19415279-6	2009	The DLT level was reached at the doses of paclitaxel 110 mg/m(2), gemcitabine 1,150 mg/m(2) and LOHP 70 mg/m(2).	Paclitaxel	42-52	codanin 1	Homo sapiens	4-7
19717209-0	2009	Potentiation of paclitaxel-induced apoptosis by galectin-13 overexpression via activation of Ask-1-p38-MAP kinase and JNK/SAPK pathways and suppression of Akt and ERK1/2 activation in U-937 human macrophage cells.	Paclitaxel	16-26	mitogen-activated protein kinase 1	Homo sapiens	99-102
20017221-0	2009	Alteration in TWIST expression: possible role in paclitaxel-induced apoptosis in human laryngeal carcinoma Hep-2 cell line.	Paclitaxel	49-59	twist family bHLH transcription factor 1	Homo sapiens	14-19
20017221-1	2009	AIM: To explore the relationship between alteration in the expression of TWIST, highly conserved transcription factor from the basic helix-loop-helix family, and apoptosis of Hep-2 cells induced by chemotherapeutic agent paclitaxel.	Paclitaxel	221-231	twist family bHLH transcription factor 1	Homo sapiens	73-78
20017221-5	2009	The mRNA and protein expression of TWIST in response to paclitaxel at 24 hours, 48 hours, and 72 hours was examined by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting, respectively.	Paclitaxel	56-66	twist family bHLH transcription factor 1	Homo sapiens	35-40
20017221-9	2009	Both mRNA and protein expression of TWIST was markedly decreased at both mRNA levels and protein levels, at 24 hours, 48 hours, and 72 hours in the paclitaxel-induced apoptosis of Hep-2 cells (P&lt;0.001).	Paclitaxel	148-158	twist family bHLH transcription factor 1	Homo sapiens	36-41
20017221-10	2009	CONCLUSION: TWIST, which has a significantly decreased expression in response to paclitaxel in Hep-2 cells, may play a pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.	Paclitaxel	81-91	twist family bHLH transcription factor 1	Homo sapiens	12-17
19717209-0	2009	Potentiation of paclitaxel-induced apoptosis by galectin-13 overexpression via activation of Ask-1-p38-MAP kinase and JNK/SAPK pathways and suppression of Akt and ERK1/2 activation in U-937 human macrophage cells.	Paclitaxel	16-26	mitogen-activated protein kinase 8	Homo sapiens	118-121
19717209-0	2009	Potentiation of paclitaxel-induced apoptosis by galectin-13 overexpression via activation of Ask-1-p38-MAP kinase and JNK/SAPK pathways and suppression of Akt and ERK1/2 activation in U-937 human macrophage cells.	Paclitaxel	16-26	AKT serine/threonine kinase 1	Homo sapiens	155-158
19717209-0	2009	Potentiation of paclitaxel-induced apoptosis by galectin-13 overexpression via activation of Ask-1-p38-MAP kinase and JNK/SAPK pathways and suppression of Akt and ERK1/2 activation in U-937 human macrophage cells.	Paclitaxel	16-26	mitogen-activated protein kinase 3	Homo sapiens	163-169
19717209-6	2009	In addition, pharmacological inhibition of JNK and p38-MAPK pathways protected the cells from paclitaxel-induced cell death.	Paclitaxel	94-104	mitogen-activated protein kinase 8	Homo sapiens	43-46
19717209-6	2009	In addition, pharmacological inhibition of JNK and p38-MAPK pathways protected the cells from paclitaxel-induced cell death.	Paclitaxel	94-104	mitogen-activated protein kinase 1	Homo sapiens	51-54
19717209-6	2009	In addition, pharmacological inhibition of JNK and p38-MAPK pathways protected the cells from paclitaxel-induced cell death.	Paclitaxel	94-104	mitogen-activated protein kinase 14	Homo sapiens	55-59
19885629-9	2009	On the other hand, taxol-induced up-regulation of MCP-1 was reduced in cells treated with U73122, an inhibitor of phospholipase C (PLC), and ectopic expression of PLC-gamma1 increased the expression of MCP-1 in taxol-treated MCF-7 cells, indicating that PLC-gamma1 functions as a positive regulator in taxol-induced MCP-1 expression.	Paclitaxel	19-24	phospholipase C gamma 1	Homo sapiens	254-264
19647441-6	2009	In this study, the FES was also used to analyze the caspase-3 activation in living cells during anti-cancer drug such as taxol, Artesunate (ART) or Dihydroartemisinin (DHA) treatment.	Paclitaxel	121-126	caspase 3	Homo sapiens	52-61
19588231-6	2009	In particular, the expression of the gene SPRY2, which has been known to act as an inhibitor on Ras/Raf/MAPK signaling, was downregulated after the treatment with paclitaxel.	Paclitaxel	163-173	zinc fingers and homeoboxes 2	Mus musculus	100-103
19712735-2	2009	The anticancer agent paclitaxel was conjugated to human serum albumin (HSA) and this drug-albumin conjugate was further equipped with folic acid, linked via an extended poly(ethylene glycol) spacer.	Paclitaxel	21-31	albumin	Homo sapiens	56-69
19949674-4	2009	Estrogen receptor (ER)-negative tumors respond well to doxorubicin (P=0.038), and progesterone receptor (PR)-negative tumors to 5-FU (P=0.039), doxetaxel (P=0.038), doxorubicin (P=0.000), epirubicin (P=0.010), and paclitaxel (P=0.003).	Paclitaxel	214-224	estrogen receptor 1	Homo sapiens	0-17
19996278-2	2009	In vitro studies have suggested that relatively low concentrations of TRAIL enhance the lethality of paclitaxel (Taxol) against human cancer cells.	Paclitaxel	101-111	TNF superfamily member 10	Homo sapiens	70-75
19996278-2	2009	In vitro studies have suggested that relatively low concentrations of TRAIL enhance the lethality of paclitaxel (Taxol) against human cancer cells.	Paclitaxel	113-118	TNF superfamily member 10	Homo sapiens	70-75
19826044-3	2009	Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity.	Paclitaxel	315-320	androgen receptor	Homo sapiens	158-175
19855003-6	2009	Sensitization to taxol was achieved by reducing levels of Mps1 or BubR1, proteins having dual roles in checkpoint activation and chromosome alignment, but not by reducing Mad2, functioning solely in the mitotic checkpoint.	Paclitaxel	17-22	macrophage expressed 1	Homo sapiens	58-62
19826044-0	2009	Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.	Paclitaxel	60-65	androgen receptor	Homo sapiens	18-35
19826044-3	2009	Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity.	Paclitaxel	78-88	androgen receptor	Homo sapiens	158-175
19826044-3	2009	Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity.	Paclitaxel	78-88	androgen receptor	Homo sapiens	177-179
19826044-3	2009	Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity.	Paclitaxel	78-88	androgen receptor	Homo sapiens	272-274
19826044-3	2009	Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity.	Paclitaxel	78-88	androgen receptor	Homo sapiens	272-274
19858400-0	2009	Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.	Paclitaxel	116-126	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39
19732770-4	2009	When microtubules are stabilized by paclitaxel (taxol), there is a strong induction of NF-kappaB even in the absence of TNF-alpha .	Paclitaxel	48-53	tumor necrosis factor	Homo sapiens	120-129
19732770-5	2009	Although there was no additive effect of taxol and TNF-alpha on NF-kappaB activity suggesting a shared mechanism of activation, taxol strongly induced the NF-kappaB reporter in the presence of a TNF receptor (TNFR) blocking antibody while TNF-alpha did not.	Paclitaxel	128-133	tumor necrosis factor	Homo sapiens	239-248
19732770-6	2009	Both TNF-alpha and taxol induce the degradation of endogenous IkappaBalpha and either taxol or TNF-alpha induction of NF-kappaB activity was blocked by inhibitors of NF-kappaB acting at different sites in the signaling pathway.	Paclitaxel	19-24	NFKB inhibitor alpha	Homo sapiens	62-74
19732770-6	2009	Both TNF-alpha and taxol induce the degradation of endogenous IkappaBalpha and either taxol or TNF-alpha induction of NF-kappaB activity was blocked by inhibitors of NF-kappaB acting at different sites in the signaling pathway.	Paclitaxel	19-24	tumor necrosis factor	Homo sapiens	95-104
19732770-6	2009	Both TNF-alpha and taxol induce the degradation of endogenous IkappaBalpha and either taxol or TNF-alpha induction of NF-kappaB activity was blocked by inhibitors of NF-kappaB acting at different sites in the signaling pathway.	Paclitaxel	86-91	tumor necrosis factor	Homo sapiens	5-14
19815708-6	2009	Here, we show that sirolimus and paclitaxel differentially induce self-digesting autophagy in vascular endothelial cells with changes in expression of LC3B, p53, and Bcl-2, considerably suppressing re-endothelialization and revascularization.	Paclitaxel	33-43	tumor protein p53	Homo sapiens	157-160
19815708-6	2009	Here, we show that sirolimus and paclitaxel differentially induce self-digesting autophagy in vascular endothelial cells with changes in expression of LC3B, p53, and Bcl-2, considerably suppressing re-endothelialization and revascularization.	Paclitaxel	33-43	BCL2 apoptosis regulator	Homo sapiens	166-171
19447545-6	2009	In addition, SG235-TRAIL in combination with the chemotherapeutic drug, taxol, produced a synergistic cytotoxic effect in cancer cells in vitro without causing significant toxicity to normal cells.	Paclitaxel	72-77	TNF superfamily member 10	Homo sapiens	19-24
19447545-9	2009	These results suggest that SG235-TRAIL is a potential novel, efficient anti-cancer agent, and in combination with taxol, it would be even more useful with considerably low toxic side effects.	Paclitaxel	114-119	TNF superfamily member 10	Homo sapiens	33-38
19826044-3	2009	Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity.	Paclitaxel	315-320	androgen receptor	Homo sapiens	177-179
19826044-4	2009	This was further supported by the observation that the activity of AR luciferase reporter genes was inhibited by paclitaxel.	Paclitaxel	113-123	androgen receptor	Homo sapiens	67-69
19826044-6	2009	However, pretreatment of C4-2 cells with the phosphoinositide 3-kinase inhibitor LY294002 restored paclitaxel inhibition of the AR.	Paclitaxel	99-109	androgen receptor	Homo sapiens	128-130
19826044-8	2009	We further showed that paclitaxel induces nuclear accumulation of FOXO1, a known AR suppressive nuclear factor, and increases the association of FOXO1 with AR proteins in the nucleus.	Paclitaxel	23-33	forkhead box O1	Homo sapiens	66-71
19826044-8	2009	We further showed that paclitaxel induces nuclear accumulation of FOXO1, a known AR suppressive nuclear factor, and increases the association of FOXO1 with AR proteins in the nucleus.	Paclitaxel	23-33	androgen receptor	Homo sapiens	81-83
19826044-8	2009	We further showed that paclitaxel induces nuclear accumulation of FOXO1, a known AR suppressive nuclear factor, and increases the association of FOXO1 with AR proteins in the nucleus.	Paclitaxel	23-33	forkhead box O1	Homo sapiens	145-150
19826044-8	2009	We further showed that paclitaxel induces nuclear accumulation of FOXO1, a known AR suppressive nuclear factor, and increases the association of FOXO1 with AR proteins in the nucleus.	Paclitaxel	23-33	androgen receptor	Homo sapiens	156-158
19826044-9	2009	FOXO1 knockdown with small interfering RNA attenuated the inhibitory effect of paclitaxel on AR transcriptional activity, expression of PSA and Nkx3.1, and cell survival.	Paclitaxel	79-89	forkhead box O1	Homo sapiens	0-5
19826044-9	2009	FOXO1 knockdown with small interfering RNA attenuated the inhibitory effect of paclitaxel on AR transcriptional activity, expression of PSA and Nkx3.1, and cell survival.	Paclitaxel	79-89	androgen receptor	Homo sapiens	93-95
19826044-10	2009	These data reveal a previously uncharacterized, FOXO1-mediated, AR-inhibitory effect of Taxol in CRPC cells that may play an important role in Taxol-mediated inhibition of CRPC growth.	Paclitaxel	88-93	forkhead box O1	Homo sapiens	48-53
19826044-10	2009	These data reveal a previously uncharacterized, FOXO1-mediated, AR-inhibitory effect of Taxol in CRPC cells that may play an important role in Taxol-mediated inhibition of CRPC growth.	Paclitaxel	88-93	androgen receptor	Homo sapiens	64-66
19826044-10	2009	These data reveal a previously uncharacterized, FOXO1-mediated, AR-inhibitory effect of Taxol in CRPC cells that may play an important role in Taxol-mediated inhibition of CRPC growth.	Paclitaxel	143-148	forkhead box O1	Homo sapiens	48-53
19826044-10	2009	These data reveal a previously uncharacterized, FOXO1-mediated, AR-inhibitory effect of Taxol in CRPC cells that may play an important role in Taxol-mediated inhibition of CRPC growth.	Paclitaxel	143-148	androgen receptor	Homo sapiens	64-66
19609211-7	2009	In addition, mtDNA-depleted cells displayed a decreased sensitivity and accumulation of chemotherapeutic drugs (doxorubicin, vincristine, and paclitaxel), potentially because of the upregulated expression of multidrug resistance 1 (MDR1) gene and its product P-glycoprotein.	Paclitaxel	142-152	ATP binding cassette subfamily B member 1	Homo sapiens	208-230
19415457-3	2009	Moreover, Taxol-induced apoptosis was associated with caspase-3 activation.	Paclitaxel	10-15	caspase 3	Homo sapiens	54-63
19623660-9	2009	Inhibition of STAT3 by AG490 followed by treatment with cisplatin or taxol resulted in a significant increase in apoptosis suggesting that hypoxia-induced STAT3 activation is responsible for chemoresistance.	Paclitaxel	69-74	signal transducer and activator of transcription 3	Homo sapiens	155-160
19632322-0	2009	Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells.	Paclitaxel	73-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
19843632-9	2009	Furthermore, we showed that acquired TRAIL resistance was effectively eliminated by combination with etoposide, doxorubicin, or paclitaxel.	Paclitaxel	128-138	TNF superfamily member 10	Homo sapiens	37-42
19887543-0	2009	A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.	Paclitaxel	19-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
19887543-0	2009	A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.	Paclitaxel	19-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-106
19665996-0	2009	USP15 plays an essential role for caspase-3 activation during Paclitaxel-induced apoptosis.	Paclitaxel	62-72	ubiquitin specific peptidase 15	Homo sapiens	0-5
19665996-0	2009	USP15 plays an essential role for caspase-3 activation during Paclitaxel-induced apoptosis.	Paclitaxel	62-72	caspase 3	Homo sapiens	34-43
19665996-3	2009	Here, we screened an siRNA library against the entire human genomes using HeLa cells, and have find that lack of USP15 (ubiquitin-specific protease 15) causes Paclitaxel resistance.	Paclitaxel	159-169	ubiquitin specific peptidase 15	Homo sapiens	113-118
19665996-3	2009	Here, we screened an siRNA library against the entire human genomes using HeLa cells, and have find that lack of USP15 (ubiquitin-specific protease 15) causes Paclitaxel resistance.	Paclitaxel	159-169	ubiquitin specific peptidase 15	Homo sapiens	120-150
19665996-4	2009	We also observed the decreased expression of USP15 in Paclitaxel-resistant human ovarian cancer samples.	Paclitaxel	54-64	ubiquitin specific peptidase 15	Homo sapiens	45-50
19665996-5	2009	In addition, we have demonstrated that USP15 plays an essential role for stability and activity of caspase-3 during Paclitaxel-induced apoptosis.	Paclitaxel	116-126	ubiquitin specific peptidase 15	Homo sapiens	39-44
19665996-5	2009	In addition, we have demonstrated that USP15 plays an essential role for stability and activity of caspase-3 during Paclitaxel-induced apoptosis.	Paclitaxel	116-126	caspase 3	Homo sapiens	99-108
19665996-6	2009	Thus, USP15 may be a candidate diagnostic marker and therapeutic target for Paclitaxel-resistant cancers.	Paclitaxel	76-86	ubiquitin specific peptidase 15	Homo sapiens	6-11
19823672-4	2009	Coincubating cells with a sublethal concentration of paclitaxel in combination with each of 2,000 small molecule compounds from the National Cancer Institute Diversity Set Library, we identified a previously uncharacterized molecule, NSC23925, that inhibits Pgp1 and reverses MDR1 (Pgp1) but does not inhibit MRP or BCRP-mediated MDR.	Paclitaxel	53-63	ATP binding cassette subfamily B member 1	Homo sapiens	276-280
19823672-4	2009	Coincubating cells with a sublethal concentration of paclitaxel in combination with each of 2,000 small molecule compounds from the National Cancer Institute Diversity Set Library, we identified a previously uncharacterized molecule, NSC23925, that inhibits Pgp1 and reverses MDR1 (Pgp1) but does not inhibit MRP or BCRP-mediated MDR.	Paclitaxel	53-63	ATP binding cassette subfamily C member 1	Homo sapiens	309-312
19887543-15	2009	IL-12 in combination with trastuzumab and paclitaxel therefore exhibits an acceptable toxicity profile and has activity in patients with HER2-overexpressing cancers.	Paclitaxel	42-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
19538176-2	2009	Recently, nanoparticle albumin-bound (nab) paclitaxel (nab-paclitaxel; Abraxane) has been approved in 2006 for use in patients with metastatic breast cancer who have failed in the combination chemotherapy, and so the nab-technology has attracted much interest in the anti-cancer drug delivery system.	Paclitaxel	43-53	albumin	Homo sapiens	23-30
19538176-2	2009	Recently, nanoparticle albumin-bound (nab) paclitaxel (nab-paclitaxel; Abraxane) has been approved in 2006 for use in patients with metastatic breast cancer who have failed in the combination chemotherapy, and so the nab-technology has attracted much interest in the anti-cancer drug delivery system.	Paclitaxel	59-69	albumin	Homo sapiens	23-30
19561399-5	2009	Pretreatment with z-VAD-FMK (a pan-caspase inhibitor) or z-IETD-FMK (a caspase-8 inhibitor) blocked TOS/paclitaxel cotreatment-induced PARP cleavage and apoptosis, suggesting that TOS potentiates the paclitaxel-induced apoptosis through enforced caspase 8 activation in H460 cells.	Paclitaxel	104-114	poly(ADP-ribose) polymerase 1	Homo sapiens	135-139
19561399-5	2009	Pretreatment with z-VAD-FMK (a pan-caspase inhibitor) or z-IETD-FMK (a caspase-8 inhibitor) blocked TOS/paclitaxel cotreatment-induced PARP cleavage and apoptosis, suggesting that TOS potentiates the paclitaxel-induced apoptosis through enforced caspase 8 activation in H460 cells.	Paclitaxel	200-210	poly(ADP-ribose) polymerase 1	Homo sapiens	135-139
19632322-1	2009	Paclitaxel (Tx)-loaded anti-HER2 immunonanoparticles (NPs-Tx-HER) were prepared by the covalent coupling of humanized monoclonal anti-HER2 antibodies (trastuzumab, Herceptin) to Tx-loaded poly (dl-lactic acid) nanoparticles (NPs-Tx) for the active targeting of tumor cells that overexpress HER2 receptors.	Paclitaxel	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-32
19632322-1	2009	Paclitaxel (Tx)-loaded anti-HER2 immunonanoparticles (NPs-Tx-HER) were prepared by the covalent coupling of humanized monoclonal anti-HER2 antibodies (trastuzumab, Herceptin) to Tx-loaded poly (dl-lactic acid) nanoparticles (NPs-Tx) for the active targeting of tumor cells that overexpress HER2 receptors.	Paclitaxel	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-138
19632322-1	2009	Paclitaxel (Tx)-loaded anti-HER2 immunonanoparticles (NPs-Tx-HER) were prepared by the covalent coupling of humanized monoclonal anti-HER2 antibodies (trastuzumab, Herceptin) to Tx-loaded poly (dl-lactic acid) nanoparticles (NPs-Tx) for the active targeting of tumor cells that overexpress HER2 receptors.	Paclitaxel	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-138
19473291-5	2009	We treated the cells with either 100 nM taxol or transfected with a plasmid vector expressing Bcl-2 siRNA or both agents together for 72 h. Knockdown of Bcl-2 potentiated efficacy of taxol for cell death.	Paclitaxel	40-45	BCL2 apoptosis regulator	Homo sapiens	153-158
19846942-6	2009	Doxycycline (5 microg/ml) below the cytotoxic level suppressed endogenous and paclitaxel-induced IL-8 expression.	Paclitaxel	78-88	C-X-C motif chemokine ligand 8	Homo sapiens	97-101
19363466-11	2009	The growth of SiHa xenograft tumors was reduced using paclitaxel combined with intronic and exonic siRNA, compared with exonic siRNA alone, confirming the synergistic relationship between p53 restoration and paclitaxel.	Paclitaxel	54-64	tumor protein p53	Homo sapiens	188-191
19363467-7	2009	The results confirmed the YB-1 dependency of Ad-Delo3-RGD and showed that Ad-Delo3-RGD has potent activity against human pancreatic cancer cells in vitro and in vivo, which was augmented by the addition of paclitaxel.	Paclitaxel	206-216	Y-box binding protein 1	Homo sapiens	26-30
19720916-13	2009	CONCLUSION: Neoadjuvant carboplatin and weekly paclitaxel +/- trastuzumab achieve high pCR rates in patients with HER2-positive and triple-negative disease without exposure to an anthracycline.	Paclitaxel	47-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-118
19473291-5	2009	We treated the cells with either 100 nM taxol or transfected with a plasmid vector expressing Bcl-2 siRNA or both agents together for 72 h. Knockdown of Bcl-2 potentiated efficacy of taxol for cell death.	Paclitaxel	183-188	BCL2 apoptosis regulator	Homo sapiens	94-99
19473291-5	2009	We treated the cells with either 100 nM taxol or transfected with a plasmid vector expressing Bcl-2 siRNA or both agents together for 72 h. Knockdown of Bcl-2 potentiated efficacy of taxol for cell death.	Paclitaxel	183-188	BCL2 apoptosis regulator	Homo sapiens	153-158
19821097-8	2009	These results suggested that transfection of pEGFP-H1/mdr1 could efficiently down-regulate the expression of mdr1 mRNA and P-gp in A2780/Taxol cells, and effectively restore the sensitivity of A2780/Taxol cells to Taxol both in vitro and in vivo.	Paclitaxel	137-142	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	54-58
19821097-8	2009	These results suggested that transfection of pEGFP-H1/mdr1 could efficiently down-regulate the expression of mdr1 mRNA and P-gp in A2780/Taxol cells, and effectively restore the sensitivity of A2780/Taxol cells to Taxol both in vitro and in vivo.	Paclitaxel	137-142	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	109-113
20079104-5	2009	The expressions of transcription factor TWIST at both mRNA and protein level in response to paclitaxel at 24 h, 48 h and 72 h were then examined by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot, respectively.	Paclitaxel	92-102	twist family bHLH transcription factor 1	Homo sapiens	40-45
19794992-0	2009	Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.	Paclitaxel	7-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
19794992-1	2009	We evaluated the efficacy and safety of weekly paclitaxel plus trastuzumab as first-line chemotherapy in women with HER2-overexpressing metastatic breast cancer (MBC), and we investigated the prognostic factors including magnitude of HER2/neu amplification in this population.	Paclitaxel	47-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
19794992-2	2009	We analyzed 54 patients with HER2-overexpressing MBC that were treated with weekly paclitaxel plus trastuzumab as first-line chemotherapy from February 2004 to December 2006.	Paclitaxel	83-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
19834284-6	2009	Similar combination effects of obovatol with other chemotherapeutic agents (paclitaxel, cisplatin, and doxorubicin) on the inhibition of cell growth and NF-kappaB activity were also found.	Paclitaxel	76-86	nuclear factor kappa B subunit 1	Homo sapiens	153-162
19918289-2	2009	The Her2/neu receptor tyrosine kinase, overexpressed by half of all primary urothelial carcinomas, has recently been examined as a therapeutic target in bladder cancer in a prospective phase II multicenter trial (NCI-198) that enrolled 109 patients with advanced bladder carcinomas for treatment with trastuzumab in combination with paclitaxel, carboplatin, and gemcitabine.	Paclitaxel	333-343	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-37
19671798-0	2009	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	29-34
19671798-0	2009	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77.	Paclitaxel	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	71-76
19671798-1	2009	We reported previously that Bcl-2 is paradoxically down-regulated in paclitaxel-resistant cancer cells.	Paclitaxel	69-79	BCL2 apoptosis regulator	Homo sapiens	28-33
19671798-2	2009	We reveal here that paclitaxel directly targets Bcl-2 in the loop domain, thereby facilitating the initiation of apoptosis.	Paclitaxel	20-30	BCL2 apoptosis regulator	Homo sapiens	48-53
19671798-3	2009	Molecular modeling revealed an extraordinary similarity between the paclitaxel binding sites in Bcl-2 and beta-tubulin, leading us to speculate that paclitaxel could be mimetic of an endogenous peptide ligand, which binds both proteins.	Paclitaxel	68-78	BCL2 apoptosis regulator	Homo sapiens	96-101
19671798-3	2009	Molecular modeling revealed an extraordinary similarity between the paclitaxel binding sites in Bcl-2 and beta-tubulin, leading us to speculate that paclitaxel could be mimetic of an endogenous peptide ligand, which binds both proteins.	Paclitaxel	149-159	BCL2 apoptosis regulator	Homo sapiens	96-101
19671798-4	2009	We tested the hypothesis that paclitaxel mimics Nur77, which, like paclitaxel, changes the function of Bcl-2.	Paclitaxel	30-40	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-53
19671798-4	2009	We tested the hypothesis that paclitaxel mimics Nur77, which, like paclitaxel, changes the function of Bcl-2.	Paclitaxel	30-40	BCL2 apoptosis regulator	Homo sapiens	103-108
19671798-4	2009	We tested the hypothesis that paclitaxel mimics Nur77, which, like paclitaxel, changes the function of Bcl-2.	Paclitaxel	67-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	48-53
19671798-4	2009	We tested the hypothesis that paclitaxel mimics Nur77, which, like paclitaxel, changes the function of Bcl-2.	Paclitaxel	67-77	BCL2 apoptosis regulator	Homo sapiens	103-108
19671798-5	2009	This premise was confirmed by Nur77 interacting with both paclitaxel targets (Bcl-2 and beta-tubulin) and a peptide sequence mimicking the Nur77 structural region, thus reproducing the paclitaxel-like effects of tubulin polymerization and opening the permeability transition pore channel in mitochondria.	Paclitaxel	58-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-35
19671798-5	2009	This premise was confirmed by Nur77 interacting with both paclitaxel targets (Bcl-2 and beta-tubulin) and a peptide sequence mimicking the Nur77 structural region, thus reproducing the paclitaxel-like effects of tubulin polymerization and opening the permeability transition pore channel in mitochondria.	Paclitaxel	58-68	BCL2 apoptosis regulator	Homo sapiens	78-83
19671798-5	2009	This premise was confirmed by Nur77 interacting with both paclitaxel targets (Bcl-2 and beta-tubulin) and a peptide sequence mimicking the Nur77 structural region, thus reproducing the paclitaxel-like effects of tubulin polymerization and opening the permeability transition pore channel in mitochondria.	Paclitaxel	185-195	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-35
19671798-5	2009	This premise was confirmed by Nur77 interacting with both paclitaxel targets (Bcl-2 and beta-tubulin) and a peptide sequence mimicking the Nur77 structural region, thus reproducing the paclitaxel-like effects of tubulin polymerization and opening the permeability transition pore channel in mitochondria.	Paclitaxel	185-195	BCL2 apoptosis regulator	Homo sapiens	78-83
19671798-5	2009	This premise was confirmed by Nur77 interacting with both paclitaxel targets (Bcl-2 and beta-tubulin) and a peptide sequence mimicking the Nur77 structural region, thus reproducing the paclitaxel-like effects of tubulin polymerization and opening the permeability transition pore channel in mitochondria.	Paclitaxel	185-195	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-144
19674193-5	2009	Here, we have shown that taxol and vinblastine induce multiple arms of the ER stress response, including up-regulation of glucose-regulated protein 78 (GRP78) expression, X-box binding protein 1 splicing and eukaryotic initiation factor 2alpha phosphorylation.	Paclitaxel	25-30	heat shock protein family A (Hsp70) member 5	Homo sapiens	122-150
19674193-5	2009	Here, we have shown that taxol and vinblastine induce multiple arms of the ER stress response, including up-regulation of glucose-regulated protein 78 (GRP78) expression, X-box binding protein 1 splicing and eukaryotic initiation factor 2alpha phosphorylation.	Paclitaxel	25-30	heat shock protein family A (Hsp70) member 5	Homo sapiens	152-157
19674193-6	2009	Abrogation of GRP78 induction sensitizes breast cancer cells to taxol and vinblastine.	Paclitaxel	64-69	heat shock protein family A (Hsp70) member 5	Homo sapiens	14-19
19674193-7	2009	Treatment with (-)-epigallocatechin gallate (EGCG), a known GRP78 inhibitor, synergistically promotes taxol- and vinblastine-induced cell death.	Paclitaxel	102-107	heat shock protein family A (Hsp70) member 5	Homo sapiens	60-65
19674193-8	2009	GRP78 knockdown or EGCG potentiates taxol- and vinblastine-induced activation of pro-apoptosis arms of the ER stress response, such as JNK phosphorylation, caspase-7 and PARP cleavage.	Paclitaxel	36-41	heat shock protein family A (Hsp70) member 5	Homo sapiens	0-5
19674193-8	2009	GRP78 knockdown or EGCG potentiates taxol- and vinblastine-induced activation of pro-apoptosis arms of the ER stress response, such as JNK phosphorylation, caspase-7 and PARP cleavage.	Paclitaxel	36-41	mitogen-activated protein kinase 8	Homo sapiens	135-138
19674193-9	2009	Inhibition of JNK and caspase-7 abrogates EGCG sensitization of breast cancer cells to taxol and vinblastine.	Paclitaxel	87-92	mitogen-activated protein kinase 8	Homo sapiens	14-17
19755824-13	2009	These findings suggest that combination therapy with trastuzumab+paclitaxel is effective as a primary therapy for HER2-positive advanced breast cancer.	Paclitaxel	65-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-118
20079104-0	2009	[Role of TWIST in the apoptosis of Hep-2 cells induced by paclitaxel].	Paclitaxel	58-68	twist family bHLH transcription factor 1	Homo sapiens	9-14
20079104-1	2009	OBJECTIVE: To explore the relationship between the expression of transcription factor TWIST and apoptosis of Hep-2 cells induced by paclitaxel.	Paclitaxel	132-142	twist family bHLH transcription factor 1	Homo sapiens	86-91
20079104-10	2009	The expression of TWIST at both mRNA and protein levels for 24 h, 48 h or 72 h in the paclitaxel-induced apoptosis of Hep-2 cells were decreased by 16.7%, 46.8%, 76.9% (F = 10.407, P &lt; 0.05) and 16.4%, 33.6%, 69.6% (F = 18.013, P &lt; 0.05) respectively.	Paclitaxel	86-96	twist family bHLH transcription factor 1	Homo sapiens	18-23
20079104-11	2009	CONCLUSIONS: TWIST, which is significantly decreased in expression in response to paclitaxel in Hep-2 cells, may play a pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.	Paclitaxel	82-92	twist family bHLH transcription factor 1	Homo sapiens	13-18
20079104-11	2009	CONCLUSIONS: TWIST, which is significantly decreased in expression in response to paclitaxel in Hep-2 cells, may play a pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.	Paclitaxel	136-146	twist family bHLH transcription factor 1	Homo sapiens	13-18
19664330-11	2009	The protein level of Bcl-2 was the lowest in BEL-7402 cells treated with sorafenib after paclitaxel.	Paclitaxel	89-99	BCL2 apoptosis regulator	Homo sapiens	21-26
19410561-4	2009	FG020326 significantly potentiated the cytotoxicity of paclitaxel, doxorubicin, and vincristine in the ABCB1 (P-glycoprotein, P-gp) overexpressing cells KBv200 and MCF-7/adr, but not in the ABCB1 negative parental cell lines KB and MCF-7.	Paclitaxel	55-65	ATP binding cassette subfamily B member 1	Homo sapiens	103-108
19410561-4	2009	FG020326 significantly potentiated the cytotoxicity of paclitaxel, doxorubicin, and vincristine in the ABCB1 (P-glycoprotein, P-gp) overexpressing cells KBv200 and MCF-7/adr, but not in the ABCB1 negative parental cell lines KB and MCF-7.	Paclitaxel	55-65	ATP binding cassette subfamily B member 1	Homo sapiens	110-124
19521235-5	2009	Knockdown of MEK resulted in a significant downregulation of paclitaxel-induced upregulation of GRP78 indicating that activation of GRP78 is a downstream event of MEK/ERK pathway activation.	Paclitaxel	61-71	mitogen-activated protein kinase 1	Homo sapiens	167-170
19723066-7	2009	Our results indicate and support the hypothesis that the apoptosis-related genes BCL2 and BCL2L12 respond similarly to treatment of the human, acute, myelocytic leukemia HL60 cells with the anticancer drugs vincristine and taxol though in a drug-specific and time-dependent manner.	Paclitaxel	223-228	BCL2 apoptosis regulator	Homo sapiens	81-85
19661300-10	2009	Both SB-T-1216 and paclitaxel activated caspase-3, caspase-9, caspase-2 and caspase-8 in sensitive as well as resistant cells.	Paclitaxel	19-29	caspase 3	Homo sapiens	40-49
19521235-0	2009	Inhibition of MEK sensitizes paclitaxel-induced apoptosis of human colorectal cancer cells by downregulation of GRP78.	Paclitaxel	29-39	mitogen-activated protein kinase kinase 7	Homo sapiens	14-17
19521235-0	2009	Inhibition of MEK sensitizes paclitaxel-induced apoptosis of human colorectal cancer cells by downregulation of GRP78.	Paclitaxel	29-39	heat shock protein family A (Hsp70) member 5	Homo sapiens	112-117
19521235-2	2009	Paclitaxel induces multiple arms of the endoplasmic reticulum stress response, including upregulation of the 78-kDa glucose-regulatory protein (GRP78) and eukaryotic initiation factor alpha phosphorylation.	Paclitaxel	0-10	heat shock protein family A (Hsp70) member 5	Homo sapiens	144-149
19521235-3	2009	Inhibition of the MEK/ERK pathway sensitized colorectal cancer cells to paclitaxel-induced apoptosis.	Paclitaxel	72-82	mitogen-activated protein kinase kinase 7	Homo sapiens	18-21
19521235-3	2009	Inhibition of the MEK/ERK pathway sensitized colorectal cancer cells to paclitaxel-induced apoptosis.	Paclitaxel	72-82	mitogen-activated protein kinase 1	Homo sapiens	22-25
19521235-5	2009	Knockdown of MEK resulted in a significant downregulation of paclitaxel-induced upregulation of GRP78 indicating that activation of GRP78 is a downstream event of MEK/ERK pathway activation.	Paclitaxel	61-71	mitogen-activated protein kinase kinase 7	Homo sapiens	13-16
19521235-5	2009	Knockdown of MEK resulted in a significant downregulation of paclitaxel-induced upregulation of GRP78 indicating that activation of GRP78 is a downstream event of MEK/ERK pathway activation.	Paclitaxel	61-71	heat shock protein family A (Hsp70) member 5	Homo sapiens	96-101
19521235-5	2009	Knockdown of MEK resulted in a significant downregulation of paclitaxel-induced upregulation of GRP78 indicating that activation of GRP78 is a downstream event of MEK/ERK pathway activation.	Paclitaxel	61-71	heat shock protein family A (Hsp70) member 5	Homo sapiens	132-137
19521235-5	2009	Knockdown of MEK resulted in a significant downregulation of paclitaxel-induced upregulation of GRP78 indicating that activation of GRP78 is a downstream event of MEK/ERK pathway activation.	Paclitaxel	61-71	mitogen-activated protein kinase kinase 7	Homo sapiens	163-166
19459857-5	2009	With BMA, TXL triggered mitochondrial membrane potential loss and cytochrome c release, whereas downstream caspase activation was not observed.	Paclitaxel	10-13	cytochrome c, somatic	Homo sapiens	66-78
19125251-5	2009	RESULTS: RAIDD showed signs of significant expression in the U-2 OS cells after being treated with paclitaxel (P &lt; 0.01).	Paclitaxel	99-109	CASP2 and RIPK1 domain containing adaptor with death domain	Homo sapiens	9-14
19125251-7	2009	Subsequent analysis by Western blot confirmed the deficiency of the expression of RAIDD protein in U-2 OS MR. On the contrary, the expression of RAIDD could be significantly induced by paclitaxel and doxorubicin in U-2 OS cells as both time and dosage were deciding factors.	Paclitaxel	185-195	CASP2 and RIPK1 domain containing adaptor with death domain	Homo sapiens	145-150
19443905-3	2009	Treatment of breast cancer cells with PRL caused variable resistance to taxol, vinblastine, doxorubicin and cisplatin.	Paclitaxel	72-77	prolactin	Homo sapiens	38-41
19530913-0	2009	Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model.	Paclitaxel	0-10	transferrin	Rattus norvegicus	59-70
19580321-3	2009	In this study, we present a combined magic angle spinning solid-state and solution NMR study of the MTBP CAP-Gly domain of mammalian dynactin and its interaction with paclitaxel-stabilized microtubules.	Paclitaxel	167-177	MDM2 binding protein	Homo sapiens	100-104
19691751-7	2009	We administered paclitaxel and trastuzumab according to a protocol for HER2-positive metastatic breast cancers.	Paclitaxel	16-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
19691751-10	2009	Trastuzumab and paclitaxel-combination with the assessment of central nervous system lesions should be considered as an option for the treatment of HER2-positive EMPD.	Paclitaxel	16-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
19663667-0	2009	Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.	Paclitaxel	81-91	vascular endothelial growth factor A	Homo sapiens	32-38
19663667-2	2009	In the present case we report a discordant VEGF-A genotype between tumor and normal tissue in a patient with a responsive hepatic lesion of chemoresistant breast cancer treated with bevacizumab and paclitaxel.	Paclitaxel	198-208	vascular endothelial growth factor A	Homo sapiens	43-49
19619321-1	2009	BACKGROUND: We previously described a sub-population of epithelial ovarian cancer (EOC) cells with a functional TLR-4/MyD88/NF-kappaB pathway (Type I EOC cells), which confers the capacity to respond to Paclitaxel, a known TLR-4 ligand, by enhancing NF-kappaB activity and upregulating cytokine secretion - events that are known to promote tumor progression.	Paclitaxel	203-213	nuclear factor kappa B subunit 1	Homo sapiens	124-133
19619321-15	2009	CONCLUSION: Administration of Paclitaxel to patients with high percentage Type I cancer cells could have detrimental effects due to Paclitaxel-induced enhancement of NF-kappaB and ERK activities, and cytokine production (e.g. IL-6), which promote chemoresistance and tumor progression.	Paclitaxel	30-40	nuclear factor kappa B subunit 1	Homo sapiens	166-175
19619321-15	2009	CONCLUSION: Administration of Paclitaxel to patients with high percentage Type I cancer cells could have detrimental effects due to Paclitaxel-induced enhancement of NF-kappaB and ERK activities, and cytokine production (e.g. IL-6), which promote chemoresistance and tumor progression.	Paclitaxel	30-40	mitogen-activated protein kinase 1	Homo sapiens	180-183
19619321-15	2009	CONCLUSION: Administration of Paclitaxel to patients with high percentage Type I cancer cells could have detrimental effects due to Paclitaxel-induced enhancement of NF-kappaB and ERK activities, and cytokine production (e.g. IL-6), which promote chemoresistance and tumor progression.	Paclitaxel	30-40	interleukin 6	Homo sapiens	226-230
19619321-15	2009	CONCLUSION: Administration of Paclitaxel to patients with high percentage Type I cancer cells could have detrimental effects due to Paclitaxel-induced enhancement of NF-kappaB and ERK activities, and cytokine production (e.g. IL-6), which promote chemoresistance and tumor progression.	Paclitaxel	132-142	nuclear factor kappa B subunit 1	Homo sapiens	166-175
19619321-15	2009	CONCLUSION: Administration of Paclitaxel to patients with high percentage Type I cancer cells could have detrimental effects due to Paclitaxel-induced enhancement of NF-kappaB and ERK activities, and cytokine production (e.g. IL-6), which promote chemoresistance and tumor progression.	Paclitaxel	132-142	mitogen-activated protein kinase 1	Homo sapiens	180-183
19619321-15	2009	CONCLUSION: Administration of Paclitaxel to patients with high percentage Type I cancer cells could have detrimental effects due to Paclitaxel-induced enhancement of NF-kappaB and ERK activities, and cytokine production (e.g. IL-6), which promote chemoresistance and tumor progression.	Paclitaxel	132-142	interleukin 6	Homo sapiens	226-230
19364972-12	2009	CONCLUSION High GGI is associated with increased sensitivity to neoadjuvant paclitaxel plus fluorouracil, adriamycin, and cyclophosphamide chemotherapy in both ER-negative and ER-positive patients, but it remains a predictor of worse survival in ER-positive patients.	Paclitaxel	76-86	estrogen receptor 1	Homo sapiens	160-162
19596939-0	2009	VEGF in patients with non-small cell lung cancer during combination chemotherapy of carboplatin and paclitaxel.	Paclitaxel	100-110	vascular endothelial growth factor A	Homo sapiens	0-4
19746521-5	2009	Preactivation of hPXR by SR12813 in MDA-MB-231 cells led to an increased resistance to Taxol at concentrations of 20 and 50 nmol/L.	Paclitaxel	87-92	nuclear receptor subfamily 1 group I member 2	Homo sapiens	17-21
19746521-8	2009	Furthermore, knockdown of hPXR via small hairpin RNA (shRNA) sensitized MDA-MB-231 and MCF-7 cells to the treatment of Taxol, vinblastine or tamoxifen.	Paclitaxel	119-124	nuclear receptor subfamily 1 group I member 2	Homo sapiens	26-30
19427995-4	2009	Here, we report for the first time that nilotinib potentiates the cytotoxicity of widely used therapeutic substrates of ABCG2, such as mitoxantrone, doxorubicin, and ABCB1 substrates including colchicine, vincristine, and paclitaxel.	Paclitaxel	222-232	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	120-125
19427995-5	2009	Nilotinib also significantly enhances the accumulation of paclitaxel in cell lines overexpressing ABCB1.	Paclitaxel	58-68	ATP binding cassette subfamily B member 1	Homo sapiens	98-103
19052714-0	2009	TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.	Paclitaxel	107-117	tumor protein p53	Homo sapiens	0-4
19052714-6	2009	CONCLUSION: The TP53 codon 72 SNP was found to be predictive of the response to chemotherapy and correlate with the time to progression in patients with advanced gastric cancer treated with paclitaxel and cisplatin chemotherapy.	Paclitaxel	190-200	tumor protein p53	Homo sapiens	16-20
19409381-8	2009	Furthermore, we show that recombinant human erythropoietin, which had been shown to be neuroprotective against paclitaxel neurotoxicity, provides neuroprotection whether it is applied to the cell body or the axons directly.	Paclitaxel	111-121	erythropoietin	Homo sapiens	44-58
19364972-12	2009	CONCLUSION High GGI is associated with increased sensitivity to neoadjuvant paclitaxel plus fluorouracil, adriamycin, and cyclophosphamide chemotherapy in both ER-negative and ER-positive patients, but it remains a predictor of worse survival in ER-positive patients.	Paclitaxel	76-86	estrogen receptor 1	Homo sapiens	176-178
19364972-12	2009	CONCLUSION High GGI is associated with increased sensitivity to neoadjuvant paclitaxel plus fluorouracil, adriamycin, and cyclophosphamide chemotherapy in both ER-negative and ER-positive patients, but it remains a predictor of worse survival in ER-positive patients.	Paclitaxel	76-86	estrogen receptor 1	Homo sapiens	176-178
19394652-7	2009	Flow cytometric analysis revealed that addition of 10 microM AEA synergistically enhanced paclitaxel-induced apoptosis, possibly through the activation of caspase-3, -8, and -9.	Paclitaxel	90-100	caspase 3	Homo sapiens	155-176
19520256-5	2009	RESULTS: Treatment with paclitaxel, sirolimus, and everolimus significantly caused a senescent phenotype and PAI-1 up-regulation, associated with a decrease in endothelial nitric oxide synthase (eNOS) and Sirt1 expression.	Paclitaxel	24-34	nitric oxide synthase 3	Homo sapiens	160-193
19217709-0	2009	Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.	Paclitaxel	65-75	tumor protein p53	Homo sapiens	8-11
19217709-0	2009	Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.	Paclitaxel	65-75	prostaglandin-endoperoxide synthase 2	Homo sapiens	32-48
19217709-10	2009	For paclitaxel treatment, an increase in COX-2 mRNA expression was observed in H460 and A549 (wild-type p53 cell lines).	Paclitaxel	4-14	prostaglandin-endoperoxide synthase 2	Homo sapiens	41-46
19217709-10	2009	For paclitaxel treatment, an increase in COX-2 mRNA expression was observed in H460 and A549 (wild-type p53 cell lines).	Paclitaxel	4-14	tumor protein p53	Homo sapiens	104-107
19217709-11	2009	Moreover, paclitaxel treatment increased COX-2 expression in ACC-LC-319 cell lines (p53 null), showing a p53-independent effect.	Paclitaxel	10-20	prostaglandin-endoperoxide synthase 2	Homo sapiens	41-46
19217709-11	2009	Moreover, paclitaxel treatment increased COX-2 expression in ACC-LC-319 cell lines (p53 null), showing a p53-independent effect.	Paclitaxel	10-20	tumor protein p53	Homo sapiens	84-87
19217709-11	2009	Moreover, paclitaxel treatment increased COX-2 expression in ACC-LC-319 cell lines (p53 null), showing a p53-independent effect.	Paclitaxel	10-20	tumor protein p53	Homo sapiens	105-108
19451417-0	2009	Metronomic schedule of paclitaxel is effective in hormone receptor-positive and hormone receptor-negative breast cancer.	Paclitaxel	23-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	50-66
19451417-0	2009	Metronomic schedule of paclitaxel is effective in hormone receptor-positive and hormone receptor-negative breast cancer.	Paclitaxel	23-33	nuclear receptor subfamily 4 group A member 1	Homo sapiens	80-96
19957654-1	2009	OBJECTIVE: To determine the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced apoptosis in Hep-2 cells by means of systematically evaluating the cytotoxicity of TRAIL alone and TRAIL in combination with chemotherapeutic agents (cisplatin, paclitaxel) or radiation in Hep-2 cells in vitro, and whether the synergistic killing effects correlated with the expression level of TRAIL receptors and the activity of caspase-8 or caspase-9.	Paclitaxel	276-286	TNF superfamily member 10	Homo sapiens	43-98
19957654-1	2009	OBJECTIVE: To determine the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced apoptosis in Hep-2 cells by means of systematically evaluating the cytotoxicity of TRAIL alone and TRAIL in combination with chemotherapeutic agents (cisplatin, paclitaxel) or radiation in Hep-2 cells in vitro, and whether the synergistic killing effects correlated with the expression level of TRAIL receptors and the activity of caspase-8 or caspase-9.	Paclitaxel	276-286	TNF superfamily member 10	Homo sapiens	100-105
19957654-6	2009	Cisplatin, paclitaxel and radiation had synergistic inhibitory effects with TRAIL on the growth of Hep-2 cell line.	Paclitaxel	11-21	TNF superfamily member 10	Homo sapiens	76-81
19318912-7	2009	Paclitaxel LDM chemotherapy also dramatically upregulated the expression of thrombospondin-1, but MTD chemotherapy did not.	Paclitaxel	0-10	thrombospondin 1	Homo sapiens	76-92
19412666-9	2009	In combination with the drugs targeted to cytoskeleton (taxol, cytochalasin D) the mutants of TRAIL induced apoptosis in resistant Hela cells overexpressing Bcl-2.	Paclitaxel	56-61	TNF superfamily member 10	Homo sapiens	94-99
19412666-9	2009	In combination with the drugs targeted to cytoskeleton (taxol, cytochalasin D) the mutants of TRAIL induced apoptosis in resistant Hela cells overexpressing Bcl-2.	Paclitaxel	56-61	BCL2 apoptosis regulator	Homo sapiens	157-162
19397590-5	2009	Flow cytometry and fluorescence microscopy revealed that although As(2)O(3) alone caused a moderate level of mitotic arrest, it greatly attenuated paclitaxel-induced mitotic arrest in cells with p53 deficiency.	Paclitaxel	147-157	tumor protein p53	Homo sapiens	195-198
19123050-5	2009	However, MDR1 (1199A) cells displayed greater resistance to vinblastine, vincristine, paclitaxel, and VP-16 (11-, 2.9-, 1.9-, and 2.9-fold, respectively).	Paclitaxel	86-96	ATP binding cassette subfamily B member 1	Homo sapiens	9-13
19385049-5	2009	In the present study,the well-characterized human neuroblastoma cell line SH-SY5Y served as a model system to separate physiological and pro-apoptotic JNK actions in the response to the cytoskeleton-interfering substances colchicine, cytochalasin D and taxol.	Paclitaxel	253-258	mitogen-activated protein kinase 8	Homo sapiens	151-154
19385049-7	2009	Using the chemical JNK inhibitor SP600125 as well as compartment-specific JNK-inhibiting constructs and dominant negative isoform mutants, we show that the nuclear subgroup of JNK2 is the dominant effector in colchicine and taxol-induced apoptosis, while cell cycle promotion is mediated by both cytoplasmic and nuclear JNK2.In contrast, cytochalasin D-triggered apoptosis is independent of JNK signaling.	Paclitaxel	224-229	mitogen-activated protein kinase 9	Homo sapiens	176-180
18839173-2	2009	In addition to rifampicin and hyperforin, the anticancer drug paclitaxel has also been shown to be an inducer of CYP3A4 via activation of the pregnane X receptor (PXR).	Paclitaxel	62-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-119
18839173-2	2009	In addition to rifampicin and hyperforin, the anticancer drug paclitaxel has also been shown to be an inducer of CYP3A4 via activation of the pregnane X receptor (PXR).	Paclitaxel	62-72	nuclear receptor subfamily 1 group I member 2	Homo sapiens	142-161
18839173-2	2009	In addition to rifampicin and hyperforin, the anticancer drug paclitaxel has also been shown to be an inducer of CYP3A4 via activation of the pregnane X receptor (PXR).	Paclitaxel	62-72	nuclear receptor subfamily 1 group I member 2	Homo sapiens	163-166
18839173-7	2009	RESULTS: Paclitaxel, erlotinib, tamoxifen, ifosfamide, flutamide and docetaxel are able to activate PXR, while only strong PXR activation leads to significant induction of CYP3A4 activity.	Paclitaxel	9-19	nuclear receptor subfamily 1 group I member 2	Homo sapiens	100-103
18839173-7	2009	RESULTS: Paclitaxel, erlotinib, tamoxifen, ifosfamide, flutamide and docetaxel are able to activate PXR, while only strong PXR activation leads to significant induction of CYP3A4 activity.	Paclitaxel	9-19	nuclear receptor subfamily 1 group I member 2	Homo sapiens	123-126
18839173-7	2009	RESULTS: Paclitaxel, erlotinib, tamoxifen, ifosfamide, flutamide and docetaxel are able to activate PXR, while only strong PXR activation leads to significant induction of CYP3A4 activity.	Paclitaxel	9-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	172-178
19424586-8	2009	Simultaneous treatment with TAO with paclitaxel resulted in an increased percentage of apoptotic cells and a significant increase in PARP cleavage and caspase-3 activation in the gastric and cervix cancer cells compared to TAO alone as well as the antagonistic groups (TAO with 5-FU or cisplatin).	Paclitaxel	37-47	poly(ADP-ribose) polymerase 1	Homo sapiens	133-137
19487283-7	2009	Up-regulation of CD and down-regulation of eEF1 seemed to be specific to senescence, as they were observed during cellular senescence induced by hydrogen peroxide or anticancer drugs (camptothecin, etoposide, or 50 ng doxorubicin) but not during apoptosis induced by Taxol or 10 microg doxorubicin or autophagy induced by tamoxifen.	Paclitaxel	267-272	eukaryotic translation elongation factor 1 beta 2	Homo sapiens	43-47
19487294-7	2009	Additionally, down-regulation of vHNF1 expression in OV207 and TOV-21G cells increased cisplatin- or paclitaxel-mediated cytotoxicity as determined by both 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and clonogenic assays and this effect was reversed by down-regulation of HSulf-1.	Paclitaxel	101-111	HNF1 homeobox B	Homo sapiens	33-38
19487294-8	2009	Moreover, nude mice bearing TOV-21G cell xenografts with stably down-regulated vHNF1 were more sensitive to cisplatin- or paclitaxel-induced cytotoxicity compared with xenografts of TOV-21G clonal lines with nontargeted control short hairpin RNA.	Paclitaxel	122-132	HNF1 homeobox B	Homo sapiens	79-84
19424586-8	2009	Simultaneous treatment with TAO with paclitaxel resulted in an increased percentage of apoptotic cells and a significant increase in PARP cleavage and caspase-3 activation in the gastric and cervix cancer cells compared to TAO alone as well as the antagonistic groups (TAO with 5-FU or cisplatin).	Paclitaxel	37-47	caspase 3	Homo sapiens	151-160
19491198-7	2009	Using a model system of paired breast cancer cell lines, we found that coactivation of STAT5 and STAT3 leads to decreased proliferation and increased sensitivity to the chemotherapeutic drugs paclitaxel and vinorelbine compared with cells that have only STAT3 activation.	Paclitaxel	192-202	signal transducer and activator of transcription 3	Homo sapiens	97-102
19461204-0	2009	The role of Bcl-xL and nuclear factor-kappaB in the effect of taxol on the viability of dendritic cells.	Paclitaxel	62-67	BCL2 like 1	Homo sapiens	12-18
19461204-0	2009	The role of Bcl-xL and nuclear factor-kappaB in the effect of taxol on the viability of dendritic cells.	Paclitaxel	62-67	nuclear factor kappa B subunit 1	Homo sapiens	23-44
19461204-4	2009	In the present study, flow cytometric analyses revealed that taxol treatment significantly increased the number of viable DCs and the expression levels of a representative anti-apoptotic protein Bcl-xL.	Paclitaxel	61-66	BCL2 like 1	Homo sapiens	195-201
19461204-6	2009	An inhibition assay using N-p-tosyl-(L)-phenylalanine chloromethyl ketone confirmed that NF-kappaB was intimately involved in the effects of taxol on DC viability.	Paclitaxel	141-146	nuclear factor kappa B subunit 1	Homo sapiens	89-98
19332559-3	2009	p53 has long been known to be activated by spindle poisons, such as nocodazole and Taxol, although the underlying mechanism remains elusive.	Paclitaxel	83-88	tumor protein p53	Homo sapiens	0-3
19424643-8	2009	It enhanced the sensitivity of A2780/taxol cells to paclitaxel with down-regulation of P-glycoprotein, XIAP and survivin.	Paclitaxel	52-62	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
19954024-0	2009	[Down-regulation of Twist1 increases the sensitivity of nasopharyngeal carcinoma cell lines HNE1 to taxol].	Paclitaxel	100-105	twist family bHLH transcription factor 1	Homo sapiens	20-26
19954024-1	2009	OBJECTIVE: To investigate whether down-regulation of Twist1 could change sensitivity of nasopharyngeal carcinoma cell line HNE1 to taxol.	Paclitaxel	131-136	twist family bHLH transcription factor 1	Homo sapiens	53-59
19954024-5	2009	Drug sensitivity of si-Twist1 HNE1 to taxol was determined by Annexin V-fluorescein isothiocyanate( FITC)/propidium lodide (PI) double-labeled flow cytometry and detection of DNA ladder.	Paclitaxel	38-43	twist family bHLH transcription factor 1	Homo sapiens	23-29
19954024-13	2009	CONCLUSIONS: Down-regulation of Twist1 could increase drug sensitivity of nasopharyngeal carcinoma cell line HNE1 to taxol by inducing apoptosis.	Paclitaxel	117-122	twist family bHLH transcription factor 1	Homo sapiens	32-38
19138818-0	2009	G-T haplotype (2677G&gt;T/A and 3435C&gt;T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern.	Paclitaxel	113-123	ATP binding cassette subfamily B member 1	Homo sapiens	47-52
19138818-6	2009	Ethnic differences in the G-T haplotype of the ABCB1 gene may be a biomarker for paclitaxel sensitivity, and future clinical validation is necessary to confirm our findings.	Paclitaxel	81-91	ATP binding cassette subfamily B member 1	Homo sapiens	47-52
19285047-8	2009	Collectively, the combination of 4-HPR and PTX diminished the survival factors (e.g., rTERT, PCNA, and Bcl-2) to make glioblastoma cells highly prone to apoptosis with activation of cysteine proteases (e.g., calpain, cathepsins, caspase-8, caspase-3).	Paclitaxel	43-46	BCL2, apoptosis regulator	Rattus norvegicus	103-108
19247716-0	2009	MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol.	Paclitaxel	108-113	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
19247716-0	2009	MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol.	Paclitaxel	108-113	vascular endothelial growth factor A	Homo sapiens	14-18
19247716-7	2009	RESULTS: The MDR cell line induced by Taxol (Hep-2T cell) was more invasive than its parent cell line (Hep-2 cell), which was at least in part mediated through the overexpressed MDR1/P-pg.	Paclitaxel	38-43	ATP binding cassette subfamily B member 1	Homo sapiens	178-182
19247716-7	2009	RESULTS: The MDR cell line induced by Taxol (Hep-2T cell) was more invasive than its parent cell line (Hep-2 cell), which was at least in part mediated through the overexpressed MDR1/P-pg.	Paclitaxel	38-43	serglycin	Homo sapiens	183-187
19447868-1	2009	PURPOSE: Vandetanib [vascular endothelial growth factor (VEGF) receptor/epidermal growth factor receptor/RET inhibitor] has shown improvements in progression-free survival (PFS) in advanced non-small cell lung cancer in three randomized phase II studies: vandetanib versus gefitinib (study 3), docetaxel +/- vandetanib (study 6), and carboplatin-paclitaxel and/or vandetanib (study 7).	Paclitaxel	346-356	vascular endothelial growth factor A	Homo sapiens	21-55
19282281-7	2009	Instead, we demonstrate that two residues found in beta5 (Ser-239 and Ser-365) are each sufficient to inhibit microtubule assembly and confer paclitaxel resistance when introduced into beta1-tubulin; yet the single mutation of residue Ser-239 in beta5 eliminates its ability to confer these phenotypes.	Paclitaxel	142-152	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	185-190
19645775-4	2009	We hypothesize that blocking NF-kappaB activity may augment paclitaxel cancer chemotherapy.	Paclitaxel	60-70	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	29-38
19383919-0	2009	Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.	Paclitaxel	16-26	ATP binding cassette subfamily B member 1	Homo sapiens	104-118
18828019-3	2009	METHODS: We evaluate the association between expression of Pgp1, MRP1, and BCRP proteins and ET-743 or PM00104 resistance in a large panel of multi-drug resistant cell lines derived from histologically unrelated human tumors that were selected with paclitaxel, doxorubicin, cisplatin, mitoxantrane, or gemcitibine.	Paclitaxel	249-259	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	75-79
18828019-4	2009	RESULTS: Paclitaxel selected resistant cell lines expressed high levels of ABCB1 (but not ABCC1 or ABCG2/BCRP) did not demonstrate cross-resistance to either ET-743 or PM00104.	Paclitaxel	9-19	ATP binding cassette subfamily B member 1	Homo sapiens	75-80
18828019-8	2009	siRNA down-regulation of ABCB1 expression in doxorubicin selected cell lines caused partial sensitization to both doxorubicin and paclitaxel but not to either ET-743 or PM00104.	Paclitaxel	130-140	ATP binding cassette subfamily B member 1	Homo sapiens	25-30
19645775-5	2009	In this study, we investigated whether the inactivation of NF-kappaB by curcumin would enhance the efficacy of paclitaxel for inhibiting breast cancer growth in vitro and in vivo.	Paclitaxel	111-121	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	59-68
19645775-6	2009	We confirmed that curcumin inhibited paclitaxel-induced activation of NF-kappaB and potentiated the growth inhibitory effect of paclitaxel in MDA-MB-231 breast cancer cells.	Paclitaxel	37-47	nuclear factor kappa B subunit 1	Homo sapiens	70-79
19389529-0	2009	Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.	Paclitaxel	107-117	mechanistic target of rapamycin kinase	Homo sapiens	46-50
19340624-6	2009	We have shown that paclitaxel increases the expression of ERalpha and ERbeta mRNA in MCF-7 line.	Paclitaxel	19-29	estrogen receptor 1	Homo sapiens	58-65
19340624-7	2009	The strongest effect of transcription inhibition ERalpha (2.5 times) and especially ERbeta (10 times) was observed after addition of 9-cis retinoic acid and paclitaxel.	Paclitaxel	157-167	estrogen receptor 1	Homo sapiens	49-56
19389529-5	2009	We report two cases of patients with metastatic melanoma who showed significant remission after combination of carboplatin and paclitaxel with the mTOR inhibitor sirolimus.	Paclitaxel	127-137	mechanistic target of rapamycin kinase	Homo sapiens	147-151
19132448-4	2009	RESULTS: In fluorescence imaging analysis, Taxol-induced apoptosis showed caspase-3 activation (13 h 50 min) was prior to BID cleavage (15 h 10 min) and subsequent significant cytochrome c release (17-18 h 20 min), whereas the cisplatin-induced apoptosis showed BID cleavage (5 h 40 min) and significant cytochrome c release (7-8 h 20 min) were prior to caspase-3 activation (14 h 20 min).	Paclitaxel	43-48	caspase 3	Homo sapiens	74-83
19372481-8	2009	RESULTS: (18)F-FBnTP cellular uptake in viable cells declined linearly with the increasing duration of paclitaxel treatment, from 3 to 24 h, and plateaued at 48 h. The extent of decrease of (18)F-FBnTP correlated strongly with the Bax-to-Bcl-2 ratio (R(2) = 0.83) and release of cytochrome c (R(2) = 0.92), but preceded in time the caspase-3 cleavage.	Paclitaxel	103-113	BCL2 associated X, apoptosis regulator	Homo sapiens	231-234
19372481-8	2009	RESULTS: (18)F-FBnTP cellular uptake in viable cells declined linearly with the increasing duration of paclitaxel treatment, from 3 to 24 h, and plateaued at 48 h. The extent of decrease of (18)F-FBnTP correlated strongly with the Bax-to-Bcl-2 ratio (R(2) = 0.83) and release of cytochrome c (R(2) = 0.92), but preceded in time the caspase-3 cleavage.	Paclitaxel	103-113	BCL2 apoptosis regulator	Homo sapiens	238-243
19372481-8	2009	RESULTS: (18)F-FBnTP cellular uptake in viable cells declined linearly with the increasing duration of paclitaxel treatment, from 3 to 24 h, and plateaued at 48 h. The extent of decrease of (18)F-FBnTP correlated strongly with the Bax-to-Bcl-2 ratio (R(2) = 0.83) and release of cytochrome c (R(2) = 0.92), but preceded in time the caspase-3 cleavage.	Paclitaxel	103-113	cytochrome c, somatic	Homo sapiens	279-291
19372481-8	2009	RESULTS: (18)F-FBnTP cellular uptake in viable cells declined linearly with the increasing duration of paclitaxel treatment, from 3 to 24 h, and plateaued at 48 h. The extent of decrease of (18)F-FBnTP correlated strongly with the Bax-to-Bcl-2 ratio (R(2) = 0.83) and release of cytochrome c (R(2) = 0.92), but preceded in time the caspase-3 cleavage.	Paclitaxel	103-113	caspase 3	Homo sapiens	332-341
19156549-4	2009	Sequential addition of phenoxodiol and paclitaxel or phenoxodiol and cisplatin showed greater inhibition of HeLa cell ENOX1 activity and growth compared to adding the drugs simultaneously or individually.	Paclitaxel	39-49	ecto-NOX disulfide-thiol exchanger 1	Homo sapiens	118-123
19156549-9	2009	In keeping with a speculative prion model, it seems as though the ENOX2 "remembers" the phenoxodiol and "teaches" other ENOX2 molecules to respond to paclitaxel and cisplatin as if phenoxodiol were still present.	Paclitaxel	150-160	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	66-71
19132448-4	2009	RESULTS: In fluorescence imaging analysis, Taxol-induced apoptosis showed caspase-3 activation (13 h 50 min) was prior to BID cleavage (15 h 10 min) and subsequent significant cytochrome c release (17-18 h 20 min), whereas the cisplatin-induced apoptosis showed BID cleavage (5 h 40 min) and significant cytochrome c release (7-8 h 20 min) were prior to caspase-3 activation (14 h 20 min).	Paclitaxel	43-48	BH3 interacting domain death agonist	Homo sapiens	122-125
19156549-9	2009	In keeping with a speculative prion model, it seems as though the ENOX2 "remembers" the phenoxodiol and "teaches" other ENOX2 molecules to respond to paclitaxel and cisplatin as if phenoxodiol were still present.	Paclitaxel	150-160	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	120-125
19132448-4	2009	RESULTS: In fluorescence imaging analysis, Taxol-induced apoptosis showed caspase-3 activation (13 h 50 min) was prior to BID cleavage (15 h 10 min) and subsequent significant cytochrome c release (17-18 h 20 min), whereas the cisplatin-induced apoptosis showed BID cleavage (5 h 40 min) and significant cytochrome c release (7-8 h 20 min) were prior to caspase-3 activation (14 h 20 min).	Paclitaxel	43-48	cytochrome c, somatic	Homo sapiens	176-188
19132448-4	2009	RESULTS: In fluorescence imaging analysis, Taxol-induced apoptosis showed caspase-3 activation (13 h 50 min) was prior to BID cleavage (15 h 10 min) and subsequent significant cytochrome c release (17-18 h 20 min), whereas the cisplatin-induced apoptosis showed BID cleavage (5 h 40 min) and significant cytochrome c release (7-8 h 20 min) were prior to caspase-3 activation (14 h 20 min).	Paclitaxel	43-48	BH3 interacting domain death agonist	Homo sapiens	262-265
19132448-4	2009	RESULTS: In fluorescence imaging analysis, Taxol-induced apoptosis showed caspase-3 activation (13 h 50 min) was prior to BID cleavage (15 h 10 min) and subsequent significant cytochrome c release (17-18 h 20 min), whereas the cisplatin-induced apoptosis showed BID cleavage (5 h 40 min) and significant cytochrome c release (7-8 h 20 min) were prior to caspase-3 activation (14 h 20 min).	Paclitaxel	43-48	cytochrome c, somatic	Homo sapiens	304-316
19132448-4	2009	RESULTS: In fluorescence imaging analysis, Taxol-induced apoptosis showed caspase-3 activation (13 h 50 min) was prior to BID cleavage (15 h 10 min) and subsequent significant cytochrome c release (17-18 h 20 min), whereas the cisplatin-induced apoptosis showed BID cleavage (5 h 40 min) and significant cytochrome c release (7-8 h 20 min) were prior to caspase-3 activation (14 h 20 min).	Paclitaxel	43-48	caspase 3	Homo sapiens	354-363
19270727-0	2009	RanBP1 downregulation sensitizes cancer cells to taxol in a caspase-3-dependent manner.	Paclitaxel	49-54	caspase 3	Homo sapiens	60-69
19278222-3	2009	In this study, we have examined augmentation of therapeutic efficacy upon coadministration of paclitaxel (PTX) and curcumin (CUR), an inhibitor of nuclear factor kappa B (NFkappaB) as well as a potent down-regulator of ABC transporters, in wild-type SKOV3 and drug resistant SKOV3(TR) human ovarian adenocarcinoma cells.	Paclitaxel	94-104	nuclear factor kappa B subunit 1	Homo sapiens	147-169
19278222-3	2009	In this study, we have examined augmentation of therapeutic efficacy upon coadministration of paclitaxel (PTX) and curcumin (CUR), an inhibitor of nuclear factor kappa B (NFkappaB) as well as a potent down-regulator of ABC transporters, in wild-type SKOV3 and drug resistant SKOV3(TR) human ovarian adenocarcinoma cells.	Paclitaxel	94-104	nuclear factor kappa B subunit 1	Homo sapiens	171-179
19270727-7	2009	Furthermore, RanBP1-interfered cells show an increased apoptotic response to taxol compared to their counterpart with normal or high RanBP1 levels, and this response is caspase-3 dependent.	Paclitaxel	77-82	caspase 3	Homo sapiens	169-178
18802696-4	2009	Paclitaxel treatment decreased Treg numbers in a TLR4-independent fashion, and preferentially affected cycling Treg expressing high levels of FoxP3.	Paclitaxel	0-10	toll-like receptor 4	Mus musculus	49-53
19426673-0	2009	PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol.	Paclitaxel	87-92	poly(ADP-ribose) polymerase 1	Homo sapiens	0-6
19426673-0	2009	PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol.	Paclitaxel	87-92	AKT serine/threonine kinase 1	Homo sapiens	52-55
19426673-3	2009	To understand the role of Akt activation in the combined use of cytostatic agent and PARP inhibition, we used taxol (paclitaxel) as an antineoplastic agent, which targets microtubules and up-regulates mitochondrial ROS production, together with (i) pharmacological inhibition (PJ-34), (ii) siRNA knock-down and (iii) transdominant expression of the DNA binding domain of PARP-1.	Paclitaxel	110-115	AKT serine/threonine kinase 1	Homo sapiens	26-29
19426673-3	2009	To understand the role of Akt activation in the combined use of cytostatic agent and PARP inhibition, we used taxol (paclitaxel) as an antineoplastic agent, which targets microtubules and up-regulates mitochondrial ROS production, together with (i) pharmacological inhibition (PJ-34), (ii) siRNA knock-down and (iii) transdominant expression of the DNA binding domain of PARP-1.	Paclitaxel	110-115	poly(ADP-ribose) polymerase 1	Homo sapiens	371-377
19426673-3	2009	To understand the role of Akt activation in the combined use of cytostatic agent and PARP inhibition, we used taxol (paclitaxel) as an antineoplastic agent, which targets microtubules and up-regulates mitochondrial ROS production, together with (i) pharmacological inhibition (PJ-34), (ii) siRNA knock-down and (iii) transdominant expression of the DNA binding domain of PARP-1.	Paclitaxel	117-127	AKT serine/threonine kinase 1	Homo sapiens	26-29
19426673-3	2009	To understand the role of Akt activation in the combined use of cytostatic agent and PARP inhibition, we used taxol (paclitaxel) as an antineoplastic agent, which targets microtubules and up-regulates mitochondrial ROS production, together with (i) pharmacological inhibition (PJ-34), (ii) siRNA knock-down and (iii) transdominant expression of the DNA binding domain of PARP-1.	Paclitaxel	117-127	poly(ADP-ribose) polymerase 1	Homo sapiens	85-89
19426673-4	2009	In all cases, PARP-1 inhibition leads to suppressed poly-ADP-ribosylation of nuclear proteins, prevention of NAD(+) depletion and significant resistance against taxol induced caspase-3 activation and apoptotic cell death.	Paclitaxel	161-166	poly(ADP-ribose) polymerase 1	Homo sapiens	14-20
19426673-4	2009	In all cases, PARP-1 inhibition leads to suppressed poly-ADP-ribosylation of nuclear proteins, prevention of NAD(+) depletion and significant resistance against taxol induced caspase-3 activation and apoptotic cell death.	Paclitaxel	161-166	caspase 3	Homo sapiens	175-184
19426673-5	2009	Paclitaxel induced a moderate increase in Akt activation, which was significantly augmented by PARP inhibition, suggesting that PARP inhibition-induced Akt activation could be responsible for the cytostatic resistance.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	42-45
19426673-5	2009	Paclitaxel induced a moderate increase in Akt activation, which was significantly augmented by PARP inhibition, suggesting that PARP inhibition-induced Akt activation could be responsible for the cytostatic resistance.	Paclitaxel	0-10	poly(ADP-ribose) polymerase 1	Homo sapiens	95-99
19426673-5	2009	Paclitaxel induced a moderate increase in Akt activation, which was significantly augmented by PARP inhibition, suggesting that PARP inhibition-induced Akt activation could be responsible for the cytostatic resistance.	Paclitaxel	0-10	poly(ADP-ribose) polymerase 1	Homo sapiens	128-132
19426673-5	2009	Paclitaxel induced a moderate increase in Akt activation, which was significantly augmented by PARP inhibition, suggesting that PARP inhibition-induced Akt activation could be responsible for the cytostatic resistance.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	152-155
19351859-7	2009	CTGF overexpression resulted in resistance to doxorubicin- and paclitaxel-induced apoptosis by up-regulation of Bcl-xL and cellular inhibitor of apoptosis protein 1 (cIAP1).	Paclitaxel	63-73	BCL2 like 1	Homo sapiens	112-118
19399413-0	2009	Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells.	Paclitaxel	66-76	ATP binding cassette subfamily B member 1	Homo sapiens	48-52
19132366-5	2009	The emission peak at 526 nm disappeared and that of 476 nm increased after STS or bufalin treatment, but taxol treatment did not induce a significant change for the SCAT3 emission spectra, indicating that caspase-3 was activated during STS- or bufalin-induced cell apoptosis, but was not involved in taxol-induced PCD.	Paclitaxel	300-305	caspase 3	Homo sapiens	205-214
19399413-9	2009	It was concluded that chitosan/pshRNA plasmid nanoparticles targeting MDR1 can effectively reverse the paclitaxel resistance in A2780/TS cells in a time-dependent manner.	Paclitaxel	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	70-74
19372587-1	2009	Overexpression of the ErbB2 receptor tyrosine kinase is prevalent in approximately 30% of human breast cancers and confers Taxol resistance.	Paclitaxel	123-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-27
19714814-5	2009	We focused on proteins which were most strongly modulated by paclitaxel resistance and in particular on the disulphide isomerase ERp57, which may represent a chemoresistance biomarker.	Paclitaxel	61-71	protein disulfide isomerase family A member 3	Homo sapiens	129-134
19714814-6	2009	ERp57 was found to interact with class III beta-tubulin (TUBB3), involved in paclitaxel resistance in ovarian and other cancers.	Paclitaxel	77-87	protein disulfide isomerase family A member 3	Homo sapiens	0-5
19714814-8	2009	Our data suggest that ERp57 plays an important role in chemoresistance mechanisms in ovarian cancer by modulating the attachment of microtubules to chromosomes following paclitaxel treatment through its interaction with TUBB3.	Paclitaxel	170-180	protein disulfide isomerase family A member 3	Homo sapiens	22-27
19372587-2	2009	Our previous work has shown that ErbB2 inhibits Taxol-induced apoptosis in breast cancer cells by transcriptionally up-regulating p21(Cip1).	Paclitaxel	48-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-38
19372587-2	2009	Our previous work has shown that ErbB2 inhibits Taxol-induced apoptosis in breast cancer cells by transcriptionally up-regulating p21(Cip1).	Paclitaxel	48-53	cyclin dependent kinase inhibitor 1A	Homo sapiens	130-133
19372587-2	2009	Our previous work has shown that ErbB2 inhibits Taxol-induced apoptosis in breast cancer cells by transcriptionally up-regulating p21(Cip1).	Paclitaxel	48-53	cyclin dependent kinase inhibitor 1A	Homo sapiens	134-138
19372587-6	2009	Both Src and STAT3 inhibitors restored Taxol sensitivity in resistant ErbB2-overexpressing breast cancer cells.	Paclitaxel	39-44	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	5-8
19372587-6	2009	Both Src and STAT3 inhibitors restored Taxol sensitivity in resistant ErbB2-overexpressing breast cancer cells.	Paclitaxel	39-44	signal transducer and activator of transcription 3	Homo sapiens	13-18
19372587-6	2009	Both Src and STAT3 inhibitors restored Taxol sensitivity in resistant ErbB2-overexpressing breast cancer cells.	Paclitaxel	39-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-75
19372587-7	2009	Our data suggest that ErbB2 overexpression can activate STAT3 through Src leading to transcriptional up-regulation of p21(Cip1) that confers Taxol resistance of breast cancer cells.	Paclitaxel	141-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-27
19372587-7	2009	Our data suggest that ErbB2 overexpression can activate STAT3 through Src leading to transcriptional up-regulation of p21(Cip1) that confers Taxol resistance of breast cancer cells.	Paclitaxel	141-146	signal transducer and activator of transcription 3	Homo sapiens	56-61
19372587-7	2009	Our data suggest that ErbB2 overexpression can activate STAT3 through Src leading to transcriptional up-regulation of p21(Cip1) that confers Taxol resistance of breast cancer cells.	Paclitaxel	141-146	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	70-73
19372587-7	2009	Our data suggest that ErbB2 overexpression can activate STAT3 through Src leading to transcriptional up-regulation of p21(Cip1) that confers Taxol resistance of breast cancer cells.	Paclitaxel	141-146	cyclin dependent kinase inhibitor 1A	Homo sapiens	118-121
19372587-7	2009	Our data suggest that ErbB2 overexpression can activate STAT3 through Src leading to transcriptional up-regulation of p21(Cip1) that confers Taxol resistance of breast cancer cells.	Paclitaxel	141-146	cyclin dependent kinase inhibitor 1A	Homo sapiens	122-126
19372587-8	2009	Our study suggests a potential clinical application of Src and STAT3 inhibitors in Taxol sensitization of ErbB2-overexpressing breast cancers.	Paclitaxel	83-88	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	55-58
19372587-8	2009	Our study suggests a potential clinical application of Src and STAT3 inhibitors in Taxol sensitization of ErbB2-overexpressing breast cancers.	Paclitaxel	83-88	signal transducer and activator of transcription 3	Homo sapiens	63-68
19372587-8	2009	Our study suggests a potential clinical application of Src and STAT3 inhibitors in Taxol sensitization of ErbB2-overexpressing breast cancers.	Paclitaxel	83-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-111
19015960-1	2009	PURPOSE: The heparin-paclitaxel conjugates using amino acid as linker (HD2), with low anticoagulant activity, the similar anticancer activity as paclitaxel, offer great potential for further investigation.	Paclitaxel	21-31	histone deacetylase 2	Homo sapiens	71-74
19015960-2	2009	METHODS: Two types of heparin-paclitaxel conjugates (HD) have been developed, in which O-acetylated heparin as carrier conjugates with paclitaxel by direct ester bond (HD1) and by inserting different amino acids as spacers, including valine, leucine, and phenylalanine (HD2a, HD2b, and HD2c), respectively.	Paclitaxel	30-40	histone deacetylase 1	Homo sapiens	168-171
19015960-2	2009	METHODS: Two types of heparin-paclitaxel conjugates (HD) have been developed, in which O-acetylated heparin as carrier conjugates with paclitaxel by direct ester bond (HD1) and by inserting different amino acids as spacers, including valine, leucine, and phenylalanine (HD2a, HD2b, and HD2c), respectively.	Paclitaxel	135-145	histone deacetylase 1	Homo sapiens	168-171
19065664-5	2009	IL13-PE38 mediated a synergistic antitumor effect with paclitaxel in OSC-19 in vitro and in vivo in the orthotopic OSCC tongue tumor model.	Paclitaxel	55-65	interleukin 13	Mus musculus	0-4
19350451-2	2009	This study was designed to characterize the cytochrome P450 (CYP) enzymes involved in 7-epi-paclitaxel metabolism, and to examine possible metabolic interactions that this C-7 epimer may have with paclitaxel.	Paclitaxel	92-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
19350451-2	2009	This study was designed to characterize the cytochrome P450 (CYP) enzymes involved in 7-epi-paclitaxel metabolism, and to examine possible metabolic interactions that this C-7 epimer may have with paclitaxel.	Paclitaxel	92-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	61-64
19059384-5	2009	In ABCB1-overexpressing cells, non-toxic doses of AG1478 were found to partially inhibit resistance to ABCB1 substrate anticancer drugs as well as increase intracellular accumulation of [3H]-paclitaxel.	Paclitaxel	191-201	ATP binding cassette subfamily B member 1	Homo sapiens	3-8
19048624-4	2009	In addition, the overexpression of HB-EGF in paclitaxel-treated SKOV3 cells resulted in modulation of paclitaxel-evoked MAPK signaling, including marked activation of ERK and Akt, and minimized activation of JNK and p38 MAPK, indicating that HB-EGF is involved in drug sensitivity through the balance of anti-apoptotic and pro-apoptotic signals induced by paclitaxel.	Paclitaxel	102-112	mitogen-activated protein kinase 1	Homo sapiens	120-124
19048624-4	2009	In addition, the overexpression of HB-EGF in paclitaxel-treated SKOV3 cells resulted in modulation of paclitaxel-evoked MAPK signaling, including marked activation of ERK and Akt, and minimized activation of JNK and p38 MAPK, indicating that HB-EGF is involved in drug sensitivity through the balance of anti-apoptotic and pro-apoptotic signals induced by paclitaxel.	Paclitaxel	102-112	mitogen-activated protein kinase 1	Homo sapiens	120-124
19048624-5	2009	The combination of paclitaxel with CRM197 had an inhibitory effect on cell proliferation and enhanced apoptosis via the inhibition of ERK and Akt activation and the stimulation of p38 and JNK activation.	Paclitaxel	19-29	mitogen-activated protein kinase 1	Homo sapiens	134-137
19048624-5	2009	The combination of paclitaxel with CRM197 had an inhibitory effect on cell proliferation and enhanced apoptosis via the inhibition of ERK and Akt activation and the stimulation of p38 and JNK activation.	Paclitaxel	19-29	AKT serine/threonine kinase 1	Homo sapiens	142-145
19048624-5	2009	The combination of paclitaxel with CRM197 had an inhibitory effect on cell proliferation and enhanced apoptosis via the inhibition of ERK and Akt activation and the stimulation of p38 and JNK activation.	Paclitaxel	19-29	mitogen-activated protein kinase 14	Homo sapiens	180-183
19048624-5	2009	The combination of paclitaxel with CRM197 had an inhibitory effect on cell proliferation and enhanced apoptosis via the inhibition of ERK and Akt activation and the stimulation of p38 and JNK activation.	Paclitaxel	19-29	mitogen-activated protein kinase 8	Homo sapiens	188-191
19065664-0	2009	IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma.	Paclitaxel	66-76	interleukin 13	Mus musculus	0-5
19354063-7	2009	Taxane (paclitaxel, docetaxel)-related reactions are generally non-IgE mediated, and premedication with corticosteroids and antihistamines is usually effective.	Paclitaxel	8-18	immunoglobulin heavy constant epsilon	Homo sapiens	67-70
19048624-3	2009	Paclitaxel induced transient ERK activation and sustained activation of JNK and p38 MAPK through the ectodomain shedding of HB-EGF in SKOV3 cells.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Homo sapiens	29-32
19048624-3	2009	Paclitaxel induced transient ERK activation and sustained activation of JNK and p38 MAPK through the ectodomain shedding of HB-EGF in SKOV3 cells.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	72-75
19048624-3	2009	Paclitaxel induced transient ERK activation and sustained activation of JNK and p38 MAPK through the ectodomain shedding of HB-EGF in SKOV3 cells.	Paclitaxel	0-10	mitogen-activated protein kinase 14	Homo sapiens	80-83
19048624-4	2009	In addition, the overexpression of HB-EGF in paclitaxel-treated SKOV3 cells resulted in modulation of paclitaxel-evoked MAPK signaling, including marked activation of ERK and Akt, and minimized activation of JNK and p38 MAPK, indicating that HB-EGF is involved in drug sensitivity through the balance of anti-apoptotic and pro-apoptotic signals induced by paclitaxel.	Paclitaxel	45-55	mitogen-activated protein kinase 1	Homo sapiens	120-124
19048624-4	2009	In addition, the overexpression of HB-EGF in paclitaxel-treated SKOV3 cells resulted in modulation of paclitaxel-evoked MAPK signaling, including marked activation of ERK and Akt, and minimized activation of JNK and p38 MAPK, indicating that HB-EGF is involved in drug sensitivity through the balance of anti-apoptotic and pro-apoptotic signals induced by paclitaxel.	Paclitaxel	45-55	mitogen-activated protein kinase 1	Homo sapiens	167-170
19048624-4	2009	In addition, the overexpression of HB-EGF in paclitaxel-treated SKOV3 cells resulted in modulation of paclitaxel-evoked MAPK signaling, including marked activation of ERK and Akt, and minimized activation of JNK and p38 MAPK, indicating that HB-EGF is involved in drug sensitivity through the balance of anti-apoptotic and pro-apoptotic signals induced by paclitaxel.	Paclitaxel	45-55	AKT serine/threonine kinase 1	Homo sapiens	175-178
19048624-4	2009	In addition, the overexpression of HB-EGF in paclitaxel-treated SKOV3 cells resulted in modulation of paclitaxel-evoked MAPK signaling, including marked activation of ERK and Akt, and minimized activation of JNK and p38 MAPK, indicating that HB-EGF is involved in drug sensitivity through the balance of anti-apoptotic and pro-apoptotic signals induced by paclitaxel.	Paclitaxel	45-55	mitogen-activated protein kinase 8	Homo sapiens	208-211
19048624-4	2009	In addition, the overexpression of HB-EGF in paclitaxel-treated SKOV3 cells resulted in modulation of paclitaxel-evoked MAPK signaling, including marked activation of ERK and Akt, and minimized activation of JNK and p38 MAPK, indicating that HB-EGF is involved in drug sensitivity through the balance of anti-apoptotic and pro-apoptotic signals induced by paclitaxel.	Paclitaxel	45-55	mitogen-activated protein kinase 14	Homo sapiens	216-219
19188671-0	2009	Race to report: are vascular endothelial growth factor genetic polymorphisms associated with outcome in advanced breast cancer patients treated with Paclitaxel plus bevacizumab?	Paclitaxel	149-159	vascular endothelial growth factor A	Homo sapiens	20-54
19079345-0	2009	Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis.	Paclitaxel	77-82	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	0-9
19276157-5	2009	Whether dysregulation of EGFR-mediated pathways precludes or sensitizes cells to paclitaxel is unknown.	Paclitaxel	81-91	epidermal growth factor receptor	Homo sapiens	25-29
19276157-13	2009	Our data suggest that EGFR expression and KRAS mutation status is predictive for clinical response to matuzumab +/- paclitaxel in patients with advanced NSCLC.	Paclitaxel	116-126	epidermal growth factor receptor	Homo sapiens	22-26
19449527-7	2009	Furthermore, pCSH1-VEGF enhanced the sensitivity of DU145 cells to Taxol and vincristine, and the values of IC50 decreased by 77.3% and 92.6%, respectively.	Paclitaxel	67-72	vascular endothelial growth factor A	Homo sapiens	19-23
18587580-4	2009	These studies demonstrated that CDDO-Me significantly inhibits IL-6 secretion in paclitaxel-resistant ovarian cancer cells and specifically suppresses IL-6- or oncostatin M-induced Stat3 nuclear translocation.	Paclitaxel	81-91	interleukin 6	Homo sapiens	63-67
18587580-4	2009	These studies demonstrated that CDDO-Me significantly inhibits IL-6 secretion in paclitaxel-resistant ovarian cancer cells and specifically suppresses IL-6- or oncostatin M-induced Stat3 nuclear translocation.	Paclitaxel	81-91	signal transducer and activator of transcription 3	Homo sapiens	181-186
18618115-4	2009	Combination of MDR-1 gene silencing and nanoparticle-mediated delivery significantly influenced the cytotoxic activity of PTX in SKOV3(TR) cells similar to what was observed in drug sensitive SKOV3 cells.	Paclitaxel	122-125	ATP binding cassette subfamily B member 1	Homo sapiens	15-20
19295274-0	2009	[Preoperative therapy using trastuzumab and weekly paclitaxel in a stage IIIB inoperable locally advanced HER2- positive breast cancer with complete pathologic response].	Paclitaxel	51-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
19295274-6	2009	We conclude that the combination of weekly paclitaxel and trastuzumab is a promising neoadjuvant therapy regimen for HER2 positive, ER-negative breast cancer.	Paclitaxel	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
18623213-8	2009	However, resistance to ptx was reversed by verapamil, which indicated that a sustained inhibition of Pgp was required for ptx to induce cytotoxicity in MDR cells.	Paclitaxel	122-125	ATP binding cassette subfamily B member 1	Homo sapiens	101-104
19718795-7	2009	Treatment of A549 tumor cells with paclitaxel resulted in &gt; 2-fold increase in the fluorescence intensity by NIR confocal microscopy, suggesting the activation of pro-caspase-3 to caspase-3.	Paclitaxel	35-45	caspase 3	Homo sapiens	166-179
19718795-7	2009	Treatment of A549 tumor cells with paclitaxel resulted in &gt; 2-fold increase in the fluorescence intensity by NIR confocal microscopy, suggesting the activation of pro-caspase-3 to caspase-3.	Paclitaxel	35-45	caspase 3	Homo sapiens	170-179
19079345-5	2009	We investigated the interactions of ATX, LPC and LPA on the apoptotic effects of Taxol, which is commonly used in breast cancer treatment.	Paclitaxel	81-86	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	36-39
19079345-7	2009	Addition of incubation medium from MDA-MB-435 melanoma cells, which secrete ATX, or recombinat ATX enabled LPC to inhibit Taxol-induced apoptosis of MCF-7 cells.	Paclitaxel	122-127	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	95-98
19079345-12	2009	Our results support the hypothesis that therapeutic inhibition of ATX activity could improve the efficacy of Taxol as a chemotherapeutic agent for cancer treatment.	Paclitaxel	109-114	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	66-69
19228734-0	2009	Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.	Paclitaxel	92-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-41
19228734-2	2009	Here, we studied whether overexpression of ErbB2 may lead to mitotic deregulation in breast cancer cells via up-regulation of survivin that confers Taxol resistance.	Paclitaxel	148-153	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-48
19228734-3	2009	EXPERIMENTAL DESIGN: ErbB2-overexpressing and ErbB2-low-expressing breast cancer cell lines were used to compare their mitotic exit rate, survivin expression level, and apoptosis level in response to Taxol.	Paclitaxel	200-205	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-26
19228734-7	2009	ErbB2-overexpressing cells exited M phase faster than ErbB2-low-expressing cells, which correlated with the increased resistance to Taxol-induced apoptosis.	Paclitaxel	132-137	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
19228734-10	2009	In addition, combination treatment of Taxol with PI3K/Akt and Src inhibitor led to increased apoptosis in ErbB2-overexpressing breast cancer cells than single treatment.	Paclitaxel	38-43	AKT serine/threonine kinase 1	Homo sapiens	54-57
19228734-10	2009	In addition, combination treatment of Taxol with PI3K/Akt and Src inhibitor led to increased apoptosis in ErbB2-overexpressing breast cancer cells than single treatment.	Paclitaxel	38-43	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	62-65
19228734-10	2009	In addition, combination treatment of Taxol with PI3K/Akt and Src inhibitor led to increased apoptosis in ErbB2-overexpressing breast cancer cells than single treatment.	Paclitaxel	38-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-111
19228734-11	2009	CONCLUSIONS: Survivin up-regulation by ErbB2 is a critical event in ErbB2-mediated faster mitotic exit and contributes to Taxol resistance.	Paclitaxel	122-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-44
19228734-11	2009	CONCLUSIONS: Survivin up-regulation by ErbB2 is a critical event in ErbB2-mediated faster mitotic exit and contributes to Taxol resistance.	Paclitaxel	122-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-73
18836089-0	2009	Association of the ABCB1 gene polymorphisms 2677G&gt;T/A and 3435C&gt;T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.	Paclitaxel	98-108	ATP binding cassette subfamily B member 1	Homo sapiens	19-24
18836089-3	2009	We evaluated the association between clinical outcome (safety and efficacy) of paclitaxel monotherapy in metastatic breast cancer patients with ABCB1 gene polymorphisms 2677G&gt;T/A or 3435C&gt;T. PATIENTS AND METHODS: Patients with metastatic breast cancer were treated with 175 mg/m(2) paclitaxel per 3-week cycle.	Paclitaxel	79-89	ATP binding cassette subfamily B member 1	Homo sapiens	144-149
18836089-3	2009	We evaluated the association between clinical outcome (safety and efficacy) of paclitaxel monotherapy in metastatic breast cancer patients with ABCB1 gene polymorphisms 2677G&gt;T/A or 3435C&gt;T. PATIENTS AND METHODS: Patients with metastatic breast cancer were treated with 175 mg/m(2) paclitaxel per 3-week cycle.	Paclitaxel	288-298	ATP binding cassette subfamily B member 1	Homo sapiens	144-149
18836089-10	2009	CONCLUSIONS: ABCB1 genotypes may be a predictor of paclitaxel activity as well as a prognostic factor in metastatic breast cancer patients.	Paclitaxel	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	13-18
19099191-5	2009	Blocking P-gp activity or depletion of PrP(c) inhibited paclitaxel (P-gp substrate)- induced invasion.	Paclitaxel	56-66	prion protein	Homo sapiens	39-45
19143748-1	2009	The purpose of this study was to evaluate the role of sequence variants in the CYP2C8, ABCB1 and CYP3A4 genes and the CYP3A4 phenotype for the pharmacokinetics and toxicity of paclitaxel in ovarian cancer patients.	Paclitaxel	176-186	ATP binding cassette subfamily B member 1	Homo sapiens	87-92
19143748-1	2009	The purpose of this study was to evaluate the role of sequence variants in the CYP2C8, ABCB1 and CYP3A4 genes and the CYP3A4 phenotype for the pharmacokinetics and toxicity of paclitaxel in ovarian cancer patients.	Paclitaxel	176-186	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103
19143748-1	2009	The purpose of this study was to evaluate the role of sequence variants in the CYP2C8, ABCB1 and CYP3A4 genes and the CYP3A4 phenotype for the pharmacokinetics and toxicity of paclitaxel in ovarian cancer patients.	Paclitaxel	176-186	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-124
19143748-6	2009	Patients heterozygous for G/A in position 2677 in ABCB1 had a significantly higher clearance of paclitaxel than most other ABCB1 variants.	Paclitaxel	96-106	ATP binding cassette subfamily B member 1	Homo sapiens	50-55
19143748-6	2009	Patients heterozygous for G/A in position 2677 in ABCB1 had a significantly higher clearance of paclitaxel than most other ABCB1 variants.	Paclitaxel	96-106	ATP binding cassette subfamily B member 1	Homo sapiens	123-128
19143748-7	2009	A lower clearance of paclitaxel was found for patients heterozygous for CYP2C8*3 when stratified according to the ABCB1 G2677T/A genotype.	Paclitaxel	21-31	ATP binding cassette subfamily B member 1	Homo sapiens	114-119
19143748-10	2009	Our findings suggest that interindividual variability in paclitaxel pharmacokinetics might be predicted by ABCB1 and CYP2C8 genotypes and provide useful information for individualized chemotherapy.	Paclitaxel	57-67	ATP binding cassette subfamily B member 1	Homo sapiens	107-112
19331197-15	2009	In conclusion, combined neoadjuvant weekly paclitaxel and trastuzumab achieved high clinical and pathological response rates for HER2 -overexpressing breast cancers, despite the omission of an anthracycline.	Paclitaxel	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
19042015-2	2009	In this study, these cationic micellar nanoparticles were employed as carriers to co-deliver paclitaxel and Herceptin for achieving targeted delivery of paclitaxel to human epidermal growth factor receptor-2 (HER2/neu)-overexpressing human breast cancer cells, and enhanced cytotoxicity through synergistic activities.	Paclitaxel	93-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	173-207
19042015-2	2009	In this study, these cationic micellar nanoparticles were employed as carriers to co-deliver paclitaxel and Herceptin for achieving targeted delivery of paclitaxel to human epidermal growth factor receptor-2 (HER2/neu)-overexpressing human breast cancer cells, and enhanced cytotoxicity through synergistic activities.	Paclitaxel	93-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	209-217
19042015-2	2009	In this study, these cationic micellar nanoparticles were employed as carriers to co-deliver paclitaxel and Herceptin for achieving targeted delivery of paclitaxel to human epidermal growth factor receptor-2 (HER2/neu)-overexpressing human breast cancer cells, and enhanced cytotoxicity through synergistic activities.	Paclitaxel	153-163	erb-b2 receptor tyrosine kinase 2	Homo sapiens	173-207
19042015-2	2009	In this study, these cationic micellar nanoparticles were employed as carriers to co-deliver paclitaxel and Herceptin for achieving targeted delivery of paclitaxel to human epidermal growth factor receptor-2 (HER2/neu)-overexpressing human breast cancer cells, and enhanced cytotoxicity through synergistic activities.	Paclitaxel	153-163	erb-b2 receptor tyrosine kinase 2	Homo sapiens	209-217
19042015-9	2009	The co-delivery of Herceptin increased the cytotoxicity of paclitaxel and this enhancement showed a dependency on their HER2 expression levels.	Paclitaxel	59-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
19099191-6	2009	Paclitaxel further facilitated the formation of P-gp/PrP(c) clusters residing in caveolar domains and promoted the association of P-gp with caveolin-1.	Paclitaxel	0-10	prion protein	Homo sapiens	53-59
19188143-5	2009	Moreover, clinically used drugs like paclitaxel, imatinib, and doxorubicin have been shown to achieve their therapeutic effects through activation of FOXO3a and FOXO3a targets.	Paclitaxel	37-47	forkhead box O3	Homo sapiens	150-156
19188143-5	2009	Moreover, clinically used drugs like paclitaxel, imatinib, and doxorubicin have been shown to achieve their therapeutic effects through activation of FOXO3a and FOXO3a targets.	Paclitaxel	37-47	forkhead box O3	Homo sapiens	161-167
19148464-0	2009	Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.	Paclitaxel	14-24	BCL2 apoptosis regulator	Homo sapiens	49-54
19046877-6	2009	Both the strong TF activity and antigen constitutively expressed by MDA-MB-231 and the TF induced by LPS, TNF-alpha and IL-1beta in MN cells and HUVEC were significantly reduced by paclitaxel.	Paclitaxel	181-191	tumor necrosis factor	Homo sapiens	106-115
19046877-6	2009	Both the strong TF activity and antigen constitutively expressed by MDA-MB-231 and the TF induced by LPS, TNF-alpha and IL-1beta in MN cells and HUVEC were significantly reduced by paclitaxel.	Paclitaxel	181-191	interleukin 1 beta	Homo sapiens	120-128
19046877-8	2009	Since paclitaxel has been shown to induce the expression of inflammatory genes in monocytes and tumour cells, we tested whether paclitaxel could influence IL-6 and IL-1beta release from the cells used in this paper.	Paclitaxel	128-138	interleukin 6	Homo sapiens	155-159
19046877-8	2009	Since paclitaxel has been shown to induce the expression of inflammatory genes in monocytes and tumour cells, we tested whether paclitaxel could influence IL-6 and IL-1beta release from the cells used in this paper.	Paclitaxel	128-138	interleukin 1 beta	Homo sapiens	164-172
19200169-13	2009	Knockdown of TLR4 induces paclitaxel chemosensitivity which might depress the Akt pathway.	Paclitaxel	26-36	AKT serine/threonine kinase 1	Homo sapiens	78-81
18793723-9	2009	PAC permeability was significantly increased in the presence of the pgp/CYP3A4 inhibitor cyclosporine A (CsA).	Paclitaxel	0-3	phosphoglycolate phosphatase	Rattus norvegicus	68-71
19148464-0	2009	Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.	Paclitaxel	14-24	estrogen receptor 1	Homo sapiens	77-94
19148464-5	2009	We also investigated members of Bcl-2 family by Western blotting and RT-PCR to clarify their role in paclitaxel resistance both in ER-positive and in ER-negative cells.	Paclitaxel	101-111	BCL2 apoptosis regulator	Homo sapiens	32-37
19148464-14	2009	This experiment also showed ER-negative cells were sensitive to paclitaxel but ER-positive cells were resistant to it.	Paclitaxel	64-74	estrogen receptor 1	Homo sapiens	28-30
19148464-15	2009	These results suggest that ER influenced chemosensitivity to paclitaxel through regulation of Bcl-2 family and regulation of the pathway may be crucial to increase the efficacy of taxanes in ER-positive breast cancer.	Paclitaxel	61-71	BCL2 apoptosis regulator	Homo sapiens	94-99
18716795-7	2009	We also show a synergy in combining the NGF receptor inhibitors with the conventional breast cancer treatments tamoxifen and taxol.	Paclitaxel	125-130	nerve growth factor	Homo sapiens	40-43
19208743-8	2009	Clustering of microarray data for these genes revealed that high YY1/E2F3 activity positively correlates with survival of patients treated with the microtubule-stabilizing drug paclitaxel.	Paclitaxel	177-187	YY1 transcription factor	Homo sapiens	65-68
19208743-8	2009	Clustering of microarray data for these genes revealed that high YY1/E2F3 activity positively correlates with survival of patients treated with the microtubule-stabilizing drug paclitaxel.	Paclitaxel	177-187	E2F transcription factor 3	Homo sapiens	69-73
19331146-4	2009	RESULTS: Activation of Akt increased paclitaxel resistance by increasing Bad phosphorylation, leading to decreased release of mitochondrial cytochrome c and caspase-3-mediated apoptosis.	Paclitaxel	37-47	AKT serine/threonine kinase 1	Homo sapiens	23-26
19148534-0	2009	Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells.	Paclitaxel	44-54	transforming acidic coiled-coil containing protein 3	Homo sapiens	22-27
19148534-2	2009	TACC3 mRNA and protein levels decreased after paclitaxel treatment in a time- and dose-dependent manner, and the transactivation of TACC3 promoter was dramatically diminished by paclitaxel.	Paclitaxel	46-56	transforming acidic coiled-coil containing protein 3	Homo sapiens	0-5
19148534-2	2009	TACC3 mRNA and protein levels decreased after paclitaxel treatment in a time- and dose-dependent manner, and the transactivation of TACC3 promoter was dramatically diminished by paclitaxel.	Paclitaxel	178-188	transforming acidic coiled-coil containing protein 3	Homo sapiens	0-5
19148534-2	2009	TACC3 mRNA and protein levels decreased after paclitaxel treatment in a time- and dose-dependent manner, and the transactivation of TACC3 promoter was dramatically diminished by paclitaxel.	Paclitaxel	178-188	transforming acidic coiled-coil containing protein 3	Homo sapiens	132-137
19148534-4	2009	In contrast to TACC3-deficient cells, paclitaxel treatment of mTACC3-overexpressing cells failed to induce G2/M phase arrest, cell growth inhibition, and apoptotic cell death.	Paclitaxel	38-48	transforming, acidic coiled-coil containing protein 3	Mus musculus	62-68
19148534-7	2009	Thus, TACC3 is thought to be the critical molecule in mediating the anticancer mechanisms of paclitaxel in p53 inactivated cells by inducing G2/M arrest and apoptosis.	Paclitaxel	93-103	transforming acidic coiled-coil containing protein 3	Homo sapiens	6-11
19148534-7	2009	Thus, TACC3 is thought to be the critical molecule in mediating the anticancer mechanisms of paclitaxel in p53 inactivated cells by inducing G2/M arrest and apoptosis.	Paclitaxel	93-103	tumor protein p53	Homo sapiens	107-110
18805633-5	2009	Furthermore, in EBNA1-NT-transfected HER2/neu-overexpressing cells, we found EBNA1-NT could down-regulate the endogenous production of p185(HER2/neu), lower transformation ability, sensitize paclitaxel-induced apoptosis and decrease tumorigenic potential.	Paclitaxel	191-201	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-41
18805633-5	2009	Furthermore, in EBNA1-NT-transfected HER2/neu-overexpressing cells, we found EBNA1-NT could down-regulate the endogenous production of p185(HER2/neu), lower transformation ability, sensitize paclitaxel-induced apoptosis and decrease tumorigenic potential.	Paclitaxel	191-201	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-45
20429424-4	2009	Indeed, FOXO1 expression was distinctively upregulated in paclitaxel resistant cell line and enhanced by exposure to paclitaxel with subcellular translocation.	Paclitaxel	58-68	forkhead box O1	Homo sapiens	8-13
20429424-4	2009	Indeed, FOXO1 expression was distinctively upregulated in paclitaxel resistant cell line and enhanced by exposure to paclitaxel with subcellular translocation.	Paclitaxel	117-127	forkhead box O1	Homo sapiens	8-13
20429424-6	2009	FOXO1 silencing in paclitaxel resistant cell line decreased its resistance through modulation of downstream targets of FOXO1 involving oxidative stress.	Paclitaxel	19-29	forkhead box O1	Homo sapiens	0-5
20429424-6	2009	FOXO1 silencing in paclitaxel resistant cell line decreased its resistance through modulation of downstream targets of FOXO1 involving oxidative stress.	Paclitaxel	19-29	forkhead box O1	Homo sapiens	119-124
19331146-4	2009	RESULTS: Activation of Akt increased paclitaxel resistance by increasing Bad phosphorylation, leading to decreased release of mitochondrial cytochrome c and caspase-3-mediated apoptosis.	Paclitaxel	37-47	cytochrome c, somatic	Homo sapiens	140-152
19331146-4	2009	RESULTS: Activation of Akt increased paclitaxel resistance by increasing Bad phosphorylation, leading to decreased release of mitochondrial cytochrome c and caspase-3-mediated apoptosis.	Paclitaxel	37-47	caspase 3	Homo sapiens	157-166
19331146-5	2009	On the other hand, inhibition of Akt prevented paclitaxel resistance by enhancing the effects of paclitaxel on Bad phosphorylation, mitochondrial cytochrome c release and caspase-3-mediated apoptosis, besides diminishing or abolishing the opposing effects of Akt activation.	Paclitaxel	47-57	AKT serine/threonine kinase 1	Homo sapiens	33-36
19331146-5	2009	On the other hand, inhibition of Akt prevented paclitaxel resistance by enhancing the effects of paclitaxel on Bad phosphorylation, mitochondrial cytochrome c release and caspase-3-mediated apoptosis, besides diminishing or abolishing the opposing effects of Akt activation.	Paclitaxel	47-57	cytochrome c, somatic	Homo sapiens	146-158
19331146-5	2009	On the other hand, inhibition of Akt prevented paclitaxel resistance by enhancing the effects of paclitaxel on Bad phosphorylation, mitochondrial cytochrome c release and caspase-3-mediated apoptosis, besides diminishing or abolishing the opposing effects of Akt activation.	Paclitaxel	47-57	caspase 3	Homo sapiens	171-180
19331146-5	2009	On the other hand, inhibition of Akt prevented paclitaxel resistance by enhancing the effects of paclitaxel on Bad phosphorylation, mitochondrial cytochrome c release and caspase-3-mediated apoptosis, besides diminishing or abolishing the opposing effects of Akt activation.	Paclitaxel	47-57	AKT serine/threonine kinase 1	Homo sapiens	259-262
19331146-5	2009	On the other hand, inhibition of Akt prevented paclitaxel resistance by enhancing the effects of paclitaxel on Bad phosphorylation, mitochondrial cytochrome c release and caspase-3-mediated apoptosis, besides diminishing or abolishing the opposing effects of Akt activation.	Paclitaxel	97-107	AKT serine/threonine kinase 1	Homo sapiens	33-36
19331146-5	2009	On the other hand, inhibition of Akt prevented paclitaxel resistance by enhancing the effects of paclitaxel on Bad phosphorylation, mitochondrial cytochrome c release and caspase-3-mediated apoptosis, besides diminishing or abolishing the opposing effects of Akt activation.	Paclitaxel	97-107	AKT serine/threonine kinase 1	Homo sapiens	259-262
19331146-6	2009	CONCLUSION: Akt-mediated Bad phosphorylation plays an important role in preservation of mitochondrial membrane systems leading to paclitaxel resistance in T24 cells.	Paclitaxel	130-140	AKT serine/threonine kinase 1	Homo sapiens	12-15
19331159-3	2009	The treatment of the colon cancer cell lines SW480 and DLD-1 with paclitaxel resulted in increased activation of the MAPK pathway, which was blocked by PD98059, a MEK inhibitor.	Paclitaxel	66-76	mitogen-activated protein kinase kinase 7	Homo sapiens	163-166
19331159-7	2009	These findings highlight the importance of the MAPK pathway in paclitaxel-induced apoptosis and suggest that a combined treatment with paclitaxel and MEK inhibitors could be an attractive therapeutic strategy against colon cancer.	Paclitaxel	63-73	mitogen-activated protein kinase kinase 7	Homo sapiens	150-153
19117986-9	2009	The significant reduction in SAC response to Taxol, but not nocodazole, coupled with the reduced binding of BubR1, but not Mad2, indicates that Bub1 is particularly critical for the SAC response to a lack of tension on kinetochores.	Paclitaxel	45-50	BUB1, mitotic checkpoint serine/threonine kinase	Mus musculus	144-148
18548321-0	2009	A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.	Paclitaxel	107-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-14
18758183-2	2009	P27 and P53 play important roles in the signal transduction leading to neointimal growth inhibition and induction of apoptosis of smooth muscle cells due to rapamycin and paclitaxel.	Paclitaxel	171-181	tumor protein p53	Homo sapiens	8-11
19118059-11	2009	CONCLUSIONS: Nonpegylated doxorubicin, paclitaxel, and trastuzumab combination is safe, does not result in clinically manifest cardiac toxicity, and has a high rate of durable responses in HER-2-overexpressing breast cancer patients.	Paclitaxel	39-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	189-194
19881253-10	2009	These results indicate that enhanced expression and function of P-gp may be a predominant mechanism of paclitaxel resistance in PR-HepG2 cells and the reduced influx via OATP1B3 may also serve to lower intracellular paclitaxel concentration in cooperation with P-gp-mediated efflux.	Paclitaxel	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	64-68
19881253-10	2009	These results indicate that enhanced expression and function of P-gp may be a predominant mechanism of paclitaxel resistance in PR-HepG2 cells and the reduced influx via OATP1B3 may also serve to lower intracellular paclitaxel concentration in cooperation with P-gp-mediated efflux.	Paclitaxel	216-226	solute carrier organic anion transporter family member 1B3	Homo sapiens	170-177
19881253-1	2009	Paclitaxel-resistant HepG2 (PR-HepG2) cells were established by long-term exposure of HepG2 cells to paclitaxel and expression and function of efflux (P-glycoprotein, MRP2) and influx (OATP1B3) transporters for paclitaxel were examined to understand the mechanisms underlying the resistance.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	151-165
19881253-1	2009	Paclitaxel-resistant HepG2 (PR-HepG2) cells were established by long-term exposure of HepG2 cells to paclitaxel and expression and function of efflux (P-glycoprotein, MRP2) and influx (OATP1B3) transporters for paclitaxel were examined to understand the mechanisms underlying the resistance.	Paclitaxel	0-10	solute carrier organic anion transporter family member 1B3	Homo sapiens	185-192
19881253-10	2009	These results indicate that enhanced expression and function of P-gp may be a predominant mechanism of paclitaxel resistance in PR-HepG2 cells and the reduced influx via OATP1B3 may also serve to lower intracellular paclitaxel concentration in cooperation with P-gp-mediated efflux.	Paclitaxel	216-226	ATP binding cassette subfamily B member 1	Homo sapiens	261-265
19258951-0	2009	Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.	Paclitaxel	136-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-60
18996227-5	2009	In HAEC, while paclitaxel (10 (-5) mol/L to 10 (-9) mol/L) treatment for 5 h up-regulated the expression of TF in a dose-dependent manner, paclitaxel cotreatment with thrombin further enhanced it.	Paclitaxel	15-25	coagulation factor II, thrombin	Homo sapiens	167-175
18996227-5	2009	In HAEC, while paclitaxel (10 (-5) mol/L to 10 (-9) mol/L) treatment for 5 h up-regulated the expression of TF in a dose-dependent manner, paclitaxel cotreatment with thrombin further enhanced it.	Paclitaxel	139-149	coagulation factor II, thrombin	Homo sapiens	167-175
18996227-7	2009	Paclitaxel also caused an 8.1-fold increase in TF mRNA expression, and paclitaxel cotreatment with thrombin caused a 13.6-fold enhancement in TF mRNA expression.	Paclitaxel	71-81	coagulation factor II, thrombin	Homo sapiens	99-107
19258951-0	2009	Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.	Paclitaxel	136-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	62-67
19258951-0	2009	Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.	Paclitaxel	136-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-72
19258951-2	2009	This exploratory analysis evaluates Her-2/neu as a prognostic factor in a large cohort of patients with advanced-stage ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy within a prospective randomized trial.	Paclitaxel	156-166	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-45
19421315-6	2009	We used the microtubules damaging agent paclitaxel (PTX), to arrest the cells in the M phase, in a p53 mutated melanoma cell line with modulated Myc level and activity.	Paclitaxel	40-50	tumor protein p53	Homo sapiens	99-102
18945821-0	2009	Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers.	Paclitaxel	38-48	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
18945821-11	2009	Finally, Q2 was shown to inhibit the transport of radiolabeled paclitaxel (Taxol) in MCF-7/DX1 cells, and it completely reversed the P-gp-mediated paclitaxel resistance phenotype.	Paclitaxel	147-157	ATP binding cassette subfamily B member 1	Homo sapiens	133-137
18357521-0	2009	Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells.	Paclitaxel	21-26	BCL2 apoptosis regulator	Homo sapiens	0-5
18357521-4	2009	In the current study, we knocked down Bcl-2 expression using cognate siRNA during low-dose taxol treatment to induce apoptosis in two human glioblastoma U138MG and U251MG cell lines.	Paclitaxel	91-96	BCL2 apoptosis regulator	Homo sapiens	38-43
18357521-5	2009	The cells were treated with either 100 nM taxol or 100 nM Bcl-2 siRNA or both for 72 h. Immunofluorescent stainings for calpain and active caspase-3 showed increases in expression and co-localization of these proteases in apoptotic cells.	Paclitaxel	42-47	caspase 3	Homo sapiens	139-148
18357521-9	2009	Our current study demonstrated that Bcl-2 siRNA significantly augmented taxol mediated apoptosis in different human glioblastoma cells through induction of calpain and caspase proteolytic activities.	Paclitaxel	72-77	BCL2 apoptosis regulator	Homo sapiens	36-41
19421315-6	2009	We used the microtubules damaging agent paclitaxel (PTX), to arrest the cells in the M phase, in a p53 mutated melanoma cell line with modulated Myc level and activity.	Paclitaxel	52-55	tumor protein p53	Homo sapiens	99-102
18947993-0	2008	In situ blood-brain barrier permeability of a C-10 paclitaxel carbamate.	Paclitaxel	51-61	chemokine (C-C motif) ligand 6	Mus musculus	46-50
18985033-1	2008	The aim of the study was to evaluate the prognostic ability of the transcriptional profiling of the HER family genes in early breast cancer, as well as to investigate the predictive value of HER2 mRNA expression for adjuvant treatment with paclitaxel.	Paclitaxel	240-250	erb-b2 receptor tyrosine kinase 2	Homo sapiens	191-195
18582981-4	2008	Clinically, a methotrexate-albumin conjugate, an albumin-binding prodrug of doxorubicin, i.e. the (6-maleimido)caproylhydrazone derivative of doxorubicin (DOXO-EMCH), and an albumin paclitaxel nanoparticle (Abraxane) have been evaluated clinically.	Paclitaxel	182-192	albumin	Homo sapiens	27-34
18582981-4	2008	Clinically, a methotrexate-albumin conjugate, an albumin-binding prodrug of doxorubicin, i.e. the (6-maleimido)caproylhydrazone derivative of doxorubicin (DOXO-EMCH), and an albumin paclitaxel nanoparticle (Abraxane) have been evaluated clinically.	Paclitaxel	182-192	albumin	Homo sapiens	49-56
18582981-4	2008	Clinically, a methotrexate-albumin conjugate, an albumin-binding prodrug of doxorubicin, i.e. the (6-maleimido)caproylhydrazone derivative of doxorubicin (DOXO-EMCH), and an albumin paclitaxel nanoparticle (Abraxane) have been evaluated clinically.	Paclitaxel	182-192	albumin	Homo sapiens	49-56
18947993-4	2008	Further studies however are needed to evaluate the therapeutic potential of the C-10 carbamates paclitaxel derivatives for the treatment of CNS diseases.	Paclitaxel	96-106	chemokine (C-C motif) ligand 6	Mus musculus	80-84
18804099-10	2008	After treatment with Taxol, increases in p-Akt and VEGF could maintain survival and angiogenesis, respectively, in PTEN-negative glioblastoma.	Paclitaxel	21-26	AKT serine/threonine kinase 1	Homo sapiens	43-46
18798274-0	2008	Intraperitoneal administration of a small interfering RNA targeting nuclear factor-kappa B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer.	Paclitaxel	96-106	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	68-90
18798274-5	2008	Apoptotic cells were increased after transfection of NF-kappaB p65 siRNA compared with control siRNA in the treatment with paclitaxel.	Paclitaxel	123-133	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	53-62
18798274-8	2008	Finally, mice treated by intraperitoneal administration of NF-kappaB p65 siRNA and paclitaxel survived for a significantly longer time than mice treated by intraperitoneal administration of paclitaxel alone (p = 0.0002).	Paclitaxel	190-200	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	59-68
18955454-7	2008	In 86 HER-2-positive patients (15%), treatment with paclitaxel-lapatinib resulted in statistically significant improvements in TTP, EFS, ORR, and CBR compared with paclitaxel-placebo.	Paclitaxel	52-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-11
18955454-13	2008	However, first-line therapy with paclitaxel-lapatinib significantly improved clinical outcomes in HER-2-positive patients.	Paclitaxel	33-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-103
18846037-7	2008	MDA7 treatment attenuated tactile allodynia produced by spinal nerve ligation or by paclitaxel in a dose-related manner.	Paclitaxel	84-94	interleukin 24	Rattus norvegicus	0-4
18514532-6	2008	Fluorescence resonance energy transfer (FRET) was used to monitor the caspase-3 activation in living cells during taxol-induced cell death.	Paclitaxel	114-119	caspase 3	Homo sapiens	70-79
18514532-9	2008	These findings suggest that taxol induces caspase-3-independent cytoplasmic vacuolization, cell swelling and cell death through ER vacuolization.	Paclitaxel	28-33	caspase 3	Homo sapiens	42-51
18845169-9	2008	Consistent with decreased P-gp pumping activity, confocal microscopic observation revealed that KB3-1 effectively diminished the expression of P-gp in paclitaxel (TAX)-treated MES-SA/DX-5 cells.	Paclitaxel	151-161	ATP binding cassette subfamily B member 1	Homo sapiens	143-147
18804099-10	2008	After treatment with Taxol, increases in p-Akt and VEGF could maintain survival and angiogenesis, respectively, in PTEN-negative glioblastoma.	Paclitaxel	21-26	vascular endothelial growth factor A	Homo sapiens	51-55
18365200-1	2008	BACKGROUND: Addition of carboplatin (C) to trastuzumab (T) and paclitaxel (P) improves the efficacy in HER2+ metastatic breast cancer (MBC).	Paclitaxel	63-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
18270703-0	2008	Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity.	Paclitaxel	31-41	interleukin 6	Rattus norvegicus	0-13
18270703-8	2008	RESULTS: IL-6 treatment prevented the behavioral and electrophysiological abnormalities produced by vincristine, cisplatin and Taxol intoxication, and similarly prevented the pathological changes in peripheral nerves.	Paclitaxel	127-132	interleukin 6	Rattus norvegicus	9-13
19000447-9	2008	The inhibition rates of paclitaxel (PTX), oxaliplatin (OXA) or cisplatin (DDP) on cancer cells were significantly lower in the group with strong P-gp expression than that with weak P-gp expression (all P&lt;0.05).	Paclitaxel	24-34	ATP binding cassette subfamily B member 1	Homo sapiens	145-149
19000447-9	2008	The inhibition rates of paclitaxel (PTX), oxaliplatin (OXA) or cisplatin (DDP) on cancer cells were significantly lower in the group with strong P-gp expression than that with weak P-gp expression (all P&lt;0.05).	Paclitaxel	24-34	ATP binding cassette subfamily B member 1	Homo sapiens	181-185
19000447-9	2008	The inhibition rates of paclitaxel (PTX), oxaliplatin (OXA) or cisplatin (DDP) on cancer cells were significantly lower in the group with strong P-gp expression than that with weak P-gp expression (all P&lt;0.05).	Paclitaxel	36-39	ATP binding cassette subfamily B member 1	Homo sapiens	145-149
19000447-10	2008	The strong expression of p53 was correlated with decreased inhibition rates of PTX and DDP on cancer cells (P&lt;0.05, P&lt;0.01).	Paclitaxel	79-82	tumor protein p53	Homo sapiens	25-28
18158619-7	2008	Reduced Bax expression and enhanced Bcl-2 expression by Id-1 were also noted in the presence of taxol.	Paclitaxel	96-101	BCL2 associated X, apoptosis regulator	Homo sapiens	8-11
18158619-7	2008	Reduced Bax expression and enhanced Bcl-2 expression by Id-1 were also noted in the presence of taxol.	Paclitaxel	96-101	BCL2 apoptosis regulator	Homo sapiens	36-41
18158619-8	2008	Taken together, we present a molecular mechanism where Id-1 regulates p53 and NF-kappaB pathways, which in turn regulates Bax and Bcl-2 genes, thus providing a survival advantage under exogenous stress such as serum-free or taxol treatment in MCF-7 breast cancer cells.	Paclitaxel	224-229	tumor protein p53	Homo sapiens	70-73
18158619-8	2008	Taken together, we present a molecular mechanism where Id-1 regulates p53 and NF-kappaB pathways, which in turn regulates Bax and Bcl-2 genes, thus providing a survival advantage under exogenous stress such as serum-free or taxol treatment in MCF-7 breast cancer cells.	Paclitaxel	224-229	nuclear factor kappa B subunit 1	Homo sapiens	78-87
18158619-8	2008	Taken together, we present a molecular mechanism where Id-1 regulates p53 and NF-kappaB pathways, which in turn regulates Bax and Bcl-2 genes, thus providing a survival advantage under exogenous stress such as serum-free or taxol treatment in MCF-7 breast cancer cells.	Paclitaxel	224-229	BCL2 associated X, apoptosis regulator	Homo sapiens	122-125
18158619-8	2008	Taken together, we present a molecular mechanism where Id-1 regulates p53 and NF-kappaB pathways, which in turn regulates Bax and Bcl-2 genes, thus providing a survival advantage under exogenous stress such as serum-free or taxol treatment in MCF-7 breast cancer cells.	Paclitaxel	224-229	BCL2 apoptosis regulator	Homo sapiens	130-135
18971636-11	2008	This regulation is observed in a transgenic p53-inducible cell system as well as in cells with wild-type p53 treated with nutlin-3, doxorubicin or paclitaxel.	Paclitaxel	147-157	tumor protein p53	Homo sapiens	44-47
19106581-9	2008	Trastuzumab and paclitaxel would be one of the optimal chemotherapies for HER2 positive breast cancer.	Paclitaxel	16-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
18974132-5	2008	In addition, taccalonolides A and E were highly active in vivo against a doxorubicin- and paclitaxel-resistant Pgp-expressing tumor, Mam17/ADR.	Paclitaxel	90-100	ATP binding cassette subfamily B member 1	Homo sapiens	111-114
19271504-5	2008	Fluorescence resonance energy transfer (FRET) and acceptor photobleaching techniques were used to analyze the caspase-3 activation in the taxol-induced cell swelling and cell dearth.	Paclitaxel	138-143	caspase 3	Homo sapiens	110-119
18927291-7	2008	By contrast, combination of F16-IL2 with paclitaxel (5 and 1 mg/kg) exhibited a significant therapeutic benefit compared with paclitaxel alone at both dose levels.	Paclitaxel	126-136	interleukin 2	Homo sapiens	32-35
19088531-2	2008	Recently, paclitaxel was linked to cutaneous lupus erythematosus in two cancer patients, showing high titers of serum anti-Ro (SS-A) antibody.	Paclitaxel	10-20	tripartite motif containing 21	Homo sapiens	127-131
18817775-1	2008	Taxol treatment of HeLa cells resulted in a transient recruitment of Caveolin-1 to the cell surface followed by internalization.	Paclitaxel	0-5	caveolin 1	Homo sapiens	69-79
18817775-3	2008	Sustained phosphorylation of Caveolin-1 is observed upon treatment and between Taxol and 10-DAB, the former shows phosphorylated Raf-1, ERK1/2 and hyperphosphorylated Bcl-2 while the later showed much less magnitude of the same.	Paclitaxel	79-84	caveolin 1	Homo sapiens	29-39
18547714-5	2008	Live confocal imaging of ASTC-a-1 cells stably expressing SCAT3 further verified that taxol-induced cytoplasm vacuolization and cell death was caspase-3-independent.	Paclitaxel	86-91	caspase 3	Homo sapiens	143-152
18723777-6	2008	Although there was a minimal effect on doxorubicin and daunorubicin, the MDR1-dependent resistance on vinblastine, vincristine, paclitaxel, and etoposide was reduced by approximately 5-fold.	Paclitaxel	128-138	ATP binding cassette subfamily B member 1	Homo sapiens	73-77
18688857-8	2008	The suppressive action of paclitaxel on meningioma cell growth was enhanced in the presence of fluvastatin or the mitogen-actvated protein kinase (ERK1/2) inhibitor PD98059.	Paclitaxel	26-36	mitogen-activated protein kinase 3	Homo sapiens	147-153
18688857-10	2008	In conclusion, our in vitro results suggest that paclitaxel alone or in combination with other inhibitors of cell growth (statins, MAPK inhibitors) could provide a potential tool for the treatment of TLR4 expressing meningiomas.	Paclitaxel	49-59	mitogen-activated protein kinase 3	Homo sapiens	131-135
18650420-12	2008	The species-specific difference between human and murine MD-2 activation of TLR4 by PTX can be explained by alterations of surface charge distribution (i.e. electrostatic potential), binding pocket size, and the locus of PTX binding within the MD-2 pocket, which results in reorganization of the 123-130 amino acid loop.	Paclitaxel	84-87	toll-like receptor 4	Mus musculus	76-80
18650420-12	2008	The species-specific difference between human and murine MD-2 activation of TLR4 by PTX can be explained by alterations of surface charge distribution (i.e. electrostatic potential), binding pocket size, and the locus of PTX binding within the MD-2 pocket, which results in reorganization of the 123-130 amino acid loop.	Paclitaxel	221-224	toll-like receptor 4	Mus musculus	76-80
18650420-3	2008	The TLR4 accessory protein, MD-2, is an essential component for the species-specific proinflammatory activity of PTX on murine cells.	Paclitaxel	113-116	toll-like receptor 4	Mus musculus	4-8
18794086-0	2008	GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.	Paclitaxel	97-107	GLI family zinc finger 2	Homo sapiens	0-4
18650420-7	2008	As measured by human tumor necrosis factor alpha production, human THP-1 monocytes expressing TLR4 and MD-2 were poorly responsive to the addition of PTX, but murine macrophages expressing TLR4 and MD-2 responded in a dose-dependent manner.	Paclitaxel	150-153	GLI family zinc finger 2	Homo sapiens	67-72
18650420-9	2008	However, HEK293 cells transfected with murine MD-2 and human TLR4 or murine MD-2 and murine TLR4 were highly responsive to PTX (10 microm), indicating that the murine MD-2/PTX interaction is required for TLR4 activation.	Paclitaxel	123-126	toll-like receptor 4	Mus musculus	92-96
18650420-9	2008	However, HEK293 cells transfected with murine MD-2 and human TLR4 or murine MD-2 and murine TLR4 were highly responsive to PTX (10 microm), indicating that the murine MD-2/PTX interaction is required for TLR4 activation.	Paclitaxel	123-126	toll-like receptor 4	Mus musculus	92-96
18650420-10	2008	To further define the structural differences for MD-2/TLR4 activation, crystal structures of both murine and human MD-2 were subjected to PTX docking by computational methods.	Paclitaxel	138-141	toll-like receptor 4	Mus musculus	54-58
18690538-5	2008	Stable overexpression of Ran also markedly inhibited the phosphorylation of Bcl-2 by paclitaxel, and inhibited the translocation of Bax, the release of cytochrome c and activation of caspase-3.	Paclitaxel	85-95	BCL2 apoptosis regulator	Homo sapiens	76-81
18690538-6	2008	Paclitaxel-induced phosphorylation of c-JUN N-terminal kinase (JNK), but not p38, extracellular signal-regulated kinase and Akt, was markedly suppressed in U373MG cells that stably expressed Ran.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	38-61
18690538-6	2008	Paclitaxel-induced phosphorylation of c-JUN N-terminal kinase (JNK), but not p38, extracellular signal-regulated kinase and Akt, was markedly suppressed in U373MG cells that stably expressed Ran.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	63-66
18690538-7	2008	These results suggest that Ran suppresses paclitaxel-induced cell death through the downregulation of JNK-mediated signal pathways.	Paclitaxel	42-52	mitogen-activated protein kinase 8	Homo sapiens	102-105
18829556-4	2008	Our hypothesis is that changes in the intrinsic (or mitochondrial) cell death pathway controlled by the BCL-2 family are key to the development of acquired paclitaxel resistance.	Paclitaxel	156-166	BCL2 apoptosis regulator	Homo sapiens	104-109
18829556-5	2008	Here we show that paclitaxel activates the mitochondrial apoptosis pathway, which can be blocked by BCL-2 overexpression.	Paclitaxel	18-28	BCL2 apoptosis regulator	Homo sapiens	100-105
18829556-6	2008	Treatment with ABT-737, a small-molecule BCL-2 antagonist, restores sensitivity to paclitaxel in BCL-2-overexpressing cells.	Paclitaxel	83-93	BCL2 apoptosis regulator	Homo sapiens	41-46
18829556-6	2008	Treatment with ABT-737, a small-molecule BCL-2 antagonist, restores sensitivity to paclitaxel in BCL-2-overexpressing cells.	Paclitaxel	83-93	BCL2 apoptosis regulator	Homo sapiens	97-102
18829556-8	2008	In these lines, acquired resistance to paclitaxel is mediated either by increased antiapoptotic BCL-2 proteins or decreased proapoptotic BCL-2 proteins.	Paclitaxel	39-49	BCL2 apoptosis regulator	Homo sapiens	96-101
18829556-8	2008	In these lines, acquired resistance to paclitaxel is mediated either by increased antiapoptotic BCL-2 proteins or decreased proapoptotic BCL-2 proteins.	Paclitaxel	39-49	BCL2 apoptosis regulator	Homo sapiens	137-142
18829556-10	2008	In summary, these findings suggest that alterations in the intrinsic apoptotic pathway controlled by BCL-2 protein family members may be crucial to causing paclitaxel resistance.	Paclitaxel	156-166	BCL2 apoptosis regulator	Homo sapiens	101-106
18829556-11	2008	Furthermore, our results suggest that combining small-molecule BCL-2 antagonists with paclitaxel may offer benefit to patients with paclitaxel-resistant tumors, an oncologic problem of great prevalence.	Paclitaxel	132-142	BCL2 apoptosis regulator	Homo sapiens	63-68
19087546-8	2008	Western blot assay showed the changes in expression levels of phosphorylated AKT and GSK-3beta, which were decreased significantly after paclitaxel and bortezomib combination treatment [(3.2 +/- 0.8)%, (19.3 +/- 0.4)%; P &lt; 0.05].	Paclitaxel	137-147	AKT serine/threonine kinase 1	Homo sapiens	77-80
18672029-9	2008	RT-PCR and Western blot analysis revealed that exposure to taxol increased the expression of p47(phox) and gp91(phox) and induced translocation of the p47(phox) to the membrane in cortical cultures.	Paclitaxel	59-64	NSFL1 (p97) cofactor (p47)	Mus musculus	93-102
18672029-9	2008	RT-PCR and Western blot analysis revealed that exposure to taxol increased the expression of p47(phox) and gp91(phox) and induced translocation of the p47(phox) to the membrane in cortical cultures.	Paclitaxel	59-64	NSFL1 (p97) cofactor (p47)	Mus musculus	97-101
18672029-9	2008	RT-PCR and Western blot analysis revealed that exposure to taxol increased the expression of p47(phox) and gp91(phox) and induced translocation of the p47(phox) to the membrane in cortical cultures.	Paclitaxel	59-64	NSFL1 (p97) cofactor (p47)	Mus musculus	93-96
18672029-9	2008	RT-PCR and Western blot analysis revealed that exposure to taxol increased the expression of p47(phox) and gp91(phox) and induced translocation of the p47(phox) to the membrane in cortical cultures.	Paclitaxel	59-64	NSFL1 (p97) cofactor (p47)	Mus musculus	112-116
18672029-12	2008	Moreover, treatment with NADPH oxidase inhibitors or suppression of gp91(phox) by siRNA significantly attenuated the taxol-induced neuronal death.	Paclitaxel	117-122	NSFL1 (p97) cofactor (p47)	Mus musculus	73-77
18766004-3	2008	The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer has been shown to correlate with resistance to paclitaxel.	Paclitaxel	134-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-62
18766004-3	2008	The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer has been shown to correlate with resistance to paclitaxel.	Paclitaxel	134-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-68
18766004-9	2008	In these HER2-positive tumors, nab-paclitaxel was equal to or better than polysorbate-based docetaxel in tumors with medium to high SPARC levels (PC3 and HT29), but not in MDA-MB-231/HER2+ tumors with low SPARC expression.	Paclitaxel	35-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
18766004-10	2008	These results demonstrated that the relative efficacy of nab-paclitaxel was significantly higher compared with polysorbate-based docetaxel in HER2-negative tumors (three of three) and in HER2-positive tumors with high levels of SPARC.	Paclitaxel	61-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-146
18829547-9	2008	Importantly, lapatinib also strongly enhanced the effect of paclitaxel on the inhibition of growth of the ABCB1-overexpressing KBv200 cell xenografts in nude mice.	Paclitaxel	60-70	ATP binding cassette subfamily B member 1	Homo sapiens	106-111
18813780-7	2008	Consistently, PTX increased p21WAF1, bax and MDM2 levels, suggesting that p53 is transcriptionally active.	Paclitaxel	14-17	BCL2 associated X, apoptosis regulator	Homo sapiens	37-40
18813780-7	2008	Consistently, PTX increased p21WAF1, bax and MDM2 levels, suggesting that p53 is transcriptionally active.	Paclitaxel	14-17	tumor protein p53	Homo sapiens	74-77
19087722-10	2008	Lysis of caspase-9 and PARP in the Ark2 and KLE cells increased greatly 24 hours after the TSA and PTX treatment.	Paclitaxel	99-102	poly(ADP-ribose) polymerase 1	Homo sapiens	23-27
19087722-11	2008	The disappearance rate of MMP in the Ark2 and AN3 cells of the TSA + PTX groups were 16.80% +/- 0.92% and 11.28% +/- 0.78% respectively, significantly higher than that of the PTX group (5.34% +/- 0.45% and 5.61% +/- 0.56% respectively) and TSA group (4.96% +/- 0.47% and 6.46% +/- 0.62% respectively, all P &lt; 0.05).	Paclitaxel	69-72	tripartite motif containing 44	Homo sapiens	46-49
19087722-7	2008	RESULTS: The growth of the Ark2, KLE, and AN3 cells of the TSA, PTX, and TSA + PTX group, especially in the latter group, was inhibited.	Paclitaxel	64-67	tripartite motif containing 44	Homo sapiens	42-45
18765553-0	2008	ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.	Paclitaxel	100-110	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
19087722-7	2008	RESULTS: The growth of the Ark2, KLE, and AN3 cells of the TSA, PTX, and TSA + PTX group, especially in the latter group, was inhibited.	Paclitaxel	79-82	tripartite motif containing 44	Homo sapiens	42-45
18574456-2	2008	For malignant gliomas, paclitaxel is prevented from reaching its target by the presence of the efflux pump P-glycoprotein (P-gp) at the blood-brain barrier.	Paclitaxel	23-33	ATP binding cassette subfamily B member 1	Homo sapiens	107-121
18574456-2	2008	For malignant gliomas, paclitaxel is prevented from reaching its target by the presence of the efflux pump P-glycoprotein (P-gp) at the blood-brain barrier.	Paclitaxel	23-33	ATP binding cassette subfamily B member 1	Homo sapiens	123-127
18765553-0	2008	ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.	Paclitaxel	100-110	ATP binding cassette subfamily B member 1	Homo sapiens	7-12
18765553-1	2008	PURPOSE: The human ABCB1 gene encodes P-glycoprotein, which transports a broad range of anticancer drugs, including paclitaxel.	Paclitaxel	116-126	ATP binding cassette subfamily B member 1	Homo sapiens	19-24
18765553-1	2008	PURPOSE: The human ABCB1 gene encodes P-glycoprotein, which transports a broad range of anticancer drugs, including paclitaxel.	Paclitaxel	116-126	ATP binding cassette subfamily B member 1	Homo sapiens	38-52
18703598-4	2008	The functional activities of MDR1 shRNA were determined by paclitaxel uptake and sensitivity to doxorubicin.	Paclitaxel	59-69	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
18685414-3	2008	A phase II study investigated the safety and efficacy of trastuzumab, carboplatin, gemcitabine, and paclitaxel in human epidermal growth factor receptor-2/neu-positive advanced urothelial carcinoma and reported promising results.	Paclitaxel	100-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-154
18685414-3	2008	A phase II study investigated the safety and efficacy of trastuzumab, carboplatin, gemcitabine, and paclitaxel in human epidermal growth factor receptor-2/neu-positive advanced urothelial carcinoma and reported promising results.	Paclitaxel	100-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	155-158
18806740-3	2008	RESULTS: Low dose of Taxol that cause apoptosis (25 nM) enhanced Rb protein phosphorylation, decreased the expression of cyclin-dependent kinase inhibitors p27(KIP1) and p21(WAF1) , and potentiated the accumulation of phosphorylated p53 and of the prolyl isomerase Pin1.	Paclitaxel	21-26	cyclin dependent kinase inhibitor 1A	Homo sapiens	170-173
18806740-3	2008	RESULTS: Low dose of Taxol that cause apoptosis (25 nM) enhanced Rb protein phosphorylation, decreased the expression of cyclin-dependent kinase inhibitors p27(KIP1) and p21(WAF1) , and potentiated the accumulation of phosphorylated p53 and of the prolyl isomerase Pin1.	Paclitaxel	21-26	cyclin dependent kinase inhibitor 1A	Homo sapiens	174-178
18806740-3	2008	RESULTS: Low dose of Taxol that cause apoptosis (25 nM) enhanced Rb protein phosphorylation, decreased the expression of cyclin-dependent kinase inhibitors p27(KIP1) and p21(WAF1) , and potentiated the accumulation of phosphorylated p53 and of the prolyl isomerase Pin1.	Paclitaxel	21-26	tumor protein p53	Homo sapiens	233-236
18703598-9	2008	The inhibition of P-glycoprotein expression by shRNA enhanced the intracellular accumulation of paclitaxel, the cellular retention of which is mediated by P-glycoprotein, thereby increasing sensitivity to the anticancer drug.	Paclitaxel	96-106	ATP binding cassette subfamily B member 1	Homo sapiens	18-32
18703598-9	2008	The inhibition of P-glycoprotein expression by shRNA enhanced the intracellular accumulation of paclitaxel, the cellular retention of which is mediated by P-glycoprotein, thereby increasing sensitivity to the anticancer drug.	Paclitaxel	96-106	ATP binding cassette subfamily B member 1	Homo sapiens	155-169
18555006-4	2008	Furthermore, endogenous expression of p19(ras) and p73beta is significantly increased by Taxol treatment, and Taxol-enhanced endogenous p73beta transcriptional activities are further amplified by p19(ras), which markedly increased cellular apoptosis in p53-null SAOS2 cancer cell line.	Paclitaxel	110-115	tumor protein p53	Homo sapiens	253-256
18625294-5	2008	These findings suggest that Hexyl-ALA could be used to selectively reduce P-gp expression in overcoming resistance to chemotherapy agents such as doxorubicin and paclitaxel.	Paclitaxel	162-172	ATP binding cassette subfamily B member 1	Homo sapiens	74-78
18698031-5	2008	RESULTS: Transient Chk1 down-regulation sensitized HCT-116 cells, p53-/- more than the p53 wild-type counterpart, to DNA-damaging agents 5-fluorouracil (5-FU), doxorubicin, and etoposide treatments, with no modification of Taxol and PS341 cytotoxic activities.	Paclitaxel	223-228	checkpoint kinase 1	Homo sapiens	19-23
18400375-8	2008	EGF plus EGFR inhibitor-primed ovarian cancer cells display increased sensitivity to taxol-induced cell death, resistant to EGF-induced cell migration and cell proliferation as well as ERK and PI3K/AKT activation.	Paclitaxel	85-90	epidermal growth factor receptor	Homo sapiens	9-13
17960385-0	2008	The effect of p53 gene expression on the inhibition of cell proliferation by paclitaxel.	Paclitaxel	77-87	tumor protein p53	Homo sapiens	14-17
18710614-11	2008	Cleavages of PARP and caspase-9 were significantly apparent in PTX plus TSA group than in PTX group or TSA group (P&lt;0.05).	Paclitaxel	63-66	poly(ADP-ribose) polymerase 1	Homo sapiens	13-17
18710614-11	2008	Cleavages of PARP and caspase-9 were significantly apparent in PTX plus TSA group than in PTX group or TSA group (P&lt;0.05).	Paclitaxel	90-93	poly(ADP-ribose) polymerase 1	Homo sapiens	13-17
18673531-8	2008	MTT assay showed that Pgp inhibitors such as cyclosporine A, verapamil and PSC833 sensitized Colo320HSR (colon, highest MDR1 expression) but not SNU-668 (gastric, highest) and SNU-C5 (gastric, no expression) to paclitaxel.	Paclitaxel	211-221	ATP binding cassette subfamily B member 1	Homo sapiens	22-25
17960385-1	2008	BACKGROUND/AIMS: We evaluated the relationship between p53 status and paclitaxel (PTX)-induced inhibition of the growth of human stomach cancer cells.	Paclitaxel	70-80	tumor protein p53	Homo sapiens	55-58
18487950-7	2008	Subsequent application of specific inhibitors revealed that the paclitaxel-induced cell death is highly impaired by active Erk1/2 and Akt, whereas the cisplatin-induced cell death is independent of both kinases.	Paclitaxel	64-74	mitogen-activated protein kinase 3	Homo sapiens	123-129
17960385-1	2008	BACKGROUND/AIMS: We evaluated the relationship between p53 status and paclitaxel (PTX)-induced inhibition of the growth of human stomach cancer cells.	Paclitaxel	82-85	tumor protein p53	Homo sapiens	55-58
18487950-7	2008	Subsequent application of specific inhibitors revealed that the paclitaxel-induced cell death is highly impaired by active Erk1/2 and Akt, whereas the cisplatin-induced cell death is independent of both kinases.	Paclitaxel	64-74	AKT serine/threonine kinase 1	Homo sapiens	134-137
17960385-9	2008	In contrast, PTX-treatment led to an increase in the cleaved form of caspase-3 in MKN45, but not MKN28 cells.	Paclitaxel	13-16	caspase 3	Homo sapiens	69-78
17960385-11	2008	CONCLUSION: Both p53 status and cyclin-B1 expression might be useful for predicting the therapeutic response of stomach cancer to PTX.	Paclitaxel	130-133	tumor protein p53	Homo sapiens	17-20
17992531-3	2008	In paclitaxel-administered cancer patients, an association of CYP3A4*16B harboring the low activity allele *16 [554C &gt; G (Thr185Ser)] has been shown with altered metabolite/paclitaxel area under the plasma concentration-time curve (AUC) ratios, suggesting a possible impact of *16B on the PK of other drugs.	Paclitaxel	3-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
17992531-3	2008	In paclitaxel-administered cancer patients, an association of CYP3A4*16B harboring the low activity allele *16 [554C &gt; G (Thr185Ser)] has been shown with altered metabolite/paclitaxel area under the plasma concentration-time curve (AUC) ratios, suggesting a possible impact of *16B on the PK of other drugs.	Paclitaxel	176-186	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
18796247-6	2008	Docetaxel induced the decrease in the activity of protein phosphatase 1 (PP1) and increase in the activity of PP2 subgroups, while paclitaxel induced the increase in the activity of PP1 and decrease in the activity of PP2 subgroups.	Paclitaxel	131-141	inorganic pyrophosphatase 1	Homo sapiens	182-185
18481305-9	2008	Our results suggest that taxol prevents rapid transport of key components, such as NuMA, to the nascent spindle poles.	Paclitaxel	25-30	nuclear mitotic apparatus protein 1	Homo sapiens	83-87
18676833-9	2008	In conclusion, the current report not only unravels a novel mechanism to link Erk/Pin1 pathway and Mcl-1-mediated chemoresistance but also provides a plausible combination therapy, Taxol (Paclitaxel) plus Sorafenib, which was shown to be effective in killing breast cancer cells.	Paclitaxel	181-186	mitogen-activated protein kinase 1	Homo sapiens	78-81
18676833-9	2008	In conclusion, the current report not only unravels a novel mechanism to link Erk/Pin1 pathway and Mcl-1-mediated chemoresistance but also provides a plausible combination therapy, Taxol (Paclitaxel) plus Sorafenib, which was shown to be effective in killing breast cancer cells.	Paclitaxel	188-198	mitogen-activated protein kinase 1	Homo sapiens	78-81
18754875-6	2008	By reverse transcription-polymerase chain reaction, the expression levels of MMP-3 and CD163 were markedly up-regulated in paclitaxel-treated dorsal root ganglion.	Paclitaxel	123-133	CD163 molecule	Rattus norvegicus	87-92
18391985-4	2008	When exposed to spindle toxins such as vinblastine and taxol, Fbw7-deficient cells undergo extensive mitotic slippage and endoreduplication, rendering them polyploid.	Paclitaxel	55-60	F-box and WD repeat domain containing 7	Homo sapiens	62-66
18937711-9	2008	Furthermore, ERalpha mRNA expression was attenuated at melatonin level of 1 x 10(-9) M. Chemosensitivity test revealed that melatonin enhanced anti-tumor effects of paclitaxel among anticancer drugs tested.	Paclitaxel	165-175	estrogen receptor 1	Homo sapiens	13-20
18704310-0	2008	Targeting of p38 mitogen-activated protein kinases to early growth response gene 1 (EGR-1) in the human paclitaxel-resistance ovarian carcinoma cells.	Paclitaxel	104-114	mitogen-activated protein kinase 14	Homo sapiens	13-16
17963215-6	2008	After epimerization at the C7, paclitaxel hydrolysis occurs mainly due to cleavage of the side chain with further hydrolysis of the ester bonds at C10, C2 and C4 with the C10 acetate hydrolysis being the relatively next most facile.	Paclitaxel	31-41	homeobox C10	Homo sapiens	147-150
17963215-6	2008	After epimerization at the C7, paclitaxel hydrolysis occurs mainly due to cleavage of the side chain with further hydrolysis of the ester bonds at C10, C2 and C4 with the C10 acetate hydrolysis being the relatively next most facile.	Paclitaxel	31-41	homeobox C10	Homo sapiens	171-174
18469851-0	2008	Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis.	Paclitaxel	53-63	tumor protein p53	Homo sapiens	81-84
18469851-10	2008	We conclude that PTX directly affects cells only in mitosis and the duration of mitosis determines cell fate, including p53-dependent G1-like arrest.	Paclitaxel	17-20	tumor protein p53	Homo sapiens	120-123
18594523-7	2008	Evaluation of signalling pathways showed that MnSOD siRNA enhanced doxorubicin- and paclitaxel-induced phosphorylation of extracellular signal-regulated kinase 1/2.	Paclitaxel	84-94	mitogen-activated protein kinase 3	Homo sapiens	122-163
18593915-10	2008	The iNOS/survivin interdependencies seem to be also of clinical relevance because immunohistochemistry revealed that low iNOS levels correlate with survivin expression (P &lt; 0.01) in carboplatin/paclitaxel-treated EOC patients with minimal postoperative residual tumor (n = 54).	Paclitaxel	197-207	nitric oxide synthase 2	Homo sapiens	4-8
18751412-1	2008	The case of a young man with stage IV chemoresistant pure seminoma overexpressing KIT, who achieved complete remission (CR) after the administration of imatinib mesylate (400 mg once daily), along with a third-line chemotherapy regimen, consisting of paclitaxel (150 mg/m2), oxaliplatin (100 mg/m2) and gemcitabine (800 mg/m2) every 2 weeks with granulocyte colony-stimulating factor (G-CSF) support is reported.	Paclitaxel	251-261	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	82-85
18751438-0	2008	Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG) study.	Paclitaxel	186-196	prostaglandin-endoperoxide synthase 2	Homo sapiens	30-46
18751438-0	2008	Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG) study.	Paclitaxel	186-196	prostaglandin-endoperoxide synthase 2	Homo sapiens	48-53
18593915-10	2008	The iNOS/survivin interdependencies seem to be also of clinical relevance because immunohistochemistry revealed that low iNOS levels correlate with survivin expression (P &lt; 0.01) in carboplatin/paclitaxel-treated EOC patients with minimal postoperative residual tumor (n = 54).	Paclitaxel	197-207	nitric oxide synthase 2	Homo sapiens	121-125
18644986-3	2008	Here, paclitaxel induced the apoptosis of cervical cancer HeLa cells and correlated with the enhanced activation of caspase-3 and TAp73, which was strongly inhibited by TAp73beta small interfering RNA (siRNA).	Paclitaxel	6-16	caspase 3	Homo sapiens	116-125
18161023-3	2008	Compared with paclitaxel or MDP alone or with a mixture of paclitaxel + MDP, 2"- O -MTC-01 significantly increases the production and expression of TNF-alpha and IL-12 from mouse peritoneal macrophages, which demonstrates a synergism of MDP and paclitaxel in one conjugated molecule.	Paclitaxel	59-69	tumor necrosis factor	Mus musculus	148-157
18161023-3	2008	Compared with paclitaxel or MDP alone or with a mixture of paclitaxel + MDP, 2"- O -MTC-01 significantly increases the production and expression of TNF-alpha and IL-12 from mouse peritoneal macrophages, which demonstrates a synergism of MDP and paclitaxel in one conjugated molecule.	Paclitaxel	59-69	tumor necrosis factor	Mus musculus	148-157
18452161-2	2008	After addition of paclitaxel to U937 cells, however, we observed an early expression of five endoplasmic reticulum (ER) stress response genes that preceded the release of cytochrome c from the mitochondria and the cleavage of the caspases.	Paclitaxel	18-28	cytochrome c, somatic	Homo sapiens	171-183
18452161-2	2008	After addition of paclitaxel to U937 cells, however, we observed an early expression of five endoplasmic reticulum (ER) stress response genes that preceded the release of cytochrome c from the mitochondria and the cleavage of the caspases.	Paclitaxel	18-28	caspase 4	Homo sapiens	230-238
18452161-4	2008	Paclitaxel treatment not only activated calpain and caspase-4, but also induced a gradual increase in the cytosolic Ca(2+) concentration at 3-6 h. Paclitaxel-induced apoptosis can be inhibited by the calpain inhibitor calpeptin and IP(3) receptor inhibitors.	Paclitaxel	0-10	caspase 4	Homo sapiens	52-61
18452161-4	2008	Paclitaxel treatment not only activated calpain and caspase-4, but also induced a gradual increase in the cytosolic Ca(2+) concentration at 3-6 h. Paclitaxel-induced apoptosis can be inhibited by the calpain inhibitor calpeptin and IP(3) receptor inhibitors.	Paclitaxel	147-157	caspase 4	Homo sapiens	52-61
18452161-7	2008	Paclitaxel-induced Bax/Bak translocation to the ER and Bax dimerization on the ER membrane occurred within 3 h, which led to a Ca(2+) efflux into cytosol.	Paclitaxel	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	19-22
18452161-7	2008	Paclitaxel-induced Bax/Bak translocation to the ER and Bax dimerization on the ER membrane occurred within 3 h, which led to a Ca(2+) efflux into cytosol.	Paclitaxel	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	55-58
18196205-12	2008	As the concentration of Paclitaxel was increased from 0 to 10, and 40 mug/ml, the viability of HCT116 cells incubated with free Paclitaxel decreased from 100 to 65 and 40%, respectively, while those encapsulated in PLGF/PLEOF NPs decreased from 93 to 54 and 28%.	Paclitaxel	24-34	placental growth factor	Homo sapiens	215-219
18196205-12	2008	As the concentration of Paclitaxel was increased from 0 to 10, and 40 mug/ml, the viability of HCT116 cells incubated with free Paclitaxel decreased from 100 to 65 and 40%, respectively, while those encapsulated in PLGF/PLEOF NPs decreased from 93 to 54 and 28%.	Paclitaxel	128-138	placental growth factor	Homo sapiens	215-219
20731930-0	2008	[Effects of paclitaxel and gefitinib on the proliferation and cell cycle of human lung adenocarcinoma cell SPC-A1.].	Paclitaxel	12-22	proline rich protein gene cluster	Homo sapiens	107-110
18441325-6	2008	Furthermore, we observed that HA-CD44 interaction induces ankyrin (a cytoskeletal protein) binding to MDR1 resulting in the efflux of chemotherapeutic drugs (e.g. doxorubicin and paclitaxel (Taxol)) and chemoresistance in these tumor cells.	Paclitaxel	179-189	ATP binding cassette subfamily B member 1	Homo sapiens	102-106
18441325-6	2008	Furthermore, we observed that HA-CD44 interaction induces ankyrin (a cytoskeletal protein) binding to MDR1 resulting in the efflux of chemotherapeutic drugs (e.g. doxorubicin and paclitaxel (Taxol)) and chemoresistance in these tumor cells.	Paclitaxel	191-196	ATP binding cassette subfamily B member 1	Homo sapiens	102-106
20731930-11	2008	Cell cycle studies showed that paclitaxel and gefitinib induced G2/M and G0/G1 arrest respectively.	Paclitaxel	31-41	crystallin gamma E, pseudogene	Homo sapiens	64-78
18599999-0	2008	[Proteomic study of paclitaxel on human cervical carcinoma HCE1].	Paclitaxel	20-30	RNA guanylyltransferase and 5'-phosphatase	Homo sapiens	59-63
18420585-4	2008	Upon paclitaxel treatment, RACK1, DLC1, and CIS mediated the degradation of BimEL through the ElonginB/C-Cullin2-CIS ubiquitin-protein isopeptide ligase complex.	Paclitaxel	5-15	DLC1 Rho GTPase activating protein	Homo sapiens	34-38
18272284-6	2008	Paclitaxel-induced cell death was inhibited by hypoxia conditioning that increased HIF-1 alpha stabilization and ERK phosphorylation.	Paclitaxel	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	83-94
18272284-6	2008	Paclitaxel-induced cell death was inhibited by hypoxia conditioning that increased HIF-1 alpha stabilization and ERK phosphorylation.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Homo sapiens	113-116
18433974-7	2008	Also inhibition of MDR1 was monitored by measuring digoxin transport on Caco-2 monolayers and paclitaxel toxicity on K562-MDR cells.	Paclitaxel	94-104	ATP binding cassette subfamily B member 1	Homo sapiens	19-23
18433974-9	2008	Digoxin permeability and paclitaxel cytotoxicity studies revealed that these herbicides are potent inhibitors of MDR1 that can modulate drug absorption and cause chemosensitization of cells.	Paclitaxel	25-35	ATP binding cassette subfamily B member 1	Homo sapiens	113-117
18324624-5	2008	Following transient expression of MDR-1 and MCJ, changes in the sensitivity of Sk-Ov-3 cells to paclitaxel were detected whereas expression of Src, Bcl-2 and Bcl-X(L) decreased the sensitivity of Sk-Ov-3 cells to carboplatin.	Paclitaxel	96-106	ATP binding cassette subfamily B member 1	Homo sapiens	34-39
17828752-0	2008	ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel.	Paclitaxel	57-67	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
17828752-1	2008	P-glycoprotein (P-gp), encoded by the ABCB1 gene, confers multi-drug resistance to a variety of antineoplastic agents, for example, paclitaxel.	Paclitaxel	132-142	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
17828752-1	2008	P-glycoprotein (P-gp), encoded by the ABCB1 gene, confers multi-drug resistance to a variety of antineoplastic agents, for example, paclitaxel.	Paclitaxel	132-142	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
17828752-1	2008	P-glycoprotein (P-gp), encoded by the ABCB1 gene, confers multi-drug resistance to a variety of antineoplastic agents, for example, paclitaxel.	Paclitaxel	132-142	ATP binding cassette subfamily B member 1	Homo sapiens	38-43
17828752-3	2008	We analyzed the allelic distribution of the G1199T/A and other polymorphisms in exons 11 and 12 of the ABCB1 gene in ovarian cancer patients treated with paclitaxel and carboplatin in order to evaluate their predictive value in vivo.	Paclitaxel	154-164	ATP binding cassette subfamily B member 1	Homo sapiens	103-108
17828752-8	2008	Genotyping of the ABCB1 gene may be important for determining the tumor resistance to paclitaxel and provide useful information for individualized therapy.	Paclitaxel	86-96	ATP binding cassette subfamily B member 1	Homo sapiens	18-23
18516295-2	2008	We have previously shown that mutational inactivation of p53 results in sensitization to paclitaxel.	Paclitaxel	89-99	tumor protein p53	Homo sapiens	57-60
18516295-7	2008	Sensitization to paclitaxel-induced apoptosis was also achieved by p53-siRNA transfection in wild type p53 H460 cells.	Paclitaxel	17-27	tumor protein p53	Homo sapiens	67-70
18516295-7	2008	Sensitization to paclitaxel-induced apoptosis was also achieved by p53-siRNA transfection in wild type p53 H460 cells.	Paclitaxel	17-27	tumor protein p53	Homo sapiens	103-106
18516298-6	2008	VEGF-A protected MDA-MB-231 cells against nab-paclitaxel cytotoxicity, whereas bevacizumab sensitized cells to the effect of the drug.	Paclitaxel	46-56	vascular endothelial growth factor A	Homo sapiens	0-6
18518845-3	2008	However, so far only genetic variants of ABCB1 have been indicated to be associated with response and pharmacokinetics of paclitaxel.	Paclitaxel	122-132	ATP binding cassette subfamily B member 1	Homo sapiens	41-46
18599999-1	2008	OBJECTIVE: To explore the mechanism of paclitaxel on the protein expression of human cervical carcinoma cell line HCE1.	Paclitaxel	39-49	RNA guanylyltransferase and 5'-phosphatase	Homo sapiens	114-118
18599999-2	2008	METHODS: The total proteins extracted from paclitaxel-treated HCE1 cells were analyzed by 2-dimensional gel electrophoresis (2-DE), and compared with those from untreated HCE1 cells.	Paclitaxel	43-53	RNA guanylyltransferase and 5'-phosphatase	Homo sapiens	62-66
18071320-2	2008	Using cervical carcinoma cells (HeLa), the present study investigates the involvement of COX-2 in apoptosis elicited by the chemotherapeutics paclitaxel, cisplatin and 5-fluorouracil.	Paclitaxel	142-152	prostaglandin-endoperoxide synthase 2	Homo sapiens	89-94
18451172-6	2008	The addition of TRAIL to either nocodazole or paclitaxel (Taxol) reduced levels of the mitotic checkpoint proteins BubR1 and Bub1.	Paclitaxel	46-56	TNF superfamily member 10	Homo sapiens	16-21
18451172-6	2008	The addition of TRAIL to either nocodazole or paclitaxel (Taxol) reduced levels of the mitotic checkpoint proteins BubR1 and Bub1.	Paclitaxel	58-63	TNF superfamily member 10	Homo sapiens	16-21
18364725-0	2008	HER2 positivity predicts a benefit from paclitaxel treatment after adjuvant chemotherapy.	Paclitaxel	40-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
17932689-0	2008	Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.	Paclitaxel	79-89	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-19
18515736-1	2008	The taxanes docetaxel (Taxotere; Sanofi-Aventis U.S. LLC, Bridgewater, NJ) and paclitaxel (Taxol; Bristol-Myers Squibb, Princeton, NJ) are highly active agents in metastatic breast cancer and may represent a safer alternative to anthracycline-based regimens when combined with the human epidermal growth factor receptor (HER)-2-targeted agent trastuzumab (Herceptin(R); Genentech Inc., South San Francisco, CA).	Paclitaxel	79-89	epidermal growth factor receptor	Homo sapiens	287-319
20731895-7	2008	RESULTS: The tumor-inhibiting rate of paclitaxel plus LY294002 (92.47%) was significantly higher than the paclitaxel alone (65.59%)(P &lt;0.05).The protein expression of bcl-2 in paclitaxel plus LY294002 group were significantly higher, while bax was significantly lower than that in the other two groups (P &lt;0.05).	Paclitaxel	38-48	B cell leukemia/lymphoma 2	Mus musculus	170-175
18275843-4	2008	In parallel, apicidin resistance to the apoptotic potential of paclitaxel is associated with induction of P-gp expression in HeLa cells, as evidenced by specific inhibition of P-gp function using either the pharmacological inhibitor verapamil or RNA silencing.	Paclitaxel	63-73	ATP binding cassette subfamily B member 1	Homo sapiens	106-110
20731894-14	2008	pEGFP-p53(RS)-801D cell line showed a notably smaller value of IC50(2.34+/-0.43 ng/mL) to Paclitaxel(TAX) than 801D(8.40+/-1.50 ng/mL, P &lt;0.05)did.	Paclitaxel	90-100	tumor protein p53	Homo sapiens	6-9
18341588-0	2008	Distinct signaling pathways of microtubule inhibitors--vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively.	Paclitaxel	71-76	mitogen-activated protein kinase 8	Homo sapiens	84-87
18423117-11	2008	CONCLUSIONS: The activation of PI-3K/Akt pathway plays an important role in paclitaxel-resistance of ovarian carcinoma cells.	Paclitaxel	76-86	AKT serine/threonine kinase 1	Homo sapiens	37-40
18423117-12	2008	PI-3K/Akt inhibitor, LY294002 has a reversal effect on the paclitaxel-resistance of A2780/Taxol cells.	Paclitaxel	59-69	AKT serine/threonine kinase 1	Homo sapiens	6-9
18341588-7	2008	These results suggest that although JNK activation plays an important role in cell death induced by both agents, vinblastine and Taxol differ markedly with respect to signaling downstream of JNK, with AP-1-dependent and -independent mechanisms, respectively.	Paclitaxel	129-134	mitogen-activated protein kinase 8	Homo sapiens	191-194
18341588-6	2008	However, inhibition of JNK or an absence of JNK protected against both vinblastine- and Taxol-induced cell death.	Paclitaxel	88-93	mitogen-activated protein kinase 8	Homo sapiens	23-26
18341588-6	2008	However, inhibition of JNK or an absence of JNK protected against both vinblastine- and Taxol-induced cell death.	Paclitaxel	88-93	mitogen-activated protein kinase 8	Homo sapiens	44-47
18256541-7	2008	Prolonged treatment with two commonly-used chemotoxic compounds, doxorubicin and paclitaxel, caused increased activation of ERK in PTEN-positive DU145 cells, but not PTEN-negative PC3 cells.	Paclitaxel	81-91	mitogen-activated protein kinase 1	Homo sapiens	124-127
18058816-2	2008	In this study, we developed a decoy cis-element oligo-deoxyribonucleic acid against NF kappaB-binding site (NF kappaB-decoy), which effectively inhibits NF kappaB activity, and tested the effect of combined therapy comprising local transfection of NF kappaB-decoy into the liver and transportal injection of paclitaxel on cancer growth and metastasis using an orthotopic murine model of colon cancer liver metastasis.	Paclitaxel	308-318	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	84-93
18058816-2	2008	In this study, we developed a decoy cis-element oligo-deoxyribonucleic acid against NF kappaB-binding site (NF kappaB-decoy), which effectively inhibits NF kappaB activity, and tested the effect of combined therapy comprising local transfection of NF kappaB-decoy into the liver and transportal injection of paclitaxel on cancer growth and metastasis using an orthotopic murine model of colon cancer liver metastasis.	Paclitaxel	308-318	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	108-117
18058816-2	2008	In this study, we developed a decoy cis-element oligo-deoxyribonucleic acid against NF kappaB-binding site (NF kappaB-decoy), which effectively inhibits NF kappaB activity, and tested the effect of combined therapy comprising local transfection of NF kappaB-decoy into the liver and transportal injection of paclitaxel on cancer growth and metastasis using an orthotopic murine model of colon cancer liver metastasis.	Paclitaxel	308-318	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	108-117
18058816-2	2008	In this study, we developed a decoy cis-element oligo-deoxyribonucleic acid against NF kappaB-binding site (NF kappaB-decoy), which effectively inhibits NF kappaB activity, and tested the effect of combined therapy comprising local transfection of NF kappaB-decoy into the liver and transportal injection of paclitaxel on cancer growth and metastasis using an orthotopic murine model of colon cancer liver metastasis.	Paclitaxel	308-318	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	108-117
18058816-4	2008	We examined the influence of NF kappaB-decoy transfer on susceptibility to paclitaxel in cancer cells and the mechanism involved using several in vitro analysis systems.	Paclitaxel	75-85	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	29-38
18058816-6	2008	In vitro experiments, including MTT-assay, fluorescence-activated cell sorter and cDNA array analysis, revealed that NF kappaB-decoy transfer significantly increased the susceptibility of cancer cells to paclitaxel, and that decreased expression of anti-apoptotic genes along with increased expression of genes relevant to the apoptosis-promotor may be involved.	Paclitaxel	204-214	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	117-126
18058816-7	2008	In vivo experiments showed that local transfection of NF kappaB-decoy into the liver followed by portal injection of paclitaxel effectively induced cancer cell apoptosis in the liver metastasis, and significantly prolonged animal survival compared to controls, without notable side effects.	Paclitaxel	117-127	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	54-63
18319717-0	2008	The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers.	Paclitaxel	76-86	forkhead box O1	Homo sapiens	19-24
18319717-2	2008	In ovarian cancer cell lines, FOXO1 expression and its correlation with paclitaxel treatment was investigated by cytotoxic assay and silencing experiment.	Paclitaxel	72-82	forkhead box O1	Homo sapiens	30-35
17468948-0	2008	HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.	Paclitaxel	45-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
17468948-1	2008	PURPOSE: We examined the correlation between HER2 expression and pathologic complete response (pCR) to paclitaxel/FAC (T/FAC) preoperative chemotherapy in breast cancer.	Paclitaxel	103-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49
18237771-6	2008	RESULTS: In A2780, PA-1, IGROV-1, and TOV-112D cells lonafarnib potentiated the growth inhibitory effects of paclitaxel.	Paclitaxel	109-119	PAXIP1 associated glutamate rich protein 1	Homo sapiens	19-23
18237771-8	2008	The combination of lonafarnib plus paclitaxel resulted in marked tumor regressions in A2780, TOV-112D, PA-1, and IGROV-1 tumor xenografts.	Paclitaxel	35-45	PAXIP1 associated glutamate rich protein 1	Homo sapiens	103-107
18237771-9	2008	Western blotting demonstrated that in PBMCs isolated from the animals, paclitaxel treatment suppressed lonafarnib-induced HDJ-2 mobility shifts.	Paclitaxel	71-81	DnaJ heat shock protein family (Hsp40) member A1	Homo sapiens	122-127
18375893-3	2008	Subsequently trastuzumab was demonstrated to improve outcomes of paclitaxel therapy for human epidermal growth factor receptor-2 (HER-2)-positive patients, and was therefore incorporated.	Paclitaxel	65-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-128
18375893-3	2008	Subsequently trastuzumab was demonstrated to improve outcomes of paclitaxel therapy for human epidermal growth factor receptor-2 (HER-2)-positive patients, and was therefore incorporated.	Paclitaxel	65-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-135
18319717-4	2008	FOXO1 expression was distinctively upregulated in paclitaxel-resistant cell line, and enhanced by exposure to paclitaxel.	Paclitaxel	50-60	forkhead box O1	Homo sapiens	0-5
18319717-4	2008	FOXO1 expression was distinctively upregulated in paclitaxel-resistant cell line, and enhanced by exposure to paclitaxel.	Paclitaxel	110-120	forkhead box O1	Homo sapiens	0-5
18319717-6	2008	FOXO1 silencing in paclitaxel-resistant cell line decreased its resistance.	Paclitaxel	19-29	forkhead box O1	Homo sapiens	0-5
18319717-8	2008	Downstream targets of FOXO1 involving oxidative stress were also attenuated in silencing experiment, suggesting its involvement in altered sensitivity to paclitaxel.	Paclitaxel	154-164	forkhead box O1	Homo sapiens	22-27
18319717-9	2008	These results indicate that FOXO1 links to cytotoxic stress induced by paclitaxel and contributes to the drug-resistance in ovarian cancers.	Paclitaxel	71-81	forkhead box O1	Homo sapiens	28-33
18234154-6	2008	Additionally, 1 microM completely reversed Pgp-mediated resistance to vinblastine, paclitaxel and depsipeptide in SW620 Ad20 cells.	Paclitaxel	83-93	ATP binding cassette subfamily B member 1	Homo sapiens	43-46
18506998-11	2008	Immunohistochemical staining showed increased expression of p65 after paclitaxel treatment, while paclitaxel in combination with AdIkappaBalpha intratumoral injection eliminated this expression accompanied by the slightly reduced expression of VEGF, with stable p53 status.	Paclitaxel	98-108	vascular endothelial growth factor A	Homo sapiens	244-248
18506998-11	2008	Immunohistochemical staining showed increased expression of p65 after paclitaxel treatment, while paclitaxel in combination with AdIkappaBalpha intratumoral injection eliminated this expression accompanied by the slightly reduced expression of VEGF, with stable p53 status.	Paclitaxel	98-108	tumor protein p53	Homo sapiens	262-265
18281707-0	2008	Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).	Paclitaxel	57-67	proteasome 26S subunit, non-ATPase 1	Homo sapiens	147-150
18393775-4	2008	The microtubule inhibitors taxol, nocodazole, and colcemid, as well as an inhibitor of actin microfilaments cytochalasin D, enhance the action of TRAIL and allow it to overcome protection caused by overexpression of Bcl-2.	Paclitaxel	27-32	TNF superfamily member 10	Homo sapiens	146-151
17987264-3	2008	Treatment of glioblastoma cells with TXL triggered production of reactive oxygen species (ROS), induced phosphorylation of p38 mitogen-activated protein kinase (MAPK), and activated the redox-sensitive c-Jun NH(2)-terminal kinase 1 (JNK1) pathway.	Paclitaxel	37-40	mitogen-activated protein kinase 14	Homo sapiens	123-159
17987264-3	2008	Treatment of glioblastoma cells with TXL triggered production of reactive oxygen species (ROS), induced phosphorylation of p38 mitogen-activated protein kinase (MAPK), and activated the redox-sensitive c-Jun NH(2)-terminal kinase 1 (JNK1) pathway.	Paclitaxel	37-40	mitogen-activated protein kinase 8	Homo sapiens	202-231
17987264-3	2008	Treatment of glioblastoma cells with TXL triggered production of reactive oxygen species (ROS), induced phosphorylation of p38 mitogen-activated protein kinase (MAPK), and activated the redox-sensitive c-Jun NH(2)-terminal kinase 1 (JNK1) pathway.	Paclitaxel	37-40	mitogen-activated protein kinase 8	Homo sapiens	233-237
18234299-11	2008	Treatment with API-59CJ-OME, carboplatin, paclitaxel or the combinations for 24 h increased nuclear expression of FOXO1 in Ishikawa cells.	Paclitaxel	42-52	forkhead box O1	Homo sapiens	114-119
18281707-12	2008	CONCLUSIONS: The combination of paclitaxel and doxifluridine might be a treatment of choice as a second line chemotherapy for patient undergone S-1 treatment.	Paclitaxel	32-42	proteasome 26S subunit, non-ATPase 1	Homo sapiens	144-147
18319335-6	2008	One of these ATFs, 3ZF-1-VP, promoted paclitaxel resistance in cell lines having mutated or inactivated p53, such as MDA-MB-435 and Kaposi"s sarcoma cell lines.	Paclitaxel	38-48	tumor protein p53	Homo sapiens	104-107
18082941-5	2008	Antineoplastic screening demonstrated that five candidates agents, docetaxel, actinomycin D, mitoxantrone, paclitaxel, and SN-38, exhibited potent inhibitory effects on OATP1B3-mediated transport of CDCA-NBD.	Paclitaxel	107-117	solute carrier organic anion transporter family member 1B3	Homo sapiens	169-176
18071906-0	2008	Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol.	Paclitaxel	98-103	AKT serine/threonine kinase 1	Homo sapiens	0-3
18762730-1	2008	In previous reports, the effects of 12 Ca2+ antagonists on a multidrug resistant transporter, P-glycoprotein/MDR1, were evaluated in terms of those on MDR1-mediated transport of [3H]digoxin and the sensitivity of vinblastine sulfate or paclitaxel, and they were able to be classified into 4 subgroups based on their actions, as those with transport inhibition and sensitivity recovery, those with or without transport inhibition but marginal sensitivity recovery, and those without both.	Paclitaxel	236-246	ATP binding cassette subfamily B member 1	Homo sapiens	94-108
18762730-1	2008	In previous reports, the effects of 12 Ca2+ antagonists on a multidrug resistant transporter, P-glycoprotein/MDR1, were evaluated in terms of those on MDR1-mediated transport of [3H]digoxin and the sensitivity of vinblastine sulfate or paclitaxel, and they were able to be classified into 4 subgroups based on their actions, as those with transport inhibition and sensitivity recovery, those with or without transport inhibition but marginal sensitivity recovery, and those without both.	Paclitaxel	236-246	ATP binding cassette subfamily B member 1	Homo sapiens	109-113
18762730-1	2008	In previous reports, the effects of 12 Ca2+ antagonists on a multidrug resistant transporter, P-glycoprotein/MDR1, were evaluated in terms of those on MDR1-mediated transport of [3H]digoxin and the sensitivity of vinblastine sulfate or paclitaxel, and they were able to be classified into 4 subgroups based on their actions, as those with transport inhibition and sensitivity recovery, those with or without transport inhibition but marginal sensitivity recovery, and those without both.	Paclitaxel	236-246	ATP binding cassette subfamily B member 1	Homo sapiens	151-155
18281549-8	2008	MSeA decreased the basal and paclitaxel-induced expression of Bcl-XL and survivin in vitro and in vivo.	Paclitaxel	29-39	BCL2 like 1	Homo sapiens	62-68
18281549-9	2008	Ectopic expression of Bcl-XL or survivin attenuated MSeA/paclitaxel-induced apoptosis.	Paclitaxel	57-67	BCL2 like 1	Homo sapiens	22-28
18281549-10	2008	CONCLUSIONS: MSeA enhanced the efficacy of paclitaxel against HRPCa in vitro and in vivo, at least in part, by down-regulating the basal and paclitaxel-induced expression of both Bcl-XL and survivin to increase caspase-mediated apoptosis.	Paclitaxel	43-53	BCL2 like 1	Homo sapiens	179-185
18281549-10	2008	CONCLUSIONS: MSeA enhanced the efficacy of paclitaxel against HRPCa in vitro and in vivo, at least in part, by down-regulating the basal and paclitaxel-induced expression of both Bcl-XL and survivin to increase caspase-mediated apoptosis.	Paclitaxel	141-151	BCL2 like 1	Homo sapiens	179-185
18071906-7	2008	Overexpression of constitutively active Akt isoforms in HeLa cells induced isoform-specific sensitivity to doxorubicin and taxol but not cisplatin.	Paclitaxel	123-128	AKT serine/threonine kinase 1	Homo sapiens	40-43
18059182-8	2008	Dominant negative PPM1H protected HeLa cells from cell death triggered by staurosporine or taxol.	Paclitaxel	91-96	protein phosphatase, Mg2+/Mn2+ dependent 1H	Homo sapiens	18-23
17953985-1	2008	This paper continued our earlier work on the poly(D,L-lactide-co-glycolide)/montmorillonite nanoparticles (PLGA/MMT NPs), which were further decorated by human epidermal growth factor receptor-2 (HER2) antibody Trastuzumab for targeted breast cancer chemotherapy with paclitaxel as a model anticancer drug.	Paclitaxel	268-278	erb-b2 receptor tyrosine kinase 2	Homo sapiens	160-194
18068334-0	2008	Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2.	Paclitaxel	0-5	mitogen-activated protein kinase 8	Homo sapiens	107-110
18068334-9	2008	Our data provide evidence that taxol-induced mitochondrial stress occurs through the activation of both JNK and p38 pathways, and suggest a novel role for UCP2 in the modulation of taxol-induced apoptosis of melanoma cells.	Paclitaxel	31-36	mitogen-activated protein kinase 8	Homo sapiens	104-107
18068334-9	2008	Our data provide evidence that taxol-induced mitochondrial stress occurs through the activation of both JNK and p38 pathways, and suggest a novel role for UCP2 in the modulation of taxol-induced apoptosis of melanoma cells.	Paclitaxel	31-36	mitogen-activated protein kinase 14	Homo sapiens	112-115
18068334-0	2008	Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2.	Paclitaxel	0-5	mitogen-activated protein kinase 14	Homo sapiens	116-119
18068334-5	2008	Taxol resulted in the activation of apoptosis signal regulated kinase (ASK)1, c-jun NH(2)-terminal kinase (JNK), p38(MAPK) and extracellular-regulated kinase (ERK) together with the downregulation of uncoupling protein 2 (UCP2).	Paclitaxel	0-5	mitogen-activated protein kinase 8	Homo sapiens	78-105
18197164-9	2008	We also demonstrated significant increase in the induction of apoptosis in ARO/IL12 and ARO/CB2 cells following incubation with 15 nM paclitaxel, indicating that tumor cells were sensitized to chemotherapy.	Paclitaxel	134-144	cannabinoid receptor 2 (macrophage)	Mus musculus	92-95
18068334-5	2008	Taxol resulted in the activation of apoptosis signal regulated kinase (ASK)1, c-jun NH(2)-terminal kinase (JNK), p38(MAPK) and extracellular-regulated kinase (ERK) together with the downregulation of uncoupling protein 2 (UCP2).	Paclitaxel	0-5	mitogen-activated protein kinase 8	Homo sapiens	107-110
18068334-5	2008	Taxol resulted in the activation of apoptosis signal regulated kinase (ASK)1, c-jun NH(2)-terminal kinase (JNK), p38(MAPK) and extracellular-regulated kinase (ERK) together with the downregulation of uncoupling protein 2 (UCP2).	Paclitaxel	0-5	mitogen-activated protein kinase 14	Homo sapiens	113-116
18068334-5	2008	Taxol resulted in the activation of apoptosis signal regulated kinase (ASK)1, c-jun NH(2)-terminal kinase (JNK), p38(MAPK) and extracellular-regulated kinase (ERK) together with the downregulation of uncoupling protein 2 (UCP2).	Paclitaxel	0-5	mitogen-activated protein kinase 1	Homo sapiens	127-157
18068334-5	2008	Taxol resulted in the activation of apoptosis signal regulated kinase (ASK)1, c-jun NH(2)-terminal kinase (JNK), p38(MAPK) and extracellular-regulated kinase (ERK) together with the downregulation of uncoupling protein 2 (UCP2).	Paclitaxel	0-5	mitogen-activated protein kinase 1	Homo sapiens	159-162
18068334-8	2008	Pretreatment of melanoma cells with the JNK inhibitor (SP600125) or the p38 inhibitor (SB203580) blocked taxol-induced UCP2 downregulation, ROS generation and apoptosis, whereas the ERK inhibitor (PD98059) had no such effect.	Paclitaxel	105-110	mitogen-activated protein kinase 8	Homo sapiens	40-43
18068334-8	2008	Pretreatment of melanoma cells with the JNK inhibitor (SP600125) or the p38 inhibitor (SB203580) blocked taxol-induced UCP2 downregulation, ROS generation and apoptosis, whereas the ERK inhibitor (PD98059) had no such effect.	Paclitaxel	105-110	mitogen-activated protein kinase 14	Homo sapiens	72-75
18068334-8	2008	Pretreatment of melanoma cells with the JNK inhibitor (SP600125) or the p38 inhibitor (SB203580) blocked taxol-induced UCP2 downregulation, ROS generation and apoptosis, whereas the ERK inhibitor (PD98059) had no such effect.	Paclitaxel	105-110	mitogen-activated protein kinase 1	Homo sapiens	182-185
18245669-6	2008	Chemical induction of MKP-1 by dexamethasone protected cells from paclitaxel-induced apoptosis but had no effect on NSC 95397.	Paclitaxel	66-76	dual specificity phosphatase 1	Homo sapiens	22-27
18288942-6	2008	Interestingly, Taxol, TRAIL, as well as several classes of small molecules induce c-FLIP downregulation in neoplastic cells.	Paclitaxel	15-20	CASP8 and FADD like apoptosis regulator	Homo sapiens	82-88
18039807-6	2008	Compared with paclitaxel, the major hydroxylation site transferred from C6alpha to C4"", and the main metabolizing P450 changed from CYP2C8 to CYP3A4 for cephalomannine.	Paclitaxel	14-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-149
18245669-7	2008	NSC 95397 phenocopied the effects of MKP-1 small inhibitory RNA by reversing the cytoprotective effects of dexamethasone in paclitaxel-treated cells.	Paclitaxel	124-134	dual specificity phosphatase 1	Homo sapiens	37-42
17893875-0	2008	Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype.	Paclitaxel	91-101	erythropoietin	Homo sapiens	0-14
18205918-0	2008	Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance.	Paclitaxel	81-91	fibroblast growth factor 2	Homo sapiens	45-49
18205918-4	2008	The relationships between bFGF concentrations and tumor chemosensitivity of patient tumors (n = 87) to paclitaxel were evaluated using linear regression analysis.	Paclitaxel	103-113	fibroblast growth factor 2	Homo sapiens	26-30
18205918-6	2008	While both analyses indicated an inverse relationship between bFGF level and tumor sensitivity to paclitaxel, the image analysis method, by providing bFGF levels in individual tumors and therefore more data points (87 numerical values as opposed to four groups of staining intensities), further enabled the quantitative analysis of the relationship in subgroups of tumors with different pathobiological properties.	Paclitaxel	98-108	fibroblast growth factor 2	Homo sapiens	62-66
18205918-6	2008	While both analyses indicated an inverse relationship between bFGF level and tumor sensitivity to paclitaxel, the image analysis method, by providing bFGF levels in individual tumors and therefore more data points (87 numerical values as opposed to four groups of staining intensities), further enabled the quantitative analysis of the relationship in subgroups of tumors with different pathobiological properties.	Paclitaxel	98-108	fibroblast growth factor 2	Homo sapiens	150-154
18205918-7	2008	The results show significant correlation between bFGF level and tumor sensitivity to the antiproliferation effect, but not the apoptotic effect, of paclitaxel.	Paclitaxel	148-158	fibroblast growth factor 2	Homo sapiens	49-53
18205918-8	2008	We further found stronger correlations of bFGF level and paclitaxel sensitivity in four tumor subgroups (high stage, positive p53 staining, negative aFGF staining, containing higher-than-median bFGF level), compared to all other groups.	Paclitaxel	57-67	fibroblast growth factor 2	Homo sapiens	42-46
18205918-8	2008	We further found stronger correlations of bFGF level and paclitaxel sensitivity in four tumor subgroups (high stage, positive p53 staining, negative aFGF staining, containing higher-than-median bFGF level), compared to all other groups.	Paclitaxel	57-67	tumor protein p53	Homo sapiens	126-129
18205918-8	2008	We further found stronger correlations of bFGF level and paclitaxel sensitivity in four tumor subgroups (high stage, positive p53 staining, negative aFGF staining, containing higher-than-median bFGF level), compared to all other groups.	Paclitaxel	57-67	fibroblast growth factor 2	Homo sapiens	194-198
18205918-9	2008	These findings suggest that the relationship between intra-tumoral bFGF level and paclitaxel sensitivity was context-dependent, which may explain the previous contradictory findings on the merit of using plasma or urine bFGF level as a prognostic indicator.	Paclitaxel	82-92	fibroblast growth factor 2	Homo sapiens	67-71
18205918-9	2008	These findings suggest that the relationship between intra-tumoral bFGF level and paclitaxel sensitivity was context-dependent, which may explain the previous contradictory findings on the merit of using plasma or urine bFGF level as a prognostic indicator.	Paclitaxel	82-92	fibroblast growth factor 2	Homo sapiens	220-224
17893875-3	2008	We found that long-term Epo treatment of A2780 cells resulted in the development of a phenotype exhibiting both enhanced Epo signaling, evidenced by increased peak levels of phospho-Erk1/2 and increased paclitaxel resistance.	Paclitaxel	203-213	erythropoietin	Homo sapiens	24-27
17893875-6	2008	Measurement of mono- and oligonucleosome formation revealed that long-term Epo treated A2780 cells exhibited markedly less apoptosis than nonerythropoietin treated cells at essentially all concentrations of paclitaxel tested.	Paclitaxel	207-217	erythropoietin	Homo sapiens	75-78
17893875-8	2008	These findings may have implications for the clinical use of recombinant human Epo and other erythropoiesis stimulating agents to correct anemia in paclitaxel-treated cancer patients.	Paclitaxel	148-158	erythropoietin	Homo sapiens	79-82
18182107-3	2008	We investigated the impact of tumor vascular endothelial growth factor A (VEGF-A) expression on the efficacy of LD paclitaxel chemotherapy and its interactions with the tyrosine kinase inhibitor SU5416 in the ID8 and ID8-Vegf models of ovarian cancer.	Paclitaxel	115-125	vascular endothelial growth factor A	Homo sapiens	74-80
18199556-0	2008	Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.	Paclitaxel	130-140	epidermal growth factor receptor	Homo sapiens	108-112
18182107-5	2008	LD paclitaxel yielded additive effects with antiangiogenic therapy against tumors with low Vegf expression, while it exhibited antagonism to antiangiogenic therapy in tumors with high Vegf expression.	Paclitaxel	3-13	vascular endothelial growth factor A	Homo sapiens	91-95
18182107-6	2008	This is the first preclinical study that models interactions of LD paclitaxel chemotherapy with antiangiogenic therapy and tumor VEGF expression and offers important lessons for the rational design of clinical trials.	Paclitaxel	67-77	vascular endothelial growth factor A	Homo sapiens	129-133
18260360-9	2008	Then, two cycles of chemotherapy with paclitaxel, ifosfamide and cisplatin were administered as salvage chemotherapy, which led to a normalization of the serum AFP level, and disappearance of the brain and spleen metastases.	Paclitaxel	38-48	alpha fetoprotein	Homo sapiens	160-163
17599040-5	2008	Comparative analysis demonstrated that HEC-1B cells proliferate slower, but are more resistant to paclitaxel-mediated cell death than Ishikawa cells, which were partially reversed upon silencing of FOXO1 in HEC-1B cells or its re-expression in Ishikawa cells.	Paclitaxel	98-108	NDC80 kinetochore complex component	Homo sapiens	39-44
17599040-5	2008	Comparative analysis demonstrated that HEC-1B cells proliferate slower, but are more resistant to paclitaxel-mediated cell death than Ishikawa cells, which were partially reversed upon silencing of FOXO1 in HEC-1B cells or its re-expression in Ishikawa cells.	Paclitaxel	98-108	forkhead box O1	Homo sapiens	198-203
18681966-6	2008	RESULTS: Delta1-9 as a single agent had no effect on the cell number in monolayer culture, but potentiated the cytotoxic effects of doxorubicin and paclitaxel.	Paclitaxel	148-158	delta like non-canonical Notch ligand 1	Homo sapiens	9-17
17603559-5	2008	Pharmacological inhibition of TXAS using the TXAS inhibitor furegrelate increased sensitivity to the chemotherapeutic agents cisplatin and paclitaxel.	Paclitaxel	139-149	thromboxane A synthase 1	Homo sapiens	30-34
17603559-5	2008	Pharmacological inhibition of TXAS using the TXAS inhibitor furegrelate increased sensitivity to the chemotherapeutic agents cisplatin and paclitaxel.	Paclitaxel	139-149	thromboxane A synthase 1	Homo sapiens	45-49
17603559-7	2008	In concordance with the pharmacological data, siRNA-mediated reduction of TXAS expression increased sensitivity to cisplatin and paclitaxel in T24 and TCC-SUP cells.	Paclitaxel	129-139	thromboxane A synthase 1	Homo sapiens	74-78
18986507-1	2008	The widespread introduction of high throughput RNA interference screening technology has revealed tumour drug sensitivity pathways to common cytotoxics such as paclitaxel, doxorubicin and 5-fluorouracil, targeted agents such as trastuzumab and inhibitors of AKT and Poly(ADP-ribose) polymerase (PARP) as well as endocrine therapies such as tamoxifen.	Paclitaxel	160-170	AKT serine/threonine kinase 1	Homo sapiens	258-261
18986507-1	2008	The widespread introduction of high throughput RNA interference screening technology has revealed tumour drug sensitivity pathways to common cytotoxics such as paclitaxel, doxorubicin and 5-fluorouracil, targeted agents such as trastuzumab and inhibitors of AKT and Poly(ADP-ribose) polymerase (PARP) as well as endocrine therapies such as tamoxifen.	Paclitaxel	160-170	poly(ADP-ribose) polymerase 1	Homo sapiens	266-293
18986507-1	2008	The widespread introduction of high throughput RNA interference screening technology has revealed tumour drug sensitivity pathways to common cytotoxics such as paclitaxel, doxorubicin and 5-fluorouracil, targeted agents such as trastuzumab and inhibitors of AKT and Poly(ADP-ribose) polymerase (PARP) as well as endocrine therapies such as tamoxifen.	Paclitaxel	160-170	poly(ADP-ribose) polymerase 1	Homo sapiens	295-299
18991631-34	2008	In contrast to typical Hsp90-binding drugs, taxol exhibits a stimulatory response.	Paclitaxel	44-49	heat shock protein 86, pseudogene 2	Mus musculus	23-28
18322419-6	2008	Paclitaxel treatment induced dose-dependent cell death and increased VEGF expression.	Paclitaxel	0-10	vascular endothelial growth factor A	Homo sapiens	69-73
17574594-5	2008	MATERIALS AND METHODS: Bcl-2 expression was analyzed in the HB cell lines HUH6 and HepT1 as well as in the HCC cell line HepG2 before and after treatment with cisplatin, doxorubicin, taxol, and etoposid.	Paclitaxel	183-188	BCL2 apoptosis regulator	Homo sapiens	23-28
18097549-5	2008	PTX-GEM molecular interactions on the apoptotic markers PARP, Bcl-2 and Bax were analyzed by immunoblotting procedures.	Paclitaxel	0-3	BCL2 apoptosis regulator	Homo sapiens	62-67
18097549-5	2008	PTX-GEM molecular interactions on the apoptotic markers PARP, Bcl-2 and Bax were analyzed by immunoblotting procedures.	Paclitaxel	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	72-75
18097549-9	2008	DNA ladder and Western blotting results in the PTX followed by GEM sequence revealed a significant increase in the apoptotic cell death of breast cancer cells related to the Bax/Bcl-2 apoptotic pathway.	Paclitaxel	47-50	BCL2 associated X, apoptosis regulator	Homo sapiens	174-177
18097549-9	2008	DNA ladder and Western blotting results in the PTX followed by GEM sequence revealed a significant increase in the apoptotic cell death of breast cancer cells related to the Bax/Bcl-2 apoptotic pathway.	Paclitaxel	47-50	BCL2 apoptosis regulator	Homo sapiens	178-183
18322419-0	2008	Paclitaxel induces vascular endothelial growth factor expression through reactive oxygen species production.	Paclitaxel	0-10	vascular endothelial growth factor A	Homo sapiens	19-53
18322419-7	2008	Paclitaxel also induced nuclear factor-kappaB activation and stabilized HIF-1alpha, which stimulated luciferase activity of HIF-1alpha response element on VEGF gene.	Paclitaxel	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	72-82
18322419-5	2008	Here, we investigated whether paclitaxel treatment affects VEGF expression for the development of paclitaxel resistance.	Paclitaxel	30-40	vascular endothelial growth factor A	Homo sapiens	59-63
18322419-5	2008	Here, we investigated whether paclitaxel treatment affects VEGF expression for the development of paclitaxel resistance.	Paclitaxel	98-108	vascular endothelial growth factor A	Homo sapiens	59-63
18322419-7	2008	Paclitaxel also induced nuclear factor-kappaB activation and stabilized HIF-1alpha, which stimulated luciferase activity of HIF-1alpha response element on VEGF gene.	Paclitaxel	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	124-134
18322419-7	2008	Paclitaxel also induced nuclear factor-kappaB activation and stabilized HIF-1alpha, which stimulated luciferase activity of HIF-1alpha response element on VEGF gene.	Paclitaxel	0-10	vascular endothelial growth factor A	Homo sapiens	155-159
18322419-8	2008	As paclitaxel treatment produced reactive oxygen species (ROS), VEGF expression was increased by H2O2 treatment and reduced by various ROS scavengers such as N-acetyl-L-cysteine, pyrrolidine dithiocarbamate and diphenylene iodonium.	Paclitaxel	3-13	vascular endothelial growth factor A	Homo sapiens	64-68
18322419-10	2008	Collectively, this suggests that paclitaxel-induced VEGF expression could be mediated by paclitaxel-induced ROS production through nuclear factor-kappaB activation and HIF-1alpha stabilization, which could affect resistance induction to antitumor therapeutics during cancer treatment.	Paclitaxel	33-43	vascular endothelial growth factor A	Homo sapiens	52-56
18322419-10	2008	Collectively, this suggests that paclitaxel-induced VEGF expression could be mediated by paclitaxel-induced ROS production through nuclear factor-kappaB activation and HIF-1alpha stabilization, which could affect resistance induction to antitumor therapeutics during cancer treatment.	Paclitaxel	33-43	hypoxia inducible factor 1 subunit alpha	Homo sapiens	168-178
18322419-10	2008	Collectively, this suggests that paclitaxel-induced VEGF expression could be mediated by paclitaxel-induced ROS production through nuclear factor-kappaB activation and HIF-1alpha stabilization, which could affect resistance induction to antitumor therapeutics during cancer treatment.	Paclitaxel	89-99	vascular endothelial growth factor A	Homo sapiens	52-56
18322419-10	2008	Collectively, this suggests that paclitaxel-induced VEGF expression could be mediated by paclitaxel-induced ROS production through nuclear factor-kappaB activation and HIF-1alpha stabilization, which could affect resistance induction to antitumor therapeutics during cancer treatment.	Paclitaxel	89-99	hypoxia inducible factor 1 subunit alpha	Homo sapiens	168-178
18022396-6	2007	Finally, we showed that diosgenin could enhance paclitaxel-induced cytotoxicity in HER2-overexpressing cancer cells.	Paclitaxel	48-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
18089869-2	2007	PATIENTS AND METHODS: Paclitaxel was added to high-dose (HD) etoposide, ifosfamide, and cisplatin (VIP; etoposide 1,500 mg/m2, ifosfamide 10,000 mg/m2, and cisplatin 100 mg/m2; cumulative dose; days -6 through -2 per cycle) at three dose levels (135, 175, and 225 mg/m2) applied on day -6.	Paclitaxel	22-32	vasoactive intestinal peptide	Homo sapiens	99-102
18231754-10	2007	It is concluded that p38MAPK pathway is related to paclitaxel resistance of ovarian carcinoma, and blockade of this pathway can promote the apoptosis of the drug-resistant cells and reverse the drug-resistance.	Paclitaxel	51-61	mitogen-activated protein kinase 14	Homo sapiens	21-28
18083698-8	2007	Estrogen receptor negativity, low expression of microtubule-associated protein tau, and perhaps HER2 amplification may define a subset of patients with higher than average sensitivity to paclitaxel.	Paclitaxel	187-197	estrogen receptor 1	Homo sapiens	0-17
18083698-8	2007	Estrogen receptor negativity, low expression of microtubule-associated protein tau, and perhaps HER2 amplification may define a subset of patients with higher than average sensitivity to paclitaxel.	Paclitaxel	187-197	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
18231754-11	2007	Moreover, p38MAPK-mediated apoptosis in paclitaxel-resistant ovarian carcinoma cells depends on the activation of p53.	Paclitaxel	40-50	mitogen-activated protein kinase 14	Homo sapiens	10-17
18231754-0	2007	The relationship between p38MAPK and apoptosis during paclitaxel resistance of ovarian cancer cells.	Paclitaxel	54-64	mitogen-activated protein kinase 14	Homo sapiens	25-32
18231754-11	2007	Moreover, p38MAPK-mediated apoptosis in paclitaxel-resistant ovarian carcinoma cells depends on the activation of p53.	Paclitaxel	40-50	tumor protein p53	Homo sapiens	114-117
18067011-5	2007	Compared to the initial regimen, paclitaxel mobilization produced greater CD34+ cell yields (median 1.53 x 10(6) CD34+ cells/kg vs. 0.79 x 10(6) CD34+ cells/kg, p = 0.004).	Paclitaxel	33-43	CD34 molecule	Homo sapiens	74-78
18231754-1	2007	To investigate the relationship between p38 mitogen-activated protein kinase (p38MAPK) and cell apoptosis during the paclitaxel resistance of ovarian carcinoma cell lines, flow cytometry (FCM) and PI staining were employed to determine the effect of p38MAPK inhibitor SB203580 on the apoptosis of A2780/Taxol cells, a drug-resistant human ovarian carcinoma cell line.	Paclitaxel	117-127	mitogen-activated protein kinase 14	Homo sapiens	40-76
18231754-1	2007	To investigate the relationship between p38 mitogen-activated protein kinase (p38MAPK) and cell apoptosis during the paclitaxel resistance of ovarian carcinoma cell lines, flow cytometry (FCM) and PI staining were employed to determine the effect of p38MAPK inhibitor SB203580 on the apoptosis of A2780/Taxol cells, a drug-resistant human ovarian carcinoma cell line.	Paclitaxel	117-127	mitogen-activated protein kinase 14	Homo sapiens	78-85
18067011-5	2007	Compared to the initial regimen, paclitaxel mobilization produced greater CD34+ cell yields (median 1.53 x 10(6) CD34+ cells/kg vs. 0.79 x 10(6) CD34+ cells/kg, p = 0.004).	Paclitaxel	33-43	CD34 molecule	Homo sapiens	113-117
18067011-5	2007	Compared to the initial regimen, paclitaxel mobilization produced greater CD34+ cell yields (median 1.53 x 10(6) CD34+ cells/kg vs. 0.79 x 10(6) CD34+ cells/kg, p = 0.004).	Paclitaxel	33-43	CD34 molecule	Homo sapiens	113-117
17652622-6	2007	This conclusion is supported by the fact that Bcl-2-overexpressing cells and Bax/Bak doubly-deficient MEFs were entirely resistant to paclitaxel-induced apoptosis.	Paclitaxel	134-144	BCL2 apoptosis regulator	Homo sapiens	46-51
18330255-6	2007	Paclitaxel could enhance its sensitivity to TRAIL by up-regulating the expressions of TRAIL death receptors in Hep-2 cells.	Paclitaxel	0-10	TNF superfamily member 10	Homo sapiens	44-49
18330255-6	2007	Paclitaxel could enhance its sensitivity to TRAIL by up-regulating the expressions of TRAIL death receptors in Hep-2 cells.	Paclitaxel	0-10	TNF superfamily member 10	Homo sapiens	86-91
18330255-7	2007	CONCLUSION: The resistance of Hep-2 cell to TRAIL could be overcome by paclitaxel.	Paclitaxel	71-81	TNF superfamily member 10	Homo sapiens	44-49
17828616-4	2007	RESULTS: The PILs formulation was able to significantly increase the HER2 mediated cellular uptake of paclitaxel compared to the PLs in cell lines overexpressing HER2 (BT-474 and SK-BR-3 cells).	Paclitaxel	102-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
17828616-11	2007	The ability of the PILs formulation to efficiently and specifically deliver paclitaxel to the HER2-overexpressing cancer cells implies that it is a promising strategy for tumor-specific therapy for HER2-overexpressing breast cancers.	Paclitaxel	76-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-98
17828616-11	2007	The ability of the PILs formulation to efficiently and specifically deliver paclitaxel to the HER2-overexpressing cancer cells implies that it is a promising strategy for tumor-specific therapy for HER2-overexpressing breast cancers.	Paclitaxel	76-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	198-202
17855368-5	2007	In addition, we also demonstrated that the physical interaction between Id-1 and Cav-1 played a key role in the epithelial-mesenchymal transition and increased cell migration rate as well as resistance to taxol-induced apoptosis in prostate cancer cells.	Paclitaxel	205-210	caveolin 1	Homo sapiens	81-86
17652622-0	2007	Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment.	Paclitaxel	119-129	apoptotic peptidase activating factor 1	Homo sapiens	0-6
17652622-4	2007	In contrast, the lack of Apaf-1 or caspase-9, key regulators of the mitochondrial pathway, not only entirely protected against paclitaxel-induced apoptosis but could even confer clonogenic survival, depending on the cell type and drug concentration.	Paclitaxel	127-137	apoptotic peptidase activating factor 1	Homo sapiens	25-31
17652622-6	2007	This conclusion is supported by the fact that Bcl-2-overexpressing cells and Bax/Bak doubly-deficient MEFs were entirely resistant to paclitaxel-induced apoptosis.	Paclitaxel	134-144	BCL2 associated X, apoptosis regulator	Homo sapiens	77-80
17652622-7	2007	Interestingly, also the single knockout of Bim or Bax, but not that of Bak or Bid, conferred partial resistance, suggesting a particular role of these mediators in the cell-death pathway activated by paclitaxel.	Paclitaxel	200-210	BCL2 associated X, apoptosis regulator	Homo sapiens	50-53
17987122-4	2007	In this study, HER2 gene status was evaluated in a large, multicentric series of 320 patients with advanced ovarian cancer, including 243 patients enrolled in a multicenter prospective clinical trial of paclitaxel/carboplatin-based chemotherapy.	Paclitaxel	203-213	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-19
18006847-4	2007	Our findings show that erlotinib significantly potentiated the sensitivity of established ABCB1 or ABCG2 substrates and increased the accumulation of paclitaxel or mitoxantrone in ABCB1- or ABCG2-overexpressing cells.	Paclitaxel	150-160	ATP binding cassette subfamily B member 1	Homo sapiens	180-185
18006847-4	2007	Our findings show that erlotinib significantly potentiated the sensitivity of established ABCB1 or ABCG2 substrates and increased the accumulation of paclitaxel or mitoxantrone in ABCB1- or ABCG2-overexpressing cells.	Paclitaxel	150-160	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	190-195
17879382-0	2007	Design and synthesis of paclitaxel conjugated with an ErbB2-recognizing peptide, EC-1.	Paclitaxel	24-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-59
17936423-8	2007	Cytochalasin D and paclitaxel, but not phalloidin and colchicine, blocked ERK1/2 phosphorylation.	Paclitaxel	19-29	mitogen-activated protein kinase 3	Homo sapiens	74-80
18025320-0	2007	Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer.	Paclitaxel	87-97	vascular endothelial growth factor A	Homo sapiens	6-40
18025320-1	2007	OBJECTIVE: To evaluate serum vascular endothelial growth factor (VEGF) as a prognostic factor in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with metronomic (weekly) paclitaxel.	Paclitaxel	217-227	vascular endothelial growth factor A	Homo sapiens	29-63
18025320-14	2007	CONCLUSIONS: Serum VEGF levels after the first dose of paclitaxel may predict response to weekly paclitaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.	Paclitaxel	55-65	vascular endothelial growth factor A	Homo sapiens	19-23
18025320-14	2007	CONCLUSIONS: Serum VEGF levels after the first dose of paclitaxel may predict response to weekly paclitaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.	Paclitaxel	97-107	vascular endothelial growth factor A	Homo sapiens	19-23
17979224-2	2007	Several other binding proteins of paclitaxel, such as Bcl-2, heat shock proteins, and NSC-1, have also been reported.	Paclitaxel	34-44	BCL2 apoptosis regulator	Homo sapiens	54-59
17879382-2	2007	In this study, we report the design and synthesis of paclitaxel (PTX) conjugated with an erbB2-recognizing peptide (EC-1).	Paclitaxel	53-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-94
17879382-2	2007	In this study, we report the design and synthesis of paclitaxel (PTX) conjugated with an erbB2-recognizing peptide (EC-1).	Paclitaxel	65-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-94
17879382-5	2007	The aim of our conjugate is to specifically deliver antitumor agent PTX to breast cancer cells that overexpress oncogenic ErbB2 with the purpose to reduce toxicity and enhance selective killing of cancer cells.	Paclitaxel	68-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-127
17686523-7	2007	Paclitaxel treatment increased immunohistochemical staining for activating transcription factor-3 (ATF-3), c-Jun and neuropeptide Y (NPY) but only in a small percentage of neuronal cell bodies and mainly in those with large cell bodies.	Paclitaxel	0-10	neuropeptide Y	Rattus norvegicus	117-131
17974988-8	2007	We found that inhibition of the p38 mitogen-activated protein kinase pathway blocked bioluminescence induction by doxorubicin, paclitaxel, and staurosporine in CMV-driven luciferase-expressing cells.	Paclitaxel	127-137	mitogen-activated protein kinase 14	Homo sapiens	32-35
17906456-5	2007	Due to substantial interindividual diversity observed in paclitaxel pharmacokinetics actual research focuses on common single nucleotide polymorphisms in genes encoding metabolizing enzymes and drug transporters such as CYP450, P-glycoprotein and the organic anion transporting polypeptide OATP1B3.	Paclitaxel	57-67	ATP binding cassette subfamily B member 1	Homo sapiens	228-242
17906456-5	2007	Due to substantial interindividual diversity observed in paclitaxel pharmacokinetics actual research focuses on common single nucleotide polymorphisms in genes encoding metabolizing enzymes and drug transporters such as CYP450, P-glycoprotein and the organic anion transporting polypeptide OATP1B3.	Paclitaxel	57-67	solute carrier organic anion transporter family member 1B3	Homo sapiens	290-297
17906456-7	2007	A haplotype of CYP3A4 was associated with paclitaxel pharmacokinetics.	Paclitaxel	42-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	15-21
17912434-6	2007	When we administered the combination treatments on the same day, PTX and IR showed a greater combined effect with 2-5A-anti-hTR on both tumor cell lines than did BCNU, CDDP and TMZ.	Paclitaxel	65-68	telomerase RNA component	Homo sapiens	124-127
17912434-8	2007	Apoptosis-inducing agents (CDDP and PTX) but not autophagy-inducing therapies (TMZ and IR) enhanced the incidence of apoptosis caused by 2-5A-anti-hTR.	Paclitaxel	36-39	telomerase RNA component	Homo sapiens	147-150
17974979-9	2007	Their sensitivities to Taxol and vinblastine were enhanced by hPXR ablation.	Paclitaxel	23-28	nuclear receptor subfamily 1 group I member 2	Homo sapiens	62-66
17686523-7	2007	Paclitaxel treatment increased immunohistochemical staining for activating transcription factor-3 (ATF-3), c-Jun and neuropeptide Y (NPY) but only in a small percentage of neuronal cell bodies and mainly in those with large cell bodies.	Paclitaxel	0-10	neuropeptide Y	Rattus norvegicus	133-136
17686523-8	2007	In conclusion, we have demonstrated that nucleolar enlargement, nuclear eccentricity, ATF-3, c-Jun and NPY are neuronal markers of paclitaxel-induced sensory neuropathy, however, these axotomy-like cell body reactions are infrequent and occur in mainly large-sized sensory neurons.	Paclitaxel	131-141	neuropeptide Y	Rattus norvegicus	103-106
17954267-1	2007	A multidrug-resistant lung cancer cell line PTX250, established by treatment with the anti-cancer drug paclitaxel, has been demonstrated to have an increased copy number in the 7q21.12 region including the MDR1/ABCB1 gene.	Paclitaxel	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	211-216
17952876-4	2007	Compared to the Rac1pIRES and Rac1V12 cells, Rac1N17 cells were more resistant to paclitaxel-triggered caspase-3 activation and apoptosis.	Paclitaxel	82-92	caspase 3	Homo sapiens	103-112
17952876-8	2007	Moreover, knockdown of the protein level of Hsp27 using small interfering RNA in Rac1N17 cells significantly increased the paclitaxel-elicited caspase-3 activation and apoptosis.	Paclitaxel	123-133	caspase 3	Homo sapiens	143-152
17952876-10	2007	It appears that the dominant negative Rac1N17 reduces the apoptosis sensitivity toward paclitaxel in the melanoma cells through upregulation of Hsp27, which inhibits its down stream drug-elicited caspase-3 activation.	Paclitaxel	87-97	caspase 3	Homo sapiens	196-205
18047955-10	2007	After combined treatment with chemotherapy and bcl-2 or bcl-xL AS-ODNs, cell death rates were significantly higher (e.g., 30.3% vs. 87.2% in HT 1197 cells for monotreatment vs. the combination of paclitaxel and bcl-xL AS-ODNs).	Paclitaxel	196-206	BCL2 apoptosis regulator	Homo sapiens	47-52
18047955-10	2007	After combined treatment with chemotherapy and bcl-2 or bcl-xL AS-ODNs, cell death rates were significantly higher (e.g., 30.3% vs. 87.2% in HT 1197 cells for monotreatment vs. the combination of paclitaxel and bcl-xL AS-ODNs).	Paclitaxel	196-206	BCL2 like 1	Homo sapiens	56-62
17954267-1	2007	A multidrug-resistant lung cancer cell line PTX250, established by treatment with the anti-cancer drug paclitaxel, has been demonstrated to have an increased copy number in the 7q21.12 region including the MDR1/ABCB1 gene.	Paclitaxel	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	206-210
17823933-0	2007	Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	108-111
17823933-1	2007	BACKGROUND: This study investigated the influence of p53 status on treatment using combined paclitaxel and irradiation for human prostate cancer (PC) in vitro and in vivo.	Paclitaxel	92-102	tumor protein p53	Homo sapiens	53-56
17823933-2	2007	METHODS: Enhancement of the radiation response by paclitaxel was determined by MTT and clonogenic assays in four sublines of the human PC cell line, LNCaP, stably transfected to express different p53 mutations found in PC patients.	Paclitaxel	50-60	tumor protein p53	Homo sapiens	196-199
17823933-5	2007	RESULTS: Paclitaxel (8-10 nM) suppressed cell proliferation by 50% by inducing G2M mitotic arrest in LNCaP cell lines transfected to overexpress wild-type or mutant p53.	Paclitaxel	9-19	tumor protein p53	Homo sapiens	165-168
17823933-10	2007	CONCLUSIONS: Pre-treatment with paclitaxel enhances radiation efficacy on cell killing and suppression of growth of human PC cell lines in vitro and in vivo via p53 independent pathways.	Paclitaxel	32-42	tumor protein p53	Homo sapiens	161-164
17823933-11	2007	Paclitaxel has potential for use as a radiosensitizer in the treatment of patients with PC with either wild-type or mutant p53 genetic status.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	123-126
17912033-1	2007	We previously reported that the Polo-like Kinase 2 gene (Plk2/Snk) is a direct target for transcriptional regulation by p53 and that silencing Plk2 sensitizes cancer cells to Taxol-induced apoptosis.	Paclitaxel	175-180	tumor protein p53	Homo sapiens	120-123
17928597-7	2007	HER2 positivity was, however, associated with a significant benefit from paclitaxel.	Paclitaxel	73-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
17928597-8	2007	The interaction between HER2 positivity and the addition of paclitaxel to the treatment was associated with a hazard ratio for recurrence of 0.59 (P=0.01).	Paclitaxel	60-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
17928597-9	2007	Patients with a HER2-positive breast cancer benefited from paclitaxel, regardless of estrogen-receptor status, but paclitaxel did not benefit patients with HER2-negative, estrogen-receptor-positive cancers.	Paclitaxel	59-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	16-20
17928597-10	2007	CONCLUSIONS: The expression or amplification, or both, of HER2 by a breast cancer is associated with a benefit from the addition of paclitaxel after adjuvant treatment with doxorubicin (&lt;60 mg per square meter) plus cyclophosphamide in node-positive breast cancer, regardless of estrogen-receptor status.	Paclitaxel	132-142	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-62
17875775-6	2007	Significant inhibition of tumor growth in mice treated with low-dose paclitaxel plus intratumoral dendritic cell vaccine, associated with increased tumor infiltration by CD4(+) and CD8(+) T cells and elevated tumor-specific IFN-gamma production by draining lymph node cells, was revealed.	Paclitaxel	69-79	interferon gamma	Mus musculus	224-233
17681754-9	2007	Paclitaxel, which induces microtubular stabilization and polymerization, exerted the opposite effects on thrombin- and TG-evoked SOCE and coupling between IP(3)RII and hTRPC1 compared with colchicine.	Paclitaxel	0-10	coagulation factor II, thrombin	Homo sapiens	105-113
17636047-7	2007	Finally, we demonstrated that PXR overexpression caused a significant decrease in cell growth inhibition and inhibited apoptosis in the presence of paclitaxel or cisplatin.	Paclitaxel	148-158	nuclear receptor subfamily 1 group I member 2	Homo sapiens	30-33
17903587-8	2007	CONCLUSION: More emphasis should be laid on MDR1/Pgp, the non-Pgp substrate chemotherapeutic agents, and the changes of cell cycle distribution to prevent MDR induced by Taxol.	Paclitaxel	170-175	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
17647266-12	2007	CONCLUSIONS: Stage II and III HER2-positive breast cancer patients achieved a high rate of PCR with trastuzumab given concurrently with paclitaxel and FEC(75) chemotherapy.	Paclitaxel	136-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
17636047-6	2007	We then found that PXR down-regulation caused a significant increase in cell growth inhibition and enhancement of apoptosis in the presence of the anticancer agents, paclitaxel, cisplatin, and MPA.	Paclitaxel	166-176	nuclear receptor subfamily 1 group I member 2	Homo sapiens	19-22
17804754-9	2007	On a total protein basis, Taxol induced ISMMC, expanded more CD8(+) cells, activated more CD56(+) NKG2D(+) cells to produce IFN-gamma, and were more potent inducers of high T-cell receptor density Perforin(+) cells than native ISMMC and peptide E75.	Paclitaxel	26-31	interferon gamma	Homo sapiens	124-133
17636258-5	2007	Topotecan- and paclitaxel-resistant prostate cancer lines were as sensitive to p53p-Ant-induced targeted necrosis as parental lines.	Paclitaxel	15-25	tumor protein p53	Homo sapiens	79-83
17608771-6	2007	Furthermore, sensitivity to PTX in these cell lines was reversed when HIF-1alpha expression was decreased by siRNA specific to HIF-1alpha in PC14PE6 and increased by overexpression of the exogenous HIF-1alpha gene in NCI-H441.	Paclitaxel	28-31	hypoxia inducible factor 1 subunit alpha	Homo sapiens	70-80
17608771-6	2007	Furthermore, sensitivity to PTX in these cell lines was reversed when HIF-1alpha expression was decreased by siRNA specific to HIF-1alpha in PC14PE6 and increased by overexpression of the exogenous HIF-1alpha gene in NCI-H441.	Paclitaxel	28-31	hypoxia inducible factor 1 subunit alpha	Homo sapiens	127-137
17608771-6	2007	Furthermore, sensitivity to PTX in these cell lines was reversed when HIF-1alpha expression was decreased by siRNA specific to HIF-1alpha in PC14PE6 and increased by overexpression of the exogenous HIF-1alpha gene in NCI-H441.	Paclitaxel	28-31	hypoxia inducible factor 1 subunit alpha	Homo sapiens	127-137
17608771-7	2007	These results suggest that HIF-1 influences the PTX sensitivity of these cells.	Paclitaxel	48-51	hypoxia inducible factor 1 subunit alpha	Homo sapiens	27-32
18038883-1	2007	We report the case of a woman with HER2-positive metastatic breast cancer who achieved prolonged complete remission of multiple liver metastases after treatment with weekly trastuzumab plus paclitaxel but relapsed in the brain soon after stopping trastuzumab maintenance therapy which had been prosecuted for almost three years.	Paclitaxel	190-200	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39
17914112-9	2007	The results suggest a mechanistic link between HDAC6 inhibition, tubulin acetylation, and the VPA-induced enhancement of paclitaxel effects, and provide the rationale for designing future combination therapies.	Paclitaxel	121-131	histone deacetylase 6	Homo sapiens	47-52
17320279-0	2007	PKC inhibitor Go6976 induces mitosis and enhances doxorubicin-paclitaxel cytotoxicity in urinary bladder carcinoma cells.	Paclitaxel	62-72	protein kinase C alpha	Homo sapiens	0-3
17560963-6	2007	Analysis of caspase-3 activity and cytochrome c release in response to PTX or ABZ treatment (24, 48 and 72 h) revealed that, compared to the parent cells, the resistant cells have diminished response to PTX and enhanced response to ABZ.	Paclitaxel	71-74	caspase 3	Homo sapiens	12-21
17581308-0	2007	Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer.	Paclitaxel	9-19	epidermal growth factor receptor	Homo sapiens	101-133
17581308-0	2007	Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer.	Paclitaxel	9-19	epidermal growth factor receptor	Homo sapiens	213-245
17581308-6	2007	In this report, combined paclitaxel and cetuximab achieved a major reduction of the skin metastases of a heavily pretreated patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) invasive ductal breast carcinoma.	Paclitaxel	25-35	epidermal growth factor receptor	Homo sapiens	137-169
17581308-6	2007	In this report, combined paclitaxel and cetuximab achieved a major reduction of the skin metastases of a heavily pretreated patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) invasive ductal breast carcinoma.	Paclitaxel	25-35	epidermal growth factor receptor	Homo sapiens	249-281
17560963-6	2007	Analysis of caspase-3 activity and cytochrome c release in response to PTX or ABZ treatment (24, 48 and 72 h) revealed that, compared to the parent cells, the resistant cells have diminished response to PTX and enhanced response to ABZ.	Paclitaxel	71-74	cytochrome c, somatic	Homo sapiens	35-47
17560963-8	2007	Levels of the anti-apoptotic protein Bcl-2 was highly elevated in CEM/dEpoB300 cells and in these cells, ABZ was more effective in lowering the Bcl-2 levels than PTX.	Paclitaxel	162-165	BCL2 apoptosis regulator	Homo sapiens	37-42
17634124-0	2007	Successful paclitaxel-based chemotherapy for an alpha-fetoprotein-producing gastric cancer patient with multiple liver metastases.	Paclitaxel	11-21	alpha fetoprotein	Homo sapiens	48-65
17701008-4	2007	The effects of patient characteristics, including single-nucleotide polymorphisms of MDR1(ABCB1), CYP2C8, CYP3A4, and CYP3A5, on the total body clearance of paclitaxel were evaluated.	Paclitaxel	157-167	ATP binding cassette subfamily B member 1	Homo sapiens	85-89
17701008-4	2007	The effects of patient characteristics, including single-nucleotide polymorphisms of MDR1(ABCB1), CYP2C8, CYP3A4, and CYP3A5, on the total body clearance of paclitaxel were evaluated.	Paclitaxel	157-167	ATP binding cassette subfamily B member 1	Homo sapiens	90-95
17701008-4	2007	The effects of patient characteristics, including single-nucleotide polymorphisms of MDR1(ABCB1), CYP2C8, CYP3A4, and CYP3A5, on the total body clearance of paclitaxel were evaluated.	Paclitaxel	157-167	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
17701008-4	2007	The effects of patient characteristics, including single-nucleotide polymorphisms of MDR1(ABCB1), CYP2C8, CYP3A4, and CYP3A5, on the total body clearance of paclitaxel were evaluated.	Paclitaxel	157-167	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	118-124
17574589-0	2007	Paclitaxel interrupts TGF-beta1 signaling between gallbladder epithelial cells and myofibroblasts.	Paclitaxel	0-10	transforming growth factor beta 1	Homo sapiens	22-31
17574589-3	2007	An observation that paclitaxel (PT), applied topically into the rat common bile duct, inhibited stricture formation led us to hypothesize that PT"s effects might be due to interruption of TGF-beta1 signaling between biliary epithelial cells and subepithelial myofibroblasts.	Paclitaxel	20-30	transforming growth factor, beta 1	Rattus norvegicus	188-197
17574589-3	2007	An observation that paclitaxel (PT), applied topically into the rat common bile duct, inhibited stricture formation led us to hypothesize that PT"s effects might be due to interruption of TGF-beta1 signaling between biliary epithelial cells and subepithelial myofibroblasts.	Paclitaxel	32-34	transforming growth factor, beta 1	Rattus norvegicus	188-197
17671148-3	2007	A phase I trial of matuzumab in combination with paclitaxel has been reported in 18 patients with EGFR-positive advanced NSCLC.	Paclitaxel	49-59	epidermal growth factor receptor	Homo sapiens	98-102
17671152-6	2007	AZD2171 is an inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3 and other tyrosine kinases that has shown clinical activity in NSCLC in combination with carboplatin and paclitaxel.	Paclitaxel	162-172	fms related receptor tyrosine kinase 1	Homo sapiens	27-34
17652710-0	2007	Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine transgenic model of retinoblastoma.	Paclitaxel	0-10	luteinizing hormone beta	Mus musculus	49-56
17652710-1	2007	PURPOSE: The purpose of this study was to investigate tumor control efficacy of paclitaxel in the treatment of retinal tumors harbored by the LH beta-Tag murine transgenic model of retinoblastoma.	Paclitaxel	80-90	luteinizing hormone beta	Mus musculus	142-149
17652710-9	2007	CONCLUSIONS: Subconjunctival delivery of paclitaxel effectively inhibits intraocular tumor burden in the LH beta-Tag model of retinoblastoma.	Paclitaxel	41-51	luteinizing hormone beta	Mus musculus	105-112
17586082-8	2007	Therefore, the paclitaxel-loaded PEGylated immunoliposome using Herceptin could serve as a promising model for future tumor specific cancer therapy of HER2 over-expressing breast cancers.	Paclitaxel	15-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	151-155
17634124-12	2007	CONCLUSION: We consider this rare case to have significant value with respect to treatment of AFP-producing gastric cancer with multiple liver metastases, and propose that combining surgery with chemotherapeutic agents such as paclitaxel may lead to a better prognosis in such cases.	Paclitaxel	227-237	alpha fetoprotein	Homo sapiens	94-97
17568772-8	2007	Moreover, such SGK1 depletion prevented the dexamethasone-induced increase in SGK1 expression, as well as the inhibitory effects of dexamethasone on paclitaxel-induced SEK1-JNK signaling and apoptosis in MDA-MB-231 breast cancer cells.	Paclitaxel	149-159	mitogen-activated protein kinase kinase 4	Homo sapiens	168-172
17498666-2	2007	We have examined whether the DNA-damaging drugs cisplatin and doxorubicin and the microtubule inhibitors docetaxel and paclitaxel can affect VEGF expression and HIF-1 activity in three human ovarian cancer cell lines.	Paclitaxel	119-129	vascular endothelial growth factor A	Homo sapiens	141-145
17498666-2	2007	We have examined whether the DNA-damaging drugs cisplatin and doxorubicin and the microtubule inhibitors docetaxel and paclitaxel can affect VEGF expression and HIF-1 activity in three human ovarian cancer cell lines.	Paclitaxel	119-129	hypoxia inducible factor 1 subunit alpha	Homo sapiens	161-166
17568772-8	2007	Moreover, such SGK1 depletion prevented the dexamethasone-induced increase in SGK1 expression, as well as the inhibitory effects of dexamethasone on paclitaxel-induced SEK1-JNK signaling and apoptosis in MDA-MB-231 breast cancer cells.	Paclitaxel	149-159	mitogen-activated protein kinase 8	Homo sapiens	173-176
17400763-3	2007	In this study, we found that in human glioblastoma cells hypoxia induces the phosphorylation of the Bcl-2 family protein Bad, thus protecting hypoxic cells from paclitaxel-induced apoptosis.	Paclitaxel	161-171	BCL2 apoptosis regulator	Homo sapiens	100-105
17485207-1	2007	A series of paclitaxel C-10 carbamates was synthesized and evaluated in a bi-directional permeability assay in comparison with paclitaxel and the blood-brain barrier-permeable C-10 ester derivative, TX-67.	Paclitaxel	12-22	homeobox C10	Homo sapiens	23-27
17594186-6	2007	Platinum-based drugs have also been successfully combined with molecularly targeted drugs (e.g., the recent approval of the vascular endothelial growth factor monoclonal antibody bevacizumab with carboplatin and paclitaxel in patients with NSCLC).	Paclitaxel	212-222	vascular endothelial growth factor A	Homo sapiens	124-158
17399942-13	2007	Using an antibody that recognizes unprocessed caspase-3, we observed that the enzyme was assumingly activated in HepG2 cells treated with 5FU and paclitaxel, but only weakly after treatment with cisplatin.	Paclitaxel	146-156	caspase 3	Homo sapiens	46-55
17174526-8	2007	Moreover, IL-10 gene therapy resulted in increased IL-10 mRNA levels in lumbar DRG and meninges, measured 2 weeks after initiation of therapy, whereas paclitaxel-induced expression of IL-1, TNF, and CD11b mRNA in lumbar DRG was markedly decreased.	Paclitaxel	151-161	integrin subunit alpha M	Rattus norvegicus	199-204
17568189-5	2007	Biochemical examination revealed that pretreatment or cotreatment of carboplatin inhibited paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation.	Paclitaxel	91-101	NFKB inhibitor alpha	Homo sapiens	110-122
17568189-5	2007	Biochemical examination revealed that pretreatment or cotreatment of carboplatin inhibited paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation.	Paclitaxel	91-101	BCL2 apoptosis regulator	Homo sapiens	139-144
17400763-5	2007	In contrast, the extracellular signal-regulated kinase 1/2 activities have only a partial effect, being able to modulate Bad phosphorylation but not paclitaxel-induced apoptosis in hypoxia.	Paclitaxel	149-159	mitogen-activated protein kinase 3	Homo sapiens	17-56
17215078-2	2007	HIF 1-alpha expression was confirmed in 36 cases (69.2%) of EOC, and HIF 1-alpha-expressing tumors had a significantly higher rate of response (p&lt;0.01) to postoperative paclitaxel/carboplatin combination chemotherapy (TC) than tumors without HIF1-alpha expression.	Paclitaxel	172-182	hypoxia inducible factor 1 subunit alpha	Homo sapiens	69-80
17620438-10	2007	The pretreatment of cells with U0126 enhanced the paclitaxel-induced cleavage of poly(ADP-ribose) polymerase and paclitaxel sensitivity.	Paclitaxel	50-60	poly(ADP-ribose) polymerase 1	Homo sapiens	81-108
17215078-2	2007	HIF 1-alpha expression was confirmed in 36 cases (69.2%) of EOC, and HIF 1-alpha-expressing tumors had a significantly higher rate of response (p&lt;0.01) to postoperative paclitaxel/carboplatin combination chemotherapy (TC) than tumors without HIF1-alpha expression.	Paclitaxel	172-182	hypoxia inducible factor 1 subunit alpha	Homo sapiens	245-255
17289311-4	2007	There was an increased level of uptake of folate-conjugated micellar PTX (i.e. FOL-P105/PTX, FOL-PL/PTX) compared to plain micellar PTX (i.e. P105/PTX, PL/PTX) in human breast cancer MDR cell sublines, MCF-7/ADR, and the uptake of folate-conjugated micellar PTX could be inhibited by free folic acid, which suggested that the level of uptake could be mediated by the folate receptor.	Paclitaxel	69-72	nuclear factor kappa B subunit 1	Homo sapiens	83-91
17575238-0	2007	Hyperglycemia-induced thioredoxin-interacting protein expression differs in breast cancer-derived cells and regulates paclitaxel IC50.	Paclitaxel	118-128	thioredoxin interacting protein	Homo sapiens	22-53
17575238-1	2007	PURPOSE: We studied the hyperglycemia-induced expression of thioredoxin-interacting protein (TXNIP) expression and its relevance on the cytotoxic activity of paclitaxel in mammary epithelial-derived cell lines.	Paclitaxel	158-168	thioredoxin interacting protein	Homo sapiens	60-91
17575238-1	2007	PURPOSE: We studied the hyperglycemia-induced expression of thioredoxin-interacting protein (TXNIP) expression and its relevance on the cytotoxic activity of paclitaxel in mammary epithelial-derived cell lines.	Paclitaxel	158-168	thioredoxin interacting protein	Homo sapiens	93-98
17575238-12	2007	The increased paclitaxel cytotoxicity is associated with an additive effect on the hyperglycemia-mediated TXNIP expression more evident in conditions of hyperglycemia than normoglycemia.	Paclitaxel	14-24	thioredoxin interacting protein	Homo sapiens	106-111
17440963-12	2007	Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance.	Paclitaxel	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	13-27
17440963-12	2007	Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance.	Paclitaxel	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
17440963-12	2007	Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance.	Paclitaxel	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	82-87
17440963-12	2007	Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance.	Paclitaxel	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	193-197
17440963-12	2007	Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance.	Paclitaxel	227-237	ATP binding cassette subfamily B member 1	Homo sapiens	13-27
17440963-12	2007	Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance.	Paclitaxel	227-237	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
17440963-12	2007	Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance.	Paclitaxel	227-237	ATP binding cassette subfamily B member 1	Homo sapiens	82-87
17267149-1	2007	As many anticancer agents paclitaxel is a substrate for ATP-binding cassette (ABC) transporters such as P-glycoprotein-mediated efflux, and its metabolism in humans mainly catalyzed by CYP 3A4 and 2C8.	Paclitaxel	26-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	185-200
17629094-0	2007	Combination chemotherapy using TS-1, Paclitaxel and cisplatin for multiple lung metastases from AFP-producing gastric cancer: a case report.	Paclitaxel	37-47	alpha fetoprotein	Homo sapiens	96-99
17545614-0	2007	Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.	Paclitaxel	66-76	estrogen receptor 1	Homo sapiens	0-23
17545614-5	2007	We showed that 17-beta estradiol significantly reduces the overall cytotoxicity of paclitaxel in BCap37-expressing ERalpha but has no influence on the ER- parental cells.	Paclitaxel	83-93	estrogen receptor 1	Homo sapiens	115-122
17545614-6	2007	Further analyses indicate that expression of ERalpha in BCap37 cells mainly interferes with paclitaxel-induced apoptotic cell death, without affecting paclitaxel-induced microtubule bundling and mitotic arrest.	Paclitaxel	92-102	estrogen receptor 1	Homo sapiens	45-52
17545614-8	2007	These findings showed that ERalpha-mediated breast tumor cell resistance to paclitaxel was through selective inhibition of paclitaxel-induced tumor cell apoptosis.	Paclitaxel	76-86	estrogen receptor 1	Homo sapiens	27-34
17545614-8	2007	These findings showed that ERalpha-mediated breast tumor cell resistance to paclitaxel was through selective inhibition of paclitaxel-induced tumor cell apoptosis.	Paclitaxel	123-133	estrogen receptor 1	Homo sapiens	27-34
17545614-9	2007	Additionally, the combination of ICI 182,780 also sensitizes MCF-7 and T47D cell lines to the treatment of paclitaxel, which further confirmed the correlation between ERalpha and drug resistance in ER+ tumor cells.	Paclitaxel	107-117	estrogen receptor 1	Homo sapiens	167-174
17399990-8	2007	Interestingly, in vitro biotransformation studies of compounds 4 and 5 using human CYP-450 isoforms revealed, that conversely to XR9576, compounds 4 and 5 inhibited CYP3A4, an enzyme that colocalizes with P-gp in the intestine and contributes to tumor cell chemoresistance by enhancing the biodisposition of numerous drugs, notably paclitaxel.	Paclitaxel	332-342	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	165-171
17531083-5	2007	Specifically, treatment with nocodazole and paclitaxel resulted in hyper-activation of ERKs and MEK in BubR1(+/-) murine embryonic fibroblasts (MEF) compared to that of wild-type MEFs.	Paclitaxel	44-54	BUB1B, mitotic checkpoint serine/threonine kinase	Mus musculus	103-108
17534145-0	2007	In vitro efficacy of immuno-chemotherapy with anti-EGFR human Fab-Taxol conjugate on A431 epidermoid carcinoma cells.	Paclitaxel	66-71	epidermal growth factor receptor	Homo sapiens	51-55
17534145-1	2007	The aims of this study were to generate a human Fab fragment against EGFR; conjugate it to paclitaxel (Taxol) as an immuno-chemotherapy agent; and investigate its in vitro anti-tumor efficacy on A431 epidermoid carcinoma cells.	Paclitaxel	91-101	epidermal growth factor receptor	Homo sapiens	69-73
17534145-1	2007	The aims of this study were to generate a human Fab fragment against EGFR; conjugate it to paclitaxel (Taxol) as an immuno-chemotherapy agent; and investigate its in vitro anti-tumor efficacy on A431 epidermoid carcinoma cells.	Paclitaxel	103-108	epidermal growth factor receptor	Homo sapiens	69-73
17534145-8	2007	Our findings suggest that this Fab-Taxol conjugate could be a potential immuno-chemotherapeutic drug for clinical treatment of EGFR-overexpressing tumors.	Paclitaxel	35-40	epidermal growth factor receptor	Homo sapiens	127-131
17686239-12	2007	CONCLUSION: Residual tumor, p53, and Pgp expression are predictive factors for the response to platinum/paclitaxel first-line adjuvant chemotherapy in advanced ovarian cancer.	Paclitaxel	104-114	tumor protein p53	Homo sapiens	28-31
17487377-4	2007	Expression of the ATP binding cassette transporter, P-glycoprotein (P-gp), in breast tumours has previously been found to correlate with poor prognosis in vivo and, accordingly, we confirmed overexpression of P-gp in both adriamycin- and paclitaxel-resistant MCF-7 cells.	Paclitaxel	238-248	ATP binding cassette subfamily B member 1	Homo sapiens	52-66
17487377-4	2007	Expression of the ATP binding cassette transporter, P-glycoprotein (P-gp), in breast tumours has previously been found to correlate with poor prognosis in vivo and, accordingly, we confirmed overexpression of P-gp in both adriamycin- and paclitaxel-resistant MCF-7 cells.	Paclitaxel	238-248	ATP binding cassette subfamily B member 1	Homo sapiens	68-72
17487377-4	2007	Expression of the ATP binding cassette transporter, P-glycoprotein (P-gp), in breast tumours has previously been found to correlate with poor prognosis in vivo and, accordingly, we confirmed overexpression of P-gp in both adriamycin- and paclitaxel-resistant MCF-7 cells.	Paclitaxel	238-248	ATP binding cassette subfamily B member 1	Homo sapiens	209-213
17373720-8	2007	The apoptotic program induced by taxol was preferentially potentiated by Akt siRNA in PTEN-mutated cell lines as regards the DU-145 cell line.	Paclitaxel	33-38	AKT serine/threonine kinase 1	Homo sapiens	73-76
17373720-9	2007	CONCLUSIONS: Silencing Akt in PTEN-mutated prostate cancer cells enhances the antitumor effects of taxol.	Paclitaxel	99-104	AKT serine/threonine kinase 1	Homo sapiens	23-26
17697605-0	2007	[Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel].	Paclitaxel	87-97	ATP binding cassette subfamily B member 1	Homo sapiens	20-24
17697605-1	2007	OBJECTIVE: To investigate the reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel.	Paclitaxel	116-126	ATP binding cassette subfamily B member 1	Homo sapiens	49-53
17686239-12	2007	CONCLUSION: Residual tumor, p53, and Pgp expression are predictive factors for the response to platinum/paclitaxel first-line adjuvant chemotherapy in advanced ovarian cancer.	Paclitaxel	104-114	ATP binding cassette subfamily B member 1	Homo sapiens	37-40
17293601-0	2007	Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.	Paclitaxel	42-52	estrogen receptor 1	Homo sapiens	129-146
17697605-13	2007	CONCLUSION: MDR1 and MDR3 gene silencing could recover sensitivity of A2780/taxol cells to paclitaxel and induce cell apoptosis, thus reversing cell resistance to paclitaxel.	Paclitaxel	91-101	ATP binding cassette subfamily B member 1	Homo sapiens	12-16
17483361-3	2007	Transient or stable overexpression of MKP-1 reduced caspase activation and DNA fragmentation while enhancing viability in the face of treatment with alkylating agents (mechlorethamine), anthracylines (doxorubicin), and microtubule inhibitors (paclitaxel).	Paclitaxel	243-253	dual specificity phosphatase 1	Homo sapiens	38-43
17697605-13	2007	CONCLUSION: MDR1 and MDR3 gene silencing could recover sensitivity of A2780/taxol cells to paclitaxel and induce cell apoptosis, thus reversing cell resistance to paclitaxel.	Paclitaxel	163-173	ATP binding cassette subfamily B member 1	Homo sapiens	12-16
17331135-5	2007	Mice transplanted with MDR1-transduced human hematopoietic cells were protected from paclitaxel chemotherapy with higher survival rate and higher level of WBC counts and RBC counts compared with mice transplanted with untransduced HSCs.	Paclitaxel	85-95	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-27
17331135-6	2007	We also demonstrated that hematopoietic cells transduced with MDR1 gene were enriched in vivo after paclitaxel chemotherapy determined by the higher percentage of human Rh-123(dull) CD45+ cells in bone marrow of mice.	Paclitaxel	100-110	ATP binding cassette subfamily B member 1	Homo sapiens	62-66
17390065-5	2007	Paclitaxel activated extracellular signal-regulated kinase (ERK), and when ERK was inhibited by a mitogen-activated ERK-regulating kinase inhibitor, the cell death and cell cycle arrest induced by paclitaxel were rescued, demonstrating that paclitaxel inhibited the cellular growth via the ERK signaling pathway.	Paclitaxel	241-251	mitogen-activated protein kinase 1	Homo sapiens	21-58
17230521-0	2007	Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells.	Paclitaxel	79-84	twist family bHLH transcription factor 1	Homo sapiens	23-28
17230521-0	2007	Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells.	Paclitaxel	79-84	AKT serine/threonine kinase 1	Homo sapiens	54-57
17230521-3	2007	Previously, we found that upregulation of TWIST was responsible for the development of acquired resistance to taxol in a nasopharyngeal carcinoma (NPC) cell line, HNE1-T3 (Wang et al., Oncogene, 2004;24:274).	Paclitaxel	110-115	twist family bHLH transcription factor 1	Homo sapiens	42-47
17230521-4	2007	In this study, we investigated the underlying molecular mechanisms responsible for the TWIST-mediated taxol resistance.	Paclitaxel	102-107	twist family bHLH transcription factor 1	Homo sapiens	87-92
17230521-5	2007	By comparison of the parental HNE1 and its derivative HNE1-T3 cell lines, we found that the resistance to taxol in HNE1-T3 cells was associated with suppression of taxol-induced apoptosis evidenced by decreased expression of Bak and Bax and increased Bcl-2, as well as inhibition of PARP and caspase cleavage and DNA ladder formation.	Paclitaxel	106-111	BCL2 associated X, apoptosis regulator	Homo sapiens	233-236
17230521-5	2007	By comparison of the parental HNE1 and its derivative HNE1-T3 cell lines, we found that the resistance to taxol in HNE1-T3 cells was associated with suppression of taxol-induced apoptosis evidenced by decreased expression of Bak and Bax and increased Bcl-2, as well as inhibition of PARP and caspase cleavage and DNA ladder formation.	Paclitaxel	106-111	BCL2 apoptosis regulator	Homo sapiens	251-256
17230521-5	2007	By comparison of the parental HNE1 and its derivative HNE1-T3 cell lines, we found that the resistance to taxol in HNE1-T3 cells was associated with suppression of taxol-induced apoptosis evidenced by decreased expression of Bak and Bax and increased Bcl-2, as well as inhibition of PARP and caspase cleavage and DNA ladder formation.	Paclitaxel	164-169	BCL2 associated X, apoptosis regulator	Homo sapiens	233-236
17230521-5	2007	By comparison of the parental HNE1 and its derivative HNE1-T3 cell lines, we found that the resistance to taxol in HNE1-T3 cells was associated with suppression of taxol-induced apoptosis evidenced by decreased expression of Bak and Bax and increased Bcl-2, as well as inhibition of PARP and caspase cleavage and DNA ladder formation.	Paclitaxel	164-169	BCL2 apoptosis regulator	Homo sapiens	251-256
17230521-6	2007	However, there was no correlation between taxol sensitivity and alterations on G2/M cell cycle distribution, suggesting that the TWIST-induced taxol resistance is mediated through protection against apoptosis but not mitotic arrest.	Paclitaxel	143-148	twist family bHLH transcription factor 1	Homo sapiens	129-134
17230521-7	2007	Analysis of additional 8 NPC cell lines showed that upregulation of TWIST was associated with resistance to microtubule disrupting agents, especially taxol, and inactivation of TWIST through small RNA interference led to increased sensitivity to taxol-induced cell death.	Paclitaxel	150-155	twist family bHLH transcription factor 1	Homo sapiens	68-73
17230521-7	2007	Analysis of additional 8 NPC cell lines showed that upregulation of TWIST was associated with resistance to microtubule disrupting agents, especially taxol, and inactivation of TWIST through small RNA interference led to increased sensitivity to taxol-induced cell death.	Paclitaxel	246-251	twist family bHLH transcription factor 1	Homo sapiens	177-182
17230521-8	2007	Subsequent studies also demonstrated that the TWIST-mediated taxol resistance may be regulated through its positive involvement with the Akt pathway.	Paclitaxel	61-66	twist family bHLH transcription factor 1	Homo sapiens	46-51
17230521-8	2007	Subsequent studies also demonstrated that the TWIST-mediated taxol resistance may be regulated through its positive involvement with the Akt pathway.	Paclitaxel	61-66	AKT serine/threonine kinase 1	Homo sapiens	137-140
17230521-9	2007	Our findings suggest an underlying molecular mechanism responsible for the TWIST-mediated chemodrug resistance and suggest a target for overcoming taxol resistance in cancer cells.	Paclitaxel	147-152	twist family bHLH transcription factor 1	Homo sapiens	75-80
17463156-6	2007	Finally, there was a significant decrease in TNF-alpha and nitric oxide but not IL-12p40 when macrophages were cultured with lipopolysaccharide (LPS) and either paclitaxel or peloruside.	Paclitaxel	161-171	tumor necrosis factor	Mus musculus	45-54
17390065-5	2007	Paclitaxel activated extracellular signal-regulated kinase (ERK), and when ERK was inhibited by a mitogen-activated ERK-regulating kinase inhibitor, the cell death and cell cycle arrest induced by paclitaxel were rescued, demonstrating that paclitaxel inhibited the cellular growth via the ERK signaling pathway.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Homo sapiens	21-58
17390065-5	2007	Paclitaxel activated extracellular signal-regulated kinase (ERK), and when ERK was inhibited by a mitogen-activated ERK-regulating kinase inhibitor, the cell death and cell cycle arrest induced by paclitaxel were rescued, demonstrating that paclitaxel inhibited the cellular growth via the ERK signaling pathway.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Homo sapiens	60-63
17390065-5	2007	Paclitaxel activated extracellular signal-regulated kinase (ERK), and when ERK was inhibited by a mitogen-activated ERK-regulating kinase inhibitor, the cell death and cell cycle arrest induced by paclitaxel were rescued, demonstrating that paclitaxel inhibited the cellular growth via the ERK signaling pathway.	Paclitaxel	197-207	mitogen-activated protein kinase 1	Homo sapiens	60-63
17390065-5	2007	Paclitaxel activated extracellular signal-regulated kinase (ERK), and when ERK was inhibited by a mitogen-activated ERK-regulating kinase inhibitor, the cell death and cell cycle arrest induced by paclitaxel were rescued, demonstrating that paclitaxel inhibited the cellular growth via the ERK signaling pathway.	Paclitaxel	197-207	mitogen-activated protein kinase 1	Homo sapiens	75-78
17390065-5	2007	Paclitaxel activated extracellular signal-regulated kinase (ERK), and when ERK was inhibited by a mitogen-activated ERK-regulating kinase inhibitor, the cell death and cell cycle arrest induced by paclitaxel were rescued, demonstrating that paclitaxel inhibited the cellular growth via the ERK signaling pathway.	Paclitaxel	197-207	mitogen-activated protein kinase 1	Homo sapiens	75-78
17390065-5	2007	Paclitaxel activated extracellular signal-regulated kinase (ERK), and when ERK was inhibited by a mitogen-activated ERK-regulating kinase inhibitor, the cell death and cell cycle arrest induced by paclitaxel were rescued, demonstrating that paclitaxel inhibited the cellular growth via the ERK signaling pathway.	Paclitaxel	197-207	mitogen-activated protein kinase 1	Homo sapiens	75-78
17390065-5	2007	Paclitaxel activated extracellular signal-regulated kinase (ERK), and when ERK was inhibited by a mitogen-activated ERK-regulating kinase inhibitor, the cell death and cell cycle arrest induced by paclitaxel were rescued, demonstrating that paclitaxel inhibited the cellular growth via the ERK signaling pathway.	Paclitaxel	241-251	mitogen-activated protein kinase 1	Homo sapiens	60-63
17390065-5	2007	Paclitaxel activated extracellular signal-regulated kinase (ERK), and when ERK was inhibited by a mitogen-activated ERK-regulating kinase inhibitor, the cell death and cell cycle arrest induced by paclitaxel were rescued, demonstrating that paclitaxel inhibited the cellular growth via the ERK signaling pathway.	Paclitaxel	241-251	mitogen-activated protein kinase 1	Homo sapiens	75-78
17390065-5	2007	Paclitaxel activated extracellular signal-regulated kinase (ERK), and when ERK was inhibited by a mitogen-activated ERK-regulating kinase inhibitor, the cell death and cell cycle arrest induced by paclitaxel were rescued, demonstrating that paclitaxel inhibited the cellular growth via the ERK signaling pathway.	Paclitaxel	241-251	mitogen-activated protein kinase 1	Homo sapiens	75-78
17390065-5	2007	Paclitaxel activated extracellular signal-regulated kinase (ERK), and when ERK was inhibited by a mitogen-activated ERK-regulating kinase inhibitor, the cell death and cell cycle arrest induced by paclitaxel were rescued, demonstrating that paclitaxel inhibited the cellular growth via the ERK signaling pathway.	Paclitaxel	241-251	mitogen-activated protein kinase 1	Homo sapiens	75-78
17438109-2	2007	Because the orphan receptor, pregnenolone X-receptor (PXR), coordinately regulates the expression of paclitaxel metabolizing and transport enzymes, controlling this process could improve therapeutic outcome.	Paclitaxel	101-111	nuclear receptor subfamily 1 group I member 2	Homo sapiens	29-52
17429319-4	2007	Instead, as shown using a mammalian two-hybrid assay, it decreased the interaction of pregnane X receptor with steroid receptor coactivator-1 in the presence of rifampin, clotrimazole, paclitaxel, or nifedipine but not in their absence.	Paclitaxel	185-195	nuclear receptor subfamily 1 group I member 2	Homo sapiens	86-105
17438109-2	2007	Because the orphan receptor, pregnenolone X-receptor (PXR), coordinately regulates the expression of paclitaxel metabolizing and transport enzymes, controlling this process could improve therapeutic outcome.	Paclitaxel	101-111	nuclear receptor subfamily 1 group I member 2	Homo sapiens	54-57
17438109-8	2007	Because loss of PXR maintains blood levels of paclitaxel upon chronic dosing, ketoconazole analogues may also serve to preserve paclitaxel blood levels on chronic dosing of drugs.	Paclitaxel	46-56	nuclear receptor subfamily 1 group I member 2	Homo sapiens	16-19
17351398-7	2007	Immunohistochemical findings indicated that paclitaxel exhibited antiangiogenic activity by inhibiting the expression of basic fibroblast growth factor and vascular endothelial growth factor within the tumor.	Paclitaxel	44-54	vascular endothelial growth factor A	Homo sapiens	156-190
17430582-0	2007	Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.	Paclitaxel	142-152	BCL2 apoptosis regulator	Homo sapiens	27-32
16924496-0	2007	A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer.	Paclitaxel	19-29	hepatocyte nuclear factor 4 alpha	Homo sapiens	60-63
16924496-1	2007	PURPOSE: A phase I study of TCF therapy, which consists of paclitaxel (TXL: Taxol) + cisplatin (CDDP) + 5-fluorouracil (5-FU), in advanced gastric cancer patients was performed to determine the recommended dose (RD) for a phase II study by checking the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of 5-FU above the fixed dose of TXL and CDDP.	Paclitaxel	59-69	hepatocyte nuclear factor 4 alpha	Homo sapiens	28-31
16924496-1	2007	PURPOSE: A phase I study of TCF therapy, which consists of paclitaxel (TXL: Taxol) + cisplatin (CDDP) + 5-fluorouracil (5-FU), in advanced gastric cancer patients was performed to determine the recommended dose (RD) for a phase II study by checking the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of 5-FU above the fixed dose of TXL and CDDP.	Paclitaxel	76-81	hepatocyte nuclear factor 4 alpha	Homo sapiens	28-31
17471022-1	2007	OBJECTIVE: To evaluate the specific killing effects of the adenoviral vector in which the CD::UPP genes were directed by the MDR1 promoter on Taxol-resistance ovarian cancer cells in vitro and in vivo.	Paclitaxel	142-147	ATP binding cassette subfamily B member 1	Homo sapiens	125-129
17204494-7	2007	Treatment of hST vesicles with either the microtubular disrupter colchicine (15 microM) or the microtubular stabilizer paclitaxel (taxol, 15 microM) resulted in distinct patterns of microtubular re-organization and PC2 redistribution.	Paclitaxel	119-129	polycystin 2, transient receptor potential cation channel	Homo sapiens	215-218
17204494-7	2007	Treatment of hST vesicles with either the microtubular disrupter colchicine (15 microM) or the microtubular stabilizer paclitaxel (taxol, 15 microM) resulted in distinct patterns of microtubular re-organization and PC2 redistribution.	Paclitaxel	131-136	polycystin 2, transient receptor potential cation channel	Homo sapiens	215-218
17204494-10	2007	Addition of either tubulin and GTP, or taxol, however, stimulated PC2 channel activity in control hST membranes.	Paclitaxel	39-44	polycystin 2, transient receptor potential cation channel	Homo sapiens	66-69
17465239-6	2007	CONCLUSION: HER2/neu overexpression is predictive for response not only to trastuzumab, but also to epirubicin and paclitaxel.	Paclitaxel	115-125	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-16
17465239-6	2007	CONCLUSION: HER2/neu overexpression is predictive for response not only to trastuzumab, but also to epirubicin and paclitaxel.	Paclitaxel	115-125	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-20
17349584-5	2007	As a consequence, Lzts1(-/-) MEFs showed accelerated mitotic progression, resistance to taxol- and nocodazole-induced M phase arrest, and improper chromosome segregation.	Paclitaxel	88-93	leucine zipper, putative tumor suppressor 1	Mus musculus	18-23
17326770-5	2007	Down-regulation of caveolin-1 by siRNA reduced the interaction between p-gp and caveolin-1, followed by a decrease in [3H]-Taxol and [3H]-Vinblastine accumulation in RBE4 cells.	Paclitaxel	123-128	caveolin 1	Rattus norvegicus	19-29
16850247-1	2007	BACKGROUND: A randomized Phase II study evaluated the activity of weekly paclitaxel versus its combination with trastuzumab for treatment of patients with advanced breast cancer overexpressing HER-2.	Paclitaxel	73-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	193-198
17245652-1	2007	PURPOSE: The aim of the study was to investigate whether 2"-ethylcarbonate-linked paclitaxel (TAX-2"-Et) circumvents P-glycoprotein (P-gp)-mediated cellular efflux and cytotoxicity enhanced by TAX-2"-Et activation within human culture cells transfected with a rabbit liver carboxylesterase (Ra-CES) cDNA.	Paclitaxel	82-92	ATP binding cassette subfamily B member 1	Homo sapiens	117-131
17190787-1	2007	By comparing ovarian carcinoma-derived KF28 cells with the corresponding anticancer drug-resistant cells, the taxol- and cisplatin-resistant properties were found to be closely related with MDR1 and BSEP, and MRP2 transporters, respectively.	Paclitaxel	110-115	ATP binding cassette subfamily B member 1	Homo sapiens	190-194
17245652-1	2007	PURPOSE: The aim of the study was to investigate whether 2"-ethylcarbonate-linked paclitaxel (TAX-2"-Et) circumvents P-glycoprotein (P-gp)-mediated cellular efflux and cytotoxicity enhanced by TAX-2"-Et activation within human culture cells transfected with a rabbit liver carboxylesterase (Ra-CES) cDNA.	Paclitaxel	82-92	ATP binding cassette subfamily B member 1	Homo sapiens	133-137
17343796-1	2007	AIM: To explore the apoptotic effect of the combined treatment of anti-p185(c-erbB-2/neu) engineered antibody with paclitaxel on p185-overexpressing human malignant breast cancer cell lines BT474 and to study its emerging mechanism.	Paclitaxel	115-125	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-84
17343796-1	2007	AIM: To explore the apoptotic effect of the combined treatment of anti-p185(c-erbB-2/neu) engineered antibody with paclitaxel on p185-overexpressing human malignant breast cancer cell lines BT474 and to study its emerging mechanism.	Paclitaxel	115-125	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-88
17343796-6	2007	Furthermore, the combined treatment of the engineered antibody with paclitaxel effectively suppressed the activation of NF-kappaB in BT474 cells.	Paclitaxel	68-78	nuclear factor kappa B subunit 1	Homo sapiens	120-129
17343796-7	2007	CONCLUSION: The combined treatment of anti-p185(c-erbB-2/neu) engineered antibody with paclitaxel rendered p185-overexpressing human malignant breast cancer cells BT474 more susceptible to paclitaxel-induced apoptosis by the effective suppression of NF-kappaB activation.	Paclitaxel	87-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-56
17343796-7	2007	CONCLUSION: The combined treatment of anti-p185(c-erbB-2/neu) engineered antibody with paclitaxel rendered p185-overexpressing human malignant breast cancer cells BT474 more susceptible to paclitaxel-induced apoptosis by the effective suppression of NF-kappaB activation.	Paclitaxel	87-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-60
17343796-7	2007	CONCLUSION: The combined treatment of anti-p185(c-erbB-2/neu) engineered antibody with paclitaxel rendered p185-overexpressing human malignant breast cancer cells BT474 more susceptible to paclitaxel-induced apoptosis by the effective suppression of NF-kappaB activation.	Paclitaxel	87-97	nuclear factor kappa B subunit 1	Homo sapiens	250-259
17343796-7	2007	CONCLUSION: The combined treatment of anti-p185(c-erbB-2/neu) engineered antibody with paclitaxel rendered p185-overexpressing human malignant breast cancer cells BT474 more susceptible to paclitaxel-induced apoptosis by the effective suppression of NF-kappaB activation.	Paclitaxel	189-199	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-56
17343796-7	2007	CONCLUSION: The combined treatment of anti-p185(c-erbB-2/neu) engineered antibody with paclitaxel rendered p185-overexpressing human malignant breast cancer cells BT474 more susceptible to paclitaxel-induced apoptosis by the effective suppression of NF-kappaB activation.	Paclitaxel	189-199	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-60
17276342-2	2007	Here, we show that Chk1, a component of the DNA damage and replication checkpoints, protects vertebrate cells against spontaneous chromosome missegregation and is required to sustain anaphase delay when spindle function is disrupted by taxol, but not when microtubules are completely depolymerized by nocodazole.	Paclitaxel	236-241	checkpoint kinase 1	Homo sapiens	19-23
16581180-8	2007	Functionally, ET-1 significantly inhibited paclitaxel-induced apoptosis in RCC cells through binding ET(A) with the ET-1 signaling mediated via the PI3-kinase/Akt pathway.	Paclitaxel	43-53	endothelin 1	Homo sapiens	14-18
16581180-8	2007	Functionally, ET-1 significantly inhibited paclitaxel-induced apoptosis in RCC cells through binding ET(A) with the ET-1 signaling mediated via the PI3-kinase/Akt pathway.	Paclitaxel	43-53	endothelin 1	Homo sapiens	116-120
16581180-8	2007	Functionally, ET-1 significantly inhibited paclitaxel-induced apoptosis in RCC cells through binding ET(A) with the ET-1 signaling mediated via the PI3-kinase/Akt pathway.	Paclitaxel	43-53	AKT serine/threonine kinase 1	Homo sapiens	159-162
17012370-10	2007	Taxol significantly decreases p38 phosphorylation and activation in response to 2ME stimulation.	Paclitaxel	0-5	mitogen-activated protein kinase 1	Homo sapiens	30-33
16972069-10	2007	PTX induced JNK activity or AKT mediated BAD phosphorylation was unaffected by cell cycle inhibitors.	Paclitaxel	0-3	mitogen-activated protein kinase 8	Homo sapiens	12-15
16972069-10	2007	PTX induced JNK activity or AKT mediated BAD phosphorylation was unaffected by cell cycle inhibitors.	Paclitaxel	0-3	AKT serine/threonine kinase 1	Homo sapiens	28-31
17660958-4	2007	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and paclitaxel.	Paclitaxel	212-222	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
17660958-4	2007	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and paclitaxel.	Paclitaxel	212-222	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-32
17660958-4	2007	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and paclitaxel.	Paclitaxel	212-222	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-32
17190831-0	2007	Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity.	Paclitaxel	45-55	caveolin 1	Homo sapiens	0-10
17190831-5	2007	We report that phosphorylation of CAV1 on Tyr-14 regulates paclitaxel-mediated apoptosis in MCF-7 breast cancer cells.	Paclitaxel	59-69	caveolin 1	Homo sapiens	34-38
17244262-5	2007	Paclitaxel treatment combined with apoptin expression significantly inhibited the survival of p53-positive human osteosarcoma U2OS and non-small lung carcinoma A549 cells, p53-negative human osteosarcoma Saos-2 cells and p53-mutant human prostate cancer Du145 cells, already at low doses of the chemotherapeutic agent.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	94-97
17244262-5	2007	Paclitaxel treatment combined with apoptin expression significantly inhibited the survival of p53-positive human osteosarcoma U2OS and non-small lung carcinoma A549 cells, p53-negative human osteosarcoma Saos-2 cells and p53-mutant human prostate cancer Du145 cells, already at low doses of the chemotherapeutic agent.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	172-175
17244262-5	2007	Paclitaxel treatment combined with apoptin expression significantly inhibited the survival of p53-positive human osteosarcoma U2OS and non-small lung carcinoma A549 cells, p53-negative human osteosarcoma Saos-2 cells and p53-mutant human prostate cancer Du145 cells, already at low doses of the chemotherapeutic agent.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	172-175
17276342-6	2007	In addition, Chk1-deficient cells exhibit increased resistance to taxol.	Paclitaxel	66-71	checkpoint kinase 1	Homo sapiens	13-17
17506771-9	2007	Microvessel density and VEGF were significantly decreased in the candesartan and candesartan-paclitaxel groups compared to the control group.	Paclitaxel	93-103	vascular endothelial growth factor A	Homo sapiens	24-28
17645840-1	2007	OBJECTIVE: To explore the effect of hypoxia and hypoxia-inducible factor-1alpha (HIF-1alpha) on the expression of multidrug resistance gene-1 (mdr-1) and its coded p-glyeoprotein (P-gp) as well as the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism.	Paclitaxel	263-273	hypoxia inducible factor 1 subunit alpha	Homo sapiens	48-79
17645840-1	2007	OBJECTIVE: To explore the effect of hypoxia and hypoxia-inducible factor-1alpha (HIF-1alpha) on the expression of multidrug resistance gene-1 (mdr-1) and its coded p-glyeoprotein (P-gp) as well as the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism.	Paclitaxel	263-273	hypoxia inducible factor 1 subunit alpha	Homo sapiens	81-91
17645840-1	2007	OBJECTIVE: To explore the effect of hypoxia and hypoxia-inducible factor-1alpha (HIF-1alpha) on the expression of multidrug resistance gene-1 (mdr-1) and its coded p-glyeoprotein (P-gp) as well as the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism.	Paclitaxel	263-273	ATP binding cassette subfamily B member 1	Homo sapiens	114-148
17645840-12	2007	CONCLUSION: Hypoxia can decrease the chemotherapeutic sensitivity of human ovarian cancer A2780 cells to paclitaxel through HIF-1alpha regulating the expression of mdr-1 and p-gp.	Paclitaxel	105-115	hypoxia inducible factor 1 subunit alpha	Homo sapiens	124-134
17645840-12	2007	CONCLUSION: Hypoxia can decrease the chemotherapeutic sensitivity of human ovarian cancer A2780 cells to paclitaxel through HIF-1alpha regulating the expression of mdr-1 and p-gp.	Paclitaxel	105-115	ATP binding cassette subfamily B member 1	Homo sapiens	164-169
17029589-10	2007	Paclitaxel-stimulated ATPase activity of MDR1 is enhanced in the presence of stigmasterol, sitosterol and campesterol, as well as cholesterol, but not ergosterol.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	41-45
17113177-0	2007	Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.	Paclitaxel	49-59	ATP binding cassette subfamily B member 1	Homo sapiens	81-95
17113177-5	2007	dosing with PTX formulated in Cremophor EL (PTX(CrEL)) induced a two-fold increase in mRNA levels of MDR1 after a 14-day dosing period.	Paclitaxel	12-15	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
17113177-5	2007	dosing with PTX formulated in Cremophor EL (PTX(CrEL)) induced a two-fold increase in mRNA levels of MDR1 after a 14-day dosing period.	Paclitaxel	44-47	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
17404021-0	2007	Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.	Paclitaxel	19-29	AKT serine/threonine kinase 1	Homo sapiens	0-3
17404021-5	2007	Here, we demonstrated that inhibition of Akt increases the efficacy of the paclitaxel-induced apoptosis in SKOV3 and PA-1 human ovarian cancer cells.	Paclitaxel	75-85	AKT serine/threonine kinase 1	Homo sapiens	41-44
17404021-9	2007	To further elucidate the mechanism of apoptosis by paclitaxel, we compared the levels of phosphorylation of Akt between paclitaxel-resistant SKOV3 cells and paclitaxel-sensitive PA-1 cells.	Paclitaxel	51-61	AKT serine/threonine kinase 1	Homo sapiens	108-111
17404021-9	2007	To further elucidate the mechanism of apoptosis by paclitaxel, we compared the levels of phosphorylation of Akt between paclitaxel-resistant SKOV3 cells and paclitaxel-sensitive PA-1 cells.	Paclitaxel	120-130	AKT serine/threonine kinase 1	Homo sapiens	108-111
17404021-9	2007	To further elucidate the mechanism of apoptosis by paclitaxel, we compared the levels of phosphorylation of Akt between paclitaxel-resistant SKOV3 cells and paclitaxel-sensitive PA-1 cells.	Paclitaxel	120-130	AKT serine/threonine kinase 1	Homo sapiens	108-111
17404021-11	2007	Interestingly, the treatment of paclitaxel decreased the amount of phosphorylated Akt in a time-dependent manner in both cell lines.	Paclitaxel	32-42	AKT serine/threonine kinase 1	Homo sapiens	82-85
17404021-12	2007	Furthermore, inhibition of Akt by specific phosphatidyinositol-3-kinase (PI3K)-Akt inhibitors (Wortmannin, and LY294002) synergistically increased the efficacy of the paclitaxel-induced apoptosis in both cell lines.	Paclitaxel	167-177	AKT serine/threonine kinase 1	Homo sapiens	27-30
17404021-12	2007	Furthermore, inhibition of Akt by specific phosphatidyinositol-3-kinase (PI3K)-Akt inhibitors (Wortmannin, and LY294002) synergistically increased the efficacy of the paclitaxel-induced apoptosis in both cell lines.	Paclitaxel	167-177	AKT serine/threonine kinase 1	Homo sapiens	79-82
17404021-13	2007	These results suggest that the addition of the Akt inhibitor may increase the therapeutic efficacy of paclitaxel for patients with ovarian cancer.	Paclitaxel	102-112	AKT serine/threonine kinase 1	Homo sapiens	47-50
17269699-4	2007	Paclitaxel loaded OB4 (PB219-PEO121) polymersome formulations were colloidally stable for 4 months at 4 degrees C and exhibited slow steady release of paclitaxel over a 5 week period at 37 degrees C. Evaluation of the in vitro cytotoxicity of paclitaxel-polymersome formulations showed that the ability of paclitaxel-loaded polymersomes to inhibit proliferation of MCF-7 human breast cancer cells was less compared to paclitaxel alone.	Paclitaxel	0-10	BMIQ7	Homo sapiens	18-21
17269699-4	2007	Paclitaxel loaded OB4 (PB219-PEO121) polymersome formulations were colloidally stable for 4 months at 4 degrees C and exhibited slow steady release of paclitaxel over a 5 week period at 37 degrees C. Evaluation of the in vitro cytotoxicity of paclitaxel-polymersome formulations showed that the ability of paclitaxel-loaded polymersomes to inhibit proliferation of MCF-7 human breast cancer cells was less compared to paclitaxel alone.	Paclitaxel	151-161	BMIQ7	Homo sapiens	18-21
17200359-0	2007	Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.	Paclitaxel	25-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-180
18086299-0	2007	CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.	Paclitaxel	77-87	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-157
17200359-1	2007	PURPOSE: Findings from our previously published phase III randomized trial showed a high pathologic complete remission (CR) rate in patients with human epidermal growth factor receptor 2-positive breast cancer after the concurrent administration of trastuzumab and paclitaxel, followed by concurrent trastuzumab and 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) preoperative chemotherapy.	Paclitaxel	265-275	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-186
17220672-7	2007	The combination of trastuzumab and paclitaxel is a promising regimen for HER 2 positive advanced breast cancer.	Paclitaxel	35-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-78
17186002-0	2007	Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.	Paclitaxel	76-86	solute carrier organic anion transporter family member 1B3	Homo sapiens	16-23
17186002-1	2007	To explore retrospectively the relationships between paclitaxel pharmacokinetics and three known, non-synonymous single-nucleotide polymorphisms (SNPs) in SLCO1B3, the gene encoding organic anion transporting polypeptide (OATP)1B3.	Paclitaxel	53-63	solute carrier organic anion transporter family member 1B3	Homo sapiens	155-162
17186002-3	2007	The 334T&gt;G (Ser112Ala), 699G&gt;A (Met233Ile), and 1564G&gt;T (Gly522Cys) loci of SLCO1B3 were screened in 475 individuals from five ethnic groups and 90 European Caucasian cancer patients treated with paclitaxel.	Paclitaxel	205-215	solute carrier organic anion transporter family member 1B3	Homo sapiens	85-92
17186002-4	2007	Only OATP1B3 was capable of transporting paclitaxel to a significant extent (P=0.003).	Paclitaxel	41-51	solute carrier organic anion transporter family member 1B3	Homo sapiens	5-12
17186002-7	2007	The studied SNPs in SLCO1B3 appear to play a limited role in the disposition of paclitaxel, although their clinical significance in other ethnic populations remains to be investigated.	Paclitaxel	80-90	solute carrier organic anion transporter family member 1B3	Homo sapiens	20-27
17299267-4	2007	This research showed that proliferation of cell lines with high-affinity IL-2 receptors derived from T cell malignancies were suppressed by the PMBN conjugated with IL-2 (PMBN-IL2 conjugate) incorporating paclitaxel (PTX) and cyclosporin A at lower concentrations than used conventionally.	Paclitaxel	205-215	interleukin 2	Homo sapiens	73-77
17299267-4	2007	This research showed that proliferation of cell lines with high-affinity IL-2 receptors derived from T cell malignancies were suppressed by the PMBN conjugated with IL-2 (PMBN-IL2 conjugate) incorporating paclitaxel (PTX) and cyclosporin A at lower concentrations than used conventionally.	Paclitaxel	205-215	interleukin 2	Homo sapiens	165-169
17299267-4	2007	This research showed that proliferation of cell lines with high-affinity IL-2 receptors derived from T cell malignancies were suppressed by the PMBN conjugated with IL-2 (PMBN-IL2 conjugate) incorporating paclitaxel (PTX) and cyclosporin A at lower concentrations than used conventionally.	Paclitaxel	217-220	interleukin 2	Homo sapiens	73-77
17299267-4	2007	This research showed that proliferation of cell lines with high-affinity IL-2 receptors derived from T cell malignancies were suppressed by the PMBN conjugated with IL-2 (PMBN-IL2 conjugate) incorporating paclitaxel (PTX) and cyclosporin A at lower concentrations than used conventionally.	Paclitaxel	217-220	interleukin 2	Homo sapiens	165-169
17299267-7	2007	The PMBN-IL2 conjugate with PTX may therefore be useful for selectively eliminating activated lymphocytes that hyperproduce high-affinity IL-2 receptors.	Paclitaxel	28-31	interleukin 2	Homo sapiens	138-142
17143528-10	2007	Our observation in this study raised the possibility that dexamethasone pretreatment antagonizes paclitaxel-induced cytotoxicity through ERK suppression and pRB dephosphorylation.	Paclitaxel	97-107	mitogen-activated protein kinase 1	Homo sapiens	137-140
17640170-5	2007	Western blot analysis showed that the expression of B cell lymphoma-2 (Bcl-2) protein, an apoptosis inhibitory protein, in both cell lines was decreased more significant by paclitaxel in combination with seal oil than by paclitaxel alone.	Paclitaxel	173-183	BCL2 apoptosis regulator	Homo sapiens	52-69
18261374-0	2007	Enhancement of paclitaxel transport and cytotoxicity by 7,3",4"-trimethoxyflavone, a P-glycoprotein inhibitor.	Paclitaxel	15-25	ATP binding cassette subfamily B member 1	Homo sapiens	85-99
18261374-2	2007	The aim of this study was to select a P-glycoprotein (Pgp)- inhibitory flavonoid to enhance paclitaxel bioavailability in the Caco-2 cell monolayer.	Paclitaxel	92-102	ATP binding cassette subfamily B member 1	Homo sapiens	38-52
18261374-2	2007	The aim of this study was to select a P-glycoprotein (Pgp)- inhibitory flavonoid to enhance paclitaxel bioavailability in the Caco-2 cell monolayer.	Paclitaxel	92-102	ATP binding cassette subfamily B member 1	Homo sapiens	54-57
18261374-10	2007	In addition, AP loading of TMF increased the paclitaxel sensitivity of paclitaxel-resistant SK-MES-1/PT4000 cells overexpressing Pgp on the BL side.	Paclitaxel	45-55	ATP binding cassette subfamily B member 1	Homo sapiens	129-132
18261374-10	2007	In addition, AP loading of TMF increased the paclitaxel sensitivity of paclitaxel-resistant SK-MES-1/PT4000 cells overexpressing Pgp on the BL side.	Paclitaxel	71-81	ATP binding cassette subfamily B member 1	Homo sapiens	129-132
17164777-0	2007	Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF.	Paclitaxel	89-94	vascular endothelial growth factor A	Homo sapiens	162-166
17640170-5	2007	Western blot analysis showed that the expression of B cell lymphoma-2 (Bcl-2) protein, an apoptosis inhibitory protein, in both cell lines was decreased more significant by paclitaxel in combination with seal oil than by paclitaxel alone.	Paclitaxel	173-183	BCL2 apoptosis regulator	Homo sapiens	71-76
17143487-0	2007	Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids.	Paclitaxel	38-43	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
17143487-7	2007	Selective small interfering RNAs (siRNA) of P-gp with MDR1-targeted short hairpin RNAs (shRNA) expression vector sensitized the cells to Taxol.	Paclitaxel	137-142	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
17143487-8	2007	These results suggest that both p27 and P-gp can modulate Taxol sensitivity respectively, while p27 requires P-gp for its full function.	Paclitaxel	58-63	zinc ribbon domain containing 2	Homo sapiens	32-35
17143487-9	2007	Increased P-gp protein expression through p27 mediation is one of the major mechanisms of Taxol resistance in ovarian cancer multicellular spheroids.	Paclitaxel	90-95	zinc ribbon domain containing 2	Homo sapiens	42-45
17640170-5	2007	Western blot analysis showed that the expression of B cell lymphoma-2 (Bcl-2) protein, an apoptosis inhibitory protein, in both cell lines was decreased more significant by paclitaxel in combination with seal oil than by paclitaxel alone.	Paclitaxel	221-231	BCL2 apoptosis regulator	Homo sapiens	52-69
17640170-5	2007	Western blot analysis showed that the expression of B cell lymphoma-2 (Bcl-2) protein, an apoptosis inhibitory protein, in both cell lines was decreased more significant by paclitaxel in combination with seal oil than by paclitaxel alone.	Paclitaxel	221-231	BCL2 apoptosis regulator	Homo sapiens	71-76
18306930-0	2007	Actin-sequestering protein, thymosin-beta-4 (TB4), inhibits caspase-3 activation in paclitaxel-induced tumor cell death.	Paclitaxel	84-94	thymosin beta 4 X-linked	Homo sapiens	28-43
17998790-6	2007	The DLT level was reached at paclitaxel 110 mg/m2, LOHP 50 mg/m2 and capecitabine 1,000 mg/m2/day.	Paclitaxel	29-39	codanin 1	Homo sapiens	4-7
18306930-0	2007	Actin-sequestering protein, thymosin-beta-4 (TB4), inhibits caspase-3 activation in paclitaxel-induced tumor cell death.	Paclitaxel	84-94	thymosin beta 4 X-linked	Homo sapiens	45-48
18306930-0	2007	Actin-sequestering protein, thymosin-beta-4 (TB4), inhibits caspase-3 activation in paclitaxel-induced tumor cell death.	Paclitaxel	84-94	caspase 3	Homo sapiens	60-69
18306930-2	2007	TB4 induces tumor metastasis and paclitaxel resistance, which is the most significant obstacle to successful therapy in tumors.	Paclitaxel	33-43	thymosin beta 4 X-linked	Homo sapiens	0-3
18306930-3	2007	Here we investigated the inhibitory effect of TB4 peptides on tumor cell death by paclitaxel.	Paclitaxel	82-92	thymosin beta 4 X-linked	Homo sapiens	46-49
18306930-10	2007	In conclusion, soluble TB4 peptides produced in cancer cells could be an obstacle to treat tumors with paclitaxel.	Paclitaxel	103-113	thymosin beta 4 X-linked	Homo sapiens	23-26
18306930-11	2007	Therefore, TB4 could be a novel target to control paclitaxel resistance.	Paclitaxel	50-60	thymosin beta 4 X-linked	Homo sapiens	11-14
17148658-7	2006	Finally, paclitaxel, a therapy that retards polycystic kidney disease in cpk mice, increased extracellular galectin-3, in which the lectin could potentially interact with cilia.	Paclitaxel	9-19	lectin, galactose binding, soluble 3	Mus musculus	107-117
16950792-7	2006	The acute addition of the microtubular disrupter colchicine (15 mum) rapidly abolished, whereas the addition of the microtubular stabilizer paclitaxel (taxol, 15 mum) increased ciliary PC2 channel activity.	Paclitaxel	140-150	polycystin 2, transient receptor potential cation channel	Canis lupus familiaris	185-188
16950792-7	2006	The acute addition of the microtubular disrupter colchicine (15 mum) rapidly abolished, whereas the addition of the microtubular stabilizer paclitaxel (taxol, 15 mum) increased ciliary PC2 channel activity.	Paclitaxel	152-157	polycystin 2, transient receptor potential cation channel	Canis lupus familiaris	185-188
17166391-4	2006	For example, paclitaxel is regarded as a relatively sensitive drug and may be chosen for the tumors with high expression of p53, while it is predicted as relatively resistant drug and should be avoided for the tumors with high expression of P-glycoprotein (P-gp).	Paclitaxel	13-23	tumor protein p53	Homo sapiens	124-127
17166391-4	2006	For example, paclitaxel is regarded as a relatively sensitive drug and may be chosen for the tumors with high expression of p53, while it is predicted as relatively resistant drug and should be avoided for the tumors with high expression of P-glycoprotein (P-gp).	Paclitaxel	13-23	ATP binding cassette subfamily B member 1	Homo sapiens	241-255
17166391-4	2006	For example, paclitaxel is regarded as a relatively sensitive drug and may be chosen for the tumors with high expression of p53, while it is predicted as relatively resistant drug and should be avoided for the tumors with high expression of P-glycoprotein (P-gp).	Paclitaxel	13-23	ATP binding cassette subfamily B member 1	Homo sapiens	257-261
16773437-4	2006	We hypothesized that patients whose tumors expressed higher amounts of IL-6 or PGP would be less likely to respond to paclitaxel, an agent affected by the PGP pathway.	Paclitaxel	118-128	interleukin 6	Homo sapiens	71-75
16904325-6	2006	In addition, in vitro metabolism studies of 23a with a subset of human CYP-450 isoforms revealed that, unlike XR9576, 23a inhibited CYP3A4, an enzyme that colocalizes with P-gp in the intestine and contributes to tumor cell chemoresistance by enhancing the biodisposition of anticancer drugs such as paclitaxel toward metabolism.	Paclitaxel	300-310	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	132-138
16904325-6	2006	In addition, in vitro metabolism studies of 23a with a subset of human CYP-450 isoforms revealed that, unlike XR9576, 23a inhibited CYP3A4, an enzyme that colocalizes with P-gp in the intestine and contributes to tumor cell chemoresistance by enhancing the biodisposition of anticancer drugs such as paclitaxel toward metabolism.	Paclitaxel	300-310	ATP binding cassette subfamily B member 1	Homo sapiens	172-176
16773437-4	2006	We hypothesized that patients whose tumors expressed higher amounts of IL-6 or PGP would be less likely to respond to paclitaxel, an agent affected by the PGP pathway.	Paclitaxel	118-128	ATP binding cassette subfamily B member 1	Homo sapiens	79-82
16773437-4	2006	We hypothesized that patients whose tumors expressed higher amounts of IL-6 or PGP would be less likely to respond to paclitaxel, an agent affected by the PGP pathway.	Paclitaxel	118-128	ATP binding cassette subfamily B member 1	Homo sapiens	155-158
16773437-5	2006	If so, then IL-6 could serve as a predictive factor for paclitaxel sensitivity.	Paclitaxel	56-66	interleukin 6	Homo sapiens	12-16
16897435-0	2006	Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007.	Paclitaxel	14-24	caveolin 1	Homo sapiens	125-135
16995873-2	2006	In accordance with previous reports, taxol and cisplatin resistance was closely correlated with expression of the multidrug resistance 1 and bile acid export pump, and multidrug resistance-associated protein 2 genes, respectively.	Paclitaxel	37-42	ATP binding cassette subfamily B member 1	Homo sapiens	114-136
16917872-6	2006	Compared to MDR1(wt), MDR1(G1199A) exhibited an increased resistance to doxorubicin, paclitaxel, vinblastine, and vincristine.	Paclitaxel	85-95	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
17189388-0	2006	Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.	Paclitaxel	159-164	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-83
17189388-15	2006	Peptide aptamer interference with AKT activation resulted in the restoration of regular sensitivity of breast cancer cells toward Taxol.	Paclitaxel	130-135	AKT serine/threonine kinase 1	Homo sapiens	34-37
16950614-0	2006	Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.	Paclitaxel	36-46	ATP binding cassette subfamily B member 1	Homo sapiens	15-20
17010629-0	2006	Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration.	Paclitaxel	46-56	erythropoietin	Homo sapiens	0-14
17010629-4	2006	Furthermore, in an animal model of paclitaxel-induced distal sensory polyneuropathy, recombinant human erythropoietin protects against distal axonal degeneration.	Paclitaxel	35-45	erythropoietin	Homo sapiens	103-117
17010629-5	2006	These findings suggest that recombinant human erythropoietin may be useful as a therapy to prevent paclitaxel-induced sensory polyneuropathy in patients undergoing chemotherapy.	Paclitaxel	99-109	erythropoietin	Homo sapiens	46-60
16544145-8	2006	CONCLUSIONS: M4N and maltose-tri-O-methyl nordihydroguaiaretic acid (maltose-M3N), a water-soluble derivative of NDGA, were also able to reverse the MDR phenotype of the tumor cells in a xenograft model system and combination therapy with M4N or maltose-M3N and paclitaxel was effective at inhibiting growth of these tumors in nude mice.	Paclitaxel	262-272	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	149-152
16950614-1	2006	Here, we evaluated the relationships between ABCB1 (P-glycoprotein, MDR1) polymorphisms and paclitaxel (Taxol)-induced toxicity and pharmacokinetics.	Paclitaxel	92-102	ATP binding cassette subfamily B member 1	Homo sapiens	45-50
16950614-1	2006	Here, we evaluated the relationships between ABCB1 (P-glycoprotein, MDR1) polymorphisms and paclitaxel (Taxol)-induced toxicity and pharmacokinetics.	Paclitaxel	92-102	ATP binding cassette subfamily B member 1	Homo sapiens	52-66
16950614-1	2006	Here, we evaluated the relationships between ABCB1 (P-glycoprotein, MDR1) polymorphisms and paclitaxel (Taxol)-induced toxicity and pharmacokinetics.	Paclitaxel	92-102	ATP binding cassette subfamily B member 1	Homo sapiens	68-72
16950614-1	2006	Here, we evaluated the relationships between ABCB1 (P-glycoprotein, MDR1) polymorphisms and paclitaxel (Taxol)-induced toxicity and pharmacokinetics.	Paclitaxel	104-109	ATP binding cassette subfamily B member 1	Homo sapiens	45-50
16950614-6	2006	This pilot study suggests that paclitaxel-induced neuropathy and neutropenia might be linked to inherited variants of ABCB1 through a mechanism that is unrelated to altered plasma pharmacokinetics.	Paclitaxel	31-41	ATP binding cassette subfamily B member 1	Homo sapiens	118-123
17121923-6	2006	Using cell cycle analysis, nuclear staining, and Western blot analysis for poly(ADP-ribose) polymerase and caspase-9 degradation products, TSA/paclitaxel showed the most dramatic activation of the apoptotic cascade.	Paclitaxel	143-153	poly(ADP-ribose) polymerase 1	Homo sapiens	75-102
20859353-0	2006	Phase II Trial of a Novel Paclitaxel Schedule As Single-Agent, First-Line Therapy for HER-2/neu-Negative Metastatic Breast Cancer: A Community-Based Study.	Paclitaxel	26-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-91
20859353-0	2006	Phase II Trial of a Novel Paclitaxel Schedule As Single-Agent, First-Line Therapy for HER-2/neu-Negative Metastatic Breast Cancer: A Community-Based Study.	Paclitaxel	26-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-95
20859353-1	2006	PURPOSE: To determine the response rate (RR), progression-free survival (PFS), and toxicity in patients with HER-2/neu-negative metastatic breast cancer treated with first-line paclitaxel in a de-escalating dosing schedule.	Paclitaxel	177-187	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-114
20859353-1	2006	PURPOSE: To determine the response rate (RR), progression-free survival (PFS), and toxicity in patients with HER-2/neu-negative metastatic breast cancer treated with first-line paclitaxel in a de-escalating dosing schedule.	Paclitaxel	177-187	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-118
17212145-6	2006	One year later, she received paclitaxel so that the sensitivity of HER2/neu dropped.	Paclitaxel	29-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
17212145-6	2006	One year later, she received paclitaxel so that the sensitivity of HER2/neu dropped.	Paclitaxel	29-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-75
17077358-8	2006	Combination therapy with EA5 and paclitaxel reduced tumor weight by 77% and 80% (95% CI = 63% to 91% and 68% to 91%), respectively, compared with paclitaxel alone and by 92% and 88% (95% CI = 87% to 97% and 80% to 94%), respectively, compared with IgG alone.	Paclitaxel	146-156	erythrocyte antigen 5	Mus musculus	25-28
16721826-10	2006	The effects of etoposide and paclitaxel on Akt also differed between ASMCs and VSMCs.	Paclitaxel	29-39	AKT serine/threonine kinase 1	Homo sapiens	43-46
16934227-9	2006	However, the paclitaxel resistant cell line appeared more sensitive to the chemosensitising effects of GW282974A, in line with its increased EGFR expression.	Paclitaxel	13-23	epidermal growth factor receptor	Homo sapiens	141-145
16721826-7	2006	Treatment with either paclitaxel or etoposide caused a transient phosphorylation/activation of p42 MAPK in ASMCs and DFs, but had no effect on phospho-p42/44 MAPK in VSMCs.	Paclitaxel	22-32	mitogen-activated protein kinase 1	Homo sapiens	95-103
16721826-7	2006	Treatment with either paclitaxel or etoposide caused a transient phosphorylation/activation of p42 MAPK in ASMCs and DFs, but had no effect on phospho-p42/44 MAPK in VSMCs.	Paclitaxel	22-32	mitogen-activated protein kinase 1	Homo sapiens	99-103
16969354-2	2006	Paclitaxel has high affinity for the P-glycoprotein (P-gp) (drug efflux pump) in the gastrointestinal tract causing low and variable oral bioavailability.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	37-51
17062688-3	2006	Taxane-induced (paclitaxel and its analogue docetaxel) phosphorylation of Bcl-2 abolishes the potential antiapoptotic effect of Bcl-2.	Paclitaxel	16-26	BCL2 apoptosis regulator	Homo sapiens	74-79
17062688-3	2006	Taxane-induced (paclitaxel and its analogue docetaxel) phosphorylation of Bcl-2 abolishes the potential antiapoptotic effect of Bcl-2.	Paclitaxel	16-26	BCL2 apoptosis regulator	Homo sapiens	128-133
17062689-0	2006	Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.	Paclitaxel	62-72	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	0-30
17062689-1	2006	PURPOSE: P-glycoprotein (P-gp; ABCB1) efficiently transports lipophilic amphipathic drugs, including the widely used anticancer drug paclitaxel (Taxol).	Paclitaxel	133-143	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	31-36
17062689-1	2006	PURPOSE: P-glycoprotein (P-gp; ABCB1) efficiently transports lipophilic amphipathic drugs, including the widely used anticancer drug paclitaxel (Taxol).	Paclitaxel	145-150	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	31-36
17062689-8	2006	In spite of this similar effect, Mrp2 and P-gp had mostly complementary functions in paclitaxel elimination.	Paclitaxel	85-95	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	33-37
17062689-15	2006	Variation in MRP2 activity might thus directly affect the effective exposure to paclitaxel, on i.v.	Paclitaxel	80-90	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	13-17
17062699-0	2006	Does MDR-1 G2677T/A polymorphism really associate with ovarian cancer response to paclitaxel chemotherapy?	Paclitaxel	82-92	ATP binding cassette subfamily B member 1	Homo sapiens	5-10
16969354-2	2006	Paclitaxel has high affinity for the P-glycoprotein (P-gp) (drug efflux pump) in the gastrointestinal tract causing low and variable oral bioavailability.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	53-57
16969354-3	2006	Previously, we demonstrated that oral paclitaxel plus the P-gp inhibitor cyclosporin (CsA) is safe and results in adequate exposure to paclitaxel.	Paclitaxel	135-145	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
17020983-12	2006	However, the statistically higher paclitaxel deposition in the periphery of metastatic brain tumors provides functional evidence corroborating reports of decreased P-glycoprotein expression in metastatic versus primary brain tumors.	Paclitaxel	34-44	ATP binding cassette subfamily B member 1	Homo sapiens	164-178
17127735-8	2006	TNFalpha, IFNgamma, and IL-10 production were all significantly inhibited in the paclitaxel-treated mice.	Paclitaxel	81-91	tumor necrosis factor	Mus musculus	0-8
17127735-8	2006	TNFalpha, IFNgamma, and IL-10 production were all significantly inhibited in the paclitaxel-treated mice.	Paclitaxel	81-91	interferon gamma	Mus musculus	10-18
17127735-8	2006	TNFalpha, IFNgamma, and IL-10 production were all significantly inhibited in the paclitaxel-treated mice.	Paclitaxel	81-91	interleukin 10	Mus musculus	24-29
17001553-0	2006	Role of human placental efflux transporter P-glycoprotein in the transfer of buprenorphine, levo-alpha-acetylmethadol, and paclitaxel.	Paclitaxel	123-133	ATP binding cassette subfamily B member 1	Homo sapiens	43-57
16998471-9	2006	Moreover, the co-delivery of paclitaxel with Bcl-2-targeted small interfering RNA (siRNA) increased cytotoxicity in MDA-MB-231 human breast cancer cells.	Paclitaxel	29-39	BCL2 apoptosis regulator	Homo sapiens	45-50
16951221-8	2006	RESULTS: Activated (phosphorylated) Stat3 is overexpressed in most paclitaxel-resistant ovarian cancer cells.	Paclitaxel	67-77	signal transducer and activator of transcription 3	Homo sapiens	36-41
16969513-0	2006	Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells.	Paclitaxel	0-10	epidermal growth factor receptor	Homo sapiens	87-91
16969513-0	2006	Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Homo sapiens	96-99
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	Paclitaxel	30-40	epidermal growth factor receptor	Homo sapiens	69-73
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	Paclitaxel	30-40	epidermal growth factor receptor	Homo sapiens	107-111
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	Paclitaxel	30-40	mitogen-activated protein kinase 8	Homo sapiens	178-181
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	Paclitaxel	30-40	mitogen-activated protein kinase 1	Homo sapiens	186-189
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	Paclitaxel	30-40	epidermal growth factor receptor	Homo sapiens	107-111
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	Paclitaxel	30-40	mitogen-activated protein kinase 1	Homo sapiens	250-253
16969513-8	2006	Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126.	Paclitaxel	139-149	epidermal growth factor receptor	Homo sapiens	69-73
16459017-0	2006	Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin.	Paclitaxel	137-147	tumor protein p53	Homo sapiens	27-30
16413734-1	2006	The binding to human serum albumin (HSA) of the antitumoural drug paclitaxel and of several structural analogues has been characterized by bioaffinity chromatography and circular dichroism.	Paclitaxel	66-76	albumin	Homo sapiens	21-34
16969513-9	2006	Taken together, our results demonstrated that the combination of paclitaxel and ceramide synergistically induced pancreatic cancer cell death through differential activation of EGFR-mediated MAP kinases.	Paclitaxel	65-75	epidermal growth factor receptor	Homo sapiens	177-181
16969513-10	2006	EGFR and ERK inhibitors may further enhance the paclitaxel and ceramide effect.	Paclitaxel	48-58	epidermal growth factor receptor	Homo sapiens	0-4
16969513-10	2006	EGFR and ERK inhibitors may further enhance the paclitaxel and ceramide effect.	Paclitaxel	48-58	mitogen-activated protein kinase 1	Homo sapiens	9-12
16951221-9	2006	Inhibition of Stat3 activation results in significant decreases in paclitaxel resistance and enhanced apoptosis.	Paclitaxel	67-77	signal transducer and activator of transcription 3	Homo sapiens	14-19
16951221-12	2006	CONCLUSIONS: These data support the hypothesis that interruption of Stat3 signaling could reverse resistance to paclitaxel and perhaps other chemotherapy agents in human cancer.	Paclitaxel	112-122	signal transducer and activator of transcription 3	Homo sapiens	68-73
17009971-1	2006	The objective of this study was to determine whether paclitaxel and a strong antioxidant, pyrrolidinedithiocarbamate (PDTC), can affect the activation of nuclear factor-kappa B (NF-kappaB) in SKOV-3 human ovarian cancer cell line and the effect of these two agents on the growth and apoptosis of the cancer cells.	Paclitaxel	53-63	nuclear factor kappa B subunit 1	Homo sapiens	154-176
16969027-0	2006	[A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy].	Paclitaxel	117-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
16969027-2	2006	As expression of HER2 showed 3+, we performed trastuzumab/paclitaxel combination therapy.	Paclitaxel	58-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-21
16969027-4	2006	It is suggested that trastuzumab/paclitaxel combination therapy might be a first-line treatment for HER2 overexpressing recurrent breast cancer which had not been treated previously with anthracycline drugs.	Paclitaxel	33-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
17009971-1	2006	The objective of this study was to determine whether paclitaxel and a strong antioxidant, pyrrolidinedithiocarbamate (PDTC), can affect the activation of nuclear factor-kappa B (NF-kappaB) in SKOV-3 human ovarian cancer cell line and the effect of these two agents on the growth and apoptosis of the cancer cells.	Paclitaxel	53-63	nuclear factor kappa B subunit 1	Homo sapiens	178-187
17009971-7	2006	Treatment of paclitaxel alone showed increased nuclear p65 protein and decreased cytoplasmic IkappaB-alpha protein expression, while pretreatment of PDTC reversed this function.	Paclitaxel	13-23	NFKB inhibitor alpha	Homo sapiens	93-106
17009971-8	2006	PDTC blocks the paclitaxel-induced activation of NF-kappaB leading to increased chemosensitivity to paclitaxel and enhanced apoptosis.	Paclitaxel	16-26	nuclear factor kappa B subunit 1	Homo sapiens	49-58
17009971-8	2006	PDTC blocks the paclitaxel-induced activation of NF-kappaB leading to increased chemosensitivity to paclitaxel and enhanced apoptosis.	Paclitaxel	100-110	nuclear factor kappa B subunit 1	Homo sapiens	49-58
16832814-6	2006	These inhibitory effects of midkine siRNA were augmented by combinational treatment with a chemotherapeutic, paclitaxel (PTX), both in vitro and in vivo.	Paclitaxel	109-119	midkine	Homo sapiens	28-35
16782806-0	2006	Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine.	Paclitaxel	142-152	AKT serine/threonine kinase 1	Homo sapiens	70-74
16782806-5	2006	Overexpression of PDK1 or Akt1 conferred similar resistance to treatment with paclitaxel or doxorubicin compared with control cells.	Paclitaxel	78-88	AKT serine/threonine kinase 1	Homo sapiens	26-30
16850393-3	2006	Paclitaxel is a Pgp and CYP3A substrate, the drastic increase in systemic exposure may be attributed to the synergistic inhibition of Pgp and CYP3A by BA in the intestine.	Paclitaxel	0-10	phosphoglycolate phosphatase	Rattus norvegicus	16-19
16850393-3	2006	Paclitaxel is a Pgp and CYP3A substrate, the drastic increase in systemic exposure may be attributed to the synergistic inhibition of Pgp and CYP3A by BA in the intestine.	Paclitaxel	0-10	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	24-29
16850393-3	2006	Paclitaxel is a Pgp and CYP3A substrate, the drastic increase in systemic exposure may be attributed to the synergistic inhibition of Pgp and CYP3A by BA in the intestine.	Paclitaxel	0-10	phosphoglycolate phosphatase	Rattus norvegicus	134-137
16850393-3	2006	Paclitaxel is a Pgp and CYP3A substrate, the drastic increase in systemic exposure may be attributed to the synergistic inhibition of Pgp and CYP3A by BA in the intestine.	Paclitaxel	0-10	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	142-147
16857764-4	2006	ET-1 (0.1 microM) was found to significantly attenuate both Paclitaxel- and serum deprivation-induced PASMC apoptosis, likely through stimulation of the ET(A) receptor (ET(A)R).	Paclitaxel	60-70	endothelin 1	Rattus norvegicus	0-4
16857764-5	2006	ET-1 also prevented Paclitaxel-induced up-regulation of pro-apoptotic Bax and cleaved (activated) caspase-3.	Paclitaxel	20-30	endothelin 1	Rattus norvegicus	0-4
16713148-0	2006	Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.	Paclitaxel	44-54	ATP binding cassette subfamily B member 1	Homo sapiens	58-72
16713148-2	2006	The objective of the study is to investigate whether a P-gp substrate, paclitaxel, delivered to MDR tumor cells in poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles is susceptible to P-gp - mediated drug efflux.	Paclitaxel	71-81	ATP binding cassette subfamily B member 1	Homo sapiens	55-59
16713148-2	2006	The objective of the study is to investigate whether a P-gp substrate, paclitaxel, delivered to MDR tumor cells in poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles is susceptible to P-gp - mediated drug efflux.	Paclitaxel	71-81	ATP binding cassette subfamily B member 1	Homo sapiens	185-189
16713148-6	2006	Resistance to nanoparticle-encapsulated paclitaxel was reversed by verapamil, a P-gp inhibitor.	Paclitaxel	40-50	ATP binding cassette subfamily B member 1	Homo sapiens	80-84
16713148-7	2006	Further, sustained inhibition of P-gp was necessary for sustaining the cytotoxicity of nanoparticle-encapsulated paclitaxel in drug-resistant cells.	Paclitaxel	113-123	ATP binding cassette subfamily B member 1	Homo sapiens	33-37
16713148-9	2006	In conclusion, our studies suggest that P-gp substrates, such as paclitaxel, delivered to MDR cells by PLGA nanoparticles, are susceptible to efflux by P-gp.	Paclitaxel	65-75	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
16713148-9	2006	In conclusion, our studies suggest that P-gp substrates, such as paclitaxel, delivered to MDR cells by PLGA nanoparticles, are susceptible to efflux by P-gp.	Paclitaxel	65-75	ATP binding cassette subfamily B member 1	Homo sapiens	152-156
16713148-10	2006	Inhibition of P-gp restores sensitivity to paclitaxel; however, sustained inhibition of P-gp is required for sustained therapeutic efficacy of nanoparticle-encapsulated drug.	Paclitaxel	43-53	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
16832814-6	2006	These inhibitory effects of midkine siRNA were augmented by combinational treatment with a chemotherapeutic, paclitaxel (PTX), both in vitro and in vivo.	Paclitaxel	121-124	midkine	Homo sapiens	28-35
16890579-0	2006	Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer.	Paclitaxel	75-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30
16547493-0	2006	Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways.	Paclitaxel	0-10	interleukin 6	Homo sapiens	56-69
16547493-0	2006	Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways.	Paclitaxel	12-17	interleukin 6	Homo sapiens	56-69
16547493-3	2006	In an attempt to explore what genes are transcriptionally regulated by the activated JNK signaling pathway upon paclitaxel treatment, we used cDNA microarrays to analyse the changes of gene expression in human ovarian cancer cells that were treated with paclitaxel and/or the JNK inhibitor SP600125.	Paclitaxel	112-122	mitogen-activated protein kinase 8	Homo sapiens	85-88
16547493-3	2006	In an attempt to explore what genes are transcriptionally regulated by the activated JNK signaling pathway upon paclitaxel treatment, we used cDNA microarrays to analyse the changes of gene expression in human ovarian cancer cells that were treated with paclitaxel and/or the JNK inhibitor SP600125.	Paclitaxel	112-122	mitogen-activated protein kinase 8	Homo sapiens	276-279
16547493-3	2006	In an attempt to explore what genes are transcriptionally regulated by the activated JNK signaling pathway upon paclitaxel treatment, we used cDNA microarrays to analyse the changes of gene expression in human ovarian cancer cells that were treated with paclitaxel and/or the JNK inhibitor SP600125.	Paclitaxel	254-264	mitogen-activated protein kinase 8	Homo sapiens	85-88
16547493-3	2006	In an attempt to explore what genes are transcriptionally regulated by the activated JNK signaling pathway upon paclitaxel treatment, we used cDNA microarrays to analyse the changes of gene expression in human ovarian cancer cells that were treated with paclitaxel and/or the JNK inhibitor SP600125.	Paclitaxel	254-264	mitogen-activated protein kinase 8	Homo sapiens	276-279
16547493-4	2006	Among 20 genes that were specifically regulated by the paclitaxel-activated JNK pathway, interleukin (IL)-6 was shown to elicit function through the JAK-STAT signaling pathway in an autocrine and/or paracrine fashion.	Paclitaxel	55-65	mitogen-activated protein kinase 8	Homo sapiens	76-79
16547493-4	2006	Among 20 genes that were specifically regulated by the paclitaxel-activated JNK pathway, interleukin (IL)-6 was shown to elicit function through the JAK-STAT signaling pathway in an autocrine and/or paracrine fashion.	Paclitaxel	55-65	interleukin 6	Homo sapiens	89-107
16547493-5	2006	Subsequently, we identified that 87.5% of eight tested ovarian cancer lines secreted detectable levels of IL-6, which could be further upregulated 2-3.2 fold by 1 microM paclitaxel.	Paclitaxel	170-180	interleukin 6	Homo sapiens	106-110
16547493-6	2006	Dissection on regulatory pathways for IL-6 indicated that (i) when ovarian cancer cells were treated with paclitaxel at low but clinically achievable concentrations (exemplified by 1 microM in this study), the JNK signaling pathway was the major stimulator of IL-6 gene regulation and (ii) at suprapharmacologically high concentrations (exemplified by 50 microM), paclitaxel exerted lipopolysaccharide-like effects, most likely through the Toll-like receptor 4 signaling pathway.	Paclitaxel	106-116	interleukin 6	Homo sapiens	38-42
16547493-6	2006	Dissection on regulatory pathways for IL-6 indicated that (i) when ovarian cancer cells were treated with paclitaxel at low but clinically achievable concentrations (exemplified by 1 microM in this study), the JNK signaling pathway was the major stimulator of IL-6 gene regulation and (ii) at suprapharmacologically high concentrations (exemplified by 50 microM), paclitaxel exerted lipopolysaccharide-like effects, most likely through the Toll-like receptor 4 signaling pathway.	Paclitaxel	106-116	mitogen-activated protein kinase 8	Homo sapiens	210-213
16547493-6	2006	Dissection on regulatory pathways for IL-6 indicated that (i) when ovarian cancer cells were treated with paclitaxel at low but clinically achievable concentrations (exemplified by 1 microM in this study), the JNK signaling pathway was the major stimulator of IL-6 gene regulation and (ii) at suprapharmacologically high concentrations (exemplified by 50 microM), paclitaxel exerted lipopolysaccharide-like effects, most likely through the Toll-like receptor 4 signaling pathway.	Paclitaxel	106-116	interleukin 6	Homo sapiens	260-264
16547493-6	2006	Dissection on regulatory pathways for IL-6 indicated that (i) when ovarian cancer cells were treated with paclitaxel at low but clinically achievable concentrations (exemplified by 1 microM in this study), the JNK signaling pathway was the major stimulator of IL-6 gene regulation and (ii) at suprapharmacologically high concentrations (exemplified by 50 microM), paclitaxel exerted lipopolysaccharide-like effects, most likely through the Toll-like receptor 4 signaling pathway.	Paclitaxel	364-374	interleukin 6	Homo sapiens	38-42
16547493-6	2006	Dissection on regulatory pathways for IL-6 indicated that (i) when ovarian cancer cells were treated with paclitaxel at low but clinically achievable concentrations (exemplified by 1 microM in this study), the JNK signaling pathway was the major stimulator of IL-6 gene regulation and (ii) at suprapharmacologically high concentrations (exemplified by 50 microM), paclitaxel exerted lipopolysaccharide-like effects, most likely through the Toll-like receptor 4 signaling pathway.	Paclitaxel	364-374	mitogen-activated protein kinase 8	Homo sapiens	210-213
16547493-7	2006	Collectively, these results suggest that paclitaxel upregulates functional IL-6 expression in human ovarian cancer cells through multiple signaling pathways.	Paclitaxel	41-51	interleukin 6	Homo sapiens	75-79
16895478-0	2006	Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS.	Paclitaxel	30-35	BCL2 apoptosis regulator	Homo sapiens	124-128
16895478-0	2006	Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS.	Paclitaxel	30-35	BCL2 associated X, apoptosis regulator	Homo sapiens	139-142
16895478-3	2006	In the case of etoposide, down-regulation of the BCL2L12-A gene variant and of CASPASE-9, as well as upregulation of BAX, was observed, whereas treatment of MCF-7 cells with taxol led to down-regulation of the mRNA levels of all genes examined.	Paclitaxel	174-179	BCL2 associated X, apoptosis regulator	Homo sapiens	117-120
16847284-10	2006	CONCLUSION: We demonstrate that assessment of HRG expression and Her-2 activation define a particular breast cancer patient population for which trastuzumab plus CDDP or taxol are extremely efficient without Her-2 overexpression.	Paclitaxel	170-175	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-70
16855376-7	2006	In addition, biochemical examinations revealed that pretreatment or cotreatment of gemcitabine inhibited paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation that are believed to play critical roles in the signal pathways leading to apoptotic cell death.	Paclitaxel	105-115	NFKB inhibitor alpha	Homo sapiens	124-136
16855376-7	2006	In addition, biochemical examinations revealed that pretreatment or cotreatment of gemcitabine inhibited paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation that are believed to play critical roles in the signal pathways leading to apoptotic cell death.	Paclitaxel	105-115	BCL2 apoptosis regulator	Homo sapiens	153-158
16890579-2	2006	We investigated the association between CYP3A4 haplotypes and pharmacokinetic parameters of paclitaxel metabolism.	Paclitaxel	92-102	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46
16820892-7	2006	Gemcitabine and paclitaxel are highly efficient in the induction of apoptosis in ovarian cancer cells, which express a particular subset of the growth suppressor protein p53.	Paclitaxel	16-26	tumor protein p53	Homo sapiens	170-173
16513327-3	2006	The present results suggest that paclitaxel can induce apoptosis of NB-1 cells, which may be mediated by down-regulation of Bcl-2 together with up-regulation of Bax.	Paclitaxel	33-43	BCL2 apoptosis regulator	Homo sapiens	124-129
16794185-0	2006	Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation.	Paclitaxel	0-10	coagulation factor II, thrombin	Homo sapiens	20-28
16794185-4	2006	Paclitaxel enhanced thrombin-induced endothelial TF protein expression in a concentration- and time-dependent manner.	Paclitaxel	0-10	coagulation factor II, thrombin	Homo sapiens	20-28
16794185-7	2006	Real-time polymerase chain reaction revealed that paclitaxel increased thrombin-induced TF mRNA expression.	Paclitaxel	50-60	coagulation factor II, thrombin	Homo sapiens	71-79
16794185-8	2006	Paclitaxel potently activated c-Jun terminal NH2 kinase (JNK) as compared with thrombin alone, whereas the thrombin-mediated phosphorylation of p38 and extracellular signal-regulated kinase remained unaffected.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	57-60
16794185-11	2006	Moreover, SP600125 blunted the effect of paclitaxel and docetaxel on thrombin-induced TF expression.	Paclitaxel	41-51	coagulation factor II, thrombin	Homo sapiens	69-77
16794185-12	2006	Paclitaxel increases endothelial TF expression via its stabilizing effect on microtubules and selective activation of JNK.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	118-121
16054293-9	2006	In addition, the BARF1 expressing cells were more resistant to apoptosis induced by a commonly used anticancer drug, taxol.	Paclitaxel	117-122	BaRF1	Human gammaherpesvirus 4	17-22
16645158-8	2006	CONCLUSIONS: Differences between the ability of rapamycin and paclitaxel to activate AKT may account for their differential cell survival and antichemotactic activities.	Paclitaxel	62-72	AKT serine/threonine kinase 1	Homo sapiens	85-88
16925970-3	2006	The main goal of this study was to evaluate the effect of either cisplatin or paclitaxel, two common used chemotherapeutic agents for solid tumors, on enhancing Apo2L/TRAIL cytotoxicity in a panel-cultured thoracic cancer cells and to examine the role of the mitochondria-dependent caspase activation cascade in mediating apoptosis of combination-treated cells.	Paclitaxel	78-88	TNF superfamily member 10	Homo sapiens	161-166
16925970-3	2006	The main goal of this study was to evaluate the effect of either cisplatin or paclitaxel, two common used chemotherapeutic agents for solid tumors, on enhancing Apo2L/TRAIL cytotoxicity in a panel-cultured thoracic cancer cells and to examine the role of the mitochondria-dependent caspase activation cascade in mediating apoptosis of combination-treated cells.	Paclitaxel	78-88	TNF superfamily member 10	Homo sapiens	167-172
16925970-9	2006	Pretreatment of these cancer cells with sublethal concentrations of either cisplatin or paclitaxel increased their susceptibility to Apo2L/TRAIL by twofold to &gt;20-fold.	Paclitaxel	88-98	TNF superfamily member 10	Homo sapiens	133-138
16925970-9	2006	Pretreatment of these cancer cells with sublethal concentrations of either cisplatin or paclitaxel increased their susceptibility to Apo2L/TRAIL by twofold to &gt;20-fold.	Paclitaxel	88-98	TNF superfamily member 10	Homo sapiens	139-144
16925970-15	2006	CONCLUSION: Cisplatin or paclitaxel synergistically interacts with Apo2L/TRAIL to mediate profound induction of apoptosis.	Paclitaxel	25-35	TNF superfamily member 10	Homo sapiens	67-72
16925970-15	2006	CONCLUSION: Cisplatin or paclitaxel synergistically interacts with Apo2L/TRAIL to mediate profound induction of apoptosis.	Paclitaxel	25-35	TNF superfamily member 10	Homo sapiens	73-78
16432835-0	2006	A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells.	Paclitaxel	64-74	cyclin dependent kinase inhibitor 1A	Homo sapiens	2-5
16432835-0	2006	A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells.	Paclitaxel	64-74	cyclin dependent kinase inhibitor 1A	Homo sapiens	6-10
16432835-10	2006	Our data suggest that p21/WAF1 inactivation may confer a strong resistance to paclitaxel in noncancerous breast epithelial cells harboring a p21/WAF1 mutant.	Paclitaxel	78-88	cyclin dependent kinase inhibitor 1A	Homo sapiens	22-25
16432835-10	2006	Our data suggest that p21/WAF1 inactivation may confer a strong resistance to paclitaxel in noncancerous breast epithelial cells harboring a p21/WAF1 mutant.	Paclitaxel	78-88	cyclin dependent kinase inhibitor 1A	Homo sapiens	26-30
16432835-10	2006	Our data suggest that p21/WAF1 inactivation may confer a strong resistance to paclitaxel in noncancerous breast epithelial cells harboring a p21/WAF1 mutant.	Paclitaxel	78-88	cyclin dependent kinase inhibitor 1A	Homo sapiens	141-144
16432835-10	2006	Our data suggest that p21/WAF1 inactivation may confer a strong resistance to paclitaxel in noncancerous breast epithelial cells harboring a p21/WAF1 mutant.	Paclitaxel	78-88	cyclin dependent kinase inhibitor 1A	Homo sapiens	145-149
16513327-3	2006	The present results suggest that paclitaxel can induce apoptosis of NB-1 cells, which may be mediated by down-regulation of Bcl-2 together with up-regulation of Bax.	Paclitaxel	33-43	BCL2 associated X, apoptosis regulator	Homo sapiens	161-164
17025021-2	2006	In this study, we found that MGS also enhanced the cytotoxicity of vinblastine, vincristine, and taxol in P-glycoprotein-overexpressing VJ-300 cells and P388/VCR cells.	Paclitaxel	97-102	ATP binding cassette subfamily B member 1	Homo sapiens	106-120
16782917-9	2006	CONCLUSION: The addition of carboplatin to paclitaxel and trastuzumab improved ORR and PFS in women with HER-2-overexpressing MBC.	Paclitaxel	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-110
16767218-9	2006	These findings uncover what we believe to be a novel pathway by which serine protease HtrA1 mediates paclitaxel- and cisplatin-induced cytotoxicity and suggest that loss of HtrA1 in ovarian and gastric cancers may contribute to in vivo chemoresistance.	Paclitaxel	101-111	coagulation factor II, thrombin	Homo sapiens	70-85
16754540-9	2006	Silica induced AM production of IL-1 and TNF-alpha, which may be inhibited by ex vivo treatment of cells with N-acetylcysteine (NAC) or microtubule modifiers such as tetrandrine and taxol.	Paclitaxel	182-187	tumor necrosis factor	Rattus norvegicus	41-50
16395709-3	2006	In fact, p38 MAPK activity is stimulated by HGF and further increased by the combined treatment with HGF and either CDDP or PTX.	Paclitaxel	124-127	mitogen-activated protein kinase 1	Homo sapiens	9-12
16395709-3	2006	In fact, p38 MAPK activity is stimulated by HGF and further increased by the combined treatment with HGF and either CDDP or PTX.	Paclitaxel	124-127	mitogen-activated protein kinase 3	Homo sapiens	13-17
16395709-7	2006	Altogether data show that p38 MAPK is necessary for HGF sensitization of ovarian cancer cells to low-doses of CDDP and PTX and might be sufficient to overcome activation of survival pathways.	Paclitaxel	119-122	mitogen-activated protein kinase 1	Homo sapiens	26-29
16395709-7	2006	Altogether data show that p38 MAPK is necessary for HGF sensitization of ovarian cancer cells to low-doses of CDDP and PTX and might be sufficient to overcome activation of survival pathways.	Paclitaxel	119-122	mitogen-activated protein kinase 3	Homo sapiens	30-34
16757703-1	2006	BACKGROUND: Inhibiting phosphorylation of platelet-derived growth factor receptor (PDGFR) by treatment with the PDGFR kinase inhibitor imatinib and the chemotherapeutic agent paclitaxel reduces the incidence and size of human prostate cancer bone lesions in nude mice.	Paclitaxel	175-185	platelet derived growth factor receptor beta	Homo sapiens	42-81
16462766-0	2006	Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT.	Paclitaxel	72-77	AKT serine/threonine kinase 1	Homo sapiens	107-110
16757703-1	2006	BACKGROUND: Inhibiting phosphorylation of platelet-derived growth factor receptor (PDGFR) by treatment with the PDGFR kinase inhibitor imatinib and the chemotherapeutic agent paclitaxel reduces the incidence and size of human prostate cancer bone lesions in nude mice.	Paclitaxel	175-185	platelet derived growth factor receptor beta	Homo sapiens	83-88
16740769-6	2006	RESULTS: Treatment of LNCaP cells with a combination of TPA and paclitaxel synergistically inhibited the growth and induced apoptosis in cultured LNCaP cells, and this treatment also induced a marked increase in phosphorylated c-Jun-NH2-kinase (JNK).	Paclitaxel	64-74	mitogen-activated protein kinase 8	Homo sapiens	227-243
16740769-6	2006	RESULTS: Treatment of LNCaP cells with a combination of TPA and paclitaxel synergistically inhibited the growth and induced apoptosis in cultured LNCaP cells, and this treatment also induced a marked increase in phosphorylated c-Jun-NH2-kinase (JNK).	Paclitaxel	64-74	mitogen-activated protein kinase 8	Homo sapiens	245-248
16574387-0	2006	Paclitaxel modifies the accumulation of tumor-diagnostic tracers in different ways in P-glycoprotein-positive and negative cancer cells.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	86-100
16574387-8	2006	CONCLUSION: Paclitaxel modifies the uptake of tumor-diagnostic tracers in both P-gp-dependent and independent manners.	Paclitaxel	12-22	ATP binding cassette subfamily B member 1	Homo sapiens	79-83
16574387-9	2006	Interpretation of the multifactorial effects of paclitaxel may promote a correct in vivo diagnosis of P-gp-positive and P-gp-negative tumors.	Paclitaxel	48-58	ATP binding cassette subfamily B member 1	Homo sapiens	102-106
16574387-1	2006	AIM: To study how paclitaxel treatment modifies the accumulation of tumor-diagnostic radiotracers in P-glycoprotein (P-gp) positive and negative cancer cells.	Paclitaxel	18-28	ATP binding cassette subfamily B member 1	Homo sapiens	101-115
16574387-9	2006	Interpretation of the multifactorial effects of paclitaxel may promote a correct in vivo diagnosis of P-gp-positive and P-gp-negative tumors.	Paclitaxel	48-58	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
16574387-1	2006	AIM: To study how paclitaxel treatment modifies the accumulation of tumor-diagnostic radiotracers in P-glycoprotein (P-gp) positive and negative cancer cells.	Paclitaxel	18-28	ATP binding cassette subfamily B member 1	Homo sapiens	117-121
16574387-6	2006	Paclitaxel (1-70microM) increased the (18)FDG uptake (up to 200%) of both P-gp-positive and P-gp-negative cells, whereas it did not modulate their (11)C-choline uptake.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	74-78
16574387-6	2006	Paclitaxel (1-70microM) increased the (18)FDG uptake (up to 200%) of both P-gp-positive and P-gp-negative cells, whereas it did not modulate their (11)C-choline uptake.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	92-96
16551737-6	2006	The tumorigenicity, metastatic potential, and sensibility of ARO/S100A4-shRNA to paclitaxel were investigated.	Paclitaxel	81-91	S100 calcium binding protein A4	Mus musculus	65-71
16704422-12	2006	The relative phosphorylation of Thr18 by VRK2B is similar in magnitude to that induced by taxol, which might use a different signalling pathway.	Paclitaxel	90-95	VRK serine/threonine kinase 2	Homo sapiens	41-45
16551737-11	2006	We also demonstrated significant induction of apoptosis in ARO/S100A4-shRNA after incubation with 15 nm paclitaxel, indicating that tumor cells were sensitized to chemotherapy as a result of S100A4 knockdown.	Paclitaxel	104-114	S100 calcium binding protein A4	Mus musculus	63-69
16551737-11	2006	We also demonstrated significant induction of apoptosis in ARO/S100A4-shRNA after incubation with 15 nm paclitaxel, indicating that tumor cells were sensitized to chemotherapy as a result of S100A4 knockdown.	Paclitaxel	104-114	S100 calcium binding protein A4	Mus musculus	191-197
16708050-10	2006	CYP3A4 conferred resistance to taxol, vinblastine and topotecan.	Paclitaxel	31-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
15990222-0	2006	Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.	Paclitaxel	75-85	tumor protein p53	Homo sapiens	13-16
16741658-2	2006	We investigated the relationship between FGF expression and paclitaxel activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.	Paclitaxel	60-70	fibroblast growth factor 1	Homo sapiens	41-44
16741658-10	2006	bFGF expression was a stronger predictor of paclitaxel resistance compared to Pgp, p53, or Bcl-2.	Paclitaxel	44-54	fibroblast growth factor 2	Homo sapiens	0-4
16741658-11	2006	CONCLUSION: These results support a role of bFGF in paclitaxel resistance in human patient tumors.	Paclitaxel	52-62	fibroblast growth factor 2	Homo sapiens	44-48
16753005-1	2006	INTRODUCTION: We have previously shown that human colorectal cancer tissue is able to inactivate the anticancer drug paclitaxel through cytochrome P450 (CYP)2C8 and CYP3A4 metabolisms.	Paclitaxel	117-127	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	165-171
16753005-6	2006	A 4.4-fold (p = 0.005) enhancement of CYP2C8 expression and a 5.6-fold (p = 0.001) increase of multidrug resistance (MDR)1 expression was observed in resistant cells exposed to paclitaxel.	Paclitaxel	177-187	ATP binding cassette subfamily B member 1	Homo sapiens	95-122
15990222-3	2006	Cells (UL-3A, UL-3B) that recovered from cisplatin (Cis) and paclitaxel (Tax) treatments showed higher levels of p53, mdr-1 and chemoresistance than untreated controls.	Paclitaxel	61-71	tumor protein p53	Homo sapiens	113-116
15990222-3	2006	Cells (UL-3A, UL-3B) that recovered from cisplatin (Cis) and paclitaxel (Tax) treatments showed higher levels of p53, mdr-1 and chemoresistance than untreated controls.	Paclitaxel	61-71	ATP binding cassette subfamily B member 1	Homo sapiens	118-123
16396631-3	2006	Treatment of HL-60 cells with taxol or okadaic acid has been shown to induce destabilization of bcl-2 mRNA, which was associated with decreased binding of trans-acting factors to bcl-2 mRNA.	Paclitaxel	30-35	BCL2 apoptosis regulator	Homo sapiens	96-101
16396631-3	2006	Treatment of HL-60 cells with taxol or okadaic acid has been shown to induce destabilization of bcl-2 mRNA, which was associated with decreased binding of trans-acting factors to bcl-2 mRNA.	Paclitaxel	30-35	BCL2 apoptosis regulator	Homo sapiens	179-184
16515784-0	2006	ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance.	Paclitaxel	63-73	mitogen-activated protein kinase 1	Homo sapiens	0-3
16914101-4	2006	In this study we show that a murine GBP, mGBP-2, confers resistance to a microtubule-stabilizing drug used in cancer therapy, paclitaxel.	Paclitaxel	126-136	lectin, galactose binding, soluble 3	Mus musculus	36-39
16515784-0	2006	ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance.	Paclitaxel	63-73	thymosin beta 4 X-linked	Homo sapiens	18-33
16515784-0	2006	ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance.	Paclitaxel	63-73	thymosin beta 4 X-linked	Homo sapiens	35-38
16515784-5	2006	TB4-HeLa cells were more resistant to paclitaxel-induced cell death than HeLa cells.	Paclitaxel	38-48	thymosin beta 4 X-linked	Homo sapiens	0-3
16580691-0	2006	3,3"-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.	Paclitaxel	26-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	81-85
16580691-16	2006	CONCLUSIONS: DIM in combination with paclitaxel synergistically inhibits growth of Her2/neu human breast cancer cells through G2M phase cell-cycle arrest and induction of apoptosis/necrosis.	Paclitaxel	37-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
16515784-6	2006	TB4 transcript expression with paclitaxel treatment was dose-dependently increased in HeLa cells but that was not in TB4-HeLa cells.	Paclitaxel	31-41	thymosin beta 4 X-linked	Homo sapiens	0-3
16580691-0	2006	3,3"-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.	Paclitaxel	26-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-89
16580691-6	2006	Because HER2/neu overexpression confers resistance to paclitaxel, and DIM has anti-tumor effects, we hypothesized that DIM will enhance the cytotoxic effects of paclitaxel, a common taxane drug, on human Her2/neu breast cancer cells by potentiating its effect on cell cycle and stimulating apoptosis.	Paclitaxel	161-171	erb-b2 receptor tyrosine kinase 2	Homo sapiens	204-208
16515784-7	2006	Small interfering RNA (siRNA) of TB4 inhibited HeLa cell growth and enhanced paclitaxel-induced cell death.	Paclitaxel	77-87	thymosin beta 4 X-linked	Homo sapiens	33-36
16515784-8	2006	Basal ERK phosphorylation was elevated and basal p38 kinase phosphorylation was reduced in paclitaxel non-treated TB4-HeLa cells.	Paclitaxel	91-101	mitogen-activated protein kinase 14	Homo sapiens	49-52
16515784-8	2006	Basal ERK phosphorylation was elevated and basal p38 kinase phosphorylation was reduced in paclitaxel non-treated TB4-HeLa cells.	Paclitaxel	91-101	thymosin beta 4 X-linked	Homo sapiens	114-117
16515784-9	2006	When treated with paclitaxel, cell death and resistance-induction were independent of ERK and p38 kinase activation.	Paclitaxel	18-28	mitogen-activated protein kinase 1	Homo sapiens	86-89
16515784-9	2006	When treated with paclitaxel, cell death and resistance-induction were independent of ERK and p38 kinase activation.	Paclitaxel	18-28	mitogen-activated protein kinase 14	Homo sapiens	94-97
16515784-10	2006	Paclitaxel-resistance of TB4-HeLa cells was overcome by the inhibition of basal ERK activity with PD98059 pre-treatment.	Paclitaxel	0-10	thymosin beta 4 X-linked	Homo sapiens	25-28
16515784-10	2006	Paclitaxel-resistance of TB4-HeLa cells was overcome by the inhibition of basal ERK activity with PD98059 pre-treatment.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Homo sapiens	80-83
16515784-11	2006	The inhibition of basal p38 kinase activity with SB203580 pre-treatment attenuated the paclitaxel-induced HeLa cell death.	Paclitaxel	87-97	mitogen-activated protein kinase 14	Homo sapiens	24-27
16515784-12	2006	In conclusion, TB4 induced paclitaxel-resistance through the elevation of basal level of ERK phosphorylation.	Paclitaxel	27-37	thymosin beta 4 X-linked	Homo sapiens	15-18
16515784-12	2006	In conclusion, TB4 induced paclitaxel-resistance through the elevation of basal level of ERK phosphorylation.	Paclitaxel	27-37	mitogen-activated protein kinase 1	Homo sapiens	89-92
16515784-13	2006	Therefore, TB4 could be a novel target to regulate paclitaxel-resistance.	Paclitaxel	51-61	thymosin beta 4 X-linked	Homo sapiens	11-14
16703753-10	2006	CONCLUSION: Paclitaxel, cisplatin and 5-FU (TCF)-chemoradiation is an active regimen; the current dose schedule tested is associated with unacceptable toxicity, and cannot be recommended for routine clinical use.	Paclitaxel	12-22	hepatocyte nuclear factor 4 alpha	Homo sapiens	44-47
16687915-4	2006	If a cell stays in mitosis too long, (e.g. mitotic arrest caused by Taxol or nocodazole), then p53 accumulates.	Paclitaxel	68-73	tumor protein p53	Homo sapiens	95-98
16803472-4	2006	We therefore examined the relationship of the paclitaxel pharmacokinetics in 13 patients with ovarian cancer to polymorphisms in CYP2C8, CYP3A5, ABCB1, and PXR.	Paclitaxel	46-56	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	137-143
16540312-0	2006	Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.	Paclitaxel	113-123	mechanistic target of rapamycin kinase	Homo sapiens	18-47
16540312-0	2006	Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.	Paclitaxel	113-123	mechanistic target of rapamycin kinase	Homo sapiens	49-53
16540312-10	2006	In addition, we showed that paclitaxel downregulated the phosphorylation of Akt in both HeLa and CaSki cells.	Paclitaxel	28-38	AKT serine/threonine kinase 1	Homo sapiens	76-79
16540312-11	2006	Interestingly, in CaSki cells, which were more suggestive of a resistant phenotype, paclitaxel induced the activation of mTOR as a downstream target of Akt.	Paclitaxel	84-94	mechanistic target of rapamycin kinase	Homo sapiens	121-125
16540312-11	2006	Interestingly, in CaSki cells, which were more suggestive of a resistant phenotype, paclitaxel induced the activation of mTOR as a downstream target of Akt.	Paclitaxel	84-94	AKT serine/threonine kinase 1	Homo sapiens	152-155
16540312-14	2006	Overall, paclitaxel exerts its anti-tumour effects on cervical cancer cells by inducing apoptosis through intrinsic pathway, and rapamycin targeted to mTOR can sensitise paclitaxel-resistant cervical cancer cells.	Paclitaxel	170-180	mechanistic target of rapamycin kinase	Homo sapiens	151-155
16803544-10	2006	After the surgery followed by four courses of weekly carboplatin and paclitaxel administration, serum levels of AFP dropped into normal range.	Paclitaxel	69-79	alpha fetoprotein	Homo sapiens	112-115
16803472-0	2006	Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.	Paclitaxel	38-48	ATP binding cassette subfamily B member 1	Homo sapiens	21-26
16803472-1	2006	Paclitaxel, an antineoplastic agent used for the treatment of ovarian cancer, is metabolized by cytochrome P450 (CYP)3A4 and CYP2C8 and is excreted from cells by ATP-binding cassette (ABCB1) (multi-drug resistance [MDR1], P-glycoprotein).	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	184-189
16803472-1	2006	Paclitaxel, an antineoplastic agent used for the treatment of ovarian cancer, is metabolized by cytochrome P450 (CYP)3A4 and CYP2C8 and is excreted from cells by ATP-binding cassette (ABCB1) (multi-drug resistance [MDR1], P-glycoprotein).	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	215-219
16803472-1	2006	Paclitaxel, an antineoplastic agent used for the treatment of ovarian cancer, is metabolized by cytochrome P450 (CYP)3A4 and CYP2C8 and is excreted from cells by ATP-binding cassette (ABCB1) (multi-drug resistance [MDR1], P-glycoprotein).	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	222-236
16803472-4	2006	We therefore examined the relationship of the paclitaxel pharmacokinetics in 13 patients with ovarian cancer to polymorphisms in CYP2C8, CYP3A5, ABCB1, and PXR.	Paclitaxel	46-56	ATP binding cassette subfamily B member 1	Homo sapiens	145-150
16803472-4	2006	We therefore examined the relationship of the paclitaxel pharmacokinetics in 13 patients with ovarian cancer to polymorphisms in CYP2C8, CYP3A5, ABCB1, and PXR.	Paclitaxel	46-56	nuclear receptor subfamily 1 group I member 2	Homo sapiens	156-159
16803472-8	2006	ABCB1 T-129C, T1236C, and G2677(A,T), however, was associated with lower area under the plasma concentration-time curve (AUC) of paclitaxel.	Paclitaxel	129-139	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
16803472-9	2006	We also observed a significant correlation between the AUC (r=-0.721) or the total clearance of paclitaxel (CL(tot)) (r= 0.673) and the ABCB1 mutant allele dosage in each patient.	Paclitaxel	96-106	ATP binding cassette subfamily B member 1	Homo sapiens	136-141
16803472-10	2006	Taken together, our findings suggest that interindividual variability in paclitaxel pharmacokinetics could be predicted by ABCB1 genotyping.	Paclitaxel	73-83	ATP binding cassette subfamily B member 1	Homo sapiens	123-128
17048679-2	2006	METHOD: Determinations in WS1-(X-026)-2001Z-paclitaxel injection were refered to compare the effect of different dosage and temperature for activated carbon on the taxol content, related material, clarity and bacterial endotoxin.	Paclitaxel	44-54	paired box 3	Homo sapiens	26-29
16731747-2	2006	In this study, we characterized a panel of human EGFR wild-type and mutant NSCLC cells for their sensitivity to gefitinib alone and in combination with cisplatin or Taxol.	Paclitaxel	165-170	epidermal growth factor receptor	Homo sapiens	49-53
16731752-0	2006	Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.	Paclitaxel	16-26	AKT serine/threonine kinase 1	Homo sapiens	166-169
16596196-6	2006	We therefore conclude that IGFBP-3, RhoGDI and MDR-1 were correlated with paclitaxel resistance.	Paclitaxel	74-84	ATP binding cassette subfamily B member 1	Homo sapiens	47-52
16678050-7	2006	Treatment of severe combined immunodeficient mice bearing subcutaneous RT-112/84 tumors with maximum tolerated doses of bioconjugate or paclitaxel showed that HYTAD1-p20 exerted a therapeutic activity comparable to that of free drug.	Paclitaxel	136-146	demilune cell and parotid protein 1	Mus musculus	166-169
16616141-0	2006	Evidence that low doses of Taxol enhance the functional transactivatory properties of p53 on p21 waf promoter in MCF-7 breast cancer cells.	Paclitaxel	27-32	tumor protein p53	Homo sapiens	86-89
16616141-1	2006	In the present study, we evidence how in breast cancer cells low doses of Taxol for 18 h determined the upregulation of p53 and p21 waf expression concomitantly with a decrease of the anti-apoptotic Bcl-2.	Paclitaxel	74-79	tumor protein p53	Homo sapiens	120-123
16616141-1	2006	In the present study, we evidence how in breast cancer cells low doses of Taxol for 18 h determined the upregulation of p53 and p21 waf expression concomitantly with a decrease of the anti-apoptotic Bcl-2.	Paclitaxel	74-79	BCL2 apoptosis regulator	Homo sapiens	199-204
16616141-3	2006	Indeed, the most important finding of this study consists with the evidence that Taxol at lower concentrations is able to produce the activation of p21 promoter via p53.	Paclitaxel	81-86	tumor protein p53	Homo sapiens	165-168
16287090-0	2006	Inactivation of Id-1 in prostate cancer cells: A potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway.	Paclitaxel	112-117	mitogen-activated protein kinase 8	Homo sapiens	140-143
16287090-6	2006	In addition, the si-Id-1-induced sensitization to taxol was associated with activation of apoptosis pathway, which is demonstrated by increased apoptotic index, DNA laddering, sub-G1 phase of the cell cycle, as well as cleaved-PARP and Caspase 3.	Paclitaxel	50-55	poly(ADP-ribose) polymerase 1	Homo sapiens	227-231
16287090-6	2006	In addition, the si-Id-1-induced sensitization to taxol was associated with activation of apoptosis pathway, which is demonstrated by increased apoptotic index, DNA laddering, sub-G1 phase of the cell cycle, as well as cleaved-PARP and Caspase 3.	Paclitaxel	50-55	caspase 3	Homo sapiens	236-245
16442503-7	2006	Vector-based shRNA against EGFR caused G1 arrest, induced apoptosis, and subsequently increased the sensitivity to cisplatin, doxorubicin and paclitaxel by about four- to seven-fold in both HLAC lines.	Paclitaxel	142-152	epidermal growth factor receptor	Homo sapiens	27-31
16287090-7	2006	Furthermore, c-Jun N-terminal kinase (JNK), one of the common pathways responsible for taxol-induced apoptosis, was also activated in the si-Id-1 transfected cells.	Paclitaxel	87-92	mitogen-activated protein kinase 8	Homo sapiens	13-36
16287090-7	2006	Furthermore, c-Jun N-terminal kinase (JNK), one of the common pathways responsible for taxol-induced apoptosis, was also activated in the si-Id-1 transfected cells.	Paclitaxel	87-92	mitogen-activated protein kinase 8	Homo sapiens	38-41
16287090-8	2006	Inhibition of JNK activity by a specific inhibitor, SP600125, blocked the si-Id-1-induced sensitivity to taxol.	Paclitaxel	105-110	mitogen-activated protein kinase 8	Homo sapiens	14-17
16551356-9	2006	After 4 h of incubation, Taxol, TSC, hydrogen peroxide and CSE caused a significant reduction in mitochondrial cytochrome C and an increase in cytosolic cytochrome C.	Paclitaxel	25-30	cytochrome c	Nicotiana tabacum	111-123
16609087-13	2006	CONCLUSION: Among patients with node-positive tumors, ER-negative breast cancer, biweekly doxorubicin/cyclophosphamide plus paclitaxel lowers the rate of recurrence and death by more than 50% in comparison with low-dose cyclophosphamide, doxorubicin, and fluorouracil as used in the first study.	Paclitaxel	124-134	estrogen receptor 1	Homo sapiens	54-56
16528475-7	2006	Mitochondrial release of cytochrome c after paclitaxel alone or in combination with RA was weak, however robust Smac release was observed.	Paclitaxel	44-54	cytochrome c, somatic	Homo sapiens	25-37
16331265-0	2006	Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.	Paclitaxel	68-78	peroxisome proliferator activated receptor gamma	Homo sapiens	20-29
16331265-0	2006	Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.	Paclitaxel	68-78	cyclin dependent kinase inhibitor 1A	Homo sapiens	148-152
16764747-2	2006	The tumor had high HER2 overexpression, so a weekly regimen of paclitaxel/trastuzumab was started after surgery of the primary breast tumor.	Paclitaxel	63-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
16612165-0	2006	[Successful bi-weekly paclitaxel treatment of an AFP-producing gastric cancer patient with peritoneal dissemination and multiple liver metastasis].	Paclitaxel	22-32	alpha fetoprotein	Homo sapiens	49-52
16231322-4	2006	This study was undertaken to elucidate the effect of FHIT expression and the role of Bcl-2-caspase signaling in paclitaxel-induced apoptosis in lung cancer cells.	Paclitaxel	112-122	BCL2 apoptosis regulator	Homo sapiens	85-90
16231322-11	2006	Bcl-2 and Bcl-xL expressions were down-regulated after paclitaxel treatment in FHIT-expressing cells, whereas Bax and Bad expressions were up-regulated.	Paclitaxel	55-65	BCL2 apoptosis regulator	Homo sapiens	0-5
16231322-11	2006	Bcl-2 and Bcl-xL expressions were down-regulated after paclitaxel treatment in FHIT-expressing cells, whereas Bax and Bad expressions were up-regulated.	Paclitaxel	55-65	BCL2 like 1	Homo sapiens	10-16
16231322-13	2006	These results indicate that paclitaxel-induced apoptosis enhanced by FHIT expression in lung cancer cells might be associated with modulation of Bcl-2-caspase signaling.	Paclitaxel	28-38	BCL2 apoptosis regulator	Homo sapiens	145-150
16515996-4	2006	MATERIALS AND METHODS: Serum CgA was assessed by immunoradiometric assay in 39 patients with HRPC treated with paclitaxel and carboplatin or mitoxantrone.	Paclitaxel	111-121	chromogranin A	Homo sapiens	29-32
16551356-9	2006	After 4 h of incubation, Taxol, TSC, hydrogen peroxide and CSE caused a significant reduction in mitochondrial cytochrome C and an increase in cytosolic cytochrome C.	Paclitaxel	25-30	cytochrome c	Nicotiana tabacum	153-165
16465425-4	2006	MVP protein levels were enhanced in SW-620 cells after a 72 h treatment with doxorubicin (Adr), etoposide (VP-16), cis-platinum (II) diammine dichloride (CDDP) or SN-38, but not vincristine (VCR) or paclitaxel (Taxol) at their IC50 concentration.	Paclitaxel	199-209	aldo-keto reductase family 1 member B	Homo sapiens	90-93
16413505-0	2006	Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.	Paclitaxel	87-97	epidermal growth factor receptor	Homo sapiens	0-32
16413505-8	2006	Compared to paclitaxel alone, PD168393 significantly enhanced paclitaxel-induced DNA fragmentation, sub-G1 fraction accumulation, mitochondrial membrane dysfunction, cytochrome C release, caspase-3 activation and eventually apoptosis.	Paclitaxel	62-72	caspase 3	Homo sapiens	188-197
16465425-4	2006	MVP protein levels were enhanced in SW-620 cells after a 72 h treatment with doxorubicin (Adr), etoposide (VP-16), cis-platinum (II) diammine dichloride (CDDP) or SN-38, but not vincristine (VCR) or paclitaxel (Taxol) at their IC50 concentration.	Paclitaxel	211-216	aldo-keto reductase family 1 member B	Homo sapiens	90-93
16364249-0	2006	TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.	Paclitaxel	52-62	tumor protein p53	Homo sapiens	0-4
16696191-7	2006	The constant of transport rate of speed, K10 (0.55 h(-1)), was much smaller in the microemulsion group compared with the Taxol group (1.55 h(-l)).	Paclitaxel	121-126	keratin 10	Rattus norvegicus	41-44
16331277-4	2006	Conversely, restoration of procaspase-3 sensitizes MCF-7 cells to chemotherapeutics including epirubicine, etoposide and taxol.	Paclitaxel	121-126	caspase 3	Homo sapiens	27-39
16110492-4	2006	Here we show by immunofluorescence microscopy that RUNX2 relocates from the nucleus to the cytoplasm when microtubules are stabilized by the chemotherapeutic agent taxol.	Paclitaxel	164-169	RUNX family transcription factor 2	Homo sapiens	51-56
16467099-1	2006	PURPOSE: P-glycoprotein, encoded by the mdr-1 gene, confers multidrug resistance to a variety of antineoplastic agents, e.g., paclitaxel.	Paclitaxel	126-136	ATP binding cassette subfamily B member 1	Homo sapiens	40-45
16467099-12	2006	CONCLUSIONS: The mdr-1 polymorphism G2677T/A in exon 21 correlates with the paclitaxel response in ovarian cancer and may be important for the function of P-glycoprotein and resistance to paclitaxel and provide useful information for individualized therapy.	Paclitaxel	76-86	ATP binding cassette subfamily B member 1	Homo sapiens	17-22
16467099-12	2006	CONCLUSIONS: The mdr-1 polymorphism G2677T/A in exon 21 correlates with the paclitaxel response in ovarian cancer and may be important for the function of P-glycoprotein and resistance to paclitaxel and provide useful information for individualized therapy.	Paclitaxel	76-86	ATP binding cassette subfamily B member 1	Homo sapiens	155-169
16467099-12	2006	CONCLUSIONS: The mdr-1 polymorphism G2677T/A in exon 21 correlates with the paclitaxel response in ovarian cancer and may be important for the function of P-glycoprotein and resistance to paclitaxel and provide useful information for individualized therapy.	Paclitaxel	188-198	ATP binding cassette subfamily B member 1	Homo sapiens	17-22
16467099-12	2006	CONCLUSIONS: The mdr-1 polymorphism G2677T/A in exon 21 correlates with the paclitaxel response in ovarian cancer and may be important for the function of P-glycoprotein and resistance to paclitaxel and provide useful information for individualized therapy.	Paclitaxel	188-198	ATP binding cassette subfamily B member 1	Homo sapiens	155-169
16188300-10	2006	Down-regulation of Bcl-X(L) enhanced the sensitivity of CaOV3, OVCAR3 and SKOV3ip1 to cisplatin and paclitaxel.	Paclitaxel	100-110	BCL2 like 1	Homo sapiens	19-27
16467098-8	2006	DISCUSSION: Using murine fibroblasts that express human ErbB2, but no other ErbB family member (NE2), these cells showed resistance to both taxol- and etoposide-induced apoptosis compared with parental cells.	Paclitaxel	140-145	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-61
16467098-8	2006	DISCUSSION: Using murine fibroblasts that express human ErbB2, but no other ErbB family member (NE2), these cells showed resistance to both taxol- and etoposide-induced apoptosis compared with parental cells.	Paclitaxel	140-145	epidermal growth factor receptor	Homo sapiens	56-60
16467099-0	2006	mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.	Paclitaxel	101-111	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
16467099-1	2006	PURPOSE: P-glycoprotein, encoded by the mdr-1 gene, confers multidrug resistance to a variety of antineoplastic agents, e.g., paclitaxel.	Paclitaxel	126-136	ATP binding cassette subfamily B member 1	Homo sapiens	9-23
16380805-8	2006	Furthermore, western blots showed an overexpression of MDR-1 in the taxol-resistant clone, while alpha- and beta-tubulins and p48/IRF9 were expressed in equal amounts in both cell lines.	Paclitaxel	68-73	ATP binding cassette subfamily B member 1	Homo sapiens	55-60
16110492-10	2006	It is possible that taxol-induced acute depletion of the nuclear levels of RUNX2 and/or other cell growth regulatory factors may represent an alternative pathway by which taxol exerts its biological effects during cancer chemotherapies.	Paclitaxel	20-25	RUNX family transcription factor 2	Homo sapiens	75-80
16110492-10	2006	It is possible that taxol-induced acute depletion of the nuclear levels of RUNX2 and/or other cell growth regulatory factors may represent an alternative pathway by which taxol exerts its biological effects during cancer chemotherapies.	Paclitaxel	171-176	RUNX family transcription factor 2	Homo sapiens	75-80
16110492-5	2006	The taxol-dependent cytoplasmic accumulation of RUNX2 is inhibited by leptomycin B, which blocks CRM-1 dependent nuclear export, and is not affected by the protein synthesis inhibitor cycloheximide.	Paclitaxel	4-9	RUNX family transcription factor 2	Homo sapiens	48-53
16356831-7	2006	Lower doses of 2-ME and paclitaxel resulted in G1 (but not G2/M) cell cycle arrest in the p53 wild type LNCaP cell line, but with minimal induction of apoptosis.	Paclitaxel	24-34	tumor protein p53	Homo sapiens	90-93
16076490-0	2006	Involvement of NF-kappaB and glutathione in cytotoxic effects of nitric oxide and taxol on human leukemia cells.	Paclitaxel	82-87	nuclear factor kappa B subunit 1	Homo sapiens	15-24
16076490-5	2006	Our previous studies demonstrated a cytotoxic effect of NO and taxol on human lymphoblastic leukemia cells triggered by inhibition of NF-kappaB activity.	Paclitaxel	63-68	nuclear factor kappa B subunit 1	Homo sapiens	134-143
16076490-9	2006	However, when cells were treated with NO or taxol in association with BSO, these compounds inhibited the constitutive activity of NF-kappaB.	Paclitaxel	44-49	nuclear factor kappa B subunit 1	Homo sapiens	130-139
16291872-9	2006	Furthermore, knockdown of either beta-cat or Tcf-4 substantially reduced cell proliferation and potentiated paclitaxel-induced apoptosis in DU145 cells, which largely were rescued by treatment with exogenous ET-1.	Paclitaxel	108-118	endothelin 1	Homo sapiens	208-212
16397234-0	2006	Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.	Paclitaxel	0-10	forkhead box O3	Homo sapiens	44-50
16739339-0	2006	P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.	Paclitaxel	102-112	tumor protein p53	Homo sapiens	0-3
16739339-1	2006	BACKGROUND: The aim of this retrospective study was to assess whether p53 gene status has any predictive or prognostic relevance in patients with advanced, poorly-differentiated serous epithelial ovarian cancer treated with paclitaxel- plus platinum-based chemotherapy.	Paclitaxel	224-234	tumor protein p53	Homo sapiens	70-73
17146157-17	2006	CONCLUSION: Combined trastuzumab and paclitaxel therapy, administered as second-line or later treatment, produced lasting objective responses and was well tolerated by women with HER-2 overexpressing metastatic breast cancer.	Paclitaxel	37-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	179-184
16397234-0	2006	Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	119-122
16397234-2	2006	We have previously shown that apoptosis of breast cancer cells in response to paclitaxel is mediated by induction of FOXO3a expression, a transcription factor downstream of the phosphatidylinositol-3-kinase/Akt signaling pathway.	Paclitaxel	78-88	forkhead box O3	Homo sapiens	117-123
16397234-2	2006	We have previously shown that apoptosis of breast cancer cells in response to paclitaxel is mediated by induction of FOXO3a expression, a transcription factor downstream of the phosphatidylinositol-3-kinase/Akt signaling pathway.	Paclitaxel	78-88	AKT serine/threonine kinase 1	Homo sapiens	207-210
16397234-3	2006	To further investigate its mechanism of action, we treated MCF-7 cells with paclitaxel and showed a dose-dependent increase in nuclear localization of FOXO3a, which coincided with decreased Akt signaling but increased c-Jun NH2-terminal kinase 1/2 (JNK1/2), p38, and extracellular signal-regulated kinase 1/2 (ERK1/2) activity.	Paclitaxel	76-86	forkhead box O3	Homo sapiens	151-157
16397234-3	2006	To further investigate its mechanism of action, we treated MCF-7 cells with paclitaxel and showed a dose-dependent increase in nuclear localization of FOXO3a, which coincided with decreased Akt signaling but increased c-Jun NH2-terminal kinase 1/2 (JNK1/2), p38, and extracellular signal-regulated kinase 1/2 (ERK1/2) activity.	Paclitaxel	76-86	AKT serine/threonine kinase 1	Homo sapiens	190-193
16397234-3	2006	To further investigate its mechanism of action, we treated MCF-7 cells with paclitaxel and showed a dose-dependent increase in nuclear localization of FOXO3a, which coincided with decreased Akt signaling but increased c-Jun NH2-terminal kinase 1/2 (JNK1/2), p38, and extracellular signal-regulated kinase 1/2 (ERK1/2) activity.	Paclitaxel	76-86	mitogen-activated protein kinase 8	Homo sapiens	249-255
16397234-3	2006	To further investigate its mechanism of action, we treated MCF-7 cells with paclitaxel and showed a dose-dependent increase in nuclear localization of FOXO3a, which coincided with decreased Akt signaling but increased c-Jun NH2-terminal kinase 1/2 (JNK1/2), p38, and extracellular signal-regulated kinase 1/2 (ERK1/2) activity.	Paclitaxel	76-86	mitogen-activated protein kinase 1	Homo sapiens	258-261
16397234-3	2006	To further investigate its mechanism of action, we treated MCF-7 cells with paclitaxel and showed a dose-dependent increase in nuclear localization of FOXO3a, which coincided with decreased Akt signaling but increased c-Jun NH2-terminal kinase 1/2 (JNK1/2), p38, and extracellular signal-regulated kinase 1/2 (ERK1/2) activity.	Paclitaxel	76-86	mitogen-activated protein kinase 1	Homo sapiens	267-308
16397234-3	2006	To further investigate its mechanism of action, we treated MCF-7 cells with paclitaxel and showed a dose-dependent increase in nuclear localization of FOXO3a, which coincided with decreased Akt signaling but increased c-Jun NH2-terminal kinase 1/2 (JNK1/2), p38, and extracellular signal-regulated kinase 1/2 (ERK1/2) activity.	Paclitaxel	76-86	mitogen-activated protein kinase 3	Homo sapiens	310-316
16397234-4	2006	Flow cytometry revealed that paclitaxel-induced apoptosis of MCF-7 cells and of other paclitaxel-sensitive breast cancer cell lines was maintained in the presence of inhibitors of p38 (SB203580) or mitogen-activated protein/ERK kinase 1 signaling (PD98059) but abrogated when cells were treated with the JNK1/2 inhibitor SP600125.	Paclitaxel	29-39	mitogen-activated protein kinase 1	Homo sapiens	180-183
16397234-4	2006	Flow cytometry revealed that paclitaxel-induced apoptosis of MCF-7 cells and of other paclitaxel-sensitive breast cancer cell lines was maintained in the presence of inhibitors of p38 (SB203580) or mitogen-activated protein/ERK kinase 1 signaling (PD98059) but abrogated when cells were treated with the JNK1/2 inhibitor SP600125.	Paclitaxel	29-39	mitogen-activated protein kinase 3	Homo sapiens	224-227
16397234-4	2006	Flow cytometry revealed that paclitaxel-induced apoptosis of MCF-7 cells and of other paclitaxel-sensitive breast cancer cell lines was maintained in the presence of inhibitors of p38 (SB203580) or mitogen-activated protein/ERK kinase 1 signaling (PD98059) but abrogated when cells were treated with the JNK1/2 inhibitor SP600125.	Paclitaxel	29-39	mitogen-activated protein kinase 8	Homo sapiens	304-310
16397234-5	2006	SP600125 reversed Akt inhibition and abolished FOXO3a nuclear accumulation in response to paclitaxel.	Paclitaxel	90-100	forkhead box O3	Homo sapiens	47-53
16397234-6	2006	Moreover, conditional activation of JNK mimicked paclitaxel activity and led to dephosphorylation of Akt and FOXO3a.	Paclitaxel	49-59	mitogen-activated protein kinase 8	Homo sapiens	36-39
16397234-8	2006	Taken together, the data show that cell death of breast cancer cells in response to paclitaxel is dependent upon JNK activation, resulting in Akt inhibition and increased FOXO3a activity.	Paclitaxel	84-94	mitogen-activated protein kinase 8	Homo sapiens	113-116
16397234-8	2006	Taken together, the data show that cell death of breast cancer cells in response to paclitaxel is dependent upon JNK activation, resulting in Akt inhibition and increased FOXO3a activity.	Paclitaxel	84-94	AKT serine/threonine kinase 1	Homo sapiens	142-145
16397234-8	2006	Taken together, the data show that cell death of breast cancer cells in response to paclitaxel is dependent upon JNK activation, resulting in Akt inhibition and increased FOXO3a activity.	Paclitaxel	84-94	forkhead box O3	Homo sapiens	171-177
16454695-6	2006	The intracellular accumulation of TPT and paclitaxel (a PgP substrate) by V/HepG2 and MRP4/HepG2 cells was determined by incubation of TPT with the cells and the amounts of the drug in cells were determined by validated HPLC methods.	Paclitaxel	42-52	ATP binding cassette subfamily B member 1	Homo sapiens	56-59
16679552-6	2006	Pretreatment of neurons with MT-stabilizing drugs paclitaxel (Taxol) and epothilone A prevented the induction of three indicators of the UPR induced by Abeta, ND, and thapsigargin, a compound known to inhibit the sarco-ER Ca(2+)-ATPase and deplete ER calcium stores, resulting in initiation of the UPR.	Paclitaxel	50-60	amyloid beta precursor protein	Homo sapiens	152-157
16515634-8	2006	The expression of HIF-1alpha was inhibited, and apoptotic index of tumor cell increased in rapamycin and rapamycin plus paclitaxel group.	Paclitaxel	120-130	hypoxia inducible factor 1 subunit alpha	Homo sapiens	18-28
16679552-6	2006	Pretreatment of neurons with MT-stabilizing drugs paclitaxel (Taxol) and epothilone A prevented the induction of three indicators of the UPR induced by Abeta, ND, and thapsigargin, a compound known to inhibit the sarco-ER Ca(2+)-ATPase and deplete ER calcium stores, resulting in initiation of the UPR.	Paclitaxel	62-67	amyloid beta precursor protein	Homo sapiens	152-157
16051289-7	2006	Meanwhile, immunoblotting analysis also showed that the co-administration of esculetin and Taxol could increase the expression of Bax and the cytosolic release of cytochrome C and enhance the expression of Fas and Fas ligand while the activation of caspase-8 and caspase-3 was also increased.	Paclitaxel	91-96	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133
16402278-4	2006	We conducted a prospective, randomized study to assess if Pgp inhibition by TAM alters deposition of paclitaxel in cerebrospinal fluid (CSF).	Paclitaxel	101-111	ATP binding cassette subfamily B member 1	Homo sapiens	58-61
16402278-11	2006	CONCLUSIONS: The trend towards lower paclitaxel CSF concentrations when given with TAM is consistent with the published finding that Pgp"s localization in the endothelial cells of the choroid plexus works in an opposite direction and keeps drugs in the CSF.	Paclitaxel	37-47	ATP binding cassette subfamily B member 1	Homo sapiens	133-136
16402278-13	2006	Conceptually, this finding implies that the Pgp in the BBB and BCSFB keeps natural toxins such as paclitaxel, from entering the brain (BBB) and, if they do enter the brain, keeps them in the CSF (BCSFB) where they may be less harmful than if they re-entered the brain.	Paclitaxel	98-108	ATP binding cassette subfamily B member 1	Homo sapiens	44-47
17657173-7	2006	SNU-449, the most resistant cell line and the only one overexpressing P-glycoprotein, was 3- to 39-fold more resistant to paclitaxel, docetaxel, and doxorubicin than were other cell lines.	Paclitaxel	122-132	ATP binding cassette subfamily B member 1	Homo sapiens	70-84
17119350-2	2006	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	Paclitaxel	378-388	mitogen-activated protein kinase 8	Homo sapiens	132-157
17119350-2	2006	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	Paclitaxel	378-388	mitogen-activated protein kinase 8	Homo sapiens	159-162
17119350-2	2006	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	Paclitaxel	378-388	BCL2 apoptosis regulator	Homo sapiens	279-284
17119350-2	2006	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	Paclitaxel	378-388	mitogen-activated protein kinase 8	Homo sapiens	315-318
16005497-5	2006	RESULTS: We found that IL-1beta and IL-6 levels were significantly increased in the coronary sinus of patients receiving either bare, paclitaxel- or sirolimus-eluting stents 20 min after stent implantation as compared with basal concentrations.	Paclitaxel	134-144	interleukin 1 beta	Homo sapiens	23-31
16005497-5	2006	RESULTS: We found that IL-1beta and IL-6 levels were significantly increased in the coronary sinus of patients receiving either bare, paclitaxel- or sirolimus-eluting stents 20 min after stent implantation as compared with basal concentrations.	Paclitaxel	134-144	interleukin 6	Homo sapiens	36-40
16051289-7	2006	Meanwhile, immunoblotting analysis also showed that the co-administration of esculetin and Taxol could increase the expression of Bax and the cytosolic release of cytochrome C and enhance the expression of Fas and Fas ligand while the activation of caspase-8 and caspase-3 was also increased.	Paclitaxel	91-96	cytochrome c, somatic	Homo sapiens	163-175
16051289-7	2006	Meanwhile, immunoblotting analysis also showed that the co-administration of esculetin and Taxol could increase the expression of Bax and the cytosolic release of cytochrome C and enhance the expression of Fas and Fas ligand while the activation of caspase-8 and caspase-3 was also increased.	Paclitaxel	91-96	caspase 3	Homo sapiens	263-272
16051289-8	2006	Finally, the ERK cascade was proven to be involved in the enhancement of esculetin on the Taxol-induced apoptosis.	Paclitaxel	90-95	mitogen-activated protein kinase 1	Homo sapiens	13-16
16361573-0	2005	Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.	Paclitaxel	159-169	Y-box binding protein 1	Homo sapiens	55-78
16342957-10	2005	Finally, bC1 was shown to disrupt and aggregate planar sheets of crystalline tubulin stabilized by paclitaxel, establishing that these structures are not suitable substrates for the formation of MBP cocrystals.	Paclitaxel	99-109	brain cytoplasmic RNA 1	Mus musculus	9-12
16361573-8	2005	RESULTS: Of 27 breast cancer tissues treated with paclitaxel, nine (33%) showed translocation of YB-1 from the cytoplasm to the nucleus together with increased expression of P-glycoprotein during the course of treatment.	Paclitaxel	50-60	Y-box binding protein 1	Homo sapiens	97-101
16361573-0	2005	Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.	Paclitaxel	159-169	ATP binding cassette subfamily B member 1	Homo sapiens	111-125
16361573-2	2005	There have been no previous studies regarding the involvement of YB-1 in the development of resistance to paclitaxel.	Paclitaxel	106-116	Y-box binding protein 1	Homo sapiens	65-69
16361573-3	2005	The present study was done to examine how paclitaxel affects the localization and expression of YB-1 in breast cancer.	Paclitaxel	42-52	Y-box binding protein 1	Homo sapiens	96-100
16361573-4	2005	EXPERIMENTAL DESIGN: We evaluated the expression and localization of YB-1 and P-glycoprotein in breast cancer tissues obtained from 27 patients before and after treatment with paclitaxel.	Paclitaxel	176-186	Y-box binding protein 1	Homo sapiens	69-73
16361573-4	2005	EXPERIMENTAL DESIGN: We evaluated the expression and localization of YB-1 and P-glycoprotein in breast cancer tissues obtained from 27 patients before and after treatment with paclitaxel.	Paclitaxel	176-186	ATP binding cassette subfamily B member 1	Homo sapiens	78-92
16361573-5	2005	The effect of paclitaxel on localization of cellular YB-1 was examined by using GFP-YB-1.	Paclitaxel	14-24	Y-box binding protein 1	Homo sapiens	53-57
16361573-7	2005	The effects of paclitaxel on MDR1 promoter activity were examined by luciferase assay.	Paclitaxel	15-25	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
16361573-8	2005	RESULTS: Of 27 breast cancer tissues treated with paclitaxel, nine (33%) showed translocation of YB-1 from the cytoplasm to the nucleus together with increased expression of P-glycoprotein during the course of treatment.	Paclitaxel	50-60	ATP binding cassette subfamily B member 1	Homo sapiens	174-188
16361573-11	2005	Confocal analysis indicated that paclitaxel induced nuclear translocation of green fluorescent fused YB-1 in MCF7 cells.	Paclitaxel	33-43	Y-box binding protein 1	Homo sapiens	101-105
16361573-12	2005	Furthermore, binding of YB-1 to the Y-box of MDR1 promoter was increased in response to treatment with paclitaxel.	Paclitaxel	103-113	Y-box binding protein 1	Homo sapiens	24-28
16361573-12	2005	Furthermore, binding of YB-1 to the Y-box of MDR1 promoter was increased in response to treatment with paclitaxel.	Paclitaxel	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	45-49
16361573-13	2005	In addition, MDR1 promoter activity was significantly up-regulated by paclitaxel in MCF7 cells (P&lt;0.001).	Paclitaxel	70-80	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
16361573-14	2005	CONCLUSIONS: The results of the present study suggested that YB-1 may be involved in the development of resistance to paclitaxel in breast cancer.	Paclitaxel	118-128	Y-box binding protein 1	Homo sapiens	61-65
16322248-9	2005	Expression of these mutant p110alpha isoforms also confers increased resistance to paclitaxel and induces abnormal mammary acinar morphogenesis in three-dimensional basement membrane cultures.	Paclitaxel	83-93	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	27-36
16273228-0	2005	Contribution of reactive oxygen species and caspase-3 to apoptosis and attenuated ICAM-1 expression by paclitaxel-treated MDA-MB-435 breast carcinoma cells.	Paclitaxel	103-113	caspase 3	Homo sapiens	44-53
16381626-1	2005	PURPOSE: The efficacy and tolerability of 2 different schedules of paclitaxel/carboplatin/trastuzumab for HER2-overexpressing metastatic breast cancer (MBC) were evaluated in this parallel multicenter phase II trial.	Paclitaxel	67-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
16381626-8	2005	CONCLUSIONS: Every-3-week and weekly regimens of paclitaxel/carboplatin/trastuzumab are highly active in women with HER2-overexpressing MBC.	Paclitaxel	49-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
16361156-0	2005	[Therapeutic effect of TAX combined with Herceptin or epirubicin against breast cancer positive for Her-2/neu].	Paclitaxel	23-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-105
16361156-0	2005	[Therapeutic effect of TAX combined with Herceptin or epirubicin against breast cancer positive for Her-2/neu].	Paclitaxel	23-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-109
16361156-6	2005	CONCLUSIONS: In patients with advanced breast cancer with positive immunostaining for Her-2/neu of grade 3+, the regimen of Herceptin plus TAX can be more effective than the chemotherapeutic regimen of EPI plus TAX.	Paclitaxel	139-142	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-95
16273228-4	2005	Paclitaxel treatment of MDA-MB-435 cells was associated with the generation of reactive oxygen species (ROS), dissipation of mitochondrial transmembrane potential, and the activation of caspase-3.	Paclitaxel	0-10	caspase 3	Homo sapiens	186-195
16273228-6	2005	In addition, a selective inhibitor of caspase-3 (Z-DEVD-FMK), as well as a pan-caspase inhibitor (Z-VAD-FMK), partially prevented the decrease in ICAM-1 expression observed following paclitaxel treatment, but did not protect against paclitaxel-induced cytotoxicity.	Paclitaxel	183-193	caspase 3	Homo sapiens	38-47
16273228-6	2005	In addition, a selective inhibitor of caspase-3 (Z-DEVD-FMK), as well as a pan-caspase inhibitor (Z-VAD-FMK), partially prevented the decrease in ICAM-1 expression observed following paclitaxel treatment, but did not protect against paclitaxel-induced cytotoxicity.	Paclitaxel	233-243	caspase 3	Homo sapiens	38-47
15945097-11	2005	In conclusion, we could remark that proteasome inhibitors (especially PS341) attenuate the resistance of MCF7/ADR cells for P-gp substrate drugs of doxorubicin and paclitaxel.	Paclitaxel	164-174	ATP binding cassette subfamily B member 1	Homo sapiens	124-128
16267627-7	2005	At this moment, potential clinically relevant application of CYP450 pharmacogenetics for anticancer therapy may be found for CYP1A2 and flutamide, CYP2A6 and tegafur, CYP2B6 and cyclophosphamide, CYP2C8 and paclitaxel, CYP2D6 and tamoxifen, and CYP3A5.	Paclitaxel	207-217	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	219-225
16267627-7	2005	At this moment, potential clinically relevant application of CYP450 pharmacogenetics for anticancer therapy may be found for CYP1A2 and flutamide, CYP2A6 and tegafur, CYP2B6 and cyclophosphamide, CYP2C8 and paclitaxel, CYP2D6 and tamoxifen, and CYP3A5.	Paclitaxel	207-217	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	245-251
16250671-6	2005	Paclitaxel markedly suppressed Smad2 and Smad3 phosphorylation and collagen deposition in SSc grafts.	Paclitaxel	0-10	SMAD family member 2	Mus musculus	31-36
16409617-0	2005	High dose chemotherapy including paclitaxel (T-ICE) combined with peripheral blood stem cell transplantation for male germ cell tumor.	Paclitaxel	33-43	carboxylesterase 2	Homo sapiens	47-50
16409617-2	2005	AIM: To evaluate the feasibility and usefulness of high dose chemotherapy including paclitaxel (T-ICE) combined with peripheral blood stem cell transplantation (PBSCT) for male germ cell tumor.	Paclitaxel	84-94	carboxylesterase 2	Homo sapiens	98-101
16299241-0	2005	Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.	Paclitaxel	92-102	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
16299241-0	2005	Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.	Paclitaxel	92-102	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	31-37
16288028-0	2005	SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.	Paclitaxel	114-124	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
16288028-0	2005	SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.	Paclitaxel	140-150	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
16288028-3	2005	Interestingly, Src inhibition has also been shown to resensitize paclitaxel-resistant cells to the cytotoxic effects of paclitaxel.	Paclitaxel	65-75	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	15-18
16288028-3	2005	Interestingly, Src inhibition has also been shown to resensitize paclitaxel-resistant cells to the cytotoxic effects of paclitaxel.	Paclitaxel	120-130	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	15-18
16288028-5	2005	The paclitaxel-resistant human (CaOV3TaxR) and mouse (ID8TaxR) ovarian cancer cell lines express large amounts of the multidrug resistance-1 (MDR-1) protein compared with the paclitaxel-sensitive parent cell lines.	Paclitaxel	4-14	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	118-140
16288028-5	2005	The paclitaxel-resistant human (CaOV3TaxR) and mouse (ID8TaxR) ovarian cancer cell lines express large amounts of the multidrug resistance-1 (MDR-1) protein compared with the paclitaxel-sensitive parent cell lines.	Paclitaxel	4-14	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	142-147
16288028-8	2005	Coinhibition of both Src and MDR-1 synergistically enhanced paclitaxel-induced cytotoxicity in paclitaxel-resistant ovarian cancer cell lines.	Paclitaxel	60-70	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	21-24
16299241-0	2005	Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.	Paclitaxel	92-102	ATP binding cassette subfamily B member 1	Homo sapiens	43-48
16299241-1	2005	PURPOSE: To retrospectively evaluate the effects of six known allelic variants in the CYP2C8, CYP3A4, CYP3A5, and ABCB1 genes on the pharmacokinetics of the anticancer agent paclitaxel (Taxol).	Paclitaxel	174-184	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	94-100
16299241-1	2005	PURPOSE: To retrospectively evaluate the effects of six known allelic variants in the CYP2C8, CYP3A4, CYP3A5, and ABCB1 genes on the pharmacokinetics of the anticancer agent paclitaxel (Taxol).	Paclitaxel	174-184	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	102-108
16288028-8	2005	Coinhibition of both Src and MDR-1 synergistically enhanced paclitaxel-induced cytotoxicity in paclitaxel-resistant ovarian cancer cell lines.	Paclitaxel	60-70	ATP binding cassette subfamily B member 1	Homo sapiens	29-34
16288028-8	2005	Coinhibition of both Src and MDR-1 synergistically enhanced paclitaxel-induced cytotoxicity in paclitaxel-resistant ovarian cancer cell lines.	Paclitaxel	95-105	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	21-24
16299241-1	2005	PURPOSE: To retrospectively evaluate the effects of six known allelic variants in the CYP2C8, CYP3A4, CYP3A5, and ABCB1 genes on the pharmacokinetics of the anticancer agent paclitaxel (Taxol).	Paclitaxel	174-184	ATP binding cassette subfamily B member 1	Homo sapiens	114-119
16275990-8	2005	This Bcl-2/Bcl-xL bispecific antisense oligonucleotide also enhanced paclitaxel chemosensitivity in PC3 cells, reducing the IC50 of paclitaxel by &gt;90%.	Paclitaxel	69-79	BCL2 apoptosis regulator	Homo sapiens	5-10
16182255-2	2005	The effect of rottlerin, a PKC-delta specific inhibitor, on TLR-4-mediated signaling was investigated in murine microglia stimulated with lipopolysaccharide and taxol.	Paclitaxel	161-166	toll-like receptor 4	Mus musculus	60-65
16211241-5	2005	We found that paclitaxel transiently induced EGFR phosphorylation and ERK and AKT activation but not JNK and p38.	Paclitaxel	14-24	AKT serine/threonine kinase 1	Homo sapiens	78-81
16211241-6	2005	Paclitaxel-induced ERK and AKT activity was inhibited by the EGFR inhibitor, PD153035; ERK inhibitor, U0126; and PI3 kinase inhibitor, LY294002, respectively.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Homo sapiens	19-22
16211241-6	2005	Paclitaxel-induced ERK and AKT activity was inhibited by the EGFR inhibitor, PD153035; ERK inhibitor, U0126; and PI3 kinase inhibitor, LY294002, respectively.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	27-30
16211241-6	2005	Paclitaxel-induced ERK and AKT activity was inhibited by the EGFR inhibitor, PD153035; ERK inhibitor, U0126; and PI3 kinase inhibitor, LY294002, respectively.	Paclitaxel	0-10	epidermal growth factor receptor	Homo sapiens	61-65
16211241-6	2005	Paclitaxel-induced ERK and AKT activity was inhibited by the EGFR inhibitor, PD153035; ERK inhibitor, U0126; and PI3 kinase inhibitor, LY294002, respectively.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Homo sapiens	87-90
16211241-8	2005	Paclitaxel-induced survivin expression was inhibited by the EGFR inhibitor, PD153035.	Paclitaxel	0-10	epidermal growth factor receptor	Homo sapiens	60-64
16211241-9	2005	Inhibitors of EGFR, ERK and PI3 kinase all enhanced paclitaxel-induced cell death.	Paclitaxel	52-62	epidermal growth factor receptor	Homo sapiens	14-18
16211241-9	2005	Inhibitors of EGFR, ERK and PI3 kinase all enhanced paclitaxel-induced cell death.	Paclitaxel	52-62	mitogen-activated protein kinase 1	Homo sapiens	20-23
16211241-10	2005	We conclude that paclitaxel transiently transactivates EGFR, leading to activation of cell survival factors, such as ERK and AKT, and expression of survivin, which are all inclusively accountable for ovarian cancer cell resistance to paclitaxel treatment.	Paclitaxel	17-27	epidermal growth factor receptor	Homo sapiens	55-59
16211241-10	2005	We conclude that paclitaxel transiently transactivates EGFR, leading to activation of cell survival factors, such as ERK and AKT, and expression of survivin, which are all inclusively accountable for ovarian cancer cell resistance to paclitaxel treatment.	Paclitaxel	17-27	mitogen-activated protein kinase 1	Homo sapiens	117-120
16211241-10	2005	We conclude that paclitaxel transiently transactivates EGFR, leading to activation of cell survival factors, such as ERK and AKT, and expression of survivin, which are all inclusively accountable for ovarian cancer cell resistance to paclitaxel treatment.	Paclitaxel	17-27	AKT serine/threonine kinase 1	Homo sapiens	125-128
16211241-10	2005	We conclude that paclitaxel transiently transactivates EGFR, leading to activation of cell survival factors, such as ERK and AKT, and expression of survivin, which are all inclusively accountable for ovarian cancer cell resistance to paclitaxel treatment.	Paclitaxel	234-244	epidermal growth factor receptor	Homo sapiens	55-59
16288028-8	2005	Coinhibition of both Src and MDR-1 synergistically enhanced paclitaxel-induced cytotoxicity in paclitaxel-resistant ovarian cancer cell lines.	Paclitaxel	95-105	ATP binding cassette subfamily B member 1	Homo sapiens	29-34
16288028-9	2005	Inhibition of Src enhanced microtubule stabilization in paclitaxel-resistant ovarian cancer cells treated with paclitaxel without affecting expression of beta-tubulin isotypes and resulted in multipolar spindle formation and apoptosis.	Paclitaxel	56-66	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	14-17
16288028-9	2005	Inhibition of Src enhanced microtubule stabilization in paclitaxel-resistant ovarian cancer cells treated with paclitaxel without affecting expression of beta-tubulin isotypes and resulted in multipolar spindle formation and apoptosis.	Paclitaxel	111-121	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	14-17
16288028-10	2005	These results show that Src inhibition restores paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells by an MDR-independent mechanism, possibly by decreasing the critical intracellular concentration at which paclitaxel induces tubulin stabilization and bundling.	Paclitaxel	48-58	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	24-27
16288028-10	2005	These results show that Src inhibition restores paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells by an MDR-independent mechanism, possibly by decreasing the critical intracellular concentration at which paclitaxel induces tubulin stabilization and bundling.	Paclitaxel	74-84	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	24-27
16288028-10	2005	These results show that Src inhibition restores paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells by an MDR-independent mechanism, possibly by decreasing the critical intracellular concentration at which paclitaxel induces tubulin stabilization and bundling.	Paclitaxel	74-84	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	24-27
16211241-0	2005	Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death.	Paclitaxel	96-106	epidermal growth factor receptor	Homo sapiens	51-55
16211241-3	2005	The objective of this study was to understand the molecular mechanism of transient induction of EGFR-mediated cell survival by paclitaxel.	Paclitaxel	127-137	epidermal growth factor receptor	Homo sapiens	96-100
16211241-4	2005	We utilized ovarian cancer cell line, Caov3, cells to investigate the effect of paclitaxel on EGFR-mediated MAP kinase and AKT activation, and the expression of survivin.	Paclitaxel	80-90	epidermal growth factor receptor	Homo sapiens	94-98
16211241-4	2005	We utilized ovarian cancer cell line, Caov3, cells to investigate the effect of paclitaxel on EGFR-mediated MAP kinase and AKT activation, and the expression of survivin.	Paclitaxel	80-90	AKT serine/threonine kinase 1	Homo sapiens	123-126
16211241-5	2005	We found that paclitaxel transiently induced EGFR phosphorylation and ERK and AKT activation but not JNK and p38.	Paclitaxel	14-24	epidermal growth factor receptor	Homo sapiens	45-49
16211241-5	2005	We found that paclitaxel transiently induced EGFR phosphorylation and ERK and AKT activation but not JNK and p38.	Paclitaxel	14-24	mitogen-activated protein kinase 1	Homo sapiens	70-73
16127422-7	2005	In contrast, the sensitivities of MCF-7/COX-2 cells to doxorubicin and paclitaxel were similar to those of the parental MCF-7 cells.	Paclitaxel	71-81	prostaglandin-endoperoxide synthase 2	Homo sapiens	40-45
16275990-8	2005	This Bcl-2/Bcl-xL bispecific antisense oligonucleotide also enhanced paclitaxel chemosensitivity in PC3 cells, reducing the IC50 of paclitaxel by &gt;90%.	Paclitaxel	69-79	BCL2 like 1	Homo sapiens	11-17
16275990-8	2005	This Bcl-2/Bcl-xL bispecific antisense oligonucleotide also enhanced paclitaxel chemosensitivity in PC3 cells, reducing the IC50 of paclitaxel by &gt;90%.	Paclitaxel	132-142	BCL2 apoptosis regulator	Homo sapiens	5-10
16275990-8	2005	This Bcl-2/Bcl-xL bispecific antisense oligonucleotide also enhanced paclitaxel chemosensitivity in PC3 cells, reducing the IC50 of paclitaxel by &gt;90%.	Paclitaxel	132-142	BCL2 like 1	Homo sapiens	11-17
16243823-4	2005	As examined by electrophoretic mobility gel shift assay, paclitaxel activated NF-kappaB in breast cancer cells and curcumin inhibited it; this inhibition was mediated through inhibition of IkappaBalpha kinase activation and IkappaBalpha phosphorylation and degradation.	Paclitaxel	57-67	nuclear factor kappa B subunit 1	Homo sapiens	78-87
16220531-17	2005	Haptoglobin expression in the serum of cancer patients (n = 7) decreased following chemotherapy (six cycles of taxol/carboplatin).	Paclitaxel	111-116	haptoglobin	Homo sapiens	0-11
16243823-4	2005	As examined by electrophoretic mobility gel shift assay, paclitaxel activated NF-kappaB in breast cancer cells and curcumin inhibited it; this inhibition was mediated through inhibition of IkappaBalpha kinase activation and IkappaBalpha phosphorylation and degradation.	Paclitaxel	57-67	NFKB inhibitor alpha	Homo sapiens	189-201
16243823-4	2005	As examined by electrophoretic mobility gel shift assay, paclitaxel activated NF-kappaB in breast cancer cells and curcumin inhibited it; this inhibition was mediated through inhibition of IkappaBalpha kinase activation and IkappaBalpha phosphorylation and degradation.	Paclitaxel	57-67	NFKB inhibitor alpha	Homo sapiens	224-236
16243823-5	2005	Curcumin also suppressed the paclitaxel-induced expression of antiapoptotic (XIAP, IAP-1, IAP-2, Bcl-2, and Bcl-xL), proliferative (cyclooxygenase 2, c-Myc, and cyclin D1), and metastatic proteins (vascular endothelial growth factor, matrix metalloproteinase-9, and intercellular adhesion molecule-1).	Paclitaxel	29-39	BCL2 apoptosis regulator	Homo sapiens	97-102
16243823-5	2005	Curcumin also suppressed the paclitaxel-induced expression of antiapoptotic (XIAP, IAP-1, IAP-2, Bcl-2, and Bcl-xL), proliferative (cyclooxygenase 2, c-Myc, and cyclin D1), and metastatic proteins (vascular endothelial growth factor, matrix metalloproteinase-9, and intercellular adhesion molecule-1).	Paclitaxel	29-39	BCL2 like 1	Homo sapiens	108-114
16243823-5	2005	Curcumin also suppressed the paclitaxel-induced expression of antiapoptotic (XIAP, IAP-1, IAP-2, Bcl-2, and Bcl-xL), proliferative (cyclooxygenase 2, c-Myc, and cyclin D1), and metastatic proteins (vascular endothelial growth factor, matrix metalloproteinase-9, and intercellular adhesion molecule-1).	Paclitaxel	29-39	prostaglandin-endoperoxide synthase 2	Homo sapiens	132-148
16216740-2	2005	A 45-year-old woman with breast cancer overexpressing HER2 and metastasizing to choroidal plexus, lymph nodes and skin received a combination of trastuzumab and paclitaxel as first-line treatment.	Paclitaxel	161-171	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
16507399-7	2005	This provides the rationale for the use of COX-2 inhibitors in combination with taxanes, as this could theoretically improve the clinical efficacy of paclitaxel and docetaxel.	Paclitaxel	150-160	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	43-48
16507399-11	2005	Randomized clinical trials would be needed to establish whether COX-2 inhibitors improve the therapeutic profile of docetaxel or paclitaxel in patients with solid tumors.	Paclitaxel	129-139	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	64-69
15875185-10	2005	Furthermore, the enhancement of antitumor effect by ningalins, at least in parts, are due to inhibiting Pgp which was supported by the observation that the ningalins compete for [3H]azidopine binding to Pgp, increase the cellular accumulation of VBL or taxol, and inhibit drug efflux from the tumor cells.	Paclitaxel	253-258	ATP binding cassette subfamily B member 1	Homo sapiens	104-107
16216740-5	2005	Choroidal metastases from breast cancer overexpressing HER2 are responsive to trastuzumab and chemotherapy (paclitaxel or vinorelbine).	Paclitaxel	108-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59
16023314-14	2005	The influx permeability of substrates increased significantly (rhodamine123=70%, taxol=220%, digoxin=290%) after the P-gp inhibitor (GF120918) was introduced, whereas the influx permeability of P-gp inhibitor and non-substrates was not affected by GF120918.	Paclitaxel	81-86	ATP binding cassette subfamily B member 1	Homo sapiens	117-121
16315863-7	2005	Treatment of MKN-45 cells with AS Bcl-2 increased sensitivity to adriamycin (ADM), cisplatin (CDDP), and paclitaxel (PTX) in vitro and in vivo.	Paclitaxel	105-115	BCL2 apoptosis regulator	Homo sapiens	34-39
16315863-7	2005	Treatment of MKN-45 cells with AS Bcl-2 increased sensitivity to adriamycin (ADM), cisplatin (CDDP), and paclitaxel (PTX) in vitro and in vivo.	Paclitaxel	117-120	BCL2 apoptosis regulator	Homo sapiens	34-39
16315863-8	2005	Similarly, treatment of BT-474, ZR-75-1, and MDA-MB-231 cells with AS Bcl-2 increased chemosensitivity to ADM, mitomycin C (MMC), PTX, and docetaxel (DOC).	Paclitaxel	130-133	BCL2 apoptosis regulator	Homo sapiens	70-75
15975716-2	2005	Immunohistochemical studies show that the expression of both GLAST and GLT-1 in the L4-L5 spinal dorsal horn is decreased by 24% (P&lt;0.001) and 23% (P&lt;0.001), respectively, in rats with taxol-induced hyperalgesia as compared with those in control rats.	Paclitaxel	191-196	solute carrier family 1 member 2	Rattus norvegicus	71-76
15864591-9	2005	Treatment of mice bearing LNCaP tumors with clusterin ASO plus paclitaxel reduced mean tumor volume and serum PSA level by more than 50% and 70%, respectively.	Paclitaxel	63-73	kallikrein B, plasma 1	Mus musculus	110-113
16101130-4	2005	R115777 +/- paclitaxel inhibited HDJ-2 farnesylation, up-regulated RhoB, transiently lowered (P)ERK/ERK and (P)Akt/Akt, reduced Raf-1 and MEK and inhibited secretion of VEGF and MMP-1.	Paclitaxel	12-22	DnaJ heat shock protein family (Hsp40) member A1	Homo sapiens	33-38
16101130-4	2005	R115777 +/- paclitaxel inhibited HDJ-2 farnesylation, up-regulated RhoB, transiently lowered (P)ERK/ERK and (P)Akt/Akt, reduced Raf-1 and MEK and inhibited secretion of VEGF and MMP-1.	Paclitaxel	12-22	mitogen-activated protein kinase 1	Homo sapiens	96-99
16101130-4	2005	R115777 +/- paclitaxel inhibited HDJ-2 farnesylation, up-regulated RhoB, transiently lowered (P)ERK/ERK and (P)Akt/Akt, reduced Raf-1 and MEK and inhibited secretion of VEGF and MMP-1.	Paclitaxel	12-22	mitogen-activated protein kinase 1	Homo sapiens	100-103
16101130-4	2005	R115777 +/- paclitaxel inhibited HDJ-2 farnesylation, up-regulated RhoB, transiently lowered (P)ERK/ERK and (P)Akt/Akt, reduced Raf-1 and MEK and inhibited secretion of VEGF and MMP-1.	Paclitaxel	12-22	AKT serine/threonine kinase 1	Homo sapiens	111-114
16101130-4	2005	R115777 +/- paclitaxel inhibited HDJ-2 farnesylation, up-regulated RhoB, transiently lowered (P)ERK/ERK and (P)Akt/Akt, reduced Raf-1 and MEK and inhibited secretion of VEGF and MMP-1.	Paclitaxel	12-22	AKT serine/threonine kinase 1	Homo sapiens	115-118
16101130-4	2005	R115777 +/- paclitaxel inhibited HDJ-2 farnesylation, up-regulated RhoB, transiently lowered (P)ERK/ERK and (P)Akt/Akt, reduced Raf-1 and MEK and inhibited secretion of VEGF and MMP-1.	Paclitaxel	12-22	mitogen-activated protein kinase kinase 7	Homo sapiens	138-141
16101130-4	2005	R115777 +/- paclitaxel inhibited HDJ-2 farnesylation, up-regulated RhoB, transiently lowered (P)ERK/ERK and (P)Akt/Akt, reduced Raf-1 and MEK and inhibited secretion of VEGF and MMP-1.	Paclitaxel	12-22	vascular endothelial growth factor A	Homo sapiens	169-173
16173788-0	2005	Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.	Paclitaxel	119-124	CEA cell adhesion molecule 3	Homo sapiens	99-102
16173788-10	2005	These studies suggest that combined RIT and Taxol therapy are suitable in breast cancers expressing either low amounts of Her2 or CEA, thus expanding the number of eligible patients for combined therapies.	Paclitaxel	44-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
16173788-10	2005	These studies suggest that combined RIT and Taxol therapy are suitable in breast cancers expressing either low amounts of Her2 or CEA, thus expanding the number of eligible patients for combined therapies.	Paclitaxel	44-49	CEA cell adhesion molecule 3	Homo sapiens	130-133
15856231-2	2005	Studies on the metabolism and disposition of paclitaxel have shown that it is primarily eliminated via hepatic metabolism by P450 enzymes (2C8 and 3A4) to essentially inactive metabolites, and that biliary and gut transport by P-glycoprotein (PGP) as well as urinary elimination of the parent compound play relatively minor roles.	Paclitaxel	45-55	ATP binding cassette subfamily B member 1	Homo sapiens	227-241
15856231-2	2005	Studies on the metabolism and disposition of paclitaxel have shown that it is primarily eliminated via hepatic metabolism by P450 enzymes (2C8 and 3A4) to essentially inactive metabolites, and that biliary and gut transport by P-glycoprotein (PGP) as well as urinary elimination of the parent compound play relatively minor roles.	Paclitaxel	45-55	ATP binding cassette subfamily B member 1	Homo sapiens	243-246
15856231-3	2005	Recent studies in vitro have shown that paclitaxel treatment increases the level of CYP2C8 and CYP3A4 in human hepatocytes as well as PGP in colon tumor cells.	Paclitaxel	40-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
15856231-3	2005	Recent studies in vitro have shown that paclitaxel treatment increases the level of CYP2C8 and CYP3A4 in human hepatocytes as well as PGP in colon tumor cells.	Paclitaxel	40-50	ATP binding cassette subfamily B member 1	Homo sapiens	134-137
15856231-8	2005	The effect of paclitaxel treatment on hepatic expression of PGP and P450 isoforms (CYP2C and CYP3A) was determined to elucidate the mechanism by which paclitaxel disposition is altered by previous drug exposure.	Paclitaxel	14-24	ATP binding cassette subfamily B member 1	Homo sapiens	60-63
15856231-8	2005	The effect of paclitaxel treatment on hepatic expression of PGP and P450 isoforms (CYP2C and CYP3A) was determined to elucidate the mechanism by which paclitaxel disposition is altered by previous drug exposure.	Paclitaxel	14-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-98
15856231-8	2005	The effect of paclitaxel treatment on hepatic expression of PGP and P450 isoforms (CYP2C and CYP3A) was determined to elucidate the mechanism by which paclitaxel disposition is altered by previous drug exposure.	Paclitaxel	151-161	ATP binding cassette subfamily B member 1	Homo sapiens	60-63
16155344-4	2005	Moreover, we observed similarly reduced taxol/GTP-stimulated tubulin polymerization from gray matter obtained from patients with AD caused by PSEN2 N141I mutation or frontotemporal dementia with parkinsonism linked to chromosome-17 caused (FTDP-17) by TAU V337M or P301L mutation.	Paclitaxel	40-45	presenilin 2	Homo sapiens	142-147
15856231-8	2005	The effect of paclitaxel treatment on hepatic expression of PGP and P450 isoforms (CYP2C and CYP3A) was determined to elucidate the mechanism by which paclitaxel disposition is altered by previous drug exposure.	Paclitaxel	151-161	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-98
16144941-5	2005	RESULTS: The current study showed that paclitaxel, discodermolide, and an analogue of epothilone B, BMS-247550, induced CYP3A4 protein expression in HepG2 hepatoma cells.	Paclitaxel	39-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-126
16144941-8	2005	To determine the mechanisms by which paclitaxel, discodermolide, and BMS-247550 activate hPXR, a mammalian two-hybrid assay was done using VP16SRC-1 (coactivator) and GAL4-SXR.	Paclitaxel	37-47	nuclear receptor subfamily 1 group I member 2	Homo sapiens	89-93
16144941-8	2005	To determine the mechanisms by which paclitaxel, discodermolide, and BMS-247550 activate hPXR, a mammalian two-hybrid assay was done using VP16SRC-1 (coactivator) and GAL4-SXR.	Paclitaxel	37-47	nuclear receptor subfamily 1 group I member 2	Homo sapiens	172-175
16140185-0	2005	Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS).	Paclitaxel	0-10	caspase 3	Homo sapiens	33-42
16140185-8	2005	Our observations were: (1) paclitaxel treatment resulted in G2/M-cycle arrest in U-2 OS cells; (2) time and dose dependent apoptosis of U-2 OS cells was induced by paclitaxel; (3) in U-2 OS cells, z-VAD-fmk blocked the paclitaxel-induced apoptosis and caspase-3 activation.	Paclitaxel	27-37	caspase 3	Homo sapiens	252-261
16140185-8	2005	Our observations were: (1) paclitaxel treatment resulted in G2/M-cycle arrest in U-2 OS cells; (2) time and dose dependent apoptosis of U-2 OS cells was induced by paclitaxel; (3) in U-2 OS cells, z-VAD-fmk blocked the paclitaxel-induced apoptosis and caspase-3 activation.	Paclitaxel	164-174	caspase 3	Homo sapiens	252-261
16140185-8	2005	Our observations were: (1) paclitaxel treatment resulted in G2/M-cycle arrest in U-2 OS cells; (2) time and dose dependent apoptosis of U-2 OS cells was induced by paclitaxel; (3) in U-2 OS cells, z-VAD-fmk blocked the paclitaxel-induced apoptosis and caspase-3 activation.	Paclitaxel	164-174	caspase 3	Homo sapiens	252-261
16140185-9	2005	These results suggest that paclitaxel-induced G2/M-cycle arrest of the G2/M phase and apoptosis via a caspase-3 pathway in U-2 OS cells.	Paclitaxel	27-37	caspase 3	Homo sapiens	102-111
16170023-3	2005	Glucose withdrawal or paclitaxel increase intracellular ceramide, down-regulate cellular FLICE inhibitory protein (cFLIP), and sensitize cells to TRAIL.	Paclitaxel	22-32	CASP8 and FADD like apoptosis regulator	Homo sapiens	115-120
15955594-8	2005	However, clinically achievable levels of gefitinib moderately reversed the Pgp-mediated resistance to paclitaxel and docetaxel in Pgp overexpressing cells.	Paclitaxel	102-112	ATP binding cassette subfamily B member 1	Homo sapiens	75-78
15955594-8	2005	However, clinically achievable levels of gefitinib moderately reversed the Pgp-mediated resistance to paclitaxel and docetaxel in Pgp overexpressing cells.	Paclitaxel	102-112	ATP binding cassette subfamily B member 1	Homo sapiens	130-133
16170037-5	2005	The evaluation of molecular pathways involved in apoptosis indicates that the Bcl-2 but not the caspases may be involved in the CDDP protection of paclitaxel-induced apoptosis.	Paclitaxel	147-157	BCL2 apoptosis regulator	Homo sapiens	78-83
16170023-3	2005	Glucose withdrawal or paclitaxel increase intracellular ceramide, down-regulate cellular FLICE inhibitory protein (cFLIP), and sensitize cells to TRAIL.	Paclitaxel	22-32	TNF superfamily member 10	Homo sapiens	146-151
16170024-6	2005	Similarly, the extent of caspase-9 and caspase-3 activation in paclitaxel-NU6140-treated cells was approximately 4-fold higher than after the paclitaxel-purvalanol A combination.	Paclitaxel	63-73	caspase 3	Homo sapiens	39-48
16170024-8	2005	A synergistic effect of the paclitaxel-NU6140 combination, as a consequence of survivin inhibition and increased activation of caspase-9 and caspase-3, was also observed in OAW42/e ovarian cancer line but not in the derived OAW42/Surv subline ectopically expressing survivin.	Paclitaxel	28-38	caspase 3	Homo sapiens	141-150
19956523-5	2005	RESULTS: RhoA significantly enhanced the resistance to lovastatin, 5-FU, taxol and vincristine, but did not affect the sensitivity to cisplatin or etoposide in SNU638.	Paclitaxel	73-78	ras homolog family member A	Homo sapiens	9-13
16115903-10	2005	CONCLUSIONS: The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers.	Paclitaxel	87-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-37
16196490-0	2005	Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention.	Paclitaxel	62-72	transferrin	Homo sapiens	39-50
16196490-1	2005	We studied the molecular mechanism of greater efficacy of paclitaxel-loaded nanoparticles (Tx-NPs) following conjugation to transferrin (Tf) ligand in breast cancer cell line.	Paclitaxel	58-68	transferrin	Homo sapiens	124-135
16196490-1	2005	We studied the molecular mechanism of greater efficacy of paclitaxel-loaded nanoparticles (Tx-NPs) following conjugation to transferrin (Tf) ligand in breast cancer cell line.	Paclitaxel	58-68	transferrin	Homo sapiens	137-139
16213899-6	2005	The effects of manumycin and paclitaxel on PTHrP expression were studied.	Paclitaxel	29-39	parathyroid hormone-like peptide	Mus musculus	43-48
19956523-8	2005	CONCLUSION: Gastric cancer cells with a high expression of RhoA could be resistant to chemotherapeutic drugs, such as taxol or vincristine, implying that treatment strategies aimed at inactivation of RhoA might be promising for improving the efficacy of these chemotherapeutic drugs.	Paclitaxel	118-123	ras homolog family member A	Homo sapiens	59-63
15778245-6	2005	MT stabilization by taxol (5 microM, 1 h) attenuated nocodazole-induced ERK1/2 and p38 MAPK activation and phosphorylation of p38 MAPK substrate 27-kDa heat shock protein and regulatory myosin light chains, the proteins involved in actin polymerization and actomyosin contraction.	Paclitaxel	20-25	mitogen-activated protein kinase 3	Homo sapiens	72-78
15908516-6	2005	When treatment with E6 siRNA was coupled with chemotherapy, the p53 activity after treatment with carboplatin and paclitaxel was additively increased, whereas the p53 activation induced by the rest of the drugs was synergistically increased.	Paclitaxel	114-124	tumor protein p53	Homo sapiens	64-67
15924242-9	2005	Antisense oligodeoxynucleotide (ASON) -mediated downregulation of p27 reduced intercellular adhesion, increased cell proliferation, downregulated P-gp expression and sensitized cells to Taxol.	Paclitaxel	186-191	dynactin subunit 6	Homo sapiens	66-69
15778245-6	2005	MT stabilization by taxol (5 microM, 1 h) attenuated nocodazole-induced ERK1/2 and p38 MAPK activation and phosphorylation of p38 MAPK substrate 27-kDa heat shock protein and regulatory myosin light chains, the proteins involved in actin polymerization and actomyosin contraction.	Paclitaxel	20-25	mitogen-activated protein kinase 1	Homo sapiens	83-86
15778245-6	2005	MT stabilization by taxol (5 microM, 1 h) attenuated nocodazole-induced ERK1/2 and p38 MAPK activation and phosphorylation of p38 MAPK substrate 27-kDa heat shock protein and regulatory myosin light chains, the proteins involved in actin polymerization and actomyosin contraction.	Paclitaxel	20-25	mitogen-activated protein kinase 1	Homo sapiens	126-129
15907983-6	2005	Among them, paclitaxel treatment suppressed the expression of the mitotic checkpoint protein BUB3.	Paclitaxel	12-22	BUB3 mitotic checkpoint protein	Homo sapiens	66-97
16080552-0	2005	AFP-producing hepatoid adenocarcinoma in association with Barrett"s esophagus with multiple liver metastasis responding to paclitaxel/CDDP: a case report.	Paclitaxel	123-133	alpha fetoprotein	Homo sapiens	0-3
15963795-0	2005	Induction of caspase-3-dependent apoptosis in human leukemia HL-60 cells by paclitaxel.	Paclitaxel	76-86	caspase 3	Homo sapiens	13-22
15963795-5	2005	CONCLUSIONS: These results suggest that paclitaxel can induce G2/M cell cycle transition and apoptosis via caspase-3 activity in HL-60 cells.	Paclitaxel	40-50	caspase 3	Homo sapiens	107-116
15907983-12	2005	Paclitaxel showed anti-proliferate activity through the membrane death receptor (DR)-mediated apoptotic pathway involving activation of caspase-8 with a TRAIL-dependent fashion as well as the mitochondrial-mediated pathway involving down-regulation of bcl-2 by cytochrome c release.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	252-257
15907983-12	2005	Paclitaxel showed anti-proliferate activity through the membrane death receptor (DR)-mediated apoptotic pathway involving activation of caspase-8 with a TRAIL-dependent fashion as well as the mitochondrial-mediated pathway involving down-regulation of bcl-2 by cytochrome c release.	Paclitaxel	0-10	cytochrome c, somatic	Homo sapiens	261-273
15907983-13	2005	Furthermore, we found siRNA-induced BUB3 knock down on cell cycle progression blocked by cell cycle arrest after paclitaxel treatment.	Paclitaxel	113-123	BUB3 mitotic checkpoint protein	Homo sapiens	36-40
15999529-9	2005	We conclude that, although siRNA against EGFR has efficacy against the PC-3 line when administered either alone vs untreated controls, with Taxol vs Taxol alone, or with cisplatin vs cisplatin alone, it is not more effective than the better characterized MR2 oligo.	Paclitaxel	140-145	epidermal growth factor receptor	Homo sapiens	41-45
15999529-9	2005	We conclude that, although siRNA against EGFR has efficacy against the PC-3 line when administered either alone vs untreated controls, with Taxol vs Taxol alone, or with cisplatin vs cisplatin alone, it is not more effective than the better characterized MR2 oligo.	Paclitaxel	149-154	epidermal growth factor receptor	Homo sapiens	41-45
16020661-0	2005	Cyclin A-associated kinase activity is needed for paclitaxel sensitivity.	Paclitaxel	50-60	cyclin A2	Homo sapiens	0-8
15688426-7	2005	Here we show that downregulation of Chk1 sensitizes tumor cells to the toxicity of paclitaxel in cell proliferation assay.	Paclitaxel	83-93	checkpoint kinase 1	Homo sapiens	36-40
15688426-8	2005	Fluorescence microscopy showed that Chk1 knockdown augments mitotic catastrophe and apoptosis in paclitaxel-treated cancer cells.	Paclitaxel	97-107	checkpoint kinase 1	Homo sapiens	36-40
15688426-10	2005	Chk1 inhibition facilitates paclitaxel-induced M-phase entry by activation of Cdc2 kinase and accumulation of cyclin B1, the required cofactor for Cdc2 kinase activity.	Paclitaxel	28-38	checkpoint kinase 1	Homo sapiens	0-4
15688426-13	2005	We show that Chk1 elimination attenuates the paclitaxel-induced activation of the anti-apoptotic p42/p44 (ERK1/2) MAP kinase pathway, additionally contributing to the sensitization.	Paclitaxel	45-55	checkpoint kinase 1	Homo sapiens	13-17
15688426-13	2005	We show that Chk1 elimination attenuates the paclitaxel-induced activation of the anti-apoptotic p42/p44 (ERK1/2) MAP kinase pathway, additionally contributing to the sensitization.	Paclitaxel	45-55	mitogen-activated protein kinase 3	Homo sapiens	106-112
16020661-7	2005	However, expression of cyclin A in DN-CDK2-transfected cells restored their sensitivity to paclitaxel.	Paclitaxel	91-101	cyclin A2	Homo sapiens	23-31
16020661-9	2005	We conclude that cyclin A-associated kinase activity is required for these cells to enter mitosis and undergo paclitaxel-induced cell death.	Paclitaxel	110-120	cyclin A2	Homo sapiens	17-25
16020661-3	2005	Here, we examined whether the activity of kinases associated with cyclin A (such as CDK2) is important in determining cellular sensitivity to paclitaxel, a taxane and mitotic inhibitor used in chemotherapy for breast and ovarian cancer.	Paclitaxel	142-152	cyclin A2	Homo sapiens	66-74
16026642-6	2005	ET-1 treatment of prostate tumor cells significantly decreased paclitaxel-induced apoptosis through activation of the ET(A) subtype.	Paclitaxel	63-73	endothelin 1	Homo sapiens	0-4
15930290-3	2005	We hypothesized that inhibiting the phosphorylation of the EGFR and vascular endothelial growth factor receptor (VEGFR) by AEE788, a dual tyrosine kinase inhibitor of EGFR and VEGFR, in combination with paclitaxel would inhibit experimental FTC bone lesions and preserve bone structure.	Paclitaxel	203-213	epidermal growth factor receptor	Homo sapiens	59-63
15731917-6	2005	Upon 24-h sequential exposure, the sequence of paclitaxel followed by oxaliplatin showed synergistic effects in AZ-521 and HST-1 cells, and greater than additive effects in KSE-1 cells, while the opposite sequence yielded marked antagonistic effects in all three cell lines.	Paclitaxel	47-57	fibroblast growth factor 4	Homo sapiens	123-128
15876424-7	2005	In the Be-Wo cell line, methadone and paclitaxel uptake was also increased in the presence of the P-gp inhibitor cyclosporin A.	Paclitaxel	38-48	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
15958559-6	2005	Furthermore, down-regulation of TWIST through small interfering RNA in androgen-independent prostate cancer cell lines, DU145 and PC3, resulted in increased sensitivity to the anticancer drug taxol-induced cell death which was associated with decreased Bcl/Bax ratio, leading to activation of the apoptosis pathway.	Paclitaxel	192-197	twist family bHLH transcription factor 1	Homo sapiens	32-37
15958559-6	2005	Furthermore, down-regulation of TWIST through small interfering RNA in androgen-independent prostate cancer cell lines, DU145 and PC3, resulted in increased sensitivity to the anticancer drug taxol-induced cell death which was associated with decreased Bcl/Bax ratio, leading to activation of the apoptosis pathway.	Paclitaxel	192-197	BCL2 associated X, apoptosis regulator	Homo sapiens	257-260
15930290-3	2005	We hypothesized that inhibiting the phosphorylation of the EGFR and vascular endothelial growth factor receptor (VEGFR) by AEE788, a dual tyrosine kinase inhibitor of EGFR and VEGFR, in combination with paclitaxel would inhibit experimental FTC bone lesions and preserve bone structure.	Paclitaxel	203-213	epidermal growth factor receptor	Homo sapiens	114-118
15735699-5	2005	Interestingly, prolonged downregulation of Hsp72 in PC-3 cells over 3 weeks aggravated these effects, as well as enhanced the sensitivity of cells to oxidative stress, radiation, cis-platinum, vinblastin and taxol.	Paclitaxel	208-213	heat shock protein family A (Hsp70) member 1A	Homo sapiens	43-48
15870870-0	2005	Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines.	Paclitaxel	51-61	tumor protein p53	Homo sapiens	82-85
15870870-5	2005	From these results, our previous study suggests that cells with mutant-type p53 may be less responsive to FP treatment and the present study indicates that another anti-cancer drug like paclitaxel, which might be mediated by a p53-independent pathway, should be selected.	Paclitaxel	186-196	tumor protein p53	Homo sapiens	76-79
15870870-5	2005	From these results, our previous study suggests that cells with mutant-type p53 may be less responsive to FP treatment and the present study indicates that another anti-cancer drug like paclitaxel, which might be mediated by a p53-independent pathway, should be selected.	Paclitaxel	186-196	tumor protein p53	Homo sapiens	227-230
15870880-5	2005	To confirm these findings, the MAPK signal transduction cascade was activated with EGF and response to doxorubicin or paclitaxel was measured in the presence/absence of the MEK-specific inhibitor, U0126.	Paclitaxel	118-128	mitogen-activated protein kinase 1	Homo sapiens	31-35
15863265-1	2005	In this study, we analyzed the role of the p53 status for paclitaxel/Taxol sensitivity in renal cell carcinomas (RCCs) of the clear cell type.	Paclitaxel	58-68	tumor protein p53	Homo sapiens	43-46
15863265-1	2005	In this study, we analyzed the role of the p53 status for paclitaxel/Taxol sensitivity in renal cell carcinomas (RCCs) of the clear cell type.	Paclitaxel	69-74	tumor protein p53	Homo sapiens	43-46
15941387-4	2005	Moreover, HER2 ligands have limited therapeutic efficacy and often they require adjuvant treatment with the chemotherapeutic Taxol.	Paclitaxel	125-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-14
15941387-11	2005	Hence, the Taxol x AHNP(bivalent) prodrug binds to HER2, induces receptor internalization and downregulation, and the subsequent release of free Taxol inside the targeted cell results in synergistic toxicity, The effect is selective towards HER2- expressing cells.	Paclitaxel	11-16	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-55
15941387-11	2005	Hence, the Taxol x AHNP(bivalent) prodrug binds to HER2, induces receptor internalization and downregulation, and the subsequent release of free Taxol inside the targeted cell results in synergistic toxicity, The effect is selective towards HER2- expressing cells.	Paclitaxel	11-16	erb-b2 receptor tyrosine kinase 2	Homo sapiens	241-245
15941387-11	2005	Hence, the Taxol x AHNP(bivalent) prodrug binds to HER2, induces receptor internalization and downregulation, and the subsequent release of free Taxol inside the targeted cell results in synergistic toxicity, The effect is selective towards HER2- expressing cells.	Paclitaxel	145-150	erb-b2 receptor tyrosine kinase 2	Homo sapiens	241-245
15738535-0	2005	Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.	Paclitaxel	100-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	180-214
15956255-4	2005	In vivo, the Akt inhibitors slow the progression of tumors when used as monotherapy or in combination with paclitaxel or rapamycin.	Paclitaxel	107-117	AKT serine/threonine kinase 1	Homo sapiens	13-16
15885467-6	2005	From cell cytotoxicity test, HepG2 cells with ASGPR are more sensitive to paclitaxel (TX)-loaded nanoparticles than free TX whereas, P388 cells, murine leukemia cell line, and SK-Hep 01, human hepatoma cell line, without ASGPR is less sensitive to TX-loaded nanoparticles than free TX, suggesting that specific interaction between HepG2 cells and galactose moiety of the nanoparticles occurred.	Paclitaxel	74-84	asialoglycoprotein receptor 1	Homo sapiens	46-51
15657900-6	2005	Co-exposure to C75 and Taxol induced a remarkable nuclear accumulation of activated p38 mitogen-activated protein kinase (p38 MAPK), which was accompanied by a synergistic nuclear accumulation of the p53 tumor-suppressor protein that was phosphorylated at Ser46, a p38 MAPK-regulated pro-apoptotic modification of p53.	Paclitaxel	23-28	mitogen-activated protein kinase 14	Homo sapiens	84-120
15657900-6	2005	Co-exposure to C75 and Taxol induced a remarkable nuclear accumulation of activated p38 mitogen-activated protein kinase (p38 MAPK), which was accompanied by a synergistic nuclear accumulation of the p53 tumor-suppressor protein that was phosphorylated at Ser46, a p38 MAPK-regulated pro-apoptotic modification of p53.	Paclitaxel	23-28	mitogen-activated protein kinase 14	Homo sapiens	122-130
15657900-6	2005	Co-exposure to C75 and Taxol induced a remarkable nuclear accumulation of activated p38 mitogen-activated protein kinase (p38 MAPK), which was accompanied by a synergistic nuclear accumulation of the p53 tumor-suppressor protein that was phosphorylated at Ser46, a p38 MAPK-regulated pro-apoptotic modification of p53.	Paclitaxel	23-28	tumor protein p53	Homo sapiens	200-203
15657900-6	2005	Co-exposure to C75 and Taxol induced a remarkable nuclear accumulation of activated p38 mitogen-activated protein kinase (p38 MAPK), which was accompanied by a synergistic nuclear accumulation of the p53 tumor-suppressor protein that was phosphorylated at Ser46, a p38 MAPK-regulated pro-apoptotic modification of p53.	Paclitaxel	23-28	mitogen-activated protein kinase 14	Homo sapiens	265-273
15657900-6	2005	Co-exposure to C75 and Taxol induced a remarkable nuclear accumulation of activated p38 mitogen-activated protein kinase (p38 MAPK), which was accompanied by a synergistic nuclear accumulation of the p53 tumor-suppressor protein that was phosphorylated at Ser46, a p38 MAPK-regulated pro-apoptotic modification of p53.	Paclitaxel	23-28	tumor protein p53	Homo sapiens	314-317
15657900-7	2005	As single agents, FAS blocker C75 and Taxol induced a significant stimulation of the proliferation and cell survival mitogen-activated protein kinase extracellular signal-regulated kinase (ERK1/ERK2 MAPK) activity, whereas, in combination, they interfered with ERK1/ERK2 activation.	Paclitaxel	38-43	mitogen-activated protein kinase 3	Homo sapiens	189-193
15657900-7	2005	As single agents, FAS blocker C75 and Taxol induced a significant stimulation of the proliferation and cell survival mitogen-activated protein kinase extracellular signal-regulated kinase (ERK1/ERK2 MAPK) activity, whereas, in combination, they interfered with ERK1/ERK2 activation.	Paclitaxel	38-43	mitogen-activated protein kinase 1	Homo sapiens	194-198
15657900-7	2005	As single agents, FAS blocker C75 and Taxol induced a significant stimulation of the proliferation and cell survival mitogen-activated protein kinase extracellular signal-regulated kinase (ERK1/ERK2 MAPK) activity, whereas, in combination, they interfered with ERK1/ERK2 activation.	Paclitaxel	38-43	mitogen-activated protein kinase 3	Homo sapiens	261-265
15657900-7	2005	As single agents, FAS blocker C75 and Taxol induced a significant stimulation of the proliferation and cell survival mitogen-activated protein kinase extracellular signal-regulated kinase (ERK1/ERK2 MAPK) activity, whereas, in combination, they interfered with ERK1/ERK2 activation.	Paclitaxel	38-43	mitogen-activated protein kinase 1	Homo sapiens	266-270
15657900-8	2005	Moreover, the combined treatment of C75 and Taxol inactivated the anti-apoptotic AKT (protein kinase B) kinase more than either agent alone, as evidenced by a synergistic down-regulation of AKT phosphorylation at its activating site Ser(473) without affecting AKT protein levels.	Paclitaxel	44-49	AKT serine/threonine kinase 1	Homo sapiens	81-84
15657900-8	2005	Moreover, the combined treatment of C75 and Taxol inactivated the anti-apoptotic AKT (protein kinase B) kinase more than either agent alone, as evidenced by a synergistic down-regulation of AKT phosphorylation at its activating site Ser(473) without affecting AKT protein levels.	Paclitaxel	44-49	AKT serine/threonine kinase 1	Homo sapiens	190-193
15657900-8	2005	Moreover, the combined treatment of C75 and Taxol inactivated the anti-apoptotic AKT (protein kinase B) kinase more than either agent alone, as evidenced by a synergistic down-regulation of AKT phosphorylation at its activating site Ser(473) without affecting AKT protein levels.	Paclitaxel	44-49	AKT serine/threonine kinase 1	Homo sapiens	190-193
15829295-3	2005	Our present studies showed that taxol, not LPS, induced cell apoptosis in human monocytic THP-1 cells, as indicated by PARP cleavage, as well as bcl-2 phosphorylation.	Paclitaxel	32-37	BCL2 apoptosis regulator	Homo sapiens	145-150
16080463-0	2005	Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.	Paclitaxel	109-119	BCL2 like 1	Homo sapiens	44-50
16080463-0	2005	Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.	Paclitaxel	109-119	CASP8 and FADD like apoptosis regulator	Homo sapiens	55-61
16080463-3	2005	In the present study, we tested the sensitivity of MCF-7 breast cancer cells overexpressing anti-apoptotic genes TRAF-1, c-FLIP, Bcl-xL, clAP-2 or Mn-SOD to paclitaxel and docetaxel.	Paclitaxel	157-167	TNF receptor associated factor 1	Homo sapiens	113-119
16080463-3	2005	In the present study, we tested the sensitivity of MCF-7 breast cancer cells overexpressing anti-apoptotic genes TRAF-1, c-FLIP, Bcl-xL, clAP-2 or Mn-SOD to paclitaxel and docetaxel.	Paclitaxel	157-167	CASP8 and FADD like apoptosis regulator	Homo sapiens	121-127
16080463-3	2005	In the present study, we tested the sensitivity of MCF-7 breast cancer cells overexpressing anti-apoptotic genes TRAF-1, c-FLIP, Bcl-xL, clAP-2 or Mn-SOD to paclitaxel and docetaxel.	Paclitaxel	157-167	BCL2 like 1	Homo sapiens	129-135
16080463-6	2005	Caspase 8 and 9 activities were measured in cells overexpressing Bcl-xL or c-FLIP exposed to docetaxel and paclitaxel using fluorescent substrate cleavage assay.	Paclitaxel	107-117	BCL2 like 1	Homo sapiens	65-71
16080463-6	2005	Caspase 8 and 9 activities were measured in cells overexpressing Bcl-xL or c-FLIP exposed to docetaxel and paclitaxel using fluorescent substrate cleavage assay.	Paclitaxel	107-117	CASP8 and FADD like apoptosis regulator	Homo sapiens	75-81
16080463-7	2005	RESULTS: MCF-7 cells overexpressing Bcl-xL but not TRAF-1, cIAP-2 or Mn-SOD were less sensitive to both paclitaxel and docetaxel compared to vector-transfected control cells.	Paclitaxel	104-114	BCL2 like 1	Homo sapiens	36-42
16080463-9	2005	2-Methoxyantimycin A3, a chemical inhibitor of Bcl-xL, sensitized Bcl-xL-overexpressing cells to paclitaxel and docetaxel, which suggests the drugs that inhibit Bcl-xL activity can be used as sensitizers to taxanes.	Paclitaxel	97-107	BCL2 like 1	Homo sapiens	47-53
16080463-9	2005	2-Methoxyantimycin A3, a chemical inhibitor of Bcl-xL, sensitized Bcl-xL-overexpressing cells to paclitaxel and docetaxel, which suggests the drugs that inhibit Bcl-xL activity can be used as sensitizers to taxanes.	Paclitaxel	97-107	BCL2 like 1	Homo sapiens	66-72
16080463-9	2005	2-Methoxyantimycin A3, a chemical inhibitor of Bcl-xL, sensitized Bcl-xL-overexpressing cells to paclitaxel and docetaxel, which suggests the drugs that inhibit Bcl-xL activity can be used as sensitizers to taxanes.	Paclitaxel	97-107	BCL2 like 1	Homo sapiens	66-72
16080463-10	2005	MCF-7 cells overexpressing c-FLIP were less sensitive to paclitaxel but not to docetaxel.	Paclitaxel	57-67	CASP8 and FADD like apoptosis regulator	Homo sapiens	27-33
16080463-12	2005	CONCLUSION: Because c-FLIP inhibits the extrinsic pathway of cell death whereas Bcl-xL inhibits the intrinsic pathway of cell death, these results suggest that overexpression of anti-apoptotic genes that inhibit either the extrinsic or intrinsic cell death pathways can reduce sensitivity of cancer cells to paclitaxel, whereas anti-apoptotic genes that inhibit only the intrinsic pathway reduce sensitivity to docetaxel.	Paclitaxel	308-318	BCL2 like 1	Homo sapiens	80-86
15592829-9	2005	Furthermore, paclitaxel induced activation of nuclear factor kappa B (NF-kappa B) in NK cells.	Paclitaxel	13-23	nuclear factor kappa B subunit 1	Homo sapiens	46-68
15592829-9	2005	Furthermore, paclitaxel induced activation of nuclear factor kappa B (NF-kappa B) in NK cells.	Paclitaxel	13-23	nuclear factor kappa B subunit 1	Homo sapiens	70-80
15592829-10	2005	NF-kappa B inhibitor pyrrolidine dithiocarbamate significantly suppressed both paclitaxel-induced perforin expression and NK cell cytotoxicity.	Paclitaxel	79-89	nuclear factor kappa B subunit 1	Homo sapiens	0-10
15834684-8	2005	On the other hand, the MAP kinase ERK1/2 is modestly inhibited by paclitaxel.	Paclitaxel	66-76	mitogen-activated protein kinase 3	Homo sapiens	34-40
16158930-0	2005	In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.	Paclitaxel	116-126	ATP binding cassette subfamily B member 1	Homo sapiens	73-87
16158953-0	2005	Sabarubicin- (MEN 10755) and paclitaxel show different kinetics in nuclear factor-kappaB (NF-kB) activation: effect of parthenolide on their cytotoxicity.	Paclitaxel	29-39	nuclear factor kappa B subunit 1	Homo sapiens	82-88
16158953-2	2005	In this paper, we studied NF-kappaB induced by the two anticancer agents Sabarubicin (MEN 10755) and paclitaxel (Taxol) and the effects of its pharmacological inhibition.	Paclitaxel	101-111	nuclear factor kappa B subunit 1	Homo sapiens	26-35
16158953-2	2005	In this paper, we studied NF-kappaB induced by the two anticancer agents Sabarubicin (MEN 10755) and paclitaxel (Taxol) and the effects of its pharmacological inhibition.	Paclitaxel	113-118	nuclear factor kappa B subunit 1	Homo sapiens	26-35
15786421-13	2005	CONCLUSIONS: STI571 was an effective chemosensitizer of antitumor drugs, such as 5-FU and paclitaxel for gastric carcinoma, targeting the PDGF/PDGFR-signaling pathway of tumor cells and stromal cells in disease progression and angiogenesis.	Paclitaxel	90-100	platelet derived growth factor receptor beta	Homo sapiens	143-148
15867388-6	2005	Mechanistically, we show that the combination of lonafarnib and paclitaxel inhibits the in vitro deacetylating activity of the only known tubulin deacetylase, histone deacetylase 6 (HDAC6).	Paclitaxel	64-74	histone deacetylase 6	Homo sapiens	159-180
15867388-6	2005	Mechanistically, we show that the combination of lonafarnib and paclitaxel inhibits the in vitro deacetylating activity of the only known tubulin deacetylase, histone deacetylase 6 (HDAC6).	Paclitaxel	64-74	histone deacetylase 6	Homo sapiens	182-187
15650019-5	2005	In contrast, the anticancer agents, cisplatin and paclitaxel, strongly activated PXR-mediated transcription through the MDR1-responsive element compared with the CYP3A4-responsive element, whereas these drugs also enhanced the MDR1 expression compared with the CYP3A4 expression.	Paclitaxel	50-60	nuclear receptor subfamily 1 group I member 2	Homo sapiens	81-84
15650019-5	2005	In contrast, the anticancer agents, cisplatin and paclitaxel, strongly activated PXR-mediated transcription through the MDR1-responsive element compared with the CYP3A4-responsive element, whereas these drugs also enhanced the MDR1 expression compared with the CYP3A4 expression.	Paclitaxel	50-60	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
15650019-5	2005	In contrast, the anticancer agents, cisplatin and paclitaxel, strongly activated PXR-mediated transcription through the MDR1-responsive element compared with the CYP3A4-responsive element, whereas these drugs also enhanced the MDR1 expression compared with the CYP3A4 expression.	Paclitaxel	50-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	162-168
15650019-5	2005	In contrast, the anticancer agents, cisplatin and paclitaxel, strongly activated PXR-mediated transcription through the MDR1-responsive element compared with the CYP3A4-responsive element, whereas these drugs also enhanced the MDR1 expression compared with the CYP3A4 expression.	Paclitaxel	50-60	ATP binding cassette subfamily B member 1	Homo sapiens	227-231
15650019-5	2005	In contrast, the anticancer agents, cisplatin and paclitaxel, strongly activated PXR-mediated transcription through the MDR1-responsive element compared with the CYP3A4-responsive element, whereas these drugs also enhanced the MDR1 expression compared with the CYP3A4 expression.	Paclitaxel	50-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	261-267
15805287-0	2005	Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.	Paclitaxel	43-48	mitogen-activated protein kinase kinase 7	Homo sapiens	56-95
15809765-0	2005	IFN-gamma enhances paclitaxel-induced apoptosis that is modulated by activation of caspases 8 and 3 with a concomitant down regulation of the AKT survival pathway in cultured human keratinocytes.	Paclitaxel	19-29	interferon gamma	Homo sapiens	0-9
15809765-0	2005	IFN-gamma enhances paclitaxel-induced apoptosis that is modulated by activation of caspases 8 and 3 with a concomitant down regulation of the AKT survival pathway in cultured human keratinocytes.	Paclitaxel	19-29	AKT serine/threonine kinase 1	Homo sapiens	142-145
15809765-7	2005	Paclitaxel treatment induced activation of the AKT survival pathway in a time-dependent manner.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	47-50
15809765-9	2005	These results indicate that paclitaxel activates both the PI3-K/AKT cell survival pathway followed by induction of apoptotic signals in cultured human keratinocytes.	Paclitaxel	28-38	AKT serine/threonine kinase 1	Homo sapiens	64-67
15809765-10	2005	The induction of apoptosis in paclitaxel-treated cells is enhanced by coadministration of IFN-gamma.	Paclitaxel	30-40	interferon gamma	Homo sapiens	90-99
15809765-11	2005	The synergistic effect of these two agents on HaCaT cells relies on a pathway involving caspases 8 and 3, with activity increasing by 48 h. Collectively, our data indicate that i) paclitaxel-induced apoptosis is enhanced by IFN-gamma; ii) the down-regulation of PI3-K/AKT survival pathway may help potentiate the apoptotic effects of paclitaxel and iii) the apoptotic signaling pathways are initiated with the activation of caspases 8 and 3 activities.	Paclitaxel	180-190	interferon gamma	Homo sapiens	224-233
15809765-11	2005	The synergistic effect of these two agents on HaCaT cells relies on a pathway involving caspases 8 and 3, with activity increasing by 48 h. Collectively, our data indicate that i) paclitaxel-induced apoptosis is enhanced by IFN-gamma; ii) the down-regulation of PI3-K/AKT survival pathway may help potentiate the apoptotic effects of paclitaxel and iii) the apoptotic signaling pathways are initiated with the activation of caspases 8 and 3 activities.	Paclitaxel	180-190	AKT serine/threonine kinase 1	Homo sapiens	268-271
15809765-11	2005	The synergistic effect of these two agents on HaCaT cells relies on a pathway involving caspases 8 and 3, with activity increasing by 48 h. Collectively, our data indicate that i) paclitaxel-induced apoptosis is enhanced by IFN-gamma; ii) the down-regulation of PI3-K/AKT survival pathway may help potentiate the apoptotic effects of paclitaxel and iii) the apoptotic signaling pathways are initiated with the activation of caspases 8 and 3 activities.	Paclitaxel	334-344	interferon gamma	Homo sapiens	224-233
15906172-6	2005	Paclitaxel association consistently increased in Caco-2 and Cor-L23/R as the size of the delivery system increased.	Paclitaxel	0-10	distribution of corticosterone in adrenal cortex cells	Mus musculus	60-63
15906172-9	2005	CONCLUSIONS: Cell-association of paclitaxel increased in 4T1, Caco-2, and Cor-L23/R as particle size increased.	Paclitaxel	33-43	distribution of corticosterone in adrenal cortex cells	Mus musculus	74-77
15864135-6	2005	CYP3A4-luciferase reporter assays revealed that the Q158K variant gave rise to much lower levels of CYP3A4 promoter activity in LS174T and HepG2 cells exposed to the PXR ligands, rifampin and paclitaxel, than did wild-type PXR.	Paclitaxel	192-202	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
15864135-6	2005	CYP3A4-luciferase reporter assays revealed that the Q158K variant gave rise to much lower levels of CYP3A4 promoter activity in LS174T and HepG2 cells exposed to the PXR ligands, rifampin and paclitaxel, than did wild-type PXR.	Paclitaxel	192-202	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-106
15864135-6	2005	CYP3A4-luciferase reporter assays revealed that the Q158K variant gave rise to much lower levels of CYP3A4 promoter activity in LS174T and HepG2 cells exposed to the PXR ligands, rifampin and paclitaxel, than did wild-type PXR.	Paclitaxel	192-202	nuclear receptor subfamily 1 group I member 2	Homo sapiens	166-169
15864135-6	2005	CYP3A4-luciferase reporter assays revealed that the Q158K variant gave rise to much lower levels of CYP3A4 promoter activity in LS174T and HepG2 cells exposed to the PXR ligands, rifampin and paclitaxel, than did wild-type PXR.	Paclitaxel	192-202	nuclear receptor subfamily 1 group I member 2	Homo sapiens	223-226
15820061-2	2005	This study was to establish a hypoxic model of ovarian cancer cell line A2780, and to investigate impacts of hypoxia and hypoxia inducible factor-1alpha (HIF-1alpha) on Taxol-induced apoptosis in A2780 cells.	Paclitaxel	169-174	hypoxia inducible factor 1 subunit alpha	Homo sapiens	121-152
15820061-2	2005	This study was to establish a hypoxic model of ovarian cancer cell line A2780, and to investigate impacts of hypoxia and hypoxia inducible factor-1alpha (HIF-1alpha) on Taxol-induced apoptosis in A2780 cells.	Paclitaxel	169-174	hypoxia inducible factor 1 subunit alpha	Homo sapiens	154-164
15820061-13	2005	HIF-1alpha might confer to resistance of cell apoptosis induced by Taxol.	Paclitaxel	67-72	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-10
15805287-1	2005	Taxol may contribute to intrinsic chemoresistance by activating the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) cytoprotective pathway in human cancer cell lines and tumors.	Paclitaxel	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	68-107
15805287-1	2005	Taxol may contribute to intrinsic chemoresistance by activating the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) cytoprotective pathway in human cancer cell lines and tumors.	Paclitaxel	0-5	mitogen-activated protein kinase kinase 7	Homo sapiens	109-112
15805287-1	2005	Taxol may contribute to intrinsic chemoresistance by activating the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) cytoprotective pathway in human cancer cell lines and tumors.	Paclitaxel	0-5	mitogen-activated protein kinase 1	Homo sapiens	153-156
15805287-2	2005	We have previously shown additivity between Taxol and the MEK inhibitor, U0126 in human cancer cell lines.	Paclitaxel	44-49	mitogen-activated protein kinase kinase 7	Homo sapiens	58-61
15805287-5	2005	Combined treatment with both drugs resulted in inhibition of tumor growth in all models and tumor regressions in three of four models tested, supporting our previous observation that Taxol"s efficacy is potentiated by MEK inhibition.	Paclitaxel	183-188	mitogen-activated protein kinase kinase 7	Homo sapiens	218-221
15788689-7	2005	The JNK inhibitor SP600125 substantially decreased the activation of caspases and apoptosis induced by MSeA combination with SN38 or etoposide and completely blocked these events induced by MSeA/paclitaxel.	Paclitaxel	195-205	mitogen-activated protein kinase 8	Homo sapiens	4-7
15725561-12	2005	Paclitaxel prodrug, a water-soluble compound concerning with its physicochemical properties, passes through the gastrointestinal mucosa more easily than paclitaxel without obstruction of P-gp and cytochrome P-450 in the gastrointestinal mucosa.	Paclitaxel	0-10	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	196-212
15563544-9	2005	Additionally, unliganded PR-A and PR-B both inhibit cell growth and provoke resistance to Taxol-induced apoptosis.	Paclitaxel	90-95	S100 calcium binding protein A6	Homo sapiens	25-29
15756002-6	2005	In addition, the overexpression of NEP enhanced susceptibility to paclitaxel, resulting in an increased occurrence of apoptotic morphologic change.	Paclitaxel	66-76	membrane metalloendopeptidase	Homo sapiens	35-38
15823106-0	2005	Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens.	Paclitaxel	87-97	C-X-C motif chemokine ligand 8	Homo sapiens	26-39
15823106-1	2005	Previous findings showed that paclitaxel induces interleukin-8 (IL-8) transcription and secretion in ovarian cancer cells in vitro.	Paclitaxel	30-40	C-X-C motif chemokine ligand 8	Homo sapiens	49-62
15823106-1	2005	Previous findings showed that paclitaxel induces interleukin-8 (IL-8) transcription and secretion in ovarian cancer cells in vitro.	Paclitaxel	30-40	C-X-C motif chemokine ligand 8	Homo sapiens	64-68
15823106-2	2005	We hypothesized that paclitaxel treatment, which is a standard care for ovarian cancer patients, may increase the secretion of IL-8, resulting in the elevated serum IL-8 levels.	Paclitaxel	21-31	C-X-C motif chemokine ligand 8	Homo sapiens	127-131
15823106-2	2005	We hypothesized that paclitaxel treatment, which is a standard care for ovarian cancer patients, may increase the secretion of IL-8, resulting in the elevated serum IL-8 levels.	Paclitaxel	21-31	C-X-C motif chemokine ligand 8	Homo sapiens	165-169
15823106-3	2005	In this study, we investigated the relationship between paclitaxel exposure and IL-8 levels of an ovarian and a breast carcinoma cell line in vitro and serums of patients with ovarian carcinoma.	Paclitaxel	56-66	C-X-C motif chemokine ligand 8	Homo sapiens	80-84
15823106-5	2005	However, supernatant levels of IL-8 assessed by enzyme-linked immunosorbent assay before and after treatment with different concentrations of paclitaxel were significantly lower in MCF-7 than in MDAH 2774.	Paclitaxel	142-152	C-X-C motif chemokine ligand 8	Homo sapiens	31-35
15823106-8	2005	The basal level of IL-8 after paclitaxel-containing treatment was found to be significantly higher in the serums of patients who had high tumor burden than in patients who had optimal debulking surgery and low tumor burden.	Paclitaxel	30-40	C-X-C motif chemokine ligand 8	Homo sapiens	19-23
15823106-9	2005	These data strongly suggest that IL-8 may be an important predictive marker for tumor volume as well as sensitivity to paclitaxel.	Paclitaxel	119-129	C-X-C motif chemokine ligand 8	Homo sapiens	33-37
16353081-0	2005	Contribution of nitric oxide and epidermal growth factor receptor in anti-metastatic potential of paclitaxel in human liver cancer cell (HebG2).	Paclitaxel	98-108	epidermal growth factor receptor	Homo sapiens	33-65
16353081-10	2005	In all of the HebG2 cells treated with paclitaxel (1.0-1000 nM) mRNA specific for EGFR, MMP-2 and MMP-9 were undetectable.	Paclitaxel	39-49	epidermal growth factor receptor	Homo sapiens	82-86
16353081-12	2005	CONCLUSION: This study suggests that: (1) increased production of NO may contribute to paclitaxel"s cytotoxicity against HebG2 cells, (2) paclitaxel may inhibit tumor metastasis via inhibition of the expression of EGFR and MMPs and (3) an inverse correlation exist between NO production and expression of EGFR and MMPs.	Paclitaxel	87-97	epidermal growth factor receptor	Homo sapiens	214-218
16353081-12	2005	CONCLUSION: This study suggests that: (1) increased production of NO may contribute to paclitaxel"s cytotoxicity against HebG2 cells, (2) paclitaxel may inhibit tumor metastasis via inhibition of the expression of EGFR and MMPs and (3) an inverse correlation exist between NO production and expression of EGFR and MMPs.	Paclitaxel	87-97	epidermal growth factor receptor	Homo sapiens	305-309
16353081-12	2005	CONCLUSION: This study suggests that: (1) increased production of NO may contribute to paclitaxel"s cytotoxicity against HebG2 cells, (2) paclitaxel may inhibit tumor metastasis via inhibition of the expression of EGFR and MMPs and (3) an inverse correlation exist between NO production and expression of EGFR and MMPs.	Paclitaxel	138-148	epidermal growth factor receptor	Homo sapiens	214-218
16353081-12	2005	CONCLUSION: This study suggests that: (1) increased production of NO may contribute to paclitaxel"s cytotoxicity against HebG2 cells, (2) paclitaxel may inhibit tumor metastasis via inhibition of the expression of EGFR and MMPs and (3) an inverse correlation exist between NO production and expression of EGFR and MMPs.	Paclitaxel	138-148	epidermal growth factor receptor	Homo sapiens	305-309
15692086-10	2005	Angiopoietin-1 promoted survival of serum-starved C2C12, HSM, and NCM (MTT, trypan blue) and prevented taxol-induced apoptosis (caspase-3).	Paclitaxel	103-108	angiopoietin 1	Mus musculus	0-14
15565326-6	2005	These genes included MDR1, a gene often implicated in both in vitro and in vivo resistance to multiple chemotherapeutics, including paclitaxel.	Paclitaxel	132-142	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
15711598-7	2005	Paclitaxel impairs microtubule function, causes G2/M cell cycle blockade, mitochondria damage, and p53-independent apoptosis.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	99-102
15668276-0	2005	Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.	Paclitaxel	105-115	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-10
15590651-0	2005	Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization.	Paclitaxel	17-22	nuclear factor kappa B subunit 1	Homo sapiens	81-102
15590651-0	2005	Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization.	Paclitaxel	17-22	AKT serine/threonine kinase 1	Homo sapiens	135-138
15590651-5	2005	This synergistic effect was not observed in normal cervical cells, 293 cells (in which Taxol down-regulates nuclear factor-kappaB (NF-kappaB)), or HeLa cells transfected with inhibitor kappaBalpha double mutant (IkappaBalpha DM), although the transfection itself sensitized the cells to Taxol-induced cytotoxicity.	Paclitaxel	87-92	nuclear factor kappa B subunit 1	Homo sapiens	108-129
15590651-5	2005	This synergistic effect was not observed in normal cervical cells, 293 cells (in which Taxol down-regulates nuclear factor-kappaB (NF-kappaB)), or HeLa cells transfected with inhibitor kappaBalpha double mutant (IkappaBalpha DM), although the transfection itself sensitized the cells to Taxol-induced cytotoxicity.	Paclitaxel	87-92	nuclear factor kappa B subunit 1	Homo sapiens	131-140
15590651-6	2005	Evaluation of signaling pathways common to Taxol and curcumin reveals that this synergism was in part related to down-regulation of NF-kappaB and serine/threonine kinase Akt pathways by curcumin.	Paclitaxel	43-48	nuclear factor kappa B subunit 1	Homo sapiens	132-141
15590651-6	2005	Evaluation of signaling pathways common to Taxol and curcumin reveals that this synergism was in part related to down-regulation of NF-kappaB and serine/threonine kinase Akt pathways by curcumin.	Paclitaxel	43-48	AKT serine/threonine kinase 1	Homo sapiens	170-173
15590651-7	2005	An electrophoretic mobility shift assay revealed that activation of NF-kappaB induced by Taxol is down-regulated by curcumin.	Paclitaxel	89-94	nuclear factor kappa B subunit 1	Homo sapiens	68-77
15590651-8	2005	We also noted that curcumin-down-regulated Taxol induced phosphorylation of the serine/threonine kinase Akt, a survival signal which in many instances is regulated by NF-kappaB.	Paclitaxel	43-48	AKT serine/threonine kinase 1	Homo sapiens	104-107
15590651-8	2005	We also noted that curcumin-down-regulated Taxol induced phosphorylation of the serine/threonine kinase Akt, a survival signal which in many instances is regulated by NF-kappaB.	Paclitaxel	43-48	nuclear factor kappa B subunit 1	Homo sapiens	167-176
15746064-4	2005	Here we have investigated the effect of combined treatment with ionizing radiation and patupilone or paclitaxel in the P-glycoprotein-overexpressing, p53-mutated human colon adenocarcinoma cell line SW480 and in murine, genetically defined E1A/ras-transformed paclitaxel-sensitive embryo fibroblasts.	Paclitaxel	101-111	tumor protein p53	Homo sapiens	150-153
15746064-7	2005	Inhibition of the drug efflux protein P-glycoprotein with verapamil resensitized SW480 cells to treatment with low doses of paclitaxel alone and in combination with IR.	Paclitaxel	124-134	ATP binding cassette subfamily B member 1	Homo sapiens	38-52
15590693-0	2005	Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.	Paclitaxel	79-89	nuclear receptor subfamily 3 group C member 1	Homo sapiens	0-23
15590693-0	2005	Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.	Paclitaxel	79-89	dual specificity phosphatase 1	Homo sapiens	32-50
15590693-0	2005	Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.	Paclitaxel	79-89	mitogen-activated protein kinase 3	Homo sapiens	32-36
15590693-6	2005	Paclitaxel treatment resulted in MAPK activation and apoptosis of MDA-MB-231 breast cancer cells, and both processes were inhibited by Dex pretreatment.	Paclitaxel	0-10	mitogen-activated protein kinase 3	Homo sapiens	33-37
15668276-0	2005	Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.	Paclitaxel	105-115	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-138
15681168-4	2005	If cells were treated with antineoplastic agents (taxol, doxorubicin or vinblastine), nuclear translocation of two NF-kappaB proteins (p50 and p65) was &gt;25% greater in biotin-deficient compared with biotin-supplemented cells.	Paclitaxel	50-55	nuclear factor kappa B subunit 1	Homo sapiens	115-124
15691646-1	2005	We measured the expression of the p53 nuclear protein and epidermal growth factor receptor (EGFR) in 46 biopsy samples from patients with advanced head and neck cancer treated with induction combination chemotherapy of 5-fluorouracil, cisplatin, and paclitaxel.	Paclitaxel	250-260	tumor protein p53	Homo sapiens	34-37
15757446-3	2005	For relapsed disease, the management hinges around the distinction between platinum-sensitive and -resistant cancer, and the recent AGO-2.5 and ICON-4 studies suggest that treating with carboplatin and paclitaxel or carboplatin and gemcitabine is recommended.	Paclitaxel	202-212	argonaute RISC catalytic component 2	Homo sapiens	132-137
15661210-8	2005	We found that Bcl-x(L) expression conferred resistance to chemotherapy-induced apoptosis resulting from treatment with cisplatin, paclitaxel, topotecan, and gemcitabine in vitro.	Paclitaxel	130-140	BCL2 like 1	Homo sapiens	14-22
15661210-9	2005	In a xenograft model, Bcl-x(L) expressing tumors continued to grow following treatment with cisplatin, paclitaxel, topotecan, and gemcitabine, in contrast to control tumors, which disappeared.	Paclitaxel	103-113	BCL2 like 1	Homo sapiens	22-30
15681168-4	2005	If cells were treated with antineoplastic agents (taxol, doxorubicin or vinblastine), nuclear translocation of two NF-kappaB proteins (p50 and p65) was &gt;25% greater in biotin-deficient compared with biotin-supplemented cells.	Paclitaxel	50-55	nuclear factor kappa B subunit 1	Homo sapiens	135-138
15713893-0	2005	Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3.	Paclitaxel	24-34	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
15713893-0	2005	Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3.	Paclitaxel	24-34	caspase 3	Homo sapiens	111-120
15643515-3	2005	Specifically, both RhoA and caRhoA induce statistically significant resistance to statin, etoposide, 5-FU and taxol while increasing sensitivity to vincristine (all p&lt;0.001).	Paclitaxel	110-115	ras homolog family member A	Homo sapiens	19-23
15700118-7	2005	With both drugs, the decrease in cellular paclitaxel sensitivity upon HER-2 inhibition is confirmed.	Paclitaxel	42-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-75
15700118-9	2005	Using clonal ribozyme-transfected SKOV-3 cells with different residual HER-2 levels, we establish a "HER-2 gene dose effect" of paclitaxel cytotoxicity.	Paclitaxel	128-138	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-76
15700118-9	2005	Using clonal ribozyme-transfected SKOV-3 cells with different residual HER-2 levels, we establish a "HER-2 gene dose effect" of paclitaxel cytotoxicity.	Paclitaxel	128-138	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-106
15700118-11	2005	Finally, paclitaxel- or HER-2-mediated alterations in the phosphorylation of MAP kinases p42/44, Stress-activated protein kinase/Jun-terminal kinase (SAPK/JNK), and p38, and effects on the activation of caspase-3, caspase-7, and bcl-2 are discussed.	Paclitaxel	9-19	mitogen-activated protein kinase 14	Homo sapiens	165-168
15700118-11	2005	Finally, paclitaxel- or HER-2-mediated alterations in the phosphorylation of MAP kinases p42/44, Stress-activated protein kinase/Jun-terminal kinase (SAPK/JNK), and p38, and effects on the activation of caspase-3, caspase-7, and bcl-2 are discussed.	Paclitaxel	9-19	caspase 3	Homo sapiens	203-212
15700118-11	2005	Finally, paclitaxel- or HER-2-mediated alterations in the phosphorylation of MAP kinases p42/44, Stress-activated protein kinase/Jun-terminal kinase (SAPK/JNK), and p38, and effects on the activation of caspase-3, caspase-7, and bcl-2 are discussed.	Paclitaxel	9-19	BCL2 apoptosis regulator	Homo sapiens	229-234
15700118-0	2005	Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells.	Paclitaxel	72-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-19
15700118-4	2005	In this paper, we explore the role of HER-2 expression and signaling levels pertaining to paclitaxel (Taxol) chemoresistance by applying three different and independent strategies in SKOV-3 ovarian carcinoma cells.	Paclitaxel	90-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-43
15700118-4	2005	In this paper, we explore the role of HER-2 expression and signaling levels pertaining to paclitaxel (Taxol) chemoresistance by applying three different and independent strategies in SKOV-3 ovarian carcinoma cells.	Paclitaxel	102-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-43
15700118-5	2005	Firstly, we show that treatment with the HER-2 inhibitory antibody trastuzumab (Herceptin), which is well established in tumor therapy, results in markedly increased, rather than decreased, cellular paclitaxel resistance.	Paclitaxel	199-209	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-46
15700118-12	2005	We conclude that paclitaxel cytotoxicity in SKOV-3 cells is "HER-2 dose-dependent" and identify cell proliferation as one underlying cellular event of this effect.	Paclitaxel	17-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-66
16110294-5	2005	As the recurrent tumor was confirmed to be HER2-positve (3+ by IHC), combination therapy with trastuzumab and paclitaxel was started.	Paclitaxel	110-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-47
15816553-2	2005	The phosphorylation of Bcl-2 is one mechanism by which anti-microtubule agents, such as paclitaxel or docetaxel, may inactivate Bcl-2.	Paclitaxel	88-98	BCL2, apoptosis regulator	Rattus norvegicus	23-28
15816553-2	2005	The phosphorylation of Bcl-2 is one mechanism by which anti-microtubule agents, such as paclitaxel or docetaxel, may inactivate Bcl-2.	Paclitaxel	88-98	BCL2, apoptosis regulator	Rattus norvegicus	128-133
15816553-6	2005	The BRK-p53 cell line was transfected with either a vector with wild type Bcl-2 or a vector in which Bcl-2 had mutations in the paclitaxel phosphorylation sites (pcDNA3.1 V5/His Bcl-2 S70, 87A).	Paclitaxel	128-138	BCL2, apoptosis regulator	Rattus norvegicus	101-106
15816553-6	2005	The BRK-p53 cell line was transfected with either a vector with wild type Bcl-2 or a vector in which Bcl-2 had mutations in the paclitaxel phosphorylation sites (pcDNA3.1 V5/His Bcl-2 S70, 87A).	Paclitaxel	128-138	BCL2, apoptosis regulator	Rattus norvegicus	101-106
15635178-8	2005	This suggests that the increase in paclitaxel sensitivity by Glycyrrhizae Radix, Rhei Rhizoma, Poria or Ephedrae Herba was caused, in part, by the inhibition of MDR1 function, and the change in paclitaxel sensitivity by the other herbal extracts was not always dependent on this.	Paclitaxel	35-45	ATP binding cassette subfamily B member 1	Homo sapiens	161-165
15592521-10	2005	Strikingly, CYR61 overexpression impaired the accumulation of wild-type p53 following Taxol exposure, while inhibition of alphavbeta3 or ERK1/ERK2 MAPK signalings completely restored Taxol-induced upregulation of p53.	Paclitaxel	86-91	tumor protein p53	Homo sapiens	72-75
15592521-10	2005	Strikingly, CYR61 overexpression impaired the accumulation of wild-type p53 following Taxol exposure, while inhibition of alphavbeta3 or ERK1/ERK2 MAPK signalings completely restored Taxol-induced upregulation of p53.	Paclitaxel	183-188	mitogen-activated protein kinase 3	Homo sapiens	137-141
15592521-10	2005	Strikingly, CYR61 overexpression impaired the accumulation of wild-type p53 following Taxol exposure, while inhibition of alphavbeta3 or ERK1/ERK2 MAPK signalings completely restored Taxol-induced upregulation of p53.	Paclitaxel	183-188	mitogen-activated protein kinase 1	Homo sapiens	142-146
15592521-10	2005	Strikingly, CYR61 overexpression impaired the accumulation of wild-type p53 following Taxol exposure, while inhibition of alphavbeta3 or ERK1/ERK2 MAPK signalings completely restored Taxol-induced upregulation of p53.	Paclitaxel	183-188	tumor protein p53	Homo sapiens	213-216
15455390-0	2005	Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.	Paclitaxel	32-42	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	116-121
15455390-4	2005	Exposing human umbilical vein ECs to low nanomolar (1-50 nM) concentrations of paclitaxel enhanced Cox-2 expression more than 2-fold, as measured by ELISA.	Paclitaxel	79-89	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	99-104
15582593-0	2005	Induction of expression of inducible nitric oxide synthase by Taxol in murine macrophage cells.	Paclitaxel	62-67	nitric oxide synthase 2, inducible	Mus musculus	27-58
15582593-2	2005	We examined the mechanism by which Taxol regulates the expression of inducible nitric oxide synthase (iNOS) in a murine macrophage cell line.	Paclitaxel	35-40	nitric oxide synthase 2, inducible	Mus musculus	69-100
15582593-2	2005	We examined the mechanism by which Taxol regulates the expression of inducible nitric oxide synthase (iNOS) in a murine macrophage cell line.	Paclitaxel	35-40	nitric oxide synthase 2, inducible	Mus musculus	102-106
15582593-3	2005	Taxol alone induced iNOS mRNA and promoter activity, but no iNOS protein or NO production.	Paclitaxel	0-5	nitric oxide synthase 2, inducible	Mus musculus	20-24
15582593-4	2005	The stability of the iNOS mRNA formed in response to Taxol was lower than that formed in response to IFN-gamma or LPS, and this may have been responsible for the lack of induction of iNOS protein and NO.	Paclitaxel	53-58	nitric oxide synthase 2, inducible	Mus musculus	21-25
15582593-5	2005	However, IFN-gamma synergized with Taxol by increasing iNOS mRNA stability, and upregulating levels of iNOS mRNA and protein, promoter activity, and NO production.	Paclitaxel	35-40	nitric oxide synthase 2, inducible	Mus musculus	55-59
15582593-6	2005	Transfection experiments with 5"-serial deletions and site-directed mutants of the iNOS promoter revealed that the pair of upstream and downstream NF-kappaB sites was crucial for promoter activity in response to Taxol, as in the case of LPS.	Paclitaxel	212-217	nitric oxide synthase 2, inducible	Mus musculus	83-87
15582593-7	2005	Electrophoretic mobility shift assays showed that both Taxol and LPS rapidly activated identical NF-kappaB complexes that could bind to the iNOS promoter.	Paclitaxel	55-60	nitric oxide synthase 2, inducible	Mus musculus	140-144
15582593-8	2005	These results suggest that Taxol shares a signaling pathway for transcriptional activation of iNOS with LPS, but that the stability of the iNOS mRNA induced by Taxol is different from that induced by LPS.	Paclitaxel	27-32	nitric oxide synthase 2, inducible	Mus musculus	94-98
15582593-8	2005	These results suggest that Taxol shares a signaling pathway for transcriptional activation of iNOS with LPS, but that the stability of the iNOS mRNA induced by Taxol is different from that induced by LPS.	Paclitaxel	160-165	nitric oxide synthase 2, inducible	Mus musculus	139-143
16280040-6	2005	Treatment of BT-474, ZR-75-1, and MDA-MB-231 cells with AS Bcl-2 increased chemosensitivity to doxorubicin (DOX), mitomycin C (MMC), paclitaxel (TXL), and docetaxel (TXT).	Paclitaxel	133-143	BCL2 apoptosis regulator	Homo sapiens	59-64
15662138-0	2005	The tumor suppressor p33ING1b enhances taxol-induced apoptosis by p53-dependent pathway in human osteosarcoma U2OS cells.	Paclitaxel	39-44	tumor protein p53	Homo sapiens	66-69
15662138-4	2005	The results showed that p33ING1b markedly increased taxol-induced growth inhibition and apoptosis in p53+/+ U2OS cells, but not in p53-mutant MG63 cells.	Paclitaxel	52-57	tumor protein p53	Homo sapiens	101-104
16122187-1	2005	PURPOSE: In this study the relationship between therapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and of the expression of proliferation markers (ki67 and S-phase fraction) and tumour suppressor gene p53 was analyzed using a human ovarian cancer xenograft model.	Paclitaxel	61-71	tumor protein p53	Homo sapiens	224-227
16360542-9	2005	HER2-positive patients had a lower ORR to gemcitabine-paclitaxel chemotherapy than women who were HER2-negative.	Paclitaxel	54-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
15662138-5	2005	Moreover, ectopic expression of p33ING1b could obviously upregulate p53, p21WAF1 and bax protein levels and activate caspase-3 in taxol-treated U2OS cells.	Paclitaxel	130-135	caspase 3	Homo sapiens	117-126
15662138-6	2005	Taken together, our data demonstrate that p33ING1b enhances taxol-induced apoptosis through p53-dependent pathway in human osteosarcoma cells.	Paclitaxel	60-65	tumor protein p53	Homo sapiens	92-95
16193644-7	2005	Among these examples are the coadministration of paclitaxel with CsA, a CYP3A4 substrate with P-glycoprotein (P-gp) modulating activity, and topotecan combined with the BCRP/P-gp transport inhibitor elacridar.	Paclitaxel	49-59	ATP binding cassette subfamily B member 1	Homo sapiens	94-108
16193644-7	2005	Among these examples are the coadministration of paclitaxel with CsA, a CYP3A4 substrate with P-glycoprotein (P-gp) modulating activity, and topotecan combined with the BCRP/P-gp transport inhibitor elacridar.	Paclitaxel	49-59	ATP binding cassette subfamily B member 1	Homo sapiens	110-114
15655291-0	2005	Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4.	Paclitaxel	75-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	111-117
15796181-8	2005	When cetuximab was combined with cisplatin or paclitaxel in the HK1 and HONE-1 cell lines, an additive enhancement of cytotoxic drug activity was demonstrated.	Paclitaxel	46-56	hexokinase 1	Homo sapiens	64-67
15655291-2	2005	Paclitaxel is metabolized by CYP2C8 and CYP3A4, and these enzymes are known to differ between individuals, although the details have not been clarified.	Paclitaxel	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46
15655291-4	2005	We investigated the effect of the polymorphisms on paclitaxel metabolism by analyzing metabolic activities of CYP2C8 and CYP3A4 and expressions of mRNA and protein.	Paclitaxel	51-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
15655291-9	2005	Inter-individual differences in paclitaxel metabolism may be related to CYP2C8 and CYP3A4 mRNA expression.	Paclitaxel	32-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
16037687-10	2005	Pretreatment of EGFR inhibitors by 24 h significantly enhanced the cytotoxic effect of doxorubicin, paclitaxel, cisplatin, and 5-fluororuacil in NPC-TW04 cells.	Paclitaxel	100-110	epidermal growth factor receptor	Homo sapiens	16-20
15585932-5	2005	The synthesis, antigen binding, and cytotoxicity of a covalent conjugate of the anticancer drug paclitaxel (taxol) to the anti-epidermal growth factor receptor (EGFR) monoclonal antibody C225 (IMC-C225; Erbitux, ImClone Systems, Somerville, NJ) are described in this chapter to illustrate the methods used for the construction and in vitro evaluation of these conjugates.	Paclitaxel	96-106	epidermal growth factor receptor	Homo sapiens	122-159
15585932-5	2005	The synthesis, antigen binding, and cytotoxicity of a covalent conjugate of the anticancer drug paclitaxel (taxol) to the anti-epidermal growth factor receptor (EGFR) monoclonal antibody C225 (IMC-C225; Erbitux, ImClone Systems, Somerville, NJ) are described in this chapter to illustrate the methods used for the construction and in vitro evaluation of these conjugates.	Paclitaxel	96-106	epidermal growth factor receptor	Homo sapiens	161-165
15585932-5	2005	The synthesis, antigen binding, and cytotoxicity of a covalent conjugate of the anticancer drug paclitaxel (taxol) to the anti-epidermal growth factor receptor (EGFR) monoclonal antibody C225 (IMC-C225; Erbitux, ImClone Systems, Somerville, NJ) are described in this chapter to illustrate the methods used for the construction and in vitro evaluation of these conjugates.	Paclitaxel	108-113	epidermal growth factor receptor	Homo sapiens	122-159
15585932-5	2005	The synthesis, antigen binding, and cytotoxicity of a covalent conjugate of the anticancer drug paclitaxel (taxol) to the anti-epidermal growth factor receptor (EGFR) monoclonal antibody C225 (IMC-C225; Erbitux, ImClone Systems, Somerville, NJ) are described in this chapter to illustrate the methods used for the construction and in vitro evaluation of these conjugates.	Paclitaxel	108-113	epidermal growth factor receptor	Homo sapiens	161-165
16127286-8	2005	Although untreated mutant p53 tumors may be responsive to first-line paclitaxel-containing therapy, it is likely that loss of p53 leads to genomic instability resulting in rapid progression to drug resistance.	Paclitaxel	69-79	tumor protein p53	Homo sapiens	26-29
15581863-10	2004	Microtubule stabilization with Taxol, however, redistributes WAVE1 to the centrosome, and anti-WAVE1 antibodies prevent both the nuclear distribution of WAVE1 and the migration and apposition of pronuclei.	Paclitaxel	31-36	WASP family member 1	Homo sapiens	61-66
16092668-0	2005	Prognostic value of immunohistochemical estimation of CD24 and Ki67 expression in cisplatin and paclitaxel treated ovarian carcinoma patients.	Paclitaxel	96-106	CD24 molecule	Homo sapiens	54-58
15576491-5	2004	MT stabilization by taxol attenuated thrombin-induced permeability, actin remodeling, and paracellular gap formation and diminished thrombin-induced activation of Rho and Rho-kinase.	Paclitaxel	20-25	coagulation factor II, thrombin	Homo sapiens	37-45
15578411-2	2004	Inflammation resolved coincident with decreases in the CD4(+) lymphocyte count during paclitaxel treatment, whereas KS cleared only after prolonged antiretroviral therapy and chemotherapy.	Paclitaxel	86-96	CD4 molecule	Homo sapiens	55-58
15340759-5	2004	Simultaneous exposure to pemetrexed and paclitaxel for 24 h produced antagonistic effects in A549 and PA1 cells, additive/antagonistic effects in MCF7 cells, and additive effects in WiDr cells.	Paclitaxel	40-50	PAXIP1 associated glutamate rich protein 1	Homo sapiens	102-105
15340759-6	2004	Pemetrexed for 24 h followed by paclitaxel for 24 h produced synergistic effects in A549 and MCF7 cells and additive effects in PA1 and WiDr cells, while the reverse sequence produced additive effects in all four cell lines.	Paclitaxel	32-42	PAXIP1 associated glutamate rich protein 1	Homo sapiens	128-131
20641303-3	2004	One of the mechanisms of cells to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and taxol, is to limit their presence inside the cells by a multidrug resistance (MDR-1) gene protein.	Paclitaxel	168-173	ATP binding cassette subfamily B member 1	Homo sapiens	246-251
15452117-6	2004	However, despite the release of cytochrome c from the mitochondria in taxol-treated cells, caspase-9 was not activated.	Paclitaxel	70-75	cytochrome c, somatic	Homo sapiens	32-44
15700849-7	2004	Differential sensitivity in a set of Taxol-resistant lines correlated to the expression of P-glycoprotein (P-gp), and its importance was demonstrated directly.	Paclitaxel	37-42	ATP binding cassette subfamily B member 1	Homo sapiens	91-105
15700849-7	2004	Differential sensitivity in a set of Taxol-resistant lines correlated to the expression of P-glycoprotein (P-gp), and its importance was demonstrated directly.	Paclitaxel	37-42	ATP binding cassette subfamily B member 1	Homo sapiens	107-111
15685822-3	2004	Because an unplanned subgroup analysis in CALGB 9344 indicated a significant benefit of paclitaxel in patients with estrogen receptor (ER)-negative disease but not ER-positive disease, the initial tAnGo trial design called for enrollment of patients with ER-negative disease.	Paclitaxel	88-98	estrogen receptor 1	Homo sapiens	116-133
15304522-7	2004	Simultaneous inactivation of CYP2C8 and CYP3A4 (paclitaxel 3"-phenyl-hydroxylation) was observed using amiodarone, isoniazid, and phenelzine with the efficiency of inactivation greater for the CYP3A4 pathway.	Paclitaxel	48-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46
15304522-7	2004	Simultaneous inactivation of CYP2C8 and CYP3A4 (paclitaxel 3"-phenyl-hydroxylation) was observed using amiodarone, isoniazid, and phenelzine with the efficiency of inactivation greater for the CYP3A4 pathway.	Paclitaxel	48-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	193-199
15685822-3	2004	Because an unplanned subgroup analysis in CALGB 9344 indicated a significant benefit of paclitaxel in patients with estrogen receptor (ER)-negative disease but not ER-positive disease, the initial tAnGo trial design called for enrollment of patients with ER-negative disease.	Paclitaxel	88-98	estrogen receptor 1	Homo sapiens	135-137
15557095-6	2004	Recombinant SPR2 protein directly bound to taxol-stabilized microtubules in vitro.	Paclitaxel	43-48	ARM repeat superfamily protein	Arabidopsis thaliana	12-16
15501691-7	2004	Nevertheless, our recent findings have revealed that mTOR may be also involved in a signaling pathway activated by microtubule-damaging drugs, including taxol and nocodazole.	Paclitaxel	153-158	mechanistic target of rapamycin kinase	Homo sapiens	53-57
15599832-3	2004	There is now evidence that PS2 patients with advanced NSCLC can benefit from single-agent chemotherapy with drugs such as vinorelbine, gemcitabine, paclitaxel, pemetrexed, and docetaxel and that combination chemotherapy may have additional advantages.	Paclitaxel	148-158	taste 2 receptor member 64 pseudogene	Homo sapiens	27-30
15599829-9	2004	A recent subset analysis of PS2 patients enrolled in a trial comparing carboplatin and paclitaxel with single-agent paclitaxel suggests that combination chemotherapy is a feasible option and is potentially preferable to single-agent therapy.	Paclitaxel	87-97	taste 2 receptor member 64 pseudogene	Homo sapiens	28-31
15369823-2	2004	Taxol bears an acetate at C10 and another at C4 thought to originate by intramolecular migration of a C5 acetate function in the process of oxetane ring formation, but many other naturally occurring taxoids bear acetate groups at C1, C2, C7, C9, and C13, in addition to C5 and C10.	Paclitaxel	0-5	homeobox C10	Homo sapiens	26-29
15599829-9	2004	A recent subset analysis of PS2 patients enrolled in a trial comparing carboplatin and paclitaxel with single-agent paclitaxel suggests that combination chemotherapy is a feasible option and is potentially preferable to single-agent therapy.	Paclitaxel	116-126	taste 2 receptor member 64 pseudogene	Homo sapiens	28-31
15514565-0	2004	G2/M blockade by paclitaxel induces caveolin-1 expression in A549 lung cancer cells: caveolin-1 as a marker of cytotoxicity.	Paclitaxel	17-27	caveolin 1	Homo sapiens	36-46
15514565-0	2004	G2/M blockade by paclitaxel induces caveolin-1 expression in A549 lung cancer cells: caveolin-1 as a marker of cytotoxicity.	Paclitaxel	17-27	caveolin 1	Homo sapiens	85-95
15514565-2	2004	Exposure to low doses of paclitaxel (taxol) is sufficient to up-regulate caveolin-1, suggesting that a mild cytotoxic stress induces a response implying caveolin and caveolae.	Paclitaxel	25-35	caveolin 1	Homo sapiens	73-83
15514565-2	2004	Exposure to low doses of paclitaxel (taxol) is sufficient to up-regulate caveolin-1, suggesting that a mild cytotoxic stress induces a response implying caveolin and caveolae.	Paclitaxel	37-42	caveolin 1	Homo sapiens	73-83
15717739-3	2004	Pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), is the only liposomal anthracycline indicated for second-line treatment of platinum- and paclitaxel-refractory ovarian cancer.	Paclitaxel	143-153	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	47-50
15476281-8	2004	Drug sensitivity to doxorubicin, cisplatin, and paclitaxel (TXL) was increased 3-4-fold when used in combination with AS bcl-2, which was determined with 50% inhibitory concentration values, compared with the control group.	Paclitaxel	48-58	BCL2 apoptosis regulator	Homo sapiens	121-126
15569997-0	2004	Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.	Paclitaxel	91-101	nuclear factor kappa B subunit 1	Homo sapiens	27-48
15569997-1	2004	We investigated whether inhibition of nuclear factor-kappaB (NFkappaB) increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.	Paclitaxel	97-107	nuclear factor kappa B subunit 1	Homo sapiens	38-59
15569997-1	2004	We investigated whether inhibition of nuclear factor-kappaB (NFkappaB) increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.	Paclitaxel	97-107	nuclear factor kappa B subunit 1	Homo sapiens	61-69
15569997-2	2004	Treatment of paclitaxel-sensitive Caov-3 cells with paclitaxel transiently activated the phosphorylation of Akt, the phosphorylation of IkappaB kinase (IKK), and the phosphorylation of inhibitor of NFkappaB (IkappaBalpha).	Paclitaxel	13-23	AKT serine/threonine kinase 1	Homo sapiens	108-111
15569997-2	2004	Treatment of paclitaxel-sensitive Caov-3 cells with paclitaxel transiently activated the phosphorylation of Akt, the phosphorylation of IkappaB kinase (IKK), and the phosphorylation of inhibitor of NFkappaB (IkappaBalpha).	Paclitaxel	13-23	nuclear factor kappa B subunit 1	Homo sapiens	198-206
15569997-2	2004	Treatment of paclitaxel-sensitive Caov-3 cells with paclitaxel transiently activated the phosphorylation of Akt, the phosphorylation of IkappaB kinase (IKK), and the phosphorylation of inhibitor of NFkappaB (IkappaBalpha).	Paclitaxel	13-23	NFKB inhibitor alpha	Homo sapiens	208-220
15569997-2	2004	Treatment of paclitaxel-sensitive Caov-3 cells with paclitaxel transiently activated the phosphorylation of Akt, the phosphorylation of IkappaB kinase (IKK), and the phosphorylation of inhibitor of NFkappaB (IkappaBalpha).	Paclitaxel	52-62	AKT serine/threonine kinase 1	Homo sapiens	108-111
15569997-2	2004	Treatment of paclitaxel-sensitive Caov-3 cells with paclitaxel transiently activated the phosphorylation of Akt, the phosphorylation of IkappaB kinase (IKK), and the phosphorylation of inhibitor of NFkappaB (IkappaBalpha).	Paclitaxel	52-62	nuclear factor kappa B subunit 1	Homo sapiens	198-206
15569997-2	2004	Treatment of paclitaxel-sensitive Caov-3 cells with paclitaxel transiently activated the phosphorylation of Akt, the phosphorylation of IkappaB kinase (IKK), and the phosphorylation of inhibitor of NFkappaB (IkappaBalpha).	Paclitaxel	52-62	NFKB inhibitor alpha	Homo sapiens	208-220
15569997-3	2004	Paclitaxel also caused a transient increase in NFkappaB activity, followed by a decrease in NFkappaB activity.	Paclitaxel	0-10	nuclear factor kappa B subunit 1	Homo sapiens	47-55
15569997-3	2004	Paclitaxel also caused a transient increase in NFkappaB activity, followed by a decrease in NFkappaB activity.	Paclitaxel	0-10	nuclear factor kappa B subunit 1	Homo sapiens	92-100
15569997-4	2004	We show an association between Akt and IKK and show that the phosphorylation of IKK induced by paclitaxel is blocked by treatment with a phosphatidylinositol 3-kinase inhibitor (wortmannin or LY294002).	Paclitaxel	95-105	AKT serine/threonine kinase 1	Homo sapiens	31-34
15569997-5	2004	Furthermore, interference of the Akt signaling cascade inhibits the transient induction of IkappaBalpha phosphorylation and NFkappaB activity by paclitaxel.	Paclitaxel	145-155	AKT serine/threonine kinase 1	Homo sapiens	33-36
15569997-5	2004	Furthermore, interference of the Akt signaling cascade inhibits the transient induction of IkappaBalpha phosphorylation and NFkappaB activity by paclitaxel.	Paclitaxel	145-155	NFKB inhibitor alpha	Homo sapiens	91-103
15569997-5	2004	Furthermore, interference of the Akt signaling cascade inhibits the transient induction of IkappaBalpha phosphorylation and NFkappaB activity by paclitaxel.	Paclitaxel	145-155	nuclear factor kappa B subunit 1	Homo sapiens	124-132
15569997-6	2004	Inhibition of NFkappaB activity by treatment with an IkappaBalpha phosphorylation inhibitor (BAY 11-7085) attenuated both basal and transient induction of IkappaBalpha phosphorylation by paclitaxel.	Paclitaxel	187-197	nuclear factor kappa B subunit 1	Homo sapiens	14-22
15569997-6	2004	Inhibition of NFkappaB activity by treatment with an IkappaBalpha phosphorylation inhibitor (BAY 11-7085) attenuated both basal and transient induction of IkappaBalpha phosphorylation by paclitaxel.	Paclitaxel	187-197	NFKB inhibitor alpha	Homo sapiens	53-65
15569997-6	2004	Inhibition of NFkappaB activity by treatment with an IkappaBalpha phosphorylation inhibitor (BAY 11-7085) attenuated both basal and transient induction of IkappaBalpha phosphorylation by paclitaxel.	Paclitaxel	187-197	NFKB inhibitor alpha	Homo sapiens	155-167
15569997-7	2004	Treatment with BAY 11-7085 also enhanced the inhibition of NFkappaB activity by paclitaxel for up to 24 hours.	Paclitaxel	80-90	nuclear factor kappa B subunit 1	Homo sapiens	59-67
15569997-10	2004	These results suggest that paclitaxel transiently induces NFkappaB activity via the phosphatidylinositol 3-kinase/Akt cascade and that combination therapy with paclitaxel and an NFkappaB inhibitor would increase the therapeutic efficacy of paclitaxel.	Paclitaxel	27-37	nuclear factor kappa B subunit 1	Homo sapiens	58-66
15569997-10	2004	These results suggest that paclitaxel transiently induces NFkappaB activity via the phosphatidylinositol 3-kinase/Akt cascade and that combination therapy with paclitaxel and an NFkappaB inhibitor would increase the therapeutic efficacy of paclitaxel.	Paclitaxel	27-37	AKT serine/threonine kinase 1	Homo sapiens	114-117
15569997-10	2004	These results suggest that paclitaxel transiently induces NFkappaB activity via the phosphatidylinositol 3-kinase/Akt cascade and that combination therapy with paclitaxel and an NFkappaB inhibitor would increase the therapeutic efficacy of paclitaxel.	Paclitaxel	27-37	nuclear factor kappa B subunit 1	Homo sapiens	178-186
15569997-10	2004	These results suggest that paclitaxel transiently induces NFkappaB activity via the phosphatidylinositol 3-kinase/Akt cascade and that combination therapy with paclitaxel and an NFkappaB inhibitor would increase the therapeutic efficacy of paclitaxel.	Paclitaxel	160-170	nuclear factor kappa B subunit 1	Homo sapiens	58-66
15569997-10	2004	These results suggest that paclitaxel transiently induces NFkappaB activity via the phosphatidylinositol 3-kinase/Akt cascade and that combination therapy with paclitaxel and an NFkappaB inhibitor would increase the therapeutic efficacy of paclitaxel.	Paclitaxel	160-170	nuclear factor kappa B subunit 1	Homo sapiens	58-66
15491750-4	2004	METHODS: Here, we investigated the effect of P-LAP to response for paclitaxel and carboplatin in advanced and recurrence endometrial carcinoma.	Paclitaxel	67-77	leucyl and cystinyl aminopeptidase	Homo sapiens	45-50
15369823-2	2004	Taxol bears an acetate at C10 and another at C4 thought to originate by intramolecular migration of a C5 acetate function in the process of oxetane ring formation, but many other naturally occurring taxoids bear acetate groups at C1, C2, C7, C9, and C13, in addition to C5 and C10.	Paclitaxel	0-5	homeobox C10	Homo sapiens	277-280
15501983-10	2004	Furthermore, rapamycin enhanced chemosensitivity to paclitaxel and carboplatin in HER2/neu-overexpressing cells, suggesting a potential approach to these poorly behaving tumors.	Paclitaxel	52-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
15492279-8	2004	After complete blockade of PTX-induced TP translation by TP antisense transfection, cleaved form of caspase-3 and poly(ADP-ribose) polymerase was increased, and this exaggeration of apoptosis also ran parallel with caspase-8 activation in a PTX dose-dependent manner.	Paclitaxel	27-30	caspase 3	Homo sapiens	100-109
15492279-8	2004	After complete blockade of PTX-induced TP translation by TP antisense transfection, cleaved form of caspase-3 and poly(ADP-ribose) polymerase was increased, and this exaggeration of apoptosis also ran parallel with caspase-8 activation in a PTX dose-dependent manner.	Paclitaxel	27-30	poly(ADP-ribose) polymerase 1	Homo sapiens	114-141
15492279-8	2004	After complete blockade of PTX-induced TP translation by TP antisense transfection, cleaved form of caspase-3 and poly(ADP-ribose) polymerase was increased, and this exaggeration of apoptosis also ran parallel with caspase-8 activation in a PTX dose-dependent manner.	Paclitaxel	241-244	caspase 3	Homo sapiens	100-109
15197489-6	2004	Upon paclitaxel treatment, caspase-2, caspase-3, and caspase-8 were activated in BCBL-1 cells.	Paclitaxel	5-15	caspase 3	Homo sapiens	38-47
15582895-0	2004	4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.	Paclitaxel	42-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-92
15582895-26	2004	- Trastuzumab and paclitaxel have shown activity and good tolerability in HER-2/neu overexpressing advanced breast cancer patients.	Paclitaxel	18-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-83
15197489-8	2004	Paclitaxel-induced apoptosis was also accompanied by an increase in the protein levels of Bax, and this effect was attenuated by antioxidants.	Paclitaxel	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	90-93
15197489-9	2004	Paclitaxel slightly decreased the expression of Bcl-2 protein, but antioxidants induced Bcl-2 protein.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	48-53
15467449-6	2004	Together, these findings suggest that p21(Cip1/WAF1) partially protects p53-null human leukemia cells from paclitaxel-mediated lethality, and raise the possibility that p21(Cip1/WAF1)-associated perturbations in signal transduction pathways as well as Bcl-2 phosphorylation status may play a role in this phenomenon.	Paclitaxel	107-117	cyclin dependent kinase inhibitor 1A	Homo sapiens	169-172
15467449-0	2004	The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells.	Paclitaxel	60-70	cyclin dependent kinase inhibitor 1A	Homo sapiens	38-41
15466208-2	2004	Rituximab treatment of Bcl-2-deficient Ramos cells and Bcl-2-expressing Daudi cells selectively decreases Bcl-(xL) expression and sensitizes the cells to paclitaxel-induced apoptosis.	Paclitaxel	154-164	BCL2 apoptosis regulator	Homo sapiens	23-28
15466208-2	2004	Rituximab treatment of Bcl-2-deficient Ramos cells and Bcl-2-expressing Daudi cells selectively decreases Bcl-(xL) expression and sensitizes the cells to paclitaxel-induced apoptosis.	Paclitaxel	154-164	BCL2 apoptosis regulator	Homo sapiens	55-60
15467449-6	2004	Together, these findings suggest that p21(Cip1/WAF1) partially protects p53-null human leukemia cells from paclitaxel-mediated lethality, and raise the possibility that p21(Cip1/WAF1)-associated perturbations in signal transduction pathways as well as Bcl-2 phosphorylation status may play a role in this phenomenon.	Paclitaxel	107-117	cyclin dependent kinase inhibitor 1A	Homo sapiens	173-177
15467449-0	2004	The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells.	Paclitaxel	60-70	cyclin dependent kinase inhibitor 1A	Homo sapiens	42-46
15467449-0	2004	The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells.	Paclitaxel	60-70	cyclin dependent kinase inhibitor 1A	Homo sapiens	47-51
15467449-1	2004	The functional significance of the cyclin-dependent kinase inhibitor (CDKI) p21(Cip1/WAF1) in paclitaxel-mediated lethality was examined in p53-null human leukemia cells (U937 and Jurkat).	Paclitaxel	94-104	cyclin dependent kinase inhibitor 1A	Homo sapiens	76-79
15466208-7	2004	Rituximab-mediated effects were corroborated by using specific inhibitors of the ERK1/2 pathway, which also reduced Bcl-(xL) levels and sensitized the NHL B cells to paclitaxel-induced apoptosis.	Paclitaxel	166-176	mitogen-activated protein kinase 3	Homo sapiens	81-87
15467449-6	2004	Together, these findings suggest that p21(Cip1/WAF1) partially protects p53-null human leukemia cells from paclitaxel-mediated lethality, and raise the possibility that p21(Cip1/WAF1)-associated perturbations in signal transduction pathways as well as Bcl-2 phosphorylation status may play a role in this phenomenon.	Paclitaxel	107-117	cyclin dependent kinase inhibitor 1A	Homo sapiens	178-182
15467449-1	2004	The functional significance of the cyclin-dependent kinase inhibitor (CDKI) p21(Cip1/WAF1) in paclitaxel-mediated lethality was examined in p53-null human leukemia cells (U937 and Jurkat).	Paclitaxel	94-104	cyclin dependent kinase inhibitor 1A	Homo sapiens	80-84
15467449-1	2004	The functional significance of the cyclin-dependent kinase inhibitor (CDKI) p21(Cip1/WAF1) in paclitaxel-mediated lethality was examined in p53-null human leukemia cells (U937 and Jurkat).	Paclitaxel	94-104	cyclin dependent kinase inhibitor 1A	Homo sapiens	85-89
15467450-0	2004	JNK is associated with Bcl-2 and PP1 in mitochondria: paclitaxel induces its activation and its association with the phosphorylated form of Bcl-2.	Paclitaxel	54-64	mitogen-activated protein kinase 8	Homo sapiens	0-3
15467449-3	2004	Nevertheless, stable expression of U937 cells with a p21(Cip1/WAF1) antisense construct blocked paclitaxel-induced G(2)M arrest and increased mitochondrial injury, caspase activation, apoptosis, and loss of clonogenic potential.	Paclitaxel	96-106	cyclin dependent kinase inhibitor 1A	Homo sapiens	53-56
15467449-3	2004	Nevertheless, stable expression of U937 cells with a p21(Cip1/WAF1) antisense construct blocked paclitaxel-induced G(2)M arrest and increased mitochondrial injury, caspase activation, apoptosis, and loss of clonogenic potential.	Paclitaxel	96-106	cyclin dependent kinase inhibitor 1A	Homo sapiens	57-61
15467450-0	2004	JNK is associated with Bcl-2 and PP1 in mitochondria: paclitaxel induces its activation and its association with the phosphorylated form of Bcl-2.	Paclitaxel	54-64	BCL2 apoptosis regulator	Homo sapiens	23-28
15467449-3	2004	Nevertheless, stable expression of U937 cells with a p21(Cip1/WAF1) antisense construct blocked paclitaxel-induced G(2)M arrest and increased mitochondrial injury, caspase activation, apoptosis, and loss of clonogenic potential.	Paclitaxel	96-106	cyclin dependent kinase inhibitor 1A	Homo sapiens	62-66
15467449-4	2004	Consistent with these results, enforced expression of p21(Cip1/WAF1) in Jurkat cells increased the percentage of cells arrested in G2M and attenuated paclitaxel-mediated mitochondrial injury and apoptosis.	Paclitaxel	150-160	cyclin dependent kinase inhibitor 1A	Homo sapiens	54-57
15467450-0	2004	JNK is associated with Bcl-2 and PP1 in mitochondria: paclitaxel induces its activation and its association with the phosphorylated form of Bcl-2.	Paclitaxel	54-64	inorganic pyrophosphatase 1	Homo sapiens	33-36
15467449-4	2004	Consistent with these results, enforced expression of p21(Cip1/WAF1) in Jurkat cells increased the percentage of cells arrested in G2M and attenuated paclitaxel-mediated mitochondrial injury and apoptosis.	Paclitaxel	150-160	cyclin dependent kinase inhibitor 1A	Homo sapiens	58-62
15467449-4	2004	Consistent with these results, enforced expression of p21(Cip1/WAF1) in Jurkat cells increased the percentage of cells arrested in G2M and attenuated paclitaxel-mediated mitochondrial injury and apoptosis.	Paclitaxel	150-160	cyclin dependent kinase inhibitor 1A	Homo sapiens	63-67
15467449-5	2004	Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation.	Paclitaxel	63-73	cyclin dependent kinase inhibitor 1A	Homo sapiens	37-40
15467449-5	2004	Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation.	Paclitaxel	63-73	cyclin dependent kinase inhibitor 1A	Homo sapiens	41-45
15467449-5	2004	Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation.	Paclitaxel	63-73	cyclin dependent kinase inhibitor 1A	Homo sapiens	46-50
15467450-0	2004	JNK is associated with Bcl-2 and PP1 in mitochondria: paclitaxel induces its activation and its association with the phosphorylated form of Bcl-2.	Paclitaxel	54-64	BCL2 apoptosis regulator	Homo sapiens	140-145
15467450-1	2004	It has been shown that the activation of JNK after paclitaxel-induced microtubule damage is parallel to Bcl-2 phosphorylation, cell cycle arrest in mitosis and apoptosis.	Paclitaxel	51-61	mitogen-activated protein kinase 8	Homo sapiens	41-44
15467450-1	2004	It has been shown that the activation of JNK after paclitaxel-induced microtubule damage is parallel to Bcl-2 phosphorylation, cell cycle arrest in mitosis and apoptosis.	Paclitaxel	51-61	BCL2 apoptosis regulator	Homo sapiens	104-109
15467450-2	2004	Using subcellular fractionation and immunocytochemistry, we found here that a pool of activated JNK is located in mitochondria of HeLa cells treated with paclitaxel.	Paclitaxel	154-164	mitogen-activated protein kinase 8	Homo sapiens	96-99
15467449-5	2004	Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation.	Paclitaxel	116-126	cyclin dependent kinase inhibitor 1A	Homo sapiens	37-40
15467449-5	2004	Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation.	Paclitaxel	116-126	cyclin dependent kinase inhibitor 1A	Homo sapiens	41-45
15467450-3	2004	Furthermore, whereas the JNK protein is present in a tripartite complex with the anti-apoptotic Bcl-2 protein and the PP1 phosphatase in mitochondria isolated from control cells, the activated form of JNK was associated with the phosphorylated form of Bcl-2, but devoid of PP1, in mitochondria isolated from paclitaxel-treated cells.	Paclitaxel	308-318	mitogen-activated protein kinase 8	Homo sapiens	25-28
15467449-5	2004	Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation.	Paclitaxel	116-126	cyclin dependent kinase inhibitor 1A	Homo sapiens	46-50
15467449-5	2004	Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation.	Paclitaxel	116-126	mitogen-activated protein kinase 8	Homo sapiens	149-152
15467450-3	2004	Furthermore, whereas the JNK protein is present in a tripartite complex with the anti-apoptotic Bcl-2 protein and the PP1 phosphatase in mitochondria isolated from control cells, the activated form of JNK was associated with the phosphorylated form of Bcl-2, but devoid of PP1, in mitochondria isolated from paclitaxel-treated cells.	Paclitaxel	308-318	BCL2 apoptosis regulator	Homo sapiens	96-101
15467449-5	2004	Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation.	Paclitaxel	116-126	BCL2 apoptosis regulator	Homo sapiens	164-169
15467449-6	2004	Together, these findings suggest that p21(Cip1/WAF1) partially protects p53-null human leukemia cells from paclitaxel-mediated lethality, and raise the possibility that p21(Cip1/WAF1)-associated perturbations in signal transduction pathways as well as Bcl-2 phosphorylation status may play a role in this phenomenon.	Paclitaxel	107-117	cyclin dependent kinase inhibitor 1A	Homo sapiens	38-41
15467450-3	2004	Furthermore, whereas the JNK protein is present in a tripartite complex with the anti-apoptotic Bcl-2 protein and the PP1 phosphatase in mitochondria isolated from control cells, the activated form of JNK was associated with the phosphorylated form of Bcl-2, but devoid of PP1, in mitochondria isolated from paclitaxel-treated cells.	Paclitaxel	308-318	mitogen-activated protein kinase 8	Homo sapiens	201-204
15467449-6	2004	Together, these findings suggest that p21(Cip1/WAF1) partially protects p53-null human leukemia cells from paclitaxel-mediated lethality, and raise the possibility that p21(Cip1/WAF1)-associated perturbations in signal transduction pathways as well as Bcl-2 phosphorylation status may play a role in this phenomenon.	Paclitaxel	107-117	cyclin dependent kinase inhibitor 1A	Homo sapiens	42-46
15467449-6	2004	Together, these findings suggest that p21(Cip1/WAF1) partially protects p53-null human leukemia cells from paclitaxel-mediated lethality, and raise the possibility that p21(Cip1/WAF1)-associated perturbations in signal transduction pathways as well as Bcl-2 phosphorylation status may play a role in this phenomenon.	Paclitaxel	107-117	cyclin dependent kinase inhibitor 1A	Homo sapiens	47-51
15467450-7	2004	Taken together, these data show that JNK activation provides a molecular linkage from microtubule damages to the mitochondrial apoptotic machinery and also point to a pivotal role for the JNK/Bcl-2/PP1 complex in the control of apoptosis following paclitaxel treatment.	Paclitaxel	248-258	mitogen-activated protein kinase 8	Homo sapiens	37-40
15467449-6	2004	Together, these findings suggest that p21(Cip1/WAF1) partially protects p53-null human leukemia cells from paclitaxel-mediated lethality, and raise the possibility that p21(Cip1/WAF1)-associated perturbations in signal transduction pathways as well as Bcl-2 phosphorylation status may play a role in this phenomenon.	Paclitaxel	107-117	tumor protein p53	Homo sapiens	72-75
15467450-7	2004	Taken together, these data show that JNK activation provides a molecular linkage from microtubule damages to the mitochondrial apoptotic machinery and also point to a pivotal role for the JNK/Bcl-2/PP1 complex in the control of apoptosis following paclitaxel treatment.	Paclitaxel	248-258	mitogen-activated protein kinase 8	Homo sapiens	188-191
15467450-7	2004	Taken together, these data show that JNK activation provides a molecular linkage from microtubule damages to the mitochondrial apoptotic machinery and also point to a pivotal role for the JNK/Bcl-2/PP1 complex in the control of apoptosis following paclitaxel treatment.	Paclitaxel	248-258	BCL2 apoptosis regulator	Homo sapiens	192-197
15467450-7	2004	Taken together, these data show that JNK activation provides a molecular linkage from microtubule damages to the mitochondrial apoptotic machinery and also point to a pivotal role for the JNK/Bcl-2/PP1 complex in the control of apoptosis following paclitaxel treatment.	Paclitaxel	248-258	inorganic pyrophosphatase 1	Homo sapiens	198-201
15475475-6	2004	Paclitaxel activated p53 protein at low concentrations but exhibited G2/M cell cycle blocking activity at higher concentrations where microtubules were stabilized.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	21-24
15517865-7	2004	Within 24 h of treatment with paclitaxel, Bcl-2 formed a doublet at 26 kilodaltons and the expression was abrogated with daunorubicin and the combination of the two drugs as determined by Western blots.	Paclitaxel	30-40	BCL2 apoptosis regulator	Homo sapiens	42-47
15486197-7	2004	In addition, paclitaxel, at cytostatic concentrations, early initiates an apoptotic signaling pathway associated with increases in the mitochondrial reducing potential, mitochondrial membrane potential, p53 expression, and Bax/Bcl-2 ratio.	Paclitaxel	13-23	tumor protein p53	Homo sapiens	203-206
15486197-7	2004	In addition, paclitaxel, at cytostatic concentrations, early initiates an apoptotic signaling pathway associated with increases in the mitochondrial reducing potential, mitochondrial membrane potential, p53 expression, and Bax/Bcl-2 ratio.	Paclitaxel	13-23	BCL2 associated X, apoptosis regulator	Homo sapiens	223-226
15486197-7	2004	In addition, paclitaxel, at cytostatic concentrations, early initiates an apoptotic signaling pathway associated with increases in the mitochondrial reducing potential, mitochondrial membrane potential, p53 expression, and Bax/Bcl-2 ratio.	Paclitaxel	13-23	BCL2 apoptosis regulator	Homo sapiens	227-232
15380635-5	2004	Lack of paclitaxel brain uptake is thought to be associated with the p-glycoprotein (p-gp) efflux transporter.	Paclitaxel	8-18	ATP binding cassette subfamily B member 1	Homo sapiens	69-83
15380635-5	2004	Lack of paclitaxel brain uptake is thought to be associated with the p-glycoprotein (p-gp) efflux transporter.	Paclitaxel	8-18	ATP binding cassette subfamily B member 1	Homo sapiens	85-89
15380635-10	2004	The results suggest that entrapment of paclitaxel in nanoparticles significantly increases the drug brain uptake and its toxicity toward p-glycoprotein expressing tumor cells.	Paclitaxel	39-49	ATP binding cassette subfamily B member 1	Homo sapiens	137-151
15556294-9	2004	In light of the overexpression of MGC4175 in association with taxol exposure, drug resistance, the coexpression of MDR1 and the mitochondrial localization of its protein, we propose to name this transcript MDR1 and Mitochondrial Taxol Resistance Associated Gene (MM-TRAG) and suggest that MM-TRAG may play a role in the development of taxol resistance in human cancer.	Paclitaxel	335-340	ATP binding cassette subfamily B member 1	Homo sapiens	206-210
15175893-0	2004	Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes.	Paclitaxel	94-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-51
15139851-9	2004	For example, a molar excess of mitoxantrone was more effective at inhibiting IAARh123 labelling of wild-type than of mutant ABCG2, while excess cisplatin, taxol and methotrexate showed significant inhibition of IAARh123 binding to both wild-type and mutant ABCG2.	Paclitaxel	155-160	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	257-262
15175893-9	2004	A comparison of the cellular concentrations of paclitaxel and docetaxel, in the cell culture models employed for evaluating CYP3A4 induction and hPXR activation, revealed that the intracellular paclitaxel levels were three-fold higher than that of docetaxel.	Paclitaxel	194-204	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-130
15294454-1	2004	Overexpression of human MDR1 P-glycoprotein [Pgp] is associated with cellular resistance to bulky amphipathic drugs, such as taxol, anthracyclines, vinca alkaloids, and epipodophyllotoxins by actively effluxing drugs from cells.	Paclitaxel	125-130	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-28
15175893-2	2004	The aim of this study was to comparatively examine the effects of paclitaxel and docetaxel, two structurally related taxane anticancer agents, on the activity and expression of hepatic CYP3A4.	Paclitaxel	66-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	185-191
15175893-6	2004	Furthermore, employing cell-based reporter gene assay in CV-1 cells, we evaluated the capacity of paclitaxel and docetaxel to activate human pregnane X receptor (hPXR), an orphan nuclear receptor that plays a key role in the transcriptional regulation of CYP3A4.	Paclitaxel	98-108	nuclear receptor subfamily 1 group I member 2	Homo sapiens	141-160
15175893-6	2004	Furthermore, employing cell-based reporter gene assay in CV-1 cells, we evaluated the capacity of paclitaxel and docetaxel to activate human pregnane X receptor (hPXR), an orphan nuclear receptor that plays a key role in the transcriptional regulation of CYP3A4.	Paclitaxel	98-108	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	255-261
15175893-7	2004	RESULTS: In concurrence with previous reports, we observed that paclitaxel potently induced CYP3A4 activity and expression in hepatocytes treated for 48-96 h. However, docetaxel did not increase the activity or the CYP3A4 immunoreactive protein levels for treatment periods up to 96 h. A marginal increase in the CYP3A4 mRNA levels was observed in cells treated with higher levels (5 and 10 microM) of docetaxel.	Paclitaxel	64-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-98
15175893-7	2004	RESULTS: In concurrence with previous reports, we observed that paclitaxel potently induced CYP3A4 activity and expression in hepatocytes treated for 48-96 h. However, docetaxel did not increase the activity or the CYP3A4 immunoreactive protein levels for treatment periods up to 96 h. A marginal increase in the CYP3A4 mRNA levels was observed in cells treated with higher levels (5 and 10 microM) of docetaxel.	Paclitaxel	64-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	215-221
15175893-7	2004	RESULTS: In concurrence with previous reports, we observed that paclitaxel potently induced CYP3A4 activity and expression in hepatocytes treated for 48-96 h. However, docetaxel did not increase the activity or the CYP3A4 immunoreactive protein levels for treatment periods up to 96 h. A marginal increase in the CYP3A4 mRNA levels was observed in cells treated with higher levels (5 and 10 microM) of docetaxel.	Paclitaxel	64-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	215-221
15175893-9	2004	A comparison of the cellular concentrations of paclitaxel and docetaxel, in the cell culture models employed for evaluating CYP3A4 induction and hPXR activation, revealed that the intracellular paclitaxel levels were three-fold higher than that of docetaxel.	Paclitaxel	47-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-130
15292386-0	2004	Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.	Paclitaxel	45-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-9
15367711-2	2004	We report here that Ad.Egr-TNF.11D is activated by the clinically important anticancer agents cisplatin, cyclophosphamide, doxorubicin, 5-fluorouracil, gemcitabine, and paclitaxel.	Paclitaxel	169-179	tumor necrosis factor	Homo sapiens	27-30
15325793-8	2004	In contrast, soluble ovalbumin was concentrated in the region of the trans-Golgi in 15% of the dendritic cells treated with paclitaxel, whereas 6% of the dendritic cells were able to concentrate liposomal antigen.	Paclitaxel	124-134	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	21-30
15358225-3	2004	Furthermore, paclitaxel rapidly activated the JNK, ERK, and p38 mitogen-activated protein kinase pathways.	Paclitaxel	13-23	Eph receptor B1	Rattus norvegicus	51-54
15304545-4	2004	Here, we use an ATF library to identify genes that participate in rendering a cell resistant to the drug Taxol, a potent anti-cancer drug that binds to tubulin and inhibits cell division.	Paclitaxel	105-110	glial cell derived neurotrophic factor	Homo sapiens	16-19
15265561-9	2004	It might be considered that the significantly enhanced bioavailability of paclitaxel by the prodrug, which is water-soluble and easy to permeat through the intestinal mucosa, is due to the avoidance of being inhibited by p-glycoprotein efflux pump in the intestinal mucosa and reduction of metabolism by cytochrome-p-450 (CYP3A) in epitherial cells of small intestine.	Paclitaxel	74-84	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	322-327
15046923-9	2004	The loading of paclitaxel in PMM 2.1.2 microspheres enhanced the deformation and adhesion of microspheres at pH 5.5.	Paclitaxel	15-25	phosphomannomutase 2	Mus musculus	29-34
15046923-10	2004	It is hypothesized that the electrostatic repulsion between paclitaxel and collagen at pH 4 reduces the adhesion energy of PMM 2.1.2-paclitaxel microsphere.	Paclitaxel	60-70	phosphomannomutase 2	Mus musculus	123-128
15046923-10	2004	It is hypothesized that the electrostatic repulsion between paclitaxel and collagen at pH 4 reduces the adhesion energy of PMM 2.1.2-paclitaxel microsphere.	Paclitaxel	133-143	phosphomannomutase 2	Mus musculus	123-128
15208671-3	2004	In HEK293 cells expressing Akt mutants, the level of Bcl-2 phosphorylation and the threshold of apoptosis induced by taxol or by nocodazole are significantly modified.	Paclitaxel	117-122	AKT serine/threonine kinase 1	Homo sapiens	27-30
15332713-0	2004	Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro.	Paclitaxel	11-21	epidermal growth factor receptor	Homo sapiens	39-43
15332713-4	2004	The aim of the present work was to compare the cytotoxic effect of taxanes, paclitaxel and docetaxel on the EGFR-expressing carcinoma cell lines A431, MDA-MB-231 and NCI-H358 under normoxic and hypoxic conditions.	Paclitaxel	76-86	epidermal growth factor receptor	Homo sapiens	108-112
15332713-6	2004	EGFR-overexpressing carcinoma cells showed hypoxia to severely affect the cytotoxicity of paclitaxel, whereas docetaxel preserved its tumor cell-killing activity even at lowest concentrations (0.5 nM), as was observed for both taxanes under normoxia.	Paclitaxel	90-100	epidermal growth factor receptor	Homo sapiens	0-4
15208671-4	2004	In cells expressing dominant-negative Akt (DN-Akt), Bcl-2 phosphorylation and p70S6KThr421/Ser424 phosphorylation induced by taxol or nocodazole were significantly enhanced as compared to cells expressing constitutively active Akt (CA-Akt) and inhibited by rapamycin.	Paclitaxel	125-130	AKT serine/threonine kinase 1	Homo sapiens	38-41
15208671-4	2004	In cells expressing dominant-negative Akt (DN-Akt), Bcl-2 phosphorylation and p70S6KThr421/Ser424 phosphorylation induced by taxol or nocodazole were significantly enhanced as compared to cells expressing constitutively active Akt (CA-Akt) and inhibited by rapamycin.	Paclitaxel	125-130	AKT serine/threonine kinase 1	Homo sapiens	46-49
15208671-4	2004	In cells expressing dominant-negative Akt (DN-Akt), Bcl-2 phosphorylation and p70S6KThr421/Ser424 phosphorylation induced by taxol or nocodazole were significantly enhanced as compared to cells expressing constitutively active Akt (CA-Akt) and inhibited by rapamycin.	Paclitaxel	125-130	AKT serine/threonine kinase 1	Homo sapiens	46-49
15208671-4	2004	In cells expressing dominant-negative Akt (DN-Akt), Bcl-2 phosphorylation and p70S6KThr421/Ser424 phosphorylation induced by taxol or nocodazole were significantly enhanced as compared to cells expressing constitutively active Akt (CA-Akt) and inhibited by rapamycin.	Paclitaxel	125-130	AKT serine/threonine kinase 1	Homo sapiens	46-49
15256461-4	2004	In vitro, Taxol enhanced caspase activation and apoptosis induction by Apo2L/TRAIL.	Paclitaxel	10-15	TNF superfamily member 10	Homo sapiens	71-76
15256461-4	2004	In vitro, Taxol enhanced caspase activation and apoptosis induction by Apo2L/TRAIL.	Paclitaxel	10-15	TNF superfamily member 10	Homo sapiens	77-82
15269161-9	2004	In addition, biochemical examinations revealed that gamma-radiation inhibited paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation and increased the protein levels of cyclin B1 and inhibitory phosphorylation of p34(cdc2).	Paclitaxel	78-88	NFKB inhibitor alpha	Homo sapiens	97-109
15241487-5	2004	Specifically, TPA induces phosphorylation at a conserved extracellular signal-regulated kinase (ERK) site in the PEST region (Thr 163) and slows turnover of the normally rapidly degraded MCL1 protein; however, okadaic acid and taxol induce ERK-independent MCL1 phosphorylation at additional discrete sites.	Paclitaxel	227-232	plasminogen activator, tissue type	Homo sapiens	14-17
15269161-9	2004	In addition, biochemical examinations revealed that gamma-radiation inhibited paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation and increased the protein levels of cyclin B1 and inhibitory phosphorylation of p34(cdc2).	Paclitaxel	78-88	BCL2 apoptosis regulator	Homo sapiens	126-131
15241487-5	2004	Specifically, TPA induces phosphorylation at a conserved extracellular signal-regulated kinase (ERK) site in the PEST region (Thr 163) and slows turnover of the normally rapidly degraded MCL1 protein; however, okadaic acid and taxol induce ERK-independent MCL1 phosphorylation at additional discrete sites.	Paclitaxel	227-232	mitogen-activated protein kinase 1	Homo sapiens	96-99
15044368-7	2004	Low doses of Taxol enhanced Bcl2 phosphorylation and led to its degradation observed on the background of a sustained or increasing Bax level and accumulation of survivin and X-chromosome-linked inhibitor of apoptosis.	Paclitaxel	13-18	BCL2 apoptosis regulator	Homo sapiens	28-32
15231674-9	2004	Notably, several KB-derived multidrug-resistant cell lines overexpressing P-gp170/MDR and MRP are resistant to vincristine, paclitaxel, and colchicine but not to BPR0L075.	Paclitaxel	124-134	ATP binding cassette subfamily C member 1	Homo sapiens	90-93
15001534-4	2004	Inhibition of paclitaxel-induced c-jun NH2-terminal kinase (JNK) activation by treatment with a specific inhibitor, SP600125, or overexpression of a dominant-negative mutant form of upstream kinases, MEK kinase 1 (MEKK1) and mitogen-activated protein kinase kinase (MKK) 7, significantly reduced the increase in phosphorylated FADD.	Paclitaxel	14-24	mitogen-activated protein kinase 8	Homo sapiens	33-58
15001534-4	2004	Inhibition of paclitaxel-induced c-jun NH2-terminal kinase (JNK) activation by treatment with a specific inhibitor, SP600125, or overexpression of a dominant-negative mutant form of upstream kinases, MEK kinase 1 (MEKK1) and mitogen-activated protein kinase kinase (MKK) 7, significantly reduced the increase in phosphorylated FADD.	Paclitaxel	14-24	mitogen-activated protein kinase 8	Homo sapiens	60-63
15001534-4	2004	Inhibition of paclitaxel-induced c-jun NH2-terminal kinase (JNK) activation by treatment with a specific inhibitor, SP600125, or overexpression of a dominant-negative mutant form of upstream kinases, MEK kinase 1 (MEKK1) and mitogen-activated protein kinase kinase (MKK) 7, significantly reduced the increase in phosphorylated FADD.	Paclitaxel	14-24	mitogen-activated protein kinase kinase 7	Homo sapiens	225-272
15001534-5	2004	It is noteworthy that pretreatment with paclitaxel significantly up-regulated MEKK1 expression, resulting in enhancement of etoposide- or cisplatin-induced MEKK1/MKK7-dependent JNK activation and apoptosis in LNCaP and DU145 cells.	Paclitaxel	40-50	mitogen-activated protein kinase kinase 7	Homo sapiens	162-166
15001534-5	2004	It is noteworthy that pretreatment with paclitaxel significantly up-regulated MEKK1 expression, resulting in enhancement of etoposide- or cisplatin-induced MEKK1/MKK7-dependent JNK activation and apoptosis in LNCaP and DU145 cells.	Paclitaxel	40-50	mitogen-activated protein kinase 8	Homo sapiens	177-180
15044368-7	2004	Low doses of Taxol enhanced Bcl2 phosphorylation and led to its degradation observed on the background of a sustained or increasing Bax level and accumulation of survivin and X-chromosome-linked inhibitor of apoptosis.	Paclitaxel	13-18	BCL2 associated X, apoptosis regulator	Homo sapiens	132-135
15252144-7	2004	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays of siRNA-treated cells demonstrated 7- to 12.4-fold reduction of paclitaxel resistance in the lines treated with the synthesized siRNA of ABCB1 and 4.7- to 7.3-fold reduction of paclitaxel resistance in the cell lines transfected with siRNA of ABCB1 expressing vectors.	Paclitaxel	133-143	ATP binding cassette subfamily B member 1	Homo sapiens	206-211
15262121-12	2004	The mRNA for MDR-1 was uniquely overexpressed in the cisplatin-resistant cell line A2780-CR9 initially treated with low doses of cisplatin and paclitaxel, but was not amplified in A2780 (P &lt; 0.01).	Paclitaxel	143-153	ATP binding cassette subfamily B member 1	Homo sapiens	13-18
15252144-3	2004	Clinical paclitaxel resistance is often associated with ABCB1 (MDR1) overexpression, and in vitro paclitaxel resistance typically demonstrates overexpression of the ABCB1 gene.	Paclitaxel	9-19	ATP binding cassette subfamily B member 1	Homo sapiens	56-61
15252144-3	2004	Clinical paclitaxel resistance is often associated with ABCB1 (MDR1) overexpression, and in vitro paclitaxel resistance typically demonstrates overexpression of the ABCB1 gene.	Paclitaxel	9-19	ATP binding cassette subfamily B member 1	Homo sapiens	63-67
15252144-3	2004	Clinical paclitaxel resistance is often associated with ABCB1 (MDR1) overexpression, and in vitro paclitaxel resistance typically demonstrates overexpression of the ABCB1 gene.	Paclitaxel	98-108	ATP binding cassette subfamily B member 1	Homo sapiens	165-170
15252144-7	2004	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays of siRNA-treated cells demonstrated 7- to 12.4-fold reduction of paclitaxel resistance in the lines treated with the synthesized siRNA of ABCB1 and 4.7- to 7.3-fold reduction of paclitaxel resistance in the cell lines transfected with siRNA of ABCB1 expressing vectors.	Paclitaxel	133-143	ATP binding cassette subfamily B member 1	Homo sapiens	312-317
15252144-4	2004	In this study, we demonstrate that paclitaxel-resistant cell lines overexpress both ABCB1 and ABCB4 (MDR3).	Paclitaxel	35-45	ATP binding cassette subfamily B member 1	Homo sapiens	84-89
15252144-9	2004	These results indicate that siRNA targeted to ABCB1 can sensitize paclitaxel-resistant ovarian cancer cells in vitro and suggest that siRNA treatment may represent a new approach for the treatment of ABCB1-mediated drug resistance.	Paclitaxel	66-76	ATP binding cassette subfamily B member 1	Homo sapiens	46-51
15252144-9	2004	These results indicate that siRNA targeted to ABCB1 can sensitize paclitaxel-resistant ovarian cancer cells in vitro and suggest that siRNA treatment may represent a new approach for the treatment of ABCB1-mediated drug resistance.	Paclitaxel	66-76	ATP binding cassette subfamily B member 1	Homo sapiens	200-205
15245881-5	2004	Therefore, substance P rather than histamine may be involved in paclitaxel hypersensitivity.	Paclitaxel	64-74	tachykinin precursor 1	Homo sapiens	11-22
15159015-0	2004	Insulin can modulate MCF-7 cell response to paclitaxel.	Paclitaxel	44-54	insulin	Homo sapiens	0-7
15245881-0	2004	Role of substance P in hypersensitivity reactions induced by paclitaxel, an anticancer agent.	Paclitaxel	61-71	tachykinin precursor 1	Homo sapiens	8-19
15245881-1	2004	The role of substance P in adverse pulmonary reactions induced by an anticancer agent paclitaxel was investigated in rats and humans who undertook post-operative chemotherapy for ovarian cancer.	Paclitaxel	86-96	tachykinin precursor 1	Homo sapiens	12-23
15245881-3	2004	Substance P level in rat plasma and bronchoalveolar lavage fluid increased after paclitaxel injection.	Paclitaxel	81-91	tachykinin precursor 1	Homo sapiens	0-11
15245881-4	2004	In 13 patients, plasma level of substance P but not histamine significantly (P &lt; 0.05) increased during paclitaxel infusion.	Paclitaxel	107-117	tachykinin precursor 1	Homo sapiens	32-43
15159015-2	2004	Our research studied whether insulin, administered separately or in combination with paclitaxel, interferes with paclitaxel-mediated biological activity in human breast cancer cells.	Paclitaxel	113-123	insulin	Homo sapiens	29-36
15159015-3	2004	Not only did insulin influence paclitaxel-mediated cell microtubule reorganization, but it also influenced MCF-7 cell sensitivity to paclitaxel.	Paclitaxel	31-41	insulin	Homo sapiens	13-20
15159015-3	2004	Not only did insulin influence paclitaxel-mediated cell microtubule reorganization, but it also influenced MCF-7 cell sensitivity to paclitaxel.	Paclitaxel	133-143	insulin	Homo sapiens	13-20
15159015-4	2004	Furthermore, combined administrations of insulin and paclitaxel affected MAPK pathway, Raf-1 activation and p53 expression levels.	Paclitaxel	53-63	tumor protein p53	Homo sapiens	108-111
15159015-5	2004	Our findings indicate that insulin seems to modulate MCF-7 cell response to paclitaxel; consequently, elevated levels of insulin could influence tumor cell resistance.	Paclitaxel	76-86	insulin	Homo sapiens	27-34
15159015-5	2004	Our findings indicate that insulin seems to modulate MCF-7 cell response to paclitaxel; consequently, elevated levels of insulin could influence tumor cell resistance.	Paclitaxel	76-86	insulin	Homo sapiens	121-128
15159020-5	2004	Down-regulation of either PKCeta or Bcl-xL in combination with vincristine or paclitaxel resulted in a significant increase in caspase-3 activity compared to that in the control oligonucleotide treated cells.	Paclitaxel	78-88	caspase 3	Homo sapiens	127-136
15205332-2	2004	We hypothesized that inhibition of phosphorylation of the epidermal growth factor receptor (EGF-R) and platelet-derived growth factor receptor (PDGF-R) expressed on tumor cells and tumor-associated endothelial cells, which is associated with tumor progression, in combination with paclitaxel would inhibit experimental prostate cancer bone metastasis and preserve bone structure.	Paclitaxel	281-291	epidermal growth factor receptor	Homo sapiens	58-90
15136595-1	2004	PURPOSE: The goal of this study was to examine the feasibility of developing a multigene predictor of pathologic complete response (pCR) to sequential weekly paclitaxel and fluorouracil + doxorubicin + cyclophosphamide (T/FAC) neoadjuvant chemotherapy regimen for breast cancer.	Paclitaxel	158-168	FA complementation group C	Homo sapiens	222-225
15158795-0	2004	Paclitaxel-HSA interaction.	Paclitaxel	0-10	albumin	Homo sapiens	11-14
15158795-4	2004	In the present work the interaction of paclitaxel with human serum albumin (HSA) in aqueous solution at physiological pH has been investigated through CD, fluorescence spectroscopy and by the antibody precipitate test.	Paclitaxel	39-49	albumin	Homo sapiens	76-79
15158795-6	2004	The paclitaxel-HSA interaction causes the conformational changes with the loss of helical stability of protein and local perturbation in the domain IIA binding pocket.	Paclitaxel	4-14	albumin	Homo sapiens	15-18
15158795-7	2004	The relative fluorescence intensity of the paclitaxel-bound HSA decreased, suggesting that perturbation around the Trp 214 residue took place.	Paclitaxel	43-53	albumin	Homo sapiens	60-63
15205332-2	2004	We hypothesized that inhibition of phosphorylation of the epidermal growth factor receptor (EGF-R) and platelet-derived growth factor receptor (PDGF-R) expressed on tumor cells and tumor-associated endothelial cells, which is associated with tumor progression, in combination with paclitaxel would inhibit experimental prostate cancer bone metastasis and preserve bone structure.	Paclitaxel	281-291	epidermal growth factor receptor	Homo sapiens	92-97
15217959-6	2004	Here we present clinical data and preliminary results of correlative science studies analyzing human epidermal growth factor receptor pathways from the following two prospective Southwest Oncology Group clinical trials performed in advanced stage BAC: S9714 testing a 96-h continuous infusion of paclitaxel (Taxol) and S0126 evaluating the small molecule EGFR inhibitor gefitinib (ZD1839 or Iressa).	Paclitaxel	296-306	epidermal growth factor receptor	Homo sapiens	101-133
15205332-2	2004	We hypothesized that inhibition of phosphorylation of the epidermal growth factor receptor (EGF-R) and platelet-derived growth factor receptor (PDGF-R) expressed on tumor cells and tumor-associated endothelial cells, which is associated with tumor progression, in combination with paclitaxel would inhibit experimental prostate cancer bone metastasis and preserve bone structure.	Paclitaxel	281-291	platelet derived growth factor receptor beta	Homo sapiens	103-142
15205332-2	2004	We hypothesized that inhibition of phosphorylation of the epidermal growth factor receptor (EGF-R) and platelet-derived growth factor receptor (PDGF-R) expressed on tumor cells and tumor-associated endothelial cells, which is associated with tumor progression, in combination with paclitaxel would inhibit experimental prostate cancer bone metastasis and preserve bone structure.	Paclitaxel	281-291	platelet derived growth factor receptor beta	Homo sapiens	144-150
14742319-0	2004	Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells.	Paclitaxel	85-90	mitogen-activated protein kinase kinase 7	Homo sapiens	17-20
15135300-8	2004	Genistein reduced Bcl-2 phosphorylation triggered by paclitaxel and vincristine without changing Bax protein expression.	Paclitaxel	53-63	BCL2 apoptosis regulator	Homo sapiens	18-23
14742319-7	2004	Treatment of the Id-1 expressing cells with a MEK inhibitor, PD098059, resulted in an increased taxol-induced apoptosis rate in Id-1 transfectants compared with the vector control.	Paclitaxel	96-101	mitogen-activated protein kinase kinase 7	Homo sapiens	46-49
14742319-8	2004	In addition, the fact that the taxol-induced apoptosis rate, down-regulation of Bcl-2 and up-regulation of Bax were suppressed by PD098059 treatment in Id-1 expressing cells indicates that the Id-1 induced cellular protection against apoptosis is mediated through Raf/MEK signalling pathways.	Paclitaxel	31-36	BCL2 apoptosis regulator	Homo sapiens	80-85
14742319-8	2004	In addition, the fact that the taxol-induced apoptosis rate, down-regulation of Bcl-2 and up-regulation of Bax were suppressed by PD098059 treatment in Id-1 expressing cells indicates that the Id-1 induced cellular protection against apoptosis is mediated through Raf/MEK signalling pathways.	Paclitaxel	31-36	BCL2 associated X, apoptosis regulator	Homo sapiens	107-110
14742319-8	2004	In addition, the fact that the taxol-induced apoptosis rate, down-regulation of Bcl-2 and up-regulation of Bax were suppressed by PD098059 treatment in Id-1 expressing cells indicates that the Id-1 induced cellular protection against apoptosis is mediated through Raf/MEK signalling pathways.	Paclitaxel	31-36	mitogen-activated protein kinase kinase 7	Homo sapiens	268-271
14742319-9	2004	Our results suggest that Id-1 may be an upstream regulator of the Raf/MEK signalling pathway, which plays an essential role in protection against taxol-induced apoptosis.	Paclitaxel	146-151	mitogen-activated protein kinase kinase 7	Homo sapiens	70-73
15081147-10	2004	Based on these results, It might be considered that the bioavailability of paclitaxel coadministered with flavone was significantly enhanced by the both inhibition of cytochrome P-450 and the P-gp efflux pump in the intestinal mucosa.	Paclitaxel	75-85	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	167-183
15242250-4	2004	All-trans retinoic acid, taxol and okadiac acid induce downregulation or inactivation of nucleolin, which destabilizes bcl-2 mRNA and triggers apoptosis.	Paclitaxel	25-30	BCL2 apoptosis regulator	Homo sapiens	119-124
15138593-0	2004	ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells.	Paclitaxel	98-108	mitogen-activated protein kinase 1	Mus musculus	0-3
15138593-2	2004	This study was carried out in order to determine the role of extracellular signal-regulated kinases (ERK) and retinoblastoma protein (pRB) in the governing mechanism resistance to paclitaxel using two lung adenocarcinoma cell lines with differing sensitivities.	Paclitaxel	180-190	mitogen-activated protein kinase 1	Mus musculus	61-99
15138593-2	2004	This study was carried out in order to determine the role of extracellular signal-regulated kinases (ERK) and retinoblastoma protein (pRB) in the governing mechanism resistance to paclitaxel using two lung adenocarcinoma cell lines with differing sensitivities.	Paclitaxel	180-190	mitogen-activated protein kinase 1	Mus musculus	101-104
15138593-3	2004	In paclitaxel-sensitive Ma-10 cells, treatment with paclitaxel induced pRB phosphorylation at Ser795 and ERK activation.	Paclitaxel	3-13	mitogen-activated protein kinase 1	Mus musculus	105-108
15138593-3	2004	In paclitaxel-sensitive Ma-10 cells, treatment with paclitaxel induced pRB phosphorylation at Ser795 and ERK activation.	Paclitaxel	52-62	mitogen-activated protein kinase 1	Mus musculus	105-108
15138593-5	2004	A specific ERK inhibitor, PD98059, blocked paclitaxel-induced ERK activation and pRB phosphorylation at Ser795 in Ma-10 cells.	Paclitaxel	43-53	mitogen-activated protein kinase 1	Mus musculus	11-14
15138593-5	2004	A specific ERK inhibitor, PD98059, blocked paclitaxel-induced ERK activation and pRB phosphorylation at Ser795 in Ma-10 cells.	Paclitaxel	43-53	mitogen-activated protein kinase 1	Mus musculus	62-65
15138593-6	2004	Furthermore, PD98059 inhibited cell cycle progression during paclitaxel treatment, the accumulation of sub-G1 population, and the cytotoxic effect by paclitaxel in Ma-10 cells, suggesting that ERK activation by paclitaxel, subsequent pRB phosphorylation, and the cell cycle progression during paclitaxel treatment are important determinants of sensitivity to paclitaxel.	Paclitaxel	61-71	mitogen-activated protein kinase 1	Mus musculus	193-196
15138593-6	2004	Furthermore, PD98059 inhibited cell cycle progression during paclitaxel treatment, the accumulation of sub-G1 population, and the cytotoxic effect by paclitaxel in Ma-10 cells, suggesting that ERK activation by paclitaxel, subsequent pRB phosphorylation, and the cell cycle progression during paclitaxel treatment are important determinants of sensitivity to paclitaxel.	Paclitaxel	150-160	mitogen-activated protein kinase 1	Mus musculus	193-196
15138593-6	2004	Furthermore, PD98059 inhibited cell cycle progression during paclitaxel treatment, the accumulation of sub-G1 population, and the cytotoxic effect by paclitaxel in Ma-10 cells, suggesting that ERK activation by paclitaxel, subsequent pRB phosphorylation, and the cell cycle progression during paclitaxel treatment are important determinants of sensitivity to paclitaxel.	Paclitaxel	150-160	mitogen-activated protein kinase 1	Mus musculus	193-196
15138593-6	2004	Furthermore, PD98059 inhibited cell cycle progression during paclitaxel treatment, the accumulation of sub-G1 population, and the cytotoxic effect by paclitaxel in Ma-10 cells, suggesting that ERK activation by paclitaxel, subsequent pRB phosphorylation, and the cell cycle progression during paclitaxel treatment are important determinants of sensitivity to paclitaxel.	Paclitaxel	150-160	mitogen-activated protein kinase 1	Mus musculus	193-196
15138593-6	2004	Furthermore, PD98059 inhibited cell cycle progression during paclitaxel treatment, the accumulation of sub-G1 population, and the cytotoxic effect by paclitaxel in Ma-10 cells, suggesting that ERK activation by paclitaxel, subsequent pRB phosphorylation, and the cell cycle progression during paclitaxel treatment are important determinants of sensitivity to paclitaxel.	Paclitaxel	150-160	mitogen-activated protein kinase 1	Mus musculus	193-196
15138560-10	2004	The early increase in TPO (the percentage increase in TPO at day 4) was significantly greater (p=0.0345) in patients treated with paclitaxel/carboplatin combination (57.8+/-44.5%) compared with single-agent carboplatin (21.3+/-34.1%).	Paclitaxel	130-140	thrombopoietin	Homo sapiens	22-25
15138560-10	2004	The early increase in TPO (the percentage increase in TPO at day 4) was significantly greater (p=0.0345) in patients treated with paclitaxel/carboplatin combination (57.8+/-44.5%) compared with single-agent carboplatin (21.3+/-34.1%).	Paclitaxel	130-140	thrombopoietin	Homo sapiens	54-57
15138560-12	2004	The observed platelet-sparing effect of the paclitaxel/carboplatin might be related to the early increase in circulating TPO levels, although the precise mechanism remains to be elucidated.	Paclitaxel	44-54	thrombopoietin	Homo sapiens	121-124
15081147-10	2004	Based on these results, It might be considered that the bioavailability of paclitaxel coadministered with flavone was significantly enhanced by the both inhibition of cytochrome P-450 and the P-gp efflux pump in the intestinal mucosa.	Paclitaxel	75-85	phosphoglycolate phosphatase	Rattus norvegicus	192-196
15060738-1	2004	PURPOSE: The taxanes paclitaxel and docetaxel are substrates for P-glycoprotein (Pgp), an ATP-binding cassette (ABC) transport protein associated with multidrug resistance (MDR).	Paclitaxel	21-31	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
15020841-0	2004	Estrogen receptor expression and sensitivity to paclitaxel in breast cancer.	Paclitaxel	48-58	estrogen receptor 1	Homo sapiens	0-17
15020841-1	2004	A retrospective analysis of CALGB trial 9344 suggested paclitaxel administration following cyclophosphamide and doxorubicin adjuvant chemotherapy is most beneficial for patients with ERalpha negative (ERalpha-) breast cancer.	Paclitaxel	55-65	estrogen receptor 1	Homo sapiens	183-190
15020841-1	2004	A retrospective analysis of CALGB trial 9344 suggested paclitaxel administration following cyclophosphamide and doxorubicin adjuvant chemotherapy is most beneficial for patients with ERalpha negative (ERalpha-) breast cancer.	Paclitaxel	55-65	estrogen receptor 1	Homo sapiens	201-208
15020841-2	2004	Since the cytotoxic effects of paclitaxel are cell cycle dependent, we postulated that the relationship between ERalpha and the effectiveness of adjuvant paclitaxel reflects the observation that ERalpha positive (ERalpha+) breast cancers proliferate more slowly than ERalpha- breast cancers.	Paclitaxel	31-41	estrogen receptor 1	Homo sapiens	112-119
15020841-2	2004	Since the cytotoxic effects of paclitaxel are cell cycle dependent, we postulated that the relationship between ERalpha and the effectiveness of adjuvant paclitaxel reflects the observation that ERalpha positive (ERalpha+) breast cancers proliferate more slowly than ERalpha- breast cancers.	Paclitaxel	31-41	estrogen receptor 1	Homo sapiens	195-202
15020841-2	2004	Since the cytotoxic effects of paclitaxel are cell cycle dependent, we postulated that the relationship between ERalpha and the effectiveness of adjuvant paclitaxel reflects the observation that ERalpha positive (ERalpha+) breast cancers proliferate more slowly than ERalpha- breast cancers.	Paclitaxel	31-41	estrogen receptor 1	Homo sapiens	195-202
15020841-2	2004	Since the cytotoxic effects of paclitaxel are cell cycle dependent, we postulated that the relationship between ERalpha and the effectiveness of adjuvant paclitaxel reflects the observation that ERalpha positive (ERalpha+) breast cancers proliferate more slowly than ERalpha- breast cancers.	Paclitaxel	31-41	estrogen receptor 1	Homo sapiens	195-202
15020841-2	2004	Since the cytotoxic effects of paclitaxel are cell cycle dependent, we postulated that the relationship between ERalpha and the effectiveness of adjuvant paclitaxel reflects the observation that ERalpha positive (ERalpha+) breast cancers proliferate more slowly than ERalpha- breast cancers.	Paclitaxel	154-164	estrogen receptor 1	Homo sapiens	112-119
15020841-2	2004	Since the cytotoxic effects of paclitaxel are cell cycle dependent, we postulated that the relationship between ERalpha and the effectiveness of adjuvant paclitaxel reflects the observation that ERalpha positive (ERalpha+) breast cancers proliferate more slowly than ERalpha- breast cancers.	Paclitaxel	154-164	estrogen receptor 1	Homo sapiens	195-202
15020841-2	2004	Since the cytotoxic effects of paclitaxel are cell cycle dependent, we postulated that the relationship between ERalpha and the effectiveness of adjuvant paclitaxel reflects the observation that ERalpha positive (ERalpha+) breast cancers proliferate more slowly than ERalpha- breast cancers.	Paclitaxel	154-164	estrogen receptor 1	Homo sapiens	195-202
15020841-2	2004	Since the cytotoxic effects of paclitaxel are cell cycle dependent, we postulated that the relationship between ERalpha and the effectiveness of adjuvant paclitaxel reflects the observation that ERalpha positive (ERalpha+) breast cancers proliferate more slowly than ERalpha- breast cancers.	Paclitaxel	154-164	estrogen receptor 1	Homo sapiens	195-202
15020841-3	2004	Three in vitro models (MCF-7, T47D and ZR-75) were examined to compare growth rates and paclitaxel-induced apoptosis in ERalpha+ and ERalpha- clones of the same, originally ERalpha+ cell line.	Paclitaxel	88-98	estrogen receptor 1	Homo sapiens	120-127
15020841-4	2004	For the T47D and ZR-75 cell lines, loss of ERalpha was associated with a decrease in doubling time and an increase in paclitaxel sensitivity.	Paclitaxel	118-128	estrogen receptor 1	Homo sapiens	43-50
15117984-15	2004	CONCLUSION: This trial confirms the activity and tolerability of weekly paclitaxel/carboplatin alone or in combination with trastuzumab in women with HER-2 overexpressing metastatic breast cancer.	Paclitaxel	72-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-155
14742744-7	2004	The importance of activated MAP kinases for DOR internalization is further demonstrated by glutamate and paclitaxel because these substances induce phosphorylation of ERK1/2 and concomitantly prevent DOR sequestration by etorphine.	Paclitaxel	105-115	tumor protein p53 inducible nuclear protein 2	Homo sapiens	44-47
14742744-7	2004	The importance of activated MAP kinases for DOR internalization is further demonstrated by glutamate and paclitaxel because these substances induce phosphorylation of ERK1/2 and concomitantly prevent DOR sequestration by etorphine.	Paclitaxel	105-115	mitogen-activated protein kinase 3	Homo sapiens	167-173
14742744-7	2004	The importance of activated MAP kinases for DOR internalization is further demonstrated by glutamate and paclitaxel because these substances induce phosphorylation of ERK1/2 and concomitantly prevent DOR sequestration by etorphine.	Paclitaxel	105-115	tumor protein p53 inducible nuclear protein 2	Homo sapiens	200-203
15141302-0	2004	Taxol activates inducible nitric oxide synthase in rat astrocytes: the role of MAP kinases and NF-kappaB.	Paclitaxel	0-5	nitric oxide synthase 2	Rattus norvegicus	16-47
15141302-5	2004	The observed effect of taxol was mediated through induction of iNOS transcription factors NF-kappaB and IRF-1, and required the activation of p38 MAP kinase and JNK.	Paclitaxel	23-28	nitric oxide synthase 2	Rattus norvegicus	63-67
15120700-9	2004	RESULTS: Of seven chemosensitive patients, five cell samples treated in vitro had increased caspase-3 activity in response to both carboplatin and paclitaxel.	Paclitaxel	147-157	caspase 3	Homo sapiens	92-101
15060738-1	2004	PURPOSE: The taxanes paclitaxel and docetaxel are substrates for P-glycoprotein (Pgp), an ATP-binding cassette (ABC) transport protein associated with multidrug resistance (MDR).	Paclitaxel	21-31	ATP binding cassette subfamily B member 1	Homo sapiens	81-84
15034938-5	2004	While treatment of cells with taxol resulted in bcl-2 phosphorylation and mitochondrial depolarization, cytochrome c was not released and pro-caspase-3 was not activated.	Paclitaxel	30-35	BCL2 apoptosis regulator	Homo sapiens	48-53
14722122-9	2004	Taxol rapidly activated the phosphatidylinositol 3-kinase/Akt and MAPK pathways.	Paclitaxel	0-5	AKT serine/threonine kinase 1	Homo sapiens	58-61
15063149-3	2004	Phorbol 12-myristate 13-acetate (PMA), a protein kinase C (PKC) regulator, was used to test the taxol-resistant cells.	Paclitaxel	96-101	peroneal muscular atrophy	Mus musculus	0-37
15063149-5	2004	To explore the mechanism of this effect, we employed flow cytometry to determine levels of p53, p21, bcl-2 and caspase proteins in the taxol-resistant cells, and found that the expression of the bcl-2 protein was markedly decreased and the expression of the caspase protein markedly increased after treatment with taxol in the presence of PMA.	Paclitaxel	135-140	B cell leukemia/lymphoma 2	Mus musculus	101-106
15063149-5	2004	To explore the mechanism of this effect, we employed flow cytometry to determine levels of p53, p21, bcl-2 and caspase proteins in the taxol-resistant cells, and found that the expression of the bcl-2 protein was markedly decreased and the expression of the caspase protein markedly increased after treatment with taxol in the presence of PMA.	Paclitaxel	135-140	B cell leukemia/lymphoma 2	Mus musculus	195-200
15063149-5	2004	To explore the mechanism of this effect, we employed flow cytometry to determine levels of p53, p21, bcl-2 and caspase proteins in the taxol-resistant cells, and found that the expression of the bcl-2 protein was markedly decreased and the expression of the caspase protein markedly increased after treatment with taxol in the presence of PMA.	Paclitaxel	314-319	B cell leukemia/lymphoma 2	Mus musculus	195-200
15063149-6	2004	These findings suggest that PMA enhances the sensitivity of taxol-resistant cells to taxol, and taxol treatment in the presence of PMA induces the apoptosis of taxol-resistant cells by inhibiting the expression of the bcl-2 protein and increasing the expression of the caspase protein.	Paclitaxel	60-65	B cell leukemia/lymphoma 2	Mus musculus	218-223
15063149-6	2004	These findings suggest that PMA enhances the sensitivity of taxol-resistant cells to taxol, and taxol treatment in the presence of PMA induces the apoptosis of taxol-resistant cells by inhibiting the expression of the bcl-2 protein and increasing the expression of the caspase protein.	Paclitaxel	85-90	B cell leukemia/lymphoma 2	Mus musculus	218-223
15063149-6	2004	These findings suggest that PMA enhances the sensitivity of taxol-resistant cells to taxol, and taxol treatment in the presence of PMA induces the apoptosis of taxol-resistant cells by inhibiting the expression of the bcl-2 protein and increasing the expression of the caspase protein.	Paclitaxel	85-90	B cell leukemia/lymphoma 2	Mus musculus	218-223
15063149-6	2004	These findings suggest that PMA enhances the sensitivity of taxol-resistant cells to taxol, and taxol treatment in the presence of PMA induces the apoptosis of taxol-resistant cells by inhibiting the expression of the bcl-2 protein and increasing the expression of the caspase protein.	Paclitaxel	85-90	B cell leukemia/lymphoma 2	Mus musculus	218-223
15114714-0	2004	[Weekly paclitaxel therapy for locoregional lymph node recurrence of estrogen-receptor-negative breast cancer].	Paclitaxel	8-18	estrogen receptor 1	Homo sapiens	69-86
15051014-7	2004	RESULTS: Both the chemotherapeutic agents gemcitabine and paclitaxel activated NF-kappaB and stimulated BCL-2 gene promoter activity.	Paclitaxel	58-68	nuclear factor kappa B subunit 1	Homo sapiens	79-88
15051014-7	2004	RESULTS: Both the chemotherapeutic agents gemcitabine and paclitaxel activated NF-kappaB and stimulated BCL-2 gene promoter activity.	Paclitaxel	58-68	BCL2 apoptosis regulator	Homo sapiens	104-109
15051014-10	2004	The apoptotic effect of gemcitabine and paclitaxel also was enhanced after Akt inhibition.	Paclitaxel	40-50	AKT serine/threonine kinase 1	Homo sapiens	75-78
14691014-9	2004	Treatment with taxol, another class of microtubule-interfering agents, also caused induction of aromatase in KGN cells.	Paclitaxel	15-20	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	96-105
15047220-0	2004	Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples.	Paclitaxel	71-81	ATP binding cassette subfamily B member 1	Homo sapiens	14-36
15047220-1	2004	OBJECTIVES: The role of MDR1 in clinical paclitaxel resistance remains poorly characterized.	Paclitaxel	41-51	ATP binding cassette subfamily B member 1	Homo sapiens	24-28
15047220-2	2004	This study sought to identify the incidence and significance of P-glycoprotein (P-gp) over-expression on survival, tumor response to paclitaxel and the effect of prior cytotoxic exposure on P-gp expression in patients with paired primary and recurrent ovarian cancer samples.	Paclitaxel	133-143	ATP binding cassette subfamily B member 1	Homo sapiens	80-84
14991204-7	2004	The clustering of beta(1)-integrins examined by immunofluorescence staining was only stimulated by irradiation, cisplatin, paclitaxel, or mitomycin in case of cell attachment to FN.	Paclitaxel	123-133	fibronectin 1	Homo sapiens	178-180
14679209-2	2004	Our earlier studies indicated that taxol- or okadaic acid-induced bcl-2 mRNA destabilization in HL-60 cells is associated with decreased binding of trans-acting factors to the ARE.	Paclitaxel	35-40	BCL2 apoptosis regulator	Homo sapiens	66-71
14679209-8	2004	Taxol or okadaic acid treatment of HL-60 cells results in proteolysis of nucleolin in a similar time frame as drug-induced bcl-2 mRNA down-regulation.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	123-128
14679209-9	2004	These findings suggest that nucleolin functions as a bcl-2-stabilizing factor and that taxol and okadaic acid treatment induces apoptosis in HL-60 cells through a process that involves down-regulation of nucleolin and destabilization of bcl-2 mRNA.	Paclitaxel	87-92	BCL2 apoptosis regulator	Homo sapiens	237-242
15152945-6	2004	CONCLUSION: Although some resistant sublines express a variant pattern of suppressor/oncogenes with low bcl-2, resistance is substantially reversed by paclitaxel treatment.	Paclitaxel	151-161	BCL2 apoptosis regulator	Homo sapiens	104-109
15010891-5	2004	These data suggest that paclitaxel interferes with the expression of alphaLbeta2 (LFA-1), alpha4beta1 (VLA-4), alpha5beta1 (VLA-5), and alpha4beta7 (LPAM-1) adhesion molecules by surviving T cells.	Paclitaxel	24-34	integrin subunit alpha 5	Homo sapiens	124-129
14975768-0	2004	Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells.	Paclitaxel	52-62	BCL2 apoptosis regulator	Homo sapiens	0-5
14975768-0	2004	Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells.	Paclitaxel	52-62	BCL2 like 1	Homo sapiens	10-16
14975768-5	2004	Instead, SNU-398 cells express high levels of the anti-apoptotic Bcl-2 and Bcl-x(L) proteins and the level of Bcl-x(L) could be further induced upon paclitaxel treatment.	Paclitaxel	149-159	BCL2 apoptosis regulator	Homo sapiens	65-70
14975768-5	2004	Instead, SNU-398 cells express high levels of the anti-apoptotic Bcl-2 and Bcl-x(L) proteins and the level of Bcl-x(L) could be further induced upon paclitaxel treatment.	Paclitaxel	149-159	BCL2 like 1	Homo sapiens	75-83
14975768-5	2004	Instead, SNU-398 cells express high levels of the anti-apoptotic Bcl-2 and Bcl-x(L) proteins and the level of Bcl-x(L) could be further induced upon paclitaxel treatment.	Paclitaxel	149-159	BCL2 like 1	Homo sapiens	110-118
14975768-7	2004	Therefore, these results strongly suggest that Bcl-2 and Bcl-x(L) play an important role in mediating resistance to paclitaxel.	Paclitaxel	116-126	BCL2 apoptosis regulator	Homo sapiens	47-52
14975768-7	2004	Therefore, these results strongly suggest that Bcl-2 and Bcl-x(L) play an important role in mediating resistance to paclitaxel.	Paclitaxel	116-126	BCL2 like 1	Homo sapiens	57-65
15161043-0	2004	Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer.	Paclitaxel	89-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-15
15161043-11	2004	Considering the high impact of progression-free survival and duration of response as outcome parameters, the sHER-2/neu status is a predictive indicator for benefit from paclitaxel chemotherapy.	Paclitaxel	170-180	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-119
14726646-7	2004	In contrast, paclitaxel-induced apoptosis MM depolarization, cytochrome C release and activation of caspase 9 were all blocked by Bcl-2.	Paclitaxel	13-23	cytochrome c, somatic	Homo sapiens	61-73
14726646-7	2004	In contrast, paclitaxel-induced apoptosis MM depolarization, cytochrome C release and activation of caspase 9 were all blocked by Bcl-2.	Paclitaxel	13-23	BCL2 apoptosis regulator	Homo sapiens	130-135
15012603-0	2004	Regulation of estrogen receptor-alpha expression in MCF-7 cells by taxol.	Paclitaxel	67-72	estrogen receptor 1	Homo sapiens	14-37
15012603-1	2004	Results presented in this study demonstrate that treatment of MCF-7 cells with taxol resulted in induction of estrogen receptor-alpha (ER alpha) gene transcription with a subsequent increase in ER alpha mRNA; this effect was promoter specific since taxol did not affect total transcription in MCF-7 cells and lacked an effect on transcription of the human acidic ribosomal phosphoprotein protein PO, progesterone receptor, and pS2 genes.	Paclitaxel	79-84	estrogen receptor 1	Homo sapiens	110-133
15012603-1	2004	Results presented in this study demonstrate that treatment of MCF-7 cells with taxol resulted in induction of estrogen receptor-alpha (ER alpha) gene transcription with a subsequent increase in ER alpha mRNA; this effect was promoter specific since taxol did not affect total transcription in MCF-7 cells and lacked an effect on transcription of the human acidic ribosomal phosphoprotein protein PO, progesterone receptor, and pS2 genes.	Paclitaxel	79-84	estrogen receptor 1	Homo sapiens	135-143
15012603-1	2004	Results presented in this study demonstrate that treatment of MCF-7 cells with taxol resulted in induction of estrogen receptor-alpha (ER alpha) gene transcription with a subsequent increase in ER alpha mRNA; this effect was promoter specific since taxol did not affect total transcription in MCF-7 cells and lacked an effect on transcription of the human acidic ribosomal phosphoprotein protein PO, progesterone receptor, and pS2 genes.	Paclitaxel	79-84	estrogen receptor 1	Homo sapiens	194-202
15012603-1	2004	Results presented in this study demonstrate that treatment of MCF-7 cells with taxol resulted in induction of estrogen receptor-alpha (ER alpha) gene transcription with a subsequent increase in ER alpha mRNA; this effect was promoter specific since taxol did not affect total transcription in MCF-7 cells and lacked an effect on transcription of the human acidic ribosomal phosphoprotein protein PO, progesterone receptor, and pS2 genes.	Paclitaxel	79-84	taste 2 receptor member 64 pseudogene	Homo sapiens	427-430
15012603-2	2004	In contrast to the increase in transcription of the ER alpha gene, taxol inhibited translation of the ER alpha mRNA.	Paclitaxel	67-72	estrogen receptor 1	Homo sapiens	102-110
15012603-4	2004	The overall result of taxol treatment was to decrease the concentration of ER alpha protein in the MCF-7 cells.	Paclitaxel	22-27	estrogen receptor 1	Homo sapiens	75-83
15012603-5	2004	Evidence is presented that the effects of taxol on ER alpha gene transcription may be mediated through the induction of p53.	Paclitaxel	42-47	estrogen receptor 1	Homo sapiens	51-59
15012603-5	2004	Evidence is presented that the effects of taxol on ER alpha gene transcription may be mediated through the induction of p53.	Paclitaxel	42-47	tumor protein p53	Homo sapiens	120-123
14991204-8	2004	By contrast, tyrosine phosphorylation, as one of the major events following beta(1)-integrin clustering, showed a 3.7-fold, FN-related enhancement, and treatment of cells with the IC(50) of radiation, cisplatin, paclitaxel, or mitomycin showed a substratum-dependent induction.	Paclitaxel	212-222	fibronectin 1	Homo sapiens	124-126
14757126-4	2004	In addition, ADC and paclitaxel prevented the IFN-gamma-triggered activation of p44/p42 mitogen-activated protein (MAP) kinase in L929 fibroblasts, suggesting a possible mechanism for the observed inhibition of iNOS expression.	Paclitaxel	21-31	interferon gamma	Mus musculus	46-55
14698135-10	2004	In the every 3-week paclitaxel group, IL-6 and IL-8 increased whereas in the weekly paclitaxel group IL-10 increased significantly compared to baseline.	Paclitaxel	20-30	interleukin 6	Homo sapiens	38-42
14698135-13	2004	In the every 3-week paclitaxel group, increase in IL-8 level correlated positively with flu-like symptom (p=0.008).	Paclitaxel	20-30	C-X-C motif chemokine ligand 8	Homo sapiens	50-54
14757126-4	2004	In addition, ADC and paclitaxel prevented the IFN-gamma-triggered activation of p44/p42 mitogen-activated protein (MAP) kinase in L929 fibroblasts, suggesting a possible mechanism for the observed inhibition of iNOS expression.	Paclitaxel	21-31	nitric oxide synthase 2, inducible	Mus musculus	211-215
14757126-5	2004	These results might have important implications for the therapeutic effect of ADC and paclitaxel, since their inhibitory action on NO release partly neutralized the NO-dependent toxicity of IFN-gamma on L929 fibrosarcoma cells.	Paclitaxel	86-96	interferon gamma	Mus musculus	190-199
14967368-9	2004	INTERVENTION(S): Immunocytochemistry for alphatubulin with or without treatment with taxol (Paclitaxel, a microtubule-enhancing agent) in set 1; aspiration and microinjection of approximately 20 picolitres ooplasm from donor young and PPM oocytes into recipient PPM oocytes in sets 2 and 3, respectively.	Paclitaxel	92-102	SET domain containing 1A, histone lysine methyltransferase	Homo sapiens	138-143
14965221-5	2004	Through analyses of a number of apoptosis-associated genes or regulatory proteins, we found that glucocorticoids and paclitaxel possess opposite regulatory role in the NF-kappa B/Ikappa Balpha signaling pathway.	Paclitaxel	117-127	nuclear factor kappa B subunit 1	Homo sapiens	168-178
14965221-6	2004	Further studies indicate that paclitaxel activates Ikappa B Kinase (IKK), which in turn causes degradation of Ikappa Balpha and activation of NF-kappa B, whereas glucocorticoids antagonize paclitaxel-mediated NF-kappa B activation through induction of Ikappa Balpha synthesis.	Paclitaxel	30-40	nuclear factor kappa B subunit 1	Homo sapiens	142-152
14965221-6	2004	Further studies indicate that paclitaxel activates Ikappa B Kinase (IKK), which in turn causes degradation of Ikappa Balpha and activation of NF-kappa B, whereas glucocorticoids antagonize paclitaxel-mediated NF-kappa B activation through induction of Ikappa Balpha synthesis.	Paclitaxel	30-40	nuclear factor kappa B subunit 1	Homo sapiens	209-219
14965221-7	2004	These results suggest that the NF-kappa B/Ikappa Balpha signaling pathway might play a critical role in the mediation or regulation of paclitaxel-induced cell death.	Paclitaxel	135-145	nuclear factor kappa B subunit 1	Homo sapiens	31-41
15023242-0	2004	Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.	Paclitaxel	0-10	estrogen receptor 1	Homo sapiens	37-54
15023242-12	2004	It may be concluded that the addition of paclitaxel to anthracycline-based therapy resulted in a statistically significant improvement in outcome in patients with ER-negative inflammatory breast cancer.	Paclitaxel	41-51	estrogen receptor 1	Homo sapiens	163-165
14967368-12	2004	RESULT(S): In set 1, taxol-untreated young oocytes had normal spindle morphology and orientation to the oolemma with no microtubules in the ooplasm.	Paclitaxel	21-26	SET domain containing 1A, histone lysine methyltransferase	Homo sapiens	14-19
14760103-9	2004	Paclitaxel phosphorylated extracellular signal-regulated kinase through EGFR activation predominantly in cancer cells.	Paclitaxel	0-10	epidermal growth factor receptor	Homo sapiens	72-76
15123142-2	2004	This monoclonal humanized antibody is indicated as a single-agent second-line or third-line treatment or in combination with paclitaxel for metastatic breast cancer with HER2 gene amplification or high overexpression of HER2 (3+ on immunohistochemistry).	Paclitaxel	125-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	170-174
14985451-7	2004	The modulation of two representative genes, CDKN1A and TOP2A, was validated by Northern analyses on a panel of seven ovarian carcinoma xenograft models undergoing treatment with paclitaxel.	Paclitaxel	178-188	cyclin dependent kinase inhibitor 1A	Homo sapiens	44-50
14985455-4	2004	In so doing, we found that disruption of E-cadherin-mediated adhesion sensitizes multicellular spheroids of HT29 in vitro to treatment with 5-fluorouracil, paclitaxel, vinblastine, and etoposide but not cisplatin.	Paclitaxel	156-166	cadherin 1	Homo sapiens	41-51
14987051-1	2004	The female steroid hormone 3,17beta-estradiol (2) was selected as an agent to target taxol (1) to estrogen receptor (ER) positive breast cancer cells.	Paclitaxel	85-90	estrogen receptor 1	Homo sapiens	98-115
14987051-1	2004	The female steroid hormone 3,17beta-estradiol (2) was selected as an agent to target taxol (1) to estrogen receptor (ER) positive breast cancer cells.	Paclitaxel	85-90	estrogen receptor 1	Homo sapiens	117-119
14762343-0	2004	Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.	Paclitaxel	16-26	AKT serine/threonine kinase 1	Homo sapiens	155-158
14762343-11	2004	Direct inhibition of nuclear factor-kappaB by BAY11-0782 also sensitized these cancer cells to paclitaxel, indicating that nuclear factor-kappaB may be the crucial intermediary step connecting phosphoinositide 3-kinase/protein kinase B (Akt) to the intrinsic susceptibility of cancer cells to chemotherapeutic agents.	Paclitaxel	95-105	AKT serine/threonine kinase 1	Homo sapiens	237-240
14719078-0	2004	Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas.	Paclitaxel	82-92	BCL2 associated X, apoptosis regulator	Homo sapiens	41-44
14719078-7	2004	Cells with strong expression of p21, p27, or Bax showed significantly higher sensitivity to cisplatin, and cells with strong expression of Bax or weak expression of cyclin E showed significantly higher sensitivity to paclitaxel.	Paclitaxel	217-227	BCL2 associated X, apoptosis regulator	Homo sapiens	139-142
14760103-0	2004	ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway.	Paclitaxel	17-27	epidermal growth factor receptor	Homo sapiens	102-134
14760103-0	2004	ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway.	Paclitaxel	65-75	epidermal growth factor receptor	Homo sapiens	102-134
14760103-10	2004	ZD1839 promoted paclitaxel-induced Bcl-2 down-regulation resulting in promoting apoptosis by blocking paclitaxel-induced activation of the EGFR-extracellular signal-regulated kinase antiapoptotic pathway independent of Akt activity in SKRC-49.	Paclitaxel	16-26	BCL2 apoptosis regulator	Homo sapiens	35-40
14760103-10	2004	ZD1839 promoted paclitaxel-induced Bcl-2 down-regulation resulting in promoting apoptosis by blocking paclitaxel-induced activation of the EGFR-extracellular signal-regulated kinase antiapoptotic pathway independent of Akt activity in SKRC-49.	Paclitaxel	16-26	epidermal growth factor receptor	Homo sapiens	139-143
14760103-10	2004	ZD1839 promoted paclitaxel-induced Bcl-2 down-regulation resulting in promoting apoptosis by blocking paclitaxel-induced activation of the EGFR-extracellular signal-regulated kinase antiapoptotic pathway independent of Akt activity in SKRC-49.	Paclitaxel	102-112	BCL2 apoptosis regulator	Homo sapiens	35-40
14760103-10	2004	ZD1839 promoted paclitaxel-induced Bcl-2 down-regulation resulting in promoting apoptosis by blocking paclitaxel-induced activation of the EGFR-extracellular signal-regulated kinase antiapoptotic pathway independent of Akt activity in SKRC-49.	Paclitaxel	102-112	epidermal growth factor receptor	Homo sapiens	139-143
14760103-10	2004	ZD1839 promoted paclitaxel-induced Bcl-2 down-regulation resulting in promoting apoptosis by blocking paclitaxel-induced activation of the EGFR-extracellular signal-regulated kinase antiapoptotic pathway independent of Akt activity in SKRC-49.	Paclitaxel	102-112	AKT serine/threonine kinase 1	Homo sapiens	219-222
14724576-0	2004	Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells.	Paclitaxel	92-97	twist family bHLH transcription factor 1	Homo sapiens	38-43
15015572-5	2004	A series of assays were also performed in which we utilized parthenolide, a specific inhibitor of NF-kappaB, to analyze the possible role that the NF-kappaB/IkappaB signaling pathway has in mediating paclitaxel-induced apoptosis.	Paclitaxel	200-210	nuclear factor kappa B subunit 1	Homo sapiens	147-156
14724576-5	2004	In this study, we report the identification of a novel role for TWIST, a basic helix-loop-helix protein, which plays a central role in cell type determination and differentiation, during generation of acquired resistance to taxol in a nasopharyngeal carcinoma cell line, HNE1-T3, using comparative genome hybridization (CGH) and subsequent RT-PCR and Western blotting.	Paclitaxel	224-229	twist family bHLH transcription factor 1	Homo sapiens	64-69
14724576-6	2004	We found that upregulation of TWIST was associated with cellular resistance to taxol but not other drugs with different mechanisms of action.	Paclitaxel	79-84	twist family bHLH transcription factor 1	Homo sapiens	30-35
14724576-8	2004	In addition, ectopic expression of TWIST into human cancer cells also led to increased resistance to both taxol and vincristine.	Paclitaxel	106-111	twist family bHLH transcription factor 1	Homo sapiens	35-40
14724588-4	2004	Here, we show that the majority of both paclitaxel- and UV-induced apoptosis can be inhibited by the pharmacological JNK inhibitor, SP600125, in MCF-7 cells.	Paclitaxel	40-50	mitogen-activated protein kinase 8	Homo sapiens	117-120
14710203-0	2004	Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.	Paclitaxel	25-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
14710203-1	2004	Synergism between anti-HER2 monoclonal antibody (trastuzumab) and paclitaxel has been shown in vitro and in vivo.	Paclitaxel	66-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
14710203-17	2004	These results confirm that weekly administration of trastuzumab and paclitaxel is active in anthracycline- and taxane-pretreated metastatic breast cancer patients HER2-overexpressing.	Paclitaxel	68-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	163-167
15015572-7	2004	Short exposures to paclitaxel also induced the phosphorylation and degradation of IkappaB-alpha, which in turn caused the activation of NF-kappaB in both cell lines.	Paclitaxel	19-29	NFKB inhibitor alpha	Homo sapiens	82-95
15015572-7	2004	Short exposures to paclitaxel also induced the phosphorylation and degradation of IkappaB-alpha, which in turn caused the activation of NF-kappaB in both cell lines.	Paclitaxel	19-29	nuclear factor kappa B subunit 1	Homo sapiens	136-145
15015572-8	2004	Parthenolide was found to inhibit paclitaxel-induced activation of the NF-kappaB/IkappaB signal pathway as well as apoptotic cell death.	Paclitaxel	34-44	nuclear factor kappa B subunit 1	Homo sapiens	71-80
15015572-9	2004	CONCLUSION: These findings suggest that paclitaxel-induced apoptosis might occur independent of a prior G2/M-phase arrest and be mediated or regulated by the NF-kappaB/IkappaB signal pathway.	Paclitaxel	40-50	nuclear factor kappa B subunit 1	Homo sapiens	158-167
15581045-2	2004	Standard first-line treatment for patients with HER-2/neu overexpressing tumors includes the combination of the humanized monoclonal antibody trastuzumab with chemotherapy, mainly paclitaxel.	Paclitaxel	180-190	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-57
14569416-3	2004	In the present study, a human ovarian cancer cell line was used to investigate the possibility that Taxol might affect the expression of Ang-1, Ang-2, and VEGF.	Paclitaxel	100-105	vascular endothelial growth factor A	Homo sapiens	155-159
14569416-11	2004	VEGF gene expression was significantly decreased by exposure to Taxol for 168 h ( P&lt;0.05).	Paclitaxel	64-69	vascular endothelial growth factor A	Homo sapiens	0-4
14569416-12	2004	The VEGF concentration in the conditioned medium was also significantly reduced by exposure to Taxol for 168 h ( P&lt;0.05).	Paclitaxel	95-100	vascular endothelial growth factor A	Homo sapiens	4-8
15217493-9	2004	The results demonstrated that doxorubicin and paclitaxel, commonly used chemotherapeutic agents for the treatment of breast cancer, when used at immunomodulating doses augmented the antitumor efficacy of gene vaccines directed against HER2/neu.	Paclitaxel	46-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	235-239
14500571-9	2004	These results indicate that E2 inhibits paclitaxel-induced cell damage by inhibiting JNK activity via phosphorylation of Akt-ASK1.	Paclitaxel	40-50	mitogen-activated protein kinase 8	Homo sapiens	85-88
14500571-6	2004	We confirmed a previous report showing that paclitaxel induces cell damage via the ASK1-c-Jun N-terminal protein kinase (JNK) cascade.	Paclitaxel	44-54	mitogen-activated protein kinase 8	Homo sapiens	83-119
14500571-6	2004	We confirmed a previous report showing that paclitaxel induces cell damage via the ASK1-c-Jun N-terminal protein kinase (JNK) cascade.	Paclitaxel	44-54	mitogen-activated protein kinase 8	Homo sapiens	121-124
14500571-7	2004	E2 inhibited the paclitaxel-induced JNK activation, and the E2-induced inhibition of the paclitaxel-induced JNK activation was attenuated in cells treated with either ICI182,780 or LY294002 or transfected with ASK1S83A, in which a consensus Akt phosphorylation site at serine-83 was converted to alanine.	Paclitaxel	17-27	mitogen-activated protein kinase 8	Homo sapiens	36-39
14500571-9	2004	These results indicate that E2 inhibits paclitaxel-induced cell damage by inhibiting JNK activity via phosphorylation of Akt-ASK1.	Paclitaxel	40-50	AKT serine/threonine kinase 1	Homo sapiens	121-124
14500571-7	2004	E2 inhibited the paclitaxel-induced JNK activation, and the E2-induced inhibition of the paclitaxel-induced JNK activation was attenuated in cells treated with either ICI182,780 or LY294002 or transfected with ASK1S83A, in which a consensus Akt phosphorylation site at serine-83 was converted to alanine.	Paclitaxel	17-27	AKT serine/threonine kinase 1	Homo sapiens	241-244
14500571-7	2004	E2 inhibited the paclitaxel-induced JNK activation, and the E2-induced inhibition of the paclitaxel-induced JNK activation was attenuated in cells treated with either ICI182,780 or LY294002 or transfected with ASK1S83A, in which a consensus Akt phosphorylation site at serine-83 was converted to alanine.	Paclitaxel	89-99	mitogen-activated protein kinase 8	Homo sapiens	108-111
14729080-6	2004	Local delivery of paclitaxel from the formulation injected intratumorally was investigated using EMT-6 tumors implanted subcutaneously on Balb/c mice.	Paclitaxel	18-28	IL2 inducible T cell kinase	Mus musculus	97-100
14500571-7	2004	E2 inhibited the paclitaxel-induced JNK activation, and the E2-induced inhibition of the paclitaxel-induced JNK activation was attenuated in cells treated with either ICI182,780 or LY294002 or transfected with ASK1S83A, in which a consensus Akt phosphorylation site at serine-83 was converted to alanine.	Paclitaxel	89-99	AKT serine/threonine kinase 1	Homo sapiens	241-244
15031599-8	2004	cDNA microarray revealed that PTX treatment upregulated expression of caspase 1, 2, 3, 4, 6, 9, 10, their activator apaf-1, and stress reaction-related genes, gadd34, gadd153 in KF, although most of them were unchanged or downregulated in KFTX.	Paclitaxel	30-33	protein phosphatase 1 regulatory subunit 15A	Homo sapiens	159-165
15034952-5	2004	FDA has approved its use for patients with metastatic breast cancer with HER 2 over-expression since 1998, as a first line treatment in association with paclitaxel or as a second or third line monotherapy.	Paclitaxel	153-163	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-78
14734682-14	2004	Increase in tumor uptake of the nonspecific PEGylated protein (111)In-DTPA-PEG-ovalbumin was also observed after poly(L-glutamic acid)-paclitaxel treatment (55.6%), although this increase was less than that observed for (111)In-DTPA-PEG-annexin V (96.7%).	Paclitaxel	135-145	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	79-88
14749477-7	2004	Paclitaxel down-regulated the expression of Bcl-x(L), Mcl-1, and cellular inhibitor of apoptosis protein-1 antiapoptotic proteins and up-regulated Bid and Apaf-1.	Paclitaxel	0-10	BCL2 like 1	Homo sapiens	44-52
14749477-7	2004	Paclitaxel down-regulated the expression of Bcl-x(L), Mcl-1, and cellular inhibitor of apoptosis protein-1 antiapoptotic proteins and up-regulated Bid and Apaf-1.	Paclitaxel	0-10	BH3 interacting domain death agonist	Homo sapiens	147-150
14749477-7	2004	Paclitaxel down-regulated the expression of Bcl-x(L), Mcl-1, and cellular inhibitor of apoptosis protein-1 antiapoptotic proteins and up-regulated Bid and Apaf-1.	Paclitaxel	0-10	apoptotic peptidase activating factor 1	Homo sapiens	155-161
14749477-10	2004	Inhibition of Bcl-x(L) expression by resveratrol was critical for chemosensitization and its functional impairment mimics resveratrol-mediated sensitization to paclitaxel-induced apoptosis.	Paclitaxel	160-170	BCL2 like 1	Homo sapiens	14-22
15031599-8	2004	cDNA microarray revealed that PTX treatment upregulated expression of caspase 1, 2, 3, 4, 6, 9, 10, their activator apaf-1, and stress reaction-related genes, gadd34, gadd153 in KF, although most of them were unchanged or downregulated in KFTX.	Paclitaxel	30-33	DNA damage inducible transcript 3	Homo sapiens	167-174
15031599-12	2004	CONCLUSIONS: p53-independent mitochondrial pathways and stress-reaction-induced pathways play critical roles in PTX-induced apoptosis in ovarian cancer cells.	Paclitaxel	112-115	tumor protein p53	Homo sapiens	13-16
15031599-13	2004	Suppression of those pathways and upregulation of bag-1 and hsp-70 played an important role in acquiring resistance to PTX.	Paclitaxel	119-122	BAG cochaperone 1	Homo sapiens	50-55
15059359-0	2004	[Effect of Herceptin combined with Taxol on patients with Her-2/neu overexpressing metastatic breast cancer].	Paclitaxel	35-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-63
15110187-10	2004	PA and TRAIL complement each other using two distinct pathways that trigger apoptosis in addition to the anti-microtubule effect of PA.	Paclitaxel	132-134	TNF superfamily member 10	Homo sapiens	7-12
15110187-11	2004	The combination of TRAIL and PA suppresses tumor growth that is otherwise resistant to treatment with either PA or TRAIL alone, by improving proapoptotic effects of the drugs.	Paclitaxel	29-31	TNF superfamily member 10	Homo sapiens	115-120
15110187-11	2004	The combination of TRAIL and PA suppresses tumor growth that is otherwise resistant to treatment with either PA or TRAIL alone, by improving proapoptotic effects of the drugs.	Paclitaxel	109-111	TNF superfamily member 10	Homo sapiens	19-24
15059359-0	2004	[Effect of Herceptin combined with Taxol on patients with Her-2/neu overexpressing metastatic breast cancer].	Paclitaxel	35-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-67
15059359-7	2004	CONCLUSION: The treatment with Herceptin and Taxol is effective and safe for patients with Her-2/neu overexpressing metastatic breast cancer.	Paclitaxel	45-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-100
14680805-3	2003	Treatment of the antisense BAG-1-transfected cells with the anti-cancer drugs staurosporine, paclitaxel, all-trans retinoic acid (ATRA), and N-(4-hydroxyphenyl) retinamide (4-HPR) resulted in significantly enhanced apoptosis and reduced cell viability relative to vector-transfected cells.	Paclitaxel	93-103	BAG cochaperone 1	Homo sapiens	27-32
14680805-6	2003	Treatment with staurosporine and paclitaxel resulted in increased cytochrome c release from mitochondria, whereas there was no change induced by treatment with ATRA and 4-HPR.	Paclitaxel	33-43	cytochrome c, somatic	Homo sapiens	66-78
14514687-1	2003	We show here that JNK1 activity is rapidly up-regulated and prolonged by specific mechanisms during apoptosis induced by paclitaxel- or ginsenoside-Rh2 in SK-HEP-1 cells.	Paclitaxel	121-131	mitogen-activated protein kinase 8	Homo sapiens	18-22
14671431-3	2003	Lonafarnib has recently been shown, in addition, to be a potent inhibitor of the transmembrane efflux transporter P-glycoprotein (P-gp), which confers cellular resistance to the substrates vincristine, taxol and paclitaxel.	Paclitaxel	202-207	ATP binding cassette subfamily B member 1	Homo sapiens	114-128
14527951-0	2003	FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines.	Paclitaxel	63-73	forkhead box O3	Homo sapiens	0-6
14527951-3	2003	Western blotting revealed that in a panel of nine breast cancer cell lines expression of FoxO1a and FoxO3a correlated with the expression of the pro-apoptotic FoxO target Bim, which was associated with paclitaxel-induced apoptosis.	Paclitaxel	202-212	forkhead box O1	Homo sapiens	89-95
14527951-3	2003	Western blotting revealed that in a panel of nine breast cancer cell lines expression of FoxO1a and FoxO3a correlated with the expression of the pro-apoptotic FoxO target Bim, which was associated with paclitaxel-induced apoptosis.	Paclitaxel	202-212	forkhead box O3	Homo sapiens	100-106
14527951-4	2003	In MCF-7 cells, which were paclitaxel-sensitive, the already high basal levels of FoxO3a and Bim protein increased dramatically after drug treatment, as did Bim mRNA, which correlated with apoptosis induction.	Paclitaxel	27-37	forkhead box O3	Homo sapiens	82-88
14527951-7	2003	Gene silencing experiments showed that small interference RNA (siRNA) specific for FoxO3a reduced the levels of FoxO3a and Bim protein as well as inhibited apoptosis in paclitaxel-treated MCF-7 cells.	Paclitaxel	169-179	forkhead box O3	Homo sapiens	83-89
14527951-9	2003	This is the first demonstration that up-regulation of FoxO3a by paclitaxel can result in increased levels of Bim mRNA and protein, which can be a direct cause of apoptosis in breast cancer cells.	Paclitaxel	64-74	forkhead box O3	Homo sapiens	54-60
14751837-6	2003	The antisense oligonucleotides also potentiated the effects of p53 activation and p21 induction by chemotherapeutic agents 10-hydroxycamptothecin, adriamycin, 5-fluorouracil, and paclitaxel.	Paclitaxel	179-189	tumor protein p53	Homo sapiens	63-66
14676119-1	2003	PURPOSE: Combining trastuzumab with doxorubicin and paclitaxel (AT) is attractive because of the activity of AT and survival improvements observed when trastuzumab is added to either agent in HER2-positive metastatic breast cancer.	Paclitaxel	52-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	192-196
14671431-3	2003	Lonafarnib has recently been shown, in addition, to be a potent inhibitor of the transmembrane efflux transporter P-glycoprotein (P-gp), which confers cellular resistance to the substrates vincristine, taxol and paclitaxel.	Paclitaxel	202-207	ATP binding cassette subfamily B member 1	Homo sapiens	130-134
14671431-3	2003	Lonafarnib has recently been shown, in addition, to be a potent inhibitor of the transmembrane efflux transporter P-glycoprotein (P-gp), which confers cellular resistance to the substrates vincristine, taxol and paclitaxel.	Paclitaxel	212-222	ATP binding cassette subfamily B member 1	Homo sapiens	114-128
14671431-3	2003	Lonafarnib has recently been shown, in addition, to be a potent inhibitor of the transmembrane efflux transporter P-glycoprotein (P-gp), which confers cellular resistance to the substrates vincristine, taxol and paclitaxel.	Paclitaxel	212-222	ATP binding cassette subfamily B member 1	Homo sapiens	130-134
14751030-11	2003	In conclusion, TRAIL in combination with troglitazone, paclitaxel, and cycloheximide induces apoptosis in thyroid cancer cells at suboptimal concentrations that cannot be achieved using TRAIL alone.	Paclitaxel	55-65	TNF superfamily member 10	Homo sapiens	15-20
14685027-2	2003	Although it has been known that taxol induces the apoptosis of cancer cells through cytochrome C release and the activation of caspases, the effect of taxol on dendritic cells (DCs) has not been studied.	Paclitaxel	32-37	cytochrome c, somatic	Homo sapiens	84-96
14768403-8	2003	The triplet combination of gemcitabine, paclitaxel, and trastuzumab is highly active and well tolerated in patients with HER2-overexpressing metastatic breast cancer.	Paclitaxel	40-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
14751030-9	2003	In both TPC-1 (TRAIL-sensitive) and FTC-133 (TRAIL-resistant) thyroid cancer cell lines, pretreatment with troglitazone, cycloheximide, and paclitaxel enhanced TRAIL-induced cell death significantly but pretreatment with geldanamycin did not.	Paclitaxel	140-150	two pore segment channel 1	Homo sapiens	8-13
14603253-7	2003	Overexpression of RASSF1A induces mitotic arrest at metaphase with aberrant mitotic cells reminiscent of such produced by the microtubule-stabilizing drug paclitaxel (taxol), including monopolar spindles, or complete lack of a mitotic spindle.	Paclitaxel	155-165	Ras association (RalGDS/AF-6) domain family member 1	Mus musculus	18-25
14603253-7	2003	Overexpression of RASSF1A induces mitotic arrest at metaphase with aberrant mitotic cells reminiscent of such produced by the microtubule-stabilizing drug paclitaxel (taxol), including monopolar spindles, or complete lack of a mitotic spindle.	Paclitaxel	167-172	Ras association (RalGDS/AF-6) domain family member 1	Mus musculus	18-25
14705863-4	2003	Increased expression of MDR1 reduces the bioavailability of MDR1 substrates such as digoxin, cyclosporin, and taxol.	Paclitaxel	110-115	ATP binding cassette subfamily B member 1	Homo sapiens	24-28
14581275-10	2003	Response to paclitaxel was associated with a fall in plasma IL-6 levels (P = 0.04) but no change in other cytokines.	Paclitaxel	12-22	interleukin 6	Homo sapiens	60-64
14581275-13	2003	Response to paclitaxel therapy correlates with a fall in plasma IL-6 levels and recent data indicate this may be a surrogate marker of KS-associated herpesvirus viral load.	Paclitaxel	12-22	interleukin 6	Homo sapiens	64-68
14688474-3	2003	Studies by a number of laboratories have also linked suppression of mitogen activated protein kinase (MAPK) signaling to enhanced Taxol toxicity.	Paclitaxel	130-135	mitogen-activated protein kinase 3	Homo sapiens	102-106
14705863-4	2003	Increased expression of MDR1 reduces the bioavailability of MDR1 substrates such as digoxin, cyclosporin, and taxol.	Paclitaxel	110-115	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
14507946-1	2003	PURPOSE: This phase II study evaluated the pharmacokinetics and safety of trastuzumab and paclitaxel given every 3 weeks to women with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic breast cancer.	Paclitaxel	90-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	177-181
14505794-0	2003	Taxol- and okadaic acid-induced destabilization of bcl-2 mRNA is associated with decreased binding of proteins to a bcl-2 instability element.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	51-56
14512701-1	2003	Taxol treatment froze the cell cycle in the G(2)/M phase, induced morphological changes characteristic of apoptotic/necrotic cell death and increased CYP3A4 enzymatic activity, CYP3A4 mRNA and protein levels in HepG2 cells overexpressing CYP3A4.	Paclitaxel	0-5	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-156
14512701-1	2003	Taxol treatment froze the cell cycle in the G(2)/M phase, induced morphological changes characteristic of apoptotic/necrotic cell death and increased CYP3A4 enzymatic activity, CYP3A4 mRNA and protein levels in HepG2 cells overexpressing CYP3A4.	Paclitaxel	0-5	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	177-183
14512701-1	2003	Taxol treatment froze the cell cycle in the G(2)/M phase, induced morphological changes characteristic of apoptotic/necrotic cell death and increased CYP3A4 enzymatic activity, CYP3A4 mRNA and protein levels in HepG2 cells overexpressing CYP3A4.	Paclitaxel	0-5	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	177-183
14512701-3	2003	P-Glycoprotein expression was only slightly increased by Taxol, however, P-glycoprotein-mediated pumping efficiency was significantly increased.	Paclitaxel	57-62	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
14512701-4	2003	Preincubation of cells with an anti-MDR1 monoclonal antibody prior to the drug treatment, coincubation of cells with a potent CYP3A4 inhibitor--ketoconazole--or with both compounds increased Taxol toxicity and proapoptotic activity, indicating that the P-glycoprotein system has a major role in Taxol disposition in hepatoblastoma cells.	Paclitaxel	191-196	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
14512701-4	2003	Preincubation of cells with an anti-MDR1 monoclonal antibody prior to the drug treatment, coincubation of cells with a potent CYP3A4 inhibitor--ketoconazole--or with both compounds increased Taxol toxicity and proapoptotic activity, indicating that the P-glycoprotein system has a major role in Taxol disposition in hepatoblastoma cells.	Paclitaxel	191-196	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-132
14512701-4	2003	Preincubation of cells with an anti-MDR1 monoclonal antibody prior to the drug treatment, coincubation of cells with a potent CYP3A4 inhibitor--ketoconazole--or with both compounds increased Taxol toxicity and proapoptotic activity, indicating that the P-glycoprotein system has a major role in Taxol disposition in hepatoblastoma cells.	Paclitaxel	295-300	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-132
13679064-3	2003	We here provide the first experimental evidence that restoring a functional androgen receptor (AR) in the androgen-independent prostate cancer PC3 cells enhances their sensitivity to growth arrest and suppresses their colony-forming ability in response to paclitaxel and gamma-irradiation.	Paclitaxel	256-266	androgen receptor	Homo sapiens	76-93
13679064-3	2003	We here provide the first experimental evidence that restoring a functional androgen receptor (AR) in the androgen-independent prostate cancer PC3 cells enhances their sensitivity to growth arrest and suppresses their colony-forming ability in response to paclitaxel and gamma-irradiation.	Paclitaxel	256-266	androgen receptor	Homo sapiens	95-97
14617792-0	2003	Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin"s lymphoma B cell lines to paclitaxel-induced apoptosis.	Paclitaxel	173-183	keratin 20	Homo sapiens	16-20
14617792-3	2003	This study examined the apoptotic signaling mediated by rituximab on rituximab- and paclitaxel-resistant CD20(+) NHL B cell lines (Ramos, Raji, Daudi, and 2F7).	Paclitaxel	84-94	keratin 20	Homo sapiens	105-109
14617792-7	2003	Paclitaxel down-regulated the expression of Bcl-xL and inhibitor of apoptosis proteins (c-IAP-1) and up-regulated the expression of Bad and Apaf-1.	Paclitaxel	0-10	BCL2 like 1	Homo sapiens	44-50
14617792-7	2003	Paclitaxel down-regulated the expression of Bcl-xL and inhibitor of apoptosis proteins (c-IAP-1) and up-regulated the expression of Bad and Apaf-1.	Paclitaxel	0-10	apoptotic peptidase activating factor 1	Homo sapiens	140-146
14617793-2	2003	Although the cytotoxic taxanes paclitaxel and docetaxel are substrates for Pgp-mediated efflux, the semisynthetic taxane analogue ortataxel inhibits drug efflux mediated by Pgp as well as, as we recently demonstrated, MRP-1 and BCRP.	Paclitaxel	31-41	ATP binding cassette subfamily B member 1	Homo sapiens	75-78
14583493-2	2003	The chemotherapeutic agent paclitaxel (Taxol) activates mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase and, combined with MEK inhibition, synergistically enhances apoptosis.	Paclitaxel	27-37	mitogen-activated protein kinase kinase 7	Homo sapiens	56-95
14583493-2	2003	The chemotherapeutic agent paclitaxel (Taxol) activates mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase and, combined with MEK inhibition, synergistically enhances apoptosis.	Paclitaxel	27-37	mitogen-activated protein kinase kinase 7	Homo sapiens	97-100
14583493-2	2003	The chemotherapeutic agent paclitaxel (Taxol) activates mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase and, combined with MEK inhibition, synergistically enhances apoptosis.	Paclitaxel	27-37	mitogen-activated protein kinase kinase 7	Homo sapiens	159-162
14583493-2	2003	The chemotherapeutic agent paclitaxel (Taxol) activates mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase and, combined with MEK inhibition, synergistically enhances apoptosis.	Paclitaxel	39-44	mitogen-activated protein kinase kinase 7	Homo sapiens	56-95
14583493-2	2003	The chemotherapeutic agent paclitaxel (Taxol) activates mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase and, combined with MEK inhibition, synergistically enhances apoptosis.	Paclitaxel	39-44	mitogen-activated protein kinase kinase 7	Homo sapiens	97-100
14583493-2	2003	The chemotherapeutic agent paclitaxel (Taxol) activates mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase and, combined with MEK inhibition, synergistically enhances apoptosis.	Paclitaxel	39-44	mitogen-activated protein kinase kinase 7	Homo sapiens	159-162
14583493-4	2003	We found that the combined treatment of paclitaxel and MEK inhibitor uniquely altered the proteins RS/DJ-1 (RNA-binding regulatory subunit/DJ-1 PARK7) and RhoGDIalpha (Rho GDP-dissociation inhibitor alpha).	Paclitaxel	40-50	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
14505794-0	2003	Taxol- and okadaic acid-induced destabilization of bcl-2 mRNA is associated with decreased binding of proteins to a bcl-2 instability element.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	116-121
14505794-2	2003	We report here that taxol or okadaic acid (OA) treatment of HL-60 cells reduced bcl-2 mRNA steady state levels to 50% of control cell levels in 20-24hr of treatment.	Paclitaxel	20-25	BCL2 apoptosis regulator	Homo sapiens	80-85
14505794-8	2003	Collectively, these results suggest a novel action of taxol and OA on bcl-2 expression, which involves bcl-2 mRNA downregulation through inactivation of bcl-2 mRNA stabilizing factors.	Paclitaxel	54-59	BCL2 apoptosis regulator	Homo sapiens	70-75
14505794-8	2003	Collectively, these results suggest a novel action of taxol and OA on bcl-2 expression, which involves bcl-2 mRNA downregulation through inactivation of bcl-2 mRNA stabilizing factors.	Paclitaxel	54-59	BCL2 apoptosis regulator	Homo sapiens	103-108
14505794-8	2003	Collectively, these results suggest a novel action of taxol and OA on bcl-2 expression, which involves bcl-2 mRNA downregulation through inactivation of bcl-2 mRNA stabilizing factors.	Paclitaxel	54-59	BCL2 apoptosis regulator	Homo sapiens	103-108
14655754-4	2003	Inhibition of PGP activity by verapamil or PSC 833 enhanced the cytotoxic effects of vincristine, doxorubicin, teniposide and taxol.	Paclitaxel	126-131	ATP binding cassette subfamily B member 1	Homo sapiens	14-17
12967311-3	2003	Significantly, like laulimalide, these analogues are poor substrates for the drug transport protein P-glycoprotein (Pgp) and are thus effective against Taxol-resistant cell lines.	Paclitaxel	152-157	ATP binding cassette subfamily B member 1	Homo sapiens	100-114
14508823-0	2003	Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.	Paclitaxel	25-35	thymoma viral proto-oncogene 1	Mus musculus	150-153
14508823-14	2003	Furthermore, Akt phosphorylation contributed to VEGF up-regulation and Akt phosphorylation was reduced more effectively by combined trastuzumab plus paclitaxel treatment compared with the other treatments.	Paclitaxel	149-159	thymoma viral proto-oncogene 1	Mus musculus	13-16
14508823-14	2003	Furthermore, Akt phosphorylation contributed to VEGF up-regulation and Akt phosphorylation was reduced more effectively by combined trastuzumab plus paclitaxel treatment compared with the other treatments.	Paclitaxel	149-159	thymoma viral proto-oncogene 1	Mus musculus	71-74
14578588-0	2003	Taxol inhibits melanoma metastases through apoptosis induction, angiogenesis inhibition, and restoration of E-cadherin and nm23 expression.	Paclitaxel	0-5	cadherin 1	Mus musculus	108-118
14578588-9	2003	Conversely, Taxol increased the expression of E-cadherin and nm23.	Paclitaxel	12-17	cadherin 1	Mus musculus	46-56
12860987-1	2003	Modification-specific antibodies were used to characterize the phosphorylation and acetylation of human p53 in response to genotoxic (UV, IR, and adriamycin) and non-genotoxic (PALA, taxol, nocodazole) stress in cultured human cells at 14 known modification sites.	Paclitaxel	183-188	tumor protein p53	Homo sapiens	104-107
12860987-5	2003	The non-genotoxic agents PALA, taxol and nocodazole induced p53 accumulation and phosphorylation at Ser6, Ser33, Ser46, and Ser392.	Paclitaxel	31-36	tumor protein p53	Homo sapiens	60-63
14522368-7	2003	Cytochrome P450 3A4 inducing anti-epileptic drugs like phenytoin, carbamazepine and phenobarbital may significantly increase the metabolism of many chemotherapeutic agents like CPT11 and paclitaxel (but also of newer biological agents like many tyrosine kinase inhibitors).	Paclitaxel	187-197	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-19
14529677-6	2003	pan-JNK expression was higher in specimens treated with both platinum agents (P = 0.038) and paclitaxel (P = 0.033).	Paclitaxel	93-103	mitogen-activated protein kinase 8	Homo sapiens	4-7
14517333-1	2003	We show that Cdc6, an essential initiation factor for DNA replication, undergoes caspase-3-mediated cleavage in the early stages of apoptosis in HeLa cells and SK-HEP-1 cells induced by etoposide, paclitaxel, ginsenoside Rh2, or tumor necrosis factor-related apoptosis-inducing ligand.	Paclitaxel	197-207	cell division cycle 6	Homo sapiens	13-17
14517333-1	2003	We show that Cdc6, an essential initiation factor for DNA replication, undergoes caspase-3-mediated cleavage in the early stages of apoptosis in HeLa cells and SK-HEP-1 cells induced by etoposide, paclitaxel, ginsenoside Rh2, or tumor necrosis factor-related apoptosis-inducing ligand.	Paclitaxel	197-207	caspase 3	Homo sapiens	81-90
12826679-2	2003	We investigated the effects of taxanes (docetaxel and paclitaxel) on cyclooxygenase-2 (COX-2) transcription and mRNA stability in human mammary epithelial cells.	Paclitaxel	54-64	prostaglandin-endoperoxide synthase 2	Homo sapiens	69-85
12826679-2	2003	We investigated the effects of taxanes (docetaxel and paclitaxel) on cyclooxygenase-2 (COX-2) transcription and mRNA stability in human mammary epithelial cells.	Paclitaxel	54-64	prostaglandin-endoperoxide synthase 2	Homo sapiens	87-92
12826679-3	2003	As reported previously for paclitaxel, docetaxel stimulated COX-2 transcription by an AP-1-dependent mechanism.	Paclitaxel	27-37	prostaglandin-endoperoxide synthase 2	Homo sapiens	60-65
12967311-3	2003	Significantly, like laulimalide, these analogues are poor substrates for the drug transport protein P-glycoprotein (Pgp) and are thus effective against Taxol-resistant cell lines.	Paclitaxel	152-157	ATP binding cassette subfamily B member 1	Homo sapiens	116-119
12897130-0	2003	Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells.	Paclitaxel	80-90	tumor protein p53	Homo sapiens	23-26
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Paclitaxel	28-38	TNF superfamily member 10	Homo sapiens	137-142
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Paclitaxel	28-38	TNF superfamily member 10	Homo sapiens	162-167
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Paclitaxel	28-38	TNF superfamily member 10	Homo sapiens	162-167
12920504-4	2003	Cytochrome p450 (CYP)-catalysed metabolism of paclitaxel was investigated in rat and human liver microsomes.	Paclitaxel	46-56	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	0-15
12920504-4	2003	Cytochrome p450 (CYP)-catalysed metabolism of paclitaxel was investigated in rat and human liver microsomes.	Paclitaxel	46-56	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	17-20
12902425-2	2003	To provide insight into both the dynamics of the pump and the effects of MDR, we radiolabeled paclitaxel, a substrate for the Pgp pump, with (18)F to study MDR in vivo with PET.	Paclitaxel	94-104	ATP binding cassette subfamily B member 1	Homo sapiens	126-129
12973835-4	2003	ErbB2-overexpressing breast tumor cells are resistant to taxol-induced apoptotic cell death.	Paclitaxel	57-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
12973835-5	2003	The underlying molecular mechanism is that ErbB2 inhibits p34(Cdc2) activation, which is required for taxol-induced apoptosis, by up-regulating p21(Cip1) and by hyperphosphorylating p34(Cdc2) on tyrosine-15.	Paclitaxel	102-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-48
14518413-9	2003	Weekly paclitaxel therapy (11 infusions) brought about a normalization of the elevated CEA levels and a good control of the pericardial effusion.	Paclitaxel	7-17	CEA cell adhesion molecule 3	Homo sapiens	87-90
12768320-1	2003	PURPOSE: Based on prior studies demonstrating the effect of 13- cis-retinoic acid and interferon alpha (CRA/IFN) in decreasing the expression of the antiapoptotic protein bcl-2, our prior clinical study of CRA/IFN with paclitaxel (TAX) administered every 3 weeks, and data demonstrating increased activity of weekly TAX against prostate cancer, we designed a phase I study of weekly TAX in combination with CRA/IFN in patients with prostate cancer and other advanced malignancies.	Paclitaxel	219-229	BCL2 apoptosis regulator	Homo sapiens	171-176
12768320-1	2003	PURPOSE: Based on prior studies demonstrating the effect of 13- cis-retinoic acid and interferon alpha (CRA/IFN) in decreasing the expression of the antiapoptotic protein bcl-2, our prior clinical study of CRA/IFN with paclitaxel (TAX) administered every 3 weeks, and data demonstrating increased activity of weekly TAX against prostate cancer, we designed a phase I study of weekly TAX in combination with CRA/IFN in patients with prostate cancer and other advanced malignancies.	Paclitaxel	219-229	interferon alpha 1	Homo sapiens	108-111
12851680-4	2003	Inhibition of NF-kappaB by a dominant negative super-repressor IkappaB mutant adenoviral construct enhanced the apoptotic potentials of paclitaxel and rhTNF-alpha in these cells.	Paclitaxel	136-146	nuclear factor kappa B subunit 1	Homo sapiens	14-23
12851680-5	2003	Using reporter assays and RT-PCR analysis, we demonstrate that paclitaxel-induced cell death was associated with an increase in NF-kappaB activation and MDR-1 gene expression.	Paclitaxel	63-73	nuclear factor kappa B subunit 1	Homo sapiens	128-137
12851680-5	2003	Using reporter assays and RT-PCR analysis, we demonstrate that paclitaxel-induced cell death was associated with an increase in NF-kappaB activation and MDR-1 gene expression.	Paclitaxel	63-73	ATP binding cassette subfamily B member 1	Homo sapiens	153-158
12851680-6	2003	Abrogation of these effects by the dominant negative IkappaB adenoviral construct suggests that induction and/or constitutive activation of NF-kappaB can block the paclitaxel-induced apoptotic signaling pathways in this cell line, possibly by increasing the expression of anti-apoptotic and MDR-1 gene products, leading to development of chemoresistance in these cells.	Paclitaxel	164-174	nuclear factor kappa B subunit 1	Homo sapiens	140-149
12851680-6	2003	Abrogation of these effects by the dominant negative IkappaB adenoviral construct suggests that induction and/or constitutive activation of NF-kappaB can block the paclitaxel-induced apoptotic signaling pathways in this cell line, possibly by increasing the expression of anti-apoptotic and MDR-1 gene products, leading to development of chemoresistance in these cells.	Paclitaxel	164-174	ATP binding cassette subfamily B member 1	Homo sapiens	291-296
12897130-0	2003	Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells.	Paclitaxel	92-97	tumor protein p53	Homo sapiens	23-26
12897130-6	2003	Since siRNA directed against Snk/Plk2 promoted death of paclitaxel-treated cells in mitosis, we envision a mitotic checkpoint wherein p53-dependent activation of Snk/Plk2 prevents mitotic catastrophe following spindle damage.	Paclitaxel	56-66	tumor protein p53	Homo sapiens	134-137
12814625-6	2003	Degradation of hY1 could also be demonstrated after treatment of A549 lung carcinoma cells treated with Staurosporin, Paclitaxel, or the histone deacetylase inhibitor LAQ824.	Paclitaxel	118-128	RNA, Ro60-associated Y1	Homo sapiens	15-18
12695858-0	2003	Adenocarcinoma cells exposed in vitro to Navelbine or Taxol increase Ep-CAM expression through a novel mechanism.	Paclitaxel	54-59	epithelial cell adhesion molecule	Homo sapiens	69-75
12838322-4	2003	Although inhibition of MEK/MAPK or PI-3K/Akt can each enhance the cytotoxicity of paclitaxel, doxorubicin, or 5-fluorouracil, inhibition of the PI-3K/Akt pathway seems to have a greater effect than inhibition of the MEK/MAPK pathway in reversing Ras-mediated drug resistance.	Paclitaxel	82-92	mitogen-activated protein kinase kinase 7	Homo sapiens	23-26
12838322-4	2003	Although inhibition of MEK/MAPK or PI-3K/Akt can each enhance the cytotoxicity of paclitaxel, doxorubicin, or 5-fluorouracil, inhibition of the PI-3K/Akt pathway seems to have a greater effect than inhibition of the MEK/MAPK pathway in reversing Ras-mediated drug resistance.	Paclitaxel	82-92	AKT serine/threonine kinase 1	Homo sapiens	41-44
14566676-5	2003	Western blot analysis demonstrated P-glycoprotein (P-gp) overexpression in taxol-resistant cells.	Paclitaxel	75-80	ATP binding cassette subfamily B member 1	Homo sapiens	35-49
14566676-5	2003	Western blot analysis demonstrated P-glycoprotein (P-gp) overexpression in taxol-resistant cells.	Paclitaxel	75-80	ATP binding cassette subfamily B member 1	Homo sapiens	51-55
14566676-10	2003	CONCLUSIONS: Taxol-resistance was primarily mediated by P-gp overexpression in KK47/TX30 cells.	Paclitaxel	13-18	ATP binding cassette subfamily B member 1	Homo sapiens	56-60
12926066-6	2003	Caspases-3/7 were dramatically activated at 48-72 hours by the novel paclitaxel analogs.	Paclitaxel	69-79	caspase 3	Homo sapiens	0-12
12695858-2	2003	Following pretreatment of various adenocarcinoma cells in culture with clinically relevant concentrations of vinorelbine tartrate (Navelbine) or paclitaxel (Taxol), cell surface expression of Ep-CAM antigen increased by two- to ten-fold compared to that of untreated control cells and was associated with arrest of cell cycle progression and accumulation of cells in the S and G2/M phases.	Paclitaxel	145-155	epithelial cell adhesion molecule	Homo sapiens	192-198
12695858-2	2003	Following pretreatment of various adenocarcinoma cells in culture with clinically relevant concentrations of vinorelbine tartrate (Navelbine) or paclitaxel (Taxol), cell surface expression of Ep-CAM antigen increased by two- to ten-fold compared to that of untreated control cells and was associated with arrest of cell cycle progression and accumulation of cells in the S and G2/M phases.	Paclitaxel	157-162	epithelial cell adhesion molecule	Homo sapiens	192-198
12911719-8	2003	Significant cytotoxic/cytostatic activity was elicited by treating ascitic MO/MA with interferon-gamma (IFN-gamma) and interleukin-2 (IL-2), but not with interleukin-12, paclitaxel, granulocyte-monocyte colony-stimulating factor (GM-CSF), or tumor necrosis factor-alpha (TNF-alpha).	Paclitaxel	170-180	interleukin 2	Homo sapiens	134-138
12812986-8	2003	Although both full-length and mutant DISC1 are found in microtubule fractions, neither form of DISC1 appears to bind directly to microtubules, but rather do so in a MIPT3-dependent fashion that is stabilized by taxol.	Paclitaxel	211-216	TRAF3 interacting protein 1	Homo sapiens	165-170
12883037-3	2003	We demonstrated that Dox and Taxol induced apoptosis through down-regulation of XIAP and phosphorylation of Bcl-2 in a concentration-dependent manner without changing expression of Bcl-xL in H460 cells.	Paclitaxel	29-34	BCL2 apoptosis regulator	Homo sapiens	108-113
12883037-3	2003	We demonstrated that Dox and Taxol induced apoptosis through down-regulation of XIAP and phosphorylation of Bcl-2 in a concentration-dependent manner without changing expression of Bcl-xL in H460 cells.	Paclitaxel	29-34	BCL2 like 1	Homo sapiens	181-187
12821934-2	2003	To determine whether the activation of p38 MAPK could be specific to cancer therapy, we investigated the activation of p38 MAPK in response to several chemotherapeutic agents, such as cisplatin, doxorubicin and taxol in several human cell lines.	Paclitaxel	211-216	mitogen-activated protein kinase 14	Homo sapiens	39-42
12815160-0	2003	Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance.	Paclitaxel	46-56	BCL2 apoptosis regulator	Homo sapiens	0-5
12815160-6	2003	CPM values after Bcl-2 immunoprecipitation was 62.8-fold higher than those of the control antibody, thereby indicating the involvement of Bcl-2 in paclitaxel binding.	Paclitaxel	147-157	BCL2 apoptosis regulator	Homo sapiens	17-22
12815160-6	2003	CPM values after Bcl-2 immunoprecipitation was 62.8-fold higher than those of the control antibody, thereby indicating the involvement of Bcl-2 in paclitaxel binding.	Paclitaxel	147-157	BCL2 apoptosis regulator	Homo sapiens	138-143
12815160-9	2003	When A2780TC cells were stably transfected with a Bcl-2 construct, paclitaxel sensitivity was partially restored, thereby supporting a direct role of Bcl-2 down-regulation in the maintenance of drug-resistance.	Paclitaxel	67-77	BCL2 apoptosis regulator	Homo sapiens	50-55
12815160-9	2003	When A2780TC cells were stably transfected with a Bcl-2 construct, paclitaxel sensitivity was partially restored, thereby supporting a direct role of Bcl-2 down-regulation in the maintenance of drug-resistance.	Paclitaxel	67-77	BCL2 apoptosis regulator	Homo sapiens	150-155
12815160-10	2003	Finally, we examined Bcl-2 by immunohistochemistry in a small subset of ovarian cancer paclitaxel-resistant patients and we noticed that the protein is down-regulated in this clinical setting with respect to the expression levels found in drug-sensitive tumors.	Paclitaxel	87-97	BCL2 apoptosis regulator	Homo sapiens	21-26
12821934-2	2003	To determine whether the activation of p38 MAPK could be specific to cancer therapy, we investigated the activation of p38 MAPK in response to several chemotherapeutic agents, such as cisplatin, doxorubicin and taxol in several human cell lines.	Paclitaxel	211-216	mitogen-activated protein kinase 14	Homo sapiens	119-122
12773170-3	2003	The binding of the anti-tumour agent Taxol to the anti-apoptosis protein Bcl-2 [Rodi, Janes, Sanganee, Holton, Wallace and Makowski (1999) J. Mol.	Paclitaxel	37-42	BCL2 apoptosis regulator	Homo sapiens	73-78
12773051-4	2003	More importantly, compound 10 was found to be equipotent in MES-SA cells and paclitaxel-resistant, p-glycoprotein overexpressed MES-SA/DX5 cells.	Paclitaxel	77-87	ATP binding cassette subfamily B member 1	Homo sapiens	99-113
12709826-0	2003	Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.	Paclitaxel	28-38	BCL2 apoptosis regulator	Homo sapiens	76-81
12796407-0	2003	Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells.	Paclitaxel	0-10	mitogen-activated protein kinase 14	Homo sapiens	55-58
12796407-4	2003	RESULTS: In MDA-MB-435 cells, paclitaxel treatment stimulated the activity of both protein kinase A and p38, and inhibited the activity of the Na(+)/H(+) exchanger isoform 1 (NHE1) with similar IC(50) concentrations as for its activation of apoptosis.	Paclitaxel	30-40	mitogen-activated protein kinase 14	Homo sapiens	104-107
12796407-4	2003	RESULTS: In MDA-MB-435 cells, paclitaxel treatment stimulated the activity of both protein kinase A and p38, and inhibited the activity of the Na(+)/H(+) exchanger isoform 1 (NHE1) with similar IC(50) concentrations as for its activation of apoptosis.	Paclitaxel	30-40	solute carrier family 9 member A1	Homo sapiens	143-173
12796407-4	2003	RESULTS: In MDA-MB-435 cells, paclitaxel treatment stimulated the activity of both protein kinase A and p38, and inhibited the activity of the Na(+)/H(+) exchanger isoform 1 (NHE1) with similar IC(50) concentrations as for its activation of apoptosis.	Paclitaxel	30-40	solute carrier family 9 member A1	Homo sapiens	175-179
12796407-5	2003	Activation and inhibition experiments demonstrated that protein kinase A and p38 participate sequentially upstream of the NHE1 in regulating the paclitaxel-induced apoptotic pathway.	Paclitaxel	145-155	mitogen-activated protein kinase 14	Homo sapiens	77-80
12796407-5	2003	Activation and inhibition experiments demonstrated that protein kinase A and p38 participate sequentially upstream of the NHE1 in regulating the paclitaxel-induced apoptotic pathway.	Paclitaxel	145-155	solute carrier family 9 member A1	Homo sapiens	122-126
12796407-6	2003	Importantly, concurrent specific inhibition of the NHE1 with paclitaxel treatment resulted in a synergistic induction of apoptosis and a reduction in the paclitaxel IC(50) for apoptosis.	Paclitaxel	61-71	solute carrier family 9 member A1	Homo sapiens	51-55
12796407-6	2003	Importantly, concurrent specific inhibition of the NHE1 with paclitaxel treatment resulted in a synergistic induction of apoptosis and a reduction in the paclitaxel IC(50) for apoptosis.	Paclitaxel	154-164	solute carrier family 9 member A1	Homo sapiens	51-55
12796407-7	2003	This sensitization of paclitaxel apoptotic action by specific inhibition of NHE1 was verified in breast cancer cell lines with different paclitaxel sensitivity.	Paclitaxel	22-32	solute carrier family 9 member A1	Homo sapiens	76-80
12796407-7	2003	This sensitization of paclitaxel apoptotic action by specific inhibition of NHE1 was verified in breast cancer cell lines with different paclitaxel sensitivity.	Paclitaxel	137-147	solute carrier family 9 member A1	Homo sapiens	76-80
12796407-8	2003	CONCLUSIONS: We have, for the first time, identified NHE1 as an essential component of paclitaxel-induced apoptosis in breast cancer cells and, importantly, identified that simultaneous inhibition of the NHE1 results in a synergistic potentiation of low-dose paclitaxel apoptotic action.	Paclitaxel	87-97	solute carrier family 9 member A1	Homo sapiens	53-57
12796407-8	2003	CONCLUSIONS: We have, for the first time, identified NHE1 as an essential component of paclitaxel-induced apoptosis in breast cancer cells and, importantly, identified that simultaneous inhibition of the NHE1 results in a synergistic potentiation of low-dose paclitaxel apoptotic action.	Paclitaxel	87-97	solute carrier family 9 member A1	Homo sapiens	204-208
12796407-8	2003	CONCLUSIONS: We have, for the first time, identified NHE1 as an essential component of paclitaxel-induced apoptosis in breast cancer cells and, importantly, identified that simultaneous inhibition of the NHE1 results in a synergistic potentiation of low-dose paclitaxel apoptotic action.	Paclitaxel	259-269	solute carrier family 9 member A1	Homo sapiens	53-57
12796407-8	2003	CONCLUSIONS: We have, for the first time, identified NHE1 as an essential component of paclitaxel-induced apoptosis in breast cancer cells and, importantly, identified that simultaneous inhibition of the NHE1 results in a synergistic potentiation of low-dose paclitaxel apoptotic action.	Paclitaxel	259-269	solute carrier family 9 member A1	Homo sapiens	204-208
12761496-0	2003	Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	59-62
12761490-4	2003	Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).	Paclitaxel	235-245	erb-b2 receptor tyrosine kinase 2	Homo sapiens	16-20
12775734-0	2003	Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.	Paclitaxel	109-119	epidermal growth factor receptor	Homo sapiens	19-51
12761496-3	2003	We demonstrated here that low doses of PTX that are unable to activate the spindle assembly checkpoint, upregulate p21 by a p53-dependent pathway and induce its translocation to the cytoplasm.	Paclitaxel	39-42	tumor protein p53	Homo sapiens	124-127
12761490-4	2003	Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).	Paclitaxel	235-245	AKT serine/threonine kinase 1	Homo sapiens	132-135
12761496-5	2003	Furthermore, the cytoplasmic p21 accumulation observed in PTX-treated cells was inhibited by LY 294002, a specific PI-3 kinase inhibitor or by the expression of a dominant-negative AKT mutant.	Paclitaxel	58-61	AKT serine/threonine kinase 1	Homo sapiens	181-184
12761496-6	2003	However, the kinase activity of AKT was unchanged in PTX-treated cells, suggesting that low doses of PTX could regulate p21 phosphorylation via inhibition of its dephosphorylation.	Paclitaxel	101-104	AKT serine/threonine kinase 1	Homo sapiens	32-35
12521996-0	2003	Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells.	Paclitaxel	32-42	BCL2 apoptosis regulator	Homo sapiens	77-82
12771935-3	2003	Following 8 h of exposure to taxol, the cell line DoHH2 (p53 wild type) exhibited mitotic arrest and engagement of apoptosis, whereas the cell line SU-DHL-4 (p53 mutant) breached cell-cycle arrest with progression to an abnormal cycle and a 24 h delay in the engagement of apoptosis.	Paclitaxel	29-34	tumor protein p53	Homo sapiens	57-60
12771935-3	2003	Following 8 h of exposure to taxol, the cell line DoHH2 (p53 wild type) exhibited mitotic arrest and engagement of apoptosis, whereas the cell line SU-DHL-4 (p53 mutant) breached cell-cycle arrest with progression to an abnormal cycle and a 24 h delay in the engagement of apoptosis.	Paclitaxel	29-34	tumor protein p53	Homo sapiens	158-161
12521996-1	2003	Overexpression of Bcl-2 in myeloma cells results in resistance to drugs such as dexamethasone (DEX), adenovirus-mediated delivery of p53 (Ad-p53), and paclitaxel (TAX), which work through the intrinsic apoptotic pathway.	Paclitaxel	151-161	BCL2 apoptosis regulator	Homo sapiens	18-23
12707013-5	2003	Microtubule-stabilizing agents, paclitaxel and epothilone B, significantly attenuated TNF-alpha-induced decreases in transendothelial electrical resistance, inhibited the cytokine-induced increases in actin stress fibers, formation of intercellular gap, and restored the TNF-alpha-compromised vascular endothelial (VE)-cadherin-based cell-cell junctions.	Paclitaxel	32-42	tumor necrosis factor	Homo sapiens	86-95
12707013-5	2003	Microtubule-stabilizing agents, paclitaxel and epothilone B, significantly attenuated TNF-alpha-induced decreases in transendothelial electrical resistance, inhibited the cytokine-induced increases in actin stress fibers, formation of intercellular gap, and restored the TNF-alpha-compromised vascular endothelial (VE)-cadherin-based cell-cell junctions.	Paclitaxel	32-42	tumor necrosis factor	Homo sapiens	271-280
12522001-0	2003	Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells.	Paclitaxel	96-106	tumor necrosis factor	Homo sapiens	13-34
12522001-3	2003	Coadministration of tumor necrosis factor (TNF) soluble receptors, or ectopic expression of CrmA or dominant-negative caspase-8, abrogated potentiation of paclitaxel-induced mitochondrial injury and apoptosis by bryostatin 1, implicating the extrinsic apoptotic pathway in this process.	Paclitaxel	155-165	tumor necrosis factor	Homo sapiens	20-41
12522001-3	2003	Coadministration of tumor necrosis factor (TNF) soluble receptors, or ectopic expression of CrmA or dominant-negative caspase-8, abrogated potentiation of paclitaxel-induced mitochondrial injury and apoptosis by bryostatin 1, implicating the extrinsic apoptotic pathway in this process.	Paclitaxel	155-165	tumor necrosis factor	Homo sapiens	43-46
12522001-5	2003	Potentiation of paclitaxel-induced apoptosis in wild-type and mutant cells by bryostatin 1 was associated with increases in TNF-alpha mRNA and protein and was mimicked by exogenous TNF-alpha.	Paclitaxel	16-26	tumor necrosis factor	Homo sapiens	124-133
12522001-5	2003	Potentiation of paclitaxel-induced apoptosis in wild-type and mutant cells by bryostatin 1 was associated with increases in TNF-alpha mRNA and protein and was mimicked by exogenous TNF-alpha.	Paclitaxel	16-26	tumor necrosis factor	Homo sapiens	181-190
12522001-6	2003	Coadministration of the selective PKC inhibitor GFX (1 microM) blocked the increase in TNF-alpha mRNA levels and apoptosis in bryostatin 1/paclitaxel-treated cells.	Paclitaxel	139-149	tumor necrosis factor	Homo sapiens	87-96
12522001-9	2003	They further suggest that this process is amplified by paclitaxel-mediated arrest of cells in G(2)M, where they are more susceptible to TNF-alpha-induced lethality.	Paclitaxel	55-65	tumor necrosis factor	Homo sapiens	136-145
12695359-1	2003	Paclitaxel, a taxane anti-microtubule agent, is known to induce CYP3A in rat and human hepatocytes.	Paclitaxel	0-10	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	64-69
12727831-6	2003	Transfection of membrane-bound p110 PI3k prevented 17-AAG inactivation of Akt and abrogated the enhancement of Taxol-induced apoptosis caused by the drug.	Paclitaxel	111-116	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Mus musculus	31-35
12802925-9	2003	Moreover, TMBL-1 cells are sensitive to paclitaxel, which could induce p53-independent apoptosis.	Paclitaxel	40-50	tumor protein p53	Homo sapiens	71-74
12731085-10	2003	By administering paclitaxel, the proportions of P-glycoprotein- and gp91-positive cells were increased in all the four mice examined.	Paclitaxel	17-27	ATP binding cassette subfamily B member 1	Homo sapiens	48-62
12731085-11	2003	When mice transplanted with Ha-MDR-IRES-gp91-transduced cells were repeatedly administered paclitaxel, the ratios of P-glycoprotein- and gp91-positive cells were maintained for over 1 year.	Paclitaxel	91-101	ATP binding cassette subfamily B member 1	Homo sapiens	117-131
12684687-4	2003	We report that Brca1-deficiency in p53-null cells was associated with increased sensitivity to the topoisomerase I poisons camptothecin and topotecan, the topoisomerase II poisons doxorubicin, mitoxantrone and etoposide, and to the platinum compounds carboplatin and oxaliplatin, but not to the antimetabolites 5-fluorouracil and gemcitabine and the taxanes docetaxel and paclitaxel.	Paclitaxel	372-382	tumor protein p53	Homo sapiens	35-38
12715164-0	2003	p53 expression and resistance against paclitaxel in patients with metastatic breast cancer.	Paclitaxel	38-48	tumor protein p53	Homo sapiens	0-3
12715164-13	2003	CONCLUSION: The immunohistochemical detection of p53 characterizes patients with metastatic breast cancer unlikely to respond to paclitaxel.	Paclitaxel	129-139	tumor protein p53	Homo sapiens	49-52
12831511-5	2003	The IC(50) values for paclitaxel, an MDR1 substrate, were 1.0 and 547 nM, respectively, whereas the cytotoxicity of 5-fluorouracil was comparable in both cells.	Paclitaxel	22-32	ATP binding cassette subfamily B member 1	Homo sapiens	37-41
12700660-0	2003	Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop.	Paclitaxel	0-10	caspase 3	Homo sapiens	86-99
12700660-3	2003	Here, we show that caspases-3 and -8 mediate a mitochondrial amplification loop that is required for the optimal release of cytochrome c, mitochondrial permeability shift transition, and cell death during apoptosis induced by treatment with the microtubule-damaging agent paclitaxel (Taxol).	Paclitaxel	272-282	caspase 3	Homo sapiens	19-36
12700660-3	2003	Here, we show that caspases-3 and -8 mediate a mitochondrial amplification loop that is required for the optimal release of cytochrome c, mitochondrial permeability shift transition, and cell death during apoptosis induced by treatment with the microtubule-damaging agent paclitaxel (Taxol).	Paclitaxel	272-282	cytochrome c, somatic	Homo sapiens	124-136
12700660-3	2003	Here, we show that caspases-3 and -8 mediate a mitochondrial amplification loop that is required for the optimal release of cytochrome c, mitochondrial permeability shift transition, and cell death during apoptosis induced by treatment with the microtubule-damaging agent paclitaxel (Taxol).	Paclitaxel	284-289	caspase 3	Homo sapiens	19-36
12700660-3	2003	Here, we show that caspases-3 and -8 mediate a mitochondrial amplification loop that is required for the optimal release of cytochrome c, mitochondrial permeability shift transition, and cell death during apoptosis induced by treatment with the microtubule-damaging agent paclitaxel (Taxol).	Paclitaxel	284-289	cytochrome c, somatic	Homo sapiens	124-136
12700660-5	2003	Taxol-induced cell death was inhibited by the use of synthetic, cell-permeable caspase-3- (zDEVD-fmk) or caspase-8-specific (zIETD-fmk) inhibitors.	Paclitaxel	0-5	caspase 3	Homo sapiens	79-88
12691824-4	2003	In addition, paclitaxel greatly increased c-Jun N-terminal protein kinase (JNK) activity whereas showing a small enhancing effect on extracellular-regulated kinases (ERK) activity.	Paclitaxel	13-23	mitogen-activated protein kinase 8	Homo sapiens	42-73
12716939-4	2003	Here we report that parkin, a protein-ubiquitin E3 ligase linked to PD, was tightly bound to microtubules in taxol-mediated microtubule coassembly assays.	Paclitaxel	109-114	amyloid beta precursor protein	Homo sapiens	17-18
12691824-4	2003	In addition, paclitaxel greatly increased c-Jun N-terminal protein kinase (JNK) activity whereas showing a small enhancing effect on extracellular-regulated kinases (ERK) activity.	Paclitaxel	13-23	mitogen-activated protein kinase 8	Homo sapiens	75-78
12691824-4	2003	In addition, paclitaxel greatly increased c-Jun N-terminal protein kinase (JNK) activity whereas showing a small enhancing effect on extracellular-regulated kinases (ERK) activity.	Paclitaxel	13-23	mitogen-activated protein kinase 1	Homo sapiens	133-164
12691824-4	2003	In addition, paclitaxel greatly increased c-Jun N-terminal protein kinase (JNK) activity whereas showing a small enhancing effect on extracellular-regulated kinases (ERK) activity.	Paclitaxel	13-23	mitogen-activated protein kinase 1	Homo sapiens	166-169
12691824-7	2003	Thus, the findings suggest that paclitaxel-induced apoptosis is mediated by JNK and occurs in parallel with suppression of the Raf-1 kinase activity in parental MCF-7 cells.	Paclitaxel	32-42	mitogen-activated protein kinase 8	Homo sapiens	76-79
26680929-2	2003	In this study, to further demonstrate the differential effect of the tumor suppressor gene, p53, on the Taxol-induced apoptosis in osteogenic sarcoma cell lines, we used p53-defected SaOS2 cells and wild type p53-expressed U2OS cells.	Paclitaxel	104-109	tumor protein p53	Homo sapiens	92-95
12704006-4	2003	The BCRP-overexpressing tumor cells are resistant to mitoxantrone, adriamycin, daunorubicin, etoposide, topotecan and irinotecan, but lack resistance to paclitaxel and vincristine.	Paclitaxel	153-163	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	4-8
12679732-3	2003	Here, we show, in drug-sensitive lung cancer cells (A549, Calu-6 or NCI-H69), that exposure to cytotoxic drugs (taxol, doxorubicin or etoposide) is sufficient to strongly up-regulate caveolin 1 and 2 protein levels.	Paclitaxel	112-117	caveolin 1	Homo sapiens	183-193
26680929-11	2003	Bax, as a proapoptotic factor, was increased in the SaOS2cells, but the Bcl-xL and Bcl-2 were decreased when the cells were exposed to 10miceoM Taxol.	Paclitaxel	144-149	BCL2 apoptosis regulator	Homo sapiens	83-88
26680929-12	2003	CONCLUSION: From these results, it was concluded that p53-defected SaOS2 cells are much more sensitive to Taxol-induced apoptosis than p53-expressed U2OS cells.	Paclitaxel	106-111	tumor protein p53	Homo sapiens	54-57
26680929-4	2003	To examine whether the differential expressions of p53, in U2OS and SaOS2 cells, were associated with Taxol-induced apoptosis, DNA fragmentation assays were performed on both cytosolic and genomic DNA.	Paclitaxel	102-107	tumor protein p53	Homo sapiens	51-54
26680929-6	2003	RESULTS: The cell viability of the p53-defected SaOS2 cells was markedly decreased with Taxol treatment.	Paclitaxel	88-93	tumor protein p53	Homo sapiens	35-38
12684432-0	2003	Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines.	Paclitaxel	59-69	tumor protein p53	Homo sapiens	94-97
26680929-9	2003	When the cells were treated with Taxol, the 89 kDa cleavage product of PARP clearly appeared as a function of time in the SaOS2 cells, but not in the U2OS cells.	Paclitaxel	33-38	poly(ADP-ribose) polymerase 1	Homo sapiens	71-75
12684432-7	2003	The cell cycle regulator p53 and its target genes p21(waf1/cip1) and BAX were induced in SCC-61 cells treated with 2 Gy, Paclitaxel, or in combination, but not in SQ-20B cells.	Paclitaxel	121-131	tumor protein p53	Homo sapiens	25-28
26680929-10	2003	The Taxol-induced apoptosis in p53 defected-osteogenic sarcoma cells was associated with the PARP cleavage as a result of the increased activity of caspase 3, and the high expressions of cyclin B1 and PLK.	Paclitaxel	4-9	tumor protein p53	Homo sapiens	31-34
12684432-7	2003	The cell cycle regulator p53 and its target genes p21(waf1/cip1) and BAX were induced in SCC-61 cells treated with 2 Gy, Paclitaxel, or in combination, but not in SQ-20B cells.	Paclitaxel	121-131	cyclin dependent kinase inhibitor 1A	Homo sapiens	50-63
12684432-7	2003	The cell cycle regulator p53 and its target genes p21(waf1/cip1) and BAX were induced in SCC-61 cells treated with 2 Gy, Paclitaxel, or in combination, but not in SQ-20B cells.	Paclitaxel	121-131	BCL2 associated X, apoptosis regulator	Homo sapiens	69-72
26680929-10	2003	The Taxol-induced apoptosis in p53 defected-osteogenic sarcoma cells was associated with the PARP cleavage as a result of the increased activity of caspase 3, and the high expressions of cyclin B1 and PLK.	Paclitaxel	4-9	poly(ADP-ribose) polymerase 1	Homo sapiens	93-97
12684432-9	2003	Interestingly, LDFRT treatment in both cell lines with or without Paclitaxel down-regulated nuclear factor kappa B activity and BCL-2 protein expression and simultaneously up-regulated BAX protein.	Paclitaxel	66-76	BCL2 apoptosis regulator	Homo sapiens	128-133
12684432-10	2003	These findings strongly suggest that LDFRT (at these doses, HRS phenomenon is observed) can be used in combination with Paclitaxel to overcome the antiapoptotic effects of BCL-2 and nuclear factor kappa B.	Paclitaxel	120-130	BCL2 apoptosis regulator	Homo sapiens	172-177
26680929-10	2003	The Taxol-induced apoptosis in p53 defected-osteogenic sarcoma cells was associated with the PARP cleavage as a result of the increased activity of caspase 3, and the high expressions of cyclin B1 and PLK.	Paclitaxel	4-9	caspase 3	Homo sapiens	148-157
26680929-11	2003	Bax, as a proapoptotic factor, was increased in the SaOS2cells, but the Bcl-xL and Bcl-2 were decreased when the cells were exposed to 10miceoM Taxol.	Paclitaxel	144-149	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
26680929-11	2003	Bax, as a proapoptotic factor, was increased in the SaOS2cells, but the Bcl-xL and Bcl-2 were decreased when the cells were exposed to 10miceoM Taxol.	Paclitaxel	144-149	BCL2 like 1	Homo sapiens	72-78
12627525-0	2003	Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.	Paclitaxel	46-56	pleckstrin and Sec7 domain containing 4	Homo sapiens	87-90
12694652-8	2003	Epo B was able to exert cytotoxic effects against cisplatinum- and paclitaxel-resistant ovarian cancer cells.	Paclitaxel	67-77	erythropoietin	Homo sapiens	0-3
12694652-11	2003	CONCLUSIONS: These data support the in vivo testing of Epo B against cisplatinum- and paclitaxel-resistant ovarian cancers, and suggest that a pretreatment with Epo B may sensitize human ovarian cancers to the cytotoxic effects of Apo-2L/TRAIL.	Paclitaxel	86-96	erythropoietin	Homo sapiens	55-58
12510025-2	2003	trans-Resveratrol reverses phosphorylation of Bcl-2 induced by paclitaxel and concomitantly blocks Raf-1 phosphorylation, also observed after paclitaxel exposure, thus suggesting that Bcl-2 inactivation may be dependent on the activation of the Raf/Ras cascade.	Paclitaxel	63-73	BCL2 apoptosis regulator	Homo sapiens	46-51
12510025-2	2003	trans-Resveratrol reverses phosphorylation of Bcl-2 induced by paclitaxel and concomitantly blocks Raf-1 phosphorylation, also observed after paclitaxel exposure, thus suggesting that Bcl-2 inactivation may be dependent on the activation of the Raf/Ras cascade.	Paclitaxel	142-152	BCL2 apoptosis regulator	Homo sapiens	184-189
12510025-3	2003	trans-Resveratrol also reverses the sustained phosphorylation of JNK/SAPK, which specifically occurs after paclitaxel exposure.Overall, our observations demonstrate that (a) the toxic action of paclitaxel on neuronal-like cells is not only related to the effect of the drug on tubulin, but also to its capacity to activate several intracellular pathways leading to inactivation of Bcl-2, thus causing cells to die by apoptosis, (b) trans-resveratrol significantly reduces paclitaxel-induced apoptosis by modulating the cellular signaling pathways which commit the cell to apoptosis.	Paclitaxel	107-117	mitogen-activated protein kinase 8	Homo sapiens	65-73
12510025-3	2003	trans-Resveratrol also reverses the sustained phosphorylation of JNK/SAPK, which specifically occurs after paclitaxel exposure.Overall, our observations demonstrate that (a) the toxic action of paclitaxel on neuronal-like cells is not only related to the effect of the drug on tubulin, but also to its capacity to activate several intracellular pathways leading to inactivation of Bcl-2, thus causing cells to die by apoptosis, (b) trans-resveratrol significantly reduces paclitaxel-induced apoptosis by modulating the cellular signaling pathways which commit the cell to apoptosis.	Paclitaxel	194-204	mitogen-activated protein kinase 8	Homo sapiens	65-73
12510025-3	2003	trans-Resveratrol also reverses the sustained phosphorylation of JNK/SAPK, which specifically occurs after paclitaxel exposure.Overall, our observations demonstrate that (a) the toxic action of paclitaxel on neuronal-like cells is not only related to the effect of the drug on tubulin, but also to its capacity to activate several intracellular pathways leading to inactivation of Bcl-2, thus causing cells to die by apoptosis, (b) trans-resveratrol significantly reduces paclitaxel-induced apoptosis by modulating the cellular signaling pathways which commit the cell to apoptosis.	Paclitaxel	194-204	BCL2 apoptosis regulator	Homo sapiens	381-386
12510025-3	2003	trans-Resveratrol also reverses the sustained phosphorylation of JNK/SAPK, which specifically occurs after paclitaxel exposure.Overall, our observations demonstrate that (a) the toxic action of paclitaxel on neuronal-like cells is not only related to the effect of the drug on tubulin, but also to its capacity to activate several intracellular pathways leading to inactivation of Bcl-2, thus causing cells to die by apoptosis, (b) trans-resveratrol significantly reduces paclitaxel-induced apoptosis by modulating the cellular signaling pathways which commit the cell to apoptosis.	Paclitaxel	194-204	mitogen-activated protein kinase 8	Homo sapiens	65-73
12510025-3	2003	trans-Resveratrol also reverses the sustained phosphorylation of JNK/SAPK, which specifically occurs after paclitaxel exposure.Overall, our observations demonstrate that (a) the toxic action of paclitaxel on neuronal-like cells is not only related to the effect of the drug on tubulin, but also to its capacity to activate several intracellular pathways leading to inactivation of Bcl-2, thus causing cells to die by apoptosis, (b) trans-resveratrol significantly reduces paclitaxel-induced apoptosis by modulating the cellular signaling pathways which commit the cell to apoptosis.	Paclitaxel	194-204	BCL2 apoptosis regulator	Homo sapiens	381-386
12722021-4	2003	The combination of gemcitabine, paclitaxel, and trastuzumab in patients with HER2-positive metastatic breast cancer with no prior chemotherapy in the metastatic setting produced a response rate of 71% and median response duration of 11 months.	Paclitaxel	32-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81
12615969-6	2003	The change in IP(3)R1 localization induced by arginine-vasopressin could be blocked by the simultaneous addition of nocodazole or taxol and depended on Ca(2+) release from intracellular stores since Ca(2+)-mobilizing agents such as thapsigargin and cyclopiazonic acid could induce the redistribution.	Paclitaxel	130-135	arginine vasopressin	Rattus norvegicus	55-66
12644839-5	2003	Cyclosporin A interfered with Taxol (0.1 microM)-induced AKT activation and BAD phosphorylation.	Paclitaxel	30-35	AKT serine/threonine kinase 1	Homo sapiens	57-60
12644839-7	2003	PI3 kinase inhibitor, wortmannin, or a dominant-negative AKT1 expression vector treatment partially enhanced Taxol-induced apoptosis indicating that PI3 kinase-AKT pathway was involved in Taxol-resistance pathway.	Paclitaxel	109-114	AKT serine/threonine kinase 1	Homo sapiens	57-61
12644839-7	2003	PI3 kinase inhibitor, wortmannin, or a dominant-negative AKT1 expression vector treatment partially enhanced Taxol-induced apoptosis indicating that PI3 kinase-AKT pathway was involved in Taxol-resistance pathway.	Paclitaxel	109-114	AKT serine/threonine kinase 1	Homo sapiens	57-60
12644839-7	2003	PI3 kinase inhibitor, wortmannin, or a dominant-negative AKT1 expression vector treatment partially enhanced Taxol-induced apoptosis indicating that PI3 kinase-AKT pathway was involved in Taxol-resistance pathway.	Paclitaxel	188-193	AKT serine/threonine kinase 1	Homo sapiens	57-61
12644839-7	2003	PI3 kinase inhibitor, wortmannin, or a dominant-negative AKT1 expression vector treatment partially enhanced Taxol-induced apoptosis indicating that PI3 kinase-AKT pathway was involved in Taxol-resistance pathway.	Paclitaxel	188-193	AKT serine/threonine kinase 1	Homo sapiens	57-60
12644839-9	2003	Our results indicate that the combination of cyclosporin A and Taxol is effective in the reversal of Taxol resistance through the inhibition of PI3 kinase-AKT1 pathway.	Paclitaxel	63-68	AKT serine/threonine kinase 1	Homo sapiens	155-159
12644839-9	2003	Our results indicate that the combination of cyclosporin A and Taxol is effective in the reversal of Taxol resistance through the inhibition of PI3 kinase-AKT1 pathway.	Paclitaxel	101-106	AKT serine/threonine kinase 1	Homo sapiens	155-159
12649200-0	2003	Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel.	Paclitaxel	147-157	AKT serine/threonine kinase 1	Homo sapiens	10-13
12649200-5	2003	Paclitaxel (5 and 100 nM) and cisplatin (10 microM) but not etoposide (1 and 10 microM) promoted TRAIL-induced apoptosis in SKRC-49 cells, which was not mediated by increased TRAIL receptor expression but by chemotherapeutic agents-induced Akt inactivation through ceramide formation derived from sphingomyelin hydrolysis.	Paclitaxel	0-10	TNF superfamily member 10	Homo sapiens	97-102
12649200-5	2003	Paclitaxel (5 and 100 nM) and cisplatin (10 microM) but not etoposide (1 and 10 microM) promoted TRAIL-induced apoptosis in SKRC-49 cells, which was not mediated by increased TRAIL receptor expression but by chemotherapeutic agents-induced Akt inactivation through ceramide formation derived from sphingomyelin hydrolysis.	Paclitaxel	0-10	AKT serine/threonine kinase 1	Homo sapiens	240-243
12633850-0	2003	Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis.	Paclitaxel	84-89	BCL2 like 1	Homo sapiens	26-32
12649200-6	2003	Of note, the low concentration (5 nM) of paclitaxel promoted ceramide formation and TRAIL-induced apoptosis predominantly in SKRC-49 cells but not in the normal renal proximal tubular epithelial cells.	Paclitaxel	41-51	TNF superfamily member 10	Homo sapiens	84-89
12618886-2	2003	Amifostine induced a G1 arrest and protected against paclitaxel toxicity in p53-proficient but not in p53-deficient cells.	Paclitaxel	53-63	tumor protein p53	Homo sapiens	76-79
12633850-2	2003	Phosphorylation of Bcl-xL can be induced by microtubule-damaging drugs such as taxol or 2-methoxyestradiol (2-ME).	Paclitaxel	79-84	BCL2 like 1	Homo sapiens	19-25
12633850-3	2003	By site-directed mutagenesis studies, we have identified that serine 62 is the necessary site for taxol- or 2-ME-induced Bcl-xL phosphorylation in prostate cancer cells.	Paclitaxel	98-103	BCL2 like 1	Homo sapiens	121-127
12649748-5	2003	Flow cytometric analysis of paclitaxel- or vinblastine-treated P815 cells revealed reduced cell-surface expression of the adhesion molecules LFA-1 (CD11a /CD18) and ICAM-1 (CD54).	Paclitaxel	28-38	integrin beta 2	Mus musculus	155-159
12409284-8	2003	Disruption of the MT network by prolonged treatments with low doses of either nocodazole or paclitaxel before the application of strain abolished the redistribution of RhoA and Rac in response to the applied forces.	Paclitaxel	92-102	ras homolog family member A	Homo sapiens	168-172
12409284-8	2003	Disruption of the MT network by prolonged treatments with low doses of either nocodazole or paclitaxel before the application of strain abolished the redistribution of RhoA and Rac in response to the applied forces.	Paclitaxel	92-102	AKT serine/threonine kinase 1	Homo sapiens	177-180
12598349-0	2003	Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer.	Paclitaxel	73-83	tumor protein p53	Homo sapiens	15-18
12643740-3	2003	In an effort to expand the development of tumor-recognizing taxanes, paclitaxel (PTX, taxol) was conjugated to the anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MAb) Erbitux (C225) to serve as a model MAb-mediated drug delivery compound.	Paclitaxel	69-79	epidermal growth factor receptor	Homo sapiens	159-163
12643740-3	2003	In an effort to expand the development of tumor-recognizing taxanes, paclitaxel (PTX, taxol) was conjugated to the anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MAb) Erbitux (C225) to serve as a model MAb-mediated drug delivery compound.	Paclitaxel	81-84	epidermal growth factor receptor	Homo sapiens	159-163
12643740-3	2003	In an effort to expand the development of tumor-recognizing taxanes, paclitaxel (PTX, taxol) was conjugated to the anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MAb) Erbitux (C225) to serve as a model MAb-mediated drug delivery compound.	Paclitaxel	86-91	epidermal growth factor receptor	Homo sapiens	159-163
12649748-6	2003	Similar results were obtained following paclitaxel or vinblastine treatment of Yac-1 lymphoma cells.	Paclitaxel	40-50	ADP-ribosyltransferase 1	Mus musculus	79-84
12631626-8	2003	Treatment with PKI 166 and more so with PKI 166 plus Taxol significantly inhibited phosphorylation of EGF-R on tumor and endothelial cells and induced significant apoptosis and endothelial cells within tumor lesions.	Paclitaxel	53-58	epidermal growth factor receptor	Homo sapiens	102-107
12725325-0	2003	Transfer of IkappaBalpha gene increase the sensitivity of paclitaxel mediated with caspase 3 activation in human lung cancer cell.	Paclitaxel	58-68	NFKB inhibitor alpha	Homo sapiens	12-24
12603385-4	2003	We recently observed a patient with refractory breast cancer who responded to rhuMAB HER-2 (trastuzumab) plus paclitaxel after progressing on paclitaxel alone.	Paclitaxel	142-152	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-90
12792974-5	2003	However, the Vmax value estimate of liver NAT activity was significantly decreased after paclitaxel pretreatment.	Paclitaxel	89-99	N-acetyltransferase 1	Rattus norvegicus	42-45
12725325-0	2003	Transfer of IkappaBalpha gene increase the sensitivity of paclitaxel mediated with caspase 3 activation in human lung cancer cell.	Paclitaxel	58-68	caspase 3	Homo sapiens	83-92
12725325-11	2003	On result, paclitaxel increased caspase 3 activity and SM5887 decreased the activity.	Paclitaxel	11-21	caspase 3	Homo sapiens	32-41
12725325-13	2003	Adenovirus mediated IkappaBalpha gene transfer improve the anti-cancer effect of paclitaxel to lung cancer cells through the regulation of caspase 3 activation.	Paclitaxel	81-91	NFKB inhibitor alpha	Homo sapiens	20-32
12725325-13	2003	Adenovirus mediated IkappaBalpha gene transfer improve the anti-cancer effect of paclitaxel to lung cancer cells through the regulation of caspase 3 activation.	Paclitaxel	81-91	caspase 3	Homo sapiens	139-148
12576925-0	2003	Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.	Paclitaxel	22-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-62
12576925-9	2003	Paclitaxel, however, gave significantly less growth inhibition than docetaxel in the HER-2/neu overexpressing MCF/18 cells (p = 0.0003).	Paclitaxel	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-94
12576925-10	2003	These data suggest that HER-2/neu overexpression may contribute to paclitaxel resistance.	Paclitaxel	67-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-33
12624662-7	2003	In addition, we found that taxol treatment induced the cleavage of pro-caspase-3, followed by apoptosis, and that the overexpression of XIAP inhibited apoptosis by attenuating the cleavage of pro-caspase-3 and caspase-3 activity.	Paclitaxel	27-32	caspase 3	Homo sapiens	67-80
12624662-7	2003	In addition, we found that taxol treatment induced the cleavage of pro-caspase-3, followed by apoptosis, and that the overexpression of XIAP inhibited apoptosis by attenuating the cleavage of pro-caspase-3 and caspase-3 activity.	Paclitaxel	27-32	caspase 3	Homo sapiens	192-205
12624662-7	2003	In addition, we found that taxol treatment induced the cleavage of pro-caspase-3, followed by apoptosis, and that the overexpression of XIAP inhibited apoptosis by attenuating the cleavage of pro-caspase-3 and caspase-3 activity.	Paclitaxel	27-32	caspase 3	Homo sapiens	71-80
12624662-8	2003	Interestingly, XIAP bound to pro-caspase-3 in LNCaP cells transiently cotransfected with myc-XIAP and caspase-3-HA cDNAs, and this interaction was inhibited by taxol treatment.	Paclitaxel	160-165	caspase 3	Homo sapiens	29-42
12624662-8	2003	Interestingly, XIAP bound to pro-caspase-3 in LNCaP cells transiently cotransfected with myc-XIAP and caspase-3-HA cDNAs, and this interaction was inhibited by taxol treatment.	Paclitaxel	160-165	caspase 3	Homo sapiens	33-42
12624662-9	2003	These results suggest that the overexpression of XIAP inhibits taxol-induced apoptosis through the decrease of caspase-3 activity and inhibition of the processing of pro-caspase-3.	Paclitaxel	63-68	caspase 3	Homo sapiens	111-120
12624662-9	2003	These results suggest that the overexpression of XIAP inhibits taxol-induced apoptosis through the decrease of caspase-3 activity and inhibition of the processing of pro-caspase-3.	Paclitaxel	63-68	caspase 3	Homo sapiens	166-179
12632493-7	2003	Paclitaxel could reduce the expression of apoptosis-regulated gene Bcl-2, and improve the expression of apoptosis-regulated gene Bax.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	67-72
12632493-7	2003	Paclitaxel could reduce the expression of apoptosis-regulated gene Bcl-2, and improve the expression of apoptosis-regulated gene Bax.	Paclitaxel	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	129-132
12518324-7	2003	The antisense oligonucleotide also potentiated the effects of p53 activation and p21 induction by chemotherapeutic agents 10-hydroxycamptothecin, adriamycin, 5-fluorouracil, and paclitaxel.	Paclitaxel	178-188	tumor protein p53	Homo sapiens	62-65
12576925-2	2003	Docetaxel has been shown to be more potent than paclitaxel in inducing bcl-2 phosphorylation and apoptosis and is clinically active in some paclitaxel-resistant breast tumors.	Paclitaxel	48-58	BCL2 apoptosis regulator	Homo sapiens	71-76
12574211-0	2003	p21 Waf-1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells.	Paclitaxel	62-72	cyclin dependent kinase inhibitor 1A	Homo sapiens	0-16
12562644-1	2003	BACKGROUND: Pharmacokinetic study has shown that co-administration of cyclosporin A (CsA), which acts as a P-glycoprotein (P-gp) and CYP-3A blocker, resulted in an 8-fold increase in the systemic exposure of oral paclitaxel.	Paclitaxel	213-223	ATP binding cassette subfamily B member 1	Homo sapiens	123-127
12566299-5	2003	Expression of antisense to the RNA component of human telomerase (hTR) inhibited telomerase activity, shortened telomere length, reduced cell growth rate, and resulted in a significant higher sensitivity to paclitaxel.	Paclitaxel	207-217	telomerase RNA component	Homo sapiens	66-69
12570657-7	2003	This review also explores pharmacologic attempts to modulate paclitaxel resistance, principally through inhibition of the MDR-1 drug efflux pump.	Paclitaxel	61-71	ATP binding cassette subfamily B member 1	Homo sapiens	122-127
12555062-5	2003	Paclitaxel-induced p70S6K(T421/S424) phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca(++), PI3K, and mammalian target of rapamycin (mTOR).	Paclitaxel	0-10	mitogen-activated protein kinase 3	Homo sapiens	143-149
12538833-0	2003	Interdependent effect of P-glycoprotein-mediated drug efflux and intracellular drug binding on intracellular paclitaxel pharmacokinetics: application of computational modeling.	Paclitaxel	109-119	ATP binding cassette subfamily B member 1	Homo sapiens	25-39
12538833-1	2003	Intracellular concentration of paclitaxel is determined by the extracellular drug concentration, the level of the mdr1 P-glycoprotein (Pgp), and binding to intracellular proteins including tubulins/microtubules.	Paclitaxel	31-41	ATP binding cassette subfamily B member 1	Homo sapiens	119-133
12538833-1	2003	Intracellular concentration of paclitaxel is determined by the extracellular drug concentration, the level of the mdr1 P-glycoprotein (Pgp), and binding to intracellular proteins including tubulins/microtubules.	Paclitaxel	31-41	ATP binding cassette subfamily B member 1	Homo sapiens	135-138
12538833-4	2003	The parameters representing Pgp-mediated drug efflux and intracellular drug binding (i.e., number of Pgp and binding sites and binding affinity) were altered systematically and used to generate computer simulations depicting the intracellular paclitaxel pharmacokinetics at clinically relevant extracellular (e.g., plasma) drug concentrations.	Paclitaxel	243-253	ATP binding cassette subfamily B member 1	Homo sapiens	28-31
12538833-4	2003	The parameters representing Pgp-mediated drug efflux and intracellular drug binding (i.e., number of Pgp and binding sites and binding affinity) were altered systematically and used to generate computer simulations depicting the intracellular paclitaxel pharmacokinetics at clinically relevant extracellular (e.g., plasma) drug concentrations.	Paclitaxel	243-253	ATP binding cassette subfamily B member 1	Homo sapiens	101-104
12581572-13	2003	Correlative data showed a trend towards decreased plasma IL-6 and TNF-alpha after each cycle of therapy presumably due to the dexamethasone premedication and/or paclitaxel.	Paclitaxel	161-171	interleukin 6	Homo sapiens	57-61
12581572-13	2003	Correlative data showed a trend towards decreased plasma IL-6 and TNF-alpha after each cycle of therapy presumably due to the dexamethasone premedication and/or paclitaxel.	Paclitaxel	161-171	tumor necrosis factor	Homo sapiens	66-75
12555073-4	2003	Taxol and other chemotherapy drugs induce c-Jun N-terminal kinase (JNK), a kinase that conveys cellular stress and death signals.	Paclitaxel	0-5	mitogen-activated protein kinase 8	Homo sapiens	42-65
12555073-4	2003	Taxol and other chemotherapy drugs induce c-Jun N-terminal kinase (JNK), a kinase that conveys cellular stress and death signals.	Paclitaxel	0-5	mitogen-activated protein kinase 8	Homo sapiens	67-70
12555073-8	2003	In contrast, overexpression of JNK significantly enhances Taxol-induced apoptosis and inhibits IGF-I survival effects.	Paclitaxel	58-63	mitogen-activated protein kinase 8	Homo sapiens	31-34
12555062-5	2003	Paclitaxel-induced p70S6K(T421/S424) phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca(++), PI3K, and mammalian target of rapamycin (mTOR).	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	162-165
12555073-10	2003	The inhibitory effect of JNK appears to be mediated by serine phosphorylation of IRS-1 (insulin receptor substrate) since both Taxol and IGF-I treatment enhanced Ser(312) IRS-1 phosphorylation, while LY294002 blocked IGF-I-mediated phosphorylation.	Paclitaxel	127-132	mitogen-activated protein kinase 8	Homo sapiens	25-28
12555062-5	2003	Paclitaxel-induced p70S6K(T421/S424) phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca(++), PI3K, and mammalian target of rapamycin (mTOR).	Paclitaxel	0-10	mechanistic target of rapamycin kinase	Homo sapiens	190-219
12555073-10	2003	The inhibitory effect of JNK appears to be mediated by serine phosphorylation of IRS-1 (insulin receptor substrate) since both Taxol and IGF-I treatment enhanced Ser(312) IRS-1 phosphorylation, while LY294002 blocked IGF-I-mediated phosphorylation.	Paclitaxel	127-132	insulin like growth factor 1	Homo sapiens	217-222
12555062-5	2003	Paclitaxel-induced p70S6K(T421/S424) phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca(++), PI3K, and mammalian target of rapamycin (mTOR).	Paclitaxel	0-10	mechanistic target of rapamycin kinase	Homo sapiens	221-225
12555062-8	2003	Inhibition of PKC and JNK prevents paclitaxel-induced p70S6K inactivation.	Paclitaxel	35-45	mitogen-activated protein kinase 8	Homo sapiens	22-25
12680177-1	2003	PURPOSE: To evaluate the efficacy and safety of weekly paclitaxel and trastuzumab in patients with HER2-positive metastatic breast cancer, with trastuzumab administered beyond disease progression.	Paclitaxel	55-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
12480272-7	2003	Also, the K(10) was much smaller in the microemulsion group (0.57 h(-1)) compared with the Taxol group (1.29 h(-1)), showing the elimination rate was much slower in the former than in the latter.	Paclitaxel	91-96	keratin 10	Rattus norvegicus	10-15
12680177-10	2003	CONCLUSION: Prolonged administration of weekly paclitaxel and trastuzumab is effective and well-tolerated in women with HER2-positive metastatic breast cancer.	Paclitaxel	47-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
12680188-2	2003	Compared with the parental HAG-1 cell line, v-src-transfected HAG/src3-1 cells became 6.0-fold and 7.5-fold sensitive to taxotere, and 1.8-fold and 3.9-fold sensitive to taxol, for 2-hour and 24-hour exposures, respectively.	Paclitaxel	170-175	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	46-49
12680188-3	2003	By contrast, HAG-1 cells transfected with activated Ras, which acts downstream of Src, acquired approximately 2.7- and 5.0-fold taxotere resistance, and 2.3- and 2.8-fold taxol resistance, for both exposures, respectively.	Paclitaxel	171-176	thioredoxin domain containing 12	Homo sapiens	13-18
12455053-0	2003	An association of Bcl-2 phosphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment.	Paclitaxel	105-115	BCL2 apoptosis regulator	Homo sapiens	18-23
12455053-0	2003	An association of Bcl-2 phosphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment.	Paclitaxel	105-115	BCL2 associated X, apoptosis regulator	Homo sapiens	44-47
12455053-3	2003	Therefore, we focused on the localization and phosphorylation of Bcl-2 and Bax, key mediators of the apoptotic pathway, after hyperthermia and paclitaxel treatment of PC-10 squamous cell carcinoma cells that excessively expressed Bcl-2 and Bax in the cytoplasm.	Paclitaxel	143-153	BCL2 apoptosis regulator	Homo sapiens	65-70
12455053-3	2003	Therefore, we focused on the localization and phosphorylation of Bcl-2 and Bax, key mediators of the apoptotic pathway, after hyperthermia and paclitaxel treatment of PC-10 squamous cell carcinoma cells that excessively expressed Bcl-2 and Bax in the cytoplasm.	Paclitaxel	143-153	BCL2 associated X, apoptosis regulator	Homo sapiens	75-78
12455053-4	2003	Paclitaxel treatment markedly induced qualitative changes in Bcl-2, whereas hyperthermia did only quantitative changes in Bax.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	61-66
12455053-6	2003	On the other hand, paclitaxel treatment induced dose- and time-dependent phosphorylation of Bcl-2.	Paclitaxel	19-29	BCL2 apoptosis regulator	Homo sapiens	92-97
12455053-11	2003	Our results suggest that the subcellular redistribution of Bax and the phosphorylation of Bcl-2 depend on the type of apoptosis inducers, such as hyperthermia and paclitaxel, and Bcl-2 has a central role in the decision of apoptotic outcome.	Paclitaxel	163-173	BCL2 associated X, apoptosis regulator	Homo sapiens	59-62
12455053-11	2003	Our results suggest that the subcellular redistribution of Bax and the phosphorylation of Bcl-2 depend on the type of apoptosis inducers, such as hyperthermia and paclitaxel, and Bcl-2 has a central role in the decision of apoptotic outcome.	Paclitaxel	163-173	BCL2 apoptosis regulator	Homo sapiens	90-95
12496426-2	2003	Alanine-scanning mutagenesis was performed to identify the mouse MD-2 residues important for conferring LPS and Taxol responsiveness on mouse TLR4, and for forming the cell surface TLR4-MD-2 complex recognized by anti-TLR4-MD-2 Ab MTS510.	Paclitaxel	112-117	toll-like receptor 4	Mus musculus	181-185
12506169-13	2003	CONCLUSION: Preoperative trastuzumab and paclitaxel is active against HER2 overexpressing early-stage breast cancer and may be feasible as part of a sequential treatment program including anthracyclines.	Paclitaxel	41-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-74
12724856-0	2003	Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker.	Paclitaxel	86-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-35
14577846-1	2003	We previously reported that Taxol, which mimics the action of LPS on murine macrophages, induces signals via mouse TLR4/MD-2, but not via human TLR4/MD-2.	Paclitaxel	28-33	toll-like receptor 4	Mus musculus	115-119
14577846-3	2003	Expression of mouse MD-2 conferred both LPS and Taxol responsiveness on HEK293 cells expressing mouse TLR4, whereas expression of human MD-2 conferred LPS responsiveness alone, suggesting that MD-2 is responsible for the species-specificity of Taxol responsiveness.	Paclitaxel	48-53	toll-like receptor 4	Mus musculus	102-106
12496426-0	2003	Identification of mouse MD-2 residues important for forming the cell surface TLR4-MD-2 complex recognized by anti-TLR4-MD-2 antibodies, and for conferring LPS and taxol responsiveness on mouse TLR4 by alanine-scanning mutagenesis.	Paclitaxel	163-168	toll-like receptor 4	Mus musculus	77-81
12496426-1	2003	The expression of MD-2, which associates with Toll-like receptor (TLR) 4 on the cell surface, confers LPS and LPS-mimetic Taxol responsiveness on TLR4.	Paclitaxel	122-127	toll-like receptor 4	Mus musculus	66-69
12496426-6	2003	These results suggest that the ability of MD-2 to form the cell surface mouse TLR4-mouse MD-2 complex recognized by MTS510 is essential for conferring LPS and Taxol responsiveness on TLR4, but not sufficient.	Paclitaxel	159-164	toll-like receptor 4	Mus musculus	78-82
12496426-1	2003	The expression of MD-2, which associates with Toll-like receptor (TLR) 4 on the cell surface, confers LPS and LPS-mimetic Taxol responsiveness on TLR4.	Paclitaxel	122-127	toll-like receptor 4	Mus musculus	146-150
12496426-2	2003	Alanine-scanning mutagenesis was performed to identify the mouse MD-2 residues important for conferring LPS and Taxol responsiveness on mouse TLR4, and for forming the cell surface TLR4-MD-2 complex recognized by anti-TLR4-MD-2 Ab MTS510.	Paclitaxel	112-117	toll-like receptor 4	Mus musculus	142-146
12496426-2	2003	Alanine-scanning mutagenesis was performed to identify the mouse MD-2 residues important for conferring LPS and Taxol responsiveness on mouse TLR4, and for forming the cell surface TLR4-MD-2 complex recognized by anti-TLR4-MD-2 Ab MTS510.	Paclitaxel	112-117	toll-like receptor 4	Mus musculus	181-185
12496426-6	2003	These results suggest that the ability of MD-2 to form the cell surface mouse TLR4-mouse MD-2 complex recognized by MTS510 is essential for conferring LPS and Taxol responsiveness on TLR4, but not sufficient.	Paclitaxel	159-164	toll-like receptor 4	Mus musculus	183-187
14705770-0	2003	Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer.	Paclitaxel	30-35	ATP binding cassette subfamily B member 1	Homo sapiens	69-83
14501017-3	2003	This study has focused on strategies to overcome P-gp-mediated efflux of Taxol analogs, MT-stabilizing agents that could be used to treat brain tumors and, potentially, neurodegenerative diseases such as Alzheimer"s disease.	Paclitaxel	73-78	ATP binding cassette subfamily B member 1	Homo sapiens	49-53
14501017-4	2003	However, taxol is a strong P-gp substrate that limits its distribution across the BBB and therapeutic potential in the CNS.	Paclitaxel	9-14	ATP binding cassette subfamily B member 1	Homo sapiens	27-31
14501017-5	2003	We have found that addition of a succinate group to the C-10 position of paclitaxel (Taxol) results in an agent, Tx-67, with reduced interactions with P-gp and enhanced permeation across the BBB in both in vitro and in situ models.	Paclitaxel	73-83	homeobox C10	Homo sapiens	56-60
14501017-5	2003	We have found that addition of a succinate group to the C-10 position of paclitaxel (Taxol) results in an agent, Tx-67, with reduced interactions with P-gp and enhanced permeation across the BBB in both in vitro and in situ models.	Paclitaxel	73-83	ATP binding cassette subfamily B member 1	Homo sapiens	151-155
14501017-5	2003	We have found that addition of a succinate group to the C-10 position of paclitaxel (Taxol) results in an agent, Tx-67, with reduced interactions with P-gp and enhanced permeation across the BBB in both in vitro and in situ models.	Paclitaxel	85-90	homeobox C10	Homo sapiens	56-60
14501017-5	2003	We have found that addition of a succinate group to the C-10 position of paclitaxel (Taxol) results in an agent, Tx-67, with reduced interactions with P-gp and enhanced permeation across the BBB in both in vitro and in situ models.	Paclitaxel	85-90	ATP binding cassette subfamily B member 1	Homo sapiens	151-155
14501017-6	2003	Our studies demonstrate the feasibility of making small chemical modifications to Taxol to generate analogs with reduced affinity for the P-gp but retention of MT-stabilizing properties, i.e., a taxane that may reach and treat therapeutic targets in the CNS.	Paclitaxel	82-87	ATP binding cassette subfamily B member 1	Homo sapiens	138-142
12499101-10	2003	CONCLUSIONS: The modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy was effective and well tolerated in patients with advanced NSCLC aged 65 years or older and/or in those with ECOG PS 2.	Paclitaxel	59-69	taste 2 receptor member 64 pseudogene	Homo sapiens	226-230
14705770-1	2003	Our aim was to compare Taxol-based chemotherapy response of non-small cell lung cancer (NSCLC) with P-glycoprotein (Pgp) or lung resistance protein expression (LRP).	Paclitaxel	23-28	ATP binding cassette subfamily B member 1	Homo sapiens	100-114
14705770-1	2003	Our aim was to compare Taxol-based chemotherapy response of non-small cell lung cancer (NSCLC) with P-glycoprotein (Pgp) or lung resistance protein expression (LRP).	Paclitaxel	23-28	ATP binding cassette subfamily B member 1	Homo sapiens	116-119
14705770-6	2003	We concluded that Taxol-based chemotherapy response of patients with NSCLC was related to Pgp but not LPR expression.	Paclitaxel	18-23	ATP binding cassette subfamily B member 1	Homo sapiens	90-93
12608532-0	2003	Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031.	Paclitaxel	33-43	ATP binding cassette subfamily B member 1	Homo sapiens	71-85
12608532-9	2003	CONCLUSIONS: Our findings suggest that about 54% of a paclitaxel oral dose is extruded to the gut lumen by P-glycoprotein.	Paclitaxel	54-64	ATP binding cassette subfamily B member 1	Homo sapiens	107-121
12608532-1	2003	PURPOSE: In an attempt to improve the oral bioavailability of paclitaxel, a novel P-glycoprotein inhibitor, KR30031, which is verapamil analog with fewer cardiovascular effects, was coadministered with paclitaxel, and to elucidate other possible causes of the low oral bioavailability of paclitaxel, an inhibitor of hepatic metabolism, ketoconazole, was also coadministered with paclitaxel.	Paclitaxel	62-72	ATP binding cassette subfamily B member 1	Homo sapiens	82-96
12608532-10	2003	Thus, the bioavailability of paclitaxel could be enhanced by coadministration of a P-glycoprotein inhibitor, KR-30031.	Paclitaxel	29-39	ATP binding cassette subfamily B member 1	Homo sapiens	83-97
12608532-1	2003	PURPOSE: In an attempt to improve the oral bioavailability of paclitaxel, a novel P-glycoprotein inhibitor, KR30031, which is verapamil analog with fewer cardiovascular effects, was coadministered with paclitaxel, and to elucidate other possible causes of the low oral bioavailability of paclitaxel, an inhibitor of hepatic metabolism, ketoconazole, was also coadministered with paclitaxel.	Paclitaxel	202-212	ATP binding cassette subfamily B member 1	Homo sapiens	82-96
12608535-1	2003	PURPOSE: We have reported that overexpression of mdr1 P-glycoprotein (Pgp) is associated with a higher sensitivity to paclitaxel-induced apoptosis (1,2).	Paclitaxel	118-128	ATP binding cassette subfamily B member 1	Homo sapiens	49-53
12608532-1	2003	PURPOSE: In an attempt to improve the oral bioavailability of paclitaxel, a novel P-glycoprotein inhibitor, KR30031, which is verapamil analog with fewer cardiovascular effects, was coadministered with paclitaxel, and to elucidate other possible causes of the low oral bioavailability of paclitaxel, an inhibitor of hepatic metabolism, ketoconazole, was also coadministered with paclitaxel.	Paclitaxel	202-212	ATP binding cassette subfamily B member 1	Homo sapiens	82-96
12608535-1	2003	PURPOSE: We have reported that overexpression of mdr1 P-glycoprotein (Pgp) is associated with a higher sensitivity to paclitaxel-induced apoptosis (1,2).	Paclitaxel	118-128	ATP binding cassette subfamily B member 1	Homo sapiens	54-68
12608535-1	2003	PURPOSE: We have reported that overexpression of mdr1 P-glycoprotein (Pgp) is associated with a higher sensitivity to paclitaxel-induced apoptosis (1,2).	Paclitaxel	118-128	ATP binding cassette subfamily B member 1	Homo sapiens	70-73
12608532-1	2003	PURPOSE: In an attempt to improve the oral bioavailability of paclitaxel, a novel P-glycoprotein inhibitor, KR30031, which is verapamil analog with fewer cardiovascular effects, was coadministered with paclitaxel, and to elucidate other possible causes of the low oral bioavailability of paclitaxel, an inhibitor of hepatic metabolism, ketoconazole, was also coadministered with paclitaxel.	Paclitaxel	202-212	ATP binding cassette subfamily B member 1	Homo sapiens	82-96
12608535-11	2003	This finding is identical to our previous finding with paclitaxel, where equal intracellular drug concentration resulted in greater apoptosis in the Pgp-rich BC19 cells.	Paclitaxel	55-65	ATP binding cassette subfamily B member 1	Homo sapiens	149-152
12608532-4	2003	These results show that P-glycoprotein plays a major role in the oral bioavailability of paclitaxel.	Paclitaxel	89-99	ATP binding cassette subfamily B member 1	Homo sapiens	24-38
12608535-12	2003	CONCLUSIONS: These data, together with the opposite effects of paclitaxel and vincristine on microtubules (i.e., polymerization versus depolymerization), indicate that the enhanced apoptosis in Pgp-rich cells is specific for antimicrotubule agents but is not related to the polymerization of microtubules.	Paclitaxel	63-73	ATP binding cassette subfamily B member 1	Homo sapiens	194-197
12584388-0	2003	Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression.	Paclitaxel	36-46	ATP binding cassette subfamily B member 1	Homo sapiens	105-119
12528803-0	2003	Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines.	Paclitaxel	27-37	ATP binding cassette subfamily B member 1	Homo sapiens	45-49
12584388-9	2003	CONCLUSIONS: Although Pgp expression in NSCLC does not fully predict chemotherapy response to paclitaxel-based therapy, detection of Pgp expression will aid in planning paclitaxel-based therapy for patients with advanced NSCLC.	Paclitaxel	169-179	ATP binding cassette subfamily B member 1	Homo sapiens	133-136
12466878-6	2002	The elicitor-induced activities of catalase (CAT) and phenylalanine ammonia-lyase (PAL) also depended mainly on inoculum age; higher PAL activity and lower CAT activity were obtained with an older inoculum, corresponding to a higher taxol yield.	Paclitaxel	233-238	catalase	Homo sapiens	35-43
12678980-6	2003	RESULTS: The resistance to chemotherapeutic agents such as cochicine, Vp-16, vincristine, doxorubcin and paclitaxel were elevated markedly by 10.6, 10.4, 11.2, 4.2 and 14.2 folds in KG1a cell line transduced with MDR1 gene.	Paclitaxel	105-115	ATP binding cassette subfamily B member 1	Homo sapiens	213-217
12459501-5	2002	The paclitaxel-induced release of cytochrome c was detected only after 24 h of incubation, was caspase-independent and permeability transition pore-dependent.	Paclitaxel	4-14	cytochrome c, somatic	Homo sapiens	34-46
12466878-6	2002	The elicitor-induced activities of catalase (CAT) and phenylalanine ammonia-lyase (PAL) also depended mainly on inoculum age; higher PAL activity and lower CAT activity were obtained with an older inoculum, corresponding to a higher taxol yield.	Paclitaxel	233-238	catalase	Homo sapiens	45-48
12419552-5	2002	Similarly, insulin-like drugs target the nuclear receptor peroxisome-proliferator-activator-receptor (PPAR)-gamma (class-II), several anti-inflammatory drugs inhibit activation of nuclear factor kappa B (NFkappaB) (class-IV), while others (e.g. flavopiridol, rapamycin, and paclitaxel) target regulation of cell-cycle proteins.	Paclitaxel	274-284	nuclear factor kappa B subunit 1	Homo sapiens	180-202
12419552-5	2002	Similarly, insulin-like drugs target the nuclear receptor peroxisome-proliferator-activator-receptor (PPAR)-gamma (class-II), several anti-inflammatory drugs inhibit activation of nuclear factor kappa B (NFkappaB) (class-IV), while others (e.g. flavopiridol, rapamycin, and paclitaxel) target regulation of cell-cycle proteins.	Paclitaxel	274-284	nuclear factor kappa B subunit 1	Homo sapiens	204-212
12516968-4	2002	Addition of SB203580, a specific inhibitor of p38, resulted in a decrease in activation of this kinase and abrogation of enhanced chemosensitivity (doxorubicin and paclitaxel) by CH-11.	Paclitaxel	164-174	mitogen-activated protein kinase 14	Homo sapiens	46-49
12540054-1	2002	We previously reported that nonomolar concentrations of Taxol and several structurally diverse microtubule (MT)-stabilizing agents significantly enhanced the survival of neurons in the presence of fibrils of amyloid beta peptide (Abeta).	Paclitaxel	56-61	amyloid beta precursor protein	Homo sapiens	230-235
12540054-4	2002	In an in vitro kinase assay, Taxol inhibited activation of cdk5 by Abeta.	Paclitaxel	29-34	amyloid beta precursor protein	Homo sapiens	67-72
12540054-6	2002	Taxol did not directly inhibit the activity of either cdk5 or calpain, indicating that other cellular components are required for the effect of the drug on Abeta activation of tau phosphorylation.	Paclitaxel	0-5	amyloid beta precursor protein	Homo sapiens	156-161
12530065-0	2002	Reduced expression of p53 and p21WAF1/CIP1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil.	Paclitaxel	83-93	tumor protein p53	Homo sapiens	22-25
12419746-1	2002	BACKGROUND: Trastuzumab (Herceptin) has clinical indication in association with paclitaxel (Taxol) for the treatment of human epidermal growth factor receptor 2 (HER2)-expressing breast cancer.	Paclitaxel	80-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-160
12419746-1	2002	BACKGROUND: Trastuzumab (Herceptin) has clinical indication in association with paclitaxel (Taxol) for the treatment of human epidermal growth factor receptor 2 (HER2)-expressing breast cancer.	Paclitaxel	80-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-166
12419746-1	2002	BACKGROUND: Trastuzumab (Herceptin) has clinical indication in association with paclitaxel (Taxol) for the treatment of human epidermal growth factor receptor 2 (HER2)-expressing breast cancer.	Paclitaxel	92-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-160
12419746-1	2002	BACKGROUND: Trastuzumab (Herceptin) has clinical indication in association with paclitaxel (Taxol) for the treatment of human epidermal growth factor receptor 2 (HER2)-expressing breast cancer.	Paclitaxel	92-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	162-166
12419746-11	2002	CONCLUSIONS: The present study shows that at least additive interactions are observed when trastuzumab is combined with either paclitaxel or docetaxel in weak to moderate or more than moderate HER2-expressing cells.	Paclitaxel	127-137	erb-b2 receptor tyrosine kinase 2	Homo sapiens	193-197
12414537-14	2002	Morphological studies demonstrated that VEGF immunoneutralization enhanced paclitaxel-induced apoptosis in these human ovarian cancers.	Paclitaxel	75-85	vascular endothelial growth factor A	Homo sapiens	40-44
12530065-0	2002	Reduced expression of p53 and p21WAF1/CIP1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil.	Paclitaxel	83-93	cyclin dependent kinase inhibitor 1A	Homo sapiens	30-42
12530065-3	2002	Biochemical examination also revealed that 5-FU inhibited expression of p21WAF1/CIP1 that may contribute to paclitaxel cytotoxicity.	Paclitaxel	108-118	cyclin dependent kinase inhibitor 1A	Homo sapiens	80-84
12530065-6	2002	RESULTS: Tumor cells transfected with antisense p53 or p21WAF1/CIP1 exhibited a significant increase in their sensitivity to paclitaxel.	Paclitaxel	125-135	tumor protein p53	Homo sapiens	48-51
12530065-6	2002	RESULTS: Tumor cells transfected with antisense p53 or p21WAF1/CIP1 exhibited a significant increase in their sensitivity to paclitaxel.	Paclitaxel	125-135	cyclin dependent kinase inhibitor 1A	Homo sapiens	63-67
12530065-7	2002	The reduced protein levels of p53 and p21WAF1/CIP1 were also found to abrogate the inhibitory effects of 5-FU on paclitaxel-induced mitotic arrest and apoptosis.	Paclitaxel	113-123	tumor protein p53	Homo sapiens	30-33
12530065-7	2002	The reduced protein levels of p53 and p21WAF1/CIP1 were also found to abrogate the inhibitory effects of 5-FU on paclitaxel-induced mitotic arrest and apoptosis.	Paclitaxel	113-123	cyclin dependent kinase inhibitor 1A	Homo sapiens	46-50
12530065-8	2002	CONCLUSION: These findings suggest that the status of p53 and p21WAF1/CIP1 might play an important role in tumor cell susceptibility to paclitaxel and its combination with other drugs such as 5-FU.	Paclitaxel	136-146	tumor protein p53	Homo sapiens	54-57
12530065-8	2002	CONCLUSION: These findings suggest that the status of p53 and p21WAF1/CIP1 might play an important role in tumor cell susceptibility to paclitaxel and its combination with other drugs such as 5-FU.	Paclitaxel	136-146	cyclin dependent kinase inhibitor 1A	Homo sapiens	70-74
12452453-0	2002	Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.	Paclitaxel	94-104	BCL2 apoptosis regulator	Homo sapiens	0-5
12452453-0	2002	Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.	Paclitaxel	94-104	BCL2 like 1	Homo sapiens	6-12
12384528-5	2002	Herceptin plus Taxol treatment led to higher levels of p34(Cdc2) kinase activity and apoptosis in ErbB2-overexpressing breast cancer cells, which is likely attributable to inhibition of Cdc2-Tyr-15 phosphorylation and p21(Cip1) expression.	Paclitaxel	15-20	cyclin dependent kinase inhibitor 1A	Homo sapiens	222-226
12384528-1	2002	The recombinant humanized anti-ErbB2/HER2 monoclonal antibody Herceptin (Trastuzumab) has been shown to significantly enhance the tumoricidaleffects of antitumor drugs such as paclitaxel (Taxol) in patients with ErbB2-overexpressing breast cancers.	Paclitaxel	176-186	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-36
12384528-1	2002	The recombinant humanized anti-ErbB2/HER2 monoclonal antibody Herceptin (Trastuzumab) has been shown to significantly enhance the tumoricidaleffects of antitumor drugs such as paclitaxel (Taxol) in patients with ErbB2-overexpressing breast cancers.	Paclitaxel	176-186	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-41
12384528-0	2002	Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.	Paclitaxel	26-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-84
12384528-8	2002	Thus, Herceptin treatment of ErbB2-overexpressing cells can inhibit ErbB2-mediated Cdc2-Tyr-15 phosphorylation and p21(Cip1) up-regulation, which allows effective p34(Cdc2) activation and induction of apoptosis upon Taxol treatment.	Paclitaxel	216-221	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-34
12384528-1	2002	The recombinant humanized anti-ErbB2/HER2 monoclonal antibody Herceptin (Trastuzumab) has been shown to significantly enhance the tumoricidaleffects of antitumor drugs such as paclitaxel (Taxol) in patients with ErbB2-overexpressing breast cancers.	Paclitaxel	188-193	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-36
12384528-1	2002	The recombinant humanized anti-ErbB2/HER2 monoclonal antibody Herceptin (Trastuzumab) has been shown to significantly enhance the tumoricidaleffects of antitumor drugs such as paclitaxel (Taxol) in patients with ErbB2-overexpressing breast cancers.	Paclitaxel	188-193	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-41
12384528-8	2002	Thus, Herceptin treatment of ErbB2-overexpressing cells can inhibit ErbB2-mediated Cdc2-Tyr-15 phosphorylation and p21(Cip1) up-regulation, which allows effective p34(Cdc2) activation and induction of apoptosis upon Taxol treatment.	Paclitaxel	216-221	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-73
12384528-3	2002	Because activation of p34(Cdc2) is required for Taxol-induced apoptosis and because overexpression of ErbB2 blocks Taxol-induced apoptosis by inhibiting p34(Cdc2) activation, we studied the effect of Herceptin treatment on p34(Cdc2) kinase activation and apoptosis in Taxol-treated human breast carcinoma cell lines MDA-MB-435, SKBr3, MDA-MB-453, and 435.eB, which is an ErbB2 transfectant of MDA-MB-435.	Paclitaxel	115-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-107
12384528-3	2002	Because activation of p34(Cdc2) is required for Taxol-induced apoptosis and because overexpression of ErbB2 blocks Taxol-induced apoptosis by inhibiting p34(Cdc2) activation, we studied the effect of Herceptin treatment on p34(Cdc2) kinase activation and apoptosis in Taxol-treated human breast carcinoma cell lines MDA-MB-435, SKBr3, MDA-MB-453, and 435.eB, which is an ErbB2 transfectant of MDA-MB-435.	Paclitaxel	115-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-107
12384528-8	2002	Thus, Herceptin treatment of ErbB2-overexpressing cells can inhibit ErbB2-mediated Cdc2-Tyr-15 phosphorylation and p21(Cip1) up-regulation, which allows effective p34(Cdc2) activation and induction of apoptosis upon Taxol treatment.	Paclitaxel	216-221	cyclin dependent kinase inhibitor 1A	Homo sapiens	119-123
12384528-5	2002	Herceptin plus Taxol treatment led to higher levels of p34(Cdc2) kinase activity and apoptosis in ErbB2-overexpressing breast cancer cells, which is likely attributable to inhibition of Cdc2-Tyr-15 phosphorylation and p21(Cip1) expression.	Paclitaxel	15-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-103
12384528-9	2002	Herceptin pretreatment renders ErbB2-overexpressing breast cancers more susceptible to Taxol-induced cell death, which may have important clinical therapeutic implications.	Paclitaxel	87-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-36
26680890-1	2002	PURPOSE: Oxaliplatin (LOHP), 5-FU, and paclitaxel (PTX) are considered highly active against advanced gastric carcinomas, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, ZD1839 is considered as a good candidate for the treatment of gastric cancers when given alone or in combination with cytotoxic agents.	Paclitaxel	39-49	epidermal growth factor receptor	Homo sapiens	130-162
12370827-3	2002	Treatment of the transfected cells with cisplatin, staurosporine, paclitaxel and doxorubicine showed that BAG-1 p50, p46 and p33 isoforms enhanced the resistance to apoptosis.	Paclitaxel	66-76	BAG cochaperone 1	Homo sapiens	106-111
12395475-5	2002	METHOD: A slow paclitaxel infusion rate with a 1/20 dose of the original concentration was administered for reinduction therapy when the patient became symptom-free after treatment with steroid and antihistamines.	Paclitaxel	15-25	BCL2 related protein A1	Homo sapiens	45-51
12121974-6	2002	The resistance to paclitaxel can be partially obliterated when ERK activity is inhibited using a MEK1/2 inhibitor.	Paclitaxel	18-28	mitogen-activated protein kinase 1	Homo sapiens	63-66
12121974-7	2002	Activation of JNK and its downstream caspase-3 by paclitaxel or vinblastine is significantly down-regulated in gamma-synuclein-expressing cells, indicating that the paclitaxel- or vinblastine-activated apoptosis pathway is blocked by gamma-synuclein.	Paclitaxel	50-60	mitogen-activated protein kinase 8	Homo sapiens	14-17
12121974-7	2002	Activation of JNK and its downstream caspase-3 by paclitaxel or vinblastine is significantly down-regulated in gamma-synuclein-expressing cells, indicating that the paclitaxel- or vinblastine-activated apoptosis pathway is blocked by gamma-synuclein.	Paclitaxel	50-60	caspase 3	Homo sapiens	37-46
12121974-7	2002	Activation of JNK and its downstream caspase-3 by paclitaxel or vinblastine is significantly down-regulated in gamma-synuclein-expressing cells, indicating that the paclitaxel- or vinblastine-activated apoptosis pathway is blocked by gamma-synuclein.	Paclitaxel	165-175	mitogen-activated protein kinase 8	Homo sapiens	14-17
12121974-7	2002	Activation of JNK and its downstream caspase-3 by paclitaxel or vinblastine is significantly down-regulated in gamma-synuclein-expressing cells, indicating that the paclitaxel- or vinblastine-activated apoptosis pathway is blocked by gamma-synuclein.	Paclitaxel	165-175	caspase 3	Homo sapiens	37-46
12374693-8	2002	The combination of paclitaxel and rhu alpha VEGF resulted in greater inhibition of tumor growth than that observed with either agent alone (98% growth inhibition, P = 0.024 versus rhualpha VEGF alone and P = 0.02 versus paclitaxel alone).	Paclitaxel	19-29	vascular endothelial growth factor A	Homo sapiens	189-193
12374693-8	2002	The combination of paclitaxel and rhu alpha VEGF resulted in greater inhibition of tumor growth than that observed with either agent alone (98% growth inhibition, P = 0.024 versus rhualpha VEGF alone and P = 0.02 versus paclitaxel alone).	Paclitaxel	220-230	vascular endothelial growth factor A	Homo sapiens	44-48
12389115-4	2002	Furthermore, the phosphorylation of Bcl-2 and Bcl-X(L) proteins in Taxol treated cells was detected at 8 h. In contrast, Taxol had no effect on the levels of Fas and FasL proteins and neither antagonistic, anti-Fas antibody affected Taxol-induced apoptosis.	Paclitaxel	67-72	BCL2 apoptosis regulator	Homo sapiens	36-41
12389115-4	2002	Furthermore, the phosphorylation of Bcl-2 and Bcl-X(L) proteins in Taxol treated cells was detected at 8 h. In contrast, Taxol had no effect on the levels of Fas and FasL proteins and neither antagonistic, anti-Fas antibody affected Taxol-induced apoptosis.	Paclitaxel	67-72	BCL2 like 1	Homo sapiens	46-54
12389115-5	2002	These results suggest that, following the phosphorylation of Bcl-2 and Bcl-X(L)proteins, Taxol-induced apoptosis is induced through the mitochondria-dependent pathway in T24 cells.	Paclitaxel	89-94	BCL2 apoptosis regulator	Homo sapiens	61-66
12237780-0	2002	Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.	Paclitaxel	14-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-43
12226754-0	2002	The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.	Paclitaxel	92-97	nuclear factor kappa B subunit 1	Homo sapiens	35-44
12226754-8	2002	This is due to the Taxol-mediated reactivation of RelA through phosphorylation and degradation of IkappaBbeta and the re-expression of NF-kappaB regulated bcl-xl gene in these cancer cells as ectopic expression of the bcl-xl gene confers resistance to Taxol-induced apoptosis in PS-341 sensitized cells.	Paclitaxel	19-24	BCL2 like 1	Homo sapiens	218-224
12226754-8	2002	This is due to the Taxol-mediated reactivation of RelA through phosphorylation and degradation of IkappaBbeta and the re-expression of NF-kappaB regulated bcl-xl gene in these cancer cells as ectopic expression of the bcl-xl gene confers resistance to Taxol-induced apoptosis in PS-341 sensitized cells.	Paclitaxel	252-257	nuclear factor kappa B subunit 1	Homo sapiens	135-144
12226754-8	2002	This is due to the Taxol-mediated reactivation of RelA through phosphorylation and degradation of IkappaBbeta and the re-expression of NF-kappaB regulated bcl-xl gene in these cancer cells as ectopic expression of the bcl-xl gene confers resistance to Taxol-induced apoptosis in PS-341 sensitized cells.	Paclitaxel	252-257	BCL2 like 1	Homo sapiens	155-161
12214265-1	2002	By inducing p53-dependent G2 arrest, the pretreatment with low concentrations of DNA damaging drugs (e.g., doxorubicin, DOX) can prevent cell death caused by microtubule-active drugs (e.g., paclitaxel, PTX), thus potentially permitting selective killing of p53-deficient cancer cells.	Paclitaxel	190-200	tumor protein p53	Homo sapiens	12-15
12218532-8	2002	In both strains, the effect of isoflurane on AngII- Ca mobilization was abolished by impairment with nocodazole, vinblastine, or paclitaxel of microtubules polymerization.	Paclitaxel	129-139	angiotensinogen	Rattus norvegicus	45-50
12087097-11	2002	We demonstrated an association between Akt and Raf-1 and showed that the phosphorylation of Raf-1 on Ser-259 induced by paclitaxel was blocked by treatment with wortmannin or LY294002.	Paclitaxel	120-130	AKT serine/threonine kinase 1	Homo sapiens	39-42
12087097-12	2002	Furthermore, interference with the Akt cascade induced by paclitaxel up-regulated Raf-1 activity, and expression of constitutively active Akt inhibited Raf-1 activity, suggesting that Akt negatively regulates Raf-1.	Paclitaxel	58-68	AKT serine/threonine kinase 1	Homo sapiens	35-38
12087097-13	2002	Our findings suggest that paclitaxel induces the phosphorylation of BAD Ser-112 via the ERK cascade, and the phosphorylation of both BAD Ser-136 and Raf-1 Ser-259 via the PI-3K-Akt cascade, and that inhibition of either of these cascades sensitizes ovarian cancer cells to paclitaxel.	Paclitaxel	26-36	mitogen-activated protein kinase 1	Homo sapiens	88-91
12087097-13	2002	Our findings suggest that paclitaxel induces the phosphorylation of BAD Ser-112 via the ERK cascade, and the phosphorylation of both BAD Ser-136 and Raf-1 Ser-259 via the PI-3K-Akt cascade, and that inhibition of either of these cascades sensitizes ovarian cancer cells to paclitaxel.	Paclitaxel	26-36	AKT serine/threonine kinase 1	Homo sapiens	177-180
12087097-0	2002	Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel.	Paclitaxel	95-105	AKT serine/threonine kinase 1	Homo sapiens	50-53
12087097-2	2002	Treatment of SW626 cells with paclitaxel activates Akt and ERK with different time frames.	Paclitaxel	30-40	AKT serine/threonine kinase 1	Homo sapiens	51-54
12087097-2	2002	Treatment of SW626 cells with paclitaxel activates Akt and ERK with different time frames.	Paclitaxel	30-40	mitogen-activated protein kinase 1	Homo sapiens	59-62
12087097-3	2002	Interference with the Akt cascade either by treatment with PI-3K inhibitor (wortmannin or LY294002) or by exogenous expression of a dominant negative Akt in SW626 cells caused decreased cell viability following treatment with paclitaxel.	Paclitaxel	226-236	AKT serine/threonine kinase 1	Homo sapiens	22-25
12087097-3	2002	Interference with the Akt cascade either by treatment with PI-3K inhibitor (wortmannin or LY294002) or by exogenous expression of a dominant negative Akt in SW626 cells caused decreased cell viability following treatment with paclitaxel.	Paclitaxel	226-236	AKT serine/threonine kinase 1	Homo sapiens	150-153
12087097-4	2002	Interference with the ERK cascade by treatment with an MEK inhibitor, PD98059, in SW626 cells also caused decreased cell viability following treatment with paclitaxel.	Paclitaxel	156-166	mitogen-activated protein kinase 1	Homo sapiens	22-25
12087097-4	2002	Interference with the ERK cascade by treatment with an MEK inhibitor, PD98059, in SW626 cells also caused decreased cell viability following treatment with paclitaxel.	Paclitaxel	156-166	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
12087097-10	2002	Moreover, because paclitaxel-induced apoptosis is mediated by activated Raf-1 and the region surrounding Ser-259 in Raf-1 conforms to a consensus sequence for phosphorylation by Akt, the regulation of Raf-1 by Akt was examined.	Paclitaxel	18-28	AKT serine/threonine kinase 1	Homo sapiens	178-181
12087097-10	2002	Moreover, because paclitaxel-induced apoptosis is mediated by activated Raf-1 and the region surrounding Ser-259 in Raf-1 conforms to a consensus sequence for phosphorylation by Akt, the regulation of Raf-1 by Akt was examined.	Paclitaxel	18-28	AKT serine/threonine kinase 1	Homo sapiens	210-213
12181740-9	2002	In contrast, dominant negative ERK2 potentiated paclitaxel-induced apoptosis.	Paclitaxel	48-58	mitogen-activated protein kinase 1	Homo sapiens	31-35
12435109-3	2002	Photoaffinity labeling of Pgp using photoreactive radiolabeled paclitaxel analogs along with molecular modeling has revealed a unique binding region for paclitaxel on the C-terminal half of Pgp.	Paclitaxel	63-73	ATP binding cassette subfamily B member 1	Homo sapiens	26-29
12209684-3	2002	Thus, the authors evaluated a possible correlation between HER2 expression in patients with high-grade, muscle-invasive urothelial carcinoma of the bladder and outcome in patients who received paclitaxel-based chemotherapy.	Paclitaxel	193-203	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
12209684-15	2002	However, contrary to other reports, the current study found that HER2 expression in the context of paclitaxel-based chemotherapy decreased the risk of death significantly.	Paclitaxel	99-109	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-69
12435109-3	2002	Photoaffinity labeling of Pgp using photoreactive radiolabeled paclitaxel analogs along with molecular modeling has revealed a unique binding region for paclitaxel on the C-terminal half of Pgp.	Paclitaxel	63-73	ATP binding cassette subfamily B member 1	Homo sapiens	190-193
12435109-3	2002	Photoaffinity labeling of Pgp using photoreactive radiolabeled paclitaxel analogs along with molecular modeling has revealed a unique binding region for paclitaxel on the C-terminal half of Pgp.	Paclitaxel	153-163	ATP binding cassette subfamily B member 1	Homo sapiens	26-29
12359058-0	2002	Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line.	Paclitaxel	36-46	ATP binding cassette subfamily B member 1	Homo sapiens	12-26
12435109-3	2002	Photoaffinity labeling of Pgp using photoreactive radiolabeled paclitaxel analogs along with molecular modeling has revealed a unique binding region for paclitaxel on the C-terminal half of Pgp.	Paclitaxel	153-163	ATP binding cassette subfamily B member 1	Homo sapiens	190-193
12175696-1	2002	The correlation between inactivation of the TP53 gene through mutation or the presence of high-risk human papillomavirus (HPV) DNA and intrinsic paclitaxel sensitivity was studied in 27 gynaecological cancer cell lines.	Paclitaxel	145-155	tumor protein p53	Homo sapiens	44-48
12359058-6	2002	Cell survival assay revealed that verapamil and cepharanthine, conventional P-gp modulators, could completely overcome paclitaxel resistance.	Paclitaxel	119-129	ATP binding cassette subfamily B member 1	Homo sapiens	76-80
12181443-11	2002	LPA/S1P-induced Akt activation may be involved in cell survival, because LPA and S1P treatment in HEY ovarian cancer cells results in a decrease in paclitaxel-induced caspase-3 activity in a PI3-K/MEK/p38-dependent manner.	Paclitaxel	148-158	AKT serine/threonine kinase 1	Homo sapiens	16-19
12181443-11	2002	LPA/S1P-induced Akt activation may be involved in cell survival, because LPA and S1P treatment in HEY ovarian cancer cells results in a decrease in paclitaxel-induced caspase-3 activity in a PI3-K/MEK/p38-dependent manner.	Paclitaxel	148-158	caspase 3	Homo sapiens	167-176
12181443-11	2002	LPA/S1P-induced Akt activation may be involved in cell survival, because LPA and S1P treatment in HEY ovarian cancer cells results in a decrease in paclitaxel-induced caspase-3 activity in a PI3-K/MEK/p38-dependent manner.	Paclitaxel	148-158	mitogen-activated protein kinase kinase 7	Homo sapiens	197-200
12181443-11	2002	LPA/S1P-induced Akt activation may be involved in cell survival, because LPA and S1P treatment in HEY ovarian cancer cells results in a decrease in paclitaxel-induced caspase-3 activity in a PI3-K/MEK/p38-dependent manner.	Paclitaxel	148-158	mitogen-activated protein kinase 14	Homo sapiens	201-204
12139759-4	2002	Taxol induces the secretion of inflammatory cytokines in murine macrophages in a toll-like receptor-4 (TLR-4)-dependent manner in addition to its anti-tumour effects, but the effect of Taxol on human macrophages is controversial.	Paclitaxel	0-5	toll-like receptor 4	Mus musculus	103-108
12139759-5	2002	In this study, we demonstrated that low doses (less than 1000 nmol/l) of Taxol induced the expression of tumour necrosis factor (TNF)-alpha in human myelomonocytic cells and that the induction of TNF-alpha mRNA was inhibited by dominant-negative myeloid differentiation protein (dnMyD88).	Paclitaxel	73-78	tumor necrosis factor	Homo sapiens	105-139
12139759-4	2002	Taxol induces the secretion of inflammatory cytokines in murine macrophages in a toll-like receptor-4 (TLR-4)-dependent manner in addition to its anti-tumour effects, but the effect of Taxol on human macrophages is controversial.	Paclitaxel	0-5	toll-like receptor 4	Mus musculus	81-101
12139759-5	2002	In this study, we demonstrated that low doses (less than 1000 nmol/l) of Taxol induced the expression of tumour necrosis factor (TNF)-alpha in human myelomonocytic cells and that the induction of TNF-alpha mRNA was inhibited by dominant-negative myeloid differentiation protein (dnMyD88).	Paclitaxel	73-78	tumor necrosis factor	Homo sapiens	196-205
12139759-7	2002	In accordance with the previous reports, Taxol induced the expression of TNF-alpha and apoptosis in a TLR4-independent manner.	Paclitaxel	41-46	tumor necrosis factor	Homo sapiens	73-82
12139759-8	2002	These results suggest that TNF-alpha expression and apoptosis, both induced by Taxol in human myelomonocytic cells, share the signal transduction molecule MyD88.	Paclitaxel	79-84	tumor necrosis factor	Homo sapiens	27-36
12126962-0	2002	Bcl-2 phosphorylation and proteasome-dependent degradation induced by paclitaxel treatment: consequences on sensitivity of isolated mitochondria to Bid.	Paclitaxel	70-80	BCL2 apoptosis regulator	Homo sapiens	0-5
12193109-1	2002	The aim of this study was to evaluate the role of endothelin-1 (ET-1) in the sensitivity of ovarian carcinoma to paclitaxel, one of the most common drugs used for the management of this tumour histotype.	Paclitaxel	113-123	endothelin 1	Homo sapiens	50-62
12193109-1	2002	The aim of this study was to evaluate the role of endothelin-1 (ET-1) in the sensitivity of ovarian carcinoma to paclitaxel, one of the most common drugs used for the management of this tumour histotype.	Paclitaxel	113-123	endothelin 1	Homo sapiens	64-68
12193109-5	2002	When the treatment with paclitaxel was performed in association with ET-1, paclitaxel-induced apoptosis was inhibited.	Paclitaxel	24-34	endothelin 1	Homo sapiens	69-73
12193109-5	2002	When the treatment with paclitaxel was performed in association with ET-1, paclitaxel-induced apoptosis was inhibited.	Paclitaxel	75-85	endothelin 1	Homo sapiens	69-73
12193109-6	2002	In order to evaluate which ET-1 receptor mediated the effect of ET-1 on protection from paclitaxel-induced apoptosis, we performed experiments using two selective antagonists for ET(A)R (BQ-123) and for ET(B)R (BQ-788).	Paclitaxel	88-98	endothelin 1	Homo sapiens	64-68
12193109-7	2002	We showed that ET(A)R blockade inhibits the ET-1-induced survival activity against paclitaxel-mediated apoptosis.	Paclitaxel	83-93	endothelin 1	Homo sapiens	44-48
12142057-4	2002	Notably, the simultaneous exposure to ZD0473 and paclitaxel for 96 h resulted in synergy (as defined by a median effect analysis) in all four cell lines (i.e. independent of cisplatin resistance and p53 status).	Paclitaxel	49-59	tumor protein p53	Homo sapiens	199-202
12126962-0	2002	Bcl-2 phosphorylation and proteasome-dependent degradation induced by paclitaxel treatment: consequences on sensitivity of isolated mitochondria to Bid.	Paclitaxel	70-80	BH3 interacting domain death agonist	Homo sapiens	148-151
12126962-1	2002	Several studies have suggested that Bcl-2 phosphorylation, which occurs during mitotic arrest induced by paclitaxel, inhibits its antiapoptotic function.	Paclitaxel	105-115	BCL2 apoptosis regulator	Homo sapiens	36-41
12126962-4	2002	In HeLa cells, in which paclitaxel induces apoptosis, the nonphosphorylated form of Bcl-2 is degraded by a proteasome-dependent degradation pathway, whereas the phosphorylated forms of mitochondrial Bcl-2 appear to be resistant to proteasome-induced degradation.	Paclitaxel	24-34	BCL2 apoptosis regulator	Homo sapiens	84-89
12126962-4	2002	In HeLa cells, in which paclitaxel induces apoptosis, the nonphosphorylated form of Bcl-2 is degraded by a proteasome-dependent degradation pathway, whereas the phosphorylated forms of mitochondrial Bcl-2 appear to be resistant to proteasome-induced degradation.	Paclitaxel	24-34	BCL2 apoptosis regulator	Homo sapiens	199-204
12126962-5	2002	We found that low concentrations of recombinant Bid triggered a greater release of cytochrome c from mitochondria isolated from paclitaxel-treated HeLa cells than from mitochondria isolated from control HeLa cells.	Paclitaxel	128-138	BH3 interacting domain death agonist	Homo sapiens	48-51
12126962-5	2002	We found that low concentrations of recombinant Bid triggered a greater release of cytochrome c from mitochondria isolated from paclitaxel-treated HeLa cells than from mitochondria isolated from control HeLa cells.	Paclitaxel	128-138	cytochrome c, somatic	Homo sapiens	83-95
12126962-8	2002	Indeed, in response to paclitaxel treatment, the level of Bcl-2 expression in mitochondria rather than its phosphorylation state could regulate the sensitivity of mitochondria to cytochrome c releasing agents in vitro.	Paclitaxel	23-33	BCL2 apoptosis regulator	Homo sapiens	58-63
12126962-8	2002	Indeed, in response to paclitaxel treatment, the level of Bcl-2 expression in mitochondria rather than its phosphorylation state could regulate the sensitivity of mitochondria to cytochrome c releasing agents in vitro.	Paclitaxel	23-33	cytochrome c, somatic	Homo sapiens	179-191
12144824-0	2002	Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer.	Paclitaxel	53-63	ATP binding cassette subfamily B member 1	Homo sapiens	0-27
12193017-3	2002	The resin-bound C-10 acylated paclitaxel derivatives (6a-6e) were then treated with various carboxylic acids in the presence of 1,3-diisopropylcarbodiimide in toluene to provide polymer-supported 7,10-diacylpaclitaxels (8a-8u).	Paclitaxel	30-40	homeobox C10	Homo sapiens	16-20
12144824-14	2002	Bcl-2 phosphorylation appeared after exposure to IC(50) PTX in all cells.	Paclitaxel	56-59	BCL2 apoptosis regulator	Homo sapiens	0-5
12144824-19	2002	CONCLUSION: MDR-1 gene expression may be a useful predictor for PTX-based chemotherapy.	Paclitaxel	64-67	ATP binding cassette subfamily B member 1	Homo sapiens	12-17
12085250-13	2002	The present study indicates that patients responded to treatment of advanced breast cancer with single-agent paclitaxel or docetaxel leads to an increase in serum IFN-gamma, IL-2, IL-6, GM-CSF cytokine levels and enhancement of PBMC NK and LAK cell activity, while they both lead to a decrease of acute phase serum cytokine levels of IL-1 and TNF-alpha.	Paclitaxel	109-119	interferon gamma	Homo sapiens	163-172
12212764-1	2002	Based on microtubule (MT) disruption observed in primary neurons exposed to fibrillar amyloid peptides (A beta), we tested the potential protective effect of MT-stabilizing drugs such as Taxol against A beta-induced disruption of the cytoskeleton.	Paclitaxel	187-192	amyloid beta precursor protein	Homo sapiens	201-207
12085250-13	2002	The present study indicates that patients responded to treatment of advanced breast cancer with single-agent paclitaxel or docetaxel leads to an increase in serum IFN-gamma, IL-2, IL-6, GM-CSF cytokine levels and enhancement of PBMC NK and LAK cell activity, while they both lead to a decrease of acute phase serum cytokine levels of IL-1 and TNF-alpha.	Paclitaxel	109-119	interleukin 2	Homo sapiens	174-178
12085250-13	2002	The present study indicates that patients responded to treatment of advanced breast cancer with single-agent paclitaxel or docetaxel leads to an increase in serum IFN-gamma, IL-2, IL-6, GM-CSF cytokine levels and enhancement of PBMC NK and LAK cell activity, while they both lead to a decrease of acute phase serum cytokine levels of IL-1 and TNF-alpha.	Paclitaxel	109-119	interleukin 6	Homo sapiens	180-184
12085250-13	2002	The present study indicates that patients responded to treatment of advanced breast cancer with single-agent paclitaxel or docetaxel leads to an increase in serum IFN-gamma, IL-2, IL-6, GM-CSF cytokine levels and enhancement of PBMC NK and LAK cell activity, while they both lead to a decrease of acute phase serum cytokine levels of IL-1 and TNF-alpha.	Paclitaxel	109-119	interleukin 1 beta	Homo sapiens	334-338
12085250-13	2002	The present study indicates that patients responded to treatment of advanced breast cancer with single-agent paclitaxel or docetaxel leads to an increase in serum IFN-gamma, IL-2, IL-6, GM-CSF cytokine levels and enhancement of PBMC NK and LAK cell activity, while they both lead to a decrease of acute phase serum cytokine levels of IL-1 and TNF-alpha.	Paclitaxel	109-119	tumor necrosis factor	Homo sapiens	343-352
12432259-0	2002	Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel.	Paclitaxel	92-102	cyclin dependent kinase inhibitor 1A	Homo sapiens	67-70
12150453-3	2002	Taxol treatment resulted in elevated expression of p53 and of p21, which was more pronounced and persistent in cyclin D1 overexpressing cells.	Paclitaxel	0-5	tumor protein p53	Homo sapiens	51-54
12432259-12	2002	In summary, only low concentrations of FL can induce p21, and, in turn, only p21-sensitive cells are protected from PTX.	Paclitaxel	116-119	cyclin dependent kinase inhibitor 1A	Homo sapiens	77-80
12432259-2	2002	By causing p53-mediated arrest, pretreatment with low concentrations of doxorubicin (DOX) protected HCT116 cells from the cytotoxicity caused by PTX.	Paclitaxel	145-148	tumor protein p53	Homo sapiens	11-14
12065438-7	2002	Clotrimazole, phenobarbital, rifampin, and sulfinpyrazone highly activated PXR and increased CYP3A4 activity; carbamazepine, dexamethasone, dexamethasone-t-butylacetate, phenytoin, sulfadimidine, and taxol weakly activated PXR and induced CYP3A4 activity, and methotrexate and probenecid showed no marked activation in either system.	Paclitaxel	200-205	nuclear receptor subfamily 1 group I member 2	Homo sapiens	75-78
12114408-4	2002	Here, we find that the combination of paclitaxel with a MEK inhibitor leads to a dramatic inactivation of the antiapoptotic Akt (protein kinase B) kinase.	Paclitaxel	38-48	AKT serine/threonine kinase 1	Homo sapiens	124-127
12114408-7	2002	Further analysis upstream of Akt shows that treatment with the combination of paclitaxel and MEK inhibitor down-regulates PI3K activity more than either agent alone.	Paclitaxel	78-88	AKT serine/threonine kinase 1	Homo sapiens	29-32
12114408-9	2002	Our results suggest the combination of paclitaxel and MEK inhibitor leads to down-regulation of the PI3K-Akt signaling in addition to the proapoptotic effects of paclitaxel and MEK inhibitor alone.	Paclitaxel	39-49	AKT serine/threonine kinase 1	Homo sapiens	105-108
12114408-9	2002	Our results suggest the combination of paclitaxel and MEK inhibitor leads to down-regulation of the PI3K-Akt signaling in addition to the proapoptotic effects of paclitaxel and MEK inhibitor alone.	Paclitaxel	39-49	mitogen-activated protein kinase kinase 7	Homo sapiens	177-180
12114408-9	2002	Our results suggest the combination of paclitaxel and MEK inhibitor leads to down-regulation of the PI3K-Akt signaling in addition to the proapoptotic effects of paclitaxel and MEK inhibitor alone.	Paclitaxel	162-172	mitogen-activated protein kinase kinase 7	Homo sapiens	54-57
12114408-0	2002	Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.	Paclitaxel	105-110	AKT serine/threonine kinase 1	Homo sapiens	64-67
12114408-2	2002	In contrast, paclitaxel also activates cell survival pathways, such as the Raf-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway.	Paclitaxel	13-23	mitogen-activated protein kinase kinase 7	Homo sapiens	75-118
12114408-2	2002	In contrast, paclitaxel also activates cell survival pathways, such as the Raf-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway.	Paclitaxel	13-23	mitogen-activated protein kinase kinase 7	Homo sapiens	120-123
12114408-4	2002	Here, we find that the combination of paclitaxel with a MEK inhibitor leads to a dramatic inactivation of the antiapoptotic Akt (protein kinase B) kinase.	Paclitaxel	38-48	mitogen-activated protein kinase kinase 7	Homo sapiens	56-59
12123338-4	2002	RESULTS: Paclitaxel administration significantly increased the epirubicinol area under the concentration-time curve, from 357+/-146 (epirubicin) to 603+/-107 (EP) and 640+/-81 h x ng/ml (GEP), and reduced the renal clearance of epirubicin and epirubicinol by 38 and 52.2% and 34.5 and 53% in GEP- and EP-treated patients, respectively, compared with epirubicin alone.	Paclitaxel	9-19	granulin precursor	Homo sapiens	187-190
12051739-0	2002	PP1 phosphatase is involved in Bcl-2 dephosphorylation after prolonged mitotic arrest induced by paclitaxel.	Paclitaxel	97-107	BCL2 apoptosis regulator	Homo sapiens	31-36
12051739-1	2002	During mitotic arrest induced by paclitaxel, most of the mitochondrial Bcl-2 is phosphorylated.	Paclitaxel	33-43	BCL2 apoptosis regulator	Homo sapiens	71-76
12063170-9	2002	It is known that Taxol, but not other microtubule-interacting agents, induces the production of cytokines, such as tumor necrosis factor alpha (TNF-alpha) in mouse macrophages.	Paclitaxel	17-22	tumor necrosis factor	Mus musculus	115-142
12063170-9	2002	It is known that Taxol, but not other microtubule-interacting agents, induces the production of cytokines, such as tumor necrosis factor alpha (TNF-alpha) in mouse macrophages.	Paclitaxel	17-22	tumor necrosis factor	Mus musculus	144-153
12063170-10	2002	The time course of Taxol-induced TNF-alpha expression coincides with that of Taxol-induced p66shc phosphorylation, and U0126 inhibits significantly Taxol-induced TNF-alpha expression in RAW 264.7 cells.	Paclitaxel	19-24	tumor necrosis factor	Mus musculus	33-42
12063170-11	2002	Our data indicate that the Taxol-induced serine phosphorylation of p66shc in RAW 264.7 cells is microtubule-independent and may be related to increased TNF-alpha expression after Taxol and LPS treatment.	Paclitaxel	27-32	tumor necrosis factor	Mus musculus	152-161
12063170-11	2002	Our data indicate that the Taxol-induced serine phosphorylation of p66shc in RAW 264.7 cells is microtubule-independent and may be related to increased TNF-alpha expression after Taxol and LPS treatment.	Paclitaxel	179-184	tumor necrosis factor	Mus musculus	152-161
12051739-0	2002	PP1 phosphatase is involved in Bcl-2 dephosphorylation after prolonged mitotic arrest induced by paclitaxel.	Paclitaxel	97-107	inorganic pyrophosphatase 1	Homo sapiens	0-3
12003772-3	2002	Incubation of PAEC with taxol (15 microM) for 2-4 h resulted in an increase in NO production, eNOS activity, and the amount of HSP90 binding to eNOS.	Paclitaxel	24-29	nitric oxide synthase 3	Homo sapiens	94-98
12003772-3	2002	Incubation of PAEC with taxol (15 microM) for 2-4 h resulted in an increase in NO production, eNOS activity, and the amount of HSP90 binding to eNOS.	Paclitaxel	24-29	nitric oxide synthase 3	Homo sapiens	144-148
12003772-5	2002	The presence of taxol in the culture medium prevented the effects of nocodazole on NO production and eNOS activity in PAEC.	Paclitaxel	16-21	nitric oxide synthase 3	Homo sapiens	101-105
12003772-6	2002	Geldanamycin, a HSP90 inhibitor, prevented the taxol-induced increase in eNOS activity.	Paclitaxel	47-52	nitric oxide synthase 3	Homo sapiens	73-77
12123338-4	2002	RESULTS: Paclitaxel administration significantly increased the epirubicinol area under the concentration-time curve, from 357+/-146 (epirubicin) to 603+/-107 (EP) and 640+/-81 h x ng/ml (GEP), and reduced the renal clearance of epirubicin and epirubicinol by 38 and 52.2% and 34.5 and 53% in GEP- and EP-treated patients, respectively, compared with epirubicin alone.	Paclitaxel	9-19	granulin precursor	Homo sapiens	292-295
12123338-6	2002	The only pharmacokinetic/pharmacodynamic relationship observed was between neutropenia and the time spent above the threshold plasma level of 0.1 micromol/l (tC0.1) of paclitaxel, with the time required to obtain a 50% decrease in neutrophil count (Et50) of GEP being 7.8 h, similar to that of EP.	Paclitaxel	168-178	granulin precursor	Homo sapiens	258-261
12050209-6	2002	The ONYX-015 virus worked synergistically with two antineoplastic drugs (doxorubicin and paclitaxel) in inducing ARO and KAT-4 cell death.	Paclitaxel	89-99	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	113-116
12006621-5	2002	By contrast, paclitaxel treatment of metaphase cells apparently causes limited disassembly of the pericentriolar material into a number of multipolar "ring-like" structures containing calmodulin, each one having multiple attached microtubules terminating in the partially disordered kinetochore/chromosome complex.	Paclitaxel	13-23	calmodulin 1	Homo sapiens	184-194
12079522-12	2002	Except for HAC-2 cells, expression of MRP genes was related to CDDP resistance, and MDR-1 gene expression was associated with PTX resistance.	Paclitaxel	126-129	ATP binding cassette subfamily B member 1	Homo sapiens	84-89
12138396-3	2002	The US Food and Drug Administration has approved the use of trastuzumab and paclitaxel as first-line treatment of HER2-overexpressing metastatic breast cancer, based on the results of a randomized phase III clinical trial showing that this combination produced higher response rates and longer survival duration than treatment with chemotherapy alone.	Paclitaxel	76-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-118
12032672-0	2002	Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent.	Paclitaxel	0-5	caspase 3	Homo sapiens	82-91
12032672-4	2002	Using MCF7 breast carcinoma cells transfected with caspase-3 gene, we showed that taxol-induced apoptosis occurred in the absence of caspase-3 and caspase-9 activation.	Paclitaxel	82-87	caspase 3	Homo sapiens	51-60
12032672-7	2002	The effect of taxol appears to be cell type-specific, since taxol-induced apoptosis in leukemia U937 cells involved caspase-3 activation step.	Paclitaxel	14-19	caspase 3	Homo sapiens	116-125
12032672-7	2002	The effect of taxol appears to be cell type-specific, since taxol-induced apoptosis in leukemia U937 cells involved caspase-3 activation step.	Paclitaxel	60-65	caspase 3	Homo sapiens	116-125
12032672-8	2002	We conclude that a unique caspase-3 and caspase-9 independent pathway is elicited by taxol to induce apoptosis in human ovarian and breast cancinoma cells.	Paclitaxel	85-90	caspase 3	Homo sapiens	26-35
11919195-4	2002	Hyperphosphorylated HDAC2 was also observed in cells synchronized with nocodazole or taxol, demonstrating regulation of HDAC phosphorylation during mitosis.	Paclitaxel	85-90	histone deacetylase 2	Homo sapiens	20-25
12049736-0	2002	Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis.	Paclitaxel	116-121	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-52
12415630-2	2002	METHODS: We investigated if P-gp expression by cancer cells affects cell cytotoxicity and cell-cycle perturbations induced by six commonly used chemotherapeutic agents (doxorubicin, daunorubicin, mitoxantrone, vinblastine, paclitaxel, and colchicine).	Paclitaxel	223-233	ATP binding cassette subfamily B member 1	Homo sapiens	28-32
11971976-10	2002	In contrast, cells expressing a kinase-defective Plk3 (Plk3(K52R)) mutant exhibited extended, deformed cytoplasmic structures, the phenotype of which was somewhat refractory to taxol treatment.	Paclitaxel	177-182	polo like kinase 3	Homo sapiens	55-59
11955677-0	2002	The effect of paclitaxel on gene expression and activity of arylamine N-acetyltransferase and DNA-2-aminofluorene adduct formation in human leukemia HL-60 cells.	Paclitaxel	14-24	DNA replication helicase/nuclease 2	Homo sapiens	94-99
11955677-6	2002	The results demonstrated that paclitaxel inhibited NAT activity and DNA-2-aminofluorene adduct formation in human leukemia HL-60 cells in a dose-dependent manner.	Paclitaxel	30-40	DNA replication helicase/nuclease 2	Homo sapiens	68-73
11971976-9	2002	Expression of a constitutively active Plk3 (Plk3-A) resulted in rapid cell shrinkage, which led to formation of cells with an elongated, unsevered, and taxol-sensitive midbody.	Paclitaxel	152-157	polo like kinase 3	Homo sapiens	38-42
11971976-9	2002	Expression of a constitutively active Plk3 (Plk3-A) resulted in rapid cell shrinkage, which led to formation of cells with an elongated, unsevered, and taxol-sensitive midbody.	Paclitaxel	152-157	polo like kinase 3	Homo sapiens	44-48
11971976-10	2002	In contrast, cells expressing a kinase-defective Plk3 (Plk3(K52R)) mutant exhibited extended, deformed cytoplasmic structures, the phenotype of which was somewhat refractory to taxol treatment.	Paclitaxel	177-182	polo like kinase 3	Homo sapiens	49-53
12049736-1	2002	ErbB2 overexpression confers resistance to taxol-induced apoptosis by inhibiting p34(Cdc2) activation.	Paclitaxel	43-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
12049736-8	2002	Thus, ErbB2 membrane RTK can confer resistance to taxol-induced apoptosis by directly phosphorylating Cdc2.	Paclitaxel	50-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-11
11988841-7	2002	Interestingly, proteasomal degradation of Pin1 facilitates dephosphorylation of phospho Bcl2 due to longer exposure of Taxol.	Paclitaxel	119-124	BCL2 apoptosis regulator	Homo sapiens	88-92
12086014-8	2002	Immunoblot analysis with an antibody against Bcl-2 phosphorylated at serine 70 demonstrated that taxol induced the phosphorylation of Bcl-2 with its enhancement in the presence of CsA.	Paclitaxel	97-102	BCL2 apoptosis regulator	Homo sapiens	134-139
12086014-10	2002	These results suggest that the enhancement of taxol-induced apoptosis by immunosuppressive drugs is at least partly due to the inhibition of calcineurin activity and the loss of the antiapoptotic function of Bcl-2 via the enhancement of phosphorylation and the reduction of expression.	Paclitaxel	46-51	BCL2 apoptosis regulator	Homo sapiens	208-213
12086014-7	2002	Taxol induced apoptosis of the cells, as assessed by Hoechst 33258 staining and by the measurement of caspase 3 activity.	Paclitaxel	0-5	caspase 3	Homo sapiens	102-111
11959083-6	2002	P-glycoprotein had a substantially greater effect on paclitaxel accumulation, efflux and bi-directional transport than for morphine.	Paclitaxel	53-63	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
12086014-8	2002	Immunoblot analysis with an antibody against Bcl-2 phosphorylated at serine 70 demonstrated that taxol induced the phosphorylation of Bcl-2 with its enhancement in the presence of CsA.	Paclitaxel	97-102	BCL2 apoptosis regulator	Homo sapiens	45-50
11959083-8	2002	These results reinforce the substantial role P-glycoprotein has in paclitaxel transport.	Paclitaxel	67-77	ATP binding cassette subfamily B member 1	Homo sapiens	45-59
11920652-6	2002	These results reveal that the lethal, dose-limiting hematotoxicity of an intensified post-transplantation chemotherapy with paclitaxel can be prevented by retroviral transfer of the MDR1 gene to a minor proportion of repopulating cells.	Paclitaxel	124-134	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	182-186
12007787-5	2002	Permanent expression of the WTH3 transgene in MDR cell lines increased to varying degrees their sensitivity to several anticancer drugs, which included doxorubicin, taxol, vinblastine, vincristine, and etoposide, as compared to the control sublines transfected with the empty vector.	Paclitaxel	165-170	RAB6C, member RAS oncogene family	Homo sapiens	28-32
12121008-6	2002	Photoaffinity labeling of P-GP using photoreactive radiolabeled paclitaxel analogs has disclosed the paclitaxel-binding domain of P-GP.	Paclitaxel	64-74	ATP binding cassette subfamily B member 1	Homo sapiens	130-134
11914905-7	2002	The inhibitory concentrations of paclitaxel, tamoxifen and cyclosporine on MMDx metabolism were in the range of those observed in patients upon administration of these drugs, which are known to be CYP3A4 substrates.	Paclitaxel	33-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	197-203
12064370-4	2002	Using human liver microsomes, we have demonstrated that OC144-093 inhibited the CYP3A mediated metabolism of paclitaxel at high concentrations only (Ki = 39.8 +/- 5.1 microM, n=3).	Paclitaxel	109-119	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-85
11901098-2	2002	In spite of their close chemical structure, the two drugs are oxidized by two different enzymes; CYP2C8 catalyzes the 6-hydroxylation on the taxane ring of paclitaxel, whereas CYP3A4 oxidizes docetaxel on the tert-butyl group of the lateral chain in C13.	Paclitaxel	156-166	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	176-182
12121008-1	2002	P-glycoprotein (P-GP)-based multidrug resistance (MDR) and undesirable side effects are significant drawbacks to the clinical use of paclitaxel and docetaxel.	Paclitaxel	133-143	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
12121008-1	2002	P-glycoprotein (P-GP)-based multidrug resistance (MDR) and undesirable side effects are significant drawbacks to the clinical use of paclitaxel and docetaxel.	Paclitaxel	133-143	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
12121008-6	2002	Photoaffinity labeling of P-GP using photoreactive radiolabeled paclitaxel analogs has disclosed the paclitaxel-binding domain of P-GP.	Paclitaxel	64-74	ATP binding cassette subfamily B member 1	Homo sapiens	26-30
12121008-6	2002	Photoaffinity labeling of P-GP using photoreactive radiolabeled paclitaxel analogs has disclosed the paclitaxel-binding domain of P-GP.	Paclitaxel	101-111	ATP binding cassette subfamily B member 1	Homo sapiens	26-30
12121008-6	2002	Photoaffinity labeling of P-GP using photoreactive radiolabeled paclitaxel analogs has disclosed the paclitaxel-binding domain of P-GP.	Paclitaxel	101-111	ATP binding cassette subfamily B member 1	Homo sapiens	130-134
11945073-6	2002	P-glycoprotein (PGP), a drug exporter encoded by ABCB1, exports both paclitaxel and colchicine.	Paclitaxel	69-79	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
11983113-9	2002	Patients receiving paclitaxel with rhG-CSF mobilized a large number of mononuclear cells/apheresis (mean, 3.7 x 10(8); range, 3.3-4.1) and CD34(+) cells/apheresis (mean, 7.2 x 10(6); range, 6.1-8.4).	Paclitaxel	19-29	CD34 molecule	Homo sapiens	139-143
11983113-13	2002	In conclusion, PBSC mobilization with paclitaxel and rhG-CSF results in a large number of mononuclear cells and CD34(+) cells with normal clonogenic potential.	Paclitaxel	38-48	CD34 molecule	Homo sapiens	112-116
11945073-6	2002	P-glycoprotein (PGP), a drug exporter encoded by ABCB1, exports both paclitaxel and colchicine.	Paclitaxel	69-79	ATP binding cassette subfamily B member 1	Homo sapiens	16-19
11945073-6	2002	P-glycoprotein (PGP), a drug exporter encoded by ABCB1, exports both paclitaxel and colchicine.	Paclitaxel	69-79	ATP binding cassette subfamily B member 1	Homo sapiens	49-54
11945073-11	2002	The glucocorticoid/paclitaxel combination also increased reporter gene expression in BE(2)C cells, which constitutively express high levels of PGP.	Paclitaxel	19-29	ATP binding cassette subfamily B member 1	Homo sapiens	143-146
11945073-13	2002	Glucocorticoids augment colchicine- or paclitaxel-mediated enhancement of transgene expression most likely by reducing drug egress through PGP.	Paclitaxel	39-49	ATP binding cassette subfamily B member 1	Homo sapiens	139-142
12027404-13	2002	In summary, while both IL-6 and IL-8 are overexpressed in paclitaxel resistant cell lines, only IL-6 has the potential to contribute directly to paclitaxel and doxorubicin resistance in U-2OS.	Paclitaxel	58-68	interleukin 6	Homo sapiens	23-27
11756412-8	2002	Glioblastoma cell lines with activated AKT/PKB show enhanced p21 stability, and they are more resistant to taxol-mediated toxicity.	Paclitaxel	107-112	AKT serine/threonine kinase 1	Homo sapiens	39-46
11890691-3	2002	The sensitivity to paclitaxel, an MDR1 substrate, in Caco-2 cells pretreated with digoxin was lower than that in non-treated cells.	Paclitaxel	19-29	ATP binding cassette subfamily B member 1	Homo sapiens	34-38
11931848-2	2002	The overexpression of the P-glycoprotein (P-gp) and/or alteration in the cellular microtubules is associated with the development of paclitaxel resistance.	Paclitaxel	133-143	ATP binding cassette subfamily B member 1	Homo sapiens	26-40
11931848-2	2002	The overexpression of the P-glycoprotein (P-gp) and/or alteration in the cellular microtubules is associated with the development of paclitaxel resistance.	Paclitaxel	133-143	ATP binding cassette subfamily B member 1	Homo sapiens	42-46
12027404-0	2002	Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells.	Paclitaxel	46-56	interleukin 6	Homo sapiens	18-22
12027404-6	2002	MTT cytotoxicity with IL-6 transfected cells demonstrates a five-fold increase in resistance to paclitaxel and a four-fold increase in resistance to doxorubicin as compared to U-2OS.	Paclitaxel	96-106	interleukin 6	Homo sapiens	22-26
12027404-13	2002	In summary, while both IL-6 and IL-8 are overexpressed in paclitaxel resistant cell lines, only IL-6 has the potential to contribute directly to paclitaxel and doxorubicin resistance in U-2OS.	Paclitaxel	58-68	C-X-C motif chemokine ligand 8	Homo sapiens	32-36
12027404-11	2002	Treatment of IL-6 transfected cells with paclitaxel, compared with drug-sensitive parental U-2OS, shows U-2OS(IL-6) are significantly more resistant to apoptosis induced by paclitaxel and exhibit decreased proteolytic activation of caspase-3.	Paclitaxel	41-51	interleukin 6	Homo sapiens	13-17
12027404-11	2002	Treatment of IL-6 transfected cells with paclitaxel, compared with drug-sensitive parental U-2OS, shows U-2OS(IL-6) are significantly more resistant to apoptosis induced by paclitaxel and exhibit decreased proteolytic activation of caspase-3.	Paclitaxel	41-51	interleukin 6	Homo sapiens	110-114
12027404-13	2002	In summary, while both IL-6 and IL-8 are overexpressed in paclitaxel resistant cell lines, only IL-6 has the potential to contribute directly to paclitaxel and doxorubicin resistance in U-2OS.	Paclitaxel	145-155	interleukin 6	Homo sapiens	96-100
12027404-11	2002	Treatment of IL-6 transfected cells with paclitaxel, compared with drug-sensitive parental U-2OS, shows U-2OS(IL-6) are significantly more resistant to apoptosis induced by paclitaxel and exhibit decreased proteolytic activation of caspase-3.	Paclitaxel	41-51	caspase 3	Homo sapiens	232-241
12027404-11	2002	Treatment of IL-6 transfected cells with paclitaxel, compared with drug-sensitive parental U-2OS, shows U-2OS(IL-6) are significantly more resistant to apoptosis induced by paclitaxel and exhibit decreased proteolytic activation of caspase-3.	Paclitaxel	173-183	interleukin 6	Homo sapiens	13-17
12168940-0	2002	Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatin.	Paclitaxel	123-133	tumor protein p53	Homo sapiens	37-40
12027404-11	2002	Treatment of IL-6 transfected cells with paclitaxel, compared with drug-sensitive parental U-2OS, shows U-2OS(IL-6) are significantly more resistant to apoptosis induced by paclitaxel and exhibit decreased proteolytic activation of caspase-3.	Paclitaxel	173-183	interleukin 6	Homo sapiens	110-114
12168940-1	2002	BACKGROUND: The purpose of the present study was to correlate the nuclear expression of p53 and p21 with response to paclitaxel and carboplatin, progression-free survival (PFS) as well as overall survival (OS), in patients with urothelial metastatic transitional-cell carcinoma (TCC).	Paclitaxel	117-127	tumor protein p53	Homo sapiens	88-91
11854432-0	2002	Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation.	Paclitaxel	54-64	endothelin 1	Homo sapiens	0-12
11895918-0	2002	Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications.	Paclitaxel	30-40	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-16
11895918-1	2002	Paclitaxel and docetaxel can induce pro-inflammatory proteins, typified by cyclooxygenase-2 (prostaglandin H synthase).	Paclitaxel	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	75-91
11854432-4	2002	Our results demonstrated that the addition of ET-1 markedly inhibited serum withdrawal and paclitaxel-induced apoptosis in a concentration-dependent manner, as demonstrated by Annexin-V assay, sub-G(1) peak in DNA content histograms, internucleosomal DNA fragmentation, and terminal deoxynucleotidyl transferase-mediated dUTP biotin nick-end labeling method.	Paclitaxel	91-101	endothelin 1	Homo sapiens	46-50
11854432-6	2002	Paclitaxel-induced apoptosis resulted in the phosphorylation of Bcl-2 that was suppressed by the addition of ET-1.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	64-69
11854432-6	2002	Paclitaxel-induced apoptosis resulted in the phosphorylation of Bcl-2 that was suppressed by the addition of ET-1.	Paclitaxel	0-10	endothelin 1	Homo sapiens	109-113
11854432-10	2002	Moreover, BQ 123 blocked the Akt-mediated pathway activated by ET-1, sensitizing ovarian carcinoma cells to paclitaxel treatment.	Paclitaxel	108-118	AKT serine/threonine kinase 1	Homo sapiens	29-32
11854432-10	2002	Moreover, BQ 123 blocked the Akt-mediated pathway activated by ET-1, sensitizing ovarian carcinoma cells to paclitaxel treatment.	Paclitaxel	108-118	endothelin 1	Homo sapiens	63-67
11854432-11	2002	These results establish a novel role for ET-1 in determining protection of ovarian carcinoma cells against paclitaxel-induced apoptosis through Bcl-2-dependent and PI3-K-mediated Akt pathways and suggest that ET-1 and ET(A)R could represent important targets for anticancer therapy.	Paclitaxel	107-117	endothelin 1	Homo sapiens	41-45
11854432-11	2002	These results establish a novel role for ET-1 in determining protection of ovarian carcinoma cells against paclitaxel-induced apoptosis through Bcl-2-dependent and PI3-K-mediated Akt pathways and suggest that ET-1 and ET(A)R could represent important targets for anticancer therapy.	Paclitaxel	107-117	BCL2 apoptosis regulator	Homo sapiens	144-149
11854432-11	2002	These results establish a novel role for ET-1 in determining protection of ovarian carcinoma cells against paclitaxel-induced apoptosis through Bcl-2-dependent and PI3-K-mediated Akt pathways and suggest that ET-1 and ET(A)R could represent important targets for anticancer therapy.	Paclitaxel	107-117	AKT serine/threonine kinase 1	Homo sapiens	179-182
11854432-11	2002	These results establish a novel role for ET-1 in determining protection of ovarian carcinoma cells against paclitaxel-induced apoptosis through Bcl-2-dependent and PI3-K-mediated Akt pathways and suggest that ET-1 and ET(A)R could represent important targets for anticancer therapy.	Paclitaxel	107-117	endothelin 1	Homo sapiens	209-213
11839679-12	2002	NMP-1 and HEY models have significant value in establishing the efficacy of candidate agents, which might address Taxol-resistant human ovarian carcinoma.	Paclitaxel	114-119	HEY	Homo sapiens	10-13
11857368-1	2002	The effect of overexpressing the antiapoptotic protein BclXL in a human ovarian carcinoma cell line has been investigated in terms of sensitivity to the 2 major drugs used to treat this disease, paclitaxel and cisplatin.	Paclitaxel	195-205	BCL2 like 1	Homo sapiens	55-60
11857368-4	2002	By contrast, parallel subcutaneous xenograft models of these isogenic ovarian carcinoma cells in vivo, differing only in BclXL status, showed that this low-level BclXL overexpression conferred significant resistance to both paclitaxel and cisplatin in comparison with parent, nontransfected tumours.	Paclitaxel	224-234	BCL2 like 1	Homo sapiens	162-167
11857368-5	2002	Whereas parent non-BclXL transfected tumours were highly responsive, with the disappearance of tumours for at least 50 days post treatment, tumours overexpressing BclXL grew back after 30 and 20 days after treatment with paclitaxel and cisplatin, respectively.	Paclitaxel	221-231	BCL2 like 1	Homo sapiens	163-168
11857368-7	2002	These data suggest that the responsiveness of ovarian cancer to paclitaxel and cisplatin in vivo, and therefore perhaps clinically, is influenced by levels of the antiapoptotic protein BclXL.	Paclitaxel	64-74	BCL2 like 1	Homo sapiens	185-190
11861387-5	2002	We demonstrate herein that introduction of an active catalytic subunit of PI3k into an ovarian cancer cell line, and thus activation of the PI3k/AKT pathway, confers resistance to the effects of paclitaxel, one of the major drugs used in ovarian cancer therapy.	Paclitaxel	195-205	AKT serine/threonine kinase 1	Homo sapiens	145-148
11843726-4	2002	The activity of paclitaxel was correlated with an elevation of cyclin B1/CDC2 activity, prolonged mitotic arrest, and Bcl-2 phosphorylation.	Paclitaxel	16-26	BCL2 apoptosis regulator	Homo sapiens	118-123
11862425-1	2002	BACKGROUND: Recent studies in mice and patients have shown that the low oral bioavailability of paclitaxel can be increased by coadministration of P-glycoprotein blockers.	Paclitaxel	96-106	ATP binding cassette subfamily B member 1	Homo sapiens	147-161
11862425-4	2002	METHODS: Paclitaxel was administered to mdr1ab P-glycoprotein knockout mice with either the conventional (controls) or a seven-fold higher amount of Cremophor EL (test group).	Paclitaxel	9-19	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	40-44
11862425-4	2002	METHODS: Paclitaxel was administered to mdr1ab P-glycoprotein knockout mice with either the conventional (controls) or a seven-fold higher amount of Cremophor EL (test group).	Paclitaxel	9-19	ATP binding cassette subfamily B member 1	Homo sapiens	47-61
11839680-2	2002	Expression of P-glycoprotein (P-gp) in cancer cells causes resistance against paclitaxel and docetaxel, as well as against vincristine and doxorubicin (ADM).	Paclitaxel	78-88	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
11839680-2	2002	Expression of P-glycoprotein (P-gp) in cancer cells causes resistance against paclitaxel and docetaxel, as well as against vincristine and doxorubicin (ADM).	Paclitaxel	78-88	ATP binding cassette subfamily B member 1	Homo sapiens	30-34
11872285-0	2002	Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer.	Paclitaxel	84-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-12
11802207-0	2002	TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.	Paclitaxel	53-63	TNF superfamily member 10	Homo sapiens	0-5
11802207-6	2002	We show here that 10 microM PA induces a significant 10- to 57-fold increase in primary lung cancer cell apoptosis and is associated with 20-215% increases in caspase-3 activity in various NSCLC cell types.	Paclitaxel	28-30	caspase 3	Homo sapiens	159-168
11802207-11	2002	These data suggest that the use of new combination treatment with PA and ligands targeting Fas or TRAIL receptors would be particularly efficacious.	Paclitaxel	66-68	TNF superfamily member 10	Homo sapiens	98-103
11860338-0	2002	A systematic SAR study of C10 modified paclitaxel analogues using a combinatorial approach.	Paclitaxel	39-49	homeobox C10	Homo sapiens	26-29
11860338-1	2002	A library with 63 paclitaxel analogues modified at the C10 position of paclitaxel has been prepared using parallel solution phase synthesis.	Paclitaxel	18-28	homeobox C10	Homo sapiens	55-58
11860338-1	2002	A library with 63 paclitaxel analogues modified at the C10 position of paclitaxel has been prepared using parallel solution phase synthesis.	Paclitaxel	71-81	homeobox C10	Homo sapiens	55-58
11860338-3	2002	These modifications at C10, however, did not lead to the total loss of activity, indicating that the C10 moiety of paclitaxel may not be directly involved in the drug-microtubule interactions, but could influence its binding affinity to P-glycoprotein.	Paclitaxel	115-125	homeobox C10	Homo sapiens	23-26
11860338-3	2002	These modifications at C10, however, did not lead to the total loss of activity, indicating that the C10 moiety of paclitaxel may not be directly involved in the drug-microtubule interactions, but could influence its binding affinity to P-glycoprotein.	Paclitaxel	115-125	homeobox C10	Homo sapiens	101-104
11860338-6	2002	This result demonstrates that the cytotoxicity against this drug resistant cancer cell line is sensitive to structural changes at the C10 position of paclitaxel.	Paclitaxel	150-160	homeobox C10	Homo sapiens	134-137
11774260-0	2002	Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells.	Paclitaxel	30-40	tumor protein p53	Homo sapiens	60-63
11774260-5	2002	Activation of caspase-3 and cleavage of poly(ADP-ribose) polymerase (PARP) were also studied in paclitaxel-induced apoptosis.	Paclitaxel	96-106	caspase 3	Homo sapiens	14-23
11774260-5	2002	Activation of caspase-3 and cleavage of poly(ADP-ribose) polymerase (PARP) were also studied in paclitaxel-induced apoptosis.	Paclitaxel	96-106	poly(ADP-ribose) polymerase 1	Homo sapiens	40-67
11774260-5	2002	Activation of caspase-3 and cleavage of poly(ADP-ribose) polymerase (PARP) were also studied in paclitaxel-induced apoptosis.	Paclitaxel	96-106	poly(ADP-ribose) polymerase 1	Homo sapiens	69-73
11774260-6	2002	We showed that paclitaxel inhibited growth and induced apoptosis in both cell lines but that the p53 mutant line (CNE-2) was less sensitive to treatment with low-dose paclitaxel.	Paclitaxel	167-177	tumor protein p53	Homo sapiens	97-100
11774260-8	2002	We observed a striking increase of p53 protein levels in NPC cells exposed to 1 and 10 nM paclitaxel but a marked inhibition at 100 nM paclitaxel treatment.	Paclitaxel	90-100	tumor protein p53	Homo sapiens	35-38
11774260-8	2002	We observed a striking increase of p53 protein levels in NPC cells exposed to 1 and 10 nM paclitaxel but a marked inhibition at 100 nM paclitaxel treatment.	Paclitaxel	135-145	tumor protein p53	Homo sapiens	35-38
11774260-10	2002	In summary, low-dose paclitaxel inhibited cell growth in NPC cells and induced apoptosis possibly by upregulation of p53.	Paclitaxel	21-31	tumor protein p53	Homo sapiens	117-120
11881914-11	2002	There was a trend toward association between EDR to paclitaxel and HER2/NEU over-expression.	Paclitaxel	52-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-75
11790161-3	2002	A large well designed multicentre study found that the addition of trastuzumab to either an anthracycline plus cyclophosphamide or to paclitaxel, as first-line therapy for metastatic breast cancer overexpressing the HER2 receptor, significantly increased time to disease progression, rate of objective response, duration of response and survival compared with chemotherapy alone.	Paclitaxel	134-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	216-220
11801563-5	2002	The Pgp substrates paclitaxel (Taxol), Adriamycin, and vinblastine were all effective using this type of combination treatment, although the chemotherapy protocols showed little or no effect as monotherapies.	Paclitaxel	19-29	ATP binding cassette subfamily B member 1	Homo sapiens	4-7
11801563-5	2002	The Pgp substrates paclitaxel (Taxol), Adriamycin, and vinblastine were all effective using this type of combination treatment, although the chemotherapy protocols showed little or no effect as monotherapies.	Paclitaxel	31-36	ATP binding cassette subfamily B member 1	Homo sapiens	4-7
11750848-6	2002	The use of TRAIL in combination with classical anticancer agents might thus boost the apoptotic response, improving the activity of DDP and paclitaxel in ovarian cancer.	Paclitaxel	140-150	TNF superfamily member 10	Homo sapiens	11-16
12440809-7	2002	Conversely, experimental and clinical data seem to show that paclitaxel enhances apoptosis through a p53-independent pathway, that probably involves the Bax gene.	Paclitaxel	61-71	tumor protein p53	Homo sapiens	101-104
11750848-5	2002	Nevertheless, although TRAIL did not significantly reduce cell growth in the A2780 and SKOV-3 cells it did enhance the activity of paclitaxel and cisplatin (DDP), the two most widely used drugs for the treatment of ovarian cancer, increasing their ability to induce apoptosis.	Paclitaxel	131-141	TNF superfamily member 10	Homo sapiens	23-28
12440809-7	2002	Conversely, experimental and clinical data seem to show that paclitaxel enhances apoptosis through a p53-independent pathway, that probably involves the Bax gene.	Paclitaxel	61-71	BCL2 associated X, apoptosis regulator	Homo sapiens	153-156
12440809-8	2002	Whereas patients with wild-type p53 tumors have a good chance to respond to platinum, patients with mutant p53 tumors may have a clinical benefit from the addition of paclitaxel to platinum-based chemotherapy.	Paclitaxel	167-177	tumor protein p53	Homo sapiens	107-110
12437026-4	2002	IL-1beta production in response to other microbial stimulators, such as Pansorbin, Sansorbin, insoluble peptidoglycan, and Taxol, was also potentiated by rCTB.	Paclitaxel	123-128	interleukin 1 beta	Mus musculus	0-8
12415618-5	2002	In the present study we circumvented resistance in taxol resistant human ovarian carcinoma cell lines with antisense oligonucleotides to PKC alpha and PKC beta mRNA and compared the effects with those obtained by Pgp-170 antisense oligonucleotides.	Paclitaxel	51-56	protein kinase C alpha	Homo sapiens	137-146
12415618-7	2002	Additionally, resistance could be reversed by treatment with taxol and antisense oligomers to PKC alpha and PKC beta.	Paclitaxel	61-66	protein kinase C alpha	Homo sapiens	94-103
12467215-4	2002	Subtoxic concentrations of PDMP sensitized drug-selected MCF7/AdrR and Pgp-overexpressing MDA435/LCC6MDR1 (MDR1 gene-transfected) cell lines to Taxol and vincristine but did not alter the chemosensitivity of the wild-type cells.	Paclitaxel	144-149	ATP binding cassette subfamily B member 1	Homo sapiens	71-74
11752211-3	2002	Using the unique inhibitory effect of glucocorticoids on paclitaxel-induced apoptosis, we recently discovered that paclitaxel-induced inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor-kappaB (NF-kappaB) activation might contribute to the mediation of paclitaxel-induced apoptosis.	Paclitaxel	57-67	NFKB inhibitor alpha	Homo sapiens	157-169
11752211-3	2002	Using the unique inhibitory effect of glucocorticoids on paclitaxel-induced apoptosis, we recently discovered that paclitaxel-induced inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor-kappaB (NF-kappaB) activation might contribute to the mediation of paclitaxel-induced apoptosis.	Paclitaxel	57-67	nuclear factor kappa B subunit 1	Homo sapiens	210-219
11752211-3	2002	Using the unique inhibitory effect of glucocorticoids on paclitaxel-induced apoptosis, we recently discovered that paclitaxel-induced inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor-kappaB (NF-kappaB) activation might contribute to the mediation of paclitaxel-induced apoptosis.	Paclitaxel	115-125	NFKB inhibitor alpha	Homo sapiens	157-169
11752211-3	2002	Using the unique inhibitory effect of glucocorticoids on paclitaxel-induced apoptosis, we recently discovered that paclitaxel-induced inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor-kappaB (NF-kappaB) activation might contribute to the mediation of paclitaxel-induced apoptosis.	Paclitaxel	115-125	nuclear factor kappa B subunit 1	Homo sapiens	187-208
11752211-3	2002	Using the unique inhibitory effect of glucocorticoids on paclitaxel-induced apoptosis, we recently discovered that paclitaxel-induced inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor-kappaB (NF-kappaB) activation might contribute to the mediation of paclitaxel-induced apoptosis.	Paclitaxel	115-125	nuclear factor kappa B subunit 1	Homo sapiens	210-219
11752211-3	2002	Using the unique inhibitory effect of glucocorticoids on paclitaxel-induced apoptosis, we recently discovered that paclitaxel-induced inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor-kappaB (NF-kappaB) activation might contribute to the mediation of paclitaxel-induced apoptosis.	Paclitaxel	115-125	NFKB inhibitor alpha	Homo sapiens	157-169
11752211-3	2002	Using the unique inhibitory effect of glucocorticoids on paclitaxel-induced apoptosis, we recently discovered that paclitaxel-induced inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor-kappaB (NF-kappaB) activation might contribute to the mediation of paclitaxel-induced apoptosis.	Paclitaxel	115-125	nuclear factor kappa B subunit 1	Homo sapiens	187-208
11752211-3	2002	Using the unique inhibitory effect of glucocorticoids on paclitaxel-induced apoptosis, we recently discovered that paclitaxel-induced inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor-kappaB (NF-kappaB) activation might contribute to the mediation of paclitaxel-induced apoptosis.	Paclitaxel	115-125	nuclear factor kappa B subunit 1	Homo sapiens	210-219
11752211-4	2002	In this study, using a novel IkappaBalpha phosphorylation inhibitor, we demonstrated that the blockage of paclitaxel-induced IkappaBalpha degradation inhibited apoptotic cell death in human breast cancer BCap37 and ovarian cancer OV2008 cell lines.	Paclitaxel	106-116	NFKB inhibitor alpha	Homo sapiens	29-41
11752211-4	2002	In this study, using a novel IkappaBalpha phosphorylation inhibitor, we demonstrated that the blockage of paclitaxel-induced IkappaBalpha degradation inhibited apoptotic cell death in human breast cancer BCap37 and ovarian cancer OV2008 cell lines.	Paclitaxel	106-116	NFKB inhibitor alpha	Homo sapiens	125-137
11752211-6	2002	Stable transfection of a mutant IkappaBalpha lacking Ser(32) and Ser(36) that was insensitive to IKK-mediated phosphorylation and degradation resulted in reduced sensitivity of tumor cells to paclitaxel-induced apoptosis.	Paclitaxel	192-202	NFKB inhibitor alpha	Homo sapiens	32-44
11752211-8	2002	These findings suggest that the activation of IKK might play a critical role in the regulation of paclitaxel-induced NF-kappaB activation that subsequently mediates paclitaxel-induced apoptotic cell death in solid tumor cells.	Paclitaxel	98-108	nuclear factor kappa B subunit 1	Homo sapiens	117-126
11752211-8	2002	These findings suggest that the activation of IKK might play a critical role in the regulation of paclitaxel-induced NF-kappaB activation that subsequently mediates paclitaxel-induced apoptotic cell death in solid tumor cells.	Paclitaxel	165-175	nuclear factor kappa B subunit 1	Homo sapiens	117-126
12467215-4	2002	Subtoxic concentrations of PDMP sensitized drug-selected MCF7/AdrR and Pgp-overexpressing MDA435/LCC6MDR1 (MDR1 gene-transfected) cell lines to Taxol and vincristine but did not alter the chemosensitivity of the wild-type cells.	Paclitaxel	144-149	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
12392159-6	2002	Further, through comparative studies and analyses of a number of genes whose expression or activation may be involved in the regulation of apoptotic cell death or drug resistance, we found that paclitaxel induced the degradation of IkappaBalpha protein, which in turn activated NF-kappaB in paclitaxel-sensitive tumor cells, but such a paclitaxel-induced activation of the NF-kappaB/IkappaBalpha cascade was not observed in either MCF7 or R3227 cells.	Paclitaxel	194-204	nuclear factor kappa B subunit 1	Homo sapiens	373-382
12392159-0	2002	The possible correlation between activation of NF-kappaB/IkappaB pathway and the susceptibility of tumor cells to paclitaxel-induced apoptosis.	Paclitaxel	114-124	nuclear factor kappa B subunit 1	Homo sapiens	47-56
12392159-6	2002	Further, through comparative studies and analyses of a number of genes whose expression or activation may be involved in the regulation of apoptotic cell death or drug resistance, we found that paclitaxel induced the degradation of IkappaBalpha protein, which in turn activated NF-kappaB in paclitaxel-sensitive tumor cells, but such a paclitaxel-induced activation of the NF-kappaB/IkappaBalpha cascade was not observed in either MCF7 or R3227 cells.	Paclitaxel	194-204	NFKB inhibitor alpha	Homo sapiens	232-244
11990771-3	2002	Clinical trials using first- and second-generation Pgp modulators did establish proof of principle that in some settings, clinical drug resistance could be overcome with the addition of a Pgp modulator-for example, clinical resistance to paclitaxel, a Pgp substrate, in women with ovarian cancer was shown to be overcome in approximately 20% with the addition of PSC 833, a highly effective Pgp modulator.	Paclitaxel	238-248	ATP binding cassette subfamily B member 1	Homo sapiens	51-54
11990771-3	2002	Clinical trials using first- and second-generation Pgp modulators did establish proof of principle that in some settings, clinical drug resistance could be overcome with the addition of a Pgp modulator-for example, clinical resistance to paclitaxel, a Pgp substrate, in women with ovarian cancer was shown to be overcome in approximately 20% with the addition of PSC 833, a highly effective Pgp modulator.	Paclitaxel	238-248	ATP binding cassette subfamily B member 1	Homo sapiens	188-191
11990771-3	2002	Clinical trials using first- and second-generation Pgp modulators did establish proof of principle that in some settings, clinical drug resistance could be overcome with the addition of a Pgp modulator-for example, clinical resistance to paclitaxel, a Pgp substrate, in women with ovarian cancer was shown to be overcome in approximately 20% with the addition of PSC 833, a highly effective Pgp modulator.	Paclitaxel	238-248	ATP binding cassette subfamily B member 1	Homo sapiens	188-191
11990771-3	2002	Clinical trials using first- and second-generation Pgp modulators did establish proof of principle that in some settings, clinical drug resistance could be overcome with the addition of a Pgp modulator-for example, clinical resistance to paclitaxel, a Pgp substrate, in women with ovarian cancer was shown to be overcome in approximately 20% with the addition of PSC 833, a highly effective Pgp modulator.	Paclitaxel	238-248	ATP binding cassette subfamily B member 1	Homo sapiens	188-191
12392159-6	2002	Further, through comparative studies and analyses of a number of genes whose expression or activation may be involved in the regulation of apoptotic cell death or drug resistance, we found that paclitaxel induced the degradation of IkappaBalpha protein, which in turn activated NF-kappaB in paclitaxel-sensitive tumor cells, but such a paclitaxel-induced activation of the NF-kappaB/IkappaBalpha cascade was not observed in either MCF7 or R3227 cells.	Paclitaxel	194-204	nuclear factor kappa B subunit 1	Homo sapiens	278-287
12392159-6	2002	Further, through comparative studies and analyses of a number of genes whose expression or activation may be involved in the regulation of apoptotic cell death or drug resistance, we found that paclitaxel induced the degradation of IkappaBalpha protein, which in turn activated NF-kappaB in paclitaxel-sensitive tumor cells, but such a paclitaxel-induced activation of the NF-kappaB/IkappaBalpha cascade was not observed in either MCF7 or R3227 cells.	Paclitaxel	194-204	NFKB inhibitor alpha	Homo sapiens	383-395
12392159-6	2002	Further, through comparative studies and analyses of a number of genes whose expression or activation may be involved in the regulation of apoptotic cell death or drug resistance, we found that paclitaxel induced the degradation of IkappaBalpha protein, which in turn activated NF-kappaB in paclitaxel-sensitive tumor cells, but such a paclitaxel-induced activation of the NF-kappaB/IkappaBalpha cascade was not observed in either MCF7 or R3227 cells.	Paclitaxel	291-301	NFKB inhibitor alpha	Homo sapiens	232-244
12392159-6	2002	Further, through comparative studies and analyses of a number of genes whose expression or activation may be involved in the regulation of apoptotic cell death or drug resistance, we found that paclitaxel induced the degradation of IkappaBalpha protein, which in turn activated NF-kappaB in paclitaxel-sensitive tumor cells, but such a paclitaxel-induced activation of the NF-kappaB/IkappaBalpha cascade was not observed in either MCF7 or R3227 cells.	Paclitaxel	291-301	nuclear factor kappa B subunit 1	Homo sapiens	278-287
12392159-6	2002	Further, through comparative studies and analyses of a number of genes whose expression or activation may be involved in the regulation of apoptotic cell death or drug resistance, we found that paclitaxel induced the degradation of IkappaBalpha protein, which in turn activated NF-kappaB in paclitaxel-sensitive tumor cells, but such a paclitaxel-induced activation of the NF-kappaB/IkappaBalpha cascade was not observed in either MCF7 or R3227 cells.	Paclitaxel	291-301	NFKB inhibitor alpha	Homo sapiens	232-244
12392159-6	2002	Further, through comparative studies and analyses of a number of genes whose expression or activation may be involved in the regulation of apoptotic cell death or drug resistance, we found that paclitaxel induced the degradation of IkappaBalpha protein, which in turn activated NF-kappaB in paclitaxel-sensitive tumor cells, but such a paclitaxel-induced activation of the NF-kappaB/IkappaBalpha cascade was not observed in either MCF7 or R3227 cells.	Paclitaxel	291-301	nuclear factor kappa B subunit 1	Homo sapiens	278-287
12392159-7	2002	These findings suggest that the activation of NF-kappaB/IkappaBalpha signaling pathway might play an important role in determining the susceptibility of tumor cells to paclitaxel-induced apoptosis.	Paclitaxel	168-178	nuclear factor kappa B subunit 1	Homo sapiens	46-55
12392159-7	2002	These findings suggest that the activation of NF-kappaB/IkappaBalpha signaling pathway might play an important role in determining the susceptibility of tumor cells to paclitaxel-induced apoptosis.	Paclitaxel	168-178	NFKB inhibitor alpha	Homo sapiens	56-68
11989523-1	2001	Herceptin extends survival in human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer patients when administered with paclitaxel or anthracycline/cyclophosphamide (AC), and the combination with 3-weekly paclitaxel is the current standard first-line therapy.	Paclitaxel	144-154	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
11751388-8	2001	Examination of pathways common to Taxol and retinoid signaling revealed that this synergy was related in part to effects on Bcl-2 expression/phosphorylation as well as the activity of the c-Jun NH(2)-terminal kinase and activator protein-1.	Paclitaxel	34-39	BCL2 apoptosis regulator	Homo sapiens	124-129
11989523-5	2001	Weekly paclitaxel plus Herceptin has produced responses in 83% of HER2-positive patients treated.	Paclitaxel	7-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
11728383-6	2001	We also observed that a paclitaxel-resistant cell line expressed Bax at a much lower level than the sensitive parental line [A2780(1A9)], consistent with its mutant p53 status.	Paclitaxel	24-34	BCL2 associated X, apoptosis regulator	Homo sapiens	65-68
11728383-6	2001	We also observed that a paclitaxel-resistant cell line expressed Bax at a much lower level than the sensitive parental line [A2780(1A9)], consistent with its mutant p53 status.	Paclitaxel	24-34	tumor protein p53	Homo sapiens	165-168
11710832-5	2001	Inhibition of the ERK1/2 MAP kinase pathway using UO126 or PD098059 re-sensitised the Taxol resistant cells at least 20-fold.	Paclitaxel	86-91	mitogen-activated protein kinase 3	Homo sapiens	18-24
11925927-6	2001	Messenger RNA of MDR1 located on chromosomal region of 7q11.2-21 was overexpressed in the paclitaxel-resistant cell lines and recognized as a potential mechanism of acquired paclitaxel-resistance.	Paclitaxel	90-100	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
11925927-6	2001	Messenger RNA of MDR1 located on chromosomal region of 7q11.2-21 was overexpressed in the paclitaxel-resistant cell lines and recognized as a potential mechanism of acquired paclitaxel-resistance.	Paclitaxel	174-184	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
11723237-9	2001	At 100 nM, both bcl-2 and PKC-alpha expression are down-regulated, and only at this concentration can "chemosensitization" to paclitaxel and carboplatin be observed.	Paclitaxel	126-136	BCL2 apoptosis regulator	Homo sapiens	16-21
11723237-9	2001	At 100 nM, both bcl-2 and PKC-alpha expression are down-regulated, and only at this concentration can "chemosensitization" to paclitaxel and carboplatin be observed.	Paclitaxel	126-136	protein kinase C alpha	Homo sapiens	26-35
11578809-1	2001	Nitric oxide (NO) and taxol are cytotoxic towards leukemia and tumor cells and interfere with the transcription factor NF-kappaB activity.	Paclitaxel	22-27	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	119-128
11578809-2	2001	NO and taxol inhibited NF-kappaB activity and were cytotoxic to human and murine leukemia cells, but at a different magnitude (30% cell killing and 80% inhibition of NF-kappaB).	Paclitaxel	7-12	nuclear factor kappa B subunit 1	Homo sapiens	23-32
11578809-2	2001	NO and taxol inhibited NF-kappaB activity and were cytotoxic to human and murine leukemia cells, but at a different magnitude (30% cell killing and 80% inhibition of NF-kappaB).	Paclitaxel	7-12	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	166-175
11578809-3	2001	Sub-effective concentrations of SNAP and taxol synergized in killing L-1210 cells but either alone or in combination completely inhibited NF-kappaB.	Paclitaxel	41-46	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	138-147
11578809-7	2001	Our results show that NO, taxol and PDTC induced apoptosis and NF-kappaB inhibition in leukemic cells but their cytotoxicity either alone or in combination, does not seem to be dependent on the inhibition of NF-KB activity.	Paclitaxel	26-31	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	63-72
11720482-0	2001	Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells.	Paclitaxel	42-52	mitogen-activated protein kinase 1	Homo sapiens	56-60
11720482-1	2001	The effects of vinorelbine and paclitaxel on the activity of extracellular signal-regulated protein kinase2 (ERK2), a member of MAP kinase, and its role in the induction of bcl-2 phosphorylation and apoptosis were evaluated in MCF-7 cells.	Paclitaxel	31-41	mitogen-activated protein kinase 1	Homo sapiens	61-107
11720482-1	2001	The effects of vinorelbine and paclitaxel on the activity of extracellular signal-regulated protein kinase2 (ERK2), a member of MAP kinase, and its role in the induction of bcl-2 phosphorylation and apoptosis were evaluated in MCF-7 cells.	Paclitaxel	31-41	mitogen-activated protein kinase 1	Homo sapiens	109-113
11720482-1	2001	The effects of vinorelbine and paclitaxel on the activity of extracellular signal-regulated protein kinase2 (ERK2), a member of MAP kinase, and its role in the induction of bcl-2 phosphorylation and apoptosis were evaluated in MCF-7 cells.	Paclitaxel	31-41	BCL2 apoptosis regulator	Homo sapiens	173-178
11720482-2	2001	We demonstrated that ERK2 was activated rapidly by vinorelbine, and was inhibited by either paclitaxel or estramustine.	Paclitaxel	92-102	mitogen-activated protein kinase 1	Homo sapiens	21-25
11720482-4	2001	In contrast, the same treatment with paclitaxel resulted in a significant decrease of ERK2 kinase activity.	Paclitaxel	37-47	mitogen-activated protein kinase 1	Homo sapiens	86-90
11720482-8	2001	Since decrease of PARP occurred quickly following the treatment of MCF-7 cells with either 0.1 microM of vinorelbine or paclitaxel, this protein may serve as an early indicator of apoptosis induced not only by DNA damaging agents, but also by antimicrotubule drugs.	Paclitaxel	120-130	poly(ADP-ribose) polymerase 1	Homo sapiens	18-22
11774038-2	2001	Phosphorylation of the Bcl-2 protein is induced on serine residues in tumor cells arrested by microtubule-targeting drugs (paclitaxel, vincristine, nocodazole) and has been associated with inactivation of antiapoptotic function through an unknown mechanism.	Paclitaxel	123-133	BCL2 apoptosis regulator	Homo sapiens	23-28
11726273-1	2001	Serine 70 in the loop region of Bcl-2 is specifically phosphorylated by paclitaxel-treatment in tumor cells and BHK cells expressing Bcl-2.	Paclitaxel	72-82	apoptosis regulator Bcl-2	Mesocricetus auratus	32-37
11726273-1	2001	Serine 70 in the loop region of Bcl-2 is specifically phosphorylated by paclitaxel-treatment in tumor cells and BHK cells expressing Bcl-2.	Paclitaxel	72-82	apoptosis regulator Bcl-2	Mesocricetus auratus	133-138
11726273-2	2001	The phosphorylation of serine 70 of Bcl-2 (pS70-Bcl-2) peaks 24 to 48 h after paclitaxel treatment and accelerates apoptosis.	Paclitaxel	78-88	BCL2 apoptosis regulator	Homo sapiens	36-41
11726273-2	2001	The phosphorylation of serine 70 of Bcl-2 (pS70-Bcl-2) peaks 24 to 48 h after paclitaxel treatment and accelerates apoptosis.	Paclitaxel	78-88	BCL2 apoptosis regulator	Homo sapiens	43-53
11726273-4	2001	These results indicate that paclitaxel-induced kinase(s) and/or its activator(s) are synthesized de novo and play an important role in paclitaxel-induced apoptosis by phosphorylating Bcl-2.	Paclitaxel	28-38	BCL2 apoptosis regulator	Homo sapiens	183-188
11726273-4	2001	These results indicate that paclitaxel-induced kinase(s) and/or its activator(s) are synthesized de novo and play an important role in paclitaxel-induced apoptosis by phosphorylating Bcl-2.	Paclitaxel	135-145	BCL2 apoptosis regulator	Homo sapiens	183-188
11726273-7	2001	Further study of breast cancers revealed 83% of tumors with high pS70-Bcl-2 expression responded to paclitaxel or docetaxel treatment, whereas 57% of those with low expression not respond.	Paclitaxel	100-110	BCL2 apoptosis regulator	Homo sapiens	65-75
11726273-8	2001	These findings suggest that pS70-Bcl-2 might be a predictive factor for prognosis and sensitivity to paclitaxel treatment for breast cancer.	Paclitaxel	101-111	BCL2 apoptosis regulator	Homo sapiens	28-38
12467231-8	2001	Studies of the centromere-associated protein mitosin revealed that treatment with lovastatin and paclitaxel resulted in increased mitosin levels and that lovastatin altered the association of mitosin with condensed chromosomes.	Paclitaxel	97-107	centromere protein F	Homo sapiens	45-52
12467231-8	2001	Studies of the centromere-associated protein mitosin revealed that treatment with lovastatin and paclitaxel resulted in increased mitosin levels and that lovastatin altered the association of mitosin with condensed chromosomes.	Paclitaxel	97-107	centromere protein F	Homo sapiens	130-137
12467231-8	2001	Studies of the centromere-associated protein mitosin revealed that treatment with lovastatin and paclitaxel resulted in increased mitosin levels and that lovastatin altered the association of mitosin with condensed chromosomes.	Paclitaxel	97-107	centromere protein F	Homo sapiens	130-137
11571289-6	2001	This effect was not likely the result of microtubule depolymerization because in the presence of taxol, which blocked nocodazole-induced depolymerization of microtubules as well as the dispersal of the perinuclear GLUT4 compartment, the inhibitory effect of 10-33 microm nocodazole on insulin-stimulated glucose uptake prevailed.	Paclitaxel	97-102	insulin	Homo sapiens	285-292
11770175-9	2001	In the treatment of women with HER2 overexpressing tumors an overall response rate of 57% for combination trastuzumab plus paclitaxel compared with 25% for paclitaxel alone was found.	Paclitaxel	123-133	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-35
11770175-9	2001	In the treatment of women with HER2 overexpressing tumors an overall response rate of 57% for combination trastuzumab plus paclitaxel compared with 25% for paclitaxel alone was found.	Paclitaxel	156-166	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-35
11707402-6	2001	Suppression of taxol-induced apoptosis occurred upstream of cytochrome c release from mitochondria in SH-SY5Y cells.	Paclitaxel	15-20	cytochrome c, somatic	Homo sapiens	60-72
11822753-2	2001	AIM: To evaluate the activity and acute toxicity of the combination of weekly paclitaxel as first-line chemotherapy and trastuzumab, in patients with HER-2/neu overexpressing advanced breast cancer (ABC).	Paclitaxel	78-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-159
11822753-5	2001	PATIENTS AND METHODS: From December 1998 to April 2000, 34 patients with HER-2/neu overexpressing ABC were treated with weekly paclitaxel; given by one-hour infusion at a dose of 90 mg/m2 immediately followed by trastuzumab, 4 mg/kg as a loading dose and 2 mg/kg i.v.	Paclitaxel	127-137	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-82
11822753-14	2001	Median time to progression was nine months while median survival had not been reached CONCLUSIONS: The combination of weekly paclitaxel and trastuzumab is a safe and active regimen for patients with HER-2/neu overexpressing ABC.	Paclitaxel	125-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	199-208
11738551-3	2001	The role of Bcl-2 in MCF-7 cell survival was confirmed by stable overexpression of Bcl-2 which resulted in suppression of apoptosis induced by doxorubicin (DOX), paclitaxel (TAX) and TNF as compared to vector-control cells.	Paclitaxel	162-172	BCL2 apoptosis regulator	Homo sapiens	12-17
11738551-3	2001	The role of Bcl-2 in MCF-7 cell survival was confirmed by stable overexpression of Bcl-2 which resulted in suppression of apoptosis induced by doxorubicin (DOX), paclitaxel (TAX) and TNF as compared to vector-control cells.	Paclitaxel	162-172	BCL2 apoptosis regulator	Homo sapiens	83-88
11710832-6	2001	Importantly, when Mdr-1 cDNA was stably expressed in the wild-type cell line to generate a highly Taxol-resistant sub-line, 1847/MDR5, ERK1/2 MAP kinases again became activated.	Paclitaxel	98-103	ATP binding cassette subfamily B member 1	Homo sapiens	18-23
11710832-6	2001	Importantly, when Mdr-1 cDNA was stably expressed in the wild-type cell line to generate a highly Taxol-resistant sub-line, 1847/MDR5, ERK1/2 MAP kinases again became activated.	Paclitaxel	98-103	mitogen-activated protein kinase 3	Homo sapiens	135-141
11710832-7	2001	This result demonstrated that the increased activity of the signalling pathway in the Taxol-resistant lines was directly attributable to MDR-1 overexpression and was not due to the effects of Taxol itself.	Paclitaxel	86-91	ATP binding cassette subfamily B member 1	Homo sapiens	137-142
11600533-3	2001	In ARO and KAT-4 cells, manumycin- plus paclitaxel-induced DNA fragmentation was blocked by the inhibitors of caspase-9, caspase-8, and caspase-3.	Paclitaxel	40-50	caspase 3	Homo sapiens	136-145
11597122-10	2001	Moreover, it blocked Taxol-induced phosphorylation of p38 and Bcl-2, and prevented a Taxol-induced change in relative mobility of the apoptosis signal-regulating kinase 1 (Ask1).	Paclitaxel	21-26	mitogen-activated protein kinase 14	Homo sapiens	54-57
11597122-10	2001	Moreover, it blocked Taxol-induced phosphorylation of p38 and Bcl-2, and prevented a Taxol-induced change in relative mobility of the apoptosis signal-regulating kinase 1 (Ask1).	Paclitaxel	21-26	BCL2 apoptosis regulator	Homo sapiens	62-67
11598801-8	2001	The anti-neoplastic agent, paclitaxel, activates ASK1 and JNK, and promotes the in vitro assembly of stable microtubules.	Paclitaxel	27-37	mitogen-activated protein kinase 8	Homo sapiens	58-61
11606389-7	2001	Moreover, low concentrations of SCH66336 exhibit synergy with the Pgp substrate/inhibitors paclitaxel, tamoxifen, and vinblastine respectively by significantly potentiating their inhibition of Pgp.	Paclitaxel	91-101	ATP binding cassette subfamily B member 1	Homo sapiens	66-69
11606389-7	2001	Moreover, low concentrations of SCH66336 exhibit synergy with the Pgp substrate/inhibitors paclitaxel, tamoxifen, and vinblastine respectively by significantly potentiating their inhibition of Pgp.	Paclitaxel	91-101	ATP binding cassette subfamily B member 1	Homo sapiens	193-196
11606393-3	2001	The common cellular phenotypes associated with paclitaxel resistance are an increased expression of the drug transport protein P-glycoprotein (P-gp), an alteration in the levels of beta-tubulin isotypes, and/or changes in the drug binding affinity of the microtubules.	Paclitaxel	47-57	ATP binding cassette subfamily B member 1	Homo sapiens	127-141
11606393-3	2001	The common cellular phenotypes associated with paclitaxel resistance are an increased expression of the drug transport protein P-glycoprotein (P-gp), an alteration in the levels of beta-tubulin isotypes, and/or changes in the drug binding affinity of the microtubules.	Paclitaxel	47-57	ATP binding cassette subfamily B member 1	Homo sapiens	143-147
11600533-0	2001	Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel.	Paclitaxel	172-182	cytochrome c, somatic	Homo sapiens	0-12
11600533-0	2001	Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel.	Paclitaxel	172-182	caspase 3	Homo sapiens	76-85
11600533-3	2001	In ARO and KAT-4 cells, manumycin- plus paclitaxel-induced DNA fragmentation was blocked by the inhibitors of caspase-9, caspase-8, and caspase-3.	Paclitaxel	40-50	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	3-6
11600533-8	2001	We concluded that the cytochrome c release was upstream of the activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells treated with manumycin plus paclitaxel, and that the interaction between manumycin and paclitaxel occurred at or upstream of cytochrome c in the apoptosis regulatory pathway in anaplastic thyroid cancer cells.	Paclitaxel	202-212	cytochrome c, somatic	Homo sapiens	22-34
11600533-8	2001	We concluded that the cytochrome c release was upstream of the activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells treated with manumycin plus paclitaxel, and that the interaction between manumycin and paclitaxel occurred at or upstream of cytochrome c in the apoptosis regulatory pathway in anaplastic thyroid cancer cells.	Paclitaxel	202-212	caspase 3	Homo sapiens	103-112
11600533-8	2001	We concluded that the cytochrome c release was upstream of the activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells treated with manumycin plus paclitaxel, and that the interaction between manumycin and paclitaxel occurred at or upstream of cytochrome c in the apoptosis regulatory pathway in anaplastic thyroid cancer cells.	Paclitaxel	202-212	cytochrome c, somatic	Homo sapiens	299-311
11600533-8	2001	We concluded that the cytochrome c release was upstream of the activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells treated with manumycin plus paclitaxel, and that the interaction between manumycin and paclitaxel occurred at or upstream of cytochrome c in the apoptosis regulatory pathway in anaplastic thyroid cancer cells.	Paclitaxel	261-271	cytochrome c, somatic	Homo sapiens	22-34
11600533-8	2001	We concluded that the cytochrome c release was upstream of the activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells treated with manumycin plus paclitaxel, and that the interaction between manumycin and paclitaxel occurred at or upstream of cytochrome c in the apoptosis regulatory pathway in anaplastic thyroid cancer cells.	Paclitaxel	261-271	caspase 3	Homo sapiens	103-112
11706391-7	2001	We have recently shown that trastuzumab can effectively sensitize ErbB2-overexpressing breast cancer cells to paclitaxel by reversing the antiapoptotic function of ErbB2.	Paclitaxel	110-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	164-169
11706391-7	2001	We have recently shown that trastuzumab can effectively sensitize ErbB2-overexpressing breast cancer cells to paclitaxel by reversing the antiapoptotic function of ErbB2.	Paclitaxel	110-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-71
11532317-0	2001	Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics.	Paclitaxel	42-52	albumin	Homo sapiens	28-41
11593424-7	2001	Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells.	Paclitaxel	80-90	cyclin dependent kinase inhibitor 2A	Homo sapiens	13-16
11593424-7	2001	Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells.	Paclitaxel	80-90	cyclin dependent kinase inhibitor 2A	Homo sapiens	17-22
11593424-7	2001	Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells.	Paclitaxel	80-90	cyclin dependent kinase inhibitor 1A	Homo sapiens	25-28
11593424-7	2001	Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells.	Paclitaxel	80-90	cyclin dependent kinase inhibitor 1A	Homo sapiens	29-33
11706391-0	2001	Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers.	Paclitaxel	29-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-19
11706391-0	2001	Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers.	Paclitaxel	76-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-109
11706391-3	2001	Although controversies exist, data from our laboratory and from clinical trials of trastuzumab indicate that ErbB2 overexpression confers chemoresistance to certain chemotherapeutic agents such as paclitaxel.	Paclitaxel	197-207	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-114
11706391-4	2001	One of the molecular mechanisms of ErbB2-mediated paclitaxel resistance is that overexpression of the ErbB2 receptor leads to deregulation of the G2/M cell cycle check-point that inhibits paclitaxel-induced apoptosis.	Paclitaxel	50-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-40
11706391-4	2001	One of the molecular mechanisms of ErbB2-mediated paclitaxel resistance is that overexpression of the ErbB2 receptor leads to deregulation of the G2/M cell cycle check-point that inhibits paclitaxel-induced apoptosis.	Paclitaxel	50-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-107
11706391-4	2001	One of the molecular mechanisms of ErbB2-mediated paclitaxel resistance is that overexpression of the ErbB2 receptor leads to deregulation of the G2/M cell cycle check-point that inhibits paclitaxel-induced apoptosis.	Paclitaxel	188-198	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-40
11706391-4	2001	One of the molecular mechanisms of ErbB2-mediated paclitaxel resistance is that overexpression of the ErbB2 receptor leads to deregulation of the G2/M cell cycle check-point that inhibits paclitaxel-induced apoptosis.	Paclitaxel	188-198	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-107
11706391-5	2001	Several promising ErbB2-targeting strategies have now been developed to conquer the adverse consequences of ErbB2 overexpression such as paclitaxel resistance.	Paclitaxel	137-147	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-23
11706391-5	2001	Several promising ErbB2-targeting strategies have now been developed to conquer the adverse consequences of ErbB2 overexpression such as paclitaxel resistance.	Paclitaxel	137-147	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-113
11593425-5	2001	To add new insight, we combined rapamycin treatment with treatment by taxol, which, by damaging microtubules, can phosphorylate BCL-2 and activate apoptosis.	Paclitaxel	70-75	BCL2 apoptosis regulator	Homo sapiens	128-133
11593425-6	2001	It was found that the mTOR kinase was activated in cells treated with taxol or with nocodazole although it was inhibited in cells pre-treated with rapamycin.	Paclitaxel	70-75	mechanistic target of rapamycin kinase	Homo sapiens	22-26
11532317-3	2001	In previous research we demonstrated that linkage to human serum albumin (HSA) was useful to increase the in vivo performance of paclitaxel.	Paclitaxel	129-139	albumin	Homo sapiens	59-72
11522652-2	2001	After single-step selection of breast adenocarcinoma cells in paclitaxel, differential display and single gene analysis demonstrated that transcriptional activation of IRF9 and other IFN-responsive genes, independent of IFN, corresponded with resistance to antimicrotubule agents.	Paclitaxel	62-72	interferon regulatory factor 9	Homo sapiens	168-172
11527708-1	2001	The preparation of two new fluorescent derivatives of paclitaxel in which the fluorophore is bonded to paclitaxel at the C-10 position is reported.	Paclitaxel	54-64	homeobox C10	Homo sapiens	121-125
11527708-1	2001	The preparation of two new fluorescent derivatives of paclitaxel in which the fluorophore is bonded to paclitaxel at the C-10 position is reported.	Paclitaxel	103-113	homeobox C10	Homo sapiens	121-125
11522652-2	2001	After single-step selection of breast adenocarcinoma cells in paclitaxel, differential display and single gene analysis demonstrated that transcriptional activation of IRF9 and other IFN-responsive genes, independent of IFN, corresponded with resistance to antimicrotubule agents.	Paclitaxel	62-72	interferon alpha 1	Homo sapiens	183-186
11555602-10	2001	Moreover, systemic low-dose daily IFN-alpha potentiated the efficacy of paclitaxel.	Paclitaxel	72-82	interferon alpha 1	Homo sapiens	34-43
11592339-4	2001	Western blot and flow cytometry were performed to determine the effects of Taxol and vinblastine on topoisomerase I and Bcl-xL protein levels and cell cycle distribution.	Paclitaxel	75-80	BCL2 like 1	Homo sapiens	120-126
11592339-8	2001	Under these conditions, both Taxol and vinblastine caused an increase in topoisomerase I protein levels, fraction of S phase cells, and extent of Bcl-xL phosphorylation immediately prior to the addition of topotecan.	Paclitaxel	29-34	BCL2 like 1	Homo sapiens	146-152
11555610-8	2001	In these cell lines, however, a significant correlation between increased expression of Hbeta4 isotype and resistance to paclitaxel was found.	Paclitaxel	121-131	potassium calcium-activated channel subfamily M regulatory beta subunit 4	Homo sapiens	88-94
11780384-10	2001	The chemoresistance to taxol decreased to 58% of SKOV3/mdr1 with mdr1 antisense ODN treatment.	Paclitaxel	23-28	ATP binding cassette subfamily B member 1	Homo sapiens	55-59
11564553-4	2001	In addition, (+)-discodermolide is active in Taxol-resistant cell lines that overexpress P-glycoprotein, the multidrug-resistant transporter.	Paclitaxel	45-50	ATP binding cassette subfamily B member 1	Homo sapiens	89-103
11780384-10	2001	The chemoresistance to taxol decreased to 58% of SKOV3/mdr1 with mdr1 antisense ODN treatment.	Paclitaxel	23-28	ATP binding cassette subfamily B member 1	Homo sapiens	65-69
11780384-11	2001	Compared with SKOV3/mdr1 cells in the control group, under a certain range of drug concentrations, the number of drug resistance colonies in mdr1 antisense ODNs treated SKOV3/mdr1 cells for taxol and doxorubicin decreased by 8.6 +/- 0.8 fold and 3.1 +/- 0.6 fold, respectively.	Paclitaxel	190-195	ATP binding cassette subfamily B member 1	Homo sapiens	141-145
11780384-11	2001	Compared with SKOV3/mdr1 cells in the control group, under a certain range of drug concentrations, the number of drug resistance colonies in mdr1 antisense ODNs treated SKOV3/mdr1 cells for taxol and doxorubicin decreased by 8.6 +/- 0.8 fold and 3.1 +/- 0.6 fold, respectively.	Paclitaxel	190-195	ATP binding cassette subfamily B member 1	Homo sapiens	141-145
11774740-6	2001	An interaction of Bax and Bcl-2 is very important to decide cell life or death, and Bcl-2 phosphorylation may control this interaction: Paclitaxel treatment induced Bcl-2 phosphorylation and typical apoptosis, whereas hyperthermia induced not Bcl-2 phosphorylation but nuclear translocation and failed to induce apoptosis.	Paclitaxel	136-146	BCL2 associated X, apoptosis regulator	Homo sapiens	18-21
11774740-6	2001	An interaction of Bax and Bcl-2 is very important to decide cell life or death, and Bcl-2 phosphorylation may control this interaction: Paclitaxel treatment induced Bcl-2 phosphorylation and typical apoptosis, whereas hyperthermia induced not Bcl-2 phosphorylation but nuclear translocation and failed to induce apoptosis.	Paclitaxel	136-146	BCL2 apoptosis regulator	Homo sapiens	26-31
11774740-6	2001	An interaction of Bax and Bcl-2 is very important to decide cell life or death, and Bcl-2 phosphorylation may control this interaction: Paclitaxel treatment induced Bcl-2 phosphorylation and typical apoptosis, whereas hyperthermia induced not Bcl-2 phosphorylation but nuclear translocation and failed to induce apoptosis.	Paclitaxel	136-146	BCL2 apoptosis regulator	Homo sapiens	84-89
11774740-6	2001	An interaction of Bax and Bcl-2 is very important to decide cell life or death, and Bcl-2 phosphorylation may control this interaction: Paclitaxel treatment induced Bcl-2 phosphorylation and typical apoptosis, whereas hyperthermia induced not Bcl-2 phosphorylation but nuclear translocation and failed to induce apoptosis.	Paclitaxel	136-146	BCL2 apoptosis regulator	Homo sapiens	84-89
11774740-6	2001	An interaction of Bax and Bcl-2 is very important to decide cell life or death, and Bcl-2 phosphorylation may control this interaction: Paclitaxel treatment induced Bcl-2 phosphorylation and typical apoptosis, whereas hyperthermia induced not Bcl-2 phosphorylation but nuclear translocation and failed to induce apoptosis.	Paclitaxel	136-146	BCL2 apoptosis regulator	Homo sapiens	84-89
11504826-0	2001	Kinetics of P-glycoprotein-mediated efflux of paclitaxel.	Paclitaxel	46-56	ATP binding cassette subfamily B member 1	Homo sapiens	12-26
11504826-1	2001	Paclitaxel is a substrate of the mdr1 P-glycoprotein (Pgp).	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	33-37
11504826-4	2001	A computational model of intracellular paclitaxel pharmacokinetics was developed to analyze for the Pgp efflux parameters.	Paclitaxel	39-49	ATP binding cassette subfamily B member 1	Homo sapiens	100-103
11504826-8	2001	In conclusion, our results indicate that the Pgp-mediated efflux represents a major efflux mechanism of paclitaxel at the low end of the clinically observed drug concentration range, but accounts for only a minor part of the efflux at higher concentrations in BC19 cells.	Paclitaxel	104-114	ATP binding cassette subfamily B member 1	Homo sapiens	45-48
11504826-1	2001	Paclitaxel is a substrate of the mdr1 P-glycoprotein (Pgp).	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	38-52
11504826-1	2001	Paclitaxel is a substrate of the mdr1 P-glycoprotein (Pgp).	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	54-57
11504826-2	2001	The objective of the present study was to determine the kinetics of the Pgp-mediated efflux and its contribution to the overall efflux of paclitaxel at the clinically achievable concentration range of 1 to 1500 nM.	Paclitaxel	138-148	ATP binding cassette subfamily B member 1	Homo sapiens	72-75
11745785-6	2001	Whereas solubility of paclitaxel was raised 8.1-, 21-, and 57-fold by physiologic levels of alpha(1)-acid glycoproteins, bovine serum albumin, and calf serum over that in protein-free solution, diffusivity of paclitaxel in free solution was reduced by 41, 49, and 74%, respectively.	Paclitaxel	22-32	albumin	Homo sapiens	128-141
11716366-6	2001	Paclitaxel induced apoptosis through activation of both caspase-8 and caspase-3.	Paclitaxel	0-10	caspase 3	Homo sapiens	70-79
11759824-1	2001	HER2 overexpression in breast cancer is associated with a poor prognosis, resistance to endocrine therapy and chemosensitivity to anthracyclines and paclitaxel.	Paclitaxel	149-159	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
11716366-7	2001	Overexpression of Bcl-XL leads to inhibition of paclitaxel-induced FasL expression and apoptosis.	Paclitaxel	48-58	BCL2 like 1	Homo sapiens	18-24
11504769-1	2001	BACKGROUND: The taxane paclitaxel (Taxol) is often of limited efficacy in chemotherapeutic regimens because some cancer cells express high levels of the efflux pump, P-glycoprotein (Pgp), which removes the drug from the cells.	Paclitaxel	23-33	ATP binding cassette subfamily B member 1	Homo sapiens	166-180
11496337-7	2001	Further, the plasma levels of extracellular domain of HER-2 in 17 patients treated with the weekly paclitaxel were measured, and also compared to their tumor response.	Paclitaxel	99-109	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-59
11496337-10	2001	In contrast, the plasma level of extracellular domain of HER-2 in responders was higher than that of non-responders in the weekly paclitaxel regimen(p=0.0512, Mann-Whitney"s U-test).	Paclitaxel	130-140	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-62
11496337-11	2001	These results suggest that tumor response to the weekly 1 h infusion of paclitaxel was not associated with the plasma concentration and the dose intensity, rather the plasma level of extracellular domain of HER-2 protein may be a predictor of tumor response in the treatment of weekly paclitaxel in relapsed breast cancer.	Paclitaxel	285-295	erb-b2 receptor tyrosine kinase 2	Homo sapiens	207-212
11489535-3	2001	IL-6 protects PC12 cells from the death induced by serum deprivation or anticancer agents, such as cisplatin, paclitaxel and 5-fluorouracil.	Paclitaxel	110-120	interleukin 6	Rattus norvegicus	0-4
11504769-8	2001	RESULTS: Pgp-expressing cells treated with IDN-5109 or with the taxane-based drug resistance reversal agent tRA96023, which blocks Pgp activity, retained 8.1- and 9.4-fold more Rh-123 (P =.0001), respectively, and 1.7- and 1.9-fold more doxorubicin (P =.001), respectively, than cells treated with paclitaxel.	Paclitaxel	298-308	ATP binding cassette subfamily B member 1	Homo sapiens	9-12
11504769-1	2001	BACKGROUND: The taxane paclitaxel (Taxol) is often of limited efficacy in chemotherapeutic regimens because some cancer cells express high levels of the efflux pump, P-glycoprotein (Pgp), which removes the drug from the cells.	Paclitaxel	23-33	ATP binding cassette subfamily B member 1	Homo sapiens	182-185
11504769-1	2001	BACKGROUND: The taxane paclitaxel (Taxol) is often of limited efficacy in chemotherapeutic regimens because some cancer cells express high levels of the efflux pump, P-glycoprotein (Pgp), which removes the drug from the cells.	Paclitaxel	35-40	ATP binding cassette subfamily B member 1	Homo sapiens	166-180
11504769-1	2001	BACKGROUND: The taxane paclitaxel (Taxol) is often of limited efficacy in chemotherapeutic regimens because some cancer cells express high levels of the efflux pump, P-glycoprotein (Pgp), which removes the drug from the cells.	Paclitaxel	35-40	ATP binding cassette subfamily B member 1	Homo sapiens	182-185
11504769-2	2001	The orally active paclitaxel analog IDN-5109 has been reported to overcome Pgp-mediated drug resistance.	Paclitaxel	18-28	ATP binding cassette subfamily B member 1	Homo sapiens	75-78
11521190-5	2001	At apoptosis-inducing concentrations, taxol weakly induces IkappaB(alpha) proteolysis and NF-kappaB translocation in K562 cells, but potently induces its transcriptional activity.	Paclitaxel	38-43	nuclear factor kappa B subunit 1	Homo sapiens	90-99
11521190-6	2001	Inhibition of NF-kappaB activity (by blocking IkappaB(alpha) degradation) significantly sensitizes cells to taxol-induced apoptosis.	Paclitaxel	108-113	nuclear factor kappa B subunit 1	Homo sapiens	14-23
11561777-0	2001	Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel.	Paclitaxel	126-136	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	22-27
11554785-3	2001	A subset of the genes examined (e.g., G-CSF, MIP-2, iNOS, and IL-1 beta, and GM-CSF) was upregulated &gt;3-20-fold by both LPS and paclitaxel in the DA-3 cell line, while IP-10 mRNA was induced by paclitaxel, but not by LPS.	Paclitaxel	131-141	chemokine (C-X-C motif) ligand 2	Mus musculus	45-50
11554785-3	2001	A subset of the genes examined (e.g., G-CSF, MIP-2, iNOS, and IL-1 beta, and GM-CSF) was upregulated &gt;3-20-fold by both LPS and paclitaxel in the DA-3 cell line, while IP-10 mRNA was induced by paclitaxel, but not by LPS.	Paclitaxel	131-141	nitric oxide synthase 2, inducible	Mus musculus	52-56
11554785-3	2001	A subset of the genes examined (e.g., G-CSF, MIP-2, iNOS, and IL-1 beta, and GM-CSF) was upregulated &gt;3-20-fold by both LPS and paclitaxel in the DA-3 cell line, while IP-10 mRNA was induced by paclitaxel, but not by LPS.	Paclitaxel	131-141	interleukin 1 beta	Mus musculus	62-71
11554785-3	2001	A subset of the genes examined (e.g., G-CSF, MIP-2, iNOS, and IL-1 beta, and GM-CSF) was upregulated &gt;3-20-fold by both LPS and paclitaxel in the DA-3 cell line, while IP-10 mRNA was induced by paclitaxel, but not by LPS.	Paclitaxel	197-207	chemokine (C-X-C motif) ligand 2	Mus musculus	45-50
11554785-3	2001	A subset of the genes examined (e.g., G-CSF, MIP-2, iNOS, and IL-1 beta, and GM-CSF) was upregulated &gt;3-20-fold by both LPS and paclitaxel in the DA-3 cell line, while IP-10 mRNA was induced by paclitaxel, but not by LPS.	Paclitaxel	197-207	nitric oxide synthase 2, inducible	Mus musculus	52-56
11554785-3	2001	A subset of the genes examined (e.g., G-CSF, MIP-2, iNOS, and IL-1 beta, and GM-CSF) was upregulated &gt;3-20-fold by both LPS and paclitaxel in the DA-3 cell line, while IP-10 mRNA was induced by paclitaxel, but not by LPS.	Paclitaxel	197-207	interleukin 1 beta	Mus musculus	62-71
11505395-2	2001	This combination also enhanced sensitivity to paclitaxel in a bcl-2 and mutant p53 expressing renal carcinoma cell line.	Paclitaxel	46-56	BCL2 apoptosis regulator	Homo sapiens	62-67
11505395-2	2001	This combination also enhanced sensitivity to paclitaxel in a bcl-2 and mutant p53 expressing renal carcinoma cell line.	Paclitaxel	46-56	tumor protein p53	Homo sapiens	79-82
11561777-4	2001	Recently, paclitaxel, a compound structurally related to docetaxel, has been shown to significantly elevate the expression of CYP3A in rat and human hepatocytes.	Paclitaxel	10-20	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	126-131
11461121-0	2001	The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells.	Paclitaxel	51-56	mitogen-activated protein kinase 3	Homo sapiens	12-19
11461121-5	2001	Here we demonstrate that Taxol activates ERK 1/2 and p38 MAP-kinases in human ovarian carcinoma cells with distinct kinetics.	Paclitaxel	25-30	mitogen-activated protein kinase 3	Homo sapiens	41-48
11461121-0	2001	The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells.	Paclitaxel	51-56	mitogen-activated protein kinase 1	Homo sapiens	24-27
11461121-5	2001	Here we demonstrate that Taxol activates ERK 1/2 and p38 MAP-kinases in human ovarian carcinoma cells with distinct kinetics.	Paclitaxel	25-30	mitogen-activated protein kinase 1	Homo sapiens	53-56
11500829-0	2001	The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol.	Paclitaxel	58-63	toll-like receptor 4	Mus musculus	22-26
11461121-6	2001	Activation of ERK1/2 has been observed at low concentrations of Taxol (1-100 nM) within 0.5-6 h, whereas longer exposure(24 h) to nanomolar concentrations of Taxol resulted in an abrogation of the ERK1/2 phosphorylation/activation.	Paclitaxel	64-69	mitogen-activated protein kinase 3	Homo sapiens	14-20
11500829-2	2001	Macrophages from C3H/HeJ mice, which have a spontaneous mutation in Toll-like receptor 4 (TLR4), are hyporesponsive to both LPS and Taxol, suggesting that LPS and Taxol may share a signaling pathway involving TLR4.	Paclitaxel	132-137	toll-like receptor 4	Mus musculus	68-88
11500829-2	2001	Macrophages from C3H/HeJ mice, which have a spontaneous mutation in Toll-like receptor 4 (TLR4), are hyporesponsive to both LPS and Taxol, suggesting that LPS and Taxol may share a signaling pathway involving TLR4.	Paclitaxel	132-137	toll-like receptor 4	Mus musculus	90-94
11500829-2	2001	Macrophages from C3H/HeJ mice, which have a spontaneous mutation in Toll-like receptor 4 (TLR4), are hyporesponsive to both LPS and Taxol, suggesting that LPS and Taxol may share a signaling pathway involving TLR4.	Paclitaxel	132-137	toll-like receptor 4	Mus musculus	209-213
11500829-2	2001	Macrophages from C3H/HeJ mice, which have a spontaneous mutation in Toll-like receptor 4 (TLR4), are hyporesponsive to both LPS and Taxol, suggesting that LPS and Taxol may share a signaling pathway involving TLR4.	Paclitaxel	163-168	toll-like receptor 4	Mus musculus	68-88
11500829-2	2001	Macrophages from C3H/HeJ mice, which have a spontaneous mutation in Toll-like receptor 4 (TLR4), are hyporesponsive to both LPS and Taxol, suggesting that LPS and Taxol may share a signaling pathway involving TLR4.	Paclitaxel	163-168	toll-like receptor 4	Mus musculus	90-94
11500829-2	2001	Macrophages from C3H/HeJ mice, which have a spontaneous mutation in Toll-like receptor 4 (TLR4), are hyporesponsive to both LPS and Taxol, suggesting that LPS and Taxol may share a signaling pathway involving TLR4.	Paclitaxel	163-168	toll-like receptor 4	Mus musculus	209-213
11500829-4	2001	When stimulated with Taxol, macrophages from wild-type mice responded robustly by secreting both TNF and NO, while macrophages from either TLR4-deficient C57BL/10ScNCr mice or MyD88 knockout mice produced only minimal amounts of TNF and NO.	Paclitaxel	21-26	tumor necrosis factor	Mus musculus	97-100
11500829-4	2001	When stimulated with Taxol, macrophages from wild-type mice responded robustly by secreting both TNF and NO, while macrophages from either TLR4-deficient C57BL/10ScNCr mice or MyD88 knockout mice produced only minimal amounts of TNF and NO.	Paclitaxel	21-26	tumor necrosis factor	Mus musculus	229-232
11500829-5	2001	Taxol-induced NF-kappa B-driven luciferase activity was reduced after transfection of RAW 264.7 macrophages with a dominant negative version of mouse MyD88.	Paclitaxel	0-5	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	14-24
11500829-6	2001	Taxol-induced microtubule-associated protein kinase (MAPK) activation and NF-kappa B nuclear translocation were absent from TLR4-null macrophages, but were preserved in MyD88 knockout macrophages with a slight delay in kinetics.	Paclitaxel	0-5	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	74-84
11500829-6	2001	Taxol-induced microtubule-associated protein kinase (MAPK) activation and NF-kappa B nuclear translocation were absent from TLR4-null macrophages, but were preserved in MyD88 knockout macrophages with a slight delay in kinetics.	Paclitaxel	0-5	toll-like receptor 4	Mus musculus	124-128
11500829-8	2001	These results suggest that Taxol and LPS not only share a TLR4/MyD88-dependent pathway in generating inflammatory mediators, but also share a TLR4-dependent/MyD88-independent pathway leading to activation of MAPK and NF-kappa B.	Paclitaxel	27-32	toll-like receptor 4	Mus musculus	58-62
11500829-8	2001	These results suggest that Taxol and LPS not only share a TLR4/MyD88-dependent pathway in generating inflammatory mediators, but also share a TLR4-dependent/MyD88-independent pathway leading to activation of MAPK and NF-kappa B.	Paclitaxel	27-32	toll-like receptor 4	Mus musculus	142-146
11500829-8	2001	These results suggest that Taxol and LPS not only share a TLR4/MyD88-dependent pathway in generating inflammatory mediators, but also share a TLR4-dependent/MyD88-independent pathway leading to activation of MAPK and NF-kappa B.	Paclitaxel	27-32	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	217-227
11552225-5	2001	The paclitaxel/doxorubicin interaction was found to be paclitaxel-dose dependent, doxorubicin concentration-dependant, and may be the result of competition for elimination mechanisms, possibly competition for hepatic and biliary transporter proteins such as p-glycoprotein, as a result of the formulation vehicle polyethoxylated castor oil (cremophor EL).	Paclitaxel	4-14	ATP binding cassette subfamily B member 1	Homo sapiens	258-272
11552225-5	2001	The paclitaxel/doxorubicin interaction was found to be paclitaxel-dose dependent, doxorubicin concentration-dependant, and may be the result of competition for elimination mechanisms, possibly competition for hepatic and biliary transporter proteins such as p-glycoprotein, as a result of the formulation vehicle polyethoxylated castor oil (cremophor EL).	Paclitaxel	55-65	ATP binding cassette subfamily B member 1	Homo sapiens	258-272
11605182-11	2001	Acquired resistance to paclitaxel can be mediated by several mechanisms, including overexpression of p-glycoprotein, altered expression of beta-tubulin isotypes, intrinsic or acquired mutations in beta-tubulin, and expression of novel genes.	Paclitaxel	23-33	ATP binding cassette subfamily B member 1	Homo sapiens	101-115
11461121-6	2001	Activation of ERK1/2 has been observed at low concentrations of Taxol (1-100 nM) within 0.5-6 h, whereas longer exposure(24 h) to nanomolar concentrations of Taxol resulted in an abrogation of the ERK1/2 phosphorylation/activation.	Paclitaxel	158-163	mitogen-activated protein kinase 3	Homo sapiens	14-20
11461121-6	2001	Activation of ERK1/2 has been observed at low concentrations of Taxol (1-100 nM) within 0.5-6 h, whereas longer exposure(24 h) to nanomolar concentrations of Taxol resulted in an abrogation of the ERK1/2 phosphorylation/activation.	Paclitaxel	158-163	mitogen-activated protein kinase 3	Homo sapiens	197-203
11461121-8	2001	p38 kinase was activated by high concentrations (1-10 microM) of Taxol within 2 h and remained active for more than 24 h. The kinetic studies showed that these effects of Taxol coincided with an inhibition of proliferation, and the onset of apoptosis.	Paclitaxel	65-70	mitogen-activated protein kinase 1	Homo sapiens	0-3
11461121-8	2001	p38 kinase was activated by high concentrations (1-10 microM) of Taxol within 2 h and remained active for more than 24 h. The kinetic studies showed that these effects of Taxol coincided with an inhibition of proliferation, and the onset of apoptosis.	Paclitaxel	171-176	mitogen-activated protein kinase 1	Homo sapiens	0-3
11461121-11	2001	An inhibitor of p38 kinase, SB203580, protected the cells partially from Taxol and, unexpectedly, activated ERK 1/2 kinases.	Paclitaxel	73-78	mitogen-activated protein kinase 1	Homo sapiens	16-19
11461121-12	2001	We conclude that the alternative use of ERK1/2 and p38 MAP-kinase pathways may be necessary for the transition from proliferation state to Taxol-induced apoptosisin human ovarian carcinoma cells.	Paclitaxel	139-144	mitogen-activated protein kinase 3	Homo sapiens	40-46
11461121-12	2001	We conclude that the alternative use of ERK1/2 and p38 MAP-kinase pathways may be necessary for the transition from proliferation state to Taxol-induced apoptosisin human ovarian carcinoma cells.	Paclitaxel	139-144	mitogen-activated protein kinase 1	Homo sapiens	51-54
11458051-0	2001	Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.	Paclitaxel	54-64	tumor protein p53	Homo sapiens	11-14
11458051-4	2001	Susceptibility of these inducible p53 TCC cells to paclitaxel and gemcitabine induced cytotoxicity was evaluated and kill significance determined between sub-lethal and lethal doses.	Paclitaxel	51-61	tumor protein p53	Homo sapiens	34-37
11458051-5	2001	RESULTS: Significant paclitaxel dose dependent cytotoxicity was observed in J82 TCC cells lacking normal p53 and tsp53 transfected cells at 37C, which was the mutant p53 temperature in transfectants between maximal and minimal kill concentrations for either (p &lt;0.001).	Paclitaxel	21-31	tumor protein p53	Homo sapiens	105-108
11458051-5	2001	RESULTS: Significant paclitaxel dose dependent cytotoxicity was observed in J82 TCC cells lacking normal p53 and tsp53 transfected cells at 37C, which was the mutant p53 temperature in transfectants between maximal and minimal kill concentrations for either (p &lt;0.001).	Paclitaxel	21-31	tumor protein p53	Homo sapiens	115-118
11458051-8	2001	CONCLUSIONS: Paclitaxel requires functionally mutated p53 to induce cell death in human bladder cells, indicating that it may be more effective against TCC with p53 mutations than against TCC, which lacks p53 abnormalities, while gemcitabine is effective regardless of p53 function.	Paclitaxel	13-23	tumor protein p53	Homo sapiens	54-57
11458051-8	2001	CONCLUSIONS: Paclitaxel requires functionally mutated p53 to induce cell death in human bladder cells, indicating that it may be more effective against TCC with p53 mutations than against TCC, which lacks p53 abnormalities, while gemcitabine is effective regardless of p53 function.	Paclitaxel	13-23	tumor protein p53	Homo sapiens	161-164
11458051-8	2001	CONCLUSIONS: Paclitaxel requires functionally mutated p53 to induce cell death in human bladder cells, indicating that it may be more effective against TCC with p53 mutations than against TCC, which lacks p53 abnormalities, while gemcitabine is effective regardless of p53 function.	Paclitaxel	13-23	tumor protein p53	Homo sapiens	161-164
11458051-8	2001	CONCLUSIONS: Paclitaxel requires functionally mutated p53 to induce cell death in human bladder cells, indicating that it may be more effective against TCC with p53 mutations than against TCC, which lacks p53 abnormalities, while gemcitabine is effective regardless of p53 function.	Paclitaxel	13-23	tumor protein p53	Homo sapiens	161-164
11455016-1	2001	Activation of the mitogen-activated protein kinase (MAPK) pathway in HeLa and Chinese hamster ovary cells after treatment with paclitaxel (Taxol) and other microtubule interacting agents has been investigated.	Paclitaxel	127-137	mitogen-activated protein kinase 1	Homo sapiens	52-56
11455016-1	2001	Activation of the mitogen-activated protein kinase (MAPK) pathway in HeLa and Chinese hamster ovary cells after treatment with paclitaxel (Taxol) and other microtubule interacting agents has been investigated.	Paclitaxel	139-144	mitogen-activated protein kinase 1	Homo sapiens	52-56
11455016-7	2001	In both cell lines, inhibition of ERK activity potentiated paclitaxel-induced PARP cleavage and phosphatidylserine externalization, suggesting that ERK activity coincided with, but did not mediate, the cytotoxic effects of paclitaxel.	Paclitaxel	59-69	mitogen-activated protein kinase 1	Homo sapiens	34-37
11455016-7	2001	In both cell lines, inhibition of ERK activity potentiated paclitaxel-induced PARP cleavage and phosphatidylserine externalization, suggesting that ERK activity coincided with, but did not mediate, the cytotoxic effects of paclitaxel.	Paclitaxel	59-69	poly(ADP-ribose) polymerase 1	Homo sapiens	78-82
11455016-7	2001	In both cell lines, inhibition of ERK activity potentiated paclitaxel-induced PARP cleavage and phosphatidylserine externalization, suggesting that ERK activity coincided with, but did not mediate, the cytotoxic effects of paclitaxel.	Paclitaxel	59-69	mitogen-activated protein kinase 1	Homo sapiens	148-151
11455016-7	2001	In both cell lines, inhibition of ERK activity potentiated paclitaxel-induced PARP cleavage and phosphatidylserine externalization, suggesting that ERK activity coincided with, but did not mediate, the cytotoxic effects of paclitaxel.	Paclitaxel	223-233	mitogen-activated protein kinase 1	Homo sapiens	34-37
11455016-9	2001	Our data confirmed additivity in those cells lines that undergo paclitaxel-induced ERK activation, and antagonism in cells with low ERK activity, suggesting that in tumors with high ERK activity, there may be an application for this strategy in therapy.	Paclitaxel	64-74	mitogen-activated protein kinase 1	Homo sapiens	83-86
11787463-3	2001	(2) Trastuzumab, a monoclonal antibody directed against HER2 protein, has been granted marketing authorisation for the treatment of metastatic breast cancer in women with high HER2 protein levels, either as third-line monotherapy, or as first-line combination therapy with paclitaxel.	Paclitaxel	273-283	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
11410862-7	2001	Furthermore, a potentiation in the growth inhibitory effect on GEO cancer cells was observed after treatment with these EGFR antisense MBOs in combination with cytotoxic drugs, including cisplatin, doxorubicin, paclitaxel, or topotecan.	Paclitaxel	211-221	epidermal growth factor receptor	Homo sapiens	120-124
11461094-0	2001	Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells.	Paclitaxel	71-81	mitogen-activated protein kinase 8	Homo sapiens	15-18
11461094-5	2001	Co-exposure of SiHa cells to SB202190 at concentrations that inhibit JNK abolished the protective effect of EGF on SiHa cells against paclitaxel-induced apoptosis.	Paclitaxel	134-144	mitogen-activated protein kinase 8	Homo sapiens	69-72
11461094-6	2001	Our findings indicate that the JNK signaling pathway plays an important role in EGF-mediated protection from paclitaxel-induced apoptosis in SiHa cells.	Paclitaxel	109-119	mitogen-activated protein kinase 8	Homo sapiens	31-34
11410863-0	2001	Expression of protein kinase C beta1 confers resistance to TNFalpha- and paclitaxel-induced apoptosis in HT-29 colon carcinoma cells.	Paclitaxel	73-83	proline rich transmembrane protein 2	Homo sapiens	14-30
11410863-6	2001	Transfected HT-29(PKC) cells, hyper-expressing the beta1 isoform of PKC, were less sensitive to TNFalpha and paclitaxel than the normal counterpart.	Paclitaxel	109-119	proline rich transmembrane protein 2	Homo sapiens	18-21
11410863-6	2001	Transfected HT-29(PKC) cells, hyper-expressing the beta1 isoform of PKC, were less sensitive to TNFalpha and paclitaxel than the normal counterpart.	Paclitaxel	109-119	proline rich transmembrane protein 2	Homo sapiens	68-71
11410863-7	2001	The present data 1) indicate that the expression of PKC influences the susceptibility of HT-29 colon cancer cells to apoptotic drugs apparently regardless of their mechanism of action, and 2) suggest paclitaxel as a potential candidate for the treatment of colon cancer, possibly in association with inhibitors of PKC (alpha and beta) at doses not cytotoxic per se.	Paclitaxel	200-210	proline rich transmembrane protein 2	Homo sapiens	52-55
11410863-7	2001	The present data 1) indicate that the expression of PKC influences the susceptibility of HT-29 colon cancer cells to apoptotic drugs apparently regardless of their mechanism of action, and 2) suggest paclitaxel as a potential candidate for the treatment of colon cancer, possibly in association with inhibitors of PKC (alpha and beta) at doses not cytotoxic per se.	Paclitaxel	200-210	proline rich transmembrane protein 2	Homo sapiens	314-317
11425537-0	2001	Synthesis of a novel C-10 spiro-epoxide of paclitaxel.	Paclitaxel	43-53	homeobox C10	Homo sapiens	21-25
11425537-1	2001	New analogues of paclitaxel (1a, active constituent of Taxol) were synthesized containing an epoxide at the C-10 position.	Paclitaxel	17-27	homeobox C10	Homo sapiens	108-112
11425537-4	2001	Deprotection and further manipulations provide the C10-spiro epoxide of paclitaxel (1b) and the corresponding C7-MOM ether (1c).	Paclitaxel	72-82	homeobox C10	Homo sapiens	51-54
11724319-9	2001	CONCLUSION: These results suggest that in SKOV-3 cells, G1-arrest induced by p16-transduction prevents paclitaxel- and vindesine-induced cell death, and in OVCAR-5 cells, the other unknown mechanisms play a role of chemoresistance.	Paclitaxel	103-113	cyclin dependent kinase inhibitor 2A	Homo sapiens	77-80
11668581-5	2001	However, heightening the Taxol sensitivity of GFP-EMTB-TC-7 cells by pre-incubating cells with the p-glycoprotein inhibitor, verapamil, did result in selective killing of cells highly expressing GFP-EMTB.	Paclitaxel	25-30	ATP binding cassette subfamily B member 1	Homo sapiens	99-113
11408609-1	2001	Effects of inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase (MEK/MAPK) cascade have been examined in relation to paclitaxel-induced apoptosis in human monocytic leukemia cells (U937).	Paclitaxel	155-165	mitogen-activated protein kinase kinase 7	Homo sapiens	103-106
11425893-4	2001	Data from non-neuronal cells indicate that taxol-induced apoptosis requires activation of N-terminal c-Jun protein kinase (JNK) that phosphorylates and inactivates Bcl-2.	Paclitaxel	43-48	mitogen-activated protein kinase 8	Homo sapiens	101-121
11425893-4	2001	Data from non-neuronal cells indicate that taxol-induced apoptosis requires activation of N-terminal c-Jun protein kinase (JNK) that phosphorylates and inactivates Bcl-2.	Paclitaxel	43-48	mitogen-activated protein kinase 8	Homo sapiens	123-126
11425893-4	2001	Data from non-neuronal cells indicate that taxol-induced apoptosis requires activation of N-terminal c-Jun protein kinase (JNK) that phosphorylates and inactivates Bcl-2.	Paclitaxel	43-48	BCL2 apoptosis regulator	Homo sapiens	164-169
11425893-7	2001	In contrast to human embryonic kidney 293 cells, expression of wild-type Bcl-2 in cortical neurons protected against taxol-induced apoptosis, and taxol did not induce Bcl-2 phosphorylation.	Paclitaxel	117-122	BCL2 apoptosis regulator	Homo sapiens	73-78
11425893-9	2001	However, taxol activated a subpool of JNK in the nucleus and stimulated c-Jun phosphorylation.	Paclitaxel	9-14	mitogen-activated protein kinase 8	Homo sapiens	38-41
11425893-10	2001	JNK inhibition or expression of a dominant-negative c-Jun abrogated taxol-induced apoptosis in cortical neurons, suggesting a role for JNK and JNK-mediated transcription in taxol-stimulated apoptosis.	Paclitaxel	68-73	mitogen-activated protein kinase 8	Homo sapiens	0-3
11425893-10	2001	JNK inhibition or expression of a dominant-negative c-Jun abrogated taxol-induced apoptosis in cortical neurons, suggesting a role for JNK and JNK-mediated transcription in taxol-stimulated apoptosis.	Paclitaxel	173-178	mitogen-activated protein kinase 8	Homo sapiens	0-3
11425893-10	2001	JNK inhibition or expression of a dominant-negative c-Jun abrogated taxol-induced apoptosis in cortical neurons, suggesting a role for JNK and JNK-mediated transcription in taxol-stimulated apoptosis.	Paclitaxel	173-178	mitogen-activated protein kinase 8	Homo sapiens	135-138
11425893-10	2001	JNK inhibition or expression of a dominant-negative c-Jun abrogated taxol-induced apoptosis in cortical neurons, suggesting a role for JNK and JNK-mediated transcription in taxol-stimulated apoptosis.	Paclitaxel	173-178	mitogen-activated protein kinase 8	Homo sapiens	135-138
11408609-2	2001	Cells treated with paclitaxel (250 nm; 6 h) followed by PD98059 [corrected] exhibited a significant increase in mitochondrial dysfunction (e.g., cytochrome c release), caspase activation, poly ADP-ribose polymerase cleavage, and apoptosis, whereas pretreatment of cells with PD98059 reduced lethality.	Paclitaxel	19-29	cytochrome c, somatic	Homo sapiens	145-157
11408609-2	2001	Cells treated with paclitaxel (250 nm; 6 h) followed by PD98059 [corrected] exhibited a significant increase in mitochondrial dysfunction (e.g., cytochrome c release), caspase activation, poly ADP-ribose polymerase cleavage, and apoptosis, whereas pretreatment of cells with PD98059 reduced lethality.	Paclitaxel	19-29	poly(ADP-ribose) polymerase 1	Homo sapiens	188-214
11408609-9	2001	Moreover, coadministration of the p38 MAPK inhibitors SB203580 and SB202190 abrogated the increase in paclitaxel-mediated apoptosis induced by PD98059.	Paclitaxel	102-112	mitogen-activated protein kinase 14	Homo sapiens	34-37
11408609-11	2001	Together, these findings suggest that subsequent exposure of paclitaxel-treated U937 cells to MEK/MAPK inhibitors induces perturbations in signaling pathways, particularly the p42/44 MAPK and p38 MAPK cascades, that lower the threshold for mitochondrial injury and induction of cell death.	Paclitaxel	61-71	mitogen-activated protein kinase kinase 7	Homo sapiens	94-97
11408609-11	2001	Together, these findings suggest that subsequent exposure of paclitaxel-treated U937 cells to MEK/MAPK inhibitors induces perturbations in signaling pathways, particularly the p42/44 MAPK and p38 MAPK cascades, that lower the threshold for mitochondrial injury and induction of cell death.	Paclitaxel	61-71	cyclin dependent kinase like 1	Homo sapiens	176-179
11410792-0	2001	Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line.	Paclitaxel	32-42	protein phosphatase 1 regulatory inhibitor subunit 1A	Homo sapiens	11-22
11408609-11	2001	Together, these findings suggest that subsequent exposure of paclitaxel-treated U937 cells to MEK/MAPK inhibitors induces perturbations in signaling pathways, particularly the p42/44 MAPK and p38 MAPK cascades, that lower the threshold for mitochondrial injury and induction of cell death.	Paclitaxel	61-71	mitogen-activated protein kinase 14	Homo sapiens	192-195
11410792-2	2001	We have previously reported that the activation of caspase-3 and caspase-8 plays a crucial role in paclitaxel-induced apoptosis.	Paclitaxel	99-109	caspase 3	Homo sapiens	51-60
11439344-5	2001	Furthermore, we observed that the levels of p53 and p21 induced by adriamycin and by low concentrations of PTX in A549 cells were comparable.	Paclitaxel	107-110	tumor protein p53	Homo sapiens	44-47
11410792-3	2001	Anti-tumor reagents including paclitaxel, irradiation, and other stimuli activate the transcription factor NF-kappaB, which has the ability to suppress the apoptotic potential of those stimuli.	Paclitaxel	30-40	nuclear factor kappa B subunit 1	Homo sapiens	107-116
11496948-0	2001	Mdr1 transfection causes enhanced apoptosis by paclitaxel: an effect  independent of drug efflux function of P-glycoprotein.	Paclitaxel	47-57	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
11496948-1	2001	PURPOSE: We previously reported that in patient tumors the expression of the mdrl p-glycoprotein (Pgp) resulted in a lower paclitaxel-induced inhibition of DNA precursor incorporation, but a higher apoptosis (Clin.	Paclitaxel	123-133	ATP binding cassette subfamily B member 1	Homo sapiens	82-96
11496948-1	2001	PURPOSE: We previously reported that in patient tumors the expression of the mdrl p-glycoprotein (Pgp) resulted in a lower paclitaxel-induced inhibition of DNA precursor incorporation, but a higher apoptosis (Clin.	Paclitaxel	123-133	ATP binding cassette subfamily B member 1	Homo sapiens	98-101
11496948-5	2001	METHODS: To separate the effect of Pgp on intracellular paclitaxel accumulation from its effects on drug sensitivity, we compared the drug activity at various extracellular and intracellular drug concentrations using the human breast MCF7 tumor cells and its mdr1-transfected variant BC19 cells.	Paclitaxel	56-66	ATP binding cassette subfamily B member 1	Homo sapiens	35-38
11496948-11	2001	CONCLUSIONS: These results confirm our previous observations in patient tumors and indicate that enhanced Pgp expression is associated with enhanced sensitivity to the apoptotic effect of paclitaxel and reduced sensitivity to its G2/M block effect, via yet-unknown mechanisms that are unrelated to the effect of Pgp on intracellular drug accumulation.	Paclitaxel	188-198	ATP binding cassette subfamily B member 1	Homo sapiens	106-109
11439344-0	2001	Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.	Paclitaxel	22-32	tumor protein p53	Homo sapiens	60-63
11439344-3	2001	At these low concentrations that are insufficient to inhibit mitotic progression, PTX induced both p53 and p21 causing G1 and G2 arrest in A549.	Paclitaxel	82-85	tumor protein p53	Homo sapiens	99-102
11439344-6	2001	This observation led us to conclude that low concentrations of PTX can induce p53 and p21 sufficiently to cause G1 and G2.	Paclitaxel	63-66	tumor protein p53	Homo sapiens	78-81
11410496-1	2001	PURPOSE: Preclinical and clinical investigation of the combination of the antiangiogenesis/anti-invasion agent carboxyamido-triazole (CAI) administered with the cytotoxic agent paclitaxel (PAX).	Paclitaxel	177-187	paxillin	Mus musculus	189-192
11459199-6	2001	In contrast, the degree of cross-resistance with the topoisomerase II inhibitors doxorubicin and etoposide was minimal and the pattern of sensitivity to the anti-microtubulin agents vinblastine and paclitaxel was different, with a two- to fourfold decreased sensitivity in the high EGFR-expressing ME180/TNF cells and only a 1.5-fold decreased sensitivity in the low EGFR-expressing ME180/Pt cells.	Paclitaxel	198-208	epidermal growth factor receptor	Homo sapiens	282-286
11459199-6	2001	In contrast, the degree of cross-resistance with the topoisomerase II inhibitors doxorubicin and etoposide was minimal and the pattern of sensitivity to the anti-microtubulin agents vinblastine and paclitaxel was different, with a two- to fourfold decreased sensitivity in the high EGFR-expressing ME180/TNF cells and only a 1.5-fold decreased sensitivity in the low EGFR-expressing ME180/Pt cells.	Paclitaxel	198-208	tumor necrosis factor	Homo sapiens	304-307
11459199-6	2001	In contrast, the degree of cross-resistance with the topoisomerase II inhibitors doxorubicin and etoposide was minimal and the pattern of sensitivity to the anti-microtubulin agents vinblastine and paclitaxel was different, with a two- to fourfold decreased sensitivity in the high EGFR-expressing ME180/TNF cells and only a 1.5-fold decreased sensitivity in the low EGFR-expressing ME180/Pt cells.	Paclitaxel	198-208	epidermal growth factor receptor	Homo sapiens	367-371
21047474-1	2001	BACKGROUND: To compare the efficacy and toxicity of paclitaxel-carboplatin (TAX-CBP) and paclitaxel-cisplatin (TAX-DDP) chemotherapy protocols for advanced non-small cell lung cancer.	Paclitaxel	52-62	CREB binding protein	Homo sapiens	80-83
11410497-0	2001	The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.	Paclitaxel	91-101	ATP binding cassette subfamily B member 1	Homo sapiens	4-18
11352950-1	2001	PURPOSE: This phase II study evaluated weekly trastuzumab and paclitaxel therapy in women with HER2-normal and HER2-overexpressing metastatic breast cancer.	Paclitaxel	62-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
11484935-2	2001	We found that four anticancer agents: etoposide, doxorubicin, bleomycin and paclitaxel induced apoptosis in human umbilical vein endothelial cells (HUVECs) (as judged by DNA fragmentation) with a time- and concentration-dependent decrease in bcl-2 protein but without the involvement of p53.	Paclitaxel	76-86	BCL2 apoptosis regulator	Homo sapiens	242-247
11484935-2	2001	We found that four anticancer agents: etoposide, doxorubicin, bleomycin and paclitaxel induced apoptosis in human umbilical vein endothelial cells (HUVECs) (as judged by DNA fragmentation) with a time- and concentration-dependent decrease in bcl-2 protein but without the involvement of p53.	Paclitaxel	76-86	tumor protein p53	Homo sapiens	287-290
11278851-0	2001	Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery.	Paclitaxel	0-10	mitogen-activated protein kinase kinase 7	Homo sapiens	51-54
11278851-0	2001	Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Homo sapiens	55-58
11278851-4	2001	All three mitogen-activated protein kinase (MAPK) family members, c-Jun N-terminal kinase (JNK), p38 MAPK, and extracellular signal-regulated kinase (ERK) were activated upon paclitaxel treatment.	Paclitaxel	175-185	mitogen-activated protein kinase 1	Homo sapiens	44-48
11278851-4	2001	All three mitogen-activated protein kinase (MAPK) family members, c-Jun N-terminal kinase (JNK), p38 MAPK, and extracellular signal-regulated kinase (ERK) were activated upon paclitaxel treatment.	Paclitaxel	175-185	mitogen-activated protein kinase 8	Homo sapiens	66-89
11278851-4	2001	All three mitogen-activated protein kinase (MAPK) family members, c-Jun N-terminal kinase (JNK), p38 MAPK, and extracellular signal-regulated kinase (ERK) were activated upon paclitaxel treatment.	Paclitaxel	175-185	mitogen-activated protein kinase 8	Homo sapiens	91-94
11278851-4	2001	All three mitogen-activated protein kinase (MAPK) family members, c-Jun N-terminal kinase (JNK), p38 MAPK, and extracellular signal-regulated kinase (ERK) were activated upon paclitaxel treatment.	Paclitaxel	175-185	mitogen-activated protein kinase 1	Homo sapiens	111-148
11278851-4	2001	All three mitogen-activated protein kinase (MAPK) family members, c-Jun N-terminal kinase (JNK), p38 MAPK, and extracellular signal-regulated kinase (ERK) were activated upon paclitaxel treatment.	Paclitaxel	175-185	mitogen-activated protein kinase 1	Homo sapiens	150-153
11356930-5	2001	In nontransformed cells, WR-1065 protected cells from the cytotoxic effects of paclitaxel in a p53-dependent manner.	Paclitaxel	79-89	tumor protein p53	Homo sapiens	95-98
11352950-1	2001	PURPOSE: This phase II study evaluated weekly trastuzumab and paclitaxel therapy in women with HER2-normal and HER2-overexpressing metastatic breast cancer.	Paclitaxel	62-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
11240255-0	2001	Paclitaxel restores radiation-induced apoptosis in a bcl-2-expressing, radiation-resistant lymphoma cell line.	Paclitaxel	0-10	B cell leukemia/lymphoma 2	Mus musculus	53-58
11288109-3	2001	In Calu-3 cells, accumulation of the Pgp substrates rhodamine 123 (Rh123) and calcein acetoxymethyl ester (calcein-AM) was increased in the presence of the specific Pgp inhibitors cyclosporin A (CsA), vinblastine, and taxol.	Paclitaxel	218-223	ATP binding cassette subfamily B member 1	Homo sapiens	37-40
11288109-3	2001	In Calu-3 cells, accumulation of the Pgp substrates rhodamine 123 (Rh123) and calcein acetoxymethyl ester (calcein-AM) was increased in the presence of the specific Pgp inhibitors cyclosporin A (CsA), vinblastine, and taxol.	Paclitaxel	218-223	ATP binding cassette subfamily B member 1	Homo sapiens	165-168
11295099-0	2001	Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines.	Paclitaxel	79-84	tumor protein p53	Homo sapiens	125-128
11465412-5	2001	Following competitive inhibition of Pgp by various Pgp modulators and substrates, even low concentrations of vinblastine, colchicine and paclitaxel substantially decreased TEER.	Paclitaxel	137-147	ATP binding cassette subfamily B member 1	Homo sapiens	36-39
11465412-5	2001	Following competitive inhibition of Pgp by various Pgp modulators and substrates, even low concentrations of vinblastine, colchicine and paclitaxel substantially decreased TEER.	Paclitaxel	137-147	ATP binding cassette subfamily B member 1	Homo sapiens	51-54
11275363-0	2001	Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition.	Paclitaxel	0-5	tumor protein p53	Homo sapiens	118-121
11275363-3	2001	DNA content analyses in A 549 (p53, +/+) and H 1299 (p53, -/-) cells, showed that taxol progressively induced G2/M arrest in both cell lines in a concentration-dependent manner, which was accompanied by a parallel decrease in the G1 population.	Paclitaxel	82-87	tumor protein p53	Homo sapiens	31-34
11275363-3	2001	DNA content analyses in A 549 (p53, +/+) and H 1299 (p53, -/-) cells, showed that taxol progressively induced G2/M arrest in both cell lines in a concentration-dependent manner, which was accompanied by a parallel decrease in the G1 population.	Paclitaxel	82-87	tumor protein p53	Homo sapiens	53-56
11477443-0	2001	HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.	Paclitaxel	154-164	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
11477443-4	2001	Our results suggest that patients with metastatic breast cancer and high soluble plasma HER-2 have a significantly poorer overall (OS) and progression-free survival (PFS) following high-dose chemotherapy with paclitaxel and ASCT.	Paclitaxel	209-219	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-93
11334731-3	2001	Overexpression of multidrug resistant protein (MRP) family members was observed in the RPMI-2650Ml cells, which were also much more invasive in vitro than the parental cell line or the paclitaxel-resistant variant.	Paclitaxel	185-195	ATP binding cassette subfamily C member 1	Homo sapiens	18-45
11334731-3	2001	Overexpression of multidrug resistant protein (MRP) family members was observed in the RPMI-2650Ml cells, which were also much more invasive in vitro than the parental cell line or the paclitaxel-resistant variant.	Paclitaxel	185-195	ATP binding cassette subfamily C member 1	Homo sapiens	47-50
11392446-8	2001	In conclusion, the uptake, accumulation, and retention of paclitaxel in solid tumors are determined by (a) factors that are independent of biological changes in tumor cells induced by paclitaxel, i.e., ratio of extracellular and intracellular concentrations, and drug binding to extracellular and intracellular macromolecules, and (b) factors that are dependent on the time- and drug concentration-dependent biological changes induced by paclitaxel, i.e., induction of apoptosis, enhancement of tubulin/microtubule production, and induction of Pgp expression.	Paclitaxel	58-68	ATP binding cassette subfamily B member 1	Homo sapiens	544-547
11329060-3	2001	Paclitaxel (Taxol), a commonly used chemotherapeutic agent, activated SXR and enhanced P-glycoprotein-mediated drug clearance.	Paclitaxel	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	70-73
11329060-3	2001	Paclitaxel (Taxol), a commonly used chemotherapeutic agent, activated SXR and enhanced P-glycoprotein-mediated drug clearance.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
11329060-3	2001	Paclitaxel (Taxol), a commonly used chemotherapeutic agent, activated SXR and enhanced P-glycoprotein-mediated drug clearance.	Paclitaxel	12-17	nuclear receptor subfamily 1 group I member 2	Homo sapiens	70-73
11329060-3	2001	Paclitaxel (Taxol), a commonly used chemotherapeutic agent, activated SXR and enhanced P-glycoprotein-mediated drug clearance.	Paclitaxel	12-17	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
11368354-11	2001	In addition, multisite Bcl2 phosphorylation induced by anti-mitotic drugs like paclitaxel may inhibit Bcl2 indicating the potential wide range of functional consequences that this post-translational modification may have on function.	Paclitaxel	79-89	BCL2 apoptosis regulator	Homo sapiens	23-27
11368354-11	2001	In addition, multisite Bcl2 phosphorylation induced by anti-mitotic drugs like paclitaxel may inhibit Bcl2 indicating the potential wide range of functional consequences that this post-translational modification may have on function.	Paclitaxel	79-89	BCL2 apoptosis regulator	Homo sapiens	102-106
11275990-4	2001	Semi-quantitative reverse transcriptast-polymerase chain reaction revealed that treatment of LNCaP cells with antisense Bcl-2 ODN decreased Bcl-2 expression in a dose-dependent and sequence-specific manner, whereas Bcl-2 expression was not affected by paclitaxel treatment.	Paclitaxel	252-262	BCL2 apoptosis regulator	Homo sapiens	120-125
11275990-5	2001	Antisense Bcl-2 ODN treatment significantly enhanced paclitaxel chemosensitivity in vitro, reducing cell viability after treatment with 1 nM paclitaxel from 76% to 42%.	Paclitaxel	53-63	B cell leukemia/lymphoma 2	Mus musculus	10-15
11275990-5	2001	Antisense Bcl-2 ODN treatment significantly enhanced paclitaxel chemosensitivity in vitro, reducing cell viability after treatment with 1 nM paclitaxel from 76% to 42%.	Paclitaxel	141-151	B cell leukemia/lymphoma 2	Mus musculus	10-15
11275990-8	2001	By 15 weeks post castration, tumor volume in mice treated with antisense Bcl-2 ODN alone or mismatch control ODN plus paclitaxel was &gt;3-fold higher than in mice treated with combined antisense Bcl-2 ODN and paclitaxel.	Paclitaxel	210-220	B cell leukemia/lymphoma 2	Mus musculus	73-78
11275990-10	2001	These findings identify combined antisense Bcl-2 and paclitaxel as a potentially new therapeutic strategy for advanced prostate cancer by enhancing paclitaxel chemosensitivity and delaying progression of hormone-refractory prostate cancer.	Paclitaxel	148-158	B cell leukemia/lymphoma 2	Mus musculus	43-48
11240255-1	2001	PURPOSE: To restore radiation-induced apoptosis in a bcl-2-expressing, radiation-resistant murine lymphoma cell line (LY-ar) by pretreatment with paclitaxel (Taxol).	Paclitaxel	146-156	B cell leukemia/lymphoma 2	Mus musculus	53-58
11240255-1	2001	PURPOSE: To restore radiation-induced apoptosis in a bcl-2-expressing, radiation-resistant murine lymphoma cell line (LY-ar) by pretreatment with paclitaxel (Taxol).	Paclitaxel	158-163	B cell leukemia/lymphoma 2	Mus musculus	53-58
11240255-2	2001	Because this cell line also has high intracellular levels of glutathione (GSH), reportedly due to the bcl-2 expression and involved in the cell"s antioxidant functions, paclitaxel treatment was correlated with GSH levels.	Paclitaxel	169-179	B cell leukemia/lymphoma 2	Mus musculus	102-107
11179455-8	2001	Paclitaxel treatment led to the proteolysis and activation of caspase-3 and -7, but not caspase-1.	Paclitaxel	0-10	caspase 3	Homo sapiens	62-78
11267864-6	2001	Combination with cisplatin or paclitaxel enhanced the cytotoxic effect of Bax induction in all but one cell line including cisplatin-resistant A2780/cDDP.	Paclitaxel	30-40	BCL2 associated X, apoptosis regulator	Homo sapiens	74-77
11179455-9	2001	Furthermore, paclitaxel-induced apoptosis and cleavage of beta-catenin and gamma-catenin were inhibited by the pan-caspase inhibitor Z-VAD-FMK and partially inhibited by the caspase-3 inhibitor Z-DEVD-FMK but were not affected by the caspase-1 inhibitor AC-YVAD-CMK.	Paclitaxel	13-23	caspase 3	Homo sapiens	174-183
11179455-9	2001	Furthermore, paclitaxel-induced apoptosis and cleavage of beta-catenin and gamma-catenin were inhibited by the pan-caspase inhibitor Z-VAD-FMK and partially inhibited by the caspase-3 inhibitor Z-DEVD-FMK but were not affected by the caspase-1 inhibitor AC-YVAD-CMK.	Paclitaxel	13-23	caspase 1	Homo sapiens	234-243
11179455-12	2001	Interestingly, the paclitaxel-induced beta-catenin fragment lost its ability to bind to E-cadherin, alpha-catenin, or APC protein and to serve as a substrate for tyrosine kinase.	Paclitaxel	19-29	cadherin 1	Homo sapiens	88-98
11160860-0	2001	Paclitaxel-induced immune suppression is associated with NF-kappaB activation via conventional PKC isotypes in lipopolysaccharide-stimulated 70Z/3 pre-B lymphocyte tumor cells.	Paclitaxel	0-10	protein kinase C, alpha	Mus musculus	95-98
11165754-8	2001	Paclitaxel showed an inhibitory effect on the growth of transplanted human OSCC and reduced the immunohistochemical expression of VEGF and CD31 and VEGF mRNA (P&lt;0.01).	Paclitaxel	0-10	vascular endothelial growth factor A	Homo sapiens	130-134
11165754-8	2001	Paclitaxel showed an inhibitory effect on the growth of transplanted human OSCC and reduced the immunohistochemical expression of VEGF and CD31 and VEGF mRNA (P&lt;0.01).	Paclitaxel	0-10	vascular endothelial growth factor A	Homo sapiens	148-152
11245462-2	2001	Here, the relationship between the mitogen-activated protein kinase (MAPK) response and apoptosis in ML-1 cells treated with vinblastine and paclitaxel was investigated.	Paclitaxel	141-151	mitogen-activated protein kinase 1	Homo sapiens	69-73
11157479-5	2001	Compared to normal controls, serum Tpo levels in patients receiving paclitaxel and carboplatin were significantly elevated 5 hours after infusion and remained elevated at day 7 (287% +/- 63% increase, P &lt;.001).	Paclitaxel	68-78	thrombopoietin	Homo sapiens	35-38
11157479-7	2001	It is concluded here that P-gp-mediated efflux of paclitaxel, and perhaps GST-mediated detoxification of carboplatin, results in relative sparing of CFU-Meg, which may then respond to locally high levels of stromal cell-derived Tpo.	Paclitaxel	50-60	ATP binding cassette subfamily B member 1	Homo sapiens	26-30
11157479-7	2001	It is concluded here that P-gp-mediated efflux of paclitaxel, and perhaps GST-mediated detoxification of carboplatin, results in relative sparing of CFU-Meg, which may then respond to locally high levels of stromal cell-derived Tpo.	Paclitaxel	50-60	thrombopoietin	Homo sapiens	228-231
11159798-0	2001	A flow cell assay for evaluation of whole cell drug efflux kinetics: analysis of paclitaxel efflux in CCRF-CEM leukemia cells overexpressing P-glycoprotein.	Paclitaxel	81-91	ATP binding cassette subfamily B member 1	Homo sapiens	141-155
11245462-6	2001	This apoptotic induction was attributed to JNK activation because: (a) non-JNK-activating concentrations of vinblastine failed to increase apoptosis in the presence of PD098059; (b) apoptosis induced by paclitaxel, which did not activate JNK, was not potentiated by PD098059; and (c) transduction of an inhibitor of JNK activity partially suppressed both JNK activity and apoptosis induced by vinblastine plus PD098059.	Paclitaxel	203-213	mitogen-activated protein kinase 8	Homo sapiens	43-46
11170175-5	2001	We next showed that a sustained activation of ERK (extracellular signal-regulated kinase) induced both tau phosphorylation and apoptosis during paclitaxel treatment (1 microM).	Paclitaxel	144-154	mitogen-activated protein kinase 1	Homo sapiens	46-49
11170175-5	2001	We next showed that a sustained activation of ERK (extracellular signal-regulated kinase) induced both tau phosphorylation and apoptosis during paclitaxel treatment (1 microM).	Paclitaxel	144-154	mitogen-activated protein kinase 1	Homo sapiens	51-88
11160861-2	2001	Here, we demonstrate that c-Jun NH(2)-terminal kinase (JNK), but not p38 mitogen-activated protein kinase or extracellular signal-regulated kinase 1/2, was persistently activated by paclitaxel or other microtubule-damaging agents within human leukemia HL-60 cells.	Paclitaxel	182-192	mitogen-activated protein kinase 8	Homo sapiens	26-53
11160861-2	2001	Here, we demonstrate that c-Jun NH(2)-terminal kinase (JNK), but not p38 mitogen-activated protein kinase or extracellular signal-regulated kinase 1/2, was persistently activated by paclitaxel or other microtubule-damaging agents within human leukemia HL-60 cells.	Paclitaxel	182-192	mitogen-activated protein kinase 8	Homo sapiens	55-58
11160861-3	2001	Overexpression of a dominant-negative mutant, mitogen-activated protein kinase kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense oligonucleotide prevented paclitaxel-induced JNK activation, Bcl-2 phosphorylation and apoptosis.	Paclitaxel	166-176	mitogen-activated protein kinase 8	Homo sapiens	117-120
11160861-3	2001	Overexpression of a dominant-negative mutant, mitogen-activated protein kinase kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense oligonucleotide prevented paclitaxel-induced JNK activation, Bcl-2 phosphorylation and apoptosis.	Paclitaxel	166-176	mitogen-activated protein kinase 8	Homo sapiens	185-188
11160861-3	2001	Overexpression of a dominant-negative mutant, mitogen-activated protein kinase kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense oligonucleotide prevented paclitaxel-induced JNK activation, Bcl-2 phosphorylation and apoptosis.	Paclitaxel	166-176	BCL2 apoptosis regulator	Homo sapiens	201-206
11160861-9	2001	Taken together, our results suggest that disruption of cytoarchitecture by paclitaxel triggers a novel apoptosis-signaling pathway, wherein an active DEVD-directed caspase (DEVDase) initially cleaves MEKK1to generate a proapoptotic kinase fragment that is able to activate JNK and subsequent Bcl-2 phosphorylation, finally eliciting cell death.	Paclitaxel	75-85	mitogen-activated protein kinase 8	Homo sapiens	273-276
11160861-9	2001	Taken together, our results suggest that disruption of cytoarchitecture by paclitaxel triggers a novel apoptosis-signaling pathway, wherein an active DEVD-directed caspase (DEVDase) initially cleaves MEKK1to generate a proapoptotic kinase fragment that is able to activate JNK and subsequent Bcl-2 phosphorylation, finally eliciting cell death.	Paclitaxel	75-85	BCL2 apoptosis regulator	Homo sapiens	292-297
11160860-6	2001	Interestingly, the activity of IkappaB kinase (IKK-beta), which plays an essential role in NF-kappaB activation through IkappaB phosphorylation, was largely enhanced in paclitaxel-treated cells, detected as IkappaBalpha phosphorylation.	Paclitaxel	169-179	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	207-219
11160860-7	2001	Because protein kinase C (PKC) is implicated in the activation of NF-kappaB via IKK-beta, the effect of paclitaxel on PKC activation was also measured.	Paclitaxel	104-114	protein kinase C, alpha	Mus musculus	118-121
11160860-8	2001	It was shown that NF-kappaB nuclear translocation and DNA binding in response to paclitaxel was completely blocked by the conventional PKC inhibitor, Go 6976.	Paclitaxel	81-91	protein kinase C, alpha	Mus musculus	135-138
11160860-9	2001	Moreover, immunoblotting analysis with paclitaxel-treated cell extract demonstrated that the conventional PKC isotype PKC-alpha was found to be involved in the regulation of paclitaxel-induced NF-kappaB activation, as determined by electrophoretic mobility shift of PKC.	Paclitaxel	39-49	protein kinase C, alpha	Mus musculus	106-109
11160860-9	2001	Moreover, immunoblotting analysis with paclitaxel-treated cell extract demonstrated that the conventional PKC isotype PKC-alpha was found to be involved in the regulation of paclitaxel-induced NF-kappaB activation, as determined by electrophoretic mobility shift of PKC.	Paclitaxel	39-49	protein kinase C, alpha	Mus musculus	118-127
11160860-9	2001	Moreover, immunoblotting analysis with paclitaxel-treated cell extract demonstrated that the conventional PKC isotype PKC-alpha was found to be involved in the regulation of paclitaxel-induced NF-kappaB activation, as determined by electrophoretic mobility shift of PKC.	Paclitaxel	39-49	protein kinase C, alpha	Mus musculus	118-121
11160860-9	2001	Moreover, immunoblotting analysis with paclitaxel-treated cell extract demonstrated that the conventional PKC isotype PKC-alpha was found to be involved in the regulation of paclitaxel-induced NF-kappaB activation, as determined by electrophoretic mobility shift of PKC.	Paclitaxel	174-184	protein kinase C, alpha	Mus musculus	106-109
11160860-9	2001	Moreover, immunoblotting analysis with paclitaxel-treated cell extract demonstrated that the conventional PKC isotype PKC-alpha was found to be involved in the regulation of paclitaxel-induced NF-kappaB activation, as determined by electrophoretic mobility shift of PKC.	Paclitaxel	174-184	protein kinase C, alpha	Mus musculus	118-127
11160860-9	2001	Moreover, immunoblotting analysis with paclitaxel-treated cell extract demonstrated that the conventional PKC isotype PKC-alpha was found to be involved in the regulation of paclitaxel-induced NF-kappaB activation, as determined by electrophoretic mobility shift of PKC.	Paclitaxel	174-184	protein kinase C, alpha	Mus musculus	118-121
11160860-10	2001	Therefore, these data suggest that paclitaxel may activate IKK-beta via conventional PKC isotypes, resulting in NF-kappaB activation and, finally, desensitization of LPS-inducible signaling pathway in 70Z/3 pre-B cells.	Paclitaxel	35-45	protein kinase C, alpha	Mus musculus	85-88
11160861-0	2001	Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells.	Paclitaxel	187-197	BCL2 apoptosis regulator	Homo sapiens	161-166
11212279-0	2001	Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.	Paclitaxel	18-28	TNF superfamily member 10	Homo sapiens	38-50
11208823-2	2001	HER2 overexpression is a potential indicator of responsiveness to doxorubicin and paclitaxel and of unresponsiveness to tamoxifen in breast carcinoma patients.	Paclitaxel	82-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
11180086-0	2001	Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy.	Paclitaxel	78-88	C-X-C motif chemokine ligand 8	Homo sapiens	0-13
11180086-1	2001	BACKGROUND: Paclitaxel has been described to induce interleukin-8 (IL-8) transcription and secretion in human ovarian carcinoma cells.	Paclitaxel	12-22	C-X-C motif chemokine ligand 8	Homo sapiens	52-65
11180086-1	2001	BACKGROUND: Paclitaxel has been described to induce interleukin-8 (IL-8) transcription and secretion in human ovarian carcinoma cells.	Paclitaxel	12-22	C-X-C motif chemokine ligand 8	Homo sapiens	67-71
11180086-2	2001	The objective of this study was to investigate possible clinical implications of the effect of paclitaxel on IL-8 serum levels in patients suffering from ovarian carcinoma.	Paclitaxel	95-105	C-X-C motif chemokine ligand 8	Homo sapiens	109-113
11180086-12	2001	CONCLUSIONS: The authors found a significant decrease in IL-8 serum levels in patients undergoing a paclitaxel-containing chemotherapy regimen, indicating that IL-8 possibly acts as a useful monitoring marker in patients with ovarian carcinoma.	Paclitaxel	100-110	C-X-C motif chemokine ligand 8	Homo sapiens	57-61
11180086-12	2001	CONCLUSIONS: The authors found a significant decrease in IL-8 serum levels in patients undergoing a paclitaxel-containing chemotherapy regimen, indicating that IL-8 possibly acts as a useful monitoring marker in patients with ovarian carcinoma.	Paclitaxel	100-110	C-X-C motif chemokine ligand 8	Homo sapiens	160-164
11212279-7	2001	Importantly, sequential treatment of PC-3, DU145, and LNCaP cells with paclitaxel followed by Apo-2L/TRAIL induced significantly more apoptosis than Apo-2L/TRAIL treatment alone (P &lt; 0.01).	Paclitaxel	71-81	TNF superfamily member 10	Homo sapiens	149-155
11212279-7	2001	Importantly, sequential treatment of PC-3, DU145, and LNCaP cells with paclitaxel followed by Apo-2L/TRAIL induced significantly more apoptosis than Apo-2L/TRAIL treatment alone (P &lt; 0.01).	Paclitaxel	71-81	TNF superfamily member 10	Homo sapiens	156-161
11212279-9	2001	These findings indicate that up-regulation of DR4 and DR5 protein levels by treatment with paclitaxel enhances subsequent Apo-2L/TRAIL-induced apoptosis of human prostate cancer cells.	Paclitaxel	91-101	TNF superfamily member 10	Homo sapiens	122-128
11313944-0	2001	Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.	Paclitaxel	0-5	mitogen-activated protein kinase 1	Homo sapiens	56-59
11212279-9	2001	These findings indicate that up-regulation of DR4 and DR5 protein levels by treatment with paclitaxel enhances subsequent Apo-2L/TRAIL-induced apoptosis of human prostate cancer cells.	Paclitaxel	91-101	TNF superfamily member 10	Homo sapiens	129-134
11313944-0	2001	Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.	Paclitaxel	0-5	mitogen-activated protein kinase 14	Homo sapiens	64-67
11313944-0	2001	Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.	Paclitaxel	0-5	tumor protein p53	Homo sapiens	91-94
11313944-2	2001	In order to analyse the molecular mechanisms of Taxol-induced cytotoxicity, we studied the involvement of mitogen-activated protein kinases (MAPK) ERK and p38 as well as the p53 pathways in Taxol-induced apoptosis.	Paclitaxel	190-195	mitogen-activated protein kinase 1	Homo sapiens	141-145
11313944-4	2001	We found that Taxol treatment strongly activated ERK, p38 MAP kinase and p53 in MAP kinase MCF7 cells prior to apoptosis.	Paclitaxel	14-19	mitogen-activated protein kinase 1	Homo sapiens	49-52
11313944-4	2001	We found that Taxol treatment strongly activated ERK, p38 MAP kinase and p53 in MAP kinase MCF7 cells prior to apoptosis.	Paclitaxel	14-19	mitogen-activated protein kinase 14	Homo sapiens	54-57
11313944-4	2001	We found that Taxol treatment strongly activated ERK, p38 MAP kinase and p53 in MAP kinase MCF7 cells prior to apoptosis.	Paclitaxel	14-19	tumor protein p53	Homo sapiens	73-76
11313944-8	2001	However, cells with inactivated p53, unlike cells harboring wild type p53, failed to arrest in G2/M after treatment with Taxol and continued to divide or go into apoptosis.	Paclitaxel	121-126	tumor protein p53	Homo sapiens	32-35
11313944-9	2001	Our data show that both ERK and p38 MAP kinase cascades are essential for apoptotic response to Taxol-induced cellular killing and are independent of p53 activity.	Paclitaxel	96-101	mitogen-activated protein kinase 1	Homo sapiens	24-27
11313944-9	2001	Our data show that both ERK and p38 MAP kinase cascades are essential for apoptotic response to Taxol-induced cellular killing and are independent of p53 activity.	Paclitaxel	96-101	mitogen-activated protein kinase 14	Homo sapiens	32-35
11313944-9	2001	Our data show that both ERK and p38 MAP kinase cascades are essential for apoptotic response to Taxol-induced cellular killing and are independent of p53 activity.	Paclitaxel	96-101	tumor protein p53	Homo sapiens	150-153
11313944-10	2001	However, p53 may serve as a survival factor in breast carcinoma cells treated with Taxol by blocking cells in G2/M phase of the cell cycle.	Paclitaxel	83-88	tumor protein p53	Homo sapiens	9-12
11139311-1	2001	Oral bioavailability of paclitaxel is very low, which is due to efficient transport of the drug by the intestinal drug efflux pump P-glycoprotein (P-gp).	Paclitaxel	24-34	ATP binding cassette subfamily B member 1	Homo sapiens	131-145
11139311-1	2001	Oral bioavailability of paclitaxel is very low, which is due to efficient transport of the drug by the intestinal drug efflux pump P-glycoprotein (P-gp).	Paclitaxel	24-34	ATP binding cassette subfamily B member 1	Homo sapiens	147-151
11521725-3	2001	Another phase II study of trastuzumab plus paclitaxel, both given weekly, in 63 HER2-positive and -negative patients with metastatic breast cancer produced an overall response rate of 62% in HER2-positive and 44% in HER2-negative patients.	Paclitaxel	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	80-84
11139311-2	2001	We have recently demonstrated that the oral bioavailability of paclitaxel can be increased at least 7-fold by co-administration of the P-gp blocker cyclosporin A (CsA).	Paclitaxel	63-73	ATP binding cassette subfamily B member 1	Homo sapiens	135-139
11244509-6	2001	p53 phosphorylation also varied in a MTI-dependent manner, as Taxol and Vincristine induced more p53 phospho-forms than nocodazole.	Paclitaxel	62-67	tumor protein p53	Homo sapiens	0-3
11244509-9	2001	Analysis of ectopically expressed p53 phospho-mutant proteins from Taxol- and nocodazole-treated cells indicated that multiple p53 amino terminal residues, including serine-15 and threonine-18, were required for Taxol-mediated phosphorylation of p53.	Paclitaxel	67-72	tumor protein p53	Homo sapiens	127-130
11244509-9	2001	Analysis of ectopically expressed p53 phospho-mutant proteins from Taxol- and nocodazole-treated cells indicated that multiple p53 amino terminal residues, including serine-15 and threonine-18, were required for Taxol-mediated phosphorylation of p53.	Paclitaxel	67-72	tumor protein p53	Homo sapiens	127-130
11244509-9	2001	Analysis of ectopically expressed p53 phospho-mutant proteins from Taxol- and nocodazole-treated cells indicated that multiple p53 amino terminal residues, including serine-15 and threonine-18, were required for Taxol-mediated phosphorylation of p53.	Paclitaxel	212-217	tumor protein p53	Homo sapiens	127-130
11244509-9	2001	Analysis of ectopically expressed p53 phospho-mutant proteins from Taxol- and nocodazole-treated cells indicated that multiple p53 amino terminal residues, including serine-15 and threonine-18, were required for Taxol-mediated phosphorylation of p53.	Paclitaxel	212-217	tumor protein p53	Homo sapiens	127-130
11521725-3	2001	Another phase II study of trastuzumab plus paclitaxel, both given weekly, in 63 HER2-positive and -negative patients with metastatic breast cancer produced an overall response rate of 62% in HER2-positive and 44% in HER2-negative patients.	Paclitaxel	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	191-195
11521725-3	2001	Another phase II study of trastuzumab plus paclitaxel, both given weekly, in 63 HER2-positive and -negative patients with metastatic breast cancer produced an overall response rate of 62% in HER2-positive and 44% in HER2-negative patients.	Paclitaxel	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	191-195
11352500-0	2001	Taxol induced Bcl-2 protein phosphorylation in human hepatocellular carcinoma QGY-7703 cell line.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	14-19
11269744-6	2001	Western blot analysis for Bcl-2 phosphorylation was carried out after 4 h and 24 h of exposure to cryptophycin 52, cryptophycin 55, paclitaxel or vinblastine.	Paclitaxel	132-142	BCL2 apoptosis regulator	Homo sapiens	26-31
11269744-8	2001	After 4 h of exposure, Bcl-2 phosphorylation was evident with 0.05 nM cryptophycin 52, 0.25 nM cryptophycin 55, 5 nM vinblastine and 50 nM paclitaxel.	Paclitaxel	139-149	BCL2 apoptosis regulator	Homo sapiens	23-28
11269744-9	2001	The hyperphosphorylated form of Bcl-2 was evident after 24 h exposure of H460 cells to 0.25 nM cryptophycin 52 or cryptophycin 55 and 50 nM vinblastine or paclitaxel.	Paclitaxel	155-165	BCL2 apoptosis regulator	Homo sapiens	32-37
11352500-2	2001	Treatment of a human hepatocellular carcinoma cell line, QGY-7703, with Taxol induced apoptosis and Bcl-2 protein phosphorylation.	Paclitaxel	72-77	BCL2 apoptosis regulator	Homo sapiens	100-105
11352500-4	2001	Bcl-2 protein was phosphorylated in Taxol-treated QGY cells within 3 h of treatment, and continued gradually up to 24 h. By 48 h, the protein was unphosphorylated.	Paclitaxel	36-41	BCL2 apoptosis regulator	Homo sapiens	0-5
11352500-7	2001	The inactivation of Bcl-2 protein phosphorylation could be one of the key mechanisms needed for the induction of apoptosis in Taxol-treated QGY cells.	Paclitaxel	126-131	BCL2 apoptosis regulator	Homo sapiens	20-25
11123270-2	2001	Taxol, which mimics the action of LPS on murine macrophages, induces signals via mouse TLR4-MD-2, but not via human TLR4-MD-2.	Paclitaxel	0-5	toll-like receptor 4	Mus musculus	87-91
11581576-0	2001	Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by Taxol.	Paclitaxel	103-108	toll-like receptor 4	Mus musculus	15-19
11581576-2	2001	The LPS-mimetic activity of Taxol is not observed in LPS-hyporesponsive C3H/HeJ mice which possess a point mutation in Toll-like receptor 4 (TLR4); therefore, TLR4 appears to be involved in both Taxol and LPS signaling.	Paclitaxel	28-33	toll-like receptor 4	Mus musculus	141-145
11581576-2	2001	The LPS-mimetic activity of Taxol is not observed in LPS-hyporesponsive C3H/HeJ mice which possess a point mutation in Toll-like receptor 4 (TLR4); therefore, TLR4 appears to be involved in both Taxol and LPS signaling.	Paclitaxel	28-33	toll-like receptor 4	Mus musculus	159-163
11581576-2	2001	The LPS-mimetic activity of Taxol is not observed in LPS-hyporesponsive C3H/HeJ mice which possess a point mutation in Toll-like receptor 4 (TLR4); therefore, TLR4 appears to be involved in both Taxol and LPS signaling.	Paclitaxel	195-200	toll-like receptor 4	Mus musculus	159-163
11464447-7	2001	Currently, Trastuzumab and paclitaxel is the only combination indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2.	Paclitaxel	27-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
11581576-5	2001	Our results demonstrated that co-expression of mouse TLR4 and mouse MD-2 was required for Taxol responsiveness, and that the TLR4/MD-2 complex is the shared molecule in Taxol and LPS signal transduction in mice.	Paclitaxel	90-95	toll-like receptor 4	Mus musculus	53-57
11581576-5	2001	Our results demonstrated that co-expression of mouse TLR4 and mouse MD-2 was required for Taxol responsiveness, and that the TLR4/MD-2 complex is the shared molecule in Taxol and LPS signal transduction in mice.	Paclitaxel	169-174	toll-like receptor 4	Mus musculus	125-129
11891611-0	2001	Technetium-99m tetrofosmin chest imaging related to p-glycoprotein expression for predicting the response with paclitaxel-based chemotherapy for non-small cell lung cancer.	Paclitaxel	111-121	ATP binding cassette subfamily B member 1	Homo sapiens	52-66
11123339-5	2001	Induction of the entire panel of genes in response to low concentrations of LPS or Taxol requires the participation of both CD14 and TLR4, whereas high concentrations of LPS or Taxol elicit the expression of a subset of LPS-inducible genes in the absence of CD14.	Paclitaxel	83-88	toll-like receptor 4	Mus musculus	133-137
11123339-6	2001	In contrast, for optimal induction of COX-2, IL-12 p35, and IL-12 p40 genes by low concentrations of LPS or by all concentrations of Taxol, CD11b/CD18 was also required.	Paclitaxel	133-138	integrin alpha M	Mus musculus	140-145
11123339-6	2001	In contrast, for optimal induction of COX-2, IL-12 p35, and IL-12 p40 genes by low concentrations of LPS or by all concentrations of Taxol, CD11b/CD18 was also required.	Paclitaxel	133-138	integrin beta 2	Mus musculus	146-150
11123339-7	2001	Mitigated induction of COX-2, IL-12 p35, and IL-12 p40 gene expression by CD11b/CD18-deficient macrophages correlated with a marked inhibition of NF-kappa B nuclear translocation and mitogen-activated protein kinase (MAPK) activation in response to Taxol and of NF-kappa B nuclear translocation in response to LPS.	Paclitaxel	249-254	integrin alpha M	Mus musculus	74-79
11123339-7	2001	Mitigated induction of COX-2, IL-12 p35, and IL-12 p40 gene expression by CD11b/CD18-deficient macrophages correlated with a marked inhibition of NF-kappa B nuclear translocation and mitogen-activated protein kinase (MAPK) activation in response to Taxol and of NF-kappa B nuclear translocation in response to LPS.	Paclitaxel	249-254	integrin beta 2	Mus musculus	80-84
11123339-8	2001	These findings suggest that for expression of a full repertoire of LPS-/Taxol-inducible genes, CD14, TLR4, and CD11b/CD18 must be coordinately engaged to deliver optimal signaling to the macrophage.	Paclitaxel	72-77	toll-like receptor 4	Mus musculus	101-105
11123339-8	2001	These findings suggest that for expression of a full repertoire of LPS-/Taxol-inducible genes, CD14, TLR4, and CD11b/CD18 must be coordinately engaged to deliver optimal signaling to the macrophage.	Paclitaxel	72-77	integrin alpha M	Mus musculus	111-116
11123339-8	2001	These findings suggest that for expression of a full repertoire of LPS-/Taxol-inducible genes, CD14, TLR4, and CD11b/CD18 must be coordinately engaged to deliver optimal signaling to the macrophage.	Paclitaxel	72-77	integrin beta 2	Mus musculus	117-121
11200057-0	2001	Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation.	Paclitaxel	50-60	transforming growth factor beta 1	Homo sapiens	19-27
11200057-1	2001	Paclitaxel (TAXOL) activates in vitro macrophage (Mo) expression of proinflammatory and cytotoxic mediators, including IL-12, tumor necrosis factor alpha (TNF-alpha), and nitric oxide (NO).	Paclitaxel	0-10	tumor necrosis factor	Homo sapiens	126-153
11200057-1	2001	Paclitaxel (TAXOL) activates in vitro macrophage (Mo) expression of proinflammatory and cytotoxic mediators, including IL-12, tumor necrosis factor alpha (TNF-alpha), and nitric oxide (NO).	Paclitaxel	0-10	tumor necrosis factor	Homo sapiens	155-164
11200057-1	2001	Paclitaxel (TAXOL) activates in vitro macrophage (Mo) expression of proinflammatory and cytotoxic mediators, including IL-12, tumor necrosis factor alpha (TNF-alpha), and nitric oxide (NO).	Paclitaxel	12-17	tumor necrosis factor	Homo sapiens	126-153
11200057-4	2001	Tumor cell-derived supernatant suppressed paclitaxel"s capacity to induce IL-12, TNF-alpha, and NO production by RAW264.7 Mo.	Paclitaxel	42-52	tumor necrosis factor	Homo sapiens	81-90
11200057-6	2001	Depletion studies revealed that IL-10 and transforming growth factor-beta1 (TGF-beta1), but not prostaglandin E2 (PGE2), impaired paclitaxel-mediated activation, suggesting that abrogation of these factors in situ might restore paclitaxel"s activating capacity and enhance anti-tumor efficacy.	Paclitaxel	130-140	transforming growth factor beta 1	Homo sapiens	42-74
11200057-6	2001	Depletion studies revealed that IL-10 and transforming growth factor-beta1 (TGF-beta1), but not prostaglandin E2 (PGE2), impaired paclitaxel-mediated activation, suggesting that abrogation of these factors in situ might restore paclitaxel"s activating capacity and enhance anti-tumor efficacy.	Paclitaxel	130-140	transforming growth factor beta 1	Homo sapiens	76-85
11200057-6	2001	Depletion studies revealed that IL-10 and transforming growth factor-beta1 (TGF-beta1), but not prostaglandin E2 (PGE2), impaired paclitaxel-mediated activation, suggesting that abrogation of these factors in situ might restore paclitaxel"s activating capacity and enhance anti-tumor efficacy.	Paclitaxel	228-238	transforming growth factor beta 1	Homo sapiens	42-74
11200057-6	2001	Depletion studies revealed that IL-10 and transforming growth factor-beta1 (TGF-beta1), but not prostaglandin E2 (PGE2), impaired paclitaxel-mediated activation, suggesting that abrogation of these factors in situ might restore paclitaxel"s activating capacity and enhance anti-tumor efficacy.	Paclitaxel	228-238	transforming growth factor beta 1	Homo sapiens	76-85
11123339-0	2001	CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression.	Paclitaxel	106-111	integrin alpha M	Mus musculus	0-5
11123339-0	2001	CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression.	Paclitaxel	106-111	integrin beta 2	Mus musculus	6-10
11891611-11	2001	Because Tc-TF chest images can correctly represent the expression of Pgp in NSCLC, it can accurately predict the chemotherapeutic response to paclitaxel.	Paclitaxel	142-152	ATP binding cassette subfamily B member 1	Homo sapiens	69-72
11007785-10	2000	Consistent with these results, localization of the fluorescent K-Ras fusion protein remained paclitaxel-sensitive in cells lacking Rce1, whereas no paclitaxel effect was observed in cells lacking the methyltransferase.	Paclitaxel	93-103	Ras converting CAAX endopeptidase 1	Homo sapiens	131-135
11326311-0	2001	Cisplatinum and taxol induce different patterns of p53 phosphorylation.	Paclitaxel	16-21	tumor protein p53	Homo sapiens	51-54
11326311-1	2001	Posttranslational modifications of p53 induced by two widely used anticancer agents, cisplatinum (DDP) and taxol were investigated in two human cancer cell lines.	Paclitaxel	107-112	tumor protein p53	Homo sapiens	35-38
11326318-2	2001	Phosphorylation of the Bcl-2 protein is induced on serine residues in tumor cells arrested by microtubule-targeting drugs (paclitaxel, vincristine, nocodazole) and has been associated with inactivation of antiapoptotic function through an unknown mechanism.	Paclitaxel	123-133	BCL2 apoptosis regulator	Homo sapiens	23-28
11694787-5	2001	In a phase II study of weekly paclitaxel plus Herceptin in patients with normal or increased tumor HER2 levels, a response was observed in 60% of patients and the regimen was well tolerated.	Paclitaxel	30-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
11156247-7	2000	Treatment with paclitaxel and C225 down-regulated the expression of basic fibroblast growth factor, vascular endothelial cell growth factor, interleukin-8, and matrix metalloproteinase type 9 and inhibited tumor-induced neovascularity compared with untreated controls (P &lt; 0.005).	Paclitaxel	15-25	C-X-C motif chemokine ligand 8	Homo sapiens	141-154
11038347-0	2000	MEK inhibition enhances paclitaxel-induced tumor apoptosis.	Paclitaxel	24-34	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
11038347-2	2000	Previously, we and others found that paclitaxel activates endogenous JNK in tumor cells, and the activation of JNK contributes to tumor cell apoptosis.	Paclitaxel	37-47	mitogen-activated protein kinase 8	Homo sapiens	69-72
11038347-3	2000	Here we find that paclitaxel activates the prosurvival MEK/ERK pathway, which conversely may compromise the efficacy of paclitaxel.	Paclitaxel	18-28	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
11038347-3	2000	Here we find that paclitaxel activates the prosurvival MEK/ERK pathway, which conversely may compromise the efficacy of paclitaxel.	Paclitaxel	18-28	mitogen-activated protein kinase 1	Homo sapiens	59-62
11038347-3	2000	Here we find that paclitaxel activates the prosurvival MEK/ERK pathway, which conversely may compromise the efficacy of paclitaxel.	Paclitaxel	120-130	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
11038347-3	2000	Here we find that paclitaxel activates the prosurvival MEK/ERK pathway, which conversely may compromise the efficacy of paclitaxel.	Paclitaxel	120-130	mitogen-activated protein kinase 1	Homo sapiens	59-62
11175336-11	2000	Additionally, the human prostate cancer cell line, LNCaP, also formed nuclear Bax/p53 complexes only after apoptosis was induced by paclitaxel.	Paclitaxel	132-142	BCL2 associated X, apoptosis regulator	Homo sapiens	78-81
11175336-11	2000	Additionally, the human prostate cancer cell line, LNCaP, also formed nuclear Bax/p53 complexes only after apoptosis was induced by paclitaxel.	Paclitaxel	132-142	tumor protein p53	Homo sapiens	82-85
11716437-0	2000	A model for the interaction of paclitaxel with the Bcl-2 loop domain: a chemical approach to induce conformation-dependent phosphorylation.	Paclitaxel	31-41	BCL2 apoptosis regulator	Homo sapiens	51-56
11716437-2	2000	Paclitaxel and baccatin III were individually docked into the Bcl-2 loop domain.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	62-67
11716437-5	2000	It was found that both paclitaxel"s core skeleton and its C-13 side chain contribute significantly to its interaction with Bcl-2.	Paclitaxel	23-33	BCL2 apoptosis regulator	Homo sapiens	123-128
11716437-6	2000	A portion of the Bcl-2 loop domain was found to be locked by the bound paclitaxel and baccatin III in a similar conformation.	Paclitaxel	71-81	BCL2 apoptosis regulator	Homo sapiens	17-22
11104578-6	2000	Results unambiguously indicate the exceptional activity of the novel taxanes toward P-gp positive cells (up to &gt;400 fold higher potency than that of paclitaxel).	Paclitaxel	152-162	ATP binding cassette subfamily B member 1	Homo sapiens	84-88
11102737-15	2000	The taxanes paclitaxel and docetaxel are considered excellent substrate drugs to test the concept that by inhibition of P-gp in the gut wall and CYP activity in gut wall and/or liver low oral bioavailability can be increased substantially.	Paclitaxel	12-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-148
12845342-4	2000	Overexpression of HER-2/neu leads to elevated tumorigenicity, enhanced metastatic potential, increased resistance to TNF-alpha-induced apoptosis and resistance to treatments such as paclitaxel and tamoxifen.	Paclitaxel	182-192	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-27
11205313-3	2000	RESULTS: The techniques used herein determined accumulation of paclitaxel/PSC 833 induced apoptotic cells with sub-G0 (hypodiploid) DNA content and blocked in the G2/M phase of the cell cycle, internucleosomal DNA fragmentation, poly (ADP-ribose) polymerase cleavage, Bcl-2 modulation and Bax up-regulation, without any significant alterations in the levels of Bcl-xL, CD95/Fas or Fas-L proteins.	Paclitaxel	63-73	BCL2 associated X, apoptosis regulator	Homo sapiens	289-292
11123425-5	2000	Apoptosis induced by a chemotherapeutic agent, 5-fluorouracil, mitomycin C, paclitaxel, doxorubicin, or cisplatin, was enhanced by Bax overexpression.	Paclitaxel	76-86	BCL2 associated X, apoptosis regulator	Homo sapiens	131-134
11236027-8	2000	A phase II trial, reviewed in this report, evaluated the efficacy and safety of weekly paclitaxel plus trastuzumab for patients with metastatic breast carcinoma, including those overexpressing and nonoverexpressing HER-2.	Paclitaxel	87-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	215-220
11099323-2	2000	Because taxanes could induce p53-independent apoptosis, we assessed the relevance of p53 gene status to response in ovarian carcinoma patients receiving paclitaxel and platinum-containing chemotherapy.	Paclitaxel	153-163	tumor protein p53	Homo sapiens	85-88
11099323-14	2000	CONCLUSION: In contrast to the limited efficacy of treatment with paclitaxel in combination with standard platinum doses against wild-type p53 ovarian tumors, patients with mutant p53 ovarian tumors were more responsive to paclitaxel-based chemotherapy.	Paclitaxel	66-76	tumor protein p53	Homo sapiens	139-142
11099323-14	2000	CONCLUSION: In contrast to the limited efficacy of treatment with paclitaxel in combination with standard platinum doses against wild-type p53 ovarian tumors, patients with mutant p53 ovarian tumors were more responsive to paclitaxel-based chemotherapy.	Paclitaxel	223-233	tumor protein p53	Homo sapiens	180-183
11205220-1	2000	BACKGROUND: The aim of this study was to assess the relationship between p53 status and the clinical outcome of patients with advanced ovarian cancer treated with a paclitaxel-based regimen.	Paclitaxel	165-175	tumor protein p53	Homo sapiens	73-76
11205220-9	2000	These results are consistent with experimental data showing that paclitaxel cytotoxicity in ovarian cancer is likely to be mediated by a p53-independent pathway.	Paclitaxel	65-75	tumor protein p53	Homo sapiens	137-140
11205313-1	2000	BACKGROUND: The non-immunosuppressive cyclosporine analog PSC 833 has been shown to reverse multidrug-resistance of neoplastic cells including the MDR-1 gene coded P-glycoprotein (P-gp)-mediated cells resistant to paclitaxel.	Paclitaxel	214-224	ATP binding cassette subfamily B member 1	Homo sapiens	147-152
11205313-1	2000	BACKGROUND: The non-immunosuppressive cyclosporine analog PSC 833 has been shown to reverse multidrug-resistance of neoplastic cells including the MDR-1 gene coded P-glycoprotein (P-gp)-mediated cells resistant to paclitaxel.	Paclitaxel	214-224	ATP binding cassette subfamily B member 1	Homo sapiens	164-178
11205313-1	2000	BACKGROUND: The non-immunosuppressive cyclosporine analog PSC 833 has been shown to reverse multidrug-resistance of neoplastic cells including the MDR-1 gene coded P-glycoprotein (P-gp)-mediated cells resistant to paclitaxel.	Paclitaxel	214-224	ATP binding cassette subfamily B member 1	Homo sapiens	180-184
11205313-3	2000	RESULTS: The techniques used herein determined accumulation of paclitaxel/PSC 833 induced apoptotic cells with sub-G0 (hypodiploid) DNA content and blocked in the G2/M phase of the cell cycle, internucleosomal DNA fragmentation, poly (ADP-ribose) polymerase cleavage, Bcl-2 modulation and Bax up-regulation, without any significant alterations in the levels of Bcl-xL, CD95/Fas or Fas-L proteins.	Paclitaxel	63-73	BCL2 like 1	Homo sapiens	361-367
11205313-3	2000	RESULTS: The techniques used herein determined accumulation of paclitaxel/PSC 833 induced apoptotic cells with sub-G0 (hypodiploid) DNA content and blocked in the G2/M phase of the cell cycle, internucleosomal DNA fragmentation, poly (ADP-ribose) polymerase cleavage, Bcl-2 modulation and Bax up-regulation, without any significant alterations in the levels of Bcl-xL, CD95/Fas or Fas-L proteins.	Paclitaxel	63-73	BCL2 apoptosis regulator	Homo sapiens	268-273
11205313-4	2000	CONCLUSION: Drug resistance modulator PSC 833 abolished the P-gp-mediated multidrug-resistance to paclitaxel and paclitaxel-induced apoptosis in human myeloid leukemia (HL-60/VCR) cells in vitro.	Paclitaxel	98-108	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
11205313-4	2000	CONCLUSION: Drug resistance modulator PSC 833 abolished the P-gp-mediated multidrug-resistance to paclitaxel and paclitaxel-induced apoptosis in human myeloid leukemia (HL-60/VCR) cells in vitro.	Paclitaxel	113-123	ATP binding cassette subfamily B member 1	Homo sapiens	60-64
11129289-4	2000	Paclitaxel was chosen for combination therapy in the preclinical study reported here due to its extensive use as a first-line therapy in ovarian cancer, its synergy with SCH58500 in preclinical cancer models, and its activation of p53-independent apoptosis, which might result in a "lowered threshold" for tumor cell death.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	231-234
11064345-0	2000	Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53.	Paclitaxel	74-84	tumor protein p53	Homo sapiens	123-126
11064345-1	2000	BACKGROUND: The current study was undertaken to investigate the influence of wild-type or mutant p53 status on the radiosensitizing effect of paclitaxel in colorectal tumor cell lines.	Paclitaxel	142-152	tumor protein p53	Homo sapiens	97-100
11235561-0	2000	[The role of bcl-2 gene family in taxol-mediated apoptosis in BJAB B cell lymphoma cell line].	Paclitaxel	34-39	BCL2 apoptosis regulator	Homo sapiens	13-18
11106232-2	2000	In experimental systems, hormonal agents, including megestrol acetate (MA), have been shown to be capable of reversing P-glycoprotein-mediated multidrug resistance to natural products, including paclitaxel.	Paclitaxel	195-205	ATP binding cassette subfamily B member 1	Homo sapiens	119-133
11106232-10	2000	Although pharmacokinetic studies were not performed as a component of this study, prior evaluation of MA pharmacokinetics and in vitro data examining the concentrations of the agent required to reverse P-glycoprotein-mediated paclitaxel resistance suggest that the majority of our patient population achieved levels of MA theoretically capable of producing this desired effect.	Paclitaxel	226-236	ATP binding cassette subfamily B member 1	Homo sapiens	202-216
11054675-5	2000	Activity increased significantly, and Western immunoblots for caspase-3 in conditioned media showed that the inactive precursor decreased after incubation with paclitaxel.	Paclitaxel	160-170	caspase 3	Homo sapiens	62-71
11235561-7	2000	The expression of bcl-2 at mRNA and protion level was decreased while that of bcl-xs transcription was increased after taxol treatment.	Paclitaxel	119-124	BCL2 apoptosis regulator	Homo sapiens	18-23
11218898-7	2000	Under effect of Taxol 5 ng/ml, the relative percents of drug-resistant colony in mdr1-ASON treated SKOV3/mdr1 cells and in SKOV3/mdr1 cells was 8% and 63%, respectively, (P &lt; 0.01).	Paclitaxel	16-21	ATP binding cassette subfamily B member 1	Homo sapiens	81-85
11235561-9	2000	Bcl-2 and bcl-xs are involved in the regulation of taxol-induced apoptosis.	Paclitaxel	51-56	BCL2 apoptosis regulator	Homo sapiens	0-5
11227215-0	2000	Bcl-2 protects neuronal cells against taxol-induced apoptosis by inducing multi-nucleation.	Paclitaxel	38-43	BCL2, apoptosis regulator	Rattus norvegicus	0-5
11054569-3	2000	MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector.	Paclitaxel	130-135	RAB6C, member RAS oncogene family	Homo sapiens	41-46
11045764-12	2000	Clonogenic assays showed that Ad5CMV-p21 reduced the sensitivity of MDA-MB-231 to VP-16 and paclitaxel.	Paclitaxel	92-102	cyclin dependent kinase inhibitor 1A	Homo sapiens	37-40
11227215-4	2000	It is shown that PC12 cells that stably overexpress Bcl-2 are protected against the toxic effect of taxol, as evidenced by the XTT assay and by a decreased fraction of propididum iodide positive cells in a dye exclusion test.	Paclitaxel	100-105	BCL2, apoptosis regulator	Rattus norvegicus	52-57
11227215-7	2000	Although taxol forced both wild-type and Bcl-2-overexpressing cells into a mitotic state, only in Bcl-2-overexpressing cells did this lead to the appearance of metabolically active, multi-nucleated cells.	Paclitaxel	9-14	BCL2, apoptosis regulator	Rattus norvegicus	41-46
11227215-8	2000	This suggests that Bcl-2 is able to induce an alternative escape pathway, downstream of the G2/M block, in taxol-treated differentiated PC12 cells.	Paclitaxel	107-112	BCL2, apoptosis regulator	Rattus norvegicus	19-24
11034077-0	2000	The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.	Paclitaxel	152-162	cyclin dependent kinase inhibitor 1A	Homo sapiens	117-121
11097380-1	2000	Cytotoxic effects of cyclophosphamide (CPA), paclitaxel (PCT), and docetaxel (DTX) and their modulation by cytochrome P450 (CYP) metabolism were studied by incubating cell lines L929 and P388D1 with or without rat liver microsomes.	Paclitaxel	45-55	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	124-127
11097380-1	2000	Cytotoxic effects of cyclophosphamide (CPA), paclitaxel (PCT), and docetaxel (DTX) and their modulation by cytochrome P450 (CYP) metabolism were studied by incubating cell lines L929 and P388D1 with or without rat liver microsomes.	Paclitaxel	57-60	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	107-122
11034077-0	2000	The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.	Paclitaxel	152-162	cyclin dependent kinase inhibitor 1A	Homo sapiens	122-126
11034069-0	2000	Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells".	Paclitaxel	0-10	cytochrome c, somatic	Homo sapiens	30-42
11034077-2	2000	A2780 human ovarian carcinoma cells, which are sensitive to cisplatin and paclitaxel, express wild-type p53 and exhibit a p53-mediated increase in p21 in response to the chemotherapeutic agents.	Paclitaxel	74-84	tumor protein p53	Homo sapiens	122-125
11034069-4	2000	In isolated neuroblas toma mitochondria, paclitaxel (10-100 microM) induced a 27-72% release o cytochrome c.	Paclitaxel	41-51	cytochrome c, somatic	Homo sapiens	95-107
11034077-3	2000	Here, we demonstrate that phosphatidylinositol 3-kinase (PI3K) and its downstream targets serine/threonine kinases AKT1 and AKT2 (AKT), are required for the full induction of p21 in A2780 cells treated with cisplatin or paclitaxel.	Paclitaxel	220-230	cyclin dependent kinase inhibitor 1A	Homo sapiens	175-178
11034077-6	2000	Experiments with additional ovarian carcinoma cell lines revealed that PI3K is involved in the expression of p21 induced by cisplatin or paclitaxel in OVCAR-10 cells, which have wild-type p53, but not in OVCAR-5 cells, which lack functional p53.	Paclitaxel	137-147	cyclin dependent kinase inhibitor 1A	Homo sapiens	109-112
11051254-2	2000	Furthermore, posttranslational modification of moderately expressed endogenous Bcl-2 has been correlated with susceptibility to paclitaxel treatment in vitro.	Paclitaxel	128-138	BCL2 apoptosis regulator	Homo sapiens	79-84
11051254-8	2000	The median survival time from initiation of paclitaxel therapy for patients with low Bcl-2 expression was 663 days (95% CI, 456-1119 days) and was not significantly different than the 450 days (95% CI, 239-1058 days) observed for patients with high Bcl-2 expression.	Paclitaxel	44-54	BCL2 apoptosis regulator	Homo sapiens	85-90
11192826-0	2000	Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer.	Paclitaxel	139-144	vascular endothelial growth factor A	Homo sapiens	50-84
11899648-1	2000	This study assesses the potential value of the tumor markers p53, HER2, and Bcl-2 in predicting the clinical response to doxorubicin and paclitaxel as single agents in the treatment of metastatic breast cancer.	Paclitaxel	137-147	tumor protein p53	Homo sapiens	61-64
11899648-1	2000	This study assesses the potential value of the tumor markers p53, HER2, and Bcl-2 in predicting the clinical response to doxorubicin and paclitaxel as single agents in the treatment of metastatic breast cancer.	Paclitaxel	137-147	BCL2 apoptosis regulator	Homo sapiens	76-81
11192826-4	2000	In experimental conditions, chemotherapeutic agents such as taxol appeared to inhibit VEGF-induced angiogenesis, while at present there are no data about the influence of chemotherapy on VEGF secretion in cancer patients.	Paclitaxel	60-65	vascular endothelial growth factor A	Homo sapiens	86-90
11192826-5	2000	This preliminary study was performed to evaluate the effect of taxol therapy on VEGF secretion in advanced cancer patients in relation to the clinical response.	Paclitaxel	63-68	vascular endothelial growth factor A	Homo sapiens	80-84
11192826-11	2000	VEGF mean values significantly decreased during taxol therapy in patients with PR or SD, whereas no decline was observed in patients with PD.	Paclitaxel	48-53	vascular endothelial growth factor A	Homo sapiens	0-4
11192826-0	2000	Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer.	Paclitaxel	139-144	vascular endothelial growth factor A	Homo sapiens	86-90
11192826-13	2000	This preliminary study would suggest that the efficacy of taxol therapy in metastatic breast cancer - at least in terms of disease stabilization - may be associated with a decrease in VEGF blood levels followed by potential inhibition of cancer-related neovascularization.	Paclitaxel	58-63	vascular endothelial growth factor A	Homo sapiens	184-188
10962577-0	2000	Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide.	Paclitaxel	0-10	NFKB inhibitor alpha	Homo sapiens	98-110
11025661-2	2000	Treatment with vincristine or paclitaxel before DNA-damage or before leptomycin B treatment reduces nuclear accumulation of p53 and expression of mdm2 and p21.	Paclitaxel	30-40	tumor protein p53	Homo sapiens	124-127
11016645-10	2000	This Taxol-mediated serine phosphorylation seen in p66shc may result from a MEK-independent signaling pathway that is activated in cells that have a prolonged or abnormal mitotic phase of the cell cycle and may play a role in signaling events that lead to cell death.	Paclitaxel	5-10	mitogen-activated protein kinase kinase 7	Homo sapiens	76-79
10976921-2	2000	To investigate this, we subjected estrogen receptor-expressing human breast cancer cells (MCF-7 and ZR-75-1) to paclitaxel (taxol) or to UV irradiation.	Paclitaxel	112-122	estrogen receptor 1	Homo sapiens	34-51
10976921-2	2000	To investigate this, we subjected estrogen receptor-expressing human breast cancer cells (MCF-7 and ZR-75-1) to paclitaxel (taxol) or to UV irradiation.	Paclitaxel	124-129	estrogen receptor 1	Homo sapiens	34-51
10976921-4	2000	Taxol or UV stimulated c-Jun N-terminal kinase (JNK) activity, which was inhibited by E2.	Paclitaxel	0-5	mitogen-activated protein kinase 8	Homo sapiens	23-46
10976921-4	2000	Taxol or UV stimulated c-Jun N-terminal kinase (JNK) activity, which was inhibited by E2.	Paclitaxel	0-5	mitogen-activated protein kinase 8	Homo sapiens	48-51
10976921-5	2000	Expression of a dominant-negative Jnk-1 protein strongly prevented taxol- or UV-induced apoptosis, whereas E2 inhibition of apoptosis was reversed by expression of constituitively active Jnk-1.	Paclitaxel	67-72	mitogen-activated protein kinase 8	Homo sapiens	34-39
10976921-6	2000	As targets for participation in apoptosis, Bcl-2 and Bcl-xl were phosphorylated in response to JNK activation by taxol or UV; this was prevented by E2.	Paclitaxel	113-118	BCL2 apoptosis regulator	Homo sapiens	43-48
10976921-6	2000	As targets for participation in apoptosis, Bcl-2 and Bcl-xl were phosphorylated in response to JNK activation by taxol or UV; this was prevented by E2.	Paclitaxel	113-118	BCL2 like 1	Homo sapiens	53-59
10976921-6	2000	As targets for participation in apoptosis, Bcl-2 and Bcl-xl were phosphorylated in response to JNK activation by taxol or UV; this was prevented by E2.	Paclitaxel	113-118	mitogen-activated protein kinase 8	Homo sapiens	95-98
10976921-7	2000	Taxol or UV activated caspase activity in a JNK-dependent fashion and caused the cleavage of procaspase-9 to caspase-9, each inhibited by E2.	Paclitaxel	0-5	mitogen-activated protein kinase 8	Homo sapiens	44-47
10956385-8	2000	In addition, when paclitaxel-induced apoptosis was inhibited by Bcl-2 over-expression, cdc2 up-regulation did not occur, leading to a lower level of activation of the cyclin B/cdc2 complex.	Paclitaxel	18-28	BCL2 apoptosis regulator	Homo sapiens	64-69
10996845-0	2000	Taxol reduces cytosolic E-cadherin and beta-catenin levels in nasopharyngeal carcinoma cell line TW-039: cross-talk between the microtubule- and actin-based cytoskeletons.	Paclitaxel	0-5	cadherin 1	Homo sapiens	24-34
10996845-2	2000	To obtain a better insight into possible cross-talk between the microtubule- and actin-based cytoskeletons, we studied the short-term effects of Taxol treatment on the expression of actin and the E-cadherin/catenin complex in the nasopharyngeal carcinoma cell line TW-039 using immunofluorescence, immunoprecipitation, and immunoblotting methods.	Paclitaxel	145-150	cadherin 1	Homo sapiens	196-206
10996845-4	2000	Levels of detergent-soluble E-cadherin fell to 53% or 58% compared to controls in cells treated, respectively, with 1 or 5 microM Taxol, while levels of detergent-soluble beta-catenin fell to 76% or 74%.	Paclitaxel	130-135	cadherin 1	Homo sapiens	28-38
10996845-6	2000	These results suggest that modulation of microtubule dynamics by Taxol may have effects on the expression of actin and the cytosolic E-cadherin and beta-catenin in nasopharyngeal carcinoma cells through pathways not involving the phosphorylation of beta-catenin.	Paclitaxel	65-70	cadherin 1	Homo sapiens	133-143
11970748-6	2000	Survival was improved under the following circumstances: (1) when 4 cycles of paclitaxel (175 mg/m2 every 3 weeks) was given following 4 cycles of conventional doxorubicin- cyclophosphamide for axillary node-positive operable breast cancer, (2) when trastuzumab was added to paclitaxel as first-line therapy for metastatic breast cancer that overexpressed HER2/neu, and (3) when docetaxel was given as second-line therapy for anthracycline-resistant disease.	Paclitaxel	78-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	356-360
11970748-6	2000	Survival was improved under the following circumstances: (1) when 4 cycles of paclitaxel (175 mg/m2 every 3 weeks) was given following 4 cycles of conventional doxorubicin- cyclophosphamide for axillary node-positive operable breast cancer, (2) when trastuzumab was added to paclitaxel as first-line therapy for metastatic breast cancer that overexpressed HER2/neu, and (3) when docetaxel was given as second-line therapy for anthracycline-resistant disease.	Paclitaxel	78-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	361-364
10974635-1	2000	We conducted this study to determine whether the sensitivity of ovarian cancer cells to paclitaxel (PTX) relates to cells undergoing p53-dependent apoptosis.	Paclitaxel	88-98	tumor protein p53	Homo sapiens	133-136
10974635-1	2000	We conducted this study to determine whether the sensitivity of ovarian cancer cells to paclitaxel (PTX) relates to cells undergoing p53-dependent apoptosis.	Paclitaxel	100-103	tumor protein p53	Homo sapiens	133-136
10974635-3	2000	In SK-OV-3 and KP cells, which have a homozygous deletion of the TP53 gene, wild-type TP53 gene-transduction markedly enhanced the sensitivity to cisplatin (CDDP), but did not enhance the sensitivity to PTX.	Paclitaxel	203-206	tumor protein p53	Homo sapiens	65-69
10974635-3	2000	In SK-OV-3 and KP cells, which have a homozygous deletion of the TP53 gene, wild-type TP53 gene-transduction markedly enhanced the sensitivity to cisplatin (CDDP), but did not enhance the sensitivity to PTX.	Paclitaxel	203-206	tumor protein p53	Homo sapiens	86-90
11070791-4	2000	Restoration of p53 protein function in LN382 cells at 34 degrees C reduced the cytotoxicity of etoposide and paclitaxel, whereas that of cisplatin and ACNU was not affected.	Paclitaxel	109-119	tumor protein p53	Homo sapiens	15-18
11070791-8	2000	These results indicate that cell cycle arrest induced by wild-type p53 function may abrogate the cytotoxic effects of etoposide and paclitaxel, which are dependent on G2M-associated apoptosis.	Paclitaxel	132-142	tumor protein p53	Homo sapiens	67-70
10962577-7	2000	We also demonstrate that NF-kappaB-inducible genes protect cancer cells against paclitaxel as MDA-MB-231 breast cancer cells modified to overexpress IkappaBalpha required lower concentrations of paclitaxel to arrest at the G2/M phase of the cell cycle and undergo apoptosis when compared to parental cells.	Paclitaxel	80-90	NFKB inhibitor alpha	Homo sapiens	149-161
10962577-7	2000	We also demonstrate that NF-kappaB-inducible genes protect cancer cells against paclitaxel as MDA-MB-231 breast cancer cells modified to overexpress IkappaBalpha required lower concentrations of paclitaxel to arrest at the G2/M phase of the cell cycle and undergo apoptosis when compared to parental cells.	Paclitaxel	195-205	NFKB inhibitor alpha	Homo sapiens	149-161
10962577-9	2000	Parthenolide, an active ingredient of herbal remedies such as feverfew (tanacetum parthenium), mimicked the effects of IkappaBalpha by inhibiting NF-kappaB DNA binding activity and Mn-SOD expression, and increasing paclitaxel-induced apoptosis of breast cancer cells.	Paclitaxel	215-225	NFKB inhibitor alpha	Homo sapiens	119-131
10791955-6	2000	MIP-T3 binds to Taxol-stabilized microtubules and to tubulin in vitro, and MIP-T3 recruits TRAF3 to microtubules when both proteins are overexpressed in HeLa cells.	Paclitaxel	16-21	TRAF3 interacting protein 1	Homo sapiens	0-6
10918072-6	2000	Here, we report an increased directional transport of several MDR1 P-glycoprotein substrates, such as digoxin, paclitaxel, and vinblastine, through polarized monolayers of MDR3-transfected cells.	Paclitaxel	111-121	ATP binding cassette subfamily B member 1	Homo sapiens	62-66
10918072-6	2000	Here, we report an increased directional transport of several MDR1 P-glycoprotein substrates, such as digoxin, paclitaxel, and vinblastine, through polarized monolayers of MDR3-transfected cells.	Paclitaxel	111-121	ATP binding cassette subfamily B member 1	Homo sapiens	67-81
10993958-5	2000	Additional cell loss occurred in 40-16 and HCT116 p53-/- cells following administration of Taxol before IR and 5-FU.	Paclitaxel	91-96	tumor protein p53	Homo sapiens	50-53
10951339-9	2000	The 1-year survival rates for patients with and without p53 mutation after treatment with weekly paclitaxel were 63% (95% confidence interval [CI], 31-100%) and 53% (95% CI, 33-86%), respectively.	Paclitaxel	97-107	tumor protein p53	Homo sapiens	56-59
10951339-11	2000	These results provide clinical support for in vitro observations that paclitaxel can bypass mutant p53 and lead to tumor cell death by alternate pathway(s).	Paclitaxel	70-80	tumor protein p53	Homo sapiens	99-102
10951339-12	2000	Paclitaxel should be considered as a component of treatment for patients with metastatic NSCLC with tumors that have p53 mutations.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	117-120
10930572-0	2000	Structural significance of the acyl group at the C-10 position and the A ring of the taxane core of paclitaxel for inducing nitric oxide and tumor necrosis factor production by murine macrophages.	Paclitaxel	100-110	tumor necrosis factor	Mus musculus	141-162
10930572-2	2000	Various synthetic analogs of paclitaxel were examined for their potencies to induce nitric oxide (NO) and tumor necrosis factor (TNF) production by murine peritoneal Mphi, and by human peripheral blood cells.	Paclitaxel	29-39	tumor necrosis factor	Mus musculus	106-127
10930572-2	2000	Various synthetic analogs of paclitaxel were examined for their potencies to induce nitric oxide (NO) and tumor necrosis factor (TNF) production by murine peritoneal Mphi, and by human peripheral blood cells.	Paclitaxel	29-39	tumor necrosis factor	Mus musculus	129-132
10878580-4	2000	We also examine the antiapoptotic function of erbB2 as one of the molecular mechanisms of ErbB2-mediated Taxol resistance and describe several emerging strategies for overcoming intrinsic ErbB2-mediated chemoresistance.	Paclitaxel	105-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-95
10988356-6	2000	Our results indicate that taxol treatment inhibits Raf-1 kinase activation while having no effect on ERK activation suggesting that ERK activation is distinct from upstream Raf-1 kinase in taxol-induced immunomodulation.	Paclitaxel	26-31	mitogen-activated protein kinase 1	Mus musculus	132-135
10945622-10	2000	In control mice treated with paste without paclitaxel, serum PSA levels increased from 2-8 ng/ml (mean, 4.3+/-2 ng/ml) to 60-292 ng/ml (mean, 181+/-88 ng/ml), and tumor volume increased from 30 to 1000 mm3.	Paclitaxel	43-53	kallikrein B, plasma 1	Mus musculus	61-64
10910051-4	2000	Growth arrest prevented paclitaxel-induced Bcl-2 phosphorylation and apoptosis without affecting paclitaxel-induced tubulin polymerization.	Paclitaxel	24-34	BCL2 apoptosis regulator	Homo sapiens	43-48
10910051-6	2000	Unlike MCF-7 cells, MCF-10A cells were arrested by epidermal growth factor withdrawal, precluding paclitaxel-induced Bcl-2 phosphorylation.	Paclitaxel	98-108	BCL2 apoptosis regulator	Homo sapiens	117-122
10854551-0	2000	Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells.	Paclitaxel	35-45	tumor protein p53	Homo sapiens	60-67
10861090-5	2000	Paclitaxel, a microtubule-stabilizing drug known to inhibit Bcl-2 antiapoptotic activity and to be highly effective in the treatment of certain neoplasms, has recently been found to be active also in patients with advanced HIV-associated KS.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	60-65
10861090-8	2000	Furthermore, paclitaxel treatment promoted apoptosis and down-regulated Bcl-2 protein expression in KS cells in vitro and in KS-like lesions in mice.	Paclitaxel	13-23	B cell leukemia/lymphoma 2	Mus musculus	72-77
10861090-9	2000	Our results suggest that paclitaxel interferes with KS by down-regulating Bcl-2 antiapoptotic effect.	Paclitaxel	25-35	B cell leukemia/lymphoma 2	Mus musculus	74-79
11100818-11	2000	Bcl-2 overexpressing and control human glioma cell clones (T98MG line) were treated in culture with the cytotoxic drugs carmustine (BCNU), paclitaxel, vincristine, and doxorubicin.	Paclitaxel	139-149	BCL2 apoptosis regulator	Homo sapiens	0-5
10854551-0	2000	Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells.	Paclitaxel	35-45	tumor protein p53	Homo sapiens	60-64
10854551-7	2000	However, in the ovarian cancer cell lines (CA-OV3, SK-OV3, 2780/CP and OAW42/CP) that have a mutant TP53 (TP53mut), the cytotoxicity induced by 60 nM paclitaxel exhibited the same relationship to Raf-1 kinase activity as previously observed in cervical tumor cell lines.	Paclitaxel	150-160	tumor protein p53	Homo sapiens	100-104
10854551-7	2000	However, in the ovarian cancer cell lines (CA-OV3, SK-OV3, 2780/CP and OAW42/CP) that have a mutant TP53 (TP53mut), the cytotoxicity induced by 60 nM paclitaxel exhibited the same relationship to Raf-1 kinase activity as previously observed in cervical tumor cell lines.	Paclitaxel	150-160	tumor protein p53	Homo sapiens	106-113
10854551-8	2000	These data suggest that the therapeutic efficacy of paclitaxel in ovarian cancer patient whose tumors have TP53mut might be increased if it is administered in combination with Raf-1 kinase inhibitors, e.g., ISIS 5132.	Paclitaxel	52-62	tumor protein p53	Homo sapiens	107-111
10871860-0	2000	Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	45-48
10881025-0	2000	Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors.	Paclitaxel	19-29	B cell leukemia/lymphoma 2	Mus musculus	45-50
10881025-9	2000	Western blotting demonstrated that paclitaxel treatment phosphorylated and inactivated Bcl-2.	Paclitaxel	35-45	B cell leukemia/lymphoma 2	Mus musculus	87-92
10871860-2	2000	While the role of p53 in the intrinsic sensitivity of human cancer cells to paclitaxel (PTX) remains controversial, its role in acquired paclitaxel resistance has never been addressed.	Paclitaxel	76-86	tumor protein p53	Homo sapiens	18-21
10871860-3	2000	In this study we examined the p53 status of three paclitaxel selected human ovarian carcinoma sublines, resistant to paclitaxel due to acquired beta-tubulin mutations which impair paclitaxel"s interaction with tubulin.	Paclitaxel	50-60	tumor protein p53	Homo sapiens	30-33
10871860-4	2000	In contrast to parental cells which have wt p53, in all PTX-resistant sublines p53 was functionally inactive.	Paclitaxel	56-59	tumor protein p53	Homo sapiens	44-47
10871860-4	2000	In contrast to parental cells which have wt p53, in all PTX-resistant sublines p53 was functionally inactive.	Paclitaxel	56-59	tumor protein p53	Homo sapiens	79-82
10871860-8	2000	While PTX resistance is primarily conferred by the tubulin mutations, the loss of functional p53 observed in all clones, suggests that this loss may facilitate the development of resistance potentially by providing a clonal advantage which promotes the isolation of paclitaxel resistant cells.	Paclitaxel	266-276	tumor protein p53	Homo sapiens	93-96
10842201-8	2000	Combined treatment of Shionogi cells with antisense Bcl-xL and Bcl-2 ODNs significantly enhanced taxol chemosensitivity compared with either agent alone, reducing the IC(50) of taxol by more than 1 log.	Paclitaxel	97-102	B cell leukemia/lymphoma 2	Mus musculus	63-68
10842201-8	2000	Combined treatment of Shionogi cells with antisense Bcl-xL and Bcl-2 ODNs significantly enhanced taxol chemosensitivity compared with either agent alone, reducing the IC(50) of taxol by more than 1 log.	Paclitaxel	177-182	B cell leukemia/lymphoma 2	Mus musculus	63-68
10749863-0	2000	Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression.	Paclitaxel	80-90	epidermal growth factor receptor	Homo sapiens	24-56
10898354-9	2000	Trastuzumab, a monoclonal antibody against the HER-2/neu oncoprotein, produced objective regression in 15-20% of patients with HER-2/neu-overexpressing breast carcinoma and improved the efficacy of paclitaxel.	Paclitaxel	198-208	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-56
10898354-9	2000	Trastuzumab, a monoclonal antibody against the HER-2/neu oncoprotein, produced objective regression in 15-20% of patients with HER-2/neu-overexpressing breast carcinoma and improved the efficacy of paclitaxel.	Paclitaxel	198-208	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-52
10749863-3	2000	Cell lines transfected with EGFRvIII and HER2 are more resistant to paclitaxel-mediated cytotoxicity, and tubulin polymerization induced by paclitaxel is suppressed compared with cells expressing wild type epidermal growth factor receptor.	Paclitaxel	68-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
10749863-3	2000	Cell lines transfected with EGFRvIII and HER2 are more resistant to paclitaxel-mediated cytotoxicity, and tubulin polymerization induced by paclitaxel is suppressed compared with cells expressing wild type epidermal growth factor receptor.	Paclitaxel	140-150	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
10749863-3	2000	Cell lines transfected with EGFRvIII and HER2 are more resistant to paclitaxel-mediated cytotoxicity, and tubulin polymerization induced by paclitaxel is suppressed compared with cells expressing wild type epidermal growth factor receptor.	Paclitaxel	140-150	epidermal growth factor receptor	Homo sapiens	206-238
10749863-10	2000	Expression of oncogenic epidermal growth factor receptor family members is associated with modulation of both beta-tubulin isotype expression and paclitaxel resistance in cells transformed by expression of the receptor.	Paclitaxel	146-156	epidermal growth factor receptor	Homo sapiens	24-56
10912951-3	2000	In paclitaxel-, adriamycin-, vincristine- and etoposide-resistant cells, overexpression of P-glycoprotein (P-gp) and a correlative reduction in drug accumulation and typical drug-sensitivity pattern were confirmed.	Paclitaxel	3-13	ATP binding cassette subfamily B member 1	Homo sapiens	91-105
10912951-3	2000	In paclitaxel-, adriamycin-, vincristine- and etoposide-resistant cells, overexpression of P-glycoprotein (P-gp) and a correlative reduction in drug accumulation and typical drug-sensitivity pattern were confirmed.	Paclitaxel	3-13	ATP binding cassette subfamily B member 1	Homo sapiens	107-111
10822281-1	2000	To define the responses of apoptotic regulatory proteins to different chemotherapeutic agents, we investigated the expression of Bcl-2 family gene products, the release of cytochrome c, and the activation of pro-caspase-3 during apoptosis induced by Taxol and Thiotepa, in the MCF-7 breast carcinoma and the HL-60 leukemia cell lines.	Paclitaxel	250-255	caspase 3	Homo sapiens	208-221
10822281-5	2000	The overall responses were qualitatively similar in both cell types, but MCF-7 cells treated with Taxol showed a significant delay in apoptosis, correlating with early up-regulation of Bcl-2 and delayed release of cytochrome c.	Paclitaxel	98-103	BCL2 apoptosis regulator	Homo sapiens	185-190
10822281-5	2000	The overall responses were qualitatively similar in both cell types, but MCF-7 cells treated with Taxol showed a significant delay in apoptosis, correlating with early up-regulation of Bcl-2 and delayed release of cytochrome c.	Paclitaxel	98-103	cytochrome c, somatic	Homo sapiens	214-226
10861441-7	2000	The checkpoint of mitotic spindle assembly, aberrant activation of cyclin-dependent kinases, and the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) are shown to be involved in paclitaxel-induced apoptosis.	Paclitaxel	196-206	mitogen-activated protein kinase 8	Homo sapiens	158-166
10767372-5	2000	Median CD34+ peaks were 24 microl (range: 10-58) in the paclitaxel-treated patients and 39 microl (range: 17-91), respectively, in the patients who received docetaxel.	Paclitaxel	56-66	CD34 molecule	Homo sapiens	7-11
10873087-9	2000	In conclusion, elevated levels of circulating HER2 ECD in patients with metastatic breast cancer correlate with reduced efficacy of a paclitaxel-doxorubicin chemotherapy combination.	Paclitaxel	134-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	46-50
10842370-9	2000	After taxol exposure, pericentrin incorporation into both spindle poles and cytoplasmic centrosomes was increased.	Paclitaxel	6-11	pericentrin (kendrin)	Mus musculus	22-33
11876996-8	2000	The expressions of bax protein and mRNA were increased and bcl-x(s) mRNA became detectable after taxol treatment.	Paclitaxel	97-102	BCL2 associated X, apoptosis regulator	Homo sapiens	19-22
11876996-8	2000	The expressions of bax protein and mRNA were increased and bcl-x(s) mRNA became detectable after taxol treatment.	Paclitaxel	97-102	BCL2 like 1	Homo sapiens	59-64
11876996-11	2000	Bax and bcl-x(s) participate in the taxol induced apoptosis of Jurkat cells.	Paclitaxel	36-41	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
11876996-11	2000	Bax and bcl-x(s) participate in the taxol induced apoptosis of Jurkat cells.	Paclitaxel	36-41	BCL2 like 1	Homo sapiens	8-13
10823417-0	2000	Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB- and AP-1-dependent mechanism.	Paclitaxel	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	24-37
10823417-0	2000	Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB- and AP-1-dependent mechanism.	Paclitaxel	0-10	nuclear factor kappa B subunit 1	Homo sapiens	83-92
10823417-4	2000	In this report, we demonstrate that a subset of human lung carcinoma cell lines respond to paclitaxel treatment with an up to a fivefold increase in the production of interleukin-8 (IL-8).	Paclitaxel	91-101	C-X-C motif chemokine ligand 8	Homo sapiens	167-180
10773023-3	2000	Endothelin-1 (ET-1), a 21-amino acid peptide that binds to G protein-coupled receptors with mitogenic and vasoconstricting activities, suppressed apoptosis of human prostatic smooth muscle cells induced by paclitaxel treatment or serum withdrawal.	Paclitaxel	206-216	endothelin 1	Homo sapiens	0-12
10773023-3	2000	Endothelin-1 (ET-1), a 21-amino acid peptide that binds to G protein-coupled receptors with mitogenic and vasoconstricting activities, suppressed apoptosis of human prostatic smooth muscle cells induced by paclitaxel treatment or serum withdrawal.	Paclitaxel	206-216	endothelin 1	Homo sapiens	14-18
10773023-8	2000	The ERK1/2 activity in these cells decreased rapidly after paclitaxel treatment or serum withdrawal, but was maintained at a 2-fold higher level in the presence of ET-1 for at least 4 h. These results suggest that the ERK1/2 pathway is activated by ET-1, and blocking this pathway abolishes the antiapoptotic effect of ET-1.	Paclitaxel	59-69	mitogen-activated protein kinase 3	Homo sapiens	4-10
10773023-8	2000	The ERK1/2 activity in these cells decreased rapidly after paclitaxel treatment or serum withdrawal, but was maintained at a 2-fold higher level in the presence of ET-1 for at least 4 h. These results suggest that the ERK1/2 pathway is activated by ET-1, and blocking this pathway abolishes the antiapoptotic effect of ET-1.	Paclitaxel	59-69	endothelin 1	Homo sapiens	164-168
10773023-8	2000	The ERK1/2 activity in these cells decreased rapidly after paclitaxel treatment or serum withdrawal, but was maintained at a 2-fold higher level in the presence of ET-1 for at least 4 h. These results suggest that the ERK1/2 pathway is activated by ET-1, and blocking this pathway abolishes the antiapoptotic effect of ET-1.	Paclitaxel	59-69	mitogen-activated protein kinase 3	Homo sapiens	218-224
10773023-8	2000	The ERK1/2 activity in these cells decreased rapidly after paclitaxel treatment or serum withdrawal, but was maintained at a 2-fold higher level in the presence of ET-1 for at least 4 h. These results suggest that the ERK1/2 pathway is activated by ET-1, and blocking this pathway abolishes the antiapoptotic effect of ET-1.	Paclitaxel	59-69	endothelin 1	Homo sapiens	249-253
10773023-8	2000	The ERK1/2 activity in these cells decreased rapidly after paclitaxel treatment or serum withdrawal, but was maintained at a 2-fold higher level in the presence of ET-1 for at least 4 h. These results suggest that the ERK1/2 pathway is activated by ET-1, and blocking this pathway abolishes the antiapoptotic effect of ET-1.	Paclitaxel	59-69	endothelin 1	Homo sapiens	249-253
10935506-0	2000	Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.	Paclitaxel	71-76	tumor protein p53	Homo sapiens	8-11
10935506-0	2000	Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.	Paclitaxel	71-76	BCL2 associated X, apoptosis regulator	Homo sapiens	24-27
10935506-4	2000	The clones expressing bax under the control of p53 obtained from the wild-type (wt) p53-expressing cell line A2780 were much more sensitive (500- to 1000-fold) to the anticancer agent taxol than the parent cell line, with a higher percentage of cells undergoing apoptosis after drug treatment that was clearly p53-dependent and bax-mediated.	Paclitaxel	184-189	BCL2 associated X, apoptosis regulator	Homo sapiens	22-25
10935506-4	2000	The clones expressing bax under the control of p53 obtained from the wild-type (wt) p53-expressing cell line A2780 were much more sensitive (500- to 1000-fold) to the anticancer agent taxol than the parent cell line, with a higher percentage of cells undergoing apoptosis after drug treatment that was clearly p53-dependent and bax-mediated.	Paclitaxel	184-189	tumor protein p53	Homo sapiens	47-50
10935506-4	2000	The clones expressing bax under the control of p53 obtained from the wild-type (wt) p53-expressing cell line A2780 were much more sensitive (500- to 1000-fold) to the anticancer agent taxol than the parent cell line, with a higher percentage of cells undergoing apoptosis after drug treatment that was clearly p53-dependent and bax-mediated.	Paclitaxel	184-189	tumor protein p53	Homo sapiens	84-87
10935506-4	2000	The clones expressing bax under the control of p53 obtained from the wild-type (wt) p53-expressing cell line A2780 were much more sensitive (500- to 1000-fold) to the anticancer agent taxol than the parent cell line, with a higher percentage of cells undergoing apoptosis after drug treatment that was clearly p53-dependent and bax-mediated.	Paclitaxel	184-189	tumor protein p53	Homo sapiens	84-87
10935506-7	2000	In conclusion, driving the p53 response (after taxol treatment) by activating the bax gene rather than the p21 gene results in induction of massive apoptosis, in vitro and in vivo, and greatly enhances sensitivity to the drug.	Paclitaxel	47-52	tumor protein p53	Homo sapiens	27-30
10935506-7	2000	In conclusion, driving the p53 response (after taxol treatment) by activating the bax gene rather than the p21 gene results in induction of massive apoptosis, in vitro and in vivo, and greatly enhances sensitivity to the drug.	Paclitaxel	47-52	BCL2 associated X, apoptosis regulator	Homo sapiens	82-85
10823417-4	2000	In this report, we demonstrate that a subset of human lung carcinoma cell lines respond to paclitaxel treatment with an up to a fivefold increase in the production of interleukin-8 (IL-8).	Paclitaxel	91-101	C-X-C motif chemokine ligand 8	Homo sapiens	182-186
10823417-6	2000	Increased IL-8 mRNA is seen as early as 45 min with a peak at 4 h after paclitaxel treatment.	Paclitaxel	72-82	C-X-C motif chemokine ligand 8	Homo sapiens	10-14
10823417-8	2000	Paclitaxel also activates the mitogen-activated protein kinase family member, JNK1, in dose-dependent fashion.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	78-82
10815883-7	2000	Characteristic apoptotic DNA laddering and cleavage of poly(ADP-ribose) polymerase were observed after combined treatment with AS ODN#2 plus paclitaxel or mitoxantrone but not with either agent alone.	Paclitaxel	141-151	poly(ADP-ribose) polymerase 1	Homo sapiens	55-82
10767372-6	2000	After paclitaxel, the percentage of CD34+ cells in S-phase was low (bromodeoxyuridine, BrdU, labelling index = 3.4+/-2%) with a concomitant presence of early apoptotic cells (8.1+/-3%).	Paclitaxel	6-16	CD34 molecule	Homo sapiens	36-40
10767372-7	2000	On the contrary, after docetaxel, the percentage of CD34+ cells in S-phase was higher (BrdU labelling index = 14.5+/-4%, p&lt;0.05 vs. paclitaxel), while early apoptotic cells were detected at a similar rate (8.	Paclitaxel	135-145	CD34 molecule	Homo sapiens	52-56
10738258-11	2000	We suggest that AS101 renders more cells susceptible to Bcl-2 phosphorylation by paclitaxel, possibly by increasing the accumulation of paclitaxel-induced cells in G(2)M. Exposure of B16 cells to clinically achievable concentrations of paclitaxel+AS101 increased the rate of apoptosis of treated cells.	Paclitaxel	81-91	B cell leukemia/lymphoma 2	Mus musculus	56-61
11876985-4	2000	The effect of Taxol at different concentrations on mdr1 gene transfer cells was determined by FCM.	Paclitaxel	14-19	ATP binding cassette subfamily B member 1	Homo sapiens	51-55
11876985-9	2000	Taxol at a certain concentration can enrich mdr1 gene transferred cells.	Paclitaxel	0-5	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
10781891-0	2000	Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.	Paclitaxel	89-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-17
10738258-4	2000	Paclitaxel+AS101 synergistically activated c-raf-1 and MAPK ERK1 and ERK2.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Mus musculus	55-59
10738258-4	2000	Paclitaxel+AS101 synergistically activated c-raf-1 and MAPK ERK1 and ERK2.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Mus musculus	69-73
10738258-8	2000	AS101+paclitaxel induced significant synergistic phosphorylation (inactivation) of the anti-apoptotic protein Bcl-2.	Paclitaxel	6-16	B cell leukemia/lymphoma 2	Mus musculus	110-115
10738258-9	2000	Whereas phosphorylation of Bcl-2 by paclitaxel was raf-dependent only, the synergistic effect of both compounds together was ras-, raf- and MAPK-dependent.	Paclitaxel	36-46	B cell leukemia/lymphoma 2	Mus musculus	27-32
10781891-4	2000	The aim of this study was to evaluate whether over-expression of the HER-2 receptor would modulate drug responsiveness to doxorubicin, cisplatin and taxol in ovarian cancer cells.	Paclitaxel	149-154	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-74
10781891-8	2000	In contrast, the sensitivity to taxol was increased approximately 70-fold in SK-OV-3 ovarian cancer cells expressing high levels of HER-2 (IC50=10(-5) nM) compared to HER-2 depleted cells (IC50=7x10(-4) nM).	Paclitaxel	32-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-137
10781891-8	2000	In contrast, the sensitivity to taxol was increased approximately 70-fold in SK-OV-3 ovarian cancer cells expressing high levels of HER-2 (IC50=10(-5) nM) compared to HER-2 depleted cells (IC50=7x10(-4) nM).	Paclitaxel	32-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	167-172
10781891-9	2000	If these findings can be confirmed in patients, it could be possible that HER-2 expression may serve as a marker for response to taxol treatment in ovarian cancer patients.	Paclitaxel	129-134	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-79
10811471-5	2000	In contrast, Ad-p53 showed additive effects with the antitubulin agents (paclitaxel and docetaxel) in all four of the cell lines tested.	Paclitaxel	73-83	tumor protein p53	Homo sapiens	16-19
10736495-13	2000	The high response rate to this regimen despite frequent p53 mutation is consistent with the p53-independent mechanism of paclitaxel.	Paclitaxel	121-131	tumor protein p53	Homo sapiens	92-95
10811474-4	2000	GCV and paclitaxel treatments resulted in increased levels of Bcl-X(L).	Paclitaxel	8-18	BCL2 like 1	Homo sapiens	62-70
10778982-15	2000	Treatment with paclitaxel in vivo increased p34 cdc2 kinase activity in the mouse mammary tumors, whereas administration of bryostatin-1 before paclitaxel prevented the p34cdc2 kinase activation by paclitaxel.	Paclitaxel	15-25	alpha- and gamma-adaptin binding protein	Mus musculus	44-47
10717242-0	2000	The effect of p53-function on the sensitivity to paclitaxel with or without hyperthermia in human colorectal carcinoma cells.	Paclitaxel	49-59	tumor protein p53	Homo sapiens	14-17
10717242-1	2000	The importance of p53-function for the sensitivity to paclitaxel with and without hyperthermia (HT) was studied in an isogenic cell line system.	Paclitaxel	54-64	tumor protein p53	Homo sapiens	18-21
10717242-2	2000	The inactivation of p53 decreased sensitivity to paclitaxel (1.1-2.5-fold), which correlated with a lower induction of apoptosis.	Paclitaxel	49-59	tumor protein p53	Homo sapiens	20-23
10717242-5	2000	In conclusion, cellular sensitivity to paclitaxel depends on p53-function by its ability to induce apoptosis.	Paclitaxel	39-49	tumor protein p53	Homo sapiens	61-64
10733772-0	2000	Paclitaxel-induced apoptosis in non-small cell lung cancer cell lines is associated with increased caspase-3 activity.	Paclitaxel	0-10	caspase 3	Homo sapiens	99-108
10733772-8	2000	Apoptotic morphologic changes were inhibited in cells cultured in the presence of paclitaxel and Ac-DEVD-CHO, a caspase-3 inhibitor.	Paclitaxel	82-92	caspase 3	Homo sapiens	112-121
10733772-9	2000	CONCLUSIONS: Paclitaxel induces apoptosis in lung cancer cell lines, as assessed by a consistent increase in caspase-3 activity, DNA laddering, and characteristic morphologic changes.	Paclitaxel	13-23	caspase 3	Homo sapiens	109-118
10733772-10	2000	Paclitaxel-induced apoptosis in human lung cancer cells is associated with caspase-3 activation but is not Fas dependent.	Paclitaxel	0-10	caspase 3	Homo sapiens	75-84
10766196-7	2000	To determine one potential reason for the greater potentiation of the effects of paclitaxel than those of Adriamycin, we determined the effects of preincubation of MCF-7 cells on paclitaxel-induced phosphorylation of Bcl-2.	Paclitaxel	179-189	BCL2 apoptosis regulator	Homo sapiens	217-222
10766196-8	2000	Pretreatment of MCF-7 cells with either 1,25(OH)2D3 or ATRA increased the phosphorylation of Bcl-2 by variable concentrations of paclitaxel.	Paclitaxel	129-139	BCL2 apoptosis regulator	Homo sapiens	93-98
11899388-6	2000	Survival was improved under the following circumstances: (1) when 4 cycles of paclitaxel (175 mg/m2 every 3 weeks) was given following 4 cycles of conventional doxorubicin-cyclophosphamide for axillary node-positive operable breast cancer, (2) when trastuzumab was added to paclitaxel as first-line therapy for metastatic breast cancer that overexpressed HER2/neu, and (3) when docetaxel was given as second-line therapy for anthracycline-resistant disease.	Paclitaxel	78-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	355-359
11899388-6	2000	Survival was improved under the following circumstances: (1) when 4 cycles of paclitaxel (175 mg/m2 every 3 weeks) was given following 4 cycles of conventional doxorubicin-cyclophosphamide for axillary node-positive operable breast cancer, (2) when trastuzumab was added to paclitaxel as first-line therapy for metastatic breast cancer that overexpressed HER2/neu, and (3) when docetaxel was given as second-line therapy for anthracycline-resistant disease.	Paclitaxel	78-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	360-363
10699953-4	2000	While MCF-10A Ha-ras cells showed an increased sensitivity, MCF-10A c-erbB-2 and MCF-10A HE cells exhibited a relative resistance to taxol and taxotere, with an approximately 3.5- to 6.5-fold higher IC(50) as compared with MCF-10A cells suggesting that c-erbB-2 overexpression has a dominant effect compared with an activated c-Ha-ras gene.	Paclitaxel	133-138	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-76
10749135-0	2000	The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis.	Paclitaxel	65-75	BH3 interacting domain death agonist	Homo sapiens	35-38
10749135-1	2000	Ectopic overexpression of Apaf-1 (2.5-fold) in human acute myelogenous leukemia HL-60 cells (HL-60/Apaf-1 cells) induced apoptosis and sensitized HL-60/Apaf-1 cells to etoposide- and paclitaxel-induced apoptosis (C. Perkins et al., Cancer Res., 58: 4561-4566, 1998).	Paclitaxel	183-193	apoptotic peptidase activating factor 1	Homo sapiens	26-32
10810342-6	2000	The sensitivity of wt p53-transfected cells (H358/p53) to paclitaxel was approximately 3-fold lower than that of H358 cells.	Paclitaxel	58-68	tumor protein p53	Homo sapiens	22-25
10810342-6	2000	The sensitivity of wt p53-transfected cells (H358/p53) to paclitaxel was approximately 3-fold lower than that of H358 cells.	Paclitaxel	58-68	tumor protein p53	Homo sapiens	50-53
10698706-2	2000	In the present study, cleavage of D4-GDI (Rho-GDI 2), an abundant haemopoietic-cell GDP dissociation inhibitor for the Ras-related Rho family GTPases, was demonstrated after treatment of BJAB Burkitt-like lymphoma cells with taxol or epirubicin.	Paclitaxel	225-230	Rho GDP dissociation inhibitor beta	Homo sapiens	42-51
10675481-2	2000	By systematic site directed mutagenesis studies, we have previously mapped taxol induced phosphorylation sites to be Ser-70 and 87 residues of Bcl2 protein.	Paclitaxel	75-80	BCL2 apoptosis regulator	Homo sapiens	143-147
10699953-8	2000	Treatment with this agent, but not with a control scramble sequence, was able to overcome the effect of c-erbB-2 overexpression on MCF-10A cell sensitivity to taxol and taxotere, with a 20- to 40-fold shift in the IC(50) values for the 2 drugs.	Paclitaxel	159-164	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-112
10741907-10	2000	Meanwhile, Ad-p53 gene transfer combined with taxol, cisplatin, doxorubicin or mitomycin C was shown to be even more effective in suppressing growth in the two cell lines.	Paclitaxel	46-51	tumor protein p53	Homo sapiens	14-17
10741911-11	2000	Expression of multidrug resistance (MDR1) mRNA, which was not observed in KF28 and KFr13 cells, was observed after induction of taxol resistance.	Paclitaxel	128-133	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
10623878-6	2000	HER2 overexpression is associated with breast cancer patient responsiveness to doxorubicin, to cyclophosphamide, methotrexate, and fluorouracil (CMF), and to paclitaxel, whereas tamoxifen was found to be ineffective and even detrimental in patients with HER2-positive tumors.	Paclitaxel	158-168	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
10679119-2	2000	Our laboratory has shown that paclitaxel induces IL-8, a member of the C-X-C family of chemokines, in subsets of human ovarian cancer cells.	Paclitaxel	30-40	C-X-C motif chemokine ligand 8	Homo sapiens	49-53
10745175-4	2000	Unlike in previous reports the mdr1 promoter was no more active in two cancer cell lines with mutations in the p53 gene than in two other lines with wild-type p53, and its expression level could not be increased by either doxorubicin or taxol.	Paclitaxel	237-242	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
10706117-10	2000	In addition, standard chemotherapeutic agents (paclitaxol and cisplatin) showed a synergistic effect when combined with ONYX-015, and this effect was p53 mutant dependent.	Paclitaxel	47-57	tumor protein p53	Homo sapiens	150-153
10673692-5	2000	The median yield of CD34+ cells from all patients included in taxol containing schedules was 9 x 106/kg (range 2-26) collected with a median of one apheresis procedure (range 1-4).	Paclitaxel	62-67	CD34 molecule	Homo sapiens	20-24
10673692-10	2000	We conclude that taxol containing schedules are effective in mobilizing PBSC and facilitate the collection of high yields of CD34+ cells (usually more than 5 x 106/kg recipient body weight) with a reduced number of apheresis procedures.	Paclitaxel	17-22	CD34 molecule	Homo sapiens	125-129
10737257-1	2000	The purpose of this study was to evaluate whether the mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) signaling pathway contributes to 12-O-tertadecanoyl phorbol 13-acetate (TPA)-mediated protection from taxol-induced apoptosis of human leukemia HL-60 cells.	Paclitaxel	233-238	mitogen-activated protein kinase kinase 7	Homo sapiens	54-124
10737257-1	2000	The purpose of this study was to evaluate whether the mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) signaling pathway contributes to 12-O-tertadecanoyl phorbol 13-acetate (TPA)-mediated protection from taxol-induced apoptosis of human leukemia HL-60 cells.	Paclitaxel	233-238	mitogen-activated protein kinase kinase 7	Homo sapiens	126-129
10737257-4	2000	Since TPA stimulates MEK signal transduction pathway in HL-60 cells, we postulated that MEK pathway may be playing a role in the ability of TPA to inhibit taxol-induced apoptosis.	Paclitaxel	155-160	mitogen-activated protein kinase kinase 7	Homo sapiens	21-24
10737257-4	2000	Since TPA stimulates MEK signal transduction pathway in HL-60 cells, we postulated that MEK pathway may be playing a role in the ability of TPA to inhibit taxol-induced apoptosis.	Paclitaxel	155-160	mitogen-activated protein kinase kinase 7	Homo sapiens	88-91
10737257-5	2000	PD098059, a specific MEK kinase inhibitor, abolished the ability of TPA to inhibit taxol-induced apoptosis.	Paclitaxel	83-88	mitogen-activated protein kinase kinase 7	Homo sapiens	21-24
10699926-10	2000	These results extend to taxol and taxotere the notion that drug-induced apoptosis is delayed upstream of caspase-3 activation in K562 cells, that such kinetics is independent of drug concentration and exposure time, and that it is linked to intrinsic cellular characteristics mapping between bcl-2 phosphorylation and cytochrome c release.	Paclitaxel	24-29	caspase 3	Homo sapiens	105-114
10699926-10	2000	These results extend to taxol and taxotere the notion that drug-induced apoptosis is delayed upstream of caspase-3 activation in K562 cells, that such kinetics is independent of drug concentration and exposure time, and that it is linked to intrinsic cellular characteristics mapping between bcl-2 phosphorylation and cytochrome c release.	Paclitaxel	24-29	BCL2 apoptosis regulator	Homo sapiens	292-297
10699926-10	2000	These results extend to taxol and taxotere the notion that drug-induced apoptosis is delayed upstream of caspase-3 activation in K562 cells, that such kinetics is independent of drug concentration and exposure time, and that it is linked to intrinsic cellular characteristics mapping between bcl-2 phosphorylation and cytochrome c release.	Paclitaxel	24-29	cytochrome c, somatic	Homo sapiens	318-330
11227490-5	2000	It was shown that Bcl-2 protects against both taxol- and okadaic acid induced neurite retraction.	Paclitaxel	46-51	BCL2, apoptosis regulator	Rattus norvegicus	18-23
11227490-6	2000	Bcl-2 overexpression also significantly reduced the increased ratio of acetylated tubulin over total tubulin induced by taxol treatment.	Paclitaxel	120-125	BCL2, apoptosis regulator	Rattus norvegicus	0-5
10676649-7	2000	After an 18-h incubation, manumycin plus paclitaxel caused enhanced activation of caspase-3 activity, cleavage of PARP into Mr 89,000 and 28,000 fragments, and internucleosomal fragmentation of DNA (all of which are characteristic of apoptotic cell death).	Paclitaxel	41-51	caspase 3	Homo sapiens	82-91
10676649-7	2000	After an 18-h incubation, manumycin plus paclitaxel caused enhanced activation of caspase-3 activity, cleavage of PARP into Mr 89,000 and 28,000 fragments, and internucleosomal fragmentation of DNA (all of which are characteristic of apoptotic cell death).	Paclitaxel	41-51	poly(ADP-ribose) polymerase 1	Homo sapiens	114-118
10676649-13	2000	Combined manumycin and paclitaxel treatments seemed as effective as manumycin against ARO cells and more effective than either manumycin or paclitaxel alone against KAT-4 cells.	Paclitaxel	23-33	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	86-89
10620631-2	2000	The objective of this study was to determine whether antisense Bcl-2 oligodeoxynucleotides could enhance paclitaxel cytotoxicity and delay androgen-independent progression.	Paclitaxel	105-115	B cell leukemia/lymphoma 2	Mus musculus	63-68
10644670-6	2000	Noticeable NFkappaB activation by Taxol was detected in Ba/F3 expressing mouse TLR4 and mouse MD-2 but not in the other transfectants.	Paclitaxel	34-39	toll-like receptor 4	Mus musculus	79-83
10644670-9	2000	Furthermore, Taxol-induced NFkappaB activation via TLR4.MD-2 was blocked by an LPS antagonist that blocks LPS-induced NFkappaB activation via TLR4.MD-2.	Paclitaxel	13-18	toll-like receptor 4	Mus musculus	51-55
10644670-9	2000	Furthermore, Taxol-induced NFkappaB activation via TLR4.MD-2 was blocked by an LPS antagonist that blocks LPS-induced NFkappaB activation via TLR4.MD-2.	Paclitaxel	13-18	toll-like receptor 4	Mus musculus	142-146
10644670-10	2000	These results demonstrated that coexpression of mouse TLR4 and mouse MD-2 is required for Taxol responsiveness and that the TLR4.MD-2 complex is the shared molecule in Taxol and LPS signal transduction in mice.	Paclitaxel	90-95	toll-like receptor 4	Mus musculus	54-58
10644670-10	2000	These results demonstrated that coexpression of mouse TLR4 and mouse MD-2 is required for Taxol responsiveness and that the TLR4.MD-2 complex is the shared molecule in Taxol and LPS signal transduction in mice.	Paclitaxel	168-173	toll-like receptor 4	Mus musculus	54-58
10644670-10	2000	These results demonstrated that coexpression of mouse TLR4 and mouse MD-2 is required for Taxol responsiveness and that the TLR4.MD-2 complex is the shared molecule in Taxol and LPS signal transduction in mice.	Paclitaxel	168-173	toll-like receptor 4	Mus musculus	124-128
10872505-1	2000	The MDR1 multidrug resistance gene encodes a high molecular weight membrane-spanning cell surface protein, P-glycoprotein, that confers multidrug resistance by pumping various cytotoxic drugs, including vinblastine, doxorubicin or paclitaxel, out of cells.	Paclitaxel	231-241	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
10872505-1	2000	The MDR1 multidrug resistance gene encodes a high molecular weight membrane-spanning cell surface protein, P-glycoprotein, that confers multidrug resistance by pumping various cytotoxic drugs, including vinblastine, doxorubicin or paclitaxel, out of cells.	Paclitaxel	231-241	ATP binding cassette subfamily B member 1	Homo sapiens	107-121
10644670-0	2000	Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol.	Paclitaxel	99-104	toll-like receptor 4	Mus musculus	6-26
10644670-3	2000	The LPS-mimetic activity of Taxol is not observed in LPS-hyporesponsive C3H/HeJ mice, which possess a point mutation in Toll-like receptor 4 (TLR4); therefore, TLR4 appears to be involved in both Taxol and LPS signaling.	Paclitaxel	28-33	toll-like receptor 4	Mus musculus	142-146
10644670-3	2000	The LPS-mimetic activity of Taxol is not observed in LPS-hyporesponsive C3H/HeJ mice, which possess a point mutation in Toll-like receptor 4 (TLR4); therefore, TLR4 appears to be involved in both Taxol and LPS signaling.	Paclitaxel	28-33	toll-like receptor 4	Mus musculus	160-164
10644670-3	2000	The LPS-mimetic activity of Taxol is not observed in LPS-hyporesponsive C3H/HeJ mice, which possess a point mutation in Toll-like receptor 4 (TLR4); therefore, TLR4 appears to be involved in both Taxol and LPS signaling.	Paclitaxel	196-201	toll-like receptor 4	Mus musculus	160-164
10644670-5	2000	To determine whether TLR4.MD-2 complex mediates a Taxol-induced signal, we constructed transformants of the mouse pro-B cell line, Ba/F3, expressing mouse TLR4 alone, both mouse TLR4 and mouse MD-2, and both mouse MD-2 and mouse TLR4 lacking the cytoplasmic portion, and then examined whether Taxol induced NFkappaB activation in these transfectants.	Paclitaxel	50-55	toll-like receptor 4	Mus musculus	21-25
11809106-6	2000	The non-responders to platinum or taxol based combination chemotherapy exhibited higher ratios of MDR1 and MRP expression than the responders (P &lt; 0.05).	Paclitaxel	34-39	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
11809106-6	2000	The non-responders to platinum or taxol based combination chemotherapy exhibited higher ratios of MDR1 and MRP expression than the responders (P &lt; 0.05).	Paclitaxel	34-39	ATP binding cassette subfamily C member 1	Homo sapiens	107-110
10623471-3	2000	All four agents tested (vinblastine, vincristine, Taxol, and colchicine) caused significant (6- to 13-fold) activation of JNK, concomitant inactivation of ERK, and a reduction in basal p38 MAPK activity.	Paclitaxel	50-55	mitogen-activated protein kinase 8	Homo sapiens	122-125
10623471-3	2000	All four agents tested (vinblastine, vincristine, Taxol, and colchicine) caused significant (6- to 13-fold) activation of JNK, concomitant inactivation of ERK, and a reduction in basal p38 MAPK activity.	Paclitaxel	50-55	mitogen-activated protein kinase 1	Homo sapiens	155-158
10623471-3	2000	All four agents tested (vinblastine, vincristine, Taxol, and colchicine) caused significant (6- to 13-fold) activation of JNK, concomitant inactivation of ERK, and a reduction in basal p38 MAPK activity.	Paclitaxel	50-55	mitogen-activated protein kinase 14	Homo sapiens	185-188
10623471-3	2000	All four agents tested (vinblastine, vincristine, Taxol, and colchicine) caused significant (6- to 13-fold) activation of JNK, concomitant inactivation of ERK, and a reduction in basal p38 MAPK activity.	Paclitaxel	50-55	mitogen-activated protein kinase 1	Homo sapiens	189-193
10620631-3	2000	METHODS: Northern and western blot analyses were used to measure changes in Bcl-2 expression in mouse Shionogi tumor cells after treatment with antisense Bcl-2 oligodeoxynucleotides and/or paclitaxel.	Paclitaxel	189-199	B cell leukemia/lymphoma 2	Mus musculus	76-81
10620631-7	2000	Paclitaxel treatment induced Bcl-2 protein phosphorylation but did not alter Bcl-2 mRNA expression.	Paclitaxel	0-10	B cell leukemia/lymphoma 2	Mus musculus	29-34
10620631-8	2000	Antisense Bcl-2 oligodeoxynucleotide treatment substantially enhanced paclitaxel chemosensitivity in a dose-dependent manner.	Paclitaxel	70-80	B cell leukemia/lymphoma 2	Mus musculus	10-15
10620631-13	2000	Combined treatment with antisense Bcl-2 oligodeoxynucleotides and paclitaxel could be a novel and attractive strategy to inhibit progression to androgen-independent disease as well as growth of hormone-refractory prostate cancer through deprivation of Bcl-2 function.	Paclitaxel	66-76	B cell leukemia/lymphoma 2	Mus musculus	252-257
10769688-3	2000	We showed that ovarian cancer cells either overexpressing constitutively active Akt/AKT1 or containing AKT2 gene amplification were highly resistant to paclitaxel than cancer cells express low AKT levels.	Paclitaxel	152-162	AKT serine/threonine kinase 1	Homo sapiens	80-83
10769688-3	2000	We showed that ovarian cancer cells either overexpressing constitutively active Akt/AKT1 or containing AKT2 gene amplification were highly resistant to paclitaxel than cancer cells express low AKT levels.	Paclitaxel	152-162	AKT serine/threonine kinase 1	Homo sapiens	84-88
10769688-3	2000	We showed that ovarian cancer cells either overexpressing constitutively active Akt/AKT1 or containing AKT2 gene amplification were highly resistant to paclitaxel than cancer cells express low AKT levels.	Paclitaxel	152-162	AKT serine/threonine kinase 1	Homo sapiens	84-87
10769688-7	2000	Furthermore, overexpression of Akt/AKT1 can inhibit the release of cytochrome c induced by paclitaxel.	Paclitaxel	91-101	AKT serine/threonine kinase 1	Homo sapiens	31-34
10769688-7	2000	Furthermore, overexpression of Akt/AKT1 can inhibit the release of cytochrome c induced by paclitaxel.	Paclitaxel	91-101	AKT serine/threonine kinase 1	Homo sapiens	35-39
10769688-7	2000	Furthermore, overexpression of Akt/AKT1 can inhibit the release of cytochrome c induced by paclitaxel.	Paclitaxel	91-101	cytochrome c, somatic	Homo sapiens	67-79
10769688-8	2000	Therefore, our findings provide evidence that aberrant expression or activation of AKT in cancer cells may confer resistance to paclitaxel.	Paclitaxel	128-138	AKT serine/threonine kinase 1	Homo sapiens	83-86
10808368-4	2000	Paclitaxel 1 microM also significantly increased the peak force of contractions elicited by endothelin-1 0.01 microM in HSV.	Paclitaxel	0-10	endothelin 1	Homo sapiens	92-104
10803921-0	2000	Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel.	Paclitaxel	85-95	DNA damage inducible transcript 3	Homo sapiens	18-25
10803921-1	2000	PURPOSE: We investigated the relationship between the basal and treatment-induced change in the tumor expression of the drug resistance gene MDR1 and the cellular injury response gene GADD153, and clinical response to paclitaxel treatment.	Paclitaxel	218-228	ATP binding cassette subfamily B member 1	Homo sapiens	141-145
10755318-4	2000	Recent in vitro studies in human colon cancer cells have linked DPPE enhancement of paclitaxel, doxorubicin and vinblastine cytotoxicity to inhibition of the P-glycoprotein (P-gp) pump.	Paclitaxel	84-94	ATP binding cassette subfamily B member 1	Homo sapiens	158-172
11052631-9	2000	CONCLUSIONS: These results suggest that the exposure duration, DT, and expression of MDR-1, bcl-2 and bax each contribute to paclitaxel sensitivity of human colorectal carcinoma cells.	Paclitaxel	125-135	BCL2 apoptosis regulator	Homo sapiens	92-97
11052631-9	2000	CONCLUSIONS: These results suggest that the exposure duration, DT, and expression of MDR-1, bcl-2 and bax each contribute to paclitaxel sensitivity of human colorectal carcinoma cells.	Paclitaxel	125-135	BCL2 associated X, apoptosis regulator	Homo sapiens	102-105
11036469-10	2000	In contrast, the expression level of P-glycoprotein was much more pronounced and showed a positive correlation (p &lt; 0.05) with the response to paclitaxel.	Paclitaxel	146-156	ATP binding cassette subfamily B member 1	Homo sapiens	37-51
10656456-2	2000	Therefore, in this study, we asked (a) whether EIA might sensitize response to paclitaxel in human HER-2/neu-overexpressing ovarian cancer cells, and, if so, what is the mechanism responsible; and (b) whether this enhanced chemosensitivity would translate into a therapeutic effect in an ovarian cancer xenograft model.	Paclitaxel	79-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-104
11036469-11	2000	Reversal of P-glycoprotein function by verapamil or Cremophor EL enhanced the growth inhibitory effects of paclitaxel and further supported the role of P-glycoprotein for paclitaxel sensitivity of human RCCs.	Paclitaxel	107-117	ATP binding cassette subfamily B member 1	Homo sapiens	12-26
11036469-11	2000	Reversal of P-glycoprotein function by verapamil or Cremophor EL enhanced the growth inhibitory effects of paclitaxel and further supported the role of P-glycoprotein for paclitaxel sensitivity of human RCCs.	Paclitaxel	171-181	ATP binding cassette subfamily B member 1	Homo sapiens	12-26
11036469-11	2000	Reversal of P-glycoprotein function by verapamil or Cremophor EL enhanced the growth inhibitory effects of paclitaxel and further supported the role of P-glycoprotein for paclitaxel sensitivity of human RCCs.	Paclitaxel	171-181	ATP binding cassette subfamily B member 1	Homo sapiens	152-166
11036469-13	2000	Moreover, expression and function of P-glycoprotein markedly contribute to paclitaxel responsiveness, although other as yet undefined drug resistance mechanisms are effective in human RCCs as well.	Paclitaxel	75-85	ATP binding cassette subfamily B member 1	Homo sapiens	37-51
11052631-0	2000	Multiple factors other than p53 influence colon cancer sensitivity to paclitaxel.	Paclitaxel	70-80	tumor protein p53	Homo sapiens	28-31
11052631-9	2000	CONCLUSIONS: These results suggest that the exposure duration, DT, and expression of MDR-1, bcl-2 and bax each contribute to paclitaxel sensitivity of human colorectal carcinoma cells.	Paclitaxel	125-135	ATP binding cassette subfamily B member 1	Homo sapiens	85-90
10656431-12	2000	The efficiency of paclitaxel during mitosis might be supported by lack of G1 arrest due to p53 deficiency.	Paclitaxel	18-28	tumor protein p53	Homo sapiens	91-94
10656431-13	2000	Therefore, patients with p53-deficient tumors may benefit from paclitaxel.	Paclitaxel	63-73	tumor protein p53	Homo sapiens	25-28
10656456-0	2000	E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.	Paclitaxel	13-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-46
10656456-0	2000	E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.	Paclitaxel	13-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-50
10656456-0	2000	E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.	Paclitaxel	13-23	caspase 3	Homo sapiens	123-132
10656456-1	2000	HER-2/neu-overexpressing breast cancer cells are more resistant to the chemotherapeutic agent paclitaxel (Taxol) than low-HER-2/neu-expressing breast cancer cells, and the adenoviral type 5 EIA can down-regulate HER-2/neu overexpression.	Paclitaxel	94-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-9
10656456-1	2000	HER-2/neu-overexpressing breast cancer cells are more resistant to the chemotherapeutic agent paclitaxel (Taxol) than low-HER-2/neu-expressing breast cancer cells, and the adenoviral type 5 EIA can down-regulate HER-2/neu overexpression.	Paclitaxel	94-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
10656456-1	2000	HER-2/neu-overexpressing breast cancer cells are more resistant to the chemotherapeutic agent paclitaxel (Taxol) than low-HER-2/neu-expressing breast cancer cells, and the adenoviral type 5 EIA can down-regulate HER-2/neu overexpression.	Paclitaxel	94-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-9
10656456-1	2000	HER-2/neu-overexpressing breast cancer cells are more resistant to the chemotherapeutic agent paclitaxel (Taxol) than low-HER-2/neu-expressing breast cancer cells, and the adenoviral type 5 EIA can down-regulate HER-2/neu overexpression.	Paclitaxel	106-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-9
10656456-1	2000	HER-2/neu-overexpressing breast cancer cells are more resistant to the chemotherapeutic agent paclitaxel (Taxol) than low-HER-2/neu-expressing breast cancer cells, and the adenoviral type 5 EIA can down-regulate HER-2/neu overexpression.	Paclitaxel	106-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
10656456-1	2000	HER-2/neu-overexpressing breast cancer cells are more resistant to the chemotherapeutic agent paclitaxel (Taxol) than low-HER-2/neu-expressing breast cancer cells, and the adenoviral type 5 EIA can down-regulate HER-2/neu overexpression.	Paclitaxel	106-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-9
10656431-9	2000	Combination of sequencing and IHC results revealed a significant association between abnormal p53 and response to paclitaxel (P = 0.011).	Paclitaxel	114-124	tumor protein p53	Homo sapiens	94-97
10656431-11	2000	Whereas clinical response to FEC was found to be dependent on normal p53, the cytotoxicity of paclitaxel was related to defective p53.	Paclitaxel	94-104	tumor protein p53	Homo sapiens	130-133
10656456-2	2000	Therefore, in this study, we asked (a) whether EIA might sensitize response to paclitaxel in human HER-2/neu-overexpressing ovarian cancer cells, and, if so, what is the mechanism responsible; and (b) whether this enhanced chemosensitivity would translate into a therapeutic effect in an ovarian cancer xenograft model.	Paclitaxel	79-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-108
10656456-3	2000	Consequently, we demonstrated that: (a) adenovirus type 5 E1A could enhance the sensitivity of paclitaxel in paclitaxel-resistant HER-2/neu-overexpressing human ovarian cancer cells in vitro by inducing apoptosis, (b) this induction was heavily dependent on activation of the caspase-3 pathway, and (c) nude mice bearing i.p.	Paclitaxel	95-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-135
10656456-3	2000	Consequently, we demonstrated that: (a) adenovirus type 5 E1A could enhance the sensitivity of paclitaxel in paclitaxel-resistant HER-2/neu-overexpressing human ovarian cancer cells in vitro by inducing apoptosis, (b) this induction was heavily dependent on activation of the caspase-3 pathway, and (c) nude mice bearing i.p.	Paclitaxel	95-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-139
10656456-3	2000	Consequently, we demonstrated that: (a) adenovirus type 5 E1A could enhance the sensitivity of paclitaxel in paclitaxel-resistant HER-2/neu-overexpressing human ovarian cancer cells in vitro by inducing apoptosis, (b) this induction was heavily dependent on activation of the caspase-3 pathway, and (c) nude mice bearing i.p.	Paclitaxel	95-105	caspase 3	Homo sapiens	276-285
10656456-3	2000	Consequently, we demonstrated that: (a) adenovirus type 5 E1A could enhance the sensitivity of paclitaxel in paclitaxel-resistant HER-2/neu-overexpressing human ovarian cancer cells in vitro by inducing apoptosis, (b) this induction was heavily dependent on activation of the caspase-3 pathway, and (c) nude mice bearing i.p.	Paclitaxel	109-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-135
10656456-3	2000	Consequently, we demonstrated that: (a) adenovirus type 5 E1A could enhance the sensitivity of paclitaxel in paclitaxel-resistant HER-2/neu-overexpressing human ovarian cancer cells in vitro by inducing apoptosis, (b) this induction was heavily dependent on activation of the caspase-3 pathway, and (c) nude mice bearing i.p.	Paclitaxel	109-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-139
10656456-4	2000	HER-2/neu-overexpressing human ovarian cancer cells and treated with both paclitaxel and E1A gene therapy survived significantly longer than did mice treated only with paclitaxel or E1A gene therapy.	Paclitaxel	74-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
10656456-4	2000	HER-2/neu-overexpressing human ovarian cancer cells and treated with both paclitaxel and E1A gene therapy survived significantly longer than did mice treated only with paclitaxel or E1A gene therapy.	Paclitaxel	74-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-9
10656456-5	2000	Thus, we concluded that the E1A gene enhanced both the in vitro and in vivo sensitivity of paclitaxel in paclitaxel-resistant HER-2/ neu-overexpressing ovarian cancer SKOV3.ipl cells.	Paclitaxel	91-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-131
10656456-5	2000	Thus, we concluded that the E1A gene enhanced both the in vitro and in vivo sensitivity of paclitaxel in paclitaxel-resistant HER-2/ neu-overexpressing ovarian cancer SKOV3.ipl cells.	Paclitaxel	91-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-136
10656456-5	2000	Thus, we concluded that the E1A gene enhanced both the in vitro and in vivo sensitivity of paclitaxel in paclitaxel-resistant HER-2/ neu-overexpressing ovarian cancer SKOV3.ipl cells.	Paclitaxel	105-115	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-131
10656456-5	2000	Thus, we concluded that the E1A gene enhanced both the in vitro and in vivo sensitivity of paclitaxel in paclitaxel-resistant HER-2/ neu-overexpressing ovarian cancer SKOV3.ipl cells.	Paclitaxel	105-115	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-136
10656456-6	2000	Because a Phase I clinical trial using E1A gene targeted to HER-2/neu down-regulation has recently been completed, the current study also provided a scientific basis to further develop a novel therapy that combines paclitaxel and E1A gene therapy and its testing in a Phase II trial.	Paclitaxel	215-225	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-69
10601557-7	2000	Western blot analysis showed that paclitaxel and PG-TXL downregulated HER2/neu expression in a similar fashion.	Paclitaxel	34-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-74
10671774-12	2000	The transport of DiI(3)-labeled HDL(3) to the lipid droplets in the perinuclear region was almost completely blocked by taxol and colchicine.	Paclitaxel	120-125	HDL3	Homo sapiens	32-38
11240649-0	2000	Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel.	Paclitaxel	149-159	interleukin 1 beta	Homo sapiens	10-18
10601557-7	2000	Western blot analysis showed that paclitaxel and PG-TXL downregulated HER2/neu expression in a similar fashion.	Paclitaxel	34-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-78
10617675-8	2000	Further comparison revealed that although MDR1 easily impaired uptake of vincristine, daunomycin, paclitaxel, and digoxin, SPGP had no effect on uptake of these drugs.	Paclitaxel	98-108	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-46
11240649-0	2000	Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel.	Paclitaxel	149-159	C-X-C motif chemokine ligand 8	Homo sapiens	32-36
11240649-0	2000	Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel.	Paclitaxel	149-159	tumor necrosis factor	Homo sapiens	56-64
11240649-7	2000	In serum, IL-6, IL-8 and MCP-1 decreased with the administration of steroids prior to paclitaxel, and increased in the 24 h after paclitaxel.	Paclitaxel	86-96	interleukin 6	Homo sapiens	10-14
11240649-7	2000	In serum, IL-6, IL-8 and MCP-1 decreased with the administration of steroids prior to paclitaxel, and increased in the 24 h after paclitaxel.	Paclitaxel	130-140	interleukin 6	Homo sapiens	10-14
11240649-10	2000	Treatment with paclitaxel is associated with an increase in expression of a limited number of cytokines in patients with ovarian cancer, notably IL-6, IL-8 and MCP-1.	Paclitaxel	15-25	interleukin 6	Homo sapiens	145-149
11240649-10	2000	Treatment with paclitaxel is associated with an increase in expression of a limited number of cytokines in patients with ovarian cancer, notably IL-6, IL-8 and MCP-1.	Paclitaxel	15-25	C-X-C motif chemokine ligand 8	Homo sapiens	151-155
10637471-8	2000	Serine/threonine phosphorylation is also involved in the regulation of the apoptosis-controlling Bcl-2 protein, as certain phosphorylation events induced by cytokines such as IL-3 are anti-apoptotic, whereas other phosphorylation events triggered by chemotherapeutic drugs such as Paclitaxel are associated with cell death.	Paclitaxel	281-291	BCL2 apoptosis regulator	Homo sapiens	97-102
18521433-7	2000	Paclitaxel induced cell cycle arrest with an accumulation of cells in sub-G1.This was accompanied in vitro by various events typical of apoptosis: phosphorylation of two anti-apoptotic proteins Bcl-2 and Bcl-(xL) , release of cytochrome c into the cytoplasm, cleavage and activation of caspase-3.	Paclitaxel	0-10	B cell leukemia/lymphoma 2	Mus musculus	194-199
10601617-2	2000	The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin.	Paclitaxel	166-176	ATP binding cassette subfamily B member 1	Homo sapiens	40-54
10601617-2	2000	The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin.	Paclitaxel	166-176	ATP binding cassette subfamily B member 1	Homo sapiens	56-60
10601617-2	2000	The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin.	Paclitaxel	166-176	ATP binding cassette subfamily B member 1	Homo sapiens	149-153
10565860-8	1999	These cells also exhibited a drug resistance profile commensurate with the previously described MRP1 overexpressing phenotype, with resistance to Vinca alkaloids, epipodophyllotoxins, and anthracyclines; additional cross-resistance to paclitaxel (Taxol), mitoxantrone, and 5-fluorouracil was observed.	Paclitaxel	235-245	ATP binding cassette subfamily C member 1	Homo sapiens	96-100
11498350-2	1999	Since Taxol is a substrate for P-glycoprotein, overexpression of this transport system is recognized as a relevant mechanism of resistance.	Paclitaxel	6-11	ATP binding cassette subfamily B member 1	Homo sapiens	31-45
12075422-0	2000	Upregulation of bax Gene Expression Promotes Paclitaxel-induced Apoptosis in Esophageal Carcinoma Cells.	Paclitaxel	45-55	BCL2 associated X, apoptosis regulator	Homo sapiens	16-19
12075422-7	2000	These results implied that Bax protein may play an important role in paclitaxel-induced apoptosis.	Paclitaxel	69-79	BCL2 associated X, apoptosis regulator	Homo sapiens	27-30
12075422-8	2000	Therefore, bax protein may be promising as an helping drug to improve therapeutic effects of paclitaxel.	Paclitaxel	93-103	BCL2 associated X, apoptosis regulator	Homo sapiens	11-14
10565860-8	1999	These cells also exhibited a drug resistance profile commensurate with the previously described MRP1 overexpressing phenotype, with resistance to Vinca alkaloids, epipodophyllotoxins, and anthracyclines; additional cross-resistance to paclitaxel (Taxol), mitoxantrone, and 5-fluorouracil was observed.	Paclitaxel	247-252	ATP binding cassette subfamily C member 1	Homo sapiens	96-100
10602425-9	1999	This strategy also allowed a selective killing of HL60/TX cells which express MDR-1, with the only difference being that the second drug, paclitaxel, was substituted for epothilones, non-Pgp substrates.	Paclitaxel	138-148	ATP binding cassette subfamily B member 1	Homo sapiens	78-83
10665656-10	1999	p53 gene transfection did not affect the extent of DNA fragmentation in either cell line, suggesting that paclitaxel may induce p53-independent apoptosis.	Paclitaxel	106-116	tumor protein p53	Homo sapiens	128-131
10576649-1	1999	The doxorubicin-selected, P-glycoprotein (P-gp)-expressing human sarcoma cell line MES-Dx5 showed the following levels of resistance relative to the non-P-gp-expressing parental MES-SA cells in a 72 h exposure to cytotoxic drugs: etoposide twofold, doxorubicin ninefold, vinblastine tenfold, taxotere 19-fold and taxol 94-fold.	Paclitaxel	313-318	ATP binding cassette subfamily B member 1	Homo sapiens	26-40
10567572-8	1999	Moreover, the combination of dominant negative ASK1, (dnASK1), dnMKK7, and dnJNK1 inhibited paclitaxel-induced BCL-2 phosphorylation.	Paclitaxel	92-102	BCL2 apoptosis regulator	Homo sapiens	111-116
10630357-0	1999	Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines.	Paclitaxel	22-32	estrogen receptor 1	Homo sapiens	59-76
10630357-4	1999	Here we reported that paclitaxel and 4-hydroxytamoxifen (4-HT) have a synergistic cytotoxic effect on the ER-negative colon cancer cell line HCT15, which is refractory to paclitaxel alone.	Paclitaxel	22-32	estrogen receptor 1	Homo sapiens	106-108
10630357-4	1999	Here we reported that paclitaxel and 4-hydroxytamoxifen (4-HT) have a synergistic cytotoxic effect on the ER-negative colon cancer cell line HCT15, which is refractory to paclitaxel alone.	Paclitaxel	171-181	estrogen receptor 1	Homo sapiens	106-108
10630357-6	1999	In addition, at 1/10 of the paclitaxel concentrations used for HCT15, 4-HT and paclitaxel also showed synergistic effect on NCI H460, an ER-negative lung cancer cell line.	Paclitaxel	28-38	estrogen receptor 1	Homo sapiens	137-139
10630357-6	1999	In addition, at 1/10 of the paclitaxel concentrations used for HCT15, 4-HT and paclitaxel also showed synergistic effect on NCI H460, an ER-negative lung cancer cell line.	Paclitaxel	79-89	estrogen receptor 1	Homo sapiens	137-139
10634000-9	1999	CONCLUSIONS: These findings suggested that, to reduce the toxicity on mononuclear cellular function when high-dose paclitaxel treatment is elected in clinical practice, paclitaxel should be infused over a longer duration of time, or the treatment should be combined with the administration of a low dose of IL-2 or IL-12.	Paclitaxel	169-179	interleukin 2	Homo sapiens	307-311
10697517-0	1999	Effect of paclitaxel pretreatment on radiation-induced p53-dependent apoptosis.	Paclitaxel	10-20	tumor protein p53	Homo sapiens	55-58
10697517-1	1999	The aim of this study was to investigate the effect of paclitaxel on radiation-induced p53-dependent apoptosis.	Paclitaxel	55-65	tumor protein p53	Homo sapiens	87-90
10697517-9	1999	The present study indicates that p53-dependent apoptosis was frequently induced in the human tumor in vivo by irradiation, but not by paclitaxel alone.	Paclitaxel	134-144	tumor protein p53	Homo sapiens	33-36
10576649-1	1999	The doxorubicin-selected, P-glycoprotein (P-gp)-expressing human sarcoma cell line MES-Dx5 showed the following levels of resistance relative to the non-P-gp-expressing parental MES-SA cells in a 72 h exposure to cytotoxic drugs: etoposide twofold, doxorubicin ninefold, vinblastine tenfold, taxotere 19-fold and taxol 94-fold.	Paclitaxel	313-318	ATP binding cassette subfamily B member 1	Homo sapiens	42-46
10576649-8	1999	Taxol, an allosteric inhibitor of [3H]-vinblastine binding to P-gp, could only displace 40% of [3H]-vinblastine (Ki = 400+/-140 nM).	Paclitaxel	0-5	ATP binding cassette subfamily B member 1	Homo sapiens	62-66
10589757-0	1999	Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.	Paclitaxel	60-70	interleukin 6	Homo sapiens	123-141
10589757-0	1999	Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.	Paclitaxel	60-70	C-X-C motif chemokine ligand 8	Homo sapiens	143-147
10589757-0	1999	Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.	Paclitaxel	191-201	interleukin 6	Homo sapiens	123-141
10589757-0	1999	Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.	Paclitaxel	191-201	C-X-C motif chemokine ligand 8	Homo sapiens	143-147
10534572-11	1999	Moreover, up-regulation of p53 and down-regulation of Bcl-2 was observed only in HPAC cells treated with Taxol.	Paclitaxel	105-110	tumor protein p53	Homo sapiens	27-30
10584203-1	1999	Taxol, an antineoplastic drug, increases the fraction of cells in G2/M phases of cell cycle, induces apoptosis of leukemic cells, and activates macrophages to produce nitric oxide (NO) in response to interferon-gamma.	Paclitaxel	0-5	interferon gamma	Homo sapiens	200-216
10534572-11	1999	Moreover, up-regulation of p53 and down-regulation of Bcl-2 was observed only in HPAC cells treated with Taxol.	Paclitaxel	105-110	BCL2 apoptosis regulator	Homo sapiens	54-59
10534697-2	1999	The aim of this study was to investigate whether depletion of the erbB-2 gene product (p185) by 17-allylamino 17-demethoxygeldanamycin would sensitize lung cancer cells to paclitaxel (Taxol) in vitro.	Paclitaxel	172-182	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-72
10534697-2	1999	The aim of this study was to investigate whether depletion of the erbB-2 gene product (p185) by 17-allylamino 17-demethoxygeldanamycin would sensitize lung cancer cells to paclitaxel (Taxol) in vitro.	Paclitaxel	184-189	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-72
10502406-0	1999	Paclitaxel induces apoptosis in Saos-2 cells with CD95L upregulation and Bcl-2 phosphorylation.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	73-78
10471519-1	1999	Recent studies on paclitaxel (Taxol), a microtubule-stabilizing agent and effective anti-cancer drug, have identified numerous cellular and molecular effects, such as induction of cytokines and tumor-suppressor genes, indirect cytotoxicity due to secretion of tumor necrosis factor, vast activation of signal-transduction pathways and selective activity against cells lacking functional p53.	Paclitaxel	18-28	tumor protein p53	Homo sapiens	387-390
10471519-1	1999	Recent studies on paclitaxel (Taxol), a microtubule-stabilizing agent and effective anti-cancer drug, have identified numerous cellular and molecular effects, such as induction of cytokines and tumor-suppressor genes, indirect cytotoxicity due to secretion of tumor necrosis factor, vast activation of signal-transduction pathways and selective activity against cells lacking functional p53.	Paclitaxel	30-35	tumor protein p53	Homo sapiens	387-390
10471519-5	1999	For example, serine protein phosphorylation, which occurs during mitotic arrest or meiosis, explains paclitaxel-induced hyperphosphorylation of Bcl-2 and Bcl-xL.	Paclitaxel	101-111	BCL2 apoptosis regulator	Homo sapiens	144-149
10567879-5	1999	At constant Bax protein levels, stable sense and antisense gene-transfected QGY-7703 cells showed that constitutive expression of Bcl-2 could render the cells more resistant to Taxol and doxorubicin.	Paclitaxel	177-182	BCL2 apoptosis regulator	Homo sapiens	130-135
10567879-7	1999	As Bcl-2 levels are directly proportional to the resistance of QGY-7703 cells to Taxol and doxorubicin, manipulation of Bcl-2 could be performed to enhance the sensitivity of liver cancer to chemotherapeutic agents.	Paclitaxel	81-86	BCL2 apoptosis regulator	Homo sapiens	3-8
10567879-7	1999	As Bcl-2 levels are directly proportional to the resistance of QGY-7703 cells to Taxol and doxorubicin, manipulation of Bcl-2 could be performed to enhance the sensitivity of liver cancer to chemotherapeutic agents.	Paclitaxel	81-86	BCL2 apoptosis regulator	Homo sapiens	120-125
10471519-5	1999	For example, serine protein phosphorylation, which occurs during mitotic arrest or meiosis, explains paclitaxel-induced hyperphosphorylation of Bcl-2 and Bcl-xL.	Paclitaxel	101-111	BCL2 like 1	Homo sapiens	154-160
10506726-11	1999	CONCLUSIONS: There was significantly less anemia and transfusions were reduced by 50% in patients randomized to receive EPO during chemotherapy with paclitaxel and carboplatin.	Paclitaxel	149-159	erythropoietin	Homo sapiens	120-123
10516758-0	1999	Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL.	Paclitaxel	22-32	BCL2 like 1	Homo sapiens	135-141
10516758-4	1999	Potentiation of paclitaxel-induced apoptosis by bryostatin 1 in U937/Bcl-xL cells occurred primarily in the G2M cell population, and was associated with alterations in Bcl-xL gel mobility and a reduction in paclitaxel-mediated stimulation of CDK1 activity.	Paclitaxel	16-26	BCL2 like 1	Homo sapiens	69-75
10516758-4	1999	Potentiation of paclitaxel-induced apoptosis by bryostatin 1 in U937/Bcl-xL cells occurred primarily in the G2M cell population, and was associated with alterations in Bcl-xL gel mobility and a reduction in paclitaxel-mediated stimulation of CDK1 activity.	Paclitaxel	16-26	BCL2 like 1	Homo sapiens	168-174
10516758-5	1999	Enhancement of paclitaxel-induced apoptosis by bryostatin 1 in Bcl-xL overexpressors was accompanied by a corresponding reduction in clonogenic potential.	Paclitaxel	15-25	BCL2 like 1	Homo sapiens	63-69
10516758-8	1999	Moreover, sequential exposure of both U937/Neo or/Bcl-xL cells to paclitaxel followed by bryostatin 1 or PD98059 was associated with a net reduction in MAP kinase activity.	Paclitaxel	66-76	BCL2 like 1	Homo sapiens	50-56
10516758-9	1999	Collectively, these findings indicate that protection against paclitaxel-mediated mitochondrial dysfunction and apoptosis in human U937 leukemia cells conferred by Bcl-xL overexpression can be substantially overcome by bryostatin 1 and possibly other agents that interrupt the MAP kinase signal transduction pathway.	Paclitaxel	62-72	BCL2 like 1	Homo sapiens	164-170
10554637-11	1999	Human lymphoblasts with mutated p53 (WTK1, LD50 = 75 microM) were more resistant to paclitaxel than wild type p53 cells (TK6, LD50 = 25 microM).	Paclitaxel	84-94	tumor protein p53	Homo sapiens	32-35
10471409-1	1999	Treatment of NIH-OVCAR-3 cells with paclitaxel, a microtubule-stabilizing agent, induces mitotic arrest and apoptosis, but also Bcl-2 phosphorylation.	Paclitaxel	36-46	BCL2 apoptosis regulator	Homo sapiens	128-133
10510942-3	1999	RESULTS: Initially, we asked whether paclitaxel-induced bcl-2 phosphorylation is triggered by the spindle assembly checkpoint via an active cdc2 kinase-dependent pathway and whether phosphorylation of endogenous bcl-2 is the signal that activates cell death machinery.	Paclitaxel	37-47	BCL2 apoptosis regulator	Homo sapiens	56-61
10510942-4	1999	Paclitaxel-induced G2/M cell cycle arrest correlated with cdc2 kinase activity and bcl-2 phosphorylation.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	83-88
10604265-4	1999	Of several agents recently shown to reduce prostate-specific antigen levels in phase II studies, 13-cis-retinoic acid and interferon-alpha can reduce the expression of bcl-2 and overcome bcl-2-mediated resistance to paclitaxel in resistant cell lines.	Paclitaxel	216-226	BCL2 apoptosis regulator	Homo sapiens	187-192
10471409-3	1999	Indeed, when paclitaxel-treated cells were induced to exit mitosis in the presence of 2-aminopurine, Bcl-2 phosphorylation and Bcl-2 down-regulation were both inhibited.	Paclitaxel	13-23	BCL2 apoptosis regulator	Homo sapiens	101-106
10471409-3	1999	Indeed, when paclitaxel-treated cells were induced to exit mitosis in the presence of 2-aminopurine, Bcl-2 phosphorylation and Bcl-2 down-regulation were both inhibited.	Paclitaxel	13-23	BCL2 apoptosis regulator	Homo sapiens	127-132
10421615-1	1999	We have previously reported that paclitaxel (Taxol) is a potent inducer of cytochrome P-450 (CYP) 3A protein and CYP3A mRNA in human hepatocyte cultures.	Paclitaxel	33-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-100
10628333-7	1999	In KB cells, Bcl-2 expression decreased only after treatment with paclitaxel.	Paclitaxel	66-76	BCL2 apoptosis regulator	Homo sapiens	13-18
10424768-7	1999	p53 and p21 protein content also increased markedly during paclitaxel exposure, accompanied by phosphorylation of Bcl-2.	Paclitaxel	59-69	tumor protein p53	Homo sapiens	0-3
10424768-7	1999	p53 and p21 protein content also increased markedly during paclitaxel exposure, accompanied by phosphorylation of Bcl-2.	Paclitaxel	59-69	BCL2 apoptosis regulator	Homo sapiens	114-119
10421615-5	1999	The maximal CYP3A activity detected after treatment with Taxol or rifampicin was similar in six separate human hepatocyte cultures, suggesting that the cultures have achieved a limit of maximally inducible CYP3A.	Paclitaxel	57-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	12-17
10446979-6	1999	Increased expression of MAP4, which occurs when p53 is transcriptionally inactive, increases microtubule polymerization, paclitaxel binding, and sensitivity to paclitaxel, a drug that stabilizes polymerized microtubules.	Paclitaxel	160-170	tumor protein p53	Homo sapiens	48-51
10421615-1	1999	We have previously reported that paclitaxel (Taxol) is a potent inducer of cytochrome P-450 (CYP) 3A protein and CYP3A mRNA in human hepatocyte cultures.	Paclitaxel	33-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-118
10421615-1	1999	We have previously reported that paclitaxel (Taxol) is a potent inducer of cytochrome P-450 (CYP) 3A protein and CYP3A mRNA in human hepatocyte cultures.	Paclitaxel	45-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-100
10421615-1	1999	We have previously reported that paclitaxel (Taxol) is a potent inducer of cytochrome P-450 (CYP) 3A protein and CYP3A mRNA in human hepatocyte cultures.	Paclitaxel	45-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-118
10421615-2	1999	Here we report that Taxol increased CYP3A-dependent testosterone 6beta-hydroxylation in intact hepatocytes.	Paclitaxel	20-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-41
10421615-4	1999	Treatment of hepatocyte cultures with concentrations of Taxol higher than 10 microM caused a dose-dependent decrease in testosterone 6beta-hydroxylase activity, amount of CYP3A protein, and total protein synthesis.	Paclitaxel	56-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	171-176
10449440-7	1999	Prevention of MT rearrangement by taxol resulted in accumulation of NaPi-2 in the subapical cell portion after 15 minutes and a strong delay in depletion of intracellular transporter after 60 minutes of PTH action.	Paclitaxel	34-39	solute carrier family 34 member 1	Rattus norvegicus	68-74
10449440-10	1999	These results suggest that NaPi-2 is downregulated in response to PTH through a rapid endocytic process in 2 separate steps: (a) internalization of the transporter into the SEA, and (b) its delivery to degradative organelles by a trafficking mechanism whose efficiency depends on a taxol-sensitive rearrangement of MTs.	Paclitaxel	282-287	solute carrier family 34 member 1	Rattus norvegicus	27-33
10405348-6	1999	In this study, we have examined the ability of paclitaxel or 2-meOE2 to antagonise TNFalpha-stimulated aromatase activity in stromal fibroblasts derived from normal or malignant breast tissues.	Paclitaxel	47-57	tumor necrosis factor	Homo sapiens	83-91
10634173-0	1999	CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.	Paclitaxel	101-111	CD34 molecule	Homo sapiens	0-4
10634173-2	1999	There are limited data regarding the pharmacodynamics and threshold CD34+ cell dose required for engraftment following high-dose paclitaxel.	Paclitaxel	129-139	CD34 molecule	Homo sapiens	68-72
10405348-7	1999	Paclitaxel inhibited basal and TNFalpha-stimulated aromatase activities by 88% and 91% respectively.	Paclitaxel	0-10	tumor necrosis factor	Homo sapiens	31-39
10405348-9	1999	Both paclitaxel and 2-meOE2 also inhibited stimulation of aromatase activity by IL-6 plus its soluble receptor and PGE(2).	Paclitaxel	5-15	interleukin 6	Homo sapiens	80-84
10430095-5	1999	The activation of caspases, specifically caspase 3, is enhanced by flavopiridol on paclitaxel-treated cells.	Paclitaxel	83-93	caspase 3	Homo sapiens	41-50
10432288-5	1999	We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis.	Paclitaxel	81-91	BCL2 apoptosis regulator	Homo sapiens	19-24
10432288-5	1999	We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis.	Paclitaxel	131-141	BCL2 apoptosis regulator	Homo sapiens	19-24
10421546-0	1999	Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2/M accumulation.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	39-42
10421546-3	1999	Although initial studies demonstrated that various DNA-damaging agents can induce p53, more recent studies have also shown p53 induction following nonDNA-damaging agents, including paclitaxel.	Paclitaxel	181-191	tumor protein p53	Homo sapiens	123-126
10421546-10	1999	RESULTS: A 4-fold increase in paclitaxel sensitivity was observed among RKO cells deficient in p53 function compared with wild-type RKO cells (IC 50: 4 nM, 1 nM, 1nM for RKO, RKO.p53.13, RC 10.3, respectively).	Paclitaxel	30-40	tumor protein p53	Homo sapiens	95-98
10421546-10	1999	RESULTS: A 4-fold increase in paclitaxel sensitivity was observed among RKO cells deficient in p53 function compared with wild-type RKO cells (IC 50: 4 nM, 1 nM, 1nM for RKO, RKO.p53.13, RC 10.3, respectively).	Paclitaxel	30-40	tumor protein p53	Homo sapiens	179-182
10421546-11	1999	The increased cytotoxic effect in RKO cells with inactive p53 correlated with an increased propensity towards micronucleation and DNA fragmentation following paclitaxel treatment.	Paclitaxel	158-168	tumor protein p53	Homo sapiens	58-61
10421546-13	1999	CONCLUSIONS: RKO cells lacking functional p53 demonstrate significantly enhanced sensitivity to paclitaxel compared with that of wild-type RKO cells.	Paclitaxel	96-106	tumor protein p53	Homo sapiens	42-45
10421546-15	1999	Although previous published reports of enhanced paclitaxel sensitivity in p53-deficient cells correlated this finding with increased G2/M arrest, we did not observe any significant correlation between paclitaxel-induced cell kill and the degree of mitotic arrest.	Paclitaxel	48-58	tumor protein p53	Homo sapiens	74-77
10517338-7	1999	Cell cycle progression and counting of trypan-blue stained cells showed that IGF-I was inducing proliferation in paclitaxel-treated but not doxorubicin-treated cells.	Paclitaxel	113-123	insulin like growth factor 1	Homo sapiens	77-82
10517338-12	1999	In contrast, IGF-I rescue of paclitaxel-induced apoptosis required both PI-3 kinase and MAPK, suggesting that IGF-I-mediated protection was due to enhancement of proliferation.	Paclitaxel	29-39	insulin like growth factor 1	Homo sapiens	13-18
10517338-12	1999	In contrast, IGF-I rescue of paclitaxel-induced apoptosis required both PI-3 kinase and MAPK, suggesting that IGF-I-mediated protection was due to enhancement of proliferation.	Paclitaxel	29-39	insulin like growth factor 1	Homo sapiens	110-115
10517338-13	1999	Therefore, IGF-I attenuated the response of breast cancer cells to doxorubicin and paclitaxel by at least two mechanisms: induction of proliferation and inhibition of apoptosis.	Paclitaxel	83-93	insulin like growth factor 1	Homo sapiens	11-16
10517345-9	1999	The sequential exposure to vinorelbine followed by paclitaxel produced additive effects for the PA1 and WiDr cells, additive and antagonistic effects for the A549 cells, and antagonistic effects for the MCF7 cells.	Paclitaxel	51-61	PAXIP1 associated glutamate rich protein 1	Homo sapiens	96-99
10517345-10	1999	The sequential exposure to paclitaxel followed by vinorelbine produced additive effects for the A549, and PA1 cells, additive and antagonistic effects for the MCF7 cells, and antagonistic effects for the WiDr cells.	Paclitaxel	27-37	PAXIP1 associated glutamate rich protein 1	Homo sapiens	106-109
10430060-0	1999	Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	190-194
10430060-1	1999	The MDR1 multidrug resistance gene confers resistance to natural-product anticancer drugs including paclitaxel.	Paclitaxel	100-110	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
10430060-2	1999	We conducted a clinical gene therapy study to determine whether retroviral-mediated transfer of MDR1 in human hematopoietic cells would result in stable engraftment, and possibly expansion, of cells containing this gene after treatment with myelosuppressive doses of paclitaxel.	Paclitaxel	267-277	ATP binding cassette subfamily B member 1	Homo sapiens	96-100
10430060-14	1999	One patient remained positive for the MDR1 transgene throughout all six cycles of paclitaxel therapy, whereas the other 2 patients showed a decrease in the number of cells containing the transgene to undetectable levels.	Paclitaxel	82-92	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
10430060-15	1999	Despite the low level of engraftment of MDR1-marked cells, a correlation was observed between the relative number of granulocytes containing the MDR1 transgene and the granulocyte nadir after paclitaxel therapy.	Paclitaxel	192-202	ATP binding cassette subfamily B member 1	Homo sapiens	145-149
10430095-7	1999	The induction of apoptosis, activation of caspase 3, and poly(ADP-ribose) polymerase cleavage in treatment regimens with paclitaxel and paclitaxel followed by flavopiridol were reversed by treatment with the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone, which supports the notion that caspases are the executioners of apoptosis in these processes.	Paclitaxel	121-131	caspase 3	Homo sapiens	42-51
10430095-7	1999	The induction of apoptosis, activation of caspase 3, and poly(ADP-ribose) polymerase cleavage in treatment regimens with paclitaxel and paclitaxel followed by flavopiridol were reversed by treatment with the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone, which supports the notion that caspases are the executioners of apoptosis in these processes.	Paclitaxel	121-131	poly(ADP-ribose) polymerase 1	Homo sapiens	57-84
10430095-7	1999	The induction of apoptosis, activation of caspase 3, and poly(ADP-ribose) polymerase cleavage in treatment regimens with paclitaxel and paclitaxel followed by flavopiridol were reversed by treatment with the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone, which supports the notion that caspases are the executioners of apoptosis in these processes.	Paclitaxel	136-146	caspase 3	Homo sapiens	42-51
10430095-7	1999	The induction of apoptosis, activation of caspase 3, and poly(ADP-ribose) polymerase cleavage in treatment regimens with paclitaxel and paclitaxel followed by flavopiridol were reversed by treatment with the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone, which supports the notion that caspases are the executioners of apoptosis in these processes.	Paclitaxel	136-146	poly(ADP-ribose) polymerase 1	Homo sapiens	57-84
10358184-0	1999	Use of a photoactivatable taxol analogue to identify unique cellular targets in murine macrophages: identification of murine CD18 as a major taxol-binding protein and a role for Mac-1 in taxol-induced gene expression.	Paclitaxel	26-31	integrin beta 2	Mus musculus	125-129
10385571-0	1999	Correlation between in vitro drug response in the EDR assay and response to primary paclitaxel and cisplatin.	Paclitaxel	84-94	paternally expressed 10	Homo sapiens	50-53
10527889-0	1999	A crucial role of caspase 3 and caspase 8 in paclitaxel-induced apoptosis.	Paclitaxel	45-55	caspase 3	Homo sapiens	18-27
10527889-6	1999	The cleavage of caspase 3, caspase 8, and DFF45/ICAD was also observed in paclitaxel-induced apoptosis, and the inhibitor of caspase 3 and caspase 8 inhibited both antitumor effects and apoptosis induced by paclitaxel.	Paclitaxel	74-84	caspase 3	Homo sapiens	16-25
10527889-6	1999	The cleavage of caspase 3, caspase 8, and DFF45/ICAD was also observed in paclitaxel-induced apoptosis, and the inhibitor of caspase 3 and caspase 8 inhibited both antitumor effects and apoptosis induced by paclitaxel.	Paclitaxel	74-84	caspase 3	Homo sapiens	125-134
10527889-6	1999	The cleavage of caspase 3, caspase 8, and DFF45/ICAD was also observed in paclitaxel-induced apoptosis, and the inhibitor of caspase 3 and caspase 8 inhibited both antitumor effects and apoptosis induced by paclitaxel.	Paclitaxel	207-217	caspase 3	Homo sapiens	16-25
10527889-6	1999	The cleavage of caspase 3, caspase 8, and DFF45/ICAD was also observed in paclitaxel-induced apoptosis, and the inhibitor of caspase 3 and caspase 8 inhibited both antitumor effects and apoptosis induced by paclitaxel.	Paclitaxel	207-217	caspase 3	Homo sapiens	125-134
10358184-8	1999	In addition, Taxol-induced IL-12 p40 mRNA was markedly reduced in Mac-1 knockout macrophages and anti-Mac-1 Ab blocked secretion of IL-12 p70 in Taxol- and LPS-stimulated macrophages.	Paclitaxel	13-18	integrin alpha M	Mus musculus	66-71
10358184-8	1999	In addition, Taxol-induced IL-12 p40 mRNA was markedly reduced in Mac-1 knockout macrophages and anti-Mac-1 Ab blocked secretion of IL-12 p70 in Taxol- and LPS-stimulated macrophages.	Paclitaxel	13-18	integrin alpha M	Mus musculus	102-107
10358184-8	1999	In addition, Taxol-induced IL-12 p40 mRNA was markedly reduced in Mac-1 knockout macrophages and anti-Mac-1 Ab blocked secretion of IL-12 p70 in Taxol- and LPS-stimulated macrophages.	Paclitaxel	145-150	integrin alpha M	Mus musculus	102-107
10358184-9	1999	Since CD18 has been described as a participant in LPS-induced binding and signal transduction, these data support the hypothesis that the interaction of murine CD18 with Taxol is involved in its proinflammatory activity.	Paclitaxel	170-175	integrin subunit beta 2	Homo sapiens	6-10
10358184-9	1999	Since CD18 has been described as a participant in LPS-induced binding and signal transduction, these data support the hypothesis that the interaction of murine CD18 with Taxol is involved in its proinflammatory activity.	Paclitaxel	170-175	integrin beta 2	Mus musculus	160-164
10400418-1	1999	Raf-1 activation and Bcl-2 hyperphosphorylation following treatment with paclitaxel (Taxol) or other microtubule-active drugs is associated with mitotic arrest.	Paclitaxel	73-83	BCL2 apoptosis regulator	Homo sapiens	21-26
10400418-1	1999	Raf-1 activation and Bcl-2 hyperphosphorylation following treatment with paclitaxel (Taxol) or other microtubule-active drugs is associated with mitotic arrest.	Paclitaxel	85-90	BCL2 apoptosis regulator	Homo sapiens	21-26
10400418-4	1999	Simultaneously with PARP cleavage, paclitaxel induces cleavage of Bcl-2 protein yielding a potentially pro-apoptotic 22 kDa product.	Paclitaxel	35-45	BCL2 apoptosis regulator	Homo sapiens	66-71
10527889-7	1999	These results suggest that activation of caspase 3 and caspase 8 plays a crucial role in paclitaxel-induced apoptosis under any concentrations of paclitaxel.	Paclitaxel	89-99	caspase 3	Homo sapiens	41-50
10527889-7	1999	These results suggest that activation of caspase 3 and caspase 8 plays a crucial role in paclitaxel-induced apoptosis under any concentrations of paclitaxel.	Paclitaxel	146-156	caspase 3	Homo sapiens	41-50
10358184-0	1999	Use of a photoactivatable taxol analogue to identify unique cellular targets in murine macrophages: identification of murine CD18 as a major taxol-binding protein and a role for Mac-1 in taxol-induced gene expression.	Paclitaxel	141-146	integrin beta 2	Mus musculus	125-129
10358184-0	1999	Use of a photoactivatable taxol analogue to identify unique cellular targets in murine macrophages: identification of murine CD18 as a major taxol-binding protein and a role for Mac-1 in taxol-induced gene expression.	Paclitaxel	141-146	integrin beta 2	Mus musculus	125-129
10358184-7	1999	This finding was supported by the concomitant failure of macrophage membranes from Mac-1 knockout mice to express immunoreactive CD18 and the major Taxol-binding protein.	Paclitaxel	148-153	integrin alpha M	Mus musculus	83-88
10376521-0	1999	Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells.	Paclitaxel	40-45	coagulation factor II, thrombin	Homo sapiens	0-15
10376521-2	1999	Taxol-induced apoptosis was associated with phosphorylation of both c-Raf-1 and Bcl-2 and activation of ERK and JNK MAP kinases.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	80-85
10376521-2	1999	Taxol-induced apoptosis was associated with phosphorylation of both c-Raf-1 and Bcl-2 and activation of ERK and JNK MAP kinases.	Paclitaxel	0-5	mitogen-activated protein kinase 3	Homo sapiens	104-107
10376521-4	1999	TPCK treatment also prevented phosphorylation of c-Raf-1 and Bcl-2 in response to Taxol treatment.	Paclitaxel	82-87	BCL2 apoptosis regulator	Homo sapiens	61-66
10376521-5	1999	The serine protease inhibitor did not alter JNK activity, but it enhanced Taxol-induced activation of ERK1/2.	Paclitaxel	74-79	coagulation factor II, thrombin	Homo sapiens	4-19
10376521-5	1999	The serine protease inhibitor did not alter JNK activity, but it enhanced Taxol-induced activation of ERK1/2.	Paclitaxel	74-79	mitogen-activated protein kinase 3	Homo sapiens	102-108
10376521-6	1999	Treatment of cells with the inhibitor of MEK activation, PD98059, prevented Taxol-induced ERK activation both in the presence and absence of TPCK, but did not influence survival of either Taxol- or Taxol plus TPCK-treated cells.	Paclitaxel	76-81	mitogen-activated protein kinase 3	Homo sapiens	90-93
10376521-8	1999	Thus, while the Taxol-induced phosphorylations of c-Raf-1 and Bcl-2 proteins appear to be coupled, these events can be disassociated from ERK1/2 activation.	Paclitaxel	16-21	BCL2 apoptosis regulator	Homo sapiens	62-67
10376521-8	1999	Thus, while the Taxol-induced phosphorylations of c-Raf-1 and Bcl-2 proteins appear to be coupled, these events can be disassociated from ERK1/2 activation.	Paclitaxel	16-21	mitogen-activated protein kinase 3	Homo sapiens	138-144
10376521-9	1999	In summary, these findings suggest that phosphorylation of c-Raf-1 and Bcl-2, but not ERK1/2, are important signaling events in Taxol-induced apoptosis of MCF-7 breast cancer cells and that a TPCK inhibitable protease(s) is required for these processes.	Paclitaxel	128-133	BCL2 apoptosis regulator	Homo sapiens	71-76
10426457-3	1999	In vitro analyses demonstrate docetaxel (Taxotere; Rhone-Poulenc Rorer, Collegeville, PA) to be 100-fold more potent than paclitaxel in bcl-2 phosphorylation and apoptotic cell death.	Paclitaxel	122-132	BCL2 apoptosis regulator	Homo sapiens	136-141
10362110-4	1999	We have recently described increased expression of the brain-specific human class III beta-tubulin isotype, encoded by the Hbeta4 gene, in both Taxol-resistant ovarian tumours and non-small-cell lung cancer cell lines.	Paclitaxel	144-149	potassium calcium-activated channel subfamily M regulatory beta subunit 4	Homo sapiens	123-129
10321832-7	1999	However, ECM prevented p21 and Bcl-2 down-regulation induced by taxol or etoposide.	Paclitaxel	64-69	BCL2 apoptosis regulator	Homo sapiens	31-36
10362110-6	1999	Taxol-resistant lung cancer cells, A549-T24, which are 17-fold resistant to Taxol and display a fourfold increase in Hbeta4 expression compared to the parental A549 cells, were treated with 1 microM antisense ODNs.	Paclitaxel	0-5	potassium calcium-activated channel subfamily M regulatory beta subunit 4	Homo sapiens	117-123
10362110-10	1999	These findings support an important role for Hbeta4 (class III) beta-tubulin expression in Taxol resistance and have potential implications for the treatment of Taxol-resistant tumours.	Paclitaxel	91-96	potassium calcium-activated channel subfamily M regulatory beta subunit 4	Homo sapiens	45-51
10362110-10	1999	These findings support an important role for Hbeta4 (class III) beta-tubulin expression in Taxol resistance and have potential implications for the treatment of Taxol-resistant tumours.	Paclitaxel	161-166	potassium calcium-activated channel subfamily M regulatory beta subunit 4	Homo sapiens	45-51
10347252-0	1999	Overexpression of p21(waf1) decreases G2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein.	Paclitaxel	75-85	cyclin dependent kinase inhibitor 1A	Homo sapiens	18-21
10347252-1	1999	We examined the effect of overexpression of p21(waf1) on cytotoxicity of paclitaxel, a microtubule stabilizer, using a tetracycline-inducible expression system in human sarcoma cells (SaOs-2) that lack both functional retinoblastoma protein and p53.	Paclitaxel	73-83	cyclin dependent kinase inhibitor 1A	Homo sapiens	44-52
10347252-3	1999	Upon p21(waf1) induction by tetracycline withdrawal, we observed a reduced apoptotic response to paclitaxel with a 3- to 6-fold increase in IC50 values compared with that of cells not induced by p21(waf1).	Paclitaxel	97-107	cyclin dependent kinase inhibitor 1A	Homo sapiens	5-8
10347252-5	1999	After treatment with paclitaxel, less accumulation of G2-M was observed in p21(waf1)-induced cells compared with non-p21(waf1)-induced cells (57% versus 74%).	Paclitaxel	21-31	cyclin dependent kinase inhibitor 1A	Homo sapiens	75-78
10347252-5	1999	After treatment with paclitaxel, less accumulation of G2-M was observed in p21(waf1)-induced cells compared with non-p21(waf1)-induced cells (57% versus 74%).	Paclitaxel	21-31	cyclin dependent kinase inhibitor 1A	Homo sapiens	75-83
10347252-6	1999	p21(waf1) induction also inhibited the increased cyclin B1-associated kinase activity induced by paclitaxel.	Paclitaxel	97-107	cyclin dependent kinase inhibitor 1A	Homo sapiens	0-3
10347252-7	1999	Overexpression of p21(waf1) in SaOs-2 cells lacking both p53 and functional retinoblastoma protein may decrease the G2-M arrest induced by paclitaxel due to suppression of the S-G2 checkpoint, resulting in a decreased apoptotic response of cells to paclitaxel.	Paclitaxel	139-149	cyclin dependent kinase inhibitor 1A	Homo sapiens	18-21
10347252-7	1999	Overexpression of p21(waf1) in SaOs-2 cells lacking both p53 and functional retinoblastoma protein may decrease the G2-M arrest induced by paclitaxel due to suppression of the S-G2 checkpoint, resulting in a decreased apoptotic response of cells to paclitaxel.	Paclitaxel	139-149	tumor protein p53	Homo sapiens	57-60
10347252-7	1999	Overexpression of p21(waf1) in SaOs-2 cells lacking both p53 and functional retinoblastoma protein may decrease the G2-M arrest induced by paclitaxel due to suppression of the S-G2 checkpoint, resulting in a decreased apoptotic response of cells to paclitaxel.	Paclitaxel	249-259	cyclin dependent kinase inhibitor 1A	Homo sapiens	18-21
10334917-0	1999	Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis.	Paclitaxel	101-111	BCL2 apoptosis regulator	Homo sapiens	12-17
10334917-1	1999	The impact of ectopic expression of an N-terminal phosphorylation loop deletant Bcl-2 protein (Bcl-2Delta32-80) on the response of U937 monoblastic leukemia cells to paclitaxel was examined.	Paclitaxel	166-176	BCL2 apoptosis regulator	Homo sapiens	80-85
10334917-3	1999	58, 3202, 1998), U937 cells overexpressing Bcl-2Delta32-80 were significantly more resistant than those overexpressing full-length protein to caspase-3 and -9 activation, PARP degradation, and apoptosis induced by paclitaxel (500 nM; 18 h).	Paclitaxel	214-224	BCL2 apoptosis regulator	Homo sapiens	43-48
10334917-5	1999	Enhanced resistance of U937/Bcl-2Delta32-80 cells to paclitaxel was observed primarily in the G2M population.	Paclitaxel	53-63	BCL2 apoptosis regulator	Homo sapiens	28-33
10334917-6	1999	Together, these findings demonstrate that deletion of the Bcl-2 phosphorylation loop domain increases resistance of U937 leukemia cells to paclitaxel-mediated mitochondrial damage and apoptosis and suggest that factors other than, or in addition to, phosphorylation contribute to Bcl-2-related cytoprotectivity against paclitaxel in this model system.	Paclitaxel	139-149	BCL2 apoptosis regulator	Homo sapiens	58-63
10334917-6	1999	Together, these findings demonstrate that deletion of the Bcl-2 phosphorylation loop domain increases resistance of U937 leukemia cells to paclitaxel-mediated mitochondrial damage and apoptosis and suggest that factors other than, or in addition to, phosphorylation contribute to Bcl-2-related cytoprotectivity against paclitaxel in this model system.	Paclitaxel	319-329	BCL2 apoptosis regulator	Homo sapiens	58-63
10344753-10	1999	These results suggest that cisplatin blocks paclitaxel-induced apoptosis at a point downstream of Bcl-2 degradation and independent of microtubule stabilization.	Paclitaxel	44-54	BCL2 apoptosis regulator	Homo sapiens	98-103
10399623-0	1999	c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy.	Paclitaxel	53-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-8
10087341-5	1999	We investigated the effect of the anti-tumour drug taxol, a known microtubule polymerizing agent, on Ca2+ handling in adult rat ventricular myocytes.	Paclitaxel	51-56	carbonic anhydrase 2	Rattus norvegicus	101-104
10087341-9	1999	In taxol-treated cells there was a reduction in the amplitude of contraction, no significant effect on the amplitude of L-type Ca2+ current, but a significant reduction in the amplitude of the Ca2+ transient.	Paclitaxel	3-8	carbonic anhydrase 2	Rattus norvegicus	193-196
10087341-12	1999	There was a significant reduction in the ratio of electrically stimulated : caffeine-induced Ca2+ transients in taxol-treated cells.	Paclitaxel	112-117	carbonic anhydrase 2	Rattus norvegicus	93-96
10087341-13	1999	This observation is consistent with the hypothesis that taxol reduces fractional SR Ca2+ release.	Paclitaxel	56-61	carbonic anhydrase 2	Rattus norvegicus	84-87
10087341-15	1999	We suggest that the negative inotropic effect of taxol may, at least in part, be the result of reduced release of Ca2+ from the SR. Microtubules may be important regulators of Ca2+ handling in the heart.	Paclitaxel	49-54	carbonic anhydrase 2	Rattus norvegicus	114-117
10087341-15	1999	We suggest that the negative inotropic effect of taxol may, at least in part, be the result of reduced release of Ca2+ from the SR. Microtubules may be important regulators of Ca2+ handling in the heart.	Paclitaxel	49-54	carbonic anhydrase 2	Rattus norvegicus	176-179
10405640-2	1999	Vinca alkaloids, paclitaxel and docetaxel are actively effluxed by P-glycoprotein and/or the MRP1.	Paclitaxel	17-27	ATP binding cassette subfamily C member 1	Homo sapiens	93-97
10212239-2	1999	MEK kinase 1 (MEKK1) activates the c-Jun NH2-terminal kinase (JNK) pathway in response to exposure of cells to microtubule toxins, including taxol.	Paclitaxel	141-146	mitogen-activated protein kinase 8	Homo sapiens	35-60
10212239-2	1999	MEK kinase 1 (MEKK1) activates the c-Jun NH2-terminal kinase (JNK) pathway in response to exposure of cells to microtubule toxins, including taxol.	Paclitaxel	141-146	mitogen-activated protein kinase 8	Homo sapiens	62-65
10196170-7	1999	Taxol treatment of cells, therefore, dissociates MEKK1 activation from the regulation of the JNK pathway.	Paclitaxel	0-5	mitogen-activated protein kinase 8	Homo sapiens	93-96
10196170-8	1999	Overexpression of anti-apoptotic Bcl2 blocked MEKK1 and taxol-induced apoptosis but did not block the caspase-dependent cleavage of MEKK1 in response to etoposide.	Paclitaxel	56-61	BCL2 apoptosis regulator	Homo sapiens	33-37
10193934-10	1999	Immunofluorescence and Western immunoblotting of cultures showed that 1 x 10(-6) M paclitaxel increased P-glycoprotein expression in Caco-2 and LoVo cells.	Paclitaxel	83-93	ATP binding cassette subfamily B member 1	Homo sapiens	104-118
10193934-14	1999	Increased P-glycoprotein expression appears to be correlated with paclitaxel resistance in polyposis and cancerous colonic cells.	Paclitaxel	66-76	ATP binding cassette subfamily B member 1	Homo sapiens	10-24
10399623-4	1999	In a therapy optimizing study with weekly dose-intensified paclitaxel monotherapy (schedule: 90 mg/m2 weekly x 6, q9w), we correlated the clinical course of stage IV breast cancer in UICC criteria with the course of the shed c-erbB-2 protein fragment and the CA 27.29 serum level.	Paclitaxel	59-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	225-233
10399623-7	1999	While the overall response rate in the study is 36%, the response rate among c-erbB-2-positive patients is 62%, indicating a high sensitivity of c-erbB-2 positive patients to dose-intense paclitaxel treatment.	Paclitaxel	188-198	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-85
10399623-7	1999	While the overall response rate in the study is 36%, the response rate among c-erbB-2-positive patients is 62%, indicating a high sensitivity of c-erbB-2 positive patients to dose-intense paclitaxel treatment.	Paclitaxel	188-198	erb-b2 receptor tyrosine kinase 2	Homo sapiens	145-153
10210535-0	1999	Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.	Paclitaxel	75-85	tumor protein p53	Homo sapiens	8-11
11550305-2	1999	We examined paclitaxel-induced killing in seven cell lines derived from human malignant astrocytic gliomas and medulloblastomas with the goal of characterizing range of sensitivity, contribution of P-glycoprotein 170-mediated drug efflux to resistance, and cross-resistance with alkylating agents.	Paclitaxel	12-22	ATP binding cassette subfamily B member 1	Homo sapiens	198-212
10561191-0	1999	Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison.	Paclitaxel	182-192	erythropoietin	Homo sapiens	0-14
10210535-0	1999	Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.	Paclitaxel	75-85	cyclin dependent kinase inhibitor 2A	Homo sapiens	16-19
10210535-8	1999	Recent evidence suggests that paclitaxel is unique in its ability to activate apoptosis in tumor cells with p53 mutations in vitro and in vivo.	Paclitaxel	30-40	tumor protein p53	Homo sapiens	108-111
10210535-11	1999	The effects of p16(INK4a) alterations in response to paclitaxel/radiation and the risk of systemic relapse are currently being evaluated.	Paclitaxel	53-63	cyclin dependent kinase inhibitor 2A	Homo sapiens	15-18
10210535-11	1999	The effects of p16(INK4a) alterations in response to paclitaxel/radiation and the risk of systemic relapse are currently being evaluated.	Paclitaxel	53-63	cyclin dependent kinase inhibitor 2A	Homo sapiens	19-24
10210540-5	1999	This finding suggested that paclitaxel/RT was a rational treatment approach for other malignancies that frequently harbor p53 mutations, such as upper gastrointestinal malignancies.	Paclitaxel	28-38	tumor protein p53	Homo sapiens	122-125
10075725-0	1999	Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells.	Paclitaxel	35-45	mitogen-activated protein kinase 8	Homo sapiens	79-102
10097113-11	1999	JNK, but not ERK or p38 MAPK, appear to be involved in the phosphorylation of Bcl-2 induced by paclitaxel.	Paclitaxel	95-105	mitogen-activated protein kinase 8	Homo sapiens	0-3
10097113-11	1999	JNK, but not ERK or p38 MAPK, appear to be involved in the phosphorylation of Bcl-2 induced by paclitaxel.	Paclitaxel	95-105	BCL2 apoptosis regulator	Homo sapiens	78-83
10097113-0	1999	Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis.	Paclitaxel	55-65	BCL2 apoptosis regulator	Homo sapiens	31-36
10097113-1	1999	At high concentrations, the tubule poison paclitaxel is able to kill cancer cells that express Bcl-2; it inhibits the antiapoptotic activity of Bcl-2 by inducing its phosphorylation.	Paclitaxel	42-52	BCL2 apoptosis regulator	Homo sapiens	95-100
10097113-1	1999	At high concentrations, the tubule poison paclitaxel is able to kill cancer cells that express Bcl-2; it inhibits the antiapoptotic activity of Bcl-2 by inducing its phosphorylation.	Paclitaxel	42-52	BCL2 apoptosis regulator	Homo sapiens	144-149
10097113-3	1999	Mutant forms of Bcl-2 with an alteration in serine at amino acid 70 (S70A) or with deletion of a 60-aa loop region between the alpha1 and alpha2 helices (Deltaloop Bcl-2, which also deletes amino acid 70) were unable to be phosphorylated by paclitaxel treatment of MDA-MB-231 cells into which the genes for the mutant proteins were transfected.	Paclitaxel	241-251	BCL2 apoptosis regulator	Homo sapiens	16-21
10097113-5	1999	In cells expressing the S70A mutant, paclitaxel induced about one-third the level of apoptosis seen with wild-type Bcl-2.	Paclitaxel	37-47	BCL2 apoptosis regulator	Homo sapiens	115-120
10097113-7	1999	Paclitaxel-induced apoptosis was associated with phosphorylation of Bcl-2 and activation of ERK and JNK MAPKs.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	68-73
10097113-7	1999	Paclitaxel-induced apoptosis was associated with phosphorylation of Bcl-2 and activation of ERK and JNK MAPKs.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Homo sapiens	92-95
10097113-7	1999	Paclitaxel-induced apoptosis was associated with phosphorylation of Bcl-2 and activation of ERK and JNK MAPKs.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	100-103
10097113-8	1999	If JNK activation was blocked by transfections with either a stress-activated protein kinase kinase dominant-negative (K--&gt;R) gene (which prevents the activation of a kinase upstream of JNK) or MAPK phosphatase-1 gene (which dephosphorylates and inactivates JNK), Bcl-2 phosphorylation did not occur, and the cells were not killed by paclitaxel.	Paclitaxel	337-347	mitogen-activated protein kinase 8	Homo sapiens	3-6
10075725-0	1999	Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells.	Paclitaxel	35-45	mitogen-activated protein kinase 8	Homo sapiens	104-107
10075725-2	1999	We and others have recently demonstrated that paclitaxel also activates the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) signal transduction pathway in various human cell types, however, no clear role has been established for JNK/SAPK in paclitaxel-induced apoptosis.	Paclitaxel	46-56	mitogen-activated protein kinase 8	Homo sapiens	76-99
10075725-2	1999	We and others have recently demonstrated that paclitaxel also activates the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) signal transduction pathway in various human cell types, however, no clear role has been established for JNK/SAPK in paclitaxel-induced apoptosis.	Paclitaxel	46-56	mitogen-activated protein kinase 8	Homo sapiens	133-141
10075725-2	1999	We and others have recently demonstrated that paclitaxel also activates the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) signal transduction pathway in various human cell types, however, no clear role has been established for JNK/SAPK in paclitaxel-induced apoptosis.	Paclitaxel	260-270	mitogen-activated protein kinase 8	Homo sapiens	133-141
10075725-6	1999	Our data indicate that: (i) activated JNK/SAPK acts upstream of membrane changes and caspase-3 activation in paclitaxel-initiated apoptotic pathways, independently of cell cycle stage, (ii) activated JNK/SAPK is not responsible for paclitaxel-induced phosphorylation of Bcl-2, and (iii) apoptosis resulting from microtubule damage may comprise multiple mechanisms, including a JNK/SAPK-dependent early phase and a JNK/SAPK-independent late phase.	Paclitaxel	109-119	mitogen-activated protein kinase 8	Homo sapiens	38-41
10075725-6	1999	Our data indicate that: (i) activated JNK/SAPK acts upstream of membrane changes and caspase-3 activation in paclitaxel-initiated apoptotic pathways, independently of cell cycle stage, (ii) activated JNK/SAPK is not responsible for paclitaxel-induced phosphorylation of Bcl-2, and (iii) apoptosis resulting from microtubule damage may comprise multiple mechanisms, including a JNK/SAPK-dependent early phase and a JNK/SAPK-independent late phase.	Paclitaxel	109-119	mitogen-activated protein kinase 9	Homo sapiens	42-46
10075725-6	1999	Our data indicate that: (i) activated JNK/SAPK acts upstream of membrane changes and caspase-3 activation in paclitaxel-initiated apoptotic pathways, independently of cell cycle stage, (ii) activated JNK/SAPK is not responsible for paclitaxel-induced phosphorylation of Bcl-2, and (iii) apoptosis resulting from microtubule damage may comprise multiple mechanisms, including a JNK/SAPK-dependent early phase and a JNK/SAPK-independent late phase.	Paclitaxel	109-119	caspase 3	Homo sapiens	85-94
10075725-6	1999	Our data indicate that: (i) activated JNK/SAPK acts upstream of membrane changes and caspase-3 activation in paclitaxel-initiated apoptotic pathways, independently of cell cycle stage, (ii) activated JNK/SAPK is not responsible for paclitaxel-induced phosphorylation of Bcl-2, and (iii) apoptosis resulting from microtubule damage may comprise multiple mechanisms, including a JNK/SAPK-dependent early phase and a JNK/SAPK-independent late phase.	Paclitaxel	109-119	mitogen-activated protein kinase 8	Homo sapiens	38-46
10075725-6	1999	Our data indicate that: (i) activated JNK/SAPK acts upstream of membrane changes and caspase-3 activation in paclitaxel-initiated apoptotic pathways, independently of cell cycle stage, (ii) activated JNK/SAPK is not responsible for paclitaxel-induced phosphorylation of Bcl-2, and (iii) apoptosis resulting from microtubule damage may comprise multiple mechanisms, including a JNK/SAPK-dependent early phase and a JNK/SAPK-independent late phase.	Paclitaxel	109-119	BCL2 apoptosis regulator	Homo sapiens	270-275
10075725-6	1999	Our data indicate that: (i) activated JNK/SAPK acts upstream of membrane changes and caspase-3 activation in paclitaxel-initiated apoptotic pathways, independently of cell cycle stage, (ii) activated JNK/SAPK is not responsible for paclitaxel-induced phosphorylation of Bcl-2, and (iii) apoptosis resulting from microtubule damage may comprise multiple mechanisms, including a JNK/SAPK-dependent early phase and a JNK/SAPK-independent late phase.	Paclitaxel	109-119	mitogen-activated protein kinase 8	Homo sapiens	200-208
10075725-6	1999	Our data indicate that: (i) activated JNK/SAPK acts upstream of membrane changes and caspase-3 activation in paclitaxel-initiated apoptotic pathways, independently of cell cycle stage, (ii) activated JNK/SAPK is not responsible for paclitaxel-induced phosphorylation of Bcl-2, and (iii) apoptosis resulting from microtubule damage may comprise multiple mechanisms, including a JNK/SAPK-dependent early phase and a JNK/SAPK-independent late phase.	Paclitaxel	109-119	mitogen-activated protein kinase 8	Homo sapiens	200-208
10075725-6	1999	Our data indicate that: (i) activated JNK/SAPK acts upstream of membrane changes and caspase-3 activation in paclitaxel-initiated apoptotic pathways, independently of cell cycle stage, (ii) activated JNK/SAPK is not responsible for paclitaxel-induced phosphorylation of Bcl-2, and (iii) apoptosis resulting from microtubule damage may comprise multiple mechanisms, including a JNK/SAPK-dependent early phase and a JNK/SAPK-independent late phase.	Paclitaxel	232-242	mitogen-activated protein kinase 8	Homo sapiens	38-41
10075725-6	1999	Our data indicate that: (i) activated JNK/SAPK acts upstream of membrane changes and caspase-3 activation in paclitaxel-initiated apoptotic pathways, independently of cell cycle stage, (ii) activated JNK/SAPK is not responsible for paclitaxel-induced phosphorylation of Bcl-2, and (iii) apoptosis resulting from microtubule damage may comprise multiple mechanisms, including a JNK/SAPK-dependent early phase and a JNK/SAPK-independent late phase.	Paclitaxel	232-242	mitogen-activated protein kinase 9	Homo sapiens	42-46
10075725-6	1999	Our data indicate that: (i) activated JNK/SAPK acts upstream of membrane changes and caspase-3 activation in paclitaxel-initiated apoptotic pathways, independently of cell cycle stage, (ii) activated JNK/SAPK is not responsible for paclitaxel-induced phosphorylation of Bcl-2, and (iii) apoptosis resulting from microtubule damage may comprise multiple mechanisms, including a JNK/SAPK-dependent early phase and a JNK/SAPK-independent late phase.	Paclitaxel	232-242	mitogen-activated protein kinase 8	Homo sapiens	38-46
10024685-0	1999	Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	14-19
10024685-4	1999	Taxol treatment of monolayers resulted in the characteristic phosphorylation of Bcl-2, which was not demonstrated in spheroid cultures.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	80-85
10024685-5	1999	Bax expression was reduced in spheroids following cisplatin or Taxol treatment, while p53 levels remained unchanged.	Paclitaxel	63-68	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
10211534-3	1999	In vitro and in vivo preclinical studies have shown that administration of trastuzumab alone or in combination with paclitaxel or carboplatin significantly inhibits the growth of breast tumor-derived cell lines that overexpress the HER2 gene product.	Paclitaxel	116-126	erb-b2 receptor tyrosine kinase 2	Homo sapiens	232-236
10026266-2	1999	This effect was (i) assessed by turbidity measurements, pelleting of microtubules, and electron microscopy, (ii) observed when tubulin assembly was induced by taxol as well as by GTP in the presence of microtubule-associated proteins or glutamate, and (iii) specific as it was not produced by the phosphofructokinase from rabbit muscle.	Paclitaxel	159-164	ATP-dependent 6-phosphofructokinase, muscle type	Oryctolagus cuniculus	297-316
9973225-11	1999	In contrast, melphalan and paclitaxel augmented TRAIL-induced apoptosis in few cell lines, and methotrexate did not augment it in any cell line.	Paclitaxel	27-37	TNF superfamily member 10	Homo sapiens	48-53
10850285-2	1999	In this study, we show that paclitaxel possesses an antiangiogenic property associated with a down-regulation of vascular endothelial growth factor (VEGF) in a highly-vascularized transgenic murine breast cancer (Met-1).	Paclitaxel	28-38	DNA methyltransferase (cytosine-5) 1	Mus musculus	213-218
10850285-3	1999	Paclitaxel, at non-cytotoxic doses of 0, 3 and 6 mg/kg/day, was administered intraperitoneally for 5 days to nude mice bearing the Met-1 breast tumor.	Paclitaxel	0-10	DNA methyltransferase (cytosine-5) 1	Mus musculus	131-136
10850285-5	1999	Paclitaxel also suppressed expression of VEGF in the Met-1 cells transplanted in nude mice or maintained in cell culture.	Paclitaxel	0-10	DNA methyltransferase (cytosine-5) 1	Mus musculus	53-58
10211948-7	1999	This G2/M restriction was further characterized by flow cytometry, which revealed cyclin A and cdc2 kinase accumulation in paclitaxel-treated cells.	Paclitaxel	123-133	cyclin A2	Homo sapiens	82-90
14634295-3	1999	In time, treatment with 1 microM paclitaxel successively induced formation of bundles, then pseudo-asters concomitantly with mitotic block and phosphorylation of bcl-2 (48 h), then phosphorylation of tau and externalization of phosphatidylserine at the early phase of apoptosis (72 h) and finally DNA fragmentation (96 h).	Paclitaxel	33-43	BCL2 apoptosis regulator	Homo sapiens	162-167
10100573-7	1999	The median stem cell yield after this dose of paclitaxel was 6.6 x 10(6) CD34+ cells/kg/apheresis (range 3.6 x 10(6)-7.7 x 10(6)).	Paclitaxel	46-56	CD34 molecule	Homo sapiens	73-77
9914158-7	1999	In taxol-treated cells, B23 is associated with the microtubule minus ends in the center of mitotic asters together with NuMA.	Paclitaxel	3-8	nuclear mitotic apparatus protein 1	Homo sapiens	120-124
10021296-0	1999	Protein kinase C isoform expression and activity alter paclitaxel resistance in vitro.	Paclitaxel	55-65	proline rich transmembrane protein 2	Homo sapiens	0-16
10021296-5	1999	Finally, the influence of PKC activity (i.e., translocation to the plasma membrane, confirmed by Western blot of plasma membrane bound protein) on resistance to paclitaxel was examined with the MTT assay in cells preincubated with PMA.	Paclitaxel	161-171	proline rich transmembrane protein 2	Homo sapiens	26-29
10021296-8	1999	Only PKC-alpha and PKC-gamma expression increased with increasing indices of paclitaxel resistance.	Paclitaxel	77-87	protein kinase C alpha	Homo sapiens	5-14
10021296-9	1999	Interestingly, PMA induction of PKC activity reversed resistance to paclitaxel in all cell lines by 2- to 3-fold, and this reversal of drug resistance was associated with a time-dependent translocation of PKC-alpha and PKC-gamma to the plasma membrane compartment.	Paclitaxel	68-78	proline rich transmembrane protein 2	Homo sapiens	32-35
10021296-10	1999	CONCLUSIONS: Increased expression of only the PKC-alpha and PKC-gamma isoforms correlates with increasing levels of paclitaxel resistance in Mes-sa cells in this in vitro experimental model.	Paclitaxel	116-126	protein kinase C alpha	Homo sapiens	46-55
10021296-11	1999	However, increased functional activity of these and other PKC isoforms leads to reversal in paclitaxel resistance.	Paclitaxel	92-102	proline rich transmembrane protein 2	Homo sapiens	58-61
9973408-8	1999	Besides TNF, the apoptosis induced by taxol and okadaic acid was also sensitive to LPS-induced NF-kappaB activation, whereas that induced by H2O2, doxorubicin, daunomycin, vincristine, and vinblastine was NF-kappaB insensitive.	Paclitaxel	38-43	tumor necrosis factor	Homo sapiens	8-11
9973408-8	1999	Besides TNF, the apoptosis induced by taxol and okadaic acid was also sensitive to LPS-induced NF-kappaB activation, whereas that induced by H2O2, doxorubicin, daunomycin, vincristine, and vinblastine was NF-kappaB insensitive.	Paclitaxel	38-43	nuclear factor kappa B subunit 1	Homo sapiens	95-104
9973408-8	1999	Besides TNF, the apoptosis induced by taxol and okadaic acid was also sensitive to LPS-induced NF-kappaB activation, whereas that induced by H2O2, doxorubicin, daunomycin, vincristine, and vinblastine was NF-kappaB insensitive.	Paclitaxel	38-43	nuclear factor kappa B subunit 1	Homo sapiens	205-214
9973408-9	1999	Tumor cells that constitutively expressed NF-kappaB also showed resistance to the apoptotic effects of TNF, taxol, and okadaic acid, but sensitivity to all other agents, indicating the critical role of NF-kappaB in blocking apoptosis induced by certain agents.	Paclitaxel	108-113	nuclear factor kappa B subunit 1	Homo sapiens	42-51
9927206-0	1999	Taxol selectively blocks microtubule dependent NF-kappaB activation by phorbol ester via inhibition of IkappaBalpha phosphorylation and degradation.	Paclitaxel	0-5	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	47-56
10190792-10	1999	In our cell line model the combination of IFN and CRA greatly enhanced the cytotoxicity of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ).	Paclitaxel	91-101	interferon alpha 1	Homo sapiens	42-45
10190792-10	1999	In our cell line model the combination of IFN and CRA greatly enhanced the cytotoxicity of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ).	Paclitaxel	103-108	interferon alpha 1	Homo sapiens	42-45
9927194-4	1999	Treatment with taxol, colchicine, or other MBAs (vincristine, podophyllotoxin, nocodazole) stimulated the activity of c-jun N-terminal kinase 1 (JNK1) in MCF-7 cells.	Paclitaxel	15-20	mitogen-activated protein kinase 8	Homo sapiens	118-143
9927206-0	1999	Taxol selectively blocks microtubule dependent NF-kappaB activation by phorbol ester via inhibition of IkappaBalpha phosphorylation and degradation.	Paclitaxel	0-5	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	103-115
9927194-4	1999	Treatment with taxol, colchicine, or other MBAs (vincristine, podophyllotoxin, nocodazole) stimulated the activity of c-jun N-terminal kinase 1 (JNK1) in MCF-7 cells.	Paclitaxel	15-20	mitogen-activated protein kinase 8	Homo sapiens	145-149
9927194-5	1999	In contrast, p38 was activated only by taxol and none of the MBAs changed the activity of extracellular signal-regulated protein kinase 2 (ERK2).	Paclitaxel	39-44	mitogen-activated protein kinase 1	Homo sapiens	13-16
9927206-2	1999	To better understand cytoskeletal regulation of NF-kappaB, experiments were performed to determine whether the microtubule (MT) stabilizing agent taxol could modulate NF-kappaB activation in the presence of different NF-kappa-B inducers.	Paclitaxel	146-151	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	167-176
9927194-10	1999	However, BAPTA/AM, a specific intracellular Ca2+ chelator, attenuated JNK1 activation by taxol but not by colchicine, and had no effect on microtubule changes induced by taxol.	Paclitaxel	89-94	mitogen-activated protein kinase 8	Homo sapiens	70-74
9927206-3	1999	Pretreatment of murine NIH3T3 and human 293 cells with 5 microM taxol resulted in complete inhibition of phorbol, 12-myristate, 13-acetate (PMA) mediated NF-kappaB activation, detected as the loss of DNA binding and reduced NF-kappaB dependent reporter gene activity.	Paclitaxel	64-69	nuclear factor kappa B subunit 1	Homo sapiens	154-163
9927206-3	1999	Pretreatment of murine NIH3T3 and human 293 cells with 5 microM taxol resulted in complete inhibition of phorbol, 12-myristate, 13-acetate (PMA) mediated NF-kappaB activation, detected as the loss of DNA binding and reduced NF-kappaB dependent reporter gene activity.	Paclitaxel	64-69	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	224-233
9927206-4	1999	Furthermore, in COS-7 and NIH3T3 cells, PMA-induced Ikappa-Balpha turnover was dramatically reduced in taxol treated cells, mediated via the inhibition of IkappaBalpha phosphorylation.	Paclitaxel	103-108	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	155-167
9927206-6	1999	In vitro kinase assays with PMA stimulated cell extracts demonstrated that taxol reduced protein kinase C activity by 30%, thus implicating the loss of PKC activity as a possible regulatory target of taxol-mediated suppression of NF-kappa-B.	Paclitaxel	75-80	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	230-240
9927206-8	1999	Both PMA and nocodazole, a MT depolymerizing agent, caused microtubule depolymerization, whereas TNF-alpha did not alter MT integrity; concomitant taxol treatment blocked both nocodazole and PMA induced depolymerization of MTs, as well as NF-kappaB induction, thus demonstrating a link between microtubule depolymerization and NF-kappaB activation.	Paclitaxel	147-152	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	239-248
9927206-8	1999	Both PMA and nocodazole, a MT depolymerizing agent, caused microtubule depolymerization, whereas TNF-alpha did not alter MT integrity; concomitant taxol treatment blocked both nocodazole and PMA induced depolymerization of MTs, as well as NF-kappaB induction, thus demonstrating a link between microtubule depolymerization and NF-kappaB activation.	Paclitaxel	147-152	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	327-336
9927206-9	1999	These observations illustrate a novel biological activity of taxol as a selective inhibitor of NF-kappa-B activity, suggesting a link between the state of microtubule integrity and gene regulation.	Paclitaxel	61-66	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	95-105
10100591-11	1999	In conclusion, Ro 32-2241, acting directly on Pgp (rather than, or in addition to, an effect on PKC), is effective in reducing or reversing resistance to doxorubicin, taxol and vinblastine in human tumour cells with a clinically relevant degree of MDR.	Paclitaxel	167-172	ATP binding cassette subfamily B member 1	Homo sapiens	46-49
9878399-4	1999	However, a subset of the peptides was identified that exhibits significant similarity to a non-conserved region of the anti-apoptotic human protein Bcl-2: ELISA assays confirmed binding of paclitaxel to Bcl-2, and circular dichroism spectroscopy demonstrated that a substantial conformational change accompanies this binding.	Paclitaxel	189-199	BCL2 apoptosis regulator	Homo sapiens	148-153
9878399-4	1999	However, a subset of the peptides was identified that exhibits significant similarity to a non-conserved region of the anti-apoptotic human protein Bcl-2: ELISA assays confirmed binding of paclitaxel to Bcl-2, and circular dichroism spectroscopy demonstrated that a substantial conformational change accompanies this binding.	Paclitaxel	189-199	BCL2 apoptosis regulator	Homo sapiens	203-208
9878399-5	1999	In vivo, treatment with paclitaxel has been shown to lead to Bcl-2 inactivation with concomitant phosphorylation of residues in a disordered, regulatory loop region of the protein.	Paclitaxel	24-34	BCL2 apoptosis regulator	Homo sapiens	61-66
9878399-6	1999	Similarity between paclitaxel-selected peptides and this loop region implicate these residues in drug binding, and suggest that the apoptotic action of paclitaxel may involve the binding of paclitaxel to Bcl-2.	Paclitaxel	19-29	BCL2 apoptosis regulator	Homo sapiens	204-209
9878399-6	1999	Similarity between paclitaxel-selected peptides and this loop region implicate these residues in drug binding, and suggest that the apoptotic action of paclitaxel may involve the binding of paclitaxel to Bcl-2.	Paclitaxel	152-162	BCL2 apoptosis regulator	Homo sapiens	204-209
9878399-6	1999	Similarity between paclitaxel-selected peptides and this loop region implicate these residues in drug binding, and suggest that the apoptotic action of paclitaxel may involve the binding of paclitaxel to Bcl-2.	Paclitaxel	152-162	BCL2 apoptosis regulator	Homo sapiens	204-209
11741204-13	1999	In summary, in paclitaxel-induced apoptosis, caspase activation was followed with a 12-hour lag time by PARP cleavage, internucleosomal DNA fragmentation, and release of DNA-histone complex to the cytoplasm.	Paclitaxel	15-25	poly(ADP-ribose) polymerase 1	Homo sapiens	104-108
10695052-4	1999	In addition, the expression patterns of Bcl-2 family members during taxol or Dox treatment were investigated.	Paclitaxel	68-73	BCL2 apoptosis regulator	Homo sapiens	40-45
10489165-3	1999	A253/Bax cells exhibited a significant increase in in vitro sensitivity to various anticancer drugs, including tomudex (9.5-fold), SN-38 (13.8-fold), doxorubicin (7.9-fold), taxol (3.1-fold), 5-FU (2.7-fold), and 5-FU/LV (4.5-fold).	Paclitaxel	174-179	BCL2 associated X, apoptosis regulator	Homo sapiens	5-8
10453723-5	1999	Ectopic expression of mutant and wild-type p53val135 attenuated taxol cytotoxicity in both T98G cells, which are mutant for p53, and LN-229 cells, which exhibit functional wild-type p53 activity.	Paclitaxel	64-69	tumor protein p53	Homo sapiens	43-46
10453723-6	1999	Interestingly, wild-type p53val135 abrogated the taxol-imposed G2/M arrest in both cell lines.	Paclitaxel	49-54	tumor protein p53	Homo sapiens	25-28
10453729-1	1999	PURPOSE: The purpose of this study was to investigate the effect of high-dose progesterone, an inhibitor of P glycoprotein, on the pharmacokinetics and toxicity of paclitaxel.	Paclitaxel	164-174	ATP binding cassette subfamily B member 1	Homo sapiens	108-122
10340147-5	1999	The percentage of the calretinin immunoreactive cells increases after the addition of colchicine to the medium while the immunoblot analysis shows a higher calretinin content in the cells treated with taxol.	Paclitaxel	201-206	calbindin 2	Homo sapiens	22-32
10340147-5	1999	The percentage of the calretinin immunoreactive cells increases after the addition of colchicine to the medium while the immunoblot analysis shows a higher calretinin content in the cells treated with taxol.	Paclitaxel	201-206	calbindin 2	Homo sapiens	156-166
9886421-9	1999	Taxol and taxotere each induced PGHS-2 expression in human monocytes suspended in 10% human serum.	Paclitaxel	0-5	prostaglandin-endoperoxide synthase 2	Homo sapiens	32-38
9886421-11	1999	Taxol induced PGHS-2 in human and murine monocytes via a p38 mitogen-associated protein kinase pathway.	Paclitaxel	0-5	prostaglandin-endoperoxide synthase 2	Homo sapiens	14-20
9864431-1	1999	GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P).	Paclitaxel	179-189	ATP binding cassette subfamily B member 1	Homo sapiens	55-69
9864431-1	1999	GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P).	Paclitaxel	179-189	ATP binding cassette subfamily B member 1	Homo sapiens	71-75
9864431-1	1999	GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P).	Paclitaxel	179-189	ATP binding cassette subfamily B member 1	Homo sapiens	162-166
9865905-9	1998	The second finding that drug-induced apoptosis was equal or higher in tumors that expressed Pgp, p53, and Bcl-2 compared to tumors that did not express these proteins supports the use of paclitaxel in treating Pgp-, p53- and Bcl-2-positive tumors.	Paclitaxel	187-197	ATP binding cassette subfamily B member 1	Homo sapiens	92-95
9920418-6	1998	Colocalization of S100B with closely arranged IFs and MTs was best evident in cells manipulated with taxol and in triton-cytoskeletons.	Paclitaxel	101-106	S100 calcium binding protein B	Homo sapiens	18-23
9865905-9	1998	The second finding that drug-induced apoptosis was equal or higher in tumors that expressed Pgp, p53, and Bcl-2 compared to tumors that did not express these proteins supports the use of paclitaxel in treating Pgp-, p53- and Bcl-2-positive tumors.	Paclitaxel	187-197	tumor protein p53	Homo sapiens	97-100
9865905-9	1998	The second finding that drug-induced apoptosis was equal or higher in tumors that expressed Pgp, p53, and Bcl-2 compared to tumors that did not express these proteins supports the use of paclitaxel in treating Pgp-, p53- and Bcl-2-positive tumors.	Paclitaxel	187-197	BCL2 apoptosis regulator	Homo sapiens	106-111
9865905-9	1998	The second finding that drug-induced apoptosis was equal or higher in tumors that expressed Pgp, p53, and Bcl-2 compared to tumors that did not express these proteins supports the use of paclitaxel in treating Pgp-, p53- and Bcl-2-positive tumors.	Paclitaxel	187-197	ATP binding cassette subfamily B member 1	Homo sapiens	210-213
9865905-9	1998	The second finding that drug-induced apoptosis was equal or higher in tumors that expressed Pgp, p53, and Bcl-2 compared to tumors that did not express these proteins supports the use of paclitaxel in treating Pgp-, p53- and Bcl-2-positive tumors.	Paclitaxel	187-197	tumor protein p53	Homo sapiens	216-219
9865905-9	1998	The second finding that drug-induced apoptosis was equal or higher in tumors that expressed Pgp, p53, and Bcl-2 compared to tumors that did not express these proteins supports the use of paclitaxel in treating Pgp-, p53- and Bcl-2-positive tumors.	Paclitaxel	187-197	BCL2 apoptosis regulator	Homo sapiens	225-230
9865921-1	1998	Paclitaxel induces a cell cycle block at G2-M phase by preventing the depolymerization of microtubules and induces p53-independent apoptosis in many cancer cells.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	115-118
10072171-5	1998	Pretreatment of hypoxic SKA cells with SIP is also shown to increase Taxol sensitivity of these cells by two-fold.	Paclitaxel	69-74	tumor protein p53 inducible nuclear protein 1	Homo sapiens	39-42
9844922-0	1998	Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome C and caspase-3 activity during Taxol-induced apoptosis of human AML HL-60 cells.	Paclitaxel	132-137	cytochrome c, somatic	Homo sapiens	89-101
9844922-0	1998	Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome C and caspase-3 activity during Taxol-induced apoptosis of human AML HL-60 cells.	Paclitaxel	132-137	caspase 3	Homo sapiens	106-115
9844922-1	1998	The antimicrotubule anticancer drug, Taxol, suppresses microtubule dynamics, causes mitotic arrest, and induces caspase-3 cleavage and activity resulting in apoptosis of human AML HL-60 cells.	Paclitaxel	37-42	caspase 3	Homo sapiens	112-121
9844922-4	1998	In the present studies following S-phase synchronization and release, HL-60 cells with enforced expression of the bcl-xL (HL-60/Bcl-xL) and/or neomycin resistance gene (HL-60/neo) were exposed to Taxol to examine CDK1-related cell-cycle events and the cyt c-triggered molecular cascade of apoptosis.	Paclitaxel	196-201	BCL2 like 1	Homo sapiens	114-120
9844922-7	1998	Data presented here show that, while Taxol-induced peak CDK1 kinase activity occurs earlier in HL-60/neo cells, there are no significant differences in cyclin B1 accumulation, tyrosine dephosphorylation of CDK1, and mitotic arrest of Taxol-treated HL-60/neo vs HL-60/Bcl-xL cells.	Paclitaxel	37-42	BCL2 like 1	Homo sapiens	267-273
9844922-8	1998	Taxol-induced CDK1 activation and mitosis preceded the cytosolic accumulation (approximately six-fold) of cyt c.	Paclitaxel	0-5	cytochrome c, somatic	Homo sapiens	106-111
10081496-3	1998	Paclitaxel given intravenously at 24 mg/kg/day on a schedule of consecutive daily injections for 5 days (d1-5) induced reproducibly, in 6 experiments, a significant (37-82%) increase in the survival time of tumor-bearing mice over saline-treated control mice.	Paclitaxel	0-10	deiodinase, iodothyronine, type I	Mus musculus	105-109
9792903-5	1998	This suggested that paclitaxel/RT was a rationale treatment approach for other malignancies which frequently harbor p53 mutations such as upper gastrointestinal malignancies.	Paclitaxel	20-30	tumor protein p53	Homo sapiens	116-119
9845355-0	1998	Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells.	Paclitaxel	54-59	caveolin 1	Homo sapiens	16-26
9845355-6	1998	Caveolin-1, but not caveolin-2, was upregulated in highly multidrug resistant SKVLBI cells that express high levels of P-glycoprotein, and in low-level Taxol-resistant A549 cell lines that express low amounts of P-glycoprotein.	Paclitaxel	152-157	caveolin 1	Homo sapiens	0-10
9804855-0	1998	Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest.	Paclitaxel	74-79	BCL2 apoptosis regulator	Homo sapiens	27-32
9804855-4	1998	We found that paclitaxel (Taxol(R)) treatment of epithelial tumor cells induced a prolonged mitotic arrest, elevated levels of mitotic kinase activity, hyperphosphorylation of Bcl-2, and subsequent cell death.	Paclitaxel	14-24	BCL2 apoptosis regulator	Homo sapiens	176-181
9804855-4	1998	We found that paclitaxel (Taxol(R)) treatment of epithelial tumor cells induced a prolonged mitotic arrest, elevated levels of mitotic kinase activity, hyperphosphorylation of Bcl-2, and subsequent cell death.	Paclitaxel	26-31	BCL2 apoptosis regulator	Homo sapiens	176-181
9804855-5	1998	The Taxol-induced Bcl-2 phosphorylation was dose-dependent.	Paclitaxel	4-9	BCL2 apoptosis regulator	Homo sapiens	18-23
9804855-6	1998	Furthermore, phosphorylated Bcl-2 remained complexed with Bax in Taxol-treated cells undergoing apoptosis.	Paclitaxel	65-70	BCL2 apoptosis regulator	Homo sapiens	28-33
9804855-6	1998	Furthermore, phosphorylated Bcl-2 remained complexed with Bax in Taxol-treated cells undergoing apoptosis.	Paclitaxel	65-70	BCL2 associated X, apoptosis regulator	Homo sapiens	58-61
9820175-5	1998	Specific substrates of CYP included testosterone (catalysed by CYP3A4), paclitaxel (CYP2C8), 7-ethoxyresorufin (CYP1A1, CYP1A2), coumarin (CYP2A6), aniline (CYP2E1) and (+/-)-bufuralol (CYP2D6).	Paclitaxel	72-82	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
9845355-8	1998	These results indicate that in low-level epothilone B- or Taxol-resistant A549 cells, increased caveolin-1 expression occurs independently of P-glycoprotein expression.	Paclitaxel	58-63	caveolin 1	Homo sapiens	96-106
9845355-10	1998	Upregulation of caveolin-1 expression in drug-sensitive A549 cells was observed acutely beginning 48 h after incubation with 10 nM Taxol.	Paclitaxel	131-136	caveolin 1	Homo sapiens	16-26
9845355-11	1998	Thus, caveolin-1 may play a role in the development of Taxol resistance in A549 cells.	Paclitaxel	55-60	caveolin 1	Homo sapiens	6-16
9809975-0	1998	BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death.	Paclitaxel	73-83	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
9809975-0	1998	BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death.	Paclitaxel	73-83	BCL2 associated X, apoptosis regulator	Homo sapiens	102-105
9809975-1	1998	SW626 cells that overexpress BAX are sensitized to the cytotoxic effects of paclitaxel and vincristine.	Paclitaxel	76-86	BCL2 associated X, apoptosis regulator	Homo sapiens	29-32
9809975-3	1998	However, we have found that several early paclitaxel-mediated events are enhanced in SW626 transfectants that overexpress BAX, including G2-M-phase arrest, tubulin polymerization, and BCL-2 phosphorylation.	Paclitaxel	42-52	BCL2 associated X, apoptosis regulator	Homo sapiens	122-125
9809975-3	1998	However, we have found that several early paclitaxel-mediated events are enhanced in SW626 transfectants that overexpress BAX, including G2-M-phase arrest, tubulin polymerization, and BCL-2 phosphorylation.	Paclitaxel	42-52	BCL2 apoptosis regulator	Homo sapiens	184-189
9809975-4	1998	We now demonstrate that these seemingly disparate effects are explained by an enhanced accumulation of paclitaxel in BAX-overexpressing cells, an effect due to diminished drug efflux.	Paclitaxel	103-113	BCL2 associated X, apoptosis regulator	Homo sapiens	117-120
9809975-5	1998	In contrast, drug efflux is increased in cells that do not overexpress BAX, resulting in low intracellular paclitaxel levels and relative resistance to the effects of this drug.	Paclitaxel	107-117	BCL2 associated X, apoptosis regulator	Homo sapiens	71-74
9844631-0	1998	Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase.	Paclitaxel	31-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-23
9803961-6	1998	Saquinavir, ritonavir and nelfinavir significantly inhibited the efflux of [3H]paclitaxel and [3H]vinblastine in P-gp-positive cells, resulting in an increase in intracellular accumulation of these drugs.	Paclitaxel	79-89	ATP binding cassette subfamily B member 1	Homo sapiens	113-117
9772293-7	1998	The accumulated p53 was biochemically active, as measured in a transient transfection assay upon treatment with gemcitabine, cisplatin, etoposide, and Taxol.	Paclitaxel	151-156	tumor protein p53	Homo sapiens	16-19
9772293-8	1998	Activity was dependent on the drug dose applied and proportional to the level of accumulated p53, except for Taxol-induced p53 accumulation which correlated inversely with p53 biochemical activity.	Paclitaxel	109-114	tumor protein p53	Homo sapiens	123-126
9772293-8	1998	Activity was dependent on the drug dose applied and proportional to the level of accumulated p53, except for Taxol-induced p53 accumulation which correlated inversely with p53 biochemical activity.	Paclitaxel	109-114	tumor protein p53	Homo sapiens	123-126
10022026-6	1998	Paclitaxel produced significant differences in volume (p &lt; 0.001), expression of bcl-2 (p &lt; 0.043), cyclin D (p &lt; 0.023), tissue PSA (p &lt; 0.001) and serum PSA (p &lt; 0.019) levels.	Paclitaxel	0-10	BCL2, apoptosis regulator	Rattus norvegicus	84-89
10022026-6	1998	Paclitaxel produced significant differences in volume (p &lt; 0.001), expression of bcl-2 (p &lt; 0.043), cyclin D (p &lt; 0.023), tissue PSA (p &lt; 0.001) and serum PSA (p &lt; 0.019) levels.	Paclitaxel	0-10	aminopeptidase puromycin sensitive	Rattus norvegicus	138-141
10022026-6	1998	Paclitaxel produced significant differences in volume (p &lt; 0.001), expression of bcl-2 (p &lt; 0.043), cyclin D (p &lt; 0.023), tissue PSA (p &lt; 0.001) and serum PSA (p &lt; 0.019) levels.	Paclitaxel	0-10	aminopeptidase puromycin sensitive	Rattus norvegicus	167-170
9844631-0	1998	Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase.	Paclitaxel	31-36	cyclin dependent kinase inhibitor 1A	Homo sapiens	74-81
9844631-1	1998	Overexpression of the receptor tyrosine kinase p185ErbB2 confers Taxol resistance in breast cancers.	Paclitaxel	65-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-56
9844631-2	1998	Here, we investigated the underlying mechanisms and found that overexpression of p185ErbB2 inhibits Taxol-induced apoptosis.	Paclitaxel	100-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	81-90
9844631-5	1998	Overexpression of p185ErbB2 in MDA-MB-435 cells by transfection transcriptionally upregulates p21Cip1, which associates with p34Cdc2, inhibits Taxol-mediated p34Cdc2 activation, delays cell entrance to G2/M phase, and thereby inhibits Taxol-induced apoptosis.	Paclitaxel	143-148	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-27
9844631-5	1998	Overexpression of p185ErbB2 in MDA-MB-435 cells by transfection transcriptionally upregulates p21Cip1, which associates with p34Cdc2, inhibits Taxol-mediated p34Cdc2 activation, delays cell entrance to G2/M phase, and thereby inhibits Taxol-induced apoptosis.	Paclitaxel	143-148	cyclin dependent kinase inhibitor 1A	Homo sapiens	94-101
9844631-5	1998	Overexpression of p185ErbB2 in MDA-MB-435 cells by transfection transcriptionally upregulates p21Cip1, which associates with p34Cdc2, inhibits Taxol-mediated p34Cdc2 activation, delays cell entrance to G2/M phase, and thereby inhibits Taxol-induced apoptosis.	Paclitaxel	235-240	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-27
9844631-5	1998	Overexpression of p185ErbB2 in MDA-MB-435 cells by transfection transcriptionally upregulates p21Cip1, which associates with p34Cdc2, inhibits Taxol-mediated p34Cdc2 activation, delays cell entrance to G2/M phase, and thereby inhibits Taxol-induced apoptosis.	Paclitaxel	235-240	cyclin dependent kinase inhibitor 1A	Homo sapiens	94-101
9844631-7	1998	Therefore, p21Cip1 participates in the regulation of a G2/M checkpoint that contributes to resistance to Taxol-induced apoptosis in p185ErbB2-overexpressing breast cancer cells.	Paclitaxel	105-110	cyclin dependent kinase inhibitor 1A	Homo sapiens	11-18
9844631-7	1998	Therefore, p21Cip1 participates in the regulation of a G2/M checkpoint that contributes to resistance to Taxol-induced apoptosis in p185ErbB2-overexpressing breast cancer cells.	Paclitaxel	105-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-141
9774721-6	1998	With myelin basic protein (MBP) as a substrate, deimination of arginyl residues was prevented by 0.5 mM paclitaxel.	Paclitaxel	104-114	myelin basic protein	Bos taurus	5-25
9769372-0	1998	In vitro cytotoxicity of paclitaxel-transferrin conjugate on H69 cells.	Paclitaxel	25-35	transferrin	Homo sapiens	36-47
9774447-0	1998	Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK).	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	124-132
9774447-0	1998	Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK).	Paclitaxel	12-17	mitogen-activated protein kinase 8	Homo sapiens	124-132
9774447-2	1998	We reported previously that paclitaxel can induce interleukin (IL)-8 promoter activation in subgroups of ovarian cancer through the activation of both AP-1 and nuclear factor kappaB.	Paclitaxel	28-38	C-X-C motif chemokine ligand 8	Homo sapiens	50-68
9774447-2	1998	We reported previously that paclitaxel can induce interleukin (IL)-8 promoter activation in subgroups of ovarian cancer through the activation of both AP-1 and nuclear factor kappaB.	Paclitaxel	28-38	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	151-181
9774447-3	1998	Further analysis of paclitaxel analogs indicates that the degree of IL-8 induction by analysis correlates with the extent of cell death; however, IL-8 itself is not the cause of cell death.	Paclitaxel	20-30	C-X-C motif chemokine ligand 8	Homo sapiens	68-72
9774447-5	1998	To decipher the upstream signals for paclitaxel-induced transcriptional activation and cell death, we studied the involvement of protein kinases that lead to the activation of AP-1, specifically the c-Jun NH2-terminal kinase (JNK1), p38, and the extracellular signal-regulated kinase 1 (ERK1).	Paclitaxel	37-47	mitogen-activated protein kinase 1	Homo sapiens	233-236
9774447-7	1998	Paclitaxel activated JNK, and to a lesser degree p38, but not ERK1.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	21-24
9774447-8	1998	Paclitaxel-induced IL-8 promoter activation was inhibited by dominant-inhibitory mutants of JNK, p38, and the super-repressor form of IkappaBalpha, but not by dominant-inhibitory forms of ERK1.	Paclitaxel	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	19-23
9774447-8	1998	Paclitaxel-induced IL-8 promoter activation was inhibited by dominant-inhibitory mutants of JNK, p38, and the super-repressor form of IkappaBalpha, but not by dominant-inhibitory forms of ERK1.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	92-95
9774447-8	1998	Paclitaxel-induced IL-8 promoter activation was inhibited by dominant-inhibitory mutants of JNK, p38, and the super-repressor form of IkappaBalpha, but not by dominant-inhibitory forms of ERK1.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Homo sapiens	97-100
9774447-9	1998	Dominant-inhibitory mutants of JNK1 also greatly reduced paclitaxel-induced cell death, and the kinetics of JNK induction was closely followed by DNA fragmentation.	Paclitaxel	57-67	mitogen-activated protein kinase 8	Homo sapiens	31-35
9774447-9	1998	Dominant-inhibitory mutants of JNK1 also greatly reduced paclitaxel-induced cell death, and the kinetics of JNK induction was closely followed by DNA fragmentation.	Paclitaxel	57-67	mitogen-activated protein kinase 8	Homo sapiens	31-34
9774447-10	1998	These results indicate (i) that paclitaxel activates the JNK signaling pathway and (ii) that JNK activation is a common point of paclitaxel-induced gene induction and cell death.	Paclitaxel	32-42	mitogen-activated protein kinase 8	Homo sapiens	57-60
9774447-10	1998	These results indicate (i) that paclitaxel activates the JNK signaling pathway and (ii) that JNK activation is a common point of paclitaxel-induced gene induction and cell death.	Paclitaxel	129-139	mitogen-activated protein kinase 8	Homo sapiens	93-96
9788601-0	1998	Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells.	Paclitaxel	61-71	apoptotic peptidase activating factor 1	Homo sapiens	18-24
9788601-5	1998	Stably overexpressing Apaf-1 levels significantly sensitized HL-60/Apaf-1 cells to apoptosis induced by clinically achievable concentrations of paclitaxel or etoposide (P &lt; 0.01).	Paclitaxel	144-154	apoptotic peptidase activating factor 1	Homo sapiens	22-28
9788601-6	1998	This increase in paclitaxel- or etoposide-induced apoptosis of HL-60/Apaf-1 cells was not associated with any significant alterations in Bcl-2, Bcl-xL, Bax, Fas, or Fas ligand expression.	Paclitaxel	17-27	apoptotic peptidase activating factor 1	Homo sapiens	69-75
9788601-9	1998	These data indicate that the intracellular levels of Apaf-1 is an important molecular determinant of the threshold for apoptosis induced by paclitaxel and etoposide.	Paclitaxel	140-150	apoptotic peptidase activating factor 1	Homo sapiens	53-59
9774721-6	1998	With myelin basic protein (MBP) as a substrate, deimination of arginyl residues was prevented by 0.5 mM paclitaxel.	Paclitaxel	104-114	myelin basic protein	Bos taurus	27-30
9839658-4	1998	In contrast to NO regulation, Mphi capacity for tumor necrosis factor-alpha (TNF-alpha) production in both normal hosts and TBHs was enhanced by paclitaxel administration.	Paclitaxel	145-155	tumor necrosis factor	Homo sapiens	48-75
10851425-7	1998	Average tumor volume in the 90Y-2IT-BAD-Lym-1 (200 microCi) plus Taxol group was reduced by 89 and 99% compared to the RIT alone and Taxol alone groups, respectively.	Paclitaxel	133-138	Fc receptor, IgG, low affinity IIb	Mus musculus	40-45
10851425-8	1998	Mice treated with 150 microCi had less toxicity than those treated with 200 microCi of 90Y-2IT-BAD-Lym-1, however, the higher radiation dose, and Taxol, were required for improved survival.	Paclitaxel	146-151	Fc receptor, IgG, low affinity IIb	Mus musculus	99-104
10851425-10	1998	In the Raji tumored nude mouse model, addition of Taxol to 90Y-2IT-BAD-Lym-1, in doses clinically achievable in humans, provided therapeutic synergy without increased or excessive toxicity.	Paclitaxel	50-55	Fc receptor, IgG, low affinity IIb	Mus musculus	71-76
9735392-1	1998	Specifically anti-microtubule agents such as taxol, vincristine, vinblastine and dolastatin can trigger Bcl2 phosphorylation at G2-M phase of the cell cycle in malignant cells derived from a variety of human cancers.	Paclitaxel	45-50	BCL2 apoptosis regulator	Homo sapiens	104-108
9735415-0	1998	Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.	Paclitaxel	54-64	BCL2 apoptosis regulator	Homo sapiens	0-5
9839658-4	1998	In contrast to NO regulation, Mphi capacity for tumor necrosis factor-alpha (TNF-alpha) production in both normal hosts and TBHs was enhanced by paclitaxel administration.	Paclitaxel	145-155	tumor necrosis factor	Homo sapiens	77-86
9716607-1	1998	Serine phosphorylation of bcl-2 has been reported after treatment of cells with protein kinase C, okadaic acid, taxol, and other chemotherapeutic agents that attack microtubules.	Paclitaxel	112-117	BCL2 apoptosis regulator	Homo sapiens	26-31
9780138-6	1998	P-glycoprotein effluxes a variety of anticancer drugs, such as doxorubicin, vinca alkaloids, etoposide and taxol, and thereby allows cancer cells to show resistance to these drugs.	Paclitaxel	107-112	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
9766754-7	1998	Therefore, an in vitro evaluation of the efficacy of paclitaxel, a P-glycoprotein substrate, in CD34 positive AML cells is warranted before considering its clinical use in acute leukaemia patients.	Paclitaxel	53-63	CD34 molecule	Homo sapiens	96-100
9766754-8	1998	Since all in vitro studies of paclitaxel reported so far have involved only CD34 negative (HL-60, U937, K562) human AML cells, the aim of the present study was to evaluate paclitaxel efficacy against CD34 positive AML cells.	Paclitaxel	172-182	CD34 molecule	Homo sapiens	200-204
9766754-9	1998	The IC50 of paclitaxel for apoptosis was significantly higher in MHH225 CD34 positive cells (12 +/- 2 microM) than in U937 CD34 negative cells (1.7 +/- 0.2 microM), P &lt; 0.001.	Paclitaxel	12-22	CD34 molecule	Homo sapiens	72-76
9766754-9	1998	The IC50 of paclitaxel for apoptosis was significantly higher in MHH225 CD34 positive cells (12 +/- 2 microM) than in U937 CD34 negative cells (1.7 +/- 0.2 microM), P &lt; 0.001.	Paclitaxel	12-22	CD34 molecule	Homo sapiens	123-127
9766754-10	1998	Paclitaxel has a significantly weaker cytotoxic effect on CD34 positive AML cells.	Paclitaxel	0-10	CD34 molecule	Homo sapiens	58-62
9766754-11	1998	One log higher concentration of paclitaxel was required in MHH225 CD34 positive AML cells to achieve the same apoptosis level achieved in U937 CD34 negative leukaemia cells.	Paclitaxel	32-42	CD34 molecule	Homo sapiens	66-70
9766754-11	1998	One log higher concentration of paclitaxel was required in MHH225 CD34 positive AML cells to achieve the same apoptosis level achieved in U937 CD34 negative leukaemia cells.	Paclitaxel	32-42	CD34 molecule	Homo sapiens	143-147
9766754-12	1998	Also, at the high concentration achievable in vivo: 10 microM paclitaxel, only half the MHH225 CD34 positive AML cells were apoptotic versus 72% of U937 CD34 negative leukaemia cells.	Paclitaxel	62-72	CD34 molecule	Homo sapiens	95-99
9766754-16	1998	In conclusion, the present study has demonstrated a clear difference between the effect of paclitaxel on CD34 negative and CD34 positive AML cells.	Paclitaxel	91-101	CD34 molecule	Homo sapiens	105-109
9766754-16	1998	In conclusion, the present study has demonstrated a clear difference between the effect of paclitaxel on CD34 negative and CD34 positive AML cells.	Paclitaxel	91-101	CD34 molecule	Homo sapiens	123-127
9751629-10	1998	Spgp transfectants have a low level resistance to Taxol but not to other drugs that form part of the multidrug resistance phenotype.	Paclitaxel	50-55	ATP binding cassette subfamily B member 11	Rattus norvegicus	0-4
9716607-5	1998	A comparison of bcl-2 from blasts treated with ATRA or taxol showed that bcl-2 was phosphorylated on serine in cells treated with either agent; however, both qualitative and quantitative differences were seen.	Paclitaxel	55-60	BCL2 apoptosis regulator	Homo sapiens	73-78
9716607-6	1998	Qualitatively, the phosphorylated isoform from taxol-treated cells was slightly larger than the native isoform and could be distinguished on 10% to 20% SDS-polyacrylamide gradient gels, while the phosphorylated bcl-2 after ATRA ran as a single band on gradient gels at the same position as control bcl-2.	Paclitaxel	47-52	BCL2 apoptosis regulator	Homo sapiens	211-216
9716607-6	1998	Qualitatively, the phosphorylated isoform from taxol-treated cells was slightly larger than the native isoform and could be distinguished on 10% to 20% SDS-polyacrylamide gradient gels, while the phosphorylated bcl-2 after ATRA ran as a single band on gradient gels at the same position as control bcl-2.	Paclitaxel	47-52	BCL2 apoptosis regulator	Homo sapiens	298-303
9716607-8	1998	We used immunoprecipitation experiments to ask if bcl-2 phosphorylated after ATRA or taxol had altered capacity to dimerize with bax.	Paclitaxel	85-90	BCL2 apoptosis regulator	Homo sapiens	50-55
9716607-11	1998	The ATRA or taxol-induced phosphorylation of bcl-2 can also be seen in blast cells obtained from AML patients.	Paclitaxel	12-17	BCL2 apoptosis regulator	Homo sapiens	45-50
9783732-5	1998	Following exposure of cells to taxol, the Bcl-2 protein displayed an alteration in mobility that was not modified appreciably by bryostatin 1 treatment.	Paclitaxel	31-36	BCL2 apoptosis regulator	Homo sapiens	42-47
9783732-6	1998	The mobility shift in Bcl-2 protein from cells exposed to taxol followed by bryostatin 1 was eliminated by treatment of lysates with the protein phosphatase 2A (PP2A); the latter effect was blocked by okadaic acid.	Paclitaxel	58-63	BCL2 apoptosis regulator	Homo sapiens	22-27
9783732-7	1998	Treatment of cells with taxol followed by bryostatin 1 did not increase the amount of total Bax (compared with treatment with taxol alone), but did increase the amount of free Bax in the supernatant fraction.	Paclitaxel	24-29	BCL2 associated X, apoptosis regulator	Homo sapiens	176-179
9783732-8	1998	Finally, the ability of bryostatin 1 to potentiate taxol-induced apoptosis in U937 cells was mimicked closely by 2"-amino-3"-methoxyflavone (PD98059), a specific inhibitor of the mitogen-activated protein kinase (MAPK) kinase (MEK).	Paclitaxel	51-56	mitogen-activated protein kinase kinase 7	Homo sapiens	227-230
9705278-8	1998	Taxol, a stabilizer of the cytoskeleton, prevented the OA- and 3, 3"-iminodipropionitrile-induced stimulation of CPT-I.	Paclitaxel	0-5	carnitine palmitoyltransferase 1B	Homo sapiens	113-118
9790794-12	1998	Bcl-xL-expressing cells were highly resistant to cisplatin and Taxol compared with controls (P &lt; 0.05).	Paclitaxel	63-68	BCL2 like 1	Homo sapiens	0-6
9738565-0	1998	Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.	Paclitaxel	37-47	ATP binding cassette subfamily B member 1	Homo sapiens	164-168
9738565-0	1998	Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.	Paclitaxel	37-47	ATP binding cassette subfamily C member 1	Homo sapiens	173-176
12016869-3	1998	Ten new taxoids containing the tetrahydrofuran ring were esterified at C14 or C10 positions with taxol/taxotere side chain.	Paclitaxel	97-102	homeobox C10	Homo sapiens	78-81
9698374-0	1998	Identification of the domains of photoincorporation of the 3"- and 7-benzophenone analogues of taxol in the carboxyl-terminal half of murine mdr1b P-glycoprotein.	Paclitaxel	95-100	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	141-146
9698374-3	1998	The contact domains between the murine mdr1b P-glycoprotein and two photoreactive Taxol analogues have been mapped by a combination of CNBr digestion and immunoprecipitation studies.	Paclitaxel	82-87	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	39-44
9698374-4	1998	We had demonstrated previously that the 3"-p-benzoyldihydrocinnamoyl (BzDC) analogue of Taxol specifically photolabeled mdr1b P-glycoprotein and now show that the corresponding C-7 analogue likewise specifically photoincorporates into the transporter.	Paclitaxel	88-93	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	120-125
9703286-0	1998	Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.	Paclitaxel	25-35	tumor protein p53	Homo sapiens	137-141
9680370-6	1998	In contrast, enhanced sensitivity to Adriamycin, Etoposide, and Taxol (Bristol-Meyers Squibb, Princeton, NJ) was revealed in max-overexpressing cells concurrently deprived of IL-3.	Paclitaxel	64-69	interleukin 3	Mus musculus	175-179
9729279-8	1998	Taxol suppressed polymerization between neurofilament light and heavy (NF-L and NF-H), and MB2 cell extract rescued it.	Paclitaxel	0-5	neurofilament light chain	Rattus norvegicus	71-75
9703286-8	1998	When relapse-free survival was estimated for all patients with TP53 alterations in their tumours, a significant better outcome for the paclitaxel/cisplatin group was found compared with the patient group receiving cyclophosphamide and cisplatin therapy (P = 0.002).	Paclitaxel	135-145	tumor protein p53	Homo sapiens	63-67
9699642-0	1998	"Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis.	Paclitaxel	115-120	BCL2 apoptosis regulator	Homo sapiens	83-88
9699663-8	1998	Using a Bcl-xL-specific monoclonal antibody, the phosphorylated form of Bcl-xL was immunoprecipitated from cells treated with paclitaxel and metabolically labeled with 32P-labeled inorganic orthophosphate.	Paclitaxel	126-136	BCL2 like 1	Homo sapiens	72-78
9699642-0	1998	"Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis.	Paclitaxel	115-120	cytochrome c, somatic	Homo sapiens	155-167
9699642-0	1998	"Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis.	Paclitaxel	31-36	BCL2 apoptosis regulator	Homo sapiens	83-88
9699642-0	1998	"Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis.	Paclitaxel	31-36	cytochrome c, somatic	Homo sapiens	155-167
9699642-1	1998	Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	133-138
9699663-9	1998	Herein, we report that Bcl-xL is phosphorylated in malignant cells after incubation with agents that target tubulin, including paclitaxel, vincristine, vinblastine, colchicine, and nocodazole.	Paclitaxel	127-137	BCL2 like 1	Homo sapiens	23-29
9699642-1	1998	Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function.	Paclitaxel	0-5	BCL2 like 1	Homo sapiens	142-148
9699642-1	1998	Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	182-187
9699663-10	1998	Moreover, paclitaxel-resistant ovarian carcinoma cell lines that have mutations in tubulin failed to exhibit phosphorylation of Bcl-xL after paclitaxel exposure, but they did demonstrate Bcl-xL phosphorylation in the presence of other tubulin-targeting agents.	Paclitaxel	10-20	BCL2 like 1	Homo sapiens	187-193
9699642-1	1998	Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function.	Paclitaxel	0-5	BCL2 like 1	Homo sapiens	192-198
9699642-11	1998	In association with Taxol-induced apoptosis, the levels of Bcl-2 that were coimmunoprecipitated with APAF-1 declined in HL-60/neo and HL-60/Bcl-2delta cells.	Paclitaxel	20-25	BCL2 apoptosis regulator	Homo sapiens	59-64
9704707-1	1998	PURPOSE: Expression of the pro-apoptotic protein BAX sensitizes ovarian cancer cell lines to paclitaxel in vitro by enhancing the pathway of programmed cell death.	Paclitaxel	93-103	BCL2 associated X, apoptosis regulator	Homo sapiens	49-52
9699642-11	1998	In association with Taxol-induced apoptosis, the levels of Bcl-2 that were coimmunoprecipitated with APAF-1 declined in HL-60/neo and HL-60/Bcl-2delta cells.	Paclitaxel	20-25	apoptotic peptidase activating factor 1	Homo sapiens	101-107
9699642-11	1998	In association with Taxol-induced apoptosis, the levels of Bcl-2 that were coimmunoprecipitated with APAF-1 declined in HL-60/neo and HL-60/Bcl-2delta cells.	Paclitaxel	20-25	BCL2 apoptosis regulator	Homo sapiens	140-145
9699642-13	1998	Previous studies have demonstrated that Taxol induces phosphorylation of Bcl-2 in association with Taxol-induced apoptosis of HL-60/neo cells.	Paclitaxel	40-45	BCL2 apoptosis regulator	Homo sapiens	73-78
9699642-13	1998	Previous studies have demonstrated that Taxol induces phosphorylation of Bcl-2 in association with Taxol-induced apoptosis of HL-60/neo cells.	Paclitaxel	99-104	BCL2 apoptosis regulator	Homo sapiens	73-78
9699642-14	1998	Immunoblot analysis demonstrated a Taxol-induced mobility shift of Bcl-2 but not p19Bcl-2delta.	Paclitaxel	35-40	BCL2 apoptosis regulator	Homo sapiens	67-72
9699642-15	1998	Taxol also increased [32P]Pi incorporation in p26Bcl-2, but not in p19Bcl-2delta or p18Bcl-xL.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	49-54
9699642-16	1998	These findings indicate that the loop domain is necessary for the Taxol-induced mobility shift and phosphorylation of Bcl-2.	Paclitaxel	66-71	BCL2 apoptosis regulator	Homo sapiens	118-123
9699642-17	1998	Loop domain also seems to be necessary for the antiapoptotic effect of Bcl-2 against Taxol-induced apoptosis but not ara-C- or etoposide-induced apoptosis.	Paclitaxel	85-90	BCL2 apoptosis regulator	Homo sapiens	71-76
9704707-6	1998	All patients whose tumors expressed high levels of BAX achieved a complete response (CR) to first-line chemotherapy that contained paclitaxel plus a platinum analogue, compared with 57% of patients in the low-BAX group (P = .036).	Paclitaxel	131-141	BCL2 associated X, apoptosis regulator	Homo sapiens	51-54
9704707-10	1998	CONCLUSION: The correlation between high BAX levels and improved clinical outcome suggests that an intact apoptotic pathway is an important determinant of chemoresponsiveness in ovarian cancer patients who receive paclitaxel.	Paclitaxel	214-224	BCL2 associated X, apoptosis regulator	Homo sapiens	41-44
9668078-2	1998	We studied the correlation between Bcl-2 phosphorylation, mitotic arrest, and apoptosis induced by the anti-tubulin agent paclitaxel.	Paclitaxel	122-132	BCL2 apoptosis regulator	Homo sapiens	35-40
9668078-14	1998	Immune complex kinase assays in cell-free systems demonstrated that Bcl-2 protein can be a substrate of Cdc2/cyclin B1 kinase isolated from paclitaxel-treated cells arrested in M phase.	Paclitaxel	140-150	BCL2 apoptosis regulator	Homo sapiens	68-73
9668078-8	1998	Similar results were obtained with SKOV3 cells, indicating that the association of paclitaxel-induced M phase arrest and Bcl-2 phosphorylation is not restricted to HeLa cells.	Paclitaxel	83-93	BCL2 apoptosis regulator	Homo sapiens	121-126
9675018-0	1998	Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes.	Paclitaxel	34-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
9675018-1	1998	In primary cultures of human hepatocytes, paclitaxel (Taxol), at pharmacological concentrations, was demonstrated to induce immunoreactive cytochrome P4503A (CYP3A).	Paclitaxel	42-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	139-145
9675018-1	1998	In primary cultures of human hepatocytes, paclitaxel (Taxol), at pharmacological concentrations, was demonstrated to induce immunoreactive cytochrome P4503A (CYP3A).	Paclitaxel	42-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	158-163
9698071-8	1998	Treatment with 50 microM of reduced polymer of spermine and glutaraldehyde, a selective blocker of the polyamine transport system, reduced MDR activity in mdr-1-transfected CHO cells and restored cellular accumulation of etoposide and taxol to control levels, effects not observed in mdr-1-transfected CHOMGBG cells.	Paclitaxel	235-240	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	155-160
9698071-4	1998	The activity of P-gp in these cells was quantified by measuring cellular accumulation of radiolabeled taxol and etoposide in the presence and absence of the P-gp modulator SDZ PSC-833 (valspodar; a semisynthetic undecapeptide derived from cyclosporin D).	Paclitaxel	102-107	glycerol-3-phosphate phosphatase	Cricetulus griseus	16-20
9698071-5	1998	The mdr-1b-transfected CHO cells accumulated 2- to 3-fold less taxol and etoposide than the controls, an accumulation defect reversed by the potent MDR modulator PSC-833.	Paclitaxel	63-68	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-10
9698071-9	1998	Notably, mdr-1-transfected CHO cells were 4- to 16-fold more resistant to the cytotoxic effects of the P-gp substrates doxorubicin, taxol, and etoposide than were the mdr-1-transfected CHOMGBG cells.	Paclitaxel	132-137	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	9-14
9675018-1	1998	In primary cultures of human hepatocytes, paclitaxel (Taxol), at pharmacological concentrations, was demonstrated to induce immunoreactive cytochrome P4503A (CYP3A).	Paclitaxel	54-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	139-145
9698071-9	1998	Notably, mdr-1-transfected CHO cells were 4- to 16-fold more resistant to the cytotoxic effects of the P-gp substrates doxorubicin, taxol, and etoposide than were the mdr-1-transfected CHOMGBG cells.	Paclitaxel	132-137	glycerol-3-phosphate phosphatase	Cricetulus griseus	103-107
9675018-1	1998	In primary cultures of human hepatocytes, paclitaxel (Taxol), at pharmacological concentrations, was demonstrated to induce immunoreactive cytochrome P4503A (CYP3A).	Paclitaxel	54-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	158-163
9675018-3	1998	In general, exposure to increasing concentrations of Taxol (0.2 to 10 microM) resulted in increases in immunoreactive CYP3A.	Paclitaxel	53-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-123
9675018-4	1998	In four of the cultures, treatment of hepatocytes with the lowest concentration of Taxol tested (0.2 microM) resulted in approximately two-fold increases in CYP3A.	Paclitaxel	83-88	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	157-162
9675018-6	1998	Taxol was almost as effective as rifampicin in inducing CYP3A in two of the cultures, but less effective than rifampicin in two other cultures.	Paclitaxel	0-5	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-61
9675018-7	1998	CYP3A4 mRNA was increased by Taxol.	Paclitaxel	29-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
9675018-9	1998	These results demonstrate that Taxol is a potent inducer of CYP3A in human hepatocytes.	Paclitaxel	31-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-65
9739439-1	1998	PURPOSE: Paclitaxel and gemcitabine possess broad spectra of clinical activity, distinct mechanisms of cytotoxicity, and are differentially affected by mutations in cell-cycle regulatory proteins, such as bcl-2.	Paclitaxel	9-19	BCL2 apoptosis regulator	Homo sapiens	205-210
9584191-2	1998	In this study, the microtubule-damaging drugs paclitaxel, vincristine, and vinblastine induced Bcl2 hyperphosphorylation and apoptosis in MCF-7 and MDA-MB-231 cells and reduced Bcl2-Bax dimerization.	Paclitaxel	46-56	BCL2 apoptosis regulator	Homo sapiens	95-99
9661897-0	1998	Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.	Paclitaxel	88-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
9661897-0	1998	Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.	Paclitaxel	88-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-131
9661897-3	1998	In cultures of naturally HER2-overexpressing cancer cells, rhuMAb HER2 inhibited growth and enhanced the cytotoxic effects of paclitaxel.	Paclitaxel	126-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-29
9661897-3	1998	In cultures of naturally HER2-overexpressing cancer cells, rhuMAb HER2 inhibited growth and enhanced the cytotoxic effects of paclitaxel.	Paclitaxel	126-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
9661897-6	1998	The combination of paclitaxel and rhuMAb HER2 resulted in the highest tumor growth inhibition and had a significantly superior complete tumor regression rate when compared with either paclitaxel or rhuMAb HER2 alone.	Paclitaxel	19-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	205-209
9661897-6	1998	The combination of paclitaxel and rhuMAb HER2 resulted in the highest tumor growth inhibition and had a significantly superior complete tumor regression rate when compared with either paclitaxel or rhuMAb HER2 alone.	Paclitaxel	184-194	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
9661042-0	1998	Evidence of p53-induced apoptosis in cancer cells exposed to taxol.	Paclitaxel	61-66	tumor protein p53	Homo sapiens	12-15
9584191-2	1998	In this study, the microtubule-damaging drugs paclitaxel, vincristine, and vinblastine induced Bcl2 hyperphosphorylation and apoptosis in MCF-7 and MDA-MB-231 cells and reduced Bcl2-Bax dimerization.	Paclitaxel	46-56	BCL2 apoptosis regulator	Homo sapiens	177-181
9584191-2	1998	In this study, the microtubule-damaging drugs paclitaxel, vincristine, and vinblastine induced Bcl2 hyperphosphorylation and apoptosis in MCF-7 and MDA-MB-231 cells and reduced Bcl2-Bax dimerization.	Paclitaxel	46-56	BCL2 associated X, apoptosis regulator	Homo sapiens	182-185
9584191-3	1998	Paclitaxel or vincristine induced increased expression of Bax, while overexpression of Bcl2 in these cell lines counteracted the effects of low doses of these drugs.	Paclitaxel	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	58-61
9584191-3	1998	Paclitaxel or vincristine induced increased expression of Bax, while overexpression of Bcl2 in these cell lines counteracted the effects of low doses of these drugs.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	87-91
9584191-4	1998	In addition, paclitaxel- and vincristine-induced activation of cyclic AMP (cAMP)-dependent protein kinase (protein kinase A [PKA]) induced Bcl2 hyperphosphorylation and apoptosis, which were blocked by the PKA inhibitor Rp diastereomers of cAMP (Rp-cAMP).	Paclitaxel	13-23	BCL2 apoptosis regulator	Homo sapiens	139-143
9584191-8	1998	Interestingly, paclitaxel or vincristine induced activation of caspase 3 and cleavage of poly(ADP-ribose) polymerase downstream of Bcl2 hyperphosphorylation.	Paclitaxel	15-25	caspase 3	Homo sapiens	63-72
9584191-8	1998	Interestingly, paclitaxel or vincristine induced activation of caspase 3 and cleavage of poly(ADP-ribose) polymerase downstream of Bcl2 hyperphosphorylation.	Paclitaxel	15-25	poly(ADP-ribose) polymerase 1	Homo sapiens	89-116
9584191-8	1998	Interestingly, paclitaxel or vincristine induced activation of caspase 3 and cleavage of poly(ADP-ribose) polymerase downstream of Bcl2 hyperphosphorylation.	Paclitaxel	15-25	BCL2 apoptosis regulator	Homo sapiens	131-135
9645476-2	1998	An NRAMP1-glutathione S-transferase fusion protein was used to test the ability of the NRAMP1 NH2-terminal domain to bind to taxol-stabilized microtubules.	Paclitaxel	125-130	solute carrier family 11 member 1	Homo sapiens	87-93
9633517-0	1998	Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis.	Paclitaxel	85-95	tumor protein p53	Homo sapiens	16-19
9633517-1	1998	Paclitaxel-induced cytotoxicity, cell cycle perturbation, and apoptosis were determined in a human ovarian cancer cell line expressing wt p53 (A2780) and in a subclone (A2780/E6) obtained upon transfection with the product of the E6 gene of the human papilloma virus HPV16.	Paclitaxel	0-10	tumor protein p53	Homo sapiens	138-141
9584207-7	1998	Paclitaxel, but not cisplatin, increased Bak and 21-kDa Bax levels in A2780/cp70 cells.	Paclitaxel	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	56-59
9633517-2	1998	The inactivation of wt p53 in A2780/E6 was verified by measuring the inability of the clone to induce p53 and p21 expression after paclitaxel treatment.	Paclitaxel	131-141	tumor protein p53	Homo sapiens	23-26
9633517-3	1998	The p53-negative clone (A2780/E6) was approximately 50-fold more sensitive to paclitaxel than wt p53-expressing A2780 cells.	Paclitaxel	78-88	tumor protein p53	Homo sapiens	4-7
9633517-5	1998	This different cell cycle arrest was accompanied by increased frequency of paclitaxel-induced p53-independent apoptosis.	Paclitaxel	75-85	tumor protein p53	Homo sapiens	94-97
9586895-11	1998	CONCLUSION: If paclitaxel is used for patients with elevated levels of AST or bilirubin, dose reductions are necessary, and an increase in toxicity can be anticipated.	Paclitaxel	15-25	solute carrier family 17 member 5	Homo sapiens	71-74
9584207-0	1998	Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.	Paclitaxel	15-25	BCL2 associated X, apoptosis regulator	Homo sapiens	100-103
9584207-0	1998	Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.	Paclitaxel	15-25	tumor protein p53	Homo sapiens	155-158
9584207-1	1998	We investigated the roles of p53 and Bcl-2 homologues in the induction of apoptosis by cisplatin and paclitaxel in wild-type p53-expressing human ovarian carcinoma cells and cisplatin-resistant derivatives that have lost p53 function.	Paclitaxel	101-111	BCL2 apoptosis regulator	Homo sapiens	37-42
9584207-1	1998	We investigated the roles of p53 and Bcl-2 homologues in the induction of apoptosis by cisplatin and paclitaxel in wild-type p53-expressing human ovarian carcinoma cells and cisplatin-resistant derivatives that have lost p53 function.	Paclitaxel	101-111	tumor protein p53	Homo sapiens	125-128
9584207-1	1998	We investigated the roles of p53 and Bcl-2 homologues in the induction of apoptosis by cisplatin and paclitaxel in wild-type p53-expressing human ovarian carcinoma cells and cisplatin-resistant derivatives that have lost p53 function.	Paclitaxel	101-111	tumor protein p53	Homo sapiens	125-128
9584207-8	1998	These data suggest that apoptosis in A2780 and A2780/cp70 is associated with an increased level of Bak and 21 kDa Bax after drug-induced damage and that functional p53 may be required for this effect after cisplatin but not after paclitaxel.	Paclitaxel	230-240	tumor protein p53	Homo sapiens	164-167
9588177-0	1998	Structural significance of the benzoyl group at the C-3"-N position of paclitaxel for nitric oxide and tumor necrosis factor production by murine macrophages.	Paclitaxel	71-81	tumor necrosis factor	Mus musculus	103-124
9588177-2	1998	Recently, we have shown that the benzoyl group at the C-3" position of paclitaxel is the most important site to induce nitric oxide (NO) and tumor necrosis factor (TNF) production by C3H/HeN M phi (Biochem.	Paclitaxel	71-81	tumor necrosis factor	Mus musculus	141-162
9588177-2	1998	Recently, we have shown that the benzoyl group at the C-3" position of paclitaxel is the most important site to induce nitric oxide (NO) and tumor necrosis factor (TNF) production by C3H/HeN M phi (Biochem.	Paclitaxel	71-81	tumor necrosis factor	Mus musculus	164-167
9588177-7	1998	In the present study, synthetic analogs of paclitaxel with replacement of the C-3"-N position were examined for their potencies to induce NO and TNF production by peritoneal M phi of LPS-responsive C3H/HeN mice and LPS-hyporesponsive C3H/HeJ mice, by human blood cells and human M phi.	Paclitaxel	43-53	tumor necrosis factor	Mus musculus	145-148
9570926-5	1998	Modulation of cell death by Bcl-xL was also observed in cells treated with etoposide, vinblastine, paclitaxel, and cisplatinum (II) diammine dichloride.	Paclitaxel	99-109	BCL2 like 1	Homo sapiens	28-34
9572489-0	1998	Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.	Paclitaxel	97-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-34
9572489-1	1998	We recently found that overexpression of p185c-erbB2 in c-erbB2 transfected MDA-MB-435 breast cancer cells (435.eB transfectants) confers a 5-9-fold increase in Taxol resistance.	Paclitaxel	161-166	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-52
9572489-1	1998	We recently found that overexpression of p185c-erbB2 in c-erbB2 transfected MDA-MB-435 breast cancer cells (435.eB transfectants) confers a 5-9-fold increase in Taxol resistance.	Paclitaxel	161-166	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-52
9572489-3	1998	Higher expression of p185c-erbB2 in these breast cancer cell lines indeed correlated well with resistance to Taxol and Taxotere, and the degree of resistance was about 100-fold that in c-erbB2-overexpressing 435.eB transfectants, demonstrating that these breast cancer cells are highly resistant to Taxol.	Paclitaxel	109-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-32
9572489-3	1998	Higher expression of p185c-erbB2 in these breast cancer cell lines indeed correlated well with resistance to Taxol and Taxotere, and the degree of resistance was about 100-fold that in c-erbB2-overexpressing 435.eB transfectants, demonstrating that these breast cancer cells are highly resistant to Taxol.	Paclitaxel	109-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-32
9572489-3	1998	Higher expression of p185c-erbB2 in these breast cancer cell lines indeed correlated well with resistance to Taxol and Taxotere, and the degree of resistance was about 100-fold that in c-erbB2-overexpressing 435.eB transfectants, demonstrating that these breast cancer cells are highly resistant to Taxol.	Paclitaxel	299-304	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-32
9572489-3	1998	Higher expression of p185c-erbB2 in these breast cancer cell lines indeed correlated well with resistance to Taxol and Taxotere, and the degree of resistance was about 100-fold that in c-erbB2-overexpressing 435.eB transfectants, demonstrating that these breast cancer cells are highly resistant to Taxol.	Paclitaxel	299-304	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-32
9572489-4	1998	Since mdr-1-encoded p-glycoprotein (p170mdr-1) has been implicated in Taxol resistance, we next examined the p170mdr-1 levels in these breast cancer cell lines that are highly resistant to Taxol.	Paclitaxel	70-75	ATP binding cassette subfamily B member 1	Homo sapiens	6-11
9572489-4	1998	Since mdr-1-encoded p-glycoprotein (p170mdr-1) has been implicated in Taxol resistance, we next examined the p170mdr-1 levels in these breast cancer cell lines that are highly resistant to Taxol.	Paclitaxel	70-75	ATP binding cassette subfamily B member 1	Homo sapiens	20-34
9572489-4	1998	Since mdr-1-encoded p-glycoprotein (p170mdr-1) has been implicated in Taxol resistance, we next examined the p170mdr-1 levels in these breast cancer cell lines that are highly resistant to Taxol.	Paclitaxel	189-194	ATP binding cassette subfamily B member 1	Homo sapiens	6-11
9572489-9	1998	Both p185c-erbB2 down-regulation and p170mdr-1 blockade significantly sensitized the breast cancer cell lines to Taxol.	Paclitaxel	113-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-16
9572489-10	1998	The results indicate that overexpression of either p185c-erbB2 or p170mdr-1 renders human breast cancer cells resistant to Taxol.	Paclitaxel	123-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-62
9572489-11	1998	Furthermore, p185c-erbB2 synergizes with p170mdr-1 conferring higher degrees of Taxol resistance.	Paclitaxel	80-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-24
9558006-4	1998	Here, we present research examining paclitaxel"s ability to alter expression of the interleukin-1beta (IL-1beta) and IL-8 cytokines in primary human monocytes, T lymphocytes, and four human breast cancer cell lines: MCF-7, ZR-75-1, MDA-MB-468, and MDA-MB-231.	Paclitaxel	36-46	interleukin 1 beta	Homo sapiens	84-101
29711384-1	1998	An "sp2 -sp3 Stille coupling" of the vinyl triflate 1 and the stannyl compound 2 is a key step toward the completion of the total synthesis of eleutherobin, a natural product exhibiting taxol-like cytotoxic activity.	Paclitaxel	186-191	Sp2 transcription factor	Homo sapiens	4-7
29711384-1	1998	An "sp2 -sp3 Stille coupling" of the vinyl triflate 1 and the stannyl compound 2 is a key step toward the completion of the total synthesis of eleutherobin, a natural product exhibiting taxol-like cytotoxic activity.	Paclitaxel	186-191	Sp3 transcription factor	Homo sapiens	9-12
9636834-18	1998	Finally, the finding that Taxol was very effective in inducing apoptosis in resistant sublines with p53 mutation supports the expression of an intact p53-independent pathway of apoptosis and suggests the pharmacological interest of Taxol in the treatment of p53-mutated tumors.	Paclitaxel	26-31	tumor protein p53	Homo sapiens	100-103
9636834-18	1998	Finally, the finding that Taxol was very effective in inducing apoptosis in resistant sublines with p53 mutation supports the expression of an intact p53-independent pathway of apoptosis and suggests the pharmacological interest of Taxol in the treatment of p53-mutated tumors.	Paclitaxel	26-31	tumor protein p53	Homo sapiens	150-153
9636834-18	1998	Finally, the finding that Taxol was very effective in inducing apoptosis in resistant sublines with p53 mutation supports the expression of an intact p53-independent pathway of apoptosis and suggests the pharmacological interest of Taxol in the treatment of p53-mutated tumors.	Paclitaxel	26-31	tumor protein p53	Homo sapiens	150-153
9636834-18	1998	Finally, the finding that Taxol was very effective in inducing apoptosis in resistant sublines with p53 mutation supports the expression of an intact p53-independent pathway of apoptosis and suggests the pharmacological interest of Taxol in the treatment of p53-mutated tumors.	Paclitaxel	232-237	tumor protein p53	Homo sapiens	100-103
9636834-18	1998	Finally, the finding that Taxol was very effective in inducing apoptosis in resistant sublines with p53 mutation supports the expression of an intact p53-independent pathway of apoptosis and suggests the pharmacological interest of Taxol in the treatment of p53-mutated tumors.	Paclitaxel	232-237	tumor protein p53	Homo sapiens	150-153
9636834-18	1998	Finally, the finding that Taxol was very effective in inducing apoptosis in resistant sublines with p53 mutation supports the expression of an intact p53-independent pathway of apoptosis and suggests the pharmacological interest of Taxol in the treatment of p53-mutated tumors.	Paclitaxel	232-237	tumor protein p53	Homo sapiens	150-153
9558006-4	1998	Here, we present research examining paclitaxel"s ability to alter expression of the interleukin-1beta (IL-1beta) and IL-8 cytokines in primary human monocytes, T lymphocytes, and four human breast cancer cell lines: MCF-7, ZR-75-1, MDA-MB-468, and MDA-MB-231.	Paclitaxel	36-46	interleukin 1 beta	Homo sapiens	103-111
9558006-4	1998	Here, we present research examining paclitaxel"s ability to alter expression of the interleukin-1beta (IL-1beta) and IL-8 cytokines in primary human monocytes, T lymphocytes, and four human breast cancer cell lines: MCF-7, ZR-75-1, MDA-MB-468, and MDA-MB-231.	Paclitaxel	36-46	C-X-C motif chemokine ligand 8	Homo sapiens	117-121
9558006-5	1998	This report shows for the first time that treatment with 5-50 microM paclitaxel increases steady-state levels of IL-1beta mRNA in unprimed human monocytes, MCF-7, and ZR-75-1 cells.	Paclitaxel	69-79	interleukin 1 beta	Homo sapiens	113-121
9563876-15	1998	In the p53null SK-OV-3 xenograft model of ovarian cancer, a dosing schedule of p53 Ad that, by itself, had a relatively minimal effect on tumor burden (16%) caused a much greater decrease in tumor burden (55%) when combined with paclitaxel.	Paclitaxel	229-239	tumor protein p53	Homo sapiens	7-10
9563876-15	1998	In the p53null SK-OV-3 xenograft model of ovarian cancer, a dosing schedule of p53 Ad that, by itself, had a relatively minimal effect on tumor burden (16%) caused a much greater decrease in tumor burden (55%) when combined with paclitaxel.	Paclitaxel	229-239	tumor protein p53	Homo sapiens	79-82
9523579-5	1998	When numbers of viable cells were determined in cultures exposed to amyloid peptide with or without paclitaxel for 24 or 96 h, the percentage of surviving cells was significantly higher in paclitaxel-treated cultures, and activation of the apoptosis-associated protease CPP32 was significantly reduced.	Paclitaxel	100-110	caspase 3	Homo sapiens	270-275
9563876-17	1998	In summary, p53 Ad for cancer shows enhanced efficacy when combined with paclitaxel.	Paclitaxel	73-83	tumor protein p53	Homo sapiens	12-15
9563897-6	1998	These results suggest that Taxol might indirectly elevate TNFalpha in tumor cells, which in turn up-regulated dThdPase in the tumor cells in the WiDr cancer xenograft.	Paclitaxel	27-32	tumor necrosis factor	Homo sapiens	58-66
9563900-0	1998	Interleukin 6 differentially potentiates the antitumor effects of taxol and vinblastine in U266 human myeloma cells.	Paclitaxel	66-71	interleukin 6	Homo sapiens	0-13
9563900-6	1998	In the presence of IL-6, the DNA distribution pattern induced by Taxol or vinblastine was altered.	Paclitaxel	65-70	interleukin 6	Homo sapiens	19-23
9563900-7	1998	Whereas IL-6 augmented the sub-G1 fraction and G2-M phase for Taxol-treated cells, only the G2-M phase was increased for vinblastine-treated cells.	Paclitaxel	62-67	interleukin 6	Homo sapiens	8-12
9563900-11	1998	In the presence of IL-6, the number of cells containing microtubule asters increased for Taxol treatment, but not for vinblastine treatment.	Paclitaxel	89-94	interleukin 6	Homo sapiens	19-23
9563900-12	1998	These data indicate that IL-6 leads to differential modulation of the cytotoxicity of Taxol and vinblastine in U266 cells.	Paclitaxel	86-91	interleukin 6	Homo sapiens	25-29
9563900-14	1998	Furthermore, our data suggest that the microtubule-associated form of mitogen-activated protein kinase may play a role in IL-6-mediated enhancement of the cytotoxicity of Taxol.	Paclitaxel	171-176	interleukin 6	Homo sapiens	122-126
9563901-1	1998	In the present study, we report our findings on the impact of p53 disruption on the sensitivity of human cell lines to the antimitotic agents Taxol and vincristine.	Paclitaxel	142-147	tumor protein p53	Homo sapiens	62-65
9563901-5	1998	We also found that contrary to gamma-irradiation, Taxol and vincristine could induce apoptosis in lymphoma cell lines harboring p53 mutations.	Paclitaxel	50-55	tumor protein p53	Homo sapiens	128-131
9563901-9	1998	The effect of p53 disruption on Taxol sensitivity was explored further in the breast carcinoma MCF-7 and colon carcinoma HCT-116 cell lines that had been stably transfected with either the human papillomavirus type-16 E6 gene or a dominant-negative mutant p53 gene.	Paclitaxel	32-37	tumor protein p53	Homo sapiens	14-17
9531522-11	1998	These data support the conclusion that rapid passive diffusion of taxol through the intestinal epithelium is partially counteracted by the action of an outwardly directed efflux pump, presumably P-glycoprotein.	Paclitaxel	66-71	ATP binding cassette subfamily B member 1	Homo sapiens	195-209
9523579-5	1998	When numbers of viable cells were determined in cultures exposed to amyloid peptide with or without paclitaxel for 24 or 96 h, the percentage of surviving cells was significantly higher in paclitaxel-treated cultures, and activation of the apoptosis-associated protease CPP32 was significantly reduced.	Paclitaxel	189-199	caspase 3	Homo sapiens	270-275
9569030-0	1998	The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells.	Paclitaxel	50-60	microtubule-associated protein 4	Mus musculus	12-16
9520464-11	1998	For instance, induction of tumor necrosis factor alpha (TNFalpha) accentuated apoptosis in cells treated with taxol compared with corresponding cells treated with taxotere.	Paclitaxel	110-115	tumor necrosis factor	Homo sapiens	27-54
9520464-11	1998	For instance, induction of tumor necrosis factor alpha (TNFalpha) accentuated apoptosis in cells treated with taxol compared with corresponding cells treated with taxotere.	Paclitaxel	110-115	tumor necrosis factor	Homo sapiens	56-64
9520464-12	1998	The functions of several induced genes (e.g., krox-24 and cyclooxygenase-2) are self-consistent with beneficial and adverse effects encountered during taxol administration.	Paclitaxel	151-156	prostaglandin-endoperoxide synthase 2	Homo sapiens	58-74
9569030-3	1998	In studying the underlying mechanism(s), we found that increased MAP4 expression, which occurs with transcriptionally silent p53, is associated with increased sensitivity to paclitaxel and decreased sensitivity to vinca alkaloids.	Paclitaxel	174-184	microtubule-associated protein 4	Mus musculus	65-69
9569030-5	1998	Immunofluorescent staining of the microtubule network revealed that cells with increased MAP4 expression displayed an increase in polymerized microtubules and an increased binding of fluorsceinated paclitaxel.	Paclitaxel	198-208	microtubule-associated protein 4	Mus musculus	89-93
9625436-3	1998	TET (3.0 microM), FAN (3.0 microM) and VER (10.0 microM) reduced the paclitaxel (TAX) concentration required to achieve 50% inhibition of cell growth (EC50) to HCT15 (P-gp-positive) cells about 3100-, 1900- and 410-fold, and these compounds also reduced the EC50 value of actinomycin D (AMD) about 36.0-, 45.9- and 18.2-fold in the cells, respectively.	Paclitaxel	69-79	ATP binding cassette subfamily B member 1	Homo sapiens	167-171
9619919-0	1998	Taxol can induce phosphorylation of BCL-2 in multiple myeloma cells and potentiate dexamethasone-induced apoptosis.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	36-41
9492385-0	1998	Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4.	Paclitaxel	16-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-93
9492385-7	1998	A high CYP3A4 activity in the patient is consistent with the repeated administration of methylprednisolone for 14 days before paclitaxel treatment, a compound known to induce the CYP3A isoform, and with the increased ratio of 6beta-hydroxycortisol/cortisol in urine, an index of CYP3A activity.	Paclitaxel	126-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	7-13
9492385-7	1998	A high CYP3A4 activity in the patient is consistent with the repeated administration of methylprednisolone for 14 days before paclitaxel treatment, a compound known to induce the CYP3A isoform, and with the increased ratio of 6beta-hydroxycortisol/cortisol in urine, an index of CYP3A activity.	Paclitaxel	126-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	7-12
9472109-0	1998	Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy.	Paclitaxel	85-95	cyclin dependent kinase inhibitor 2A	Homo sapiens	20-23
9472109-4	1998	Treatment of the p16-null glioma cells, U-251 MG and D-54 MG, with paclitaxel and topotecan, resulted in cell death within 4 days.	Paclitaxel	67-77	cyclin dependent kinase inhibitor 2A	Homo sapiens	17-20
9472109-5	1998	However, overexpression of exogenous wild-type p16 protein using an adenovirus vector resulted in G1 arrest of glioma cells and resistance to the anticancer effect of paclitaxel or topotecan.	Paclitaxel	167-177	cyclin dependent kinase inhibitor 2A	Homo sapiens	47-50
9472109-6	1998	Specifically, the p16-expressing cells showed a 30-fold increase in the ID50 of topotecan and a more than 40-fold increase in the ID50 of paclitaxel.	Paclitaxel	138-148	cyclin dependent kinase inhibitor 2A	Homo sapiens	18-21
9604852-3	1998	Paclitaxel inhibited bcl-2 expression suggesting an apoptotic mechanism.	Paclitaxel	0-10	B cell leukemia/lymphoma 2	Mus musculus	21-26
9619919-5	1998	Only concentrations of taxol that phosphorylated BCL-2 interacted with dexamethasone for enhanced apoptotic death.	Paclitaxel	23-28	BCL2 apoptosis regulator	Homo sapiens	49-54
9619919-6	1998	Geldanamycin, which prevented taxol-induced BCL-2 phosphorylation, also prevented the potentiated cytotoxicity.	Paclitaxel	30-35	BCL2 apoptosis regulator	Homo sapiens	44-49
9443400-5	1998	Paclitaxel caused a rapid and transient increase in c-Jun NH2-terminal kinase (JNK) activity, a proposed mediator of stress activation pathways.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	52-77
9543698-1	1998	Taxol, an anticancer drug, has been known not only to block cell division by stabilizing microtubules but also to activate murine macrophages to express TNF-alpha, interleukin-1, and to produce nitric oxide (NO).	Paclitaxel	0-5	tumor necrosis factor	Mus musculus	153-162
9478937-3	1998	We have observed that paclitaxel (Taxol), docetaxel (Taxotere), vinblastine, vincristine, nocodazole, and colchicine activate the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) signaling pathway in a variety of human cells.	Paclitaxel	22-32	mitogen-activated protein kinase 8	Homo sapiens	187-195
9478937-3	1998	We have observed that paclitaxel (Taxol), docetaxel (Taxotere), vinblastine, vincristine, nocodazole, and colchicine activate the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) signaling pathway in a variety of human cells.	Paclitaxel	34-39	mitogen-activated protein kinase 8	Homo sapiens	187-195
9510502-3	1998	KR-30035 potentiated the paclitaxel-induced cytotoxicity to HCT15 [P-glycoprotein (P-gp)-expressed cells] to over 15-fold greater than that of verapamil and KR-30032 was equipotent with verapamil (EC50: 0.07, 5.0 and 3.3 nM at 1.0 microg/ml).	Paclitaxel	25-35	ATP binding cassette subfamily B member 1	Homo sapiens	67-81
9510502-3	1998	KR-30035 potentiated the paclitaxel-induced cytotoxicity to HCT15 [P-glycoprotein (P-gp)-expressed cells] to over 15-fold greater than that of verapamil and KR-30032 was equipotent with verapamil (EC50: 0.07, 5.0 and 3.3 nM at 1.0 microg/ml).	Paclitaxel	25-35	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
9516927-0	1998	Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.	Paclitaxel	125-130	ATP binding cassette subfamily B member 1	Homo sapiens	32-36
9516927-0	1998	Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.	Paclitaxel	125-130	ATP binding cassette subfamily B member 1	Homo sapiens	38-52
9516927-7	1998	Compared with Pgp-negative tumors, a significant increase in doxorubicin and Taxol resistance was seen for breast cancers that expressed Pgp, regardless of prior treatment.	Paclitaxel	77-82	ATP binding cassette subfamily B member 1	Homo sapiens	14-17
9516927-7	1998	Compared with Pgp-negative tumors, a significant increase in doxorubicin and Taxol resistance was seen for breast cancers that expressed Pgp, regardless of prior treatment.	Paclitaxel	77-82	ATP binding cassette subfamily B member 1	Homo sapiens	137-140
9516927-8	1998	A strong correlation between the degree of Pgp expression and in vitro resistance to Taxol and doxorubicin (but not to 5-fluorouracil) was found when either IHC scores or image analysis-based methods were used to quantify Pgp expression (n = 185, P &lt; 0.0001).	Paclitaxel	85-90	ATP binding cassette subfamily B member 1	Homo sapiens	43-46
9516927-8	1998	A strong correlation between the degree of Pgp expression and in vitro resistance to Taxol and doxorubicin (but not to 5-fluorouracil) was found when either IHC scores or image analysis-based methods were used to quantify Pgp expression (n = 185, P &lt; 0.0001).	Paclitaxel	85-90	ATP binding cassette subfamily B member 1	Homo sapiens	222-225
9489571-5	1998	The incidence of DNA fragmentation after 24 h exposure to 20 nM paclitaxel was 12.4 +/- 3.3% for NMT-1, and 13.0 +/- 1.9% for NMT-1R.	Paclitaxel	64-74	N-myristoyltransferase 1	Rattus norvegicus	97-102
9443400-5	1998	Paclitaxel caused a rapid and transient increase in c-Jun NH2-terminal kinase (JNK) activity, a proposed mediator of stress activation pathways.	Paclitaxel	0-10	mitogen-activated protein kinase 8	Homo sapiens	79-82
9443400-6	1998	By contrast, exposure to paclitaxel produced a transient reduction in the extracellular signal-regulated mitogen-activated protein kinase 2 (ERK2) activity, a proposed mediator of growth factor-stimulated proliferation pathways.	Paclitaxel	25-35	mitogen-activated protein kinase 1	Homo sapiens	105-139
9443400-6	1998	By contrast, exposure to paclitaxel produced a transient reduction in the extracellular signal-regulated mitogen-activated protein kinase 2 (ERK2) activity, a proposed mediator of growth factor-stimulated proliferation pathways.	Paclitaxel	25-35	mitogen-activated protein kinase 1	Homo sapiens	141-145
9443400-7	1998	Transient activation of the c-Jun-NH2-terminal kinase/AP-1 pathway, together with down-regulation of ERK2 activity, may be a key event in the early response of RPMI-1788 B lymphoblasts to paclitaxel exposure.	Paclitaxel	188-198	mitogen-activated protein kinase 1	Homo sapiens	101-105
9472635-0	1998	Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	111-116
9472635-6	1998	Similarly, high concentrations of taxol were required to induce p53 activity in the p53 wild-type cell line LN-229.	Paclitaxel	34-39	tumor protein p53	Homo sapiens	64-67
9472635-6	1998	Similarly, high concentrations of taxol were required to induce p53 activity in the p53 wild-type cell line LN-229.	Paclitaxel	34-39	tumor protein p53	Homo sapiens	84-87
9472635-8	1998	However, taxol induced a mobility shift of the bcl-2 protein on immunoblot analysis, indicative of bcl-2 phosphorylation.	Paclitaxel	9-14	BCL2 apoptosis regulator	Homo sapiens	47-52
9472635-8	1998	However, taxol induced a mobility shift of the bcl-2 protein on immunoblot analysis, indicative of bcl-2 phosphorylation.	Paclitaxel	9-14	BCL2 apoptosis regulator	Homo sapiens	99-104
9472635-10	1998	Considering (1) that phosphorylation of bcl-2 interferes with its heterodimerization with bax and (2) the inhibition of CD95-mediated apoptosis by bcl-2, we propose that taxol sensitizes malignant glioma cells to CD95 ligand by increasing the functional bax/bcl-2 rheostat in favour of bax and thus cell death.	Paclitaxel	170-175	BCL2 apoptosis regulator	Homo sapiens	40-45
9472635-10	1998	Considering (1) that phosphorylation of bcl-2 interferes with its heterodimerization with bax and (2) the inhibition of CD95-mediated apoptosis by bcl-2, we propose that taxol sensitizes malignant glioma cells to CD95 ligand by increasing the functional bax/bcl-2 rheostat in favour of bax and thus cell death.	Paclitaxel	170-175	BCL2 associated X, apoptosis regulator	Homo sapiens	90-93
9472635-10	1998	Considering (1) that phosphorylation of bcl-2 interferes with its heterodimerization with bax and (2) the inhibition of CD95-mediated apoptosis by bcl-2, we propose that taxol sensitizes malignant glioma cells to CD95 ligand by increasing the functional bax/bcl-2 rheostat in favour of bax and thus cell death.	Paclitaxel	170-175	BCL2 apoptosis regulator	Homo sapiens	147-152
9472635-10	1998	Considering (1) that phosphorylation of bcl-2 interferes with its heterodimerization with bax and (2) the inhibition of CD95-mediated apoptosis by bcl-2, we propose that taxol sensitizes malignant glioma cells to CD95 ligand by increasing the functional bax/bcl-2 rheostat in favour of bax and thus cell death.	Paclitaxel	170-175	BCL2 associated X, apoptosis regulator	Homo sapiens	254-257
9472635-10	1998	Considering (1) that phosphorylation of bcl-2 interferes with its heterodimerization with bax and (2) the inhibition of CD95-mediated apoptosis by bcl-2, we propose that taxol sensitizes malignant glioma cells to CD95 ligand by increasing the functional bax/bcl-2 rheostat in favour of bax and thus cell death.	Paclitaxel	170-175	BCL2 apoptosis regulator	Homo sapiens	147-152
9472635-10	1998	Considering (1) that phosphorylation of bcl-2 interferes with its heterodimerization with bax and (2) the inhibition of CD95-mediated apoptosis by bcl-2, we propose that taxol sensitizes malignant glioma cells to CD95 ligand by increasing the functional bax/bcl-2 rheostat in favour of bax and thus cell death.	Paclitaxel	170-175	BCL2 associated X, apoptosis regulator	Homo sapiens	254-257
9438385-4	1998	We subsequently observed that the activation of CPP32/Yama protease as well as the cleavage of its substrate poly(ADP-ribose) polymerase occurred 9 h after Taxol treatment.	Paclitaxel	156-161	caspase 3	Homo sapiens	48-53
9523735-2	1998	In addition to its cytotoxic effects on ovarian cancer cells, taxol can transcriptionally activate genes such as IL-8 that may play a role in tumorigenesis.	Paclitaxel	62-67	C-X-C motif chemokine ligand 8	Homo sapiens	113-117
9523735-6	1998	Some of the taxol analogs modified at positions C-1 and/or C-2 with increased hydrophobicity induced IL-8 expression more than threefold over that induced by taxol or taxotere and more than 20-fold over control cells.	Paclitaxel	12-17	homeobox B7	Homo sapiens	48-51
9523735-6	1998	Some of the taxol analogs modified at positions C-1 and/or C-2 with increased hydrophobicity induced IL-8 expression more than threefold over that induced by taxol or taxotere and more than 20-fold over control cells.	Paclitaxel	12-17	C-X-C motif chemokine ligand 8	Homo sapiens	101-105
9523735-6	1998	Some of the taxol analogs modified at positions C-1 and/or C-2 with increased hydrophobicity induced IL-8 expression more than threefold over that induced by taxol or taxotere and more than 20-fold over control cells.	Paclitaxel	158-163	C-X-C motif chemokine ligand 8	Homo sapiens	101-105
9654107-6	1998	Simultaneous exposure to paclitaxel and SN-38 for 24 h produced antagonistic (subadditive and protective) effects in the human lung cancer cell line A549, the breast cancer cell line MCF7, and the colon cancer cell line WiDr, and produced additive effects in the ovarian cancer cell line PA1.	Paclitaxel	25-35	PAXIP1 associated glutamate rich protein 1	Homo sapiens	288-291
9438385-4	1998	We subsequently observed that the activation of CPP32/Yama protease as well as the cleavage of its substrate poly(ADP-ribose) polymerase occurred 9 h after Taxol treatment.	Paclitaxel	156-161	caspase 3	Homo sapiens	54-58
9396713-2	1997	Endothelin (ET)-1, a 21-amino-acid peptide with mitogenic and vasoconstricting activities, not only acts as a mitogen, but also attenuates paclitaxel-induced apoptosis in smooth muscle cells.	Paclitaxel	139-149	endothelin 1	Homo sapiens	0-17
10063968-8	1998	The simultaneous exposure to paclitaxel and methotrexate produced additive to antagonistic effects in the A549 and PA1 cells, and antagonistic effects in the MCF7 and WiDr cells.	Paclitaxel	29-39	PAXIP1 associated glutamate rich protein 1	Homo sapiens	115-118
10388129-11	1998	Other combination regimens that appear to hold substantial promise as first-line metastatic treatment are paclitaxel with carboplatin and paclitaxel with trastuzumab (anti-HER2 antibody).	Paclitaxel	138-148	erb-b2 receptor tyrosine kinase 2	Homo sapiens	172-176
9396713-3	1997	In both human pericardial and prostatic smooth muscle cells, addition of ET-1 reduced paclitaxel-induced DNA fragmentation and phosphatidylserine on the cell surface, two characteristics of apoptosis.	Paclitaxel	86-96	endothelin 1	Homo sapiens	73-77
9815642-0	1997	Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel.	Paclitaxel	121-131	cyclin dependent kinase inhibitor 2A	Homo sapiens	32-35
9815642-0	1997	Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel.	Paclitaxel	121-131	cyclin dependent kinase inhibitor 2A	Homo sapiens	39-42
9815642-9	1997	However, when adenovirally mediated p16 replacement was combined with the chemotherapeutics cisplatin and paclitaxel, a marked chemoresistance was observed in genetically corrected cells.	Paclitaxel	106-116	cyclin dependent kinase inhibitor 2A	Homo sapiens	36-39
9337349-2	1997	MDA-MB-435 human breast cancer cells that have been transfected with oncogene c-erbB2 complementary DNA (435.eb cells) express high levels of the transmembrane glycoprotein p185(c-erbB2) and exhibit increased resistance to the chemotherapeutic agent paclitaxel via p170(mdr-1)-independent mechanisms.	Paclitaxel	250-260	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-85
9496387-0	1997	Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) BACKGROUND: Multidrug resistance has been associated with expression of the multidrug resistance protein (MRP).	Paclitaxel	48-58	ATP binding cassette subfamily C member 1	Homo sapiens	124-152
9496387-0	1997	Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) BACKGROUND: Multidrug resistance has been associated with expression of the multidrug resistance protein (MRP).	Paclitaxel	48-58	ATP binding cassette subfamily C member 1	Homo sapiens	154-157
9566762-6	1997	The MEF.He clone, but not the MEF.HeJ clone, expressed IL-6 mRNA in response to taxol or ceramide, whereas MEF.HeJ clones as well as the MEF.He clone expressed IL-6 mRNA in response to IL-1alpha.	Paclitaxel	80-85	interleukin 6	Mus musculus	55-59
9566762-7	1997	These results indicate that in the responses to LPS, taxol and ceramide, MEF retain the same reactivity as that of the mouse strains from which the MEF were derived, and LPS shares the IL-6 signal transduction pathway with taxol and ceramide, but not with IL-1.	Paclitaxel	53-58	interleukin 6	Mus musculus	185-189
9566762-7	1997	These results indicate that in the responses to LPS, taxol and ceramide, MEF retain the same reactivity as that of the mouse strains from which the MEF were derived, and LPS shares the IL-6 signal transduction pathway with taxol and ceramide, but not with IL-1.	Paclitaxel	223-228	interleukin 6	Mus musculus	185-189
21590211-2	1997	Cells expressing Bcl-2 (COLO320) and those that did not (DLD-1), underwent apoptosis after 24 h exposure to 1 mu M taxol.	Paclitaxel	115-120	BCL2 apoptosis regulator	Homo sapiens	17-22
21590211-4	1997	The molecular weight of Bcl-2 was increased to above 26 kDa in COLO320 and LoVo cells after a 4 h exposure to taxol.	Paclitaxel	110-115	BCL2 apoptosis regulator	Homo sapiens	24-29
21590211-5	1997	Incubating the cells with genistein, a protein tyrosine kinase inhibitor, inhibited the taxol-induced modified Bcl-2 expression and apoptosis.	Paclitaxel	88-93	BCL2 apoptosis regulator	Homo sapiens	111-116
21590211-6	1997	These results suggest that taxol induces apoptosis in cells arrested in G(2)/M phase which might be partly explained by Bcl-2 inactivation by phosphorylation in human colon carcinoma cell lines.	Paclitaxel	27-32	BCL2 apoptosis regulator	Homo sapiens	120-125
9496382-0	1997	Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: need of comparative clinical trials in resistant patients.	Paclitaxel	29-39	ATP binding cassette subfamily C member 1	Homo sapiens	88-91
9815592-6	1997	The SKOV3ip1 cells do not express p53 protein; hence, the induction of apoptosis by paclitaxel is through a p53-independent pathway.	Paclitaxel	84-94	tumor protein p53	Homo sapiens	108-111
9815595-0	1997	Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression.	Paclitaxel	0-5	BCL2 like 1	Homo sapiens	100-106
9815595-5	1997	Treatment of LNCaP cells with 10 nm Taxol led, after 24 h, to relatively specific and almost total down-regulation of bcl-xL protein in the absence of alteration of bax, bak, or bcl-2 levels.	Paclitaxel	36-41	BCL2 like 1	Homo sapiens	118-124
9815595-5	1997	Treatment of LNCaP cells with 10 nm Taxol led, after 24 h, to relatively specific and almost total down-regulation of bcl-xL protein in the absence of alteration of bax, bak, or bcl-2 levels.	Paclitaxel	36-41	BCL2 associated X, apoptosis regulator	Homo sapiens	165-168
9815595-5	1997	Treatment of LNCaP cells with 10 nm Taxol led, after 24 h, to relatively specific and almost total down-regulation of bcl-xL protein in the absence of alteration of bax, bak, or bcl-2 levels.	Paclitaxel	36-41	BCL2 apoptosis regulator	Homo sapiens	178-183
9346882-10	1997	PKC iota also protects K562 cells against taxol-induced apoptosis, indicating that it plays a general protective role against apoptotic stimuli.	Paclitaxel	42-47	proline rich transmembrane protein 2	Homo sapiens	0-3
9374103-8	1997	In addition, available evidence suggests that patients with poor prognosis associated with overexpression of c-erb B2 (HER2) have a higher probability of responding to paclitaxel than patients with HER2-negative tumors.	Paclitaxel	168-178	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-117
9402312-0	1997	Effects of cisplatin and taxol on inducible nitric oxide synthase, gastrin and somatostatin in gastrointestinal toxicity.	Paclitaxel	25-30	nitric oxide synthase 2	Rattus norvegicus	34-65
9402312-0	1997	Effects of cisplatin and taxol on inducible nitric oxide synthase, gastrin and somatostatin in gastrointestinal toxicity.	Paclitaxel	25-30	somatostatin	Rattus norvegicus	79-91
9402312-1	1997	Cisplatin (9 mg/kg) or taxol (20 mg/kg) treatment of Wistar rats produced a sharp decrease in inducible nitric oxide synthase (iNOS) and gastrin in the pyloric region of the stomach, and an increase in iNOS and somatostatin in the pancreatic islets.	Paclitaxel	23-28	nitric oxide synthase 2	Rattus norvegicus	94-125
9402312-1	1997	Cisplatin (9 mg/kg) or taxol (20 mg/kg) treatment of Wistar rats produced a sharp decrease in inducible nitric oxide synthase (iNOS) and gastrin in the pyloric region of the stomach, and an increase in iNOS and somatostatin in the pancreatic islets.	Paclitaxel	23-28	nitric oxide synthase 2	Rattus norvegicus	127-131
9402312-1	1997	Cisplatin (9 mg/kg) or taxol (20 mg/kg) treatment of Wistar rats produced a sharp decrease in inducible nitric oxide synthase (iNOS) and gastrin in the pyloric region of the stomach, and an increase in iNOS and somatostatin in the pancreatic islets.	Paclitaxel	23-28	nitric oxide synthase 2	Rattus norvegicus	202-206
9402312-1	1997	Cisplatin (9 mg/kg) or taxol (20 mg/kg) treatment of Wistar rats produced a sharp decrease in inducible nitric oxide synthase (iNOS) and gastrin in the pyloric region of the stomach, and an increase in iNOS and somatostatin in the pancreatic islets.	Paclitaxel	23-28	somatostatin	Rattus norvegicus	211-223
9402312-3	1997	It is proposed that a decline of the iNOS and gastrin after cisplatin or taxol treatments is related to distention of the stomach, and possibly nausea and vomiting.	Paclitaxel	73-78	nitric oxide synthase 2	Rattus norvegicus	37-41
9317152-1	1997	Activation of macrophages by LPS and taxol results in production of IL-1, IL-6, TNF-alpha, and granulocyte-macrophage CSF (GM-CSF), which are involved in regulating hemopoiesis, inflammation, and immune responses.	Paclitaxel	37-42	interleukin 6	Mus musculus	74-78
9317152-1	1997	Activation of macrophages by LPS and taxol results in production of IL-1, IL-6, TNF-alpha, and granulocyte-macrophage CSF (GM-CSF), which are involved in regulating hemopoiesis, inflammation, and immune responses.	Paclitaxel	37-42	tumor necrosis factor	Mus musculus	80-89
9380024-5	1997	Multidrug-resistant human colon and ovarian carcinoma cells overexpressing P-glycoprotein, which are 900- and 2800-fold resistant to paclitaxel, respectively, relative to the parental lines, retained significant sensitivity to discodermolide (25- and 89-fold more resistant relative to the parental lines).	Paclitaxel	133-143	ATP binding cassette subfamily B member 1	Homo sapiens	75-89
9353423-2	1997	Independently of these mechanisms, taxol induces distinct immunological efficacy when it acts as a second signal for activation of tumoricidal activity by interferon gamma (IFN gamma)-primed murine normal host macrophages.	Paclitaxel	35-40	interferon gamma	Mus musculus	155-171
9353423-2	1997	Independently of these mechanisms, taxol induces distinct immunological efficacy when it acts as a second signal for activation of tumoricidal activity by interferon gamma (IFN gamma)-primed murine normal host macrophages.	Paclitaxel	35-40	interferon gamma	Mus musculus	173-182
9353423-3	1997	We reported that tumor-distal macrophages, which mediate immunosuppression through dysregulated nitric oxide (NO) and tumor necrosis factor alpha (TNF alpha) production, are differentially regulated by taxol.	Paclitaxel	202-207	tumor necrosis factor	Mus musculus	118-145
9353423-3	1997	We reported that tumor-distal macrophages, which mediate immunosuppression through dysregulated nitric oxide (NO) and tumor necrosis factor alpha (TNF alpha) production, are differentially regulated by taxol.	Paclitaxel	202-207	tumor necrosis factor	Mus musculus	147-156
9374103-8	1997	In addition, available evidence suggests that patients with poor prognosis associated with overexpression of c-erb B2 (HER2) have a higher probability of responding to paclitaxel than patients with HER2-negative tumors.	Paclitaxel	168-178	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-123
9374103-8	1997	In addition, available evidence suggests that patients with poor prognosis associated with overexpression of c-erb B2 (HER2) have a higher probability of responding to paclitaxel than patients with HER2-negative tumors.	Paclitaxel	168-178	erb-b2 receptor tyrosine kinase 2	Homo sapiens	198-202
9374103-10	1997	Should HER2 status be a predictor of response to paclitaxel and paclitaxel-based therapy, the use of the drug could be tailored to specific patient characteristics.	Paclitaxel	49-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	7-11
9374103-10	1997	Should HER2 status be a predictor of response to paclitaxel and paclitaxel-based therapy, the use of the drug could be tailored to specific patient characteristics.	Paclitaxel	64-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	7-11
9322876-4	1997	The drugs both undergo hepatic metabolism; however, the specific cytochrome P-450 (CYP) enzymes responsible for hydroxylation are CYP 2C8 for paclitaxel and CYP 3A4 for docetaxel.	Paclitaxel	142-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	65-81
9275183-5	1997	In an attempt to reconcile this apparent discrepancy, we examined the requirement for p53 in the cytotoxic effects of tumor necrosis factor alpha (TNF-alpha), a cytokine released from murine macrophages upon paclitaxel treatment.	Paclitaxel	208-218	tumor necrosis factor	Mus musculus	118-145
9275183-6	1997	Conditioned medium from paclitaxel-treated macrophages was capable of inducing p53-independent apoptosis when applied to transformed mouse embryonic fibroblasts and was inhibitable by antibodies against TNF-alpha.	Paclitaxel	24-34	tumor necrosis factor	Mus musculus	203-212
9271387-0	1997	Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter.	Paclitaxel	33-43	C-X-C motif chemokine ligand 8	Homo sapiens	90-103
9271387-0	1997	Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter.	Paclitaxel	45-50	C-X-C motif chemokine ligand 8	Homo sapiens	90-103
9271387-3	1997	Previously, we demonstrated that paclitaxel can induce interleukin-8 (IL-8) gene expression at the transcriptional level in subsets of human ovarian cancer lines.	Paclitaxel	33-43	C-X-C motif chemokine ligand 8	Homo sapiens	55-68
9271387-3	1997	Previously, we demonstrated that paclitaxel can induce interleukin-8 (IL-8) gene expression at the transcriptional level in subsets of human ovarian cancer lines.	Paclitaxel	33-43	C-X-C motif chemokine ligand 8	Homo sapiens	70-74
9271387-6	1997	Paclitaxel only activated the IL-8 promoter in responsive cells.	Paclitaxel	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	30-34
9271387-7	1997	The AP-1 and NF-kappaB binding sites in the IL-8 promoter are required for activation by paclitaxel; in contrast, a C/EBP site required for IL-8 promoter activation in other cell types is not involved.	Paclitaxel	89-99	C-X-C motif chemokine ligand 8	Homo sapiens	44-48
9271387-10	1997	These results demonstrate a molecular mechanism for cell-specific paclitaxel-induced IL-8 gene expression which may have clinical relevance.	Paclitaxel	66-76	C-X-C motif chemokine ligand 8	Homo sapiens	85-89
9322876-4	1997	The drugs both undergo hepatic metabolism; however, the specific cytochrome P-450 (CYP) enzymes responsible for hydroxylation are CYP 2C8 for paclitaxel and CYP 3A4 for docetaxel.	Paclitaxel	142-152	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-86
9285690-9	1997	Thus, we concluded that the adenovirus type 5 E1A gene can sensitize paclitaxel-resistant HER-2/neu-overexpressing breast cancer cells to the drug by repressing HER-2/neu expression.	Paclitaxel	69-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-95
9446255-14	1997	Indeed, SDZ PSC 833 concentrations that fully reverse MDR in vitro are achievable in vivo, plasma samples from patients treated with SDZ PSC 833 restored the sensitivity of MDR human sarcoma cells to paclitaxel, etoposide and doxorubicin.	Paclitaxel	200-210	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	173-176
9285690-9	1997	Thus, we concluded that the adenovirus type 5 E1A gene can sensitize paclitaxel-resistant HER-2/neu-overexpressing breast cancer cells to the drug by repressing HER-2/neu expression.	Paclitaxel	69-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-99
9285690-0	1997	Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.	Paclitaxel	76-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-27
9285690-9	1997	Thus, we concluded that the adenovirus type 5 E1A gene can sensitize paclitaxel-resistant HER-2/neu-overexpressing breast cancer cells to the drug by repressing HER-2/neu expression.	Paclitaxel	69-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	161-166
9285690-0	1997	Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.	Paclitaxel	76-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-31
9285690-9	1997	Thus, we concluded that the adenovirus type 5 E1A gene can sensitize paclitaxel-resistant HER-2/neu-overexpressing breast cancer cells to the drug by repressing HER-2/neu expression.	Paclitaxel	69-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	167-170
9285690-0	1997	Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.	Paclitaxel	88-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-27
9285690-0	1997	Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.	Paclitaxel	88-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-31
9285245-6	1997	In response to IFN-gamma-priming and taxol triggering, TBH M phi s increase their production of NO as compared to resting M phi s; however, unlike normal host M phi s, taxol-induced TBH M phi NO production was significantly suboptimal.	Paclitaxel	168-173	interferon gamma	Homo sapiens	15-24
9285690-1	1997	Breast cancer cells that overexpress HER-2/neu are more resistant to chemotherapeutic agents such as paclitaxel (Taxol) and docetaxel (Taxotere) than those that do not overexpress HER-2/neu.	Paclitaxel	101-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-46
9285690-1	1997	Breast cancer cells that overexpress HER-2/neu are more resistant to chemotherapeutic agents such as paclitaxel (Taxol) and docetaxel (Taxotere) than those that do not overexpress HER-2/neu.	Paclitaxel	113-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-46
9231713-3	1997	Down-regulation of both ET(B) receptor mRNA and the number of binding sites for ET-1 was also observed in quiescent astrocytes treated with taxol, a microtubule-stabilizing agent.	Paclitaxel	140-145	endothelin 1	Rattus norvegicus	80-84
9150481-2	1997	Cpk/cpk mice treated weekly with paclitaxel (Taxol) can live to over six months of age.	Paclitaxel	33-43	cystin 1	Mus musculus	0-3
9169462-1	1997	Role of protein kinase C. Paclitaxel can induce tumor necrosis factor (TNF) and interleukin-1 gene expression, similar to lipopolysaccharides.	Paclitaxel	26-36	tumor necrosis factor	Homo sapiens	71-74
9169462-2	1997	Since lipopolysaccharide-induced expression of TNF is related to activation of NF-kappaB, we determined whether NF-kappaB could be activated by paclitaxel.	Paclitaxel	144-154	tumor necrosis factor	Homo sapiens	47-50
9169462-2	1997	Since lipopolysaccharide-induced expression of TNF is related to activation of NF-kappaB, we determined whether NF-kappaB could be activated by paclitaxel.	Paclitaxel	144-154	nuclear factor kappa B subunit 1	Homo sapiens	112-121
9169462-4	1997	Like paclitaxel, vinblastine, vincristine, daunomycin, and doxorubicin each caused activation of NF-kappaB.	Paclitaxel	5-15	nuclear factor kappa B subunit 1	Homo sapiens	97-106
9267668-6	1997	The mean daily collection of CD34+ cells was 5.46 x 10(6)/kg for patients receiving 200 mg/m2 of paclitaxel and 3 gm/m2 of Cy as compared to 2.77 for patients receiving the lower doses (p = 0.0005).	Paclitaxel	97-107	CD34 molecule	Homo sapiens	29-33
9267668-11	1997	Increasing the doses of paclitaxel and Cy increased the number of CD34+ cells collected and decreased the number of apheresis procedures necessary to collect target cell doses.	Paclitaxel	24-34	CD34 molecule	Homo sapiens	66-70
9206986-9	1997	This suggested that paclitaxel/RT would be a rational treatment approach for other malignancies with a high frequency of p53 mutations, such as gastric and pancreatic cancers.	Paclitaxel	20-30	tumor protein p53	Homo sapiens	121-124
9192815-9	1997	The relative sensitivity of the monolayer cell cultures was associated with a decrease in bcl-X(L) protein levels after Taxol exposure, an effect not observed in drug-exposed spheroids.	Paclitaxel	120-125	BCL2 like 1	Homo sapiens	90-98
9127007-5	1997	However, at high concentrations of LPS or Taxol, a CD14-independent pathway of activation is observed: this pathway leads to minimal IP-10 gene induction, even though induction of TNF-alpha and IL-1beta occurs.	Paclitaxel	42-47	tumor necrosis factor	Mus musculus	180-189
9127007-5	1997	However, at high concentrations of LPS or Taxol, a CD14-independent pathway of activation is observed: this pathway leads to minimal IP-10 gene induction, even though induction of TNF-alpha and IL-1beta occurs.	Paclitaxel	42-47	interleukin 1 beta	Mus musculus	194-202
9127007-7	1997	These data suggest the existence of two pathways of activation by both LPS and Taxol: one that is CD14 dependent and leads to induction of TNF-alpha, IL-1beta, and IP-10 gene induction, and a CD14-independent pathway that results in the induction of TNF-alpha and IL-1beta, with minimal induction of IP-10.	Paclitaxel	79-84	tumor necrosis factor	Mus musculus	139-148
9127007-7	1997	These data suggest the existence of two pathways of activation by both LPS and Taxol: one that is CD14 dependent and leads to induction of TNF-alpha, IL-1beta, and IP-10 gene induction, and a CD14-independent pathway that results in the induction of TNF-alpha and IL-1beta, with minimal induction of IP-10.	Paclitaxel	79-84	interleukin 1 beta	Mus musculus	150-158
9127007-7	1997	These data suggest the existence of two pathways of activation by both LPS and Taxol: one that is CD14 dependent and leads to induction of TNF-alpha, IL-1beta, and IP-10 gene induction, and a CD14-independent pathway that results in the induction of TNF-alpha and IL-1beta, with minimal induction of IP-10.	Paclitaxel	79-84	tumor necrosis factor	Mus musculus	250-259
9127007-7	1997	These data suggest the existence of two pathways of activation by both LPS and Taxol: one that is CD14 dependent and leads to induction of TNF-alpha, IL-1beta, and IP-10 gene induction, and a CD14-independent pathway that results in the induction of TNF-alpha and IL-1beta, with minimal induction of IP-10.	Paclitaxel	79-84	interleukin 1 beta	Mus musculus	264-272
9150481-2	1997	Cpk/cpk mice treated weekly with paclitaxel (Taxol) can live to over six months of age.	Paclitaxel	33-43	cystin 1	Mus musculus	4-7
9150481-2	1997	Cpk/cpk mice treated weekly with paclitaxel (Taxol) can live to over six months of age.	Paclitaxel	45-50	cystin 1	Mus musculus	0-3
9150481-2	1997	Cpk/cpk mice treated weekly with paclitaxel (Taxol) can live to over six months of age.	Paclitaxel	45-50	cystin 1	Mus musculus	4-7
9150481-5	1997	We found that taxanes that are active in promoting microtubule assembly, including paclitaxel, 10-deactyl-taxol and cephalomannine increased the survival of polycystic cpk/cpk mice significantly longer than control animals.	Paclitaxel	83-93	cystin 1	Mus musculus	168-171
9150481-7	1997	We conclude that the ability to promote microtubule assembly may be necessary for paclitaxel and related taxanes to modulate the progression of polycystic kidney progression in cpk/cpk mice.	Paclitaxel	82-92	cystin 1	Mus musculus	177-180
9150481-7	1997	We conclude that the ability to promote microtubule assembly may be necessary for paclitaxel and related taxanes to modulate the progression of polycystic kidney progression in cpk/cpk mice.	Paclitaxel	82-92	cystin 1	Mus musculus	181-184
9070502-5	1997	This activity was pronounced in sublines expressing tubulin-associated and P-glycoprotein-mediated drug resistance, indicating involvement of these mechanisms in paclitaxel resistance and their modulation by CEL.	Paclitaxel	162-172	ATP binding cassette subfamily B member 1	Homo sapiens	75-89
9108094-3	1997	Taxol (paclitaxel) is more effective in the presence of mutant p53.	Paclitaxel	0-5	tumor protein p53	Homo sapiens	63-66
9108094-3	1997	Taxol (paclitaxel) is more effective in the presence of mutant p53.	Paclitaxel	7-17	tumor protein p53	Homo sapiens	63-66
9108094-13	1997	The synergistic therapeutic effect of Taxol with (90)Y-ChL6 may relate to the p53 mutant status and BCL2 expression in HBT 3477 cells, observations that increase the likelihood that the results of this study are relevant to therapy for breast cancer in patients.	Paclitaxel	38-43	tumor protein p53	Homo sapiens	78-81
9108094-13	1997	The synergistic therapeutic effect of Taxol with (90)Y-ChL6 may relate to the p53 mutant status and BCL2 expression in HBT 3477 cells, observations that increase the likelihood that the results of this study are relevant to therapy for breast cancer in patients.	Paclitaxel	38-43	BCL2 apoptosis regulator	Homo sapiens	100-104
9158184-4	1997	Substituting taxol for etoposide in etoposide, ifosfamide and cisplatin (VIP), followed by high dose, is one possibility.	Paclitaxel	13-18	vasoactive intestinal peptide	Homo sapiens	73-76
9176102-8	1997	Taxol at 28 microM also significantly inhibited chemiluminescence, superoxide anion production and myeloperoxidase release from neutrophils stimulated by opsonized zymosan.	Paclitaxel	0-5	myeloperoxidase	Homo sapiens	99-114
9067280-0	1997	Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells.	Paclitaxel	74-84	BCL2 like 1	Homo sapiens	0-6
9067280-1	1997	Paclitaxel has been shown to activate Raf-1 and cause phosphorylation of Bcl-2, which has been correlated with paclitaxel-induced apoptosis of cancer cells.	Paclitaxel	0-10	BCL2 apoptosis regulator	Homo sapiens	73-78
9067280-1	1997	Paclitaxel has been shown to activate Raf-1 and cause phosphorylation of Bcl-2, which has been correlated with paclitaxel-induced apoptosis of cancer cells.	Paclitaxel	111-121	BCL2 apoptosis regulator	Homo sapiens	73-78
9067280-2	1997	In the present studies, we demonstrate that in human AML HL-60 cells that express Bcl-2 but little Bcl-xL (HL-60/neo cells), paclitaxel-induced phosphorylation of Bcl-2 is followed by increased intracellular free Bax levels.	Paclitaxel	125-135	BCL2 apoptosis regulator	Homo sapiens	82-87
9118049-0	1997	Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin.	Paclitaxel	71-81	erythropoietin	Homo sapiens	0-14
9118049-1	1997	BACKGROUND: The authors report on anemia observed during preoperative paclitaxel and carboplatin chemotherapy in patients with advanced head and neck carcinoma and discuss how the use of recombinant human erythropoietin (r-HuEPO) ameliorates this anemia, reducing the need for subsequent packed red blood cell (PRBC) transfusions.	Paclitaxel	70-80	erythropoietin	Homo sapiens	205-219
9067280-2	1997	In the present studies, we demonstrate that in human AML HL-60 cells that express Bcl-2 but little Bcl-xL (HL-60/neo cells), paclitaxel-induced phosphorylation of Bcl-2 is followed by increased intracellular free Bax levels.	Paclitaxel	125-135	BCL2 apoptosis regulator	Homo sapiens	163-168
9041221-1	1997	Woo et al (Nature 368:750-753) reported that parenteral administration of paclitaxel arrested the striking renal enlargement and prolonged life in C57BL/6J-cpk/cpk mice with a rapidly progressive form of polycystic kidney disease (PKD).	Paclitaxel	74-84	cystin 1	Mus musculus	156-159
9067280-2	1997	In the present studies, we demonstrate that in human AML HL-60 cells that express Bcl-2 but little Bcl-xL (HL-60/neo cells), paclitaxel-induced phosphorylation of Bcl-2 is followed by increased intracellular free Bax levels.	Paclitaxel	125-135	BCL2 associated X, apoptosis regulator	Homo sapiens	213-216
9041221-1	1997	Woo et al (Nature 368:750-753) reported that parenteral administration of paclitaxel arrested the striking renal enlargement and prolonged life in C57BL/6J-cpk/cpk mice with a rapidly progressive form of polycystic kidney disease (PKD).	Paclitaxel	74-84	cystin 1	Mus musculus	160-163
9041221-3	1997	Paclitaxel was administered by intraperitoneal injection to C57BL/6J-cpk/cpk mice and Han:SPRD-Cy/Cy rats with rapidly progressive PKD and to DBA/2FG-pcy/pcy mice and Han:SPRD-Cy/+ rats with slowly progressive PKD.	Paclitaxel	0-10	cystin 1	Mus musculus	69-72
9041221-3	1997	Paclitaxel was administered by intraperitoneal injection to C57BL/6J-cpk/cpk mice and Han:SPRD-Cy/Cy rats with rapidly progressive PKD and to DBA/2FG-pcy/pcy mice and Han:SPRD-Cy/+ rats with slowly progressive PKD.	Paclitaxel	0-10	cystin 1	Mus musculus	73-76
9041221-4	1997	Paclitaxel (150 micrograms/wk) prolonged the survival of cpk/cpk mice from 24.5 days to more than 65 days and decreased kidney weight relative to body weight from 16.5% at 21 days of age to 8.2% at more than 65 days of age.	Paclitaxel	0-10	cystin 1	Mus musculus	57-60
9041221-4	1997	Paclitaxel (150 micrograms/wk) prolonged the survival of cpk/cpk mice from 24.5 days to more than 65 days and decreased kidney weight relative to body weight from 16.5% at 21 days of age to 8.2% at more than 65 days of age.	Paclitaxel	0-10	cystin 1	Mus musculus	61-64
9041221-13	1997	We conclude that paclitaxel diminished the rate of renal enlargement and increased the life span of cpk/cpk mice but not Cy/Cy rats with rapidly progressive forms of PKD.	Paclitaxel	17-27	cystin 1	Mus musculus	100-103
9041221-13	1997	We conclude that paclitaxel diminished the rate of renal enlargement and increased the life span of cpk/cpk mice but not Cy/Cy rats with rapidly progressive forms of PKD.	Paclitaxel	17-27	cystin 1	Mus musculus	104-107
9041188-4	1997	By using for each cell line the paclitaxel IC50, we found that these concentrations were sufficient to induce an increase in p53 levels in all of the four wt p53-expressing cells, whereas in the mutated p53-expressing cells, the levels were unaffected.	Paclitaxel	32-42	tumor protein p53	Homo sapiens	125-128
9041188-4	1997	By using for each cell line the paclitaxel IC50, we found that these concentrations were sufficient to induce an increase in p53 levels in all of the four wt p53-expressing cells, whereas in the mutated p53-expressing cells, the levels were unaffected.	Paclitaxel	32-42	tumor protein p53	Homo sapiens	158-161
9041188-4	1997	By using for each cell line the paclitaxel IC50, we found that these concentrations were sufficient to induce an increase in p53 levels in all of the four wt p53-expressing cells, whereas in the mutated p53-expressing cells, the levels were unaffected.	Paclitaxel	32-42	tumor protein p53	Homo sapiens	158-161
9010146-2	1997	METHODS: We conducted a randomized, double-blind, placebo-controlled dose-escalation study of MGDF in 53 patients with lung cancer who were treated with carboplatin and paclitaxel.	Paclitaxel	169-179	thrombopoietin	Homo sapiens	94-98
10743071-7	1997	CONCLUSION: In human breast cancer cells the induction of apoptosis by taxol was closely associated with mitotic arrest of cell cycle, and altered expression of bcl-2 and bax gene, possibly playing an important role in regulating taxol-induced apoptosis.	Paclitaxel	71-76	BCL2 apoptosis regulator	Homo sapiens	161-166
10743071-7	1997	CONCLUSION: In human breast cancer cells the induction of apoptosis by taxol was closely associated with mitotic arrest of cell cycle, and altered expression of bcl-2 and bax gene, possibly playing an important role in regulating taxol-induced apoptosis.	Paclitaxel	71-76	BCL2 associated X, apoptosis regulator	Homo sapiens	171-174
10743071-7	1997	CONCLUSION: In human breast cancer cells the induction of apoptosis by taxol was closely associated with mitotic arrest of cell cycle, and altered expression of bcl-2 and bax gene, possibly playing an important role in regulating taxol-induced apoptosis.	Paclitaxel	230-235	BCL2 apoptosis regulator	Homo sapiens	161-166
10743071-7	1997	CONCLUSION: In human breast cancer cells the induction of apoptosis by taxol was closely associated with mitotic arrest of cell cycle, and altered expression of bcl-2 and bax gene, possibly playing an important role in regulating taxol-induced apoptosis.	Paclitaxel	230-235	BCL2 associated X, apoptosis regulator	Homo sapiens	171-174
9105396-0	1997	Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells.	Paclitaxel	15-20	ATP binding cassette subfamily B member 1	Homo sapiens	36-50
9105396-0	1997	Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells.	Paclitaxel	15-20	ATP binding cassette subfamily B member 1	Homo sapiens	60-74
9105396-4	1997	In contrast, the 2008/13 clones followed the classical P-glycoprotein-mediated resistance phenotype until a 245-fold taxol-resistant clone (2008/13/2) was obtained, which was followed by a further increase in the degree of resistance but significant down-regulation of P-glycoprotein expression in the 252-fold taxol-resistant 2008/13/4 cells.	Paclitaxel	117-122	ATP binding cassette subfamily B member 1	Homo sapiens	269-283
9009167-6	1997	Taxol also activated Raf-1 kinase and ERK1/ERK2 MAP kinases in these cells.	Paclitaxel	0-5	mitogen-activated protein kinase 1	Mus musculus	43-47
9025751-2	1997	A complete clinical remission, using two cycles of 131I-labeled murine MN-14 anti-CEA monoclonal antibody (MAb), given intravenously, is reported in a patient with advanced ovarian cancer refractory to paclitaxel (Taxol) therapy.	Paclitaxel	202-212	carcinoembryonic antigen gene family	Mus musculus	82-85
9025751-2	1997	A complete clinical remission, using two cycles of 131I-labeled murine MN-14 anti-CEA monoclonal antibody (MAb), given intravenously, is reported in a patient with advanced ovarian cancer refractory to paclitaxel (Taxol) therapy.	Paclitaxel	214-219	carcinoembryonic antigen gene family	Mus musculus	82-85
9815684-5	1997	B. Deisseroth, Cancer Gene Ther., 1: 21-25, 1994), which involve transplantation of mouse marrow cells modified with the human MDR-1 cDNA, showed that the majority of the marrow cells of these animals were resistant to repetitive administration of myelotoxic doses of Taxol, a MDR-1-transported drug.	Paclitaxel	268-273	ATP binding cassette subfamily B member 1	Homo sapiens	127-132
9053494-5	1997	RESULTS: The medians of average daily CD34+ cell yields for patients who received paclitaxel plus CY, CE, and CEP with G-CSF were 12.9, 11.03, and 5.37 x 10(6)/kg, respectively, compared with 2.02 x 10(6)/kg in the reference group that received CY with G-CSF (P = &lt; .0001, .002, and .09, respectively).	Paclitaxel	82-92	CD34 molecule	Homo sapiens	38-42
9053494-6	1997	On first-day collections, patients who received paclitaxel plus CY, CE, and CEP with G-CSF yielded medians of 11.07, 8.09, and 3.52 x 10(6) CD34+ cells/kg, respectively, compared with 0.90 x 10(6)/kg in the reference group that received CY with G-CSF (P = .0006, .02, and .09, respectively).	Paclitaxel	48-58	CD34 molecule	Homo sapiens	140-144
9009089-3	1997	We also determined how these mechanisms would affect the accumulation and cytotoxicity of a PGP substrate, such as Taxol (paclitaxel).	Paclitaxel	115-120	ATP binding cassette subfamily B member 1	Homo sapiens	92-95
9009089-3	1997	We also determined how these mechanisms would affect the accumulation and cytotoxicity of a PGP substrate, such as Taxol (paclitaxel).	Paclitaxel	122-132	ATP binding cassette subfamily B member 1	Homo sapiens	92-95
9009089-8	1997	PGP, but not MRP, overexpression significantly impaired paclitaxel accumulation and paclitaxel-induced apoptosis, as well as reduced its cytotoxic effects as determined by the MTT assay.	Paclitaxel	56-66	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
9009089-8	1997	PGP, but not MRP, overexpression significantly impaired paclitaxel accumulation and paclitaxel-induced apoptosis, as well as reduced its cytotoxic effects as determined by the MTT assay.	Paclitaxel	84-94	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
9009089-9	1997	In contrast, enforced and much higher expression of Bcl-2 in HL-60/Bcl-2 (five-fold) or Bcl-xL in HL-60/Bcl-xL cells (10-fold) significantly reduced paclitaxel-induced apoptosis and the loss of cell viability, without affecting its intracellular accumulation.	Paclitaxel	149-159	BCL2 apoptosis regulator	Homo sapiens	52-57
9009089-9	1997	In contrast, enforced and much higher expression of Bcl-2 in HL-60/Bcl-2 (five-fold) or Bcl-xL in HL-60/Bcl-xL cells (10-fold) significantly reduced paclitaxel-induced apoptosis and the loss of cell viability, without affecting its intracellular accumulation.	Paclitaxel	149-159	BCL2 apoptosis regulator	Homo sapiens	67-72
9009089-9	1997	In contrast, enforced and much higher expression of Bcl-2 in HL-60/Bcl-2 (five-fold) or Bcl-xL in HL-60/Bcl-xL cells (10-fold) significantly reduced paclitaxel-induced apoptosis and the loss of cell viability, without affecting its intracellular accumulation.	Paclitaxel	149-159	BCL2 like 1	Homo sapiens	88-94
9009089-9	1997	In contrast, enforced and much higher expression of Bcl-2 in HL-60/Bcl-2 (five-fold) or Bcl-xL in HL-60/Bcl-xL cells (10-fold) significantly reduced paclitaxel-induced apoptosis and the loss of cell viability, without affecting its intracellular accumulation.	Paclitaxel	149-159	BCL2 like 1	Homo sapiens	104-110
9009089-12	1997	In addition, these findings suggest that, for Bcl-2 and Bcl-xL, enforced overexpression to high levels is necessary to induce paclitaxel resistance in HL-60 cells.	Paclitaxel	126-136	BCL2 apoptosis regulator	Homo sapiens	46-51
9009089-12	1997	In addition, these findings suggest that, for Bcl-2 and Bcl-xL, enforced overexpression to high levels is necessary to induce paclitaxel resistance in HL-60 cells.	Paclitaxel	126-136	BCL2 like 1	Homo sapiens	56-62
9000560-3	1997	Comparison of the effects of taxol and its analogue, taxotere, indicates that taxotere is capable of inducing bcl2 phosphorylation and apoptotic cell death at 100-fold lower concentrations than taxol.	Paclitaxel	29-34	BCL2 apoptosis regulator	Homo sapiens	110-114
9009167-7	1997	These results demonstrate that taxol affects tyrosine phosphorylation of Shc and this may result in the activation of the Raf-1/MAPK cascade.	Paclitaxel	31-36	mitogen-activated protein kinase 1	Mus musculus	128-132
9147616-0	1997	Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-alpha.	Paclitaxel	38-48	tumor necrosis factor	Mus musculus	64-91
9147616-2	1997	Our aim was to determine whether TNF increases the antitumor efficacy of paclitaxel and if so whether the increase is mediated through the enhancement of apoptosis induction by paclitaxel.	Paclitaxel	73-83	tumor necrosis factor	Mus musculus	33-36
9147616-10	1997	Histological analysis of treated MCa-K tumors revealed that TNF alone did not induce apoptosis of tumor cells, but in the combination it enhanced the apoptotic response to paclitaxel.	Paclitaxel	172-182	tumor necrosis factor	Mus musculus	60-63
9147616-11	1997	Thus, TNF increased the antitumor efficacy of paclitaxel by enhancing cellular sensitivity to paclitaxel"s induction of apoptosis.	Paclitaxel	46-56	tumor necrosis factor	Mus musculus	6-9
9147616-11	1997	Thus, TNF increased the antitumor efficacy of paclitaxel by enhancing cellular sensitivity to paclitaxel"s induction of apoptosis.	Paclitaxel	94-104	tumor necrosis factor	Mus musculus	6-9
8988053-1	1997	Recent studies have shown that paclitaxel leads to activation of Raf-1 kinase and have suggested that this activation is essential for bcl-2 phosphorylation and apoptosis.	Paclitaxel	31-41	BCL2 apoptosis regulator	Homo sapiens	135-140
9184173-1	1997	Cytoplasmic phospholipase A2 (PLA2) is known to be phosphorylated and activated by MAP kinase (Lin et al 1993, Cell 72: 269-278), an important downstream component of signal transduction, whereas paclitaxel has been shown to inhibit isoprenylation of ras proteins (Danesi et al 1995, Mol Pharmacol 47: 1106-1111).	Paclitaxel	196-206	phospholipase A2 group IB	Homo sapiens	12-28
9184173-1	1997	Cytoplasmic phospholipase A2 (PLA2) is known to be phosphorylated and activated by MAP kinase (Lin et al 1993, Cell 72: 269-278), an important downstream component of signal transduction, whereas paclitaxel has been shown to inhibit isoprenylation of ras proteins (Danesi et al 1995, Mol Pharmacol 47: 1106-1111).	Paclitaxel	196-206	phospholipase A2 group IB	Homo sapiens	30-34
9116321-7	1997	In addition, in MCF-7 cells, estradiol-induced increase in the intracellular p26Bcl-2 to p21Bax ratios was associated with a significant reduction in the large-sized DNA fragmentation induced by treatment with taxol.	Paclitaxel	210-215	BCL2 apoptosis regulator	Homo sapiens	80-85
9116321-9	1997	These results suggest that by modulating p26Bcl-2 levels, estrogens may affect the antitumor activity of taxol and potentially of other anti-breast cancer drugs against estrogen responsive human breast cancer cells.	Paclitaxel	105-110	BCL2 apoptosis regulator	Homo sapiens	44-49
8988053-2	1997	In the present study, we demonstrate that, in addition to paclitaxel, other agents that interact with tubulin and microtubules also induce Raf-1/bcl-2 phosphorylation, whereas DNA-damaging drugs, antimetabolites, and alkylating agents do not.	Paclitaxel	58-68	BCL2 apoptosis regulator	Homo sapiens	145-150
8988053-5	1997	The requirement for disruption of microtubules in this signaling cascade was strengthened further using paclitaxel analogues by demonstrating a correlation between tubulin polymerization, Raf-1/bcl-2 phosphorylation, and cytotoxicity.	Paclitaxel	104-114	BCL2 apoptosis regulator	Homo sapiens	194-199
9372859-2	1997	Paclitaxel (at concentrations 1-10 nmol) stimulated the cytotoxic effect of irradiation in HL-60 and to a lesser extent also in HL-60/ADR, but not in HL-60/VCR cells.	Paclitaxel	0-10	aldo-keto reductase family 1 member B	Homo sapiens	134-137
9272128-7	1997	Our studies of combinations of high-dose cyclosporin (CsA) or PSC 833 with etoposide, doxorubicin, or paclitaxel have produced data regarding the role of Pgp in the clinical pharmacology of these agents.	Paclitaxel	102-112	ATP binding cassette subfamily B member 1	Homo sapiens	154-157
9219509-0	1997	Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration.	Paclitaxel	14-24	ATP binding cassette subfamily B member 1	Homo sapiens	37-51
9219509-6	1997	RESULTS: Cross-resistance to paclitaxel in P-glycoprotein-expressing sublines was shown to be comparable to that of other drugs transported by P-glycoprotein.	Paclitaxel	29-39	ATP binding cassette subfamily B member 1	Homo sapiens	43-57
9219509-7	1997	Sensitivity to paclitaxel could be modulated by cyclosporin A in unselected cell lines expressing P-glycoprotein and not in P-glycoprotein-negative cell lines.	Paclitaxel	15-25	ATP binding cassette subfamily B member 1	Homo sapiens	98-112
9219509-8	1997	Resistance to paclitaxel was reduced tenfold by increasing the duration of exposure in P-glycoprotein-expressing cells.	Paclitaxel	14-24	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
9219509-10	1997	CONCLUSIONS: These studies extend observations on the schedule dependence of paclitaxel cytotoxicity and the role of P-glycoprotein in mediating paclitaxel sensitivity.	Paclitaxel	145-155	ATP binding cassette subfamily B member 1	Homo sapiens	117-131
9219509-11	1997	The schedule dependence of relative resistance suggests that infusional paclitaxel may help in overcoming P-glycoprotein-mediated resistance.	Paclitaxel	72-82	ATP binding cassette subfamily B member 1	Homo sapiens	106-120
8943066-0	1996	BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway.	Paclitaxel	13-23	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
9007036-1	1997	The purpose of this study was to determine if Taxol induced CYP3A in primary cultures of rat hepatocytes and, if so, whether induction of CYP3A would increase acetaminophen toxicity.	Paclitaxel	46-51	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	60-65
9007036-2	1997	Taxol caused a concentration-dependent increase in the amount of immunoreactive CYP3A and in the steady-state levels of CYP3A1/DEX but not CYP3A2 mRNA.	Paclitaxel	0-5	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	80-85
9007036-6	1997	Triacetyloleandomycin, a selective inhibitor of CYP3A, completely protected the cells against acetaminophen toxicity in both Taxol- and dexamethasone-pretreated cells and prevented the increase in covalent binding of acetaminophen to cellular proteins.	Paclitaxel	125-130	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	48-53
9007036-7	1997	These results demonstrate that Taxol, like dexamethasone, induces CYP3A and that increases in this P450 are responsible for increased acetaminophen toxicity.	Paclitaxel	31-36	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	66-71
8986780-8	1996	CaMV ATF cosedimented with microtubules and, surprisingly, it bound to Taxol-stabilized microtubules at high ionic strength, thus suggesting an atypical interaction when compared with that usually described for microtubule-binding proteins.	Paclitaxel	71-76	glial cell derived neurotrophic factor	Homo sapiens	5-8
8943066-0	1996	BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway.	Paclitaxel	13-23	tumor protein p53	Homo sapiens	52-55
8943066-3	1996	The cytotoxicity of paclitaxel, vincristine, and doxorubicin was significantly enhanced in BAX transfectants compared with control clones, whereas the cytotoxicity profile of carboplatin, etoposide, and hydroxyurea was unchanged.	Paclitaxel	20-30	BCL2 associated X, apoptosis regulator	Homo sapiens	91-94
8943066-4	1996	Increased paclitaxel-induced cytotoxicity of BAX clones was associated with enhanced apoptosis, as assessed by morphologic and flow cytometric criteria.	Paclitaxel	10-20	BCL2 associated X, apoptosis regulator	Homo sapiens	45-48
9042212-0	1996	Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells.	Paclitaxel	85-90	ATP binding cassette subfamily B member 1	Homo sapiens	29-32
8808711-0	1996	Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.	Paclitaxel	86-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	18-26
8831715-7	1996	For example, lower levels of taxol resistance are associated with overexpression of MRP than with overexpression of P-glycoprotein.	Paclitaxel	29-34	ATP binding cassette subfamily C member 1	Homo sapiens	84-87
8831715-7	1996	For example, lower levels of taxol resistance are associated with overexpression of MRP than with overexpression of P-glycoprotein.	Paclitaxel	29-34	ATP binding cassette subfamily B member 1	Homo sapiens	116-130
8858130-2	1996	In the present study, a variety of synthetic analogs of paclitaxel were examined for their potencies to induce nitric oxide (NO) and tumor necrosis factor (TNF) production by peritoneal M phi from LPS-responsive C3H/HeN, and LPS-hyporesponsive C3H/HeJ mice, and by M phi-like LPS-responsive J774.1 and its mutant LPS-hyporesponsive J7.DEF3 cells.	Paclitaxel	56-66	tumor necrosis factor	Mus musculus	133-154
8858130-2	1996	In the present study, a variety of synthetic analogs of paclitaxel were examined for their potencies to induce nitric oxide (NO) and tumor necrosis factor (TNF) production by peritoneal M phi from LPS-responsive C3H/HeN, and LPS-hyporesponsive C3H/HeJ mice, and by M phi-like LPS-responsive J774.1 and its mutant LPS-hyporesponsive J7.DEF3 cells.	Paclitaxel	56-66	tumor necrosis factor	Mus musculus	156-159
8808711-0	1996	Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.	Paclitaxel	86-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-30
8808711-2	1996	To investigate whether overexpression of the c-erbB-2/neu-encoded p185 can indeed lead to increased chemoresistance in breast cancers, we introduced the human c-erbB-2/neu gene into the very low p185-expressing MDA-MB435 human breast cancer cells and examined Taxol sensitivities among the parental MDA-MB-435 cells and stable transfectants which express increased levels of p185.	Paclitaxel	260-265	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-57
8808711-9	1996	These data demonstrated that overexpression of c-erbB-2/neu can lead to intrinsic Taxol resistance independent from mdr-1 mechanisms.	Paclitaxel	82-87	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-55
8808711-9	1996	These data demonstrated that overexpression of c-erbB-2/neu can lead to intrinsic Taxol resistance independent from mdr-1 mechanisms.	Paclitaxel	82-87	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-59
8877707-5	1996	Transfer of the selectable marker multidrug resistance 1 (mdr1), FMEV, in contrast to conventional MoMuLV-related vectors currently in use for clinical protocols, mediated background-free selectability of transduced human HPC in the presence of myeloablative doses of the cytostatic agent paclitaxel in vitro.	Paclitaxel	289-299	ATP binding cassette subfamily B member 1	Homo sapiens	34-56
8853905-0	1996	Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis.	Paclitaxel	31-36	BCL2 like 1	Homo sapiens	0-6
8853905-0	1996	Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis.	Paclitaxel	31-36	caspase 3	Homo sapiens	45-49
8853905-4	1996	In the present studies, we determined the effects of enforced overexpression of the antiapoptosis Bcl-xL protein on taxol-mediated microtubule and cell cycle perturbations, as well as on taxol-induced apoptosis and associated Yama protease activity in human myeloid leukemia HL-60 cells.	Paclitaxel	116-121	BCL2 like 1	Homo sapiens	98-104
8853905-5	1996	Our data demonstrate that high Bcl-xL levels do not affect the microtubular bundling or mitotic arrest due to taxol but significantly inhibit the morphological, flow cytometric, and DNA fragmentation features associated with taxol-induced apoptosis.	Paclitaxel	225-230	BCL2 like 1	Homo sapiens	31-37
8853905-6	1996	This resulted in a significant improvement in the survival of taxol-treated cells that possess high Bcl-xL levels.	Paclitaxel	62-67	BCL2 like 1	Homo sapiens	100-106
8853905-7	1996	In the control HL-60 cells, following taxol treatment, whereas the mRNA of Yama was not induced, taxol-induced apoptosis was associated with Yama activation and PARP as well as lamin B1 degradation.	Paclitaxel	97-102	caspase 3	Homo sapiens	141-145
8853905-7	1996	In the control HL-60 cells, following taxol treatment, whereas the mRNA of Yama was not induced, taxol-induced apoptosis was associated with Yama activation and PARP as well as lamin B1 degradation.	Paclitaxel	97-102	poly(ADP-ribose) polymerase 1	Homo sapiens	161-165
8853905-9	1996	These results suggest that Bcl-xL antagonizes taxol-induced apoptosis by a mechanism that interferes with the activation of a key protease involved in the execution of apoptosis.	Paclitaxel	46-51	BCL2 like 1	Homo sapiens	27-33
8757879-3	1996	Inducible NO synthase protein expression induced by taxol and LPS in the macrophages was also suppressed by colchicine, but colchicine did not suppress the transcription of iNOS mRNA in the macrophages after stimulation with taxol or LPS.	Paclitaxel	52-57	nitric oxide synthase 2, inducible	Mus musculus	0-21
8826941-3	1996	In vitro data and animal studies suggest that paclitaxel may have a unique ability to activate tumor cell apoptosis in the absence of wild-type p53 function.	Paclitaxel	46-56	tumor protein p53	Homo sapiens	144-147
8826941-4	1996	The authors sought to determine whether p53 mutations affect response to paclitaxel/RT in patients with locally advanced NSCLC.	Paclitaxel	73-83	tumor protein p53	Homo sapiens	40-43
8826941-13	1996	These results suggest that paclitaxel/RT may be an active regimen for patients with other locally advanced neoplasms with high rates of p53 gene mutations.	Paclitaxel	27-37	tumor protein p53	Homo sapiens	136-139
8795571-1	1996	We assessed the cytotoxic interaction between paclitaxel and 5-fluorouracil administered at various schedules against four human carcinoma cell lines, A549, MCF7, PA1 and WiDr.	Paclitaxel	46-56	PAXIP1 associated glutamate rich protein 1	Homo sapiens	163-166
8795571-7	1996	Simultaneous exposure to paclitaxel and 5-fluorouracil for 24 h showed mainly subadditive effects in A549, MCF7 and WiDr cell lines, whereas it showed additive effects in PA1 cells.	Paclitaxel	25-35	PAXIP1 associated glutamate rich protein 1	Homo sapiens	171-174
8795571-9	1996	Sequential exposure to 5-fluorouracil followed by paclitaxel showed subadditive effects in A549, MCF7 and PA1 cells.	Paclitaxel	50-60	PAXIP1 associated glutamate rich protein 1	Homo sapiens	106-109
8795571-12	1996	Interestingly, the continuous (5-day) exposure to paclitaxel and 5-fluorouracil had additive effects in A549, PA1 and WiDr cells, indicating that the prolonged simultaneous administration of these agents may circumvent the antagonistic interaction produced by short-term simultaneous administration.	Paclitaxel	50-60	PAXIP1 associated glutamate rich protein 1	Homo sapiens	110-113
8702804-0	1996	Paclitaxel activation of the GADD153 promoter through a cellular injury response element containing an essential Sp1 binding site.	Paclitaxel	0-10	DNA damage inducible transcript 3	Homo sapiens	29-36
8702804-1	1996	The GADD153 promoter is transcriptionally activated by paclitaxel-induced injury.	Paclitaxel	55-65	DNA damage inducible transcript 3	Homo sapiens	4-11
8702804-9	1996	These data indicate that paclitaxel activates the GADD153 promoter through a constitutively occupied Sp1 site at -61 bases.	Paclitaxel	25-35	DNA damage inducible transcript 3	Homo sapiens	50-57
8877707-5	1996	Transfer of the selectable marker multidrug resistance 1 (mdr1), FMEV, in contrast to conventional MoMuLV-related vectors currently in use for clinical protocols, mediated background-free selectability of transduced human HPC in the presence of myeloablative doses of the cytostatic agent paclitaxel in vitro.	Paclitaxel	289-299	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
8818330-10	1996	Associated with its effect on microtubule assembly, taxol prevented the inhibitory effects of nocodazole and colchicine on cyclic GMP accumulation and iNOS mRNA levels.	Paclitaxel	52-57	nitric oxide synthase 2	Homo sapiens	151-155
8763853-0	1996	The interaction of taxol and vinblastine with radiation induction of p53 and p21 WAF1/CIP1.	Paclitaxel	19-24	tumor protein p53	Homo sapiens	69-72
8763853-0	1996	The interaction of taxol and vinblastine with radiation induction of p53 and p21 WAF1/CIP1.	Paclitaxel	19-24	cyclin dependent kinase inhibitor 1A	Homo sapiens	77-90
8763853-4	1996	We examined the induction of p53 and its downstream target, p21WAF1/CIP1, by the microtubule active agents taxol and vinblastine with radiation.	Paclitaxel	107-112	tumor protein p53	Homo sapiens	29-32
8763853-4	1996	We examined the induction of p53 and its downstream target, p21WAF1/CIP1, by the microtubule active agents taxol and vinblastine with radiation.	Paclitaxel	107-112	cyclin dependent kinase inhibitor 1A	Homo sapiens	60-72
8763853-5	1996	An increase in induction of both p53 and p21 WAF1/CIP1 was demonstrated when radiation was added to either taxol or vinblastine treatment.	Paclitaxel	107-112	tumor protein p53	Homo sapiens	33-36
8763853-5	1996	An increase in induction of both p53 and p21 WAF1/CIP1 was demonstrated when radiation was added to either taxol or vinblastine treatment.	Paclitaxel	107-112	cyclin dependent kinase inhibitor 1A	Homo sapiens	41-54
8641795-0	1996	Paclitaxel (Taxol)-induced NF-kappaB translocation in murine macrophages.	Paclitaxel	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	27-36
8818651-2	1996	Two other anticancer drugs, mechlorethamine (nitrogen mustard) and taxol, enhanced CAT gene expression but the degree of sensitization was not as great as cisplatin.	Paclitaxel	67-72	catalase	Homo sapiens	83-86
9816243-1	1996	The multiple drug resistance (MDR) gene P-glycoprotein product is a transmembrane efflux pump that prevents toxicity of a variety of chemotherapeutic agents, including the anthracyclines, Vinca alkaloids, podophyllins, and taxol.	Paclitaxel	223-228	ATP binding cassette subfamily B member 1	Homo sapiens	40-54
21544450-0	1996	P-glycoprotein-associated resistance to taxol and taxotere and its reversal by dexniguldipine-HCl, dexverapamil-HCl, or cyclosporin A.	Paclitaxel	40-45	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
8641795-8	1996	Moreover, paclitaxel- and protein-free LPS-induced translocation of NF-kappaB was seen only in macrophages derived from LPS-responsive C3H/OuJ mice and not from the LPS-hyporesponsive C3H/HeJ mice, a finding that is consistent with those of previous genetic studies linking paclitaxel responsiveness to the Lps gene.	Paclitaxel	10-20	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	68-77
8641795-8	1996	Moreover, paclitaxel- and protein-free LPS-induced translocation of NF-kappaB was seen only in macrophages derived from LPS-responsive C3H/OuJ mice and not from the LPS-hyporesponsive C3H/HeJ mice, a finding that is consistent with those of previous genetic studies linking paclitaxel responsiveness to the Lps gene.	Paclitaxel	274-284	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	68-77
8616855-11	1996	To investigate the basis of the variable tumor response to taxol, we determined the expression of multidrug resistance P-glycoprotein (Pgp), p53, and bcl-2 proteins, using immunohistochemical staining and Western blot analysis.	Paclitaxel	59-64	ATP binding cassette subfamily B member 1	Homo sapiens	119-133
8616855-15	1996	Pgp expression correlated differently with taxol-induced inhibition of DNA synthesis than with apoptosis; Pgp-positive tumors showed a significantly higher Emax (63%) and IC30 (4.2 microM) but also a higher apoptotic index (17%) than Pgp-negative tumors (Emax 36%; IC30, 0.3 microM; and apoptotic index; 6%; P &lt; 0.05 for all cases).	Paclitaxel	43-48	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
8616855-15	1996	Pgp expression correlated differently with taxol-induced inhibition of DNA synthesis than with apoptosis; Pgp-positive tumors showed a significantly higher Emax (63%) and IC30 (4.2 microM) but also a higher apoptotic index (17%) than Pgp-negative tumors (Emax 36%; IC30, 0.3 microM; and apoptotic index; 6%; P &lt; 0.05 for all cases).	Paclitaxel	43-48	ATP binding cassette subfamily B member 1	Homo sapiens	106-109
8616855-15	1996	Pgp expression correlated differently with taxol-induced inhibition of DNA synthesis than with apoptosis; Pgp-positive tumors showed a significantly higher Emax (63%) and IC30 (4.2 microM) but also a higher apoptotic index (17%) than Pgp-negative tumors (Emax 36%; IC30, 0.3 microM; and apoptotic index; 6%; P &lt; 0.05 for all cases).	Paclitaxel	43-48	ATP binding cassette subfamily B member 1	Homo sapiens	106-109
8616855-18	1996	Pgp overexpression appears to protect cells from the antiproliferative effect of taxol but correlated with a higher apoptosis.	Paclitaxel	81-86	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
8651611-0	1996	Effects of taxol on TNF-alpha and IL-6 production by human peripheral blood cells.	Paclitaxel	11-16	tumor necrosis factor	Homo sapiens	20-29
8651611-0	1996	Effects of taxol on TNF-alpha and IL-6 production by human peripheral blood cells.	Paclitaxel	11-16	interleukin 6	Homo sapiens	34-38
8620503-0	1996	Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	47-52
8620503-5	1996	Recently, taxol was reported to induce Bcl-2 phosphorylation and inactivation.	Paclitaxel	10-15	BCL2 apoptosis regulator	Homo sapiens	39-44
8620503-9	1996	Thus, our data support a role for a distinct subcellular component of Raf-1, which is taxol but not phorbol myristate acetate sensitive, in mediating an apoptotic pathway involving Bc1-2.	Paclitaxel	86-91	charged multivesicular body protein 2A	Homo sapiens	181-186
8640809-0	1996	Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.	Paclitaxel	0-5	BCL2 apoptosis regulator	Homo sapiens	14-19
8640809-1	1996	Treatment of prostate cancer cell lines expressing bcl-2 with taxol induces bcl-2 phosphorylation and programmed cell death, whereas treatment of bcl-2-negative prostate cancer cells with taxol does not induce apoptosis.	Paclitaxel	62-67	BCL2 apoptosis regulator	Homo sapiens	51-56
8640809-1	1996	Treatment of prostate cancer cell lines expressing bcl-2 with taxol induces bcl-2 phosphorylation and programmed cell death, whereas treatment of bcl-2-negative prostate cancer cells with taxol does not induce apoptosis.	Paclitaxel	62-67	BCL2 apoptosis regulator	Homo sapiens	76-81
8640809-1	1996	Treatment of prostate cancer cell lines expressing bcl-2 with taxol induces bcl-2 phosphorylation and programmed cell death, whereas treatment of bcl-2-negative prostate cancer cells with taxol does not induce apoptosis.	Paclitaxel	62-67	BCL2 apoptosis regulator	Homo sapiens	76-81
8640809-2	1996	bcl-2 phosphorylation seems to inhibit its binding to bax since less bax was observed in immunocomplex with bcl-2 in taxol-treated cancer cells.	Paclitaxel	117-122	BCL2 apoptosis regulator	Homo sapiens	0-5
8640809-2	1996	bcl-2 phosphorylation seems to inhibit its binding to bax since less bax was observed in immunocomplex with bcl-2 in taxol-treated cancer cells.	Paclitaxel	117-122	BCL2 associated X, apoptosis regulator	Homo sapiens	54-57
8640809-2	1996	bcl-2 phosphorylation seems to inhibit its binding to bax since less bax was observed in immunocomplex with bcl-2 in taxol-treated cancer cells.	Paclitaxel	117-122	BCL2 associated X, apoptosis regulator	Homo sapiens	69-72
8640809-2	1996	bcl-2 phosphorylation seems to inhibit its binding to bax since less bax was observed in immunocomplex with bcl-2 in taxol-treated cancer cells.	Paclitaxel	117-122	BCL2 apoptosis regulator	Homo sapiens	108-113
8640809-3	1996	These findings support the use of the anticancer drug taxol for the treatment of bcl-2-positive prostate cancers and other bcl-2-positive malignancies, such as follicular lymphoma.	Paclitaxel	54-59	BCL2 apoptosis regulator	Homo sapiens	81-86
8640809-3	1996	These findings support the use of the anticancer drug taxol for the treatment of bcl-2-positive prostate cancers and other bcl-2-positive malignancies, such as follicular lymphoma.	Paclitaxel	54-59	BCL2 apoptosis regulator	Homo sapiens	123-128
8640818-0	1996	Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer.	Paclitaxel	0-5	C-X-C motif chemokine ligand 8	Homo sapiens	46-50
8640818-4	1996	Taxol induced secretion of interleukin (IL) 8 but not IL-6, IL-1alpha, or IL-1beta in 4 of 10 samples.	Paclitaxel	0-5	C-X-C motif chemokine ligand 8	Homo sapiens	27-45
8641795-9	1996	Finally, the LPS structural antagonist Rhodobacter sphaeroides diphosphoryl lipid A inhibited both LPS-and paclitaxel-induced NF-kappaB activation, suggesting a common receptor component in this activation.	Paclitaxel	107-117	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	126-135
8641795-0	1996	Paclitaxel (Taxol)-induced NF-kappaB translocation in murine macrophages.	Paclitaxel	12-17	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	27-36
8641795-5	1996	In this report, we have extended these findings by demonstrating that paclitaxel, like LPS, is able to stimulate the translocation of primarily p50-p65 heterodimers of NF-kappaB to the nucleus.	Paclitaxel	70-80	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	168-177
8641795-7	1996	The kinetics of NF-kappaB activation by paclitaxel are slower than those of LPS: by 15 min poststimulation, LPS-induced NF-kappaB activation was readily detected, whereas the paclitaxel-induced NF-kappaB activation was minimal.	Paclitaxel	40-50	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	16-25
8641795-7	1996	The kinetics of NF-kappaB activation by paclitaxel are slower than those of LPS: by 15 min poststimulation, LPS-induced NF-kappaB activation was readily detected, whereas the paclitaxel-induced NF-kappaB activation was minimal.	Paclitaxel	40-50	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	120-129
8641795-7	1996	The kinetics of NF-kappaB activation by paclitaxel are slower than those of LPS: by 15 min poststimulation, LPS-induced NF-kappaB activation was readily detected, whereas the paclitaxel-induced NF-kappaB activation was minimal.	Paclitaxel	40-50	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	120-129
8641795-7	1996	The kinetics of NF-kappaB activation by paclitaxel are slower than those of LPS: by 15 min poststimulation, LPS-induced NF-kappaB activation was readily detected, whereas the paclitaxel-induced NF-kappaB activation was minimal.	Paclitaxel	175-185	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	16-25
8573197-4	1996	Although verapamil, an inhibitor of P-glycoprotein function, markedly increased the efficacy of taxol against the rodent cells (WS, WR, and CHO), the expression of P-glycoprotein was found only at low levels in the WR cells.	Paclitaxel	96-101	ATP binding cassette subfamily B member 1	Homo sapiens	36-50
8907264-3	1996	Murine models have demonstrated that retrovirus-mediated MDR transfer in bone marrow cells can render animals resistant to myeloablative doses of Taxol, and in vitro studies have shown that MDR-transduced human CD34+ cells can generate drug-resistant multipotential hemopoietic progenitors such as long term culture-initiating cells.	Paclitaxel	146-151	CD34 molecule	Homo sapiens	211-215
8573197-4	1996	Although verapamil, an inhibitor of P-glycoprotein function, markedly increased the efficacy of taxol against the rodent cells (WS, WR, and CHO), the expression of P-glycoprotein was found only at low levels in the WR cells.	Paclitaxel	96-101	ATP binding cassette subfamily B member 1	Homo sapiens	164-178
8573197-10	1996	These results lead us to propose the presence in the rodent cells of an alternative taxol transport system that is distinct from the P-glycoprotein and MRP systems.	Paclitaxel	84-89	ATP binding cassette subfamily B member 1	Homo sapiens	133-147
8543832-5	1996	This IL-8 gene expression was inhibited by pretreatment with 5 microM taxol, a microtubule-stabilizing agent.	Paclitaxel	70-75	C-X-C motif chemokine ligand 8	Homo sapiens	5-9
9816180-3	1996	In the present study, the modulatory activity of the novel pyridine analogue PAK-104P on MRP-mediated resistance to doxorubicin and paclitaxel was investigated in two doxorubicin-selected human tumor cell lines [HT1080/DR4 (sarcoma) and HL60/ADR (leukemia)] and compared with the nonimmunosuppressive cyclosporine analogue PSC-833.	Paclitaxel	132-142	ATP binding cassette subfamily C member 1	Homo sapiens	89-92
21153290-7	1996	Colchicine (1 muM) and taxol (1 muM) inhibited the basal PRL secretion by 38 and 44%, respectively.	Paclitaxel	23-28	latexin	Homo sapiens	32-35
21153290-7	1996	Colchicine (1 muM) and taxol (1 muM) inhibited the basal PRL secretion by 38 and 44%, respectively.	Paclitaxel	23-28	prolactin	Homo sapiens	57-60
21153290-8	1996	In addition, colchicine (1 muM) and taxol (1 muM) significantly inhibited TRH-stimulated PRL secretion.	Paclitaxel	36-41	latexin	Homo sapiens	45-48
21153290-8	1996	In addition, colchicine (1 muM) and taxol (1 muM) significantly inhibited TRH-stimulated PRL secretion.	Paclitaxel	36-41	prolactin	Homo sapiens	89-92
21153290-9	1996	TRH-stimulated PRL secretion in control, colchicine-, and taxol-treated cells was 13.9, 9.1, and 6 ng/mL, respectively.	Paclitaxel	58-63	prolactin	Homo sapiens	15-18
8604001-6	1996	We have extended this observation to show that LPS induces transient resistance to the cytotoxic drugs taxol and doxorubicin.	Paclitaxel	103-108	toll-like receptor 4	Mus musculus	47-50
8543832-6	1996	Colchicine or vinblastine, microtubule-disrupting agents, induced IL-8 gene expression, which was also inhibited by taxol treatment.	Paclitaxel	116-121	C-X-C motif chemokine ligand 8	Homo sapiens	66-70
8612305-5	1996	On simultaneous exposure to paclitaxel and cisplatin, additive and subadditive (slight antagonistic) effects were observed in A549, MCF7, and PA1 cells, while sub-additive and protective (antagonistic) effects were observed in WiDr cells.	Paclitaxel	28-38	PAXIP1 associated glutamate rich protein 1	Homo sapiens	142-145
8554977-0	1996	Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153.	Paclitaxel	14-19	DNA damage inducible transcript 3	Homo sapiens	104-111
8554977-4	1996	Activation of the GADD153 promoter coupled to the luciferase gene and transfected into human ovarian carcinoma 2008 cells correlated well with the increase in endogenous GADD153 mRNA after treatment with taxol but not after treatment with cDDP.	Paclitaxel	204-209	DNA damage inducible transcript 3	Homo sapiens	18-25
8554977-4	1996	Activation of the GADD153 promoter coupled to the luciferase gene and transfected into human ovarian carcinoma 2008 cells correlated well with the increase in endogenous GADD153 mRNA after treatment with taxol but not after treatment with cDDP.	Paclitaxel	204-209	DNA damage inducible transcript 3	Homo sapiens	170-177
8554977-9	1996	We conclude that (1) taxol and cDDP activate GADD153 promoter activity through different mechanisms; (2) the signal transduction pathway mediating induction by cDDP involves a tyrosine kinase inhibitable by tyrphostin B46; and (3) that inhibition of this signal transduction pathway by tyrphostin synergistically enhances cDDP toxicity.	Paclitaxel	21-26	DNA damage inducible transcript 3	Homo sapiens	45-52
8548875-7	1996	Both the ARH-D60 and ARM-80 cell lines are resistant to doxorubicin and cross-resistant to mitoxantrone, vinca alkaloids, taxol and m-AMSA while maintaining sensitivity to antimetabolites and alkylating agents.	Paclitaxel	122-127	low density lipoprotein receptor adaptor protein 1	Homo sapiens	9-12
8612305-7	1996	On sequential exposure to cisplatin first, followed by paclitaxel, additive effects were observed in PA1 cells, while additive, sub-additive, and protective effects were observed in A549, MCF7, and WiDr cells.	Paclitaxel	55-65	PAXIP1 associated glutamate rich protein 1	Homo sapiens	101-104
8537394-0	1995	Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance.	Paclitaxel	117-122	tubulin, beta 2A class IIA	Mus musculus	22-30
8564846-0	1996	Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis.	Paclitaxel	53-58	tumor protein p53	Homo sapiens	15-18
8564846-2	1996	Normal human fibroblasts depleted of functional p53 by SV40 T antigen or HPV-16 E6, and primary embryo fibroblasts from p53 null mice showed seven- to ninefold increased cytotoxicity by paclitaxel.	Paclitaxel	186-196	tumor protein p53	Homo sapiens	120-123
8564846-3	1996	Reduced levels of p53 correlated with increased G2/M phase arrest, micronucleation, and p53-independent paclitaxel-induced apoptosis.	Paclitaxel	104-114	tumor protein p53	Homo sapiens	18-21
8564846-3	1996	Reduced levels of p53 correlated with increased G2/M phase arrest, micronucleation, and p53-independent paclitaxel-induced apoptosis.	Paclitaxel	104-114	tumor protein p53	Homo sapiens	88-91
8768096-3	1996	Depolymerization of microtubular system by colcemid and its disorganization by taxol lead to rapid and drastic changes in morphology of all cytoskeletal systems and in the organization of matrix network: fibronectin and tenascin filaments became disordered and, in particular, lost any orientation.	Paclitaxel	79-84	fibronectin 1	Homo sapiens	204-215
8537394-6	1995	Although expressed at an extremely low level in the parental cells, expression of the M beta 2 isotype was increased 21-fold (&lt; 0.005) in the cell line most resistant to taxol.	Paclitaxel	173-178	tubulin, beta 2A class IIA	Mus musculus	86-94
8537394-7	1995	These findings suggest that a cell can alter its relative tubulin isotype composition in response to an external stress and specifically imply that altered expression of M beta 2, the class II beta-tubulin isotype, may contribute to the development of high resistance to taxol.	Paclitaxel	271-276	tubulin, beta 2A class IIA	Mus musculus	170-178
8521385-0	1995	Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53.	Paclitaxel	25-30	tumor protein p53	Homo sapiens	108-111
8703657-6	1995	In particular, enzymes of the CYP3A subfamily play a role in the metabolism of many anticancer drugs, including epipodophyllotoxins, ifosphamide, tamoxifen, taxol and vinca alkaloids.	Paclitaxel	157-162	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-35
8521385-2	1995	We examined the ability of three microtubule-active agents, taxol, vinblastine, and nocodazole, to increase p53 levels and activate p53-dependent processes.	Paclitaxel	60-65	tumor protein p53	Homo sapiens	108-111
8521385-2	1995	We examined the ability of three microtubule-active agents, taxol, vinblastine, and nocodazole, to increase p53 levels and activate p53-dependent processes.	Paclitaxel	60-65	tumor protein p53	Homo sapiens	132-135
9815937-2	1995	Recent studies have also shown that Taxol-induced apoptosis, but not Taxol-induced microtubular bundling or mitotic arrest, is significantly inhibited in cells that overexpress the bcl-2 gene product p26BCL-2.	Paclitaxel	36-41	BCL2 apoptosis regulator	Homo sapiens	181-186
8581880-4	1995	Taxol (1 microM) also inhibited osteoclast spreading (45%) on fibronectin-coated slides.	Paclitaxel	0-5	fibronectin 1	Homo sapiens	62-73
9815937-3	1995	In the present studies we examined the effects of several modulators of activities of protein kinases on Taxol-induced DNA fragmentation and apoptosis in human pre-B leukemia 697 cells transfected with the cDNA of the bcl-2 gene and expressing high intracellular levels of p26BCL-2 (697/BCL-2 cells).	Paclitaxel	105-110	BCL2 apoptosis regulator	Homo sapiens	218-223
9815937-3	1995	In the present studies we examined the effects of several modulators of activities of protein kinases on Taxol-induced DNA fragmentation and apoptosis in human pre-B leukemia 697 cells transfected with the cDNA of the bcl-2 gene and expressing high intracellular levels of p26BCL-2 (697/BCL-2 cells).	Paclitaxel	105-110	BCL2 apoptosis regulator	Homo sapiens	276-281
7479762-7	1995	The increases in both force and LC20 phosphorylation, after addition of nocodazole, could be blocked or reversed by stabilizing the microtubules with paclitaxel (former generic name, taxol).	Paclitaxel	150-160	myosin light chain 9	Homo sapiens	32-36
7475274-3	1995	Exposure to 1.0 mumol/l taxol for 24 h or HIDAC &gt; or = 10 mumol/l for 4 h induced internucleosomal DNA fragmentation and the morphologic features of apoptosis in CD34+, HLA-DR+ cells.	Paclitaxel	24-29	CD34 molecule	Homo sapiens	165-169
7475274-8	1995	Taxol and Ara-C mediated apoptosis of CD34+, HLA-DR+ cells, and its inhibition by pIXY321, was not accompanied by any significant alteration in the intracellular p26BCL-2 levels.	Paclitaxel	0-5	CD34 molecule	Homo sapiens	38-42
7473140-8	1995	Inhibitor experiments suggest that typical CYP3A substrates/inhibitors (e.g., cyclosporin, epipodophyllotoxins) may significantly interact with paclitaxel in vivo.	Paclitaxel	144-154	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-48
7479762-7	1995	The increases in both force and LC20 phosphorylation, after addition of nocodazole, could be blocked or reversed by stabilizing the microtubules with paclitaxel (former generic name, taxol).	Paclitaxel	183-188	myosin light chain 9	Homo sapiens	32-36
7669666-1	1995	The MDR1 gene product P-glycoprotein (P-gp) extrudes several anticancer drugs including taxol and fluorescent dyes such as rhodamine (Rh123).	Paclitaxel	88-93	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
7553639-0	1995	Taxol induction of p21WAF1 and p53 requires c-raf-1.	Paclitaxel	0-5	tumor protein p53	Homo sapiens	31-34
7553639-3	1995	Herein, we show that taxol induced dose- and time-dependent accumulation of the cyclin inhibitor p21WAF1 in both p53 wild-type and p53-null cells, although the degree of induction was greater in cells expressing wild-type p53.	Paclitaxel	21-26	tumor protein p53	Homo sapiens	113-116
7553639-3	1995	Herein, we show that taxol induced dose- and time-dependent accumulation of the cyclin inhibitor p21WAF1 in both p53 wild-type and p53-null cells, although the degree of induction was greater in cells expressing wild-type p53.	Paclitaxel	21-26	tumor protein p53	Homo sapiens	131-134
7553639-3	1995	Herein, we show that taxol induced dose- and time-dependent accumulation of the cyclin inhibitor p21WAF1 in both p53 wild-type and p53-null cells, although the degree of induction was greater in cells expressing wild-type p53.	Paclitaxel	21-26	tumor protein p53	Homo sapiens	131-134
7553639-4	1995	In MCF7 cells, wild-type p53 protein was also induced after taxol treatment, and this induction was mediated primarily by increased protein stability.	Paclitaxel	60-65	tumor protein p53	Homo sapiens	25-28
7553639-5	1995	Taxol induced both p21WAF1 and wild-type p53 optimally in MCF7 cells after 20-24-h exposure with an EC50(3) of 5 nM.	Paclitaxel	0-5	tumor protein p53	Homo sapiens	41-44
7553639-6	1995	In p53-null PC3M cells, p21WAF1 was similarly induced after 24-h exposure to taxol.	Paclitaxel	77-82	tumor protein p53	Homo sapiens	3-6
7669666-1	1995	The MDR1 gene product P-glycoprotein (P-gp) extrudes several anticancer drugs including taxol and fluorescent dyes such as rhodamine (Rh123).	Paclitaxel	88-93	ATP binding cassette subfamily B member 1	Homo sapiens	22-36
7669666-1	1995	The MDR1 gene product P-glycoprotein (P-gp) extrudes several anticancer drugs including taxol and fluorescent dyes such as rhodamine (Rh123).	Paclitaxel	88-93	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
7553639-8	1995	Previous depletion of c-raf-1 inhibited both the p21WAF1- and p53-inducing properties of taxol, as well as the activation of MAP kinase.	Paclitaxel	89-94	tumor protein p53	Homo sapiens	62-65
7553639-10	1995	Furthermore, the ability of taxol to both induce wild-type p53 in MCF7 cells and activate MAP kinase is also dependent on c-raf-1 expression.	Paclitaxel	28-33	tumor protein p53	Homo sapiens	59-62
7554101-3	1995	Treatment of 5637 bladder carcinoma cells with estramustine and taxol inhibited u-PA secretion into the conditioned medium in a drug concentration-dependent fashion.	Paclitaxel	64-69	plasminogen activator, urokinase	Homo sapiens	80-84
7581225-3	1995	Depolymerization of the microtubular system by colcemid and its disorganization by taxol led to rapid and drastic changes in the organization of matrix network: fibronectin and tenascin filaments became disordered and, in particular, lost any orientation.	Paclitaxel	83-88	fibronectin 1	Homo sapiens	161-172
7601572-11	1995	This study provides evidence that (a) altered cellular pharmacokinetics is related to MRP expression; (b) MRP-mediated phenotype is characterized by a specific pattern of cross-resistance, which does not involve taxol; and (c) verapamil may be effective in modulating the function of the MRP gene product.	Paclitaxel	212-217	ATP binding cassette subfamily C member 1	Homo sapiens	106-109
7622101-8	1995	Finally, resistance to taxol may be mediated by enhanced expression of P-glycoprotein, while presumed other mechanisms such as alterations in tubulin structure, the cellular "target" of taxol, and changes in polymerization of tubulin are still largely unresolved.	Paclitaxel	23-28	ATP binding cassette subfamily B member 1	Homo sapiens	71-85
7601572-11	1995	This study provides evidence that (a) altered cellular pharmacokinetics is related to MRP expression; (b) MRP-mediated phenotype is characterized by a specific pattern of cross-resistance, which does not involve taxol; and (c) verapamil may be effective in modulating the function of the MRP gene product.	Paclitaxel	212-217	ATP binding cassette subfamily C member 1	Homo sapiens	106-109
7753834-2	1995	Using the phosphatase inhibitor okadaic acid or the chemotherapeutic drug taxol, we found that Bcl-2 was phosphorylated in lymphoid cells.	Paclitaxel	74-79	BCL2 apoptosis regulator	Homo sapiens	95-100
7541450-7	1995	The mean daily yield of CD34+ cells/kg/collection was 3.5 (range, 0.8 to 28.9) after Taxol and CY, as compared with 1.3 (range, 0.1 to 7.0) for patients who received CY alone (P = .01).	Paclitaxel	85-90	CD34 molecule	Homo sapiens	24-28
7541450-8	1995	All patients who received CY and Taxol reached a target level of 5 x 10(6) CD34+ cells/kg, as compared with five of nine patients (55.5%) who received CY alone (P = .03).	Paclitaxel	33-38	CD34 molecule	Homo sapiens	75-79
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	interferon gamma	Mus musculus	16-25
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	tumor necrosis factor	Mus musculus	74-83
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	nitric oxide synthase 2, inducible	Mus musculus	127-148
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	nitric oxide synthase 2, inducible	Mus musculus	150-154
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	tumor necrosis factor	Mus musculus	245-254
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	tumor necrosis factor	Mus musculus	245-254
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	interferon gamma	Mus musculus	16-25
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	tumor necrosis factor	Mus musculus	74-83
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	nitric oxide synthase 2, inducible	Mus musculus	127-148
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	nitric oxide synthase 2, inducible	Mus musculus	150-154
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	tumor necrosis factor	Mus musculus	245-254
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	tumor necrosis factor	Mus musculus	245-254
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	interferon gamma	Mus musculus	16-25
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	tumor necrosis factor	Mus musculus	74-83
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	nitric oxide synthase 2, inducible	Mus musculus	127-148
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	nitric oxide synthase 2, inducible	Mus musculus	150-154
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	tumor necrosis factor	Mus musculus	245-254
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	tumor necrosis factor	Mus musculus	245-254
7759887-9	1995	STSN and polymyxin B potently inhibited taxol-induced TNF-alpha secretion and TNF-alpha gene expression as well as iNOS gene expression by rIFN-gamma plus taxol.	Paclitaxel	40-45	tumor necrosis factor	Mus musculus	54-63
7759887-9	1995	STSN and polymyxin B potently inhibited taxol-induced TNF-alpha secretion and TNF-alpha gene expression as well as iNOS gene expression by rIFN-gamma plus taxol.	Paclitaxel	155-160	nitric oxide synthase 2, inducible	Mus musculus	115-119
7759887-12	1995	In conclusion, the present results strongly suggest that the capacity of taxol to increase NO synthesis from rIFN-gamma-primed macrophages is the result of taxol-induced TNF-alpha secretion via the signal transduction pathway of PKC activation.	Paclitaxel	73-78	tumor necrosis factor	Mus musculus	170-179
7759887-12	1995	In conclusion, the present results strongly suggest that the capacity of taxol to increase NO synthesis from rIFN-gamma-primed macrophages is the result of taxol-induced TNF-alpha secretion via the signal transduction pathway of PKC activation.	Paclitaxel	156-161	tumor necrosis factor	Mus musculus	170-179
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	30-35	tumor necrosis factor	Mus musculus	74-83
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	30-35	nitric oxide synthase 2, inducible	Mus musculus	127-148
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	30-35	nitric oxide synthase 2, inducible	Mus musculus	150-154
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	30-35	tumor necrosis factor	Mus musculus	245-254
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	30-35	tumor necrosis factor	Mus musculus	245-254
7670142-3	1995	The P-glycoprotein expressing, multidrug resistant sublines developed to daunorubicin (K/DNR), doxorubicin (K/DOX) and epirubicin (K/EPR) were cross-resistant to the other anthracyclines and to vinblastine, taxol, colchicine and actinomycin D, but were not resistant to idarubicin or etoposide.	Paclitaxel	207-212	ATP binding cassette subfamily B member 1	Homo sapiens	4-18
7552988-0	1995	Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit.	Paclitaxel	14-19	ATP binding cassette subfamily B member 1	Homo sapiens	115-120
7552989-0	1995	Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene.	Paclitaxel	27-32	CD34 molecule	Homo sapiens	90-94
7552989-0	1995	Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene.	Paclitaxel	27-32	ATP binding cassette subfamily B member 1	Homo sapiens	174-179
7552989-7	1995	The resistance to taxol of the CD34 selected transduced cells, as judged by the plating efficiency of clonogenic progenitor cells derived from these cells by growth in methylcellulose supplemented with taxol was much higher in the transduced cells than in untransduced cells.	Paclitaxel	18-23	CD34 molecule	Homo sapiens	31-35
7552989-7	1995	The resistance to taxol of the CD34 selected transduced cells, as judged by the plating efficiency of clonogenic progenitor cells derived from these cells by growth in methylcellulose supplemented with taxol was much higher in the transduced cells than in untransduced cells.	Paclitaxel	202-207	CD34 molecule	Homo sapiens	31-35
7597432-13	1995	When monocytes were stimulated with endotoxin, IL-1 beta production was greatest at 48 hours, suggesting that paclitaxel can prime cells to produce greater quantities of cytokines after a second stimulus.	Paclitaxel	110-120	interleukin 1 beta	Homo sapiens	47-56
7610396-2	1995	Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), a dipertene compound extracted from the Pacific yew Taxus brevifolia, appeared a good candidate for study as an addition to the ICE regimen (ICE-T) because of its broad antitumor activity, its unique mechanism of action, and its toxicity profile, which was not expected to impact the ICE regimen adversely.	Paclitaxel	0-10	carboxylesterase 2	Homo sapiens	193-196
7610396-2	1995	Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), a dipertene compound extracted from the Pacific yew Taxus brevifolia, appeared a good candidate for study as an addition to the ICE regimen (ICE-T) because of its broad antitumor activity, its unique mechanism of action, and its toxicity profile, which was not expected to impact the ICE regimen adversely.	Paclitaxel	0-10	carboxylesterase 2	Homo sapiens	206-209
7542257-1	1995	The effects of the microtubular drugs colcemid and taxol on the morphological changes induced by hepatocyte growth factor/scatter factor (HGF/SF) in MDCK cells were studied.	Paclitaxel	51-56	hepatocyte growth factor	Canis lupus familiaris	138-144
7645972-0	1995	Addition of hTNF alpha potentiates cytotoxicity of taxol in human ovarian cancer lines.	Paclitaxel	51-56	tumor necrosis factor	Homo sapiens	12-22
7645972-4	1995	The SKVLB cells overexpressed the multidrug resistant gene (MDR-1) which confers a resistance to taxol.	Paclitaxel	97-102	ATP binding cassette subfamily B member 1	Homo sapiens	60-65
7645972-5	1995	We observed that the combination of low concentration of hTNF alpha with taxol could increase the cytotoxic activity of taxol in SKOV3 cells.	Paclitaxel	120-125	tumor necrosis factor	Homo sapiens	57-61
7645972-6	1995	Furthermore, a four-hour pretreatment with taxol before adding hTNF alpha to the culture has shown a significant increase in their cytotoxic activity.	Paclitaxel	43-48	tumor necrosis factor	Homo sapiens	63-73
7645972-9	1995	This indicates that taxol could alter the mechanism of hTNF alpha-resistance.	Paclitaxel	20-25	tumor necrosis factor	Homo sapiens	55-59
8521300-0	1995	LPS and Taxol activate Lyn kinase autophosphorylation in Lps(n), but not in Lpsd), macrophages.	Paclitaxel	8-13	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	23-26
8521300-1	1995	BACKGROUND: The anti-tumor agent, Taxol, has been shown in murine macrophages to stimulate tumor necrosis factor (TNF), modulate TNF receptors, induce a large panel of immediate-early genes, and induce protein tyrosine phosphorylation indistinguishably from LPS.	Paclitaxel	34-39	tumor necrosis factor	Mus musculus	91-112
8521300-1	1995	BACKGROUND: The anti-tumor agent, Taxol, has been shown in murine macrophages to stimulate tumor necrosis factor (TNF), modulate TNF receptors, induce a large panel of immediate-early genes, and induce protein tyrosine phosphorylation indistinguishably from LPS.	Paclitaxel	34-39	tumor necrosis factor	Mus musculus	114-117
8521300-1	1995	BACKGROUND: The anti-tumor agent, Taxol, has been shown in murine macrophages to stimulate tumor necrosis factor (TNF), modulate TNF receptors, induce a large panel of immediate-early genes, and induce protein tyrosine phosphorylation indistinguishably from LPS.	Paclitaxel	34-39	tumor necrosis factor	Mus musculus	129-132
8521300-4	1995	We therefore sought to evaluate the activation of lyn kinase by LPS and Taxol in LPS-responsive (Lps(n)) and LPS-hyporesponsive (Lps(d)) macrophages.	Paclitaxel	72-77	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	50-53
8521300-8	1995	RESULTS: Within seconds of stimulation, LPS and Taxol induce in Lps(n) macrophages a depression of autophosphorylation, followed within minutes by autophosphorylation of both p53 and p56 lyn species.	Paclitaxel	48-53	tumor protein p53	Homo sapiens	175-178
8521300-8	1995	RESULTS: Within seconds of stimulation, LPS and Taxol induce in Lps(n) macrophages a depression of autophosphorylation, followed within minutes by autophosphorylation of both p53 and p56 lyn species.	Paclitaxel	48-53	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	183-190
8521300-11	1995	CONCLUSIONS: Decreased lyn kinase activity within seconds and autophosphorylation within minutes of LPS or Taxol stimulation in Lps(n) macrophages strongly supports the hypothesis that LPS and Taxol share a common signaling pathway.	Paclitaxel	193-198	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	23-26
7706748-0	1995	Taxol and colchicine increase LPS-induced pro-IL-1 beta production, but do not increase IL-1 beta secretion.	Paclitaxel	0-5	interleukin 1 beta	Homo sapiens	42-55
7706748-0	1995	Taxol and colchicine increase LPS-induced pro-IL-1 beta production, but do not increase IL-1 beta secretion.	Paclitaxel	0-5	interleukin 1 beta	Homo sapiens	46-55
7706748-4	1995	For example, it is known that taxol and colchicine, two drugs that affect microtubule structure and function, increase LPS-induced IL-1 beta release.	Paclitaxel	30-35	interleukin 1 beta	Homo sapiens	131-140
7706748-9	1995	These findings indicate that taxol and colchicine increase LPS-induced IL-1 beta release by an increase in the production of the precursor molecule.	Paclitaxel	29-34	interleukin 1 beta	Homo sapiens	71-80
7542257-5	1995	HGF/SF induced spreading in taxol-treated MDCK cells but these cells retained a non-polarized discoid shape and a pattern of actin microfilament bundles characteristic of the untreated cells.	Paclitaxel	28-33	hepatocyte growth factor	Canis lupus familiaris	0-6
7767900-0	1995	Activation of NF-kappa B in murine macrophages by taxol.	Paclitaxel	50-55	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	14-24
7536686-6	1995	Application of 10 mg/kg NGF caused a significant elevation in peptide-immunoreactivity in control animals and in taxol-treated mice, i.e., statistically significant increase in peptide concentrations and in the number of substance P- and CGRP-immunoreactive DRG-neurons, suggesting a recruitment of additional peptide cells.	Paclitaxel	113-118	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	238-242
7536686-1	1995	In our study we have used morphological and radio-immunological methods for the investigation of calcitonin gene-related peptide (CGRP) and substance P in cervical dorsal root ganglia (DRGs) in mice after administration of taxol or cisplatin and in spontaneously diabetic animals (db/db mice).	Paclitaxel	223-228	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	97-128
7536686-1	1995	In our study we have used morphological and radio-immunological methods for the investigation of calcitonin gene-related peptide (CGRP) and substance P in cervical dorsal root ganglia (DRGs) in mice after administration of taxol or cisplatin and in spontaneously diabetic animals (db/db mice).	Paclitaxel	223-228	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	130-134
7536686-5	1995	Measurement of peptide levels in the taxol-treated groups and in diabetic mice demonstrated a decrease predominantly for CGRP.	Paclitaxel	37-42	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	121-125
7529746-4	1995	Taxol alone induced murine C3H/He macrophages to secrete tumor necrosis factor alpha (TNF) and to produce nitric oxide (NO) with kinetics similar to that of LPS.	Paclitaxel	0-5	tumor necrosis factor	Mus musculus	57-84
7529746-4	1995	Taxol alone induced murine C3H/He macrophages to secrete tumor necrosis factor alpha (TNF) and to produce nitric oxide (NO) with kinetics similar to that of LPS.	Paclitaxel	0-5	tumor necrosis factor	Mus musculus	86-89
7529746-6	1995	RsDPLA inhibited taxol-induced TNF and NO production from C3H/He macrophages in a dose-dependent manner.	Paclitaxel	17-22	tumor necrosis factor	Mus musculus	31-34
7529746-8	1995	Polymyxin B blocked the inhibitory effect of RsDPLA on taxol-induced TNF production.	Paclitaxel	55-60	tumor necrosis factor	Mus musculus	69-72
7529746-9	1995	The inhibitory activity of RsDPLA appeared to be reversible since macrophages still responded to taxol in inducing TNF production after the RsDPLA was washed out with phosphate-buffered saline prior to the addition of taxol.	Paclitaxel	97-102	tumor necrosis factor	Mus musculus	115-118
7529746-10	1995	Taxol-induced TNF production was not inhibited by colchicine, vinblastine, or 10-deacetylbaccatine III.	Paclitaxel	0-5	tumor necrosis factor	Mus musculus	14-17
7529746-13	1995	Taxol-induced TNF production by the mutant cells was also inhibited by RsDPLA.	Paclitaxel	0-5	tumor necrosis factor	Mus musculus	14-17
7707396-10	1995	rHuIFN alpha-2a potentiated MRK-16 reversal of multidrug resistance with both doxorubicin and paclitaxel on HT-29mdr1 cells and with vincristine on AdrR MCF-7 and HCT-15 tumor cells.	Paclitaxel	94-104	adrenergic receptor, alpha 2a	Mus musculus	7-15
7707396-10	1995	rHuIFN alpha-2a potentiated MRK-16 reversal of multidrug resistance with both doxorubicin and paclitaxel on HT-29mdr1 cells and with vincristine on AdrR MCF-7 and HCT-15 tumor cells.	Paclitaxel	94-104	mitogen-activated protein kinase kinase kinase 20	Homo sapiens	28-31
7749130-15	1995	Paclitaxel is an excellent substrate for P-glycoprotein, the protein product of the multidrug resistance-1 (mdr-1) gene, and phase I trials are under way combining paclitaxel with several known blockers of Pgp function.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	41-55
7749130-15	1995	Paclitaxel is an excellent substrate for P-glycoprotein, the protein product of the multidrug resistance-1 (mdr-1) gene, and phase I trials are under way combining paclitaxel with several known blockers of Pgp function.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	84-106
7749130-15	1995	Paclitaxel is an excellent substrate for P-glycoprotein, the protein product of the multidrug resistance-1 (mdr-1) gene, and phase I trials are under way combining paclitaxel with several known blockers of Pgp function.	Paclitaxel	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	108-113
7749130-15	1995	Paclitaxel is an excellent substrate for P-glycoprotein, the protein product of the multidrug resistance-1 (mdr-1) gene, and phase I trials are under way combining paclitaxel with several known blockers of Pgp function.	Paclitaxel	164-174	ATP binding cassette subfamily B member 1	Homo sapiens	41-55
7749130-15	1995	Paclitaxel is an excellent substrate for P-glycoprotein, the protein product of the multidrug resistance-1 (mdr-1) gene, and phase I trials are under way combining paclitaxel with several known blockers of Pgp function.	Paclitaxel	164-174	ATP binding cassette subfamily B member 1	Homo sapiens	84-106
7749130-15	1995	Paclitaxel is an excellent substrate for P-glycoprotein, the protein product of the multidrug resistance-1 (mdr-1) gene, and phase I trials are under way combining paclitaxel with several known blockers of Pgp function.	Paclitaxel	164-174	ATP binding cassette subfamily B member 1	Homo sapiens	108-113
7767900-3	1995	Here, we report that taxol rapidly activated nuclear factor kappa B (NF-kappa B) in mouse peritoneal macrophages.	Paclitaxel	21-26	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	45-67
7767900-3	1995	Here, we report that taxol rapidly activated nuclear factor kappa B (NF-kappa B) in mouse peritoneal macrophages.	Paclitaxel	21-26	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	69-79
7767900-5	1995	Taxol-induced nuclear translocation of NF-kappa B was inhibited by pyrrolidine dithiocarbamate, an antioxidant, but not by cycloheximide, a protein synthesis inhibitor.	Paclitaxel	0-5	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	39-49
7767900-6	1995	The ability of taxol to activate NF-kappa B may help account for its induction of immunoregulatory and cytotoxic cytokines, which in turn may contribute to its antitumor effects.	Paclitaxel	15-20	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	33-43
22358644-6	1995	MDR gene transduction corrects the sensitivity of CD34(+) cells to taxol, an MDR drug substrate, and enriches the marrow for MDR-transduced cells.	Paclitaxel	67-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-3
22358644-6	1995	MDR gene transduction corrects the sensitivity of CD34(+) cells to taxol, an MDR drug substrate, and enriches the marrow for MDR-transduced cells.	Paclitaxel	67-72	CD34 molecule	Homo sapiens	50-54
22358644-6	1995	MDR gene transduction corrects the sensitivity of CD34(+) cells to taxol, an MDR drug substrate, and enriches the marrow for MDR-transduced cells.	Paclitaxel	67-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	77-80
22358644-6	1995	MDR gene transduction corrects the sensitivity of CD34(+) cells to taxol, an MDR drug substrate, and enriches the marrow for MDR-transduced cells.	Paclitaxel	67-72	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	77-80
7583354-4	1995	Activation of NF-kappa B and accumulation of TNF-alpha mRNA correlated semiquantitatively under the following conditions: (1) inhibition of NF-kappa B by dithiocarbamates; (2) induction of TNF synthesis by taxol; (3) partial induction of TNF-alpha mRNA by various inducers in macrophages from lpsd mice; and (4) inhibition of NF-kappa B activation by a protease inhibitor.	Paclitaxel	206-211	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	14-24
7583354-4	1995	Activation of NF-kappa B and accumulation of TNF-alpha mRNA correlated semiquantitatively under the following conditions: (1) inhibition of NF-kappa B by dithiocarbamates; (2) induction of TNF synthesis by taxol; (3) partial induction of TNF-alpha mRNA by various inducers in macrophages from lpsd mice; and (4) inhibition of NF-kappa B activation by a protease inhibitor.	Paclitaxel	206-211	tumor necrosis factor	Mus musculus	45-54
7583354-4	1995	Activation of NF-kappa B and accumulation of TNF-alpha mRNA correlated semiquantitatively under the following conditions: (1) inhibition of NF-kappa B by dithiocarbamates; (2) induction of TNF synthesis by taxol; (3) partial induction of TNF-alpha mRNA by various inducers in macrophages from lpsd mice; and (4) inhibition of NF-kappa B activation by a protease inhibitor.	Paclitaxel	206-211	tumor necrosis factor	Mus musculus	45-48
7959286-5	1994	On the contrary, both taxol and taxotere caused a significant suppression of lymphocyte growth and activation with IL-2 at 10 and 50 micrograms/ml.	Paclitaxel	22-27	interleukin 2	Homo sapiens	115-119
7654318-3	1994	Using the phosphatase inhibitor okadaic acid (OA) or chemotherapeutic agents such as Taxol and 5"-fluorouracil, we found that bcl-2 can be phosphorylated.	Paclitaxel	85-90	BCL2 apoptosis regulator	Homo sapiens	126-131
7654318-4	1994	Since OA or Taxol treatment leads to apoptosis, it seems that phosphorylation of bcl-2 leads to its inactivation.	Paclitaxel	12-17	BCL2 apoptosis regulator	Homo sapiens	81-86
7654318-8	1994	Treatment with the phosphatase inhibitor or with chemotherapeutic agents (Taxol, 5"-fluorouracil) led to severe apoptosis of these cells, along with hyperphosphorylation of bcl-2.	Paclitaxel	74-79	BCL2 apoptosis regulator	Homo sapiens	173-178
7869824-2	1995	Taxol significantly inhibited contraction induced by phenylephrine, angiotensin II, phorbol 12,13-dibutyrate and increasing concentrations of calcium.	Paclitaxel	0-5	angiotensinogen	Rattus norvegicus	68-82
7954398-0	1994	Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity.	Paclitaxel	38-43	tumor necrosis factor	Homo sapiens	78-105
7954398-7	1994	Structure-activity studies using taxol and related taxanes have been done to determine the relationship between the effects of taxol on TNF-alpha gene expression and its cytotoxic and microtubule-stabilizing activities.	Paclitaxel	33-38	tumor necrosis factor	Homo sapiens	136-145
7954398-7	1994	Structure-activity studies using taxol and related taxanes have been done to determine the relationship between the effects of taxol on TNF-alpha gene expression and its cytotoxic and microtubule-stabilizing activities.	Paclitaxel	127-132	tumor necrosis factor	Homo sapiens	136-145
7954398-8	1994	Using Northern blot analysis, it was found that changes in the structure of taxol that did not alter cytotoxicity did prevent the induction of TNF-alpha gene expression.	Paclitaxel	76-81	tumor necrosis factor	Homo sapiens	143-152
7954398-9	1994	The data presented in this paper demonstrate that the effects of taxol on TNF-alpha gene expression are distinct from its known cytotoxic properties.	Paclitaxel	65-70	tumor necrosis factor	Homo sapiens	74-83
7834963-5	1994	Cytochrome P450 enzymes of the CYP3A and CYP2C subfamilies appear to be involved in hepatic metabolism of paclitaxel.	Paclitaxel	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-36
7526093-2	1994	Since overexpression of the bcl-2 gene has been reported to retard apoptosis due to a variety of anticancer agents, we examined and compared taxol-induced intracellular microtubular bundling and apoptosis in pre-B human leukemia 697 cells and their counterparts which have been transfected with and overexpress cDNA derived from the bcl-2 gene.	Paclitaxel	141-146	BCL2 apoptosis regulator	Homo sapiens	28-33
7526093-3	1994	Treatment with 0.1 or 1.0 mumol/l taxol for 24 h resulted in internucleosomal DNA fragmentation and morphologic features of apoptosis in 697 cells, but not in 697/BCL-2 cells.	Paclitaxel	34-39	BCL2 apoptosis regulator	Homo sapiens	163-168
7526093-4	1994	However, indirect immunofluorescent staining with anti-tubulin antibody revealed that taxol treatment produces stable microtubule bundles resistant to calcium-mediated disassembly in 697, as well as 697/BCL-2 cells.	Paclitaxel	86-91	BCL2 apoptosis regulator	Homo sapiens	203-208
7526093-12	1994	The delayed onset of taxol-induced DNA fragmentation and apoptosis in 697/BCL-2 cells without down-regulation of p26BCL-2 levels suggests that an alternative mechanism of taxol-mediated apoptosis might be triggered which is unimpeded by high p26BCL-2 levels, or taxol-induced prolongation of mitotic arrest may lead to the inactivation or inhibition of that mechanism by which p26BCL-2 is able to block apoptosis.	Paclitaxel	21-26	BCL2 apoptosis regulator	Homo sapiens	74-79
7966458-1	1994	The antigenic property of paclitaxel was examined using its protein mixtures (paclitaxel + OVA, paclitaxel + GSA, paclitaxel + RSA) in guinea pigs and mice in comparison with ovalbumin (OVA) and the protein conjugate of 4-aminoantipriyne (AAP).	Paclitaxel	26-36	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	175-184
7916458-3	1994	MRP-overexpressing SW-1573 cells are resistant to doxorubicin, daunorubicin, vincristine, VP-16, colchicine, and rhodamine 123, but not to 4"-(9-acridinylamino)methanesulfon-m-anisidide or taxol.	Paclitaxel	189-194	ATP binding cassette subfamily C member 1	Homo sapiens	0-3
7915297-5	1994	Activation of PMN by fMLP (10(-6) M) resulted in a significant increase in membrane fluidity that was attenuated by PMN pretreatment with phalloidin or taxol.	Paclitaxel	152-157	formyl peptide receptor 1	Homo sapiens	21-25
7966458-6	1994	When mice were sensitized with paclitaxel or paclitaxel + OVA adsorbed to alum.	Paclitaxel	45-55	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	58-61
7913410-0	1994	Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme.	Paclitaxel	14-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-102
7908721-5	1994	The cpk mouse is a well-characterized recessive PKD model and we find that cpk/cpk mice develop PKD and die from uraemia by 4-5 weeks of age, but when treated weekly with taxol they survive for more than 200 days with minimal loss of renal function, show limited collecting-dust cyst enlargement, and attain adult size.	Paclitaxel	171-176	cystin 1	Mus musculus	4-7
7913709-9	1994	The effect of microtubule inhibitors on transferrin receptor mobility was reversed by pretreating cells with taxol, a microtubule-stabilizing agent.	Paclitaxel	109-114	transferrin	Homo sapiens	40-51
7911495-8	1994	Taxol inhibited the FMLP induction of C1qR up-regulation, indicating that the ability to move the intracellular stores of C1qR depends on normal microtubule functioning.	Paclitaxel	0-5	formyl peptide receptor 1	Homo sapiens	20-24
7911495-8	1994	Taxol inhibited the FMLP induction of C1qR up-regulation, indicating that the ability to move the intracellular stores of C1qR depends on normal microtubule functioning.	Paclitaxel	0-5	CD93 molecule	Homo sapiens	38-42
7911495-8	1994	Taxol inhibited the FMLP induction of C1qR up-regulation, indicating that the ability to move the intracellular stores of C1qR depends on normal microtubule functioning.	Paclitaxel	0-5	CD93 molecule	Homo sapiens	122-126
7912193-5	1994	Taxol-stabilized microtubules bound to GST-Kar3 on a coverslip shorten as they glide, resulting in faster lagging end, than leading end, velocities.	Paclitaxel	0-5	Kar3p	Saccharomyces cerevisiae S288C	43-47
7919958-7	1994	Taxol, which stabilizes microtubules and arrests cells at the G1 phase of the cell cycle, down-regulated mts1 gene expression in both F1 and ML8 lines.	Paclitaxel	0-5	S100 calcium binding protein A4	Mus musculus	105-109
7908721-5	1994	The cpk mouse is a well-characterized recessive PKD model and we find that cpk/cpk mice develop PKD and die from uraemia by 4-5 weeks of age, but when treated weekly with taxol they survive for more than 200 days with minimal loss of renal function, show limited collecting-dust cyst enlargement, and attain adult size.	Paclitaxel	171-176	cystin 1	Mus musculus	75-78
7908721-5	1994	The cpk mouse is a well-characterized recessive PKD model and we find that cpk/cpk mice develop PKD and die from uraemia by 4-5 weeks of age, but when treated weekly with taxol they survive for more than 200 days with minimal loss of renal function, show limited collecting-dust cyst enlargement, and attain adult size.	Paclitaxel	171-176	cystin 1	Mus musculus	75-78
7907372-6	1994	Thus the cytochrome P-450-mediated biotransformation of taxol to 6 alpha-hydroxytaxol can be classified as a detoxification reaction.	Paclitaxel	56-61	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	9-25
7907352-5	1994	During mitotic arrest due to taxol, bcl-2 remains associated with condensed chromosomes but is lost after &gt; 2 days at approximately the same time as the appearance of apoptotic features in these cells.	Paclitaxel	29-34	BCL2 apoptosis regulator	Homo sapiens	36-41
7912076-6	1994	Taxol-induced aneuploidy increased the proportion of G0G1 phase cells, increased p53 positivity, and down-regulated mts1.	Paclitaxel	0-5	cyclin dependent kinase inhibitor 2A	Mus musculus	116-120
7912076-7	1994	This suggests that mts1 transcription may have been negatively regulated, possibly on account of the stabilization of microtubules by taxol.	Paclitaxel	134-139	cyclin dependent kinase inhibitor 2A	Mus musculus	19-23
7907000-1	1994	We studied the effect of the anticancer drug taxol on the cytotoxic mechanism of major histocompatibility complex nonrestricted lymphocytes and their activation with interleukin 2.	Paclitaxel	45-50	interleukin 2	Homo sapiens	166-179
7907000-5	1994	In addition, taxol inhibited activation of lymphocytes with interleukin 2; however, the cytotoxicity of interleukin 2-preactivated lymphocytes was less sensitive to taxol treatment.	Paclitaxel	13-18	interleukin 2	Homo sapiens	60-73
7907395-7	1994	Following treatment with clinically relevant concentration of taxol (1.0 microM for 24 h), HL-60 but not HL-60/TAX1000 cells display intracellular microtubular bundling, markedly enhanced accumulation of the cells in G2/M phase of cell-cycle and internucleosomal DNA fragmentation associated with apoptosis which is independent of bcl-2 gene expression.	Paclitaxel	62-67	BCL2 apoptosis regulator	Homo sapiens	331-336
7907000-5	1994	In addition, taxol inhibited activation of lymphocytes with interleukin 2; however, the cytotoxicity of interleukin 2-preactivated lymphocytes was less sensitive to taxol treatment.	Paclitaxel	13-18	interleukin 2	Homo sapiens	104-117
7907000-5	1994	In addition, taxol inhibited activation of lymphocytes with interleukin 2; however, the cytotoxicity of interleukin 2-preactivated lymphocytes was less sensitive to taxol treatment.	Paclitaxel	165-170	interleukin 2	Homo sapiens	104-117
7506736-10	1994	However, this gene and cytostatic metabolite were induced synergistically by combinations of taxol or LPS with IFN-gamma.	Paclitaxel	93-98	interferon gamma	Mus musculus	111-120
7903909-0	1994	Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation.	Paclitaxel	0-5	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-77
7923556-10	1994	administration to male mice, paclitaxel clearance (CLtb) was 3.25 ml min-1 kg-1 and the terminal half-life (t1/2) was 69 min.	Paclitaxel	29-39	clathrin, light polypeptide (Lcb)	Mus musculus	51-55
7923556-20	1994	delivery of paclitaxel at 22.5 and 11.25 mg/kg; however, the CLtb calculated in these studies was much lower than that associated with 3-h continuous i.v.	Paclitaxel	12-22	clathrin, light polypeptide (Lcb)	Mus musculus	61-65
8101863-5	1993	We report that RsDPLA and SDZ 880.431 potently inhibited taxol-induced TNF secretion, gene activation, and protein-tyrosine phosphorylation.	Paclitaxel	57-62	tumor necrosis factor	Mus musculus	71-74
8105099-4	1993	Overexpression of P-glycoprotein is one mechanism of in vitro resistance to a number of currently used cytotoxic agents including paclitaxel.	Paclitaxel	130-140	ATP binding cassette subfamily B member 1	Homo sapiens	18-32
8105099-5	1993	PURPOSE: Our aim was to develop a bioassay to measure plasma levels of Cremophor and to determine whether or not plasma levels of Cremophor achieved during paclitaxel therapy are sufficient to inhibit the activity of the P-glycoprotein.	Paclitaxel	156-166	ATP binding cassette subfamily B member 1	Homo sapiens	221-235
8105099-16	1993	CONCLUSION: The concentrations of Cremophor measured in plasma drawn from patients after a 3-hour infusion of paclitaxel at 135 or 175 mg/m2 were found to be sufficient to inhibit P-glycoprotein activity in vitro.	Paclitaxel	110-120	ATP binding cassette subfamily B member 1	Homo sapiens	180-194
7901310-1	1993	Taxol is a potent, microtubule-stabilizing, antineoplastic drug that induces interleukin-1-beta (IL-1-beta) and tumor necrosis factor-alpha (TNF-alpha) release by thioglycolate-elicited mouse peritoneal macrophages.	Paclitaxel	0-5	interleukin 1 beta	Mus musculus	77-95
7901310-1	1993	Taxol is a potent, microtubule-stabilizing, antineoplastic drug that induces interleukin-1-beta (IL-1-beta) and tumor necrosis factor-alpha (TNF-alpha) release by thioglycolate-elicited mouse peritoneal macrophages.	Paclitaxel	0-5	interleukin 1 beta	Mus musculus	97-106
7901310-1	1993	Taxol is a potent, microtubule-stabilizing, antineoplastic drug that induces interleukin-1-beta (IL-1-beta) and tumor necrosis factor-alpha (TNF-alpha) release by thioglycolate-elicited mouse peritoneal macrophages.	Paclitaxel	0-5	tumor necrosis factor	Mus musculus	112-139
7901310-1	1993	Taxol is a potent, microtubule-stabilizing, antineoplastic drug that induces interleukin-1-beta (IL-1-beta) and tumor necrosis factor-alpha (TNF-alpha) release by thioglycolate-elicited mouse peritoneal macrophages.	Paclitaxel	0-5	tumor necrosis factor	Mus musculus	141-150
7901279-2	1993	Three lines of evidence support this hypothesis: a) Taxol, a microtubule-binding diterpene, mimics the ability of LPS to induce cytokines and down-regulate receptors for TNF-alpha.	Paclitaxel	52-57	tumor necrosis factor	Mus musculus	170-179
7901310-5	1993	However, at all doses of endotoxin from 1 pg/ml to 1 microgram/ml, the addition of taxol resulted in a 50% to 100% increase in IL-1-beta release (p &lt; 0.001) and a 25% to 50% increase in TNF-alpha release (p &lt; 0.01).	Paclitaxel	83-88	interleukin 1 beta	Homo sapiens	127-136
7901310-5	1993	However, at all doses of endotoxin from 1 pg/ml to 1 microgram/ml, the addition of taxol resulted in a 50% to 100% increase in IL-1-beta release (p &lt; 0.001) and a 25% to 50% increase in TNF-alpha release (p &lt; 0.01).	Paclitaxel	83-88	tumor necrosis factor	Homo sapiens	189-198
7901310-6	1993	In contrast, taxol caused a reduction in intracellular pro-IL-1-beta levels.	Paclitaxel	13-18	interleukin 1 beta	Homo sapiens	59-68
7901310-7	1993	Kinetic studies demonstrated that taxol enhanced IL-1-beta release by mononuclear cells at all time points tested from 4.5 hours to 18 hours after stimulation.	Paclitaxel	34-39	interleukin 1 beta	Homo sapiens	49-58
8104544-4	1993	Significant differences in sensitivity to taxol among these cell lines were observed; the most resistant cell line SK-N-FI is characterized by very high levels of MDR1 expression and the most sensitive SK-N-AS by very low levels.	Paclitaxel	42-47	ATP binding cassette subfamily B member 1	Homo sapiens	163-167
8100207-6	1993	In addition, taxol also interfered with the induction of lymphokine-activated cytotoxicity and with lymphocyte growth in IL-2 cultures.	Paclitaxel	13-18	interleukin 2	Homo sapiens	57-67
8100819-2	1993	The mechanism of binding of microtubule-associated protein 2 (MAP2) to taxol-stabilized microtubules (MTs) was examined through Scatchard analysis of equilibrium binding and by immunoelectron microscopy.	Paclitaxel	71-76	microtubule-associated protein 2	Mus musculus	28-60
8100819-2	1993	The mechanism of binding of microtubule-associated protein 2 (MAP2) to taxol-stabilized microtubules (MTs) was examined through Scatchard analysis of equilibrium binding and by immunoelectron microscopy.	Paclitaxel	71-76	microtubule-associated protein 2	Mus musculus	62-66
8100207-6	1993	In addition, taxol also interfered with the induction of lymphokine-activated cytotoxicity and with lymphocyte growth in IL-2 cultures.	Paclitaxel	13-18	interleukin 2	Homo sapiens	121-125
8100207-7	1993	However, IL-2 preactivated NK cells displayed substantial levels of cytotoxicity even after taxol treatment.	Paclitaxel	92-97	interleukin 2	Homo sapiens	9-13
1361719-0	1992	Divergent effects of taxol on tumor necrosis factor-alpha-mediated cytolysis of ovarian carcinoma cells.	Paclitaxel	21-26	tumor necrosis factor	Homo sapiens	30-57
8096557-3	1993	In addition, taxol treatment decreased BCL-2 oncogene expression, which is known to block PCD.	Paclitaxel	13-18	BCL2 apoptosis regulator	Homo sapiens	39-44
7912530-4	1993	In human tumors resistant to Taxol, P-glycoprotein could be responsible for maintaining the drug below cytotoxic levels.	Paclitaxel	29-34	ATP binding cassette subfamily B member 1	Homo sapiens	36-50
7912530-5	1993	Analyses of the MDR promoters that are involved in P-glycoprotein expression and overproduction revealed an interesting recombination event in a Taxol-resistant cell line.	Paclitaxel	145-150	ATP binding cassette subfamily B member 1	Homo sapiens	51-65
7912536-6	1993	Immunoprecipitation of these tyrosine phosphoproteins followed by Western blotting with a microtubule-associated protein-2 (MAP-2) kinase MAb revealed that both Taxol and LPS induced the tyrosine phosphorylation of a MAP-2 kinase-like protein.	Paclitaxel	161-166	microtubule-associated protein 2	Mus musculus	90-122
7912536-6	1993	Immunoprecipitation of these tyrosine phosphoproteins followed by Western blotting with a microtubule-associated protein-2 (MAP-2) kinase MAb revealed that both Taxol and LPS induced the tyrosine phosphorylation of a MAP-2 kinase-like protein.	Paclitaxel	161-166	microtubule-associated protein 2	Mus musculus	124-129
7912536-6	1993	Immunoprecipitation of these tyrosine phosphoproteins followed by Western blotting with a microtubule-associated protein-2 (MAP-2) kinase MAb revealed that both Taxol and LPS induced the tyrosine phosphorylation of a MAP-2 kinase-like protein.	Paclitaxel	161-166	microtubule-associated protein 2	Mus musculus	217-222
7912536-7	1993	In addition, MAP-2 kinase-like activity was stimulated in the presence of Taxol or LPS.	Paclitaxel	74-79	microtubule-associated protein 2	Mus musculus	13-18
7912536-8	1993	Examination of cellular mRNA levels in LPS and Taxol-activated macrophages by Northern blot analysis revealed increased expression of Interleukin-1 beta, and tumor necrosis factor-alpha cytokine mRNAs.	Paclitaxel	47-52	interleukin 1 beta	Mus musculus	134-185
1361719-1	1992	OBJECTIVE: Our objective was to study the combined effect of taxol and tumor necrosis factor-alpha on the cytolysis of human ovarian carcinoma cell lines, because taxol has been shown to be active against ovarian carcinoma and has also been shown to increase tumor necrosis factor-alpha release from macrophages.	Paclitaxel	163-168	tumor necrosis factor	Homo sapiens	71-98
1361719-3	1992	RESULTS: At therapeutic concentrations taxol caused a significant increase in tumor necrosis factor-alpha-mediated cytolysis of Caov-3 and A2780 (p &lt; or = 0.05).	Paclitaxel	39-44	tumor necrosis factor	Homo sapiens	78-105
1361719-4	1992	By contrast, taxol caused a decrease in the tumor necrosis factor-alpha-mediated cytolysis of SK-OV-3 and NIH:OVCAR-3 (p &lt; or = 0.01).	Paclitaxel	13-18	tumor necrosis factor	Homo sapiens	44-71
1350792-4	1992	Likewise, Taxol induced TNF alpha secretion.	Paclitaxel	10-15	tumor necrosis factor	Mus musculus	24-33
1357667-12	1992	In addition, the bone marrow cells of several mice initially positive for MDR gene by PCR, and subsequently negative, were exposed to taxol, a drug whose detoxification depends on MDR gene expression; a positive signal was obtained in all of these mice, indicating drug selection of MDR-positive marrow cells.	Paclitaxel	134-139	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	74-77
1357667-12	1992	In addition, the bone marrow cells of several mice initially positive for MDR gene by PCR, and subsequently negative, were exposed to taxol, a drug whose detoxification depends on MDR gene expression; a positive signal was obtained in all of these mice, indicating drug selection of MDR-positive marrow cells.	Paclitaxel	134-139	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	180-183
1357667-12	1992	In addition, the bone marrow cells of several mice initially positive for MDR gene by PCR, and subsequently negative, were exposed to taxol, a drug whose detoxification depends on MDR gene expression; a positive signal was obtained in all of these mice, indicating drug selection of MDR-positive marrow cells.	Paclitaxel	134-139	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	180-183
1357667-13	1992	Cell sorting studies of these mice also show an increased number of high-MDR-expressing marrow cells, selected after exposure to taxol.	Paclitaxel	129-134	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	73-76
1357667-14	1992	Thus, in this live animal model MDR transduction is effective in selecting a human MDR-expressing population of marrow cells resistant to taxol chemotherapy.	Paclitaxel	138-143	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-35
1357667-14	1992	Thus, in this live animal model MDR transduction is effective in selecting a human MDR-expressing population of marrow cells resistant to taxol chemotherapy.	Paclitaxel	138-143	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	83-86
1356126-4	1992	Toward this end, the ability of taxol to induce TNF-alpha mRNA and five other genes (IL-1 beta, IP-10, D3, D7, and D8) associated with LPS-activation of macrophages was examined by Northern blot analysis.	Paclitaxel	32-37	tumor necrosis factor	Mus musculus	48-57
1356126-4	1992	Toward this end, the ability of taxol to induce TNF-alpha mRNA and five other genes (IL-1 beta, IP-10, D3, D7, and D8) associated with LPS-activation of macrophages was examined by Northern blot analysis.	Paclitaxel	32-37	interleukin 1 beta	Mus musculus	85-94
1352414-2	1992	When mice transplanted with bone marrow cells containing a transferred MDR1 gene were treated with the cytotoxic drug taxol, a substantial enrichment for transduced bone marrow cells was observed.	Paclitaxel	118-123	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	71-75
1353517-0	1992	Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages.	Paclitaxel	0-5	tumor necrosis factor	Mus musculus	77-104
1353517-4	1992	In a dose-dependent manner, LPS-free taxol induced release of biologically active tumor necrosis factor alpha (TNF) by inflammatory murine macrophages.	Paclitaxel	37-42	tumor necrosis factor	Mus musculus	82-109
1353517-4	1992	In a dose-dependent manner, LPS-free taxol induced release of biologically active tumor necrosis factor alpha (TNF) by inflammatory murine macrophages.	Paclitaxel	37-42	tumor necrosis factor	Mus musculus	111-114
1353517-5	1992	Taxol-induced production of TNF was inhibitable by interleukin-10.	Paclitaxel	0-5	tumor necrosis factor	Mus musculus	28-31
1353517-5	1992	Taxol-induced production of TNF was inhibitable by interleukin-10.	Paclitaxel	0-5	interleukin 10	Mus musculus	51-65
1353517-6	1992	By Northern blot, taxol (10 and 1 microM) induced TNF mRNA expression to an extent similar to LPS.	Paclitaxel	18-23	tumor necrosis factor	Mus musculus	50-53
1353517-7	1992	Induction of TNF mRNA by 10 microM taxol was detectable at 45 min of stimulation, maximal at 90 min, and evident for at least 8 h. The same low concentration of taxol also induced interleukin 1 (IL-1) alpha and beta mRNA expression.	Paclitaxel	35-40	tumor necrosis factor	Mus musculus	13-16
1353517-7	1992	Induction of TNF mRNA by 10 microM taxol was detectable at 45 min of stimulation, maximal at 90 min, and evident for at least 8 h. The same low concentration of taxol also induced interleukin 1 (IL-1) alpha and beta mRNA expression.	Paclitaxel	161-166	tumor necrosis factor	Mus musculus	13-16
1353517-8	1992	We conclude that taxol triggers macrophages for TNF and IL-1 production.	Paclitaxel	17-22	tumor necrosis factor	Mus musculus	48-51
1401239-8	1992	A small amount of P600 consistently copurified with taxol-stabilized microtubules.	Paclitaxel	52-57	interleukin 13	Homo sapiens	18-22
1356126-5	1992	Taxol alone (1-30 microM) induced murine C3H/OuJ macrophages to secrete bioactive TNF-alpha and express increased levels of each of the six genes under investigation.	Paclitaxel	0-5	tumor necrosis factor	Mus musculus	82-91
1351422-3	1992	Taxol inhibited the induction of DNA synthesis after stimulation with FBS or EGF in TIG-1, but did not in 3Y1.	Paclitaxel	0-5	retinoic acid receptor responder 1	Homo sapiens	84-89
1351422-4	1992	12-O-tetradecanoylphorbol-13-acetate (TPA) induced DNA synthesis in TIG-1, which was reduced only partly by taxol.	Paclitaxel	108-113	retinoic acid receptor responder 1	Homo sapiens	68-73
1351422-7	1992	In TIG-1 cells, when taxol was added within 6 h, about halfway into the initiation of DNA synthesis after the addition of FBS or EGF, the inhibition of DNA synthesis still occurred.	Paclitaxel	21-26	retinoic acid receptor responder 1	Homo sapiens	3-8
2271567-4	1990	The dissociation constant for MAP-2 binding to taxol-stabilized tubules was 3.4 microM in the absence of m2" and 14 microM in the presence of 1.5 mM of the m2" peptide.	Paclitaxel	47-52	microtubule-associated protein 2	Mus musculus	30-35
1680550-5	1991	Chemosensitization of MDR1 mice to daunomycin and taxol, measured by a fall in WBC, is detectable at a dose as low as 0.01 mg/kg R-verapamil.	Paclitaxel	50-55	malic enzyme complex, mitochondrial	Mus musculus	22-26
1868977-3	1991	Transgenic mice that express the MDR1 gene in their bone marrow have been developed, and because of this expression these mice are resistant to the bone marrow-suppressive effects of daunomycin, doxorubicin, taxol, and several other anticancer drugs.	Paclitaxel	208-213	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-37
19912790-8	1991	The presence of taxol (10 muM), a microtubule stabilizer, reversed colchicine- but not nocodazole-induced m3-mAChR mRNA down-regulation that occurred at 8 h. Taxol was also able to reverse, at least in part, carbachol-induced m3-mAChR mRNA down-regulation after 8 h of exposure.	Paclitaxel	16-21	latexin	Homo sapiens	26-29
19912790-8	1991	The presence of taxol (10 muM), a microtubule stabilizer, reversed colchicine- but not nocodazole-induced m3-mAChR mRNA down-regulation that occurred at 8 h. Taxol was also able to reverse, at least in part, carbachol-induced m3-mAChR mRNA down-regulation after 8 h of exposure.	Paclitaxel	158-163	latexin	Homo sapiens	26-29
1688856-4	1990	This polypeptide was identified as MAP 1A on the basis of its co-migration on SDS gels with MAP 1A from brain microtubules; its co-assembly with microtubules in the presence of taxol or during cycles of assembly-disassembly; and its cross-reaction with well-characterized antibodies against MAP 1A in immunoblotting and immunoprecipitation assays.	Paclitaxel	177-182	microtubule-associated protein 1 A	Mus musculus	35-41
1970196-2	1990	The microtubule stabilizer taxol shared two actions of LPS on macrophages: it rapidly decreased TNF-alpha receptors and triggered TNF-alpha release.	Paclitaxel	27-32	tumor necrosis factor	Mus musculus	96-105
1970196-2	1990	The microtubule stabilizer taxol shared two actions of LPS on macrophages: it rapidly decreased TNF-alpha receptors and triggered TNF-alpha release.	Paclitaxel	27-32	tumor necrosis factor	Mus musculus	130-139
33771522-5	2021	PTX increased miR-221-3p expression and regulated MDM2/P53 expression in the PTX-sensitive NSCLC strain (A549).	Paclitaxel	0-3	tumor protein p53	Homo sapiens	55-58
33771522-5	2021	PTX increased miR-221-3p expression and regulated MDM2/P53 expression in the PTX-sensitive NSCLC strain (A549).	Paclitaxel	77-80	tumor protein p53	Homo sapiens	55-58
33771522-13	2021	In conclusion, miR-221-3p overexpression could regulate MDM2/p53 signaling pathway to reverse the PTX resistance of NSCLC and induce apoptosis in vitro and vivo.	Paclitaxel	98-101	tumor protein p53	Homo sapiens	61-64
33818027-9	2021	In presence of Taxol, TSA induced four-fold increase in the expression of HDAC1 and downregulated Dnmt1&3alpha genes.	Paclitaxel	15-20	histone deacetylase 1	Homo sapiens	74-79
33822373-4	2021	EXPERIMENTAL APPROACH: Prevention or reversal of paclitaxel-induced mechanical sensitivity were assessed following IP or oral administration of CBD, KLS-13019, or morphine.	Paclitaxel	49-59	prostaglandin I receptor (IP)	Mus musculus	115-117
33822373-6	2021	KEY RESULTS: Like CBD, IP or oral KLS-13019 prevented the development of mechanical sensitivity associated with paclitaxel administration.	Paclitaxel	112-122	prostaglandin I receptor (IP)	Mus musculus	23-25
33809310-0	2021	[89Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models.	Paclitaxel	38-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
33811599-0	2021	Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study).	Paclitaxel	44-54	albumin	Homo sapiens	30-37
33811599-1	2021	BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-PTX), a novel taxane formulation, was developed to avoid cremophor/ethanol-associated toxicities including peripheral neuropathy and hypersensitivity.	Paclitaxel	39-49	albumin	Homo sapiens	25-32
33818320-5	2021	Importantly, Taxol-resistant cells had a higher glycolysis rate and upregulated expression of the key glycolysis enzymes hexokinase 2 (HK2) and lactate dehydrogenase A (LDHA) than Taxol-sensitive cells.	Paclitaxel	13-18	lactate dehydrogenase A	Homo sapiens	144-167
33818320-5	2021	Importantly, Taxol-resistant cells had a higher glycolysis rate and upregulated expression of the key glycolysis enzymes hexokinase 2 (HK2) and lactate dehydrogenase A (LDHA) than Taxol-sensitive cells.	Paclitaxel	13-18	lactate dehydrogenase A	Homo sapiens	169-173
33818320-5	2021	Importantly, Taxol-resistant cells had a higher glycolysis rate and upregulated expression of the key glycolysis enzymes hexokinase 2 (HK2) and lactate dehydrogenase A (LDHA) than Taxol-sensitive cells.	Paclitaxel	180-185	lactate dehydrogenase A	Homo sapiens	144-167
33818320-6	2021	Further research demonstrated that UCA1 could directly regulate glycolysis by regulating HK2 and LDHA expression, which contributes to Taxol resistance.	Paclitaxel	135-140	lactate dehydrogenase A	Homo sapiens	97-101
33809707-8	2021	Notably, there were significantly more cytotoxic CD8+ T cells in tumors of mice treated with PTX plus the HO-1 inhibitor, zinc protophorphyrin IX (ZnPP) than in mice treated with PTX alone.	Paclitaxel	93-96	heme oxygenase 1	Mus musculus	106-110
33809707-8	2021	Notably, there were significantly more cytotoxic CD8+ T cells in tumors of mice treated with PTX plus the HO-1 inhibitor, zinc protophorphyrin IX (ZnPP) than in mice treated with PTX alone.	Paclitaxel	179-182	heme oxygenase 1	Mus musculus	106-110
33809707-12	2021	Conversely, the PTX-induced upregulation of the M2 marker gene, Il10 in CD11b+ myeloid cells from 4T1 tumor-bearing mice treated was dramatically reduced by the administration of the HO-1 inhibitor.	Paclitaxel	16-19	heme oxygenase 1	Mus musculus	183-187
33809079-5	2021	Moreover, we found that GBP5 expression negatively correlated with the 50% inhibitory concentration (IC50) of paclitaxel in a panel of TNBC cell lines.	Paclitaxel	110-120	guanylate binding protein 5	Homo sapiens	24-28
33809079-6	2021	The gene knockdown of GBP5 increased the IC50 of paclitaxel in the tested TNBC cells.	Paclitaxel	49-59	guanylate binding protein 5	Homo sapiens	22-26
33809079-8	2021	Computational simulation by the Gene Set Enrichment Analysis program and cell-based assays demonstrated that GBP5 probably enhances the cytotoxic effectiveness of paclitaxel via activating the Akt/mTOR signaling axis and suppressing autophagy formation in TNBC cells.	Paclitaxel	163-173	guanylate binding protein 5	Homo sapiens	109-113
33809079-8	2021	Computational simulation by the Gene Set Enrichment Analysis program and cell-based assays demonstrated that GBP5 probably enhances the cytotoxic effectiveness of paclitaxel via activating the Akt/mTOR signaling axis and suppressing autophagy formation in TNBC cells.	Paclitaxel	163-173	AKT serine/threonine kinase 1	Homo sapiens	193-196
33809079-8	2021	Computational simulation by the Gene Set Enrichment Analysis program and cell-based assays demonstrated that GBP5 probably enhances the cytotoxic effectiveness of paclitaxel via activating the Akt/mTOR signaling axis and suppressing autophagy formation in TNBC cells.	Paclitaxel	163-173	mechanistic target of rapamycin kinase	Homo sapiens	197-201
33809310-2	2021	This study evaluates whether human epidermal growth factor receptor 2 (HER2) expression level utilizing advanced molecular positron emission tomography (PET) imaging is correlated with PTX treatment efficacy in preclinical mouse models of HER2+ breast cancer.	Paclitaxel	185-188	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-69
33809310-2	2021	This study evaluates whether human epidermal growth factor receptor 2 (HER2) expression level utilizing advanced molecular positron emission tomography (PET) imaging is correlated with PTX treatment efficacy in preclinical mouse models of HER2+ breast cancer.	Paclitaxel	185-188	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
33809310-10	2021	This study shows PTX treatment efficacy is positively correlated with HER2 expression level in human breast cancer mouse models.	Paclitaxel	17-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-74
33793827-15	2021	CONCLUSIONS: PG can enhance the sensitivity of PTX-resistant ovarian cancer cells SK-OV-3/PTX to PTX, and this effect is related to inhibiting NF-kappaB from entering the nucleus and down-regulating the expression of P-gp protein.	Paclitaxel	47-50	ATP binding cassette subfamily B member 1	Homo sapiens	217-221
33806325-10	2021	Therefore, we demonstrated that decursin may be an important compound for the treatment of paclitaxel-induced neuropathic pain that functions via TRPV1 inhibition and recovery of damaged neuronal networks.	Paclitaxel	91-101	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	146-151
34992683-0	2022	Paclitaxel resistance is mediated by NF-kappaB on mesenchymal primary breast cancer cells.	Paclitaxel	0-10	nuclear factor kappa B subunit 1	Homo sapiens	37-46
33235314-2	2021	We hypothesised that adding the epidermal growth-factor receptor (EGFR) inhibitor cetuximab to standard first-line chemotherapy with paclitaxel and carboplatin would improve PFS and RR in unfavourable CUP.	Paclitaxel	133-143	epidermal growth factor receptor	Homo sapiens	32-64
33235314-2	2021	We hypothesised that adding the epidermal growth-factor receptor (EGFR) inhibitor cetuximab to standard first-line chemotherapy with paclitaxel and carboplatin would improve PFS and RR in unfavourable CUP.	Paclitaxel	133-143	epidermal growth factor receptor	Homo sapiens	66-70
8791772-0	1996	Assays of CYP2C8- and CYP3A4-mediated metabolism of taxol in vivo and in vitro.	Paclitaxel	52-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-28
34920124-0	2022	AMP-activated protein kinase re-sensitizes A549 to paclitaxel via up-regulating solute carrier organic anion transporter family member 1B3 expression.	Paclitaxel	51-61	solute carrier organic anion transporter family member 1B3	Homo sapiens	80-138
34920124-2	2022	Solute carrier organic anion transporter family member 1B3 (SLCO1B3) is a PTX influx transporter and its low expression has been proved to be relevant with PTX resistance.	Paclitaxel	156-159	solute carrier organic anion transporter family member 1B3	Homo sapiens	0-58
34920124-2	2022	Solute carrier organic anion transporter family member 1B3 (SLCO1B3) is a PTX influx transporter and its low expression has been proved to be relevant with PTX resistance.	Paclitaxel	156-159	solute carrier organic anion transporter family member 1B3	Homo sapiens	60-67
34920124-7	2022	Then, we have explored the relationship between SLCO1B3 and PTX: SLCO1B3 expression significantly decreased when A549 cells were treated with PTX or in A549 PTX resistant cells (A549-PTX) and the intracellular PTX concentration in A549-PTX was also lower.	Paclitaxel	60-63	solute carrier organic anion transporter family member 1B3	Homo sapiens	48-55
34920124-7	2022	Then, we have explored the relationship between SLCO1B3 and PTX: SLCO1B3 expression significantly decreased when A549 cells were treated with PTX or in A549 PTX resistant cells (A549-PTX) and the intracellular PTX concentration in A549-PTX was also lower.	Paclitaxel	60-63	solute carrier organic anion transporter family member 1B3	Homo sapiens	65-72
34920124-7	2022	Then, we have explored the relationship between SLCO1B3 and PTX: SLCO1B3 expression significantly decreased when A549 cells were treated with PTX or in A549 PTX resistant cells (A549-PTX) and the intracellular PTX concentration in A549-PTX was also lower.	Paclitaxel	142-145	solute carrier organic anion transporter family member 1B3	Homo sapiens	48-55
34920124-7	2022	Then, we have explored the relationship between SLCO1B3 and PTX: SLCO1B3 expression significantly decreased when A549 cells were treated with PTX or in A549 PTX resistant cells (A549-PTX) and the intracellular PTX concentration in A549-PTX was also lower.	Paclitaxel	142-145	solute carrier organic anion transporter family member 1B3	Homo sapiens	65-72
34920124-7	2022	Then, we have explored the relationship between SLCO1B3 and PTX: SLCO1B3 expression significantly decreased when A549 cells were treated with PTX or in A549 PTX resistant cells (A549-PTX) and the intracellular PTX concentration in A549-PTX was also lower.	Paclitaxel	157-160	solute carrier organic anion transporter family member 1B3	Homo sapiens	48-55
34920124-7	2022	Then, we have explored the relationship between SLCO1B3 and PTX: SLCO1B3 expression significantly decreased when A549 cells were treated with PTX or in A549 PTX resistant cells (A549-PTX) and the intracellular PTX concentration in A549-PTX was also lower.	Paclitaxel	157-160	solute carrier organic anion transporter family member 1B3	Homo sapiens	65-72
34920124-7	2022	Then, we have explored the relationship between SLCO1B3 and PTX: SLCO1B3 expression significantly decreased when A549 cells were treated with PTX or in A549 PTX resistant cells (A549-PTX) and the intracellular PTX concentration in A549-PTX was also lower.	Paclitaxel	183-186	solute carrier organic anion transporter family member 1B3	Homo sapiens	48-55
34920124-7	2022	Then, we have explored the relationship between SLCO1B3 and PTX: SLCO1B3 expression significantly decreased when A549 cells were treated with PTX or in A549 PTX resistant cells (A549-PTX) and the intracellular PTX concentration in A549-PTX was also lower.	Paclitaxel	183-186	solute carrier organic anion transporter family member 1B3	Homo sapiens	65-72
34920124-7	2022	Then, we have explored the relationship between SLCO1B3 and PTX: SLCO1B3 expression significantly decreased when A549 cells were treated with PTX or in A549 PTX resistant cells (A549-PTX) and the intracellular PTX concentration in A549-PTX was also lower.	Paclitaxel	210-213	solute carrier organic anion transporter family member 1B3	Homo sapiens	48-55
34920124-7	2022	Then, we have explored the relationship between SLCO1B3 and PTX: SLCO1B3 expression significantly decreased when A549 cells were treated with PTX or in A549 PTX resistant cells (A549-PTX) and the intracellular PTX concentration in A549-PTX was also lower.	Paclitaxel	236-239	solute carrier organic anion transporter family member 1B3	Homo sapiens	48-55
34920124-7	2022	Then, we have explored the relationship between SLCO1B3 and PTX: SLCO1B3 expression significantly decreased when A549 cells were treated with PTX or in A549 PTX resistant cells (A549-PTX) and the intracellular PTX concentration in A549-PTX was also lower.	Paclitaxel	236-239	solute carrier organic anion transporter family member 1B3	Homo sapiens	65-72
34920124-10	2022	Moreover, in vitro and in vivo experiments have showed that metformin not only obviously inhibited A549-PTX tumor xenograft and A549-PTX proliferation alone, but also enhanced PTX efficacy to A549-PTX and this may be relevant to SLCO1B3.	Paclitaxel	133-136	solute carrier organic anion transporter family member 1B3	Homo sapiens	229-236
34920124-10	2022	Moreover, in vitro and in vivo experiments have showed that metformin not only obviously inhibited A549-PTX tumor xenograft and A549-PTX proliferation alone, but also enhanced PTX efficacy to A549-PTX and this may be relevant to SLCO1B3.	Paclitaxel	176-179	solute carrier organic anion transporter family member 1B3	Homo sapiens	229-236
34920124-10	2022	Moreover, in vitro and in vivo experiments have showed that metformin not only obviously inhibited A549-PTX tumor xenograft and A549-PTX proliferation alone, but also enhanced PTX efficacy to A549-PTX and this may be relevant to SLCO1B3.	Paclitaxel	197-200	solute carrier organic anion transporter family member 1B3	Homo sapiens	229-236
34920124-11	2022	To verify it, we have treated A549 cells with AMPK both activators and an inhibitor, and then found that AMPK activators could weaken the PTX effect in inhibiting SLCO1B3 while its inhibitor has opposite effect.	Paclitaxel	138-141	solute carrier organic anion transporter family member 1B3	Homo sapiens	163-170
34920124-12	2022	With knockdown of SLCO1B3, the effect of AMPK in re-sensitizing A549 to paclitaxel has decreased.	Paclitaxel	72-82	solute carrier organic anion transporter family member 1B3	Homo sapiens	18-25
34920124-13	2022	To sum up, activation of AMPK can up-regulate SLCO1B3 expression, enhance the sensitivity of A549 cells to PTX, providing a new way to re-sensitize PTX resistance.	Paclitaxel	148-151	solute carrier organic anion transporter family member 1B3	Homo sapiens	46-53
33197899-6	2021	As a result, these NR1/AgNPs decorated drug nanocrystals exhibited dramatically improved cellular uptake efficiency, in vitro anti-cancer activity and anti-migratory effect against a variety of cancer cells, which was attributable to the synergistic or at least additive effect from AgNPs and PTX, enhanced cellular uptake efficiency through NR1-receptor interaction, pH-responsive drug release and nano-scaled nature.	Paclitaxel	293-296	glutamate ionotropic receptor NMDA type subunit 1	Homo sapiens	19-22
33197899-7	2021	In particular, high anti-cancer activity and low side effect from these NR1/AgNPs decorated PTX nanocrystals were well balanced in terms of good selectivity and biocompatibility.	Paclitaxel	92-95	glutamate ionotropic receptor NMDA type subunit 1	Homo sapiens	72-75
33817712-6	2020	Particularly, dual combination of Paclitaxel and Cisplatin decreased the immunoreactivities of PI3K, pErk-1/2, Akt-1, and pAkt-1/2/3.	Paclitaxel	34-44	AKT serine/threonine kinase 1	Homo sapiens	111-116
28766096-4	2018	RESULTS: Increased phosphorylation levels of ERK, Mnk1, and eIF4E were observed in ovarian cancer cell exposed to chemotherapeutic agents, and paclitaxel-resistant SK-OV-3-r cells, and is a common response of ovarian cancer patients undergoing chemotherapy.	Paclitaxel	143-153	mitogen-activated protein kinase 1	Homo sapiens	45-48
34992683-8	2022	Additionally, it was demonstrated that paclitaxel-induced degradation of the inhibitor of NF-kappaB, activation of NF-kappaB in a dose-dependent manner, and Bcl-2 and Bcl-xL upregulation.	Paclitaxel	39-49	nuclear factor kappa B subunit 1	Homo sapiens	90-99
34992683-8	2022	Additionally, it was demonstrated that paclitaxel-induced degradation of the inhibitor of NF-kappaB, activation of NF-kappaB in a dose-dependent manner, and Bcl-2 and Bcl-xL upregulation.	Paclitaxel	39-49	nuclear factor kappa B subunit 1	Homo sapiens	115-124
34992683-8	2022	Additionally, it was demonstrated that paclitaxel-induced degradation of the inhibitor of NF-kappaB, activation of NF-kappaB in a dose-dependent manner, and Bcl-2 and Bcl-xL upregulation.	Paclitaxel	39-49	BCL2 apoptosis regulator	Homo sapiens	157-162
34992683-8	2022	Additionally, it was demonstrated that paclitaxel-induced degradation of the inhibitor of NF-kappaB, activation of NF-kappaB in a dose-dependent manner, and Bcl-2 and Bcl-xL upregulation.	Paclitaxel	39-49	BCL2 like 1	Homo sapiens	167-173
34992683-10	2022	ALLN inhibited paclitaxel-induced NF-kappaB activation and restored the sensitivity to paclitaxel.	Paclitaxel	15-25	nuclear factor kappa B subunit 1	Homo sapiens	34-43
34992683-11	2022	Together, these data suggest that targeting the NF-kappaB/IKK axis might be a promising strategy to overcome paclitaxel resistance.	Paclitaxel	109-119	nuclear factor kappa B subunit 1	Homo sapiens	48-61
34896572-5	2022	Tween 80 inhibited the basal ATPase activity of P-gp and MRP1 in a dose-dependent manner (0.0002% to 0.02%) and demonstrated significant reversing effects on the doxorubicin, paclitaxel, and vincristine resistance at the concentration of 0.001% (7.63 muM).	Paclitaxel	175-185	ATP binding cassette subfamily B member 1	Homo sapiens	48-52
34932952-9	2022	The DeltaGbind energies of tubulin-P2 and tubulin-paclitaxel were -68.25 +- 12.98 and -146.05 +- 16.17 kJ mol-1, respectively, which were in line with the results of the experimental test.	Paclitaxel	50-60	peripheral myelin protein 2	Homo sapiens	35-49
34563619-7	2022	Paclitaxel also shortened SCN slice rhythms, increased the amplitude of adrenal gland oscillations in PER2::luciferase cultures, and increased the concentration of pro-inflammatory cytokines and chemokines released from the SCN.	Paclitaxel	0-10	period circadian clock 2	Mus musculus	102-106
34737212-9	2022	In vitro, combined treatment with AP-1 or SIK2 inhibitors with carboplatin or paclitaxel demonstrated synergistic effects.	Paclitaxel	78-88	salt inducible kinase 2	Homo sapiens	42-46
34312098-2	2022	The aim of this study is to compare the efficacy and late-onset cardiac toxicity of neoadjuvant chemotherapy regimens, trastuzumab plus paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (PH-FECH) versus trastuzumab plus docetaxel and carboplatin (TCH), for human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC).	Paclitaxel	136-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	285-319
34312098-2	2022	The aim of this study is to compare the efficacy and late-onset cardiac toxicity of neoadjuvant chemotherapy regimens, trastuzumab plus paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (PH-FECH) versus trastuzumab plus docetaxel and carboplatin (TCH), for human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC).	Paclitaxel	136-146	erb-b2 receptor tyrosine kinase 2	Homo sapiens	330-334
34752986-0	2022	CD44-targeted, indocyanine green-paclitaxel-loaded human serum albumin nanoparticles for potential image-guided drug delivery.	Paclitaxel	33-43	albumin	Homo sapiens	57-70
34752986-2	2022	In this study we evaluated the potential of an indocyanine green (ICG) and paclitaxel (PTX) loaded human serum albumin (HSA) nanoparticles that was conjugated with hyaluronic acid for use in image-guided drug delivery targeted to CD44-positive non-small cell lung cancer (NSCLC).	Paclitaxel	75-85	albumin	Homo sapiens	105-118
34752986-2	2022	In this study we evaluated the potential of an indocyanine green (ICG) and paclitaxel (PTX) loaded human serum albumin (HSA) nanoparticles that was conjugated with hyaluronic acid for use in image-guided drug delivery targeted to CD44-positive non-small cell lung cancer (NSCLC).	Paclitaxel	87-90	albumin	Homo sapiens	105-118
34758639-1	2022	Background: In node-negative HER2-overexpressed breast cancers, adjuvant paclitaxel plus trastuzumab treatment is a successful de-escalation approach with excellent survival outcomes.	Paclitaxel	73-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
34896572-5	2022	Tween 80 inhibited the basal ATPase activity of P-gp and MRP1 in a dose-dependent manner (0.0002% to 0.02%) and demonstrated significant reversing effects on the doxorubicin, paclitaxel, and vincristine resistance at the concentration of 0.001% (7.63 muM).	Paclitaxel	175-185	ATP binding cassette subfamily B member 1	Homo sapiens	57-61
34304352-3	2022	Paclitaxel is predominantly metabolized in the liver by cytochrome P450 (CYP) 2C8 to produce 6alpha-hydroxypaclitaxel and by CYP3A4 to produce 3"-p-hydroxypaclitaxel.	Paclitaxel	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-131
34304352-4	2022	In this study, we evaluated the inhibitory or inducing effects of goshajinkigan extract (GJG) and its representative and bioavailable constituents, geniposidic acid, plantagoguanidinic acid, paeoniflorin, catalpol, loganin, and neoline, on the metabolism of paclitaxel via CYP2C8 and CYP3A4 using pooled human liver microsomes and cultured human cryopreserved hepatocytes to provide the drug information about the pharmacokinetic interaction of this combination therapy.	Paclitaxel	258-268	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	284-290
34915631-14	2021	The expression levels of ENO1, PI3K/Akt signaling pathway related proteins including p-PI3K and p-Akt and the expression levels of PCNA, MMP-9 and Bcl-2 in siRNA-ENO1 group and paclitaxel+ siRNA-NC group were lower than those in siRNA-NC group (P<0.05).	Paclitaxel	177-187	BCL2 apoptosis regulator	Homo sapiens	147-152
34610478-3	2022	Here an elaborately designed nanocarriers (NCs) named as Tf-5-ALA-PTX-NCs is demonstrated to address this problem.	Paclitaxel	66-69	transferrin	Homo sapiens	57-59
34856211-7	2022	Annexin V/PI test, cell cycle analysis, activation of cleaved PARP1 confirm that VOA plus PTX induce apoptotic cell death.	Paclitaxel	90-93	poly(ADP-ribose) polymerase 1	Homo sapiens	62-67
34610478-5	2022	Results demonstrated that Tf-5-ALA-PTX-NCs significantly enhanced the targeting drug delivery to MCF-7 cells, synergistically induced apoptosis and death of MCF-7 cells in vitro, and highly efficient tumor ablation in vivo.	Paclitaxel	35-38	transferrin	Homo sapiens	26-28
34648615-6	2021	Transient overexpression of MDR1 increased drug tolerance of HCT-8 cells on paclitaxel, doxorubicin HCl and vincristine sulphate (2.11- to 2.27-fold increase), but not on cyclosporin A, daunorubicin HCl and nitazoxanide.	Paclitaxel	76-86	ATP binding cassette subfamily B member 1	Homo sapiens	28-32
34915631-14	2021	The expression levels of ENO1, PI3K/Akt signaling pathway related proteins including p-PI3K and p-Akt and the expression levels of PCNA, MMP-9 and Bcl-2 in siRNA-ENO1 group and paclitaxel+ siRNA-NC group were lower than those in siRNA-NC group (P<0.05).	Paclitaxel	177-187	AKT serine/threonine kinase 1	Homo sapiens	36-39
34915631-15	2021	The expression levels of ENO1, p-PI3K, p-Akt, PCNA, MMP-9 and Bcl-2 in paclitaxel+ siRNA-ENO1 group were lower than those in siRNA-ENO1 group or paclitaxel+ siRNA-NC group (P<0.05).	Paclitaxel	71-81	AKT serine/threonine kinase 1	Homo sapiens	41-44
34915631-15	2021	The expression levels of ENO1, p-PI3K, p-Akt, PCNA, MMP-9 and Bcl-2 in paclitaxel+ siRNA-ENO1 group were lower than those in siRNA-ENO1 group or paclitaxel+ siRNA-NC group (P<0.05).	Paclitaxel	71-81	BCL2 apoptosis regulator	Homo sapiens	62-67
34915631-15	2021	The expression levels of ENO1, p-PI3K, p-Akt, PCNA, MMP-9 and Bcl-2 in paclitaxel+ siRNA-ENO1 group were lower than those in siRNA-ENO1 group or paclitaxel+ siRNA-NC group (P<0.05).	Paclitaxel	145-155	BCL2 apoptosis regulator	Homo sapiens	62-67
34915631-16	2021	Conclusion: siRNA targeting inhibition of ENO1 expression can enhance the inhibitory effect of paclitaxel on proliferation, invasion and apoptosis of SK-HEP-1 cells, and its mechanism may be related to the inhibition of PI3K/AKT signaling pathway.	Paclitaxel	95-105	AKT serine/threonine kinase 1	Homo sapiens	225-228
34977876-5	2021	Reversal of MDR against ABCB1 chemotherapeutic drugs increased intracellular accumulation of (3H)-paclitaxel accumulation, and decreased drug efflux activity was observed in MDR SW620/Ad300 cells after ABCB1 gene knockout.	Paclitaxel	98-108	ATP binding cassette subfamily B member 1	Homo sapiens	24-29
34927791-6	2022	By generating a DSB in the regulatory region of the ABCB1 gene using a lentiviral sgRNA vector, we can induce the formation of Taxol-resistant colonies.	Paclitaxel	127-132	ATP binding cassette subfamily B member 1	Homo sapiens	52-57
34977876-6	2021	Further tests using the 3D multicellular tumor spheroid model suggested that deficiency in ABCB1 restrained tumor spheroid growth and restore sensitivity to paclitaxel in MDR tumor spheroids.	Paclitaxel	157-167	ATP binding cassette subfamily B member 1	Homo sapiens	91-96
34855343-3	2021	The hierarchical nanoparticles (MPH-NP@A) are composed of pH-sensitive hyaluronic acid-acetal-PTX prodrugs (HA-ace-PTX(SH)) chaperoned by alphaPD-L1 and metalloproteinase-9 (MMP-9)-responsive outer shells, which could be fast cleaved to release alphaPD-L1 in the tumor microenvironment (TME).	Paclitaxel	94-97	L1 cell adhesion molecule	Homo sapiens	146-172
34774620-8	2021	Ectopic expression of SARI induces cancer-specific cell death in human OSCC cell lines and in a paclitaxel plus cisplatin non-responder OSCC patient-derived (PDC1) cell line.	Paclitaxel	96-106	programmed cell death 1	Mus musculus	158-162
34855343-3	2021	The hierarchical nanoparticles (MPH-NP@A) are composed of pH-sensitive hyaluronic acid-acetal-PTX prodrugs (HA-ace-PTX(SH)) chaperoned by alphaPD-L1 and metalloproteinase-9 (MMP-9)-responsive outer shells, which could be fast cleaved to release alphaPD-L1 in the tumor microenvironment (TME).	Paclitaxel	115-118	L1 cell adhesion molecule	Homo sapiens	146-172
34743946-4	2021	The data obtained show that PTX-induced MDA, NF-kappaB, IL-1beta, TNF-alpha, COX-2, nNOS, JAK2, STAT3, and GFAP levels decreased with HES administration.	Paclitaxel	28-31	interleukin 1 alpha	Rattus norvegicus	56-64
34925737-0	2021	A Meta-Analysis of the Efficacy of Albumin Paclitaxel versus Docetaxel in the Treatment of Breast Cancer.	Paclitaxel	43-53	albumin	Homo sapiens	35-42
34743946-4	2021	The data obtained show that PTX-induced MDA, NF-kappaB, IL-1beta, TNF-alpha, COX-2, nNOS, JAK2, STAT3, and GFAP levels decreased with HES administration.	Paclitaxel	28-31	tumor necrosis factor	Rattus norvegicus	66-75
34743946-5	2021	Moreover, it was observed that SOD, CAT, and GPx activities inhibited by PTX increased with HES administration.	Paclitaxel	73-76	catalase	Rattus norvegicus	36-39
34743946-6	2021	It was determined that PTX caused apoptosis in the sciatic nerve by increasing Caspase-3 and Bax levels and suppressing Bcl-2 levels.	Paclitaxel	23-26	BCL2, apoptosis regulator	Rattus norvegicus	120-125
34903710-7	2021	Our follow-up analyses in a panel of BC cell lines of different molecular subtypes identified NOXA protein expression as a key determinant of paclitaxel sensitivity in triple-negative breast cancer (TNBC) cells.	Paclitaxel	142-152	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	94-98
34903710-8	2021	Moreover, we noted highest additive effects between paclitaxel and chemical inhibition of BCLX, but not BCL2 or MCL1, documenting dependence of TNBC cells on BCLX for survival and paclitaxel sensitivity defined by NOXA expression levels.	Paclitaxel	52-62	BCL2 like 1	Homo sapiens	90-94
34903710-8	2021	Moreover, we noted highest additive effects between paclitaxel and chemical inhibition of BCLX, but not BCL2 or MCL1, documenting dependence of TNBC cells on BCLX for survival and paclitaxel sensitivity defined by NOXA expression levels.	Paclitaxel	52-62	BCL2 like 1	Homo sapiens	158-162
34903710-8	2021	Moreover, we noted highest additive effects between paclitaxel and chemical inhibition of BCLX, but not BCL2 or MCL1, documenting dependence of TNBC cells on BCLX for survival and paclitaxel sensitivity defined by NOXA expression levels.	Paclitaxel	52-62	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	214-218
34903710-8	2021	Moreover, we noted highest additive effects between paclitaxel and chemical inhibition of BCLX, but not BCL2 or MCL1, documenting dependence of TNBC cells on BCLX for survival and paclitaxel sensitivity defined by NOXA expression levels.	Paclitaxel	180-190	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	214-218
34904193-9	2022	PECS-101 also decreased PTX-induced increase in Tnf, Il6, and Aif1 (Iba-1) gene expression in the DRGs and the loss of intra-epidermal nerve fibers.	Paclitaxel	24-27	tumor necrosis factor	Mus musculus	48-51
34904193-9	2022	PECS-101 also decreased PTX-induced increase in Tnf, Il6, and Aif1 (Iba-1) gene expression in the DRGs and the loss of intra-epidermal nerve fibers.	Paclitaxel	24-27	interleukin 6	Mus musculus	53-56
34917174-1	2021	Purpose: To evaluate efficacy and safety of veliparib combined with carboplatin/paclitaxel in patients with advanced human epidermal growth factor receptor 2 (HER2)-negative, germline BRCA (gBRCA)-associated breast cancer defined by hormone receptor (HR) and gBRCA1/2 mutation status.	Paclitaxel	80-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-157
34917174-1	2021	Purpose: To evaluate efficacy and safety of veliparib combined with carboplatin/paclitaxel in patients with advanced human epidermal growth factor receptor 2 (HER2)-negative, germline BRCA (gBRCA)-associated breast cancer defined by hormone receptor (HR) and gBRCA1/2 mutation status.	Paclitaxel	80-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-163
34925737-9	2021	Conclusion: Albumin paclitaxel treatment can better reduce the incidence of neutropenia in breast cancer patients and is of great significance to the safety of breast cancer patients.	Paclitaxel	20-30	albumin	Homo sapiens	12-19
34925737-1	2021	Objective: To use meta-analysis to systematically compare the efficacy and adverse reaction rates of albumin paclitaxel and docetaxel in the treatment of breast cancer.	Paclitaxel	109-119	albumin	Homo sapiens	101-108
34925737-2	2021	Methods: This study included Chinese and English literature studies on clinical controlled studies of albumin paclitaxel and docetaxel in the treatment of breast cancer by searching CNKI, Weipu, Wanfang, PubMed, Embase, and Cochrane Library.	Paclitaxel	110-120	albumin	Homo sapiens	102-109
34415232-0	2021	MicroRNA-624-mediated ARRDC3/YAP/HIF1alpha axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel.	Paclitaxel	125-135	hypoxia inducible factor 1 subunit alpha	Homo sapiens	33-42
34313784-8	2021	Uptake of both Rho123 and paclitaxel was decreased in SNAI1-transfected cells, and this decrease was blocked by verapamil, a P-gp inhibitor.	Paclitaxel	26-36	snail family transcriptional repressor 1	Homo sapiens	54-59
34313784-8	2021	Uptake of both Rho123 and paclitaxel was decreased in SNAI1-transfected cells, and this decrease was blocked by verapamil, a P-gp inhibitor.	Paclitaxel	26-36	ATP binding cassette subfamily B member 1	Homo sapiens	125-129
34313784-9	2021	The reduced susceptibility of SNAI1-transfected cells to paclitaxel was reversed by elacridar, another P-gp inhibitor.	Paclitaxel	57-67	snail family transcriptional repressor 1	Homo sapiens	30-35
34313784-9	2021	The reduced susceptibility of SNAI1-transfected cells to paclitaxel was reversed by elacridar, another P-gp inhibitor.	Paclitaxel	57-67	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
34873207-4	2021	Paclitaxel induced intrinsic apoptosis by activating caspase-3, caspase-9 and PARP.	Paclitaxel	0-10	caspase 3	Homo sapiens	53-62
34873207-5	2021	In addition, the significant increase in autophagy marker LC3B-II, together with Atg5, class III PI3K and Beclin-1, and the down-regulation of p62 following paclitaxel treatment verified that paclitaxel induced autophagy.	Paclitaxel	192-202	autophagy related 5	Homo sapiens	81-85
34415232-10	2021	miR-624 downregulated ARRDC3 to increase YAP and HIF1alpha expression so as to enhance ESCC cell resistance to CIS and PT in vitro and in vivo.	Paclitaxel	119-121	hypoxia inducible factor 1 subunit alpha	Homo sapiens	49-58
34607103-11	2021	Moreover, the CS2 group could also respond to 5-fluorouracil, cisplatin, and paclitaxel.	Paclitaxel	77-87	chorionic somatomammotropin hormone 2	Homo sapiens	14-17
34709112-0	2021	Long non-coding RNA (LncRNA) SNHG7/ Eukaryotic translation initiation factor 4 gamma 2 (EIF4G2) involves in the malignant events of ovarian cancer cells with paclitaxel resistant.	Paclitaxel	158-168	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	36-86
34709112-0	2021	Long non-coding RNA (LncRNA) SNHG7/ Eukaryotic translation initiation factor 4 gamma 2 (EIF4G2) involves in the malignant events of ovarian cancer cells with paclitaxel resistant.	Paclitaxel	158-168	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	88-94
34709112-8	2021	Taken together, these results demonstrated that lncRNA SNHG7 could affect the degradation of EIF4G2 to regulate the sensitivity of ovarian cancer to Paclitaxel, inhibit cell viability, migration and invasion.	Paclitaxel	149-159	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	93-99
34709112-9	2021	The interaction of lncRNA SNHG7 and EIF4G2 plays an important role in the migrative and invasive activity and Paclitaxel -resistance of ovarian cancer cells.	Paclitaxel	110-120	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	36-42
34648812-0	2021	FV-429 enhances the efficacy of paclitaxel in NSCLC by reprogramming HIF-1alpha-modulated FattyAcid metabolism.	Paclitaxel	32-42	hypoxia inducible factor 1 subunit alpha	Homo sapiens	69-79
34648812-2	2021	Here, we found that the occurrence and progress of hypoxic insensitivity to paclitaxel in non-small cell lung cancer (NSCLC) are closely associated with the HIF-1alpha pathway.	Paclitaxel	76-86	hypoxia inducible factor 1 subunit alpha	Homo sapiens	157-167
34799660-8	2021	Mechanistically, our findings suggest that PKR controls paclitaxel chemosensitivity through repressing Bcl2 expression.	Paclitaxel	56-66	BCL2 apoptosis regulator	Homo sapiens	103-107
34791636-14	2021	iBET-151 plus paclitaxel significantly promoted cell cycle arrest and apoptosis and suppressed c-Myc, Bcl-2 and Bcl-xL expression.	Paclitaxel	14-24	B cell leukemia/lymphoma 2	Mus musculus	102-107
33866918-0	2021	The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death.	Paclitaxel	71-81	natriuretic peptide A	Homo sapiens	97-101
33866918-2	2021	In this study, we show evidence that 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs), act as immunogenic cell death (ICD) inducers, stimulating an antitumor response which results in synergistic antitumor activity by combining anti-PD-L1 antibody (aPD-L1) in vivo.	Paclitaxel	70-80	natriuretic peptide A	Homo sapiens	96-100
34781168-0	2021	TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.	Paclitaxel	133-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-151
34781168-1	2021	BACKGROUND: Hormone-resistant HER2-negative or triple-negative advanced breast cancers (ABC) are routinely treated with paclitaxel chemotherapy.	Paclitaxel	120-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
34590151-9	2021	C-erbB-2 knockout had an inhibitory effect on the proliferation, migration and invasion of HEC-1A cells; cell proliferation and invasion of the group carrying PTX and plasmids simultaneously were significantly weakened.	Paclitaxel	159-162	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-8
34116927-0	2021	Acylglycerol kinase promotes paclitaxel resistance in nasopharyngeal carcinoma cells by regulating FOXM1 via the JAK2/STAT3 pathway.	Paclitaxel	29-39	signal transducer and activator of transcription 3	Homo sapiens	118-123
34116927-12	2021	An in vivo tumour xenograft assay also verified that AGK knockdown inhibited tumour growth and mitigated paclitaxel resistance by regulating the JAK2/STAT3/FOXM1 axis.	Paclitaxel	105-115	signal transducer and activator of transcription 3	Homo sapiens	150-155
34907739-9	2021	Furthermore, in Ehrlich solid tumor mice, rosmarinic acid, and/or Paclitaxel significantly suppressed tumor growth with an increase in apoptotic markers P53 and Caspase-3 levels, and suppressed the Bcl2/Bax ratio.	Paclitaxel	66-76	B cell leukemia/lymphoma 2	Mus musculus	198-202
34626199-3	2021	Dysregulation of JAK/STAT pathways and JAK2 copy number gains were observed in the four paclitaxel-resistant PDX tumors.	Paclitaxel	88-98	Janus kinase 1	Homo sapiens	17-20
34626199-5	2021	However, JAK1/2 inhibitor treatment resulted in restoration of paclitaxel sensitivity in two out of four paclitaxel-resistant PDX models and JAK1/2 inhibitor alone significantly suppressed the tumor growth in one out of the two remaining PDX models.	Paclitaxel	63-73	Janus kinase 1	Homo sapiens	9-15
34799660-9	2021	Pharmacological inhibition of Bcl2 with FDA-approved agent venetoclax overcomes paclitaxel resistance in preclinical animal models of ovarian cancer.	Paclitaxel	80-90	BCL2 apoptosis regulator	Homo sapiens	30-34
34912792-2	2021	To overcome this phenomenon, herein, a mitochondrial-directed pH-sensitive polyvinyl alcohol (PVA) nanogel incorporating the hexokinase inhibitor lonidamine (LND) and the chemotherapeutic drug paclitaxel (PTX) was developed to restore the activity of PTX and synergistically treat drug-resistant tumors.	Paclitaxel	205-208	hexokinase 1	Homo sapiens	125-135
34847067-0	2021	Correction for: Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT/FoxO1 pathway.	Paclitaxel	51-61	AKT serine/threonine kinase 1	Homo sapiens	127-130
34847067-0	2021	Correction for: Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT/FoxO1 pathway.	Paclitaxel	51-61	forkhead box O1	Homo sapiens	131-136
34861374-1	2022	BACKGROUND: In the BROCADE3 trial (NCT02163694), addition of the poly(ADP-ribose) polymerase (PARP) inhibitor, veliparib, to carboplatin/paclitaxel improved progression-free survival (PFS) (hazard ratio (HR) 0.71, 95% confidence interval 0.57-0.88; P=0.002) in patients with advanced HER2-negative, germline BRCA1/2-mutated breast cancer.	Paclitaxel	137-147	poly(ADP-ribose) polymerase 1	Homo sapiens	94-98
34912792-2	2021	To overcome this phenomenon, herein, a mitochondrial-directed pH-sensitive polyvinyl alcohol (PVA) nanogel incorporating the hexokinase inhibitor lonidamine (LND) and the chemotherapeutic drug paclitaxel (PTX) was developed to restore the activity of PTX and synergistically treat drug-resistant tumors.	Paclitaxel	251-254	hexokinase 1	Homo sapiens	125-135
34942984-7	2021	Furthermore, in paclitaxel-resistant breast cancer cell lines, MCF-7R and MDA-MB-231R, a combination of JI017 and paclitaxel overcame paclitaxel resistance by blocking epithelial-mesenchymal transition (EMT) processes, such as the downregulation of E-cadherin expression and the upregulation of HIF-1alpha, vimentin, Snail, and Slug expression.	Paclitaxel	134-144	hypoxia inducible factor 1 subunit alpha	Homo sapiens	295-305
34837170-0	2022	AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.	Paclitaxel	51-61	AKT serine/threonine kinase 1	Homo sapiens	25-28
34837170-4	2022	In this study, we aimed at investigating the potential of using AZD4547, an orally bioavailable FGFR inhibitor, to overcome taxol-resistance by targeting the FGFR/Akt/SOX2 axis in HNSCC.	Paclitaxel	124-129	AKT serine/threonine kinase 1	Homo sapiens	163-166
34942984-7	2021	Furthermore, in paclitaxel-resistant breast cancer cell lines, MCF-7R and MDA-MB-231R, a combination of JI017 and paclitaxel overcame paclitaxel resistance by blocking epithelial-mesenchymal transition (EMT) processes, such as the downregulation of E-cadherin expression and the upregulation of HIF-1alpha, vimentin, Snail, and Slug expression.	Paclitaxel	134-144	snail family transcriptional repressor 1	Homo sapiens	317-322
34942984-7	2021	Furthermore, in paclitaxel-resistant breast cancer cell lines, MCF-7R and MDA-MB-231R, a combination of JI017 and paclitaxel overcame paclitaxel resistance by blocking epithelial-mesenchymal transition (EMT) processes, such as the downregulation of E-cadherin expression and the upregulation of HIF-1alpha, vimentin, Snail, and Slug expression.	Paclitaxel	114-124	cadherin 1	Homo sapiens	249-259
34942984-7	2021	Furthermore, in paclitaxel-resistant breast cancer cell lines, MCF-7R and MDA-MB-231R, a combination of JI017 and paclitaxel overcame paclitaxel resistance by blocking epithelial-mesenchymal transition (EMT) processes, such as the downregulation of E-cadherin expression and the upregulation of HIF-1alpha, vimentin, Snail, and Slug expression.	Paclitaxel	114-124	hypoxia inducible factor 1 subunit alpha	Homo sapiens	295-305
34942984-7	2021	Furthermore, in paclitaxel-resistant breast cancer cell lines, MCF-7R and MDA-MB-231R, a combination of JI017 and paclitaxel overcame paclitaxel resistance by blocking epithelial-mesenchymal transition (EMT) processes, such as the downregulation of E-cadherin expression and the upregulation of HIF-1alpha, vimentin, Snail, and Slug expression.	Paclitaxel	114-124	snail family transcriptional repressor 1	Homo sapiens	317-322
34830408-5	2021	Nevertheless, FOXO3a serves as an interesting potential target in therapies as it is regulated during treatment with very common anti-cancer drugs such as paclitaxel, cisplatin, docetaxel, and doxorubicin.	Paclitaxel	155-165	forkhead box O3	Homo sapiens	14-20
34942984-7	2021	Furthermore, in paclitaxel-resistant breast cancer cell lines, MCF-7R and MDA-MB-231R, a combination of JI017 and paclitaxel overcame paclitaxel resistance by blocking epithelial-mesenchymal transition (EMT) processes, such as the downregulation of E-cadherin expression and the upregulation of HIF-1alpha, vimentin, Snail, and Slug expression.	Paclitaxel	134-144	cadherin 1	Homo sapiens	249-259
34901149-4	2021	reported that FHIT binds and delocalizes annexin A4 (ANXA4) from plasma membrane to cytosol in paclitaxel-resistant lung cancer cells, thus restoring their chemosensitivity to the drug.	Paclitaxel	95-105	annexin A4	Homo sapiens	41-51
34901149-4	2021	reported that FHIT binds and delocalizes annexin A4 (ANXA4) from plasma membrane to cytosol in paclitaxel-resistant lung cancer cells, thus restoring their chemosensitivity to the drug.	Paclitaxel	95-105	annexin A4	Homo sapiens	53-58
34901149-6	2021	This short sequence of FHIT protein was not only able to bind ANXA4 but also to hold its target in the cytosol during paclitaxel treatment, thus avoiding ANXA4 translocation to the inner side of the cell membrane.	Paclitaxel	118-128	annexin A4	Homo sapiens	62-67
34901149-6	2021	This short sequence of FHIT protein was not only able to bind ANXA4 but also to hold its target in the cytosol during paclitaxel treatment, thus avoiding ANXA4 translocation to the inner side of the cell membrane.	Paclitaxel	118-128	annexin A4	Homo sapiens	154-159
34959271-2	2021	Here, we developed a hybrid thermosensitive nanoparticle (TMNP) which could co-deliver paclitaxel-loaded transferrin (PTX@TF) and marimastat-loaded thermosensitive liposomes (MMST/LTSLs) for the dual targeting of cancer cells and the microenvironment.	Paclitaxel	87-97	transferrin	Homo sapiens	105-116
34773540-8	2022	Moreover, the potent apoptotic effects of paclitaxel may help augment the overall cytotoxicity of the proposed triple combination in HER2 + BC cells.	Paclitaxel	42-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-137
34723530-2	2021	Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo(1,5-a)pyrimidine derivative WS-898 as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC50 = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar.	Paclitaxel	186-196	ATP binding cassette subfamily B member 1	Homo sapiens	149-154
34834551-0	2021	Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene.	Paclitaxel	60-70	tumor protein p53	Homo sapiens	126-130
34834551-7	2021	Accordingly, HCC cell lines harboring mutant TP53 or wild-type CTNNB1 genes are more sensitive to paclitaxel treatment.	Paclitaxel	98-108	tumor protein p53	Homo sapiens	45-49
34834551-8	2021	Therefore, our results imply that HCC patients with mutant TP53 or wild-type CTNNB1 genes may benefit from the paclitaxel therapy.	Paclitaxel	111-121	tumor protein p53	Homo sapiens	59-63
34858183-6	2021	Results: ABCB1 was significantly higher expressed in tumor tissue compared to esophageal tissue, during both the first and last cycle of paclitaxel (cycle 1: p < 0.01; cycle 5/6: p = 0.01).	Paclitaxel	137-147	ATP binding cassette subfamily B member 1	Homo sapiens	9-14
34723530-2	2021	Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo(1,5-a)pyrimidine derivative WS-898 as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC50 = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar.	Paclitaxel	198-201	ATP binding cassette subfamily B member 1	Homo sapiens	149-154
34723530-3	2021	WS-898 inhibited the efflux function of ABCB1, thus leading to decreased efflux and increased intracellular PTX concentration in SW620/Ad300 cells.	Paclitaxel	108-111	ATP binding cassette subfamily B member 1	Homo sapiens	40-45
34723530-7	2021	The results suggest that WS-898 is a highly effective triazolo(1,5-a)pyrimidine-based ABCB1 inhibitor and shows promise in reversing ABCB1-mediated PTX resistance.	Paclitaxel	148-151	ATP binding cassette subfamily B member 1	Homo sapiens	133-138
34740994-0	2021	LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability.	Paclitaxel	27-37	metadherin	Homo sapiens	110-114
34761351-9	2021	Besides, miR-383-5p restoration and the combined therapy of miR-383-5p restoration with paclitaxel could remarkably increase apoptosis, decrease cell viability, arrest the cell cycle, inhibit clonogenicity, suppress tumor migration, suppress the PI3K/Akt signaling pathway, and down-regulate PD-L1 expression of BC cells.	Paclitaxel	88-98	AKT serine/threonine kinase 1	Homo sapiens	251-254
34740994-9	2021	In general, our study found (1) miR-26a-5p was a protective factor of breast cancer, while OTUD6B-AS1 and MTDH were risk factors; (2) OTUD6B-AS1 was the up-stream regulator of miR-26a-5p verified by luciferase; (3) up-regulation of miR-26a-5p and down-regulation of MTDH promoted cellular cytotoxicity of paclitaxel (PTX) in vitro and in vivo.	Paclitaxel	317-320	metadherin	Homo sapiens	106-110
34740994-9	2021	In general, our study found (1) miR-26a-5p was a protective factor of breast cancer, while OTUD6B-AS1 and MTDH were risk factors; (2) OTUD6B-AS1 was the up-stream regulator of miR-26a-5p verified by luciferase; (3) up-regulation of miR-26a-5p and down-regulation of MTDH promoted cellular cytotoxicity of paclitaxel (PTX) in vitro and in vivo.	Paclitaxel	317-320	metadherin	Homo sapiens	266-270
34740994-9	2021	In general, our study found (1) miR-26a-5p was a protective factor of breast cancer, while OTUD6B-AS1 and MTDH were risk factors; (2) OTUD6B-AS1 was the up-stream regulator of miR-26a-5p verified by luciferase; (3) up-regulation of miR-26a-5p and down-regulation of MTDH promoted cellular cytotoxicity of paclitaxel (PTX) in vitro and in vivo.	Paclitaxel	305-315	metadherin	Homo sapiens	106-110
34740994-9	2021	In general, our study found (1) miR-26a-5p was a protective factor of breast cancer, while OTUD6B-AS1 and MTDH were risk factors; (2) OTUD6B-AS1 was the up-stream regulator of miR-26a-5p verified by luciferase; (3) up-regulation of miR-26a-5p and down-regulation of MTDH promoted cellular cytotoxicity of paclitaxel (PTX) in vitro and in vivo.	Paclitaxel	305-315	metadherin	Homo sapiens	266-270
34582111-0	2021	FSC231 alleviates paclitaxel-induced neuralgia by inhibiting the interactions between PICK1 and GluA2 and activates GSK-3beta and ERK1/2.	Paclitaxel	18-28	glutamate ionotropic receptor AMPA type subunit 2	Rattus norvegicus	96-101
34309886-9	2021	Paclitaxel significantly (p < .05) increased caspase-3 and p-53 and decreased Bcl-2 genes expression than control.	Paclitaxel	0-10	BCL2, apoptosis regulator	Rattus norvegicus	78-83
34738481-3	2021	In the treatment of locally advanced complex LCNEC, it is unique to first administer radiotherapy combined with albumin-bound paclitaxel plus carboplatin, followed by durvalumab for immune maintenance treatment after concurrent radiotherapy and chemotherapy to achieve complete remission.	Paclitaxel	126-136	albumin	Homo sapiens	112-119
34795003-12	2021	Finally, in an orthotopic murine metastatic OV model, sFIS assay predicted the higher capacity of chemo-immunotherapy (paclitaxel-carboplatin plus anti-TNF antibody combination) in achieving a pro-immunogenic peripheral milieu (si-IFN/ISG responseHIGHsi-NFkappaB responseLOW), which aligned with high antitumor efficacy.	Paclitaxel	119-129	tumor necrosis factor	Mus musculus	152-155
34738481-9	2021	The patient achieved complete remission, which was a challenge with this rare carcinoma, through albumin-bound paclitaxel plus platinum-based chemotherapy combined with radiotherapy and durvalumab for immune maintenance therapy.	Paclitaxel	111-121	albumin	Homo sapiens	97-104
34749510-5	2021	Results: Compared with the control group, the PTX + PSO-PLNs group showed increased apoptosis and reduced migration, invasion and expression of phosphorylated IRAK1 and NF-kappaB, with significant inhibition of tumor growth and lung metastases and no obvious toxicity.	Paclitaxel	46-49	nuclear factor kappa B subunit 1	Homo sapiens	169-178
34528694-10	2021	UBQLN1 knockdown also enhanced breast cancer cell chemosensitivity to paclitaxel.	Paclitaxel	70-80	ubiquilin 1	Homo sapiens	0-6
34584572-0	2021	Targeting Mps1 in combination with paclitaxel inhibits osteosarcoma progression by modulating spindle assembly checkpoint and Akt/mTOR signaling.	Paclitaxel	35-45	AKT serine/threonine kinase 1	Homo sapiens	126-129
34584572-0	2021	Targeting Mps1 in combination with paclitaxel inhibits osteosarcoma progression by modulating spindle assembly checkpoint and Akt/mTOR signaling.	Paclitaxel	35-45	mechanistic target of rapamycin kinase	Homo sapiens	130-134
34584572-9	2021	Cells subjected to combined Mps1 knockdown and PTX treatment exhibited activation of SAC and inhibition of Akt/mTOR signaling compared with Mps1 knockdown or PTX treatment alone.	Paclitaxel	47-50	AKT serine/threonine kinase 1	Homo sapiens	107-110
34584572-9	2021	Cells subjected to combined Mps1 knockdown and PTX treatment exhibited activation of SAC and inhibition of Akt/mTOR signaling compared with Mps1 knockdown or PTX treatment alone.	Paclitaxel	47-50	mechanistic target of rapamycin kinase	Homo sapiens	111-115
34584572-9	2021	Cells subjected to combined Mps1 knockdown and PTX treatment exhibited activation of SAC and inhibition of Akt/mTOR signaling compared with Mps1 knockdown or PTX treatment alone.	Paclitaxel	158-161	AKT serine/threonine kinase 1	Homo sapiens	107-110
34584572-9	2021	Cells subjected to combined Mps1 knockdown and PTX treatment exhibited activation of SAC and inhibition of Akt/mTOR signaling compared with Mps1 knockdown or PTX treatment alone.	Paclitaxel	158-161	mechanistic target of rapamycin kinase	Homo sapiens	111-115
34617400-6	2021	Moreover, compared with paclitaxel, PTX-OCT conjugates induced lower expression of MDR-1 gene both in vitro and in vivo.	Paclitaxel	24-34	ATP binding cassette subfamily B member 1	Homo sapiens	83-88
34799910-0	2021	P1-39: Paclitaxel induces growth inhibition in gefitinib-resistant PC9-MET cells by downregulating MDM2 and activating p53.	Paclitaxel	7-17	tumor protein p53	Homo sapiens	119-122
34768915-4	2021	Combination treatment with UA and PTX inhibited cell proliferation and cell growth more effectively than either treatment alone by inducing more significant apoptosis, as indicated by increased sub-G1 phase distribution and protein levels of cleaved-PARP and cleaved caspase-9.	Paclitaxel	34-37	poly(ADP-ribose) polymerase 1	Homo sapiens	250-254
34365218-4	2021	Utilizing improved PIP3-AKT and ERK1/2 activation Bioluminescence Resonance Energy Transfer (BRET) sensors, we report chemotherapy-induced ERK1/2 activation predominantly in cisplatin-paclitaxel resistant EOC cells and increased activation of both ERK1/2 and AKT in malignant ascites derived cancer cells from platinum-resistant patients but not from treatment-naive or platinum-sensitive relapse patients.	Paclitaxel	184-194	mitogen-activated protein kinase 3	Homo sapiens	139-145
34835622-0	2021	A Multifunctional Polymeric Micelle for Targeted Delivery of Paclitaxel by the Inhibition of the P-Glycoprotein Transporters.	Paclitaxel	61-71	ATP binding cassette subfamily B member 1	Homo sapiens	97-111
34835622-9	2021	The orally administered PT-R-Ms efficiently overcome intestinal barriers and inhibit the P-gP efflux pump, resulting in increased bioavailability of PTX (up to 8-fold) in comparison to pure PTX.	Paclitaxel	149-152	ATP binding cassette subfamily B member 1	Homo sapiens	89-93
34835622-9	2021	The orally administered PT-R-Ms efficiently overcome intestinal barriers and inhibit the P-gP efflux pump, resulting in increased bioavailability of PTX (up to 8-fold) in comparison to pure PTX.	Paclitaxel	190-193	ATP binding cassette subfamily B member 1	Homo sapiens	89-93
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Paclitaxel	102-107	mitogen-activated protein kinase 3	Homo sapiens	72-78
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Paclitaxel	102-107	ATP binding cassette subfamily C member 1	Homo sapiens	275-280
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Paclitaxel	102-107	BCL2 apoptosis regulator	Homo sapiens	324-328
34778301-1	2021	Objective: The purpose of this study was to investigate the anticancer activity and the potential imaging use of the innovative combination of magnetic nanoparticles (MNPs)-Fe3O4, paclitaxel (PTX), and trastuzumab (Herceptin) in HER2-positive breast cancer.	Paclitaxel	180-190	erb-b2 receptor tyrosine kinase 2	Homo sapiens	229-233
34768915-0	2021	Ursolic Acid Accelerates Paclitaxel-Induced Cell Death in Esophageal Cancer Cells by Suppressing Akt/FOXM1 Signaling Cascade.	Paclitaxel	25-35	AKT serine/threonine kinase 1	Homo sapiens	97-100
34768915-5	2021	Similar to the cell growth suppressive effect, the combination of UA and PTX significantly inhibited cell migration by targeting uPA, MMP-9, and E-cadherin in ESCC cells.	Paclitaxel	73-76	proline rich acidic protein 1	Homo sapiens	129-132
34768915-5	2021	Similar to the cell growth suppressive effect, the combination of UA and PTX significantly inhibited cell migration by targeting uPA, MMP-9, and E-cadherin in ESCC cells.	Paclitaxel	73-76	cadherin 1	Homo sapiens	145-155
34768915-6	2021	In addition, combination treatment with UA and PTX significantly activated p-GSK-3beta and suppressed the activation of Akt and FOXM1 in ESCC cells.	Paclitaxel	47-50	AKT serine/threonine kinase 1	Homo sapiens	120-123
34768915-9	2021	Thus, UA effectively potentiates the anti-tumor efficacy of PTX by targeting the Akt/FOXM1 cascade since combination treatment shows significantly more anti-tumor potential than PTX alone both in vitro and in vivo.	Paclitaxel	60-63	AKT serine/threonine kinase 1	Homo sapiens	81-84
34695904-0	2021	(Multi-center real world study of the efficacy and safety of albumin-bound paclitaxel in the treatment of advanced breast cancer).	Paclitaxel	75-85	albumin	Homo sapiens	61-68
34695904-1	2021	Objective: To observe the efficacy and safety of albumin-bound paclitaxel in the treatment of metastatic breast cancer.	Paclitaxel	63-73	albumin	Homo sapiens	49-56
34695904-2	2021	Methods: Multi-center data of patients who accepted single-drug albumin-bound paclitaxel or combination regimens from 2013 to 2019 were collected and the efficacy and safety were evaluated.	Paclitaxel	78-88	albumin	Homo sapiens	64-71
34695904-6	2021	The ORRs of Luminal, human epidermal growth factor receptor 2 (HER2) overexpression and triple-negative breast cancer patients underwent albumin-bound paclitaxel treatment were 37.3%, 45.5% and 31.0%, respectively, the DCRs were 85.5%, 68.2% and 78.9%, respectively.	Paclitaxel	151-161	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-61
34695904-6	2021	The ORRs of Luminal, human epidermal growth factor receptor 2 (HER2) overexpression and triple-negative breast cancer patients underwent albumin-bound paclitaxel treatment were 37.3%, 45.5% and 31.0%, respectively, the DCRs were 85.5%, 68.2% and 78.9%, respectively.	Paclitaxel	151-161	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-67
34695904-6	2021	The ORRs of Luminal, human epidermal growth factor receptor 2 (HER2) overexpression and triple-negative breast cancer patients underwent albumin-bound paclitaxel treatment were 37.3%, 45.5% and 31.0%, respectively, the DCRs were 85.5%, 68.2% and 78.9%, respectively.	Paclitaxel	151-161	albumin	Homo sapiens	137-144
34695904-8	2021	The ORR and DCR of patients who accepted traditional paclitaxel treatment before the albumin-bound paclitaxel treatment were 35.8% and 82.1%, respectively.	Paclitaxel	99-109	albumin	Homo sapiens	85-92
34695904-11	2021	Conclusions: Albumin-bound paclitaxel single or combination regimen is still significant efficient for various molecular subtypes of breast cancer patients or patients with traditional paclitaxel resistance or multi-line chemotherapy failure.	Paclitaxel	27-37	albumin	Homo sapiens	13-20
34695904-11	2021	Conclusions: Albumin-bound paclitaxel single or combination regimen is still significant efficient for various molecular subtypes of breast cancer patients or patients with traditional paclitaxel resistance or multi-line chemotherapy failure.	Paclitaxel	185-195	albumin	Homo sapiens	13-20
34695906-2	2021	Methods: SinoMed, CNKI, WanFang MED ONLINE, VIP, PubMed, MEDLINE, Cochrane Library, Embase and ClinicalTrials.gov were searched to collect the papers or clinical studies of paclitaxel liposomes and paclitaxel combined with platinum in concurrent chemoradiotherapy for unresectable cervical carcinoma from the inception to January 15th 2021 in Chinese and English.	Paclitaxel	173-183	vasoactive intestinal peptide	Homo sapiens	44-47
34681904-6	2021	AK-I-190 induced G1 arrest and effectively inhibited cell proliferation and colony formation in combination with paclitaxel in an androgen receptor-negative CRPC cell line.	Paclitaxel	113-123	androgen receptor	Homo sapiens	130-147
34745981-8	2021	The mechanism underlying Paclitaxel resistance resides in a significant increase in P-glycoprotein expression and, when this drug efflux pump was blocked with Verapamil, cells re-acquired Paclitaxel sensitivity.	Paclitaxel	25-35	ATP binding cassette subfamily B member 1	Homo sapiens	84-98
34803458-2	2021	Here, it is aimed to investigate the differences in the expression levels of let-7a, miR-10b, miR-21, miR-125b, miR-145, miR-155, miR-200c, miR-221, miR-222 and miR-335, which associated with gene and proteins in MCF-7 (parental) and MCF-7s (Mammosphere/stem cell-enriched population/CD44+/CD24-cells) cells treated with paclitaxel.	Paclitaxel	321-331	CD24 molecule	Homo sapiens	290-294
34126457-1	2021	In this study, we designed and developed a novel asialoglycoprotein receptor (ASGPR)-targeted PEGylated paclitaxel (PTX) nanoliposome for hepatocellular carcinoma (HCC).	Paclitaxel	116-119	asialoglycoprotein receptor 1	Homo sapiens	49-76
34126457-1	2021	In this study, we designed and developed a novel asialoglycoprotein receptor (ASGPR)-targeted PEGylated paclitaxel (PTX) nanoliposome for hepatocellular carcinoma (HCC).	Paclitaxel	116-119	asialoglycoprotein receptor 1	Homo sapiens	78-83
34435645-7	2021	In addition, proteasome inhibitors combined with paclitaxel led to decreased MCL1 apoptosis regulator, BCL2 family member/Caspase-9/poly (ADP-ribose) polymerase apoptosis signaling triggered by CDK1/cyclin B1.	Paclitaxel	49-59	BCL2 apoptosis regulator	Homo sapiens	103-107
34660779-4	2021	Treatment with PAC and ATRA induced cell cycle arrest at the G2/M phase and apoptosis by upregulating p53 and caspase-8 expression and increased the intracellular calcium (Ca2+) level possibly by enhancing Ca2+ uptake via plasma membrane channels.	Paclitaxel	15-18	tumor protein p53	Homo sapiens	102-105
34608124-3	2021	In contrast, bortezomib and paclitaxel could drive U2OS or MG63 toward apoptosis effectively, suggesting that apoptosis induced by bortezomib or paclitaxel is p53-independent.	Paclitaxel	145-155	tumor protein p53	Homo sapiens	159-162
34608124-4	2021	The expressions of Bcl2 family members such as Bcl2, Bcl-xl, and Puma could be seen in U2OS and MG63 cells with or without doxorubicin, bortezomib, or paclitaxel treatment.	Paclitaxel	151-161	BCL2 apoptosis regulator	Homo sapiens	19-23
34608124-4	2021	The expressions of Bcl2 family members such as Bcl2, Bcl-xl, and Puma could be seen in U2OS and MG63 cells with or without doxorubicin, bortezomib, or paclitaxel treatment.	Paclitaxel	151-161	BCL2 apoptosis regulator	Homo sapiens	47-51
34608124-4	2021	The expressions of Bcl2 family members such as Bcl2, Bcl-xl, and Puma could be seen in U2OS and MG63 cells with or without doxorubicin, bortezomib, or paclitaxel treatment.	Paclitaxel	151-161	BCL2 like 1	Homo sapiens	53-59
34685613-0	2021	7-Epitaxol Induces Apoptosis and Autophagy in Head and Neck Squamous Cell Carcinoma through Inhibition of the ERK Pathway.	Paclitaxel	0-10	mitogen-activated protein kinase 1	Homo sapiens	110-113
34685613-8	2021	Furthermore, the MAPK inhibitors indicated that 7-Epitaxol induces apoptosis and autophagy marker proteins (cleaved-PARP and LC3-I/II) by reducing the phosphorylation of ERK1/2.	Paclitaxel	48-58	mitogen-activated protein kinase 3	Homo sapiens	170-176
34685613-9	2021	In conclusion, these findings indicate the involvement of 7-Epitaxol in inducing apoptosis and autophagy through ERK1/2 signaling pathway, which identify 7-Epitaxol as a potent cytotoxic agent in HNSCC.	Paclitaxel	58-68	mitogen-activated protein kinase 3	Homo sapiens	113-119
34685613-9	2021	In conclusion, these findings indicate the involvement of 7-Epitaxol in inducing apoptosis and autophagy through ERK1/2 signaling pathway, which identify 7-Epitaxol as a potent cytotoxic agent in HNSCC.	Paclitaxel	154-164	mitogen-activated protein kinase 3	Homo sapiens	113-119
34481023-2	2021	However, there is only one albumin nanoparticle product (paclitaxel-albumin nanoparticle) on the market.	Paclitaxel	57-67	albumin	Homo sapiens	27-34
34481023-2	2021	However, there is only one albumin nanoparticle product (paclitaxel-albumin nanoparticle) on the market.	Paclitaxel	57-67	albumin	Homo sapiens	68-75
34390205-9	2021	PN was reported more commonly by women treated with paclitaxel (52%) and docetaxel (39%), versus other chemotherapy (17%) (p < 0.0001).	Paclitaxel	52-62	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	0-2
34390205-10	2021	In multivariable analyses, treatment type (chemotherapy vs. none; OR, 95% CI: 3.31, 2.4-4.6), chemotherapy type (taxane vs. no-taxane; 4.74, 3.1-7.3), and taxane type (paclitaxel vs. docetaxel; 1.59, 1.0-2.5) were associated with higher odds of PN.	Paclitaxel	168-178	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	245-247
34435645-7	2021	In addition, proteasome inhibitors combined with paclitaxel led to decreased MCL1 apoptosis regulator, BCL2 family member/Caspase-9/poly (ADP-ribose) polymerase apoptosis signaling triggered by CDK1/cyclin B1.	Paclitaxel	49-59	poly(ADP-ribose) polymerase 1	Homo sapiens	132-160
34681199-8	2021	Paclitaxel-induced neuropathic pain was associated with nitration of proteins in the spinal cord including MnSOD, glutamine synthetase, and glutamate transporter GLT-1.	Paclitaxel	0-10	solute carrier family 1 member 2	Rattus norvegicus	162-167
34457060-0	2021	Role of JNK activation in paclitaxel-induced apoptosis in human head and neck squamous cell carcinoma.	Paclitaxel	26-36	mitogen-activated protein kinase 8	Homo sapiens	8-11
34457060-8	2021	In addition, paclitaxel activated the c-Jun N-terminal kinase (JNK), but not extracellular signal-regulated kinase or p38 mitogen-activated protein kinase.	Paclitaxel	13-23	mitogen-activated protein kinase 8	Homo sapiens	38-61
34457060-8	2021	In addition, paclitaxel activated the c-Jun N-terminal kinase (JNK), but not extracellular signal-regulated kinase or p38 mitogen-activated protein kinase.	Paclitaxel	13-23	mitogen-activated protein kinase 8	Homo sapiens	63-66
34457060-9	2021	The paclitaxel-activated JNK contributed to paclitaxel-induced apoptosis, activation of caspase-3, -6, -7, -8 and -9, and reduction of  Psim.	Paclitaxel	4-14	mitogen-activated protein kinase 8	Homo sapiens	25-28
34457060-9	2021	The paclitaxel-activated JNK contributed to paclitaxel-induced apoptosis, activation of caspase-3, -6, -7, -8 and -9, and reduction of  Psim.	Paclitaxel	4-14	caspase 3	Homo sapiens	88-116
34457060-9	2021	The paclitaxel-activated JNK contributed to paclitaxel-induced apoptosis, activation of caspase-3, -6, -7, -8 and -9, and reduction of  Psim.	Paclitaxel	44-54	mitogen-activated protein kinase 8	Homo sapiens	25-28
34457060-11	2021	Notably, Bid was truncated following treatment with paclitaxel.	Paclitaxel	52-62	BH3 interacting domain death agonist	Homo sapiens	9-12
34457060-12	2021	Taken together, the results of the present study suggest that paclitaxel-activated JNK is required for caspase activation and loss of  Psim, which results in apoptosis of HNSCC cells.	Paclitaxel	62-72	mitogen-activated protein kinase 8	Homo sapiens	83-86
34507591-7	2021	RESULTS: Pre-treatment with PEGPH20 modified tumour tissue architecture and improved the antitumor activity of paclitaxel in the SKOV3/HAS3 tumour model, favouring its accumulation and more homogeneous intra-tumour distribution, as assessed by quantitative and qualitative analysis.	Paclitaxel	111-121	sperm adhesion molecule 1	Homo sapiens	28-35
34595177-3	2021	This study focused on the impact of HIF1alpha on predicting response and survival of taxane-based neoadjuvant therapy (NAT) for breast cancer (BC) patients and the concrete mechanism that HIF1alpha mediated paclitaxel chemo-insensitivity.	Paclitaxel	207-217	hypoxia inducible factor 1 subunit alpha	Homo sapiens	188-197
34595177-4	2021	We evaluated HIF1alpha expression immunohistochemically from biopsies of 108 BC patients receiving paclitaxel-cisplatin NAT.	Paclitaxel	99-109	hypoxia inducible factor 1 subunit alpha	Homo sapiens	13-22
34595177-10	2021	Experiments in vitro verified that HIF1alpha/IL-17 pathway influences paclitaxel sensitivity to BC cells.	Paclitaxel	70-80	hypoxia inducible factor 1 subunit alpha	Homo sapiens	35-44
34507591-0	2021	PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.	Paclitaxel	117-127	sperm adhesion molecule 1	Homo sapiens	43-50
34507591-8	2021	PEGPH20 also reduced HA content influencing, though less markedly, PTX distribution and antitumor activity in the BxPC3 tumour model.	Paclitaxel	67-70	sperm adhesion molecule 1	Homo sapiens	0-7
34196474-5	2021	Immune checkpoint inhibitor (Anti-PD-1 antibody) is trapped in the interior of the porous ZGO@TiO2 with paclitaxel (PTX) loaded liposome encapsulation to form ZGO@TiO2 @ALP.	Paclitaxel	104-114	programmed cell death 1	Mus musculus	34-38
34566640-4	2021	Based on the results, PTX inhibited the migration of RA-FLS in a dose-dependent manner and significantly reduced the spontaneous expression of IL-6, IL-8, and RANKL mRNA and TNF-alpha-induced transcription of the IL-1 beta, IL-8, MMP-8, and MMP-9 genes.	Paclitaxel	22-25	interleukin 6	Mus musculus	143-147
34566640-4	2021	Based on the results, PTX inhibited the migration of RA-FLS in a dose-dependent manner and significantly reduced the spontaneous expression of IL-6, IL-8, and RANKL mRNA and TNF-alpha-induced transcription of the IL-1 beta, IL-8, MMP-8, and MMP-9 genes.	Paclitaxel	22-25	tumor necrosis factor	Mus musculus	174-183
34566640-6	2021	Mechanistic studies revealed that PTX significantly inhibited the TNF-alpha-induced phosphorylation of ERK1/2 and JNK in the mitogen-activated protein kinase (MAPK) pathway and suppressed the TNF-alpha-induced activation of AKT, p70S6K, 4EBP1, and HIF-1alpha in the AKT/mTOR pathway.	Paclitaxel	34-37	tumor necrosis factor	Mus musculus	66-75
34566640-6	2021	Mechanistic studies revealed that PTX significantly inhibited the TNF-alpha-induced phosphorylation of ERK1/2 and JNK in the mitogen-activated protein kinase (MAPK) pathway and suppressed the TNF-alpha-induced activation of AKT, p70S6K, 4EBP1, and HIF-1alpha in the AKT/mTOR pathway.	Paclitaxel	34-37	tumor necrosis factor	Mus musculus	192-201
34566640-6	2021	Mechanistic studies revealed that PTX significantly inhibited the TNF-alpha-induced phosphorylation of ERK1/2 and JNK in the mitogen-activated protein kinase (MAPK) pathway and suppressed the TNF-alpha-induced activation of AKT, p70S6K, 4EBP1, and HIF-1alpha in the AKT/mTOR pathway.	Paclitaxel	34-37	thymoma viral proto-oncogene 1	Mus musculus	224-227
34566640-6	2021	Mechanistic studies revealed that PTX significantly inhibited the TNF-alpha-induced phosphorylation of ERK1/2 and JNK in the mitogen-activated protein kinase (MAPK) pathway and suppressed the TNF-alpha-induced activation of AKT, p70S6K, 4EBP1, and HIF-1alpha in the AKT/mTOR pathway.	Paclitaxel	34-37	thymoma viral proto-oncogene 1	Mus musculus	266-269
34566640-8	2021	In conclusion, PTX inhibits the migration and inflammatory mediator production of RA-FLS by targeting the MAPK and AKT/mTOR signaling pathways, which provides an experimental basis for the potential application in the treatment of RA.	Paclitaxel	15-18	thymoma viral proto-oncogene 1	Mus musculus	115-118
34370483-0	2021	ERK-Peptide-Inhibitor-Modified Ferritin Enhanced the Therapeutic Effects of Paclitaxel in Cancer Cells and Spheroids.	Paclitaxel	76-86	mitogen-activated protein kinase 1	Homo sapiens	0-3
34590611-2	2021	Furthermore, Cav-1 is critical for the uptake of albumin as well as nab-paclitaxel in PDAC cells.	Paclitaxel	72-82	caveolin 1	Homo sapiens	13-18
34490849-1	2022	ABSTRACT: Activation of toll-like receptor 4 (TLR4) in the dorsal root ganglion (DRG) and spinal cord contributes to the generation of paclitaxel-related chemotherapy-induced peripheral neuropathy (CIPN).	Paclitaxel	135-145	toll-like receptor 4	Rattus norvegicus	24-44
34490849-1	2022	ABSTRACT: Activation of toll-like receptor 4 (TLR4) in the dorsal root ganglion (DRG) and spinal cord contributes to the generation of paclitaxel-related chemotherapy-induced peripheral neuropathy (CIPN).	Paclitaxel	135-145	toll-like receptor 4	Rattus norvegicus	46-50
34196474-5	2021	Immune checkpoint inhibitor (Anti-PD-1 antibody) is trapped in the interior of the porous ZGO@TiO2 with paclitaxel (PTX) loaded liposome encapsulation to form ZGO@TiO2 @ALP.	Paclitaxel	104-114	alopecia, recessive	Mus musculus	169-172
34196474-5	2021	Immune checkpoint inhibitor (Anti-PD-1 antibody) is trapped in the interior of the porous ZGO@TiO2 with paclitaxel (PTX) loaded liposome encapsulation to form ZGO@TiO2 @ALP.	Paclitaxel	116-119	programmed cell death 1	Mus musculus	34-38
34196474-5	2021	Immune checkpoint inhibitor (Anti-PD-1 antibody) is trapped in the interior of the porous ZGO@TiO2 with paclitaxel (PTX) loaded liposome encapsulation to form ZGO@TiO2 @ALP.	Paclitaxel	116-119	alopecia, recessive	Mus musculus	169-172
34196474-7	2021	After intravenous injection, ultrasound irradiation at GBM sites initiates ROS generation from ZGO@TiO2 @ALP, leading to liposome destruction for PTX and anti-PD-1 antibody release to kill tumors and induce local inflammation, which in-turn attractes more ZGO@TiO2 @ALP-NEs to migrate into tumor sites for augmented and sustained therapy.	Paclitaxel	146-149	alopecia, recessive	Mus musculus	105-108
34196474-7	2021	After intravenous injection, ultrasound irradiation at GBM sites initiates ROS generation from ZGO@TiO2 @ALP, leading to liposome destruction for PTX and anti-PD-1 antibody release to kill tumors and induce local inflammation, which in-turn attractes more ZGO@TiO2 @ALP-NEs to migrate into tumor sites for augmented and sustained therapy.	Paclitaxel	146-149	alopecia, recessive	Mus musculus	266-269
34268580-8	2021	BBB Pgp activity in the model was optimized using measured CSF data for the Pgp substrates ivermectin, indinavir, vincristine, docetaxel, paclitaxel, olanzapine and citalopram, as no useful in vitro data were available.	Paclitaxel	138-148	ATP binding cassette subfamily B member 1	Homo sapiens	4-7
34268580-8	2021	BBB Pgp activity in the model was optimized using measured CSF data for the Pgp substrates ivermectin, indinavir, vincristine, docetaxel, paclitaxel, olanzapine and citalopram, as no useful in vitro data were available.	Paclitaxel	138-148	ATP binding cassette subfamily B member 1	Homo sapiens	76-79
34479917-0	2021	Paclitaxel Impedes EGFR-mutated PC9 Cell Growth via Reactive Oxygen Species-mediated DNA Damage and EGFR/PI3K/AKT/mTOR Signaling Pathway Suppression.	Paclitaxel	0-10	epidermal growth factor receptor	Homo sapiens	19-23
34080040-7	2021	All patients with CCNE1 amplification (n = 7), TP53 R175H substitution (n = 6), and RB1 mutation (n = 4) had poor response to paclitaxel plus carboplatin.	Paclitaxel	126-136	tumor protein p53	Homo sapiens	47-51
34479917-0	2021	Paclitaxel Impedes EGFR-mutated PC9 Cell Growth via Reactive Oxygen Species-mediated DNA Damage and EGFR/PI3K/AKT/mTOR Signaling Pathway Suppression.	Paclitaxel	0-10	epidermal growth factor receptor	Homo sapiens	100-104
34479917-3	2021	In this study, the molecular mechanism underlying the anticancer activity of paclitaxel was investigated in vitro in a human NSCLC cell line carrying the EGFR exon 19 deletion (PC9).	Paclitaxel	77-87	epidermal growth factor receptor	Homo sapiens	154-158
34479917-8	2021	In addition, we found that paclitaxel effectively suppressed the EGFR/PI3K/AKT/mTOR signaling pathway to impede PC9 cell growth.	Paclitaxel	27-37	epidermal growth factor receptor	Homo sapiens	65-69
34479917-8	2021	In addition, we found that paclitaxel effectively suppressed the EGFR/PI3K/AKT/mTOR signaling pathway to impede PC9 cell growth.	Paclitaxel	27-37	AKT serine/threonine kinase 1	Homo sapiens	75-78
34479917-8	2021	In addition, we found that paclitaxel effectively suppressed the EGFR/PI3K/AKT/mTOR signaling pathway to impede PC9 cell growth.	Paclitaxel	27-37	mechanistic target of rapamycin kinase	Homo sapiens	79-83
34479917-10	2021	CONCLUSION: Paclitaxel showed anticancer effects against NSCLC by activating extrinsic and intrinsic apoptotic pathways through enhancing ROS generation, inducing cell cycle arrest, and suppressing EGFR/PI3K/AKT/mTOR signaling pathway.	Paclitaxel	12-22	epidermal growth factor receptor	Homo sapiens	198-202
34479917-10	2021	CONCLUSION: Paclitaxel showed anticancer effects against NSCLC by activating extrinsic and intrinsic apoptotic pathways through enhancing ROS generation, inducing cell cycle arrest, and suppressing EGFR/PI3K/AKT/mTOR signaling pathway.	Paclitaxel	12-22	AKT serine/threonine kinase 1	Homo sapiens	208-211
34479917-10	2021	CONCLUSION: Paclitaxel showed anticancer effects against NSCLC by activating extrinsic and intrinsic apoptotic pathways through enhancing ROS generation, inducing cell cycle arrest, and suppressing EGFR/PI3K/AKT/mTOR signaling pathway.	Paclitaxel	12-22	mechanistic target of rapamycin kinase	Homo sapiens	212-216
34479918-8	2021	The apoptotic effects of paclitaxel were observed by increased levels of cleaved caspase-3 (Asp 175), cleaved caspase-9 (Asp 330) and cleaved PARP (Asp 214).	Paclitaxel	25-35	caspase 3	Homo sapiens	81-90
34278475-0	2021	(Retracted) MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3.	Paclitaxel	70-80	protein disulfide isomerase family A member 3	Homo sapiens	136-141
34172499-1	2021	A Phase 1 study defined a tolerable combination of the ATR inhibitor ceralasertib with paclitaxel and responses were seen in melanoma patients who had progressed on an immune checkpoint inhibitor.	Paclitaxel	87-97	ATR serine/threonine kinase	Homo sapiens	55-58
34688321-0	2021	A New Recombinant Fibronectin/Cadherin Protein-Hydrophobically Modified Glycol Chitosan/Paclitaxel Layer-By-Layer Self-Assembly Strategy for the Postoperative Therapy of Osteosarcoma and Correlated Bone Injury.	Paclitaxel	88-98	fibronectin 1	Homo sapiens	18-29
34363313-4	2021	We show that diverse stress stimuli, including etoposide, brefeldin A and paclitaxel, as well as heat stress and gamma-irradiation, caused formation of a complex containing ATG5-ATG12, FADD and caspase-8 leading to activation of downstream caspases in caspase-9-deficient cells.	Paclitaxel	74-84	autophagy related 5	Homo sapiens	173-177
34363313-4	2021	We show that diverse stress stimuli, including etoposide, brefeldin A and paclitaxel, as well as heat stress and gamma-irradiation, caused formation of a complex containing ATG5-ATG12, FADD and caspase-8 leading to activation of downstream caspases in caspase-9-deficient cells.	Paclitaxel	74-84	autophagy related 12	Homo sapiens	178-183
34278466-0	2021	Chemokine CCL20 promotes the paclitaxel resistance of CD44+CD117+ cells via the Notch1 signaling pathway in ovarian cancer.	Paclitaxel	29-39	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	59-64
34278466-0	2021	Chemokine CCL20 promotes the paclitaxel resistance of CD44+CD117+ cells via the Notch1 signaling pathway in ovarian cancer.	Paclitaxel	29-39	notch receptor 1	Homo sapiens	80-86
34278466-2	2021	The aim of the present study was to investigate the underlying mechanism of CCL20/CCR6/Notch1 signaling in paclitaxel (PTX) resistance of a CD44+CD117+ subgroup of cells in ovarian cancer.	Paclitaxel	107-117	notch receptor 1	Homo sapiens	87-93
34512368-3	2021	In this review, we focus on summarizing some representative natural active compounds, mainly including curcumin, resveratrol, paclitaxel, Bufalin, and Ursolic acid that may ultimately trigger cancer cell death through the regulation of some key autophagic signaling pathways, such as RAS-RAF-MEK-ERK, PI3K-AKT-mTOR, AMPK, ULK1, Beclin-1, Atg5 and p53.	Paclitaxel	126-136	mitogen-activated protein kinase kinase 7	Homo sapiens	292-295
34278466-2	2021	The aim of the present study was to investigate the underlying mechanism of CCL20/CCR6/Notch1 signaling in paclitaxel (PTX) resistance of a CD44+CD117+ subgroup of cells in ovarian cancer.	Paclitaxel	107-117	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	145-150
34278466-2	2021	The aim of the present study was to investigate the underlying mechanism of CCL20/CCR6/Notch1 signaling in paclitaxel (PTX) resistance of a CD44+CD117+ subgroup of cells in ovarian cancer.	Paclitaxel	119-122	notch receptor 1	Homo sapiens	87-93
34278466-2	2021	The aim of the present study was to investigate the underlying mechanism of CCL20/CCR6/Notch1 signaling in paclitaxel (PTX) resistance of a CD44+CD117+ subgroup of cells in ovarian cancer.	Paclitaxel	119-122	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	145-150
34126209-8	2021	The combination of PTX and LAP can be useful in HER2-negative breast cancer treatment.	Paclitaxel	19-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-52
34338752-0	2021	Correction: LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a.	Paclitaxel	38-43	AKT serine/threonine kinase 1	Homo sapiens	104-107
34465889-0	2022	Ubiquitination of NF-kappaB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance.	Paclitaxel	95-105	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	18-27
34575432-4	2021	Here, we report on the synthesis, physicochemical characterization, and in vitro evaluation of biocompatibility and anti-tumor activity of novel magnetically targetable SPIONs based on magnetite (Fe3O4) nanoparticles" surface modified with beta-cyclodextrin (CD) and paclitaxel (PTX)-guest-host inclusion complexes (Fe3O4@beta-CD/PTX).	Paclitaxel	267-277	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	322-333
34575432-4	2021	Here, we report on the synthesis, physicochemical characterization, and in vitro evaluation of biocompatibility and anti-tumor activity of novel magnetically targetable SPIONs based on magnetite (Fe3O4) nanoparticles" surface modified with beta-cyclodextrin (CD) and paclitaxel (PTX)-guest-host inclusion complexes (Fe3O4@beta-CD/PTX).	Paclitaxel	279-282	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	322-333
34575432-6	2021	Pristine Fe3O4@beta-CD and Fe3O4@beta-CD/PTX thin films were physicochemically characterized by X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FT-IR), thermal analysis, scanning electron microscopy (SEM), and transmission electron microscopy (TEM).	Paclitaxel	41-44	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	33-40
34512368-3	2021	In this review, we focus on summarizing some representative natural active compounds, mainly including curcumin, resveratrol, paclitaxel, Bufalin, and Ursolic acid that may ultimately trigger cancer cell death through the regulation of some key autophagic signaling pathways, such as RAS-RAF-MEK-ERK, PI3K-AKT-mTOR, AMPK, ULK1, Beclin-1, Atg5 and p53.	Paclitaxel	126-136	mitogen-activated protein kinase 1	Homo sapiens	296-299
34512368-3	2021	In this review, we focus on summarizing some representative natural active compounds, mainly including curcumin, resveratrol, paclitaxel, Bufalin, and Ursolic acid that may ultimately trigger cancer cell death through the regulation of some key autophagic signaling pathways, such as RAS-RAF-MEK-ERK, PI3K-AKT-mTOR, AMPK, ULK1, Beclin-1, Atg5 and p53.	Paclitaxel	126-136	AKT serine/threonine kinase 1	Homo sapiens	306-309
34437536-6	2021	The NAD(P)H quinone dehydrogenase 1 (NQO1) gene was found to be associated with the dose-response of arsenic trioxide, erlotinib, trametinib, and a combination treatment of paclitaxel + epirubicin.	Paclitaxel	173-183	NAD(P)H quinone dehydrogenase 1	Homo sapiens	4-35
34437536-6	2021	The NAD(P)H quinone dehydrogenase 1 (NQO1) gene was found to be associated with the dose-response of arsenic trioxide, erlotinib, trametinib, and a combination treatment of paclitaxel + epirubicin.	Paclitaxel	173-183	NAD(P)H quinone dehydrogenase 1	Homo sapiens	37-41
34512368-3	2021	In this review, we focus on summarizing some representative natural active compounds, mainly including curcumin, resveratrol, paclitaxel, Bufalin, and Ursolic acid that may ultimately trigger cancer cell death through the regulation of some key autophagic signaling pathways, such as RAS-RAF-MEK-ERK, PI3K-AKT-mTOR, AMPK, ULK1, Beclin-1, Atg5 and p53.	Paclitaxel	126-136	mechanistic target of rapamycin kinase	Homo sapiens	310-314
34512368-3	2021	In this review, we focus on summarizing some representative natural active compounds, mainly including curcumin, resveratrol, paclitaxel, Bufalin, and Ursolic acid that may ultimately trigger cancer cell death through the regulation of some key autophagic signaling pathways, such as RAS-RAF-MEK-ERK, PI3K-AKT-mTOR, AMPK, ULK1, Beclin-1, Atg5 and p53.	Paclitaxel	126-136	autophagy related 5	Homo sapiens	338-342
34408017-0	2021	Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel.	Paclitaxel	86-96	protein arginine methyltransferase 5	Homo sapiens	23-28
34405891-13	2022	Apatinib strengthened sensitivity of GC cells to PTX by inhibiting JAK/STAT3 signaling pathway.	Paclitaxel	49-52	signal transducer and activator of transcription 3	Homo sapiens	71-76
34567947-0	2021	Potential effectiveness of combining bevacizumab with paclitaxel for treating HER2-positive metastatic breast cancer.	Paclitaxel	54-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
34567947-2	2021	Here, we describe seven patients with HER2-positive metastatic breast cancer who underwent bevacizumab (BV) and paclitaxel (PTX) combination therapy after several HER2-targeted therapies.	Paclitaxel	112-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
34567947-2	2021	Here, we describe seven patients with HER2-positive metastatic breast cancer who underwent bevacizumab (BV) and paclitaxel (PTX) combination therapy after several HER2-targeted therapies.	Paclitaxel	124-127	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
34567947-5	2021	Therefore, bevacizumab combined with paclitaxel is potentially effective in the treatment of HER2-positive metastatic breast cancer, if standard HER2-targeted therapy fails.	Paclitaxel	37-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
34466284-12	2021	The IC50 for cisplatin and paclitaxel were significantly increased by Keap1 knockdown in A549 and H1299 cell lines.	Paclitaxel	27-37	kelch like ECH associated protein 1	Homo sapiens	70-75
34452170-2	2021	Nanoparticle albumin-bound (nab)-technology, such as nab-paclitaxel (Abraxane ), has attracted significant interest in drug delivery research.	Paclitaxel	57-67	albumin	Homo sapiens	13-20
34161810-4	2021	Our tests demonstrated satisfactory preparation of paclitaxel-loaded, PD-L1-targeted albumin nanoparticles (PD-L1/PTX@HSA).	Paclitaxel	51-61	albumin	Homo sapiens	114-121
34452218-3	2021	This innovative approach explored the great capacity of both polyamidoamine (PAMAM)-paclitaxel (PTX) conjugate and polyethylenimine (PEI) polymers to complex a p53-encoding plasmid DNA (pDNA), highlighting the utility of considering two compacting agents.	Paclitaxel	84-94	tumor protein p53	Homo sapiens	160-163
34376246-16	2021	CONCLUSION: These combined data showed that HGWD could inhibit paclitaxel-evoked inflammatory and oxidative responses in peripheral nervous system viaTLR4/NF-kappaB and PI3K/Akt-Nrf2 pathways involvement.	Paclitaxel	63-73	AKT serine/threonine kinase 1	Rattus norvegicus	174-177
34376246-16	2021	CONCLUSION: These combined data showed that HGWD could inhibit paclitaxel-evoked inflammatory and oxidative responses in peripheral nervous system viaTLR4/NF-kappaB and PI3K/Akt-Nrf2 pathways involvement.	Paclitaxel	63-73	NFE2 like bZIP transcription factor 2	Rattus norvegicus	178-182
34347777-0	2021	Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.	Paclitaxel	49-59	ATP binding cassette subfamily B member 1	Homo sapiens	34-39
34535390-7	2022	RESULTS: In MDA-MB-468/Taxol cells, RTEs & Taxol treatment increased cell apoptosis, reduced cell viability and proliferation, up-regulated anti-autophagy marker LC3I/LC3II ratio, and enhanced mTOR level.	Paclitaxel	43-48	mechanistic target of rapamycin kinase	Homo sapiens	193-197
34535390-8	2022	With RTEs & Taxol treatment, mTOR silencing downregulated LC3I/LC3II ratio, increased cell viability and proliferation, and reduced cell apoptosis, while mTOR overexpression showed the opposite results.	Paclitaxel	12-17	mechanistic target of rapamycin kinase	Homo sapiens	29-33
34535390-8	2022	With RTEs & Taxol treatment, mTOR silencing downregulated LC3I/LC3II ratio, increased cell viability and proliferation, and reduced cell apoptosis, while mTOR overexpression showed the opposite results.	Paclitaxel	12-17	mechanistic target of rapamycin kinase	Homo sapiens	154-158
34535390-10	2022	After RTEs & Taxol injection, xenograft tumor was smaller, and AKT, mTOR, LC3I/LC3II ratio and apoptotic marker cleaved caspase-3 were increased.	Paclitaxel	13-18	AKT serine/threonine kinase 1	Homo sapiens	63-66
34535390-10	2022	After RTEs & Taxol injection, xenograft tumor was smaller, and AKT, mTOR, LC3I/LC3II ratio and apoptotic marker cleaved caspase-3 were increased.	Paclitaxel	13-18	mechanistic target of rapamycin kinase	Homo sapiens	68-72
34535390-10	2022	After RTEs & Taxol injection, xenograft tumor was smaller, and AKT, mTOR, LC3I/LC3II ratio and apoptotic marker cleaved caspase-3 were increased.	Paclitaxel	13-18	caspase 3	Homo sapiens	120-129
34535390-11	2022	CONCLUSION: RTEs enhanced the chemosensitivity of resistant TNBC cells to Taxol through inhibiting PI3K/Akt/mTOR-mediated autophagy.	Paclitaxel	74-79	AKT serine/threonine kinase 1	Homo sapiens	104-107
34535390-11	2022	CONCLUSION: RTEs enhanced the chemosensitivity of resistant TNBC cells to Taxol through inhibiting PI3K/Akt/mTOR-mediated autophagy.	Paclitaxel	74-79	mechanistic target of rapamycin kinase	Homo sapiens	108-112
34347777-8	2021	ABCB1 expression was upregulated in paclitaxel-resistant TOV-21G (q < 1x10-300), OVCAR3 (q = 7.4x10-156) and novel ovarian tumor organoid (p = 2.4x10-4) models.	Paclitaxel	36-46	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
34347777-10	2021	We tested a panel of tyrosine kinase inhibitors for the ability to sensitize resistant ABCB1-overexpressing ovarian cancer cell lines to paclitaxel.	Paclitaxel	137-147	ATP binding cassette subfamily B member 1	Homo sapiens	87-92
34347777-11	2021	We observed synergy when we combined poziotinib or lapatinib with paclitaxel in resistant TOV-21G and OVCAR3 cells.	Paclitaxel	66-76	carbonic anhydrase 3	Homo sapiens	102-108
34347777-12	2021	Silencing ABCB1 expression in paclitaxel-resistant TOV-21G and OVCAR3 cells reduced paclitaxel IC50 by 20.7 and 6.2-fold, respectively.	Paclitaxel	30-40	ATP binding cassette subfamily B member 1	Homo sapiens	10-15
34347777-12	2021	Silencing ABCB1 expression in paclitaxel-resistant TOV-21G and OVCAR3 cells reduced paclitaxel IC50 by 20.7 and 6.2-fold, respectively.	Paclitaxel	30-40	carbonic anhydrase 3	Homo sapiens	63-69
34347777-12	2021	Silencing ABCB1 expression in paclitaxel-resistant TOV-21G and OVCAR3 cells reduced paclitaxel IC50 by 20.7 and 6.2-fold, respectively.	Paclitaxel	84-94	ATP binding cassette subfamily B member 1	Homo sapiens	10-15
34347777-12	2021	Silencing ABCB1 expression in paclitaxel-resistant TOV-21G and OVCAR3 cells reduced paclitaxel IC50 by 20.7 and 6.2-fold, respectively.	Paclitaxel	84-94	carbonic anhydrase 3	Homo sapiens	63-69
34347777-13	2021	Furthermore, we demonstrated direct inhibition of paclitaxel-induced ABCB1 transporter activity by both lapatinib and poziotinib.	Paclitaxel	50-60	ATP binding cassette subfamily B member 1	Homo sapiens	69-74
34347777-14	2021	In conclusion, lapatinib and poziotinib combined with paclitaxel synergizes to inhibit the proliferation of ABCB1-overexpressing ovarian cancer cells in vitro.	Paclitaxel	54-64	ATP binding cassette subfamily B member 1	Homo sapiens	108-113
34318540-8	2021	In addition, KD also inhibited the expression of pro-inflammatory cytokines and the TLR4/NF-kappaB signaling pathway in the dorsal root ganglion (DRG) in paclitaxel-treated rats.	Paclitaxel	154-164	toll-like receptor 4	Rattus norvegicus	84-88
34255109-12	2021	Immunohistochemical analysis of NF-kappaB in SKOV-3 tumors treated with BA in combination with paclitaxel revealed antitumor effect in terms of inhibition of NF-kappaB.	Paclitaxel	95-105	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	32-41
34404077-9	2021	Bevacizumab plus paclitaxel is reportedly effective against HER2-negative metastatic breast cancer.	Paclitaxel	17-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
34255109-12	2021	Immunohistochemical analysis of NF-kappaB in SKOV-3 tumors treated with BA in combination with paclitaxel revealed antitumor effect in terms of inhibition of NF-kappaB.	Paclitaxel	95-105	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	158-167
34320531-3	2021	The addition of trastuzumab to carboplatin-paclitaxel improved progression-free survival of patients with human epidermal growth factor receptor 2 (HER2)-positive uterine serous carcinoma.	Paclitaxel	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-146
34278497-7	2021	Moreover, knockdown of EphA8 expression increased the chemosensitivity of BC cells to paclitaxel.	Paclitaxel	86-96	EPH receptor A8	Homo sapiens	23-28
34360846-6	2021	ATC paclitaxel-resistant cells highlighted an overexpression of ABCB1 and a hyper-activation of the NF-kappaB compared to sensitive cells.	Paclitaxel	4-14	ATP binding cassette subfamily B member 1	Homo sapiens	64-69
34225215-0	2021	Circular RNA PLEC acts as a sponge of microRNA-198 to promote gastric carcinoma cell resistance to paclitaxel and tumorigenesis.	Paclitaxel	99-109	microRNA 198	Homo sapiens	38-50
34225215-7	2021	MiR-198 inhibitor reversed the effect of circPLEC downreguAlation in PTX-resistant GC cells, and MUC19 downregulation weakened GC resistance to PTX and tumorigenesis and improved the apoptosis of PTX-resistant GC cells.	Paclitaxel	69-72	microRNA 198	Homo sapiens	0-7
34225215-8	2021	In summary, circPLEC acts as a sponge of miR-198 to promote the PTX resistance and tumorigenesis of GC cells by regulating MUC19 expression.	Paclitaxel	64-67	microRNA 198	Homo sapiens	41-48
34293716-10	2021	Consistent with this model, the overexpression of IL-6 reversed the OGFRP1 knockdown-mediated reductions in docetaxel and paclitaxel IC50 values for these PC cells.	Paclitaxel	122-132	interleukin 6	Homo sapiens	50-54
34360846-6	2021	ATC paclitaxel-resistant cells highlighted an overexpression of ABCB1 and a hyper-activation of the NF-kappaB compared to sensitive cells.	Paclitaxel	4-14	nuclear factor kappa B subunit 1	Homo sapiens	100-109
34320531-3	2021	The addition of trastuzumab to carboplatin-paclitaxel improved progression-free survival of patients with human epidermal growth factor receptor 2 (HER2)-positive uterine serous carcinoma.	Paclitaxel	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
34261493-3	2021	We evaluated the success of modifying Neuropilin-1 targeting peptide (RGE) on the EV membrane of ICG/PTX@RGE-EV using super-resolution fluorescence microscopy and flow cytometry.	Paclitaxel	101-104	neuropilin 1	Mus musculus	38-50
34270886-4	2021	We found that expression of KDM5A and P-glycoprotein (P-gp), which plays a critical role in the development of paclitaxel resistance, were significantly higher in PTX-Calu-3 cells compared to SK-LI-1, Calu-3, and A549 cells.. We observed a significant increase in the expression of mesenchymal markers N-cadherin and vimentin, and a concomitant decrease in expression of E-cadherin and alpha-catenin in PTX-Calu-3 compared to SK-LI-1, Calu-3, and A549 lung cancer cell lines.	Paclitaxel	111-121	ATP binding cassette subfamily B member 1	Homo sapiens	38-52
34270886-4	2021	We found that expression of KDM5A and P-glycoprotein (P-gp), which plays a critical role in the development of paclitaxel resistance, were significantly higher in PTX-Calu-3 cells compared to SK-LI-1, Calu-3, and A549 cells.. We observed a significant increase in the expression of mesenchymal markers N-cadherin and vimentin, and a concomitant decrease in expression of E-cadherin and alpha-catenin in PTX-Calu-3 compared to SK-LI-1, Calu-3, and A549 lung cancer cell lines.	Paclitaxel	111-121	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
34359562-3	2021	Furthermore, as a centrosome kinase, SIK2 has been shown to regulate the G2/M transition, and its depletion sensitizes ovarian cancer to paclitaxel-based chemotherapy.	Paclitaxel	137-147	salt inducible kinase 2	Homo sapiens	37-41
34359562-4	2021	Here, we report the consequences of SIK2 inhibition on mitosis and synergies with paclitaxel in ovarian cancer using a novel and selective inhibitor, MRIA9.	Paclitaxel	82-92	salt inducible kinase 2	Homo sapiens	36-40
34359562-8	2021	Our study suggests selective targeting of SIK2 in ovarian cancer as a therapeutic strategy for overcoming paclitaxel resistance.	Paclitaxel	106-116	salt inducible kinase 2	Homo sapiens	42-46
34261493-9	2021	ICG/PTX@RGE-EV effectively targeted U251 cells, with activation of the Caspase-3 pathway and elevated apoptosis in U251 cells through chemotherapy combined with hyperthermia.	Paclitaxel	4-7	caspase 3	Homo sapiens	71-80
34156070-4	2021	We show that yeast oxidative stress response mutants (sod1Delta, tsa1Delta and cta1Delta) and DNA damage response mutants (mre11 , sgs1  and sub1 ) are highly sensitive to Taxol.	Paclitaxel	172-177	ATP-dependent DNA helicase SGS1	Saccharomyces cerevisiae S288C	131-135
34236783-11	2022	As for cytokines, rapamycin or paclitaxel concentrations >=1 ug/mL could significantly increase the level of inflammatory cytokines IL-6 (P<0.05 or P<0.01), which was enhanced with the increase of drug concentration.	Paclitaxel	31-41	interleukin 6	Homo sapiens	132-136
34236783-12	2022	However, rapamycin or paclitaxel concentrations >=1 mug/mL could significantly reduce the levels of anti-inflammatory cytokines IL-35 and transforming growth factor beta (TGF-beta) (P<0.05 or P<0.01), which decreased with the increase of drug concentration.	Paclitaxel	22-32	tumor necrosis factor	Homo sapiens	138-169
34229754-0	2021	Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1alpha-AKT-mTOR pathway in esophageal squamous cell carcinoma.	Paclitaxel	115-125	AKT serine/threonine kinase 1	Homo sapiens	145-148
34229754-0	2021	Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1alpha-AKT-mTOR pathway in esophageal squamous cell carcinoma.	Paclitaxel	115-125	mechanistic target of rapamycin kinase	Homo sapiens	149-153
34229754-10	2021	In addition, we showed, for the first time, the paclitaxel combined with apatinib and CQ exhibited the best antitumor effect on ESCC both in vivo and in vitro via the IRE-1alpha-AKT-mTOR pathway.	Paclitaxel	48-58	AKT serine/threonine kinase 1	Homo sapiens	178-181
34229754-10	2021	In addition, we showed, for the first time, the paclitaxel combined with apatinib and CQ exhibited the best antitumor effect on ESCC both in vivo and in vitro via the IRE-1alpha-AKT-mTOR pathway.	Paclitaxel	48-58	mechanistic target of rapamycin kinase	Homo sapiens	182-186
34229754-13	2021	The combination of apatinib and CQ sensitized ESCC cells to paclitaxel to induce apoptosis through the IRE-1alpha-AKT-mTOR signaling pathway, thus providing the basis for its use in innovative anticancer therapeutic strategies.	Paclitaxel	60-70	AKT serine/threonine kinase 1	Homo sapiens	114-117
34229754-13	2021	The combination of apatinib and CQ sensitized ESCC cells to paclitaxel to induce apoptosis through the IRE-1alpha-AKT-mTOR signaling pathway, thus providing the basis for its use in innovative anticancer therapeutic strategies.	Paclitaxel	60-70	mechanistic target of rapamycin kinase	Homo sapiens	118-122
34386337-1	2021	A commercial albumin-bound paclitaxel nano-formulation has been considered a gold standard against breast cancer.	Paclitaxel	27-37	albumin	Homo sapiens	13-20
34386337-3	2021	Herein, we report an albumin-bound tumor redox-responsive paclitaxel prodrugs nano-delivery strategy.	Paclitaxel	58-68	albumin	Homo sapiens	21-28
34386337-4	2021	Using diverse linkages (thioether bond and disulfide bond), paclitaxel (PTX) was conjugated with an albumin-binding maleimide (MAL) functional group.	Paclitaxel	60-70	albumin	Homo sapiens	100-107
34386337-4	2021	Using diverse linkages (thioether bond and disulfide bond), paclitaxel (PTX) was conjugated with an albumin-binding maleimide (MAL) functional group.	Paclitaxel	72-75	albumin	Homo sapiens	100-107
34386337-6	2021	By immediately binding to blood circulating albumin after intravenous administration, NPs are rapidly disintegrated into small prodrug/albumin nanoaggregates in vivo, facilitating PTX prodrugs accumulation in the tumor region via albumin receptor-mediated active targeting.	Paclitaxel	180-183	albumin	Homo sapiens	44-51
34386337-6	2021	By immediately binding to blood circulating albumin after intravenous administration, NPs are rapidly disintegrated into small prodrug/albumin nanoaggregates in vivo, facilitating PTX prodrugs accumulation in the tumor region via albumin receptor-mediated active targeting.	Paclitaxel	180-183	albumin	Homo sapiens	135-142
34386337-6	2021	By immediately binding to blood circulating albumin after intravenous administration, NPs are rapidly disintegrated into small prodrug/albumin nanoaggregates in vivo, facilitating PTX prodrugs accumulation in the tumor region via albumin receptor-mediated active targeting.	Paclitaxel	180-183	albumin	Homo sapiens	230-237
34285578-0	2021	Silencing of circHIPK3 Sensitizes Paclitaxel-Resistant Breast Cancer Cells to Chemotherapy by Regulating HK2 Through Targeting miR-1286.	Paclitaxel	34-44	homeodomain interacting protein kinase 3	Homo sapiens	13-22
34285578-11	2021	Results: Our results showed that circHIPK3 was up-regulated in PTX-resistant BC tissues and cells compared with the sensitive counterparts.	Paclitaxel	63-66	homeodomain interacting protein kinase 3	Homo sapiens	33-42
34285578-12	2021	The silencing of circHIPK3 promoted PTX sensitivity of PTX-resistant BC cells in vitro and in vivo.	Paclitaxel	36-39	homeodomain interacting protein kinase 3	Homo sapiens	17-26
34285578-12	2021	The silencing of circHIPK3 promoted PTX sensitivity of PTX-resistant BC cells in vitro and in vivo.	Paclitaxel	55-58	homeodomain interacting protein kinase 3	Homo sapiens	17-26
34285578-15	2021	The increased expression of miR-1286 sensitized PTX-resistant BC cells to PTX in vitro by down-regulating HK2.	Paclitaxel	48-51	microRNA 1286	Homo sapiens	28-36
34285578-15	2021	The increased expression of miR-1286 sensitized PTX-resistant BC cells to PTX in vitro by down-regulating HK2.	Paclitaxel	74-77	microRNA 1286	Homo sapiens	28-36
34285578-16	2021	Conclusion: Our findings demonstrated that the silencing of circHIPK3 sensitized PTX-resistant BC cells to PTX therapy at least in part via the regulation of the miR-1286/HK2 axis.	Paclitaxel	81-84	homeodomain interacting protein kinase 3	Homo sapiens	60-69
34285578-16	2021	Conclusion: Our findings demonstrated that the silencing of circHIPK3 sensitized PTX-resistant BC cells to PTX therapy at least in part via the regulation of the miR-1286/HK2 axis.	Paclitaxel	81-84	microRNA 1286	Homo sapiens	162-170
34285578-16	2021	Conclusion: Our findings demonstrated that the silencing of circHIPK3 sensitized PTX-resistant BC cells to PTX therapy at least in part via the regulation of the miR-1286/HK2 axis.	Paclitaxel	107-110	homeodomain interacting protein kinase 3	Homo sapiens	60-69
34285578-16	2021	Conclusion: Our findings demonstrated that the silencing of circHIPK3 sensitized PTX-resistant BC cells to PTX therapy at least in part via the regulation of the miR-1286/HK2 axis.	Paclitaxel	107-110	microRNA 1286	Homo sapiens	162-170
34131286-12	2021	Last, drug response analysis revealed lncRNA ENSG00000230082 (PRRT3-AS1) is a potential resistance biomarker for paclitaxel in BRCA treatment.	Paclitaxel	113-123	proline rich transmembrane protein 3	Homo sapiens	62-67
34280009-0	2021	ABCB1 Single Nucleotide Polymorphism Genotypes as Predictors of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer.	Paclitaxel	64-74	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
34280009-5	2021	Methods: We extracted genomic DNA from samples collected from 92 Egyptian female breast cancer patients receiving weekly paclitaxel and used them to genotype ABCB1 G1236A (rs1128503) and ABCB1 G3435A (rs1045642).	Paclitaxel	121-131	ATP binding cassette subfamily B member 1	Homo sapiens	158-163
34280009-5	2021	Methods: We extracted genomic DNA from samples collected from 92 Egyptian female breast cancer patients receiving weekly paclitaxel and used them to genotype ABCB1 G1236A (rs1128503) and ABCB1 G3435A (rs1045642).	Paclitaxel	121-131	ATP binding cassette subfamily B member 1	Homo sapiens	187-192
34280009-13	2021	Conclusion: The ABCB1 G1236A, BSA, and history of diabetes are valid predictors of PIPN, which can enable the personalization of paclitaxel dosing to prevent PIPN.	Paclitaxel	129-139	ATP binding cassette subfamily B member 1	Homo sapiens	16-21
34097831-0	2021	Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel.	Paclitaxel	116-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-59
34256895-0	2021	Identifying prognostic factors associated with overall survival in second-line paclitaxel plus ramucirumab treated human epidermal growth factor receptor 2-negative advanced/recurrent gastric cancer.	Paclitaxel	79-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-155
34256895-1	2021	This study aimed to identify the overall survival prolongation index in patients who received paclitaxel plus ramucirumab as second line chemotherapy for human epidermal growth factor receptor (HER) 2-negative advanced/ recurrent gastric cancer (AGC).	Paclitaxel	94-104	epidermal growth factor receptor	Homo sapiens	160-192
34256895-1	2021	This study aimed to identify the overall survival prolongation index in patients who received paclitaxel plus ramucirumab as second line chemotherapy for human epidermal growth factor receptor (HER) 2-negative advanced/ recurrent gastric cancer (AGC).	Paclitaxel	94-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-200
34206743-1	2021	UNC-45A (Protein unc-45 homolog A) is a cytoskeletal-associated protein with a dual and non-mutually exclusive role as a regulator of the actomyosin system and a Microtubule (MT)-destabilizing protein, which is overexpressed in human cancers including in ovarian cancer patients resistant to the MT-stabilizing drug paclitaxel.	Paclitaxel	316-326	unc-45 myosin chaperone A	Homo sapiens	0-7
34206743-1	2021	UNC-45A (Protein unc-45 homolog A) is a cytoskeletal-associated protein with a dual and non-mutually exclusive role as a regulator of the actomyosin system and a Microtubule (MT)-destabilizing protein, which is overexpressed in human cancers including in ovarian cancer patients resistant to the MT-stabilizing drug paclitaxel.	Paclitaxel	316-326	unc-45 myosin chaperone A	Homo sapiens	9-33
34097831-2	2021	Cytochrome P450 enzymes CYP3A4 and CYP2C8, which metabolically inactivate PTX in hepatic tissue, are overexpressed in malignant breast tissues.	Paclitaxel	74-77	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30
34097831-3	2021	CYP3A4 expression correlates with PTX therapy failure and poor outcomes, though no direct evidence of CYP3A4 contributing to PTX sensitivity exists.	Paclitaxel	34-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
34097831-5	2021	Using a photo-activated CO-releasing molecule, we have assessed the ability of CO to alter the pharmacokinetics of PTX in breast cancer cells via inhibition of CYP3A4/2C8 and determined that CO does enhance sensitivity of breast cancer cells to PTX.	Paclitaxel	115-118	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	160-170
34097831-6	2021	Inhibition of CYP3A4/2C8 by CO could therefore be a promising therapeutic strategy to enhance PTX response in breast cancer.	Paclitaxel	94-97	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-24
34284965-13	2022	CONCLUSION: Our work demonstrated that CXCL8 may be a potential molecule to be targeted for the treatment of PTX-resistant TNBC.	Paclitaxel	109-112	C-X-C motif chemokine ligand 8	Homo sapiens	39-44
34202848-0	2021	Paclitaxel-Loaded Folate-Targeted Albumin-Alginate Nanoparticles Crosslinked with Ethylenediamine.	Paclitaxel	0-10	albumin	Homo sapiens	34-41
34284965-0	2022	CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers.	Paclitaxel	35-45	C-X-C motif chemokine ligand 8	Homo sapiens	0-5
34284965-1	2022	BACKGROUND: This study aimed to demonstrate CXCL8 expression in TNBC tissues and cells, and elucidate the functional mechanism of CXCL8 in paclitaxel (PTX)-resistant TNBC.	Paclitaxel	139-149	C-X-C motif chemokine ligand 8	Homo sapiens	44-49
34284965-1	2022	BACKGROUND: This study aimed to demonstrate CXCL8 expression in TNBC tissues and cells, and elucidate the functional mechanism of CXCL8 in paclitaxel (PTX)-resistant TNBC.	Paclitaxel	139-149	C-X-C motif chemokine ligand 8	Homo sapiens	130-135
34284965-1	2022	BACKGROUND: This study aimed to demonstrate CXCL8 expression in TNBC tissues and cells, and elucidate the functional mechanism of CXCL8 in paclitaxel (PTX)-resistant TNBC.	Paclitaxel	151-154	C-X-C motif chemokine ligand 8	Homo sapiens	44-49
34284965-1	2022	BACKGROUND: This study aimed to demonstrate CXCL8 expression in TNBC tissues and cells, and elucidate the functional mechanism of CXCL8 in paclitaxel (PTX)-resistant TNBC.	Paclitaxel	151-154	C-X-C motif chemokine ligand 8	Homo sapiens	130-135
34168432-1	2021	Background: The aim of this work was to develop a novel and feasible modification strategy by utilizing the supramolecular effect of 2-hydroxypropyl-beta-cyclodextrin (2-HP-beta-CD) for enhancing the biological transport efficiency of paclitaxel (PTX)-loaded poly(lactide-co-glycolide) (PLGA) nanoparticles.	Paclitaxel	235-245	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	173-180
34284965-5	2022	The protein expression and distribution of CXCL8 were examined by immunohistochemistry, MTT assay and colony formation assay were performed to determine cell viability of TNBC cells treated with PTX.	Paclitaxel	195-198	C-X-C motif chemokine ligand 8	Homo sapiens	43-48
34284965-10	2022	CXCL8 was upregulated in PTX-resistant TNBC cells.	Paclitaxel	25-28	C-X-C motif chemokine ligand 8	Homo sapiens	0-5
34284965-11	2022	Knockdown of CXCL8 increased the sensitivity of TNBC cells to PTX.	Paclitaxel	62-65	C-X-C motif chemokine ligand 8	Homo sapiens	13-18
34284965-12	2022	Mechanically, CXCL8 deficiency regulated PTX resistance in TNBC cells via cell apoptosis signaling pathway.	Paclitaxel	41-44	C-X-C motif chemokine ligand 8	Homo sapiens	14-19
34145425-0	2021	MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.	Paclitaxel	44-54	heat shock protein family A (Hsp70) member 5	Homo sapiens	68-73
34145425-0	2021	MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.	Paclitaxel	44-54	AKT serine/threonine kinase 1	Homo sapiens	91-94
34145425-4	2021	Our previous study showed that glucose-regulated protein 78 (GRP78) is involved in the resistance of OC cells to PTX.	Paclitaxel	113-116	heat shock protein family A (Hsp70) member 5	Homo sapiens	31-59
34145425-4	2021	Our previous study showed that glucose-regulated protein 78 (GRP78) is involved in the resistance of OC cells to PTX.	Paclitaxel	113-116	heat shock protein family A (Hsp70) member 5	Homo sapiens	61-66
34145425-7	2021	Here, we show that miR-181c, predicted to target GRP78, was downregulated in PTX-resistant OC cells and tissues.	Paclitaxel	77-80	heat shock protein family A (Hsp70) member 5	Homo sapiens	49-54
34145425-9	2021	Overexpression of miR-181c sensitized resistant OC to PTX by inhibiting the PI3K/Akt pathway in vitro and in vivo.	Paclitaxel	54-57	AKT serine/threonine kinase 1	Homo sapiens	81-84
34145425-10	2021	Taken together, our findings indicate that the delivery of miR-181c can efficiently suppress GRP78 expression and GRP78-mediated PTX resistance in OC and suggest that this strategy has therapeutic potential.	Paclitaxel	129-132	heat shock protein family A (Hsp70) member 5	Homo sapiens	114-119
34168432-1	2021	Background: The aim of this work was to develop a novel and feasible modification strategy by utilizing the supramolecular effect of 2-hydroxypropyl-beta-cyclodextrin (2-HP-beta-CD) for enhancing the biological transport efficiency of paclitaxel (PTX)-loaded poly(lactide-co-glycolide) (PLGA) nanoparticles.	Paclitaxel	247-250	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	173-180
34168432-2	2021	Methods: PTX-loaded 2-HP-beta-CD-modified PLGA nanoparticles (2-HP-beta-CD/PLGA NPs) were prepared using the modified emulsion method.	Paclitaxel	9-12	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	25-32
34168432-2	2021	Methods: PTX-loaded 2-HP-beta-CD-modified PLGA nanoparticles (2-HP-beta-CD/PLGA NPs) were prepared using the modified emulsion method.	Paclitaxel	9-12	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	67-74
34168432-6	2021	Pharmacokinetic analysis showed that the AUC value of 2-HP-beta-CD/PLGA NPs was 2.4-fold higher than commercial Taxol  and 1.7-fold higher than plain PLGA NPs.	Paclitaxel	112-117	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	59-66
34168432-8	2021	Conclusion: The results of this study suggest that the formulation that contains 2-HP-beta-CD can prolong PTX release, enhance drug transport efficiency and serve as a potential tumor targeting system for PTX.	Paclitaxel	106-109	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	86-93
34168432-8	2021	Conclusion: The results of this study suggest that the formulation that contains 2-HP-beta-CD can prolong PTX release, enhance drug transport efficiency and serve as a potential tumor targeting system for PTX.	Paclitaxel	205-208	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	86-93
34198613-2	2021	The aim of this study was to determine the effect of paclitaxel (PTX) and doxorubicin (DOX) therapy on the betaIII-tubulin, carbonic anhydrase IX (CA IX), and survivin expression in chemically-induced rat mammary tumors.	Paclitaxel	53-63	carbonic anhydrase 9	Rattus norvegicus	124-145
34198613-2	2021	The aim of this study was to determine the effect of paclitaxel (PTX) and doxorubicin (DOX) therapy on the betaIII-tubulin, carbonic anhydrase IX (CA IX), and survivin expression in chemically-induced rat mammary tumors.	Paclitaxel	53-63	carbonic anhydrase 9	Rattus norvegicus	147-152
34198613-2	2021	The aim of this study was to determine the effect of paclitaxel (PTX) and doxorubicin (DOX) therapy on the betaIII-tubulin, carbonic anhydrase IX (CA IX), and survivin expression in chemically-induced rat mammary tumors.	Paclitaxel	65-68	carbonic anhydrase 9	Rattus norvegicus	124-145
34198613-2	2021	The aim of this study was to determine the effect of paclitaxel (PTX) and doxorubicin (DOX) therapy on the betaIII-tubulin, carbonic anhydrase IX (CA IX), and survivin expression in chemically-induced rat mammary tumors.	Paclitaxel	65-68	carbonic anhydrase 9	Rattus norvegicus	147-152
34198613-8	2021	The expression of betaIII-tubulin, CA IX, and survivin increased significantly after treatment with both cytostatics (PTX and DOX).	Paclitaxel	118-121	carbonic anhydrase 9	Rattus norvegicus	35-40
34094655-8	2021	Accordingly, we review several methods that have been used to target SETDB1, such as using Mithramycin A, Mithralog EC-8042, 3"-deazaneplanocin A (DZNep), and paclitaxel.	Paclitaxel	159-169	SET domain bifurcated histone lysine methyltransferase 1	Homo sapiens	69-75
33735118-14	2021	MiR-149-5p overexpression suppressed paclitaxel resistance and cell progression in paclitaxel-resistant ovarian cancer cells by interacting with SIK2.	Paclitaxel	37-47	salt inducible kinase 2	Homo sapiens	145-149
33735118-14	2021	MiR-149-5p overexpression suppressed paclitaxel resistance and cell progression in paclitaxel-resistant ovarian cancer cells by interacting with SIK2.	Paclitaxel	83-93	salt inducible kinase 2	Homo sapiens	145-149
34093893-6	2021	There was a good response to re-challenge 177Lu-PSMA therapy and low-dose docetaxel (Taxol-177Lu-PSMA) with no recorded tumour resistance.	Paclitaxel	85-90	folate hydrolase 1	Homo sapiens	97-101
34064007-8	2021	Thereby, these bioinspired nanoparticles charged with both trastuzumab and paclitaxel may represent an excellent approach to improve current HER2-positive breast cancer therapies.	Paclitaxel	75-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-145
34066839-0	2021	Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma.	Paclitaxel	59-69	heme oxygenase 1	Mus musculus	0-16
34066839-3	2021	We present evidence that nab-paclitaxel-gemcitabine (NPG) and/or a hypoxic tumor microenvironment (TME) up-regulate heme oxygenase-1 (HO-1), providing a survival advantage for tumors.	Paclitaxel	29-39	heme oxygenase 1	Mus musculus	116-132
34066839-3	2021	We present evidence that nab-paclitaxel-gemcitabine (NPG) and/or a hypoxic tumor microenvironment (TME) up-regulate heme oxygenase-1 (HO-1), providing a survival advantage for tumors.	Paclitaxel	29-39	heme oxygenase 1	Mus musculus	134-138
34164520-18	2021	Restoration of Nox1 in Fbxw7-overexpressed TR colon cancer cells significantly recovered the Taxol resistance, which could be further overridden by glycolysis inhibition.	Paclitaxel	93-98	coagulation factor II thrombin receptor	Homo sapiens	43-45
34393439-3	2021	Hence, we report the binding features of 10-Deacetyltaxol, 7-Epi-10-deacetyltaxol, 7-Epi-Taxol and 6alpha-Hydroxypaclitaxel with mTOR for further consideration.	Paclitaxel	83-94	mechanistic target of rapamycin kinase	Homo sapiens	129-133
34276826-8	2021	P-gp and CYP450 inhibitors incorporation further improved the oral bioavailability of PTX to 42.60%, 8-fold increase compared with that of PTX itself (4.75%).	Paclitaxel	86-89	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
34276826-8	2021	P-gp and CYP450 inhibitors incorporation further improved the oral bioavailability of PTX to 42.60%, 8-fold increase compared with that of PTX itself (4.75%).	Paclitaxel	139-142	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
34268990-0	2021	Sequential anthracycline and weekly paclitaxel might be more effective compared to docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients.	Paclitaxel	36-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
34773731-9	2021	In presence of Taxol, TSA induced four-fold increase in the expression of HDAC1 and downregulated Dnmt1&3alpha genes.	Paclitaxel	15-20	histone deacetylase 1	Homo sapiens	74-79
34164520-0	2021	Attenuating glucose metabolism by Fbxw7 promotes Taxol sensitivity of colon cancer cells through downregulating NADPH oxidase 1 (Nox1).	Paclitaxel	49-54	F-box and WD repeat domain containing 7	Homo sapiens	34-39
34164520-5	2021	However, the biological roles and mechanisms of Fbxw7 in Taxol resistance are still under investigation.	Paclitaxel	57-62	F-box and WD repeat domain containing 7	Homo sapiens	48-53
34164520-11	2021	Results: Overexpression of Fbxw7 sensitized colon cancer cells to Taxol.	Paclitaxel	66-71	F-box and WD repeat domain containing 7	Homo sapiens	27-32
34164520-13	2021	From the established Taxol-resistant (TR) cell line from HCT-116, Fbxw7 was found to be markedly downregulated in HCT-116 TR cells.	Paclitaxel	21-26	coagulation factor II thrombin receptor	Homo sapiens	38-40
34164520-13	2021	From the established Taxol-resistant (TR) cell line from HCT-116, Fbxw7 was found to be markedly downregulated in HCT-116 TR cells.	Paclitaxel	21-26	F-box and WD repeat domain containing 7	Homo sapiens	66-71
34164520-13	2021	From the established Taxol-resistant (TR) cell line from HCT-116, Fbxw7 was found to be markedly downregulated in HCT-116 TR cells.	Paclitaxel	21-26	coagulation factor II thrombin receptor	Homo sapiens	122-124
34164520-17	2021	Finally, rescue experiments demonstrated that the Fbxw7-promoted Taxol sensitivity was partially through the Nox1-glycolysis axis.	Paclitaxel	65-70	F-box and WD repeat domain containing 7	Homo sapiens	50-55
34164520-18	2021	Restoration of Nox1 in Fbxw7-overexpressed TR colon cancer cells significantly recovered the Taxol resistance, which could be further overridden by glycolysis inhibition.	Paclitaxel	93-98	F-box and WD repeat domain containing 7	Homo sapiens	23-28
34094037-10	2021	PD-1 expression was significantly (P<0.05) lower in the group treated with paclitaxel and carboplatin combination as compared with the placebo.	Paclitaxel	75-85	programmed cell death 1	Mus musculus	0-4
34393439-2	2021	Therefore, it is of interest to study the molecular docking-based binding of paclitaxel (a FDA approved drug for oral cancer) and its analogues with mTOR.	Paclitaxel	77-87	mechanistic target of rapamycin kinase	Homo sapiens	149-153
35614289-5	2022	Among non-cytotoxic synthetic analogs (1-14), several derivatives effectively and significantly sensitized MDR cells by interfering with the drug transport function of P-gp to three anticancer drugs, vincristine, paclitaxel, and doxorubicin.	Paclitaxel	213-223	ATP binding cassette subfamily B member 1	Homo sapiens	168-172
34393690-13	2021	Unlike the alphavbeta3 positive, but caspase-3 negative breast cancer MCF-7 cells, treatment of the alphavbeta3 and caspase-3 positive lung cancer A549 cells with Paclitaxel showed significant fluorescence enhancement within 30 minutes, which correlated with caspase-3 specific activation of LS422-AuNPs fluorescence.	Paclitaxel	163-173	caspase 3	Homo sapiens	37-46
34393690-13	2021	Unlike the alphavbeta3 positive, but caspase-3 negative breast cancer MCF-7 cells, treatment of the alphavbeta3 and caspase-3 positive lung cancer A549 cells with Paclitaxel showed significant fluorescence enhancement within 30 minutes, which correlated with caspase-3 specific activation of LS422-AuNPs fluorescence.	Paclitaxel	163-173	caspase 3	Homo sapiens	116-125
34393690-13	2021	Unlike the alphavbeta3 positive, but caspase-3 negative breast cancer MCF-7 cells, treatment of the alphavbeta3 and caspase-3 positive lung cancer A549 cells with Paclitaxel showed significant fluorescence enhancement within 30 minutes, which correlated with caspase-3 specific activation of LS422-AuNPs fluorescence.	Paclitaxel	163-173	caspase 3	Homo sapiens	259-268
34308901-7	2021	Further investigation using an in vitro neuron model of Abeta-induced axonal transport disruption confirmed PTX prevented axonal transport deficits.	Paclitaxel	108-111	histocompatibility 2, class II antigen A, beta 1	Mus musculus	56-61
35533911-1	2022	Wight et Arn reversed paclitaxel-induced MDR in vitro and in vivo by inhibiting both P-gp and MRP2.	Paclitaxel	22-32	ATP binding cassette subfamily B member 1	Homo sapiens	85-89
34818258-0	2021	Overexpression of miR-138-5p Sensitizes Taxol-Resistant Epithelial Ovarian Cancer Cells through Targeting Cyclin-Dependent Kinase 6.	Paclitaxel	40-45	cyclin dependent kinase 6	Homo sapiens	106-131
34818258-12	2021	Finally, rescue experiments clearly elucidated restoration of CDK6 in miR-138-5p-overexpressing ovarian cancer cells successfully recovered the Taxol resistance.	Paclitaxel	144-149	cyclin dependent kinase 6	Homo sapiens	62-66
34818258-13	2021	CONCLUSION: In summary, these findings suggest important molecular mechanisms for the miR-138-5p-mediated Taxol sensitivity of ovarian cancer via directly targeting CDK6, suggesting miR-138-5p is an effective therapeutic target for the noncoding RNA-based anti-chemoresistance treatment.	Paclitaxel	106-111	cyclin dependent kinase 6	Homo sapiens	165-169
35533911-11	2022	RESULTS: Compared to parental cells, HeLa/Tax cells overexpress P-gp and MRP2 and are approximately 100-360 fold more resistant to the anticancer drugs PTX, docetaxel, and vinblastine.	Paclitaxel	152-155	ATP binding cassette subfamily B member 1	Homo sapiens	64-68
35533911-13	2022	Knockdown of P-gp with small interfering RNA partially reversed MT2-induced sensitivity to PTX in HeLa/Tax cells.	Paclitaxel	91-94	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
35533911-16	2022	In nude mice bearing HeLa/Tax xenografts, the combination treatment with MT2 and PTX exerted a synergistic inhibitory effect on the growth of tumors and the expression of P-gp and MRP2 without increasing toxicity.	Paclitaxel	81-84	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	180-184
35509138-4	2022	In response to paclitaxel, females had reduced mechanical hypersensitivity and a greater frequency of anti-inflammatory CD4+ T cells (FoxP3, IL-10, IL-4) in the DRG than male and ovariectomized female mice.	Paclitaxel	15-25	interleukin 10	Mus musculus	141-146
35614037-0	2022	Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions.	Paclitaxel	0-10	complement component 5a receptor 1	Mus musculus	31-36
35614037-2	2022	Here, we demonstrated that paclitaxel can bind and activate complement component 5a receptor 1 (C5aR1) and that this binding is crucial in the etiology of paclitaxel-induced CIPN and anaphylaxis.	Paclitaxel	27-37	complement component 5a receptor 1	Mus musculus	96-101
35614037-2	2022	Here, we demonstrated that paclitaxel can bind and activate complement component 5a receptor 1 (C5aR1) and that this binding is crucial in the etiology of paclitaxel-induced CIPN and anaphylaxis.	Paclitaxel	155-165	complement component 5a receptor 1	Mus musculus	96-101
35614037-4	2022	By in vitro studies, we confirmed the specific and competitive nature of the C5aR1-paclitaxel binding and found that it triggers intracellularly the NFkB/P38 pathway and c-Fos.	Paclitaxel	83-93	complement component 5a receptor 1	Mus musculus	77-82
35614037-5	2022	In F11 neuronal cells and rat dorsal root ganglia, C5aR1 inhibition protected from paclitaxel-induced neuropathological effects, while in paclitaxel-treated mice, the absence (knock-out mice) or the inhibition of C5aR1 significantly ameliorated CIPN symptoms-in terms of cold and mechanical allodynia-and reduced the chronic pathological state in the paw.	Paclitaxel	83-93	complement component 5a receptor 1	Mus musculus	213-218
35614037-6	2022	Finally, we found that C5aR1 inhibition can counteract paclitaxel-induced anaphylactic cytokine release in macrophages in vitro, as well as the onset of HSRs in mice.	Paclitaxel	55-65	complement component 5a receptor 1	Mus musculus	23-28
35614037-7	2022	Altogether these data identified C5aR1 as a key mediator and a new potential pharmacological target for the prevention and treatment of CIPN and HSRs induced by paclitaxel.	Paclitaxel	161-171	complement component 5a receptor 1	Mus musculus	33-38
35628603-7	2022	In SKOV3, but not in CAOV3 cells, syndecan-3 depletion reduced cell viability both under basal conditions and under chemotherapy with cisplatin, or cisplatin and paclitaxel.	Paclitaxel	162-172	syndecan 3	Homo sapiens	34-44
35597872-10	2022	CONCLUSIONS: EGFR signaling-mediated G6PD expression plays a pivotal role in paclitaxel resistance, highlighting the potential of targeting EGFR to overcome paclitaxel resistance in TNBC and NSCLC cells overexpressing G6PD.	Paclitaxel	157-167	epidermal growth factor receptor	Homo sapiens	13-17
35597872-10	2022	CONCLUSIONS: EGFR signaling-mediated G6PD expression plays a pivotal role in paclitaxel resistance, highlighting the potential of targeting EGFR to overcome paclitaxel resistance in TNBC and NSCLC cells overexpressing G6PD.	Paclitaxel	157-167	epidermal growth factor receptor	Homo sapiens	140-144
35597872-0	2022	Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.	Paclitaxel	46-56	epidermal growth factor receptor	Homo sapiens	10-42
35597872-8	2022	Blockade of the EGFR pathway inhibited G6PD expression and sensitised those paclitaxel-resistant cells to paclitaxel treatment in vitro and in vivo.	Paclitaxel	76-86	epidermal growth factor receptor	Homo sapiens	16-20
35597872-8	2022	Blockade of the EGFR pathway inhibited G6PD expression and sensitised those paclitaxel-resistant cells to paclitaxel treatment in vitro and in vivo.	Paclitaxel	106-116	epidermal growth factor receptor	Homo sapiens	16-20
35597872-10	2022	CONCLUSIONS: EGFR signaling-mediated G6PD expression plays a pivotal role in paclitaxel resistance, highlighting the potential of targeting EGFR to overcome paclitaxel resistance in TNBC and NSCLC cells overexpressing G6PD.	Paclitaxel	77-87	epidermal growth factor receptor	Homo sapiens	13-17
35597872-10	2022	CONCLUSIONS: EGFR signaling-mediated G6PD expression plays a pivotal role in paclitaxel resistance, highlighting the potential of targeting EGFR to overcome paclitaxel resistance in TNBC and NSCLC cells overexpressing G6PD.	Paclitaxel	77-87	epidermal growth factor receptor	Homo sapiens	140-144
35628603-8	2022	While analysis of the SIOVDB database did not reveal differences in Syndecan-3 expression between patients, sensitive, resistant or refractory to chemotherapy, KM Plotter analysis of 1435 ovarian cancer patients revealed that high syndecan-3 expression was associated with reduced survival in patients treated with taxol and platin.	Paclitaxel	315-320	syndecan 3	Homo sapiens	231-241
35583817-0	2022	Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Antagonist, with Nab-Paclitaxel in Solid Tumors.	Paclitaxel	136-146	nuclear receptor subfamily 3 group C member 1	Homo sapiens	91-114
35588308-8	2022	Treatment with AVB-500 + paclitaxel decreased AKT signaling which resulted in a decrease in basal glycolysis.	Paclitaxel	25-35	AKT serine/threonine kinase 1	Homo sapiens	46-49
35595817-5	2022	Low VSNL1 and CD44 expression predicted the benefit of sequential paclitaxel treatment for all three endpoints.	Paclitaxel	66-76	visinin like 1	Homo sapiens	4-9
35595817-7	2022	This is the first study to identify VSNL1 and CD44 RNA expression levels as biomarkers for selecting GC patients that are likely to benefit from sequential paclitaxel treatment followed by fluorinated-pyrimidine-based adjuvant chemotherapy.	Paclitaxel	156-166	visinin like 1	Homo sapiens	36-41
35634452-9	2022	However, whole cell voltage clamp experiments in TRPM8 expressing TRG neurons indicated that both oxaliplatin and paclitaxel increased Hyperpolarization-Activated Cyclic Nucleotide-Gated channel (HCN), voltage gated sodium channel (Nav), and menthol evoked TRPM8 currents.	Paclitaxel	114-124	sodium channel, voltage-gated, type X, alpha	Mus musculus	202-230
35526525-0	2022	Cobimetinib Sensitizes Cervical Cancer to Paclitaxel via Suppressing Paclitaxel-Induced ERK Activation.	Paclitaxel	42-52	mitogen-activated protein kinase 1	Mus musculus	88-91
35534752-2	2022	METHODS: Using a Markov model, the clinical effectiveness of managing HR+, HER2- MBC in postmenopausal women with either a CDK4/6i (either ribociclib or palbociclib) and fulvestrant, fulvestrant alone, and chemotherapy (single-agent paclitaxel or capecitabine) was measured in terms of quality-adjusted life-years (QALYs).	Paclitaxel	233-243	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
35526525-0	2022	Cobimetinib Sensitizes Cervical Cancer to Paclitaxel via Suppressing Paclitaxel-Induced ERK Activation.	Paclitaxel	69-79	mitogen-activated protein kinase 1	Mus musculus	88-91
35526525-9	2022	In addition, paclitaxel activates ERK in cervical cancer cells, and this can be reversed by cobimetinib.	Paclitaxel	13-23	mitogen-activated protein kinase 1	Mus musculus	34-37
35571619-13	2022	Finally, the rescue of miR-33b-5p in DANCR-overexpressing PC3-TXR cells successfully overrode the DANCR-promoted Taxol resistance.	Paclitaxel	113-118	differentiation antagonizing non-protein coding RNA	Homo sapiens	37-42
35571619-0	2022	lncRNA-DANCR Promotes Taxol Resistance of Prostate Cancer Cells through Modulating the miR-33b-5p-LDHA Axis.	Paclitaxel	22-27	lactate dehydrogenase A	Homo sapiens	98-102
35571619-5	2022	However, the precise roles of DANCR in the Taxol sensitivity of PCa and the underlying molecular mechanisms remain largely unknown.	Paclitaxel	43-48	differentiation antagonizing non-protein coding RNA	Homo sapiens	30-35
35571619-7	2022	Silencing DANCR or overexpressing miR-33b-5p effectively enhanced the Taxol sensitivity of PCa cells.	Paclitaxel	70-75	differentiation antagonizing non-protein coding RNA	Homo sapiens	10-15
35571619-13	2022	Finally, the rescue of miR-33b-5p in DANCR-overexpressing PC3-TXR cells successfully overrode the DANCR-promoted Taxol resistance.	Paclitaxel	113-118	differentiation antagonizing non-protein coding RNA	Homo sapiens	98-103
35437787-6	2022	MicroRNAs (miRNAs) can have opposite effects on PTX resistance (stimulation or inhibition) via influencing YES1, SK2, MRP1, and STAT3.	Paclitaxel	48-51	signal transducer and activator of transcription 3	Homo sapiens	128-133
35184686-9	2022	MiR-144-5p overexpression and PTX further up-regulated E-cadherin level and down-regulated those of MMP-9 and N-cadherin in thyroid carcinoma cells.	Paclitaxel	30-33	cadherin 1	Mus musculus	55-65
35015188-1	2022	BACKGROUND: A subgroup analysis of data from a nationwide study (KCSG-ST19-16) was performed to evaluate the efficacy and safety of second-line ramucirumab plus paclitaxel treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma.	Paclitaxel	161-171	erb-b2 receptor tyrosine kinase 2	Homo sapiens	205-239
35015188-1	2022	BACKGROUND: A subgroup analysis of data from a nationwide study (KCSG-ST19-16) was performed to evaluate the efficacy and safety of second-line ramucirumab plus paclitaxel treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma.	Paclitaxel	161-171	erb-b2 receptor tyrosine kinase 2	Homo sapiens	241-245
35015188-5	2022	The objective response rate to ramucirumab plus paclitaxel treatment was significantly higher in patients with HER2-positive disease compared to those with HER2-negative disease (23.0% (95% confidence interval (CI), 15.9-30.1) vs. 15.1% (95% CI, 12.3-17.9), p = 0.025).	Paclitaxel	48-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
35015188-8	2022	CONCLUSIONS: In patients with HER2-positive gastric or GEJ adenocarcinoma, the objective response rate to second-line treatment with ramucirumab plus paclitaxel was significantly higher compared to patients with HER2-negative disease.	Paclitaxel	150-160	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
35506169-6	2022	The depletion and pharmacological inhibition of USP9X by WP1130, an inhibitor of USP9X, downregulate endogenous Snail1 protein, inhibit cell migration, invasion, metastasis, and increase cellular sensitivity to cisplatin and paclitaxel both in vitro and in vivo, whereas the reconstitution of Snail1 in cells with USP9X depletion at least partially reverses these phenotypes.	Paclitaxel	225-235	snail family transcriptional repressor 1	Homo sapiens	112-118
35477477-9	2022	CONCLUSIONS: Our studies suggested that high expression of RIPK2 is related to Taxol resistance in serous ovarian cancer, and that RIPK2 induces Taxol resistance through NOD1/RIPK2/NF-kappaB inflammatory pathway activation and tumor microenvironment changes.	Paclitaxel	145-150	nuclear factor kappa B subunit 1	Homo sapiens	181-190
35405088-21	2022	INTERPRETATION: The WSG-ADAPT-HER2+/HR- trial showed good survival rates in patients with a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel.	Paclitaxel	201-211	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
35122700-2	2022	The phase IB/II TAKTIC trial (NCT01980277) has shown that combining a dual AKT and p70 ribosomal protein S6 kinase (p70S6K) inhibitor (LY2780301) taken orally with weekly paclitaxel in HER2-negative advanced breast cancer is feasible, with preliminary evidence of efficacy.	Paclitaxel	171-181	AKT serine/threonine kinase 1	Homo sapiens	75-78
35365420-7	2022	Of 100 patients who received neoadjuvant chemotherapy (NAC), high ADAM12 expression was significantly associated with poor DFS in a subset of patients treated with the nab-paclitaxel (PTX) neoadjuvant regimen (P = 0.03), whereas the prognostic value of ADAM12 was not evident in patients not treated with nab-PTX (P = 0.12).	Paclitaxel	172-182	ADAM metallopeptidase domain 12	Homo sapiens	66-72
35365420-7	2022	Of 100 patients who received neoadjuvant chemotherapy (NAC), high ADAM12 expression was significantly associated with poor DFS in a subset of patients treated with the nab-paclitaxel (PTX) neoadjuvant regimen (P = 0.03), whereas the prognostic value of ADAM12 was not evident in patients not treated with nab-PTX (P = 0.12).	Paclitaxel	172-182	ADAM metallopeptidase domain 12	Homo sapiens	253-259
35348291-0	2022	Circ_0011292 knockdown mitigates progression and drug resistance in PTX-resistant non-small-cell lung cancer cells by regulating miR-433-3p/CHEK1 axis.	Paclitaxel	68-71	checkpoint kinase 1	Homo sapiens	140-145
35348291-14	2022	Circ_0011292 or CHEK1 knockdown enhanced PTX sensitivity and cell apoptosis, and repressed cell proliferation, migration, and invasion in PTX-resistant NSCLC cells.	Paclitaxel	41-44	checkpoint kinase 1	Homo sapiens	16-21
35348291-14	2022	Circ_0011292 or CHEK1 knockdown enhanced PTX sensitivity and cell apoptosis, and repressed cell proliferation, migration, and invasion in PTX-resistant NSCLC cells.	Paclitaxel	138-141	checkpoint kinase 1	Homo sapiens	16-21
35348291-16	2022	Meanwhile, silencing miR-433-3p or overexpressing CHEK1 respectively abrogated the impacts of circ_0011292 deletion or miR-433-3p introduction on PTX resistance and cell progression in PTX-resistant NSCLC cells in vitro.	Paclitaxel	146-149	checkpoint kinase 1	Homo sapiens	50-55
35348291-16	2022	Meanwhile, silencing miR-433-3p or overexpressing CHEK1 respectively abrogated the impacts of circ_0011292 deletion or miR-433-3p introduction on PTX resistance and cell progression in PTX-resistant NSCLC cells in vitro.	Paclitaxel	185-188	checkpoint kinase 1	Homo sapiens	50-55
35348291-19	2022	CONCLUSION: Circ_0011292 could accelerate PTX resistance and cell malignant progression of NSCLC cells partially through the regulation of circ_0011292/miR-433-3p/CHEK1 axis.	Paclitaxel	42-45	checkpoint kinase 1	Homo sapiens	163-168
35144218-0	2022	Combination of ruthenium (II) polypyridyl complex Delta-Ru1 and Taxol enhances the anti-cancer effect on Taxol-resistant cancer cells through Caspase-1/GSDMD-mediated pyroptosis.	Paclitaxel	64-69	caspase 1	Homo sapiens	142-151
35144218-0	2022	Combination of ruthenium (II) polypyridyl complex Delta-Ru1 and Taxol enhances the anti-cancer effect on Taxol-resistant cancer cells through Caspase-1/GSDMD-mediated pyroptosis.	Paclitaxel	105-110	caspase 1	Homo sapiens	142-151
35144218-9	2022	Taken together, the Delta-Ru1 & Taxol combination can induce cell death through Caspase-1/GSDMD-mediated pyroptosis to enhance the therapeutic effect on HeLa/Taxol cells.	Paclitaxel	32-37	caspase 1	Homo sapiens	80-89
35144131-0	2022	Targeted delivery of cancer drug paclitaxel to chordomas tumor cells via an RNA nanoparticle harboring an EGFR aptamer.	Paclitaxel	33-43	epidermal growth factor receptor	Homo sapiens	106-110
35566044-9	2022	In contrast, 5 nM Paclitaxel induces TP53 transcription in excess of BCL-2 and Bax.	Paclitaxel	18-28	tumor protein p53	Homo sapiens	37-41
35566044-9	2022	In contrast, 5 nM Paclitaxel induces TP53 transcription in excess of BCL-2 and Bax.	Paclitaxel	18-28	BCL2 apoptosis regulator	Homo sapiens	69-74
35449387-8	2022	All selected selenoesters inhibited P-gp efflux in a dose-dependent manner while simultaneously altering the expression of the ABC genes, especially P-gp in paclitaxel-resistant breast carcinoma cells (MCF-7/PAX).	Paclitaxel	157-167	ATP binding cassette subfamily B member 1	Homo sapiens	149-153
35440807-6	2022	Inhibition of the release of exosomes by GW4869 or inhibition of STAT3 phosphorylation by stattic could effectively reverse the resistance to paclitaxel mediated by exosomal PD-L1.	Paclitaxel	142-152	signal transducer and activator of transcription 3	Homo sapiens	65-70
35440807-9	2022	Our results suggested that exosomal PD-L1 may contribute to drug resistance to paclitaxel by regulating the STAT3/miR-21/PTEN/Akt axis and promote tumorigenic phenotype.	Paclitaxel	79-89	signal transducer and activator of transcription 3	Homo sapiens	108-113
35440807-9	2022	Our results suggested that exosomal PD-L1 may contribute to drug resistance to paclitaxel by regulating the STAT3/miR-21/PTEN/Akt axis and promote tumorigenic phenotype.	Paclitaxel	79-89	AKT serine/threonine kinase 1	Homo sapiens	126-129
35420780-2	2022	In this research, CD24high cells accounted for the vast majority of TNBC cells, and they were insensitive to Taxol but sensitive to ferroptosis agonists and effectively escaped phagocytosis by tumor-associated macrophages.	Paclitaxel	109-114	CD24 molecule	Homo sapiens	18-22
35509628-7	2022	Furthermore, HDS-2 and HDS-3 potentiated paclitaxel-induced cytotoxicity by 19.1-22.45% (P < 0.05) and 10.52-18.03% (P < 0.05), respectively, inhibited the expression of cyclinB1, Bcl-2, and pMCL-1, and increased the percentage of necrosis cell in the condition of paclitaxel exposure.	Paclitaxel	41-51	B cell leukemia/lymphoma 2	Mus musculus	180-185
35448926-8	2022	Patients with a history of treatment with paclitaxel, docetaxel, or albumin paclitaxel during the adjuvant phase or after recurrent metastasis had an ORR of 32.9% and a DCR of 69.9% when treated with eribulin.	Paclitaxel	76-86	albumin	Homo sapiens	68-75
35459800-6	2022	In an in vivo murine tumor model of spontaneous metastatic prostate cancer, IFNgamma systemic pretreatment upregulated the expression of HLA-A and decreased E-cadherin expression in the primary tumor, and more importantly in the metastatic site led to increased apoptosis and limited micrometastases in combination with paclitaxel treatment compared to diffuse metastatic disease in control and monotherapy treatment groups.	Paclitaxel	320-330	interferon gamma	Mus musculus	76-84
35386184-10	2022	Simultaneous treatment of HIFU and PTX decreased the activities of CAT and SOD and increased the concentration of MDA.	Paclitaxel	35-38	catalase	Mus musculus	67-70
35531104-2	2022	Numerous studies have shown that traditional HER2 inhibitors and chemotherapeutics such as albumin-paclitaxel, liposomal doxorubicin, and cyclophosphamide (TAC regimen) have different degrees of cardiotoxicity.	Paclitaxel	99-109	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49
35169864-0	2022	Knockdown of long non-coding RNA DDX11-AS1 inhibits the proliferation, migration and paclitaxel resistance of breast cancer cells by upregulating microRNA-497 expression.	Paclitaxel	85-95	DEAD/H-box helicase 11	Homo sapiens	33-38
35169864-10	2022	The present study demonstrated that the expression levels of lncRNA DDX11-AS1 were markedly increased in paclitaxel (PTX)-resistant breast cancer cell lines.	Paclitaxel	105-115	DEAD/H-box helicase 11	Homo sapiens	68-73
35169864-10	2022	The present study demonstrated that the expression levels of lncRNA DDX11-AS1 were markedly increased in paclitaxel (PTX)-resistant breast cancer cell lines.	Paclitaxel	117-120	DEAD/H-box helicase 11	Homo sapiens	68-73
35169864-11	2022	By contrast, knockdown of DDX11-AS1 expression inhibited PTX resistance of breast cancer cells, and suppressed the proliferation, invasion and migration of breast cancer cells, which was achieved via upregulation of miR-497 expression.	Paclitaxel	57-60	DEAD/H-box helicase 11	Homo sapiens	26-31
35169864-12	2022	In conclusion, knockdown of lncRNA DDX11-AS1 could inhibit the proliferation, migration and PTX resistance of breast cancer cells by upregulating miR-497 expression.	Paclitaxel	92-95	DEAD/H-box helicase 11	Homo sapiens	35-40
35361803-4	2022	Here we evolved over 100 subclones of the Emicro-Myc; p19ARF-/- cell line to be resistant to one of four classical chemotherapy agents: doxorubicin, vincristine, paclitaxel, and cisplatin.	Paclitaxel	162-172	cyclin dependent kinase inhibitor 2A	Homo sapiens	54-60
35314692-1	2022	To investigate pharmacogenetic interactions among VEGF-A, VEGFR-2, IL-8, HIF-1alpha, EPAS-1, and TSP-1 SNPs and their role on progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with bevacizumab plus first-line paclitaxel or with paclitaxel alone.	Paclitaxel	242-252	thrombospondin 1	Homo sapiens	97-102
35419287-8	2022	The ferroptosis-related p53-SLC7A11-GPX4 pathway was also altered under different treatment propofol, doxorubicin, or paclitaxel regimens.	Paclitaxel	118-128	tumor protein p53	Homo sapiens	24-27
35456562-4	2022	The most successful example is Abraxane, an exogenous human serum albumin (HSA)-bound paclitaxel formulation approved by the FDA and used to treat locally advanced or metastatic tumors.	Paclitaxel	86-96	albumin	Homo sapiens	60-73
35448163-7	2022	Furthermore, a few lncRNAs, such as AFAP1-AS1 and LINC01014, block the efficiency of chemotherapeutic drugs, including cisplatin, 5-fluorouracil, paclitaxel, and gefitinib, used for ESCC treatment.	Paclitaxel	146-156	long intergenic non-protein coding RNA 1014	Homo sapiens	50-59
35240035-4	2022	Taxol and other microtubule interacting agents bind to both P-glycoprotein (ABCB1), a drug efflux pump that reduces intracellular drug accumulation, and the tubulin/microtubule system.	Paclitaxel	0-5	ATP binding cassette subfamily B member 1	Homo sapiens	60-74
35240035-4	2022	Taxol and other microtubule interacting agents bind to both P-glycoprotein (ABCB1), a drug efflux pump that reduces intracellular drug accumulation, and the tubulin/microtubule system.	Paclitaxel	0-5	ATP binding cassette subfamily B member 1	Homo sapiens	76-81
35314692-1	2022	To investigate pharmacogenetic interactions among VEGF-A, VEGFR-2, IL-8, HIF-1alpha, EPAS-1, and TSP-1 SNPs and their role on progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with bevacizumab plus first-line paclitaxel or with paclitaxel alone.	Paclitaxel	261-271	thrombospondin 1	Homo sapiens	97-102
35314692-6	2022	In the bevacizumab plus paclitaxel group, the MDR software provided two pharmacogenetic interaction profiles consisting of the combination between specific VEGF-A rs833061 and VEGFR-2 rs1870377 genotypes.	Paclitaxel	24-34	vascular endothelial growth factor A	Homo sapiens	156-162
35350768-7	2022	The incubation with 3 microM of palbociclib for 2h significantly increased the intracellular accumulation of (3H)-paclitaxel, a substrate of ABCB1, in ABCB1 overexpressing KB-C2 cells but not in the corresponding non-resistant parental KB-3-1 cell line.	Paclitaxel	114-124	ATP binding cassette subfamily B member 1	Homo sapiens	141-146
35326664-4	2022	The parent cell lines were exposed to short-term treatment with gefitinib or paclitaxel and then were assessed for EGFR T790M mutation and C-MET expression.	Paclitaxel	77-87	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	139-144
35051418-12	2022	The effect of KHDRBS3 overexpression on PTX resistance and glycolysis was rescued by MIR17HG overexpression.	Paclitaxel	40-43	KH domain containing, RNA binding, signal transduction associated 3	Mus musculus	14-21
35051418-14	2022	MIR17HG overexpression suppressed the IC50 of PTX and glycolysis by targeting CLDN6.	Paclitaxel	46-49	claudin 6	Homo sapiens	78-83
35372004-13	2022	These results suggest that low-dose nab-paclitaxel plus tislelizumab is well tolerated and effective in elderly patients with advanced NSCLC, including those with EGFR/ALK variations.	Paclitaxel	40-50	epidermal growth factor receptor	Homo sapiens	163-167
35350768-7	2022	The incubation with 3 microM of palbociclib for 2h significantly increased the intracellular accumulation of (3H)-paclitaxel, a substrate of ABCB1, in ABCB1 overexpressing KB-C2 cells but not in the corresponding non-resistant parental KB-3-1 cell line.	Paclitaxel	114-124	ATP binding cassette subfamily B member 1	Homo sapiens	151-156
35350768-8	2022	However, the incubation of KB-C2 cells with 3 muM of palbociclib for 72 h decreased the intracellular accumulation of (3H)-paclitaxel due to an increase in the expression of the ABCB1 protein.	Paclitaxel	123-133	ATP binding cassette subfamily B member 1	Homo sapiens	178-183
35327403-3	2022	Here, we report that infigratinib (BGJ 398), a potent FGFR1-4 inhibitor, restores sensitivity of a broad spectrum of ABCB1-overexpressing cancer cells to certain chemotherapeutic agents, including paclitaxel (PTX) and doxorubicin (Dox).	Paclitaxel	197-207	ATP binding cassette subfamily B member 1	Homo sapiens	117-122
35240000-11	2022	Western blot analysis indicated that zerumbone significantly upregulated BAX, caspase-7, and caspase-9 expression and decreased BCL-2 expression, thereby inducing proapoptotic protein-mediated cell death combined with PTX.	Paclitaxel	218-221	BCL2 apoptosis regulator	Homo sapiens	128-133
35330134-3	2022	In this study, we utilize homology modelling and molecular docking analysis to determine the binding affinity and the potential interaction sites of MRP1 with Carboplatin, Gemcitabine, Doxorubicin, Paclitaxel, and Topotecan.	Paclitaxel	198-208	ATP binding cassette subfamily B member 1	Homo sapiens	149-153
35330134-7	2022	Interestingly, our data showed that Carboplatin, Paclitaxel, and Topotecan bind specifically to Asn510 residue in the transmembrane domains 1 of the MRP1.	Paclitaxel	49-59	ATP binding cassette subfamily B member 1	Homo sapiens	149-153
35327403-3	2022	Here, we report that infigratinib (BGJ 398), a potent FGFR1-4 inhibitor, restores sensitivity of a broad spectrum of ABCB1-overexpressing cancer cells to certain chemotherapeutic agents, including paclitaxel (PTX) and doxorubicin (Dox).	Paclitaxel	209-212	ATP binding cassette subfamily B member 1	Homo sapiens	117-122
35327403-5	2022	Indeed, when MDR-overexpressing cancer cells were treated with a combination of BGJ 398 and PTX (or Dox), we observed a significant increase of apoptosis which was evidenced by an increased expression of cleaved forms of PARP, caspase-3, and increased numbers of Annexin V-positive cells, as well.	Paclitaxel	92-95	caspase 3	Homo sapiens	227-236
35327403-7	2022	As expected, no apoptosis was found in ABCB1-overexpressing cancer cells treated with PTX, Dox, or BGJ 398 alone.	Paclitaxel	86-89	ATP binding cassette subfamily B member 1	Homo sapiens	39-44
35238054-0	2022	TRPM2-AS promotes paclitaxel resistance in prostate cancer by regulating FOXK1 via sponging miR-497-5p.	Paclitaxel	18-28	forkhead box K1	Homo sapiens	73-78
35238054-7	2022	FOXK1 was identified as a target of miR-497-5p and FOXK1 overexpression showed similar effects on cell progression and PTX resistance with miR-497-5p inhibition in PTX-resistant PCa cells.	Paclitaxel	119-122	forkhead box K1	Homo sapiens	0-5
35238054-7	2022	FOXK1 was identified as a target of miR-497-5p and FOXK1 overexpression showed similar effects on cell progression and PTX resistance with miR-497-5p inhibition in PTX-resistant PCa cells.	Paclitaxel	119-122	forkhead box K1	Homo sapiens	51-56
35238054-8	2022	In conclusion, TRPM2-AS knockdown suppressed cell progression and PTX resistance in PTX-resistant PCa cells by miR-497-5p/FOXK1 axis.	Paclitaxel	66-69	forkhead box K1	Homo sapiens	122-127
35238054-8	2022	In conclusion, TRPM2-AS knockdown suppressed cell progression and PTX resistance in PTX-resistant PCa cells by miR-497-5p/FOXK1 axis.	Paclitaxel	84-87	forkhead box K1	Homo sapiens	122-127
35263200-9	2022	Consistent with studies, Paclitaxel exhibited a significant inhibitory effect on Adriamycin-resistant DLBCL, which may have played a role in the five hub genes (UBC, TSR1, WDR46, HSP90AA1 and NOP56) and ribosome biosynthesis in eukaryotes pathway, but the specific regulation needs further experimental verification.	Paclitaxel	25-35	TSR1 ribosome maturation factor	Homo sapiens	166-170
35263200-9	2022	Consistent with studies, Paclitaxel exhibited a significant inhibitory effect on Adriamycin-resistant DLBCL, which may have played a role in the five hub genes (UBC, TSR1, WDR46, HSP90AA1 and NOP56) and ribosome biosynthesis in eukaryotes pathway, but the specific regulation needs further experimental verification.	Paclitaxel	25-35	WD repeat domain 46	Homo sapiens	172-177
35263200-6	2022	Five hub genes (UBC, TSR1, WDR46, HSP90AA1, and NOP56) were obtained via network analysis from 971 differentially expressed genes (DEGs) based on the RNA-seq of Paclitaxel-intervened Pfeiffer/ADM.	Paclitaxel	161-171	TSR1 ribosome maturation factor	Homo sapiens	21-25
35263200-9	2022	Consistent with studies, Paclitaxel exhibited a significant inhibitory effect on Adriamycin-resistant DLBCL, which may have played a role in the five hub genes (UBC, TSR1, WDR46, HSP90AA1 and NOP56) and ribosome biosynthesis in eukaryotes pathway, but the specific regulation needs further experimental verification.	Paclitaxel	25-35	NOP56 ribonucleoprotein	Homo sapiens	192-197
35263200-6	2022	Five hub genes (UBC, TSR1, WDR46, HSP90AA1, and NOP56) were obtained via network analysis from 971 differentially expressed genes (DEGs) based on the RNA-seq of Paclitaxel-intervened Pfeiffer/ADM.	Paclitaxel	161-171	WD repeat domain 46	Homo sapiens	27-32
35263200-6	2022	Five hub genes (UBC, TSR1, WDR46, HSP90AA1, and NOP56) were obtained via network analysis from 971 differentially expressed genes (DEGs) based on the RNA-seq of Paclitaxel-intervened Pfeiffer/ADM.	Paclitaxel	161-171	NOP56 ribonucleoprotein	Homo sapiens	48-53
35139880-7	2022	Drug response was coupled to elevated expression of EGFR, Mdm2, Ptch1 and Tsc1 (Erlotinib), or Nras and Ptch1 (Paclitaxel) and reduced expression of Egfr, Erbb2 and Foxa (Paclitaxel).	Paclitaxel	111-121	patched 1	Homo sapiens	104-109
35083840-1	2022	The first-line treatment of advanced and metastatic human epidermal growth factor receptor type 2 (HER2+) breast cancer requires two HER2-targeting antibodies (trastuzumab and pertuzumab) and a taxane (docetaxel or paclitaxel).	Paclitaxel	215-225	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
35083840-1	2022	The first-line treatment of advanced and metastatic human epidermal growth factor receptor type 2 (HER2+) breast cancer requires two HER2-targeting antibodies (trastuzumab and pertuzumab) and a taxane (docetaxel or paclitaxel).	Paclitaxel	215-225	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-137
35281113-3	2022	Through analyzing the effect of HRD status on response efficacy of anticancer drugs and elucidating its related mechanisms of action, we found rucaparib (PARP inhibitor) and doxorubicin (anthracycline) sensitive in HR-deficient patients, while paclitaxel sensitive in the HR-proficient.	Paclitaxel	244-254	poly(ADP-ribose) polymerase 1	Homo sapiens	154-158
35281908-12	2022	JG remarkably enhanced the anticancer effect of PTX by increasing the red blood cell and platelet counts; increasing hemoglobin, interleukin (IL)-2, and tumor necrosis factor-alpha levels; increasing CD4+T cells and the CD4+/CD8+ ratio; and decreasing IL-10 levels.	Paclitaxel	48-51	tumor necrosis factor	Mus musculus	153-180
35281908-12	2022	JG remarkably enhanced the anticancer effect of PTX by increasing the red blood cell and platelet counts; increasing hemoglobin, interleukin (IL)-2, and tumor necrosis factor-alpha levels; increasing CD4+T cells and the CD4+/CD8+ ratio; and decreasing IL-10 levels.	Paclitaxel	48-51	interleukin 10	Mus musculus	252-257
35250589-8	2022	Conclusion: TMI-1 partially protects against paclitaxel-induced neurotoxicity by reversing the upregulation of TRPV1 and decreasing levels of inflammatory cytokines, including TNF-alpha, IL-1beta, and IL-6 in neuronal cells.	Paclitaxel	45-55	tumor necrosis factor	Rattus norvegicus	176-185
35250589-8	2022	Conclusion: TMI-1 partially protects against paclitaxel-induced neurotoxicity by reversing the upregulation of TRPV1 and decreasing levels of inflammatory cytokines, including TNF-alpha, IL-1beta, and IL-6 in neuronal cells.	Paclitaxel	45-55	interleukin 1 alpha	Rattus norvegicus	187-195
35168606-10	2022	The proteomics data indicated that the expressions of key enzymes glycerophosphocholine phosphodiesterase 1 (GPCPD1) and glycerophosphodiester phosphodiesterase 1 (GDE1) were significantly lower in the PTX-resistant tumors compared to the PTX-sensitive tumors (both P < 0.01).	Paclitaxel	202-205	glycerophosphodiester phosphodiesterase 1	Homo sapiens	121-162
35168606-10	2022	The proteomics data indicated that the expressions of key enzymes glycerophosphocholine phosphodiesterase 1 (GPCPD1) and glycerophosphodiester phosphodiesterase 1 (GDE1) were significantly lower in the PTX-resistant tumors compared to the PTX-sensitive tumors (both P < 0.01).	Paclitaxel	202-205	glycerophosphodiester phosphodiesterase 1	Homo sapiens	164-168
35168606-10	2022	The proteomics data indicated that the expressions of key enzymes glycerophosphocholine phosphodiesterase 1 (GPCPD1) and glycerophosphodiester phosphodiesterase 1 (GDE1) were significantly lower in the PTX-resistant tumors compared to the PTX-sensitive tumors (both P < 0.01).	Paclitaxel	239-242	glycerophosphodiester phosphodiesterase 1	Homo sapiens	121-162
35168606-10	2022	The proteomics data indicated that the expressions of key enzymes glycerophosphocholine phosphodiesterase 1 (GPCPD1) and glycerophosphodiester phosphodiesterase 1 (GDE1) were significantly lower in the PTX-resistant tumors compared to the PTX-sensitive tumors (both P < 0.01).	Paclitaxel	239-242	glycerophosphodiester phosphodiesterase 1	Homo sapiens	164-168
35168606-11	2022	Decreased expressions of GPCPD1 and GDE1 in choline metabolism led to an increased GPC levels in the PTX-resistant EOCs, which was observed as an elevated total choline (tCho) on in vivo 1H-MRS.	Paclitaxel	101-104	glycerophosphodiester phosphodiesterase 1	Homo sapiens	36-40
35205672-0	2022	DKK3, Downregulated in Invasive Epithelial Ovarian Cancer, Is Associated with Chemoresistance and Enhanced Paclitaxel Susceptibility via Inhibition of the beta-Catenin-P-Glycoprotein Signaling Pathway.	Paclitaxel	107-117	dickkopf WNT signaling pathway inhibitor 3	Homo sapiens	0-4
35205672-0	2022	DKK3, Downregulated in Invasive Epithelial Ovarian Cancer, Is Associated with Chemoresistance and Enhanced Paclitaxel Susceptibility via Inhibition of the beta-Catenin-P-Glycoprotein Signaling Pathway.	Paclitaxel	107-117	ATP binding cassette subfamily B member 1	Homo sapiens	168-182
35205672-12	2022	DKK3 was lost in paclitaxel-resistant cells, while beta-catenin and P-glycoprotein were upregulated.	Paclitaxel	17-27	dickkopf WNT signaling pathway inhibitor 3	Homo sapiens	0-4
35205672-12	2022	DKK3 was lost in paclitaxel-resistant cells, while beta-catenin and P-glycoprotein were upregulated.	Paclitaxel	17-27	ATP binding cassette subfamily B member 1	Homo sapiens	68-82
35205672-13	2022	Exogenous secreted DKK3, incorporated by cells, enhanced anti-tumoral effect and paclitaxel susceptibility in paclitaxel-resistant cells, and reduced the levels of active beta-catenin and its downstream P-glycoprotein, suggesting that DKK3 can be used as a therapeutic for targeting paclitaxel-resistant cancer.	Paclitaxel	81-91	dickkopf WNT signaling pathway inhibitor 3	Homo sapiens	19-23
35205672-13	2022	Exogenous secreted DKK3, incorporated by cells, enhanced anti-tumoral effect and paclitaxel susceptibility in paclitaxel-resistant cells, and reduced the levels of active beta-catenin and its downstream P-glycoprotein, suggesting that DKK3 can be used as a therapeutic for targeting paclitaxel-resistant cancer.	Paclitaxel	110-120	dickkopf WNT signaling pathway inhibitor 3	Homo sapiens	19-23
35205672-13	2022	Exogenous secreted DKK3, incorporated by cells, enhanced anti-tumoral effect and paclitaxel susceptibility in paclitaxel-resistant cells, and reduced the levels of active beta-catenin and its downstream P-glycoprotein, suggesting that DKK3 can be used as a therapeutic for targeting paclitaxel-resistant cancer.	Paclitaxel	283-293	dickkopf WNT signaling pathway inhibitor 3	Homo sapiens	19-23
35186774-0	2022	Corrigendum: Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein.	Paclitaxel	31-41	ATP binding cassette subfamily B member 1	Homo sapiens	120-134
35137851-7	2022	Also, MLT had a protective effect against testicular apoptosis induced by TXL, as shown by the elevated expression of Bcl-2 and decreased expression of P53 and caspase-3.	Paclitaxel	74-77	BCL2, apoptosis regulator	Rattus norvegicus	118-123
35014689-0	2022	Inhibition of FOXO1-mediated autophagy promotes paclitaxel-induced apoptosis of MDA-MB-231 cells.	Paclitaxel	48-58	forkhead box O1	Homo sapiens	14-19
35200072-0	2022	Knockdown of nuclear receptor binding SET domain-containing protein 1 (NSD1) inhibits proliferation and facilitates apoptosis in paclitaxel-resistant breast cancer cells via inactivating the Wnt/beta-catenin signaling pathway.	Paclitaxel	129-139	Wnt family member 10B	Homo sapiens	191-194
35200072-10	2022	We conclude that NSD1 knockdown inhibits the viability and promotes the apoptosis of paclitaxel-resistant BC cells by inactivating the NSD1/H3K27me3/Wnt10b/beta-catenin signaling pathway.	Paclitaxel	85-95	Wnt family member 10B	Homo sapiens	149-155
35014689-5	2022	Furthermore, it was found that forkhead box transcription factor O1 (FOXO1) enhanced PTX-induced autophagy through a transcriptional activation pattern in MDA-MB-231 cells, which was associated with the downstream target genes autophagy related 5, class III phosphoinositide 3-kinase vacuolar protein sorting 34, autophagy related 4B cysteine peptidase, beclin 1 and microtubule associated protein 1 light chain 3beta.	Paclitaxel	85-88	forkhead box O1	Homo sapiens	31-67
35014689-5	2022	Furthermore, it was found that forkhead box transcription factor O1 (FOXO1) enhanced PTX-induced autophagy through a transcriptional activation pattern in MDA-MB-231 cells, which was associated with the downstream target genes autophagy related 5, class III phosphoinositide 3-kinase vacuolar protein sorting 34, autophagy related 4B cysteine peptidase, beclin 1 and microtubule associated protein 1 light chain 3beta.	Paclitaxel	85-88	forkhead box O1	Homo sapiens	69-74
35014689-6	2022	Knocking down FOXO1 attenuated the survival of MDA-MB-231 cells in response to PTX treatment.	Paclitaxel	79-82	forkhead box O1	Homo sapiens	14-19
35153800-10	2022	Treatment with either colchicine or paclitaxel uncoupled the morphological and/or traction stress responses of angiotensin II stimulated VSMCs.	Paclitaxel	36-46	angiotensinogen	Homo sapiens	111-125
34974521-10	2022	CD147 protected cancer cells from paclitaxel-induced caspase-3 mediated apoptosis regardless of p53 status.	Paclitaxel	34-44	caspase 3	Homo sapiens	53-62
35239875-0	2022	Low-dose paclitaxel modulates the cross talk between the JNK and Smad signaling in primary biliary fibroblasts.	Paclitaxel	9-19	mitogen-activated protein kinase 8	Homo sapiens	57-60
35239875-4	2022	The effect of low-dose paclitaxel on the transforming growth factor beta 1-induced inhibition of type I collagen and connective tissue growth factor expression and JNK and Smad2L phosphorylation was also observed.	Paclitaxel	23-33	transforming growth factor beta 1	Homo sapiens	41-74
35239875-4	2022	The effect of low-dose paclitaxel on the transforming growth factor beta 1-induced inhibition of type I collagen and connective tissue growth factor expression and JNK and Smad2L phosphorylation was also observed.	Paclitaxel	23-33	mitogen-activated protein kinase 8	Homo sapiens	164-167
35239875-7	2022	Low-dose paclitaxel inhibited the expression of type I collagen induced by transforming growth factor beta 1 and may inhibit the secretion of collagen in biliary fibroblasts.	Paclitaxel	9-19	transforming growth factor beta 1	Homo sapiens	75-108
35239875-8	2022	CONCLUSION: The activation of JNK/Smad2L induced by transforming growth factor beta 1 is involved in the occurrence of benign bile duct stricture that is mediated by the overexpression of type I collagen and connective tissue growth factor, and low-dose paclitaxel may inhibit the phosphorylation of JNK/Smad2L.	Paclitaxel	254-264	mitogen-activated protein kinase 8	Homo sapiens	30-33
35239875-8	2022	CONCLUSION: The activation of JNK/Smad2L induced by transforming growth factor beta 1 is involved in the occurrence of benign bile duct stricture that is mediated by the overexpression of type I collagen and connective tissue growth factor, and low-dose paclitaxel may inhibit the phosphorylation of JNK/Smad2L.	Paclitaxel	254-264	transforming growth factor beta 1	Homo sapiens	52-85
35159310-8	2022	Finally, MTT assays demonstrated that LDR-IR decreased sensitivity to paclitaxel or barasertib in TIG-3 cells but not in A549 cells.	Paclitaxel	70-80	phospholipase A and acyltransferase 4	Homo sapiens	98-103
35058503-6	2022	Knockdown of p53, RBL2, or the DREAM component LIN37 increased AURKA/B pathway gene expression and reduced paclitaxel and radiation toxicity in NSCLC cells.	Paclitaxel	107-117	tumor protein p53	Homo sapiens	13-16
35280672-0	2022	Paclitaxel treatment enhances lymphatic metastasis of B16F10 melanoma cells via CCL21/CCR7 axis.	Paclitaxel	0-10	chemokine (C-C motif) receptor 7	Mus musculus	86-90
35280672-4	2022	Further study demonstrated that PTX upregulated the expression of C-C chemokine receptor type 7 (CCR7) in B16F10 cells, enhancing their migration through the activation of JNK and p38 signalling pathways.	Paclitaxel	32-35	chemokine (C-C motif) receptor 7	Mus musculus	66-95
35280672-4	2022	Further study demonstrated that PTX upregulated the expression of C-C chemokine receptor type 7 (CCR7) in B16F10 cells, enhancing their migration through the activation of JNK and p38 signalling pathways.	Paclitaxel	32-35	chemokine (C-C motif) receptor 7	Mus musculus	97-101
35280672-5	2022	Loss of CCR7 or blockade of C-C motif chemokine ligand 21 (CCL21)/CCR7 axis abolished the pro-migration effect of PTX on B16F10 melanoma cells.	Paclitaxel	114-117	chemokine (C-C motif) receptor 7	Mus musculus	8-12
35280672-5	2022	Loss of CCR7 or blockade of C-C motif chemokine ligand 21 (CCL21)/CCR7 axis abolished the pro-migration effect of PTX on B16F10 melanoma cells.	Paclitaxel	114-117	chemokine (C-C motif) receptor 7	Mus musculus	66-70
35163066-4	2022	In the present study, we demonstrated, by using both primary epidermal keratinocytes (NHEK) and a 3D epidermis model, that paclitaxel impairs different cellular processes: paclitaxel increased the release of IL-1alpha, IL-6, and IL-8 inflammatory cytokines, produced reactive oxygen species (ROS) release and apoptosis, and reduced the endothelial tube formation in the dermal microvascular endothelial cells (HDMEC).	Paclitaxel	123-133	interleukin 6	Homo sapiens	219-223
35163066-4	2022	In the present study, we demonstrated, by using both primary epidermal keratinocytes (NHEK) and a 3D epidermis model, that paclitaxel impairs different cellular processes: paclitaxel increased the release of IL-1alpha, IL-6, and IL-8 inflammatory cytokines, produced reactive oxygen species (ROS) release and apoptosis, and reduced the endothelial tube formation in the dermal microvascular endothelial cells (HDMEC).	Paclitaxel	123-133	C-X-C motif chemokine ligand 8	Homo sapiens	229-233
35163066-4	2022	In the present study, we demonstrated, by using both primary epidermal keratinocytes (NHEK) and a 3D epidermis model, that paclitaxel impairs different cellular processes: paclitaxel increased the release of IL-1alpha, IL-6, and IL-8 inflammatory cytokines, produced reactive oxygen species (ROS) release and apoptosis, and reduced the endothelial tube formation in the dermal microvascular endothelial cells (HDMEC).	Paclitaxel	172-182	interleukin 6	Homo sapiens	219-223
35163066-4	2022	In the present study, we demonstrated, by using both primary epidermal keratinocytes (NHEK) and a 3D epidermis model, that paclitaxel impairs different cellular processes: paclitaxel increased the release of IL-1alpha, IL-6, and IL-8 inflammatory cytokines, produced reactive oxygen species (ROS) release and apoptosis, and reduced the endothelial tube formation in the dermal microvascular endothelial cells (HDMEC).	Paclitaxel	172-182	C-X-C motif chemokine ligand 8	Homo sapiens	229-233
35173861-9	2022	After Apa intervention, PTX-resistant MGC803 cells showed decreased cell migration, invasion and proliferation, reduced MDR1, P-gp and VEGFR2 levels, and increased Bax protein level.	Paclitaxel	24-27	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
35173861-9	2022	After Apa intervention, PTX-resistant MGC803 cells showed decreased cell migration, invasion and proliferation, reduced MDR1, P-gp and VEGFR2 levels, and increased Bax protein level.	Paclitaxel	24-27	BCL2 associated X, apoptosis regulator	Homo sapiens	164-167
35052626-0	2022	The Beneficial Effects of Heme Oxygenase 1 and Hydrogen Sulfide Activation in the Management of Neuropathic Pain, Anxiety- and Depressive-like Effects of Paclitaxel in Mice.	Paclitaxel	154-164	heme oxygenase 1	Mus musculus	26-42
35087749-0	2021	Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.	Paclitaxel	37-47	albumin	Homo sapiens	23-30
35087749-1	2021	Background: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as neoadjuvant chemotherapy (NAC) for breast cancer remains controversial.	Paclitaxel	39-49	albumin	Homo sapiens	25-32
35087749-1	2021	Background: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as neoadjuvant chemotherapy (NAC) for breast cancer remains controversial.	Paclitaxel	55-65	albumin	Homo sapiens	25-32
35070991-1	2021	Background: Citarinostat (CC-96241; previously ACY-241), an oral inhibitor of histone deacetylases (HDACs) with selectivity for HDAC6, has demonstrated synergistic anticancer activity with paclitaxel in multiple solid tumor models.	Paclitaxel	189-199	histone deacetylase 6	Homo sapiens	128-133
35282117-11	2022	Four genes showed significant association with the estimated half-maximal inhibitory concentration (IC50) of paclitaxel: bone morphogenetic protein 1 (BMP1), dumbbell former 4 protein (DBF4), angiogenin (ANG), and MAP7 domain containing 2 (MAP7D2).	Paclitaxel	109-119	DBF4 zinc finger	Homo sapiens	158-183
35282117-11	2022	Four genes showed significant association with the estimated half-maximal inhibitory concentration (IC50) of paclitaxel: bone morphogenetic protein 1 (BMP1), dumbbell former 4 protein (DBF4), angiogenin (ANG), and MAP7 domain containing 2 (MAP7D2).	Paclitaxel	109-119	DBF4 zinc finger	Homo sapiens	185-189
35242683-2	2022	In this study, we assessed the efficacy and safety of neoadjuvant pyrotinib plus trastuzumab and albumin-bound paclitaxel in women with human epidermal growth factor receptor 2-positive early or locally advanced BC.	Paclitaxel	111-121	albumin	Homo sapiens	97-104
35019820-8	2022	Furthermore, Nab-paclitaxel and IL-15 fusion protein showed a significant suppression of NF-kappaB-mediated immune suppressive markers and increased expression of CD8, Granzyme B, CD62L, CD49b, and CD86 without obvious organ toxicity.	Paclitaxel	17-27	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	89-98
35019820-8	2022	Furthermore, Nab-paclitaxel and IL-15 fusion protein showed a significant suppression of NF-kappaB-mediated immune suppressive markers and increased expression of CD8, Granzyme B, CD62L, CD49b, and CD86 without obvious organ toxicity.	Paclitaxel	17-27	selectin, lymphocyte	Mus musculus	180-185
35019820-8	2022	Furthermore, Nab-paclitaxel and IL-15 fusion protein showed a significant suppression of NF-kappaB-mediated immune suppressive markers and increased expression of CD8, Granzyme B, CD62L, CD49b, and CD86 without obvious organ toxicity.	Paclitaxel	17-27	integrin alpha 2	Mus musculus	187-192
35019820-8	2022	Furthermore, Nab-paclitaxel and IL-15 fusion protein showed a significant suppression of NF-kappaB-mediated immune suppressive markers and increased expression of CD8, Granzyme B, CD62L, CD49b, and CD86 without obvious organ toxicity.	Paclitaxel	17-27	CD86 antigen	Mus musculus	198-202
35242683-11	2022	Conclusions: In women with human epidermal growth factor receptor 2-positive early or locally advanced BC, neoadjuvant pyrotinib plus trastuzumab and albumin-bound paclitaxel effectively promoted total pCR rate with an acceptable safety profile (ClinicalTrials.gov, NCT04152057).	Paclitaxel	164-174	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-67
35242683-11	2022	Conclusions: In women with human epidermal growth factor receptor 2-positive early or locally advanced BC, neoadjuvant pyrotinib plus trastuzumab and albumin-bound paclitaxel effectively promoted total pCR rate with an acceptable safety profile (ClinicalTrials.gov, NCT04152057).	Paclitaxel	164-174	albumin	Homo sapiens	150-157
34655345-2	2022	In the APT trial, weekly paclitaxel/trastuzumab in node negative HER2+ BC with tumors < 3 cm was associated with a 7-year invasive disease-free survival of 93%.	Paclitaxel	25-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-69
35242683-2	2022	In this study, we assessed the efficacy and safety of neoadjuvant pyrotinib plus trastuzumab and albumin-bound paclitaxel in women with human epidermal growth factor receptor 2-positive early or locally advanced BC.	Paclitaxel	111-121	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-176
35173526-0	2022	SOX8 Affects Tumoral SPARC Expression by Regulating EZH2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC.	Paclitaxel	101-111	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	52-56
35173526-9	2022	EZH2 inhibitor, UNC1999, can reverse the effect of SOX8 on chemo-resistance of albumin-bound paclitaxel.	Paclitaxel	93-103	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	0-4
35173526-8	2022	SOX8 transcriptionally regulated EZH2, which reduced expression of SPARC by promoting the methylation of SPARC, thereby reducing the transport of albumin-bound paclitaxel in pancreatic cancer cells.	Paclitaxel	160-170	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	33-37
35173526-10	2022	Collectively, our data revealed SOX8/EZH2/SPARC signaling induced primary chemo-resistance of albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.	Paclitaxel	108-118	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	37-41
2573965-2	1989	An ultrastructural analysis of cells in which basal and ACTH-induced steroidogenesis was inhibited by taxol.	Paclitaxel	102-107	pro-opiomelanocortin-alpha	Mus musculus	56-60
35531363-3	2022	Here we demonstrate a patient with recurrent uterine carcinosarcoma whose local recurrence and metastatic recurrence had a varied response to paclitaxel in combination with DKN-01, a monoclonal antibody against DKK1, a modulator of Wnt/beta-catenin and PI3K/AKT signaling pathways.	Paclitaxel	142-152	AKT serine/threonine kinase 1	Homo sapiens	258-261
6133864-4	1983	(i) The fast reaction occurred over a period of milliseconds and the rate was a function of the ATP concentration, whereas, the slow reaction occurred over a period of several seconds and was independent of ATP concentration; (ii) the amplitude of the fast reaction was directly proportional to the amount of dynein bound to the microtubule lattice; and (iii) only the slow phase was inhibited by the addition of the microtubule-stabilizing drug, taxol.	Paclitaxel	447-452	ATPase phospholipid transporting 8A2	Homo sapiens	96-99
2573965-7	1989	Taxol, a microtubule polymerizer, inhibits basal and ACTH-induced steroidogenesis in these cells, presumably at the step where mitochondria obtain cholesterol.	Paclitaxel	0-5	pro-opiomelanocortin-alpha	Mus musculus	53-57
2573965-8	1989	We examined the ultrastructure of taxol-treated, unstimulated and ACTH-stimulated cells, seeking alterations which conceivably could interefer with the proposed organelle transport and encounters, and thus correlate with taxol"s inhibition of steroidogenesis.	Paclitaxel	221-226	pro-opiomelanocortin-alpha	Mus musculus	66-70
2573965-12	1989	Taxol inhibited basal and ACTH-induced steroidogenesis in a dose-dependent fashion.	Paclitaxel	0-5	pro-opiomelanocortin-alpha	Mus musculus	26-30
2573965-13	1989	In both unstimulated and ACTH-stimulated cells, taxol 50 formed numerous microtubule bundles, but did not markedly change the distribution of mitochondria and lipid droplets.	Paclitaxel	48-53	pro-opiomelanocortin-alpha	Mus musculus	25-29
34003380-9	2021	IF staining revealed that TLR4, TRPV1, and microglial activation were all upregulated in PAC-injected rats and exhibited early and significant downregulation in SHBOT-treated rats.	Paclitaxel	89-92	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	32-37
2573965-15	1989	Taxol permitted an ACTH-induced cell rounding and microfilament rearrangement considered to facilitate organelle motility.	Paclitaxel	0-5	pro-opiomelanocortin-alpha	Mus musculus	19-23
2575805-2	1989	Reversibility of taxol"s inhibition of basal and ACTH-induced steroidogenesis is unaccompanied by reversibility of taxol-induced changes in cell ultrastructure.	Paclitaxel	17-22	pro-opiomelanocortin-alpha	Mus musculus	49-53
34010730-4	2021	It is found that RES reduces the anticancer action of paclitaxel only in the human breast cancer cells that express HER3 protein.	Paclitaxel	54-64	erb-b2 receptor tyrosine kinase 3	Homo sapiens	116-120
34010730-6	2021	The induction of HER3 expression by RES confers resistance of breast cancer cells against paclitaxel cytotoxicity.	Paclitaxel	90-100	erb-b2 receptor tyrosine kinase 3	Homo sapiens	17-21
2575805-3	1989	Taxol inhibits the basal and ACTH-stimulated steroidogenesis of cultured mouse adrenocortical tumor cells, presumably by preventing the arrival of cholesterol in mitochondria.	Paclitaxel	0-5	pro-opiomelanocortin-alpha	Mus musculus	29-33
2575805-5	1989	However, taxol"s alterations in ultrastructure appear likely to permit both a microtubule-based organelle transport proposed to bring mitochondria of unstimulated cells close to alternate sources of cholesterol--the SER and lipid droplets--and postulated ACTH-caused increases in these encounters.	Paclitaxel	9-14	pro-opiomelanocortin-alpha	Mus musculus	255-259
3126498-3	1988	The in vitro-synthesized product of the largest cDNA comigrates with Drosophila kinesin heavy chain on NaDodSO4/polyacrylamide gels and binds to taxol-stabilized microtubules in the presence of the nonhydrolyzable analogue of ATP, 5"-adenylyl imidodiphosphate, but not in the presence of ATP or 0.1 M KCl.	Paclitaxel	145-150	Kinesin heavy chain	Drosophila melanogaster	80-99
33709519-0	2021	Effect of rs67085638 in long non-coding RNA (CCAT1) on colon cancer chemoresistance to paclitaxel through modulating the microRNA-24-3p and FSCN1.	Paclitaxel	87-97	fascin actin-bundling protein 1	Homo sapiens	140-145
33709519-2	2021	Also, CCAT1 could affect chemoresistance of cancer cells to paclitaxel (PTX) via regulating miR-24-3p and FSCN1 expression.	Paclitaxel	60-70	fascin actin-bundling protein 1	Homo sapiens	106-111
33709519-2	2021	Also, CCAT1 could affect chemoresistance of cancer cells to paclitaxel (PTX) via regulating miR-24-3p and FSCN1 expression.	Paclitaxel	72-75	fascin actin-bundling protein 1	Homo sapiens	106-111
33709519-3	2021	In this study, we aimed to investigate the effect of rs67085638 on the expression of CCAT1/miR-24-3p/FSCN1 and the response of colon cancer to the treatment of PTX.	Paclitaxel	160-163	fascin actin-bundling protein 1	Homo sapiens	101-106
2891714-6	1987	Microtubule-associated proteins (MAPs), including species previously identified only by taxol-based purification such as MAP 1B and kinesin, were found to copurify with tubulin through reversible assembly cycles.	Paclitaxel	88-93	microtubule associated protein 1B	Bos taurus	121-127
2867785-7	1986	Taxol induced a very high eta spec, 4-times the steady-state value in the initial phase of assembly, which slowly declined again to a steady state, an effect which was also found for assembly of purified tubulin assembled in the absence of the microtubule-associated proteins.	Paclitaxel	0-5	endothelin receptor type A	Homo sapiens	26-29
33561696-7	2021	Through taxol and nocodazole treatment, and microinjection of siRNA, it was demonstrated that Fbf1 had an important role in the spindle assembly and chromosome separation during mouse oocyte meiosis In particular, microinjection of Fbf1-siRNA resulted in severe abnormalities in the spindle and chromosome arrangement, decreased aggregation of microtubules, disrupted the first oocyte meiosis, and the extrusion of the first polar body.	Paclitaxel	8-13	Fas (TNFRSF6) binding factor 1	Mus musculus	94-98
33571724-10	2021	Carboplatin and paclitaxel altered the expression of EPCR and thrombomodulin in OAW42 cells with a modest effect on EA.hy926 cells.	Paclitaxel	16-26	protein C receptor	Homo sapiens	53-57
3536962-7	1986	This tight temporal and topographical linkage between titin and myosin is also observed in postmitotic, mononucleated myoblasts and multinucleated myotubes when myofibrillogenesis is perturbed with Colcemid or taxol.	Paclitaxel	210-215	titin	Homo sapiens	54-59
2857725-2	1985	Taxol inhibited the following steroidogenic processes within the Y-1 and MLTC-1 cells: (1) hormonal increase of steroid production, (2) dibutyryl cyclic AMP-increased steroid production, and (3) hormone-stimulated pregnenolone production.	Paclitaxel	0-5	transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)	Mus musculus	65-68
7225331-10	1981	Zn2+ induced taxol-treated MTP to form sheets.	Paclitaxel	13-18	microsomal triglyceride transfer protein	Bos taurus	27-30
33982563-0	2021	Multifunctional Liposomes Enable Active Targeting and Twinfilin 1 Silencing to Reverse Paclitaxel Resistance in Brain Metastatic Breast Cancer.	Paclitaxel	87-97	twinfilin actin binding protein 1	Homo sapiens	54-65
34050450-7	2021	Also, significant downregulation of several genes like MUC1 and MKI67 in MCF-7 cells treated with doxorubicin showed much lower gene expression (- 37.63, - 10.88 folds) when compared with cells treated with paclitaxel (- 2.47, - 2.05 folds) or the combination treatment (- 18.99, - 2.81 folds), respectively.	Paclitaxel	207-217	mucin 1, cell surface associated	Homo sapiens	55-59
33859743-13	2021	DRD2 also promoted BrCa cells sensitivity to Paclitaxel.	Paclitaxel	45-55	dopamine receptor D2	Homo sapiens	0-4
33982563-4	2021	The current study found that TWF1 gene, an epithelial-mesenchymal transition-associated gene, was overexpressed in brain metastatic breast cancer (231-BR) cells and was associated with the PTX resistance of 231-BR cells.	Paclitaxel	189-192	twinfilin actin binding protein 1	Homo sapiens	29-33
33982563-5	2021	Knockdown of TWF1 by small interference RNA (siRNA) in 231-BR cells could effectively increase the sensitivity of brain metastatic breast cancer cells to paclitaxel.	Paclitaxel	154-164	twinfilin actin binding protein 1	Homo sapiens	13-17
33999360-0	2021	Long non-coding RNA TPT1-AS1 sensitizes breast cancer cell to paclitaxel and inhibits cell proliferation by miR-3156-5p/caspase 2 axis.	Paclitaxel	62-72	prostaglandin D2 receptor	Homo sapiens	25-28
33999360-8	2021	In breast cancer cells, TPT1-AS1 overexpression repressed cell proliferation and sensitized breast cancer cells to paclitaxel.	Paclitaxel	115-125	prostaglandin D2 receptor	Homo sapiens	29-32
34030451-2	2021	We recently experienced three cases of SMARCA4-DTS who were treated with atezolizumab in combination with bevacizumab, paclitaxel and carboplatin (ABCP) as the first-line therapy.	Paclitaxel	119-129	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	39-46
33985619-8	2022	c-Src-Caspase-8 interaction initiates EMT and chemoresistance viaCaspase-8 phosphorylation and lncCRLA expression, to which the dasatinib/paclitaxel liposome+siFLIP regimen was lethal.	Paclitaxel	138-148	caspase 8	Homo sapiens	6-15
34041032-8	2021	Knock-down of EXDPF sensitized SKOV3 cells to the treatment of the front-line drug, paclitaxel.	Paclitaxel	84-94	pancreatic progenitor cell differentiation and proliferation factor	Homo sapiens	14-19
33402387-0	2021	Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma.	Paclitaxel	56-66	interleukin 1 receptor associated kinase 1	Homo sapiens	14-19
33402387-4	2021	Moreover, both paclitaxel-resistant NPC cells and relapsed/metastatic clinical samples exhibited increased IRAK1 phosphorylation and that pacritinib could abolish the IRAK1 phosphorylation to suppress S100A9 expression.	Paclitaxel	15-25	interleukin 1 receptor associated kinase 1	Homo sapiens	107-112
33608947-6	2021	In addition, in vivo experiments confirm more capability of the NL2-functionalized nanocomposite for reducing tumor size, drug distribution in the body, and more aggregation of PTX in tumor tissue.	Paclitaxel	177-180	membrane metalloendopeptidase like 1	Homo sapiens	64-67
33608947-7	2021	Overall, it is concluded that tumor imaging is possible using luminescent LaVO4 :Eu3+ core and NL2 peptide increases significantly the specificity of PTX in combination with a functionalized luminescent polymeric carrier.	Paclitaxel	150-153	membrane metalloendopeptidase like 1	Homo sapiens	95-98
33985619-3	2022	c-Src-mediated Caspase-8 phosphorylation essential for EMT in lung adenocarcinoma cell lines preferentially occurs in cells with the mesenchymal phenotype, resulting in chemoresistance to cisplatin plus paclitaxel inpatients with resectable lung adenocarcinoma and a significantly worse 5-year PFS.	Paclitaxel	203-213	caspase 8	Homo sapiens	15-24
33985619-5	2022	Paclitaxel-triggered necroptosis in lung adenocarcinoma cells was dependent on the phosphorylation or deficiency of Caspase-8, during which FADD interacted with RIPK1 to activateRIPK1/RIPK3/MLKL signaling axis.	Paclitaxel	0-10	caspase 8	Homo sapiens	116-125
33602962-9	2021	YBX2-mediated CT45 expression was associated with increased levels of self-renewal capacity and paclitaxel resistance.	Paclitaxel	96-106	cancer/testis antigen family 45 member A1	Homo sapiens	14-18
33151424-0	2021	Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells.	Paclitaxel	36-46	prostaglandin D2 receptor	Homo sapiens	24-27
33151424-6	2021	RESULTS: ZEB1-AS1 depletion using siRNA in chemosensitive A2780 cells significantly increased PTX and DDP resistance.	Paclitaxel	94-97	prostaglandin D2 receptor	Homo sapiens	14-17
33985619-5	2022	Paclitaxel-triggered necroptosis in lung adenocarcinoma cells was dependent on the phosphorylation or deficiency of Caspase-8, during which FADD interacted with RIPK1 to activateRIPK1/RIPK3/MLKL signaling axis.	Paclitaxel	0-10	mixed lineage kinase domain like pseudokinase	Homo sapiens	190-194
33151424-7	2021	In contrast, ZEB1-AS1 overexpression in PTX- and DDP-resistant A2780/resistant (A2780/R) cells reversed the observed drug resistance.	Paclitaxel	40-43	prostaglandin D2 receptor	Homo sapiens	18-21
33151424-8	2021	Thus, ZEB1-AS1 plays an important role in PTX and DDP resistance in EOC cells.	Paclitaxel	42-45	prostaglandin D2 receptor	Homo sapiens	11-14
33985619-7	2022	Dasatinib mitigated c-Src-mediated phosphorylation of Caspase-8-induced EMT and enhanced necroptosis in mesenchymal-like lung adenocarcinoma cells treated with paclitaxel, while c-FLIP knockdown predominantly sensitized the mesenchymal-like lung adenocarcinoma cells to paclitaxel+dasatinib.	Paclitaxel	160-170	caspase 8	Homo sapiens	54-63
33151424-13	2021	CCK8 assay results suggested that MMP19 knockdown promoted ZEB1-AS1-induced chemoresistance to PTX and DDP in A2780 cells.	Paclitaxel	95-98	matrix metallopeptidase 19	Homo sapiens	34-39
33151424-13	2021	CCK8 assay results suggested that MMP19 knockdown promoted ZEB1-AS1-induced chemoresistance to PTX and DDP in A2780 cells.	Paclitaxel	95-98	prostaglandin D2 receptor	Homo sapiens	64-67
32459889-7	2021	A 3-compartment population PK (PPK) model with saturable elimination was developed to describe the paclitaxel whole blood concentrations in pediatrics.	Paclitaxel	99-109	kallikrein B1	Homo sapiens	31-34
32459889-9	2021	PPK estimates are consistent with the fast and deep distribution of paclitaxel that was previously observed in adults.	Paclitaxel	68-78	kallikrein B1	Homo sapiens	0-3
33985619-7	2022	Dasatinib mitigated c-Src-mediated phosphorylation of Caspase-8-induced EMT and enhanced necroptosis in mesenchymal-like lung adenocarcinoma cells treated with paclitaxel, while c-FLIP knockdown predominantly sensitized the mesenchymal-like lung adenocarcinoma cells to paclitaxel+dasatinib.	Paclitaxel	270-280	caspase 8	Homo sapiens	54-63
33958764-1	2021	Nanoparticulate albumin bound paclitaxel (nab-paclitaxel, nab-PTX) is among the most widely prescribed nanomedicines in clinical use, yet it remains unclear how nanoformulation affects nab-PTX behaviour in the tumour microenvironment.	Paclitaxel	30-40	albumin	Mus musculus	16-23
33621742-0	2021	Corrigendum to "Paclitaxel alleviates the sepsis-induced acute kidney injury via lnc-MALAT1/miR-370-3p/HMGB1 axis" [Life Sci.	Paclitaxel	16-26	microRNA 370	Homo sapiens	92-99
33621742-0	2021	Corrigendum to "Paclitaxel alleviates the sepsis-induced acute kidney injury via lnc-MALAT1/miR-370-3p/HMGB1 axis" [Life Sci.	Paclitaxel	16-26	high mobility group box 1	Homo sapiens	103-108
33958764-1	2021	Nanoparticulate albumin bound paclitaxel (nab-paclitaxel, nab-PTX) is among the most widely prescribed nanomedicines in clinical use, yet it remains unclear how nanoformulation affects nab-PTX behaviour in the tumour microenvironment.	Paclitaxel	46-56	albumin	Mus musculus	16-23
33002289-6	2021	GA, paclitaxel, and carboplatin alone or in combination arrested cell cycle progression at the G2/M phase and induced Pre-G1 apoptosis.	Paclitaxel	4-14	pregnancy-induced hypertension (pre-eclampsia, eclampsia, toxemia of pregnancy included)	Homo sapiens	118-124
33684416-3	2021	We previously demonstrated that taxanes (paclitaxel and docetaxel) induce Schwann cell dedifferentiation, characterized by increased expression of p75 and galectin-3, ultimately leading to demyelination.	Paclitaxel	41-51	PC4 and SFRS1 interacting protein 1	Homo sapiens	147-150
33550530-0	2021	DNMT3b SUMOylation Mediated MMP-2 Upregulation Contribute to Paclitaxel Induced Neuropathic Pain.	Paclitaxel	61-71	matrix metallopeptidase 2	Rattus norvegicus	28-33
33684416-3	2021	We previously demonstrated that taxanes (paclitaxel and docetaxel) induce Schwann cell dedifferentiation, characterized by increased expression of p75 and galectin-3, ultimately leading to demyelination.	Paclitaxel	41-51	galectin 3	Homo sapiens	155-165
33995980-2	2021	ER is predictive to show beneficiaries of hormonal therapy and a prognostic marker to establish tumors that will resist paclitaxel induced apoptosis so a cost effective combination of anthracylines can be used as treatment in our low resource setting thus improving survival, reducing recurrence, and cost.	Paclitaxel	120-130	epiregulin	Homo sapiens	0-2
33665229-0	2021	Molecular subtyping and functional validation of TTK, TPX2, UBE2C, and LRP8 in sensitivity of TNBC to paclitaxel.	Paclitaxel	102-112	TTK protein kinase	Homo sapiens	49-52
33665229-5	2021	Mechanistically, depletion of TTK, TPX2, UBE2C, CDCA7, MELK, NFE2L3, DDX39A, and LRP8 led to substantial inhibition of colony formation of TNBC models, which was further enhanced in the presence of paclitaxel.	Paclitaxel	198-208	TTK protein kinase	Homo sapiens	30-33
33550530-3	2021	Our present study revealed that MMP-2 is also upregulated in paclitaxel induced neuropathic pain (NP), and knockdown it by siRNA can ameliorate mechanical allodynia.	Paclitaxel	61-71	matrix metallopeptidase 2	Rattus norvegicus	32-37
33481008-0	2021	circGFRA1 affects the sensitivity of triple negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.	Paclitaxel	76-86	microRNA 361	Homo sapiens	95-102
33481008-3	2021	This study aimed to clarify that circGFRA1 affects the sensitivity of TNBC cells to paclitaxel (PTX) by the miR-361-5p/TLR4 pathway.	Paclitaxel	84-94	microRNA 361	Homo sapiens	108-115
33550530-8	2021	Further investigation suggested that DNMT3b binding activity to the promoter region of the MMP-2 gene is significantly decreased in paclitaxel treated rats, and the administration of GA can reverse these effects, which is also accompanied by changes in the promoter methylation status of the MMP-2 gene.	Paclitaxel	132-142	matrix metallopeptidase 2	Rattus norvegicus	91-96
33481008-3	2021	This study aimed to clarify that circGFRA1 affects the sensitivity of TNBC cells to paclitaxel (PTX) by the miR-361-5p/TLR4 pathway.	Paclitaxel	96-99	microRNA 361	Homo sapiens	108-115
33481008-7	2021	It has been proven that circGFRA1 knockdown can inhibit the resistance of TNBC cells to PTX by promoting the expression of miR-361-5p, and subsequently reduce the expression of TLR4.	Paclitaxel	88-91	microRNA 361	Homo sapiens	123-130
33912444-11	2021	Moreover, rapamycin, an inhibitor of mTOR complex 1 (mTORC1), downregulated BCRP expression and enhanced the effects of particular drugs, including doxorubicin and paclitaxel.	Paclitaxel	164-174	CREB regulated transcription coactivator 1	Mus musculus	53-59
33550530-8	2021	Further investigation suggested that DNMT3b binding activity to the promoter region of the MMP-2 gene is significantly decreased in paclitaxel treated rats, and the administration of GA can reverse these effects, which is also accompanied by changes in the promoter methylation status of the MMP-2 gene.	Paclitaxel	132-142	matrix metallopeptidase 2	Rattus norvegicus	292-297
33550530-9	2021	Our study demonstrates that MMP-2 up-regulation mediated by DNMT3b SUMOylation is essential for paclitaxel induced NP development, which brings us new therapeutic options for CIPN.	Paclitaxel	96-106	matrix metallopeptidase 2	Rattus norvegicus	28-33
32892537-7	2021	Importantly, we found 3 new heterozygous TUBB1 variants predicting amino acid substitutions, G146R (in 1 patient), E123Q (in 1 patient) and T274M (in 4 patients), the latter variant being associated with milder thrombocytopenia in cancer patients treated with paclitaxel.	Paclitaxel	260-270	tubulin beta 1 class VI	Homo sapiens	41-46
33556367-2	2021	SOR inhibits several human CYPs, including CYP2C8, which is a major enzyme in the elimination of oncology drugs like paclitaxel and imatinib.	Paclitaxel	117-127	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	43-49
33556367-5	2021	The present study evaluated the capacity of the major N-oxide metabolite of SOR (SNO) to inhibit CYP2C8-dependent paclitaxel 6alpha-hydroxylation.	Paclitaxel	114-124	strawberry notch homolog 1	Homo sapiens	81-84
33556367-5	2021	The present study evaluated the capacity of the major N-oxide metabolite of SOR (SNO) to inhibit CYP2C8-dependent paclitaxel 6alpha-hydroxylation.	Paclitaxel	114-124	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	97-103
33683482-6	2021	Arm 2 patients received nab-paclitaxel, then cetuximab with radiation.	Paclitaxel	28-38	Jupiter microtubule associated homolog 1	Homo sapiens	0-5
33413403-9	2021	Knockdown of ADAM10 in MDA-MB-231 cells led to a significant decrease in cell proliferation, migration, invasion and the IC50 value of paclitaxel and adriamycin, while induced cell cycle arrest and apoptosis.	Paclitaxel	135-145	ADAM metallopeptidase domain 10	Homo sapiens	13-19
33414428-7	2021	We found that our new three drug-NP not only effectively inhibited TNBC cell viability and cell migration, but also significantly diminished paclitaxel-induced and/or CA4-induced CSC enrichment in TNBC cells, partially through inhibiting the upregulated Hippo/YAP signaling.	Paclitaxel	141-151	Yes1 associated transcriptional regulator	Homo sapiens	260-263
33738259-9	2021	Furthermore, Hsp90 enhanced the AKT/GSK3beta signaling, and AKT signaling played a critical role in Hsp90-induced accumulation and transcriptional activity of beta-catenin, as well as multi-drug resistance to paclitaxel and cisplatin.	Paclitaxel	209-219	glycogen synthase kinase 3 alpha	Homo sapiens	36-44
33402387-5	2021	Functional studies in both in vitro and in vivo models showed that genetic or pharmacological blockade of IRAK1 overcame the resistance to paclitaxel, and combined treatment of pacritinib with paclitaxel exhibited superior anti-tumor effect.	Paclitaxel	139-149	interleukin 1 receptor associated kinase 1	Homo sapiens	106-111
33402387-6	2021	Together, these findings demonstrated an important role of the IRAK1-S100A9 axis in mediating resistance to paclitaxel.	Paclitaxel	108-118	interleukin 1 receptor associated kinase 1	Homo sapiens	63-68
33896831-9	2021	CONCLUSIONS: Our results first revealed that TPM3, EFHD2, KRT19 and vimentin were novel autoantibodies in the ascites of relapsed PTX-resistant GC patients.	Paclitaxel	130-133	keratin 19	Homo sapiens	58-63
33549629-9	2021	Similarly, treatment with 3HF suppressed the paclitaxel-induced increase in mRNA expression of several inflammatory cytokines including tumor necrosis factor -alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), CGRP, and Substance P. However, the daily treatment of 3HF did not affect the motor behaviors of rats.	Paclitaxel	45-55	calcitonin-related polypeptide alpha	Rattus norvegicus	234-238
33888980-7	2021	The results of molecular docking revealed that Taxol, Rutin, Genkwanine, and Luteolin-glucoside have a high affinity with ACE2 and 3CLpro.	Paclitaxel	47-52	angiotensin converting enzyme 2	Homo sapiens	122-126
33708767-10	2021	The inhibition of C1QBP notably blocked metastasis of TNBC cells and increased their sensitivity to PTX under hypoxic conditions.	Paclitaxel	100-103	complement C1q binding protein	Homo sapiens	18-23
32698755-0	2021	iRGD Co-Administration with Paclitaxel-Loaded PLGA Nanoparticles Enhance Targeting and Antitumor Effect in Colorectal Cancer Treatment.	Paclitaxel	28-38	interferon gamma inducible protein 47	Mus musculus	0-4
32698755-1	2021	OBJECTIVE: To explore the targeting effect of PLGA-NP and iRGD co-administration with PTX-PLGA NP (PTX-PLGA + iRGD) on colorectal cancer.	Paclitaxel	86-89	interferon gamma inducible protein 47	Mus musculus	110-114
32698755-4	2021	Whether iRGD co-administration with PTX-PLGA NP (PTX-PLGA + iRGD) in colorectal cancer models enabled PTX to achieve better anti-tumor efficiency and biocompatibility was further assessed.	Paclitaxel	36-39	interferon gamma inducible protein 47	Mus musculus	60-64
32698755-4	2021	Whether iRGD co-administration with PTX-PLGA NP (PTX-PLGA + iRGD) in colorectal cancer models enabled PTX to achieve better anti-tumor efficiency and biocompatibility was further assessed.	Paclitaxel	49-52	interferon gamma inducible protein 47	Mus musculus	8-12
32698755-4	2021	Whether iRGD co-administration with PTX-PLGA NP (PTX-PLGA + iRGD) in colorectal cancer models enabled PTX to achieve better anti-tumor efficiency and biocompatibility was further assessed.	Paclitaxel	49-52	interferon gamma inducible protein 47	Mus musculus	8-12
32698755-6	2021	As a result, PTX-PLGA + iRGD achieved better anti-tumor efficacy than PTX and PTX-PLGA.	Paclitaxel	70-73	interferon gamma inducible protein 47	Mus musculus	24-28
32698755-6	2021	As a result, PTX-PLGA + iRGD achieved better anti-tumor efficacy than PTX and PTX-PLGA.	Paclitaxel	70-73	interferon gamma inducible protein 47	Mus musculus	24-28
33279635-9	2021	Body mass recovery was associated with the wheel running-induced recovery of body composition, paclitaxel-induced alterations to hypothalamic melanocortin signaling and associated peripheral circulating hormones (ghrelin and leptin).	Paclitaxel	95-105	ghrelin	Mus musculus	213-220
33931967-11	2021	More importantly, we observed that USP35 knockdown sensitized lung cancer cells to cisplatin and paclitaxel chemotherapy.	Paclitaxel	97-107	ubiquitin specific peptidase 35	Homo sapiens	35-40
33200571-5	2021	As expected, LHRH-DCMs are more efficiently internalized into human TNBC cells through receptor-mediated endocytosis, resulting in stronger cytotoxicity against these cancer cells than the non-targeted counterpart when encapsulated with paclitaxel (PTX).	Paclitaxel	237-247	gonadotropin releasing hormone 1	Homo sapiens	13-17
33200571-5	2021	As expected, LHRH-DCMs are more efficiently internalized into human TNBC cells through receptor-mediated endocytosis, resulting in stronger cytotoxicity against these cancer cells than the non-targeted counterpart when encapsulated with paclitaxel (PTX).	Paclitaxel	249-252	gonadotropin releasing hormone 1	Homo sapiens	13-17
33037137-7	2021	UCN-01, a kinase inhibitor/mitochondrial uncoupler that has been shown to lead to Puma-induced mitochondrial apoptosis and ATP synthase inhibitor Oligomycin demonstrated effectiveness against spheroids, while spheroids were refractory to cisplatin and paclitaxel.	Paclitaxel	252-262	BCL2 binding component 3	Mus musculus	82-86
33089875-0	2021	Selective activation of metabotropic glutamate receptor 7 blocks paclitaxel-induced acute neuropathic pain and suppresses spinal glial reactivity in rats.	Paclitaxel	65-75	glutamate metabotropic receptor 7	Rattus norvegicus	24-57
33200571-7	2021	Finally, in vivo therapeutic studies show that PTX-LHRH-DCMs outperform both the corresponding nontargeted PTX-DCMs and the current clinical formulation (Taxol) in an orthotopic TNBC model.	Paclitaxel	47-50	gonadotropin releasing hormone 1	Homo sapiens	51-55
33446524-10	2021	Taken together, these data suggest that candesartan acyl-beta-D-glucuronide is actively transported by OATPs into hepatocytes, and drug-drug interactions may occur with coadministration of candesartan and CYP2C8 substrates including paclitaxel as a result of the inhibition of CYP2C8 function.	Paclitaxel	233-243	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	205-211
33200571-7	2021	Finally, in vivo therapeutic studies show that PTX-LHRH-DCMs outperform both the corresponding nontargeted PTX-DCMs and the current clinical formulation (Taxol) in an orthotopic TNBC model.	Paclitaxel	154-159	gonadotropin releasing hormone 1	Homo sapiens	51-55
33396362-0	2020	Gabapentin and Duloxetine Prevent Oxaliplatin- and Paclitaxel-Induced Peripheral Neuropathy by Inhibiting Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Phosphorylation in Spinal Cords of Mice.	Paclitaxel	51-61	mitogen-activated protein kinase 3	Mus musculus	106-147
33396362-0	2020	Gabapentin and Duloxetine Prevent Oxaliplatin- and Paclitaxel-Induced Peripheral Neuropathy by Inhibiting Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Phosphorylation in Spinal Cords of Mice.	Paclitaxel	51-61	mitogen-activated protein kinase 3	Mus musculus	149-155
33446524-12	2021	Thus, candesartan acyl-beta-D-glucuronide might represent a potential mediator of drug-drug interactions between candesartan and CYP2C8 substrates, such as paclitaxel, in clinical settings.	Paclitaxel	156-166	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	129-135
33396362-11	2020	Moreover, PD0325901 prevented the development of oxaliplatin- and paclitaxel-induced neuropathic-like pain behavior by inhibiting ERK1/2 activation in the spinal cord of mice.	Paclitaxel	66-76	mitogen-activated protein kinase 3	Mus musculus	130-136
33708420-6	2021	PD-1 inhibitor with chemotherapy [albumin paclitaxel 100 mg/m2 on days 1 and 8 + carboplatin with an area under the curve (AUC) of 5 on day 1] were administered every 3 weeks intravenously, and surgery was performed approximately 3-5 weeks after the second dose.	Paclitaxel	42-52	programmed cell death 1	Homo sapiens	0-4
33201400-7	2021	Immunohistochemical expressions of 8-OHdG, caspase-3 and LC3B in the PTX-induced spinal cord tissue were decreased after administration of CUR.	Paclitaxel	69-72	caspase 3	Rattus norvegicus	43-52
33663585-8	2021	On ER+ breast cancer cell lines, it was synergistic in vitro and had enhanced in vivo antitumor activity with both paclitaxel and eribulin.	Paclitaxel	115-125	epiregulin	Homo sapiens	3-5
33513866-8	2021	Combination therapy with paclitaxel, however, typical of standard-of-care for patients in palliative care, abolished CXCR3-specific T-cell recruitment stimulated by sitagliptin.	Paclitaxel	25-35	C-X-C motif chemokine receptor 3	Homo sapiens	117-122
33380810-2	2020	This study investigated the regulatory effects of RAB17 on the non-coding RNA network of the paclitaxel-resistant ovarian cancer cell A2780/PTX.	Paclitaxel	93-103	RAB17, member RAS oncogene family	Homo sapiens	50-55
33549629-0	2021	Attenuation of nociceptive and paclitaxel-induced neuropathic pain by targeting inflammatory, CGRP and Substance P signaling using 3-Hydroxyflavone.	Paclitaxel	31-41	calcitonin-related polypeptide alpha	Rattus norvegicus	94-98
33380810-10	2020	RAB17 knockdown increased the cell sensitivity to paclitaxel, inhibited proliferation, and caused cell cycle arrest in the G1 phase in A2780/PTX.	Paclitaxel	50-60	RAB17, member RAS oncogene family	Homo sapiens	0-5
33649523-6	2021	CYP2C8*3/*4 variant carriers showed a trend of association with overall AEs in pts treated with paclitaxel and nab-paclitaxel (RR = 1.28; 95% CI 0.96, 1.67; p = 0.0898).	Paclitaxel	96-106	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
33473256-0	2020	miR-708-5p enhances erlotinib/paclitaxel efficacy and overcomes chemoresistance in lung cancer cells.	Paclitaxel	30-40	microRNA 708	Homo sapiens	0-7
33255050-3	2021	Here, we report on the synthesis of NHG-QDs nanosystem (NS) conjugated with an amino-modified MUC-1 aptamer (Ap) and loaded with hydrophobic paclitaxel (PTX).	Paclitaxel	153-156	mucin 1, cell surface associated	Homo sapiens	94-99
33649523-6	2021	CYP2C8*3/*4 variant carriers showed a trend of association with overall AEs in pts treated with paclitaxel and nab-paclitaxel (RR = 1.28; 95% CI 0.96, 1.67; p = 0.0898).	Paclitaxel	115-125	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
33473256-9	2020	Moreover, combination treatment of erlotinib (ERL) or paclitaxel (PAC) with miR-708-5p enhances COX-2 and mPGES-1 protein suppression.	Paclitaxel	54-64	microRNA 708	Homo sapiens	76-83
33473256-9	2020	Moreover, combination treatment of erlotinib (ERL) or paclitaxel (PAC) with miR-708-5p enhances COX-2 and mPGES-1 protein suppression.	Paclitaxel	66-69	microRNA 708	Homo sapiens	76-83
33649523-9	2021	Despite the population was heterogeneous, CYP3A4*22 and CYP2C8 SNPs may influence paclitaxel and nab-paclitaxel toxicity and ABCB1 c.3435 may affect taxanes effectiveness, even if any statistically significant was found.	Paclitaxel	82-92	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	56-62
33473256-10	2020	We also show that combination chemotherapeutic and miR-708-5p treatment intensifies the anti-proliferative and pro-apoptotic effects of ERL and PAC.	Paclitaxel	144-147	microRNA 708	Homo sapiens	51-58
33128175-12	2021	PAC also upregulated rAxin2 in mice.	Paclitaxel	0-3	axin 2	Rattus norvegicus	21-27
33754055-10	2021	Additionally, PTX-ss-TMP NPs also had a stronger anti-angiogenesis effect in HUVECs than free drug, which was mediated by VEGFR2-involved downstream signals.	Paclitaxel	14-17	kinase insert domain protein receptor	Mus musculus	122-128
33221685-1	2021	BACKGROUND: This study aimed to evaluate the effect of salvage therapy with nab-paclitaxel (nab-p) or temozolomide (TMZ) combined with antiangiogenic drugs in programmed death 1 (PD-1) inhibitor-resistant patients with unresectable metastatic melanoma.	Paclitaxel	80-90	programmed cell death 1	Homo sapiens	159-177
33221685-1	2021	BACKGROUND: This study aimed to evaluate the effect of salvage therapy with nab-paclitaxel (nab-p) or temozolomide (TMZ) combined with antiangiogenic drugs in programmed death 1 (PD-1) inhibitor-resistant patients with unresectable metastatic melanoma.	Paclitaxel	80-90	programmed cell death 1	Homo sapiens	179-183
33323915-15	2020	Elevated Nox4 expression was also improved by paclitaxel.	Paclitaxel	46-56	NADPH oxidase 4	Mus musculus	9-13
33317551-10	2020	Expression of PAWR could predict platinum responsiveness in ovarian cancer and there was a positive correlation between PAWR gene effect and paclitaxel sensitivity.	Paclitaxel	141-151	pro-apoptotic WT1 regulator	Homo sapiens	14-18
33317551-10	2020	Expression of PAWR could predict platinum responsiveness in ovarian cancer and there was a positive correlation between PAWR gene effect and paclitaxel sensitivity.	Paclitaxel	141-151	pro-apoptotic WT1 regulator	Homo sapiens	120-124
33113434-0	2020	Paclitaxel increases sensitivity of SKOV3 cells to hyperthermia by inhibiting heat shock protein 27.	Paclitaxel	0-10	heat shock protein family B (small) member 2	Homo sapiens	78-99
33396362-12	2020	In summary, our findings suggest that gabapentin, duloxetine, and PD0325901 prevent the development of oxaliplatin- and paclitaxel-induced neuropathic-like pain behavior by inhibiting ERK1/2 phosphorylation in mice.	Paclitaxel	120-130	mitogen-activated protein kinase 3	Mus musculus	184-190
33608947-0	2021	Targeted delivery of paclitaxel by NL2 peptide-functionalized on core-shell LaVO4: Eu3@ poly (levodopa) luminescent nanoparticles.	Paclitaxel	21-31	membrane metalloendopeptidase like 1	Homo sapiens	35-38
33396362-13	2020	Therefore, inhibiting ERK1/2 phosphorylation could be an effective preventive strategy against oxaliplatin- and paclitaxel-induced neuropathy.	Paclitaxel	112-122	mitogen-activated protein kinase 3	Mus musculus	22-28
33113434-3	2020	The aim of the present study was to investigate whether paclitaxel can exert antitumor effects by inhibiting heat shock protein 27 (HSP27) expression during HIPEC treatment.	Paclitaxel	56-66	heat shock protein family B (small) member 2	Homo sapiens	109-130
33113434-3	2020	The aim of the present study was to investigate whether paclitaxel can exert antitumor effects by inhibiting heat shock protein 27 (HSP27) expression during HIPEC treatment.	Paclitaxel	56-66	heat shock protein family B (small) member 2	Homo sapiens	132-137
33113434-9	2020	Furthermore, paclitaxel could upregulate the Bax / Bcl-2 ratio by inhibiting HSP27 expression, and in turn, promoting apoptosis due to hyperthermia.	Paclitaxel	13-23	heat shock protein family B (small) member 2	Homo sapiens	77-82
33113434-10	2020	Paclitaxel could also promote apoptosis by inhibiting HSP27 in SKOV3 cells.	Paclitaxel	0-10	heat shock protein family B (small) member 2	Homo sapiens	54-59
33597970-7	2021	mRNA expression analysis using The Cancer Genome Atlas database revealed that RPGRIP1L was highly expressed in several cancer types, especially in pancreatic adenocarcinoma, and correlated with patient survival and sensitivity to paclitaxel, probably through the TGF-beta signaling pathway.	Paclitaxel	230-240	transforming growth factor alpha	Homo sapiens	263-271
33206588-11	2021	The exosomes elevated miR-451a and inhibited ADAM10 to suppress the paclitaxel resistance, cell cycle transition, proliferation, migration and invasion, and promote apoptosis of HCC cells.	Paclitaxel	68-78	ADAM metallopeptidase domain 10	Homo sapiens	45-51
33555529-10	2021	Moreover, miR-424-5p restoration in combination with Taxol treatment decreased the colony formation by regulating Oct-4 and led to G2 arrest via modulating Cdk-2 expression.	Paclitaxel	53-58	cyclin dependent kinase 2	Homo sapiens	156-161
33091531-9	2021	The joining of a durable PD-1 blockage significantly boosted the efficacy of PTX@HSST on multiple tumor models, including lung metastatic tumors and even multidrug-resistant tumors.	Paclitaxel	77-80	programmed cell death 1	Homo sapiens	25-29
33370338-0	2020	The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.	Paclitaxel	40-50	MYD88 innate immune signal transduction adaptor	Homo sapiens	26-31
33370338-3	2020	In this study, we demonstrate a key link between senescence and inflammation and how this complex network involving the biomarkers MAD2, TLR4 and MyD88 drives paclitaxel resistance in ovarian cancer.	Paclitaxel	159-169	MYD88 innate immune signal transduction adaptor	Homo sapiens	146-151
33376345-0	2020	Effect of Ect2 Expression on the Growth of Triple-Negative Breast Cancer Cells with Paclitaxel Intervention.	Paclitaxel	84-94	ect2 oncogene	Mus musculus	10-14
33259730-0	2020	miR-146a Enhances the Sensitivity of Breast Cancer Cells to Paclitaxel by Downregulating IRAK1.	Paclitaxel	60-70	interleukin 1 receptor associated kinase 1	Homo sapiens	89-94
33259730-13	2020	Compared with MCF-7/PTX cells, the expression of miR-146a gene in MCF-7 cells was significantly increased, while the expression of IRAK1 gene was significantly reduced (p < 0.05).	Paclitaxel	20-23	interleukin 1 receptor associated kinase 1	Homo sapiens	131-136
33259730-17	2020	Conclusion: miR-146a can enhance the sensitivity of breast cancer cells to PTX; the mechanism may be related to the downregulation of IRAK1.	Paclitaxel	75-78	interleukin 1 receptor associated kinase 1	Homo sapiens	134-139
31913724-0	2020	OCTN2-targeted nanoparticles for oral delivery of paclitaxel: differential impact of the polyethylene glycol linker size on drug delivery in vitro, in situ, and in vivo.	Paclitaxel	50-60	solute carrier family 22 member 5	Homo sapiens	0-5
33376345-1	2020	Object: To identify the expression levels of ECT2 (epithelial cell transforming sequence 2) in triple-negative breast cancer (TNBC) before and after administration of paclitaxel (PTX) and explore the interaction between ECT2 and PTX in breast cancer treatment.	Paclitaxel	167-177	ect2 oncogene	Mus musculus	45-49
33376345-1	2020	Object: To identify the expression levels of ECT2 (epithelial cell transforming sequence 2) in triple-negative breast cancer (TNBC) before and after administration of paclitaxel (PTX) and explore the interaction between ECT2 and PTX in breast cancer treatment.	Paclitaxel	167-177	ect2 oncogene	Mus musculus	51-90
33162028-2	2021	In this study, angiopep-2 modified lipid-coated mesoporous silica nanoparticle loading paclitaxel (ANG-LP-MSN-PTX) was developed to transport paclitaxel (PTX) across BBB mediated by low-density lipoprotein receptor-related protein 1 (LRP1), which is over-expressed on both BBB and glioma cells.	Paclitaxel	87-97	LDL receptor related protein 1	Rattus norvegicus	182-232
33376345-1	2020	Object: To identify the expression levels of ECT2 (epithelial cell transforming sequence 2) in triple-negative breast cancer (TNBC) before and after administration of paclitaxel (PTX) and explore the interaction between ECT2 and PTX in breast cancer treatment.	Paclitaxel	179-182	ect2 oncogene	Mus musculus	45-49
33376345-1	2020	Object: To identify the expression levels of ECT2 (epithelial cell transforming sequence 2) in triple-negative breast cancer (TNBC) before and after administration of paclitaxel (PTX) and explore the interaction between ECT2 and PTX in breast cancer treatment.	Paclitaxel	179-182	ect2 oncogene	Mus musculus	51-90
33319669-5	2021	PTX resistance pathways that involve major regulatory proteins/RNAs like RNF8/Twist/ROR1, TLR, ErbB3/ErbB2, BRCA1-IRIS, MENA, LIN9, MiRNA, FoxM1 and IRAK1 have expanded the complexity of resistance mechanisms, and brought newer insights for development of drug targets.	Paclitaxel	0-3	erb-b2 receptor tyrosine kinase 3	Homo sapiens	95-100
33319669-5	2021	PTX resistance pathways that involve major regulatory proteins/RNAs like RNF8/Twist/ROR1, TLR, ErbB3/ErbB2, BRCA1-IRIS, MENA, LIN9, MiRNA, FoxM1 and IRAK1 have expanded the complexity of resistance mechanisms, and brought newer insights for development of drug targets.	Paclitaxel	0-3	lin-9 DREAM MuvB core complex component	Homo sapiens	126-130
33121324-14	2020	MEG3/miR-4513/PBLD axis modulated PTX-resistance and the development of breast cancer cells, which might provide a promising therapeutic strategy for breast cancer.	Paclitaxel	34-37	phenazine biosynthesis like protein domain containing	Homo sapiens	14-18
33162028-2	2021	In this study, angiopep-2 modified lipid-coated mesoporous silica nanoparticle loading paclitaxel (ANG-LP-MSN-PTX) was developed to transport paclitaxel (PTX) across BBB mediated by low-density lipoprotein receptor-related protein 1 (LRP1), which is over-expressed on both BBB and glioma cells.	Paclitaxel	87-97	LDL receptor related protein 1	Rattus norvegicus	234-238
33412753-0	2020	Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells.	Paclitaxel	82-92	delta/notch like EGF repeat containing	Homo sapiens	27-30
33162028-2	2021	In this study, angiopep-2 modified lipid-coated mesoporous silica nanoparticle loading paclitaxel (ANG-LP-MSN-PTX) was developed to transport paclitaxel (PTX) across BBB mediated by low-density lipoprotein receptor-related protein 1 (LRP1), which is over-expressed on both BBB and glioma cells.	Paclitaxel	142-152	LDL receptor related protein 1	Rattus norvegicus	182-232
32998017-0	2020	Paclitaxel alleviates the sepsis-induced acute kidney injury via lnc-MALAT1/miR-370-3p/HMGB1 axis.	Paclitaxel	0-10	microRNA 370	Homo sapiens	76-83
33058284-8	2020	Overexpression of LOX, LOXL3, and LOXL4 mRNA indicated worse OS and PFS among OC patients who received platinum, taxol, and taxol + platinum chemotherapy.	Paclitaxel	113-118	lysyl oxidase like 4	Homo sapiens	34-39
33162028-2	2021	In this study, angiopep-2 modified lipid-coated mesoporous silica nanoparticle loading paclitaxel (ANG-LP-MSN-PTX) was developed to transport paclitaxel (PTX) across BBB mediated by low-density lipoprotein receptor-related protein 1 (LRP1), which is over-expressed on both BBB and glioma cells.	Paclitaxel	142-152	LDL receptor related protein 1	Rattus norvegicus	234-238
33058284-8	2020	Overexpression of LOX, LOXL3, and LOXL4 mRNA indicated worse OS and PFS among OC patients who received platinum, taxol, and taxol + platinum chemotherapy.	Paclitaxel	124-129	lysyl oxidase like 4	Homo sapiens	34-39
32998017-0	2020	Paclitaxel alleviates the sepsis-induced acute kidney injury via lnc-MALAT1/miR-370-3p/HMGB1 axis.	Paclitaxel	0-10	high mobility group box 1	Homo sapiens	87-92
32998017-9	2020	Besides, paclitaxel restrained the expression of HMGB1 via regulating lnc-MALAT1/miR-370-3p axis.	Paclitaxel	9-19	high mobility group box 1	Homo sapiens	49-54
33162028-2	2021	In this study, angiopep-2 modified lipid-coated mesoporous silica nanoparticle loading paclitaxel (ANG-LP-MSN-PTX) was developed to transport paclitaxel (PTX) across BBB mediated by low-density lipoprotein receptor-related protein 1 (LRP1), which is over-expressed on both BBB and glioma cells.	Paclitaxel	110-113	LDL receptor related protein 1	Rattus norvegicus	182-232
32998017-10	2020	SIGNIFICANCE: Paclitaxel could protect against LPS-induced AKI via the regulation of lnc-MALAT1/miR-370-3p/HMGB1 axis and the expression of TNF-alpha, IL-6 and IL-1beta, revealing that paclitaxel might act as a therapy drug in reducing sepsis-associated AKI.	Paclitaxel	14-24	microRNA 370	Homo sapiens	96-103
32998017-10	2020	SIGNIFICANCE: Paclitaxel could protect against LPS-induced AKI via the regulation of lnc-MALAT1/miR-370-3p/HMGB1 axis and the expression of TNF-alpha, IL-6 and IL-1beta, revealing that paclitaxel might act as a therapy drug in reducing sepsis-associated AKI.	Paclitaxel	14-24	high mobility group box 1	Homo sapiens	107-112
33162028-2	2021	In this study, angiopep-2 modified lipid-coated mesoporous silica nanoparticle loading paclitaxel (ANG-LP-MSN-PTX) was developed to transport paclitaxel (PTX) across BBB mediated by low-density lipoprotein receptor-related protein 1 (LRP1), which is over-expressed on both BBB and glioma cells.	Paclitaxel	110-113	LDL receptor related protein 1	Rattus norvegicus	234-238
33262643-13	2020	Intra-RVM administration of p38 mitogen-activated protein kinase (p38 MAPK) inhibitor SB203580 alleviated paclitaxel-induced pain in a similar manner to PCPA.	Paclitaxel	106-116	mitogen activated protein kinase 14	Rattus norvegicus	28-64
32847971-0	2020	Dysregulation of EAAT2 and VGLUT2 spinal glutamate transports via histone deacetylase 2 (HDAC2) contributes to paclitaxel-induced painful neuropathy.	Paclitaxel	111-121	histone deacetylase 2	Rattus norvegicus	66-87
32847971-0	2020	Dysregulation of EAAT2 and VGLUT2 spinal glutamate transports via histone deacetylase 2 (HDAC2) contributes to paclitaxel-induced painful neuropathy.	Paclitaxel	111-121	histone deacetylase 2	Rattus norvegicus	89-94
33262643-13	2020	Intra-RVM administration of p38 mitogen-activated protein kinase (p38 MAPK) inhibitor SB203580 alleviated paclitaxel-induced pain in a similar manner to PCPA.	Paclitaxel	106-116	mitogen activated protein kinase 14	Rattus norvegicus	66-74
33790078-12	2021	Moreover, the RAC1/p21 (RAC1) activated kinase 1 (PAK1)/LIM kinase 1 (LIMK1)/Cofilin pathway was significantly activated in paclitaxel-resistant HCC94 and C-33A cells, while miR-509-3p overexpression significantly inactivated this pathway.	Paclitaxel	124-134	p21 (RAC1) activated kinase 1	Homo sapiens	50-54
33262643-14	2020	Intrathecal injection of ondansetron, a 5-HT3 receptor antagonist, partially reversed paclitaxel-induced pain, indicating that 5-HT3 receptors were involved in descending serotoninergic modulation of spinal pain processing.	Paclitaxel	86-96	5-hydroxytryptamine receptor 3A	Rattus norvegicus	40-54
33061608-0	2020	Downregulation of circNRIP1 Suppresses the Paclitaxel Resistance of Ovarian Cancer via Regulating the miR-211-5p/HOXC8 Axis.	Paclitaxel	43-53	nuclear receptor interacting protein 1	Homo sapiens	18-27
33061608-2	2020	Nevertheless, the role of circRNA nuclear receptor-interacting protein 1 (circNRIP1) in the paclitaxel (PTX) resistance of ovarian cancer (OC) remains unclear.	Paclitaxel	92-102	nuclear receptor interacting protein 1	Homo sapiens	74-83
33790078-12	2021	Moreover, the RAC1/p21 (RAC1) activated kinase 1 (PAK1)/LIM kinase 1 (LIMK1)/Cofilin pathway was significantly activated in paclitaxel-resistant HCC94 and C-33A cells, while miR-509-3p overexpression significantly inactivated this pathway.	Paclitaxel	124-134	LIM domain kinase 1	Homo sapiens	70-75
33061608-2	2020	Nevertheless, the role of circRNA nuclear receptor-interacting protein 1 (circNRIP1) in the paclitaxel (PTX) resistance of ovarian cancer (OC) remains unclear.	Paclitaxel	104-107	nuclear receptor interacting protein 1	Homo sapiens	74-83
33061608-9	2020	Results: CircNRIP1 was highly expressed in PTX-resistant OC tissues and cells.	Paclitaxel	43-46	nuclear receptor interacting protein 1	Homo sapiens	9-18
32871457-0	2020	Modulating TRPV4 channels with paclitaxel and lithium.	Paclitaxel	31-41	transient receptor potential cation channel subfamily V member 4	Homo sapiens	11-16
32871457-3	2020	However, the direct effect of PTX and lithium on TRPV4 is not clear.	Paclitaxel	30-33	transient receptor potential cation channel subfamily V member 4	Homo sapiens	49-54
32871457-5	2020	The addition of pharmacologically appropriate levels of PTX increased the expression of TRPV4, TRPV4 currents, and TRPV4-dependent calcium fluxes.	Paclitaxel	56-59	transient receptor potential cation channel subfamily V member 4	Homo sapiens	88-93
33061608-10	2020	Silencing of circNRIP1 repressed the PTX resistance of OC cells in vitro and OC tumor in vivo.	Paclitaxel	37-40	nuclear receptor interacting protein 1	Homo sapiens	13-22
33790078-12	2021	Moreover, the RAC1/p21 (RAC1) activated kinase 1 (PAK1)/LIM kinase 1 (LIMK1)/Cofilin pathway was significantly activated in paclitaxel-resistant HCC94 and C-33A cells, while miR-509-3p overexpression significantly inactivated this pathway.	Paclitaxel	124-134	cofilin 1	Homo sapiens	77-84
33061608-11	2020	Furthermore, circNRIP1 sponged miR-211-5p, and miR-211-5p inhibitor could reverse the inhibitory effect of circNRIP1 knockdown on the PTX resistance of OC cells.	Paclitaxel	134-137	nuclear receptor interacting protein 1	Homo sapiens	13-22
33061608-11	2020	Furthermore, circNRIP1 sponged miR-211-5p, and miR-211-5p inhibitor could reverse the inhibitory effect of circNRIP1 knockdown on the PTX resistance of OC cells.	Paclitaxel	134-137	nuclear receptor interacting protein 1	Homo sapiens	107-116
32871457-5	2020	The addition of pharmacologically appropriate levels of PTX increased the expression of TRPV4, TRPV4 currents, and TRPV4-dependent calcium fluxes.	Paclitaxel	56-59	transient receptor potential cation channel subfamily V member 4	Homo sapiens	95-100
32871457-5	2020	The addition of pharmacologically appropriate levels of PTX increased the expression of TRPV4, TRPV4 currents, and TRPV4-dependent calcium fluxes.	Paclitaxel	56-59	transient receptor potential cation channel subfamily V member 4	Homo sapiens	95-100
32871457-6	2020	Prolonged exposure to PTX amplified the acute effects of TRPV4 expression, currents, and calcium fluxes.	Paclitaxel	22-25	transient receptor potential cation channel subfamily V member 4	Homo sapiens	57-62
33061608-12	2020	In addition, miR-211-5p targeted HOXC8, and HOXC8 overexpression could reverse the suppression effect of miR-211-5p on the PTX resistance of OC cells.	Paclitaxel	123-126	homeobox C8	Homo sapiens	44-49
32965065-0	2021	Blockade of Bradykinin Receptors or Angiotensin II Type 2 Receptor Prevents Paclitaxel-Associated Acute Pain Syndrome in Mice.	Paclitaxel	76-86	angiotensin II receptor, type 2	Mus musculus	36-66
33061608-14	2020	Conclusion: CircNRIP1 silencing could inhibit the PTX resistance of OC via regulating the miR-211-5p/HOXC8 axis, showing that circNRIP1 might be a potential target for OC resistance treatment.	Paclitaxel	50-53	nuclear receptor interacting protein 1	Homo sapiens	12-21
33061608-14	2020	Conclusion: CircNRIP1 silencing could inhibit the PTX resistance of OC via regulating the miR-211-5p/HOXC8 axis, showing that circNRIP1 might be a potential target for OC resistance treatment.	Paclitaxel	50-53	homeobox C8	Homo sapiens	101-106
33061608-14	2020	Conclusion: CircNRIP1 silencing could inhibit the PTX resistance of OC via regulating the miR-211-5p/HOXC8 axis, showing that circNRIP1 might be a potential target for OC resistance treatment.	Paclitaxel	50-53	nuclear receptor interacting protein 1	Homo sapiens	126-135
33061425-12	2020	Paclitaxel treatment inhibited the expression of circ-BIRC6 and YWHAZ while promoted the expression of miR-877-5p.	Paclitaxel	0-10	baculoviral IAP repeat-containing 6	Mus musculus	54-59
33061425-13	2020	Circ-BIRC6 overexpression or miR-877-5p interference reversed the inhibitory effect of paclitaxel on HCC tumorigenesis.	Paclitaxel	87-97	baculoviral IAP repeat-containing 6	Mus musculus	5-10
33061425-17	2020	Conclusion: Paclitaxel limited HCC tumorigenesis via modulating circ-BIRC6/miR-877-5p/YWHAZ axis, providing a novel therapeutic approach for the treatment of HCC.	Paclitaxel	12-22	baculoviral IAP repeat-containing 6	Mus musculus	69-74
32963602-0	2020	Paclitaxel inhibits the migration of CD133+ U251 malignant glioma cells by reducing the expression of glycolytic enzymes.	Paclitaxel	0-10	prominin 1	Homo sapiens	37-42
32963602-3	2020	The present study investigated the role of low-dose paclitaxel (PTX) in changing the expression levels of key genes and proteins during glycolysis in CD133+ U251 glioma cells and explored the relevant regulatory mechanisms of action at the molecular level.	Paclitaxel	52-62	prominin 1	Homo sapiens	150-155
32963602-3	2020	The present study investigated the role of low-dose paclitaxel (PTX) in changing the expression levels of key genes and proteins during glycolysis in CD133+ U251 glioma cells and explored the relevant regulatory mechanisms of action at the molecular level.	Paclitaxel	64-67	prominin 1	Homo sapiens	150-155
32963602-12	2020	Since glycolysis plays an indispensable role in the proliferation and migration of stem cell-like glioma cells, PTX may inhibit tumor cell growth by downregulating the gene and protein expression levels of glycolytic enzymes in CD133+ glioma cells.	Paclitaxel	112-115	prominin 1	Homo sapiens	228-233
33376345-8	2020	Cell apoptosis occurred in the PTX, sh-ECT2 and sh-ECT2-PTX groups.	Paclitaxel	56-59	ect2 oncogene	Mus musculus	51-55
32657612-8	2020	In addition, TNBC cells treated with NRP1 antagonist significantly potentiated the effect of PTX on cell proliferation, cell migration, and cell apoptosis.	Paclitaxel	93-96	neuropilin 1	Homo sapiens	37-41
33376345-9	2020	About the Ki-67 proliferation index, the PTX, LV-ECT2-PTX, sh-ECT2 and sh-ECT2-PTX groups were significantly different from the control group.	Paclitaxel	54-57	ect2 oncogene	Mus musculus	49-53
32982226-3	2020	Materials and Methods: TfR-T12 peptide-modified PEG-PLA polymer was synthesized to deliver paclitaxel (PTX) for glioma therapy.	Paclitaxel	91-101	transferrin receptor	Homo sapiens	23-26
33376345-9	2020	About the Ki-67 proliferation index, the PTX, LV-ECT2-PTX, sh-ECT2 and sh-ECT2-PTX groups were significantly different from the control group.	Paclitaxel	54-57	ect2 oncogene	Mus musculus	49-53
32982226-3	2020	Materials and Methods: TfR-T12 peptide-modified PEG-PLA polymer was synthesized to deliver paclitaxel (PTX) for glioma therapy.	Paclitaxel	103-106	transferrin receptor	Homo sapiens	23-26
32982226-5	2020	Results: TfR-T12-PEG-PLA/PTX polymeric micelles (TfR-T12-PMs) could be absorbed rapidly by tumor cells, and traversed effectively the BBB monolayers.	Paclitaxel	25-28	transferrin receptor	Homo sapiens	9-12
33028939-7	2020	The paclitaxel-resistant cells showed stronger E2F2 expression than the parental cells, while E2F2 inhibition sensitized the resistant cells to paclitaxel.	Paclitaxel	4-14	E2F transcription factor 2	Homo sapiens	47-51
33028939-7	2020	The paclitaxel-resistant cells showed stronger E2F2 expression than the parental cells, while E2F2 inhibition sensitized the resistant cells to paclitaxel.	Paclitaxel	144-154	E2F transcription factor 2	Homo sapiens	94-98
33028939-8	2020	Forced E2F2 expression in the parental cells led to the acquisition of paclitaxel resistance, while miR-522-3p inhibited E2F2 expression and was associated with retinoblastoma protein phosphorylation attenuation, which resulted in G0/G1 arrest.	Paclitaxel	71-81	E2F transcription factor 2	Homo sapiens	7-11
32982226-5	2020	Results: TfR-T12-PEG-PLA/PTX polymeric micelles (TfR-T12-PMs) could be absorbed rapidly by tumor cells, and traversed effectively the BBB monolayers.	Paclitaxel	25-28	transferrin receptor	Homo sapiens	49-52
32982226-6	2020	TfR-T12-PMs can effectively inhibit the proliferation of U87MG cells in vitro, and TfR-T12-PMs loaded with paclitaxel presented better antiglioma effect with prolonged median survival of nude mice-bearing glioma than the unmodified PMs.	Paclitaxel	107-117	transferrin receptor	Homo sapiens	83-86
33028939-10	2020	In conclusion, miR-522-3p attenuated the degree of paclitaxel resistance in vitro through the downregulation of E2F2; miR-522-3p supplementation may be a therapeutic target for paclitaxel-resistant ovarian cancer.	Paclitaxel	51-61	E2F transcription factor 2	Homo sapiens	112-116
33376345-11	2020	PTX therapy had significantly improved efficacy after silencing ECT2.	Paclitaxel	0-3	ect2 oncogene	Mus musculus	64-68
32943934-8	2020	Moxibustion combined with paclitaxel increased the number of white blood cells, thymus index, and spleen index, and enhanced immune function by upregulating interferon-gamma and interleukin-2 and downregulating interleukin-10 and transforming growth factor-beta1.	Paclitaxel	26-36	transforming growth factor, beta 1	Mus musculus	230-262
33376345-12	2020	This finding indicates that the inhibition of ECT2 expression may facilitate the treatment of breast cancer as a new regimen and provide a theoretical basis for the development of new targeted drugs as a replacement for PTX in breast cancer treatment.	Paclitaxel	220-223	ect2 oncogene	Mus musculus	46-50
33319669-5	2021	PTX resistance pathways that involve major regulatory proteins/RNAs like RNF8/Twist/ROR1, TLR, ErbB3/ErbB2, BRCA1-IRIS, MENA, LIN9, MiRNA, FoxM1 and IRAK1 have expanded the complexity of resistance mechanisms, and brought newer insights for development of drug targets.	Paclitaxel	0-3	interleukin 1 receptor associated kinase 1	Homo sapiens	149-154
33027666-4	2020	Expression of a non-phosphorylatable raptor mutant reactivates mTORC1 and significantly reduces cytotoxicity of the mitotic poison Taxol.	Paclitaxel	131-136	regulatory associated protein of MTOR complex 1	Homo sapiens	37-43
32847971-5	2020	HDAC2 and transcription factor YY1 were also upregulated, and their interaction and co-localization were confirmed following paclitaxel treatment using co-immunoprecipitation (Co-IP).	Paclitaxel	125-135	histone deacetylase 2	Rattus norvegicus	0-5
33042272-8	2020	Mechanistically, MITR counteracted MEF2A-induced transcriptional suppression of IL11, ultimately causing paclitaxel resistance.	Paclitaxel	105-115	myocyte enhancer factor 2A	Homo sapiens	35-40
32847971-6	2020	Inhibition or knockdown of HDAC2 expression by valproic acid (VPA), BRD6688 or HDAC2 siRNA (small interfering RNA) not only attenuated paclitaxel-induced mechanical allodynia but also suppressed HDAC2 upregulation, glutamate accumulation and the corresponding changes in EAAT2/VGLUT/synaptophysin expression and HDAC2/YY1 interaction.	Paclitaxel	135-145	histone deacetylase 2	Rattus norvegicus	27-32
32064933-6	2020	Six genes (KANK1, ALDH3A1, GALNT14, PIK3R3, LRG1, WEE2), which may be related to paclitaxel resistance in lung adenocarcinoma, were identified.	Paclitaxel	81-91	aldehyde dehydrogenase 3 family member A1	Homo sapiens	18-25
32847971-6	2020	Inhibition or knockdown of HDAC2 expression by valproic acid (VPA), BRD6688 or HDAC2 siRNA (small interfering RNA) not only attenuated paclitaxel-induced mechanical allodynia but also suppressed HDAC2 upregulation, glutamate accumulation and the corresponding changes in EAAT2/VGLUT/synaptophysin expression and HDAC2/YY1 interaction.	Paclitaxel	135-145	histone deacetylase 2	Rattus norvegicus	79-84
32847971-6	2020	Inhibition or knockdown of HDAC2 expression by valproic acid (VPA), BRD6688 or HDAC2 siRNA (small interfering RNA) not only attenuated paclitaxel-induced mechanical allodynia but also suppressed HDAC2 upregulation, glutamate accumulation and the corresponding changes in EAAT2/VGLUT/synaptophysin expression and HDAC2/YY1 interaction.	Paclitaxel	135-145	histone deacetylase 2	Rattus norvegicus	79-84
32847971-6	2020	Inhibition or knockdown of HDAC2 expression by valproic acid (VPA), BRD6688 or HDAC2 siRNA (small interfering RNA) not only attenuated paclitaxel-induced mechanical allodynia but also suppressed HDAC2 upregulation, glutamate accumulation and the corresponding changes in EAAT2/VGLUT/synaptophysin expression and HDAC2/YY1 interaction.	Paclitaxel	135-145	histone deacetylase 2	Rattus norvegicus	79-84
33042272-10	2020	Conclusion: Our in vitro and in vivo genetic and cellular analyses elucidated the pivotal role of MITR/MEF2A/IL11 axis in paclitaxel resistance and provided a novel therapeutic strategy for TNBC patients to overcome poor chemotherapy responses.	Paclitaxel	122-132	myocyte enhancer factor 2A	Homo sapiens	103-108
32427586-4	2020	Paclitaxel induces HIF-1-dependent expression of S100A10, which forms a complex with ANXA2 that interacts with histone chaperone SPT6 and histone demethylase KDM6A.	Paclitaxel	0-10	SPT6 homolog, histone chaperone and transcription elongation factor	Homo sapiens	129-133
33121324-12	2020	Interestingly, miR-4513 mimic could abolish the role of PBLD upregulation in cell behaviors and PTX-resistance in MCF-7 and MDA-MB-231 cells.	Paclitaxel	96-99	phenazine biosynthesis like protein domain containing	Homo sapiens	56-60
32993973-0	2020	Redox- and MMP-2-sensitive drug delivery nanoparticles based on gelatin and albumin for tumor targeted delivery of paclitaxel.	Paclitaxel	115-125	matrix metallopeptidase 2	Homo sapiens	11-16
32943985-0	2020	XIST lost induces ovarian cancer stem cells to acquire taxol resistance via a KMT2C-dependent way.	Paclitaxel	55-60	lysine (K)-specific methyltransferase 2C	Mus musculus	78-83
32943985-13	2020	Overexpression of KMT2C inhibited XIST silencing-induced proliferation of cancer stem cells, and KMT2C was able to mediate paclitaxel resistance induced by XIST in ovarian cancer.	Paclitaxel	123-133	lysine (K)-specific methyltransferase 2C	Mus musculus	18-23
32943985-13	2020	Overexpression of KMT2C inhibited XIST silencing-induced proliferation of cancer stem cells, and KMT2C was able to mediate paclitaxel resistance induced by XIST in ovarian cancer.	Paclitaxel	123-133	lysine (K)-specific methyltransferase 2C	Mus musculus	97-102
32943985-15	2020	Conclusion: XIST promoted the sensitivity of ovarian cancer stem cells to paclitaxel in a KMT2C-dependent manner.	Paclitaxel	74-84	lysine (K)-specific methyltransferase 2C	Mus musculus	90-95
33256016-12	2020	SKOV-3 cells co-treated with sitagliptin and paclitaxel decreased concentrations of MMP-1, MMP-2, MMP-7, MMP-10, TIMP-1, TIMP-2.	Paclitaxel	45-55	matrix metallopeptidase 2	Homo sapiens	91-96
33138677-0	2020	LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.	Paclitaxel	46-56	actin filament associated protein 1	Mus musculus	7-12
32806062-8	2020	With the ability to effectively inhibit activated platelets and TGF-beta secretion in tumors, Ptx@AlbSNO can enhance intratumoral immune cell infiltration to reverse the immunosuppressive tumor microenvironment.	Paclitaxel	94-97	transforming growth factor alpha	Homo sapiens	64-72
33138677-0	2020	LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.	Paclitaxel	92-102	actin filament associated protein 1	Mus musculus	7-12
33096483-6	2020	PGK1 regulated glucose metabolism and deteriorated PCOS-like mouse metabolic disorder, and paclitaxel rescued the phenotype of PCOS-like mice and reduced ovarian PGK1 and AR protein levels.	Paclitaxel	91-101	ferredoxin reductase	Mus musculus	171-173
32833503-0	2022	Circ_0011292 Enhances Paclitaxel Resistance in Non-Small Cell Lung Cancer by Regulating miR-379-5p/TRIM65 Axis.	Paclitaxel	22-32	microRNA 379	Homo sapiens	88-95
32833503-0	2022	Circ_0011292 Enhances Paclitaxel Resistance in Non-Small Cell Lung Cancer by Regulating miR-379-5p/TRIM65 Axis.	Paclitaxel	22-32	tripartite motif containing 65	Homo sapiens	99-105
32833503-15	2022	Besides, miR-379-5p potentiated PTX sensitivity by targeting TRIM65.	Paclitaxel	32-35	microRNA 379	Homo sapiens	9-16
32833503-15	2022	Besides, miR-379-5p potentiated PTX sensitivity by targeting TRIM65.	Paclitaxel	32-35	tripartite motif containing 65	Homo sapiens	61-67
32833503-16	2022	Also, circ_0011292 increased PTX resistance by sponging miR-379-5p.	Paclitaxel	29-32	microRNA 379	Homo sapiens	56-63
32833503-17	2022	Conclusion: Circ_0011292 facilitated tumorigenesis and PTX resistance in NSCLC by regulating the miR-379-5p/TRIM65 axis, suggesting that circ_0011292 was a promising therapeutic target for NSCLC chemotherapy.	Paclitaxel	55-58	microRNA 379	Homo sapiens	97-104
32867128-13	2020	HMGB1 silencing causes loss of response to paclitaxel, whereas silencing of HMGB2 slightly increases sensitivity to olaparib.	Paclitaxel	43-53	high mobility group box 1	Homo sapiens	0-5
32660221-0	2020	Evaluation of miR-34a Effect on CCND1 mRNA Level and Sensitization of Breast Cancer Cell Lines to Paclitaxel.	Paclitaxel	98-108	microRNA 34a	Homo sapiens	14-21
32913503-10	2020	Immunohistochemical staining demonstrated that SPR064 and paclitaxel significantly reduced the expression of Ki-67 and BCL-xL in the endometrial tumors of both obese and lean mice.	Paclitaxel	58-68	BCL2-like 1	Mus musculus	119-125
32833503-17	2022	Conclusion: Circ_0011292 facilitated tumorigenesis and PTX resistance in NSCLC by regulating the miR-379-5p/TRIM65 axis, suggesting that circ_0011292 was a promising therapeutic target for NSCLC chemotherapy.	Paclitaxel	55-58	tripartite motif containing 65	Homo sapiens	108-114
32628454-1	2020	The paclitaxel (PTX) resistance in most epithelial ovarian cancers (EOCs) with increasing membrane expression of mucin 16 (MUC16) is mediated by the Toll-like receptor-myeloid differentiation factor 2/myeloid differentiation factor 88 (TLR4-MD2/MyD88) signaling pathway.	Paclitaxel	16-19	MYD88 innate immune signal transduction adaptor	Homo sapiens	245-250
32628454-2	2020	6-shogaol (6S), an alpha, beta-unsaturated carbonyl compound with lipophilic property, can block PTX-induced formation of the TLR4/MD-2 complex that activates the MyD88/NF-kV signaling pathway.	Paclitaxel	97-100	MYD88 innate immune signal transduction adaptor	Homo sapiens	163-168
32782439-0	2020	Long non-coding RNA SNHG6 regulates the sensitivity of prostate cancer cells to paclitaxel by sponging miR-186.	Paclitaxel	80-90	microRNA 186	Homo sapiens	103-110
32660221-10	2020	Moreover, it can reduce the expression of CCND1 mRNA independent of the paclitaxel effect.	Paclitaxel	72-82	cyclin D1	Homo sapiens	42-47
32782439-12	2020	Furthermore, miR-186 downregulation reversed SNHG6 silencing-mediated cell sensitivity to PTX, proliferation, migration, and invasion in PTX-resistant PCa cells.	Paclitaxel	90-93	microRNA 186	Homo sapiens	13-20
32505840-12	2020	The synergetic effect was played by Xiaoaiping injection inhibiting paclitaxel-induced PXR and CAR expression, which subsequently inhibited CYP450 enzymes CYP2C8 and CYP3A4, transporter P-gp and anti-apoptotic proteins Bcl-2 and Bcl-xl in SK-OV-3 cells.	Paclitaxel	68-78	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	155-161
32782439-12	2020	Furthermore, miR-186 downregulation reversed SNHG6 silencing-mediated cell sensitivity to PTX, proliferation, migration, and invasion in PTX-resistant PCa cells.	Paclitaxel	137-140	microRNA 186	Homo sapiens	13-20
32782439-13	2020	Conclusions: SNHG6 knockdown elevated the sensitivity of PTX-resistant PCa cells to PTX by sponging miR-186, indicating that SNHG6 might be a therapeutic target for PCa.	Paclitaxel	57-60	microRNA 186	Homo sapiens	100-107
32782439-13	2020	Conclusions: SNHG6 knockdown elevated the sensitivity of PTX-resistant PCa cells to PTX by sponging miR-186, indicating that SNHG6 might be a therapeutic target for PCa.	Paclitaxel	84-87	microRNA 186	Homo sapiens	100-107
32922547-10	2020	Knockdown of ZIC2 inhibited sphere-forming capacity and decreased cisplatin and paclitaxel resistance.	Paclitaxel	80-90	Zic family member 2	Homo sapiens	13-17
31993881-0	2020	The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy.	Paclitaxel	51-56	gasdermin D	Homo sapiens	22-27
32632453-0	2020	Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO.	Paclitaxel	41-51	non-POU domain containing octamer binding	Homo sapiens	140-144
32632453-8	2020	Knockdown of NONO with siRNA sensitized TNBC to PTX.	Paclitaxel	48-51	non-POU domain containing octamer binding	Homo sapiens	13-17
31993881-5	2020	In this study, we observed that Taxol treatment caused pyroptotic cell death, along with activation of Caspase-1 and maturation of IL-1beta, as well as cleavage of GSDMD, which is the canonical pyroptosis executor.	Paclitaxel	32-37	gasdermin D	Homo sapiens	164-169
32275943-0	2020	HMGB1 release promotes paclitaxel resistance in castration-resistant prostate cancer cells via activating c-Myc expression.	Paclitaxel	23-33	high mobility group box 1	Homo sapiens	0-5
32275943-3	2020	In this study, we reported that PTX-induced constant HMGB1 expression and release confers to PTX resistance in mCRPC cells via activating and sustaining c-Myc signaling.	Paclitaxel	32-35	high mobility group box 1	Homo sapiens	53-58
32275943-3	2020	In this study, we reported that PTX-induced constant HMGB1 expression and release confers to PTX resistance in mCRPC cells via activating and sustaining c-Myc signaling.	Paclitaxel	93-96	high mobility group box 1	Homo sapiens	53-58
32275943-4	2020	PTX upregulated HMGB1 expression and triggered its release in human mCRPC cells.	Paclitaxel	0-3	high mobility group box 1	Homo sapiens	16-21
32275943-5	2020	Silencing HMGB1 by RNAi and blocking HMGB1 release by glycyrrhizin or HMGB1 neutralizing antibody sensitized the response of PTX-resistant mCRPC cells to PTX.	Paclitaxel	125-128	high mobility group box 1	Homo sapiens	10-15
31993881-6	2020	Furthermore, Taxol-induced pyroptotic cell death could be suppressed by Caspase-1 inhibitor (Z-YVAD-FMK) and GSDMD knockout.	Paclitaxel	13-18	gasdermin D	Homo sapiens	109-114
32275943-5	2020	Silencing HMGB1 by RNAi and blocking HMGB1 release by glycyrrhizin or HMGB1 neutralizing antibody sensitized the response of PTX-resistant mCRPC cells to PTX.	Paclitaxel	125-128	high mobility group box 1	Homo sapiens	37-42
32275943-5	2020	Silencing HMGB1 by RNAi and blocking HMGB1 release by glycyrrhizin or HMGB1 neutralizing antibody sensitized the response of PTX-resistant mCRPC cells to PTX.	Paclitaxel	125-128	high mobility group box 1	Homo sapiens	37-42
31993881-7	2020	Moreover, NPC parental cells demonstrated higher levels of pyroptosis than Taxol-resistant cells, and pyroptosis mediated by Caspase-1/GSDMD suppression induced by a Caspase-1 inhibitor and GSDMD knockout could induce a Taxol-resistant phenotype in vitro and in vivo.	Paclitaxel	220-225	gasdermin D	Homo sapiens	135-140
32275943-5	2020	Silencing HMGB1 by RNAi and blocking HMGB1 release by glycyrrhizin or HMGB1 neutralizing antibody sensitized the response of PTX-resistant mCRPC cells to PTX.	Paclitaxel	154-157	high mobility group box 1	Homo sapiens	37-42
32275943-5	2020	Silencing HMGB1 by RNAi and blocking HMGB1 release by glycyrrhizin or HMGB1 neutralizing antibody sensitized the response of PTX-resistant mCRPC cells to PTX.	Paclitaxel	154-157	high mobility group box 1	Homo sapiens	37-42
31993881-7	2020	Moreover, NPC parental cells demonstrated higher levels of pyroptosis than Taxol-resistant cells, and pyroptosis mediated by Caspase-1/GSDMD suppression induced by a Caspase-1 inhibitor and GSDMD knockout could induce a Taxol-resistant phenotype in vitro and in vivo.	Paclitaxel	220-225	gasdermin D	Homo sapiens	166-195
32275943-8	2020	Therefore, HMGB1/c-Myc axis is critical in the development of PTX resistance, and targeting HMGB1/c-Myc axis would counteract PTX resistance in mCRPC cells.	Paclitaxel	62-65	high mobility group box 1	Homo sapiens	11-16
32275943-8	2020	Therefore, HMGB1/c-Myc axis is critical in the development of PTX resistance, and targeting HMGB1/c-Myc axis would counteract PTX resistance in mCRPC cells.	Paclitaxel	126-129	high mobility group box 1	Homo sapiens	92-97
31838201-5	2020	Herein, we developed endogenous human ferritin heavy chain nanocage (HFn) as PTX carrier, which could specifically bind to widely overexpressed transferrin receptor 1 (TfR1) on BBB and glioma cells.	Paclitaxel	77-80	transferrin receptor	Homo sapiens	144-166
31993881-8	2020	By transfecting an siRNA targeting Beclin-1 into NPC Taxol-resistant cells, we discovered that autophagy could negatively regulate pyroptosis by inhibiting Caspase-1/GSDMD activation.	Paclitaxel	53-58	gasdermin D	Homo sapiens	166-171
31838201-5	2020	Herein, we developed endogenous human ferritin heavy chain nanocage (HFn) as PTX carrier, which could specifically bind to widely overexpressed transferrin receptor 1 (TfR1) on BBB and glioma cells.	Paclitaxel	77-80	transferrin receptor	Homo sapiens	168-172
31993881-9	2020	Taken together, our results indicated that Caspase-1/GSDMD mediated Taxol-induced pyroptosis and a Taxol-resistant phenotype in NPC cell lines, which may be regulated by autophagy.	Paclitaxel	68-73	gasdermin D	Homo sapiens	53-58
31993881-9	2020	Taken together, our results indicated that Caspase-1/GSDMD mediated Taxol-induced pyroptosis and a Taxol-resistant phenotype in NPC cell lines, which may be regulated by autophagy.	Paclitaxel	99-104	gasdermin D	Homo sapiens	53-58
32700628-6	2020	Conclusion: Our results support prior evidence that FZD3 rs7001034 is protective of PN and may be useful for individualizing paclitaxel treatment to prevent PN.	Paclitaxel	125-135	frizzled class receptor 3	Homo sapiens	52-56
33016107-0	2020	CAVIN2 is frequently silenced by CpG methylation and sensitizes lung cancer cells to paclitaxel and 5-FU.	Paclitaxel	85-95	caveolae associated protein 2	Homo sapiens	0-6
32779438-12	2020	Overexpression of GATA5 was not only alone but also synergized with Paclitaxel to inhibit expression of CD44 and CD133 in Bel7402 or PLC/PRF/5 cells.	Paclitaxel	68-78	prominin 1	Homo sapiens	113-118
33016107-6	2020	Furthermore, ectopic expression of CAVIN2 inhibits cell proliferation in vivo and in vitro by inducing G2/M cell cycle arrest, which sensitizes the chemosensitivity of lung cancer cells to paclitaxel and 5-fluorouracil, but not cisplatin.	Paclitaxel	189-199	caveolae associated protein 2	Homo sapiens	35-41
32371002-3	2020	Paclitaxel (PTX) and acriflavine (ACF) were identified as the most promising molecules to inhibit CAF development.	Paclitaxel	0-10	lysine acetyltransferase 2B	Homo sapiens	98-101
33016107-7	2020	Conclusion: CAVIN2 is a tumor suppressor in non-small-cell lung cancer and can sensitize lung cancer cells to paclitaxel and 5-fluorouracil.	Paclitaxel	110-120	caveolae associated protein 2	Homo sapiens	12-18
32371002-3	2020	Paclitaxel (PTX) and acriflavine (ACF) were identified as the most promising molecules to inhibit CAF development.	Paclitaxel	12-15	lysine acetyltransferase 2B	Homo sapiens	98-101
32945387-0	2020	Downregulated Mucin 1 alleviates paclitaxel resistance in non-small cell lung cancer cells.	Paclitaxel	33-43	mucin 1, cell surface associated	Homo sapiens	14-21
32570786-2	2020	To analyze the contribution of transient receptor potential vanilloid 1 (TRPV1) in the development of PTX-induced mechanical allodynia/hyperalgesia and thermal hyperalgesia, TRPV1 expression in the rat spinal cord was analyzed after intraperitoneal administration of 2 and 4 mg/kg PTX.	Paclitaxel	102-105	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	73-78
32570786-2	2020	To analyze the contribution of transient receptor potential vanilloid 1 (TRPV1) in the development of PTX-induced mechanical allodynia/hyperalgesia and thermal hyperalgesia, TRPV1 expression in the rat spinal cord was analyzed after intraperitoneal administration of 2 and 4 mg/kg PTX.	Paclitaxel	102-105	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	174-179
32945387-3	2020	The present study was designed to investigate the expression patterns, functions and underlying mechanisms of MUC1 in regulating paclitaxel-resistant cell line A549/PR in NSCLC.	Paclitaxel	129-139	mucin 1, cell surface associated	Homo sapiens	110-114
32570786-3	2020	PTX treatment increased the expression of TRPV1 protein in the spinal cord.	Paclitaxel	0-3	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	42-47
32945387-8	2020	Silence of MUC1 could obviously suppress the proliferation and promote apoptosis of A549/PR cells in treatment of paclitaxel through up-regulating the expression of Bax and Caspase-3, and down-regulating the expression of Bcl-2, suggesting that chemotherapy combined with the modulation of MUC1 might be characterized as a promising therapeutic approach to overcome paclitaxel-resistance in NSCLC in the future.	Paclitaxel	114-124	mucin 1, cell surface associated	Homo sapiens	11-15
32570786-4	2020	Immunohistochemistry showed that PTX (4 mg/kg) treatment increased TRPV1 protein expression in the superficial layers of the spinal dorsal horn 14 days after treatment.	Paclitaxel	33-36	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	67-72
32570786-5	2020	Behavioral assessment using the paw withdrawal response showed that PTX-induced mechanical allodynia/hyperalgesia and thermal hyperalgesia after 14 days was significantly inhibited by oral or intrathecal administration of the TRPV1 antagonist AMG9810.	Paclitaxel	68-71	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	226-231
32570786-6	2020	We found that intrathecal administration of small interfering RNA (siRNA) to knock down TRPV1 protein expression in the spinal cord significantly decreased PTX-induced mechanical allodynia/hyperalgesia and thermal hyperalgesia.	Paclitaxel	156-159	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	88-93
32570786-7	2020	Together, these results demonstrate that TRPV1 receptor expression in spinal cord contributes, at least in part, to the development of PTX-induced painful peripheral neuropathy.	Paclitaxel	135-138	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	41-46
32570786-8	2020	TRPV1 receptor antagonists may be useful in the prevention and treatment of PTX-induced peripheral neuropathic pain.	Paclitaxel	76-79	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	0-5
32945387-8	2020	Silence of MUC1 could obviously suppress the proliferation and promote apoptosis of A549/PR cells in treatment of paclitaxel through up-regulating the expression of Bax and Caspase-3, and down-regulating the expression of Bcl-2, suggesting that chemotherapy combined with the modulation of MUC1 might be characterized as a promising therapeutic approach to overcome paclitaxel-resistance in NSCLC in the future.	Paclitaxel	366-376	mucin 1, cell surface associated	Homo sapiens	11-15
32958832-7	2020	Furthermore, we demonstrated that inhibition of RSK2-mediated autophagy rendered breast cancer cells more sensitive to paclitaxel, a chemotherapeutic agent that induces ER stress-mediated cell death.	Paclitaxel	119-129	ribosomal protein S6 kinase A3	Homo sapiens	48-52
32529309-7	2020	A confirmatory In Vitro study with paclitaxel, the 6alpha-hydroxylation of which is exclusively mediated by CYP2C8, was consistent with a potent inhibition of this enzyme by curcumin.	Paclitaxel	35-45	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	108-114
33014430-0	2020	EDIL3 promotes epithelial-mesenchymal transition and paclitaxel resistance through its interaction with integrin alphaVbeta3 in cancer cells.	Paclitaxel	53-63	EGF like repeats and discoidin domains 3	Homo sapiens	0-5
32393766-2	2020	Here, we show that palbociclib, a CDK4/6 inhibitor, and paclitaxel, a microtubule inhibitor, synergize with the BET inhibitor JQ1 in TNBC lines.	Paclitaxel	56-66	delta/notch like EGF repeat containing	Homo sapiens	112-115
33014430-2	2020	We performed a differential gene expression analysis comparing paclitaxel-resistant vs. paclitaxel-sensitive breast cancer cells that showed the upregulation of EDIL3 (EGF Like Repeats and Discoidin I Like Domains Protein 3).	Paclitaxel	63-73	EGF like repeats and discoidin domains 3	Homo sapiens	161-166
33014430-2	2020	We performed a differential gene expression analysis comparing paclitaxel-resistant vs. paclitaxel-sensitive breast cancer cells that showed the upregulation of EDIL3 (EGF Like Repeats and Discoidin I Like Domains Protein 3).	Paclitaxel	88-98	EGF like repeats and discoidin domains 3	Homo sapiens	161-166
33014430-4	2020	Our results demonstrated that EDIL3 expression levels were increased in paclitaxel-resistant breast and prostate cancer cells, and in subsets of high-grade breast and prostate tumors.	Paclitaxel	72-82	EGF like repeats and discoidin domains 3	Homo sapiens	30-35
32113682-2	2020	Here, we demonstrated that knockdown of DEDD in MCF-7 cells resulted in characteristic drug resistance to doxorubicin and paclitaxel, and overexpression of DEDD in MDA-MB-231 cells increased their sensitivity to doxorubicin and paclitaxel.	Paclitaxel	122-132	death effector domain containing	Homo sapiens	40-44
32113682-2	2020	Here, we demonstrated that knockdown of DEDD in MCF-7 cells resulted in characteristic drug resistance to doxorubicin and paclitaxel, and overexpression of DEDD in MDA-MB-231 cells increased their sensitivity to doxorubicin and paclitaxel.	Paclitaxel	228-238	death effector domain containing	Homo sapiens	40-44
33014430-6	2020	EDIL3 knockdown reverted EMT and sensitized cells to paclitaxel.	Paclitaxel	53-63	EGF like repeats and discoidin domains 3	Homo sapiens	0-5
32113682-2	2020	Here, we demonstrated that knockdown of DEDD in MCF-7 cells resulted in characteristic drug resistance to doxorubicin and paclitaxel, and overexpression of DEDD in MDA-MB-231 cells increased their sensitivity to doxorubicin and paclitaxel.	Paclitaxel	228-238	death effector domain containing	Homo sapiens	156-160
33014430-7	2020	In contrast, EDIL3 overexpression or the culture of cells in the presence of EDIL3-enriched medium induced EMT and paclitaxel resistance.	Paclitaxel	115-125	EGF like repeats and discoidin domains 3	Homo sapiens	13-18
33014430-7	2020	In contrast, EDIL3 overexpression or the culture of cells in the presence of EDIL3-enriched medium induced EMT and paclitaxel resistance.	Paclitaxel	115-125	EGF like repeats and discoidin domains 3	Homo sapiens	77-82
33014430-9	2020	In summary, EDIL3 may contribute to EMT and paclitaxel resistance through autocrine or paracrine signaling in cancer cells.	Paclitaxel	44-54	EGF like repeats and discoidin domains 3	Homo sapiens	12-17
33014430-10	2020	Blockade of EDIL3-integrin alphaVbeta3 interaction by cilengitide restores sensitivity to paclitaxel and reverts EMT in paclitaxel-resistant cancer cells.	Paclitaxel	90-100	EGF like repeats and discoidin domains 3	Homo sapiens	12-17
32321829-9	2020	Furthermore, BCL2L14-ETV6 fusions prime partial epithelial-mesenchymal transition and endow resistance to paclitaxel treatment.	Paclitaxel	106-116	BCL2 like 14	Homo sapiens	13-20
33014430-10	2020	Blockade of EDIL3-integrin alphaVbeta3 interaction by cilengitide restores sensitivity to paclitaxel and reverts EMT in paclitaxel-resistant cancer cells.	Paclitaxel	120-130	EGF like repeats and discoidin domains 3	Homo sapiens	12-17
32829374-9	2020	In addition, it reduced the expression of class III beta-tubulin protein and increase the sensitivity of drug-resistant cells to paclitaxel.	Paclitaxel	129-139	tubulin beta 3 class III	Homo sapiens	42-64
32829374-11	2020	CONCLUSIONS Octreotide-paclitaxel conjugate can reverse the paclitaxel resistance of A2780/Taxol human ovarian cancer cells by inhibiting the activity of p38 MAPK signaling pathway.	Paclitaxel	23-33	mitogen-activated protein kinase 14	Mus musculus	154-162
32829374-11	2020	CONCLUSIONS Octreotide-paclitaxel conjugate can reverse the paclitaxel resistance of A2780/Taxol human ovarian cancer cells by inhibiting the activity of p38 MAPK signaling pathway.	Paclitaxel	60-70	mitogen-activated protein kinase 14	Mus musculus	154-162
32203789-9	2020	In particular, it showed superior toxicity towards A549/Taxol cells that overexpressed CYP1B1, which further supported its potential to be an effective CYP1B1 inhibitor.	Paclitaxel	56-61	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	87-93
32628454-1	2020	The paclitaxel (PTX) resistance in most epithelial ovarian cancers (EOCs) with increasing membrane expression of mucin 16 (MUC16) is mediated by the Toll-like receptor-myeloid differentiation factor 2/myeloid differentiation factor 88 (TLR4-MD2/MyD88) signaling pathway.	Paclitaxel	4-14	MYD88 innate immune signal transduction adaptor	Homo sapiens	245-250
32203789-9	2020	In particular, it showed superior toxicity towards A549/Taxol cells that overexpressed CYP1B1, which further supported its potential to be an effective CYP1B1 inhibitor.	Paclitaxel	56-61	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	152-158
32395074-0	2020	ATG5 knockout promotes paclitaxel sensitivity in drug-resistant cells via induction of necrotic cell death.	Paclitaxel	23-33	autophagy related 5	Mus musculus	0-4
32395074-2	2020	Here, we investigated paclitaxel sensitivity in cells with knockout (KO) of ATG5 gene.	Paclitaxel	22-32	autophagy related 5	Mus musculus	76-80
32395074-5	2020	The ATG5 KO restored the sensitivity of Ras-NIH 3T3/Mdr cells to paclitaxel.	Paclitaxel	65-75	autophagy related 5	Mus musculus	4-8
32395074-7	2020	These results raise the possibility that low level of resistance to paclitaxel in ATG5 KO cells may be related to other roles of ATG5 independent of its function in autophagy.	Paclitaxel	68-78	autophagy related 5	Mus musculus	82-86
32848392-13	2020	We also confirmed that AMD-NP-PTX worked through targeting CXCL12/CXCR4 axis, thereby disturbing its downstream signaling pathways including epithelial-mesenchymal transition (EMT) processes and nuclear factor kappaB (NF-kappaB) pathway.	Paclitaxel	30-33	C-X-C motif chemokine ligand 12	Homo sapiens	59-65
32395074-9	2020	Additionally, ATG5 KO caused necrosis of a high proportion of cells after paclitaxel treatment.	Paclitaxel	74-84	autophagy related 5	Mus musculus	14-18
32700738-0	2020	LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a.	Paclitaxel	26-31	microRNA 34a	Homo sapiens	131-138
32395074-10	2020	These data suggest that the difference in sensitivity to paclitaxel between ATG5 KO and their parental MDR cells may result from the disparity in the proportions of necrotic cells in both populations.	Paclitaxel	57-67	autophagy related 5	Mus musculus	76-80
32395074-11	2020	Thus, our results demonstrate that the ATG5 KO in paclitaxel resistant cells leads to a marked G2/M arrest and sensitizes cells to paclitaxel-induced necrosis.	Paclitaxel	50-60	autophagy related 5	Mus musculus	39-43
32395074-11	2020	Thus, our results demonstrate that the ATG5 KO in paclitaxel resistant cells leads to a marked G2/M arrest and sensitizes cells to paclitaxel-induced necrosis.	Paclitaxel	131-141	autophagy related 5	Mus musculus	39-43
32700738-5	2020	HOTAIR knockdown suppresses proliferation, invasion and promotes apoptosis of in HepG2/Taxol and SMMC7721/Taxol cells through up-regulating miR-34a by MTT assay, transwell invasion assays and flow cytometry, while down-regulation of miR-34a had an opposite effect on reversing Taxol resistance.	Paclitaxel	106-111	microRNA 34a	Homo sapiens	140-147
32700738-7	2020	Besides, HOTAIR knockdown impaired Taxol-resistance in HCC by accommodating Akt phosphorylation and Wnt/beta-catenin signaling via interacting with miR-34a.	Paclitaxel	35-40	microRNA 34a	Homo sapiens	148-155
32278794-6	2020	We found that expression of DCDC2, ANKRD18B, ALDH1A1, c14orf105, ITGBL1 and NEB was overexpressed in taxol-resistant cells, suggesting the involvement of these AR-related genes in taxol resistance.	Paclitaxel	101-106	ankyrin repeat domain 18B	Homo sapiens	35-43
32278794-6	2020	We found that expression of DCDC2, ANKRD18B, ALDH1A1, c14orf105, ITGBL1 and NEB was overexpressed in taxol-resistant cells, suggesting the involvement of these AR-related genes in taxol resistance.	Paclitaxel	101-106	coiled-coil domain containing 198	Homo sapiens	54-63
32425595-8	2020	Xenograft tumor assay was applied for assessing the influence of UCA1 on PTX resistance of BC in vivo.	Paclitaxel	73-76	urothelial cancer associated 1	Homo sapiens	65-69
32425595-9	2020	Results: UCA1 expressed highly in PTX-resistant BC tissues and cells and regulated PTX resistance in BC cells by affecting cell viability and apoptosis in part.	Paclitaxel	34-37	urothelial cancer associated 1	Homo sapiens	9-13
32278794-6	2020	We found that expression of DCDC2, ANKRD18B, ALDH1A1, c14orf105, ITGBL1 and NEB was overexpressed in taxol-resistant cells, suggesting the involvement of these AR-related genes in taxol resistance.	Paclitaxel	101-106	nebulin	Homo sapiens	76-79
32425595-9	2020	Results: UCA1 expressed highly in PTX-resistant BC tissues and cells and regulated PTX resistance in BC cells by affecting cell viability and apoptosis in part.	Paclitaxel	83-86	urothelial cancer associated 1	Homo sapiens	9-13
32425595-10	2020	UCA1 negatively interacted with miR-613 and modulated PTX resistance via sponging miR-613.	Paclitaxel	54-57	urothelial cancer associated 1	Homo sapiens	0-4
32278794-6	2020	We found that expression of DCDC2, ANKRD18B, ALDH1A1, c14orf105, ITGBL1 and NEB was overexpressed in taxol-resistant cells, suggesting the involvement of these AR-related genes in taxol resistance.	Paclitaxel	180-185	ankyrin repeat domain 18B	Homo sapiens	35-43
32425595-10	2020	UCA1 negatively interacted with miR-613 and modulated PTX resistance via sponging miR-613.	Paclitaxel	54-57	microRNA 613	Homo sapiens	82-89
32278794-6	2020	We found that expression of DCDC2, ANKRD18B, ALDH1A1, c14orf105, ITGBL1 and NEB was overexpressed in taxol-resistant cells, suggesting the involvement of these AR-related genes in taxol resistance.	Paclitaxel	180-185	coiled-coil domain containing 198	Homo sapiens	54-63
32425595-11	2020	CDK12 was a downstream gene of miR-613 and miR-613 exerted the modulation of PTX resistance via targeting CDK12.	Paclitaxel	77-80	microRNA 613	Homo sapiens	31-38
32425595-11	2020	CDK12 was a downstream gene of miR-613 and miR-613 exerted the modulation of PTX resistance via targeting CDK12.	Paclitaxel	77-80	microRNA 613	Homo sapiens	43-50
32570786-0	2020	Paclitaxel Induces Upregulation of Transient Receptor Potential Vanilloid 1 Expression in the Rat Spinal Cord.	Paclitaxel	0-10	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	35-75
32425595-13	2020	The regulatory role of UCA1 in PTX resistance of BC was achieved by miR-613/CDK12 axis in vivo.	Paclitaxel	31-34	urothelial cancer associated 1	Homo sapiens	23-27
32425595-13	2020	The regulatory role of UCA1 in PTX resistance of BC was achieved by miR-613/CDK12 axis in vivo.	Paclitaxel	31-34	microRNA 613	Homo sapiens	68-75
32425595-14	2020	Conclusion: UCA1 mediated PTX resistance in BC through the miR-613/CDK12 axis, manifesting that UCA1 might improve the PTX treatment of BC as a significant therapeutic biomarker.	Paclitaxel	26-29	urothelial cancer associated 1	Homo sapiens	12-16
32425595-14	2020	Conclusion: UCA1 mediated PTX resistance in BC through the miR-613/CDK12 axis, manifesting that UCA1 might improve the PTX treatment of BC as a significant therapeutic biomarker.	Paclitaxel	26-29	microRNA 613	Homo sapiens	59-66
32570786-2	2020	To analyze the contribution of transient receptor potential vanilloid 1 (TRPV1) in the development of PTX-induced mechanical allodynia/hyperalgesia and thermal hyperalgesia, TRPV1 expression in the rat spinal cord was analyzed after intraperitoneal administration of 2 and 4 mg/kg PTX.	Paclitaxel	102-105	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	31-71
32425595-14	2020	Conclusion: UCA1 mediated PTX resistance in BC through the miR-613/CDK12 axis, manifesting that UCA1 might improve the PTX treatment of BC as a significant therapeutic biomarker.	Paclitaxel	119-122	urothelial cancer associated 1	Homo sapiens	12-16
32425595-14	2020	Conclusion: UCA1 mediated PTX resistance in BC through the miR-613/CDK12 axis, manifesting that UCA1 might improve the PTX treatment of BC as a significant therapeutic biomarker.	Paclitaxel	119-122	microRNA 613	Homo sapiens	59-66
32547883-0	2020	Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-kappaB and ERK pathways.	Paclitaxel	38-48	interleukin 1 receptor associated kinase 1	Homo sapiens	78-83
32425595-14	2020	Conclusion: UCA1 mediated PTX resistance in BC through the miR-613/CDK12 axis, manifesting that UCA1 might improve the PTX treatment of BC as a significant therapeutic biomarker.	Paclitaxel	119-122	urothelial cancer associated 1	Homo sapiens	96-100
32368142-13	2020	Conclusion: We demonstrated that PIK3CG was a potential target for the therapy of CLBC and inhibition of PIK3CG activation could reinforce the therapeutic effect of this aggressive disease by PTX.	Paclitaxel	192-195	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Mus musculus	105-111
32547883-2	2020	Previously, we have reported that interleukin-1 receptor-associated kinase 1 (IRAK1) and its downstream pathways are associated with PTX resistance in TNBC cells.	Paclitaxel	133-136	interleukin 1 receptor associated kinase 1	Homo sapiens	34-76
32547883-2	2020	Previously, we have reported that interleukin-1 receptor-associated kinase 1 (IRAK1) and its downstream pathways are associated with PTX resistance in TNBC cells.	Paclitaxel	133-136	interleukin 1 receptor associated kinase 1	Homo sapiens	78-83
32547883-3	2020	In this study, we sought to investigate the combination treatment of ginsenoside panaxatriol (GPT), one of the main active components in Panax ginseng, with PTX on viability and apoptosis of TNBC PTX resistant cells, and explore the role of IRAK1 mediated signaling pathways in the therapeutic effects.	Paclitaxel	157-160	interleukin 1 receptor associated kinase 1	Homo sapiens	241-246
32096645-3	2020	Up to 78% of paclitaxel was released from HSA within 2 h owing to MMP2 protein cleavage.	Paclitaxel	13-23	matrix metallopeptidase 2	Homo sapiens	66-70
32547883-15	2020	Conclusion: Our study demonstrates that GPT can resensitize TNBC PTX resistant cells to PTX by inhibiting the IRAK1/NF-kappaB and ERK pathways and reducing stem cell characteristics.	Paclitaxel	88-91	interleukin 1 receptor associated kinase 1	Homo sapiens	110-115
32240873-9	2020	Moreover, the glucocorticoid (with PTX or PTX-NPs) downregulated TXR1 gene by 26% (P < 0.01) and 28.4% (P < 0.05) respectively.	Paclitaxel	35-38	proline rich 13	Homo sapiens	65-69
32176872-5	2020	DNA aptamer-displaying nanoparticles encapsulating the anti-cancer drug paclitaxel were able to bind to cells overexpressing MUC1 and induce cell death.	Paclitaxel	72-82	mucin 1, cell surface associated	Homo sapiens	125-129
32240873-9	2020	Moreover, the glucocorticoid (with PTX or PTX-NPs) downregulated TXR1 gene by 26% (P < 0.01) and 28.4% (P < 0.05) respectively.	Paclitaxel	42-45	proline rich 13	Homo sapiens	65-69
32202508-0	2020	Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT/FoxO1 pathway.	Paclitaxel	35-45	integrin subunit alpha 2	Homo sapiens	14-19
32202508-7	2020	We also found that ITGA2 regulated the phosphorylation of forkhead box O1 (FoxO1) by mediating AKT phosphorylation, which provided a reasonable explanation for ITGA2"s role in ovarian cancer"s resistance to albumin paclitaxel.	Paclitaxel	215-225	integrin subunit alpha 2	Homo sapiens	19-24
32240873-11	2020	The main PTX metabolizing gene CYP2C8, in contrast, was upregulated, especially in cells cotreated with PTX/DEX (P < 0.001).	Paclitaxel	9-12	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	31-37
32202508-7	2020	We also found that ITGA2 regulated the phosphorylation of forkhead box O1 (FoxO1) by mediating AKT phosphorylation, which provided a reasonable explanation for ITGA2"s role in ovarian cancer"s resistance to albumin paclitaxel.	Paclitaxel	215-225	integrin subunit alpha 2	Homo sapiens	160-165
32240873-11	2020	The main PTX metabolizing gene CYP2C8, in contrast, was upregulated, especially in cells cotreated with PTX/DEX (P < 0.001).	Paclitaxel	104-107	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	31-37
32395375-0	2020	Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers.	Paclitaxel	96-106	cyclin dependent kinase 2	Homo sapiens	67-92
32240873-12	2020	Conclusively, the study reports that cotreatment of breast cancer cells with submolar concentration of DEX acts as similar as the nanoformulated PTX, possibly through its modulatory effects on the expression of the main PTX metabolizing gene (CYP2C8) and downregulating Taxol resistance gene.	Paclitaxel	220-223	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	243-249
32240873-12	2020	Conclusively, the study reports that cotreatment of breast cancer cells with submolar concentration of DEX acts as similar as the nanoformulated PTX, possibly through its modulatory effects on the expression of the main PTX metabolizing gene (CYP2C8) and downregulating Taxol resistance gene.	Paclitaxel	270-275	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	243-249
32486385-0	2020	A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.	Paclitaxel	88-98	CREB regulated transcription coactivator 2	Mus musculus	19-27
31713924-8	2020	The results of the Western blot analysis demonstrated that DHA and the DHA-Taxol combination caused an increase in the expression of the talin2 protein rather than the control cells under both normoxic and hypoxic conditions.	Paclitaxel	75-80	talin 2	Homo sapiens	137-143
31831565-3	2020	We investigated the distribution, toxicity, and efficacy of LIPU delivery of two different formulations of paclitaxel, albumin-bound paclitaxel (ABX) and paclitaxel dissolved in cremophor (CrEL-PTX), in preclinical glioma models.	Paclitaxel	133-143	albumin	Mus musculus	119-126
31831565-3	2020	We investigated the distribution, toxicity, and efficacy of LIPU delivery of two different formulations of paclitaxel, albumin-bound paclitaxel (ABX) and paclitaxel dissolved in cremophor (CrEL-PTX), in preclinical glioma models.	Paclitaxel	133-143	albumin	Mus musculus	119-126
32457290-3	2020	Paclitaxel- and doxorubicin-resistant cancer cells showed higher expression of MDR1 and HSF1.	Paclitaxel	0-10	heat shock transcription factor 1	Homo sapiens	88-92
31918714-6	2020	Subsequently, TPH/PTX caused mitochondrial outer membrane permeabilization (MOMP) by inhibiting antiapoptotic Bcl-2, leading to cytochrome C release and activation of caspase-3 and caspase-9.	Paclitaxel	18-21	caspase 9	Mus musculus	181-190
33463256-3	2020	Human serum albumin (HSA), a biocompatible carrier material, has been successfully used for the delivery of paclitaxel (Abraxane).	Paclitaxel	108-118	albumin	Mus musculus	6-19
32364081-0	2020	Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells.	Paclitaxel	0-10	proline rich 13	Homo sapiens	55-59
32364081-0	2020	Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells.	Paclitaxel	0-10	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	72-78
32364081-2	2020	This work was designated to explore the effect of paclitaxel-loaded poly lactic-co-glycolic acid (PLGA) nanoparticles on the viability of cancer cells, the expression of Taxol resistance gene I (TXR1) and paclitaxel metabolizing genes.	Paclitaxel	50-60	proline rich 13	Homo sapiens	195-199
32364081-2	2020	This work was designated to explore the effect of paclitaxel-loaded poly lactic-co-glycolic acid (PLGA) nanoparticles on the viability of cancer cells, the expression of Taxol resistance gene I (TXR1) and paclitaxel metabolizing genes.	Paclitaxel	170-175	proline rich 13	Homo sapiens	195-199
32364081-2	2020	This work was designated to explore the effect of paclitaxel-loaded poly lactic-co-glycolic acid (PLGA) nanoparticles on the viability of cancer cells, the expression of Taxol resistance gene I (TXR1) and paclitaxel metabolizing genes.	Paclitaxel	205-215	proline rich 13	Homo sapiens	195-199
32089062-0	2020	Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.	Paclitaxel	50-60	fascin actin-bundling protein 1	Homo sapiens	109-114
31783010-2	2020	Given the complex nature of taxol-resistance, we further delved into its mechanisms and demonstrated that CYP1B1 was associated to taxol response in taxol-resistant A549/Taxol cells.	Paclitaxel	28-33	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	106-112
31783010-2	2020	Given the complex nature of taxol-resistance, we further delved into its mechanisms and demonstrated that CYP1B1 was associated to taxol response in taxol-resistant A549/Taxol cells.	Paclitaxel	131-136	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	106-112
31783010-2	2020	Given the complex nature of taxol-resistance, we further delved into its mechanisms and demonstrated that CYP1B1 was associated to taxol response in taxol-resistant A549/Taxol cells.	Paclitaxel	131-136	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	106-112
31783010-2	2020	Given the complex nature of taxol-resistance, we further delved into its mechanisms and demonstrated that CYP1B1 was associated to taxol response in taxol-resistant A549/Taxol cells.	Paclitaxel	170-175	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	106-112
31783010-3	2020	Compared to its parent A549 counterpart, A549/Taxol presented much higher level of CYP1B1, which was paralleled by increased aryl hydrocarbon receptor (AhR) expression likely due to the long term taxol exposure and thereby allowed a subsequent up-regulation of CYP1B1.	Paclitaxel	46-51	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	83-89
31783010-3	2020	Compared to its parent A549 counterpart, A549/Taxol presented much higher level of CYP1B1, which was paralleled by increased aryl hydrocarbon receptor (AhR) expression likely due to the long term taxol exposure and thereby allowed a subsequent up-regulation of CYP1B1.	Paclitaxel	46-51	aryl hydrocarbon receptor	Homo sapiens	125-150
31783010-3	2020	Compared to its parent A549 counterpart, A549/Taxol presented much higher level of CYP1B1, which was paralleled by increased aryl hydrocarbon receptor (AhR) expression likely due to the long term taxol exposure and thereby allowed a subsequent up-regulation of CYP1B1.	Paclitaxel	46-51	aryl hydrocarbon receptor	Homo sapiens	152-155
31783010-3	2020	Compared to its parent A549 counterpart, A549/Taxol presented much higher level of CYP1B1, which was paralleled by increased aryl hydrocarbon receptor (AhR) expression likely due to the long term taxol exposure and thereby allowed a subsequent up-regulation of CYP1B1.	Paclitaxel	46-51	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	261-267
31783010-3	2020	Compared to its parent A549 counterpart, A549/Taxol presented much higher level of CYP1B1, which was paralleled by increased aryl hydrocarbon receptor (AhR) expression likely due to the long term taxol exposure and thereby allowed a subsequent up-regulation of CYP1B1.	Paclitaxel	196-201	aryl hydrocarbon receptor	Homo sapiens	125-150
31783010-4	2020	Inhibition of CYP1B1 by TMS [(E)-2,3",4,5"-tetramethoxystilbene], the specific CYP1B1 inhibitor, remarkably enhanced the sensitivity of A549/Taxol to taxol.	Paclitaxel	141-146	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	14-20
31783010-4	2020	Inhibition of CYP1B1 by TMS [(E)-2,3",4,5"-tetramethoxystilbene], the specific CYP1B1 inhibitor, remarkably enhanced the sensitivity of A549/Taxol to taxol.	Paclitaxel	141-146	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	79-85
31783010-4	2020	Inhibition of CYP1B1 by TMS [(E)-2,3",4,5"-tetramethoxystilbene], the specific CYP1B1 inhibitor, remarkably enhanced the sensitivity of A549/Taxol to taxol.	Paclitaxel	150-155	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	14-20
32089062-11	2020	Moreover, FSCN1 restoration attenuated miR-24-3p-mediated inhibition of PTX resistance.	Paclitaxel	72-75	fascin actin-bundling protein 1	Homo sapiens	10-15
31783010-4	2020	Inhibition of CYP1B1 by TMS [(E)-2,3",4,5"-tetramethoxystilbene], the specific CYP1B1 inhibitor, remarkably enhanced the sensitivity of A549/Taxol to taxol.	Paclitaxel	150-155	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	79-85
31783010-5	2020	Moreover, pre-incubation of taxol with human recombinant CYP1B1 did not affect drug toxicity in A549 cells, precluding the possibility of drug resistance ascribed to CYP1B1 due to directly inactivating taxol.	Paclitaxel	28-33	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	57-63
32089062-12	2020	Besides, FSCN1 level was enhanced in PCa and PTX-resistant PCa cells and regulated by CCAT1 and miR-24-3p.	Paclitaxel	45-48	fascin actin-bundling protein 1	Homo sapiens	9-14
31783010-5	2020	Moreover, pre-incubation of taxol with human recombinant CYP1B1 did not affect drug toxicity in A549 cells, precluding the possibility of drug resistance ascribed to CYP1B1 due to directly inactivating taxol.	Paclitaxel	202-207	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	166-172
31783010-6	2020	Indeed, CYP1B1 is responsible for bio-transforming estrogen (E2) into the carcinogenetic metabolite that would inhibit microtubule stabilization induced by taxol and thereby compromising treatment efficacy.	Paclitaxel	156-161	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	8-14
31883395-7	2020	Adriyamicin/cyclophosphamide and Paclitaxel resistant MDA-MB-231 cells activated NRP-1/TNC/Integrin beta3/FAK/NF-kappaBp65 axis and displayed a decrease in breast cancer resistant protein (BCRP/ABCB2).	Paclitaxel	33-43	neuropilin 1	Homo sapiens	81-86
31783010-7	2020	Remarkably, our data revealed potent CYP1B1 inhibition efficacy of 4-hydroxyemodin (HEM) as reflected by both molecular docking simulations and EROD assay, which posed HEM the advantage of breaking the vicious circle between E2 and CYP1B1, not only favoring to overcome taxol-resistance, but also offering long term benefit via circumventing carcinogenesis and tumor progression induced by E2.	Paclitaxel	270-275	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	37-43
31093891-8	2020	CONCLUSIONS: These results indicate that ultrasound-mediated PTX-miR-34a-MBs synergistically inhibit the growth of cervical cancer via the upregulation of miR-34a and downregulation of Bcl-2 and CDK6.	Paclitaxel	61-64	cyclin-dependent kinase 6	Mus musculus	195-199
31883395-7	2020	Adriyamicin/cyclophosphamide and Paclitaxel resistant MDA-MB-231 cells activated NRP-1/TNC/Integrin beta3/FAK/NF-kappaBp65 axis and displayed a decrease in breast cancer resistant protein (BCRP/ABCB2).	Paclitaxel	33-43	protein tyrosine kinase 2	Homo sapiens	106-109
31883395-7	2020	Adriyamicin/cyclophosphamide and Paclitaxel resistant MDA-MB-231 cells activated NRP-1/TNC/Integrin beta3/FAK/NF-kappaBp65 axis and displayed a decrease in breast cancer resistant protein (BCRP/ABCB2).	Paclitaxel	33-43	RELA proto-oncogene, NF-kB subunit	Homo sapiens	110-122
31856423-7	2020	Western blotting was performed to investigate changes in the expression levels of YAP, TAZ, Bcl-2, and EGFR in U87 and U251 cells treated with BPD, cisplatin, and paclitaxel, both as monotherapies and in combination.	Paclitaxel	163-173	Yes1 associated transcriptional regulator	Homo sapiens	82-85
32431514-9	2020	Moreover, combination of TET and PTX obviously induced cell cycle arrest in SKOV3/PTX cells via increasing the level of p21 and decreasing the levels of c-Myc and Cyclin D1.	Paclitaxel	33-36	cyclin D1	Homo sapiens	163-172
33243106-4	2020	In this article, we reviewed recent advancements elucidating major mechanisms of PTX resistance in NSCLC, including the overexpression of ABC transporters, alternations to tubulin structures, and the involvement of cytokines, miRNAs, kinase signaling pathways, and epithelial-mesenchymal transition.	Paclitaxel	81-84	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	138-141
32431514-12	2020	Conclusion: We found that TET could enhance the sensitivity of SKOV3/PTX cells to PTX via inhibiting the beta-catenin/c-Myc/Cyclin D1 signaling pathway.	Paclitaxel	69-72	cyclin D1	Homo sapiens	124-133
32362607-0	2020	The analgesic effect of metformin on paclitaxel-induced neuropathic pain model in rats: By considering pathological results.	Paclitaxel	37-47	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	24-33
32606750-0	2020	Connexin 43 Modulates the Cellular Resistance to Paclitaxel via Targeting beta-Tubulin in Triple-Negative Breast Cancer.	Paclitaxel	49-59	gap junction protein alpha 1	Homo sapiens	0-11
32431514-12	2020	Conclusion: We found that TET could enhance the sensitivity of SKOV3/PTX cells to PTX via inhibiting the beta-catenin/c-Myc/Cyclin D1 signaling pathway.	Paclitaxel	82-85	cyclin D1	Homo sapiens	124-133
32362607-3	2020	In this study, we investigated the analgesic effect of MET in paclitaxel (PAC)-induced neuropathic pain.	Paclitaxel	62-72	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	55-58
32362607-3	2020	In this study, we investigated the analgesic effect of MET in paclitaxel (PAC)-induced neuropathic pain.	Paclitaxel	74-77	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	55-58
32079653-7	2020	We demonstrate that pharmacological inhibition of ERRgamma with the selective inverse agonist GSK5182 increases antitumor efficacy of the chemotherapeutic paclitaxel on poor outcome BCa tumor organoids.	Paclitaxel	155-165	estrogen related receptor gamma	Homo sapiens	50-58
32362607-10	2020	Four hundred milligram/kilogram concentration of MET remarkably decreased PAC-induced neuropathic pain.	Paclitaxel	74-77	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	49-52
32362607-12	2020	Conclusion: The pathological results of the current study for the first time demonstrated that MET beside of its antidiabetic effects reversed neuropathic pain induced by PAC.	Paclitaxel	171-174	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	95-98
32252059-9	2020	CONCLUSION: This result suggests that the PFKL rs2073436C>G and GPI rs7248411C>G are useful for predicting the clinical outcome of first-line paclitaxel-cisplatin chemotherapy in NSCLC.	Paclitaxel	142-152	phosphofructokinase, liver type	Homo sapiens	42-46
32606750-3	2020	Methods: We constructed and employed the Connexin 43 (Cx43) overexpression lentiviral vectors and Cx43 siRNA in paclitaxel-treated MDA-MB-231 cells.	Paclitaxel	112-122	gap junction protein alpha 1	Homo sapiens	98-102
32606750-7	2020	Results: The results showed that Cx43 hindered cell proliferation and promoted apoptosis in the paclitaxel-treated MDA-MB-231 cells.	Paclitaxel	96-106	gap junction protein alpha 1	Homo sapiens	33-37
32606750-14	2020	Conclusion: Overexpression of Cx43 could modulate the cellular resistance to paclitaxel via targeting beta-tubulin in triple-negative breast cancer.	Paclitaxel	77-87	gap junction protein alpha 1	Homo sapiens	30-34
32252059-9	2020	CONCLUSION: This result suggests that the PFKL rs2073436C>G and GPI rs7248411C>G are useful for predicting the clinical outcome of first-line paclitaxel-cisplatin chemotherapy in NSCLC.	Paclitaxel	142-152	glucose-6-phosphate isomerase	Homo sapiens	64-67
32273769-0	2020	Circ-ABCB10 Contributes to Paclitaxel Resistance in Breast Cancer Through Let-7a-5p/DUSP7 Axis.	Paclitaxel	27-37	dual specificity phosphatase 7	Homo sapiens	84-89
33423483-3	2019	Herein, we applied natural human H chain ferritin (HFtn) nanocages that can bind to tumor cells via interacting with the human transferritin receptor 1 (TfR1) leading to its endocytosis as the PTX carrier for the targeted delivery.	Paclitaxel	193-196	transferrin receptor	Homo sapiens	127-151
33423483-3	2019	Herein, we applied natural human H chain ferritin (HFtn) nanocages that can bind to tumor cells via interacting with the human transferritin receptor 1 (TfR1) leading to its endocytosis as the PTX carrier for the targeted delivery.	Paclitaxel	193-196	transferrin receptor	Homo sapiens	153-157
32112854-4	2020	Small sized albumin nanoparticle of paclitaxel (HSA-PTX) with strong tumor-penetration ability was encapsulated into the CAP-(a FAP-alpha responsive cleavable amphiphilic peptide) modified thermosensitive liposomes (CAP-TSL).	Paclitaxel	36-46	fibroblast activation protein	Mus musculus	128-137
32273769-11	2020	DUSP7 is a direct target of let-7a-5p in BC cells, and the accumulation of DUSP7 reversed the promoting effects of let-7a-5p overexpression on the PTX sensitivity and apoptosis and the inhibitory impact on the invasion and autophagy of PTX-resistant BC cells.	Paclitaxel	147-150	dual specificity phosphatase 7	Homo sapiens	0-5
32089062-13	2020	Our data suggested interference of CCAT1 contributed to PTX sensitivity in PCa by regulating miR-24-3p and FSCN1, indicating a novel avenue for treatment of PCa through regulating chemoresistance.	Paclitaxel	56-59	fascin actin-bundling protein 1	Homo sapiens	107-112
32273769-11	2020	DUSP7 is a direct target of let-7a-5p in BC cells, and the accumulation of DUSP7 reversed the promoting effects of let-7a-5p overexpression on the PTX sensitivity and apoptosis and the inhibitory impact on the invasion and autophagy of PTX-resistant BC cells.	Paclitaxel	147-150	dual specificity phosphatase 7	Homo sapiens	75-80
32273769-11	2020	DUSP7 is a direct target of let-7a-5p in BC cells, and the accumulation of DUSP7 reversed the promoting effects of let-7a-5p overexpression on the PTX sensitivity and apoptosis and the inhibitory impact on the invasion and autophagy of PTX-resistant BC cells.	Paclitaxel	236-239	dual specificity phosphatase 7	Homo sapiens	0-5
32273769-11	2020	DUSP7 is a direct target of let-7a-5p in BC cells, and the accumulation of DUSP7 reversed the promoting effects of let-7a-5p overexpression on the PTX sensitivity and apoptosis and the inhibitory impact on the invasion and autophagy of PTX-resistant BC cells.	Paclitaxel	236-239	dual specificity phosphatase 7	Homo sapiens	75-80
32090232-0	2020	Low-dose paclitaxel via hyaluronan-functionalized bovine serum albumin nanoparticulate assembly for metastatic melanoma treatment.	Paclitaxel	9-19	albumin	Mus musculus	57-70
32495881-9	2020	Resistance to paclitaxel was reversed after GBP1 knockdown in paclitaxel resistance A549 cells (A549/Taxol).	Paclitaxel	14-24	guanylate binding protein 1	Homo sapiens	44-48
32495881-9	2020	Resistance to paclitaxel was reversed after GBP1 knockdown in paclitaxel resistance A549 cells (A549/Taxol).	Paclitaxel	62-72	guanylate binding protein 1	Homo sapiens	44-48
32495881-9	2020	Resistance to paclitaxel was reversed after GBP1 knockdown in paclitaxel resistance A549 cells (A549/Taxol).	Paclitaxel	101-106	guanylate binding protein 1	Homo sapiens	44-48
31586636-0	2019	Pharmacological interventions targeting Wnt/beta-catenin signaling pathway attenuate paclitaxel-induced peripheral neuropathy.	Paclitaxel	85-95	Wnt family member 3A	Rattus norvegicus	40-43
31586636-7	2019	Moreover, Wnt signaling proteins (Wnt3a, beta-catenin, c-myc and Dvl1), inflammatory marker (matrix metalloproteinase 2) and endoplasmic reticulum stress marker (GRP78) were found to be upregulated in the sciatic nerves of paclitaxel-treated rats accompanied with loss of intraepidermal nerve fiber density as compared to the control rats.	Paclitaxel	223-233	Wnt family member 3A	Rattus norvegicus	10-13
31586636-8	2019	Intrathecal administration of Wnt inhibitors (each at dose of 10 and 30 muM) for three consecutive days to paclitaxel-treated rats, significantly improved behavioral pain thresholds and nerve functional parameters by inhibition of Wnt signaling, inflammation, endoplasmic reticulum stress and improvement of intraepidermal nerve fiber density.	Paclitaxel	107-117	Wnt family member 3A	Rattus norvegicus	30-33
31586636-8	2019	Intrathecal administration of Wnt inhibitors (each at dose of 10 and 30 muM) for three consecutive days to paclitaxel-treated rats, significantly improved behavioral pain thresholds and nerve functional parameters by inhibition of Wnt signaling, inflammation, endoplasmic reticulum stress and improvement of intraepidermal nerve fiber density.	Paclitaxel	107-117	Wnt family member 3A	Rattus norvegicus	231-234
31692005-7	2019	Overall, paclitaxel-based combinations were superior to paclitaxel alone in objective response rate (ORR) (odds ratio [OR] 1.60, 95% credible interval [CrI] 1.15-2.16) and overall survival (OS) (hazard ratio [HR] 1.08, 95% CrI 1.01-1.15).	Paclitaxel	9-19	EP300 interacting inhibitor of differentiation 1	Homo sapiens	223-228
31772161-9	2019	Collectively, our work has demonstrated that the MUC1-EGFR-CREB/GRbeta axis stimulates IL-6 expression to induce CSCs enrichment and importantly, this effect can be abrogated by erlotinib, uncovering a novel strategy to treat paclitaxel-resistant cervical cancer.	Paclitaxel	226-236	mucin 1, cell surface associated	Homo sapiens	49-53
31775332-5	2019	Mechanistically, TLR4 (Toll-Like Receptor 4) and downstream signaling MyD88 (Myeloid Differentiation Primary Response 88) and TRPV1 (Transient Receptor Potential Vallinoid 1) were upregulated in dorsal root ganglion (DRGs) of paclitaxel-treated rats, whereas EA reduced their overexpression.	Paclitaxel	226-236	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	126-131
32392914-0	2020	ATG5 knockout promotes paclitaxel sensitivity in drug-resistant cells via induction of necrotic cell death.	Paclitaxel	23-33	autophagy related 5	Mus musculus	0-4
31775332-6	2019	Ca2+ imaging further indicated that TRPV1 channel activity was enhanced in DRG neurons of paclitaxel-treated rats whereas EA suppressed the enhanced TRPV1 channel activity.	Paclitaxel	90-100	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	36-41
32521934-0	2020	Paclitaxel inhibits transforming growth factor-beta-increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration.	Paclitaxel	0-10	mitogen-activated protein kinase 14	Mus musculus	118-126
31775332-9	2019	These results demonstrated that EA alleviates paclitaxel-induced peripheral neuropathic pain via mechanisms possibly involving suppressing TLR4 signaling and TRPV1 upregulation in DRG neurons, which further result in reduced spinal glia activation.	Paclitaxel	46-56	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	158-163
31659102-2	2019	CDX2 promotes the expression of multidrug resistance 1 (MDR1) and confers resistance to paclitaxel.	Paclitaxel	88-98	cdx2	None	0-4
32392914-2	2020	Here, we investigated paclitaxel sensitivity in cells with knockout (KO) of ATG5 gene.	Paclitaxel	22-32	autophagy related 5	Mus musculus	76-80
32392914-5	2020	The ATG5 KO restored the sensitivity of Ras-NIH 3T3/Mdr cells to paclitaxel.	Paclitaxel	65-75	autophagy related 5	Mus musculus	4-8
32392914-7	2020	These results raise the possibility that low level of resistance to paclitaxel in ATG5 KO cells may be related to other roles of ATG5 independent of its function in autophagy.	Paclitaxel	68-78	autophagy related 5	Mus musculus	82-86
32392914-9	2020	Additionally, ATG5 KO caused necrosis of a high proportion of cells after paclitaxel treatment.	Paclitaxel	74-84	autophagy related 5	Mus musculus	14-18
32521934-12	2020	Also, PTx inhibited TGF-beta-induced Smad3 activation.	Paclitaxel	6-9	SMAD family member 3	Mus musculus	37-42
32392914-10	2020	These data suggest that the difference in sensitivity to paclitaxel between ATG5 KO and their parental MDR cells may result from the disparity in the proportions of necrotic cells in both populations.	Paclitaxel	57-67	autophagy related 5	Mus musculus	76-80
32392914-11	2020	Thus, our results demonstrate that the ATG5 KO in paclitaxel resistant cells leads to a marked G2/M arrest and sensitizes cells to paclitaxel-induced necrosis.	Paclitaxel	50-60	autophagy related 5	Mus musculus	39-43
31659102-9	2019	CONCLUSION: CDX2 promotes resistance to paclitaxel and sensitivity to 5-FU.	Paclitaxel	40-50	cdx2	None	12-16
32521934-14	2020	Remarkably, p38 MAPK mediated PTx inhibition of uPA activity induced by TGF-beta but it was not implicated on cell migration inhibition.	Paclitaxel	30-33	mitogen-activated protein kinase 14	Mus musculus	12-20
32392914-11	2020	Thus, our results demonstrate that the ATG5 KO in paclitaxel resistant cells leads to a marked G2/M arrest and sensitizes cells to paclitaxel-induced necrosis.	Paclitaxel	131-141	autophagy related 5	Mus musculus	39-43
31420851-0	2020	LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.	Paclitaxel	13-23	lin-9 DREAM MuvB core complex component	Homo sapiens	0-4
31802868-0	2019	Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.	Paclitaxel	85-95	interferon gamma inducible protein 47	Mus musculus	21-25
31802868-3	2019	Materials and methods: To improve colorectal cancer treatment, in this study, we prepared a paclitaxel (PTX)-loaded PLGA nanoparticle (PLGA-PTX) and evaluated its tumor-targeting and antitumor activity by co-administration with iRGD.	Paclitaxel	92-102	interferon gamma inducible protein 47	Mus musculus	228-232
32246247-0	2020	CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxel.	Paclitaxel	72-82	prominin 1	Homo sapiens	0-5
31420851-3	2020	In this study we assessed the association of LIN9 expression with paclitaxel resistance and clarified the underlying mechanisms for the first time.	Paclitaxel	66-76	lin-9 DREAM MuvB core complex component	Homo sapiens	45-49
32246247-9	2020	Additionally, we found that the simultaneous use of CD133-siRNA and paclitaxel increased the paclitaxel-induced apoptosis.	Paclitaxel	93-103	prominin 1	Homo sapiens	52-57
31802868-3	2019	Materials and methods: To improve colorectal cancer treatment, in this study, we prepared a paclitaxel (PTX)-loaded PLGA nanoparticle (PLGA-PTX) and evaluated its tumor-targeting and antitumor activity by co-administration with iRGD.	Paclitaxel	104-107	interferon gamma inducible protein 47	Mus musculus	228-232
31420851-7	2020	LIN9 expression was upregulated in paclitaxel-resistant TNBC cells compared to their parental cells.	Paclitaxel	35-45	lin-9 DREAM MuvB core complex component	Homo sapiens	0-4
31420851-8	2020	Knockdown of LIN9 or treatment of paclitaxel-resistant TNBC cells with a bromo- and extra-terminal domain inhibitor (BETi) JQ1 which also decreased LIN9 expression enhanced the sensitivity of paclitaxel-resistant TNBC cells to paclitaxel.	Paclitaxel	34-44	lin-9 DREAM MuvB core complex component	Homo sapiens	148-152
31420851-8	2020	Knockdown of LIN9 or treatment of paclitaxel-resistant TNBC cells with a bromo- and extra-terminal domain inhibitor (BETi) JQ1 which also decreased LIN9 expression enhanced the sensitivity of paclitaxel-resistant TNBC cells to paclitaxel.	Paclitaxel	192-202	lin-9 DREAM MuvB core complex component	Homo sapiens	13-17
32410959-6	2020	In paclitaxel-treated mice, both the CB1 PAM GAT211 and the opioid analgesic morphine reduced paclitaxel-induced behavioral hypersensitivities to mechanical and cold stimulation in a dose-dependent manner.	Paclitaxel	3-13	cannabinoid receptor 1 (brain)	Mus musculus	37-40
31420851-8	2020	Knockdown of LIN9 or treatment of paclitaxel-resistant TNBC cells with a bromo- and extra-terminal domain inhibitor (BETi) JQ1 which also decreased LIN9 expression enhanced the sensitivity of paclitaxel-resistant TNBC cells to paclitaxel.	Paclitaxel	192-202	lin-9 DREAM MuvB core complex component	Homo sapiens	148-152
32410959-6	2020	In paclitaxel-treated mice, both the CB1 PAM GAT211 and the opioid analgesic morphine reduced paclitaxel-induced behavioral hypersensitivities to mechanical and cold stimulation in a dose-dependent manner.	Paclitaxel	94-104	cannabinoid receptor 1 (brain)	Mus musculus	37-40
31702036-7	2019	Silencing of ST3Gal3 by small interfering RNA reversed these effects and increased the protein levels of caspase-8/3, which may contribute to paclitaxel-induced apoptosis.	Paclitaxel	142-152	caspase 8	Homo sapiens	105-116
31420851-8	2020	Knockdown of LIN9 or treatment of paclitaxel-resistant TNBC cells with a bromo- and extra-terminal domain inhibitor (BETi) JQ1 which also decreased LIN9 expression enhanced the sensitivity of paclitaxel-resistant TNBC cells to paclitaxel.	Paclitaxel	192-202	lin-9 DREAM MuvB core complex component	Homo sapiens	13-17
31702036-8	2019	The results of the present study suggested that ST3Gal3 was a target for paclitaxel--related resistance during ovarian cancer chemotherapy.	Paclitaxel	73-83	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	48-55
32425595-0	2020	Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis.	Paclitaxel	35-45	urothelial cancer associated 1	Homo sapiens	20-24
32425595-0	2020	Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis.	Paclitaxel	35-45	microRNA 613	Homo sapiens	78-85
31420851-8	2020	Knockdown of LIN9 or treatment of paclitaxel-resistant TNBC cells with a bromo- and extra-terminal domain inhibitor (BETi) JQ1 which also decreased LIN9 expression enhanced the sensitivity of paclitaxel-resistant TNBC cells to paclitaxel.	Paclitaxel	192-202	lin-9 DREAM MuvB core complex component	Homo sapiens	148-152
31420851-10	2020	In conclusion, high LIN9 expression contributed to poor clinical outcomes and paclitaxel resistance in TNBC and BETi, targeting LIN9 expression, could be a reversible drug for PTX-resistant TNBC patients.	Paclitaxel	78-88	lin-9 DREAM MuvB core complex component	Homo sapiens	128-132
32106859-9	2020	Importantly, cisplatin and paclitaxel promote miR-522 secretion from CAFs by activating USP7/hnRNPA1 axis, leading to ALOX15 suppression and decreased lipid-ROS accumulation in cancer cells, and ultimately result in decreased chemo-sensitivity.	Paclitaxel	27-37	heterogeneous nuclear ribonucleoprotein A1	Homo sapiens	93-100
32425595-2	2020	This study was designed to explore the molecular mechanism of long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) in PTX resistance of BC.	Paclitaxel	135-138	urothelial cancer associated 1	Homo sapiens	91-124
32425595-2	2020	This study was designed to explore the molecular mechanism of long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) in PTX resistance of BC.	Paclitaxel	135-138	urothelial cancer associated 1	Homo sapiens	126-130
32158279-0	2020	TGF-beta-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel.	Paclitaxel	106-116	transforming growth factor alpha	Homo sapiens	0-8
32158279-11	2020	Our findings suggest that TGF-beta-induced TMEPAI attenuates the response of TNBC to doxorubicin and paclitaxel, but not to cisplatin and bicalutamide.	Paclitaxel	101-111	transforming growth factor alpha	Homo sapiens	26-34
32351985-9	2020	However, overexpression of TGF-beta3 was associated with poor OS from the use of platins and poor PFS of Taxol or a platin+Taxol in women with ovarian carcinoma.	Paclitaxel	105-110	transforming growth factor beta 3	Homo sapiens	27-36
32351985-9	2020	However, overexpression of TGF-beta3 was associated with poor OS from the use of platins and poor PFS of Taxol or a platin+Taxol in women with ovarian carcinoma.	Paclitaxel	123-128	transforming growth factor beta 3	Homo sapiens	27-36
32158279-12	2020	Conclusion: TGF-beta induced TMEPAI contributes to the reduced response of TNBC treatment to doxorubicin and paclitaxel, but minimal on cisplatin and bicalutamide.	Paclitaxel	109-119	transforming growth factor alpha	Homo sapiens	12-20
31732654-5	2020	Moreover, the appearance of partial EMT or mesenchymal-like carcinoma cells in MDA-MB-468 tumors treated with the paclitaxel-nilotinib combination resulted in upregulation of cancer stem cell (CSC) markers and susceptibility to FAK inhibitor.	Paclitaxel	114-124	protein tyrosine kinase 2	Homo sapiens	228-231
31691396-9	2020	The levels of 5-HT3R detected by immunohistochemistry were higher in the superficial dorsal horn (laminae I-II) of paclitaxel-injected animals.	Paclitaxel	115-125	5-hydroxytryptamine receptor 3A	Rattus norvegicus	14-20
31998833-3	2020	Here, we report that paclitaxel (PTX)-DART nanoparticles directed to the cell surface receptor fibroblast growth factor-inducible 14 (Fn14) outperformed both the corresponding PTX-loaded, nontargeted nanoparticles and Abraxane, an FDA-approved PTX nanoformulation, in both a primary triple-negative breast cancer (TNBC) model and an intracranial model reflecting TNBC growth following metastatic dissemination to the brain.	Paclitaxel	21-31	TNF receptor superfamily member 12A	Homo sapiens	134-138
32226772-8	2020	The combination of DCST1-AS1 and ANXA1 also contributes to enhancement of the resistance of BT-549 cells to doxorubicin and paclitaxel.	Paclitaxel	124-134	prostaglandin D2 receptor	Homo sapiens	25-28
32189969-0	2020	Long Noncoding RNA TUG1 Promotes Autophagy-Associated Paclitaxel Resistance by Sponging miR-29b-3p in Ovarian Cancer Cells.	Paclitaxel	54-64	taurine up-regulated 1	Homo sapiens	19-23
31998833-3	2020	Here, we report that paclitaxel (PTX)-DART nanoparticles directed to the cell surface receptor fibroblast growth factor-inducible 14 (Fn14) outperformed both the corresponding PTX-loaded, nontargeted nanoparticles and Abraxane, an FDA-approved PTX nanoformulation, in both a primary triple-negative breast cancer (TNBC) model and an intracranial model reflecting TNBC growth following metastatic dissemination to the brain.	Paclitaxel	33-36	TNF receptor superfamily member 12A	Homo sapiens	134-138
32521851-8	2020	Further, the chemo-sensitivity of (BC) cells to paclitaxel and doxorubicin was seen to be enhanced under miR-335 overexpression.	Paclitaxel	48-58	microRNA 335	Homo sapiens	105-112
31937780-5	2020	cGAS/STING-dependent apoptotic effects are required for paclitaxel response in vivo, and they are amplified by sequential, but not synchronous, administration of BH3 mimetics.	Paclitaxel	56-66	stimulator of interferon response cGAMP interactor 1	Homo sapiens	5-10
31937590-8	2020	The most discriminatory miRNA, with the highest  fold change , was miR-451a, which regulates the expression of the drug-transporter protein P-glycoprotein, potentially promoting paclitaxel resistance.	Paclitaxel	178-188	microRNA 451a	Homo sapiens	67-75
31902922-0	2020	In Vitro Effects of Paclitaxel and Cremophor EL on Human Riboflavin Transporter SLC52A2.	Paclitaxel	20-30	solute carrier family 52 member 2	Homo sapiens	80-87
31937590-9	2020	CONCLUSION: MiR-451a could be a predictive marker for PN caused by paclitaxel-containing chemotherapy; however, further investigation of the underlying mechanism is required to determine the role of miR-451a.	Paclitaxel	67-77	microRNA 451a	Homo sapiens	12-20
31783010-0	2020	Overcoming Taxol-resistance in A549 Cells: A Comprehensive Strategy of Targeting P-gp transporter, AKT/ERK Pathways, and Cytochrome P450 Enzyme CYP1B1 by 4-hydroxyemodin.	Paclitaxel	11-16	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	144-150
32016960-0	2020	Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.	Paclitaxel	53-63	urothelial cancer associated 1	Homo sapiens	20-24
32016960-3	2020	However, the function of lncRNA urothelial carcinoma associated1 (UCA1) in paclitaxel (PTX) resistance of OC is not well elucidated.	Paclitaxel	75-85	urothelial cancer associated 1	Homo sapiens	66-70
32016960-3	2020	However, the function of lncRNA urothelial carcinoma associated1 (UCA1) in paclitaxel (PTX) resistance of OC is not well elucidated.	Paclitaxel	87-90	urothelial cancer associated 1	Homo sapiens	66-70
32016960-9	2020	RESULTS: UCA1 was markedly upregulated in OC tissues and PTX-resistant OC cells.	Paclitaxel	57-60	urothelial cancer associated 1	Homo sapiens	9-13
32016960-10	2020	Silencing of UCA1 restrained the PTX resistance, reduced the proliferation, migration, invasion and enhanced the apoptosis of PTX-resistant OC cells.	Paclitaxel	33-36	urothelial cancer associated 1	Homo sapiens	13-17
32016960-10	2020	Silencing of UCA1 restrained the PTX resistance, reduced the proliferation, migration, invasion and enhanced the apoptosis of PTX-resistant OC cells.	Paclitaxel	126-129	urothelial cancer associated 1	Homo sapiens	13-17
32016960-11	2020	MiR-654-5p could be sponged by UCA1, and the inhibitory effect of its overexpression on the progression of PTX-resistant OC cells could be reversed by overexpressed-UCA1.	Paclitaxel	107-110	urothelial cancer associated 1	Homo sapiens	165-169
31902922-7	2020	In this study, human riboflavin transporter SLC52A2 was used to analyze the effects of paclitaxel and CrEL.	Paclitaxel	87-97	solute carrier family 52 member 2	Homo sapiens	44-51
31690669-8	2020	Furthermore, the H3K4 presenter WDR5 functioned as a molecular determinant that mediated cytokine induction by paclitaxel.	Paclitaxel	111-121	WD repeat domain 5	Mus musculus	32-36
32016960-15	2020	CONCLUSIONS: LncRNA UCA1 plays an active role in PTX resistance of OC and is crucial to maintain the development of PTX resistance in OC, which provides a new therapeutic target for the study of OC chemoresistance.	Paclitaxel	49-52	urothelial cancer associated 1	Homo sapiens	20-24
32016960-15	2020	CONCLUSIONS: LncRNA UCA1 plays an active role in PTX resistance of OC and is crucial to maintain the development of PTX resistance in OC, which provides a new therapeutic target for the study of OC chemoresistance.	Paclitaxel	116-119	urothelial cancer associated 1	Homo sapiens	20-24
32407275-0	2020	The sodium channel Nav1.7 is involved in paclitaxel-induced peripheral neuropathy though ERK1/2 signaling in rats.	Paclitaxel	41-51	mitogen activated protein kinase 3	Rattus norvegicus	89-95
31511646-0	2020	Correction: PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer.	Paclitaxel	91-101	hexokinase 2	Homo sapiens	45-57
32407275-7	2020	In addition, paclitaxel up-regulated extracellular signal-regulated kinase (ERK1/2) phosphorylation in DRG.	Paclitaxel	13-23	mitogen activated protein kinase 3	Rattus norvegicus	76-82
31432702-5	2019	Mechanism studies indicated that the DQA modified paclitaxel plus ligustrazine micelles could down-regulate the expressions of VEGF, MMP2, TGF-beta1 and E-cadherin in A549 cells.	Paclitaxel	50-60	matrix metallopeptidase 2	Homo sapiens	133-137
32248718-0	2020	Xiao-Ai-Ping Injection Enhances Effect of Paclitaxel to Suppress Breast Cancer Proliferation and Metastasis via Activating Transcription Factor 3.	Paclitaxel	42-52	transcription factor 3	Homo sapiens	123-145
31553933-6	2019	The results indicated that the paclitaxel-loaded Fru-RGD-Lip had the strongest growth inhibition against GLUT5 and alphavbeta3 overexpressed MDA-MB-231 and 4T1 cells.	Paclitaxel	31-41	zinc finger and BTB domain containing 22	Homo sapiens	49-52
31775332-0	2019	Electroacupuncture Alleviates Paclitaxel-Induced Peripheral Neuropathic Pain in Rats via Suppressing TLR4 Signaling and TRPV1 Upregulation in Sensory Neurons.	Paclitaxel	30-40	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	120-125
31942189-0	2020	Bazedoxifene enhances paclitaxel efficacy to suppress glioblastoma via altering Hippo/YAP pathway.	Paclitaxel	22-32	Yes1 associated transcriptional regulator	Homo sapiens	86-89
31718559-0	2019	Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer.	Paclitaxel	52-62	Yes1 associated transcriptional regulator	Homo sapiens	39-42
31718559-7	2019	Sub-lethal doses of the proton pump inhibitor esomeprazole (EMSO) in combination with paclitaxel (PTX) increased the PTX sensitivity in PTX-resistant EOC cells, as compared to PTX single treatments by inhibiting YAP and reserving pH gradient created by the V-ATPase D1.	Paclitaxel	86-96	Yes1 associated transcriptional regulator	Homo sapiens	212-215
31718559-7	2019	Sub-lethal doses of the proton pump inhibitor esomeprazole (EMSO) in combination with paclitaxel (PTX) increased the PTX sensitivity in PTX-resistant EOC cells, as compared to PTX single treatments by inhibiting YAP and reserving pH gradient created by the V-ATPase D1.	Paclitaxel	98-101	Yes1 associated transcriptional regulator	Homo sapiens	212-215
31942189-5	2020	Combination of bazedoxifene and paclitaxel also accelerated YAP phosphorylation and inactivation.	Paclitaxel	32-42	Yes1 associated transcriptional regulator	Homo sapiens	60-63
31718559-9	2019	CONCLUSIONS: These results suggested that sub-lethal doses of esomeprazole reverse YAP-mediated PTX resistance through the inhibiting of both YAP expression and acidic tumor microenvironment created by the V-ATPase D1.	Paclitaxel	96-99	Yes1 associated transcriptional regulator	Homo sapiens	83-86
31562256-10	2020	In vivo, LY2090314 plus nab-paclitaxel significantly prolonged mice survival duration.Our study demonstrates a unique role for TAK1 in controlling YAP/TAZ in pancreatic cancer.	Paclitaxel	28-38	mitogen-activated protein kinase kinase kinase 7	Mus musculus	127-131
31707979-0	2019	Paclitaxel-activated astrocytes produce mechanical allodynia in mice by releasing tumor necrosis factor-alpha and stromal-derived cell factor 1.	Paclitaxel	0-10	chemokine (C-X-C motif) ligand 12	Mus musculus	114-143
31707979-8	2019	Cultured astrocytes were activated by paclitaxel with significant increases in protein levels for tumor necrosis factor-alpha (TNF-alpha) and stromal-derived cell factor 1 (SDF-1).	Paclitaxel	38-48	chemokine (C-X-C motif) ligand 12	Mus musculus	142-171
31707979-8	2019	Cultured astrocytes were activated by paclitaxel with significant increases in protein levels for tumor necrosis factor-alpha (TNF-alpha) and stromal-derived cell factor 1 (SDF-1).	Paclitaxel	38-48	chemokine (C-X-C motif) ligand 12	Mus musculus	173-178
31707979-9	2019	Importantly, intrathecal injection of paclitaxel-activated astrocytes produced mechanical allodynia that was reversed by TNF-alpha and SDF-1 neutralizing antibodies.	Paclitaxel	38-48	chemokine (C-X-C motif) ligand 12	Mus musculus	135-140
31707979-10	2019	CONCLUSION: Our results suggest for the first time that paclitaxel can directly activate astrocytes, which are sufficient to produce acute pain by releasing TNF-alpha and SDF-1.	Paclitaxel	56-66	chemokine (C-X-C motif) ligand 12	Mus musculus	171-176
31562256-10	2020	In vivo, LY2090314 plus nab-paclitaxel significantly prolonged mice survival duration.Our study demonstrates a unique role for TAK1 in controlling YAP/TAZ in pancreatic cancer.	Paclitaxel	28-38	yes-associated protein 1	Mus musculus	147-150
31819016-0	2019	Posttranscriptional regulation of AKT by circular RNA angiomotin- like 1 mediates chemoresistance against paclitaxel in breast cancer cells.	Paclitaxel	106-116	angiomotin like 1	Homo sapiens	54-72
31616965-5	2019	A significant decrease in proliferating (Ki67+) CD3+CD8- T cells and FoxP3+(CD3+CD8-) regulatory T cells was observed in the tumor stroma after cisplatin and paclitaxel treatment, with increased rates of cytotoxic CD8+ T cells, including activated and CD8+Tbet+ T cells.	Paclitaxel	158-168	forkhead box P3	Homo sapiens	69-74
31467112-0	2019	Breast cancer risk-associated SNPs in the mTOR promoter form de novo KLF5 and ZEB1 binding sites that influence the cellular response to paclitaxel.	Paclitaxel	137-147	Kruppel like factor 5	Homo sapiens	69-73
31467112-5	2019	Mechanistically, the -141T allele of Ht2 creates a novel ZEB1 binding site; meanwhile, the -78C allele of Ht1 exists as an emerging KLF5 binding site, which synergistically induces promote/inhibit mTOR expression, cell proliferation and excretion of cytotoxic drugs through the ZEB1/KLF5-mTOR-CCND1/ABCB1 cascade, thereby affecting the response to PTX treatment in vivo and in vitro.	Paclitaxel	348-351	Kruppel like factor 5	Homo sapiens	132-136
30782035-5	2019	Knockdown of NEAT1 could reverse the paclitaxel-resistance through induction of apoptosis by increasing cleaved PARP and cleaved caspase-3 expression.	Paclitaxel	37-47	collagen type XI alpha 2 chain	Homo sapiens	112-116
31467112-5	2019	Mechanistically, the -141T allele of Ht2 creates a novel ZEB1 binding site; meanwhile, the -78C allele of Ht1 exists as an emerging KLF5 binding site, which synergistically induces promote/inhibit mTOR expression, cell proliferation and excretion of cytotoxic drugs through the ZEB1/KLF5-mTOR-CCND1/ABCB1 cascade, thereby affecting the response to PTX treatment in vivo and in vitro.	Paclitaxel	348-351	Kruppel like factor 5	Homo sapiens	283-287
31467112-5	2019	Mechanistically, the -141T allele of Ht2 creates a novel ZEB1 binding site; meanwhile, the -78C allele of Ht1 exists as an emerging KLF5 binding site, which synergistically induces promote/inhibit mTOR expression, cell proliferation and excretion of cytotoxic drugs through the ZEB1/KLF5-mTOR-CCND1/ABCB1 cascade, thereby affecting the response to PTX treatment in vivo and in vitro.	Paclitaxel	348-351	cyclin D1	Homo sapiens	293-298
31488699-10	2019	These findings indicate that Transgelin 2 promotes paclitaxel resistance and the migration and invasion of breast cancer by directly interacting with PTEN and activating the PI3K/Akt/GSK-3beta pathway.	Paclitaxel	51-61	glycogen synthase kinase 3 alpha	Homo sapiens	183-192
31578579-8	2019	In in vitro studies, in acquired paclitaxel (PTX)-resistant EOC cells, the silencing of CTGF expression led to the restoration of PTX sensitivity.	Paclitaxel	33-43	cellular communication network factor 2	Homo sapiens	88-92
31467112-6	2019	Our results suggest the existence of a ZEB1/KLF5-mTOR-CCND1/ABCB1 axis in human cells that could be involved in PTX response pathways and functionally regulate inter-individualized breast cancer susceptibility and prognosis.	Paclitaxel	112-115	Kruppel like factor 5	Homo sapiens	44-48
31467112-6	2019	Our results suggest the existence of a ZEB1/KLF5-mTOR-CCND1/ABCB1 axis in human cells that could be involved in PTX response pathways and functionally regulate inter-individualized breast cancer susceptibility and prognosis.	Paclitaxel	112-115	cyclin D1	Homo sapiens	54-59
31467112-7	2019	Implications: The current study highlights the function of haplotypes of mTOR -78C/-141G and -78G/-141T, in affecting breast cancer susceptibility and PTX response regulated by ZEB1/KLF5-mTOR-CCND1/ABCB1 axis.	Paclitaxel	151-154	Kruppel like factor 5	Homo sapiens	182-186
31467112-7	2019	Implications: The current study highlights the function of haplotypes of mTOR -78C/-141G and -78G/-141T, in affecting breast cancer susceptibility and PTX response regulated by ZEB1/KLF5-mTOR-CCND1/ABCB1 axis.	Paclitaxel	151-154	cyclin D1	Homo sapiens	192-197
31664305-0	2019	Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells.	Paclitaxel	56-61	high mobility group box 1	Homo sapiens	81-86
31664305-10	2019	We found that interference of HMGB1 enhanced the chemosensitivity of Taxol by inhibiting autophagy and inducing apoptosis in MCF-7 cells.	Paclitaxel	69-74	high mobility group box 1	Homo sapiens	30-35
31664305-11	2019	Taken together, our findings suggested that miR-129-5p increased the chemosensitivity of MCF-7 cells to Taxol through suppressing autophagy and enhancing apoptosis by inhibiting HMGB1.	Paclitaxel	104-109	high mobility group box 1	Homo sapiens	178-183
31664305-12	2019	Using miR-129-5p/HMGB1/autophagy-based therapeutic strategies may be a potential treatment for overcoming Taxol resistance in breast cancer.	Paclitaxel	106-111	high mobility group box 1	Homo sapiens	17-22
31023863-9	2019	Among the seven polymorphisms selected for genotyping, the variant alleles of EPHA5-rs7349683, EPHA6-rs301927, and EPHA8-rs209709 were associated with an increased risk of paclitaxel-induced neuropathy.	Paclitaxel	172-182	EPH receptor A5	Homo sapiens	78-83
31578579-8	2019	In in vitro studies, in acquired paclitaxel (PTX)-resistant EOC cells, the silencing of CTGF expression led to the restoration of PTX sensitivity.	Paclitaxel	45-48	cellular communication network factor 2	Homo sapiens	88-92
31519809-6	2019	Importantly, AMPK expression and activity was found to be critical for paclitaxel chemosensitivity in breast cancer cells and positively correlated with relapse-free survival in systemically treated breast cancer patients.	Paclitaxel	71-81	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	13-17
31578579-8	2019	In in vitro studies, in acquired paclitaxel (PTX)-resistant EOC cells, the silencing of CTGF expression led to the restoration of PTX sensitivity.	Paclitaxel	130-133	cellular communication network factor 2	Homo sapiens	88-92
31720085-0	2019	The resistance of esophageal cancer cells to paclitaxel can be reduced by the knockdown of long noncoding RNA DDX11-AS1 through TAF1/TOP2A inhibition.	Paclitaxel	45-55	prostaglandin D2 receptor	Homo sapiens	116-119
31464090-8	2019	Conversely, activation of IFN/JAK2 and ER stress response pathways in NPC cells reduced paclitaxel resistance and increased apoptosis.	Paclitaxel	88-98	Janus kinase 2	Homo sapiens	30-34
31919315-8	2019	The sensitivity of CDDP-R B16F10 cell line with stably transfected T-cadherin to paclitaxel was examined by MTT assay.	Paclitaxel	81-91	cadherin 13	Mus musculus	67-77
31350703-6	2019	Thus, MDR1, and increased amounts of Gb4Cer, Leb and GM3 were suggested to be involved in the anticancer drug-resistance to hydrophobic paclitaxel and docetaxel, and GM3 was to basic cisplatin.	Paclitaxel	136-146	beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group)	Homo sapiens	37-43
31720085-0	2019	The resistance of esophageal cancer cells to paclitaxel can be reduced by the knockdown of long noncoding RNA DDX11-AS1 through TAF1/TOP2A inhibition.	Paclitaxel	45-55	TATA-box binding protein associated factor 1	Homo sapiens	128-132
31720085-3	2019	The present study aims to define the role of the long noncoding RNA (lncRNA) DDX11-AS1 in the progression of EC with the involvement of PTX-resistant EC cells.	Paclitaxel	136-139	prostaglandin D2 receptor	Homo sapiens	83-86
31720085-8	2019	DDX11-AS1 could promote TOP2A transcription via TAF1, and the knockdown of TOP2A or DDX11-AS1 could increase the sensitivity of EC cells to PTX.	Paclitaxel	140-143	prostaglandin D2 receptor	Homo sapiens	90-93
31720085-11	2019	In conclusion, our findings suggest that DDX11-AS1 knockdown results in reduced resistance of EC cells to PTX by inhibiting TOP2A transcription via TAF1.	Paclitaxel	106-109	prostaglandin D2 receptor	Homo sapiens	47-50
31720085-11	2019	In conclusion, our findings suggest that DDX11-AS1 knockdown results in reduced resistance of EC cells to PTX by inhibiting TOP2A transcription via TAF1.	Paclitaxel	106-109	TATA-box binding protein associated factor 1	Homo sapiens	148-152
31352515-0	2019	Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.	Paclitaxel	34-44	cyclin dependent kinase 19	Homo sapiens	106-111
31352515-12	2019	miR-18a-5p mimics or downregulation of CDK19 decreased tumor growth in xenograft mice implanted with MCF-7/PTX cells.	Paclitaxel	107-110	microRNA 18	Mus musculus	0-7
31919315-20	2019	T-cadherin can reverse the CDDP resistance to CDDP-R B16F10 cell line, and promote its sensitivity to paclitaxel.	Paclitaxel	102-112	cadherin 13	Mus musculus	0-10
31352515-13	2019	In summary, we identified that CASC2 activated PTX resistance in breast cancer through regulation of miR-18a-5p/CDK19.	Paclitaxel	47-50	cyclin dependent kinase 19	Homo sapiens	112-117
31772161-5	2019	In this context, MUC1 induces CSCs enrichment in paclitaxel-resistant cells via activation of EGFR, which directly enhances IL-6 transcription through cAMP response element-binding protein (CREB) and glucocorticoid receptor beta (GRbeta).	Paclitaxel	49-59	mucin 1, cell surface associated	Homo sapiens	17-21
30367323-7	2019	Results In the in vitro model, the expression of twelve drug-transporters genes was found to be significantly down-regulated after exposure to paclitaxel, including ABCC10, SLC28A3, SLC29A2, and ATP7B (involved in the transport of taxanes, antimetabolites, and cisplatin, respectively).	Paclitaxel	143-153	solute carrier family 28 member 3	Homo sapiens	173-180
31308076-7	2019	In concert with these results, we show that MUC1-C and TWIST1 also drive EMT and stemness in association with acquired paclitaxel (PTX) resistance.	Paclitaxel	119-129	mucin 1, cell surface associated	Homo sapiens	44-48
31308076-7	2019	In concert with these results, we show that MUC1-C and TWIST1 also drive EMT and stemness in association with acquired paclitaxel (PTX) resistance.	Paclitaxel	131-134	mucin 1, cell surface associated	Homo sapiens	44-48
31512803-4	2019	Moreover, by administering the CDK4/6 inhibitor palbociclib, we show that transit amplifying and stem/progenitor cells can be protected from paclitaxel cytotoxicity through G1 arrest, without premature catagen induction and additional hair follicle damage.	Paclitaxel	141-151	cyclin dependent kinase 4	Homo sapiens	31-37
31400383-3	2019	We synthesized both paclitaxel and docetaxel prodrugs to formulate as ephrin A2-targeted liposomes stabilized in the aqueous core with sucroseoctasulfate (SOS).	Paclitaxel	20-30	ephrin A2	Homo sapiens	70-79
31766723-5	2019	Inhibition of Cx43 expression using siRNA increased Bcl-2 protein levels in SCC25 (tongue squamous cell carcinoma) cells, while forced Cx43 expression reduced Bcl-2 levels and supported paclitaxel cytotoxicity in FaDu (hypopharynx squamous cell carcinoma) cells.	Paclitaxel	186-196	gap junction protein alpha 1	Homo sapiens	135-139
31576113-0	2019	Paclitaxel alleviated sepsis-induced acute lung injury by activating MUC1 and suppressing TLR-4/NF-kappaB pathway.	Paclitaxel	0-10	mucin 1, transmembrane	Mus musculus	69-73
31576113-13	2019	At the upstream level, paclitaxel-upregulated expression levels of MUC1 in both in vivo and in vitro experiments.	Paclitaxel	23-33	mucin 1, transmembrane	Mus musculus	67-71
31576113-14	2019	The inhibitory effects of paclitaxel on TLR 4-NF-kappaB/p65 activation were reversed in lung tissues of septic mice pre-treated with MUC1 inhibitor and in MUC1-knockdown A549 cells.	Paclitaxel	26-36	mucin 1, transmembrane	Mus musculus	133-137
31576113-14	2019	The inhibitory effects of paclitaxel on TLR 4-NF-kappaB/p65 activation were reversed in lung tissues of septic mice pre-treated with MUC1 inhibitor and in MUC1-knockdown A549 cells.	Paclitaxel	26-36	mucin 1, transmembrane	Mus musculus	155-159
31576113-15	2019	Protection of paclitaxel on sepsis-induced ALI and decrease of inflammatory cytokines were also abolished by inhibition of MUC1.	Paclitaxel	14-24	mucin 1, transmembrane	Mus musculus	123-127
31576113-16	2019	Conclusion: Collectively, these results indicated paclitaxel could significantly alleviate acute lung injury in CLP-induced septic mice and LPS-stimulated lung type II epithelial cell line A549 by activating MUC1 and suppressing TLR-4/NF-kappaB pathway.	Paclitaxel	50-60	mucin 1, transmembrane	Mus musculus	208-212
31660072-13	2019	Consistently, inhibiting p300/CBP substantially decreased CapG-dependent upregulation of PIK3R1/P50 and subsequent PI3K/Akt activation, resulting in increased sensitivity to paclitaxel treatment in breast cancer cells.	Paclitaxel	174-184	E1A binding protein p300	Homo sapiens	25-29
31575759-3	2019	BOS172722 synergizes with paclitaxel to induce gross chromosomal segregation defects caused by MPS1 inhibitor-mediated abrogation of the mitotic delay induced by paclitaxel treatment.	Paclitaxel	26-36	TTK protein kinase	Homo sapiens	95-99
31766723-8	2019	On the contrary, silencing of the Cx43 gene GJA1 (gap junction protein alpha-1) can result in increased Bcl-2 expression and reduced paclitaxel efficiency.	Paclitaxel	133-143	gap junction protein alpha 1	Homo sapiens	34-38
31575759-3	2019	BOS172722 synergizes with paclitaxel to induce gross chromosomal segregation defects caused by MPS1 inhibitor-mediated abrogation of the mitotic delay induced by paclitaxel treatment.	Paclitaxel	162-172	TTK protein kinase	Homo sapiens	95-99
31766723-8	2019	On the contrary, silencing of the Cx43 gene GJA1 (gap junction protein alpha-1) can result in increased Bcl-2 expression and reduced paclitaxel efficiency.	Paclitaxel	133-143	gap junction protein alpha 1	Homo sapiens	44-48
31766723-8	2019	On the contrary, silencing of the Cx43 gene GJA1 (gap junction protein alpha-1) can result in increased Bcl-2 expression and reduced paclitaxel efficiency.	Paclitaxel	133-143	gap junction protein alpha 1	Homo sapiens	50-78
31506466-0	2019	Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells.	Paclitaxel	77-87	cyclin dependent kinase 4	Homo sapiens	23-29
31766357-7	2019	Overall, these data provide a functional insight that supports the prognostic value of RASSF1 gene methylation on survival of early-stage lung cancer patients receiving perioperative paclitaxel-based treatment compared to gemcitabine-based treatment, identifying IAP-2 as a novel biomarker indicative of YAP-1-mediated modulation of chemo-sensitivity in lung cancer.	Paclitaxel	183-193	baculoviral IAP repeat containing 2	Homo sapiens	263-268
31211507-2	2019	Here, we showed that paclitaxel, the major chemotherapy drug for breast cancer, induced ISR and phosphorylated ser51 residue of EIF2S1 by EIF2AK3 and EIF2AK4.	Paclitaxel	21-31	eukaryotic translation initiation factor 2 subunit alpha	Homo sapiens	128-134
31211507-3	2019	When exposed to paclitaxel, cancer cells activated the EIF2AK3/EIF2AK4-pEIF2S1-ATF4 axis and maintained redox homoeostasis by inducing expression of the major antioxidant enzymes HMOX1, SHMT2 and SLC7A11.	Paclitaxel	16-26	solute carrier family 7 (cationic amino acid transporter, y+ system), member 11	Mus musculus	196-203
31540428-1	2019	Cytochrome P450 2C8 (CYP2C8) epoxygenase is responsible for the metabolism of over 60 clinically relevant drugs, notably the anticancer drug Taxol (paclitaxel, PAC).	Paclitaxel	141-146	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-19
31540428-1	2019	Cytochrome P450 2C8 (CYP2C8) epoxygenase is responsible for the metabolism of over 60 clinically relevant drugs, notably the anticancer drug Taxol (paclitaxel, PAC).	Paclitaxel	141-146	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	21-27
31540428-1	2019	Cytochrome P450 2C8 (CYP2C8) epoxygenase is responsible for the metabolism of over 60 clinically relevant drugs, notably the anticancer drug Taxol (paclitaxel, PAC).	Paclitaxel	148-158	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-19
31766357-7	2019	Overall, these data provide a functional insight that supports the prognostic value of RASSF1 gene methylation on survival of early-stage lung cancer patients receiving perioperative paclitaxel-based treatment compared to gemcitabine-based treatment, identifying IAP-2 as a novel biomarker indicative of YAP-1-mediated modulation of chemo-sensitivity in lung cancer.	Paclitaxel	183-193	Yes1 associated transcriptional regulator	Homo sapiens	304-309
31744174-8	2019	A reduction in monomeric alpha-tubulin levels by treatment with the chemotherapeutic paclitaxel resulted in a decline in the nuclear accumulation of c-Jun in melanoma cells in an experimental murine model and in patients" tissues.	Paclitaxel	85-95	jun proto-oncogene	Mus musculus	149-154
31322257-0	2019	Erythropoietin receptor induces a paclitaxel resistance phenotype in mammary adenocarcinoma cells.	Paclitaxel	34-44	erythropoietin receptor	Rattus norvegicus	0-23
31322257-3	2019	Indeed, results of the present study uncovered the role of EPOR in the resistance of EPOR-overexpressing RAMA 37-28 cells to paclitaxel chemotherapy.	Paclitaxel	125-135	erythropoietin receptor	Rattus norvegicus	59-63
31322257-3	2019	Indeed, results of the present study uncovered the role of EPOR in the resistance of EPOR-overexpressing RAMA 37-28 cells to paclitaxel chemotherapy.	Paclitaxel	125-135	erythropoietin receptor	Rattus norvegicus	85-89
31322257-4	2019	In this regard, EPOR silencing in the presence of paclitaxel therapy decreased RAMA 37-28 cell proliferation, confirming its role in the sensitivity or resistance of RAMA 37-28 cells to paclitaxel.	Paclitaxel	50-60	erythropoietin receptor	Rattus norvegicus	16-20
31322257-4	2019	In this regard, EPOR silencing in the presence of paclitaxel therapy decreased RAMA 37-28 cell proliferation, confirming its role in the sensitivity or resistance of RAMA 37-28 cells to paclitaxel.	Paclitaxel	186-196	erythropoietin receptor	Rattus norvegicus	16-20
31432846-2	2019	Oil-soluble Ag2S QDs and PTX were first loaded into nanogels formed with engineered polypeptide PC10A by ultrasonic treatment to prepare PC10A/Ag2S QD/PTX nanogels.	Paclitaxel	151-154	angiotensin II receptor type 1	Homo sapiens	12-16
31432846-3	2019	The multifunctional PC10A/Ag2S QD/PTX hydrogels were prepared by dissolving the PC10A/Ag2S QD/PTX nanogels into the PC10A hydrogel.	Paclitaxel	34-37	angiotensin II receptor type 1	Homo sapiens	26-30
31432846-3	2019	The multifunctional PC10A/Ag2S QD/PTX hydrogels were prepared by dissolving the PC10A/Ag2S QD/PTX nanogels into the PC10A hydrogel.	Paclitaxel	34-37	angiotensin II receptor type 1	Homo sapiens	86-90
31432846-3	2019	The multifunctional PC10A/Ag2S QD/PTX hydrogels were prepared by dissolving the PC10A/Ag2S QD/PTX nanogels into the PC10A hydrogel.	Paclitaxel	94-97	angiotensin II receptor type 1	Homo sapiens	26-30
31432846-4	2019	The PC10A/Ag2S QD/PTX hydrogel can be injected directly into the site of tumors.	Paclitaxel	18-21	angiotensin II receptor type 1	Homo sapiens	10-14
31432846-5	2019	In vitro and in vivo toxicity results showed that the PC10A/Ag2S QD/PTX hydrogel presented excellent biocompatibility.	Paclitaxel	68-71	angiotensin II receptor type 1	Homo sapiens	60-64
31432846-7	2019	In addition, real-time monitoring of the in vivo degradation of the PC10A/Ag2S QD/PTX hydrogel was achieved by near-infrared fluorescence imaging and photoacoustic imaging.	Paclitaxel	82-85	angiotensin II receptor type 1	Homo sapiens	74-78
31432846-8	2019	These results demonstrated that this injectable multifunctional PC10A/Ag2S QD/PTX hydrogel has the potential as a theranostic platform for sustained cancer treatments.	Paclitaxel	78-81	angiotensin II receptor type 1	Homo sapiens	70-74
31123858-8	2019	CONCLUSIONS: The present study suggests that CYP2C8*3 is a potential predictor of hematological toxicities related to paclitaxel/carboplatin treatment.	Paclitaxel	118-128	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	45-51
31273338-0	2019	The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway.	Paclitaxel	76-86	inositol 1,4,5-triphosphate receptor associated 1	Homo sapiens	4-9
31273338-0	2019	The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway.	Paclitaxel	76-86	prostaglandin D2 receptor	Homo sapiens	10-13
31273338-2	2019	In this study, lncRNA array of CNE-1 and HNE-2 paclitaxel-resistant cells and their parental strains revealed that the paclitaxel-resistant strains had significantly lower MRVI1-AS1 (murine retrovirus integration site 1 homolog antisense RNA 1) expression than the parental strains, and that MRVI1-AS1 overexpression in vitro and in vivo increased paclitaxel chemosensitivity.	Paclitaxel	119-129	inositol 1,4,5-triphosphate receptor associated 1	Homo sapiens	172-177
31273338-2	2019	In this study, lncRNA array of CNE-1 and HNE-2 paclitaxel-resistant cells and their parental strains revealed that the paclitaxel-resistant strains had significantly lower MRVI1-AS1 (murine retrovirus integration site 1 homolog antisense RNA 1) expression than the parental strains, and that MRVI1-AS1 overexpression in vitro and in vivo increased paclitaxel chemosensitivity.	Paclitaxel	119-129	prostaglandin D2 receptor	Homo sapiens	178-181
31815052-0	2019	Impact of BMI1 expression on the apoptotic effect of paclitaxel in colorectal cancer.	Paclitaxel	53-63	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	10-14
31273338-2	2019	In this study, lncRNA array of CNE-1 and HNE-2 paclitaxel-resistant cells and their parental strains revealed that the paclitaxel-resistant strains had significantly lower MRVI1-AS1 (murine retrovirus integration site 1 homolog antisense RNA 1) expression than the parental strains, and that MRVI1-AS1 overexpression in vitro and in vivo increased paclitaxel chemosensitivity.	Paclitaxel	119-129	inositol 1,4,5-triphosphate receptor associated 1	Homo sapiens	172-177
31273338-2	2019	In this study, lncRNA array of CNE-1 and HNE-2 paclitaxel-resistant cells and their parental strains revealed that the paclitaxel-resistant strains had significantly lower MRVI1-AS1 (murine retrovirus integration site 1 homolog antisense RNA 1) expression than the parental strains, and that MRVI1-AS1 overexpression in vitro and in vivo increased paclitaxel chemosensitivity.	Paclitaxel	119-129	prostaglandin D2 receptor	Homo sapiens	178-181
31411627-4	2019	Following the pH and MMP-2 dual sensitive structure design, the micelle may sequentially release sunitinib inside the tumor extracellular matrix and PTX into cancer cells through responding to enriched MMP-2 levels and decreased pH, respectively.	Paclitaxel	149-152	matrix metallopeptidase 2	Homo sapiens	21-26
31411627-4	2019	Following the pH and MMP-2 dual sensitive structure design, the micelle may sequentially release sunitinib inside the tumor extracellular matrix and PTX into cancer cells through responding to enriched MMP-2 levels and decreased pH, respectively.	Paclitaxel	149-152	matrix metallopeptidase 2	Homo sapiens	202-207
31299200-6	2019	Accordingly, expression of cGAS and IRF3 in cancer cells makes mouse xenograft tumors responsive to the anti-mitotic agent Taxol.	Paclitaxel	123-128	interferon regulatory factor 3	Mus musculus	36-40
31370861-5	2019	RESULTS: TGF-beta and smad3 were overexpressed only in A549/TAX cells, silencing TGF-beta or smad3 in A549/TAX cells decreased the expression of CTSL and enhanced their sensitivity to paclitaxel.	Paclitaxel	184-194	SMAD family member 3	Homo sapiens	22-27
31815052-5	2019	In this study, we found that the apoptotic effect of paclitaxel is more profound in BMI1-depleted cells.	Paclitaxel	53-63	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	84-88
31370861-5	2019	RESULTS: TGF-beta and smad3 were overexpressed only in A549/TAX cells, silencing TGF-beta or smad3 in A549/TAX cells decreased the expression of CTSL and enhanced their sensitivity to paclitaxel.	Paclitaxel	184-194	SMAD family member 3	Homo sapiens	93-98
31815052-6	2019	The apoptotic effect is exerted by promoting caspase-8-independent apoptotic pathways after combination with paclitaxel in BMI1 knockdown cells.	Paclitaxel	109-119	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	123-127
31815052-10	2019	Consistent with in vitro data, a synergic anti-growth effect of BMI1 depletion with paclitaxel treatment was shown in vivo.	Paclitaxel	84-94	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	64-68
31815052-11	2019	In conclusion, paclitaxel has a stronger suppressive effect on tumor growth and proliferation in CRC with low BMI1 expression.	Paclitaxel	15-25	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	110-114
31346547-8	2019	Results: CCK-8 assays indicated that miR-107 mimics augmented Taxol-induced cell viability inhibition.	Paclitaxel	62-67	microRNA 107	Homo sapiens	37-44
31815052-12	2019	Thus, in CRC patients, paclitaxel could be specifically indicated for patients with low BMI1 expression.	Paclitaxel	23-33	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	88-92
31346547-9	2019	Flow cytometry showed that miR-107 mimics augmented Taxol-induced elevation of cell apoptosis.	Paclitaxel	52-57	microRNA 107	Homo sapiens	27-34
31702036-0	2019	ST3Gal3 confers paclitaxel-mediated chemoresistance in ovarian cancer cells by attenuating caspase-8/3 signaling.	Paclitaxel	16-26	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	0-7
31273188-6	2019	Moreover, knockdown of PCAT1 arrested the cell cycle at G2/M phase, reduced the expression of cyclin B1 and CDC2, and caused cells to be more sensitive to paclitaxel.	Paclitaxel	155-165	prostate cancer associated transcript 1	Homo sapiens	23-28
31047896-13	2019	CDK6 knockdown attenuated the effects of miR-29c inhibition on paclitaxel cytotoxicity in breast cancer cells.	Paclitaxel	63-73	microRNA 29c	Homo sapiens	41-48
31047896-15	2019	SIGNIFICANCE: LINC00511 knockdown enhanced paclitaxel cytotoxicity in breast cancer cells via regulating miR-29c/CDK6 axis.	Paclitaxel	43-53	microRNA 29c	Homo sapiens	105-112
31340839-12	2019	Moreover, KIFC1 was activated by TCF-4, and KIFC1 inhibition enhanced HCC cell sensitivity to paclitaxel.	Paclitaxel	94-104	kinesin family member C1	Homo sapiens	10-15
31340839-12	2019	Moreover, KIFC1 was activated by TCF-4, and KIFC1 inhibition enhanced HCC cell sensitivity to paclitaxel.	Paclitaxel	94-104	kinesin family member C1	Homo sapiens	44-49
31340839-13	2019	CONCLUSIONS: Our findings suggest that KIFC1, activated by TCF-4, functions as an oncogene and promotes HCC pathogenesis through regulating HMGA1 transcriptional activity and that KIFC1 is a potential therapeutic target to enhance the paclitaxel sensitivity of HCC.	Paclitaxel	235-245	kinesin family member C1	Homo sapiens	39-44
31340839-13	2019	CONCLUSIONS: Our findings suggest that KIFC1, activated by TCF-4, functions as an oncogene and promotes HCC pathogenesis through regulating HMGA1 transcriptional activity and that KIFC1 is a potential therapeutic target to enhance the paclitaxel sensitivity of HCC.	Paclitaxel	235-245	transcription factor 4	Homo sapiens	59-64
31340839-13	2019	CONCLUSIONS: Our findings suggest that KIFC1, activated by TCF-4, functions as an oncogene and promotes HCC pathogenesis through regulating HMGA1 transcriptional activity and that KIFC1 is a potential therapeutic target to enhance the paclitaxel sensitivity of HCC.	Paclitaxel	235-245	kinesin family member C1	Homo sapiens	180-185
31406477-7	2019	Moreover, the expression levels of Bcl-2, survivin, CDK2 and MMP-2 significantly decreased in SCLC cells treated with paclitaxel targeting nanobubbles, whereas the expression of caspase-3 and Rb were increased.	Paclitaxel	118-128	cyclin dependent kinase 2	Homo sapiens	52-56
31406477-7	2019	Moreover, the expression levels of Bcl-2, survivin, CDK2 and MMP-2 significantly decreased in SCLC cells treated with paclitaxel targeting nanobubbles, whereas the expression of caspase-3 and Rb were increased.	Paclitaxel	118-128	matrix metallopeptidase 2	Homo sapiens	61-66
30878390-0	2019	MiR-155-3p acts as a tumor suppressor and reverses paclitaxel resistance via negative regulation of MYD88 in human breast cancer.	Paclitaxel	51-61	MYD88 innate immune signal transduction adaptor	Homo sapiens	100-105
30878390-4	2019	Moreover, miR-155-3p showed a negative effect on apoptosis, invasion and metastasis, reverses paclitaxel resistance by suppression of the corresponding target gene MYD88 in vitro and in vivo experiments.	Paclitaxel	94-104	MYD88 innate immune signal transduction adaptor	Homo sapiens	164-169
31169019-3	2019	qRT-PCR assays were used to assess the expression levels of miR-21-5p and PDCD4 mRNA, and western blotting was used to detect PDCD4 protein level in PTX-resistant BC cell lines.	Paclitaxel	149-152	programmed cell death 4	Homo sapiens	126-131
31169019-4	2019	Dual-luciferase reporter assay was used to observe the interaction between miR-21-5p and PDCD4 in PTX-resistant BC cell lines.	Paclitaxel	98-101	programmed cell death 4	Homo sapiens	89-94
31169019-7	2019	Then, we found that miR-21-5p was upregulated and PDCD4 was downregulated in BC tissues and PTX-resistant BC cell lines.	Paclitaxel	92-95	programmed cell death 4	Homo sapiens	50-55
31169019-8	2019	MiR-21-5p silencing or PDCD4 overexpression ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines.	Paclitaxel	56-59	programmed cell death 4	Homo sapiens	23-28
31169019-8	2019	MiR-21-5p silencing or PDCD4 overexpression ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines.	Paclitaxel	104-107	programmed cell death 4	Homo sapiens	23-28
31169019-10	2019	MiR-21-5p exerted its regulatory effect by PDCD4 in PTX-resistant BC cell lines.	Paclitaxel	52-55	programmed cell death 4	Homo sapiens	43-48
31169019-12	2019	Therefore, our study demonstrated that miR-21-5p silencing ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines at least partly by targeting PDCD4, providing miR-21-5p as an effective therapeutic target for PTX-resistant BC treatment.	Paclitaxel	71-74	programmed cell death 4	Homo sapiens	176-181
31169019-12	2019	Therefore, our study demonstrated that miR-21-5p silencing ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines at least partly by targeting PDCD4, providing miR-21-5p as an effective therapeutic target for PTX-resistant BC treatment.	Paclitaxel	119-122	programmed cell death 4	Homo sapiens	176-181
31169019-12	2019	Therefore, our study demonstrated that miR-21-5p silencing ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines at least partly by targeting PDCD4, providing miR-21-5p as an effective therapeutic target for PTX-resistant BC treatment.	Paclitaxel	119-122	programmed cell death 4	Homo sapiens	176-181
30892073-11	2019	Conclusion: KB-1471A8.2 could significantly inhibit the development and paclitaxel resistance of ovarian cancer cells, at least partly, by suppressing CDK4 expression.	Paclitaxel	72-82	cyclin dependent kinase 4	Homo sapiens	151-155
30317630-12	2019	While the phosphatidylinositol 3-kinase (PI3K)/serine/threonine protein kinase (AKT) pathway is significantly activated by taxol, taxol-induced ABCB1 expression, histone posttranslational modifications, and p300 binding to ARE4 are suppressed following inhibition of the PI3K/AKT cellular pathway.	Paclitaxel	130-135	E1A binding protein p300	Homo sapiens	207-211
30317630-13	2019	These results demonstrate that the AKT/p300/AR axis can be activated to target ABCB1 gene expression in response to taxol, thus revealing a new treatment target to counter taxol resistance.	Paclitaxel	116-121	E1A binding protein p300	Homo sapiens	39-43
30317630-13	2019	These results demonstrate that the AKT/p300/AR axis can be activated to target ABCB1 gene expression in response to taxol, thus revealing a new treatment target to counter taxol resistance.	Paclitaxel	172-177	E1A binding protein p300	Homo sapiens	39-43
31206033-0	2019	miR-107 Enhances the Sensitivity of Breast Cancer Cells to Paclitaxel.	Paclitaxel	59-69	microRNA 107	Homo sapiens	0-7
31206033-5	2019	Here, the present study aimed to lucubrate the underlying mechanisms of miR-107 in regulating the sensitivity of breast cancer cells to PTX.	Paclitaxel	136-139	microRNA 107	Homo sapiens	72-79
31206033-8	2019	In addition, miR-107 may prominently enhance PTX induced reduction of cell viability and the promotion of cell apoptosis in breast cancer, and the variation could be reversed by co-transfected with pcDNA3.1-TPD52.	Paclitaxel	45-48	microRNA 107	Homo sapiens	13-20
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	126-129	microRNA 107	Homo sapiens	9-16
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	126-129	cyclin D1	Homo sapiens	96-105
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	126-129	microRNA 107	Homo sapiens	216-223
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	268-271	microRNA 107	Homo sapiens	9-16
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	268-271	cyclin D1	Homo sapiens	96-105
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	268-271	microRNA 107	Homo sapiens	216-223
31192127-4	2019	Overexpression of Aurora-A in EC cell lines (Ishikawa and HEC-1B cells) promotes cell proliferation and induced paclitaxel- and cisplatin-resistance.	Paclitaxel	112-122	aurora kinase A	Homo sapiens	18-26
30954217-0	2019	An ATG5 knockout promotes paclitaxel resistance in v-Ha-ras-transformed NIH 3T3 cells.	Paclitaxel	26-36	autophagy related 5	Mus musculus	3-7
30954217-5	2019	We found that the ATG5 KO led to paclitaxel resistance in Ras-NIH 3T3 cells through an ATP-binding cassette (ABC) transporter-independent mechanism.	Paclitaxel	33-43	autophagy related 5	Mus musculus	18-22
30954217-7	2019	Additionally, the proportion of early apoptotic cells significantly decreased in ATG5 KO cells treated with paclitaxel than in parental cells.	Paclitaxel	108-118	autophagy related 5	Mus musculus	81-85
30954217-8	2019	Interestingly, overexpression of ATG5 N-terminal cleavage product in ATG5 KO cells restored their sensitivity to paclitaxel.	Paclitaxel	113-123	autophagy related 5	Mus musculus	33-37
30954217-8	2019	Interestingly, overexpression of ATG5 N-terminal cleavage product in ATG5 KO cells restored their sensitivity to paclitaxel.	Paclitaxel	113-123	autophagy related 5	Mus musculus	69-73
30954217-9	2019	Taken together, our results suggest that ATG5 KO cells are resistant to paclitaxel due to the inability to produce tATG5.	Paclitaxel	72-82	autophagy related 5	Mus musculus	41-45
31164954-3	2019	Viability assays revealed a significant decrease in cell viability with pharmacological inhibition of DUSP6 using (E/Z)-BCI hydrochloride in ovarian cancer cells treated with carboplatin or paclitaxel, compared to treatment with either agent alone.	Paclitaxel	190-200	dual specificity phosphatase 6	Homo sapiens	102-107
31164954-7	2019	Pathway focused quantitative PCR also revealed suppression of ERBB3 in cells co-treated with BCI plus carboplatin or paclitaxel.	Paclitaxel	117-127	erb-b2 receptor tyrosine kinase 3	Homo sapiens	62-67
31101119-10	2019	Ectopic overexpression of NNMT significantly inhibited the apoptotic cell death and suppression of colony formation induced by adriamycin and paclitaxel.	Paclitaxel	142-152	nicotinamide N-methyltransferase	Homo sapiens	26-30
31101119-12	2019	Either inhibition of SIRT1 by EX527 or knockdown of SIRT1 by siRNA could reverse NNMT-mediated resistance to adriamycin and paclitaxel, which suggests that SIRT1 plays a critical role in NNMT-related chemoresistance in breast cancer.	Paclitaxel	124-134	nicotinamide N-methyltransferase	Homo sapiens	81-85
31101119-12	2019	Either inhibition of SIRT1 by EX527 or knockdown of SIRT1 by siRNA could reverse NNMT-mediated resistance to adriamycin and paclitaxel, which suggests that SIRT1 plays a critical role in NNMT-related chemoresistance in breast cancer.	Paclitaxel	124-134	nicotinamide N-methyltransferase	Homo sapiens	187-191
30471427-0	2019	Monoclonal Antibody Targeting the Matrix Metalloproteinase 9 Prevents and Reverses Paclitaxel-Induced Peripheral Neuropathy in Mice.	Paclitaxel	83-93	matrix metallopeptidase 9	Mus musculus	34-60
30471427-4	2019	Here, we report that paclitaxel-induced mechanical allodynia is associated with transcriptional increase in matrix metalloproteinase (MMP) 2 and 9 and decrease in metallopeptidase inhibitor 1 (TIMP1), a strong endogenous MMP9 inhibitor.	Paclitaxel	21-31	matrix metallopeptidase 9	Mus musculus	221-225
30471427-5	2019	Consistently, MMP9 protein levels are increased in DRG neurons in vivo and in vitro after paclitaxel treatment, and it is demonstrated, for the first time, that intrathecal injections of exogenous TIMP1 or a monoclonal antibody targeting MMP9 (MMP9 mAb) significantly prevented and reversed paclitaxel-induced mechanical allodynia in male and female mice.	Paclitaxel	90-100	matrix metallopeptidase 9	Mus musculus	14-18
30683943-0	2019	Paclitaxel alleviates monocrotaline-induced pulmonary arterial hypertension via inhibition of FoxO1-mediated autophagy.	Paclitaxel	0-10	forkhead box O1	Rattus norvegicus	94-99
30683943-12	2019	Treatment of PAH rats with paclitaxel reduced FoxO1 phosphorylation and increased FoxO1 nuclear accumulation, despite increased FoxO1 expression, therefore suppressed autophagy, finally reduced elevated RVSP, RV/LV+S, and %MT in MCT-induced PAH.	Paclitaxel	27-37	forkhead box O1	Rattus norvegicus	46-51
30683943-12	2019	Treatment of PAH rats with paclitaxel reduced FoxO1 phosphorylation and increased FoxO1 nuclear accumulation, despite increased FoxO1 expression, therefore suppressed autophagy, finally reduced elevated RVSP, RV/LV+S, and %MT in MCT-induced PAH.	Paclitaxel	27-37	forkhead box O1	Rattus norvegicus	82-87
30683943-12	2019	Treatment of PAH rats with paclitaxel reduced FoxO1 phosphorylation and increased FoxO1 nuclear accumulation, despite increased FoxO1 expression, therefore suppressed autophagy, finally reduced elevated RVSP, RV/LV+S, and %MT in MCT-induced PAH.	Paclitaxel	27-37	forkhead box O1	Rattus norvegicus	82-87
30683943-13	2019	Taken together, paclitaxel inhibits pulmonary vascular remodeling by FoxO1-mediated autophagy suppression, suggesting that paclitaxel might be a novel therapeutic agent for the prevention and treatment of PAH.	Paclitaxel	16-26	forkhead box O1	Rattus norvegicus	69-74
30683943-13	2019	Taken together, paclitaxel inhibits pulmonary vascular remodeling by FoxO1-mediated autophagy suppression, suggesting that paclitaxel might be a novel therapeutic agent for the prevention and treatment of PAH.	Paclitaxel	123-133	forkhead box O1	Rattus norvegicus	69-74
30705408-11	2019	Moreover, Aurora A"s activation correlates with microtubule stabilization induced by the microtubule stabilizer paclitaxel, implicating that stabilized microtubules caused by RITA depletion could also account for increased active Aurora A.	Paclitaxel	112-122	aurora kinase A	Mus musculus	10-18
30705408-11	2019	Moreover, Aurora A"s activation correlates with microtubule stabilization induced by the microtubule stabilizer paclitaxel, implicating that stabilized microtubules caused by RITA depletion could also account for increased active Aurora A.	Paclitaxel	112-122	aurora kinase A	Mus musculus	230-238
30986993-0	2019	Increase Paclitaxel Sensitivity to Better Suppress Serous Epithelial Ovarian Cancer via Ablating Androgen Receptor/Aryl Hydrocarbon Receptor-ABCG2 Axis.	Paclitaxel	9-19	aryl hydrocarbon receptor	Homo sapiens	115-140
30986993-7	2019	RESULTS: We found AR/aryl hydrocarbon receptor (AhR)-mediates ABCG2 expression and leads to a change in paclitaxel cytotoxicity/sensitivity in EOC serous subtype cell lines.	Paclitaxel	104-114	aryl hydrocarbon receptor	Homo sapiens	18-46
30986993-7	2019	RESULTS: We found AR/aryl hydrocarbon receptor (AhR)-mediates ABCG2 expression and leads to a change in paclitaxel cytotoxicity/sensitivity in EOC serous subtype cell lines.	Paclitaxel	104-114	aryl hydrocarbon receptor	Homo sapiens	48-51
30229430-8	2019	We propose that 5-DMN cooperates with PTX to induce apoptosis via the caspase pathway (by modulating caspase-3, caspase-8, and caspase-9 activities).	Paclitaxel	38-41	caspase 8	Homo sapiens	112-121
30520096-4	2019	Through logistic regression, COX regression, and correlation analysis with bootstrapping, we found that four genes (CDK8, FAM64A, MARC2, and OCEL1) were associated with drug sensitivity of PTX.	Paclitaxel	189-192	occludin/ELL domain containing 1	Homo sapiens	141-146
30871874-2	2019	We previously reported that coadministration of indomethacin plus minocycline (IPM) was antihyperalgesic in a cannabinoid type 1 (CB1) receptor-dependent manner in a mouse model of paclitaxel-induced neuropathic pain.	Paclitaxel	181-191	cannabinoid receptor 1 (brain)	Mus musculus	130-133
31068300-0	2019	[Silencing RRM1 gene reverses paclitaxel resistance in human breast cancer cell line MCF- 7/R by inducing cell apoptosis].	Paclitaxel	30-40	ribonucleotide reductase catalytic subunit M1	Homo sapiens	11-15
31068300-9	2019	Transfection with the specific siRNAs significantly reduced the expression of RRM1 in MCF-7/R cells (P &amp;lt; 0.05), which showed a significantly lower IC50 value of paclitaxel than the cells transfected with the negative control siRNA (P &amp;lt; 0.05).	Paclitaxel	168-178	ribonucleotide reductase catalytic subunit M1	Homo sapiens	78-82
31068300-10	2019	RRM1 silencing significantly inhibited the proliferation (P &amp;lt; 0.01) and enhanced the apoptosis-inducing effect of paclitaxel in MCF-7/R cells (P &amp;lt; 0.001); RRM1 silencing also resulted in obviously reduced Akt phosphorylation, suppressed Bcl-2 expression and promoted the expression of p53 protein in MCF-7/R cells.	Paclitaxel	121-131	ribonucleotide reductase catalytic subunit M1	Homo sapiens	0-4
31068300-10	2019	RRM1 silencing significantly inhibited the proliferation (P &amp;lt; 0.01) and enhanced the apoptosis-inducing effect of paclitaxel in MCF-7/R cells (P &amp;lt; 0.001); RRM1 silencing also resulted in obviously reduced Akt phosphorylation, suppressed Bcl-2 expression and promoted the expression of p53 protein in MCF-7/R cells.	Paclitaxel	121-131	ribonucleotide reductase catalytic subunit M1	Homo sapiens	169-173
31068300-12	2019	CONCLUSIONS: RRM1 gene silencing can reverse paclitaxel resistance in human breast cancer cell line MCF-7/R by promoting cell apoptosis.	Paclitaxel	45-55	ribonucleotide reductase catalytic subunit M1	Homo sapiens	13-17
30624982-0	2019	Altered skeletal muscle microtubule-mitochondrial VDAC2 binding is related to bioenergetic impairments after paclitaxel but not vinblastine chemotherapies.	Paclitaxel	109-119	voltage dependent anion channel 2	Homo sapiens	50-55
30624982-6	2019	Paclitaxel increased both alpha- and betaII-tubulin-VDAC2 interactions, whereas vinblastine had no effect.	Paclitaxel	0-10	voltage dependent anion channel 2	Homo sapiens	52-57
30668434-11	2019	Furthermore, PTX plus curcumin most impressively activated caspase-3, effector of apoptosis pathways, and reduced the expression of the anti-apoptotic protein Bcl-2.	Paclitaxel	13-16	caspase 3	Rattus norvegicus	59-68
30804792-13	2018	Taxol up-regulated the protein levels of P-H2A, PARP, Chk1, p53, and p21 and down-regulated Bcl-Xl and Mcl-1, and RAP reversed the expression of all these proteins.	Paclitaxel	0-5	BCL2-like 1	Mus musculus	92-98
30804792-13	2018	Taxol up-regulated the protein levels of P-H2A, PARP, Chk1, p53, and p21 and down-regulated Bcl-Xl and Mcl-1, and RAP reversed the expression of all these proteins.	Paclitaxel	0-5	myeloid cell leukemia sequence 1	Mus musculus	103-108
30804792-13	2018	Taxol up-regulated the protein levels of P-H2A, PARP, Chk1, p53, and p21 and down-regulated Bcl-Xl and Mcl-1, and RAP reversed the expression of all these proteins.	Paclitaxel	0-5	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	114-117
30804792-14	2018	Conclusion: These results suggested that RAP can protect immune cells from Taxol-induced toxicity, by changing the cell cycle and apoptosis.	Paclitaxel	75-80	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	41-44
30711942-2	2019	This study aimed at examining whether betaIII-tubulin (TUBB3), present in various types of normal tissues and cancer, is a biomarker for the response of colorectal neoplasms to paclitaxel.	Paclitaxel	177-187	tubulin beta 3 class III	Homo sapiens	55-60
30711942-6	2019	Paclitaxel toxicity was evaluated in TUBB3-silenced and control HCT116 cell lines.	Paclitaxel	0-10	tubulin beta 3 class III	Homo sapiens	37-42
30711942-8	2019	TUBB3-expressing CRCs tended to have poor prognosis and silencing of TUBB3 sensitized the cells to paclitaxel.	Paclitaxel	99-109	tubulin beta 3 class III	Homo sapiens	69-74
30467925-0	2019	Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance.	Paclitaxel	84-89	Yes1 associated transcriptional regulator	Homo sapiens	21-45
30467925-5	2019	Knockdown of YAP1 increased epithelial-mesenchymal transition response in a taxol-resistant TNBC cell line.	Paclitaxel	76-81	Yes1 associated transcriptional regulator	Homo sapiens	13-17
30622051-0	2019	MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.	Paclitaxel	79-89	Janus kinase 2	Homo sapiens	43-47
32123828-6	2019	Additionally, proteins namely VASP, coronin-1A, stathmin, and suprabasin were confidently identified in ovarian chemotherapy subjects, possibly in response to combined paclitaxel and carboplatin drug therapy to ovarian cancer.	Paclitaxel	168-178	vasodilator stimulated phosphoprotein	Homo sapiens	30-34
30761140-3	2019	Here we showed that paclitaxel pre-treatment greatly enhanced ATP- or nigericin-induced NLRP3 inflammasome activation as indicated by increased release of cleaved caspase-1 and mature IL-1beta, enhanced formation of ASC speck, and increased gasdermin D cleavage and pyroptosis.	Paclitaxel	20-30	steroid sulfatase	Mus musculus	216-219
30682083-8	2019	The set of 84 predicted drug combinations for example holds the combination of the PARP inhibitor olaparib and paclitaxel, which showed efficacy in phase II clinical studies.	Paclitaxel	111-121	collagen type XI alpha 2 chain	Homo sapiens	83-87
31345098-6	2019	Depletion of kinesin-8s, KIF18A and/or KIF18B obstructed interphase microtubule clearing at mitotic entry in paclitaxel-treated cells, with KIF18B making the larger contribution.	Paclitaxel	109-119	kinesin family member 18A	Sus scrofa	25-31
31345098-6	2019	Depletion of kinesin-8s, KIF18A and/or KIF18B obstructed interphase microtubule clearing at mitotic entry in paclitaxel-treated cells, with KIF18B making the larger contribution.	Paclitaxel	109-119	kinesin family member 18B	Sus scrofa	39-45
31345098-6	2019	Depletion of kinesin-8s, KIF18A and/or KIF18B obstructed interphase microtubule clearing at mitotic entry in paclitaxel-treated cells, with KIF18B making the larger contribution.	Paclitaxel	109-119	kinesin family member 18B	Sus scrofa	140-146
31345098-7	2019	Of the severing proteins, depletion of spastin, but not katanin, reduced microtubule loss as cells entered mitosis in the presence of paclitaxel.	Paclitaxel	134-144	spastin	Sus scrofa	39-46
31345098-8	2019	These results support a model in which KIF18A, KIF18B, and spastin promote interphase microtubule array disassembly at mitotic entry and can overcome paclitaxel-induced microtubule stability specifically at the G2/M transition.	Paclitaxel	150-160	kinesin family member 18A	Sus scrofa	39-45
31345098-8	2019	These results support a model in which KIF18A, KIF18B, and spastin promote interphase microtubule array disassembly at mitotic entry and can overcome paclitaxel-induced microtubule stability specifically at the G2/M transition.	Paclitaxel	150-160	kinesin family member 18B	Sus scrofa	47-53
31345098-8	2019	These results support a model in which KIF18A, KIF18B, and spastin promote interphase microtubule array disassembly at mitotic entry and can overcome paclitaxel-induced microtubule stability specifically at the G2/M transition.	Paclitaxel	150-160	spastin	Sus scrofa	59-66
30431158-4	2019	Here we show that paclitaxel treatment in rats increases the alpha2delta-1 expression level in the dorsal root ganglion and spinal cord and the mRNA levels of GluN1, GluN2A, and GluN2B in the spinal cord.	Paclitaxel	18-28	glutamate ionotropic receptor NMDA type subunit 1	Rattus norvegicus	159-164
30788785-6	2019	We also describe the measurement of the activity of the cytochrome P450 expressed by taking the example of cytochrome P450 2J2, the primary P450 expressed in the human heart and CYP725A4, the primary cytochrome P450 expressed in the first step of taxol synthesis.	Paclitaxel	247-252	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	107-126
30325723-11	2019	Conclusions: The data revealed specific signaling pathways leading to paclitaxel-induced peripheral neuropathic pain, including the activation of PI3K-mTOR, PIC signal, and substance P and CGRP.	Paclitaxel	70-80	calcitonin-related polypeptide alpha	Rattus norvegicus	189-193
31045551-5	2019	Bcl-2 and Caspase-3 in vascular smooth muscle and endothelial cells (VSMC, EC) were significantly down-regulated and up-regulated after the cells were treated with gefitinib and paclitaxel.	Paclitaxel	178-188	caspase 3	Rattus norvegicus	10-19
30359947-4	2019	Here we describe a novel part of a signaling route in which c-Myc enhances paclitaxel sensitivity through upregulation of miR-203b-3p and miR-203a-3p; two clustered antiapoptosis protein Bcl-xL controlling microRNAs.	Paclitaxel	75-85	microRNA 203a	Homo sapiens	138-146
30251669-4	2018	RESULTS: Cytotoxicity and cellular accumulation studies showed that  NO significantly inhibited the ATPase activity of P-gp in isolated membranes and in NCI/ADR-RES tumor cells, causing an increase in drug accumulation and reversals of adriamycin and taxol resistance in the MDR cells.	Paclitaxel	251-256	dynein axonemal heavy chain 8	Homo sapiens	100-106
30218861-10	2018	This preventative effect was associated with suppressed paclitaxel-induced TRPV1 up-regulation and spinal astrocyte activation, as well as decreased production of spinal TNF-alpha and IL-1beta.	Paclitaxel	56-66	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	75-80
30575917-8	2018	Besides, miR-4282 also significantly enhanced the sensitivity of breast cancer cells to paclitaxel.	Paclitaxel	88-98	microRNA 4282	Homo sapiens	9-17
30272330-0	2018	Downregulation of miR-200c-3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2.	Paclitaxel	86-96	microRNA 200c	Homo sapiens	18-26
30272330-2	2018	The aim of the present study was to investigate the role and mechanism of action of miR-200c-3p in the resistance of breast cancer to paclitaxel.	Paclitaxel	134-144	microRNA 200c	Homo sapiens	84-92
30272330-3	2018	It was observed that miR-200c-3p expression, as determined by reverse transcription-quantitative polymerase chain reaction analysis, was significantly downregulated in paclitaxel-resistant MCF-7/Tax cells compared with parental MCF-7 cells.	Paclitaxel	168-178	microRNA 200c	Homo sapiens	21-29
30272330-4	2018	Overexpression of miR-200c-3p increased the chemosensitivity to paclitaxel and enhanced apoptosis in MCF-7/Tax cells, whereas the downregulation of miR-200c-3p exerted the opposite effect.	Paclitaxel	64-74	microRNA 200c	Homo sapiens	18-26
30272330-8	2018	Taken together, the results of the present study indicated that miR-200c-3p plays a key role in the development of paclitaxel resistance in breast cancer, possibly partially through regulating SOX2 expression, suggesting that the miR-200c-3p-SOX2 loop may serve as a potential target for the reversal of paclitaxel resistance in breast cancer.	Paclitaxel	115-125	microRNA 200c	Homo sapiens	64-72
30272330-8	2018	Taken together, the results of the present study indicated that miR-200c-3p plays a key role in the development of paclitaxel resistance in breast cancer, possibly partially through regulating SOX2 expression, suggesting that the miR-200c-3p-SOX2 loop may serve as a potential target for the reversal of paclitaxel resistance in breast cancer.	Paclitaxel	115-125	microRNA 200c	Homo sapiens	230-238
30272330-8	2018	Taken together, the results of the present study indicated that miR-200c-3p plays a key role in the development of paclitaxel resistance in breast cancer, possibly partially through regulating SOX2 expression, suggesting that the miR-200c-3p-SOX2 loop may serve as a potential target for the reversal of paclitaxel resistance in breast cancer.	Paclitaxel	304-314	microRNA 200c	Homo sapiens	64-72
30272330-8	2018	Taken together, the results of the present study indicated that miR-200c-3p plays a key role in the development of paclitaxel resistance in breast cancer, possibly partially through regulating SOX2 expression, suggesting that the miR-200c-3p-SOX2 loop may serve as a potential target for the reversal of paclitaxel resistance in breast cancer.	Paclitaxel	304-314	microRNA 200c	Homo sapiens	230-238
30477228-10	2018	Additionally, silencing both MAP1LC3B and SQSTM1 enhanced the cytotoxic effects of paclitaxel in the tumorspheres of BMSCC cells.	Paclitaxel	83-93	microtubule associated protein 1 light chain 3 beta	Homo sapiens	29-37
30190114-3	2018	METHODS: We assessed the sensitivity of ovarian (OVCAR8) and uterine (ARK1) cancer cell lines to SQ1274 and paclitaxel using XTT assays.	Paclitaxel	108-118	aurora kinase A	Homo sapiens	70-74
30190114-7	2018	RESULTS: First, we demonstrate that SQ1274 has a much lower IC50 than paclitaxel in both ARK1 (1.26 nM vs. 15.34 nM, respectively) and OVCAR8 (1.34 nM vs. 10.29 nM, respectively) cancer cell lines.	Paclitaxel	70-80	aurora kinase A	Homo sapiens	89-93
30104402-9	2018	PRDX6 predicted a poorer OS in patients treated with Taxol and Taxol+Platin chemotherapy.Conclusion: These results suggest that there are distinct prognostic values of PRDX family members in patients with ovarian cancer, and that the expression of PRDX3, PRDX5, and PRDX6 mRNAs are a useful prognostic indicator in the effect of chemotherapy in ovarian cancer patients.	Paclitaxel	53-58	peroxiredoxin 6	Homo sapiens	0-5
30104402-9	2018	PRDX6 predicted a poorer OS in patients treated with Taxol and Taxol+Platin chemotherapy.Conclusion: These results suggest that there are distinct prognostic values of PRDX family members in patients with ovarian cancer, and that the expression of PRDX3, PRDX5, and PRDX6 mRNAs are a useful prognostic indicator in the effect of chemotherapy in ovarian cancer patients.	Paclitaxel	53-58	peroxiredoxin 6	Homo sapiens	266-271
30104402-9	2018	PRDX6 predicted a poorer OS in patients treated with Taxol and Taxol+Platin chemotherapy.Conclusion: These results suggest that there are distinct prognostic values of PRDX family members in patients with ovarian cancer, and that the expression of PRDX3, PRDX5, and PRDX6 mRNAs are a useful prognostic indicator in the effect of chemotherapy in ovarian cancer patients.	Paclitaxel	63-68	peroxiredoxin 6	Homo sapiens	0-5
30104402-9	2018	PRDX6 predicted a poorer OS in patients treated with Taxol and Taxol+Platin chemotherapy.Conclusion: These results suggest that there are distinct prognostic values of PRDX family members in patients with ovarian cancer, and that the expression of PRDX3, PRDX5, and PRDX6 mRNAs are a useful prognostic indicator in the effect of chemotherapy in ovarian cancer patients.	Paclitaxel	63-68	peroxiredoxin 6	Homo sapiens	266-271
30016392-2	2018	We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients receiving weekly paclitaxel could improve outcomes in such patients.	Paclitaxel	112-122	CREB regulated transcription coactivator 1	Homo sapiens	65-72
30210616-11	2018	In addition, compared with VP alone, VP and TAX combination therapy had a greater inhibitory effect on YAP expression.	Paclitaxel	44-47	Yes1 associated transcriptional regulator	Homo sapiens	103-106
29959202-8	2018	In addition, single treatment with pertuzumab, lumretuzumab, or afatinib decreased tumor volume and weight, whereas combination treatment with these drugs and taxol enhanced generation of cleaved caspase 3, PARP, and TUNEL-positive cells compared with each single treatment.	Paclitaxel	159-164	collagen type XI alpha 2 chain	Homo sapiens	207-211
30093840-9	2018	This novel approach targeting of HER3 was able to enhance the therapeutic efficacy of trastuzumab and paclitaxel against HER2-overexpressing breast cancer.	Paclitaxel	102-112	erb-b2 receptor tyrosine kinase 3	Homo sapiens	33-37
29978708-4	2018	The resulting LbL miR708/PTX-MTNst showed dose-dependent cytotoxicity in HCT-116 and DLD-1 colorectal carcinoma cell lines, which was remarkably superior to that of free PTX or LbL PTX-MTNst.	Paclitaxel	25-28	microRNA 708	Homo sapiens	18-24
29978708-4	2018	The resulting LbL miR708/PTX-MTNst showed dose-dependent cytotoxicity in HCT-116 and DLD-1 colorectal carcinoma cell lines, which was remarkably superior to that of free PTX or LbL PTX-MTNst.	Paclitaxel	170-173	microRNA 708	Homo sapiens	18-24
30094097-6	2018	We found that trametinib, an MEK inhibitor, suppressed oxaliplatin-, paclitaxel-, vincristine-, and bortezomib-induced cold and mechanical allodynia in mice.	Paclitaxel	69-79	midkine	Mus musculus	29-32
29540562-0	2018	Monoacylglycerol Lipase Inhibitors Reverse Paclitaxel-Induced Nociceptive Behavior and Proinflammatory Markers in a Mouse Model of Chemotherapy-Induced Neuropathy.	Paclitaxel	43-53	monoglyceride lipase	Mus musculus	0-23
29540562-3	2018	As inhibitors of monoacylglycerol lipase (MAGL), the primary hydrolytic enzyme of the endogenous cannabinoid, 2-arachidonyolglycerol, produces antinociceptive effects in numerous rodent models of pain, we investigated whether inhibitors of this enzyme (i.e., JZL184 and MJN110) would reverse paclitaxel-induced mechanical allodynia in mice.	Paclitaxel	292-302	monoglyceride lipase	Mus musculus	17-40
29540562-3	2018	As inhibitors of monoacylglycerol lipase (MAGL), the primary hydrolytic enzyme of the endogenous cannabinoid, 2-arachidonyolglycerol, produces antinociceptive effects in numerous rodent models of pain, we investigated whether inhibitors of this enzyme (i.e., JZL184 and MJN110) would reverse paclitaxel-induced mechanical allodynia in mice.	Paclitaxel	292-302	monoglyceride lipase	Mus musculus	42-46
29540562-5	2018	Complementary genetic and pharmacologic approaches revealed that the antiallodynic effects of each drug require both cannabinoid receptors, CB1 and CB2 MJN110 reduced paclitaxel-mediated increased expression of monocyte chemoattractant protein-1 (MCP-1, CCL2) and phospho-p38 MAPK in dorsal root ganglia as well as MCP-1 in spinal dorsal horn.	Paclitaxel	167-177	cannabinoid receptor 1 (brain)	Mus musculus	140-143
29540562-10	2018	Taken together, these data indicate that MAGL inhibitors reverse paclitaxel-induced neuropathic pain without interfering with chemotherapeutic efficacy.	Paclitaxel	65-75	monoglyceride lipase	Mus musculus	41-45
29715459-0	2018	Mesenchymal stem cells drive paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells via paracrine of neuregulin 1.	Paclitaxel	29-39	erb-b2 receptor tyrosine kinase 3	Homo sapiens	60-65
29715459-0	2018	Mesenchymal stem cells drive paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells via paracrine of neuregulin 1.	Paclitaxel	29-39	neuregulin 1	Homo sapiens	116-128
29715459-1	2018	We had previously demonstrated that increased expression of ErbB3 is required for ErbB2-mediated paclitaxel resistance in breast cancer cells.	Paclitaxel	97-107	erb-b2 receptor tyrosine kinase 3	Homo sapiens	60-65
29715459-2	2018	In the present study, we have explored the possible role of mesenchymal stem cells (MSCs) in regulating the paclitaxel-sensitivity of ErbB2/ErbB3-coexpressing breast cancer cells.	Paclitaxel	108-118	erb-b2 receptor tyrosine kinase 3	Homo sapiens	140-145
29715459-4	2018	Coculture or treatment with conditioned medium of MSCs not only decreases the anti-proliferation effect of paclitaxel on ErbB2/ErbB3-coexpressing breast cancer cells, but also significantly inhibits paclitaxel-induced apoptosis.	Paclitaxel	107-117	erb-b2 receptor tyrosine kinase 3	Homo sapiens	127-132
29715459-5	2018	We further demonstrate that this MSCs-drived paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells could be attributed to upregulation of Survivin via paracrine effect of NRG-1/ErbB3/PI-3K/Akt signaling, as either specific knockdown expression of ErbB3, or blocking of downstream PI-3K/Akt signaling, or specific inhibition of Survivin can completely reverse this effect.	Paclitaxel	45-55	erb-b2 receptor tyrosine kinase 3	Homo sapiens	76-81
29715459-5	2018	We further demonstrate that this MSCs-drived paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells could be attributed to upregulation of Survivin via paracrine effect of NRG-1/ErbB3/PI-3K/Akt signaling, as either specific knockdown expression of ErbB3, or blocking of downstream PI-3K/Akt signaling, or specific inhibition of Survivin can completely reverse this effect.	Paclitaxel	45-55	neuregulin 1	Homo sapiens	187-192
29715459-5	2018	We further demonstrate that this MSCs-drived paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells could be attributed to upregulation of Survivin via paracrine effect of NRG-1/ErbB3/PI-3K/Akt signaling, as either specific knockdown expression of ErbB3, or blocking of downstream PI-3K/Akt signaling, or specific inhibition of Survivin can completely reverse this effect.	Paclitaxel	45-55	erb-b2 receptor tyrosine kinase 3	Homo sapiens	193-198
29715459-5	2018	We further demonstrate that this MSCs-drived paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells could be attributed to upregulation of Survivin via paracrine effect of NRG-1/ErbB3/PI-3K/Akt signaling, as either specific knockdown expression of ErbB3, or blocking of downstream PI-3K/Akt signaling, or specific inhibition of Survivin can completely reverse this effect.	Paclitaxel	45-55	erb-b2 receptor tyrosine kinase 3	Homo sapiens	193-198
29715459-6	2018	Moreover, targeted knockdown of NRG-1 expression in MSCs abrogates theirs effect on paclitaxel sensitivity of ErbB2/ErbB3-coexpressing breast cancer cells.	Paclitaxel	84-94	neuregulin 1	Homo sapiens	32-37
29715459-6	2018	Moreover, targeted knockdown of NRG-1 expression in MSCs abrogates theirs effect on paclitaxel sensitivity of ErbB2/ErbB3-coexpressing breast cancer cells.	Paclitaxel	84-94	erb-b2 receptor tyrosine kinase 3	Homo sapiens	116-121
29715459-7	2018	Taken together, our study indicate that paracrine of NRG-1 by MSCs induces paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells through PI-3K/Akt signaling-dependent upregulation of Survivin.	Paclitaxel	75-85	neuregulin 1	Homo sapiens	53-58
29715459-7	2018	Taken together, our study indicate that paracrine of NRG-1 by MSCs induces paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells through PI-3K/Akt signaling-dependent upregulation of Survivin.	Paclitaxel	75-85	erb-b2 receptor tyrosine kinase 3	Homo sapiens	106-111
29715459-8	2018	Our findings suggest that simultaneously targeting mesenchymal stem cells in tumor microenvironment may be a novel strategy to overcome paclitaxel resistance in patients with ErbB2/ErbB3-coexpressing breast cancer.	Paclitaxel	136-146	erb-b2 receptor tyrosine kinase 3	Homo sapiens	181-186
29549161-7	2018	Istiratumab (MM-141), a novel bispecific antibody that blocks IGF-1R and ErbB3, restored the activity of paclitaxel and gemcitabine in the presence of IGF-1 and HRG in vitro Dual IGF-1R/ErbB3 blocking enhanced chemosensitivity through inhibition of AKT phosphorylation and promotion of IGF-1R and ErbB3 degradation.	Paclitaxel	105-115	erb-b2 receptor tyrosine kinase 3	Homo sapiens	73-78
29549161-7	2018	Istiratumab (MM-141), a novel bispecific antibody that blocks IGF-1R and ErbB3, restored the activity of paclitaxel and gemcitabine in the presence of IGF-1 and HRG in vitro Dual IGF-1R/ErbB3 blocking enhanced chemosensitivity through inhibition of AKT phosphorylation and promotion of IGF-1R and ErbB3 degradation.	Paclitaxel	105-115	erb-b2 receptor tyrosine kinase 3	Homo sapiens	186-191
29549161-7	2018	Istiratumab (MM-141), a novel bispecific antibody that blocks IGF-1R and ErbB3, restored the activity of paclitaxel and gemcitabine in the presence of IGF-1 and HRG in vitro Dual IGF-1R/ErbB3 blocking enhanced chemosensitivity through inhibition of AKT phosphorylation and promotion of IGF-1R and ErbB3 degradation.	Paclitaxel	105-115	erb-b2 receptor tyrosine kinase 3	Homo sapiens	186-191
29531019-7	2018	On the contrary, the antitumor drug Paclitaxel is also known to activate the TLR4 MyD88-dependent signaling pathway and mimics LPS action.	Paclitaxel	36-46	MYD88 innate immune signal transduction adaptor	Homo sapiens	82-87
29496457-1	2018	In this study, we prepared paclitaxel (PTX) loaded bovine serum albumin (BSA) microparticles (MPs) of different sizes (0.5, 1.0, and 3.0 microm) and converted them into dry powders (DPs) of a uniform size (~5.0 microm) through spray-drying techniques.	Paclitaxel	27-37	albumin	Mus musculus	58-71
29496457-1	2018	In this study, we prepared paclitaxel (PTX) loaded bovine serum albumin (BSA) microparticles (MPs) of different sizes (0.5, 1.0, and 3.0 microm) and converted them into dry powders (DPs) of a uniform size (~5.0 microm) through spray-drying techniques.	Paclitaxel	39-42	albumin	Mus musculus	58-71
29605290-0	2018	Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors.	Paclitaxel	43-53	programmed cell death 1	Homo sapiens	74-77
29410067-8	2018	Two subpopulations based on the KRT19 expression levels in KYSE-30 cells exhibited different paclitaxel sensitivity, suggesting the existence of an intrinsic paclitaxel resistance in KYSE-30 cells.	Paclitaxel	93-103	keratin 19	Homo sapiens	32-37
29410067-8	2018	Two subpopulations based on the KRT19 expression levels in KYSE-30 cells exhibited different paclitaxel sensitivity, suggesting the existence of an intrinsic paclitaxel resistance in KYSE-30 cells.	Paclitaxel	158-168	keratin 19	Homo sapiens	32-37
29666962-12	2018	CONCLUSIONS: These data demonstrate potential use of indatuximab ravtansine in combination with docetaxel or paclitaxel for CD138-positive TNBC.	Paclitaxel	109-119	syndecan 1	Homo sapiens	124-129
29656300-0	2018	The Sineoculis Homeobox Homolog 1 (SIX1) Gene Regulates Paclitaxel Resistance by Affecting Reactive Oxygen Species and Autophagy in Human Hepatocellular Carcinoma Cell Line HepG2.	Paclitaxel	56-66	SIX homeobox 1	Homo sapiens	4-33
29656300-0	2018	The Sineoculis Homeobox Homolog 1 (SIX1) Gene Regulates Paclitaxel Resistance by Affecting Reactive Oxygen Species and Autophagy in Human Hepatocellular Carcinoma Cell Line HepG2.	Paclitaxel	56-66	SIX homeobox 1	Homo sapiens	35-39
29656300-1	2018	BACKGROUND The objective of this study was to explore the role of SIX1 in paclitaxel (TAX) resistance of HepG2 cells via reactive oxygen species (ROS) and autophagy pathway.	Paclitaxel	74-84	SIX homeobox 1	Homo sapiens	66-70
29643394-0	2018	Author Correction: Kanglaite sensitizes colorectal cancer cells to Taxol via NF-kappaBeta inhibition and connexin 43 upregulation.	Paclitaxel	67-72	gap junction protein alpha 1	Homo sapiens	105-116
29454704-6	2018	The selective inhibition of CYP2C8-catalyzed paclitaxel hydroxylation by fisetin and geraldol were confirmed in pooled human liver microsomes (HLMs).	Paclitaxel	45-55	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	28-34
29439899-2	2018	Because of the implications, we examined a series of key vinblastine analogs that emerged from our studies in functional cell growth inhibition assays for their sensitivity to high expression of class III beta-tubulin (human non-small cell lung cancer cell line A549 vs taxol-resistant A549-T24).	Paclitaxel	270-275	tubulin beta 3 class III	Homo sapiens	195-217
29494610-3	2018	Using the Cox regression model, a risk model (Taxol score) was developed to assess the outcome of ovarian cancer patients who underwent chemotherapy with Taxol.	Paclitaxel	46-51	cytochrome c oxidase subunit 8A	Homo sapiens	10-13
29422491-4	2018	KB9520-activated ERbeta had an additive effect on growth inhibition in combination with cisplatin and paclitaxel, respectively.	Paclitaxel	102-112	estrogen receptor 2	Homo sapiens	17-23
29434713-0	2018	Paclitaxel inhibits breast cancer metastasis via suppression of Aurora kinase-mediated cofilin-1 activity.	Paclitaxel	0-10	cofilin 1	Homo sapiens	87-96
29434713-6	2018	Results additionally demonstrated that Paclitaxel treatment suppressed Aurora kinase and cofilin-1 activity in breast cancer cells.	Paclitaxel	39-49	cofilin 1	Homo sapiens	89-98
29434713-7	2018	The potential mechanism indicated that activation of Aurora kinase activity stimulated cofilin-1 activity, which canceled Paclitaxel-inhibited growth and aggressiveness of breast cancer cells.	Paclitaxel	122-132	cofilin 1	Homo sapiens	87-96
29434713-10	2018	Notably, Aurora kinase and cofilin-1 activity were downregulated by Paclitaxel in tumor tissues.	Paclitaxel	68-78	cofilin 1	Homo sapiens	27-36
29434713-11	2018	In conclusion, these results indicated that Paclitaxel inhibited breast cancer cell growth and metastasis via suppression of Aurora kinase-mediated cofilin-1 activity, suggesting Paclitaxel may be an efficient anticancer agent for the treatment of this disease.	Paclitaxel	44-54	cofilin 1	Homo sapiens	148-157
29434713-11	2018	In conclusion, these results indicated that Paclitaxel inhibited breast cancer cell growth and metastasis via suppression of Aurora kinase-mediated cofilin-1 activity, suggesting Paclitaxel may be an efficient anticancer agent for the treatment of this disease.	Paclitaxel	179-189	cofilin 1	Homo sapiens	148-157
29084921-6	2018	In addition, the REDD1-mediated proliferation, apoptosis, and autophagy are found to be negatively regulated by miR-22 in vitro, which intensify the paclitaxel sensitivity via inhibition of the well-acknowledged REDD1-EEF2K-autophagy axis.	Paclitaxel	149-159	eukaryotic elongation factor 2 kinase	Homo sapiens	218-223
29154935-0	2018	Ghrelin alleviates paclitaxel-induced peripheral neuropathy by reducing oxidative stress and enhancing mitochondrial anti-oxidant functions in mice.	Paclitaxel	19-29	ghrelin	Mus musculus	0-7
29154935-4	2018	We investigated the pharmacological potential of ghrelin in preventing paclitaxel-induced peripheral neuropathy using wild-type mice, ghrelin-null mice, and growth hormone secretagogue receptor-null mice.	Paclitaxel	71-81	ghrelin	Mus musculus	49-56
29154935-8	2018	Our results suggest that ghrelin administration exerts a protective effect against paclitaxel-induced neuropathy by reducing oxidative stress and enhancing mitochondrial anti-oxidant functions, and that endogenous ghrelin has a neuroprotective effect that is mediated by ghrelin/growth hormone secretagogue receptor signaling.	Paclitaxel	83-93	ghrelin	Mus musculus	25-32
29233683-9	2018	This XRCC4-dependent, SRPK1/SRSF1-mediated regulatory mechanism was conserved in apoptosis in Jurkat human leukemia cells triggered by STS, and by two widely used anti-cancer agents, Paclitaxel and Vincristine.	Paclitaxel	183-193	X-ray repair cross complementing 4	Homo sapiens	5-10
29233683-9	2018	This XRCC4-dependent, SRPK1/SRSF1-mediated regulatory mechanism was conserved in apoptosis in Jurkat human leukemia cells triggered by STS, and by two widely used anti-cancer agents, Paclitaxel and Vincristine.	Paclitaxel	183-193	SRSF protein kinase 1	Homo sapiens	22-27
30355931-0	2018	Effect of Paclitaxel+Hirudin on the TLR4-MyD88 Signaling Pathway During Inflammatory Activation of Human Coronary Artery Smooth Muscle Cells and Mechanistic Analysis.	Paclitaxel	10-20	MYD88 innate immune signal transduction adaptor	Homo sapiens	41-46
30355931-3	2018	This study aimed to explore the anti-inflammatory and anti-restenosis mechanisms of paclitaxel+hirudin with regard to the TLR4/MyD88/NF-kappaB pathway.	Paclitaxel	84-94	MYD88 innate immune signal transduction adaptor	Homo sapiens	127-132
30101722-8	2018	After treatment with paclitaxel, cyclin D1 and CDK4 protein levels were similar to control values; meanwhile, cylinE1 and CDK2 protein amounts were reduced, with increased cyclin B1 levels, compared with control values (p&lt;0.05).	Paclitaxel	21-31	cyclin D1	Homo sapiens	33-42
30101722-8	2018	After treatment with paclitaxel, cyclin D1 and CDK4 protein levels were similar to control values; meanwhile, cylinE1 and CDK2 protein amounts were reduced, with increased cyclin B1 levels, compared with control values (p&lt;0.05).	Paclitaxel	21-31	cyclin dependent kinase 4	Homo sapiens	47-51
30101722-8	2018	After treatment with paclitaxel, cyclin D1 and CDK4 protein levels were similar to control values; meanwhile, cylinE1 and CDK2 protein amounts were reduced, with increased cyclin B1 levels, compared with control values (p&lt;0.05).	Paclitaxel	21-31	cyclin dependent kinase 2	Homo sapiens	122-126
29155365-6	2018	Knockdown of ALDH2 attenuated the CSC characteristics of resistant cancer cells and enhanced their sensitivity to Taxol or VCR.	Paclitaxel	114-119	aldehyde dehydrogenase 2 family member	Homo sapiens	13-18
29074619-0	2017	Presynaptic mGluR5 receptor controls glutamatergic input through protein kinase C-NMDA receptors in paclitaxel-induced neuropathic pain.	Paclitaxel	100-110	glutamate receptor, ionotropic, kainate 1	Mus musculus	12-18
29074619-8	2017	Furthermore, mGluR5 protein levels in the dorsal root ganglion and spinal cord synaptosomes were significantly higher in paclitaxel- than in vehicle-treated rats.	Paclitaxel	121-131	glutamate receptor, ionotropic, kainate 1	Mus musculus	13-19
29074619-11	2017	Our findings suggest that paclitaxel-induced painful neuropathy is associated with increased presynaptic mGluR5 activity at the spinal cord level, which serves as upstream signaling for PKC-mediated tonic activation of NMDARs.	Paclitaxel	26-36	glutamate receptor, ionotropic, kainate 1	Mus musculus	105-111
29299167-0	2017	MicroRNA-128 suppresses paclitaxel-resistant lung cancer by inhibiting MUC1-C and BMI-1 in cancer stem cells.	Paclitaxel	24-34	mucin 1, cell surface associated	Homo sapiens	71-75
29299167-0	2017	MicroRNA-128 suppresses paclitaxel-resistant lung cancer by inhibiting MUC1-C and BMI-1 in cancer stem cells.	Paclitaxel	24-34	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	82-87
29123088-0	2017	A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer.	Paclitaxel	34-44	nucleolin	Homo sapiens	16-25
29123088-3	2017	Here we design and synthesize a highly water-soluble nucleolin aptamer-paclitaxel conjugate (NucA-PTX) that selectively delivers PTX to the tumor site.	Paclitaxel	71-81	nucleolin	Homo sapiens	53-62
29123088-3	2017	Here we design and synthesize a highly water-soluble nucleolin aptamer-paclitaxel conjugate (NucA-PTX) that selectively delivers PTX to the tumor site.	Paclitaxel	98-101	nucleolin	Homo sapiens	53-62
28942682-3	2017	Here, we reported an EphB4 receptor-targeting polymeric nanoplatform containing hollow gold nanospheres (HAuNS) and the anticancer drug paclitaxel (PTX) for cancer photothermal-chemotherapy.	Paclitaxel	136-146	EPH receptor B4	Homo sapiens	21-26
28942682-3	2017	Here, we reported an EphB4 receptor-targeting polymeric nanoplatform containing hollow gold nanospheres (HAuNS) and the anticancer drug paclitaxel (PTX) for cancer photothermal-chemotherapy.	Paclitaxel	148-151	EPH receptor B4	Homo sapiens	21-26
28049022-0	2017	Albumin-coated nanocrystals for carrier-free delivery of paclitaxel.	Paclitaxel	57-67	albumin	Mus musculus	0-7
28049022-5	2017	To overcome these challenges, we developed an albumin-coated nanocrystal (NC) formulation of paclitaxel (PTX) with 90% drug loading and high serum stability.	Paclitaxel	93-103	albumin	Mus musculus	46-53
28049022-5	2017	To overcome these challenges, we developed an albumin-coated nanocrystal (NC) formulation of paclitaxel (PTX) with 90% drug loading and high serum stability.	Paclitaxel	105-108	albumin	Mus musculus	46-53
28049022-8	2017	Cim-F-alb remained more stable in undiluted serum than Abraxane, a commercial albumin-based PTX nanoparticle formulation, while maintaining comparable cytotoxicity to those of Abraxane and solvent-dissolved PTX.	Paclitaxel	92-95	albumin	Mus musculus	78-85
28981108-0	2017	Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer.	Paclitaxel	40-50	microRNA 451a	Homo sapiens	15-22
28981108-4	2017	We show that miR-451 is decreased in human breast cancer specimens and in paclitaxel-resistant (PR) cells.	Paclitaxel	74-84	microRNA 451a	Homo sapiens	13-20
28981108-9	2017	Taken together, our findings suggested that miR-451 might be considered as important and potential target in paclitaxel-resistant breast cancer treatment.	Paclitaxel	109-119	microRNA 451a	Homo sapiens	44-51
29212208-6	2017	Mechanistically, we demonstrated that Taxol induced expression of stress and stemness markers including GRP78 and CD133 was significantly reduced by addition of Ruxolitinib.	Paclitaxel	38-43	prominin 1	Homo sapiens	114-119
28849180-6	2017	Silencing of Aurora A reduced the activity of SRC and downregulated the ERK and Akt/mTOR pathways, which led to re-sensitization of the resistant MCF-7/T cells to Taxol in vitro.	Paclitaxel	163-168	aurora kinase A	Homo sapiens	13-21
28849180-7	2017	These results suggested that the activation of Aurora A and the subsequent upregulation of ERK and Akt through SRC induced Taxol-resistance in breast cancer cells, and inhibiting Aurora A and the related SRC/EKT/Akt pathway could restore the sensitivity of breast cancer cells to Taxol.	Paclitaxel	123-128	aurora kinase A	Homo sapiens	47-55
28849180-7	2017	These results suggested that the activation of Aurora A and the subsequent upregulation of ERK and Akt through SRC induced Taxol-resistance in breast cancer cells, and inhibiting Aurora A and the related SRC/EKT/Akt pathway could restore the sensitivity of breast cancer cells to Taxol.	Paclitaxel	280-285	aurora kinase A	Homo sapiens	47-55
28849180-7	2017	These results suggested that the activation of Aurora A and the subsequent upregulation of ERK and Akt through SRC induced Taxol-resistance in breast cancer cells, and inhibiting Aurora A and the related SRC/EKT/Akt pathway could restore the sensitivity of breast cancer cells to Taxol.	Paclitaxel	280-285	aurora kinase A	Homo sapiens	179-187
28980921-6	2017	The microtubule depolymerizer colchicine promoted cell surface recovery of CD71 but inhibited that of GPA; the microtubule stabilizer paclitaxel inhibited cell surface recovery of CD71 but promoted that of GPA; the microfilament depolymerizer cytochalasin D had no effect on cell surface recovery of CD71 and GPA; the microfilament stabilizer phalloidin inhibited cell surface recovery of GPA.	Paclitaxel	134-144	transferrin receptor	Homo sapiens	180-184
28980921-6	2017	The microtubule depolymerizer colchicine promoted cell surface recovery of CD71 but inhibited that of GPA; the microtubule stabilizer paclitaxel inhibited cell surface recovery of CD71 but promoted that of GPA; the microfilament depolymerizer cytochalasin D had no effect on cell surface recovery of CD71 and GPA; the microfilament stabilizer phalloidin inhibited cell surface recovery of GPA.	Paclitaxel	134-144	transferrin receptor	Homo sapiens	180-184
28731125-0	2017	N-peptide of vMIP-II reverses paclitaxel-resistance by regulating miRNA-335 in breast cancer.	Paclitaxel	30-40	microRNA 335	Homo sapiens	66-75
28731125-3	2017	In our previous studies, we have shown that microRNA-335 (miR-335) decreased obviously between paclitaxel-resistant (PR) and parental breast cancer cells through miRNA microarray.	Paclitaxel	95-105	microRNA 335	Homo sapiens	44-56
28731125-3	2017	In our previous studies, we have shown that microRNA-335 (miR-335) decreased obviously between paclitaxel-resistant (PR) and parental breast cancer cells through miRNA microarray.	Paclitaxel	95-105	microRNA 335	Homo sapiens	58-65
28731125-11	2017	Additionally, ectopic expression of miR-335 or depletion of its target gene SETD8 could enhance the sensitivity of PR cells to paclitaxel.	Paclitaxel	127-137	microRNA 335	Homo sapiens	36-43
28731125-11	2017	Additionally, ectopic expression of miR-335 or depletion of its target gene SETD8 could enhance the sensitivity of PR cells to paclitaxel.	Paclitaxel	127-137	lysine methyltransferase 5A	Homo sapiens	76-81
31334335-0	2019	FoxM1 Induced Paclitaxel Resistance via Activation of the FoxM1/PHB1/RAF-MEK-ERK Pathway and Enhancement of the ABCA2 Transporter.	Paclitaxel	14-24	prohibitin 1	Homo sapiens	64-68
31334335-0	2019	FoxM1 Induced Paclitaxel Resistance via Activation of the FoxM1/PHB1/RAF-MEK-ERK Pathway and Enhancement of the ABCA2 Transporter.	Paclitaxel	14-24	zinc fingers and homeoboxes 2	Homo sapiens	69-72
31334335-2	2019	Here, a novel role between FoxM1 (FoxM1b and FoxM1c) and Prohibitin1 (PHB1) in paclitaxel resistance has been identified.	Paclitaxel	79-89	prohibitin 1	Homo sapiens	57-68
31334335-2	2019	Here, a novel role between FoxM1 (FoxM1b and FoxM1c) and Prohibitin1 (PHB1) in paclitaxel resistance has been identified.	Paclitaxel	79-89	prohibitin 1	Homo sapiens	70-74
31334335-5	2019	FoxM1 contributed to the PHB1/C-RAF interaction and phosphorylation of ERK1/2 kinases, thus promoting paclitaxel resistance.	Paclitaxel	102-112	prohibitin 1	Homo sapiens	25-29
31334335-5	2019	FoxM1 contributed to the PHB1/C-RAF interaction and phosphorylation of ERK1/2 kinases, thus promoting paclitaxel resistance.	Paclitaxel	102-112	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	30-35
31334335-7	2019	Besides, we identified that ABCA2 promoted paclitaxel resistance under the regulation of FoxM1/PHB1/RAF-MEK-ERK.	Paclitaxel	43-53	prohibitin 1	Homo sapiens	95-99
31334335-7	2019	Besides, we identified that ABCA2 promoted paclitaxel resistance under the regulation of FoxM1/PHB1/RAF-MEK-ERK.	Paclitaxel	43-53	zinc fingers and homeoboxes 2	Homo sapiens	100-103
31334335-12	2019	Targeting FoxM1 and its downstream effector PHB1 increased the sensitivity of pancreatic cells to paclitaxel treatment, providing potential therapeutic strategies for patients with paclitaxel resistance.	Paclitaxel	98-108	prohibitin 1	Homo sapiens	44-48
31334335-12	2019	Targeting FoxM1 and its downstream effector PHB1 increased the sensitivity of pancreatic cells to paclitaxel treatment, providing potential therapeutic strategies for patients with paclitaxel resistance.	Paclitaxel	181-191	prohibitin 1	Homo sapiens	44-48
30673970-10	2019	Response to paclitaxel was restricted to tumors with low PC3 and PC4 (log-rank p = 0.0021).	Paclitaxel	12-22	proprotein convertase subtilisin/kexin type 4	Homo sapiens	65-68
30779921-0	2019	miR-29c regulates resistance to paclitaxel in nasopharyngeal cancer by targeting ITGB1.	Paclitaxel	32-42	microRNA 29c	Homo sapiens	0-7
30779921-4	2019	We assessed the effects of miR-29c, an miRNA identified in a genome-wide study of Taxol resistance, on genes associated with resistance in NPC cells.	Paclitaxel	82-87	microRNA 29c	Homo sapiens	27-34
30779921-5	2019	We established Taxol resistance in two human NPC cell lines, SUNE-1 and C666-1 (SUNE-1-Taxol and C666-1-Taxol) and found that miR-29c was downregulated and integrin beta-1 (ITGB1) was upregulated in Taxol-resistant NPC cells compared with parental NPC cells.	Paclitaxel	15-20	microRNA 29c	Homo sapiens	126-133
30779921-5	2019	We established Taxol resistance in two human NPC cell lines, SUNE-1 and C666-1 (SUNE-1-Taxol and C666-1-Taxol) and found that miR-29c was downregulated and integrin beta-1 (ITGB1) was upregulated in Taxol-resistant NPC cells compared with parental NPC cells.	Paclitaxel	87-92	microRNA 29c	Homo sapiens	126-133
30779921-6	2019	Further investigations using a TUNEL assay and BAX/BCL-2 ratio, found that overexpression of miR-29c and knockdown of ITGB1 can resensitize drug-resistant NPC cells to Taxol and promote apoptosis.	Paclitaxel	168-173	microRNA 29c	Homo sapiens	93-100
30779921-9	2019	Overall, these data demonstrate that miR-29c regulates resistance to Taxol in NPC by targeting ITGB1.	Paclitaxel	69-74	microRNA 29c	Homo sapiens	37-44
30779921-10	2019	Our research indicates that miR-29c may have potential use in Taxol-resistant NPC therapy.	Paclitaxel	62-67	microRNA 29c	Homo sapiens	28-35
30387134-9	2019	In conclusion, our studies demonstrate that poly I:C reinforces the potency of cytotoxic chemotherapeutics in PTX-resistant cell line through the TLR3-UNC93B1-IFN-beta signaling pathway, which supplies a novel mechanism of poly I:C for the chemotherapy sensitizing effect in a PTX-resistant tumor.	Paclitaxel	277-280	toll like receptor 3	Homo sapiens	146-150
30387134-9	2019	In conclusion, our studies demonstrate that poly I:C reinforces the potency of cytotoxic chemotherapeutics in PTX-resistant cell line through the TLR3-UNC93B1-IFN-beta signaling pathway, which supplies a novel mechanism of poly I:C for the chemotherapy sensitizing effect in a PTX-resistant tumor.	Paclitaxel	277-280	interferon beta 1	Homo sapiens	159-167
31106153-7	2019	In vitro validation of the former result showed an increase in the secreted and cellular NRP-1 levels in resistant MDA-MB-231 cells to the most common NAC regimen Adriyamicin/cyclophosphamide+Paclitaxel (AC+PAC).	Paclitaxel	192-202	neuropilin 1	Homo sapiens	89-94
31044156-4	2019	Since paclitaxel is known to target BCL2 and TUBB1, we used pan-cancer genomic data from hundreds of patients to show that a single-nucleotide variant in the BCL2 sequence can predict a patient"s response to paclitaxel.	Paclitaxel	6-16	tubulin beta 1 class VI	Homo sapiens	45-50
31044156-4	2019	Since paclitaxel is known to target BCL2 and TUBB1, we used pan-cancer genomic data from hundreds of patients to show that a single-nucleotide variant in the BCL2 sequence can predict a patient"s response to paclitaxel.	Paclitaxel	208-218	tubulin beta 1 class VI	Homo sapiens	45-50
30982496-0	2019	miR-205-5p contributes to paclitaxel resistance and progression of endometrial cancer by downregulating FOXO1.	Paclitaxel	26-36	microRNA 205	Homo sapiens	0-7
30394198-7	2019	Furthermore, MIR-G-1 promoted serum starvation-induced nuclear macroautophagy/autophagy, and accelerated taxol (TAX)-induced DNA-damage repair in cervical cancer cells.	Paclitaxel	105-110	MLX interacting protein	Homo sapiens	13-16
30739035-7	2019	Challenge with the CB1 antagonist rimonabant precipitated CB1-dependent withdrawal in paclitaxel-treated mice receiving WIN55,212-2 but not URB597 or URB937.	Paclitaxel	86-96	cannabinoid receptor 1 (brain)	Mus musculus	19-22
30739035-7	2019	Challenge with the CB1 antagonist rimonabant precipitated CB1-dependent withdrawal in paclitaxel-treated mice receiving WIN55,212-2 but not URB597 or URB937.	Paclitaxel	86-96	cannabinoid receptor 1 (brain)	Mus musculus	58-61
31011626-4	2019	Microarray analysis identified long non-coding RNA urothelial carcinoma-associated 1 (UCA1) upregulation, which contributed to both enhanced paclitaxel resistance and OVV spread.	Paclitaxel	141-151	urothelial cancer associated 1	Homo sapiens	51-84
31011626-4	2019	Microarray analysis identified long non-coding RNA urothelial carcinoma-associated 1 (UCA1) upregulation, which contributed to both enhanced paclitaxel resistance and OVV spread.	Paclitaxel	141-151	urothelial cancer associated 1	Homo sapiens	86-90
30988621-2	2019	IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.	Paclitaxel	85-95	interleukin 1 receptor associated kinase 1	Homo sapiens	0-5
30350259-0	2019	Aldehyde dehydrogenase 2 genotype in tolerability of alcohol contained in paclitaxel in Japanese breast cancer patients.	Paclitaxel	74-84	aldehyde dehydrogenase 2 family member	Homo sapiens	0-24
30350259-5	2019	In this study, we examined the safety of PTX for patients with the ALDH2 GA genotype.	Paclitaxel	41-44	aldehyde dehydrogenase 2 family member	Homo sapiens	67-72
30350259-9	2019	CONCLUSIONS: Our study suggests that PTX up to 100 mg/m2 can be used safely for patients with the ALDH2 GA genotype.	Paclitaxel	37-40	aldehyde dehydrogenase 2 family member	Homo sapiens	98-103
30350259-10	2019	To confirm the necessity of a genotyping test for ALDH2, further studies evaluating alcohol sensitivity in response to PTX among patients with the ALDH2 AA genotype are required.	Paclitaxel	119-122	aldehyde dehydrogenase 2 family member	Homo sapiens	147-152
30914582-7	2019	Among microtubule toxins, clinically effective paclitaxel(PTX)and VNB had a greater effect than colchicine and nocodazole on polyploidy induction in MX-1 cells.	Paclitaxel	47-57	MX dynamin like GTPase 1	Homo sapiens	149-153
30260001-7	2019	The present results also showed that melatonin and taxol induced GSK3-beta nuclear and Snail cytosolic localization.	Paclitaxel	51-56	glycogen synthase kinase 3 beta	Homo sapiens	65-74
31031868-0	2019	Inhibition of RNA-Binding Protein Musashi-1 Suppresses Malignant Properties and Reverses Paclitaxel Resistance in Ovarian Carcinoma.	Paclitaxel	89-99	musashi RNA binding protein 1	Homo sapiens	34-43
31031868-4	2019	The objective of this study was to investigate the expression, suppression of malignant properties and reversal of paclitaxel resistance inhibiting RNA-binding protein Musashi-1 with siRNA in ovarian cancer cells.	Paclitaxel	115-125	musashi RNA binding protein 1	Homo sapiens	168-177
31031868-9	2019	Reversal of paclitaxel resistance assay was used to evaluate the role of MSI-1 in paclitaxel resistance of OC cells.	Paclitaxel	82-92	musashi RNA binding protein 1	Homo sapiens	73-78
31031868-13	2019	Moreover, MSI-1 expression inhibition reverses paclitaxel-resistance in OC cells.	Paclitaxel	47-57	musashi RNA binding protein 1	Homo sapiens	10-15
31031868-14	2019	We further display that MSI-1 effectively protects OC cells from paclitaxel-induced apoptosis by increasing the expression of p-Bcl-2 through ERK signaling pathway activation.	Paclitaxel	65-75	musashi RNA binding protein 1	Homo sapiens	24-29
31031868-15	2019	In vivo, MSI-1 siRNA clearly showed a strong effect on tumor growth inhibition and paclitaxel-resistance reversal.	Paclitaxel	83-93	musashi RNA binding protein 1	Homo sapiens	9-14
31031868-16	2019	Conclusions: These findings suggest that MSI-1 overexpression is associated with the prognosis of OC patients, and knockdown of MSI-1 can suppress malignant properties and reverse paclitaxel-resistance in OC cells.	Paclitaxel	180-190	musashi RNA binding protein 1	Homo sapiens	128-133
30863067-13	2019	The activation of protein kinase B (AKT)/glycogen synthase kinase 3 beta (GSK3beta) signaling pathway also blocked by PTX in cultured HKFs and keloid tissues.	Paclitaxel	118-121	glycogen synthase kinase 3 beta	Homo sapiens	41-72
30863067-13	2019	The activation of protein kinase B (AKT)/glycogen synthase kinase 3 beta (GSK3beta) signaling pathway also blocked by PTX in cultured HKFs and keloid tissues.	Paclitaxel	118-121	glycogen synthase kinase 3 beta	Homo sapiens	74-82
30452790-0	2019	Neutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrin-Targeted Conjugate.	Paclitaxel	49-59	elastase, neutrophil expressed	Homo sapiens	0-19
30421127-6	2019	PTX-loaded protein nanoparticles displaying DNA aptamers known to bind to the MUC1 tumor marker resulted in increased cytotoxicity with MCF-7 breast cancer cells compared to PTX-loaded protein nanoparticles without the DNA aptamer modification.	Paclitaxel	0-3	mucin 1, cell surface associated	Homo sapiens	78-82
30723412-0	2018	Enhanced Anti-tumor of Pep-1 Modified Superparamagnetic Iron Oxide/PTX Loaded Polymer Nanoparticles.	Paclitaxel	67-70	prolyl endopeptidase	Homo sapiens	23-26
30723412-5	2018	The resulting Pep-NP-SPION/PTX showed a spherical morphology and an average size of 100 nm.	Paclitaxel	27-30	prolyl endopeptidase	Homo sapiens	14-17
30723412-7	2018	The IC50 value of Pep-NP-SPION/PTX and NP-SPION/PTX was determined to be 10.2 and 19.4 mug/mL, respectively.	Paclitaxel	31-34	prolyl endopeptidase	Homo sapiens	18-21
30723412-10	2018	Furthermore, Pep-NP-SPION/PTX presented desirable in vivo anti-tumor effects based on active targeting and magnetic targeting characteristics.	Paclitaxel	26-29	prolyl endopeptidase	Homo sapiens	13-16
30723412-11	2018	Altogether, Pep-NP-SPION/PTX can offer magnetic targeting and receptor mediated targeting to enhance the anti-tumor outcome.	Paclitaxel	25-28	prolyl endopeptidase	Homo sapiens	12-15
30545630-8	2019	Importantly, two neddylation conjugating E2 enzymes, UBE2M and UBE2F, were found to play essential roles in PTX-induced cytotoxicity and tubulin polymerization in OCCs.	Paclitaxel	108-111	ubiquitin conjugating enzyme E2 F (putative)	Homo sapiens	63-68
30431082-11	2019	Notably, ERp57-siRNA and 100 nM paclitaxel co-treatment downregulated Bcl-2, Bcl-xl, MMP2, MMP9, TUBB3 and P-gp expression levels and upregulated the expression of Bax protein.	Paclitaxel	32-42	matrix metallopeptidase 2	Homo sapiens	85-89
30431082-11	2019	Notably, ERp57-siRNA and 100 nM paclitaxel co-treatment downregulated Bcl-2, Bcl-xl, MMP2, MMP9, TUBB3 and P-gp expression levels and upregulated the expression of Bax protein.	Paclitaxel	32-42	tubulin beta 3 class III	Homo sapiens	97-102
30520341-0	2019	Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure.	Paclitaxel	49-59	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	18-24
30520341-7	2019	CONCLUSION: Contrary to previous publications, CYP2C8*3 may confer increased paclitaxel metabolic activity.	Paclitaxel	77-87	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	47-53
30520341-8	2019	SLCO1B1 and CYP2C8 genotype may explain some paclitaxel pharmacokinetic variability.	Paclitaxel	45-55	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	12-18
30511588-3	2019	Paclitaxel has been reported to act as an adjuvant for Th2 inflammation while downregulating TGF-beta activation.	Paclitaxel	0-10	transforming growth factor, beta 1	Mus musculus	93-101
30511588-5	2019	We hypothesized that paclitaxel would augment Th2 inflammation while blocking TGF-beta activation and PH after schistosomiasis exposure.	Paclitaxel	21-31	transforming growth factor, beta 1	Mus musculus	78-86
30511588-12	2019	Inflammation was significantly suppressed, contrary to our hypothesis, with decreased IL-4 and IL-13 levels, smaller granulomas, and less active TGF-beta following paclitaxel treatment.	Paclitaxel	164-174	transforming growth factor, beta 1	Mus musculus	145-153
30511588-15	2019	Paclitaxel protects against Schistosoma-induced PH in mice, although by blocking proximate Th2 inflammation rather than suppressing distal TGF-beta activation.	Paclitaxel	0-10	transforming growth factor, beta 1	Mus musculus	139-147
30359947-0	2019	MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells.	Paclitaxel	70-80	microRNA 203a	Homo sapiens	28-36
30553276-7	2018	The association between c-Src-mediated DMAP1 phosphorylation and paclitaxel activity in vivo and clinicopathologic characteristics were analyzed.	Paclitaxel	65-75	DNA methyltransferase 1 associated protein 1	Homo sapiens	39-44
30553276-11	2018	Blocking DMAP1 pTyr-246 potentiates paclitaxel-inhibited tumor growth.	Paclitaxel	36-46	DNA methyltransferase 1 associated protein 1	Homo sapiens	9-14
30521500-0	2018	LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1.	Paclitaxel	20-30	long intergenic non-protein coding RNA 1118	Homo sapiens	0-9
30521500-0	2018	LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1.	Paclitaxel	20-30	microRNA 134	Homo sapiens	85-92
30521500-8	2018	Biological function experiments showed LINC01118 could facilitate paclitaxel resistance and promote migration and invasion while inhibiting apoptosis of EOC cells.	Paclitaxel	66-76	long intergenic non-protein coding RNA 1118	Homo sapiens	39-48
30521500-10	2018	CONCLUSIONS LINC01118 acted as an oncogene and modulated EOC paclitaxel sensitivity by regulating miR-134/ABCC1.	Paclitaxel	61-71	long intergenic non-protein coding RNA 1118	Homo sapiens	12-21
30521500-10	2018	CONCLUSIONS LINC01118 acted as an oncogene and modulated EOC paclitaxel sensitivity by regulating miR-134/ABCC1.	Paclitaxel	61-71	microRNA 134	Homo sapiens	98-105
30292755-0	2018	A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer.	Paclitaxel	82-92	S-phase kinase associated protein 2	Homo sapiens	62-66
30292755-8	2018	In addition, Skp2 was found to be over-expressed in paclitaxel-resistant cells, and the transfection of Skp2 siRNA recovered the sensitivity of paclitaxel in PC-3-Pa cells.	Paclitaxel	52-62	S-phase kinase associated protein 2	Homo sapiens	13-17
30292755-8	2018	In addition, Skp2 was found to be over-expressed in paclitaxel-resistant cells, and the transfection of Skp2 siRNA recovered the sensitivity of paclitaxel in PC-3-Pa cells.	Paclitaxel	144-154	S-phase kinase associated protein 2	Homo sapiens	13-17
30292755-8	2018	In addition, Skp2 was found to be over-expressed in paclitaxel-resistant cells, and the transfection of Skp2 siRNA recovered the sensitivity of paclitaxel in PC-3-Pa cells.	Paclitaxel	144-154	S-phase kinase associated protein 2	Homo sapiens	104-108
28823711-11	2018	GAT211 produced synergistic antiallodynic effects with fatty acid amide hydrolase and monoacylglycerol lipase inhibitors in paclitaxel-treated mice.	Paclitaxel	124-134	monoglyceride lipase	Mus musculus	86-109
29985480-0	2018	PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer.	Paclitaxel	79-89	hexokinase 2	Homo sapiens	33-45
29985480-7	2018	Interestingly, PIM2 kinase inhibitor SMI-4a could abrogate the effects of phosphorylated HK2 Thr473 on paclitaxel resistance in vitro and in vivo.	Paclitaxel	103-113	hexokinase 2	Homo sapiens	89-92
30099017-7	2018	Meanwhile, the antimetastasis mechanism studies confirmed that the combination of the chemotherapeutic PTX and the autophagy inhibitor HCQ further suppressed the degradation of paxillin, the expression of MMP9 and MMP2.	Paclitaxel	103-106	matrix metallopeptidase 9	Mus musculus	205-209
30340507-8	2018	Dickkopf-1 (DKK-1), a Wnt pathway inhibitor, and L685,458, an inhibitor of the Notch pathway, reversed the resistance to PTX and stem phenotype conversion induced by HIF-2alpha overexpression.	Paclitaxel	121-124	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	0-10
30340507-8	2018	Dickkopf-1 (DKK-1), a Wnt pathway inhibitor, and L685,458, an inhibitor of the Notch pathway, reversed the resistance to PTX and stem phenotype conversion induced by HIF-2alpha overexpression.	Paclitaxel	121-124	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	12-17
30326563-6	2018	PTX+BGJ398 induced cell cycle arrest and apoptosis in UC cells with mesenchymal characteristics was accompanied by downregulation of cyclin D1 protein and upregulation of gamma-histone 2A family member X and cleaved poly(ADP-ribose) polymerase.	Paclitaxel	0-3	cyclin D1	Homo sapiens	133-142
30257426-0	2018	The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines.	Paclitaxel	51-61	matrix Gla protein	Homo sapiens	12-30
30257426-0	2018	The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines.	Paclitaxel	51-61	matrix Gla protein	Homo sapiens	32-35
30257426-4	2018	A detailed MGP expression analysis in sensitive (A2780) and resistant to paclitaxel (PAC) (A2780PR) and topotecan (TOP) (A2780TR) ovarian cancer cell lines and their corresponding media was performed.	Paclitaxel	73-83	matrix Gla protein	Homo sapiens	11-14
30257426-9	2018	MGP is an important factor that might contribute to cancer resistance mechanism by augmenting the interaction of cells with ECM components leading to increased resistance of ovarian cancer cells to paclitaxel and topotecan.	Paclitaxel	198-208	matrix Gla protein	Homo sapiens	0-3
30280784-0	2018	Jagged2 promotes cancer stem cell properties of triple negative breast cancer cells and paclitaxel resistance via regulating microRNA-200.	Paclitaxel	88-98	jagged canonical Notch ligand 2	Homo sapiens	0-7
30280784-4	2018	Jagged2 expression in paclitaxel-resistant group and non-resistance group before and after treatment was detected by quantitative Real-time-polymerase chain reaction (qRT-PCR), respectively.	Paclitaxel	22-32	jagged canonical Notch ligand 2	Homo sapiens	0-7
30280784-5	2018	After Jagged2 knockdown in paclitaxel-resistant MDA-MB-231 cells (MDA-MB-231/TXR), expression of CD44+CD24-ESA+ subset was detected by flow cytometry.	Paclitaxel	27-37	jagged canonical Notch ligand 2	Homo sapiens	6-13
30280784-7	2018	RESULTS: Jagged2 was highly expressed in paclitaxel-resistant TNBC tissues and cells.	Paclitaxel	41-51	jagged canonical Notch ligand 2	Homo sapiens	9-16
30280784-9	2018	Knockdown of Jagged2 inhibited CSC properties and paclitaxel resistance, whereas upregulated microRNA-200 expression.	Paclitaxel	50-60	jagged canonical Notch ligand 2	Homo sapiens	13-20
30280784-10	2018	The inhibited CSC properties and paclitaxel resistance induced by Jagged2 knockdown were reversed by microRNA-200 knockdown.	Paclitaxel	33-43	jagged canonical Notch ligand 2	Homo sapiens	66-73
30280784-11	2018	CONCLUSIONS: Jagged2 maintains CSC properties of TNBC cells and paclitaxel resistance via regulating microRNA-200.	Paclitaxel	64-74	jagged canonical Notch ligand 2	Homo sapiens	13-20
30015868-10	2018	Furthermore, the ectopic expression of their target gene myeloid differentiation primary response gene 88 (MYD88) or tumor protein 53-induced nuclear protein 1 (TP53INP1) combined with NT21MP enhanced the sensitivity of the breast cancer cells to paclitaxel.	Paclitaxel	247-257	MYD88 innate immune signal transduction adaptor	Homo sapiens	107-112
30015868-11	2018	Taken together, these findings suggested that miR-155-3p/5p and their target genes MYD88 and TP53INP1 may serve as novel biomarkers for NT21MP therapy through the CXCR4 pathway for improving sensitivity to paclitaxel in breast cancer.	Paclitaxel	206-216	MYD88 innate immune signal transduction adaptor	Homo sapiens	83-88
30093840-7	2018	Concurrent expression of miR-125a and miR-205 via the miRNA cluster transfection significantly enhanced trastuzumab-mediated growth inhibition and cell cycle G1 arrest in BT474 cells and markedly increased paclitaxel-induced apoptosis in another HER2-overexpressing breast cancer cell line HCC1954.	Paclitaxel	206-216	microRNA 125a	Homo sapiens	25-33
30093840-7	2018	Concurrent expression of miR-125a and miR-205 via the miRNA cluster transfection significantly enhanced trastuzumab-mediated growth inhibition and cell cycle G1 arrest in BT474 cells and markedly increased paclitaxel-induced apoptosis in another HER2-overexpressing breast cancer cell line HCC1954.	Paclitaxel	206-216	microRNA 205	Homo sapiens	38-45
30068371-2	2018	Purpose of this study was to compare toxicity and oncologic outcome of dCRT with either cisplatin and 5-fluoruracil (CDDP/5FU) or carboplatin and paclitaxel (Carb/TAX) in patients with SCC.	Paclitaxel	146-156	syntaxin 8	Homo sapiens	158-162
29978708-6	2018	In DLD-1 xenograft tumor-bearing mice, the nanoparticles accumulated in the tumor, resulting in remarkable tumor regression, with the PTX and miR708-loaded nanoparticles showing significantly greater inhibitory effects than the free PTX or PTX-loaded nanoparticles.	Paclitaxel	233-236	microRNA 708	Mus musculus	142-148
29978708-6	2018	In DLD-1 xenograft tumor-bearing mice, the nanoparticles accumulated in the tumor, resulting in remarkable tumor regression, with the PTX and miR708-loaded nanoparticles showing significantly greater inhibitory effects than the free PTX or PTX-loaded nanoparticles.	Paclitaxel	233-236	microRNA 708	Mus musculus	142-148
29660518-0	2018	HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.	Paclitaxel	49-59	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	92-95
29660518-7	2018	These findings revealed that HOXB4 knockdown enhanced the cytotoxic effects of Taxol and DDP by downregulating ABC transporters via inhibiting the PI3K/Akt pathway in ovarian cancer cells.	Paclitaxel	79-84	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	111-114
30019863-0	2018	Differential altered expression of let-7a and miR-205 tumor-suppressor miRNAs in different subtypes of breast cancer under treatment with Taxol.	Paclitaxel	138-143	microRNA 205	Homo sapiens	46-53
30019863-2	2018	OBJECTIVES: In this study, we aimed to investigate the expression pattern of let-7a and miR-205 tumorsuppressor miRNAs in breast cancer cell lines under treatment with paclitaxel.	Paclitaxel	168-178	microRNA 205	Homo sapiens	88-95
29683800-12	2018	Western blot analysis indicated that P-gp, Bcl-2, and PARP protein were more abundant in MGC803/PTX and SW620/PTX cells compared with MGC803 and SW620 cells, whereas Bax protein levels were lower in resistant cells.	Paclitaxel	96-99	collagen type XI alpha 2 chain	Homo sapiens	54-58
29683800-12	2018	Western blot analysis indicated that P-gp, Bcl-2, and PARP protein were more abundant in MGC803/PTX and SW620/PTX cells compared with MGC803 and SW620 cells, whereas Bax protein levels were lower in resistant cells.	Paclitaxel	110-113	collagen type XI alpha 2 chain	Homo sapiens	54-58
28934847-0	2018	Participation of CCL1 in Snail-Positive Fibroblasts in Colorectal Cancer Contribute to 5-Fluorouracil/Paclitaxel Chemoresistance.	Paclitaxel	102-112	chemokine (C-C motif) ligand 1	Mus musculus	17-21
29691121-5	2018	RESULTS: Both paclitaxel and epothilone B promoted keratinocyte differentiation, accumulation of junctional proteins at the cell cortex, and the early appearance of lamellar bodies in immature RHE, whereas destabilization of microtubules by nocodazole had the reverse effect.	Paclitaxel	14-24	factor interacting with PAPOLA and CPSF1	Homo sapiens	193-196
29897944-6	2018	Autophagic flux upon paclitaxel treatment in vitro was assessed by immunoblotting of LC3B-II and quantitative assessment of WIP1 mRNA.	Paclitaxel	21-31	microtubule associated protein 1 light chain 3 beta	Homo sapiens	85-89
29577893-4	2018	Thus, the goal of this study was to evaluate the participation of TRPV1 in a model of acute nociception induced by paclitaxel in rats and mice.	Paclitaxel	115-125	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	66-71
29706628-5	2018	Moreover, paclitaxel regulates a number of cancer-associated RNA alternative splicing events, including genes involved in cellular response to DNA damage stimulus, preassembly of GPI anchor in ER membrane, transcription, and DNA repair.	Paclitaxel	10-20	glucose-6-phosphate isomerase	Homo sapiens	179-182
29748662-4	2018	Mechanistically, reducing PRC1 blocks mitotic exit of HCC cells at telophase in a spindle assembly checkpoint independent manner, and acts synergistically with microtubule-associated agents (MTAs) to suppress p53-wt or p53-null HCC cells in a p53- or p14ARF-dependent manner; while overexpressing PRC1 increases the resistance of HCC to taxol.	Paclitaxel	337-342	protein regulator of cytokinesis 1	Homo sapiens	26-30
29565447-0	2018	CAFs enhance paclitaxel resistance by inducing EMT through the IL-6/JAK2/STAT3 pathway.	Paclitaxel	13-23	Janus kinase 2	Homo sapiens	68-72
29319606-10	2018	TAT-GESV also blocked the paclitaxel-induced phosphorylation at Ser15 of p53, a substrate of p38 MAPK.	Paclitaxel	26-36	mitogen-activated protein kinase 14	Mus musculus	93-101
29719390-4	2018	PTX was encapsulated into the hydrophobic core of the PEI-PLA polymers by dialysis, and then the survivin siRNA was loaded onto the PTX-loaded NPs (PEI-PLA/PTX) through electrostatic interaction between siRNA and PEI block.	Paclitaxel	132-135	baculoviral IAP repeat-containing 5	Mus musculus	97-105
29719390-4	2018	PTX was encapsulated into the hydrophobic core of the PEI-PLA polymers by dialysis, and then the survivin siRNA was loaded onto the PTX-loaded NPs (PEI-PLA/PTX) through electrostatic interaction between siRNA and PEI block.	Paclitaxel	132-135	baculoviral IAP repeat-containing 5	Mus musculus	97-105
29569435-2	2018	To solve this problem, a glucose transporter-mediated and matrix metalloproteinase 2 (MMP2)-triggered mitochondrion-targeting conjugate [glucose-polyethylene glycol (PEG)-peptide-triphenylphosponium-polyamidoamine (PAMAM)-PTX] composed of a PAMAM dendrimer and enzymatic detachable glucose-PEG was constructed for mitochondrial delivery of PTX.	Paclitaxel	222-225	matrix metallopeptidase 2	Homo sapiens	58-84
29569435-2	2018	To solve this problem, a glucose transporter-mediated and matrix metalloproteinase 2 (MMP2)-triggered mitochondrion-targeting conjugate [glucose-polyethylene glycol (PEG)-peptide-triphenylphosponium-polyamidoamine (PAMAM)-PTX] composed of a PAMAM dendrimer and enzymatic detachable glucose-PEG was constructed for mitochondrial delivery of PTX.	Paclitaxel	222-225	matrix metallopeptidase 2	Homo sapiens	86-90
29569435-2	2018	To solve this problem, a glucose transporter-mediated and matrix metalloproteinase 2 (MMP2)-triggered mitochondrion-targeting conjugate [glucose-polyethylene glycol (PEG)-peptide-triphenylphosponium-polyamidoamine (PAMAM)-PTX] composed of a PAMAM dendrimer and enzymatic detachable glucose-PEG was constructed for mitochondrial delivery of PTX.	Paclitaxel	340-343	matrix metallopeptidase 2	Homo sapiens	58-84
29569435-2	2018	To solve this problem, a glucose transporter-mediated and matrix metalloproteinase 2 (MMP2)-triggered mitochondrion-targeting conjugate [glucose-polyethylene glycol (PEG)-peptide-triphenylphosponium-polyamidoamine (PAMAM)-PTX] composed of a PAMAM dendrimer and enzymatic detachable glucose-PEG was constructed for mitochondrial delivery of PTX.	Paclitaxel	340-343	matrix metallopeptidase 2	Homo sapiens	86-90
29555820-6	2018	We observed that a loss of Aurora A activity directly affects SAC function, that Aurora A is essential for maintaining the checkpoint protein Mad2 on unattached kinetochores and that inhibition of Aurora A leads to loss of the SAC, even in the presence of nocodazole or Taxol.	Paclitaxel	270-275	aurora kinase A	Homo sapiens	27-35
29707144-6	2018	Accordingly, our OvCa cell line studies showed that the EMSY gene knockdown sensitized A2780 and IGROV1 cells to paclitaxel.	Paclitaxel	113-123	EMSY transcriptional repressor, BRCA2 interacting	Homo sapiens	56-60
29339084-9	2018	MiR-613 weakens the resistance of TNBC cells against paclitaxel rather than adriamycin, cyclophosphamide, docetaxel, and kaempferol.	Paclitaxel	53-63	microRNA 613	Homo sapiens	0-7
29034548-17	2018	SIGNIFICANCE: Electroacupuncture (EA) activates spinal 5-HT1A receptors to inhibit p-CaMKII to alleviate paclitaxel-induced pain.	Paclitaxel	105-115	5-hydroxytryptamine receptor 1A	Rattus norvegicus	55-61
29560416-1	2018	Neuronal calcium sensor-1 (NCS-1) has been identified as a binding partner of the taxane, paclitaxel.	Paclitaxel	90-100	neuronal calcium sensor 1	Homo sapiens	0-25
29560416-1	2018	Neuronal calcium sensor-1 (NCS-1) has been identified as a binding partner of the taxane, paclitaxel.	Paclitaxel	90-100	neuronal calcium sensor 1	Homo sapiens	27-32
29560416-2	2018	Our previous study showed that overexpression of NCS-1 increased the efficacy of paclitaxel in vitro, but was associated with poor clinical outcome.	Paclitaxel	81-91	neuronal calcium sensor 1	Homo sapiens	49-54
29452092-3	2018	MiR-630 expression levels were detected in ovarian cancer cell line SKOV3 and paclitaxel-resistant SKOV3 (SKOV3-TR) via microarray and qRT-PCR.	Paclitaxel	78-88	microRNA 630	Homo sapiens	0-7
29452092-7	2018	Inhibition of miR-630 decreased cell proliferation and enhanced the sensitivity of SKOV3-TR and SKOV3 cells to paclitaxel.	Paclitaxel	111-121	microRNA 630	Homo sapiens	14-21
29452092-8	2018	In the chemosensitivity assay, we observed that the miR-630 inhibitor exhibited a synergistic effect with paclitaxel on SKOV3-TR cells.	Paclitaxel	106-116	microRNA 630	Homo sapiens	52-59
29452092-11	2018	An in vivo PDX study showed that the miR-630 inhibitor sensitized chemoresistant ovarian cancer to paclitaxel.	Paclitaxel	99-109	microRNA 630	Homo sapiens	37-44
29223619-10	2018	In agreement with these findings CYP2C protein expression and CYP2C8-mediated paclitaxel 6alpha-hydroxylation were unimpaired in cirrhotic livers.	Paclitaxel	78-88	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	62-68
29663921-3	2018	A CSO-SS-Hex polymer micelle was used for PTX incorporation and GSH-triggered intracellular release.	Paclitaxel	42-45	hematopoietically expressed homeobox	Homo sapiens	9-12
29663921-7	2018	The HA/CSO-SS-Hex/Fe3O4/PTX micelle was stable under physiological conditions, while it was sensitive to release the loaded drug in the presence of 10 mM glutathione (GSH).	Paclitaxel	24-27	hematopoietically expressed homeobox	Homo sapiens	14-17
29663921-9	2018	Cell viability tests revealed that HA/CSO-SS-Hex/Fe3O4/PTX micelle displayed enhanced cytotoxicity against A549, B16F10 and HepG2 cell lines compared to non-targeted formulations of PTX.	Paclitaxel	55-58	hematopoietically expressed homeobox	Homo sapiens	45-48
29663921-9	2018	Cell viability tests revealed that HA/CSO-SS-Hex/Fe3O4/PTX micelle displayed enhanced cytotoxicity against A549, B16F10 and HepG2 cell lines compared to non-targeted formulations of PTX.	Paclitaxel	182-185	hematopoietically expressed homeobox	Homo sapiens	45-48
29663921-12	2018	Thus, the novel HA/CSO-SS-Hex/Fe3O4/PTX micelle is highly effective for targeted drug delivery and might have potential implications for the chemotherapy of primary tumors and their metastases.	Paclitaxel	36-39	hematopoietically expressed homeobox	Homo sapiens	26-29
28283888-1	2018	Kinin B1 (B1R) and B2 receptors (B2R) and the transient receptor potential vanilloid 4 (TRPV4) channel are known to play a critical role in the peripheral neuropathy induced by paclitaxel (PTX) in rodents.	Paclitaxel	177-187	bradykinin receptor, beta 2	Mus musculus	33-36
28283888-1	2018	Kinin B1 (B1R) and B2 receptors (B2R) and the transient receptor potential vanilloid 4 (TRPV4) channel are known to play a critical role in the peripheral neuropathy induced by paclitaxel (PTX) in rodents.	Paclitaxel	189-192	bradykinin receptor, beta 2	Mus musculus	33-36
28283888-7	2018	The selective kinin B1R (des-Arg9-[Leu8]-bradykinin) and B2R (HOE 140) antagonists reduced the mechanical hyperalgesia induced by PTX, with efficacies and time response profiles similar to those observed for the TRPV4 antagonist (HC-067047).	Paclitaxel	130-133	bradykinin receptor, beta 2	Mus musculus	57-60
28283888-10	2018	The selective PKCepsilon inhibitor (epsilonV1-2) reduced the hypotonicity-induced overt nociception in PTX-treated mice with the same magnitude observed for the kinin receptor antagonists.	Paclitaxel	103-106	protein kinase C, epsilon	Mus musculus	14-24
28283888-12	2018	This mechanism of interaction may contribute to PTX-induced peripheral neuropathy through the activation of PKCepsilon.	Paclitaxel	48-51	protein kinase C, epsilon	Mus musculus	108-118
29344663-5	2018	To investigate the effect of the recombinant virus on chemotherapeutics, paclitaxel was added to MDA-MB-468 cells and it was demonstrated that rAAV2-ZsGreen-shRNA-hIGFBP-2-infected MDA-MB-468 cells were highly chemosensitive to paclitaxel compared with rAAV2-ZsGreen-shRNA-scramble-injected cells.	Paclitaxel	73-83	insulin like growth factor binding protein 2	Homo sapiens	163-171
29344663-5	2018	To investigate the effect of the recombinant virus on chemotherapeutics, paclitaxel was added to MDA-MB-468 cells and it was demonstrated that rAAV2-ZsGreen-shRNA-hIGFBP-2-infected MDA-MB-468 cells were highly chemosensitive to paclitaxel compared with rAAV2-ZsGreen-shRNA-scramble-injected cells.	Paclitaxel	228-238	insulin like growth factor binding protein 2	Homo sapiens	163-171
29176398-2	2018	Our study aims to investigate the role of gC1qR in paclitaxel-induced apoptosis of human ovarian cancer cells and to elucidate its potential molecular mechanism.	Paclitaxel	51-61	complement C1q binding protein	Homo sapiens	42-47
29176398-8	2018	Cells treated with paclitaxel showed increased gC1qR gene expression, cell apoptosis, and mitochondria dysfunction, and the effects on these cells could be abrogated by the addition of gC1qR small-interfering RNA or alpha-lipoic acid that was used to protect the mitochondria function.	Paclitaxel	19-29	complement C1q binding protein	Homo sapiens	47-52
29176398-8	2018	Cells treated with paclitaxel showed increased gC1qR gene expression, cell apoptosis, and mitochondria dysfunction, and the effects on these cells could be abrogated by the addition of gC1qR small-interfering RNA or alpha-lipoic acid that was used to protect the mitochondria function.	Paclitaxel	19-29	complement C1q binding protein	Homo sapiens	185-190
29176398-9	2018	In summary, these data support a mechanism that gC1qR-induced mitochondria dysfunction was involved in the paclitaxel-mediated apoptosis of ovarian cancer cells.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited.	Paclitaxel	107-117	complement C1q binding protein	Homo sapiens	48-53
29367628-0	2018	The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.	Paclitaxel	97-107	aurora kinase A	Homo sapiens	66-74
29367628-5	2018	Our findings revealed a novel function for UBC13 in regulating paclitaxel sensitivity through a DNMT1-CHFR-Aurora A pathway in ovarian cancer cells.	Paclitaxel	63-73	aurora kinase A	Homo sapiens	107-115
28869599-5	2018	This distinct mitotic phenotype was interlinked with Paclitaxel-mediated radiosensitization via overexpression of mitotic Aurora kinase A (AURKA) and its cofactor TPX2 whose knockdown rescued the bipolar mode of cell division and largely attenuated the radiosensitizing effects of Paclitaxel.	Paclitaxel	53-63	aurora kinase A	Homo sapiens	122-137
28869599-5	2018	This distinct mitotic phenotype was interlinked with Paclitaxel-mediated radiosensitization via overexpression of mitotic Aurora kinase A (AURKA) and its cofactor TPX2 whose knockdown rescued the bipolar mode of cell division and largely attenuated the radiosensitizing effects of Paclitaxel.	Paclitaxel	53-63	aurora kinase A	Homo sapiens	139-144
28869599-5	2018	This distinct mitotic phenotype was interlinked with Paclitaxel-mediated radiosensitization via overexpression of mitotic Aurora kinase A (AURKA) and its cofactor TPX2 whose knockdown rescued the bipolar mode of cell division and largely attenuated the radiosensitizing effects of Paclitaxel.	Paclitaxel	281-291	aurora kinase A	Homo sapiens	122-137
28869599-5	2018	This distinct mitotic phenotype was interlinked with Paclitaxel-mediated radiosensitization via overexpression of mitotic Aurora kinase A (AURKA) and its cofactor TPX2 whose knockdown rescued the bipolar mode of cell division and largely attenuated the radiosensitizing effects of Paclitaxel.	Paclitaxel	281-291	aurora kinase A	Homo sapiens	139-144
30043652-4	2018	Action mechanism studies manifested that DQA modified paclitaxel plus honokiol micelles could activate apoptotic enzymes caspase-3 and caspase-9 as well as down-regulate FAK, PI3K, MMP-2 and MMP-9.	Paclitaxel	54-64	caspase 9	Mus musculus	135-144
30043652-4	2018	Action mechanism studies manifested that DQA modified paclitaxel plus honokiol micelles could activate apoptotic enzymes caspase-3 and caspase-9 as well as down-regulate FAK, PI3K, MMP-2 and MMP-9.	Paclitaxel	54-64	matrix metallopeptidase 9	Mus musculus	191-196
29305809-0	2018	Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.	Paclitaxel	55-65	E1A binding protein p300	Homo sapiens	33-38
30064123-12	2018	Furthermore, CA increased the PTX-induced activation of Bax, Bid, and downstream cleaved PARP, and phosphorylation of extracellular signal regulated kinase1/2 and c-Jun NH2-terminal protein kinase1/2.	Paclitaxel	30-33	collagen type XI alpha 2 chain	Homo sapiens	89-93
30355931-8	2018	Paclitaxel+hirudin inhibited the levels of key proteins and the gene expression, except for that of the MyD88 gene, of the TLR4-MyD88 pathway.	Paclitaxel	0-10	MYD88 innate immune signal transduction adaptor	Homo sapiens	128-133
30355931-10	2018	After epoxomicin intervention, the inhibitory effects of paclitaxel+hirudin on the key genes and proteins of the TLR4-MyD88 pathway were significantly weakened, which even reached pre-intervention levels.	Paclitaxel	57-67	MYD88 innate immune signal transduction adaptor	Homo sapiens	118-123
30355931-11	2018	Paclitaxel+hirudin affected the MyD88 protein in a dosage-dependent manner.	Paclitaxel	0-10	MYD88 innate immune signal transduction adaptor	Homo sapiens	32-37
30355931-12	2018	CONCLUSION: The paclitaxel+hirudin compound promotes MyD88 degradation in the TLR4/MyD88/NF-kappaB pathway to reduce the activity of TLR4 and NF-kappaB p65 and to weaken the LPS-initiated inflammatory reactions of IL-1beta, IL-6, and TNF-alpha.	Paclitaxel	16-26	MYD88 innate immune signal transduction adaptor	Homo sapiens	53-58
30355931-12	2018	CONCLUSION: The paclitaxel+hirudin compound promotes MyD88 degradation in the TLR4/MyD88/NF-kappaB pathway to reduce the activity of TLR4 and NF-kappaB p65 and to weaken the LPS-initiated inflammatory reactions of IL-1beta, IL-6, and TNF-alpha.	Paclitaxel	16-26	MYD88 innate immune signal transduction adaptor	Homo sapiens	83-88
30355931-12	2018	CONCLUSION: The paclitaxel+hirudin compound promotes MyD88 degradation in the TLR4/MyD88/NF-kappaB pathway to reduce the activity of TLR4 and NF-kappaB p65 and to weaken the LPS-initiated inflammatory reactions of IL-1beta, IL-6, and TNF-alpha.	Paclitaxel	16-26	RELA proto-oncogene, NF-kB subunit	Homo sapiens	152-155
29399166-7	2018	It was identified that the expression levels of Twist, TOPO IIalpha, MRP and P-gp were upregulated and LRP was downregulated in human breast cancer tissues, which was consistent with the expression of these proteins in the Taxol -resistant MCF-7 cell model.	Paclitaxel	223-228	major vault protein	Homo sapiens	103-106
28733703-5	2017	Senescence-associated-beta-galactosidase activity was increased by peloruside A, similar to paclitaxel, discodermolde, and doxorubicin, with a potency heirarchy of doxorubicin &gt; paclitaxel &gt; discodermolide &gt; peloruside, based on IC25 concentrations that inhibit proliferation.	Paclitaxel	92-102	galactosidase beta 1	Homo sapiens	22-40
28733703-5	2017	Senescence-associated-beta-galactosidase activity was increased by peloruside A, similar to paclitaxel, discodermolde, and doxorubicin, with a potency heirarchy of doxorubicin &gt; paclitaxel &gt; discodermolide &gt; peloruside, based on IC25 concentrations that inhibit proliferation.	Paclitaxel	181-191	galactosidase beta 1	Homo sapiens	22-40
29039556-8	2017	Furthermore, the results of real-time PCR and western blotting revealed that Huaier extract decreased p65 and c-Met expression and increased IkappaBalpha expression, while paclitaxel increased p65 expression and reduced IkappaBalpha and c-Met expression.	Paclitaxel	172-182	RELA proto-oncogene, NF-kB subunit	Homo sapiens	193-196
29179722-10	2017	The caspase-9 and caspase-3 cascade was activated by the AG-PEG-SS-PLA/PTX nanomicelles through upregulation of the pro-apoptotic proteins Bax and Bid and suppression of the anti-apoptotic protein Bcl-2, thereby increasing apoptosis.	Paclitaxel	71-74	caspase 9	Mus musculus	4-13
29179722-10	2017	The caspase-9 and caspase-3 cascade was activated by the AG-PEG-SS-PLA/PTX nanomicelles through upregulation of the pro-apoptotic proteins Bax and Bid and suppression of the anti-apoptotic protein Bcl-2, thereby increasing apoptosis.	Paclitaxel	71-74	BH3 interacting domain death agonist	Mus musculus	147-150
29123088-3	2017	Here we design and synthesize a highly water-soluble nucleolin aptamer-paclitaxel conjugate (NucA-PTX) that selectively delivers PTX to the tumor site.	Paclitaxel	129-132	nucleolin	Homo sapiens	53-62
29123088-4	2017	By connecting a tumor-targeting nucleolin aptamer (NucA) to the active hydroxyl group at 2" position of PTX via a cathepsin B sensitive dipeptide bond, NucA-PTX remains stable and inactive in the circulation.	Paclitaxel	104-107	nucleolin	Homo sapiens	32-41
29123088-4	2017	By connecting a tumor-targeting nucleolin aptamer (NucA) to the active hydroxyl group at 2" position of PTX via a cathepsin B sensitive dipeptide bond, NucA-PTX remains stable and inactive in the circulation.	Paclitaxel	157-160	nucleolin	Homo sapiens	32-41
29068219-5	2017	The turnover rate of MBP-BAPT was calculated for the product N-debenzoylpaclitaxel, a key intermediate to various bioactive paclitaxel analogues.	Paclitaxel	72-82	myelin basic protein	Homo sapiens	21-24
29048649-0	2017	Paclitaxel-mediated human aryl hydrocarbon receptor mRNA translation by an internal ribosomal entry site-dependent mechanism.	Paclitaxel	0-10	aryl hydrocarbon receptor	Homo sapiens	26-51
29048649-6	2017	Interestingly, we found that AHR expression is induced in ovarian (A2780), breast (MDA-MB231), hepatic (Bel7402) and colorectal cancer cells (SW620) by chemotherapeutic drug paclitaxel (PTX) through IRES-dependent translation mechanism.	Paclitaxel	174-184	aryl hydrocarbon receptor	Homo sapiens	29-32
29048649-6	2017	Interestingly, we found that AHR expression is induced in ovarian (A2780), breast (MDA-MB231), hepatic (Bel7402) and colorectal cancer cells (SW620) by chemotherapeutic drug paclitaxel (PTX) through IRES-dependent translation mechanism.	Paclitaxel	186-189	aryl hydrocarbon receptor	Homo sapiens	29-32
29048649-7	2017	Moreover, IRES activity is increased in the PTX-resistant ovarian cancer cells in which AHR protein expression was also enhanced.	Paclitaxel	44-47	aryl hydrocarbon receptor	Homo sapiens	88-91
29048649-8	2017	These results strongly suggest an important role for AHR IRES-dependent translation mechanism in cancer cell response to paclitaxel treatment.	Paclitaxel	121-131	aryl hydrocarbon receptor	Homo sapiens	53-56
29024661-0	2017	Paclitaxel Reduces Axonal Bclw to Initiate IP3R1-Dependent Axon Degeneration.	Paclitaxel	0-10	BCL2 like 2	Homo sapiens	26-30
29024661-5	2017	Concomitantly paclitaxel impairs axonal trafficking of RNA-granules and reduces synthesis of Bclw (bcl2l2), a Bcl2 family member that binds IP3R1 and restrains axon degeneration.	Paclitaxel	14-24	BCL2 like 2	Homo sapiens	93-97
29024661-5	2017	Concomitantly paclitaxel impairs axonal trafficking of RNA-granules and reduces synthesis of Bclw (bcl2l2), a Bcl2 family member that binds IP3R1 and restrains axon degeneration.	Paclitaxel	14-24	BCL2 like 2	Homo sapiens	99-105
29024661-6	2017	Surprisingly, Bclw or a stapled peptide corresponding to the Bclw BH4 domain interact with axonal IP3R1 and prevent paclitaxel-induced degeneration, while Bcl2 and BclxL cannot do so.	Paclitaxel	116-126	BCL2 like 2	Homo sapiens	14-18
29024661-6	2017	Surprisingly, Bclw or a stapled peptide corresponding to the Bclw BH4 domain interact with axonal IP3R1 and prevent paclitaxel-induced degeneration, while Bcl2 and BclxL cannot do so.	Paclitaxel	116-126	BCL2 like 2	Homo sapiens	61-65
29025057-5	2017	Microtubule poisons treatment (nocodazole and taxol) showed that filamentous assembly of NQO2 and its co-localization with microtubules require microtubule integrity and normal dynamics.	Paclitaxel	46-51	N-ribosyldihydronicotinamide quinone reductase 2	Mus musculus	89-93
28870072-5	2017	The paclitaxel (PTX)-loaded PEG2k-ppTAT-PEG1k-PE micelles showed significant MMP2-dependent cellular uptake, tumor penetration, and anticancer activity in various cancer cells and three-dimensional multicellular spheroids.	Paclitaxel	4-14	matrix metallopeptidase 2	Homo sapiens	77-81
28870072-5	2017	The paclitaxel (PTX)-loaded PEG2k-ppTAT-PEG1k-PE micelles showed significant MMP2-dependent cellular uptake, tumor penetration, and anticancer activity in various cancer cells and three-dimensional multicellular spheroids.	Paclitaxel	16-19	matrix metallopeptidase 2	Homo sapiens	77-81
28810580-0	2017	Connexin 43 enhances paclitaxel cytotoxicity in colorectal cancer cell lines.	Paclitaxel	21-31	gap junction protein alpha 1	Homo sapiens	0-11
28810580-2	2017	The purpose of this study was to investigate the role of connexin 43 (Cx43), which is a structural component of gap junctional communication (GJC), in paclitaxel cytotoxicity in colorectal cancer cells.	Paclitaxel	151-161	gap junction protein alpha 1	Homo sapiens	57-68
28810580-2	2017	The purpose of this study was to investigate the role of connexin 43 (Cx43), which is a structural component of gap junctional communication (GJC), in paclitaxel cytotoxicity in colorectal cancer cells.	Paclitaxel	151-161	gap junction protein alpha 1	Homo sapiens	70-74
28810580-9	2017	Cx43 transfection significantly increased the mitotic arrest, tubulin polymerization and apoptosis effects of paclitaxel (P&lt;0.05).	Paclitaxel	110-120	gap junction protein alpha 1	Homo sapiens	0-4
28810580-11	2017	These results indicate that Cx43 may serve as a target of paclitaxel chemotherapy for colorectal cancer.	Paclitaxel	58-68	gap junction protein alpha 1	Homo sapiens	28-32
28451807-2	2017	A recent case study showed that the antiplatelet agent clopidogrel inhibits paclitaxel metabolism via cytochrome P450 (CYP) 2C8, resulting in severe PIPN.	Paclitaxel	76-86	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	102-127
28748102-4	2017	METHODS: Paclitaxel-treated PC12 cells were assessed for neurite length and performed Western blot analysis for growth-associated protein-43 (GAP-43) and light neurofilament protein (NF-L) levels in the presence of nerve growth factor (NGF); they were re-assessed, with additional testing for acetylcholinesterase levels, after application of one of the kampo.	Paclitaxel	9-19	growth associated protein 43	Rattus norvegicus	112-140
28748102-4	2017	METHODS: Paclitaxel-treated PC12 cells were assessed for neurite length and performed Western blot analysis for growth-associated protein-43 (GAP-43) and light neurofilament protein (NF-L) levels in the presence of nerve growth factor (NGF); they were re-assessed, with additional testing for acetylcholinesterase levels, after application of one of the kampo.	Paclitaxel	9-19	growth associated protein 43	Rattus norvegicus	142-148
28748102-4	2017	METHODS: Paclitaxel-treated PC12 cells were assessed for neurite length and performed Western blot analysis for growth-associated protein-43 (GAP-43) and light neurofilament protein (NF-L) levels in the presence of nerve growth factor (NGF); they were re-assessed, with additional testing for acetylcholinesterase levels, after application of one of the kampo.	Paclitaxel	9-19	nerve growth factor	Rattus norvegicus	215-234
28748102-4	2017	METHODS: Paclitaxel-treated PC12 cells were assessed for neurite length and performed Western blot analysis for growth-associated protein-43 (GAP-43) and light neurofilament protein (NF-L) levels in the presence of nerve growth factor (NGF); they were re-assessed, with additional testing for acetylcholinesterase levels, after application of one of the kampo.	Paclitaxel	9-19	nerve growth factor	Rattus norvegicus	236-239
28819416-5	2017	Endometrial CD133+ tumor cells enhanced proliferation rate, colony formation, chemotaxis migration ability, and chemoresistance to cisplatin, paclitaxel, and doxorubicin than CD133- cells.	Paclitaxel	142-152	prominin 1	Homo sapiens	12-17
28587902-5	2017	Therefore, we hypothesized that paclitaxel may induce peripheral neuropathy due to changes in Mfn2, Arhgef10, and Prx mRNA expression.	Paclitaxel	32-42	Rho guanine nucleotide exchange factor 10	Rattus norvegicus	100-108
28668839-8	2017	CONCLUSION: Decrease of plasma BNP concentration correlated with PFS after a treatment of combination bevacizumab plus carboplatin-paclitaxel.	Paclitaxel	131-141	natriuretic peptide B	Homo sapiens	31-34
28534969-6	2017	Co-treatment with purvalanol A and taxol weakened the expression of Bcl-2 and activated the extrinsic cell death pathway through the activation of caspase-3 and caspase-8.	Paclitaxel	35-40	caspase 8	Homo sapiens	161-170
28416606-12	2017	Collectively, our findings suggest that paclitaxel targets the TRA2A-RSRC2 splicing pathway, and deregulated TRA2A and RSRC2 expression may confer paclitaxel resistance.	Paclitaxel	147-157	transformer 2 alpha homolog	Homo sapiens	109-114
28440494-5	2017	The ability of PTX to stimulate intranuclear translocation of NF-kappaB was determined by evaluating the expression of the p65 subunit of NF-kappaB.	Paclitaxel	15-18	RELA proto-oncogene, NF-kB subunit	Homo sapiens	123-147
28440494-8	2017	PTX treatment of THP-1 macrophages for 1 h induced marked intranuclear translocation of NF-kappaB p65.	Paclitaxel	0-3	RELA proto-oncogene, NF-kB subunit	Homo sapiens	98-101
28195491-4	2017	Herein we report trichosanthin, a plant protein toxin, possesses synergistic effect with paclitaxel (PTX) in the PTX-resistance A549/T nonsmall cell lung cancer (NSCLC) cells, by reversing PTX-caused caspase 9 phosphorylation and inducing caspase 3-dependent apoptosis.	Paclitaxel	89-99	caspase 9	Mus musculus	200-209
28195491-4	2017	Herein we report trichosanthin, a plant protein toxin, possesses synergistic effect with paclitaxel (PTX) in the PTX-resistance A549/T nonsmall cell lung cancer (NSCLC) cells, by reversing PTX-caused caspase 9 phosphorylation and inducing caspase 3-dependent apoptosis.	Paclitaxel	101-104	caspase 9	Mus musculus	200-209
28195491-4	2017	Herein we report trichosanthin, a plant protein toxin, possesses synergistic effect with paclitaxel (PTX) in the PTX-resistance A549/T nonsmall cell lung cancer (NSCLC) cells, by reversing PTX-caused caspase 9 phosphorylation and inducing caspase 3-dependent apoptosis.	Paclitaxel	113-116	caspase 9	Mus musculus	200-209
28195491-4	2017	Herein we report trichosanthin, a plant protein toxin, possesses synergistic effect with paclitaxel (PTX) in the PTX-resistance A549/T nonsmall cell lung cancer (NSCLC) cells, by reversing PTX-caused caspase 9 phosphorylation and inducing caspase 3-dependent apoptosis.	Paclitaxel	113-116	caspase 9	Mus musculus	200-209
27825116-5	2017	Rb1 and compound K treatment also sensitized the CSCs to clinically relevant doses of cisplatin and paclitaxel.	Paclitaxel	100-110	RB transcriptional corepressor 1	Homo sapiens	0-3
28417924-10	2017	Investigation with real time quantitative PCR analysis revealed the limiting expression of chemo-resistant genes (ABCG2 and MDR1) after applying PLGA NPs as a drug delivery system for PTX.	Paclitaxel	184-187	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	114-119
28206956-0	2017	NF-kappaB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.	Paclitaxel	87-97	microRNA 134	Homo sapiens	36-43
28206956-3	2017	The results demonstrate that NF-kappaB1, c-Rel, and ELK1 are involved as transcription factors in repressing miR-134 expression in paclitaxel-resistant ovarian cancer cells.	Paclitaxel	131-141	microRNA 134	Homo sapiens	109-116
28258248-6	2017	Moreover, HGF in CAF matrix attenuated paclitaxel (PAC)-caused inhibition of cell proliferation and increase in cell apoptosis through activating c-Met/PI3K/Akt and GRP78 pathways in SKOV3 and HO-8910 cells.	Paclitaxel	39-49	hepatocyte growth factor	Homo sapiens	10-13
28258248-6	2017	Moreover, HGF in CAF matrix attenuated paclitaxel (PAC)-caused inhibition of cell proliferation and increase in cell apoptosis through activating c-Met/PI3K/Akt and GRP78 pathways in SKOV3 and HO-8910 cells.	Paclitaxel	39-49	lysine acetyltransferase 2B	Homo sapiens	17-20
28258248-6	2017	Moreover, HGF in CAF matrix attenuated paclitaxel (PAC)-caused inhibition of cell proliferation and increase in cell apoptosis through activating c-Met/PI3K/Akt and GRP78 pathways in SKOV3 and HO-8910 cells.	Paclitaxel	51-54	hepatocyte growth factor	Homo sapiens	10-13
28258248-6	2017	Moreover, HGF in CAF matrix attenuated paclitaxel (PAC)-caused inhibition of cell proliferation and increase in cell apoptosis through activating c-Met/PI3K/Akt and GRP78 pathways in SKOV3 and HO-8910 cells.	Paclitaxel	51-54	lysine acetyltransferase 2B	Homo sapiens	17-20
28881758-0	2017	Suppression of pyruvate dehydrogenase kinase-2 re-sensitizes paclitaxel-resistant human lung cancer cells to paclitaxel.	Paclitaxel	61-71	pyruvate dehydrogenase kinase 2	Homo sapiens	15-46
28881758-0	2017	Suppression of pyruvate dehydrogenase kinase-2 re-sensitizes paclitaxel-resistant human lung cancer cells to paclitaxel.	Paclitaxel	109-119	pyruvate dehydrogenase kinase 2	Homo sapiens	15-46
28881758-3	2017	In this study, the role of PDK2 in mediating paclitaxel resistance in lung cancer cells was investigated using biochemical and isotopic tracing methods.	Paclitaxel	45-55	pyruvate dehydrogenase kinase 2	Homo sapiens	27-31
28881758-4	2017	Increased expression of PDK2 was observed in paclitaxel-resistant cells ascompared totheir parental cells.	Paclitaxel	45-55	pyruvate dehydrogenase kinase 2	Homo sapiens	24-28
28881758-5	2017	Down-regulation of PDK2 usingsiRNA increased the sensitivity to paclitaxel of resistant lung cancer cells.	Paclitaxel	64-74	pyruvate dehydrogenase kinase 2	Homo sapiens	19-23
28881758-7	2017	Moreover, combining paclitaxel withthe specific PDK2 inhibitor dichloroacetate had a synergistic inhibitory effect on the viability of paclitaxel-resistant lung cancer cells.	Paclitaxel	135-145	pyruvate dehydrogenase kinase 2	Homo sapiens	48-52
28881758-8	2017	These results indicate that paclitaxel-induced expression of PDK2 serves as an important mechanism for acquired paclitaxel resistance of lung cancer cells.	Paclitaxel	28-38	pyruvate dehydrogenase kinase 2	Homo sapiens	61-65
28881758-8	2017	These results indicate that paclitaxel-induced expression of PDK2 serves as an important mechanism for acquired paclitaxel resistance of lung cancer cells.	Paclitaxel	112-122	pyruvate dehydrogenase kinase 2	Homo sapiens	61-65
28881758-9	2017	They also highlight the importance of PDK2 for potential therapeutic interventions in patients who have developed a resistance to paclitaxel.	Paclitaxel	130-140	pyruvate dehydrogenase kinase 2	Homo sapiens	38-42
28232485-7	2017	These findings indicate that LINC00672 can influence LASP1 expression as a locus-restricted cofactor for p53-mediated gene suppression, thus impacting EC malignancies and chemosensitivity to paclitaxel.	Paclitaxel	191-201	LIM and SH3 protein 1	Mus musculus	53-58
27599706-4	2017	METHODS: This study predicted the magnitude of the DDI between efavirenz, an inducer of CYP3A4 and inhibitor of CYP2C8, and dual CYP3A4/CYP2C8 substrates (repaglinide, montelukast, pioglitazone, paclitaxel) using a physiologically based pharmacokinetic (PBPK) modeling approach integrating concurrent effects on CYPs.	Paclitaxel	195-205	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	136-142
28108516-7	2017	In vivo, coadministration of tPA improved the anticancer efficacy of nanoparticle-encapsulated paclitaxel in subcutaneous syngeneic mouse melanoma and orthotopic xenograft lung cancer models.	Paclitaxel	95-105	plasminogen activator, tissue	Mus musculus	29-32
28177917-9	2017	Treatment of oocytes with the tubulin-disturbing reagents nocodazole (induces MTs depolymerization) or taxol (prevents MTs depolymerization) did not affect CKAP5 expression but led to a rearrangement of CKAP5.	Paclitaxel	103-108	cytoskeleton associated protein 5	Mus musculus	203-208
28277541-0	2017	The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells.	Paclitaxel	36-46	ATP binding cassette subfamily C member 5	Homo sapiens	10-15
28277541-3	2017	The drug efflux mediated by ATP-binding cassette (ABC) transporters and the survival signals activated by forkhead box (FOX) molecules are critical in the development of paclitaxel drug resistance.	Paclitaxel	170-180	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	28-48
28277541-3	2017	The drug efflux mediated by ATP-binding cassette (ABC) transporters and the survival signals activated by forkhead box (FOX) molecules are critical in the development of paclitaxel drug resistance.	Paclitaxel	170-180	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	50-53
28277541-10	2017	The depletion of FOXM1 or ABCC5 with siRNA significantly blocked drug efflux and increased the intracellular concentrations of paclitaxel, thereby promoting paclitaxel-induced cell death.	Paclitaxel	127-137	ATP binding cassette subfamily C member 5	Homo sapiens	26-31
28277541-10	2017	The depletion of FOXM1 or ABCC5 with siRNA significantly blocked drug efflux and increased the intracellular concentrations of paclitaxel, thereby promoting paclitaxel-induced cell death.	Paclitaxel	157-167	ATP binding cassette subfamily C member 5	Homo sapiens	26-31
28277541-12	2017	This study is the first to identify the roles of FOXM1 in drug efflux and paclitaxel resistance by regulating the gene transcription of abcc5, one of the ABC transporters.	Paclitaxel	74-84	ATP binding cassette subfamily C member 5	Homo sapiens	136-141
28277541-12	2017	This study is the first to identify the roles of FOXM1 in drug efflux and paclitaxel resistance by regulating the gene transcription of abcc5, one of the ABC transporters.	Paclitaxel	74-84	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	154-157
28277541-13	2017	Small molecular inhibitors of FOXM1 or ABCC5 have the potential to overcome paclitaxel chemoresistance in NPC patients.	Paclitaxel	76-86	ATP binding cassette subfamily C member 5	Homo sapiens	39-44
28280335-3	2017	Only one protein, namely, glucosamine 6-phosphate N-acetyltransferase 1 (GNA1), showed significant differential expression (P&lt;0.05) in the cutoff of 2.0 fold, suggesting that Abr can be used safely as a substitute for PTX.	Paclitaxel	221-224	glucosamine-phosphate N-acetyltransferase 1	Homo sapiens	73-77
28534376-1	2017	PURPOSE: To analyse the role of von Hippel-Lindau (VHL) and transforming growth factor beta-induced (TGFBI) in synergistic mechanisms of 5-aza-2"-deoxycytidine (DAC) and paclitaxel (PTX) against renal cell carcinoma (RCC).	Paclitaxel	170-180	arylacetamide deacetylase	Homo sapiens	161-164
28534376-1	2017	PURPOSE: To analyse the role of von Hippel-Lindau (VHL) and transforming growth factor beta-induced (TGFBI) in synergistic mechanisms of 5-aza-2"-deoxycytidine (DAC) and paclitaxel (PTX) against renal cell carcinoma (RCC).	Paclitaxel	182-185	arylacetamide deacetylase	Homo sapiens	161-164
28235398-14	2017	TSPYL5 overexpression in LNCaP cells increased the cell sensitivity to chemotherapy drugs such as docetaxel and paclitaxel, as measured by the cellular viability.	Paclitaxel	112-122	TSPY like 5	Homo sapiens	0-6
28260895-7	2017	Furthermore, the antitumor effect of P-H/M was significantly improved compared with PTX-loaded micelles or HK-loaded micelles in vivo.	Paclitaxel	84-87	peptidylglycine alpha-amidating monooxygenase	Mus musculus	37-42
28238899-3	2017	Montelukast and ketoconazole showed a potent and concentration-dependent inhibition of CYP2C8-mediated paclitaxel 6alpha-hydroxylation and CYP3A4-mediated triazolam alpha-hydroxylation, respectively, without dependence on the buffer condition.	Paclitaxel	103-113	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	87-93
28642204-1	2017	The overexpression of survivin in breast cancer cells is an important factor of paclitaxel (PTX) resistance in breast cancer.	Paclitaxel	80-90	baculoviral IAP repeat-containing 5	Mus musculus	22-30
28642204-1	2017	The overexpression of survivin in breast cancer cells is an important factor of paclitaxel (PTX) resistance in breast cancer.	Paclitaxel	92-95	baculoviral IAP repeat-containing 5	Mus musculus	22-30
28642204-4	2017	Moreover, in vitro studies on the 4T1 breast cancer cells revealed that PTX/siRNA/SS-L offered significant advantages over other experimental groups, such as higher cellular uptake, successful endolysosomal escape, reduced survivin expression, the lowest cell viability and wound healing rate, as well as the highest apoptosis rate.	Paclitaxel	72-75	baculoviral IAP repeat-containing 5	Mus musculus	223-231
28819108-0	2017	Spag6 Mutant Mice Have Defects in Development and Function of Spiral Ganglion Neurons, Apoptosis, and Higher Sensitivity to Paclitaxel.	Paclitaxel	124-134	sperm associated antigen 6	Mus musculus	0-5
28819108-12	2017	Finally, Spag6 mutant SGNs were more sensitive to the microtubule stabilizing agent, paclitaxel.	Paclitaxel	85-95	sperm associated antigen 6	Mus musculus	9-14
28796259-8	2017	Moreover, co-administration of the inhibitors of MUC1-EGFR-ABCB1 with paclitaxel significantly blocked not only tumor growth but also relapse in xenograft mouse model.	Paclitaxel	70-80	mucin 1, transmembrane	Mus musculus	49-53
28664915-8	2017	CONCLUSIONS: If validated in a larger cohort of patients, the decreased AMPK-AKT-mTOR activation and phosphorylation of FOXO1 T24/FOXO3 T32 may help identify carboplatin-paclitaxel-resistant EOC patients.	Paclitaxel	170-180	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	72-76
28749468-8	2017	We report that paclitaxel treatment activates both the IRE-1 and PERK kinases and that the increase in paclitaxel-mediated cell death through WWOX is dependent on active ER stress pathway.	Paclitaxel	15-25	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	55-60
28654894-8	2017	Further, ERbeta agonists showed tumor suppressive functions in therapy-resistant ovarian cancer model cells and sensitized ovarian cancer cells to cisplatin and paclitaxel treatment.	Paclitaxel	161-171	estrogen receptor 2	Homo sapiens	9-15
28730839-0	2017	TRPV1 receptors contribute to paclitaxel-induced c-Fos expression in spinal cord dorsal horn neurons.	Paclitaxel	30-40	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	0-5
28730839-2	2017	Here we examined the role of spinal cord TRPV1 receptors in the mechanisms leading to activation of dorsal horn neurons after paclitaxel (PAC) treatment.	Paclitaxel	126-136	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	41-46
28730839-2	2017	Here we examined the role of spinal cord TRPV1 receptors in the mechanisms leading to activation of dorsal horn neurons after paclitaxel (PAC) treatment.	Paclitaxel	138-141	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	41-46
28730839-6	2017	PAC treatment induced significant upregulation of c-Fos nuclear expression in superficial dorsal horn neurons that was diminished by TRPV1 receptor antagonists pre-incubation.	Paclitaxel	0-3	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	133-138
28730839-7	2017	These results further substantiated the role of spinal TRPV1 receptors in the development of paclitaxel-induced neuropathic pain and contribute to better understanding of the pathological mechanisms involved.	Paclitaxel	93-103	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	55-60
28404507-3	2017	We previously demonstrated that chronic treatment with paclitaxel (3-5days) reduces neuropeptide release stimulated by agonists of TRPV1.	Paclitaxel	55-65	transient receptor potential cation channel subfamily V member 1	Homo sapiens	131-136
28541685-2	2017	Previously, we reported nucleotide-binding oligomerization domain-containing protein 1 (NOD1) antagonists (11, 12) and a NOD2 antagonist (9) that sensitized docetaxel (DTX) or paclitaxel (PTX) treatment for breast or lung cancer.	Paclitaxel	176-186	nucleotide binding oligomerization domain containing 2	Homo sapiens	121-125
28541685-3	2017	In this article, we describe for the first time a 1,4-benzodiazepine-2,5-dione (BZD) derivative (26bh) that acts as a dual NOD1/NOD2 antagonist and inhibits both nuclear factor kappaB (NF-kappaB) and mitogen-activated protein kinase (MAPK) inflammatory signaling, thereby sensitizing PTX to suppress Lewis lung carcinoma (LLC) growth.	Paclitaxel	284-287	nucleotide binding oligomerization domain containing 2	Homo sapiens	128-132
28190463-11	2017	CONCLUSION: These results suggest that prophylactic topical application of PF is effective in alleviating PTX-induced mechanical allodynia by protecting sensory nerves from demyelination via activation of the A1R.	Paclitaxel	106-109	adenosine A1 receptor	Mus musculus	209-212
28428276-7	2017	Delivery of miR-34a and rubone decreased PC3-TXR cell viability with increasing paclitaxel concentration.	Paclitaxel	80-90	chromobox 8	Mus musculus	41-44
31702036-0	2019	ST3Gal3 confers paclitaxel-mediated chemoresistance in ovarian cancer cells by attenuating caspase-8/3 signaling.	Paclitaxel	16-26	caspase 8	Homo sapiens	91-102
28428276-9	2017	Paclitaxel IC50 in PC3 and PC3-TXR cells was 55.6 and 2,580 nmol/L, respectively, but decreased to 49.8 and 93.2 nmol/L when treated in combination with rubone, demonstrating a reversal of paclitaxel resistance by rubone.	Paclitaxel	0-10	chromobox 8	Mus musculus	19-22
28428276-9	2017	Paclitaxel IC50 in PC3 and PC3-TXR cells was 55.6 and 2,580 nmol/L, respectively, but decreased to 49.8 and 93.2 nmol/L when treated in combination with rubone, demonstrating a reversal of paclitaxel resistance by rubone.	Paclitaxel	0-10	chromobox 8	Mus musculus	27-30
28075581-0	2017	Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis.	Paclitaxel	47-57	nucleotide-binding oligomerization domain containing 2	Mus musculus	13-17
28075581-0	2017	Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis.	Paclitaxel	103-113	nucleotide-binding oligomerization domain containing 2	Mus musculus	13-17
31702036-3	2019	The present study demonstrated that paclitaxel-induced chemoresistance in ovarian cancer cells upregulated the expression of ST3Gal3 and reduced the activity of caspase-8/3.	Paclitaxel	36-46	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	125-132
31702036-3	2019	The present study demonstrated that paclitaxel-induced chemoresistance in ovarian cancer cells upregulated the expression of ST3Gal3 and reduced the activity of caspase-8/3.	Paclitaxel	36-46	caspase 8	Homo sapiens	161-172
28392418-9	2017	Our results suggest that microtubule stabilizing agents, such as taxol, may prevent the morphological defects observed in SPG4-KO neurons not simply by restoring the altered anterograde transport to basal levels but rather by increasing the retrograde velocity of axonal cargoes.	Paclitaxel	65-70	spastin	Homo sapiens	122-126
28341962-0	2017	Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.	Paclitaxel	40-50	E1A binding protein p300	Homo sapiens	18-23
27842858-2	2017	In addition, through modifying by tLyP-1, the anticancer scope of tLyP-1-HA-PTX conjugate was expanded from tumor cells expressing CD44 receptors to those of expressing NRP1 receptors.	Paclitaxel	76-79	neuropilin 1	Homo sapiens	169-173
27842858-5	2017	The tLyP-1-HA-PTX conjugate was especially endowed with efficient cell-penetrating and tumor NRP1 receptor targeting ability and compensate for the decreasing of uptake caused by suppression of CD44 receptor, which is more significant when NRP1 receptor is highly expressed.	Paclitaxel	14-17	neuropilin 1	Homo sapiens	93-97
27842858-5	2017	The tLyP-1-HA-PTX conjugate was especially endowed with efficient cell-penetrating and tumor NRP1 receptor targeting ability and compensate for the decreasing of uptake caused by suppression of CD44 receptor, which is more significant when NRP1 receptor is highly expressed.	Paclitaxel	14-17	neuropilin 1	Homo sapiens	240-244
31702036-5	2019	A higher expression of ST3Gal3 was correlated with an increased resistance to paclitaxel, while the downregulation of ST3Gal3 resulted in paclitaxel-induced apoptosis.	Paclitaxel	78-88	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	23-30
31702036-5	2019	A higher expression of ST3Gal3 was correlated with an increased resistance to paclitaxel, while the downregulation of ST3Gal3 resulted in paclitaxel-induced apoptosis.	Paclitaxel	138-148	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	118-125
31702036-6	2019	Paclitaxel upregulated ST3Gal3 expression at the mRNA and protein levels in HO8910PM cells, but not in SKOV3 cells.	Paclitaxel	0-10	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	23-30
29333445-8	2017	Experiments using the microtubule stabilizer Taxol showed that caspase-8 signaling is retrogradely transported by microtubules from the site of axotomy to the neuronal soma.	Paclitaxel	45-50	caspase 8	Homo sapiens	63-72
28341962-11	2017	RESULTS: Cells lacking EP300 became more resistant to paclitaxel whereas EP300 overexpression increased their sensitivity to the drug.	Paclitaxel	54-64	E1A binding protein p300	Homo sapiens	23-28
28341962-15	2017	Importantly, two key genes in apoptosis and stemness, BCL2 and ABCG2, were also upregulated in EP300-knockout colon carcinoma cells and their paclitaxel-resistant derivatives.	Paclitaxel	142-152	E1A binding protein p300	Homo sapiens	95-100
31702036-7	2019	Silencing of ST3Gal3 by small interfering RNA reversed these effects and increased the protein levels of caspase-8/3, which may contribute to paclitaxel-induced apoptosis.	Paclitaxel	142-152	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	13-20
31666085-1	2019	BACKGROUND: Macrophage-derived high mobility group box 1 (HMGB1), a damage-associated molecular pattern (DAMP) protein, plays a key role in the development of chemotherapy-induced peripheral neuropathy (CIPN) caused by paclitaxel in rodents.	Paclitaxel	219-229	high mobility group box 1	Mus musculus	31-56
28599485-0	2017	miRNA-34a enhances the sensitivity of gastric cancer cells to treatment with paclitaxel by targeting E2F5.	Paclitaxel	77-87	microRNA 34a	Homo sapiens	0-9
28599485-0	2017	miRNA-34a enhances the sensitivity of gastric cancer cells to treatment with paclitaxel by targeting E2F5.	Paclitaxel	77-87	E2F transcription factor 5	Homo sapiens	101-105
28599485-3	2017	The present study reports that micro (mi) RNA-34a, a tumor suppressor in various types of cancer, may be an important regulator of chemoresistance in GC, as miRNA-34a mimics and inhibitors, enhance and inhibit the chemotherapeutic efficacy of paclitaxel, respectively.	Paclitaxel	243-253	microRNA 34a	Homo sapiens	157-166
28599485-5	2017	Previous studies have demonstrated that the inhibition of E2F5 by specific E2F5 small interfering RNA also increases the sensitivity of GC cells to paclitaxel.	Paclitaxel	148-158	E2F transcription factor 5	Homo sapiens	58-62
28599485-5	2017	Previous studies have demonstrated that the inhibition of E2F5 by specific E2F5 small interfering RNA also increases the sensitivity of GC cells to paclitaxel.	Paclitaxel	148-158	E2F transcription factor 5	Homo sapiens	75-79
28599485-6	2017	In conclusion, the present data suggest that miRNA-34a enhances the treatment of sensitive GC cells to paclitaxel by targeting E2F5.	Paclitaxel	103-113	microRNA 34a	Homo sapiens	45-54
28599485-6	2017	In conclusion, the present data suggest that miRNA-34a enhances the treatment of sensitive GC cells to paclitaxel by targeting E2F5.	Paclitaxel	103-113	E2F transcription factor 5	Homo sapiens	127-131
29069726-5	2017	However, whether enhanced TUBB3 expression is directly involved in promoting taxol resistance remains a subject of debate.	Paclitaxel	77-82	tubulin beta 3 class III	Homo sapiens	26-31
29953775-3	2017	Resistence of ovarian cancer cells to paclitaxel and cisplatin is associated with a reduced expression of miR-30c, miR-130, and miR335, which results in activation of M-CSF, the known factor of resistance to cytostatic drugs.	Paclitaxel	38-48	microRNA 30c-1	Homo sapiens	106-113
29953775-3	2017	Resistence of ovarian cancer cells to paclitaxel and cisplatin is associated with a reduced expression of miR-30c, miR-130, and miR335, which results in activation of M-CSF, the known factor of resistance to cytostatic drugs.	Paclitaxel	38-48	microRNA 335	Homo sapiens	128-134
28714351-7	2017	The expression of NLRP3 was located in CD68-labeled macrophages infiltrating in L4-6 dorsal root ganglia and sciatic nerve, and paclitaxel increased the expression of NLRP3 in macrophage.	Paclitaxel	128-138	Cd68 molecule	Rattus norvegicus	39-43
29069726-6	2017	Here, we have used several approaches to assess the functional relation of TUBB3 overexpression and taxol resistance.	Paclitaxel	100-105	tubulin beta 3 class III	Homo sapiens	75-80
31666085-1	2019	BACKGROUND: Macrophage-derived high mobility group box 1 (HMGB1), a damage-associated molecular pattern (DAMP) protein, plays a key role in the development of chemotherapy-induced peripheral neuropathy (CIPN) caused by paclitaxel in rodents.	Paclitaxel	219-229	high mobility group box 1	Mus musculus	58-63
29069726-7	2017	First, we generated a number of taxol-resistant cell lines, to find that TUBB3 expression was elevated in a resistant cell line (RPE-20) derived from untransformed retinal pigment epithelial (RPE) cells, but the abundance of TUBB3 remained unchanged in four other cell lines after taxol treatment.	Paclitaxel	32-37	tubulin beta 3 class III	Homo sapiens	73-78
29069726-7	2017	First, we generated a number of taxol-resistant cell lines, to find that TUBB3 expression was elevated in a resistant cell line (RPE-20) derived from untransformed retinal pigment epithelial (RPE) cells, but the abundance of TUBB3 remained unchanged in four other cell lines after taxol treatment.	Paclitaxel	281-286	tubulin beta 3 class III	Homo sapiens	73-78
28003747-0	2016	MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell.	Paclitaxel	76-86	microRNA 200c	Homo sapiens	0-13
29069726-9	2017	Indeed, we could show that TUBB3 levels were dynamically regulated upon taxol exposure and withdrawal, unrelated to the resistance phenotype.	Paclitaxel	72-77	tubulin beta 3 class III	Homo sapiens	27-32
31666085-10	2019	Oxaliplatin was 10- to 100-fold less potent than paclitaxel in releasing HMGB1 from macrophage-like RAW264.7 cells.	Paclitaxel	49-59	high mobility group box 1	Mus musculus	73-78
29069726-11	2017	We demonstrate that solely enhancing TUBB3 expression results in a very minor decrease in the sensitivity to taxol.	Paclitaxel	109-114	tubulin beta 3 class III	Homo sapiens	37-42
29069726-13	2017	We find that TUBB3 depletion had a minimal effect on the sensitivity to taxol in one of these cell lines, but had no effect in all of the others.	Paclitaxel	72-77	tubulin beta 3 class III	Homo sapiens	13-18
29069726-14	2017	Based on these findings we propose that TUBB3 overexpression can only marginally affect the sensitivity to taxol in cultured cell lines.	Paclitaxel	107-112	tubulin beta 3 class III	Homo sapiens	40-45
31754402-6	2019	Methods: NLCs targeted to NSCLC cells by a synthetic Luteinizing Hormone-Releasing Hormone (LHRH) decapeptide was used for the simultaneous delivery of paclitaxel (TAX) and a pool of siRNAs targeted to the four major forms of EGFR-TKs.	Paclitaxel	152-162	gonadotropin releasing hormone 1	Homo sapiens	53-90
31754402-6	2019	Methods: NLCs targeted to NSCLC cells by a synthetic Luteinizing Hormone-Releasing Hormone (LHRH) decapeptide was used for the simultaneous delivery of paclitaxel (TAX) and a pool of siRNAs targeted to the four major forms of EGFR-TKs.	Paclitaxel	152-162	gonadotropin releasing hormone 1	Homo sapiens	92-96
31600977-0	2019	The Involvement of the RhoA/ROCK Signaling Pathway in Hypersensitivity Reactions Induced by Paclitaxel Injection.	Paclitaxel	92-102	ras homolog family member A	Mus musculus	23-27
28195448-6	2017	Noteworthy is that "DPA-SCP + white light" achieves a high SER10 value of 1.62, which is much larger than that of the most popularly used radiosensitizers, gold nanoparticles (1.19), and paclitaxel (1.32).	Paclitaxel	187-197	urocortin 3	Homo sapiens	24-27
28072604-2	2017	Here, we found that application of paclitaxel or vincristine increased the protein and mRNA expression of CXCL12 and frequency and amplitude of miniature excitatory post synaptic currents (mEPSCs) in spinal dorsal horn neurons.	Paclitaxel	35-45	chemokine (C-X-C motif) ligand 12	Mus musculus	106-112
28072604-5	2017	In addition, paclitaxel and vincristine both could increase the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and the acetylation of histone H4 in the CXCL12-expressing neurons.	Paclitaxel	13-23	chemokine (C-X-C motif) ligand 12	Mus musculus	183-189
31600977-9	2019	The RhoA/ROCK signaling pathway was activated by paclitaxel injection.	Paclitaxel	49-59	ras homolog family member A	Mus musculus	4-8
31600977-12	2019	Histamine release and RhoA/ROCK pathway activation, rather than complement activation, played an important role in paclitaxel injection-induced HSRs.	Paclitaxel	115-125	ras homolog family member A	Mus musculus	22-26
31490008-0	2019	CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.	Paclitaxel	16-26	nucleus accumbens associated 1	Homo sapiens	56-61
31490008-0	2019	CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.	Paclitaxel	16-26	growth arrest and DNA damage inducible alpha	Homo sapiens	62-68
28221793-0	2017	Correction to Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis.	Paclitaxel	61-71	nucleotide binding oligomerization domain containing 2	Homo sapiens	27-31
31490008-0	2019	CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.	Paclitaxel	80-90	nucleus accumbens associated 1	Homo sapiens	56-61
31490008-0	2019	CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.	Paclitaxel	80-90	growth arrest and DNA damage inducible alpha	Homo sapiens	62-68
31490008-4	2019	In this study, in vitro and in vivo data suggested that CRM197 treatment sensitized paclitaxel-resistant ovarian cancer cells to paclitaxel, at least in part, via nucleus accumbens-1 (NAC-1) and its downstream pathway, DNA damage-inducible 45-gamma interacting protein (Gadd45gip1)/growth arrest and DNA damage-inducible 45 (Gadd45), in A2780/Taxol and SKOV3/Taxol cells.	Paclitaxel	84-94	nucleus accumbens associated 1	Homo sapiens	163-182
31490008-6	2019	This study provides the first mechanism through which CRM197 significantly reverses resistance against paclitaxel by modulating the NAC-1/Gadd45gip1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells, and the mechanism of HB-EGF inhibition as a novel therapeutic strategy for patients with paclitaxel-resistant ovarian cancer.	Paclitaxel	103-113	nucleus accumbens associated 1	Homo sapiens	132-137
28176922-0	2017	Inhibition of Skp2 sensitizes lung cancer cells to paclitaxel.	Paclitaxel	51-61	S-phase kinase associated protein 2	Homo sapiens	14-18
28176922-3	2017	We report here that Skp2 positively regulated mitotic arrest deficient 2 (MAD2) expression and that inhibition of Skp2 sensitizes human lung cancer cells to paclitaxel.	Paclitaxel	157-167	S-phase kinase associated protein 2	Homo sapiens	114-118
31490008-6	2019	This study provides the first mechanism through which CRM197 significantly reverses resistance against paclitaxel by modulating the NAC-1/Gadd45gip1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells, and the mechanism of HB-EGF inhibition as a novel therapeutic strategy for patients with paclitaxel-resistant ovarian cancer.	Paclitaxel	103-113	growth arrest and DNA damage inducible alpha	Homo sapiens	138-144
28176922-7	2017	Most importantly, pharmacological inhibition of Skp2 sensitized A549 and NCI-H1299 cells to paclitaxel.	Paclitaxel	92-102	S-phase kinase associated protein 2	Homo sapiens	48-52
28176922-8	2017	Our results demonstrated that SKP2 positively regulates the gene expression of MAD2 through p27-CDKs-E2F1 signaling pathway and that inhibition of Skp2 sensitizes A549 and NCI-H1299 cells to paclitaxel, suggesting that small molecule inhibitors of Skp2 are potential agents for the treatment of lung cancer with upregulation of Skp2.	Paclitaxel	191-201	S-phase kinase associated protein 2	Homo sapiens	147-151
31490008-6	2019	This study provides the first mechanism through which CRM197 significantly reverses resistance against paclitaxel by modulating the NAC-1/Gadd45gip1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells, and the mechanism of HB-EGF inhibition as a novel therapeutic strategy for patients with paclitaxel-resistant ovarian cancer.	Paclitaxel	167-177	nucleus accumbens associated 1	Homo sapiens	132-137
31490008-6	2019	This study provides the first mechanism through which CRM197 significantly reverses resistance against paclitaxel by modulating the NAC-1/Gadd45gip1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells, and the mechanism of HB-EGF inhibition as a novel therapeutic strategy for patients with paclitaxel-resistant ovarian cancer.	Paclitaxel	167-177	GADD45G interacting protein 1	Homo sapiens	138-148
31490008-6	2019	This study provides the first mechanism through which CRM197 significantly reverses resistance against paclitaxel by modulating the NAC-1/Gadd45gip1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells, and the mechanism of HB-EGF inhibition as a novel therapeutic strategy for patients with paclitaxel-resistant ovarian cancer.	Paclitaxel	167-177	growth arrest and DNA damage inducible alpha	Homo sapiens	138-144
31490008-6	2019	This study provides the first mechanism through which CRM197 significantly reverses resistance against paclitaxel by modulating the NAC-1/Gadd45gip1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells, and the mechanism of HB-EGF inhibition as a novel therapeutic strategy for patients with paclitaxel-resistant ovarian cancer.	Paclitaxel	167-177	nucleus accumbens associated 1	Homo sapiens	132-137
27922665-1	2017	To the best of our knowledge, the present study is the first to demonstrate that treatment of vemurafenib-resistant SKMEL28 (SKMEL28-R) cells with paclitaxel leads to a shift in localization of the E3-ligase BBAP from the cytoplasm to the nucleus, consequently decreasing the metastatic ability of this cell line.	Paclitaxel	147-157	deltex E3 ubiquitin ligase 3L	Homo sapiens	208-212
27878971-0	2016	Pregnane X receptors regulate CYP2C8 and P-glycoprotein to impact on the resistance of NSCLC cells to Taxol.	Paclitaxel	102-107	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	30-36
31490008-6	2019	This study provides the first mechanism through which CRM197 significantly reverses resistance against paclitaxel by modulating the NAC-1/Gadd45gip1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells, and the mechanism of HB-EGF inhibition as a novel therapeutic strategy for patients with paclitaxel-resistant ovarian cancer.	Paclitaxel	167-177	GADD45G interacting protein 1	Homo sapiens	138-148
31490008-6	2019	This study provides the first mechanism through which CRM197 significantly reverses resistance against paclitaxel by modulating the NAC-1/Gadd45gip1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells, and the mechanism of HB-EGF inhibition as a novel therapeutic strategy for patients with paclitaxel-resistant ovarian cancer.	Paclitaxel	167-177	growth arrest and DNA damage inducible alpha	Homo sapiens	138-144
31540428-1	2019	Cytochrome P450 2C8 (CYP2C8) epoxygenase is responsible for the metabolism of over 60 clinically relevant drugs, notably the anticancer drug Taxol (paclitaxel, PAC).	Paclitaxel	148-158	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	21-27
27878971-3	2016	We aim to research the effect of PXR on Taxol-resistant non-small-cell lung cancer (NSCLC cells) via regulating CYP2C8 and P-gp.	Paclitaxel	40-45	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	112-118
31291454-5	2019	In addition, deletion of ULK1 increases chromosome instability and cytotoxicity of paclitaxel, resulting in significant impairment of cancer cell growth.	Paclitaxel	83-93	unc-51 like autophagy activating kinase 1	Homo sapiens	25-29
27878971-13	2016	Furthermore, the hydroxylation products of Taxol analyzed by HPLC were increased in comparison to the SR12813 untreated group, indicating that high expressions of CYP2C8 and P-gp enhanced the resistance of A549 cells to Taxol.	Paclitaxel	43-48	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	163-169
29368881-0	2016	Targeting Therapy of Neuropilin-1 Receptors Overexpressed Breast Cancer by Paclitaxel-Loaded CK3-Conjugated Polymeric Micelles.	Paclitaxel	75-85	neuropilin 1	Homo sapiens	21-33
28090373-0	2016	hGBP-1 Expression Predicts Shorter Progression-Free Survival in Ovarian Cancers, While Contributing to Paclitaxel Resistance.	Paclitaxel	103-113	guanylate binding protein 1	Homo sapiens	0-6
28090373-3	2016	The large GTPase, hGBP-1, has been implicated in paclitaxel resistance in ovarian cell lines.	Paclitaxel	49-59	guanylate binding protein 1	Homo sapiens	18-24
28090373-4	2016	Forced expression of hGBP-1 in SKOV3 ovarian cancer cells protects them from paclitaxel-induced cell death.	Paclitaxel	77-87	guanylate binding protein 1	Homo sapiens	21-27
28090373-7	2016	However, at least 80% of the ovarian tumors that recurred after therapies that included a tax-ane, either paclitaxel or docetaxel, were positive for hGBP-1.	Paclitaxel	106-116	guanylate binding protein 1	Homo sapiens	149-155
31359594-0	2019	Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.	Paclitaxel	44-54	aurora kinase A	Homo sapiens	0-15
28090373-9	2016	Based on these studies, hGBP-1 could prove to be a potential biomarker for paclitaxel resistance in ovarian cancer.	Paclitaxel	75-85	guanylate binding protein 1	Homo sapiens	24-30
27831559-8	2016	In addition, we provided some experimental evidences that miR-17 and miR-20b attenuated breast cancer resistance to taxol in vitro and in vivo models.	Paclitaxel	116-121	microRNA 17	Homo sapiens	58-64
27831559-8	2016	In addition, we provided some experimental evidences that miR-17 and miR-20b attenuated breast cancer resistance to taxol in vitro and in vivo models.	Paclitaxel	116-121	microRNA 20b	Homo sapiens	69-76
27831559-11	2016	Together, our results indicated that loss of miR-17 and miR-20b enhanced breast cancer resistance to taxol by upregulating NCOA3 levels.	Paclitaxel	101-106	microRNA 17	Homo sapiens	45-51
27831559-11	2016	Together, our results indicated that loss of miR-17 and miR-20b enhanced breast cancer resistance to taxol by upregulating NCOA3 levels.	Paclitaxel	101-106	microRNA 20b	Homo sapiens	56-63
27831559-12	2016	Our study suggested miR-17, miR-20b and NCOA3 may serve as some predictive biomarkers and potential therapeutic targets in taxol-resistant breast cancer treatment.	Paclitaxel	123-128	microRNA 17	Homo sapiens	20-26
27831559-12	2016	Our study suggested miR-17, miR-20b and NCOA3 may serve as some predictive biomarkers and potential therapeutic targets in taxol-resistant breast cancer treatment.	Paclitaxel	123-128	microRNA 20b	Homo sapiens	28-35
31359594-7	2019	We observe that paclitaxel-resistant TNBC cells exhibit high expression of Aurora-A and FOXM1.	Paclitaxel	16-26	aurora kinase A	Homo sapiens	75-83
31359594-8	2019	Overexpression of Aurora-A offers TNBC cells an additional growth advantage and protection against paclitaxel.	Paclitaxel	99-109	aurora kinase A	Homo sapiens	18-26
31359594-11	2019	In conclusion, our study reveals additional mechanism through which Aurora-A regulates FOXM1 and provides a new therapeutic strategy to treat paclitaxel-resistant triple-negative breast cancer.	Paclitaxel	142-152	aurora kinase A	Homo sapiens	68-76
31416135-6	2019	The paclitaxel-combined XAV939 treatment induced apoptosis by suppressing Bcl-2 and by increasing the cleavage of caspases-3 and PARP.	Paclitaxel	4-14	collagen type XI alpha 2 chain	Homo sapiens	129-133
27708225-9	2016	NAG-1 and pro-inflammatory NF-kappaB were positively associated with resistance to paclitaxel in MyD88-positive type I EOC cells.	Paclitaxel	83-93	MYD88 innate immune signal transduction adaptor	Homo sapiens	97-102
31123858-3	2019	OBJECTIVE: To evaluate the role of ABCB1 1236C&gt;T, 3435C&gt;T; CYP2C8*3; CYP3A5*3C variants on paclitaxel/carboplatin toxicities.	Paclitaxel	97-107	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	65-71
31423204-0	2019	Programmed cell death factor 4 enhances the chemosensitivity of colorectal cancer cells to Taxol.	Paclitaxel	91-96	programmed cell death 4	Homo sapiens	0-30
27629142-0	2016	Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis.	Paclitaxel	47-57	heat shock protein 86, pseudogene 1	Mus musculus	30-35
27629142-0	2016	Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis.	Paclitaxel	47-57	mitogen-activated protein kinase 14	Mus musculus	136-139
31423204-3	2019	In this study, the effect of PDCD4 in the sensitivity of CRC to the chemotherapy drug Taxol was investigated.	Paclitaxel	86-91	programmed cell death 4	Homo sapiens	29-34
27629142-4	2016	In this study, we generated a cell line of acquired resistance to paclitaxel therapy, A2780T, which is cross-resistant to other antimitotic drugs, such as PLK1 inhibitor or AURKA inhibitor.	Paclitaxel	66-76	aurora kinase A	Mus musculus	173-178
31423204-5	2019	Upregulation of PDCD4 significantly enhanced the sensitivity of CRC cells to Taxol, by partially contributing to pro-apoptosis and anti-invasion pathways, both through upregulation of the apoptosis-associated protein Bax, and downregulation of the anti-apoptosis protein Bcl-2 and invasion-associated proteins MMP-9.	Paclitaxel	77-82	programmed cell death 4	Homo sapiens	16-21
27687545-0	2016	Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel.	Paclitaxel	13-23	keratin 6A	Homo sapiens	73-76
27687545-3	2016	Here, we analyzed the mechanism of PTX resistance using a human prostate cancer cell line, PC3, and its PTX-resistant subline, PC3-PR.	Paclitaxel	35-38	keratin 6A	Homo sapiens	91-94
27687545-3	2016	Here, we analyzed the mechanism of PTX resistance using a human prostate cancer cell line, PC3, and its PTX-resistant subline, PC3-PR.	Paclitaxel	35-38	keratin 6A	Homo sapiens	127-130
27687545-3	2016	Here, we analyzed the mechanism of PTX resistance using a human prostate cancer cell line, PC3, and its PTX-resistant subline, PC3-PR.	Paclitaxel	104-107	keratin 6A	Homo sapiens	127-130
31333464-5	2019	Paclitaxel (PTX, 2 mg/kg), given on days 0, 2, 4, and 6, produced robust mechanical allodynia in both sexes at 2 weeks.	Paclitaxel	0-10	paired-like homeodomain transcription factor 2	Mus musculus	12-18
31646803-10	2019	Overexpression of miR-335 can increase the sensitivity of tumor cells to paclitaxel, cisplatin and doxorubicin, and improve the effect of chemotherapy.	Paclitaxel	73-83	microRNA 335	Homo sapiens	18-25
27687545-4	2016	Compared with PC3, PC3-PR exhibited some unique phenotypes that might be associated with PTX resistance, including decreased expression of acetylated alpha-tubulin and the cell cycle regulator p21, and increased expression of betaIII tubulin, histone deacetylase 6 (HDAC6), and the anti-apoptotic protein Bcl2.	Paclitaxel	89-92	keratin 6A	Homo sapiens	19-22
27770785-12	2016	Vimentin phosphorylation catalyzed by cell division cycle 2 (Cdc2) kinase was induced from Schwann cells in the sciatic nerves after taxol injection and crush injury, and phospho-vimentin levels were further upregulated by BGJTD treatment.	Paclitaxel	133-138	vimentin	Rattus norvegicus	0-8
27737687-0	2016	LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.	Paclitaxel	17-27	baculoviral IAP repeat containing 2	Homo sapiens	59-64
31141661-5	2019	The PLGLAG linker was cleavable by the enzyme matrix metalloproteinase-2 (MMP-2) in the tumor tissue, causing CXB release and turning the negatively charged nanosphere into a positively charged one to facilitate PTX delivery into cancer cells.	Paclitaxel	212-215	matrix metallopeptidase 2	Homo sapiens	46-72
31141661-5	2019	The PLGLAG linker was cleavable by the enzyme matrix metalloproteinase-2 (MMP-2) in the tumor tissue, causing CXB release and turning the negatively charged nanosphere into a positively charged one to facilitate PTX delivery into cancer cells.	Paclitaxel	212-215	matrix metallopeptidase 2	Homo sapiens	74-79
30952674-7	2019	In addition, JAQ1 F(ab)2-mediated GPVI inhibition increased intratumoral accumulation of coadministered chemotherapeutic agents, such as Doxil and paclitaxel, thereby resulting in a profound antitumor effect.	Paclitaxel	147-157	glycoprotein 6 (platelet)	Mus musculus	34-38
27633667-10	2016	RESULTS: In vitro treatment with LBH589 significantly reduced the viability of both taxol-sensitive and taxol-resistant ovarian cancer cell lines (p &lt; 0.01).	Paclitaxel	84-89	limb-bud and heart	Mus musculus	33-36
27633667-10	2016	RESULTS: In vitro treatment with LBH589 significantly reduced the viability of both taxol-sensitive and taxol-resistant ovarian cancer cell lines (p &lt; 0.01).	Paclitaxel	104-109	limb-bud and heart	Mus musculus	33-36
27458019-9	2016	Paclitaxel treatment significantly increased the protein level of GluN2A and phosphorylated GluN1 in the dorsal root ganglion.	Paclitaxel	0-10	glutamate ionotropic receptor NMDA type subunit 1	Rattus norvegicus	92-97
31160603-0	2019	EPHB6 mutation induces cell adhesion-mediated paclitaxel resistance via EPHA2 and CDH11 expression.	Paclitaxel	46-56	EPH receptor B6	Homo sapiens	0-5
31160603-3	2019	Here, the recapitulation of pharmacogenomic data revealed that the mutation of EPHB6 is associated with paclitaxel resistance in cancer cells.	Paclitaxel	104-114	EPH receptor B6	Homo sapiens	79-84
31160603-4	2019	Experimental data confirmed that the EPHB6 mutation induces paclitaxel resistance in various cancer types, including lung, skin, and liver cancers.	Paclitaxel	60-70	EPH receptor B6	Homo sapiens	37-42
27498772-0	2016	Quercetin ameliorates paclitaxel-induced neuropathic pain by stabilizing mast cells, and subsequently blocking PKCepsilon-dependent activation of TRPV1.	Paclitaxel	22-32	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	146-151
27498772-12	2016	Furthermore, quercetin administration dose-dependently suppressed the increased expression levels of PKCepsilon and TRPV1 in the spinal cords and DRGs of paclitaxel-treated rats and mice.	Paclitaxel	154-164	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	116-121
31160603-5	2019	EPHB6 mutation-induced paclitaxel resistance was mediated by an interaction with EPHA2, which promotes c-Jun N-terminal kinase (JNK)-mediated cadherin 11 (CDH11) expression.	Paclitaxel	23-33	EPH receptor B6	Homo sapiens	0-5
31160603-8	2019	The present results suggest that the EPHB6 mutation and its downstream EPHA2/JNK/CDH11/RhoA/FAK signaling axis are novel diagnostic and therapeutic targets for overcoming paclitaxel resistance in cancer patients.	Paclitaxel	171-181	EPH receptor B6	Homo sapiens	37-42
27059733-10	2016	In summary, our study elucidated that exogenous galectin-3 might induce paclitaxel resistance through TLR4 signaling activation by inhibiting TLR4-Cav-1 interaction, revealing a novel insight into paclitaxel resistance induction.	Paclitaxel	197-207	galectin 3	Homo sapiens	48-58
31160603-8	2019	The present results suggest that the EPHB6 mutation and its downstream EPHA2/JNK/CDH11/RhoA/FAK signaling axis are novel diagnostic and therapeutic targets for overcoming paclitaxel resistance in cancer patients.	Paclitaxel	171-181	protein tyrosine kinase 2	Homo sapiens	92-95
30244336-10	2019	Western blot and RT-PCR studies showed that only the LARP1 and CCND1 genes were over-expressed up to 2-5 times in all paclitaxel-resistant cell lines compared to the other investigated genes.	Paclitaxel	118-128	La ribonucleoprotein 1, translational regulator	Homo sapiens	53-58
27328733-6	2016	Downregulation of nuclear S100A4 by low-dose paclitaxel was associated with a strong reduction in RhoA and Cdc42 GTPase activity, MT1-MMP expression, and MMP-9 secretion.	Paclitaxel	45-55	cell division cycle 42	Homo sapiens	107-112
27328733-6	2016	Downregulation of nuclear S100A4 by low-dose paclitaxel was associated with a strong reduction in RhoA and Cdc42 GTPase activity, MT1-MMP expression, and MMP-9 secretion.	Paclitaxel	45-55	matrix metallopeptidase 14	Homo sapiens	130-137
26883251-9	2016	Compared with vector cell, overexpressed linc-ROR cell presented decreased sensibility of 5-FU and paclitaxel with decreased E-cadherin expression, increased Vimentin, N-cadherin expression, and invasion ability (all P &lt; 0.05).	Paclitaxel	99-109	long intergenic non-protein coding RNA, regulator of reprogramming	Homo sapiens	41-49
30244336-10	2019	Western blot and RT-PCR studies showed that only the LARP1 and CCND1 genes were over-expressed up to 2-5 times in all paclitaxel-resistant cell lines compared to the other investigated genes.	Paclitaxel	118-128	cyclin D1	Homo sapiens	63-68
31156650-6	2019	However, paclitaxel could induce robust activation of caspase-1 in BMDMs in the presence of NLRP3 inflammasome-activating signal 2, such as ATP or nigericin.	Paclitaxel	9-19	caspase 1	Mus musculus	54-63
27474498-7	2016	administration of the anti-HMGB1-neutralizing antibody or recombinant human soluble thrombomodulin (rhsTM), known to inactivate HMGB1, prevented the development of hyperalgesia and/or allodynia induced by paclitaxel or vincristine in rats.	Paclitaxel	205-215	high mobility group box 1	Homo sapiens	27-32
30387134-0	2019	Toll-like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3-UNC93B1-IFN-beta signaling axis in paclitaxel-resistant colon cancer.	Paclitaxel	135-145	toll like receptor 3	Homo sapiens	0-20
27474498-7	2016	administration of the anti-HMGB1-neutralizing antibody or recombinant human soluble thrombomodulin (rhsTM), known to inactivate HMGB1, prevented the development of hyperalgesia and/or allodynia induced by paclitaxel or vincristine in rats.	Paclitaxel	205-215	high mobility group box 1	Homo sapiens	128-133
30387134-0	2019	Toll-like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3-UNC93B1-IFN-beta signaling axis in paclitaxel-resistant colon cancer.	Paclitaxel	135-145	toll like receptor 3	Homo sapiens	95-99
30387134-0	2019	Toll-like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3-UNC93B1-IFN-beta signaling axis in paclitaxel-resistant colon cancer.	Paclitaxel	135-145	interferon beta 1	Homo sapiens	108-116
30387134-3	2019	Herein, we tested whether the TLR3 agonist polyinosinic: polycytidylic acid (poly I:C) can improve chemotherapeutic efficacy in paclitaxel (PTX) resistant cell lines.	Paclitaxel	128-138	toll like receptor 3	Homo sapiens	30-34
30387134-3	2019	Herein, we tested whether the TLR3 agonist polyinosinic: polycytidylic acid (poly I:C) can improve chemotherapeutic efficacy in paclitaxel (PTX) resistant cell lines.	Paclitaxel	140-143	toll like receptor 3	Homo sapiens	30-34
30387134-6	2019	In addition, when TLR3 was overexpressed in HCT-8/PTX cells, we found that TLR3 contributed to the production of IFN-beta that reduced cell viability, and poly I:C preferentially activated the TLR3-UNC93B1 signaling pathway to mediate this effect.	Paclitaxel	50-53	toll like receptor 3	Homo sapiens	18-22
30387134-6	2019	In addition, when TLR3 was overexpressed in HCT-8/PTX cells, we found that TLR3 contributed to the production of IFN-beta that reduced cell viability, and poly I:C preferentially activated the TLR3-UNC93B1 signaling pathway to mediate this effect.	Paclitaxel	50-53	toll like receptor 3	Homo sapiens	75-79
30387134-6	2019	In addition, when TLR3 was overexpressed in HCT-8/PTX cells, we found that TLR3 contributed to the production of IFN-beta that reduced cell viability, and poly I:C preferentially activated the TLR3-UNC93B1 signaling pathway to mediate this effect.	Paclitaxel	50-53	interferon beta 1	Homo sapiens	113-121
28003747-10	2016	After BCSC were transfected with SLN/miR-200c, the expression of class III beta-tubulin was effectively downregulated and the cellular cytotoxicity of PTX-loaded NLC (NLC/PTX) against BCSC was enhanced significantly (**P&lt;0.01).	Paclitaxel	151-154	microRNA 200c	Homo sapiens	37-45
30387134-6	2019	In addition, when TLR3 was overexpressed in HCT-8/PTX cells, we found that TLR3 contributed to the production of IFN-beta that reduced cell viability, and poly I:C preferentially activated the TLR3-UNC93B1 signaling pathway to mediate this effect.	Paclitaxel	50-53	toll like receptor 3	Homo sapiens	75-79
28003747-10	2016	After BCSC were transfected with SLN/miR-200c, the expression of class III beta-tubulin was effectively downregulated and the cellular cytotoxicity of PTX-loaded NLC (NLC/PTX) against BCSC was enhanced significantly (**P&lt;0.01).	Paclitaxel	151-154	tubulin beta 3 class III	Homo sapiens	65-87
28003747-10	2016	After BCSC were transfected with SLN/miR-200c, the expression of class III beta-tubulin was effectively downregulated and the cellular cytotoxicity of PTX-loaded NLC (NLC/PTX) against BCSC was enhanced significantly (**P&lt;0.01).	Paclitaxel	171-174	microRNA 200c	Homo sapiens	37-45
30387134-7	2019	Moreover, cotreatment of poly I:C and PTX acted synergistically to induce cell apoptosis of HCT-8/PTX via upregulating the expression of TLR3 and its molecular chaperone UNC93B1, assisting in the secretion of IFN-beta.	Paclitaxel	38-41	toll like receptor 3	Homo sapiens	137-141
28003747-10	2016	After BCSC were transfected with SLN/miR-200c, the expression of class III beta-tubulin was effectively downregulated and the cellular cytotoxicity of PTX-loaded NLC (NLC/PTX) against BCSC was enhanced significantly (**P&lt;0.01).	Paclitaxel	171-174	tubulin beta 3 class III	Homo sapiens	65-87
26915688-7	2016	Furthermore, we found that knockdown of RhoB expression by RhoB siRNA not only significantly reduced hypoxia-enhanced cell migration and cell survival in hypoxia but also increased the sensitivity of cell to paclitaxel (PTX), a chemotherapeutic agent, and reduced Dex-enhanced resistance to PTX-chemotherapy in A549 cells.	Paclitaxel	208-218	ras homolog family member B	Rattus norvegicus	40-44
26915688-7	2016	Furthermore, we found that knockdown of RhoB expression by RhoB siRNA not only significantly reduced hypoxia-enhanced cell migration and cell survival in hypoxia but also increased the sensitivity of cell to paclitaxel (PTX), a chemotherapeutic agent, and reduced Dex-enhanced resistance to PTX-chemotherapy in A549 cells.	Paclitaxel	208-218	ras homolog family member B	Rattus norvegicus	59-63
30387134-7	2019	Moreover, cotreatment of poly I:C and PTX acted synergistically to induce cell apoptosis of HCT-8/PTX via upregulating the expression of TLR3 and its molecular chaperone UNC93B1, assisting in the secretion of IFN-beta.	Paclitaxel	38-41	interferon beta 1	Homo sapiens	209-217
26915688-7	2016	Furthermore, we found that knockdown of RhoB expression by RhoB siRNA not only significantly reduced hypoxia-enhanced cell migration and cell survival in hypoxia but also increased the sensitivity of cell to paclitaxel (PTX), a chemotherapeutic agent, and reduced Dex-enhanced resistance to PTX-chemotherapy in A549 cells.	Paclitaxel	220-223	ras homolog family member B	Rattus norvegicus	40-44
26915688-7	2016	Furthermore, we found that knockdown of RhoB expression by RhoB siRNA not only significantly reduced hypoxia-enhanced cell migration and cell survival in hypoxia but also increased the sensitivity of cell to paclitaxel (PTX), a chemotherapeutic agent, and reduced Dex-enhanced resistance to PTX-chemotherapy in A549 cells.	Paclitaxel	220-223	ras homolog family member B	Rattus norvegicus	59-63
30387134-7	2019	Moreover, cotreatment of poly I:C and PTX acted synergistically to induce cell apoptosis of HCT-8/PTX via upregulating the expression of TLR3 and its molecular chaperone UNC93B1, assisting in the secretion of IFN-beta.	Paclitaxel	98-101	toll like receptor 3	Homo sapiens	137-141
26915688-7	2016	Furthermore, we found that knockdown of RhoB expression by RhoB siRNA not only significantly reduced hypoxia-enhanced cell migration and cell survival in hypoxia but also increased the sensitivity of cell to paclitaxel (PTX), a chemotherapeutic agent, and reduced Dex-enhanced resistance to PTX-chemotherapy in A549 cells.	Paclitaxel	291-294	ras homolog family member B	Rattus norvegicus	40-44
26915688-7	2016	Furthermore, we found that knockdown of RhoB expression by RhoB siRNA not only significantly reduced hypoxia-enhanced cell migration and cell survival in hypoxia but also increased the sensitivity of cell to paclitaxel (PTX), a chemotherapeutic agent, and reduced Dex-enhanced resistance to PTX-chemotherapy in A549 cells.	Paclitaxel	291-294	ras homolog family member B	Rattus norvegicus	59-63
27764753-0	2016	Inactivation of transforming growth factor-beta-activated kinase 1 promotes taxol efficacy in ovarian cancer cells.	Paclitaxel	76-81	mitogen-activated protein kinase kinase kinase 7	Mus musculus	16-66
27764753-4	2016	Here, we showed that in vitro, taxol-resistant cells expressed higher TAK1, and the ratio of p-TAK1/TAK1 positively associated with taxol resistance in ovarian cancer cells.	Paclitaxel	31-36	mitogen-activated protein kinase kinase kinase 7	Mus musculus	70-74
27764753-4	2016	Here, we showed that in vitro, taxol-resistant cells expressed higher TAK1, and the ratio of p-TAK1/TAK1 positively associated with taxol resistance in ovarian cancer cells.	Paclitaxel	31-36	mitogen-activated protein kinase kinase kinase 7	Mus musculus	95-99
26915688-9	2016	RhoB also enhanced the resistance of cell to PTX-chemotherapy and mediated the pro-survival effect of Dex.	Paclitaxel	45-48	ras homolog family member B	Rattus norvegicus	0-4
26869361-12	2016	Moreover, a 2 nM dose of paclitaxel for 24 h significantly inhibited the TGF-beta1-stimulated activation of Smad2/3, JNK and ERK1/2 in IMCD cells.	Paclitaxel	25-35	mitogen activated protein kinase 3	Rattus norvegicus	125-131
27764753-4	2016	Here, we showed that in vitro, taxol-resistant cells expressed higher TAK1, and the ratio of p-TAK1/TAK1 positively associated with taxol resistance in ovarian cancer cells.	Paclitaxel	31-36	mitogen-activated protein kinase kinase kinase 7	Mus musculus	95-99
27764753-4	2016	Here, we showed that in vitro, taxol-resistant cells expressed higher TAK1, and the ratio of p-TAK1/TAK1 positively associated with taxol resistance in ovarian cancer cells.	Paclitaxel	132-137	mitogen-activated protein kinase kinase kinase 7	Mus musculus	95-99
27764753-4	2016	Here, we showed that in vitro, taxol-resistant cells expressed higher TAK1, and the ratio of p-TAK1/TAK1 positively associated with taxol resistance in ovarian cancer cells.	Paclitaxel	132-137	mitogen-activated protein kinase kinase kinase 7	Mus musculus	95-99
27764753-5	2016	Inactivation of TAK1 by inhibitor 5Z-7-oxozeaenol or gene knockdown sensitized taxol cytotoxicity in vitro, promoting cell apoptosis and mitosis arrest.	Paclitaxel	79-84	mitogen-activated protein kinase kinase kinase 7	Mus musculus	16-20
30387134-7	2019	Moreover, cotreatment of poly I:C and PTX acted synergistically to induce cell apoptosis of HCT-8/PTX via upregulating the expression of TLR3 and its molecular chaperone UNC93B1, assisting in the secretion of IFN-beta.	Paclitaxel	98-101	interferon beta 1	Homo sapiens	209-217
27764753-8	2016	Thus, targeting TAK1 pathway is a promising strategy to enhance taxol response in ovarian cancer treatment.	Paclitaxel	64-69	mitogen-activated protein kinase kinase kinase 7	Mus musculus	16-20
30387134-9	2019	In conclusion, our studies demonstrate that poly I:C reinforces the potency of cytotoxic chemotherapeutics in PTX-resistant cell line through the TLR3-UNC93B1-IFN-beta signaling pathway, which supplies a novel mechanism of poly I:C for the chemotherapy sensitizing effect in a PTX-resistant tumor.	Paclitaxel	110-113	toll like receptor 3	Homo sapiens	146-150
27878971-13	2016	Furthermore, the hydroxylation products of Taxol analyzed by HPLC were increased in comparison to the SR12813 untreated group, indicating that high expressions of CYP2C8 and P-gp enhanced the resistance of A549 cells to Taxol.	Paclitaxel	220-225	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	163-169
27878971-15	2016	The cell viability, cell proliferation, and Taxol metabolites were regulated by the expressions of PXR, P-gp, and CYP2C8.	Paclitaxel	44-49	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	114-120
30387134-9	2019	In conclusion, our studies demonstrate that poly I:C reinforces the potency of cytotoxic chemotherapeutics in PTX-resistant cell line through the TLR3-UNC93B1-IFN-beta signaling pathway, which supplies a novel mechanism of poly I:C for the chemotherapy sensitizing effect in a PTX-resistant tumor.	Paclitaxel	110-113	interferon beta 1	Homo sapiens	159-167
27878971-16	2016	That is, PXR expression has an important effect on the resistance of NSCLC cells to Taxol via upregulating P-gp and CYP2C8.	Paclitaxel	84-89	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	116-122
30471427-6	2019	Analyses of DRG tissues showed that MMP9 mAb significantly decreased oxidative stress and neuroinflammatory mediators interleukin-6 and tumor necrosis factor alpha, as well as prevented paclitaxel-induced loss of intraepidermal nerve fibers.	Paclitaxel	186-196	matrix metallopeptidase 9	Mus musculus	36-40
30782852-2	2019	In the past decade, OATPs, primarily OATP1A2, OATP1B1, and OATP1B3, have emerged as potential mediators of chemotherapy disposition, including drugs such as methotrexate, doxorubicin, paclitaxel, docetaxel, irinotecan and its important metabolite 7-ethyl-10-hydroxycamptothecin, and certain tyrosine kinase inhibitors.	Paclitaxel	184-194	solute carrier organic anion transporter family member 1A2	Homo sapiens	37-44
28051262-10	2016	MiR-379 overexpression sensitized Huh7 and HepG2 cells to 5-FU, PTX and DOX and also enhanced DOX-induced cell apoptosis.	Paclitaxel	64-67	microRNA 379	Homo sapiens	0-7
27175797-0	2016	Skp2 is associated with paclitaxel resistance in prostate cancer cells.	Paclitaxel	24-34	S-phase kinase associated protein 2	Homo sapiens	0-4
27175797-4	2016	In the present study, we investigated the role of Skp2 in paclitaxel-resistant DU145-TxR or PC-3-TxR cells by Skp2 silencing or using Skp2 inhibitors.	Paclitaxel	58-68	S-phase kinase associated protein 2	Homo sapiens	50-54
27175797-6	2016	Knockdown of Skp2 or Skp2 inhibitor treatment in DU145-TxR or PC-3-TxR cells restored paclitaxel sensitivity.	Paclitaxel	86-96	S-phase kinase associated protein 2	Homo sapiens	13-17
27175797-6	2016	Knockdown of Skp2 or Skp2 inhibitor treatment in DU145-TxR or PC-3-TxR cells restored paclitaxel sensitivity.	Paclitaxel	86-96	S-phase kinase associated protein 2	Homo sapiens	21-25
27175797-10	2016	These results suggest that Skp2 is associated with prostate cancer cell resistance to paclitaxel.	Paclitaxel	86-96	S-phase kinase associated protein 2	Homo sapiens	27-31
27255186-5	2016	Bel 7402 cell resistance to paclitaxel was associated with the expression of the "stemness" markers CD44 and CD133.	Paclitaxel	28-38	prominin 1	Homo sapiens	109-114
27840924-4	2016	The present study aimed to examine the roles of DEC1 and DEC2 in human prostate cancer DU145 and PC-3 cells that were treated with paclitaxel.	Paclitaxel	131-141	deleted in esophageal cancer 1	Homo sapiens	48-52
27840924-5	2016	The expression of DEC1 and DEC2 was decreased in DU145 cells but was increased in PC-3 cells when treated with paclitaxel.	Paclitaxel	111-121	deleted in esophageal cancer 1	Homo sapiens	18-22
30658067-0	2019	Investigation of the potential theranostic role of KDM5B/miR-29c signaling axis in paclitaxel resistant endometrial carcinoma.	Paclitaxel	83-93	lysine demethylase 5B	Homo sapiens	51-56
28002342-4	2016	Patients in arm 2 (n = 90) received 6 to 8 cycles of paclitaxel and carboplatin.	Paclitaxel	53-63	Jupiter microtubule associated homolog 1	Homo sapiens	12-17
27736846-0	2016	Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.	Paclitaxel	105-115	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	13-19
27736846-9	2016	When adjusted for age, body surface area and total cumulative paclitaxel dose, CYP2C8*3 carriers had an increased risk of peripheral neuropathy (HR=1.59, P=0.045).	Paclitaxel	62-72	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	79-85
27831559-0	2016	Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3.	Paclitaxel	90-95	microRNA 17	Homo sapiens	24-35
26551762-0	2016	The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.	Paclitaxel	76-86	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	12-18
26551762-1	2016	The aim of the present study was to further investigate a previously identified metabolic interaction between losartan and paclitaxel, which is one of the marker substrates of CYP2C8, by using human liver microsomes (HLMs) from donors with different CYP2C8 and CYP2C9 genotypes.	Paclitaxel	123-133	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	176-182
26551762-9	2016	Further study is needed to define the effect of CYP2C8 genotypes on losartan-paclitaxel interaction.	Paclitaxel	77-87	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	48-54
27831559-0	2016	Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3.	Paclitaxel	90-95	microRNA 20b	Homo sapiens	40-52
27831559-7	2016	By real-time PCR analysis, we found that miR-17 and miR-20b were significantly reduced in taxol-resistant breast cancer tissues and cells.	Paclitaxel	90-95	microRNA 17	Homo sapiens	41-47
27831559-7	2016	By real-time PCR analysis, we found that miR-17 and miR-20b were significantly reduced in taxol-resistant breast cancer tissues and cells.	Paclitaxel	90-95	microRNA 20b	Homo sapiens	52-59
26036724-0	2016	Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma.	Paclitaxel	82-92	tyrosine aminotransferase	Homo sapiens	37-40
26036724-2	2016	Liposomes modified with transferrin (Tf) and cell-penetrating peptide TAT was prepared, which encapsulated two kinds of chemotherapy drugs, paclitaxel and doxorubicin (Tf/TAT-PTX/DOX-LP).	Paclitaxel	140-150	tyrosine aminotransferase	Homo sapiens	70-73
27754697-2	2016	This study is aimed to determine the impact of the MBP hematopoietic PBX-interaction protein (HPIP) on breast cancer cell sensitivity to paclitaxel.	Paclitaxel	137-147	myelin basic protein	Homo sapiens	51-54
30658067-0	2019	Investigation of the potential theranostic role of KDM5B/miR-29c signaling axis in paclitaxel resistant endometrial carcinoma.	Paclitaxel	83-93	microRNA 29c	Homo sapiens	57-64
30658067-2	2019	In this study, we explored the clinical significance of Histone demethylase KDM5B gene and its effects on paclitaxel (PTX) sensitivity in EC.	Paclitaxel	106-116	lysine demethylase 5B	Homo sapiens	76-81
30658067-2	2019	In this study, we explored the clinical significance of Histone demethylase KDM5B gene and its effects on paclitaxel (PTX) sensitivity in EC.	Paclitaxel	118-121	lysine demethylase 5B	Homo sapiens	76-81
30658067-4	2019	The elevated KDM5B expression was associated with high pathological grade and low PTX sensitivity.	Paclitaxel	82-85	lysine demethylase 5B	Homo sapiens	13-18
30658067-5	2019	The functional role of KDM5B in PTX-resistant Ishikawa-R and HEC1A-R cells were examined by gene silencing experiments.	Paclitaxel	32-35	lysine demethylase 5B	Homo sapiens	23-28
27791151-2	2016	Here, we report increased expression of the cytochrome-P450-epoxygenase CYP2J6 and increased concentrations of its linoleic acid metabolite 9,10-EpOME (9,10-epoxy-12Z-octadecenoic acid) in dorsal root ganglia (DRGs) of paclitaxel-treated mice as a model of CIPNP.	Paclitaxel	219-229	cytochrome P450, family 2, subfamily j, polypeptide 6	Mus musculus	72-78
26581910-5	2016	Our results showed that miR-143, but not let-7b, increased sensitization of KRAS mutant tumor cells to paclitaxel.	Paclitaxel	103-113	microRNA 143	Homo sapiens	24-31
30658067-6	2019	RESULTS: Knockdown of KDM5B resulted in the re-sensitization towards paclitaxel in both resistant cell lines.	Paclitaxel	69-79	lysine demethylase 5B	Homo sapiens	22-27
30658067-8	2019	The up-regulation of miR-29c-3p using exogenous mimic molecules markedly increased PTX sensitivity in both cell lines and reduced expression of KDM5B while the inhibitor of miR-29-3p resulted in the opposite effects.	Paclitaxel	83-86	microRNA 29c	Homo sapiens	21-28
30658067-9	2019	Notably, we also demonstrated that the level of miR-29c-3p was inversely correlated to the invasive, colony-forming abilities and PTX resistance in both cell lines.	Paclitaxel	130-133	microRNA 29c	Homo sapiens	48-55
26820132-0	2016	Erratum to: Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.	Paclitaxel	63-73	MYD88 innate immune signal transduction adaptor	Homo sapiens	36-41
30658067-11	2019	In conclusion, high-expression of KDM5B is associated with the poor response to PTX in EC patients.	Paclitaxel	80-83	lysine demethylase 5B	Homo sapiens	34-39
30658067-12	2019	Silencing of KDM5B led to the reversal of PTX resistance through miR-29c-3p/KDM5B pathway in EC.	Paclitaxel	42-45	lysine demethylase 5B	Homo sapiens	13-18
27090655-9	2016	Analyzing mechanism of action interference of the mTOR inhibitor sirolimus shows specific impact on the drug resistance signature imposed by cisplatin and paclitaxel, further holding evidence for a synthetic lethal interaction to paclitaxel mechanism of action involving cyclin D1.	Paclitaxel	230-240	cyclin D1	Homo sapiens	271-280
27626163-5	2016	Overexpression of galectin-3 increased the resistance for cisplatin and paclitaxel-induced cell death.	Paclitaxel	72-82	galectin 3	Homo sapiens	18-28
26930229-5	2016	The results indicate that paclitaxel could apparently inhibit the cell viability, induces the elevation of S and G2/M phases of HTFs, and downregulates the expression of both TGF-beta1 and CTGF.	Paclitaxel	26-36	cellular communication network factor 2	Homo sapiens	189-193
30658067-12	2019	Silencing of KDM5B led to the reversal of PTX resistance through miR-29c-3p/KDM5B pathway in EC.	Paclitaxel	42-45	microRNA 29c	Homo sapiens	65-72
26930229-6	2016	Meanwhile, the levels of fibronectin extra domain A (EDA), collagen and collagen lattice contraction were apparently reduced after treatment with paclitaxel.	Paclitaxel	146-156	ectodysplasin A	Homo sapiens	53-56
26930229-7	2016	Overall, paclitaxel could apparently inhibit the proliferation of HTFs and leads to cell cycle arrest at both S and G2/M phases, attenuates the generation of collagen and collagen lattice contraction, decreases the expressions of TGF-beta1, CTGF and fibronectin EDA.	Paclitaxel	9-19	cellular communication network factor 2	Homo sapiens	241-245
27714074-0	2016	miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC).	Paclitaxel	39-49	microRNA 186	Homo sapiens	0-7
30658067-12	2019	Silencing of KDM5B led to the reversal of PTX resistance through miR-29c-3p/KDM5B pathway in EC.	Paclitaxel	42-45	lysine demethylase 5B	Homo sapiens	76-81
27714074-6	2016	We found that overexpression of miR-186 sensitized A549 and H1299 cells to paclitaxel, whereas inhibition of miR-186 conferred resistance in these cells.	Paclitaxel	75-85	microRNA 186	Homo sapiens	32-39
26930229-7	2016	Overall, paclitaxel could apparently inhibit the proliferation of HTFs and leads to cell cycle arrest at both S and G2/M phases, attenuates the generation of collagen and collagen lattice contraction, decreases the expressions of TGF-beta1, CTGF and fibronectin EDA.	Paclitaxel	9-19	ectodysplasin A	Homo sapiens	262-265
30827506-6	2019	The ascorbic acid restriction enhanced the somatic and visceral hypersensitivity following intraplantar and intracolonic NaHS, respectively, and paclitaxel-induced neuropathy in GNL/SMP30-knockout mice, while it had no such effect in wild-type mice.	Paclitaxel	145-155	regucalcin	Mus musculus	182-187
26910911-5	2016	MiR-27b, up-regulated by E7, promoted CaSki and SiHa cell proliferation and invasion, inhibit paclitaxel-induced apoptosis.	Paclitaxel	94-104	microRNA 27b	Homo sapiens	0-7
26910911-9	2016	Our study demonstrated that HPV16 E7 could increase DGCR8 to promote the generation of miR-27b, which accelerated cell proliferation and inhibited paclitaxel-induced cell apoptosis through down-regulating PLK2.	Paclitaxel	147-157	microRNA 27b	Homo sapiens	87-94
27636161-2	2016	In this study, by utilizing the overexpression of Interleukin 13 receptor alpha2 (IL-13Ralpha2) on the glioma cells and heparan sulfate on neovascular endothelial cells, we developed a paclitaxel (PTX) loaded Pep-1 and CGKRK peptide-modified PEG-PLGA nanoparticle (PC-NP-PTX) for glioma cells and neovasculature dual-targeted chemotherapy to enhance the antiglioma efficacy.	Paclitaxel	185-195	interleukin 13 receptor subunit alpha 2	Homo sapiens	50-80
27636161-2	2016	In this study, by utilizing the overexpression of Interleukin 13 receptor alpha2 (IL-13Ralpha2) on the glioma cells and heparan sulfate on neovascular endothelial cells, we developed a paclitaxel (PTX) loaded Pep-1 and CGKRK peptide-modified PEG-PLGA nanoparticle (PC-NP-PTX) for glioma cells and neovasculature dual-targeted chemotherapy to enhance the antiglioma efficacy.	Paclitaxel	185-195	interleukin 13 receptor subunit alpha 2	Homo sapiens	82-94
27636161-2	2016	In this study, by utilizing the overexpression of Interleukin 13 receptor alpha2 (IL-13Ralpha2) on the glioma cells and heparan sulfate on neovascular endothelial cells, we developed a paclitaxel (PTX) loaded Pep-1 and CGKRK peptide-modified PEG-PLGA nanoparticle (PC-NP-PTX) for glioma cells and neovasculature dual-targeted chemotherapy to enhance the antiglioma efficacy.	Paclitaxel	197-200	interleukin 13 receptor subunit alpha 2	Homo sapiens	50-80
27636161-2	2016	In this study, by utilizing the overexpression of Interleukin 13 receptor alpha2 (IL-13Ralpha2) on the glioma cells and heparan sulfate on neovascular endothelial cells, we developed a paclitaxel (PTX) loaded Pep-1 and CGKRK peptide-modified PEG-PLGA nanoparticle (PC-NP-PTX) for glioma cells and neovasculature dual-targeted chemotherapy to enhance the antiglioma efficacy.	Paclitaxel	197-200	interleukin 13 receptor subunit alpha 2	Homo sapiens	82-94
27472162-0	2016	iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.	Paclitaxel	71-81	interferon gamma inducible protein 47	Mus musculus	0-4
27472162-5	2016	Here we studied whether intraperitoneally administered paclitaxel-loaded iRGD-polymersomes show improved efficacy in the treatment of peritoneal carcinomatosis.	Paclitaxel	55-65	interferon gamma inducible protein 47	Mus musculus	73-77
26898799-10	2016	We investigated if mDia2 functional inhibition via a small molecule inhibitor SMIFH2 combined with chemotherapeutics, such as taxol and cisplatin, inhibits the viability of EOC monolayers and clinically relevant spheroids.	Paclitaxel	126-131	diaphanous related formin 3	Mus musculus	19-24
27472162-9	2016	Finally, iRGD-polymersomes loaded with paclitaxel showed improved efficacy in peritoneal tumor growth inhibition and in suppression of local dissemination compared to the pristine paclitaxel-polymersomes or Abraxane.	Paclitaxel	39-49	interferon gamma inducible protein 47	Mus musculus	9-13
30643929-15	2019	CONCLUSIONS: TUBB3 negative expression prior treatment and pCR may indicate a better prognosis for stage II and III ESCC patients after nab-paclitaxel plus cisplatin neoadjuvant chemotherapy following radical esophagectomy.	Paclitaxel	140-150	tubulin beta 3 class III	Homo sapiens	13-18
27472162-9	2016	Finally, iRGD-polymersomes loaded with paclitaxel showed improved efficacy in peritoneal tumor growth inhibition and in suppression of local dissemination compared to the pristine paclitaxel-polymersomes or Abraxane.	Paclitaxel	180-190	interferon gamma inducible protein 47	Mus musculus	9-13
27472162-10	2016	Our study demonstrates that iRGD-functionalization improves efficacy of paclitaxel-polymersomes for intraperitoneal treatment of peritoneal carcinomatosis.	Paclitaxel	72-82	interferon gamma inducible protein 47	Mus musculus	28-32
27022257-9	2016	Tumors from all groups showed reduction in immunohistochemical expression of ICAM, MCP-1, and MMP-9; LDE-PTX and Simva presented the lowest MMP-9 expression.	Paclitaxel	105-108	matrix metallopeptidase 9	Mus musculus	140-145
30578561-11	2019	Knockout of IL-1 receptors prevented the development of acute pain induced by paclitaxel in mice.	Paclitaxel	78-88	interleukin 1 complex	Mus musculus	12-16
27505863-10	2016	Paclitaxel-induced PRC1 expression, but PRC1 knockdown did not modify the paclitaxel cytotoxicity in vitro.	Paclitaxel	0-10	protein regulator of cytokinesis 1	Homo sapiens	19-23
30471295-2	2019	Recently spinal Toll-like receptor 4 (TLR4) and the transient receptor potential cation channel subfamily V member 1 (TRPV1) were identified to be involved in the pro-nociceptive effect of paclitaxel.	Paclitaxel	189-199	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	52-116
30471295-2	2019	Recently spinal Toll-like receptor 4 (TLR4) and the transient receptor potential cation channel subfamily V member 1 (TRPV1) were identified to be involved in the pro-nociceptive effect of paclitaxel.	Paclitaxel	189-199	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	118-123
26998273-3	2016	Secondly, the cell sensitivity to 4NQO and Taxol was determined when the POLD4 expression level was downregulated by siRNA.	Paclitaxel	43-48	DNA polymerase delta 4, accessory subunit	Homo sapiens	73-78
30786006-7	2019	Altogether, our results indicate that NK007, an analog of tylophorine, can overcome paclitaxel (PTX) resistance through p38MAPK activation and HK2 degradation.	Paclitaxel	84-94	hexokinase 2	Homo sapiens	143-146
26900348-8	2016	RESULTS: We identified 22 TSGs involved in PTX resistance, including BRCA1, TP53, PTEN, APC, CDKN1A, CDKN2A, HIN-1, RASSF1, YAP, ING4, PLK2, FBW7, BLU, LZTS1, REST, FADD, PDCD4, TGFBI, ING1, Bax, PinX1 and hEx.	Paclitaxel	43-46	programmed cell death 4	Homo sapiens	171-176
26900348-8	2016	RESULTS: We identified 22 TSGs involved in PTX resistance, including BRCA1, TP53, PTEN, APC, CDKN1A, CDKN2A, HIN-1, RASSF1, YAP, ING4, PLK2, FBW7, BLU, LZTS1, REST, FADD, PDCD4, TGFBI, ING1, Bax, PinX1 and hEx.	Paclitaxel	43-46	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	196-201
26900348-8	2016	RESULTS: We identified 22 TSGs involved in PTX resistance, including BRCA1, TP53, PTEN, APC, CDKN1A, CDKN2A, HIN-1, RASSF1, YAP, ING4, PLK2, FBW7, BLU, LZTS1, REST, FADD, PDCD4, TGFBI, ING1, Bax, PinX1 and hEx.	Paclitaxel	43-46	hematopoietically expressed homeobox	Homo sapiens	206-209
27590579-0	2016	Guanylate-Binding Protein-1 protects ovarian cancer cell lines but not breast cancer cell lines from killing by paclitaxel.	Paclitaxel	112-122	guanylate binding protein 1	Homo sapiens	0-27
27590579-1	2016	Forced expression of the cytokine-induced large GTPase, human Guanylate-Binding Protein-1 (hGBP-1), in ovarian cancer cell lines increases resistance to paclitaxel.	Paclitaxel	153-163	guanylate binding protein 1	Homo sapiens	62-89
27590579-1	2016	Forced expression of the cytokine-induced large GTPase, human Guanylate-Binding Protein-1 (hGBP-1), in ovarian cancer cell lines increases resistance to paclitaxel.	Paclitaxel	153-163	guanylate binding protein 1	Homo sapiens	91-97
27590579-5	2016	Expression of the isotype of the hGBP-1-interacting protein, PIM1, which may contribute to paclitaxel resistance when associated with hGBP-1, is different in breast and ovarian cancer cell lines.	Paclitaxel	91-101	guanylate binding protein 1	Homo sapiens	33-39
27590579-5	2016	Expression of the isotype of the hGBP-1-interacting protein, PIM1, which may contribute to paclitaxel resistance when associated with hGBP-1, is different in breast and ovarian cancer cell lines.	Paclitaxel	91-101	guanylate binding protein 1	Homo sapiens	134-140
27236538-0	2016	Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2).	Paclitaxel	37-47	microRNA 203a	Homo sapiens	18-25
27236538-0	2016	Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2).	Paclitaxel	49-54	microRNA 203a	Homo sapiens	18-25
27236538-4	2016	In this study, we report a miR-203-SIK2 axis that involves in the regulation of Taxol sensitivity in colon cancer cells.	Paclitaxel	80-85	microRNA 203a	Homo sapiens	27-34
26838546-6	2016	Paclitaxel/MWE decreased EEA1 immunofluorescence staining and increased the expression of PTEN, indicating that the regimen inhibited the formation of the recycling endosome, which is required for cytokinesis.	Paclitaxel	0-10	early endosome antigen 1	Homo sapiens	25-29
27236538-6	2016	We report miR-203 is correlated with Taxol sensitivity: overexpression of miR-203 sensitizes colon cancer cells and the Taxol-resistant cells display downregulated miR-203 compared with Taxol-sensitive cells.	Paclitaxel	37-42	microRNA 203a	Homo sapiens	10-17
30786006-7	2019	Altogether, our results indicate that NK007, an analog of tylophorine, can overcome paclitaxel (PTX) resistance through p38MAPK activation and HK2 degradation.	Paclitaxel	96-99	hexokinase 2	Homo sapiens	143-146
27236538-6	2016	We report miR-203 is correlated with Taxol sensitivity: overexpression of miR-203 sensitizes colon cancer cells and the Taxol-resistant cells display downregulated miR-203 compared with Taxol-sensitive cells.	Paclitaxel	37-42	microRNA 203a	Homo sapiens	74-81
27236538-6	2016	We report miR-203 is correlated with Taxol sensitivity: overexpression of miR-203 sensitizes colon cancer cells and the Taxol-resistant cells display downregulated miR-203 compared with Taxol-sensitive cells.	Paclitaxel	37-42	microRNA 203a	Homo sapiens	74-81
27236538-6	2016	We report miR-203 is correlated with Taxol sensitivity: overexpression of miR-203 sensitizes colon cancer cells and the Taxol-resistant cells display downregulated miR-203 compared with Taxol-sensitive cells.	Paclitaxel	120-125	microRNA 203a	Homo sapiens	10-17
27236538-6	2016	We report miR-203 is correlated with Taxol sensitivity: overexpression of miR-203 sensitizes colon cancer cells and the Taxol-resistant cells display downregulated miR-203 compared with Taxol-sensitive cells.	Paclitaxel	120-125	microRNA 203a	Homo sapiens	10-17
27236538-8	2016	Overexpression of miR-203 complementary pairs to the 3" untranslated region (UTR) of SIK2, leading to the sensitization of Taxol resistant cells.	Paclitaxel	123-128	microRNA 203a	Homo sapiens	18-25
27236538-10	2016	Finally, we demonstrate recovery of SIK2 by overexpression of SIK2-desensitized Taxol-resistant cells, supporting the miR-203-mediated sensitization to Taxol, is through the inhibition of SIK2.	Paclitaxel	80-85	microRNA 203a	Homo sapiens	118-125
26808812-2	2016	We used in vitro and in vivo approaches to assess the impact of NMNAT2 reduction on cellular and physiological functions induced by treatment with a vinca alkaloid (vincristine) and a taxane-based (paclitaxel) chemotherapeutic agent.	Paclitaxel	198-208	nicotinamide nucleotide adenylyltransferase 2	Mus musculus	64-70
30804792-0	2018	Astragalus Polysaccharide RAP Selectively Attenuates Paclitaxel-Induced Cytotoxicity Toward RAW 264.7 Cells by Reversing Cell Cycle Arrest and Apoptosis.	Paclitaxel	53-63	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	26-29
26808812-4	2016	Nonetheless, primary cortical cultures derived from NMNAT2-/- embryos showed reduced cell viability in response to either vincristine or paclitaxel treatment whereas those derived from NMNAT2 heterozygous (NMNAT2+/-) mice were preferentially sensitive to vincristine-induced degeneration.	Paclitaxel	137-147	nicotinamide nucleotide adenylyltransferase 2	Mus musculus	52-58
27236538-10	2016	Finally, we demonstrate recovery of SIK2 by overexpression of SIK2-desensitized Taxol-resistant cells, supporting the miR-203-mediated sensitization to Taxol, is through the inhibition of SIK2.	Paclitaxel	152-157	microRNA 203a	Homo sapiens	118-125
27195913-0	2016	Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src.	Paclitaxel	19-29	caspase 8	Homo sapiens	93-102
27195913-4	2016	The present study reported that phosphorylated caspase-8 at tyrosine 380 (p-Casp8) was characterized as a biomarker of chemoresistance to TP regimen (cisplatin and paclitaxel) in patients with resectable lung adenocarcinoma with significantly poorer 5-year disease-free survival (DFS) and overall survival (OS).	Paclitaxel	164-174	caspase 8	Homo sapiens	47-72
27195913-4	2016	The present study reported that phosphorylated caspase-8 at tyrosine 380 (p-Casp8) was characterized as a biomarker of chemoresistance to TP regimen (cisplatin and paclitaxel) in patients with resectable lung adenocarcinoma with significantly poorer 5-year disease-free survival (DFS) and overall survival (OS).	Paclitaxel	164-174	caspase 8	Homo sapiens	76-81
27195913-6	2016	Subsequently, we identified a novel mechanism by which paclitaxel induced necroptosis in lung adenocarcinoma cells that was dependent upon p-Casp8, receptor-interacting protein kinase 1 (RIPK1), and RIPK3.	Paclitaxel	55-65	caspase 8	Homo sapiens	141-146
26246283-0	2016	Enhancement of paclitaxel-induced breast cancer cell death via the glycogen synthase kinase-3beta-mediated B-cell lymphoma 2 regulation.	Paclitaxel	15-25	glycogen synthase kinase 3 beta	Homo sapiens	67-97
26246283-2	2016	Here, we show that B-cell lymphoma 2 (Bcl-2), an anti-apoptotic protein, is regulated by GSK-3beta and that GSK-3beta-mediated regulation of Bcl-2 is crucial for mitochondrial-dependent cell death in paclitaxel-stimulated cells.	Paclitaxel	200-210	glycogen synthase kinase 3 beta	Homo sapiens	108-117
26246283-3	2016	We demonstrate that MCF7 GSK-3beta siRNA cells are more sensitive to cell death than MCF7 GFP control cells and that in the absence of GSK-3beta, Bcl-2 levels are reduced, a result enhanced by paclitaxel.	Paclitaxel	193-203	glycogen synthase kinase 3 beta	Homo sapiens	25-34
27195913-7	2016	Moreover, dasatinib, a c-Src inhibitor, dephosphorylated caspase-8 to facilitate necroptosis, rather than apoptosis, in paclitaxel-treated p-Casp8-expressing lung adenocarcinoma cells.	Paclitaxel	120-130	caspase 8	Homo sapiens	57-66
27195913-7	2016	Moreover, dasatinib, a c-Src inhibitor, dephosphorylated caspase-8 to facilitate necroptosis, rather than apoptosis, in paclitaxel-treated p-Casp8-expressing lung adenocarcinoma cells.	Paclitaxel	120-130	caspase 8	Homo sapiens	141-146
26246283-7	2016	Taken together, our data suggest that GSK-3beta-dependent regulation of Bcl-2 is crucial for mitochondria-dependent cell death in paclitaxel-mediated breast cancer therapy.	Paclitaxel	130-140	glycogen synthase kinase 3 beta	Homo sapiens	38-47
30804792-1	2018	Purpose: The purpose of this study was to determine if an Astragalus polysaccharide (RAP) can protect immune cells from the toxic side effects of paclitaxel (Taxol), a powerful anti-tumor drug whose equally powerful side effects limit its clinical use.	Paclitaxel	146-156	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	85-88
27095936-11	2016	However, combined treatment of everolimus and paclitaxel significantly reduced BCL2 and CCND1 mRNA expression (p &lt; 0.05).	Paclitaxel	46-56	cyclin D1	Homo sapiens	88-93
27304668-12	2016	Normal blood lymphocytes assay indicated that GLU is able to induce selective toxicity in cancer cells and in silico molecular docking studies support the choice of GLU as ABC inhibitor to enhance PTX efficacy.	Paclitaxel	197-200	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	172-175
30804792-1	2018	Purpose: The purpose of this study was to determine if an Astragalus polysaccharide (RAP) can protect immune cells from the toxic side effects of paclitaxel (Taxol), a powerful anti-tumor drug whose equally powerful side effects limit its clinical use.	Paclitaxel	158-163	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	85-88
27095936-13	2016	CONCLUSIONS: Down-regulation of CCND1 and BCL2 expression may be an important mechanism by which everolimus increases the therapeutic window of paclitaxel in cervical cancers.	Paclitaxel	144-154	cyclin D1	Homo sapiens	32-37
30804792-2	2018	Methods: We hypothesized that RAP can reduce the toxic effects induced by Taxol.	Paclitaxel	74-79	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	30-33
30804792-6	2018	Second, a co-culture cell model was used to study the protective effect of RAP on cells vis-a-vis Taxol.	Paclitaxel	98-103	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	75-78
30804792-9	2018	Results: RAP prolonged the life span of tumor-bearing mice treated with Taxol.	Paclitaxel	72-77	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	9-12
30804792-10	2018	The in vitro experiments showed that Taxol suppressed the proliferation of RAW 264.7 cells while RAP protected the RAW 264.7 cells from Taxol-induced suppression.	Paclitaxel	136-141	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	97-100
27076919-9	2016	Consistent with these cytotoxic profiles, cisplatin/mitomycin C, triapine, and paclitaxel differed in the capacity to induce phosphorylation of H2AX, and produced unique inhibitory patterns of DNA/RNA syntheses in HL-60 human leukemia cells.	Paclitaxel	79-89	H2A.X variant histone	Homo sapiens	144-148
27207777-0	2016	Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.	Paclitaxel	160-170	cyclin dependent kinase 19	Homo sapiens	0-26
27207777-0	2016	Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.	Paclitaxel	160-170	cyclin dependent kinase 19	Homo sapiens	28-33
27207777-7	2016	Moreover, CDK11 knockdown enhances the cytotoxic effect of paclitaxel to inhibit cell growth in ovarian cancer cells.	Paclitaxel	59-69	cyclin dependent kinase 19	Homo sapiens	10-15
30609116-7	2019	All the results in vitro and in vivo suggested that Glu-RGD-Lip would be a potential delivery system for PTX to treat integrin alphav beta3 -overexpressing tumor-bearing mice.	Paclitaxel	105-108	calcium channel, voltage-dependent, beta 3 subunit	Mus musculus	134-139
27362808-6	2016	We found miR-205 downregulated in both MCF-7/A02 and CALDOX cells, two drug-resistant derivatives of MCF-7 and Cal51 cells, and its ectopic expression led to an increase in apoptosis resensitization of both drug-resistant cell lines to doxorubicin and taxol.	Paclitaxel	252-257	microRNA 205	Homo sapiens	9-16
30773131-5	2019	Additionally, in combination with Taxol, SynB1-ELP-dnMAML showed more potent tumor growth retardation.	Paclitaxel	34-39	diazepam binding inhibitor-like 5	Mus musculus	47-50
27279639-0	2016	Targeted Silencing of S100A8 Gene by miR-24 to Increase Chemotherapy Sensitivity of Endometrial Carcinoma Cells to Paclitaxel.	Paclitaxel	115-125	S100 calcium binding protein A8	Homo sapiens	22-28
26467040-2	2016	CYP2C8, an important member of this subfamily, metabolizes the anticancer drug paclitaxel, certain antidiabetic drugs, and endogenous substrates, including arachidonic acid, to physiologically active epoxyeicosatrienoic acids.	Paclitaxel	79-89	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
26721703-3	2016	CYP2C8 substrate drugs include amodiaquine, cerivastatin, dasabuvir, enzalutamide, imatinib, loperamide, montelukast, paclitaxel, pioglitazone, repaglinide, and rosiglitazone, and the number is increasing.	Paclitaxel	118-128	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
30634553-1	2019	In this study, we prepared an injectable drug delivery depot system based on a visible light-cured glycol chitosan (GC) hydrogel containing paclitaxel (PTX)-complexed beta-cyclodextrin (beta-CD) (GC/CD/PTX) for ovarian cancer (OC) therapy using a tumor-bearing mouse model.	Paclitaxel	140-150	beta-carotene oxygenase 1	Mus musculus	186-193
26831807-6	2016	In this review, we focus on (1) analysis of transient receptor potential vanilloid 1 (TRPV1) channel expression in the rat dorsal root ganglion (DRG) after paclitaxel treatment and (2) analysis of transient receptor potential ankyrin 1 (TRPA1) channel in the DRG after oxaliplatin treatment.	Paclitaxel	156-166	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	44-84
26831807-6	2016	In this review, we focus on (1) analysis of transient receptor potential vanilloid 1 (TRPV1) channel expression in the rat dorsal root ganglion (DRG) after paclitaxel treatment and (2) analysis of transient receptor potential ankyrin 1 (TRPA1) channel in the DRG after oxaliplatin treatment.	Paclitaxel	156-166	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	86-91
26831807-7	2016	This review describes that (1) paclitaxel-induced neuropathic pain may be the result of up-regulation of TRPV1 in small- and medium-diameter DRG neurons.	Paclitaxel	31-41	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	105-110
27279639-12	2016	CONCLUSIONS miR-24 acts as a tumor-suppressing gene to inhibit malignant proliferation and advance chemotherapy sensitivity to paclitaxel in EC by targeted silencing of the S100A8 gene.	Paclitaxel	127-137	S100 calcium binding protein A8	Homo sapiens	173-179
27284014-0	2016	Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation.	Paclitaxel	45-55	tubulin beta 3 class III	Homo sapiens	118-123
27146520-6	2016	PS and PSC displayed similar sustained PTX release patterns.	Paclitaxel	39-42	PSC	Homo sapiens	7-10
26516138-9	2015	CONCLUSIONS: Increased miR-451 expression may negatively regulate Bcl-2 mRNA and protein expression, followed by affecting the protein expression of caspase 3, and accelerate the apoptosis in breast cancer, indicating that miR-451 might influence the drug resistances of the Paclitaxel-resistant breast cancer cell line.	Paclitaxel	275-285	microRNA 451a	Homo sapiens	223-230
30634553-1	2019	In this study, we prepared an injectable drug delivery depot system based on a visible light-cured glycol chitosan (GC) hydrogel containing paclitaxel (PTX)-complexed beta-cyclodextrin (beta-CD) (GC/CD/PTX) for ovarian cancer (OC) therapy using a tumor-bearing mouse model.	Paclitaxel	152-155	beta-carotene oxygenase 1	Mus musculus	186-193
30634553-9	2019	Consequently, we suggest that the GC/CD system might have clinical potential for OC therapy by improving the water solubility of PTX, as PTX is included into the cavity of beta-CD.	Paclitaxel	137-140	beta-carotene oxygenase 1	Mus musculus	172-179
27383301-5	2016	RESULTS: Expression of the miR-134 gene cluster was found to be significantly lower in the paclitaxel-resistant cell line than in the paclitaxel-sensitive cell line, while the expression of the miR-17-92 gene cluster was significantly higher in the paclitaxel-resistant cells.	Paclitaxel	91-101	microRNA 134	Homo sapiens	27-34
30880751-10	2019	Combination of paclitaxel with overexpression of miR-34a significantly decreased cell viability compared to cell treated with miR-34a or paclitaxel alone.	Paclitaxel	15-25	microRNA 34a	Homo sapiens	126-133
27383301-5	2016	RESULTS: Expression of the miR-134 gene cluster was found to be significantly lower in the paclitaxel-resistant cell line than in the paclitaxel-sensitive cell line, while the expression of the miR-17-92 gene cluster was significantly higher in the paclitaxel-resistant cells.	Paclitaxel	134-144	microRNA 134	Homo sapiens	27-34
27383301-5	2016	RESULTS: Expression of the miR-134 gene cluster was found to be significantly lower in the paclitaxel-resistant cell line than in the paclitaxel-sensitive cell line, while the expression of the miR-17-92 gene cluster was significantly higher in the paclitaxel-resistant cells.	Paclitaxel	134-144	microRNA 134	Homo sapiens	27-34
27166255-0	2016	A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells.	Paclitaxel	73-83	fragile histidine triad diadenosine triphosphatase	Homo sapiens	2-6
27166255-1	2016	We recently reported that Fhit is in a molecular complex with annexin A4 (ANXA4); following to their binding, Fhit delocalizes ANXA4 from plasma membrane to cytosol in paclitaxel-resistant lung cancer cells, thus restoring their chemosensitivity to the drug.	Paclitaxel	168-178	fragile histidine triad diadenosine triphosphatase	Homo sapiens	26-30
27166255-1	2016	We recently reported that Fhit is in a molecular complex with annexin A4 (ANXA4); following to their binding, Fhit delocalizes ANXA4 from plasma membrane to cytosol in paclitaxel-resistant lung cancer cells, thus restoring their chemosensitivity to the drug.	Paclitaxel	168-178	fragile histidine triad diadenosine triphosphatase	Homo sapiens	110-114
27166255-4	2016	Interestingly, Fhit peptide also recapitulates the property of the native protein in inhibiting Annexin A4 translocation from cytosol to plasma membrane in A549 and Calu-2 lung cancer cells treated with paclitaxel.	Paclitaxel	203-213	fragile histidine triad diadenosine triphosphatase	Homo sapiens	15-19
27166255-5	2016	Finally, the combination of Tat-Fhit peptide and paclitaxel synergistically increases the apoptotic rate of cultured lung cancer cells and blocks in vivo tumor formation.Our findings address to the identification of chemically simplified Fhit derivatives that mimic Fhit tumor suppressor functions; intriguingly, this approach might lead to the generation of novel anticancer drugs to be used in combination with conventional therapies in Fhit-negative tumors to prevent or delay chemoresistance.	Paclitaxel	49-59	fragile histidine triad diadenosine triphosphatase	Homo sapiens	238-242
27166255-5	2016	Finally, the combination of Tat-Fhit peptide and paclitaxel synergistically increases the apoptotic rate of cultured lung cancer cells and blocks in vivo tumor formation.Our findings address to the identification of chemically simplified Fhit derivatives that mimic Fhit tumor suppressor functions; intriguingly, this approach might lead to the generation of novel anticancer drugs to be used in combination with conventional therapies in Fhit-negative tumors to prevent or delay chemoresistance.	Paclitaxel	49-59	fragile histidine triad diadenosine triphosphatase	Homo sapiens	238-242
27166255-5	2016	Finally, the combination of Tat-Fhit peptide and paclitaxel synergistically increases the apoptotic rate of cultured lung cancer cells and blocks in vivo tumor formation.Our findings address to the identification of chemically simplified Fhit derivatives that mimic Fhit tumor suppressor functions; intriguingly, this approach might lead to the generation of novel anticancer drugs to be used in combination with conventional therapies in Fhit-negative tumors to prevent or delay chemoresistance.	Paclitaxel	49-59	fragile histidine triad diadenosine triphosphatase	Homo sapiens	238-242
26581910-0	2016	MicroRNA-143 replenishment re-sensitizes colorectal cancer cells harboring mutant, but not wild-type, KRAS to paclitaxel treatment.	Paclitaxel	110-120	microRNA 143	Homo sapiens	0-12
26503059-0	2015	IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.	Paclitaxel	85-95	interleukin 1 receptor associated kinase 1	Homo sapiens	0-5
26503059-2	2015	Here we report that interleukin-1 receptor-associated kinase 1 (IRAK1) is overexpressed in a subset of breast cancers, in particular triple-negative breast cancer (TNBC), where it acts to drive aggressive growth, metastasis and acquired resistance to paclitaxel treatment.	Paclitaxel	251-261	interleukin 1 receptor associated kinase 1	Homo sapiens	20-62
26503059-2	2015	Here we report that interleukin-1 receptor-associated kinase 1 (IRAK1) is overexpressed in a subset of breast cancers, in particular triple-negative breast cancer (TNBC), where it acts to drive aggressive growth, metastasis and acquired resistance to paclitaxel treatment.	Paclitaxel	251-261	interleukin 1 receptor associated kinase 1	Homo sapiens	64-69
26503059-4	2015	Importantly, paclitaxel treatment induces strong IRAK1 phosphorylation, an increase in inflammatory cytokine expression, enrichment of cancer stem cells and acquired resistance to paclitaxel treatment.	Paclitaxel	13-23	interleukin 1 receptor associated kinase 1	Homo sapiens	49-54
26503059-5	2015	Pharmacologic inhibition of IRAK1 is able to reverse paclitaxel resistance by triggering massive apoptosis at least in part through inhibiting p38-MCL1 pro-survival pathway.	Paclitaxel	53-63	interleukin 1 receptor associated kinase 1	Homo sapiens	28-33
26503059-6	2015	Our study thus demonstrates IRAK1 as a promising therapeutic target for TNBC metastasis and paclitaxel resistance.	Paclitaxel	92-102	interleukin 1 receptor associated kinase 1	Homo sapiens	28-33
26065826-0	2015	MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy.	Paclitaxel	49-59	mitogen activated protein kinase 3	Rattus norvegicus	0-4
26065826-8	2015	The TLR4 antagonist LPS derived from Rhodobacter sphaeroides (LPS-RS) inhibited paclitaxel-induced phosphorylation of ERK1/2 and P38.	Paclitaxel	80-90	mitogen activated protein kinase 3	Rattus norvegicus	118-124
26065826-8	2015	The TLR4 antagonist LPS derived from Rhodobacter sphaeroides (LPS-RS) inhibited paclitaxel-induced phosphorylation of ERK1/2 and P38.	Paclitaxel	80-90	mitogen activated protein kinase 14	Rattus norvegicus	129-132
26722421-9	2015	15 genes of 762 transcripts on this chromosome region were consistently up-regulated detected by cDNA microarray in three taxol resistant sub-lines, and functionally clustered into various groups, including genes related to vascular formation vascular formation (ANGPT1), apoptosis (MYC, TOP1MT), cell adhesion and cell cycle (PPP1R16A, SDC2, CA2, ANKRD46), gene regulation (HRSP12, ZNF696, SLC39A4, POP1), metabolism (PYCRL).	Paclitaxel	122-127	POP1 homolog, ribonuclease P/MRP subunit	Homo sapiens	400-404
26722421-10	2015	Inhibition of ANGPT1 expression significantly increased the sensitivity of CNE-1/taxol to paclitaxol.	Paclitaxel	90-100	angiopoietin 1	Homo sapiens	14-20
26722421-12	2015	ANGPT1 may be associated with taxol resistance of NPC cells.	Paclitaxel	30-35	angiopoietin 1	Homo sapiens	0-6
26025631-3	2015	Lentiviral transfection of inhibitors of miR-200c or miR-141 in parental OVCAR-3 triggered EMT and rendered the cells resistant to paclitaxel and carboplatin.	Paclitaxel	131-141	microRNA 200c	Homo sapiens	41-49
26025631-8	2015	MiR-200c and miR-141 mimics conferred resistance to carboplatin in MES-OV/TP cells, similar to OVCAR-3/TP, but sensitized MES-OV to paclitaxel.	Paclitaxel	132-142	microRNA 200c	Homo sapiens	0-8
26622855-12	2015	Furthermore, paclitaxel was observed to inhibit oral cancer cell proliferation through increased MMP-2 and MMP-9 protein levels.	Paclitaxel	13-23	matrix metallopeptidase 2	Homo sapiens	97-102
26424893-0	2015	The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4.	Paclitaxel	28-38	transient receptor potential cation channel subfamily V member 1	Homo sapiens	94-99
26424893-2	2015	The hypothesis tested was that paclitaxel produces these adverse effects at least in part by sensitizing transient receptor potential vanilloid subtype 1 (TRPV1) through Toll-like receptor 4 (TLR4) signaling.	Paclitaxel	31-41	transient receptor potential cation channel subfamily V member 1	Homo sapiens	105-153
26424893-2	2015	The hypothesis tested was that paclitaxel produces these adverse effects at least in part by sensitizing transient receptor potential vanilloid subtype 1 (TRPV1) through Toll-like receptor 4 (TLR4) signaling.	Paclitaxel	31-41	transient receptor potential cation channel subfamily V member 1	Homo sapiens	155-160
26424893-3	2015	The data show that paclitaxel-induced behavioral hypersensitivity is prevented and reversed by spinal administration of a TRPV1 antagonist.	Paclitaxel	19-29	transient receptor potential cation channel subfamily V member 1	Homo sapiens	122-127
26424893-4	2015	The number of TRPV1(+) neurons is increased in the dorsal root ganglia (DRG) in paclitaxel-treated rats and is colocalized with TLR4 in rat and human DRG neurons.	Paclitaxel	80-90	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	14-19
26424893-5	2015	Cotreatment of rats with lipopolysaccharide from the photosynthetic bacterium Rhodobacter sphaeroides (LPS-RS), a TLR4 inhibitor, prevents the increase in numbers of TRPV1(+) neurons by paclitaxel treatment.	Paclitaxel	186-196	transient receptor potential cation channel subfamily V member 1	Homo sapiens	166-171
26424893-6	2015	Perfusion of paclitaxel or the archetypal TLR4 agonist LPS activated both rat DRG and spinal neurons directly and produced acute sensitization of TRPV1 in both groups of cells via a TLR4-mediated mechanism.	Paclitaxel	13-23	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	146-151
26424893-7	2015	Paclitaxel and LPS sensitize TRPV1 in HEK293 cells stably expressing human TLR4 and transiently expressing human TRPV1.	Paclitaxel	0-10	transient receptor potential cation channel subfamily V member 1	Homo sapiens	29-34
26424893-7	2015	Paclitaxel and LPS sensitize TRPV1 in HEK293 cells stably expressing human TLR4 and transiently expressing human TRPV1.	Paclitaxel	0-10	transient receptor potential cation channel subfamily V member 1	Homo sapiens	113-118
26424893-9	2015	Finally, paclitaxel activates and sensitizes TRPV1 responses directly in dissociated human DRG neurons.	Paclitaxel	9-19	transient receptor potential cation channel subfamily V member 1	Homo sapiens	45-50
26424893-10	2015	In summary, TLR4 was activated by paclitaxel and led to sensitization of TRPV1.	Paclitaxel	34-44	transient receptor potential cation channel subfamily V member 1	Homo sapiens	73-78
26424893-12	2015	Significance statement: In this original work, it is shown for the first time that paclitaxel activates peripheral sensory and spinal neurons directly and sensitizes these cells to transient receptor potential vanilloid subtype 1 (TRPV1)-mediated capsaicin responses via Toll-like receptor 4 (TLR4) in multiple species.	Paclitaxel	83-93	transient receptor potential cation channel subfamily V member 1	Homo sapiens	181-229
26424893-12	2015	Significance statement: In this original work, it is shown for the first time that paclitaxel activates peripheral sensory and spinal neurons directly and sensitizes these cells to transient receptor potential vanilloid subtype 1 (TRPV1)-mediated capsaicin responses via Toll-like receptor 4 (TLR4) in multiple species.	Paclitaxel	83-93	transient receptor potential cation channel subfamily V member 1	Homo sapiens	231-236
25998561-0	2015	A tumor-penetrating recombinant protein anti-EGFR-iRGD enhance efficacy of paclitaxel in 3D multicellular spheroids and gastric cancer in vivo.	Paclitaxel	75-85	interferon gamma inducible protein 47	Mus musculus	50-54
26087191-4	2015	COL11A1 or c/EBPbeta downregulation suppressed chemoresistance, whereas COL11A1 overexpression attenuated sensitivity to cisplatin and paclitaxel.The c/EBPbeta binding site in the COL11A1 promoter was identified as the major determinant of cisplatin- and paclitaxel-induced COL11A1 expression.	Paclitaxel	135-145	CCAAT enhancer binding protein beta	Homo sapiens	150-159
26087191-4	2015	COL11A1 or c/EBPbeta downregulation suppressed chemoresistance, whereas COL11A1 overexpression attenuated sensitivity to cisplatin and paclitaxel.The c/EBPbeta binding site in the COL11A1 promoter was identified as the major determinant of cisplatin- and paclitaxel-induced COL11A1 expression.	Paclitaxel	255-265	CCAAT enhancer binding protein beta	Homo sapiens	150-159
26183396-4	2015	We have recently shown that high levels of TAZ in cancer cells result in Taxol resistance through up-regulation of downstream targets Cyr61 and CTGF.	Paclitaxel	73-78	cellular communication network factor 2	Homo sapiens	144-148
26223974-0	2015	MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88.	Paclitaxel	70-80	MYD88 innate immune signal transduction adaptor	Homo sapiens	94-99
26223974-14	2015	CONCLUSION: Our findings suggest that miRNA-149 mediates the susceptibility of paclitaxel by regulating MyD88 expression in ovarian cancer cells.	Paclitaxel	79-89	MYD88 innate immune signal transduction adaptor	Homo sapiens	104-109
25851250-0	2015	Gonadotropin-releasing hormone receptor-targeted paclitaxel-degarelix conjugate: synthesis and in vitro evaluation.	Paclitaxel	49-59	gonadotropin releasing hormone receptor	Homo sapiens	0-39
25681288-6	2015	PPCat further contains paclitaxel to enhance in vivo delivery and transfection of survivin siRNA.	Paclitaxel	23-33	baculoviral IAP repeat-containing 5	Mus musculus	82-90
25904556-0	2015	CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.	Paclitaxel	128-138	cannabinoid receptor 1 (brain)	Mus musculus	0-3
25904556-10	2015	produced catalepsy in WT mice, which precluded determination of antiallodynic efficacy but produced sustained CB2-mediated suppression of paclitaxel-induced allodynia in CB1KO mice; these antiallodynic effects were blocked by the CB2 antagonist 6-iodopravadoline (AM630).	Paclitaxel	138-148	cannabinoid receptor 1 (brain)	Mus musculus	170-173
26015406-0	2015	Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment.	Paclitaxel	84-94	myristoylated alanine rich protein kinase C substrate	Homo sapiens	9-15
26015406-5	2015	Among chemotherapeutic agents, mitotic inhibitors, including paclitaxel, vincristine or eribulin, notably promoted phospho-MARCKS accumulation in multiple breast cancer cells.	Paclitaxel	61-71	myristoylated alanine rich protein kinase C substrate	Homo sapiens	123-129
26086592-3	2015	Here, we silenced the taxol-sensitizer genes identified (acrbp, atp6v0d2, fgd4, hs6st2, psma6, and tubgcp2) in nine other cancer cell types (including lung, cervical, ovarian, and hepatocellular carcinoma cell lines) that showed reduced cell viability in the presence of a sub-lethal concentration of taxol.	Paclitaxel	22-27	heparan sulfate 6-O-sulfotransferase 2	Homo sapiens	80-86
26086592-3	2015	Here, we silenced the taxol-sensitizer genes identified (acrbp, atp6v0d2, fgd4, hs6st2, psma6, and tubgcp2) in nine other cancer cell types (including lung, cervical, ovarian, and hepatocellular carcinoma cell lines) that showed reduced cell viability in the presence of a sub-lethal concentration of taxol.	Paclitaxel	22-27	tubulin gamma complex associated protein 2	Homo sapiens	99-106
26086592-7	2015	Notably, four of the five inducible taxol-sensitizer genes tested (acrbp, atp6v0d2, psma6, and tubgcp2) were upregulated in a taxol-resistant ovarian cancer cell line.	Paclitaxel	36-41	tubulin gamma complex associated protein 2	Homo sapiens	95-102
26086592-7	2015	Notably, four of the five inducible taxol-sensitizer genes tested (acrbp, atp6v0d2, psma6, and tubgcp2) were upregulated in a taxol-resistant ovarian cancer cell line.	Paclitaxel	126-131	tubulin gamma complex associated protein 2	Homo sapiens	95-102
25928036-0	2015	Proteomic Profiling of Paclitaxel Treated Cells Identifies a Novel Mechanism of Drug Resistance Mediated by PDCD4.	Paclitaxel	23-33	programmed cell death 4	Homo sapiens	108-113
25928036-4	2015	Notably, the tumor suppressor PDCD4 involved in translation suppression was down-regulated by PTX.	Paclitaxel	94-97	programmed cell death 4	Homo sapiens	30-35
25928036-5	2015	We demonstrated that PDCD4 is a cell-cycle regulated protein and that changes in its abundance are sufficient to alter PTX sensitivity in multiple human cancer cell lines.	Paclitaxel	119-122	programmed cell death 4	Homo sapiens	21-26
25928036-6	2015	Immunoprecipitation of PDCD4-RNA complexes and RT-PCR revealed that PDCD4 mediated PTX sensitivity acts through its interaction with mRNA of UBE2S, a ubiquitin K11 linkage conjugating enzyme critical for mitotic exit.	Paclitaxel	83-86	programmed cell death 4	Homo sapiens	23-28
25928036-6	2015	Immunoprecipitation of PDCD4-RNA complexes and RT-PCR revealed that PDCD4 mediated PTX sensitivity acts through its interaction with mRNA of UBE2S, a ubiquitin K11 linkage conjugating enzyme critical for mitotic exit.	Paclitaxel	83-86	programmed cell death 4	Homo sapiens	68-73
25928036-7	2015	Lastly, high levels of PDCD4 in lung cancer tissues are positively correlated with the longer overall survival time of the examined lung cancer patients with PTX involved adjuvant therapy.	Paclitaxel	158-161	programmed cell death 4	Homo sapiens	23-28
25928036-8	2015	Therefore, our proteomic screen for paclitaxel targets not only provided novel insight into the cellular resistance to paclitaxel via the PDCD4-mitotic exit regulation axis, but also offered a predictive biomarker for paclitaxel-based personalized chemotherapy in the treatment of lung cancer.	Paclitaxel	36-46	programmed cell death 4	Homo sapiens	138-143
25928036-8	2015	Therefore, our proteomic screen for paclitaxel targets not only provided novel insight into the cellular resistance to paclitaxel via the PDCD4-mitotic exit regulation axis, but also offered a predictive biomarker for paclitaxel-based personalized chemotherapy in the treatment of lung cancer.	Paclitaxel	119-129	programmed cell death 4	Homo sapiens	138-143
25928036-8	2015	Therefore, our proteomic screen for paclitaxel targets not only provided novel insight into the cellular resistance to paclitaxel via the PDCD4-mitotic exit regulation axis, but also offered a predictive biomarker for paclitaxel-based personalized chemotherapy in the treatment of lung cancer.	Paclitaxel	119-129	programmed cell death 4	Homo sapiens	138-143
25424246-7	2015	There were no significant differences found for the inhibitory effects caused by the four inhibitors of the paclitaxel metabolism in HL54, indicating that both CYP2C8 and CYP3A4 play important roles in paclitaxel metabolism in HL54.	Paclitaxel	202-212	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	160-166
25424246-10	2015	The CYP2C8*3 allele carriers are likely susceptible to the interactions of losartan and CYP3A4 inhibitors to paclitaxel metabolism.	Paclitaxel	109-119	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	4-10
25820241-9	2015	In vivo investigation of prodrugs in nude mice bearing NCI-H446 cancer xenografts confirmed that OCT(Phe)-PEG-PTX prodrug exhibited stronger antitumor efficacy and lower systemic toxicity than mPEG-PTX and commercial Taxol.	Paclitaxel	217-222	plexin A2	Mus musculus	97-100
26137169-0	2015	Hybrid-polymerase chain reaction to identify novel target genes of miR-134 in paclitaxel resistant human ovarian carcinoma cells.	Paclitaxel	78-88	microRNA 134	Homo sapiens	67-74
26137169-3	2015	The objective of this study was to apply hybrid-polymerase chain reaction (PCR) to screen target genes of miR-134 in ovarian carcinoma paclitaxel resistant SKOV3-TR30 cells, and to provide a number of novel targets of miR-134 for further study of ovarian cancer paclitaxel resistance.	Paclitaxel	135-145	microRNA 134	Homo sapiens	106-113
26137169-3	2015	The objective of this study was to apply hybrid-polymerase chain reaction (PCR) to screen target genes of miR-134 in ovarian carcinoma paclitaxel resistant SKOV3-TR30 cells, and to provide a number of novel targets of miR-134 for further study of ovarian cancer paclitaxel resistance.	Paclitaxel	135-145	microRNA 134	Homo sapiens	218-225
26137169-3	2015	The objective of this study was to apply hybrid-polymerase chain reaction (PCR) to screen target genes of miR-134 in ovarian carcinoma paclitaxel resistant SKOV3-TR30 cells, and to provide a number of novel targets of miR-134 for further study of ovarian cancer paclitaxel resistance.	Paclitaxel	262-272	microRNA 134	Homo sapiens	106-113
26137169-3	2015	The objective of this study was to apply hybrid-polymerase chain reaction (PCR) to screen target genes of miR-134 in ovarian carcinoma paclitaxel resistant SKOV3-TR30 cells, and to provide a number of novel targets of miR-134 for further study of ovarian cancer paclitaxel resistance.	Paclitaxel	262-272	microRNA 134	Homo sapiens	218-225
26137169-10	2015	In conclusion, this study was the first to apply an effective method of hybrid-PCR to screen putative target mRNAs of miR-134 in paclitaxel resistant SKOV3-TR30 cells and indicate that miR-134 may contribute to the induction of SKOV3-TR30 paclitaxel resistance by targeting these genes.	Paclitaxel	129-139	microRNA 134	Homo sapiens	118-125
26137169-10	2015	In conclusion, this study was the first to apply an effective method of hybrid-PCR to screen putative target mRNAs of miR-134 in paclitaxel resistant SKOV3-TR30 cells and indicate that miR-134 may contribute to the induction of SKOV3-TR30 paclitaxel resistance by targeting these genes.	Paclitaxel	129-139	microRNA 134	Homo sapiens	185-192
26137169-10	2015	In conclusion, this study was the first to apply an effective method of hybrid-PCR to screen putative target mRNAs of miR-134 in paclitaxel resistant SKOV3-TR30 cells and indicate that miR-134 may contribute to the induction of SKOV3-TR30 paclitaxel resistance by targeting these genes.	Paclitaxel	239-249	microRNA 134	Homo sapiens	118-125
26137169-10	2015	In conclusion, this study was the first to apply an effective method of hybrid-PCR to screen putative target mRNAs of miR-134 in paclitaxel resistant SKOV3-TR30 cells and indicate that miR-134 may contribute to the induction of SKOV3-TR30 paclitaxel resistance by targeting these genes.	Paclitaxel	239-249	microRNA 134	Homo sapiens	185-192
25849888-6	2015	Interestingly, we found that c-myc and cyclin D1 increased significantly in transfected cells with increasing PTX concentration, and cell-survival rates remained at 60% while the PTX concentration increased.	Paclitaxel	110-113	cyclin D1	Homo sapiens	39-48
25849888-6	2015	Interestingly, we found that c-myc and cyclin D1 increased significantly in transfected cells with increasing PTX concentration, and cell-survival rates remained at 60% while the PTX concentration increased.	Paclitaxel	179-182	cyclin D1	Homo sapiens	39-48
25963978-9	2015	Knockdown of NIPBL in non-small cell lung cancer cell lines significantly reduced cellular proliferation, migration, and invasion, and enhanced cellular apoptosis and sensitivity to cisplatin, paclitaxel, and gemcitabine hydrochloride.	Paclitaxel	193-203	NIPBL cohesin loading factor	Homo sapiens	13-18
25964544-0	2015	Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response.	Paclitaxel	89-99	tubulin beta 3 class III	Homo sapiens	0-22
25964544-1	2015	AIM: In order to clarify whether class III beta-tubulin (TUBB3) is a predictive marker for paclitaxel (PTX) chemotherapy, chemosensitivity was examined using an in vitro drug sensitivity assay.	Paclitaxel	91-101	tubulin beta 3 class III	Homo sapiens	33-55
25964544-1	2015	AIM: In order to clarify whether class III beta-tubulin (TUBB3) is a predictive marker for paclitaxel (PTX) chemotherapy, chemosensitivity was examined using an in vitro drug sensitivity assay.	Paclitaxel	91-101	tubulin beta 3 class III	Homo sapiens	57-62
25964544-9	2015	CONCLUSION: High TUBB3 expression in NSCLC appeared to correlate with lower PTX sensitivity.	Paclitaxel	76-79	tubulin beta 3 class III	Homo sapiens	17-22
25987214-5	2015	Activation of AhR by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in AhR overexpressing breast cancer cells effectively suppressed the apoptotic response induced by UV-irradiation, doxorubicin, lapatinib and paclitaxel.	Paclitaxel	206-216	aryl hydrocarbon receptor	Homo sapiens	14-17
25987214-5	2015	Activation of AhR by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in AhR overexpressing breast cancer cells effectively suppressed the apoptotic response induced by UV-irradiation, doxorubicin, lapatinib and paclitaxel.	Paclitaxel	206-216	aryl hydrocarbon receptor	Homo sapiens	67-70
25643607-0	2015	Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3beta/beta-catenin signalling.	Paclitaxel	35-45	glycogen synthase kinase 3 beta	Homo sapiens	91-100
25595597-7	2015	Assessment of desloratadine, amodiaquine, and paclitaxel metabolism by a panel of individual CHHs demonstrated that CYP2C8 marker activity robustly correlated with 3-hydroxydesloratadine formation (r(2) of 0.70-0.90).	Paclitaxel	46-56	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	116-122
25457277-0	2015	Human CD14+ cells loaded with Paclitaxel inhibit in vitro cell proliferation of glioblastoma.	Paclitaxel	30-40	CD14 molecule	Homo sapiens	6-10
25457277-8	2015	RESULTS: Both CD14+ and DCs were able to incorporate PTX and release the drug in the CM in a time-dependent manner (maximal release over 24 h).	Paclitaxel	53-56	CD14 molecule	Homo sapiens	14-18
25457277-10	2015	CONCLUSIONS: Our results are the first demonstration that peripheral blood-derived CD14+ and DCs, in addition to their application for immunotherapy for GB, could also be used to delivery anti-cancer drugs, such as PTX, to kill GB cells.	Paclitaxel	215-218	CD14 molecule	Homo sapiens	83-87
25732874-3	2015	Our paclitaxel-carrying ND prodrug, ND(PXL), is activated following proteolytic cleavage by MMP9, resulting in localized cytotoxic chemotherapy.	Paclitaxel	4-14	matrix metallopeptidase 9	Mus musculus	92-96
25499080-3	2015	Silencing of p53 or KRAS in A549 or H358 cells either enhanced or attenuated the resistance of cells to cisplatin and taxol through promotion or suppression of the NF-kappaB p65 nuclear translocation.	Paclitaxel	118-123	RELA proto-oncogene, NF-kB subunit	Homo sapiens	174-177
25516145-0	2015	CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.	Paclitaxel	69-79	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	0-6
25516145-4	2015	The aim of the present study was to determine the role of CYP1B1 expression in the drug resistance of OC to the taxane, paclitaxel (PTX).	Paclitaxel	120-130	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	58-64
25516145-4	2015	The aim of the present study was to determine the role of CYP1B1 expression in the drug resistance of OC to the taxane, paclitaxel (PTX).	Paclitaxel	132-135	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	58-64
25516145-9	2015	In some cell lines, PTX induced CYP1B1 expression, which resulted in drug resistance.	Paclitaxel	20-23	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	32-38
25516145-12	2015	The inhibition of CYP1B1 expression by specific agents may provide a novel therapeutic strategy for the treatment of patients resistant to PTX and may improve the prognosis of these patients.	Paclitaxel	139-142	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	18-24
25973302-9	2015	Finally, we demonstrated that MK enhanced the cytotoxicity of paclitaxel and/or cisplatin by accumulated cisplatin and paclitaxel through inhibited the expression of multidrug resistance-associated protein 3 (MRP3).	Paclitaxel	62-72	ATP binding cassette subfamily C member 3	Homo sapiens	166-207
25973302-9	2015	Finally, we demonstrated that MK enhanced the cytotoxicity of paclitaxel and/or cisplatin by accumulated cisplatin and paclitaxel through inhibited the expression of multidrug resistance-associated protein 3 (MRP3).	Paclitaxel	62-72	ATP binding cassette subfamily C member 3	Homo sapiens	209-213
26370682-9	2015	In addition, the present study raised the possibility that Clock and Bmal1 may in part play a role in preventing the cells from entering G1 to S phase of cell cycle via suppression of CyclinD1 expression, and thus acquiring resistance to Paclitaxel.	Paclitaxel	238-248	cyclin D1	Homo sapiens	184-192
25535399-0	2014	Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes.	Paclitaxel	0-10	glycogen synthase kinase 3 beta	Homo sapiens	65-70
25535399-5	2014	RESULTS: A significant relationship between the GSK-3B rs6438552 polymorphism and paclitaxel-induced neurotoxicity was evident.	Paclitaxel	82-92	glycogen synthase kinase 3 beta	Homo sapiens	48-54
25335891-6	2014	TRAIP-depleted cells bypassed taxol-induced mitotic arrest and displayed significantly reduced kinetochore levels of MAD2 (also known as MAD2L1) but not of other spindle checkpoint proteins in the presence of nocodazole.	Paclitaxel	30-35	TRAF interacting protein	Homo sapiens	0-5
25175513-0	2014	hMSH2 expression is associated with paclitaxel resistance in ovarian carcinoma, and inhibition of hMSH2 expression in vitro restores paclitaxel sensitivity.	Paclitaxel	36-46	mutS homolog 2	Homo sapiens	0-5
25175513-0	2014	hMSH2 expression is associated with paclitaxel resistance in ovarian carcinoma, and inhibition of hMSH2 expression in vitro restores paclitaxel sensitivity.	Paclitaxel	133-143	mutS homolog 2	Homo sapiens	98-103
25175513-1	2014	The objective of the present study was to investigate the association between paclitaxel resistance, gene copy number, and gene expression in ovarian carcinoma, and to restore paclitaxel sensitivity in a paclitaxel-resistant ovarian carcinoma cell line by using hMSH2-targeting siRNA.	Paclitaxel	78-88	mutS homolog 2	Homo sapiens	262-267
25175513-1	2014	The objective of the present study was to investigate the association between paclitaxel resistance, gene copy number, and gene expression in ovarian carcinoma, and to restore paclitaxel sensitivity in a paclitaxel-resistant ovarian carcinoma cell line by using hMSH2-targeting siRNA.	Paclitaxel	176-186	mutS homolog 2	Homo sapiens	262-267
25175513-1	2014	The objective of the present study was to investigate the association between paclitaxel resistance, gene copy number, and gene expression in ovarian carcinoma, and to restore paclitaxel sensitivity in a paclitaxel-resistant ovarian carcinoma cell line by using hMSH2-targeting siRNA.	Paclitaxel	176-186	mutS homolog 2	Homo sapiens	262-267
25175513-2	2014	Paclitaxel-resistant ovarian carcinoma cell lines OC3/TAX300 and OC3/TAX50 and their parental cell lines were analyzed by comparative genomic hybridization, and the expression levels of hMSH2 in ovarian carcinoma cell lines and tissues were determined.	Paclitaxel	0-10	mutS homolog 2	Homo sapiens	186-191
25175513-3	2014	An siRNA targeted to hMSH2 mRNA was used to transfect a paclitaxel-resistant cell line.	Paclitaxel	56-66	mutS homolog 2	Homo sapiens	21-26
25175513-6	2014	hMSH2 was overexpressed in 93.9 and 47.6% of paclitaxel-treated and untreated ovarian carcinoma tissue samples (P=0.0001), respectively.	Paclitaxel	45-55	mutS homolog 2	Homo sapiens	0-5
25175513-9	2014	hMSH2 siRNA increased paclitaxel sensitivity, inhibited OC3/TAX300 cell proliferation (G2/M arrest), and increased susceptibility to apoptosis.	Paclitaxel	22-32	mutS homolog 2	Homo sapiens	0-5
25175513-10	2014	hMSH2 expression was upregulated in ovarian carcinoma cell lines and tissues after paclitaxel treatment.	Paclitaxel	83-93	mutS homolog 2	Homo sapiens	0-5
25175513-11	2014	hMSH2 overexpression is related to paclitaxel resistance and poor prognosis.	Paclitaxel	35-45	mutS homolog 2	Homo sapiens	0-5
25175513-12	2014	Inhibition of hMSH2 expression in vitro restores paclitaxel sensitivity in paclitaxel-resistant ovarian carcinoma cell lines and indicates a new direction in adjuvant therapy for ovarian carcinoma.	Paclitaxel	49-59	mutS homolog 2	Homo sapiens	14-19
24219311-5	2014	Also, FA-M-beta-CyD increased antitumor activity of paclitaxel, a class IV compound in the biopharmaceutical classification system (BCS), but not 5-fluorouracil, a class III compound in the BCS.	Paclitaxel	52-62	cytochrome b-245, beta polypeptide	Mus musculus	16-19
25400759-0	2014	MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo.	Paclitaxel	53-63	microRNA 634	Homo sapiens	0-7
25400759-4	2014	Furthermore, we clarified the role of miR-634, most significantly downregulated in the paclitaxel-resistant CNE-1/Taxol, in regulating the paclitaxel sensitivity in NPC cells.	Paclitaxel	87-97	microRNA 634	Homo sapiens	38-45
25400759-4	2014	Furthermore, we clarified the role of miR-634, most significantly downregulated in the paclitaxel-resistant CNE-1/Taxol, in regulating the paclitaxel sensitivity in NPC cells.	Paclitaxel	139-149	microRNA 634	Homo sapiens	38-45
25400759-5	2014	We restored miR-634 expression in the CNE-1/Taxol cells by lentivirus infection, and found restoration of miR-634 re-sensitized the CNE-1/Taxol cells to paclitaxel in vitro by MTT assay and colony formation assay.	Paclitaxel	153-163	microRNA 634	Homo sapiens	106-113
25400759-6	2014	In xenograft mouse model, we found that miR-634 inhibited tumor growth and enhanced paclitaxel sensitivity.	Paclitaxel	84-94	microRNA 634	Homo sapiens	40-47
24882083-2	2014	This study was directed to evaluate the inhibitory effects of cisplatin and paclitaxel on two CYP450 enzymes namely CYP2E1 and CYP3A1/2 in hepatic microsomes isolated from normal and turmeric pretreated rats.	Paclitaxel	76-86	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	127-133
24882083-9	2014	The inhibitory influence of paclitaxel (10, 50 and 100 muM) on CYP3A1/2 decreased with increasing the drug concentration and this inhibition was augmented by turmeric pretreatment.	Paclitaxel	28-38	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	63-69
24882083-10	2014	Interestingly, the inhibition of this enzyme by paclitaxel (10 muM) was switched from mixed type in normal microsomes to competitive manner in turmeric pretreated ones with a marked reduction of Ki values reflecting greater inhibitory influence of paclitaxel on CYP3A1/2 by turmeric pretreatment.	Paclitaxel	48-58	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	262-268
25055934-10	2014	Markers of apoptosis (caspase-3) and proliferation (Ki-67) were only significantly altered in rats treated with both lapatinib and paclitaxel.	Paclitaxel	131-141	caspase 3	Rattus norvegicus	22-31
25065758-6	2014	Strikingly, the EB1-mediated recruitment of TRIO to microtubule ends is required for proper neurite outgrowth, and stabilization of the microtubule network by paclitaxel affects both the TRIO-NAV1 interaction and the accumulation of these proteins in neurite extensions.	Paclitaxel	159-169	trio Rho guanine nucleotide exchange factor	Homo sapiens	187-191
25065758-6	2014	Strikingly, the EB1-mediated recruitment of TRIO to microtubule ends is required for proper neurite outgrowth, and stabilization of the microtubule network by paclitaxel affects both the TRIO-NAV1 interaction and the accumulation of these proteins in neurite extensions.	Paclitaxel	159-169	neuron navigator 1	Homo sapiens	192-196
24925370-10	2014	Paclitaxel treatment further enhanced the expression of increased ABC transporters transcripts in cells overexpressing SHH.	Paclitaxel	0-10	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	66-69
24925370-12	2014	Higher level of SHH leads to increase in ABC transporters expression in a manner dependent on paclitaxel.	Paclitaxel	94-104	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	41-44
26949019-4	2016	FosB expression was increased by treatment with doxorubicin, taxol and siSETDB1.	Paclitaxel	61-66	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	0-4
26758421-0	2016	Bufalin enhances antitumor effect of paclitaxel on cervical tumorigenesis via inhibiting the integrin alpha2/beta5/FAK signaling pathway.	Paclitaxel	37-47	integrin subunit alpha 2	Homo sapiens	93-108
26758421-0	2016	Bufalin enhances antitumor effect of paclitaxel on cervical tumorigenesis via inhibiting the integrin alpha2/beta5/FAK signaling pathway.	Paclitaxel	37-47	tubulin beta 4A class IVa	Homo sapiens	109-114
26758421-0	2016	Bufalin enhances antitumor effect of paclitaxel on cervical tumorigenesis via inhibiting the integrin alpha2/beta5/FAK signaling pathway.	Paclitaxel	37-47	protein tyrosine kinase 2	Homo sapiens	115-118
26446447-10	2016	CONCLUSION: This is the first report of a clopidogrel-paclitaxel interaction, suggesting that clinically used doses of clopidogrel can reduce the cytochrome P450 2C8 (CYP2C8)-mediated systemic clearance of paclitaxel, leading to an increased risk of paclitaxel toxicity.	Paclitaxel	54-64	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	146-165
26446447-10	2016	CONCLUSION: This is the first report of a clopidogrel-paclitaxel interaction, suggesting that clinically used doses of clopidogrel can reduce the cytochrome P450 2C8 (CYP2C8)-mediated systemic clearance of paclitaxel, leading to an increased risk of paclitaxel toxicity.	Paclitaxel	54-64	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	167-173
26446447-10	2016	CONCLUSION: This is the first report of a clopidogrel-paclitaxel interaction, suggesting that clinically used doses of clopidogrel can reduce the cytochrome P450 2C8 (CYP2C8)-mediated systemic clearance of paclitaxel, leading to an increased risk of paclitaxel toxicity.	Paclitaxel	206-216	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	146-165
26446447-10	2016	CONCLUSION: This is the first report of a clopidogrel-paclitaxel interaction, suggesting that clinically used doses of clopidogrel can reduce the cytochrome P450 2C8 (CYP2C8)-mediated systemic clearance of paclitaxel, leading to an increased risk of paclitaxel toxicity.	Paclitaxel	206-216	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	167-173
26446447-10	2016	CONCLUSION: This is the first report of a clopidogrel-paclitaxel interaction, suggesting that clinically used doses of clopidogrel can reduce the cytochrome P450 2C8 (CYP2C8)-mediated systemic clearance of paclitaxel, leading to an increased risk of paclitaxel toxicity.	Paclitaxel	206-216	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	146-165
26446447-10	2016	CONCLUSION: This is the first report of a clopidogrel-paclitaxel interaction, suggesting that clinically used doses of clopidogrel can reduce the cytochrome P450 2C8 (CYP2C8)-mediated systemic clearance of paclitaxel, leading to an increased risk of paclitaxel toxicity.	Paclitaxel	206-216	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	167-173
26659667-9	2016	Eribulin but not paclitaxel-induced EB1 expression ~2.2-fold while paclitaxel but not eribulin mildly suppressed EB3 expression.	Paclitaxel	67-77	microtubule-associated protein, RP/EB family, member 3	Mus musculus	113-116
26658369-5	2016	Immunohistochemistry showed that paclitaxel (4mg/kg) treatment significantly increased substance P expression (37.6+-3.7% on day 7, 43.6+-4.6% on day 14) in the superficial layers of the spinal dorsal horn, whereas calcitonin gene-related peptide (CGRP) expression was unchanged.	Paclitaxel	33-43	calcitonin-related polypeptide alpha	Rattus norvegicus	215-246
26658369-5	2016	Immunohistochemistry showed that paclitaxel (4mg/kg) treatment significantly increased substance P expression (37.6+-3.7% on day 7, 43.6+-4.6% on day 14) in the superficial layers of the spinal dorsal horn, whereas calcitonin gene-related peptide (CGRP) expression was unchanged.	Paclitaxel	33-43	calcitonin-related polypeptide alpha	Rattus norvegicus	248-252
26773176-0	2016	The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line.	Paclitaxel	30-40	SIX homeobox 1	Homo sapiens	12-16
26773176-11	2016	In paclitaxel-resistant cells, there was a significant increase in Six1 and BCL-2 mRNA levels (p = 0.0007) with a marked decrease in pro-apoptotic Bax mRNA expression level (p = 0.03); however, there was no significant change in P53 expression (p = 0.025).	Paclitaxel	3-13	SIX homeobox 1	Homo sapiens	67-71
26290405-0	2016	Effect of buffer conditions on CYP2C8-mediated paclitaxel 6alpha-hydroxylation and CYP3A4-mediated triazolam alpha- and 4-hydroxylation by human liver microsomes.	Paclitaxel	47-57	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	31-37
26626440-3	2015	Here, we investigated the role of miR-186 in sensitizing ovarian cancer cells to paclitaxel and cisplatin.	Paclitaxel	81-91	microRNA 186	Homo sapiens	34-41
26626440-8	2015	After miR-186 transfection, all the cell lines showed increased sensitivity to paclitaxel and cisplatin.	Paclitaxel	79-89	microRNA 186	Homo sapiens	6-13
26626440-12	2015	CONCLUSION: Our results are the first to demonstrate that miR-186 may sensitize ovarian cancer cell to paclitaxel and cisplatin by targeting ABCB1 and modulating the expression of GST-pi.	Paclitaxel	103-113	microRNA 186	Homo sapiens	58-65
26452028-7	2015	In vitro studies showed that CHI3L1 up-regulated the expression of anti-apoptotic Mcl-1 protein and hampered paclitaxel-induced apoptosis of ovarian cancer cells.	Paclitaxel	109-119	chitinase 3 like 1	Homo sapiens	29-35
26360705-0	2015	Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.	Paclitaxel	28-38	Janus kinase 2	Homo sapiens	14-18
26360705-6	2015	OC3/TAX300 cells treated with JAK2-siRNA exhibited stalled growth, increased cell cycle arrest in G2/M phase, and enhanced apoptosis in response to paclitaxel.	Paclitaxel	148-158	Janus kinase 2	Homo sapiens	30-34
26360705-8	2015	To determine whether JAK2 promotes paclitaxel resistance via phosphorylation of signal transducer and activator of transcription 3 (STAT3), a transcription factor known to be involved in resistance to chemotherapy, we treated OC3/TAX300 cells with JAK2 kinase inhibitor AG490.	Paclitaxel	35-45	Janus kinase 2	Homo sapiens	21-25
26360705-10	2015	CONCLUSIONS: Collectively, we conclude that the JAK2-STAT3 pathway promotes the development of paclitaxel resistance via upregulating the expression of prosurvival and antiapoptotic genes.	Paclitaxel	95-105	Janus kinase 2	Homo sapiens	48-52
26516138-0	2015	Influence of MiR-451 on Drug Resistances of Paclitaxel-Resistant Breast Cancer Cell Line.	Paclitaxel	44-54	microRNA 451a	Homo sapiens	13-20
26516138-1	2015	BACKGROUND: This study aimed to investigate the potential influence of microRNA-451 (miR-451) in drug resistances of the Paclitaxel-resistant breast cancer cell line by transfecting miR-451 mimics and miR-451 inhibitors to MCE-7, MCF-7/EPI, and MCF-7/DOC.	Paclitaxel	121-131	microRNA 451a	Homo sapiens	71-83
26516138-1	2015	BACKGROUND: This study aimed to investigate the potential influence of microRNA-451 (miR-451) in drug resistances of the Paclitaxel-resistant breast cancer cell line by transfecting miR-451 mimics and miR-451 inhibitors to MCE-7, MCF-7/EPI, and MCF-7/DOC.	Paclitaxel	121-131	microRNA 451a	Homo sapiens	85-92
26516138-9	2015	CONCLUSIONS: Increased miR-451 expression may negatively regulate Bcl-2 mRNA and protein expression, followed by affecting the protein expression of caspase 3, and accelerate the apoptosis in breast cancer, indicating that miR-451 might influence the drug resistances of the Paclitaxel-resistant breast cancer cell line.	Paclitaxel	275-285	microRNA 451a	Homo sapiens	23-30
26324059-5	2015	Overexpression of proteins in the lipid metabolism processes, such as E3 ubiquitin-protein ligase RNF139 (RNF139) and Hydroxymethylglutaryl-CoA synthase (HMGCS1), have not been reported previously in the study of paclitaxel resistance, suggesting possibly different mechanism between nanoparticle and single molecular drug resistance.	Paclitaxel	213-223	ring finger protein 139	Homo sapiens	98-104
26324059-5	2015	Overexpression of proteins in the lipid metabolism processes, such as E3 ubiquitin-protein ligase RNF139 (RNF139) and Hydroxymethylglutaryl-CoA synthase (HMGCS1), have not been reported previously in the study of paclitaxel resistance, suggesting possibly different mechanism between nanoparticle and single molecular drug resistance.	Paclitaxel	213-223	ring finger protein 139	Homo sapiens	106-112
26363097-0	2015	Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.	Paclitaxel	52-62	microRNA 134	Homo sapiens	29-36
26363097-3	2015	Over-expression of miR-134 enhanced the sensitivity of SKOV3-TR30 cells to paclitaxel, and increased paclitaxel-induced apoptosis.	Paclitaxel	75-85	microRNA 134	Homo sapiens	19-26
26363097-3	2015	Over-expression of miR-134 enhanced the sensitivity of SKOV3-TR30 cells to paclitaxel, and increased paclitaxel-induced apoptosis.	Paclitaxel	101-111	microRNA 134	Homo sapiens	19-26
26363097-6	2015	In conclusion, our findings indicate that repression of miR-134 and consequent up-regulation of Pak2 might contribute to paclitaxel resistance.	Paclitaxel	121-131	microRNA 134	Homo sapiens	56-63
26363097-6	2015	In conclusion, our findings indicate that repression of miR-134 and consequent up-regulation of Pak2 might contribute to paclitaxel resistance.	Paclitaxel	121-131	p21 (RAC1) activated kinase 2	Homo sapiens	96-100
26722421-9	2015	15 genes of 762 transcripts on this chromosome region were consistently up-regulated detected by cDNA microarray in three taxol resistant sub-lines, and functionally clustered into various groups, including genes related to vascular formation vascular formation (ANGPT1), apoptosis (MYC, TOP1MT), cell adhesion and cell cycle (PPP1R16A, SDC2, CA2, ANKRD46), gene regulation (HRSP12, ZNF696, SLC39A4, POP1), metabolism (PYCRL).	Paclitaxel	122-127	angiopoietin 1	Homo sapiens	263-269
26722421-9	2015	15 genes of 762 transcripts on this chromosome region were consistently up-regulated detected by cDNA microarray in three taxol resistant sub-lines, and functionally clustered into various groups, including genes related to vascular formation vascular formation (ANGPT1), apoptosis (MYC, TOP1MT), cell adhesion and cell cycle (PPP1R16A, SDC2, CA2, ANKRD46), gene regulation (HRSP12, ZNF696, SLC39A4, POP1), metabolism (PYCRL).	Paclitaxel	122-127	DNA topoisomerase I mitochondrial	Homo sapiens	288-294
27005093-0	2015	Nucleolin targeting AS1411 aptamer modified pH-sensitive micelles: A dual-functional strategy for paclitaxel delivery.	Paclitaxel	98-108	nucleolin	Homo sapiens	0-9
26232188-3	2015	Our aim was to determine the interaction between the ERalpha/ERbeta ratio and the response to cytotoxic treatments such as cisplatin (CDDP), paclitaxel (PTX) and tamoxifen (TAM).	Paclitaxel	141-151	estrogen receptor 2	Homo sapiens	61-67
26232188-3	2015	Our aim was to determine the interaction between the ERalpha/ERbeta ratio and the response to cytotoxic treatments such as cisplatin (CDDP), paclitaxel (PTX) and tamoxifen (TAM).	Paclitaxel	153-156	estrogen receptor 2	Homo sapiens	61-67
26366090-7	2015	Moreover, cordycepin plus cisplatin and/or paclitaxel significantly induced cleavage of caspase-8, caspase-9, caspase-3, and poly ADP-ribose polymerase, and phosphorylation of c-Jun NH2-terminal kinase, extracellular signal-regulated kinase, p38, and p53 proteins in MA-10 cells.	Paclitaxel	43-53	caspase 9	Mus musculus	99-108
26366090-7	2015	Moreover, cordycepin plus cisplatin and/or paclitaxel significantly induced cleavage of caspase-8, caspase-9, caspase-3, and poly ADP-ribose polymerase, and phosphorylation of c-Jun NH2-terminal kinase, extracellular signal-regulated kinase, p38, and p53 proteins in MA-10 cells.	Paclitaxel	43-53	mitogen-activated protein kinase 14	Mus musculus	242-245
26347363-4	2015	The pharmacokinetic profiles of PTX released from PSC after intravenous administration were studied in rats.	Paclitaxel	32-35	PSC	Homo sapiens	50-53
26347363-9	2015	CONCLUSION: Based on these results, PSC could be considered as a potential therapeutic PTX delivery system for breast cancer with low renal toxicity.	Paclitaxel	87-90	PSC	Homo sapiens	36-39
26305791-0	2015	Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.	Paclitaxel	177-187	microRNA 205	Homo sapiens	36-43
26086430-7	2015	Finally, the in vivo studies on NCI-H466 tumor-bearing nude mice demonstrated that the OCT(Phe)-PEG-ss-PTX possessed superior tumor-targeting ability and antitumor activity over mPEG-PTX, OCT(Phe)-PEG-PTX and Taxol, as well as minimal collateral damage.	Paclitaxel	209-214	plexin A2	Mus musculus	87-90
26152689-10	2015	CCNG1, validated as a direct target of miR-9, mediates paclitaxel resistance.	Paclitaxel	55-65	cyclin G1	Homo sapiens	0-5
26152689-13	2015	CONCLUSIONS: Methylation-associated miR-9 down-regulation is probably one of the key mechanisms for paclitaxel resistance in EOC cells, via targeting CCNG1.	Paclitaxel	100-110	cyclin G1	Homo sapiens	150-155
25936586-3	2015	CTXA reversibly inhibited the CYP1A2-catalyzed phenacetin O-deethylation, CYP2C8-catalyzed paclitaxel 6-hydroxylation, and CYP2C9-catalyzed diclofenac 4"-hydroxylation with half-maximal inhibitory concentration (IC50) values of 3.9, 4.7, and 2.9 microM, respectively.	Paclitaxel	91-101	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	74-80
26115510-8	2015	Moreover, treatment with the CAF matrix inhibited spontaneous and medium or high dose of paclitaxel-induced A549 cell apoptosis.	Paclitaxel	89-99	lysine acetyltransferase 2B	Homo sapiens	29-32
26115510-9	2015	Inhibition of PI3K or GRP78 attenuated the CAF matrix-mediated inhibition on paclitaxel-induced A549 cell apoptosis.	Paclitaxel	77-87	lysine acetyltransferase 2B	Homo sapiens	43-46
26115510-10	2015	Our data indicated that HGF in the CAF matrix activated the Met/PI3K/AKT and up-regulated GRP78 expression, promoting chemoresistance to paclitaxel-mediated apoptosis in A549 cells.	Paclitaxel	137-147	hepatocyte growth factor	Homo sapiens	24-27
26115510-10	2015	Our data indicated that HGF in the CAF matrix activated the Met/PI3K/AKT and up-regulated GRP78 expression, promoting chemoresistance to paclitaxel-mediated apoptosis in A549 cells.	Paclitaxel	137-147	lysine acetyltransferase 2B	Homo sapiens	35-38
26015406-6	2015	We further show that phospho-MARCKS acted upstream of Src activation upon paclitaxel exposure.	Paclitaxel	74-84	myristoylated alanine rich protein kinase C substrate	Homo sapiens	29-35
26015406-7	2015	Reduction of phospho-MARCKS by knockdown of MARCKS or pharmacological agents increased paclitaxel sensitivity.	Paclitaxel	87-97	myristoylated alanine rich protein kinase C substrate	Homo sapiens	21-27
26015406-7	2015	Reduction of phospho-MARCKS by knockdown of MARCKS or pharmacological agents increased paclitaxel sensitivity.	Paclitaxel	87-97	myristoylated alanine rich protein kinase C substrate	Homo sapiens	44-50
26015406-8	2015	Particularly, a known phospho-MARCKS inhibitor, MANS peptide, was demonstrated to increase paclitaxel efficacy and attenuate angiogenesis/metastasis of xenografted breast cancer cells by decreasing abundance of phospho-MARCKS and messages of inflammatory mediators.	Paclitaxel	91-101	myristoylated alanine rich protein kinase C substrate	Homo sapiens	30-36
26015406-9	2015	Our data suggest that unresponsiveness of breast cancer to paclitaxel treatment is, at least in part, mediated by phospho-MARCKS and also provide an alternative therapeutic strategy against breast cancer by improving taxanes sensitivity.	Paclitaxel	59-69	myristoylated alanine rich protein kinase C substrate	Homo sapiens	122-128
26049416-6	2015	METHODS: We have examined the effect of Apc loss in MMTV-PyMT mouse breast cancer cells on gene expression changes of ATP-binding cassette transporters and immunofluorescence to determine proliferative and apoptotic response of cells to cisplatin, doxorubicin and paclitaxel.	Paclitaxel	264-274	APC regulator of WNT signaling pathway	Homo sapiens	40-43
26049416-12	2015	In the human metaplastic breast cancer cell line MDA-MB-157, APC knockdown led to paclitaxel and cisplatin resistance.	Paclitaxel	82-92	APC regulator of WNT signaling pathway	Homo sapiens	61-64
24347266-8	2014	However, when BMDCs from paclitaxel-treated mice were injected into wild-type EMT/6-bearing mice, a substantial increase in tumor growth and BMDC infiltration was detected compared to osteopontin-depleted EMT/6-bearing mice injected with BMDCs from paclitaxel-treated mice.	Paclitaxel	25-35	secreted phosphoprotein 1	Mus musculus	184-195
25015454-10	2014	HeLa/PTX cells, with higher levels of ROS and Txr1 mRNA expression, are more resistant to PTX than HeLa cells.	Paclitaxel	5-8	proline rich 13	Homo sapiens	46-50
25015454-10	2014	HeLa/PTX cells, with higher levels of ROS and Txr1 mRNA expression, are more resistant to PTX than HeLa cells.	Paclitaxel	90-93	proline rich 13	Homo sapiens	46-50
30880751-10	2019	Combination of paclitaxel with overexpression of miR-34a significantly decreased cell viability compared to cell treated with miR-34a or paclitaxel alone.	Paclitaxel	137-147	microRNA 34a	Homo sapiens	49-56
24959746-4	2014	METHODOLOGY/PRINCIPAL FINDINGS: Our results from cell viability assays exposing CAR agonist or inverse-agonist to mouse and human lung cancer cells modulated the antineoplastic effect of paclitaxel.	Paclitaxel	187-197	coxsackie virus and adenovirus receptor	Mus musculus	80-83
25783790-8	2015	Furthermore, overexpression of miR-34a increased chemosensitivity of breast cancer cells to paclitaxel (PTX) by downregulating the Notch1 pathway.	Paclitaxel	92-102	microRNA 34a	Homo sapiens	31-38
25783790-8	2015	Furthermore, overexpression of miR-34a increased chemosensitivity of breast cancer cells to paclitaxel (PTX) by downregulating the Notch1 pathway.	Paclitaxel	104-107	microRNA 34a	Homo sapiens	31-38
25783790-9	2015	Mammosphere formation and expression of the stemness factor ALDH1 were also reduced in the cells treated with miR-34a and PTX compared to those treated with PTX alone.	Paclitaxel	157-160	microRNA 34a	Homo sapiens	110-117
24959746-6	2014	Interestingly, the mCAR agonist TCPOBOP enhanced the expression of two tumor suppressor genes, namely WT1 and MGMT, which were additively enhanced in cells treated with CAR agonist in combination with paclitaxel.	Paclitaxel	201-211	coxsackie virus and adenovirus receptor	Mus musculus	19-23
30114390-3	2018	We had earlier shown that the microRNA-143 (miR-143) replenishment not only chemosensitizers CRC cell line with mutant KRAS instead of wild-type KRAS gene, to paclitaxel-mediated cytotoxicity, but also inhibits cell migration and invasion ability.	Paclitaxel	159-169	microRNA 143	Homo sapiens	30-42
24847940-7	2014	The PTX prodrug conjugate (PGD) was compared to unbound PTX through in vitro evaluations against breast cancer cells and normal kidney cells as well as through in vivo evaluations using xenograft mice models.	Paclitaxel	4-7	3-phosphoglycerate dehydrogenase	Mus musculus	27-30
24847940-9	2014	Regression analysis between the magnitude of PGD-induced cytotoxic increase over PTX and cathepsin B expression showed a strong, statistically significant correlation (r(2) = 0.652, p &lt; 0.05).	Paclitaxel	81-84	phosphoglycerate dehydrogenase	Homo sapiens	45-48
24847940-10	2014	The PGD conjugate also demonstrated a markedly higher tumor reduction as compared to PTX treatment alone in MDA-MB-231 tumor xenograft models, with PGD-treated tumor volumes being 48% and 34% smaller than PTX-treated volumes at weeks 2 and 3 after treatment initiation.	Paclitaxel	85-88	phosphoglycerate dehydrogenase	Homo sapiens	4-7
24847940-10	2014	The PGD conjugate also demonstrated a markedly higher tumor reduction as compared to PTX treatment alone in MDA-MB-231 tumor xenograft models, with PGD-treated tumor volumes being 48% and 34% smaller than PTX-treated volumes at weeks 2 and 3 after treatment initiation.	Paclitaxel	205-208	phosphoglycerate dehydrogenase	Homo sapiens	4-7
25783790-10	2015	Taken together, our results indicate that miR-34a inhibited breast cancer stemness and increased the chemosensitivity to PTX partially by downregulating the Notch1 pathway, suggesting that miR-34a/Notch1 play an important role in regulating breast cancer stem cells.	Paclitaxel	121-124	microRNA 34a	Homo sapiens	42-49
25783790-10	2015	Taken together, our results indicate that miR-34a inhibited breast cancer stemness and increased the chemosensitivity to PTX partially by downregulating the Notch1 pathway, suggesting that miR-34a/Notch1 play an important role in regulating breast cancer stem cells.	Paclitaxel	121-124	microRNA 34a	Homo sapiens	189-196
26261543-6	2015	HMGB1 was upregulated in paclitaxel resistant EC cells, it mediated autophagy and contributed to chemotherapy resistance in endometrial carcinoma in vitro.	Paclitaxel	25-35	high mobility group box 1	Homo sapiens	0-5
30114390-3	2018	We had earlier shown that the microRNA-143 (miR-143) replenishment not only chemosensitizers CRC cell line with mutant KRAS instead of wild-type KRAS gene, to paclitaxel-mediated cytotoxicity, but also inhibits cell migration and invasion ability.	Paclitaxel	159-169	microRNA 143	Homo sapiens	44-51
25887886-4	2015	Tumors from mice treated with combined therapy of paclitaxel and the IL1 receptor antagonist anakinra exhibit increased number of M2 macrophages and vessel leakiness when compared with paclitaxel monotherapy-treated mice, indicating a prometastatic role of M2 macrophages in the IL1beta-deprived microenvironment.	Paclitaxel	185-195	interleukin 1 complex	Mus musculus	69-72
30269613-2	2018	Herein, a low-density lipoprotein receptor-related protein and a RNA aptamer bound CD133 were used as dual-targeting ligands to prepare dual-modified cationic liposomes (DP-CLPs) loaded with survivin siRNA and paclitaxel (DP-CLPs-PTX-siRNA) for actively targeting imaging and treating CD133+ glioma stem cells after passing through the blood-brain barrier.	Paclitaxel	210-220	baculoviral IAP repeat-containing 5	Mus musculus	191-199
25886093-0	2015	Alterations in ovarian cancer cell adhesion drive taxol resistance by increasing microtubule dynamics in a FAK-dependent manner.	Paclitaxel	50-55	protein tyrosine kinase 2	Homo sapiens	107-110
25886093-7	2015	Adhesion strength correlated best with Taxol-sensitivity, and was found to be independent of microtubule polymerization but dependent on focal adhesion kinase (FAK), which was up-regulated in Taxol-resistant cells.	Paclitaxel	192-197	protein tyrosine kinase 2	Homo sapiens	137-158
25886093-7	2015	Adhesion strength correlated best with Taxol-sensitivity, and was found to be independent of microtubule polymerization but dependent on focal adhesion kinase (FAK), which was up-regulated in Taxol-resistant cells.	Paclitaxel	192-197	protein tyrosine kinase 2	Homo sapiens	160-163
25681684-2	2015	Among various molecular factors, presence of MyD88, a component of TLR-4/MyD88 mediated NF-kappaB signaling in EOC tumors is reported to cause intrinsic paclitaxel resistance and poor survival.	Paclitaxel	153-163	MYD88 innate immune signal transduction adaptor	Homo sapiens	45-50
25681684-2	2015	Among various molecular factors, presence of MyD88, a component of TLR-4/MyD88 mediated NF-kappaB signaling in EOC tumors is reported to cause intrinsic paclitaxel resistance and poor survival.	Paclitaxel	153-163	MYD88 innate immune signal transduction adaptor	Homo sapiens	73-78
25681684-5	2015	Using isogenic cellular matrices of cisplatin, paclitaxel and platinum-taxol resistant MyD88(negative) A2780 ovarian cancer cells expressing a NF-kappaB reporter sensor, we showed that enhanced NF-kappaB activity was required for cisplatin but not for paclitaxel resistance.	Paclitaxel	252-262	MYD88 innate immune signal transduction adaptor	Homo sapiens	87-92
24800949-11	2014	Coadministration of pazopanib and lapatinib, weak inhibitors of CYP2C8 and CYP3A4, had an inhibitory effect on paclitaxel clearance.	Paclitaxel	111-121	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	64-70
24886434-5	2014	RESULTS: Treatment of isolated tumor cells from the ascites of ovarian cancer patients and HEY ovarian cancer cell line with paclitaxel resulted in a CSC-like residual population which coincided with the activation of Janus activated kinase 2 (JAK2) and signal transducer and activation of transcription 3 (STAT3) pathway in paclitaxel surviving cells.	Paclitaxel	325-335	Janus kinase 2	Homo sapiens	244-248
24886434-6	2014	Both paclitaxel-induced JAK2/STAT3 activation and CSC-like characteristics were inhibited by a low dose JAK2-specific small molecule inhibitor CYT387 (1 muM) in vitro.	Paclitaxel	5-15	Janus kinase 2	Homo sapiens	24-28
24886434-6	2014	Both paclitaxel-induced JAK2/STAT3 activation and CSC-like characteristics were inhibited by a low dose JAK2-specific small molecule inhibitor CYT387 (1 muM) in vitro.	Paclitaxel	5-15	Janus kinase 2	Homo sapiens	104-108
24886434-9	2014	These results were consistent with significantly reduced activation of JAK2 and STAT3 in paclitaxel and CYT387-treated cell-derived xenografts compared to paclitaxel only-treated cell derived xenografts.	Paclitaxel	89-99	Janus kinase 2	Homo sapiens	71-75
25681684-9	2015	Intriguingly, silencing of MyD88 in cisplatin resistant and MyD88(positive) TOV21G and SKOV3 cells showed enhanced NF-kappaB activity after cisplatin but not after paclitaxel or platinum-taxol treatments.	Paclitaxel	187-192	MYD88 innate immune signal transduction adaptor	Homo sapiens	27-32
25681684-9	2015	Intriguingly, silencing of MyD88 in cisplatin resistant and MyD88(positive) TOV21G and SKOV3 cells showed enhanced NF-kappaB activity after cisplatin but not after paclitaxel or platinum-taxol treatments.	Paclitaxel	187-192	MYD88 innate immune signal transduction adaptor	Homo sapiens	60-65
29991529-0	2018	Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.	Paclitaxel	0-5	protein tyrosine kinase 6	Homo sapiens	14-17
25625960-10	2015	To our knowledge, this is the first study in endometrial carcinoma to show a correlation between overexpression of AURKA and tumor grade, histological type and sensitivity to paclitaxel.	Paclitaxel	175-185	aurora kinase A	Homo sapiens	115-120
24519927-6	2014	In isolated mouse cardiomyocytes, prolonged culture or treatment with taxol resulted in pronounced redistribution of JP2 from T-tubules to the peripheral plasma membrane, without changing total JP2 expression.	Paclitaxel	70-75	junctophilin 2	Mus musculus	117-120
24519927-6	2014	In isolated mouse cardiomyocytes, prolonged culture or treatment with taxol resulted in pronounced redistribution of JP2 from T-tubules to the peripheral plasma membrane, without changing total JP2 expression.	Paclitaxel	70-75	junctophilin 2	Mus musculus	194-197
25625960-11	2015	AURKA is a promising therapeutic target in endometrial cancer and the combination therapy with AURKA inhibitors and paclitaxel could be effective for endometrial cancer that is resistant to conventional treatment and has a poor prognosis.	Paclitaxel	116-126	aurora kinase A	Homo sapiens	0-5
24525192-7	2014	Moreover, immunoblotting analysis also showed that the co-administration of luteolin and paclitaxel activated caspase-8 and caspase-3 and increased the expression of Fas.	Paclitaxel	89-99	caspase 8	Homo sapiens	110-119
29991529-0	2018	Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.	Paclitaxel	0-5	aryl hydrocarbon receptor	Homo sapiens	76-79
29991529-5	2018	Brk was robustly induced following exposure of TNBC model systems to chemotherapeutic agents (Taxol or 5-fluorouracil) and growth in suspension [ultra-low attachment (ULA)].	Paclitaxel	94-99	protein tyrosine kinase 6	Homo sapiens	0-3
24782986-8	2014	The addition of CYT387 with paclitaxel resulted in the suppression of JAK2/STAT3 activation and abrogation of Oct4 and CD117 expression in mouse xenografts.	Paclitaxel	28-38	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	110-114
24782986-10	2014	These data suggest that the systemic administration of paclitaxel enhances Oct4- and CD117-associated CSC-like marker expression in surviving cancer cells in vivo, which can be suppressed by the addition of the JAK2-specific inhibitor CYT387, leading to a significantly smaller tumor burden.	Paclitaxel	55-65	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	75-79
25657335-4	2015	With this in mind, we have developed self-assembly polymeric micelles (PM) able to efficiently co-load an anti-survivin siRNA and a chemotherapeutic agent, such as paclitaxel (PXL; survivin siRNA/PXL PM).	Paclitaxel	164-174	baculoviral IAP repeat-containing 5	Mus musculus	111-119
25657335-5	2015	Previously, we have successfully demonstrated that the downregulation of survivin by using siRNA-containing PM strongly sensitizes different cancer cells to paclitaxel.	Paclitaxel	157-167	baculoviral IAP repeat-containing 5	Mus musculus	73-81
25657335-8	2015	The results obtained in mice xenografed with SKOV3-tr revealed a significant downregulation of survivin expression in tumor tissues together with a potent anticancer activity of survivin siRNA/PXL PM, while the tumors remained unaffected with the same quantity of free paclitaxel.	Paclitaxel	269-279	baculoviral IAP repeat-containing 5	Mus musculus	95-103
25657335-8	2015	The results obtained in mice xenografed with SKOV3-tr revealed a significant downregulation of survivin expression in tumor tissues together with a potent anticancer activity of survivin siRNA/PXL PM, while the tumors remained unaffected with the same quantity of free paclitaxel.	Paclitaxel	269-279	baculoviral IAP repeat-containing 5	Mus musculus	178-186
25633416-9	2015	FOXM1 effector genes such as CDK4, p53 and cyclin D1 were downregulated in gastric cancer cells by combination treatment with DIM and paclitaxel.	Paclitaxel	134-144	cyclin dependent kinase 4	Homo sapiens	29-33
24817940-7	2014	ErbB3 overexpression and AKT/ERK activation in PTX-resistant cell lines were validated, respectively, by quantitative PCR and immunoblotting.	Paclitaxel	47-50	erb-b2 receptor tyrosine kinase 3	Homo sapiens	0-5
29991529-6	2018	Notably, both Taxol and ULA resulted in upregulation of the Aryl hydrocarbon receptor (AhR), a known mediator of cancer prosurvival phenotypes.	Paclitaxel	14-19	aryl hydrocarbon receptor	Homo sapiens	60-85
29991529-6	2018	Notably, both Taxol and ULA resulted in upregulation of the Aryl hydrocarbon receptor (AhR), a known mediator of cancer prosurvival phenotypes.	Paclitaxel	14-19	aryl hydrocarbon receptor	Homo sapiens	87-90
29991529-8	2018	Furthermore, Brk expression was upregulated in Taxol-resistant breast cancer (MCF-7) models.	Paclitaxel	47-52	protein tyrosine kinase 6	Homo sapiens	13-16
29991529-9	2018	Ultimately, Brk was critical for TNBC cell proliferation and survival during Taxol treatment and in the context of ULA as well as for basal cancer cell migration, acquired biological phenotypes that enable cancer cells to successfully complete the metastatic cascade.	Paclitaxel	77-82	protein tyrosine kinase 6	Homo sapiens	12-15
25613006-2	2015	Paclitaxel (PTX) was first covalently conjugated to pullulan (Pull) through a Cathepsin K-sensitive tetrapeptide spacer followed by a self-immolative aminobenzyl alcohol spacer to obtain Pull-(GGPNle-phi-PTX).	Paclitaxel	0-10	cathepsin K	Mus musculus	78-89
30243650-0	2018	Paclitaxel alleviates liver fibrosis induced by bile duct ligation in rats: Role of TGF-beta1, IL-10 and c-Myc.	Paclitaxel	0-10	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	105-110
25613006-2	2015	Paclitaxel (PTX) was first covalently conjugated to pullulan (Pull) through a Cathepsin K-sensitive tetrapeptide spacer followed by a self-immolative aminobenzyl alcohol spacer to obtain Pull-(GGPNle-phi-PTX).	Paclitaxel	12-15	cathepsin K	Mus musculus	78-89
25613006-6	2015	Paclitaxel was rapidly released from the bioconjugate by Cathepsin K cleavage under pathological conditions.	Paclitaxel	0-10	cathepsin K	Mus musculus	57-68
23504048-5	2014	Single and combined use of paclitaxel and SN-38 produced significant cytolethality against the cervical adenocarcinoma cell line CAC-1.	Paclitaxel	27-37	transmembrane protein 54	Homo sapiens	129-134
30243650-8	2018	This antifibrotic effect of PTX was further examined through its inhibitory effect on TGF-beta1 mRNA and protein expression in addition to c-Myc mRNA expression.	Paclitaxel	28-31	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	139-144
23504048-8	2014	MTT assay and the IC50 demonstrated that paclitaxel had strong cytotoxicity against CAC-1 as well as other cancer cells.	Paclitaxel	41-51	transmembrane protein 54	Homo sapiens	84-89
30243650-10	2018	In conclusion, this study suggests that PTX at low dose has the potential to treat BDL-induced liver fibrosis in rats possibly through suppression of TGF-beta1 and c-Myc and activation of IL-10 pathways.	Paclitaxel	40-43	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	164-169
24527095-0	2014	TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma in vitro.	Paclitaxel	39-49	MYD88 innate immune signal transduction adaptor	Homo sapiens	62-67
30367895-1	2018	TRA2A, Transformer2A proteins, plays important roles in paclitaxel resistance and progression of breast cancer.	Paclitaxel	56-66	transformer 2 alpha homolog	Homo sapiens	0-5
24466094-11	2014	Lastly, CYB5D2 expression conferred HeLa cell survival from chemotherapeutic agents (paclitaxel, cisplatin and doxorubicin), with its ability to promote survival being dependent on its heme-binding ability.	Paclitaxel	85-95	cytochrome b5 domain containing 2	Homo sapiens	8-14
33429519-7	2015	The star-shaped PDCP had a large hydrophobic core to load hydrophobic drugs (e.g., paclitaxel).	Paclitaxel	83-93	steroidogenic acute regulatory protein	Homo sapiens	4-8
25081641-2	2015	GBP1:PIM1 binding initiates a signaling pathway that induces resistance to common chemotherapeutics such as paclitaxel.	Paclitaxel	108-118	guanylate binding protein 1	Homo sapiens	0-4
25081641-4	2015	It resulted that only GTP decreases the formation of the GBP1:PIM1 complex through an allosteric mechanism, putting the bases for the identification of new compounds potentially able to revert resistance to paclitaxel.	Paclitaxel	207-217	guanylate binding protein 1	Homo sapiens	57-61
25435430-0	2015	MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis.	Paclitaxel	24-34	microRNA 17	Homo sapiens	103-109
25081695-1	2014	PURPOSE: To study the expression of insulin-like growth factor binding proteins (IGFBPs) in paclitaxel-treated gastric cancer SGC-7901 cells, and to further investigate underlying mechanisms.	Paclitaxel	92-102	insulin like growth factor binding protein 2	Homo sapiens	81-87
30179591-0	2018	Paclitaxel-induced HMGB1 release from macrophages and its implication for peripheral neuropathy in mice: Evidence for a neuroimmune crosstalk.	Paclitaxel	0-10	high mobility group box 1	Mus musculus	19-24
25081695-2	2014	MATERIALS AND METHODS: Real time PCR and Western blot assays were applied to detect the mRNA and protein expression of IGFBP-2, -3 and -5 after paclitaxel (10 nM) treatment of SGC-7901 cells.	Paclitaxel	144-154	insulin like growth factor binding protein 2	Homo sapiens	119-137
25435430-5	2015	Previously, utilizing miRNA arrays we reported that downregulation of miR-17 is at least partly involved in the development of paclitaxel resistance in lung cancer cells by modulating Beclin-1 expression [1].	Paclitaxel	127-137	microRNA 17	Homo sapiens	70-76
25435430-8	2015	Moreover, in this report we showed that the combined overexpression of miR-16 and miR-17 and subsequent paclitaxel treatment greatly sensitized paclitaxel resistant lung cancer cells to paclitaxel by inducing apoptosis via caspase-3 mediated pathway.	Paclitaxel	144-154	microRNA 17	Homo sapiens	82-88
25435430-8	2015	Moreover, in this report we showed that the combined overexpression of miR-16 and miR-17 and subsequent paclitaxel treatment greatly sensitized paclitaxel resistant lung cancer cells to paclitaxel by inducing apoptosis via caspase-3 mediated pathway.	Paclitaxel	144-154	microRNA 17	Homo sapiens	82-88
25435430-10	2015	Our results indicated that though miR-17 and miR-16 had no common target, both miR-16 and miR-17 jointly played roles in the development of paclitaxel resistance in lung cancer.	Paclitaxel	140-150	microRNA 17	Homo sapiens	34-40
30179591-2	2018	Paclitaxel treatment developed mechanical allodynia in mice, as assessed by von Frey test, which was prevented by an anti-HMGB1-neutralizing antibody or thrombomodulin alfa capable of inactivating HMGB1.	Paclitaxel	0-10	high mobility group box 1	Mus musculus	122-127
25435430-10	2015	Our results indicated that though miR-17 and miR-16 had no common target, both miR-16 and miR-17 jointly played roles in the development of paclitaxel resistance in lung cancer.	Paclitaxel	140-150	microRNA 17	Homo sapiens	90-96
24220933-5	2014	MATERIALS AND METHODS: TUBB3 expression was investigated by immunohistochemistry performed on diagnostic biopsies and on available subsequent resection specimens in 65 NSCLC patients stage T1-3N0-2 who received neoadjuvant carboplatin and paclitaxel (NAC-group).	Paclitaxel	239-249	tubulin beta 3 class III	Homo sapiens	23-28
30179591-2	2018	Paclitaxel treatment developed mechanical allodynia in mice, as assessed by von Frey test, which was prevented by an anti-HMGB1-neutralizing antibody or thrombomodulin alfa capable of inactivating HMGB1.	Paclitaxel	0-10	high mobility group box 1	Mus musculus	197-202
26451776-7	2015	CONCLUSION: The serum level of Pokemon correlated with efficacy of cisplatin and paclitaxel combination chemotherapy and survival time, which indicated that Pokemon may be a potentially useful biomarker for predicting treatment effectiveness of first-line chemotherapy and prognosis in NSCLC.	Paclitaxel	81-91	zinc finger and BTB domain containing 7A	Homo sapiens	31-38
30179591-6	2018	Paclitaxel increased accumulation of reactive oxygen species (ROS) and phosphorylation of p38MAPK, NF-kappaB p65 and I-kappaB in RAW264.7 cells.	Paclitaxel	0-10	mitogen-activated protein kinase 14	Mus musculus	90-97
26451776-7	2015	CONCLUSION: The serum level of Pokemon correlated with efficacy of cisplatin and paclitaxel combination chemotherapy and survival time, which indicated that Pokemon may be a potentially useful biomarker for predicting treatment effectiveness of first-line chemotherapy and prognosis in NSCLC.	Paclitaxel	81-91	zinc finger and BTB domain containing 7A	Homo sapiens	157-164
30179591-8	2018	Co-culture of neuron-like NG108-15 cells or stimulation with their conditioned medium promoted paclitaxel-induced HMGB1 release from RAW264.7 cells.	Paclitaxel	95-105	high mobility group box 1	Mus musculus	114-119
30179591-9	2018	Our data indicate that HMGB1 released from macrophages through the ROS/p38MAPK/NF-kappaB/HAT pathway participates in the paclitaxel-induced peripheral neuropathy in mice, and unveils an emerging therapeutic avenue targeting a neuroimmune crosstalk in CIPN.	Paclitaxel	121-131	high mobility group box 1	Mus musculus	23-28
24376711-0	2013	Induction of paclitaxel resistance by ERalpha mediated prohibitin mitochondrial-nuclear shuttling.	Paclitaxel	13-23	prohibitin 1	Homo sapiens	55-65
24376711-8	2013	Additionally, restoration of Paclitaxel sensitivity by ERalpha knockdown could be overcome by PHB overexpression and, conversely, PHB knockdown decreased E2 induced Paclitaxel resistance.	Paclitaxel	29-39	prohibitin 1	Homo sapiens	94-97
30179591-9	2018	Our data indicate that HMGB1 released from macrophages through the ROS/p38MAPK/NF-kappaB/HAT pathway participates in the paclitaxel-induced peripheral neuropathy in mice, and unveils an emerging therapeutic avenue targeting a neuroimmune crosstalk in CIPN.	Paclitaxel	121-131	mitogen-activated protein kinase 14	Mus musculus	71-78
24376711-8	2013	Additionally, restoration of Paclitaxel sensitivity by ERalpha knockdown could be overcome by PHB overexpression and, conversely, PHB knockdown decreased E2 induced Paclitaxel resistance.	Paclitaxel	165-175	prohibitin 1	Homo sapiens	130-133
24376711-9	2013	These findings demonstrate that PHB lies downstream of ERalpha and mediates estrogen-dependent Paclitaxel resistance signaling cascades.	Paclitaxel	95-105	prohibitin 1	Homo sapiens	32-35
24752740-8	2014	Dysregulation of Tcf4-regulated ion transporters and increased cytosolic acidification were observed in HS3ST2-expressing MDA-MB-231 cells, which is a possible underlying cause of increased chemosensitivity towards doxorubicine and paclitaxel in these cells.	Paclitaxel	232-242	transcription factor 4	Homo sapiens	17-21
30180951-2	2018	We successfully prepared the paclitaxel (PTX) loaded anti-LHRHR targeted phase-transformation lipid nanoparticles (PTX-anti-LHRHR-PTNPs) for ovarian cancer in this study combined with LIFU has the following characteristics: On the one hand, it showed smaller size and greater stability than blood cells, which significantly prolonged its half-life in the body, and can actively target ovarian cancer OVCAR-3 cells, and smoothly penetrate the endothelial gap into the tumor site for specifically killing the ovarian cancer cells.	Paclitaxel	29-39	gonadotropin releasing hormone receptor	Homo sapiens	58-63
25499220-7	2014	Thus, Fulvestrant but not Tamoxifen, antagonist against ER-alpha, can restore the Taxol sensitivity in VHL- or BRCA1-deficient cells.	Paclitaxel	82-87	von Hippel-Lindau tumor suppressor	Homo sapiens	103-107
24070631-4	2013	In this study, we uncovered that increased activation of glycogen synthase kinase 3beta (GSK3beta) in the spinal dorsal horn was concurrently associated with increased protein expressions of GFAP, IL-1beta and a decreased protein expression of glial glutamate transporter 1 (GLT-1), as well as the development and maintenance of taxol-induced neuropathic pain.	Paclitaxel	329-334	glycogen synthase kinase 3 beta	Homo sapiens	57-87
24070631-4	2013	In this study, we uncovered that increased activation of glycogen synthase kinase 3beta (GSK3beta) in the spinal dorsal horn was concurrently associated with increased protein expressions of GFAP, IL-1beta and a decreased protein expression of glial glutamate transporter 1 (GLT-1), as well as the development and maintenance of taxol-induced neuropathic pain.	Paclitaxel	329-334	glycogen synthase kinase 3 beta	Homo sapiens	89-97
24070631-6	2013	The changes of all these biomarkers were basically prevented when animals received pre-emptive lithium (a GSK3beta inhibitor) treatment, which also prevented the development of taxol-induced neuropathic pain.	Paclitaxel	177-182	glycogen synthase kinase 3 beta	Homo sapiens	106-114
24070631-8	2013	The taxol-induced increased GSK3beta activities and decreased AKT and mTOR activities in the spinal dorsal horn were also reversed by lithium.	Paclitaxel	4-9	glycogen synthase kinase 3 beta	Homo sapiens	28-36
25546354-12	2014	Western blot analysis showed that Suberoylanilide hydroxamic acid alone or in combination with paclitaxel enhanced caspase-3 protein expression and degraded ID1 protein expression in OC3/P cells.	Paclitaxel	95-105	inhibitor of DNA binding 1, HLH protein	Homo sapiens	157-160
30180951-2	2018	We successfully prepared the paclitaxel (PTX) loaded anti-LHRHR targeted phase-transformation lipid nanoparticles (PTX-anti-LHRHR-PTNPs) for ovarian cancer in this study combined with LIFU has the following characteristics: On the one hand, it showed smaller size and greater stability than blood cells, which significantly prolonged its half-life in the body, and can actively target ovarian cancer OVCAR-3 cells, and smoothly penetrate the endothelial gap into the tumor site for specifically killing the ovarian cancer cells.	Paclitaxel	29-39	gonadotropin releasing hormone receptor	Homo sapiens	124-129
30180951-2	2018	We successfully prepared the paclitaxel (PTX) loaded anti-LHRHR targeted phase-transformation lipid nanoparticles (PTX-anti-LHRHR-PTNPs) for ovarian cancer in this study combined with LIFU has the following characteristics: On the one hand, it showed smaller size and greater stability than blood cells, which significantly prolonged its half-life in the body, and can actively target ovarian cancer OVCAR-3 cells, and smoothly penetrate the endothelial gap into the tumor site for specifically killing the ovarian cancer cells.	Paclitaxel	41-44	gonadotropin releasing hormone receptor	Homo sapiens	58-63
30180951-2	2018	We successfully prepared the paclitaxel (PTX) loaded anti-LHRHR targeted phase-transformation lipid nanoparticles (PTX-anti-LHRHR-PTNPs) for ovarian cancer in this study combined with LIFU has the following characteristics: On the one hand, it showed smaller size and greater stability than blood cells, which significantly prolonged its half-life in the body, and can actively target ovarian cancer OVCAR-3 cells, and smoothly penetrate the endothelial gap into the tumor site for specifically killing the ovarian cancer cells.	Paclitaxel	41-44	gonadotropin releasing hormone receptor	Homo sapiens	124-129
25269478-3	2014	Attenuating MPHOSPH1 expression with a tumor-selective shRNA-expressing adenovirus (Ad-shMPP1) was sufficient to arrest HCC cell proliferation in a manner associated with an accumulation of multinucleated polyploid cells, induction of postmitotic apoptosis, and increased sensitivity to taxol cytotoxicity.	Paclitaxel	287-292	kinesin family member 20B	Mus musculus	12-20
23733406-8	2013	Furthermore, AhR knockdown in MDA-MB-231 cells sensitized them to paclitaxel treatment, evident by a decrease in the required cytotoxic dose.	Paclitaxel	66-76	aryl hydrocarbon receptor	Homo sapiens	13-16
30180951-2	2018	We successfully prepared the paclitaxel (PTX) loaded anti-LHRHR targeted phase-transformation lipid nanoparticles (PTX-anti-LHRHR-PTNPs) for ovarian cancer in this study combined with LIFU has the following characteristics: On the one hand, it showed smaller size and greater stability than blood cells, which significantly prolonged its half-life in the body, and can actively target ovarian cancer OVCAR-3 cells, and smoothly penetrate the endothelial gap into the tumor site for specifically killing the ovarian cancer cells.	Paclitaxel	115-118	gonadotropin releasing hormone receptor	Homo sapiens	58-63
30180951-2	2018	We successfully prepared the paclitaxel (PTX) loaded anti-LHRHR targeted phase-transformation lipid nanoparticles (PTX-anti-LHRHR-PTNPs) for ovarian cancer in this study combined with LIFU has the following characteristics: On the one hand, it showed smaller size and greater stability than blood cells, which significantly prolonged its half-life in the body, and can actively target ovarian cancer OVCAR-3 cells, and smoothly penetrate the endothelial gap into the tumor site for specifically killing the ovarian cancer cells.	Paclitaxel	115-118	gonadotropin releasing hormone receptor	Homo sapiens	124-129
30180951-4	2018	On the other hand, PTX-anti-LHRHR-PTNPs can be targeted to focus after being injected intravenously and remain in the tumor target tissue for a long time.	Paclitaxel	19-22	gonadotropin releasing hormone receptor	Homo sapiens	28-33
25321193-5	2014	Patients with high preoperative Sdc-1 serum levels were less responsive to 5-Fluorouracil, Oxaliplatin, Irintecan, Cisplatin or Paclitaxel chemotherapy.	Paclitaxel	128-138	syndecan 1	Homo sapiens	32-37
30250048-7	2018	Similarly, targeting GSK3beta with knockout or RNAi reduced mitotic arrest in the presence of Taxol.	Paclitaxel	94-99	glycogen synthase kinase 3 beta	Homo sapiens	21-29
25386925-9	2014	We also demonstrated that taxol attenuated migration and invasion in cervical cancer cells by activating the miR-107, in which miR-107 play an important role in regulating the expression of MCL1.	Paclitaxel	26-31	microRNA 107	Homo sapiens	109-116
24293316-3	2013	We show here that Doxorubicin, 5-Fluorouracil, Paclitaxel and Cisplatin treatments trigger, in various human cancer cell lines, an increase of netrin-1 expression which is accompanied by netrin-1 receptors increase.	Paclitaxel	47-57	netrin 1	Mus musculus	187-195
30126852-0	2018	LINC00473 promotes the Taxol resistance via miR-15a in colorectal cancer.	Paclitaxel	23-28	microRNA 15a	Homo sapiens	44-51
25386925-9	2014	We also demonstrated that taxol attenuated migration and invasion in cervical cancer cells by activating the miR-107, in which miR-107 play an important role in regulating the expression of MCL1.	Paclitaxel	26-31	microRNA 107	Homo sapiens	127-134
29959920-3	2018	We show that ribavirin, an anti-viral drug and pharmacological eIF4E inhibitor, effectively inhibits proliferation and decreases viability of paclitaxel-resistant cervical cancer and 5-FU-resistant colon cancer cells while is less toxic to human fibroblast cells.	Paclitaxel	142-152	eukaryotic translation initiation factor 4E	Homo sapiens	63-68
25230206-0	2014	Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer.	Paclitaxel	9-19	C-C motif chemokine ligand 21	Homo sapiens	89-94
24385485-3	2013	In a gel overlay assay with taxol-stabilized MTs, cingulin showed strong binding to MTs, and a domain analysis showed that this binding occurred through cingulin"s N-terminal region.	Paclitaxel	28-33	cingulin	Mus musculus	50-58
24385485-3	2013	In a gel overlay assay with taxol-stabilized MTs, cingulin showed strong binding to MTs, and a domain analysis showed that this binding occurred through cingulin"s N-terminal region.	Paclitaxel	28-33	cingulin	Mus musculus	153-161
29959920-9	2018	Our work demonstrates that eIF4E inhibition using inhibitor or siRNA, either as single agent or in combination, could sensitize chemoresistant cancer cells to paclitaxel or 5-FU treatment and thereby improving the efficacy of chemodrug.	Paclitaxel	159-169	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
24278179-11	2013	ALDH1A1, SOX2, CXCR4 and SDF-1 mRNA levels were higher in metastatic lesions than in primary tumors, and were significantly elevated in both locations by paclitaxel treatment.	Paclitaxel	154-164	C-X-C motif chemokine ligand 12	Homo sapiens	25-30
25283777-10	2014	Straightening of protofilaments (pfs) at microtubule ends with paclitaxel significantly attenuates end-recognition by DCX, but not EB1.	Paclitaxel	63-73	doublecortin	Homo sapiens	118-121
30091920-5	2018	Unlike mifepristone, 28 could be codosed with chemotherapeutic agents readily metabolized by CYP2C8 such as paclitaxel.	Paclitaxel	108-118	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	93-99
25045845-10	2014	Our data reveal that PinX1 could be used as a novel predictor for CSCC patient response to paclitaxel, and the role of PinX1-mediated paclitaxel sensitivity might represent a new direction for the development of a new generation of microtubule drugs.	Paclitaxel	134-144	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	119-124
24278179-15	2013	In contrast, paclitaxel (although reducing primary tumor growth) promotes the selection of ALDH+ cells that likely modify the lung microenvironment to foster metastasis.	Paclitaxel	13-23	aldehyde dehydrogenase family 3, subfamily A1	Mus musculus	91-95
24156365-1	2013	The use of self-assembled monolayers (SAMs) as a polymer-free platform to deliver an antiproliferative drug, paclitaxel (PAT), from a stent material cobalt-chromium (CoCr) alloy has been previously demonstrated.	Paclitaxel	109-119	methionine adenosyltransferase 1A	Homo sapiens	38-42
25211704-2	2014	Class III beta-tubulin plays a prominent role in the development of drug resistance to paclitaxel by allowing the incorporation of the GBP1 GTPase into microtubules.	Paclitaxel	87-97	tubulin beta 3 class III	Homo sapiens	0-22
25211704-2	2014	Class III beta-tubulin plays a prominent role in the development of drug resistance to paclitaxel by allowing the incorporation of the GBP1 GTPase into microtubules.	Paclitaxel	87-97	guanylate binding protein 1	Homo sapiens	135-139
24223161-0	2013	Fhit delocalizes annexin a4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel.	Paclitaxel	96-106	fragile histidine triad diadenosine triphosphatase	Homo sapiens	0-4
30066948-0	2018	Knockdown of miR-935 increases paclitaxel sensitivity via regulation of SOX7 in non-small-cell lung cancer.	Paclitaxel	31-41	SRY-box transcription factor 7	Homo sapiens	72-76
24223161-4	2013	Here we report that overexpression of Fhit prevents Annexin A4 translocation from cytosol to plasma membrane in A549 lung cancer cells treated with paclitaxel.	Paclitaxel	148-158	fragile histidine triad diadenosine triphosphatase	Homo sapiens	38-42
25211704-3	2014	Once in the cytoskeleton, GBP1 binds to prosurvival kinases such as PIM1 and initiates a signaling pathway that induces resistance to paclitaxel.	Paclitaxel	134-144	guanylate binding protein 1	Homo sapiens	26-30
25211704-4	2014	Therefore, the inhibition of the GBP1:PIM1 interaction could potentially revert resistance to paclitaxel.	Paclitaxel	94-104	guanylate binding protein 1	Homo sapiens	33-37
30127274-8	2018	Moreover, Sp17high (PD-L1+MHCII-) cell populations showed significantly enhanced resistance to Paclitaxel-induced cell death in vitro compared to Sp17low (PD-L1-MHCII+) cells, which was associated in turn with increased STAT3 expression.	Paclitaxel	95-105	sperm autoantigenic protein 17	Mus musculus	10-14
29715474-0	2018	TRPV4 inhibition prevents paclitaxel-induced neurotoxicity in preclinical models.	Paclitaxel	26-36	transient receptor potential cation channel subfamily V member 4	Homo sapiens	0-5
25138213-3	2014	Celastrol and Taxol decreased the expression of HDAC3 in cancer cell lines sensitive to anti-cancer drugs.	Paclitaxel	14-19	histone deacetylase 3	Homo sapiens	48-53
29715474-7	2018	In the context of paclitaxel-induced neurotoxicity, blocking Ca2+ influx through TRPV4 channels reduced cell death in cultured DRGN.	Paclitaxel	18-28	transient receptor potential cation channel subfamily V member 4	Homo sapiens	81-86
25275030-6	2014	Up-regulation of the MDR1 and CYP2C8 genes were shown to be potential mechanisms of paclitaxel resistance in the resistant cells.	Paclitaxel	84-94	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	30-36
29715474-9	2018	In summary, these results underline the relevance of TRPV4 signaling for the pathogenesis of paclitaxel-induced neuropathy and suggest novel preventive strategies.	Paclitaxel	93-103	transient receptor potential cation channel subfamily V member 4	Homo sapiens	53-58
24882083-0	2014	Pretreatment with turmeric modulates the inhibitory influence of cisplatin and paclitaxel on CYP2E1 and CYP3A1/2 in isolated rat hepatic microsomes.	Paclitaxel	79-89	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	104-110
29777711-0	2018	UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.	Paclitaxel	13-23	urothelial cancer associated 1	Homo sapiens	0-4
29777711-3	2018	The objective of this work was to investigate the role and molecular mechanisms of urothelial carcinoma associated 1 (UCA1) in paclitaxel (PTX) resistance in OC.	Paclitaxel	127-137	urothelial cancer associated 1	Homo sapiens	83-116
29777711-3	2018	The objective of this work was to investigate the role and molecular mechanisms of urothelial carcinoma associated 1 (UCA1) in paclitaxel (PTX) resistance in OC.	Paclitaxel	127-137	urothelial cancer associated 1	Homo sapiens	118-122
29777711-3	2018	The objective of this work was to investigate the role and molecular mechanisms of urothelial carcinoma associated 1 (UCA1) in paclitaxel (PTX) resistance in OC.	Paclitaxel	139-142	urothelial cancer associated 1	Homo sapiens	83-116
25197933-2	2014	In this study, total aglycones of MTC (ETA) showed the ability to sensitize KB-3-1, HeLa, HepG2 and K562 cells to paclitaxel treatment.	Paclitaxel	114-124	endothelin receptor type A	Homo sapiens	39-42
29777711-3	2018	The objective of this work was to investigate the role and molecular mechanisms of urothelial carcinoma associated 1 (UCA1) in paclitaxel (PTX) resistance in OC.	Paclitaxel	139-142	urothelial cancer associated 1	Homo sapiens	118-122
25197933-3	2014	More inspiringly, ETA markedly enhanced the antitumor activity of paclitaxel in nude mice bearing HeLa or KB-3-1 xenografts.	Paclitaxel	66-76	endothelin receptor type A	Mus musculus	18-21
29777711-4	2018	Our results indicated that UCA1 was significantly up-regulated in PTX-resistant OC cells (SKOV3/PTX and HeyA-8/PTX) compared with their parental cells (SKOV3 and HeyA-8).	Paclitaxel	66-69	urothelial cancer associated 1	Homo sapiens	27-31
25197933-4	2014	Compared to treatment with paclitaxel alone, treatment with combination of paclitaxel and ETA achieved significant reduction in volume and weight of HeLa tumors (p&lt;0.05), and remarkable inhibition to the growth of KB-3-1 tumors (p&lt;10-6).	Paclitaxel	27-37	endothelin receptor type A	Homo sapiens	90-93
29777711-4	2018	Our results indicated that UCA1 was significantly up-regulated in PTX-resistant OC cells (SKOV3/PTX and HeyA-8/PTX) compared with their parental cells (SKOV3 and HeyA-8).	Paclitaxel	96-99	urothelial cancer associated 1	Homo sapiens	27-31
24992675-11	2014	Upregulation of miR-29b also reduced levels of Mcl-1 and sensitized ES2 cells to low-dose paclitaxel.	Paclitaxel	90-100	microRNA 29b-1	Homo sapiens	16-23
29777711-4	2018	Our results indicated that UCA1 was significantly up-regulated in PTX-resistant OC cells (SKOV3/PTX and HeyA-8/PTX) compared with their parental cells (SKOV3 and HeyA-8).	Paclitaxel	96-99	urothelial cancer associated 1	Homo sapiens	27-31
29777711-5	2018	Functionally, UCA1 knockdown sensitized SKOV3/PTX and HeyA-8/PTX cells to PTX through enhancing PTX-induced apoptosis.	Paclitaxel	46-49	urothelial cancer associated 1	Homo sapiens	14-18
29777711-5	2018	Functionally, UCA1 knockdown sensitized SKOV3/PTX and HeyA-8/PTX cells to PTX through enhancing PTX-induced apoptosis.	Paclitaxel	61-64	urothelial cancer associated 1	Homo sapiens	14-18
29777711-5	2018	Functionally, UCA1 knockdown sensitized SKOV3/PTX and HeyA-8/PTX cells to PTX through enhancing PTX-induced apoptosis.	Paclitaxel	61-64	urothelial cancer associated 1	Homo sapiens	14-18
29777711-5	2018	Functionally, UCA1 knockdown sensitized SKOV3/PTX and HeyA-8/PTX cells to PTX through enhancing PTX-induced apoptosis.	Paclitaxel	61-64	urothelial cancer associated 1	Homo sapiens	14-18
29777711-6	2018	Mechanistically, UCA1 silencing induced PTX sensitivity of SKOV3/PTX and HeyA-8/PTX cells by de-repressing ABCB1 through sponging miR-129.	Paclitaxel	40-43	urothelial cancer associated 1	Homo sapiens	17-21
24905776-2	2014	PTX was grafted to the mPEG-b-PLG by esterification to give mPEG-b-PLG-g-PTX.	Paclitaxel	0-3	plasminogen	Homo sapiens	30-33
24905776-2	2014	PTX was grafted to the mPEG-b-PLG by esterification to give mPEG-b-PLG-g-PTX.	Paclitaxel	0-3	plasminogen	Homo sapiens	67-70
29777711-6	2018	Mechanistically, UCA1 silencing induced PTX sensitivity of SKOV3/PTX and HeyA-8/PTX cells by de-repressing ABCB1 through sponging miR-129.	Paclitaxel	65-68	urothelial cancer associated 1	Homo sapiens	17-21
24905776-3	2014	DOX HCl was encapsulated via electrostatic interaction and hydrophobic stack between the DOX HCl and mPEG-b-PLG-g-PTX in aqueous solution.	Paclitaxel	114-117	plasminogen	Homo sapiens	108-111
29777711-6	2018	Mechanistically, UCA1 silencing induced PTX sensitivity of SKOV3/PTX and HeyA-8/PTX cells by de-repressing ABCB1 through sponging miR-129.	Paclitaxel	65-68	urothelial cancer associated 1	Homo sapiens	17-21
24905776-6	2014	For in vivo treatment of xenograft human breast tumor (MCF-7), the mPEG-b-PLG-g-PTX-DOX nanoparticles exhibited remarkable tumor inhibition effect with a 95.5% tumor-suppression-rate which was significantly higher than those of related single anticancer agents such as free DOX HCl and mPEG-b-PLG-g-PTX.	Paclitaxel	80-83	plasminogen	Homo sapiens	74-77
24905776-6	2014	For in vivo treatment of xenograft human breast tumor (MCF-7), the mPEG-b-PLG-g-PTX-DOX nanoparticles exhibited remarkable tumor inhibition effect with a 95.5% tumor-suppression-rate which was significantly higher than those of related single anticancer agents such as free DOX HCl and mPEG-b-PLG-g-PTX.	Paclitaxel	80-83	plasminogen	Homo sapiens	293-296
29777711-7	2018	Collectively, our study elaborated a novel UCA1/miR-129/ABCB1 regulatory axis underlying PTX resistance of OC cells, providing a potential therapeutic target for OC.	Paclitaxel	89-92	urothelial cancer associated 1	Homo sapiens	43-47
24905776-6	2014	For in vivo treatment of xenograft human breast tumor (MCF-7), the mPEG-b-PLG-g-PTX-DOX nanoparticles exhibited remarkable tumor inhibition effect with a 95.5% tumor-suppression-rate which was significantly higher than those of related single anticancer agents such as free DOX HCl and mPEG-b-PLG-g-PTX.	Paclitaxel	79-83	plasminogen	Homo sapiens	74-77
24905776-6	2014	For in vivo treatment of xenograft human breast tumor (MCF-7), the mPEG-b-PLG-g-PTX-DOX nanoparticles exhibited remarkable tumor inhibition effect with a 95.5% tumor-suppression-rate which was significantly higher than those of related single anticancer agents such as free DOX HCl and mPEG-b-PLG-g-PTX.	Paclitaxel	79-83	plasminogen	Homo sapiens	293-296
29689254-5	2018	Taxol 6-hydroxylation and astemizole O-desmethyastemizole were determined as probe activities for CYP2C8 and CYP2J2, respectively.	Paclitaxel	0-5	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	98-104
25137071-0	2014	Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.	Paclitaxel	165-175	microRNA 205	Homo sapiens	24-31
25137071-14	2014	CONCLUSIONS: The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy.	Paclitaxel	155-165	microRNA 205	Homo sapiens	44-51
29689254-5	2018	Taxol 6-hydroxylation and astemizole O-desmethyastemizole were determined as probe activities for CYP2C8 and CYP2J2, respectively.	Paclitaxel	0-5	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	109-115
24812269-6	2014	Notably, we found that YAP was not phosphorylated and inactivated after antitubulin drug treatment in taxol-resistant cancer cells.	Paclitaxel	102-107	Yes1 associated transcriptional regulator	Homo sapiens	23-26
29937937-7	2018	Oncomine analyses of multiple breast cancer patient datasets show that reduced AMPH-1 mRNA level is significantly associated with breast cancer patients having metastatic events, advanced stage, poor clinical outcomes, and Paclitaxel+FEC treatment resistance.	Paclitaxel	223-233	amphiphysin	Homo sapiens	79-85
25127716-0	2014	Involvement of the chemokine CCL3 and the purinoceptor P2X7 in the spinal cord in paclitaxel-induced mechanical allodynia.	Paclitaxel	82-92	C-C motif chemokine ligand 3	Rattus norvegicus	29-33
25127716-8	2014	Paclitaxel-treated rats showed a significant increase in the expression of mRNAs for CCL3 and its receptor CCR5 in the SDH.	Paclitaxel	0-10	C-C motif chemokine ligand 3	Rattus norvegicus	85-89
25127716-9	2014	Intrathecal administration of a CCL3-neutralizing antibody not only attenuated the development of paclitaxel-induced mechanical allodynia but also reversed its maintenance.	Paclitaxel	98-108	C-C motif chemokine ligand 3	Rattus norvegicus	32-36
25127716-10	2014	Paclitaxel also upregulated expression of purinoceptor P2X7 receptors (P2X7Rs), which have been implicated in the release of CCL3 from microglia, in the SDH.	Paclitaxel	0-10	C-C motif chemokine ligand 3	Rattus norvegicus	125-129
25127716-12	2014	CONCLUSIONS: Our findings suggest a contribution of CCL3 and P2X7Rs in the SDH to paclitaxel-induced allodynia and may provide new therapeutic targets for paclitaxel-induced painful neuropathy.	Paclitaxel	82-92	C-C motif chemokine ligand 3	Rattus norvegicus	52-56
25127716-12	2014	CONCLUSIONS: Our findings suggest a contribution of CCL3 and P2X7Rs in the SDH to paclitaxel-induced allodynia and may provide new therapeutic targets for paclitaxel-induced painful neuropathy.	Paclitaxel	155-165	C-C motif chemokine ligand 3	Rattus norvegicus	52-56
25118927-4	2014	3-Methyladenine or ATG7 siRNA, autophagy inhibitors, could restore sensitivity of HeLa-R cells to paclitaxel compared with parental HeLa cells.	Paclitaxel	98-108	autophagy related 7	Homo sapiens	19-23
25089613-8	2014	Under hypoxia, downregulation of HIF-1alpha and upregulation of caspase-3, caspase-8, caspase-9, LC3 and Beclin-1 were observed when paclitaxel was combined with oxygen-CNT.	Paclitaxel	133-143	caspase 8	Homo sapiens	75-84
25322600-3	2014	RESULT: Nasopharyngeal carcinoma cells resistant to radiation was successfully established; cell colony formation assay showed that paclitaxel has obvious sensitizing effect on radiotherapy; FACS results showed that: CNE-2S1 treated by paclitaxel were arrested in G2M phase; paclitaxel and radiotherapy treatments significantly improved the CNE-2S1 apoptosis ratio; Western blot results showed that paclitaxel and combined radiotherapy can reduce the CNE-2S1 cells SHP-1 expression levels.	Paclitaxel	132-142	nuclear receptor subfamily 0 group B member 2	Homo sapiens	465-470
25322600-3	2014	RESULT: Nasopharyngeal carcinoma cells resistant to radiation was successfully established; cell colony formation assay showed that paclitaxel has obvious sensitizing effect on radiotherapy; FACS results showed that: CNE-2S1 treated by paclitaxel were arrested in G2M phase; paclitaxel and radiotherapy treatments significantly improved the CNE-2S1 apoptosis ratio; Western blot results showed that paclitaxel and combined radiotherapy can reduce the CNE-2S1 cells SHP-1 expression levels.	Paclitaxel	236-246	nuclear receptor subfamily 0 group B member 2	Homo sapiens	465-470
25322600-3	2014	RESULT: Nasopharyngeal carcinoma cells resistant to radiation was successfully established; cell colony formation assay showed that paclitaxel has obvious sensitizing effect on radiotherapy; FACS results showed that: CNE-2S1 treated by paclitaxel were arrested in G2M phase; paclitaxel and radiotherapy treatments significantly improved the CNE-2S1 apoptosis ratio; Western blot results showed that paclitaxel and combined radiotherapy can reduce the CNE-2S1 cells SHP-1 expression levels.	Paclitaxel	236-246	nuclear receptor subfamily 0 group B member 2	Homo sapiens	465-470
25322600-3	2014	RESULT: Nasopharyngeal carcinoma cells resistant to radiation was successfully established; cell colony formation assay showed that paclitaxel has obvious sensitizing effect on radiotherapy; FACS results showed that: CNE-2S1 treated by paclitaxel were arrested in G2M phase; paclitaxel and radiotherapy treatments significantly improved the CNE-2S1 apoptosis ratio; Western blot results showed that paclitaxel and combined radiotherapy can reduce the CNE-2S1 cells SHP-1 expression levels.	Paclitaxel	236-246	nuclear receptor subfamily 0 group B member 2	Homo sapiens	465-470
25202944-0	2014	[Preparation and evaluation of RGD and TAT co-modified paclitaxel loaded liposome].	Paclitaxel	55-65	tyrosine aminotransferase	Homo sapiens	39-42
25202944-1	2014	OBJECTIVE: To prepare Arg-Gly-Asp (RGD) and cell penetrating peptide TAT co-modified paclitaxel loaded liposome (RGD/TAT-LP-PTX) for MCF-7 cell inhibition.	Paclitaxel	85-95	tyrosine aminotransferase	Homo sapiens	69-72
25202944-1	2014	OBJECTIVE: To prepare Arg-Gly-Asp (RGD) and cell penetrating peptide TAT co-modified paclitaxel loaded liposome (RGD/TAT-LP-PTX) for MCF-7 cell inhibition.	Paclitaxel	85-95	tyrosine aminotransferase	Homo sapiens	117-120
25078587-15	2014	The reduced RFC mRNA expression in PTX-resistant osteosarcoma cells may be related to the decrease in intracellular (3)H-MTX concentration.	Paclitaxel	35-38	solute carrier family 19 member 1	Homo sapiens	12-15
24959746-7	2014	Also, in silico analysis showed that both paclitaxel and CAR agonist TCPOBOP docked into the mCAR structure but not the inverse agonist androstenol.	Paclitaxel	42-52	coxsackie virus and adenovirus receptor	Mus musculus	93-97
24959746-11	2014	CONCLUSIONS/SIGNIFICANCE: Taken together, our results demonstrated that CAR agonists modulate the antineoplastic efficacy of paclitaxel in mouse and human cancer cell lines.	Paclitaxel	125-135	coxsackie virus and adenovirus receptor	Mus musculus	72-75
32263806-5	2014	On the basis of the aggregation inhibition, GO loaded with a hydrophobic drug, paclitaxel (PTX), were encapsulated by polyelectrolytes, showing a high loading capability of 0.4 mg mg-1 and good dispersion stability.	Paclitaxel	79-89	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	180-184
32263806-5	2014	On the basis of the aggregation inhibition, GO loaded with a hydrophobic drug, paclitaxel (PTX), were encapsulated by polyelectrolytes, showing a high loading capability of 0.4 mg mg-1 and good dispersion stability.	Paclitaxel	91-94	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	180-184
24901765-1	2014	An efficient enantioselective synthesis of the ABC tricyclic core of the anticancer drug Taxol is reported.	Paclitaxel	89-94	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	47-50
24067278-0	2014	SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.	Paclitaxel	62-72	secreted acidic cysteine rich glycoprotein	Mus musculus	0-5
24067278-5	2014	Paclitaxel concentrations were significantly decreased in SPARC null plasma samples and tissues when administered as low-dose m-nab-paclitaxel.	Paclitaxel	0-10	secreted acidic cysteine rich glycoprotein	Mus musculus	58-63
24067278-8	2014	The interaction of plasma SPARC and albumin-bound drugs is observed at low doses of nab-paclitaxel but is saturated at therapeutic doses in murine tumours.	Paclitaxel	88-98	secreted acidic cysteine rich glycoprotein	Mus musculus	26-31
24462773-0	2014	CTGF increases drug resistance to paclitaxel by upregulating survivin expression in human osteosarcoma cells.	Paclitaxel	34-44	cellular communication network factor 2	Homo sapiens	0-4
24462773-7	2014	Overexpression of CTGF increased the resistance to paclitaxel-mediated cell apoptosis.	Paclitaxel	51-61	cellular communication network factor 2	Homo sapiens	18-22
24462773-8	2014	In contrast, knockdown of CTGF expression by CTGF shRNA increased the chemotherapeutic effect of paclitaxel.	Paclitaxel	97-107	cellular communication network factor 2	Homo sapiens	26-30
24462773-8	2014	In contrast, knockdown of CTGF expression by CTGF shRNA increased the chemotherapeutic effect of paclitaxel.	Paclitaxel	97-107	cellular communication network factor 2	Homo sapiens	45-49
24462773-9	2014	In addition, CTGF increased resistance to paclitaxel-induced apoptosis through upregulation of survivin expression.	Paclitaxel	42-52	cellular communication network factor 2	Homo sapiens	13-17
24600008-6	2014	Pharmacological disruption of the microtubule network using nocodazole or disabling it using paclitaxel (originally named taxol) decreased the restriction of N-MLV and HIV-1 by human or simian alleles of TRIM5alpha, respectively.	Paclitaxel	93-103	tripartite motif containing 5	Homo sapiens	204-214
24600008-6	2014	Pharmacological disruption of the microtubule network using nocodazole or disabling it using paclitaxel (originally named taxol) decreased the restriction of N-MLV and HIV-1 by human or simian alleles of TRIM5alpha, respectively.	Paclitaxel	122-127	tripartite motif containing 5	Homo sapiens	204-214
24722794-0	2014	The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III beta-tubulin, MAPT, and survivin.	Paclitaxel	74-84	tubulin beta 3 class III	Homo sapiens	108-130
24722794-2	2014	This study was carried out to investigate the relationships between the expressions of class III beta-tubulin, microtubule-associated protein tau (MAPT), survivin, and the sensitivity of primary gastric cancer (GC) to paclitaxel treatment.	Paclitaxel	218-228	tubulin beta 3 class III	Homo sapiens	87-109
24722794-8	2014	The sensitivity of GC patients to paclitaxel treatment was inversely correlated with the mRNA and protein expressions of class III beta-tubulin (P &lt; 0.01), MAPT (P &lt; 0.05), and survivin (P &lt; 0.05).	Paclitaxel	34-44	tubulin beta 3 class III	Homo sapiens	121-143
24722794-10	2014	Our results indicate that the expression levels of class III beta-tubulin, MAPT, and survivin are good biomarkers for predicting the sensitivity of GC to paclitaxel treatment.	Paclitaxel	154-164	tubulin beta 3 class III	Homo sapiens	51-73
24755562-0	2014	miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression.	Paclitaxel	40-50	microRNA 17	Homo sapiens	0-9
24755562-5	2014	We identified miR-17-5p was one of most significantly downregulated miRNAs in paclitaxel-resistant lung cancer cells compared to paclitaxel sensitive parental cells.	Paclitaxel	78-88	microRNA 17	Homo sapiens	14-23
24755562-5	2014	We identified miR-17-5p was one of most significantly downregulated miRNAs in paclitaxel-resistant lung cancer cells compared to paclitaxel sensitive parental cells.	Paclitaxel	129-139	microRNA 17	Homo sapiens	14-23
24755562-6	2014	We found that overexpression of miR-17-5p sensitized paclitaxel resistant lung cancer cells to paclitaxel induced apoptotic cell death.	Paclitaxel	53-63	microRNA 17	Homo sapiens	32-41
24755562-6	2014	We found that overexpression of miR-17-5p sensitized paclitaxel resistant lung cancer cells to paclitaxel induced apoptotic cell death.	Paclitaxel	95-105	microRNA 17	Homo sapiens	32-41
24755562-8	2014	Overexpression of miR-17-5p into paclitaxel resistant lung cancer cells reduced beclin1 expression and a concordant decease in cellular autophagy.	Paclitaxel	33-43	microRNA 17	Homo sapiens	18-27
24755562-10	2014	Our results indicated that paclitaxel resistance of lung cancer is associated with downregulation of miR-17-5p expression which might cause upregulation of BECN1 expression.	Paclitaxel	27-37	microRNA 17	Homo sapiens	101-110
24782986-7	2014	At the molecular level, mouse tumors remaining after paclitaxel administration showed a significant increase in the expression of Oct4 and CD117 coinciding with a significant activation of the JAK2/STAT3 pathway compared to control tumors.	Paclitaxel	53-63	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	130-134
24476576-2	2014	Because paclitaxel is metabolized by CYP2C8 and CYP3A4, the possibility of drug-drug interactions mediated by enzyme inhibition may exist between the combining agents.	Paclitaxel	8-18	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	37-43
24476576-9	2014	The present results suggest that potent and pathway-dependent inhibition of CYP2C8 and/or CYP3A4 pathways by kinase inhibitors may alter the ratio of paclitaxel metabolites in vivo, and that such changes can be clinically relevant as differential metabolism has been linked to paclitaxel-induced neurotoxicity in cancer patients.	Paclitaxel	150-160	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	76-82
24476576-9	2014	The present results suggest that potent and pathway-dependent inhibition of CYP2C8 and/or CYP3A4 pathways by kinase inhibitors may alter the ratio of paclitaxel metabolites in vivo, and that such changes can be clinically relevant as differential metabolism has been linked to paclitaxel-induced neurotoxicity in cancer patients.	Paclitaxel	277-287	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	76-82
24619206-5	2014	GRAMD1B silencing is achieved in tumours following MePS2-modified siRNA treatment, leading to a synergistic anti-tumour effect in combination with paclitaxel.	Paclitaxel	147-157	GRAM domain containing 1B	Mus musculus	0-7
24361227-0	2014	Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.	Paclitaxel	145-155	solute carrier family 28 member 3	Homo sapiens	25-32
24361227-0	2014	Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.	Paclitaxel	145-155	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	34-41
24361227-0	2014	Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.	Paclitaxel	145-155	ribonucleotide reductase catalytic subunit M1	Homo sapiens	46-50
24374060-0	2014	Paclitaxel alters the evoked release of calcitonin gene-related peptide from rat sensory neurons in culture.	Paclitaxel	0-10	calcitonin-related polypeptide alpha	Rattus norvegicus	40-71
24374060-6	2014	The effects of paclitaxel on the release of CGRP were stimulant-, concentration-, and time-dependent.	Paclitaxel	15-25	calcitonin-related polypeptide alpha	Rattus norvegicus	44-48
24374060-7	2014	When neurons were stimulated with capsaicin or AITC, a low concentration of paclitaxel (10nM) augmented transmitter release, whereas a high concentration (300 nM) reduced transmitter release in a time-dependent manner; however, when high extracellular potassium was used as the evoking stimulus, all concentrations of paclitaxel augmented CGRP release from sensory neurons.	Paclitaxel	76-86	calcitonin-related polypeptide alpha	Rattus norvegicus	339-343
24375949-4	2014	Furthermore, a significant increase in the ratios of glutathione peroxidase/glutathione reductase, superoxide dismutase/glutathione peroxidase, and superoxide dismutase/catalase in PTX-treated cells was observed, compared with control cells.	Paclitaxel	181-184	glutathione-disulfide reductase	Homo sapiens	76-97
24287627-2	2014	In this study, we developed a novel method of preparing human serum albumin (HSA) nanoparticles for targeted delivery of paclitaxel (PTX) to tumors.	Paclitaxel	121-131	albumin	Mus musculus	62-75
24287627-2	2014	In this study, we developed a novel method of preparing human serum albumin (HSA) nanoparticles for targeted delivery of paclitaxel (PTX) to tumors.	Paclitaxel	133-136	albumin	Mus musculus	62-75
24224127-0	2013	Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibody.	Paclitaxel	15-20	parathyroid hormone like hormone	Homo sapiens	120-125
24224127-7	2013	In in vitro combination studies, the mAb enhances the effect of the chemotherapeutic drugs taxol and doxorubicin in PTHrP-positive TNBC cells in an additive manner.	Paclitaxel	91-96	parathyroid hormone like hormone	Homo sapiens	116-121
24079327-1	2013	OBJECTIVE: Monocholesterylsuccinate (CHS)-modified paclitaxel-loaded discoidal reconstituted high density lipoproteins (cP-d-rHDL) as novel biomimetic nanocarriers that were developed for tumor targeting delivery to avoid unexpected drug leakage from discoidal reconstituted high density lipoproteins (d-rHDL) during remodeling process associated with lecithin-cholesterol acyltransferase (LCAT).	Paclitaxel	51-61	lecithin cholesterol acyltransferase	Mus musculus	352-388
24079327-1	2013	OBJECTIVE: Monocholesterylsuccinate (CHS)-modified paclitaxel-loaded discoidal reconstituted high density lipoproteins (cP-d-rHDL) as novel biomimetic nanocarriers that were developed for tumor targeting delivery to avoid unexpected drug leakage from discoidal reconstituted high density lipoproteins (d-rHDL) during remodeling process associated with lecithin-cholesterol acyltransferase (LCAT).	Paclitaxel	51-61	lecithin cholesterol acyltransferase	Mus musculus	390-394
23680185-10	2013	FXR-dependent chemoprotection was also efficient against other DNA-damaging compounds, such as doxorubicin, mitomycin C and potassium dichromate, but not against non-genotoxic drugs, such as colchicine, paclitaxel, acetaminophen, artesunate and sorafenib.	Paclitaxel	203-213	nuclear receptor subfamily 1 group H member 4	Homo sapiens	0-3
23876400-3	2013	We investigated the role of the chemokine (C-C motif) receptor 1 (CCR1) and its ligand, chemokine (C-C motif) ligand 5 (CCL5), in taxane-resistant CRPC using paclitaxel-resistant prostate cancer cells (PC3PR) established from PC3 cells.	Paclitaxel	158-168	C-C motif chemokine receptor 1	Homo sapiens	32-64
24080340-5	2014	In the CD133(-) subpopulation, the exposure to taxol induced the activation of apoptosis signal-regulating kinase1 (ASK1)/c-jun-N-terminal kinase (JNK), p38, extracellular signal regulated kinase (ERK) pathways and Bax expression, while in CD133(+) cells taxol was able only to enhance the activity of the ERK pathway.	Paclitaxel	255-260	prominin 1	Homo sapiens	7-12
24080340-6	2014	In CD133(+) cells, the direct gene transfer of Bax overcame the acquired resistance to taxol.	Paclitaxel	87-92	prominin 1	Homo sapiens	3-8
29910679-0	2018	The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer.	Paclitaxel	52-62	dual specificity phosphatase 5	Homo sapiens	19-24
29910679-5	2018	The PTX resistant cells showed stronger cell proliferation ability by exhibiting the upregulation of CENPF, CDC6, MCM3, CLSPN and SMC1A expression.	Paclitaxel	4-7	minichromosome maintenance complex component 3	Homo sapiens	114-118
23708960-0	2013	CARMA3 overexpression accelerates cell proliferation and inhibits paclitaxel-induced apoptosis through NF-kappaB regulation in breast cancer cells.	Paclitaxel	66-76	caspase recruitment domain family member 10	Homo sapiens	0-6
29910679-5	2018	The PTX resistant cells showed stronger cell proliferation ability by exhibiting the upregulation of CENPF, CDC6, MCM3, CLSPN and SMC1A expression.	Paclitaxel	4-7	claspin	Homo sapiens	120-125
23708960-5	2013	Furthermore, knockdown of CARMA3 expression in MDA-MB-435 cells with high endogenous expression decreased cell proliferation and sensitized cell to paclitaxel-induced apoptosis, while overexpression of CARMA3 in MDA-MB-231 cell line promoted cell proliferation and inhibited apoptosis.	Paclitaxel	148-158	caspase recruitment domain family member 10	Homo sapiens	26-32
24738341-5	2014	Treatment with nanoparticles, paclitaxel and anti-ABCG2 antibody remarkably inhibited the growth of CD138-CD34- cells in vitro and their derived tumors in xenografts.	Paclitaxel	30-40	syndecan 1	Mus musculus	100-105
29910679-6	2018	Furthermore, DUSP1 and DUSP5 expression was significantly downregulated in PTX resistant cells.	Paclitaxel	75-78	dual specificity phosphatase 5	Homo sapiens	23-28
29910679-10	2018	In conclusion, our data suggest that loss of DUSP5 expression results in PTX resistance and tumor progression, providing a rationale for a therapeutic agent that restores DUSP5 in BLBC.	Paclitaxel	73-76	dual specificity phosphatase 5	Homo sapiens	45-50
28509576-4	2018	In this study, we investigated the effect of paclitaxel treatment on the expression levels of two oncomirs (oncomiRs), miR-21 and miR-203, in breast cancer cell lines.	Paclitaxel	45-55	microRNA 203a	Homo sapiens	130-137
23199370-9	2014	Treatment with nocodazole led to disruption of proper spindle pole localization of active AMPK, while paclitaxel induced excessive polymerization of spindle MT and formation of ectopic asters with accentuated AMPK colocalization.	Paclitaxel	102-112	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	209-213
23869586-13	2013	Low levels of paclitaxel (40 nM) were found to significantly reduce mRNA levels for these tubulin genes along with a 2-3-fold increase in miR-200c.	Paclitaxel	14-24	microRNA 200c	Homo sapiens	138-146
23869586-15	2013	Our work indicates that paclitaxel-induced reduction of ZEB1 and beta-tubulin isotypes are, in part, due to increased activity of miR-200c.	Paclitaxel	24-34	microRNA 200c	Homo sapiens	130-138
29409974-6	2018	Consistently, miR-542-3p mimic was much more effective than miR-203 mimic not only in inhibition of Survivin, but also in enhancement of paclitaxel-induced apoptosis in HER2-overexpressing breast cancer cells.	Paclitaxel	137-147	microRNA 203a	Homo sapiens	60-67
24452475-0	2014	Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.	Paclitaxel	59-69	MYD88 innate immune signal transduction adaptor	Homo sapiens	101-106
29409974-10	2018	Thus, miR-542-3p-replacement therapy is an excellent approach to overcome HER3-mediated paclitaxel resistance and significantly enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.	Paclitaxel	88-98	erb-b2 receptor tyrosine kinase 3	Homo sapiens	74-78
24452475-1	2014	Paclitaxel, a known TLR4 ligand, leads to activation of TLR4/MyD88-dependent pathway that mediates chemoresistance and tumor progression in epithelial ovarian carcinoma (EOC).	Paclitaxel	0-10	MYD88 innate immune signal transduction adaptor	Homo sapiens	61-66
24452475-4	2014	Therefore, AO-I could significantly sensitize the response of MyD88(+) EOC cells to paclitaxel by blocking MD-2-mediated TLR4/MyD88 signaling, and that AO-I-paclitaxel combination could be a promising strategy for the treatment of EOC with a functional TLR4/MyD88/NF-kappaB pathway.	Paclitaxel	84-94	MYD88 innate immune signal transduction adaptor	Homo sapiens	62-67
24452475-4	2014	Therefore, AO-I could significantly sensitize the response of MyD88(+) EOC cells to paclitaxel by blocking MD-2-mediated TLR4/MyD88 signaling, and that AO-I-paclitaxel combination could be a promising strategy for the treatment of EOC with a functional TLR4/MyD88/NF-kappaB pathway.	Paclitaxel	84-94	MYD88 innate immune signal transduction adaptor	Homo sapiens	126-131
24452475-4	2014	Therefore, AO-I could significantly sensitize the response of MyD88(+) EOC cells to paclitaxel by blocking MD-2-mediated TLR4/MyD88 signaling, and that AO-I-paclitaxel combination could be a promising strategy for the treatment of EOC with a functional TLR4/MyD88/NF-kappaB pathway.	Paclitaxel	84-94	MYD88 innate immune signal transduction adaptor	Homo sapiens	126-131
23758167-2	2013	We report here the use of the Tat CPP as a molecular building unit to construct well-defined supramolecular nanofibers that can be utilized as a nanoscale vector to encapsulate the hydrophobic drug paclitaxel (PTX) (loading efficiency: 89.7 +- 5.0%) with a high loading capacity (6.8 +- 0.4%).	Paclitaxel	198-208	tyrosine aminotransferase	Homo sapiens	30-33
23758167-2	2013	We report here the use of the Tat CPP as a molecular building unit to construct well-defined supramolecular nanofibers that can be utilized as a nanoscale vector to encapsulate the hydrophobic drug paclitaxel (PTX) (loading efficiency: 89.7 +- 5.0%) with a high loading capacity (6.8 +- 0.4%).	Paclitaxel	210-213	tyrosine aminotransferase	Homo sapiens	30-33
29636883-4	2018	We found that the embryonic transcription factor Brachyury inhibits Paclitaxel induced apoptosis in different cells, including PCH1 and U2OS cells.	Paclitaxel	68-78	T-box transcription factor 1	Homo sapiens	49-58
29636883-8	2018	We further showed that CA9 is responsible for Paclitaxel resistance in PCH1 cell.	Paclitaxel	46-56	carbonic anhydrase 9	Homo sapiens	23-26
25374178-0	2014	Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel.	Paclitaxel	86-96	caspase 8	Homo sapiens	30-39
29636883-9	2018	Our data suggest that CA9 plays a role in Brachyury mediated Paclitaxel resistance and serves as a potential target for chordoma treatment.	Paclitaxel	61-71	carbonic anhydrase 9	Homo sapiens	22-25
29636883-9	2018	Our data suggest that CA9 plays a role in Brachyury mediated Paclitaxel resistance and serves as a potential target for chordoma treatment.	Paclitaxel	61-71	T-box transcription factor 1	Homo sapiens	42-51
29533973-8	2018	Recent studies indicate that induction of polyamine catabolic enzymes SSAT and spermine oxidase (SMO) play key roles in the anti-proliferative and apoptotic effects of polyamine analogues and their combinations with chemotherapeutic agents such as 5-fluorouracil (5-FU) and paclitaxel.	Paclitaxel	274-284	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	70-74
25177037-0	2014	Losartan competitively inhibits CYP2C8-dependent paclitaxel metabolism in vitro.	Paclitaxel	49-59	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	32-38
24346096-1	2014	INTRODUCTION: nab-Paclitaxel (nab-P) is approved, in the United States, in combination with carboplatin for the first-line treatment of advanced non-small-cell lung cancer, based on a randomized phase 3 trial of nab-P plus carboplatin (nab-P/C) versus solvent-based paclitaxel plus carboplatin (sb-P/C).	Paclitaxel	18-28	selenium binding protein 1	Homo sapiens	295-301
23536207-1	2013	CYP2C8 plays an important role in the metabolism of various drugs, such as paclitaxel, repaglinide and ibuprofen.	Paclitaxel	75-85	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
23536207-2	2013	Polymorphisms in the CYP2C8 gene were shown to influence interindividual differences in the pharmacokinetics of paclitaxel, repaglinide and ibuprofen enantiomers.	Paclitaxel	112-122	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	21-27
23536207-4	2013	Further, the effects of genotype-phenotype correlations of CYP2C8 alleles on the metabolism of paclitaxel, repaglinide and ibuprofen enantiomers were evaluated.	Paclitaxel	95-105	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	59-65
23536207-5	2013	The CLint values of CYP2C8.2, CYP2C8.3 and CYP2C8.4 for paclitaxel were 47.7%, 64.3% and 30.2% of that of CYP2C8.1 (p&lt;0.01).	Paclitaxel	56-66	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	20-26
23536207-5	2013	The CLint values of CYP2C8.2, CYP2C8.3 and CYP2C8.4 for paclitaxel were 47.7%, 64.3% and 30.2% of that of CYP2C8.1 (p&lt;0.01).	Paclitaxel	56-66	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	30-36
23536207-5	2013	The CLint values of CYP2C8.2, CYP2C8.3 and CYP2C8.4 for paclitaxel were 47.7%, 64.3% and 30.2% of that of CYP2C8.1 (p&lt;0.01).	Paclitaxel	56-66	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	30-36
23536207-5	2013	The CLint values of CYP2C8.2, CYP2C8.3 and CYP2C8.4 for paclitaxel were 47.7%, 64.3% and 30.2% of that of CYP2C8.1 (p&lt;0.01).	Paclitaxel	56-66	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	106-114
29534020-0	2018	Copper-Free "Click" Chemistry-Based Synthesis and Characterization of Carbonic Anhydrase-IX Anchored Albumin-Paclitaxel Nanoparticles for Targeting Tumor Hypoxia.	Paclitaxel	109-119	carbonic anhydrase 9	Homo sapiens	70-91
29534020-4	2018	Toward this, we developed a Carbonic Anhydrase IX (CA IX) receptor targeting human serum albumin (HSA) carriers to deliver the potent anticancer drug, Paclitaxel (PTX).	Paclitaxel	151-161	carbonic anhydrase 9	Homo sapiens	28-49
29534020-4	2018	Toward this, we developed a Carbonic Anhydrase IX (CA IX) receptor targeting human serum albumin (HSA) carriers to deliver the potent anticancer drug, Paclitaxel (PTX).	Paclitaxel	151-161	carbonic anhydrase 9	Homo sapiens	51-56
29534020-4	2018	Toward this, we developed a Carbonic Anhydrase IX (CA IX) receptor targeting human serum albumin (HSA) carriers to deliver the potent anticancer drug, Paclitaxel (PTX).	Paclitaxel	163-166	carbonic anhydrase 9	Homo sapiens	28-49
24253898-0	2014	Silencing MAP3K1 expression through RNA interference enhances paclitaxel-induced cell cycle arrest in human breast cancer cells.	Paclitaxel	62-72	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	10-16
29534020-4	2018	Toward this, we developed a Carbonic Anhydrase IX (CA IX) receptor targeting human serum albumin (HSA) carriers to deliver the potent anticancer drug, Paclitaxel (PTX).	Paclitaxel	163-166	carbonic anhydrase 9	Homo sapiens	51-56
24253898-1	2014	The objective of this study is to compare the expression level of MAP3K1 between normal mammary gland cells and breast cancer cells, and to analyze the effects of silencing MAP3K1 on breast cancer cells with paclitaxel treatment.	Paclitaxel	208-218	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	173-179
24253898-7	2014	MAP3K1 siRNA transfection significantly reduced the expression level of MAP3K1, and enhanced paclitaxel-induced cell proliferation inhibition and cell cycle arrest in breast cancer cells.	Paclitaxel	93-103	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	0-6
23863734-6	2013	In addition, there was a good response rate(50%, PR 3)among the patients previously treated with paclitaxel.	Paclitaxel	97-107	proteinase 3	Homo sapiens	49-53
24253898-8	2014	Targeting MAP3K1 expression through small RNA interference can promote the therapeutic effects of paclitaxel in breast cancer.	Paclitaxel	98-108	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	10-16
29534020-6	2018	A novel method of synthesis involving copper free "click" chemistry (Dibenzocyclooctyl, DBCO) moiety with an azide-labeled reaction partner, known as Strain-Promoted Alkyne Azide Cycloaddition (SPAAC) along with a desolvation method for PTX loading were used in the present study to arrive at the CA IX selective nano-carriers, HSA-PTX-ATZ.	Paclitaxel	237-240	carbonic anhydrase 9	Homo sapiens	297-302
24220856-8	2014	Pearson"s correlation identified 2 miRNAs (miR-367 and miR-30a-5p) associated with the NCI40 cell line in vitro paclitaxel response (P&lt;0.0003).	Paclitaxel	112-122	microRNA 367	Homo sapiens	43-50
24220856-8	2014	Pearson"s correlation identified 2 miRNAs (miR-367 and miR-30a-5p) associated with the NCI40 cell line in vitro paclitaxel response (P&lt;0.0003).	Paclitaxel	112-122	microRNA 30a	Homo sapiens	55-62
29491095-0	2018	Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.	Paclitaxel	118-128	tubulin beta 3 class III	Homo sapiens	14-36
24220856-10	2014	Overexpression of miR-367 in the paclitaxel-sensitive cells [PA1; IC50, 1.69 nM, high miR-367 (2.997), low miR-30a-5p (-0.323)] further increased paclitaxel sensitivity, whereas miR-367 depletion decreased paclitaxel sensitivity.	Paclitaxel	33-43	microRNA 367	Homo sapiens	18-25
24220856-10	2014	Overexpression of miR-367 in the paclitaxel-sensitive cells [PA1; IC50, 1.69 nM, high miR-367 (2.997), low miR-30a-5p (-0.323)] further increased paclitaxel sensitivity, whereas miR-367 depletion decreased paclitaxel sensitivity.	Paclitaxel	146-156	microRNA 367	Homo sapiens	18-25
24220856-10	2014	Overexpression of miR-367 in the paclitaxel-sensitive cells [PA1; IC50, 1.69 nM, high miR-367 (2.997), low miR-30a-5p (-0.323)] further increased paclitaxel sensitivity, whereas miR-367 depletion decreased paclitaxel sensitivity.	Paclitaxel	146-156	microRNA 367	Homo sapiens	18-25
24220856-11	2014	In contrast, overexpression and depletion of miR-30a-5p in the paclitaxel-resistant cells [OVCAR4; IC50, 17.8 nM, low miR-367 (-0.640), high miR-30a-5p (3.270)] decreased and increased paclitaxel sensitivity, respectively.	Paclitaxel	63-73	microRNA 30a	Homo sapiens	45-52
24220856-11	2014	In contrast, overexpression and depletion of miR-30a-5p in the paclitaxel-resistant cells [OVCAR4; IC50, 17.8 nM, low miR-367 (-0.640), high miR-30a-5p (3.270)] decreased and increased paclitaxel sensitivity, respectively.	Paclitaxel	63-73	microRNA 367	Homo sapiens	118-125
23562605-13	2013	In conclusion, our results indicate that paclitaxel-evoked cold hypernociception depends on the activation of CCR2 due to the spinal release of CCL2 and the subsequent microglial activation.	Paclitaxel	41-51	chemokine (C-C motif) receptor 2	Mus musculus	110-114
29491095-2	2018	The aim of this study was to clarify the predictive value of TUBB3 expression for the anticancer effects of first-line cisplatin-based chemotherapy and second-line paclitaxel-based chemotherapy in patients with urothelial cancer (UC).	Paclitaxel	164-174	tubulin beta 3 class III	Homo sapiens	61-66
24024333-3	2013	Immunocytochemistry, Reverse transcription-polymerase chain reaction and western blotting were used to analyze the expression of MAPK1 (mitogen-activated protein kinases 1) and cyclin D1 in response to siRNA (small interfering RNA) transfection and taxol treatment.	Paclitaxel	249-254	cyclin D1	Homo sapiens	177-186
29491095-9	2018	However, positive expression of TUBB3 was significantly associated with unfavourable overall survival in patients receiving second-line paclitaxel-based chemotherapy (p=0.021).	Paclitaxel	136-146	tubulin beta 3 class III	Homo sapiens	32-37
26168135-9	2014	shRNA depletion of cIAP1 enhanced chemosensitivity of ovarian cancer cells to Taxol and carboplatin-induced apoptosis.	Paclitaxel	78-83	baculoviral IAP repeat containing 2	Homo sapiens	19-24
29491095-11	2018	CONCLUSION: TUBB3 expression was identified as a useful predictive factor for survival after second-line paclitaxel-based therapy in patients with cisplatin-resistant UC.	Paclitaxel	105-115	tubulin beta 3 class III	Homo sapiens	12-17
29448632-9	2018	Co-cultured with paclitaxel, the survival rates of CD133+Bmi-1RNAi cells were lower.	Paclitaxel	17-27	prominin 1	Homo sapiens	51-56
24349128-8	2013	We were able to validate our method by recovering known mechanisms and as an application example of our method, we identified a mechanism that may further explain the synergism between paclitaxel and doxorubicin in TFAC treatment: Paclitaxel may attenuate MELK gene expression, resulting in lower levels of its target MYBL2, already associated with doxorubicin synergism in hepatocellular carcinoma cell lines.	Paclitaxel	185-195	maternal embryonic leucine zipper kinase	Homo sapiens	256-260
24349128-8	2013	We were able to validate our method by recovering known mechanisms and as an application example of our method, we identified a mechanism that may further explain the synergism between paclitaxel and doxorubicin in TFAC treatment: Paclitaxel may attenuate MELK gene expression, resulting in lower levels of its target MYBL2, already associated with doxorubicin synergism in hepatocellular carcinoma cell lines.	Paclitaxel	231-241	maternal embryonic leucine zipper kinase	Homo sapiens	256-260
23833655-2	2013	We previously demonstrated that C6 ceramide and paclitaxel function synergistically to induce ovarian cancer cell death via modulation of the PI3/AKT cell survival pathway.	Paclitaxel	48-58	peptidase inhibitor 3	Homo sapiens	142-145
29253957-0	2018	Conjugation of paclitaxel to C-6 hexanediamine-modified hyaluronic acid for targeted drug delivery to enhance antitumor efficacy.	Paclitaxel	15-25	complement C6	Homo sapiens	29-32
23602343-10	2013	These results suggest that paclitaxel treatment increases TRPV1 expression in DRG neurons and may contribute to functional peripheral neuropathic pain.	Paclitaxel	27-37	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	58-63
24135868-0	2013	High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.	Paclitaxel	61-71	alpha-1-microglobulin/bikunin precursor	Homo sapiens	20-24
24135868-9	2013	Our data indicated that the high level of serum AMBP could predict the poor response of the AGC patients treated with the paclitaxel-capecitabine chemotherapy, which could be used as a potential biomarker to identify patients who would benefit from this chemotherapeutic regimen.	Paclitaxel	122-132	alpha-1-microglobulin/bikunin precursor	Homo sapiens	48-52
29253957-2	2018	In this study, a novel HA-based drug conjugate, HA-6-PTX, was designed and successfully synthesized by chemically grafting PTX to the C-6 position of N-acetyl-d-glucosamine (GlcNAc) of hyaluronic acid (HA) using hexanediamine as the linker.	Paclitaxel	53-56	complement C6	Homo sapiens	134-137
29192128-7	2018	Unexpectedly, zinc transporters, but not TRPA1, are required for zinc-induced inhibition of TRPV1-dependent chronic neuropathic pain produced by paclitaxel.	Paclitaxel	145-155	transient receptor potential cation channel subfamily V member 1	Homo sapiens	92-97
24184484-0	2013	Six1 mediates resistance to paclitaxel in breast cancer cells.	Paclitaxel	28-38	SIX homeobox 1	Homo sapiens	0-4
23627607-7	2013	The up-regulated miRNAs (miR-320a, 22 and 129-5p) and down-regulated miRNAs (miR-9, 155 and 640) were confirmed in paclitaxel-resistant FFPE tumor samples, compared with paclitaxel-sensitive samples.	Paclitaxel	115-125	microRNA 320a	Homo sapiens	25-33
24184484-3	2013	We herein investigate the relationship between Six1 and resistance of paclitaxel in this study.	Paclitaxel	70-80	SIX homeobox 1	Homo sapiens	47-51
24184484-4	2013	The results indicate that six1 is a mediator of the paclitaxel resistance in breast cancer.	Paclitaxel	52-62	SIX homeobox 1	Homo sapiens	26-30
23462296-4	2013	This study demonstrates alterations in ABC and SLC gene expression levels in methotrexate, cisplatin, doxorubicin, vincristine, topotecan and paclitaxel-resistant variant of W1 ovarian cancer cell line.	Paclitaxel	142-152	C-C motif chemokine ligand 21	Homo sapiens	47-50
29192128-8	2018	Together, our study demonstrates a novel mechanism underlying the analgesic effect of zinc on paclitaxel-induced neuropathic pain that relies on the function of TRPV1.SIGNIFICANCE STATEMENT The chemotherapy-induced peripheral neuropathy is a major limiting factor affecting the chemotherapy patients.	Paclitaxel	94-104	transient receptor potential cation channel subfamily V member 1	Homo sapiens	161-166
24184484-5	2013	The expression level of Six1 in breast cancer cells correlates with their resistance to paclitaxel.	Paclitaxel	88-98	SIX homeobox 1	Homo sapiens	24-28
29192128-10	2018	We demonstrate that zinc prevents paclitaxel-induced mechanical hypersensitivity via inhibiting the TRPV1 channel, which is involved in the sensitization of peripheral nociceptors in chemotherapy.	Paclitaxel	34-44	transient receptor potential cation channel subfamily V member 1	Homo sapiens	100-105
24184484-6	2013	On the one hand, forced overexpression of Six1 in Six1-low/paclitaxel-sensitive MCF-7 or HS578T breast cancer cells induce their resistance to paclitaxel treatment directly; On the other hand, knockdown of endogenous Six1 in Six1-high/drug-resistant BT-474 breast cancer cells sensitized these cells to paclitaxel treatment.	Paclitaxel	59-69	SIX homeobox 1	Homo sapiens	42-46
24184484-6	2013	On the one hand, forced overexpression of Six1 in Six1-low/paclitaxel-sensitive MCF-7 or HS578T breast cancer cells induce their resistance to paclitaxel treatment directly; On the other hand, knockdown of endogenous Six1 in Six1-high/drug-resistant BT-474 breast cancer cells sensitized these cells to paclitaxel treatment.	Paclitaxel	59-69	SIX homeobox 1	Homo sapiens	50-54
29316433-3	2018	Anti-TIM-3 antibody improved response to paclitaxel chemotherapy in models of triple-negative and luminal B disease, with no evidence of toxicity.	Paclitaxel	41-51	hepatitis A virus cellular receptor 2	Mus musculus	5-10
24184484-6	2013	On the one hand, forced overexpression of Six1 in Six1-low/paclitaxel-sensitive MCF-7 or HS578T breast cancer cells induce their resistance to paclitaxel treatment directly; On the other hand, knockdown of endogenous Six1 in Six1-high/drug-resistant BT-474 breast cancer cells sensitized these cells to paclitaxel treatment.	Paclitaxel	59-69	SIX homeobox 1	Homo sapiens	50-54
24184484-6	2013	On the one hand, forced overexpression of Six1 in Six1-low/paclitaxel-sensitive MCF-7 or HS578T breast cancer cells induce their resistance to paclitaxel treatment directly; On the other hand, knockdown of endogenous Six1 in Six1-high/drug-resistant BT-474 breast cancer cells sensitized these cells to paclitaxel treatment.	Paclitaxel	59-69	SIX homeobox 1	Homo sapiens	50-54
24184484-6	2013	On the one hand, forced overexpression of Six1 in Six1-low/paclitaxel-sensitive MCF-7 or HS578T breast cancer cells induce their resistance to paclitaxel treatment directly; On the other hand, knockdown of endogenous Six1 in Six1-high/drug-resistant BT-474 breast cancer cells sensitized these cells to paclitaxel treatment.	Paclitaxel	143-153	SIX homeobox 1	Homo sapiens	42-46
24184484-6	2013	On the one hand, forced overexpression of Six1 in Six1-low/paclitaxel-sensitive MCF-7 or HS578T breast cancer cells induce their resistance to paclitaxel treatment directly; On the other hand, knockdown of endogenous Six1 in Six1-high/drug-resistant BT-474 breast cancer cells sensitized these cells to paclitaxel treatment.	Paclitaxel	143-153	SIX homeobox 1	Homo sapiens	50-54
24184484-6	2013	On the one hand, forced overexpression of Six1 in Six1-low/paclitaxel-sensitive MCF-7 or HS578T breast cancer cells induce their resistance to paclitaxel treatment directly; On the other hand, knockdown of endogenous Six1 in Six1-high/drug-resistant BT-474 breast cancer cells sensitized these cells to paclitaxel treatment.	Paclitaxel	143-153	SIX homeobox 1	Homo sapiens	50-54
24184484-6	2013	On the one hand, forced overexpression of Six1 in Six1-low/paclitaxel-sensitive MCF-7 or HS578T breast cancer cells induce their resistance to paclitaxel treatment directly; On the other hand, knockdown of endogenous Six1 in Six1-high/drug-resistant BT-474 breast cancer cells sensitized these cells to paclitaxel treatment.	Paclitaxel	143-153	SIX homeobox 1	Homo sapiens	50-54
24184484-6	2013	On the one hand, forced overexpression of Six1 in Six1-low/paclitaxel-sensitive MCF-7 or HS578T breast cancer cells induce their resistance to paclitaxel treatment directly; On the other hand, knockdown of endogenous Six1 in Six1-high/drug-resistant BT-474 breast cancer cells sensitized these cells to paclitaxel treatment.	Paclitaxel	143-153	SIX homeobox 1	Homo sapiens	42-46
24184484-6	2013	On the one hand, forced overexpression of Six1 in Six1-low/paclitaxel-sensitive MCF-7 or HS578T breast cancer cells induce their resistance to paclitaxel treatment directly; On the other hand, knockdown of endogenous Six1 in Six1-high/drug-resistant BT-474 breast cancer cells sensitized these cells to paclitaxel treatment.	Paclitaxel	143-153	SIX homeobox 1	Homo sapiens	50-54
24184484-6	2013	On the one hand, forced overexpression of Six1 in Six1-low/paclitaxel-sensitive MCF-7 or HS578T breast cancer cells induce their resistance to paclitaxel treatment directly; On the other hand, knockdown of endogenous Six1 in Six1-high/drug-resistant BT-474 breast cancer cells sensitized these cells to paclitaxel treatment.	Paclitaxel	143-153	SIX homeobox 1	Homo sapiens	50-54
24184484-6	2013	On the one hand, forced overexpression of Six1 in Six1-low/paclitaxel-sensitive MCF-7 or HS578T breast cancer cells induce their resistance to paclitaxel treatment directly; On the other hand, knockdown of endogenous Six1 in Six1-high/drug-resistant BT-474 breast cancer cells sensitized these cells to paclitaxel treatment.	Paclitaxel	143-153	SIX homeobox 1	Homo sapiens	50-54
23614074-8	2013	After paclitaxel administration, an increase in caspase-3 IR in DRG cells was observed, which was co-localized with NF200-positive myelinated neurons.	Paclitaxel	6-16	caspase 3	Rattus norvegicus	48-57
23614074-9	2013	Post-treatment with EP decreased the paclitaxel-induced caspase-3 IR.	Paclitaxel	37-47	caspase 3	Rattus norvegicus	56-65
23243220-2	2013	We aimed to determine the influence of the individual human OATP1B1, OATP1B3, and OATP1A2 transporters on the in vivo disposition of the anticancer drugs methotrexate and paclitaxel by using liver-specific humanized OATP1A/1B transgenic mice.	Paclitaxel	171-181	solute carrier organic anion transporter family member 1A2	Homo sapiens	82-89
24184484-7	2013	Besides, Six1 overexpression confers resistance to paclitaxel-mediated apoptosis in breast cancer cells.	Paclitaxel	51-61	SIX homeobox 1	Homo sapiens	9-13
23243220-5	2013	Furthermore, hepatic expression of OATP1B3 and OATP1A2, but not OATP1B1, resulted in increased liver uptake of paclitaxel (2 mg/kg).	Paclitaxel	111-121	solute carrier organic anion transporter family member 1A2	Homo sapiens	47-54
30282072-2	2018	In this study, we aimed to evaluate whether miR-34a attenuates chemoresistance to paclitaxel by regulating target genes associated with drug resistance.	Paclitaxel	82-92	microRNA 34a	Homo sapiens	44-51
23243220-6	2013	At 10 mg/kg, a modest effect of only OATP1A2 on paclitaxel liver uptake was observed.	Paclitaxel	48-58	solute carrier organic anion transporter family member 1A2	Homo sapiens	37-44
24184484-8	2013	Furthermore, clinical data and the publicly available breast cancer gene expression datasets display that the association of Six1 expression with paclitaxel sensitivity is clinically relevant.	Paclitaxel	146-156	SIX homeobox 1	Homo sapiens	125-129
24184484-9	2013	In conclusion, these data suggest that Six1 may function as an important modifier of the paclitaxel response in breast cancer cells, and serve as a potential target for overcoming paclitaxel resistance in breast cancer.	Paclitaxel	89-99	SIX homeobox 1	Homo sapiens	39-43
24184484-9	2013	In conclusion, these data suggest that Six1 may function as an important modifier of the paclitaxel response in breast cancer cells, and serve as a potential target for overcoming paclitaxel resistance in breast cancer.	Paclitaxel	180-190	SIX homeobox 1	Homo sapiens	39-43
24156365-1	2013	The use of self-assembled monolayers (SAMs) as a polymer-free platform to deliver an antiproliferative drug, paclitaxel (PAT), from a stent material cobalt-chromium (CoCr) alloy has been previously demonstrated.	Paclitaxel	121-124	methionine adenosyltransferase 1A	Homo sapiens	38-42
30282072-10	2018	The CCK-8 assay showed that miR-34a overexpression resulted in increased sensitivity to paclitaxel while miR-34a down-regulation resulted in chemoresistance to paclitaxel in vitro.	Paclitaxel	88-98	microRNA 34a	Homo sapiens	28-35
30282072-10	2018	The CCK-8 assay showed that miR-34a overexpression resulted in increased sensitivity to paclitaxel while miR-34a down-regulation resulted in chemoresistance to paclitaxel in vitro.	Paclitaxel	160-170	microRNA 34a	Homo sapiens	105-112
24062525-0	2013	Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.	Paclitaxel	58-68	protein tyrosine kinase 2	Homo sapiens	8-29
30282072-16	2018	CONCLUSION: Our results showed that miR-34a is involved in the development of chemosensitivity to paclitaxel.	Paclitaxel	98-108	microRNA 34a	Homo sapiens	36-43
24062525-12	2013	CONCLUSIONS: We have identified a novel pathway whereby FAK inhibition with VS-6063 overcomes YB-1-mediated paclitaxel resistance by an AKT-dependent pathway.	Paclitaxel	108-118	protein tyrosine kinase 2	Homo sapiens	56-59
30282072-17	2018	By regulating the JAG1/Notch1 axis, miR-34a or its target genes JAG1 or Notch1 might serve as potential predictive biomarkers of response to paclitaxel-based chemotherapy and/or therapeutic targets that will help to overcome chemoresistance at the mCRPC stage.	Paclitaxel	141-151	microRNA 34a	Homo sapiens	36-43
29483955-8	2018	In vitro analysis of cell viability, apoptosis and cell cycle revealed that Abra/anti-HER2 NPs showed more anti-tumor efficacy against HER2(+) SK-BR-3 cells than Abraxane  at equivalent PTX concentration.	Paclitaxel	186-189	actin binding Rho activating protein	Homo sapiens	76-80
24088129-2	2013	We determined the frequency of polymorphisms in the CYP2D6 gene associated with activation of tamoxifen, and those of the genes CYP2C8, CYP3A5 and DPYD associated with toxicity of paclitaxel and capecitabine.	Paclitaxel	180-190	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	128-134
22430212-5	2013	In mitotic cells, paclitaxel blocked activation of the class III phosphatidyl inositol 3 kinase, Vps34, a critical initiator of autophagosome formation.	Paclitaxel	18-28	phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens	97-102
29737088-9	2018	Compared with control group,the serum NGF level significantly decreased ( P&lt;0.05) in paclitaxel group,while the serum NGF level in low and high dose of ShenFu Injection groups were higher than paclitaxel group,particularly in the high dose group ( P&lt;0.05).	Paclitaxel	88-98	nerve growth factor	Rattus norvegicus	38-41
23178685-7	2013	Finally, CAC1 increased paclitaxel-induced cell death in ERalpha-positive MCF7 cells, which are paclitaxel-resistant.	Paclitaxel	24-34	transmembrane protein 54	Homo sapiens	9-13
23178685-7	2013	Finally, CAC1 increased paclitaxel-induced cell death in ERalpha-positive MCF7 cells, which are paclitaxel-resistant.	Paclitaxel	96-106	transmembrane protein 54	Homo sapiens	9-13
23907428-14	2013	CONCLUSION: These data suggest that nab-paclitaxel and gemcitabine decreases CAF content inducing a marked alteration in cancer stroma that results in tumour softening.	Paclitaxel	40-50	lysine acetyltransferase 2B	Homo sapiens	77-80
23967091-5	2013	Our results further demonstrated that PTX inhibited the effect of TGF-beta1 on regulating the expression of Smad3 and phosphorylated Smad3 (p-Smad3), and restored the levels of E-cadherin, vimentin and alpha-SMA.	Paclitaxel	38-41	vimentin	Rattus norvegicus	189-197
23967091-8	2013	The action of PTX to ameliorate TGF-beta1-induced EMT was promoted by miR-140, which increased E-cadherin levels and reduced the expression of vimentin, Smad3 and p-Smad3.	Paclitaxel	14-17	vimentin	Rattus norvegicus	143-151
29737088-12	2018	CONCLUSION: Shenfu Injection can reduce the peripheral neurotoxicity of paclitaxel by promoting the expression of NGF in serum.	Paclitaxel	72-82	nerve growth factor	Rattus norvegicus	114-117
24460334-2	2013	The present study sought to determine the role of Gal-3 in chemoresistance of the human SKOV-3 ovarian cancer cell line to paclitaxel (PTX) using recombinant human Gal-3 (rhGal-3) and PectaSol-C modified citrus pectin (Pect-MCP) as a specific Gal-3 competitive inhibitor.	Paclitaxel	123-133	galectin 3	Homo sapiens	50-55
29326595-3	2017	Accumulating evidences indicates that antagonists of TRPA1 and TRPM8 may protect against cisplatin, oxaliplatin, and paclitaxel-induced mitochondrial oxidative stress, inflammation, cold allodynia, and hyperalgesia.	Paclitaxel	117-127	transient receptor potential cation channel subfamily A member 1	Homo sapiens	53-58
24168763-0	2013	Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.	Paclitaxel	84-94	erb-b2 receptor tyrosine kinase 3	Homo sapiens	25-30
24168763-1	2013	INTRODUCTION: Elevated expression of erbB3 rendered erbB2-overexpressing breast cancer cells resistant to paclitaxel via PI-3 K/Akt-dependent upregulation of Survivin.	Paclitaxel	106-116	erb-b2 receptor tyrosine kinase 3	Homo sapiens	37-42
24168763-11	2013	RESULTS: MM-121 significantly facilitated paclitaxel-mediated anti-proliferative/anti-survival effects on SKBR3 cells transfected with a control vector or erbB3 cDNA.	Paclitaxel	42-52	erb-b2 receptor tyrosine kinase 3	Homo sapiens	155-160
24168763-13	2013	MM-121 enhances paclitaxel-induced poly(ADP-ribose) polymerase (PARP) cleavage, activation of caspase-8 and -3, and apoptosis in both paclitaxel-sensitive and -resistant cells.	Paclitaxel	16-26	caspase 8	Homo sapiens	94-110
24168763-17	2013	CONCLUSIONS: The combinations of MM-121 and paclitaxel not only inhibit tumor cell proliferation, but also promote erbB2-overexpressing breast cancer cells to undergo apoptosis via downregulation of Survivin in vitro and in vivo, suggesting that inactivation of erbB3 with MM-121 enhances paclitaxel-mediated antitumor activity against erbB2-overexpressing breast cancers.	Paclitaxel	44-54	erb-b2 receptor tyrosine kinase 3	Homo sapiens	262-267
23807165-9	2013	Modulation of these microRNAs resensitizes PTX-resistant cancer cells by targeting BCL10, caspase-7, and ZEB1.	Paclitaxel	43-46	BCL10 immune signaling adaptor	Homo sapiens	83-88
29326595-3	2017	Accumulating evidences indicates that antagonists of TRPA1 and TRPM8 may protect against cisplatin, oxaliplatin, and paclitaxel-induced mitochondrial oxidative stress, inflammation, cold allodynia, and hyperalgesia.	Paclitaxel	117-127	transient receptor potential cation channel subfamily M member 8	Homo sapiens	63-68
23585021-2	2013	Overexpression of tubulin-beta-III and p-glycoprotein has been linked to paclitaxel resistance in many cancers but has been undercharacterized among USCs.	Paclitaxel	73-83	tubulin beta 3 class III	Homo sapiens	18-34
23585021-4	2013	In this study, relationships are clarified, in USCs relative to ovarian serous carcinomas (OSCs), between tubulin-beta-III and p-glycoprotein expression, clinical outcome, and in vitro chemoresponsiveness to epothilone B, ixabepilone, and paclitaxel.	Paclitaxel	239-249	tubulin beta 3 class III	Homo sapiens	106-122
23585021-12	2013	CONCLUSIONS: Tubulin-beta-III overexpression in USCs discriminates poor prognosis, serves as a marker for sensitivity to epothilones, and may contribute to paclitaxel resistance.	Paclitaxel	156-166	tubulin beta 3 class III	Homo sapiens	13-29
23155185-0	2013	Targeted delivery of paclitaxel to EphA2-expressing cancer cells.	Paclitaxel	21-31	Eph receptor A2	Mus musculus	35-40
23536207-0	2013	Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro.	Paclitaxel	69-79	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	13-19
29169729-4	2017	Ectopic expression of miR-193b-3p and PAK3 knockdown repressed cell proliferation, promoted paclitaxel-induced cytotoxicity, and reinforced paclitaxel-mediated caspase-3 activity increase in OC cells.	Paclitaxel	92-102	microRNA 193b	Homo sapiens	22-30
23582684-0	2013	The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.	Paclitaxel	63-73	interferon gamma inducible protein 47	Mus musculus	41-45
29169729-4	2017	Ectopic expression of miR-193b-3p and PAK3 knockdown repressed cell proliferation, promoted paclitaxel-induced cytotoxicity, and reinforced paclitaxel-mediated caspase-3 activity increase in OC cells.	Paclitaxel	140-150	microRNA 193b	Homo sapiens	22-30
23582684-0	2013	The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.	Paclitaxel	63-73	metallothionein 1J, pseudogene	Homo sapiens	81-84
29169729-6	2017	Moreover, enforced expression of PAK3 partially overturned the effects of miR-193b-3p on OC cell proliferation and paclitaxel sensitivity.	Paclitaxel	115-125	microRNA 193b	Homo sapiens	74-82
23582684-2	2013	In this study, MT1-AF7p peptide, which presents high binding affinity to membrane type-1 matrix metalloproteinase (MT1-MMP) that over-expressed on both angiogenic blood vessels and glioma cells, was employed to decorate the paclitaxel-loaded PEG-PLA nanoparticles (MT1-NP-PTX) to mediate glioblastoma targeting.	Paclitaxel	224-234	matrix metallopeptidase 14	Homo sapiens	73-113
23582684-2	2013	In this study, MT1-AF7p peptide, which presents high binding affinity to membrane type-1 matrix metalloproteinase (MT1-MMP) that over-expressed on both angiogenic blood vessels and glioma cells, was employed to decorate the paclitaxel-loaded PEG-PLA nanoparticles (MT1-NP-PTX) to mediate glioblastoma targeting.	Paclitaxel	224-234	matrix metallopeptidase 14	Homo sapiens	115-122
23648676-4	2013	In the present study, P450 metabolic activity was investigated in the small intestine of MacfaCAM and MacfaCHN, and cynomolgus macaques bred in Indonesia (MacfaIDN) using P450 substrates, including 7-ethoxyresorufin, coumarin, bupropion, paclitaxel, diclofenac, S-mephenytoin, bufuralol, chlorzoxazone, and testosterone.	Paclitaxel	238-248	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	22-26
23582684-2	2013	In this study, MT1-AF7p peptide, which presents high binding affinity to membrane type-1 matrix metalloproteinase (MT1-MMP) that over-expressed on both angiogenic blood vessels and glioma cells, was employed to decorate the paclitaxel-loaded PEG-PLA nanoparticles (MT1-NP-PTX) to mediate glioblastoma targeting.	Paclitaxel	224-234	metallothionein 1J, pseudogene	Homo sapiens	115-118
29169729-7	2017	In conclusion, miR-193b-3p possessed anti-tumor activity in OC through inhibiting cell proliferation and enhancing paclitaxel sensitivity by targeting PAK3.	Paclitaxel	115-125	microRNA 193b	Homo sapiens	15-23
28991240-6	2017	Consistent with YB1 signaling being known to cause taxol resistance, combination of ceritinib with paclitaxel displayed strong synergy, particularly in cells expressing high FAK autophosphorylation, which we show to be prevalent in lung cancer.	Paclitaxel	99-109	protein tyrosine kinase 2	Homo sapiens	174-177
29299167-9	2017	These results suggested miR-128 as an attractive therapeutic strategy for PTX-resistant lung cancer via inhibition of BMI-1 and MUC1-C.	Paclitaxel	74-77	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	118-123
23792647-0	2013	A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.	Paclitaxel	44-54	cyclin dependent kinase 4	Homo sapiens	2-8
23064469-7	2013	Higher expression levels of p-CFL1 in taxol-resistant cells were demonstrated.	Paclitaxel	38-43	cofilin 1	Homo sapiens	30-34
23064469-9	2013	These findings suggest that p-CFL1 is upregulated in taxol-resistant             ovarian cancer and this upregulation is a chara-cteristic of taxol resistance             both in vitro and in vivo.	Paclitaxel	53-58	cofilin 1	Homo sapiens	30-34
23064469-9	2013	These findings suggest that p-CFL1 is upregulated in taxol-resistant             ovarian cancer and this upregulation is a chara-cteristic of taxol resistance             both in vitro and in vivo.	Paclitaxel	142-147	cofilin 1	Homo sapiens	30-34
23792647-7	2013	CDK4 short interfering RNA (siRNA) significantly increased paclitaxel sensitivity in KRAS mutation-positive H23 cells.	Paclitaxel	59-69	cyclin dependent kinase 4	Homo sapiens	0-4
23792647-10	2013	Combined CINK4 and paclitaxel produced synergistic anti-proliferative activity and increased apoptosis through reduced cyclin D1 and Bcl-2 in KRAS mutation-positive cancer cells.	Paclitaxel	19-29	cyclin D1	Homo sapiens	119-128
29299167-9	2017	These results suggested miR-128 as an attractive therapeutic strategy for PTX-resistant lung cancer via inhibition of BMI-1 and MUC1-C.	Paclitaxel	74-77	mucin 1, cell surface associated	Homo sapiens	128-132
28756208-0	2017	Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species.	Paclitaxel	98-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	74-80
23514751-0	2013	SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.	Paclitaxel	16-26	sirtuin 6	Homo sapiens	0-5
23514751-1	2013	In this study, we report the identification of a novel role of SIRT6 in both epirubicin and paclitaxel resistance in breast cancer.	Paclitaxel	92-102	sirtuin 6	Homo sapiens	63-68
23514751-2	2013	We found that SIRT6 protein levels are elevated in paclitaxel- and epirubicin-resistant MCF-7 cells compared with the parental sensitive cells.	Paclitaxel	51-61	sirtuin 6	Homo sapiens	14-19
23514751-3	2013	SIRT6 knockout and depletion sensitized cells to both paclitaxel and epirubicin treatment, whereas SIRT6 ectopic overexpression led to increased resistance to paclitaxel and epirubicin.	Paclitaxel	54-64	sirtuin 6	Homo sapiens	0-5
23514751-3	2013	SIRT6 knockout and depletion sensitized cells to both paclitaxel and epirubicin treatment, whereas SIRT6 ectopic overexpression led to increased resistance to paclitaxel and epirubicin.	Paclitaxel	159-169	sirtuin 6	Homo sapiens	99-104
23514751-7	2013	Further cell viability studies demonstrate that deletion of FOXO1/3/4 in MEFs can confer sensitivity to both paclitaxel and epirubicin, suggesting that SIRT6 reduces paclitaxel and epirubicin sensitivity, at least in part, through modulating FOXO acetylation and expression.	Paclitaxel	109-119	sirtuin 6	Homo sapiens	152-157
23514751-7	2013	Further cell viability studies demonstrate that deletion of FOXO1/3/4 in MEFs can confer sensitivity to both paclitaxel and epirubicin, suggesting that SIRT6 reduces paclitaxel and epirubicin sensitivity, at least in part, through modulating FOXO acetylation and expression.	Paclitaxel	166-176	sirtuin 6	Homo sapiens	152-157
23326511-5	2013	Additionally, sublethal downregulation of PTPMT1 synergizes with low doses of paclitaxel to promote cancer cell death.	Paclitaxel	78-88	protein tyrosine phosphatase mitochondrial 1	Homo sapiens	42-48
23534290-5	2013	Thus, in ATC cells the ionizing radiation and Ptx exhibited competitive effects upon phosphorylation of cell cycle controllers: p53, pRb, CHK2, cAbl and expression of Bax.	Paclitaxel	46-49	RB transcriptional corepressor 1	Homo sapiens	133-136
23534290-5	2013	Thus, in ATC cells the ionizing radiation and Ptx exhibited competitive effects upon phosphorylation of cell cycle controllers: p53, pRb, CHK2, cAbl and expression of Bax.	Paclitaxel	46-49	checkpoint kinase 2	Homo sapiens	138-142
23443122-8	2012	These results suggest that carboplatin and paclitaxel may induce drug resistance mediated by MDR1 and MRP3, which may be enhanced by the simultaneous use of both drugs.	Paclitaxel	43-53	ATP binding cassette subfamily C member 3	Homo sapiens	102-106
23514751-10	2013	Collectively, our data suggest that SIRT6 has a role in paclitaxel and epirubicin sensitivity via targeting FOXO proteins and that SIRT6 could be a useful biomarker and therapeutic target for paclitaxel- and epirubicin-resistant cancer.	Paclitaxel	56-66	sirtuin 6	Homo sapiens	36-41
23514751-10	2013	Collectively, our data suggest that SIRT6 has a role in paclitaxel and epirubicin sensitivity via targeting FOXO proteins and that SIRT6 could be a useful biomarker and therapeutic target for paclitaxel- and epirubicin-resistant cancer.	Paclitaxel	192-202	sirtuin 6	Homo sapiens	131-136
23640974-6	2013	Genetic variants of paclitaxel pharmacokinetics tested were CYP3A4*22, CYP2C8*3, CYP2C8*4, and ABCB1 3435 C&gt;T. The association between CYP3A4*22 and neurotoxicity observed in the exploratory cohort was validated in an independent patient cohort (n = 239).	Paclitaxel	20-30	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	71-77
23640974-6	2013	Genetic variants of paclitaxel pharmacokinetics tested were CYP3A4*22, CYP2C8*3, CYP2C8*4, and ABCB1 3435 C&gt;T. The association between CYP3A4*22 and neurotoxicity observed in the exploratory cohort was validated in an independent patient cohort (n = 239).	Paclitaxel	20-30	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	81-87
28756208-2	2017	This study evaluated the mechanisms by which MDA-MB-468 breast cancer cells that stably expressed CYP2J2 (MDA-2J2 cells) were protected against killing by the anti-cancer agent paclitaxel.	Paclitaxel	177-187	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	98-104
28847739-7	2017	Paclitaxel (PTX) loaded BCM (BCM-PTX) exhibited higher stability than non-crosslinked micelles (NCM) in the presence of plasma or serum.	Paclitaxel	0-10	tumor necrosis factor receptor superfamily, member 17	Mus musculus	24-27
23510855-4	2013	The surface of the micelles was conjugated successfully with a peptide, which has the specific-binding with EphB4, a member of the Eph family of receptor tyrosine kinases overexpressed on cell membrane of numerous tumors, to increase the delivery of PTX into tumor cells.	Paclitaxel	250-253	EPH receptor B4	Homo sapiens	108-113
22964375-0	2012	Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance.	Paclitaxel	106-116	kallikrein related peptidase 5	Homo sapiens	29-33
28847739-7	2017	Paclitaxel (PTX) loaded BCM (BCM-PTX) exhibited higher stability than non-crosslinked micelles (NCM) in the presence of plasma or serum.	Paclitaxel	0-10	tumor necrosis factor receptor superfamily, member 17	Mus musculus	29-36
23038675-1	2012	Glycolipid and transporter protein gene expression in ovarian serous carcinoma-derived 2008 cells, and their paclitaxel-resistant Px2 and cisplatin-resistant C13 forms was examined to confirm the previous finding, i.e., that it was characteristically altered in anticancer drug-resistant cells established on continuous cultivation of ovarian carcinoma-derived KF28 cells in the different anticancer drug-containing media.	Paclitaxel	109-119	pannexin 2	Homo sapiens	130-133
23580645-8	2013	Paclitaxel had no effect on TGF-beta-induced Smad activation and Smad-dependent gene transcription but inhibited actin polymerization, nuclear accumulation of megakaryoblastic leukemia-1 protein, and SRF activation.	Paclitaxel	0-10	myocardin related transcription factor A	Homo sapiens	159-194
28847739-7	2017	Paclitaxel (PTX) loaded BCM (BCM-PTX) exhibited higher stability than non-crosslinked micelles (NCM) in the presence of plasma or serum.	Paclitaxel	12-15	tumor necrosis factor receptor superfamily, member 17	Mus musculus	24-27
23580645-9	2013	The microtubule-associated formin, mDIA2, localized to actin stress fibers upon treatment with TGF-beta, and paclitaxel prevented this localization.	Paclitaxel	109-119	diaphanous related formin 3	Mus musculus	35-40
28847739-7	2017	Paclitaxel (PTX) loaded BCM (BCM-PTX) exhibited higher stability than non-crosslinked micelles (NCM) in the presence of plasma or serum.	Paclitaxel	12-15	tumor necrosis factor receptor superfamily, member 17	Mus musculus	29-36
23628417-8	2013	Also, BLU plus paclitaxel decreased phosphorylation of p70 ribosomal S6 kinase, as well as decreasing the phosphorylation of glycogen synthase kinase-3beta, which is one of the representative targets of the mammalian target of rapamycin signaling cascade.	Paclitaxel	15-25	glycogen synthase kinase 3 beta	Homo sapiens	125-155
28847739-13	2017	In in vivo tumor treatment study, PTX loaded BCM showed superior therapeutic efficacy than that of NCM and Taxol.	Paclitaxel	34-37	tumor necrosis factor receptor superfamily, member 17	Mus musculus	45-48
23624503-9	2013	Silencing of Cdx1 expression and treatment with lysosomal inhibitor bafilomycin A increased paclitaxel-induced cytotoxicity in CD44(+)CD24(+)Cdx1(+) cells.	Paclitaxel	92-102	caudal type homeobox 1	Homo sapiens	13-17
22766748-9	2012	This study indicated that low levels of TUBB3 in serum could predict better response and survival for advanced gastric cancer patients receiving paclitaxel plus capecitabine, which could be used to select patients who would benefit from this regimen.	Paclitaxel	145-155	tubulin beta 3 class III	Homo sapiens	40-45
23624503-9	2013	Silencing of Cdx1 expression and treatment with lysosomal inhibitor bafilomycin A increased paclitaxel-induced cytotoxicity in CD44(+)CD24(+)Cdx1(+) cells.	Paclitaxel	92-102	caudal type homeobox 1	Homo sapiens	141-145
28631095-10	2017	The systemic administration of rAAV-DCN up-regulates DCN in neuroblastoma and accelerates the intratumoral uptake of nab-paclitaxel by inhibiting stabilin-1 mediated SPARC degradation.	Paclitaxel	121-131	secreted acidic cysteine rich glycoprotein	Mus musculus	166-171
23624503-12	2013	CONCLUSION: Cdx1 exerts a protective role in colon cancer stem cells, which play a crucial role in chemoresistance to paclitaxel through activation of autophagy.	Paclitaxel	118-128	caudal type homeobox 1	Homo sapiens	12-16
23348568-10	2013	In addition, we demonstrated that inhibition of Aurora-A attenuates USP7-mediated taxane resistance, suggesting that combinatorial drug regimens of Taxol and Aurora-A inhibitors may improve the outcome of chemotherapy response in cancer patients resistant to taxane treatment.	Paclitaxel	148-153	aurora kinase A	Homo sapiens	48-56
23074172-0	2012	Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.	Paclitaxel	92-102	microRNA 200c	Homo sapiens	15-23
28849180-0	2017	Silencing Aurora A leads to re-sensitization of breast cancer cells to Taxol through downregulation of SRC-mediated ERK and mTOR pathways.	Paclitaxel	71-76	aurora kinase A	Homo sapiens	10-18
23281375-1	2012	OBJECTIVE: To determine the effect of RNA interference with transferred pshRNA/PHB on the biological characteristics of paclitaxel-resistant ovarian cancer cell lines.	Paclitaxel	120-130	prohibitin 1	Homo sapiens	79-82
23281375-11	2012	The IC50 of paclitaxel in the PHB1 and PHB3 groups significantly decreased after transfection for 72 h compared with the negative control group(P&lt;0.05).	Paclitaxel	12-22	prohibitin 1	Homo sapiens	30-34
23281375-13	2012	CONCLUSION: The shRNA/PHB can effectively suppress the expression of PHB gene in paclitaxel-resistant ovarian cancer cell lines.	Paclitaxel	81-91	prohibitin 1	Homo sapiens	22-25
23281375-13	2012	CONCLUSION: The shRNA/PHB can effectively suppress the expression of PHB gene in paclitaxel-resistant ovarian cancer cell lines.	Paclitaxel	81-91	prohibitin 1	Homo sapiens	69-72
23281375-14	2012	The cell proliferation in paclitaxel-resistant cell lines with removed PHB gene is significantly reduced.	Paclitaxel	26-36	prohibitin 1	Homo sapiens	71-74
22689054-6	2013	GRP78 stabilized CLU protein and its hypoglycosylated forms, in particular after paclitaxel treatment.	Paclitaxel	81-91	clusterin	Homo sapiens	17-20
28849180-2	2017	Previous studies suggested that Aurora A is involved in the development of the Taxol-resistance of breast cancer.	Paclitaxel	79-84	aurora kinase A	Homo sapiens	32-40
23371322-8	2013	We also found the combined treatment group with p110beta siRNA and PTX showed a significant inhibition of tumor growth of SKpac cells compared to the PTX-only treated group in a xenograft nude mouse model.	Paclitaxel	150-153	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Mus musculus	48-56
28979809-0	2017	MiRNA-107 enhances chemosensitivity to paclitaxel by targeting antiapoptotic factor Bcl-w in non small cell lung cancer.	Paclitaxel	39-49	BCL2 like 2	Homo sapiens	84-89
23380587-9	2013	Efficient autophagy by hypertonic stress required microtubule remodeling and was DYNC/dynein-dependent as autophagosome clustering was enhanced by paclitaxel-induced microtubule stabilization and was reduced by nocodazole-induced tubulin depolymerization as well as chemical (EHNA) or genetic [DCTN2/dynactin 2 (p50) overexpression] interference of DYNC activity.	Paclitaxel	147-157	dynactin subunit 2	Homo sapiens	294-299
23281375-15	2012	The apoptotic rate and the paclitaxel sensitivity of resistant cell lines with removed PHB gene are significantly increased.	Paclitaxel	27-37	prohibitin 1	Homo sapiens	87-90
23281375-16	2012	PHB gene is related to paclitaxel-resistance and interfering PHB gene expression may reduce paclitaxel resistance in ovarian cancer.	Paclitaxel	23-33	prohibitin 1	Homo sapiens	0-3
28979809-1	2017	The aim of this study is to elucidate whether and how miR-107 participates in the modulation of paclitaxel sensitivity in non small cell lung cancer (NSCLC).	Paclitaxel	96-106	microRNA 107	Homo sapiens	54-61
23281375-16	2012	PHB gene is related to paclitaxel-resistance and interfering PHB gene expression may reduce paclitaxel resistance in ovarian cancer.	Paclitaxel	92-102	prohibitin 1	Homo sapiens	0-3
23281375-16	2012	PHB gene is related to paclitaxel-resistance and interfering PHB gene expression may reduce paclitaxel resistance in ovarian cancer.	Paclitaxel	92-102	prohibitin 1	Homo sapiens	61-64
23391494-4	2013	When nanocapsules are filled with a far-red fluorochrome (DiD) and Paclitaxel, the presence of the NFL-TBS.40-63 peptide increases their uptake by glioblastoma cells in culture as evaluated by FACS analysis, and thus reduces their proliferation.	Paclitaxel	67-77	acyl-CoA synthetase long-chain family member 1	Mus musculus	193-197
28979809-2	2017	By qRT-PCR, we found that miR-107 is significantly down-regulated in paclitaxel-resistant A549/Taxol cells compared with corresponding paclitaxel-sensitive counterparts.	Paclitaxel	69-79	microRNA 107	Homo sapiens	26-33
23443842-10	2013	Moreover, PTX treatment markedly suppressed Smad2 phosphorylation.	Paclitaxel	10-13	SMAD family member 2	Homo sapiens	44-49
28979809-2	2017	By qRT-PCR, we found that miR-107 is significantly down-regulated in paclitaxel-resistant A549/Taxol cells compared with corresponding paclitaxel-sensitive counterparts.	Paclitaxel	135-145	microRNA 107	Homo sapiens	26-33
23443842-11	2013	These data suggest that at a low-dose, PTX can significantly suppress the TGF-beta/Smad signalling pathway by inhibiting Smad2 phosphorylation in the human peritoneum and that this can reduce stromal fibrosis.	Paclitaxel	39-42	SMAD family member 2	Homo sapiens	121-126
28979809-3	2017	Overexpression of miR-107 suppresses paclitaxel resistance of A549/Taxol cells through directly inhibiting Bcl-w.	Paclitaxel	37-47	microRNA 107	Homo sapiens	18-25
28979809-3	2017	Overexpression of miR-107 suppresses paclitaxel resistance of A549/Taxol cells through directly inhibiting Bcl-w.	Paclitaxel	37-47	BCL2 like 2	Homo sapiens	107-112
28979809-3	2017	Overexpression of miR-107 suppresses paclitaxel resistance of A549/Taxol cells through directly inhibiting Bcl-w.	Paclitaxel	67-72	microRNA 107	Homo sapiens	18-25
23537295-6	2013	In addition, immunohistochemical studies on mouse tumors injected with cisplatin or paclitaxel treated residual cells displayed higher staining for the proliferative antigen Ki67, oncogeneic CA125, epithelial E-cadherin as well as cancer stem cell markers such as Oct4 and CD117, compared to mice injected with control untreated cells.	Paclitaxel	84-94	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	264-268
22960115-8	2012	RESULTS: Treatment with Taxol, hUCMSCs or Taxol+hUCMSCs reduced the extent of astrocytic activation, increased axonal preservation and decreased the number of caspase-3(+) and ED-1(+) cells, but these effects were more pronounced in the Taxol+hUCMSCs group.	Paclitaxel	24-29	caspase 3	Rattus norvegicus	159-168
22960115-8	2012	RESULTS: Treatment with Taxol, hUCMSCs or Taxol+hUCMSCs reduced the extent of astrocytic activation, increased axonal preservation and decreased the number of caspase-3(+) and ED-1(+) cells, but these effects were more pronounced in the Taxol+hUCMSCs group.	Paclitaxel	42-47	caspase 3	Rattus norvegicus	159-168
28979809-3	2017	Overexpression of miR-107 suppresses paclitaxel resistance of A549/Taxol cells through directly inhibiting Bcl-w.	Paclitaxel	67-72	BCL2 like 2	Homo sapiens	107-112
22960115-8	2012	RESULTS: Treatment with Taxol, hUCMSCs or Taxol+hUCMSCs reduced the extent of astrocytic activation, increased axonal preservation and decreased the number of caspase-3(+) and ED-1(+) cells, but these effects were more pronounced in the Taxol+hUCMSCs group.	Paclitaxel	42-47	caspase 3	Rattus norvegicus	159-168
28979809-4	2017	Overexpression of miR-107 promotes apoptosis and inhibits proliferation and mobility of A549/Taxol cells under treatment with paclitaxel in vitro.	Paclitaxel	126-136	microRNA 107	Homo sapiens	18-25
28979809-5	2017	Moreover, miR-107 inhibits in vivo paclitaxel resistance in xenograft model.	Paclitaxel	35-45	microRNA 107	Homo sapiens	10-17
28979809-6	2017	MiR-107/Bcl-w axis regulates paclitaxel chemoresistance through PI3K-Akt pathway.	Paclitaxel	29-39	microRNA 107	Homo sapiens	0-7
23321641-9	2013	Cells with overactive Cdk2 fail to arrest after mitotic slippage in the presence of paclitaxel or cytokinesis failure during treatment with cytochalasin-B, generating 8N populations.	Paclitaxel	84-94	cyclin dependent kinase 2	Homo sapiens	22-26
28979809-6	2017	MiR-107/Bcl-w axis regulates paclitaxel chemoresistance through PI3K-Akt pathway.	Paclitaxel	29-39	BCL2 like 2	Homo sapiens	8-13
23391723-7	2013	The TGF-beta type I receptor kinase inhibitor LY2157299, a neutralizing TGF-beta type II receptor antibody, and SMAD4 siRNA all blocked paclitaxel-induced IL8 transcription and CSC expansion.	Paclitaxel	136-146	SMAD family member 4	Homo sapiens	112-117
22971921-5	2012	SP cells are resistant to paclitaxel because of the upregulation of ABCB1 and ABCB5.	Paclitaxel	26-36	ATP binding cassette subfamily B member 5	Homo sapiens	78-83
28979809-7	2017	Our results suggest that up-regulation of miR-107 resensitizes paclitaxel-resistant NSCLC cells by targeting Bcl-w, which reveals a potential mechanism of miR-107 in reversing drug resistance.	Paclitaxel	63-73	microRNA 107	Homo sapiens	42-49
24716145-3	2012	Both SB and PTX alone or SB+PTX treatment inhibited 4T1 cell migration and motility possibly through downregulation of the serpin protease nexin-1 (PN-1) and N-cadherin expression, inhibition of matrix metalloprotease (MMP)-9 activity, and upregulation of E-cadherin.	Paclitaxel	12-15	serine (or cysteine) peptidase inhibitor, clade E, member 2	Mus musculus	148-152
24716145-3	2012	Both SB and PTX alone or SB+PTX treatment inhibited 4T1 cell migration and motility possibly through downregulation of the serpin protease nexin-1 (PN-1) and N-cadherin expression, inhibition of matrix metalloprotease (MMP)-9 activity, and upregulation of E-cadherin.	Paclitaxel	12-15	matrix metallopeptidase 9	Mus musculus	195-225
24716145-3	2012	Both SB and PTX alone or SB+PTX treatment inhibited 4T1 cell migration and motility possibly through downregulation of the serpin protease nexin-1 (PN-1) and N-cadherin expression, inhibition of matrix metalloprotease (MMP)-9 activity, and upregulation of E-cadherin.	Paclitaxel	28-31	serine (or cysteine) peptidase inhibitor, clade E, member 2	Mus musculus	148-152
24716145-3	2012	Both SB and PTX alone or SB+PTX treatment inhibited 4T1 cell migration and motility possibly through downregulation of the serpin protease nexin-1 (PN-1) and N-cadherin expression, inhibition of matrix metalloprotease (MMP)-9 activity, and upregulation of E-cadherin.	Paclitaxel	28-31	matrix metallopeptidase 9	Mus musculus	195-225
24716145-6	2012	In vivo study using the allograft 4T1(pGL-COX-2/Luc) metastatic mouse model indicated that SB co-treated with PTX can significantly suppress lung metastasis of 4T1 cells likely through inhibiting cell proliferation and angiogenesis.	Paclitaxel	110-113	cytochrome c oxidase II, mitochondrial	Mus musculus	42-47
22684772-0	2012	Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.	Paclitaxel	82-92	tubulin beta 3 class III	Homo sapiens	34-39
22684772-10	2012	However, TUBB3 expression was significantly lower in the paclitaxel-sensitive group compared to the paclitaxel-resistant group (47.6 % vs. 77.8 %, P &lt; 0.05).	Paclitaxel	57-67	tubulin beta 3 class III	Homo sapiens	9-14
22684772-10	2012	However, TUBB3 expression was significantly lower in the paclitaxel-sensitive group compared to the paclitaxel-resistant group (47.6 % vs. 77.8 %, P &lt; 0.05).	Paclitaxel	100-110	tubulin beta 3 class III	Homo sapiens	9-14
22843789-6	2012	There is also evidence that markers in additional genes, including EPHA5 (rs7349683) and FZD3 (rs10771973), were associated with the onset or severity of paclitaxel-induced sensory peripheral neuropathy.	Paclitaxel	154-164	EPH receptor A5	Homo sapiens	67-72
22843789-6	2012	There is also evidence that markers in additional genes, including EPHA5 (rs7349683) and FZD3 (rs10771973), were associated with the onset or severity of paclitaxel-induced sensory peripheral neuropathy.	Paclitaxel	154-164	frizzled class receptor 3	Homo sapiens	89-93
22711747-3	2012	In Mdr1a knockout rats, loperamide and paclitaxel oral bioavailability was 2- and 4-fold increased, respectively, whereas clearance was significantly reduced (40-42%), consistent with the expected 10- to 20-fold reduction in paclitaxel excretion.	Paclitaxel	39-49	ATP binding cassette subfamily B member 1A	Rattus norvegicus	3-8
22711747-3	2012	In Mdr1a knockout rats, loperamide and paclitaxel oral bioavailability was 2- and 4-fold increased, respectively, whereas clearance was significantly reduced (40-42%), consistent with the expected 10- to 20-fold reduction in paclitaxel excretion.	Paclitaxel	225-235	ATP binding cassette subfamily B member 1A	Rattus norvegicus	3-8
22374518-6	2012	The potential influence of E2/ERalpha on the therapeutic efficacy of paclitaxel was then evaluated.	Paclitaxel	69-79	ATPase, H+ transporting, lysosomal V1 subunit E1	Mus musculus	27-37
22680343-1	2012	WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT:   Paclitaxel and rosiglitazone are primarily metabolized by CYP2C8 and their in vitro metabolism by human liver microsomes is correlated.	Paclitaxel	44-54	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	102-108
22527101-0	2012	CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.	Paclitaxel	87-97	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
22527101-12	2012	Patients carrying CYP2C8*3 are more likely to achieve clinical complete response from neoadjuvant paclitaxel treatment, but may also be at increased risk of experiencing severe peripheral neurotoxicity.	Paclitaxel	98-108	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	18-24
22595795-8	2012	Conversely, in chemotherapy-resistant EW7 spheroids or M8 cells, the combination of hIFNbeta with drugs that mainly operate at the genotoxic level (doxorubicin, methotrexate and paclitaxel) presented only additive effects.	Paclitaxel	178-188	interferon beta 1	Homo sapiens	84-92
22485250-0	2012	ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.	Paclitaxel	99-109	erb-b2 receptor tyrosine kinase 3	Homo sapiens	0-5
22404109-4	2012	We demonstrate that HDA14 can deacetylate alpha-tubulin, associates with alpha/beta-tubulin and is retained on GTP/taxol-stabilized microtubules, at least in part, by direct association with the PP2A-A2 subunit.	Paclitaxel	115-120	histone deacetylase 14	Arabidopsis thaliana	20-25
22709569-0	2012	Knockdown of PLC-gamma-2 and calmodulin 1 genes sensitizes human cervical adenocarcinoma cells to doxorubicin and paclitaxel.	Paclitaxel	114-124	phospholipase C gamma 2	Homo sapiens	13-24
22238053-11	2012	Treatment of AGS cells with 10 muM cisplatin, 0.5 muM etoposide and 10 nM taxol affected the BCL2, BAX and BCL2L12 mRNA levels, compared to the untreated cells.	Paclitaxel	74-79	BCL2 like 12	Homo sapiens	107-114
22210018-2	2012	METHODS: A population pharmacokinetic model of AMG 386 (N = 141) was developed and applied in an exposure-response analysis using data from patients (N = 160) with recurrent ovarian cancer who received paclitaxel plus AMG 386 (3 or 10 mg/kg once weekly) or placebo.	Paclitaxel	202-212	amelogenin X-linked	Homo sapiens	47-50
22533866-1	2012	BACKGROUND: MyD88 is an adaptor protein for TLR-4 signaling known to mediate paclitaxel resistance in epithelial ovarian carcinoma (EOC).	Paclitaxel	77-87	MYD88 innate immune signal transduction adaptor	Homo sapiens	12-17
21821547-0	2012	Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.	Paclitaxel	103-113	cyclin dependent kinase 2	Homo sapiens	65-69
22281755-0	2012	Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells.	Paclitaxel	100-110	aurora kinase A	Homo sapiens	20-28
22281755-5	2012	The results showed that treatment of human breast carcinoma cells (SK-BR-3 and MDA-MB-231) by Aurora A short hairpin RNA (shRNA) driven by stathmin gene promoter not only inhibited the cells proliferation, but also enhanced the chemosensitivity to paclitaxel via downregulation of Aurora A mRNA and protein expression, which further decreased the phosphatidylinositol 3 kinase/Akt and p-BRCA1 protein expression.	Paclitaxel	248-258	aurora kinase A	Homo sapiens	94-102
22320903-0	2012	Identification of a novel role of Septin 10 in paclitaxel-resistance in cancers through a functional genomics screen.	Paclitaxel	47-57	septin 10	Homo sapiens	34-43
22320903-4	2012	We isolated two paclitaxel-resistant clones carrying the siRNA specific to septin 10 (SEPT10) and to budding uninhibited by benzimidazoles 3.	Paclitaxel	16-26	septin 10	Homo sapiens	75-84
22320903-4	2012	We isolated two paclitaxel-resistant clones carrying the siRNA specific to septin 10 (SEPT10) and to budding uninhibited by benzimidazoles 3.	Paclitaxel	16-26	septin 10	Homo sapiens	86-92
22320903-7	2012	Furthermore, we found that paclitaxel-resistant tumors had decreased expression of SEPT10.	Paclitaxel	27-37	septin 10	Homo sapiens	83-89
22320903-8	2012	Thus, SEPT10 may be a novel candidate molecule that acts as a good indicator of paclitaxel-resistant carcinomas.	Paclitaxel	80-90	septin 10	Homo sapiens	6-12
22278362-7	2012	RESULTS: We show that the microtubule network in SEPT9_i4 over-expressing cells resists disruption by paclitaxel or cold incubation but also repolymerises tubulin more slowly after microtubule depolymerisation.	Paclitaxel	102-112	septin 9	Homo sapiens	49-54
22419594-3	2012	We have developed an inquiry-based module that uses the mutagenesis of the yeast reductase, YDL124w, to study the bioorganic synthesis of the taxol side-chain, a pharmacologically important molecule.	Paclitaxel	142-147	aldo-keto reductase superfamily protein	Saccharomyces cerevisiae S288C	92-99
22018777-1	2012	Association of estrogen receptor (ER), progesterone receptor (PR), HER2, Ki67 and 70-gene classifier (70-GC) with a response to paclitaxel (PAC) (n=79) or docetaxel (DOC) (n=55) was investigated in the neoadjuvant setting for breast cancer patients.	Paclitaxel	128-138	progesterone receptor	Homo sapiens	39-60
21643015-2	2012	We recently showed that absence or depletion of protein Daxx increases cellular taxol (paclitaxel) resistance-a common trait of patients diagnosed with several malignancies, including breast cancer.	Paclitaxel	80-85	death domain associated protein	Homo sapiens	56-60
21643015-2	2012	We recently showed that absence or depletion of protein Daxx increases cellular taxol (paclitaxel) resistance-a common trait of patients diagnosed with several malignancies, including breast cancer.	Paclitaxel	87-97	death domain associated protein	Homo sapiens	56-60
21643015-3	2012	Further investigation of Daxx-mediated taxol response revealed that Daxx is important for the proper timing of mitosis progression and cyclin B stability.	Paclitaxel	39-44	death domain associated protein	Homo sapiens	25-29
21643015-3	2012	Further investigation of Daxx-mediated taxol response revealed that Daxx is important for the proper timing of mitosis progression and cyclin B stability.	Paclitaxel	39-44	death domain associated protein	Homo sapiens	68-72
21643015-5	2012	Rassf1/Daxx depletion or expression of Daxx-binding domain of Rassf1 elevates cyclin B stability and increases taxol resistance in cells and mouse xenograft models.	Paclitaxel	111-116	death domain associated protein	Homo sapiens	39-43
21643015-7	2012	These data suggest that Daxx and Rassf1 define a mitotic stress checkpoint that enables cells to exit mitosis as micronucleated cells (and eventually die) when encountered with specific mitotic stress stimuli, including taxol.	Paclitaxel	220-225	death domain associated protein	Homo sapiens	24-28
21471564-2	2012	Data from the metastatic setting suggest high tumor class III beta-tubulin (TUBB3) expression is a determinant of insensitivity to tubulin-targeting agents (e.g. vinorelbine, paclitaxel).	Paclitaxel	175-185	tubulin beta 3 class III	Homo sapiens	52-74
21471564-2	2012	Data from the metastatic setting suggest high tumor class III beta-tubulin (TUBB3) expression is a determinant of insensitivity to tubulin-targeting agents (e.g. vinorelbine, paclitaxel).	Paclitaxel	175-185	tubulin beta 3 class III	Homo sapiens	76-81
21959006-8	2012	In vitro and in vivo studies demonstrate that Coxsackie adenovirus receptor (CAR) or foliate receptor (FR)-mediated uptake of FA-Ad-loaded PTX induced highly anti-tumor activity.	Paclitaxel	139-142	coxsackie virus and adenovirus receptor	Mus musculus	46-75
21959006-8	2012	In vitro and in vivo studies demonstrate that Coxsackie adenovirus receptor (CAR) or foliate receptor (FR)-mediated uptake of FA-Ad-loaded PTX induced highly anti-tumor activity.	Paclitaxel	139-142	coxsackie virus and adenovirus receptor	Mus musculus	77-80
22211095-1	2012	OBJECTIVE: We have analyzed the association between clusterin expression in endometrial cancer cells and their resistance to paclitaxel.	Paclitaxel	125-135	clusterin	Homo sapiens	52-61
22211095-5	2012	Using clusterin siRNA, we analyzed the association between clusterin expression and paclitaxel IC(50) in each cell line.	Paclitaxel	84-94	clusterin	Homo sapiens	59-68
22211095-7	2012	RESULTS: Paclitaxel IC(50) was significantly higher in KLE cells, which expressed higher levels of clusterin, than in ECC-1 cells, which expressed lower levels of clusterin.	Paclitaxel	9-19	clusterin	Homo sapiens	99-108
22211095-7	2012	RESULTS: Paclitaxel IC(50) was significantly higher in KLE cells, which expressed higher levels of clusterin, than in ECC-1 cells, which expressed lower levels of clusterin.	Paclitaxel	9-19	clusterin	Homo sapiens	163-172
22211095-12	2012	CONCLUSION: Estrogen increases the paclitaxel resistance of endometrial cancer cell lines, by increasing clusterin expression.	Paclitaxel	35-45	clusterin	Homo sapiens	105-114
22949827-0	2012	Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma.	Paclitaxel	57-62	cyclin D1	Homo sapiens	80-89
22949827-1	2012	The present study was designed to investigate the effects of cyclooxygenase (COX) inhibitors in combination with taxol on the expression of cyclin D1 and Ki-67 in human ovarian SKOV-3 carcinoma cells xenograft-bearing mice.	Paclitaxel	113-118	cyclin D1	Homo sapiens	140-149
22150676-6	2012	DCK (12), DMDCK (15), 16, 21, 23 and 24 at 4 microm achieved 91%~99% decrease in IC50 value (concentration inhibiting cell growth by 50%) of anticancer agents vinblastine, doxorubicin, puromycin and paclitaxel, and were more active than others.	Paclitaxel	199-209	deoxycytidine kinase	Homo sapiens	0-3
22768203-13	2012	Treatment with PTX and CYA combination restored the expression of miR200c and 34a, confirming their role in modulating chemoresistance.	Paclitaxel	15-18	microRNA 200c	Homo sapiens	66-73
22185350-0	2011	Clusterin is a potential molecular predictor for ovarian cancer patient"s survival: targeting clusterin improves response to paclitaxel.	Paclitaxel	125-135	clusterin	Homo sapiens	0-9
22185350-0	2011	Clusterin is a potential molecular predictor for ovarian cancer patient"s survival: targeting clusterin improves response to paclitaxel.	Paclitaxel	125-135	clusterin	Homo sapiens	94-103
22185350-7	2011	Either siRNA or second generation antisense oligodeoxynucleotide against CLU (OGX-011), which is currently evaluated in clinical phase II trials in other cancer s, was used to modulate sensitivity to paclitaxel (TX) in ovarian cancer cells in vitro.	Paclitaxel	200-210	clusterin	Homo sapiens	73-76
21880414-0	2011	5-aza-2"-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-beta-catenin expression.	Paclitaxel	74-84	lymphoid enhancer binding factor 1	Homo sapiens	99-103
21880414-1	2011	We investigated the molecular mechanisms by which 5-aza-2"-deoxycytidine (DAC) and paclitaxel (PTX) use lymphoid enhancer-binding factor 1 (LEF1) and the Wnt/beta-catenin pathway to synergistically interact against renal cell carcinoma (RCC).	Paclitaxel	83-93	lymphoid enhancer binding factor 1	Homo sapiens	104-138
21880414-1	2011	We investigated the molecular mechanisms by which 5-aza-2"-deoxycytidine (DAC) and paclitaxel (PTX) use lymphoid enhancer-binding factor 1 (LEF1) and the Wnt/beta-catenin pathway to synergistically interact against renal cell carcinoma (RCC).	Paclitaxel	83-93	lymphoid enhancer binding factor 1	Homo sapiens	140-144
21880414-1	2011	We investigated the molecular mechanisms by which 5-aza-2"-deoxycytidine (DAC) and paclitaxel (PTX) use lymphoid enhancer-binding factor 1 (LEF1) and the Wnt/beta-catenin pathway to synergistically interact against renal cell carcinoma (RCC).	Paclitaxel	95-98	lymphoid enhancer binding factor 1	Homo sapiens	104-138
21880414-1	2011	We investigated the molecular mechanisms by which 5-aza-2"-deoxycytidine (DAC) and paclitaxel (PTX) use lymphoid enhancer-binding factor 1 (LEF1) and the Wnt/beta-catenin pathway to synergistically interact against renal cell carcinoma (RCC).	Paclitaxel	95-98	lymphoid enhancer binding factor 1	Homo sapiens	140-144
21880414-3	2011	The regulation of LEF1/beta-catenin protein expression by DAC and/or PTX was examined by Western blot and immunoprecipitation.	Paclitaxel	69-72	lymphoid enhancer binding factor 1	Homo sapiens	18-22
21880414-5	2011	Our results confirmed that DAC and PTX synergistically decreased the expression of LEF1 in vivo and in vitro.	Paclitaxel	35-38	lymphoid enhancer binding factor 1	Homo sapiens	83-87
21880414-6	2011	Moreover, treatment of RCC cell lines with the combination of DAC and PTX caused a synergistic decrease in LEF1/phospho-beta-catenin.	Paclitaxel	70-73	lymphoid enhancer binding factor 1	Homo sapiens	107-111
21903260-5	2011	iRGD on PCL-PVP nanoparticle surface facilitated the nanoparticles to accumulate in tumor site and enhanced their penetration in tumor tissues, both of which improved the efficacy of paclitaxel-loaded nanoparticles in impeding tumor growth and prolonging the life time of H22 tumor-bearing mice.	Paclitaxel	183-193	interferon gamma inducible protein 47	Mus musculus	0-4
21978935-0	2011	Cooperative phosphorylation of FADD by Aur-A and Plk1 in response to taxol triggers both apoptotic and necrotic cell death.	Paclitaxel	69-74	aurora kinase A	Homo sapiens	39-44
21978935-1	2011	Administration of the antimitotic chemotherapeutic taxol is known to cause accumulation of the mitotic kinase Aurora-A (Aur-A).	Paclitaxel	51-56	aurora kinase A	Homo sapiens	110-118
21978935-1	2011	Administration of the antimitotic chemotherapeutic taxol is known to cause accumulation of the mitotic kinase Aurora-A (Aur-A).	Paclitaxel	51-56	aurora kinase A	Homo sapiens	120-125
21978935-2	2011	Here, we report that Aur-A phosphorylates S203 of the Fas associated with death domain protein (FADD) in response to taxol treatment.	Paclitaxel	117-122	aurora kinase A	Homo sapiens	21-26
21978935-8	2011	Collectively, our data show the existence of cooperative actions between Aur-A and Plk1 mitotic kinases in response to taxol, providing a molecular explanation for the action mechanism of taxol.	Paclitaxel	119-124	aurora kinase A	Homo sapiens	73-78
21978935-8	2011	Collectively, our data show the existence of cooperative actions between Aur-A and Plk1 mitotic kinases in response to taxol, providing a molecular explanation for the action mechanism of taxol.	Paclitaxel	188-193	aurora kinase A	Homo sapiens	73-78
22019170-7	2011	Data revealed that paclitaxel induced an increase of Cdk1 activity and DR5 expression on the Golgi complex that was associated with increased cleavage of caspase-8, a DR5 downstream factor, and caspase-3 into catalytically active fragments.	Paclitaxel	19-29	caspase 8	Homo sapiens	154-163
22019170-10	2011	Also, paclitaxel caused an increase of nuclear but not of Golgi associated PKC-delta activity.	Paclitaxel	6-16	protein kinase C delta	Homo sapiens	75-84
22019170-12	2011	CONCLUSIONS: Data suggest that paclitaxel induces nuclear translocation and activation of PKC-delta, which in turn causes Golgi-Cdk1 activation, leading to Golgi associated DR5 up-regulation, and caspase-8 and 3 activation.	Paclitaxel	31-41	protein kinase C delta	Homo sapiens	90-99
21987172-4	2011	In response to endoplasmic reticulum stress inducers, including paclitaxel, YB-1 is translocated to the nucleus to transactivate clusterin.	Paclitaxel	64-74	clusterin	Homo sapiens	129-138
21987172-6	2011	Knockdown of either YB-1 or clusterin sensitized prostate cancer cells to paclitaxel, whereas their overexpression increased resistance to taxane.	Paclitaxel	74-84	clusterin	Homo sapiens	28-37
21987172-7	2011	Clusterin overexpression rescued cells from increased paclitaxel-induced apoptosis following YB-1 knockdown; in contrast, however, YB-1 overexpression did not rescue cells from increased paclitaxel-induced apoptosis following clusterin knockdown.	Paclitaxel	54-64	clusterin	Homo sapiens	0-9
21987172-8	2011	Collectively, these data indicate that YB-1 transactivation of clusterin in response to stress is a critical mediator of paclitaxel resistance in prostate cancer.	Paclitaxel	121-131	clusterin	Homo sapiens	63-72
21919130-6	2011	CD133(+) cells were more resistant to cisplatin/paclitaxel-induced cytotoxicity in comparison with CD133(-) cells.	Paclitaxel	48-58	prominin 1	Homo sapiens	0-5
21685373-4	2011	We compared the results obtained to mice treated with PTX and AMD3100, a small-molecule drug antagonist of CXCR4 which, like G-CSF, can be used to mobilize hematopoietic cells.	Paclitaxel	54-57	colony stimulating factor 3 (granulocyte)	Mus musculus	125-130
21685373-5	2011	We show that PTX combined with G-CSF treatment facilitates revascularization, leading to an improvement in blood perfusion in LLC tumors, and a decrease in hypoxia in EMT/6 tumors, thus enhancing tumor growth in comparison to PTX or PTX and AMD3100 therapies.	Paclitaxel	226-229	colony stimulating factor 3 (granulocyte)	Mus musculus	31-36
21685373-5	2011	We show that PTX combined with G-CSF treatment facilitates revascularization, leading to an improvement in blood perfusion in LLC tumors, and a decrease in hypoxia in EMT/6 tumors, thus enhancing tumor growth in comparison to PTX or PTX and AMD3100 therapies.	Paclitaxel	226-229	colony stimulating factor 3 (granulocyte)	Mus musculus	31-36
21523861-4	2011	Our previous studies showed ODC overexpression prevented etoposide-, paclitaxel-, and cisplatin-induced apoptosis.	Paclitaxel	69-79	ornithine decarboxylase 1	Homo sapiens	28-31
21549688-0	2011	The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein.	Paclitaxel	85-90	DLG associated protein 5	Homo sapiens	110-114
21549688-2	2011	HURP plays an important role during mitotic spindle formation, a process that is targeted by various anti-cancer drugs like taxol.	Paclitaxel	124-129	DLG associated protein 5	Homo sapiens	0-4
21549688-3	2011	However, the role of HURP during the establishment of taxol chemoresistance in HCC remains unclear.	Paclitaxel	54-59	DLG associated protein 5	Homo sapiens	21-25
21549688-4	2011	In this study, we observed that high HURP protein level correlates with taxol resistance in HCC cells.	Paclitaxel	72-77	DLG associated protein 5	Homo sapiens	37-41
23364970-8	2013	The relationship between TUBB3 and paclitaxel resistance was assessed with small interfering TUBB3 RNA.	Paclitaxel	35-45	tubulin beta 3 class III	Homo sapiens	25-30
23364970-10	2013	RESULTS: Hypoxia induced paclitaxel resistance was decreased by knockdown of TUBB3.	Paclitaxel	25-35	tubulin beta 3 class III	Homo sapiens	77-82
23364970-12	2013	Hypoxia-dependent upregulation of HIF-1alpha and TUBB3 was reduced in response to paclitaxel treatment.	Paclitaxel	82-92	tubulin beta 3 class III	Homo sapiens	49-54
23223572-5	2013	In mec-7 mutants, the ALM mechanosensory neuron forms a long ectopic neurite that extends posteriorly, a phenotype that can be mimicked in wild-type worms with a microtubule-stabilizing drug (paclitaxel), and suppressed by mutations in unc-33/CRMP2 and the kinesin-related gene, vab-8.	Paclitaxel	192-202	Tubulin beta-1 chain	Caenorhabditis elegans	3-8
23099063-6	2013	ICAM-1-selective delivery of paclitaxel produced potent tumor suppression of not only ICAM-1-positive cervical cancer cells but also ICAM-1-negative tumors, presumably by causing cytotoxicity in tumor-associated endothelium (CD31(+)) and macrophages (CD68(+)) over-expressing ICAM-1.	Paclitaxel	29-39	platelet and endothelial cell adhesion molecule 1	Homo sapiens	225-229
23629743-2	2013	Nilotinib demonstrated preferential inhibition of CYP2C8-mediated paclitaxel 6alpha-hydroxylation, rosiglitazone hydroxylation and amodiaquine N-deethylation in human liver microsomes, with IC50 values of 0.4, 7.5 and 0.7 microM, respectively.	Paclitaxel	66-76	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	50-56
23378760-3	2013	Both types of PTX-loaded nanoparticles were equally effective at inhibiting proliferation of MDCKII cells, but PTX-loaded micelles were more cytotoxic than nanospheres in MDCKII-MDR1 cells.	Paclitaxel	111-114	ATP binding cassette subfamily B member 1	Canis lupus familiaris	171-182
22907189-10	2013	The coadministration of COL-3 with paclitaxel significantly increased the transcript levels of IL-6 in the spleen and decreased CX3CL1 transcripts in the brain in comparison to treatment with paclitaxel alone.	Paclitaxel	35-45	chemokine (C-X3-C motif) ligand 1	Mus musculus	128-134
23064469-0	2013	Upregulation of phosphorylated cofilin 1 correlates with taxol resistance             in human ovarian cancer in vitro and in vivo.	Paclitaxel	57-62	cofilin 1	Homo sapiens	31-40
23064469-3	2013	In this study, we demonstrated             that the protein, phosphorylated cofilin 1 (p-CFL1) correlates with taxol resistance             in human ovarian cancer cells.	Paclitaxel	111-116	cofilin 1	Homo sapiens	76-85
23064469-3	2013	In this study, we demonstrated             that the protein, phosphorylated cofilin 1 (p-CFL1) correlates with taxol resistance             in human ovarian cancer cells.	Paclitaxel	111-116	cofilin 1	Homo sapiens	89-93
23064469-6	2013	Cofilin 1             (CFL1) was selected as a candidate which may play an important role in taxol resistance.	Paclitaxel	93-98	cofilin 1	Homo sapiens	0-9
23064469-6	2013	Cofilin 1             (CFL1) was selected as a candidate which may play an important role in taxol resistance.	Paclitaxel	93-98	cofilin 1	Homo sapiens	23-27
23087055-6	2012	In addition, a number of cytotoxic substrates, including docetaxel, paclitaxel, and Ara-C, increased the ABCC10 basal ATPase activity.	Paclitaxel	68-78	dynein, axonemal, heavy chain 8	Mus musculus	118-124
23037716-0	2012	Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells.	Paclitaxel	0-10	aurora kinase A	Homo sapiens	24-39
22988235-3	2012	We previously identified two proteins in the cellular pathway that lead to Taxol-induced peripheral neuropathy, neuronal calcium sensor-1 (NCS-1) and calpain.	Paclitaxel	75-80	neuronal calcium sensor 1	Homo sapiens	112-137
22988235-3	2012	We previously identified two proteins in the cellular pathway that lead to Taxol-induced peripheral neuropathy, neuronal calcium sensor-1 (NCS-1) and calpain.	Paclitaxel	75-80	neuronal calcium sensor 1	Homo sapiens	139-144
22988235-4	2012	Prolonged treatment with Taxol induces activation of calpain, degradation of NCS-1, and loss of intracellular calcium signaling.	Paclitaxel	25-30	neuronal calcium sensor 1	Homo sapiens	77-82
22988235-6	2012	We found that the co-administration of either lithium or ibudilast to neuroblastoma cells that were treated with Taxol or vincristine inhibited activation of calpain and the reductions in NCS-1 levels and calcium signaling associated with these chemotherapeutic drugs.	Paclitaxel	113-118	neuronal calcium sensor 1	Homo sapiens	188-193
22847181-0	2012	Mitochondrial uncoupling protein 2 regulates the effects of paclitaxel on Stat3 activation and cellular survival in lung cancer cells.	Paclitaxel	60-70	uncoupling protein 2	Homo sapiens	0-34
22847181-7	2012	Silencing high UCP-2 expression with small interfering RNA (siRNA) in A549 and H460 cells restored paclitaxel-induced Stat3 activation.	Paclitaxel	99-109	uncoupling protein 2	Homo sapiens	15-20
22812695-0	2012	Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera.	Paclitaxel	12-22	mucin 1, cell surface associated	Homo sapiens	77-81
22812695-0	2012	Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera.	Paclitaxel	12-22	microRNA let-7i	Homo sapiens	90-96
22812695-1	2012	The purpose of this study was to establish tumor tissue specific delivery of let-7i miRNA to reverse paclitaxel-induced chemoresistance.	Paclitaxel	101-111	microRNA let-7i	Homo sapiens	77-83
22812695-3	2012	Results demonstrated that the chimera can specifically be delivered into OVCAR-3 cells and the released let-7i significantly sensitized the role of paclitaxel in inhibiting cell proliferation, inducing cell apoptosis, and decreasing long-term cell survival.	Paclitaxel	148-158	microRNA let-7i	Homo sapiens	104-110
22812695-5	2012	Our study indicated that this MUC1/let-7i chimera can specifically reverse chemoresistance to paclitaxel.	Paclitaxel	94-104	mucin 1, cell surface associated	Homo sapiens	30-34
22812695-5	2012	Our study indicated that this MUC1/let-7i chimera can specifically reverse chemoresistance to paclitaxel.	Paclitaxel	94-104	microRNA let-7i	Homo sapiens	35-41
22743248-8	2012	Recent studies suggest that TLR4-MyD88-ERK signaling may be a novel target for reversing chemoresistance to paclitaxel.	Paclitaxel	108-118	MYD88 innate immune signal transduction adaptor	Homo sapiens	33-38
22743248-9	2012	Our flow cytometry and Western blot data showed that paclitaxel activated TLR4-MyD88-ERK signaling and that IS treatment could effectively inhibit this paclitaxel-induced activation of TLR4-MyD88-ERK signaling.	Paclitaxel	53-63	MYD88 innate immune signal transduction adaptor	Homo sapiens	79-84
22743248-9	2012	Our flow cytometry and Western blot data showed that paclitaxel activated TLR4-MyD88-ERK signaling and that IS treatment could effectively inhibit this paclitaxel-induced activation of TLR4-MyD88-ERK signaling.	Paclitaxel	53-63	MYD88 innate immune signal transduction adaptor	Homo sapiens	190-195
22743248-9	2012	Our flow cytometry and Western blot data showed that paclitaxel activated TLR4-MyD88-ERK signaling and that IS treatment could effectively inhibit this paclitaxel-induced activation of TLR4-MyD88-ERK signaling.	Paclitaxel	152-162	MYD88 innate immune signal transduction adaptor	Homo sapiens	190-195
22684370-4	2012	NALM-6/SP-B cells were also more resistant to FK228, which             has a similar chemical structure to SP-B, and were slightly more resistant to             the P-gp substrates doxorubicin and vincristine than parental cells, but displayed             similar susceptibility to other HDAC inhibitors and to paclitaxel as the parental             cells.	Paclitaxel	311-321	surfactant protein B	Homo sapiens	7-11
22374518-11	2012	In summary, this study demonstrated that E2/ERalpha attenuates therapeutic efficacy of paclitaxel in an isogenic ERalpha+ xenograft model.	Paclitaxel	87-97	ATPase, H+ transporting, lysosomal V1 subunit E1	Mus musculus	41-51
22581025-5	2012	CD44+/CD133+ EC-CICs were also             more resistant to growth inhibition induced by the chemotherapeutic drugs cisplatin             and paclitaxel.	Paclitaxel	143-153	prominin 1	Homo sapiens	6-11
22680343-3	2012	A probe of CYP2C8 that is easy to administer and interpret may be valuable for individualized dosing of paclitaxel.	Paclitaxel	104-114	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	11-17
22680343-6	2012	However, it is acknowledged that there is a need for further studies evaluating the use of rosiglitazone as a CYP2C8 probe and quantifying the relationship, in order to guide dosing of narrow therapeutic index drugs metabolized primarily by CYP2C8, such as paclitaxel.	Paclitaxel	257-267	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	241-247
22680343-10	2012	CONCLUSIONS: The correlation between the exposure of rosiglitazone and paclitaxel likely reflects mutual dependence on the activity of CYP2C8.	Paclitaxel	71-81	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	135-141
22460833-0	2012	Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia.	Paclitaxel	51-61	prostaglandin-endoperoxide synthase 2	Mus musculus	12-28
22460833-1	2012	The effect of the cyclooxygenase-2 (COX-2) inhibitor etodolac on the mechanical allodynia induced by paclitaxel was investigated in mice and compared with the effects of the nonselective COX inhibitors indomethacin and diclofenac, the selective COX-2 inhibitor celecoxib, the calcium channel alpha(2)delta subunit inhibitor pregabalin, the sodium channel blocker mexiletine, and the serotonin-norepinephrine reuptake inhibitor duloxetine.	Paclitaxel	101-111	prostaglandin-endoperoxide synthase 2	Mus musculus	36-41
22306125-0	2012	Association between class III beta-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.	Paclitaxel	70-80	tubulin beta 3 class III	Homo sapiens	20-42
22306125-1	2012	BACKGROUND: It has been proposed that the level of class III beta-tubulin gene expression can be used to predict clinical sensitivity to paclitaxel/vinorebine-based chemotherapy in non-small cell lung cancer (NSCLC) patients.	Paclitaxel	137-147	tubulin beta 3 class III	Homo sapiens	51-73
22306125-3	2012	We conducted a meta-analysis of all relevant published data to provide a combined statistical assessment of the proposed association of expression variations of class III beta-tubulin with objective response and median survival in patients with NSCLC treated with paclitaxel/vinorebine-based chemotherapy.	Paclitaxel	264-274	tubulin beta 3 class III	Homo sapiens	161-183
22306125-4	2012	METHODS: We conducted the meta-analysis using data from ten studies, each of which evaluated the correlation between class III beta-tubulin expression levels and objective response in patients treated with paclitaxel/vinorebine-based chemotherapy for NSCLC patients.	Paclitaxel	206-216	tubulin beta 3 class III	Homo sapiens	117-139
22306125-11	2012	The objective response rate for paclitaxel/vinorebine-based chemotherapy was significantly higher in patients with low/negative class III beta-tubulin expression (OR=0.28; 95% CI, 0.20-0.41; P&lt;0.00001).	Paclitaxel	32-42	tubulin beta 3 class III	Homo sapiens	128-150
22306125-17	2012	This result supports the usefulness of class III beta-tubulin mRNA level as a biomarker for sensitivity to paclitaxel/vinorebine-based chemotherapy in NSCLC patients.	Paclitaxel	107-117	tubulin beta 3 class III	Homo sapiens	39-61
22437668-9	2012	A subset of SLC genes, namely SLC31A2, SLC43A1, SLC35A5, and SLC41A2, was associated with paclitaxel sensitivity and had regulating single nucleotide polymorphisms that were also associated with paclitaxel-induced cytotoxicity.	Paclitaxel	90-100	solute carrier family 43 member 1	Homo sapiens	39-46
22437668-9	2012	A subset of SLC genes, namely SLC31A2, SLC43A1, SLC35A5, and SLC41A2, was associated with paclitaxel sensitivity and had regulating single nucleotide polymorphisms that were also associated with paclitaxel-induced cytotoxicity.	Paclitaxel	195-205	solute carrier family 43 member 1	Homo sapiens	39-46
22410115-7	2012	Co-delivery of brain-targeted CDX-PEG-PLA-PTX micelle dramatically enhanced gene transfection efficiency in the intracranial brain tumor.	Paclitaxel	42-45	caudal type homeobox 1	Mus musculus	30-33
22410115-10	2012	Herein, we verify the high potency of co-delivery of TRAIL gene and paclitaxel in the intervention of intracranial glioblastoma by employing tumor-targeted gene carrier RGD-PEG-PEI and brain-targeted micelle CDX-PEG-PLA, respectively.	Paclitaxel	68-78	caudal type homeobox 1	Mus musculus	208-211
22229645-12	2012	ascorbic acid and topical DI-VCP in the paclitaxel-treated rats were characterized by the faster onset and greater magnitude, compared with their effects in the L5SNC rats.	Paclitaxel	40-50	valosin-containing protein	Rattus norvegicus	29-32
22229645-13	2012	Dermal ascorbic acid levels in the hindpaw significantly decreased after paclitaxel treatment, but not L5SNC, which was reversed by topical DI-VCP.	Paclitaxel	73-83	valosin-containing protein	Rattus norvegicus	143-146
22056875-5	2012	Increased CCNG1 expression accompanies paclitaxel-induced, SAC-mediated mitotic arrest, independent of p53 integrity or signaling through the SAC component, BUBR1.	Paclitaxel	39-49	cyclin G1	Homo sapiens	10-15
22056875-6	2012	CCNG1 overexpression promotes cell survival after paclitaxel exposure.	Paclitaxel	50-60	cyclin G1	Homo sapiens	0-5
22056875-7	2012	Conversely, CCNG1 depletion by RNA interference delays slippage and enhances paclitaxel-induced apoptosis.	Paclitaxel	77-87	cyclin G1	Homo sapiens	12-17
22506922-9	2012	Dual-loaded micelles demonstrated significantly higher cytotoxicity in the resistant MDCKII-MDR1 cells than micelles loaded with PTX alone.	Paclitaxel	129-132	ATP binding cassette subfamily B member 1	Canis lupus familiaris	92-96
22320903-6	2012	Interestingly, overexpression of SEPT10 increased cells" sensitivity to paclitaxel; we also found that SEPT10 is an important regulator for microtubule stability.	Paclitaxel	72-82	septin 10	Homo sapiens	33-39
22392081-0	2012	Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts.	Paclitaxel	0-10	ectodysplasin A	Homo sapiens	73-76
22392081-2	2012	In this study, we show that the antibody F8, which recognizes perivascular and stromal EDA-fibronectin (EDA-Fn), when conjugated to interleukin-2 (F8-IL2) can effectively inhibit the growth of EDA-Fn-expressing melanomas in combination with paclitaxel.	Paclitaxel	241-251	ectodysplasin A	Homo sapiens	87-90
22392081-2	2012	In this study, we show that the antibody F8, which recognizes perivascular and stromal EDA-fibronectin (EDA-Fn), when conjugated to interleukin-2 (F8-IL2) can effectively inhibit the growth of EDA-Fn-expressing melanomas in combination with paclitaxel.	Paclitaxel	241-251	ectodysplasin A	Homo sapiens	104-107
22392081-2	2012	In this study, we show that the antibody F8, which recognizes perivascular and stromal EDA-fibronectin (EDA-Fn), when conjugated to interleukin-2 (F8-IL2) can effectively inhibit the growth of EDA-Fn-expressing melanomas in combination with paclitaxel.	Paclitaxel	241-251	ectodysplasin A	Homo sapiens	104-107
22134971-2	2012	Exposure of cells to taxol induced time-dependent cytotoxicity and cytoplasmic vacuolization without the involvement of Bax, Bak, Mcl-1, Bcl-XL, and caspase-3.	Paclitaxel	21-26	myeloid cell leukemia sequence 1	Mus musculus	130-135
22134971-2	2012	Exposure of cells to taxol induced time-dependent cytotoxicity and cytoplasmic vacuolization without the involvement of Bax, Bak, Mcl-1, Bcl-XL, and caspase-3.	Paclitaxel	21-26	BCL2-like 1	Mus musculus	137-143
22134971-3	2012	Although taxol treatment induced activating transcription factor 6 (ATF6) cleavage indicative of endoplasmic reticulum (ER) stress, silencing ATF6 by shATF6 did not prevent taxol-induced both cytotoxcity and cytoplasmic vacuolization, suggesting that taxol-induced cytoplasmic vacuolization and cell death were not due to ER stress.	Paclitaxel	9-14	activating transcription factor 6	Mus musculus	68-72
22036101-3	2012	PTX, an anti-cancer agent, formed inclusion complexations with beta-CD conjugated AuNPs, and effectively released from the AuNP-2" surface-functionalized with PEG, beta-cyclodextrin (beta-CD) and paclitaxel (PTX) using the intracellular glutathione (GSH) level (10 mm).	Paclitaxel	0-3	beta-carotene oxygenase 1	Mus musculus	63-70
22036101-3	2012	PTX, an anti-cancer agent, formed inclusion complexations with beta-CD conjugated AuNPs, and effectively released from the AuNP-2" surface-functionalized with PEG, beta-cyclodextrin (beta-CD) and paclitaxel (PTX) using the intracellular glutathione (GSH) level (10 mm).	Paclitaxel	0-3	beta-carotene oxygenase 1	Mus musculus	183-190
22396773-9	2012	Studies have also demonstrated that other chemotherapeutic agents (e.g. etoposide, cisplatin, paclitaxel and vinblastine) similarly induce increased IFN-beta secretion and elevated MHC I expression.	Paclitaxel	94-104	interferon beta 1	Homo sapiens	149-157
21880414-9	2011	This study suggests that LEF1 can enhance the proliferation of RCC cells and that the LEF1/beta-catenin complex plays an important role in the synergy of DAC and PTX against RCC cells.	Paclitaxel	162-165	lymphoid enhancer binding factor 1	Homo sapiens	86-90
21880414-10	2011	Moreover, the synergy between DAC and PTX may be more effective in RCC cells expressing high levels of LEF1.	Paclitaxel	38-41	lymphoid enhancer binding factor 1	Homo sapiens	103-107
22019170-12	2011	CONCLUSIONS: Data suggest that paclitaxel induces nuclear translocation and activation of PKC-delta, which in turn causes Golgi-Cdk1 activation, leading to Golgi associated DR5 up-regulation, and caspase-8 and 3 activation.	Paclitaxel	31-41	caspase 8	Homo sapiens	196-211
20652449-4	2011	Importantly, we showed that silencing of eIF4E sensitized MDA-MB-231 cells to chemotherapeutic drugs of cisplatin, adriamycin, paclitaxel and docetaxel as assessed by MTT assay.	Paclitaxel	127-137	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
21999531-1	2011	Poly(ethylene glycol)-block-poly(d,l-lactic acid) (PEG-b-PLA) micelles act as a 3-in-1 nanocontainer for three poorly water-soluble drugs-paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin (PTX/17-AAG/RAPA)-for cancer therapy.	Paclitaxel	138-148	transcriptional regulating factor 1	Homo sapiens	216-220
21788069-2	2011	We developed a nanoparticulate drug delivery system decorated with AS1411 (Ap), a DNA aptamer specifically binding to nucleolin which was highly expressed in the plasma membrane of both cancer cells and endothelial cells in angiogenic blood vessels, as the targeting ligand to facilitate anti-glioma delivery of paclitaxel (PTX).	Paclitaxel	312-322	nucleolin	Rattus norvegicus	118-127
21788069-2	2011	We developed a nanoparticulate drug delivery system decorated with AS1411 (Ap), a DNA aptamer specifically binding to nucleolin which was highly expressed in the plasma membrane of both cancer cells and endothelial cells in angiogenic blood vessels, as the targeting ligand to facilitate anti-glioma delivery of paclitaxel (PTX).	Paclitaxel	324-327	nucleolin	Rattus norvegicus	118-127
21864901-6	2011	In several types of cells, the surface modification of nanocapsules with a cell-penetrating peptide, Hph1, greatly facilitates cellular uptake and apoptosis-inducing effects of paclitaxel.	Paclitaxel	177-187	hyperphenylalaninemia 1	Mus musculus	101-105
21775054-2	2011	We found that co-administration perifosine with paclitaxel in human ovarian cancer cells led to the inhibition of AKT/mTOR complex 1 (mTORC1), a marked increase in ceramide and reactive oxygen species (ROS) production, and a striking increase in the activation of pro-apoptosis pathways, including caspase 3, c-Jun N-terminal kinases (JNK) and AMP-activated protein kinase (AMPK).	Paclitaxel	48-58	CREB regulated transcription coactivator 1	Mus musculus	134-140
21984124-10	2011	Also, paclitaxel down-regulated the expression of miR-192, miR-217 and miR -377, while miR-15 was up-regulated in the remnant kidney.	Paclitaxel	6-16	microRNA 217	Rattus norvegicus	59-66
21763756-5	2011	In addition, blocking downstream signaling pathways of PAR2, including phospholipase C (PLC), protein kinase A (PKA), and protein kinase Cepsilon (PKC), effectively attenuated paclitaxel-induced mechanical, heat, or cold hypersensitivity.	Paclitaxel	176-186	protein kinase C, epsilon	Mus musculus	147-150
21763756-7	2011	These results revealed specific cellular signaling pathways leading to paclitaxel-induced neuropathy, including the activation of PAR2 and downstream enzymes PLC, PKCepsilon, and PKA and resultant sensitization of TRPV1, TRPV4, and TRPA1.	Paclitaxel	71-81	protein kinase C, epsilon	Mus musculus	163-173
21808066-0	2011	Protection of neuronal calcium sensor 1 protein in cells treated with paclitaxel.	Paclitaxel	70-80	neuronal calcium sensor 1	Homo sapiens	14-39
21808066-3	2011	We previously reported that prolonged treatment with paclitaxel activates a calcium-dependent enzyme, calpain, which degrades neuronal calcium sensor 1 (NCS-1) and subsequent loss of intracellular calcium signaling.	Paclitaxel	53-63	neuronal calcium sensor 1	Homo sapiens	126-151
21808066-3	2011	We previously reported that prolonged treatment with paclitaxel activates a calcium-dependent enzyme, calpain, which degrades neuronal calcium sensor 1 (NCS-1) and subsequent loss of intracellular calcium signaling.	Paclitaxel	53-63	neuronal calcium sensor 1	Homo sapiens	153-158
21808066-9	2011	Expression of either mutated version of NCS-1 in neuroblastoma cells protected intracellular calcium signals from paclitaxel-induced changes.	Paclitaxel	114-124	neuronal calcium sensor 1	Homo sapiens	40-45
21808066-10	2011	These results support our hypothesis that it is possible to protect cells from paclitaxel-induced degradation of NCS-1 by inhibiting calpain activity.	Paclitaxel	79-89	neuronal calcium sensor 1	Homo sapiens	113-118
21702053-2	2011	Recently, the genetic variants CYP2C8*3, CYP2C8-HapC, and CYP3A5*3 were associated with paclitaxel-induced neurotoxicity.	Paclitaxel	88-98	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	31-37
21702053-2	2011	Recently, the genetic variants CYP2C8*3, CYP2C8-HapC, and CYP3A5*3 were associated with paclitaxel-induced neurotoxicity.	Paclitaxel	88-98	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	41-47
21868450-10	2011	In contrast, the microtubule stabilizers paclitaxel and epothilone B increased cytosolic Smad3 binding to beta2-tubulin and enhanced the inhibitory effect of cGMP on Smad3 nuclear translocation and PAI-1 expression in response to TGF-beta1.	Paclitaxel	41-51	SMAD family member 3	Homo sapiens	89-94
21868450-10	2011	In contrast, the microtubule stabilizers paclitaxel and epothilone B increased cytosolic Smad3 binding to beta2-tubulin and enhanced the inhibitory effect of cGMP on Smad3 nuclear translocation and PAI-1 expression in response to TGF-beta1.	Paclitaxel	41-51	SMAD family member 3	Homo sapiens	166-171
21761117-0	2011	Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel.	Paclitaxel	128-138	clusterin	Homo sapiens	14-23
21642840-5	2011	A combined treatment with taxol and pristimerin induced cervical cancer cell death by increasing intracellular reactive oxygen species levels, upregulation of death receptor death receptor 5 (DR5), activation of Bax, and dissipation of mitochondrial membrane potential.	Paclitaxel	26-31	tumor necrosis factor receptor superfamily, member 10b	Mus musculus	192-195
21669266-0	2011	Paclitaxel conjugation with the analog of the gonadotropin-releasing hormone as a targeting moiety.	Paclitaxel	0-10	gonadotropin releasing hormone 1	Homo sapiens	46-76
21669266-2	2011	The molecule of the peptide hormone GnRH was modified to allow its connection to paclitaxel via spacer.	Paclitaxel	81-91	gonadotropin releasing hormone 1	Homo sapiens	36-40
21669266-9	2011	In conclusion, the paclitaxel conjugate with the analog of GnRH exhibited targeted antiproliferative effect for which its further testing will be implemented.	Paclitaxel	19-29	gonadotropin releasing hormone 1	Homo sapiens	59-63
21596106-7	2011	In the paclitaxel-treated rats, upregulation of Ca(v)3.2 and CSE at protein levels was not detected in the dorsal root ganglia (DRG), spinal cord or peripheral tissues including the hindpaws, whereas H(2)S content in hindpaw tissues was significantly elevated.	Paclitaxel	7-17	cystathionine gamma-lyase	Rattus norvegicus	61-64
21596106-8	2011	Together, our study demonstrates the effectiveness of NNC 55-0396 in inhibiting Ca(v)3.2, and then suggests that paclitaxel-evoked neuropathic pain might involve the enhanced activity of T-type calcium channels and/or CSE in rats, but not upregulation of Ca(v)3.2 and CSE at protein levels, differing from the previous evidence for the neuropathic pain model induced by spinal nerve cutting in which Ca(v)3.2 was dramatically upregulated in DRG.	Paclitaxel	113-123	cystathionine gamma-lyase	Rattus norvegicus	218-221
21596106-8	2011	Together, our study demonstrates the effectiveness of NNC 55-0396 in inhibiting Ca(v)3.2, and then suggests that paclitaxel-evoked neuropathic pain might involve the enhanced activity of T-type calcium channels and/or CSE in rats, but not upregulation of Ca(v)3.2 and CSE at protein levels, differing from the previous evidence for the neuropathic pain model induced by spinal nerve cutting in which Ca(v)3.2 was dramatically upregulated in DRG.	Paclitaxel	113-123	cystathionine gamma-lyase	Rattus norvegicus	268-271
21305272-0	2011	In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance.	Paclitaxel	51-61	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	34-40
21305272-1	2011	OBJECTIVES: This study aimed to characterize the effects of bovine serum albumin (BSA) on the kinetics of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation in vitro; determine whether the addition of BSA to incubations improves the prediction of paclitaxel hepatic clearance via this pathway in vivo; and assess interindividual variability in predicted clearance.	Paclitaxel	123-133	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	106-112
21305272-1	2011	OBJECTIVES: This study aimed to characterize the effects of bovine serum albumin (BSA) on the kinetics of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation in vitro; determine whether the addition of BSA to incubations improves the prediction of paclitaxel hepatic clearance via this pathway in vivo; and assess interindividual variability in predicted clearance.	Paclitaxel	245-255	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	106-112
21305272-7	2011	CONCLUSIONS: Human liver microsomal K(m) and intrinsic clearance values are over- and underpredicted, respectively, when incubations of the CYP2C8 substrate paclitaxel are performed without BSA supplementation.	Paclitaxel	157-167	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	140-146
20974125-4	2011	Our previous study showed that exogenous expression of gamma-synuclein in ovarian and breast cancer cells significantly enhanced cell migration and resistance to paclitaxel-induced apoptotic death.	Paclitaxel	162-172	synuclein gamma	Homo sapiens	55-70
20974125-8	2011	Immunofluorescence staining demonstrated that gamma-synuclein can colocalize with microtubule in HeLa cells and decrease rigidity of microtubule bundles caused by paclitaxel.	Paclitaxel	163-173	synuclein gamma	Homo sapiens	46-61
20974125-9	2011	In human ovarian cancer epithelial A2780 cells, gamma-synuclein overexpression improved cell adhesion and microtubule structure upon paclitaxel treatment.	Paclitaxel	133-143	synuclein gamma	Homo sapiens	48-63
21634028-5	2011	We found that paclitaxel induced a 2-3 fold increase in mRNA for beta-tubulin IIA and III genes, TUBB2A, and TUBB3.	Paclitaxel	14-24	tubulin beta 3 class III	Homo sapiens	109-114
21875478-0	2011	[nm23-H1-siRNA enhances the chemosensitivity to liposome-encapsulated paclitaxel in lung adenocarcinoma cells in vitro].	Paclitaxel	70-80	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	1-8
21875478-1	2011	OBJECTIVE: To study the chemosensitivity of lung adenocarcinoma cell line A549 cells to liposome-encapsulated paclitaxel after treatment by nm23-H1-small interference RNA (nm23-H1-siRNA) in vitro.	Paclitaxel	110-120	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	140-147
21875478-1	2011	OBJECTIVE: To study the chemosensitivity of lung adenocarcinoma cell line A549 cells to liposome-encapsulated paclitaxel after treatment by nm23-H1-small interference RNA (nm23-H1-siRNA) in vitro.	Paclitaxel	110-120	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	172-179
21875478-6	2011	After treatment for 48 hours with liposome-encapsulated paclitaxel, the cell mortality rate was increased with the increasing concentration of liposome-encapsulated paclitaxel in both groups, but increased higher in the nm23-H1-siRNA-transfected group.	Paclitaxel	56-66	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	220-227
21875478-9	2011	CONCLUSIONS: Nm23-H1 is related with the chemoresistance to liposome-encapsulated paclitaxel in lung adenocarcinoma cell line A549 cells.	Paclitaxel	82-92	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	13-20
21875478-10	2011	Inhibition of the expression of nm23-H1 by nm23-H1-siRNA can improve the in vitro chemosensitivity of A549 cells to liposome-encapsulated paclitaxel.	Paclitaxel	138-148	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	32-39
21875478-10	2011	Inhibition of the expression of nm23-H1 by nm23-H1-siRNA can improve the in vitro chemosensitivity of A549 cells to liposome-encapsulated paclitaxel.	Paclitaxel	138-148	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	32-36
20848147-2	2011	CYP2C8 is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel in the human liver.	Paclitaxel	86-96	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
20848147-8	2011	Paclitaxel binding ability of CYP2C8.4 increased about two times while CYP2C8 P404A decreased about two times than that of WT CYP2C8.	Paclitaxel	0-10	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	30-36
21289088-7	2011	Paclitaxel inhibits microtubule detachment, increases the number of assembly-competent tubulin patches, and inhibits microtubule shortening, thus providing an explanation for why the drug can counteract the phenotypic effects of beta5 overexpression.	Paclitaxel	0-10	tubulin beta 4A class IVa	Homo sapiens	229-234
21220478-2	2011	EXPERIMENTAL DESIGN: We treated a panel of NSCLC lines with a dose matrix of paclitaxel and navitoclax (formerly ABT-263), an inhibitor of Bcl-2, Bcl-x(L), and Bcl-w (1), and evaluated synergy.	Paclitaxel	77-87	BCL2 like 2	Homo sapiens	160-165
21549688-5	2011	Following HURP knockdown, HCC cells show a more sensitive response to taxol treatment.	Paclitaxel	70-75	DLG associated protein 5	Homo sapiens	10-14
21549688-6	2011	Notably, sorafenib, a tyrosine kinase inhibitor approved for the treatment of HCC, inhibits HURP expression primarily at the transcriptional level and sensitizes HCC cells to sub-lethal doses of taxol.	Paclitaxel	195-200	DLG associated protein 5	Homo sapiens	92-96
21549688-10	2011	Taken together, our results indicate that HURP acts as a novel survival protein that protects HCC cells against taxol-induced cell death.	Paclitaxel	112-117	DLG associated protein 5	Homo sapiens	42-46
21549688-11	2011	In addition, the regulation of HURP gene expression by NF-kappaB signaling appears to be critical for the response of HCC cells to taxol.	Paclitaxel	131-136	DLG associated protein 5	Homo sapiens	31-35
21327421-2	2011	Paclitaxel is metabolized in the liver by CYP2C8 and CYP3A4 and transported by P-glycoprotein.	Paclitaxel	0-10	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	42-48
21584498-0	2011	Function of Aurora kinase A in Taxol-resistant breast cancer and its correlation with P-gp.	Paclitaxel	31-36	aurora kinase A	Homo sapiens	12-27
21584498-5	2011	In the present study, we aimed to clarify the functional role of Aurora kinase A in breast cancer resistance to Taxol, and to determine the means to overcome this resistance.	Paclitaxel	112-117	aurora kinase A	Homo sapiens	65-80
21584498-6	2011	The correlation between the expression levels of Aurora kinase A and chemoresistance to Taxol in breast cancer cells, and resistance to Taxol in a xenograft model were demonstrated.	Paclitaxel	88-93	aurora kinase A	Homo sapiens	49-64
21584498-6	2011	The correlation between the expression levels of Aurora kinase A and chemoresistance to Taxol in breast cancer cells, and resistance to Taxol in a xenograft model were demonstrated.	Paclitaxel	136-141	aurora kinase A	Homo sapiens	49-64
21584498-9	2011	The expression of Aurora A was determined to be capable of enhancing the sensitivity of cells resistant to Taxol in vitro and in vivo using stable knockdown Aurora kinase A cells.	Paclitaxel	107-112	aurora kinase A	Homo sapiens	18-26
21822799-0	2011	Cdk2 acts upstream of mitochondrial permeability transition during paclitaxel-induced apoptosis.	Paclitaxel	67-77	cyclin dependent kinase 2	Homo sapiens	0-4
21822799-2	2011	Here we demonstrate that the upregulation of cyclin-dependent kinase 2 (Cdk2) activity coincides with the loss of mitochondrial membrane potential (MMP) in paclitaxel-induced apoptosis.	Paclitaxel	156-166	cyclin dependent kinase 2	Homo sapiens	45-70
21822799-2	2011	Here we demonstrate that the upregulation of cyclin-dependent kinase 2 (Cdk2) activity coincides with the loss of mitochondrial membrane potential (MMP) in paclitaxel-induced apoptosis.	Paclitaxel	156-166	cyclin dependent kinase 2	Homo sapiens	72-76
21822799-3	2011	Ectopic expression of the dominant negative Cdk2 (Cdk2-dn) and a specific Cdk2 inhibitor, p21( WAF1/CIP1 ), effectively suppresses the loss of MMP, the release of cytochrome c, and subsequent activation of caspase-3 in paclitaxel-treated cells.	Paclitaxel	219-229	cyclin dependent kinase 2	Homo sapiens	44-48
21822799-3	2011	Ectopic expression of the dominant negative Cdk2 (Cdk2-dn) and a specific Cdk2 inhibitor, p21( WAF1/CIP1 ), effectively suppresses the loss of MMP, the release of cytochrome c, and subsequent activation of caspase-3 in paclitaxel-treated cells.	Paclitaxel	219-229	cyclin dependent kinase 2	Homo sapiens	50-54
21822799-3	2011	Ectopic expression of the dominant negative Cdk2 (Cdk2-dn) and a specific Cdk2 inhibitor, p21( WAF1/CIP1 ), effectively suppresses the loss of MMP, the release of cytochrome c, and subsequent activation of caspase-3 in paclitaxel-treated cells.	Paclitaxel	219-229	cyclin dependent kinase 2	Homo sapiens	50-54
21480900-9	2011	TRPV1 knock-down in rats inverted the effect of the microtubule-modulating drugs, Taxol and Nocodazole, on estrogen-induced and PKCepsilon-dependent mechanical pain sensitization.	Paclitaxel	82-87	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	0-5
21272926-9	2011	While INF-alpha showed only slight enhancement of the cell-death effect of PTX in PTX-sensitive cells, INF-alpha itself strongly induced apoptosis in PTX-resistant cells regardless of PTX concentration.	Paclitaxel	75-78	interferon alpha 17	Homo sapiens	6-15
21272926-11	2011	SP could be a target of INF-alpha, and resistance to PTX might be overcome by INF-alpha.	Paclitaxel	53-56	interferon alpha 17	Homo sapiens	78-87
21163887-10	2011	Since TTK inhibition is known to induce override of the mitotic spindle assembly checkpoint (SAC), we challenged mutated cancer cells with the microtubule-stabilizing drug paclitaxel.	Paclitaxel	172-182	TTK protein kinase	Homo sapiens	6-9
20883815-7	2011	Up-regulation of Cyclin-D1, Cox-2, XIAP and cIAP1 and phosphorylation of MAPKs, were completely inhibited on inactivation of NF-kappaB assigning a key regulatory role to NF-kappaB in the synergistic effect of paclitaxel and curcumin.	Paclitaxel	209-219	cyclin D1	Homo sapiens	17-26
20883815-7	2011	Up-regulation of Cyclin-D1, Cox-2, XIAP and cIAP1 and phosphorylation of MAPKs, were completely inhibited on inactivation of NF-kappaB assigning a key regulatory role to NF-kappaB in the synergistic effect of paclitaxel and curcumin.	Paclitaxel	209-219	baculoviral IAP repeat containing 2	Homo sapiens	44-49
21046120-7	2011	RESULTS: There was a significant positive correlation between hsMAD2 mRNA expression and the sensitivity to paclitaxel in four neuroblastoma cell lines.	Paclitaxel	108-118	SMAD family member 2	Homo sapiens	62-68
21046120-8	2011	High hsMAD2 expression may be correlated with paclitaxel-induced apoptosis.	Paclitaxel	46-56	SMAD family member 2	Homo sapiens	5-11
28979809-7	2017	Our results suggest that up-regulation of miR-107 resensitizes paclitaxel-resistant NSCLC cells by targeting Bcl-w, which reveals a potential mechanism of miR-107 in reversing drug resistance.	Paclitaxel	63-73	BCL2 like 2	Homo sapiens	109-114
21240255-4	2011	Interestingly, one of the seven genes, NACC1, encoding NAC1 was previously reported to be involved in the development of tumor recurrence in ovarian serous carcinoma and to have a causal role in the development of paclitaxel resistance.	Paclitaxel	214-224	nucleus accumbens associated 1	Homo sapiens	39-44
28979809-7	2017	Our results suggest that up-regulation of miR-107 resensitizes paclitaxel-resistant NSCLC cells by targeting Bcl-w, which reveals a potential mechanism of miR-107 in reversing drug resistance.	Paclitaxel	63-73	microRNA 107	Homo sapiens	155-162
21240255-4	2011	Interestingly, one of the seven genes, NACC1, encoding NAC1 was previously reported to be involved in the development of tumor recurrence in ovarian serous carcinoma and to have a causal role in the development of paclitaxel resistance.	Paclitaxel	214-224	nucleus accumbens associated 1	Homo sapiens	55-59
20224928-5	2011	SAHA induced NT5E mRNA expression in paclitaxel-resistant YCC-B1 cell.	Paclitaxel	37-47	5'-nucleotidase ecto	Homo sapiens	13-17
28224612-1	2017	Paclitaxel is mainly eliminated by CYP2C8 in the liver.	Paclitaxel	0-10	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	35-41
21791871-1	2011	The aim of this study was to assess the effects of diosmetin and hesperetin, two flavonoids present in various medicinal products, on CYP2C8 activity of human liver microsomes using paclitaxel oxidation to 6alpha-hydroxy-paclitaxel as a probe reaction.	Paclitaxel	182-192	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	134-140
21196304-0	2011	DNA methyltransferase inhibitor CDA-2 synergizes with high-dose thiotepa and paclitaxel in killing breast cancer stem cells.	Paclitaxel	77-87	activation induced cytidine deaminase	Homo sapiens	32-37
21511720-5	2011	Conversely, treating oocytes with low concentrations of taxol resulted in a spindle with multiple poles attached to the cortex, but still each of these poles were associated with activated cortical Cdc42 at the appropriate time.	Paclitaxel	56-61	cell division cycle 42 L homeolog	Xenopus laevis	198-203
21525288-7	2011	Defects in axon formation caused by perturbations of the DLK-JNK pathway were significantly improved by Taxol.	Paclitaxel	104-109	mitogen-activated protein kinase kinase kinase 12	Mus musculus	57-60
21525288-8	2011	However, defects in short-neurite formation caused by perturbations of the DLK-JNK pathway were enhanced by Taxol.	Paclitaxel	108-113	mitogen-activated protein kinase kinase kinase 12	Mus musculus	75-78
28315766-6	2017	Furthermore, to address whether BMP4 was required to enhance the metastatic in EC109/Taxol cells, the pharmacological inhibitor of BMP signaling dorsomorphin was used; meanwhile, we found that the migration and invasion abilities were inhibited.	Paclitaxel	85-90	bone morphogenetic protein 4	Homo sapiens	32-36
21349946-0	2011	Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF.	Paclitaxel	0-5	cellular communication network factor 2	Homo sapiens	140-144
20566053-3	2011	The paclitaxel-loaded mPEG-b-P(OA-DLLA)-b-mPEG NPs were prepared by nanoprecipitation and then characterized by LPSA, TEM and (1)H-NMR.	Paclitaxel	4-14	tenomodulin	Mus musculus	118-121
20726858-9	2010	However, gemcitabine, paclitaxel, or cisplatin treatment enhanced the Akt activation, heterodimer formation of EGFR with HER3, and secretion of amphiregulin, indicating that the presence of gemcitabine promoted the activity of targeted molecules including amphiregulin, Akt, and HER3 for pancreatic cancer therapy.	Paclitaxel	22-32	erb-b2 receptor tyrosine kinase 3	Homo sapiens	121-125
20726858-9	2010	However, gemcitabine, paclitaxel, or cisplatin treatment enhanced the Akt activation, heterodimer formation of EGFR with HER3, and secretion of amphiregulin, indicating that the presence of gemcitabine promoted the activity of targeted molecules including amphiregulin, Akt, and HER3 for pancreatic cancer therapy.	Paclitaxel	22-32	erb-b2 receptor tyrosine kinase 3	Homo sapiens	279-283
21349946-5	2011	Short hairpin RNA-mediated knockdown of both Cyr61 and CTGF reversed TAZ-induced Taxol resistance in breast cancer cells.	Paclitaxel	81-86	cellular communication network factor 2	Homo sapiens	55-59
21349946-6	2011	Interaction of TAZ with the TEAD family of transcription factors was essential for TAZ to activate the Cyr61/CTGF promoters and to induce Taxol resistance.	Paclitaxel	138-143	cellular communication network factor 2	Homo sapiens	109-113
21349946-7	2011	Our findings define the TAZ-TEAD-Cyr61/CTGF signaling pathway as an important modifier of the Taxol response in breast cancer cells, as well as highlighting it as a novel therapeutic target to treat drug-resistant breast cancers that arise commonly at advanced stages of disease.	Paclitaxel	94-99	cellular communication network factor 2	Homo sapiens	39-43
28487996-0	2017	miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression.	Paclitaxel	20-30	microRNA 30a	Homo sapiens	0-7
20708296-0	2010	TIP47 confers resistance to taxol-induced cell death by preventing the nuclear translocation of AIF and Endonuclease G.	Paclitaxel	28-33	perilipin 3	Mus musculus	0-5
20708296-0	2010	TIP47 confers resistance to taxol-induced cell death by preventing the nuclear translocation of AIF and Endonuclease G.	Paclitaxel	28-33	endonuclease G	Mus musculus	104-118
20708296-3	2010	Overexpression of TIP47 protected NIH3T3 cells from taxol-induced cell death, while suppression of TIP47 by siRNA facilitated cell death.	Paclitaxel	52-57	perilipin 3	Mus musculus	18-23
20708296-4	2010	TIP47, but not its truncated form, t-TIP47, decreased taxol-induced cell death as determined by propidium iodide and fluorescent Annexin V staining.	Paclitaxel	54-59	perilipin 3	Mus musculus	0-5
20708296-5	2010	Recombinant TIP47, but not t-TIP47, partially prevented taxol-induced depolarization of mitochondria in vitro.	Paclitaxel	56-61	perilipin 3	Mus musculus	12-17
21682141-5	2011	The validated 3D structure of tubulin beta-1 chain and Bcl-2 protein was taken to study their interaction with paclitaxel.	Paclitaxel	111-121	tubulin beta class I	Homo sapiens	30-50
28487996-5	2017	Here, by comparing microRNA (miRNA) expression levels using miRNA arrays, we observed differential expression of miR-30a-5p in two independent lung cancer cell pairs (paclitaxel-resistant vs paclitaxel-sensitive A549 cell lines).	Paclitaxel	167-177	microRNA 30a	Homo sapiens	113-120
21682141-7	2011	Results showed that out of 84 analogues taken from PubChem, CID_44322802 had glide score of -9.62, as compared to -5.86 of paclitaxel with tubulin beta-1 chain.	Paclitaxel	123-133	tubulin beta class I	Homo sapiens	139-159
20708296-6	2010	Overexpression of TIP47, but not its truncated form, prevented the taxol-induced nuclear and cytoplasmic translocation of AIF and Endonuclease G, as well as the taxol-induced depolarization of mitochondria in NIH3T3 cells.	Paclitaxel	67-72	perilipin 3	Mus musculus	18-23
20708296-6	2010	Overexpression of TIP47, but not its truncated form, prevented the taxol-induced nuclear and cytoplasmic translocation of AIF and Endonuclease G, as well as the taxol-induced depolarization of mitochondria in NIH3T3 cells.	Paclitaxel	67-72	endonuclease G	Mus musculus	130-144
28487996-5	2017	Here, by comparing microRNA (miRNA) expression levels using miRNA arrays, we observed differential expression of miR-30a-5p in two independent lung cancer cell pairs (paclitaxel-resistant vs paclitaxel-sensitive A549 cell lines).	Paclitaxel	191-201	microRNA 30a	Homo sapiens	113-120
20708296-6	2010	Overexpression of TIP47, but not its truncated form, prevented the taxol-induced nuclear and cytoplasmic translocation of AIF and Endonuclease G, as well as the taxol-induced depolarization of mitochondria in NIH3T3 cells.	Paclitaxel	161-166	perilipin 3	Mus musculus	18-23
20708296-7	2010	Furthermore, overexpression of TIP47 facilitated Bcl-2 expression and suppressed Bax expression in taxol-treated cells.	Paclitaxel	99-104	perilipin 3	Mus musculus	31-36
28487996-6	2017	Overexpression of miR-30a-5p sensitizes NSCLC cells to paclitaxel both in vitro and in vivo.	Paclitaxel	55-65	microRNA 30a	Homo sapiens	18-25
28487996-7	2017	In addition, miR-30a-5p increases paclitaxel sensitivity by promoting chemotherapy-induced apoptosis via downregulating BCL-2, a key apoptosis regulator.	Paclitaxel	34-44	microRNA 30a	Homo sapiens	13-20
21421722-16	2011	Activated caspase-3 after paclitaxel treatment increased to 69.55% +- 16.27% and was significantly higher than that in the control (12.26% +- 5.39%; P &lt; 0.001).	Paclitaxel	26-36	caspase-3	Oryctolagus cuniculus	10-19
28487996-8	2017	High miR-30a-5p expression is positively correlated with enhanced responsiveness to paclitaxel and predicts a more favorable clinical outcome in NSCLC patients.	Paclitaxel	84-94	microRNA 30a	Homo sapiens	5-12
21314952-10	2011	RESULTS: 43 SNPs were found significantly associated (FDR&lt;0.005) with paclitaxel response, with 10 belonging to protein-coding genes (CFTR, ROBO1, PTPRD, BTBD12, DCT, SNTG1, SGCD, LPHN2, GRIK1, ZNF607).	Paclitaxel	73-83	protein tyrosine phosphatase receptor type D	Homo sapiens	150-155
21472357-1	2010	In the present study, we investigated the effect of the taxol resistance gene 1 (TXR1) on taxol resistance in gastric cancer (GC).	Paclitaxel	56-61	proline rich 13	Homo sapiens	81-85
21472357-7	2010	Exogenous expression of TXR1 in BGC823 cells induced taxol resistance, and siRNA knockdown of TXR1 sensitized human GC cells to taxol.	Paclitaxel	53-58	proline rich 13	Homo sapiens	24-28
21314952-10	2011	RESULTS: 43 SNPs were found significantly associated (FDR&lt;0.005) with paclitaxel response, with 10 belonging to protein-coding genes (CFTR, ROBO1, PTPRD, BTBD12, DCT, SNTG1, SGCD, LPHN2, GRIK1, ZNF607).	Paclitaxel	73-83	sarcoglycan delta	Homo sapiens	177-181
21472357-7	2010	Exogenous expression of TXR1 in BGC823 cells induced taxol resistance, and siRNA knockdown of TXR1 sensitized human GC cells to taxol.	Paclitaxel	128-133	proline rich 13	Homo sapiens	94-98
28487996-10	2017	These data indicate that miR-30a-5p may be useful to treat paclitaxel-resistant lung cancer and may also provide a biomarker to predict paclitaxel responsiveness in lung cancer.	Paclitaxel	59-69	microRNA 30a	Homo sapiens	25-32
21472357-8	2010	The results show that low expression of TXR1 is correlated with a favorable prognosis in GC patients and that TXR1 likely plays a role in taxol resistance in GC cells.	Paclitaxel	138-143	proline rich 13	Homo sapiens	110-114
21115120-0	2011	Selective impairment of CD4+CD25+Foxp3+ regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis.	Paclitaxel	62-72	forkhead box P3	Homo sapiens	33-38
28487996-10	2017	These data indicate that miR-30a-5p may be useful to treat paclitaxel-resistant lung cancer and may also provide a biomarker to predict paclitaxel responsiveness in lung cancer.	Paclitaxel	136-146	microRNA 30a	Homo sapiens	25-32
20959065-0	2010	[Paclitaxel blocks immunologic escape through up-regulating TAP-1, TAP-2 and eliminatiing Treg cells in 3LL-bearing mice].	Paclitaxel	1-11	transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)	Mus musculus	67-72
28487996-12	2017	miR-30a-5p enhances NSCLC paclitaxel sensitivity in vitro and in vivo.	Paclitaxel	26-36	microRNA 30a	Homo sapiens	0-7
20959065-9	2010	RESULTS: The expression of TAP-1 (5.68%+/-0.65%), TAP-2 (89.54%+/-4.8%) was remarkably higher in paclitaxel-pretreating 3LL group than that in 3LL bearing mice group with TAP-1 (1.93%+/-0.25%), TAP-2 (67.78%+/-5.08%), P=0.006, P=0.036 respectively.	Paclitaxel	97-107	transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)	Mus musculus	50-55
20959065-9	2010	RESULTS: The expression of TAP-1 (5.68%+/-0.65%), TAP-2 (89.54%+/-4.8%) was remarkably higher in paclitaxel-pretreating 3LL group than that in 3LL bearing mice group with TAP-1 (1.93%+/-0.25%), TAP-2 (67.78%+/-5.08%), P=0.006, P=0.036 respectively.	Paclitaxel	97-107	transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)	Mus musculus	194-199
20959065-12	2010	CONCLUSIONS: Paclitaxel may block immunologic escape in the treatment of 3LL bearing mice partly through up-regulation TAP-1, TAP-2 and eliminating Treg cells.	Paclitaxel	13-23	transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)	Mus musculus	126-131
21069434-6	2011	More interestingly, the apoptosis inhibition by overexpression of the X-linked inhibitor of apoptosis (XIAP) did not fully block the cell death by paclitaxel, implying that apoptosis inhibition might accelerate the autophagic components of the paclitaxel response.	Paclitaxel	244-254	X-linked inhibitor of apoptosis	Mus musculus	70-101
21069434-6	2011	More interestingly, the apoptosis inhibition by overexpression of the X-linked inhibitor of apoptosis (XIAP) did not fully block the cell death by paclitaxel, implying that apoptosis inhibition might accelerate the autophagic components of the paclitaxel response.	Paclitaxel	244-254	X-linked inhibitor of apoptosis	Mus musculus	103-107
28487996-13	2017	miR-30a-5p sensitizes NSCLC cells to paclitaxel by inducing apoptosis through BCL-2 inhibition.	Paclitaxel	37-47	microRNA 30a	Homo sapiens	0-7
28346424-10	2017	Furthermore, genetically depleting or pharmacologically inactivating Skp2 synergistically re-sensitized CRPC cells toward chemotherapies such as paclitaxel or doxorubicin.	Paclitaxel	145-155	S-phase kinase-associated protein 2	Mus musculus	69-73
20927325-5	2010	ERK3 co-localized with alpha-tubulin on the spindle fibers and asters in oocytes after taxol treatment.	Paclitaxel	87-92	mitogen-activated protein kinase 6	Mus musculus	0-4
20622903-6	2010	In this setting, reducible HMGB1 binds to the receptor for advanced glycation end products (RAGEs), but not to Toll-like receptor 4, induces Beclin1-dependent autophagy and promotes tumor resistance to alkylators (melphalan), tubulin disrupting agents (paclitaxel), DNA crosslinkers (ultraviolet light) and DNA intercalators (oxaliplatin or adriamycin).	Paclitaxel	253-263	high mobility group box 1	Homo sapiens	27-32
20944137-6	2010	CD-1-transfected cells also had higher cell death when treated with CDDP (p&lt;0.05) or PAX, exhibiting 30-60% higher death rates than cells transfected with the wt-p53 gene and 130-160% higher than untransfected cells.	Paclitaxel	88-91	CD1c molecule	Homo sapiens	0-4
28729624-6	2017	By contrast, paclitaxel led to dedifferentiation of Schwann cells into an immature state, characterized by increased expression of p75 and galectin-3.	Paclitaxel	13-23	nerve growth factor receptor	Rattus norvegicus	131-134
21912664-3	2011	Paclitaxel (PTX) loaded poly (lactic-co-glycolic-acid) (PLGA) nanoparticles were formulated by an emulsion/evaporation method, and MUC1 aptamers (Apt) were conjugated to the particle surface through a DNA spacer.	Paclitaxel	0-10	mucin 1, cell surface associated	Homo sapiens	131-135
28701724-5	2017	MT depolymerisation (nocodazole treatment) or stabilization (taxol treatment) further enhanced DCX exchange rates, however the exchange rates for the C-terminal truncated DCX protein were resistant to the impact of taxol-induced stabilization.	Paclitaxel	61-66	doublecortin	Homo sapiens	95-98
21912664-6	2011	Moreover, the PTX loaded Apt-NPs enhanced in vitro drug delivery and cytotoxicity to MUC1(+) cancer cells, as compared with non-targeted nanoparticles that lack the MUC1 aptamer (P&lt;0.01).	Paclitaxel	14-17	mucin 1, cell surface associated	Homo sapiens	85-89
21912664-6	2011	Moreover, the PTX loaded Apt-NPs enhanced in vitro drug delivery and cytotoxicity to MUC1(+) cancer cells, as compared with non-targeted nanoparticles that lack the MUC1 aptamer (P&lt;0.01).	Paclitaxel	14-17	mucin 1, cell surface associated	Homo sapiens	165-169
21738583-7	2011	We also demonstrate that high concentrations of taxol, which hyperpolymerizes microtubules, inhibit retinoschisin secretion.	Paclitaxel	48-53	retinoschisin 1	Homo sapiens	100-113
19533419-9	2010	Results indicate that bi-specifics targeting clusterin are statistically effective, and are similarly enhanced by Rapamycin, or Taxol.	Paclitaxel	128-133	clusterin	Homo sapiens	45-54
20660297-3	2010	Down-regulation of ERbeta by short hairpin RNA constructs sensitized NSCLC cells to various apoptosis-inducing agents such as cisplatin, taxol, and etoposide.	Paclitaxel	137-142	estrogen receptor 2	Homo sapiens	19-25
20498641-0	2010	Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.	Paclitaxel	37-47	erb-b2 receptor tyrosine kinase 3	Homo sapiens	23-28
28701724-5	2017	MT depolymerisation (nocodazole treatment) or stabilization (taxol treatment) further enhanced DCX exchange rates, however the exchange rates for the C-terminal truncated DCX protein were resistant to the impact of taxol-induced stabilization.	Paclitaxel	215-220	doublecortin	Homo sapiens	171-174
20498641-2	2010	In this study, we determine the role of erbB3 in erbB2-mediated paclitaxel resistance in breast cancer cells.	Paclitaxel	64-74	erb-b2 receptor tyrosine kinase 3	Homo sapiens	40-45
28187446-6	2017	Gene expression profiling of paclitaxel-residual, -resistant and naive MDA-MB-231 cells demonstrated that paclitaxel-residual, as opposed to -resistant cells, were characterized by an apoptotic signature, with downregulation of anti-apoptotic genes (BCL2, BIRC5), induction of apoptosis inducers (IL24, PDCD4), and enrichment of TNFalpha/NF-kappaB pathway, including upregulation of TNFSF15, coupled with cell-cycle arrest.	Paclitaxel	106-116	programmed cell death 4	Homo sapiens	303-308
20498641-3	2010	The overexpression of exogenous erbB3 via either stable or transient transfection in erbB2-overexpressing, but not epidermal growth factor receptor (EGFR)-expressing, breast cancer cells significantly decreases paclitaxel-induced growth inhibition and apoptosis.	Paclitaxel	211-221	erb-b2 receptor tyrosine kinase 3	Homo sapiens	32-37
20498641-4	2010	Consistently, knockdown of erbB3 expression with a specific short hairpin RNA (shRNA) in breast cancer cells with coexpression of both erbB2 and erbB3 enhances paclitaxel-induced apoptosis evidenced by increased DNA fragmentation, poly (ADP-ribose) polymerase (PARP) cleavage and activation of caspase-3 and -8.	Paclitaxel	160-170	erb-b2 receptor tyrosine kinase 3	Homo sapiens	27-32
20498641-4	2010	Consistently, knockdown of erbB3 expression with a specific short hairpin RNA (shRNA) in breast cancer cells with coexpression of both erbB2 and erbB3 enhances paclitaxel-induced apoptosis evidenced by increased DNA fragmentation, poly (ADP-ribose) polymerase (PARP) cleavage and activation of caspase-3 and -8.	Paclitaxel	160-170	erb-b2 receptor tyrosine kinase 3	Homo sapiens	145-150
20498641-8	2010	These data demonstrate that heterodimerization of erbB2/erbB3 is a prerequisite for erbB2 tyrosine kinase activation; and elevated expression of erbB3 is required for erbB2-mediated paclitaxel resistance in breast cancer cells via PI-3K/Akt/mTOR signaling pathway-dependent upregulation of Survivin.	Paclitaxel	182-192	erb-b2 receptor tyrosine kinase 3	Homo sapiens	145-150
20977456-10	2010	The CYP3A inhibitors ketoconazole and troleandomycin, and the CYP2C8 inhibitors quercetin and paclitaxel decreased imatinib oxidation.	Paclitaxel	94-104	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	62-68
28952225-1	2017	PURPOSE: To analyse the role of von Hippel-Lindau (VHL) and transforming growth factor beta-induced (TGFBI) in synergistic mechanisms of 5-aza-2"-deoxycytidine (DAC) and paclitaxel (PTX) against renal cell carcinoma (RCC).	Paclitaxel	170-180	arylacetamide deacetylase	Homo sapiens	161-164
21166887-2	2010	PX2 and PX24 were established from 2008 human ovarian cancer cells by 2-h single exposure or 24-h continuous exposure to paclitaxel.	Paclitaxel	121-131	pannexin 2	Homo sapiens	0-3
21166887-3	2010	PX2 acquired paclitaxel resistance faster than PX24 by twofold.	Paclitaxel	13-23	pannexin 2	Homo sapiens	0-3
21166887-5	2010	In 2-h exposure, PX2 showed 53.86 +- 4.96 (mean +- standard deviation [SD]) fold paclitaxel resistance while PX24 showed 9.51 +- 1.01 fold resistance (P = 0.002).	Paclitaxel	81-91	pannexin 2	Homo sapiens	17-20
21166887-6	2010	In 24-h exposure, PX2 showed 2.31 +- 0.3 fold paclitaxel resistance while PX24 showed 28.17 +- 0.98 fold resistance (P = 0.040).	Paclitaxel	46-56	pannexin 2	Homo sapiens	18-21
20657843-10	2010	The functional interaction of TRPV4 and the cytoskeleton is mutual as Taxol, a microtubule stabilizer, reduces the Ca2+-influx via TRPV4.	Paclitaxel	70-75	transient receptor potential cation channel subfamily V member 4	Homo sapiens	30-35
20657843-10	2010	The functional interaction of TRPV4 and the cytoskeleton is mutual as Taxol, a microtubule stabilizer, reduces the Ca2+-influx via TRPV4.	Paclitaxel	70-75	transient receptor potential cation channel subfamily V member 4	Homo sapiens	131-136
20939180-8	2010	The overexpressed SNCG also reduced sensitivity of HepG2 cells to antimicrotubule drugs: after PTX or VCR treatment, the proportion of HepG2/SNCG cells in G2/M arrest was significantly lower than that in HepG2/Neo cells.	Paclitaxel	95-98	synuclein gamma	Homo sapiens	18-22
28952225-1	2017	PURPOSE: To analyse the role of von Hippel-Lindau (VHL) and transforming growth factor beta-induced (TGFBI) in synergistic mechanisms of 5-aza-2"-deoxycytidine (DAC) and paclitaxel (PTX) against renal cell carcinoma (RCC).	Paclitaxel	182-185	arylacetamide deacetylase	Homo sapiens	161-164
28275088-5	2017	Overexpression of NCS-1 was also shown to increase the efficacy of paclitaxel-induced cell death in a manner that was independent of cellular proliferation.	Paclitaxel	67-77	neuronal calcium sensor 1	Homo sapiens	18-23
20378772-4	2010	Systemic injection with iRGD improved the therapeutic index of drugs of various compositions, including a small molecule (doxorubicin), nanoparticles (nab-paclitaxel and doxorubicin liposomes), and a monoclonal antibody (trastuzumab).	Paclitaxel	155-165	interferon gamma inducible protein 47	Mus musculus	24-28
20610805-9	2010	Consistently, the cleaved PARP and p-BCL2 proteins were subsequently increased after paclitaxel treatment, as also predicted by the bioinformatics analysis.	Paclitaxel	85-95	collagen type XI alpha 2 chain	Homo sapiens	26-30
28416606-0	2017	TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing.	Paclitaxel	15-25	transformer 2 alpha homolog	Homo sapiens	0-5
20576288-1	2010	We reported a precise engineered nanocapsule encapsulating a neovasculature disruption agent, combretastatin A4 (CA4) in a matrix that was made up of paclitaxel (PTX) conjugated amphiphilic polyester.	Paclitaxel	150-160	carbonic anhydrase 4	Homo sapiens	113-116
28416606-7	2017	In addition, TRA2A promotes paclitaxel resistance of TNBC by specifically controlling cancer-related splicing, which is independent of other splicing factors.	Paclitaxel	28-38	transformer 2 alpha homolog	Homo sapiens	13-18
20576288-1	2010	We reported a precise engineered nanocapsule encapsulating a neovasculature disruption agent, combretastatin A4 (CA4) in a matrix that was made up of paclitaxel (PTX) conjugated amphiphilic polyester.	Paclitaxel	162-165	carbonic anhydrase 4	Homo sapiens	113-116
19727732-8	2010	Combination treatments of BENSpm with 5-FU or paclitaxel resulted in induction of SSAT mRNA and activity in both cell lines compared to either drug alone, while SMO mRNA and activity were increased only in MDA-MB-231 cells.	Paclitaxel	46-56	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	82-86
28416606-8	2017	TRA2A overexpression could promote AS of CALU, RSRC2, and PALM during paclitaxel treatment of TNBC cells.	Paclitaxel	70-80	transformer 2 alpha homolog	Homo sapiens	0-5
19727732-10	2010	Further, RNAi studies demonstrated that both SSAT and SMO play a significant role in the response of MDA-MB-231 cells to treatment with BENSpm and 5-FU or paclitaxel.	Paclitaxel	155-165	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	45-49
28416606-12	2017	Collectively, our findings suggest that paclitaxel targets the TRA2A-RSRC2 splicing pathway, and deregulated TRA2A and RSRC2 expression may confer paclitaxel resistance.	Paclitaxel	40-50	transformer 2 alpha homolog	Homo sapiens	63-68
20051827-3	2010	The purposes of this study were to examine whether cisplatin could reverse the taxol-resistant phenotype of NPC cells, and to evaluate the role of the taxol-resistant gene (TXR1)/thrombospondin (TSP1) pathway in the reversal of taxol resistance.	Paclitaxel	151-156	proline rich 13	Homo sapiens	173-177
20421446-0	2010	Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation.	Paclitaxel	76-86	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	27-33
28541685-0	2017	Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo.	Paclitaxel	161-171	nucleotide binding oligomerization domain containing 2	Homo sapiens	131-135
20421446-1	2010	CYP2C8 has a major role in the metabolism of the anticancer agents 13-cis retinoic acid (13cisRA) and paclitaxel.	Paclitaxel	102-112	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
20421446-2	2010	There is evidence that polymorphisms in the CYP2C8 gene contribute to observed interindividual differences in paclitaxel metabolism.	Paclitaxel	110-120	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	44-50
20421446-4	2010	In the current study, the effect of two common nonsynonymous CYP2C8 polymorphisms, CYP2C8*3 (R139K and K399R) and *4 (I264M), on the metabolism of 13cisRA and paclitaxel was examined using an Escherichia coli expression system with coexpression of human cytochrome P450 reductase.	Paclitaxel	159-169	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	61-67
20421446-4	2010	In the current study, the effect of two common nonsynonymous CYP2C8 polymorphisms, CYP2C8*3 (R139K and K399R) and *4 (I264M), on the metabolism of 13cisRA and paclitaxel was examined using an Escherichia coli expression system with coexpression of human cytochrome P450 reductase.	Paclitaxel	159-169	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	83-89
20051827-3	2010	The purposes of this study were to examine whether cisplatin could reverse the taxol-resistant phenotype of NPC cells, and to evaluate the role of the taxol-resistant gene (TXR1)/thrombospondin (TSP1) pathway in the reversal of taxol resistance.	Paclitaxel	151-156	proline rich 13	Homo sapiens	173-177
20051827-10	2010	An approximate seven-fold increase in TXR1 mRNA expression and an 8.9-fold decrease in TSP1 mRNA expression were observed in taxol-resistant cells compared with their parental cells.	Paclitaxel	125-130	proline rich 13	Homo sapiens	38-42
20421446-7	2010	However, when the effects of the individual polymorphisms making up the CYP2C8*3 allele were considered, a significantly lower level of paclitaxel 6alpha-hydroxylase activity was associated with the K399R enzyme.	Paclitaxel	136-146	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	72-78
28541685-0	2017	Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo.	Paclitaxel	173-176	nucleotide binding oligomerization domain containing 2	Homo sapiens	131-135
20403547-3	2010	Two studies have shown that patients receiving paclitaxel whose tumours expressed high levels of class III beta-tubulin had a lower response rate and shorter survival, whereas this variable was not found to be predictive in patients receiving regimens without TBA.	Paclitaxel	47-57	tubulin beta 3 class III	Homo sapiens	97-119
28243976-0	2017	Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.	Paclitaxel	74-84	cyclin dependent kinase 4	Homo sapiens	14-18
20099905-2	2010	Partial depletion of Mps1 protein levels sensitizes transformed, but not untransformed, human cells to therapeutic doses of the anticancer agent Taxol, making it an attractive novel therapeutic cancer target.	Paclitaxel	145-150	TTK protein kinase	Homo sapiens	21-25
28243976-9	2017	We also found that palbociclib inhibited the activity of P-glycoprotein (Pgp), and that siRNA-mediated CDK4 knockdown sensitized multidrug resistant (MDR) SKOV3TR and OVCAR8TR cells to paclitaxel.	Paclitaxel	185-195	cyclin dependent kinase 4	Homo sapiens	103-107
19688827-7	2010	Treatment with rapamycin and paclitaxel resulted in decreased phosphorylation of S6 and 4E-BP1, two critical downstream targets of the mTOR pathway.	Paclitaxel	29-39	ribosomal protein S6	Homo sapiens	81-94
20457237-6	2010	Furthermore, the possibility of solubilizing paclitaxel (PTX), a water-insoluble antitumor drug, with OGC micelles was also explored.	Paclitaxel	45-55	solute carrier family 25 member 11	Homo sapiens	102-105
20457237-6	2010	Furthermore, the possibility of solubilizing paclitaxel (PTX), a water-insoluble antitumor drug, with OGC micelles was also explored.	Paclitaxel	57-60	solute carrier family 25 member 11	Homo sapiens	102-105
28243976-10	2017	CONCLUSIONS: Inhibition of CDK4 by palbociclib can enhance paclitaxel sensitivity in both Rb-positive and Rb-negative MDR ovarian cancer cells by increasing apoptosis.	Paclitaxel	59-69	cyclin dependent kinase 4	Homo sapiens	27-31
20457237-7	2010	PTX was successfully loaded into OGC micelles by using a simple dialysis process.	Paclitaxel	0-3	solute carrier family 25 member 11	Homo sapiens	33-36
20614491-4	2010	RESULTS: The paclitaxel treatment markedly suppressed Smad2/3 phosphorylation.	Paclitaxel	13-23	SMAD family member 2	Homo sapiens	54-61
27496854-0	2017	Crosstalk between E2f1 and c-Myc mediates hepato-protective effect of royal jelly on taxol-induced damages.	Paclitaxel	85-90	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	27-32
20372107-6	2010	Paclitaxel, given in metronomic sequence with the CTGF/E7 DNA vaccine enhanced the vaccine"s potential to delay tumor growth and decreased metastatic tumors in vivo better than the CTGF/E7 DNA vaccine alone.	Paclitaxel	0-10	cellular communication network factor 2	Homo sapiens	50-54
20372107-6	2010	Paclitaxel, given in metronomic sequence with the CTGF/E7 DNA vaccine enhanced the vaccine"s potential to delay tumor growth and decreased metastatic tumors in vivo better than the CTGF/E7 DNA vaccine alone.	Paclitaxel	0-10	cellular communication network factor 2	Homo sapiens	181-185
20118656-0	2010	The promise of paclitaxel-peptide conjugates for MMP-2-targeted drug delivery.	Paclitaxel	15-25	matrix metallopeptidase 2	Homo sapiens	49-54
28293855-4	2017	We investigated multiple ABC efflux pumps (ABCB1, ABCB5, ABCB8, ABCC1, ABCC2, ABCG1, and ABCG2) reportedly associated with melanoma drug resistance in different human melanoma cells and tested the efficacy of five different anti-cancer compounds (cisplatin, doxorubicin, oridonin, paclitaxel, vemurafenib) with decreased GH action.	Paclitaxel	281-291	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	25-28
20361940-10	2010	The knockdown of survivin mRNA expression by its specific siRNA induced apoptosis of cancer cells when the cells were treated with LY294002 or taxol.	Paclitaxel	143-148	baculoviral IAP repeat containing 5	Gallus gallus	17-25
27983936-6	2017	Furthermore, we found that downregulation of Btbd7 promoted cell apoptosis and increased the sensitivity to paclitaxel in CD133+ and parental cells.	Paclitaxel	108-118	BTB domain containing 7	Homo sapiens	45-50
20101233-12	2010	Forced overexpression of eIF4E induces resistance to androgen-withdrawal and paclitaxel treatment in the prostate LNCaP cells in vitro.	Paclitaxel	77-87	eukaryotic translation initiation factor 4E	Homo sapiens	25-30
27983936-6	2017	Furthermore, we found that downregulation of Btbd7 promoted cell apoptosis and increased the sensitivity to paclitaxel in CD133+ and parental cells.	Paclitaxel	108-118	prominin 1	Homo sapiens	122-127
19748175-4	2010	Meanwhile, CD133(+) CSCs were substantially resistant to standard chemotherapy, wherein both in vitro and in vivo treatment with paclitaxel resulted in a marked enrichment for CD133(+) CSCs.	Paclitaxel	129-139	prominin 1	Homo sapiens	11-16
28285942-12	2017	Co-immunoprecipitation experiments revealed the presence of the PSD95-nNOS complex in lumbar spinal cord of paclitaxel-treated rats, although ZL006 did not reliably disrupt the complex in all subjects.	Paclitaxel	108-118	discs large MAGUK scaffold protein 4	Rattus norvegicus	64-69
19748175-4	2010	Meanwhile, CD133(+) CSCs were substantially resistant to standard chemotherapy, wherein both in vitro and in vivo treatment with paclitaxel resulted in a marked enrichment for CD133(+) CSCs.	Paclitaxel	129-139	prominin 1	Homo sapiens	176-181
28231544-10	2017	Ginsenoside Rg3 combined Paclitaxel inhibited NF-kappaB activation, decreased NF-kappaB p65 and Bcl-2 protein expressions, increased Bax and Caspase-3 protein expressions.	Paclitaxel	25-35	RELA proto-oncogene, NF-kB subunit	Homo sapiens	88-91
19903471-0	2010	Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel.	Paclitaxel	107-117	ATP binding cassette subfamily B member 1A	Rattus norvegicus	30-35
28235687-9	2017	In spleens, IM+PTX therapy elevated proportion of whole lymphocytes in the account of myelo-monocytic cells characteristic with low expression of CD11c+ and bearing Fc receptor (CD16/32) as well as T-lymphocytes, NK cells and dendritic cells.	Paclitaxel	15-18	integrin alpha X	Mus musculus	146-151
28350120-7	2017	Downregulation of OVGP1 was significantly associated with shorter OS in all subgroups of OC patients, including subgroups of 752 patients treated with chemotherapy regimens containing taxol, 763 with both platin and taxol, 1364 with platin, 371 patients with grade 1-2 disease, 968 with grade 3 disease, 1148 with stage III-IV disease, and 439 with TP53 mutations.	Paclitaxel	184-189	oviductal glycoprotein 1	Homo sapiens	18-23
20133800-6	2010	Transiently silencing either PHB1 or GSTpi gene expression using siRNA in the paclitaxel-resistant cancer cell sublines partially sensitized these cells toward paclitaxel.	Paclitaxel	160-170	prohibitin 1	Homo sapiens	29-33
20133800-7	2010	Intriguingly, silencing PHB1 but not GSTpi resulted in activation of the intrinsic apoptosis pathway in response to paclitaxel.	Paclitaxel	116-126	prohibitin 1	Homo sapiens	24-28
28350120-7	2017	Downregulation of OVGP1 was significantly associated with shorter OS in all subgroups of OC patients, including subgroups of 752 patients treated with chemotherapy regimens containing taxol, 763 with both platin and taxol, 1364 with platin, 371 patients with grade 1-2 disease, 968 with grade 3 disease, 1148 with stage III-IV disease, and 439 with TP53 mutations.	Paclitaxel	216-221	oviductal glycoprotein 1	Homo sapiens	18-23
20133800-8	2010	Similarly, stably silencing either PHB1 or GSTpi significantly improved paclitaxel sensitivity in A549TR cells both in vitro and in vivo.	Paclitaxel	72-82	prohibitin 1	Homo sapiens	35-39
20133800-9	2010	Our results indicate that PHB1 is a mediator of paclitaxel resistance and that this resistance may depend on the cellular localization of the protein.	Paclitaxel	48-58	prohibitin 1	Homo sapiens	26-30
28358263-0	2017	LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis.	Paclitaxel	42-52	cytoplasmic polyadenylation element binding protein 2	Homo sapiens	95-100
22966274-3	2010	The purpose of this study was to evaluate the possible relationship between paclitaxel-induced neurotoxicity and the distribution of genetic variations with reported functional significance in the ABCB1, CYP2C8 and CYP3A4 genes that are all implicated in taxol metabolism.	Paclitaxel	76-86	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	204-210
22966274-3	2010	The purpose of this study was to evaluate the possible relationship between paclitaxel-induced neurotoxicity and the distribution of genetic variations with reported functional significance in the ABCB1, CYP2C8 and CYP3A4 genes that are all implicated in taxol metabolism.	Paclitaxel	255-260	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	204-210
19826413-10	2009	In PTX-sensitive, MyD88(neg) A2780 cells, TLR4 stimulation upregulated TRIF, and TLR4 silencing eliminated this effect.	Paclitaxel	3-6	MYD88 innate immune signal transduction adaptor	Homo sapiens	18-23
28358263-11	2017	In addition, our results also showed that miR-181a was a modulator of paclitaxel sensitivity due to its regulative effect on cell apoptosis via targeting CPEB2 in NPC cells.	Paclitaxel	70-80	cytoplasmic polyadenylation element binding protein 2	Homo sapiens	154-159
28358263-12	2017	Taken together, lncRNA CCAT1 regulates the sensitivity of paclitaxel in NPC cells via miR-181a/CPEB2 axis.	Paclitaxel	58-68	cytoplasmic polyadenylation element binding protein 2	Homo sapiens	95-100
20021611-0	2009	Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.	Paclitaxel	83-93	tubulin beta 3 class III	Homo sapiens	24-45
28221793-0	2017	Correction to Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis.	Paclitaxel	117-127	nucleotide binding oligomerization domain containing 2	Homo sapiens	27-31
19815708-6	2009	Here, we show that sirolimus and paclitaxel differentially induce self-digesting autophagy in vascular endothelial cells with changes in expression of LC3B, p53, and Bcl-2, considerably suppressing re-endothelialization and revascularization.	Paclitaxel	33-43	microtubule associated protein 1 light chain 3 beta	Homo sapiens	151-155
28178652-3	2017	On the other hand, miR-17-5p induced apoptosis in breast cancer cells, and overexpression of miR-17-5p sensitized MCF-7 cells to paclitaxel-induced apoptosis via STAT3.	Paclitaxel	129-139	microRNA 17	Homo sapiens	19-28
19447545-0	2009	Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells.	Paclitaxel	76-81	Alzheimer disease, familial, type 5	Homo sapiens	19-22
28178652-3	2017	On the other hand, miR-17-5p induced apoptosis in breast cancer cells, and overexpression of miR-17-5p sensitized MCF-7 cells to paclitaxel-induced apoptosis via STAT3.	Paclitaxel	129-139	microRNA 17	Homo sapiens	93-102
19561399-0	2009	Alpha-tocopheryl succinate potentiates the paclitaxel-induced apoptosis through enforced caspase 8 activation in human H460 lung cancer cells.	Paclitaxel	43-53	caspase 8	Homo sapiens	89-98
28203091-6	2017	miR-30c also enhances the sensitivity of Caki-1 cells to anticancer agents, including sorafenib and paclitaxel.	Paclitaxel	100-110	microRNA 30c-1	Homo sapiens	0-7
19561399-5	2009	Pretreatment with z-VAD-FMK (a pan-caspase inhibitor) or z-IETD-FMK (a caspase-8 inhibitor) blocked TOS/paclitaxel cotreatment-induced PARP cleavage and apoptosis, suggesting that TOS potentiates the paclitaxel-induced apoptosis through enforced caspase 8 activation in H460 cells.	Paclitaxel	104-114	caspase 8	Homo sapiens	71-80
19561399-5	2009	Pretreatment with z-VAD-FMK (a pan-caspase inhibitor) or z-IETD-FMK (a caspase-8 inhibitor) blocked TOS/paclitaxel cotreatment-induced PARP cleavage and apoptosis, suggesting that TOS potentiates the paclitaxel-induced apoptosis through enforced caspase 8 activation in H460 cells.	Paclitaxel	104-114	caspase 8	Homo sapiens	246-255
19561399-5	2009	Pretreatment with z-VAD-FMK (a pan-caspase inhibitor) or z-IETD-FMK (a caspase-8 inhibitor) blocked TOS/paclitaxel cotreatment-induced PARP cleavage and apoptosis, suggesting that TOS potentiates the paclitaxel-induced apoptosis through enforced caspase 8 activation in H460 cells.	Paclitaxel	200-210	caspase 8	Homo sapiens	71-80
27932243-0	2017	Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma.	Paclitaxel	90-100	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
27932243-3	2017	In this work, we show that ribavirin, an anti-viral drug, effectively augments sensitivity of OTSCC cells to paclitaxel via inhibiting mTOR/eIF4E signaling pathway.	Paclitaxel	109-119	eukaryotic translation initiation factor 4E	Homo sapiens	140-145
19806032-4	2009	Taxol treatment and immunoprecipitation show that Astrin may interact with the centrosomal proteins Aurora-A or Plk1 to regulate microtubule organization and spindle pole integrity.	Paclitaxel	0-5	sperm associated antigen 5	Mus musculus	50-56
19806032-4	2009	Taxol treatment and immunoprecipitation show that Astrin may interact with the centrosomal proteins Aurora-A or Plk1 to regulate microtubule organization and spindle pole integrity.	Paclitaxel	0-5	aurora kinase A	Mus musculus	100-108
27932243-9	2017	In addition, eIF4E depletion significantly enhances the anti-proliferative and pro-apoptotic effects of paclitaxel, demonstrating the critical role of eIF4E in OTSCC cell response to paclitaxel.	Paclitaxel	104-114	eukaryotic translation initiation factor 4E	Homo sapiens	13-18
27932243-9	2017	In addition, eIF4E depletion significantly enhances the anti-proliferative and pro-apoptotic effects of paclitaxel, demonstrating the critical role of eIF4E in OTSCC cell response to paclitaxel.	Paclitaxel	104-114	eukaryotic translation initiation factor 4E	Homo sapiens	151-156
27932243-9	2017	In addition, eIF4E depletion significantly enhances the anti-proliferative and pro-apoptotic effects of paclitaxel, demonstrating the critical role of eIF4E in OTSCC cell response to paclitaxel.	Paclitaxel	183-193	eukaryotic translation initiation factor 4E	Homo sapiens	13-18
27932243-9	2017	In addition, eIF4E depletion significantly enhances the anti-proliferative and pro-apoptotic effects of paclitaxel, demonstrating the critical role of eIF4E in OTSCC cell response to paclitaxel.	Paclitaxel	183-193	eukaryotic translation initiation factor 4E	Homo sapiens	151-156
19668227-0	2009	Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules.	Paclitaxel	0-10	caspase 8	Homo sapiens	22-31
19668227-3	2009	Paclitaxel, a microtubule-stabilizing agent, induces a caspase-dependent apoptosis, although the precise mechanism(s) remain unclear.	Paclitaxel	0-10	caspase 8	Homo sapiens	55-62
27779649-11	2016	Curcumin alone and combined with paclitaxel increased p53, Bid, caspase-3, caspase-8 and Bax gene expression in MDA-MB-231, whereas Bcl-xL decreased such expression in MDA-MB-231 cells.	Paclitaxel	33-43	caspase 8	Homo sapiens	75-84
19668227-4	2009	Here, we used genetic approaches to evaluate the role of caspase 8 in paclitaxel-mediated apoptosis.	Paclitaxel	70-80	caspase 8	Homo sapiens	57-66
19668227-5	2009	We observed that caspase 8-expressing cells are more sensitive to paclitaxel than caspase 8-deficient cells.	Paclitaxel	66-76	caspase 8	Homo sapiens	17-26
27875556-9	2016	The microtubule inhibitor nocodazole and stabilizer paclitaxel respectively attenuated and enhanced the effect of MxA, implicating microtubule integrity in this process.	Paclitaxel	52-62	MX dynamin like GTPase 1	Homo sapiens	114-117
19668227-6	2009	Mechanistically, caspase 8 was found associated with microtubules, and this interaction increased after paclitaxel treatment.	Paclitaxel	104-114	caspase 8	Homo sapiens	17-26
19668227-9	2009	Microtubule association, and paclitaxel sensitivity, depends on a critical lysine (K156) within a microtubule-binding motif (KLD) in DED-b of caspase 8.	Paclitaxel	29-39	caspase 8	Homo sapiens	142-151
19520687-10	2009	Severe neutropenia (G3 and G4) was seen in seven patients associated with greater AUC, peak concentration (C(max)) and the duration of plasma concentration &gt;50 ng/ml of paclitaxel.	Paclitaxel	172-182	BAG cochaperone 6	Homo sapiens	19-29
27896032-6	2016	Thus, comparison in mRNA expression between untreated control, vehicle-treated and paclitaxel treated animals was done for Nav1.1, Nav1.2, Nav1.3, Nav1.6, Nax as well as Navbeta1-Navbeta4.	Paclitaxel	83-93	neuron navigator 1	Mus musculus	123-127
27896032-8	2016	Paclitaxel treatment significantly increased the mRNA expression of Nav1.1, Nav1.2, Nav1.6 and Nax, but not Nav1.3, sodium channel alpha subunits compared to vehicle-treated animals.	Paclitaxel	0-10	sodium channel, voltage-gated, type II, alpha	Mus musculus	76-82
27896032-8	2016	Paclitaxel treatment significantly increased the mRNA expression of Nav1.1, Nav1.2, Nav1.6 and Nax, but not Nav1.3, sodium channel alpha subunits compared to vehicle-treated animals.	Paclitaxel	0-10	neuron navigator 1	Mus musculus	68-72
27896032-8	2016	Paclitaxel treatment significantly increased the mRNA expression of Nav1.1, Nav1.2, Nav1.6 and Nax, but not Nav1.3, sodium channel alpha subunits compared to vehicle-treated animals.	Paclitaxel	0-10	sodium channel, voltage-gated, type VII, alpha	Mus musculus	95-98
27541441-5	2016	We also evaluated its subsequent miR-200c function in paclitaxel resistance human lung cancer (A549/T) cells in culture and tumor xenografts in nude mice.	Paclitaxel	54-64	microRNA 200c	Homo sapiens	33-41
19724684-0	2009	Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo.	Paclitaxel	79-84	galectin 3	Homo sapiens	10-20
19724684-4	2009	In this study, we tested the hypothesis that inhibiting galectin-3 antiapoptotic function using a synthetic low-molecular weight carbohydrate-based compound lactulosyl-L-leucine (Lac-L-Leu) will augment apoptosis induced in human cancer cells by paclitaxel and increase its efficacy against established metastases.	Paclitaxel	246-256	galectin 3	Homo sapiens	56-66
27541441-7	2016	All these evidences indicated that this miR-200c delivery via polyphosphazene vesicles could act as a potential new therapeutic option for paclitaxel resistant human lung cancer.	Paclitaxel	139-149	microRNA 200c	Homo sapiens	40-48
27530131-11	2016	4-HPR also enhanced the activity against neuroblastoma xenografts of vincristine or paclitaxel, but the latter combinations were less active than 4-HPR + ABT-751.	Paclitaxel	84-94	haptoglobin-related protein	Homo sapiens	2-5
19703346-8	2009	Rifampicin (a potent inhibitor of organic anion transporting polypeptide (Oatp) 2), but not indometacin (a representative inhibitor of organic anion transporter (Oat) 2 and Oatp1) treatment, significantly inhibited the uptake of paclitaxel and TAX-2"-Et.	Paclitaxel	229-239	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	34-81
19703346-9	2009	We characterized the rifampicin-sensitive uptake of paclitaxel and TAX-2"-Et using rat hepatocytes treated with PCN, which dramatically enhances hepatic Oatp2 protein levels.	Paclitaxel	52-62	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	153-158
19945225-6	2010	RESULTS: Omicronbjective response rate was notably better when paclitaxel was used as every three weeks regimen (7 studies, 1772 patients, fixed effect model pooled RR 1.20 95%CI 1.08-1.32 p&lt;0.001).	Paclitaxel	63-73	ribonucleotide reductase catalytic subunit M1	Homo sapiens	165-169
27895747-0	2016	Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9.	Paclitaxel	59-69	microRNA 24-1	Homo sapiens	18-29
20001297-4	2010	Paclitaxel therapy downregulated expression of vascular endothelial growth factor receptor-2 (VEGFR2) and up-regulated expression of thrombospondin-1.	Paclitaxel	0-10	kinase insert domain protein receptor	Mus musculus	47-92
20001297-4	2010	Paclitaxel therapy downregulated expression of vascular endothelial growth factor receptor-2 (VEGFR2) and up-regulated expression of thrombospondin-1.	Paclitaxel	0-10	kinase insert domain protein receptor	Mus musculus	94-100
20346445-3	2010	PTX treatment also enhances maturation marker expression on CD11c(+) DCs isolated from vaccine-draining lymph nodes.	Paclitaxel	0-3	integrin alpha X	Mus musculus	60-65
19638449-11	2009	These Cul3-silenced MCF7 cells are highly resistant to oxidative stress induced by H(2)O(2,) to the carcinogen benzo(a)pyrene, and to both Doxorubicin and Paclitaxel.	Paclitaxel	155-165	cullin 3	Homo sapiens	6-10
27664577-9	2016	Employing mRNA expression profiling of all known human ABC transporters and subsequent Western blot analysis of the expression of selected transporters, we demonstrated that only the ABCB1/PgP and ABCC3/MRP3 proteins were up-regulated in both paclitaxel-resistant sublines.	Paclitaxel	243-253	ATP binding cassette subfamily C member 3	Homo sapiens	197-202
20001661-0	2010	The protective effect of beta-1,3-D-glucan on taxol-induced hepatotoxicity: a histopathological and stereological study.	Paclitaxel	46-51	calcium channel, voltage-dependent, beta 3 subunit	Mus musculus	25-33
27664577-9	2016	Employing mRNA expression profiling of all known human ABC transporters and subsequent Western blot analysis of the expression of selected transporters, we demonstrated that only the ABCB1/PgP and ABCC3/MRP3 proteins were up-regulated in both paclitaxel-resistant sublines.	Paclitaxel	243-253	ATP binding cassette subfamily C member 3	Homo sapiens	203-207
20814160-3	2010	Hydroxylation activities of mfCYP3A4 and mfCYP3A5 toward coumarin, paclitaxel, diclofenac, flurbiprofen, and S-mephenytoin were below detectable levels, as was also true for CYP3A4 and CYP3A5.	Paclitaxel	67-77	cytochrome P450 family 3 subfamily A member 5	Macaca fascicularis	41-49
19591684-6	2009	DCs treated with antimicrotubule agents vincristine, vinblastine, and paclitaxel or with antimetabolites 5-aza-2-deoxycytidine and methotrexate, showed increased expression of CD83 and CD40 molecules.	Paclitaxel	70-80	CD40 molecule	Homo sapiens	185-189
19591684-7	2009	Expression of CD80 on DCs was also stimulated by vinblastine, paclitaxel, azacytidine, methotrexate, and mitomycin C used in low nontoxic concentrations.	Paclitaxel	62-72	CD80 molecule	Homo sapiens	14-18
27714074-9	2016	The miR-186 mimic enhanced the tumor growth inhibitory effects of paclitaxel in A549 xenografts.	Paclitaxel	66-76	microRNA 186	Homo sapiens	4-11
21147873-13	2010	The observed greater plasma concentrations of paclitaxel given concurrently with pazopanib suggest that pazopanib is a weak inhibitor of CYP3A4 and CYP2C8.	Paclitaxel	46-56	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	148-154
27615739-3	2016	The truncated bFGF peptide (tbFGF), which could effectively bind to FGFR1 overexpressed on tumor neovasculature endothelial cells and tumor cells, was selected to modify PLGA nanoparticles (D/P-NPs) simultaneously loaded with PEDF gene and paclitaxel in this study.	Paclitaxel	240-250	fibroblast growth factor 2	Mus musculus	14-18
19168279-2	2009	We demonstrated that DAC could significantly increase the susceptibility of PC cells to PTX, and confirmed the synergy of DAC and PTX.	Paclitaxel	88-91	arylacetamide deacetylase	Homo sapiens	21-24
19168279-2	2009	We demonstrated that DAC could significantly increase the susceptibility of PC cells to PTX, and confirmed the synergy of DAC and PTX.	Paclitaxel	130-133	arylacetamide deacetylase	Homo sapiens	21-24
19168279-3	2009	DAC enhanced the PTX induced up-regulation of caspase activity and antiproliferative effect, resulting in an increase of cells in subG1 and G2/M phases.	Paclitaxel	17-20	arylacetamide deacetylase	Homo sapiens	0-3
20641397-9	2004	observed that the anti-tumor activity of HGS-ETR1 could be enhanced in mice bearing colorectal cancer cell xenograft tumors with pretreatment with paclitaxel (7).	Paclitaxel	147-157	CUGBP, Elav-like family member 3	Mus musculus	45-49
27456785-4	2016	We then showed that structurally diverse ERbeta-selective agonists also relieved allodynia in CINP caused by taxol, oxaliplatin, and vincristine.	Paclitaxel	109-114	estrogen receptor 2	Homo sapiens	41-47
27059733-3	2016	Whether circulating galectin-3 is involved in paclitaxel resistance in ovarian cancer remains unknown.	Paclitaxel	46-56	galectin 3	Homo sapiens	20-30
27059733-4	2016	The current study investigated the effect of galectin-3 on toll-like receptor 4 (TLR4) signaling and thus paclitaxel resistance.	Paclitaxel	106-116	galectin 3	Homo sapiens	45-55
27059733-5	2016	With blood and cancer tissue samples obtained from 102 patients, we identified associations between serum galectin-3 level or TLR4 expression and paclitaxel resistance phenotype.	Paclitaxel	146-156	galectin 3	Homo sapiens	106-116
19282281-7	2009	Instead, we demonstrate that two residues found in beta5 (Ser-239 and Ser-365) are each sufficient to inhibit microtubule assembly and confer paclitaxel resistance when introduced into beta1-tubulin; yet the single mutation of residue Ser-239 in beta5 eliminates its ability to confer these phenotypes.	Paclitaxel	142-152	tubulin beta 4A class IVa	Homo sapiens	51-56
27059733-6	2016	In vitro, treatment with exogenous galectin-3 restored cell survival and migration of SKOV-3 and ES-2 cells was decreased by galectin-3 silencing and paclitaxel treatment.	Paclitaxel	150-160	galectin 3	Homo sapiens	35-45
19340624-0	2009	The vitamin A family can significantly decrease the expression of ERbeta of ERs positive breast cancer cells in the presence or absence of ER ligands and paclitaxel.	Paclitaxel	154-164	estrogen receptor 2	Homo sapiens	66-72
27059733-7	2016	Furthermore, exogenous galectin-3 boosted expression of TLR4, MyD88, and p-p65, as well as interleukin (IL)-6, IL-8, and vascular endothelial growth factor (VEGF) release induced by paclitaxel.	Paclitaxel	182-192	galectin 3	Homo sapiens	23-33
19340624-6	2009	We have shown that paclitaxel increases the expression of ERalpha and ERbeta mRNA in MCF-7 line.	Paclitaxel	19-29	estrogen receptor 2	Homo sapiens	70-76
19340624-7	2009	The strongest effect of transcription inhibition ERalpha (2.5 times) and especially ERbeta (10 times) was observed after addition of 9-cis retinoic acid and paclitaxel.	Paclitaxel	157-167	estrogen receptor 2	Homo sapiens	84-90
27059733-10	2016	In summary, our study elucidated that exogenous galectin-3 might induce paclitaxel resistance through TLR4 signaling activation by inhibiting TLR4-Cav-1 interaction, revealing a novel insight into paclitaxel resistance induction.	Paclitaxel	72-82	galectin 3	Homo sapiens	48-58
28620450-8	2016	Minimum redundancy maximum relevance feature selection of a paclitaxel-based SVM classifier based on expression of genes  BCL2L1, BBC3, FGF2, FN1, and  TWIST1 was 81.1% accurate in 53 CT patients.	Paclitaxel	60-70	BCL2 binding component 3	Homo sapiens	130-134
27447567-4	2016	Herein, we conjugated the paclitaxel with a hexapeptide which is specific recognized by MMP2 protein.	Paclitaxel	26-36	matrix metallopeptidase 2	Homo sapiens	88-92
19101991-5	2009	Agents such as bleomycin, As(2)O(3) and H(2)O(2), which produce reactive oxygen species (ROS), also induced CatS expression; however, other agents that damage DNA such as taxol and cisplatin did not.	Paclitaxel	171-176	cathepsin S	Felis catus	108-112
19351859-5	2009	Overexpression of CTGF in MCF7 cells (MCF7/CTGF) enhanced clonogenic ability, cell viability, and resistance to apoptosis on exposure to doxorubicin and paclitaxel.	Paclitaxel	153-163	cellular communication network factor 2	Homo sapiens	18-22
27447567-5	2016	The conjugate is dissociated upon the MMP2 specific proteolysis at COOH terminal of hexapeptide, PVGLIG.The results clearly indicated that the PVGLIG-paclitaxel conjugate significantly enhanced the tumor specificity against HT-1080 and U87-MG tumour cells.	Paclitaxel	150-160	matrix metallopeptidase 2	Homo sapiens	38-42
19351859-5	2009	Overexpression of CTGF in MCF7 cells (MCF7/CTGF) enhanced clonogenic ability, cell viability, and resistance to apoptosis on exposure to doxorubicin and paclitaxel.	Paclitaxel	153-163	cellular communication network factor 2	Homo sapiens	43-47
27447567-6	2016	Our finding suggested that the hexapeptide PVGLIG is capable to act as a controlled and sustained drug carrier of paclitaxel for the treatment against tumour proliferation and metastasis with high MMP2 expression.	Paclitaxel	114-124	matrix metallopeptidase 2	Homo sapiens	197-201
19351859-7	2009	CTGF overexpression resulted in resistance to doxorubicin- and paclitaxel-induced apoptosis by up-regulation of Bcl-xL and cellular inhibitor of apoptosis protein 1 (cIAP1).	Paclitaxel	63-73	cellular communication network factor 2	Homo sapiens	0-4
19351859-7	2009	CTGF overexpression resulted in resistance to doxorubicin- and paclitaxel-induced apoptosis by up-regulation of Bcl-xL and cellular inhibitor of apoptosis protein 1 (cIAP1).	Paclitaxel	63-73	baculoviral IAP repeat containing 2	Homo sapiens	123-164
27304668-0	2016	Glaucarubinone sensitizes KB cells to paclitaxel by inhibiting ABC transporters via ROS-dependent and p53-mediated activation of apoptotic signaling pathways.	Paclitaxel	38-48	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	63-66
19351859-7	2009	CTGF overexpression resulted in resistance to doxorubicin- and paclitaxel-induced apoptosis by up-regulation of Bcl-xL and cellular inhibitor of apoptosis protein 1 (cIAP1).	Paclitaxel	63-73	baculoviral IAP repeat containing 2	Homo sapiens	166-171
27109765-14	2016	We found that PSM improved anti-cancer efficacy of paclitaxel in SSTR2 positive glioma of rats.	Paclitaxel	51-61	somatostatin receptor 2	Rattus norvegicus	65-70
19190325-8	2009	Down-regulation of hSNF2H or disruption of hSNF2H and Rsf-1 interaction enhanced paclitaxel sensitivity in tumor cells with Rsf-1 up-regulation.	Paclitaxel	81-91	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5	Homo sapiens	19-25
19190325-8	2009	Down-regulation of hSNF2H or disruption of hSNF2H and Rsf-1 interaction enhanced paclitaxel sensitivity in tumor cells with Rsf-1 up-regulation.	Paclitaxel	81-91	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5	Homo sapiens	43-49
19190325-10	2009	In conclusion, our results suggest that Rsf-1 is the major gene within the 11q13.5 amplicon that contributes to paclitaxel resistance, and the formation of the Rsf-1/hSNF2H complex is required for inducing this phenotype.	Paclitaxel	112-122	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5	Homo sapiens	166-172
27347418-1	2016	Paclitaxel is mainly inactivated in vivo by cytochrome P5402C8 (CYP2C8).	Paclitaxel	0-10	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	64-70
19200169-12	2009	CONCLUSIONS: It suggests that TLR4 negatively regulates paclitaxel chemotherapy and MyD88 is an essential downstream factor to TLR4 signalling for this resistance.	Paclitaxel	56-66	MYD88 innate immune signal transduction adaptor	Homo sapiens	84-89
27196755-4	2016	In this article, we demonstrate that PKCdelta silencing favors mitotic arrest after paclitaxel treatment in PC3 and LNCaP cells; however, this is associated with resistance to paclitaxel-induced apoptosis.	Paclitaxel	84-94	protein kinase C delta	Homo sapiens	37-45
19074887-7	2008	Using this approach, we found up-regulation of TUBB3 in TAX50, but not EPO3, cells, showing that TUBB3 mediates the resistance to paclitaxel but not to patupilone.	Paclitaxel	130-140	tubulin beta 3 class III	Homo sapiens	47-52
19074887-7	2008	Using this approach, we found up-regulation of TUBB3 in TAX50, but not EPO3, cells, showing that TUBB3 mediates the resistance to paclitaxel but not to patupilone.	Paclitaxel	130-140	tubulin beta 3 class III	Homo sapiens	97-102
27196755-4	2016	In this article, we demonstrate that PKCdelta silencing favors mitotic arrest after paclitaxel treatment in PC3 and LNCaP cells; however, this is associated with resistance to paclitaxel-induced apoptosis.	Paclitaxel	176-186	protein kinase C delta	Homo sapiens	37-45
27277808-2	2016	In the present study, we found that neuropathic pain induced by the chemotherapeutic drug paclitaxel or L5 ventral root transection significantly impaired the function of GABAergic synapses of spinal dorsal horn neurons via the reduction of the GAD67 expression.	Paclitaxel	90-100	glutamate decarboxylase 1	Rattus norvegicus	245-250
27284014-2	2016	The correlation of point mutations in class III beta-tubulin (TUBB3) and the prominent overexpression of ATP-binding cassette P-glycoprotein (ABCB1), a multidrug resistance gene, have been protruding mechanisms of resistance to microtubule disruptors such as paclitaxel (PTX) for many cancers.	Paclitaxel	259-269	tubulin beta 3 class III	Homo sapiens	62-67
18719023-9	2008	Furthermore, both tamoxifen and paclitaxel significantly and synergistically enhanced the growth inhibition of MCF-7 cells by EGCG through the down-regulation of Skp2 protein.	Paclitaxel	32-42	S-phase kinase associated protein 2	Homo sapiens	162-166
27284014-2	2016	The correlation of point mutations in class III beta-tubulin (TUBB3) and the prominent overexpression of ATP-binding cassette P-glycoprotein (ABCB1), a multidrug resistance gene, have been protruding mechanisms of resistance to microtubule disruptors such as paclitaxel (PTX) for many cancers.	Paclitaxel	271-274	tubulin beta 3 class III	Homo sapiens	62-67
18158619-6	2008	Finally, Id-1 played a protective role against taxol-induced apoptosis in breast cancer cells as assessed by MTT assay and apoptotic cell count upon taxol treatment (0-200 nM).	Paclitaxel	47-52	inhibitor of DNA binding 1, HLH protein	Homo sapiens	9-13
27284014-5	2016	We found that feedback activation of TUBB3 can be triggered through the FOXO3a-dependent regulation of ABCB1, which resulted in the accentuation of induced PTX resistance and encouraged multiplicity in acquired cross-resistance.	Paclitaxel	156-159	tubulin beta 3 class III	Homo sapiens	37-42
18158619-6	2008	Finally, Id-1 played a protective role against taxol-induced apoptosis in breast cancer cells as assessed by MTT assay and apoptotic cell count upon taxol treatment (0-200 nM).	Paclitaxel	149-154	inhibitor of DNA binding 1, HLH protein	Homo sapiens	9-13
18158619-7	2008	Reduced Bax expression and enhanced Bcl-2 expression by Id-1 were also noted in the presence of taxol.	Paclitaxel	96-101	inhibitor of DNA binding 1, HLH protein	Homo sapiens	56-60
27284014-9	2016	In addition, we found that secretome factors from PTX-resistant cancer cells with acquired cross-resistance support a P-gp-dependent association in multidrug resistance (MDR) development, which assisted the FOXO3a-mediated control of TUBB3 feedback.	Paclitaxel	50-53	tubulin beta 3 class III	Homo sapiens	234-239
18158619-8	2008	Taken together, we present a molecular mechanism where Id-1 regulates p53 and NF-kappaB pathways, which in turn regulates Bax and Bcl-2 genes, thus providing a survival advantage under exogenous stress such as serum-free or taxol treatment in MCF-7 breast cancer cells.	Paclitaxel	224-229	inhibitor of DNA binding 1, HLH protein	Homo sapiens	55-59
27284014-10	2016	The direct silencing of TUBB3 reverses induced multiple cross-resistance, reduces drug-resistant tumor mass, and suppresses the impaired microtubule stability status of PTX-resistant cells with transient cross-resistance.	Paclitaxel	169-172	tubulin beta 3 class III	Homo sapiens	24-29
27313461-1	2016	In this study, we report a novel kind of targeting with paclitaxel (PTX)-loaded silk fibroin nanoparticles conjugated with iRGD-EGFR nanobody recombinant protein (anti-EGFR-iRGD).	Paclitaxel	56-66	interferon gamma inducible protein 47	Mus musculus	123-127
18617895-5	2008	Functionally, short hairpin RNA knockdown of YAP in breast cell lines suppressed anoikis, increased migration and invasiveness, inhibited the response to taxol and enhanced tumor growth in nude mice.	Paclitaxel	154-159	yes-associated protein 1	Mus musculus	45-48
27313461-1	2016	In this study, we report a novel kind of targeting with paclitaxel (PTX)-loaded silk fibroin nanoparticles conjugated with iRGD-EGFR nanobody recombinant protein (anti-EGFR-iRGD).	Paclitaxel	56-66	interferon gamma inducible protein 47	Mus musculus	173-177
27313461-1	2016	In this study, we report a novel kind of targeting with paclitaxel (PTX)-loaded silk fibroin nanoparticles conjugated with iRGD-EGFR nanobody recombinant protein (anti-EGFR-iRGD).	Paclitaxel	68-71	interferon gamma inducible protein 47	Mus musculus	123-127
19087546-8	2008	Western blot assay showed the changes in expression levels of phosphorylated AKT and GSK-3beta, which were decreased significantly after paclitaxel and bortezomib combination treatment [(3.2 +/- 0.8)%, (19.3 +/- 0.4)%; P &lt; 0.05].	Paclitaxel	137-147	glycogen synthase kinase 3 beta	Homo sapiens	85-94
27313461-1	2016	In this study, we report a novel kind of targeting with paclitaxel (PTX)-loaded silk fibroin nanoparticles conjugated with iRGD-EGFR nanobody recombinant protein (anti-EGFR-iRGD).	Paclitaxel	68-71	interferon gamma inducible protein 47	Mus musculus	173-177
27313785-0	2016	Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.	Paclitaxel	156-166	cyclin dependent kinase 4	Homo sapiens	11-17
27313785-6	2016	The CDK4/6 pathway was constitutively active in both parental and paclitaxel-resistant T47D cells; thus, both cell types were highly sensitive to the inhibitory effects of single-agent palbociclib on cell growth and cell cycle progression.	Paclitaxel	66-76	cyclin dependent kinase 4	Homo sapiens	4-10
27159676-0	2016	MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression.	Paclitaxel	18-28	microRNA 125a	Homo sapiens	0-8
18064460-2	2008	PATIENTS AND METHODS: We investigated in patients with T2-T3 N0-3 ER, PgR &lt;10% and HER2 negative breast cancers the activity both in terms of pathological (pCR) and objective responses of four courses of cisplatin containing chemotherapy (ECF, epirubicin, cisplatin, and fluorouracil as continuous infusion) followed by three courses of weekly paclitaxel.	Paclitaxel	347-357	progesterone receptor	Homo sapiens	70-73
26596839-0	2016	Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.	Paclitaxel	51-61	MYD88 innate immune signal transduction adaptor	Homo sapiens	24-29
18714397-0	2008	Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer.	Paclitaxel	25-35	clusterin	Homo sapiens	0-9
26596839-1	2016	MyD88 was reported to be associated with paclitaxel sensitivity in lung cancer; however, its roles in breast cancer remain unclear.	Paclitaxel	41-51	MYD88 innate immune signal transduction adaptor	Homo sapiens	0-5
18714397-0	2008	Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer.	Paclitaxel	47-57	clusterin	Homo sapiens	0-9
18714397-5	2008	We also investigated clusterin in paclitaxel resistance by modulating the endogenous clusterin expression in ovarian cancer cells and treating the cells with purified clusterin.	Paclitaxel	34-44	clusterin	Homo sapiens	21-30
26596839-11	2016	Knockdown of MyD88 reduced the proliferation, migration, and invasion of MCF-7 cells and increased the sensitivity of MCF-7 cells to paclitaxel treatment through the inhibition of activation of NF-kappaB via PI3K/Akt.	Paclitaxel	133-143	MYD88 innate immune signal transduction adaptor	Homo sapiens	13-18
18714397-6	2008	Results indicate that high-clusterin-expressing ovarian cancer cells are more resistant to paclitaxel.	Paclitaxel	91-101	clusterin	Homo sapiens	27-36
18714397-7	2008	Moreover, exposing ovarian cancer cells to exogenous clusterin increases cells" resistance to paclitaxel.	Paclitaxel	94-104	clusterin	Homo sapiens	53-62
18714397-8	2008	Finally, using size exclusion chromatography and fluorescently labeled paclitaxel, we demonstrated that clusterin binds to paclitaxel.	Paclitaxel	71-81	clusterin	Homo sapiens	104-113
26851390-2	2016	Here, we report the design and development of novel endosomal pH-activatable paclitaxel prodrug micelles based on hyaluronic acid-b-dendritic oligoglycerol (HA-dOG-PTX-PM) for active targeting and effective treatment of CD44-overexpressing human breast cancer xenografts in nude mice.	Paclitaxel	77-87	CD44 molecule	Canis lupus familiaris	220-224
26832791-7	2016	However, in line with its unique mode of action, when combined with paclitaxel, low doses of Mps1 inhibitor reduced paclitaxel-induced mitotic arrest by the weakening of SAC activity.	Paclitaxel	68-78	TTK protein kinase	Homo sapiens	93-97
18814764-1	2008	In diabetic patients, the use of drug-eluting stents (paclitaxel-PES or sirolimus-SES) reduces the risk of restenosis as compared to bare-metal stents.	Paclitaxel	54-64	pescadillo ribosomal biogenesis factor 1	Homo sapiens	65-68
26832791-7	2016	However, in line with its unique mode of action, when combined with paclitaxel, low doses of Mps1 inhibitor reduced paclitaxel-induced mitotic arrest by the weakening of SAC activity.	Paclitaxel	116-126	TTK protein kinase	Homo sapiens	93-97
18594523-4	2008	Knockdown of MnSOD by small-interfering RNA (siRNA) led to an increase in superoxide generation and sensitisation of ovarian cancer cells to the two front-line anti-cancer agents doxorubicin and paclitaxel whose action involved free-radical generation.	Paclitaxel	195-205	superoxide dismutase 2	Homo sapiens	13-18
18594523-7	2008	Evaluation of signalling pathways showed that MnSOD siRNA enhanced doxorubicin- and paclitaxel-induced phosphorylation of extracellular signal-regulated kinase 1/2.	Paclitaxel	84-94	superoxide dismutase 2	Homo sapiens	46-51
26995790-11	2016	CONCLUSIONS: Dual antagonism of ETAR and ETBR signaling sensitizes experimental brain metastases to paclitaxel and may represent a new therapeutic option for patients with brain metastases.	Paclitaxel	100-110	endothelin receptor type A	Homo sapiens	32-36
18452161-4	2008	Paclitaxel treatment not only activated calpain and caspase-4, but also induced a gradual increase in the cytosolic Ca(2+) concentration at 3-6 h. Paclitaxel-induced apoptosis can be inhibited by the calpain inhibitor calpeptin and IP(3) receptor inhibitors.	Paclitaxel	0-10	inositol 1,4,5-trisphosphate receptor type 3	Homo sapiens	232-246
26699227-0	2016	Biological evaluation of PEG modified nanosuspensions based on human serum albumin for tumor targeted delivery of paclitaxel.	Paclitaxel	114-124	albumin	Mus musculus	69-82
18452161-4	2008	Paclitaxel treatment not only activated calpain and caspase-4, but also induced a gradual increase in the cytosolic Ca(2+) concentration at 3-6 h. Paclitaxel-induced apoptosis can be inhibited by the calpain inhibitor calpeptin and IP(3) receptor inhibitors.	Paclitaxel	147-157	inositol 1,4,5-trisphosphate receptor type 3	Homo sapiens	232-246
18516296-2	2008	In this study, we investigate the potential use of a PPAR-gamma ligand, troglitazone (Tro), in combination with either of two chemotherapeutic agents, cisplatin (Cis) or paclitaxel (Pac), for the treatment of NSCLC.	Paclitaxel	182-185	peroxisome proliferator activated receptor gamma	Mus musculus	53-63
26699227-3	2016	Accordingly, a PTX-loaded nanosuspension based on human serum albumin (HSA) with PEG modifiers (PTX-PEG-HSA) has been developed to optimize the in-vivo biodistribution, pharmacokinetics and safety of PTX over traditional PTX-HSA nanosuspensions prepared using the accepted method for Abraxane .	Paclitaxel	15-18	albumin	Mus musculus	56-69
18483383-0	2008	A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.	Paclitaxel	85-90	nucleus accumbens associated 1	Homo sapiens	16-57
18483383-4	2008	SiRNA system and NAC-1 gene transfection were used to asses NAC-1 function in Taxol resistance in vivo.	Paclitaxel	78-83	nucleus accumbens associated 1	Homo sapiens	60-65
26878391-0	2016	MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression.	Paclitaxel	18-28	microRNA 125a	Homo sapiens	0-8
26878391-5	2016	We demonstrate that miR-125a was one of most significantly downregulated miRNAs in paclitaxel-resistant cells, which also acquired cisplatin resistance.	Paclitaxel	83-93	microRNA 125a	Homo sapiens	20-28
26878391-6	2016	And that the upregulation of miR-125a sensitized HeLa/PR and CaSki/PR cells to paclitaxel both in vitro and in vivo and to cisplatin in vitro.	Paclitaxel	79-89	microRNA 125a	Homo sapiens	29-37
18483383-8	2008	Overexpression of NAC-1 was observed in only the Taxol-resistant KF28TX and KFr13 TX cells but not in KF28 or cisplatin-resistant KFr13 cells.	Paclitaxel	49-54	nucleus accumbens associated 1	Homo sapiens	18-23
18483383-9	2008	To confirm that NAC-1 expression was related to Taxol resistance, we used two independent but complementary approaches.	Paclitaxel	48-53	nucleus accumbens associated 1	Homo sapiens	16-21
26878391-7	2016	Moreover, we determined that miR-125a increased paclitaxel and cisplatin sensitivity by downregulating STAT3.	Paclitaxel	48-58	microRNA 125a	Homo sapiens	29-37
18483383-10	2008	NAC-1 gene knockdown in both KF28TX and KFr13TX rescued paclitaxel sensitivity.	Paclitaxel	56-66	nucleus accumbens associated 1	Homo sapiens	0-5
18483383-11	2008	Additionally, engineered expression of NAC-1 in RK3E cells induced paclitaxel resistance.	Paclitaxel	67-77	nucleus accumbens associated 1	Rattus norvegicus	39-44
26878391-8	2016	MiR-125a enhanced paclitaxel and cisplatin sensitivity by promoting chemotherapy-induced apoptosis.	Paclitaxel	18-28	microRNA 125a	Homo sapiens	0-8
18483383-12	2008	CONCLUSIONS: These results suggest that NAC-1 regulates Taxol resistance in ovarian cancer and may provide an effective target for chemotherapeutic intervention in Taxol-resistant tumors.	Paclitaxel	56-61	nucleus accumbens associated 1	Homo sapiens	40-45
20145425-6	2010	The results showed that the decrease in VASP phosphorylation paralleled the inhibition of cAMP-dependent protein kinase (PKA) activity in the presence of paclitaxel (10 microg/l).	Paclitaxel	154-164	vasodilator stimulated phosphoprotein	Homo sapiens	40-44
20145425-9	2010	These data suggest that the inhibitory effect of paclitaxel may be produced by decreasing the phosphorylation of VASP via inhibition of PKA activity during ECV304 cell adhesion and migration.	Paclitaxel	49-59	vasodilator stimulated phosphoprotein	Homo sapiens	113-117
18483383-12	2008	CONCLUSIONS: These results suggest that NAC-1 regulates Taxol resistance in ovarian cancer and may provide an effective target for chemotherapeutic intervention in Taxol-resistant tumors.	Paclitaxel	164-169	nucleus accumbens associated 1	Homo sapiens	40-45
26878391-9	2016	Clinically, miR-125a expression was associated with an increased responsiveness to paclitaxel combined with cisplatin and a more favorable outcome.	Paclitaxel	83-93	microRNA 125a	Homo sapiens	12-20
26878391-10	2016	These data indicate that miR-125a may be a useful method to enable treatment of chemoresistant CC and may also provide a biomarker for predicting paclitaxel and cisplatin responsiveness in CC.	Paclitaxel	146-156	microRNA 125a	Homo sapiens	25-33
26838546-5	2016	Differences in the expression and activation of Aurora A and Plk1 between cells treated with paclitaxel/MWE and paclitaxel alone suggested that the combined treatment caused a defect in the early steps of cytokinesis.	Paclitaxel	93-103	aurora kinase A	Homo sapiens	48-56
18177856-2	2008	Here we tested the effects of structurally different clinically used microtubules-interfering agents (MIAs), such as colchicine, vincristine, vinblastine, nocodazole and taxol on aryl hydrocarbon receptor signaling pathway in human hepatocytes.	Paclitaxel	170-175	aryl hydrocarbon receptor	Homo sapiens	179-204
21113235-4	2009	Using genomic approaches, we have previously identified an association between a BTB/POZ gene, Nac1, and paclitaxel resistance in ovarian cancer.	Paclitaxel	105-115	nucleus accumbens associated 1	Homo sapiens	95-99
26573761-5	2016	Paclitaxel resistance was also studied after experimental downregulation of EP300 or E-cadherin.	Paclitaxel	0-10	E1A binding protein p300	Homo sapiens	76-81
19732951-3	2009	Recently we reported that the chemotherapeutic agent, paclitaxel (taxol) triggers mu-calpain dependent proteolysis of NCS-1, leading to reduced Ca(2+)-signaling within the cell.	Paclitaxel	54-64	neuronal calcium sensor 1	Homo sapiens	118-123
19732951-3	2009	Recently we reported that the chemotherapeutic agent, paclitaxel (taxol) triggers mu-calpain dependent proteolysis of NCS-1, leading to reduced Ca(2+)-signaling within the cell.	Paclitaxel	66-71	neuronal calcium sensor 1	Homo sapiens	118-123
19674193-8	2009	GRP78 knockdown or EGCG potentiates taxol- and vinblastine-induced activation of pro-apoptosis arms of the ER stress response, such as JNK phosphorylation, caspase-7 and PARP cleavage.	Paclitaxel	36-41	collagen type XI alpha 2 chain	Homo sapiens	170-174
26779808-6	2016	Importantly, the levels of oncoproteins phosphoinositide-3 kinase/Akt, mucin 1 cytoplasmic domain (MUC1-C) and beta-catenin were also significantly elevated in A549/PTX.	Paclitaxel	165-168	mucin 1, cell surface associated	Homo sapiens	71-78
19661300-10	2009	Both SB-T-1216 and paclitaxel activated caspase-3, caspase-9, caspase-2 and caspase-8 in sensitive as well as resistant cells.	Paclitaxel	19-29	caspase 8	Homo sapiens	76-85
20727268-5	2008	RESULTS: The resistance index of A549/Gem" to gemcitabine was 163.228, and the cell line also exhibited cross-resistance to vinorelbine, taxotere, fluorouraci, etoposide and cisplatin, but kept sensitivity to paclitaxol and oxaliplatin.	Paclitaxel	209-219	GTP binding protein overexpressed in skeletal muscle	Homo sapiens	38-41
20727268-9	2008	The resistance index of A549/Gem to gemcitabine was 129.783, and the cell line also held cross-resistance to vinorelbine, taxotere, etoposide, cisplatin and sensitivity to paclitaxol.	Paclitaxel	172-182	GTP binding protein overexpressed in skeletal muscle	Homo sapiens	29-32
18068334-9	2008	Our data provide evidence that taxol-induced mitochondrial stress occurs through the activation of both JNK and p38 pathways, and suggest a novel role for UCP2 in the modulation of taxol-induced apoptosis of melanoma cells.	Paclitaxel	181-186	uncoupling protein 2	Homo sapiens	155-159
26779808-6	2016	Importantly, the levels of oncoproteins phosphoinositide-3 kinase/Akt, mucin 1 cytoplasmic domain (MUC1-C) and beta-catenin were also significantly elevated in A549/PTX.	Paclitaxel	165-168	mucin 1, cell surface associated	Homo sapiens	99-103
19476987-7	2009	The effect of SNCG knockdown in SPEC2 cells on cell proliferation and sensitivity to paclitaxel-induced apoptosis was measured using a cell viability assay, BrdU incorporation assay, as well as cleaved PARP analyses.	Paclitaxel	85-95	synuclein gamma	Homo sapiens	14-18
19476987-11	2009	Knockdown of SNCG in SPEC2 cells caused a significant decrease in cell proliferation and increased sensitivity to paclitaxel-induced apoptosis.	Paclitaxel	114-124	synuclein gamma	Homo sapiens	13-17
18039807-6	2008	Compared with paclitaxel, the major hydroxylation site transferred from C6alpha to C4"", and the main metabolizing P450 changed from CYP2C8 to CYP3A4 for cephalomannine.	Paclitaxel	14-24	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	133-139
26779808-7	2016	Furthermore, nuclear translocation of MUC1-C and beta-catenin increased in A549/PTX.	Paclitaxel	80-83	mucin 1, cell surface associated	Homo sapiens	38-42
26779808-8	2016	The c-SRC protein, an activator of MUC1-C, was also overexpressed in A549/PTX.	Paclitaxel	74-77	mucin 1, cell surface associated	Homo sapiens	35-39
26779808-9	2016	These observations led to the hypothesis that enhanced expression of MUC1-C is associated with stemness and PTX resistance in NSCLCs.	Paclitaxel	108-111	mucin 1, cell surface associated	Homo sapiens	69-73
26779808-10	2016	To test this, we knocked down or overexpressed MUC1-C in A549/PTX and found that inhibition of MUC1-C expression coupled with PTX treatment was sufficient to reduce the sphere-forming ability and survival of A549/PTX.	Paclitaxel	62-65	mucin 1, cell surface associated	Homo sapiens	47-51
18681966-0	2008	Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity.	Paclitaxel	117-127	prolactin receptor	Homo sapiens	0-18
19509143-8	2009	CD133(+) cells purified from endometrioid adenocarcinomas were resistant to cisplatin-induced and paclitaxel-induced cytotoxicity and expressed a peculiar gene signature consisting of high levels of matrix metalloproteases, interleukin-8, CD44, and CXCR4.	Paclitaxel	98-108	prominin 1	Homo sapiens	0-5
26779808-10	2016	To test this, we knocked down or overexpressed MUC1-C in A549/PTX and found that inhibition of MUC1-C expression coupled with PTX treatment was sufficient to reduce the sphere-forming ability and survival of A549/PTX.	Paclitaxel	126-129	mucin 1, cell surface associated	Homo sapiens	47-51
26779808-10	2016	To test this, we knocked down or overexpressed MUC1-C in A549/PTX and found that inhibition of MUC1-C expression coupled with PTX treatment was sufficient to reduce the sphere-forming ability and survival of A549/PTX.	Paclitaxel	126-129	mucin 1, cell surface associated	Homo sapiens	47-51
26779808-11	2016	In summary, our in vitro and in vivo studies have revealed a potential mechanism of MUC1-C-mediated PTX resistance and provided insights into a novel therapeutic measure for lung cancers.	Paclitaxel	100-103	mucin 1, cell surface associated	Homo sapiens	84-88
27383277-0	2016	Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression.	Paclitaxel	28-38	Yes1 associated transcriptional regulator	Homo sapiens	61-64
19434475-3	2009	The same abundance was observed in the spindle of Taxol-treated brick1 mitotic protodermal cells.	Paclitaxel	50-55	protein BRICK1	Zea mays	64-70
17947357-6	2008	Moreover, treatment of mouse ovarian cancer cells with a combination of SP600125 and paclitaxel, an established chemotherapeutic agent used in the treatment of ovarian cancer, or with MIS enabled inhibition of cell proliferation at a lower dose than with each treatment alone.	Paclitaxel	85-95	anti-Mullerian hormone	Mus musculus	184-187
18097549-5	2008	PTX-GEM molecular interactions on the apoptotic markers PARP, Bcl-2 and Bax were analyzed by immunoblotting procedures.	Paclitaxel	0-3	collagen type XI alpha 2 chain	Homo sapiens	56-60
27383277-3	2016	Several factors including YAP over-expression can cause PTX resistance.	Paclitaxel	56-59	Yes1 associated transcriptional regulator	Homo sapiens	26-29
19500405-0	2009	Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.	Paclitaxel	0-10	deoxycytidine kinase	Homo sapiens	58-78
27383277-4	2016	In this study, we aimed to verify the role YAP plays in PTX resistance, explore the reversal of PTX resistance by verteporfin (VP) and investigate the effect of combination therapy of PTX and VP on the PTX resistant colon cancer cells (HCT-8/T).	Paclitaxel	56-59	Yes1 associated transcriptional regulator	Homo sapiens	43-46
19500405-0	2009	Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.	Paclitaxel	0-10	cytidine deaminase	Homo sapiens	83-101
19500405-2	2009	Therefore, we classified the drug-drug interaction and the effects of paclitaxel on deoxycytidine kinase (dCK) and cytidine deaminase (CDA) in three NSCLC cell lines.	Paclitaxel	70-80	deoxycytidine kinase	Homo sapiens	84-104
19500405-2	2009	Therefore, we classified the drug-drug interaction and the effects of paclitaxel on deoxycytidine kinase (dCK) and cytidine deaminase (CDA) in three NSCLC cell lines.	Paclitaxel	70-80	cytidine deaminase	Homo sapiens	115-133
19500405-2	2009	Therefore, we classified the drug-drug interaction and the effects of paclitaxel on deoxycytidine kinase (dCK) and cytidine deaminase (CDA) in three NSCLC cell lines.	Paclitaxel	70-80	cytidine deaminase	Homo sapiens	135-138
19500405-10	2009	Paclitaxel significantly decreased dCK and CDA mRNA levels in H460 and H520 cells (40% to 60%, P &lt; 0.05) and lowered dCK protein (24% to 56%, P &lt; 0.05) without affecting CDA protein.	Paclitaxel	0-10	cytidine deaminase	Homo sapiens	43-46
18974847-5	2008	We synthesized an AMF/PGI-paclitaxel conjugate and found it to be as efficient as free paclitaxel in inducing cytotoxicity and apoptosis in tumor cells that readily internalize AMF/PGI compared to tumor cells that poorly internalize AMF/PGI.	Paclitaxel	26-36	glucose-6-phosphate isomerase	Homo sapiens	22-25
19500405-10	2009	Paclitaxel significantly decreased dCK and CDA mRNA levels in H460 and H520 cells (40% to 60%, P &lt; 0.05) and lowered dCK protein (24% to 56%, P &lt; 0.05) without affecting CDA protein.	Paclitaxel	0-10	cytidine deaminase	Homo sapiens	176-179
27383277-9	2016	RESULTS: YAP was stronger expressed in HCT-8/T than in HCT-8, and PTX resistance was positively correlated with the level of YAP expression.	Paclitaxel	66-69	Yes1 associated transcriptional regulator	Homo sapiens	125-128
27383277-10	2016	VP, a strongly YAP inhibitor, could reduce the PTX resistance on HCT-8/T cells without light activation by inhibiting YAP.	Paclitaxel	47-50	Yes1 associated transcriptional regulator	Homo sapiens	118-121
27383277-11	2016	Beside, VP and PTX combination therapy showed synergism on inhibition of YAP and cytotoxicity to HCT-8/T.	Paclitaxel	15-18	Yes1 associated transcriptional regulator	Homo sapiens	73-76
18974847-5	2008	We synthesized an AMF/PGI-paclitaxel conjugate and found it to be as efficient as free paclitaxel in inducing cytotoxicity and apoptosis in tumor cells that readily internalize AMF/PGI compared to tumor cells that poorly internalize AMF/PGI.	Paclitaxel	26-36	glucose-6-phosphate isomerase	Homo sapiens	181-184
18974847-5	2008	We synthesized an AMF/PGI-paclitaxel conjugate and found it to be as efficient as free paclitaxel in inducing cytotoxicity and apoptosis in tumor cells that readily internalize AMF/PGI compared to tumor cells that poorly internalize AMF/PGI.	Paclitaxel	26-36	glucose-6-phosphate isomerase	Homo sapiens	181-184
27383277-13	2016	CONCLUSIONS: VP can reverse the PTX resistance induced by YAP over-expression in HCT-8/T cells without photoactivation through inhibiting YAP expression.	Paclitaxel	32-35	Yes1 associated transcriptional regulator	Homo sapiens	58-61
19122647-0	2009	Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells.	Paclitaxel	103-113	tubulin beta 3 class III	Homo sapiens	8-30
27095936-0	2016	Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel.	Paclitaxel	120-130	cyclin D1	Homo sapiens	17-22
19122647-8	2009	TUBB3 protein expression correlated well with chemosensitivity to paclitaxel-induced apoptosis (P&lt;0.05).	Paclitaxel	66-76	tubulin beta 3 class III	Homo sapiens	0-5
27095936-3	2016	In this study, we aimed to investigate the effects of everolimus, gemcitabine, and paclitaxel in terms of cell viability and mRNA expression levels of GRP78, CCND1, CASP2, and BCL2 genes.	Paclitaxel	83-93	cyclin D1	Homo sapiens	158-163
18163013-0	2007	B-type natriuretic peptide as a marker of asymptomatic re-stenosis after coronary implantation of a paclitaxel-eluting stent.	Paclitaxel	100-110	natriuretic peptide B	Homo sapiens	0-26
26356996-0	2015	Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells.	Paclitaxel	14-24	microRNA 143	Homo sapiens	57-64
26356996-8	2015	According to our data, cisplatin and paclitaxel strongly decreased T24 cells" viability, showing in parallel the ability to significantly down-regulate miR-143 levels, and up-regulate the expression levels of miR-145, miR-183, miR-96, and miR-182, which, in their total, demonstrated case-specific variations after recovery period.	Paclitaxel	37-47	microRNA 143	Homo sapiens	152-159
18977553-0	2009	Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.	Paclitaxel	115-125	tubulin beta 3 class III	Homo sapiens	24-46
26585835-0	2015	Corrigendum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.	Paclitaxel	98-108	interleukin 1 receptor associated kinase 1	Homo sapiens	13-18
18977553-11	2009	This retrospective study indicates that immunostaining for ERCC1 and class III beta-tubulin may be useful for predicting survival in NSCLC patients receiving carboplatin and paclitaxel against recurrent tumors after curative resection and can provide information critical for planning personalized chemotherapy.	Paclitaxel	174-184	tubulin beta 3 class III	Homo sapiens	69-91
17982636-5	2007	The shRNAs targeting SMAD4, LZTS2, ST14 and VHL all increased the cell"s sensitivity to paclitaxel.	Paclitaxel	88-98	SMAD family member 4	Homo sapiens	21-26
26567528-0	2015	Improved anti-glioblastoma efficacy by IL-13Ralpha2 mediated copolymer nanoparticles loaded with paclitaxel.	Paclitaxel	97-107	interleukin 13 receptor subunit alpha 2	Homo sapiens	39-51
17855368-5	2007	In addition, we also demonstrated that the physical interaction between Id-1 and Cav-1 played a key role in the epithelial-mesenchymal transition and increased cell migration rate as well as resistance to taxol-induced apoptosis in prostate cancer cells.	Paclitaxel	205-210	inhibitor of DNA binding 1, HLH protein	Homo sapiens	72-76
17701008-4	2007	The effects of patient characteristics, including single-nucleotide polymorphisms of MDR1(ABCB1), CYP2C8, CYP3A4, and CYP3A5, on the total body clearance of paclitaxel were evaluated.	Paclitaxel	157-167	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	98-104
19305429-0	2009	NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway.	Paclitaxel	65-75	nucleus accumbens associated 1	Homo sapiens	0-5
19305429-3	2009	We have assessed this possibility and shown a correlation between NAC-1 expression and ex vivo paclitaxel resistance in ovarian serous carcinoma tissues and cell lines.	Paclitaxel	95-105	nucleus accumbens associated 1	Homo sapiens	66-71
19305429-4	2009	We found that expression of Gadd45-gamma-interacting protein 1 (Gadd45gip1), a downstream target negatively regulated by NAC-1, was reduced in paclitaxel-resistant cells.	Paclitaxel	143-153	GADD45G interacting protein 1	Homo sapiens	28-62
19305429-4	2009	We found that expression of Gadd45-gamma-interacting protein 1 (Gadd45gip1), a downstream target negatively regulated by NAC-1, was reduced in paclitaxel-resistant cells.	Paclitaxel	143-153	GADD45G interacting protein 1	Homo sapiens	64-74
19305429-4	2009	We found that expression of Gadd45-gamma-interacting protein 1 (Gadd45gip1), a downstream target negatively regulated by NAC-1, was reduced in paclitaxel-resistant cells.	Paclitaxel	143-153	nucleus accumbens associated 1	Homo sapiens	121-126
19305429-5	2009	Ectopic expression of NAC-1 or knockdown of Gadd45gip1 conferred paclitaxel resistance, whereas NAC-1 knockdown or ectopic expression of Gadd45gip1 increased paclitaxel sensitivity.	Paclitaxel	65-75	nucleus accumbens associated 1	Homo sapiens	22-27
19305429-5	2009	Ectopic expression of NAC-1 or knockdown of Gadd45gip1 conferred paclitaxel resistance, whereas NAC-1 knockdown or ectopic expression of Gadd45gip1 increased paclitaxel sensitivity.	Paclitaxel	158-168	GADD45G interacting protein 1	Homo sapiens	137-147
19305429-8	2009	Thus, this study provides new evidence that NAC-1 upregulation and homodimerization contribute to tumor recurrence by equipping ovarian cancer cells with the paclitaxel-resistant phenotype through negative regulation of the Gadd45 pathway.	Paclitaxel	158-168	nucleus accumbens associated 1	Homo sapiens	44-49
17634533-7	2007	Moreover, AURKA overexpression was associated with improved overall survival in optimal debulked patients receiving taxol/carboplatin therapy (n=43, P=0.018).	Paclitaxel	116-121	aurora kinase A	Homo sapiens	10-15
26422373-0	2015	Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers.	Paclitaxel	31-41	albumin	Mus musculus	51-64
19318582-7	2009	Moreover, PDCD4-overexpressing cells are sensitive to cisplatin and paclitaxel but not to etoposide or 5-fluorouracil.	Paclitaxel	68-78	programmed cell death 4	Homo sapiens	10-15
19714814-6	2009	ERp57 was found to interact with class III beta-tubulin (TUBB3), involved in paclitaxel resistance in ovarian and other cancers.	Paclitaxel	77-87	tubulin beta 3 class III	Homo sapiens	57-62
19714814-8	2009	Our data suggest that ERp57 plays an important role in chemoresistance mechanisms in ovarian cancer by modulating the attachment of microtubules to chromosomes following paclitaxel treatment through its interaction with TUBB3.	Paclitaxel	170-180	tubulin beta 3 class III	Homo sapiens	220-225
26422373-1	2015	In our study, we aimed to develop a codelivery nanoparticulate system of pirarubicin (THP) and paclitaxel (PTX) (Co-AN) using human serum albumin to improve the therapeutic effect and reduce systemic toxicities.	Paclitaxel	95-105	albumin	Mus musculus	132-145
19143748-1	2009	The purpose of this study was to evaluate the role of sequence variants in the CYP2C8, ABCB1 and CYP3A4 genes and the CYP3A4 phenotype for the pharmacokinetics and toxicity of paclitaxel in ovarian cancer patients.	Paclitaxel	176-186	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	79-85
19143748-7	2009	A lower clearance of paclitaxel was found for patients heterozygous for CYP2C8*3 when stratified according to the ABCB1 G2677T/A genotype.	Paclitaxel	21-31	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	72-78
17174526-6	2007	The data show that paclitaxel treatment induces mRNA expression of IL-1, TNF, and immune cell markers in lumbar DRG.	Paclitaxel	19-29	tumor necrosis factor-like	Rattus norvegicus	73-76
26422373-1	2015	In our study, we aimed to develop a codelivery nanoparticulate system of pirarubicin (THP) and paclitaxel (PTX) (Co-AN) using human serum albumin to improve the therapeutic effect and reduce systemic toxicities.	Paclitaxel	107-110	albumin	Mus musculus	132-145
17174526-8	2007	Moreover, IL-10 gene therapy resulted in increased IL-10 mRNA levels in lumbar DRG and meninges, measured 2 weeks after initiation of therapy, whereas paclitaxel-induced expression of IL-1, TNF, and CD11b mRNA in lumbar DRG was markedly decreased.	Paclitaxel	151-161	tumor necrosis factor-like	Rattus norvegicus	190-193
19143748-10	2009	Our findings suggest that interindividual variability in paclitaxel pharmacokinetics might be predicted by ABCB1 and CYP2C8 genotypes and provide useful information for individualized chemotherapy.	Paclitaxel	57-67	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	117-123
25812766-8	2015	In this paper, we investigated the ability of a combination of the cytotoxic drug paclitaxel plus carbachol, a cholinergic agonist, at low doses, to induce death in breast tumor MCF-7 cells, via mAChR activation, and the role of nitric oxide synthase (NOS) and arginase in this effect.	Paclitaxel	82-92	nitric oxide synthase 1	Homo sapiens	229-250
19052873-2	2009	Apoptosis gene microarray analysis demonstrated that GADD45alpha was significantly induced in U-2 OS cells after exposure to paclitaxel (P &lt; 0.0001).	Paclitaxel	125-135	growth arrest and DNA damage inducible alpha	Homo sapiens	53-64
19052873-4	2009	Subsequent analysis by Western blot confirmed that the expression of GADD45alpha could be significantly induced by paclitaxel and doxorubicin in U-2 OS cells but not in U-2 OS MR cells.	Paclitaxel	115-125	growth arrest and DNA damage inducible alpha	Homo sapiens	69-80
17620430-6	2007	The combination of ZD4054 and paclitaxel led to the potentiation of all these effects, indicating that ZD4054, by blocking the ET(A)R-dependent proliferative, invasive, and antiapoptotic signals, can enhance sensitivity to paclitaxel.	Paclitaxel	30-40	endothelin receptor type A	Homo sapiens	127-133
26640594-4	2015	Either hTERT siRNA or BIBR1532 in combination with paclitaxel promoted a synergistic inhibitory effect on cell growth through induction of Annexin V expression and a remarkable reduction in cell invasion through reduction of protein expression of MMP9, MMP2, and MMP3.	Paclitaxel	51-61	matrix metallopeptidase 2	Homo sapiens	253-257
17267149-1	2007	As many anticancer agents paclitaxel is a substrate for ATP-binding cassette (ABC) transporters such as P-glycoprotein-mediated efflux, and its metabolism in humans mainly catalyzed by CYP 3A4 and 2C8.	Paclitaxel	26-36	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	56-76
17267149-1	2007	As many anticancer agents paclitaxel is a substrate for ATP-binding cassette (ABC) transporters such as P-glycoprotein-mediated efflux, and its metabolism in humans mainly catalyzed by CYP 3A4 and 2C8.	Paclitaxel	26-36	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	78-81
19287064-1	2009	BACKGROUND &amp; OBJECTIVE: Expression of class III beta-tubulin represents newly discovered marker of resistance to taxol-based chemotherapy in a wide spectra of carcinomas.	Paclitaxel	117-122	tubulin beta 3 class III	Homo sapiens	42-64
19287064-3	2009	This study was done to determine class III beta-tubulin expression in a large series of colonic carcinomas, covering tumours with different degree of differentiation in order to evaluate its prospective significance in resistance to taxol-based chemotherapeutics and to compare the immunostaining profile of two widely used monoclonal antibodies, TU-20 and TuJ-1 METHODS: Sixty patients with colorectal carcinoma were enrolled; all of them were treated surgically by the resection.	Paclitaxel	233-238	tubulin beta 3 class III	Homo sapiens	33-55
26500892-1	2015	BACKGROUND: The miR-17-5p was overexpressed in ovarian cancer cells, and those cells were treated with paclitaxel.	Paclitaxel	103-113	microRNA 17	Homo sapiens	16-25
19077237-4	2008	Recent data has shown that overexpression of Aurora-A can confer resistance to the taxane paclitaxel.	Paclitaxel	90-100	aurora kinase A	Homo sapiens	45-53
17591831-6	2007	With regard to the predictive role of Aurora-A, it has been shown that its overexpression disrupts the spindle checkpoint activated by paclitaxel (Taxol) or nocodazole treatment, thus inducing the cells to become resistant to these drugs.	Paclitaxel	135-145	aurora kinase A	Homo sapiens	38-46
17591831-6	2007	With regard to the predictive role of Aurora-A, it has been shown that its overexpression disrupts the spindle checkpoint activated by paclitaxel (Taxol) or nocodazole treatment, thus inducing the cells to become resistant to these drugs.	Paclitaxel	147-152	aurora kinase A	Homo sapiens	38-46
17591831-7	2007	The development therefore of small molecules with an Aurora-A inhibition function may make it possible to reduce or block the oncogenic activity of Aurora-A and in addition may improve the survival of oncological patients showing resistance to paclitaxel or nocodazole treatment.	Paclitaxel	244-254	aurora kinase A	Homo sapiens	53-61
18395930-3	2008	We also examined class III beta-tubulin protein expression in 50 patients treated with a platinum-based drug plus paclitaxel.	Paclitaxel	114-124	tubulin beta 3 class III	Homo sapiens	17-39
18395930-6	2008	Among 50 patients treated with a platinum-based drug plus paclitaxel, loss of class III beta-tubulin protein expression was also associated with a better prognosis (p=0.0303).	Paclitaxel	58-68	tubulin beta 3 class III	Homo sapiens	78-100
26500892-3	2015	The Caspase-Glo3/7 and TUNEL assay were used to examine the effect of miR-17-5p on paclitaxel-induced apoptosis in ovarian cancer cells.	Paclitaxel	83-93	microRNA 17	Homo sapiens	70-79
26356819-9	2015	Induction of microtubule stability, through Stathmin 1 silencing or paclitaxel treatment, combined with ruxolitinib could be an effective strategy for promoting apoptosis in JAK2(V617F) cells.	Paclitaxel	68-78	Janus kinase 2	Homo sapiens	174-178
18270979-8	2008	Second, p-MEK1/2 was localized to the centers of cytoplasmic microtubule asters induced by taxol.	Paclitaxel	91-96	mitogen activated protein kinase kinase 1	Rattus norvegicus	10-16
18852119-3	2008	Knockdown of AF1q decreased the apoptosis induced by doxorubicin, Taxol, gamma-radiation, IFN-alpha, and IFN-gamma in A431 cells.	Paclitaxel	66-71	MLLT11 transcription factor 7 cofactor	Homo sapiens	13-17
17487377-6	2007	Cytokeratin-8, keratin-19, Hsp-27, 14-3-3 epsilon, annexin-A2 and phosphoglycerate kinase-1 showed altered expression in both adriamycin- and paclitaxel-resistant cells.	Paclitaxel	142-152	keratin 19	Homo sapiens	15-25
17230521-5	2007	By comparison of the parental HNE1 and its derivative HNE1-T3 cell lines, we found that the resistance to taxol in HNE1-T3 cells was associated with suppression of taxol-induced apoptosis evidenced by decreased expression of Bak and Bax and increased Bcl-2, as well as inhibition of PARP and caspase cleavage and DNA ladder formation.	Paclitaxel	106-111	collagen type XI alpha 2 chain	Homo sapiens	283-287
17230521-5	2007	By comparison of the parental HNE1 and its derivative HNE1-T3 cell lines, we found that the resistance to taxol in HNE1-T3 cells was associated with suppression of taxol-induced apoptosis evidenced by decreased expression of Bak and Bax and increased Bcl-2, as well as inhibition of PARP and caspase cleavage and DNA ladder formation.	Paclitaxel	164-169	collagen type XI alpha 2 chain	Homo sapiens	283-287
26206775-2	2015	Our laboratory has previously identified that RhoB upregulation serves as a novel molecular therapeutic target and agents upregulating RhoB combined with paclitaxel lead to antitumor synergy.	Paclitaxel	154-164	ras homolog family member B	Homo sapiens	46-50
18714397-8	2008	Finally, using size exclusion chromatography and fluorescently labeled paclitaxel, we demonstrated that clusterin binds to paclitaxel.	Paclitaxel	123-133	clusterin	Homo sapiens	104-113
18714397-9	2008	In summary, our findings suggest that high levels of clusterin expression increase paclitaxel resistance in ovarian cancer cells by physically binding to paclitaxel, which may prevent paclitaxel from interacting with microtubules to induce apoptosis.	Paclitaxel	83-93	clusterin	Homo sapiens	53-62
18714397-9	2008	In summary, our findings suggest that high levels of clusterin expression increase paclitaxel resistance in ovarian cancer cells by physically binding to paclitaxel, which may prevent paclitaxel from interacting with microtubules to induce apoptosis.	Paclitaxel	154-164	clusterin	Homo sapiens	53-62
18714397-9	2008	In summary, our findings suggest that high levels of clusterin expression increase paclitaxel resistance in ovarian cancer cells by physically binding to paclitaxel, which may prevent paclitaxel from interacting with microtubules to induce apoptosis.	Paclitaxel	154-164	clusterin	Homo sapiens	53-62
17429319-4	2007	Instead, as shown using a mammalian two-hybrid assay, it decreased the interaction of pregnane X receptor with steroid receptor coactivator-1 in the presence of rifampin, clotrimazole, paclitaxel, or nifedipine but not in their absence.	Paclitaxel	185-195	nuclear receptor coactivator 1	Homo sapiens	111-141
26206775-8	2015	Combinatorial synergy with paclitaxel is dependent upon RhoB and BIMEL while upregulation of RhoB and only p21 blocks synergy.	Paclitaxel	27-37	ras homolog family member B	Homo sapiens	56-60
26206775-10	2015	This study intimates that the combination of belinostat/vorinostat with paclitaxel may prove to be an effective therapeutic strategy via the novel observation that class II/(I) HDACi antagonize HDAC6-mediated suppression of RhoB and subsequent BIMEL, thereby promoting antitumor synergy.	Paclitaxel	72-82	ras homolog family member B	Homo sapiens	224-228
25988668-5	2015	Increased levels of CXCR2, CXCR4, S1P/S1PR1, PlGF and PDGF-BB were identified in the serum or primary tumour tissues of tumour-bearing mice treated by paclitaxel.	Paclitaxel	151-161	placental growth factor	Mus musculus	45-49
17482960-8	2007	CONCLUSIONS: DAC and PTX caused synergistic growth suppression of RCC, suggesting that DAC could strikingly increase the susceptibility of RCC to PTX and that combination chemotherapy with DAC and PTX might be a novel strategy to improve the clinical response rate of RCC.	Paclitaxel	21-24	arylacetamide deacetylase	Homo sapiens	87-90
17482960-8	2007	CONCLUSIONS: DAC and PTX caused synergistic growth suppression of RCC, suggesting that DAC could strikingly increase the susceptibility of RCC to PTX and that combination chemotherapy with DAC and PTX might be a novel strategy to improve the clinical response rate of RCC.	Paclitaxel	21-24	arylacetamide deacetylase	Homo sapiens	87-90
17482960-8	2007	CONCLUSIONS: DAC and PTX caused synergistic growth suppression of RCC, suggesting that DAC could strikingly increase the susceptibility of RCC to PTX and that combination chemotherapy with DAC and PTX might be a novel strategy to improve the clinical response rate of RCC.	Paclitaxel	146-149	arylacetamide deacetylase	Homo sapiens	13-16
17482960-8	2007	CONCLUSIONS: DAC and PTX caused synergistic growth suppression of RCC, suggesting that DAC could strikingly increase the susceptibility of RCC to PTX and that combination chemotherapy with DAC and PTX might be a novel strategy to improve the clinical response rate of RCC.	Paclitaxel	146-149	arylacetamide deacetylase	Homo sapiens	87-90
17482960-8	2007	CONCLUSIONS: DAC and PTX caused synergistic growth suppression of RCC, suggesting that DAC could strikingly increase the susceptibility of RCC to PTX and that combination chemotherapy with DAC and PTX might be a novel strategy to improve the clinical response rate of RCC.	Paclitaxel	146-149	arylacetamide deacetylase	Homo sapiens	87-90
17482960-8	2007	CONCLUSIONS: DAC and PTX caused synergistic growth suppression of RCC, suggesting that DAC could strikingly increase the susceptibility of RCC to PTX and that combination chemotherapy with DAC and PTX might be a novel strategy to improve the clinical response rate of RCC.	Paclitaxel	146-149	arylacetamide deacetylase	Homo sapiens	13-16
17482960-8	2007	CONCLUSIONS: DAC and PTX caused synergistic growth suppression of RCC, suggesting that DAC could strikingly increase the susceptibility of RCC to PTX and that combination chemotherapy with DAC and PTX might be a novel strategy to improve the clinical response rate of RCC.	Paclitaxel	146-149	arylacetamide deacetylase	Homo sapiens	87-90
17482960-8	2007	CONCLUSIONS: DAC and PTX caused synergistic growth suppression of RCC, suggesting that DAC could strikingly increase the susceptibility of RCC to PTX and that combination chemotherapy with DAC and PTX might be a novel strategy to improve the clinical response rate of RCC.	Paclitaxel	146-149	arylacetamide deacetylase	Homo sapiens	87-90
17923851-0	2008	Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism.	Paclitaxel	70-80	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	26-32
17923851-3	2008	Two novel CYP2C8 haplotypes, named B and C with frequencies of 24 and 22% in Caucasians, respectively, were identified and caused a significantly increased and reduced paclitaxel 6alpha-hydroxylation, respectively, as evident from analyses of 49 human liver samples.	Paclitaxel	168-178	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	10-16
18593940-6	2008	An unbiased approach consisting of RNA interference and high content analysis was used to show that amplification and concomitant overexpression of the gene encoding the ABCC3 drug transporter is responsible for conferring in vitro resistance to paclitaxel and MMAE.	Paclitaxel	246-256	ATP binding cassette subfamily C member 3	Homo sapiens	170-175
18597657-5	2008	Marsh and colleagues analyzed the CYP1B1*3 (Val432Leu) polymorphism in patients with high-risk stage III and IV breast cancer, who received dose-intense paclitaxel in combination with doxorubicin and cyclophosphamide.	Paclitaxel	153-163	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	34-40
18597657-7	2008	If confirmed in independent cohorts CYP1B1*3 may prove to be an important factor that helps to differentiate between paclitaxel-sensitive and resistant breast cancer patients.	Paclitaxel	117-127	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	36-42
18597657-8	2008	However, the mechanism behind the association between CYP1B1*3 and prognosis of paclitaxel-treated patients remains unclear.	Paclitaxel	80-90	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	54-60
18597657-11	2008	Although still speculative, a possible explanation is an association between CYP1B1*3 with still unknown factors that, on their part, influence paclitaxel sensitivity.	Paclitaxel	144-154	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	77-83
26074357-8	2015	RESULTS: The expression of miR-130a was down-regulated in all paclitaxel-resistant cell lines compared with parental PC-3 cells.	Paclitaxel	62-72	microRNA 130a	Homo sapiens	27-35
18403640-7	2008	In addition, knockdown of PI3K-C2alpha to levels that by themselves do not induce apoptosis sensitize cells to the anticancer agent Taxol (paclitaxel).	Paclitaxel	132-137	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	Homo sapiens	26-38
18403640-7	2008	In addition, knockdown of PI3K-C2alpha to levels that by themselves do not induce apoptosis sensitize cells to the anticancer agent Taxol (paclitaxel).	Paclitaxel	139-149	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	Homo sapiens	26-38
17404103-2	2007	We recently showed that, in vitro, hepatocyte growth factor (HGF) enhances death of human ovarian cancer cell lines treated with cisplatin (CDDP) and paclitaxel.	Paclitaxel	150-160	hepatocyte growth factor	Homo sapiens	35-59
17404103-2	2007	We recently showed that, in vitro, hepatocyte growth factor (HGF) enhances death of human ovarian cancer cell lines treated with cisplatin (CDDP) and paclitaxel.	Paclitaxel	150-160	hepatocyte growth factor	Homo sapiens	61-64
17404103-5	2007	In vitro, we assayed growth, motility, invasiveness, and the response to CDDP and paclitaxel of the HGF-secreting bulk unselected cell populations.	Paclitaxel	82-92	hepatocyte growth factor	Homo sapiens	100-103
17404103-10	2007	RESULTS: In vitro, HGF-secreting cells did not show altered proliferation rates and survival but were strongly sensitized to the death triggered by CDDP and paclitaxel, alone or in combination.	Paclitaxel	157-167	hepatocyte growth factor	Homo sapiens	19-22
26074357-10	2015	Transfection of a miR-130a precursor into a paclitaxel-resistant cell line suppressed cell growth and increased the sensitivity to paclitaxel.	Paclitaxel	44-54	microRNA 130a	Homo sapiens	18-26
26074357-10	2015	Transfection of a miR-130a precursor into a paclitaxel-resistant cell line suppressed cell growth and increased the sensitivity to paclitaxel.	Paclitaxel	131-141	microRNA 130a	Homo sapiens	18-26
26074357-12	2015	CONCLUSIONS: Our results suggested that reduced expression of miR-130a may be involved in the paclitaxel-resistance and that miR-130a could be a therapeutic target for taxane-resistant prostate cancer patients.	Paclitaxel	94-104	microRNA 130a	Homo sapiens	62-70
18505052-0	2008	Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site.	Paclitaxel	94-104	tubulin beta 3 class III	Homo sapiens	21-43
18505052-7	2008	CONCLUSION: These findings show that in tumor cells a high level of expression of class III beta-tubulin, but not Delta2-alpha-tubulin or tau, is associated with resistance to paclitaxel and a poor prognosis in CUP patients receiving paclitaxel.	Paclitaxel	176-186	tubulin beta 3 class III	Homo sapiens	82-104
17363484-6	2007	The synergistic activity of MCP110 and paclitaxel was further established by experiments showing that in Kaposi"s sarcoma oncogenically transformed cell lines, cellular models for tumors treated with taxanes in the clinic and in which Raf-dependent signaling plays an important role, MCP110 synergizes with paclitaxel and limit growth.	Paclitaxel	39-49	zinc fingers and homeoboxes 2	Homo sapiens	235-238
26246468-8	2015	In ovo, PAR-4 decreases ovarian tumour development and increases the response to taxol treatment.	Paclitaxel	81-86	pro-apoptotic WT1 regulator	Homo sapiens	8-13
16581180-8	2007	Functionally, ET-1 significantly inhibited paclitaxel-induced apoptosis in RCC cells through binding ET(A) with the ET-1 signaling mediated via the PI3-kinase/Akt pathway.	Paclitaxel	43-53	endothelin receptor type A	Homo sapiens	101-106
18505052-7	2008	CONCLUSION: These findings show that in tumor cells a high level of expression of class III beta-tubulin, but not Delta2-alpha-tubulin or tau, is associated with resistance to paclitaxel and a poor prognosis in CUP patients receiving paclitaxel.	Paclitaxel	234-244	tubulin beta 3 class III	Homo sapiens	82-104
18506998-11	2008	Immunohistochemical staining showed increased expression of p65 after paclitaxel treatment, while paclitaxel in combination with AdIkappaBalpha intratumoral injection eliminated this expression accompanied by the slightly reduced expression of VEGF, with stable p53 status.	Paclitaxel	70-80	RELA proto-oncogene, NF-kB subunit	Homo sapiens	60-63
26118539-3	2015	By employing a biocompatible condensation reaction, we rationally designed a taxol derivative Ac-Arg-Val-Arg-Arg-Cys(StBu)-Lys(taxol)-2-cyanobenzothiazole (CBT-Taxol) which could be subjected to furin-controlled condensation and self-assembly of taxol nanoparticles (Taxol-NPs).	Paclitaxel	77-82	furin, paired basic amino acid cleaving enzyme	Homo sapiens	195-200
18237851-3	2008	Two studies have shown patients with advanced non-small-cell lung cancer receiving paclitaxel whose tumours expressed high levels of class III beta-tubulin had a lower response to paclitaxel and shorter survival, whereas this variable was not found to be predictive in patients receiving regimens without tubulin-binding agents.	Paclitaxel	83-93	tubulin beta 3 class III	Homo sapiens	133-155
18237851-3	2008	Two studies have shown patients with advanced non-small-cell lung cancer receiving paclitaxel whose tumours expressed high levels of class III beta-tubulin had a lower response to paclitaxel and shorter survival, whereas this variable was not found to be predictive in patients receiving regimens without tubulin-binding agents.	Paclitaxel	180-190	tubulin beta 3 class III	Homo sapiens	133-155
17211474-0	2007	Role of the progesterone receptor for paclitaxel resistance in primary breast cancer.	Paclitaxel	38-48	progesterone receptor	Homo sapiens	12-33
17211474-7	2007	We observed a clear association of the PR status with chemosensitivity to paclitaxel.	Paclitaxel	74-84	progesterone receptor	Homo sapiens	39-41
17211474-9	2007	Similarly, high levels of PR mRNA expression were associated with decreased paclitaxel chemosensitivity (P=0.007).	Paclitaxel	76-86	progesterone receptor	Homo sapiens	26-28
17211474-11	2007	Multiple regression analysis identified PR receptor status and T-stage as independent predictors of paclitaxel chemosensitivity, whereas the ER, N-stage, grading and age were not influential.	Paclitaxel	100-110	progesterone receptor	Homo sapiens	40-42
17211474-12	2007	In conclusion, in vitro sensitivity to paclitaxel was higher for PR-negative compared with PR-positive breast carcinoma cells.	Paclitaxel	39-49	progesterone receptor	Homo sapiens	65-67
17211474-12	2007	In conclusion, in vitro sensitivity to paclitaxel was higher for PR-negative compared with PR-positive breast carcinoma cells.	Paclitaxel	39-49	progesterone receptor	Homo sapiens	91-93
17979224-7	2007	Binding affinity of paclitaxel against the partial recombinant protein of NFX1 (424aa-876aa) was confirmed by pull-down assays and surface plasmon resonance analyses.	Paclitaxel	20-30	nuclear transcription factor, X-box binding 1	Homo sapiens	74-78
26118539-3	2015	By employing a biocompatible condensation reaction, we rationally designed a taxol derivative Ac-Arg-Val-Arg-Arg-Cys(StBu)-Lys(taxol)-2-cyanobenzothiazole (CBT-Taxol) which could be subjected to furin-controlled condensation and self-assembly of taxol nanoparticles (Taxol-NPs).	Paclitaxel	127-132	furin, paired basic amino acid cleaving enzyme	Homo sapiens	195-200
26118539-3	2015	By employing a biocompatible condensation reaction, we rationally designed a taxol derivative Ac-Arg-Val-Arg-Arg-Cys(StBu)-Lys(taxol)-2-cyanobenzothiazole (CBT-Taxol) which could be subjected to furin-controlled condensation and self-assembly of taxol nanoparticles (Taxol-NPs).	Paclitaxel	127-132	furin, paired basic amino acid cleaving enzyme	Homo sapiens	195-200
17709370-8	2007	Both DMSO and ethanol increased the Km and decreased the CL(int) of CYP2C8-mediated paclitaxel hydroxylation in a concentration-dependent manner.	Paclitaxel	84-94	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	68-74
26071354-6	2015	miR-101 expression increased the in vitro anti-CRC activity of conventional chemo-agents: paclitaxel and doxorubicin.	Paclitaxel	90-100	microRNA 101a	Mus musculus	0-7
17224914-8	2007	Alternatively, the role of CYP1B1 in estrogen metabolism may influence the risk of invasive or paclitaxel resistant breast cancer in patients carrying the CYP1B1*3 allele.	Paclitaxel	95-105	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	27-33
17224914-8	2007	Alternatively, the role of CYP1B1 in estrogen metabolism may influence the risk of invasive or paclitaxel resistant breast cancer in patients carrying the CYP1B1*3 allele.	Paclitaxel	95-105	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	155-161
17106249-8	2006	In mice with orthotopic ovarian tumors, treatment with combined paclitaxel and IP EphA2-targeting siRNA-DOPC reduced tumor growth by 48-81% compared to paclitaxel/control siRNA-DOPC IP (HeyA8: 0.34 g v 0.66 g; SKOV3ip1: 0.04 v 0.21, p&lt;0.01).	Paclitaxel	152-162	Eph receptor A2	Mus musculus	82-87
17106249-9	2006	This reduction was comparable to concurrently-treated mice with paclitaxel and EphA2 siRNA-DOPC injected IV, which showed a reduction in growth by 45-69% compared to paclitaxel/control siRNA-DOPC injected IV (HeyA8: 0.23g v. 0.42g; SKOV3ip1: 0.04 v. 0.13 g).	Paclitaxel	166-176	Eph receptor A2	Mus musculus	79-84
26071354-9	2015	Further, miR-101 enhanced paclitaxel-induced anti-HCT-116 activity in vivo.	Paclitaxel	26-36	microRNA 101a	Mus musculus	9-16
26033570-9	2015	The downregulation of mimitin and 14-3-3 zeta/delta using specific siRNA in paclitaxel-resistant ovarian cancer cells led to an increase in the resistance index to paclitaxel.	Paclitaxel	76-86	NADH:ubiquinone oxidoreductase complex assembly factor 2	Homo sapiens	22-45
17148761-4	2006	Paclitaxel significantly increased in vivo expression of TRAIL-R1 and TRAIL-R2 in a time-dependent manner.	Paclitaxel	0-10	TNF receptor superfamily member 10a	Homo sapiens	57-65
17148761-5	2006	The imaging results were confirmed by immunoblots for steady-state protein levels (&gt;20-fold increase in TRAIL-R1 and TRAIL-R2 levels in tumor xenografts by 48 h after paclitaxel administration).	Paclitaxel	170-180	TNF receptor superfamily member 10a	Homo sapiens	107-115
17917407-7	2007	Caspase-3 and TUNEL assay to detect apoptosis in vitro demonstrated that paclitaxel or ATII alone significantly enhanced and their combination further accelerated cardiomyocyte apoptosis, which was again significantly inhibited by colchicine.	Paclitaxel	73-83	caspase 3	Rattus norvegicus	0-9
17652710-0	2007	Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine transgenic model of retinoblastoma.	Paclitaxel	0-10	temporal alpha-galactosidase	Mus musculus	57-60
17652710-1	2007	PURPOSE: The purpose of this study was to investigate tumor control efficacy of paclitaxel in the treatment of retinal tumors harbored by the LH beta-Tag murine transgenic model of retinoblastoma.	Paclitaxel	80-90	temporal alpha-galactosidase	Mus musculus	150-153
17652710-9	2007	CONCLUSIONS: Subconjunctival delivery of paclitaxel effectively inhibits intraocular tumor burden in the LH beta-Tag model of retinoblastoma.	Paclitaxel	41-51	temporal alpha-galactosidase	Mus musculus	113-116
26033570-9	2015	The downregulation of mimitin and 14-3-3 zeta/delta using specific siRNA in paclitaxel-resistant ovarian cancer cells led to an increase in the resistance index to paclitaxel.	Paclitaxel	164-174	NADH:ubiquinone oxidoreductase complex assembly factor 2	Homo sapiens	22-45
26033570-11	2015	Mimitin and 14-3-3 protein zeta/delta are potential markers of paclitaxel resistance and prognostic factors in ovarian cancer.	Paclitaxel	63-73	NADH:ubiquinone oxidoreductase complex assembly factor 2	Homo sapiens	0-7
25388329-3	2015	However, how neuroinflammation and TRPA1 and TRPV4 are linked to cause pain in paclitaxel-treated animals is not known.	Paclitaxel	79-89	transient receptor potential cation channel subfamily A member 1	Homo sapiens	35-40
17114292-0	2006	Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism.	Paclitaxel	0-10	neuronal calcium sensor 1	Homo sapiens	89-114
17114292-5	2006	We identified a taxol binding protein, neuronal Ca(2+) sensor 1 (NCS-1), a Ca(2+) binding protein that interacts with the inositol 1,4,5-trisphosphate receptor from a human brain cDNA phage display library.	Paclitaxel	16-21	neuronal calcium sensor 1	Homo sapiens	39-63
17114292-5	2006	We identified a taxol binding protein, neuronal Ca(2+) sensor 1 (NCS-1), a Ca(2+) binding protein that interacts with the inositol 1,4,5-trisphosphate receptor from a human brain cDNA phage display library.	Paclitaxel	16-21	neuronal calcium sensor 1	Homo sapiens	65-70
17510977-4	2007	We have also shown that microtubule-interfering agents (MIAs) such as nocodazole, vinblastine, paclitaxel, and vincristine, known to arrest cells at G2/M, also phosphorylate AB-DIP.	Paclitaxel	95-105	glutamine rich 1	Homo sapiens	174-180
25388329-3	2015	However, how neuroinflammation and TRPA1 and TRPV4 are linked to cause pain in paclitaxel-treated animals is not known.	Paclitaxel	79-89	transient receptor potential cation channel subfamily V member 4	Homo sapiens	45-50
17620430-6	2007	The combination of ZD4054 and paclitaxel led to the potentiation of all these effects, indicating that ZD4054, by blocking the ET(A)R-dependent proliferative, invasive, and antiapoptotic signals, can enhance sensitivity to paclitaxel.	Paclitaxel	223-233	endothelin receptor type A	Homo sapiens	127-133
17114292-6	2006	Taxol increased binding of NCS-1 to the inositol 1,4,5-trisphosphate receptor.	Paclitaxel	0-5	neuronal calcium sensor 1	Homo sapiens	27-32
17114292-7	2006	Short hairpin RNA-mediated knockdown of NCS-1 in the same cell line abrogated the response to taxol but not to other agonists stimulating the phosphoinositide signaling pathway.	Paclitaxel	94-99	neuronal calcium sensor 1	Homo sapiens	40-45
25388329-7	2015	RESULTS: Paclitaxel treatment increased the expression and release of TNF-alpha in satellite glial cells and increased the expression of TRPA1 and TRPV4 in DRG neurons in animals.	Paclitaxel	9-19	transient receptor potential cation channel subfamily A member 1	Homo sapiens	137-142
25388329-7	2015	RESULTS: Paclitaxel treatment increased the expression and release of TNF-alpha in satellite glial cells and increased the expression of TRPA1 and TRPV4 in DRG neurons in animals.	Paclitaxel	9-19	transient receptor potential cation channel subfamily V member 4	Homo sapiens	147-152
17559677-8	2007	CONCLUSION: Our results show that increased expression of LIMK1 results in chromosomal abnormalities, aberrant cell cycle progression and alteration of normal cellular response to microtubule stabilizing agent Taxol; and that LIMK1 expression may be associated with cancerous phenotype of the prostate.	Paclitaxel	210-215	LIM domain kinase 1	Homo sapiens	58-63
25388329-10	2015	In vivo, vector-mediated TNFsR release from DRG neurons reduced paclitaxel-induced up-regulation of TRPA1 and TRPV4 expression and prevented paclitaxel-induced pain.	Paclitaxel	64-74	transient receptor potential cation channel subfamily A member 1	Homo sapiens	100-105
17591831-7	2007	The development therefore of small molecules with an Aurora-A inhibition function may make it possible to reduce or block the oncogenic activity of Aurora-A and in addition may improve the survival of oncological patients showing resistance to paclitaxel or nocodazole treatment.	Paclitaxel	244-254	aurora kinase A	Homo sapiens	148-156
25388329-10	2015	In vivo, vector-mediated TNFsR release from DRG neurons reduced paclitaxel-induced up-regulation of TRPA1 and TRPV4 expression and prevented paclitaxel-induced pain.	Paclitaxel	64-74	transient receptor potential cation channel subfamily V member 4	Homo sapiens	110-115
25388329-11	2015	CONCLUSION: These results suggest that paclitaxel activation of TLR-4 to cause release of TNF-alpha from satellite glial cells increases the expression of TRPA1 and TRPV4 in DRG neurons to cause neuropathic pain.	Paclitaxel	39-49	transient receptor potential cation channel subfamily A member 1	Homo sapiens	155-160
25388329-11	2015	CONCLUSION: These results suggest that paclitaxel activation of TLR-4 to cause release of TNF-alpha from satellite glial cells increases the expression of TRPA1 and TRPV4 in DRG neurons to cause neuropathic pain.	Paclitaxel	39-49	transient receptor potential cation channel subfamily V member 4	Homo sapiens	165-170
16797537-4	2006	At the time of peak pain severity, rats with paclitaxel- and vincristine-evoked painful peripheral neuropathies had a significant decrease (24% and 44%, respectively) in the number of intraepidermal nerve fibers (IENF) in the hind paw glabrous skin and an increase (217% and 121%, respectively) in the number of PGP9.5-positive LCs, relative to control.	Paclitaxel	45-55	ubiquitin C-terminal hydrolase L1	Rattus norvegicus	312-318
26126538-2	2015	The expression of HDAC3 was decreased in cancer cell lines resistant to anti-cancer drugs such as celastrol and taxol.	Paclitaxel	112-117	histone deacetylase 3	Homo sapiens	18-23
16857764-4	2006	ET-1 (0.1 microM) was found to significantly attenuate both Paclitaxel- and serum deprivation-induced PASMC apoptosis, likely through stimulation of the ET(A) receptor (ET(A)R).	Paclitaxel	60-70	endothelin receptor type A	Rattus norvegicus	169-175
16857764-5	2006	ET-1 also prevented Paclitaxel-induced up-regulation of pro-apoptotic Bax and cleaved (activated) caspase-3.	Paclitaxel	20-30	caspase 3	Rattus norvegicus	98-107
17021819-0	2007	Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.	Paclitaxel	38-48	tubulin beta 3 class III	Homo sapiens	0-22
17021819-1	2007	PURPOSE: In this study, we determine the prevalence and the prognostic value of the class III beta-tubulin microtubule protein examined immunohistochemically, in tumors of 40 patients with carcinomas of unknown primary site treated with paclitaxel-based chemotherapy.	Paclitaxel	237-247	tubulin beta 3 class III	Homo sapiens	84-106
17021819-8	2007	CONCLUSIONS: These findings suggest that a high level of expression of class III beta-tubulin in tumor cells is associated with resistance to paclitaxel and decreased survival in patients with carcinomas of unknown primary receiving paclitaxel-based chemotherapy.	Paclitaxel	142-152	tubulin beta 3 class III	Homo sapiens	71-93
17021819-8	2007	CONCLUSIONS: These findings suggest that a high level of expression of class III beta-tubulin in tumor cells is associated with resistance to paclitaxel and decreased survival in patients with carcinomas of unknown primary receiving paclitaxel-based chemotherapy.	Paclitaxel	233-243	tubulin beta 3 class III	Homo sapiens	71-93
25964202-0	2015	Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.	Paclitaxel	86-96	pyruvate kinase, muscle	Mus musculus	15-20
16598766-0	2006	p27kip1 overexpression promotes paclitaxel-induced apoptosis in pRb-defective SaOs-2 cells.	Paclitaxel	32-42	RB transcriptional corepressor 1	Homo sapiens	64-67
25964202-11	2015	Although previous studies indicated that silencing of MDR-1 alone sensitized MDR ovarian cancer to paclitaxel only modestly, these data suggest that concurrent silencing of PKM-2 improves the efficacy of paclitaxel against MDR ovarian cancer.	Paclitaxel	204-214	pyruvate kinase, muscle	Mus musculus	173-178
16598766-2	2006	We evaluated the role of p27kip1 in paclitaxel-induced apoptosis in the pRb-defective SaOs-2 cells.	Paclitaxel	36-46	RB transcriptional corepressor 1	Homo sapiens	72-75
16598766-7	2006	In conclusion, we demonstrated that transfection of the pRb-defective SaOs-2 cells with the p27kip1 gene via plasmid increases their susceptibility to paclitaxel-induced apoptosis.	Paclitaxel	151-161	RB transcriptional corepressor 1	Homo sapiens	56-59
17531083-5	2007	Specifically, treatment with nocodazole and paclitaxel resulted in hyper-activation of ERKs and MEK in BubR1(+/-) murine embryonic fibroblasts (MEF) compared to that of wild-type MEFs.	Paclitaxel	44-54	midkine	Mus musculus	96-99
26085115-0	2015	Coadministration of indomethacin and minocycline attenuates established paclitaxel-induced neuropathic thermal hyperalgesia: Involvement of cannabinoid CB1 receptors.	Paclitaxel	72-82	cannabinoid receptor 1 (brain)	Mus musculus	152-155
17400210-6	2007	Treatment of ARVM with paclitaxel or antibodies to ErbB2 caused a significant increase in myofilament degradation, similarly as observed with an inhibitor of MAPK-signaling, but not apoptosis, necrosis or changes in mitochondrial activity.	Paclitaxel	23-33	mitogen activated protein kinase 3	Rattus norvegicus	158-162
17400210-7	2007	Paclitaxel-treatment and anti-ErbB2 reduced Erk1/2 phosphorylation.	Paclitaxel	0-10	mitogen activated protein kinase 3	Rattus norvegicus	44-50
17482960-7	2007	DAC could enhance the PTX-induced upregulation of caspase activity and antiproliferative effect to increase the fraction of cells in the sub-G1 and G2/M phase.	Paclitaxel	22-25	arylacetamide deacetylase	Homo sapiens	0-3
16895478-0	2006	Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS.	Paclitaxel	30-35	BCL2 like 12	Homo sapiens	130-137
16395709-1	2006	We recently showed that Hepatocyte Growth Factor (HGF), known as a survival factor, unexpectedly enhances apoptosis in human ovarian cancer cells treated with the front-line chemotherapeutics cisplatin (CDDP) and paclitaxel (PTX).	Paclitaxel	213-223	hepatocyte growth factor	Homo sapiens	24-48
16395709-1	2006	We recently showed that Hepatocyte Growth Factor (HGF), known as a survival factor, unexpectedly enhances apoptosis in human ovarian cancer cells treated with the front-line chemotherapeutics cisplatin (CDDP) and paclitaxel (PTX).	Paclitaxel	213-223	hepatocyte growth factor	Homo sapiens	50-53
16395709-1	2006	We recently showed that Hepatocyte Growth Factor (HGF), known as a survival factor, unexpectedly enhances apoptosis in human ovarian cancer cells treated with the front-line chemotherapeutics cisplatin (CDDP) and paclitaxel (PTX).	Paclitaxel	225-228	hepatocyte growth factor	Homo sapiens	24-48
16757703-13	2006	Treatment with imatinib and more so with imatinib and paclitaxel decreased mean vessel density (three CD31/PECAM-1-positive cells, 95% confidence interval [CI] = 0 to 9; and control group = 38 CD31/PECAM-1-positive cells, 95% CI = 17 to 59) (P &lt; .001), which was followed by apoptosis of tumor cells.	Paclitaxel	54-64	platelet/endothelial cell adhesion molecule 1	Mus musculus	102-106
17409444-8	2007	ASNS overexpression also induced resistance to apoptosis triggered by cisplatin [cis-diammine-dichloroplatinum (CDDP)] and carboplatin, but not by 5-fluorouracil, paclitaxel, etoposide, or gemcitabine.	Paclitaxel	163-173	asparagine synthetase (glutamine-hydrolyzing)	Homo sapiens	0-4
26010812-2	2015	Synthesis of the ABC Ring of Paclitaxel by SmI2-Mediated Cyclization.	Paclitaxel	29-39	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	17-20
17404103-0	2007	The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.	Paclitaxel	105-115	hepatocyte growth factor	Homo sapiens	29-53
16757703-13	2006	Treatment with imatinib and more so with imatinib and paclitaxel decreased mean vessel density (three CD31/PECAM-1-positive cells, 95% confidence interval [CI] = 0 to 9; and control group = 38 CD31/PECAM-1-positive cells, 95% CI = 17 to 59) (P &lt; .001), which was followed by apoptosis of tumor cells.	Paclitaxel	54-64	platelet/endothelial cell adhesion molecule 1	Mus musculus	107-114
16757703-13	2006	Treatment with imatinib and more so with imatinib and paclitaxel decreased mean vessel density (three CD31/PECAM-1-positive cells, 95% confidence interval [CI] = 0 to 9; and control group = 38 CD31/PECAM-1-positive cells, 95% CI = 17 to 59) (P &lt; .001), which was followed by apoptosis of tumor cells.	Paclitaxel	54-64	platelet/endothelial cell adhesion molecule 1	Mus musculus	193-197
26010812-3	2015	A convergent synthesis of the ABC ring of antitumor natural product paclitaxel (Taxol) is described.	Paclitaxel	68-78	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	30-33
16757703-13	2006	Treatment with imatinib and more so with imatinib and paclitaxel decreased mean vessel density (three CD31/PECAM-1-positive cells, 95% confidence interval [CI] = 0 to 9; and control group = 38 CD31/PECAM-1-positive cells, 95% CI = 17 to 59) (P &lt; .001), which was followed by apoptosis of tumor cells.	Paclitaxel	54-64	platelet/endothelial cell adhesion molecule 1	Mus musculus	198-205
17441356-0	2007	[Study on the relationship between Aurora A expression in cancer cell and treatment efficacy of taxol for prostate cancer].	Paclitaxel	96-101	aurora kinase A	Homo sapiens	35-43
26010812-3	2015	A convergent synthesis of the ABC ring of antitumor natural product paclitaxel (Taxol) is described.	Paclitaxel	80-85	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	30-33
17441356-1	2007	OBJECTIVE: To explore the relationship between Aurora A expression and cell sensitivity to taxol, and elucidate the effect of Aurora A on the treatment efficacy of taxol for prostate cancer.	Paclitaxel	91-96	aurora kinase A	Homo sapiens	47-55
16231322-0	2006	FHIT protein enhances paclitaxel-induced apoptosis in lung cancer cells.	Paclitaxel	22-32	fragile histidine triad diadenosine triphosphatase	Homo sapiens	0-4
16231322-4	2006	This study was undertaken to elucidate the effect of FHIT expression and the role of Bcl-2-caspase signaling in paclitaxel-induced apoptosis in lung cancer cells.	Paclitaxel	112-122	caspase 8	Homo sapiens	91-98
17441356-1	2007	OBJECTIVE: To explore the relationship between Aurora A expression and cell sensitivity to taxol, and elucidate the effect of Aurora A on the treatment efficacy of taxol for prostate cancer.	Paclitaxel	164-169	aurora kinase A	Homo sapiens	126-134
16231322-8	2006	Paclitaxel enhanced apoptosis in FHIT-expressing cells compared to that in control vector-transfected cells, and this enhancement was suppressed by siRNA treatment.	Paclitaxel	0-10	fragile histidine triad diadenosine triphosphatase	Homo sapiens	33-37
17441356-7	2007	RESULTS: Up-regulation of Aurora A expression reduced the cell inhibition and apoptosis rates when treated by taxol, but the down-regulation of Aurora A expression after DNAzymes applied increased the cell inhibition and apoptosis rates when treated by taxol.	Paclitaxel	110-115	aurora kinase A	Homo sapiens	26-34
26010999-4	2015	The ABC ring of paclitaxel, synthesized starting from 1,3-cyclohexanedione and tri-O-acetyl-d-glucal by SmI2-mediated cyclization as the key transformation, was successfully converted to Takahashi"s tetracyclic oxetane intermediate.	Paclitaxel	16-26	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	4-7
17441356-7	2007	RESULTS: Up-regulation of Aurora A expression reduced the cell inhibition and apoptosis rates when treated by taxol, but the down-regulation of Aurora A expression after DNAzymes applied increased the cell inhibition and apoptosis rates when treated by taxol.	Paclitaxel	253-258	aurora kinase A	Homo sapiens	144-152
17441356-8	2007	CONCLUSION: There is a positive relationship between Aurora A expression and treatment efficacy of taxol for prostate cancer, and inhibiting Aurora A expression will enhance the treatment efficacy of taxol for prostate cancer.	Paclitaxel	99-104	aurora kinase A	Homo sapiens	53-61
17441356-8	2007	CONCLUSION: There is a positive relationship between Aurora A expression and treatment efficacy of taxol for prostate cancer, and inhibiting Aurora A expression will enhance the treatment efficacy of taxol for prostate cancer.	Paclitaxel	99-104	aurora kinase A	Homo sapiens	141-149
16231322-10	2006	When caspase activation was blocked by a pan-caspase inhibitor in FHIT-expressing cells, paclitaxel-induced apoptotic cell death was decreased similar to that in control vector-transfected cells.	Paclitaxel	89-99	caspase 8	Homo sapiens	5-12
16231322-10	2006	When caspase activation was blocked by a pan-caspase inhibitor in FHIT-expressing cells, paclitaxel-induced apoptotic cell death was decreased similar to that in control vector-transfected cells.	Paclitaxel	89-99	caspase 8	Homo sapiens	45-52
16231322-10	2006	When caspase activation was blocked by a pan-caspase inhibitor in FHIT-expressing cells, paclitaxel-induced apoptotic cell death was decreased similar to that in control vector-transfected cells.	Paclitaxel	89-99	fragile histidine triad diadenosine triphosphatase	Homo sapiens	66-70
16231322-11	2006	Bcl-2 and Bcl-xL expressions were down-regulated after paclitaxel treatment in FHIT-expressing cells, whereas Bax and Bad expressions were up-regulated.	Paclitaxel	55-65	fragile histidine triad diadenosine triphosphatase	Homo sapiens	79-83
17441356-8	2007	CONCLUSION: There is a positive relationship between Aurora A expression and treatment efficacy of taxol for prostate cancer, and inhibiting Aurora A expression will enhance the treatment efficacy of taxol for prostate cancer.	Paclitaxel	200-205	aurora kinase A	Homo sapiens	53-61
17441356-8	2007	CONCLUSION: There is a positive relationship between Aurora A expression and treatment efficacy of taxol for prostate cancer, and inhibiting Aurora A expression will enhance the treatment efficacy of taxol for prostate cancer.	Paclitaxel	200-205	aurora kinase A	Homo sapiens	141-149
16231322-13	2006	These results indicate that paclitaxel-induced apoptosis enhanced by FHIT expression in lung cancer cells might be associated with modulation of Bcl-2-caspase signaling.	Paclitaxel	28-38	fragile histidine triad diadenosine triphosphatase	Homo sapiens	69-73
25424246-0	2015	Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.	Paclitaxel	43-53	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	95-101
16733646-0	2007	A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-alpha2b in patients with solid tumors.	Paclitaxel	79-89	interferon alpha 2	Homo sapiens	95-113
25895965-0	2015	Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.	Paclitaxel	127-137	angiopoietin 1	Homo sapiens	51-65
16733646-2	2007	The toxicity, pharmacokinetics, and pharmacodynamics of paclitaxel with interferon-alpha2b (IFN-alpha2b) were assessed in patients with solid tumors to assess the feasibility of this novel anti-angiogenic regimen.	Paclitaxel	56-66	interferon alpha 2	Homo sapiens	72-90
16380805-7	2006	cDNA subtraction revealed increased expression of six genes, including clathrin heavy chain, alpha3-tubulin, a neuroblastoma-specific Thymosin beta, the ribosomal protein L7a, HLA-B associated transcript 3 and collagen IIIalpha1 in the taxol-resistant cell line.	Paclitaxel	236-241	BAG cochaperone 6	Homo sapiens	176-228
25895965-0	2015	Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.	Paclitaxel	127-137	angiopoietin 2	Homo sapiens	66-80
16076490-7	2006	NO- and taxol-induced a depletion of GSH levels in CEM cells, which was potentialized by l-buthionine-S,R-sulfoximine (BSO), an inhibitor of gamma-GCS.	Paclitaxel	8-13	glutamate-cysteine ligase catalytic subunit	Homo sapiens	141-150
16778834-0	2007	Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death.	Paclitaxel	112-122	neurotrophic receptor tyrosine kinase 2	Homo sapiens	73-77
25724736-4	2015	The results showed that taxol rapidly induced UPR activation and that hypoxia modulated taxol-induced UPR activation differently according to the different UPR pathways (PERK, ATF6, and IRE1alpha).	Paclitaxel	88-93	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	186-195
17234772-4	2007	The SNCG-BubR1 interaction inhibits mitotic checkpoint control upon spindle damage caused by anticancer drugs, such as nocodazole and taxol.	Paclitaxel	134-139	synuclein gamma	Homo sapiens	4-8
17234772-10	2007	Overexpression of enhanced green fluorescent protein-tagged ANK reduces SNCG-mediated resistance to paclitaxel treatment by approximately 3.5-fold.	Paclitaxel	100-110	synuclein gamma	Homo sapiens	72-76
16291872-9	2006	Furthermore, knockdown of either beta-cat or Tcf-4 substantially reduced cell proliferation and potentiated paclitaxel-induced apoptosis in DU145 cells, which largely were rescued by treatment with exogenous ET-1.	Paclitaxel	108-118	transcription factor 4	Homo sapiens	45-50
16299241-1	2005	PURPOSE: To retrospectively evaluate the effects of six known allelic variants in the CYP2C8, CYP3A4, CYP3A5, and ABCB1 genes on the pharmacokinetics of the anticancer agent paclitaxel (Taxol).	Paclitaxel	174-184	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	86-92
25625960-7	2015	AURKA inhibition in endometrial cancer cell lines significantly decreased cell growth, invasion and migration (P&lt;0.05), and increased chemosensitivity to paclitaxel.	Paclitaxel	157-167	aurora kinase A	Homo sapiens	0-5
17159505-3	2007	Using the SNU-719 gastric cancer cell line, which is naturally infected with Epstein-Barr virus, we found that the chemotherapeutic agents, such as 5-fluorouracil, cis-platinum and taxol, induced the expressions of BMRF1, BZLF1 and BRLF1 proteins that are usually found in the lytic form of the virus.	Paclitaxel	181-186	BMRF1	Human gammaherpesvirus 4	215-220
25523336-0	2015	RPL13A as a reference gene for normalizing mRNA transcription of ovarian cancer cells with paclitaxel and 10-hydroxycamptothecin treatments.	Paclitaxel	91-101	ribosomal protein L13a	Homo sapiens	0-6
18078515-7	2007	CONCLUSION: These data suggest that combined treatment with antibodies to clusterin or antisense clusterin oligodeoxynucleotides and paclitaxel, doxorubicin, or tamoxifen could be a novel and attractive strategy to inhibit the progression of breast carcinoma by regulation of the clusterin function.	Paclitaxel	133-143	clusterin	Homo sapiens	97-106
18078515-7	2007	CONCLUSION: These data suggest that combined treatment with antibodies to clusterin or antisense clusterin oligodeoxynucleotides and paclitaxel, doxorubicin, or tamoxifen could be a novel and attractive strategy to inhibit the progression of breast carcinoma by regulation of the clusterin function.	Paclitaxel	133-143	clusterin	Homo sapiens	97-106
15828024-5	2005	TGF-beta1-induced EC barrier dysfunction was linked to partial dissolution of peripheral MT meshwork and decreased levels of stable (acetylated) MT pool, whereas MT stabilization by taxol (5 microM) attenuated TGF-beta1-induced barrier dysfunction and actin remodeling.	Paclitaxel	182-187	transforming growth factor beta 1	Bos taurus	210-219
15828024-6	2005	TGF-beta1 induced sustained activation of small GTPase Rho and its effector Rho-kinase; phosphorylation of myosin binding subunit of myosin specific phosphatase; MLC phosphorylation; EC contraction; and gap formation, which was abolished by inhibition of Rho and Rho-kinase, and by MT stabilization with taxol.	Paclitaxel	304-309	transforming growth factor beta 1	Bos taurus	0-9
16024801-5	2005	When a phosphorylation site mutant Sil is stably expressed, the duration of the spindle checkpoint is shortened in cells challenged with taxol or nocodazole, and the cells revert to a G2-like state.	Paclitaxel	137-142	STIL centriolar assembly protein	Homo sapiens	35-38
18086299-0	2007	CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.	Paclitaxel	77-87	CD40 molecule	Homo sapiens	0-4
25523336-9	2015	The current study identified various reference genes suitable under different circumstances, while RPL13A was indicated to be the most suitable reference gene for analyzing the transcription profile of ovarian cancer cells following treatment with PTX and HCPT.	Paclitaxel	248-251	ribosomal protein L13a	Homo sapiens	99-105
25560085-5	2015	The activity of multiple Ad5 vectors, including dl922-947 (E1A CR2-deleted), dl1520 (E1B-55K deleted) and Ad5 WT, was significantly increased in paclitaxel resistant ovarian cancer in vitro and in vivo.	Paclitaxel	145-155	Alzheimer disease, familial, type 5	Homo sapiens	25-28
17069796-0	2007	Global functional analysis of nucleophosmin in Taxol response, cancer, chromatin regulation, and ribosomal DNA transcription.	Paclitaxel	47-52	nucleophosmin 1	Homo sapiens	30-43
15897904-2	2005	In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state.	Paclitaxel	33-43	eukaryotic translation initiation factor 4E	Homo sapiens	135-166
15897904-2	2005	In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state.	Paclitaxel	33-43	eukaryotic translation initiation factor 4E	Homo sapiens	168-174
15897904-2	2005	In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state.	Paclitaxel	33-43	eukaryotic translation initiation factor 4E	Homo sapiens	225-231
15897904-2	2005	In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state.	Paclitaxel	45-48	eukaryotic translation initiation factor 4E	Homo sapiens	135-166
15897904-2	2005	In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state.	Paclitaxel	45-48	eukaryotic translation initiation factor 4E	Homo sapiens	168-174
15897904-2	2005	In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state.	Paclitaxel	45-48	eukaryotic translation initiation factor 4E	Homo sapiens	225-231
17069796-5	2007	Cells with reduced NPM were treated with Taxol followed by microarray profiling accompanied by gene/protein pathway analyses.	Paclitaxel	41-46	nucleophosmin 1	Homo sapiens	19-22
17009338-1	2006	It was reported that paclitaxel is an inhibitor of hepatic P-glycoprotein (P-gp) and hepatic microsomal cytochrome P450 (CYP) 3A1/2, and that naringin is an inhibitor of biliary P-gp and CYP3A1/2 in rats.	Paclitaxel	21-31	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	104-131
25560085-5	2015	The activity of multiple Ad5 vectors, including dl922-947 (E1A CR2-deleted), dl1520 (E1B-55K deleted) and Ad5 WT, was significantly increased in paclitaxel resistant ovarian cancer in vitro and in vivo.	Paclitaxel	145-155	Alzheimer disease, familial, type 5	Homo sapiens	106-109
25560085-12	2015	Inhibition of CDK4/6 using PD-0332991 was able both to reverse paclitaxel resistance and reduce adenovirus efficacy.	Paclitaxel	63-73	cyclin dependent kinase 4	Homo sapiens	14-20
16890274-0	2006	Clusterin confers paclitaxel resistance in cervical cancer.	Paclitaxel	18-28	clusterin	Homo sapiens	0-9
15897904-3	2005	We found that PTX induced the hyperphosphorylation of 4E-BP1 in the breast cancer cell line, MDA MB 231, which reduced its association with eIF-4E, but did not alter the expression and phosphorylation of eIF-4E.	Paclitaxel	14-17	eukaryotic translation initiation factor 4E	Homo sapiens	140-146
16890274-1	2006	OBJECTIVE: To measure clusterin expression in cervical cancer tissues and cell lines and to evaluate whether clusterin confers resistance to paclitaxel in cervical cancer cells.	Paclitaxel	141-151	clusterin	Homo sapiens	109-118
25633416-9	2015	FOXM1 effector genes such as CDK4, p53 and cyclin D1 were downregulated in gastric cancer cells by combination treatment with DIM and paclitaxel.	Paclitaxel	134-144	cyclin D1	Homo sapiens	43-52
15897904-6	2005	The hyperphosphorylation of 4E-BP1 by PTX increased the association of eIF-4E with eIF-4G, whereas cotreatment with purvalanol A inhibited the association of eIF-4E with eIF-4G in PTX treated cells.	Paclitaxel	38-41	eukaryotic translation initiation factor 4E	Homo sapiens	71-77
15897904-7	2005	Taken together, our data suggest that PTX-increases the functional level of eIF-4E by promoting the hyperphosphorylation and release of 4E-BP1 through a cdk1-dependent mechanism.	Paclitaxel	38-41	eukaryotic translation initiation factor 4E	Homo sapiens	76-82
25634491-6	2015	Treatment with paclitaxel resulted in greater increases in cleaved-PARP expression in the 2D-culture compared with the 3D-culture, but only in cell lines forming dense 3D-MCSs, suggesting that MCS formation protected the cells from paclitaxel-induced apoptosis.	Paclitaxel	15-25	collagen type XI alpha 2 chain	Homo sapiens	67-71
15688426-13	2005	We show that Chk1 elimination attenuates the paclitaxel-induced activation of the anti-apoptotic p42/p44 (ERK1/2) MAP kinase pathway, additionally contributing to the sensitization.	Paclitaxel	45-55	interferon induced protein 44	Homo sapiens	101-104
16894566-5	2006	Ectopic expression of Aurora-A renders cells resistant to cisplatin (CDDP), etoposide and paclitaxel-induced apoptosis and stimulates Akt1 and Akt2 activity in wild-type p53 but not p53-null ovarian cancer cells.	Paclitaxel	90-100	aurora kinase A	Homo sapiens	22-30
25788267-7	2015	Most importantly, when administered intraperitoneally, combination of BSN and paclitaxel significantly decreased the tumor development in a xenograft lung cancer mouse model associated with down-modulation of phospho-STAT3, Ki-67 and CD31.	Paclitaxel	78-88	platelet/endothelial cell adhesion molecule 1	Mus musculus	234-238
16752223-9	2006	Our results suggest that several ABC transporters in human breast cancer cells may affect the clinical response to neoadjuvant chemotherapy, and transcriptional profiling of these genes may be useful to predict the pathologic response to sequential weekly paclitaxel/FEC in breast cancer patients.	Paclitaxel	256-266	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	33-36
16020661-5	2005	Transfection of a dominant-negative (DN)-CDK2 evoked resistance to paclitaxel by preventing cellular progression to mitosis through loss of CDK1 activity.	Paclitaxel	67-77	cyclin dependent kinase 2	Homo sapiens	41-45
16020661-6	2005	Reexpression of wild-type CDK2 in DN-CDK2-transfected cancer cells restored CDK2 activity but not paclitaxel sensitivity.	Paclitaxel	98-108	cyclin dependent kinase 2	Homo sapiens	26-30
16020661-7	2005	However, expression of cyclin A in DN-CDK2-transfected cells restored their sensitivity to paclitaxel.	Paclitaxel	91-101	cyclin dependent kinase 2	Homo sapiens	38-42
25788678-5	2015	Persistent activation of PKCbetaII, PKCdelta, and PKCepsilon was also observed in the dorsal root ganglion neurons after chronic treatment with paclitaxel in a mouse model of PIPN.	Paclitaxel	144-154	protein kinase C, epsilon	Mus musculus	50-60
16080463-3	2005	In the present study, we tested the sensitivity of MCF-7 breast cancer cells overexpressing anti-apoptotic genes TRAF-1, c-FLIP, Bcl-xL, clAP-2 or Mn-SOD to paclitaxel and docetaxel.	Paclitaxel	157-167	superoxide dismutase 2	Homo sapiens	147-153
16080463-6	2005	Caspase 8 and 9 activities were measured in cells overexpressing Bcl-xL or c-FLIP exposed to docetaxel and paclitaxel using fluorescent substrate cleavage assay.	Paclitaxel	107-117	caspase 8	Homo sapiens	0-9
25788678-6	2015	Isoform-selective inhibitors of PKCbetaII, PKCdelta, and PKCepsilon given intrathecally dose-dependently attenuated paclitaxel-induced mechanical allodynia and heat hyperalgesia.	Paclitaxel	116-126	protein kinase C, epsilon	Mus musculus	57-67
16554162-3	2006	Both prodrugs were well detoxified and easily cleaved in the presence of beta-D-glucuronidase with fast removal of the spacer, releasing paclitaxel.	Paclitaxel	137-147	glucuronidase beta	Homo sapiens	73-93
25752395-8	2015	Cotreatment of CA with IR or taxol in normal cells induced protective effects with phosphorylation- dependent patterns at Ser326 of HSF1.	Paclitaxel	29-34	heat shock factor 1	Mus musculus	132-136
16773211-0	2006	Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.	Paclitaxel	93-103	synuclein gamma	Homo sapiens	14-29
16773211-5	2006	In this study, we show that responses of 12 breast cancer cell lines to paclitaxel-induced mitotic arrest and cytotoxicity highly correlate with SNCG expression status.	Paclitaxel	72-82	synuclein gamma	Homo sapiens	145-149
16773211-6	2006	SNCG-positive cells exhibit a significant higher resistance to paclitaxel-induced mitotic arrest than SNCG-negative cells (p&lt;0.01).	Paclitaxel	63-73	synuclein gamma	Homo sapiens	0-4
16773211-8	2006	These new findings suggest that SNCG expression in breast carcinomas is probably a causal factor contributing to the poor patient response to paclitaxel treatment.	Paclitaxel	142-152	synuclein gamma	Homo sapiens	32-36
16753005-0	2006	Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8.	Paclitaxel	43-53	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	86-105
16753005-1	2006	INTRODUCTION: We have previously shown that human colorectal cancer tissue is able to inactivate the anticancer drug paclitaxel through cytochrome P450 (CYP)2C8 and CYP3A4 metabolisms.	Paclitaxel	117-127	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	136-160
16753005-6	2006	A 4.4-fold (p = 0.005) enhancement of CYP2C8 expression and a 5.6-fold (p = 0.001) increase of multidrug resistance (MDR)1 expression was observed in resistant cells exposed to paclitaxel.	Paclitaxel	177-187	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	38-44
16753005-7	2006	When paclitaxel was removed from the culture medium, CYP2C8, but not MDR1 expression, reverted to basal levels and the resistance to paclitaxel decreased 3.2-fold (p = 0.005).	Paclitaxel	5-15	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	53-59
16753005-9	2006	CONCLUSIONS: Caco-2 cells are capable of increasing the expression levels of CYP2C8 as a response to long-term exposure to paclitaxel.	Paclitaxel	123-133	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	77-83
15829295-7	2005	Using splenic macrophages harvested from IRAK-1 knockout and control mice, we further demonstrated that the presence of IRAK-1 is required for taxol-induced PARP cleavage.	Paclitaxel	143-148	interleukin-1 receptor-associated kinase 1	Mus musculus	120-126
16353081-10	2005	In all of the HebG2 cells treated with paclitaxel (1.0-1000 nM) mRNA specific for EGFR, MMP-2 and MMP-9 were undetectable.	Paclitaxel	39-49	matrix metallopeptidase 2	Homo sapiens	88-93
16353081-12	2005	CONCLUSION: This study suggests that: (1) increased production of NO may contribute to paclitaxel"s cytotoxicity against HebG2 cells, (2) paclitaxel may inhibit tumor metastasis via inhibition of the expression of EGFR and MMPs and (3) an inverse correlation exist between NO production and expression of EGFR and MMPs.	Paclitaxel	87-97	matrix metallopeptidase 2	Homo sapiens	223-227
16353081-12	2005	CONCLUSION: This study suggests that: (1) increased production of NO may contribute to paclitaxel"s cytotoxicity against HebG2 cells, (2) paclitaxel may inhibit tumor metastasis via inhibition of the expression of EGFR and MMPs and (3) an inverse correlation exist between NO production and expression of EGFR and MMPs.	Paclitaxel	87-97	matrix metallopeptidase 2	Homo sapiens	314-318
16353081-12	2005	CONCLUSION: This study suggests that: (1) increased production of NO may contribute to paclitaxel"s cytotoxicity against HebG2 cells, (2) paclitaxel may inhibit tumor metastasis via inhibition of the expression of EGFR and MMPs and (3) an inverse correlation exist between NO production and expression of EGFR and MMPs.	Paclitaxel	138-148	matrix metallopeptidase 2	Homo sapiens	223-227
16353081-12	2005	CONCLUSION: This study suggests that: (1) increased production of NO may contribute to paclitaxel"s cytotoxicity against HebG2 cells, (2) paclitaxel may inhibit tumor metastasis via inhibition of the expression of EGFR and MMPs and (3) an inverse correlation exist between NO production and expression of EGFR and MMPs.	Paclitaxel	138-148	matrix metallopeptidase 2	Homo sapiens	314-318
16803472-1	2006	Paclitaxel, an antineoplastic agent used for the treatment of ovarian cancer, is metabolized by cytochrome P450 (CYP)3A4 and CYP2C8 and is excreted from cells by ATP-binding cassette (ABCB1) (multi-drug resistance [MDR1], P-glycoprotein).	Paclitaxel	0-10	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	125-131
16803472-4	2006	We therefore examined the relationship of the paclitaxel pharmacokinetics in 13 patients with ovarian cancer to polymorphisms in CYP2C8, CYP3A5, ABCB1, and PXR.	Paclitaxel	46-56	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	129-135
26045992-3	2015	In this study, by overexpression or silencing of Aur A in cervical cancer cell lines, we found that overexpression of Aur A promoted cell proliferation through G1/S cell cycle transition and anti-apoptosis, xenograft tumor growth and chemoresistance to Taxol.	Paclitaxel	253-258	aurora kinase A	Homo sapiens	118-123
16854453-13	2006	In breast cancer cells, activated Raf conferred resistance to the chemotherapeutic drugs doxorubicin and paclitaxel.	Paclitaxel	105-115	zinc fingers and homeoboxes 2	Homo sapiens	34-37
15770517-8	2005	A human clusterin ASO targeting the translation initiation site and incorporating MOE-gapmer backbone (OGX-011) synergistically enhanced the cytotoxic effects of paclitaxel in human xenografts of prostate, renal cell, bladder, and lung cancer.	Paclitaxel	162-172	clusterin	Homo sapiens	8-17
15455390-2	2005	The aims of our study were to compare the distribution of paclitaxel into ECs with other cell types, to assess the effects of low doses of paclitaxel on Cox-2 expression and to determine the combined effects of paclitaxel and Cox-2 inhibitors on angiogenesis in vitro and in patients with cancer.	Paclitaxel	139-149	mitochondrial Cytochrome c oxidase subunit II	Drosophila melanogaster	153-158
15455390-2	2005	The aims of our study were to compare the distribution of paclitaxel into ECs with other cell types, to assess the effects of low doses of paclitaxel on Cox-2 expression and to determine the combined effects of paclitaxel and Cox-2 inhibitors on angiogenesis in vitro and in patients with cancer.	Paclitaxel	139-149	mitochondrial Cytochrome c oxidase subunit II	Drosophila melanogaster	153-158
26045992-4	2015	We further found that inhibition of Aur A with its specific inhibitor VX-680 enhanced the antitumor effect of Taxol via inducing apoptosis.	Paclitaxel	110-115	aurora kinase A	Homo sapiens	36-41
25583261-13	2015	CONCLUSIONS: In addition to driving TNBC tumor formation, BRCA1-IRIS overexpression drives their intrinsic and acquired paclitaxel resistance, partly by activating autocrine signaling loops EGF/EGFR-ErbB2 and NRG1/ErbB2-ErbB3.	Paclitaxel	120-130	erb-b2 receptor tyrosine kinase 3	Homo sapiens	220-225
16028104-3	2006	In this report we characterize GBP1 and demonstrate that GBP1 expression is consistently upregulated in 7 of 8 paclitaxel or doxorubicin-resistant human cancer cell lines as compared to its expression in the relevant drug-sensitive parental lines.	Paclitaxel	111-121	guanylate binding protein 1	Homo sapiens	57-61
25994081-0	2015	THE INHIBITORY EFFECT OF PACLITAXEL ON (Kv2.1) K+ CURRENT IN H9c2 CELLS.	Paclitaxel	25-35	potassium voltage-gated channel subfamily B member 1	Rattus norvegicus	40-45
16028104-5	2006	Parallel analysis of the Cancer Cell Line Profiling Array determined that GBP1 expression in a majority of cell lines derived from human tumors of different tissue origin was induced to variable levels following exposure to multiple stress agents including paclitaxel and doxorubicin.	Paclitaxel	257-267	guanylate binding protein 1	Homo sapiens	74-78
16028104-6	2006	Importantly, stable expression of a GBP1 transgene in the paclitaxel-sensitive ovarian cancer cell line OVCAR8 was sufficient to confer moderate paclitaxel resistance.	Paclitaxel	58-68	guanylate binding protein 1	Homo sapiens	36-40
15528207-5	2005	Moreover, taxol-induced stabilization of microtubules released STAT5B from its binding, and we show that STAT5B binds specifically to the highly dynamic microtubules and is absent of the stable microtubule subpopulation.	Paclitaxel	10-15	signal transducer and activator of transcription 5B	Homo sapiens	63-69
15528207-5	2005	Moreover, taxol-induced stabilization of microtubules released STAT5B from its binding, and we show that STAT5B binds specifically to the highly dynamic microtubules and is absent of the stable microtubule subpopulation.	Paclitaxel	10-15	signal transducer and activator of transcription 5B	Homo sapiens	105-111
16028104-6	2006	Importantly, stable expression of a GBP1 transgene in the paclitaxel-sensitive ovarian cancer cell line OVCAR8 was sufficient to confer moderate paclitaxel resistance.	Paclitaxel	145-155	guanylate binding protein 1	Homo sapiens	36-40
25994081-2	2015	Paclitaxel inhibited Kv2.1 voltage-dependent K(+) current (IKur) with ultra-rapidly activating and slowly inactivating kinetics in a concentration-dependent manner.	Paclitaxel	0-10	potassium voltage-gated channel subfamily B member 1	Rattus norvegicus	21-26
25994081-5	2015	The time-dependent inhibition suggests that paclitaxel might be an open channel blocker of Kv2.1.	Paclitaxel	44-54	potassium voltage-gated channel subfamily B member 1	Rattus norvegicus	91-96
25994081-6	2015	This inhibition of Kv2.1 may be involved in the adverse effects of paclitaxel on cardiac and neuronal cells.	Paclitaxel	67-77	potassium voltage-gated channel subfamily B member 1	Rattus norvegicus	19-24
16595340-4	2006	Moreover, Tax-induced tubulin hyperpolymerization augmented the surface expression of the IL-2R ss -chain and enhanced the association of the IL-2R beta -chain with cytoskeletal tubulin.	Paclitaxel	10-13	interleukin 2 receptor subunit alpha	Homo sapiens	90-95
16595340-4	2006	Moreover, Tax-induced tubulin hyperpolymerization augmented the surface expression of the IL-2R ss -chain and enhanced the association of the IL-2R beta -chain with cytoskeletal tubulin.	Paclitaxel	10-13	interleukin 2 receptor subunit beta	Homo sapiens	142-152
26162837-6	2015	In rats with neuropathy induced by L5 spinal nerve cutting or by repeated administration of paclitaxel, an anticancer drug, the neuropathic hyperalgesia is reversed by inhibitors of CSE or T-channels and by silencing of Cav3.2.	Paclitaxel	92-102	cystathionase (cystathionine gamma-lyase)	Mus musculus	182-185
27699666-0	2006	High-Performance Liquid Chromatography Analysis of CYP2C8-Catalyzed Paclitaxel 6alpha-Hydroxylation.	Paclitaxel	68-78	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	51-57
15665297-7	2005	These cIAP1-overexpressing cells also exhibited cytokinesis defects over 10 times more often than control cells and displayed a mitotic checkpoint abnormality with production of polyploid cells when exposed to microtubule-targeting drugs nocodazole and paclitaxel (Taxol).	Paclitaxel	253-263	baculoviral IAP repeat containing 2	Homo sapiens	6-11
15665297-7	2005	These cIAP1-overexpressing cells also exhibited cytokinesis defects over 10 times more often than control cells and displayed a mitotic checkpoint abnormality with production of polyploid cells when exposed to microtubule-targeting drugs nocodazole and paclitaxel (Taxol).	Paclitaxel	265-270	baculoviral IAP repeat containing 2	Homo sapiens	6-11
27699666-3	2006	A reverse-phase, high-performance liquid chromatographic assay is described for the analysis of paclitaxel 6alpha-hydroxylation catalyzed by human liver microsomes or cDNA-expressed P450 enzyme CYP2C8.	Paclitaxel	96-106	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	194-200
27699666-5	2006	This method is applicable to enzymatic studies for determination of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation activity.	Paclitaxel	85-95	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	68-74
26451776-0	2015	Pretreatment Pokemon Level as a Predictor of Response to Cisplatin and Paclitaxel in Patients with Unresectable Non-Small Cell Lung Cancer.	Paclitaxel	71-81	zinc finger and BTB domain containing 7A	Homo sapiens	13-20
16267627-7	2005	At this moment, potential clinically relevant application of CYP450 pharmacogenetics for anticancer therapy may be found for CYP1A2 and flutamide, CYP2A6 and tegafur, CYP2B6 and cyclophosphamide, CYP2C8 and paclitaxel, CYP2D6 and tamoxifen, and CYP3A5.	Paclitaxel	207-217	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	196-202
15604254-8	2004	Although cell proliferation is not altered, paclitaxel treatment impairs secretion of MMP-2/MMP-9 and significantly reduces invasive activity in our new cell invasion assay.	Paclitaxel	44-54	matrix metallopeptidase 2	Homo sapiens	86-91
26115084-0	2015	Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.	Paclitaxel	44-54	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	8-27
26115084-0	2015	Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.	Paclitaxel	70-80	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	8-27
25230791-4	2014	Furthermore, PTX and cetuximab combination treatment reduced the expression of p65 (NF-kappaB) protein in OSCC cells.	Paclitaxel	13-16	RELA proto-oncogene, NF-kB subunit	Homo sapiens	79-82
15452117-7	2004	Inhibitors of caspases-8, -6, or -3 partially inhibited taxol-induced apoptosis, whereas the caspase-10 inhibitor totally abrogated this process.	Paclitaxel	56-61	caspase 8	Homo sapiens	14-28
16250671-0	2005	Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice.	Paclitaxel	0-10	transforming growth factor, beta 1	Mus musculus	21-28
16250671-3	2005	Aberrant TGFbeta/Smad signaling can be controlled by stabilization of microtubules with paclitaxel.	Paclitaxel	88-98	transforming growth factor, beta 1	Mus musculus	9-16
25230791-8	2014	In addition, immunohistochemical staining revealed that expression of p65 was downregulated in HSC2 tumors treated with PTX and cetuximab.	Paclitaxel	120-123	RELA proto-oncogene, NF-kB subunit	Homo sapiens	70-73
16250671-6	2005	Paclitaxel markedly suppressed Smad2 and Smad3 phosphorylation and collagen deposition in SSc grafts.	Paclitaxel	0-10	SMAD family member 3	Mus musculus	41-46
15304522-7	2004	Simultaneous inactivation of CYP2C8 and CYP3A4 (paclitaxel 3"-phenyl-hydroxylation) was observed using amiodarone, isoniazid, and phenelzine with the efficiency of inactivation greater for the CYP3A4 pathway.	Paclitaxel	48-58	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	29-35
16250671-10	2005	CONCLUSION: Low-dose paclitaxel can significantly suppress TGFbeta/Smad activity and lessen fibrosis in SCID mice.	Paclitaxel	21-31	transforming growth factor, beta 1	Mus musculus	59-66
25230791-9	2014	Our results indicate that cetuximab may enhance the effect of PTX in OSCC through the downregulation of PTX induced p65 expression.	Paclitaxel	62-65	RELA proto-oncogene, NF-kB subunit	Homo sapiens	116-119
16250671-12	2005	Although prolonged chemotherapy with paclitaxel at higher doses is associated with pro-fibrotic and anti-angiogenic changes, the findings described here indicate that low-dose paclitaxel may have therapeutic benefits for SSc via modulating TGFbeta signaling.	Paclitaxel	176-186	transforming growth factor, beta 1	Mus musculus	240-247
25230791-9	2014	Our results indicate that cetuximab may enhance the effect of PTX in OSCC through the downregulation of PTX induced p65 expression.	Paclitaxel	104-107	RELA proto-oncogene, NF-kB subunit	Homo sapiens	116-119
25344919-0	2014	High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients.	Paclitaxel	119-129	inhibitor of DNA binding 1, HLH protein	Homo sapiens	5-8
16203790-15	2005	The results also show induction of previously undescribed metabolic pathways for docetaxel, one of which may be analogous to the known 6-alpha-hydroxylation of paclitaxel by CYP2C8.	Paclitaxel	160-170	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	174-180
16101130-4	2005	R115777 +/- paclitaxel inhibited HDJ-2 farnesylation, up-regulated RhoB, transiently lowered (P)ERK/ERK and (P)Akt/Akt, reduced Raf-1 and MEK and inhibited secretion of VEGF and MMP-1.	Paclitaxel	12-22	ras homolog family member B	Homo sapiens	67-71
16101130-4	2005	R115777 +/- paclitaxel inhibited HDJ-2 farnesylation, up-regulated RhoB, transiently lowered (P)ERK/ERK and (P)Akt/Akt, reduced Raf-1 and MEK and inhibited secretion of VEGF and MMP-1.	Paclitaxel	12-22	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	128-133
15856231-0	2005	P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.	Paclitaxel	22-32	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-4
15327838-4	2004	Further, the PEP8-TAT2 peptide inhibits cell death-associated Cdk2 activity and thereby prevents apoptotic progression in paclitaxel-treated cells.	Paclitaxel	122-132	cyclin dependent kinase 2	Homo sapiens	62-66
15001534-4	2004	Inhibition of paclitaxel-induced c-jun NH2-terminal kinase (JNK) activation by treatment with a specific inhibitor, SP600125, or overexpression of a dominant-negative mutant form of upstream kinases, MEK kinase 1 (MEKK1) and mitogen-activated protein kinase kinase (MKK) 7, significantly reduced the increase in phosphorylated FADD.	Paclitaxel	14-24	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	200-212
15001534-4	2004	Inhibition of paclitaxel-induced c-jun NH2-terminal kinase (JNK) activation by treatment with a specific inhibitor, SP600125, or overexpression of a dominant-negative mutant form of upstream kinases, MEK kinase 1 (MEKK1) and mitogen-activated protein kinase kinase (MKK) 7, significantly reduced the increase in phosphorylated FADD.	Paclitaxel	14-24	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	214-219
15001534-5	2004	It is noteworthy that pretreatment with paclitaxel significantly up-regulated MEKK1 expression, resulting in enhancement of etoposide- or cisplatin-induced MEKK1/MKK7-dependent JNK activation and apoptosis in LNCaP and DU145 cells.	Paclitaxel	40-50	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	78-83
15001534-5	2004	It is noteworthy that pretreatment with paclitaxel significantly up-regulated MEKK1 expression, resulting in enhancement of etoposide- or cisplatin-induced MEKK1/MKK7-dependent JNK activation and apoptosis in LNCaP and DU145 cells.	Paclitaxel	40-50	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	156-161
15001534-6	2004	Interestingly, MEKK1 up-regulation and the synergistic effects of paclitaxel on anticancer drug-induced apoptosis were abolished by overexpression of mutant FADD (Ser194--&gt;Ala).	Paclitaxel	66-76	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	15-20
15856231-2	2005	Studies on the metabolism and disposition of paclitaxel have shown that it is primarily eliminated via hepatic metabolism by P450 enzymes (2C8 and 3A4) to essentially inactive metabolites, and that biliary and gut transport by P-glycoprotein (PGP) as well as urinary elimination of the parent compound play relatively minor roles.	Paclitaxel	45-55	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	125-129
15856231-3	2005	Recent studies in vitro have shown that paclitaxel treatment increases the level of CYP2C8 and CYP3A4 in human hepatocytes as well as PGP in colon tumor cells.	Paclitaxel	40-50	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	84-90
15856231-8	2005	The effect of paclitaxel treatment on hepatic expression of PGP and P450 isoforms (CYP2C and CYP3A) was determined to elucidate the mechanism by which paclitaxel disposition is altered by previous drug exposure.	Paclitaxel	14-24	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	68-72
25344919-3	2014	In this study, we observed that NSCLC cells with high Id1 protein expression were vulnerable to the treatment of paclitaxel and cisplatin.	Paclitaxel	113-123	inhibitor of DNA binding 1, HLH protein	Homo sapiens	54-57
15856231-8	2005	The effect of paclitaxel treatment on hepatic expression of PGP and P450 isoforms (CYP2C and CYP3A) was determined to elucidate the mechanism by which paclitaxel disposition is altered by previous drug exposure.	Paclitaxel	151-161	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	68-72
25344919-4	2014	In addition, paclitaxel and cisplatin caused Id1 protein degradation through ubiquitination.	Paclitaxel	13-23	inhibitor of DNA binding 1, HLH protein	Homo sapiens	45-48
25344919-6	2014	Furthermore, immunohistochemical staining for Id1 followed by Kaplan-Meier survival analysis showed that surgically treated NSCLC patients with high Id1 expression in primary tumor tissues had better disease-free and overall survivals after adjuvant paclitaxel and cisplatin chemotherapy.	Paclitaxel	250-260	inhibitor of DNA binding 1, HLH protein	Homo sapiens	149-152
15196026-9	2004	Mutation of CYP2C8 at position 359 (S359I), a site of genetic polymorphism in CYP2C9, resulted in relatively minor changes in paclitaxel- and torsemide-hydroxylase activities.	Paclitaxel	126-136	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	12-18
25344919-8	2014	The distinct role of Id1 reported in this study may arise from the phenomenon of Id1 dependence of NSCLC cells for survival, which renders the cancer cells additionally susceptive to the adjuvant chemotherapy with paclitaxel and cisplatin.	Paclitaxel	214-224	inhibitor of DNA binding 1, HLH protein	Homo sapiens	21-24
25344919-8	2014	The distinct role of Id1 reported in this study may arise from the phenomenon of Id1 dependence of NSCLC cells for survival, which renders the cancer cells additionally susceptive to the adjuvant chemotherapy with paclitaxel and cisplatin.	Paclitaxel	214-224	inhibitor of DNA binding 1, HLH protein	Homo sapiens	81-84
15933212-2	2005	CYP2C8 is an important member of the CYP2C subfamily, which metabolizes both endogenous compounds (i.e., arachidonic acids and retinoic acid) and xenobiotics (e.g., paclitaxel).	Paclitaxel	165-175	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
25411045-5	2014	Also, we found significant activations of spinal cytosolic phospholipase A2 and calcium-independent phospholipase A2 after the paclitaxel treatment.	Paclitaxel	127-137	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	49-75
15917656-4	2005	Taxol-stabilized tubulin, but not depolymerized tubulin coimmunoprecipitates with RGS14 from cell extracts.	Paclitaxel	0-5	regulator of G protein signaling 14	Homo sapiens	82-87
15242250-4	2004	All-trans retinoic acid, taxol and okadiac acid induce downregulation or inactivation of nucleolin, which destabilizes bcl-2 mRNA and triggers apoptosis.	Paclitaxel	25-30	nucleolin	Homo sapiens	89-98
15138593-4	2004	In contrast, in paclitaxel-resistant Ma-31 cells, paclitaxel dephosphorylated pRB at Ser795 without affecting ERK activity.	Paclitaxel	16-26	RB transcriptional corepressor 1	Homo sapiens	78-81
15138593-4	2004	In contrast, in paclitaxel-resistant Ma-31 cells, paclitaxel dephosphorylated pRB at Ser795 without affecting ERK activity.	Paclitaxel	50-60	RB transcriptional corepressor 1	Homo sapiens	78-81
15130763-6	2004	Treatment with Doxorubicin, Paclitaxel or 5-Fluorouracil induced a breakdown of the mitochondrial membrane potential and apoptotic cell death in p56/Lck expressing Jurkat and the retransfected JCaM1.6/Lck cells within 48h of treatment.	Paclitaxel	28-38	cyclin dependent kinase like 2	Homo sapiens	145-148
25253692-0	2014	Increased spinal cord Na+-K+-2Cl- cotransporter-1 (NKCC1) activity contributes to impairment of synaptic inhibition in paclitaxel-induced neuropathic pain.	Paclitaxel	119-129	solute carrier family 12 member 2	Rattus norvegicus	51-56
15130763-11	2004	In conclusion, the tyrosine kinase p56/Lck is essential for apoptosis induction by Doxorubicin, Paclitaxel and 5-Fluorouracil regulating early steps of the mitochondrial apoptosis signaling cascade, including alteration of mitochondrial functions and caspase-activation.	Paclitaxel	96-106	cyclin dependent kinase like 2	Homo sapiens	35-38
15130763-11	2004	In conclusion, the tyrosine kinase p56/Lck is essential for apoptosis induction by Doxorubicin, Paclitaxel and 5-Fluorouracil regulating early steps of the mitochondrial apoptosis signaling cascade, including alteration of mitochondrial functions and caspase-activation.	Paclitaxel	96-106	caspase 8	Homo sapiens	251-258
14695913-9	2004	Aurora-A was not found in the spindle region when colchicine or staurosporine was used to inhibit microtubule organization, while it accumulated as several dots in the cytoplasm after taxol treatment.	Paclitaxel	184-189	aurora kinase A	Mus musculus	0-8
15894563-10	2005	The interactions of alphaB-crystallin and tubulin/MT were observed with immunoprecipitation with an anti-alpha-tubulin antibody and taxol-dependent MT assembly.	Paclitaxel	132-137	crystallin, alpha B	Rattus norvegicus	20-37
15901749-1	2005	Interindividual differences in the pharmacokinetics of paclitaxel and its metabolites in Japanese ovarian cancer patients were investigated in relation to genetic polymorphisms of the CYP2C8, CYP3A4, and MDR1 genes.	Paclitaxel	55-65	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	184-190
25253692-5	2014	Paclitaxel treatment significantly increased protein levels, but not mRNA levels, of NKCC1 in spinal cords.	Paclitaxel	0-10	solute carrier family 12 member 2	Rattus norvegicus	85-90
25253692-6	2014	Inhibition of NKCC1 with bumetanide reversed the paclitaxel effect on GABA-mediated hyperpolarization and GABA reversal potentials.	Paclitaxel	49-59	solute carrier family 12 member 2	Rattus norvegicus	14-19
15899810-1	2005	C19ORF5 is a sequence homologue of microtubule-associated proteins MAP1A/MAP1B of unknown function, except for its association with mitochondria-associated proteins and the paclitaxel-like microtubule stabilizer and candidate tumor suppressor RASSF1A.	Paclitaxel	173-183	microtubule associated protein 1S	Homo sapiens	0-7
15899810-3	2005	Although normally distributed throughout the cytosol without microtubular association, C19ORF5C specifically accumulated on stabilized microtubules in paclitaxel-treated cells and interacted directly with paclitaxel-stabilized microtubules in vitro.	Paclitaxel	151-161	microtubule associated protein 1S	Homo sapiens	87-95
25253692-9	2014	Remarkably, paclitaxel increased NKCC1 protein levels at the plasma membrane and reduced NKCC1 levels in the cytosol of spinal cords.	Paclitaxel	12-22	solute carrier family 12 member 2	Rattus norvegicus	33-38
15899810-3	2005	Although normally distributed throughout the cytosol without microtubular association, C19ORF5C specifically accumulated on stabilized microtubules in paclitaxel-treated cells and interacted directly with paclitaxel-stabilized microtubules in vitro.	Paclitaxel	205-215	microtubule associated protein 1S	Homo sapiens	87-95
14679209-8	2004	Taxol or okadaic acid treatment of HL-60 cells results in proteolysis of nucleolin in a similar time frame as drug-induced bcl-2 mRNA down-regulation.	Paclitaxel	0-5	nucleolin	Homo sapiens	73-82
14679209-9	2004	These findings suggest that nucleolin functions as a bcl-2-stabilizing factor and that taxol and okadaic acid treatment induces apoptosis in HL-60 cells through a process that involves down-regulation of nucleolin and destabilization of bcl-2 mRNA.	Paclitaxel	87-92	nucleolin	Homo sapiens	204-213
15809765-0	2005	IFN-gamma enhances paclitaxel-induced apoptosis that is modulated by activation of caspases 8 and 3 with a concomitant down regulation of the AKT survival pathway in cultured human keratinocytes.	Paclitaxel	19-29	caspase 8	Homo sapiens	83-99
25253692-9	2014	Remarkably, paclitaxel increased NKCC1 protein levels at the plasma membrane and reduced NKCC1 levels in the cytosol of spinal cords.	Paclitaxel	12-22	solute carrier family 12 member 2	Rattus norvegicus	89-94
15809765-11	2005	The synergistic effect of these two agents on HaCaT cells relies on a pathway involving caspases 8 and 3, with activity increasing by 48 h. Collectively, our data indicate that i) paclitaxel-induced apoptosis is enhanced by IFN-gamma; ii) the down-regulation of PI3-K/AKT survival pathway may help potentiate the apoptotic effects of paclitaxel and iii) the apoptotic signaling pathways are initiated with the activation of caspases 8 and 3 activities.	Paclitaxel	180-190	caspase 8	Homo sapiens	88-104
15809765-11	2005	The synergistic effect of these two agents on HaCaT cells relies on a pathway involving caspases 8 and 3, with activity increasing by 48 h. Collectively, our data indicate that i) paclitaxel-induced apoptosis is enhanced by IFN-gamma; ii) the down-regulation of PI3-K/AKT survival pathway may help potentiate the apoptotic effects of paclitaxel and iii) the apoptotic signaling pathways are initiated with the activation of caspases 8 and 3 activities.	Paclitaxel	180-190	caspase 8	Homo sapiens	424-440
25253692-11	2014	In addition, inhibition of the motor protein dynein blocked paclitaxel-induced subcellular redistribution of NKCC1, whereas inhibition of kinesin-5 mimicked the paclitaxel effect.	Paclitaxel	60-70	solute carrier family 12 member 2	Rattus norvegicus	109-114
15809768-8	2005	The cytotoxity assay results demonstrated that cells overexpressing the Id-1 gene increased in their resistance to doxorubicin, paclitaxel and cyclophosphamide.	Paclitaxel	128-138	inhibitor of DNA binding 1, HLH protein	Homo sapiens	72-76
15809768-9	2005	MIF expression can drive cells to increase in their resistance to paclitaxel, and GSTpi expression confers drug resistance to doxorubicin and cyclophosphamide.	Paclitaxel	66-76	macrophage migration inhibitory factor	Homo sapiens	0-3
25253692-12	2014	Our findings suggest that increased NKCC1 activity contributes to diminished spinal synaptic inhibition and neuropathic pain caused by paclitaxel.	Paclitaxel	135-145	solute carrier family 12 member 2	Rattus norvegicus	36-41
14676216-4	2004	Perturbing the p120-microtubule interaction with nocodazole or taxol markedly affected both the tubulin interaction and the balance between cytoplasmic and nuclear p120.	Paclitaxel	63-68	catenin delta 1	Homo sapiens	15-19
25253692-13	2014	Paclitaxel disrupts intracellular NKCC1 trafficking by interfering with microtubule dynamics and associated motor proteins.	Paclitaxel	0-10	solute carrier family 12 member 2	Rattus norvegicus	34-39
14676216-4	2004	Perturbing the p120-microtubule interaction with nocodazole or taxol markedly affected both the tubulin interaction and the balance between cytoplasmic and nuclear p120.	Paclitaxel	63-68	catenin delta 1	Homo sapiens	164-168
25175513-12	2014	Inhibition of hMSH2 expression in vitro restores paclitaxel sensitivity in paclitaxel-resistant ovarian carcinoma cell lines and indicates a new direction in adjuvant therapy for ovarian carcinoma.	Paclitaxel	75-85	mutS homolog 2	Homo sapiens	14-19
25175786-0	2014	MyD88 expression is associated with paclitaxel resistance in lung cancer A549 cells.	Paclitaxel	36-46	MYD88 innate immune signal transduction adaptor	Homo sapiens	0-5
15781655-2	2005	The seco-taxane IDN5390 was chosen for its selective activity in paclitaxel-resistant cells with an overexpression of class III beta-tubulin.	Paclitaxel	65-75	tubulin beta 3 class III	Homo sapiens	118-140
25175786-1	2014	The purpose of the present study was to investigate the relationship between myeloid differentiation primary response gene 88 (MyD88) expression and the resistance to paclitaxel of A549 lung cancer cells.	Paclitaxel	167-177	MYD88 innate immune signal transduction adaptor	Homo sapiens	127-132
15781655-4	2005	In the presence of an anti-class III beta-tubulin as a blocking antibody, tubulin polymerization induced by paclitaxel and IDN5390 was enhanced and not affected, respectively, whereas synergism was abolished, thereby indicating that IDN5390 activity is not modulated by class III beta-tubulin levels.	Paclitaxel	108-118	tubulin beta 3 class III	Homo sapiens	27-49
15781655-4	2005	In the presence of an anti-class III beta-tubulin as a blocking antibody, tubulin polymerization induced by paclitaxel and IDN5390 was enhanced and not affected, respectively, whereas synergism was abolished, thereby indicating that IDN5390 activity is not modulated by class III beta-tubulin levels.	Paclitaxel	108-118	tubulin beta 3 class III	Homo sapiens	270-292
15781655-5	2005	Such properties can be explained by taking into consideration the composition of class III beta-tubulin paclitaxel binding site; in fact, Ser277 interacting with paclitaxel C group in class I is replaced by an Arginine in class III.	Paclitaxel	104-114	tubulin beta 3 class III	Homo sapiens	81-103
15781655-5	2005	Such properties can be explained by taking into consideration the composition of class III beta-tubulin paclitaxel binding site; in fact, Ser277 interacting with paclitaxel C group in class I is replaced by an Arginine in class III.	Paclitaxel	162-172	tubulin beta 3 class III	Homo sapiens	81-103
15026542-8	2004	Clusterin ASO or siRNA decreased clusterin mRNA expression in A549 cells &gt;75% in a dose-dependent, sequence-specific manner, and significantly enhanced chemosensitivity to paclitaxel in vitro.	Paclitaxel	175-185	clusterin	Homo sapiens	0-9
15026542-10	2004	In vivo administration of clusterin ASO, compared to mismatch control oligonucleotide, synergistically enhanced the effects of paclitaxel or gemcitibine to significantly delay A549 tumor growth.	Paclitaxel	127-137	clusterin	Homo sapiens	26-35
25175786-7	2014	The results showed that the overexpression of MyD88 increased the resistance of lung cancer A549 cells to paclitaxel, while the suppression of MyD88 increased the sensitivity of A549 lung cancer cells to paclitaxel.	Paclitaxel	106-116	MYD88 innate immune signal transduction adaptor	Homo sapiens	46-51
25175786-7	2014	The results showed that the overexpression of MyD88 increased the resistance of lung cancer A549 cells to paclitaxel, while the suppression of MyD88 increased the sensitivity of A549 lung cancer cells to paclitaxel.	Paclitaxel	204-214	MYD88 innate immune signal transduction adaptor	Homo sapiens	143-148
25175786-8	2014	Following the paclitaxel treatment, a decreased apoptosis and G2 phase ratio, an increased cell migration ratio, and an increased production of IL-8 were found in MyD88-overexpressed A549 cells.	Paclitaxel	14-24	MYD88 innate immune signal transduction adaptor	Homo sapiens	163-168
25175786-10	2014	These findings suggested that the expression level of MyD88 is closely associated with paclitaxel resistance in A549 lung cancer cells.	Paclitaxel	87-97	MYD88 innate immune signal transduction adaptor	Homo sapiens	54-59
15601807-1	2005	Cytochrome P450 2C8 is involved in the metabolism of drugs such as paclitaxel, repaglinide, rosiglitazone, and cerivastatin, among others.	Paclitaxel	67-77	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-19
25175786-11	2014	Thus, the downregulation of MyD88 in A549 cells increased its sensitivity to paclitaxel treatment, whereas the upregulation of MyD88 substantiates its paclitaxel resistance.	Paclitaxel	77-87	MYD88 innate immune signal transduction adaptor	Homo sapiens	28-33
25175786-11	2014	Thus, the downregulation of MyD88 in A549 cells increased its sensitivity to paclitaxel treatment, whereas the upregulation of MyD88 substantiates its paclitaxel resistance.	Paclitaxel	151-161	MYD88 innate immune signal transduction adaptor	Homo sapiens	127-132
25160618-5	2014	Enzyme reconstitution experiments showed that both microsomal and mitochondrial WT CYP2C8 efficiently catalyzed paclitaxel 6-hydroxylation.	Paclitaxel	112-122	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	83-89
16260854-2	2005	Patients with newly diagnosed inoperable non-small cell lung cancer received paclitaxel (100 mg/m(2)) as a 1-h infusion on d 1,8,15,28,35, and 42.	Paclitaxel	77-87	leiomodin 1	Homo sapiens	123-126
14722235-8	2004	Rifampin, paclitaxel, and hyperforin sensitivity was conferred to rat PXR when Phe305 was converted to leucine, whereas attenuation of sensitivity was observed when Leu308 of human PXR was replaced with phenylalanine.	Paclitaxel	10-20	nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus	70-73
14587026-10	2003	4-HPR was much weaker than the natural retinoids with respect to Taxol sensitization, consistent with the proposed requirement for reduced Bcl-2 in this synergy.	Paclitaxel	65-70	haptoglobin-related protein	Homo sapiens	2-5
14617792-7	2003	Paclitaxel down-regulated the expression of Bcl-xL and inhibitor of apoptosis proteins (c-IAP-1) and up-regulated the expression of Bad and Apaf-1.	Paclitaxel	0-10	baculoviral IAP repeat containing 2	Homo sapiens	88-95
15581350-4	2004	Twenty CYP2C8 site-directed mutants were constructed and expressed in yeast to compare their catalytic activities using five CYP2C8 substrates that exhibit different structures and sizes [paclitaxel, fluvastatin, retinoic acid, a sulfaphenazole derivative (DMZ), and diclofenac].	Paclitaxel	188-198	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	7-13
25268318-0	2014	Thiamet-G-mediated inhibition of O-GlcNAcase sensitizes human leukemia cells to microtubule-stabilizing agent paclitaxel.	Paclitaxel	110-120	O-GlcNAcase	Homo sapiens	33-44
15581350-6	2004	Serine 100 appears to be involved in hydrogen bonding interactions with a polar site of the CYP2C8 substrate pharmacophore, as shown by the 3-4-fold increase in the K(m) of paclitaxel and DMZ hydroxylation after the S100A mutation.	Paclitaxel	173-183	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	92-98
15581350-9	2004	The S114F and F205A mutants were the best catalysts for retinoic acid and paclitaxel (or fluvastatin) hydroxylation, respectively, with k(cat)/K(m) values 5 and 2.1 (or 2.4) times higher, respectively, than those found for CYP2C8.	Paclitaxel	74-84	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	223-229
14561082-1	2003	A novel water-soluble paclitaxel complex has been prepared by inclusion complexation with bridged bis(beta-cyclodextrin)s and characterized by means of (1)H NMR, SEM, powder X-ray diffraction patterns, TG-DTA, DSC, FT-IR, and 2D NOESY.	Paclitaxel	22-32	desmocollin 3	Homo sapiens	210-213
25268318-3	2014	Here, we show that the highly selective O-GlcNAcase (OGA) inhibitor thiamet-G significantly sensitized human leukemia cell lines to paclitaxel, with an approximate 10-fold leftward shift of IC50.	Paclitaxel	132-142	O-GlcNAcase	Homo sapiens	40-51
12973835-5	2003	The underlying molecular mechanism is that ErbB2 inhibits p34(Cdc2) activation, which is required for taxol-induced apoptosis, by up-regulating p21(Cip1) and by hyperphosphorylating p34(Cdc2) on tyrosine-15.	Paclitaxel	102-107	alpha and gamma adaptin binding protein	Homo sapiens	58-61
15585644-2	2004	The purpose of this study is to investigate the possible role of pRb2/p130 in the sensitivity of ovarian cancer to camptothecin, doxorubicin, and taxol.	Paclitaxel	146-151	proline rich protein BstNI subfamily 2	Homo sapiens	65-69
25268318-3	2014	Here, we show that the highly selective O-GlcNAcase (OGA) inhibitor thiamet-G significantly sensitized human leukemia cell lines to paclitaxel, with an approximate 10-fold leftward shift of IC50.	Paclitaxel	132-142	O-GlcNAcase	Homo sapiens	53-56
25344863-6	2014	In Taxol-resistant cells, down-regulation of bcl-xL expression by the DNAzyme reversed the chemo-resistant phenotype of the cancer cells.	Paclitaxel	3-8	BCL2-like 1	Mus musculus	45-51
12807915-12	2003	G beta/tubulin colocalization increased after pretreatment of cells with the microtubule-depolymerizing agent, colchicine, and was inhibited by taxol.	Paclitaxel	144-149	succinate-CoA ligase GDP-forming subunit beta	Homo sapiens	0-6
25344863-7	2014	In a xenograft mouse model, the DNAzyme was delivered into the tumors via an ALZET osmotic pump and shown to chemosensitize PC3 tumor when treating with Taxol.	Paclitaxel	153-158	chromobox 8	Mus musculus	124-127
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Paclitaxel	28-38	TNF receptor superfamily member 10a	Homo sapiens	137-153
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Paclitaxel	28-38	TNF receptor superfamily member 10a	Homo sapiens	154-157
15386340-10	2004	Taxol and oxaliplatin significantly increased the levels of expression of COX-2, PGES, GST-mu, and GST-pi in a number of different experimental protocols.	Paclitaxel	0-5	prostaglandin-endoperoxide synthase 2	Mus musculus	74-79
15492279-8	2004	After complete blockade of PTX-induced TP translation by TP antisense transfection, cleaved form of caspase-3 and poly(ADP-ribose) polymerase was increased, and this exaggeration of apoptosis also ran parallel with caspase-8 activation in a PTX dose-dependent manner.	Paclitaxel	27-30	caspase 8	Homo sapiens	215-224
15492279-10	2004	These results indicate that PTX-induced TP up-regulation is associated with decreased caspase-8 activation.	Paclitaxel	28-31	caspase 8	Homo sapiens	86-95
25045845-0	2014	The telomere/telomerase binding factor PinX1 regulates paclitaxel sensitivity depending on spindle assembly checkpoint in human cervical squamous cell carcinomas.	Paclitaxel	55-65	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	39-44
25045845-2	2014	We investigated the roles and underlying molecular mechanisms of PinX1 in cervical squamous cell carcinomas (CSCC) cells response to paclitaxel and its clinical significances.	Paclitaxel	133-143	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	65-70
25045845-3	2014	The expression dynamics of PinX1 was first examined by immunohistochemistry in 122 advanced CSCC patients treated with cisplatin/paclitaxel chemotherapy.	Paclitaxel	129-139	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	27-32
15358225-3	2004	Furthermore, paclitaxel rapidly activated the JNK, ERK, and p38 mitogen-activated protein kinase pathways.	Paclitaxel	13-23	mitogen activated protein kinase 14	Rattus norvegicus	60-63
25045845-4	2014	The expression of PinX1 was significantly associated with the effects of cisplatin/paclitaxel chemotherapy in advanced CSCCs (P&lt;0.05).	Paclitaxel	83-93	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	18-23
25045845-5	2014	High expression of PinX1 correlated with CSCC"s response to cisplatin/paclitaxel chemotherapy, and was an independent predictor of shortened survival (P&lt;0.05).	Paclitaxel	70-80	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	19-24
15358225-4	2004	A specific inhibitor of JNK, SP600125, abolished paclitaxel-induced HO-1 mRNA expression, whereas PD98059, a specific inhibitor of ERK, and SB203580, a specific inhibitor of p38, had no significant effect.	Paclitaxel	49-59	mitogen activated protein kinase 14	Rattus norvegicus	174-177
25045845-6	2014	A series of in vivo and in vitro assays were performed to elucidate the function of PinX1 on CSCC cells chemosensitivity to paclitaxel and underlying mechanisms.	Paclitaxel	124-134	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	84-89
15269161-9	2004	In addition, biochemical examinations revealed that gamma-radiation inhibited paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation and increased the protein levels of cyclin B1 and inhibitory phosphorylation of p34(cdc2).	Paclitaxel	78-88	cyclin H	Homo sapiens	228-231
12669189-4	2003	Paclitaxel 6"-hydroxylation and CYP2C8 expression correlated with paraoxon formation ( P&lt;0.01), indicating CYP2C8 involvement.	Paclitaxel	0-10	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	110-116
25045845-7	2014	In CSCC cells, the levels of PinX1 were only associated with the cytotoxicity and sensitivity of paclitaxel, in which knockdown of PinX1 dramatically enhanced paclitaxel cytotoxicity, whereas the reestablishment of PinX1 levels substantially reduced the paclitaxel-induced killing effect.	Paclitaxel	97-107	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	29-34
12761490-4	2003	Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).	Paclitaxel	235-245	erb-b2 receptor tyrosine kinase 3	Homo sapiens	62-66
15141302-5	2004	The observed effect of taxol was mediated through induction of iNOS transcription factors NF-kappaB and IRF-1, and required the activation of p38 MAP kinase and JNK.	Paclitaxel	23-28	interferon regulatory factor 1	Rattus norvegicus	104-109
15141302-5	2004	The observed effect of taxol was mediated through induction of iNOS transcription factors NF-kappaB and IRF-1, and required the activation of p38 MAP kinase and JNK.	Paclitaxel	23-28	mitogen activated protein kinase 14	Rattus norvegicus	142-145
25045845-7	2014	In CSCC cells, the levels of PinX1 were only associated with the cytotoxicity and sensitivity of paclitaxel, in which knockdown of PinX1 dramatically enhanced paclitaxel cytotoxicity, whereas the reestablishment of PinX1 levels substantially reduced the paclitaxel-induced killing effect.	Paclitaxel	97-107	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	131-136
25045845-7	2014	In CSCC cells, the levels of PinX1 were only associated with the cytotoxicity and sensitivity of paclitaxel, in which knockdown of PinX1 dramatically enhanced paclitaxel cytotoxicity, whereas the reestablishment of PinX1 levels substantially reduced the paclitaxel-induced killing effect.	Paclitaxel	97-107	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	131-136
25045845-7	2014	In CSCC cells, the levels of PinX1 were only associated with the cytotoxicity and sensitivity of paclitaxel, in which knockdown of PinX1 dramatically enhanced paclitaxel cytotoxicity, whereas the reestablishment of PinX1 levels substantially reduced the paclitaxel-induced killing effect.	Paclitaxel	159-169	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	29-34
25045845-7	2014	In CSCC cells, the levels of PinX1 were only associated with the cytotoxicity and sensitivity of paclitaxel, in which knockdown of PinX1 dramatically enhanced paclitaxel cytotoxicity, whereas the reestablishment of PinX1 levels substantially reduced the paclitaxel-induced killing effect.	Paclitaxel	159-169	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	131-136
12894555-8	2003	TP gene expression was significantly increased at 72 hours 1 nM Taxol exposure compared to the control by RT-PCR (p = 0.020).	Paclitaxel	64-69	thymidine phosphorylase	Homo sapiens	0-2
12894555-9	2003	Western blot analysis confirmed that the TP protein level was elevated compared to the control at 72 hours 1 nM Taxol exposure.	Paclitaxel	112-117	thymidine phosphorylase	Homo sapiens	41-43
25045845-7	2014	In CSCC cells, the levels of PinX1 were only associated with the cytotoxicity and sensitivity of paclitaxel, in which knockdown of PinX1 dramatically enhanced paclitaxel cytotoxicity, whereas the reestablishment of PinX1 levels substantially reduced the paclitaxel-induced killing effect.	Paclitaxel	159-169	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	131-136
12894555-12	2003	CONCLUSION: Our results show that a low concentration of Taxol is a candidate for increasing TP expression in a human ovarian carcinoma cell line, and that cells with an elevated level of TP expression can be further sensitized to Furtulon.	Paclitaxel	57-62	thymidine phosphorylase	Homo sapiens	93-95
12644839-7	2003	PI3 kinase inhibitor, wortmannin, or a dominant-negative AKT1 expression vector treatment partially enhanced Taxol-induced apoptosis indicating that PI3 kinase-AKT pathway was involved in Taxol-resistance pathway.	Paclitaxel	109-114	peptidase inhibitor 3	Homo sapiens	0-3
12644839-7	2003	PI3 kinase inhibitor, wortmannin, or a dominant-negative AKT1 expression vector treatment partially enhanced Taxol-induced apoptosis indicating that PI3 kinase-AKT pathway was involved in Taxol-resistance pathway.	Paclitaxel	109-114	peptidase inhibitor 3	Homo sapiens	149-152
15100167-5	2004	In addition, the formation of the hydroxy metabolite correlated well with CYP2C8-selective paclitaxel 6alpha-hydroxylation (r(2) approximately 0.92; p &lt; 0.0001) and amodiaquine N-de-ethylation (r(2) approximately 0.91; p &lt; 0.0001) in a bank of human liver microsomes (n = 15 organ donors).	Paclitaxel	91-101	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	74-80
15099972-9	2004	However, PAC-1 expression was significantly higher in effusions obtained before the institution of treatment with both platinum compounds (P = 0.029) and paclitaxel (P = 0.036).	Paclitaxel	154-164	dual specificity phosphatase 2	Homo sapiens	9-14
15012603-1	2004	Results presented in this study demonstrate that treatment of MCF-7 cells with taxol resulted in induction of estrogen receptor-alpha (ER alpha) gene transcription with a subsequent increase in ER alpha mRNA; this effect was promoter specific since taxol did not affect total transcription in MCF-7 cells and lacked an effect on transcription of the human acidic ribosomal phosphoprotein protein PO, progesterone receptor, and pS2 genes.	Paclitaxel	79-84	progesterone receptor	Homo sapiens	400-421
25045845-7	2014	In CSCC cells, the levels of PinX1 were only associated with the cytotoxicity and sensitivity of paclitaxel, in which knockdown of PinX1 dramatically enhanced paclitaxel cytotoxicity, whereas the reestablishment of PinX1 levels substantially reduced the paclitaxel-induced killing effect.	Paclitaxel	159-169	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	29-34
25045845-7	2014	In CSCC cells, the levels of PinX1 were only associated with the cytotoxicity and sensitivity of paclitaxel, in which knockdown of PinX1 dramatically enhanced paclitaxel cytotoxicity, whereas the reestablishment of PinX1 levels substantially reduced the paclitaxel-induced killing effect.	Paclitaxel	159-169	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	131-136
14569416-8	2004	Quantitative real-time RT-PCR indicated that Ang-1 gene expression was significantly decreased by exposure to 2 nM Taxol for 168 h ( P&lt;0.05 vs control cells).	Paclitaxel	115-120	angiopoietin 1	Homo sapiens	45-50
25045845-7	2014	In CSCC cells, the levels of PinX1 were only associated with the cytotoxicity and sensitivity of paclitaxel, in which knockdown of PinX1 dramatically enhanced paclitaxel cytotoxicity, whereas the reestablishment of PinX1 levels substantially reduced the paclitaxel-induced killing effect.	Paclitaxel	159-169	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	131-136
14569416-9	2004	Western blot analysis confirmed that the Ang-1 protein level was decreased by exposure to 2 nM Taxol for 168 h. Ang-2 gene expression did not significantly differ between control cells and those exposed to Taxol for any of the indicated times.	Paclitaxel	95-100	angiopoietin 1	Homo sapiens	41-46
12644839-7	2003	PI3 kinase inhibitor, wortmannin, or a dominant-negative AKT1 expression vector treatment partially enhanced Taxol-induced apoptosis indicating that PI3 kinase-AKT pathway was involved in Taxol-resistance pathway.	Paclitaxel	188-193	peptidase inhibitor 3	Homo sapiens	0-3
12644839-7	2003	PI3 kinase inhibitor, wortmannin, or a dominant-negative AKT1 expression vector treatment partially enhanced Taxol-induced apoptosis indicating that PI3 kinase-AKT pathway was involved in Taxol-resistance pathway.	Paclitaxel	188-193	peptidase inhibitor 3	Homo sapiens	149-152
14569416-10	2004	The Ang-1/ Ang-2 gene expression ratio was significantly decreased by exposure to Taxol for 168 h ( P&lt;0.05 vs control cells).	Paclitaxel	82-87	angiopoietin 1	Homo sapiens	4-9
12644839-9	2003	Our results indicate that the combination of cyclosporin A and Taxol is effective in the reversal of Taxol resistance through the inhibition of PI3 kinase-AKT1 pathway.	Paclitaxel	63-68	peptidase inhibitor 3	Homo sapiens	144-147
14569416-10	2004	The Ang-1/ Ang-2 gene expression ratio was significantly decreased by exposure to Taxol for 168 h ( P&lt;0.05 vs control cells).	Paclitaxel	82-87	angiopoietin 2	Homo sapiens	11-16
25045845-8	2014	In addition, we identified that the ability of PinX1 to stabilize the tension between sister kinetochores and maintain the spindle assembly checkpoint was the main reason CSCC cells undergo apoptosis when treated with paclitaxel, and further studies demonstrated that shortened distance between sisters kinetochores by nocodazole confers upon PinX1-replenished cells a sensitivity to the death inducing paclitaxel effects.	Paclitaxel	218-228	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	47-52
12644839-9	2003	Our results indicate that the combination of cyclosporin A and Taxol is effective in the reversal of Taxol resistance through the inhibition of PI3 kinase-AKT1 pathway.	Paclitaxel	101-106	peptidase inhibitor 3	Homo sapiens	144-147
25045845-8	2014	In addition, we identified that the ability of PinX1 to stabilize the tension between sister kinetochores and maintain the spindle assembly checkpoint was the main reason CSCC cells undergo apoptosis when treated with paclitaxel, and further studies demonstrated that shortened distance between sisters kinetochores by nocodazole confers upon PinX1-replenished cells a sensitivity to the death inducing paclitaxel effects.	Paclitaxel	218-228	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	343-348
25045845-8	2014	In addition, we identified that the ability of PinX1 to stabilize the tension between sister kinetochores and maintain the spindle assembly checkpoint was the main reason CSCC cells undergo apoptosis when treated with paclitaxel, and further studies demonstrated that shortened distance between sisters kinetochores by nocodazole confers upon PinX1-replenished cells a sensitivity to the death inducing paclitaxel effects.	Paclitaxel	403-413	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	47-52
15138361-0	2004	Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas ligand expression and induces apoptosis which can be inhibited through the CD40 receptor.	Paclitaxel	0-10	CD40 molecule	Homo sapiens	142-146
15138361-6	2004	Finally, the paclitaxel sensitivity of the CD40-negative cell line KS was compared to that of its CD40-positive transfectant KS-CD40.	Paclitaxel	13-23	CD40 molecule	Homo sapiens	43-47
25045845-9	2014	Furthermore, our study of CSCC cells xenografts in nude mice confirmed the role of PinX1 in paclitaxel sensitivity in vivo.	Paclitaxel	92-102	PIN2/TERF1 interacting, telomerase inhibitor 1	Mus musculus	83-88
15138361-10	2004	Interestingly, stimulation of the CD40 receptor inhibited paclitaxel-induced apoptosis in the transfected cell line KS-CD40, suggesting a role of this receptor in the modulation of chemosensitivity.	Paclitaxel	58-68	CD40 molecule	Homo sapiens	34-38
12634614-3	2003	Mdr1a/1b(-/-) mice excrete very low quantities of unchanged paclitaxel.	Paclitaxel	60-70	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	0-5
15138361-10	2004	Interestingly, stimulation of the CD40 receptor inhibited paclitaxel-induced apoptosis in the transfected cell line KS-CD40, suggesting a role of this receptor in the modulation of chemosensitivity.	Paclitaxel	58-68	CD40 molecule	Homo sapiens	119-123
25107571-5	2014	RESULTS: Patients with negative expression of APE1, ERCC1 or TUBB3 benefited from platinum plus paclitaxel regimen chemotherapy.	Paclitaxel	96-106	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	46-50
12951326-2	2003	The microtubule disrupting agents nocodazole and colchicine strongly up-regulated CTGF expression, which was prevented upon stabilization of the microtubules by paclitaxel.	Paclitaxel	161-171	cellular communication network factor 2	Homo sapiens	82-86
12579291-3	2003	The sensitivity of PC3 cells to paclitaxel was increased by pretreatment with monoclonal antibody (mAb) to clusterin or antisense (AS) oligodeoxynucleotide (ODN) targeting the clusterin gene in a dose-dependent manner at up to 50 microg/ml or 1 microM, respectively.	Paclitaxel	32-42	clusterin	Homo sapiens	107-116
12579291-3	2003	The sensitivity of PC3 cells to paclitaxel was increased by pretreatment with monoclonal antibody (mAb) to clusterin or antisense (AS) oligodeoxynucleotide (ODN) targeting the clusterin gene in a dose-dependent manner at up to 50 microg/ml or 1 microM, respectively.	Paclitaxel	32-42	clusterin	Homo sapiens	176-185
12579291-6	2003	These findings suggest that the sensitivity of PC3 cells to paclitaxel-induced cytotoxicity may be regulated by the intracellular rather than extracellular level of clusterin.	Paclitaxel	60-70	clusterin	Homo sapiens	165-174
12966166-5	2003	Syt IX also colocalizes with tubulin at the microtubules organizing center (MTOC) and remains associated with tubulin clusters formed in taxol-treated cells.	Paclitaxel	137-142	synaptotagmin 5	Rattus norvegicus	0-6
25107571-5	2014	RESULTS: Patients with negative expression of APE1, ERCC1 or TUBB3 benefited from platinum plus paclitaxel regimen chemotherapy.	Paclitaxel	96-106	tubulin beta 3 class III	Homo sapiens	61-66
25107571-9	2014	Moreover, patients with both APE1- and ERCC1-negative or both APE1- and TUBB3-negative tumors had significantly higher response rate, longer median PFS and OS following treatment with platinum and paclitaxel (P &lt; 0.05).	Paclitaxel	197-207	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	29-33
25107571-9	2014	Moreover, patients with both APE1- and ERCC1-negative or both APE1- and TUBB3-negative tumors had significantly higher response rate, longer median PFS and OS following treatment with platinum and paclitaxel (P &lt; 0.05).	Paclitaxel	197-207	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	62-66
12953069-14	2003	Depolymerizing microtubules with nocodazole increased nuclear p120, whereas stabilizing tubulin with taxol reduced nuclear p120 and strongly increased p120 association with microtubules.	Paclitaxel	101-106	catenin delta 1	Homo sapiens	123-127
25107571-9	2014	Moreover, patients with both APE1- and ERCC1-negative or both APE1- and TUBB3-negative tumors had significantly higher response rate, longer median PFS and OS following treatment with platinum and paclitaxel (P &lt; 0.05).	Paclitaxel	197-207	tubulin beta 3 class III	Homo sapiens	72-77
12953069-14	2003	Depolymerizing microtubules with nocodazole increased nuclear p120, whereas stabilizing tubulin with taxol reduced nuclear p120 and strongly increased p120 association with microtubules.	Paclitaxel	101-106	catenin delta 1	Homo sapiens	123-127
25107571-10	2014	CONCLUSION: The data indicate that APE1, ERCC1 and TUBB3 could be a useful biomarker to predict clinical outcome in patients with advanced NSCLC receiving first-line platinum-paclitaxel chemotherapy.	Paclitaxel	175-185	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	35-39
25107571-10	2014	CONCLUSION: The data indicate that APE1, ERCC1 and TUBB3 could be a useful biomarker to predict clinical outcome in patients with advanced NSCLC receiving first-line platinum-paclitaxel chemotherapy.	Paclitaxel	175-185	tubulin beta 3 class III	Homo sapiens	51-56
12417528-12	2002	Arl3 behaved as a microtubule-associated protein: it co-localized with microtubules in HeLa cells and this was enhanced following microtubule stabilization with taxol.	Paclitaxel	161-166	ADP ribosylation factor like GTPase 3	Homo sapiens	0-4
12967198-8	2003	In addition, the DCQ formation significantly correlated with the CYP3A4/5-catalyzed midazolam 1-hydroxylation (r = 0.868) and CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation (r = 0.900).	Paclitaxel	143-153	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	126-132
12226754-8	2002	This is due to the Taxol-mediated reactivation of RelA through phosphorylation and degradation of IkappaBbeta and the re-expression of NF-kappaB regulated bcl-xl gene in these cancer cells as ectopic expression of the bcl-xl gene confers resistance to Taxol-induced apoptosis in PS-341 sensitized cells.	Paclitaxel	19-24	RELA proto-oncogene, NF-kB subunit	Homo sapiens	50-54
25327563-9	2014	The increase in CD133+ cells resulting from ARID3B expression was accompanied by enhanced paclitaxel resistance.	Paclitaxel	90-100	prominin 1	Homo sapiens	16-21
12226754-8	2002	This is due to the Taxol-mediated reactivation of RelA through phosphorylation and degradation of IkappaBbeta and the re-expression of NF-kappaB regulated bcl-xl gene in these cancer cells as ectopic expression of the bcl-xl gene confers resistance to Taxol-induced apoptosis in PS-341 sensitized cells.	Paclitaxel	252-257	RELA proto-oncogene, NF-kB subunit	Homo sapiens	50-54
12087097-0	2002	Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel.	Paclitaxel	95-105	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	41-46
12087097-10	2002	Moreover, because paclitaxel-induced apoptosis is mediated by activated Raf-1 and the region surrounding Ser-259 in Raf-1 conforms to a consensus sequence for phosphorylation by Akt, the regulation of Raf-1 by Akt was examined.	Paclitaxel	18-28	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	72-77
12087097-10	2002	Moreover, because paclitaxel-induced apoptosis is mediated by activated Raf-1 and the region surrounding Ser-259 in Raf-1 conforms to a consensus sequence for phosphorylation by Akt, the regulation of Raf-1 by Akt was examined.	Paclitaxel	18-28	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	116-121
12087097-10	2002	Moreover, because paclitaxel-induced apoptosis is mediated by activated Raf-1 and the region surrounding Ser-259 in Raf-1 conforms to a consensus sequence for phosphorylation by Akt, the regulation of Raf-1 by Akt was examined.	Paclitaxel	18-28	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	116-121
12959183-11	2003	Oncogenic activation of gamma-synuclein promotes cell survival and provides resistance to paclitaxel, but such a resistance is partially overcome by an MEK inhibitor that suppresses ERK activity.	Paclitaxel	90-100	synuclein gamma	Homo sapiens	24-39
25016949-1	2014	AIM: To investigate the role of microtubule associated protein-tau (MAP-tau) and beta-tubulin III (TUBB3) in predicting the chemosensitivity of paclitaxel in patients with advanced gastric cancer (GC).	Paclitaxel	144-154	tubulin beta 3 class III	Homo sapiens	99-104
25016949-3	2014	The associations of MAP-tau and TUBB3 expressions with paclitaxel sensitivity were assessed using in vitro and in vivo xenograft analysis.	Paclitaxel	55-65	tubulin beta 3 class III	Homo sapiens	32-37
12738804-8	2003	Further, our data obtained from experiments involving in vitro taxol-polymerization of tubulin and confocal immunofluorescence suggest that PS1, via CLIP-170, may serve as an anchor to the microtubules for specific subcellular fractions containing amyloidogenic fragments.	Paclitaxel	63-68	presenilin 1	Homo sapiens	140-143
12193553-7	2002	Significantly, transient transfection with ch Survivin-142 in primary cultures of hen granulosa cells attenuates taxol- and N-octanoylsphingosine- (C8-ceramide-) induced caspase-3 activity, whereas overexpression of ch Survivin-short (a truncated variant that lacks much of the functional BIR domain plus the entire alpha-helix coil domain) lacks this antiapoptotic activity.	Paclitaxel	113-118	baculoviral IAP repeat containing 5	Gallus gallus	46-54
25016949-7	2014	In in vitro studies, the sensitivity of paclitaxel in human gastric cancer cells was inversely correlated with the expression levels of MAP-tau and TUBB3, as in in vivo animal xenografts.	Paclitaxel	40-50	tubulin beta 3 class III	Homo sapiens	148-153
12139759-0	2002	MyD88 is involved in the signalling pathway for Taxol-induced apoptosis and TNF-alpha expression in human myelomonocytic cells.	Paclitaxel	48-53	MYD88 innate immune signal transduction adaptor	Homo sapiens	0-5
12750265-6	2003	ET(A)R blockade also results in the sensitization to paclitaxel-induced apoptosis.	Paclitaxel	53-63	endothelin receptor type A	Homo sapiens	0-6
25016949-8	2014	CONCLUSIONS: The combination of MAP-tau and TUBB3 was found to predict chemosensitivity to paclitaxel in gastric cancer in vitro and in vivo.	Paclitaxel	91-101	tubulin beta 3 class III	Homo sapiens	44-49
25256200-0	2014	Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam (PAPPA): one-year clinical outcome of a pilot study.	Paclitaxel	28-38	pappalysin 1	Homo sapiens	127-132
12732316-2	2003	Engineered P450 expression is needed for low-cost production of antineoplastic drugs such as taxol or indole alkaloids and offers the possibility to increase the content of nutraceuticals such as phytoestrogens and antioxidants in plants.	Paclitaxel	93-98	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	11-15
12510025-2	2003	trans-Resveratrol reverses phosphorylation of Bcl-2 induced by paclitaxel and concomitantly blocks Raf-1 phosphorylation, also observed after paclitaxel exposure, thus suggesting that Bcl-2 inactivation may be dependent on the activation of the Raf/Ras cascade.	Paclitaxel	142-152	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	99-104
12510025-2	2003	trans-Resveratrol reverses phosphorylation of Bcl-2 induced by paclitaxel and concomitantly blocks Raf-1 phosphorylation, also observed after paclitaxel exposure, thus suggesting that Bcl-2 inactivation may be dependent on the activation of the Raf/Ras cascade.	Paclitaxel	142-152	zinc fingers and homeoboxes 2	Homo sapiens	99-102
12150453-0	2002	Overexpression of cyclin D1 enhances taxol induced mitotic death in MCF7 cells.	Paclitaxel	37-42	cyclin D1	Homo sapiens	18-27
12150453-2	2002	A moderate overexpression of ectopic cyclin D1 accelerated these G2/M associated events and resulted in a reduced clonogenic survival upon taxol treatment.	Paclitaxel	139-144	cyclin D1	Homo sapiens	37-46
12150453-3	2002	Taxol treatment resulted in elevated expression of p53 and of p21, which was more pronounced and persistent in cyclin D1 overexpressing cells.	Paclitaxel	0-5	cyclin D1	Homo sapiens	111-120
12150453-4	2002	Overexpression of cyclin D1 altered sensitivity to taxol by modulating exit from mitosis, which is controlled by p21.	Paclitaxel	51-56	cyclin D1	Homo sapiens	18-27
24905776-0	2014	A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.	Paclitaxel	30-40	plasminogen	Homo sapiens	56-59
12150453-5	2002	These results indicate that overexpression of cyclin D1 sensitizes MCF7 cells to treatment with taxol.	Paclitaxel	96-101	cyclin D1	Homo sapiens	46-55
12063170-8	2002	Taxol also induced phosphorylation of p38 and JNK MAP kinases within 8-15 min after drug treatment.	Paclitaxel	0-5	mitogen-activated protein kinase 14	Mus musculus	38-41
12559175-0	2003	AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.	Paclitaxel	97-102	aurora kinase A	Homo sapiens	0-8
12559175-2	2003	Here we show that elevated Aurora-A expression at levels that reflect cancer-associated gene amplification overrides the checkpoint mechanism that monitors mitotic spindle assembly, inducing resistance to the chemotherapeutic agent paclitaxel (Taxol).	Paclitaxel	232-242	aurora kinase A	Homo sapiens	27-35
12559175-2	2003	Here we show that elevated Aurora-A expression at levels that reflect cancer-associated gene amplification overrides the checkpoint mechanism that monitors mitotic spindle assembly, inducing resistance to the chemotherapeutic agent paclitaxel (Taxol).	Paclitaxel	244-249	aurora kinase A	Homo sapiens	27-35
24905776-1	2014	Herein, we develop a co-delivery system of paclitaxel (PTX) and doxorubicin hydrochloride (DOX HCl) based on methoxypoly(ethylene glycol)-block-poly(L-glutamic acid) (mPEG-b-PLG) for cancer treatment.	Paclitaxel	43-53	plasminogen	Homo sapiens	174-177
12559175-6	2003	Consistent with this conclusion, elevated Aurora-A expression causes resistance to apoptosis induced by Taxol in a human cancer cell line.	Paclitaxel	104-109	aurora kinase A	Homo sapiens	42-50
24905776-1	2014	Herein, we develop a co-delivery system of paclitaxel (PTX) and doxorubicin hydrochloride (DOX HCl) based on methoxypoly(ethylene glycol)-block-poly(L-glutamic acid) (mPEG-b-PLG) for cancer treatment.	Paclitaxel	55-58	plasminogen	Homo sapiens	174-177
12384528-5	2002	Herceptin plus Taxol treatment led to higher levels of p34(Cdc2) kinase activity and apoptosis in ErbB2-overexpressing breast cancer cells, which is likely attributable to inhibition of Cdc2-Tyr-15 phosphorylation and p21(Cip1) expression.	Paclitaxel	15-20	alpha and gamma adaptin binding protein	Homo sapiens	55-58
11901098-2	2002	In spite of their close chemical structure, the two drugs are oxidized by two different enzymes; CYP2C8 catalyzes the 6-hydroxylation on the taxane ring of paclitaxel, whereas CYP3A4 oxidizes docetaxel on the tert-butyl group of the lateral chain in C13.	Paclitaxel	156-166	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	97-103
25153728-0	2014	The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1alpha and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.	Paclitaxel	35-45	CREB regulated transcription coactivator 1	Mus musculus	104-110
12121974-5	2002	We have found that gamma-synuclein-expressing cells are significantly more resistant to the chemotherapeutic drugs paclitaxel and vinblastine as compared with the parental cells.	Paclitaxel	115-125	synuclein gamma	Homo sapiens	19-34
12121974-7	2002	Activation of JNK and its downstream caspase-3 by paclitaxel or vinblastine is significantly down-regulated in gamma-synuclein-expressing cells, indicating that the paclitaxel- or vinblastine-activated apoptosis pathway is blocked by gamma-synuclein.	Paclitaxel	50-60	synuclein gamma	Homo sapiens	111-126
12121974-7	2002	Activation of JNK and its downstream caspase-3 by paclitaxel or vinblastine is significantly down-regulated in gamma-synuclein-expressing cells, indicating that the paclitaxel- or vinblastine-activated apoptosis pathway is blocked by gamma-synuclein.	Paclitaxel	50-60	synuclein gamma	Homo sapiens	234-249
25015454-0	2014	Paclitaxel-resistant HeLa cells have up-regulated levels of reactive oxygen species and increased expression of taxol resistance gene 1.	Paclitaxel	0-10	proline rich 13	Homo sapiens	112-135
12121974-7	2002	Activation of JNK and its downstream caspase-3 by paclitaxel or vinblastine is significantly down-regulated in gamma-synuclein-expressing cells, indicating that the paclitaxel- or vinblastine-activated apoptosis pathway is blocked by gamma-synuclein.	Paclitaxel	165-175	synuclein gamma	Homo sapiens	111-126
12121974-7	2002	Activation of JNK and its downstream caspase-3 by paclitaxel or vinblastine is significantly down-regulated in gamma-synuclein-expressing cells, indicating that the paclitaxel- or vinblastine-activated apoptosis pathway is blocked by gamma-synuclein.	Paclitaxel	165-175	synuclein gamma	Homo sapiens	234-249
12087097-11	2002	We demonstrated an association between Akt and Raf-1 and showed that the phosphorylation of Raf-1 on Ser-259 induced by paclitaxel was blocked by treatment with wortmannin or LY294002.	Paclitaxel	120-130	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	47-52
12133409-2	2002	METHODS: COC1 cell line was treated with RelA antisense oligonucleotide combining with tumor necrosis factor (TNF)-alpha or paclitaxel at appropriate concentrations and duration.	Paclitaxel	124-134	RELA proto-oncogene, NF-kB subunit	Homo sapiens	41-45
12133409-4	2002	RESULTS: The apoptosis increased obviously in COC1 rells if treated by RelA antisense oligonucleotide combining with paclitaxel 50 micromol/L than paclitaxel 50 micromol/L only (27.4 +/- 0.5)% vs (12.3 +/- 0.6)% (P &lt; 0.01), when treated 12 hs; (31.7 +/- 0.3)% vs (13.0 +/- 0.5)% (P &lt; 0.01) when treated 24 hs.	Paclitaxel	117-127	RELA proto-oncogene, NF-kB subunit	Homo sapiens	71-75
12133409-4	2002	RESULTS: The apoptosis increased obviously in COC1 rells if treated by RelA antisense oligonucleotide combining with paclitaxel 50 micromol/L than paclitaxel 50 micromol/L only (27.4 +/- 0.5)% vs (12.3 +/- 0.6)% (P &lt; 0.01), when treated 12 hs; (31.7 +/- 0.3)% vs (13.0 +/- 0.5)% (P &lt; 0.01) when treated 24 hs.	Paclitaxel	147-157	RELA proto-oncogene, NF-kB subunit	Homo sapiens	71-75
12133409-7	2002	CONCLUSION: RelA antisense oligonucleotide may induce apoptosis susceptibility of COC1 cells to TNF-alpha or paclitaxel.	Paclitaxel	109-119	RELA proto-oncogene, NF-kB subunit	Homo sapiens	12-16
12087097-11	2002	We demonstrated an association between Akt and Raf-1 and showed that the phosphorylation of Raf-1 on Ser-259 induced by paclitaxel was blocked by treatment with wortmannin or LY294002.	Paclitaxel	120-130	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	92-97
12087097-12	2002	Furthermore, interference with the Akt cascade induced by paclitaxel up-regulated Raf-1 activity, and expression of constitutively active Akt inhibited Raf-1 activity, suggesting that Akt negatively regulates Raf-1.	Paclitaxel	58-68	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	82-87
12087097-13	2002	Our findings suggest that paclitaxel induces the phosphorylation of BAD Ser-112 via the ERK cascade, and the phosphorylation of both BAD Ser-136 and Raf-1 Ser-259 via the PI-3K-Akt cascade, and that inhibition of either of these cascades sensitizes ovarian cancer cells to paclitaxel.	Paclitaxel	26-36	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	149-154
12087097-13	2002	Our findings suggest that paclitaxel induces the phosphorylation of BAD Ser-112 via the ERK cascade, and the phosphorylation of both BAD Ser-136 and Raf-1 Ser-259 via the PI-3K-Akt cascade, and that inhibition of either of these cascades sensitizes ovarian cancer cells to paclitaxel.	Paclitaxel	273-283	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	149-154
12193109-7	2002	We showed that ET(A)R blockade inhibits the ET-1-induced survival activity against paclitaxel-mediated apoptosis.	Paclitaxel	83-93	endothelin receptor type A	Homo sapiens	15-21
25015454-1	2014	This study is to establish a paclitaxel (PTX)-resistant human cervical carcinoma HeLa cell line (HeLa/PTX) and to investigate its redox characteristics and the expression of taxol resistance gene 1 (Txr1).	Paclitaxel	29-39	proline rich 13	Homo sapiens	174-197
25015454-1	2014	This study is to establish a paclitaxel (PTX)-resistant human cervical carcinoma HeLa cell line (HeLa/PTX) and to investigate its redox characteristics and the expression of taxol resistance gene 1 (Txr1).	Paclitaxel	29-39	proline rich 13	Homo sapiens	199-203
25015454-1	2014	This study is to establish a paclitaxel (PTX)-resistant human cervical carcinoma HeLa cell line (HeLa/PTX) and to investigate its redox characteristics and the expression of taxol resistance gene 1 (Txr1).	Paclitaxel	41-44	proline rich 13	Homo sapiens	174-197
25015454-1	2014	This study is to establish a paclitaxel (PTX)-resistant human cervical carcinoma HeLa cell line (HeLa/PTX) and to investigate its redox characteristics and the expression of taxol resistance gene 1 (Txr1).	Paclitaxel	41-44	proline rich 13	Homo sapiens	199-203
25015454-9	2014	HeLa/PTX cells had higher levels of ROS (P&lt;0.01) and Txr1 mRNA (P&lt;0.01), lower level of GSH (P &lt; 0.05), and lower activities of SOD (P&lt;0.01) and GPx (P &lt; 0.05) than HeLa cells.	Paclitaxel	5-8	proline rich 13	Homo sapiens	56-60
12201487-2	2002	Exposure to combinations of paclitaxel or carboplatin and 317615 x 2HCl with MX-1 cells in culture resulted in cell survival that reflected primarily additivity of the two agents.	Paclitaxel	28-38	MX dynamin like GTPase 1	Homo sapiens	77-81
24726707-9	2014	In PACLI-treated mice LPP1 and pregabalin reduced tactile allodynia by 12-63% and 8-50%, respectively (p&lt;0.01).	Paclitaxel	3-8	phospholipid phosphatase 1	Mus musculus	22-26
12063170-3	2002	Taxol-induced serine phosphorylation of p66shc results from a MEK-independent signaling pathway that is activated in A549 cells that have a prolonged or abnormal mitotic phase of the cell cycle [Cancer Res.	Paclitaxel	0-5	midkine	Mus musculus	62-65
12063170-5	2002	In contrast, in murine macrophage RAW 264.7 cells, micromolar concentrations of Taxol but not other microtubule-interacting agents induced serine phosphorylation of p66shc that correlated with the phosphorylation of Raf-1 and extracellular signal-regulated kinase (ERK1/2), within 15-30 min after Taxol treatment.	Paclitaxel	80-85	mitogen-activated protein kinase 3	Mus musculus	265-271
11895918-3	2002	Accordingly, we compared a panel of sixteen taxanes, including paclitaxel and docetaxel, for their ability to induce cyclooxygenase-2 in a murine macrophage cell line (RAW 264.7) and in human peripheral blood monocytes.	Paclitaxel	63-73	prostaglandin-endoperoxide synthase 2	Mus musculus	117-133
11867757-0	2002	Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow.	Paclitaxel	20-30	ATP binding cassette subfamily B member 1	Canis lupus familiaris	114-118
11839682-1	2002	PURPOSE: Here we report on the role of mitochondria, death receptors (DRs), and caspases in exerting the cytotoxic effect of clinically relevant concentrations of paclitaxel in the non-small cell lung cancer cell line NCI-H460.	Paclitaxel	163-173	caspase 8	Homo sapiens	80-88
24726707-17	2014	CONCLUSIONS: LPP1 and pregabalin reduce pain in OXPT and PACLI-treated mice.	Paclitaxel	57-62	phospholipid phosphatase 1	Mus musculus	13-17
11805197-7	2002	Both the formation of DEAQ and the clearance of AQ showed excellent correlations (r(2) = 0.98 and 0.95) with 6alpha-hydroxylation of paclitaxel, a marker substrate for CYP2C8.	Paclitaxel	133-143	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	168-174
11791385-3	2001	Because CAF therapy was not effective, we tried to treat the patient with systemic and intra-arterial chemotherapy using paclitaxel.	Paclitaxel	121-131	lysine acetyltransferase 2B	Homo sapiens	8-11
25028548-1	2014	In the present study, we prepared a novel delivery system of iRGD (CRGDK/RGPD/EC)-modified sterically stabilized liposomes (SSLs) containing conjugated linoleic acid-paclitaxel (CLA-PTX).	Paclitaxel	166-176	interferon gamma inducible protein 47	Mus musculus	61-65
11571289-6	2001	This effect was not likely the result of microtubule depolymerization because in the presence of taxol, which blocked nocodazole-induced depolymerization of microtubules as well as the dispersal of the perinuclear GLUT4 compartment, the inhibitory effect of 10-33 microm nocodazole on insulin-stimulated glucose uptake prevailed.	Paclitaxel	97-102	solute carrier family 2 member 4	Homo sapiens	214-219
12415618-7	2002	Additionally, resistance could be reversed by treatment with taxol and antisense oligomers to PKC alpha and PKC beta.	Paclitaxel	61-66	protein kinase C beta	Homo sapiens	108-116
11767116-0	2001	Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism.	Paclitaxel	97-107	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	58-64
11767116-8	2001	These results suggest that not only the double variant (R139K/K399R, CYP2C8*3) but also our novel variant P404A in the CYP2C8 gene are less efficient in paclitaxel metabolism.	Paclitaxel	153-163	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	69-75
11767116-8	2001	These results suggest that not only the double variant (R139K/K399R, CYP2C8*3) but also our novel variant P404A in the CYP2C8 gene are less efficient in paclitaxel metabolism.	Paclitaxel	153-163	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	119-125
11678778-16	2001	New polymorphisms have been discovered in CYP2C8, which metabolizes taxol (paclitaxel).	Paclitaxel	68-73	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	42-48
11678778-16	2001	New polymorphisms have been discovered in CYP2C8, which metabolizes taxol (paclitaxel).	Paclitaxel	75-85	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	42-48
24534904-8	2014	Meanwhile, real-time polymerase chain reaction array revealed an alteration in expression of some neuronal ion channel genes including up-regulation of hyperpolarization-activated cyclic nucleotide-gated channel 1 (fold change 1.76 +- 0.06) and Nav1.7 (1.26 +- 0.02) and down-regulation of Kir channels (Kir1.1, 0.73 +- 0.05, Kir3.4, 0.66 +- 0.06) in paclitaxel-treated animals.	Paclitaxel	351-361	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4	Homo sapiens	290-293
11593420-3	2001	Induction of BRCA1 in the presence of Taxol and Vincristine resulted in a dramatic increase in cell death; an effect that was preceded by an acute arrest at the G2/M phase of the cell cycle and which correlated with BRCA1 mediated induction of GADD45.	Paclitaxel	38-43	growth arrest and DNA damage inducible alpha	Homo sapiens	244-250
11593420-6	2001	Inducible expression of GADD45 in the presence of Taxol induced both G2 and mitotic arrest in these cells consistent with a role for GADD45 in contributing to these effects.	Paclitaxel	50-55	growth arrest and DNA damage inducible alpha	Homo sapiens	24-30
11554785-6	2001	As both GM-CSF and IP-10 have been implicated in tumor rejection in vivo through either indirect actions on the host immune system or by inhibiting tumor angiogenesis, our data strengthen the hypothesis that tumor cell-derived inflammatory mediators may, in part, underlie the anti-tumor efficacy of paclitaxel in breast cancer.	Paclitaxel	300-310	chemokine (C-X-C motif) ligand 10	Mus musculus	19-24
11606393-8	2001	The expression of retinoic acid receptor (RAR)-gamma was significantly higher in the paclitaxel-resistant (2008/13/4 and 2008/17/4) cells than in the parental (2008) cells.	Paclitaxel	85-95	retinoic acid receptor gamma	Homo sapiens	18-52
11606393-10	2001	Whereas the 2008, 2008/13/4, and 2008/17/4 cells were found to resist the antiproliferative effects of all-trans-retinoic acid, the paclitaxel-resistant cells were 6- to 7-fold cross-resistant to the antiproliferative effects of CD437 (a synthetic RAR-gamma-selective agonist; 6-[-(1-admantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid) compared with the sensitivity of the parental cells.	Paclitaxel	132-142	retinoic acid receptor gamma	Homo sapiens	248-257
11600533-0	2001	Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel.	Paclitaxel	172-182	caspase 8	Homo sapiens	61-70
11571636-6	2001	Northern blot analysis was used to assess changes in clusterin mRNA expression after ASO and paclitaxel treatment.	Paclitaxel	93-103	clusterin	Homo sapiens	53-62
24534904-8	2014	Meanwhile, real-time polymerase chain reaction array revealed an alteration in expression of some neuronal ion channel genes including up-regulation of hyperpolarization-activated cyclic nucleotide-gated channel 1 (fold change 1.76 +- 0.06) and Nav1.7 (1.26 +- 0.02) and down-regulation of Kir channels (Kir1.1, 0.73 +- 0.05, Kir3.4, 0.66 +- 0.06) in paclitaxel-treated animals.	Paclitaxel	351-361	potassium inwardly rectifying channel subfamily J member 1	Homo sapiens	304-310
11410792-2	2001	We have previously reported that the activation of caspase-3 and caspase-8 plays a crucial role in paclitaxel-induced apoptosis.	Paclitaxel	99-109	caspase 8	Homo sapiens	65-74
24630273-8	2014	The skin innervation of protein gene product 9.5 (PGP 9.5)-immunoreactive (IR) IENFs in paclitaxel groups revealed the decreasing levels of density (73.54+-0.72%, 63.17+-1.77%, 61.79+-2.68%, respectively; vs. vehicle group, p&lt;0.05) throughout the entire experimental period.	Paclitaxel	88-98	ubiquitin C-terminal hydrolase L1	Rattus norvegicus	24-48
11179455-12	2001	Interestingly, the paclitaxel-induced beta-catenin fragment lost its ability to bind to E-cadherin, alpha-catenin, or APC protein and to serve as a substrate for tyrosine kinase.	Paclitaxel	19-29	APC regulator of WNT signaling pathway	Homo sapiens	118-121
11179455-13	2001	All our data demonstrate that the caspase-mediated cleavage of beta-catenin, gamma-catenin, and APC protein might contribute to paclitaxel-induced apoptosis.	Paclitaxel	128-138	APC regulator of WNT signaling pathway	Homo sapiens	96-99
11160861-3	2001	Overexpression of a dominant-negative mutant, mitogen-activated protein kinase kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense oligonucleotide prevented paclitaxel-induced JNK activation, Bcl-2 phosphorylation and apoptosis.	Paclitaxel	166-176	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	89-94
11160861-9	2001	Taken together, our results suggest that disruption of cytoarchitecture by paclitaxel triggers a novel apoptosis-signaling pathway, wherein an active DEVD-directed caspase (DEVDase) initially cleaves MEKK1to generate a proapoptotic kinase fragment that is able to activate JNK and subsequent Bcl-2 phosphorylation, finally eliciting cell death.	Paclitaxel	75-85	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	200-205
11212279-9	2001	These findings indicate that up-regulation of DR4 and DR5 protein levels by treatment with paclitaxel enhances subsequent Apo-2L/TRAIL-induced apoptosis of human prostate cancer cells.	Paclitaxel	91-101	TNF receptor superfamily member 10a	Homo sapiens	46-49
11123339-0	2001	CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression.	Paclitaxel	106-111	CD14 antigen	Mus musculus	32-36
11668219-0	2001	Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.	Paclitaxel	73-83	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	23-29
11668219-1	2001	Cytochrome P450 (CYP) 2C8 is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel (Taxol).	Paclitaxel	105-115	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-25
11668219-1	2001	Cytochrome P450 (CYP) 2C8 is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel (Taxol).	Paclitaxel	117-122	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-25
11668219-12	2001	Thus, CYP2C8*3 is defective in the metabolism of two important CYP2C8 substrates: the anticancer drug paclitaxel and the physiologically important compound arachidonic acid.	Paclitaxel	102-112	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	6-12
24630273-8	2014	The skin innervation of protein gene product 9.5 (PGP 9.5)-immunoreactive (IR) IENFs in paclitaxel groups revealed the decreasing levels of density (73.54+-0.72%, 63.17+-1.77%, 61.79+-2.68%, respectively; vs. vehicle group, p&lt;0.05) throughout the entire experimental period.	Paclitaxel	88-98	ubiquitin C-terminal hydrolase L1	Rattus norvegicus	50-57
11326311-7	2001	After both taxol and DDP treatments, an activation of hCHK2 was found and this is likely to be responsible for phosphorylation at Ser20.	Paclitaxel	11-16	checkpoint kinase 2	Homo sapiens	54-59
24630273-10	2014	On the contrary, the density for peptidergic calcitonin gene-related peptide (CGRP)-IR IENFs in paclitaxel groups were revealed the similar decreasing levels (82.75+-0.91%, 84.34+-3.20%, 81.99+-0.25%, respectively; vs. vehicle group, p&lt;0.05).	Paclitaxel	96-106	calcitonin-related polypeptide alpha	Rattus norvegicus	45-76
11077039-0	2000	Caspase-8 activation independent of CD95/CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4).	Paclitaxel	67-77	caspase 8	Homo sapiens	0-9
11077039-4	2000	By using both enzymatic assay and immunoblot detection of cleaved fragments, we showed that caspase-8, a central component of the CD95-induced apoptotic pathway, was significantly activated during paclitaxel exposure, contemporary to apoptosis occurrence.	Paclitaxel	197-207	caspase 8	Homo sapiens	92-101
11556844-3	2001	The MDD2 cell line was significantly more resistant to the cytotoxic effects of vinblastine and paclitaxel than the MN1 cell line.	Paclitaxel	96-106	MDD2	Homo sapiens	4-8
11556844-8	2001	Addition of flavopiridol to vinblastine- and paclitaxel-treated cells reversed the MDD2-resistant phenotype by inducing G(1)cell cycle arrest and inhibiting endoreduplication.	Paclitaxel	45-55	MDD2	Homo sapiens	83-87
24630273-10	2014	On the contrary, the density for peptidergic calcitonin gene-related peptide (CGRP)-IR IENFs in paclitaxel groups were revealed the similar decreasing levels (82.75+-0.91%, 84.34+-3.20%, 81.99+-0.25%, respectively; vs. vehicle group, p&lt;0.05).	Paclitaxel	96-106	calcitonin-related polypeptide alpha	Rattus norvegicus	78-82
24729449-7	2014	RESULTS: Natural taxane paclitaxel from Taxus brevifolia activated the Raf-1/extracellular signal-regulated kinase (ERK) pathway, leading to an activation of ribosomal S6 kinases (RSK)/YB-1 signaling.	Paclitaxel	24-34	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	71-76
24886434-5	2014	RESULTS: Treatment of isolated tumor cells from the ascites of ovarian cancer patients and HEY ovarian cancer cell line with paclitaxel resulted in a CSC-like residual population which coincided with the activation of Janus activated kinase 2 (JAK2) and signal transducer and activation of transcription 3 (STAT3) pathway in paclitaxel surviving cells.	Paclitaxel	125-135	Janus kinase 2	Homo sapiens	218-242
11521190-9	2001	Using a chimeric GAL4-RelA transactivator, we find that taxol potently activates GAL4-RelA-dependent transcription.	Paclitaxel	56-61	RELA proto-oncogene, NF-kB subunit	Homo sapiens	22-26
11521190-9	2001	Using a chimeric GAL4-RelA transactivator, we find that taxol potently activates GAL4-RelA-dependent transcription.	Paclitaxel	56-61	RELA proto-oncogene, NF-kB subunit	Homo sapiens	86-90
10945622-3	2000	Paclitaxel was dissolved (10% w/w) in a blend of a biodegradable triblock copolymer of a random copolymer of D,L-lactide and epsilon-caprolactone (PLC) with poly(ethyleneglycol) [PEG; PLC-PEG-PLC] blended with methoxypoly(ethylene glycol) in a 40:60 ratio.	Paclitaxel	0-10	perlecan (heparan sulfate proteoglycan 2)	Mus musculus	147-150
10945622-3	2000	Paclitaxel was dissolved (10% w/w) in a blend of a biodegradable triblock copolymer of a random copolymer of D,L-lactide and epsilon-caprolactone (PLC) with poly(ethyleneglycol) [PEG; PLC-PEG-PLC] blended with methoxypoly(ethylene glycol) in a 40:60 ratio.	Paclitaxel	0-10	perlecan (heparan sulfate proteoglycan 2)	Mus musculus	184-187
10945622-3	2000	Paclitaxel was dissolved (10% w/w) in a blend of a biodegradable triblock copolymer of a random copolymer of D,L-lactide and epsilon-caprolactone (PLC) with poly(ethyleneglycol) [PEG; PLC-PEG-PLC] blended with methoxypoly(ethylene glycol) in a 40:60 ratio.	Paclitaxel	0-10	perlecan (heparan sulfate proteoglycan 2)	Mus musculus	184-187
11521190-11	2001	Our results indicate that RelA transactivation is an important downstream target of the PKC iota-mediated Bcr-Abl signaling pathway and is required for resistance to taxol-induced apoptosis.	Paclitaxel	166-171	RELA proto-oncogene, NF-kB subunit	Homo sapiens	26-30
24886434-5	2014	RESULTS: Treatment of isolated tumor cells from the ascites of ovarian cancer patients and HEY ovarian cancer cell line with paclitaxel resulted in a CSC-like residual population which coincided with the activation of Janus activated kinase 2 (JAK2) and signal transducer and activation of transcription 3 (STAT3) pathway in paclitaxel surviving cells.	Paclitaxel	125-135	Janus kinase 2	Homo sapiens	244-248
11554785-3	2001	A subset of the genes examined (e.g., G-CSF, MIP-2, iNOS, and IL-1 beta, and GM-CSF) was upregulated &gt;3-20-fold by both LPS and paclitaxel in the DA-3 cell line, while IP-10 mRNA was induced by paclitaxel, but not by LPS.	Paclitaxel	131-141	peripheral blood stem cell response to granulocyte colony stimulating factor 1	Mus musculus	38-43
24886434-5	2014	RESULTS: Treatment of isolated tumor cells from the ascites of ovarian cancer patients and HEY ovarian cancer cell line with paclitaxel resulted in a CSC-like residual population which coincided with the activation of Janus activated kinase 2 (JAK2) and signal transducer and activation of transcription 3 (STAT3) pathway in paclitaxel surviving cells.	Paclitaxel	325-335	Janus kinase 2	Homo sapiens	218-242
11554785-3	2001	A subset of the genes examined (e.g., G-CSF, MIP-2, iNOS, and IL-1 beta, and GM-CSF) was upregulated &gt;3-20-fold by both LPS and paclitaxel in the DA-3 cell line, while IP-10 mRNA was induced by paclitaxel, but not by LPS.	Paclitaxel	131-141	chemokine (C-X-C motif) ligand 10	Mus musculus	171-176
11554785-3	2001	A subset of the genes examined (e.g., G-CSF, MIP-2, iNOS, and IL-1 beta, and GM-CSF) was upregulated &gt;3-20-fold by both LPS and paclitaxel in the DA-3 cell line, while IP-10 mRNA was induced by paclitaxel, but not by LPS.	Paclitaxel	197-207	peripheral blood stem cell response to granulocyte colony stimulating factor 1	Mus musculus	38-43
24637579-5	2014	The metabolism of paclitaxel is mediated primarily by the P450 cytochrome enzymes CYP2C8 and CYP3A, whereas docetaxel is only metabolized by CYP3A4.	Paclitaxel	18-28	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	82-88
11454729-4	2001	Paclitaxel 6alpha-hydroxylase activity catalyzed by CYP2C8 was not affected by PEITC up to 100 microM.	Paclitaxel	0-10	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	52-58
11001384-0	2000	Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel.	Paclitaxel	73-83	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	23-28
11001384-3	2000	We have recently reported that there is a marked Raf-1 kinase dependency of paclitaxel resistance in human cervical and ovarian tumor cell lines.	Paclitaxel	76-86	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	49-54
10848628-4	2000	Consistent with these observations is the ability of pericentrin to cosediment with taxol-stabilized microtubules in a dynein- and dynactin-dependent manner.	Paclitaxel	84-89	pericentrin L homeolog	Xenopus laevis	53-64
24462773-11	2014	In a mouse xenograft model, overexpression of CTGF promoted resistance to paclitaxel.	Paclitaxel	74-84	cellular communication network factor 2	Mus musculus	46-50
10738258-4	2000	Paclitaxel+AS101 synergistically activated c-raf-1 and MAPK ERK1 and ERK2.	Paclitaxel	0-10	mitogen-activated protein kinase 3	Mus musculus	60-64
11571636-11	2001	Pretreatment of Caki-2 cells with clusterin ASO significantly enhanced chemosensitivity to paclitaxel in vitro.	Paclitaxel	91-101	clusterin	Homo sapiens	34-43
11571636-13	2001	In vivo administration of clusterin ASO plus paclitaxel acted synergistically to increase apoptosis and significantly delay Caki-2 tumor growth, compared to mismatch control oligonucleotide plus paclitaxel.	Paclitaxel	195-205	clusterin	Homo sapiens	26-35
11571636-14	2001	In addition, TUNEL staining revealed increased apoptotic cells in tumors treated with clusterin ASO plus paclitaxel compared to treatment with either clusterin ASO or paclitaxel alone.	Paclitaxel	167-177	clusterin	Homo sapiens	86-95
24462773-12	2014	In contrast, knockdown of CTGF expression increased the therapeutic effect of paclitaxel in this model.	Paclitaxel	78-88	cellular communication network factor 2	Homo sapiens	26-30
10778982-14	2000	The efficacy of paclitaxel is dependent on mitotic entry, a step that requires activation of p34cdc2 kinase activity.	Paclitaxel	16-26	cyclin-dependent kinase 1	Mus musculus	93-100
24462773-13	2014	In conclusion, our data indicate that CTGF might be a critical oncogene of human osteosarcoma involved in resistance to paclitaxel treatment.	Paclitaxel	120-130	cellular communication network factor 2	Homo sapiens	38-42
24706167-2	2014	The purpose of this analysis was to expand on a previous reported association of CYP2C8*3 and PIPN risk by investigating additional polymorphisms in CYP2C8 and in hundreds of other genes potentially relevant to paclitaxel pharmacokinetics.	Paclitaxel	211-221	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	81-87
10659951-4	2000	Troglitazone (5 microM) significantly inhibited CYP2C8-dependent paclitaxel 6alpha-hydroxylation and CYP2C9-dependent S-warfarin 7-hydroxylation.	Paclitaxel	65-75	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	48-54
10400418-1	1999	Raf-1 activation and Bcl-2 hyperphosphorylation following treatment with paclitaxel (Taxol) or other microtubule-active drugs is associated with mitotic arrest.	Paclitaxel	73-83	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	0-5
10400418-1	1999	Raf-1 activation and Bcl-2 hyperphosphorylation following treatment with paclitaxel (Taxol) or other microtubule-active drugs is associated with mitotic arrest.	Paclitaxel	85-90	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	0-5
11419031-9	2001	These data support further evaluation of the newer chemotherapeutic drugs, and especially the camptothecins (irinotecan and topotecan) and the taxanes (paclitaxel and docetaxel), in the initial treatment of SCLC.	Paclitaxel	152-162	SCLC1	Homo sapiens	207-211
24654922-6	2014	RESULTS: Patients on nab-paclitaxel + gemcitabine spent a significantly longer time in every state and experienced significantly greater overall Q-TWiST (+1.7 months [95% CI = 0.8, 2.7]) than those receiving gemcitabine alone (8.2 months [95% CI = 7.5, 8.9] vs 6.5 months [95% CI = 5.8, 7.0]), assuming base-case utilities of TOX/REL = 0.50.	Paclitaxel	25-35	thymocyte selection associated high mobility group box	Homo sapiens	326-329
11350918-9	2001	Tumor regression was observed in all mice after treatment with ZD1839 plus paclitaxel, and it was accompanied by a significant potentiation in inhibition of TGF-alpha, VEGF, and bFGF expression with a few or no microvessels.	Paclitaxel	75-85	fibroblast growth factor 2	Mus musculus	178-182
10400418-4	1999	Simultaneously with PARP cleavage, paclitaxel induces cleavage of Bcl-2 protein yielding a potentially pro-apoptotic 22 kDa product.	Paclitaxel	35-45	collagen type XI alpha 2 chain	Homo sapiens	20-24
10527889-7	1999	These results suggest that activation of caspase 3 and caspase 8 plays a crucial role in paclitaxel-induced apoptosis under any concentrations of paclitaxel.	Paclitaxel	89-99	caspase 8	Homo sapiens	55-64
10527889-7	1999	These results suggest that activation of caspase 3 and caspase 8 plays a crucial role in paclitaxel-induced apoptosis under any concentrations of paclitaxel.	Paclitaxel	146-156	caspase 8	Homo sapiens	55-64
24774218-10	2014	And, in cervical SCC patients after treatment with Taxol chemotherapy, the expression level of miR-143 was higher and the positive expression of bcl-2 protein was lower.	Paclitaxel	51-56	microRNA 143	Homo sapiens	95-102
10318938-5	1999	Geldanamycin, a specific inhibitor of the Hsp 90 family, blocked the nuclear translocation of NF-kappaB and expression of tumor necrosis factor in macrophages treated with Taxol or with LPS.	Paclitaxel	172-177	heat shock protein 86, pseudogene 1	Mus musculus	42-48
10318938-7	1999	Thus, Taxol binds Hsps, and Hsp 90 helps mediate the activation of macrophages by Taxol and by LPS.	Paclitaxel	82-87	heat shock protein 86, pseudogene 1	Mus musculus	28-34
11279616-3	2001	Expression of cx43 in human glioblastoma cells significantly increased sensitivity to several common chemotherapeutic agents, including etoposide, paclitaxel (Taxol) and doxorubicin, compared with control-transfected cells.	Paclitaxel	147-157	gap junction protein alpha 1	Homo sapiens	14-18
11279616-3	2001	Expression of cx43 in human glioblastoma cells significantly increased sensitivity to several common chemotherapeutic agents, including etoposide, paclitaxel (Taxol) and doxorubicin, compared with control-transfected cells.	Paclitaxel	159-164	gap junction protein alpha 1	Homo sapiens	14-18
10212239-2	1999	MEK kinase 1 (MEKK1) activates the c-Jun NH2-terminal kinase (JNK) pathway in response to exposure of cells to microtubule toxins, including taxol.	Paclitaxel	141-146	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	0-12
10212239-2	1999	MEK kinase 1 (MEKK1) activates the c-Jun NH2-terminal kinase (JNK) pathway in response to exposure of cells to microtubule toxins, including taxol.	Paclitaxel	141-146	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	14-19
24642627-0	2014	Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells.	Paclitaxel	87-97	S-phase kinase associated protein 2	Homo sapiens	68-72
10212239-4	1999	Targeted disruption of MEKK1 expression in embryonic stem cells resulted in the loss of JNK activation and increased apoptosis in response to taxol.	Paclitaxel	142-147	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	23-28
10196170-6	1999	MEKK1 became activated in HEK293 cells exposed to taxol, but in contrast to etoposide-treatment, taxol failed to increase JNK activity.	Paclitaxel	50-55	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	0-5
10196170-7	1999	Taxol treatment of cells, therefore, dissociates MEKK1 activation from the regulation of the JNK pathway.	Paclitaxel	0-5	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	49-54
11222383-1	2001	The activation of caspase-8, a crucial upstream mediator of death receptor signaling, was investigated in epirubicin- and Taxol-induced apoptosis of B-lymphoma cells.	Paclitaxel	122-127	caspase 8	Homo sapiens	18-27
11222383-3	2001	Indeed, active caspase-8 was readily detected after treatment of mature and immature B-lymphoid cells with epirubicin or Taxol.	Paclitaxel	121-126	caspase 8	Homo sapiens	15-24
11165754-8	2001	Paclitaxel showed an inhibitory effect on the growth of transplanted human OSCC and reduced the immunohistochemical expression of VEGF and CD31 and VEGF mRNA (P&lt;0.01).	Paclitaxel	0-10	platelet and endothelial cell adhesion molecule 1	Homo sapiens	139-143
23524581-12	2014	Recent studies have shown that PTX-stabilized microtubules serves as a scaffold for pro-caspase-8 binding and induction of apoptosis downstream of induced-proximity activation of caspase-8.	Paclitaxel	31-34	caspase 8	Homo sapiens	88-97
11179426-4	2001	We found that MT nucleation by centrosomes from Xenopus sperm or somatic cells and MT assembly promoted by dimethyl sulfoxide or paclitaxel induced stathmin/Op18 hyperphosphorylation in Xenopus egg extracts, leading to new stathmin/Op18 isoforms phosphorylated on Ser 16.	Paclitaxel	129-139	stathmin 1 L homeolog	Xenopus laevis	157-161
11581577-3	2001	At low doses of LPS or Taxol, all genes were also CD14-dependent; however, IP-10 and ICSBP remained poorly inducible even at much higher concentrations.	Paclitaxel	23-28	CD14 antigen	Mus musculus	50-54
11123339-5	2001	Induction of the entire panel of genes in response to low concentrations of LPS or Taxol requires the participation of both CD14 and TLR4, whereas high concentrations of LPS or Taxol elicit the expression of a subset of LPS-inducible genes in the absence of CD14.	Paclitaxel	83-88	CD14 antigen	Mus musculus	124-128
11123339-5	2001	Induction of the entire panel of genes in response to low concentrations of LPS or Taxol requires the participation of both CD14 and TLR4, whereas high concentrations of LPS or Taxol elicit the expression of a subset of LPS-inducible genes in the absence of CD14.	Paclitaxel	83-88	CD14 antigen	Mus musculus	258-262
11123339-5	2001	Induction of the entire panel of genes in response to low concentrations of LPS or Taxol requires the participation of both CD14 and TLR4, whereas high concentrations of LPS or Taxol elicit the expression of a subset of LPS-inducible genes in the absence of CD14.	Paclitaxel	177-182	CD14 antigen	Mus musculus	124-128
11123339-5	2001	Induction of the entire panel of genes in response to low concentrations of LPS or Taxol requires the participation of both CD14 and TLR4, whereas high concentrations of LPS or Taxol elicit the expression of a subset of LPS-inducible genes in the absence of CD14.	Paclitaxel	177-182	CD14 antigen	Mus musculus	258-262
11123339-6	2001	In contrast, for optimal induction of COX-2, IL-12 p35, and IL-12 p40 genes by low concentrations of LPS or by all concentrations of Taxol, CD11b/CD18 was also required.	Paclitaxel	133-138	prostaglandin-endoperoxide synthase 2	Mus musculus	38-43
10711847-7	1999	Improvement in locoregional and distant control rates may occur when FHX is combined with additional systemically active agents (cisplatin then paclitaxel) and hyperfractionated radiotherapy is used.	Paclitaxel	144-154	forkhead box J2	Homo sapiens	69-72
9852137-3	1998	Here we report that paclitaxel can induce MnSOD gene expression in human lung adenocarcinoma cell line A549 in a time- and dose-dependent manner.	Paclitaxel	20-30	superoxide dismutase 2	Homo sapiens	42-47
9844922-3	1998	Taxol-induced G2/M transition is mediated by p34(cdc-2) (CDK1) which, if prematurely activated, may also trigger apoptosis.	Paclitaxel	0-5	cyclin H	Homo sapiens	45-48
23524581-12	2014	Recent studies have shown that PTX-stabilized microtubules serves as a scaffold for pro-caspase-8 binding and induction of apoptosis downstream of induced-proximity activation of caspase-8.	Paclitaxel	31-34	caspase 8	Homo sapiens	179-188
24338942-6	2014	Others and we have shown that with a variety of tumours in both mice and rats, the inhibition of the SDF-1/CXCR4 pathway delays or prevents the recurrence of implanted or autochthonous tumours following irradiation or following treatment with vascular disrupting agents or some chemotherapeutic drugs such as paclitaxel.	Paclitaxel	309-319	C-X-C motif chemokine ligand 12	Rattus norvegicus	101-106
9721870-2	1998	Recent evidence indicates that Taxol alters specific intracellular signal transduction events, such as the activation of Raf-1 kinase, that may be essential for drug-induced apoptosis.	Paclitaxel	31-36	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	121-126
11123339-8	2001	These findings suggest that for expression of a full repertoire of LPS-/Taxol-inducible genes, CD14, TLR4, and CD11b/CD18 must be coordinately engaged to deliver optimal signaling to the macrophage.	Paclitaxel	72-77	CD14 antigen	Mus musculus	95-99
24440197-0	2014	Paclitaxel-induced hyperalgesia modulates negative affective component of pain and NR1 receptor expression in the frontal cortex in rats.	Paclitaxel	0-10	glutamate ionotropic receptor NMDA type subunit 1	Rattus norvegicus	83-86
11061987-3	2000	In-gel kinase assays with myelin basic protein as substrate revealed that taxol treatment significantly (P &lt;/= 0.05) reduced the activity of a 55 kD kinase present in cytoskeletal extracts from CV-1 cells.	Paclitaxel	74-79	myelin basic protein	Homo sapiens	26-46
9622663-0	1998	NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule: in vitro study of adult rat sympathetic ganglion explants.	Paclitaxel	70-75	nerve growth factor	Rattus norvegicus	0-3
9622663-1	1998	The simultaneous administration of nerve growth factor (NGF) has been found to prevent experimental neuropathies induced by anti-cancer drugs such as cisplatin, vincristine and taxol.	Paclitaxel	177-182	nerve growth factor	Rattus norvegicus	35-54
9622663-1	1998	The simultaneous administration of nerve growth factor (NGF) has been found to prevent experimental neuropathies induced by anti-cancer drugs such as cisplatin, vincristine and taxol.	Paclitaxel	177-182	nerve growth factor	Rattus norvegicus	56-59
9622663-4	1998	NGF significantly prevented the inhibition of neurite outgrowth by vincristine and taxol regardless of treatment schedules.	Paclitaxel	83-88	nerve growth factor	Rattus norvegicus	0-3
9622663-7	1998	These results indicate that NGF-treatment is effective for the toxic sympathetic nerve injury induced by vincristine and taxol regardless of the treatment schedule, but is not protective against cisplatin-induced nerve cell injury.	Paclitaxel	121-126	nerve growth factor	Rattus norvegicus	28-31
11106262-1	2000	Previous studies in mice with disrupted mdr1a P-glycoprotein genes have shown that the oral bioavailability of paclitaxel is very low because of the presence of this drug-transporting protein in the intestinal wall.	Paclitaxel	111-121	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	40-45
24591819-9	2014	Seventeen miRNAs were overexpressed in Taxol-resistant cells, including miR-663, miR-622, and HS_188.	Paclitaxel	39-44	microRNA 663a	Homo sapiens	72-79
10974411-6	2000	Interestingly, these cell lines showed cross-resistance to paclitaxel, cisplatin, and doxorubicin, suggesting that other factors such as HSP27 and Mn-SOD could be also involved in the mechanism of multidrug resistance in these cell lines.	Paclitaxel	59-69	superoxide dismutase 2	Homo sapiens	147-153
9607567-0	1998	High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity.	Paclitaxel	62-72	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	5-10
9607567-3	1998	Recent reports suggest that the Raf-1 protein kinase may have a profound influence on the level of paclitaxel-induced apoptosis.	Paclitaxel	99-109	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	32-37
9607567-4	1998	We have critically evaluated the relationship between Raf-1 kinase activity and de novo paclitaxel resistance in early-passage human cervical tumors.	Paclitaxel	88-98	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	54-59
9607567-5	1998	In the 12 cell lines studied, Raf-1 kinase activity was inversely correlated (P = 0.0016) with the level of cytotoxicity induced by 60 nM paclitaxel.	Paclitaxel	138-148	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	30-35
9607567-6	1998	The relationship between these two parameters seems to be more than an epiphenomenon, because genetic down-regulation of Raf-1 kinase activity led to an approximately 4-fold increase in paclitaxel-induced cytotoxicity.	Paclitaxel	186-196	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	121-126
24591819-9	2014	Seventeen miRNAs were overexpressed in Taxol-resistant cells, including miR-663, miR-622, and HS_188.	Paclitaxel	39-44	microRNA 622	Homo sapiens	81-88
9607567-7	1998	The data from both our transfection studies and those on the 12 unperturbed cell lines are consistent with Raf-1 kinase being a negative determinant of paclitaxel-induced cytotoxicity.	Paclitaxel	152-162	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	107-112
9607567-8	1998	Because the cytotoxicity of paclitaxel is primarily attributable to apoptosis, these data suggest that Raf-1 kinase acts to suppress paclitaxel-induced apoptosis.	Paclitaxel	28-38	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	103-108
24591819-10	2014	Underexpressed miRNAs in Taxol-sensitive cells included miR-497, miR-187, miR-195, and miR-107.	Paclitaxel	25-30	microRNA 497	Homo sapiens	56-63
9607567-8	1998	Because the cytotoxicity of paclitaxel is primarily attributable to apoptosis, these data suggest that Raf-1 kinase acts to suppress paclitaxel-induced apoptosis.	Paclitaxel	133-143	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	103-108
9607567-9	1998	These data suggest that the clinical effectiveness of paclitaxel could be substantially improved by the use of Raf-1 kinase inhibitors, provided that a similar relationship between Raf-1 kinase activity and paclitaxel cytotoxicity exists in the clinic, especially in those tumor sites where paclitaxel is the current treatment of choice e.g., ovarian and breast cancer.	Paclitaxel	54-64	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	111-116
9607567-9	1998	These data suggest that the clinical effectiveness of paclitaxel could be substantially improved by the use of Raf-1 kinase inhibitors, provided that a similar relationship between Raf-1 kinase activity and paclitaxel cytotoxicity exists in the clinic, especially in those tumor sites where paclitaxel is the current treatment of choice e.g., ovarian and breast cancer.	Paclitaxel	54-64	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	181-186
11062745-0	2000	Damage of the kinesin heavy chain gene contributes to the antagonism of cisplatin and paclitaxel.	Paclitaxel	86-96	kinesin family member 5B	Homo sapiens	14-33
24591819-10	2014	Underexpressed miRNAs in Taxol-sensitive cells included miR-497, miR-187, miR-195, and miR-107.	Paclitaxel	25-30	microRNA 107	Homo sapiens	87-94
24480438-0	2014	Role of nerve growth factor-tyrosine kinase receptor A signaling in paclitaxel-induced peripheral neuropathy in rats.	Paclitaxel	68-78	nerve growth factor	Rattus norvegicus	8-27
10988356-7	2000	Furthermore, paclitaxel pretreatment caused down-regulation of stress-activated MAPKs, JNK and p38 MAPK in lipopolysaccharide (LPS)-stimulated mouse splenic lymphocytes, demonstrating that spleen cells are induced to a state hyporesponsive to LPS stimulation by pre-exposing them to paclitaxel.	Paclitaxel	13-23	mitogen-activated protein kinase 14	Mus musculus	95-103
24480438-3	2014	We investigated expression levels of NGF and its receptors in the dorsal root ganglia (DRG) and spinal dorsal horn (DH) following paclitaxel treatment.	Paclitaxel	130-140	nerve growth factor	Rattus norvegicus	37-40
10988356-8	2000	Taken together, these results suggest that down-regulation of JNK/p38 MAP kinase may contribute to paclitaxel-induced immunosuppression in mouse splenic lymphocytes.	Paclitaxel	99-109	mitogen-activated protein kinase 14	Mus musculus	66-69
24480438-5	2014	administration of paclitaxel induced significant mechanical hypersensitivity and cold allodynia in rats, significantly increased the expression of NGF and its receptor tyrosine kinase receptor A (trkA) in the DRG, and increased NGF expression in the DH.	Paclitaxel	18-28	nerve growth factor	Rattus norvegicus	147-150
10676649-13	2000	Combined manumycin and paclitaxel treatments seemed as effective as manumycin against ARO cells and more effective than either manumycin or paclitaxel alone against KAT-4 cells.	Paclitaxel	23-33	TATA-box binding protein associated factor 1	Homo sapiens	165-170
24480438-5	2014	administration of paclitaxel induced significant mechanical hypersensitivity and cold allodynia in rats, significantly increased the expression of NGF and its receptor tyrosine kinase receptor A (trkA) in the DRG, and increased NGF expression in the DH.	Paclitaxel	18-28	nerve growth factor	Rattus norvegicus	228-231
24480438-7	2014	Moreover, expression of NEDD4-2, a negative regulator of trkA, was significantly increased in the DRG of paclitaxel-treated rats.	Paclitaxel	105-115	NEDD4 like E3 ubiquitin protein ligase	Rattus norvegicus	24-31
24480438-10	2014	Our results suggest that NGF-trkA signaling is involved in mechanical allodynia in paclitaxel-induced neuropathy.	Paclitaxel	83-93	nerve growth factor	Rattus norvegicus	25-28
24495785-5	2014	The combination of PEITC and taxol also reduced expressions of cell cycle regulator Cdk1, and anti-apoptotic protein bcl-2, enhanced expression of Bax and cleavage of PARP proteins.	Paclitaxel	29-34	collagen type XI alpha 2 chain	Homo sapiens	167-171
10557046-0	1999	Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy.	Paclitaxel	77-87	inversin	Homo sapiens	38-41
24080340-0	2014	Identification and analysis of CD133(+) melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response.	Paclitaxel	90-95	prominin 1	Homo sapiens	31-36
10557046-2	1999	We report two cases of s-AML with inv(16)(p13q22) who had prior exposure to paclitaxel.	Paclitaxel	76-86	inversin	Homo sapiens	34-37
10557046-3	1999	Additionally, two previously reported cases of s-AML with inv(16) had prior paclitaxel exposure raising the possibility that the taxanes may predispose to this specific syndrome of s-AML.	Paclitaxel	76-86	inversin	Homo sapiens	58-61
24080340-2	2014	Herein, we functionally analyzed melanoma stem-like cells (MSC)/CD133(+) cells on their resistance and response to taxol-induced apoptosis.	Paclitaxel	115-120	prominin 1	Homo sapiens	64-69
24080340-3	2014	Besides being taxol resistant, the CD133(+) cells demonstrated a growth advantage over the CD133(-) subpopulation.	Paclitaxel	14-19	prominin 1	Homo sapiens	35-40
24080340-4	2014	Taxol induced apoptosis on CD133(-) cells, but not on CD133(+) cells.	Paclitaxel	0-5	prominin 1	Homo sapiens	27-32
24080340-5	2014	In the CD133(-) subpopulation, the exposure to taxol induced the activation of apoptosis signal-regulating kinase1 (ASK1)/c-jun-N-terminal kinase (JNK), p38, extracellular signal regulated kinase (ERK) pathways and Bax expression, while in CD133(+) cells taxol was able only to enhance the activity of the ERK pathway.	Paclitaxel	47-52	prominin 1	Homo sapiens	7-12
24080340-5	2014	In the CD133(-) subpopulation, the exposure to taxol induced the activation of apoptosis signal-regulating kinase1 (ASK1)/c-jun-N-terminal kinase (JNK), p38, extracellular signal regulated kinase (ERK) pathways and Bax expression, while in CD133(+) cells taxol was able only to enhance the activity of the ERK pathway.	Paclitaxel	47-52	prominin 1	Homo sapiens	240-245
10525540-3	1999	Microinjection experiments show that HSET activity is essential for meiotic spindle organization in murine oocytes and taxol-induced aster assembly in cultured cells.	Paclitaxel	119-124	kinesin family member C5B	Mus musculus	37-41
24005572-0	2014	Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel.	Paclitaxel	188-198	tubulin beta 3 class III	Homo sapiens	0-22
24005572-4	2014	Herein, we describe changes in class III beta-tubulin in patients with advanced ovarian carcinoma in response to NACT, in relationship to clinical outcome, and between patients who underwent NACT versus primary debulking; we characterize in vitro chemosensitivity to paclitaxel/patupilone of cell lines established from this patient population, and class III beta-tubulin expression following repeated exposure to paclitaxel.	Paclitaxel	267-277	tubulin beta 3 class III	Homo sapiens	31-53
24005572-4	2014	Herein, we describe changes in class III beta-tubulin in patients with advanced ovarian carcinoma in response to NACT, in relationship to clinical outcome, and between patients who underwent NACT versus primary debulking; we characterize in vitro chemosensitivity to paclitaxel/patupilone of cell lines established from this patient population, and class III beta-tubulin expression following repeated exposure to paclitaxel.	Paclitaxel	414-424	tubulin beta 3 class III	Homo sapiens	31-53
20654527-5	1999	The functionality of each expressed CYP2C was assessed by determining specific catalytic activities in these cells, that is, taxol-6-hydroxylation for CYP2C8; diclofenac-4"-hydroxylation for CYP2C9; S-mephenytoin-4"-hydroxylation for CYP2C18; S-mephenytoin-4"-hydroxylation for CYP2C19.	Paclitaxel	125-130	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	151-157
10527889-0	1999	A crucial role of caspase 3 and caspase 8 in paclitaxel-induced apoptosis.	Paclitaxel	45-55	caspase 8	Homo sapiens	32-41
10527889-6	1999	The cleavage of caspase 3, caspase 8, and DFF45/ICAD was also observed in paclitaxel-induced apoptosis, and the inhibitor of caspase 3 and caspase 8 inhibited both antitumor effects and apoptosis induced by paclitaxel.	Paclitaxel	74-84	caspase 8	Homo sapiens	27-36
24005572-8	2014	In vitro subculture with paclitaxel resulted in class III beta-tubulin upregulation, however, cell lines that overexpressed class III beta-tubulin remained sensitive to patupilone.	Paclitaxel	25-35	tubulin beta 3 class III	Homo sapiens	48-70
24005572-9	2014	Overexpression of class III beta-tubulin in patients dispositioned to NACT may thus identify an intrinsically aggressive phenotype, and predict poor overall survival and paclitaxel resistance.	Paclitaxel	170-180	tubulin beta 3 class III	Homo sapiens	18-40
23430338-6	2014	Expression of MAGE-A11 was significantly associated with a poorer response to treatment with DDP, 5-FU, docetaxel, and paclitaxel.	Paclitaxel	119-129	MAGE family member A11	Homo sapiens	14-22
10527889-6	1999	The cleavage of caspase 3, caspase 8, and DFF45/ICAD was also observed in paclitaxel-induced apoptosis, and the inhibitor of caspase 3 and caspase 8 inhibited both antitumor effects and apoptosis induced by paclitaxel.	Paclitaxel	74-84	DNA fragmentation factor subunit alpha	Homo sapiens	42-47
10527889-6	1999	The cleavage of caspase 3, caspase 8, and DFF45/ICAD was also observed in paclitaxel-induced apoptosis, and the inhibitor of caspase 3 and caspase 8 inhibited both antitumor effects and apoptosis induced by paclitaxel.	Paclitaxel	74-84	DNA fragmentation factor subunit alpha	Homo sapiens	48-52
10527889-6	1999	The cleavage of caspase 3, caspase 8, and DFF45/ICAD was also observed in paclitaxel-induced apoptosis, and the inhibitor of caspase 3 and caspase 8 inhibited both antitumor effects and apoptosis induced by paclitaxel.	Paclitaxel	74-84	caspase 8	Homo sapiens	139-148
10527889-6	1999	The cleavage of caspase 3, caspase 8, and DFF45/ICAD was also observed in paclitaxel-induced apoptosis, and the inhibitor of caspase 3 and caspase 8 inhibited both antitumor effects and apoptosis induced by paclitaxel.	Paclitaxel	207-217	DNA fragmentation factor subunit alpha	Homo sapiens	42-47
10527889-6	1999	The cleavage of caspase 3, caspase 8, and DFF45/ICAD was also observed in paclitaxel-induced apoptosis, and the inhibitor of caspase 3 and caspase 8 inhibited both antitumor effects and apoptosis induced by paclitaxel.	Paclitaxel	207-217	DNA fragmentation factor subunit alpha	Homo sapiens	48-52
10527889-6	1999	The cleavage of caspase 3, caspase 8, and DFF45/ICAD was also observed in paclitaxel-induced apoptosis, and the inhibitor of caspase 3 and caspase 8 inhibited both antitumor effects and apoptosis induced by paclitaxel.	Paclitaxel	207-217	caspase 8	Homo sapiens	139-148
25343293-0	2014	Knockdown of clusterin expression increases the in vitro sensitivity of human prostate cancer cells to paclitaxel.	Paclitaxel	103-113	clusterin	Homo sapiens	13-22
10362110-9	1999	Immunofluorescence staining of cells treated with AS1 ODN revealed a decrease in class III protein expression which corresponded to a 39% increase in sensitivity to Taxol (P &lt; 0.005).	Paclitaxel	165-170	prostaglandin D2 receptor	Homo sapiens	50-53
25343293-7	2014	Interestingly, clusterin mRNA expression was reduced in paclitaxel-treated cells, and the cytotoxic effect of paclitaxel was more potent when cells were incubated with clusterin siRNA.	Paclitaxel	56-66	clusterin	Homo sapiens	15-24
25343293-7	2014	Interestingly, clusterin mRNA expression was reduced in paclitaxel-treated cells, and the cytotoxic effect of paclitaxel was more potent when cells were incubated with clusterin siRNA.	Paclitaxel	56-66	clusterin	Homo sapiens	168-177
25343293-7	2014	Interestingly, clusterin mRNA expression was reduced in paclitaxel-treated cells, and the cytotoxic effect of paclitaxel was more potent when cells were incubated with clusterin siRNA.	Paclitaxel	110-120	clusterin	Homo sapiens	168-177
25343293-9	2014	Taken together, these results indicate that clusterin plays a crucial role in PC3 cell proliferation and that clusterin depletion may contribute to enhanced sensitivity of PC3 cells to anticancer agents such as paclitaxel.	Paclitaxel	211-221	clusterin	Homo sapiens	44-53
25343293-9	2014	Taken together, these results indicate that clusterin plays a crucial role in PC3 cell proliferation and that clusterin depletion may contribute to enhanced sensitivity of PC3 cells to anticancer agents such as paclitaxel.	Paclitaxel	211-221	clusterin	Homo sapiens	110-119
24070631-0	2013	Inhibition of glycogen synthase kinase 3beta activity with lithium prevents and attenuates paclitaxel-induced neuropathic pain.	Paclitaxel	91-101	glycogen synthase kinase 3 beta	Homo sapiens	14-44
24175976-6	2013	Also, Fol-c1-beta-CyD increased antitumor activities of paclitaxel and vinblastine, but not 5-fluorouracil.	Paclitaxel	56-66	cytochrome b-245, beta polypeptide	Mus musculus	18-21
24260253-6	2013	A xenograft study showed that mice treated with Pac and bicalutamide showed worse outcome supporting our hypothesis that upregulation of c-jun might act as a potent antiapoptotic factor.	Paclitaxel	48-51	jun proto-oncogene	Mus musculus	137-142
23990115-6	2013	Furthermore, AMG 900 potentiated the antiproliferative effects of paclitaxel and ixabepilone at low nanomolar concentrations.	Paclitaxel	66-76	amelogenin X-linked	Homo sapiens	13-16
23990115-7	2013	In mice, AMG 900 significantly inhibited the growth of MDA-MB-231 (F(11); parental), MDA-MB-231 (F(11)) PTX-r (paclitaxel-resistant variant), and DU4475 xenografts.	Paclitaxel	111-121	amelogenin X-linked	Homo sapiens	9-12
24165036-0	2013	Overexpression of Heat Shock Transcription Factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel.	Paclitaxel	113-123	heat shock transcription factor 1	Homo sapiens	18-51
24165036-10	2013	RESULTS: Cells overexpressing HSF1 and characterized by increased HSPs accumulation were more resistant to doxorubicin or paclitaxel, but not to cisplatin, vinblastine or bortezomib.	Paclitaxel	122-132	heat shock transcription factor 1	Homo sapiens	30-34
24165036-14	2013	CONCLUSIONS: HSF1 overexpression facilitates the survival of melanoma cells treated with doxorubicin or paclitaxel.	Paclitaxel	104-114	heat shock transcription factor 1	Homo sapiens	13-17
24196083-0	2013	[A case of poorly differentiated adenocarcinoma of the uterine cervix treated with paclitaxel and carboplatin after positive PAX 8 immunostaining].	Paclitaxel	83-93	paired box 8	Homo sapiens	125-130
24273886-6	2013	The results showed that paclitaxel detoxified in the single-transfected MDCK-MDR1 cell because of P-gp efflux.	Paclitaxel	24-34	ATP binding cassette subfamily B member 1	Canis lupus familiaris	77-81
23776197-7	2013	A meta-analysis of EPHA5-rs7349683, the top marker for paclitaxel induced neuropathy in a previous GWAS (r(2)=0.79 with rs1159057), gave a hazard ratio (HR) estimate of 1.68 (p=1.4x10(-9)).	Paclitaxel	55-65	EPH receptor A5	Homo sapiens	19-24
23776197-10	2013	CONCLUSIONS: This study provides independent support of EPHA5-rs7349683 and XKR4-rs4737264 as the first markers of risk of paclitaxel induced neuropathy.	Paclitaxel	123-133	EPH receptor A5	Homo sapiens	56-61
23661607-8	2013	RESULTS: We show that Plk1 phosphorylation of CLIP-170 and p150(Glued) affects cellular responses to paclitaxel.	Paclitaxel	101-111	chromatin assembly factor 1 subunit A	Homo sapiens	59-70
23661607-9	2013	Expression of Plk1-unphosphorylatable mutants of CLIP-170 and p150(Glued) results in increased paclitaxel-induced apoptosis, increased protein degradation of the AR, and decreased nuclear accumulation of the AR in response to androgen in prostate cancer cells.	Paclitaxel	95-105	chromatin assembly factor 1 subunit A	Homo sapiens	62-66
23869764-10	2013	Silencing KLF5 by small interfering RNA in sphere cells down-regulated survivin expression, which also sensitized the sphere cells to apoptosis induced by chemotherapeutic drugs (cisplatin or paclitaxel).	Paclitaxel	192-202	Kruppel like factor 5	Homo sapiens	10-14
23847086-9	2013	Estrogen receptor-beta (ER-beta) and its downstream tumor suppressor forkhead box O1 levels were significantly elevated in CAPE and combination groups compared to DOC or PTX-alone.	Paclitaxel	170-173	estrogen receptor 2	Homo sapiens	0-22
9493910-0	1998	Taxol induces concomitant hyperphosphorylation and reorganization of vimentin intermediate filaments in 9L rat brain tumor cells.	Paclitaxel	0-5	vimentin	Rattus norvegicus	69-77
9493910-3	1998	Herein, we report that taxol induces hyperphosphorylation and reorganization of the vimentin intermediate filament in 9L rat brain tumor cells, in concentration- and time-dependent manner.	Paclitaxel	23-28	vimentin	Rattus norvegicus	84-92
9493910-4	1998	Phosphorylation of vimentin was maximum at 10(-6) M of taxol treatment for 8 h and diminished at higher (10(-5) M) concentration.	Paclitaxel	55-60	vimentin	Rattus norvegicus	19-27
9493910-5	1998	Enhanced phosphorylation of vimentin was detectable at 2 h treatment with 10(-6) M taxol and was maximum after 12 h of treatment.	Paclitaxel	83-88	vimentin	Rattus norvegicus	28-36
9493910-6	1998	Taxol-induced phosphorylation of vimentin was largely abolished in cells pretreated with staurosporine and bisindolymaleimide but was unaffected by H-89, KT-5926, SB203580, genistein, and olomoucine.	Paclitaxel	0-5	vimentin	Rattus norvegicus	33-41
9493910-9	1998	Moreover, there was a concomitant reorganization of the vimentin intermediate filament in the taxol-treated cells, whereas the microtubules and the actin microfilaments were less affected.	Paclitaxel	94-99	vimentin	Rattus norvegicus	56-64
9493910-10	1998	Taken together, our data demonstrate that taxol induces hyperphosphorylation of vimentin with concomitant reorganization of the vimentin intermediate filament and that this process may be mediated via a protein kinase C signaling pathway.	Paclitaxel	42-47	vimentin	Rattus norvegicus	80-88
23847086-9	2013	Estrogen receptor-beta (ER-beta) and its downstream tumor suppressor forkhead box O1 levels were significantly elevated in CAPE and combination groups compared to DOC or PTX-alone.	Paclitaxel	170-173	estrogen receptor 2	Homo sapiens	24-31
9493910-10	1998	Taken together, our data demonstrate that taxol induces hyperphosphorylation of vimentin with concomitant reorganization of the vimentin intermediate filament and that this process may be mediated via a protein kinase C signaling pathway.	Paclitaxel	42-47	vimentin	Rattus norvegicus	128-136
23844053-6	2013	We also show that overexpression of EphB4 promotes cellular proliferation, colony formation, and motility, while EphB4 inhibition reduces cellular viability in vitro, halts the growth of established tumors in mouse xenograft models when used as a single-target strategy, and causes near-complete regression of established tumors when used in combination with paclitaxel.	Paclitaxel	359-369	Eph receptor B4	Mus musculus	36-41
9443400-0	1998	Transient stimulation of the c-Jun-NH2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts.	Paclitaxel	160-170	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	55-74
9443400-1	1998	We demonstrate here that paclitaxel exposure to RPMI-1788 B lymphoblasts caused a dose- and time-dependent increase in nuclear factor activator protein 1 (AP-1) DNA binding activity.	Paclitaxel	25-35	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	134-153
9443400-1	1998	We demonstrate here that paclitaxel exposure to RPMI-1788 B lymphoblasts caused a dose- and time-dependent increase in nuclear factor activator protein 1 (AP-1) DNA binding activity.	Paclitaxel	25-35	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	155-159
9443400-3	1998	Consistent with these biochemical events, paclitaxel stimulated AP-1-dependent chloramphenicol acetyltransferase (CAT) reporter gene transcription in vivo, as directed from a tetradecanoyl phorbol acetate-inducible promoter.	Paclitaxel	42-52	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	64-68
9443400-4	1998	AP-1 binding activity of nuclear extracts isolated from paclitaxel treated cells was reduced following immunodepletion with antibodies directed against individual Jun family proteins, whereas anti-cFos, anti-Fra1, and anti-FosB antibodies were not inhibitory.	Paclitaxel	56-66	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	0-4
23844053-6	2013	We also show that overexpression of EphB4 promotes cellular proliferation, colony formation, and motility, while EphB4 inhibition reduces cellular viability in vitro, halts the growth of established tumors in mouse xenograft models when used as a single-target strategy, and causes near-complete regression of established tumors when used in combination with paclitaxel.	Paclitaxel	359-369	Eph receptor B4	Mus musculus	113-118
9815561-5	1997	Loss of either hMSH2 or hMLH1 function was associated with low level resistance to cisplatin, carboplatin, and etoposide, but there was no resistance to melphalan, perfosfamide, 5-fluorouracil, doxorubicin, or paclitaxel.	Paclitaxel	210-220	mutS homolog 2	Homo sapiens	15-20
23583215-2	2013	Resistance to paclitaxel has been linked to serous papillary overexpression of class III beta-tubulin in several human cancers but inadequately characterized among clear cell carcinoma of the ovary.	Paclitaxel	14-24	tubulin beta 3 class III	Homo sapiens	79-101
9299500-1	1997	Exogenous angiogenin undergoes rapid nuclear translocation in cultured human umbilical artery endothelial cells at 37 degrees C but not at 4 degrees C. Treatment of cells with colchicine, nocodazole and taxol, which disrupt the microtubule system, does not affect the nuclear translocation process of angiogenin, suggesting that cells transport internalized angiogenin in a microtubule independent fashion.	Paclitaxel	203-208	angiogenin	Homo sapiens	10-20
23583215-5	2013	In this study, we clarify the relationship between class III beta-tubulin and p-glycoprotein expression in clear cell carcinoma of the ovary, clinical outcome, and in vitro responsiveness to patupilone and paclitaxel.	Paclitaxel	206-216	tubulin beta 3 class III	Homo sapiens	51-73
9299500-1	1997	Exogenous angiogenin undergoes rapid nuclear translocation in cultured human umbilical artery endothelial cells at 37 degrees C but not at 4 degrees C. Treatment of cells with colchicine, nocodazole and taxol, which disrupt the microtubule system, does not affect the nuclear translocation process of angiogenin, suggesting that cells transport internalized angiogenin in a microtubule independent fashion.	Paclitaxel	203-208	angiogenin	Homo sapiens	301-311
9299500-1	1997	Exogenous angiogenin undergoes rapid nuclear translocation in cultured human umbilical artery endothelial cells at 37 degrees C but not at 4 degrees C. Treatment of cells with colchicine, nocodazole and taxol, which disrupt the microtubule system, does not affect the nuclear translocation process of angiogenin, suggesting that cells transport internalized angiogenin in a microtubule independent fashion.	Paclitaxel	203-208	angiogenin	Homo sapiens	301-311
23583215-14	2013	CONCLUSION: Class III beta-tubulin overexpression in clear cell carcinoma of the ovary discriminates poor prognosis, serves as a marker for sensitivity to patupilone, and may contribute to paclitaxel resistance.	Paclitaxel	189-199	tubulin beta 3 class III	Homo sapiens	12-34
9127007-3	1997	A comparison of responses of macrophages from wild-type mice with those from mice lacking CD14 due to a targeted disruption of the CD14 gene (CD14-deficient knockout (CD14KO)) revealed that like LPS, Taxol induces both CD14-dependent and -independent pathways of gene activation, although the CD14 dependency of Taxol stimulation is much less striking than that observed with LPS.	Paclitaxel	200-205	CD14 antigen	Mus musculus	90-94
23389639-3	2013	Furthermore, paclitaxel was shown to downregulate VEGF and Ang-1 expression in tumor cells, and to increase the secretion of TSP-1 in the tumor microenvironment.	Paclitaxel	13-23	angiopoietin 1	Homo sapiens	59-64
9175720-4	1997	We report that preincubation of cells with TGF-beta3 for 24 hr resulted in enhanced clonogenicity following exposure to vinblastine, vincristine, etoposide, taxol, ara-C, methotrexate, or 5-FU.	Paclitaxel	157-162	transforming growth factor beta 3	Homo sapiens	43-52
23007175-2	2013	To obtain the monoclonal antibody (MAb) against paclitaxel for paclitaxel determination using immunoassay, 7-xylosyltaxol was conjugated to the carrier protein bovine serum albumin (BSA) to construct the immunogen, and the ratio of hapten in XylTax-BSA conjugate was determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.	Paclitaxel	48-58	albumin	Mus musculus	167-180
9050899-7	1997	Consequently, the oral bioavailability in mice receiving 10 mg paclitaxel per kg body weight increased from only 11% in wt mice to 35% in mdr1a(-/-) mice.	Paclitaxel	63-73	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	138-143
9050899-12	1997	drug administration of paclitaxel (10 mg/kg) to mice with a cannulated gall bladder, 11% of the dose was recovered within 90 min in the intestinal contents of wt mice vs. &lt;3% in mdr1a(-/-) mice.	Paclitaxel	23-33	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	181-186
24313208-5	2013	CD133+ cells and CD133- control cells were treated with paclitaxel and exposed respectively to X-rays emitted by linear accelerator with a dose of 10 Gy.	Paclitaxel	56-66	prominin 1	Homo sapiens	0-5
9061205-4	1997	Enzyme-catalyzed hydrolysis of the glucuronic acid moiety by human beta-glucuronidase results in the liberation of the parent drug paclitaxel via gamma or delta lactam formation with half-lives of 45 min and 2 h (1 and 2b).	Paclitaxel	131-141	glucuronidase beta	Homo sapiens	67-85
24313208-12	2013	At 24, 48, and 72 hours of treatment with paclitaxel, the cell surviving rates of CD133+ cells were 90.1% +/- 5.9%, 85.1% +/- 7.1% and 70.3% +/- 6.4% and lower than those of CD133- cells, respectively (t = 5.24, t = 8.18, t = 8.14, P &lt; 0.01) .	Paclitaxel	42-52	prominin 1	Homo sapiens	82-87
9118459-4	1997	paclitaxel therapy of mice bearing s.c. M109, beginning on day 4 or 5 posttumor implant and continuing for 5 days, resulted in a range of maximum gross log cell kill (LCK) values (reflective of delays in tumor growth) and maximum relative median survival time (% T/C) values (reflective of increases in lifespan) of 1.0-2.1 and 132-162% (and one outlying result of 235%), respectively.	Paclitaxel	0-10	lymphocyte protein tyrosine kinase	Mus musculus	167-170
9118459-6	1997	These LCK and %T/C values were always within 0.5 LCK and 15%, respectively, of the concomitantly obtained maximum effects of paclitaxel.	Paclitaxel	125-135	lymphocyte protein tyrosine kinase	Mus musculus	6-9
24313208-12	2013	At 24, 48, and 72 hours of treatment with paclitaxel, the cell surviving rates of CD133+ cells were 90.1% +/- 5.9%, 85.1% +/- 7.1% and 70.3% +/- 6.4% and lower than those of CD133- cells, respectively (t = 5.24, t = 8.18, t = 8.14, P &lt; 0.01) .	Paclitaxel	42-52	prominin 1	Homo sapiens	174-179
9118459-9	1997	Evaluated in parallel, paclitaxel achieved a maximum LCK of 2.1-4.5 following every other day x 5 i.v.	Paclitaxel	23-33	lymphocyte protein tyrosine kinase	Mus musculus	53-56
9118459-11	1997	When paclitaxel was assayed in several experiments using the staged (50-100 mg) s.c. L2987 tumor model, maximum LCK of 0.9-&gt;4.1 were produced following every other day x 5 i.v.	Paclitaxel	5-15	lymphocyte protein tyrosine kinase	Mus musculus	112-115
23750239-6	2013	It was further explored that miR-26a increased sensitivity of breast cancer cells to paclitaxel in which MCL-1 was involved.	Paclitaxel	85-95	microRNA 26a-1	Homo sapiens	29-36
23564469-9	2013	Both multivariable and propensity score-adjusted Cox models demonstrated a slight inferiority associated with carboplatin-gemcitabine or carboplatin-docetaxel versus carboplatin-paclitaxel, with a hazard ratio of 1.10 (95% confidence interval, 1.04-1.15) and 1.09 (95% confidence interval, 1.02-1.16), respectively, in propensity score-stratified models.	Paclitaxel	178-188	cytochrome c oxidase subunit 8A	Homo sapiens	49-52
9415374-5	1997	Nocodazole, taxol, and kinesin anti-sense oligonucleotide inhibited translocation of microinjected MBP mRNA, while cytochalasin B and kinesin sense oligonucleotide did not.	Paclitaxel	12-17	myelin basic protein	Homo sapiens	99-102
23730523-2	2013	Nab-paclitaxel (nab-P), an albumin-bound formulation of paclitaxel, appears to decrease levels of cytidine deaminase, which is the primary gemcitabine catabolic enzyme, this likely increases sensitivity to GEM when these agents are combined.	Paclitaxel	4-14	cytidine deaminase	Homo sapiens	98-116
8703990-12	1996	FACS analysis of taxol -treated and alpha-amanitin-treated cells corroborated these data.	Paclitaxel	17-22	acyl-CoA synthetase long-chain family member 1	Mus musculus	0-4
8735367-6	1996	InsP3-induced tyrosine phosphorylation of MAP kinase is prevented by BAPTA and taxol, but not by nocodazole.	Paclitaxel	79-84	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	42-52
8913833-5	1996	Using the same reversed-phase HPLC technique as developed for paclitaxel, CA-4 was shown to bind to serum proteins (&gt; or = 30,000 mw) &gt; 99% and to albumin approximately 70%.	Paclitaxel	62-72	carbonic anhydrase 4	Mus musculus	74-78
7529746-14	1995	125I-labeled LPS and 3H-labeled taxol was reported to bind to J774.1 cells predominantly via CD14 and microtubules, respectively.	Paclitaxel	32-37	CD14 antigen	Mus musculus	93-97
7923194-0	1994	Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.	Paclitaxel	31-36	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	70-89
7901279-11	1993	Taxol mimics LPS with respect to immediate MAPK activation, later transcriptional events, and the genetic control of both sets of responses.	Paclitaxel	0-5	mitogen-activated protein kinase 3	Mus musculus	43-47
7901342-7	1993	With this low quantitation threshold, we found the plasma disappearance of paclitaxel to be triphasic, with half-lives t1/2(alpha), t1/2(beta), and t1/2(gamma) mean values for the different treatment arms of 0.19 hours (range, 0.01 to 0.4), 1.9 hours (range, 0.5 to 2.8), and 20.7 hours (range, 4 to 65), respectively.	Paclitaxel	75-85	interleukin 1 receptor like 1	Homo sapiens	119-129
7901342-7	1993	With this low quantitation threshold, we found the plasma disappearance of paclitaxel to be triphasic, with half-lives t1/2(alpha), t1/2(beta), and t1/2(gamma) mean values for the different treatment arms of 0.19 hours (range, 0.01 to 0.4), 1.9 hours (range, 0.5 to 2.8), and 20.7 hours (range, 4 to 65), respectively.	Paclitaxel	75-85	interleukin 1 receptor like 1	Homo sapiens	148-158
1319319-8	1992	Pretreatment of cells with taxol, an agent that specifically promotes microtubule polymerization, decreases acrylamide-stimulated (as well as colchicine or ACTH-stimulated) steroidogenesis, implying that there must also be some shared elements in the stimulating pathways.	Paclitaxel	27-32	pro-opiomelanocortin-alpha	Mus musculus	156-160
1607388-6	1992	Altering the number and distribution of microtubules with taxol or nocodazole produced corresponding changes in the localization of the expressed kinesin heavy chain.	Paclitaxel	58-63	kinesin family member 5B	Homo sapiens	146-165
1354220-0	1992	Ability to organize microtubules in taxol-treated mitotic PtK2 cells goes with the SPN antigen and not with the centrosome.	Paclitaxel	36-41	protein tyrosine kinase 2	Homo sapiens	58-62
1354220-8	1992	Microinjection of SPN-3 antibody into taxol-treated mitotic PtK2 cells causes disruption of the asters as judged by tubulin staining of the same cells.	Paclitaxel	38-43	protein tyrosine kinase 2	Homo sapiens	60-64
1353539-5	1992	NGFR-IR was also seen on taxol (0.85 micrograms/ml)-exposed cells, an agent that promotes MT assembly.	Paclitaxel	25-30	nerve growth factor receptor	Rattus norvegicus	0-4
1353539-6	1992	Cells treated simultaneously with cytochalasin D and taxol had a dramatically augmented NGFR-IR on their surfaces, which exceeded levels obtained with either agent alone.	Paclitaxel	53-58	nerve growth factor receptor	Rattus norvegicus	88-92
33798550-11	2021	Using a xenograft model, we showed that miR-98 overexpression reversed paclitaxel resistance to CD44+ GCSCs.	Paclitaxel	71-81	microRNA 98	Homo sapiens	40-46
33798550-13	2021	Overexpressed BCAT1 reversed xenograft tumor formation ability and attenuated the paclitaxel chemosensitivity induced by miR-98 downregulation.	Paclitaxel	82-92	microRNA 98	Homo sapiens	121-127
33775687-6	2021	Paclitaxel exhibited differential efficacy in CYP2C8- and empty vector-transduced cells (significant differences between 10.9 - 24.4% for 0.01, 0.1 and 1 muM concentrations), but neither montelukast nor clotrimazole was capable of affecting this asymmetry.	Paclitaxel	0-10	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	46-52
33818320-2	2021	This study investigated the roles of lncRNA urothelial carcinoma-associated 1 (UCA1) in the modulation of Taxol resistance in human colorectal cancer cells.	Paclitaxel	106-111	urothelial cancer associated 1	Homo sapiens	44-77
33818320-2	2021	This study investigated the roles of lncRNA urothelial carcinoma-associated 1 (UCA1) in the modulation of Taxol resistance in human colorectal cancer cells.	Paclitaxel	106-111	urothelial cancer associated 1	Homo sapiens	79-83
33818320-4	2021	Construction of the UCA1 overexpression vector revealed that high UCA1 expression was responsible for Taxol resistance and that Taxol can induce UCA1 expression.	Paclitaxel	102-107	urothelial cancer associated 1	Homo sapiens	20-24
33818320-4	2021	Construction of the UCA1 overexpression vector revealed that high UCA1 expression was responsible for Taxol resistance and that Taxol can induce UCA1 expression.	Paclitaxel	102-107	urothelial cancer associated 1	Homo sapiens	66-70
33818320-4	2021	Construction of the UCA1 overexpression vector revealed that high UCA1 expression was responsible for Taxol resistance and that Taxol can induce UCA1 expression.	Paclitaxel	102-107	urothelial cancer associated 1	Homo sapiens	66-70
33818320-4	2021	Construction of the UCA1 overexpression vector revealed that high UCA1 expression was responsible for Taxol resistance and that Taxol can induce UCA1 expression.	Paclitaxel	128-133	urothelial cancer associated 1	Homo sapiens	20-24
33818320-5	2021	Importantly, Taxol-resistant cells had a higher glycolysis rate and upregulated expression of the key glycolysis enzymes hexokinase 2 (HK2) and lactate dehydrogenase A (LDHA) than Taxol-sensitive cells.	Paclitaxel	13-18	hexokinase 2	Homo sapiens	121-133
33818320-5	2021	Importantly, Taxol-resistant cells had a higher glycolysis rate and upregulated expression of the key glycolysis enzymes hexokinase 2 (HK2) and lactate dehydrogenase A (LDHA) than Taxol-sensitive cells.	Paclitaxel	13-18	hexokinase 2	Homo sapiens	135-138
33818320-6	2021	Further research demonstrated that UCA1 could directly regulate glycolysis by regulating HK2 and LDHA expression, which contributes to Taxol resistance.	Paclitaxel	135-140	urothelial cancer associated 1	Homo sapiens	35-39
33818320-6	2021	Further research demonstrated that UCA1 could directly regulate glycolysis by regulating HK2 and LDHA expression, which contributes to Taxol resistance.	Paclitaxel	135-140	hexokinase 2	Homo sapiens	89-92
33818320-8	2021	We report the modulation of UCA-1-regulated glycolysis as a novel anticancer strategy along with the novel role of UCA1 in Taxol resistance.	Paclitaxel	123-128	urothelial cancer associated 1	Homo sapiens	115-119
8791772-0	1996	Assays of CYP2C8- and CYP3A4-mediated metabolism of taxol in vivo and in vitro.	Paclitaxel	52-57	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	10-16
34935867-5	2022	Here, we demonstrate that paclitaxel triggers Sarm1-dependent cADPR production in distal axons, promoting intra-axonal calcium flux from both intracellular and extracellular calcium stores.	Paclitaxel	26-36	sterile alpha and TIR motif containing 1	Homo sapiens	46-51
34808333-0	2022	FOXM1-mediated activation of phospholipase D1 promotes lipid droplet accumulation and reduces ROS to support paclitaxel resistance in metastatic cancer cells.	Paclitaxel	109-119	phospholipase D1	Mus musculus	29-45
34808333-8	2022	PLD1 promoted LD accumulation, which reduced the level of reactive oxygen species (ROS) and maintained endoplasmic reticulum (ER) homeostasis in resistant cells with the treatment of paclitaxel.	Paclitaxel	183-193	phospholipase D1	Mus musculus	0-4
34896780-11	2022	Quantitative RT-PCR showed that the combination of paclitaxel and LV could significantly reduce the expression of CYP2C8, an important drug-metabolizing enzyme.	Paclitaxel	51-61	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	114-120
34896780-13	2022	Our results suggest that LV might increase the sensitivity of resistant prostate cancer cells to paclitaxel through inhibition of CYP2C8 and could be utilized as a chemosensitizer for paclitaxel-resistant prostate cancer cells.	Paclitaxel	97-107	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	130-136
34666995-4	2022	Paclitaxel (PTX) chemotherapy enhanced rapid ECM remodeling and mechano-structural changes in the lungs of tumor-free mice, and the protein expression and activity of the ECM remodeling enzyme lysyl oxidase (LOX) increased in response to PTX.	Paclitaxel	0-10	lysyl oxidase	Mus musculus	193-206
34666995-4	2022	Paclitaxel (PTX) chemotherapy enhanced rapid ECM remodeling and mechano-structural changes in the lungs of tumor-free mice, and the protein expression and activity of the ECM remodeling enzyme lysyl oxidase (LOX) increased in response to PTX.	Paclitaxel	0-10	lysyl oxidase	Mus musculus	208-211
34666995-4	2022	Paclitaxel (PTX) chemotherapy enhanced rapid ECM remodeling and mechano-structural changes in the lungs of tumor-free mice, and the protein expression and activity of the ECM remodeling enzyme lysyl oxidase (LOX) increased in response to PTX.	Paclitaxel	12-15	lysyl oxidase	Mus musculus	193-206
34666995-4	2022	Paclitaxel (PTX) chemotherapy enhanced rapid ECM remodeling and mechano-structural changes in the lungs of tumor-free mice, and the protein expression and activity of the ECM remodeling enzyme lysyl oxidase (LOX) increased in response to PTX.	Paclitaxel	12-15	lysyl oxidase	Mus musculus	208-211
34666995-4	2022	Paclitaxel (PTX) chemotherapy enhanced rapid ECM remodeling and mechano-structural changes in the lungs of tumor-free mice, and the protein expression and activity of the ECM remodeling enzyme lysyl oxidase (LOX) increased in response to PTX.	Paclitaxel	238-241	lysyl oxidase	Mus musculus	193-206
34666995-4	2022	Paclitaxel (PTX) chemotherapy enhanced rapid ECM remodeling and mechano-structural changes in the lungs of tumor-free mice, and the protein expression and activity of the ECM remodeling enzyme lysyl oxidase (LOX) increased in response to PTX.	Paclitaxel	238-241	lysyl oxidase	Mus musculus	208-211
34666995-7	2022	Lastly, in a clinically relevant metastatic breast carcinoma model, LOX inhibition counteracted the metastasis-promoting, ECM-related effects of PTX.	Paclitaxel	145-148	lysyl oxidase	Mus musculus	68-71
34737212-9	2022	In vitro, combined treatment with AP-1 or SIK2 inhibitors with carboplatin or paclitaxel demonstrated synergistic effects.	Paclitaxel	78-88	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	34-38
34924121-0	2022	Role of neuron-derived ATP in paclitaxel-induced HMGB1 release from macrophages and peripheral neuropathy.	Paclitaxel	30-40	high mobility group box 1	Mus musculus	49-54
34924121-1	2022	We examined the role of ATP and high mobility group box 1 (HMGB1) in paclitaxel-induced peripheral neuropathy (PIPN).	Paclitaxel	69-79	high mobility group box 1	Mus musculus	59-64
34924121-3	2022	Paclitaxel and ATP synergistically released HMGB1 from macrophage-like RAW264.7 cells, but not neuron-like NG108-15 cells.	Paclitaxel	0-10	high mobility group box 1	Mus musculus	44-49
34924121-4	2022	The paclitaxel-induced HMGB1 release from RAW264.7 cells was accelerated by co-culture with NG108-15 cells in a manner dependent on P2X7 or P2X4.	Paclitaxel	4-14	high mobility group box 1	Mus musculus	23-28
34855343-4	2021	The released alphaPD-L1 sequentially synergizes with PTX released in the cytoplasm for boosted chemoimmunotherapy due to direct killing of PTX and intensified immune responses through immunogenic cell death (ICD) as well as suppression of immune escape by blocking the PD-1/PD-L1 axis.	Paclitaxel	53-56	programmed cell death 1	Homo sapiens	269-273
34743946-4	2021	The data obtained show that PTX-induced MDA, NF-kappaB, IL-1beta, TNF-alpha, COX-2, nNOS, JAK2, STAT3, and GFAP levels decreased with HES administration.	Paclitaxel	28-31	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	77-82
34743946-6	2021	It was determined that PTX caused apoptosis in the sciatic nerve by increasing Caspase-3 and Bax levels and suppressing Bcl-2 levels.	Paclitaxel	23-26	caspase 3	Rattus norvegicus	79-88
10352302-7	1999	Paclitaxel enhanced p40 expression in a dose-dependent manner.	Paclitaxel	0-10	interleukin 9	Homo sapiens	20-23
9886421-0	1999	Effect of taxol and taxotere on gene expression in macrophages: induction of the prostaglandin H synthase-2 isoenzyme.	Paclitaxel	10-15	prostaglandin-endoperoxide synthase 2	Mus musculus	81-107
9886421-2	1999	We hypothesized that prostaglandin H synthase-2 (PGHS-2) was one of the unidentified genes induced by taxol.	Paclitaxel	102-107	prostaglandin-endoperoxide synthase 2	Mus musculus	21-47
9886421-2	1999	We hypothesized that prostaglandin H synthase-2 (PGHS-2) was one of the unidentified genes induced by taxol.	Paclitaxel	102-107	prostaglandin-endoperoxide synthase 2	Mus musculus	49-55
9886421-3	1999	Taxol alone or taxol plus IFN-gamma increased PGE2 formation, PGHS-2 protein expression, and PGHS-2 mRNA expression in RAW 264.7 murine macrophages.	Paclitaxel	0-5	prostaglandin-endoperoxide synthase 2	Mus musculus	62-68
9886421-3	1999	Taxol alone or taxol plus IFN-gamma increased PGE2 formation, PGHS-2 protein expression, and PGHS-2 mRNA expression in RAW 264.7 murine macrophages.	Paclitaxel	0-5	prostaglandin-endoperoxide synthase 2	Mus musculus	93-99
9886421-5	1999	A selective inhibitor of PGHS-2 blocked PGE2 formation by cells incubated with taxol; a selective inhibitor of PGHS-1 had no effect.	Paclitaxel	79-84	prostaglandin-endoperoxide synthase 2	Mus musculus	25-31
9886421-12	1999	The inclusion of PGHS-2 among the early response genes induced in leukocytes may be relevant to the beneficial and adverse effects encountered during taxol administration.	Paclitaxel	150-155	prostaglandin-endoperoxide synthase 2	Mus musculus	17-23
9852137-14	1998	Thus, paclitaxel, vinblastine, and vincristine each specifically activate PKCdelta, whereas PMA, thymeleatoxin, and dPPA activate multiple isoenzymes.	Paclitaxel	6-16	protein kinase C delta	Homo sapiens	74-82
9582369-9	1998	Suppression of apoptosis induced by okadaic acid, H2O2, and taxol was also inhibited by Mn-SOD but not that induced by vincristine, vinblastine, or daunomycin.	Paclitaxel	60-65	superoxide dismutase 2	Homo sapiens	88-94
9633517-6	1998	Initial studies on proteases activation tend to exclude a direct role of ICE and CPP32 in the induction of apoptosis in these cells and show a paclitaxel-dependent increase in FLICE levels, whose biological relevance is however at present not defined.	Paclitaxel	143-153	caspase 8	Homo sapiens	176-181
9710718-2	1998	We studied the effects of cytotoxic concentrations of Taxol (TXL) on cyclin D1 and B1 expression on human ovarian cancer cell lines.	Paclitaxel	54-59	cyclin D1	Homo sapiens	69-78
9710718-2	1998	We studied the effects of cytotoxic concentrations of Taxol (TXL) on cyclin D1 and B1 expression on human ovarian cancer cell lines.	Paclitaxel	61-64	cyclin D1	Homo sapiens	69-78
9469365-13	1998	CONCLUSION: The addition of infusional paclitaxel and hyperfractionated RT to FHX is feasible.	Paclitaxel	39-49	forkhead box J2	Homo sapiens	78-81
9461009-1	1998	The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC).	Paclitaxel	71-81	SCLC1	Homo sapiens	171-175
9461009-1	1998	The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC).	Paclitaxel	83-88	SCLC1	Homo sapiens	171-175
9461009-2	1998	Patients with SCLC relapsing within 3 months of cytotoxic therapy received paclitaxel 175 mg m(-2) intravenously over 3 h every 3 weeks.	Paclitaxel	75-85	SCLC1	Homo sapiens	14-18
9461009-9	1998	Paclitaxel is active in drug-resistant SCLC.	Paclitaxel	0-10	SCLC1	Homo sapiens	39-43
9317152-1	1997	Activation of macrophages by LPS and taxol results in production of IL-1, IL-6, TNF-alpha, and granulocyte-macrophage CSF (GM-CSF), which are involved in regulating hemopoiesis, inflammation, and immune responses.	Paclitaxel	37-42	interleukin 1 complex	Mus musculus	68-72
9240465-5	1997	Interestingly, the expression of P-40 was also higher in two tumor cell lines (SKTax6a and A2780CP) that were selected with paclitaxel or cisplatin but do not express P-gp or MRP.	Paclitaxel	124-134	interleukin 9	Homo sapiens	33-37
9127007-3	1997	A comparison of responses of macrophages from wild-type mice with those from mice lacking CD14 due to a targeted disruption of the CD14 gene (CD14-deficient knockout (CD14KO)) revealed that like LPS, Taxol induces both CD14-dependent and -independent pathways of gene activation, although the CD14 dependency of Taxol stimulation is much less striking than that observed with LPS.	Paclitaxel	200-205	CD14 antigen	Mus musculus	131-135
9127007-3	1997	A comparison of responses of macrophages from wild-type mice with those from mice lacking CD14 due to a targeted disruption of the CD14 gene (CD14-deficient knockout (CD14KO)) revealed that like LPS, Taxol induces both CD14-dependent and -independent pathways of gene activation, although the CD14 dependency of Taxol stimulation is much less striking than that observed with LPS.	Paclitaxel	200-205	CD14 antigen	Mus musculus	131-135
9127007-3	1997	A comparison of responses of macrophages from wild-type mice with those from mice lacking CD14 due to a targeted disruption of the CD14 gene (CD14-deficient knockout (CD14KO)) revealed that like LPS, Taxol induces both CD14-dependent and -independent pathways of gene activation, although the CD14 dependency of Taxol stimulation is much less striking than that observed with LPS.	Paclitaxel	200-205	CD14 antigen	Mus musculus	131-135
9127007-3	1997	A comparison of responses of macrophages from wild-type mice with those from mice lacking CD14 due to a targeted disruption of the CD14 gene (CD14-deficient knockout (CD14KO)) revealed that like LPS, Taxol induces both CD14-dependent and -independent pathways of gene activation, although the CD14 dependency of Taxol stimulation is much less striking than that observed with LPS.	Paclitaxel	200-205	CD14 antigen	Mus musculus	131-135
9127007-5	1997	However, at high concentrations of LPS or Taxol, a CD14-independent pathway of activation is observed: this pathway leads to minimal IP-10 gene induction, even though induction of TNF-alpha and IL-1beta occurs.	Paclitaxel	42-47	CD14 antigen	Mus musculus	51-55
9127007-5	1997	However, at high concentrations of LPS or Taxol, a CD14-independent pathway of activation is observed: this pathway leads to minimal IP-10 gene induction, even though induction of TNF-alpha and IL-1beta occurs.	Paclitaxel	42-47	chemokine (C-X-C motif) ligand 10	Mus musculus	133-138
9127007-7	1997	These data suggest the existence of two pathways of activation by both LPS and Taxol: one that is CD14 dependent and leads to induction of TNF-alpha, IL-1beta, and IP-10 gene induction, and a CD14-independent pathway that results in the induction of TNF-alpha and IL-1beta, with minimal induction of IP-10.	Paclitaxel	79-84	CD14 antigen	Mus musculus	98-102
9127007-7	1997	These data suggest the existence of two pathways of activation by both LPS and Taxol: one that is CD14 dependent and leads to induction of TNF-alpha, IL-1beta, and IP-10 gene induction, and a CD14-independent pathway that results in the induction of TNF-alpha and IL-1beta, with minimal induction of IP-10.	Paclitaxel	79-84	chemokine (C-X-C motif) ligand 10	Mus musculus	164-169
9127007-7	1997	These data suggest the existence of two pathways of activation by both LPS and Taxol: one that is CD14 dependent and leads to induction of TNF-alpha, IL-1beta, and IP-10 gene induction, and a CD14-independent pathway that results in the induction of TNF-alpha and IL-1beta, with minimal induction of IP-10.	Paclitaxel	79-84	CD14 antigen	Mus musculus	192-196
9127007-7	1997	These data suggest the existence of two pathways of activation by both LPS and Taxol: one that is CD14 dependent and leads to induction of TNF-alpha, IL-1beta, and IP-10 gene induction, and a CD14-independent pathway that results in the induction of TNF-alpha and IL-1beta, with minimal induction of IP-10.	Paclitaxel	79-84	chemokine (C-X-C motif) ligand 10	Mus musculus	300-305
9067280-1	1997	Paclitaxel has been shown to activate Raf-1 and cause phosphorylation of Bcl-2, which has been correlated with paclitaxel-induced apoptosis of cancer cells.	Paclitaxel	0-10	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	38-43
9067280-1	1997	Paclitaxel has been shown to activate Raf-1 and cause phosphorylation of Bcl-2, which has been correlated with paclitaxel-induced apoptosis of cancer cells.	Paclitaxel	111-121	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	38-43
9061948-7	1997	The redistribution of phragmoplastin may require microtubule reorganization because the microtubule-stabilizing drug taxol inhibited phragmoplastin redistribution.	Paclitaxel	117-122	dynamin-related protein 12A	Glycine max	22-36
9061948-7	1997	The redistribution of phragmoplastin may require microtubule reorganization because the microtubule-stabilizing drug taxol inhibited phragmoplastin redistribution.	Paclitaxel	117-122	dynamin-related protein 12A	Glycine max	133-147
9016810-6	1997	In addition, the microtubule stabilizer taxol prevented the malonyl-CoA-independent stimulation of CPT-I induced by AICAR.	Paclitaxel	40-45	carnitine palmitoyltransferase 1B	Rattus norvegicus	99-104
34893642-8	2021	Silencing MSMO1 could significantly enhance the sensitivity of MDA-MB-231 cells to paclitaxel and doxorubicin through modulating mTORC1 signaling pathway.	Paclitaxel	83-93	CREB regulated transcription coactivator 1	Mus musculus	129-135
34950596-0	2021	A Novel miR-98 Negatively Regulates the Resistance of Endometrial Cancer Cells to Paclitaxel by Suppressing ABCC10/MRP-7.	Paclitaxel	82-92	microRNA 98	Homo sapiens	8-14
34950596-8	2021	Moreover, miR-98 serves as a tumor suppressor to inhibit MRP-7 expression, leading to the repression of paclitaxel resistance.	Paclitaxel	104-114	microRNA 98	Homo sapiens	10-16
34950596-10	2021	Taken together, these findings demonstrate that upregulation of MRP-7 and NEAT1, and downregulation of miR-98 have important roles in conferring paclitaxel resistance to EC cells.	Paclitaxel	145-155	microRNA 98	Homo sapiens	103-109
34873207-4	2021	Paclitaxel induced intrinsic apoptosis by activating caspase-3, caspase-9 and PARP.	Paclitaxel	0-10	collagen type XI alpha 2 chain	Homo sapiens	78-82
23602343-0	2013	Effect of paclitaxel on transient receptor potential vanilloid 1 in rat dorsal root ganglion.	Paclitaxel	10-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	24-64
34905470-0	2021	Nuclear receptor binding SET domain protein 1 promotes epithelial-mesenchymal transition in paclitaxel-resistant breast cancer cells via regulating nuclear factor kappa B and F-box and leucine-rich repeat protein 11.	Paclitaxel	92-102	nuclear receptor binding SET domain protein 1	Homo sapiens	0-45
34905470-11	2021	Furthermore, NSD1 silencing promoted paclitaxel sensitivity of paclitaxel-resistant BC cells and suppressed tumor growth and paclitaxel resistance in vivo.	Paclitaxel	37-47	nuclear receptor binding SET domain protein 1	Homo sapiens	13-17
34905470-11	2021	Furthermore, NSD1 silencing promoted paclitaxel sensitivity of paclitaxel-resistant BC cells and suppressed tumor growth and paclitaxel resistance in vivo.	Paclitaxel	63-73	nuclear receptor binding SET domain protein 1	Homo sapiens	13-17
34905470-11	2021	Furthermore, NSD1 silencing promoted paclitaxel sensitivity of paclitaxel-resistant BC cells and suppressed tumor growth and paclitaxel resistance in vivo.	Paclitaxel	125-135	nuclear receptor binding SET domain protein 1	Homo sapiens	13-17
9007036-2	1997	Taxol caused a concentration-dependent increase in the amount of immunoreactive CYP3A and in the steady-state levels of CYP3A1/DEX but not CYP3A2 mRNA.	Paclitaxel	0-5	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	120-126
23602343-2	2013	To analyze the contribution of transient receptor potential vanilloid 1 (TRPV1) in the development of paclitaxel-induced thermal hyperalgesia, TRPV1 expression in the rat dorsal root ganglion (DRG) was analyzed after paclitaxel treatment.	Paclitaxel	102-112	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	73-78
34905470-13	2021	Collectively, NSD1 facilitates the EMT, migration and invasion in paclitaxel-resistant BC cells via regulating NF-kB and FBXL11.	Paclitaxel	66-76	nuclear receptor binding SET domain protein 1	Homo sapiens	14-18
23602343-4	2013	Paclitaxel-induced thermal hyperalgesia after day 14 was significantly inhibited by the TRP antagonist ruthenium red (3 mg/kg, s.c.) and the TRPV1 antagonist capsazepine (30 mg/kg, s.c.).	Paclitaxel	0-10	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	141-146
8638189-3	1996	Another interesting finding in this patient was that the administration of paclitaxel led to a prompt resolution of parathyroid hormone-related protein (PTHrP)-mediated hypercalcemia, which had previously proven to be refractory to multiple conventional antihypercalcemic agents as well as anthracycline-containing chemotherapy combination.	Paclitaxel	75-85	parathyroid hormone like hormone	Homo sapiens	116-151
8638189-3	1996	Another interesting finding in this patient was that the administration of paclitaxel led to a prompt resolution of parathyroid hormone-related protein (PTHrP)-mediated hypercalcemia, which had previously proven to be refractory to multiple conventional antihypercalcemic agents as well as anthracycline-containing chemotherapy combination.	Paclitaxel	75-85	parathyroid hormone like hormone	Homo sapiens	153-158
23602343-5	2013	Paclitaxel (2 and 4 mg/kg) treatment increased the expression of TRPV1 mRNA and protein in DRG neurons.	Paclitaxel	0-10	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	65-70
8638189-4	1996	The need for definitive guidelines for paclitaxel administration in the setting of hepatic dysfunction and the potentially unique sensitivity of PTHrP--producing cells to paclitaxel are discussed.	Paclitaxel	171-181	parathyroid hormone like hormone	Homo sapiens	145-150
23602343-6	2013	Immunohistochemistry showed that paclitaxel (4 mg/kg) treatment increased TRPV1 protein expression in small and medium DRG neurons 14 days after treatment.	Paclitaxel	33-43	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	74-79
8640766-12	1996	These data suggest that stringent exposure to paclitaxel selected clones with reduced transcript levels of 5beta and beta4 beta-tubulin isotypes, but that these reduced levels were not directly involved in the resistance of the clones to paclitaxel.	Paclitaxel	46-56	tubulin beta 3 class III	Homo sapiens	117-122
8881404-13	1996	Actin network was modified neither by colchicine and paclitaxel used in the same conditions.	Paclitaxel	53-63	actin alpha 2, smooth muscle	Sus scrofa	0-5
7473140-3	1995	Four metabolites of paclitaxel (6 alpha-hydroxypaclitaxel, metabolites B, C and A) were formed in vitro, via CYP2C8, 3A4, 3A4 and both 2C8 and 3A4, respectively.	Paclitaxel	20-30	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	109-115
7473140-10	1995	We report that 6 alpha-hydroxypaclitaxel, formed via CYP2C8, is not the predominant paclitaxel metabolite in all individuals, and that CYP3A4 catalytic activity is important to overall paclitaxel metabolism in humans.	Paclitaxel	30-40	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	53-59
8714689-0	1995	Effects of taxol on the polymerization and posttranslational modification of class III beta-tubulin in P19 embryonal carcinoma cells.	Paclitaxel	11-16	tubulin beta 3 class III	Homo sapiens	77-99
8714689-3	1995	Treatment of undifferentiated P19 cells with concentrations of taxol greater than 4 x 10(-8) M caused microtubule bundling and multiple aster formation and promoted polymerization of the low levels of class III beta-tubulin found in these cells.	Paclitaxel	63-68	tubulin beta 3 class III	Homo sapiens	201-223
8714689-5	1995	At taxol concentrations greater than 1 x 10(-7) M, enhanced assembly of class III beta-tubulin was apparent, although long neurites were not observed.	Paclitaxel	3-8	tubulin beta 3 class III	Homo sapiens	72-94
8714689-6	1995	Using isoelectric focusing followed by western blotting, we detected an additional isoform of class III beta-tubulin after treatment with 10(-6) M taxol.	Paclitaxel	147-152	tubulin beta 3 class III	Homo sapiens	94-116
8714689-7	1995	The results indicate taxol treatment alters the normal subcellular sorting of tubulin isotypes, promotes the polymerization and posttranslational modification of class III beta-tubulin, and interferes with neurite outgrowth.	Paclitaxel	21-26	tubulin beta 3 class III	Homo sapiens	162-184
7529746-19	1995	Although the binding studies failed to examine cross competition for binding to macrophages, a possible explanation of these results is that LPS, RsDPLA, and taxol share the same molecule(s) on murine macrophages for their functional receptor(s), which is neither CD14 nor tubulin.	Paclitaxel	158-163	CD14 antigen	Mus musculus	264-268
7796460-6	1995	Purified MAP1B binds efficiently to both unpolymerised tubulin and polymerised tubulin and co-sediments with taxol-stabilised microtubules.	Paclitaxel	109-114	microtubule associated protein 1B	Bos taurus	9-14
7913736-0	1994	Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro.	Paclitaxel	78-83	nerve growth factor	Rattus norvegicus	0-19
7901279-7	1993	a) Taxol, like LPS, rapidly induces tyrosine phosphorylation of MAPK in mouse macrophages, and triggers MAPK to phosphorylate an exogenous substrate.	Paclitaxel	3-8	mitogen-activated protein kinase 3	Mus musculus	64-68
7901279-7	1993	a) Taxol, like LPS, rapidly induces tyrosine phosphorylation of MAPK in mouse macrophages, and triggers MAPK to phosphorylate an exogenous substrate.	Paclitaxel	3-8	mitogen-activated protein kinase 3	Mus musculus	104-108
7901279-8	1993	b) Tyrosine phosphorylation of MAPK is an extremely rapid cellular response both to taxol and LPS.	Paclitaxel	84-89	mitogen-activated protein kinase 3	Mus musculus	31-35
8096513-2	1993	Multidrug resistance cell lines selected with either vinblastine, colchicine, or taxol from the drug-sensitive murine macrophage-like cell line J774.2 overexpress the mdr1a and/or mdr1b genes, and overproduce P-glycoprotein.	Paclitaxel	81-86	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	167-172
7912536-5	1993	We found that Taxol, like lipopolysaccharides (LPS), caused a marked increase in tyrosine phosphorylation of three proteins having M(r) of 40 (p40), 41 (p41), and 43 (p43) kd in RAW cells.	Paclitaxel	14-19	erythrocyte membrane protein band 4.1	Mus musculus	153-156
1356126-4	1992	Toward this end, the ability of taxol to induce TNF-alpha mRNA and five other genes (IL-1 beta, IP-10, D3, D7, and D8) associated with LPS-activation of macrophages was examined by Northern blot analysis.	Paclitaxel	32-37	chemokine (C-X-C motif) ligand 10	Mus musculus	96-101
1353517-7	1992	Induction of TNF mRNA by 10 microM taxol was detectable at 45 min of stimulation, maximal at 90 min, and evident for at least 8 h. The same low concentration of taxol also induced interleukin 1 (IL-1) alpha and beta mRNA expression.	Paclitaxel	35-40	interleukin 1 complex	Mus musculus	180-193
1353517-7	1992	Induction of TNF mRNA by 10 microM taxol was detectable at 45 min of stimulation, maximal at 90 min, and evident for at least 8 h. The same low concentration of taxol also induced interleukin 1 (IL-1) alpha and beta mRNA expression.	Paclitaxel	161-166	interleukin 1 complex	Mus musculus	180-193
1353517-8	1992	We conclude that taxol triggers macrophages for TNF and IL-1 production.	Paclitaxel	17-22	interleukin 1 complex	Mus musculus	56-60
33807987-2	2021	Here, we report novel findings that highlight the ability of cathepsin S expression to be up-regulated under Paclitaxel-stimulatory conditions in kidney cell lines and it being able to cleave the apoptotic p21 BAX protein in intact cells and in vitro.	Paclitaxel	109-119	cathepsin S	Homo sapiens	61-72
33807987-5	2021	Finally, CS-PEP1 may possess promising activity as a potential anti-cancer therapeutic against chemotherapeutic-resistant Renal Clear Cell Carcinoma kidney cancer cells and for combined uses with therapeutics such as Paclitaxel.	Paclitaxel	217-227	citrate synthase	Homo sapiens	9-11
28766096-4	2018	RESULTS: Increased phosphorylation levels of ERK, Mnk1, and eIF4E were observed in ovarian cancer cell exposed to chemotherapeutic agents, and paclitaxel-resistant SK-OV-3-r cells, and is a common response of ovarian cancer patients undergoing chemotherapy.	Paclitaxel	143-153	eukaryotic translation initiation factor 4E	Homo sapiens	60-65
34808333-9	2022	Moreover, inhibition of PLD1 reversed FOXM1-conferred paclitaxel resistance in vitro and in vivo.	Paclitaxel	54-64	phospholipase D1	Mus musculus	24-28
34808333-10	2022	This study, for the first time, reveals the role of FOXM1-mediated PLD1 in LD accumulation and paclitaxel resistance.	Paclitaxel	95-105	phospholipase D1	Mus musculus	67-71
34808333-12	2022	Generally, our results identified FOXM1 as a driver of paclitaxel resistance via activation of PLD1 to promote of LD accumulation, which contributes to the maintenace of ER homeostasis when metastatic cancer cells are confronted with ROS induced by paclitaxel.	Paclitaxel	55-65	phospholipase D1	Mus musculus	95-99
34808333-12	2022	Generally, our results identified FOXM1 as a driver of paclitaxel resistance via activation of PLD1 to promote of LD accumulation, which contributes to the maintenace of ER homeostasis when metastatic cancer cells are confronted with ROS induced by paclitaxel.	Paclitaxel	249-259	phospholipase D1	Mus musculus	95-99
34974029-6	2022	In vivo, SPARC KD and SPARC WT subcutaneous xenografts in mice achieved similar maximum intratumoral concentrations of nab-paclitaxel, though drug clearance from SPARC WT tumors was significantly slower.	Paclitaxel	123-133	secreted acidic cysteine rich glycoprotein	Mus musculus	9-14
34974029-6	2022	In vivo, SPARC KD and SPARC WT subcutaneous xenografts in mice achieved similar maximum intratumoral concentrations of nab-paclitaxel, though drug clearance from SPARC WT tumors was significantly slower.	Paclitaxel	123-133	secreted acidic cysteine rich glycoprotein	Mus musculus	22-27
34974029-7	2022	We confirmed such SPARC-mediated long-term intratumoral accumulation of nab-paclitaxel in Ewing sarcoma PDX with high expression of SPARC, which accumulated significantly more nab-paclitaxel than SPARC-low PDX.	Paclitaxel	76-86	secreted acidic cysteine rich glycoprotein	Mus musculus	18-23
34974029-7	2022	We confirmed such SPARC-mediated long-term intratumoral accumulation of nab-paclitaxel in Ewing sarcoma PDX with high expression of SPARC, which accumulated significantly more nab-paclitaxel than SPARC-low PDX.	Paclitaxel	180-190	secreted acidic cysteine rich glycoprotein	Mus musculus	18-23
34974029-7	2022	We confirmed such SPARC-mediated long-term intratumoral accumulation of nab-paclitaxel in Ewing sarcoma PDX with high expression of SPARC, which accumulated significantly more nab-paclitaxel than SPARC-low PDX.	Paclitaxel	180-190	secreted acidic cysteine rich glycoprotein	Mus musculus	132-137
34695177-10	2021	Moreover, downregulation of LINC01296 promotes paclitaxel sensitivity in NSCLC.	Paclitaxel	47-57	long intergenic non-protein coding RNA 1296	Homo sapiens	28-37
34695177-11	2021	These results demonstrated that the LINC01296/miR-143-3p/ATG2B axis is crucial in promoting the development of NSCLC and paclitaxel resistance.	Paclitaxel	121-131	long intergenic non-protein coding RNA 1296	Homo sapiens	36-45
34695177-11	2021	These results demonstrated that the LINC01296/miR-143-3p/ATG2B axis is crucial in promoting the development of NSCLC and paclitaxel resistance.	Paclitaxel	121-131	autophagy related 2B	Homo sapiens	57-62
34791636-14	2021	iBET-151 plus paclitaxel significantly promoted cell cycle arrest and apoptosis and suppressed c-Myc, Bcl-2 and Bcl-xL expression.	Paclitaxel	14-24	BCL2-like 1	Mus musculus	112-118
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Paclitaxel	102-107	cyclin D1	Homo sapiens	310-319
34353674-0	2021	Corrigendum to "The telomere/telomerase binding factor PinX1 regulates paclitaxel sensitivity depending on spindle assembly checkpoint in human cervical squamous cell carcinomas" (Canc.	Paclitaxel	71-81	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	55-60
34746097-3	2021	Here, the redox-responsive star-shaped polymeric prodrug (PSSP) and the dimeric prodrug of paclitaxel (PTX) were prepared.	Paclitaxel	103-106	steroidogenic acute regulatory protein	Homo sapiens	27-31
34746097-4	2021	Then the dimeric prodrug of PTX (diPTX, diP) was loaded into the core of the star-shaped polymeric prodrug micelles of PSSP by hydrophobic interaction forming the redox-responsive prodrug micelles of diPTX@PSSP for intracellular drug release in tumor cells.	Paclitaxel	28-31	steroidogenic acute regulatory protein	Homo sapiens	77-81
34729116-10	2021	In addition, TTYH1 was related to a better clinical outcome in OC patients with platinums-based chemotherapy, but only indicated improved overall survival in OC patients who received taxol or platin + taxol chemotherapy.	Paclitaxel	183-188	tweety family member 1	Homo sapiens	13-18
34729116-10	2021	In addition, TTYH1 was related to a better clinical outcome in OC patients with platinums-based chemotherapy, but only indicated improved overall survival in OC patients who received taxol or platin + taxol chemotherapy.	Paclitaxel	201-206	tweety family member 1	Homo sapiens	13-18
34660779-4	2021	Treatment with PAC and ATRA induced cell cycle arrest at the G2/M phase and apoptosis by upregulating p53 and caspase-8 expression and increased the intracellular calcium (Ca2+) level possibly by enhancing Ca2+ uptake via plasma membrane channels.	Paclitaxel	15-18	caspase 8	Homo sapiens	110-119
34692516-0	2021	Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation.	Paclitaxel	68-78	cellular communication network factor 2	Mus musculus	91-95
34692516-4	2021	Apart from inhibiting TNBC cell migration via CTGF, ATL-1 downregulated the expression of CTGF in fibroblasts and decreased the ability of breast cancer cells to transform fibroblasts into cancer-associated fibroblasts (CAFs), which in turn increased the sensitivity of TNBC cells to paclitaxel.	Paclitaxel	284-294	cellular communication network factor 2	Mus musculus	90-94
34676207-2	2021	The present study managed to investigate this issue and found that ANXA6-exo promoted PTX resistance and cancer progression in BC cells in a Yes-associated protein 1 (YAP1)-dependent manner.	Paclitaxel	86-89	Yes1 associated transcriptional regulator	Homo sapiens	167-171
34676207-6	2021	Moreover, the underlying mechanisms were uncovered, and we evidenced that ANXA6-exo up-regulated YAP1 to promote Hippo pathway dysregulation, and the promoting effects of ANXA6-exo on PTX resistance and cancer aggressiveness in BC cells were abrogated by silencing YAP1.	Paclitaxel	184-187	Yes1 associated transcriptional regulator	Homo sapiens	265-269
34608124-4	2021	The expressions of Bcl2 family members such as Bcl2, Bcl-xl, and Puma could be seen in U2OS and MG63 cells with or without doxorubicin, bortezomib, or paclitaxel treatment.	Paclitaxel	151-161	BCL2 binding component 3	Homo sapiens	65-69
34685613-8	2021	Furthermore, the MAPK inhibitors indicated that 7-Epitaxol induces apoptosis and autophagy marker proteins (cleaved-PARP and LC3-I/II) by reducing the phosphorylation of ERK1/2.	Paclitaxel	48-58	collagen type XI alpha 2 chain	Homo sapiens	116-120
34457060-10	2021	In addition, caspase-8 and -9 inhibitors, respectively, significantly decreased paclitaxel-induced apoptosis.	Paclitaxel	80-90	caspase 8	Homo sapiens	13-29
34603450-4	2021	The mRNA expression of RRM1, TUBB3, and ERCC1 was detected in the experimental group before chemotherapy, and based on the detected expression, the chemotherapy regimen of cisplatin plus gemcitabine or cisplatin plus paclitaxel was chosen.	Paclitaxel	217-227	ribonucleotide reductase catalytic subunit M1	Homo sapiens	23-27
34603450-9	2021	In the detected group, the prognosis of patients with low expression of RRM1 was better than that of patients with high expression of RRM1 after paclitaxel treatment (P=0.0039).	Paclitaxel	145-155	ribonucleotide reductase catalytic subunit M1	Homo sapiens	72-76
34603450-9	2021	In the detected group, the prognosis of patients with low expression of RRM1 was better than that of patients with high expression of RRM1 after paclitaxel treatment (P=0.0039).	Paclitaxel	145-155	ribonucleotide reductase catalytic subunit M1	Homo sapiens	134-138
34628927-6	2021	CONCLUSIONS: Anti PD-1/L1 blockade combined with therapeutic approaches is safe and effective in BC, in particular for PD-L1 antibody atezolizumab plus nab-paclitaxel by inducing PD-1/L1 expression and the number of cytotoxic T cells.	Paclitaxel	156-166	programmed cell death 1	Homo sapiens	18-22
34628927-6	2021	CONCLUSIONS: Anti PD-1/L1 blockade combined with therapeutic approaches is safe and effective in BC, in particular for PD-L1 antibody atezolizumab plus nab-paclitaxel by inducing PD-1/L1 expression and the number of cytotoxic T cells.	Paclitaxel	156-166	programmed cell death 1	Homo sapiens	179-183
34080040-7	2021	All patients with CCNE1 amplification (n = 7), TP53 R175H substitution (n = 6), and RB1 mutation (n = 4) had poor response to paclitaxel plus carboplatin.	Paclitaxel	126-136	RB transcriptional corepressor 1	Homo sapiens	84-87
34363313-4	2021	We show that diverse stress stimuli, including etoposide, brefeldin A and paclitaxel, as well as heat stress and gamma-irradiation, caused formation of a complex containing ATG5-ATG12, FADD and caspase-8 leading to activation of downstream caspases in caspase-9-deficient cells.	Paclitaxel	74-84	caspase 8	Homo sapiens	194-203
34363313-4	2021	We show that diverse stress stimuli, including etoposide, brefeldin A and paclitaxel, as well as heat stress and gamma-irradiation, caused formation of a complex containing ATG5-ATG12, FADD and caspase-8 leading to activation of downstream caspases in caspase-9-deficient cells.	Paclitaxel	74-84	caspase 8	Homo sapiens	240-248
34321341-0	2021	Functional Interaction Between TRPV4 And NCS1 and the Effects of Paclitaxel.	Paclitaxel	65-75	transient receptor potential cation channel subfamily V member 4	Homo sapiens	31-36
34321341-0	2021	Functional Interaction Between TRPV4 And NCS1 and the Effects of Paclitaxel.	Paclitaxel	65-75	neuronal calcium sensor 1	Homo sapiens	41-45
34321341-6	2021	Exposure to PTX amplified the acute effects of TRPV4 expression, currents, and calcium fluxes, but decreased the expression of NCS1.	Paclitaxel	12-15	transient receptor potential cation channel subfamily V member 4	Homo sapiens	47-52
34321341-6	2021	Exposure to PTX amplified the acute effects of TRPV4 expression, currents, and calcium fluxes, but decreased the expression of NCS1.	Paclitaxel	12-15	neuronal calcium sensor 1	Homo sapiens	127-131
34321341-9	2021	Increased expression of NCS1 enhances TRPV4 dependent currents, which are further amplified by treatment with the chemotherapeutic drug, paclitaxel, an effect associated with adverse effects of chemotherapy, including neuropathy.	Paclitaxel	137-147	neuronal calcium sensor 1	Homo sapiens	24-28
34321341-9	2021	Increased expression of NCS1 enhances TRPV4 dependent currents, which are further amplified by treatment with the chemotherapeutic drug, paclitaxel, an effect associated with adverse effects of chemotherapy, including neuropathy.	Paclitaxel	137-147	transient receptor potential cation channel subfamily V member 4	Homo sapiens	38-43
34465889-0	2022	Ubiquitination of NF-kappaB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance.	Paclitaxel	95-105	F-box and WD-40 domain protein 2	Mus musculus	35-40
34465889-8	2022	FBXW2 overexpression abrogates the effects of p65 on paclitaxel resistance in vitro and in vivo.	Paclitaxel	53-63	F-box and WD-40 domain protein 2	Mus musculus	0-5
34097996-7	2021	PFBL efficiently reduced the PC3-tumor xenograft in NOD-SCID mice alone and in synergy with Paclitaxel.	Paclitaxel	92-102	chromobox 8	Mus musculus	29-32
34240603-2	2021	In this study, inspired by the enriched innate immune cell type tumor-associated macrophages (TAMs) in TNBC, we proposed a matrix metalloprotease 2 (MMP2) responsive integrated immunochemotherapeutic strategy to deliver paclitaxel (PTX) and anti-CD47 (aCD47) by detachable immune liposomes (ILips).	Paclitaxel	220-230	matrix metallopeptidase 2	Homo sapiens	123-147
34240603-2	2021	In this study, inspired by the enriched innate immune cell type tumor-associated macrophages (TAMs) in TNBC, we proposed a matrix metalloprotease 2 (MMP2) responsive integrated immunochemotherapeutic strategy to deliver paclitaxel (PTX) and anti-CD47 (aCD47) by detachable immune liposomes (ILips).	Paclitaxel	220-230	matrix metallopeptidase 2	Homo sapiens	149-153
34240603-2	2021	In this study, inspired by the enriched innate immune cell type tumor-associated macrophages (TAMs) in TNBC, we proposed a matrix metalloprotease 2 (MMP2) responsive integrated immunochemotherapeutic strategy to deliver paclitaxel (PTX) and anti-CD47 (aCD47) by detachable immune liposomes (ILips).	Paclitaxel	232-235	matrix metallopeptidase 2	Homo sapiens	123-147
34137394-3	2021	The proposed 1-oxa-1,3-butadiene derivative conjugated to a FITC fluorochrome selectively and rapidly labels the cancer cells pretreated with the dienophile-taxol.	Paclitaxel	157-162	OXA1L mitochondrial inner membrane protein	Homo sapiens	15-20
34285578-0	2021	Silencing of circHIPK3 Sensitizes Paclitaxel-Resistant Breast Cancer Cells to Chemotherapy by Regulating HK2 Through Targeting miR-1286.	Paclitaxel	34-44	hexokinase 2	Homo sapiens	105-108
34285578-15	2021	The increased expression of miR-1286 sensitized PTX-resistant BC cells to PTX in vitro by down-regulating HK2.	Paclitaxel	48-51	hexokinase 2	Homo sapiens	106-109
34285578-15	2021	The increased expression of miR-1286 sensitized PTX-resistant BC cells to PTX in vitro by down-regulating HK2.	Paclitaxel	74-77	hexokinase 2	Homo sapiens	106-109
34285578-16	2021	Conclusion: Our findings demonstrated that the silencing of circHIPK3 sensitized PTX-resistant BC cells to PTX therapy at least in part via the regulation of the miR-1286/HK2 axis.	Paclitaxel	81-84	hexokinase 2	Homo sapiens	171-174
34285578-16	2021	Conclusion: Our findings demonstrated that the silencing of circHIPK3 sensitized PTX-resistant BC cells to PTX therapy at least in part via the regulation of the miR-1286/HK2 axis.	Paclitaxel	107-110	hexokinase 2	Homo sapiens	171-174
34250246-7	2021	HULC was significantly upregulated and miR-137 was downregulated in PTX-resistant OC tissues and cells.	Paclitaxel	68-71	microRNA 137	Mus musculus	39-46
34250246-11	2021	miR-137 inhibitor or ITGB8 overexpression mitigated the suppressive impacts of HULC knockdown on PTX resistance.	Paclitaxel	97-100	microRNA 137	Mus musculus	0-7
34250246-11	2021	miR-137 inhibitor or ITGB8 overexpression mitigated the suppressive impacts of HULC knockdown on PTX resistance.	Paclitaxel	97-100	integrin beta 8	Mus musculus	21-26
34250246-12	2021	Collectively, HULC modulated ITGB8 expression to promote PTX resistance of OC by sponging miR-137.	Paclitaxel	57-60	integrin beta 8	Mus musculus	29-34
34250246-12	2021	Collectively, HULC modulated ITGB8 expression to promote PTX resistance of OC by sponging miR-137.	Paclitaxel	57-60	microRNA 137	Mus musculus	90-97
34518310-1	2021	PURPOSE: MPS1 kinase inhibitor, BAY 1217389 (BAY) synergizes with paclitaxel.	Paclitaxel	66-76	TTK protein kinase	Homo sapiens	9-13
34116927-0	2021	Acylglycerol kinase promotes paclitaxel resistance in nasopharyngeal carcinoma cells by regulating FOXM1 via the JAK2/STAT3 pathway.	Paclitaxel	29-39	Janus kinase 2	Homo sapiens	113-117
34116927-12	2021	An in vivo tumour xenograft assay also verified that AGK knockdown inhibited tumour growth and mitigated paclitaxel resistance by regulating the JAK2/STAT3/FOXM1 axis.	Paclitaxel	105-115	Janus kinase 2	Homo sapiens	145-149
34180747-10	2021	Ki-67, EGFR, and angiogenesis markers (Factor VIII, CD31, and CD34) expression were significantly lower in the PTX-NPs group compared with other groups (p < .05).	Paclitaxel	111-114	coagulation factor VIII	Mus musculus	39-50
34180747-10	2021	Ki-67, EGFR, and angiogenesis markers (Factor VIII, CD31, and CD34) expression were significantly lower in the PTX-NPs group compared with other groups (p < .05).	Paclitaxel	111-114	platelet/endothelial cell adhesion molecule 1	Mus musculus	52-56
34626199-0	2021	JAK2 regulates paclitaxel resistance in triple negative breast cancers.	Paclitaxel	15-25	Janus kinase 2	Homo sapiens	0-4
34626199-3	2021	Dysregulation of JAK/STAT pathways and JAK2 copy number gains were observed in the four paclitaxel-resistant PDX tumors.	Paclitaxel	88-98	Janus kinase 2	Homo sapiens	39-43
34626199-10	2021	Our data suggest that the JAK2 gene may play a critical role in determining responses of TNBC to paclitaxel by modulating the intrinsic susceptibility of cancer cells against paclitaxel and also by eliciting functional transitions of CAF subtypes in the tumor microenvironment.	Paclitaxel	97-107	Janus kinase 2	Homo sapiens	26-30
34626199-10	2021	Our data suggest that the JAK2 gene may play a critical role in determining responses of TNBC to paclitaxel by modulating the intrinsic susceptibility of cancer cells against paclitaxel and also by eliciting functional transitions of CAF subtypes in the tumor microenvironment.	Paclitaxel	175-185	Janus kinase 2	Homo sapiens	26-30
34626199-12	2021	JAK2 signaling was associated with paclitaxel resistance in TNBC PDX models.	Paclitaxel	35-45	Janus kinase 2	Homo sapiens	0-4
34847067-0	2021	Correction for: Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT/FoxO1 pathway.	Paclitaxel	51-61	integrin subunit alpha 2	Homo sapiens	30-35
34901149-4	2021	reported that FHIT binds and delocalizes annexin A4 (ANXA4) from plasma membrane to cytosol in paclitaxel-resistant lung cancer cells, thus restoring their chemosensitivity to the drug.	Paclitaxel	95-105	fragile histidine triad diadenosine triphosphatase	Homo sapiens	14-18
34901149-6	2021	This short sequence of FHIT protein was not only able to bind ANXA4 but also to hold its target in the cytosol during paclitaxel treatment, thus avoiding ANXA4 translocation to the inner side of the cell membrane.	Paclitaxel	118-128	fragile histidine triad diadenosine triphosphatase	Homo sapiens	23-27
34740994-9	2021	In general, our study found (1) miR-26a-5p was a protective factor of breast cancer, while OTUD6B-AS1 and MTDH were risk factors; (2) OTUD6B-AS1 was the up-stream regulator of miR-26a-5p verified by luciferase; (3) up-regulation of miR-26a-5p and down-regulation of MTDH promoted cellular cytotoxicity of paclitaxel (PTX) in vitro and in vivo.	Paclitaxel	317-320	prostaglandin D2 receptor	Homo sapiens	141-144
34633023-2	2021	This study details a novel four-in-one RRX/BMS/CA4/PTX nanomedicine by simple nanoprecipitation.	Paclitaxel	51-54	carbonic anhydrase 4	Mus musculus	47-50
34309886-9	2021	Paclitaxel significantly (p < .05) increased caspase-3 and p-53 and decreased Bcl-2 genes expression than control.	Paclitaxel	0-10	caspase 3	Rattus norvegicus	45-54
34600241-1	2021	Acquired paclitaxel (PTX) chemoresistance in triple-negative breast cancer (TNBC) can be inferred from the overexpression of toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MyD88) proteins and the activation of the TLR4/MyD88 cascading signalling pathway.	Paclitaxel	21-24	MYD88 innate immune signal transduction adaptor	Homo sapiens	249-254
34790572-8	2021	Further, SLC7A11 induced the protein expression of other autophagy genes, such as LC3, Atg16L1, and Atg7, and the expression of the respective proteins was further increased when the cells were treated with paclitaxel.	Paclitaxel	207-217	solute carrier family 7 (cationic amino acid transporter, y+ system), member 11	Mus musculus	9-16
34790572-8	2021	Further, SLC7A11 induced the protein expression of other autophagy genes, such as LC3, Atg16L1, and Atg7, and the expression of the respective proteins was further increased when the cells were treated with paclitaxel.	Paclitaxel	207-217	autophagy related 16 like 1	Homo sapiens	87-94
34790572-8	2021	Further, SLC7A11 induced the protein expression of other autophagy genes, such as LC3, Atg16L1, and Atg7, and the expression of the respective proteins was further increased when the cells were treated with paclitaxel.	Paclitaxel	207-217	autophagy related 7	Homo sapiens	100-104
34584572-6	2021	PTX treatment significantly inhibited Mps1 expression, as well as migration of OS cells both in vitro.	Paclitaxel	0-3	TTK protein kinase	Homo sapiens	38-42
34737698-13	2021	Overall, this study explored the effect of Xihuang pill in treating advanced TNBC cells and showed that naringenin, which is the key active compound of Xihuang pill, could lessen the stemness of TNBC cells to produce a synergistic effect on PTX by regulating the NR3C2 gene.	Paclitaxel	241-244	nuclear receptor subfamily 3 group C member 2	Homo sapiens	263-268
34091434-0	2021	Corrigendum to "The telomere/telomerase binding factor PinX1 regulates paclitaxel sensitivity depending on spindle assembly checkpoint in human cervical squamous cell carcinomas" (Canc.	Paclitaxel	71-81	PIN2 (TERF1) interacting telomerase inhibitor 1	Homo sapiens	55-60
34329591-2	2021	By investigating the molecular mechanism underlying this relocalization, we found that acute paclitaxel treatment triggers the release from stress fibers and subsequent proteasome-mediated degradation of binder of Rho GTPases 2 (BORG2)/Cdc42 effector protein 3 (Cdc42EP3) and to a lesser extent of BORG3/Cdc42EP5, two Cdc42 effectors that link septins to actin in interphase cells.	Paclitaxel	93-103	CDC42 effector protein 5	Homo sapiens	298-303
34329591-2	2021	By investigating the molecular mechanism underlying this relocalization, we found that acute paclitaxel treatment triggers the release from stress fibers and subsequent proteasome-mediated degradation of binder of Rho GTPases 2 (BORG2)/Cdc42 effector protein 3 (Cdc42EP3) and to a lesser extent of BORG3/Cdc42EP5, two Cdc42 effectors that link septins to actin in interphase cells.	Paclitaxel	93-103	CDC42 effector protein 5	Homo sapiens	304-312
34329591-2	2021	By investigating the molecular mechanism underlying this relocalization, we found that acute paclitaxel treatment triggers the release from stress fibers and subsequent proteasome-mediated degradation of binder of Rho GTPases 2 (BORG2)/Cdc42 effector protein 3 (Cdc42EP3) and to a lesser extent of BORG3/Cdc42EP5, two Cdc42 effectors that link septins to actin in interphase cells.	Paclitaxel	93-103	cell division cycle 42	Homo sapiens	318-323
34685531-4	2021	In macrophage-like RAW264.7 cells, bortezomib as well as MG132, a well-known proteasome inhibitor, caused HMGB1 release, an effect inhibited by caspase inhibitors but not inhibitors of NF-kappaB and p38 MAP kinase, known to mediate paclitaxel-induced HMGB1 release from macrophages.	Paclitaxel	232-242	high mobility group box 1	Mus musculus	251-256
34575568-8	2021	Our study suggested that short-term exposure to both PEs did not affect the PK of PTX in rats, but multiple doses of EL-35 increased the AUC and MRT of PTX by downregulating the hepatic expression of Cyp2c22.	Paclitaxel	152-155	cytochrome P450, family 2, subfamily c, polypeptide 22	Rattus norvegicus	200-207
34566640-4	2021	Based on the results, PTX inhibited the migration of RA-FLS in a dose-dependent manner and significantly reduced the spontaneous expression of IL-6, IL-8, and RANKL mRNA and TNF-alpha-induced transcription of the IL-1 beta, IL-8, MMP-8, and MMP-9 genes.	Paclitaxel	22-25	chemokine (C-X-C motif) ligand 15	Mus musculus	149-153
34566640-4	2021	Based on the results, PTX inhibited the migration of RA-FLS in a dose-dependent manner and significantly reduced the spontaneous expression of IL-6, IL-8, and RANKL mRNA and TNF-alpha-induced transcription of the IL-1 beta, IL-8, MMP-8, and MMP-9 genes.	Paclitaxel	22-25	chemokine (C-X-C motif) ligand 15	Mus musculus	224-228
34566640-4	2021	Based on the results, PTX inhibited the migration of RA-FLS in a dose-dependent manner and significantly reduced the spontaneous expression of IL-6, IL-8, and RANKL mRNA and TNF-alpha-induced transcription of the IL-1 beta, IL-8, MMP-8, and MMP-9 genes.	Paclitaxel	22-25	matrix metallopeptidase 9	Mus musculus	241-246
34566640-6	2021	Mechanistic studies revealed that PTX significantly inhibited the TNF-alpha-induced phosphorylation of ERK1/2 and JNK in the mitogen-activated protein kinase (MAPK) pathway and suppressed the TNF-alpha-induced activation of AKT, p70S6K, 4EBP1, and HIF-1alpha in the AKT/mTOR pathway.	Paclitaxel	34-37	mitogen-activated protein kinase 3	Mus musculus	103-109
34252520-0	2021	Paclitaxel anticancer activity is enhanced by the MEK 1/2 inhibitor PD98059 in vitro and by PD98059-loaded nanoparticles in BRAFV600E melanoma-bearing mice.	Paclitaxel	0-10	mitogen-activated protein kinase kinase 1	Mus musculus	50-57
34278466-0	2021	Chemokine CCL20 promotes the paclitaxel resistance of CD44+CD117+ cells via the Notch1 signaling pathway in ovarian cancer.	Paclitaxel	29-39	C-C motif chemokine ligand 20	Homo sapiens	10-15
34278466-2	2021	The aim of the present study was to investigate the underlying mechanism of CCL20/CCR6/Notch1 signaling in paclitaxel (PTX) resistance of a CD44+CD117+ subgroup of cells in ovarian cancer.	Paclitaxel	107-117	C-C motif chemokine ligand 20	Homo sapiens	76-81
34278466-2	2021	The aim of the present study was to investigate the underlying mechanism of CCL20/CCR6/Notch1 signaling in paclitaxel (PTX) resistance of a CD44+CD117+ subgroup of cells in ovarian cancer.	Paclitaxel	119-122	C-C motif chemokine ligand 20	Homo sapiens	76-81
34126209-3	2021	Mechanisms which contribute to multidrug resistance of breast cancer cells to PTX include the active removal of the drug from the cell related to the increased activity of ABC family membrane transporters.	Paclitaxel	78-81	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	172-175
34338752-0	2021	Correction: LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a.	Paclitaxel	38-43	microRNA 34a	Homo sapiens	143-150
34370741-3	2021	We previously created APC knockdown cells (APC shRNA1) using the human TNBC cells, MDA-MB-157, and showed that APC loss induces PTX resistance.	Paclitaxel	128-131	APC regulator of WNT signaling pathway	Homo sapiens	22-25
34370741-3	2021	We previously created APC knockdown cells (APC shRNA1) using the human TNBC cells, MDA-MB-157, and showed that APC loss induces PTX resistance.	Paclitaxel	128-131	APC regulator of WNT signaling pathway	Homo sapiens	43-53
34370741-4	2021	To understand the mechanisms behind APC-mediated PTX response, we performed cell cycle analysis and analyzed cell cycle related proteins.	Paclitaxel	49-52	APC regulator of WNT signaling pathway	Homo sapiens	36-39
34370741-5	2021	Cell cycle analysis indicated increased G2/M population in both PTX-treated APC shRNA1 and parental cells, suggesting that APC expression does not alter PTX-induced G2/M arrest.	Paclitaxel	64-67	APC regulator of WNT signaling pathway	Homo sapiens	76-86
34308742-6	2021	The treatment effect of taxol varied in monolayer and tumor spheroids and pHi changes were able to reflect these difference.	Paclitaxel	24-29	glucose-6-phosphate isomerase	Homo sapiens	74-77
34308742-9	2021	These findings elucidate the significance of pHi in the mechanisms of taxol action on cervical cancer cells and will be valuable for development of new approaches for cancer treatment.	Paclitaxel	70-75	glucose-6-phosphate isomerase	Homo sapiens	45-48
34118726-6	2021	Our data have collectively reflected that Taxol can prevent ovarian cancer with abnormal expression of MUC1.	Paclitaxel	42-47	mucin 1, cell surface associated	Homo sapiens	103-107
34225215-0	2021	Circular RNA PLEC acts as a sponge of microRNA-198 to promote gastric carcinoma cell resistance to paclitaxel and tumorigenesis.	Paclitaxel	99-109	plectin	Homo sapiens	13-17
34225215-7	2021	MiR-198 inhibitor reversed the effect of circPLEC downreguAlation in PTX-resistant GC cells, and MUC19 downregulation weakened GC resistance to PTX and tumorigenesis and improved the apoptosis of PTX-resistant GC cells.	Paclitaxel	144-147	mucin 19, oligomeric	Homo sapiens	97-102
34225215-7	2021	MiR-198 inhibitor reversed the effect of circPLEC downreguAlation in PTX-resistant GC cells, and MUC19 downregulation weakened GC resistance to PTX and tumorigenesis and improved the apoptosis of PTX-resistant GC cells.	Paclitaxel	196-199	mucin 19, oligomeric	Homo sapiens	97-102
34293716-8	2021	Knocking down OGFRP1 augmented the sensitivity of these PC cells to docetaxel and paclitaxel in vitro and in vivo.	Paclitaxel	82-92	opioid growth factor receptor pseudogene 1	Homo sapiens	14-20
34293716-10	2021	Consistent with this model, the overexpression of IL-6 reversed the OGFRP1 knockdown-mediated reductions in docetaxel and paclitaxel IC50 values for these PC cells.	Paclitaxel	122-132	opioid growth factor receptor pseudogene 1	Homo sapiens	68-74
34240603-2	2021	In this study, inspired by the enriched innate immune cell type tumor-associated macrophages (TAMs) in TNBC, we proposed a matrix metalloprotease 2 (MMP2) responsive integrated immunochemotherapeutic strategy to deliver paclitaxel (PTX) and anti-CD47 (aCD47) by detachable immune liposomes (ILips).	Paclitaxel	232-235	matrix metallopeptidase 2	Homo sapiens	149-153
34264566-0	2021	The combination therapy of targeting both paclitaxel and Dendrophthoe pentandra leaves extract nanoparticles for improvement breast cancer treatment efficacy by reducing TUBB3 and MAP4 expressions.	Paclitaxel	42-52	tubulin beta 3 class III	Homo sapiens	170-175
34264566-6	2021	The combination of paclitaxel-NPDP significantly decreases the expressions of TUBB3 (P<0.001) and MAP4 (P<0.001) in MCF-7 cells.	Paclitaxel	19-29	tubulin beta 3 class III	Homo sapiens	78-83
34236783-12	2022	However, rapamycin or paclitaxel concentrations >=1 mug/mL could significantly reduce the levels of anti-inflammatory cytokines IL-35 and transforming growth factor beta (TGF-beta) (P<0.05 or P<0.01), which decreased with the increase of drug concentration.	Paclitaxel	22-32	transforming growth factor alpha	Homo sapiens	171-179
34229754-0	2021	Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1alpha-AKT-mTOR pathway in esophageal squamous cell carcinoma.	Paclitaxel	115-125	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	134-144
34229754-10	2021	In addition, we showed, for the first time, the paclitaxel combined with apatinib and CQ exhibited the best antitumor effect on ESCC both in vivo and in vitro via the IRE-1alpha-AKT-mTOR pathway.	Paclitaxel	48-58	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	167-177
34229754-13	2021	The combination of apatinib and CQ sensitized ESCC cells to paclitaxel to induce apoptosis through the IRE-1alpha-AKT-mTOR signaling pathway, thus providing the basis for its use in innovative anticancer therapeutic strategies.	Paclitaxel	60-70	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	103-113
34163033-0	2021	A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer.	Paclitaxel	42-52	SMAD family member 4	Homo sapiens	94-99
34163033-10	2021	Targeting this SRI/Smad4/ZEB1/miR-142-5p loop may reverse the PTX-resistance.	Paclitaxel	62-65	SMAD family member 4	Homo sapiens	19-24
35614037-4	2022	By in vitro studies, we confirmed the specific and competitive nature of the C5aR1-paclitaxel binding and found that it triggers intracellularly the NFkB/P38 pathway and c-Fos.	Paclitaxel	83-93	mitogen-activated protein kinase 14	Mus musculus	154-157
35610945-7	2022	RESULTS: RNAseq results have identified 384 DEGs (adjusted P-value < 0.05; fold change >= 2) in the DRG of rats 14 days after paclitaxel injection in total, including 97 up-regulated genes, and 287 down-regulated genes.	Paclitaxel	126-136	delta(4)-desaturase, sphingolipid 1	Rattus norvegicus	44-48
35552677-9	2022	Mechanistically, SSR3 confers susceptibility to PTX through regulation of phosphorylation of ER stress sensor IRE1alpha.	Paclitaxel	48-51	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	110-119
35184686-9	2022	MiR-144-5p overexpression and PTX further up-regulated E-cadherin level and down-regulated those of MMP-9 and N-cadherin in thyroid carcinoma cells.	Paclitaxel	30-33	matrix metallopeptidase 9	Mus musculus	100-105
35144218-0	2022	Combination of ruthenium (II) polypyridyl complex Delta-Ru1 and Taxol enhances the anti-cancer effect on Taxol-resistant cancer cells through Caspase-1/GSDMD-mediated pyroptosis.	Paclitaxel	64-69	gasdermin D	Homo sapiens	152-157
35144218-0	2022	Combination of ruthenium (II) polypyridyl complex Delta-Ru1 and Taxol enhances the anti-cancer effect on Taxol-resistant cancer cells through Caspase-1/GSDMD-mediated pyroptosis.	Paclitaxel	105-110	gasdermin D	Homo sapiens	152-157
35144218-9	2022	Taken together, the Delta-Ru1 & Taxol combination can induce cell death through Caspase-1/GSDMD-mediated pyroptosis to enhance the therapeutic effect on HeLa/Taxol cells.	Paclitaxel	32-37	gasdermin D	Homo sapiens	90-95
35477569-0	2022	An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer.	Paclitaxel	73-83	aldehyde dehydrogenase 2 family member	Homo sapiens	14-19
35477569-0	2022	An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer.	Paclitaxel	73-83	zinc fingers and homeoboxes 2	Homo sapiens	49-52
35477569-4	2022	METHODS: We identified ALDH2 as a PTX resistance-related gene using gene microarray analysis.	Paclitaxel	34-37	aldehyde dehydrogenase 2 family member	Homo sapiens	23-28
35477569-5	2022	Subsequently, a series of functional analysis in cell lines, patient samples and xenograft models were performed to explore the functional role, clinical significance and the aberrant regulation mechanism of ALDH2 in PTX resistance of NSCLC.	Paclitaxel	217-220	aldehyde dehydrogenase 2 family member	Homo sapiens	208-213
35477569-6	2022	Furthermore, the pharmacological agents targeting ALDH2 and epigenetic enzyme were used to investigate the diverse reversing strategy against PTX resistance.	Paclitaxel	142-145	aldehyde dehydrogenase 2 family member	Homo sapiens	50-55
35477569-7	2022	RESULTS: Upregulation of ALDH2 expression is highly associated with resistance to PTX using in vitro and in vivo analyses of NSCLC cells along with clinicopathological analyses of NSCLC patients.	Paclitaxel	82-85	aldehyde dehydrogenase 2 family member	Homo sapiens	25-30
35477569-8	2022	ALDH2-overexpressing NSCLC cells exhibited significantly reduced PTX sensitivity and increased biological characteristics of malignancy in vitro and tumor growth and metastasis in vivo.	Paclitaxel	65-68	aldehyde dehydrogenase 2 family member	Homo sapiens	0-5
35449387-8	2022	All selected selenoesters inhibited P-gp efflux in a dose-dependent manner while simultaneously altering the expression of the ABC genes, especially P-gp in paclitaxel-resistant breast carcinoma cells (MCF-7/PAX).	Paclitaxel	157-167	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	127-130
35492735-5	2022	The purpose of this study is to clarify the role of Ca2+/calmodulin-dependent protein kinase II (CaMKII)-positive glutamatergic neurons in the amygdala in paclitaxel-induced pain and negative affective symptoms.	Paclitaxel	155-165	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	97-103
35492735-12	2022	In summary, our findings suggest that CaMKII neurons in the amygdala are critical for neuropathic pain and anxiety behaviors induced by paclitaxel chemotherapy.	Paclitaxel	136-146	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	38-44
35391656-0	2022	Downregulation of Circ-CEP128 Enhances the Paclitaxel Sensitivity of Cervical Cancer Through Regulating miR-432-5p/MCL1.	Paclitaxel	43-53	microRNA 432	Mus musculus	104-111
35391656-0	2022	Downregulation of Circ-CEP128 Enhances the Paclitaxel Sensitivity of Cervical Cancer Through Regulating miR-432-5p/MCL1.	Paclitaxel	43-53	myeloid cell leukemia sequence 1	Mus musculus	115-119
35391656-12	2022	MiR-432-5p was found to be sponged by circ-CEP128, and its inhibitor could reverse the promoting function of circ-CEP128 silencing on the paclitaxel sensitivity of CC cells.	Paclitaxel	138-148	microRNA 432	Mus musculus	0-7
35391656-14	2022	Besides, overexpressed MCL1 also could reverse the enhancing effect of miR-432-5p on the paclitaxel sensitivity of CC cells.	Paclitaxel	89-99	myeloid cell leukemia sequence 1	Mus musculus	23-27
35391656-14	2022	Besides, overexpressed MCL1 also could reverse the enhancing effect of miR-432-5p on the paclitaxel sensitivity of CC cells.	Paclitaxel	89-99	microRNA 432	Mus musculus	71-78
35463372-0	2022	Variations in Circulating Levels of Angiopoietin-2 Over Time Are Predictive of Ramucirumab-Paclitaxel Therapy Outcome in Advanced Gastric Cancer: Results of Prospective Study.	Paclitaxel	91-101	angiopoietin 2	Homo sapiens	36-50
35409328-10	2022	Finally, we investigated the binding stability of the top-ranked three drugs (Paclitaxel, Vincristine, Vinorelbine) by using 100 ns MD-based MM-PBSA simulations with the three top-ranked proposed receptors (AURKA, CDK1, TOP2A) and observed their stable performance.	Paclitaxel	78-88	aurora kinase A	Homo sapiens	207-212
35218640-9	2022	In terms of serious adverse events, grade 3 or 4 (G3/4) neutropenia, G3/4 febrile neutropenia, G3/4 arthritis, and G3/4 alopecia occurred less often under weekly paclitaxel treatment.	Paclitaxel	162-172	BAG cochaperone 6	Homo sapiens	36-54
35173243-5	2022	In our study, it was shown the micelles modified with Angiopep-2 had high loading efficiency of paclitaxel and lapatinib (Ang-MIC-PTX/LP).	Paclitaxel	96-106	angiogenin	Homo sapiens	122-125
35173243-5	2022	In our study, it was shown the micelles modified with Angiopep-2 had high loading efficiency of paclitaxel and lapatinib (Ang-MIC-PTX/LP).	Paclitaxel	130-133	angiogenin	Homo sapiens	122-125
35173243-6	2022	In addition, Ang-MIC-PTX/LP could transport across the in vitro BBB model and accumulate in breast cancer cells.	Paclitaxel	21-24	angiogenin	Homo sapiens	13-16
35173243-8	2022	Ang-MIC-PTX/LP could also extend the life span of brain metastasis mouse models.	Paclitaxel	8-11	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	0-3
35200072-0	2022	Knockdown of nuclear receptor binding SET domain-containing protein 1 (NSD1) inhibits proliferation and facilitates apoptosis in paclitaxel-resistant breast cancer cells via inactivating the Wnt/beta-catenin signaling pathway.	Paclitaxel	129-139	nuclear receptor binding SET domain protein 1	Homo sapiens	13-69
35200072-0	2022	Knockdown of nuclear receptor binding SET domain-containing protein 1 (NSD1) inhibits proliferation and facilitates apoptosis in paclitaxel-resistant breast cancer cells via inactivating the Wnt/beta-catenin signaling pathway.	Paclitaxel	129-139	nuclear receptor binding SET domain protein 1	Homo sapiens	71-75
35200072-10	2022	We conclude that NSD1 knockdown inhibits the viability and promotes the apoptosis of paclitaxel-resistant BC cells by inactivating the NSD1/H3K27me3/Wnt10b/beta-catenin signaling pathway.	Paclitaxel	85-95	nuclear receptor binding SET domain protein 1	Homo sapiens	17-21
35200072-10	2022	We conclude that NSD1 knockdown inhibits the viability and promotes the apoptosis of paclitaxel-resistant BC cells by inactivating the NSD1/H3K27me3/Wnt10b/beta-catenin signaling pathway.	Paclitaxel	85-95	nuclear receptor binding SET domain protein 1	Homo sapiens	135-139
35105904-0	2022	Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene.	Paclitaxel	36-46	BRCA1 interacting protein C-terminal helicase 1	Mus musculus	80-85
35173830-6	2022	KIF2A knockdown inhibited proliferation, invasion, EMT, stemness, but enhanced chemosensitivity to cisplatin and paclitaxel in both A549 and NCI-H1975 cells.	Paclitaxel	113-123	kinesin family member 2A	Homo sapiens	0-5
34996504-3	2022	METHODS: We performed RNA sequencing (RNA-seq) on samples from patients who were resistant or sensitive to nab-paclitaxel, and identified Zinc Finger Protein 64 (ZFP64) as critical for nab-paclitaxel resistance in GC.	Paclitaxel	189-199	ZFP64 zinc finger protein	Homo sapiens	138-160
34996504-3	2022	METHODS: We performed RNA sequencing (RNA-seq) on samples from patients who were resistant or sensitive to nab-paclitaxel, and identified Zinc Finger Protein 64 (ZFP64) as critical for nab-paclitaxel resistance in GC.	Paclitaxel	189-199	ZFP64 zinc finger protein	Homo sapiens	162-167
34996504-8	2022	Importantly, compared to treatment with nab-paclitaxel alone, nab-paclitaxel plus GAL-1 blockade significantly enhanced the anti-tumor effect in mouse models, particularly in humanized mice.	Paclitaxel	44-54	lectin, galactose binding, soluble 1	Mus musculus	82-87
35173526-9	2022	EZH2 inhibitor, UNC1999, can reverse the effect of SOX8 on chemo-resistance of albumin-bound paclitaxel.	Paclitaxel	93-103	SRY-box transcription factor 8	Homo sapiens	51-55
35173526-10	2022	Collectively, our data revealed SOX8/EZH2/SPARC signaling induced primary chemo-resistance of albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.	Paclitaxel	108-118	SRY-box transcription factor 8	Homo sapiens	32-36
23602343-8	2013	TRPV1 immunostaining was up-regulated in paw skin day 14 after paclitaxel treatment.	Paclitaxel	63-73	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	0-5
23624503-3	2013	METHODS: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCT116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells).	Paclitaxel	60-70	caudal type homeobox 1	Homo sapiens	126-130
23624503-3	2013	METHODS: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCT116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells).	Paclitaxel	60-70	caudal type homeobox 1	Homo sapiens	146-150
23624503-6	2013	The isolated CD44(+)CD24(+)Cdx1(+) cells showed higher resistance to paclitaxel-induced cytotoxicity than CD44(+)CD24(+)p53wt cells.	Paclitaxel	69-79	caudal type homeobox 1	Homo sapiens	27-31
34284854-0	2021	Phosphorylation of Cofilin-1 Enhances Paclitaxel Resistance of Epithelial Ovarian Cancer Cells by Inhibiting Apoptosis.	Paclitaxel	38-48	cofilin 1	Homo sapiens	19-28
23624503-7	2013	The resistance of CD44(+)CD24(+)Cdx1(+) cells to paclitaxel is associated with upregulation of Cdx1 and Bcl-2 expression, caspase-3 activity, and the ratio of LC3-II/LC3-I.	Paclitaxel	49-59	caudal type homeobox 1	Homo sapiens	32-36
34284854-1	2021	Objective: To investigate the molecular mechanism of high phosphorylation levels of cofilin-1 (p-CFL-1) associated with paclitaxel resistance in epithelial ovarian cancer (EOC) cells.	Paclitaxel	120-130	cofilin 1	Homo sapiens	84-93
34284854-1	2021	Objective: To investigate the molecular mechanism of high phosphorylation levels of cofilin-1 (p-CFL-1) associated with paclitaxel resistance in epithelial ovarian cancer (EOC) cells.	Paclitaxel	120-130	cofilin 1	Homo sapiens	97-102
23624503-7	2013	The resistance of CD44(+)CD24(+)Cdx1(+) cells to paclitaxel is associated with upregulation of Cdx1 and Bcl-2 expression, caspase-3 activity, and the ratio of LC3-II/LC3-I.	Paclitaxel	49-59	caudal type homeobox 1	Homo sapiens	95-99
34284854-7	2021	Results: High levels of p-CFL-1 were observed in EOC cells that survived treatment with high doses of paclitaxel.	Paclitaxel	102-112	cofilin 1	Homo sapiens	26-31
23467907-13	2013	Furthermore, HGF/c-Met inhibition by MK8033 represents a promising new therapeutic avenue to increase OVCA sensitivity to carboplatin plus paclitaxel.	Paclitaxel	139-149	hepatocyte growth factor	Homo sapiens	13-16
34284854-9	2021	Cytoplasmic accumulation of p-CFL-1 inhibited paclitaxel-induced mitochondrial apoptosis.	Paclitaxel	46-56	cofilin 1	Homo sapiens	30-35
34284854-10	2021	SSH-1 silencing mediated CFL-1 phosphorylation in paclitaxel-resistant SKOV3 cells.	Paclitaxel	50-60	cofilin 1	Homo sapiens	25-30
34284854-12	2021	Conclusion: The SSH-1/p-CFL-1 signaling pathway mediates paclitaxel resistance by apoptosis inhibition in EOC and is expected to be a potential prognostic predictor.	Paclitaxel	57-67	cofilin 1	Homo sapiens	24-29
23590835-13	2013	We identified a set of eight genes (EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32 and NNMT) showing significant gene-drug correlation with paclitaxel, docetaxel, erlotinib, everolimus and dasatinib.	Paclitaxel	136-146	nicotinamide N-methyltransferase	Homo sapiens	83-87
34145425-0	2021	MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.	Paclitaxel	44-54	microRNA 181c	Homo sapiens	0-8
34145425-7	2021	Here, we show that miR-181c, predicted to target GRP78, was downregulated in PTX-resistant OC cells and tissues.	Paclitaxel	77-80	microRNA 181c	Homo sapiens	19-27
23462296-4	2013	This study demonstrates alterations in ABC and SLC gene expression levels in methotrexate, cisplatin, doxorubicin, vincristine, topotecan and paclitaxel-resistant variant of W1 ovarian cancer cell line.	Paclitaxel	142-152	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	39-42
34145425-9	2021	Overexpression of miR-181c sensitized resistant OC to PTX by inhibiting the PI3K/Akt pathway in vitro and in vivo.	Paclitaxel	54-57	microRNA 181c	Homo sapiens	18-26
34145425-10	2021	Taken together, our findings indicate that the delivery of miR-181c can efficiently suppress GRP78 expression and GRP78-mediated PTX resistance in OC and suggest that this strategy has therapeutic potential.	Paclitaxel	129-132	microRNA 181c	Homo sapiens	59-67
23404055-4	2013	Ectopic overexpression of CDK2AP1 in A549 cells in vitro greatly impaired their proliferation and colony-forming ability and enhanced their chemosensitivity to cisplatin and paclitaxel and caused cell cycle arrest at G1/S transition accompanied by the reduction of expression of CDK4 and CDK7.	Paclitaxel	174-184	CDK2 (cyclin-dependent kinase 2)-associated protein 1	Mus musculus	26-33
34164520-0	2021	Attenuating glucose metabolism by Fbxw7 promotes Taxol sensitivity of colon cancer cells through downregulating NADPH oxidase 1 (Nox1).	Paclitaxel	49-54	NADPH oxidase 1	Homo sapiens	112-127
34164520-0	2021	Attenuating glucose metabolism by Fbxw7 promotes Taxol sensitivity of colon cancer cells through downregulating NADPH oxidase 1 (Nox1).	Paclitaxel	49-54	NADPH oxidase 1	Homo sapiens	129-133
34164520-16	2021	Nox1 therefore promotes the Taxol resistance and glucose metabolism of colon cancer cells.	Paclitaxel	28-33	NADPH oxidase 1	Homo sapiens	0-4
34164520-17	2021	Finally, rescue experiments demonstrated that the Fbxw7-promoted Taxol sensitivity was partially through the Nox1-glycolysis axis.	Paclitaxel	65-70	NADPH oxidase 1	Homo sapiens	109-113
34164520-18	2021	Restoration of Nox1 in Fbxw7-overexpressed TR colon cancer cells significantly recovered the Taxol resistance, which could be further overridden by glycolysis inhibition.	Paclitaxel	93-98	NADPH oxidase 1	Homo sapiens	15-19
35588308-6	2022	We showed that chemotherapy resistant endometrial cancer cells (ARK1, uterine serous carcinoma and PUC198, grade 3 endometrioid adenocarcinoma) had improved sensitivity and synergy with paclitaxel and carboplatin when treated in combination with AVB-500.	Paclitaxel	186-196	aurora kinase A	Homo sapiens	64-68
35588308-7	2022	We also found that in vivo intraperitoneal models with ARK1 and PUC198 cells had decreased tumor burden when treated with AVB-500 + paclitaxel compared to paclitaxel alone.	Paclitaxel	132-142	aurora kinase A	Homo sapiens	55-59
35588308-7	2022	We also found that in vivo intraperitoneal models with ARK1 and PUC198 cells had decreased tumor burden when treated with AVB-500 + paclitaxel compared to paclitaxel alone.	Paclitaxel	155-165	aurora kinase A	Homo sapiens	55-59
23391723-6	2013	In TNBC cell lines and mouse xenografts, the chemotherapeutic drug paclitaxel increased autocrine TGF-beta signaling and IL-8 expression and enriched for CSCs, as indicated by mammosphere formation and CSC markers.	Paclitaxel	67-77	transforming growth factor, beta 1	Mus musculus	98-106
35534752-2	2022	METHODS: Using a Markov model, the clinical effectiveness of managing HR+, HER2- MBC in postmenopausal women with either a CDK4/6i (either ribociclib or palbociclib) and fulvestrant, fulvestrant alone, and chemotherapy (single-agent paclitaxel or capecitabine) was measured in terms of quality-adjusted life-years (QALYs).	Paclitaxel	233-243	cyclin dependent kinase 4	Homo sapiens	123-130
35534752-7	2022	The mean QALYs lived per MBC patient with CDK4/6i (either ribociclib or palbociclib) combination therapy, fulvestrant, paclitaxel and capecitabine were estimated to be 1.4, 1.0, 0.9 and 0.7, respectively.	Paclitaxel	119-129	cyclin dependent kinase 4	Homo sapiens	42-49
23391723-6	2013	In TNBC cell lines and mouse xenografts, the chemotherapeutic drug paclitaxel increased autocrine TGF-beta signaling and IL-8 expression and enriched for CSCs, as indicated by mammosphere formation and CSC markers.	Paclitaxel	67-77	chemokine (C-X-C motif) ligand 15	Mus musculus	121-125
23391723-7	2013	The TGF-beta type I receptor kinase inhibitor LY2157299, a neutralizing TGF-beta type II receptor antibody, and SMAD4 siRNA all blocked paclitaxel-induced IL8 transcription and CSC expansion.	Paclitaxel	136-146	transforming growth factor beta receptor 2	Homo sapiens	72-97
23364970-13	2013	Expressions of HIF-1alpha and TUBB3 were most decreased when AGS cells were treated with a combination of paclitaxel and anti-VEGFR-1.	Paclitaxel	106-116	tubulin beta 3 class III	Homo sapiens	30-35
23364970-15	2013	CONCLUSION: We suggest that blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in TUBB3-expressing gastric cancer cells.	Paclitaxel	69-79	tubulin beta 3 class III	Homo sapiens	95-100
23207293-8	2013	Addition of exogenous recombinant MIF to LNCaP and PC-3 cells stimulated the AKT and ERK1/2 signalling pathways, the expression of genes involved in PCa, as well as proliferation and resistance to paclitaxel and thapsigargin-induced apoptosis.	Paclitaxel	197-207	macrophage migration inhibitory factor	Homo sapiens	34-37
35396925-0	2022	Exosomal circDNER enhances paclitaxel resistance and tumorigenicity of lung cancer via targeting miR-139-5p/ITGB8.	Paclitaxel	27-37	integrin subunit beta 8	Homo sapiens	108-113
35477569-11	2022	NSCLC/PTX cells re-acquired sensitivity to PTX in vivo and in vitro when ALDH2 was inhibited by pharmacological agents, including the ALDH2 inhibitors Daidzin (DZN)/Disulfiram (DSF) and JIB04, which reverses the effect of EHMT2.	Paclitaxel	6-9	aldehyde dehydrogenase 2 family member	Homo sapiens	73-78
35477569-11	2022	NSCLC/PTX cells re-acquired sensitivity to PTX in vivo and in vitro when ALDH2 was inhibited by pharmacological agents, including the ALDH2 inhibitors Daidzin (DZN)/Disulfiram (DSF) and JIB04, which reverses the effect of EHMT2.	Paclitaxel	6-9	aldehyde dehydrogenase 2 family member	Homo sapiens	134-139
35477569-11	2022	NSCLC/PTX cells re-acquired sensitivity to PTX in vivo and in vitro when ALDH2 was inhibited by pharmacological agents, including the ALDH2 inhibitors Daidzin (DZN)/Disulfiram (DSF) and JIB04, which reverses the effect of EHMT2.	Paclitaxel	43-46	aldehyde dehydrogenase 2 family member	Homo sapiens	73-78
35477569-11	2022	NSCLC/PTX cells re-acquired sensitivity to PTX in vivo and in vitro when ALDH2 was inhibited by pharmacological agents, including the ALDH2 inhibitors Daidzin (DZN)/Disulfiram (DSF) and JIB04, which reverses the effect of EHMT2.	Paclitaxel	43-46	aldehyde dehydrogenase 2 family member	Homo sapiens	134-139
35477569-12	2022	CONCLUSION: Our findings suggest that ALDH2 status can help predict patient response to PTX therapy and ALDH2 inhibition may be a promising strategy to overcome PTX resistance in the clinic.	Paclitaxel	88-91	aldehyde dehydrogenase 2 family member	Homo sapiens	38-43
35477569-12	2022	CONCLUSION: Our findings suggest that ALDH2 status can help predict patient response to PTX therapy and ALDH2 inhibition may be a promising strategy to overcome PTX resistance in the clinic.	Paclitaxel	161-164	aldehyde dehydrogenase 2 family member	Homo sapiens	104-109
23228696-8	2013	Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and paclitaxel as well as cell viability and DNA repair capacity.	Paclitaxel	153-163	reticulon 3	Homo sapiens	53-57
35509628-7	2022	Furthermore, HDS-2 and HDS-3 potentiated paclitaxel-induced cytotoxicity by 19.1-22.45% (P < 0.05) and 10.52-18.03% (P < 0.05), respectively, inhibited the expression of cyclinB1, Bcl-2, and pMCL-1, and increased the percentage of necrosis cell in the condition of paclitaxel exposure.	Paclitaxel	41-51	cyclin B1	Mus musculus	170-178
23396109-0	2013	Downregulation of miR-17&amp;#126;92 Expression Increase Paclitaxel Sensitivity in Human Ovarian Carcinoma SKOV3-TR30 Cells via BIM Instead of PTEN.	Paclitaxel	57-67	microRNA 17	Homo sapiens	18-24
35131469-1	2022	Two kinds of amphiphilic block copolymers of TfR-T12-PEG-PLGA and TATH7-PEG-PLGA were synthesized to self-assembly nano-composite micelles for encapsulating paclitaxel and imiquimod synchronously.	Paclitaxel	157-167	transferrin receptor	Mus musculus	45-48
35169864-0	2022	Knockdown of long non-coding RNA DDX11-AS1 inhibits the proliferation, migration and paclitaxel resistance of breast cancer cells by upregulating microRNA-497 expression.	Paclitaxel	85-95	prostaglandin D2 receptor	Homo sapiens	39-42
35169864-0	2022	Knockdown of long non-coding RNA DDX11-AS1 inhibits the proliferation, migration and paclitaxel resistance of breast cancer cells by upregulating microRNA-497 expression.	Paclitaxel	85-95	microRNA 497	Homo sapiens	146-158
35169864-10	2022	The present study demonstrated that the expression levels of lncRNA DDX11-AS1 were markedly increased in paclitaxel (PTX)-resistant breast cancer cell lines.	Paclitaxel	105-115	prostaglandin D2 receptor	Homo sapiens	74-77
23114713-9	2013	These findings indicate that blocking MUC1-C function could be effective in combination with taxol and DOX for the treatment of breast cancer.	Paclitaxel	93-98	mucin 1, cell surface associated	Homo sapiens	38-42
35169864-10	2022	The present study demonstrated that the expression levels of lncRNA DDX11-AS1 were markedly increased in paclitaxel (PTX)-resistant breast cancer cell lines.	Paclitaxel	117-120	prostaglandin D2 receptor	Homo sapiens	74-77
35169864-11	2022	By contrast, knockdown of DDX11-AS1 expression inhibited PTX resistance of breast cancer cells, and suppressed the proliferation, invasion and migration of breast cancer cells, which was achieved via upregulation of miR-497 expression.	Paclitaxel	57-60	prostaglandin D2 receptor	Homo sapiens	32-35
35169864-12	2022	In conclusion, knockdown of lncRNA DDX11-AS1 could inhibit the proliferation, migration and PTX resistance of breast cancer cells by upregulating miR-497 expression.	Paclitaxel	92-95	prostaglandin D2 receptor	Homo sapiens	41-44
35448163-7	2022	Furthermore, a few lncRNAs, such as AFAP1-AS1 and LINC01014, block the efficiency of chemotherapeutic drugs, including cisplatin, 5-fluorouracil, paclitaxel, and gefitinib, used for ESCC treatment.	Paclitaxel	146-156	prostaglandin D2 receptor	Homo sapiens	42-45
23178957-3	2013	The aim of the present study was to evaluate whether expression of resistance genes (MDR1, MRP3 and LRP) can predict clinical outcome in NSCLC patients treated with paclitaxel and carboplatin.	Paclitaxel	165-175	ATP binding cassette subfamily C member 3	Homo sapiens	91-95
22370637-9	2013	We demonstrate that Bmf (Bcl-2-modifying factor) is a target of miR-34c-5p, and that its silencing, together with that of c-myc, a known target of miR-34c-5p, contributes to resistance to apoptosis induced by paclitaxel through p53 downregulation.	Paclitaxel	209-219	Bcl2 modifying factor	Homo sapiens	20-23
35302839-6	2022	Paclitaxel-treated macrophages down-regulated cell surface CSF1R whose expression was negatively correlated with patient survival in multiple malignancies.	Paclitaxel	0-10	colony stimulating factor 1 receptor	Homo sapiens	59-64
22370637-9	2013	We demonstrate that Bmf (Bcl-2-modifying factor) is a target of miR-34c-5p, and that its silencing, together with that of c-myc, a known target of miR-34c-5p, contributes to resistance to apoptosis induced by paclitaxel through p53 downregulation.	Paclitaxel	209-219	Bcl2 modifying factor	Homo sapiens	25-47
23283368-5	2013	Indeed, pazopanib potently inhibited aurora A, with pazopanib/paclitaxel synergy recapitulated by aurora A short hairpin RNA knockdown or by specific aurora A pharmacological inhibition.	Paclitaxel	62-72	aurora kinase A	Homo sapiens	98-106
35149198-5	2022	Western blot and immunohistochemistry suggested that a cumulative dosage of PTX (8 mg/kg) upregulated TRPV1 expression in the lumbar DRG and spinal dorsal horn (SDH) at day 14 post treatment.	Paclitaxel	76-79	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	102-107
35051418-10	2022	KHDRBS3 knockdown restrained the IC50 of PTX, cell proliferation, colony formation and glycolysis in SKOV3-R and A2780-R cells in vitro and enhanced PTX sensitivity in a xenograft mouse model in vivo.	Paclitaxel	41-44	KH RNA binding domain containing, signal transduction associated 3	Homo sapiens	0-7
35051418-10	2022	KHDRBS3 knockdown restrained the IC50 of PTX, cell proliferation, colony formation and glycolysis in SKOV3-R and A2780-R cells in vitro and enhanced PTX sensitivity in a xenograft mouse model in vivo.	Paclitaxel	149-152	KH RNA binding domain containing, signal transduction associated 3	Homo sapiens	0-7
23283368-5	2013	Indeed, pazopanib potently inhibited aurora A, with pazopanib/paclitaxel synergy recapitulated by aurora A short hairpin RNA knockdown or by specific aurora A pharmacological inhibition.	Paclitaxel	62-72	aurora kinase A	Homo sapiens	98-106
23283368-6	2013	Pazopanib/paclitaxel synergy was reversed by aurora A knockdown.	Paclitaxel	10-20	aurora kinase A	Homo sapiens	45-53
23283368-7	2013	Moreover, aurora A (but not B or C) message and protein levels were significantly increased in patient ATCs, and durable benefit resulted from pilot clinical translation of pazopanib/paclitaxel therapy in a patient with metastatic ATC.	Paclitaxel	183-193	aurora kinase A	Homo sapiens	10-18
23066953-11	2013	Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation.	Paclitaxel	94-104	prominin 1	Homo sapiens	5-10
35042769-4	2022	Moreover, duvelisib prevented paclitaxel-induced sensitization of TRPV1 receptors, increased PI3K/Akt-signalling in small-diameter DRG neurons and an increase of CD68+ cells within DRGs.	Paclitaxel	30-40	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	66-71
35263200-6	2022	Five hub genes (UBC, TSR1, WDR46, HSP90AA1, and NOP56) were obtained via network analysis from 971 differentially expressed genes (DEGs) based on the RNA-seq of Paclitaxel-intervened Pfeiffer/ADM.	Paclitaxel	161-171	ubiquitin C	Homo sapiens	16-19
35263200-9	2022	Consistent with studies, Paclitaxel exhibited a significant inhibitory effect on Adriamycin-resistant DLBCL, which may have played a role in the five hub genes (UBC, TSR1, WDR46, HSP90AA1 and NOP56) and ribosome biosynthesis in eukaryotes pathway, but the specific regulation needs further experimental verification.	Paclitaxel	25-35	ubiquitin C	Homo sapiens	161-164
23066953-11	2013	Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation.	Paclitaxel	94-104	prominin 1	Homo sapiens	22-27
23066953-11	2013	Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation.	Paclitaxel	94-104	prominin 1	Homo sapiens	22-27
35194034-8	2022	We found that DRAK1 protein was destabilized through K48-linked polyubiquitination promoted by the Cullin scaffold protein 3 (CUL3) / speckle-type POZ (poxvirus and zinc finger protein) protein (SPOP) E3 ubiquitin ligase in paclitaxel-resistant cells.	Paclitaxel	224-234	cullin 3	Homo sapiens	99-124
23327190-0	2013	MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer.	Paclitaxel	60-70	microRNA 125a	Homo sapiens	0-8
35194034-8	2022	We found that DRAK1 protein was destabilized through K48-linked polyubiquitination promoted by the Cullin scaffold protein 3 (CUL3) / speckle-type POZ (poxvirus and zinc finger protein) protein (SPOP) E3 ubiquitin ligase in paclitaxel-resistant cells.	Paclitaxel	224-234	cullin 3	Homo sapiens	126-130
23259428-4	2013	Class III beta-tubulin overexpression has been linked to resistance to paclitaxel and correlated with poor survival in ovarian, breast, gastric, non-small-cell lung cancer and unknown primary tumors.	Paclitaxel	71-81	tubulin beta 3 class III	Homo sapiens	0-22
35214172-0	2022	Preclinical PET Imaging of Granzyme B Shows Promotion of Immunological Response Following Combination Paclitaxel and Immune Checkpoint Inhibition in Triple Negative Breast Cancer.	Paclitaxel	102-112	granzyme B	Mus musculus	27-37
35205737-0	2022	CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer.	Paclitaxel	40-45	GADD45G interacting protein 1	Homo sapiens	0-5
35205737-0	2022	CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer.	Paclitaxel	40-45	cyclin dependent kinase 2	Homo sapiens	6-10
35205737-8	2022	Overall, the resistance to the anti-proliferative effects induced by taxol can be significantly reduced by the combined treatment with selective CRIF1-CDK2 interface inhibitors, making a conceptual advance in the CDK-related cancer treatment.	Paclitaxel	69-74	GADD45G interacting protein 1	Homo sapiens	145-150
35205737-8	2022	Overall, the resistance to the anti-proliferative effects induced by taxol can be significantly reduced by the combined treatment with selective CRIF1-CDK2 interface inhibitors, making a conceptual advance in the CDK-related cancer treatment.	Paclitaxel	69-74	cyclin dependent kinase 2	Homo sapiens	151-155
35250589-6	2022	Results: PAC administration decreased the length of neurites and upregulated the expression of TRPV1 in 50B11 cells.	Paclitaxel	9-12	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	95-100
23610522-0	2013	Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice.	Paclitaxel	0-10	syndecan 1	Mus musculus	49-54
35250589-8	2022	Conclusion: TMI-1 partially protects against paclitaxel-induced neurotoxicity by reversing the upregulation of TRPV1 and decreasing levels of inflammatory cytokines, including TNF-alpha, IL-1beta, and IL-6 in neuronal cells.	Paclitaxel	45-55	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	111-116
35137851-7	2022	Also, MLT had a protective effect against testicular apoptosis induced by TXL, as shown by the elevated expression of Bcl-2 and decreased expression of P53 and caspase-3.	Paclitaxel	74-77	caspase 3	Rattus norvegicus	160-169
23610522-3	2013	The purpose of this study was to investigate the inhibitory effect of paclitaxel-loaded Fe3O4 nanoparticles (PTX-NPs) on CD138(-) CD34(-) tumor stem cells in multiple myeloma-bearing mice.	Paclitaxel	70-80	syndecan 1	Mus musculus	121-126
23805870-4	2013	MTT assays demonstrated that both blank non-crosslinked and crosslinked NPs showed low cytotoxicity to NCL-H460 cells while PTX-loaded non-crosslinked and crosslinked NPs exhibited obvious cytotoxicity against NCL-H460 cells, and the cytotoxicity was both dose-dependent and time-dependent.	Paclitaxel	124-127	nucleolin	Homo sapiens	103-106
35001532-5	2022	Decreased expressions of germ cell proliferation-associated protein PCNA and meiosis-related protein SYCP3 induced by PTX were determined by Western blot, while MLT ameliorated this effect and increased the expressions of PCNA, SYCP3, DMC1, STRA8 and fertility-related protein of HSPA2, resulting in significantly improved spermatogenesis and sperm quality levels.	Paclitaxel	118-121	DNA meiotic recombinase 1	Mus musculus	235-239
35132320-0	2022	Long Noncoding RNA RMRP Contributes to Paclitaxel Sensitivity of Ovarian Cancer by Regulating miR-580-3p/MICU1 Signaling.	Paclitaxel	39-49	RNA component of mitochondrial RNA processing endoribonuclease	Homo sapiens	19-23
35132320-0	2022	Long Noncoding RNA RMRP Contributes to Paclitaxel Sensitivity of Ovarian Cancer by Regulating miR-580-3p/MICU1 Signaling.	Paclitaxel	39-49	mitochondrial calcium uptake 1	Homo sapiens	105-110
35132320-4	2022	In this investigation, we reported an innovative function of the long noncoding RNA RMRP in promoting PTX resistance and glycolysis of ovarian cancer cells.	Paclitaxel	102-105	RNA component of mitochondrial RNA processing endoribonuclease	Homo sapiens	84-88
35132320-5	2022	We observed that RMRP was highly expressed in the ovarian cancer samples, in which the expression of RMRP was elevated in the PTX-resistant patients compared with the PTX-sensitive patients.	Paclitaxel	126-129	RNA component of mitochondrial RNA processing endoribonuclease	Homo sapiens	17-21
23805870-4	2013	MTT assays demonstrated that both blank non-crosslinked and crosslinked NPs showed low cytotoxicity to NCL-H460 cells while PTX-loaded non-crosslinked and crosslinked NPs exhibited obvious cytotoxicity against NCL-H460 cells, and the cytotoxicity was both dose-dependent and time-dependent.	Paclitaxel	124-127	nucleolin	Homo sapiens	210-213
23483678-12	2013	The CD40 agonist mAb CP-870,893, given on either of two schedules in combination with paclitaxel and carboplatin, was safe for patients affected with advanced solid tumors.	Paclitaxel	86-96	CD40 molecule	Homo sapiens	4-8
35132320-5	2022	We observed that RMRP was highly expressed in the ovarian cancer samples, in which the expression of RMRP was elevated in the PTX-resistant patients compared with the PTX-sensitive patients.	Paclitaxel	126-129	RNA component of mitochondrial RNA processing endoribonuclease	Homo sapiens	101-105
35132320-5	2022	We observed that RMRP was highly expressed in the ovarian cancer samples, in which the expression of RMRP was elevated in the PTX-resistant patients compared with the PTX-sensitive patients.	Paclitaxel	167-170	RNA component of mitochondrial RNA processing endoribonuclease	Homo sapiens	17-21
35132320-5	2022	We observed that RMRP was highly expressed in the ovarian cancer samples, in which the expression of RMRP was elevated in the PTX-resistant patients compared with the PTX-sensitive patients.	Paclitaxel	167-170	RNA component of mitochondrial RNA processing endoribonuclease	Homo sapiens	101-105
35132320-7	2022	Functionally, we found that the silencing of RMRP by siRNA significantly enhanced the PTX sensitivity of PTX-resistant ovarian cancer cells, in which the IC50 of PTX was reduced by RMRP depletion.	Paclitaxel	86-89	RNA component of mitochondrial RNA processing endoribonuclease	Homo sapiens	45-49
35132320-7	2022	Functionally, we found that the silencing of RMRP by siRNA significantly enhanced the PTX sensitivity of PTX-resistant ovarian cancer cells, in which the IC50 of PTX was reduced by RMRP depletion.	Paclitaxel	86-89	RNA component of mitochondrial RNA processing endoribonuclease	Homo sapiens	181-185
23534290-6	2013	At the same time, the combined effect of radiation and Ptx enhanced antiapoptotic Bcl-2 phosphorylation, caspases activation and survivin expression.	Paclitaxel	55-58	caspase 8	Homo sapiens	105-113
35132320-7	2022	Functionally, we found that the silencing of RMRP by siRNA significantly enhanced the PTX sensitivity of PTX-resistant ovarian cancer cells, in which the IC50 of PTX was reduced by RMRP depletion.	Paclitaxel	162-165	RNA component of mitochondrial RNA processing endoribonuclease	Homo sapiens	45-49
35132320-7	2022	Functionally, we found that the silencing of RMRP by siRNA significantly enhanced the PTX sensitivity of PTX-resistant ovarian cancer cells, in which the IC50 of PTX was reduced by RMRP depletion.	Paclitaxel	162-165	RNA component of mitochondrial RNA processing endoribonuclease	Homo sapiens	181-185
35132320-13	2022	Thus, we concluded that RMRP contributes to PTX resistance and glycolysis of ovarian cancer by enhancing MICU1 expression through sponging miR-580-3p.	Paclitaxel	44-47	RNA component of mitochondrial RNA processing endoribonuclease	Homo sapiens	24-28
23064763-8	2012	STAT5B delivery was decreased to a similar extent by addition of taxol (a microtubule-stabilizing drug) or trichostatin A (a deacetylase inhibitor), agents that promote microtubule acetylation in the absence of alcohol.	Paclitaxel	65-70	signal transducer and activator of transcription 5B	Homo sapiens	0-6
35280672-4	2022	Further study demonstrated that PTX upregulated the expression of C-C chemokine receptor type 7 (CCR7) in B16F10 cells, enhancing their migration through the activation of JNK and p38 signalling pathways.	Paclitaxel	32-35	mitogen-activated protein kinase 14	Mus musculus	180-183
23443122-0	2012	Modulation of MDR1 and MRP3 gene expression in lung cancer cells after paclitaxel and carboplatin exposure.	Paclitaxel	71-81	ATP binding cassette subfamily C member 3	Homo sapiens	23-27
35204377-3	2022	Exosomes are vesicular cargos that transport multiple miRNAs, mRNAs and proteins from one cell to another cell and some of these factors can influence specific determinants of gemcitabine activity, such as the nucleoside transporter hENT1, or multidrug resistance proteins involved in the resistance to paclitaxel.	Paclitaxel	303-313	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	233-238
22766748-0	2012	Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.	Paclitaxel	124-134	tubulin beta 3 class III	Homo sapiens	16-21
35084430-7	2022	Paclitaxel induced tactile and cool hypersensitivity of the hindpaw and a loss of nonpeptidergic hindpaw IENFs visualized with anti-protein gene product (PGP) 9.5 and CGRP.	Paclitaxel	0-10	ubiquitin C-terminal hydrolase L1	Rattus norvegicus	127-162
22766748-1	2012	The overexpression of beta-tubulin III (TUBB3) in tumor tissues was reversely related with the efficacy of paclitaxel and clinical outcome in different cancers.	Paclitaxel	107-117	tubulin beta 3 class III	Homo sapiens	40-45
35084430-7	2022	Paclitaxel induced tactile and cool hypersensitivity of the hindpaw and a loss of nonpeptidergic hindpaw IENFs visualized with anti-protein gene product (PGP) 9.5 and CGRP.	Paclitaxel	0-10	calcitonin-related polypeptide alpha	Rattus norvegicus	167-171
22766748-2	2012	In this study, we aimed to investigate the association between serum levels of TUBB3 and clinical outcome in advanced gastric cancer patients receiving first-line paclitaxel plus capecitabine.	Paclitaxel	163-173	tubulin beta 3 class III	Homo sapiens	79-84
35019820-8	2022	Furthermore, Nab-paclitaxel and IL-15 fusion protein showed a significant suppression of NF-kappaB-mediated immune suppressive markers and increased expression of CD8, Granzyme B, CD62L, CD49b, and CD86 without obvious organ toxicity.	Paclitaxel	17-27	granzyme B	Mus musculus	168-178
35019820-9	2022	In conclusion, combination therapy of Nab-paclitaxel and IL-15 fusion protein can effectively stimulate the antitumor activity of immune effector cells, thereby inhibiting immunosuppressive cells within the TME of colorectal cancer, and the overall therapeutic effect has a significant advantage over monotherapy.AbbreviationsInterleukin 15, IL-15; Human serum albumin, HSA; Myeloid-derived suppressor cells, MDSC; Albumin binding domain, ABD; Tumor drainage lymph node, TDLN; Natural killer (NK); Tumor-draining lymph node (TDLN); Tumor infiltrating lymphocyte, TIL; Immunogenic cell death, ICD; Enhanced permeability retention, EPR; Liposomal doxorubicin, Doxil; 5-fluorouracil, 5-FU.	Paclitaxel	42-52	T-associated maternal effect	Mus musculus	207-210
22999213-1	2012	BACKGROUND: Hepatocyte Growth Factor (HGF) enhances cytotoxicity of paclitaxel (PTX) and cisplatin (CDDP) in human ovarian cancer cells.	Paclitaxel	68-78	hepatocyte growth factor	Homo sapiens	12-36
35019820-9	2022	In conclusion, combination therapy of Nab-paclitaxel and IL-15 fusion protein can effectively stimulate the antitumor activity of immune effector cells, thereby inhibiting immunosuppressive cells within the TME of colorectal cancer, and the overall therapeutic effect has a significant advantage over monotherapy.AbbreviationsInterleukin 15, IL-15; Human serum albumin, HSA; Myeloid-derived suppressor cells, MDSC; Albumin binding domain, ABD; Tumor drainage lymph node, TDLN; Natural killer (NK); Tumor-draining lymph node (TDLN); Tumor infiltrating lymphocyte, TIL; Immunogenic cell death, ICD; Enhanced permeability retention, EPR; Liposomal doxorubicin, Doxil; 5-fluorouracil, 5-FU.	Paclitaxel	42-52	albumin	Mus musculus	355-368
35531363-3	2022	Here we demonstrate a patient with recurrent uterine carcinosarcoma whose local recurrence and metastatic recurrence had a varied response to paclitaxel in combination with DKN-01, a monoclonal antibody against DKK1, a modulator of Wnt/beta-catenin and PI3K/AKT signaling pathways.	Paclitaxel	142-152	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	211-215
22999213-1	2012	BACKGROUND: Hepatocyte Growth Factor (HGF) enhances cytotoxicity of paclitaxel (PTX) and cisplatin (CDDP) in human ovarian cancer cells.	Paclitaxel	68-78	hepatocyte growth factor	Homo sapiens	38-41
22999213-1	2012	BACKGROUND: Hepatocyte Growth Factor (HGF) enhances cytotoxicity of paclitaxel (PTX) and cisplatin (CDDP) in human ovarian cancer cells.	Paclitaxel	80-83	hepatocyte growth factor	Homo sapiens	12-36
22999213-1	2012	BACKGROUND: Hepatocyte Growth Factor (HGF) enhances cytotoxicity of paclitaxel (PTX) and cisplatin (CDDP) in human ovarian cancer cells.	Paclitaxel	80-83	hepatocyte growth factor	Homo sapiens	38-41
22824824-10	2012	Six of them (DLC1, CHFR, ABCC5, PEG10, ERBB2, and GSTP1) were independently confirmed to contribute to taxol resistance by both methylation-specific PCR and quantitative real-time PCR.	Paclitaxel	103-108	ATP binding cassette subfamily C member 5	Homo sapiens	25-30
22709569-5	2012	RESULTS: Here we show that carbonate apatite-mediated delivery of siRNA against PLC-gamma-2 (PLCG2) and calmodulin 1 (CALM1) genes has led to the sensitization of a human cervical cancer cell line to doxorubicin- and paclitaxel depending on the dosage of the individual drug whereas no such enhancement in cell death was observed with cisplatin irrespective of the dosage following intracellular delivery of the siRNAs.	Paclitaxel	217-227	phospholipase C gamma 2	Homo sapiens	80-91
22709569-5	2012	RESULTS: Here we show that carbonate apatite-mediated delivery of siRNA against PLC-gamma-2 (PLCG2) and calmodulin 1 (CALM1) genes has led to the sensitization of a human cervical cancer cell line to doxorubicin- and paclitaxel depending on the dosage of the individual drug whereas no such enhancement in cell death was observed with cisplatin irrespective of the dosage following intracellular delivery of the siRNAs.	Paclitaxel	217-227	phospholipase C gamma 2	Homo sapiens	93-98
22709569-6	2012	CONCLUSION: Thus, PLCG2 and CALM1 genes are two potential targets for gene knockdown in doxorubicin and paclitaxel-based chemotherapy of cervical cancer.	Paclitaxel	104-114	phospholipase C gamma 2	Homo sapiens	18-23
22238053-0	2012	Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol.	Paclitaxel	189-194	BCL2 like 12	Homo sapiens	78-85
22369881-5	2012	Using immunoblotting, we demonstrated induction of both megalin and clusterin in MCF-7 cells by previous paclitaxel treatment.	Paclitaxel	105-115	LDL receptor related protein 2	Homo sapiens	56-63
22465666-6	2012	Activation of PKCdelta rescues the interaction during paclitaxel exposure and suppresses the paclitaxel-mediated cell death.	Paclitaxel	54-64	protein kinase C delta	Homo sapiens	14-22
22465666-6	2012	Activation of PKCdelta rescues the interaction during paclitaxel exposure and suppresses the paclitaxel-mediated cell death.	Paclitaxel	93-103	protein kinase C delta	Homo sapiens	14-22
21750964-1	2012	Sequential doxorubicin/paclitaxel (AT) followed by CMF treatment was shown to be an active neoadjuvant chemotherapy regimen in the first European Cooperative Trial in Operable Breast Cancer (ECTO I trial).	Paclitaxel	23-33	tripartite motif containing 33	Homo sapiens	191-195
21785462-6	2012	First, hEx dramatically inhibits cell proliferation in two human cancer cell lines, MDA-MB-231 and MDA-MB-436 cells, and sensitizes these cells to the chemotherapeutic drug Taxol.	Paclitaxel	173-178	hematopoietically expressed homeobox	Homo sapiens	7-10
21785462-7	2012	Furthermore, downregulation of hEx in the immortalized MCF10A breast cell line leads to enhanced proliferation and resistance to Taxol treatment.	Paclitaxel	129-134	hematopoietically expressed homeobox	Homo sapiens	31-34
22177224-11	2012	Moreover, mRNA levels of glutathione peroxidase 4 and glutathione-S-reductase were significantly lower in diabetic groups treated with paclitaxel.	Paclitaxel	135-145	glutathione peroxidase 4	Rattus norvegicus	25-49
22306008-7	2012	The ABCB5 transfectants showed approximately 1.5-fold higher resistance to doxorubicin, and 2- to 3-fold higher resistance to paclitaxel and docetaxel.	Paclitaxel	126-136	ATP binding cassette subfamily B member 5	Homo sapiens	4-9
22740869-0	2012	Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1.	Paclitaxel	40-45	proline rich 13	Homo sapiens	63-86
22740869-1	2012	The purpose of this study was to determine the role of taxol resistance gene 1 (TXR1) in a taxol-resistant breast cancer cell line.	Paclitaxel	55-60	proline rich 13	Homo sapiens	80-84
22740869-7	2012	When TXR1 was exogenously expressed, a taxol-resistant phenotype was further induced and the expression levels of BCRP, GSTP1 and MVP increased.	Paclitaxel	39-44	proline rich 13	Homo sapiens	5-9
22740869-9	2012	These results suggest that an increased expression of TXR1 is a novel mechanism for reversing the taxol resistance of breast cancer cells.	Paclitaxel	98-103	proline rich 13	Homo sapiens	54-58
23251610-7	2012	We tried to investigate the possible mechanisms of this synergistic efficacy induced by PZQ and PTX, and we found that the co-treatment of the two drugs could markedly decrease expression of X-linked inhibitor of apoptosis protein (XIAP), an anti-apoptotic protein.	Paclitaxel	96-99	X-linked inhibitor of apoptosis	Mus musculus	191-230
23251610-7	2012	We tried to investigate the possible mechanisms of this synergistic efficacy induced by PZQ and PTX, and we found that the co-treatment of the two drugs could markedly decrease expression of X-linked inhibitor of apoptosis protein (XIAP), an anti-apoptotic protein.	Paclitaxel	96-99	X-linked inhibitor of apoptosis	Mus musculus	232-236
23251610-8	2012	Our data further demonstrated that down-regulation of XIAP was required for the synergistic interaction between PZQ and PTX.	Paclitaxel	120-123	X-linked inhibitor of apoptosis	Mus musculus	54-58
23028798-0	2012	Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.	Paclitaxel	90-100	tubulin beta 3 class III	Homo sapiens	18-40
22074808-4	2012	2ME significantly increases the level of p38 and MLC phosphorylation in both endothelial monolayers and murine lungs; this increase is suppressed in the presence of taxol.	Paclitaxel	165-170	mitogen-activated protein kinase 14	Mus musculus	41-44
23358102-8	2011	CONCLUSION: TUBB3, TS and TP expressions could predict the response of advanced gastric cancer patients receiving capecitabine-based and paclitaxel-based chemotherapy.	Paclitaxel	137-147	tubulin beta 3 class III	Homo sapiens	12-17
21955049-9	2011	We think that all patients with GCC of stage Ib1 or more should undergo adjuvant chemotherapy of paclitaxel and carboplatin or other adjuvant therapies.	Paclitaxel	97-107	guanylate cyclase 2C	Homo sapiens	32-35
21978934-8	2011	In mice in which Lewis lung carcinoma cells were injected intravenously, treatment with paclitaxel, but not gemcitabine or vehicle, accelerated metastases in a manner that could be blocked by an MMP9 inhibitor.	Paclitaxel	88-98	matrix metallopeptidase 9	Mus musculus	195-199
21413088-7	2011	The expressions of MMP-1 and MMP-2 did not change when a conventional tumoricidal agent paclitaxel was used.	Paclitaxel	88-98	matrix metallopeptidase 2	Homo sapiens	29-34
21726541-3	2011	In this study, the contribution of the redox partners cytochrome P450 reductase (CPR) and cytochrome b5 to the substrate dependent activity of CYP2C8.3 (R139K, K399R) was investigated in human liver microsomes (HLMs) and Escherichia coli expressed recombinant CYP2C8 proteins using amodiaquine, paclitaxel, rosiglitazone and cerivastatin as probe substrates.	Paclitaxel	295-305	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	143-149
21327452-9	2011	CONCLUSION: These findings suggest that Gal-3 expression can be a prognostic factor for PFS and may be involved in regulating the response to paclitaxel-based chemotherapy in the treatment of EOC.	Paclitaxel	142-152	galectin 3	Homo sapiens	40-45
21866617-0	2011	Role of granulocyte colony-stimulating factor in paclitaxel-induced intestinal barrier breakdown and bacterial translocation in rats.	Paclitaxel	49-59	colony stimulating factor 3	Rattus norvegicus	8-45
21866617-4	2011	Here, we investigated the effects of paclitaxel on the intestinal barrier, and whether G-CSF could prevent paclitaxel-induced bacterial translocation.	Paclitaxel	107-117	colony stimulating factor 3	Rattus norvegicus	87-92
21866617-11	2011	RESULTS: Paclitaxel induced apoptosis in 12.5% of jejunum villus cells, which was reduced to 3.8% by G-CSF treatment.Apoptosis in the control group was 0.6%.	Paclitaxel	9-19	colony stimulating factor 3	Rattus norvegicus	101-106
21866617-17	2011	G-CSF treatment protects the intestinal barrier, prevents bacterial translocation, and attenuates paclitaxel-induced intestinal side-effects.	Paclitaxel	98-108	colony stimulating factor 3	Rattus norvegicus	0-5
21518725-3	2011	We observed that silencing of B7-H3, via stable short hairpin RNA or transient short interfering RNA transfection, increased the sensitivity of multiple human breast cancer cell lines to paclitaxel as a result of enhanced drug-induced apoptosis.	Paclitaxel	187-197	CD276 molecule	Homo sapiens	30-35
21586171-0	2011	Thymidine Phosphorylase/beta-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.	Paclitaxel	157-167	thymidine phosphorylase	Homo sapiens	0-23
21586171-7	2011	CONCLUSIONS: In Chinese advanced gastric cancer, Thymidine Phosphorylase positive &amp; beta-tubulin III negative might predict response and prognosis to capecitabine plus paclitaxel chemotherapy.	Paclitaxel	172-182	thymidine phosphorylase	Homo sapiens	49-72
21354697-3	2011	Importantly, miR-203 overexpression increased the cytotoxic role of paclitaxel in the p53-mutated colon cancer cells, but not in the p53 wild-type cells.	Paclitaxel	68-78	microRNA 203a	Homo sapiens	13-20
21290210-5	2011	RESULTS: Our results showed that PAC and DOX increased the intracellular expression of APM proteins, including calmodulin, LMP2, LMP7, TAP1 and tapasin.	Paclitaxel	33-36	proteasome 20S subunit beta 9	Homo sapiens	123-127
21290210-5	2011	RESULTS: Our results showed that PAC and DOX increased the intracellular expression of APM proteins, including calmodulin, LMP2, LMP7, TAP1 and tapasin.	Paclitaxel	33-36	proteasome 20S subunit beta 8	Homo sapiens	129-133
21436692-7	2011	Complementary DNA microarray analysis demonstrated enhanced glycogen synthase kinase-3alpha (GSK-3alpha) expression in paclitaxel-resistant ovarian carcinoma cells.	Paclitaxel	119-129	glycogen synthase kinase 3 alpha	Homo sapiens	60-91
21436692-7	2011	Complementary DNA microarray analysis demonstrated enhanced glycogen synthase kinase-3alpha (GSK-3alpha) expression in paclitaxel-resistant ovarian carcinoma cells.	Paclitaxel	119-129	glycogen synthase kinase 3 alpha	Homo sapiens	93-103
21436692-8	2011	Real-time reverse transcriptase polymerase chain reaction analysis revealed that the paclitaxel-resistant subline exhibited a 7.0 +- 1.8-fold increase in GSK-3alpha messenger RNA expression.	Paclitaxel	85-95	glycogen synthase kinase 3 alpha	Homo sapiens	154-164
21327324-0	2011	Basic helix-loop-helix transcription factors DEC1 and DEC2 regulate the paclitaxel-induced apoptotic pathway of MCF-7 human breast cancer cells.	Paclitaxel	72-82	deleted in esophageal cancer 1	Homo sapiens	45-49
21327324-3	2011	In this study, we sought to examine the roles of DEC1 and DEC2 in MCF-7 human breast cancer cells that had been treated with paclitaxel.	Paclitaxel	125-135	deleted in esophageal cancer 1	Homo sapiens	49-53
21327324-4	2011	The expression of DEC1 and DEC2 was up-regulated in paclitaxel-treated MCF-7 cells.	Paclitaxel	52-62	deleted in esophageal cancer 1	Homo sapiens	18-22
21327324-5	2011	Knockdown of DEC1 by siRNA decreased the amount of cleaved poly (ADP-ribose) polymerase (PARP), after treatment with paclitaxel, whereas DEC2 knockdown increased the amount of cleaved PARP in both the presence and absence of paclitaxel.	Paclitaxel	117-127	deleted in esophageal cancer 1	Homo sapiens	13-17
21327324-5	2011	Knockdown of DEC1 by siRNA decreased the amount of cleaved poly (ADP-ribose) polymerase (PARP), after treatment with paclitaxel, whereas DEC2 knockdown increased the amount of cleaved PARP in both the presence and absence of paclitaxel.	Paclitaxel	225-235	deleted in esophageal cancer 1	Homo sapiens	13-17
21327324-6	2011	Immunofluorescent staining revealed that paclitaxel treatment increased the amount of DEC1 in the nucleus, and increased the amount of DEC2 in both the nucleus and cytoplasm.	Paclitaxel	41-51	deleted in esophageal cancer 1	Homo sapiens	86-90
20212519-4	2011	We selected 13 relevant polymorphisms in genes encoding paclitaxel metabolizing enzymes (CYP2C8, CYP3A4 and CYP3A5) and transporters (organic anion transporting polypeptide (OATP) 1B1, OATP1B3 and P-glycoprotein) and genotyped them in 118 Spanish cancer patients treated with paclitaxel.	Paclitaxel	56-66	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	89-95
20860011-0	2011	Truncated bFGF-mediated cationic liposomal paclitaxel for tumor-targeted drug delivery: improved pharmacokinetics and biodistribution in tumor-bearing mice.	Paclitaxel	43-53	fibroblast growth factor 2	Mus musculus	10-14
24212635-10	2011	CONCLUSIONS: Zoledronic acid enhances fluvastatin and paclitaxel activity against T24 in a synergistic manner and this is mediated largely by inhibition of both the Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways via isoprenylation inhibition.	Paclitaxel	54-64	zinc fingers and homeoboxes 2	Homo sapiens	169-172
21091668-7	2011	The addition of paclitaxel, which competes with the MD-2 ligand, could inhibit the effects of anti-beta2GPI/beta2GPI on TLR-4, MD-2, MyD88 and TF expression.	Paclitaxel	16-26	MYD88 innate immune signal transduction adaptor	Homo sapiens	133-138
21056987-2	2011	This information may be important for understanding paclitaxel metabolism in vivo and in the investigation of the role of genetic polymorphisms in the metabolizing enzymes CYP2C8 and CYP3A4/CYP3A5 and the ABCB1 transporter.	Paclitaxel	52-62	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	172-178
20739958-0	2011	Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.	Paclitaxel	68-78	high mobility group box 1	Homo sapiens	116-121
21229611-7	2011	Interestingly, lacking of Hsf1 expression and suppressing Hsf1 by siRNA also made cells more resistant to the cytotoxic effects of paclitaxel.	Paclitaxel	131-141	heat shock transcription factor 1	Homo sapiens	26-30
21229611-7	2011	Interestingly, lacking of Hsf1 expression and suppressing Hsf1 by siRNA also made cells more resistant to the cytotoxic effects of paclitaxel.	Paclitaxel	131-141	heat shock transcription factor 1	Homo sapiens	58-62
21046120-0	2011	HsMAD2 mRNA expression may be a predictor of sensitivity to paclitaxel and survival in neuroblastoma.	Paclitaxel	60-70	SMAD family member 2	Homo sapiens	0-6
21046120-1	2011	PURPOSE: We investigated the associations between hsMAD2 mRNA expression in tumor cells and sensitivity to paclitaxel or patient prognosis in neuroblastoma.	Paclitaxel	107-117	SMAD family member 2	Homo sapiens	50-56
21270338-8	2011	UROD down-regulation also radiosensitized several different models of human cancer, as well as sensitized tumors to chemotherapeutic agents, including 5-fluorouracil, cisplatin, and paclitaxel.	Paclitaxel	182-192	uroporphyrinogen decarboxylase	Homo sapiens	0-4
22205945-5	2011	Incorporation of PTX into hMSCs was studied by using FICT-labelled-PTX and analyzed by FACS and confocal microscopy.	Paclitaxel	17-20	acyl-CoA synthetase long-chain family member 1	Mus musculus	87-91
20935223-6	2010	AMG 900 inhibited the proliferation of 26 tumor cell lines, including cell lines resistant to the antimitotic drug paclitaxel and to other aurora kinase inhibitors (AZD1152, MK-0457, and PHA-739358), at low nanomolar concentrations.	Paclitaxel	115-125	amelogenin X-linked	Homo sapiens	0-3
21059223-8	2010	We showed that a potent Aurora-A kinase inhibitor was able to reverse paclitaxel resistance in the ZNF217-overexpressing cells.	Paclitaxel	70-80	aurora kinase A	Homo sapiens	24-32
20540095-9	2010	The cells cultivated on Az-chitosan-QHREDGS demonstrated significantly lower levels of caspase 3/7 activation after taxol treatment in comparison to cells cultivated on the control hydrogels, glass substrate, or Az-chitosan linked to RGD, an established integrin binding peptide that did not protect against apoptosis.	Paclitaxel	116-121	caspase 3	Rattus norvegicus	87-96
20687223-0	2010	MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.	Paclitaxel	19-29	microRNA 34a	Homo sapiens	0-7
20687223-12	2010	Thus, in PC3PR cells, reduced expression of miR-34a confers paclitaxel resistance via up-regulating SIRT1 and Bcl2 expression.	Paclitaxel	60-70	microRNA 34a	Homo sapiens	44-51
20687223-13	2010	CONCLUSIONS: MiR-34a and its downstream targets SIRT1 and Bcl2 play important roles in the development of paclitaxel resistance, all of which can be useful biomarkers and promising therapeutic targets for the drug resistance in hormone-refractory prostate cancer.	Paclitaxel	106-116	microRNA 34a	Homo sapiens	13-20
20457237-9	2010	Moreover, a series of safety studies including hemolysis, hypersensitivity, maximum tolerated dose, acute toxicity, and organ toxicity revealed that the PTX-loaded OGC micelles had advantages over the commercially available injectable preparation of PTX (Taxol((R))), in terms of low toxicity levels and increased tolerated dose.	Paclitaxel	153-156	solute carrier family 25 member 11	Homo sapiens	164-167
20457237-10	2010	Additionally, cytotoxicity studies showed that the PTX-loaded OGC micelles were comparable to the commercial formulation, but the blank micelles were far less toxic than the Cremophor EL vehicle.	Paclitaxel	51-54	solute carrier family 25 member 11	Homo sapiens	62-65
20457237-11	2010	These results suggest that OGC is a promising carrier for injectable PTX micelles.	Paclitaxel	69-72	solute carrier family 25 member 11	Homo sapiens	27-30
20353770-0	2010	Murine erythropoietic impairment induced by paclitaxel: interactions of GATA-1 and erythroid Kruppel-like transcription factors, apoptotic related proteins and erythropoietin receptor.	Paclitaxel	44-54	GATA binding protein 1	Mus musculus	72-78
20353770-4	2010	Results showed a massive impairment of erythropoiesis early post paclitaxel administration (1-2 days), which involved induction of high Bax/Bcl-x(L) ratio, caspase-3 activation, disruptions of the medullar niche and cell death by both apoptosis and necrosis.	Paclitaxel	65-75	BCL2-like 1	Mus musculus	140-148
2571074-3	1989	Similarly, taxol, a microtubule-stabilizing drug, selectively reduced the slow phase of LPL release, without influencing the rapid release of LPL into the medium or cellular LPL activity.	Paclitaxel	11-16	lipoprotein lipase	Homo sapiens	88-91
2571074-5	1989	Heparin-releasable LPL could be resolved into two fractions by chromatography on con A-Sepharose; this pattern of elution was not affected by the prior treatment of cardiac myocytes with taxol.	Paclitaxel	187-192	lipoprotein lipase	Homo sapiens	19-22
20406806-0	2010	MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression.	Paclitaxel	20-30	ribosomal protein S6 kinase A5	Homo sapiens	120-124
20406806-12	2010	Furthermore, MSK1 knockdown reduced paclitaxel-resistance of PC3PR cells, indicating that miR-148a attenuates paclitaxel-resistance of hormone-refractory, drug-resistant PC3PR cells in part by regulating MSK1 expression.	Paclitaxel	36-46	ribosomal protein S6 kinase A5	Homo sapiens	13-17
2564894-6	1989	These observations suggested that esters at C-2" and/or C-7, which would tend to promote water solubility, might serve as useful prodrugs of taxol.	Paclitaxel	141-146	complement C2	Homo sapiens	44-47
20406806-12	2010	Furthermore, MSK1 knockdown reduced paclitaxel-resistance of PC3PR cells, indicating that miR-148a attenuates paclitaxel-resistance of hormone-refractory, drug-resistant PC3PR cells in part by regulating MSK1 expression.	Paclitaxel	110-120	ribosomal protein S6 kinase A5	Homo sapiens	13-17
20434553-7	2010	Results showed that coadministration of OVA with paclitaxel induced significantly higher IgG, IgG1, IgG2a, IgG2b, IgG3 and IgM responses than when OVA was used alone.	Paclitaxel	49-59	Immunoglobulin heavy constant gamma 3	Mus musculus	114-118
20434553-9	2010	Incubation of a murine macrophage-like cell line with paclitaxel significantly increased TNF-alpha and -10 released from the cells and expression of microRNAs such as miR-155, miR-147, miR-146a and miR-132.	Paclitaxel	54-64	microRNA 155	Mus musculus	167-174
3045269-12	1988	When we added tubulin to this suspension and polymerized it in the presence of taxol, neurofilaments were crosslinked with microtubules by MAP2 crossbridges.	Paclitaxel	79-84	microtubule-associated protein 2	Rattus norvegicus	139-143
20434553-9	2010	Incubation of a murine macrophage-like cell line with paclitaxel significantly increased TNF-alpha and -10 released from the cells and expression of microRNAs such as miR-155, miR-147, miR-146a and miR-132.	Paclitaxel	54-64	microRNA 147	Mus musculus	176-183
20939180-10	2010	Meanwhile, HepG2/SNCG cells showed higher resistance to PTX and VCR than HepG2/Neo cells, with resistance index 21 and 15 respectively.	Paclitaxel	56-59	synuclein gamma	Homo sapiens	17-21
20417177-0	2010	Suppression of histone deacetylase 3 (HDAC3) enhances apoptosis induced by paclitaxel in human maxillary cancer cells in vitro and in vivo.	Paclitaxel	75-85	histone deacetylase 3	Homo sapiens	15-36
2863145-4	1985	By contrast, when microtubules were polymerized with taxol after isotonic cell lysis a considerable enrichment of MAP-1 and MAP-2 was achieved; again, plectin co-distributed only partially.	Paclitaxel	53-58	Blood pressure QTL 196	Rattus norvegicus	114-119
2863145-4	1985	By contrast, when microtubules were polymerized with taxol after isotonic cell lysis a considerable enrichment of MAP-1 and MAP-2 was achieved; again, plectin co-distributed only partially.	Paclitaxel	53-58	microtubule-associated protein 2	Rattus norvegicus	124-129
2863145-7	1985	When the spatial arrangement of the high Mr proteins on taxol-polymerized C6 cell microtubules was directly visualized using gold-immunoelectron microscopy, a periodical, apparently helical, decoration of microtubules was found for MAP-1 and MAP-2; plectin was irregularly arrayed.	Paclitaxel	56-61	Blood pressure QTL 196	Rattus norvegicus	232-237
2858069-9	1985	(2) Microtubule inhibitors (colchicine, taxol and nocodazole) suppressed the rate of release of acetylcholinesterase.	Paclitaxel	40-45	acetylcholinesterase	Rattus norvegicus	96-116
20417177-0	2010	Suppression of histone deacetylase 3 (HDAC3) enhances apoptosis induced by paclitaxel in human maxillary cancer cells in vitro and in vivo.	Paclitaxel	75-85	histone deacetylase 3	Homo sapiens	38-43
20417177-5	2010	Here, we showed that paclitaxel-induced apoptosis was enhanced significantly by addition of ASOs for HDAC3 in cultured cells.	Paclitaxel	21-31	histone deacetylase 3	Homo sapiens	101-106
6489451-9	1984	Moreover, stabilization of cytoplasmic microtubules with taxol has been found to block microtubule disassembly and initiation of DNA synthesis by colchicine and to inhibit thrombin- and EGF-stimulated DNA synthesis under serum-free conditions.	Paclitaxel	57-62	epidermal growth factor	Homo sapiens	186-189
20417177-7	2010	We provide new evidence that HDAC3 is a novel molecular target whose inactivation can potentiate the efficacy of anti-cancer drugs disrupting microtubules such as paclitaxel.	Paclitaxel	163-173	histone deacetylase 3	Homo sapiens	29-34
20436269-3	2010	When cytokine-dependent FL5.12 cells were cultured in the presence of IL-3, which stimulated multiple proliferation and anti-apoptotic cascades, MEK, PI3K and mTOR inhibitors transiently suppressed but did not totally inhibit cell cycle progression or induce apoptosis while chemotherapeutic drugs such as doxorubicin and paclitaxel were more effective in inducing cell cycle arrest and apoptosis.	Paclitaxel	322-332	midkine	Mus musculus	145-148
6376120-2	1984	When insoluble cell fractions were prepared by incubation of isotonic cell extracts with 20 microM taxol, polypeptides co-migrating with MAP-1 and MAP-2 upon gel electrophoresis were observed in virtually all cases examined.	Paclitaxel	99-104	mannosidase processing 1	Mus musculus	137-142
20178647-1	2010	BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC).	Paclitaxel	122-132	interferon alpha 2	Homo sapiens	92-110
20018861-0	2010	Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment.	Paclitaxel	73-83	G2 and S-phase expressed 1	Homo sapiens	6-12
20018861-6	2010	Finally, we demonstrate that hGTSE-1 mediated-p21(CIP1/WAF1) stabilization is clearly involved in the ability of cells to counteract cytotoxicity induced by the microtubule poison paclitaxel.	Paclitaxel	180-190	G2 and S-phase expressed 1	Homo sapiens	29-36
6141064-4	1984	After taxol treatment, the juxtanuclear accumulation of vimentin filaments and the centrioles were rarely observed in the same area.	Paclitaxel	6-11	vimentin	Homo sapiens	56-64
20133800-0	2010	Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells.	Paclitaxel	10-20	prohibitin 1	Homo sapiens	50-61
20133800-4	2010	Using a proteomics approach, elevated levels of Prohibitin1 (PHB1) and GSTpi were found associated with paclitaxel resistance in discrete subcellular fractions of two drug-resistant sublines relative to their sensitive sublines.	Paclitaxel	104-114	prohibitin 1	Homo sapiens	48-59
20133800-4	2010	Using a proteomics approach, elevated levels of Prohibitin1 (PHB1) and GSTpi were found associated with paclitaxel resistance in discrete subcellular fractions of two drug-resistant sublines relative to their sensitive sublines.	Paclitaxel	104-114	prohibitin 1	Homo sapiens	61-65
6117076-0	1981	Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin.	Paclitaxel	15-20	tubulin alpha-1B chain	Cricetulus griseus	91-104
20133800-6	2010	Transiently silencing either PHB1 or GSTpi gene expression using siRNA in the paclitaxel-resistant cancer cell sublines partially sensitized these cells toward paclitaxel.	Paclitaxel	78-88	prohibitin 1	Homo sapiens	29-33
6117076-9	1981	Seventeen temperature-resistant revertants of the alpha-tubulin mutant were selected for their ability to grow at 40 degrees C and three of these revertants were found to have simultaneously lost their taxol resistance and the electrophoretic variant alpha-tubulin.	Paclitaxel	202-207	tubulin alpha-1B chain	Cricetulus griseus	50-63
20029418-6	2010	Class III beta-tubulin overexpression conferred resistance to paclitaxel and vinorelbine, whereas downregulation of class III beta-tubulin rendered cells more sensitive to these two drugs.	Paclitaxel	62-72	tubulin beta 3 class III	Homo sapiens	0-22
33848578-8	2021	Also, green tea and PTX combination induced apoptosis in ovarian cancer cells by blocking the phosphorylation of Akt and the expression of Bcl-2 while inducing Bax, Cyt-C, cleaved-caspase 3, and cleaved-caspase 9.	Paclitaxel	20-23	caspase 9	Homo sapiens	203-212
33894420-8	2021	Meanwhile, CCT combined with taxol caused significant ER stress through improving phosphorylated PERK, eukaryotic translation initiation factor 2alpha (eIF2alpha), C/EBP homologous protein (CHOP) and glucose-regulated protein 78 (GRP78).	Paclitaxel	29-34	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	97-101
33894420-10	2021	Intriguingly, PERK knockdown markedly abolished the regulatory role of CCT and taxol cotreatments in cell proliferation suppression and apoptosis induction, indicating the importance of PERK for CCT to perform its anti-cancer bioactivity.	Paclitaxel	79-84	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	14-18
33894420-10	2021	Intriguingly, PERK knockdown markedly abolished the regulatory role of CCT and taxol cotreatments in cell proliferation suppression and apoptosis induction, indicating the importance of PERK for CCT to perform its anti-cancer bioactivity.	Paclitaxel	79-84	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	186-190
33894420-12	2021	Together, all these results suggested that promoting PERK activation by CCT may be an effective therapeutic strategy to improve CRC to taxol treatment.	Paclitaxel	135-140	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	53-57
19875160-8	2010	Increased PARP cleavage was noted in the paclitaxel+SAHA groups.	Paclitaxel	41-51	collagen type XI alpha 2 chain	Homo sapiens	10-14
34022297-10	2021	TLR4 expression in chemoresponsive TNBC was also validated in TNBC cell lines upon Paclitaxel (PTX) treatment.	Paclitaxel	83-93	toll like receptor 4	Homo sapiens	0-4
34022297-10	2021	TLR4 expression in chemoresponsive TNBC was also validated in TNBC cell lines upon Paclitaxel (PTX) treatment.	Paclitaxel	95-98	toll like receptor 4	Homo sapiens	0-4
33999360-0	2021	Long non-coding RNA TPT1-AS1 sensitizes breast cancer cell to paclitaxel and inhibits cell proliferation by miR-3156-5p/caspase 2 axis.	Paclitaxel	62-72	tumor protein, translationally-controlled 1	Homo sapiens	20-24
33999360-8	2021	In breast cancer cells, TPT1-AS1 overexpression repressed cell proliferation and sensitized breast cancer cells to paclitaxel.	Paclitaxel	115-125	tumor protein, translationally-controlled 1	Homo sapiens	24-28
20049172-7	2010	We have previously reported that reintroduction of miR-200c to aggressive cells that lack miR-200c expression restores sensitivity to paclitaxel.	Paclitaxel	134-144	microRNA 200c	Homo sapiens	51-59
33151424-1	2021	PURPOSE: The long noncoding RNA (lncRNA) ZEB1-AS1 is reported overexpressed in sensitive ovarian cancer cells A2780 compared with paclitaxel (PTX)-and cisplatin (DDP)- resistant.	Paclitaxel	130-140	ZEB1 antisense RNA 1	Homo sapiens	41-49
33151424-1	2021	PURPOSE: The long noncoding RNA (lncRNA) ZEB1-AS1 is reported overexpressed in sensitive ovarian cancer cells A2780 compared with paclitaxel (PTX)-and cisplatin (DDP)- resistant.	Paclitaxel	142-145	ZEB1 antisense RNA 1	Homo sapiens	41-49
33151424-4	2021	A combination of siRNA, plasmids, CCK8 and flow cytometry was used to detect the effect of ZEB1-AS1 on ovarian cancer cell A2780 PTX and DDP resistance.	Paclitaxel	129-132	ZEB1 antisense RNA 1	Homo sapiens	91-99
33621742-0	2021	Corrigendum to "Paclitaxel alleviates the sepsis-induced acute kidney injury via lnc-MALAT1/miR-370-3p/HMGB1 axis" [Life Sci.	Paclitaxel	16-26	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	85-91
33896831-9	2021	CONCLUSIONS: Our results first revealed that TPM3, EFHD2, KRT19 and vimentin were novel autoantibodies in the ascites of relapsed PTX-resistant GC patients.	Paclitaxel	130-133	EF-hand domain family member D2	Homo sapiens	51-56
33556340-0	2021	TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.	Paclitaxel	108-113	toll like receptor 4	Homo sapiens	0-4
33556340-2	2021	Recent studies showed that ectopic overexpression of toll-like receptor 4 (TLR4) in ovarian cancer cells leads to upregulation of the androgen receptor (AR) and transactivation of taxol resistance genes, thereby causing chemoresistance.	Paclitaxel	180-185	toll like receptor 4	Homo sapiens	53-73
33556340-2	2021	Recent studies showed that ectopic overexpression of toll-like receptor 4 (TLR4) in ovarian cancer cells leads to upregulation of the androgen receptor (AR) and transactivation of taxol resistance genes, thereby causing chemoresistance.	Paclitaxel	180-185	toll like receptor 4	Homo sapiens	75-79
33556340-4	2021	Based on transcriptomic analysis, we show that IL-6 functions as a hub gene among the upregulated genes in taxol-treated TLR4-overexpressing ovarian cancer cells.	Paclitaxel	107-112	toll like receptor 4	Homo sapiens	121-125
33556340-5	2021	Both the TLR4 activator taxol and IL-6 can induce AKT phosphorylation, whereas TLR4 knockdown or inhibition of the IL-6 signal transducer GP130 abrogates AKT activation.	Paclitaxel	24-29	toll like receptor 4	Homo sapiens	9-13
33417085-8	2021	RESULTS: Upon FOXA1 knockdown in luminal MCF-7 and T47D cells, we found an increase in doxorubicin and paclitaxel sensitivity as well as a decrease in anchorage independence.	Paclitaxel	103-113	forkhead box A1	Homo sapiens	14-19
33931981-12	2021	CONCLUSION: Our study demonstrates that PIM2 mediates PFKFB3 phosphorylation thus regulates glycolysis and paclitaxel resistance to promote tumor progression in BC and provides preclinical evidence for targeting PFKFB3 as a new strategy in BC treatment to battle paclitaxel resistance.	Paclitaxel	263-273	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	54-60
33931981-12	2021	CONCLUSION: Our study demonstrates that PIM2 mediates PFKFB3 phosphorylation thus regulates glycolysis and paclitaxel resistance to promote tumor progression in BC and provides preclinical evidence for targeting PFKFB3 as a new strategy in BC treatment to battle paclitaxel resistance.	Paclitaxel	263-273	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	212-218
33867704-7	2021	The levels of Bcl2 gene expression were significantly decreased and P53gene expression were markedly increased in Paclitaxel and Di allyl sulfide treated animals when compared with cancer bearing animals.	Paclitaxel	114-124	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	68-71
33867704-8	2021	The treatment with combination of Paclitaxel and Di allyl sulfide effectively reduced Bcl2 protein expression and also increased P53gene expression.	Paclitaxel	34-44	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	129-132
33422634-7	2021	Moreover, the data suggests that the synergistic effect of CG and PTX played a role in a mitochondrial intrinsic pathway through the apoptotic gene expression of Bax, caspase-9 and caspase-3.	Paclitaxel	66-69	caspase 9	Homo sapiens	167-176
33738259-5	2021	Hsp90 downregulation by shHsp90 or inhibitor BIIB021 increased the sensitivity of multi-drug resistant ovarian cancer cells to paclitaxel and cisplatin, and augmented the drugs-induced apoptosis.	Paclitaxel	127-137	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
33738259-9	2021	Furthermore, Hsp90 enhanced the AKT/GSK3beta signaling, and AKT signaling played a critical role in Hsp90-induced accumulation and transcriptional activity of beta-catenin, as well as multi-drug resistance to paclitaxel and cisplatin.	Paclitaxel	209-219	heat shock protein 90 alpha family class A member 1	Homo sapiens	13-18
33738259-9	2021	Furthermore, Hsp90 enhanced the AKT/GSK3beta signaling, and AKT signaling played a critical role in Hsp90-induced accumulation and transcriptional activity of beta-catenin, as well as multi-drug resistance to paclitaxel and cisplatin.	Paclitaxel	209-219	heat shock protein 90 alpha family class A member 1	Homo sapiens	100-105
33738259-9	2021	Furthermore, Hsp90 enhanced the AKT/GSK3beta signaling, and AKT signaling played a critical role in Hsp90-induced accumulation and transcriptional activity of beta-catenin, as well as multi-drug resistance to paclitaxel and cisplatin.	Paclitaxel	209-219	catenin beta 1	Homo sapiens	159-171
33691261-6	2021	In vitro and in vivo studies indicate that the mechanisms underlying the resistance to PTX and docetaxel are primarily due to alterations in alpha-tubulin and beta-tubulin.	Paclitaxel	87-90	tubulin alpha 1b	Homo sapiens	141-154
33691261-14	2021	We broadly discuss the roles of inhibitors of P-gp and other efflux pumps, in the reversal of PTX and docetaxel resistance in cancer cells and the significance of using a nanomedicine delivery system in this context.	Paclitaxel	94-97	phosphoglycolate phosphatase	Homo sapiens	46-50
33650658-0	2021	Circadian clock protein CRY1 prevents paclitaxel-induced senescence of bladder cancer cells by promoting p53 degradation.	Paclitaxel	38-48	cryptochrome circadian regulator 1	Homo sapiens	24-28
33650658-9	2021	It was identified that the circadian protein cryptochrome1 (CRY1) accumulated in these quiescent cisplatin-resistant cells, and that CRY1 knockdown restored PTX-induced senescence.	Paclitaxel	157-160	cryptochrome circadian regulator 1	Homo sapiens	45-58
33650658-9	2021	It was identified that the circadian protein cryptochrome1 (CRY1) accumulated in these quiescent cisplatin-resistant cells, and that CRY1 knockdown restored PTX-induced senescence.	Paclitaxel	157-160	cryptochrome circadian regulator 1	Homo sapiens	60-64
33650658-9	2021	It was identified that the circadian protein cryptochrome1 (CRY1) accumulated in these quiescent cisplatin-resistant cells, and that CRY1 knockdown restored PTX-induced senescence.	Paclitaxel	157-160	cryptochrome circadian regulator 1	Homo sapiens	133-137
33650658-11	2021	These data suggested that the accumulated CRY1 in cisplatin-resistant cells could prevent PTX-induced senescence by promoting p53 degradation.	Paclitaxel	90-93	cryptochrome circadian regulator 1	Homo sapiens	42-46
33279635-9	2021	Body mass recovery was associated with the wheel running-induced recovery of body composition, paclitaxel-induced alterations to hypothalamic melanocortin signaling and associated peripheral circulating hormones (ghrelin and leptin).	Paclitaxel	95-105	leptin	Mus musculus	225-231
33718033-2	2021	Methods: We previously developed a polyethylene glycol-based (PEG-based) immunostimulatory nanocarrier (PEG2k-Fmoc-NLG919) which can efficiently co-deliver an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor and the chemotherapeutic agent, paclitaxel.	Paclitaxel	238-248	indoleamine 2,3-dioxygenase 1	Homo sapiens	159-188
33718039-0	2021	Triptolide inhibits epithelial-mesenchymal transition phenotype through the p70S6k/GSK3/beta-catenin signaling pathway in taxol-resistant human lung adenocarcinoma.	Paclitaxel	122-127	ribosomal protein S6 kinase B1	Homo sapiens	76-82
33718039-0	2021	Triptolide inhibits epithelial-mesenchymal transition phenotype through the p70S6k/GSK3/beta-catenin signaling pathway in taxol-resistant human lung adenocarcinoma.	Paclitaxel	122-127	catenin beta 1	Homo sapiens	88-100
33718039-13	2021	Conclusions: Our study provides evidence that triptolide can reverse EMT in taxol-resistant lung adenocarcinoma cells and impairs tumor growth by inhibiting the p70S6K/GSK3/beta-catenin pathway, indicating that triptolide has potential to be used as a new therapeutic agent for taxol-resistant lung adenocarcinoma.	Paclitaxel	278-283	ribosomal protein S6 kinase B1	Homo sapiens	161-167
33513992-6	2021	The addition of RTV can inhibit the P-gp and CYP3A4-mediated metabolism of PTX, thus aiding in reversing MDR and sensitizing the cells toward PTX.	Paclitaxel	75-78	phosphoglycolate phosphatase	Homo sapiens	36-40
33290562-5	2021	It was observed for the first time in all three cell lines that 4-demethylwyosine (imG-14) substitutes for hydroxywybutosine (OHyW) due to tRNA-wybutosine synthesizing enzyme-2 (TYW2) downregulation and becomes the predominant modification at the 37th position of tRNAphe in the taxol-resistant strains.	Paclitaxel	279-284	tRNA methyltransferase 12 homolog	Homo sapiens	178-182
33290562-7	2021	The time courses of the increase in imG-14 and downregulation of TYW2 are consistent with each other as well as consistent with the time course of the development of taxol-resistance.	Paclitaxel	166-171	tRNA methyltransferase 12 homolog	Homo sapiens	65-69
33290562-8	2021	Knockdown of TYW2 in HeLa cells caused both an accumulation of imG-14 and reduction in taxol potency.	Paclitaxel	87-92	tRNA methyltransferase 12 homolog	Homo sapiens	13-17
33290562-9	2021	Taken together, low expression of TYW2 enzyme promotes the cancer survival and resistance to taxol therapy, implying a novel mechanism for taxol resistance.	Paclitaxel	93-98	tRNA methyltransferase 12 homolog	Homo sapiens	34-38
33290562-9	2021	Taken together, low expression of TYW2 enzyme promotes the cancer survival and resistance to taxol therapy, implying a novel mechanism for taxol resistance.	Paclitaxel	139-144	tRNA methyltransferase 12 homolog	Homo sapiens	34-38
33506900-0	2021	Exosomes derived from Taxol-resistant nasopharyngeal carcinoma (NPC) cells transferred DDX53 to NPC cells and promoted cancer resistance to Taxol.	Paclitaxel	22-27	DEAD-box helicase 53	Homo sapiens	87-92
33506900-10	2021	RESULTS: We found that the IC50 to Taxolin CNE1-TR was much higher than that in CNE1 cells and DDX53 was highly expressed in Taxol-resistant CNE1-TR cells.	Paclitaxel	35-40	DEAD-box helicase 53	Homo sapiens	95-100
33506900-16	2021	Finally, the increased levels of MDR1 were significantly reversed following with adding DDX53 si-DDX53-CNE1-TR exosomes, and the increased IC50 to Taxol was obviously reversed.	Paclitaxel	147-152	DEAD-box helicase 53	Homo sapiens	88-93
33506900-16	2021	Finally, the increased levels of MDR1 were significantly reversed following with adding DDX53 si-DDX53-CNE1-TR exosomes, and the increased IC50 to Taxol was obviously reversed.	Paclitaxel	147-152	DEAD-box helicase 53	Homo sapiens	97-102
33506900-17	2021	CONCLUSIONS: This study firstly discovered that DDX53 was highly expressed in Taxol-resistant NPC cells, which could be transferred into normal NPC cells via exosome secretion.	Paclitaxel	78-83	DEAD-box helicase 53	Homo sapiens	48-53
33506900-18	2021	The transferred DDX53 could upregulate the expression of MDR1 in NPC cells to promote the resistant capacity to Taxol, which provided a novel insight for understanding NPC and might be a potential therapeutic target for NPC.	Paclitaxel	112-117	DEAD-box helicase 53	Homo sapiens	16-21
33409256-8	2020	Paclitaxel accelerates apoptosis in Pin1 silenced H-Ras MCF10A cells.	Paclitaxel	0-10	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	36-40
33409256-8	2020	Paclitaxel accelerates apoptosis in Pin1 silenced H-Ras MCF10A cells.	Paclitaxel	0-10	HRas proto-oncogene, GTPase	Homo sapiens	50-55
33370338-0	2020	The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.	Paclitaxel	40-50	mitotic arrest deficient 2 like 1	Homo sapiens	16-20
33370338-0	2020	The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.	Paclitaxel	40-50	toll like receptor 4	Homo sapiens	21-25
33370338-3	2020	In this study, we demonstrate a key link between senescence and inflammation and how this complex network involving the biomarkers MAD2, TLR4 and MyD88 drives paclitaxel resistance in ovarian cancer.	Paclitaxel	159-169	mitotic arrest deficient 2 like 1	Homo sapiens	131-135
33370338-3	2020	In this study, we demonstrate a key link between senescence and inflammation and how this complex network involving the biomarkers MAD2, TLR4 and MyD88 drives paclitaxel resistance in ovarian cancer.	Paclitaxel	159-169	toll like receptor 4	Homo sapiens	137-141
33370338-5	2020	Interestingly, siRNA knockdown of MAD2 led to a significant increase in TLR4 gene expression, this was coupled with the development of a highly paclitaxel-resistant cell phenotype.	Paclitaxel	144-154	mitotic arrest deficient 2 like 1	Homo sapiens	34-38
33370338-5	2020	Interestingly, siRNA knockdown of MAD2 led to a significant increase in TLR4 gene expression, this was coupled with the development of a highly paclitaxel-resistant cell phenotype.	Paclitaxel	144-154	toll like receptor 4	Homo sapiens	72-76
33319669-5	2021	PTX resistance pathways that involve major regulatory proteins/RNAs like RNF8/Twist/ROR1, TLR, ErbB3/ErbB2, BRCA1-IRIS, MENA, LIN9, MiRNA, FoxM1 and IRAK1 have expanded the complexity of resistance mechanisms, and brought newer insights for development of drug targets.	Paclitaxel	0-3	ring finger protein 8	Homo sapiens	73-77
32988260-2	2020	In March 2019, the combination of nab-paclitaxel and atezolizumab was approved by the US FDA for patients with PD-L1 positive metastatic triple-negative breast cancer based on positive results of the Impassion130 trial.	Paclitaxel	38-48	CD274 molecule	Homo sapiens	111-116
33085566-4	2020	Applying patch-clamp recordings to Merkel cells in situ in whisker hair follicles, we show that Piezo2-mediated mechanically activated (MA) currents in Merkel cells are significantly potentiated by microtubule stabilizer paclitaxel, but reduced by microtubule destabilizer vincristine.	Paclitaxel	221-231	piezo-type mechanosensitive ion channel component 2	Mus musculus	96-102
32998017-10	2020	SIGNIFICANCE: Paclitaxel could protect against LPS-induced AKI via the regulation of lnc-MALAT1/miR-370-3p/HMGB1 axis and the expression of TNF-alpha, IL-6 and IL-1beta, revealing that paclitaxel might act as a therapy drug in reducing sepsis-associated AKI.	Paclitaxel	14-24	interleukin 1 alpha	Homo sapiens	160-168
33294730-7	2021	Significantly, the released PTX and CUR could induce the immunogenic cell death (ICD) to promote adaptive anti-tumor immunogenicity and inhibit immunosuppression through suppressing the activity of indoleamine 2,3-dioxygenase 1 (IDO1) enzyme respectively.	Paclitaxel	28-31	indoleamine 2,3-dioxygenase 1	Homo sapiens	198-227
33294730-7	2021	Significantly, the released PTX and CUR could induce the immunogenic cell death (ICD) to promote adaptive anti-tumor immunogenicity and inhibit immunosuppression through suppressing the activity of indoleamine 2,3-dioxygenase 1 (IDO1) enzyme respectively.	Paclitaxel	28-31	indoleamine 2,3-dioxygenase 1	Homo sapiens	229-233
32963602-9	2020	In CD1133+ cells treated with PTX, a dose-dependent reduction in the expression levels of the key glycolytic enzymes GLUT1, PKM and LDHA was observed at both the mRNA and protein levels.	Paclitaxel	30-33	pyruvate kinase M1/2	Homo sapiens	124-127
33000256-5	2020	A bioinformatics analysis of gene expression profiles in PTX-resistant cells indicated that SERPINE1 was significantly associated with PTX resistance.	Paclitaxel	57-60	serpin family E member 1	Homo sapiens	92-100
33000256-5	2020	A bioinformatics analysis of gene expression profiles in PTX-resistant cells indicated that SERPINE1 was significantly associated with PTX resistance.	Paclitaxel	135-138	serpin family E member 1	Homo sapiens	92-100
33000256-6	2020	Furthermore, the levels of SERPINE1 mRNA and protein were higher in PTX-resistant cells with respect to those in PTX-sensitive parent cells.	Paclitaxel	68-71	serpin family E member 1	Homo sapiens	27-35
33000256-6	2020	Furthermore, the levels of SERPINE1 mRNA and protein were higher in PTX-resistant cells with respect to those in PTX-sensitive parent cells.	Paclitaxel	113-116	serpin family E member 1	Homo sapiens	27-35
33000256-11	2020	The present study demonstrated SERPINE1 as an oncogene in PTX drug resistance of breast cancer, and revealed that it may serve as a possible target for treating BC.	Paclitaxel	58-61	serpin family E member 1	Homo sapiens	31-39
33087151-9	2020	TAOK3 shRNA exhibited the most significant reduction in IC50 values in response to paclitaxel treatment.	Paclitaxel	83-93	TAO kinase 3	Homo sapiens	0-5
33087151-10	2020	Ectopic downregulation of TAOK3 resulted in paclitaxel-resistant breast cancer cells sensitize to paclitaxel treatment in vitro and in vivo.	Paclitaxel	44-54	TAO kinase 3	Homo sapiens	26-31
33087151-10	2020	Ectopic downregulation of TAOK3 resulted in paclitaxel-resistant breast cancer cells sensitize to paclitaxel treatment in vitro and in vivo.	Paclitaxel	98-108	TAO kinase 3	Homo sapiens	26-31
33087151-13	2020	TAOK3 inhibitor, CP43, and shRNA of NF-kappaB both reduced the paclitaxel resistance in TAOK3 overexpressed cells.	Paclitaxel	63-73	TAO kinase 3	Homo sapiens	0-5
33087151-13	2020	TAOK3 inhibitor, CP43, and shRNA of NF-kappaB both reduced the paclitaxel resistance in TAOK3 overexpressed cells.	Paclitaxel	63-73	TAO kinase 3	Homo sapiens	88-93
33028939-0	2020	Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells.	Paclitaxel	0-10	microRNA 522	Homo sapiens	34-41
33027666-6	2020	Moreover, pharmacological inhibition of eIF4A is able to enhance the effects of Taxol and restore sensitivity in Taxol-resistant cancer cells.	Paclitaxel	80-85	eukaryotic translation initiation factor 4A2	Homo sapiens	40-45
33027666-6	2020	Moreover, pharmacological inhibition of eIF4A is able to enhance the effects of Taxol and restore sensitivity in Taxol-resistant cancer cells.	Paclitaxel	113-118	eukaryotic translation initiation factor 4A2	Homo sapiens	40-45
33019717-5	2020	PTX-res MCF-7 cells exhibited increased motility profile with EMT, PI3K/Akt, and MAPK pathway induction.	Paclitaxel	0-3	IL2 inducible T cell kinase	Homo sapiens	62-65
32847971-7	2020	These findings indicate that loss of the balance between glutamate release and reuptake due to dysregulation EAAT2/VGLUT2/synaptophysin cascade in the spinal dorsal horn plays an important role in the development of paclitaxel-induced neuropathic pain.	Paclitaxel	216-226	solute carrier family 17 member 6	Rattus norvegicus	115-121
32982454-10	2020	The clinical analysis showed that IMUP is associated with lymph node metastasis and the outcome of neoadjuvant taxol-based therapy.	Paclitaxel	111-116	chromosome 19 open reading frame 33	Homo sapiens	34-38
32941465-4	2020	We found that the class IV dendritic arborization (C4da) sensory neuron-specific expression of PINK1 significantly ameliorated the paclitaxel-induced thermal hyperalgesia phenotype.	Paclitaxel	131-141	PTEN-induced putative kinase 1	Drosophila melanogaster	95-100
32941465-6	2020	Interestingly, analysis of the C4da neuron morphology suggests that PINK1 expression alleviates paclitaxel-induced thermal hypersensitivity by means other than preventing alterations in sensory dendrites in C4da neurons.	Paclitaxel	96-106	PTEN-induced putative kinase 1	Drosophila melanogaster	68-73
32941465-7	2020	We found that paclitaxel induces mitochondrial dysfunction in C4da neurons and that PINK1 expression suppressed the paclitaxel-induced increase in mitophagy in C4da neurons.	Paclitaxel	116-126	PTEN-induced putative kinase 1	Drosophila melanogaster	84-89
32941465-8	2020	These results suggest that PINK1 mitigates paclitaxel-induced sensory dendrite alterations and restores mitochondrial homeostasis in C4da neurons and that improvement in mitochondrial quality control could be a promising strategy for the treatment of CIPN.	Paclitaxel	43-53	PTEN-induced putative kinase 1	Drosophila melanogaster	27-32
32791450-0	2020	Circular RNA circTNPO3 Regulates Paclitaxel Resistance of Ovarian Cancer Cells by miR-1299/NEK2 Signaling Pathway.	Paclitaxel	33-43	microRNA 1299	Homo sapiens	82-90
32791450-0	2020	Circular RNA circTNPO3 Regulates Paclitaxel Resistance of Ovarian Cancer Cells by miR-1299/NEK2 Signaling Pathway.	Paclitaxel	33-43	NIMA related kinase 2	Homo sapiens	91-95
32791450-7	2020	In conclusion, circTNPO3 contributed to PTX resistance of OC cells at least partly through upregulating NEK2 expression by sponging miR-1299.	Paclitaxel	40-43	NIMA related kinase 2	Homo sapiens	104-108
32791450-7	2020	In conclusion, circTNPO3 contributed to PTX resistance of OC cells at least partly through upregulating NEK2 expression by sponging miR-1299.	Paclitaxel	40-43	microRNA 1299	Homo sapiens	132-140
20049172-7	2010	We have previously reported that reintroduction of miR-200c to aggressive cells that lack miR-200c expression restores sensitivity to paclitaxel.	Paclitaxel	134-144	microRNA 200c	Homo sapiens	90-98
20049172-10	2010	Lastly, we observe a decrease in proliferation in cells transfected with miR-200c mimic, and cells where ZEB1 is knocked down stably, demonstrating that the ability of miR-200c to enhance sensitivity to paclitaxel is not due to an increased proliferation rate.	Paclitaxel	203-213	microRNA 200c	Homo sapiens	168-176
19826413-8	2009	In MyD88(+) SCOV3 cells, LPS or PTX binding to TLR4 induced IRAK4 activation and cJun phosphorylation, activated the NF-kappaB pathway and promoted interleukin (IL)-8, IL-6, vascular endothelial growth factor and monocyte chemotactic protein-1 production and resistance to drug-induced apoptosis.	Paclitaxel	32-35	MYD88 innate immune signal transduction adaptor	Homo sapiens	3-8
32913475-0	2020	EPAS1 targeting by miR-152-3p in Paclitaxel-resistant Breast Cancer.	Paclitaxel	33-43	endothelial PAS domain protein 1	Homo sapiens	0-5
32913475-6	2020	The relationship between EPAS1 and miR-152-3p and their roles in paclitaxel resistance of breast cancer were further investigated using RNA interference and transfection techniques.	Paclitaxel	65-75	endothelial PAS domain protein 1	Homo sapiens	25-30
19935798-1	2009	BACKGROUND: CYP2C8/9 polymorphisms may influence breast cancer-free survival after diagnosis due to their role in the metabolism of tamoxifen, paclitaxel, and other chemotherapy.	Paclitaxel	143-153	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	12-18
32913475-10	2020	Moreover, transfection with EPAS1 siRNA enhanced the susceptibility and apoptosis rate of MCF-7/TAX cells to paclitaxel.	Paclitaxel	109-119	endothelial PAS domain protein 1	Homo sapiens	28-33
32913475-11	2020	Co-transfection of miR-152-3p mimics and EPAS1 increased paclitaxel sensitivity and apoptosis induced by the drug.	Paclitaxel	57-67	endothelial PAS domain protein 1	Homo sapiens	41-46
32913475-12	2020	Conclusion: miR-152-3p inhibits the survival of MCF-7/TAX cells and promotes their apoptosis by targeting the expression of EPAS1, thereby, enhancing the sensitivity of these breast cancer cells to paclitaxel.	Paclitaxel	198-208	endothelial PAS domain protein 1	Homo sapiens	124-129
20214592-3	2009	In the structure of CYP2C8, the large active site cavity exhibits a trifurcated topology that approximates a T or Y shape, which is consistent with the finding that CYP2C8 can efficiently oxidize relatively large substrates such as paclitaxel and cerivastatin.	Paclitaxel	232-242	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	20-26
32580047-0	2020	Caffeine inhibits the anticancer activity of paclitaxel via down-regulation of alpha-tubulin acetylation.	Paclitaxel	45-55	tubulin alpha 1b	Homo sapiens	79-92
32580047-3	2020	Here, we investigated whether caffeine inhibits the antitumor activity of paclitaxel via down-regulation of alpha-tubulin acetylation.	Paclitaxel	74-84	tubulin alpha 1b	Homo sapiens	108-121
32580047-7	2020	Additionally, caffeine enhanced migration ability, inhibited apoptosis, and decreased the acetylation of alpha-tubulin in paclitaxel-treated cancer cells.	Paclitaxel	122-132	tubulin alpha 1b	Homo sapiens	105-118
32580047-8	2020	Furthermore, caffeine decreased the inhibitory effect of paclitaxel on tumor growth through down-regulation of alpha-tubulin acetylation in vivo.	Paclitaxel	57-67	tubulin alpha 1b	Homo sapiens	111-124
32580047-9	2020	Taken together, these findings demonstrate that caffeine inhibits the anticancer activity of paclitaxel via down-regulation of alpha-tubulin acetylation, suggesting that patients receiving treatment with taxanes, such as paclitaxel, should avoid consuming caffeinated beverages or foods.	Paclitaxel	93-103	tubulin alpha 1b	Homo sapiens	127-140
20214592-3	2009	In the structure of CYP2C8, the large active site cavity exhibits a trifurcated topology that approximates a T or Y shape, which is consistent with the finding that CYP2C8 can efficiently oxidize relatively large substrates such as paclitaxel and cerivastatin.	Paclitaxel	232-242	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	165-171
32768937-0	2020	Low dose HSP90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-beta and paclitaxel in A549 cells.	Paclitaxel	129-139	heat shock protein 90 alpha family class A member 1	Homo sapiens	9-14
20214592-6	2009	CYP2C8 is a major catalyst in the metabolism of paclitaxel, amodiaquine, troglitazone, amiodarone, verapamil and ibuprofen, with a secondary role in the biotransformation of cerivastatin and fluvastatin.	Paclitaxel	48-58	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
19415457-0	2009	Human beta-galactoside alpha-2,3-sialyltransferase (ST3Gal III) attenuated Taxol-induced apoptosis in ovarian cancer cells by downregulating caspase-8 activity.	Paclitaxel	75-80	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	52-62
32420678-0	2020	Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells.	Paclitaxel	130-140	H19 imprinted maternally expressed transcript	Homo sapiens	19-22
32420678-5	2020	In this study, it was detected that the expression level of H19 was increased in BC paclitaxel-resistant (PR) cells subline (MCF-7/PR) in comparison with MCF-7 parental cells.	Paclitaxel	84-94	H19 imprinted maternally expressed transcript	Homo sapiens	60-63
19415457-0	2009	Human beta-galactoside alpha-2,3-sialyltransferase (ST3Gal III) attenuated Taxol-induced apoptosis in ovarian cancer cells by downregulating caspase-8 activity.	Paclitaxel	75-80	caspase 8	Homo sapiens	141-150
19415457-2	2009	In this report, we found that Taxol treatment resulted in caspase-8-dependent apoptosis in SKOV3 human ovarian cancer cells.	Paclitaxel	30-35	caspase 8	Homo sapiens	58-67
19415457-4	2009	Interestingly, Taxol treatment upregulated alpha-2,3-sialyltransferase (ST3Gal III) expression and forced expression of ST3Gal III attenuated Taxol-induced apoptosis.	Paclitaxel	15-20	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	72-82
19415457-4	2009	Interestingly, Taxol treatment upregulated alpha-2,3-sialyltransferase (ST3Gal III) expression and forced expression of ST3Gal III attenuated Taxol-induced apoptosis.	Paclitaxel	142-147	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	120-130
19415457-5	2009	Furthermore, ST3Gal III overexpression inhibited Taxol-triggered caspase-8 activation, indicating that ST3Gal III upregulation produces cellular resistance to Taxol and hence reduces the efficacy of Taxol therapy.	Paclitaxel	49-54	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	13-23
19415457-5	2009	Furthermore, ST3Gal III overexpression inhibited Taxol-triggered caspase-8 activation, indicating that ST3Gal III upregulation produces cellular resistance to Taxol and hence reduces the efficacy of Taxol therapy.	Paclitaxel	49-54	caspase 8	Homo sapiens	65-74
19415457-5	2009	Furthermore, ST3Gal III overexpression inhibited Taxol-triggered caspase-8 activation, indicating that ST3Gal III upregulation produces cellular resistance to Taxol and hence reduces the efficacy of Taxol therapy.	Paclitaxel	49-54	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	103-113
19415457-5	2009	Furthermore, ST3Gal III overexpression inhibited Taxol-triggered caspase-8 activation, indicating that ST3Gal III upregulation produces cellular resistance to Taxol and hence reduces the efficacy of Taxol therapy.	Paclitaxel	159-164	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	13-23
19415457-5	2009	Furthermore, ST3Gal III overexpression inhibited Taxol-triggered caspase-8 activation, indicating that ST3Gal III upregulation produces cellular resistance to Taxol and hence reduces the efficacy of Taxol therapy.	Paclitaxel	159-164	caspase 8	Homo sapiens	65-74
32450725-3	2020	The results of the IMpassion130 trial have recently led to the approval of the combination of atezolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable locally advanced or metastatic, PD-L1-positive TNBC.	Paclitaxel	115-125	CD274 molecule	Homo sapiens	216-221
19415457-5	2009	Furthermore, ST3Gal III overexpression inhibited Taxol-triggered caspase-8 activation, indicating that ST3Gal III upregulation produces cellular resistance to Taxol and hence reduces the efficacy of Taxol therapy.	Paclitaxel	159-164	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	103-113
32401077-8	2020	In addition, PTX + SPS-NEs significantly inhibited tumor growth by 72.82% and increased the secretion of serum IL-2, TNF-alpha and IFN-gamma.	Paclitaxel	13-16	interleukin 2	Mus musculus	111-115
19415457-5	2009	Furthermore, ST3Gal III overexpression inhibited Taxol-triggered caspase-8 activation, indicating that ST3Gal III upregulation produces cellular resistance to Taxol and hence reduces the efficacy of Taxol therapy.	Paclitaxel	159-164	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	13-23
2777757-6	1989	PLAA caused selective dissociation of MAP 1 and MAP 2 from microtubules polymerized by taxol.	Paclitaxel	87-92	Blood pressure QTL 196	Rattus norvegicus	38-43
19415457-5	2009	Furthermore, ST3Gal III overexpression inhibited Taxol-triggered caspase-8 activation, indicating that ST3Gal III upregulation produces cellular resistance to Taxol and hence reduces the efficacy of Taxol therapy.	Paclitaxel	159-164	caspase 8	Homo sapiens	65-74
19415457-5	2009	Furthermore, ST3Gal III overexpression inhibited Taxol-triggered caspase-8 activation, indicating that ST3Gal III upregulation produces cellular resistance to Taxol and hence reduces the efficacy of Taxol therapy.	Paclitaxel	159-164	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Homo sapiens	103-113
19732951-4	2009	Degradation of NCS-1 may be critical in the induction of peripheral neuropathy associated with taxol treatment for breast and ovarian cancer.	Paclitaxel	95-100	neuronal calcium sensor 1	Homo sapiens	15-20
32412771-0	2020	miR-145-5p attenuates paclitaxel resistance and suppresses the progression in drug-resistant breast cancer cell lines.	Paclitaxel	22-32	microRNA 145	Homo sapiens	0-7
19732951-10	2009	The reduced ability of mu-calpain treated NCS-1 to bind Ca(2+) may explain the altered Ca(2+) signaling in the presence of taxol and suggests a strategy for therapeutic intervention of peripheral neuropathy in cancer patients undergoing taxol treatment.	Paclitaxel	123-128	neuronal calcium sensor 1	Homo sapiens	42-47
32412771-9	2020	The results showed that miR-145-5p was downregulated in BC tissues and cells and associated with PTX resistance of BC cells.	Paclitaxel	97-100	microRNA 145	Homo sapiens	24-31
2900642-6	1988	The responding ability of taxol-treated lymphocytes is not restored to control levels by the addition of interleukin 2, leading to the suggestion that interleukin 2 receptors do not emerge or function normally in these cells.	Paclitaxel	26-31	interleukin 2	Mus musculus	151-164
32412771-10	2020	Overexpression of miR-145-5p or SOX2 knockdown repressed the proliferation, migration, invasion, and attenuated PTX resistance in PTX-resistant BC cells.	Paclitaxel	112-115	microRNA 145	Homo sapiens	18-25
32412771-10	2020	Overexpression of miR-145-5p or SOX2 knockdown repressed the proliferation, migration, invasion, and attenuated PTX resistance in PTX-resistant BC cells.	Paclitaxel	130-133	microRNA 145	Homo sapiens	18-25
32412771-12	2020	The inhibitory effects of miR-145-5p on the proliferation, migration, invasion, and PTX resistance were antagonized by SOX2 level restoration in PTX-resistant BC cells.	Paclitaxel	84-87	microRNA 145	Homo sapiens	26-33
32412771-12	2020	The inhibitory effects of miR-145-5p on the proliferation, migration, invasion, and PTX resistance were antagonized by SOX2 level restoration in PTX-resistant BC cells.	Paclitaxel	145-148	microRNA 145	Homo sapiens	26-33
19732951-10	2009	The reduced ability of mu-calpain treated NCS-1 to bind Ca(2+) may explain the altered Ca(2+) signaling in the presence of taxol and suggests a strategy for therapeutic intervention of peripheral neuropathy in cancer patients undergoing taxol treatment.	Paclitaxel	237-242	neuronal calcium sensor 1	Homo sapiens	42-47
32412771-14	2020	In conclusion, our study suggested that miR-145-5p reduced PTX resistance and repressed the progression at least partly by targeting SOX2 in PTX-resistant BC cells, highlighting miR-145-5p as a promising biomarker for BC treatment.	Paclitaxel	59-62	microRNA 145	Homo sapiens	40-47
32412771-14	2020	In conclusion, our study suggested that miR-145-5p reduced PTX resistance and repressed the progression at least partly by targeting SOX2 in PTX-resistant BC cells, highlighting miR-145-5p as a promising biomarker for BC treatment.	Paclitaxel	59-62	microRNA 145	Homo sapiens	178-185
19761371-3	2009	The CYP2C8*2 and *3 alleles have been associated in vitro with decreased metabolism of paclitaxel and arachidonic acid.	Paclitaxel	87-97	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	4-10
32412771-14	2020	In conclusion, our study suggested that miR-145-5p reduced PTX resistance and repressed the progression at least partly by targeting SOX2 in PTX-resistant BC cells, highlighting miR-145-5p as a promising biomarker for BC treatment.	Paclitaxel	141-144	microRNA 145	Homo sapiens	40-47
32412771-14	2020	In conclusion, our study suggested that miR-145-5p reduced PTX resistance and repressed the progression at least partly by targeting SOX2 in PTX-resistant BC cells, highlighting miR-145-5p as a promising biomarker for BC treatment.	Paclitaxel	141-144	microRNA 145	Homo sapiens	178-185
32628454-1	2020	The paclitaxel (PTX) resistance in most epithelial ovarian cancers (EOCs) with increasing membrane expression of mucin 16 (MUC16) is mediated by the Toll-like receptor-myeloid differentiation factor 2/myeloid differentiation factor 88 (TLR4-MD2/MyD88) signaling pathway.	Paclitaxel	16-19	toll like receptor 4	Homo sapiens	236-240
32628454-2	2020	6-shogaol (6S), an alpha, beta-unsaturated carbonyl compound with lipophilic property, can block PTX-induced formation of the TLR4/MD-2 complex that activates the MyD88/NF-kV signaling pathway.	Paclitaxel	97-100	toll like receptor 4	Homo sapiens	126-130
6641705-7	1983	In agreement with the immunolocalization, MAP-1, but not MAP-2, was found as a prominent component of microtubules proteins polymerized in vitro by taxol from soluble N2A cell extracts.	Paclitaxel	148-153	mannosidase processing 1	Mus musculus	42-47
19664331-15	2009	CONCLUSION: The radiosensitizing effect of paclitaxel on KB cells may be due to the down-regulated expression of PRC1 and cyclin B2, resulting in inhibition of mitotic spindle formation and cell necrosis.	Paclitaxel	43-53	protein regulator of cytokinesis 1	Homo sapiens	113-117
33667788-5	2021	Paclitaxel, doxorubicin, tamoxifen, erlotinib, gefitinib, temozolomide, and methotrexate are among therapeutic agents whose efficacy is influenced by the expression of H19.	Paclitaxel	0-10	H19 imprinted maternally expressed transcript	Homo sapiens	168-171
34046939-11	2021	CircMYBL2 played a positive role in the PTX resistance and malignant activities of PTX-sensitive and PTX-resistant CC cells by regulating the miR-665/EGFR network, providing a novel therapeutic strategy for the treatment of CC patients resistant to PTX.	Paclitaxel	40-43	MYB proto-oncogene like 2	Homo sapiens	0-9
34046939-11	2021	CircMYBL2 played a positive role in the PTX resistance and malignant activities of PTX-sensitive and PTX-resistant CC cells by regulating the miR-665/EGFR network, providing a novel therapeutic strategy for the treatment of CC patients resistant to PTX.	Paclitaxel	83-86	MYB proto-oncogene like 2	Homo sapiens	0-9
32354736-0	2020	Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis.	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	64-68
32354736-0	2020	Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis.	Paclitaxel	0-10	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	69-73
32354736-6	2020	These findings suggest that the effectiveness of paclitaxel relied upon the activation of antitumor immunity through ICD via TLR4 and highlighted the importance of CALR expression in cancer cells as an indicator of response to paclitaxel chemotherapy in ovarian cancer.	Paclitaxel	49-59	toll like receptor 4	Homo sapiens	125-129
32743678-0	2020	HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.	Paclitaxel	16-26	HOX transcript antisense RNA	Homo sapiens	0-6
32743678-4	2020	This study aims to investigate the effect, as well as the mechanism of HOTAIR in promoting paclitaxel resistance of OC.	Paclitaxel	91-101	HOX transcript antisense RNA	Homo sapiens	71-77
32743678-8	2020	RESULTS: An increased expression level of HOTAIR was observed in ovarian cancer cell lines following treatment with paclitaxel.	Paclitaxel	116-126	HOX transcript antisense RNA	Homo sapiens	42-48
32743678-9	2020	When the expression of HOTAIR was down-regulated, the proliferation of ovarian cancer cells was found to be inhibited, coupled with enhanced cell sensitivity to paclitaxel.	Paclitaxel	161-171	HOX transcript antisense RNA	Homo sapiens	23-29
32743678-12	2020	Strikingly, our results also revealed that HOTAIR plays a regulatory role in the expression of checkpoint kinase 1 (CHEK1), and that the restored paclitaxel sensitivity through knockdown of HOTAIR can be weakened by CHEK1 up-regulation.	Paclitaxel	146-156	HOX transcript antisense RNA	Homo sapiens	43-49
34046939-11	2021	CircMYBL2 played a positive role in the PTX resistance and malignant activities of PTX-sensitive and PTX-resistant CC cells by regulating the miR-665/EGFR network, providing a novel therapeutic strategy for the treatment of CC patients resistant to PTX.	Paclitaxel	83-86	microRNA 665	Homo sapiens	142-149
34046939-11	2021	CircMYBL2 played a positive role in the PTX resistance and malignant activities of PTX-sensitive and PTX-resistant CC cells by regulating the miR-665/EGFR network, providing a novel therapeutic strategy for the treatment of CC patients resistant to PTX.	Paclitaxel	83-86	MYB proto-oncogene like 2	Homo sapiens	0-9
34046939-11	2021	CircMYBL2 played a positive role in the PTX resistance and malignant activities of PTX-sensitive and PTX-resistant CC cells by regulating the miR-665/EGFR network, providing a novel therapeutic strategy for the treatment of CC patients resistant to PTX.	Paclitaxel	83-86	microRNA 665	Homo sapiens	142-149
34046939-11	2021	CircMYBL2 played a positive role in the PTX resistance and malignant activities of PTX-sensitive and PTX-resistant CC cells by regulating the miR-665/EGFR network, providing a novel therapeutic strategy for the treatment of CC patients resistant to PTX.	Paclitaxel	83-86	MYB proto-oncogene like 2	Homo sapiens	0-9
34046939-11	2021	CircMYBL2 played a positive role in the PTX resistance and malignant activities of PTX-sensitive and PTX-resistant CC cells by regulating the miR-665/EGFR network, providing a novel therapeutic strategy for the treatment of CC patients resistant to PTX.	Paclitaxel	83-86	microRNA 665	Homo sapiens	142-149
32743678-12	2020	Strikingly, our results also revealed that HOTAIR plays a regulatory role in the expression of checkpoint kinase 1 (CHEK1), and that the restored paclitaxel sensitivity through knockdown of HOTAIR can be weakened by CHEK1 up-regulation.	Paclitaxel	146-156	HOX transcript antisense RNA	Homo sapiens	190-196
32743678-13	2020	Consistently, in vivo data confirmed that the therapeutic efficacy of paclitaxel can be enhanced through down-regulation of HOTAIR, and that CHEK1 is the down-stream target of HOTAIR in inducing paclitaxel resistance.	Paclitaxel	70-80	HOX transcript antisense RNA	Homo sapiens	124-130
32743678-13	2020	Consistently, in vivo data confirmed that the therapeutic efficacy of paclitaxel can be enhanced through down-regulation of HOTAIR, and that CHEK1 is the down-stream target of HOTAIR in inducing paclitaxel resistance.	Paclitaxel	70-80	HOX transcript antisense RNA	Homo sapiens	176-182
32743678-13	2020	Consistently, in vivo data confirmed that the therapeutic efficacy of paclitaxel can be enhanced through down-regulation of HOTAIR, and that CHEK1 is the down-stream target of HOTAIR in inducing paclitaxel resistance.	Paclitaxel	195-205	HOX transcript antisense RNA	Homo sapiens	176-182
32743678-14	2020	CONCLUSION: HOTAIR confers paclitaxel resistance in epithelial ovarian cancer by increasing the protein level of CHEK1.	Paclitaxel	27-37	HOX transcript antisense RNA	Homo sapiens	12-18
32275943-0	2020	HMGB1 release promotes paclitaxel resistance in castration-resistant prostate cancer cells via activating c-Myc expression.	Paclitaxel	23-33	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	106-111
32275943-3	2020	In this study, we reported that PTX-induced constant HMGB1 expression and release confers to PTX resistance in mCRPC cells via activating and sustaining c-Myc signaling.	Paclitaxel	32-35	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	153-158
32275943-7	2020	Inhibiting c-Myc expression by RNAi or c-MyC inhibitor significantly enhance the sensitivity of PTX-resistant CRPC cells to PTX.	Paclitaxel	96-99	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	11-16
19664331-15	2009	CONCLUSION: The radiosensitizing effect of paclitaxel on KB cells may be due to the down-regulated expression of PRC1 and cyclin B2, resulting in inhibition of mitotic spindle formation and cell necrosis.	Paclitaxel	43-53	cyclin B2	Homo sapiens	122-131
32275943-7	2020	Inhibiting c-Myc expression by RNAi or c-MyC inhibitor significantly enhance the sensitivity of PTX-resistant CRPC cells to PTX.	Paclitaxel	96-99	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	39-44
19723066-0	2009	Molecular response of HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, including the new member BCL2L12.	Paclitaxel	72-77	BCL2 like 12	Homo sapiens	155-162
32275943-7	2020	Inhibiting c-Myc expression by RNAi or c-MyC inhibitor significantly enhance the sensitivity of PTX-resistant CRPC cells to PTX.	Paclitaxel	124-127	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	11-16
32275943-7	2020	Inhibiting c-Myc expression by RNAi or c-MyC inhibitor significantly enhance the sensitivity of PTX-resistant CRPC cells to PTX.	Paclitaxel	124-127	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	39-44
32275943-8	2020	Therefore, HMGB1/c-Myc axis is critical in the development of PTX resistance, and targeting HMGB1/c-Myc axis would counteract PTX resistance in mCRPC cells.	Paclitaxel	62-65	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	17-22
32275943-8	2020	Therefore, HMGB1/c-Myc axis is critical in the development of PTX resistance, and targeting HMGB1/c-Myc axis would counteract PTX resistance in mCRPC cells.	Paclitaxel	126-129	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	98-103
32594651-0	2020	Paclitaxel induces apoptosis through the TAK1-JNK activation pathway.	Paclitaxel	0-10	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	41-45
33030848-2	2021	Programmed death ligand 1 (PD-L1) on immune cells (IC) using the VENTANA SP142 assay is linked to improved clinical outcome in atezolizumab plus nab-paclitaxel-treated patients with mTNBC in the IMpassion130 study.	Paclitaxel	149-159	CD274 molecule	Homo sapiens	0-25
33030848-2	2021	Programmed death ligand 1 (PD-L1) on immune cells (IC) using the VENTANA SP142 assay is linked to improved clinical outcome in atezolizumab plus nab-paclitaxel-treated patients with mTNBC in the IMpassion130 study.	Paclitaxel	149-159	CD274 molecule	Homo sapiens	27-32
19723066-7	2009	Our results indicate and support the hypothesis that the apoptosis-related genes BCL2 and BCL2L12 respond similarly to treatment of the human, acute, myelocytic leukemia HL60 cells with the anticancer drugs vincristine and taxol though in a drug-specific and time-dependent manner.	Paclitaxel	223-228	BCL2 like 12	Homo sapiens	90-97
19125251-8	2009	It also demonstrated the cleavage of PARP associated with RAIDD expression in U-2 OS cells, but not however in U-2 OS MR cells after being treated with paclitaxel or doxorubicin.	Paclitaxel	152-162	collagen type XI alpha 2 chain	Homo sapiens	37-41
32727972-0	2020	MicroRNA Let-7c Contributes to Paclitaxel Resistance via Aurora-B in Endometrial Serous Carcinoma.	Paclitaxel	31-41	microRNA let-7c	Homo sapiens	9-15
19578772-9	2009	The quantification of MVD showed the lowest count for EndoTAG-1-treated tumours (11.78+/-2.68 vessels/mm(2)) followed by Gl (15.64+/-6.68 vessels/mm(3)), Pax (18.22+/-9.50 vessels/mm(3)) and CL (40.9+/-32.8 vessels/mm(3)).	Paclitaxel	154-157	mevalonate diphosphate decarboxylase	Rattus norvegicus	22-25
32779438-0	2020	Overexpression of GATA5 Stimulates Paclitaxel to Inhibit Malignant Behaviors of Hepatocellular Carcinoma Cells.	Paclitaxel	35-45	GATA binding protein 5	Homo sapiens	18-23
32779438-1	2020	Objective: Explore the effect of GATA5 expression on Paclitaxel inhibiting growth of hepatocellular carcinoma (HCC) cells.	Paclitaxel	53-63	GATA binding protein 5	Homo sapiens	33-38
32779438-8	2020	Results: Inhibiting expression of GATA5 reduced sensitivity of HLE cells to Paclitaxel, while overexpression of GATA5 increased sensitivity of Bel7402 cells and PLC/PRF/5 cells to Paclitaxel.	Paclitaxel	76-86	GATA binding protein 5	Homo sapiens	34-39
32779438-8	2020	Results: Inhibiting expression of GATA5 reduced sensitivity of HLE cells to Paclitaxel, while overexpression of GATA5 increased sensitivity of Bel7402 cells and PLC/PRF/5 cells to Paclitaxel.	Paclitaxel	180-190	GATA binding protein 5	Homo sapiens	112-117
32779438-9	2020	Overexpression of GATA5 played a role in stimulating Paclitaxel to inhibit growth, colony formation and migration, as well as enhance apoptosis in HCC cells.	Paclitaxel	53-63	GATA binding protein 5	Homo sapiens	18-23
32779438-10	2020	Overexpression of GATA5 also promoted Paclitaxel to inhibit expression of reprogramming genes, such as Nanog, EpCAM, c-Myc and Sox2 in Bel7402 and PLC/PRF/5 cells.	Paclitaxel	38-48	GATA binding protein 5	Homo sapiens	18-23
32779438-10	2020	Overexpression of GATA5 also promoted Paclitaxel to inhibit expression of reprogramming genes, such as Nanog, EpCAM, c-Myc and Sox2 in Bel7402 and PLC/PRF/5 cells.	Paclitaxel	38-48	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	117-122
33813392-8	2021	CONCLUSION: Serum expression levels of IGHG3 and A1AG1 proteins may be useful to recruit an NSCLC subpopulation that can benefit from CAR plus PTX standard therapy.	Paclitaxel	143-146	immunoglobulin heavy constant gamma 3 (G3m marker)	Homo sapiens	39-44
33709519-0	2021	Effect of rs67085638 in long non-coding RNA (CCAT1) on colon cancer chemoresistance to paclitaxel through modulating the microRNA-24-3p and FSCN1.	Paclitaxel	87-97	colon cancer associated transcript 1	Homo sapiens	45-50
33709519-2	2021	Also, CCAT1 could affect chemoresistance of cancer cells to paclitaxel (PTX) via regulating miR-24-3p and FSCN1 expression.	Paclitaxel	60-70	colon cancer associated transcript 1	Homo sapiens	6-11
33709519-2	2021	Also, CCAT1 could affect chemoresistance of cancer cells to paclitaxel (PTX) via regulating miR-24-3p and FSCN1 expression.	Paclitaxel	72-75	colon cancer associated transcript 1	Homo sapiens	6-11
33709519-3	2021	In this study, we aimed to investigate the effect of rs67085638 on the expression of CCAT1/miR-24-3p/FSCN1 and the response of colon cancer to the treatment of PTX.	Paclitaxel	160-163	colon cancer associated transcript 1	Homo sapiens	85-90
33709519-11	2021	The findings of this study demonstrated that the presence of the minor allele of rs67085638 increased the expression of CCAT1 and accordingly enhanced the resistance to PTX.	Paclitaxel	169-172	colon cancer associated transcript 1	Homo sapiens	120-125
33709519-12	2021	Down-regulation of CCAT1 significantly re-stored the sensitivity to PTX of colon cancer cells.	Paclitaxel	68-71	colon cancer associated transcript 1	Homo sapiens	19-24
32779438-12	2020	Overexpression of GATA5 was not only alone but also synergized with Paclitaxel to inhibit expression of CD44 and CD133 in Bel7402 or PLC/PRF/5 cells.	Paclitaxel	68-78	GATA binding protein 5	Homo sapiens	18-23
32779438-13	2020	Conclusion: Overexpression of GATA5 played a role in enhancing Paclitaxel to inhibit the malignant behaviors of HCC cells.	Paclitaxel	63-73	GATA binding protein 5	Homo sapiens	30-35
32779438-15	2020	Targeting GATA5 is an available strategy for applying paclitaxel to therapy of patients with HCC.	Paclitaxel	54-64	GATA binding protein 5	Homo sapiens	10-15
19619321-1	2009	BACKGROUND: We previously described a sub-population of epithelial ovarian cancer (EOC) cells with a functional TLR-4/MyD88/NF-kappaB pathway (Type I EOC cells), which confers the capacity to respond to Paclitaxel, a known TLR-4 ligand, by enhancing NF-kappaB activity and upregulating cytokine secretion - events that are known to promote tumor progression.	Paclitaxel	203-213	MYD88 innate immune signal transduction adaptor	Homo sapiens	118-123
32574155-0	2020	A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer.	Paclitaxel	65-75	CD274 molecule	Homo sapiens	2-7
32574155-13	2020	Moreover, we developed a PD-L1 aptamer-paclitaxel conjugate which showed improved cellular uptake and anti-proliferation efficacy in PD-L1 over-expressed TNBC cells.	Paclitaxel	39-49	CD274 molecule	Homo sapiens	25-30
19584264-5	2009	In addition, depletion of Bcl-xl rescued the apoptotic response to Taxol.	Paclitaxel	67-72	BCL2-like 1	Mus musculus	26-32
32574155-13	2020	Moreover, we developed a PD-L1 aptamer-paclitaxel conjugate which showed improved cellular uptake and anti-proliferation efficacy in PD-L1 over-expressed TNBC cells.	Paclitaxel	39-49	CD274 molecule	Homo sapiens	133-138
33618911-0	2021	Corrigendum to "Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression" [Lung Cancer 88/2 (2015) 131-138].	Paclitaxel	87-97	serine/threonine kinase 11	Homo sapiens	33-37
33618911-0	2021	Corrigendum to "Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression" [Lung Cancer 88/2 (2015) 131-138].	Paclitaxel	87-97	serine/threonine kinase 11	Homo sapiens	41-45
33571724-10	2021	Carboplatin and paclitaxel altered the expression of EPCR and thrombomodulin in OAW42 cells with a modest effect on EA.hy926 cells.	Paclitaxel	16-26	thrombomodulin	Homo sapiens	62-76
32142859-3	2020	Here, we report Runt-related transcription factor 1 (RUNX1) as a novel transcriptional regulator which along with another known regulator Forkhead Box O3 (FOXO3a), drives the dynamic modulation of IGF1R expression during platinum-taxol resistance development in EOC cells.	Paclitaxel	230-235	RUNX family transcription factor 1	Homo sapiens	16-51
19446767-0	2009	Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo.	Paclitaxel	38-48	tyrosine aminotransferase	Mus musculus	25-29
32142859-3	2020	Here, we report Runt-related transcription factor 1 (RUNX1) as a novel transcriptional regulator which along with another known regulator Forkhead Box O3 (FOXO3a), drives the dynamic modulation of IGF1R expression during platinum-taxol resistance development in EOC cells.	Paclitaxel	230-235	RUNX family transcription factor 1	Homo sapiens	53-58
19446767-1	2009	Cell-penetrating peptide (TATp) was attached to the distal tips of polyethyleneglycol (PEG) moieties of polyethyleneglycol-phosphatidylethanolamine (PEG-PE) micelles loaded with paclitaxel (PCT).	Paclitaxel	178-188	tyrosine aminotransferase	Mus musculus	26-30
30666557-4	2020	We also provided an overview of genes, including RSF1, CDK5, and SGOL1, whose disruption can synergize with the currently available drugs such as paclitaxel and sorafenib.	Paclitaxel	146-156	cyclin dependent kinase 5	Homo sapiens	55-59
33747900-0	2021	Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer.	Paclitaxel	42-52	phosphoglycerate kinase 1	Homo sapiens	13-17
33747900-0	2021	Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer.	Paclitaxel	42-52	XIAP associated factor 1	Homo sapiens	79-83
33747900-4	2021	Thus, we concentrated the present research on the role of PGK1 in the sensitivity to paclitaxel treatment and the possible underlying mechanisms in TNBC.	Paclitaxel	85-95	phosphoglycerate kinase 1	Homo sapiens	58-62
30666557-4	2020	We also provided an overview of genes, including RSF1, CDK5, and SGOL1, whose disruption can synergize with the currently available drugs such as paclitaxel and sorafenib.	Paclitaxel	146-156	shugoshin 1	Homo sapiens	65-70
33747900-6	2021	The effect of PGK1 on apoptosis induced by paclitaxel treatment was examined in vitro by flow cytometry cell apoptosis assays.	Paclitaxel	43-53	phosphoglycerate kinase 1	Homo sapiens	14-18
19446767-1	2009	Cell-penetrating peptide (TATp) was attached to the distal tips of polyethyleneglycol (PEG) moieties of polyethyleneglycol-phosphatidylethanolamine (PEG-PE) micelles loaded with paclitaxel (PCT).	Paclitaxel	190-193	tyrosine aminotransferase	Mus musculus	26-30
33747900-7	2021	Western blotting was performed to examine the impact of PGK1 on paclitaxel-induced apoptosis.	Paclitaxel	64-74	phosphoglycerate kinase 1	Homo sapiens	56-60
19446767-3	2009	TATp-modified PCT-loaded micelles were administered intratumorally in mice and the induction of apoptosis in tumor cells was studied after 48h with the Terminal Deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling (TUNEL) assay using free PCT and TATp-free PCT-loaded PEG-PE micelles as controls.	Paclitaxel	14-17	tyrosine aminotransferase	Mus musculus	0-4
33747900-9	2021	Results: We observed that silencing PGK1 sensitized triple-negative breast cancer (TNBC) cell lines to paclitaxel treatment as a result of increased drug-induced apoptosis.	Paclitaxel	103-113	phosphoglycerate kinase 1	Homo sapiens	36-40
33747900-12	2021	Moreover, we found that downregulation of XAF1 reduced paclitaxel-induced apoptosis in PGK1-silenced triple-negative cell lines.	Paclitaxel	55-65	XIAP associated factor 1	Homo sapiens	42-46
19446767-3	2009	TATp-modified PCT-loaded micelles were administered intratumorally in mice and the induction of apoptosis in tumor cells was studied after 48h with the Terminal Deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling (TUNEL) assay using free PCT and TATp-free PCT-loaded PEG-PE micelles as controls.	Paclitaxel	14-17	tyrosine aminotransferase	Mus musculus	253-257
33747900-12	2021	Moreover, we found that downregulation of XAF1 reduced paclitaxel-induced apoptosis in PGK1-silenced triple-negative cell lines.	Paclitaxel	55-65	phosphoglycerate kinase 1	Homo sapiens	87-91
33747900-13	2021	Conclusion: Our results identified PGK1 as a potential biomarker for the treatment of TNBC, and inhibition of PGK1 expression might represent a novel strategy to sensitize TNBC to paclitaxel treatment.	Paclitaxel	180-190	phosphoglycerate kinase 1	Homo sapiens	110-114
31441020-8	2020	Paclitaxel, a microtubule-stabilizing drug, reduces the activation of STMN1 and significantly decreases cell migration and invasion in ACC cell lines and ACC cells from secondary cell culture (all p &lt; 0.0001).	Paclitaxel	0-10	stathmin 1	Homo sapiens	70-75
19446767-3	2009	TATp-modified PCT-loaded micelles were administered intratumorally in mice and the induction of apoptosis in tumor cells was studied after 48h with the Terminal Deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling (TUNEL) assay using free PCT and TATp-free PCT-loaded PEG-PE micelles as controls.	Paclitaxel	245-248	tyrosine aminotransferase	Mus musculus	0-4
19446767-3	2009	TATp-modified PCT-loaded micelles were administered intratumorally in mice and the induction of apoptosis in tumor cells was studied after 48h with the Terminal Deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling (TUNEL) assay using free PCT and TATp-free PCT-loaded PEG-PE micelles as controls.	Paclitaxel	245-248	tyrosine aminotransferase	Mus musculus	0-4
19446767-4	2009	A significant apoptotic cell death was observed in tumors treated with PCT-loaded micelles modified with TATp, while the treatment with free PCT or with non-modified PCT-loaded micelles resulted in much smaller number of TUNEL-positive cells within tumors.	Paclitaxel	71-74	tyrosine aminotransferase	Mus musculus	105-109
32001481-0	2020	FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.	Paclitaxel	40-50	CD274 molecule	Homo sapiens	149-154
19500405-11	2009	However, paclitaxel increased both dCK (10% to 50%) and CDA (75% to 153%) activity (P &lt; 0.05).	Paclitaxel	9-19	cytidine deaminase	Homo sapiens	56-59
19500405-13	2009	The ratio of dCK to CDA mRNA levels corresponded to the combination index (CI) estimated for sequential paclitaxel-gemcitabine.	Paclitaxel	104-114	cytidine deaminase	Homo sapiens	20-23
19500405-14	2009	CONCLUSION: In summary, paclitaxel altered the mRNA levels and specific activity of dCK and CDA and these effects could be dependent on histological subtype.	Paclitaxel	24-34	cytidine deaminase	Homo sapiens	92-95
18941747-0	2009	Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form.	Paclitaxel	47-57	dihydropyrimidinase	Mus musculus	91-94
32435154-0	2020	HE4 overexpression decreases pancreatic cancer Capan-1 cell sensitivity to paclitaxel via cell cycle regulation.	Paclitaxel	75-85	WAP four-disulfide core domain 2	Homo sapiens	0-3
32435154-8	2020	Results: HE4 overexpression not only promoted the proliferation of the Capan-1 pancreatic cells, but also significantly decreased cell sensitivity to paclitaxel.	Paclitaxel	150-160	WAP four-disulfide core domain 2	Homo sapiens	9-12
32435154-9	2020	Results from western blotting showed that paclitaxel inhibited cell proliferation by decreasing the expression of PCNA and increasing the expression of p21.	Paclitaxel	42-52	proliferating cell nuclear antigen	Homo sapiens	114-118
32435154-9	2020	Results from western blotting showed that paclitaxel inhibited cell proliferation by decreasing the expression of PCNA and increasing the expression of p21.	Paclitaxel	42-52	H3 histone pseudogene 16	Homo sapiens	152-155
33326171-0	2021	GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.	Paclitaxel	95-105	glutathione S-transferase pi 1	Homo sapiens	0-5
33717068-8	2021	Importantly, the levels of miR-148b-5p significantly changed the sensitivity of GC cells to several anti-cancer drugs (Doxorubicin, P < 0.05, Paclitaxel, P < 0.01, Docetaxel, P < 0.05).	Paclitaxel	142-152	microRNA 148b	Homo sapiens	27-35
32435154-11	2020	Conclusion: These findings suggest that HE4 could be a potential therapeutic target for the sensitization of pancreatic cancer cells to paclitaxel treatment.	Paclitaxel	136-146	WAP four-disulfide core domain 2	Homo sapiens	40-43
32435154-12	2020	HE4 expression levels may be used to predict the sensitivity of pancreatic cancer patients to paclitaxel.	Paclitaxel	94-104	WAP four-disulfide core domain 2	Homo sapiens	0-3
33602962-9	2021	YBX2-mediated CT45 expression was associated with increased levels of self-renewal capacity and paclitaxel resistance.	Paclitaxel	96-106	Y-box binding protein 2	Homo sapiens	0-4
18941747-1	2009	PURPOSE: This study was conducted to examine the absorption and tissue distribution characteristics of paclitaxel-loaded DHP 107, a Cremophor EL-free, mucoadhesive lipid oral dosage form.	Paclitaxel	103-113	dihydropyrimidinase	Mus musculus	121-124
18941747-9	2009	CONCLUSIONS: Oral administration of DHP 107 provided a substantial systemic absorption of paclitaxel.	Paclitaxel	90-100	dihydropyrimidinase	Mus musculus	36-39
20641397-10	2004	Using HGS-ETR1 labeled with radioactive technetium ((99m)Tc) ((99m)Tc-EC-HGS-ETR1), the investigators determined that the activity of HGS-ETR1 was increased because the pretreatment with paclitaxel upregulated the expression of TRAIL-R1 in Colo205 cell xenograft tumors in nude mice.	Paclitaxel	187-197	TNF receptor superfamily member 10a	Homo sapiens	228-236
33566315-0	2022	Sirtuin2 correlates with lymph node metastasis, increased FIGO stage, worse overall survival, and reduced chemosensitivity to cisplatin and paclitaxel in endometrial cancer.	Paclitaxel	140-150	sirtuin 2	Homo sapiens	0-8
33566315-5	2022	Besides, SIRT2 was modulated by plasmid transfection in EC cells, then their chemosensitivity to cisplatin and paclitaxel was evaluated.	Paclitaxel	111-121	sirtuin 2	Homo sapiens	9-14
32494162-11	2020	Moreover, overexpression of miR-153-5p prominently increased PTX-induced cell cycle arrest at G2/M phase in MDA-MB-231/PTX cells via downregulation of CDK1, cyclin B1 and p-Akt.	Paclitaxel	61-64	cyclin dependent kinase 1	Homo sapiens	151-155
32494162-11	2020	Moreover, overexpression of miR-153-5p prominently increased PTX-induced cell cycle arrest at G2/M phase in MDA-MB-231/PTX cells via downregulation of CDK1, cyclin B1 and p-Akt.	Paclitaxel	61-64	cyclin B1	Homo sapiens	157-166
33566315-10	2022	SIRT2 overexpression decreased chemosensitivity to cisplatin and paclitaxel in Ishikawa cells, while SIRT2 knockdown increased chemosensitivity to cisplatin and paclitaxel in KLE cells (all P < 0.05).	Paclitaxel	65-75	sirtuin 2	Homo sapiens	0-5
33566315-11	2022	CONCLUSION: SIRT2 correlates with lymph node metastasis, increased FIGO stage, worse OS, and reduced chemosensitivity to cisplatin and paclitaxel in EC.	Paclitaxel	135-145	sirtuin 2	Homo sapiens	12-17
32775453-5	2020	Inhibiting the expression of miR-520h could enhance the sensitivity to paclitaxel in paclitaxel-resistant MCF-7/Taxol cells.	Paclitaxel	85-95	microRNA 520h	Homo sapiens	29-37
20641403-10	2004	observed that the anti-tumor activity of HGS-ETR1 could be enhanced in mice bearing colorectal cancer cell xenograft tumors with pretreatment with paclitaxel (7).	Paclitaxel	147-157	CUGBP, Elav-like family member 3	Mus musculus	45-49
32775453-7	2020	OTUD3 plays a necessary role in the paclitaxel resistance effect of miR-520h, and cotreatment with a miR-520h inhibitor and OTUD3 overexpression significantly enhanced MCF-7 cell sensitivity to paclitaxel.	Paclitaxel	36-46	OTU deubiquitinase 3	Homo sapiens	0-5
32775453-7	2020	OTUD3 plays a necessary role in the paclitaxel resistance effect of miR-520h, and cotreatment with a miR-520h inhibitor and OTUD3 overexpression significantly enhanced MCF-7 cell sensitivity to paclitaxel.	Paclitaxel	36-46	microRNA 520h	Homo sapiens	68-76
32775453-7	2020	OTUD3 plays a necessary role in the paclitaxel resistance effect of miR-520h, and cotreatment with a miR-520h inhibitor and OTUD3 overexpression significantly enhanced MCF-7 cell sensitivity to paclitaxel.	Paclitaxel	36-46	microRNA 520h	Homo sapiens	101-109
32775453-7	2020	OTUD3 plays a necessary role in the paclitaxel resistance effect of miR-520h, and cotreatment with a miR-520h inhibitor and OTUD3 overexpression significantly enhanced MCF-7 cell sensitivity to paclitaxel.	Paclitaxel	36-46	OTU deubiquitinase 3	Homo sapiens	124-129
32775453-7	2020	OTUD3 plays a necessary role in the paclitaxel resistance effect of miR-520h, and cotreatment with a miR-520h inhibitor and OTUD3 overexpression significantly enhanced MCF-7 cell sensitivity to paclitaxel.	Paclitaxel	194-204	OTU deubiquitinase 3	Homo sapiens	0-5
32775453-7	2020	OTUD3 plays a necessary role in the paclitaxel resistance effect of miR-520h, and cotreatment with a miR-520h inhibitor and OTUD3 overexpression significantly enhanced MCF-7 cell sensitivity to paclitaxel.	Paclitaxel	194-204	microRNA 520h	Homo sapiens	68-76
20641403-11	2004	Using HGS-ETR1 labeled with radioactive indium ((111)In) ((111)In-EC-HGS-ETR1), the investigators determined that the activity of HGS-ETR1 was increased because the pretreatment with paclitaxel upregulated the expression of TRAIL-R1 in Colo205 cell xenograft tumors in nude mice.	Paclitaxel	183-193	CUGBP Elav-like family member 3	Homo sapiens	10-14
32775453-7	2020	OTUD3 plays a necessary role in the paclitaxel resistance effect of miR-520h, and cotreatment with a miR-520h inhibitor and OTUD3 overexpression significantly enhanced MCF-7 cell sensitivity to paclitaxel.	Paclitaxel	194-204	microRNA 520h	Homo sapiens	101-109
32775453-7	2020	OTUD3 plays a necessary role in the paclitaxel resistance effect of miR-520h, and cotreatment with a miR-520h inhibitor and OTUD3 overexpression significantly enhanced MCF-7 cell sensitivity to paclitaxel.	Paclitaxel	194-204	OTU deubiquitinase 3	Homo sapiens	124-129
32775453-10	2020	Therefore, our findings showed that miR-520h targeted the OTUD3-PTEN axis to drive paclitaxel resistance, and this miR might be an important potential target for breast cancer treatment.	Paclitaxel	83-93	microRNA 520h	Homo sapiens	36-44
20641403-11	2004	Using HGS-ETR1 labeled with radioactive indium ((111)In) ((111)In-EC-HGS-ETR1), the investigators determined that the activity of HGS-ETR1 was increased because the pretreatment with paclitaxel upregulated the expression of TRAIL-R1 in Colo205 cell xenograft tumors in nude mice.	Paclitaxel	183-193	CUGBP Elav-like family member 3	Homo sapiens	73-77
32775453-10	2020	Therefore, our findings showed that miR-520h targeted the OTUD3-PTEN axis to drive paclitaxel resistance, and this miR might be an important potential target for breast cancer treatment.	Paclitaxel	83-93	OTU deubiquitinase 3	Homo sapiens	58-63
32775453-10	2020	Therefore, our findings showed that miR-520h targeted the OTUD3-PTEN axis to drive paclitaxel resistance, and this miR might be an important potential target for breast cancer treatment.	Paclitaxel	83-93	phosphatase and tensin homolog	Homo sapiens	64-68
33542225-6	2021	The PKG inhibitor KT5823 played synergistic anti-tumor effects with cisplatin and paclitaxel to gastric cancer cells in in vitro cellular and in vivo tumor-bearing mouse models.	Paclitaxel	82-92	protein kinase cGMP-dependent 1	Homo sapiens	4-7
20641403-11	2004	Using HGS-ETR1 labeled with radioactive indium ((111)In) ((111)In-EC-HGS-ETR1), the investigators determined that the activity of HGS-ETR1 was increased because the pretreatment with paclitaxel upregulated the expression of TRAIL-R1 in Colo205 cell xenograft tumors in nude mice.	Paclitaxel	183-193	CUGBP Elav-like family member 3	Homo sapiens	73-77
32154964-7	2020	We found that PTX/Fol-c1 -beta-CyD killed not only FRalpha-expressing cells but also FRalpha-negative cells.	Paclitaxel	14-17	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	85-92
20641403-11	2004	Using HGS-ETR1 labeled with radioactive indium ((111)In) ((111)In-EC-HGS-ETR1), the investigators determined that the activity of HGS-ETR1 was increased because the pretreatment with paclitaxel upregulated the expression of TRAIL-R1 in Colo205 cell xenograft tumors in nude mice.	Paclitaxel	183-193	TNF receptor superfamily member 10a	Homo sapiens	224-232
32154964-8	2020	In the FRalpha-negative A2780 cells, knockdown of proton-coupled folate transporter (PCFT) significantly decreased the cytotoxicity of PTX/Fol-c1 -beta-CyD, whereas knockdown of FRalpha did not.	Paclitaxel	135-138	solute carrier family 46 member 1	Homo sapiens	50-83
20641892-10	2004	observed that the anti-tumor activity of HGS-ETR1 could be enhanced in mice bearing colorectal cancer cell xenograft tumors with pretreatment with paclitaxel (7).	Paclitaxel	147-157	CUGBP, Elav-like family member 3	Mus musculus	45-49
32154964-8	2020	In the FRalpha-negative A2780 cells, knockdown of proton-coupled folate transporter (PCFT) significantly decreased the cytotoxicity of PTX/Fol-c1 -beta-CyD, whereas knockdown of FRalpha did not.	Paclitaxel	135-138	solute carrier family 46 member 1	Homo sapiens	85-89
32154964-9	2020	By contrast, knockdown of either FRalpha or proton-coupled folate transporter (PCFT) decreased the cytotoxicity of PTX/Fol-c1 -beta-CyD in FRalpha-expressing SK-OV-3 cells.	Paclitaxel	115-118	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	33-40
33203600-8	2021	MTT and annexin V/propidium iodide dual staining results demonstrated that co-loading of CDDP and PTX into PSPm had a synergistic effect in killing lung cancer cells and exerted superior antitumor activity over the combination of single drug-loaded PSPm or the combination of free-CDDP and free-PTX at equivalent drug amounts.	Paclitaxel	98-101	annexin A5	Homo sapiens	8-17
19458229-10	2009	The phr microtubule defect can be phenocopied by taxol, while microtubule destabilization in vitro using nocodazole prevents loop formation.	Paclitaxel	49-54	pheromonal response	Mus musculus	4-7
33584295-7	2020	Both IP and IV PTX produced mechanical hypersensitivity for at least three weeks; however, only IV PTX decreased PR breakpoints, and this decrease was not alleviated by morphine.	Paclitaxel	99-102	transmembrane protein 37	Rattus norvegicus	113-115
32154964-9	2020	By contrast, knockdown of either FRalpha or proton-coupled folate transporter (PCFT) decreased the cytotoxicity of PTX/Fol-c1 -beta-CyD in FRalpha-expressing SK-OV-3 cells.	Paclitaxel	115-118	solute carrier family 46 member 1	Homo sapiens	44-77
32154964-9	2020	By contrast, knockdown of either FRalpha or proton-coupled folate transporter (PCFT) decreased the cytotoxicity of PTX/Fol-c1 -beta-CyD in FRalpha-expressing SK-OV-3 cells.	Paclitaxel	115-118	solute carrier family 46 member 1	Homo sapiens	79-83
32154964-10	2020	Furthermore, the cytotoxicity of PTX/Fol-c1 -beta-CyD in A2780 cells was increased at acidic pH, and this increase was suppressed by PCFT inhibitor.	Paclitaxel	33-36	solute carrier family 46 member 1	Homo sapiens	133-137
31855318-2	2020	Here, we constructed NSCLC cells with paclitaxel resistance (A549-PR) and showed that A549-PR exhibited a remarkably stronger stemness than the parental A549 cells, which is evident by the increase of spheroid formation capacity, stemness marker expression, and ALDH1 activity.	Paclitaxel	38-48	aldehyde dehydrogenase 1 family member A1	Homo sapiens	262-267
19285047-8	2009	Collectively, the combination of 4-HPR and PTX diminished the survival factors (e.g., rTERT, PCNA, and Bcl-2) to make glioblastoma cells highly prone to apoptosis with activation of cysteine proteases (e.g., calpain, cathepsins, caspase-8, caspase-3).	Paclitaxel	43-46	caspase 3	Rattus norvegicus	240-249
32252517-4	2020	Scaffolds composed of fast, medium, and slow degrading Ace-DEX resulted in 14.1%, 2.9%, and 1.3% paclitaxel released per day.	Paclitaxel	97-107	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	55-58
32252517-8	2020	Additionally, the acid-sensitive Ace-DEX scaffolds were shown to respond to the lower pH conditions associated with GBM tumors, releasing more paclitaxel in vivo when a tumor was present in contrast to nonacid sensitive PLA scaffolds.	Paclitaxel	143-153	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	33-36
32368142-9	2020	Targeting PIK3CG potentiated CLBC cells growth inhibition in 2D and 3D cultures by PTX.	Paclitaxel	83-86	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Homo sapiens	10-16
32368142-10	2020	Inhibition of PIK3CG activation could enhance CLBC cells apoptosis and migration suppression induced by PTX.	Paclitaxel	104-107	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Homo sapiens	14-20
33504822-4	2021	We previously reported that NCS1 expression was reduced following paclitaxel-induced peripheral neuropathy.	Paclitaxel	66-76	neuronal calcium sensor 1	Mus musculus	28-32
33481008-0	2021	circGFRA1 affects the sensitivity of triple negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.	Paclitaxel	76-86	toll like receptor 4	Homo sapiens	106-110
33481008-3	2021	This study aimed to clarify that circGFRA1 affects the sensitivity of TNBC cells to paclitaxel (PTX) by the miR-361-5p/TLR4 pathway.	Paclitaxel	84-94	toll like receptor 4	Homo sapiens	119-123
33481008-3	2021	This study aimed to clarify that circGFRA1 affects the sensitivity of TNBC cells to paclitaxel (PTX) by the miR-361-5p/TLR4 pathway.	Paclitaxel	96-99	toll like receptor 4	Homo sapiens	119-123
18716777-1	2009	PURPOSE: The aim of the RiTa trial is to establish a feasible combination of bendamustine and paclitaxel in a weekly schedule in anthracycline pre-treated metastatic breast cancer patients.	Paclitaxel	94-104	RBPJ interacting and tubulin associated 1	Homo sapiens	24-28
33436648-8	2021	Subsequent cDNA array analysis confirmed multiple PI3K-AKT pathway members such as AKT2, PIK3R3, CDKN1A, CCND2 and FGF2 to be upregulated in PTX-resistant cells.	Paclitaxel	141-144	AKT serine/threonine kinase 2	Homo sapiens	83-87
32018185-9	2020	An imbalance in favor of cases was noted only in few genes including PRX, which was previously highlighted as a candidate CIPN gene in patients receiving paclitaxel.	Paclitaxel	154-164	periaxin	Homo sapiens	69-72
19221504-5	2009	Inhibition of Aurora A using MLN8054, a selective small-molecule inhibitor of Aurora A, in paclitaxel- or nocodazole-treated cells induces cells to become multinucleated.	Paclitaxel	91-101	aurora kinase A	Homo sapiens	14-22
32096451-0	2020	Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.	Paclitaxel	0-10	COPI coat complex subunit alpha	Homo sapiens	150-154
32975708-2	2021	Our preclinical study suggested that TEKT4 germline variations in breast cancer are associated with paclitaxel resistance and increase vinorelbine sensitivity.	Paclitaxel	100-110	tektin 4	Homo sapiens	37-42
19221504-5	2009	Inhibition of Aurora A using MLN8054, a selective small-molecule inhibitor of Aurora A, in paclitaxel- or nocodazole-treated cells induces cells to become multinucleated.	Paclitaxel	91-101	aurora kinase A	Homo sapiens	78-86
32218821-0	2020	The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy.	Paclitaxel	152-162	secreted protein acidic and cysteine rich	Homo sapiens	39-83
33049093-7	2021	Unfortunately, esomeprazole could only result in a slight decrease in the expression of P-gp in A549/Taxol cells.	Paclitaxel	101-106	phosphoglycolate phosphatase	Homo sapiens	88-92
19221504-9	2009	This finding was corroborated by demonstrating that Aurora A depletion using RNA interference in paclitaxel-treated cells also induces multinucleation.	Paclitaxel	97-107	aurora kinase A	Homo sapiens	52-60
18832053-3	2009	Using 2D-PAGE followed by Nano-LC-ESI-Q-ToF analysis, we found that MIAs such as vincristine (Oncovin) or paclitaxel (Taxol) and KSP inhibitors such as S-tritil-l-cysteine induce the phosphorylation of the nuclear protein p54(nrb) in HeLa cells.	Paclitaxel	106-116	interferon induced protein with tetratricopeptide repeats 2	Homo sapiens	222-225
32609449-0	2020	Lichenoid inflammation of DSAP lesions following treatment with durvalumab, olaparib and paclitaxel: A potential diagnostic pitfall mimicking lichenoid drug eruptions associated with PDL-1 inhibitors.	Paclitaxel	89-99	CD274 molecule	Homo sapiens	183-188
32020211-0	2020	Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer.	Paclitaxel	65-75	G protein signaling modulator 2	Homo sapiens	18-23
19239702-0	2009	Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells.	Paclitaxel	14-24	cyclin dependent kinase 2	Homo sapiens	49-53
32020211-4	2020	Immunohistochemical analysis consistently revealed a significant association of GPSM2 protein levels with paclitaxel sensitivity in breast cancer patients.	Paclitaxel	106-116	G protein signaling modulator 2	Homo sapiens	80-85
32020211-5	2020	Knockdown of GPSM2 reduced the sensitivity of breast cancer cells to paclitaxel via regulation of the cell cycle.	Paclitaxel	69-79	G protein signaling modulator 2	Homo sapiens	13-18
32020211-7	2020	These results suggest that GPSM2 plays an important role in breast cancer resistance, supporting its utility as a potential target for improving drug susceptibility in patients as well as a marker of paclitaxel sensitivity.	Paclitaxel	200-210	G protein signaling modulator 2	Homo sapiens	27-32
19239702-4	2009	We hypothesized that cyclin-dependent kinase (CDK) 1 activity and CDK2 activity in cancer cells, which reflect the activation state of the spindle assembly checkpoint and the growth state, respectively, predict sensitivity to paclitaxel.	Paclitaxel	226-236	cyclin dependent kinase 2	Homo sapiens	66-70
32110040-2	2020	Here we observed whether the ABCC2 (G1249A) polymorphism impacts the transport abilities of MRP2-dependent paclitaxel, docetaxel, and doxorubicin in recombinant LLC-PK1 cell lines.	Paclitaxel	107-117	ATP binding cassette subfamily C member 2	Sus scrofa	29-34
32110040-2	2020	Here we observed whether the ABCC2 (G1249A) polymorphism impacts the transport abilities of MRP2-dependent paclitaxel, docetaxel, and doxorubicin in recombinant LLC-PK1 cell lines.	Paclitaxel	107-117	ATP binding cassette subfamily C member 2	Sus scrofa	92-96
32110040-4	2020	Results: The recombinant ABCC2 1249A variant cell line showed higher IC50 values for paclitaxel and doxorubicin than ABCC2 1249G wild-type cell system (p<0.01).	Paclitaxel	85-95	ATP binding cassette subfamily C member 2	Sus scrofa	25-30
32110040-5	2020	Intracellular accumulations of paclitaxel and doxorubicin in cells transfected with ABCC2 1249A variant allele were significantly decreased compared to cells transfected with ABCC2 1249G wild-type allele (p<0.01).	Paclitaxel	31-41	ATP binding cassette subfamily C member 2	Sus scrofa	84-89
19239702-10	2009	Baseline CDK2 specific activity was higher in tumors that were sensitive to paclitaxel than in tumors that were resistant to paclitaxel.	Paclitaxel	76-86	cyclin dependent kinase 2	Homo sapiens	9-13
32110040-6	2020	The efflux ratios of paclitaxel and doxorubicin across ABCC2 1249A cell line were significantly increased compared with ABCC2 1249G cell system (p<0.01).	Paclitaxel	21-31	ATP binding cassette subfamily C member 2	Sus scrofa	55-60
32110040-6	2020	The efflux ratios of paclitaxel and doxorubicin across ABCC2 1249A cell line were significantly increased compared with ABCC2 1249G cell system (p<0.01).	Paclitaxel	21-31	ATP binding cassette subfamily C member 2	Sus scrofa	120-125
32110040-8	2020	Conclusion: Our results indicate that ABCC2 (G1249A) polymorphism affects the transport activities of MRP2-dependent paclitaxel and doxorubicin, resulting in greater efflux of these anticancer drugs.	Paclitaxel	117-127	ATP binding cassette subfamily C member 2	Sus scrofa	38-43
32110040-8	2020	Conclusion: Our results indicate that ABCC2 (G1249A) polymorphism affects the transport activities of MRP2-dependent paclitaxel and doxorubicin, resulting in greater efflux of these anticancer drugs.	Paclitaxel	117-127	ATP binding cassette subfamily C member 2	Sus scrofa	102-106
19239702-10	2009	Baseline CDK2 specific activity was higher in tumors that were sensitive to paclitaxel than in tumors that were resistant to paclitaxel.	Paclitaxel	125-135	cyclin dependent kinase 2	Homo sapiens	9-13
19239702-11	2009	CONCLUSIONS: The change in CDK1 specific activity of xenograft tumors after paclitaxel treatment and the CDK2 specific activity before paclitaxel treatment are both associated with the drug sensitivity in vivo.	Paclitaxel	135-145	cyclin dependent kinase 2	Homo sapiens	105-109
31286496-0	2020	Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.	Paclitaxel	97-107	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	165-170
19112990-3	2008	The use of drug-eluting stents--paclitaxel (PES) or sirolimus (SES)--dramatically reduces the risk of restenosis as compared to bare-metal stents; nevertheless, the rate of restenosis remains almost double in diabetic patients compared to that observed in non-diabetic subjects.	Paclitaxel	32-42	pescadillo ribosomal biogenesis factor 1	Homo sapiens	44-47
31826492-0	2020	Anisamide-functionalized pH-responsive amphiphilic chitosan-based paclitaxel micelles for sigma-1 receptor targeted prostate cancer treatment.	Paclitaxel	66-76	sigma non-opioid intracellular receptor 1	Mus musculus	90-106
31826492-4	2020	We demonstrated that PTX-loaded a-OMPC micelles (PTX-aM) enhanced the cellular internalization via the affinity between anisamide and sigma-1 receptor, rapidly released drug in endo/lysosomes and elevated the cytotoxicity against PC-3 cells.	Paclitaxel	21-24	sigma non-opioid intracellular receptor 1	Mus musculus	134-150
18796247-6	2008	Docetaxel induced the decrease in the activity of protein phosphatase 1 (PP1) and increase in the activity of PP2 subgroups, while paclitaxel induced the increase in the activity of PP1 and decrease in the activity of PP2 subgroups.	Paclitaxel	131-141	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	218-221
31826492-4	2020	We demonstrated that PTX-loaded a-OMPC micelles (PTX-aM) enhanced the cellular internalization via the affinity between anisamide and sigma-1 receptor, rapidly released drug in endo/lysosomes and elevated the cytotoxicity against PC-3 cells.	Paclitaxel	49-52	sigma non-opioid intracellular receptor 1	Mus musculus	134-150
18687998-8	2008	Northern analysis shows that PRP-4 is overexpressed in several paclitaxel-resistant cell lines and confirms that PRP-4 expression could be significantly repressed by PRP-4 lentiviral short hairpin RNA.	Paclitaxel	63-73	pre-mRNA processing factor 4	Homo sapiens	29-34
31655296-8	2020	A subset of patients with c-Myc expression showed significantly improved PFS with alisertib/paclitaxel.	Paclitaxel	92-102	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	26-31
18687998-9	2008	Both clonogenic and MTT assays confirm that transcriptional repression of PRP-4 could reverse paclitaxel resistance 5-10-fold in SKOV-3(TR).	Paclitaxel	94-104	pre-mRNA processing factor 4	Homo sapiens	74-79
18687998-10	2008	Finally, overexpression of PRP-4 in drug-sensitive cells could induce a modest level of drug resistance to paclitaxel, doxorubicin, and vincristine.	Paclitaxel	107-117	pre-mRNA processing factor 4	Homo sapiens	27-32
32376564-1	2020	OBJECTIVE: To investigate the effect of overexpression of leukemia inhibitory factor (LIF) on cisplatin and paclitaxel resistance of endometrial cancer cells in vitro.	Paclitaxel	108-118	LIF interleukin 6 family cytokine	Homo sapiens	58-84
32376564-1	2020	OBJECTIVE: To investigate the effect of overexpression of leukemia inhibitory factor (LIF) on cisplatin and paclitaxel resistance of endometrial cancer cells in vitro.	Paclitaxel	108-118	LIF interleukin 6 family cytokine	Homo sapiens	86-89
18612434-4	2008	Furthermore, LC-CD133(+), unlike LC-CD133(-), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy.	Paclitaxel	210-220	prominin 1	Homo sapiens	16-21
32376564-5	2020	The effect of STAT3 silencing on apoptosis of the LIF-overexpressing cells induced by cisplatin or paclitaxel was investigated.	Paclitaxel	99-109	LIF interleukin 6 family cytokine	Homo sapiens	50-53
32376564-7	2020	LIF overexpression significantly attenuated cisplatin-or paclitaxel-induced apoptosis of the endometrial cancer cells (P < 0.05) and markedly increased mitochondrial membrane potential of the cells (P < 0.05).	Paclitaxel	57-67	LIF interleukin 6 family cytokine	Homo sapiens	0-3
32376564-10	2020	CONCLUSIONS: s Overexpression of LIF can enhance cisplatin and paclitaxel resistance to endometrial cancer cells in vitro.	Paclitaxel	63-73	LIF interleukin 6 family cytokine	Homo sapiens	33-36
31628941-10	2020	Combining CUR and 1,25(OH)2D3 to PAX caused a downregulation in both MDR-1 and ALDH-1 gene expression in MCF-7 besides a decrease in their protein levels.	Paclitaxel	33-36	aldehyde dehydrogenase 1 family member A1	Homo sapiens	79-85
31628941-14	2020	Overall, the present study showed that PAX, as a monotherapy, demonstrated acquired resistance possibly by increasing MDR-1 expression and enriching CSCs population, as evidenced by increased ALDH-1.	Paclitaxel	39-42	aldehyde dehydrogenase 1 family member A1	Homo sapiens	192-198
19080518-2	2008	METHODS: The up-regulated genes of JAK2, HSP, NADH and the down-regulated gene of COP9, which were revealed by micro-array from our previous study were examined by RT-PCR and real-time-PCR in 33 cases of ovarian cancer who previously received taxol-based chemotherapy (group 1), and 21 cases of ovarian cancer who never received chemotherapy before operation (group 2).	Paclitaxel	243-248	Janus kinase 2	Homo sapiens	35-39
31911964-11	2019	The most positive reaction to p53 was observed in MSG30 or 60 + PTX groups compared to other groups.	Paclitaxel	64-67	transformation related protein 53, pseudogene	Mus musculus	30-33
31934276-6	2019	Immunohistochemical staining showed that paclitaxel combined with BEZ235 reduced the numbers of Ki-67- and GPC3-positive HepG2 cells in tumor tissues.	Paclitaxel	41-51	glypican 3	Homo sapiens	107-111
18583944-4	2008	Taxol-treated oocytes exhibited a number of cytoplasmic asters, in which both Plk1 and p-MEK1/2 were present, indicating that they might be complexed to participate in the acentrosomal spindle formation at the MTOCs during oocyte meiosis.	Paclitaxel	0-5	mitogen-activated protein kinase kinase 1	Mus musculus	89-95
31867270-10	2019	In order to test this, we generated a paclitaxel-resistant TNBC cell line which demonstrated an elevated level of eIF4A along with increased levels of cancer stemness markers (ALDH activity and CD44), pluripotency transcription factors (SOX2, OCT4, and NANOG) and drug transporters (ABCB1, ABCG2, and ABCC1).	Paclitaxel	38-48	aldehyde dehydrogenase 1 family member A1	Homo sapiens	176-180
31867270-10	2019	In order to test this, we generated a paclitaxel-resistant TNBC cell line which demonstrated an elevated level of eIF4A along with increased levels of cancer stemness markers (ALDH activity and CD44), pluripotency transcription factors (SOX2, OCT4, and NANOG) and drug transporters (ABCB1, ABCG2, and ABCC1).	Paclitaxel	38-48	POU class 5 homeobox 1	Homo sapiens	243-247
31586636-0	2019	Pharmacological interventions targeting Wnt/beta-catenin signaling pathway attenuate paclitaxel-induced peripheral neuropathy.	Paclitaxel	85-95	catenin beta 1	Rattus norvegicus	44-56
31604667-12	2019	An ARID1A-deficient case that was resistant to multiple cytotoxic drugs, including paclitaxel plus carboplatin in the adjuvant and etoposide plus irinotecan in the first-line treatment, exhibited a dramatic response to gemcitabine in the second-line treatment.	Paclitaxel	83-93	AT-rich interaction domain 1A	Homo sapiens	3-9
17701176-8	2008	Pilot efficacy studies in mice showed variability but demonstrated a significant inhibition of tumor growth following the systemic administration of a single dose of PTX-loaded anti-VEGFR2 conjugated PLLA microspheres as compared to non-antibody-conjugated PTX-loaded microspheres.	Paclitaxel	166-169	kinase insert domain protein receptor	Mus musculus	182-188
31875434-5	2019	The 50% inhibitory concentrations (IC50) of paclitaxel in the control and PKD1 knockdown cell lines were detected by CCK-8.	Paclitaxel	44-54	polycystin 1, transient receptor potential channel interacting	Homo sapiens	74-78
31875434-9	2019	Additionally, inhibiting PKD1 expression could downregulate the expression of P-gp, thereby decreasing both the IC50 and resistance index of paclitaxel.	Paclitaxel	141-151	polycystin 1, transient receptor potential channel interacting	Homo sapiens	25-29
18317222-0	2008	Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.	Paclitaxel	0-5	tubulin beta 3 class III	Homo sapiens	118-140
31875434-9	2019	Additionally, inhibiting PKD1 expression could downregulate the expression of P-gp, thereby decreasing both the IC50 and resistance index of paclitaxel.	Paclitaxel	141-151	phosphoglycolate phosphatase	Homo sapiens	78-82
32026322-3	2019	In this study, we investigated whether TLR4 expression is affected upon the treatment of breast and ovarian cancer cells with common chemotherapeutics (paclitaxel, cisplatin, doxorubicin, and arsenic trioxide) and if TLR4 inhibition using its specific inhibitor TAK-242 could enhance cancer cells" response to the drugs.	Paclitaxel	152-162	toll like receptor 4	Homo sapiens	39-43
18317222-3	2008	Previous reports suggested that class III beta-tubulin induced taxol resistance in association with a reduced effect on microtubule dynamic instability.	Paclitaxel	63-68	tubulin beta 3 class III	Homo sapiens	32-54
32026322-7	2019	It was also identified that co-treatment of paclitaxel and TAK-242 not only led to enhanced G2/M arrest and apoptosis but also satisfactorily decreased the expression of TLR4 and different interleukins in these cells.	Paclitaxel	44-54	toll like receptor 4	Homo sapiens	170-174
18317222-12	2008	Taxol-resistant SKOV cells showed high-level class III beta-tubulin expression compared with wild-type SKOV cells.	Paclitaxel	0-5	tubulin beta 3 class III	Homo sapiens	45-67
31775332-5	2019	Mechanistically, TLR4 (Toll-Like Receptor 4) and downstream signaling MyD88 (Myeloid Differentiation Primary Response 88) and TRPV1 (Transient Receptor Potential Vallinoid 1) were upregulated in dorsal root ganglion (DRGs) of paclitaxel-treated rats, whereas EA reduced their overexpression.	Paclitaxel	226-236	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	77-120
18317222-13	2008	Taxol sensitivity differing among histological subtypes in EOC is associated with the expression of class III beta-tubulin.	Paclitaxel	0-5	tubulin beta 3 class III	Homo sapiens	100-122
18068334-0	2008	Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2.	Paclitaxel	0-5	uncoupling protein 2	Homo sapiens	133-153
31545492-0	2019	Gambogic acid increases the sensitivity to paclitaxel in drug-resistant triple-negative breast cancer via the SHH signaling pathway.	Paclitaxel	43-53	sonic hedgehog signaling molecule	Homo sapiens	110-113
18068334-5	2008	Taxol resulted in the activation of apoptosis signal regulated kinase (ASK)1, c-jun NH(2)-terminal kinase (JNK), p38(MAPK) and extracellular-regulated kinase (ERK) together with the downregulation of uncoupling protein 2 (UCP2).	Paclitaxel	0-5	uncoupling protein 2	Homo sapiens	200-220
31545492-6	2019	The present results indicated that GA significantly inhibited the viability and enhanced the rate of apoptosis in paclitaxel-resistant MDA-MB-231 cells via activating the SHH signaling pathway.	Paclitaxel	114-124	sonic hedgehog signaling molecule	Homo sapiens	171-174
18068334-5	2008	Taxol resulted in the activation of apoptosis signal regulated kinase (ASK)1, c-jun NH(2)-terminal kinase (JNK), p38(MAPK) and extracellular-regulated kinase (ERK) together with the downregulation of uncoupling protein 2 (UCP2).	Paclitaxel	0-5	uncoupling protein 2	Homo sapiens	222-226
31545492-7	2019	In vivo experiments confirmed that GA treatment enhanced the sensitivity of MDA-MB-231 cells to paclitaxel via the SHH signaling pathway.	Paclitaxel	96-106	sonic hedgehog signaling molecule	Homo sapiens	115-118
31545492-8	2019	In conclusion, the combination of GA with paclitaxel may increase the antitumor effects on paclitaxel-resistant TNBC via downregulating the SHH signaling pathway.	Paclitaxel	42-52	sonic hedgehog signaling molecule	Homo sapiens	140-143
18068334-8	2008	Pretreatment of melanoma cells with the JNK inhibitor (SP600125) or the p38 inhibitor (SB203580) blocked taxol-induced UCP2 downregulation, ROS generation and apoptosis, whereas the ERK inhibitor (PD98059) had no such effect.	Paclitaxel	105-110	uncoupling protein 2	Homo sapiens	119-123
31545492-8	2019	In conclusion, the combination of GA with paclitaxel may increase the antitumor effects on paclitaxel-resistant TNBC via downregulating the SHH signaling pathway.	Paclitaxel	91-101	sonic hedgehog signaling molecule	Homo sapiens	140-143
33225598-5	2021	We found decreased YTHDC1 and increased RBM15 expressions were associated with ovarian cancer cell metastases and HNRNPC was a predictor of paclitaxel resistance.	Paclitaxel	140-150	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	114-120
31720085-0	2019	The resistance of esophageal cancer cells to paclitaxel can be reduced by the knockdown of long noncoding RNA DDX11-AS1 through TAF1/TOP2A inhibition.	Paclitaxel	45-55	DNA topoisomerase II alpha	Homo sapiens	133-138
18669163-4	2008	Recently, it was observed that overexpression of Aurora-A renders cells resistant to cisplatin (CDDP)-, etoposide-, and paclitaxel-induced apoptosis.	Paclitaxel	120-130	aurora kinase A	Homo sapiens	49-57
31720085-8	2019	DDX11-AS1 could promote TOP2A transcription via TAF1, and the knockdown of TOP2A or DDX11-AS1 could increase the sensitivity of EC cells to PTX.	Paclitaxel	140-143	DNA topoisomerase II alpha	Homo sapiens	75-80
31720085-11	2019	In conclusion, our findings suggest that DDX11-AS1 knockdown results in reduced resistance of EC cells to PTX by inhibiting TOP2A transcription via TAF1.	Paclitaxel	106-109	DNA topoisomerase II alpha	Homo sapiens	124-129
31660072-0	2019	CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1/P50.	Paclitaxel	28-38	capping actin protein, gelsolin like	Homo sapiens	0-4
31660072-7	2019	Results: Increased expression of actin-binding protein CapG strongly correlated with the resistance to paclitaxel chemotherapy and decreased probability to achieve pathological complete response in breast cancer patients.	Paclitaxel	103-113	capping actin protein, gelsolin like	Homo sapiens	55-59
31660072-8	2019	Overexpressing CapG significantly enhanced paclitaxel resistance in breast cancer cells and xenograft tumors.	Paclitaxel	43-53	capping actin protein, gelsolin like	Homo sapiens	15-19
31660072-13	2019	Consistently, inhibiting p300/CBP substantially decreased CapG-dependent upregulation of PIK3R1/P50 and subsequent PI3K/Akt activation, resulting in increased sensitivity to paclitaxel treatment in breast cancer cells.	Paclitaxel	174-184	capping actin protein, gelsolin like	Homo sapiens	58-62
31660072-14	2019	Conclusion: High CapG levels may predict poor paclitaxel response in breast cancer patients.	Paclitaxel	46-56	capping actin protein, gelsolin like	Homo sapiens	17-21
31506466-5	2019	Importantly, these inhibitory effects on glucose metabolism were enhanced by palbociclib/paclitaxel sequential combination; the superior efficacy of such combination was ascribed to the ability of paclitaxel to inhibit palbociclib-mediated induction of AKT and to further down-regulate the Rb/E2F/c-myc signaling.	Paclitaxel	197-207	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	297-302
32694383-4	2021	In primary rat DRG culture with paclitaxel, an increase of pERK and pp38 was observed at two hours and this was accompanied by an increase in expression and release of CCL2.	Paclitaxel	32-42	C-C motif chemokine ligand 2	Rattus norvegicus	168-172
18974847-8	2008	Intratumoral injection of AMF/PGI-paclitaxel induced significantly higher tumor regression compared to free paclitaxel, even in B16-F1 cells, known to be resistant to taxol treatment.	Paclitaxel	34-44	glucose-6-phosphate isomerase 1	Mus musculus	30-33
31484456-6	2019	On 4T1 cells, siRNAs against AKT and ERBB2 plus paclitaxel or docetaxel resulted in the largest increase in anti-cancer effects compared to CA/paclitaxel or CA/docetaxel.	Paclitaxel	143-153	erb-b2 receptor tyrosine kinase 2	Mus musculus	37-42
18974847-8	2008	Intratumoral injection of AMF/PGI-paclitaxel induced significantly higher tumor regression compared to free paclitaxel, even in B16-F1 cells, known to be resistant to taxol treatment.	Paclitaxel	167-172	glucose-6-phosphate isomerase 1	Mus musculus	30-33
18974847-10	2008	Free AMF/PGI exhibited a pro-survival role, reducing the cytotoxic effect of both AMF/PGI-paclitaxel and free paclitaxel suggesting that AMF/PGI-paclitaxel targets a pathway associated with resistance to chemotherapeutic agents.	Paclitaxel	90-100	glucose-6-phosphate isomerase	Homo sapiens	9-12
18974847-10	2008	Free AMF/PGI exhibited a pro-survival role, reducing the cytotoxic effect of both AMF/PGI-paclitaxel and free paclitaxel suggesting that AMF/PGI-paclitaxel targets a pathway associated with resistance to chemotherapeutic agents.	Paclitaxel	90-100	glucose-6-phosphate isomerase	Homo sapiens	86-89
18974847-10	2008	Free AMF/PGI exhibited a pro-survival role, reducing the cytotoxic effect of both AMF/PGI-paclitaxel and free paclitaxel suggesting that AMF/PGI-paclitaxel targets a pathway associated with resistance to chemotherapeutic agents.	Paclitaxel	90-100	glucose-6-phosphate isomerase	Homo sapiens	86-89
31786875-0	2019	Targeted antitumor activity of Ginsenoside (Rg1) in paclitaxel-resistant human nasopharyngeal cancer cells are mediated through activation of autophagic cell death, cell apoptosis, endogenous ROS production, S phase cell cycle arrest and inhibition of m-TOR/PI3K/AKT signalling pathway.	Paclitaxel	52-62	protein phosphatase 1 regulatory subunit 3A	Homo sapiens	44-47
31786875-2	2019	The main purpose of this study was to examine the anticancer effects of the naturally occurring compound Ginsenoside (Rg1) against paclitaxel-resistant human nasopharyngeal cancer cells along with evaluation of its effects on cell autophagy, apoptosis, ROS production, cell cycle progression and m-TOR/PI3K/AKT signalling pathway.	Paclitaxel	131-141	protein phosphatase 1 regulatory subunit 3A	Homo sapiens	118-121
33396481-5	2020	Soluble thrombomodulin (TMalpha), known to degrade HMGB1 in a thrombin-dependent manner, prevents CIPN in rodents treated with paclitaxel, oxaliplatin, or vincristine and in patients with colorectal cancer undergoing oxaliplatin-based chemotherapy.	Paclitaxel	127-137	thrombomodulin	Homo sapiens	8-22
17900261-1	2007	Paclitaxel (PTX), one of the key drugs used to treat ovarian cancer, activates the Raf-mitogen-activated protein kinase kinase (MEK) and phosphatidylinositol 3"-kinase (PI3K) pathways, both considered to be proliferation and cell-survival pathways.	Paclitaxel	0-10	midkine	Mus musculus	83-126
33473256-9	2020	Moreover, combination treatment of erlotinib (ERL) or paclitaxel (PAC) with miR-708-5p enhances COX-2 and mPGES-1 protein suppression.	Paclitaxel	54-64	prostaglandin E synthase	Mus musculus	106-113
33473256-9	2020	Moreover, combination treatment of erlotinib (ERL) or paclitaxel (PAC) with miR-708-5p enhances COX-2 and mPGES-1 protein suppression.	Paclitaxel	66-69	prostaglandin E synthase	Mus musculus	106-113
33364839-0	2020	Erratum: Integrative Gene Expression Profiling Reveals That Dysregulated Triple microRNAs Confer Paclitaxel Resistance in Non-Small Cell Lung Cancer via Cotargeting MAPT [Corrigendum].	Paclitaxel	97-107	microtubule associated protein tau	Homo sapiens	165-169
31211507-2	2019	Here, we showed that paclitaxel, the major chemotherapy drug for breast cancer, induced ISR and phosphorylated ser51 residue of EIF2S1 by EIF2AK3 and EIF2AK4.	Paclitaxel	21-31	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	138-145
31273338-0	2019	The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway.	Paclitaxel	76-86	activating transcription factor 3	Homo sapiens	14-18
31273338-2	2019	In this study, lncRNA array of CNE-1 and HNE-2 paclitaxel-resistant cells and their parental strains revealed that the paclitaxel-resistant strains had significantly lower MRVI1-AS1 (murine retrovirus integration site 1 homolog antisense RNA 1) expression than the parental strains, and that MRVI1-AS1 overexpression in vitro and in vivo increased paclitaxel chemosensitivity.	Paclitaxel	119-129	inositol 1,4,5-triphosphate receptor associated 1	Mus musculus	292-297
31273338-2	2019	In this study, lncRNA array of CNE-1 and HNE-2 paclitaxel-resistant cells and their parental strains revealed that the paclitaxel-resistant strains had significantly lower MRVI1-AS1 (murine retrovirus integration site 1 homolog antisense RNA 1) expression than the parental strains, and that MRVI1-AS1 overexpression in vitro and in vivo increased paclitaxel chemosensitivity.	Paclitaxel	119-129	inositol 1,4,5-triphosphate receptor associated 1	Mus musculus	292-297
31273338-3	2019	Further, MRVI1-AS1 upregulated ATF3 (activating transcription factor 3) by simultaneously inhibiting miR-513a-5p (microRNA-513a-5p) and miR-27b-3p expression levels to increase NPC paclitaxel chemosensitivity.	Paclitaxel	181-191	inositol 1,4,5-triphosphate receptor associated 1	Mus musculus	9-14
31273338-3	2019	Further, MRVI1-AS1 upregulated ATF3 (activating transcription factor 3) by simultaneously inhibiting miR-513a-5p (microRNA-513a-5p) and miR-27b-3p expression levels to increase NPC paclitaxel chemosensitivity.	Paclitaxel	181-191	activating transcription factor 3	Homo sapiens	31-35
31273338-3	2019	Further, MRVI1-AS1 upregulated ATF3 (activating transcription factor 3) by simultaneously inhibiting miR-513a-5p (microRNA-513a-5p) and miR-27b-3p expression levels to increase NPC paclitaxel chemosensitivity.	Paclitaxel	181-191	activating transcription factor 3	Homo sapiens	37-70
31273338-7	2019	Overall, the results indicate that the MRVI1-AS1/ATF3 signaling pathway can increase NPC paclitaxel chemosensitivity by modulating the Hippo-TAZ signaling pathway.	Paclitaxel	89-99	inositol 1,4,5-triphosphate receptor associated 1	Mus musculus	39-44
31273338-7	2019	Overall, the results indicate that the MRVI1-AS1/ATF3 signaling pathway can increase NPC paclitaxel chemosensitivity by modulating the Hippo-TAZ signaling pathway.	Paclitaxel	89-99	activating transcription factor 3	Homo sapiens	49-53
33323915-18	2020	Furthermore, paclitaxel suppressed the palmitate-induced fibrosis molecules, fibronectin and TGF-ss1.	Paclitaxel	13-23	fibronectin 1	Mus musculus	77-88
33363381-0	2020	UBE2N Regulates Paclitaxel Sensitivity of Ovarian Cancer via Fos/P53 Axis.	Paclitaxel	16-26	ubiquitin conjugating enzyme E2 N	Homo sapiens	0-5
33363381-2	2020	In this work, we found that ubiquitin-conjugating enzyme E2 N (UBE2N) is downregulated in paclitaxel-resistant ovarian cancer cells.	Paclitaxel	90-100	ubiquitin conjugating enzyme E2 N	Homo sapiens	28-61
33363381-2	2020	In this work, we found that ubiquitin-conjugating enzyme E2 N (UBE2N) is downregulated in paclitaxel-resistant ovarian cancer cells.	Paclitaxel	90-100	ubiquitin conjugating enzyme E2 N	Homo sapiens	63-68
33363381-3	2020	It suggests UBE2N to be critical in the regulation of paclitaxel sensitivity in ovarian cancer.	Paclitaxel	54-64	ubiquitin conjugating enzyme E2 N	Homo sapiens	12-17
17900261-1	2007	Paclitaxel (PTX), one of the key drugs used to treat ovarian cancer, activates the Raf-mitogen-activated protein kinase kinase (MEK) and phosphatidylinositol 3"-kinase (PI3K) pathways, both considered to be proliferation and cell-survival pathways.	Paclitaxel	0-10	midkine	Mus musculus	128-131
31337279-0	2019	Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer.	Paclitaxel	27-37	phosphatase and tensin homolog	Homo sapiens	75-79
17900261-1	2007	Paclitaxel (PTX), one of the key drugs used to treat ovarian cancer, activates the Raf-mitogen-activated protein kinase kinase (MEK) and phosphatidylinositol 3"-kinase (PI3K) pathways, both considered to be proliferation and cell-survival pathways.	Paclitaxel	12-15	midkine	Mus musculus	83-126
17900261-1	2007	Paclitaxel (PTX), one of the key drugs used to treat ovarian cancer, activates the Raf-mitogen-activated protein kinase kinase (MEK) and phosphatidylinositol 3"-kinase (PI3K) pathways, both considered to be proliferation and cell-survival pathways.	Paclitaxel	12-15	midkine	Mus musculus	128-131
31413745-0	2019	SphK1 functions downstream of IGF-1 to modulate IGF-1-induced EMT, migration and paclitaxel resistance of A549 cells: A preliminary in vitro study.	Paclitaxel	81-91	sphingosine kinase 1	Homo sapiens	0-5
33363381-10	2020	Results: Overexpressed UBE2N enhanced the paclitaxel sensitivity of ovarian cancer cells in vitro and in vivo.	Paclitaxel	42-52	ubiquitin conjugating enzyme E2 N	Homo sapiens	23-28
17900261-2	2007	The present study aimed to clarify whether and how MEK and PI3K inhibitors affect sensitivity to PTX in ovarian cancer cells.	Paclitaxel	97-100	midkine	Mus musculus	51-54
33363381-13	2020	Only Fos proto-oncogene, AP-1 transcription factor subunit (Fos), was overexpressed upon decreasing UBE2N levels, indicating a poor outcome for patients treated with paclitaxel.	Paclitaxel	166-176	ubiquitin conjugating enzyme E2 N	Homo sapiens	100-105
31413745-6	2019	The results showed that, IGF-1 treatment of A549 cells stimulated the expression of SphK1, the activation of ERK and AKT, the cell migration, and the expression of EMT hallmark proteins, while inhibition of SphK1 by its specific inhibitor SKI-II suppressed all the above changes and increased the sensitivity of A549 cells to paclitaxel.	Paclitaxel	326-336	sphingosine kinase 1	Homo sapiens	207-212
31413745-7	2019	Our data demonstrate that SphK1 acts as a downstream effector of IGF-1 and plays a critical role in IGF-1-induced EMT, cell migration and paclitaxel resistance of A549 cells, suggesting that SphK1 might be a potential therapeutic target for NSCLC.	Paclitaxel	138-148	sphingosine kinase 1	Homo sapiens	26-31
31413745-7	2019	Our data demonstrate that SphK1 acts as a downstream effector of IGF-1 and plays a critical role in IGF-1-induced EMT, cell migration and paclitaxel resistance of A549 cells, suggesting that SphK1 might be a potential therapeutic target for NSCLC.	Paclitaxel	138-148	sphingosine kinase 1	Homo sapiens	191-196
17900261-3	2007	We treated five ovarian cancer cell lines using PTX combined with MEK inhibitor (PD98059 [PD]) and PI3K inhibitor (LY294002 [LY]), then assessed cell viability, apoptosis, and expression of phosphorylated (p) MEK and pAkt.	Paclitaxel	48-51	midkine	Mus musculus	209-212
17714470-0	2007	Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia.	Paclitaxel	50-60	tubulin beta 3 class III	Homo sapiens	0-22
31308851-0	2019	MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2.	Paclitaxel	83-93	eukaryotic translation initiation factor 4A2	Homo sapiens	112-118
31140859-0	2019	EZH2 Confers Sensitivity of Breast Cancer Cells to Taxol by Attenuating p21 Expression Epigenetically.	Paclitaxel	51-56	H3 histone pseudogene 16	Homo sapiens	72-75
31140859-6	2019	Meanwhile, p21, the inhibitor of cell cycle entry, interference upregulated, while overexpression downregulated apoptosis induced by taxol.	Paclitaxel	133-138	H3 histone pseudogene 16	Homo sapiens	11-14
31140859-8	2019	Collectively, EZH2 attenuates chemoresistance of breast cancer cells to taxol by dampening p21 epigenetically.	Paclitaxel	72-77	H3 histone pseudogene 16	Homo sapiens	91-94
33291081-8	2020	MCF7 cells overexpressing CCDC170 were more sensitive to paclitaxel.	Paclitaxel	57-67	coiled-coil domain containing 170	Homo sapiens	26-33
33259730-0	2020	miR-146a Enhances the Sensitivity of Breast Cancer Cells to Paclitaxel by Downregulating IRAK1.	Paclitaxel	60-70	microRNA 146a	Homo sapiens	0-8
33259730-1	2020	Objective: To investigate the effect of miR-146a on the sensitivity of breast cancer cells to paclitaxel (PTX).	Paclitaxel	94-104	microRNA 146a	Homo sapiens	40-48
33259730-1	2020	Objective: To investigate the effect of miR-146a on the sensitivity of breast cancer cells to paclitaxel (PTX).	Paclitaxel	106-109	microRNA 146a	Homo sapiens	40-48
33259730-13	2020	Compared with MCF-7/PTX cells, the expression of miR-146a gene in MCF-7 cells was significantly increased, while the expression of IRAK1 gene was significantly reduced (p < 0.05).	Paclitaxel	20-23	microRNA 146a	Homo sapiens	49-57
33259730-17	2020	Conclusion: miR-146a can enhance the sensitivity of breast cancer cells to PTX; the mechanism may be related to the downregulation of IRAK1.	Paclitaxel	75-78	microRNA 146a	Homo sapiens	12-20
17714470-1	2007	AIMS: Class III beta-tubulin (TUBB3) reduces microtubule stability and confers resistance to microtubule-stabilizing taxanes, including paclitaxel and docetaxel.	Paclitaxel	136-146	tubulin beta 3 class III	Homo sapiens	6-28
17714470-1	2007	AIMS: Class III beta-tubulin (TUBB3) reduces microtubule stability and confers resistance to microtubule-stabilizing taxanes, including paclitaxel and docetaxel.	Paclitaxel	136-146	tubulin beta 3 class III	Homo sapiens	30-35
31646806-0	2019	Comparisons of efficacy and safety between docetaxel + cisplatin and paclitaxel + cisplatin and their effects on serum HE4, CA125 and ROMA indicators in patients with ovarian carcinoma.	Paclitaxel	69-79	WAP four-disulfide core domain 2	Homo sapiens	119-122
17640356-15	2007	CONCLUSION: TP in peripheral mononuclear blood cells was hardly regulated under therapy with paclitaxel.	Paclitaxel	93-103	thymidine phosphorylase	Homo sapiens	12-14
31002261-0	2019	Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel.	Paclitaxel	87-97	Fc fragment of IgG receptor and transporter	Mus musculus	0-20
31002261-0	2019	Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel.	Paclitaxel	87-97	Fc fragment of IgG receptor and transporter	Mus musculus	22-26
32920426-2	2020	In this article, a quinazolinone derivative (36b) as a NOD1/2 dual antagonist was identified that significantly sensitizes B16 tumor-bearing mice to paclitaxel treatment by inhibiting both nuclear factor kappaB (NF-kappaB) and mitogen-activated protein kinase inflammatory signaling that mediated by NOD1/2.	Paclitaxel	149-159	nucleotide-binding oligomerization domain containing 1	Mus musculus	55-61
32920426-2	2020	In this article, a quinazolinone derivative (36b) as a NOD1/2 dual antagonist was identified that significantly sensitizes B16 tumor-bearing mice to paclitaxel treatment by inhibiting both nuclear factor kappaB (NF-kappaB) and mitogen-activated protein kinase inflammatory signaling that mediated by NOD1/2.	Paclitaxel	149-159	nucleotide-binding oligomerization domain containing 1	Mus musculus	300-306
32998017-0	2020	Paclitaxel alleviates the sepsis-induced acute kidney injury via lnc-MALAT1/miR-370-3p/HMGB1 axis.	Paclitaxel	0-10	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	69-75
32998017-5	2020	KEY FINDINGS: Lnc-MALAT1 was increased both in the serum of sepsis patients and cells injured by LPS, which could inhibit the cell proliferation, promote the cell apoptosis and increase the expression of TNF-alpha, IL-6 and IL-1beta caused by paclitaxel.	Paclitaxel	243-253	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	18-24
31002261-9	2019	In contrast, the tissue penetration of pac-T in these organs of FcRn-KO mice was similar to that of wild-type mice.	Paclitaxel	39-44	Fc fragment of IgG receptor and transporter	Mus musculus	64-68
31002261-11	2019	In comparison, the difference of excretion of pac-T in feces between FcRn-KO mice and wild-type mice was smaller than that of nab-P.	Paclitaxel	46-51	Fc fragment of IgG receptor and transporter	Mus musculus	69-73
17558302-0	2007	CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population.	Paclitaxel	71-81	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
30540465-3	2019	Here, potential of mean force (PMF) calculations are used to identify the transport-competent minimum free energy binding locations of five compounds, Hoechst 33342, Rhodamine 123, paclitaxel, tariquidar, and verapamil to P-gp.	Paclitaxel	181-191	phosphoglycolate phosphatase	Homo sapiens	222-226
32998017-9	2020	Besides, paclitaxel restrained the expression of HMGB1 via regulating lnc-MALAT1/miR-370-3p axis.	Paclitaxel	9-19	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	74-80
32998017-10	2020	SIGNIFICANCE: Paclitaxel could protect against LPS-induced AKI via the regulation of lnc-MALAT1/miR-370-3p/HMGB1 axis and the expression of TNF-alpha, IL-6 and IL-1beta, revealing that paclitaxel might act as a therapy drug in reducing sepsis-associated AKI.	Paclitaxel	14-24	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	89-95
17558302-1	2007	OBJECTIVE: CYP2C8 is known to metabolize various drugs including an anticancer drug paclitaxel.	Paclitaxel	84-94	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	11-17
17558302-10	2007	CONCLUSION: CYP2C8*IG group haplotypes were associated with increased area under concentration-time curve of C3"-p-hydroxy-paclitaxel and area under concentration-time curve ratio of C3"-p-hydroxy-paclitaxel/paclitaxel.	Paclitaxel	123-133	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	12-18
17285590-5	2007	Furthermore, the expression (at both mRNA and protein level) of the different isotypes have been analyzed demonstrating an association between low cell sensitivity to paclitaxel and Class III beta-tubulin expression increasing.	Paclitaxel	167-177	tubulin beta 3 class III	Homo sapiens	182-204
33097020-2	2020	Standard-of-care paclitaxel (PTX), combined with birinapant (BRP), a bivalent mimetic of the apoptosis antagonist SMAC (second mitochondria-derived activator of caspases), exerts synergistic killing of PANC-1 human pancreatic adenocarcinoma cells.	Paclitaxel	17-27	diablo IAP-binding mitochondrial protein	Homo sapiens	114-118
33097020-2	2020	Standard-of-care paclitaxel (PTX), combined with birinapant (BRP), a bivalent mimetic of the apoptosis antagonist SMAC (second mitochondria-derived activator of caspases), exerts synergistic killing of PANC-1 human pancreatic adenocarcinoma cells.	Paclitaxel	17-27	diablo IAP-binding mitochondrial protein	Homo sapiens	120-169
33097020-2	2020	Standard-of-care paclitaxel (PTX), combined with birinapant (BRP), a bivalent mimetic of the apoptosis antagonist SMAC (second mitochondria-derived activator of caspases), exerts synergistic killing of PANC-1 human pancreatic adenocarcinoma cells.	Paclitaxel	29-32	diablo IAP-binding mitochondrial protein	Homo sapiens	120-169
33070779-0	2020	NFATc2-dependent epigenetic upregulation of CXCL14 is involved in the development of neuropathic pain induced by paclitaxel.	Paclitaxel	113-123	nuclear factor of activated T-cells 2	Rattus norvegicus	0-6
33070779-5	2020	RESULTS: We found that paclitaxel treatment increased the nuclear expression of NFATc2 in the spinal dorsal horn, and knockdown of NFATc2 with NFATc2 siRNA significantly attenuated the mechanical allodynia induced by paclitaxel.	Paclitaxel	23-33	nuclear factor of activated T-cells 2	Rattus norvegicus	80-86
33070779-5	2020	RESULTS: We found that paclitaxel treatment increased the nuclear expression of NFATc2 in the spinal dorsal horn, and knockdown of NFATc2 with NFATc2 siRNA significantly attenuated the mechanical allodynia induced by paclitaxel.	Paclitaxel	217-227	nuclear factor of activated T-cells 2	Rattus norvegicus	80-86
33070779-5	2020	RESULTS: We found that paclitaxel treatment increased the nuclear expression of NFATc2 in the spinal dorsal horn, and knockdown of NFATc2 with NFATc2 siRNA significantly attenuated the mechanical allodynia induced by paclitaxel.	Paclitaxel	217-227	nuclear factor of activated T-cells 2	Rattus norvegicus	131-137
33070779-5	2020	RESULTS: We found that paclitaxel treatment increased the nuclear expression of NFATc2 in the spinal dorsal horn, and knockdown of NFATc2 with NFATc2 siRNA significantly attenuated the mechanical allodynia induced by paclitaxel.	Paclitaxel	217-227	nuclear factor of activated T-cells 2	Rattus norvegicus	131-137
31179271-0	2019	Discovery of Coumarin as Microtubule Affinity-Regulating Kinase 4 Inhibitor That Sensitize Hepatocellular Carcinoma to Paclitaxel.	Paclitaxel	119-129	microtubule affinity regulating kinase 4	Homo sapiens	25-65
31179271-4	2019	We recently have disclosed that microtubule affinity-regulating kinase 4 (MARK4) increases the microtubule dynamics and confers paclitaxel resistance in HCC, suggesting MARK4 as an attractive target to overcome paclitaxel resistance.	Paclitaxel	128-138	microtubule affinity regulating kinase 4	Homo sapiens	32-72
31179271-4	2019	We recently have disclosed that microtubule affinity-regulating kinase 4 (MARK4) increases the microtubule dynamics and confers paclitaxel resistance in HCC, suggesting MARK4 as an attractive target to overcome paclitaxel resistance.	Paclitaxel	128-138	microtubule affinity regulating kinase 4	Homo sapiens	74-79
31179271-4	2019	We recently have disclosed that microtubule affinity-regulating kinase 4 (MARK4) increases the microtubule dynamics and confers paclitaxel resistance in HCC, suggesting MARK4 as an attractive target to overcome paclitaxel resistance.	Paclitaxel	128-138	microtubule affinity regulating kinase 4	Homo sapiens	169-174
31179271-4	2019	We recently have disclosed that microtubule affinity-regulating kinase 4 (MARK4) increases the microtubule dynamics and confers paclitaxel resistance in HCC, suggesting MARK4 as an attractive target to overcome paclitaxel resistance.	Paclitaxel	211-221	microtubule affinity regulating kinase 4	Homo sapiens	32-72
31179271-4	2019	We recently have disclosed that microtubule affinity-regulating kinase 4 (MARK4) increases the microtubule dynamics and confers paclitaxel resistance in HCC, suggesting MARK4 as an attractive target to overcome paclitaxel resistance.	Paclitaxel	211-221	microtubule affinity regulating kinase 4	Homo sapiens	74-79
31179271-4	2019	We recently have disclosed that microtubule affinity-regulating kinase 4 (MARK4) increases the microtubule dynamics and confers paclitaxel resistance in HCC, suggesting MARK4 as an attractive target to overcome paclitaxel resistance.	Paclitaxel	211-221	microtubule affinity regulating kinase 4	Homo sapiens	169-174
30673970-10	2019	Response to paclitaxel was restricted to tumors with low PC3 and PC4 (log-rank p = 0.0021).	Paclitaxel	12-22	proprotein convertase subtilisin/kexin type 1	Homo sapiens	57-60
30942454-3	2019	To investigate whether miRNA-302a (miR-302a) is involved in mediating chemo-resistance to paclitaxel in prostate cancer, a series of in vitro analyses were performed in paclitaxel-resistant prostate cancer PC-3PR cells and non-resistant prostate cancer PC-3 cells.	Paclitaxel	90-100	microRNA 302a	Homo sapiens	35-43
30942454-5	2019	Notably, ectopic expression of miR-302a also increased resistance to paclitaxel in wild-type PC-3 cells.	Paclitaxel	69-79	microRNA 302a	Homo sapiens	31-39
30942454-6	2019	By contrast, silencing of miR-302a in PC-3PR cells sensitized the cells to paclitaxel.	Paclitaxel	75-85	microRNA 302a	Homo sapiens	26-34
30942454-7	2019	Gene and protein expression analyses suggested that the miR-302a target gene breast cancer resistance protein (BCRP) may mediate chemo-resistance to paclitaxel in PC-3PR cells.	Paclitaxel	149-159	microRNA 302a	Homo sapiens	56-64
30714183-5	2019	METHODS: PC3 and DU145 cells were treated with different concentrations of Zn and/or PTX.	Paclitaxel	85-88	proprotein convertase subtilisin/kexin type 1	Homo sapiens	9-12
33070779-6	2020	Further binding site analysis utilizing ChIP-seq assay combining with gene expression profile revealed a shift of NFATc2 binding site closer to TTS of target genes in dorsal horn after paclitaxel treatment.	Paclitaxel	185-195	nuclear factor of activated T-cells 2	Rattus norvegicus	114-120
33070779-9	2020	CONCLUSION: These results suggested that enhanced interaction between p300 and NFATc2 mediated the epigenetic upregulation of CXCL14 in the spinal dorsal horn, which contributed to the chemotherapeutic paclitaxel-induced chronic pain.	Paclitaxel	202-212	nuclear factor of activated T-cells 2	Rattus norvegicus	79-85
17285590-6	2007	Antisense oligonucleotide (ODN) experiments confirmed that the inhibition of Class III beta-tubulin could at least partially increase paclitaxel-chemosensitivity.	Paclitaxel	134-144	tubulin beta 3 class III	Homo sapiens	77-99
31006192-0	2019	[Role and mechanism of the regulation of nuclear factor-kappaB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].	Paclitaxel	145-155	heparin-binding EGF-like growth factor	Mus musculus	66-124
17285590-9	2007	Our study suggests that Class III beta-tubulin tumor expression could be considered a predictive biomarker of paclitaxel-clinical resistance for breast cancer patients.	Paclitaxel	110-120	tubulin beta 3 class III	Homo sapiens	24-46
31006192-1	2019	Objective: To investigate the role and mechanism of the regulation of nuclear factor-kappaB (NF-kappaB) by heparin binding-epidermal growth factor-like growth factor (HB-EGF) in paclitaxel resistance of ovarian cancer in vitro and in vivo.	Paclitaxel	178-188	heparin-binding EGF-like growth factor	Mus musculus	107-165
17471023-0	2007	Daxx shortens mitotic arrest caused by paclitaxel.	Paclitaxel	39-49	death domain associated protein	Homo sapiens	0-4
31006192-1	2019	Objective: To investigate the role and mechanism of the regulation of nuclear factor-kappaB (NF-kappaB) by heparin binding-epidermal growth factor-like growth factor (HB-EGF) in paclitaxel resistance of ovarian cancer in vitro and in vivo.	Paclitaxel	178-188	heparin-binding EGF-like growth factor	Mus musculus	167-173
31006192-10	2019	The expression level of HB-EGF, EGFR and NF-kappaB protein between A2780 and A2780/Taxol groups in vivo and in vitro were higher than these in A2780+CRM197 and A2780/Taxol+CRM197 group, while the expression level of HB-EGF, EGFR and NF-kappaB protein in A2780 group were lower than those in A2780/Taxol groups in vivo and in vitro (P&lt;0.05).	Paclitaxel	83-88	heparin-binding EGF-like growth factor	Mus musculus	24-30
31006192-10	2019	The expression level of HB-EGF, EGFR and NF-kappaB protein between A2780 and A2780/Taxol groups in vivo and in vitro were higher than these in A2780+CRM197 and A2780/Taxol+CRM197 group, while the expression level of HB-EGF, EGFR and NF-kappaB protein in A2780 group were lower than those in A2780/Taxol groups in vivo and in vitro (P&lt;0.05).	Paclitaxel	83-88	heparin-binding EGF-like growth factor	Mus musculus	216-222
31006192-10	2019	The expression level of HB-EGF, EGFR and NF-kappaB protein between A2780 and A2780/Taxol groups in vivo and in vitro were higher than these in A2780+CRM197 and A2780/Taxol+CRM197 group, while the expression level of HB-EGF, EGFR and NF-kappaB protein in A2780 group were lower than those in A2780/Taxol groups in vivo and in vitro (P&lt;0.05).	Paclitaxel	83-88	epidermal growth factor receptor	Mus musculus	224-228
31006192-14	2019	HB-EGF may induce the paclitaxel resistance of ovarian cancer by the regulation of EGFR/NF-kappaB/P-gp pathway.	Paclitaxel	22-32	heparin-binding EGF-like growth factor	Mus musculus	0-6
31006192-14	2019	HB-EGF may induce the paclitaxel resistance of ovarian cancer by the regulation of EGFR/NF-kappaB/P-gp pathway.	Paclitaxel	22-32	epidermal growth factor receptor	Mus musculus	83-87
33043814-10	2020	Furthermore, the expression of STAT1, PD-1, and PD-L1 was lower in paclitaxel-resistant cells than sensitive cells.	Paclitaxel	67-77	CD274 molecule	Homo sapiens	48-53
32564116-0	2020	ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers.	Paclitaxel	97-107	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	10-15
32564116-11	2020	CONCLUSIONS: ABCB1 c.1236C>T and ERCC1 c.118C>T might serve as potential biomarkers for the risk of moderate-to-severe toxicities to carboplatin/paclitaxel chemotherapy of gynecological cancers.	Paclitaxel	145-155	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	33-38
32847971-0	2020	Dysregulation of EAAT2 and VGLUT2 spinal glutamate transports via histone deacetylase 2 (HDAC2) contributes to paclitaxel-induced painful neuropathy.	Paclitaxel	111-121	solute carrier family 17 member 6	Rattus norvegicus	27-33
17471023-3	2007	By screening a cohort of breast cancer cell lines, we observed a correlation between level of protein Daxx and response to paclitaxel.	Paclitaxel	123-133	death domain associated protein	Homo sapiens	102-106
17471023-4	2007	Cells lines expressing increased level of Daxx displayed a robust paclitaxel response with nearly all cells undergoing micronucleation, while cell lines with low amount of Daxx showed a decrease in micronucleation, and accumulation in mitosis.	Paclitaxel	66-76	death domain associated protein	Homo sapiens	42-46
30959904-6	2019	PTX/LAP-loaded micelles showed greater toxicity compared to the binary mixture of PTX and LAP after 48 h and 72 h. Only free PTX alone induced P-gp activity.	Paclitaxel	0-3	phosphoglycolate phosphatase	Homo sapiens	143-147
32591993-7	2020	Induction of PD-L1 expression was also present when paclitaxel-cisplatin chemotherapeutic treatment was combined with HDAC inhibitor treatment.	Paclitaxel	52-62	CD274 molecule	Homo sapiens	13-18
17471023-6	2007	Human cell lines expressing anti-Daxx siRNA as well as Daxx-/- mouse fibroblasts showed similar cellular response to paclitaxel.	Paclitaxel	117-127	death domain associated protein	Homo sapiens	33-37
17471023-6	2007	Human cell lines expressing anti-Daxx siRNA as well as Daxx-/- mouse fibroblasts showed similar cellular response to paclitaxel.	Paclitaxel	117-127	death domain associated protein	Homo sapiens	55-59
17471023-7	2007	Importantly, absence or depletion of Daxx resulted in cell survival after paclitaxel treatment, as measured by colony formation assay.	Paclitaxel	74-84	death domain associated protein	Homo sapiens	37-41
32707243-7	2020	The obtained results indicated that the synthesized magnetic MIL-53 NMOFs loaded- PA-g-CS/PU/TMZ-PTX nanofibers (shell flow rate: 0.8 mLh-1) could be used as a targeted delivery of anticancer agents with maximum apoptosis of 49.6% of U-87 MG glioblastoma cells under AMF during chemotherapy/hyperthermia combination therapy.	Paclitaxel	97-100	procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1	Mus musculus	134-139
31737223-4	2019	In this study, we developed paclitaxel amino lipid (PAL) derived nanoparticles (NPs) to incorporate both chemotherapy drugs and P53 mRNA.	Paclitaxel	28-38	transformation related protein 53, pseudogene	Mus musculus	128-131
31737223-5	2019	The PAL P53 mRNA NPs showed superior properties compared to Abraxane  and Lipusu  used in the clinic including high paclitaxel loading capacity (24 wt.%, calculated by paclitaxel in PAL), PAL encapsulation efficiency (94.7% +- 6.8%) and mRNA encapsulation efficiency (88.7% +- 0.7%).	Paclitaxel	116-126	transformation related protein 53, pseudogene	Mus musculus	8-11
17471023-8	2007	We conclude that Daxx may be an important predictive factor in cellular response to paclitaxel, which emphasizes a critical but unknown function of this protein in mitotic progression, which, when disabled, leads to survival advantages upon paclitaxel treatment.	Paclitaxel	84-94	death domain associated protein	Homo sapiens	17-21
31737223-5	2019	The PAL P53 mRNA NPs showed superior properties compared to Abraxane  and Lipusu  used in the clinic including high paclitaxel loading capacity (24 wt.%, calculated by paclitaxel in PAL), PAL encapsulation efficiency (94.7% +- 6.8%) and mRNA encapsulation efficiency (88.7% +- 0.7%).	Paclitaxel	168-178	transformation related protein 53, pseudogene	Mus musculus	8-11
17471023-8	2007	We conclude that Daxx may be an important predictive factor in cellular response to paclitaxel, which emphasizes a critical but unknown function of this protein in mitotic progression, which, when disabled, leads to survival advantages upon paclitaxel treatment.	Paclitaxel	241-251	death domain associated protein	Homo sapiens	17-21
30899303-0	2019	Mir-26b inhibits growth and resistance to paclitaxel chemotherapy by silencing the CDC6 gene in gastric cancer.	Paclitaxel	42-52	microRNA 26b	Homo sapiens	0-7
30899303-2	2019	The aim of this study was to investigate whether miR-26b is involved in the proliferation and resistance to paclitaxel chemotherapy in gastric cancer cells.	Paclitaxel	108-118	microRNA 26b	Homo sapiens	49-56
17342753-1	2007	BACKGROUND: IRL-1620, a potent endothelin B receptor agonist, enhanced the efficacy of paclitaxel in a breast tumor model, but its effect in prostate cancer is not known.	Paclitaxel	87-97	endothelin receptor type B	Rattus norvegicus	31-52
30899303-14	2019	Conclusions: miR-26b inhibits growth and resistance to paclitaxel chemotherapy by silencing the CDC6 gene in the gastric cancer cell line SGC7901.	Paclitaxel	55-65	microRNA 26b	Homo sapiens	13-20
30260001-6	2019	Melatonin and taxol markedly reduced DJ-1 and ID-1 and increased KLF17 messenger RNA and protein expression levels.	Paclitaxel	14-19	Parkinsonism associated deglycase	Homo sapiens	37-50
33061425-0	2020	Paclitaxel Suppresses Hepatocellular Carcinoma Tumorigenesis Through Regulating Circ-BIRC6/miR-877-5p/YWHAZ Axis.	Paclitaxel	0-10	baculoviral IAP repeat containing 6	Homo sapiens	80-90
32603693-6	2020	Using Western blot analysis and immunohistochemistry, we found that paclitaxel increased the expression of phosphatidylinositol 3-kinase (PI3K) and phospho-Akt (p-Akt) in the DRG.	Paclitaxel	68-78	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	Rattus norvegicus	107-136
17029589-10	2007	Paclitaxel-stimulated ATPase activity of MDR1 is enhanced in the presence of stigmasterol, sitosterol and campesterol, as well as cholesterol, but not ergosterol.	Paclitaxel	0-10	dynein axonemal heavy chain 8	Homo sapiens	22-28
32898439-2	2020	The aim of this study was to evaluate the potential usefulness of 99mTc-HYNIC-(Ser)3-LTVPWY peptide for detecting HER2 alteration after paclitaxel therapy of ovarian tumor xenografts in nude mice.	Paclitaxel	136-146	erb-b2 receptor tyrosine kinase 2	Mus musculus	114-118
32898439-11	2020	Conclusions: The response of HER2 status to paclitaxel in mice bearing HER2-expression tumors was profitably monitored by HER2 targeted 99mTc-HYNIC-(Ser)3-LTVPWY peptide that was agreement with IHC.	Paclitaxel	44-54	erb-b2 receptor tyrosine kinase 2	Mus musculus	29-33
32898439-11	2020	Conclusions: The response of HER2 status to paclitaxel in mice bearing HER2-expression tumors was profitably monitored by HER2 targeted 99mTc-HYNIC-(Ser)3-LTVPWY peptide that was agreement with IHC.	Paclitaxel	44-54	erb-b2 receptor tyrosine kinase 2	Mus musculus	71-75
32898439-11	2020	Conclusions: The response of HER2 status to paclitaxel in mice bearing HER2-expression tumors was profitably monitored by HER2 targeted 99mTc-HYNIC-(Ser)3-LTVPWY peptide that was agreement with IHC.	Paclitaxel	44-54	erb-b2 receptor tyrosine kinase 2	Mus musculus	71-75
32943934-8	2020	Moxibustion combined with paclitaxel increased the number of white blood cells, thymus index, and spleen index, and enhanced immune function by upregulating interferon-gamma and interleukin-2 and downregulating interleukin-10 and transforming growth factor-beta1.	Paclitaxel	26-36	interleukin 2	Mus musculus	178-191
32943934-9	2020	Notably, moxibustion combined with paclitaxel inhibited the angiogenesis of tumors through the downregulation of CD34, HIF-1alpha, and VEGFA, and overcame the immunosuppressive microenvironment by inhibiting the PD-1/PD-L1 signaling pathway.	Paclitaxel	35-45	CD34 antigen	Mus musculus	113-117
32943934-9	2020	Notably, moxibustion combined with paclitaxel inhibited the angiogenesis of tumors through the downregulation of CD34, HIF-1alpha, and VEGFA, and overcame the immunosuppressive microenvironment by inhibiting the PD-1/PD-L1 signaling pathway.	Paclitaxel	35-45	hypoxia inducible factor 1, alpha subunit	Mus musculus	119-129
30817750-8	2019	Multivariate analysis revealed four SNPs in VKORC1 (rs2884737), SLC22A14 (rs4679028), GSTA2 (rs6577), and DCK (rs4643786) were associated with paclitaxel toxicities.	Paclitaxel	143-153	vitamin K epoxide reductase complex subunit 1	Homo sapiens	44-50
30778300-3	2019	When mouse MG6 cells were stimulated with the TLR4 ligands lipopolysaccharide (LPS) and paclitaxel, we found that interferon regulatory factor 1 (IRF1) protein expression and activation was upregulated, transcription of interferon-beta (IFN-beta) was accelerated, induction/activation of STAT1 and activation of STAT3 were promoted, and subsequently iNOS expression was upregulated.	Paclitaxel	88-98	interferon regulatory factor 1	Mus musculus	114-144
30778300-3	2019	When mouse MG6 cells were stimulated with the TLR4 ligands lipopolysaccharide (LPS) and paclitaxel, we found that interferon regulatory factor 1 (IRF1) protein expression and activation was upregulated, transcription of interferon-beta (IFN-beta) was accelerated, induction/activation of STAT1 and activation of STAT3 were promoted, and subsequently iNOS expression was upregulated.	Paclitaxel	88-98	interferon regulatory factor 1	Mus musculus	146-150
30679989-7	2019	Following PTX intervention, the expression levels of Ki67 and cyclin B1 were significantly reduced when compared with the model group (P&lt;0.01), while p27Kip1 expression was significantly increased (P&lt;0.01).	Paclitaxel	10-13	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	153-160
30679989-9	2019	These effects of PTX may be associated with increased expression of p27Kip1 and decreased expression of cyclin B1.	Paclitaxel	17-20	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	68-75
33042272-8	2020	Mechanistically, MITR counteracted MEF2A-induced transcriptional suppression of IL11, ultimately causing paclitaxel resistance.	Paclitaxel	105-115	interleukin 11	Homo sapiens	80-84
33042272-10	2020	Conclusion: Our in vitro and in vivo genetic and cellular analyses elucidated the pivotal role of MITR/MEF2A/IL11 axis in paclitaxel resistance and provided a novel therapeutic strategy for TNBC patients to overcome poor chemotherapy responses.	Paclitaxel	122-132	interleukin 11	Homo sapiens	109-113
30292104-10	2019	Intracellular drug uptake of plain drug PTX on breast cancer cells (MDA-MB-231) shows more or less constant drug levels in 2 to 6 h, suggesting drug efflux by the P-gp transporters, over TAP NPs, in which PTX uptake was more than 95.52 +- 11.01% in 6 h, as analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS).	Paclitaxel	40-43	phosphoglycolate phosphatase	Homo sapiens	163-167
17143528-10	2007	Our observation in this study raised the possibility that dexamethasone pretreatment antagonizes paclitaxel-induced cytotoxicity through ERK suppression and pRB dephosphorylation.	Paclitaxel	97-107	RB transcriptional corepressor 1	Homo sapiens	157-160
30545630-8	2019	Importantly, two neddylation conjugating E2 enzymes, UBE2M and UBE2F, were found to play essential roles in PTX-induced cytotoxicity and tubulin polymerization in OCCs.	Paclitaxel	108-111	ubiquitin conjugating enzyme E2 M	Homo sapiens	53-58
17140455-10	2006	Furthermore, CD133 positive cells were significantly resistant to chemotherapeutic agents including temozolomide, carboplatin, paclitaxel (Taxol) and etoposide (VP16) compared to autologous CD133 negative cells.	Paclitaxel	127-137	prominin 1	Homo sapiens	13-18
30366077-4	2019	Here, we demonstrated that PTX mediated the Cancer-Immunity Cycle could be enhanced by PD-L1 knockdown (KD) and followed mTOR pathway inhibition in tumor cells.	Paclitaxel	27-30	mechanistic target of rapamycin kinase	Mus musculus	121-125
30530177-6	2019	However, the use of paclitaxel is seriously limited (its bioavailability is &lt;10%) due to several long-standing challenges: its poor water solubility (0.3 mug/mL), its being a substrate for the efflux multidrug transporter P-gp, and, in the case of oral delivery, its first-pass metabolism by certain enzymes.	Paclitaxel	20-30	phosphoglycolate phosphatase	Homo sapiens	225-229
30431082-11	2019	Notably, ERp57-siRNA and 100 nM paclitaxel co-treatment downregulated Bcl-2, Bcl-xl, MMP2, MMP9, TUBB3 and P-gp expression levels and upregulated the expression of Bax protein.	Paclitaxel	32-42	phosphoglycolate phosphatase	Homo sapiens	107-111
32619088-5	2020	Knockdown of Linc00839 significantly suppressed proliferation, invasion, and migration, sensitized cells to paclitaxel in vitro and inhibited transplant tumor development in vivo.	Paclitaxel	108-118	long intergenic non-protein coding RNA 839	Homo sapiens	13-22
32427586-4	2020	Paclitaxel induces HIF-1-dependent expression of S100A10, which forms a complex with ANXA2 that interacts with histone chaperone SPT6 and histone demethylase KDM6A.	Paclitaxel	0-10	annexin A2	Homo sapiens	85-90
17140455-10	2006	Furthermore, CD133 positive cells were significantly resistant to chemotherapeutic agents including temozolomide, carboplatin, paclitaxel (Taxol) and etoposide (VP16) compared to autologous CD133 negative cells.	Paclitaxel	139-144	prominin 1	Homo sapiens	13-18
17009338-1	2006	It was reported that paclitaxel is an inhibitor of hepatic P-glycoprotein (P-gp) and hepatic microsomal cytochrome P450 (CYP) 3A1/2, and that naringin is an inhibitor of biliary P-gp and CYP3A1/2 in rats.	Paclitaxel	21-31	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	187-193
32807808-6	2020	Importantly, transgenic overexpression of TMPRSS13 in CRC cell lines increased tolerance to apoptosis-inducing agents, including paclitaxel and HA14-1.	Paclitaxel	129-139	transmembrane serine protease 13	Homo sapiens	42-50
30320402-1	2019	Our previous studies have identified that silencing oncoprotein 18 (Op18)/stathmin via RNA interference (RNAi) inhibited autocrine interleukin-10 (IL-10) and enhanced the sensitivity to Taxol in NCI-H1299 non-small cell lung cancer cells.	Paclitaxel	186-191	stathmin 1	Homo sapiens	52-66
32632453-0	2020	Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO.	Paclitaxel	41-51	long intergenic non-protein coding RNA, p53 induced transcript	Homo sapiens	20-29
30320402-1	2019	Our previous studies have identified that silencing oncoprotein 18 (Op18)/stathmin via RNA interference (RNAi) inhibited autocrine interleukin-10 (IL-10) and enhanced the sensitivity to Taxol in NCI-H1299 non-small cell lung cancer cells.	Paclitaxel	186-191	stathmin 1	Homo sapiens	68-72
17009338-5	2006	The significantly greater AUC could be due mainly to an inhibition of metabolism of paclitaxel via CYP3A1/2 by oral naringin.	Paclitaxel	84-94	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	99-105
30320402-1	2019	Our previous studies have identified that silencing oncoprotein 18 (Op18)/stathmin via RNA interference (RNAi) inhibited autocrine interleukin-10 (IL-10) and enhanced the sensitivity to Taxol in NCI-H1299 non-small cell lung cancer cells.	Paclitaxel	186-191	stathmin 1	Homo sapiens	74-82
32632453-4	2020	Here, we established two paclitaxel (PTX)-resistant TNBC cancer cell lines using an intermittent and stepwise method and found that long non-coding RNA long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT) was significantly decreased in PTX-resistant cancer cells.	Paclitaxel	25-35	long intergenic non-protein coding RNA, p53 induced transcript	Homo sapiens	215-224
32632453-4	2020	Here, we established two paclitaxel (PTX)-resistant TNBC cancer cell lines using an intermittent and stepwise method and found that long non-coding RNA long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT) was significantly decreased in PTX-resistant cancer cells.	Paclitaxel	37-40	long intergenic non-protein coding RNA, p53 induced transcript	Homo sapiens	215-224
32632453-5	2020	Ectopic expression of LINC-PINT sensitized both PTX-resistant TNBC and wild-type TNBC to PTX.	Paclitaxel	48-51	long intergenic non-protein coding RNA, p53 induced transcript	Homo sapiens	22-31
30520341-8	2019	SLCO1B1 and CYP2C8 genotype may explain some paclitaxel pharmacokinetic variability.	Paclitaxel	45-55	solute carrier organic anion transporter family member 1B1	Homo sapiens	0-7
16890274-3	2006	The correlation between clusterin expression level and paclitaxel IC50 in cervical cancer cell lines was evaluated.	Paclitaxel	55-65	clusterin	Homo sapiens	24-33
30511588-3	2019	Paclitaxel has been reported to act as an adjuvant for Th2 inflammation while downregulating TGF-beta activation.	Paclitaxel	0-10	heart and neural crest derivatives expressed 2	Mus musculus	55-58
30511588-5	2019	We hypothesized that paclitaxel would augment Th2 inflammation while blocking TGF-beta activation and PH after schistosomiasis exposure.	Paclitaxel	21-31	heart and neural crest derivatives expressed 2	Mus musculus	46-49
32632453-5	2020	Ectopic expression of LINC-PINT sensitized both PTX-resistant TNBC and wild-type TNBC to PTX.	Paclitaxel	89-92	long intergenic non-protein coding RNA, p53 induced transcript	Homo sapiens	22-31
16890274-4	2006	The effect of clusterin siRNA on paclitaxel resistance was evaluated by XTT assays.	Paclitaxel	33-43	clusterin	Homo sapiens	14-23
30511588-15	2019	Paclitaxel protects against Schistosoma-induced PH in mice, although by blocking proximate Th2 inflammation rather than suppressing distal TGF-beta activation.	Paclitaxel	0-10	heart and neural crest derivatives expressed 2	Mus musculus	91-94
16890274-6	2006	Clusterin expression levels were correlated with paclitaxel resistance in cervical cancer cell lines, and transfection of clusterin siRNA into HeLaS3 cells significantly decreased their resistance to paclitaxel (P&lt;0.05).	Paclitaxel	49-59	clusterin	Homo sapiens	0-9
30359947-0	2019	MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells.	Paclitaxel	70-80	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-3
30359947-4	2019	Here we describe a novel part of a signaling route in which c-Myc enhances paclitaxel sensitivity through upregulation of miR-203b-3p and miR-203a-3p; two clustered antiapoptosis protein Bcl-xL controlling microRNAs.	Paclitaxel	75-85	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	60-65
32535103-0	2020	0FF0DTargeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1.	Paclitaxel	29-39	glutathione S-transferase pi 1	Homo sapiens	84-89
32535103-8	2020	We further identified that G6PD promotes paclitaxel resistance by regulating the expression of glutathione S-transferase P1 (GSTP1), which confers resistance to chemotherapy by detoxifying several anticancer drugs.	Paclitaxel	41-51	glutathione S-transferase pi 1	Homo sapiens	95-123
32535103-8	2020	We further identified that G6PD promotes paclitaxel resistance by regulating the expression of glutathione S-transferase P1 (GSTP1), which confers resistance to chemotherapy by detoxifying several anticancer drugs.	Paclitaxel	41-51	glutathione S-transferase pi 1	Homo sapiens	125-130
16890274-6	2006	Clusterin expression levels were correlated with paclitaxel resistance in cervical cancer cell lines, and transfection of clusterin siRNA into HeLaS3 cells significantly decreased their resistance to paclitaxel (P&lt;0.05).	Paclitaxel	200-210	clusterin	Homo sapiens	122-131
16890274-7	2006	CONCLUSION: Our finding that clusterin expression was significantly higher in cervical cancer than in normal cervical tissues suggests that clusterin may confer paclitaxel resistance in cervical cancer cells.	Paclitaxel	161-171	clusterin	Homo sapiens	29-38
16890274-7	2006	CONCLUSION: Our finding that clusterin expression was significantly higher in cervical cancer than in normal cervical tissues suggests that clusterin may confer paclitaxel resistance in cervical cancer cells.	Paclitaxel	161-171	clusterin	Homo sapiens	140-149
30447706-1	2018	BACKGROUND: We investigated correlations of miR-21 gene polymorphisms including rs1292037 (A &gt; G) and rs13137 (A &gt; T) with the chemosensitivity to cisplatin plus paclitaxel, and prognosis before cervical cancer (CC) surgery, which may provide a novel target for prevention and treatment of CC.	Paclitaxel	168-178	microRNA 21	Homo sapiens	44-50
30447706-5	2018	RESULTS: rs1292037 (A &gt; G) locus AG, GG, AG + GG and G allele in miR-21 gene may increase chemoresistance to cisplatin plus paclitaxel in CC.	Paclitaxel	127-137	microRNA 21	Homo sapiens	68-74
17940625-0	2006	MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer.	Paclitaxel	34-44	MYD88 innate immune signal transduction adaptor	Homo sapiens	0-5
30243219-1	2018	N-acetylcysteine modified hyaluronic acid-paclitaxel (NAC-HA-PTX) conjugate was designed to improve the water solubility and oral bioavailability of PTX through mucosal bioadhesion ability.	Paclitaxel	42-52	synuclein alpha	Homo sapiens	54-57
30243219-5	2018	The pharmacokinetic study showed that the area under the curve (AUC0-24h) of NAC-HA-PTX micelles was 2.32-fold and 2.56-fold higher compared to that of HA-PTX micelles and PTX solution (Taxol) after oral administration, respectively.	Paclitaxel	186-191	synuclein alpha	Homo sapiens	77-80
32353410-5	2020	NSCLCs cell lines have decreased FNDC5 expression compared with the normal human lung epithelial cells, which was further downregulated in paclitaxel-resistant cells.	Paclitaxel	139-149	fibronectin type III domain containing 5	Homo sapiens	33-38
32353410-7	2020	Besides, we found that FNDC5 increased paclitaxel chemosensitivity in paclitaxel-sensitive or resistant NSCLCs cell lines via downregulating multidrug resistance protein 1 (MDR1).	Paclitaxel	39-49	fibronectin type III domain containing 5	Homo sapiens	23-28
32353410-7	2020	Besides, we found that FNDC5 increased paclitaxel chemosensitivity in paclitaxel-sensitive or resistant NSCLCs cell lines via downregulating multidrug resistance protein 1 (MDR1).	Paclitaxel	70-80	fibronectin type III domain containing 5	Homo sapiens	23-28
32353410-9	2020	FNDC5 promotes paclitaxel sensitivity of NSCLCs cells via inhibiting NF-kappaB/MDR1 signaling, and FNDC5 might be a novel therapeutic target for the treatment of NSCLCs.	Paclitaxel	15-25	fibronectin type III domain containing 5	Homo sapiens	0-5
32594651-6	2020	We show that in HEK293 and 8305C cells, PTX enhanced the endogenous TAK1/TAB1 level and induced cells apoptosis in a dose- and time-dependent manner.	Paclitaxel	40-43	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	68-72
32594651-7	2020	Upon TAK1 overexpression in HEK293 cells treated with PTX, apoptosis rate, JNK phosphorylation and PARP cleavage increased contrary to heat-shocked or untreated cells.	Paclitaxel	54-57	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	5-9
17940625-2	2006	Recently, we described the expression of MyD88 in ovarian cancer cells that were resistant to the cytotoxic agent paclitaxel.	Paclitaxel	114-124	MYD88 innate immune signal transduction adaptor	Homo sapiens	41-46
32594651-8	2020	CRISPR-editing of the tak1 gene upon PTX treatment resulted in lower phospho-JNK and PARP cleavage levels than in cells transfected with the control or the TAK1- or TAB1 + TAK1-containing plasmids.	Paclitaxel	37-40	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	22-26
32594651-8	2020	CRISPR-editing of the tak1 gene upon PTX treatment resulted in lower phospho-JNK and PARP cleavage levels than in cells transfected with the control or the TAK1- or TAB1 + TAK1-containing plasmids.	Paclitaxel	37-40	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	172-176
30429459-2	2018	Here we uncovered that either sulforaphane-cysteine (SFN-Cys) or sulforaphane-N-acetyl-cysteine (SFN-NAC) induced apoptosis via phosphorylated ERK1/2-mediated upregulation of 26 S proteasome and Hsp70, and downregulation of betaIII-tubulin, XIAP, Tau, Stathmin1 and alpha-tubulin causing microtubule disruption in human PTX-resistant non-small cell lung cancer (NSCLC) cells.	Paclitaxel	320-323	RNA exonuclease 2	Homo sapiens	53-56
32594651-10	2020	We conclude that PTX induces HEK293 and 8305C cell apoptosis through the TAK1-JNK activation pathway, potentially highlighting TAK1"s role in chemosensitivity.	Paclitaxel	17-20	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	73-77
30221728-10	2018	Pristimerin and paclitaxel inhibited extracellular signal-regulated kinase (ERK)1/2/p90RSK signaling, consistent with autophagy indicators, namely p62 degradation and beclin 1 expression.	Paclitaxel	16-26	ribosomal protein S6 kinase A1	Homo sapiens	84-90
32594651-10	2020	We conclude that PTX induces HEK293 and 8305C cell apoptosis through the TAK1-JNK activation pathway, potentially highlighting TAK1"s role in chemosensitivity.	Paclitaxel	17-20	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	127-131
17940625-4	2006	The objective of this study was to determine the correlation of MyD88 expression in primary and recurrent epithelial ovarian cancers with the response to carboplatin and paclitaxel combination chemotherapy.	Paclitaxel	170-180	MYD88 innate immune signal transduction adaptor	Homo sapiens	64-69
29985480-0	2018	PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer.	Paclitaxel	79-89	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	0-4
17940625-10	2006	It was evident that MyD88 expression in ovarian cancer cells accurately predicts a poor response to paclitaxel chemotherapy as shown by a short progression-free interval and overall survival.	Paclitaxel	100-110	MYD88 innate immune signal transduction adaptor	Homo sapiens	20-25
29985480-7	2018	Interestingly, PIM2 kinase inhibitor SMI-4a could abrogate the effects of phosphorylated HK2 Thr473 on paclitaxel resistance in vitro and in vivo.	Paclitaxel	103-113	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	15-19
30340507-6	2018	Furthermore, HIF-2alpha overexpression induced a stem cell phenotype, the resistance to PTX and enhanced protein expression of stem cell markers, c-Myc, OCT4 and Nanog.	Paclitaxel	88-91	endothelial PAS domain protein 1	Homo sapiens	13-23
30340507-8	2018	Dickkopf-1 (DKK-1), a Wnt pathway inhibitor, and L685,458, an inhibitor of the Notch pathway, reversed the resistance to PTX and stem phenotype conversion induced by HIF-2alpha overexpression.	Paclitaxel	121-124	endothelial PAS domain protein 1	Homo sapiens	166-176
30340507-9	2018	In addition, HIF-2alpha overexpression enhanced tumorigenicity and resistance of xenograft tumors to PTX, increased activation of the Wnt and Notch pathways and induced a stem cell phenotype in vivo.	Paclitaxel	101-104	endothelial PAS domain protein 1	Homo sapiens	13-23
16887804-9	2006	The protective effect of NGF against rotenone toxicity was occluded by the microtubule-stabilizing drug taxol.	Paclitaxel	104-109	nerve growth factor	Rattus norvegicus	25-28
30340507-10	2018	CONCLUSION: In conclusion, HIF-2alpha promoted stem phenotype conversion and induced resistance to PTX by activating Wnt and Notch pathways.	Paclitaxel	99-102	endothelial PAS domain protein 1	Homo sapiens	27-37
30043438-3	2018	Here, we report a 33-year-old primipara who underwent four courses of NAC therapy, paclitaxel and cisplatin, from 17 to 27 weeks of gestation due to uterine cervical cancer stage IB2.	Paclitaxel	83-93	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	179-182
32669274-0	2020	Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter.	Paclitaxel	22-32	CD274 molecule	Homo sapiens	36-41
17009971-7	2006	Treatment of paclitaxel alone showed increased nuclear p65 protein and decreased cytoplasmic IkappaB-alpha protein expression, while pretreatment of PDTC reversed this function.	Paclitaxel	13-23	RELA proto-oncogene, NF-kB subunit	Homo sapiens	55-58
30066930-6	2018	The results indicated that curcumin and paclitaxel induced apoptosis and necrosis, which was demonstrated through multiple methods, including assays of caspase-3/7 activity, Annexin V, poly(ADP-ribose) polymerase-1 activation and protein expression of caspase-3, nuclear factor (NF)-kappaB transcription factor and proliferating cell nuclear antigen.	Paclitaxel	40-50	annexin A5	Homo sapiens	174-183
16516478-8	2006	Opposite effects of flavonoid derivatives on the P-gp highly expressing and MDA-MB-435 non-expressing cell lines indicate that paclitaxel is not only transported by P-gp and let us assume that Mrp2 or ABCC5 seem to be good transport-candidates in these cells.	Paclitaxel	127-137	ATP binding cassette subfamily C member 5	Homo sapiens	201-206
30218010-3	2018	We used Site Directed Spin Labeling combined with EPR spectroscopy to monitor Tau upon binding to either Taxol-stabilized MTs or to alphabeta-tubulin when Tau is directly used as an inducer of MTs formation.	Paclitaxel	105-110	microtubule associated protein tau	Homo sapiens	78-81
29885837-0	2018	TKTL1 modulates the response of paclitaxel-resistant human ovarian cancer cells to paclitaxel.	Paclitaxel	32-42	transketolase like 1	Homo sapiens	0-5
29885837-0	2018	TKTL1 modulates the response of paclitaxel-resistant human ovarian cancer cells to paclitaxel.	Paclitaxel	83-93	transketolase like 1	Homo sapiens	0-5
32733972-13	2020	Hence, these results provide evidence that SHP alleviates PTX-induced constipation and intestinal morphological damage but augments the effects of PTX on the expression of cytokines in the TLR4 pathway and IL-1beta.	Paclitaxel	147-150	interleukin 1 alpha	Mus musculus	206-214
31838201-0	2020	Target delivering paclitaxel by ferritin heavy chain nanocages for glioma treatment.	Paclitaxel	18-28	ferritin heavy chain 1	Homo sapiens	32-52
31838201-5	2020	Herein, we developed endogenous human ferritin heavy chain nanocage (HFn) as PTX carrier, which could specifically bind to widely overexpressed transferrin receptor 1 (TfR1) on BBB and glioma cells.	Paclitaxel	77-80	ferritin heavy chain 1	Homo sapiens	38-58
32278794-9	2020	Overall, we identified six TLR4- and AR-regulated genes involved in taxol resistance.	Paclitaxel	68-73	toll like receptor 4	Homo sapiens	27-31
32278794-10	2020	Our results reveal that the TLR4/AR axis plays a critical role in taxol resistance and that genistein is a candidate compound to limit chemoresistance and improve cancer treatment in ovarian cancer.	Paclitaxel	66-71	toll like receptor 4	Homo sapiens	28-32
29885837-3	2018	We investigated whether inhibiting TKTL1 in OC3/TAX300 cells could re-sensitize paclitaxel-resistant cells to paclitaxel and proposed a mechanism of action.	Paclitaxel	80-90	transketolase like 1	Homo sapiens	35-40
29885837-3	2018	We investigated whether inhibiting TKTL1 in OC3/TAX300 cells could re-sensitize paclitaxel-resistant cells to paclitaxel and proposed a mechanism of action.	Paclitaxel	110-120	transketolase like 1	Homo sapiens	35-40
16395709-1	2006	We recently showed that Hepatocyte Growth Factor (HGF), known as a survival factor, unexpectedly enhances apoptosis in human ovarian cancer cells treated with the front-line chemotherapeutics cisplatin (CDDP) and paclitaxel (PTX).	Paclitaxel	225-228	hepatocyte growth factor	Homo sapiens	50-53
29885837-5	2018	Inhibition of TKTL1 significantly decreased the cellular proliferation rate and IC50 for paclitaxel.	Paclitaxel	89-99	transketolase like 1	Homo sapiens	14-19
29885837-7	2018	A 2.2-fold increase in the ROS level and an obvious increase in the cell apoptosis rate were observed in the si-TKTL1+paclitaxel group compared with those in the negative si-TKTL1+paclitaxel and OC3/Tax300 + paclitaxel groups.	Paclitaxel	118-128	transketolase like 1	Homo sapiens	112-117
29885837-7	2018	A 2.2-fold increase in the ROS level and an obvious increase in the cell apoptosis rate were observed in the si-TKTL1+paclitaxel group compared with those in the negative si-TKTL1+paclitaxel and OC3/Tax300 + paclitaxel groups.	Paclitaxel	118-128	transketolase like 1	Homo sapiens	174-179
32485058-6	2020	Paclitaxel induced overexpression of C-C motif chemokine ligand 2 (CCL2), tumour necrosis alpha (TNFalpha) and interleukin-6 (IL-6) in DRGs, where the presence of macrophages was demonstrated.	Paclitaxel	0-10	C-C motif chemokine ligand 2	Homo sapiens	37-65
32485058-6	2020	Paclitaxel induced overexpression of C-C motif chemokine ligand 2 (CCL2), tumour necrosis alpha (TNFalpha) and interleukin-6 (IL-6) in DRGs, where the presence of macrophages was demonstrated.	Paclitaxel	0-10	C-C motif chemokine ligand 2	Homo sapiens	67-71
29885837-7	2018	A 2.2-fold increase in the ROS level and an obvious increase in the cell apoptosis rate were observed in the si-TKTL1+paclitaxel group compared with those in the negative si-TKTL1+paclitaxel and OC3/Tax300 + paclitaxel groups.	Paclitaxel	180-190	transketolase like 1	Homo sapiens	112-117
16395709-7	2006	Altogether data show that p38 MAPK is necessary for HGF sensitization of ovarian cancer cells to low-doses of CDDP and PTX and might be sufficient to overcome activation of survival pathways.	Paclitaxel	119-122	hepatocyte growth factor	Homo sapiens	52-55
29885837-7	2018	A 2.2-fold increase in the ROS level and an obvious increase in the cell apoptosis rate were observed in the si-TKTL1+paclitaxel group compared with those in the negative si-TKTL1+paclitaxel and OC3/Tax300 + paclitaxel groups.	Paclitaxel	180-190	transketolase like 1	Homo sapiens	112-117
29885837-11	2018	Collectively, TKTL1 down-regulation sensitized paclitaxel-resistant OC3/Tax300 ovarian cancer cells to paclitaxel.	Paclitaxel	47-57	transketolase like 1	Homo sapiens	14-19
32529197-6	2020	Thus, the PTX/PECN NPs presented a lower IC50 of 3.14 mug mL-1 than that of the PTX/PECT NPs (7.67 mug mL-1) and free PTX (4.65 mug mL-1).	Paclitaxel	10-13	L1 cell adhesion molecule	Mus musculus	58-62
32529197-6	2020	Thus, the PTX/PECN NPs presented a lower IC50 of 3.14 mug mL-1 than that of the PTX/PECT NPs (7.67 mug mL-1) and free PTX (4.65 mug mL-1).	Paclitaxel	10-13	L1 cell adhesion molecule	Mus musculus	103-107
32529197-6	2020	Thus, the PTX/PECN NPs presented a lower IC50 of 3.14 mug mL-1 than that of the PTX/PECT NPs (7.67 mug mL-1) and free PTX (4.65 mug mL-1).	Paclitaxel	10-13	L1 cell adhesion molecule	Mus musculus	103-107
29885837-11	2018	Collectively, TKTL1 down-regulation sensitized paclitaxel-resistant OC3/Tax300 ovarian cancer cells to paclitaxel.	Paclitaxel	103-113	transketolase like 1	Homo sapiens	14-19
30249901-8	2018	Moreover, knockdown of FHL1 promoted the activation of caspase-3 and caspase-9, which were induced by paclitaxel.	Paclitaxel	102-112	four and a half LIM domains 1	Homo sapiens	23-27
30249901-8	2018	Moreover, knockdown of FHL1 promoted the activation of caspase-3 and caspase-9, which were induced by paclitaxel.	Paclitaxel	102-112	caspase 9	Homo sapiens	69-78
16647893-10	2006	Carboplatin and paclitaxel sensitivities were determined and connexin 43 expression was associated with sensitivity to paclitaxel.	Paclitaxel	119-129	gap junction protein alpha 1	Homo sapiens	61-72
30249901-10	2018	Conclusion: FHL1 promote paclitaxel resistance in hepatocellular carcinomas cells through regulating apoptosis induced by paclitaxel, suggesting that FHL1 may be a promising molecular target for HCC therapy.	Paclitaxel	25-35	four and a half LIM domains 1	Homo sapiens	12-16
30249901-10	2018	Conclusion: FHL1 promote paclitaxel resistance in hepatocellular carcinomas cells through regulating apoptosis induced by paclitaxel, suggesting that FHL1 may be a promising molecular target for HCC therapy.	Paclitaxel	25-35	four and a half LIM domains 1	Homo sapiens	150-154
30249901-10	2018	Conclusion: FHL1 promote paclitaxel resistance in hepatocellular carcinomas cells through regulating apoptosis induced by paclitaxel, suggesting that FHL1 may be a promising molecular target for HCC therapy.	Paclitaxel	122-132	four and a half LIM domains 1	Homo sapiens	12-16
30249901-10	2018	Conclusion: FHL1 promote paclitaxel resistance in hepatocellular carcinomas cells through regulating apoptosis induced by paclitaxel, suggesting that FHL1 may be a promising molecular target for HCC therapy.	Paclitaxel	122-132	four and a half LIM domains 1	Homo sapiens	150-154
32647677-14	2020	Besides, Tan-I treatment can notably increase Paclitaxel-inducing cell senescence by promoting DNA damage and senescence-associated proteins such as p21 and p16.	Paclitaxel	46-56	H3 histone pseudogene 16	Homo sapiens	149-152
16647893-12	2006	Sensitivity to paclitaxel maybe associated with connexin 43.	Paclitaxel	15-25	gap junction protein alpha 1	Homo sapiens	48-59
31883148-8	2020	Furthermore, transport of cationic drugs, metformin and paclitaxel in HepG2 cells was blunted by OCT inhibitors, suggesting that hOCT1 and hOCT3 expressed in HepG2 cells exhibit notable impacts on cationic drug actions.	Paclitaxel	56-66	plexin A2	Homo sapiens	97-100
30181335-0	2018	Retraction: Potentiation of Paclitaxel Activity by the HSP90 Inhibitor 17-allylamino-17-demethoxygeldanamycin in Human Ovarian Carcinoma Cell Lines with High Levels of Activated AKT.	Paclitaxel	28-38	heat shock protein 90 alpha family class A member 1	Homo sapiens	55-60
32068666-4	2020	In mouse models, proinflammatory IL-20 levels in serum and dorsal root ganglia fluctuated with paclitaxel treatment.	Paclitaxel	95-105	interleukin 20	Mus musculus	33-38
16287090-0	2006	Inactivation of Id-1 in prostate cancer cells: A potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway.	Paclitaxel	112-117	inhibitor of DNA binding 1, HLH protein	Homo sapiens	16-20
32068666-6	2020	Mechanistically, paclitaxel up-regulated IL-20 via dysregulated Ca homeostasis, which augmented chemotherapy-induced neurotoxicity.	Paclitaxel	17-27	interleukin 20	Mus musculus	41-46
32068666-8	2020	Together, targeting IL-20 ameliorates paclitaxel-induced peripheral neuropathy by suppressing neuroinflammation and restoring Ca homeostasis.	Paclitaxel	38-48	interleukin 20	Mus musculus	20-25
16287090-5	2006	By using colony forming assay and MTT assay, we found that inactivation of Id-1 resulted in both decreased colony forming ability and cell viability in prostate cancer cells, after taxol treatment.	Paclitaxel	181-186	inhibitor of DNA binding 1, HLH protein	Homo sapiens	75-79
32068666-9	2020	Therefore, the anti-IL-20 monoclonal antibody is a promising therapeutic for the prevention and treatment of paclitaxel-induced neuropathy.	Paclitaxel	109-119	interleukin 20	Mus musculus	20-25
30051119-6	2018	The entropically driven release of paclitaxel at various concentrations and physiological temperatures was modeled and their application to the PC3 prostrate cancer cell line was investigated by treating in vitro.	Paclitaxel	35-45	chromobox 8	Homo sapiens	144-147
32897218-5	2020	RESULTS: Compared with paclitaxel-sensitive SK-BR-3 cells, paclitaxel-resistant SK-BR-3 cells showed significantly increased the IC50 of paclitaxel with up-regulated MALAT1 expression and down-regulated miR-485-3p expression (P < 0.05).	Paclitaxel	59-69	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	166-172
16287090-6	2006	In addition, the si-Id-1-induced sensitization to taxol was associated with activation of apoptosis pathway, which is demonstrated by increased apoptotic index, DNA laddering, sub-G1 phase of the cell cycle, as well as cleaved-PARP and Caspase 3.	Paclitaxel	50-55	inhibitor of DNA binding 1, HLH protein	Homo sapiens	20-24
32897218-5	2020	RESULTS: Compared with paclitaxel-sensitive SK-BR-3 cells, paclitaxel-resistant SK-BR-3 cells showed significantly increased the IC50 of paclitaxel with up-regulated MALAT1 expression and down-regulated miR-485-3p expression (P < 0.05).	Paclitaxel	59-69	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	166-172
32897218-6	2020	Silencing MALAT1 or overexpressing miR-485-3p obviously lowered the IC50 of paclitaxel and the expression of P-gp and Bcl-2 and increased the expression of Bax in SK-BR-3/PR cells (P < 0.05).	Paclitaxel	76-86	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	10-16
16287090-7	2006	Furthermore, c-Jun N-terminal kinase (JNK), one of the common pathways responsible for taxol-induced apoptosis, was also activated in the si-Id-1 transfected cells.	Paclitaxel	87-92	inhibitor of DNA binding 1, HLH protein	Homo sapiens	141-145
32897218-7	2020	miR-485-3p was identified as the target of MALAT1, and inhibiting miR-485-3p significantly reverse the effect of MALAT1 silencing on IC50 of paclitaxel and the expressions of P-gp, Bcl-2 and Bax in SK-BR-3/PR cells (P < 0.05).	Paclitaxel	141-151	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	43-49
32897218-7	2020	miR-485-3p was identified as the target of MALAT1, and inhibiting miR-485-3p significantly reverse the effect of MALAT1 silencing on IC50 of paclitaxel and the expressions of P-gp, Bcl-2 and Bax in SK-BR-3/PR cells (P < 0.05).	Paclitaxel	141-151	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	113-119
29408734-2	2018	Previous studies have shown that local administration of the microtubule-stabilizing drug paclitaxel or epothilone B (Epo B) reduce fibrotic scar formation and axonal dieback as well as induce axonal growth/sprouting after SCI.	Paclitaxel	90-100	erythropoietin	Rattus norvegicus	118-121
16287090-8	2006	Inhibition of JNK activity by a specific inhibitor, SP600125, blocked the si-Id-1-induced sensitivity to taxol.	Paclitaxel	105-110	inhibitor of DNA binding 1, HLH protein	Homo sapiens	77-81
30013393-10	2018	The expression level of PKM1 was upregulated in rMKN45-PTX, leading to an increase in the PKM1/PKM2 ratio.	Paclitaxel	55-58	pyruvate kinase M1/2	Homo sapiens	95-99
32897218-7	2020	miR-485-3p was identified as the target of MALAT1, and inhibiting miR-485-3p significantly reverse the effect of MALAT1 silencing on IC50 of paclitaxel and the expressions of P-gp, Bcl-2 and Bax in SK-BR-3/PR cells (P < 0.05).	Paclitaxel	141-151	phosphoglycolate phosphatase	Homo sapiens	175-179
32897218-8	2020	CONCLUSIONS: MALAT1 can modulate paclitaxel resistance in breast cancer cells possibly by targeting miR-485-3p to down-regulate P-gp and Bcl-2 and up-regulate Bax.	Paclitaxel	33-43	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	13-19
32897218-8	2020	CONCLUSIONS: MALAT1 can modulate paclitaxel resistance in breast cancer cells possibly by targeting miR-485-3p to down-regulate P-gp and Bcl-2 and up-regulate Bax.	Paclitaxel	33-43	phosphoglycolate phosphatase	Homo sapiens	128-132
16287090-9	2006	These results indicate that increased Id-1 expression in prostate cancer cells may play a protective role against apoptosis, and downregulation of Id-1 may be a potential target to increase sensitivity of taxol-induced apoptosis in prostate cancer cells.	Paclitaxel	205-210	inhibitor of DNA binding 1, HLH protein	Homo sapiens	147-151
30038720-0	2018	GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes.	Paclitaxel	105-115	glutathione S-transferase pi 1	Homo sapiens	0-5
29683800-12	2018	Western blot analysis indicated that P-gp, Bcl-2, and PARP protein were more abundant in MGC803/PTX and SW620/PTX cells compared with MGC803 and SW620 cells, whereas Bax protein levels were lower in resistant cells.	Paclitaxel	96-99	phosphoglycolate phosphatase	Homo sapiens	37-41
16551869-10	2006	The addition of paclitaxel to the treatment with SU6668 significantly decreased the hemoglobin content and the number of CD31-positive vessels in Matrigel plugs in vivo.	Paclitaxel	16-26	platelet and endothelial cell adhesion molecule 1	Homo sapiens	121-125
29683800-12	2018	Western blot analysis indicated that P-gp, Bcl-2, and PARP protein were more abundant in MGC803/PTX and SW620/PTX cells compared with MGC803 and SW620 cells, whereas Bax protein levels were lower in resistant cells.	Paclitaxel	110-113	phosphoglycolate phosphatase	Homo sapiens	37-41
29319606-10	2018	TAT-GESV also blocked the paclitaxel-induced phosphorylation at Ser15 of p53, a substrate of p38 MAPK.	Paclitaxel	26-36	transformation related protein 53, pseudogene	Mus musculus	73-76
32548230-2	2020	SPARC overexpression occurs in multiple tumors including pancreatic ductal adenocarcinoma (PDAC) and may predict favorable response to nab-paclitaxel.	Paclitaxel	139-149	secreted protein acidic and cysteine rich	Homo sapiens	0-5
16465425-4	2006	MVP protein levels were enhanced in SW-620 cells after a 72 h treatment with doxorubicin (Adr), etoposide (VP-16), cis-platinum (II) diammine dichloride (CDDP) or SN-38, but not vincristine (VCR) or paclitaxel (Taxol) at their IC50 concentration.	Paclitaxel	199-209	major vault protein	Homo sapiens	0-3
16465425-4	2006	MVP protein levels were enhanced in SW-620 cells after a 72 h treatment with doxorubicin (Adr), etoposide (VP-16), cis-platinum (II) diammine dichloride (CDDP) or SN-38, but not vincristine (VCR) or paclitaxel (Taxol) at their IC50 concentration.	Paclitaxel	211-216	major vault protein	Homo sapiens	0-3
32427904-2	2020	This work presents the results of an experimental study of cancer drugs (prodigiosin or paclitaxel) conjugated to Luteinizing Hormone-Releasing Hormone (LHRH) for the specific targeting and treatment of triple negative breast cancer (TNBC).	Paclitaxel	88-98	gonadotropin releasing hormone 1	Mus musculus	114-151
29701902-0	2018	Low doses of Paclitaxel repress breast cancer invasion through DJ-1/KLF17 signalling pathway.	Paclitaxel	13-23	Parkinsonism associated deglycase	Homo sapiens	63-67
16364248-5	2006	Transduced HURP was capable of specifically enhancing the chemosensitivity of deoxycytosine analogs, such as gemcitabine, ARA-C, and 5-AZA-CdR, but neither had an effect on the response of DNA intercalating agents, such as cisplatin, carboplatin, and doxorubicin, nor on the response of microtubule stabilizers, such as paclitaxel, docetaxel, and vinblastine.	Paclitaxel	320-330	DLG associated protein 5	Mus musculus	11-15
29701902-7	2018	Furthermore, paclitaxel-inhibiting breast cancer metastasis is associated with down-regulation of DJ-1 and ID-1 mRNA expression level with a concurrent increase in KLF17 expression.	Paclitaxel	13-23	Parkinsonism associated deglycase	Homo sapiens	98-111
29701902-9	2018	Our results show for the first time that paclitaxel inhibits breast cancer metastasis through regulating DJ-1/KLF17/ID-1 signalling pathway; repressed DJ-1 and ID-1 and enhanced KLF17 expression.	Paclitaxel	41-51	Parkinsonism associated deglycase	Homo sapiens	105-109
29701902-9	2018	Our results show for the first time that paclitaxel inhibits breast cancer metastasis through regulating DJ-1/KLF17/ID-1 signalling pathway; repressed DJ-1 and ID-1 and enhanced KLF17 expression.	Paclitaxel	41-51	Parkinsonism associated deglycase	Homo sapiens	151-164
29719832-9	2018	These factors are co-located with AXL-expressing cells in situ in normal and breast cancer tissues, and associated with resistance to paclitaxel.	Paclitaxel	134-144	AXL receptor tyrosine kinase	Homo sapiens	34-37
32427904-2	2020	This work presents the results of an experimental study of cancer drugs (prodigiosin or paclitaxel) conjugated to Luteinizing Hormone-Releasing Hormone (LHRH) for the specific targeting and treatment of triple negative breast cancer (TNBC).	Paclitaxel	88-98	gonadotropin releasing hormone 1	Mus musculus	153-157
32427904-5	2020	The inhibitions are attributed to the respective adhesive interactions between LHRH molecular recognition units on the prodigiosin (PGS) and paclitaxel (PTX) drugs and overexpressed LHRH receptors on the breast cancer cells and tumors.	Paclitaxel	141-151	gonadotropin releasing hormone 1	Mus musculus	79-83
32427904-5	2020	The inhibitions are attributed to the respective adhesive interactions between LHRH molecular recognition units on the prodigiosin (PGS) and paclitaxel (PTX) drugs and overexpressed LHRH receptors on the breast cancer cells and tumors.	Paclitaxel	153-156	gonadotropin releasing hormone 1	Mus musculus	79-83
32440550-3	2020	Here, we report development of the FX@HP nanocomplex composed of fluorinated polymerized CXCR4 antagonism (FX) and paclitaxel-loaded human serum albumin (HP) for pulmonary delivery of anti-PD-L1 small interfering RNA (siPD-L1) to treat orthotopic lung tumors.	Paclitaxel	115-125	CD274 molecule	Homo sapiens	189-194
16028104-0	2006	GBP1 overexpression is associated with a paclitaxel resistance phenotype.	Paclitaxel	41-51	guanylate binding protein 1	Homo sapiens	0-4
16028104-1	2006	In the search for novel genes involved in the paclitaxel resistance phenotype, prior studies of gene expression in paclitaxel-resistant cell lines and their paired drug-sensitive parental lines using high-density Affymetrix GeneChip arrays identified guanylate-binding protein 1 (GBP1) gene as an overexpressed transcript.	Paclitaxel	46-56	guanylate binding protein 1	Homo sapiens	251-278
16028104-1	2006	In the search for novel genes involved in the paclitaxel resistance phenotype, prior studies of gene expression in paclitaxel-resistant cell lines and their paired drug-sensitive parental lines using high-density Affymetrix GeneChip arrays identified guanylate-binding protein 1 (GBP1) gene as an overexpressed transcript.	Paclitaxel	46-56	guanylate binding protein 1	Homo sapiens	280-284
29392887-0	2018	High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy.	Paclitaxel	114-124	AT-rich interaction domain 1A	Homo sapiens	25-31
32035195-5	2020	Drug synergism study shows that resistance against KSP inhibition can be suppressed by the action of microtubule-stabilizing paclitaxel, because microtubule stabilization prevents a different kinesin Kif15 from replacing all essential functions of KSP when KSP is inhibited.	Paclitaxel	125-135	kinesin family member 15	Homo sapiens	200-205
32775453-5	2020	Inhibiting the expression of miR-520h could enhance the sensitivity to paclitaxel in paclitaxel-resistant MCF-7/Taxol cells.	Paclitaxel	71-81	microRNA 520h	Homo sapiens	29-37
29392887-3	2018	Here, we report that an AT-rich interaction domain 1A (ARID1A) transcript is up-regulated in paclitaxel-sensitive TNBC cells but down-regulated in paclitaxel-resistant cells upon paclitaxel treatment.	Paclitaxel	93-103	AT-rich interaction domain 1A	Homo sapiens	55-61
29392887-3	2018	Here, we report that an AT-rich interaction domain 1A (ARID1A) transcript is up-regulated in paclitaxel-sensitive TNBC cells but down-regulated in paclitaxel-resistant cells upon paclitaxel treatment.	Paclitaxel	147-157	AT-rich interaction domain 1A	Homo sapiens	55-61
29392887-3	2018	Here, we report that an AT-rich interaction domain 1A (ARID1A) transcript is up-regulated in paclitaxel-sensitive TNBC cells but down-regulated in paclitaxel-resistant cells upon paclitaxel treatment.	Paclitaxel	147-157	AT-rich interaction domain 1A	Homo sapiens	55-61
29392887-4	2018	Moreover, ARID1A expression was negatively correlated with the IC50 concentration of paclitaxel in the tested TNBC cell lines.	Paclitaxel	85-95	AT-rich interaction domain 1A	Homo sapiens	10-16
16028104-1	2006	In the search for novel genes involved in the paclitaxel resistance phenotype, prior studies of gene expression in paclitaxel-resistant cell lines and their paired drug-sensitive parental lines using high-density Affymetrix GeneChip arrays identified guanylate-binding protein 1 (GBP1) gene as an overexpressed transcript.	Paclitaxel	115-125	guanylate binding protein 1	Homo sapiens	251-278
29392887-5	2018	Kaplan-Meier analyses revealed that ARID1A down-regulation was related to a poorer response to paclitaxel-based chemotherapy in patients with TNBCs as measured by the recurrence-free survival probability.	Paclitaxel	95-105	AT-rich interaction domain 1A	Homo sapiens	36-42
29392887-6	2018	The pharmaceutical inhibition with p38MAPK-specific inhibitor SCIO-469 revealed that p38MAPK-related signalling axis regulates ARID1A expression and thereby modulates paclitaxel sensitivity in TNBC cells.	Paclitaxel	167-177	AT-rich interaction domain 1A	Homo sapiens	127-133
16028104-1	2006	In the search for novel genes involved in the paclitaxel resistance phenotype, prior studies of gene expression in paclitaxel-resistant cell lines and their paired drug-sensitive parental lines using high-density Affymetrix GeneChip arrays identified guanylate-binding protein 1 (GBP1) gene as an overexpressed transcript.	Paclitaxel	115-125	guanylate binding protein 1	Homo sapiens	280-284
29392887-7	2018	These findings suggest that ARID1A could be used as a prognostic factor to estimate the pathological complete response for TNBC patients who decide to receive paclitaxel-based chemotherapy.	Paclitaxel	159-169	AT-rich interaction domain 1A	Homo sapiens	28-34
16719379-0	2006	High-performance liquid chromatography analysis of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation.	Paclitaxel	68-78	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	51-57
29393480-6	2018	PC-9/ZD cells were more sensitive to paclitaxel and docetaxel than PC-9 cells and knockdown of T790M decreased this sensitivity.	Paclitaxel	37-47	proprotein convertase subtilisin/kexin type 9	Homo sapiens	0-4
32495881-12	2020	Furthermore, it could promote NSCLC development and paclitaxel resistance by inducing Wnt/beta-catenin signaling pathway.	Paclitaxel	52-62	catenin beta 1	Homo sapiens	90-102
32408327-0	2020	[A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation].	Paclitaxel	114-124	CD274 molecule	Homo sapiens	68-73
16719379-3	2006	A reverse-phase, high-performance liquid chromatographic assay is described for the analysis of paclitaxel 6alpha-hydroxylation catalyzed by human liver microsomes or cDNA-expressed P450 enzyme CYP2C8.	Paclitaxel	96-106	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	194-200
16719379-5	2006	This method is applicable to enzymatic studies for determination of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation activity.	Paclitaxel	85-95	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	68-74
16051289-7	2006	Meanwhile, immunoblotting analysis also showed that the co-administration of esculetin and Taxol could increase the expression of Bax and the cytosolic release of cytochrome C and enhance the expression of Fas and Fas ligand while the activation of caspase-8 and caspase-3 was also increased.	Paclitaxel	91-96	caspase 8	Homo sapiens	249-258
16373699-8	2005	Clusterin expression increased after estrogen withdrawal and paclitaxel treatment in vitro in MCF-7 cells.	Paclitaxel	61-71	clusterin	Homo sapiens	0-9
32203949-3	2020	Here, we synthesize a drug conjugate MP by linking the IDO inhibitor, D-1-methyltryptophan (D-1MT), to the chemotherapeutic agent, paclitaxel (PTX), through an ester bond.	Paclitaxel	131-141	indoleamine 2,3-dioxygenase 1	Homo sapiens	55-58
32203949-3	2020	Here, we synthesize a drug conjugate MP by linking the IDO inhibitor, D-1-methyltryptophan (D-1MT), to the chemotherapeutic agent, paclitaxel (PTX), through an ester bond.	Paclitaxel	143-146	indoleamine 2,3-dioxygenase 1	Homo sapiens	55-58
32203949-9	2020	These results prove that the design of twin drug from the IDO inhibitor and PTX synergizes the anti-tumor effect and shows promise in clinical translation.	Paclitaxel	76-79	indoleamine 2,3-dioxygenase 1	Homo sapiens	58-61
27787294-9	2018	After controlling for comorbidity, receipt of neoadjuvant therapy, and nodal involvement, a longer survival was associated with undergoing combination gemcitabine and nab-paclitaxel [time ratio (TR) = 1.26, 95% CI: 1.02-1.57, P = 0.035) or capecitabine and radiation (TR = 1.25, 95% CI: 1.04-1.51, P = 0.018).	Paclitaxel	171-181	nodal growth differentiation factor	Homo sapiens	71-76
28283888-0	2018	Kinin Receptors Sensitize TRPV4 Channel and Induce Mechanical Hyperalgesia: Relevance to Paclitaxel-Induced Peripheral Neuropathy in Mice.	Paclitaxel	89-99	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	26-31
28283888-1	2018	Kinin B1 (B1R) and B2 receptors (B2R) and the transient receptor potential vanilloid 4 (TRPV4) channel are known to play a critical role in the peripheral neuropathy induced by paclitaxel (PTX) in rodents.	Paclitaxel	177-187	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	46-86
28283888-1	2018	Kinin B1 (B1R) and B2 receptors (B2R) and the transient receptor potential vanilloid 4 (TRPV4) channel are known to play a critical role in the peripheral neuropathy induced by paclitaxel (PTX) in rodents.	Paclitaxel	177-187	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	88-93
28283888-1	2018	Kinin B1 (B1R) and B2 receptors (B2R) and the transient receptor potential vanilloid 4 (TRPV4) channel are known to play a critical role in the peripheral neuropathy induced by paclitaxel (PTX) in rodents.	Paclitaxel	189-192	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	46-86
28283888-1	2018	Kinin B1 (B1R) and B2 receptors (B2R) and the transient receptor potential vanilloid 4 (TRPV4) channel are known to play a critical role in the peripheral neuropathy induced by paclitaxel (PTX) in rodents.	Paclitaxel	189-192	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	88-93
28283888-3	2018	Herein, we investigated whether kinins sensitize TRPV4 channels in order to maintain PTX-induced peripheral neuropathy in mice.	Paclitaxel	85-88	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	49-54
29486738-0	2018	Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.	Paclitaxel	52-62	toll like receptor 4	Homo sapiens	22-42
29486738-3	2018	This study aims to explore the effect of TLR4 in PTX resistance in triple-negative BCA and advanced melanoma and the effect of compound A (CpdA) to attenuate this resistance.	Paclitaxel	49-52	toll like receptor 4	Homo sapiens	41-45
29486738-5	2018	The response to PTX of TLR4-transient knockdown cells by siRNA transfection was evaluated compared to the control cells.	Paclitaxel	16-19	toll like receptor 4	Homo sapiens	23-27
29486738-8	2018	RESULTS: PTX could markedly induce TLR4 expression in both MDA-MB-231 BCA and MDA-MB-435 melanoma cell lines having a basal level of TLR4 whereas no significant induction in TLR4-transient knockdown cells occurred.	Paclitaxel	9-12	toll like receptor 4	Homo sapiens	35-39
32054769-9	2020	Like LIN9, genetic or pharmacologic blockade of NEK2 activity in the presence of paclitaxel synergistically induced mitotic abnormalities in nearly 100% of cells and completely restored sensitivity to paclitaxel, in vitro.	Paclitaxel	81-91	NIMA related kinase 2	Homo sapiens	48-52
32054769-9	2020	Like LIN9, genetic or pharmacologic blockade of NEK2 activity in the presence of paclitaxel synergistically induced mitotic abnormalities in nearly 100% of cells and completely restored sensitivity to paclitaxel, in vitro.	Paclitaxel	201-211	NIMA related kinase 2	Homo sapiens	48-52
29486738-8	2018	RESULTS: PTX could markedly induce TLR4 expression in both MDA-MB-231 BCA and MDA-MB-435 melanoma cell lines having a basal level of TLR4 whereas no significant induction in TLR4-transient knockdown cells occurred.	Paclitaxel	9-12	toll like receptor 4	Homo sapiens	133-137
16373699-9	2005	OGX-011 or siRNA clusterin decreased clusterin levels by &gt;90% in a dose-dependent, sequence-specific manner and significantly enhanced chemosensitivity to paclitaxel in vitro.	Paclitaxel	158-168	clusterin	Homo sapiens	17-26
29486738-8	2018	RESULTS: PTX could markedly induce TLR4 expression in both MDA-MB-231 BCA and MDA-MB-435 melanoma cell lines having a basal level of TLR4 whereas no significant induction in TLR4-transient knockdown cells occurred.	Paclitaxel	9-12	toll like receptor 4	Homo sapiens	133-137
29486738-10	2018	IL-6, IL-8 and XIAP showed increased expressions in PTX-treated cells and this over-production effect was inhibited in TLR4-transient knockdown cells.	Paclitaxel	52-55	toll like receptor 4	Homo sapiens	119-123
16373699-9	2005	OGX-011 or siRNA clusterin decreased clusterin levels by &gt;90% in a dose-dependent, sequence-specific manner and significantly enhanced chemosensitivity to paclitaxel in vitro.	Paclitaxel	158-168	clusterin	Homo sapiens	37-46
29486738-14	2018	CONCLUSIONS: The acquired TLR4-mediated PTX resistance in BCA and melanoma is explained partly by the paracrine effect of IL-6 and IL-8 released into the tumor microenvironment and over-production of anti-apoptotic protein, XIAP, in BCA cells and importantly CpdA could reduce this effect and sensitize PTX-induced apoptosis in a synergistic manner.	Paclitaxel	40-43	toll like receptor 4	Homo sapiens	26-30
29486738-14	2018	CONCLUSIONS: The acquired TLR4-mediated PTX resistance in BCA and melanoma is explained partly by the paracrine effect of IL-6 and IL-8 released into the tumor microenvironment and over-production of anti-apoptotic protein, XIAP, in BCA cells and importantly CpdA could reduce this effect and sensitize PTX-induced apoptosis in a synergistic manner.	Paclitaxel	303-306	toll like receptor 4	Homo sapiens	26-30
16373699-10	2005	When combined, OGX-011 or siRNA clusterin reduced the IC50 by 2-log compared with paclitaxel alone.	Paclitaxel	82-92	clusterin	Homo sapiens	32-41
29486738-15	2018	In conclusion, the possible impact of TLR4-dependent signaling pathway in PTX resistance in BCA and melanoma is proposed and using PTX in combination with CpdA may attenuate TLR4-mediated PTX resistance in the treatment of the patients.	Paclitaxel	74-77	toll like receptor 4	Homo sapiens	38-42
29486738-15	2018	In conclusion, the possible impact of TLR4-dependent signaling pathway in PTX resistance in BCA and melanoma is proposed and using PTX in combination with CpdA may attenuate TLR4-mediated PTX resistance in the treatment of the patients.	Paclitaxel	131-134	toll like receptor 4	Homo sapiens	174-178
16373715-0	2005	Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel.	Paclitaxel	133-143	tubulin beta 3 class III	Homo sapiens	0-22
29486738-15	2018	In conclusion, the possible impact of TLR4-dependent signaling pathway in PTX resistance in BCA and melanoma is proposed and using PTX in combination with CpdA may attenuate TLR4-mediated PTX resistance in the treatment of the patients.	Paclitaxel	131-134	toll like receptor 4	Homo sapiens	174-178
16373715-2	2005	In this study, we assessed the prognostic and predictive value of class III beta-tubulin in tumors of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with paclitaxel-based or other regimens that did not include tubulin-binding agents.	Paclitaxel	195-205	tubulin beta 3 class III	Homo sapiens	66-88
16373715-3	2005	Expression of class III beta-tubulin was examined immunohistochemically in 91 tumor samples obtained before treatment from patients with stage III and IV NSCLC, including 47 who received paclitaxel-based regimens and 44 who received regimens without tubulin-binding agents.	Paclitaxel	187-197	tubulin beta 3 class III	Homo sapiens	14-36
16373715-8	2005	These findings suggest that the expression levels of class III beta-tubulin in tumor cells is predictive of response to therapy and patient outcome in patients with NSCLC receiving paclitaxel-based chemotherapy but is not a general prognostic factor in this patient population.	Paclitaxel	181-191	tubulin beta 3 class III	Homo sapiens	53-75
29438316-3	2018	Here we assessed the PD-L1 expression on different breast cancer cell lines under standard in vitro culture conditions and as a function of Epirubicin or Paclitaxel treatment.	Paclitaxel	154-164	CD274 molecule	Homo sapiens	21-26
29438316-6	2018	Epirubicin treatment caused a decrease and Paclitaxel treatment an increased PD-L1 expression in MDA-MB-231 cells.	Paclitaxel	43-53	CD274 molecule	Homo sapiens	77-82
16299241-0	2005	Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.	Paclitaxel	92-102	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	15-21
16275990-8	2005	This Bcl-2/Bcl-xL bispecific antisense oligonucleotide also enhanced paclitaxel chemosensitivity in PC3 cells, reducing the IC50 of paclitaxel by &gt;90%.	Paclitaxel	69-79	keratin 6A	Homo sapiens	100-103
29367423-4	2018	Here, we report that treatment of human or murine TNBC cells with carboplatin, doxorubicin, gemcitabine, or paclitaxel induces the coordinate transcriptional induction of CD47, CD73, and PDL1 mRNA and protein expression, leading to a marked increase in the percentage of CD47+CD73+PDL1+ breast cancer cells.	Paclitaxel	108-118	5' nucleotidase, ecto	Mus musculus	177-181
16275990-8	2005	This Bcl-2/Bcl-xL bispecific antisense oligonucleotide also enhanced paclitaxel chemosensitivity in PC3 cells, reducing the IC50 of paclitaxel by &gt;90%.	Paclitaxel	132-142	keratin 6A	Homo sapiens	100-103
29367423-4	2018	Here, we report that treatment of human or murine TNBC cells with carboplatin, doxorubicin, gemcitabine, or paclitaxel induces the coordinate transcriptional induction of CD47, CD73, and PDL1 mRNA and protein expression, leading to a marked increase in the percentage of CD47+CD73+PDL1+ breast cancer cells.	Paclitaxel	108-118	5' nucleotidase, ecto	Mus musculus	276-280
16243823-5	2005	Curcumin also suppressed the paclitaxel-induced expression of antiapoptotic (XIAP, IAP-1, IAP-2, Bcl-2, and Bcl-xL), proliferative (cyclooxygenase 2, c-Myc, and cyclin D1), and metastatic proteins (vascular endothelial growth factor, matrix metalloproteinase-9, and intercellular adhesion molecule-1).	Paclitaxel	29-39	baculoviral IAP repeat containing 2	Homo sapiens	90-95
29441192-0	2018	Knockdown of LncRNA MAPT-AS1 inhibites proliferation and migration and sensitizes cancer cells to paclitaxel by regulating MAPT expression in ER-negative breast cancers.	Paclitaxel	98-108	microtubule associated protein tau	Homo sapiens	20-24
29441192-7	2018	MAPT-AS1 is correlated with the cell growth, invasiveness and paclitaxel resistance by regulating its natural comparable sense transcripts MAPT in ER-negative breast cancer cells.	Paclitaxel	62-72	microtubule associated protein tau	Homo sapiens	0-4
29441192-13	2018	MAPT-AS1 is correlated with the cell growth, invasiveness and paclitaxel resistance in ER-negative breast cancer cells through antisense pairing with MAPT.	Paclitaxel	62-72	microtubule associated protein tau	Homo sapiens	0-4
16243823-5	2005	Curcumin also suppressed the paclitaxel-induced expression of antiapoptotic (XIAP, IAP-1, IAP-2, Bcl-2, and Bcl-xL), proliferative (cyclooxygenase 2, c-Myc, and cyclin D1), and metastatic proteins (vascular endothelial growth factor, matrix metalloproteinase-9, and intercellular adhesion molecule-1).	Paclitaxel	29-39	cyclin D1	Homo sapiens	161-170
29056557-0	2018	AKAP150 involved in paclitaxel-induced neuropathic pain via inhibiting CN/NFAT2 pathway and downregulating IL-4.	Paclitaxel	20-30	nuclear factor of activated T cells 2	Homo sapiens	74-79
29056557-8	2018	Overexpression of NFAT2 by intrathecal injection of the AAV5-NFAT2-GFP virus alleviated the pain behavior induced by paclitaxel via increasing the expression of IL-4.	Paclitaxel	117-127	nuclear factor of activated T cells 2	Homo sapiens	18-23
16170023-3	2005	Glucose withdrawal or paclitaxel increase intracellular ceramide, down-regulate cellular FLICE inhibitory protein (cFLIP), and sensitize cells to TRAIL.	Paclitaxel	22-32	caspase 8	Homo sapiens	89-94
29056557-8	2018	Overexpression of NFAT2 by intrathecal injection of the AAV5-NFAT2-GFP virus alleviated the pain behavior induced by paclitaxel via increasing the expression of IL-4.	Paclitaxel	117-127	nuclear factor of activated T cells 2	Homo sapiens	61-66
29056557-10	2018	Our results indicated that regulation of IL-4 via the CN/NFAT2 pathway mediated by AKAP150 could be a pivotal treatment target for paclitaxel-induced neuropathic pain and or other neuropsychiatric disorders.	Paclitaxel	131-141	nuclear factor of activated T cells 2	Homo sapiens	57-62
16115934-0	2005	High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.	Paclitaxel	59-69	mucin 1, cell surface associated	Homo sapiens	122-127
29255002-3	2018	Hence, the potential of change in the expression and function of Nav1.7 protein in DRGs from male rats with paclitaxel-related CIPN and from male and female humans with cancer-related neuropathic pain was tested here.	Paclitaxel	108-118	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	65-71
29255002-5	2018	Whole-cell patch-clamp recordings in rat DRG neurons revealed that paclitaxel induced an enhancement of ProTx II (a selective Nav1.7 channel blocker)-sensitive sodium currents.	Paclitaxel	67-77	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	126-132
16095531-3	2005	Our goals were to investigate whether TUBB mutations and mismatch repair defects underlie paclitaxel and cisplatin resistance.	Paclitaxel	90-100	tubulin beta class I	Homo sapiens	38-42
28937965-7	2018	Furthermore, ARTN promotes drug resistance such as antiestrogens, doxorubicin, fulvestrant, paclitaxel, tamoxifen and trastuzumab.	Paclitaxel	92-102	artemin	Homo sapiens	13-17
29367628-0	2018	The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.	Paclitaxel	97-107	ubiquitin conjugating enzyme E2 N	Homo sapiens	18-23
29367628-0	2018	The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.	Paclitaxel	97-107	checkpoint with forkhead and ring finger domains	Homo sapiens	61-65
15907802-1	2005	C19ORF5 is a homologue of microtubule-associated protein MAP1B that interacts with natural paclitaxel-like microtubule stabilizer and candidate tumor suppressor RASSF1A.	Paclitaxel	91-101	microtubule associated protein 1S	Homo sapiens	0-7
29367628-2	2018	Here, using DIGE quantitative proteomics, we identified UBC13 as down-regulated in paclitaxel-resistant ovarian cancer cells, and it was further revealed by immunohistochemical staining that UBC13 low-expression was associated with poorer prognosis and shorter survival of the patients.	Paclitaxel	83-93	ubiquitin conjugating enzyme E2 N	Homo sapiens	56-61
29367628-2	2018	Here, using DIGE quantitative proteomics, we identified UBC13 as down-regulated in paclitaxel-resistant ovarian cancer cells, and it was further revealed by immunohistochemical staining that UBC13 low-expression was associated with poorer prognosis and shorter survival of the patients.	Paclitaxel	83-93	ubiquitin conjugating enzyme E2 N	Homo sapiens	191-196
29367628-3	2018	Through gene function experiments, we found that paclitaxel exposure induced UBC13 down-regulation, and the enforced change in UBC13 expression altered the sensitivity to paclitaxel.	Paclitaxel	49-59	ubiquitin conjugating enzyme E2 N	Homo sapiens	77-82
29367628-3	2018	Through gene function experiments, we found that paclitaxel exposure induced UBC13 down-regulation, and the enforced change in UBC13 expression altered the sensitivity to paclitaxel.	Paclitaxel	171-181	ubiquitin conjugating enzyme E2 N	Homo sapiens	127-132
29367628-5	2018	Our findings revealed a novel function for UBC13 in regulating paclitaxel sensitivity through a DNMT1-CHFR-Aurora A pathway in ovarian cancer cells.	Paclitaxel	63-73	ubiquitin conjugating enzyme E2 N	Homo sapiens	43-48
29367628-5	2018	Our findings revealed a novel function for UBC13 in regulating paclitaxel sensitivity through a DNMT1-CHFR-Aurora A pathway in ovarian cancer cells.	Paclitaxel	63-73	checkpoint with forkhead and ring finger domains	Homo sapiens	102-106
29367628-6	2018	UBC13 could potentially be employed as a therapeutic molecular drug for reversing paclitaxel resistance in ovarian cancer patients.	Paclitaxel	82-92	ubiquitin conjugating enzyme E2 N	Homo sapiens	0-5
29416920-9	2018	Activation of phospho-AKT ser473 and PIK3IP1 was observed in RAD001-treated paclitaxel-sensitive and resistant OCCC cells.	Paclitaxel	76-86	phosphoinositide-3-kinase interacting protein 1	Homo sapiens	37-44
30043652-4	2018	Action mechanism studies manifested that DQA modified paclitaxel plus honokiol micelles could activate apoptotic enzymes caspase-3 and caspase-9 as well as down-regulate FAK, PI3K, MMP-2 and MMP-9.	Paclitaxel	54-64	PTK2 protein tyrosine kinase 2	Mus musculus	170-173
15907802-2	2005	Although normally distributed throughout the cytosol, C19ORF5 specifically associates with microtubules stabilized by paclitaxel or RASSF1A.	Paclitaxel	118-128	microtubule associated protein 1S	Homo sapiens	54-61
30355931-10	2018	After epoxomicin intervention, the inhibitory effects of paclitaxel+hirudin on the key genes and proteins of the TLR4-MyD88 pathway were significantly weakened, which even reached pre-intervention levels.	Paclitaxel	57-67	toll like receptor 4	Homo sapiens	113-117
30355931-12	2018	CONCLUSION: The paclitaxel+hirudin compound promotes MyD88 degradation in the TLR4/MyD88/NF-kappaB pathway to reduce the activity of TLR4 and NF-kappaB p65 and to weaken the LPS-initiated inflammatory reactions of IL-1beta, IL-6, and TNF-alpha.	Paclitaxel	16-26	toll like receptor 4	Homo sapiens	78-82
30355931-12	2018	CONCLUSION: The paclitaxel+hirudin compound promotes MyD88 degradation in the TLR4/MyD88/NF-kappaB pathway to reduce the activity of TLR4 and NF-kappaB p65 and to weaken the LPS-initiated inflammatory reactions of IL-1beta, IL-6, and TNF-alpha.	Paclitaxel	16-26	toll like receptor 4	Homo sapiens	133-137
15907983-12	2005	Paclitaxel showed anti-proliferate activity through the membrane death receptor (DR)-mediated apoptotic pathway involving activation of caspase-8 with a TRAIL-dependent fashion as well as the mitochondrial-mediated pathway involving down-regulation of bcl-2 by cytochrome c release.	Paclitaxel	0-10	caspase 8	Homo sapiens	136-145
16020661-3	2005	Here, we examined whether the activity of kinases associated with cyclin A (such as CDK2) is important in determining cellular sensitivity to paclitaxel, a taxane and mitotic inhibitor used in chemotherapy for breast and ovarian cancer.	Paclitaxel	142-152	cyclin dependent kinase 2	Homo sapiens	84-88
29263668-15	2017	Conclusion: These results strongly revealed that NaC-mPEG-PDLLA micelles can tumor-target delivery of PTX and enhance drug penetration in tumor, suggesting that NaC-mPEG-PDLLA micelles are promising nanocarrier systems for anticancer drugs delivery.	Paclitaxel	102-105	synuclein alpha	Homo sapiens	49-52
29263668-15	2017	Conclusion: These results strongly revealed that NaC-mPEG-PDLLA micelles can tumor-target delivery of PTX and enhance drug penetration in tumor, suggesting that NaC-mPEG-PDLLA micelles are promising nanocarrier systems for anticancer drugs delivery.	Paclitaxel	102-105	synuclein alpha	Homo sapiens	161-164
16026642-6	2005	ET-1 treatment of prostate tumor cells significantly decreased paclitaxel-induced apoptosis through activation of the ET(A) subtype.	Paclitaxel	63-73	endothelin receptor type A	Homo sapiens	118-123
29156899-6	2017	Activation of the cannabinoid receptor-2 (CB-2) receptor by AM1710 blocked paclitaxel-induced mechanical and cold allodynia in one study.	Paclitaxel	75-85	cannabinoid receptor 2	Homo sapiens	18-40
15829295-3	2005	Our present studies showed that taxol, not LPS, induced cell apoptosis in human monocytic THP-1 cells, as indicated by PARP cleavage, as well as bcl-2 phosphorylation.	Paclitaxel	32-37	collagen type XI alpha 2 chain	Homo sapiens	119-123
29156899-6	2017	Activation of the cannabinoid receptor-2 (CB-2) receptor by AM1710 blocked paclitaxel-induced mechanical and cold allodynia in one study.	Paclitaxel	75-85	cannabinoid receptor 2	Homo sapiens	42-46
15829295-7	2005	Using splenic macrophages harvested from IRAK-1 knockout and control mice, we further demonstrated that the presence of IRAK-1 is required for taxol-induced PARP cleavage.	Paclitaxel	143-148	interleukin-1 receptor-associated kinase 1	Mus musculus	41-47
15828763-4	2005	As a model system, a competitive phase-separation immunoassay based on the ELP-SpA format was established for paclitaxel (taxol) with IC(50) (20.18 nM) and the lower detection limit (2.94 nM) very similar to those reported for the ELISA format.	Paclitaxel	110-120	surfactant protein A1	Homo sapiens	79-82
28815582-1	2017	We have shown that collagen type XI alpha 1 (COL11A1) promotes ovarian cancer progression and is associated with chemoresistance to cisplatin and paclitaxel in ovarian cancer cells.	Paclitaxel	146-156	collagen type XI alpha 1 chain	Homo sapiens	19-43
28815582-1	2017	We have shown that collagen type XI alpha 1 (COL11A1) promotes ovarian cancer progression and is associated with chemoresistance to cisplatin and paclitaxel in ovarian cancer cells.	Paclitaxel	146-156	collagen type XI alpha 1 chain	Homo sapiens	45-52
15828763-4	2005	As a model system, a competitive phase-separation immunoassay based on the ELP-SpA format was established for paclitaxel (taxol) with IC(50) (20.18 nM) and the lower detection limit (2.94 nM) very similar to those reported for the ELISA format.	Paclitaxel	122-127	surfactant protein A1	Homo sapiens	79-82
15563544-9	2005	Additionally, unliganded PR-A and PR-B both inhibit cell growth and provoke resistance to Taxol-induced apoptosis.	Paclitaxel	90-95	RB transcriptional corepressor 1	Homo sapiens	34-38
28904132-0	2017	Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.	Paclitaxel	56-66	AXL receptor tyrosine kinase	Homo sapiens	43-46
28904132-4	2017	We also examined the role of the epithelial-mesenchymal transition (EMT) in AXL-mediated paclitaxel resistance.	Paclitaxel	89-99	AXL receptor tyrosine kinase	Homo sapiens	76-79
28904132-7	2017	Knockdown or inhibition of AXL increased sensitivity of USC cell lines to paclitaxel in vitro and increased cellular accumulation of paclitaxel.	Paclitaxel	74-84	AXL receptor tyrosine kinase	Homo sapiens	27-30
28904132-7	2017	Knockdown or inhibition of AXL increased sensitivity of USC cell lines to paclitaxel in vitro and increased cellular accumulation of paclitaxel.	Paclitaxel	133-143	AXL receptor tyrosine kinase	Homo sapiens	27-30
28904132-8	2017	AXL promoted chemoresistance even in cells that underwent the EMT in vitro Finally, in vivo studies of combination treatment with BGB324 and paclitaxel showed a greater than 51% decrease in tumor volume after 2 weeks of treatment when compared with no treatment or single-agent treatments (P &lt; 0.001).	Paclitaxel	141-151	AXL receptor tyrosine kinase	Homo sapiens	0-3
15681168-4	2005	If cells were treated with antineoplastic agents (taxol, doxorubicin or vinblastine), nuclear translocation of two NF-kappaB proteins (p50 and p65) was &gt;25% greater in biotin-deficient compared with biotin-supplemented cells.	Paclitaxel	50-55	RELA proto-oncogene, NF-kB subunit	Homo sapiens	143-146
28904132-9	2017	Our results show that AXL expression mediates chemoresistance independent of EMT and prevents accumulation of paclitaxel.	Paclitaxel	110-120	AXL receptor tyrosine kinase	Homo sapiens	22-25
15389801-10	2005	Chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, doxorubicin, and camptothecin) significantly augmented TRAIL-induced apoptosis in cancer cells through up-regulation of DR4, DR5, Bax, and Bak, and induction of caspase activation.	Paclitaxel	24-34	tumor necrosis factor receptor superfamily, member 10b	Mus musculus	198-201
29162853-5	2017	We found that miR-152 expression sensitized the breast cancer cells to paclitaxel treatment by inhibiting beta-catenin and PKM2 expression.	Paclitaxel	71-81	catenin beta 1	Homo sapiens	106-118
29162853-5	2017	We found that miR-152 expression sensitized the breast cancer cells to paclitaxel treatment by inhibiting beta-catenin and PKM2 expression.	Paclitaxel	71-81	pyruvate kinase M1/2	Homo sapiens	123-127
15984158-7	2005	Aurora-A was not found in the spindle region when colchicine or staurosporine was used to inhibit microtubule organization, while it accumulated as several dots in the cytoplasm after taxol treatment.	Paclitaxel	184-189	aurora kinase A	Homo sapiens	0-8
29340013-4	2017	Our previous work showed that the effectiveness of the spindle poison paclitaxel in inhibiting cancer cell growth was dependent on the expression of RANBP1, a regulatory target of the serine/threonine kinase SGK1.	Paclitaxel	70-80	RAN binding protein 1	Homo sapiens	149-155
15671559-0	2005	Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.	Paclitaxel	66-76	tubulin beta 3 class III	Homo sapiens	0-22
29101359-6	2017	We furthermore show the complementary binding region on all three monoclonal antibodies to be the CDR H3 loop of the Fab region, and show that they all have nano to micromolar affinity for HSA Peptide 40 and nab-paclitaxel nanoparticles.	Paclitaxel	212-222	FA complementation group B	Homo sapiens	117-120
15671559-10	2005	By a direct comparison of the three main known mechanisms of paclitaxel resistance, this study indicates that overexpression of class III beta-tubulin is the most prominent mechanism of paclitaxel resistance in ovarian cancer.	Paclitaxel	61-71	tubulin beta 3 class III	Homo sapiens	128-150
28940895-0	2017	miR-339-5p downregulation contributes to Taxol resistance in small-cell lung cancer by targeting alpha1,2-fucosyltransferase 1.	Paclitaxel	41-46	fucosyltransferase 1 (H blood group)	Homo sapiens	97-126
15671559-10	2005	By a direct comparison of the three main known mechanisms of paclitaxel resistance, this study indicates that overexpression of class III beta-tubulin is the most prominent mechanism of paclitaxel resistance in ovarian cancer.	Paclitaxel	186-196	tubulin beta 3 class III	Homo sapiens	128-150
15655291-0	2005	Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4.	Paclitaxel	75-85	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	100-106
28729402-5	2017	We have recently developed an NCAM-targeted nanosized conjugate of paclitaxel bound to a biodegradable polyglutamic acid polymer.	Paclitaxel	67-77	neural cell adhesion molecule 1	Homo sapiens	30-34
15655291-2	2005	Paclitaxel is metabolized by CYP2C8 and CYP3A4, and these enzymes are known to differ between individuals, although the details have not been clarified.	Paclitaxel	0-10	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	29-35
15655291-4	2005	We investigated the effect of the polymorphisms on paclitaxel metabolism by analyzing metabolic activities of CYP2C8 and CYP3A4 and expressions of mRNA and protein.	Paclitaxel	51-61	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	110-116
15655291-9	2005	Inter-individual differences in paclitaxel metabolism may be related to CYP2C8 and CYP3A4 mRNA expression.	Paclitaxel	32-42	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	72-78
29184868-1	2017	We describe an extremely rare case of advanced pure primary ovarian squamous cell carcinoma (SCC), treated by adjuvant chemotherapy with dose-dense paclitaxel combined with carboplatin (dd-TC) plus the combination chemotherapy with irinotecan and cisplatin (CPT-P), with long-term recurrence-free survival.	Paclitaxel	148-158	serpin family B member 3	Homo sapiens	93-96
15655291-10	2005	CYP2C8 is the primary metabolic pathway of paclitaxel, but there is a "shifting phenomenon" in the metabolic pathway of paclitaxel in the liver of some human subjects.	Paclitaxel	43-53	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
15197489-6	2004	Upon paclitaxel treatment, caspase-2, caspase-3, and caspase-8 were activated in BCBL-1 cells.	Paclitaxel	5-15	caspase 8	Homo sapiens	53-62
15486190-8	2004	Conversely, exposure of paclitaxel-arrested mitotic cells to DPI causes a precipitous drop in cyclin B and Thr(288) phosphorylated Aurora-A levels and leads to mitotic catastrophe in a range of cancerous and noncancerous cells.	Paclitaxel	24-34	aurora kinase A	Homo sapiens	131-139
29074857-8	2017	Response of the surrogates to treatment with paclitaxel was measured by optical imaging and by analysis of lactate dehydrogenase and caspase-cleaved cytokeratin 18 in the perfused medium.	Paclitaxel	45-55	keratin 18	Homo sapiens	149-163
15548364-3	2004	Using a p73-specific antibody, we confirmed that c-Abl is required for cisplatin-induced p73 upregulation, and further demonstrate that the p73 protein is upregulated by UV irradiation and other stress stimuli including sorbitol, hydrogen peroxide, nocodazol, and taxol.	Paclitaxel	264-269	tumor protein p73	Homo sapiens	8-11
29066719-6	2017	We further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.	Paclitaxel	198-208	integrin subunit beta 6	Homo sapiens	111-116
28991260-7	2017	We demonstrate that TIS Cal51 cells treated with 75 nM PTX for 7 days became senescent (senescence-associated beta-galactosidase (SA-beta-Gal) positive, Ki67-negative, increased p21 and p16, G2/M cell cycle arrest) and released significantly more EVs (P=0.0002) and exosomes (P=0.0007) than non-senescent control cells.	Paclitaxel	55-58	H3 histone pseudogene 16	Homo sapiens	178-181
15548364-3	2004	Using a p73-specific antibody, we confirmed that c-Abl is required for cisplatin-induced p73 upregulation, and further demonstrate that the p73 protein is upregulated by UV irradiation and other stress stimuli including sorbitol, hydrogen peroxide, nocodazol, and taxol.	Paclitaxel	264-269	tumor protein p73	Homo sapiens	89-92
29190954-7	2017	Combined delivery of UA and PTX synergistically reduced cell proliferation and induced apoptosis in these cells by lowering COX-2, PCNA, and Bcl-2 expression and by increasing Bax expression.	Paclitaxel	28-31	proliferating cell nuclear antigen	Homo sapiens	131-135
15548364-3	2004	Using a p73-specific antibody, we confirmed that c-Abl is required for cisplatin-induced p73 upregulation, and further demonstrate that the p73 protein is upregulated by UV irradiation and other stress stimuli including sorbitol, hydrogen peroxide, nocodazol, and taxol.	Paclitaxel	264-269	tumor protein p73	Homo sapiens	89-92
15205600-11	2004	In all but one AHR-free PT, pre- and post-exposure histamine concentrations remained normal (post-exposure: 2.86+/-11.88 nM, normal values &lt;10 nM).	Paclitaxel	24-26	aryl hydrocarbon receptor	Homo sapiens	15-18
29093604-9	2017	Secretion of the cytokines CCL5, CCL2 and IL-6 increased after paclitaxel treatment in several endometrial cancer cell lines, but no general effect on cytokine secretion was detected after heparin treatment.	Paclitaxel	63-73	C-C motif chemokine ligand 2	Homo sapiens	33-37
32065231-5	2020	When taxol is used to stabilise MTs or colchicine to dissociate MTs, S100P"s stimulation of migration is abolished.	Paclitaxel	5-10	S100 calcium binding protein P	Homo sapiens	69-74
15256704-5	2004	The CYP2C8 model was validated by examining the bound orientation of paclitaxel and showing that it is consistent with the formation of the 6-beta hydroxylated derivative during metabolism.	Paclitaxel	69-79	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	4-10
29085488-10	2017	In addition, downregulation of HOXC6 decreased the sensitivity of ESCC cell lines to cisplatin and paclitaxel, resulting in an increased half-maximal inhibitory concentration.	Paclitaxel	99-109	homeobox C6	Homo sapiens	31-36
29085510-0	2017	Regulation of paclitaxel sensitivity in prostate cancer cells by PTEN/maspin signaling.	Paclitaxel	14-24	phosphatase and tensin homolog	Homo sapiens	65-69
29085510-0	2017	Regulation of paclitaxel sensitivity in prostate cancer cells by PTEN/maspin signaling.	Paclitaxel	14-24	serpin family B member 5	Homo sapiens	70-76
29085510-3	2017	In the present study, it was found that paclitaxel induced more apoptosis and maspin expression in phosphatase and tensin homolog (PTEN)-positive 22Rv1 cells than PTEN-negative LNCaP cells.	Paclitaxel	40-50	serpin family B member 5	Homo sapiens	78-84
29085510-3	2017	In the present study, it was found that paclitaxel induced more apoptosis and maspin expression in phosphatase and tensin homolog (PTEN)-positive 22Rv1 cells than PTEN-negative LNCaP cells.	Paclitaxel	40-50	phosphatase and tensin homolog	Homo sapiens	131-135
32215185-6	2020	AZD8186 in combination with paclitaxel, eribulin had synergistic effects on growth inhibition in PTEN loss cells.	Paclitaxel	28-38	phosphatase and tensin homolog	Homo sapiens	97-101
32215185-7	2020	AZD8186 promoted apoptosis in PTEN loss cells which was synergized by paclitaxel.	Paclitaxel	70-80	phosphatase and tensin homolog	Homo sapiens	30-34
29085510-4	2017	Knockdown of PTEN in 22Rv1 cells resulted in increased resistance to paclitaxel and impaired the induction of maspin expression by paclitaxel.	Paclitaxel	69-79	phosphatase and tensin homolog	Homo sapiens	13-17
15256704-6	2004	Docked paclitaxel was found to form a hydrogen bond with the side chain of Asn 99, which is a characteristic residue of CYP2C8 and is located in the additional pocket.	Paclitaxel	7-17	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	120-126
29085510-4	2017	Knockdown of PTEN in 22Rv1 cells resulted in increased resistance to paclitaxel and impaired the induction of maspin expression by paclitaxel.	Paclitaxel	131-141	phosphatase and tensin homolog	Homo sapiens	13-17
29085510-4	2017	Knockdown of PTEN in 22Rv1 cells resulted in increased resistance to paclitaxel and impaired the induction of maspin expression by paclitaxel.	Paclitaxel	131-141	serpin family B member 5	Homo sapiens	110-116
29085510-5	2017	Overexpression of PTEN sensitized LNCaP cells to paclitaxel treatment and increased maspin induction by paclitaxel.	Paclitaxel	49-59	phosphatase and tensin homolog	Homo sapiens	18-22
29085510-5	2017	Overexpression of PTEN sensitized LNCaP cells to paclitaxel treatment and increased maspin induction by paclitaxel.	Paclitaxel	104-114	phosphatase and tensin homolog	Homo sapiens	18-22
29085510-5	2017	Overexpression of PTEN sensitized LNCaP cells to paclitaxel treatment and increased maspin induction by paclitaxel.	Paclitaxel	104-114	serpin family B member 5	Homo sapiens	84-90
32166458-0	2020	PD-L1 monoclonal antibody-decorated nanoliposomes loaded with Paclitaxel and P-gp transport inhibitor for the synergistic chemotherapy against multidrug resistant gastric cancers.	Paclitaxel	62-72	CD274 molecule	Homo sapiens	0-5
29085510-6	2017	Furthermore, knocking down maspin abrogated PTEN-induced paclitaxel sensitivity in LNCaP cells.	Paclitaxel	57-67	serpin family B member 5	Homo sapiens	27-33
15159015-4	2004	Furthermore, combined administrations of insulin and paclitaxel affected MAPK pathway, Raf-1 activation and p53 expression levels.	Paclitaxel	53-63	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	87-92
29085510-6	2017	Furthermore, knocking down maspin abrogated PTEN-induced paclitaxel sensitivity in LNCaP cells.	Paclitaxel	57-67	phosphatase and tensin homolog	Homo sapiens	44-48
29085510-7	2017	PTEN/maspin signaling may be important for regulating the susceptibility to paclitaxel in prostate cancer.	Paclitaxel	76-86	phosphatase and tensin homolog	Homo sapiens	0-4
14742319-0	2004	Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells.	Paclitaxel	85-90	inhibitor of DNA binding 1, HLH protein	Homo sapiens	0-4
29085510-7	2017	PTEN/maspin signaling may be important for regulating the susceptibility to paclitaxel in prostate cancer.	Paclitaxel	76-86	serpin family B member 5	Homo sapiens	5-11
29137317-7	2017	Furthermore, inhibition of Mcl-1 or PI3K/Akt pathway significantly reversed the resistant phenotype of Taxol-resistant human gastric cancer cells.	Paclitaxel	103-108	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	27-32
32166458-2	2020	Herein, we have investigated the potential of PD-L1 mAb-conjugated nanoliposome to serve as a targeted delivery platform for the co-delivery of paclitaxel (PTX) and p-gp specific transport inhibitor (TQD, tariquidar) in drug-resistant gastric cancers.	Paclitaxel	144-154	CD274 molecule	Homo sapiens	46-51
32166458-2	2020	Herein, we have investigated the potential of PD-L1 mAb-conjugated nanoliposome to serve as a targeted delivery platform for the co-delivery of paclitaxel (PTX) and p-gp specific transport inhibitor (TQD, tariquidar) in drug-resistant gastric cancers.	Paclitaxel	156-159	CD274 molecule	Homo sapiens	46-51
14742319-0	2004	Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells.	Paclitaxel	85-90	zinc fingers and homeoboxes 2	Homo sapiens	13-16
29137317-8	2017	Taken together, our findings broaden the view of PI3K/Akt pathway as an important regulator in Taxol acquired resistance, and implicate Mcl-1 as a specific therapeutic target for the treatment of Taxol-resistant human gastric cancer.	Paclitaxel	196-201	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	136-141
14742319-5	2004	In this study, we investigated if ectopic Id-1 expression in nasopharyngeal carcinoma cells had any protective effect on taxol-induced death, which is also regulated through Raf/MEK pathway.	Paclitaxel	121-126	inhibitor of DNA binding 1, HLH protein	Homo sapiens	42-46
14742319-6	2004	Using four stable Id-1 transfectant clones, we found that exogenous Id-1 expression led to phosphorylation of Raf-1 and MEK1/2 kinases, which was associated with resistance to taxol.	Paclitaxel	176-181	inhibitor of DNA binding 1, HLH protein	Homo sapiens	68-72
14742319-6	2004	Using four stable Id-1 transfectant clones, we found that exogenous Id-1 expression led to phosphorylation of Raf-1 and MEK1/2 kinases, which was associated with resistance to taxol.	Paclitaxel	176-181	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	110-115
14742319-7	2004	Treatment of the Id-1 expressing cells with a MEK inhibitor, PD098059, resulted in an increased taxol-induced apoptosis rate in Id-1 transfectants compared with the vector control.	Paclitaxel	96-101	inhibitor of DNA binding 1, HLH protein	Homo sapiens	17-21
28696100-2	2017	Nab-PTX, a human serum albumin (HSA) nanoparticle of paclitaxel (PTX), indicates enhanced matrix penetration in PDA probably due to its small size in vivo and high affinity of HSA with secreted protein acidic and rich in cysteine (SPARC), overexpressed in the PDA stroma.	Paclitaxel	4-7	secreted protein acidic and cysteine rich	Homo sapiens	185-229
31901301-0	2020	Retraction notice to "STAT3-dependent TXNDC17 expression mediates Taxol resistance through inducing autophagy in human colorectal cancer cells" [GENE 584 (1) (2016) 75-82].	Paclitaxel	66-71	thioredoxin domain containing 17	Homo sapiens	38-45
14742319-7	2004	Treatment of the Id-1 expressing cells with a MEK inhibitor, PD098059, resulted in an increased taxol-induced apoptosis rate in Id-1 transfectants compared with the vector control.	Paclitaxel	96-101	inhibitor of DNA binding 1, HLH protein	Homo sapiens	128-132
28696100-2	2017	Nab-PTX, a human serum albumin (HSA) nanoparticle of paclitaxel (PTX), indicates enhanced matrix penetration in PDA probably due to its small size in vivo and high affinity of HSA with secreted protein acidic and rich in cysteine (SPARC), overexpressed in the PDA stroma.	Paclitaxel	4-7	secreted protein acidic and cysteine rich	Homo sapiens	231-236
14742319-8	2004	In addition, the fact that the taxol-induced apoptosis rate, down-regulation of Bcl-2 and up-regulation of Bax were suppressed by PD098059 treatment in Id-1 expressing cells indicates that the Id-1 induced cellular protection against apoptosis is mediated through Raf/MEK signalling pathways.	Paclitaxel	31-36	inhibitor of DNA binding 1, HLH protein	Homo sapiens	152-156
28758908-6	2017	The aim of this work was to analyze the enhancement of the anticancer effect of TRAIL by paclitaxel, cabazitaxel and docetaxel in the whole population of PC3 and DU145 prostate cancer cells, but also in CD44+/CD24- prostate cancer stem cells.	Paclitaxel	89-99	chromobox 8	Homo sapiens	154-157
32215056-8	2020	We revealed for the first time that loss of Pin1 leads to increased sensitivity to Taxol but only in the absence of functional BRCA1.	Paclitaxel	83-88	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	44-48
14742319-8	2004	In addition, the fact that the taxol-induced apoptosis rate, down-regulation of Bcl-2 and up-regulation of Bax were suppressed by PD098059 treatment in Id-1 expressing cells indicates that the Id-1 induced cellular protection against apoptosis is mediated through Raf/MEK signalling pathways.	Paclitaxel	31-36	inhibitor of DNA binding 1, HLH protein	Homo sapiens	193-197
32189969-5	2020	A combination of small interfering RNA (siRNA), cell counting kit 8 (CCK8), colony formation assay and nude mouse model were used to detect the effect of TUG1 on ovarian cancer cell PTX-resistance.	Paclitaxel	182-185	taurine upregulated gene 1	Mus musculus	154-158
32189969-8	2020	Knockdown of TUG1 by siRNA decreased ovarian cancer cell and xenograft tumor PTX resistance with or without PTX treatment.	Paclitaxel	77-80	taurine upregulated gene 1	Mus musculus	13-17
32189969-8	2020	Knockdown of TUG1 by siRNA decreased ovarian cancer cell and xenograft tumor PTX resistance with or without PTX treatment.	Paclitaxel	108-111	taurine upregulated gene 1	Mus musculus	13-17
32189969-12	2020	Conclusion: Our findings suggest that TUG1, through targeting miR-29b-3p, induces autophagy and consequently results in PTX resistance in ovarian cancer.	Paclitaxel	120-123	taurine upregulated gene 1	Mus musculus	38-42
28748102-4	2017	METHODS: Paclitaxel-treated PC12 cells were assessed for neurite length and performed Western blot analysis for growth-associated protein-43 (GAP-43) and light neurofilament protein (NF-L) levels in the presence of nerve growth factor (NGF); they were re-assessed, with additional testing for acetylcholinesterase levels, after application of one of the kampo.	Paclitaxel	9-19	acetylcholinesterase	Rattus norvegicus	293-313
28534969-7	2017	Further experiments indicated that Cdc2 kinase activities, including the expression of Cdc2 and the level of phospho-Cdc2 (Thr161) were significantly higher in taxol-resistant NCI-H1299 cells compared with the relatively sensitive CNE1 cells before and following treatment with taxol.	Paclitaxel	160-165	cyclin dependent kinase 1	Homo sapiens	35-39
28534969-7	2017	Further experiments indicated that Cdc2 kinase activities, including the expression of Cdc2 and the level of phospho-Cdc2 (Thr161) were significantly higher in taxol-resistant NCI-H1299 cells compared with the relatively sensitive CNE1 cells before and following treatment with taxol.	Paclitaxel	160-165	cyclin dependent kinase 1	Homo sapiens	87-91
28534969-7	2017	Further experiments indicated that Cdc2 kinase activities, including the expression of Cdc2 and the level of phospho-Cdc2 (Thr161) were significantly higher in taxol-resistant NCI-H1299 cells compared with the relatively sensitive CNE1 cells before and following treatment with taxol.	Paclitaxel	160-165	cyclin dependent kinase 1	Homo sapiens	87-91
28534969-7	2017	Further experiments indicated that Cdc2 kinase activities, including the expression of Cdc2 and the level of phospho-Cdc2 (Thr161) were significantly higher in taxol-resistant NCI-H1299 cells compared with the relatively sensitive CNE1 cells before and following treatment with taxol.	Paclitaxel	278-283	cyclin dependent kinase 1	Homo sapiens	35-39
28534969-8	2017	These findings suggest that Cdc2 is positively associatd with the development of taxol resistance.	Paclitaxel	81-86	cyclin dependent kinase 1	Homo sapiens	28-32
14742319-8	2004	In addition, the fact that the taxol-induced apoptosis rate, down-regulation of Bcl-2 and up-regulation of Bax were suppressed by PD098059 treatment in Id-1 expressing cells indicates that the Id-1 induced cellular protection against apoptosis is mediated through Raf/MEK signalling pathways.	Paclitaxel	31-36	zinc fingers and homeoboxes 2	Homo sapiens	264-267
28534969-9	2017	The Cdc2 inhibitor, purvalanol A, enhanced the cytotoxic effects of taxol through Op18/stathmin.	Paclitaxel	68-73	cyclin dependent kinase 1	Homo sapiens	4-8
28534969-9	2017	The Cdc2 inhibitor, purvalanol A, enhanced the cytotoxic effects of taxol through Op18/stathmin.	Paclitaxel	68-73	stathmin 1	Homo sapiens	82-86
14742319-9	2004	Our results suggest that Id-1 may be an upstream regulator of the Raf/MEK signalling pathway, which plays an essential role in protection against taxol-induced apoptosis.	Paclitaxel	146-151	inhibitor of DNA binding 1, HLH protein	Homo sapiens	25-29
28534969-9	2017	The Cdc2 inhibitor, purvalanol A, enhanced the cytotoxic effects of taxol through Op18/stathmin.	Paclitaxel	68-73	stathmin 1	Homo sapiens	87-95
14742319-9	2004	Our results suggest that Id-1 may be an upstream regulator of the Raf/MEK signalling pathway, which plays an essential role in protection against taxol-induced apoptosis.	Paclitaxel	146-151	zinc fingers and homeoboxes 2	Homo sapiens	66-69
32521853-0	2020	Efficacy of albumin-bound paclitaxel in the treatment of advanced refractory breast cancer and its effect on serum resistin.	Paclitaxel	26-36	resistin	Homo sapiens	115-123
15110841-0	2004	Taxol derivatives are selective inhibitors of DNA polymerase alpha.	Paclitaxel	0-5	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	46-66
32521853-1	2020	PURPOSE: This study aimed to investigate the efficacy of albumin-bound paclitaxel (nab-paclitaxel) in the treatment of advanced refractory breast cancer (BC) and its effect on serum resistin.	Paclitaxel	71-81	resistin	Homo sapiens	182-190
32521853-1	2020	PURPOSE: This study aimed to investigate the efficacy of albumin-bound paclitaxel (nab-paclitaxel) in the treatment of advanced refractory breast cancer (BC) and its effect on serum resistin.	Paclitaxel	87-97	resistin	Homo sapiens	182-190
32521853-9	2020	CONCLUSION: The results indicated that nab-paclitaxel is very effective in treating advanced refractory BC and reduces the level of serum resistin.	Paclitaxel	43-53	resistin	Homo sapiens	138-146
28540720-10	2017	Interestingly, the synchronous release of paclitaxel (PTX) and the TOS fragment from the PTX-loaded HSST caused synergetic tumor cell killing and tumor growth inhibition.	Paclitaxel	42-52	N-deacetylase and N-sulfotransferase 1	Homo sapiens	100-104
28540720-10	2017	Interestingly, the synchronous release of paclitaxel (PTX) and the TOS fragment from the PTX-loaded HSST caused synergetic tumor cell killing and tumor growth inhibition.	Paclitaxel	89-92	N-deacetylase and N-sulfotransferase 1	Homo sapiens	100-104
15010891-5	2004	These data suggest that paclitaxel interferes with the expression of alphaLbeta2 (LFA-1), alpha4beta1 (VLA-4), alpha5beta1 (VLA-5), and alpha4beta7 (LPAM-1) adhesion molecules by surviving T cells.	Paclitaxel	24-34	integrin subunit alpha L	Homo sapiens	82-87
28632150-0	2017	Centrosomal Protein 70 Is a Mediator of Paclitaxel Sensitivity.	Paclitaxel	40-50	centrosomal protein 70	Homo sapiens	0-22
28632150-3	2017	However, it remains elusive whether Cep70 is implicated in the sensitivity of the anti-microtubule drug paclitaxel in breast cancer.	Paclitaxel	104-114	centrosomal protein 70	Homo sapiens	36-41
32080166-6	2020	We further identified that STAT3 functions to promote the transcription of the activating transcription factor 6 (ATF6), which induces endoplasmic reticulum stress to promote cellular autophagy, granting cancer cell resistance to both cisplatin and paclitaxel treatment.	Paclitaxel	249-259	activating transcription factor 6	Homo sapiens	79-112
32080166-6	2020	We further identified that STAT3 functions to promote the transcription of the activating transcription factor 6 (ATF6), which induces endoplasmic reticulum stress to promote cellular autophagy, granting cancer cell resistance to both cisplatin and paclitaxel treatment.	Paclitaxel	249-259	activating transcription factor 6	Homo sapiens	114-118
32110051-0	2020	Knockdown of FOXO6 Inhibits Glycolysis and Reduces Cell Resistance to Paclitaxel in HCC Cells via PI3K/Akt Signaling Pathway.	Paclitaxel	70-80	forkhead box O6	Homo sapiens	13-18
28632150-4	2017	Here we provide evidence that Cep70 is a mediator of paclitaxel sensitivity in breast cancer.	Paclitaxel	53-63	centrosomal protein 70	Homo sapiens	30-35
28632150-5	2017	Cell proliferation assays show that Cep70 expression correlates with paclitaxel sensitivity in breast cancer cell lines.	Paclitaxel	69-79	centrosomal protein 70	Homo sapiens	36-41
32110051-4	2020	Therefore, this study was set out to investigate the effect of FOXO6 on glycolysis and cytotoxicity of paclitaxel in HCC cells and its potential mechanism.	Paclitaxel	103-113	forkhead box O6	Homo sapiens	63-68
14676196-5	2004	CYP2C8 is one of the principal hepatic drug-metabolizing enzymes that oxidizes therapeutic drugs such as taxol and cerivastatin and endobiotics such as retinoic acid and arachidonic acid.	Paclitaxel	105-110	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
32110051-11	2020	Furthermore, it was found that when activated by 740Y-P, PI3K/Akt signaling pathway could resist the effects of FOXO6 knockdown on the cytotoxicity and glycolysis of paclitaxel in HCC cells.	Paclitaxel	166-176	forkhead box O6	Homo sapiens	112-117
32089626-0	2020	Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells.	Paclitaxel	76-86	E2F transcription factor 1	Homo sapiens	40-66
28632150-6	2017	In addition, paclitaxel sensitivity varies when altering Cep70 expression level.	Paclitaxel	13-23	centrosomal protein 70	Homo sapiens	57-62
28632150-7	2017	Mechanistic studies reveal that Cep70 interacts with tubulin, and promotes the ability of paclitaxel to stimulate microtubule assembly.	Paclitaxel	90-100	centrosomal protein 70	Homo sapiens	32-37
28632150-8	2017	These data demonstrate that Cep70 mediates paclitaxel sensitivity in breast cancer.	Paclitaxel	43-53	centrosomal protein 70	Homo sapiens	28-33
14996735-0	2004	Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin.	Paclitaxel	74-84	hepatocyte growth factor	Homo sapiens	0-24
28498440-5	2017	Transfection of pCDNA3.1(+)/GAS increased (P&lt;0.05) while transfection of siGAS (P&lt;0.05) and co-treated with paclitaxel (TAX) and vincristine (VCR) combination (TAX-VCR) decreased (P&lt;0.01) the cell viability of SGC7901, SGC7901/VCR and SGC7901/ADR.	Paclitaxel	114-124	gastrin	Homo sapiens	28-31
28440494-2	2017	The present study assessed whether paclitaxel (PTX) suppresses M2 macrophages, by acting as a Toll-like receptor 4 (TLR4) agonist.	Paclitaxel	35-45	toll like receptor 4	Homo sapiens	94-114
28440494-2	2017	The present study assessed whether paclitaxel (PTX) suppresses M2 macrophages, by acting as a Toll-like receptor 4 (TLR4) agonist.	Paclitaxel	35-45	toll like receptor 4	Homo sapiens	116-120
28440494-2	2017	The present study assessed whether paclitaxel (PTX) suppresses M2 macrophages, by acting as a Toll-like receptor 4 (TLR4) agonist.	Paclitaxel	47-50	toll like receptor 4	Homo sapiens	94-114
32089626-2	2020	AIM: To investigate the effect of miR-34c and its upstream transcription factor E2F1 on paclitaxel combined with cisplatin resistance in GC cells.	Paclitaxel	88-98	E2F transcription factor 1	Homo sapiens	80-84
32089626-9	2020	After inducing GC cells to be resistant to paclitaxel and cisplatin, E2F1 expression increased while miR-34c expression decreased.	Paclitaxel	43-53	E2F transcription factor 1	Homo sapiens	69-73
32089626-10	2020	Both silencing E2F1 and over-expressing miR-34c could increase the sensitivity of drug-resistant GC cells to paclitaxel combined with cisplatin, promote cell apoptosis and inhibit cell proliferation.	Paclitaxel	109-119	E2F transcription factor 1	Homo sapiens	15-19
32089626-12	2020	Rescue experiments demonstrated that inhibiting miR-34c could significantly weaken the sensitization of drug resistant cells, and Si E2F1 to paclitaxel combined with cisplatin.	Paclitaxel	141-151	E2F transcription factor 1	Homo sapiens	133-137
28440494-2	2017	The present study assessed whether paclitaxel (PTX) suppresses M2 macrophages, by acting as a Toll-like receptor 4 (TLR4) agonist.	Paclitaxel	47-50	toll like receptor 4	Homo sapiens	116-120
28440494-4	2017	The effects of PTX on macrophage expression of CD204, a marker of M2 macrophages and NOS2, a marker of M1 macrophages, was evaluated by western blotting.	Paclitaxel	15-18	macrophage scavenger receptor 1	Homo sapiens	47-52
32089626-13	2020	CONCLUSION: E2F1 inhibits miR-34c to promote the proliferation of GC cells and enhance the resistance to paclitaxel combined with cisplatin, and silencing E2F1 is conducive to improving the efficacy of paclitaxel combined with cisplatin in GC cells.	Paclitaxel	105-115	E2F transcription factor 1	Homo sapiens	12-16
14996735-3	2004	The apoptotic effect of the front-line chemotherapeutic drugs paclitaxel and cisplatin on cells treated with HGF was studied.	Paclitaxel	62-72	hepatocyte growth factor	Homo sapiens	109-112
32089626-13	2020	CONCLUSION: E2F1 inhibits miR-34c to promote the proliferation of GC cells and enhance the resistance to paclitaxel combined with cisplatin, and silencing E2F1 is conducive to improving the efficacy of paclitaxel combined with cisplatin in GC cells.	Paclitaxel	202-212	E2F transcription factor 1	Homo sapiens	12-16
32089626-13	2020	CONCLUSION: E2F1 inhibits miR-34c to promote the proliferation of GC cells and enhance the resistance to paclitaxel combined with cisplatin, and silencing E2F1 is conducive to improving the efficacy of paclitaxel combined with cisplatin in GC cells.	Paclitaxel	202-212	E2F transcription factor 1	Homo sapiens	155-159
28440494-6	2017	In THP-1 macrophages, low-dose PTX (1 and 5 nM) inhibited the expression of CD204, enhanced the expression of NOS2, and significantly suppressed the phosphorylation of Stat3, which is essential for the M2 phenotype.	Paclitaxel	31-34	macrophage scavenger receptor 1	Homo sapiens	76-81
28440494-7	2017	Low-dose PTX also inhibited CD204 expression in primary macrophages derived from PBMCs.	Paclitaxel	9-12	macrophage scavenger receptor 1	Homo sapiens	28-33
28440494-9	2017	Low-dose PTX inhibited the M2 phenotype and induced the M1 phenotype via TLR4 signaling, suggesting that low-dose PTX can alter the macrophage phenotype, whereas clinical doses can kill cancer cells.	Paclitaxel	9-12	toll like receptor 4	Homo sapiens	73-77
14996735-4	2004	In ovarian cancer cell lines, pretreatment with HGF surprisingly enhances the apoptotic response to low doses of paclitaxel and cisplatin.	Paclitaxel	113-123	hepatocyte growth factor	Homo sapiens	48-51
28440494-9	2017	Low-dose PTX inhibited the M2 phenotype and induced the M1 phenotype via TLR4 signaling, suggesting that low-dose PTX can alter the macrophage phenotype, whereas clinical doses can kill cancer cells.	Paclitaxel	114-117	toll like receptor 4	Homo sapiens	73-77
14655049-2	2004	METHODS: An in vivo paclitaxel-resistant subline (OM1/Tvivo) was established from the parental human ovarian cancer cell line (OVMG1) by repeated paclitaxel administration into tumor-bearing mice.	Paclitaxel	20-30	importin 8	Mus musculus	50-53
28242239-0	2017	Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro.	Paclitaxel	62-72	toll like receptor 4	Homo sapiens	8-28
28242239-5	2017	Clinically, DDI was observed for combination chemotherapy of paclitaxel (TLR4 ligand) and irinotecan.	Paclitaxel	61-71	toll like receptor 4	Homo sapiens	73-77
32166677-0	2020	Application of Paclitaxel-loaded EGFR Peptide-conjugated Magnetic Polymeric Liposomes for Liver Cancer Therapy.	Paclitaxel	15-25	epidermal growth factor receptor	Mus musculus	33-37
32166677-5	2020	In addition, paclitaxel (PTX) was incorporated into small EGFR-conjugated MPLs (102.0+-0.7 nm), resulting in spherical particles with high drug encapsulation efficiency (>90%).	Paclitaxel	13-23	epidermal growth factor receptor	Mus musculus	58-62
32166677-5	2020	In addition, paclitaxel (PTX) was incorporated into small EGFR-conjugated MPLs (102.0+-0.7 nm), resulting in spherical particles with high drug encapsulation efficiency (>90%).	Paclitaxel	25-28	epidermal growth factor receptor	Mus musculus	58-62
32166677-6	2020	The use of the magnetic targeting for enhancing the transport of PTX-loaded EGFR-conjugated MPLs to the tumor site was further confirmed by detecting PTX levels.	Paclitaxel	65-68	epidermal growth factor receptor	Mus musculus	76-80
32166677-6	2020	The use of the magnetic targeting for enhancing the transport of PTX-loaded EGFR-conjugated MPLs to the tumor site was further confirmed by detecting PTX levels.	Paclitaxel	150-153	epidermal growth factor receptor	Mus musculus	76-80
32166677-7	2020	In conclusion, PTX-loaded EGFR-conjugated MPLs could potentially be used as an effective drug delivery system for targeted liver cancer therapy.	Paclitaxel	15-18	epidermal growth factor receptor	Mus musculus	26-30
31489998-0	2020	Guanylate-binding protein-2 inhibits colorectal cancer cell growth and increases the sensitivity to paclitaxel of paclitaxel-resistant colorectal cancer cells by interfering Wnt signaling.	Paclitaxel	100-110	guanylate binding protein 2	Homo sapiens	0-27
28242239-8	2017	Paclitaxel treatment increased the levels of irinotecan metabolites, SN-38 and SN-38 glucuronide (SN-38G) in TLR4-dependent manner.	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	109-113
28423714-4	2017	Hepatoma cells transduced with MRP2pr-OATP1B1-V5 resulted in dexamethasone-sensitive inducible OATP1B1 expression and enhanced selective antitumor response to OATP1B1 substrates (paclitaxel, Bamet-R2 and Bamet-UD2).	Paclitaxel	179-189	solute carrier organic anion transporter family member 1B1	Homo sapiens	38-45
14655049-2	2004	METHODS: An in vivo paclitaxel-resistant subline (OM1/Tvivo) was established from the parental human ovarian cancer cell line (OVMG1) by repeated paclitaxel administration into tumor-bearing mice.	Paclitaxel	146-156	importin 8	Mus musculus	50-53
14655049-4	2004	An in vitro paclitaxel-resistant subline (OM1/Tvitro) was established by exposure to stepwise increased concentrations of the drug in a cell culture medium.	Paclitaxel	12-22	importin 8	Mus musculus	42-45
14655049-9	2004	Compared with the OM1/Cvivo subline, the OM1/Tvivo tumor showed stable drug-resistance and lower drug distribution after paclitaxel administration into mice, whereas cultured OM1/Tvivo cells lost both completely.	Paclitaxel	121-131	importin 8	Mus musculus	41-44
14655049-9	2004	Compared with the OM1/Cvivo subline, the OM1/Tvivo tumor showed stable drug-resistance and lower drug distribution after paclitaxel administration into mice, whereas cultured OM1/Tvivo cells lost both completely.	Paclitaxel	121-131	importin 8	Mus musculus	41-44
28522974-8	2017	Furthermore, expression of glutaminolysis-related genes GLS, SLC7A11 and SLC1A5 were significantly decreased in the colorectal carcinoma cells treated with low-dose PTX.	Paclitaxel	165-168	solute carrier family 7 member 11	Homo sapiens	61-68
28522974-11	2017	Up-regulation of p53 and p21 in colorectal carcinoma cells treated with low-dose PTX also contributed to inhibition of tumor cell growth.	Paclitaxel	81-84	H3 histone pseudogene 16	Homo sapiens	25-28
31489998-0	2020	Guanylate-binding protein-2 inhibits colorectal cancer cell growth and increases the sensitivity to paclitaxel of paclitaxel-resistant colorectal cancer cells by interfering Wnt signaling.	Paclitaxel	114-124	guanylate binding protein 2	Homo sapiens	0-27
31489998-4	2020	In this study, the authors are determined to dig into the role that GBP-2 plays in the sensitivity of CRC to PTX, therefore, possibly indicating a promising gene therapy target for CRC.	Paclitaxel	109-112	guanylate binding protein 2	Homo sapiens	68-73
14569416-3	2004	In the present study, a human ovarian cancer cell line was used to investigate the possibility that Taxol might affect the expression of Ang-1, Ang-2, and VEGF.	Paclitaxel	100-105	angiopoietin 1	Homo sapiens	137-142
31489998-8	2020	The level of GBP-2 mRNA and protein in PTX-resistant CRC cell lines was significantly lower than in nonresistant cell lines.	Paclitaxel	39-42	guanylate binding protein 2	Homo sapiens	13-18
31489998-9	2020	Forced exogenous expression of GBP-2 in PTX-resistant CRC cell lines resulted in more sensitivity to PTX because of the demonstration of less cell proliferation, invasion, and more apoptosis.	Paclitaxel	40-43	guanylate binding protein 2	Homo sapiens	31-36
31489998-9	2020	Forced exogenous expression of GBP-2 in PTX-resistant CRC cell lines resulted in more sensitivity to PTX because of the demonstration of less cell proliferation, invasion, and more apoptosis.	Paclitaxel	101-104	guanylate binding protein 2	Homo sapiens	31-36
31489998-11	2020	GBP-2 upregulation could enhance the killing effect of PTX in both PTX-sensitive CRC cells and PTX-resistant CRC cells by suppressing Wnt signaling.	Paclitaxel	55-58	guanylate binding protein 2	Homo sapiens	0-5
28415820-8	2017	We found that the expression of PD-L1 could be efficiently disrupted by CRISPR/Cas9 system and PD-L1 knockdown increased drug sensitivities for doxorubicin and paclitaxel.	Paclitaxel	160-170	CD274 molecule	Homo sapiens	32-37
28415820-8	2017	We found that the expression of PD-L1 could be efficiently disrupted by CRISPR/Cas9 system and PD-L1 knockdown increased drug sensitivities for doxorubicin and paclitaxel.	Paclitaxel	160-170	CD274 molecule	Homo sapiens	95-100
31489998-11	2020	GBP-2 upregulation could enhance the killing effect of PTX in both PTX-sensitive CRC cells and PTX-resistant CRC cells by suppressing Wnt signaling.	Paclitaxel	67-70	guanylate binding protein 2	Homo sapiens	0-5
31489998-11	2020	GBP-2 upregulation could enhance the killing effect of PTX in both PTX-sensitive CRC cells and PTX-resistant CRC cells by suppressing Wnt signaling.	Paclitaxel	67-70	guanylate binding protein 2	Homo sapiens	0-5
14569416-3	2004	In the present study, a human ovarian cancer cell line was used to investigate the possibility that Taxol might affect the expression of Ang-1, Ang-2, and VEGF.	Paclitaxel	100-105	angiopoietin 2	Homo sapiens	144-149
15581045-4	2004	To improve on these results, we investigated a triplet, paclitaxel-gemcitabine-trastuzumab (TGH), in a phase II study.	Paclitaxel	56-66	carboxylesterase 1	Homo sapiens	92-95
31704732-0	2020	EZH2 loss drives resistance to carboplatin and paclitaxel in serous ovarian cancers expressing ATM.	Paclitaxel	47-57	ATM serine/threonine kinase	Homo sapiens	95-98
28304139-1	2017	BACKGROUND: The study was conducted to evaluate the efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel (NAB-paclitaxel) treatment in patients with advanced non-small-cell lung cancer (NSCLC) who have undergone multi-line therapy, and to investigate the association of secreted protein acidic and rich in cysteine (SPARC) expression status with clinical outcome.	Paclitaxel	121-131	secreted protein acidic and cysteine rich	Homo sapiens	297-341
28304139-1	2017	BACKGROUND: The study was conducted to evaluate the efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel (NAB-paclitaxel) treatment in patients with advanced non-small-cell lung cancer (NSCLC) who have undergone multi-line therapy, and to investigate the association of secreted protein acidic and rich in cysteine (SPARC) expression status with clinical outcome.	Paclitaxel	121-131	secreted protein acidic and cysteine rich	Homo sapiens	343-348
14505794-5	2003	ARE 1 binding activity was substantially reduced in extracts of cells treated for 20 hr with taxol or OA and was abolished after 32 hr of treatment.	Paclitaxel	93-98	VPS52 subunit of GARP complex	Homo sapiens	0-5
14531288-0	2003	[MyD88 is involved in the signaling pathway for paclitaxel-induced apoptosis].	Paclitaxel	48-58	MYD88 innate immune signal transduction adaptor	Homo sapiens	1-6
28322796-0	2017	Modulation of the sphingolipid rheostat is involved in paclitaxel resistance of the human prostate cancer cell line PC3-PR.	Paclitaxel	55-65	proprotein convertase subtilisin/kexin type 1	Homo sapiens	116-119
28232485-7	2017	These findings indicate that LINC00672 can influence LASP1 expression as a locus-restricted cofactor for p53-mediated gene suppression, thus impacting EC malignancies and chemosensitivity to paclitaxel.	Paclitaxel	191-201	transformation related protein 53, pseudogene	Mus musculus	105-108
28356132-13	2017	In particular, the sensitivity to paclitaxel was reactivated in E-cadherin-overexpressing PC3-TxR and DU145-TxR cells.	Paclitaxel	34-44	proprotein convertase subtilisin/kexin type 1	Homo sapiens	90-93
28356132-14	2017	When E-cadherin expression was silenced in parental PC3 and DU145 cells, the expression of Vimentin and Snail was up-regulated, and, particularly, the sensitivity to paclitaxel was decreased.	Paclitaxel	166-176	proprotein convertase subtilisin/kexin type 1	Homo sapiens	52-55
31966052-6	2020	A total of 26 patients exhibited highly methylated PD-L1; in this group, the median progression-free survival time of patients receiving platinum/fluorouracil chemotherapy was 4.2 months longer than those receiving paclitaxel/fluorouracil chemotherapy, and the risk of disease progression in patients receiving paclitaxel/fluorouracil chemotherapy was 5.009 times higher compared with patients who received platinum/fluorouracil chemotherapy.	Paclitaxel	215-225	CD274 molecule	Homo sapiens	51-56
31966052-6	2020	A total of 26 patients exhibited highly methylated PD-L1; in this group, the median progression-free survival time of patients receiving platinum/fluorouracil chemotherapy was 4.2 months longer than those receiving paclitaxel/fluorouracil chemotherapy, and the risk of disease progression in patients receiving paclitaxel/fluorouracil chemotherapy was 5.009 times higher compared with patients who received platinum/fluorouracil chemotherapy.	Paclitaxel	311-321	CD274 molecule	Homo sapiens	51-56
32194804-0	2020	Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets.	Paclitaxel	36-41	transformation related protein 53, pseudogene	Mus musculus	100-103
28152500-7	2017	PFKFB4 depletion increased caspase 3/7 activity, and levels of reactive oxygen species only in mitotically arrested cells, and significantly enhanced mitotic cell death after paclitaxel treatment.	Paclitaxel	175-185	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4	Homo sapiens	0-6
12855658-9	2003	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cytotoxicity analysis of both MAGE2 and MAGE6 transfectants demonstrates a 4-fold increase in resistance to paclitaxel and 2-fold increase in resistance to doxorubicin but not to other drugs, such as topotecan and cisplatin, through a nonmultidrug resistance-1 mechanism.	Paclitaxel	169-179	MAGE family member A2B	Homo sapiens	91-96
28454290-7	2017	In addition, the Akt2-3shRNA vector, containing three shRNAs targeting Akt2, showed the best effect of all the shRNA vectors in reversing paclitaxel-induced resistance in SKOV3 cells.	Paclitaxel	138-148	AKT serine/threonine kinase 2	Homo sapiens	17-21
28454290-7	2017	In addition, the Akt2-3shRNA vector, containing three shRNAs targeting Akt2, showed the best effect of all the shRNA vectors in reversing paclitaxel-induced resistance in SKOV3 cells.	Paclitaxel	138-148	AKT serine/threonine kinase 2	Homo sapiens	71-75
31783010-0	2020	Overcoming Taxol-resistance in A549 Cells: A Comprehensive Strategy of Targeting P-gp transporter, AKT/ERK Pathways, and Cytochrome P450 Enzyme CYP1B1 by 4-hydroxyemodin.	Paclitaxel	11-16	phosphoglycolate phosphatase	Homo sapiens	81-85
32401925-5	2020	Administration of beta-elemene+paclitaxel arrested SKOV3 cell cycle at S phase and down-regulated CDK1, cyclin-B1, and P27 gene expression and apoptotic-related resistant gene expression of MDR1, LRP, and TS in SKOV3 cells.	Paclitaxel	31-41	cyclin dependent kinase 1	Homo sapiens	98-102
32401925-5	2020	Administration of beta-elemene+paclitaxel arrested SKOV3 cell cycle at S phase and down-regulated CDK1, cyclin-B1, and P27 gene expression and apoptotic-related resistant gene expression of MDR1, LRP, and TS in SKOV3 cells.	Paclitaxel	31-41	cyclin B1	Homo sapiens	104-113
12855658-9	2003	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cytotoxicity analysis of both MAGE2 and MAGE6 transfectants demonstrates a 4-fold increase in resistance to paclitaxel and 2-fold increase in resistance to doxorubicin but not to other drugs, such as topotecan and cisplatin, through a nonmultidrug resistance-1 mechanism.	Paclitaxel	169-179	MAGE family member A6	Homo sapiens	101-106
28253574-1	2017	Objective: To investigate the effect and mechanism of CRM197, the heparin binding-epidermal growth factor-like growth factor (HB-EGF) inhibitor, on the reverse of the resistance of ovarian cancer to paclitaxel.	Paclitaxel	199-209	heparin binding EGF like growth factor	Homo sapiens	126-132
12858347-8	2003	In addition, IL-2Ralpha-expressing cells were significantly more resistant to apoptosis induction by a tripeptidyl proteasome inhibitor (ALLN) and two chemotherapeutic drugs (VP-16 and taxol) than the control or IL-2Rgamma+ cells.	Paclitaxel	185-190	interleukin 2 receptor subunit alpha	Homo sapiens	13-23
28253574-9	2017	The expression level of HB-EGF protein in A2780/Taxol+CRM197 group (1.44+-0.29) was significantly lower than HB-EGF protein in A2780/Taxol group (2.72+-0.32), respectively (P&lt;0.05).	Paclitaxel	48-53	heparin binding EGF like growth factor	Homo sapiens	24-30
28253574-9	2017	The expression level of HB-EGF protein in A2780/Taxol+CRM197 group (1.44+-0.29) was significantly lower than HB-EGF protein in A2780/Taxol group (2.72+-0.32), respectively (P&lt;0.05).	Paclitaxel	133-138	heparin binding EGF like growth factor	Homo sapiens	24-30
28253574-10	2017	The expression level of EGFR protein (0.71+-0.25) and P-gp protein (0.82+-0.19) in A2780/Taxol+CRM197 group was significantly lower than EGFR protein (1.87+-0.31) and P-gp protein (1.84+-0.27) of A2780/Taxol group (P&lt;0.05).	Paclitaxel	89-94	phosphoglycolate phosphatase	Homo sapiens	54-58
28253574-10	2017	The expression level of EGFR protein (0.71+-0.25) and P-gp protein (0.82+-0.19) in A2780/Taxol+CRM197 group was significantly lower than EGFR protein (1.87+-0.31) and P-gp protein (1.84+-0.27) of A2780/Taxol group (P&lt;0.05).	Paclitaxel	89-94	phosphoglycolate phosphatase	Homo sapiens	167-171
31853314-0	2020	miR-31-5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC.	Paclitaxel	56-61	microRNA 31	Homo sapiens	0-6
31853314-8	2020	In conclusion, the present preclinical results indicated that targeting miR-31-5p may enhance the efficacy of TAX- and DDP-mediated chemotherapy in TNBC.	Paclitaxel	110-113	microRNA 31	Homo sapiens	72-78
31511646-0	2020	Correction: PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer.	Paclitaxel	91-101	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	12-16
31906029-3	2019	In the present study, taxol (TAX) and nocodazole (NOC) significantly induced apoptosis with increased expression of phosphorylated PERK (pPERK; Tyr980) in four human colon cancer cell lines, including HCT-15, COLO205, HT-20, and LOVO cells.	Paclitaxel	22-27	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	131-135
31906029-3	2019	In the present study, taxol (TAX) and nocodazole (NOC) significantly induced apoptosis with increased expression of phosphorylated PERK (pPERK; Tyr980) in four human colon cancer cell lines, including HCT-15, COLO205, HT-20, and LOVO cells.	Paclitaxel	29-32	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	131-135
31906029-4	2019	Induction of G2/M arrest by TAX and NOC with increases in phosphorylated Cdc25C and cyclin B1 protein were observed in human colon cancer cells.	Paclitaxel	28-31	cell division cycle 25C	Homo sapiens	73-79
28253574-15	2017	The expression scores of P-gp protein in A2780/Taxol+CRM197 tumors (3.8+-1.1) were lower than that in A2780/Taxol tumors (8.8+-2.7, P&lt;0.05).	Paclitaxel	47-52	phosphoglycolate phosphatase	Homo sapiens	25-29
28253574-16	2017	Conclusion: CRM197 reverses the resistance of ovarian cancer to paclitaxel by increasing caspase-3 activity to advance apoptosis via EGFR/MDR1/P-gp pathway.	Paclitaxel	64-74	phosphoglycolate phosphatase	Homo sapiens	143-147
31906029-4	2019	Induction of G2/M arrest by TAX and NOC with increases in phosphorylated Cdc25C and cyclin B1 protein were observed in human colon cancer cells.	Paclitaxel	28-31	cyclin B1	Homo sapiens	84-93
12796407-0	2003	Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells.	Paclitaxel	0-10	solute carrier family 9 member C1	Homo sapiens	113-129
31906029-6	2019	Interestingly, TAX- and NOC-induced pPERK (Tyr980) protein expression was inhibited by adding the JNK inhibitors, SP and JNKI, and application of the PERK inhibitor GSK2606414 (GSK) significantly reduced apoptosis and G2/M arrest by TAX and NOC, with decreased pPERK (Tyr980) and pJNK, phosphorylated Cdc25C, and Cyc B1 protein expressions in human colon cancer cells.	Paclitaxel	15-18	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	37-41
31906029-6	2019	Interestingly, TAX- and NOC-induced pPERK (Tyr980) protein expression was inhibited by adding the JNK inhibitors, SP and JNKI, and application of the PERK inhibitor GSK2606414 (GSK) significantly reduced apoptosis and G2/M arrest by TAX and NOC, with decreased pPERK (Tyr980) and pJNK, phosphorylated Cdc25C, and Cyc B1 protein expressions in human colon cancer cells.	Paclitaxel	15-18	cell division cycle 25C	Homo sapiens	301-307
31906029-6	2019	Interestingly, TAX- and NOC-induced pPERK (Tyr980) protein expression was inhibited by adding the JNK inhibitors, SP and JNKI, and application of the PERK inhibitor GSK2606414 (GSK) significantly reduced apoptosis and G2/M arrest by TAX and NOC, with decreased pPERK (Tyr980) and pJNK, phosphorylated Cdc25C, and Cyc B1 protein expressions in human colon cancer cells.	Paclitaxel	233-236	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	37-41
31906029-7	2019	Decreased viability by TAX and NOC was inhibited by knockdown of PERK using PERK siRNA in COLO205 and HCT-15 cells.	Paclitaxel	23-26	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	65-69
31906029-7	2019	Decreased viability by TAX and NOC was inhibited by knockdown of PERK using PERK siRNA in COLO205 and HCT-15 cells.	Paclitaxel	23-26	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	76-80
28190463-7	2017	Schwann cell line LY-PPB6 pre-treated with PF and then treated with PTX was used to analyse the expression of the transcription factor CHOP, a marker of endoplasmic reticulum (ER) stress, by western blotting.	Paclitaxel	68-71	DNA-damage inducible transcript 3	Mus musculus	135-139
28190463-9	2017	Moreover, in cultured Schwann cells, PF downregulated PTX-induced expression of CHOP, indicating the inhibition of ER stress.	Paclitaxel	54-57	DNA-damage inducible transcript 3	Mus musculus	80-84
28077325-0	2017	Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR.	Paclitaxel	64-74	stratifin	Homo sapiens	8-20
28077325-1	2017	In this study, we presented the role of 14-3-3sigma to activate CK2-Hsp90beta-PXR-MDR1 pathway on rifampin and paclitaxel treated LS174T cells and in vivo LS174T cell-xenografted nude mouse model.	Paclitaxel	111-121	stratifin	Homo sapiens	40-51
28077325-1	2017	In this study, we presented the role of 14-3-3sigma to activate CK2-Hsp90beta-PXR-MDR1 pathway on rifampin and paclitaxel treated LS174T cells and in vivo LS174T cell-xenografted nude mouse model.	Paclitaxel	111-121	heat shock protein 90 alpha family class B member 1	Homo sapiens	68-77
28077325-2	2017	Following several in vitro and in vivo experiments, rifampin and paclitaxel were found to be stimulated the CK2-Hsp90beta-PXR-MDR1 pathway.	Paclitaxel	65-75	heat shock protein 90 alpha family class B member 1	Homo sapiens	112-121
28077325-10	2017	P-gp overexpression was induced only when 14-3-3sigma transfected LS174T cells were treated with rifampin and paclitaxel, whereas 14-3-3sigma inhibition by nonpeptidic inhibitor, BV02 and 14-3-3sigma siRNA reduced rifampin induced PXR and P-gp expression.	Paclitaxel	110-120	stratifin	Homo sapiens	42-53
12796407-0	2003	Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells.	Paclitaxel	0-10	solute carrier family 9 member C1	Homo sapiens	131-134
12796407-0	2003	Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells.	Paclitaxel	0-10	solute carrier family 9 member C1	Homo sapiens	136-139
31906029-8	2019	Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI.	Paclitaxel	139-142	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	180-184
12894555-3	2003	The aim of this study was to determine whether Paclitaxel (Taxol) induces TP expression and whether increased TP expression is further sensitized to Furtulon, using a human ovarian carcinoma cell line.	Paclitaxel	47-57	thymidine phosphorylase	Homo sapiens	74-76
27893326-13	2017	Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months for ERCC1-positive patients (HR, 1.11; 95% CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative patients (HR, 0.99; 95% CI, 0.73 to 1.33; interaction P = .64).	Paclitaxel	163-173	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	95-100
31793989-0	2019	Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through regulates ZEB1 expression by sponging miR-124-3p.	Paclitaxel	38-48	Pvt1 oncogene	Homo sapiens	18-22
12894555-3	2003	The aim of this study was to determine whether Paclitaxel (Taxol) induces TP expression and whether increased TP expression is further sensitized to Furtulon, using a human ovarian carcinoma cell line.	Paclitaxel	59-64	thymidine phosphorylase	Homo sapiens	74-76
31793989-0	2019	Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through regulates ZEB1 expression by sponging miR-124-3p.	Paclitaxel	38-48	microRNA 124-3	Homo sapiens	130-140
31793989-4	2019	But the function of circ-PVT1 involved in PTX resistance of GC is still unknown.	Paclitaxel	42-45	Pvt1 oncogene	Homo sapiens	25-29
25136768-10	2017	The results imply that IGF-1 may attenuate apoptosis to improve neuronal cell viability and promote neurite growth of DRG neurons with PT-induced neurotoxicity.	Paclitaxel	135-137	insulin-like growth factor 1	Rattus norvegicus	23-28
12522001-3	2003	Coadministration of tumor necrosis factor (TNF) soluble receptors, or ectopic expression of CrmA or dominant-negative caspase-8, abrogated potentiation of paclitaxel-induced mitochondrial injury and apoptosis by bryostatin 1, implicating the extrinsic apoptotic pathway in this process.	Paclitaxel	155-165	caspase 8	Homo sapiens	118-127
31793989-5	2019	In the present study, the expression levels of circ-PVT1, miR-124-3p and ZEB1 in PTX-resistant GC tissues and cells were detected by quantitative real-time polymerase chain reaction (RT-qPCR).	Paclitaxel	81-84	Pvt1 oncogene	Homo sapiens	52-56
31793989-5	2019	In the present study, the expression levels of circ-PVT1, miR-124-3p and ZEB1 in PTX-resistant GC tissues and cells were detected by quantitative real-time polymerase chain reaction (RT-qPCR).	Paclitaxel	81-84	microRNA 124-3	Homo sapiens	58-68
31793989-10	2019	The role of circ-PVT1 in PTX resistance of GC in vivo was measured by xenograft tumor model.	Paclitaxel	25-28	Pvt1 oncogene	Homo sapiens	17-21
28138318-9	2016	Paclitaxel increased the levels of phosphorylated protein kinase C, phosphorylated nuclear factor kappaB, phosphodiesterase 4D (PDE4D), IL-1beta, and monocyte chemoattractant protein-1 in the lumbar dorsal root ganglia; however, tempol decreased these levels.	Paclitaxel	0-10	C-C motif chemokine ligand 2	Rattus norvegicus	150-184
31793989-11	2019	Our results showed that circ-PVT1 expression was upregulated in PTX-resistant GC tissues and cells.	Paclitaxel	64-67	Pvt1 oncogene	Homo sapiens	29-33
31793989-12	2019	Circ-PVT1 downregulation enhanced PTX sensitivity in PTX-resistant GC cells by negatively regulating miR-124-3p.	Paclitaxel	34-37	Pvt1 oncogene	Homo sapiens	5-9
31793989-12	2019	Circ-PVT1 downregulation enhanced PTX sensitivity in PTX-resistant GC cells by negatively regulating miR-124-3p.	Paclitaxel	34-37	microRNA 124-3	Homo sapiens	101-111
14993419-2	2003	The overexpression of aurora-A, a Ser-Thr kinase known to localize to centrosomes during mitosis, appears to imbue cancerous cells with resistance to spindle-checkpoint-targeting drugs such as paclitaxel (Taxol).	Paclitaxel	193-203	aurora kinase A	Homo sapiens	22-30
27632200-2	2017	Previously, it was shown that Tau, a microtubule-associated protein (MAP) localized to neuronal axons, regulates the average number of PFs in microtubules with increasing inner radius &lt;RinMT&gt; observed for increasing Tau/tubulin-dimer molar ratio PhiTau at paclitaxel/tubulin-dimer molar ratio LambdaPtxl=1/1.	Paclitaxel	262-272	regulator of microtubule dynamics 1	Homo sapiens	37-67
27632200-2	2017	Previously, it was shown that Tau, a microtubule-associated protein (MAP) localized to neuronal axons, regulates the average number of PFs in microtubules with increasing inner radius &lt;RinMT&gt; observed for increasing Tau/tubulin-dimer molar ratio PhiTau at paclitaxel/tubulin-dimer molar ratio LambdaPtxl=1/1.	Paclitaxel	262-272	regulator of microtubule dynamics 1	Homo sapiens	69-72
27632200-9	2017	GENERAL SIGNIFICANCE: Investigating MAP-mediated interactions between microtubules (as it relates to in vivo behavior) requires the elimination or minimization of paclitaxel.	Paclitaxel	163-173	regulator of microtubule dynamics 1	Homo sapiens	36-39
29953775-3	2017	Resistence of ovarian cancer cells to paclitaxel and cisplatin is associated with a reduced expression of miR-30c, miR-130, and miR335, which results in activation of M-CSF, the known factor of resistance to cytostatic drugs.	Paclitaxel	38-48	colony stimulating factor 1	Homo sapiens	167-172
31793989-12	2019	Circ-PVT1 downregulation enhanced PTX sensitivity in PTX-resistant GC cells by negatively regulating miR-124-3p.	Paclitaxel	53-56	Pvt1 oncogene	Homo sapiens	5-9
14993419-2	2003	The overexpression of aurora-A, a Ser-Thr kinase known to localize to centrosomes during mitosis, appears to imbue cancerous cells with resistance to spindle-checkpoint-targeting drugs such as paclitaxel (Taxol).	Paclitaxel	205-210	aurora kinase A	Homo sapiens	22-30
31793989-12	2019	Circ-PVT1 downregulation enhanced PTX sensitivity in PTX-resistant GC cells by negatively regulating miR-124-3p.	Paclitaxel	53-56	microRNA 124-3	Homo sapiens	101-111
31793989-15	2019	Circ-PVT1 knockdown increased PTX sensitivity of GC in vivo.	Paclitaxel	30-33	Pvt1 oncogene	Homo sapiens	5-9
14993419-5	2003	Thus, the design of new drugs that specifically target aurora-A rather than other checkpoint proteins might alleviate the resistance to Taxol-like clinical therapeutics observed in some tumors.	Paclitaxel	136-141	aurora kinase A	Homo sapiens	55-63
31793989-16	2019	Taken together, our studies disclosed that circ-PVT1 facilitated PTX resistance by upregulating ZEB1 mediated via miR-124-3p, suggesting an underlying therapeutic strategy for GC.	Paclitaxel	65-68	Pvt1 oncogene	Homo sapiens	48-52
31793989-16	2019	Taken together, our studies disclosed that circ-PVT1 facilitated PTX resistance by upregulating ZEB1 mediated via miR-124-3p, suggesting an underlying therapeutic strategy for GC.	Paclitaxel	65-68	microRNA 124-3	Homo sapiens	114-124
12700660-5	2003	Taxol-induced cell death was inhibited by the use of synthetic, cell-permeable caspase-3- (zDEVD-fmk) or caspase-8-specific (zIETD-fmk) inhibitors.	Paclitaxel	0-5	caspase 8	Homo sapiens	105-114
31842957-14	2019	In addition to the recently approved combination of atezolizumab and nab-paclitaxel for PD-L1-positive mTNBC, new treatments resulting in durable clinical responses, prolonged survival, and manageable safety profile would greatly benefit patients with mTNBC.	Paclitaxel	73-83	CD274 molecule	Homo sapiens	88-93
27365266-4	2017	By sensitivity enhancement ratio, PTX alone, dual drug combinations, and Triolimus treatment at 2 x 10-9 m have radiosensitizing effects with potency as follows: PTX alone (PTX) &gt; PTX and RAP (P/R) &gt; Triolimus (TRIO) &gt; PTX and 17-AAG (P/17) &gt;17-AAG and RAP (17/R).	Paclitaxel	34-37	LDL receptor related protein associated protein 1	Homo sapiens	183-194
12691824-0	2003	Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells.	Paclitaxel	51-61	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	19-24
27840408-12	2016	Silencing of CTSL reversed the chemoresistance in A549/DDP and A549/TAX cells, whereas overexpression of CTSL attenuated the sensitivity of A549 cells to cisplatin or paclitaxel.	Paclitaxel	167-177	cathepsin L	Mus musculus	105-109
30829071-0	2019	Plastin 3 down-regulation augments the sensitivity of MDA-MB-231 cells to paclitaxel via the p38 MAPK signalling pathway.	Paclitaxel	74-84	plastin 3	Homo sapiens	0-9
30829071-2	2019	Herein, we show that the down-regulation of PLS3 by PLS3 gene silencing augments the sensitivity of MDA-MB-231 triple-negative breast cancer cells to paclitaxel.	Paclitaxel	150-160	plastin 3	Homo sapiens	44-48
27840408-15	2016	In xenograft nude mouse model, the mice implanted with A549 cells overexpressing CTSL exhibited significantly reduced sensitivity to paclitaxel treatment, and increased expression of EMT-associated proteins and transcription factors in tumor tissues.	Paclitaxel	133-143	cathepsin L	Mus musculus	81-85
30829071-2	2019	Herein, we show that the down-regulation of PLS3 by PLS3 gene silencing augments the sensitivity of MDA-MB-231 triple-negative breast cancer cells to paclitaxel.	Paclitaxel	150-160	plastin 3	Homo sapiens	52-56
27840408-16	2016	CONCLUSION: Cisplatin and paclitaxel resistance is associated with CTSL upregulation-induced EMT in A549 cells.	Paclitaxel	26-36	cathepsin L	Mus musculus	67-71
12691824-1	2003	Experiments were carried out to determine the role of Raf-1 kinase in the development of drug resistance and apoptosis induced by paclitaxel.	Paclitaxel	130-140	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	54-59
27840408-17	2016	Thus, CTSL-mediated EMT may be exploited as a target to enhance the efficacy of cisplatin or paclitaxel against lung cancer and other types of malignancies.	Paclitaxel	93-103	cathepsin L	Mus musculus	6-10
30829071-3	2019	Interestingly, a low concentration of paclitaxel was able to induce strong apoptosis in the PLS3-silenced cells.	Paclitaxel	38-48	plastin 3	Homo sapiens	92-96
30829071-4	2019	Further study revealed that p38 MAPK signalling was responsible for the increased sensitivity to paclitaxel in these cells, as the p38 MAPK inhibitor SB203580 impaired the changes mediated by PLS3 down-regulation in response to paclitaxel.	Paclitaxel	97-107	plastin 3	Homo sapiens	192-196
30829071-4	2019	Further study revealed that p38 MAPK signalling was responsible for the increased sensitivity to paclitaxel in these cells, as the p38 MAPK inhibitor SB203580 impaired the changes mediated by PLS3 down-regulation in response to paclitaxel.	Paclitaxel	228-238	plastin 3	Homo sapiens	192-196
12691824-3	2003	Paclitaxel treatment of parental MCF-7 cells caused a marked inhibition of Raf-1 kinase activity, concomitant with its mobility shift after 18 h exposure.	Paclitaxel	0-10	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	75-80
30829071-5	2019	Therefore, our study identifies PLS3 as a potential target for enhancing the p38 MAPK-mediated apoptosis induced by paclitaxel.	Paclitaxel	116-126	plastin 3	Homo sapiens	32-36
12691824-7	2003	Thus, the findings suggest that paclitaxel-induced apoptosis is mediated by JNK and occurs in parallel with suppression of the Raf-1 kinase activity in parental MCF-7 cells.	Paclitaxel	32-42	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	127-132
30829071-8	2019	The finding that PLS3 could be a critical regulator of paclitaxel sensitivity may have important implications for breast cancer chemotherapy.	Paclitaxel	55-65	plastin 3	Homo sapiens	17-21
27289016-4	2016	This study showed that Op18/stathmin silencing by RNA interference (RNAi) combined taxol cooperatively improved cellular apoptosis in CNE1 cells mainly via initiating endogenous death receptor pathway, impaired the capabilities of cellular proliferation and cellular migration and down-regulated the half maximal inhibitory concentration (IC50 ) of taxol, meanwhile decreased the expression of the upstream extracellular regulated kinase 1 (ERK1) in vitro.	Paclitaxel	83-88	stathmin 1	Homo sapiens	23-27
27289016-4	2016	This study showed that Op18/stathmin silencing by RNA interference (RNAi) combined taxol cooperatively improved cellular apoptosis in CNE1 cells mainly via initiating endogenous death receptor pathway, impaired the capabilities of cellular proliferation and cellular migration and down-regulated the half maximal inhibitory concentration (IC50 ) of taxol, meanwhile decreased the expression of the upstream extracellular regulated kinase 1 (ERK1) in vitro.	Paclitaxel	83-88	stathmin 1	Homo sapiens	28-36
27289016-4	2016	This study showed that Op18/stathmin silencing by RNA interference (RNAi) combined taxol cooperatively improved cellular apoptosis in CNE1 cells mainly via initiating endogenous death receptor pathway, impaired the capabilities of cellular proliferation and cellular migration and down-regulated the half maximal inhibitory concentration (IC50 ) of taxol, meanwhile decreased the expression of the upstream extracellular regulated kinase 1 (ERK1) in vitro.	Paclitaxel	349-354	stathmin 1	Homo sapiens	23-27
27289016-4	2016	This study showed that Op18/stathmin silencing by RNA interference (RNAi) combined taxol cooperatively improved cellular apoptosis in CNE1 cells mainly via initiating endogenous death receptor pathway, impaired the capabilities of cellular proliferation and cellular migration and down-regulated the half maximal inhibitory concentration (IC50 ) of taxol, meanwhile decreased the expression of the upstream extracellular regulated kinase 1 (ERK1) in vitro.	Paclitaxel	349-354	stathmin 1	Homo sapiens	28-36
27289016-5	2016	Evidence also showed that taxol cytotoxicity was markedly augmented for Op18/stathmin RNAi in other NPC cells.	Paclitaxel	26-31	stathmin 1	Homo sapiens	72-76
27289016-5	2016	Evidence also showed that taxol cytotoxicity was markedly augmented for Op18/stathmin RNAi in other NPC cells.	Paclitaxel	26-31	stathmin 1	Homo sapiens	77-85
12649748-0	2003	Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody.	Paclitaxel	12-22	intercellular adhesion molecule 1	Mus musculus	63-67
27289016-8	2016	These findings suggest that silencing Op18/stathmin by RNAi promotes chemosensitization of NPC to taxol and reverses malignant phenotypes of NPC, which provides a new clue for treating drug-resistant tumours.	Paclitaxel	98-103	stathmin 1	Homo sapiens	38-42
27289016-8	2016	These findings suggest that silencing Op18/stathmin by RNAi promotes chemosensitization of NPC to taxol and reverses malignant phenotypes of NPC, which provides a new clue for treating drug-resistant tumours.	Paclitaxel	98-103	stathmin 1	Homo sapiens	43-51
28002342-3	2016	Patients in arm 1 (n = 88) received 4 cycles of paclitaxel and carboplatin followed by 2 to 4 cycles of gemcitabine-based combination chemotherapy.	Paclitaxel	48-58	ADRM1 26S proteasome ubiquitin receptor	Homo sapiens	12-17
30880491-4	2019	Afterwards, it was used in combination with previously designed EGFR specific A-P-NLC (AEYLR peptide-PEG-modified paclitaxel loaded NLC) to achieve the goal to kill the cancer cells and CSCs, simultaneously.	Paclitaxel	114-124	epidermal growth factor receptor	Mus musculus	64-68
12649748-0	2003	Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody.	Paclitaxel	12-22	CD3 antigen, epsilon polypeptide	Mus musculus	211-214
12649748-3	2003	P815 cells that had survived culture for 24 h in the presence of paclitaxel (5 or 50 micro g/ml) or vinblastine (1.5 or 15 micro g/ml) were rendered resistant to anti-CD3-activated killer-T (AK-T) cell-mediated cytolysis in a standard (51)Cr-release assay.	Paclitaxel	65-75	CD3 antigen, epsilon polypeptide	Mus musculus	167-170
12649748-5	2003	Flow cytometric analysis of paclitaxel- or vinblastine-treated P815 cells revealed reduced cell-surface expression of the adhesion molecules LFA-1 (CD11a /CD18) and ICAM-1 (CD54).	Paclitaxel	28-38	intercellular adhesion molecule 1	Mus musculus	165-171
27773824-8	2016	By contrast, cannabinoid CB1 and CB2 receptor antagonists partially attenuated the antinociceptive actions of desipramine in a manner that was restricted to the development phase of paclitaxel-induced neuropathic pain only.	Paclitaxel	182-192	cannabinoid receptor 2	Homo sapiens	33-36
12649748-5	2003	Flow cytometric analysis of paclitaxel- or vinblastine-treated P815 cells revealed reduced cell-surface expression of the adhesion molecules LFA-1 (CD11a /CD18) and ICAM-1 (CD54).	Paclitaxel	28-38	intercellular adhesion molecule 1	Mus musculus	173-177
31536779-6	2019	Molecular and pharmacological targeting of ABCB1/P-gp did not modify its cytotoxic effect in NCI-H295R cells, while it increased the paclitaxel-induced toxicity.	Paclitaxel	133-143	phosphoglycolate phosphatase	Homo sapiens	49-53
12649748-7	2003	RT-PCR analysis revealed reduced levels of mRNAs coding for CD11a and CD54 in paclitaxel- or vinblastine-pretreated P815 cells.	Paclitaxel	78-88	intercellular adhesion molecule 1	Mus musculus	70-74
31775332-5	2019	Mechanistically, TLR4 (Toll-Like Receptor 4) and downstream signaling MyD88 (Myeloid Differentiation Primary Response 88) and TRPV1 (Transient Receptor Potential Vallinoid 1) were upregulated in dorsal root ganglion (DRGs) of paclitaxel-treated rats, whereas EA reduced their overexpression.	Paclitaxel	226-236	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	70-75
12649748-8	2003	Collectively, these data lead us to conclude that paclitaxel and vinblastine render P815 mastocytoma cells resistant to T cell-mediated cytotoxicity by interfering with CD11a and CD54 expression by the tumor cells.	Paclitaxel	50-60	intercellular adhesion molecule 1	Mus musculus	179-183
12631622-11	2003	MCF-7 cells overexpressing constitutively active Raf-1 were also more resistant to paclitaxel, which, like doxorubicin, is a substrate of P-glycoprotein.	Paclitaxel	83-93	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	49-54
33304996-6	2019	When combined with the chemotherapy paclitaxel, DR5-targeting carriers showed potent antitumor activity in vivo, demonstrating the multifunctional capabilities of peptide-based supramolecular nanostructures.	Paclitaxel	36-46	TNF receptor superfamily member 10b	Homo sapiens	48-51
27904705-11	2016	In addition, the levels of anti-CII antibodies as well as serum tumor necrosis factor (TNF)-alpha and vascular endothelial growth factor (VEGF) levels were remarkably lower in PTX group than those in 5% GS controls (p&lt;0.05).	Paclitaxel	176-179	vascular endothelial growth factor A	Rattus norvegicus	102-136
27904705-11	2016	In addition, the levels of anti-CII antibodies as well as serum tumor necrosis factor (TNF)-alpha and vascular endothelial growth factor (VEGF) levels were remarkably lower in PTX group than those in 5% GS controls (p&lt;0.05).	Paclitaxel	176-179	vascular endothelial growth factor A	Rattus norvegicus	138-142
27831559-0	2016	Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3.	Paclitaxel	90-95	nuclear receptor coactivator 3	Homo sapiens	123-128
27831559-3	2016	In this study, nuclear receptor coactivator 3 (NCOA3) was found to be significantly increased in taxol-resistant breast cancer tissues and cells.	Paclitaxel	97-102	nuclear receptor coactivator 3	Homo sapiens	15-45
27831559-3	2016	In this study, nuclear receptor coactivator 3 (NCOA3) was found to be significantly increased in taxol-resistant breast cancer tissues and cells.	Paclitaxel	97-102	nuclear receptor coactivator 3	Homo sapiens	47-52
27831559-4	2016	Moreover, overexpression of NCOA3 enhanced breast cancer cell resistance to taxol, whereas depletion of NCOA3 decreased taxol resistance.	Paclitaxel	76-81	nuclear receptor coactivator 3	Homo sapiens	28-33
27831559-4	2016	Moreover, overexpression of NCOA3 enhanced breast cancer cell resistance to taxol, whereas depletion of NCOA3 decreased taxol resistance.	Paclitaxel	120-125	nuclear receptor coactivator 3	Homo sapiens	104-109
31712703-4	2019	In paclitaxel-treated mice, increased fatigue and decreased cognitive performance occurred in parallel with reduced microglia immunoreactivity, increased circulating chemokine expression (CXCL1), as well as transient increases in pro-inflammatory cytokine/chemokine (Il-1beta, Tnfalpha, Il-6, and Cxcl1) gene expression in the brain.	Paclitaxel	3-13	interleukin 1 alpha	Mus musculus	267-275
31707979-7	2019	RESULTS: Systemic injection of paclitaxel resulted in increased expression of glial fibrillary acidic protein (a common marker of astrocytic activation), as well as both systemic or intrathecal injection of paclitaxel induced pain hypersensitivity indicated by the development of mechanical allodynia, which was significantly reversed by the astrocytic inhibitor L-alpha-AA.	Paclitaxel	31-41	glial fibrillary acidic protein	Mus musculus	78-109
27626498-6	2016	Interestingly, ectopic of DRG1 reduces taxol induced apoptosis of lung adenocarcinoma cells.	Paclitaxel	39-44	developmentally regulated GTP binding protein 1	Homo sapiens	26-30
27626498-8	2016	These studies highlight the expanding role of DRG1 in tumorigenesis and reveal a mechanism of DRG1 in taxol resistance.	Paclitaxel	102-107	developmentally regulated GTP binding protein 1	Homo sapiens	94-98
12558997-0	2003	Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons.	Paclitaxel	66-76	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	Mus musculus	58-61
27669502-6	2016	RESULTS: Global RNA expression profiling and subsequent correlation studies of gene expression level and drug response has identified that elevated expression of cyclin A1 (CCNA1) was significantly associated with cellular resistance to paclitaxel, doxorubicin and 5-fluorouracil.	Paclitaxel	237-247	cyclin A1	Homo sapiens	173-178
31675995-8	2019	Arr2 attenuated the promotion of caspase-3 and caspase-9 by paclitaxel and mediated the increase of TLR2 and several inflammatory cytokines.	Paclitaxel	60-70	caspase 9	Homo sapiens	47-56
31839159-6	2019	Combination of atezolizumab with nab-paclitaxel in a phase III study has recently seen success in terms of improved progression free and overall survival for the PD-L1 -positive population of metastatic TNBC in the first line/newly relapsed setting [3].	Paclitaxel	37-47	CD274 molecule	Homo sapiens	162-167
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	25-35	cyclin A1	Homo sapiens	12-21
31616965-5	2019	A significant decrease in proliferating (Ki67+) CD3+CD8- T cells and FoxP3+(CD3+CD8-) regulatory T cells was observed in the tumor stroma after cisplatin and paclitaxel treatment, with increased rates of cytotoxic CD8+ T cells, including activated and CD8+Tbet+ T cells.	Paclitaxel	158-168	T-box transcription factor 21	Homo sapiens	256-260
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	25-35	cyclin A1	Homo sapiens	111-120
12558997-4	2003	Taxol did not inhibit cdk5 directly but significantly blocked Abeta-induced calpain activation and decreased formation of the cdk5 activator, p25, from p35.	Paclitaxel	0-5	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	Mus musculus	142-145
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	25-35	cyclin A1	Homo sapiens	111-120
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	25-35	cyclin A1	Homo sapiens	111-120
31363957-4	2019	This effect in cancer cells with low GRK5 levels could be because of blunted histone deacetylase 6 (HDAC6) activity that leads to an increase in alpha-tubulin acetylation levels, which augments paclitaxel sensitivity.	Paclitaxel	194-204	tubulin alpha 1b	Homo sapiens	145-158
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	25-35	cyclin A1	Homo sapiens	111-120
12558997-4	2003	Taxol did not inhibit cdk5 directly but significantly blocked Abeta-induced calpain activation and decreased formation of the cdk5 activator, p25, from p35.	Paclitaxel	0-5	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	Mus musculus	152-155
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	164-174	cyclin A1	Homo sapiens	12-21
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	164-174	cyclin A1	Homo sapiens	111-120
31540773-0	2019	Down-regulation of UTP23 promotes paclitaxel resistance and predicts poorer prognosis in ovarian cancer.	Paclitaxel	34-44	UTP23 small subunit processome component	Homo sapiens	19-24
31540773-2	2019	UTP23, a small sub-unit processome component, is down-regulated in a paclitaxel-resistant cell line SKOV3-TR30 compared with its parental SKOV3 cells based on our previous study.	Paclitaxel	69-79	UTP23 small subunit processome component	Homo sapiens	0-5
31540773-5	2019	Then we used short hairpin RNA (shRNA), over-expression plasmid and cell counting kit-8 (CCK-8) assay to evaluate the function of UTP23 on modulating paclitaxel resistance in ovarian cancer.	Paclitaxel	150-160	UTP23 small subunit processome component	Homo sapiens	130-135
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	164-174	cyclin A1	Homo sapiens	111-120
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	164-174	cyclin A1	Homo sapiens	111-120
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	164-174	cyclin A1	Homo sapiens	111-120
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	164-174	cyclin A1	Homo sapiens	12-21
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	164-174	cyclin A1	Homo sapiens	111-120
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	164-174	cyclin A1	Homo sapiens	111-120
12558997-5	2003	Taxol specifically inhibited the Abeta-induced activation of the cytosolic cdk5-p25 complex, but not the membrane-associated cdk5-p35 complex.	Paclitaxel	0-5	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	Mus musculus	80-83
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	164-174	cyclin A1	Homo sapiens	111-120
27669502-7	2016	The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity.	Paclitaxel	164-174	cyclin A1	Homo sapiens	111-120
31540773-9	2019	Decreased UTP23 expression was observed in ovarian cancer tissues with paclitaxel resistance.	Paclitaxel	71-81	UTP23 small subunit processome component	Homo sapiens	10-15
31540773-11	2019	Further UTP23 silence by shRNA increased paclitaxel resistance in SKOV3 and A2780 cells.	Paclitaxel	41-51	UTP23 small subunit processome component	Homo sapiens	8-13
14705770-0	2003	Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer.	Paclitaxel	30-35	major vault protein	Homo sapiens	88-119
31540773-12	2019	And UTP23 over-expression by plasmid decreased paclitaxel resistance in SKOV3-TR30 and A2780-TR cells.	Paclitaxel	47-57	UTP23 small subunit processome component	Homo sapiens	4-9
31540773-15	2019	CONCLUSION: Our findings elucidated a previously unknown function for UTP23 in regulating paclitaxel sensitivity and UTP23 could serve as a potential prognostic predictor for ovarian cancer.	Paclitaxel	90-100	UTP23 small subunit processome component	Homo sapiens	70-75
12384528-8	2002	Thus, Herceptin treatment of ErbB2-overexpressing cells can inhibit ErbB2-mediated Cdc2-Tyr-15 phosphorylation and p21(Cip1) up-regulation, which allows effective p34(Cdc2) activation and induction of apoptosis upon Taxol treatment.	Paclitaxel	216-221	alpha and gamma adaptin binding protein	Homo sapiens	163-166
27785897-1	2016	There are many reports on paclitaxel, ifosfamide, and cisplatin (TIP) therapy, following standard bleomycin, etoposide, and cisplatin (BEP) therapy, for salvage treatment of testicular malignant germ cell tumors, but there are no reports on its use for ovarian malignant tumors.	Paclitaxel	26-36	TOR signaling pathway regulator	Homo sapiens	65-68
12325073-0	2002	WldS mice are resistant to paclitaxel (taxol) neuropathy.	Paclitaxel	27-37	wallerian degeneration	Mus musculus	0-4
27714074-0	2016	miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC).	Paclitaxel	39-49	microtubule associated protein tau	Homo sapiens	64-68
27739029-13	2016	We employed paclitaxel and cisplatin in A549 cells with HCRP1 depletion.	Paclitaxel	12-22	HCRP1	Homo sapiens	56-61
27739029-14	2016	HCRP1 depletion decreased the effect of paclitaxel and cisplatin in A549 cells.	Paclitaxel	40-50	HCRP1	Homo sapiens	0-5
27636161-2	2016	In this study, by utilizing the overexpression of Interleukin 13 receptor alpha2 (IL-13Ralpha2) on the glioma cells and heparan sulfate on neovascular endothelial cells, we developed a paclitaxel (PTX) loaded Pep-1 and CGKRK peptide-modified PEG-PLGA nanoparticle (PC-NP-PTX) for glioma cells and neovasculature dual-targeted chemotherapy to enhance the antiglioma efficacy.	Paclitaxel	185-195	progestagen associated endometrial protein	Homo sapiens	209-212
31772851-0	2019	Nivolumab plus Carboplatin and Paclitaxel as the First-line Therapy for Advanced Squamous Cell Carcinoma of the Lung with Strong Programmed Death-ligand 1 Expression: A Case Report.	Paclitaxel	31-41	CD274 molecule	Homo sapiens	129-154
31299179-0	2019	The alpha7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal.	Paclitaxel	72-82	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	4-29
12325073-0	2002	WldS mice are resistant to paclitaxel (taxol) neuropathy.	Paclitaxel	39-44	wallerian degeneration	Mus musculus	0-4
31631140-3	2019	We experienced that NAC with ramucirumab(RAM)plus paclitaxel(PTX)was effective in locallyadvanced gastric cancer, but that with SOX was ineffective.	Paclitaxel	50-60	synuclein alpha	Homo sapiens	20-23
27622658-0	2016	SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.	Paclitaxel	100-110	secreted protein acidic and cysteine rich	Homo sapiens	0-5
12325073-5	2002	WldS mice were resistant to paclitaxel neuropathy by all measures, and the resistance was because of protection against axonal degeneration.	Paclitaxel	28-38	wallerian degeneration	Mus musculus	0-4
27622658-8	2016	Furthermore, ovarian cancer cells have a reduced motility and decreased response to the chemotherapeutic agent paclitaxel when plated on ECM derived from mesothelial cells lacking SPARC compared to control mesothelial-derived ECM.	Paclitaxel	111-121	multimerin 1	Homo sapiens	137-140
12139759-8	2002	These results suggest that TNF-alpha expression and apoptosis, both induced by Taxol in human myelomonocytic cells, share the signal transduction molecule MyD88.	Paclitaxel	79-84	MYD88 innate immune signal transduction adaptor	Homo sapiens	155-160
12396726-4	2002	In this report, we characterized the viability of various human tumor cells in vitro after combination treatment with IFN-beta protein and the chemotherapeutic drugs, cis-platinum (II) diamine dichloride (cisplatin), 5-fluorouracil (5-FU), paclitaxel (Taxol) and gemcitabine.	Paclitaxel	240-250	interferon beta 1	Homo sapiens	118-126
25853480-9	2016	In vitro cytotoxicity analysis demonstrated that the PTX-loaded F127-CS/NaC micelles were of great efficiency in inhibiting the growth of drug-resistant breast cancer MCF-7 cells (MCF-7/Adr).	Paclitaxel	53-56	synuclein alpha	Homo sapiens	72-75
25853480-10	2016	The intragastric administration of the PTX-loaded F127-CS/NaC micelles in rats provided a 4.33-fold higher absolute bioavailability compared to commercial Taxol , indicating an efficient oral absorption of PTX delivered by micelles.	Paclitaxel	39-42	synuclein alpha	Homo sapiens	58-61
25853480-10	2016	The intragastric administration of the PTX-loaded F127-CS/NaC micelles in rats provided a 4.33-fold higher absolute bioavailability compared to commercial Taxol , indicating an efficient oral absorption of PTX delivered by micelles.	Paclitaxel	206-209	synuclein alpha	Homo sapiens	58-61
25853480-11	2016	These findings signify that F127-CS/NaC micelle may be a promising carrier for the delivery of PTX.	Paclitaxel	95-98	synuclein alpha	Homo sapiens	36-39
27195913-6	2016	Subsequently, we identified a novel mechanism by which paclitaxel induced necroptosis in lung adenocarcinoma cells that was dependent upon p-Casp8, receptor-interacting protein kinase 1 (RIPK1), and RIPK3.	Paclitaxel	55-65	receptor interacting serine/threonine kinase 1	Homo sapiens	148-185
27195913-6	2016	Subsequently, we identified a novel mechanism by which paclitaxel induced necroptosis in lung adenocarcinoma cells that was dependent upon p-Casp8, receptor-interacting protein kinase 1 (RIPK1), and RIPK3.	Paclitaxel	55-65	receptor interacting serine/threonine kinase 1	Homo sapiens	187-192
31350703-6	2019	Thus, MDR1, and increased amounts of Gb4Cer, Leb and GM3 were suggested to be involved in the anticancer drug-resistance to hydrophobic paclitaxel and docetaxel, and GM3 was to basic cisplatin.	Paclitaxel	136-146	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	45-48
31352515-0	2019	Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.	Paclitaxel	34-44	microRNA 18a	Homo sapiens	95-102
31352515-12	2019	miR-18a-5p mimics or downregulation of CDK19 decreased tumor growth in xenograft mice implanted with MCF-7/PTX cells.	Paclitaxel	107-110	cyclin-dependent kinase 19	Mus musculus	39-44
31352515-13	2019	In summary, we identified that CASC2 activated PTX resistance in breast cancer through regulation of miR-18a-5p/CDK19.	Paclitaxel	47-50	microRNA 18a	Homo sapiens	101-108
30367323-7	2019	Results In the in vitro model, the expression of twelve drug-transporters genes was found to be significantly down-regulated after exposure to paclitaxel, including ABCC10, SLC28A3, SLC29A2, and ATP7B (involved in the transport of taxanes, antimetabolites, and cisplatin, respectively).	Paclitaxel	143-153	ATP binding cassette subfamily C member 10	Homo sapiens	165-171
30367323-8	2019	The protein expression of ABCB1/P-gp increased by 1.3-fold after paclitaxel administration.	Paclitaxel	65-75	phosphoglycolate phosphatase	Homo sapiens	32-36
30367323-9	2019	Finally, the protein expression of ABCB1/P-gp and ABCG2/BCRP was higher in cotyledons from mothers treated with multiple doses of paclitaxel during pregnancy than in cotyledons perfused with a single dose of paclitaxel.	Paclitaxel	130-140	phosphoglycolate phosphatase	Homo sapiens	41-45
30367323-9	2019	Finally, the protein expression of ABCB1/P-gp and ABCG2/BCRP was higher in cotyledons from mothers treated with multiple doses of paclitaxel during pregnancy than in cotyledons perfused with a single dose of paclitaxel.	Paclitaxel	208-218	phosphoglycolate phosphatase	Homo sapiens	41-45
27446381-6	2016	The combination of HM and PTX exerted synergistic effects on proliferation inhibition and apoptosis induction in SGC-7901 cells, with down-regulation of COX-2, PCNA and Bcl-2 and up-regulation of Bax expression.	Paclitaxel	26-29	proliferating cell nuclear antigen	Homo sapiens	160-164
12396726-4	2002	In this report, we characterized the viability of various human tumor cells in vitro after combination treatment with IFN-beta protein and the chemotherapeutic drugs, cis-platinum (II) diamine dichloride (cisplatin), 5-fluorouracil (5-FU), paclitaxel (Taxol) and gemcitabine.	Paclitaxel	252-257	interferon beta 1	Homo sapiens	118-126
12093283-6	2002	As shown by turbidimetry, pelleting experiments, and electron microscopy, p25 binds to paclitaxel-stabilized microtubules and bundles them.	Paclitaxel	87-97	tubulin polymerization promoting protein	Bos taurus	74-77
27447629-6	2016	Moreover, the RRBP1 expression is induced by chemotherapeutic drug paclitaxel or adriamycin in human hepatocellular carcinoma cells and accompanied with the increased expression of La autoantigen (La), which binds to RRBP1 IRES element and facilitates translation initiation.	Paclitaxel	67-77	ribosome binding protein 1	Homo sapiens	14-19
31488093-12	2019	CONCLUSIONS: LncRNA MEG3 polymorphisms were associated with the chemotherapy response and toxicity of paclitaxel and cisplatin.	Paclitaxel	102-112	maternally expressed 3	Homo sapiens	20-24
31164413-0	2019	The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.	Paclitaxel	44-54	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	27-32
27216190-0	2016	Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL.	Paclitaxel	14-24	dicer 1, ribonuclease III	Homo sapiens	0-5
12093283-7	2002	p25 induces formation of unusual (mainly double-walled) microtubules from tubulin in the absence of paclitaxel.	Paclitaxel	100-110	tubulin polymerization promoting protein	Bos taurus	0-3
27216190-0	2016	Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL.	Paclitaxel	14-24	AXL receptor tyrosine kinase	Homo sapiens	106-109
12019187-3	2002	With concentrations ranging from 5 to 100 microM, trimethoprim exhibited a selective inhibitory effect on CYP2C8-mediated paclitaxel 6alpha-hydroxylation in human liver microsomes and recombinant CYP2C8, with apparent IC(50) (K(i)) values of 54 microM (32 microM) and 75 microM, respectively.	Paclitaxel	122-132	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	106-112
27216190-2	2016	Here, we report that adenovirus-type 5 E1A-mediated elevation of the miRNA-processing enzyme Dicer is sufficient to enhance paclitaxel sensitization and reduce cancer stem-like cell properties in this setting.	Paclitaxel	124-134	dicer 1, ribonuclease III	Homo sapiens	93-98
27216190-3	2016	Elevating Dicer expression increased levels of the AXL kinase targeting miRNA miR-494, thereby repressing AXL expression to increase paclitaxel sensitivity.	Paclitaxel	133-143	dicer 1, ribonuclease III	Homo sapiens	10-15
27216190-3	2016	Elevating Dicer expression increased levels of the AXL kinase targeting miRNA miR-494, thereby repressing AXL expression to increase paclitaxel sensitivity.	Paclitaxel	133-143	AXL receptor tyrosine kinase	Homo sapiens	51-54
27216190-3	2016	Elevating Dicer expression increased levels of the AXL kinase targeting miRNA miR-494, thereby repressing AXL expression to increase paclitaxel sensitivity.	Paclitaxel	133-143	microRNA 494	Homo sapiens	78-85
27216190-3	2016	Elevating Dicer expression increased levels of the AXL kinase targeting miRNA miR-494, thereby repressing AXL expression to increase paclitaxel sensitivity.	Paclitaxel	133-143	AXL receptor tyrosine kinase	Homo sapiens	106-109
31452741-11	2019	Finally, the present study demonstrated that cisplatin combined with paclitaxel induced apoptosis and decreased the tumor markers in NPC cells through the Wnt/beta-catenin signaling pathway.	Paclitaxel	69-79	catenin beta 1	Homo sapiens	159-171
31163384-5	2019	Specifically, SGK1 affects paclitaxel sensitivity in RKO colon carcinoma cells by modulating the specificity protein 1 (SP1)-dependent expression of Ran-specific GTPase-activating protein (RANBP1), a member of the GTP-binding nuclear protein Ran (RAN) network that is required for the organization and function of the mitotic spindle.	Paclitaxel	27-37	RAN, member RAS oncogene family	Homo sapiens	149-152
31163384-5	2019	Specifically, SGK1 affects paclitaxel sensitivity in RKO colon carcinoma cells by modulating the specificity protein 1 (SP1)-dependent expression of Ran-specific GTPase-activating protein (RANBP1), a member of the GTP-binding nuclear protein Ran (RAN) network that is required for the organization and function of the mitotic spindle.	Paclitaxel	27-37	RAN binding protein 1	Homo sapiens	189-195
31163384-5	2019	Specifically, SGK1 affects paclitaxel sensitivity in RKO colon carcinoma cells by modulating the specificity protein 1 (SP1)-dependent expression of Ran-specific GTPase-activating protein (RANBP1), a member of the GTP-binding nuclear protein Ran (RAN) network that is required for the organization and function of the mitotic spindle.	Paclitaxel	27-37	RAN, member RAS oncogene family	Homo sapiens	189-192
27270990-6	2016	Taxol induced alpha-tubulin acetylation and post-I/R cell cycle arrest.	Paclitaxel	0-5	tubulin alpha 1b	Homo sapiens	14-27
12050209-6	2002	The ONYX-015 virus worked synergistically with two antineoplastic drugs (doxorubicin and paclitaxel) in inducing ARO and KAT-4 cell death.	Paclitaxel	89-99	TATA-box binding protein associated factor 1	Homo sapiens	121-126
27338042-5	2016	The effect of miR-18a mediated autophagy on PTX sensitivity was assessed by measuring IC50 and PTX induced cell apoptosis.	Paclitaxel	44-47	microRNA 18a	Homo sapiens	14-21
27338042-5	2016	The effect of miR-18a mediated autophagy on PTX sensitivity was assessed by measuring IC50 and PTX induced cell apoptosis.	Paclitaxel	95-98	microRNA 18a	Homo sapiens	14-21
27338042-6	2016	RESULTS: MDA-MB-231/PTX cells had both higher miR-18a expression and basal autophagy than MDA-MB-231 cells.	Paclitaxel	20-23	microRNA 18a	Homo sapiens	46-53
31340839-13	2019	CONCLUSIONS: Our findings suggest that KIFC1, activated by TCF-4, functions as an oncogene and promotes HCC pathogenesis through regulating HMGA1 transcriptional activity and that KIFC1 is a potential therapeutic target to enhance the paclitaxel sensitivity of HCC.	Paclitaxel	235-245	high mobility group AT-hook 1	Homo sapiens	140-145
27383301-5	2016	RESULTS: Expression of the miR-134 gene cluster was found to be significantly lower in the paclitaxel-resistant cell line than in the paclitaxel-sensitive cell line, while the expression of the miR-17-92 gene cluster was significantly higher in the paclitaxel-resistant cells.	Paclitaxel	91-101	miR-17-92a-1 cluster host gene	Homo sapiens	194-203
12049736-0	2002	Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis.	Paclitaxel	116-121	cyclin H	Homo sapiens	34-37
27383301-5	2016	RESULTS: Expression of the miR-134 gene cluster was found to be significantly lower in the paclitaxel-resistant cell line than in the paclitaxel-sensitive cell line, while the expression of the miR-17-92 gene cluster was significantly higher in the paclitaxel-resistant cells.	Paclitaxel	134-144	miR-17-92a-1 cluster host gene	Homo sapiens	194-203
27383301-5	2016	RESULTS: Expression of the miR-134 gene cluster was found to be significantly lower in the paclitaxel-resistant cell line than in the paclitaxel-sensitive cell line, while the expression of the miR-17-92 gene cluster was significantly higher in the paclitaxel-resistant cells.	Paclitaxel	134-144	miR-17-92a-1 cluster host gene	Homo sapiens	194-203
30920880-3	2019	The patients in the paclitaxel plus fluorouracil group were treated with paclitaxel and fluorouracil one cycle per week in dCRT for five cycles followed by paclitaxel and fluorouracil one cycle per month in consolidation chemotherapy for two cycles.	Paclitaxel	20-30	crt	Drosophila melanogaster	123-127
12049736-1	2002	ErbB2 overexpression confers resistance to taxol-induced apoptosis by inhibiting p34(Cdc2) activation.	Paclitaxel	43-48	cyclin H	Homo sapiens	81-84
12086014-8	2002	Immunoblot analysis with an antibody against Bcl-2 phosphorylated at serine 70 demonstrated that taxol induced the phosphorylation of Bcl-2 with its enhancement in the presence of CsA.	Paclitaxel	97-102	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	180-183
27196760-9	2016	Finally, TRX-E-002-1 given as maintenance treatment after paclitaxel significantly delayed disease recurrence.	Paclitaxel	58-68	thioredoxin	Homo sapiens	9-12
11901191-2	2002	Etoposide and paclitaxel induced Cer formation and apoptosis in PKCdelta-positive LNCaP and DU145 cells but not in PKCdelta-negative LN-TPA or PC-3 cells.	Paclitaxel	14-24	protein kinase C delta	Homo sapiens	64-72
27184254-4	2016	METHODS: MTS assays and western blots for cleaved PARP were used to assess resistance of HE4-overexpressing SKOV3 and OVCAR8 clones to cisplatin and paclitaxel.	Paclitaxel	149-159	WAP four-disulfide core domain 2	Homo sapiens	89-92
27184254-8	2016	RESULTS: HE4-overexpressing SKOV3 and OVCAR8 clones displayed increased resistance to cisplatin and paclitaxel.	Paclitaxel	100-110	WAP four-disulfide core domain 2	Homo sapiens	9-12
27184254-15	2016	CONCLUSIONS: Overexpression of HE4 promotes collateral resistance to cisplatin and paclitaxel, and downregulation of HE4 partially reverses this chemoresistance.	Paclitaxel	83-93	WAP four-disulfide core domain 2	Homo sapiens	31-34
31295843-0	2019	Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer.	Paclitaxel	111-121	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	14-43
31295843-0	2019	Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer.	Paclitaxel	136-146	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	14-43
31295843-2	2019	This review investigated whether the inhibition of phosphatidylinositol 3-kinase (PI3K) signaling overcomes paclitaxel resistance in cervical cancer.	Paclitaxel	108-118	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	51-80
31295843-8	2019	PTX + PI3K inhibitor combined therapy showed a synergistic effect by strengthening paclitaxel-induced S and G2M arrest in PTX-R cell sublines by the inactivation of cyclin A1, cyclin B1, cyclin E, and Cdc2 expression.	Paclitaxel	0-3	cyclin A1	Homo sapiens	165-174
31295843-8	2019	PTX + PI3K inhibitor combined therapy showed a synergistic effect by strengthening paclitaxel-induced S and G2M arrest in PTX-R cell sublines by the inactivation of cyclin A1, cyclin B1, cyclin E, and Cdc2 expression.	Paclitaxel	0-3	cyclin B1	Homo sapiens	176-185
31295843-8	2019	PTX + PI3K inhibitor combined therapy showed a synergistic effect by strengthening paclitaxel-induced S and G2M arrest in PTX-R cell sublines by the inactivation of cyclin A1, cyclin B1, cyclin E, and Cdc2 expression.	Paclitaxel	0-3	cyclin dependent kinase 1	Homo sapiens	201-205
31295843-8	2019	PTX + PI3K inhibitor combined therapy showed a synergistic effect by strengthening paclitaxel-induced S and G2M arrest in PTX-R cell sublines by the inactivation of cyclin A1, cyclin B1, cyclin E, and Cdc2 expression.	Paclitaxel	83-93	cyclin A1	Homo sapiens	165-174
31295843-8	2019	PTX + PI3K inhibitor combined therapy showed a synergistic effect by strengthening paclitaxel-induced S and G2M arrest in PTX-R cell sublines by the inactivation of cyclin A1, cyclin B1, cyclin E, and Cdc2 expression.	Paclitaxel	83-93	cyclin B1	Homo sapiens	176-185
31295843-8	2019	PTX + PI3K inhibitor combined therapy showed a synergistic effect by strengthening paclitaxel-induced S and G2M arrest in PTX-R cell sublines by the inactivation of cyclin A1, cyclin B1, cyclin E, and Cdc2 expression.	Paclitaxel	83-93	cyclin dependent kinase 1	Homo sapiens	201-205
26905328-7	2016	RESULTS: In the carcinoma cell line, the PTEN knockdown enhanced sensitivity to cisplatin, rucaparib, doxorubicin, camptothecin, paclitaxel, and irradiation.	Paclitaxel	129-139	phosphatase and tensin homolog	Homo sapiens	41-45
12236102-6	2002	In K-mitotic cells, after a 3-6 h treatment with nocodazole or taxol, considerable dissociation of XCAP-E and pEg7 from chromosomes was observed without significant changes in overall level of chromosome compactization.	Paclitaxel	63-68	non-SMC condensin I complex subunit D2 S homeolog	Xenopus laevis	110-114
26890991-9	2016	In addition, ENP induced more A549 tumor cell apoptosis than Taxol and NP when paclitaxel (PTX) was loaded.	Paclitaxel	79-89	centromere protein H	Mus musculus	13-16
26890991-9	2016	In addition, ENP induced more A549 tumor cell apoptosis than Taxol and NP when paclitaxel (PTX) was loaded.	Paclitaxel	91-94	centromere protein H	Mus musculus	13-16
26890991-11	2016	Treatment with PTX-loaded ENP (ENP-PTX) significantly reduced the A549 tumor growth in nude mice while NP-PTX- and Taxol-treated mice had lower response to the therapy.	Paclitaxel	15-18	centromere protein H	Mus musculus	26-29
26890991-11	2016	Treatment with PTX-loaded ENP (ENP-PTX) significantly reduced the A549 tumor growth in nude mice while NP-PTX- and Taxol-treated mice had lower response to the therapy.	Paclitaxel	15-18	centromere protein H	Mus musculus	31-38
26890991-11	2016	Treatment with PTX-loaded ENP (ENP-PTX) significantly reduced the A549 tumor growth in nude mice while NP-PTX- and Taxol-treated mice had lower response to the therapy.	Paclitaxel	35-38	centromere protein H	Mus musculus	26-29
26980709-4	2016	Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERalpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells.	Paclitaxel	43-53	DNA methyltransferase 3 beta	Homo sapiens	103-109
30979740-9	2019	An increased response to nab-paclitaxel was observed only in PIK3CAwt breast cancer, with univariate significance for the complete cohort (P = 0.009) and the TNBC (P = 0.013) and multivariate significance in the HER2pos subcohort (test for interaction P = 0.0074).	Paclitaxel	29-39	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Homo sapiens	61-65
26980709-4	2016	Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERalpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells.	Paclitaxel	43-53	DNA methyltransferase 3 beta	Homo sapiens	142-148
31367531-12	2019	Leptin"s effects on Paclitaxel cytotoxicity in EmCa cells was determined by the CCK8 and Cellometer-based Annexin V assays.	Paclitaxel	20-30	leptin	Homo sapiens	0-6
11749612-7	2001	Prodrugs in which the novel spacer systems were incorporated between a specific tripeptide specifier and the parent drug doxorubicin or paclitaxel proved to be significantly faster activated by plasmin in comparison with prodrugs containing conventional spacer systems.	Paclitaxel	136-146	plasminogen	Homo sapiens	194-201
31367531-14	2019	Experimental data suggest that leptin induced the expression of NILCO molecules, promoted proliferation and S- phase progression, and reduced Paclitaxel cytotoxicity on EmCa cells.	Paclitaxel	142-152	leptin	Homo sapiens	31-37
31367531-17	2019	Remarkably, the use of the leptin signaling antagonist, IONP-LPrA2, re-sensitized EmCa cells to Paclitaxel.	Paclitaxel	96-106	leptin	Homo sapiens	27-33
31367531-19	2019	Most aggressive type II EmCa cells were higher sensitive to leptin, which appears to increase proliferation, cell cycle progression, aggressiveness, and chemoresistance to Paclitaxel.	Paclitaxel	172-182	leptin	Homo sapiens	60-66
26980709-4	2016	Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERalpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells.	Paclitaxel	55-58	DNA methyltransferase 3 beta	Homo sapiens	103-109
26980709-4	2016	Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERalpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells.	Paclitaxel	55-58	DNA methyltransferase 3 beta	Homo sapiens	142-148
26980709-4	2016	Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERalpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells.	Paclitaxel	170-173	DNA methyltransferase 3 beta	Homo sapiens	103-109
26980709-4	2016	Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERalpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells.	Paclitaxel	170-173	DNA methyltransferase 3 beta	Homo sapiens	142-148
26858237-0	2016	Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.	Paclitaxel	109-119	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
26858237-7	2016	The beneficial effect of the Hsp90 inhibitor on paclitaxel-induced cytotoxicity was reduced when GR was depleted in TNBC cells but could be recovered with GR overexpression.	Paclitaxel	48-58	heat shock protein 90 alpha family class A member 1	Homo sapiens	29-34
26858237-8	2016	These findings suggest that GR-regulated anti-apoptotic and pro-proliferative signaling networks in TNBC are disrupted by Hsp90 inhibitors, thereby sensitizing TNBC to paclitaxel-induced cell death.	Paclitaxel	168-178	heat shock protein 90 alpha family class A member 1	Homo sapiens	122-127
31181850-0	2019	Taxol-Loaded MSC-Derived Exosomes Provide a Therapeutic Vehicle to Target Metastatic Breast Cancer and Other Carcinoma Cells.	Paclitaxel	0-5	musculin	Homo sapiens	13-16
31181850-3	2019	While MSC control exosomes revealed little if any growth inhibition on the tumor cells, exposure to taxol-loaded MSC-derived exosomes was associated with 80-90% cytotoxicity.	Paclitaxel	100-105	musculin	Homo sapiens	113-116
31181850-5	2019	Quantification by LC-MS/MS analysis demonstrated a 7.6-fold reduced taxol concentration in MSC exosomes when compared to equivalent cytotoxic in vitro effects achieved with taxol substances, indicating a specific and more efficient tumor-targeting property.	Paclitaxel	68-73	musculin	Homo sapiens	91-94
31181850-6	2019	Consequently, MSC-derived taxol exosomes were tested in vivo.	Paclitaxel	26-31	musculin	Homo sapiens	14-17
26880267-7	2016	In cell viability assay on cultured cancer cell lines (MKN-45P, SKOV3, CT26), paclitaxel-loaded polymersomes were more toxic than free drug or albumin-bound paclitaxel (Abraxane).	Paclitaxel	78-88	DEAD-box helicase 53	Homo sapiens	71-75
11579083-5	2001	Here we report that both depolymerization of microtubules by colchicine or nocodazole and stabilization of microtubules by taxol increased the lateral mobility of beta(2) integrins, activating adhesion.	Paclitaxel	123-128	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	163-170
26572150-2	2016	Our previous studies have demonstrated that inhibition of HB-EGF by the special inhibitor, cross-reacting material 197 (CRM197), potently inhibits the anti-tumor activity in paclitaxel-resistant ovarian cancer.	Paclitaxel	174-184	heparin binding EGF like growth factor	Homo sapiens	58-64
26572150-3	2016	Here, we found that inhibition of HB-EGF by CRM197 significantly reverses the resistance to paclitaxel in paclitaxel-resistant ovarian carcinoma cell line (A2780/Taxol).	Paclitaxel	92-102	heparin binding EGF like growth factor	Homo sapiens	34-40
26572150-3	2016	Here, we found that inhibition of HB-EGF by CRM197 significantly reverses the resistance to paclitaxel in paclitaxel-resistant ovarian carcinoma cell line (A2780/Taxol).	Paclitaxel	106-116	heparin binding EGF like growth factor	Homo sapiens	34-40
26572150-7	2016	Collectively, HB-EGF is a molecular target for the resistance of ovarian cancer to paclitaxel and CRM197 as a HB-EGF-targeted agent might be a chemosensitizing agent for paclitaxel-resistant ovarian carcinoma.	Paclitaxel	83-93	heparin binding EGF like growth factor	Homo sapiens	14-20
26572150-7	2016	Collectively, HB-EGF is a molecular target for the resistance of ovarian cancer to paclitaxel and CRM197 as a HB-EGF-targeted agent might be a chemosensitizing agent for paclitaxel-resistant ovarian carcinoma.	Paclitaxel	170-180	heparin binding EGF like growth factor	Homo sapiens	14-20
26572150-7	2016	Collectively, HB-EGF is a molecular target for the resistance of ovarian cancer to paclitaxel and CRM197 as a HB-EGF-targeted agent might be a chemosensitizing agent for paclitaxel-resistant ovarian carcinoma.	Paclitaxel	170-180	heparin binding EGF like growth factor	Homo sapiens	110-116
26572150-8	2016	Our findings provide novel possible mechanisms for HB-EGF to be a target to restore the chemosensitivity to paclitaxel.	Paclitaxel	108-118	heparin binding EGF like growth factor	Homo sapiens	51-57
27021436-0	2016	Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1.	Paclitaxel	50-60	microRNA 21	Homo sapiens	36-41
26900771-7	2016	Of particular significance given that drug resistance is a major cause of chemotherapy failure, the PTX-transporter conjugate, designed to evade Pgp export and release free PTX after cell entry, shows efficacy against PTX-resistant ovarian cancer cells.	Paclitaxel	100-103	phosphoglycolate phosphatase	Homo sapiens	145-148
26900771-7	2016	Of particular significance given that drug resistance is a major cause of chemotherapy failure, the PTX-transporter conjugate, designed to evade Pgp export and release free PTX after cell entry, shows efficacy against PTX-resistant ovarian cancer cells.	Paclitaxel	173-176	phosphoglycolate phosphatase	Homo sapiens	145-148
26898472-8	2016	Stabilization of midzone MTs with low amounts of Taxol rescues cytokinesis in INCENP actin-binding mutant-expressing cells.	Paclitaxel	49-54	Inner centromere protein	Drosophila melanogaster	78-84
26881937-0	2016	Regulation of Oncoprotein 18/Stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells.	Paclitaxel	82-87	stathmin 1	Homo sapiens	14-28
26881937-0	2016	Regulation of Oncoprotein 18/Stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells.	Paclitaxel	82-87	stathmin 1	Homo sapiens	29-37
26881937-5	2016	These findings suggest that ERK-mediated Op18/stathmin is involved in taxol resistance of tumors; blockage of ERK signal improves the sensitivity of tumor cells to taxol, which provides new clues for treating taxol-resistant carcinomas.	Paclitaxel	70-75	stathmin 1	Homo sapiens	41-45
26881937-5	2016	These findings suggest that ERK-mediated Op18/stathmin is involved in taxol resistance of tumors; blockage of ERK signal improves the sensitivity of tumor cells to taxol, which provides new clues for treating taxol-resistant carcinomas.	Paclitaxel	70-75	stathmin 1	Homo sapiens	46-54
26881937-5	2016	These findings suggest that ERK-mediated Op18/stathmin is involved in taxol resistance of tumors; blockage of ERK signal improves the sensitivity of tumor cells to taxol, which provides new clues for treating taxol-resistant carcinomas.	Paclitaxel	164-169	stathmin 1	Homo sapiens	41-45
26881937-5	2016	These findings suggest that ERK-mediated Op18/stathmin is involved in taxol resistance of tumors; blockage of ERK signal improves the sensitivity of tumor cells to taxol, which provides new clues for treating taxol-resistant carcinomas.	Paclitaxel	164-169	stathmin 1	Homo sapiens	41-45
26863629-4	2016	miR-217 and CAGE oppositely regulated the response to anti-cancer drugs such as taxol, gefitinib and trastuzumab, an inhibitor of HER2.	Paclitaxel	80-85	DEAD-box helicase 53	Homo sapiens	12-16
25961928-2	2016	In here, we show that FOXM1 depletion can sensitize breast cancer cells and mouse embryonic fibroblasts into entering paclitaxel-induced senescence, with the loss of clonogenic ability, and the induction of senescence-associated beta-galactosidase activity and flat cell morphology.	Paclitaxel	118-128	galactosidase, beta 1	Mus musculus	229-247
25961928-4	2016	Similar to FOXM1, KIF20A expression is downregulated by paclitaxel in the sensitive MCF-7 breast cancer cells and deregulated in the paclitaxel-resistant MCF-7Tax(R) cells.	Paclitaxel	56-66	kinesin family member 20A	Homo sapiens	18-24
25961928-4	2016	Similar to FOXM1, KIF20A expression is downregulated by paclitaxel in the sensitive MCF-7 breast cancer cells and deregulated in the paclitaxel-resistant MCF-7Tax(R) cells.	Paclitaxel	133-143	kinesin family member 20A	Homo sapiens	18-24
25961928-5	2016	KIF20A depletion also renders MCF-7 and MCF-7Tax(R) cells more sensitive to paclitaxel-induced cellular senescence.	Paclitaxel	76-86	kinesin family member 20A	Homo sapiens	0-6
25961928-6	2016	Crucially, resembling paclitaxel treatment, silencing of FOXM1 and KIF20A similarly promotes abnormal mitotic spindle morphology and chromosome alignment, which have been shown to induce mitotic catastrophe-dependent senescence.	Paclitaxel	22-32	kinesin family member 20A	Homo sapiens	67-73
25961928-8	2016	Statistical analysis reveals that both FOXM1 and KIF20A protein and mRNA expression significantly associates with poor survival, consistent with a role of FOXM1 and KIF20A in paclitaxel action and resistance.	Paclitaxel	175-185	kinesin family member 20A	Homo sapiens	49-55
25961928-8	2016	Statistical analysis reveals that both FOXM1 and KIF20A protein and mRNA expression significantly associates with poor survival, consistent with a role of FOXM1 and KIF20A in paclitaxel action and resistance.	Paclitaxel	175-185	kinesin family member 20A	Homo sapiens	165-171
25961928-9	2016	Collectively, our findings suggest that paclitaxel targets the FOXM1-KIF20A axis to drive abnormal mitotic spindle formation and mitotic catastrophe and that deregulated FOXM1 and KIF20A expression may confer paclitaxel resistance.	Paclitaxel	40-50	kinesin family member 20A	Homo sapiens	69-75
25961928-9	2016	Collectively, our findings suggest that paclitaxel targets the FOXM1-KIF20A axis to drive abnormal mitotic spindle formation and mitotic catastrophe and that deregulated FOXM1 and KIF20A expression may confer paclitaxel resistance.	Paclitaxel	209-219	kinesin family member 20A	Homo sapiens	180-186
26636714-0	2016	Combined Delivery of Let-7b MicroRNA and Paclitaxel via Biodegradable Nanoassemblies for the Treatment of KRAS Mutant Cancer.	Paclitaxel	41-51	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	106-110
26636714-5	2016	In non-small cell lung cancer A549 cells that harbor mutant KRAS, paclitaxel and let-7b mimic-loaded nanoassemblies (N-PTX/let-7b) markedly potentiated the cytotoxicity of paclitaxel, induced apoptosis, and diminished the invasiveness of tumor cells.	Paclitaxel	66-76	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	60-64
26582496-5	2016	As a result of taxol disruption, alterations in macroautophagy, like altered cellular distribution of the autophagy-related protein light chain 3 beta (LC3B) and the expression of Atg5 were found compared with Cd group.	Paclitaxel	15-20	autophagy related 5	Rattus norvegicus	180-184
26442525-0	2015	Restoration of paclitaxel resistance by CDK1 intervention in drug-resistant ovarian cancer.	Paclitaxel	15-25	cyclin dependent kinase 1	Homo sapiens	40-44
26442525-4	2015	Cyclin-dependent kinase 1 (CDK1) was found to be a potential target of transcription factors to regulate paclitaxel resistance.	Paclitaxel	105-115	cyclin dependent kinase 1	Homo sapiens	0-25
26442525-4	2015	Cyclin-dependent kinase 1 (CDK1) was found to be a potential target of transcription factors to regulate paclitaxel resistance.	Paclitaxel	105-115	cyclin dependent kinase 1	Homo sapiens	27-31
26442525-5	2015	As a result of the subsequent pharmacogenomics analysis, CDK1 inhibitor alsterpaullone was also indicated as a promising chemical that may be used in combinatorial therapies to reverse paclitaxel-induced chemoresistance.	Paclitaxel	185-195	cyclin dependent kinase 1	Homo sapiens	57-61
26442525-6	2015	Although a CDK1 inhibitor has the potential to kill cancer cells, short-term treatment over 2 weeks at sublethal doses effectively induced cell death only upon additional treatment with paclitaxel.	Paclitaxel	186-196	cyclin dependent kinase 1	Homo sapiens	11-15
26442525-8	2015	Thus, we suggest that inhibition of CDK1 with alsterpaullone may be a novel therapeutic method to reverse paclitaxel-induced resistance in ovarian cancer cells.	Paclitaxel	106-116	cyclin dependent kinase 1	Homo sapiens	36-40
26462028-3	2015	Paclitaxel, one of the cytotoxic taxane-drugs such as docetaxel, increases mesenchymal markers (Vimentin and Fibronectin) and decreases an epithelial marker (Zo-1).	Paclitaxel	0-10	vimentin	Homo sapiens	96-104
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	Paclitaxel	107-117	transforming growth factor beta receptor 1	Homo sapiens	70-74
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	Paclitaxel	107-117	POU class 5 homeobox 1	Homo sapiens	284-288
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	Paclitaxel	107-117	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	303-306
26246051-7	2015	Second, paclitaxel but not zerumbone induced Cdk1 activity.	Paclitaxel	8-18	cyclin dependent kinase 1	Homo sapiens	45-49
26324059-5	2015	Overexpression of proteins in the lipid metabolism processes, such as E3 ubiquitin-protein ligase RNF139 (RNF139) and Hydroxymethylglutaryl-CoA synthase (HMGCS1), have not been reported previously in the study of paclitaxel resistance, suggesting possibly different mechanism between nanoparticle and single molecular drug resistance.	Paclitaxel	213-223	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	154-160
26506310-6	2015	However, the airway cilia of mice lacking the radial spoke head protein Rsph4a undergo rotational movement instead of planar beating, are prone to microtubule rearrangement, and are sensitive to Taxol.	Paclitaxel	195-200	radial spoke head 4 homolog A (Chlamydomonas)	Mus musculus	72-78
26665000-8	2015	Neural differentiation markers NFL (for neurons), beta III-tubulin (for neurons), GFAP (for astrocytes), and CNPase (for oligodendrocytes) were detected in the taxol-treated C6 cells.	Paclitaxel	160-165	2',3'-cyclic nucleotide 3' phosphodiesterase	Rattus norvegicus	109-115
26265061-1	2015	UNLABELLED: Paclitaxel (PTX) is a potent anticancer drug which suffers limitations of extremely low oral bioavailability due to low solubility, rapid metabolism and efflux by P-gp transporters.	Paclitaxel	12-22	phosphoglycolate phosphatase	Homo sapiens	175-179
26265061-1	2015	UNLABELLED: Paclitaxel (PTX) is a potent anticancer drug which suffers limitations of extremely low oral bioavailability due to low solubility, rapid metabolism and efflux by P-gp transporters.	Paclitaxel	24-27	phosphoglycolate phosphatase	Homo sapiens	175-179
26722421-9	2015	15 genes of 762 transcripts on this chromosome region were consistently up-regulated detected by cDNA microarray in three taxol resistant sub-lines, and functionally clustered into various groups, including genes related to vascular formation vascular formation (ANGPT1), apoptosis (MYC, TOP1MT), cell adhesion and cell cycle (PPP1R16A, SDC2, CA2, ANKRD46), gene regulation (HRSP12, ZNF696, SLC39A4, POP1), metabolism (PYCRL).	Paclitaxel	122-127	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	283-286
26726449-6	2015	Nanoparticles composed of disulfide cross-linked branched PEI (ssPEI) and anti-cancer therapeutic gene miRNA-145 were complexed based on the electrostatic interaction and coated over the paclitaxel-loaded nanofiber.	Paclitaxel	187-197	microRNA 145	Homo sapiens	103-112
26344694-11	2015	In summary, our results suggest that paclitaxel and epirubicin target the FOXK2 to modulate their cytotoxicity and deregulated FOXK2 confers drug resistance.	Paclitaxel	37-47	forkhead box K2	Homo sapiens	74-79
26344694-11	2015	In summary, our results suggest that paclitaxel and epirubicin target the FOXK2 to modulate their cytotoxicity and deregulated FOXK2 confers drug resistance.	Paclitaxel	37-47	forkhead box K2	Homo sapiens	127-132
26617855-4	2015	RESULTS: There was a significant dysregulation in the global gene expression of the FOLR1-suppressed taxol-resistant nasopharyngeal carcinoma cell lines.	Paclitaxel	101-106	folate receptor alpha	Homo sapiens	84-89
26617855-8	2015	CONCLUSION: The suppression of FOLR1 by RNA interference altered gene expression profile of taxol-resistant nasopharyngeal carcinoma cell lines.	Paclitaxel	92-97	folate receptor alpha	Homo sapiens	31-36
26617855-9	2015	The apoptosis-related genes and the gene alterations in viral carcinogenesis, MAPK signaling pathways might be important in FOLR1 siRNA-induced taxol-resistant reversal.	Paclitaxel	144-149	folate receptor alpha	Homo sapiens	124-129
31174562-12	2019	Patients with positive Nek2B expression were less sensitive to paclitaxel-containing neoadjuvant chemotherapy.	Paclitaxel	63-73	NIMA related kinase 2	Homo sapiens	23-27
31174562-13	2019	Interestingly, in a panel of established TNBC cell line, Nek2B and beta-catenin were highly expressed in cells exhibiting paclitaxel resistance.	Paclitaxel	122-132	catenin beta 1	Homo sapiens	67-79
31174562-18	2019	The tumors treated by Nek2B siRNA associated with paclitaxel were the smallest in nude mouse, and Nek2B can regulate the expression of beta-catenin and wnt downstream target genes in vivo.	Paclitaxel	50-60	NIMA (never in mitosis gene a)-related expressed kinase 2	Mus musculus	22-26
31169019-6	2019	Xenograft mice assay was used to validate the important role of miR-21-5p as a regulator on PTX-resistance BC cells growth in vivo.	Paclitaxel	92-95	microRNA 215	Mus musculus	64-73
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	126-129	catenin beta 1	Homo sapiens	79-91
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	126-129	catenin beta 1	Homo sapiens	307-319
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	268-271	catenin beta 1	Homo sapiens	79-91
31206033-9	2019	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, beta-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/beta-catenin signaling pathway.	Paclitaxel	268-271	catenin beta 1	Homo sapiens	307-319
30784282-0	2019	Ambra1 inhibits paclitaxel-induced apoptosis in breast cancer cells by modulating the Bim/mitochondrial pathway.	Paclitaxel	16-26	autophagy and beclin 1 regulator 1	Homo sapiens	0-6
30784282-0	2019	Ambra1 inhibits paclitaxel-induced apoptosis in breast cancer cells by modulating the Bim/mitochondrial pathway.	Paclitaxel	16-26	BCL2 like 11	Homo sapiens	86-89
30784282-5	2019	Moreover, whether Ambra1 participates in the regulation of paclitaxel-induced apoptosis in breast cancer cells is not clear.	Paclitaxel	59-69	autophagy and beclin 1 regulator 1	Homo sapiens	18-24
30784282-6	2019	Here, we show that Ambra1 inhibits paclitaxel-induced apoptosis in breast cancer cells.	Paclitaxel	35-45	autophagy and beclin 1 regulator 1	Homo sapiens	19-25
31164954-5	2019	Expression of EGR1, a promoter of apoptosis, was higher in cells co-treated with BCI and paclitaxel or carboplatin than in cells treated with chemotherapeutic agents alone, while expression of the proto-oncogene c-JUN was decreased with co-treatment.	Paclitaxel	89-99	early growth response 1	Homo sapiens	14-18
30230544-3	2019	ClC-3 was highly expressed in the P-glycoprotein (P-gp)-dependent human lung adenocarcinoma cell line (A549)/paclitaxel (PTX) and the human breast carcinoma cell line (MCF-7)/doxorubicin (DOX) resistant cells.	Paclitaxel	109-119	chloride voltage-gated channel 3	Homo sapiens	0-5
30230544-3	2019	ClC-3 was highly expressed in the P-glycoprotein (P-gp)-dependent human lung adenocarcinoma cell line (A549)/paclitaxel (PTX) and the human breast carcinoma cell line (MCF-7)/doxorubicin (DOX) resistant cells.	Paclitaxel	121-124	chloride voltage-gated channel 3	Homo sapiens	0-5
30230544-4	2019	Changes in the ClC-3 expression resulted in the development of drug resistance in formerly drug-sensitive A549 or MCF-7 cells, and drug sensitivity in formerly drug-resistant A549/Taxol and MCF-7/DOX cells.	Paclitaxel	180-185	chloride voltage-gated channel 3	Homo sapiens	15-20
30230544-5	2019	Double transgenic MMTV-PyMT/CLCN3 mice with spontaneous mammary cancer and ClC-3 overexpression demonstrated drug resistance to PTX and DOX.	Paclitaxel	128-131	chloride voltage-gated channel 3	Homo sapiens	28-33
30414958-3	2019	We tested the hypothesis that activation of CB2 receptor by MDA7 modulates microglial dysregulation, suppresses the overexpression of brain-derived neurotrophic factor (BDNF) in microglia in the dorsal horn, and attenuates the central sensitization and pain behavior induced by paclitaxel.	Paclitaxel	278-288	cannabinoid receptor 2	Rattus norvegicus	44-47
30414958-7	2019	Paclitaxel induced the expression of CB2 receptors and production of interleukin (IL)-6 in microglia in the dorsal horn.	Paclitaxel	0-10	cannabinoid receptor 2	Rattus norvegicus	37-40
30414958-9	2019	Paclitaxel induced epigenetic upregulation of IRF8 and P2X purinoceptor 4 (P2X4) in microglia and subsequently increased the expression of alpha isoform of calcium/calmodulin-dependent protein kinase II (CaMKIIalpha), transcriptional factors p-CREB and DeltaFosB, leading to the overproduction of BDNF in microglia.	Paclitaxel	0-10	interferon regulatory factor 8	Rattus norvegicus	46-50
30414958-9	2019	Paclitaxel induced epigenetic upregulation of IRF8 and P2X purinoceptor 4 (P2X4) in microglia and subsequently increased the expression of alpha isoform of calcium/calmodulin-dependent protein kinase II (CaMKIIalpha), transcriptional factors p-CREB and DeltaFosB, leading to the overproduction of BDNF in microglia.	Paclitaxel	0-10	cAMP responsive element binding protein 1	Rattus norvegicus	244-248
30117103-7	2019	Development of mechanical and thermal allodynia was prevented completely in paclitaxel-treated hHsp27 transgenic mice.	Paclitaxel	76-86	heat shock protein family B (small) member 1	Homo sapiens	95-101
30117103-8	2019	Strikingly, hHsp27 protected against paclitaxel-induced neurotoxicity in vivo including degeneration of afferent nerve fibers, demyelination, mitochondrial swelling, apoptosis, and restored sensory nerve action potential.	Paclitaxel	37-47	heat shock protein family B (small) member 1	Homo sapiens	12-18
31179330-6	2019	Meanwhile, the apoptosis of cells induced by cisplatin or paclitaxel was assessed by Annexin-V/propidium iodide staining analysis.	Paclitaxel	58-68	annexin A5	Homo sapiens	85-94
31179330-9	2019	Moreover, Annexin-V/propidium iodide staining analysis revealed that decreased expression of survivin could evidently increase the apoptosis rate of laryngeal carcinoma cells that were induced by cisplatin or paclitaxel evidently (P &lt; 0.05).	Paclitaxel	209-219	annexin A5	Homo sapiens	10-19
31013972-8	2019	There are 12, 10 and 11 paclitaxel biosynthesis genes promoters that could be activated by MYC2, MYC3 and MYC4.	Paclitaxel	24-34	Basic helix-loop-helix (bHLH) DNA-binding family protein	Arabidopsis thaliana	91-95
31013972-8	2019	There are 12, 10 and 11 paclitaxel biosynthesis genes promoters that could be activated by MYC2, MYC3 and MYC4.	Paclitaxel	24-34	Basic helix-loop-helix (bHLH) DNA-binding family protein	Arabidopsis thaliana	97-101
31049098-17	2019	CONCLUSION: Paclitaxel, Ifosfamide, and Cisplatin (TIP) regimen give significant clinical benefit in penile cancer with nodal involvement.	Paclitaxel	12-22	TOR signaling pathway regulator	Homo sapiens	51-54
30978971-3	2019	Paclitaxel (PTX) was functionalized with an esterification reaction at the C2" hydroxyl group of PTX with glutaric anhydride and conjugated with the cyclic peptide [W(WR)4K(betaAla)] in DMF to obtain the peptide-drug conjugate PTX1.	Paclitaxel	0-10	paired like homeodomain 1	Homo sapiens	227-231
30978971-3	2019	Paclitaxel (PTX) was functionalized with an esterification reaction at the C2" hydroxyl group of PTX with glutaric anhydride and conjugated with the cyclic peptide [W(WR)4K(betaAla)] in DMF to obtain the peptide-drug conjugate PTX1.	Paclitaxel	12-15	paired like homeodomain 1	Homo sapiens	227-231
30229430-8	2019	We propose that 5-DMN cooperates with PTX to induce apoptosis via the caspase pathway (by modulating caspase-3, caspase-8, and caspase-9 activities).	Paclitaxel	38-41	caspase 9	Homo sapiens	127-136
30520096-4	2019	Through logistic regression, COX regression, and correlation analysis with bootstrapping, we found that four genes (CDK8, FAM64A, MARC2, and OCEL1) were associated with drug sensitivity of PTX.	Paclitaxel	189-192	mitochondrial amidoxime reducing component 2	Homo sapiens	130-135
30851646-7	2019	Mechanistically, BI6727/paclitaxel/proTAME stabilize Cyclin B1 and trigger mitotic arrest, which initiates mitochondrial apoptosis by inactivation of antiapoptotic BCL-2 family proteins, followed by activation of caspase-dependent effector pathways.	Paclitaxel	24-34	cyclin B1	Homo sapiens	53-62
30816511-6	2019	Furthermore, TRIM11 downregulation enhanced the pro-apoptotic effect of chemotherapy drugs on breast cancer cells, and high levels of TRIM11 expression were observed in cisplatin- and paclitaxel-resistant breast cancer tissues.	Paclitaxel	184-194	tripartite motif containing 11	Homo sapiens	13-19
30816511-6	2019	Furthermore, TRIM11 downregulation enhanced the pro-apoptotic effect of chemotherapy drugs on breast cancer cells, and high levels of TRIM11 expression were observed in cisplatin- and paclitaxel-resistant breast cancer tissues.	Paclitaxel	184-194	tripartite motif containing 11	Homo sapiens	134-140
32254809-5	2019	The results of the role of autophagy in the sensitivity of chemotherapeutic PTX to glioma cells showed that the stemness-associating genes (SOX2, POU5F1 and NANOG) of live glioma cells increased in the presence of PTX, while they dropped sharply with the combination including CQ.	Paclitaxel	76-79	POU class 5 homeobox 1	Homo sapiens	146-152
30911062-5	2019	Hence, we hypothesized that HER2/beta-catenin mediates paclitaxel resistance in breast cancer and suppression of HER2/beta-catenin signaling could overcome paclitaxel resistance.	Paclitaxel	55-65	catenin beta 1	Homo sapiens	33-45
30911062-5	2019	Hence, we hypothesized that HER2/beta-catenin mediates paclitaxel resistance in breast cancer and suppression of HER2/beta-catenin signaling could overcome paclitaxel resistance.	Paclitaxel	156-166	catenin beta 1	Homo sapiens	118-130
30911062-9	2019	In addition, tumors from paclitaxel and PFL-treated mice showed reduced HER2 and beta-catenin expression, along with increased apoptosis.	Paclitaxel	25-35	erb-b2 receptor tyrosine kinase 2	Mus musculus	72-76
30911062-10	2019	Taken together our results demonstrate a novel role of HER2/beta-catenin in paclitaxel resistance and open up new avenues for application of PFL as a therapeutic option for overcoming paclitaxel resistance.	Paclitaxel	76-86	catenin beta 1	Homo sapiens	60-72
30668349-0	2019	Augmented cytotoxic effects of paclitaxel by curcumin induced overexpression of folate receptor-alpha for enhanced targeted drug delivery in HeLa cells.	Paclitaxel	31-41	folate receptor alpha	Homo sapiens	80-101
30865895-6	2019	Significantly, USP21 depletion sensitized BLBC cell lines and mouse xenograft tumors to paclitaxel, an anti-mitotic, frontline therapy in BLBC treatment.	Paclitaxel	88-98	ubiquitin specific peptidase 21	Mus musculus	15-20
30911326-13	2019	Furthermore, SKN/PTX-induced downregulation of PKM2 (a key enzyme in glycolysis) and the suppression of its activity were inhibited by a ROS scavenger N-acetyl cysteine (NAC), suggesting that the synergy of the SKN/PTX combination may be not rely on PKM2 suppression.	Paclitaxel	17-20	pyruvate kinase M1/2	Homo sapiens	47-51
30911326-13	2019	Furthermore, SKN/PTX-induced downregulation of PKM2 (a key enzyme in glycolysis) and the suppression of its activity were inhibited by a ROS scavenger N-acetyl cysteine (NAC), suggesting that the synergy of the SKN/PTX combination may be not rely on PKM2 suppression.	Paclitaxel	17-20	pyruvate kinase M1/2	Homo sapiens	250-254
26169455-9	2015	Paclitaxel led to only slight alterations of cyclin and CDK inhibitor expression (P &gt; .05).	Paclitaxel	0-10	proliferating cell nuclear antigen	Homo sapiens	45-51
26366090-7	2015	Moreover, cordycepin plus cisplatin and/or paclitaxel significantly induced cleavage of caspase-8, caspase-9, caspase-3, and poly ADP-ribose polymerase, and phosphorylation of c-Jun NH2-terminal kinase, extracellular signal-regulated kinase, p38, and p53 proteins in MA-10 cells.	Paclitaxel	43-53	caspase 8	Mus musculus	88-97
26366090-7	2015	Moreover, cordycepin plus cisplatin and/or paclitaxel significantly induced cleavage of caspase-8, caspase-9, caspase-3, and poly ADP-ribose polymerase, and phosphorylation of c-Jun NH2-terminal kinase, extracellular signal-regulated kinase, p38, and p53 proteins in MA-10 cells.	Paclitaxel	43-53	transformation related protein 53, pseudogene	Mus musculus	251-254
26366090-8	2015	CONCLUSION: Cordycepin plus cisplatin and/or paclitaxel can have an additive effect on apoptosis in MA-10 cells, with activation of caspase, mitogen-activated protein kinase, and p53 signal pathways.	Paclitaxel	45-55	transformation related protein 53, pseudogene	Mus musculus	179-182
26305791-0	2015	Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.	Paclitaxel	177-187	microRNA 19a	Homo sapiens	24-31
26076081-9	2015	The same efficacy was only obtained with an 8-fold dose of paclitaxel (8 mg/kg) as Taxol plus XR9576, a potent P-gp inhibitor.	Paclitaxel	59-69	phosphoglycolate phosphatase	Homo sapiens	111-115
26550314-0	2015	Clinical efficacy and safety of paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for Stage IB2-IIB cervical cancer.	Paclitaxel	32-42	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	155-158
26086430-1	2015	A redox-sensitive prodrug, octreotide(Phe)-polyethene glycol-disulfide bond-paclitaxel [OCT(Phe)-PEG-ss-PTX], was successfully developed for targeted intracellular delivery of PTX.	Paclitaxel	76-86	plexin A2	Homo sapiens	88-91
30600025-1	2019	Herein, we describe a novel amphipathic chitosan derivative (N-octyl-N"-phthalyl-O-phosphoryl chitosan, abbreviated as OPPC) as an effective oral delivery platform for P-gp substrates, especially paclitaxel (PTX).	Paclitaxel	196-206	phosphoglycolate phosphatase	Homo sapiens	168-172
30600025-1	2019	Herein, we describe a novel amphipathic chitosan derivative (N-octyl-N"-phthalyl-O-phosphoryl chitosan, abbreviated as OPPC) as an effective oral delivery platform for P-gp substrates, especially paclitaxel (PTX).	Paclitaxel	208-211	phosphoglycolate phosphatase	Homo sapiens	168-172
11714450-9	2001	When we assessed the mRNA levels of the multidrug resistance-associated protein (MRP), which may be an efflux pump for DDP, the combination of paclitaxel or SN-38 with DDP down-regulated these levels, which are up-regulated by DDP alone.	Paclitaxel	143-153	ATP binding cassette subfamily C member 3	Homo sapiens	40-79
30592293-0	2019	Bromodomain-containing protein 7 sensitizes breast cancer cells to paclitaxel by activating Bcl2-antagonist/killer protein.	Paclitaxel	67-77	bromodomain containing 7	Homo sapiens	0-32
30592293-1	2019	Our previous study demonstrated that bromodomain-containing protein 7 (BRD7) inhibits cell proliferation and tumor growth, restoring the expression of B-cell lymphoma 2 antagonist/killer (Bak) sensitized breast cancer cells to paclitaxel.	Paclitaxel	227-237	bromodomain containing 7	Homo sapiens	37-69
30592293-1	2019	Our previous study demonstrated that bromodomain-containing protein 7 (BRD7) inhibits cell proliferation and tumor growth, restoring the expression of B-cell lymphoma 2 antagonist/killer (Bak) sensitized breast cancer cells to paclitaxel.	Paclitaxel	227-237	bromodomain containing 7	Homo sapiens	71-75
30592293-8	2019	Furthermore, ectopic expression of BRD7 inhibited cell proliferation, tumor growth and sensitized cancer cells to paclitaxel, while knockdown of Bak abolished BRD7-mediated inhibitory effects on cell proliferation and paclitaxel sensitization in breast cancer cells whether in vitro and in vivo.	Paclitaxel	114-124	bromodomain containing 7	Homo sapiens	35-39
30592293-8	2019	Furthermore, ectopic expression of BRD7 inhibited cell proliferation, tumor growth and sensitized cancer cells to paclitaxel, while knockdown of Bak abolished BRD7-mediated inhibitory effects on cell proliferation and paclitaxel sensitization in breast cancer cells whether in vitro and in vivo.	Paclitaxel	218-228	bromodomain containing 7	Homo sapiens	159-163
30592293-9	2019	The results demonstrated that BRD7 inhibits cell proliferation and sensitizes breast cancer cells to paclitaxel by activating Bak; they also provide promising targets for the diagnosis and treatment of breast cancer.	Paclitaxel	101-111	bromodomain containing 7	Homo sapiens	30-34
30668434-9	2019	Our results also supported the involvement of p53-p21 axis in the anticancer effects of curcumin and PTX.	Paclitaxel	101-104	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	46-49
26547077-7	2015	Chemotherapeutic drugs such as doxorubicin, paclitaxel, and bortezomib augmented the effect of both TRAIL variants, and the enhancing effect was more pronounced for DR5-B.	Paclitaxel	44-54	TNF receptor superfamily member 10b	Homo sapiens	165-168
25947567-12	2015	SPARC resulted up-regulated in both cell lines treated with bevacizumab+nab-paclitaxel.	Paclitaxel	76-86	secreted protein acidic and cysteine rich	Homo sapiens	0-5
25858687-8	2015	In addition, combination of paclitaxel and lentinan could activate apoptosis signal regulating kinase-1 (ASK1)/p38 mitogen-activated protein kinase (MAPK) signal which also contributed to cell apoptosis.	Paclitaxel	28-38	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	67-103
25858687-8	2015	In addition, combination of paclitaxel and lentinan could activate apoptosis signal regulating kinase-1 (ASK1)/p38 mitogen-activated protein kinase (MAPK) signal which also contributed to cell apoptosis.	Paclitaxel	28-38	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	105-109
25858687-9	2015	Taken together, co-treatment with paclitaxel and lentinan exerts synergistic apoptotic effects in A549 cells through inducing ROS production, and activating NLRP3 inflammasome and ASK1/p38 MAPK signal pathway.	Paclitaxel	34-44	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	180-184
11714450-9	2001	When we assessed the mRNA levels of the multidrug resistance-associated protein (MRP), which may be an efflux pump for DDP, the combination of paclitaxel or SN-38 with DDP down-regulated these levels, which are up-regulated by DDP alone.	Paclitaxel	143-153	ATP binding cassette subfamily C member 3	Homo sapiens	81-84
11606393-13	2001	The sensitivity of the 2008 transfected clones (displaying increased expression of RAR-gamma) to the cytotoxic effects of paclitaxel, etoposide, vincristine, and CD437 was similar to that observed in the parental 2008 cells.	Paclitaxel	122-132	retinoic acid receptor gamma	Homo sapiens	83-92
26063585-7	2015	Further analysis revealed that high expression of IGF2 was an unfavorable factor for the prognosis of the ovarian cancer patients at clinical stage I + II, stage III, histological grade 2, grade 3 or those treated with chemotherapy containing platin and Taxol.	Paclitaxel	254-259	insulin like growth factor 2	Homo sapiens	50-54
26146988-0	2015	CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.	Paclitaxel	15-25	cyclin dependent kinase 5	Homo sapiens	0-4
30791462-0	2019	Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer.	Paclitaxel	0-10	Rous sarcoma oncogene	Mus musculus	19-22
30791462-6	2019	Paclitaxel treatment increased Src activation in ovarian cancer cells, causing enrichment of CSC marker expression in the surviving cells in vitro and in xenografts of nude mice.	Paclitaxel	0-10	Rous sarcoma oncogene	Mus musculus	31-34
26146988-2	2015	Knockdown of CDK5 enhances paclitaxel sensitivity in human ovarian cancer cells.	Paclitaxel	27-37	cyclin dependent kinase 5	Homo sapiens	13-17
11600533-3	2001	In ARO and KAT-4 cells, manumycin- plus paclitaxel-induced DNA fragmentation was blocked by the inhibitors of caspase-9, caspase-8, and caspase-3.	Paclitaxel	40-50	caspase 8	Homo sapiens	121-130
26146988-3	2015	This study explores the mechanisms by which CDK5 regulates paclitaxel sensitivity in human ovarian cancers.	Paclitaxel	59-69	cyclin dependent kinase 5	Homo sapiens	44-48
26146988-6	2015	Knockdown of CDK5 with siRNAs inhibits activation of AKT which significantly correlates with decreased cell growth and enhanced paclitaxel sensitivity in ovarian cancer cell lines.	Paclitaxel	128-138	cyclin dependent kinase 5	Homo sapiens	13-17
11600533-8	2001	We concluded that the cytochrome c release was upstream of the activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells treated with manumycin plus paclitaxel, and that the interaction between manumycin and paclitaxel occurred at or upstream of cytochrome c in the apoptosis regulatory pathway in anaplastic thyroid cancer cells.	Paclitaxel	202-212	caspase 8	Homo sapiens	88-97
26146988-7	2015	In addition, CDK5 knockdown alone and in combination with paclitaxel induced G1 cell cycle arrest and caspase 3 dependent apoptotic cell death associated with post-translational upregulation and nuclear translocation of TP53 and p27(Kip1) as well as TP53-dependent transcriptional induction of p21(Cip1) in wild type TP53 cancer cells.	Paclitaxel	58-68	cyclin dependent kinase 5	Homo sapiens	13-17
26146988-7	2015	In addition, CDK5 knockdown alone and in combination with paclitaxel induced G1 cell cycle arrest and caspase 3 dependent apoptotic cell death associated with post-translational upregulation and nuclear translocation of TP53 and p27(Kip1) as well as TP53-dependent transcriptional induction of p21(Cip1) in wild type TP53 cancer cells.	Paclitaxel	58-68	interferon alpha inducible protein 27	Homo sapiens	229-232
11716366-6	2001	Paclitaxel induced apoptosis through activation of both caspase-8 and caspase-3.	Paclitaxel	0-10	caspase 8	Homo sapiens	56-65
11468188-6	2001	Instead fluorescence microscopy demonstrated colocalization of full-length GFP- and epitope-tagged pyrin with microtubules; this was markedly accentuated in paclitaxel-treated cells.	Paclitaxel	157-167	MEFV innate immuity regulator, pyrin	Homo sapiens	99-104
25975389-7	2015	Metformin treatment was also found to augment its anti-proliferative effect in SKOV3 and taxol-resistant SKOV3/TR cells transfected with Axl and Tyro3 specific siRNAs, siAxl and siTyro3, respectively, suggesting that metformin might target Axl and Tyro3 RTKs to restrain cell proliferation.	Paclitaxel	89-94	AXL receptor tyrosine kinase	Homo sapiens	137-140
25975389-7	2015	Metformin treatment was also found to augment its anti-proliferative effect in SKOV3 and taxol-resistant SKOV3/TR cells transfected with Axl and Tyro3 specific siRNAs, siAxl and siTyro3, respectively, suggesting that metformin might target Axl and Tyro3 RTKs to restrain cell proliferation.	Paclitaxel	89-94	AXL receptor tyrosine kinase	Homo sapiens	170-173
26555418-0	2015	[Effects of miRNA-21 on paclitaxel-resistance in human breast cancer cells].	Paclitaxel	24-34	microRNA 21	Homo sapiens	12-20
11461121-4	2001	We have shown previously that Taxol activates ERK 1/2 MAP-kinases and results in the formation of GRB2/SHC complexes in murine macrophage-like RAW 267.4 cells.	Paclitaxel	30-35	mitogen-activated protein kinase 3	Mus musculus	46-53
26555418-1	2015	OBJECTIVE: To investigate the effects of miR-21 on paclitaxel-resistance in human breast cancer MCF-7/PR and SKBR-3/PR cells.	Paclitaxel	51-61	microRNA 21	Homo sapiens	41-47
26555418-4	2015	The expression of Bax, Bcl-2 and miR-21 in parental and paclitaxel-resistant cells was detected by RT-PCR and Western blotting.	Paclitaxel	56-66	microRNA 21	Homo sapiens	33-39
11416148-3	2001	We show here that in Rat1 cells expressing an exogenous c-myc allele, distinct apoptotic pathways can be inhibited by Bcl-2 or Bcl-acta yet be distinguished by their sensitivity to Bcl-cb5 as either susceptible (serum withdrawal, taxol, and ceramide) or refractory (etoposide and doxorubicin).	Paclitaxel	230-235	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	56-61
25720064-2	2015	FTY720 has been shown to reduce the nociceptive behavior in the paclitaxel model for chemotherapy-induced neuropathic pain through downregulation of S1P receptor 1 (S1P1) in microglia of the spinal cord.	Paclitaxel	64-74	sphingosine-1-phosphate receptor 1	Mus musculus	149-163
25720064-2	2015	FTY720 has been shown to reduce the nociceptive behavior in the paclitaxel model for chemotherapy-induced neuropathic pain through downregulation of S1P receptor 1 (S1P1) in microglia of the spinal cord.	Paclitaxel	64-74	sphingosine-1-phosphate receptor 1	Mus musculus	165-169
25783790-9	2015	Mammosphere formation and expression of the stemness factor ALDH1 were also reduced in the cells treated with miR-34a and PTX compared to those treated with PTX alone.	Paclitaxel	122-125	aldehyde dehydrogenase 1 family member A1	Homo sapiens	60-65
25783790-9	2015	Mammosphere formation and expression of the stemness factor ALDH1 were also reduced in the cells treated with miR-34a and PTX compared to those treated with PTX alone.	Paclitaxel	157-160	aldehyde dehydrogenase 1 family member A1	Homo sapiens	60-65
11353846-5	2001	However, rhoB deletion also affected apoptotic susceptibility to Taxol, an agent that disrupts microtubule dynamics.	Paclitaxel	65-70	ras homolog family member B	Homo sapiens	9-13
25625774-0	2015	Silencing of glutaminase 1 resensitizes Taxol-resistant breast cancer cells to Taxol.	Paclitaxel	40-45	glutaminase	Homo sapiens	13-24
25625774-0	2015	Silencing of glutaminase 1 resensitizes Taxol-resistant breast cancer cells to Taxol.	Paclitaxel	79-84	glutaminase	Homo sapiens	13-24
11179455-0	2001	Disruption of cell adhesion and caspase-mediated proteolysis of beta- and gamma-catenins and APC protein in paclitaxel-induced apoptosis.	Paclitaxel	108-118	APC regulator of WNT signaling pathway	Homo sapiens	64-96
26030092-0	2015	Stathmin potentiates vinflunine and inhibits Paclitaxel activity.	Paclitaxel	45-55	stathmin 1	Homo sapiens	0-8
11179455-6	2001	Western blot analysis revealed that paclitaxel caused a time- and concentration-dependent cleavage of beta-catenin, gamma-catenin, and APC protein, but not alpha-catenin or E-cadherin.	Paclitaxel	36-46	APC regulator of WNT signaling pathway	Homo sapiens	135-138
26030092-5	2015	In the present study we investigated the binding of recombinant stathmin to purified tubulin in the presence of paclitaxel or another Vinca alkaloid, vinflunine, using Isothermal Titration Calorimetry (ITC).	Paclitaxel	112-122	stathmin 1	Homo sapiens	64-72
26030092-7	2015	Further investigation using turbidity and co-sedimentation showed that stathmin inhibited paclitaxel microtubule-stabilizing activity.	Paclitaxel	90-100	stathmin 1	Homo sapiens	71-79
11160641-5	2001	Four agents were competitive inhibitors of CYP1B1 activity: flutamide (K(i) = 1.0 microM), paclitaxel (K(i) = 31.6 microM), mitoxantrone (K(i) = 11.6 microM), and docetaxel (K(i) = 28.0 microM).	Paclitaxel	91-101	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	43-49
25849888-0	2015	beta-Catenin expression is regulated by an IRES-dependent mechanism and stimulated by paclitaxel in human ovarian cancer cells.	Paclitaxel	86-96	catenin beta 1	Homo sapiens	0-12
25849888-3	2015	In the present study, we found that PTX induced different transcription and translation levels of beta-catenin in the human ovarian cancer cell lines A2780 and SKOV3.	Paclitaxel	36-39	catenin beta 1	Homo sapiens	98-110
25857405-8	2015	The results indicate that DAO-cross-linked POEGMEA-b-PCEA-PTX conjugate micelles will be a useful nanodrug carrier for prostate cancer therapy.	Paclitaxel	58-61	D-amino acid oxidase	Homo sapiens	26-29
25684390-0	2015	Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells.	Paclitaxel	62-72	microRNA 433	Homo sapiens	31-38
25684390-3	2015	The objective of this study was to investigate the role of the microRNA miR-433 in the cellular response of OC cells to paclitaxel treatment.	Paclitaxel	120-130	microRNA 433	Homo sapiens	72-79
25684390-8	2015	Furthermore, in relation to a chemotherapeutic response, quantitative real-time polymerase chain reaction (qRT-PCR) analysis revealed that only PEO1 and PEO4 OC cells with the highest miR-433 expression survive paclitaxel treatment.	Paclitaxel	211-221	microRNA 433	Homo sapiens	184-191
25708932-0	2015	C-MYC modulation induces responsiveness to paclitaxel in adrenocortical cancer cell lines.	Paclitaxel	43-53	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-5
25769882-0	2015	Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.	Paclitaxel	71-81	serine/threonine kinase 11	Homo sapiens	17-21
25769882-0	2015	Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.	Paclitaxel	71-81	serine/threonine kinase 11	Homo sapiens	25-29
25769882-7	2015	The up-regulation of MDR1 protein and transcripts in EKVX cells was specifically associated with the expression of wild-type LKB1 and mainly responsible for the increased cellular resistance to paclitaxel.	Paclitaxel	194-204	serine/threonine kinase 11	Homo sapiens	125-129
25769882-10	2015	In contrast, in some NSCLC, the presence of LKB1 may facilitate increases in either MDR1 or class III beta-tubulin expression which can lead to paclitaxel resistance.	Paclitaxel	144-154	serine/threonine kinase 11	Homo sapiens	44-48
25596561-8	2015	As such, ABT-737 and S1 sensitized CML to paclitaxel by Mcl-1 inhibition, indirect inhibition through Bim antagonizing Mcl-1, or direct inhibition through binding to Mcl-1 itself.	Paclitaxel	42-52	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	56-61
26116605-4	2015	Ki-67 was positive in ~50% of tumor cell nuclei and the accompanying mitotic index was 19 mitotic figures/10 high power fields.Expression of SPARC in tumors has been correlated with sensitivity to nanoparticle albumin-bound paclitaxel (Nab-paclitaxel), particularly in the context of robust cell cycle progression into the mitotic phase.	Paclitaxel	224-234	secreted protein acidic and cysteine rich	Homo sapiens	141-146
25611552-3	2015	In this study, we investigated BAF57 expression in ovarian cancer cell lines and their sensitivities to cisplatin, doxorubicin, paclitaxel, and 5-fluorouracil.	Paclitaxel	128-138	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1	Homo sapiens	31-36
25611552-5	2015	Paclitaxel sensitivity was also correlated with BAF57 expression, but without significance.	Paclitaxel	0-10	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1	Homo sapiens	48-53
25096912-7	2015	In 17-AAG- and paclitaxel-treated cells, compared with paclitaxel alone-treated cells, the protein levels of hsp90, hsp70, and hsc70 increased.	Paclitaxel	15-25	heat shock protein 90 alpha family class A member 1	Homo sapiens	109-114
25096912-7	2015	In 17-AAG- and paclitaxel-treated cells, compared with paclitaxel alone-treated cells, the protein levels of hsp90, hsp70, and hsc70 increased.	Paclitaxel	55-65	heat shock protein 90 alpha family class A member 1	Homo sapiens	109-114
25681684-2	2015	Among various molecular factors, presence of MyD88, a component of TLR-4/MyD88 mediated NF-kappaB signaling in EOC tumors is reported to cause intrinsic paclitaxel resistance and poor survival.	Paclitaxel	153-163	toll like receptor 4	Homo sapiens	67-72
26191375-13	2015	Moreover, depletion of BRUCE in this cell line achieved a more profound level of cell killing when coupled to low doses of cisplatin and taxol combined, rather than either drug used alone.	Paclitaxel	137-142	baculoviral IAP repeat containing 6	Homo sapiens	23-28
25633416-7	2015	Treatment with DIM plus paclitaxel substantially increased apoptosis as indicated by increased levels of cleaved polyADP-ribose polymerase (PARP) and cleaved caspase-9 protein.	Paclitaxel	24-34	caspase 9	Homo sapiens	158-167
25811469-1	2015	We assessed the capability of paclitaxel, one of the taxanes, to induce death in two prostate cancer lines, LNCaP and PC3.	Paclitaxel	30-40	chromobox 8	Homo sapiens	118-121
25874011-6	2015	We found that increasing cytoplasmic abundance of HSPB11 in NIH3T3 cells protected against paclitaxel-induced apoptosis, while suppressing HSPB11 in HeLa cells sensitised the cells toward paclitaxel.	Paclitaxel	91-101	heat shock protein family B (small), member 11	Mus musculus	50-56
25874011-8	2015	More importantly, increased cytoplasmic level of HSPB11 in NIH3T3 cells enhanced the inhibitory phosphorylation of DLP1 and attenuated paclitaxel-induced mitochondrial fission.	Paclitaxel	135-145	heat shock protein family B (small), member 11	Mus musculus	49-55
25868824-0	2015	Paclitaxel induces acute pain via directly activating toll like receptor 4.	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	54-74
25868824-8	2015	Paclitaxel causes activation of toll like receptor 4 (TLR4) in the spinal dorsal horn and dorsal root ganglions.	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	32-52
25868824-8	2015	Paclitaxel causes activation of toll like receptor 4 (TLR4) in the spinal dorsal horn and dorsal root ganglions.	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	54-58
25868824-9	2015	Through activating TLR4, paclitaxel increases glutamatergic synaptic activities and reduces glial glutamate transporter activities in the dorsal horn.	Paclitaxel	25-35	toll like receptor 4	Homo sapiens	19-23
25868824-10	2015	Activations of TLR4 are necessary in the genesis of paclitaxel-induced acute pain.	Paclitaxel	52-62	toll like receptor 4	Homo sapiens	15-19
25885449-9	2015	RESULTS: We observe that FEN1 is significantly up-regulated upon treatment of chemotherapeutic drugs such as mitomycin C (MMC) and Taxol in breast cancer cells.	Paclitaxel	131-136	flap structure-specific endonuclease 1	Homo sapiens	25-29
25785038-6	2015	Application of TrkA siRNA to cancer cell also increased the chemo-sensitivity to paclitaxel, and further promoted apoptosis in cancer cell through the activation of caspase-3.	Paclitaxel	81-91	neurotrophic tyrosine kinase, receptor, type 1	Mus musculus	15-19
25785038-7	2015	Moreover, TrkA siRNA increased the efficacy of paclitaxel and decreased the incidence of lung metastasis in tumor xenografted mice.	Paclitaxel	47-57	neurotrophic tyrosine kinase, receptor, type 1	Mus musculus	10-14
25445692-3	2015	In this study we showed that the co-delivery of antagomir-10b with paclitaxel (PTX) by a novel liposomal delivery system modified with an anti-microbial peptide [D]-H6L9 (D-Lip) could significantly both hinder the migration of 4T1 cells and induce evident cellular apoptosis and cell death in the meantime.	Paclitaxel	79-82	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	173-176
25445692-7	2015	Taken together, these results demonstrated that D-Lip could act as a sufficient tool in co-delivering antagomir-10b and PTX.	Paclitaxel	120-123	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	50-53
25776964-2	2015	PTX improves the pharmaceutical efficacy of the first-line pancreatic cancer drug, gemcitabine (GEM), through suppression of the tumor stroma and inhibiting the expression of the GEM-inactivating enzyme, cytidine deaminase (CDA).	Paclitaxel	0-3	cytidine deaminase	Mus musculus	204-222
25776964-2	2015	PTX improves the pharmaceutical efficacy of the first-line pancreatic cancer drug, gemcitabine (GEM), through suppression of the tumor stroma and inhibiting the expression of the GEM-inactivating enzyme, cytidine deaminase (CDA).	Paclitaxel	0-3	cytidine deaminase	Mus musculus	224-227
25776964-6	2015	We demonstrate that ratiometric PTX incorporation and delivery by our LB-MSNP could suppress CDA expression, contemporaneous with induction of oxidative stress as the operating principle for PTX synergy.	Paclitaxel	32-35	cytidine deaminase	Mus musculus	93-96
25776964-11	2015	IV injection of MSNP-delivered PTX/GEM in a PANC-1 orthotopic model effectively inhibited primary tumor growth and eliminated metastatic foci.	Paclitaxel	31-34	pancreas protein 1	Mus musculus	44-50
25640847-7	2015	Moreover, EA remarkably suppressed the PTX-enhanced phosphorylation of the NMDA receptor NR2B subunit in the spinal dorsal horn, and intrathecal pretreatment of naloxone, idazoxan (IDA) or propranolol blocked the effect of EA.	Paclitaxel	39-42	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	89-93
25607466-0	2015	TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer.	Paclitaxel	17-27	thioredoxin domain containing 17	Homo sapiens	0-7
25607466-3	2015	Here, we showed that TXNDC17 screened from 356 differentially expressed proteins by LC-MS/MS label-free quantitative proteomics was more highly expressed in paclitaxel-resistant ovarian cancer cells and tissues, and the high expression of TXNDC17 was associated with poorer prognostic factors and exhibited shortened survival in 157 ovarian cancer patients.	Paclitaxel	157-167	thioredoxin domain containing 17	Homo sapiens	21-28
25607466-3	2015	Here, we showed that TXNDC17 screened from 356 differentially expressed proteins by LC-MS/MS label-free quantitative proteomics was more highly expressed in paclitaxel-resistant ovarian cancer cells and tissues, and the high expression of TXNDC17 was associated with poorer prognostic factors and exhibited shortened survival in 157 ovarian cancer patients.	Paclitaxel	157-167	thioredoxin domain containing 17	Homo sapiens	239-246
25607466-4	2015	Moreover, paclitaxel exposure induced upregulation of TXNDC17 and BECN1 expression, increase of autophagosome formation, and autophagic flux that conferred cytoprotection for ovarian cancer cells from paclitaxel.	Paclitaxel	10-20	thioredoxin domain containing 17	Homo sapiens	54-61
25607466-5	2015	TXNDC17 inhibition by siRNA or enforced overexpression by a pcDNA3.1(+)-TXNDC17 plasmid correspondingly decreased or increased the autophagy response and paclitaxel resistance.	Paclitaxel	154-164	thioredoxin domain containing 17	Homo sapiens	0-7
25607466-5	2015	TXNDC17 inhibition by siRNA or enforced overexpression by a pcDNA3.1(+)-TXNDC17 plasmid correspondingly decreased or increased the autophagy response and paclitaxel resistance.	Paclitaxel	154-164	thioredoxin domain containing 17	Homo sapiens	72-79
25756509-6	2015	We found 13 differentially expressed miRNAs, of which miR-1204 was significantly downregulated in the paclitaxel-resistant CNE-1/Taxol cells.	Paclitaxel	102-112	microRNA 1204	Homo sapiens	54-62
25756509-6	2015	We found 13 differentially expressed miRNAs, of which miR-1204 was significantly downregulated in the paclitaxel-resistant CNE-1/Taxol cells.	Paclitaxel	129-134	microRNA 1204	Homo sapiens	54-62
25756509-7	2015	We restored miR-1204 expression in the CNE-1/Taxol, HNE-2/Taxol and 5-8F/Taxol cells and found that restoration of miR-1204 re-sensitized the paclitaxel-resistant CNE-1/Taxol, HNE-2/Taxol and 5-8F/Taxol cells to paclitaxel both in vitro.	Paclitaxel	142-152	microRNA 1204	Homo sapiens	115-123
25756509-7	2015	We restored miR-1204 expression in the CNE-1/Taxol, HNE-2/Taxol and 5-8F/Taxol cells and found that restoration of miR-1204 re-sensitized the paclitaxel-resistant CNE-1/Taxol, HNE-2/Taxol and 5-8F/Taxol cells to paclitaxel both in vitro.	Paclitaxel	212-222	microRNA 1204	Homo sapiens	115-123
25835050-3	2015	We investigated the survival phenotype and the protein level of c-myc, a B-RAF target molecule, in melanoma cells, carrying a different mutational status in B-RAF, upon paclitaxel, doxorubicin and H2O2 treatment.	Paclitaxel	169-179	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	64-69
25134663-0	2015	Knockdown of Akt2 expression by shRNA inhibits proliferation, enhances apoptosis, and increases chemosensitivity to paclitaxel in human colorectal cancer cells.	Paclitaxel	116-126	AKT serine/threonine kinase 2	Homo sapiens	13-17
25134663-5	2015	Furthermore, our results demonstrated that Akt2 knockdown correlated with elevated chemosensitivity of HCT116 cells to paclitaxel.	Paclitaxel	119-129	AKT serine/threonine kinase 2	Homo sapiens	43-47
25807633-0	2015	Role of Smac in apoptosis of lung cancer cells A549 induced by Taxol.	Paclitaxel	63-68	diablo IAP-binding mitochondrial protein	Homo sapiens	8-12
25807633-2	2015	In this study, we investigate the role of Smac in Taxol-induced apoptosis of lung cancer cell in vitro.	Paclitaxel	50-55	diablo IAP-binding mitochondrial protein	Homo sapiens	42-46
25807633-6	2015	Flow cytometry was used to analyze apoptosis of cells induced by Taxol with Annexin V/PI double staining technique.	Paclitaxel	65-70	annexin A5	Homo sapiens	76-85
25807633-10	2015	The apoptosis rate was significantly higher in PcDNA3.1/Smac + Taxol group than in other groups (p &lt; 0.05).	Paclitaxel	63-68	diablo IAP-binding mitochondrial protein	Homo sapiens	56-60
25807633-11	2015	CONCLUSIONS: Transfected Smac can enhance the chemosensitivity of the non-small cell lung cancer cell line A549 to Taxol.	Paclitaxel	115-120	diablo IAP-binding mitochondrial protein	Homo sapiens	25-29
25466507-8	2015	Three chemotherapeutic agents with different mechanism of action (5-fluorouracil, bortezomib and paclitaxel) significantly induced GCNT3 expression in several cancer cells, being observed the correlation between antitumour action and GCNT3 modulation, whereas this gene was not modulated in cells that do not respond to treatment.	Paclitaxel	97-107	glucosaminyl (N-acetyl) transferase 3, mucin type	Homo sapiens	131-136
25466507-8	2015	Three chemotherapeutic agents with different mechanism of action (5-fluorouracil, bortezomib and paclitaxel) significantly induced GCNT3 expression in several cancer cells, being observed the correlation between antitumour action and GCNT3 modulation, whereas this gene was not modulated in cells that do not respond to treatment.	Paclitaxel	97-107	glucosaminyl (N-acetyl) transferase 3, mucin type	Homo sapiens	234-239
31149552-4	2019	Here, we present a case of a 77-year-old woman who underwent adjuvant chemotherapy (combined paclitaxel and carboplatin) for ovarian cancer, and then developed acute arteritis after receiving G-CSF.	Paclitaxel	93-103	colony stimulating factor 3	Homo sapiens	192-197
30804792-13	2018	Taxol up-regulated the protein levels of P-H2A, PARP, Chk1, p53, and p21 and down-regulated Bcl-Xl and Mcl-1, and RAP reversed the expression of all these proteins.	Paclitaxel	0-5	transformation related protein 53, pseudogene	Mus musculus	60-63
30478151-10	2019	Knockdown and inhibition of AXL dose-dependently improved response to paclitaxel and carboplatin in both cell lines and primary cells.	Paclitaxel	70-80	AXL receptor tyrosine kinase	Homo sapiens	28-31
30622051-0	2019	MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.	Paclitaxel	79-89	adhesion G protein-coupled receptor E5	Homo sapiens	29-33
30622051-5	2019	In LPS-stimulated or paclitaxel-resistant ovarian cancer cells, stimulation with recombinant human CD55 (rhCD55) of CD97 in ovarian cancer cells activated NF-kappaB-dependent miR-503-5p down-regulation and the JAK2/STAT3 pathway, consequently promoting the migratory and invasive capacity.	Paclitaxel	21-31	adhesion G protein-coupled receptor E5	Homo sapiens	116-120
32123828-6	2019	Additionally, proteins namely VASP, coronin-1A, stathmin, and suprabasin were confidently identified in ovarian chemotherapy subjects, possibly in response to combined paclitaxel and carboplatin drug therapy to ovarian cancer.	Paclitaxel	168-178	stathmin 1	Homo sapiens	48-56
30761140-0	2019	Paclitaxel Enhances the Innate Immunity by Promoting NLRP3 Inflammasome Activation in Macrophages.	Paclitaxel	0-10	NLR family, pyrin domain containing 3	Mus musculus	53-58
30761140-3	2019	Here we showed that paclitaxel pre-treatment greatly enhanced ATP- or nigericin-induced NLRP3 inflammasome activation as indicated by increased release of cleaved caspase-1 and mature IL-1beta, enhanced formation of ASC speck, and increased gasdermin D cleavage and pyroptosis.	Paclitaxel	20-30	NLR family, pyrin domain containing 3	Mus musculus	88-93
30761140-6	2019	Concurrently, the paclitaxel-mediated enhancement of NLRP3 inflammasome activation was significantly suppressed by resveratrol, NAD+, or MEC-17 knockdown, indicating the involvement of paclitaxel-induced alpha-tubulin acetylation in the augmentation of NLRP3 inflammasome activation.	Paclitaxel	18-28	NLR family, pyrin domain containing 3	Mus musculus	53-58
30761140-6	2019	Concurrently, the paclitaxel-mediated enhancement of NLRP3 inflammasome activation was significantly suppressed by resveratrol, NAD+, or MEC-17 knockdown, indicating the involvement of paclitaxel-induced alpha-tubulin acetylation in the augmentation of NLRP3 inflammasome activation.	Paclitaxel	18-28	NLR family, pyrin domain containing 3	Mus musculus	253-258
30761140-6	2019	Concurrently, the paclitaxel-mediated enhancement of NLRP3 inflammasome activation was significantly suppressed by resveratrol, NAD+, or MEC-17 knockdown, indicating the involvement of paclitaxel-induced alpha-tubulin acetylation in the augmentation of NLRP3 inflammasome activation.	Paclitaxel	185-195	NLR family, pyrin domain containing 3	Mus musculus	53-58
30761140-6	2019	Concurrently, the paclitaxel-mediated enhancement of NLRP3 inflammasome activation was significantly suppressed by resveratrol, NAD+, or MEC-17 knockdown, indicating the involvement of paclitaxel-induced alpha-tubulin acetylation in the augmentation of NLRP3 inflammasome activation.	Paclitaxel	185-195	NLR family, pyrin domain containing 3	Mus musculus	253-258
30761140-9	2019	Collectively, our data indicate that paclitaxel potentiated NLRP3 inflammasome activation by inducing alpha-tubulin acetylation and thereby conferred enhanced antibacterial innate responses, suggesting its potential application against pathogenic infections beyond its use as a chemotherapeutic agent.	Paclitaxel	37-47	NLR family, pyrin domain containing 3	Mus musculus	60-65
30622177-4	2019	Expression of ROR1 also enhanced the capacity of breast cancer cells to invade Matrigel, form spheroids, engraft in Rag2-/-[Formula: see text] mice, or survive treatment with paclitaxel.	Paclitaxel	175-185	receptor tyrosine kinase-like orphan receptor 1	Mus musculus	14-18
30556139-5	2019	The EC50 of paclitaxel and vinorelbine decreased in the presence of a P-gp inhibitor in CW-2 and CL-11 cells that highly express P-gp.	Paclitaxel	12-22	phosphoglycolate phosphatase	Homo sapiens	70-74
30556139-5	2019	The EC50 of paclitaxel and vinorelbine decreased in the presence of a P-gp inhibitor in CW-2 and CL-11 cells that highly express P-gp.	Paclitaxel	12-22	phosphoglycolate phosphatase	Homo sapiens	129-133
30325723-7	2019	Paclitaxel also amplified the expression of p-mTOR, mTOR-mediated phosphorylation of p70 ribosomal S6 protein kinase 1 (p-S6K1), 4E-binding protein 1 (p-4E-BP1) in the DRG.	Paclitaxel	0-10	ribosomal protein S6 kinase B1	Rattus norvegicus	122-126
30583585-4	2018	The expression of LOX, COL1A2, COL3A1, and ALDH1A1 was performed in sensitive (A2780, W1) and resistant to paclitaxel (PAC) (A2780PR1 and W1PR2) and topotecan (TOP) (W1TR) cell lines at the mRNA (real-time PCR analysis) and protein level (Western blot and immunofluorescence analysis).	Paclitaxel	107-117	aldehyde dehydrogenase 1 family member A1	Homo sapiens	43-50
30583585-12	2018	This represents the study where molecules related with CSCs (ALDH1A1) and ECM (LOX, collagens) models of drug resistance are described as occurring simultaneously in ovarian cancer cells treated with PAC and TOP.	Paclitaxel	200-203	aldehyde dehydrogenase 1 family member A1	Homo sapiens	61-68
30444601-6	2018	In vitro and in vivo results confirmed that PTX-NP showed pH-dependent intestinal site-specific drug release, P-gp inhibitory function by tannic acid (TA), prolonged intestinal retention, and improved trans-epithelial transport properties.	Paclitaxel	44-47	phosphoglycolate phosphatase	Homo sapiens	110-114
30251669-4	2018	RESULTS: Cytotoxicity and cellular accumulation studies showed that  NO significantly inhibited the ATPase activity of P-gp in isolated membranes and in NCI/ADR-RES tumor cells, causing an increase in drug accumulation and reversals of adriamycin and taxol resistance in the MDR cells.	Paclitaxel	251-256	phosphoglycolate phosphatase	Homo sapiens	119-123
25983747-10	2015	Local delivery of paclitaxel from a PEM inhibited growth of pancreatic/cholangiocarcinoma tumors in nude mice by suppressing angiogenesis via the mTOR and inducing apoptosis signal pathway.	Paclitaxel	18-28	mechanistic target of rapamycin kinase	Mus musculus	146-150
25552929-7	2015	We found that let-7f, let-7a, miR-19b and miR-340-5p were reduced by &gt;2 fold, and miR-543* and miR-684 were upregulated by at least 50% in paclitaxel LDM therapy.	Paclitaxel	142-152	microRNA 543	Homo sapiens	85-92
25333998-2	2015	SNX-2112, a selective heat shock protein 90 (Hsp90) inhibitor, was recently reported as being effective in combination with cisplatin and paclitaxel.	Paclitaxel	138-148	heat shock protein 90 alpha family class A member 1	Homo sapiens	22-43
25333998-2	2015	SNX-2112, a selective heat shock protein 90 (Hsp90) inhibitor, was recently reported as being effective in combination with cisplatin and paclitaxel.	Paclitaxel	138-148	heat shock protein 90 alpha family class A member 1	Homo sapiens	45-50
25402202-0	2015	The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study.	Paclitaxel	84-94	ATP binding cassette subfamily C member 10	Homo sapiens	68-74
11179426-4	2001	We found that MT nucleation by centrosomes from Xenopus sperm or somatic cells and MT assembly promoted by dimethyl sulfoxide or paclitaxel induced stathmin/Op18 hyperphosphorylation in Xenopus egg extracts, leading to new stathmin/Op18 isoforms phosphorylated on Ser 16.	Paclitaxel	129-139	stathmin 1 L homeolog	Xenopus laevis	232-236
25402202-3	2015	The ABC transporter subfamily C member 10 (ABCC10), also known as multi-drug resistance protein 7 (MRP7) efflux transporter, is a major mediator of paclitaxel resistance.	Paclitaxel	148-158	ATP binding cassette subfamily C member 10	Homo sapiens	43-49
25402202-3	2015	The ABC transporter subfamily C member 10 (ABCC10), also known as multi-drug resistance protein 7 (MRP7) efflux transporter, is a major mediator of paclitaxel resistance.	Paclitaxel	148-158	ATP binding cassette subfamily C member 10	Homo sapiens	66-97
25402202-3	2015	The ABC transporter subfamily C member 10 (ABCC10), also known as multi-drug resistance protein 7 (MRP7) efflux transporter, is a major mediator of paclitaxel resistance.	Paclitaxel	148-158	ATP binding cassette subfamily C member 10	Homo sapiens	99-103
30454700-0	2018	Role of DDX53 in taxol-resistance of cervix cancer cells in vitro.	Paclitaxel	17-22	DEAD-box helicase 53	Homo sapiens	8-13
11212279-5	2001	Treatment with paclitaxel or taxotere increased DR4 and/or DR5 protein levels (up to 8-fold) without affecting the protein levels of DcR1 and DcR2, Apo-2L/TRAIL, Fas, or Fas ligand.	Paclitaxel	15-25	TNF receptor superfamily member 10a	Homo sapiens	48-51
30454700-3	2018	In this study, the role of DDX53 in taxol-resistance of cervix cancer cells was investigated.	Paclitaxel	36-41	DEAD-box helicase 53	Homo sapiens	27-32
30454700-4	2018	In taxol-resistant HelaTR cells, DDX53 was significantly increased as compared to the parental HeLa cells.	Paclitaxel	3-8	DEAD-box helicase 53	Homo sapiens	33-38
30454700-7	2018	Overexpression of DDX53 in HeLa and SiHa markedly led to greater resistance to taxol and cisplatin, whereas knockdown of DDX53 in HelaTR cells restored sensitivity, demonstrating that DDX53 regulated taxol resistance in cervix cancer cells.	Paclitaxel	79-84	DEAD-box helicase 53	Homo sapiens	18-23
30454700-7	2018	Overexpression of DDX53 in HeLa and SiHa markedly led to greater resistance to taxol and cisplatin, whereas knockdown of DDX53 in HelaTR cells restored sensitivity, demonstrating that DDX53 regulated taxol resistance in cervix cancer cells.	Paclitaxel	200-205	DEAD-box helicase 53	Homo sapiens	18-23
25402202-4	2015	Here, we determine the effect of NVP-BHG712, a specific EphB4 receptor inhibitor, on 1) paclitaxel resistance in HEK293 cells transfected with ABCC10, 2) the growth of tumors in athymic nude mice that received NVP-BHG712 and paclitaxel systemically and 3) the pharmacokinetics of paclitaxel in presence or absence of NVP-BHG712.	Paclitaxel	88-98	ATP binding cassette subfamily C member 10	Homo sapiens	143-149
25402202-5	2015	NVP-BHG712 (0.5 muM), in HEK293/ABCC10 cells, significantly enhanced the intracellular accumulation of paclitaxel by inhibiting the efflux activity of ABCC10 without altering the expression level of the ABCC10 protein.	Paclitaxel	103-113	ATP binding cassette subfamily C member 10	Homo sapiens	32-38
25402202-5	2015	NVP-BHG712 (0.5 muM), in HEK293/ABCC10 cells, significantly enhanced the intracellular accumulation of paclitaxel by inhibiting the efflux activity of ABCC10 without altering the expression level of the ABCC10 protein.	Paclitaxel	103-113	ATP binding cassette subfamily C member 10	Homo sapiens	151-157
25402202-5	2015	NVP-BHG712 (0.5 muM), in HEK293/ABCC10 cells, significantly enhanced the intracellular accumulation of paclitaxel by inhibiting the efflux activity of ABCC10 without altering the expression level of the ABCC10 protein.	Paclitaxel	103-113	ATP binding cassette subfamily C member 10	Homo sapiens	151-157
25402202-6	2015	Furthermore, NVP-BHG712 (25 mg/kg, p.o., q3d x 6), in combination with paclitaxel (15 mg/kg, i.p., q3d x 6), significantly inhibited the growth of ABCC10-expressing tumors in athymic nude mice.	Paclitaxel	71-81	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	147-153
25402202-8	2015	The combination of NVP-BHG712 and paclitaxel could serve as a novel and useful therapeutic strategy to attenuate paclitaxel resistance mediated by the expression of the ABCC10 transporter.	Paclitaxel	34-44	ATP binding cassette subfamily C member 10	Homo sapiens	169-175
25402202-8	2015	The combination of NVP-BHG712 and paclitaxel could serve as a novel and useful therapeutic strategy to attenuate paclitaxel resistance mediated by the expression of the ABCC10 transporter.	Paclitaxel	113-123	ATP binding cassette subfamily C member 10	Homo sapiens	169-175
30454700-7	2018	Overexpression of DDX53 in HeLa and SiHa markedly led to greater resistance to taxol and cisplatin, whereas knockdown of DDX53 in HelaTR cells restored sensitivity, demonstrating that DDX53 regulated taxol resistance in cervix cancer cells.	Paclitaxel	200-205	DEAD-box helicase 53	Homo sapiens	121-126
30454700-7	2018	Overexpression of DDX53 in HeLa and SiHa markedly led to greater resistance to taxol and cisplatin, whereas knockdown of DDX53 in HelaTR cells restored sensitivity, demonstrating that DDX53 regulated taxol resistance in cervix cancer cells.	Paclitaxel	200-205	DEAD-box helicase 53	Homo sapiens	121-126
30454700-11	2018	Taken together, these results suggest that DDX53 plays a critical role in taxol-resistance by activating autophagy and a potential therapeutic target for the treatment of taxol-resistant cervix cancer.	Paclitaxel	74-79	DEAD-box helicase 53	Homo sapiens	43-48
30454700-11	2018	Taken together, these results suggest that DDX53 plays a critical role in taxol-resistance by activating autophagy and a potential therapeutic target for the treatment of taxol-resistant cervix cancer.	Paclitaxel	171-176	DEAD-box helicase 53	Homo sapiens	43-48
25550688-7	2014	An attempt made in the present study demonstrated that the acquired resistance to DOX was via or partially via NF-kappaB activation but not its upstream receptor TLR4, while PTX can induce the drug resistance via TLR4-NF-kappaB pathway.	Paclitaxel	174-177	toll like receptor 4	Homo sapiens	213-217
25546354-10	2014	Q-PCR showed the combination of Suberoylanilide hydroxamic acid and paclitaxel reduced intracellular bcl-2 and c-myc gene expression and increased bax gene expression more distinctly than the application of SAHA or paclitaxel alone.	Paclitaxel	68-78	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	111-116
25386925-9	2014	We also demonstrated that taxol attenuated migration and invasion in cervical cancer cells by activating the miR-107, in which miR-107 play an important role in regulating the expression of MCL1.	Paclitaxel	26-31	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	190-194
11096346-7	2000	MRP expression slightly increased in KF and KFTx after exposure to PTX.	Paclitaxel	67-70	ATP binding cassette subfamily C member 3	Homo sapiens	0-3
25368265-1	2014	AIM: To evaluate the predictive value of the expression of the secreted protein acidic and rich in cysteine (SPARC) for nab-paclitaxel in metastatic breast cancer (MBC).	Paclitaxel	124-134	secreted protein acidic and cysteine rich	Homo sapiens	63-107
25368265-1	2014	AIM: To evaluate the predictive value of the expression of the secreted protein acidic and rich in cysteine (SPARC) for nab-paclitaxel in metastatic breast cancer (MBC).	Paclitaxel	124-134	secreted protein acidic and cysteine rich	Homo sapiens	109-114
30222360-2	2018	We have previously reported a PEG-NLG-based immunostimulatory nanocarrier (PEG2k-Fmoc-NLG919) for co-delivery of an IDO1 inhibitor (NLG919) and a chemotherapeutic agent (paclitaxel, PTX).	Paclitaxel	170-180	indoleamine 2,3-dioxygenase 1	Homo sapiens	116-120
11042690-8	2000	In addition to detecting growth factor-mediated activation, the assay was also able to detect paclitaxel-mediated Raf-1 activation.	Paclitaxel	94-104	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	114-119
30153562-0	2018	A collagen microchannel scaffold carrying paclitaxel-liposomes induces neuronal differentiation of neural stem cells through Wnt/beta-catenin signaling for spinal cord injury repair.	Paclitaxel	42-52	catenin beta 1	Rattus norvegicus	129-141
30153562-11	2018	Moreover, mRNA-Seq and western blotting results revealed that PTX-triggered neuronal differentiation occurred through Wnt/beta-catenin signaling pathway.	Paclitaxel	62-65	catenin beta 1	Rattus norvegicus	122-134
30190114-4	2018	We used western blot and quantitative real-time PCR to analyze changes in AXL RNA and protein expression by SQ1274 and paclitaxel.	Paclitaxel	119-129	AXL receptor tyrosine kinase	Homo sapiens	74-77
25257554-8	2014	The expressions of lncRNA CDKN2B-AS1, HOTAIR and MALAT1 were dramatically reduced with the increasing concentration of cisplatin and paclitaxel and also lengthening of the treatment duration.	Paclitaxel	133-143	HOX transcript antisense RNA	Homo sapiens	38-44
25257554-8	2014	The expressions of lncRNA CDKN2B-AS1, HOTAIR and MALAT1 were dramatically reduced with the increasing concentration of cisplatin and paclitaxel and also lengthening of the treatment duration.	Paclitaxel	133-143	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	49-55
30084832-7	2018	Dual knockdown of IKBKB/STK39 or EDN2/TBK1 enhanced paclitaxel sensitivity more than silencing single kinases.	Paclitaxel	52-62	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	18-23
10956217-0	2000	Synthesis and biological evaluation of 2"-carbamate-linked and 2"-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin.	Paclitaxel	95-105	plasminogen	Homo sapiens	161-168
30084832-7	2018	Dual knockdown of IKBKB/STK39 or EDN2/TBK1 enhanced paclitaxel sensitivity more than silencing single kinases.	Paclitaxel	52-62	TANK binding kinase 1	Homo sapiens	38-42
30084832-10	2018	Knockdown of IKBKB/STK39 or EDN2/TBK1 enhanced paclitaxel sensitivity in two ovarian xenograft models.Conclusions: Sequential knockdown of dual kinases increased microtubule stability by decreasing p38-mediated phosphorylation of MAP4 and enhanced response to paclitaxel in ovarian cancer cell lines and xenografts, suggesting a strategy to improve primary therapy.	Paclitaxel	47-57	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	13-18
30084832-10	2018	Knockdown of IKBKB/STK39 or EDN2/TBK1 enhanced paclitaxel sensitivity in two ovarian xenograft models.Conclusions: Sequential knockdown of dual kinases increased microtubule stability by decreasing p38-mediated phosphorylation of MAP4 and enhanced response to paclitaxel in ovarian cancer cell lines and xenografts, suggesting a strategy to improve primary therapy.	Paclitaxel	47-57	TANK binding kinase 1	Homo sapiens	33-37
30084832-10	2018	Knockdown of IKBKB/STK39 or EDN2/TBK1 enhanced paclitaxel sensitivity in two ovarian xenograft models.Conclusions: Sequential knockdown of dual kinases increased microtubule stability by decreasing p38-mediated phosphorylation of MAP4 and enhanced response to paclitaxel in ovarian cancer cell lines and xenografts, suggesting a strategy to improve primary therapy.	Paclitaxel	260-270	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	13-18
24695965-5	2014	SAC satisfaction is reversible, however, as addition of taxol during metaphase stops cyclin B1 degradation by the APC/C.	Paclitaxel	56-61	cyclin B1	Homo sapiens	85-94
10945642-4	2000	Pretreating U373 human glioblastoma cells with recombinant SF/HGF partially abrogated their cytotoxic responses to gamma irradiation, cisplatin, camptothecin, Adriamycin, and Taxol in vitro.	Paclitaxel	175-180	hepatocyte growth factor	Homo sapiens	59-65
25122070-0	2014	Prostate cancer cell response to paclitaxel is affected by abnormally expressed securin PTTG1.	Paclitaxel	33-43	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	80-87
25122070-0	2014	Prostate cancer cell response to paclitaxel is affected by abnormally expressed securin PTTG1.	Paclitaxel	33-43	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	88-93
30322956-3	2018	The work by Wanderley and colleagues indicates that the TLR4 agonist taxol can restore the anticancer activity of tumor-associated macrophages and improve the clinical efficacy of immune checkpoint inhibitors.	Paclitaxel	69-74	toll like receptor 4	Homo sapiens	56-60
25122070-3	2014	By using two prostate cancer cell lines with different responses to paclitaxel treatment, we have identified two situations in which PTTG1 influences cell fate differentially.	Paclitaxel	68-78	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	133-138
10854551-0	2000	Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells.	Paclitaxel	35-45	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	0-5
25122070-4	2014	In slippage-prone PC3 cells, both PTTG1 downregulation and overexpression induce an increase in mitotic cells that is associated with diminished apoptosis after paclitaxel treatment.	Paclitaxel	161-171	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	34-39
25122070-5	2014	In LNCaP cells, however, PTTG1 downregulation prevents mitotic entry and, subsequently, inhibits mitosis-associated, paclitaxel-induced apoptosis.	Paclitaxel	117-127	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	25-30
25122070-6	2014	In contrast, PTTG1 overexpression induces an increase in mitotic cells and apoptosis after paclitaxel treatment.	Paclitaxel	91-101	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	13-18
25122070-7	2014	We have also identified a role for Mcl-1 protein in preventing apoptosis during mitosis in PC3 cells, as simultaneous PTTG1 and Mcl-1 silencing enhances mitosis-associated apoptosis after paclitaxel treatment.	Paclitaxel	188-198	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	35-40
30275055-0	2018	Retraction: Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL.	Paclitaxel	26-36	AXL receptor tyrosine kinase	Homo sapiens	118-121
30173893-0	2018	Paclitaxel promotes lung cancer cell apoptosis via MEG3-P53 pathway activation.	Paclitaxel	0-10	maternally expressed 3	Homo sapiens	51-55
30173893-3	2018	This study aimed to explore the effects of PTX on the expression of MEG3 and its anti-tumor mechanism in lung cancer cells.	Paclitaxel	43-46	maternally expressed 3	Homo sapiens	68-72
30173893-10	2018	PTX significantly inhibited the proliferation of NSCLC cells and increased the expressions of MEG3 and P53.	Paclitaxel	0-3	maternally expressed 3	Homo sapiens	94-98
10854551-1	2000	We have recently reported that there is a significant Raf-1 kinase dependency of paclitaxel resistance in human cervical tumor cell lines.	Paclitaxel	81-91	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	54-59
10854551-2	2000	In light of the possibility that Raf-1 kinase inhibitors could be used to enhance paclitaxel responsiveness in ovarian cancer, we have characterized the Raf-1 kinase dependency of paclitaxel resistance in ovarian cancer cells.	Paclitaxel	82-92	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	33-38
25111376-7	2014	Combining taxol with growth factors and aminoacids deprivation leaded to a more than additive reduction of cell viability compared to single treatments in PTEN-mutant LNCaP cells.	Paclitaxel	10-15	phosphatase and tensin homolog	Homo sapiens	155-159
25111376-9	2014	CONCLUSIONS: Silencing Bcl-2 in PTEN-mutated prostate cancer cells enhances the apoptotic effects of combined starvation and taxol treatments, indicating that inhibition of Bcl-2 may be of significant value in PTEN-mutant tumor therapy.	Paclitaxel	125-130	phosphatase and tensin homolog	Homo sapiens	32-36
30173893-11	2018	The downregulation of MEG3 attenuated PTX-induced cytotoxicity, whereas upregulation of MEG3 induced cell death and increased P53 expression.	Paclitaxel	38-41	maternally expressed 3	Homo sapiens	22-26
10854551-2	2000	In light of the possibility that Raf-1 kinase inhibitors could be used to enhance paclitaxel responsiveness in ovarian cancer, we have characterized the Raf-1 kinase dependency of paclitaxel resistance in ovarian cancer cells.	Paclitaxel	180-190	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	33-38
30173893-13	2018	Our results suggest that the MEG3-P53 pathway is involved in the apoptosis of A549 cells induced by PTX.	Paclitaxel	100-103	maternally expressed 3	Homo sapiens	29-33
25111376-9	2014	CONCLUSIONS: Silencing Bcl-2 in PTEN-mutated prostate cancer cells enhances the apoptotic effects of combined starvation and taxol treatments, indicating that inhibition of Bcl-2 may be of significant value in PTEN-mutant tumor therapy.	Paclitaxel	125-130	phosphatase and tensin homolog	Homo sapiens	210-214
10854551-2	2000	In light of the possibility that Raf-1 kinase inhibitors could be used to enhance paclitaxel responsiveness in ovarian cancer, we have characterized the Raf-1 kinase dependency of paclitaxel resistance in ovarian cancer cells.	Paclitaxel	180-190	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	153-158
30104402-6	2018	Additionally, PRDX5 predicted a lower PFS in all ovarian cancer patients treated with Platin, Taxol, and Taxol+Platin chemotherapy.	Paclitaxel	94-99	peroxiredoxin 5	Homo sapiens	14-19
30104402-6	2018	Additionally, PRDX5 predicted a lower PFS in all ovarian cancer patients treated with Platin, Taxol, and Taxol+Platin chemotherapy.	Paclitaxel	105-110	peroxiredoxin 5	Homo sapiens	14-19
10854551-3	2000	The relationship between Raf-1 kinase activity and the sensitivity to clinically relevant paclitaxel concentrations was determined in four ovarian cancer cell lines (CA-OV3, SK-OV3, 2780/WT and OAW42/WT).	Paclitaxel	90-100	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	25-30
30104402-9	2018	PRDX6 predicted a poorer OS in patients treated with Taxol and Taxol+Platin chemotherapy.Conclusion: These results suggest that there are distinct prognostic values of PRDX family members in patients with ovarian cancer, and that the expression of PRDX3, PRDX5, and PRDX6 mRNAs are a useful prognostic indicator in the effect of chemotherapy in ovarian cancer patients.	Paclitaxel	53-58	peroxiredoxin 5	Homo sapiens	255-260
30104402-9	2018	PRDX6 predicted a poorer OS in patients treated with Taxol and Taxol+Platin chemotherapy.Conclusion: These results suggest that there are distinct prognostic values of PRDX family members in patients with ovarian cancer, and that the expression of PRDX3, PRDX5, and PRDX6 mRNAs are a useful prognostic indicator in the effect of chemotherapy in ovarian cancer patients.	Paclitaxel	63-68	peroxiredoxin 5	Homo sapiens	255-260
25258543-5	2014	The lncRNA plasma-cytoma variant translocation 1 (PVT1) was found to exhibit higher expression in both gastric cancer tissues and the SGC7901 paclitaxel-resistant cell line.	Paclitaxel	142-152	Pvt1 oncogene	Homo sapiens	11-48
25258543-5	2014	The lncRNA plasma-cytoma variant translocation 1 (PVT1) was found to exhibit higher expression in both gastric cancer tissues and the SGC7901 paclitaxel-resistant cell line.	Paclitaxel	142-152	Pvt1 oncogene	Homo sapiens	50-54
10854551-4	2000	Furthermore, in recognition that such a drug combination would initially be used in patients whose tumors have recurred following cisplatin/paclitaxel treatment, we also determined the Raf-1 kinase dependency of paclitaxel cytotoxicity in cisplatin resistant variants of two of the ovarian cell lines (2780/CP and OAW42/CP).	Paclitaxel	212-222	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	185-190
25258543-8	2014	RESULTS: PVT1 showed higher expression in human gastric cancer tissues than in adjacent non-cancerous tissues and in SGC7901 paclitaxel-resistant cells compared with SGC7901 cells.	Paclitaxel	125-135	Pvt1 oncogene	Homo sapiens	9-13
25258543-11	2014	Therefore, PVT1 shows potential as a novel therapeutic target for the treatment of gastric cancer and enhancement of paclitaxel sensitivity.	Paclitaxel	117-127	Pvt1 oncogene	Homo sapiens	11-15
30229821-0	2018	Down-regulation of miR-29a facilitates apoptosis of colorectal carcinoma cell SW480 and suppresses its Paclitaxel resistance.	Paclitaxel	103-113	microRNA 29a	Homo sapiens	19-26
30229821-3	2018	This study aimed to investigate the role and related mechanism of miR-29a in mediating Paclitaxel sensitivity of colorectal carcinoma cells.	Paclitaxel	87-97	microRNA 29a	Homo sapiens	66-73
30229821-8	2018	In vitro cultured SW480/Paclitaxel cells were transfected with miR-29a or pcDNA3.1-PTEN.	Paclitaxel	24-34	microRNA 29a	Homo sapiens	63-70
10854551-5	2000	In the two cell lines (2780/WT and OAW42/WT) that possess a wild-type TP53 (TP53wt), the relationship between Raf-1 kinase activity and paclitaxel resistance was different from that observed in the cervical tumor cell lines.	Paclitaxel	136-146	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	110-115
30229821-8	2018	In vitro cultured SW480/Paclitaxel cells were transfected with miR-29a or pcDNA3.1-PTEN.	Paclitaxel	24-34	phosphatase and tensin homolog	Homo sapiens	83-87
10854551-6	2000	In these cell lines, paclitaxel-induced far more cell killing than would have been predicted from their Raf-1 kinase activity.	Paclitaxel	21-31	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	104-109
30229821-12	2018	Moreover, further higher miR-29a and lower PTEN expressions were observed in SW480/Paclitaxel cells.	Paclitaxel	83-93	microRNA 29a	Homo sapiens	25-32
30229821-12	2018	Moreover, further higher miR-29a and lower PTEN expressions were observed in SW480/Paclitaxel cells.	Paclitaxel	83-93	phosphatase and tensin homolog	Homo sapiens	43-47
30229821-14	2018	Transfection of miR-29a inhibitor or pcDNA3.1-PTEN remarkably elevated PTEN expression, suppressed p-AKT expression, weakened proliferation, and enhanced apoptosis of SW480/Paclitaxel cells.	Paclitaxel	173-183	microRNA 29a	Homo sapiens	16-23
25058922-0	2014	CKD712, a synthetic isoquinoline alkaloid, enhances the anti-cancer effects of paclitaxel in MDA-MB-231 cells through regulation of PTEN.	Paclitaxel	79-89	phosphatase and tensin homolog	Homo sapiens	132-136
25058922-1	2014	AIMS: It has been reported that in human glioblastoma cells, phosphotase and tensin homolog (PTEN) positive cells are more prone to paclitaxel-induced apoptosis than PTEN-negative cells.	Paclitaxel	132-142	phosphatase and tensin homolog	Homo sapiens	93-97
25058922-1	2014	AIMS: It has been reported that in human glioblastoma cells, phosphotase and tensin homolog (PTEN) positive cells are more prone to paclitaxel-induced apoptosis than PTEN-negative cells.	Paclitaxel	132-142	phosphatase and tensin homolog	Homo sapiens	166-170
10854551-8	2000	These data suggest that the therapeutic efficacy of paclitaxel in ovarian cancer patient whose tumors have TP53mut might be increased if it is administered in combination with Raf-1 kinase inhibitors, e.g., ISIS 5132.	Paclitaxel	52-62	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	176-181
25058922-10	2014	SIGNIFICANCE: CKD712 strongly enhances the anti-cancer effects (proliferation, invasion, and apoptosis) of paclitaxel on MDA-MB-231 cells by regulating PTEN and NF-kappaB activity.	Paclitaxel	107-117	phosphatase and tensin homolog	Homo sapiens	152-156
10842201-8	2000	Combined treatment of Shionogi cells with antisense Bcl-xL and Bcl-2 ODNs significantly enhanced taxol chemosensitivity compared with either agent alone, reducing the IC(50) of taxol by more than 1 log.	Paclitaxel	97-102	BCL2-like 1	Mus musculus	52-58
25137071-0	2014	Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.	Paclitaxel	165-175	microRNA 19a	Homo sapiens	12-19
25137071-14	2014	CONCLUSIONS: The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy.	Paclitaxel	155-165	microRNA 19a	Homo sapiens	32-39
30229821-14	2018	Transfection of miR-29a inhibitor or pcDNA3.1-PTEN remarkably elevated PTEN expression, suppressed p-AKT expression, weakened proliferation, and enhanced apoptosis of SW480/Paclitaxel cells.	Paclitaxel	173-183	phosphatase and tensin homolog	Homo sapiens	46-50
25089613-8	2014	Under hypoxia, downregulation of HIF-1alpha and upregulation of caspase-3, caspase-8, caspase-9, LC3 and Beclin-1 were observed when paclitaxel was combined with oxygen-CNT.	Paclitaxel	133-143	caspase 9	Homo sapiens	86-95
10842201-8	2000	Combined treatment of Shionogi cells with antisense Bcl-xL and Bcl-2 ODNs significantly enhanced taxol chemosensitivity compared with either agent alone, reducing the IC(50) of taxol by more than 1 log.	Paclitaxel	177-182	BCL2-like 1	Mus musculus	52-58
10722720-1	2000	We found that antitumor drugs such as cytotrienin A, camptothecin, taxol, and 5-fluorouracil induced the activation of a 36-kDa protein kinase (p36 myelin basic protein (MBP) kinase) during apoptosis in human promyelocytic leukemia HL-60 cells.	Paclitaxel	67-72	myelin basic protein	Homo sapiens	170-173
24625457-0	2014	Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.	Paclitaxel	36-46	colony stimulating factor 3	Homo sapiens	20-25
24786296-6	2014	This study systematically explored intrinsic link between ERalpha and the P-gp over-expression in paclitaxel-resistant ERalpha(+) breast cancer cell lines and mouse model in molecular details.	Paclitaxel	98-108	estrogen receptor 1 (alpha)	Mus musculus	58-65
29856087-0	2018	HOTAIR enhanced paclitaxel and doxorubicin resistance in gastric cancer cells partly through inhibiting miR-217 expression.	Paclitaxel	16-26	HOX transcript antisense RNA	Homo sapiens	0-6
29856087-3	2018	In this study, we showed that overexpression of HOTAIR enhanced paclitaxel and doxorubicin resistance in GC cells.	Paclitaxel	64-74	HOX transcript antisense RNA	Homo sapiens	48-54
29856087-11	2018	These data suggested that overexpression of HOTAIR enhanced paclitaxel and doxorubicin resistance in GC cells through inhibiting miR-217 expression.	Paclitaxel	60-70	HOX transcript antisense RNA	Homo sapiens	44-50
29971911-0	2018	Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.	Paclitaxel	37-47	ferritin heavy chain 1 pseudogene 3	Homo sapiens	20-26
29971911-3	2018	In this study, we investigate the physiopathologic role of lncRNA ferritin heavy chain 1 pseudogene 3 (FTH1P3) on the paclitaxel (PTX) resistance in breast cancer.	Paclitaxel	118-128	ferritin heavy chain 1 pseudogene 3	Homo sapiens	66-101
29971911-3	2018	In this study, we investigate the physiopathologic role of lncRNA ferritin heavy chain 1 pseudogene 3 (FTH1P3) on the paclitaxel (PTX) resistance in breast cancer.	Paclitaxel	118-128	ferritin heavy chain 1 pseudogene 3	Homo sapiens	103-109
29971911-3	2018	In this study, we investigate the physiopathologic role of lncRNA ferritin heavy chain 1 pseudogene 3 (FTH1P3) on the paclitaxel (PTX) resistance in breast cancer.	Paclitaxel	130-133	ferritin heavy chain 1 pseudogene 3	Homo sapiens	66-101
29971911-3	2018	In this study, we investigate the physiopathologic role of lncRNA ferritin heavy chain 1 pseudogene 3 (FTH1P3) on the paclitaxel (PTX) resistance in breast cancer.	Paclitaxel	130-133	ferritin heavy chain 1 pseudogene 3	Homo sapiens	103-109
24786296-6	2014	This study systematically explored intrinsic link between ERalpha and the P-gp over-expression in paclitaxel-resistant ERalpha(+) breast cancer cell lines and mouse model in molecular details.	Paclitaxel	98-108	estrogen receptor 1 (alpha)	Mus musculus	119-126
25313764-3	2014	AIM: The aim of the study was to evaluate this new series of 1-(2",4"-difluorophenyl)-3-(substituted phenyl)-1,3 propanediones (PR 1-7) for their caspase dependent apoptotic activity by using a reporter gene mediated caspase-3 sensor in chemo sensitive and paclitaxel resistant ovarian cancer cells.	Paclitaxel	257-267	transmembrane protein 37	Homo sapiens	128-134
29971911-4	2018	Results showed that lncRNA FTH1P3 was up-regulated in paclitaxel-resistant breast cancer tissue and cells (MCF-7/PTX and MDA-MB-231/PTX cells) compared with paclitaxel-sensitive tissue and parental cell lines (MCF-7, MDA-MB-231).	Paclitaxel	54-64	ferritin heavy chain 1 pseudogene 3	Homo sapiens	27-33
10676879-4	2000	Remarkably, incubation of the tenascin-C-negative cells with the microtubule stabilizer taxol (10 microM) restored down-regulation of total muscarinic acetylcholine receptors to normal levels.	Paclitaxel	88-93	tenascin C	Mus musculus	30-38
29971911-4	2018	Results showed that lncRNA FTH1P3 was up-regulated in paclitaxel-resistant breast cancer tissue and cells (MCF-7/PTX and MDA-MB-231/PTX cells) compared with paclitaxel-sensitive tissue and parental cell lines (MCF-7, MDA-MB-231).	Paclitaxel	113-116	ferritin heavy chain 1 pseudogene 3	Homo sapiens	27-33
29971911-4	2018	Results showed that lncRNA FTH1P3 was up-regulated in paclitaxel-resistant breast cancer tissue and cells (MCF-7/PTX and MDA-MB-231/PTX cells) compared with paclitaxel-sensitive tissue and parental cell lines (MCF-7, MDA-MB-231).	Paclitaxel	132-135	ferritin heavy chain 1 pseudogene 3	Homo sapiens	27-33
29971911-4	2018	Results showed that lncRNA FTH1P3 was up-regulated in paclitaxel-resistant breast cancer tissue and cells (MCF-7/PTX and MDA-MB-231/PTX cells) compared with paclitaxel-sensitive tissue and parental cell lines (MCF-7, MDA-MB-231).	Paclitaxel	157-167	ferritin heavy chain 1 pseudogene 3	Homo sapiens	27-33
29971911-5	2018	Gain- and loss-of-function experiments revealed that FTH1P3 silencing decreased the 50% inhibitory concentration (IC50) value of paclitaxel and induced cell cycle arrest at G2/M phase, while FTH1P3-enhanced expression exerted the opposite effects.	Paclitaxel	129-139	ferritin heavy chain 1 pseudogene 3	Homo sapiens	53-59
29971911-6	2018	In vivo, xenograft mice assay showed that FTH1P3 silencing suppressed the tumour growth of paclitaxel-resistant breast cancer cells and ABCB1 protein expression.	Paclitaxel	91-101	ferritin heavy chain 1 pseudogene 3	Homo sapiens	42-48
29971911-8	2018	In summary, our results reveal the potential regulatory mechanism of FTH1P3 on breast cancer paclitaxel resistance through miR-206/ABCB1, providing a novel insight for the breast cancer chemoresistance.	Paclitaxel	93-103	ferritin heavy chain 1 pseudogene 3	Homo sapiens	69-75
24708177-10	2014	STMN1 knockdown inhibited proliferation and increased the sensitivity of EHCC cells to paclitaxel.	Paclitaxel	87-97	stathmin 1	Homo sapiens	0-5
24722794-0	2014	The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III beta-tubulin, MAPT, and survivin.	Paclitaxel	74-84	microtubule associated protein tau	Homo sapiens	132-136
24722794-2	2014	This study was carried out to investigate the relationships between the expressions of class III beta-tubulin, microtubule-associated protein tau (MAPT), survivin, and the sensitivity of primary gastric cancer (GC) to paclitaxel treatment.	Paclitaxel	218-228	microtubule associated protein tau	Homo sapiens	111-145
24722794-2	2014	This study was carried out to investigate the relationships between the expressions of class III beta-tubulin, microtubule-associated protein tau (MAPT), survivin, and the sensitivity of primary gastric cancer (GC) to paclitaxel treatment.	Paclitaxel	218-228	microtubule associated protein tau	Homo sapiens	147-151
24722794-8	2014	The sensitivity of GC patients to paclitaxel treatment was inversely correlated with the mRNA and protein expressions of class III beta-tubulin (P &lt; 0.01), MAPT (P &lt; 0.05), and survivin (P &lt; 0.05).	Paclitaxel	34-44	microtubule associated protein tau	Homo sapiens	159-163
24722794-10	2014	Our results indicate that the expression levels of class III beta-tubulin, MAPT, and survivin are good biomarkers for predicting the sensitivity of GC to paclitaxel treatment.	Paclitaxel	154-164	microtubule associated protein tau	Homo sapiens	75-79
18521433-7	2000	Paclitaxel induced cell cycle arrest with an accumulation of cells in sub-G1.This was accompanied in vitro by various events typical of apoptosis: phosphorylation of two anti-apoptotic proteins Bcl-2 and Bcl-(xL) , release of cytochrome c into the cytoplasm, cleavage and activation of caspase-3.	Paclitaxel	0-10	BCL2-like 1	Mus musculus	204-211
24782986-4	2014	In the first approach, we demonstrate that a single intraperitoneal administration of paclitaxel in mice 7 days after subcutaneous transplantation of the HEY ovarian cancer cell line resulted in a significant increase in the expression of CA125, Oct4, and CD117 in mice xenografts compared to control mice xenografts which did not receive paclitaxel.	Paclitaxel	86-96	POU class 5 homeobox 1	Homo sapiens	246-250
24782986-7	2014	At the molecular level, mouse tumors remaining after paclitaxel administration showed a significant increase in the expression of Oct4 and CD117 coinciding with a significant activation of the JAK2/STAT3 pathway compared to control tumors.	Paclitaxel	53-63	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	139-144
24782986-7	2014	At the molecular level, mouse tumors remaining after paclitaxel administration showed a significant increase in the expression of Oct4 and CD117 coinciding with a significant activation of the JAK2/STAT3 pathway compared to control tumors.	Paclitaxel	53-63	Janus kinase 2	Mus musculus	193-197
24782986-8	2014	The addition of CYT387 with paclitaxel resulted in the suppression of JAK2/STAT3 activation and abrogation of Oct4 and CD117 expression in mouse xenografts.	Paclitaxel	28-38	Janus kinase 2	Mus musculus	70-74
30086790-11	2018	The upregulated p27 consequently inhibits cell proliferation, cell cycle progression and tumorigenesis, whereas promotes cell apoptosis under paclitaxel treatment.	Paclitaxel	142-152	cyclin dependent kinase inhibitor 1B	Homo sapiens	16-19
10565827-9	1999	A microtubule stabilizer (paclitaxel,Taxol) mimicked, in part, the effects of EGF and TGF-alpha, whereas a microtubule disruptive drug (colchicine) prevented the protective effects of these growth factors.	Paclitaxel	26-36	transforming growth factor alpha	Homo sapiens	86-95
30078441-0	2018	RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers.	Paclitaxel	89-99	reticulon 4	Homo sapiens	0-4
24639283-0	2014	Association between CHFR methylation and chemosensitivity of paclitaxel in advanced gastric cancer.	Paclitaxel	61-71	checkpoint with forkhead and ring finger domains	Homo sapiens	20-24
10565827-9	1999	A microtubule stabilizer (paclitaxel,Taxol) mimicked, in part, the effects of EGF and TGF-alpha, whereas a microtubule disruptive drug (colchicine) prevented the protective effects of these growth factors.	Paclitaxel	37-42	transforming growth factor alpha	Homo sapiens	86-95
30078441-7	2018	Finally, RTN4 knockdown affected tubulin stability and promoted higher cytotoxic effects with chemotherapeutic paclitaxel in cancer cells both in vitro and in vivo.	Paclitaxel	111-121	reticulon 4	Homo sapiens	9-13
10602425-7	1999	Therefore, these drugs precluded Bcl-2/Raf-1 phosphorylation, PARP cleavage and cell death which are otherwise induced by paclitaxel, a mitosis-selective apoptotic drug for HL60 cells.	Paclitaxel	122-132	collagen type XI alpha 2 chain	Homo sapiens	62-66
30008912-6	2018	Treatment of beta-elemene-paclitaxel arrested the cell cycle and decreased cyclin-dependent kinase, cyclin-B1, P21 and P27 expression levels and decreased resistant genes alterations of ATP binding cassette subfamily B member 1, LDL receptor related protein and TS in U-2OS cells.	Paclitaxel	26-36	cyclin B1	Homo sapiens	100-109
30008912-6	2018	Treatment of beta-elemene-paclitaxel arrested the cell cycle and decreased cyclin-dependent kinase, cyclin-B1, P21 and P27 expression levels and decreased resistant genes alterations of ATP binding cassette subfamily B member 1, LDL receptor related protein and TS in U-2OS cells.	Paclitaxel	26-36	H3 histone pseudogene 16	Homo sapiens	111-114
30008912-6	2018	Treatment of beta-elemene-paclitaxel arrested the cell cycle and decreased cyclin-dependent kinase, cyclin-B1, P21 and P27 expression levels and decreased resistant genes alterations of ATP binding cassette subfamily B member 1, LDL receptor related protein and TS in U-2OS cells.	Paclitaxel	26-36	interferon alpha inducible protein 27	Homo sapiens	119-122
30008912-9	2018	Immunostaining demonstrated that beta-elemene-paclitaxel treatment increased apoptotic bodies, GPR124 and increased endostatin, TIMP-1 and TIMP-2 expression in tumor tissues.	Paclitaxel	46-56	collagen type XVIII alpha 1 chain	Homo sapiens	116-126
24481648-6	2014	In the present study, we report for the first time that ponatinib also potentiates the cytotoxicity of widely used therapeutic substrates of MRP7, such as paclitaxel, docetaxel, vincristine and vinblastine.	Paclitaxel	155-165	ATP binding cassette subfamily C member 10	Homo sapiens	141-145
24481648-7	2014	Ponatinib significantly enhances the accumulation of [3H]-paclitaxel in cells expressing MRP7.	Paclitaxel	58-68	ATP binding cassette subfamily C member 10	Homo sapiens	89-93
23996744-9	2014	Moreover, HSP27 suppression resulted in the sensitization of xenografts to low doses of the chemotherapeutic paclitaxel, likely because HSP27 protected microtubules from bundling caused by the drug.	Paclitaxel	109-119	heat shock protein family B (small) member 1	Homo sapiens	10-15
23996744-9	2014	Moreover, HSP27 suppression resulted in the sensitization of xenografts to low doses of the chemotherapeutic paclitaxel, likely because HSP27 protected microtubules from bundling caused by the drug.	Paclitaxel	109-119	heat shock protein family B (small) member 1	Homo sapiens	136-141
29688614-2	2018	The preparation of fibrous materials of polylactide (PLA) and polyethylene glycol (PEG) loaded with paclitaxel (PTX, 1 or 10 wt%) is presented.	Paclitaxel	100-110	paired like homeodomain 1	Homo sapiens	112-118
10553948-0	1999	Nerve growth factor prevention of aged-rat sympathetic neuron injury by cisplatin, vincristine and taxol--in vitro explant study.	Paclitaxel	99-104	nerve growth factor	Rattus norvegicus	0-19
29531019-7	2018	On the contrary, the antitumor drug Paclitaxel is also known to activate the TLR4 MyD88-dependent signaling pathway and mimics LPS action.	Paclitaxel	36-46	toll like receptor 4	Homo sapiens	77-81
29531019-8	2018	Therefore, we evaluated if PC1/3 knock-down (KD) macrophages could be activated by Paclitaxel and efficient against glioma.	Paclitaxel	83-93	proprotein convertase subtilisin/kexin type 1	Homo sapiens	27-30
24431074-3	2014	The ABC transporter subfamily C member 10 (ABCC10), also known as multidrug resistance protein 7 (MRP7) efflux transporter, is a major mediator of paclitaxel resistance.	Paclitaxel	147-157	ATP binding cassette subfamily C member 10	Homo sapiens	43-49
24431074-3	2014	The ABC transporter subfamily C member 10 (ABCC10), also known as multidrug resistance protein 7 (MRP7) efflux transporter, is a major mediator of paclitaxel resistance.	Paclitaxel	147-157	ATP binding cassette subfamily C member 10	Homo sapiens	66-96
24431074-3	2014	The ABC transporter subfamily C member 10 (ABCC10), also known as multidrug resistance protein 7 (MRP7) efflux transporter, is a major mediator of paclitaxel resistance.	Paclitaxel	147-157	ATP binding cassette subfamily C member 10	Homo sapiens	98-102
24431074-5	2014	Our in vitro studies indicated that masitinib (2.5 mumol/L) enhanced the intracellular accumulation and decreased the efflux of paclitaxel by inhibiting the ABCC10 transport activity without altering the expression level of ABCC10 protein.	Paclitaxel	128-138	ATP binding cassette subfamily C member 10	Homo sapiens	157-163
24420921-0	2014	Tetraacylated lipid A and paclitaxel-selective activation of TLR4/MD-2 conferred through hydrophobic interactions.	Paclitaxel	26-36	toll like receptor 4	Homo sapiens	61-65
10553948-2	1999	The inhibition of neurite outgrowth by cisplatin, vincristine and taxol was markedly prevented by co-treatment with NGF.	Paclitaxel	66-71	nerve growth factor	Rattus norvegicus	116-119
24420921-5	2014	Both TLR4 mutants were inactive when stimulated with lipid IVa or paclitaxel, but retained significant activation when stimulated with LPS or hexaacylated lipid A.	Paclitaxel	66-76	toll like receptor 4	Homo sapiens	5-9
29658576-4	2018	In addition, paclitaxel upregulated the expression of Bax and cytochrome c, but reduced expression of apoptosis regulator Bcl-2, resulting in activation of caspase-3, chromatin condensation, karyopyknosis, intracellular vacuolization, increased production of ROS and MDA, and decreased activity of SOD.	Paclitaxel	13-23	BCL2 apoptosis regulator	Canis lupus familiaris	122-127
29658576-4	2018	In addition, paclitaxel upregulated the expression of Bax and cytochrome c, but reduced expression of apoptosis regulator Bcl-2, resulting in activation of caspase-3, chromatin condensation, karyopyknosis, intracellular vacuolization, increased production of ROS and MDA, and decreased activity of SOD.	Paclitaxel	13-23	caspase 3	Canis lupus familiaris	156-165
24420921-6	2014	We show that the phenylalanine residue at position 126 of mouse MD-2 is indispensable only for activation with paclitaxel.	Paclitaxel	111-121	lymphocyte antigen 96	Mus musculus	64-68
10553948-4	1999	These results indicate that, just as in young adult rats, NGF prevents toxic sympathetic nerve injury induced by vincristine and taxol even in aged rats, but does not protect against cisplatin-induced nerve cell injury.	Paclitaxel	129-134	nerve growth factor	Rattus norvegicus	58-61
10471534-4	1999	In the present study, the effects of paclitaxel and nocodazole, 2 drugs known to affect microtubules with opposite mechanisms of action, have been tested for their effect on the secretion of uPA and MMPs in cultures of F3II mouse mammary-tumor cells.	Paclitaxel	37-47	matrix metallopeptidase 9	Mus musculus	199-203
29899826-9	2018	This conclusion is supported by data showing that BI6727/paclitaxel-co-treatment stabilizes FBW7, a component of SCF-type ubiquitin ligases that bind and regulate key modulators of cell division and growth including MCL-1 and Cyclin E. This identification of a novel synthetic lethality of PLK1 inhibitors and a microtubule-stabilizing drug has important implications for developing PLK1 inhibitor-based combination treatments in CCNE1-amplified HGSOC cells.	Paclitaxel	57-67	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	216-221
10511592-11	1999	CONCLUSIONS: LRP is involved in resistance to doxorubicin, vincristine, etoposide, paclitaxel, and gramicidin D and has an important role in the transport of doxorubicin from the nucleus to the cytoplasm.	Paclitaxel	83-93	major vault protein	Homo sapiens	13-16
29771413-0	2018	Overexpression of PER3 reverses paclitaxel resistance of prostate cancer cells by inhibiting the Notch pathway.	Paclitaxel	32-42	period circadian regulator 3	Homo sapiens	18-22
29771413-1	2018	OBJECTIVE: To investigate the levels of period circadian protein homolog 3 (PER3) in paclitaxel-resistant prostate cancer patients and the effect of PER3 on paclitaxel-resistant prostate cancer cell lines.	Paclitaxel	85-95	period circadian regulator 3	Homo sapiens	40-74
29771413-1	2018	OBJECTIVE: To investigate the levels of period circadian protein homolog 3 (PER3) in paclitaxel-resistant prostate cancer patients and the effect of PER3 on paclitaxel-resistant prostate cancer cell lines.	Paclitaxel	85-95	period circadian regulator 3	Homo sapiens	76-80
29771413-4	2018	PER3 was overexpressed or knocked down in a paclitaxel-resistant prostate cancer cell line, followed by measuring its IC50 as well as changes in cell cycle and apoptosis.	Paclitaxel	44-54	period circadian regulator 3	Homo sapiens	0-4
29771413-6	2018	RESULTS: The results of fluorescence quantitative PCR showed that the expression of PER3 in the paclitaxel-resistant prostate cancer group was lower than that in the non-resistant group, and the relative expression of PER3 was decreased after treatment.	Paclitaxel	96-106	period circadian regulator 3	Homo sapiens	84-88
29771413-6	2018	RESULTS: The results of fluorescence quantitative PCR showed that the expression of PER3 in the paclitaxel-resistant prostate cancer group was lower than that in the non-resistant group, and the relative expression of PER3 was decreased after treatment.	Paclitaxel	96-106	period circadian regulator 3	Homo sapiens	218-222
29771413-7	2018	Fluorescent quantitative PCR and Western blot showed that the expression of PER3 in paclitaxel-resistant prostate cancer cells was higher than that of the untreated counterparts.	Paclitaxel	84-94	period circadian regulator 3	Homo sapiens	76-80
29771413-9	2018	Subsequently, we detected decreased expression of Notch1 in PER3 over-expressed paclitaxel-resistant cell lines by Western blot; this attenuated resistance in paclitaxel-resistant cell lines.	Paclitaxel	80-90	period circadian regulator 3	Homo sapiens	60-64
29771413-9	2018	Subsequently, we detected decreased expression of Notch1 in PER3 over-expressed paclitaxel-resistant cell lines by Western blot; this attenuated resistance in paclitaxel-resistant cell lines.	Paclitaxel	159-169	period circadian regulator 3	Homo sapiens	60-64
29771413-10	2018	CONCLUSIONS: PER3 can induce sensitivity of paclitaxel-resistant cell lines to paclitaxel by inhibiting the expression of Notch1.	Paclitaxel	44-54	period circadian regulator 3	Homo sapiens	13-17
24517272-8	2014	CONCLUSIONS: These results suggest that activation of the sigma1R is necessary for development of the sensory nerve mitochondrial damage and neuropathic pain produced by paclitaxel.	Paclitaxel	170-180	sigma non-opioid intracellular receptor 1	Mus musculus	58-65
24517272-9	2014	Therefore, sigma1R antagonists might have therapeutic value for the prevention of paclitaxel-induced neuropathy.	Paclitaxel	82-92	sigma non-opioid intracellular receptor 1	Mus musculus	11-18
24080340-5	2014	In the CD133(-) subpopulation, the exposure to taxol induced the activation of apoptosis signal-regulating kinase1 (ASK1)/c-jun-N-terminal kinase (JNK), p38, extracellular signal regulated kinase (ERK) pathways and Bax expression, while in CD133(+) cells taxol was able only to enhance the activity of the ERK pathway.	Paclitaxel	255-260	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	79-114
24306928-0	2014	A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells.	Paclitaxel	17-27	stathmin 1	Homo sapiens	60-68
24306928-3	2014	We hypothesized that decreasing the expression level of Stathmin might improve the effectiveness of paclitaxel in the treatment of nasopharyngeal carcinoma (NPC).	Paclitaxel	100-110	stathmin 1	Homo sapiens	56-64
24306928-8	2014	The effect of paclitaxel on Stathmin expression in NPC cells and, in addition, A375, MGC and HeLa cells was determined by RT-PCR and Western blotting.	Paclitaxel	14-24	stathmin 1	Homo sapiens	28-36
24306928-12	2014	Furthermore, we found that Stathmin expression in the tumor cells is down-regulated by paclitaxel treatment.	Paclitaxel	87-97	stathmin 1	Homo sapiens	27-35
24306928-14	2014	Paclitaxel reduces the expression of Stathmin, and combining Stathmin silencing with paclitaxel treatment enhances MT polymerization.	Paclitaxel	0-10	stathmin 1	Homo sapiens	37-45
10484078-7	1999	Inhibition of microsomal ATRA 4-hydroxylation was elicited by chemicals that interact with CYP2C8 (paclitaxel and diclofenac), but not those that interact with CYP2C9 (sulfaphenazole, tolbutamide, and torasemide).	Paclitaxel	99-109	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	91-97
24738341-5	2014	Treatment with nanoparticles, paclitaxel and anti-ABCG2 antibody remarkably inhibited the growth of CD138-CD34- cells in vitro and their derived tumors in xenografts.	Paclitaxel	30-40	CD34 antigen	Mus musculus	106-110
29771413-10	2018	CONCLUSIONS: PER3 can induce sensitivity of paclitaxel-resistant cell lines to paclitaxel by inhibiting the expression of Notch1.	Paclitaxel	79-89	period circadian regulator 3	Homo sapiens	13-17
29649113-8	2018	Short-term exposure to PAC led to increased expression of the MDR1 and BCRP genes in the A2780 and W1 cell lines.	Paclitaxel	23-26	BCR pseudogene 1	Homo sapiens	71-75
29282807-7	2018	RESULTS: Compared with control rats, plasma levels of IL-1alpha, IL-1beta, IL-6, TNF-alpha, INF-gamma and MCP-1 were significantly upregulated in paclitaxel-treated rats.	Paclitaxel	146-156	C-C motif chemokine ligand 2	Rattus norvegicus	106-111
24484617-2	2014	The chemotherapeutic agent nanoparticle albumin-encapsulated (NAB)-paclitaxel has been postulated to exploit SPARC expression to target neoplastic cells.	Paclitaxel	67-77	secreted protein acidic and cysteine rich	Homo sapiens	109-114
10695015-14	1999	These findings indicate that LRP is involved in resistance to ADM, VCR, VP-16, taxol and gramicidin D, and has an important role in the transport of ADM from the nucleus to the cytoplasm.	Paclitaxel	79-84	major vault protein	Homo sapiens	29-32
24475288-3	2014	Using the human embryonal carcinoma cell line NTera2/D1, we confirmed that exposure to the differentiating agent retinoic acid produced a reduction in pluripotency markers NANOG and POU5F1 (Oct3/4) and an acute concentration-dependent increase in resistance to both cisplatin and paclitaxel that reached as high as 18-fold for cisplatin and 61-fold for paclitaxel within four days.	Paclitaxel	280-290	POU class 5 homeobox 1	Homo sapiens	190-196
24475288-3	2014	Using the human embryonal carcinoma cell line NTera2/D1, we confirmed that exposure to the differentiating agent retinoic acid produced a reduction in pluripotency markers NANOG and POU5F1 (Oct3/4) and an acute concentration-dependent increase in resistance to both cisplatin and paclitaxel that reached as high as 18-fold for cisplatin and 61-fold for paclitaxel within four days.	Paclitaxel	353-363	POU class 5 homeobox 1	Homo sapiens	190-196
24452475-0	2014	Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.	Paclitaxel	59-69	toll like receptor 4	Homo sapiens	96-100
24452475-1	2014	Paclitaxel, a known TLR4 ligand, leads to activation of TLR4/MyD88-dependent pathway that mediates chemoresistance and tumor progression in epithelial ovarian carcinoma (EOC).	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	20-24
29393480-7	2018	In addition, PC-9/GR cells were less sensitive to chemotherapeutic drugs tested, including cisplatin, gemcitabine, pemetrexed, paclitaxel and docetaxel, compared to PC-9 and PC-9/ZD cells.	Paclitaxel	127-137	proprotein convertase subtilisin/kexin type 9	Homo sapiens	13-17
29556305-6	2018	The present data indicate that Taxol may enhance the pro-apoptotic effects of TRAIL overexpression in HeLa cells by increasing cleaved caspase-3 and DR5 expression levels and decreasing Bcl-2 expression levels.	Paclitaxel	31-36	TNF receptor superfamily member 10b	Homo sapiens	149-152
24452475-1	2014	Paclitaxel, a known TLR4 ligand, leads to activation of TLR4/MyD88-dependent pathway that mediates chemoresistance and tumor progression in epithelial ovarian carcinoma (EOC).	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	56-60
24452475-2	2014	Atractylenolide-I (AO-I), a novel TLR4-antagonizing agent, inhibits TLR4 signaling by interfering with the binding of LPS or paclitaxel to membrane TLR4 of human leukocytes.	Paclitaxel	125-135	toll like receptor 4	Homo sapiens	68-72
29368408-7	2018	Drug resistance cancer cells showed a higher microtubule associated protein (Tau) expression, which was considered as one of the reasons for Taxol resistance.	Paclitaxel	141-146	regulator of microtubule dynamics 1	Homo sapiens	45-75
10362110-0	1999	Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol.	Paclitaxel	87-92	tubulin beta 3 class III	Homo sapiens	30-52
29682172-3	2018	We demonstrate that paclitaxel treatment enhanced JAK2/STAT3 activation which resulted in the enrichment of cancer stem cell (CSC)-like phenotype in the surviving ovarian cancer cells in vitro and in in vivo mouse xenografts.	Paclitaxel	20-30	Janus kinase 2	Mus musculus	50-54
29682172-4	2018	Combined treatment with paclitaxel and momelotinib inhibited paclitaxel-induced JAK2/STAT3 activation and CSC-like development in mice xenografts, and consequently reduced the tumor burden significantly greater than that achieved by paclitaxel-treatment alone.	Paclitaxel	24-34	Janus kinase 2	Mus musculus	80-84
29682172-4	2018	Combined treatment with paclitaxel and momelotinib inhibited paclitaxel-induced JAK2/STAT3 activation and CSC-like development in mice xenografts, and consequently reduced the tumor burden significantly greater than that achieved by paclitaxel-treatment alone.	Paclitaxel	61-71	Janus kinase 2	Mus musculus	80-84
29682172-4	2018	Combined treatment with paclitaxel and momelotinib inhibited paclitaxel-induced JAK2/STAT3 activation and CSC-like development in mice xenografts, and consequently reduced the tumor burden significantly greater than that achieved by paclitaxel-treatment alone.	Paclitaxel	61-71	Janus kinase 2	Mus musculus	80-84
29439899-6	2018	They match or exceed the potency of vinblastine and they display more potent activity against taxol-resistant A549-T24 than even wild type A549 cells (1.2-2-fold), complementing our prior observations that they also display no sensitivity to overexpression of Pgp (HCT116/VM46 vs HCT116) and are not subject to resistance derived from Pgp efflux.	Paclitaxel	94-99	phosphoglycolate phosphatase	Homo sapiens	260-263
24452475-2	2014	Atractylenolide-I (AO-I), a novel TLR4-antagonizing agent, inhibits TLR4 signaling by interfering with the binding of LPS or paclitaxel to membrane TLR4 of human leukocytes.	Paclitaxel	125-135	toll like receptor 4	Homo sapiens	68-72
24452475-4	2014	Therefore, AO-I could significantly sensitize the response of MyD88(+) EOC cells to paclitaxel by blocking MD-2-mediated TLR4/MyD88 signaling, and that AO-I-paclitaxel combination could be a promising strategy for the treatment of EOC with a functional TLR4/MyD88/NF-kappaB pathway.	Paclitaxel	84-94	toll like receptor 4	Homo sapiens	121-125
24520227-10	2014	Pretreatment with celecoxib also increased activation of caspase-9, -3 and cleaved PARP following paclitaxel-treatment.	Paclitaxel	98-108	caspase 9	Homo sapiens	57-66
25423693-2	2014	There is conflicting data regarding microtubule-associated protein tau as predictive marker of paclitaxel sensitivity.	Paclitaxel	95-105	microtubule associated protein tau	Homo sapiens	36-70
24173825-5	2014	Pretreatment of CRC cells with caffeine significantly inhibited paclitaxel-induced cytotoxicity by increasing the levels of the antiapoptotic Bcl-2 family member, Mcl-1.	Paclitaxel	64-74	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	163-168
10362110-4	1999	We have recently described increased expression of the brain-specific human class III beta-tubulin isotype, encoded by the Hbeta4 gene, in both Taxol-resistant ovarian tumours and non-small-cell lung cancer cell lines.	Paclitaxel	144-149	tubulin beta 3 class III	Homo sapiens	76-98
24173825-8	2014	Moreover, administration of caffeine may decrease chemotherapeutic responses to paclitaxel by the MEK-ERK mediated upregulation of Mcl-1.	Paclitaxel	80-90	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	131-136
10219964-4	1999	Arachidonic acid (50 microM) significantly inhibited CYP1A1- and 1A2-dependent 7-ethoxycoumarin O-deethylations, CYP2C8-dependent taxol 6alpha-hydroxylation and CYP2C19-dependent R-warfarin 7-hydroxylation.	Paclitaxel	130-135	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	113-119
29439899-6	2018	They match or exceed the potency of vinblastine and they display more potent activity against taxol-resistant A549-T24 than even wild type A549 cells (1.2-2-fold), complementing our prior observations that they also display no sensitivity to overexpression of Pgp (HCT116/VM46 vs HCT116) and are not subject to resistance derived from Pgp efflux.	Paclitaxel	94-99	phosphoglycolate phosphatase	Homo sapiens	335-338
28771725-0	2018	TLR4 and NFkappaB signaling is critical for taxol resistance in ovarian carcinoma cells.	Paclitaxel	44-49	toll like receptor 4	Homo sapiens	0-4
24367683-11	2013	When 14-3-3z overexpressing neurons were treated with the microtubule stabilizing drug taxol, tau Ser(262) phosphorylation decreased and synaptophysin level was restored.	Paclitaxel	87-92	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta	Rattus norvegicus	5-12
28771725-1	2018	We report here that toll-like receptor 4 (TLR4) and ABCB1 are upregulated in SKOV3 ovarian carcinoma cells that acquired resistance to the anticancer drug taxol.	Paclitaxel	155-160	toll like receptor 4	Homo sapiens	20-40
10219964-11	1999	In human liver microsomes, arachidonic acid inhibited CYP1A2-dependent theophylline hydroxylation, CYP2C8-dependent taxol 6alpha-hydroxylation and CYP2C19-dependent omeprazole 5-hydroxylation.	Paclitaxel	116-121	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	99-105
28771725-1	2018	We report here that toll-like receptor 4 (TLR4) and ABCB1 are upregulated in SKOV3 ovarian carcinoma cells that acquired resistance to the anticancer drug taxol.	Paclitaxel	155-160	toll like receptor 4	Homo sapiens	42-46
24349128-8	2013	We were able to validate our method by recovering known mechanisms and as an application example of our method, we identified a mechanism that may further explain the synergism between paclitaxel and doxorubicin in TFAC treatment: Paclitaxel may attenuate MELK gene expression, resulting in lower levels of its target MYBL2, already associated with doxorubicin synergism in hepatocellular carcinoma cell lines.	Paclitaxel	185-195	MYB proto-oncogene like 2	Homo sapiens	318-323
24349128-8	2013	We were able to validate our method by recovering known mechanisms and as an application example of our method, we identified a mechanism that may further explain the synergism between paclitaxel and doxorubicin in TFAC treatment: Paclitaxel may attenuate MELK gene expression, resulting in lower levels of its target MYBL2, already associated with doxorubicin synergism in hepatocellular carcinoma cell lines.	Paclitaxel	231-241	MYB proto-oncogene like 2	Homo sapiens	318-323
28771725-2	2018	Silencing of TLR4 using short-hairpin RNA sensitized taxol-resistant SKOV3 cells to taxol (4.6 fold), whereas ectopic expression of TLR4 in parental, taxol-sensitive SKOV3 cells or TLR4-null HEK293 cells induced taxol resistance (~2 fold).	Paclitaxel	53-58	toll like receptor 4	Homo sapiens	13-17
9914158-3	1999	Colocalization of B23 with the protein NuMA (Nuclear Mitotic Apparatus protein) was studied in mitotic cells and taxol-arrested cells.	Paclitaxel	113-118	nucleophosmin 1	Homo sapiens	18-21
28771725-2	2018	Silencing of TLR4 using short-hairpin RNA sensitized taxol-resistant SKOV3 cells to taxol (4.6 fold), whereas ectopic expression of TLR4 in parental, taxol-sensitive SKOV3 cells or TLR4-null HEK293 cells induced taxol resistance (~2 fold).	Paclitaxel	84-89	toll like receptor 4	Homo sapiens	13-17
28771725-2	2018	Silencing of TLR4 using short-hairpin RNA sensitized taxol-resistant SKOV3 cells to taxol (4.6 fold), whereas ectopic expression of TLR4 in parental, taxol-sensitive SKOV3 cells or TLR4-null HEK293 cells induced taxol resistance (~2 fold).	Paclitaxel	84-89	toll like receptor 4	Homo sapiens	13-17
28771725-2	2018	Silencing of TLR4 using short-hairpin RNA sensitized taxol-resistant SKOV3 cells to taxol (4.6 fold), whereas ectopic expression of TLR4 in parental, taxol-sensitive SKOV3 cells or TLR4-null HEK293 cells induced taxol resistance (~2 fold).	Paclitaxel	84-89	toll like receptor 4	Homo sapiens	13-17
28771725-4	2018	Inactivation of TLR4 using chemical inhibitors (CLI-095 and AO-I) downregulated ABCB1 protein expression and enhanced the cytotoxic activity of taxol in taxol-resistant SKOV3 cells.	Paclitaxel	144-149	toll like receptor 4	Homo sapiens	16-20
28771725-4	2018	Inactivation of TLR4 using chemical inhibitors (CLI-095 and AO-I) downregulated ABCB1 protein expression and enhanced the cytotoxic activity of taxol in taxol-resistant SKOV3 cells.	Paclitaxel	153-158	toll like receptor 4	Homo sapiens	16-20
28771725-6	2018	Notably, the NFkappaB pathway was significantly activated by taxol, and inhibition of this pathway suppressed TLR4-regulated ABCB1 expression.	Paclitaxel	61-66	toll like receptor 4	Homo sapiens	110-114
28771725-7	2018	Furthermore, taxol-induced NFkappaB signaling was reduced following TLR4 silencing in taxol-resistant SKOV3 cells.	Paclitaxel	13-18	toll like receptor 4	Homo sapiens	68-72
24155014-0	2013	Paclitaxel resistance by random mutagenesis of alpha-tubulin.	Paclitaxel	0-10	tubulin alpha 1b	Homo sapiens	47-60
24155014-1	2013	Many mammalian beta-tubulin mutations that confer paclitaxel resistance have been characterized, but little is currently known about the role of alpha-tubulin mutations in drug resistance.	Paclitaxel	50-60	beta tubulin	Cricetulus griseus	15-27
24155014-2	2013	Previous studies using two-dimensional gel electrophoresis showed that alpha-tubulin mutations occur with a frequency equal to beta-tubulin mutations among CHO cells selected for resistance to paclitaxel but the identities of those mutations are largely unknown.	Paclitaxel	193-203	tubulin alpha-1B chain	Cricetulus griseus	71-84
24155014-3	2013	We have now sequenced the major alpha-tubulin gene in several paclitaxel resistant CHO cell lines with lesions in genomic DNA and identified five mutations that predominately affect the amino terminal part of the protein.	Paclitaxel	62-72	tubulin alpha-1B chain	Cricetulus griseus	32-45
24155014-4	2013	We also used random mutagenesis and transfection of alpha-tubulin cDNA to select further paclitaxel resistant mutants in an effort to remove genomic constraints that may limit the diversity of mutations.	Paclitaxel	89-99	tubulin alpha 1b	Homo sapiens	52-65
9914158-7	1999	In taxol-treated cells, B23 is associated with the microtubule minus ends in the center of mitotic asters together with NuMA.	Paclitaxel	3-8	nucleophosmin 1	Homo sapiens	24-27
24114859-4	2013	However, we did identify mean SFN methylation associated with PFS (hazard ratio, HR = 1.01 per 1% increase in methylation, q = 0.028); particularly in the paclitaxel (HR = 1.01, q = 0.006), but not in the docetaxel arm in stratified analyses.	Paclitaxel	155-165	stratifin	Homo sapiens	30-33
9914158-8	1999	Association of B23 with microtubule minus ends of mitotic asters was further confirmed with an in vitro assay, where B23 was found by western blotting to co-sediment with taxol-induced microtubule asters formed in a mitotic cell extract.	Paclitaxel	171-176	nucleophosmin 1	Homo sapiens	15-18
9914158-8	1999	Association of B23 with microtubule minus ends of mitotic asters was further confirmed with an in vitro assay, where B23 was found by western blotting to co-sediment with taxol-induced microtubule asters formed in a mitotic cell extract.	Paclitaxel	171-176	nucleophosmin 1	Homo sapiens	117-120
9914158-11	1999	Immunodepletion of B23 from the mitotic extract revealed that taxol-induced microtubule asters were still observed in B23-immunodepleted mitotic extract, indicating that the presence of B23 at the poles is unlikely to be essential for spindle formation or stabilisation.	Paclitaxel	62-67	nucleophosmin 1	Homo sapiens	19-22
9914158-11	1999	Immunodepletion of B23 from the mitotic extract revealed that taxol-induced microtubule asters were still observed in B23-immunodepleted mitotic extract, indicating that the presence of B23 at the poles is unlikely to be essential for spindle formation or stabilisation.	Paclitaxel	62-67	nucleophosmin 1	Homo sapiens	118-121
23659854-4	2013	Furthermore, pre-treatment of PC3 cells with F3-targeted liposomes containing anti-PLK1 siRNA enabled a 3-fold reduction of paclitaxel IC50 and a 2.5-fold augment of the percentage of cancer cells in G2/mitosis arrest, which ultimately culminated in cell death.	Paclitaxel	124-134	proprotein convertase subtilisin/kexin type 1	Homo sapiens	30-33
30359298-0	2018	The new 6q27 tumor suppressor DACT2, frequently silenced by CpG methylation, sensitizes nasopharyngeal cancer cells to paclitaxel and 5-FU toxicity via beta-catenin/Cdc25c signaling and G2/M arrest.	Paclitaxel	119-129	catenin beta 1	Homo sapiens	152-164
9914158-11	1999	Immunodepletion of B23 from the mitotic extract revealed that taxol-induced microtubule asters were still observed in B23-immunodepleted mitotic extract, indicating that the presence of B23 at the poles is unlikely to be essential for spindle formation or stabilisation.	Paclitaxel	62-67	nucleophosmin 1	Homo sapiens	118-121
30359298-0	2018	The new 6q27 tumor suppressor DACT2, frequently silenced by CpG methylation, sensitizes nasopharyngeal cancer cells to paclitaxel and 5-FU toxicity via beta-catenin/Cdc25c signaling and G2/M arrest.	Paclitaxel	119-129	cell division cycle 25C	Homo sapiens	165-171
23735541-10	2013	Decrease of p53 and Bcl-2, fragmentation of DNA, increase of Bax and, finally, activation of caspases 3 and 9 in NB4 leukaemia cells make the apoptotic process induced by Ptx irreversible.	Paclitaxel	171-174	caspase 9	Homo sapiens	93-109
10945480-1	1999	We report the activities of taxol (an anticancer drug) and colchicine, which are inhibitors of microtubule organization, on the complexation and transport of Na+, K+, Mg2+ and Ca2+ ions across a liquid membrane, using a spectrophotometric procedure.	Paclitaxel	28-33	mucin 7, secreted	Homo sapiens	167-170
23877225-0	2013	The overexpression of P21-activated kinase 5 (PAK5) promotes paclitaxel-chemoresistance of epithelial ovarian cancer.	Paclitaxel	61-71	p21 (RAC1) activated kinase 5	Homo sapiens	22-44
23877225-0	2013	The overexpression of P21-activated kinase 5 (PAK5) promotes paclitaxel-chemoresistance of epithelial ovarian cancer.	Paclitaxel	61-71	p21 (RAC1) activated kinase 5	Homo sapiens	46-50
23877225-3	2013	It is remarkable that we found PAK5 was overexpressed in epithelial ovarian cancer (EOC), which is faced with an obstacle of paclitaxel resistance.	Paclitaxel	125-135	p21 (RAC1) activated kinase 5	Homo sapiens	31-35
28589243-0	2018	RNAi targeting STMN alleviates the resistance to taxol and collectively contributes to down regulate the malignancy of NSCLC cells in vitro and in vivo.	Paclitaxel	49-54	stathmin 1	Homo sapiens	15-19
28589243-5	2018	These findings suggest that silencing STMN alleviates the resistance to taxol and collectively contributes to induce the dysfunction of multiple signals and down regulate the malignancy of tumors; thus, STMN is a promising target in treating refractory tumors.	Paclitaxel	72-77	stathmin 1	Homo sapiens	38-42
28589243-5	2018	These findings suggest that silencing STMN alleviates the resistance to taxol and collectively contributes to induce the dysfunction of multiple signals and down regulate the malignancy of tumors; thus, STMN is a promising target in treating refractory tumors.	Paclitaxel	72-77	stathmin 1	Homo sapiens	203-207
23877225-7	2013	Remarkably, those patients who recurred within 6 months after accepting tumor reductive surgery and the following carboplatin + paclitaxel chemotherapy had the highest PAK5 expression (P = 0.015).	Paclitaxel	128-138	p21 (RAC1) activated kinase 5	Homo sapiens	168-172
23877225-8	2013	Moreover, in in vitro studies, we found that SK-OV-3 cell growth was decreased while paclitaxel chemosensitivity was correspondingly increased with the down-regulation of PAK5.	Paclitaxel	85-95	p21 (RAC1) activated kinase 5	Homo sapiens	171-175
10945480-2	1999	Taxol, a diterpenoid compound, that has been demonstrated to possess a potent antitumour activity, is shown to extract Na+, K+, Mg2+ and Ca2+ ions from the aqueous solution to the organic phase with preference for Ca2+ ions.	Paclitaxel	0-5	mucin 7, secreted	Homo sapiens	128-131
23877225-9	2013	Taken together, our study demonstrated that PAK5 is correlated to human EOC and increased PAK5 expression promotes EOC progression, and PAK5 regulates EOC cell paclitaxel chemoresistance.	Paclitaxel	160-170	p21 (RAC1) activated kinase 5	Homo sapiens	44-48
23877225-9	2013	Taken together, our study demonstrated that PAK5 is correlated to human EOC and increased PAK5 expression promotes EOC progression, and PAK5 regulates EOC cell paclitaxel chemoresistance.	Paclitaxel	160-170	p21 (RAC1) activated kinase 5	Homo sapiens	90-94
9865921-0	1998	CDK4 down-regulation induced by paclitaxel is associated with G1 arrest in gastric cancer cells.	Paclitaxel	32-42	cyclin dependent kinase 4	Homo sapiens	0-4
23877225-9	2013	Taken together, our study demonstrated that PAK5 is correlated to human EOC and increased PAK5 expression promotes EOC progression, and PAK5 regulates EOC cell paclitaxel chemoresistance.	Paclitaxel	160-170	p21 (RAC1) activated kinase 5	Homo sapiens	90-94
23553437-6	2013	We show that specific blocking of IL-4 and IL-13-mediated STAT6 activation by either an IL-4-binding fusion protein APG598 or an IL-4R antagonist APG201 (R121D/Y124D) renders HL cells more prone to apoptotic killing by chemotherapeutic drugs such as Mitomycin C, 5-Fluorouracil, Etopside, Doxorubicin and Paclitaxel.	Paclitaxel	305-315	signal transducer and activator of transcription 6	Homo sapiens	58-63
28870680-8	2018	Nuclear Myc protein expression benefitted patients treated with paclitaxel (interaction P = .052 for DFS; P = .049 for OS).	Paclitaxel	64-74	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	8-11
28870680-11	2018	Nuclear Myc protein expression seems predictive for benefit from adjuvant paclitaxel.	Paclitaxel	74-84	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	8-11
9865921-2	1998	We observed that gastric cancer cells treated with paclitaxel have shown a cyclin-dependent kinase (CDK)4 down-regulation.	Paclitaxel	51-61	cyclin dependent kinase 4	Homo sapiens	100-105
24023282-5	2013	Interestingly, ABC294640 administered to Caov-3 ovarian cancer cells in conjunction with paclitaxel induced apoptotic cell death through activation of caspase-9.	Paclitaxel	89-99	caspase 9	Homo sapiens	151-160
9865921-3	1998	This paclitaxel-induced CDK4 down-regulation resulted in a cell cycle arrest at G1-S phase.	Paclitaxel	5-15	cyclin dependent kinase 4	Homo sapiens	24-28
23967091-5	2013	Our results further demonstrated that PTX inhibited the effect of TGF-beta1 on regulating the expression of Smad3 and phosphorylated Smad3 (p-Smad3), and restored the levels of E-cadherin, vimentin and alpha-SMA.	Paclitaxel	38-41	cadherin 1	Rattus norvegicus	177-187
9865921-5	1998	Ectopic expression of CDK4 in SNU cells resulted in a release of paclitaxel-induced G1 arrest.	Paclitaxel	65-75	cyclin dependent kinase 4	Homo sapiens	22-26
23967091-8	2013	The action of PTX to ameliorate TGF-beta1-induced EMT was promoted by miR-140, which increased E-cadherin levels and reduced the expression of vimentin, Smad3 and p-Smad3.	Paclitaxel	14-17	cadherin 1	Rattus norvegicus	95-105
29434885-0	2018	Low-dose paclitaxel downregulates MYC proto-oncogene bHLH transcription factor expression in colorectal carcinoma cells.	Paclitaxel	9-19	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	34-37
9865921-6	1998	The release of G1 arrest by enforced expression of CDK4 seems to make the cells more sensitive to paclitaxel-induced apoptosis.	Paclitaxel	98-108	cyclin dependent kinase 4	Homo sapiens	51-55
29434885-8	2018	These results suggest that low-dose PTX downregulates c-Myc and P-c-Myc expression, subsequently inhibiting the cell cycle at G0/G1 in colorectal carcinoma.	Paclitaxel	36-39	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	54-59
23967153-3	2013	Present study assessed a new use of GSP on the MDR reversal activity and its possible molecular mechanisms in MDR1-overpressing paclitaxel resistant ovarian cancer cells.	Paclitaxel	128-138	GSM1	Homo sapiens	36-39
9781607-9	1998	Dose-limiting toxicities (febrile neutropenia and severe fatigue) were observed in two of six patients at level VIII (paclitaxel 225 mg/m2 and carboplatin 400 mg/m2) and therefore the previous dose-level (paclitaxel 200 mg/m2 and carboplatin 400 mg/m2) was considered as the maximum tolerated dose.	Paclitaxel	118-128	cytochrome c oxidase subunit 8A	Homo sapiens	112-116
23967153-4	2013	Our results showed GSP significantly enhanced the cytotoxicity of paclitaxel and adriamycin in paclitaxel resistant A2780/T cells but its parental A2780 cells.	Paclitaxel	66-76	GSM1	Homo sapiens	19-22
23967153-4	2013	Our results showed GSP significantly enhanced the cytotoxicity of paclitaxel and adriamycin in paclitaxel resistant A2780/T cells but its parental A2780 cells.	Paclitaxel	95-105	GSM1	Homo sapiens	19-22
29434885-8	2018	These results suggest that low-dose PTX downregulates c-Myc and P-c-Myc expression, subsequently inhibiting the cell cycle at G0/G1 in colorectal carcinoma.	Paclitaxel	36-39	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	66-71
29382898-2	2018	The developed PTX loaded Mn:ZnS NPs with different CPPs (PEN, pVEC and R9) showed enhanced anti-cancer effect compared to bare PTX, which has been validated by MTT assay followed by apoptosis assay and DNA fragmentation analysis.	Paclitaxel	14-17	proprotein convertase subtilisin/kexin type 1 inhibitor	Homo sapiens	57-60
9713996-10	1998	Likewise, in a paclitaxel-selected MCF-7 subline where CASP sequences (at 7q22) were shown to be fused to MDR1, WCP7 showed an elongated chromosome 7 with a homogeneously staining regions (hsr); BAC-derived probes demonstrated that the hsr was composed of highly amplified MDR1 and CASP sequences.	Paclitaxel	15-25	cut like homeobox 1	Homo sapiens	55-59
29271375-13	2018	NEDD4-1 knockdown in vivo decreased proliferation, migration, and invasion and improved chemosensitivity to cisplatin and paclitaxel in A549 cells.	Paclitaxel	122-132	NEDD4 E3 ubiquitin protein ligase	Homo sapiens	0-7
23263912-8	2013	CONCLUSIONS: We first reported that TS 3"-UTR ins6/ins6 genotype could predict the poor survival of advanced gastric cancer patients treated with capecitabine plus paclitaxel, which would be further verified in a large multicenter study.	Paclitaxel	164-174	thymidylate synthetase	Homo sapiens	36-38
23802633-5	2013	Treatment of the paclitaxel-resistant cell lines with ABT-737, an inhibitor of BCL2 and BCLxL, or simultaneous knock-down of BCL2 and BCLxL dramatically increased the cells" sensitivity, while knock-down of MCL1, another member of the BCL2 family, had only a minimal effect.	Paclitaxel	17-27	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	207-211
23799854-0	2013	A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells.	Paclitaxel	47-57	leukotriene B4 receptor 2	Homo sapiens	2-27
23799854-5	2013	The potential role of BLT2 in the paclitaxel resistance of MCF-7/DOX cells was assessed using a pharmacological inhibitor and small interfering RNA knockdown, and the BLT2-associated resistance mechanism was assessed.	Paclitaxel	34-44	leukotriene B4 receptor 2	Homo sapiens	22-26
23799854-7	2013	The inhibition of BLT2 by pre-treatment with LY255283 or siBLT2 knockdown significantly sensitised MCF-7/DOX cells to paclitaxel and induced significant levels of apoptotic death, suggesting that BLT2 mediates paclitaxel resistance.	Paclitaxel	118-128	leukotriene B4 receptor 2	Homo sapiens	18-22
30347597-0	2018	Downregulation of long noncoding RNA PVT1 attenuates paclitaxel resistance in glioma cells.	Paclitaxel	53-63	Pvt1 oncogene	Homo sapiens	37-41
23799854-7	2013	The inhibition of BLT2 by pre-treatment with LY255283 or siBLT2 knockdown significantly sensitised MCF-7/DOX cells to paclitaxel and induced significant levels of apoptotic death, suggesting that BLT2 mediates paclitaxel resistance.	Paclitaxel	118-128	leukotriene B4 receptor 2	Homo sapiens	59-63
9925253-0	1998	Paclitaxel is preferentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens.	Paclitaxel	0-10	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	78-83
23799854-7	2013	The inhibition of BLT2 by pre-treatment with LY255283 or siBLT2 knockdown significantly sensitised MCF-7/DOX cells to paclitaxel and induced significant levels of apoptotic death, suggesting that BLT2 mediates paclitaxel resistance.	Paclitaxel	210-220	leukotriene B4 receptor 2	Homo sapiens	18-22
23799854-8	2013	We also demonstrated that BLT2-induced paclitaxel resistance was associated with the upregulation of P-glycoprotein.	Paclitaxel	39-49	leukotriene B4 receptor 2	Homo sapiens	26-30
23799854-10	2013	CONCLUSION: Together, our results demonstrate that BLT2 is a novel therapeutic target that sensitises drug-resistant breast cancer cells to paclitaxel.	Paclitaxel	140-150	leukotriene B4 receptor 2	Homo sapiens	51-55
23807165-0	2013	Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.	Paclitaxel	46-56	microRNA 106a	Homo sapiens	17-25
23807165-0	2013	Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.	Paclitaxel	46-56	microRNA 591	Homo sapiens	30-37
23807165-5	2013	RESULTS: Upregulation of miR-106a and downregulation of miR-591 were associated with PTX resistance in ovarian cancer cells and human tumour samples.	Paclitaxel	85-88	microRNA 106a	Homo sapiens	25-33
23807165-5	2013	RESULTS: Upregulation of miR-106a and downregulation of miR-591 were associated with PTX resistance in ovarian cancer cells and human tumour samples.	Paclitaxel	85-88	microRNA 591	Homo sapiens	56-63
23807165-6	2013	Transfection with anti-miR-106a or pre-miR-591 resensitized PTX-resistant SKpac cells to PTX by enhancing apoptosis (23 and 42% increase), and inhibited their cell migration (43 and 56% decrease) and proliferation (64 and 65% decrease).	Paclitaxel	60-63	microRNA 106a	Homo sapiens	23-31
23807165-6	2013	Transfection with anti-miR-106a or pre-miR-591 resensitized PTX-resistant SKpac cells to PTX by enhancing apoptosis (23 and 42% increase), and inhibited their cell migration (43 and 56% decrease) and proliferation (64 and 65% decrease).	Paclitaxel	60-63	microRNA 591	Homo sapiens	39-46
23807165-6	2013	Transfection with anti-miR-106a or pre-miR-591 resensitized PTX-resistant SKpac cells to PTX by enhancing apoptosis (23 and 42% increase), and inhibited their cell migration (43 and 56% decrease) and proliferation (64 and 65% decrease).	Paclitaxel	89-92	microRNA 106a	Homo sapiens	23-31
30347597-9	2018	Down-regulation of lncRNA PVT1 inhibited the SHG-44 RE cell viability and increased glioma SHG-44 RE cells apoptosis after paclitaxel treatment, suggesting that inhibition of lncRNA PVT1 improved paclitaxel sensibility in human glioma cells.	Paclitaxel	123-133	Pvt1 oncogene	Homo sapiens	26-30
30347597-9	2018	Down-regulation of lncRNA PVT1 inhibited the SHG-44 RE cell viability and increased glioma SHG-44 RE cells apoptosis after paclitaxel treatment, suggesting that inhibition of lncRNA PVT1 improved paclitaxel sensibility in human glioma cells.	Paclitaxel	123-133	Pvt1 oncogene	Homo sapiens	182-186
30347597-9	2018	Down-regulation of lncRNA PVT1 inhibited the SHG-44 RE cell viability and increased glioma SHG-44 RE cells apoptosis after paclitaxel treatment, suggesting that inhibition of lncRNA PVT1 improved paclitaxel sensibility in human glioma cells.	Paclitaxel	196-206	Pvt1 oncogene	Homo sapiens	26-30
30347597-9	2018	Down-regulation of lncRNA PVT1 inhibited the SHG-44 RE cell viability and increased glioma SHG-44 RE cells apoptosis after paclitaxel treatment, suggesting that inhibition of lncRNA PVT1 improved paclitaxel sensibility in human glioma cells.	Paclitaxel	196-206	Pvt1 oncogene	Homo sapiens	182-186
30347597-10	2018	CONCLUSION: Down-regulation of PVT1 could enhance chemosensitivity of paclitaxel, induce apoptosis of glioma cells and noteworthy inhibit glioma cells proliferation.	Paclitaxel	70-80	Pvt1 oncogene	Homo sapiens	31-35
30347597-11	2018	Our findings of PVT1 could contribute to attenuate paclitaxel resistance in clinical medicine.	Paclitaxel	51-61	Pvt1 oncogene	Homo sapiens	16-20
30355931-0	2018	Effect of Paclitaxel+Hirudin on the TLR4-MyD88 Signaling Pathway During Inflammatory Activation of Human Coronary Artery Smooth Muscle Cells and Mechanistic Analysis.	Paclitaxel	10-20	toll like receptor 4	Homo sapiens	36-40
30355931-3	2018	This study aimed to explore the anti-inflammatory and anti-restenosis mechanisms of paclitaxel+hirudin with regard to the TLR4/MyD88/NF-kappaB pathway.	Paclitaxel	84-94	toll like receptor 4	Homo sapiens	122-126
23807165-6	2013	Transfection with anti-miR-106a or pre-miR-591 resensitized PTX-resistant SKpac cells to PTX by enhancing apoptosis (23 and 42% increase), and inhibited their cell migration (43 and 56% decrease) and proliferation (64 and 65% decrease).	Paclitaxel	89-92	microRNA 591	Homo sapiens	39-46
23807165-8	2013	CONCLUSION: MiR-106a and miR-591 have important roles in conferring PTX resistance to ovarian cancer cells.	Paclitaxel	68-71	microRNA 106a	Homo sapiens	12-20
23807165-8	2013	CONCLUSION: MiR-106a and miR-591 have important roles in conferring PTX resistance to ovarian cancer cells.	Paclitaxel	68-71	microRNA 591	Homo sapiens	25-32
23807165-9	2013	Modulation of these microRNAs resensitizes PTX-resistant cancer cells by targeting BCL10, caspase-7, and ZEB1.	Paclitaxel	43-46	caspase 7	Homo sapiens	90-99
30355931-6	2018	After MyD88 knockdown and selective blocking of MyD88 degradation with epoxomicin, the effects of paclitaxel+hirudin stenting on key sites of the TLR4/MyD88/NF-kappaB pathway were detected using ELISA, Q-PCR, and western blot analysis.	Paclitaxel	98-108	toll like receptor 4	Homo sapiens	146-150
9925253-1	1998	BACKGROUND AND PURPOSE: Low Raf- kinase activity has been reported to be associated with radioresistance in epithelial tumor cell lines and with paclitaxel sensitivity in cervical tumor cells.	Paclitaxel	145-155	zinc fingers and homeoboxes 2	Homo sapiens	28-31
30355931-8	2018	Paclitaxel+hirudin inhibited the levels of key proteins and the gene expression, except for that of the MyD88 gene, of the TLR4-MyD88 pathway.	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	123-127
9925253-6	1998	Paclitaxel was preferentially cytotoxic to radioresistant tumor clones, with the level of paclitaxel-induced cytotoxicity being significantly (P = 0.0016) influenced by Raf-1 kinase activity levels.	Paclitaxel	0-10	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	169-174
30101722-8	2018	After treatment with paclitaxel, cyclin D1 and CDK4 protein levels were similar to control values; meanwhile, cylinE1 and CDK2 protein amounts were reduced, with increased cyclin B1 levels, compared with control values (p&lt;0.05).	Paclitaxel	21-31	cyclin B1	Homo sapiens	172-181
30101722-10	2018	Lobaplatin and paclitaxel combination did not affect cyclin D1 and CDK4 protein levels (p&gt;0.05); meanwhile, cyclin E1 and CDK2 levels were increased, with reduced cyclin B1 amounts, compared with control values (p&lt;0.05).	Paclitaxel	15-25	cyclin B1	Homo sapiens	166-175
22907429-8	2013	We determined that knockdown of HOXC6 expression in MDR cells increased their sensitivity to paclitaxel.	Paclitaxel	93-103	homeobox C6	Homo sapiens	32-37
9925253-6	1998	Paclitaxel was preferentially cytotoxic to radioresistant tumor clones, with the level of paclitaxel-induced cytotoxicity being significantly (P = 0.0016) influenced by Raf-1 kinase activity levels.	Paclitaxel	90-100	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	169-174
9925253-7	1998	CONCLUSIONS: Our in vitro data indicate that there are marked, but completely opposite, Raf-1 kinase dependencies of radiation and paclitaxel cytotoxicity in cervical tumor cells.	Paclitaxel	131-141	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	88-93
9925253-9	1998	Circumstantially, our data suggest that the greatest therapeutic gains might accrue if paclitaxel was administered when there is the greatest proportion of tumor clones with low Raf-1 kinase activity.	Paclitaxel	87-97	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	178-183
9721870-4	1998	Raf-1 activation was observed at Taxol concentrations of 9 nM and greater.	Paclitaxel	33-38	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	0-5
23496232-0	2013	Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.	Paclitaxel	11-21	stathmin 1	Homo sapiens	77-85
29322800-0	2018	USF1 gene polymorphisms may associate with the efficacy and safety of chemotherapy based on paclitaxel and prognosis in the treatment of ovarian cancer.	Paclitaxel	92-102	upstream transcription factor 1	Homo sapiens	0-4
29322800-1	2018	This study was supposed to investigate the correlation between the functional single nucleotide polymorphisms (SNPs) (rs2516839 and rs3737787) in USF1 gene and the efficacy and safety of paclitaxel-based chemotherapy and prognosis in the treatment of ovarian cancer (OC).	Paclitaxel	187-197	upstream transcription factor 1	Homo sapiens	146-150
29322800-4	2018	The correlation between USF1 gene polymorphisms and paclitaxel-based chemotherapy resistance was analyzed using Logistic regression analysis.	Paclitaxel	52-62	upstream transcription factor 1	Homo sapiens	24-28
23543364-5	2013	Here, we tested the hypothesis that PEA-15 phosphorylated at both Ser104 and Ser116 (pPEA-15) sensitizes ovarian cancer cells to paclitaxel.	Paclitaxel	129-139	proliferation and apoptosis adaptor protein 15	Homo sapiens	36-42
23543364-6	2013	We first found that knockdown of PEA-15 in PEA-15-high expressing HEY and OVTOKO ovarian cancer cells resulted in paclitaxel resistance, whereas re-expression of PEA-15 in these cells led to paclitaxel sensitization.	Paclitaxel	114-124	proliferation and apoptosis adaptor protein 15	Homo sapiens	33-39
23543364-6	2013	We first found that knockdown of PEA-15 in PEA-15-high expressing HEY and OVTOKO ovarian cancer cells resulted in paclitaxel resistance, whereas re-expression of PEA-15 in these cells led to paclitaxel sensitization.	Paclitaxel	114-124	proliferation and apoptosis adaptor protein 15	Homo sapiens	43-49
23543364-6	2013	We first found that knockdown of PEA-15 in PEA-15-high expressing HEY and OVTOKO ovarian cancer cells resulted in paclitaxel resistance, whereas re-expression of PEA-15 in these cells led to paclitaxel sensitization.	Paclitaxel	114-124	proliferation and apoptosis adaptor protein 15	Homo sapiens	43-49
9454730-8	1998	We also demonstrate that pEg2 binds directly to taxol stabilised microtubules in vitro.	Paclitaxel	48-53	aurora kinase A S homeolog	Xenopus laevis	25-29
23543364-6	2013	We first found that knockdown of PEA-15 in PEA-15-high expressing HEY and OVTOKO ovarian cancer cells resulted in paclitaxel resistance, whereas re-expression of PEA-15 in these cells led to paclitaxel sensitization.	Paclitaxel	191-201	proliferation and apoptosis adaptor protein 15	Homo sapiens	33-39
23543364-7	2013	We next found that SKOV3.ip1-DD cells (expressing phosphomimetic PEA-15) were more sensitive to paclitaxel than SKOV3.ip1-AA cells (expressing nonphosphorylatable PEA-15).	Paclitaxel	96-106	proliferation and apoptosis adaptor protein 15	Homo sapiens	65-71
23632482-8	2013	Consistent with this hypothesis, (212)Pb-TCMC-trastuzumab treatment in response to paclitaxel reduced expression and phosphorylation of BubR1, which is likely attributable to disruption of a functional Aurora B, leading to impairment of the mitotic spindle checkpoint.	Paclitaxel	83-93	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	136-141
29322800-10	2018	Taken together, our results suggest that the rs2516839 polymorphism in USF1 gene may associate with the efficacy and safety of paclitaxel-based chemotherapy and prognosis in the treatment of OC.	Paclitaxel	127-137	upstream transcription factor 1	Homo sapiens	71-75
29435178-9	2018	These findings suggest that the effects of nab-paclitaxel-based chemotherapy can be enhanced through specific inhibition of MEK1/2 kinase activity, and supports the clinical application of trametinib in combination with standard nab-paclitaxel-based chemotherapy in PDAC patients.	Paclitaxel	47-57	mitogen-activated protein kinase kinase 1	Homo sapiens	124-130
23628417-3	2013	BLU and paclitaxel induced cell cycle arrest in the G2/M phase through the reduction of cyclin dependent kinase 1, cyclin B1, while promoting both p16 and p27 expression.	Paclitaxel	8-18	cyclin dependent kinase 1	Homo sapiens	88-113
23628417-3	2013	BLU and paclitaxel induced cell cycle arrest in the G2/M phase through the reduction of cyclin dependent kinase 1, cyclin B1, while promoting both p16 and p27 expression.	Paclitaxel	8-18	cyclin B1	Homo sapiens	115-124
9484812-8	1998	In addition, analysis of paclitaxel-resistant cells that were selected at increasing levels of the drug (Pac 2, 4, 6, 8 and 10) exhibited a positive correlation between increasing betaIII levels and increasing resistance to paclitaxel.	Paclitaxel	25-35	tubulin folding cofactor E	Homo sapiens	105-126
23628417-5	2013	As expected, the Bax and p21 activities were enhanced by BLU or paclitaxel, while a combination of BLU and paclitaxel were additively promoted, whereas Bcl-xL and NF-kappaB including Bcl-2 activity were inactivated.	Paclitaxel	64-74	H3 histone pseudogene 16	Homo sapiens	25-28
22733135-7	2013	These findings may be relevant for the clinical management of prostate cancer as DCDC2 may signal tumors more prone to relapse and resistant to taxol treatment.	Paclitaxel	144-149	doublecortin domain containing 2	Homo sapiens	81-86
29246304-8	2017	administration of AXL-aptamer treatment markedly enhanced the antitumor efficacy of paclitaxel in mice.	Paclitaxel	84-94	AXL receptor tyrosine kinase	Mus musculus	18-21
9484812-8	1998	In addition, analysis of paclitaxel-resistant cells that were selected at increasing levels of the drug (Pac 2, 4, 6, 8 and 10) exhibited a positive correlation between increasing betaIII levels and increasing resistance to paclitaxel.	Paclitaxel	224-234	tubulin folding cofactor E	Homo sapiens	105-126
9443400-7	1998	Transient activation of the c-Jun-NH2-terminal kinase/AP-1 pathway, together with down-regulation of ERK2 activity, may be a key event in the early response of RPMI-1788 B lymphoblasts to paclitaxel exposure.	Paclitaxel	188-198	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	54-58
29371916-0	2017	The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.	Paclitaxel	59-69	interleukin 17 receptor B	Homo sapiens	11-27
14577220-0	1998	High-performance liquid chromatographic analysis of CYP2C8-catalyzed paclitaxel 6 alpha-hydroxylation.	Paclitaxel	69-79	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	52-58
28933054-7	2017	In addition, the proliferating and invasive abilities were decreased, and the apoptosis ability and paclitaxel sensitivity were increased in STMN1-suppressed LSCC cells compared with control cells.	Paclitaxel	100-110	stathmin 1	Homo sapiens	141-146
28815582-3	2017	Small interfering RNA-mediated reduction in COL11A1 protein levels increased the chemosensitivity to cisplatin and paclitaxel via downregulated TWIST1 expression.	Paclitaxel	115-125	collagen type XI alpha 1 chain	Homo sapiens	44-51
22877241-0	2013	GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients.	Paclitaxel	60-70	tectorin alpha	Homo sapiens	41-46
23128939-2	2013	We hypothesize that local administration of paclitaxel-loaded expansile nanoparticles (pax-eNP) at the time of cytoreductive surgery decreases local tumor recurrence.	Paclitaxel	44-54	centromere protein H	Mus musculus	91-94
9887359-9	1998	When taxol, which inhibits microtubule depolymerization, was added to the culture medium of neoT cells, a polymerized microtubule network was observed, and the reclustering of cathepsin D and lamp-1 occurred in an unidirectional manner towards the perinuclear region.	Paclitaxel	5-10	cathepsin D	Homo sapiens	176-187
27844290-7	2017	Moreover, enalapril (an ACE inhibitor) enhanced the mechanical allodynia induced by a low dose of paclitaxel.	Paclitaxel	98-108	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	24-27
27844290-8	2017	Likewise, paclitaxel injection inhibited ACE activity and increased the expressions of B1 and B2 receptors and bradykinin-related peptides levels in peripheral tissue.	Paclitaxel	10-20	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	41-44
29162879-5	2017	Moreover, miR-30e regulates cell proliferation, migration, invasion and increases chemosensitivity of MDA-MB-231 cells to paclitaxel by inhibiting its target IRS1.	Paclitaxel	122-132	microRNA 30e	Homo sapiens	10-17
23613870-7	2013	Interestingly, both DRC and SCC were resistant to paclitaxel in comparison to parental Hep3B cells.	Paclitaxel	50-60	serpin family B member 3	Homo sapiens	28-31
23391494-4	2013	When nanocapsules are filled with a far-red fluorochrome (DiD) and Paclitaxel, the presence of the NFL-TBS.40-63 peptide increases their uptake by glioblastoma cells in culture as evaluated by FACS analysis, and thus reduces their proliferation.	Paclitaxel	67-77	neurofilament, light polypeptide	Mus musculus	99-102
23478574-2	2013	In the present study, we show that paclitaxel induces MDR1 expression in the MCF-7 breast cancer cell line in a MAPK/Egr-1-dependent manner.	Paclitaxel	35-45	early growth response 1	Homo sapiens	117-122
9887359-9	1998	When taxol, which inhibits microtubule depolymerization, was added to the culture medium of neoT cells, a polymerized microtubule network was observed, and the reclustering of cathepsin D and lamp-1 occurred in an unidirectional manner towards the perinuclear region.	Paclitaxel	5-10	lysosomal associated membrane protein 1	Homo sapiens	192-198
23478574-3	2013	Paclitaxel exposure activated the Erk1/2/MAPK pathway and promoted the accumulation of the early response transcription factor Egr-1 in MCF-7 cells.	Paclitaxel	0-10	early growth response 1	Homo sapiens	127-132
23478574-5	2013	Loss of Egr-1 function in paclitaxel-resistant MCF-7 cells decreased MDR1 expression, whereas inhibiting Erk1/2 activity reduced both Egr-1 accumulation and MDR1 expression.	Paclitaxel	26-36	early growth response 1	Homo sapiens	8-13
9322876-4	1997	The drugs both undergo hepatic metabolism; however, the specific cytochrome P-450 (CYP) enzymes responsible for hydroxylation are CYP 2C8 for paclitaxel and CYP 3A4 for docetaxel.	Paclitaxel	142-152	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	130-137
23478574-6	2013	These findings suggest that Erk1/2-induced Egr-1 accumulation activates MDR1 transcription and thereby induces the drug resistance observed in paclitaxel-resistant MCF-7 cells.	Paclitaxel	143-153	early growth response 1	Homo sapiens	43-48
23318472-6	2013	In cultured renal tubular HK-2 cells, paclitaxel decreased the DNA-binding activity of nuclear factor-kappaB (NF-kappaB) during LPS treatment, inhibited the degradation of the inhibitor of kappaB-alpha, and blocked the expression and activation of NF-kappaB p65.	Paclitaxel	38-48	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	258-261
29162879-5	2017	Moreover, miR-30e regulates cell proliferation, migration, invasion and increases chemosensitivity of MDA-MB-231 cells to paclitaxel by inhibiting its target IRS1.	Paclitaxel	122-132	insulin receptor substrate 1	Homo sapiens	158-162
9245792-9	1997	In cells recovering from nocodazole treatment and in taxol-treated mitotic cells, IAK1 is associated with microtubule organizing centers.	Paclitaxel	53-58	aurora kinase A	Mus musculus	82-86
28923854-11	2017	In mouse xenograft models, cancer cells, where Cav-1 was attenuated, exhibited resistance to the antitumor effects of nab-paclitaxel therapy.	Paclitaxel	122-132	caveolin 1, caveolae protein	Mus musculus	47-52
31271140-11	2017	In addition, we revealed that free paclitaxel treatment resulted in higher levels of IL-6, IL-10, PDL-1, TGF-beta1, TNF-alpha and VEGF, while the expression levels of these inflammatory factors were much lower in the other two groups, especially in the Nano-PTX-GEL treated groups.	Paclitaxel	35-45	CD274 molecule	Homo sapiens	98-103
29072615-8	2017	Collectively, our data show that LSS-11 is a potent naphthalimide-based chemosensitizer that could enhance cell death in paclitaxel-resistant lung cancer cells through the DR5/PARP1 pathway and STAT3/MDR1/MRP1 STAT3 inhibition.	Paclitaxel	121-131	TNF receptor superfamily member 10b	Homo sapiens	172-175
29093604-11	2017	Conclusion: Further in-depth studies are needed to investigate the functions of cytokines CCL2, CCL5 and IL-6 in endometrial cancer cells treated with paclitaxel.	Paclitaxel	151-161	C-C motif chemokine ligand 2	Homo sapiens	90-94
23318472-7	2013	At the upstream level, paclitaxel reduced LPS-induced association of myeloid differentiation protein-2 (MD-2) with Toll-like receptor 4 (TLR4).	Paclitaxel	23-33	lymphocyte antigen 96	Mus musculus	69-102
32260700-9	2013	Confocal laser scanning microscopy (CLSM) and flow cytometric analysis suggested that HeLa cell death induced by free PTX or PTX-loaded PHNRs occurred via apoptosis, which was detected by Annexin V antibody and propidium iodide staining.	Paclitaxel	118-121	annexin A5	Homo sapiens	188-197
32260700-9	2013	Confocal laser scanning microscopy (CLSM) and flow cytometric analysis suggested that HeLa cell death induced by free PTX or PTX-loaded PHNRs occurred via apoptosis, which was detected by Annexin V antibody and propidium iodide staining.	Paclitaxel	125-128	annexin A5	Homo sapiens	188-197
29552052-12	2017	( The mRNA expression of androgen receptor (AR) and prostate specific antigen (PSA) decreased in paclitaxel and noscapine combination-treated of LNCaP cells (P&lt;0.05).	Paclitaxel	97-107	kallikrein related peptidase 3	Homo sapiens	52-77
23537295-6	2013	In addition, immunohistochemical studies on mouse tumors injected with cisplatin or paclitaxel treated residual cells displayed higher staining for the proliferative antigen Ki67, oncogeneic CA125, epithelial E-cadherin as well as cancer stem cell markers such as Oct4 and CD117, compared to mice injected with control untreated cells.	Paclitaxel	84-94	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	273-278
9231713-3	1997	Down-regulation of both ET(B) receptor mRNA and the number of binding sites for ET-1 was also observed in quiescent astrocytes treated with taxol, a microtubule-stabilizing agent.	Paclitaxel	140-145	endothelin receptor type B	Rattus norvegicus	24-29
9174131-5	1997	Ovcar-3 cell attachment, migration and in vitro invasion were significantly decreased after paclitaxel treatment (P = 0.02, P &lt; 0.01 and P = 0.001, respectively) whereas no alteration in the secretion of latent MMP-2 was noted.	Paclitaxel	92-102	matrix metallopeptidase 2	Homo sapiens	214-219
23552883-5	2013	We found that miR-31 was downregulated in KFr13Tx cells, and that re-introduction of miR31 re-sensitized them to PTX both in vitro and in vivo.	Paclitaxel	113-116	microRNA 31	Homo sapiens	85-90
23552883-6	2013	miR-31 was found to bind to the 3"-UTR of mRNA of MET, and the decrease in MET correlated to higher sensitivity to PTX.	Paclitaxel	115-118	microRNA 31	Homo sapiens	0-6
23552883-8	2013	In addition, lower levels of miR31 and higher expression of MET in human ovarian cancer specimens were significantly correlated with PTX chemoresistance and poor prognosis.	Paclitaxel	133-136	microRNA 31	Homo sapiens	29-34
23552883-9	2013	This study demonstrated miR31-dependent regulation of MET for chemoresistance of ovarian cancer, raising the possibility that combination therapy with a MET inhibitor and PTX will increase PTX efficacy.	Paclitaxel	171-174	microRNA 31	Homo sapiens	24-29
23552883-9	2013	This study demonstrated miR31-dependent regulation of MET for chemoresistance of ovarian cancer, raising the possibility that combination therapy with a MET inhibitor and PTX will increase PTX efficacy.	Paclitaxel	189-192	microRNA 31	Homo sapiens	24-29
23333498-0	2013	Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation.	Paclitaxel	84-94	telomerase reverse transcriptase	Homo sapiens	134-139
23264559-11	2013	Sub-nanomolar concentrations of the microtubule-binding drugs, paclitaxel and vinblastine, increased acetylated alpha-tubulin levels in patient cells to control levels, indicating the utility of this cell model for screening other candidate compounds for drug therapies.	Paclitaxel	63-73	tubulin alpha 1b	Homo sapiens	112-125
23364970-9	2013	AGS cells were treated with anti-VEGFR-1, anti-VEGFR-2, placental growth factor (PlGF), bevacizuamb, and paclitaxel.	Paclitaxel	105-115	jagged canonical Notch ligand 1	Homo sapiens	0-3
23879997-8	2013	When DNA damage occurred in A375 cells exposed to paclitaxel, expression of P-EGFR, P-ERK and P-AKT proteins was increased.	Paclitaxel	50-60	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	84-89
23228696-4	2013	In this current study, paclitaxel was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.	Paclitaxel	23-33	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	182-187
23228696-5	2013	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).	Paclitaxel	10-20	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	29-34
23228696-6	2013	Specific inhibition of ERCC1 with siRNA was found to enhance the paclitaxel-induced cytotoxic effect and growth inhibition.	Paclitaxel	65-75	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	23-28
23199742-9	2013	In conclusion, the VEGF/PTX NP-coated stents promote early endothelium healing while inhibit smooth muscle cell proliferation through sequential release of the VEGF gene and paclitaxel.	Paclitaxel	24-27	vascular endothelial growth factor A	Sus scrofa	160-164
23199742-9	2013	In conclusion, the VEGF/PTX NP-coated stents promote early endothelium healing while inhibit smooth muscle cell proliferation through sequential release of the VEGF gene and paclitaxel.	Paclitaxel	174-184	vascular endothelial growth factor A	Sus scrofa	19-23
23223572-5	2013	In mec-7 mutants, the ALM mechanosensory neuron forms a long ectopic neurite that extends posteriorly, a phenotype that can be mimicked in wild-type worms with a microtubule-stabilizing drug (paclitaxel), and suppressed by mutations in unc-33/CRMP2 and the kinesin-related gene, vab-8.	Paclitaxel	192-202	Amidohydro-rel domain-containing protein;Protein unc-33	Caenorhabditis elegans	236-242
23697160-3	2013	Based on our research over the years, we reviewed the latest developments in signaling pathways, the effects of related genes and proteins on apoptosis during paclitaxel-induced apoptosis process, including the paclitaxel-producing gene in microbial fermentation process, cyclin, telomerase of apoptosis.	Paclitaxel	159-169	proliferating cell nuclear antigen	Homo sapiens	272-278
23484165-11	2013	The main mechanisms of drug resistance were due to P-gp expression in the doxorubicin, vincristine, and paclitaxel resistant cell lines and BCRP expression in the topotecan resistant cell line.	Paclitaxel	104-114	phosphoglycolate phosphatase	Homo sapiens	51-55
23378760-0	2013	The combined use of paclitaxel-loaded nanoparticles with a low-molecular-weight copolymer inhibitor of P-glycoprotein to overcome drug resistance.	Paclitaxel	20-30	PGP	Canis lupus familiaris	103-117
23378760-5	2013	Furthermore, the cytotoxicity of these PTX-loaded nanoparticles was enhanced when these systems were subsequently or concurrently combined with a low-molecular-weight MePEG-b-PCL diblock copolymer, which we have previously demonstrated to be an effective P-gp inhibitor.	Paclitaxel	39-42	PGP	Canis lupus familiaris	255-259
23378760-6	2013	These results suggest that the dual functionality of MePEG-b-PCL might be useful in delivering drug intracellularly and in modulating P-gp in order to optimize the cytotoxicity of PTX in multidrug-resistant cells.	Paclitaxel	180-183	PGP	Canis lupus familiaris	134-138
23379109-3	2013	Preclinical data indicated an increase of drug accumulation in tumor tissues via nab-paclitaxel administration which appears to be related to direct interaction with albumin-binding proteins including stromal SPARC.	Paclitaxel	85-95	secreted protein acidic and cysteine rich	Homo sapiens	209-214
23128493-7	2013	ESC cells with high levels of BubR1 were less             sensitive to the anti-microtubule drugs paclitaxel and nocodazole.	Paclitaxel	98-108	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	30-35
23128493-8	2013	Recombinant             adenovirus-mediated enforced expression of BubR1 in relatively sensitive ESC cell             lines resulted in increased resistance to paclitaxel.	Paclitaxel	160-170	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	67-72
23128493-9	2013	Conversely, RNAi-mediated             knockdown of BubR1 restored ESC cell sensitivity to paclitaxel.	Paclitaxel	90-100	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	51-56
23128493-11	2013	Taken together, our results suggest that upregulation of BubR1 expression             may be associated with ESC resistance to paclitaxel treatment.	Paclitaxel	127-137	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	57-62
23577147-7	2013	A Cdk inhibitor, roscovitine, blocked paclitaxel-induced MCL-1 degradation and apoptosis, suggesting that Cdk activation at mitotic arrest could induce subsequent MCL-1 degradation in a proteasome-dependent manner.	Paclitaxel	38-48	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	57-62
23577147-7	2013	A Cdk inhibitor, roscovitine, blocked paclitaxel-induced MCL-1 degradation and apoptosis, suggesting that Cdk activation at mitotic arrest could induce subsequent MCL-1 degradation in a proteasome-dependent manner.	Paclitaxel	38-48	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	163-168
23393594-2	2013	MRP7 is highly expressed in non-small cell lung cancer cells, and Mrp7-KO mice are highly sensitive to paclitaxel, making MRP7 an attractive chemotherapeutic target of non-small cell lung cancer.	Paclitaxel	103-113	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	66-70
23393594-2	2013	MRP7 is highly expressed in non-small cell lung cancer cells, and Mrp7-KO mice are highly sensitive to paclitaxel, making MRP7 an attractive chemotherapeutic target of non-small cell lung cancer.	Paclitaxel	103-113	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	122-126
23393594-5	2013	We found that tariquidar, at 0.1 and 0.3 microM, significantly potentiated the sensitivity of MRP7-transfected HEK293 cells to MRP7 substrates and increased the intracellular accumulation of paclitaxel.	Paclitaxel	191-201	ATP binding cassette subfamily C member 10	Homo sapiens	94-98
24026363-0	2013	The ClC-3 chloride channel associated with microtubules is a target of paclitaxel in its induced-apoptosis.	Paclitaxel	71-81	chloride voltage-gated channel 3	Homo sapiens	4-9
24026363-5	2013	After ClC-3 was knocked-down by ClC-3-siRNA, hypotonicity-activated and paclitaxel-induced chloride currents were obviously decreased, indicating that the chloride channel involved in paclitaxel-induced apoptosis may be ClC-3.	Paclitaxel	72-82	chloride voltage-gated channel 3	Homo sapiens	6-11
24026363-5	2013	After ClC-3 was knocked-down by ClC-3-siRNA, hypotonicity-activated and paclitaxel-induced chloride currents were obviously decreased, indicating that the chloride channel involved in paclitaxel-induced apoptosis may be ClC-3.	Paclitaxel	72-82	chloride voltage-gated channel 3	Homo sapiens	32-37
24026363-5	2013	After ClC-3 was knocked-down by ClC-3-siRNA, hypotonicity-activated and paclitaxel-induced chloride currents were obviously decreased, indicating that the chloride channel involved in paclitaxel-induced apoptosis may be ClC-3.	Paclitaxel	72-82	chloride voltage-gated channel 3	Homo sapiens	32-37
24026363-5	2013	After ClC-3 was knocked-down by ClC-3-siRNA, hypotonicity-activated and paclitaxel-induced chloride currents were obviously decreased, indicating that the chloride channel involved in paclitaxel-induced apoptosis may be ClC-3.	Paclitaxel	184-194	chloride voltage-gated channel 3	Homo sapiens	6-11
24026363-5	2013	After ClC-3 was knocked-down by ClC-3-siRNA, hypotonicity-activated and paclitaxel-induced chloride currents were obviously decreased, indicating that the chloride channel involved in paclitaxel-induced apoptosis may be ClC-3.	Paclitaxel	184-194	chloride voltage-gated channel 3	Homo sapiens	32-37
24026363-5	2013	After ClC-3 was knocked-down by ClC-3-siRNA, hypotonicity-activated and paclitaxel-induced chloride currents were obviously decreased, indicating that the chloride channel involved in paclitaxel-induced apoptosis may be ClC-3.	Paclitaxel	184-194	chloride voltage-gated channel 3	Homo sapiens	32-37
24026363-7	2013	These suggest that ClC-3 is a critical target of paclitaxel and the involvement of ClC-3 in apoptosis may be associated with its accumulation with membrane microtubules and its over activation.	Paclitaxel	49-59	chloride voltage-gated channel 3	Homo sapiens	19-24
23087055-2	2012	Abcc10(-/-) mice exhibit increased tissue sensitivity and lethality resulting from paclitaxel exposure compared with wild-type counterparts, arguing ABCC10 functions as a major determinant of taxane sensitivity in mice.	Paclitaxel	83-93	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	0-6
23087055-6	2012	In addition, a number of cytotoxic substrates, including docetaxel, paclitaxel, and Ara-C, increased the ABCC10 basal ATPase activity.	Paclitaxel	68-78	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	105-111
23087055-9	2012	Thus, concomitant use of these agents might restore the intracellular accumulation and potency of ABCC10-exported cytotoxic drugs, such as paclitaxel.	Paclitaxel	139-149	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	98-104
23095743-3	2012	Acquired resistance of ER-MC cells to either ionizing radiation (IR) or paclitaxel was accompanied by increased ARTN expression.	Paclitaxel	72-82	artemin	Homo sapiens	112-116
23095743-4	2012	Small interfering RNA (siRNA)-mediated depletion of ARTN in either IR- or paclitaxel-resistant ER-MC cells restored cell sensitivity to IR or paclitaxel.	Paclitaxel	74-84	artemin	Homo sapiens	52-56
23095743-4	2012	Small interfering RNA (siRNA)-mediated depletion of ARTN in either IR- or paclitaxel-resistant ER-MC cells restored cell sensitivity to IR or paclitaxel.	Paclitaxel	142-152	artemin	Homo sapiens	52-56
22544540-6	2012	Additionally, our previous study proved that TIMP-1 significantly decreased the sensitivity of breast cancer cells to paclitaxel-induced apoptosis by enhancing degradation of cyclin B1.	Paclitaxel	118-128	cyclin B1	Homo sapiens	175-184
23023313-6	2012	Western blot analysis using whole cell lysates             from MCF-7 and MDA-MB-231 cells treated with taxol demonstrated that taxol treatment             inhibited expression of cyclin A and cyclin B1 proteins in a time-dependent manner.	Paclitaxel	104-109	cyclin B1	Homo sapiens	193-202
23023313-6	2012	Western blot analysis using whole cell lysates             from MCF-7 and MDA-MB-231 cells treated with taxol demonstrated that taxol treatment             inhibited expression of cyclin A and cyclin B1 proteins in a time-dependent manner.	Paclitaxel	128-133	cyclin B1	Homo sapiens	193-202
22965228-5	2012	We show that when treated with Taxol, slippage-resistant HT29 colon carcinoma cells display robust Cdk1 activity and extensive Mcl-1/Bcl-x(L) phosphorylation and die in mitosis, whereas slippage-prone DLD-1 colon carcinoma cells display weak Cdk1 activity and partial and transient Mcl-1/Bcl-x(L) phosphorylation and die in subsequent interphase or survive.	Paclitaxel	31-36	cyclin dependent kinase 1	Homo sapiens	99-103
22965228-5	2012	We show that when treated with Taxol, slippage-resistant HT29 colon carcinoma cells display robust Cdk1 activity and extensive Mcl-1/Bcl-x(L) phosphorylation and die in mitosis, whereas slippage-prone DLD-1 colon carcinoma cells display weak Cdk1 activity and partial and transient Mcl-1/Bcl-x(L) phosphorylation and die in subsequent interphase or survive.	Paclitaxel	31-36	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	127-132
22965228-5	2012	We show that when treated with Taxol, slippage-resistant HT29 colon carcinoma cells display robust Cdk1 activity and extensive Mcl-1/Bcl-x(L) phosphorylation and die in mitosis, whereas slippage-prone DLD-1 colon carcinoma cells display weak Cdk1 activity and partial and transient Mcl-1/Bcl-x(L) phosphorylation and die in subsequent interphase or survive.	Paclitaxel	31-36	cyclin dependent kinase 1	Homo sapiens	242-246
22965228-5	2012	We show that when treated with Taxol, slippage-resistant HT29 colon carcinoma cells display robust Cdk1 activity and extensive Mcl-1/Bcl-x(L) phosphorylation and die in mitosis, whereas slippage-prone DLD-1 colon carcinoma cells display weak Cdk1 activity and partial and transient Mcl-1/Bcl-x(L) phosphorylation and die in subsequent interphase or survive.	Paclitaxel	31-36	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	282-287
22871423-1	2012	We developed a paclitaxel-conjugated polymeric micelle, ABP-PEG3.5k-Paclitaxel (APP) consisting of poly (ethylene glycol) (PEG) and arginine-grafted poly (cystaminebisacrylamide-diaminohexane) (ABP) for the co-delivery of gene and drug.	Paclitaxel	15-25	amine oxidase, copper-containing 1	Mus musculus	56-59
22871423-1	2012	We developed a paclitaxel-conjugated polymeric micelle, ABP-PEG3.5k-Paclitaxel (APP) consisting of poly (ethylene glycol) (PEG) and arginine-grafted poly (cystaminebisacrylamide-diaminohexane) (ABP) for the co-delivery of gene and drug.	Paclitaxel	15-25	amine oxidase, copper-containing 1	Mus musculus	194-197
22871423-1	2012	We developed a paclitaxel-conjugated polymeric micelle, ABP-PEG3.5k-Paclitaxel (APP) consisting of poly (ethylene glycol) (PEG) and arginine-grafted poly (cystaminebisacrylamide-diaminohexane) (ABP) for the co-delivery of gene and drug.	Paclitaxel	68-78	amine oxidase, copper-containing 1	Mus musculus	56-59
22847181-8	2012	In addition, paclitaxel-induced Stat3 activation led to the upregulation of survivin and Mcl-1, which in turn facilitated cell survival.	Paclitaxel	13-23	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	89-94
22847181-10	2012	Treatment with paclitaxel activated Stat3 in CL1-5 but not in CL1-0 cells, whereas in CL1-5 cells, the overexpression of UCP-2 with complementary DNA (cDNA) blocked Stat3 activation.	Paclitaxel	15-25	adhesion G protein-coupled receptor L1	Homo sapiens	45-48
23030458-10	2012	The human MDR1 gene-transfected and thus paclitaxel-resistant MDCKII-MDR1 P-gp overexpressing cells were used for cytotoxicity evaluation.	Paclitaxel	41-51	phosphoglycolate phosphatase	Homo sapiens	74-78
23060048-6	2012	The combination of PD173074 with paclitaxel or doxorubicin showed synergistic activity in the 3 FGFR2 mutant cell lines evaluated.	Paclitaxel	33-43	fibroblast growth factor receptor 2	Homo sapiens	96-101
23060048-7	2012	In addition, although nonmutant cell lines were resistant to FGFR inhibition alone, the addition of PD173074 potentiated the cytostatic effect of paclitaxel and doxorubicin in a subset of FGFR2 wild-type endometrial cancer cell lines.	Paclitaxel	146-156	fibroblast growth factor receptor 2	Homo sapiens	188-193
22896703-7	2012	Interestingly, the inhibition of HOXC6 using siRNA led to the repression of Bcl-2 expression and induced caspase-3-dependent apoptosis; overexpression of HOXC6 in HNSCC cells increased the resistance to paclitaxel-induced apoptosis.	Paclitaxel	203-213	homeobox C6	Homo sapiens	33-38
22896703-7	2012	Interestingly, the inhibition of HOXC6 using siRNA led to the repression of Bcl-2 expression and induced caspase-3-dependent apoptosis; overexpression of HOXC6 in HNSCC cells increased the resistance to paclitaxel-induced apoptosis.	Paclitaxel	203-213	homeobox C6	Homo sapiens	154-159
22877735-6	2012	The incorporation of Ptx in GM1 reached an optimum at GM1/Ptx 20/1 molar ratio when performed at room temperature.	Paclitaxel	21-24	paired like homeodomain 1	Homo sapiens	54-66
22613208-7	2012	The drug-loaded cationic micelles can then interact with siRNA to form stable complexes (PTX/DA3/siRNA).	Paclitaxel	89-92	piezo type mechanosensitive ion channel component 2	Homo sapiens	93-96
22918237-7	2012	Furthermore, the depletion of 4E-BP1 sensitized HepG2 and HeLa cells to the microtubule disruption agent paclitaxel.	Paclitaxel	105-115	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	30-36
22743248-0	2012	Icariside II potentiates paclitaxel-induced apoptosis in human melanoma A375 cells by inhibiting TLR4 signaling pathway.	Paclitaxel	25-35	toll like receptor 4	Homo sapiens	97-101
22743248-8	2012	Recent studies suggest that TLR4-MyD88-ERK signaling may be a novel target for reversing chemoresistance to paclitaxel.	Paclitaxel	108-118	toll like receptor 4	Homo sapiens	28-32
22743248-9	2012	Our flow cytometry and Western blot data showed that paclitaxel activated TLR4-MyD88-ERK signaling and that IS treatment could effectively inhibit this paclitaxel-induced activation of TLR4-MyD88-ERK signaling.	Paclitaxel	53-63	toll like receptor 4	Homo sapiens	74-78
22743248-9	2012	Our flow cytometry and Western blot data showed that paclitaxel activated TLR4-MyD88-ERK signaling and that IS treatment could effectively inhibit this paclitaxel-induced activation of TLR4-MyD88-ERK signaling.	Paclitaxel	53-63	toll like receptor 4	Homo sapiens	185-189
22743248-9	2012	Our flow cytometry and Western blot data showed that paclitaxel activated TLR4-MyD88-ERK signaling and that IS treatment could effectively inhibit this paclitaxel-induced activation of TLR4-MyD88-ERK signaling.	Paclitaxel	152-162	toll like receptor 4	Homo sapiens	185-189
23019416-5	2012	Consistent with the hypothesis that tubulin deacetylase activity might affect cell response to the anti-motility activity of taxanes, we found that overexpression of the tubulin deacetylase SIRT2 increased cell motility and reduced cell response to the anti-motility activity of paclitaxel.	Paclitaxel	279-289	sirtuin 2	Homo sapiens	190-195
23019416-6	2012	Conversely, the SIRT2 inhibitor splitomicin reduced cell motility and potentiated the anti-motility activity of paclitaxel.	Paclitaxel	112-122	sirtuin 2	Homo sapiens	16-21
22374518-11	2012	In summary, this study demonstrated that E2/ERalpha attenuates therapeutic efficacy of paclitaxel in an isogenic ERalpha+ xenograft model.	Paclitaxel	87-97	estrogen receptor 1 (alpha)	Mus musculus	44-51
22437668-9	2012	A subset of SLC genes, namely SLC31A2, SLC43A1, SLC35A5, and SLC41A2, was associated with paclitaxel sensitivity and had regulating single nucleotide polymorphisms that were also associated with paclitaxel-induced cytotoxicity.	Paclitaxel	90-100	solute carrier family 31 member 2	Homo sapiens	30-37
22437668-9	2012	A subset of SLC genes, namely SLC31A2, SLC43A1, SLC35A5, and SLC41A2, was associated with paclitaxel sensitivity and had regulating single nucleotide polymorphisms that were also associated with paclitaxel-induced cytotoxicity.	Paclitaxel	90-100	solute carrier family 35 member A5	Homo sapiens	48-55
22437668-9	2012	A subset of SLC genes, namely SLC31A2, SLC43A1, SLC35A5, and SLC41A2, was associated with paclitaxel sensitivity and had regulating single nucleotide polymorphisms that were also associated with paclitaxel-induced cytotoxicity.	Paclitaxel	195-205	solute carrier family 31 member 2	Homo sapiens	30-37
22437668-9	2012	A subset of SLC genes, namely SLC31A2, SLC43A1, SLC35A5, and SLC41A2, was associated with paclitaxel sensitivity and had regulating single nucleotide polymorphisms that were also associated with paclitaxel-induced cytotoxicity.	Paclitaxel	195-205	solute carrier family 35 member A5	Homo sapiens	48-55
22437668-11	2012	Using RNA interference, we demonstrated increased paclitaxel susceptibility with knockdown of three SLC genes, SLC31A2, SLC35A5, and SLC41A2.	Paclitaxel	50-60	solute carrier family 31 member 2	Homo sapiens	111-118
22437668-11	2012	Using RNA interference, we demonstrated increased paclitaxel susceptibility with knockdown of three SLC genes, SLC31A2, SLC35A5, and SLC41A2.	Paclitaxel	50-60	solute carrier family 35 member A5	Homo sapiens	120-127
22673514-5	2012	CRSBP-1 ligands stimulate contraction of the ER network in a CRSBP-1-dependent and paclitaxel (a microtubule-stabilizing agent)-sensitive manner.	Paclitaxel	83-93	lymphatic vessel endothelial hyaluronan receptor 1	Homo sapiens	0-7
22489661-7	2012	Interestingly, both radiation and paclitaxel significantly increased PTEN protein expression and phosphorylation.	Paclitaxel	34-44	phosphatase and tensin homolog	Homo sapiens	69-73
22489661-8	2012	Further identification of the affected PTEN downstream molecules showed that Akt phosphorylation at Ser(473) and Thr(308) residues was significantly decreased, whereas Bax and cleaved caspase-3 levels were significantly increased in tumor tissues treated with both radiation and paclitaxel.	Paclitaxel	279-289	phosphatase and tensin homolog	Homo sapiens	39-43
22489661-11	2012	CONCLUSIONS: Our study suggested that a PTEN-PI3K-Akt-Bax signaling cascade is involved in the therapeutic effect of combined radiation/paclitaxel treatment in NSCLC without p53 expression.	Paclitaxel	136-146	phosphatase and tensin homolog	Homo sapiens	40-44
22506922-3	2012	In this study, paclitaxel (PTX) was co-encapsulated in actively targeted (anticancer mAb 2C5-modified) polymeric lipid-core PEG-PE-based micelles with Cyclosporine A (CycA), which is one of the most effective first generation P-gp inhibitors.	Paclitaxel	15-25	PGP	Canis lupus familiaris	226-230
22506922-3	2012	In this study, paclitaxel (PTX) was co-encapsulated in actively targeted (anticancer mAb 2C5-modified) polymeric lipid-core PEG-PE-based micelles with Cyclosporine A (CycA), which is one of the most effective first generation P-gp inhibitors.	Paclitaxel	27-30	PGP	Canis lupus familiaris	226-230
22506922-8	2012	P-gp inhibition with CycA caused an increase in the cytotoxicity of PTX.	Paclitaxel	68-71	PGP	Canis lupus familiaris	0-4
21618519-6	2012	Introducing let-7g into ADR-RES cells expressing both IMP-1 and MDR1 reduced expression of both proteins rendering the cells more sensitive to treatment with either Taxol or vinblastine without affecting the sensitivity of the cells to carboplatin, a non-MDR1 substrate.	Paclitaxel	165-170	microRNA let-7g	Homo sapiens	12-18
22134971-2	2012	Exposure of cells to taxol induced time-dependent cytotoxicity and cytoplasmic vacuolization without the involvement of Bax, Bak, Mcl-1, Bcl-XL, and caspase-3.	Paclitaxel	21-26	BCL2-antagonist/killer 1	Mus musculus	125-128
22069160-4	2012	The mitotic arrest deficiency protein 2 (MAD2), is a centrally important mediator of the cellular response to paclitaxel.	Paclitaxel	110-120	mitotic arrest deficient 2 like 1	Homo sapiens	4-39
22069160-4	2012	The mitotic arrest deficiency protein 2 (MAD2), is a centrally important mediator of the cellular response to paclitaxel.	Paclitaxel	110-120	mitotic arrest deficient 2 like 1	Homo sapiens	41-45
22069160-7	2012	The in vitro analyses of five ovarian cancer cell lines demonstrated that cells with low MAD2 expression were less sensitive to paclitaxel.	Paclitaxel	128-138	mitotic arrest deficient 2 like 1	Homo sapiens	89-93
22069160-8	2012	Furthermore, paclitaxel-induced activation of the spindle assembly checkpoint (SAC) and apoptotic cell death was abrogated in cells transfected with MAD2 siRNA.	Paclitaxel	13-23	mitotic arrest deficient 2 like 1	Homo sapiens	149-153
22069160-13	2012	Importantly, reduced MAD2 protein expression in pre-miR-433-transfected A2780 cells rendered these cells less sensitive to paclitaxel.	Paclitaxel	123-133	mitotic arrest deficient 2 like 1	Homo sapiens	21-25
22069160-13	2012	Importantly, reduced MAD2 protein expression in pre-miR-433-transfected A2780 cells rendered these cells less sensitive to paclitaxel.	Paclitaxel	123-133	microRNA 433	Homo sapiens	52-59
22069160-14	2012	In conclusion, loss of MAD2 protein expression results in increased resistance to paclitaxel in EOC cells.	Paclitaxel	82-92	mitotic arrest deficient 2 like 1	Homo sapiens	23-27
22069160-15	2012	Measuring MAD2 IHC staining intensity may predict paclitaxel responses in women presenting with high-grade serous EOC.	Paclitaxel	50-60	mitotic arrest deficient 2 like 1	Homo sapiens	10-14
22258694-0	2012	TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism.	Paclitaxel	24-34	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	10-15
28729222-11	2017	Spinal cord immunohistochemistry revealed that preventive treatment with BCP reduced p38 MAPK and NF-kappaB activation, as well as the increased Iba-1 and IL-1beta immunoreactivity promoted by PTX.	Paclitaxel	193-196	induction of brown adipocytes 1	Mus musculus	145-150
29190892-5	2017	This H19 overexpression was contributed to cancer cell resistance to anthracyclines and paclitaxel as knockdown of H19 lncRNA by a specific H19 shRNA in Dox-resistant cells significantly improved the cell sensitivity to anthracyclines and paclitaxel.	Paclitaxel	88-98	H19 imprinted maternally expressed transcript	Homo sapiens	5-8
29190892-5	2017	This H19 overexpression was contributed to cancer cell resistance to anthracyclines and paclitaxel as knockdown of H19 lncRNA by a specific H19 shRNA in Dox-resistant cells significantly improved the cell sensitivity to anthracyclines and paclitaxel.	Paclitaxel	88-98	H19 imprinted maternally expressed transcript	Homo sapiens	115-118
29190892-5	2017	This H19 overexpression was contributed to cancer cell resistance to anthracyclines and paclitaxel as knockdown of H19 lncRNA by a specific H19 shRNA in Dox-resistant cells significantly improved the cell sensitivity to anthracyclines and paclitaxel.	Paclitaxel	88-98	H19 imprinted maternally expressed transcript	Homo sapiens	115-118
29190892-5	2017	This H19 overexpression was contributed to cancer cell resistance to anthracyclines and paclitaxel as knockdown of H19 lncRNA by a specific H19 shRNA in Dox-resistant cells significantly improved the cell sensitivity to anthracyclines and paclitaxel.	Paclitaxel	239-249	H19 imprinted maternally expressed transcript	Homo sapiens	5-8
29190892-5	2017	This H19 overexpression was contributed to cancer cell resistance to anthracyclines and paclitaxel as knockdown of H19 lncRNA by a specific H19 shRNA in Dox-resistant cells significantly improved the cell sensitivity to anthracyclines and paclitaxel.	Paclitaxel	239-249	H19 imprinted maternally expressed transcript	Homo sapiens	115-118
29190892-5	2017	This H19 overexpression was contributed to cancer cell resistance to anthracyclines and paclitaxel as knockdown of H19 lncRNA by a specific H19 shRNA in Dox-resistant cells significantly improved the cell sensitivity to anthracyclines and paclitaxel.	Paclitaxel	239-249	H19 imprinted maternally expressed transcript	Homo sapiens	115-118
29158806-4	2017	Results : The higher expression levels of ALDH1 and Notch related genes, especially Notch3 were associated with CSCs and with chemoresistant OSCs and paclitaxel-resistant SKpac ovarian cancer cells.	Paclitaxel	150-160	aldehyde dehydrogenase 1 family member A1	Homo sapiens	42-47
29158806-4	2017	Results : The higher expression levels of ALDH1 and Notch related genes, especially Notch3 were associated with CSCs and with chemoresistant OSCs and paclitaxel-resistant SKpac ovarian cancer cells.	Paclitaxel	150-160	notch receptor 3	Homo sapiens	84-90
29113360-6	2017	Cell viability and Annexin V/PI staining showed that miR-488 downregulated cell survival and increased apoptosis rate when treated with cisplatin and paclitaxel.	Paclitaxel	150-160	annexin A5	Homo sapiens	19-28
28604143-8	2017	NLG919 can potentiate the antitumor efficacy of paclitaxel without increasing its side effects, suggesting that the combination of IDO inhibitor-based immunotherapy with chemotherapy could be a potential strategy for cancer treatment.	Paclitaxel	48-58	indoleamine 2,3-dioxygenase 1	Mus musculus	131-134
29137407-4	2017	Knockdown of SNHG12 reversed the resistance to cisplatin, paclitaxel and gefitinib in A549/DDP, A549/PTX and PC9/AB2 cells through inducing cell apoptosis.	Paclitaxel	58-68	proprotein convertase subtilisin/kexin type 9	Homo sapiens	109-112
29228548-7	2017	The addition of a CSF1R inhibitor restored response to anti-angiogenesis therapy, resulting in 83% lower tumor burden compared to treatment with anti-VEGF antibody and paclitaxel alone.	Paclitaxel	168-178	colony stimulating factor 1 receptor	Mus musculus	18-23
28817737-9	2017	Myc/MDA-468 cells were resistant to standard chemotherapeutic treatments such as iniparib (PARP inhibitor) plus cisplatin, / iniparib, cisplatin, paclitaxel and docetaxel.	Paclitaxel	146-156	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-3
28817737-10	2017	However, Myc/MDA-231 cells, which showed EMT changes responded to iniparib with cisplatin, but were resistant to other drugs, such as iniparib, cisplatin, paclitaxel and docetaxel.	Paclitaxel	155-165	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	9-12
28796259-8	2017	Moreover, co-administration of the inhibitors of MUC1-EGFR-ABCB1 with paclitaxel significantly blocked not only tumor growth but also relapse in xenograft mouse model.	Paclitaxel	70-80	epidermal growth factor receptor	Mus musculus	54-58
28576551-2	2017	Herein, a new ligand-PEG-lipid conjugate, E-selectin binding peptide-polyethene glycol-1-octadecylamine (Esbp-PEG-OA), was used as the targeting molecule of micelle self-assembled form hyaluronic acid-paclitaxel (HA-PTX) conjugate.	Paclitaxel	201-211	selectin E	Homo sapiens	42-52
28600629-0	2017	Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance to paclitaxel in lung adenocarcinoma.	Paclitaxel	71-81	KCNQ1 opposite strand/antisense transcript 1	Homo sapiens	33-41
28600629-7	2017	The expression of KCNQ1OT1 in LAD patients insensitive to paclitaxel was much higher than that in LAD patients sensitive to paclitaxel; the KCNQ1OT1 expression in A549/PA cells was also much higher than that in control A549 cells.	Paclitaxel	124-134	KCNQ1 opposite strand/antisense transcript 1	Homo sapiens	18-26
28600629-8	2017	The half maximal inhibitory concentration (IC50) of paclitaxel in A549/PA cells was depressed by KCNQ1OT1 knockdown, chemoresistance of A549/PA cells was inhibited significantly.	Paclitaxel	52-62	KCNQ1 opposite strand/antisense transcript 1	Homo sapiens	97-105
28749468-8	2017	We report that paclitaxel treatment activates both the IRE-1 and PERK kinases and that the increase in paclitaxel-mediated cell death through WWOX is dependent on active ER stress pathway.	Paclitaxel	15-25	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	65-69
28458158-7	2017	Moreover, we found that HCRP1 is negatively correlated with multi-drug resistant related proteins after cells were treated with paclitaxel, cisplatin or gefitinib, indicating its inhibiting effect of chemotherapy resistance.	Paclitaxel	128-138	HCRP1	Homo sapiens	24-29
28534969-0	2017	The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro.	Paclitaxel	73-78	cyclin dependent kinase 1	Homo sapiens	4-8
28534969-0	2017	The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro.	Paclitaxel	73-78	cyclin dependent kinase 1	Homo sapiens	9-13
28534969-0	2017	The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro.	Paclitaxel	73-78	stathmin 1	Homo sapiens	87-91
28534969-0	2017	The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro.	Paclitaxel	73-78	stathmin 1	Homo sapiens	92-100
28534969-3	2017	In this study, the CDK1 inhibitor, purvalanol A was applied to explore the relevance of Cdc2 signaling and taxol sensitivity through analyses, such as cellular proliferation and apoptosis assays, ELISA, western blot analysis and immunoprecipitation.	Paclitaxel	107-112	cyclin dependent kinase 1	Homo sapiens	19-23
28534969-5	2017	In combination, purvalanol A and taxol mainly decreased the expression of oncoprotein 18 (Op18)/stathmin and phosphorylation at Ser16 and Ser38, while purvalanol A alone inhibited the phosphorylation of Op18/stathmin at all 4 serine sites.	Paclitaxel	33-38	stathmin 1	Homo sapiens	74-88
28534969-5	2017	In combination, purvalanol A and taxol mainly decreased the expression of oncoprotein 18 (Op18)/stathmin and phosphorylation at Ser16 and Ser38, while purvalanol A alone inhibited the phosphorylation of Op18/stathmin at all 4 serine sites.	Paclitaxel	33-38	stathmin 1	Homo sapiens	90-94
28534969-5	2017	In combination, purvalanol A and taxol mainly decreased the expression of oncoprotein 18 (Op18)/stathmin and phosphorylation at Ser16 and Ser38, while purvalanol A alone inhibited the phosphorylation of Op18/stathmin at all 4 serine sites.	Paclitaxel	33-38	stathmin 1	Homo sapiens	96-104
28534969-5	2017	In combination, purvalanol A and taxol mainly decreased the expression of oncoprotein 18 (Op18)/stathmin and phosphorylation at Ser16 and Ser38, while purvalanol A alone inhibited the phosphorylation of Op18/stathmin at all 4 serine sites.	Paclitaxel	33-38	stathmin 1	Homo sapiens	203-207
28534969-5	2017	In combination, purvalanol A and taxol mainly decreased the expression of oncoprotein 18 (Op18)/stathmin and phosphorylation at Ser16 and Ser38, while purvalanol A alone inhibited the phosphorylation of Op18/stathmin at all 4 serine sites.	Paclitaxel	33-38	stathmin 1	Homo sapiens	208-216
28396365-0	2017	A Novel Galectin-1 Inhibitor Discovered through One-Bead Two-Compound Library Potentiates the Antitumor Effects of Paclitaxel in vivo.	Paclitaxel	115-125	galectin 1	Homo sapiens	8-18
28714373-7	2017	Finally, we assessed the role of miR-21 in mediating renal cell carcinoma chemoresistance and further showed that miR-21 silencing significantly (1) increased chemosensitivity of paclitaxel, 5-fluorouracil, oxaliplatin, and dovitinib; (2) decreased expression of multi-drug resistance genes; and (4) increased SLC22A1/OCT1, SLC22A2/OCT2, and SLC31A1/CTR1 platinum influx transporter expression.	Paclitaxel	179-189	microRNA 21	Homo sapiens	114-120
28541685-2	2017	Previously, we reported nucleotide-binding oligomerization domain-containing protein 1 (NOD1) antagonists (11, 12) and a NOD2 antagonist (9) that sensitized docetaxel (DTX) or paclitaxel (PTX) treatment for breast or lung cancer.	Paclitaxel	176-186	nucleotide binding oligomerization domain containing 1	Homo sapiens	24-86
28541685-2	2017	Previously, we reported nucleotide-binding oligomerization domain-containing protein 1 (NOD1) antagonists (11, 12) and a NOD2 antagonist (9) that sensitized docetaxel (DTX) or paclitaxel (PTX) treatment for breast or lung cancer.	Paclitaxel	176-186	nucleotide binding oligomerization domain containing 1	Homo sapiens	88-92
28541685-2	2017	Previously, we reported nucleotide-binding oligomerization domain-containing protein 1 (NOD1) antagonists (11, 12) and a NOD2 antagonist (9) that sensitized docetaxel (DTX) or paclitaxel (PTX) treatment for breast or lung cancer.	Paclitaxel	188-191	nucleotide binding oligomerization domain containing 1	Homo sapiens	24-86
28541685-2	2017	Previously, we reported nucleotide-binding oligomerization domain-containing protein 1 (NOD1) antagonists (11, 12) and a NOD2 antagonist (9) that sensitized docetaxel (DTX) or paclitaxel (PTX) treatment for breast or lung cancer.	Paclitaxel	188-191	nucleotide binding oligomerization domain containing 1	Homo sapiens	88-92
28541685-3	2017	In this article, we describe for the first time a 1,4-benzodiazepine-2,5-dione (BZD) derivative (26bh) that acts as a dual NOD1/NOD2 antagonist and inhibits both nuclear factor kappaB (NF-kappaB) and mitogen-activated protein kinase (MAPK) inflammatory signaling, thereby sensitizing PTX to suppress Lewis lung carcinoma (LLC) growth.	Paclitaxel	284-287	nucleotide binding oligomerization domain containing 1	Homo sapiens	123-127
28428276-10	2017	Systemic administration of micelles carrying paclitaxel and rubone inhibited orthotopic prostate tumor growth in nude mice, compared with monotherapy, by reversing the expression of miR-34a, SIRT1, cyclin D1, and E-cadherin.	Paclitaxel	45-55	sirtuin 1	Mus musculus	191-196
28265007-3	2017	The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major membrane protein transporters responsible for the efflux of paclitaxel, constituting one of the most important mechanisms of paclitaxel resistance.	Paclitaxel	183-193	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	96-102
28265007-3	2017	The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major membrane protein transporters responsible for the efflux of paclitaxel, constituting one of the most important mechanisms of paclitaxel resistance.	Paclitaxel	183-193	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	103-107
28265007-3	2017	The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major membrane protein transporters responsible for the efflux of paclitaxel, constituting one of the most important mechanisms of paclitaxel resistance.	Paclitaxel	248-258	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	96-102
28265007-3	2017	The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major membrane protein transporters responsible for the efflux of paclitaxel, constituting one of the most important mechanisms of paclitaxel resistance.	Paclitaxel	248-258	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	103-107
28265007-4	2017	Here, we demonstrated that the Bruton tyrosine kinase inhibitor, ibrutinib, significantly enhanced the antitumor activity of paclitaxel by antagonizing the efflux function of ABCB1 and ABCC10 in cells overexpressing these transporters.	Paclitaxel	125-135	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	185-191
28265007-8	2017	Importantly, ibrutinib could effectively enhance paclitaxel-induced inhibition on the growth of ABCB1- and ABCC10-overexpressing tumors in nude athymic mice.	Paclitaxel	49-59	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	107-113
28265007-9	2017	These results demonstrate that the combination of ibrutinib and paclitaxel can effectively antagonize ABCB1- or ABCC10-mediated paclitaxel resistance that could be of great clinical interest.	Paclitaxel	64-74	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	112-118
28265007-9	2017	These results demonstrate that the combination of ibrutinib and paclitaxel can effectively antagonize ABCB1- or ABCC10-mediated paclitaxel resistance that could be of great clinical interest.	Paclitaxel	128-138	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	112-118
28242239-9	2017	Paclitaxel-mediated induction of genes involved in irinotecan metabolism such as Cyp3a11 and Ugt1a1 was TLR4-dependent, while induction of the transporter Mrp2 was TLR4-independent.	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	104-108
28242239-9	2017	Paclitaxel-mediated induction of genes involved in irinotecan metabolism such as Cyp3a11 and Ugt1a1 was TLR4-dependent, while induction of the transporter Mrp2 was TLR4-independent.	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	164-168
28242239-10	2017	These novel findings demonstrate that paclitaxel can affect irinotecan metabolism by a TLR4-dependent mechanism.	Paclitaxel	38-48	toll like receptor 4	Homo sapiens	87-91
28320862-6	2017	IRS-2 colocalization with tubulin is enhanced upon Taxol-mediated microtubule stabilization, which, together with the signaling data, suggests that the microtubule cytoskeleton may facilitate access of IRS-2 to downstream effectors such as AKT.	Paclitaxel	51-56	insulin receptor substrate 2	Homo sapiens	0-5
28320862-6	2017	IRS-2 colocalization with tubulin is enhanced upon Taxol-mediated microtubule stabilization, which, together with the signaling data, suggests that the microtubule cytoskeleton may facilitate access of IRS-2 to downstream effectors such as AKT.	Paclitaxel	51-56	insulin receptor substrate 2	Homo sapiens	202-207
28423727-0	2017	Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.	Paclitaxel	0-10	CD22 antigen	Mus musculus	50-54
28285918-4	2017	Hoechst 33258 staining and the Annexin-V FITC assay demonstrated that paclitaxel synergized with jesridonin in a stronger induction of apoptosis than treatment with paclitaxel or jesridonin alone.	Paclitaxel	70-80	annexin A5	Homo sapiens	31-40
28447761-0	2017	miR-21 inhibitor suppresses cell proliferation and colony formation through regulating the PTEN/AKT pathway and improves paclitaxel sensitivity in cervical cancer cells.	Paclitaxel	121-131	microRNA 21	Homo sapiens	0-6
28447761-10	2017	Furthermore, the miR-21 inhibitor significantly enhanced the inhibition efficacy of PTX at a range of concentrations in cervical cancer cells.	Paclitaxel	84-87	microRNA 21	Homo sapiens	17-23
28447761-11	2017	It was concluded that inhibition of miR-21 suppressed cell proliferation and colony formation through regulating the PTEN/AKT pathway, and improved PTX sensitivity in cervical cancer cells.	Paclitaxel	148-151	microRNA 21	Homo sapiens	36-42
28529574-3	2017	The present study aimed to investigate the effect of stathmin 1 (STMN1) on paclitaxel-induced chemoresistance, as well as the underlying mechanism.	Paclitaxel	75-85	stathmin 1	Homo sapiens	53-63
28529574-3	2017	The present study aimed to investigate the effect of stathmin 1 (STMN1) on paclitaxel-induced chemoresistance, as well as the underlying mechanism.	Paclitaxel	75-85	stathmin 1	Homo sapiens	65-70
28529574-5	2017	Furthermore, treatment with paclitaxel led to upregulation of STMN1 in U-2OS cells, accompanied by activation of autophagy, which may attenuate the cytotoxicity of paclitaxel in OS cells.	Paclitaxel	28-38	stathmin 1	Homo sapiens	62-67
28529574-6	2017	Following knockdown of STMN1 expression, paclitaxel-induced autophagy was significantly reduced, accompanied by increased cytotoxicity of paclitaxel to U-2OS cells.	Paclitaxel	41-51	stathmin 1	Homo sapiens	23-28
28529574-6	2017	Following knockdown of STMN1 expression, paclitaxel-induced autophagy was significantly reduced, accompanied by increased cytotoxicity of paclitaxel to U-2OS cells.	Paclitaxel	138-148	stathmin 1	Homo sapiens	23-28
28529574-8	2017	In conclusion, the present study demonstrated that knockdown of STMN1 enhances osteosarcoma cell chemosensitivity to paclitaxel through inhibition of autophagy.	Paclitaxel	117-127	stathmin 1	Homo sapiens	64-69
28322796-3	2017	PTX (20 nM) suppressed cell proliferation and increased various ceramide species in PC3, but not PC3-PR, cells.	Paclitaxel	0-3	proprotein convertase subtilisin/kexin type 1	Homo sapiens	84-87
28322796-6	2017	Inhibition of SPHK1 using siRNA or a pharmacological inhibitor decreased S1P levels in PC3-PR cells and inhibited proliferation in the presence or absence of PTX, suggesting that SPHK1 is at least partially responsible for PTX resistance.	Paclitaxel	158-161	sphingosine kinase 1	Homo sapiens	14-19
28322796-6	2017	Inhibition of SPHK1 using siRNA or a pharmacological inhibitor decreased S1P levels in PC3-PR cells and inhibited proliferation in the presence or absence of PTX, suggesting that SPHK1 is at least partially responsible for PTX resistance.	Paclitaxel	223-226	sphingosine kinase 1	Homo sapiens	14-19
28322796-6	2017	Inhibition of SPHK1 using siRNA or a pharmacological inhibitor decreased S1P levels in PC3-PR cells and inhibited proliferation in the presence or absence of PTX, suggesting that SPHK1 is at least partially responsible for PTX resistance.	Paclitaxel	223-226	sphingosine kinase 1	Homo sapiens	179-184
28334732-3	2017	This study aimed to investigate STMN1 as a prognostic and predictive indicator of response to paclitaxel therapy in patients with GC, including inoperable cases.	Paclitaxel	94-104	stathmin 1	Homo sapiens	32-37
28334732-5	2017	The roles of STMN1 in cancer cell proliferation and sensitivity to a microtubule-targeting drug, paclitaxel, were confirmed by knockdown experiments using GC cell lines.	Paclitaxel	97-107	stathmin 1	Homo sapiens	13-18
28334732-9	2017	Knockdown of STMN1 in GC cell lines inhibited proliferation and sensitised the cells to paclitaxel by enhancing apoptosis.	Paclitaxel	88-98	stathmin 1	Homo sapiens	13-18
28334732-10	2017	CONCLUSIONS: STMN1 is a possible biomarker for paclitaxel sensitivity and poor prognosis in GC and could be a novel therapeutic target in metastatic GC.	Paclitaxel	47-57	stathmin 1	Homo sapiens	13-18
28301933-4	2017	Ferritin moieties endow PLGA-NPs with targeting capability, exploiting SCARA5 receptors overexpressed by these tumor cells, that results in an increased paclitaxel cytotoxicity.	Paclitaxel	153-163	scavenger receptor class A member 5	Homo sapiens	71-77
28212576-4	2017	MTT assay and flow cytometry revealed that Gal-1 knockdown improved sensitivity to paclitaxel (PTX) and adriamycin (ADR) in MCF-7/PTX and MCF-7/ADR cells via inhibition of cell viability and promotion of cell apoptosis, while MDR1 overexpression weakened the sensitivity to PTX and ADR induced by Gal-1 knockdown.	Paclitaxel	83-93	galectin 1	Homo sapiens	43-48
28212576-4	2017	MTT assay and flow cytometry revealed that Gal-1 knockdown improved sensitivity to paclitaxel (PTX) and adriamycin (ADR) in MCF-7/PTX and MCF-7/ADR cells via inhibition of cell viability and promotion of cell apoptosis, while MDR1 overexpression weakened the sensitivity to PTX and ADR induced by Gal-1 knockdown.	Paclitaxel	95-98	galectin 1	Homo sapiens	43-48
28212576-4	2017	MTT assay and flow cytometry revealed that Gal-1 knockdown improved sensitivity to paclitaxel (PTX) and adriamycin (ADR) in MCF-7/PTX and MCF-7/ADR cells via inhibition of cell viability and promotion of cell apoptosis, while MDR1 overexpression weakened the sensitivity to PTX and ADR induced by Gal-1 knockdown.	Paclitaxel	130-133	galectin 1	Homo sapiens	43-48
28212576-4	2017	MTT assay and flow cytometry revealed that Gal-1 knockdown improved sensitivity to paclitaxel (PTX) and adriamycin (ADR) in MCF-7/PTX and MCF-7/ADR cells via inhibition of cell viability and promotion of cell apoptosis, while MDR1 overexpression weakened the sensitivity to PTX and ADR induced by Gal-1 knockdown.	Paclitaxel	130-133	galectin 1	Homo sapiens	43-48
28212576-5	2017	Furthermore, the negative effects of Gal-1 knockdown on sensitivity to PTX and ADR in MCF-7/PTX and MCF-7/ADR cells were revealed to be mediated via the suppression of Raf-1/AP-1 pathway.	Paclitaxel	71-74	galectin 1	Homo sapiens	37-42
28212576-5	2017	Furthermore, the negative effects of Gal-1 knockdown on sensitivity to PTX and ADR in MCF-7/PTX and MCF-7/ADR cells were revealed to be mediated via the suppression of Raf-1/AP-1 pathway.	Paclitaxel	92-95	galectin 1	Homo sapiens	37-42
28423567-7	2017	The subsequent experiments were performed in order to dissect the signal transduction pathways under GRO/KC control, eventually modulated by paclitaxel and/or reparixin.	Paclitaxel	141-151	C-X-C motif chemokine ligand 1	Rattus norvegicus	101-104
28259950-6	2017	Conversely, Taxol mainly decreased the expression of Op18/stathmin and the phosphorylation at Ser25 and Ser63 sites.	Paclitaxel	12-17	stathmin 1	Homo sapiens	53-57
28259950-6	2017	Conversely, Taxol mainly decreased the expression of Op18/stathmin and the phosphorylation at Ser25 and Ser63 sites.	Paclitaxel	12-17	stathmin 1	Homo sapiens	58-66
28259950-7	2017	Silencing of Op18/stathmin by RNA interference (RNAi) led to a great reduction in the differences in the cell proliferation inhibition between VBL and Taxol.	Paclitaxel	151-156	stathmin 1	Homo sapiens	13-17
28259950-7	2017	Silencing of Op18/stathmin by RNA interference (RNAi) led to a great reduction in the differences in the cell proliferation inhibition between VBL and Taxol.	Paclitaxel	151-156	stathmin 1	Homo sapiens	18-26
28259950-8	2017	VBL treatment notably weakened the expression of PP2A, Bcl-2, NF-kappaB and interleukin-10 (IL-10) and autocrine IL-10 compared with Taxol; whereas PP2A was substantially increased following Taxol induction.	Paclitaxel	191-196	protein phosphatase 2 phosphatase activator	Homo sapiens	148-152
28259950-9	2017	High expression of Op18/stathmin was found to be negatively correlated with the sensitivity of Taxol in the NSCLC cells, but had a minor impact on VBL cytotoxicity.	Paclitaxel	95-100	stathmin 1	Homo sapiens	19-23
28259950-9	2017	High expression of Op18/stathmin was found to be negatively correlated with the sensitivity of Taxol in the NSCLC cells, but had a minor impact on VBL cytotoxicity.	Paclitaxel	95-100	stathmin 1	Homo sapiens	24-32
28259950-10	2017	These findings revealed that both VBL and Taxol induce cell apoptosis through Op18/stathmin, but the mechanisms are completely different.	Paclitaxel	42-47	stathmin 1	Homo sapiens	78-82
28259950-10	2017	These findings revealed that both VBL and Taxol induce cell apoptosis through Op18/stathmin, but the mechanisms are completely different.	Paclitaxel	42-47	stathmin 1	Homo sapiens	83-91
28259950-11	2017	VBL is an attractive alternative to the treatment of Taxol-resistant tumors with high expression of Op18/stathmin.	Paclitaxel	53-58	stathmin 1	Homo sapiens	100-104
28259950-11	2017	VBL is an attractive alternative to the treatment of Taxol-resistant tumors with high expression of Op18/stathmin.	Paclitaxel	53-58	stathmin 1	Homo sapiens	105-113
28454472-0	2017	Hsp90 inhibitor SY-016 induces G2/M arrest and apoptosis in paclitaxel-resistant human ovarian cancer cells.	Paclitaxel	60-70	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
28454472-1	2017	The aim of the present study was to evaluate the in vitro effect of a heat shock protein (Hsp)90 inhibitor, SY-016, on the paclitaxel (PTX)-resistant human ovarian cancer cell line OVCAR-3PTX, and explore its mechanism of apoptosis.	Paclitaxel	123-133	heat shock protein 90 alpha family class A member 1	Homo sapiens	70-96
28454472-1	2017	The aim of the present study was to evaluate the in vitro effect of a heat shock protein (Hsp)90 inhibitor, SY-016, on the paclitaxel (PTX)-resistant human ovarian cancer cell line OVCAR-3PTX, and explore its mechanism of apoptosis.	Paclitaxel	135-138	heat shock protein 90 alpha family class A member 1	Homo sapiens	70-96
28237486-4	2017	CONCLUSIONS: Targeted inhibition of Notch1 gene may enhance the killing effects of paclitaxel on triple negative breast cancer cells by up-regulating the expression of Caspase-3 and Caspase-9 and inhibiting the expression of Bcl-2.	Paclitaxel	83-93	caspase 9	Homo sapiens	182-191
27832973-9	2017	Drug administration of the combination of paclitaxel with the TNFalpha nanobody in vivo significantly enhanced the efficacy against 4T-1 breast tumor proliferation and lung metastasis; meanwhile, E-cadherin tumor epithelial marker expression was upregulated, supporting the anti-tumor therapeutic relevance of paclitaxel and the TNFalpha nanobody on EMT.	Paclitaxel	42-52	IL2 inducible T cell kinase	Homo sapiens	350-353
27447746-7	2017	The chemosensitivity of BTG1 transfectants to paclitaxel, cisplatin, MG132 or SAHA was positively correlated with its apoptotic induction.	Paclitaxel	46-56	BTG anti-proliferation factor 1	Mus musculus	24-28
28125674-9	2017	In the peripheral nervous system, PTX induced expression of the neuronal injury marker activating transcription factor-3 in IB4+ and NF200+ sensory neurons as well as an increase in the chemokines CCL2 and CCL3 in the lumbar dorsal root ganglion.	Paclitaxel	34-37	chemokine (C-C motif) ligand 3	Mus musculus	206-210
28125674-10	2017	In the central nervous system, PTX induced significant astrocyte activation in the spinal cord dorsal horn, and both PTX and OXA caused reduction of P2ry12+ homeostatic microglia, with no measurable changes in IBA-1+ microglia/macrophages in the dorsal and ventral horns.	Paclitaxel	117-120	purinergic receptor P2Y, G-protein coupled 12	Mus musculus	149-155
28125674-11	2017	We also found that PTX induced up-regulation of several inflammatory cytokines and chemokines (TNF-alpha, IFN-gamma, CCL11, CCL4, CCL3, IL-12p70 and GM-CSF) in the spinal cord.	Paclitaxel	19-22	chemokine (C-C motif) ligand 3	Mus musculus	130-134
27750197-3	2017	Among all derivatives, 23 is the most potent P-gp modulator with EC50 of 120-165 nM in reversing paclitaxel, DOX, vinblastine and vincristine resistance.	Paclitaxel	97-107	phosphoglycolate phosphatase	Homo sapiens	45-49
28647734-0	2017	MiR-4673 Modulates Paclitaxel-Induced Oxidative Stress and Loss of Mitochondrial Membrane Potential by Targeting 8-Oxoguanine-DNA Glycosylase-1.	Paclitaxel	19-29	8-oxoguanine DNA glycosylase	Homo sapiens	113-143
28647734-9	2017	In addition, silencing OGG1 enhanced inhibitory effects of PTX on apoptosis, MMP loss and ROS generation, which is similar to effects of miR-4673.	Paclitaxel	59-62	8-oxoguanine DNA glycosylase	Homo sapiens	23-27
28647734-10	2017	Moreover, enforced expression of OGG1 compromised promoting effects of miR-4673 on PTX-induced apoptosis, MMP loss and ROS generation.	Paclitaxel	83-86	8-oxoguanine DNA glycosylase	Homo sapiens	33-37
22258694-2	2012	The transient receptor potential vanilloid 4 (TRPV4) channel has been reported to contribute to paclitaxel-evoked allodynia in rodents.	Paclitaxel	96-106	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	4-44
22258694-2	2012	The transient receptor potential vanilloid 4 (TRPV4) channel has been reported to contribute to paclitaxel-evoked allodynia in rodents.	Paclitaxel	96-106	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	46-51
22258694-5	2012	Paclitaxel-evoked mechanical allodynia was reduced partially by the TRPA1 antagonist, HC-030031, and the TRPV4 antagonist, HC-067047, and was completely abated by the combination of the two antagonists.	Paclitaxel	0-10	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	105-110
22258694-11	2012	Paclitaxel via oxygen radical formation targets TRPA1 and TRPV4, and both channels are key for the delayed development of mechanical allodynia.	Paclitaxel	0-10	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	58-63
22585996-0	2012	nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.	Paclitaxel	4-14	cytidine deaminase	Mus musculus	60-78
22585996-5	2012	Correspondingly, paclitaxel reduced the levels of cytidine deaminase protein in cultured cells through reactive oxygen species-mediated degradation, resulting in the increased stabilization of gemcitabine.	Paclitaxel	17-27	cytidine deaminase	Mus musculus	50-68
22619888-0	2012	The efficacy of neoadjuvant paclitaxel-carboplatin chemotherapy followed by radical hysterectomy compared to radical hysterectomy alone in bulky stage IB2-IIA cervical cancer.	Paclitaxel	28-38	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	151-154
22619888-1	2012	OBJECTIVE: To compare the efficacy of neoadjuvant paclitaxel-carboplatin chemotherapy followed by radical hysterectomy with radical hysterectomy alone in patients with bulky cervical cancer stage IB2-IIA.	Paclitaxel	50-60	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	196-199
22114138-11	2012	Clonogenic cell survival following a series of DNA damaging agents was variable: PTEN-deficient cells were sensitive to ionizing radiation, mitomycin-C, UV, H(2)O(2), and methyl methanesulfonate but not to cisplatin, camptothecin, or paclitaxel.	Paclitaxel	234-244	phosphatase and tensin homolog	Homo sapiens	81-85
20938714-4	2012	This study describes a thermally responsive macromolecular carrier, elastin-like polypeptide (ELP) for the delivery of paclitaxel.	Paclitaxel	119-129	nuclear receptor subfamily 5 group A member 1	Homo sapiens	68-92
20938714-4	2012	This study describes a thermally responsive macromolecular carrier, elastin-like polypeptide (ELP) for the delivery of paclitaxel.	Paclitaxel	119-129	nuclear receptor subfamily 5 group A member 1	Homo sapiens	94-97
20938714-5	2012	Paclitaxel was bound to ELP by conjugation with the 6-maleimidocaproyl hydrazone derivative of paclitaxel, an acid-sensitive paclitaxel prodrug, for the potential treatment of breast cancer.	Paclitaxel	0-10	nuclear receptor subfamily 5 group A member 1	Homo sapiens	24-27
20938714-5	2012	Paclitaxel was bound to ELP by conjugation with the 6-maleimidocaproyl hydrazone derivative of paclitaxel, an acid-sensitive paclitaxel prodrug, for the potential treatment of breast cancer.	Paclitaxel	95-105	nuclear receptor subfamily 5 group A member 1	Homo sapiens	24-27
20938714-5	2012	Paclitaxel was bound to ELP by conjugation with the 6-maleimidocaproyl hydrazone derivative of paclitaxel, an acid-sensitive paclitaxel prodrug, for the potential treatment of breast cancer.	Paclitaxel	125-135	nuclear receptor subfamily 5 group A member 1	Homo sapiens	24-27
20938714-8	2012	The ELP-delivered paclitaxel in the presence of hyperthermia inhibits MCF-7 cell proliferation by stabilizing the microtubule structures, arresting the cells at the G2/M stage, and inducing apoptosis in a manner similar to conventional paclitaxel.	Paclitaxel	18-28	nuclear receptor subfamily 5 group A member 1	Homo sapiens	4-7
20938714-8	2012	The ELP-delivered paclitaxel in the presence of hyperthermia inhibits MCF-7 cell proliferation by stabilizing the microtubule structures, arresting the cells at the G2/M stage, and inducing apoptosis in a manner similar to conventional paclitaxel.	Paclitaxel	236-246	nuclear receptor subfamily 5 group A member 1	Homo sapiens	4-7
20938714-10	2012	These data provide an in vitro proof of concept for the use of ELP as a delivery vehicle of paclitaxel.	Paclitaxel	92-102	nuclear receptor subfamily 5 group A member 1	Homo sapiens	63-66
28920260-8	2012	In our case, positive immunohistochemical analysis for caveolin-1 in the tumor vascular endothelia suggests that the complete response may have been facilitated by enhanced transportation of paclitaxel through the tumor vascular barrier via caveolin-1, despite being negative for secreted protein acidic and rich in cysteine (SPARC) in tumor cells.	Paclitaxel	191-201	secreted protein acidic and cysteine rich	Homo sapiens	326-331
22156929-3	2012	SPARC (secreted protein acidic rich in cysteine) is an albumin-binding matrix-associated protein that is proposed to act as a mechanism for the increased efficacy of a nanoparticle albumin-bound preparation of the antimicrotubular drug Paclitaxel (nab-paclitaxel).	Paclitaxel	252-262	secreted protein acidic and cysteine rich	Homo sapiens	0-5
22236187-0	2012	Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel.	Paclitaxel	121-131	UDP-glucose ceramide glucosyltransferase	Homo sapiens	0-25
28647734-11	2017	CONCLUSION: miR-4673 modulates PTX-induced apoptosis, MMP loss and ROS generation by targeting OGG1.	Paclitaxel	31-34	8-oxoguanine DNA glycosylase	Homo sapiens	95-99
9174131-6	1997	However, the intracellular localization of the immunoreactive protein for MMP-2 was altered in response to paclitaxel treatment.	Paclitaxel	107-117	matrix metallopeptidase 2	Homo sapiens	74-79
22439872-1	2012	In the present work, concomitant use of self-microemulsifying drug delivery systems (SMEDDS) and a novel third-generation P-gp inhibitor, GF120918 (elacridar), for the effective transport of taxanes (paclitaxel and docetaxel) across an in vitro model of the intestinal epithelium and uptake into tumor cells were investigated.	Paclitaxel	200-210	phosphoglycolate phosphatase	Homo sapiens	122-126
27862665-8	2017	RESULTS: Knockdown of HE4 in OVCAR-3 cells resulted in reduction in cell growth and increased sensitivity to paclitaxel and cisplatin compared to control cells.	Paclitaxel	109-119	WAP four-disulfide core domain 2	Homo sapiens	22-25
9127007-0	1997	CD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol.	Paclitaxel	150-155	CD14 antigen	Mus musculus	0-4
27862665-9	2017	This effect originated from the decreased activation of cell-growth-related signaling, such as AKT and Erk mediated by epidermal growth factor (EGF), while overexpression of HE4 resulted in enhanced cell growth and suppressed the anti-tumorigenic activity of paclitaxel.	Paclitaxel	259-269	WAP four-disulfide core domain 2	Homo sapiens	174-177
27852894-8	2017	Reduction of microtubule growth with paclitaxel suppresses GFP-Kif15 motility, demonstrating that dynamic microtubules contribute to Kif15 behavior.	Paclitaxel	37-47	kinesin family member 15	Homo sapiens	63-68
23090716-0	2012	Paclitaxel increases high voltage-dependent calcium channel current in dorsal root ganglion neurons of the rat.	Paclitaxel	0-10	calcium voltage-gated channel subunit alpha1 I	Rattus norvegicus	26-59
23090716-3	2012	In this study, we investigated the effects of paclitaxel on the voltage-dependent calcium channel (VDCC) current in rat dorsal root ganglion (DRG) neurons using the whole-cell patch clamp technique.	Paclitaxel	46-56	calcium voltage-gated channel subunit alpha1 I	Rattus norvegicus	64-97
23090716-3	2012	In this study, we investigated the effects of paclitaxel on the voltage-dependent calcium channel (VDCC) current in rat dorsal root ganglion (DRG) neurons using the whole-cell patch clamp technique.	Paclitaxel	46-56	calcium voltage-gated channel subunit alpha1 I	Rattus norvegicus	99-103
27852894-8	2017	Reduction of microtubule growth with paclitaxel suppresses GFP-Kif15 motility, demonstrating that dynamic microtubules contribute to Kif15 behavior.	Paclitaxel	37-47	kinesin family member 15	Homo sapiens	133-138
9127007-0	1997	CD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol.	Paclitaxel	150-155	CD14 antigen	Mus musculus	19-23
27845892-5	2016	In the present study, the high expression of lncRNA H19 was identified as a powerful factor associated with paclitaxel (PTX) resistance in ERalpha-positive breast cancer cells, but not in ERalpha-negative breast cancer cells.	Paclitaxel	108-118	H19 imprinted maternally expressed transcript	Homo sapiens	52-55
23090716-6	2012	Using the patch clamp method, we observed that paclitaxel (4 mg/kg) treatment significantly increased the VDCC current in small- and medium-diameter DRG neurons.	Paclitaxel	47-57	calcium voltage-gated channel subunit alpha1 I	Rattus norvegicus	106-110
23090716-7	2012	Moreover, paclitaxel-induced increase in the VDCC current in medium-diameter DRG neurons was completely inhibited by 10 and 100 muM gabapentin.	Paclitaxel	10-20	calcium voltage-gated channel subunit alpha1 I	Rattus norvegicus	45-49
23090716-9	2012	Western blotting revealed that paclitaxel increased protein levels of the VDCC subunit alpha2delta-1 (Ca(v)alpha2delta-1) in DRG neurons.	Paclitaxel	31-41	calcium voltage-gated channel subunit alpha1 I	Rattus norvegicus	74-78
27845892-5	2016	In the present study, the high expression of lncRNA H19 was identified as a powerful factor associated with paclitaxel (PTX) resistance in ERalpha-positive breast cancer cells, but not in ERalpha-negative breast cancer cells.	Paclitaxel	120-123	H19 imprinted maternally expressed transcript	Homo sapiens	52-55
27845892-6	2016	LncRNA H19 attenuated cell apoptosis in response to PTX treatment by inhibiting transcription of pro-apoptotic genes BIK and NOXA.	Paclitaxel	52-55	H19 imprinted maternally expressed transcript	Homo sapiens	7-10
23090716-11	2012	Thus, paclitaxel treatment increases the VDCC current in small- and medium-diameter DRG neurons and upregulates Ca(v)alpha2delta-1.	Paclitaxel	6-16	calcium voltage-gated channel subunit alpha1 I	Rattus norvegicus	41-45
23090716-12	2012	The antihyperalgesic action of gabapentin may be due to inhibition of paclitaxel-induced increases in the VDCC current in DRG neurons.	Paclitaxel	70-80	calcium voltage-gated channel subunit alpha1 I	Rattus norvegicus	106-110
9127007-0	1997	CD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol.	Paclitaxel	150-155	CD14 antigen	Mus musculus	19-23
9127007-2	1997	Since CD14 is central to the recognition of LPS by macrophages, we sought to examine a role for CD14 in the response to Taxol vs LPS.	Paclitaxel	120-125	CD14 antigen	Mus musculus	96-100
22668020-10	2012	This chemosensitization effect could be a result of the intensification of pro-apoptotic JNK activation, and repression of anti-apoptotic p-ERK, p-Bad and p-IkappaBalpha expression stimulated by paclitaxel.	Paclitaxel	195-205	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	138-143
9042153-12	1997	Microtubular stabilizer taxol (5 microM) abolished inhibitory activity of colchicine, increasing the expression of sPLA2 3.2-fold compared with that in control cells cultured without taxol.	Paclitaxel	24-29	phospholipase A2 group IIA	Rattus norvegicus	115-120
23029028-5	2012	Compared with the control cells, the velocity of directed motion was reduced by 30% due to the suppression of high speed movements of EGF-QDs along the microtubules in PTX-treated cells.	Paclitaxel	168-171	epidermal growth factor	Homo sapiens	134-137
23029028-7	2012	Moreover, PTX shortened endosomal trafficking and prevented EGF-QDs from moving to the perinuclear area via the rapid delivery of EGF-QDs into the peripheral lysosomes.	Paclitaxel	10-13	epidermal growth factor	Homo sapiens	60-63
23029028-7	2012	Moreover, PTX shortened endosomal trafficking and prevented EGF-QDs from moving to the perinuclear area via the rapid delivery of EGF-QDs into the peripheral lysosomes.	Paclitaxel	10-13	epidermal growth factor	Homo sapiens	130-133
27721193-0	2016	Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study.	Paclitaxel	77-87	colony stimulating factor 3	Homo sapiens	24-61
9009167-6	1997	Taxol also activated Raf-1 kinase and ERK1/ERK2 MAP kinases in these cells.	Paclitaxel	0-5	mitogen-activated protein kinase 3	Mus musculus	38-42
27721193-1	2016	INTRODUCTION: The necessity of using granulocyte-colony stimulating factor (G-CSF) during dose-dense (DD) paclitaxel (T) after doxorubicin and cyclophosphamide (AC) is unclear.	Paclitaxel	106-116	colony stimulating factor 3	Homo sapiens	76-81
9066642-8	1997	Resistance to taxol and doxorubicin of the MDR cells grown as MTS was almost completely reversed by SDZ PSC 833.	Paclitaxel	14-19	MLRL	Homo sapiens	62-65
22723956-3	2012	Using in vitro approaches, we demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-3p mimic has a general effect on paclitaxel response in NSCLC cell lines, which may provide a novel adjuvant strategy to paclitaxel in the treatment of lung cancer.	Paclitaxel	121-131	microRNA 337	Homo sapiens	80-87
22723956-3	2012	Using in vitro approaches, we demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-3p mimic has a general effect on paclitaxel response in NSCLC cell lines, which may provide a novel adjuvant strategy to paclitaxel in the treatment of lung cancer.	Paclitaxel	183-193	microRNA 337	Homo sapiens	80-87
22723956-3	2012	Using in vitro approaches, we demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-3p mimic has a general effect on paclitaxel response in NSCLC cell lines, which may provide a novel adjuvant strategy to paclitaxel in the treatment of lung cancer.	Paclitaxel	183-193	microRNA 337	Homo sapiens	142-149
27601168-10	2016	In addition, CK18 knockdown decreased cell migration and enhanced the sensitivity of lung cancer cells to paclitaxel.	Paclitaxel	106-116	keratin 18	Homo sapiens	13-17
22723956-3	2012	Using in vitro approaches, we demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-3p mimic has a general effect on paclitaxel response in NSCLC cell lines, which may provide a novel adjuvant strategy to paclitaxel in the treatment of lung cancer.	Paclitaxel	183-193	microRNA 337	Homo sapiens	80-87
27831559-11	2016	Together, our results indicated that loss of miR-17 and miR-20b enhanced breast cancer resistance to taxol by upregulating NCOA3 levels.	Paclitaxel	101-106	nuclear receptor coactivator 3	Homo sapiens	123-128
8988045-7	1997	Taxol (6 mg/kg i.p., n = 17) inhibited bFGF and VEGF-induced neovascularization by 45% and 37%, respectively.	Paclitaxel	0-5	fibroblast growth factor 2	Mus musculus	39-43
27831559-12	2016	Our study suggested miR-17, miR-20b and NCOA3 may serve as some predictive biomarkers and potential therapeutic targets in taxol-resistant breast cancer treatment.	Paclitaxel	123-128	nuclear receptor coactivator 3	Homo sapiens	40-45
22723956-3	2012	Using in vitro approaches, we demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-3p mimic has a general effect on paclitaxel response in NSCLC cell lines, which may provide a novel adjuvant strategy to paclitaxel in the treatment of lung cancer.	Paclitaxel	183-193	microRNA 337	Homo sapiens	142-149
22723956-4	2012	By combining in vitro and in silico approaches, we identified STAT3 and RAP1A as direct targets that mediate the effect of miR-337-3p on paclitaxel sensitivity.	Paclitaxel	137-147	RAP1A, member of RAS oncogene family	Homo sapiens	72-77
22723956-4	2012	By combining in vitro and in silico approaches, we identified STAT3 and RAP1A as direct targets that mediate the effect of miR-337-3p on paclitaxel sensitivity.	Paclitaxel	137-147	microRNA 337	Homo sapiens	123-130
22723956-6	2012	The identification of a miR-337-3p as a modulator of cellular response to taxanes, and STAT3 and RAP1A as regulatory targets which mediate that response, defines a novel regulatory pathway modulating paclitaxel sensitivity in lung cancer cells, which may provide novel adjuvant strategies along with paclitaxel in the treatment of lung cancer and may also provide biomarkers for predicting paclitaxel response in NSCLC.	Paclitaxel	200-210	microRNA 337	Homo sapiens	24-31
8988053-1	1997	Recent studies have shown that paclitaxel leads to activation of Raf-1 kinase and have suggested that this activation is essential for bcl-2 phosphorylation and apoptosis.	Paclitaxel	31-41	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	65-70
21880414-9	2011	This study suggests that LEF1 can enhance the proliferation of RCC cells and that the LEF1/beta-catenin complex plays an important role in the synergy of DAC and PTX against RCC cells.	Paclitaxel	162-165	catenin beta 1	Homo sapiens	91-103
27659528-0	2016	Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/PI3K/Akt pathway.	Paclitaxel	14-24	phosphatase and tensin homolog	Homo sapiens	137-141
8988053-3	1997	Activation of Raf-1 kinase by paclitaxel is linked to tubulin polymerization; the effect is blunted in paclitaxel-resistant cells, the tubulin of which does not polymerize following the addition of paclitaxel.	Paclitaxel	30-40	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	14-19
27659528-7	2016	Mechanistic analysis revealed that administration of geridonin in combination with paclitaxel up-regulated the tumor suppressor PTEN and inhibited phosphorylation of Akt and MDM2.	Paclitaxel	83-93	phosphatase and tensin homolog	Homo sapiens	128-132
8988053-3	1997	Activation of Raf-1 kinase by paclitaxel is linked to tubulin polymerization; the effect is blunted in paclitaxel-resistant cells, the tubulin of which does not polymerize following the addition of paclitaxel.	Paclitaxel	103-113	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	14-19
21953449-0	2011	Collapsin response mediator proteins (CRMPs) are a new class of microtubule-associated protein (MAP) that selectively interacts with assembled microtubules via a taxol-sensitive binding interaction.	Paclitaxel	162-167	regulator of microtubule dynamics 1	Homo sapiens	64-94
21953449-0	2011	Collapsin response mediator proteins (CRMPs) are a new class of microtubule-associated protein (MAP) that selectively interacts with assembled microtubules via a taxol-sensitive binding interaction.	Paclitaxel	162-167	regulator of microtubule dynamics 1	Homo sapiens	96-99
8988053-3	1997	Activation of Raf-1 kinase by paclitaxel is linked to tubulin polymerization; the effect is blunted in paclitaxel-resistant cells, the tubulin of which does not polymerize following the addition of paclitaxel.	Paclitaxel	103-113	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	14-19
8988053-4	1997	In contrast, vincristine and vinblastine, drugs to which the paclitaxel-resistant cells retain sensitivity were able to bring about Raf-1 phosphorylation.	Paclitaxel	61-71	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	132-137
8988053-5	1997	The requirement for disruption of microtubules in this signaling cascade was strengthened further using paclitaxel analogues by demonstrating a correlation between tubulin polymerization, Raf-1/bcl-2 phosphorylation, and cytotoxicity.	Paclitaxel	104-114	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	188-193
9443612-6	1997	At 20 degrees C, the effect of 0.05 microg/ml of paclitaxel on MTP could be detected, whereas at 37 degrees C, &gt; 1 microg/ml of paclitaxel was required to detect a significant effect relative to untreated MTP.	Paclitaxel	49-59	microsomal triglyceride transfer protein	Bos taurus	63-66
22060185-0	2011	Neuroprotection of paclitaxel against cerebral ischemia/reperfusion-induced brain injury through JNK3 signaling pathway.	Paclitaxel	19-29	mitogen-activated protein kinase 10	Homo sapiens	97-101
22060185-2	2011	Our data showed that paclitaxel can down-regulate the increased MLK3, JNK3, c-Jun, Bcl-2, and caspase-3 phosphorylation induced by ischemia injury.	Paclitaxel	21-31	mitogen-activated protein kinase 10	Homo sapiens	70-74
22060185-4	2011	These results indicated that paclitaxel has neuroprotection in ischemic injury through JNK3 signaling pathway and provided a novel possible drug in therapeutics of brain ischemia.	Paclitaxel	29-39	mitogen-activated protein kinase 10	Homo sapiens	87-91
22019170-12	2011	CONCLUSIONS: Data suggest that paclitaxel induces nuclear translocation and activation of PKC-delta, which in turn causes Golgi-Cdk1 activation, leading to Golgi associated DR5 up-regulation, and caspase-8 and 3 activation.	Paclitaxel	31-41	cyclin dependent kinase 1	Homo sapiens	128-132
22019170-12	2011	CONCLUSIONS: Data suggest that paclitaxel induces nuclear translocation and activation of PKC-delta, which in turn causes Golgi-Cdk1 activation, leading to Golgi associated DR5 up-regulation, and caspase-8 and 3 activation.	Paclitaxel	31-41	TNF receptor superfamily member 10b	Homo sapiens	173-176
27930644-5	2016	In combination with nab-paclitaxel, confirmed response rates were 46% in a PD-L1-unselected population in the first-line metastatic triple-negative breast cancer setting.	Paclitaxel	24-34	CD274 molecule	Homo sapiens	75-80
27414207-0	2016	A Combination Therapy with Baicalein and Taxol Promotes Mitochondria-Mediated Cell Apoptosis: Involving in Akt/beta-Catenin Signaling Pathway.	Paclitaxel	41-46	catenin beta 1	Homo sapiens	111-123
27414207-10	2016	In conclusion, our result revealed that baicalein combinated with taxol at low concentrations could exert synergistic antitumor effects in ovarian cancer cells through mitochondria-mediated cell apoptosis and Akt/beta-catenin signaling pathway.	Paclitaxel	66-71	catenin beta 1	Homo sapiens	213-225
27687545-4	2016	Compared with PC3, PC3-PR exhibited some unique phenotypes that might be associated with PTX resistance, including decreased expression of acetylated alpha-tubulin and the cell cycle regulator p21, and increased expression of betaIII tubulin, histone deacetylase 6 (HDAC6), and the anti-apoptotic protein Bcl2.	Paclitaxel	89-92	H3 histone pseudogene 16	Homo sapiens	193-196
21984124-10	2011	Also, paclitaxel down-regulated the expression of miR-192, miR-217 and miR -377, while miR-15 was up-regulated in the remnant kidney.	Paclitaxel	6-16	microRNA 377	Rattus norvegicus	71-79
21984124-11	2011	In vitro, in tubular epithelial cells (NRK-52E), paclitaxel also inhibited TGF-beta1-induced Smad2/3 activation and normalized ILK, COL(I)A1, COL(IV)A2 and alpha-SMA expression.	Paclitaxel	49-59	SMAD family member 2	Rattus norvegicus	93-100
21984124-11	2011	In vitro, in tubular epithelial cells (NRK-52E), paclitaxel also inhibited TGF-beta1-induced Smad2/3 activation and normalized ILK, COL(I)A1, COL(IV)A2 and alpha-SMA expression.	Paclitaxel	49-59	integrin-linked kinase	Rattus norvegicus	127-130
9142436-0	1997	Effects of nanomolar taxol on crane-fly spermatocyte spindles indicate that acetylation of kinetochore microtubules can be used as a marker of poleward tubulin flux.	Paclitaxel	21-26	alpha-Tubulin at 85E	Drosophila melanogaster	152-159
21594648-0	2011	Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells.	Paclitaxel	34-44	phosphatase and tensin homolog	Homo sapiens	91-95
21763756-2	2011	In this study, we tested the hypothesis that paclitaxel may release mast cell tryptase, which activates protease-activated receptor 2 (PAR2) and, subsequently, protein kinases A and C, resulting in mechanical and thermal (both heat and cold) hypersensitivity.	Paclitaxel	45-55	coagulation factor II (thrombin) receptor-like 1	Mus musculus	104-133
21763756-2	2011	In this study, we tested the hypothesis that paclitaxel may release mast cell tryptase, which activates protease-activated receptor 2 (PAR2) and, subsequently, protein kinases A and C, resulting in mechanical and thermal (both heat and cold) hypersensitivity.	Paclitaxel	45-55	coagulation factor II (thrombin) receptor-like 1	Mus musculus	135-139
21763756-4	2011	FSLLRY-amide, a selective PAR2 antagonist, blocked paclitaxel-induced neuropathic pain behaviors in a dose- and time-dependent manner.	Paclitaxel	51-61	coagulation factor II (thrombin) receptor-like 1	Mus musculus	26-30
21763756-5	2011	In addition, blocking downstream signaling pathways of PAR2, including phospholipase C (PLC), protein kinase A (PKA), and protein kinase Cepsilon (PKC), effectively attenuated paclitaxel-induced mechanical, heat, or cold hypersensitivity.	Paclitaxel	176-186	coagulation factor II (thrombin) receptor-like 1	Mus musculus	55-59
27783948-0	2016	Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3.	Paclitaxel	62-72	FMS-like tyrosine kinase 4	Mus musculus	102-108
21763756-7	2011	These results revealed specific cellular signaling pathways leading to paclitaxel-induced neuropathy, including the activation of PAR2 and downstream enzymes PLC, PKCepsilon, and PKA and resultant sensitization of TRPV1, TRPV4, and TRPA1.	Paclitaxel	71-81	coagulation factor II (thrombin) receptor-like 1	Mus musculus	130-134
21763756-7	2011	These results revealed specific cellular signaling pathways leading to paclitaxel-induced neuropathy, including the activation of PAR2 and downstream enzymes PLC, PKCepsilon, and PKA and resultant sensitization of TRPV1, TRPV4, and TRPA1.	Paclitaxel	71-81	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	221-226
21868450-10	2011	In contrast, the microtubule stabilizers paclitaxel and epothilone B increased cytosolic Smad3 binding to beta2-tubulin and enhanced the inhibitory effect of cGMP on Smad3 nuclear translocation and PAI-1 expression in response to TGF-beta1.	Paclitaxel	41-51	serpin family E member 1	Homo sapiens	198-203
27774979-12	2016	Silencing of HMGB3 enhanced sensitive to cisplatin and paclitaxel, and reduced sensitive to oxaliplatin.	Paclitaxel	55-65	high mobility group box 3	Homo sapiens	13-18
9142436-12	1997	We expected that if our assumptions were correct, taxol would slow tubulin addition at the kinetochore but acetylation would continue, and the gap in acetylation would get smaller.	Paclitaxel	50-55	alpha-Tubulin at 85E	Drosophila melanogaster	67-74
8713118-2	1996	The microtubule stabilizer taxol abolished the changes in CPT-I activity induced by the effectors tested.	Paclitaxel	27-32	carnitine palmitoyltransferase 1B	Rattus norvegicus	58-63
27763524-8	2016	Moreover, 2 h incubation with curcumin powder, solid dispersion formulation, and its physical mixture resulted in differential cytotoxic effect of paclitaxel in P-gp overexpressed LLC-PK1-P-gp and MDA-MB-231 cells through the inhibition of P-gp-mediated paclitaxel efflux.	Paclitaxel	147-157	phosphoglycolate phosphatase	Homo sapiens	161-165
27763524-8	2016	Moreover, 2 h incubation with curcumin powder, solid dispersion formulation, and its physical mixture resulted in differential cytotoxic effect of paclitaxel in P-gp overexpressed LLC-PK1-P-gp and MDA-MB-231 cells through the inhibition of P-gp-mediated paclitaxel efflux.	Paclitaxel	254-264	phosphoglycolate phosphatase	Homo sapiens	161-165
21394739-8	2011	RESULTS: Expression of the TMPRSS2/ERG fusions in PC3 cells increased radiation sensitivity and decreased paclitaxel sensitivity.	Paclitaxel	106-116	chromobox 8	Homo sapiens	50-53
21719246-6	2011	Cytotoxicity of paclitaxel in OVCAR-3, SK-OV-3 and OATP1B1- and OATP1B3-transfected SK-OV-3 cells was performed using the CellTiter-Glo assay.	Paclitaxel	16-26	solute carrier organic anion transporter family member 1B1	Homo sapiens	51-58
21719246-9	2011	The higher mRNA levels for OATP1B1 and OATP1B3 found in SK-OV-3 cells correlated with higher initial uptake rates for paclitaxel.	Paclitaxel	118-128	solute carrier organic anion transporter family member 1B1	Homo sapiens	27-34
21719246-11	2011	CONCLUSIONS: Our results revealed OATP1B1 and OATP1B3 as high-affinity paclitaxel transporters expressed in ovarian cancer cell lines and tumor tissues, suggesting a role for these polypeptides in the disposition of paclitaxel during therapy.	Paclitaxel	71-81	solute carrier organic anion transporter family member 1B1	Homo sapiens	34-41
27737687-0	2016	LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.	Paclitaxel	17-27	baculoviral IAP repeat containing 3	Homo sapiens	69-74
8816284-12	1996	In cultures treated with the microtubule stabilizing drug taxol, the amount of stress fibers and nascent I-bands was greatly diminished as previously reported by others; however, nebulin was found associated with myofibrils in a mature striated distribution.	Paclitaxel	58-63	nebulin	Homo sapiens	179-186
27737687-13	2016	Molecular studies revealed that paclitaxel increased TNFalpha expression, thereby leading to the recruitment of various factors and the formation of the TRADD-TRAF2-RIP1-cIAP complex.	Paclitaxel	32-42	receptor interacting serine/threonine kinase 1	Homo sapiens	165-169
27737687-16	2016	In nude mouse xenograft experiments, the combination of LCL161 and paclitaxel degraded cIAP1,2, activated caspase-3 and inhibited tumor growth with few toxic effects.	Paclitaxel	67-77	baculoviral IAP repeat-containing 3	Mus musculus	87-94
27611665-4	2016	Cdc6 depletion by RNAi or Norcantharidin inhibited PTX-induced Cdc6 up-regulation, maintained Cdk1 activity, and repressed Cohesin/Rad21 cleavage.	Paclitaxel	51-54	cyclin dependent kinase 1	Homo sapiens	94-98
27611665-4	2016	Cdc6 depletion by RNAi or Norcantharidin inhibited PTX-induced Cdc6 up-regulation, maintained Cdk1 activity, and repressed Cohesin/Rad21 cleavage.	Paclitaxel	51-54	RAD21 cohesin complex component	Homo sapiens	131-136
27262378-9	2016	Hence, it has been concluded that downregulation of ABCB1 and subsequent induction of paclitaxel-mediated cell cycle arrest and apoptotic signaling may be the cause for the chemosensitizing potential of ferulic acid in P-gp overexpressing cell lines.	Paclitaxel	86-96	phosphoglycolate phosphatase	Homo sapiens	219-223
21741827-1	2011	BACKGROUND: The aim of this study was to investigate whether c-myc amplification in human breast cancer is associated with response to neoadjuvant chemotherapy comprising paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (P-FEC).	Paclitaxel	171-181	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	61-66
8824733-5	1996	Examination of relative location of gamma-tubulin and microtubule asters in taxol-treated mitotic cells 3T3, HeLa and PtK2 revealed that the number of taxol-induced microtubule asters exceeded the number of gamma-tubulin-positive spots.	Paclitaxel	76-81	protein tyrosine kinase 2	Homo sapiens	118-122
21546534-6	2011	Cells transfected with stathmin siRNA showed long and bundled microtubule polymers and sensitized the Y79 cells significantly to paclitaxel and vincristine.	Paclitaxel	129-139	stathmin 1	Homo sapiens	23-31
21546534-8	2011	Strategies to inhibit stathmin will help to enhance the cytotoxic effect of paclitaxel while reducing toxicity (or side effects) to normal cells caused by high doses.	Paclitaxel	76-86	stathmin 1	Homo sapiens	22-30
21111509-7	2011	A low expression level of TS or of DPD was associated with a better response and longer survival in patients treated with S-1-carboplatin but not in those treated with paclitaxel-carboplatin.	Paclitaxel	168-178	thymidylate synthetase	Homo sapiens	26-28
27443528-8	2016	The most abundant expression of ALDH1A1 was noted in paclitaxel- and topotecan-resistant cell lines where two populations of ALDH-positive and ALDH-negative cells could be observed.	Paclitaxel	53-63	aldehyde dehydrogenase 1 family member A1	Homo sapiens	32-39
27443528-8	2016	The most abundant expression of ALDH1A1 was noted in paclitaxel- and topotecan-resistant cell lines where two populations of ALDH-positive and ALDH-negative cells could be observed.	Paclitaxel	53-63	aldehyde dehydrogenase 1 family member A1	Homo sapiens	32-36
27443528-8	2016	The most abundant expression of ALDH1A1 was noted in paclitaxel- and topotecan-resistant cell lines where two populations of ALDH-positive and ALDH-negative cells could be observed.	Paclitaxel	53-63	aldehyde dehydrogenase 1 family member A1	Homo sapiens	125-129
27059733-10	2016	In summary, our study elucidated that exogenous galectin-3 might induce paclitaxel resistance through TLR4 signaling activation by inhibiting TLR4-Cav-1 interaction, revealing a novel insight into paclitaxel resistance induction.	Paclitaxel	72-82	toll like receptor 4	Homo sapiens	142-146
27059733-10	2016	In summary, our study elucidated that exogenous galectin-3 might induce paclitaxel resistance through TLR4 signaling activation by inhibiting TLR4-Cav-1 interaction, revealing a novel insight into paclitaxel resistance induction.	Paclitaxel	197-207	toll like receptor 4	Homo sapiens	102-106
27059733-10	2016	In summary, our study elucidated that exogenous galectin-3 might induce paclitaxel resistance through TLR4 signaling activation by inhibiting TLR4-Cav-1 interaction, revealing a novel insight into paclitaxel resistance induction.	Paclitaxel	197-207	toll like receptor 4	Homo sapiens	142-146
27409838-0	2016	Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.	Paclitaxel	56-66	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	34-38
27409838-5	2016	We investigated the role of FBXW7 and their substrates MCL1 and PLK1 in regulating the apoptotic response to paclitaxel treatment in breast cancer cells and their expression in breast cancer tissues.	Paclitaxel	109-119	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	55-59
20816848-2	2011	High stathmin levels have been associated with the development of resistance to the widely used anti-cancer drug taxol (( )Taxol, paclitaxel).	Paclitaxel	113-118	stathmin 1	Homo sapiens	5-13
20816848-2	2011	High stathmin levels have been associated with the development of resistance to the widely used anti-cancer drug taxol (( )Taxol, paclitaxel).	Paclitaxel	123-128	stathmin 1	Homo sapiens	5-13
20816848-2	2011	High stathmin levels have been associated with the development of resistance to the widely used anti-cancer drug taxol (( )Taxol, paclitaxel).	Paclitaxel	130-140	stathmin 1	Homo sapiens	5-13
8824733-5	1996	Examination of relative location of gamma-tubulin and microtubule asters in taxol-treated mitotic cells 3T3, HeLa and PtK2 revealed that the number of taxol-induced microtubule asters exceeded the number of gamma-tubulin-positive spots.	Paclitaxel	151-156	protein tyrosine kinase 2	Homo sapiens	118-122
20816848-3	2011	The mechanisms of stathmin-mediated taxol resistance are not well-understood at the molecular level.	Paclitaxel	36-41	stathmin 1	Homo sapiens	18-26
20816848-7	2011	Sensitivity to taxol was reduced significantly (by 44%) in a clonogenic assay, and stathmin appeared to protect the cells from the spindle-damaging effects of taxol.	Paclitaxel	159-164	stathmin 1	Homo sapiens	83-91
9186547-3	1996	However, alendronate pretreatment of mice (0.1 mg/kg twice weekly or weekly) and dosing along with taxol (10-50 mg/kg/day, twice weekly, or weekly) blocked the growth of PC-3 ML tumors in the bone marrow and soft tissues in a statistically significant manner and improved survival rates significantly (p &lt; 0.001) by 4-5 weeks.	Paclitaxel	99-104	chromobox 8	Mus musculus	170-174
20816848-9	2011	Stathmin overexpression protected the cells from taxol-induced abnormal mitoses, and thus induced taxol resistance.	Paclitaxel	49-54	stathmin 1	Homo sapiens	0-8
20816848-9	2011	Stathmin overexpression protected the cells from taxol-induced abnormal mitoses, and thus induced taxol resistance.	Paclitaxel	98-103	stathmin 1	Homo sapiens	0-8
21634028-5	2011	We found that paclitaxel induced a 2-3 fold increase in mRNA for beta-tubulin IIA and III genes, TUBB2A, and TUBB3.	Paclitaxel	14-24	tubulin beta 2A class IIa	Homo sapiens	97-103
21634028-10	2011	We found a significant decrease in the tumor suppressor, miR-100, in MCF7 cells in response to paclitaxel treatment.	Paclitaxel	95-105	microRNA 100	Homo sapiens	57-64
21634028-11	2011	Transfection of MCF7 cells with miR-100 significantly reduced beta-tubulin I, IIA, IIB and V mRNA and prevented paclitaxel-induced increases in beta-tubulin isotypes.	Paclitaxel	112-122	microRNA 100	Homo sapiens	32-39
27409838-7	2016	Forced expression of FBXW7 or downregulation of MCL1 or PLK1 restored sensitivity to paclitaxel in MDA-MB-468R cells.	Paclitaxel	85-95	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	48-52
27409838-10	2016	In breast cancer tissues, loss of FBXW7 correlated with adverse prognosis markers and loss of FBXW7 and MCL1 or PLK1 accumulation were associated with diminished disease-free survival in paclitaxel-treated patients.	Paclitaxel	187-197	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	104-108
27409838-11	2016	We conclude that FBXW7 regulates the response to paclitaxel by targeting MCL1 and PLK1 in breast cancer cells and thus targeting these substrates may be a valuable adjunct for paclitaxel treatment.	Paclitaxel	49-59	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	73-77
20677914-1	2011	Aminopeptidase N (APN), recognized by Asn-Gly-Arg (NGR) peptides, is expressed in the pericytes associated with the BBB, and the main objective of this study is to confirm the hypothesis that NGR-modified DSPE-PEG micelles containing paclitaxel (NGR-M-PTX) can bind to and kill brain tumor angiogenic blood vessels and penetrate into the brain tumor interstitial space, resulting in direct cell death.	Paclitaxel	234-244	alanyl aminopeptidase, membrane	Rattus norvegicus	0-16
8801338-9	1995	HP beta CyD allowed paclitaxel administration at higher doses and had an MTD of 25 mg drug/kg.	Paclitaxel	20-30	cytochrome b-245, beta polypeptide	Mus musculus	8-11
20677914-1	2011	Aminopeptidase N (APN), recognized by Asn-Gly-Arg (NGR) peptides, is expressed in the pericytes associated with the BBB, and the main objective of this study is to confirm the hypothesis that NGR-modified DSPE-PEG micelles containing paclitaxel (NGR-M-PTX) can bind to and kill brain tumor angiogenic blood vessels and penetrate into the brain tumor interstitial space, resulting in direct cell death.	Paclitaxel	234-244	alanyl aminopeptidase, membrane	Rattus norvegicus	18-21
27342144-4	2016	Reciprocally, PROS1 knockdown inhibited cell invasiveness and migration, caused the growth inhibition of castration-resistant tumor xenograft under androgen-depleted conditions, and potentiated Taxol (a widely prescribed anti-neoplastic agent)-mediated cell death in PC3 cells.	Paclitaxel	194-199	protein S	Homo sapiens	14-19
21600073-5	2011	Ndc80 was localized on microtubules and asters in the cytoplasm after taxol treatment, while Ndc80 staining was diffuse after disruption of microtubules by nocodazole treatment, confirming its microtubule localization.	Paclitaxel	70-75	NDC80 kinetochore complex component	Mus musculus	0-5
27311481-6	2016	By contrast, SIRT2 and HDAC6 acted similarly on the morphologically different, hyperacetylated microtubule structures induced by taxol, MAP2c overexpression or hyperosmotic stress.	Paclitaxel	129-134	sirtuin 2	Homo sapiens	13-18
8801338-10	1995	The CyDs tested are marginal in feasibility for paclitaxel administration, and their use in taxane formulation will require a reduction of the dose-limiting toxicity of the CyD itself.	Paclitaxel	48-58	cytochrome b-245, beta polypeptide	Mus musculus	4-7
1356977-0	1992	The involvement of a LINE-1 element in a DNA rearrangement upstream of the mdr1a gene in a taxol multidrug-resistant murine cell line.	Paclitaxel	91-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	75-80
26852748-5	2016	Moreover, microRNA (miR)-216b levels were significantly downregulated in paclitaxel-treated NSCLC cells.	Paclitaxel	73-83	microRNA 216b	Homo sapiens	10-29
26852748-7	2016	Together, these data suggest that paclitaxel may decrease miR-216b levels in NSCLC cells, which subsequently upregulates Beclin-1 to increase NSCLC cell autophagy to antagonize paclitaxel-induced cell death.	Paclitaxel	34-44	microRNA 216b	Homo sapiens	58-66
26852748-8	2016	Strategies that increase miR-216b levels or inhibit cell autophagy may improve the outcome of paclitaxel treatment in NSCLC therapy.	Paclitaxel	94-104	microRNA 216b	Homo sapiens	25-33
21576088-0	2011	Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.	Paclitaxel	41-51	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	16-22
21576088-0	2011	Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.	Paclitaxel	41-51	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	24-28
21576088-4	2011	Mouse embryo fibroblasts derived from Abcc10(-/-) mice were hypersensitive to docetaxel, paclitaxel, vincristine, and cytarabine (Ara-C) and exhibited increased cellular drug accumulation, relative to wild-type controls.	Paclitaxel	89-99	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	38-44
21576088-5	2011	Abcc10(-/-) null mice treated with paclitaxel exhibited increased lethality associated with neutropenia and marked bone marrow toxicity.	Paclitaxel	35-45	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	0-6
26883251-7	2016	Under different concentrations of 5-FU and paclitaxel in MDA-MB231 cell, E-cadherin mRNA and protein expressions increased gradually with the increase of concentrations, and Vimentin and N-cadherin mRNA and protein expressions decreased gradually with the decrease of concentrations (all P &lt; 0.05).	Paclitaxel	43-53	vimentin	Homo sapiens	174-182
27474498-7	2016	administration of the anti-HMGB1-neutralizing antibody or recombinant human soluble thrombomodulin (rhsTM), known to inactivate HMGB1, prevented the development of hyperalgesia and/or allodynia induced by paclitaxel or vincristine in rats.	Paclitaxel	205-215	thrombomodulin	Homo sapiens	84-98
1350792-5	1992	But Taxol seemed to be a weak inducer of the two interleukins IL-1 and IL-2, since their detection occurred late in the cell culture supernatants.	Paclitaxel	4-9	interleukin 1 complex	Mus musculus	62-66
1981943-1	1990	Formerly, we reported for microtubule protein (MTP), i.e. tubulin plus microtubule-associated proteins (MAPs), from porcine brain that the protofilament number of microtubules and the percentage of aberrant assemblies depend on taxol and MAP activity (Bohm et al., BBA 800, 119, 1984).	Paclitaxel	228-233	microsomal triglyceride transfer protein	Gallus gallus	26-45
21826992-6	2011	Compared with the vehicle control, Taxol up-regulated mRNA and protein levels of P-gp, whereas Celecoxib down-regulated mRNA and protein levels of P-gp and BCRP (P &lt; 0.05).	Paclitaxel	35-40	phosphoglycolate phosphatase	Homo sapiens	81-85
21490216-6	2011	We report that BACE1 knock-out and wild-type nerves degenerated at a similar rate after axotomy and to a similar extent in the experimental neuropathies produced by administration of paclitaxel and acrylamide.	Paclitaxel	183-193	beta-site APP cleaving enzyme 1	Mus musculus	15-20
1981943-1	1990	Formerly, we reported for microtubule protein (MTP), i.e. tubulin plus microtubule-associated proteins (MAPs), from porcine brain that the protofilament number of microtubules and the percentage of aberrant assemblies depend on taxol and MAP activity (Bohm et al., BBA 800, 119, 1984).	Paclitaxel	228-233	microsomal triglyceride transfer protein	Gallus gallus	47-50
27240325-1	2016	In the realm of natural product chemistry, few isolates have risen to the level of fame justifiably accorded to Taxol (1) and its chemical siblings.	Paclitaxel	112-117	benign adult familial myoclonic epilepsy 2	Homo sapiens	83-87
1981943-3	1990	Comparing the structural features of assemblies formed from these kinds of MTP with each other no significant differences were found, excepted chicken MTP which produces more aberrant assemblies in the presence of taxol.	Paclitaxel	214-219	microsomal triglyceride transfer protein	Gallus gallus	75-78
1981943-3	1990	Comparing the structural features of assemblies formed from these kinds of MTP with each other no significant differences were found, excepted chicken MTP which produces more aberrant assemblies in the presence of taxol.	Paclitaxel	214-219	microsomal triglyceride transfer protein	Gallus gallus	151-154
21440127-3	2011	We hypothesized that local delivery of paclitaxel through 100-nm expansile polymer nanoparticles (pax-eNP) immediately after tumor resection could prevent local recurrence.	Paclitaxel	39-49	centromere protein H	Mus musculus	102-105
32796817-5	2020	Knockdown of E2F1 and CCND1 reduced cell proliferation and PTX-sensitivity, whereas overexpression of them had the opposite effect.	Paclitaxel	59-62	E2F transcription factor 1 L homeolog	Xenopus laevis	13-17
27354589-7	2016	RESULTS: Incubation with paclitaxel, and with carboplatin significantly reduced cell growth without a definitive increase of intracellular HSPB1 expression.	Paclitaxel	25-35	heat shock protein family B (small) member 1	Homo sapiens	139-144
26869361-9	2016	Paclitaxel also inhibited the UUO-induced activation of Smad2/3 and c-Jun N-terminal kinase (JNK).	Paclitaxel	0-10	SMAD family member 2	Rattus norvegicus	56-63
26869361-9	2016	Paclitaxel also inhibited the UUO-induced activation of Smad2/3 and c-Jun N-terminal kinase (JNK).	Paclitaxel	0-10	mitogen-activated protein kinase 8	Rattus norvegicus	68-91
26869361-9	2016	Paclitaxel also inhibited the UUO-induced activation of Smad2/3 and c-Jun N-terminal kinase (JNK).	Paclitaxel	0-10	mitogen-activated protein kinase 8	Rattus norvegicus	93-96
26869361-11	2016	In TGF-beta1-treated IMCD cells, treatment with 1 and 2 nM paclitaxel for 72 h reduced fibronectin, alpha-SMA and PAI-1 protein expression.	Paclitaxel	59-69	fibronectin 1	Rattus norvegicus	87-98
26869361-11	2016	In TGF-beta1-treated IMCD cells, treatment with 1 and 2 nM paclitaxel for 72 h reduced fibronectin, alpha-SMA and PAI-1 protein expression.	Paclitaxel	59-69	actin gamma 2, smooth muscle	Rattus norvegicus	100-109
26869361-12	2016	Moreover, a 2 nM dose of paclitaxel for 24 h significantly inhibited the TGF-beta1-stimulated activation of Smad2/3, JNK and ERK1/2 in IMCD cells.	Paclitaxel	25-35	SMAD family member 2	Rattus norvegicus	108-115
25797481-3	2015	For this purpose, PTX-loaded albumin nanoparticles (APN) were prepared and encapsulated in PEGylated hybrid liposomes containing CUR (CL-APN) via a thin-film hydration technique.	Paclitaxel	18-21	alanyl aminopeptidase, membrane	Homo sapiens	52-55
27082499-5	2016	Co-treatment of STK16-IN-1 with chemotherapeutics such as cisplatin, doxorubicin, colchicine, and paclitaxel results in a slight potentiation of the antiproliferative effects of the chemotherapeutics.	Paclitaxel	98-108	serine/threonine kinase 16	Homo sapiens	16-21
25797481-3	2015	For this purpose, PTX-loaded albumin nanoparticles (APN) were prepared and encapsulated in PEGylated hybrid liposomes containing CUR (CL-APN) via a thin-film hydration technique.	Paclitaxel	18-21	alanyl aminopeptidase, membrane	Homo sapiens	137-140
34968866-8	2022	In human pancreatic cancer cell lines, MDC-22 enhanced the growth inhibitory effect of irinotecan, and to a lesser degree those of gemcitabine and nab-paclitaxel.	Paclitaxel	151-161	C-C motif chemokine ligand 22	Homo sapiens	39-42
27478778-0	2016	Silencing of High Mobility Group Isoform I-C (HMGI-C) Enhances Paclitaxel Chemosensitivity in Breast Adenocarcinoma Cells (MDA-MB-468).	Paclitaxel	63-73	high mobility group AT-hook 2	Homo sapiens	46-52
26551762-0	2016	The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.	Paclitaxel	76-86	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	23-29
26551762-1	2016	The aim of the present study was to further investigate a previously identified metabolic interaction between losartan and paclitaxel, which is one of the marker substrates of CYP2C8, by using human liver microsomes (HLMs) from donors with different CYP2C8 and CYP2C9 genotypes.	Paclitaxel	123-133	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	261-267
34839191-6	2022	Cofilin-1 knockdown in FBXO31-overexpression cells reversed FBXO31-induced suppression of cell apoptosis, suggesting FBXO31-mediated Taxol chemoresistance is associated with cofilin-1.	Paclitaxel	133-138	cofilin 1	Homo sapiens	0-9
27338042-10	2016	Both drug sensitivity assay and flow cytometry analysis confirmed that the effect of miR-18a on increasing IC50 and decreasing PTX induced apoptosis in MDA-MB-231 cells could largely be abrogated by treatment with bafilomycin A1 (Baf.	Paclitaxel	127-130	microRNA 18a	Homo sapiens	85-92
27338042-12	2016	CONCLUSIONS: MiR-18a upregulation results in enhanced autophagy via inhibiting mTOR signaling pathway in TNBC cells, which is a mechanism contributing to paclitaxel resistance.	Paclitaxel	154-164	microRNA 18a	Homo sapiens	13-20
27338043-0	2016	MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer.	Paclitaxel	60-70	microRNA 18a	Homo sapiens	0-7
27338043-8	2016	RESULTS: Tissues from patients with stable disease (SD, n = 5) and progressive disease (PD, n = 2) to paclitaxel (PTX) containing neoadjuvant chemotherapy had significantly higher miR-18a expression than that from patients with partial response (PR, n = 13).	Paclitaxel	102-112	microRNA 18a	Homo sapiens	180-187
27338043-8	2016	RESULTS: Tissues from patients with stable disease (SD, n = 5) and progressive disease (PD, n = 2) to paclitaxel (PTX) containing neoadjuvant chemotherapy had significantly higher miR-18a expression than that from patients with partial response (PR, n = 13).	Paclitaxel	114-117	microRNA 18a	Homo sapiens	180-187
27338043-9	2016	MDA-MB-231/PTX cells had higher miR-18a expression than MDA-MB-231 cells.	Paclitaxel	11-14	microRNA 18a	Homo sapiens	32-39
27338043-11	2016	MiR-18a overexpression significantly increased PTX IC50 and reduced PTX induced cell apoptosis, while miR-18a suppression substantially decreased PTX IC50 and increased PTX induced cell apoptosis.	Paclitaxel	47-50	microRNA 18a	Homo sapiens	0-7
27338043-11	2016	MiR-18a overexpression significantly increased PTX IC50 and reduced PTX induced cell apoptosis, while miR-18a suppression substantially decreased PTX IC50 and increased PTX induced cell apoptosis.	Paclitaxel	68-71	microRNA 18a	Homo sapiens	0-7
34839191-6	2022	Cofilin-1 knockdown in FBXO31-overexpression cells reversed FBXO31-induced suppression of cell apoptosis, suggesting FBXO31-mediated Taxol chemoresistance is associated with cofilin-1.	Paclitaxel	133-138	cofilin 1	Homo sapiens	174-183
34953979-5	2022	The innovative liposomal nanosystem was rationally designed by a remote loading of BMS-202 (a small molecule PD-1/PD-L1 inhibitor) and PSN into the liposomes for a ROS-sensitive paclitaxel release and sustained BMS-202 release.	Paclitaxel	178-188	programmed cell death 1	Homo sapiens	109-113
27338043-11	2016	MiR-18a overexpression significantly increased PTX IC50 and reduced PTX induced cell apoptosis, while miR-18a suppression substantially decreased PTX IC50 and increased PTX induced cell apoptosis.	Paclitaxel	68-71	microRNA 18a	Homo sapiens	0-7
27338043-11	2016	MiR-18a overexpression significantly increased PTX IC50 and reduced PTX induced cell apoptosis, while miR-18a suppression substantially decreased PTX IC50 and increased PTX induced cell apoptosis.	Paclitaxel	68-71	microRNA 18a	Homo sapiens	0-7
27338043-12	2016	CONCLUSIONS: This study found that miR-18a is an important miRNA that suppresses Dicer expression and increases PTX resistance in TNBC cells.	Paclitaxel	112-115	microRNA 18a	Homo sapiens	35-42
34953982-5	2022	Meanwhile, CQ-HF/PTX nanogels play two roles in anti-metastasis: i) For reducing the "attractive force", it could block the CXCR4/SDF-1 pathway, preventing tumor cells metastasis to the lung; ii) For reinforcing "adhesion force", it could inhibit the excessive autophagy for hindering the degradation of paxillin and enhancing the cell adhesion.	Paclitaxel	17-20	C-X-C motif chemokine ligand 12	Homo sapiens	130-135
34304352-3	2022	Paclitaxel is predominantly metabolized in the liver by cytochrome P450 (CYP) 2C8 to produce 6alpha-hydroxypaclitaxel and by CYP3A4 to produce 3"-p-hydroxypaclitaxel.	Paclitaxel	0-10	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	56-81
34304352-4	2022	In this study, we evaluated the inhibitory or inducing effects of goshajinkigan extract (GJG) and its representative and bioavailable constituents, geniposidic acid, plantagoguanidinic acid, paeoniflorin, catalpol, loganin, and neoline, on the metabolism of paclitaxel via CYP2C8 and CYP3A4 using pooled human liver microsomes and cultured human cryopreserved hepatocytes to provide the drug information about the pharmacokinetic interaction of this combination therapy.	Paclitaxel	258-268	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	273-279
27109260-0	2016	Paclitaxel inhibits selenoprotein S expression and attenuates endoplasmic reticulum stress.	Paclitaxel	0-10	selenoprotein S	Homo sapiens	20-35
34964544-0	2022	Peptide Modified Albumin-Paclitaxel Nanoparticles for Improving Chemotherapy and Preventing Metastasis.	Paclitaxel	25-35	albumin	Mus musculus	17-24
27109260-7	2016	From this, paclitaxel (PTX) was identified to efficiently inhibit the promoter activity of the SelS gene, and further results revealed that PTX significantly inhibited the tunicamycin-induced upregulation of SelS at the mRNA and protein levels in HepG2 and HEK293T cells.	Paclitaxel	11-21	selenoprotein S	Homo sapiens	95-99
27109260-7	2016	From this, paclitaxel (PTX) was identified to efficiently inhibit the promoter activity of the SelS gene, and further results revealed that PTX significantly inhibited the tunicamycin-induced upregulation of SelS at the mRNA and protein levels in HepG2 and HEK293T cells.	Paclitaxel	11-21	selenoprotein S	Homo sapiens	208-212
27109260-7	2016	From this, paclitaxel (PTX) was identified to efficiently inhibit the promoter activity of the SelS gene, and further results revealed that PTX significantly inhibited the tunicamycin-induced upregulation of SelS at the mRNA and protein levels in HepG2 and HEK293T cells.	Paclitaxel	23-26	selenoprotein S	Homo sapiens	95-99
27109260-7	2016	From this, paclitaxel (PTX) was identified to efficiently inhibit the promoter activity of the SelS gene, and further results revealed that PTX significantly inhibited the tunicamycin-induced upregulation of SelS at the mRNA and protein levels in HepG2 and HEK293T cells.	Paclitaxel	23-26	selenoprotein S	Homo sapiens	208-212
27109260-7	2016	From this, paclitaxel (PTX) was identified to efficiently inhibit the promoter activity of the SelS gene, and further results revealed that PTX significantly inhibited the tunicamycin-induced upregulation of SelS at the mRNA and protein levels in HepG2 and HEK293T cells.	Paclitaxel	140-143	selenoprotein S	Homo sapiens	95-99
27109260-7	2016	From this, paclitaxel (PTX) was identified to efficiently inhibit the promoter activity of the SelS gene, and further results revealed that PTX significantly inhibited the tunicamycin-induced upregulation of SelS at the mRNA and protein levels in HepG2 and HEK293T cells.	Paclitaxel	140-143	selenoprotein S	Homo sapiens	208-212
27109260-9	2016	Taken together, these results suggest that PTX is able to inhibit SelS expression during ER stress and attenuate ER stress.	Paclitaxel	43-46	selenoprotein S	Homo sapiens	66-70
34964544-3	2022	The hydrophobic drug (paclitaxel) induced albumin self-assembly after treatment of albumin with L-cysteine, forming drug-loaded nanoparticles with a size of 100-200 nm.	Paclitaxel	22-32	albumin	Mus musculus	42-49
34964544-3	2022	The hydrophobic drug (paclitaxel) induced albumin self-assembly after treatment of albumin with L-cysteine, forming drug-loaded nanoparticles with a size of 100-200 nm.	Paclitaxel	22-32	albumin	Mus musculus	83-90
26833548-2	2016	PTX can be encapsulated by the NPs with various molar ratios of L-lactide (LA) and 6-O-methacryloyl-D-galactopyranose (MAGP) during the process of self-assembly, and the resulting NPs exhibit high drug loading efficacy and substantial stability in aqueous solution.	Paclitaxel	0-3	microfibril associated protein 2	Homo sapiens	83-117
34968485-0	2022	DIAPH1 facilitates paclitaxel-mediated cytotoxicity of ovarian cancer cells.	Paclitaxel	19-29	diaphanous related formin 1	Homo sapiens	0-6
26833548-2	2016	PTX can be encapsulated by the NPs with various molar ratios of L-lactide (LA) and 6-O-methacryloyl-D-galactopyranose (MAGP) during the process of self-assembly, and the resulting NPs exhibit high drug loading efficacy and substantial stability in aqueous solution.	Paclitaxel	0-3	microfibril associated protein 2	Homo sapiens	119-123
34968485-4	2022	A possible explanation for this finding is that Ovca cells with high DIAPH1 levels are more sensitive to PTX.	Paclitaxel	105-108	diaphanous related formin 1	Homo sapiens	69-75
26934847-0	2016	Downregulation of importin-9 protects MCF-7 cells against apoptosis induced by the combination of garlic-derived alliin and paclitaxel.	Paclitaxel	124-134	importin 9	Homo sapiens	18-28
26934847-3	2016	The aim of the present study was to study the impact of altered actin transport between the cytoplasm and nucleus by the downregulation of importin-9 (IPO9) in breast adenocarcinoma MCF-7 cells exposed to an apoptosis-inducing combination of garlic-derived S-allyl-L-cysteine sulfoxide (alliin) and paclitaxel (PTX).	Paclitaxel	299-309	importin 9	Homo sapiens	139-149
26934847-3	2016	The aim of the present study was to study the impact of altered actin transport between the cytoplasm and nucleus by the downregulation of importin-9 (IPO9) in breast adenocarcinoma MCF-7 cells exposed to an apoptosis-inducing combination of garlic-derived S-allyl-L-cysteine sulfoxide (alliin) and paclitaxel (PTX).	Paclitaxel	299-309	importin 9	Homo sapiens	151-155
26934847-3	2016	The aim of the present study was to study the impact of altered actin transport between the cytoplasm and nucleus by the downregulation of importin-9 (IPO9) in breast adenocarcinoma MCF-7 cells exposed to an apoptosis-inducing combination of garlic-derived S-allyl-L-cysteine sulfoxide (alliin) and paclitaxel (PTX).	Paclitaxel	311-314	importin 9	Homo sapiens	139-149
34968485-6	2022	Our data showed that down-regulation of DIAPH1 expression decreased PTX sensitivity in both cell lines by reducing apoptosis or necrosis.	Paclitaxel	68-71	diaphanous related formin 1	Homo sapiens	40-46
34968485-7	2022	Analysis of MT stability by Western blotting revealed a decreased concentration of stable, detyrosinated MTs in PTX-treated DIAPH1 knock-down compared to control cells.	Paclitaxel	112-115	diaphanous related formin 1	Homo sapiens	124-130
34968485-9	2022	In vitro analysis with recombinant DIAPH1 protein showed that PTX and DIAPH1 exhibited additive effects on MT-polymerization, showing that also in a cell-free system DIAPH1 increased the effect of PTX on MT-stability.	Paclitaxel	197-200	diaphanous related formin 1	Homo sapiens	35-41
26934847-3	2016	The aim of the present study was to study the impact of altered actin transport between the cytoplasm and nucleus by the downregulation of importin-9 (IPO9) in breast adenocarcinoma MCF-7 cells exposed to an apoptosis-inducing combination of garlic-derived S-allyl-L-cysteine sulfoxide (alliin) and paclitaxel (PTX).	Paclitaxel	311-314	importin 9	Homo sapiens	151-155
34968485-9	2022	In vitro analysis with recombinant DIAPH1 protein showed that PTX and DIAPH1 exhibited additive effects on MT-polymerization, showing that also in a cell-free system DIAPH1 increased the effect of PTX on MT-stability.	Paclitaxel	197-200	diaphanous related formin 1	Homo sapiens	70-76
26934847-6	2016	Moreover, the effect of the downregulation of IPO9 on cell death induced by the combination of PTX and alliin was also investigated.	Paclitaxel	95-98	importin 9	Homo sapiens	46-50
34968485-9	2022	In vitro analysis with recombinant DIAPH1 protein showed that PTX and DIAPH1 exhibited additive effects on MT-polymerization, showing that also in a cell-free system DIAPH1 increased the effect of PTX on MT-stability.	Paclitaxel	197-200	diaphanous related formin 1	Homo sapiens	166-172
34968485-10	2022	Together, our data strongly indicate that DIAPH1 increases the response of Ovca cells to PTX by enhancing PTX-mediated MT-stability.	Paclitaxel	89-92	diaphanous related formin 1	Homo sapiens	42-48
26993770-0	2016	MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression.	Paclitaxel	46-56	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	80-85
34968485-10	2022	Together, our data strongly indicate that DIAPH1 increases the response of Ovca cells to PTX by enhancing PTX-mediated MT-stability.	Paclitaxel	106-109	diaphanous related formin 1	Homo sapiens	42-48
26993770-5	2016	Up-regulation of IKBKB suppressed Taxol-induced apoptosis and led to an increased resistance to Taxol, and restoring IKBKB expression in miR-16-overexpressing breast cancer cells recovered Taxol resistance.	Paclitaxel	34-39	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	17-22
26993770-5	2016	Up-regulation of IKBKB suppressed Taxol-induced apoptosis and led to an increased resistance to Taxol, and restoring IKBKB expression in miR-16-overexpressing breast cancer cells recovered Taxol resistance.	Paclitaxel	96-101	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	17-22
34415232-0	2021	MicroRNA-624-mediated ARRDC3/YAP/HIF1alpha axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel.	Paclitaxel	125-135	Yes1 associated transcriptional regulator	Homo sapiens	29-32
26993770-5	2016	Up-regulation of IKBKB suppressed Taxol-induced apoptosis and led to an increased resistance to Taxol, and restoring IKBKB expression in miR-16-overexpressing breast cancer cells recovered Taxol resistance.	Paclitaxel	96-101	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	17-22
26993770-6	2016	Moreover, miR-16 was highly expressed in Taxol-sensitive breast cancer tissues compared with Taxol-resistant tissues, and there was an inverse correlation between miR-16 expression and IKBKB expression in breast cancer tissues.	Paclitaxel	41-46	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	185-190
26993770-6	2016	Moreover, miR-16 was highly expressed in Taxol-sensitive breast cancer tissues compared with Taxol-resistant tissues, and there was an inverse correlation between miR-16 expression and IKBKB expression in breast cancer tissues.	Paclitaxel	93-98	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	185-190
34415232-10	2021	miR-624 downregulated ARRDC3 to increase YAP and HIF1alpha expression so as to enhance ESCC cell resistance to CIS and PT in vitro and in vivo.	Paclitaxel	119-121	Yes1 associated transcriptional regulator	Homo sapiens	41-44
26993770-8	2016	Taken together, our data demonstrates that miR-16 sensitizes breast cancer cells to Taxol through the suppression of IKBKB expression, and targeting miR-16/IKBKB axis will be a promising strategy for overcoming Taxol resistance in breast cancer.	Paclitaxel	84-89	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	117-122
26993770-8	2016	Taken together, our data demonstrates that miR-16 sensitizes breast cancer cells to Taxol through the suppression of IKBKB expression, and targeting miR-16/IKBKB axis will be a promising strategy for overcoming Taxol resistance in breast cancer.	Paclitaxel	84-89	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	156-161
34696661-0	2021	Carbonic anhydrase 12 gene silencing reverses the sensitivity of paclitaxel in drug-resistant breast cancer cells.	Paclitaxel	65-75	carbonic anhydrase 12	Homo sapiens	0-21
26993770-8	2016	Taken together, our data demonstrates that miR-16 sensitizes breast cancer cells to Taxol through the suppression of IKBKB expression, and targeting miR-16/IKBKB axis will be a promising strategy for overcoming Taxol resistance in breast cancer.	Paclitaxel	211-216	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	117-122
26993770-8	2016	Taken together, our data demonstrates that miR-16 sensitizes breast cancer cells to Taxol through the suppression of IKBKB expression, and targeting miR-16/IKBKB axis will be a promising strategy for overcoming Taxol resistance in breast cancer.	Paclitaxel	211-216	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	156-161
34696661-1	2021	This study aimed to investigate the effects of carbonic anhydrase 12 (CA12)-siRNA on the paclitaxel sensitivity of breast cancer cells.	Paclitaxel	89-99	carbonic anhydrase 12	Homo sapiens	47-68
34696661-1	2021	This study aimed to investigate the effects of carbonic anhydrase 12 (CA12)-siRNA on the paclitaxel sensitivity of breast cancer cells.	Paclitaxel	89-99	carbonic anhydrase 12	Homo sapiens	70-74
26988911-1	2016	We previously reported that ATP7B is involved in cisplatin resistance and ATP7A confers multidrug resistance (MDR) in cancer cells.In this study, we show that ATP7B expressing cells also are resistant to doxorubicin, SN-38, etoposide, and paclitaxel as well as cisplatin.In ATP7B expressing cells, doxorubicin relocated from the nuclei to the late-endosome at 4 hours after doxorubicin exposure.	Paclitaxel	239-249	ATPase copper transporting beta	Gallus gallus	159-164
34696661-7	2021	The growth rate of CA12-siRNA treated MCF-7 TaxR cells with paclitaxel (PTX) co-culture was markedly declined at 48 hours.	Paclitaxel	60-70	carbonic anhydrase 12	Homo sapiens	19-23
34696661-7	2021	The growth rate of CA12-siRNA treated MCF-7 TaxR cells with paclitaxel (PTX) co-culture was markedly declined at 48 hours.	Paclitaxel	72-75	carbonic anhydrase 12	Homo sapiens	19-23
34696661-11	2021	Our results indicated that the application of PTX combined silencing CA12 was able to activate the mitochondrial apoptosis pathway and promote MCF-7 TaxR apoptosis.	Paclitaxel	46-49	carbonic anhydrase 12	Homo sapiens	69-73
34696661-12	2021	CA12 silencing in the PTX-resistant breast cancer cell can reverse the sensitivity of PTX.	Paclitaxel	86-89	carbonic anhydrase 12	Homo sapiens	0-4
34109887-7	2021	CONCLUSIONS: This carrier strategy for small molecule drugs is based on naturally evolved interactions between long-chain fatty acids (LCFAs) and Human Serum Albumin (HSA), demonstrated here for PTX.	Paclitaxel	195-198	albumin	Mus musculus	152-165
26988911-1	2016	We previously reported that ATP7B is involved in cisplatin resistance and ATP7A confers multidrug resistance (MDR) in cancer cells.In this study, we show that ATP7B expressing cells also are resistant to doxorubicin, SN-38, etoposide, and paclitaxel as well as cisplatin.In ATP7B expressing cells, doxorubicin relocated from the nuclei to the late-endosome at 4 hours after doxorubicin exposure.	Paclitaxel	239-249	ATPase copper transporting beta	Gallus gallus	159-164
34626199-14	2021	JAK2 regulated paclitaxel-resistant CAF phenotype transition.	Paclitaxel	15-25	Janus kinase 2	Homo sapiens	0-4
26910911-7	2016	The tumor suppressor PLK2 inhibited SiHa cell proliferation, reduced cell viability, and promoted paclitaxel/cisplatin -induced apoptosis.	Paclitaxel	98-108	polo like kinase 2	Homo sapiens	21-25
26910911-9	2016	Our study demonstrated that HPV16 E7 could increase DGCR8 to promote the generation of miR-27b, which accelerated cell proliferation and inhibited paclitaxel-induced cell apoptosis through down-regulating PLK2.	Paclitaxel	147-157	polo like kinase 2	Homo sapiens	205-209
21044799-3	2011	Anti-tumor efficacy of paclitaxel-loaded pH-responsive expansile nanoparticles (Pax-eNP) was evaluated in vitro and in in vivo murine models of malignant peritoneal mesothelioma.	Paclitaxel	23-33	centromere protein H	Mus musculus	84-87
34761735-9	2021	Patients in the high MKL1 expression group showed sensitivity to paclitaxel, while those in the low expression group showed potential sensitivity for cisplatin and docetaxel.	Paclitaxel	65-75	myocardin related transcription factor A	Homo sapiens	21-25
26892177-0	2016	Downregulation of cytokeratin 18 is associated with paclitaxel-resistance and tumor aggressiveness in prostate cancer.	Paclitaxel	52-62	keratin 18	Homo sapiens	18-32
34740994-9	2021	In general, our study found (1) miR-26a-5p was a protective factor of breast cancer, while OTUD6B-AS1 and MTDH were risk factors; (2) OTUD6B-AS1 was the up-stream regulator of miR-26a-5p verified by luciferase; (3) up-regulation of miR-26a-5p and down-regulation of MTDH promoted cellular cytotoxicity of paclitaxel (PTX) in vitro and in vivo.	Paclitaxel	305-315	prostaglandin D2 receptor	Homo sapiens	141-144
26892177-4	2016	By comparing the nuclear matrix protein (NMP) patterns of DU145-TxR cells, the previously established stable paclitaxel-resistant PCa cells, with that of the parental DU145 cells using two-dimensional electrophoresis, we found that cytokeratin 18 (CK18) is downregulated in DU145-TxR cells.	Paclitaxel	109-119	keratin 18	Homo sapiens	232-246
26892177-5	2016	The downregulation of CK18 in DU145-TxR cells at mRNA, NMP and total cellular protein levels was validated by real-time RT-PCR, immunoblotting and immunofluorescence, indicating that the downregulation of CK18 was a global effect in DU145-TxR cells due to paclitaxel-resistance.	Paclitaxel	256-266	keratin 18	Homo sapiens	22-26
21934338-0	2011	Paclitaxel, ifosfamide and cisplatin (TIP) beyond its original indication for salvage treatment of germ cell tumors.	Paclitaxel	0-10	TOR signaling pathway regulator	Homo sapiens	38-41
34600241-0	2021	Synthesis of small molecules targeting paclitaxel-induced MyD88 expression in triple-negative breast cancer cell lines.	Paclitaxel	39-49	MYD88 innate immune signal transduction adaptor	Homo sapiens	58-63
34600241-1	2021	Acquired paclitaxel (PTX) chemoresistance in triple-negative breast cancer (TNBC) can be inferred from the overexpression of toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MyD88) proteins and the activation of the TLR4/MyD88 cascading signalling pathway.	Paclitaxel	9-19	MYD88 innate immune signal transduction adaptor	Homo sapiens	157-200
21187454-4	2010	The CCL2 gene expression evaluated by RT-PCR was investigated in relation to chemo-response/clinical outcomes in the OC patients and to sensitivity to cisplatin/paclitaxel in the OCCLs.	Paclitaxel	161-171	C-C motif chemokine ligand 2	Homo sapiens	4-8
21187454-9	2010	The cells expressing higher levels of CCL2 were more sensitive to paclitaxel and cisplatin as compared to those lines expressing lower levels of this chemokine.	Paclitaxel	66-76	C-C motif chemokine ligand 2	Homo sapiens	38-42
26943585-0	2016	Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells" sensitivity to paclitaxel.	Paclitaxel	91-101	mitotic arrest deficient 2 like 1	Homo sapiens	6-10
21187454-10	2010	Up-regulation of CCL2 in the PAT-7 cell line further enhanced the response of these cells to paclitaxel (p = 0.0001) and led to decreased invasion (p = 0.0009).	Paclitaxel	93-103	C-C motif chemokine ligand 2	Homo sapiens	17-21
34600241-1	2021	Acquired paclitaxel (PTX) chemoresistance in triple-negative breast cancer (TNBC) can be inferred from the overexpression of toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MyD88) proteins and the activation of the TLR4/MyD88 cascading signalling pathway.	Paclitaxel	9-19	MYD88 innate immune signal transduction adaptor	Homo sapiens	202-207
34600241-1	2021	Acquired paclitaxel (PTX) chemoresistance in triple-negative breast cancer (TNBC) can be inferred from the overexpression of toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MyD88) proteins and the activation of the TLR4/MyD88 cascading signalling pathway.	Paclitaxel	9-19	MYD88 innate immune signal transduction adaptor	Homo sapiens	249-254
34600241-1	2021	Acquired paclitaxel (PTX) chemoresistance in triple-negative breast cancer (TNBC) can be inferred from the overexpression of toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MyD88) proteins and the activation of the TLR4/MyD88 cascading signalling pathway.	Paclitaxel	21-24	MYD88 innate immune signal transduction adaptor	Homo sapiens	157-200
34600241-1	2021	Acquired paclitaxel (PTX) chemoresistance in triple-negative breast cancer (TNBC) can be inferred from the overexpression of toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MyD88) proteins and the activation of the TLR4/MyD88 cascading signalling pathway.	Paclitaxel	21-24	MYD88 innate immune signal transduction adaptor	Homo sapiens	202-207
34582111-0	2021	FSC231 alleviates paclitaxel-induced neuralgia by inhibiting the interactions between PICK1 and GluA2 and activates GSK-3beta and ERK1/2.	Paclitaxel	18-28	protein interacting with PRKCA 1	Rattus norvegicus	86-91
21215055-0	2010	[Role of folate receptor 1 in paclitaxel-resistance of nasopharyngeal carcinoma cells].	Paclitaxel	30-40	folate receptor alpha	Homo sapiens	9-26
21215055-2	2010	METHODS: The expressions of FOLR1 in CNE-1, CNE-1/Taxol (paclitaxel-resistance cells) and NP69 was detected by cDNA microarray, reverse transcriptase-polymerase chain reaction (RT-PCR), Western blot and immunocytochemistry.	Paclitaxel	50-55	folate receptor alpha	Homo sapiens	28-33
21215055-2	2010	METHODS: The expressions of FOLR1 in CNE-1, CNE-1/Taxol (paclitaxel-resistance cells) and NP69 was detected by cDNA microarray, reverse transcriptase-polymerase chain reaction (RT-PCR), Western blot and immunocytochemistry.	Paclitaxel	57-67	folate receptor alpha	Homo sapiens	28-33
25982274-5	2016	Through protecting cells from paclitaxel-induced apoptosis, expression of miR-520h promoted the drug resistance of human breast cancer cells.	Paclitaxel	30-40	microRNA 520h	Homo sapiens	74-82
34582111-0	2021	FSC231 alleviates paclitaxel-induced neuralgia by inhibiting the interactions between PICK1 and GluA2 and activates GSK-3beta and ERK1/2.	Paclitaxel	18-28	glycogen synthase kinase 3 alpha	Rattus norvegicus	116-125
21215055-4	2010	RESULTS: The expressions of FOLR1 gene in CNE-1/Taxol cells and CNE-1 cells were 2636.0 and 176.0, respectively.	Paclitaxel	48-53	folate receptor alpha	Homo sapiens	28-33
21215055-6	2010	The high expression of FOLR1 in CNE-1/Taxol was verified by semi-quantative RT-PCR, and its expression level was positively correlated to the degree of drug-resistance (r(2) = 0.8719).	Paclitaxel	38-43	folate receptor alpha	Homo sapiens	23-28
34582111-2	2021	METHODS: The expression level of PICK1 in dorsal root ganglion (DRG) of rats was changed by vector plasmid, and the effect of PICK1 on paclitaxel (PTL)-induced neuralgia of rats was observed in collaboration with FSC231 treatment.	Paclitaxel	135-145	protein interacting with PRKCA 1	Rattus norvegicus	33-38
21215055-8	2010	The sensitivity of CNE-1/Taxol to paclitaxel significantly increased after inhibition of FOLR1 gene expression by siRNA, and its IC(50) value was decreased by 59.6% (t = 6.92, P &lt; 0.01).	Paclitaxel	34-44	folate receptor alpha	Homo sapiens	89-94
34582111-2	2021	METHODS: The expression level of PICK1 in dorsal root ganglion (DRG) of rats was changed by vector plasmid, and the effect of PICK1 on paclitaxel (PTL)-induced neuralgia of rats was observed in collaboration with FSC231 treatment.	Paclitaxel	135-145	protein interacting with PRKCA 1	Rattus norvegicus	126-131
21215055-9	2010	CONCLUSIONS: The expression of FOLR1 is closely related to the occurrence of NPC and Taxol resistance.	Paclitaxel	85-90	folate receptor alpha	Homo sapiens	31-36
34582111-2	2021	METHODS: The expression level of PICK1 in dorsal root ganglion (DRG) of rats was changed by vector plasmid, and the effect of PICK1 on paclitaxel (PTL)-induced neuralgia of rats was observed in collaboration with FSC231 treatment.	Paclitaxel	147-150	protein interacting with PRKCA 1	Rattus norvegicus	33-38
34582111-2	2021	METHODS: The expression level of PICK1 in dorsal root ganglion (DRG) of rats was changed by vector plasmid, and the effect of PICK1 on paclitaxel (PTL)-induced neuralgia of rats was observed in collaboration with FSC231 treatment.	Paclitaxel	147-150	protein interacting with PRKCA 1	Rattus norvegicus	126-131
21215055-10	2010	FOLR1 gene may be one of the important target molecules in NPC treatment and reversion of the paclitaxel-resistance in NPC.	Paclitaxel	94-104	folate receptor alpha	Homo sapiens	0-5
34582111-8	2021	CONCLUSION: FSC231 activates GSK-3beta/ERK1/2 by inhibiting the interaction between PICK1 and GluA2 and alleviates PTL-induced DRG neuralgia in rats.	Paclitaxel	115-118	glycogen synthase kinase 3 alpha	Rattus norvegicus	29-38
26304156-1	2016	BACKGROUND: A recent phase III trial compared the efficacy of cisplatin-topotecan (a topoisomerase I inhibitor) followed by carboplatin-paclitaxel (Arm 1) versus paclitaxel-carboplatin (Arm 2) in women with newly diagnosed stage IIB or greater ovarian cancer.	Paclitaxel	136-146	ADRM1 26S proteasome ubiquitin receptor	Homo sapiens	148-153
34582111-8	2021	CONCLUSION: FSC231 activates GSK-3beta/ERK1/2 by inhibiting the interaction between PICK1 and GluA2 and alleviates PTL-induced DRG neuralgia in rats.	Paclitaxel	115-118	mitogen activated protein kinase 3	Rattus norvegicus	39-45
34749510-5	2021	Results: Compared with the control group, the PTX + PSO-PLNs group showed increased apoptosis and reduced migration, invasion and expression of phosphorylated IRAK1 and NF-kappaB, with significant inhibition of tumor growth and lung metastases and no obvious toxicity.	Paclitaxel	46-49	interleukin 1 receptor associated kinase 1	Homo sapiens	159-164
25961928-0	2016	Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.	Paclitaxel	0-10	kinesin family member 20A	Homo sapiens	37-43
20091169-10	2010	CONCLUSIONS: The MTD for weekly paclitaxel plus daily PTK/ZK is 75 mg/m(2) and 750 mg. PK analysis revealed a significant drug-drug interaction, with an increase in paclitaxel clearance.	Paclitaxel	165-175	protein tyrosine kinase 2 beta	Homo sapiens	54-57
34768915-6	2021	In addition, combination treatment with UA and PTX significantly activated p-GSK-3beta and suppressed the activation of Akt and FOXM1 in ESCC cells.	Paclitaxel	47-50	glycogen synthase kinase 3 alpha	Homo sapiens	77-86
34803458-2	2021	Here, it is aimed to investigate the differences in the expression levels of let-7a, miR-10b, miR-21, miR-125b, miR-145, miR-155, miR-200c, miR-221, miR-222 and miR-335, which associated with gene and proteins in MCF-7 (parental) and MCF-7s (Mammosphere/stem cell-enriched population/CD44+/CD24-cells) cells treated with paclitaxel.	Paclitaxel	321-331	microRNA 200c	Homo sapiens	130-138
26820614-6	2016	Additionally, expression of chimeric P-gp was able to confer a paclitaxel-resistant phenotype to HeLa cells characteristic of P-gp-mediated drug resistance.	Paclitaxel	63-73	phosphoglycolate phosphatase	Homo sapiens	37-41
26820614-6	2016	Additionally, expression of chimeric P-gp was able to confer a paclitaxel-resistant phenotype to HeLa cells characteristic of P-gp-mediated drug resistance.	Paclitaxel	63-73	phosphoglycolate phosphatase	Homo sapiens	126-130
34803458-2	2021	Here, it is aimed to investigate the differences in the expression levels of let-7a, miR-10b, miR-21, miR-125b, miR-145, miR-155, miR-200c, miR-221, miR-222 and miR-335, which associated with gene and proteins in MCF-7 (parental) and MCF-7s (Mammosphere/stem cell-enriched population/CD44+/CD24-cells) cells treated with paclitaxel.	Paclitaxel	321-331	microRNA 335	Homo sapiens	161-168
26900348-8	2016	RESULTS: We identified 22 TSGs involved in PTX resistance, including BRCA1, TP53, PTEN, APC, CDKN1A, CDKN2A, HIN-1, RASSF1, YAP, ING4, PLK2, FBW7, BLU, LZTS1, REST, FADD, PDCD4, TGFBI, ING1, Bax, PinX1 and hEx.	Paclitaxel	43-46	polo like kinase 2	Homo sapiens	135-139
20130910-0	2010	Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma.	Paclitaxel	61-71	collagen type XVIII alpha 1 chain	Homo sapiens	18-28
34692516-7	2021	Collectively, our data indicate that ATL-1 can sensitize TNBC cells to paclitaxel by blocking CTGF expression and fibroblast activation and could be helpful in future research to determine the value of ATL-1 in the clinical setting.	Paclitaxel	71-81	cellular communication network factor 2	Mus musculus	94-98
20130910-5	2010	RESULTS: The anti-tumor efficacy of paclitaxel was significantly improved 7 days after the treatment of rh-endostatin.	Paclitaxel	36-46	collagen type XVIII alpha 1 chain	Homo sapiens	107-117
20498641-7	2010	Mechanistic studies indicate that the specific phosphoinositide 3-kinase (PI-3K), Akt and mammalian target of rapamycin (mTOR) inhibitors, but not the mitogen-activated protein kinase kinase (MEK) inhibitor, not only abrogate erbB3-mediated upregulation of Survivin, but also reinforce the erbB2/erbB3-coexpressing breast cancer cells to paclitaxel-induced growth inhibition.	Paclitaxel	338-348	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	47-72
26900348-8	2016	RESULTS: We identified 22 TSGs involved in PTX resistance, including BRCA1, TP53, PTEN, APC, CDKN1A, CDKN2A, HIN-1, RASSF1, YAP, ING4, PLK2, FBW7, BLU, LZTS1, REST, FADD, PDCD4, TGFBI, ING1, Bax, PinX1 and hEx.	Paclitaxel	43-46	Fas associated via death domain	Homo sapiens	165-169
26900348-8	2016	RESULTS: We identified 22 TSGs involved in PTX resistance, including BRCA1, TP53, PTEN, APC, CDKN1A, CDKN2A, HIN-1, RASSF1, YAP, ING4, PLK2, FBW7, BLU, LZTS1, REST, FADD, PDCD4, TGFBI, ING1, Bax, PinX1 and hEx.	Paclitaxel	43-46	inhibitor of growth family member 1	Homo sapiens	185-189
26838546-6	2016	Paclitaxel/MWE decreased EEA1 immunofluorescence staining and increased the expression of PTEN, indicating that the regimen inhibited the formation of the recycling endosome, which is required for cytokinesis.	Paclitaxel	0-10	phosphatase and tensin homolog	Homo sapiens	90-94
26838546-7	2016	Paclitaxel/MWE also retarded tumor growth in a TSGH 8301 xenograft model via activation of PTEN and Caspase 3.	Paclitaxel	0-10	phosphatase and tensin homolog	Homo sapiens	91-95
26838546-8	2016	These data demonstrated a synergistic effect on the anticancer efficacy of paclitaxel through MWE supplementation by promoting mitotic catastrophe through the activation of PTEN, providing a novel and effective therapeutic option for bladder cancer treatment strategies.	Paclitaxel	75-85	phosphatase and tensin homolog	Homo sapiens	173-177
20460378-7	2010	We verified that miR-125b, miR-221, miR-222, and miR-923 were up-regulated in Taxol-resistant cancer cells by real-time PCR.	Paclitaxel	78-83	microRNA 221	Homo sapiens	27-34
20460378-7	2010	We verified that miR-125b, miR-221, miR-222, and miR-923 were up-regulated in Taxol-resistant cancer cells by real-time PCR.	Paclitaxel	78-83	microRNA 222	Homo sapiens	36-43
34746887-2	2021	In this study, we present a case of SMARCA4-UT with vertebral and chest wall invasion that successfully underwent conversion surgery after treatment with atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin.	Paclitaxel	200-210	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	36-43
20219607-0	2010	Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.	Paclitaxel	28-38	erb-b2 receptor tyrosine kinase 2	Mus musculus	16-20
34298004-5	2021	Both BAS-DOX and BAS-TX showed up-regulation of FOXC1 and its experimental down-regulation re-sensitized cells to doxorubicin and paclitaxel.	Paclitaxel	130-140	forkhead box C1	Homo sapiens	48-53
20651349-12	2010	Silencing of beta-catenin decreased transcription of these ABC transporter genes; beta-catenin-silenced cells became relatively sensitive to paclitaxel and irinotecan.	Paclitaxel	141-151	catenin beta 1	Homo sapiens	13-25
20651349-12	2010	Silencing of beta-catenin decreased transcription of these ABC transporter genes; beta-catenin-silenced cells became relatively sensitive to paclitaxel and irinotecan.	Paclitaxel	141-151	catenin beta 1	Homo sapiens	82-94
25867061-3	2016	Here, we show a strong correlation between miR-621 expression and chemosensitivity to paclitaxel plus carboplatin (PTX/CBP) regimen, an effective neoadjuvant chemotherapy for breast cancer patients.	Paclitaxel	86-96	microRNA 621	Homo sapiens	43-50
26636884-0	2016	Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance.	Paclitaxel	47-57	toll like receptor 4	Homo sapiens	135-139
20822025-5	2010	RESULT: The efflux rate of paclitaxel was faster than the absorption rates across the MDR1-MDCK II monolayer cells with highly expressed P-gp.	Paclitaxel	27-37	phosphoglycolate phosphatase	Homo sapiens	137-141
26636884-8	2016	Consequently, TLR4 knock down within SKOV-3 cells resensitized them toward paclitaxel (PTX) treatment, and apoptotic events increased.	Paclitaxel	75-85	toll like receptor 4	Homo sapiens	14-18
34638704-7	2021	Moreover, the down-regulation of TRPV1 in DRG of Nogo-A KO rats after injection of CFA was reversed by intrathecal injection of paclitaxel, a microtubule stabilizer.	Paclitaxel	128-138	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	33-38
26636884-8	2016	Consequently, TLR4 knock down within SKOV-3 cells resensitized them toward paclitaxel (PTX) treatment, and apoptotic events increased.	Paclitaxel	87-90	toll like receptor 4	Homo sapiens	14-18
26148901-0	2016	Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.	Paclitaxel	65-75	stathmin 1	Homo sapiens	109-114
19727732-10	2010	Further, RNAi studies demonstrated that both SSAT and SMO play a significant role in the response of MDA-MB-231 cells to treatment with BENSpm and 5-FU or paclitaxel.	Paclitaxel	155-165	smoothened, frizzled class receptor	Homo sapiens	54-57
20395330-8	2010	RESULTS: Baseline uptake of (99m)Tc-annexin V in breast tumors was about 2-fold higher than the uptake in normal breast tissue (demonstrating some ongoing apoptosis); tracer uptake increased at 1 and 3 h after paclitaxel administration (to almost double the baseline value) and then declined to levels even lower than baseline.	Paclitaxel	210-220	annexin A5	Homo sapiens	36-45
26148901-4	2016	MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C&gt;T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel.	Paclitaxel	218-228	stathmin 1	Homo sapiens	84-89
34175815-6	2021	Upstream mediators of EMT such as ZEB1/2, TGF-beta, microRNAs, and so on are involved in regulating response of cancer cells to PTX and DTX.	Paclitaxel	128-131	transforming growth factor alpha	Homo sapiens	42-50
26270131-0	2016	Taxol prevents myocardial ischemia-reperfusion injury by inducing JNK-mediated HO-1 expression.	Paclitaxel	0-5	mitogen-activated protein kinase 8	Rattus norvegicus	66-69
20646644-5	2010	In comparisons with other groups, the treatment of paclitaxel and then zoledronic acid induced the maximal apoptosis (14.96%) and necrosis (14.37%) as shown by Annexin V-FITC/PI double-staining flow cytometry.	Paclitaxel	51-61	annexin A5	Homo sapiens	160-169
34479917-7	2021	Furthermore, paclitaxel induced ROS-mediated DNA damage that triggered the activation of the extrinsic pathway of apoptosis via the up-regulation of death receptor (DR5) and caspase-8 activation.	Paclitaxel	13-23	caspase 8	Homo sapiens	174-183
26270131-4	2016	OBJECTIVE: We hypothesize that taxol protects cardiac myocytes possibly by preserving myocardial mitochondrial function and inducing HO-1 expression through the JNK pathway.	Paclitaxel	31-36	mitogen-activated protein kinase 8	Rattus norvegicus	161-164
26270131-13	2016	Furthermore, the expression level of HO-1 increased with taxol treatments, which could be inhibited by the specific inhibitor of JNK, SP600125.	Paclitaxel	57-62	mitogen-activated protein kinase 8	Rattus norvegicus	129-132
26270131-16	2016	Interestingly, taxol induced the expression of HO-1 via the JNK pathway in cardiac myocytes.	Paclitaxel	15-20	mitogen-activated protein kinase 8	Rattus norvegicus	60-63
20085902-0	2010	Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.	Paclitaxel	98-108	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	44-49
34479917-9	2021	Paclitaxel induced cell cycle arrest at the G1 phase in response to DNA damage, in association with the suppression of CDC25A, Cdk2 and Cyclin E1 protein expression.	Paclitaxel	0-10	cyclin dependent kinase 2	Homo sapiens	127-131
34479918-8	2021	The apoptotic effects of paclitaxel were observed by increased levels of cleaved caspase-3 (Asp 175), cleaved caspase-9 (Asp 330) and cleaved PARP (Asp 214).	Paclitaxel	25-35	collagen type XI alpha 2 chain	Homo sapiens	142-146
20145118-7	2010	We found that a pan-MLK inhibitor (CEP-11004) limited Taxol-induced cell death and that E(2) accentuated this limitation.	Paclitaxel	54-59	mitogen-activated protein kinase kinase kinase 13	Homo sapiens	20-23
34405891-12	2022	JAK2 partially reversed the effect of apatinib on enhancing sensitivity of GC cells to PTX.	Paclitaxel	87-90	Janus kinase 2	Homo sapiens	0-4
34421585-4	2021	Compared with paclitaxel or HY alone, the level of reactive oxygen species (ROS) increased significantly, while glutathione reductase (GR) activity and intracellular glutathione (GSH) levels decreased significantly in the combination group.	Paclitaxel	14-24	glutathione reductase	Mus musculus	112-133
20082533-0	2010	Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells.	Paclitaxel	61-66	microRNA 21	Homo sapiens	18-24
20082533-4	2010	The 50% inhibitory concentration (IC50) values for taxol were significantly decreased to a greater extent in the cells transfected with miR-21 inhibitor compared with cells treated with taxol alone.	Paclitaxel	51-56	microRNA 21	Homo sapiens	136-142
20082533-4	2010	The 50% inhibitory concentration (IC50) values for taxol were significantly decreased to a greater extent in the cells transfected with miR-21 inhibitor compared with cells treated with taxol alone.	Paclitaxel	186-191	microRNA 21	Homo sapiens	136-142
20082533-5	2010	Taxol treatment also increased the percentage of apoptotic breast cancer cells in miR-21 inhibitor transfected cells compared with control cells.	Paclitaxel	0-5	microRNA 21	Homo sapiens	82-88
20082533-6	2010	Furthermore, treatment of the miR-21 inhibitor-transfected cells with the anti-cancer drugs taxol resulted in significantly reduced cell viability and invasiveness compared with control cells.	Paclitaxel	92-97	microRNA 21	Homo sapiens	30-36
26782519-0	2015	Effects of stathmin 1 silencing by siRNA on sensitivity of esophageal cancer cells Eca-109 to paclitaxel.	Paclitaxel	94-104	stathmin 1	Homo sapiens	11-21
26782519-1	2015	We investigated the effects of stathmin 1 (STMN1) silencing by small interfering (siRNA) on the sensitivity of esophageal cancer cells Eca-109 to paclitaxel.	Paclitaxel	146-156	stathmin 1	Homo sapiens	31-41
26782519-4	2015	The effects of STMN1 silencing by siRNA on the sensitivity of esophageal cancer cells Eca-109 to paclitaxel was tested by MTT and colony formation assays.	Paclitaxel	97-107	stathmin 1	Homo sapiens	15-20
26782519-7	2015	The sensitivity of STMN1 siRNA-transfected Eca-109 cells to paclitaxel was significantly increased (P &lt; 0.01).	Paclitaxel	60-70	stathmin 1	Homo sapiens	19-24
26782519-9	2015	STMN1 silencing by siRNA may enhance the sensitivity of esophageal cancer cells Eca-109 to paclitaxel and induce apoptosis.	Paclitaxel	91-101	stathmin 1	Homo sapiens	0-5
34421585-4	2021	Compared with paclitaxel or HY alone, the level of reactive oxygen species (ROS) increased significantly, while glutathione reductase (GR) activity and intracellular glutathione (GSH) levels decreased significantly in the combination group.	Paclitaxel	14-24	glutathione reductase	Mus musculus	135-137
34131286-12	2021	Last, drug response analysis revealed lncRNA ENSG00000230082 (PRRT3-AS1) is a potential resistance biomarker for paclitaxel in BRCA treatment.	Paclitaxel	113-123	prostaglandin D2 receptor	Homo sapiens	68-71
19720054-5	2010	Our results showed that lapatinib and erlotinib dose-dependently enhanced the sensitivity of MRP7-transfected HEK293 cells to several established MRP7 substrates, specifically docetaxel, paclitaxel, vinblastine and vinorelbine, whereas there was no or a less effect on the control vector transfected HEK293 cells.	Paclitaxel	187-197	ATP binding cassette subfamily C member 10	Homo sapiens	93-97
34097831-2	2021	Cytochrome P450 enzymes CYP3A4 and CYP2C8, which metabolically inactivate PTX in hepatic tissue, are overexpressed in malignant breast tissues.	Paclitaxel	74-77	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	35-41
26474677-1	2015	The combination of high dose of oral lapatinib (LAPA), a HER2 tyrosine kinase inhibitor, with intravenous paclitaxel (PTX) exhibited a clinical survival advantage compared with PTX alone against HER2 positive breast cancer.	Paclitaxel	106-116	erb-b2 receptor tyrosine kinase 2	Mus musculus	195-199
26474677-1	2015	The combination of high dose of oral lapatinib (LAPA), a HER2 tyrosine kinase inhibitor, with intravenous paclitaxel (PTX) exhibited a clinical survival advantage compared with PTX alone against HER2 positive breast cancer.	Paclitaxel	118-121	erb-b2 receptor tyrosine kinase 2	Mus musculus	195-199
26474677-6	2015	The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells.	Paclitaxel	55-58	erb-b2 receptor tyrosine kinase 2	Mus musculus	96-100
34088893-7	2021	We investigated the in vitro effect of Smac-mimetic added to carboplatin and paclitaxel treatment of ovarian cancer cells expressing wild type and low Caspase 8 levels, which resulted in a 2-4-fold enhancement of cell death.	Paclitaxel	77-87	caspase 8	Homo sapiens	151-160
26474677-6	2015	The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells.	Paclitaxel	211-214	erb-b2 receptor tyrosine kinase 2	Mus musculus	96-100
26474677-6	2015	The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells.	Paclitaxel	211-214	erb-b2 receptor tyrosine kinase 2	Mus musculus	96-100
26474677-9	2015	To summarize, this localized co-delivery system with good synergistic effects between LAPA and PTX might offer a potential strategy for HER2 and P-gp positive breast cancer.	Paclitaxel	95-98	erb-b2 receptor tyrosine kinase 2	Mus musculus	136-140
26462028-8	2015	These data together suggest that blocking the Snail-induced EMT with the ALK5 inhibitor attenuates metastasis after paclitaxel-therapy and that this combinatorial approach could prove useful in treating breast cancer.	Paclitaxel	116-126	transforming growth factor beta receptor 1	Homo sapiens	73-77
20552056-5	2010	Taxol (which stabilizes microtubules) normalized the PD tubulin ratio and reduced alpha-synuclein oligomerization.	Paclitaxel	0-5	synuclein alpha	Homo sapiens	82-97
19944065-6	2010	EGCG pretreatment caused a 29% and 38% decrease in TF activity on thrombin and thrombin/paclitaxel treatment, respectively.	Paclitaxel	88-98	coagulation factor III, tissue factor	Homo sapiens	51-53
19944065-7	2010	Real-time polymerase chain reaction (PCR) showed that thrombin and thrombin/paclitaxel-induced 3.0-fold and 4.6-fold TF mRNA expressions compared with the control.	Paclitaxel	76-86	coagulation factor III, tissue factor	Homo sapiens	117-119
19944065-8	2010	EGCG pretreatment caused an 82% and 72% decrease in TF mRNA expression on thrombin and thrombin/paclitaxel treatment, respectively.	Paclitaxel	96-106	coagulation factor III, tissue factor	Homo sapiens	52-54
19944065-9	2010	The c-Jun terminal NH2 kinase (JNK) inhibitor SP600125 reduced thrombin/paclitaxel-induced TF expression.	Paclitaxel	72-82	coagulation factor III, tissue factor	Homo sapiens	91-93
19944065-12	2010	In conclusion, EGCG can inhibit TF expression in thrombin/paclitaxel-stimulated endothelial cells via the inhibition of JNK phosphorylation.	Paclitaxel	58-68	coagulation factor III, tissue factor	Homo sapiens	32-34
20346445-1	2010	Subclinical doses of Paclitaxel (PTX) given 1day prior to a HER-2/neu (neu)-targeted, granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting whole-cell vaccine enhances neu-specific T cell responses and slows neu(+) tumor growth in tolerized HER-2/neu (neu-N) mice.	Paclitaxel	21-31	erb-b2 receptor tyrosine kinase 2	Mus musculus	60-69
20346445-1	2010	Subclinical doses of Paclitaxel (PTX) given 1day prior to a HER-2/neu (neu)-targeted, granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting whole-cell vaccine enhances neu-specific T cell responses and slows neu(+) tumor growth in tolerized HER-2/neu (neu-N) mice.	Paclitaxel	21-31	erb-b2 receptor tyrosine kinase 2	Mus musculus	66-69
20346445-1	2010	Subclinical doses of Paclitaxel (PTX) given 1day prior to a HER-2/neu (neu)-targeted, granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting whole-cell vaccine enhances neu-specific T cell responses and slows neu(+) tumor growth in tolerized HER-2/neu (neu-N) mice.	Paclitaxel	21-31	erb-b2 receptor tyrosine kinase 2	Mus musculus	71-74
20346445-1	2010	Subclinical doses of Paclitaxel (PTX) given 1day prior to a HER-2/neu (neu)-targeted, granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting whole-cell vaccine enhances neu-specific T cell responses and slows neu(+) tumor growth in tolerized HER-2/neu (neu-N) mice.	Paclitaxel	21-31	erb-b2 receptor tyrosine kinase 2	Mus musculus	71-74
20346445-2	2010	We demonstrate that co-administration of PTX and Cyclophosphamide (CY) synergizes to slow tumor growth, and that in vitro, DC precursors exposed to PTX before LPS maturation results in greater co-stimulatory molecule expression, IL-12 production, and the ability to induce CD8(+) T cells with enhanced lytic activity against neu(+) tumors.	Paclitaxel	148-151	erb-b2 receptor tyrosine kinase 2	Mus musculus	325-328
26464363-8	2015	Thereafter, changed in expression of single miRNAs (miR221*, miR222 and miR222*) following paclitaxel treatment were analyzed using a quantitative real-time polymerase chain reaction (qRT-PCR).	Paclitaxel	91-101	microRNA 221	Homo sapiens	52-58
20001661-2	2010	The protective effects of the strong antioxidant, beta-1,3-D-glucan, against liver damage induced by taxol were also investigated.	Paclitaxel	101-106	hemoglobin, beta adult major chain	Mus musculus	50-58
34149413-6	2021	Furthermore, autophagy in ADQ-treated breast CSCs was blocked by taxol via regulation of beta-catenin/ABCG2 signaling.	Paclitaxel	65-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	102-107
19855003-6	2009	Sensitization to taxol was achieved by reducing levels of Mps1 or BubR1, proteins having dual roles in checkpoint activation and chromosome alignment, but not by reducing Mad2, functioning solely in the mitotic checkpoint.	Paclitaxel	17-22	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	66-71
26464363-8	2015	Thereafter, changed in expression of single miRNAs (miR221*, miR222 and miR222*) following paclitaxel treatment were analyzed using a quantitative real-time polymerase chain reaction (qRT-PCR).	Paclitaxel	91-101	microRNA 222	Homo sapiens	61-67
26464363-8	2015	Thereafter, changed in expression of single miRNAs (miR221*, miR222 and miR222*) following paclitaxel treatment were analyzed using a quantitative real-time polymerase chain reaction (qRT-PCR).	Paclitaxel	91-101	microRNA 222	Homo sapiens	72-78
26464363-11	2015	Regulation of miR222* expression under paclitaxel treatment seems to be different in human papillomavirus (HPV)-negative and HPV-positive HNSCC cell lines.	Paclitaxel	39-49	microRNA 222	Homo sapiens	14-20
19826044-3	2009	Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity.	Paclitaxel	78-88	phosphatase and tensin homolog	Homo sapiens	43-47
34277801-0	2021	Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer.	Paclitaxel	43-53	BCL2-like 1	Mus musculus	71-77
19826044-3	2009	Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity.	Paclitaxel	78-88	kallikrein related peptidase 3	Homo sapiens	197-228
19665763-12	2009	paclitaxel combined with daily administration of 1-MT significantly prolonged the survival of the SK-IDO-xenografted mice compared to treatment with paclitaxel alone.	Paclitaxel	0-10	indoleamine 2,3-dioxygenase 1	Mus musculus	101-104
26442514-0	2015	Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer.	Paclitaxel	57-67	indoleamine 2,3-dioxygenase 1	Homo sapiens	89-116
26442514-8	2015	The supplemented cultures showed that the most significant differences in the expression of IDO were observed in the group treated with paclitaxel associated with 1-MT continuous supplementation, reducing enzyme expression from 12.06 to 3.56 %.	Paclitaxel	136-146	indoleamine 2,3-dioxygenase 1	Homo sapiens	92-95
26503059-5	2015	Pharmacologic inhibition of IRAK1 is able to reverse paclitaxel resistance by triggering massive apoptosis at least in part through inhibiting p38-MCL1 pro-survival pathway.	Paclitaxel	53-63	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	147-151
34277801-2	2021	This study aimed to investigate the synergistic effects of apatinib and paclitaxel (PTX) on triple-negative breast cancer (TNBC) in vivo and in vitro, and to explore the molecular mechanism of the PI3K/p65/Bcl-xl pathway.	Paclitaxel	72-82	BCL2-like 1	Mus musculus	206-212
34277801-2	2021	This study aimed to investigate the synergistic effects of apatinib and paclitaxel (PTX) on triple-negative breast cancer (TNBC) in vivo and in vitro, and to explore the molecular mechanism of the PI3K/p65/Bcl-xl pathway.	Paclitaxel	84-87	BCL2-like 1	Mus musculus	206-212
34277801-4	2021	Western blot (WB) was conducted to detect protein expression levels of PI3K, p65, and Bcl-xl after the application of apatinib and PTX.	Paclitaxel	131-134	BCL2-like 1	Mus musculus	86-92
25904021-8	2015	Collectively, our observations provide evidence that NSC23925 in combination with paclitaxel may prevent the onset of Pgp or antiapoptotic-mediated paclitaxel resistance, and improve the long-term clinical outcome in patients with ovarian cancer.	Paclitaxel	82-92	phosphoglycolate phosphatase	Homo sapiens	118-121
19787264-10	2009	Conversely, at least one isoform of BRD8 gave growth advantage and resistance to taxol when stably overexpressed in HeLa cells.	Paclitaxel	81-86	bromodomain containing 8	Homo sapiens	36-40
26065826-10	2015	Paclitaxel treatment resulted in phosphorylation of Inhibitor alpha of NFkappaB (IkappaBalpha) in DRG resulting in an apparent release of NFkappaB from the IkappaBalpha-NFkappaB complex as increased expression of nuclear NFkappaB was also observed.	Paclitaxel	0-10	NFKB inhibitor alpha	Rattus norvegicus	81-93
34277801-10	2021	Conclusions: Apatinib could enhance the anti-tumor effect of PTX on TNBC cells through the PI3K/p65/Bcl-xl molecular pathway, and apatinib combined with PTX might be a promising option for TNBC treatment.	Paclitaxel	61-64	BCL2-like 1	Mus musculus	100-106
26065826-10	2015	Paclitaxel treatment resulted in phosphorylation of Inhibitor alpha of NFkappaB (IkappaBalpha) in DRG resulting in an apparent release of NFkappaB from the IkappaBalpha-NFkappaB complex as increased expression of nuclear NFkappaB was also observed.	Paclitaxel	0-10	NFKB inhibitor alpha	Rattus norvegicus	156-168
26722421-9	2015	15 genes of 762 transcripts on this chromosome region were consistently up-regulated detected by cDNA microarray in three taxol resistant sub-lines, and functionally clustered into various groups, including genes related to vascular formation vascular formation (ANGPT1), apoptosis (MYC, TOP1MT), cell adhesion and cell cycle (PPP1R16A, SDC2, CA2, ANKRD46), gene regulation (HRSP12, ZNF696, SLC39A4, POP1), metabolism (PYCRL).	Paclitaxel	122-127	pyrroline-5-carboxylate reductase 3	Homo sapiens	419-424
19560278-0	2009	Stress hormones mediate drug resistance to paclitaxel in human breast cancer cells through a CDK-1-dependent pathway.	Paclitaxel	43-53	cyclin dependent kinase 1	Homo sapiens	93-98
35220552-8	2022	In addition, the low-WM score group was expected to be more sensitive to programmed cell death protein 1 (PD-1) therapy and showed lower predicted IC50 of chemotherapy drugs paclitaxel and cisplatin treatment.	Paclitaxel	174-184	programmed cell death 1	Homo sapiens	73-104
19560278-7	2009	Inhibition of CDK-1 abrogated stress hormone-mediated reversal of paclitaxel-induced cytotoxicity, indicating that the protective effect of stress hormones act through a CDK-1-dependent mechanism.	Paclitaxel	66-76	cyclin dependent kinase 1	Homo sapiens	14-19
19560278-7	2009	Inhibition of CDK-1 abrogated stress hormone-mediated reversal of paclitaxel-induced cytotoxicity, indicating that the protective effect of stress hormones act through a CDK-1-dependent mechanism.	Paclitaxel	66-76	cyclin dependent kinase 1	Homo sapiens	170-175
19823672-4	2009	Coincubating cells with a sublethal concentration of paclitaxel in combination with each of 2,000 small molecule compounds from the National Cancer Institute Diversity Set Library, we identified a previously uncharacterized molecule, NSC23925, that inhibits Pgp1 and reverses MDR1 (Pgp1) but does not inhibit MRP or BCRP-mediated MDR.	Paclitaxel	53-63	BCR pseudogene 1	Homo sapiens	316-320
35220552-8	2022	In addition, the low-WM score group was expected to be more sensitive to programmed cell death protein 1 (PD-1) therapy and showed lower predicted IC50 of chemotherapy drugs paclitaxel and cisplatin treatment.	Paclitaxel	174-184	programmed cell death 1	Homo sapiens	106-110
25797390-9	2015	Treatment with paclitaxel made the tubulopodia rigid, preventing their attachment to the TCR-binding surface and the reorientation of the cell body with the intracellular structures.	Paclitaxel	15-25	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	89-92
35179085-6	2022	These results could be because more PTX-loaded Tf/FA-F127-PLA Ps entered C6 cells through both FA-Folate Receptor (FR) and Tf-Transferrin Receptor (TfR) specific affinity and thus possessed the better anti-tumor ability.	Paclitaxel	36-39	transferrin receptor	Homo sapiens	123-146
26424893-0	2015	The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4.	Paclitaxel	28-38	toll like receptor 4	Homo sapiens	117-121
26424893-2	2015	The hypothesis tested was that paclitaxel produces these adverse effects at least in part by sensitizing transient receptor potential vanilloid subtype 1 (TRPV1) through Toll-like receptor 4 (TLR4) signaling.	Paclitaxel	31-41	toll like receptor 4	Homo sapiens	170-190
26424893-2	2015	The hypothesis tested was that paclitaxel produces these adverse effects at least in part by sensitizing transient receptor potential vanilloid subtype 1 (TRPV1) through Toll-like receptor 4 (TLR4) signaling.	Paclitaxel	31-41	toll like receptor 4	Homo sapiens	192-196
26424893-5	2015	Cotreatment of rats with lipopolysaccharide from the photosynthetic bacterium Rhodobacter sphaeroides (LPS-RS), a TLR4 inhibitor, prevents the increase in numbers of TRPV1(+) neurons by paclitaxel treatment.	Paclitaxel	186-196	toll like receptor 4	Homo sapiens	114-118
26424893-7	2015	Paclitaxel and LPS sensitize TRPV1 in HEK293 cells stably expressing human TLR4 and transiently expressing human TRPV1.	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	75-79
26424893-10	2015	In summary, TLR4 was activated by paclitaxel and led to sensitization of TRPV1.	Paclitaxel	34-44	toll like receptor 4	Homo sapiens	12-16
26424893-12	2015	Significance statement: In this original work, it is shown for the first time that paclitaxel activates peripheral sensory and spinal neurons directly and sensitizes these cells to transient receptor potential vanilloid subtype 1 (TRPV1)-mediated capsaicin responses via Toll-like receptor 4 (TLR4) in multiple species.	Paclitaxel	83-93	toll like receptor 4	Homo sapiens	271-291
26424893-12	2015	Significance statement: In this original work, it is shown for the first time that paclitaxel activates peripheral sensory and spinal neurons directly and sensitizes these cells to transient receptor potential vanilloid subtype 1 (TRPV1)-mediated capsaicin responses via Toll-like receptor 4 (TLR4) in multiple species.	Paclitaxel	83-93	toll like receptor 4	Homo sapiens	293-297
19654226-7	2009	Moreover, in paclitaxel-treated, MOG-immunized mice, there was a complete inhibition of the recruitment of myeloid cells (especially macrophages) to the peripheral lymphoid organs.	Paclitaxel	13-23	myelin oligodendrocyte glycoprotein	Mus musculus	33-36
19674193-5	2009	Here, we have shown that taxol and vinblastine induce multiple arms of the ER stress response, including up-regulation of glucose-regulated protein 78 (GRP78) expression, X-box binding protein 1 splicing and eukaryotic initiation factor 2alpha phosphorylation.	Paclitaxel	25-30	X-box binding protein 1	Homo sapiens	171-194
19674193-9	2009	Inhibition of JNK and caspase-7 abrogates EGCG sensitization of breast cancer cells to taxol and vinblastine.	Paclitaxel	87-92	caspase 7	Homo sapiens	22-31
26087191-4	2015	COL11A1 or c/EBPbeta downregulation suppressed chemoresistance, whereas COL11A1 overexpression attenuated sensitivity to cisplatin and paclitaxel.The c/EBPbeta binding site in the COL11A1 promoter was identified as the major determinant of cisplatin- and paclitaxel-induced COL11A1 expression.	Paclitaxel	135-145	collagen type XI alpha 1 chain	Homo sapiens	72-79
19410561-4	2009	FG020326 significantly potentiated the cytotoxicity of paclitaxel, doxorubicin, and vincristine in the ABCB1 (P-glycoprotein, P-gp) overexpressing cells KBv200 and MCF-7/adr, but not in the ABCB1 negative parental cell lines KB and MCF-7.	Paclitaxel	55-65	phosphoglycolate phosphatase	Homo sapiens	126-130
26087191-4	2015	COL11A1 or c/EBPbeta downregulation suppressed chemoresistance, whereas COL11A1 overexpression attenuated sensitivity to cisplatin and paclitaxel.The c/EBPbeta binding site in the COL11A1 promoter was identified as the major determinant of cisplatin- and paclitaxel-induced COL11A1 expression.	Paclitaxel	135-145	collagen type XI alpha 1 chain	Homo sapiens	72-79
35179085-6	2022	These results could be because more PTX-loaded Tf/FA-F127-PLA Ps entered C6 cells through both FA-Folate Receptor (FR) and Tf-Transferrin Receptor (TfR) specific affinity and thus possessed the better anti-tumor ability.	Paclitaxel	36-39	transferrin receptor	Homo sapiens	148-151
26087191-4	2015	COL11A1 or c/EBPbeta downregulation suppressed chemoresistance, whereas COL11A1 overexpression attenuated sensitivity to cisplatin and paclitaxel.The c/EBPbeta binding site in the COL11A1 promoter was identified as the major determinant of cisplatin- and paclitaxel-induced COL11A1 expression.	Paclitaxel	135-145	collagen type XI alpha 1 chain	Homo sapiens	72-79
26087191-4	2015	COL11A1 or c/EBPbeta downregulation suppressed chemoresistance, whereas COL11A1 overexpression attenuated sensitivity to cisplatin and paclitaxel.The c/EBPbeta binding site in the COL11A1 promoter was identified as the major determinant of cisplatin- and paclitaxel-induced COL11A1 expression.	Paclitaxel	255-265	collagen type XI alpha 1 chain	Homo sapiens	0-7
26087191-4	2015	COL11A1 or c/EBPbeta downregulation suppressed chemoresistance, whereas COL11A1 overexpression attenuated sensitivity to cisplatin and paclitaxel.The c/EBPbeta binding site in the COL11A1 promoter was identified as the major determinant of cisplatin- and paclitaxel-induced COL11A1 expression.	Paclitaxel	255-265	collagen type XI alpha 1 chain	Homo sapiens	72-79
26087191-4	2015	COL11A1 or c/EBPbeta downregulation suppressed chemoresistance, whereas COL11A1 overexpression attenuated sensitivity to cisplatin and paclitaxel.The c/EBPbeta binding site in the COL11A1 promoter was identified as the major determinant of cisplatin- and paclitaxel-induced COL11A1 expression.	Paclitaxel	255-265	collagen type XI alpha 1 chain	Homo sapiens	72-79
26087191-4	2015	COL11A1 or c/EBPbeta downregulation suppressed chemoresistance, whereas COL11A1 overexpression attenuated sensitivity to cisplatin and paclitaxel.The c/EBPbeta binding site in the COL11A1 promoter was identified as the major determinant of cisplatin- and paclitaxel-induced COL11A1 expression.	Paclitaxel	255-265	collagen type XI alpha 1 chain	Homo sapiens	72-79
19661300-10	2009	Both SB-T-1216 and paclitaxel activated caspase-3, caspase-9, caspase-2 and caspase-8 in sensitive as well as resistant cells.	Paclitaxel	19-29	caspase 9	Homo sapiens	51-60
19661300-10	2009	Both SB-T-1216 and paclitaxel activated caspase-3, caspase-9, caspase-2 and caspase-8 in sensitive as well as resistant cells.	Paclitaxel	19-29	caspase 2	Homo sapiens	62-71
19661300-11	2009	CONCLUSION: Cell death induced by both paclitaxel and novel taxane SB-T-1216 in breast cancer cells is associated with caspase activation and with the formation of interphase microtubule bundles.	Paclitaxel	39-49	caspase 2	Homo sapiens	119-126
19591684-6	2009	DCs treated with antimicrotubule agents vincristine, vinblastine, and paclitaxel or with antimetabolites 5-aza-2-deoxycytidine and methotrexate, showed increased expression of CD83 and CD40 molecules.	Paclitaxel	70-80	CD83 molecule	Homo sapiens	176-180
18977553-0	2009	Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.	Paclitaxel	115-125	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
18977553-11	2009	This retrospective study indicates that immunostaining for ERCC1 and class III beta-tubulin may be useful for predicting survival in NSCLC patients receiving carboplatin and paclitaxel against recurrent tumors after curative resection and can provide information critical for planning personalized chemotherapy.	Paclitaxel	174-184	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	59-64
35218722-9	2022	Moreover, functional experiments demonstrated that SMYD5 silencing abrogated cell proliferation, migration and invasion and enhanced paclitaxel sensitivity in HCC.	Paclitaxel	133-143	SMYD family member 5	Homo sapiens	51-56
19305429-7	2009	Reducing Gadd45gamma expression by small hairpin RNAs partially enhanced paclitaxel resistance.	Paclitaxel	73-83	growth arrest and DNA damage inducible gamma	Homo sapiens	9-20
19247716-0	2009	MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol.	Paclitaxel	108-113	phosphoglycolate phosphatase	Homo sapiens	5-9
26183396-4	2015	We have recently shown that high levels of TAZ in cancer cells result in Taxol resistance through up-regulation of downstream targets Cyr61 and CTGF.	Paclitaxel	73-78	cellular communication network factor 1	Homo sapiens	134-139
35634452-9	2022	However, whole cell voltage clamp experiments in TRPM8 expressing TRG neurons indicated that both oxaliplatin and paclitaxel increased Hyperpolarization-Activated Cyclic Nucleotide-Gated channel (HCN), voltage gated sodium channel (Nav), and menthol evoked TRPM8 currents.	Paclitaxel	114-124	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	49-54
26344694-0	2015	Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer.	Paclitaxel	41-51	forkhead box K2	Homo sapiens	0-15
26344694-3	2015	Clonogenic and cell viability assays showed that enhanced FOXK2 expression sensitizes MCF-7 breast cancer cells to paclitaxel or epirubicin treatment, whereas FOXK2 depletion by small interfering RNAs (siRNAs) confers drug resistance.	Paclitaxel	115-125	forkhead box K2	Homo sapiens	58-63
26344694-4	2015	Our data also showed that the activation of the tumour suppressor FOXO3a by paclitaxel and epirubicin is mediated through the induction of FOXK2, as depletion of FOXK2 by siRNA limits the induction of FOXO3a by these drugs in MCF-7 cells.	Paclitaxel	76-86	forkhead box K2	Homo sapiens	139-144
19412420-0	2009	SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients.	Paclitaxel	65-75	secreted protein acidic and cysteine rich	Homo sapiens	0-5
26344694-6	2015	Furthermore, we also uncovered that FOXK2 is deregulated and, therefore, can express at high levels in the nucleus of both the paclitaxel and epirubicin drug-resistant MCF-7 cells.	Paclitaxel	127-137	forkhead box K2	Homo sapiens	36-41
35634452-9	2022	However, whole cell voltage clamp experiments in TRPM8 expressing TRG neurons indicated that both oxaliplatin and paclitaxel increased Hyperpolarization-Activated Cyclic Nucleotide-Gated channel (HCN), voltage gated sodium channel (Nav), and menthol evoked TRPM8 currents.	Paclitaxel	114-124	transient receptor potential cation channel, subfamily M, member 8	Mus musculus	257-262
26004124-7	2015	The present study demonstrated that miR-148a inhibited cell proliferation and promoted the paclitaxel-induced apoptosis of ovarian cancer cells.	Paclitaxel	91-101	microRNA 148a	Homo sapiens	36-44
19412420-2	2009	It was hypothesized that because of a SPARC-albumin interaction, tumoral SPARC facilitates the accumulation of albumin in the tumor and increases the effectiveness of albumin-bound paclitaxel (nab-paclitaxel).	Paclitaxel	181-191	secreted protein acidic and cysteine rich	Homo sapiens	38-43
19412420-2	2009	It was hypothesized that because of a SPARC-albumin interaction, tumoral SPARC facilitates the accumulation of albumin in the tumor and increases the effectiveness of albumin-bound paclitaxel (nab-paclitaxel).	Paclitaxel	181-191	secreted protein acidic and cysteine rich	Homo sapiens	73-78
19412420-6	2009	Response to nab-paclitaxel was higher for SPARC-positive patients (10/12, 83%) than SPARC-negative patients (1/4, 25%).	Paclitaxel	16-26	secreted protein acidic and cysteine rich	Homo sapiens	42-47
26004124-12	2015	Therefore, the results of the present study suggested that miR-148a inhibited the proliferation and promoted the paclitaxel-induced apoptosis of ovarian cancer cells, and this may be partly attributed to direct targeting of PDIA3.	Paclitaxel	113-123	microRNA 148a	Homo sapiens	59-67
19412420-6	2009	Response to nab-paclitaxel was higher for SPARC-positive patients (10/12, 83%) than SPARC-negative patients (1/4, 25%).	Paclitaxel	16-26	secreted protein acidic and cysteine rich	Homo sapiens	84-89
35586672-4	2022	Cellular viability, apoptosis, apoptotic factors, and RAP1 signaling regulators were detected in the PNC cells (CNE-1 and HNE-2) and the subcutaneous CNE-1 transplanted nude mice treated with PTX or/and TSAIII.	Paclitaxel	192-195	RAS-related protein 1a	Mus musculus	54-58
19414339-0	2009	Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles.	Paclitaxel	37-47	epidermal growth factor	Mus musculus	66-69
19414339-3	2009	MATERIALS AND METHODS: EGF was conjugated to poly [MPC-co-n-butyl methacrylate-co-p-nitrophenyloxycarbonyl poly (ethylene glycol) methacrylate] (PMBN) and mixed with PTX.	Paclitaxel	166-169	epidermal growth factor	Mus musculus	23-26
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	34-37	epidermal growth factor	Mus musculus	56-59
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	34-37	epidermal growth factor	Mus musculus	77-80
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	34-37	epidermal growth factor receptor	Mus musculus	94-98
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	34-37	epidermal growth factor receptor	Mus musculus	118-122
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	86-89	epidermal growth factor	Mus musculus	56-59
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	86-89	epidermal growth factor	Mus musculus	77-80
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	86-89	epidermal growth factor receptor	Mus musculus	94-98
25894372-0	2015	Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer.	Paclitaxel	43-53	stathmin 1	Homo sapiens	18-26
25894372-11	2015	The findings demonstrated that paclitaxel effect may be interfered with stathmin; overexpression of stathmin is a predictive marker for a worse prognosis in patients with NSCLC who were treated by both platinum and paclitaxel chemotherapy.	Paclitaxel	31-41	stathmin 1	Homo sapiens	72-80
25894372-11	2015	The findings demonstrated that paclitaxel effect may be interfered with stathmin; overexpression of stathmin is a predictive marker for a worse prognosis in patients with NSCLC who were treated by both platinum and paclitaxel chemotherapy.	Paclitaxel	31-41	stathmin 1	Homo sapiens	100-108
25894372-11	2015	The findings demonstrated that paclitaxel effect may be interfered with stathmin; overexpression of stathmin is a predictive marker for a worse prognosis in patients with NSCLC who were treated by both platinum and paclitaxel chemotherapy.	Paclitaxel	215-225	stathmin 1	Homo sapiens	100-108
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	86-89	epidermal growth factor	Mus musculus	56-59
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	86-89	epidermal growth factor	Mus musculus	77-80
26036638-0	2015	MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.	Paclitaxel	53-63	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	91-96
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	86-89	epidermal growth factor receptor	Mus musculus	94-98
35430566-7	2022	RESULTS: SLFN12 over-expression increased TNBC sensitivity to radiation, carboplatin, paclitaxel, zoledronic acid, and camptothecin, but not to olaparib.	Paclitaxel	86-96	schlafen family member 12	Homo sapiens	9-15
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	86-89	epidermal growth factor	Mus musculus	56-59
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	86-89	epidermal growth factor	Mus musculus	77-80
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	86-89	epidermal growth factor receptor	Mus musculus	94-98
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	86-89	epidermal growth factor	Mus musculus	56-59
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	86-89	epidermal growth factor	Mus musculus	77-80
19414339-4	2009	The cytotoxicity of the resulting PTX incorporated into EGF-conjugated PMBN (EGF-PMBN-PTX) on EGFR-overexpressing and EGFR-deficient cell lines was compared with PTX incorporated into PMBN alone (PMBN-PTX) and PTX alone.	Paclitaxel	86-89	epidermal growth factor receptor	Mus musculus	94-98
19414339-6	2009	EGF-PMBN-PTX, PMBN-PTX, PTX or NaCl solution was injected intraperitoneally.	Paclitaxel	9-12	epidermal growth factor	Mus musculus	0-3
19414339-7	2009	RESULTS: The cytotoxicity and antitumor effect of EGF-PMBN-PTX were significantly greater than those of PMBN-PTX for EGFR-overexpressing cells but not for an EGFR-deficient line.	Paclitaxel	59-62	epidermal growth factor	Mus musculus	50-53
19414339-7	2009	RESULTS: The cytotoxicity and antitumor effect of EGF-PMBN-PTX were significantly greater than those of PMBN-PTX for EGFR-overexpressing cells but not for an EGFR-deficient line.	Paclitaxel	109-112	epidermal growth factor receptor	Mus musculus	117-121
19414339-8	2009	CONCLUSION: These results suggest that EGF-PMBN-PTX may represent a more potent targeted therapy for tumors overexpressing EGFR.	Paclitaxel	48-51	epidermal growth factor	Mus musculus	39-42
19414339-8	2009	CONCLUSION: These results suggest that EGF-PMBN-PTX may represent a more potent targeted therapy for tumors overexpressing EGFR.	Paclitaxel	48-51	epidermal growth factor receptor	Mus musculus	123-127
26036638-2	2015	The aim of our study was to investigate the functional role of both miR-101 and MCL-1 in the sensitivity of human triple-negative breast cancer (TNBC) to paclitaxel.	Paclitaxel	154-164	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	80-85
26036638-10	2015	Suppression of MCL-1 enhanced the sensitivity of MDA-MB-435 cells to paclitaxel.	Paclitaxel	69-79	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	15-20
26036638-11	2015	Furthermore, miR-101 increased paclitaxel sensitivity by inhibiting MCL-1 expression.	Paclitaxel	31-41	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	68-73
25896630-5	2015	Using an EMT PCR array based on the screening of 84 genes, the expression of FOXC2 was notably upregulated in paclitaxel-resistant NPC cells (CNE2/t).	Paclitaxel	110-120	forkhead box C2	Homo sapiens	77-82
25896630-8	2015	In an NPC xenograft mouse model, the downregulation of FOXC2 expression in the resistant NPC cells increased their sensitivity to paclitaxel treatment, resulting in reduced tumor growth.	Paclitaxel	130-140	forkhead box C2	Mus musculus	55-60
26146988-7	2015	In addition, CDK5 knockdown alone and in combination with paclitaxel induced G1 cell cycle arrest and caspase 3 dependent apoptotic cell death associated with post-translational upregulation and nuclear translocation of TP53 and p27(Kip1) as well as TP53-dependent transcriptional induction of p21(Cip1) in wild type TP53 cancer cells.	Paclitaxel	58-68	cyclin dependent kinase inhibitor 1B	Homo sapiens	233-237
26146988-8	2015	Treatment of HEYA8 and A2780 wild type TP53 xenografts in nu/nu mice with CDK5 siRNA and paclitaxel produced significantly greater growth inhibition than either treatment alone.	Paclitaxel	89-99	transformation related protein 53	Mus musculus	39-43
26146988-10	2015	CDK5 modulates paclitaxel sensitivity by regulating AKT activation, the cell cycle and caspase-dependent apoptosis.	Paclitaxel	15-25	cyclin dependent kinase 5	Homo sapiens	0-4
19048624-4	2009	In addition, the overexpression of HB-EGF in paclitaxel-treated SKOV3 cells resulted in modulation of paclitaxel-evoked MAPK signaling, including marked activation of ERK and Akt, and minimized activation of JNK and p38 MAPK, indicating that HB-EGF is involved in drug sensitivity through the balance of anti-apoptotic and pro-apoptotic signals induced by paclitaxel.	Paclitaxel	102-112	heparin binding EGF like growth factor	Homo sapiens	35-41
19048624-4	2009	In addition, the overexpression of HB-EGF in paclitaxel-treated SKOV3 cells resulted in modulation of paclitaxel-evoked MAPK signaling, including marked activation of ERK and Akt, and minimized activation of JNK and p38 MAPK, indicating that HB-EGF is involved in drug sensitivity through the balance of anti-apoptotic and pro-apoptotic signals induced by paclitaxel.	Paclitaxel	102-112	heparin binding EGF like growth factor	Homo sapiens	35-41
19048624-6	2009	More prominently, the administration of paclitaxel with CRM197 resulted in synergistic anti-tumor effects in SKOV3 cells and in SKOV3 cells overexpressing HB-EGF in xenografted mice.	Paclitaxel	40-50	heparin binding EGF like growth factor	Homo sapiens	155-161
35437787-6	2022	MicroRNAs (miRNAs) can have opposite effects on PTX resistance (stimulation or inhibition) via influencing YES1, SK2, MRP1, and STAT3.	Paclitaxel	48-51	sphingosine kinase 2	Homo sapiens	113-116
26146988-11	2015	CDK5 inhibition can potentiate paclitaxel activity in human ovarian cancer cells.	Paclitaxel	31-41	cyclin dependent kinase 5	Homo sapiens	0-4
19471665-1	2009	OBJECTIVE: To compare the efficacy of neoadjuvant chemotherapy with paclitaxel plus platinum followed by radical hysterectomy with radical surgery alone in patients with stage IB2-IIA bulky cervical cancer.	Paclitaxel	68-78	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	176-179
35437787-6	2022	MicroRNAs (miRNAs) can have opposite effects on PTX resistance (stimulation or inhibition) via influencing YES1, SK2, MRP1, and STAT3.	Paclitaxel	48-51	mutS homolog 3	Homo sapiens	118-122
35449243-8	2022	Both in vitro and in vivo, NEDD9-depletion attenuated stemness, CIN, cell/tumor growth, while enhancing paclitaxel effectiveness.	Paclitaxel	104-114	neural precursor cell expressed, developmentally down-regulated 9	Homo sapiens	27-32
25827073-0	2015	AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis.	Paclitaxel	27-37	microRNA 21	Homo sapiens	76-82
25827073-0	2015	AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis.	Paclitaxel	27-37	cyclin dependent kinase 5	Homo sapiens	83-87
35535347-15	2022	Moreover, there was a positive correlation between NEIL3 levels and chemosensitivity to cisplatin and paclitaxel.	Paclitaxel	102-112	nei like DNA glycosylase 3	Homo sapiens	51-56
25827073-4	2015	Here we showed that abnormal activation of miR-21/CDK5 axis was associated with breast cancer lymph node metastasis, which was also contribute to high dose taxol-induced invasion and epithelial mesenchymal transition (EMT) in both breast cancer cell line MDA-MB-231 and glioblastoma cell line U87VIII.	Paclitaxel	156-161	microRNA 21	Homo sapiens	43-49
25827073-4	2015	Here we showed that abnormal activation of miR-21/CDK5 axis was associated with breast cancer lymph node metastasis, which was also contribute to high dose taxol-induced invasion and epithelial mesenchymal transition (EMT) in both breast cancer cell line MDA-MB-231 and glioblastoma cell line U87VIII.	Paclitaxel	156-161	cyclin dependent kinase 5	Homo sapiens	50-54
25827073-9	2015	Taken together, our work demonstrated that AC1MMYR2 appeared to be a promising strategy in combating taxol induced cancer metastasis by targeting miR-21/CDK5 axis, which highlighted the potential for development of therapeutic modalities for better clinic taxol application.	Paclitaxel	101-106	microRNA 21	Homo sapiens	146-152
25827073-9	2015	Taken together, our work demonstrated that AC1MMYR2 appeared to be a promising strategy in combating taxol induced cancer metastasis by targeting miR-21/CDK5 axis, which highlighted the potential for development of therapeutic modalities for better clinic taxol application.	Paclitaxel	101-106	cyclin dependent kinase 5	Homo sapiens	153-157
19107118-6	2009	We also observed that radiation-induced AC upregulation was sufficient to create cross-resistance to chemotherapy as demonstrated by decreased sensitivity to Taxol and C(6) ceramide compared to controls.	Paclitaxel	158-163	N-acylsphingosine amidohydrolase 1	Homo sapiens	40-42
35566403-11	2022	Neoadjuvant chemotherapy (NACT) containing both paclitaxel and cisplatin induced a reduction in stromal FoxP3 Treg numbers and an increase in stromal and intratumoral CD8 T cells.	Paclitaxel	48-58	forkhead box P3	Homo sapiens	104-109
19128972-1	2009	Three fluorescent probes 3a,3b, and 4 have been synthesized through conjugation of fluorescein and difluorescein groups to the 7-OH of C-2 modified paclitaxel and cephalomannine derivatives with very high affinity to microtubules.	Paclitaxel	148-158	complement C2	Homo sapiens	135-138
25838397-7	2015	Consistent with these findings, chemosensitive ovarian cells grown in the presence of recombinant POSTN promoted resistance to carboplatin and paclitaxel treatment in vitro.	Paclitaxel	143-153	periostin	Homo sapiens	98-103
26086592-3	2015	Here, we silenced the taxol-sensitizer genes identified (acrbp, atp6v0d2, fgd4, hs6st2, psma6, and tubgcp2) in nine other cancer cell types (including lung, cervical, ovarian, and hepatocellular carcinoma cell lines) that showed reduced cell viability in the presence of a sub-lethal concentration of taxol.	Paclitaxel	22-27	ATPase H+ transporting V0 subunit d2	Homo sapiens	64-72
18842333-0	2009	Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells.	Paclitaxel	65-75	AKT serine/threonine kinase 2	Homo sapiens	19-23
35391656-15	2022	In conclusion, the present study showed that circ-CEP128 silencing could increase the paclitaxel sensitivity of CC by regulating the miR-432-5p/MCL1 axis.	Paclitaxel	86-96	microRNA 432	Mus musculus	133-140
18842333-1	2009	PURPOSE: Although multiple mechanisms have been implicated in paclitaxel (PTX)-induced resistance in ovarian cancer, recent evidence has suggested that Akt2 has an important role in the protection of cells from paclitaxel-induced apoptosis.	Paclitaxel	62-72	AKT serine/threonine kinase 2	Homo sapiens	152-156
18842333-1	2009	PURPOSE: Although multiple mechanisms have been implicated in paclitaxel (PTX)-induced resistance in ovarian cancer, recent evidence has suggested that Akt2 has an important role in the protection of cells from paclitaxel-induced apoptosis.	Paclitaxel	211-221	AKT serine/threonine kinase 2	Homo sapiens	152-156
18842333-2	2009	In the present study, we investigated the role of the Akt2/survivin pathway in paclitaxel-induced resistance by a modified method to generate an effective shRNA vector.	Paclitaxel	79-89	AKT serine/threonine kinase 2	Homo sapiens	54-58
18842333-3	2009	METHODS: We applied RNAi-mediated silencing techniques to investigate the mechanism of the Akt2/survivin pathway on PTX-induced resistance in ovarian cancer cells (A2780 and SKOV3).	Paclitaxel	116-119	AKT serine/threonine kinase 2	Homo sapiens	91-95
18842333-6	2009	RESULTS: Akt2 down-regulation sensitized ovarian cancer cells to paclitaxel-induced apoptosis, and inhibited survivin expression.	Paclitaxel	65-75	AKT serine/threonine kinase 2	Homo sapiens	9-13
26086592-7	2015	Notably, four of the five inducible taxol-sensitizer genes tested (acrbp, atp6v0d2, psma6, and tubgcp2) were upregulated in a taxol-resistant ovarian cancer cell line.	Paclitaxel	36-41	ATPase H+ transporting V0 subunit d2	Homo sapiens	74-82
26086592-7	2015	Notably, four of the five inducible taxol-sensitizer genes tested (acrbp, atp6v0d2, psma6, and tubgcp2) were upregulated in a taxol-resistant ovarian cancer cell line.	Paclitaxel	126-131	ATPase H+ transporting V0 subunit d2	Homo sapiens	74-82
35391656-15	2022	In conclusion, the present study showed that circ-CEP128 silencing could increase the paclitaxel sensitivity of CC by regulating the miR-432-5p/MCL1 axis.	Paclitaxel	86-96	myeloid cell leukemia sequence 1	Mus musculus	144-148
35149198-7	2022	Additionally, PTX increased CGRP and substance P (SP) expression in the DRG and SDH, induced SDH microglia and astrocyte activation, and upregulated spinal tumor necrosis factor-alpha (TNF-alpha) but not IL-1beta or IL-10 expression.	Paclitaxel	14-17	calcitonin-related polypeptide alpha	Rattus norvegicus	28-32
19118001-1	2009	Multidrug resistance protein 7 (MRP7; ABCC10) is an ATP-binding cassette transporter which is able to transport amphipathic anions and confer resistance to docetaxel and, to a lesser extent, vincristine and paclitaxel.	Paclitaxel	207-217	ATP binding cassette subfamily C member 10	Homo sapiens	0-30
19118001-1	2009	Multidrug resistance protein 7 (MRP7; ABCC10) is an ATP-binding cassette transporter which is able to transport amphipathic anions and confer resistance to docetaxel and, to a lesser extent, vincristine and paclitaxel.	Paclitaxel	207-217	ATP binding cassette subfamily C member 10	Homo sapiens	32-36
35149198-9	2022	Furthermore, DUL (20 mg/kg/day) for 5 days markedly ameliorated PTX-induced TRPV1, CGRP, and SP upregulation in the DRG and SDH, and mitigated PTX-induced spinal cord glia activation and TNF-alpha expression.	Paclitaxel	64-67	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	76-81
19118001-1	2009	Multidrug resistance protein 7 (MRP7; ABCC10) is an ATP-binding cassette transporter which is able to transport amphipathic anions and confer resistance to docetaxel and, to a lesser extent, vincristine and paclitaxel.	Paclitaxel	207-217	ATP binding cassette subfamily C member 10	Homo sapiens	38-44
19118001-7	2009	In this drug-sensitive cellular background, MRP7 conferred high levels of resistance to docetaxel (46-fold), paclitaxel (116-fold), SN-38 (65-fold), daunorubicin (7.5-fold), etoposide (11-fold), and vincristine (56-fold).	Paclitaxel	109-119	ATP binding cassette subfamily C member 10	Homo sapiens	44-48
25938556-10	2015	Notably, the half-maximal inhibitory concentrations (IC50) of GrB-Anis70-CPs were determined to be 6.25 and 5.94 nM for H460 and PC-3 cells, respectively, which were 2-3 orders of magnitude lower than that of chemotherapeutic drugs, such as paclitaxel.	Paclitaxel	241-251	granzyme B	Homo sapiens	62-65
35149198-9	2022	Furthermore, DUL (20 mg/kg/day) for 5 days markedly ameliorated PTX-induced TRPV1, CGRP, and SP upregulation in the DRG and SDH, and mitigated PTX-induced spinal cord glia activation and TNF-alpha expression.	Paclitaxel	64-67	calcitonin-related polypeptide alpha	Rattus norvegicus	83-87
25625774-5	2015	By investigating the glutamine metabolism of breast cancer cells in response to treatment with Taxol in vitro, it was observed that Taxol induced the uptake of glutamine and the expression of GLS1.	Paclitaxel	95-100	glutaminase	Homo sapiens	192-196
25625774-5	2015	By investigating the glutamine metabolism of breast cancer cells in response to treatment with Taxol in vitro, it was observed that Taxol induced the uptake of glutamine and the expression of GLS1.	Paclitaxel	132-137	glutaminase	Homo sapiens	192-196
35149198-10	2022	Moreover, the pharmacological blockade of TRPV1 resulted in an analgesic effect on PTX-induced hyperalgesia.	Paclitaxel	83-86	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	42-47
25625774-6	2015	Notably, Taxol-resistant cancer cells exhibited upregulation in the metabolism of glutamine and expression of GLS1.	Paclitaxel	9-14	glutaminase	Homo sapiens	110-114
35149198-11	2022	Collectively, these results suggest that DUL alleviates PTX-induced peripheral neuropathic pain by suppressing TRPV1 upregulation in the lumbar DRG and SDH, which is followed by a reduction in CGRP and SP release, as well as spinal glia activation and TNF-alpha expression.	Paclitaxel	56-59	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	111-116
25625774-7	2015	In addition, overexpression of GLS1 rendered cancer cells resistant to Taxol, indicating that GLS1 may be the therapeutic target for overcoming Taxol resistance in clinical therapeutics.	Paclitaxel	71-76	glutaminase	Homo sapiens	31-35
25625774-7	2015	In addition, overexpression of GLS1 rendered cancer cells resistant to Taxol, indicating that GLS1 may be the therapeutic target for overcoming Taxol resistance in clinical therapeutics.	Paclitaxel	144-149	glutaminase	Homo sapiens	31-35
19920864-14	2009	sequential administration of gemcitabine followed by paclitaxel in first line treatment of advanced NSCLC had a favourable toxicity profile, a median TTP and OS comparable with other sequential trials and might, therefore, be a treatment option for NSCLC patients with high ERCC1 expression.	Paclitaxel	53-63	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	274-279
25625774-7	2015	In addition, overexpression of GLS1 rendered cancer cells resistant to Taxol, indicating that GLS1 may be the therapeutic target for overcoming Taxol resistance in clinical therapeutics.	Paclitaxel	144-149	glutaminase	Homo sapiens	94-98
35149198-11	2022	Collectively, these results suggest that DUL alleviates PTX-induced peripheral neuropathic pain by suppressing TRPV1 upregulation in the lumbar DRG and SDH, which is followed by a reduction in CGRP and SP release, as well as spinal glia activation and TNF-alpha expression.	Paclitaxel	56-59	calcitonin-related polypeptide alpha	Rattus norvegicus	193-197
25625774-8	2015	The results also demonstrated that knock-down of GLS1 using small interfering RNA, resensitized the Taxol-resistant breast cancer cells to Taxol.	Paclitaxel	100-105	glutaminase	Homo sapiens	49-53
25625774-8	2015	The results also demonstrated that knock-down of GLS1 using small interfering RNA, resensitized the Taxol-resistant breast cancer cells to Taxol.	Paclitaxel	139-144	glutaminase	Homo sapiens	49-53
35051418-0	2022	KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer.	Paclitaxel	17-27	KH RNA binding domain containing, signal transduction associated 3	Homo sapiens	0-7
25849888-6	2015	Interestingly, we found that c-myc and cyclin D1 increased significantly in transfected cells with increasing PTX concentration, and cell-survival rates remained at 60% while the PTX concentration increased.	Paclitaxel	110-113	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	29-34
25849888-6	2015	Interestingly, we found that c-myc and cyclin D1 increased significantly in transfected cells with increasing PTX concentration, and cell-survival rates remained at 60% while the PTX concentration increased.	Paclitaxel	179-182	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	29-34
25849888-8	2015	These results indicate that beta-catenin translation is initiated via the IRES and this is regulated by PTX, suggesting that regulation of the IRES-dependent translation of beta-catenin may be involved in the cancer cell response to PTX treatment.	Paclitaxel	104-107	catenin beta 1	Homo sapiens	28-40
18804099-0	2008	Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis.	Paclitaxel	102-107	phosphatase and tensin homolog	Homo sapiens	53-57
18804099-0	2008	Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis.	Paclitaxel	102-107	phosphatase and tensin homolog	Homo sapiens	78-82
18804099-4	2008	We examined the sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for induction of apoptosis.	Paclitaxel	105-110	phosphatase and tensin homolog	Homo sapiens	56-60
18804099-4	2008	We examined the sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for induction of apoptosis.	Paclitaxel	105-110	phosphatase and tensin homolog	Homo sapiens	81-85
35051418-4	2022	Here, we investigate the role of KHDRBS3 in glycolysis and increased resistance to PTX.	Paclitaxel	83-86	KH RNA binding domain containing, signal transduction associated 3	Homo sapiens	33-40
35051418-8	2022	Here, we investigate the role of KHDRBS3 in glycolysis and increased resistance to PTX.	Paclitaxel	83-86	KH RNA binding domain containing, signal transduction associated 3	Homo sapiens	33-40
35051418-9	2022	The expression of KHDRBS3 was up-regulated in PTX-resistant cells.	Paclitaxel	46-49	KH RNA binding domain containing, signal transduction associated 3	Homo sapiens	18-25
18664590-0	2008	Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats.	Paclitaxel	138-148	cannabinoid receptor 2	Rattus norvegicus	36-39
25849888-8	2015	These results indicate that beta-catenin translation is initiated via the IRES and this is regulated by PTX, suggesting that regulation of the IRES-dependent translation of beta-catenin may be involved in the cancer cell response to PTX treatment.	Paclitaxel	104-107	catenin beta 1	Homo sapiens	173-185
25849888-8	2015	These results indicate that beta-catenin translation is initiated via the IRES and this is regulated by PTX, suggesting that regulation of the IRES-dependent translation of beta-catenin may be involved in the cancer cell response to PTX treatment.	Paclitaxel	233-236	catenin beta 1	Homo sapiens	28-40
18664590-2	2008	The present studies were conducted to evaluate the efficacy of cannabinoid CB(2) receptor activation in suppressing painful peripheral neuropathy evoked by chemotherapeutic treatment with the antitumor agent paclitaxel.	Paclitaxel	208-218	cannabinoid receptor 2	Rattus norvegicus	75-89
25849888-8	2015	These results indicate that beta-catenin translation is initiated via the IRES and this is regulated by PTX, suggesting that regulation of the IRES-dependent translation of beta-catenin may be involved in the cancer cell response to PTX treatment.	Paclitaxel	233-236	catenin beta 1	Homo sapiens	173-185
35327403-5	2022	Indeed, when MDR-overexpressing cancer cells were treated with a combination of BGJ 398 and PTX (or Dox), we observed a significant increase of apoptosis which was evidenced by an increased expression of cleaved forms of PARP, caspase-3, and increased numbers of Annexin V-positive cells, as well.	Paclitaxel	92-95	collagen type XI alpha 2 chain	Homo sapiens	221-225
18766004-10	2008	These results demonstrated that the relative efficacy of nab-paclitaxel was significantly higher compared with polysorbate-based docetaxel in HER2-negative tumors (three of three) and in HER2-positive tumors with high levels of SPARC.	Paclitaxel	61-71	secreted protein acidic and cysteine rich	Homo sapiens	228-233
35238054-6	2022	MiR-497-5p was bound to TRPM2-AS and its inhibition reversed the effects of TRPM2-AS knockdown on cell progression and PTX resistance in PTX-resistant PCa cells.	Paclitaxel	119-122	microRNA 497	Homo sapiens	0-7
25973606-6	2015	Our in-depth study revealed that high LDHB expression conferred resistance to taxol but not 5-fluorouracil or cisplatin.	Paclitaxel	78-83	lactate dehydrogenase B	Homo sapiens	38-42
35238054-6	2022	MiR-497-5p was bound to TRPM2-AS and its inhibition reversed the effects of TRPM2-AS knockdown on cell progression and PTX resistance in PTX-resistant PCa cells.	Paclitaxel	137-140	microRNA 497	Homo sapiens	0-7
25973606-7	2015	LDHB deletion sensitized OSCC cell lines to taxol, whereas the introduction of LDHB decreased sensitivity to taxol treatment.	Paclitaxel	44-49	lactate dehydrogenase B	Homo sapiens	0-4
35238054-8	2022	In conclusion, TRPM2-AS knockdown suppressed cell progression and PTX resistance in PTX-resistant PCa cells by miR-497-5p/FOXK1 axis.	Paclitaxel	66-69	microRNA 497	Homo sapiens	111-118
25973606-7	2015	LDHB deletion sensitized OSCC cell lines to taxol, whereas the introduction of LDHB decreased sensitivity to taxol treatment.	Paclitaxel	109-114	lactate dehydrogenase B	Homo sapiens	79-83
25973606-8	2015	Taxol induced a pronounced impact on LDHB-down-regulated OSCC cells in terms of apoptosis, G2/M phase cell cycle arrest and energy metabolism.	Paclitaxel	0-5	lactate dehydrogenase B	Homo sapiens	37-41
18818514-3	2008	Here, we show that modified Arl2 expression level influences sensitivity to various anticancer compounds such as taxol, navelbine, gemcitabine and doxorubicin in MCF7 derived cell lines.	Paclitaxel	113-118	ADP ribosylation factor like GTPase 2	Homo sapiens	28-32
35238054-8	2022	In conclusion, TRPM2-AS knockdown suppressed cell progression and PTX resistance in PTX-resistant PCa cells by miR-497-5p/FOXK1 axis.	Paclitaxel	84-87	microRNA 497	Homo sapiens	111-118
35079981-0	2022	Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest.	Paclitaxel	50-60	par-3 family cell polarity regulator	Homo sapiens	17-21
18691855-8	2008	RESULTS: TE1, with lower hsMAD2 and BubR1, showed greater sensitivity to paclitaxel and docetaxel compared with TE2, with higher hsMAD2 and BubR1.	Paclitaxel	73-83	mitotic arrest deficient 2 like 1	Homo sapiens	25-31
18691855-8	2008	RESULTS: TE1, with lower hsMAD2 and BubR1, showed greater sensitivity to paclitaxel and docetaxel compared with TE2, with higher hsMAD2 and BubR1.	Paclitaxel	73-83	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	36-41
18691855-14	2008	Low hsMAD2 and BubR1 was associated with sensitivity to paclitaxel and docetaxel.	Paclitaxel	56-66	mitotic arrest deficient 2 like 1	Homo sapiens	4-10
25825248-3	2015	A sensitive electrochemical biosensor is also presented for the determination of Taxol based on ds-DNA decorated multiwall carbon nanotubes-TiO2/ZrO2-chitosan-modified pencil electrode (ds-DNA-MWNTs-TiO2/ZrO2-CHIT-PGE).	Paclitaxel	81-86	chitinase 1	Homo sapiens	209-213
18691855-14	2008	Low hsMAD2 and BubR1 was associated with sensitivity to paclitaxel and docetaxel.	Paclitaxel	56-66	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	15-20
35079981-3	2022	Here we aimed to explore a role of Polarity protein Par3 in improving paclitaxel effectiveness.	Paclitaxel	70-80	par-3 family cell polarity regulator	Homo sapiens	52-56
35079981-4	2022	METHODS: Breast cancer specimens from 45 patients were collected to study the relationship between Par3 expression and paclitaxel efficacy.	Paclitaxel	119-129	par-3 family cell polarity regulator	Homo sapiens	99-103
27040946-0	2015	Antagonism of miRNA-21 Sensitizes Human Gastric Cancer Cells to Paclitaxel.	Paclitaxel	64-74	microRNA 21	Homo sapiens	14-22
27040946-3	2015	The present study aimed to investigate the role of miR-21 in the development of drug resistance to paclitaxel in gastric cancer cells.	Paclitaxel	99-109	microRNA 21	Homo sapiens	51-57
18644619-9	2008	CONCLUSIONS: The combination of paclitaxel, topotecan and carboplatin with G-CSF support appears active with acceptable toxicity in patients with metastatic or recurrent carcinoma of the endometrium.	Paclitaxel	32-42	colony stimulating factor 3	Homo sapiens	75-80
35079981-10	2022	RESULTS: Par3 expression was associated with good response of paclitaxel in breast cancer patients.	Paclitaxel	62-72	par-3 family cell polarity regulator	Homo sapiens	9-13
35079981-11	2022	Consistently, Par3 over-expression significantly sensitized breast cancer cells to paclitaxel by promoting cell apoptosis and reducing cell proliferation.	Paclitaxel	83-93	par-3 family cell polarity regulator	Homo sapiens	14-18
18813780-0	2008	Low doses of paclitaxel potently induce apoptosis in human retinoblastoma Y79 cells by up-regulating E2F1.	Paclitaxel	13-23	E2F transcription factor 1	Homo sapiens	101-105
27040946-4	2015	Our study found that the expression of miR-21 upregulated in the paclitaxel resistant cell line SGC7901/paclitaxel compared to its parental line SGC7901.	Paclitaxel	65-75	microRNA 21	Homo sapiens	39-45
27040946-4	2015	Our study found that the expression of miR-21 upregulated in the paclitaxel resistant cell line SGC7901/paclitaxel compared to its parental line SGC7901.	Paclitaxel	104-114	microRNA 21	Homo sapiens	39-45
18813780-3	2008	The effect of PTX is accompanied by a potent induction of E2F1 which appears to play a critical role in the effects induced by PTX.	Paclitaxel	14-17	E2F transcription factor 1	Homo sapiens	58-62
18813780-3	2008	The effect of PTX is accompanied by a potent induction of E2F1 which appears to play a critical role in the effects induced by PTX.	Paclitaxel	127-130	E2F transcription factor 1	Homo sapiens	58-62
27040946-5	2015	Moreover, over-expression of miR-21 significantly decreased antiproliferative effects and apoptosis induced by paclitaxel, while knockdown of miR-21 dramatically increased antiproliferative effects and apoptosis induction by paclitaxel.	Paclitaxel	111-121	microRNA 21	Homo sapiens	29-35
35079981-12	2022	In Par3 overexpressing cells upon paclitaxel treatment, we observed intensified cell cycle arrests at metaphase.	Paclitaxel	34-44	par-3 family cell polarity regulator	Homo sapiens	3-7
18813780-4	2008	PTX induced a dose- and time-dependent effect, with G2/M arrest, cyclines A, E and B1 accumulation and a marked modification in the status of Cdc2-cyclin B1 complex, the major player of the G2/M checkpoint.	Paclitaxel	0-3	cyclin dependent kinase 1	Homo sapiens	142-146
18813780-4	2008	PTX induced a dose- and time-dependent effect, with G2/M arrest, cyclines A, E and B1 accumulation and a marked modification in the status of Cdc2-cyclin B1 complex, the major player of the G2/M checkpoint.	Paclitaxel	0-3	cyclin B1	Homo sapiens	147-156
35079981-13	2022	Further exploration showed that Par3 over-expression stabilized microtubules of breast cancer cells in response to paclitaxel and resists to microtubules instability induced by nocodazole, a microtubule-depolymerizing agent.	Paclitaxel	115-125	par-3 family cell polarity regulator	Homo sapiens	32-36
18806740-3	2008	RESULTS: Low dose of Taxol that cause apoptosis (25 nM) enhanced Rb protein phosphorylation, decreased the expression of cyclin-dependent kinase inhibitors p27(KIP1) and p21(WAF1) , and potentiated the accumulation of phosphorylated p53 and of the prolyl isomerase Pin1.	Paclitaxel	21-26	interferon alpha inducible protein 27	Homo sapiens	156-159
25867275-0	2015	Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.	Paclitaxel	113-123	phosphoglycerate kinase 1	Homo sapiens	0-25
25867275-8	2015	Furthermore, patients who underwent paclitaxel chemotherapy with high levels PGK1 expression had shorter OS than did those with low levels of PGK1 expression (P&lt;0.001).	Paclitaxel	36-46	phosphoglycerate kinase 1	Homo sapiens	77-81
18806740-3	2008	RESULTS: Low dose of Taxol that cause apoptosis (25 nM) enhanced Rb protein phosphorylation, decreased the expression of cyclin-dependent kinase inhibitors p27(KIP1) and p21(WAF1) , and potentiated the accumulation of phosphorylated p53 and of the prolyl isomerase Pin1.	Paclitaxel	21-26	cyclin dependent kinase inhibitor 1B	Homo sapiens	160-164
25867275-9	2015	Multivariate analysis indicated that PGK1 (P=0.001) was an independent predictor in the patients treated with paclitaxel.	Paclitaxel	110-120	phosphoglycerate kinase 1	Homo sapiens	37-41
18806740-3	2008	RESULTS: Low dose of Taxol that cause apoptosis (25 nM) enhanced Rb protein phosphorylation, decreased the expression of cyclin-dependent kinase inhibitors p27(KIP1) and p21(WAF1) , and potentiated the accumulation of phosphorylated p53 and of the prolyl isomerase Pin1.	Paclitaxel	21-26	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	265-269
35079981-14	2022	CONCLUSION: Par3 facilitates polymeric forms of tubulin and stabilizes microtubule structure, which aggravates paclitaxel-induced delay at the metaphase-anaphase transition, leading to proliferation inhibition and apoptosis of breast cancer cells.	Paclitaxel	111-121	par-3 family cell polarity regulator	Homo sapiens	12-16
18806740-4	2008	High Taxol doses (100 and 1000 nM) that cause necrosis-like cell death drastically decreased Pin1 level in both cell lines.	Paclitaxel	5-10	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	93-97
18806740-7	2008	At higher doses of Taxol, there was a dramatic decrease of Pin1 levels which may be a reason for G(2)/M cell cycle arrest.	Paclitaxel	19-24	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	59-63
25867275-10	2015	CONCLUSIONS: PGK1 is a prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.	Paclitaxel	66-76	phosphoglycerate kinase 1	Homo sapiens	13-17
35079981-15	2022	Par3 has a potential role in sensitizing breast cancer cells to paclitaxel, which may provide a more precise assessment of individual treatment and novel therapeutic targets.	Paclitaxel	64-74	par-3 family cell polarity regulator	Homo sapiens	0-4
18806742-2	2008	In this study, the activity of telomerase reverse transcriptase (hTERT) and its gene expression levels were investigated in paclitaxel, docetaxel, vincristine and doxorubicin resistant human MCF-7 breast adenocarcinoma cells.	Paclitaxel	124-134	telomerase reverse transcriptase	Homo sapiens	65-70
34995995-1	2022	BACKGROUND: Taxol-resistance gene 1 (TXR1) is closely correlated with the paclitaxel resistance in the cancer chemotherapy.	Paclitaxel	74-84	proline rich 13	Homo sapiens	12-35
25572118-0	2015	Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel.	Paclitaxel	98-108	stathmin 1	Homo sapiens	10-18
25572118-5	2015	In this study we investigated the effect of stathmin gene silencing, using small interfering RNA (stathmin siRNA), on the efficacy of PTX in ESCC.	Paclitaxel	134-137	stathmin 1	Homo sapiens	44-52
34995995-1	2022	BACKGROUND: Taxol-resistance gene 1 (TXR1) is closely correlated with the paclitaxel resistance in the cancer chemotherapy.	Paclitaxel	74-84	proline rich 13	Homo sapiens	37-41
25572118-5	2015	In this study we investigated the effect of stathmin gene silencing, using small interfering RNA (stathmin siRNA), on the efficacy of PTX in ESCC.	Paclitaxel	134-137	stathmin 1	Homo sapiens	98-106
25572118-8	2015	Thus, combined chemotherapeutic agent PTX and stathmin siRNA could potentially enhance the therapeutic outcomes of PTX in treating ESCC.	Paclitaxel	115-118	stathmin 1	Homo sapiens	46-54
25643607-0	2015	Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3beta/beta-catenin signalling.	Paclitaxel	35-45	catenin beta 1	Homo sapiens	101-113
18982869-0	2008	Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line.	Paclitaxel	40-50	S100 calcium binding protein P	Homo sapiens	18-23
18982869-3	2008	In this study, we investigated the association of S100P expression with paclitaxel sensitivity in ovarian cancer cell lines.	Paclitaxel	72-82	S100 calcium binding protein P	Homo sapiens	50-55
18982869-7	2008	The effect of S100P expression level on the survival of cells exposed to paclitaxel was measured using the MTT assay.	Paclitaxel	73-83	S100 calcium binding protein P	Homo sapiens	14-19
18982869-10	2008	RESULTS: Lower S100P expression was associated with a survival advantage in OVCAR3 cells exposed to paclitaxel; the survival advantage in SKOV3 cells was smaller (P &lt; 0.05).	Paclitaxel	100-110	S100 calcium binding protein P	Homo sapiens	15-20
18982869-11	2008	The survival advantage associated with decreased S100P expression was even greater for SKOV3 and OVCAR3 cells that had been transfected with S100P siRNA before being exposed to paclitaxel (P &lt; 0.05).	Paclitaxel	177-187	S100 calcium binding protein P	Homo sapiens	49-54
35014689-5	2022	Furthermore, it was found that forkhead box transcription factor O1 (FOXO1) enhanced PTX-induced autophagy through a transcriptional activation pattern in MDA-MB-231 cells, which was associated with the downstream target genes autophagy related 5, class III phosphoinositide 3-kinase vacuolar protein sorting 34, autophagy related 4B cysteine peptidase, beclin 1 and microtubule associated protein 1 light chain 3beta.	Paclitaxel	85-88	autophagy related 4B cysteine peptidase	Homo sapiens	313-352
18982869-12	2008	Consistent with this, the OVCAR3 cell clone that was transfected to overexpress S100P was more sensitive to paclitaxel (P &lt; 0.05).	Paclitaxel	108-118	S100 calcium binding protein P	Homo sapiens	80-85
18982869-13	2008	CONCLUSIONS: Low S100P expression contributes to drug resistance to paclitaxel in ovarian cancer cell lines.	Paclitaxel	68-78	S100 calcium binding protein P	Homo sapiens	17-22
18982869-14	2008	S100P expression thus might be a marker that can predict the effectiveness of paclitaxel based chemotherapy.	Paclitaxel	78-88	S100 calcium binding protein P	Homo sapiens	0-5
35014689-5	2022	Furthermore, it was found that forkhead box transcription factor O1 (FOXO1) enhanced PTX-induced autophagy through a transcriptional activation pattern in MDA-MB-231 cells, which was associated with the downstream target genes autophagy related 5, class III phosphoinositide 3-kinase vacuolar protein sorting 34, autophagy related 4B cysteine peptidase, beclin 1 and microtubule associated protein 1 light chain 3beta.	Paclitaxel	85-88	microtubule associated protein 1 light chain 3 beta	Homo sapiens	367-417
35141332-6	2022	Both the protein and mRNA expression levels of FOXM1 and ABCC5 transporters were significantly higher in the paclitaxel-resistant Caski/Taxol cells compared with Caski cells (P < 0.05).	Paclitaxel	109-119	ATP binding cassette subfamily C member 5	Homo sapiens	57-62
18676833-9	2008	In conclusion, the current report not only unravels a novel mechanism to link Erk/Pin1 pathway and Mcl-1-mediated chemoresistance but also provides a plausible combination therapy, Taxol (Paclitaxel) plus Sorafenib, which was shown to be effective in killing breast cancer cells.	Paclitaxel	181-186	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	82-86
25677062-8	2015	RESULTS: Paclitaxel treated cells eventually developed MDR with overexpression of Pgp and MDR1, and with high activity of Pgp, while paclitaxel-NSC23925 co-treated cells remained sensitive to chemotherapeutic agents in both in vitro and in vivo models.	Paclitaxel	9-19	phosphoglycolate phosphatase	Homo sapiens	82-85
25677062-8	2015	RESULTS: Paclitaxel treated cells eventually developed MDR with overexpression of Pgp and MDR1, and with high activity of Pgp, while paclitaxel-NSC23925 co-treated cells remained sensitive to chemotherapeutic agents in both in vitro and in vivo models.	Paclitaxel	9-19	phosphoglycolate phosphatase	Homo sapiens	122-125
25483711-3	2015	Here we showed that Trx1 and FOXO1 were involved in paclitaxel (PTX)-induced drug resistance in ovarian cancer A2780 cells.	Paclitaxel	52-62	thioredoxin	Homo sapiens	20-24
25483711-3	2015	Here we showed that Trx1 and FOXO1 were involved in paclitaxel (PTX)-induced drug resistance in ovarian cancer A2780 cells.	Paclitaxel	64-67	thioredoxin	Homo sapiens	20-24
18676833-9	2008	In conclusion, the current report not only unravels a novel mechanism to link Erk/Pin1 pathway and Mcl-1-mediated chemoresistance but also provides a plausible combination therapy, Taxol (Paclitaxel) plus Sorafenib, which was shown to be effective in killing breast cancer cells.	Paclitaxel	181-186	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	99-104
18676833-9	2008	In conclusion, the current report not only unravels a novel mechanism to link Erk/Pin1 pathway and Mcl-1-mediated chemoresistance but also provides a plausible combination therapy, Taxol (Paclitaxel) plus Sorafenib, which was shown to be effective in killing breast cancer cells.	Paclitaxel	188-198	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	82-86
25483711-4	2015	PTX induced reactive oxygen species (ROS) and resulted in Trx1 and FOXO1 nuclear translocation.	Paclitaxel	0-3	thioredoxin	Homo sapiens	58-62
18676833-9	2008	In conclusion, the current report not only unravels a novel mechanism to link Erk/Pin1 pathway and Mcl-1-mediated chemoresistance but also provides a plausible combination therapy, Taxol (Paclitaxel) plus Sorafenib, which was shown to be effective in killing breast cancer cells.	Paclitaxel	188-198	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	99-104
35141332-10	2022	The knockdown of FOXM1 with shRNA or Siomycin A promotes paclitaxel-induced cell death by regulating ABCC5 gene transcription.	Paclitaxel	57-67	ATP binding cassette subfamily C member 5	Homo sapiens	101-106
35058503-6	2022	Knockdown of p53, RBL2, or the DREAM component LIN37 increased AURKA/B pathway gene expression and reduced paclitaxel and radiation toxicity in NSCLC cells.	Paclitaxel	107-117	potassium voltage-gated channel interacting protein 3	Homo sapiens	31-36
34996504-0	2022	Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer.	Paclitaxel	62-72	lectin, galactose binding, soluble 1	Mus musculus	16-21
34996504-2	2022	Here, we aim to reveal the underlying mechanisms of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) resistance in GC.	Paclitaxel	79-89	albumin	Mus musculus	65-72
18508881-0	2008	Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice.	Paclitaxel	40-50	interleukin 2	Mus musculus	10-23
25767476-4	2015	The paclitaxel biosynthetic pathway promoters contained a large number of E-box sites (CANNTG), similar to the binding sites for the key MJ-inducible transcription factor AtMYC2 from Arabidopsis thaliana.	Paclitaxel	4-14	Basic helix-loop-helix (bHLH) DNA-binding family protein	Arabidopsis thaliana	171-177
34996504-2	2022	Here, we aim to reveal the underlying mechanisms of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) resistance in GC.	Paclitaxel	95-105	albumin	Mus musculus	65-72
34996504-3	2022	METHODS: We performed RNA sequencing (RNA-seq) on samples from patients who were resistant or sensitive to nab-paclitaxel, and identified Zinc Finger Protein 64 (ZFP64) as critical for nab-paclitaxel resistance in GC.	Paclitaxel	111-121	ZFP64 zinc finger protein	Homo sapiens	138-160
25689802-6	2015	We show the potential of the model for gene perturbation studies by demonstrating decreased expression of TUBB2A results in significantly increased sensitivity of neurons to paclitaxel (0.23 +- 0.06 decrease in total neurite outgrowth, P = 0.011).	Paclitaxel	174-184	tubulin beta 2A class IIa	Homo sapiens	106-112
18704310-0	2008	Targeting of p38 mitogen-activated protein kinases to early growth response gene 1 (EGR-1) in the human paclitaxel-resistance ovarian carcinoma cells.	Paclitaxel	104-114	early growth response 1	Homo sapiens	54-82
34996504-3	2022	METHODS: We performed RNA sequencing (RNA-seq) on samples from patients who were resistant or sensitive to nab-paclitaxel, and identified Zinc Finger Protein 64 (ZFP64) as critical for nab-paclitaxel resistance in GC.	Paclitaxel	111-121	ZFP64 zinc finger protein	Homo sapiens	162-167
18704310-0	2008	Targeting of p38 mitogen-activated protein kinases to early growth response gene 1 (EGR-1) in the human paclitaxel-resistance ovarian carcinoma cells.	Paclitaxel	104-114	early growth response 1	Homo sapiens	84-89
18704310-1	2008	To investigate the relationship between the expression of early growth response gene 1 (EGR-1) and p38MAPK pathway in the paclitaxel resistance of ovarian carcinoma cells, the effect of p38MAPK inhibitor SB203580 on cell apoptosis was examined by using Hoechst 33258 staining.	Paclitaxel	122-132	early growth response 1	Homo sapiens	58-86
35282117-11	2022	Four genes showed significant association with the estimated half-maximal inhibitory concentration (IC50) of paclitaxel: bone morphogenetic protein 1 (BMP1), dumbbell former 4 protein (DBF4), angiogenin (ANG), and MAP7 domain containing 2 (MAP7D2).	Paclitaxel	109-119	angiogenin	Homo sapiens	192-202
18704310-1	2008	To investigate the relationship between the expression of early growth response gene 1 (EGR-1) and p38MAPK pathway in the paclitaxel resistance of ovarian carcinoma cells, the effect of p38MAPK inhibitor SB203580 on cell apoptosis was examined by using Hoechst 33258 staining.	Paclitaxel	122-132	early growth response 1	Homo sapiens	88-93
18704310-13	2008	The expression of EGR-1 mediated by p38MAPK pathway plays a critical role in paclitaxel resistance of ovarian carcinoma cells.	Paclitaxel	77-87	early growth response 1	Homo sapiens	18-23
35282117-11	2022	Four genes showed significant association with the estimated half-maximal inhibitory concentration (IC50) of paclitaxel: bone morphogenetic protein 1 (BMP1), dumbbell former 4 protein (DBF4), angiogenin (ANG), and MAP7 domain containing 2 (MAP7D2).	Paclitaxel	109-119	angiogenin	Homo sapiens	204-207
35173526-0	2022	SOX8 Affects Tumoral SPARC Expression by Regulating EZH2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC.	Paclitaxel	101-111	SRY-box transcription factor 8	Homo sapiens	0-4
35173526-7	2022	SOX8 reduced apoptosis and G2/M cell cycle arrest caused by albumin-bound paclitaxel.	Paclitaxel	74-84	SRY-box transcription factor 8	Homo sapiens	0-4
18636193-5	2008	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay indicated that overexpression of S100P sensitized OVCAR3 cells for chemotherapeutic drugs (paclitaxel, oxaliplatin, 5-fluorouracil, etoposide and epirubicin) induced cytotoxicity more than vector-only controls.	Paclitaxel	156-166	S100 calcium binding protein P	Homo sapiens	98-103
24531713-5	2015	We showed that paclitaxel induced BDNF expression and apoptosis simultaneously in a cell cycle-dependent manner.	Paclitaxel	15-25	brain derived neurotrophic factor	Mus musculus	34-38
35173526-8	2022	SOX8 transcriptionally regulated EZH2, which reduced expression of SPARC by promoting the methylation of SPARC, thereby reducing the transport of albumin-bound paclitaxel in pancreatic cancer cells.	Paclitaxel	160-170	SRY-box transcription factor 8	Homo sapiens	0-4
25351620-0	2015	Ephrin type-A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3-kinase/Akt signalling pathway.	Paclitaxel	50-60	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	97-122
2775202-3	1989	Incubation of intact mitochondria with Taxol-stabilized microtubules resulted in the selective trapping of both MAPs 1 and 2 on mitochondria, indicating that an interaction between the two organelles occurred through a site on the arm-like projection of MAPs.	Paclitaxel	39-44	Blood pressure QTL 196	Rattus norvegicus	112-124
25351620-6	2015	Furthermore, paclitaxel stimulation and EphA2 over-expression resulted in activation of the phosphoinositide 3-kinase (PI3K)/Akt signalling pathway in NPC cells.	Paclitaxel	13-23	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	92-117
26514453-3	2015	P-gp mediates resistance to a broad-spectrum of anticancer drugs including doxorubicin, taxol, and vinca alkaloids by actively expelling the drugs from cells.	Paclitaxel	88-93	phosphoglycolate phosphatase	Homo sapiens	0-4
25607466-6	2015	Additionally, the downregulation of BECN1 by siRNA attenuated the activation of autophagy and cytoprotection from paclitaxel induced by TXNDC17 overexpression in ovarian cancer cells.	Paclitaxel	114-124	thioredoxin domain containing 17	Homo sapiens	136-143
25607466-7	2015	Thus, our findings suggest that TXNDC17, through participation of BECN1, induces autophagy and consequently results in paclitaxel resistance in ovarian cancer.	Paclitaxel	119-129	thioredoxin domain containing 17	Homo sapiens	32-39
25821560-0	2015	Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel.	Paclitaxel	80-90	checkpoint with forkhead and ring finger domains	Homo sapiens	15-19
25821560-5	2015	When treated with docetaxel or paclitaxel, cell viability was lower in CHFR methylated esophageal cancer cells than in unmethylated cells (p&lt;0.05).	Paclitaxel	31-41	checkpoint with forkhead and ring finger domains	Homo sapiens	71-75
25821560-7	2015	In CHFR methylated cells, treatment with docetaxel or paclitaxel resulted in almost all cells being suspended in G0/G1 phase of the cell cycle.	Paclitaxel	54-64	checkpoint with forkhead and ring finger domains	Homo sapiens	3-7
25656018-3	2015	A case of penile cancer with inguinal metastases that responded well to neoadjuvant chemotherapy with paclitaxel, ifosfamide and cisplatin (TIP) is described.	Paclitaxel	102-112	TOR signaling pathway regulator	Homo sapiens	140-143
25134457-0	2015	In vitro synergistic efficacy of conjugated linoleic acid, oleic acid, safflower oil and taxol cytotoxicity on PC3 cells.	Paclitaxel	89-94	chromobox 8	Homo sapiens	111-114
25134457-1	2015	The aim of this study was to determine in vitro synergistic efficacy of conjugated linoleic acid (CLA), oleic acid (OLA), safflower oil and taxol (Tax) cytotoxicity on human prostate cancer (PC3) cell line.	Paclitaxel	140-145	chromobox 8	Homo sapiens	191-194
25134457-6	2015	Cytotoxic synergy between Tax, OLA and CLA shows enhanced cytotoxicity on PC3 which might be used in the therapy of prostate cancer.	Paclitaxel	26-29	chromobox 8	Homo sapiens	74-77
25535399-0	2014	Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes.	Paclitaxel	0-10	microtubule associated protein tau	Homo sapiens	56-60
25341372-0	2014	Efficacy and tolerability of TIP (paclitaxel, ifosfamide and cisplatin) incorporated into induction chemotherapy for patients with intermediate- or poor-risk metastatic germ cell tumors.	Paclitaxel	34-44	TOR signaling pathway regulator	Homo sapiens	29-32
25341372-1	2014	The objective of this study was to analyze the clinical outcomes of TIP (paclitaxel, ifosfamide and cisplatin) incorporated into induction chemotherapy for patients with metastatic germ cell tumor (GCT) characterized by unfavorable clinical features.	Paclitaxel	73-83	TOR signaling pathway regulator	Homo sapiens	68-71
25379611-0	2014	Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines.	Paclitaxel	47-52	stathmin 1	Homo sapiens	0-4
25379611-0	2014	Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines.	Paclitaxel	47-52	stathmin 1	Homo sapiens	5-13
25379611-6	2014	Microtubule dynamics analysis demonstrated that taxol treatment destroyed normal microtubule arrays and caused obvious microtubule collapse in CNE1, Hep3B-2, MGC, and MCF-7 rather than NCI-H1299, while the latter expressed high levels of microtubule-destabilizing protein Op18/stathmin.	Paclitaxel	48-53	stathmin 1	Homo sapiens	272-276
25379611-6	2014	Microtubule dynamics analysis demonstrated that taxol treatment destroyed normal microtubule arrays and caused obvious microtubule collapse in CNE1, Hep3B-2, MGC, and MCF-7 rather than NCI-H1299, while the latter expressed high levels of microtubule-destabilizing protein Op18/stathmin.	Paclitaxel	48-53	stathmin 1	Homo sapiens	277-285
25379611-7	2014	Inhibition of Op18/stathmin expression increased the sensitivity to taxol and promoted cellular apoptosis in NCI-H1299 cells.	Paclitaxel	68-73	stathmin 1	Homo sapiens	14-18
25379611-7	2014	Inhibition of Op18/stathmin expression increased the sensitivity to taxol and promoted cellular apoptosis in NCI-H1299 cells.	Paclitaxel	68-73	stathmin 1	Homo sapiens	19-27
25379611-9	2014	High expression of Op18/stathmin is perhaps a crucial determinant of taxol-resistant development in NCI-H1299 cells.	Paclitaxel	69-74	stathmin 1	Homo sapiens	19-23
25379611-9	2014	High expression of Op18/stathmin is perhaps a crucial determinant of taxol-resistant development in NCI-H1299 cells.	Paclitaxel	69-74	stathmin 1	Homo sapiens	24-32
25374078-0	2014	[Adenovirus-mediated interleukin-24 enhances the inhibitory effect of paclitaxel on the growth of lung cancer A549 cells].	Paclitaxel	70-80	interleukin 24	Homo sapiens	21-35
25274031-0	2014	Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner.	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	58-62
25274031-2	2014	Work in preclinical models of breast cancer has shown that acquired chemoresistance to the widely used drug paclitaxel can be mediated by activation of the Toll-like receptor TLR4 in cancer cells.	Paclitaxel	108-118	toll like receptor 4	Homo sapiens	175-179
25274031-4	2014	While paclitaxel treatment was largely efficacious in inhibiting TLR4-negative tumors, it significantly increased the incidence and burden of pulmonary and lymphatic metastasis by TLR4-positive tumors.	Paclitaxel	6-16	toll like receptor 4	Homo sapiens	65-69
25274031-4	2014	While paclitaxel treatment was largely efficacious in inhibiting TLR4-negative tumors, it significantly increased the incidence and burden of pulmonary and lymphatic metastasis by TLR4-positive tumors.	Paclitaxel	6-16	toll like receptor 4	Homo sapiens	180-184
25274031-5	2014	TLR4 activation by paclitaxel strongly increased the expression of inflammatory mediators, not only locally in the primary tumor microenvironment but also systemically in the blood, lymph nodes, spleen, bone marrow, and lungs.	Paclitaxel	19-29	toll like receptor 4	Homo sapiens	0-4
25274031-7	2014	In contrast, paclitaxel-mediated activation of TLR4-positive tumors induced de novo generation of deep intratumoral lymphatic vessels that were highly permissive to invasion by malignant cells.	Paclitaxel	13-23	toll like receptor 4	Homo sapiens	47-51
25274031-8	2014	These results suggest that paclitaxel therapy of patients with TLR4-expressing tumors may activate systemic inflammatory circuits that promote angiogenesis, lymphangiogenesis, and metastasis, both at local sites and premetastatic niches where invasion occurs in distal organs.	Paclitaxel	27-37	toll like receptor 4	Homo sapiens	63-67
25122070-7	2014	We have also identified a role for Mcl-1 protein in preventing apoptosis during mitosis in PC3 cells, as simultaneous PTTG1 and Mcl-1 silencing enhances mitosis-associated apoptosis after paclitaxel treatment.	Paclitaxel	188-198	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	118-123
25122070-7	2014	We have also identified a role for Mcl-1 protein in preventing apoptosis during mitosis in PC3 cells, as simultaneous PTTG1 and Mcl-1 silencing enhances mitosis-associated apoptosis after paclitaxel treatment.	Paclitaxel	188-198	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	128-133
24510775-0	2014	miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.	Paclitaxel	43-53	microRNA 145	Homo sapiens	0-7
24510775-2	2014	In our study, paclitaxel-resistant ovarian cancer patients and cell lines had decreased miR-145 levels and expressed high levels of Sp1 and Cdk6.	Paclitaxel	14-24	microRNA 145	Homo sapiens	88-95
25034033-5	2014	In the absence of p600, this translocation is interrupted in favour of a sustained self-aggregation that is prevented by the microtubule-stabilizing drug paclitaxel.	Paclitaxel	154-164	ubiquitin protein ligase E3 component n-recognin 4	Homo sapiens	18-22
25093335-4	2014	Treatment with NPB304 increased paclitaxel-induced apoptosis in a p53-dependent manner through PARP cleavage.	Paclitaxel	32-42	transformation related protein 53, pseudogene	Mus musculus	66-69
24925370-0	2014	The role of the SHH gene in prostate cancer cell resistance to paclitaxel.	Paclitaxel	63-73	sonic hedgehog signaling molecule	Homo sapiens	16-19
24925370-7	2014	The effect of SHH overexpression in cells after treatment with paclitaxel was measured by MTT assay, crystal violet assay and flow cytometry.	Paclitaxel	63-73	sonic hedgehog signaling molecule	Homo sapiens	14-17
24925370-9	2014	RESULTS: Expression of exogenous SHH protein in DU145 and LNCaP cell lines enhanced their resistance to paclitaxel along with increased expression of ABC transporters transcripts.	Paclitaxel	104-114	sonic hedgehog signaling molecule	Homo sapiens	33-36
24925370-10	2014	Paclitaxel treatment further enhanced the expression of increased ABC transporters transcripts in cells overexpressing SHH.	Paclitaxel	0-10	sonic hedgehog signaling molecule	Homo sapiens	119-122
24925370-11	2014	CONCLUSIONS: Overexpression of SHH enhances PCa cell lines resistance to paclitaxel.	Paclitaxel	73-83	sonic hedgehog signaling molecule	Homo sapiens	31-34
24925370-12	2014	Higher level of SHH leads to increase in ABC transporters expression in a manner dependent on paclitaxel.	Paclitaxel	94-104	sonic hedgehog signaling molecule	Homo sapiens	16-19
24792619-12	2014	In this subgroup, for those women who received paclitaxel and platinum agents combined (n = 57), reduced MAD2 intensity also identified women with a shorter RFS (P &lt; .007).	Paclitaxel	47-57	mitotic arrest deficient 2 like 1	Homo sapiens	105-109
24939301-6	2014	The percentage of cells in G0-G1 and G2-M phases was reduced, and that in S phase increased after treatment for 72 h. The expression of cyclin D1 and B1, p27 and PCNA in VSMCs of paclitaxel-treated group was up-regulated, but that of p21 down-regulated as compared with VECs.	Paclitaxel	179-189	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	154-157
24823476-0	2014	Enriched variations in TEKT4 and breast cancer resistance to paclitaxel.	Paclitaxel	61-71	tektin 4	Homo sapiens	23-28
24823476-6	2014	These two TEKT4 germline variations in a high cis linkage are biologically relevant, as the ectopic expression of variant TEKT4 deregulates the microtubule stability, antagonizes the paclitaxel-induced stabilizing effect of microtubules and increases paclitaxel resistance.	Paclitaxel	183-193	tektin 4	Homo sapiens	10-15
24823476-6	2014	These two TEKT4 germline variations in a high cis linkage are biologically relevant, as the ectopic expression of variant TEKT4 deregulates the microtubule stability, antagonizes the paclitaxel-induced stabilizing effect of microtubules and increases paclitaxel resistance.	Paclitaxel	183-193	tektin 4	Homo sapiens	122-127
24823476-6	2014	These two TEKT4 germline variations in a high cis linkage are biologically relevant, as the ectopic expression of variant TEKT4 deregulates the microtubule stability, antagonizes the paclitaxel-induced stabilizing effect of microtubules and increases paclitaxel resistance.	Paclitaxel	251-261	tektin 4	Homo sapiens	10-15
24823476-6	2014	These two TEKT4 germline variations in a high cis linkage are biologically relevant, as the ectopic expression of variant TEKT4 deregulates the microtubule stability, antagonizes the paclitaxel-induced stabilizing effect of microtubules and increases paclitaxel resistance.	Paclitaxel	251-261	tektin 4	Homo sapiens	122-127
24823476-7	2014	Furthermore, TEKT4 germline variations are associated with reduced disease-free survival and overall survival compared with wild-type TEKT4 in patients undergoing paclitaxel-based chemotherapy.	Paclitaxel	163-173	tektin 4	Homo sapiens	13-18
24525192-6	2014	Co-administration of luteolin and paclitaxel resulted in an increase in apoptosis compared with the treatment of paclitaxel alone as evidenced by the results of a diamidino-2-phenylindole (DAPI) stain and Annexin-V-based assay.	Paclitaxel	34-44	annexin A5	Homo sapiens	205-214
24782986-8	2014	The addition of CYT387 with paclitaxel resulted in the suppression of JAK2/STAT3 activation and abrogation of Oct4 and CD117 expression in mouse xenografts.	Paclitaxel	28-38	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	119-124
24782986-10	2014	These data suggest that the systemic administration of paclitaxel enhances Oct4- and CD117-associated CSC-like marker expression in surviving cancer cells in vivo, which can be suppressed by the addition of the JAK2-specific inhibitor CYT387, leading to a significantly smaller tumor burden.	Paclitaxel	55-65	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	85-90
24782986-10	2014	These data suggest that the systemic administration of paclitaxel enhances Oct4- and CD117-associated CSC-like marker expression in surviving cancer cells in vivo, which can be suppressed by the addition of the JAK2-specific inhibitor CYT387, leading to a significantly smaller tumor burden.	Paclitaxel	55-65	Janus kinase 2	Mus musculus	211-215
24562672-0	2014	Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer.	Paclitaxel	68-78	thymidylate synthetase	Homo sapiens	0-20
24377747-0	2014	Royal jelly protects from taxol-induced testicular damages via improvement of antioxidant status and up-regulation of E2f1.	Paclitaxel	26-31	E2F transcription factor 1	Rattus norvegicus	118-122
24530529-1	2014	In this study, we show that atraxia telangiectasia mutated kinase (ATM) activity is generally upregulated by different apoptotic stimuli, i.e. TNF-alpha, TRAIL, paclitaxel, or UV.	Paclitaxel	161-171	ATM serine/threonine kinase	Homo sapiens	28-65
24530529-1	2014	In this study, we show that atraxia telangiectasia mutated kinase (ATM) activity is generally upregulated by different apoptotic stimuli, i.e. TNF-alpha, TRAIL, paclitaxel, or UV.	Paclitaxel	161-171	ATM serine/threonine kinase	Homo sapiens	67-70
24431074-6	2014	Furthermore, masitinib, in combination with paclitaxel, significantly inhibited the growth of ABCC10-expressing tumors in nude athymic mice in vivo.	Paclitaxel	44-54	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	94-100
24431074-8	2014	In conclusion, the combination of paclitaxel and masitinib could serve as a novel and useful therapeutic strategy to reverse paclitaxel resistance mediated by ABCC10.	Paclitaxel	34-44	ATP binding cassette subfamily C member 10	Homo sapiens	159-165
24431074-8	2014	In conclusion, the combination of paclitaxel and masitinib could serve as a novel and useful therapeutic strategy to reverse paclitaxel resistance mediated by ABCC10.	Paclitaxel	125-135	ATP binding cassette subfamily C member 10	Homo sapiens	159-165
24469707-3	2014	Results showed that treatment of Taxol could increase the inhibition rate of tumour growth, positive expression levels of Caspase-3, Bax and decrease positive expression levels of Bcl-2 and Bcl-2/Bax, expression levels of HGF, MACC1 and C-met proteins and MACC1 mRNA in tumour tissue of CC mice.	Paclitaxel	33-38	met proto-oncogene	Mus musculus	237-242
24469707-4	2014	It can be concluded that inhibitory activity of Taxol against tumour growth in CC mice is closely associated with its modulating positive expression of Bcl-2, Bax, Caspase-3, expression of HGF, MACC1, Caspase-3 and C-met proteins and MACC1 mRNA in tumour of CC mice.	Paclitaxel	48-53	met proto-oncogene	Mus musculus	215-220
24527095-0	2014	TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma in vitro.	Paclitaxel	39-49	toll like receptor 4	Homo sapiens	0-4
24527095-2	2014	Paclitaxel (Pac) has been previously reported to be a ligand to Toll-like receptor 4 (TLR4).	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	64-84
24527095-2	2014	Paclitaxel (Pac) has been previously reported to be a ligand to Toll-like receptor 4 (TLR4).	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	86-90
24527095-2	2014	Paclitaxel (Pac) has been previously reported to be a ligand to Toll-like receptor 4 (TLR4).	Paclitaxel	0-3	toll like receptor 4	Homo sapiens	64-84
24527095-2	2014	Paclitaxel (Pac) has been previously reported to be a ligand to Toll-like receptor 4 (TLR4).	Paclitaxel	0-3	toll like receptor 4	Homo sapiens	86-90
23969104-3	2014	This two-vial formulation of PTX-loaded lipid nanoemulsion (TPLE) could significantly reduce extraction of reticuloendothelial system (RES) organs and increase tumor uptake, and exhibited more potent antitumor efficacy on bearing A2780 or Bcap-37 tumor nude mice compared to conventional PTX-loaded lipid nanoemulsion (CPLE).	Paclitaxel	29-32	prohibitin 2	Mus musculus	239-246
24281000-8	2014	Furthermore, although CHKA silencing did not directly induce cell death, a significant increase of sensitivity to platinum, paclitaxel and doxorubicin was observed even in a drug-resistant context.	Paclitaxel	124-134	choline kinase alpha	Homo sapiens	22-26
24505235-8	2014	uPAR expression was maintained when resistance was modeled in triple-negative breast cancer by generating doxorubicin and paclitaxel resistant MDA-MB-231 cells (MDA-MB-231 DoxR and MDA-MB-231 TaxR).	Paclitaxel	122-132	plasminogen activator, urokinase receptor	Homo sapiens	0-4
24239580-1	2014	Paclitaxel, a potential anticancer agent against solid tumors has been restricted from its oral use due to poor water solubility as well as Pgp efflux property.	Paclitaxel	0-10	phosphoglycolate phosphatase	Homo sapiens	140-143
25081695-0	2014	Expression and underlying roles of IGFBP-3 in paclitaxel-treated gastric cancer SGC-7901 cells.	Paclitaxel	46-56	insulin like growth factor binding protein 3	Homo sapiens	35-42
25081695-6	2014	RESULTS: Compared to the control group, only IGFBP-3 expression was elevated significantly after paclitaxel (10 nM) treatment (p&lt;0.05).	Paclitaxel	97-107	insulin like growth factor binding protein 3	Homo sapiens	45-52
25081695-9	2014	CONCLUSIONS: IGFBP-3 exhibits anti-apoptotic effects on paclitaxel-treated SGC-7901 cells via elevating Bcl-2 expression.	Paclitaxel	56-66	insulin like growth factor binding protein 3	Homo sapiens	13-20
25483095-0	2014	Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells.	Paclitaxel	44-54	mitotic arrest deficient 2 like 1	Homo sapiens	0-4
25483095-0	2014	Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells.	Paclitaxel	44-54	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	9-14
25483095-7	2014	We discovered that paclitaxel treatment increased cell survival in MKN45 cells interfered for Mad2 or BubR1 expression.	Paclitaxel	19-29	mitotic arrest deficient 2 like 1	Homo sapiens	94-98
25483095-7	2014	We discovered that paclitaxel treatment increased cell survival in MKN45 cells interfered for Mad2 or BubR1 expression.	Paclitaxel	19-29	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	102-107
24180279-4	2014	The most active compound of this series acts as a CDK1 inhibitor, and was found to cause cell cycle arrest at G2/M phase, to induce apoptosis by preventing the phosphorylation of survivin in Thr(34) and to increase the cytotoxic activity of paclitaxel in STO cells.	Paclitaxel	241-251	cyclin dependent kinase 1	Homo sapiens	50-54
25648659-1	2014	OBJECTIVE: The aim of the present study was to investigate the differences between therapeutic granulocyte-colony stimulating factor (G-CSF) cycles and prophylactic G-CSF cycles in patients receiving paclitaxel and carboplatin combination chemotherapy for ovarian cancer.	Paclitaxel	200-210	colony stimulating factor 3	Homo sapiens	95-132
25648659-1	2014	OBJECTIVE: The aim of the present study was to investigate the differences between therapeutic granulocyte-colony stimulating factor (G-CSF) cycles and prophylactic G-CSF cycles in patients receiving paclitaxel and carboplatin combination chemotherapy for ovarian cancer.	Paclitaxel	200-210	colony stimulating factor 3	Homo sapiens	134-139
25648659-1	2014	OBJECTIVE: The aim of the present study was to investigate the differences between therapeutic granulocyte-colony stimulating factor (G-CSF) cycles and prophylactic G-CSF cycles in patients receiving paclitaxel and carboplatin combination chemotherapy for ovarian cancer.	Paclitaxel	200-210	colony stimulating factor 3	Homo sapiens	165-170
24195507-0	2014	Cyclin-dependent kinase 1 inhibitor RO3306 promotes mitotic slippage in paclitaxel-treated HepG2 cells.	Paclitaxel	72-82	cyclin dependent kinase 1	Homo sapiens	0-25
24247637-6	2014	In addition, treatment with paclitaxel plus doxorubicin significantly increased apoptosis as indicated by increased cleaved poly(ADP-ribose) polymerase and cleaved caspase-7 and -9 levels.	Paclitaxel	28-38	caspase 7	Homo sapiens	164-180
23982874-5	2014	Interestingly, when treated with a combination of ellipticine and paclitaxel, the percentage of ALDH1A1-positive BCSCs dropped by several fold in vitro.	Paclitaxel	66-76	aldehyde dehydrogenase 1 family member A1	Homo sapiens	96-103
24008043-2	2013	To obviate these limitations, dual-targeting paclitaxel-loaded nanoparticles were developed by decoration with peptide-22 (PNP-PTX), a peptide with special affinity for low-density lipoprotein receptor (LDLR), to transport the drug across the BBB, and then target brain tumour cells.	Paclitaxel	45-55	purine-nucleoside phosphorylase	Mus musculus	123-126
24278179-11	2013	ALDH1A1, SOX2, CXCR4 and SDF-1 mRNA levels were higher in metastatic lesions than in primary tumors, and were significantly elevated in both locations by paclitaxel treatment.	Paclitaxel	154-164	aldehyde dehydrogenase 1 family member A1	Homo sapiens	0-7
24036847-0	2013	Knockdown of cyclophilin A reverses paclitaxel resistance in human endometrial cancer cells via suppression of MAPK kinase pathways.	Paclitaxel	36-46	peptidylprolyl isomerase A	Homo sapiens	13-26
24036847-3	2013	As a natural continuation, this study aimed to reveal the correlation between CypA and paclitaxel resistance and evaluate the possibility of CypA as a therapeutic target for reversal of resistance.	Paclitaxel	87-97	peptidylprolyl isomerase A	Homo sapiens	78-82
24036847-5	2013	CypA was knocked down by RNA interference, and the subsequent effects on the alteration of paclitaxel resistance were examined by MTT, flow cytometry and migratory/invasive transwell assays.	Paclitaxel	91-101	peptidylprolyl isomerase A	Homo sapiens	0-4
24036847-7	2013	RESULTS: CypA knockdown led to significant inhibition of cell proliferation, induction of apoptosis and suppression of migratory/invasive capacity in HEC-1-B/TAX and AN3CA/TAX cells when exposed to paclitaxel.	Paclitaxel	198-208	peptidylprolyl isomerase A	Homo sapiens	9-13
24036847-10	2013	CONCLUSIONS: These results demonstrated that CypA expression was up-regulated in paclitaxel-resistant cancer cells, and knockdown of CypA could reverse the paclitaxel resistance through, at least partly, suppression of MAPK kinase pathways, presenting a possibility of CypA serving as a therapeutic target to overcome paclitaxel resistance.	Paclitaxel	81-91	peptidylprolyl isomerase A	Homo sapiens	45-49
24036847-10	2013	CONCLUSIONS: These results demonstrated that CypA expression was up-regulated in paclitaxel-resistant cancer cells, and knockdown of CypA could reverse the paclitaxel resistance through, at least partly, suppression of MAPK kinase pathways, presenting a possibility of CypA serving as a therapeutic target to overcome paclitaxel resistance.	Paclitaxel	81-91	peptidylprolyl isomerase A	Homo sapiens	133-137
24036847-10	2013	CONCLUSIONS: These results demonstrated that CypA expression was up-regulated in paclitaxel-resistant cancer cells, and knockdown of CypA could reverse the paclitaxel resistance through, at least partly, suppression of MAPK kinase pathways, presenting a possibility of CypA serving as a therapeutic target to overcome paclitaxel resistance.	Paclitaxel	81-91	peptidylprolyl isomerase A	Homo sapiens	133-137
24036847-10	2013	CONCLUSIONS: These results demonstrated that CypA expression was up-regulated in paclitaxel-resistant cancer cells, and knockdown of CypA could reverse the paclitaxel resistance through, at least partly, suppression of MAPK kinase pathways, presenting a possibility of CypA serving as a therapeutic target to overcome paclitaxel resistance.	Paclitaxel	156-166	peptidylprolyl isomerase A	Homo sapiens	133-137
24036847-10	2013	CONCLUSIONS: These results demonstrated that CypA expression was up-regulated in paclitaxel-resistant cancer cells, and knockdown of CypA could reverse the paclitaxel resistance through, at least partly, suppression of MAPK kinase pathways, presenting a possibility of CypA serving as a therapeutic target to overcome paclitaxel resistance.	Paclitaxel	156-166	peptidylprolyl isomerase A	Homo sapiens	133-137
24036847-10	2013	CONCLUSIONS: These results demonstrated that CypA expression was up-regulated in paclitaxel-resistant cancer cells, and knockdown of CypA could reverse the paclitaxel resistance through, at least partly, suppression of MAPK kinase pathways, presenting a possibility of CypA serving as a therapeutic target to overcome paclitaxel resistance.	Paclitaxel	156-166	peptidylprolyl isomerase A	Homo sapiens	133-137
24036847-10	2013	CONCLUSIONS: These results demonstrated that CypA expression was up-regulated in paclitaxel-resistant cancer cells, and knockdown of CypA could reverse the paclitaxel resistance through, at least partly, suppression of MAPK kinase pathways, presenting a possibility of CypA serving as a therapeutic target to overcome paclitaxel resistance.	Paclitaxel	156-166	peptidylprolyl isomerase A	Homo sapiens	133-137
23989978-9	2013	In vivo, nab-paclitaxel showed antitumor activity in both rhabdomyosarcoma (RH4 and RD) and neuroblastoma [SK-N-BE(2) and CHLA-20] xenograft models.	Paclitaxel	13-23	Rh blood group D antigen	Homo sapiens	76-79
23989978-12	2013	In the RH4 model, increased local relapse-free intervals were observed with nab-paclitaxel treatment (37.7 +- 3.2 days) comparing with paclitaxel (13.6 +- 2.07 days).	Paclitaxel	80-90	Rh blood group D antigen	Homo sapiens	7-10
23989978-12	2013	In the RH4 model, increased local relapse-free intervals were observed with nab-paclitaxel treatment (37.7 +- 3.2 days) comparing with paclitaxel (13.6 +- 2.07 days).	Paclitaxel	135-145	Rh blood group D antigen	Homo sapiens	7-10
24042258-6	2013	Phosphorylated mTOR and 4E-BP1 levels were elevated in gastric cancer cells and tumor tissues by nab-paclitaxel.	Paclitaxel	97-111	tortured	Mus musculus	15-30
24042258-14	2013	Our findings suggest that BEZ235 exerts some antitumor effects against gastric cancer and enhances effects of nab-paclitaxel through inhibition of cell proliferation and modulation of the PI3K/mTOR pathway.	Paclitaxel	110-124	mechanistic target of rapamycin kinase	Mus musculus	193-197
24179511-4	2013	Using the paclitaxel-resistant A2780/PTX cell line, it was demonstrated that high aldehyde dehydrogenase 1 (ALDH1) activity identifies CSCs from diverse sources.	Paclitaxel	10-20	aldehyde dehydrogenase 1 family member A1	Homo sapiens	82-106
24179511-4	2013	Using the paclitaxel-resistant A2780/PTX cell line, it was demonstrated that high aldehyde dehydrogenase 1 (ALDH1) activity identifies CSCs from diverse sources.	Paclitaxel	10-20	aldehyde dehydrogenase 1 family member A1	Homo sapiens	108-113
23816345-8	2013	CLTC colocalized with TUBB at the enlarged spindle and with cytoplasmic asters after taxol treatment; it disassembled and distributed into the cytoplasm along with TUBB after nocodazole treatment.	Paclitaxel	85-90	clathrin, heavy polypeptide (Hc)	Mus musculus	0-4
23686402-1	2013	PURPOSE: As the result of a recent national shortage in paclitaxel, some patients who were receiving or scheduled to receive weekly paclitaxel were converted to every 3-week (q3w) docetaxel with granulocyte colony-stimulating factor support.	Paclitaxel	56-66	colony stimulating factor 3	Homo sapiens	195-232
24069321-5	2013	We found that BBA concentration-dependently enhanced the sensitivity of MRP7-transfected HEK293 cells to paclitaxel, docetaxel and vinblastine.	Paclitaxel	105-115	ATP binding cassette subfamily C member 10	Homo sapiens	72-76
24019914-6	2013	When administered to mice already bearing established PyMT tumors, anti-CD115 treatment prolonged their survival and potentiated the effect of chemotherapy with Paclitaxel.	Paclitaxel	161-171	colony stimulating factor 1 receptor	Mus musculus	72-77
24036660-3	2013	We immunohistochemically analyzed cytoplasmic HuR expression in tumor biopsy cores obtained from 139 patients with invasive breast cancers who received paclitaxel and anthracycline-based neoadjuvant chemotherapy.	Paclitaxel	152-162	ELAV like RNA binding protein 1	Homo sapiens	46-49
23625295-13	2013	TUBA1B knockout in HCC cells inhibited cell proliferation, and attenuated resistance to paclitaxel.	Paclitaxel	88-98	tubulin alpha 1b	Homo sapiens	0-6
23625295-14	2013	CONCLUSIONS: Our results indicated that TUBA1B expression was upregulated in HCC tumor tissues and proliferating HCC cells, and an increased TUBA1B expression was associated with poor overall survival and resistance to paclitaxel of HCC patients.	Paclitaxel	219-229	tubulin alpha 1b	Homo sapiens	141-147
23263912-0	2013	Polymorphism of TS 3"-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.	Paclitaxel	127-137	thymidylate synthetase	Homo sapiens	16-18
22512726-5	2013	The effects of paclitaxel, cyclophosphamide, and gemcitabine, are antineoplastic agents, were examined on the in vitro enzyme activity of glutathione S-transferase and were determined to be inhibitors for the enzyme.	Paclitaxel	15-25	glutathione S-transferase kappa 1	Homo sapiens	138-163
23499896-2	2013	By approximately imitating the schedules of dose-dense and dose-escalation administration with paclitaxel, two novel multidrug resistant (MDR) cell lines Bads-200 and Bats-72 were successfully developed from drug-sensitive breast cancer cell line BCap37, respectively.	Paclitaxel	95-105	prohibitin 2	Homo sapiens	247-253
23684934-6	2013	Digoxin, vinblastine and paclitaxel, established P-gp substrates inhibited transport of NMQ with estimated K(i) values of 250, 0.1 and 0.6 muM, respectively.	Paclitaxel	25-35	phosphoglycolate phosphatase	Homo sapiens	49-53
23875078-1	2013	OBJECTIVE: The purpose of this study was to investigate whether selective cyclooxygenase (COX) inhibitors promote paclitaxel-induced apoptosis in taxane-resistant ovarian cancer cells by suppressing MDR1/P-glycoprotein (P-gp) expression.	Paclitaxel	114-124	phosphoglycolate phosphatase	Homo sapiens	220-224
23875078-5	2013	RESULTS: P-gp was upregulated in taxane-resistant ovarian cancer cells compared to paired paclitaxel-sensitive ovarian cancer cells.	Paclitaxel	90-100	phosphoglycolate phosphatase	Homo sapiens	9-13
23875078-11	2013	COX inhibitors could be potent therapeutic tools to promote paclitaxel sensitization of taxane-resistant ovarian cancers by suppressing MDR1/P-gp, which is responsible for the efflux of chemotherapeutic agents.	Paclitaxel	60-70	phosphoglycolate phosphatase	Homo sapiens	141-145
23782748-0	2013	Prognostic value of organic anion transporting polypeptide 1B3 and copper transporter 1 expression in endometrial cancer patients treated with paclitaxel and carboplatin.	Paclitaxel	143-153	solute carrier family 31 member 1	Homo sapiens	67-87
23562605-9	2013	Besides, the implication of microglial activation is supported by the increase in the immunolabelling of Iba-1, but not GFAP, in the spinal cord of paclitaxel-treated mice and by the inhibition of cold hyperalgesia produced by the i.t.	Paclitaxel	148-158	induction of brown adipocytes 1	Mus musculus	105-110
23525656-5	2013	Our results revealed that tandutinib significantly enhanced the sensitivity of MRP7-transfected HEK293 cells to the 2 established MRP7 substrates, paclitaxel and vincristine, whereas there was less or no effect on the control vector-transfected HEK293 cells.	Paclitaxel	147-157	ATP binding cassette subfamily C member 10	Homo sapiens	79-83
22797066-3	2013	In this study, we targeted the HER2 receptor using the monoclonal antibody (mAb) Herceptin (Trastuzumab) chemically conjugated to Doxorubicin or Taxol.	Paclitaxel	145-150	erb-b2 receptor tyrosine kinase 2	Mus musculus	31-35
23528739-12	2013	In addition the ability of SLN to travel across biological barriers due to its matrix lipid nature was explored upon comparing the efficacy of the drug loaded SLN with the conventional marketed drug product (Taxol ).	Paclitaxel	208-213	sarcolipin	Homo sapiens	27-30
23528739-13	2013	The cellular uptake studies showed that the developed Ptx loaded SLN were in fact internalized and demonstrated higher efficacy in the cancer cells death process than Taxol.	Paclitaxel	54-57	sarcolipin	Homo sapiens	65-68
23507139-5	2013	Importantly, HBx also countered the action of anticancer drug Paclitaxel suggesting its possible role in drug resistance.	Paclitaxel	62-72	X protein	Hepatitis B virus	13-16
23423488-13	2013	CONCLUSIONS: DNA methylation, dysregulation of miR-34c-5p, and MAPT expression are critical factors in the chemoresistance of gastric cancer to paclitaxel.	Paclitaxel	144-154	microtubule associated protein tau	Homo sapiens	63-67
23618950-7	2013	This inhibition was markedly enhanced when stathmin-inhibited breast cancer cells were exposed to low concentrations of taxol, which resulted in virtually complete loss of the malignant phenotype.	Paclitaxel	120-125	stathmin 1	Homo sapiens	43-51
23184673-3	2013	The produced SLN/siRNA complexes efficiently deliver both of paclitaxel and Bcl-2 targeted siRNA into human lung carcinoma cells and exhibit synergistic anticancer activities by triggering caspase-mediated apoptosis as determined by median effect plot analysis.	Paclitaxel	61-71	sarcolipin	Homo sapiens	13-16
23318472-0	2013	Paclitaxel ameliorates lipopolysaccharide-induced kidney injury by binding myeloid differentiation protein-2 to block Toll-like receptor 4-mediated nuclear factor-kappaB activation and cytokine production.	Paclitaxel	0-10	lymphocyte antigen 96	Mus musculus	75-108
23436791-6	2013	A synergistic effect in the inhibition of cell proliferation by ATP-competitive and ATP-noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all Pim-1 inhibitors tested in showed synergism with the known anticancer agent, paclitaxel.	Paclitaxel	255-265	proprotein convertase subtilisin/kexin type 1	Homo sapiens	162-165
23340795-11	2013	We found that             siRNA and ASO against Nek2 worked synergistically with paclitaxel and doxorubicin             by promoting cell apoptosis.	Paclitaxel	81-91	NIMA related kinase 2	Homo sapiens	48-52
23263828-0	2013	A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy.	Paclitaxel	29-39	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	131-136
23263828-14	2013	Our study indicates that the expression of ERCC1 evaluated by immunohistochemistry is a promising predictive marker for response in patients with metastatic ESCC receiving cisplatin-paclitaxel regimen.	Paclitaxel	182-192	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	43-48
23856142-14	2013	CONCLUSION: Targeting to inhibit antiapoptotic mitochondrial gene Bcl-2 expression in A549 cells specifically decreased the mRNA of ERCC1, TYMS, and TOP2alpha genes, and significantly increased the sensitivities of A549 cells to chemotherapeutic agents such as etoposide, cisplatin, paclitaxel and navelbine.	Paclitaxel	283-293	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	132-137
25309961-11	2013	We likewise found that diploid TLX1-expressing DN2mt cells treated with the mitotic inhibitor paclitaxel bypassed the mitotic checkpoint and displayed chromosomal instability.	Paclitaxel	94-104	T cell leukemia, homeobox 1	Mus musculus	31-35
23243220-2	2013	We aimed to determine the influence of the individual human OATP1B1, OATP1B3, and OATP1A2 transporters on the in vivo disposition of the anticancer drugs methotrexate and paclitaxel by using liver-specific humanized OATP1A/1B transgenic mice.	Paclitaxel	171-181	solute carrier organic anion transporter family member 1B1	Homo sapiens	60-67
23174537-6	2013	RESULTS: We demonstrated that Akt1 and Akt2 downregulation by RNAi highly sensitizes KLE cells to cisplatin by inducing the activation of pro-apoptotic factors such as the cleavage of caspases-3, -6, -9 and PARP; downregulation of all Akt isoforms leads to increased sensitivity to doxorubicin while only Akt1-2 downregulation increases taxol sensitivity.	Paclitaxel	337-342	AKT serine/threonine kinase 2	Homo sapiens	39-43
23229199-9	2013	When EC0156 cells were             treated with paclitaxel, stathmin was stably phosphorylated and migration was             impaired.	Paclitaxel	48-58	stathmin 1	Homo sapiens	60-68
23178685-7	2013	Finally, CAC1 increased paclitaxel-induced cell death in ERalpha-positive MCF7 cells, which are paclitaxel-resistant.	Paclitaxel	24-34	estrogen receptor 1	Rattus norvegicus	57-64
23178685-7	2013	Finally, CAC1 increased paclitaxel-induced cell death in ERalpha-positive MCF7 cells, which are paclitaxel-resistant.	Paclitaxel	96-106	estrogen receptor 1	Rattus norvegicus	57-64
24601044-1	2013	PURPOSE: The purpose of this study was to evaluate the efficacy and toxicity of paclitaxel and cisplatin as neoadjuvant chemotherapy for patients with Stage IB2 to IIB cervical cancer and determine factors accountable for response.	Paclitaxel	80-90	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	157-160
23215690-0	2013	2-Hydroxypropyl-beta-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.	Paclitaxel	50-60	sarcolipin	Homo sapiens	43-46
23689165-0	2013	Intracellular ATP-binding cassette transporter A3 is expressed in lung cancer cells and modulates susceptibility to cisplatin and paclitaxel.	Paclitaxel	130-140	ATP binding cassette subfamily A member 3	Homo sapiens	14-49
23689165-5	2013	Genetic silencing of ABCA3 in the NSCLC cell line models A549, NCI-H1650 and NCI-H1975 significantly increased tumor cell susceptibility to the cytostatic effects of both cisplatin (in all cell lines) and paclitaxel (in two of three cell lines).	Paclitaxel	205-215	ATP binding cassette subfamily A member 3	Homo sapiens	21-26
24098140-8	2013	We show that coel-1 disruption results in developmental hypersensitivity to the microtubule drug paclitaxel/taxol, and that overexpression of coel-1 has broad effects during embryonic development and perturbs specialized microtubules in the touch receptor neurons (TRNs).	Paclitaxel	97-107	tubulin folding COfactor E-Like protein	Caenorhabditis elegans	13-19
24098140-8	2013	We show that coel-1 disruption results in developmental hypersensitivity to the microtubule drug paclitaxel/taxol, and that overexpression of coel-1 has broad effects during embryonic development and perturbs specialized microtubules in the touch receptor neurons (TRNs).	Paclitaxel	108-113	tubulin folding COfactor E-Like protein	Caenorhabditis elegans	13-19
23554900-12	2013	In the MCF7 breast cancer cell line, leptin could induce cell proliferation and reduced the efficacy of all breast cancer therapies (tamoxifen, 5-fluorouracil, taxol and vinblastin).	Paclitaxel	160-165	leptin	Homo sapiens	37-43
23460921-5	2013	Nab-paclitaxel treatment increased expression of the mitotic-spindle associated phospho-stathmin irrespective of the baseline total or phosphorylated stathmin level, and induced mitotic cell death as confirmed through increased expression of cleaved-PARP and caspase-3.	Paclitaxel	4-14	stathmin 1	Homo sapiens	88-96
23460921-5	2013	Nab-paclitaxel treatment increased expression of the mitotic-spindle associated phospho-stathmin irrespective of the baseline total or phosphorylated stathmin level, and induced mitotic cell death as confirmed through increased expression of cleaved-PARP and caspase-3.	Paclitaxel	4-14	stathmin 1	Homo sapiens	150-158
22964375-0	2012	Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance.	Paclitaxel	106-116	kallikrein related peptidase 7	Homo sapiens	45-49
22964375-3	2012	We also reported that KLK7 overexpression confers chemoresistance to paclitaxel, and cell survival via integrins.	Paclitaxel	69-79	kallikrein related peptidase 7	Homo sapiens	22-26
22964375-8	2012	KLK4-7-transfected cells were more resistant to paclitaxel (10-100 nmol/L: 38-54%), but not to carboplatin, which was associated with decreased apoptotic stimuli.	Paclitaxel	48-58	kallikrein related peptidase 7	Homo sapiens	0-6
22964375-9	2012	However, the KLK4-7-induced paclitaxel resistance was not blocked by the MEK1/2 inhibitor, U0126.	Paclitaxel	28-38	kallikrein related peptidase 7	Homo sapiens	13-19
23154549-0	2012	Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy?	Paclitaxel	194-204	keratin 18	Homo sapiens	77-81
23087208-0	2012	Taxol-stabilized microtubules promote the formation of filaments from unmodified full-length Tau in vitro.	Paclitaxel	0-5	microtubule associated protein tau	Homo sapiens	93-96
23087208-8	2012	Strikingly, we found that Taxol-stabilized MTs promote Tau filament formation without characterized Tau-filament inducers.	Paclitaxel	26-31	microtubule associated protein tau	Homo sapiens	55-58
22872288-8	2012	The PTTG1 knockdown PC3 cell line also exhibited significantly reduced migration through Matrigel in a transwell assay of invasive potential, and down-regulation of PTTG1 could lead to increased sensitivity of these prostate cancer cells to a commonly used anticancer drug, taxol.	Paclitaxel	274-279	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	4-9
22872288-8	2012	The PTTG1 knockdown PC3 cell line also exhibited significantly reduced migration through Matrigel in a transwell assay of invasive potential, and down-regulation of PTTG1 could lead to increased sensitivity of these prostate cancer cells to a commonly used anticancer drug, taxol.	Paclitaxel	274-279	proprotein convertase subtilisin/kexin type 1	Homo sapiens	20-23
22872288-8	2012	The PTTG1 knockdown PC3 cell line also exhibited significantly reduced migration through Matrigel in a transwell assay of invasive potential, and down-regulation of PTTG1 could lead to increased sensitivity of these prostate cancer cells to a commonly used anticancer drug, taxol.	Paclitaxel	274-279	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	165-170
23421205-1	2012	In this work, pH-sensitive nanoparticles based on polyketal copolymer (PK3) were formulated by encapsulating hydrophilic doxorubicin hydrochloride (DOX) and hydrophobic paclitaxel (PTX) into the polymer, respectively.	Paclitaxel	169-179	pyruvate kinase M1/2	Homo sapiens	71-74
23421205-1	2012	In this work, pH-sensitive nanoparticles based on polyketal copolymer (PK3) were formulated by encapsulating hydrophilic doxorubicin hydrochloride (DOX) and hydrophobic paclitaxel (PTX) into the polymer, respectively.	Paclitaxel	181-184	pyruvate kinase M1/2	Homo sapiens	71-74
23421205-4	2012	The results demonstrated that the drug loading content increased with the increase of drug/polymer mass ratio, and PTX was entrapped into PK3 nanoparticles more effectively due to its hydrophobic character and the single emulsion method.	Paclitaxel	115-118	pyruvate kinase M1/2	Homo sapiens	138-141
23421205-6	2012	The cytotoxicity assay of blank nanoparticles indicated that polyketal copolymer (PK3) was biocompatible and suitable as drug vehicle, while PK3 nanoparticle encapsulating DOX or PTX could kill the cancer cells sufficiently and efficiently.	Paclitaxel	179-182	pyruvate kinase M1/2	Homo sapiens	141-144
23000902-5	2012	We find that the apparent affinities of P-gp for anticancer drugs actinomycin D and paclitaxel are approximately 4,000 and 100 times higher, respectively, in the membrane bilayer than in detergent.	Paclitaxel	84-94	phosphoglycolate phosphatase	Homo sapiens	40-44
23010708-6	2012	Notch3 overexpression was observed in both the cisplatin-resistant KFr13 and cisplatin/paclitaxel-resistant KFr13Tx cells.	Paclitaxel	87-97	notch receptor 3	Homo sapiens	0-6
22954140-7	2012	We demonstrated that TMEM45A expression was associated with taxol resistance.	Paclitaxel	60-65	transmembrane protein 45A	Homo sapiens	21-28
22954140-8	2012	TMEM45A expression was increased both in MDA-MB-231 human breast cancer cells and in HepG2 human hepatoma cells in conditions where protection of cells against apoptosis induced by chemotherapeutic agents was observed, i.e. under hypoxia in the presence of taxol or etoposide.	Paclitaxel	257-262	transmembrane protein 45A	Homo sapiens	0-7
22954140-12	2012	CONCLUSION: Altogether, our results unravel a new mechanism for taxol and etoposide resistance mediated by TMEM45A.	Paclitaxel	64-69	transmembrane protein 45A	Homo sapiens	107-114
22734125-5	2012	In vitro, vascular endothelial growth factor prevented primary dorsal root ganglion cultures from paclitaxel-induced neuronal stress and cell death by counteracting mitochondrial membrane potential decreases and normalizing hyperacetylation of alpha-tubulin.	Paclitaxel	98-108	tubulin alpha 1b	Homo sapiens	244-257
22374518-0	2012	Estrogen receptor alpha attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.	Paclitaxel	59-69	estrogen receptor 1 (alpha)	Mus musculus	0-23
22578167-5	2012	We found that sildenafil and vardenafil dose-dependently enhanced the sensitivity of MRP7-transfected HEK293 cells to paclitaxel, docetaxel and vinblastine, while tadalafil had only a minimal effect.	Paclitaxel	118-128	ATP binding cassette subfamily C member 10	Homo sapiens	85-89
22315133-2	2012	The aim of this study was to investigate whether 14-3-3sigma expression is also associated with resistance to neoadjuvant chemotherapy consisting of paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (P-FEC) in human breast cancer patients.	Paclitaxel	149-159	stratifin	Homo sapiens	49-60
22553355-9	2012	Smo antagonists sensitized chemotherapy-resistant cell lines to paclitaxel, but not to carboplatin.	Paclitaxel	64-74	smoothened, frizzled class receptor	Homo sapiens	0-3
22608923-6	2012	By contrast, depletion of Pin1 in cancer cells leads to elevated Fbw7 expression, which subsequently reduces Mcl-1 abundance, sensitizing cancer cells to Taxol.	Paclitaxel	154-159	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	26-30
22609777-4	2012	Here, we found that HB-EGF was over-expressed in a paclitaxel-resistant human ovarian carcinoma cell line (A2780/Taxol) and a cisplatin-resistant cell line (A2780/CDDP), as well as the xenograft mouse tissue samples with these cells.	Paclitaxel	51-61	heparin binding EGF like growth factor	Homo sapiens	20-26
22609777-9	2012	These results suggest that CRM197 as an HB-EGF-targeted agent has potent anti-tumor activity in paclitaxel- and cisplatin-resistant ovarian cancer which over-express HB-EGF.	Paclitaxel	96-106	heparin binding EGF like growth factor	Homo sapiens	40-46
22445254-7	2012	It was demonstrated that three PCL-modified P105 monomers and micelles inhibited P-gP efflux activity in the resistant SKOV-3/PTX cells via at least three intracellular events: 1) inhibition of ATPase of P-gP, 2) decrease of membrane microviscosity and 3) a loss of mitochondrial membrane potential and subsequent decrease of ATP levels at the concentration of monomers (0.001%) and/or micelles (0.01-1.0%).	Paclitaxel	126-129	phosphoglycolate phosphatase	Homo sapiens	81-85
22820595-7	2012	CG combined with Taxol increased the expression of Bax and reduced the expression of p53 and VEGF in the tumor xenografts.	Paclitaxel	17-22	transformation related protein 53, pseudogene	Mus musculus	85-88
22345163-8	2012	Using small interfering RNA approach, we knocked down ERCC2 expression and observed a block in the G(2)/M phase, with a consistent increase in paclitaxel sensitivity and no change in cisplatin sensitivity.	Paclitaxel	143-153	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	54-59
22345163-11	2012	We concluded that the increased paclitaxel sensitivity of ERCC2 variant cell lines is a consequence of lower gene expression, likely due to decreased stability of the variant ERCC2 mRNA.	Paclitaxel	32-42	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	58-63
22345163-11	2012	We concluded that the increased paclitaxel sensitivity of ERCC2 variant cell lines is a consequence of lower gene expression, likely due to decreased stability of the variant ERCC2 mRNA.	Paclitaxel	32-42	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	175-180
22425383-0	2012	Increased accumulation and retention of micellar paclitaxel in drug-sensitive and P-glycoprotein-expressing cell lines following ultrasound exposure.	Paclitaxel	49-59	PGP	Canis lupus familiaris	82-96
22425383-2	2012	The purpose of this work was to evaluate the effect of this ultrasound regimen on the cellular accumulation of paclitaxel (PTX) loaded in copolymer micellar of methoxy poly(ethylene glycol)-block-poly(D,L-lactide) (MePEG-b-PDLLA) in both drug-sensitive (MDCKII and MCF-7) and P-glycoprotein (Pgp)-expressing (MDCKII-MDR and NCI-ADR) cell lines.	Paclitaxel	111-121	PGP	Canis lupus familiaris	276-290
22425383-2	2012	The purpose of this work was to evaluate the effect of this ultrasound regimen on the cellular accumulation of paclitaxel (PTX) loaded in copolymer micellar of methoxy poly(ethylene glycol)-block-poly(D,L-lactide) (MePEG-b-PDLLA) in both drug-sensitive (MDCKII and MCF-7) and P-glycoprotein (Pgp)-expressing (MDCKII-MDR and NCI-ADR) cell lines.	Paclitaxel	111-121	PGP	Canis lupus familiaris	292-295
22425383-2	2012	The purpose of this work was to evaluate the effect of this ultrasound regimen on the cellular accumulation of paclitaxel (PTX) loaded in copolymer micellar of methoxy poly(ethylene glycol)-block-poly(D,L-lactide) (MePEG-b-PDLLA) in both drug-sensitive (MDCKII and MCF-7) and P-glycoprotein (Pgp)-expressing (MDCKII-MDR and NCI-ADR) cell lines.	Paclitaxel	123-126	PGP	Canis lupus familiaris	276-290
22425383-2	2012	The purpose of this work was to evaluate the effect of this ultrasound regimen on the cellular accumulation of paclitaxel (PTX) loaded in copolymer micellar of methoxy poly(ethylene glycol)-block-poly(D,L-lactide) (MePEG-b-PDLLA) in both drug-sensitive (MDCKII and MCF-7) and P-glycoprotein (Pgp)-expressing (MDCKII-MDR and NCI-ADR) cell lines.	Paclitaxel	123-126	PGP	Canis lupus familiaris	292-295
22425383-7	2012	These data suggest that ultrasound may facilitate the uptake of intact paclitaxel-loaded micelles into cells, allowing greater retention of drug in both Pgp and non-Pgp-expressing cells.	Paclitaxel	71-81	PGP	Canis lupus familiaris	153-156
22425383-7	2012	These data suggest that ultrasound may facilitate the uptake of intact paclitaxel-loaded micelles into cells, allowing greater retention of drug in both Pgp and non-Pgp-expressing cells.	Paclitaxel	71-81	PGP	Canis lupus familiaris	165-168
22533866-1	2012	BACKGROUND: MyD88 is an adaptor protein for TLR-4 signaling known to mediate paclitaxel resistance in epithelial ovarian carcinoma (EOC).	Paclitaxel	77-87	toll like receptor 4	Homo sapiens	44-49
21821547-0	2012	Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.	Paclitaxel	103-113	cyclin dependent kinase 1	Homo sapiens	56-60
22281755-0	2012	Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells.	Paclitaxel	100-110	stathmin 1	Homo sapiens	45-53
22281755-5	2012	The results showed that treatment of human breast carcinoma cells (SK-BR-3 and MDA-MB-231) by Aurora A short hairpin RNA (shRNA) driven by stathmin gene promoter not only inhibited the cells proliferation, but also enhanced the chemosensitivity to paclitaxel via downregulation of Aurora A mRNA and protein expression, which further decreased the phosphatidylinositol 3 kinase/Akt and p-BRCA1 protein expression.	Paclitaxel	248-258	stathmin 1	Homo sapiens	139-147
18496885-0	2008	Enzymatic stability of 2"-ethylcarbonate-linked paclitaxel in serum and conversion to paclitaxel by rabbit liver carboxylesterase for use in prodrug/enzyme therapy.	Paclitaxel	86-96	liver carboxylesterase 1	Oryctolagus cuniculus	107-129
18455782-12	2008	CONCLUSIONS: The combination of paclitaxel, epirubicin and carboplatin with G-CSF support appears active in patients with metastatic or recurrent carcinoma of the endometrium.	Paclitaxel	32-42	colony stimulating factor 3	Homo sapiens	76-81
18590557-2	2008	Here, we investigate the clinical potential of the second mitochondria-derived activator of caspase (Smac/DIABLO) in enhancing the apoptosis-inducing potential of commonly used anticancer drugs (paclitaxel, doxorubicin, etoposide, tamoxifen), irradiation and TRAIL in breast carcinoma.	Paclitaxel	195-205	diablo IAP-binding mitochondrial protein	Homo sapiens	51-99
18590557-2	2008	Here, we investigate the clinical potential of the second mitochondria-derived activator of caspase (Smac/DIABLO) in enhancing the apoptosis-inducing potential of commonly used anticancer drugs (paclitaxel, doxorubicin, etoposide, tamoxifen), irradiation and TRAIL in breast carcinoma.	Paclitaxel	195-205	diablo IAP-binding mitochondrial protein	Homo sapiens	106-112
18590557-6	2008	RESULTS: Overexpression of Smac/DIABLO gene (full-length or Delta55 Smac/DIABLO) or treatment with Smac/DIABLO peptide enhances apoptosis induced by paclitaxel, doxorubicin, etoposide, tamoxifen, and irradiation in breast cancer cells.	Paclitaxel	149-159	diablo IAP-binding mitochondrial protein	Homo sapiens	27-31
18590557-6	2008	RESULTS: Overexpression of Smac/DIABLO gene (full-length or Delta55 Smac/DIABLO) or treatment with Smac/DIABLO peptide enhances apoptosis induced by paclitaxel, doxorubicin, etoposide, tamoxifen, and irradiation in breast cancer cells.	Paclitaxel	149-159	diablo IAP-binding mitochondrial protein	Homo sapiens	32-38
18590557-6	2008	RESULTS: Overexpression of Smac/DIABLO gene (full-length or Delta55 Smac/DIABLO) or treatment with Smac/DIABLO peptide enhances apoptosis induced by paclitaxel, doxorubicin, etoposide, tamoxifen, and irradiation in breast cancer cells.	Paclitaxel	149-159	diablo IAP-binding mitochondrial protein	Homo sapiens	68-72
18590557-6	2008	RESULTS: Overexpression of Smac/DIABLO gene (full-length or Delta55 Smac/DIABLO) or treatment with Smac/DIABLO peptide enhances apoptosis induced by paclitaxel, doxorubicin, etoposide, tamoxifen, and irradiation in breast cancer cells.	Paclitaxel	149-159	diablo IAP-binding mitochondrial protein	Homo sapiens	68-72
18604988-0	2008	Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with pluronic P105/poly(caprolactone) copolymers.	Paclitaxel	62-72	nucleoporin 107	Rattus norvegicus	87-91
18604988-1	2008	A novel polymeric micellar formulation of paclitaxel (PTX) with Pluronic/poly(caprolactone) (P105/ PCL50) has been developed with the purpose of improving in vitro release and in vivo circulating time of PTX in comparison to the current Taxol injection.	Paclitaxel	42-52	nucleoporin 107	Rattus norvegicus	93-97
18604988-1	2008	A novel polymeric micellar formulation of paclitaxel (PTX) with Pluronic/poly(caprolactone) (P105/ PCL50) has been developed with the purpose of improving in vitro release and in vivo circulating time of PTX in comparison to the current Taxol injection.	Paclitaxel	54-57	nucleoporin 107	Rattus norvegicus	93-97
18604988-1	2008	A novel polymeric micellar formulation of paclitaxel (PTX) with Pluronic/poly(caprolactone) (P105/ PCL50) has been developed with the purpose of improving in vitro release and in vivo circulating time of PTX in comparison to the current Taxol injection.	Paclitaxel	204-207	nucleoporin 107	Rattus norvegicus	93-97
18604988-1	2008	A novel polymeric micellar formulation of paclitaxel (PTX) with Pluronic/poly(caprolactone) (P105/ PCL50) has been developed with the purpose of improving in vitro release and in vivo circulating time of PTX in comparison to the current Taxol injection.	Paclitaxel	237-242	nucleoporin 107	Rattus norvegicus	93-97
18604988-2	2008	This study was designed to investigate the preparation, in vitro release, in vivo pharmacokinetics and tissue distribution of the PTX-loaded, biodegradable, polymeric, P105/PCL50 micelle system.	Paclitaxel	130-133	nucleoporin 107	Rattus norvegicus	168-172
18604988-8	2008	These results suggested that the P105/ PCL50 polymeric micelles may efficiently load, protect and retain PTX in both in vitro and in vivo environments, and could be a useful drug carrier for i.v.	Paclitaxel	105-108	nucleoporin 107	Rattus norvegicus	33-37
18445659-3	2008	The expression levels of ABCC10 showed a significant inverse correlation with paclitaxel sensitivity (r = 0.574; P &lt; 0.05) in 17 non-small cell lung cancer (NSCLC) cells unlike the expression levels of ABCB1.	Paclitaxel	78-88	ATP binding cassette subfamily C member 10	Homo sapiens	25-31
18445659-4	2008	Pretreatment with the ABCC10 inhibitor sulfinpyrazone altered the sensitivity to paclitaxel in ABCC10-expressing NSCLC cells, concomitant with increased intracellular paclitaxel accumulation.	Paclitaxel	81-91	ATP binding cassette subfamily C member 10	Homo sapiens	22-28
18445659-4	2008	Pretreatment with the ABCC10 inhibitor sulfinpyrazone altered the sensitivity to paclitaxel in ABCC10-expressing NSCLC cells, concomitant with increased intracellular paclitaxel accumulation.	Paclitaxel	81-91	ATP binding cassette subfamily C member 10	Homo sapiens	95-101
18445659-4	2008	Pretreatment with the ABCC10 inhibitor sulfinpyrazone altered the sensitivity to paclitaxel in ABCC10-expressing NSCLC cells, concomitant with increased intracellular paclitaxel accumulation.	Paclitaxel	167-177	ATP binding cassette subfamily C member 10	Homo sapiens	22-28
18445659-5	2008	These findings suggest that expression of the ABCC10 gene is induced by paclitaxel and that ABCC10 confers paclitaxel resistance by enhancing the efflux for paclitaxel.	Paclitaxel	72-82	ATP binding cassette subfamily C member 10	Homo sapiens	46-52
18445659-5	2008	These findings suggest that expression of the ABCC10 gene is induced by paclitaxel and that ABCC10 confers paclitaxel resistance by enhancing the efflux for paclitaxel.	Paclitaxel	107-117	ATP binding cassette subfamily C member 10	Homo sapiens	46-52
18445659-5	2008	These findings suggest that expression of the ABCC10 gene is induced by paclitaxel and that ABCC10 confers paclitaxel resistance by enhancing the efflux for paclitaxel.	Paclitaxel	107-117	ATP binding cassette subfamily C member 10	Homo sapiens	92-98
18445659-5	2008	These findings suggest that expression of the ABCC10 gene is induced by paclitaxel and that ABCC10 confers paclitaxel resistance by enhancing the efflux for paclitaxel.	Paclitaxel	107-117	ATP binding cassette subfamily C member 10	Homo sapiens	46-52
18445659-5	2008	These findings suggest that expression of the ABCC10 gene is induced by paclitaxel and that ABCC10 confers paclitaxel resistance by enhancing the efflux for paclitaxel.	Paclitaxel	107-117	ATP binding cassette subfamily C member 10	Homo sapiens	92-98
18445659-6	2008	To confirm this hypothesis, we tested the effect on paclitaxel cytotoxicity of decreasing the expression of ABCC10 by small interfering RNA and found that this enhanced paclitaxel cytotoxicity in NCI-H23 cells concomitant with increased intracellular paclitaxel accumulation.	Paclitaxel	52-62	ATP binding cassette subfamily C member 10	Homo sapiens	108-114
18445659-6	2008	To confirm this hypothesis, we tested the effect on paclitaxel cytotoxicity of decreasing the expression of ABCC10 by small interfering RNA and found that this enhanced paclitaxel cytotoxicity in NCI-H23 cells concomitant with increased intracellular paclitaxel accumulation.	Paclitaxel	169-179	ATP binding cassette subfamily C member 10	Homo sapiens	108-114
18445659-6	2008	To confirm this hypothesis, we tested the effect on paclitaxel cytotoxicity of decreasing the expression of ABCC10 by small interfering RNA and found that this enhanced paclitaxel cytotoxicity in NCI-H23 cells concomitant with increased intracellular paclitaxel accumulation.	Paclitaxel	169-179	ATP binding cassette subfamily C member 10	Homo sapiens	108-114
18445659-7	2008	These data indicate that ABCC10 may be one of the biomarkers for paclitaxel resistance in NSCLC.	Paclitaxel	65-75	ATP binding cassette subfamily C member 10	Homo sapiens	25-31
18279928-1	2008	OBJECTIVES: To determine the feasibility and toxicity of adjuvant paclitaxel plus estramustine in prostate cancer patients at high risk of a 2-year PSA failure after prostatectomy.	Paclitaxel	66-76	aminopeptidase puromycin sensitive	Homo sapiens	148-151
18182245-0	2008	Upregulation of tissue factor expression and thrombogenic activity in human aortic smooth muscle cells by irradiation, rapamycin and paclitaxel.	Paclitaxel	133-143	coagulation factor III, tissue factor	Homo sapiens	16-29
18182245-3	2008	This study examined the impact of rapamycin and paclitaxel on TF expression and compares the TF activity induction of both drugs and irradiation in SMCs.	Paclitaxel	48-58	coagulation factor III, tissue factor	Homo sapiens	62-64
18182245-6	2008	RESULTS: Rapamycin or paclitaxel increased the TF mRNA expression 5-fold and the TF activity 4- to 6-fold with a maximum at 5 h. Irradiation induced TF activity 2- to 4-fold with a maximum at 7 days.	Paclitaxel	22-32	coagulation factor III, tissue factor	Homo sapiens	47-49
18182245-6	2008	RESULTS: Rapamycin or paclitaxel increased the TF mRNA expression 5-fold and the TF activity 4- to 6-fold with a maximum at 5 h. Irradiation induced TF activity 2- to 4-fold with a maximum at 7 days.	Paclitaxel	22-32	coagulation factor III, tissue factor	Homo sapiens	81-83
18182245-6	2008	RESULTS: Rapamycin or paclitaxel increased the TF mRNA expression 5-fold and the TF activity 4- to 6-fold with a maximum at 5 h. Irradiation induced TF activity 2- to 4-fold with a maximum at 7 days.	Paclitaxel	22-32	coagulation factor III, tissue factor	Homo sapiens	81-83
18182245-7	2008	CONCLUSION: The fast increase of TF expression in SMCs post rapamycin and paclitaxel treatment may explain acute stent thrombosis when anti-thrombotic therapies are withdrawn, whereas the irradiation induced long term increase of cellular thrombogenicity may contribute to late thrombosis post intracoronary brachytherapy.	Paclitaxel	74-84	coagulation factor III, tissue factor	Homo sapiens	33-35
18234883-5	2008	Similarly, mechanical hyperalgesia induced by paclitaxel, vincristine, or diabetes was strongly reduced in TRPV4 knock-out mice.	Paclitaxel	46-56	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	107-112
18032926-7	2007	In addition, we found that PC-3/Vinbeta#1 and #2 became resistant to the treatment with 100 nM paclitaxel for 48 h. On the other hand, when siRNA-mediated vinexinbeta gene silencing was performed, PC-3 cell growth was suppressed.	Paclitaxel	95-105	proprotein convertase subtilisin/kexin type 1	Homo sapiens	27-41
17825817-0	2007	Translation regulation after taxol treatment in NIH3T3 cells involves the elongation factor (eEF)2.	Paclitaxel	29-34	eukaryotic translation elongation factor 2	Mus musculus	93-98
17825817-8	2007	We found that taxol treatment did not induce changes in eIF2alpha phosphorylation, but strongly decreased eIF4G, eIF4E and 4E-BP1 expression levels.	Paclitaxel	14-19	eukaryotic translation initiation factor 4E	Mus musculus	113-129
17825817-12	2007	On the contrary, taxol treatment increased elongation factor eEF2 phosphorylation in a calpain-independent manner, supporting a role for eEF2 in taxol-induced translation inhibition.	Paclitaxel	17-22	eukaryotic translation elongation factor 2	Mus musculus	61-65
17825817-12	2007	On the contrary, taxol treatment increased elongation factor eEF2 phosphorylation in a calpain-independent manner, supporting a role for eEF2 in taxol-induced translation inhibition.	Paclitaxel	17-22	eukaryotic translation elongation factor 2	Mus musculus	137-141
17825817-12	2007	On the contrary, taxol treatment increased elongation factor eEF2 phosphorylation in a calpain-independent manner, supporting a role for eEF2 in taxol-induced translation inhibition.	Paclitaxel	145-150	eukaryotic translation elongation factor 2	Mus musculus	137-141
17912033-1	2007	We previously reported that the Polo-like Kinase 2 gene (Plk2/Snk) is a direct target for transcriptional regulation by p53 and that silencing Plk2 sensitizes cancer cells to Taxol-induced apoptosis.	Paclitaxel	175-180	polo like kinase 2	Homo sapiens	32-50
17912033-1	2007	We previously reported that the Polo-like Kinase 2 gene (Plk2/Snk) is a direct target for transcriptional regulation by p53 and that silencing Plk2 sensitizes cancer cells to Taxol-induced apoptosis.	Paclitaxel	175-180	polo like kinase 2	Homo sapiens	57-61
17912033-1	2007	We previously reported that the Polo-like Kinase 2 gene (Plk2/Snk) is a direct target for transcriptional regulation by p53 and that silencing Plk2 sensitizes cancer cells to Taxol-induced apoptosis.	Paclitaxel	175-180	polo like kinase 2	Homo sapiens	62-65
17912033-1	2007	We previously reported that the Polo-like Kinase 2 gene (Plk2/Snk) is a direct target for transcriptional regulation by p53 and that silencing Plk2 sensitizes cancer cells to Taxol-induced apoptosis.	Paclitaxel	175-180	polo like kinase 2	Homo sapiens	143-147
17909044-8	2007	Importantly, betaIII-siRNA cells displayed a significant dose-dependent increase in Annexin V staining when treated with either paclitaxel or cisplatin, compared with controls.	Paclitaxel	128-138	annexin A5	Homo sapiens	84-93
17903587-8	2007	CONCLUSION: More emphasis should be laid on MDR1/Pgp, the non-Pgp substrate chemotherapeutic agents, and the changes of cell cycle distribution to prevent MDR induced by Taxol.	Paclitaxel	170-175	phosphoglycolate phosphatase	Homo sapiens	49-52
17636258-5	2007	Topotecan- and paclitaxel-resistant prostate cancer lines were as sensitive to p53p-Ant-induced targeted necrosis as parental lines.	Paclitaxel	15-25	solute carrier family 25 member 6	Homo sapiens	84-87
17762397-0	2007	Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.	Paclitaxel	22-32	colony stimulating factor 3	Homo sapiens	38-75
17762397-15	2007	In untreated metastatic breast cancer patients, the weekly administration of epirubicin and paclitaxel with granulocyte colony-stimulating factor support seems to be extremely tolerable and active, and deserves further investigation into a phase III trial.	Paclitaxel	92-102	colony stimulating factor 3	Homo sapiens	108-145
17581879-3	2007	We also observed a Taxol-specific reduction in neuronal calcium sensor 1 (NCS-1) protein levels, a known modulator of InsP(3) receptor (InsP(3)R) activity.	Paclitaxel	19-24	neuronal calcium sensor 1	Rattus norvegicus	47-72
17581879-3	2007	We also observed a Taxol-specific reduction in neuronal calcium sensor 1 (NCS-1) protein levels, a known modulator of InsP(3) receptor (InsP(3)R) activity.	Paclitaxel	19-24	neuronal calcium sensor 1	Rattus norvegicus	74-79
17581879-8	2007	We also found that NCS-1 is readily degraded by mu-calpain in vitro and that mu-calpain activity is increased in Taxol but not vehicle-treated cells.	Paclitaxel	113-118	neuronal calcium sensor 1	Rattus norvegicus	19-24
17581879-9	2007	From these results, we conclude that prolonged exposure to Taxol activates mu-calpain, which leads to the degradation of NCS-1, which, in turn, attenuates InsP(3)mediated Ca(2+) signaling.	Paclitaxel	59-64	neuronal calcium sensor 1	Rattus norvegicus	121-126
17534145-0	2007	In vitro efficacy of immuno-chemotherapy with anti-EGFR human Fab-Taxol conjugate on A431 epidermoid carcinoma cells.	Paclitaxel	66-71	FA complementation group B	Homo sapiens	62-65
17534145-1	2007	The aims of this study were to generate a human Fab fragment against EGFR; conjugate it to paclitaxel (Taxol) as an immuno-chemotherapy agent; and investigate its in vitro anti-tumor efficacy on A431 epidermoid carcinoma cells.	Paclitaxel	91-101	FA complementation group B	Homo sapiens	48-51
17534145-1	2007	The aims of this study were to generate a human Fab fragment against EGFR; conjugate it to paclitaxel (Taxol) as an immuno-chemotherapy agent; and investigate its in vitro anti-tumor efficacy on A431 epidermoid carcinoma cells.	Paclitaxel	103-108	FA complementation group B	Homo sapiens	48-51
17534145-3	2007	The Fab was then conjugated with the chemotherapeutic Taxol, and cell proliferation inhibition and apoptosis (TUNEL) assays were conducted to determine the effect of this Fab-drug conjugate on A431 cells.	Paclitaxel	54-59	FA complementation group B	Homo sapiens	4-7
17534145-8	2007	Our findings suggest that this Fab-Taxol conjugate could be a potential immuno-chemotherapeutic drug for clinical treatment of EGFR-overexpressing tumors.	Paclitaxel	35-40	FA complementation group B	Homo sapiens	31-34
17607532-3	2007	Both rapamycin and paclitaxel decrease endothelial cell migration and proliferation; moreover, they induce tissue factor expression through specific interaction with signal transduction mediators.	Paclitaxel	19-29	coagulation factor III, tissue factor	Homo sapiens	107-120
17266036-0	2007	Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo.	Paclitaxel	64-74	alanyl (membrane) aminopeptidase	Mus musculus	15-31
17266036-3	2007	In the current study, we investigated the role of APN/CD13 in paclitaxel (PAC)-resistance of ovarian carcinoma (OVCA) cells.	Paclitaxel	62-72	alanyl (membrane) aminopeptidase	Mus musculus	50-53
17266036-3	2007	In the current study, we investigated the role of APN/CD13 in paclitaxel (PAC)-resistance of ovarian carcinoma (OVCA) cells.	Paclitaxel	62-72	alanyl (membrane) aminopeptidase	Mus musculus	54-58
17266036-3	2007	In the current study, we investigated the role of APN/CD13 in paclitaxel (PAC)-resistance of ovarian carcinoma (OVCA) cells.	Paclitaxel	74-77	alanyl (membrane) aminopeptidase	Mus musculus	50-53
17266036-11	2007	The present findings showed that APN/CD13 may be involved in decreased sensitivity to PAC in OVCA cells and that the mechanism of this effect involves its enzyme activity at least in part.	Paclitaxel	86-89	alanyl (membrane) aminopeptidase	Mus musculus	33-36
17266036-11	2007	The present findings showed that APN/CD13 may be involved in decreased sensitivity to PAC in OVCA cells and that the mechanism of this effect involves its enzyme activity at least in part.	Paclitaxel	86-89	alanyl (membrane) aminopeptidase	Mus musculus	37-41
17373720-7	2007	Potentiation by siRNA of taxol cytotoxicity was significantly greater in mutated-PTEN cells than in prostate cells expressing wild-type PTEN.	Paclitaxel	25-30	phosphatase and tensin homolog	Homo sapiens	81-85
17373720-7	2007	Potentiation by siRNA of taxol cytotoxicity was significantly greater in mutated-PTEN cells than in prostate cells expressing wild-type PTEN.	Paclitaxel	25-30	phosphatase and tensin homolog	Homo sapiens	136-140
17373720-8	2007	The apoptotic program induced by taxol was preferentially potentiated by Akt siRNA in PTEN-mutated cell lines as regards the DU-145 cell line.	Paclitaxel	33-38	phosphatase and tensin homolog	Homo sapiens	86-90
17373720-9	2007	CONCLUSIONS: Silencing Akt in PTEN-mutated prostate cancer cells enhances the antitumor effects of taxol.	Paclitaxel	99-104	phosphatase and tensin homolog	Homo sapiens	30-34
16930823-0	2007	Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells.	Paclitaxel	135-145	basigin (Ok blood group)	Homo sapiens	14-19
16930823-4	2007	The suppression of CD147 expression also sensitized cells to be more sensitive to paclitaxel.	Paclitaxel	82-92	basigin (Ok blood group)	Homo sapiens	19-24
17234259-0	2007	Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.	Paclitaxel	61-71	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	41-46
17234259-10	2007	CONCLUSIONS: This study demonstrates that weakened spindle checkpoint with reduced expression of BubR1, but not Mad2, is associated with acquired paclitaxel resistance in ovarian carcinoma cells.	Paclitaxel	146-156	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	97-102
17291686-3	2007	Here we investigated the effects of all-trans-retinoic acid (ATRA) and MIAs, i.e. colchicine, nocodazole and taxol on the regulation of retinoic acid receptor (RAR) genes in primary cultures of rat hepatocytes.	Paclitaxel	109-114	retinoic acid receptor alpha	Homo sapiens	160-163
17206490-10	2007	Exposure time-dependent antitumoral effects of paclitaxel treatments at 3-, 24-, and 96-h against the histocultured HCC PLC/PRF/5 xenograft tumors were also observed.	Paclitaxel	47-57	heparan sulfate proteoglycan 2	Homo sapiens	120-123
17158352-8	2007	Rapamycin and paclitaxel treated endothelial cells produced dose-dependent increases in PAI-1.	Paclitaxel	14-24	serpin family E member 1	Homo sapiens	88-93
16778834-0	2007	Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death.	Paclitaxel	112-122	BCL2 like 11	Homo sapiens	18-21
17195202-4	2007	METHODS: Thirty consecutive patients with LMS bifurcation stenosis +/- multivessel disease were treated with SCS technique using paclitaxel-eluting stents.	Paclitaxel	129-139	succinate-CoA ligase GDP/ADP-forming subunit alpha	Sus scrofa	109-112
17195202-15	2007	CONCLUSION: The SCS technique for treating LMS bifurcation disease with paclitaxel-eluting stents is safe and feasible.	Paclitaxel	72-82	succinate-CoA ligase GDP/ADP-forming subunit alpha	Sus scrofa	16-19
17113177-10	2007	Further, in vitro studies in human ovarian carcinoma cells also demonstrated a significant induction in the efflux activity of PGP with intermittent dosing schedules to PTX(CrEL) whereas this was not seen in cells dosed with PTX(film).	Paclitaxel	169-172	phosphoglycolate phosphatase	Homo sapiens	127-130
17113177-10	2007	Further, in vitro studies in human ovarian carcinoma cells also demonstrated a significant induction in the efflux activity of PGP with intermittent dosing schedules to PTX(CrEL) whereas this was not seen in cells dosed with PTX(film).	Paclitaxel	225-228	phosphoglycolate phosphatase	Homo sapiens	127-130
17234772-4	2007	The SNCG-BubR1 interaction inhibits mitotic checkpoint control upon spindle damage caused by anticancer drugs, such as nocodazole and taxol.	Paclitaxel	134-139	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	9-14
17255281-1	2007	PURPOSE: STA-4783 is a new compound that markedly enhances the therapeutic index of paclitaxel against human tumor xenograft models.	Paclitaxel	84-94	GCY	Homo sapiens	9-12
17255281-7	2007	In patients receiving 175 mg/m(2) paclitaxel, the incidence of severe toxicity increased with escalation of the STA-4783 dose above 263 mg/m(2), and 438 mg/m(2) was the maximum tolerated dose.	Paclitaxel	34-44	GCY	Homo sapiens	112-115
17255281-11	2007	The total body clearance of paclitaxel decreased significantly with escalation of the STA-4783 dose.	Paclitaxel	28-38	GCY	Homo sapiens	86-89
17255281-12	2007	CONCLUSIONS: The STA-4783/paclitaxel combination was well tolerated with a toxicity profile similar to single-agent paclitaxel.	Paclitaxel	26-36	GCY	Homo sapiens	17-20
17255281-13	2007	Enhanced systemic exposure to paclitaxel resulting from a dose-dependent interaction with STA-4783 was associated with increased toxicity.	Paclitaxel	30-40	GCY	Homo sapiens	90-93
17159505-3	2007	Using the SNU-719 gastric cancer cell line, which is naturally infected with Epstein-Barr virus, we found that the chemotherapeutic agents, such as 5-fluorouracil, cis-platinum and taxol, induced the expressions of BMRF1, BZLF1 and BRLF1 proteins that are usually found in the lytic form of the virus.	Paclitaxel	181-186	protein Zta	Human gammaherpesvirus 4	222-227
17069796-1	2007	Analysis of lung cancer response to chemotherapeutic agents showed the accumulation of a Taxol-induced protein that reacted with an anti-phospho-MEK1/2 antibody.	Paclitaxel	89-94	mitogen-activated protein kinase kinase 1	Homo sapiens	145-151
18334854-3	2007	In stage III, G3 serous carcinoma, increased RARalpha expression was an independent prognostic factor associated with lower chemoresponse to first-line chemotherapy (taxol and carboplatin) and shorter PFS (p &lt; 0.002).RARbeta and ERalpha expression did not correlate with RARalpha tumor characteristics or PFS and survival.	Paclitaxel	166-171	retinoic acid receptor alpha	Homo sapiens	45-53
17172428-7	2006	Interestingly, exposure of cells infected with an anti-stathmin adenovirus to Taxol or etoposide resulted in a complete loss of proliferation and clonogenicity, whereas exposure of the same cells to 5-FU or Adriamycin potentiated the growth-inhibitory effects of the anti-stathmin ribozyme, but the cells continued to proliferate.	Paclitaxel	78-83	stathmin 1	Homo sapiens	55-63
17172428-7	2006	Interestingly, exposure of cells infected with an anti-stathmin adenovirus to Taxol or etoposide resulted in a complete loss of proliferation and clonogenicity, whereas exposure of the same cells to 5-FU or Adriamycin potentiated the growth-inhibitory effects of the anti-stathmin ribozyme, but the cells continued to proliferate.	Paclitaxel	78-83	stathmin 1	Homo sapiens	272-280
17172428-9	2006	In contrast, cells infected with the anti-stathmin adenovirus showed a marked increase in apoptosis on exposure to Taxol or etoposide and a modest increase on exposure to 5-FU or Adriamycin.	Paclitaxel	115-120	stathmin 1	Homo sapiens	42-50
17172428-11	2006	Moreover, triple combination of anti-stathmin ribozyme with low noninhibitory concentrations of Taxol and etoposide resulted in a profound synergistic inhibition of proliferation, clonogenicity, and marked induction of apoptosis.	Paclitaxel	96-101	stathmin 1	Homo sapiens	37-45
16822511-0	2006	Taxol and tau overexpression induced calpain-dependent degradation of the microtubule-destabilizing protein SCG10.	Paclitaxel	0-5	stathmin 2	Rattus norvegicus	108-113
16822511-6	2006	In this report, we show that treatment of PC12 cells and neuroblastoma cells with the microtubule-stabilizing drug Taxol induced a rapid degradation of the SCG10 protein.	Paclitaxel	115-120	stathmin 2	Rattus norvegicus	156-161
16822511-9	2006	Collectively, these results indicate that tau overexpression and Taxol treatment induced a calpain-dependent degradation of the microtubule-destabilizing protein SCG10.	Paclitaxel	65-70	stathmin 2	Rattus norvegicus	162-167
17077358-13	2006	CONCLUSIONS: EA5 in combination with paclitaxel decreased tumor growth in an orthotopic ovarian cancer mouse model through antiangiogenic mechanisms associated with reduced levels of VEGF and phosphorylated Src.	Paclitaxel	37-47	Rous sarcoma oncogene	Mus musculus	207-210
17409984-0	2006	Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.	Paclitaxel	18-28	colony stimulating factor 3	Homo sapiens	62-67
17062689-2	2006	We found previously that human multidrug resistance protein 2 (MRP2; ABCC2) also transports paclitaxel in vitro, and although we expected that paclitaxel pharmacokinetics would be dominated by P-gp, the effect of Mrp2 was tested in vivo.	Paclitaxel	143-153	phosphoglycolate phosphatase	Homo sapiens	193-197
16783819-7	2006	All these effects of JAM-A absence are mitigated by the microtubule-stabilizing compound taxol.	Paclitaxel	89-94	F11 receptor	Mus musculus	21-26
16783819-9	2006	However, overexpression of JAM-A in the JAM-A-deficient cells increased integrin adhesiveness to the same levels as those observed in taxol-treated JAM-A-deficient cells.	Paclitaxel	134-139	F11 receptor	Mus musculus	27-32
16794185-0	2006	Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation.	Paclitaxel	0-10	coagulation factor III, tissue factor	Homo sapiens	49-62
16794185-3	2006	This study investigates the effect of paclitaxel on tissue factor (TF) expression in human endothelial cells.	Paclitaxel	38-48	coagulation factor III, tissue factor	Homo sapiens	52-65
16794185-3	2006	This study investigates the effect of paclitaxel on tissue factor (TF) expression in human endothelial cells.	Paclitaxel	38-48	coagulation factor III, tissue factor	Homo sapiens	67-69
16794185-7	2006	Real-time polymerase chain reaction revealed that paclitaxel increased thrombin-induced TF mRNA expression.	Paclitaxel	50-60	coagulation factor III, tissue factor	Homo sapiens	88-90
16794185-11	2006	Moreover, SP600125 blunted the effect of paclitaxel and docetaxel on thrombin-induced TF expression.	Paclitaxel	41-51	coagulation factor III, tissue factor	Homo sapiens	86-88
16794185-12	2006	Paclitaxel increases endothelial TF expression via its stabilizing effect on microtubules and selective activation of JNK.	Paclitaxel	0-10	coagulation factor III, tissue factor	Homo sapiens	33-35
16801540-6	2006	Hydrogen/deuterium exchange (HDX) coupled to liquid chromatography-electrospray ionization MS demonstrated a marked reduction in deuterium incorporation in both beta-and alpha-tubulin when Taxol was present.	Paclitaxel	189-194	tubulin alpha 1b	Homo sapiens	161-183
16925970-3	2006	The main goal of this study was to evaluate the effect of either cisplatin or paclitaxel, two common used chemotherapeutic agents for solid tumors, on enhancing Apo2L/TRAIL cytotoxicity in a panel-cultured thoracic cancer cells and to examine the role of the mitochondria-dependent caspase activation cascade in mediating apoptosis of combination-treated cells.	Paclitaxel	78-88	caspase 6	Homo sapiens	282-289
16740767-3	2006	We hypothesized that inhibiting the phosphorylation of EGFR and VEGFR by treatment with NVP-AEE788 (AEE788), a novel dual specific EGFR and VEGFR inhibitor, either alone or in combination with paclitaxel, would inhibit the growth of FTC xenografts in an orthotopic nude mouse model.	Paclitaxel	193-203	epidermal growth factor receptor	Mus musculus	55-59
16740767-3	2006	We hypothesized that inhibiting the phosphorylation of EGFR and VEGFR by treatment with NVP-AEE788 (AEE788), a novel dual specific EGFR and VEGFR inhibitor, either alone or in combination with paclitaxel, would inhibit the growth of FTC xenografts in an orthotopic nude mouse model.	Paclitaxel	193-203	epidermal growth factor receptor	Mus musculus	65-69
16518797-8	2006	In these cells, the distribution of the Jupiter:GFP fusion protein reproduces microtubule behavior upon treatment by the drugs colchicine and taxol.	Paclitaxel	142-147	jupiter	Drosophila melanogaster	40-47
16731752-0	2006	Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.	Paclitaxel	16-26	heat shock protein 90 alpha family class A member 1	Homo sapiens	43-48
16618750-4	2006	Cells that endured treatment with taxol showed reduced expression of Smac and released minimal amounts of this protein from the mitochondria.	Paclitaxel	34-39	diablo IAP-binding mitochondrial protein	Homo sapiens	69-73
16618750-5	2006	Down-regulation of c-IAP1 and survivin increased the cytotoxicity of cisplatin and doxorubicin, whereas overexpression of Smac improved the efficacy of taxol.	Paclitaxel	152-157	diablo IAP-binding mitochondrial protein	Homo sapiens	122-126
16528475-8	2006	While RA/paclitaxel-treated MCF-7 (pcDNA3) cultures contained condensed apoptotic nuclei, MCF-7(survivin-S) nuclei were morphologically distinct with hypercondensed disorganized chromatin and released mitochondrial AIF-1.	Paclitaxel	9-19	allograft inflammatory factor 1	Homo sapiens	215-220
16528475-9	2006	RA also reduced paclitaxel-associated levels of cyclin B1 expression consistent with mitotic exit.	Paclitaxel	16-26	cyclin B1	Homo sapiens	48-57
16551860-1	2006	PURPOSE: BMS-275183 is an orally administered C-4 methyl carbonate analogue of paclitaxel.	Paclitaxel	79-89	complement C4A (Rodgers blood group)	Homo sapiens	46-49
16520664-14	2006	Thus, in metastatic breast cancer patients pre-treated with anthracyclines, the weekly administration of paclitaxel, 5-FU and folinic acid with G-CSF support seems to be extremely tolerable and active.	Paclitaxel	105-115	colony stimulating factor 3	Homo sapiens	144-149
16505109-8	2006	Activation of erythropoietin-mediated signaling in R3230 cells was associated with dose-dependent inhibition of apoptosis in response to Taxol treatment and serum starvation, an effect that was blocked by the addition of a phosphatidylinositol-3-kinase inhibitor.	Paclitaxel	137-142	erythropoietin	Rattus norvegicus	14-28
16914900-6	2006	In vitro incubation of human erythrocytes with 10 microM paclitaxel again significantly increased annexin-V-binding (by 129%) and augmented the increase of annexin-V-binding following cellular stress.	Paclitaxel	57-67	annexin A5	Homo sapiens	98-107
16914900-6	2006	In vitro incubation of human erythrocytes with 10 microM paclitaxel again significantly increased annexin-V-binding (by 129%) and augmented the increase of annexin-V-binding following cellular stress.	Paclitaxel	57-67	annexin A5	Homo sapiens	156-165
16361064-0	2006	Altered discharges of spinal wide dynamic range neurons and down-regulation of glutamate transporter expression in rats with paclitaxel-induced hyperalgesia.	Paclitaxel	125-135	solute carrier family 1 member 3	Rattus norvegicus	79-100
17119350-2	2006	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	Paclitaxel	378-388	Fas associated via death domain	Homo sapiens	56-102
17119350-2	2006	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	Paclitaxel	378-388	Fas associated via death domain	Homo sapiens	104-108
17119350-2	2006	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	Paclitaxel	378-388	Fas associated via death domain	Homo sapiens	319-323
16267627-7	2005	At this moment, potential clinically relevant application of CYP450 pharmacogenetics for anticancer therapy may be found for CYP1A2 and flutamide, CYP2A6 and tegafur, CYP2B6 and cyclophosphamide, CYP2C8 and paclitaxel, CYP2D6 and tamoxifen, and CYP3A5.	Paclitaxel	207-217	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	125-131
16093365-2	2005	Paclitaxel has been proposed to selectively interact with a binding site on P-gp that is distinct from the vinblastine and digoxin-binding site.	Paclitaxel	0-10	PGP	Canis lupus familiaris	76-80
15948138-9	2005	AEE788 treatment alone or in combination with paclitaxel inhibited the phosphorylation of EGF-R and VEGF-R on tumor cells and tumor-associated endothelial cells.	Paclitaxel	46-56	epidermal growth factor receptor	Mus musculus	90-95
16138009-0	2005	Low concentrations of taxol cause mitotic delay followed by premature dissociation of p55CDC from Mad2 and BubR1 and abrogation of the spindle checkpoint, leading to aneuploidy.	Paclitaxel	22-27	mitotic arrest deficient 2 like 1	Homo sapiens	98-102
16138009-0	2005	Low concentrations of taxol cause mitotic delay followed by premature dissociation of p55CDC from Mad2 and BubR1 and abrogation of the spindle checkpoint, leading to aneuploidy.	Paclitaxel	22-27	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	107-112
16138009-6	2005	Low concentrations of Taxol dissociated p55CDC-Mad2 or p55CDC-BubR1 complexes after mitosis, whereas high concentrations of Taxol sustained the protein complex formation leading to mitotic block.	Paclitaxel	22-27	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	62-67
15975716-2	2005	Immunohistochemical studies show that the expression of both GLAST and GLT-1 in the L4-L5 spinal dorsal horn is decreased by 24% (P&lt;0.001) and 23% (P&lt;0.001), respectively, in rats with taxol-induced hyperalgesia as compared with those in control rats.	Paclitaxel	191-196	solute carrier family 1 member 3	Rattus norvegicus	61-66
15975716-3	2005	These changes were further confirmed using an enzyme-linked immunosorbent assay that confirmed downregulation of GLAST by 36% (P&lt;0.05) and GLT-1 by 18% (P&lt;0.05) in the L4-L5 spinal cord of taxol-treated rats.	Paclitaxel	195-200	solute carrier family 1 member 3	Rattus norvegicus	113-118
15800935-5	2005	MLL xenografts were treated with vehicle, atrasentan, paclitaxel, and paclitaxel+atrasentan.	Paclitaxel	70-80	lysine methyltransferase 2A	Homo sapiens	0-3
16101130-4	2005	R115777 +/- paclitaxel inhibited HDJ-2 farnesylation, up-regulated RhoB, transiently lowered (P)ERK/ERK and (P)Akt/Akt, reduced Raf-1 and MEK and inhibited secretion of VEGF and MMP-1.	Paclitaxel	12-22	matrix metallopeptidase 1	Homo sapiens	178-183
15856231-8	2005	The effect of paclitaxel treatment on hepatic expression of PGP and P450 isoforms (CYP2C and CYP3A) was determined to elucidate the mechanism by which paclitaxel disposition is altered by previous drug exposure.	Paclitaxel	14-24	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	83-88
15856231-8	2005	The effect of paclitaxel treatment on hepatic expression of PGP and P450 isoforms (CYP2C and CYP3A) was determined to elucidate the mechanism by which paclitaxel disposition is altered by previous drug exposure.	Paclitaxel	151-161	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	83-88
15856231-11	2005	Activity and protein levels for CYP2C in liver were elevated at 24 and 96 h after paclitaxel dosing.	Paclitaxel	82-92	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	32-37
15856231-12	2005	Cremophor EL, a carrier solvent for paclitaxel, also caused elevated CYP2C activity.	Paclitaxel	36-46	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	69-74
15812674-2	2005	In the study reported here, we investigated HERG expression in various cancer cell lines, its correlation with chemosensitivity to vincristine, paclitaxel, and hydroxy-camptothecin, and its biochemical modulation.	Paclitaxel	144-154	potassium voltage-gated channel subfamily H member 2	Homo sapiens	44-48
15812674-7	2005	RESULTS: HERG expression levels differed widely between various human cancer cell lines and HT-29 cells expressing high levels of HERG were more sensitive than A549 cells expressing low levels of HERG to vincristine, paclitaxel, and hydroxy-camptothecin.	Paclitaxel	217-227	potassium voltage-gated channel subfamily H member 2	Homo sapiens	9-13
15812674-8	2005	In terms of IC50, the chemosensitivities of herg-transfected A549 cells to vincristine, paclitaxel and hydroxy-camptothecin were significantly increased.	Paclitaxel	88-98	potassium voltage-gated channel subfamily H member 2	Homo sapiens	44-48
15812674-13	2005	There were synergistic effects between erythromycin and vincristine, paclitaxel, and hydroxy-camptothecin, and chemosensitivity was correlated with HERG expression level.	Paclitaxel	69-79	potassium voltage-gated channel subfamily H member 2	Homo sapiens	148-152
15812674-14	2005	CONCLUSIONS: HERG expression levels and chemosensitivity were positively correlated for vincristine, paclitaxel, and hydroxy-camptothecin.	Paclitaxel	101-111	potassium voltage-gated channel subfamily H member 2	Homo sapiens	13-17
16061679-9	2005	In contrast, these concentrations of gefitinib caused a dose-dependent reversal of resistance to paclitaxel in CL1/Pac cells, to doxorubicin in MCF7/ADR cells, and to topotecan in CL1/Tpt and MCF7/TPT cells.	Paclitaxel	97-107	adhesion G protein-coupled receptor L1	Homo sapiens	111-114
15897904-7	2005	Taken together, our data suggest that PTX-increases the functional level of eIF-4E by promoting the hyperphosphorylation and release of 4E-BP1 through a cdk1-dependent mechanism.	Paclitaxel	38-41	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	136-142
15897904-7	2005	Taken together, our data suggest that PTX-increases the functional level of eIF-4E by promoting the hyperphosphorylation and release of 4E-BP1 through a cdk1-dependent mechanism.	Paclitaxel	38-41	cyclin dependent kinase 1	Homo sapiens	153-157
15863265-6	2005	Although CD95 up-regulation was observed in renal cell carcinoma with wild-type p53 upon paclitaxel treatment, paclitaxel-induced apoptosis itself is triggered independently from the CD95 system.	Paclitaxel	89-99	Fas cell surface death receptor	Homo sapiens	9-13
16158930-3	2005	In this study, we characterized one of these compounds, termed tetrandrine, and evaluated its reversal activity on P-gp-mediated drug resistance to paclitaxel in vitro and in vivo.	Paclitaxel	148-158	phosphoglycolate phosphatase	Homo sapiens	115-119
16158930-4	2005	MATERIALS AND METHODS: Using the human MDR tumor cell line KBv200 and its drug sensitive parental cell line, the reversal activity of tetrandrine on P-gp-mediated resistance to paclitaxel and docetaxel were determined by MTT and other in vitro drug evaluation assays.	Paclitaxel	177-187	phosphoglycolate phosphatase	Homo sapiens	149-153
15746578-9	2005	Chelerythrine showed additive effects with mitoxantrone in both cell lines and with paclitaxel in PC3 cells.	Paclitaxel	84-94	chromobox 8	Homo sapiens	98-101
15711598-0	2005	Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim.	Paclitaxel	57-67	BCL2 like 11	Homo sapiens	121-124
15711598-2	2005	Susceptibility to killing by paclitaxel correlated with expression of the BH3-only protein, Bim, but not with other members of Bcl-2 family.	Paclitaxel	29-39	BCL2 like 11	Homo sapiens	92-95
15711598-3	2005	NSCLC cell lines with the highest level of Bim expression are most susceptible to apoptosis induction after paclitaxel treatment.	Paclitaxel	108-118	BCL2 like 11	Homo sapiens	43-46
15711598-4	2005	Forced expression of Bim increased paclitaxel-mediated killing of cells expressing an undetectable level of Bim.	Paclitaxel	35-45	BCL2 like 11	Homo sapiens	21-24
15711598-4	2005	Forced expression of Bim increased paclitaxel-mediated killing of cells expressing an undetectable level of Bim.	Paclitaxel	35-45	BCL2 like 11	Homo sapiens	108-111
15711598-5	2005	Conversely, knock down of Bim, but not Bcl-2 expression, decreased the susceptibility of tumor cells to paclitaxel-mediated killing.	Paclitaxel	104-114	BCL2 like 11	Homo sapiens	26-29
15711598-8	2005	These results established Bim as a critical molecular link between the microtubule poison, paclitaxel, and apoptosis.	Paclitaxel	91-101	BCL2 like 11	Homo sapiens	26-29
15897162-2	2005	CASE REPORT: We describe here a 40-year-old female patient with metastatic breast cancer who developed a photosensitive rash 1 month after initiation of paclitaxel and trastuzumab therapy.	Paclitaxel	153-163	HRas proto-oncogene, GTPase	Homo sapiens	120-126
15700118-11	2005	Finally, paclitaxel- or HER-2-mediated alterations in the phosphorylation of MAP kinases p42/44, Stress-activated protein kinase/Jun-terminal kinase (SAPK/JNK), and p38, and effects on the activation of caspase-3, caspase-7, and bcl-2 are discussed.	Paclitaxel	9-19	caspase 7	Homo sapiens	214-223
15592521-11	2005	Moreover, antisense downregulation of CYR61 expression abolished the anchorage-independent growth of breast cancer cells engineered to overexpress HRG, and significantly increased their sensitivity to Taxol.	Paclitaxel	201-206	cellular communication network factor 1	Homo sapiens	38-43
15592521-12	2005	Our data provide evidence that CYR61 is sufficient to promote breast cancer cell proliferation, cell survival, and Taxol resistance through a alphavbeta3-activated ERK1/ERK2 MAPK signaling.	Paclitaxel	115-120	cellular communication network factor 1	Homo sapiens	31-36
15378273-0	2005	Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.	Paclitaxel	44-54	interleukin 2	Mus musculus	100-113
15378273-3	2005	In the work described here, the effects of interleukin-2 pretreatment on pharmacokinetics and toxicity of paclitaxel orally administered were investigated.	Paclitaxel	106-116	interleukin 2	Mus musculus	43-56
15378273-15	2005	rIL2 thus increased paclitaxel absorption for the 15 min following oral intake of the drug but did not enhance the overall exposure.	Paclitaxel	20-30	interleukin 2	Rattus norvegicus	0-4
15378273-16	2005	CONCLUSION: We found that a 3-day pretreatment with rIL2 had some in vivo inhibitory effects on P-gp activity for a short period after oral dosing of paclitaxel.	Paclitaxel	150-160	interleukin 2	Rattus norvegicus	52-56
15378273-17	2005	Those results encourage further investigation of the effect of rIL2 on the overall exposure of paclitaxel.	Paclitaxel	95-105	interleukin 2	Rattus norvegicus	63-67
15662138-0	2005	The tumor suppressor p33ING1b enhances taxol-induced apoptosis by p53-dependent pathway in human osteosarcoma U2OS cells.	Paclitaxel	39-44	inhibitor of growth family member 1	Homo sapiens	21-29
15662138-4	2005	The results showed that p33ING1b markedly increased taxol-induced growth inhibition and apoptosis in p53+/+ U2OS cells, but not in p53-mutant MG63 cells.	Paclitaxel	52-57	inhibitor of growth family member 1	Homo sapiens	24-32
15662138-5	2005	Moreover, ectopic expression of p33ING1b could obviously upregulate p53, p21WAF1 and bax protein levels and activate caspase-3 in taxol-treated U2OS cells.	Paclitaxel	130-135	inhibitor of growth family member 1	Homo sapiens	32-40
15711122-0	2005	An intact ING1-P53 pathway can potentiate the cytotoxic effects of taxol.	Paclitaxel	67-72	inhibitor of growth family member 1	Homo sapiens	10-14
15567316-0	2005	Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation.	Paclitaxel	77-87	leptin	Homo sapiens	89-92
15567316-5	2005	We have developed a well characterized novel lyophilized liposome-based paclitaxel (LEP-ETU) formulation that is sterile, stable and easy-to-use.	Paclitaxel	72-82	leptin	Homo sapiens	84-87
15564376-5	2004	Treatment of cells with taxol, a drug that suppresses MT dynamics, rapidly induced detachment of tau from MTs.	Paclitaxel	24-29	microtubule associated protein tau L homeolog	Xenopus laevis	97-100
15368466-2	2004	The tumor suppressor p53 is one important molecular mechanism of chemotherapy resistance that in some studies predicted tumor sensitivity to paclitaxel.	Paclitaxel	141-151	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	21-24
15386340-10	2004	Taxol and oxaliplatin significantly increased the levels of expression of COX-2, PGES, GST-mu, and GST-pi in a number of different experimental protocols.	Paclitaxel	0-5	prostaglandin E synthase	Mus musculus	81-85
15556294-0	2004	MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines.	Paclitaxel	87-92	transmembrane protein 243	Homo sapiens	0-7
15358225-3	2004	Furthermore, paclitaxel rapidly activated the JNK, ERK, and p38 mitogen-activated protein kinase pathways.	Paclitaxel	13-23	mitogen-activated protein kinase 8	Rattus norvegicus	46-49
15358225-4	2004	A specific inhibitor of JNK, SP600125, abolished paclitaxel-induced HO-1 mRNA expression, whereas PD98059, a specific inhibitor of ERK, and SB203580, a specific inhibitor of p38, had no significant effect.	Paclitaxel	49-59	mitogen-activated protein kinase 8	Rattus norvegicus	24-27
15358225-6	2004	These results demonstrated that paclitaxel induces the expression of HO-1 via the JNK pathway in VSMC and that HO-1 expression might be responsible for the anti-proliferative effect of paclitaxel on VSMC.	Paclitaxel	32-42	mitogen-activated protein kinase 8	Rattus norvegicus	82-85
15358225-6	2004	These results demonstrated that paclitaxel induces the expression of HO-1 via the JNK pathway in VSMC and that HO-1 expression might be responsible for the anti-proliferative effect of paclitaxel on VSMC.	Paclitaxel	185-195	mitogen-activated protein kinase 8	Rattus norvegicus	82-85
15269161-3	2004	EXPERIMENTAL DESIGN: Paclitaxel and gamma-radiation were administered in three different sequences designated as pre-radiated, co-radiated, and post-radiated to BCap37 (human breast cancer cell line) and KB (human epidermoid carcinoma cell line) cells.	Paclitaxel	21-31	prohibitin 2	Homo sapiens	161-167
15269161-9	2004	In addition, biochemical examinations revealed that gamma-radiation inhibited paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation and increased the protein levels of cyclin B1 and inhibitory phosphorylation of p34(cdc2).	Paclitaxel	78-88	cyclin dependent kinase 1	Homo sapiens	232-236
15347472-5	2004	RESULTS: In sirolimus and sirolimus + paclitaxel groups protein expression of HIF-1alpha was inhibited.	Paclitaxel	38-48	hypoxia inducible factor 1, alpha subunit	Mus musculus	78-88
15197811-8	2004	In minimally pretreated patients, G-CSF allowed paclitaxel dose escalation to 110 mg/m(2).	Paclitaxel	48-58	colony stimulating factor 3	Homo sapiens	34-39
15366642-6	2004	CONCLUSION: This study demonstrates that a less intensive combination of paclitaxel/carboplatin is active and well tolerated in advanced NSCLC patients who are older than 60 years including those with a poor PS 3-4.	Paclitaxel	73-83	pregnancy specific beta-1-glycoprotein 9	Homo sapiens	208-214
15210851-6	2004	Sensitivity to paclitaxel correlated with decreased BubR1 protein expression in human cancer cell lines, including those derived from breast and ovarian cancers.	Paclitaxel	15-25	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	52-57
15210851-7	2004	Silencing of BubR1 via RNA interference inactivated the mitotic checkpoint in drug-resistant cells, and reversed resistance to paclitaxel and nocodazole.	Paclitaxel	127-137	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	13-18
15181605-8	2004	In patients with breast cancer, the key Cancer and Leukemia Group B 9741 trial showed that dose-dense doxorubicin, cyclophosphamide, and paclitaxel chemotherapy with granulocyte colony-stimulating factor (G-CSF), repeated every 2 weeks, is superior to the same regimen administered at standard 3-weekly intervals.	Paclitaxel	137-147	colony stimulating factor 3	Homo sapiens	166-203
15181605-8	2004	In patients with breast cancer, the key Cancer and Leukemia Group B 9741 trial showed that dose-dense doxorubicin, cyclophosphamide, and paclitaxel chemotherapy with granulocyte colony-stimulating factor (G-CSF), repeated every 2 weeks, is superior to the same regimen administered at standard 3-weekly intervals.	Paclitaxel	137-147	colony stimulating factor 3	Homo sapiens	205-210
15141302-5	2004	The observed effect of taxol was mediated through induction of iNOS transcription factors NF-kappaB and IRF-1, and required the activation of p38 MAP kinase and JNK.	Paclitaxel	23-28	mitogen-activated protein kinase 8	Rattus norvegicus	161-164
15063149-5	2004	To explore the mechanism of this effect, we employed flow cytometry to determine levels of p53, p21, bcl-2 and caspase proteins in the taxol-resistant cells, and found that the expression of the bcl-2 protein was markedly decreased and the expression of the caspase protein markedly increased after treatment with taxol in the presence of PMA.	Paclitaxel	135-140	transformation related protein 53, pseudogene	Mus musculus	91-94
15059905-3	2004	Suppression of Mad2 and BubR1 in paclitaxel-treated cancer cells abolished checkpoint function, resulting in paclitaxel resistance that correlated with suppression of cyclin-dependent kinase-1 activity.	Paclitaxel	33-43	mitotic arrest deficient 2 like 1	Homo sapiens	15-19
15059905-3	2004	Suppression of Mad2 and BubR1 in paclitaxel-treated cancer cells abolished checkpoint function, resulting in paclitaxel resistance that correlated with suppression of cyclin-dependent kinase-1 activity.	Paclitaxel	33-43	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	24-29
15059905-3	2004	Suppression of Mad2 and BubR1 in paclitaxel-treated cancer cells abolished checkpoint function, resulting in paclitaxel resistance that correlated with suppression of cyclin-dependent kinase-1 activity.	Paclitaxel	33-43	cyclin dependent kinase 1	Homo sapiens	167-192
15059905-3	2004	Suppression of Mad2 and BubR1 in paclitaxel-treated cancer cells abolished checkpoint function, resulting in paclitaxel resistance that correlated with suppression of cyclin-dependent kinase-1 activity.	Paclitaxel	109-119	mitotic arrest deficient 2 like 1	Homo sapiens	15-19
15059905-3	2004	Suppression of Mad2 and BubR1 in paclitaxel-treated cancer cells abolished checkpoint function, resulting in paclitaxel resistance that correlated with suppression of cyclin-dependent kinase-1 activity.	Paclitaxel	109-119	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	24-29
15059905-4	2004	In contrast, overexpression of Mad2 in cells with a checkpoint defect attributable to low Mad2 expression restored checkpoint function, resulting in enhanced paclitaxel sensitivity that correlated with enhanced cyclin-dependent kinase-1 activity.	Paclitaxel	158-168	mitotic arrest deficient 2 like 1	Homo sapiens	31-35
15059905-4	2004	In contrast, overexpression of Mad2 in cells with a checkpoint defect attributable to low Mad2 expression restored checkpoint function, resulting in enhanced paclitaxel sensitivity that correlated with enhanced cyclin-dependent kinase-1 activity.	Paclitaxel	158-168	mitotic arrest deficient 2 like 1	Homo sapiens	90-94
15059905-4	2004	In contrast, overexpression of Mad2 in cells with a checkpoint defect attributable to low Mad2 expression restored checkpoint function, resulting in enhanced paclitaxel sensitivity that correlated with enhanced cyclin-dependent kinase-1 activity.	Paclitaxel	158-168	cyclin dependent kinase 1	Homo sapiens	211-236
14975768-3	2004	The growth inhibitory effect induced by paclitaxel correlated with levels of intracellular p21 and resulted in cell cycle arrest at the G2/M phase.	Paclitaxel	40-50	H3 histone pseudogene 16	Homo sapiens	91-94
14726646-7	2004	In contrast, paclitaxel-induced apoptosis MM depolarization, cytochrome C release and activation of caspase 9 were all blocked by Bcl-2.	Paclitaxel	13-23	caspase 9	Homo sapiens	100-109
14871965-7	2004	Immunohistochemical analyses revealed that PDGF-R activation was blocked by STI571 administered alone or in combination with paclitaxel.	Paclitaxel	125-135	platelet derived growth factor receptor, beta polypeptide	Mus musculus	43-49
14985451-7	2004	The modulation of two representative genes, CDKN1A and TOP2A, was validated by Northern analyses on a panel of seven ovarian carcinoma xenograft models undergoing treatment with paclitaxel.	Paclitaxel	178-188	DNA topoisomerase II alpha	Homo sapiens	55-60
14500571-0	2004	Estrogen inhibits paclitaxel-induced apoptosis via the phosphorylation of apoptosis signal-regulating kinase 1 in human ovarian cancer cell lines.	Paclitaxel	18-28	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	74-110
15138361-0	2004	Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas ligand expression and induces apoptosis which can be inhibited through the CD40 receptor.	Paclitaxel	0-10	Fas ligand	Homo sapiens	63-73
15138361-7	2004	RESULTS AND CONCLUSION: While the cytotoxic effect of mitoxantrone did not correlate with Fas expression, the results presented here suggest some involvement of the Fas/Fas-L system in paclitaxel-induced apoptosis.	Paclitaxel	185-195	Fas ligand	Homo sapiens	169-174
14527951-0	2003	FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines.	Paclitaxel	63-73	BCL2 like 11	Homo sapiens	37-40
14527951-3	2003	Western blotting revealed that in a panel of nine breast cancer cell lines expression of FoxO1a and FoxO3a correlated with the expression of the pro-apoptotic FoxO target Bim, which was associated with paclitaxel-induced apoptosis.	Paclitaxel	202-212	BCL2 like 11	Homo sapiens	171-174
14527951-4	2003	In MCF-7 cells, which were paclitaxel-sensitive, the already high basal levels of FoxO3a and Bim protein increased dramatically after drug treatment, as did Bim mRNA, which correlated with apoptosis induction.	Paclitaxel	27-37	BCL2 like 11	Homo sapiens	93-96
14527951-4	2003	In MCF-7 cells, which were paclitaxel-sensitive, the already high basal levels of FoxO3a and Bim protein increased dramatically after drug treatment, as did Bim mRNA, which correlated with apoptosis induction.	Paclitaxel	27-37	BCL2 like 11	Homo sapiens	157-160
14527951-7	2003	Gene silencing experiments showed that small interference RNA (siRNA) specific for FoxO3a reduced the levels of FoxO3a and Bim protein as well as inhibited apoptosis in paclitaxel-treated MCF-7 cells.	Paclitaxel	169-179	BCL2 like 11	Homo sapiens	123-126
14527951-8	2003	Furthermore, siRNA specific for Bim reduced the levels of Bim protein and inhibited apoptosis in paclitaxel-treated MCF-7 cells.	Paclitaxel	97-107	BCL2 like 11	Homo sapiens	32-35
14527951-9	2003	This is the first demonstration that up-regulation of FoxO3a by paclitaxel can result in increased levels of Bim mRNA and protein, which can be a direct cause of apoptosis in breast cancer cells.	Paclitaxel	64-74	BCL2 like 11	Homo sapiens	109-112
14751837-6	2003	The antisense oligonucleotides also potentiated the effects of p53 activation and p21 induction by chemotherapeutic agents 10-hydroxycamptothecin, adriamycin, 5-fluorouracil, and paclitaxel.	Paclitaxel	179-189	H3 histone pseudogene 16	Homo sapiens	82-85
14609744-3	2003	The order of permeability rate of Taxol across the four cell lines was SKNDZ&gt;LNCaP&gt;PC-3&gt;CHP212.	Paclitaxel	34-39	chromobox 8	Homo sapiens	89-93
14609744-4	2003	Pretreatment of the cell lines with CapNO (100 microM) enhanced permeability of Taxol across prostate PC-3 and LNCaP cells, but not neuroblastoma SKNDZ and CHP212 cells.	Paclitaxel	80-85	chromobox 8	Homo sapiens	102-106
14609744-5	2003	Taxol inhibited cell growth at nanomolar levels with IC(50)s of 0.21, 17.4, 96.4 and 842.9 nM corresponding to SKNDZ, PC-3, LNCaP and CHP212 cells, respectively.	Paclitaxel	0-5	chromobox 8	Homo sapiens	118-122
14609744-7	2003	Enhancing effect of CapNO (100 microM) on Taxol cytotoxicity were found in PC-3 and LNCaP cells, but not in SKNDZ and CHP212.	Paclitaxel	42-47	chromobox 8	Homo sapiens	75-79
14579288-4	2003	NF-kappaB activation in Ba/F3 cells expressing murine Toll-like receptor (TLR) 4 and MD-2 was inhibited by Tm-Gp in a CD14/LPS-binding protein (LBP)-dependent manner when stimulated with LPS or its active center lipid A but not when stimulated with Taxol.	Paclitaxel	249-254	lymphocyte antigen 96	Mus musculus	85-89
14508823-0	2003	Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.	Paclitaxel	25-35	erb-b2 receptor tyrosine kinase 2	Mus musculus	62-68
14508823-12	2003	In vitro, the ErbB-2-overexpressing cells treated with combined trastuzumab plus paclitaxel secreted less VEGF than the cells treated with trastuzumab, paclitaxel, or control (185.9 pg/mL vs. 233.2 pg/mL, 261.3 pg/mL, and 286.4 pg/mL, respectively).	Paclitaxel	81-91	erb-b2 receptor tyrosine kinase 2	Mus musculus	14-20
14508823-12	2003	In vitro, the ErbB-2-overexpressing cells treated with combined trastuzumab plus paclitaxel secreted less VEGF than the cells treated with trastuzumab, paclitaxel, or control (185.9 pg/mL vs. 233.2 pg/mL, 261.3 pg/mL, and 286.4 pg/mL, respectively).	Paclitaxel	152-162	erb-b2 receptor tyrosine kinase 2	Mus musculus	14-20
14508823-15	2003	CONCLUSIONS: Combined trastuzumab plus paclitaxel treatment more effectively inhibited ErbB-2-mediated angiogenesis than either treatment alone, which resulted in more pronounced tumoricidal effects.	Paclitaxel	39-49	erb-b2 receptor tyrosine kinase 2	Mus musculus	87-93
12848775-8	2003	CONCLUSIONS: This analysis provides a model which accurately characterized the increase in paclitaxel exposure, which is most likely to be due to P-gp inhibition in the bile canaliculi, in the presence of zosuquidar 3HCl (Cmax &gt; 350 microg x l(-1)) and is predictive of paclitaxel pharmacokinetics following a 3 h infusion.	Paclitaxel	273-283	phosphoglycolate phosphatase	Homo sapiens	146-150
12743738-8	2003	The MTD of paclitaxel proved to be 160 mg/m(2), and the DLT was neutropenia, which improved well following treatment with G-CSF.	Paclitaxel	11-21	colony stimulating factor 3	Homo sapiens	122-127
12660240-0	2003	Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis.	Paclitaxel	116-121	diablo IAP-binding mitochondrial protein	Homo sapiens	40-44
12660240-0	2003	Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis.	Paclitaxel	116-121	diablo IAP-binding mitochondrial protein	Homo sapiens	45-51
12660240-9	2003	In conclusion, our results provide the first evidence that the interaction between Smac/DIABLO and Survivin is an essential step underling the inhibition of apoptosis induced by Taxol.	Paclitaxel	178-183	diablo IAP-binding mitochondrial protein	Homo sapiens	83-87
12660240-9	2003	In conclusion, our results provide the first evidence that the interaction between Smac/DIABLO and Survivin is an essential step underling the inhibition of apoptosis induced by Taxol.	Paclitaxel	178-183	diablo IAP-binding mitochondrial protein	Homo sapiens	88-94
12749848-6	2003	Ad CMV-Smac can combine with other proapoptotic factors, such as cisplatin, paclitaxel, and procaspase-3, to produce greater levels of apoptosis in transfected cells.	Paclitaxel	76-86	diablo IAP-binding mitochondrial protein	Homo sapiens	7-11
12782601-12	2003	Treatment with PKI 166 also decreased the expression of phosphorylated EGF-R by tumor cells and tumor-associated endothelial cells, and this was even more pronounced with PKI 166 plus Taxol treatment.	Paclitaxel	184-189	epidermal growth factor receptor	Mus musculus	71-76
12644539-14	2003	Mice treated with STI571 or STI571 plus paclitaxel had less phosphorylated PDGF-R on tumor cells and tumor-associated endothelial cells, less tumor cell proliferation, statistically significantly more apoptotic tumor cells (all P&lt;.001), and fewer tumor-associated endothelial cells (P&lt;.001) than control mice.	Paclitaxel	40-50	platelet derived growth factor receptor, beta polypeptide	Mus musculus	75-81
12700634-4	2003	IGF1 also suppressed apoptosis induced by taxol and brefeldin A.	Paclitaxel	42-47	insulin-like growth factor 1	Rattus norvegicus	0-4
12518324-7	2003	The antisense oligonucleotide also potentiated the effects of p53 activation and p21 induction by chemotherapeutic agents 10-hydroxycamptothecin, adriamycin, 5-fluorouracil, and paclitaxel.	Paclitaxel	178-188	H3 histone pseudogene 16	Homo sapiens	81-84
12555073-10	2003	The inhibitory effect of JNK appears to be mediated by serine phosphorylation of IRS-1 (insulin receptor substrate) since both Taxol and IGF-I treatment enhanced Ser(312) IRS-1 phosphorylation, while LY294002 blocked IGF-I-mediated phosphorylation.	Paclitaxel	127-132	insulin receptor substrate 1	Homo sapiens	81-86
12555073-10	2003	The inhibitory effect of JNK appears to be mediated by serine phosphorylation of IRS-1 (insulin receptor substrate) since both Taxol and IGF-I treatment enhanced Ser(312) IRS-1 phosphorylation, while LY294002 blocked IGF-I-mediated phosphorylation.	Paclitaxel	127-132	insulin receptor substrate 1	Homo sapiens	171-176
12527362-0	2003	Bcl-rambo beta, a special splicing variant with an insertion of an Alu-like cassette, promotes etoposide- and Taxol-induced cell death.	Paclitaxel	110-115	BCL2 like 13	Homo sapiens	0-9
12510150-8	2003	Inhibition of MEK1 mediated phosphorylation has been shown to enhance paclitaxel (Taxol) induced apoptosis in breast, ovarian, and lung tumor cell lines in-vitro.	Paclitaxel	70-80	mitogen-activated protein kinase kinase 1	Homo sapiens	14-18
12510150-8	2003	Inhibition of MEK1 mediated phosphorylation has been shown to enhance paclitaxel (Taxol) induced apoptosis in breast, ovarian, and lung tumor cell lines in-vitro.	Paclitaxel	82-87	mitogen-activated protein kinase kinase 1	Homo sapiens	14-18
12510150-9	2003	Since CAS is also phosphorylated (activated) by MEK1, and since the anti-cancer drug Taxol alters the microtubule assembly and activates pro-apoptotic signaling pathways, altering the activity/phosphorylation status of CAS via MEK1 inhibition may present a potential strategy in experimental cancer therapy.	Paclitaxel	85-90	chromosome segregation 1 like	Homo sapiens	6-9
12510150-9	2003	Since CAS is also phosphorylated (activated) by MEK1, and since the anti-cancer drug Taxol alters the microtubule assembly and activates pro-apoptotic signaling pathways, altering the activity/phosphorylation status of CAS via MEK1 inhibition may present a potential strategy in experimental cancer therapy.	Paclitaxel	85-90	chromosome segregation 1 like	Homo sapiens	219-222
12510150-9	2003	Since CAS is also phosphorylated (activated) by MEK1, and since the anti-cancer drug Taxol alters the microtubule assembly and activates pro-apoptotic signaling pathways, altering the activity/phosphorylation status of CAS via MEK1 inhibition may present a potential strategy in experimental cancer therapy.	Paclitaxel	85-90	mitogen-activated protein kinase kinase 1	Homo sapiens	227-231
14577846-1	2003	We previously reported that Taxol, which mimics the action of LPS on murine macrophages, induces signals via mouse TLR4/MD-2, but not via human TLR4/MD-2.	Paclitaxel	28-33	lymphocyte antigen 96	Mus musculus	120-124
14577846-3	2003	Expression of mouse MD-2 conferred both LPS and Taxol responsiveness on HEK293 cells expressing mouse TLR4, whereas expression of human MD-2 conferred LPS responsiveness alone, suggesting that MD-2 is responsible for the species-specificity of Taxol responsiveness.	Paclitaxel	48-53	lymphocyte antigen 96	Mus musculus	20-24
14577846-4	2003	Furthermore, mouse MD-2 mutants, in which Gln-22 was changed to other amino acids, showed dramatically reduced ability to confer Taxol responsiveness, although their ability to confer LPS responsiveness was not affected.	Paclitaxel	129-134	lymphocyte antigen 96	Mus musculus	19-23
12496426-0	2003	Identification of mouse MD-2 residues important for forming the cell surface TLR4-MD-2 complex recognized by anti-TLR4-MD-2 antibodies, and for conferring LPS and taxol responsiveness on mouse TLR4 by alanine-scanning mutagenesis.	Paclitaxel	163-168	lymphocyte antigen 96	Mus musculus	24-28
12496426-0	2003	Identification of mouse MD-2 residues important for forming the cell surface TLR4-MD-2 complex recognized by anti-TLR4-MD-2 antibodies, and for conferring LPS and taxol responsiveness on mouse TLR4 by alanine-scanning mutagenesis.	Paclitaxel	163-168	lymphocyte antigen 96	Mus musculus	82-86
12496426-0	2003	Identification of mouse MD-2 residues important for forming the cell surface TLR4-MD-2 complex recognized by anti-TLR4-MD-2 antibodies, and for conferring LPS and taxol responsiveness on mouse TLR4 by alanine-scanning mutagenesis.	Paclitaxel	163-168	lymphocyte antigen 96	Mus musculus	82-86
12496426-1	2003	The expression of MD-2, which associates with Toll-like receptor (TLR) 4 on the cell surface, confers LPS and LPS-mimetic Taxol responsiveness on TLR4.	Paclitaxel	122-127	lymphocyte antigen 96	Mus musculus	18-22
12496426-2	2003	Alanine-scanning mutagenesis was performed to identify the mouse MD-2 residues important for conferring LPS and Taxol responsiveness on mouse TLR4, and for forming the cell surface TLR4-MD-2 complex recognized by anti-TLR4-MD-2 Ab MTS510.	Paclitaxel	112-117	lymphocyte antigen 96	Mus musculus	65-69
12478465-4	2002	This applies to several clinically important settings, for instance to paclitaxel-induced killing of breast cancer cells, in which the ErbB2 receptor kinase can mediate apoptosis inhibition through inactivation of Cdk1.	Paclitaxel	71-81	cyclin dependent kinase 1	Homo sapiens	214-218
12540054-4	2002	In an in vitro kinase assay, Taxol inhibited activation of cdk5 by Abeta.	Paclitaxel	29-34	cyclin dependent kinase 5	Homo sapiens	59-63
12451012-4	2002	METHODS AND RESULTS: Tissue factor-targeted nanoparticles containing doxorubicin or paclitaxel at 0, 0.2, or 2.0 mole% of the outer lipid layer were targeted for 30 minutes to VSMCs and significantly inhibited their proliferation in culture over the next 3 days.	Paclitaxel	84-94	coagulation factor III, tissue factor	Homo sapiens	21-34
12434296-5	2002	We report that lack of the Pms2 gene is associated with an increased sensitivity, ranging from 2-6-fold, to some types of anticancer agents including the topoisomerase II poisons doxorubicin, etoposide and mitoxantrone, the platinum compounds cisplatin and oxaliplatin, the taxanes docetaxel and paclitaxel, and the antimetabolite gemcitabine.	Paclitaxel	296-306	PMS1 homolog 2, mismatch repair system component	Homo sapiens	27-31
12384528-5	2002	Herceptin plus Taxol treatment led to higher levels of p34(Cdc2) kinase activity and apoptosis in ErbB2-overexpressing breast cancer cells, which is likely attributable to inhibition of Cdc2-Tyr-15 phosphorylation and p21(Cip1) expression.	Paclitaxel	15-20	cyclin dependent kinase 1	Homo sapiens	59-63
12389115-3	2002	In response to Taxol-treatment, caspase-9 activity increased at 8 h, and both caspase-2 and -3 activities were increased twofold relative to control cultures at 16 h. Moreover, treatment with the broad-spectrum caspase inhibitor (z-VAD-fmk) or the caspase-9 specific inhibitor (z-LEHD-fmk) effectively protected T24 cells against Taxol-triggered apoptosis.	Paclitaxel	15-20	caspase 9	Homo sapiens	32-41
12389115-3	2002	In response to Taxol-treatment, caspase-9 activity increased at 8 h, and both caspase-2 and -3 activities were increased twofold relative to control cultures at 16 h. Moreover, treatment with the broad-spectrum caspase inhibitor (z-VAD-fmk) or the caspase-9 specific inhibitor (z-LEHD-fmk) effectively protected T24 cells against Taxol-triggered apoptosis.	Paclitaxel	15-20	caspase 2	Homo sapiens	78-94
12389115-3	2002	In response to Taxol-treatment, caspase-9 activity increased at 8 h, and both caspase-2 and -3 activities were increased twofold relative to control cultures at 16 h. Moreover, treatment with the broad-spectrum caspase inhibitor (z-VAD-fmk) or the caspase-9 specific inhibitor (z-LEHD-fmk) effectively protected T24 cells against Taxol-triggered apoptosis.	Paclitaxel	15-20	caspase 9	Homo sapiens	248-257
12121974-6	2002	The resistance to paclitaxel can be partially obliterated when ERK activity is inhibited using a MEK1/2 inhibitor.	Paclitaxel	18-28	mitogen-activated protein kinase kinase 1	Homo sapiens	97-103
12167714-6	2002	Overexpression of a Plk phosphorylation site-deficient mutant of TCTP induced a dramatic increase in the number of multinucleate cells, rounded cells with condensed ball-like nuclei, and cells undergoing cell death, similar to both the reported anti-Plk antibody microinjection and the low-concentration taxol treatment phenotypes.	Paclitaxel	304-309	tumor protein, translationally-controlled 1	Homo sapiens	65-69
12492109-4	2002	Subsequent characterization of XIST expression in a panel of female cancer cell lines showed that the expression level of XIST correlates significantly with Taxol sensitivity.	Paclitaxel	157-162	X inactive specific transcript	Homo sapiens	31-35
12492109-4	2002	Subsequent characterization of XIST expression in a panel of female cancer cell lines showed that the expression level of XIST correlates significantly with Taxol sensitivity.	Paclitaxel	157-162	X inactive specific transcript	Homo sapiens	122-126
12492109-5	2002	The clinical relevance of this observation is demonstrated by the strong association between XIST RNA levels and disease-free periods of ovarian cancer patients in a group of 21 ovarian cancer cases with Taxol in the therapeutic regiments.	Paclitaxel	204-209	X inactive specific transcript	Homo sapiens	93-97
11980661-5	2002	Moreover, SEMA3F also functioned to block apoptosis of transfected A9 cells treated with Taxol or Adriamycin.	Paclitaxel	89-94	semaphorin 3F	Homo sapiens	10-16
21864883-7	2012	Nuclear HSP90 expression was significantly higher in post-chemotherapy compared to pre-chemotherapy effusions (P = .005), significantly related to previous treatment with both platinol (P = .024) and paclitaxel (P = .007).	Paclitaxel	200-210	heat shock protein 90 alpha family class A member 1	Homo sapiens	8-13
21864883-13	2012	However, HSP90 may be of predictive value as to who will benefit from treatment with HSP90 inhibitors to potentiate the effectiveness of platinol and paclitaxel in patients with recurrent advanced ovarian carcinoma effusions.	Paclitaxel	150-160	heat shock protein 90 alpha family class A member 1	Homo sapiens	9-14
21864883-13	2012	However, HSP90 may be of predictive value as to who will benefit from treatment with HSP90 inhibitors to potentiate the effectiveness of platinol and paclitaxel in patients with recurrent advanced ovarian carcinoma effusions.	Paclitaxel	150-160	heat shock protein 90 alpha family class A member 1	Homo sapiens	85-90
22167194-4	2012	Extended (&gt;24 h) treatment of HeLa cells with a microtubule disrupting agent including nocodazole and taxol or release of mitotic shake-off cells into fresh medium induced BubR1-M. BubR1-M was derived from neither phosphorylation nor acetylation.	Paclitaxel	105-110	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	175-180
22167194-4	2012	Extended (&gt;24 h) treatment of HeLa cells with a microtubule disrupting agent including nocodazole and taxol or release of mitotic shake-off cells into fresh medium induced BubR1-M. BubR1-M was derived from neither phosphorylation nor acetylation.	Paclitaxel	105-110	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	184-189
22157765-3	2012	First, the autophagy activity in cancer cells increased after cis-dichloro-diamine platinum (cis-DDP) or Taxol treatment, as indicated by the enhanced expression of beclin 1, a key regulator of autophagy, and increased number of LC3-positive autophagosomes.	Paclitaxel	105-110	beclin 1, autophagy related	Mus musculus	165-173
22157765-3	2012	First, the autophagy activity in cancer cells increased after cis-dichloro-diamine platinum (cis-DDP) or Taxol treatment, as indicated by the enhanced expression of beclin 1, a key regulator of autophagy, and increased number of LC3-positive autophagosomes.	Paclitaxel	105-110	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	229-232
21479552-7	2012	In the NCI-60 cell line dataset, overexpression of the kinesin KIFC3 is significantly correlated with resistance to both docetaxel (P &lt; 0.001) and paclitaxel (P &lt; 0.001), but not to platinum-based chemotherapy, including carboplatin (P = 0.49) and cisplatin (P = 0.10).	Paclitaxel	150-160	kinesin family member C3	Homo sapiens	63-68
21479552-8	2012	Overexpression of KIFC3 and KIF5A in pre-chemotherapy samples similarly predicted resistance to paclitaxel in the MDACC cohorts (P = 0.01); no KIF predicted resistance to fluorouracil-epirubicin-cyclophosphamide or cisplatin in BLBC patient cohorts treated without taxanes.	Paclitaxel	96-106	kinesin family member C3	Homo sapiens	18-23
21359954-4	2012	In MDA-MB-453 cells, DNMT3b KD reduces the IC(50) for DOX from 0.086 to 0.048 muM (44% reduction), for PAX from 0.497 to 0.376 nM (24%), and for 5-FU from 0.817 to 0.145 mM (82%).	Paclitaxel	103-106	DNA methyltransferase 3 beta	Homo sapiens	21-27
21359954-6	2012	5-aza treatment of DNMT3b KD cells reduced the IC(50) for DOX to 0.036 muM (59%), for PAX to 0.313 nM (37%) and for 5-FU to 0.067 (92%).	Paclitaxel	86-89	DNA methyltransferase 3 beta	Homo sapiens	19-25
21359954-8	2012	The effectiveness of DOX, PAX, and 5-FU is enhanced through targeted and/or pharmacological inhibition of DNMT3b, strongly suggesting that combined epigenetic and cytotoxic treatment will improve the efficacy of breast cancer chemotherapy.	Paclitaxel	26-29	DNA methyltransferase 3 beta	Homo sapiens	106-112
22517709-8	2012	CONCLUSION: Our findings support that with carboplatin/ paclitaxel combination chemotherapy, important parameters of the immune system (IFN-gamma, CD4, CD4/CD8) can be used as prognostic factors for survival, while others (IL-3) as indicators of toxicity.	Paclitaxel	56-66	interleukin 3	Homo sapiens	223-227
22723956-6	2012	The identification of a miR-337-3p as a modulator of cellular response to taxanes, and STAT3 and RAP1A as regulatory targets which mediate that response, defines a novel regulatory pathway modulating paclitaxel sensitivity in lung cancer cells, which may provide novel adjuvant strategies along with paclitaxel in the treatment of lung cancer and may also provide biomarkers for predicting paclitaxel response in NSCLC.	Paclitaxel	200-210	RAP1A, member of RAS oncogene family	Homo sapiens	97-102
21880414-0	2011	5-aza-2"-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-beta-catenin expression.	Paclitaxel	74-84	catenin beta 1	Homo sapiens	112-124
21880414-1	2011	We investigated the molecular mechanisms by which 5-aza-2"-deoxycytidine (DAC) and paclitaxel (PTX) use lymphoid enhancer-binding factor 1 (LEF1) and the Wnt/beta-catenin pathway to synergistically interact against renal cell carcinoma (RCC).	Paclitaxel	83-93	catenin beta 1	Homo sapiens	158-170
21880414-1	2011	We investigated the molecular mechanisms by which 5-aza-2"-deoxycytidine (DAC) and paclitaxel (PTX) use lymphoid enhancer-binding factor 1 (LEF1) and the Wnt/beta-catenin pathway to synergistically interact against renal cell carcinoma (RCC).	Paclitaxel	95-98	catenin beta 1	Homo sapiens	158-170
21880414-3	2011	The regulation of LEF1/beta-catenin protein expression by DAC and/or PTX was examined by Western blot and immunoprecipitation.	Paclitaxel	69-72	catenin beta 1	Homo sapiens	23-35
21880414-6	2011	Moreover, treatment of RCC cell lines with the combination of DAC and PTX caused a synergistic decrease in LEF1/phospho-beta-catenin.	Paclitaxel	70-73	catenin beta 1	Homo sapiens	120-132
21963198-3	2011	We therefore developed a murine model of multimodal therapy in which we evaluated paclitaxel-loaded expansile nanoparticles (Pax-eNP) for delivering intracavitary chemotherapy in malignant mesothelioma.	Paclitaxel	82-92	centromere protein H	Mus musculus	129-132
21963198-4	2011	METHODS: Paclitaxel-loaded expansile nanoparticles (Pax-eNP) of 100 nm, designed to release drug at an endosomal pH below 5, were synthesized.	Paclitaxel	9-19	centromere protein H	Mus musculus	56-59
21978935-0	2011	Cooperative phosphorylation of FADD by Aur-A and Plk1 in response to taxol triggers both apoptotic and necrotic cell death.	Paclitaxel	69-74	Fas associated via death domain	Homo sapiens	31-35
21978935-2	2011	Here, we report that Aur-A phosphorylates S203 of the Fas associated with death domain protein (FADD) in response to taxol treatment.	Paclitaxel	117-122	Fas associated via death domain	Homo sapiens	54-94
21978935-2	2011	Here, we report that Aur-A phosphorylates S203 of the Fas associated with death domain protein (FADD) in response to taxol treatment.	Paclitaxel	117-122	Fas associated via death domain	Homo sapiens	96-100
22019170-0	2011	Paclitaxel induces apoptosis through activation of nuclear protein kinase C-delta and subsequent activation of Golgi associated Cdk1 in human hormone refractory prostate cancer.	Paclitaxel	0-10	cyclin dependent kinase 1	Homo sapiens	128-132
22019170-7	2011	Data revealed that paclitaxel induced an increase of Cdk1 activity and DR5 expression on the Golgi complex that was associated with increased cleavage of caspase-8, a DR5 downstream factor, and caspase-3 into catalytically active fragments.	Paclitaxel	19-29	cyclin dependent kinase 1	Homo sapiens	53-57
22019170-7	2011	Data revealed that paclitaxel induced an increase of Cdk1 activity and DR5 expression on the Golgi complex that was associated with increased cleavage of caspase-8, a DR5 downstream factor, and caspase-3 into catalytically active fragments.	Paclitaxel	19-29	TNF receptor superfamily member 10b	Homo sapiens	71-74
22019170-7	2011	Data revealed that paclitaxel induced an increase of Cdk1 activity and DR5 expression on the Golgi complex that was associated with increased cleavage of caspase-8, a DR5 downstream factor, and caspase-3 into catalytically active fragments.	Paclitaxel	19-29	TNF receptor superfamily member 10b	Homo sapiens	167-170
21901230-7	2011	Moreover, anti-beta2GPI/beta2GPI complex-induced IRAKs and TRAFs expression and activation were attenuated by knockdown of ANX2 by infection with ANX2-specific RNA interference lentiviruses (LV-RNAi-ANX2) or by treatment with paclitaxel, which inhibits TLR4 as an antagonist of myeloid differentiation protein 2 (MD-2) ligand.	Paclitaxel	226-236	apolipoprotein H	Homo sapiens	15-23
21901230-7	2011	Moreover, anti-beta2GPI/beta2GPI complex-induced IRAKs and TRAFs expression and activation were attenuated by knockdown of ANX2 by infection with ANX2-specific RNA interference lentiviruses (LV-RNAi-ANX2) or by treatment with paclitaxel, which inhibits TLR4 as an antagonist of myeloid differentiation protein 2 (MD-2) ligand.	Paclitaxel	226-236	apolipoprotein H	Homo sapiens	24-32
21901230-7	2011	Moreover, anti-beta2GPI/beta2GPI complex-induced IRAKs and TRAFs expression and activation were attenuated by knockdown of ANX2 by infection with ANX2-specific RNA interference lentiviruses (LV-RNAi-ANX2) or by treatment with paclitaxel, which inhibits TLR4 as an antagonist of myeloid differentiation protein 2 (MD-2) ligand.	Paclitaxel	226-236	annexin A2	Homo sapiens	123-127
21901230-7	2011	Moreover, anti-beta2GPI/beta2GPI complex-induced IRAKs and TRAFs expression and activation were attenuated by knockdown of ANX2 by infection with ANX2-specific RNA interference lentiviruses (LV-RNAi-ANX2) or by treatment with paclitaxel, which inhibits TLR4 as an antagonist of myeloid differentiation protein 2 (MD-2) ligand.	Paclitaxel	226-236	annexin A2	Homo sapiens	146-150
21901230-7	2011	Moreover, anti-beta2GPI/beta2GPI complex-induced IRAKs and TRAFs expression and activation were attenuated by knockdown of ANX2 by infection with ANX2-specific RNA interference lentiviruses (LV-RNAi-ANX2) or by treatment with paclitaxel, which inhibits TLR4 as an antagonist of myeloid differentiation protein 2 (MD-2) ligand.	Paclitaxel	226-236	annexin A2	Homo sapiens	146-150
21824652-0	2011	The intracellular uptake of CD95 modified paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles.	Paclitaxel	42-52	Fas cell surface death receptor	Homo sapiens	28-32
21824652-5	2011	CD95 modified paclitaxel-loaded PLGA microparticles are shown to be significantly more effective compared to conventional paclitaxel therapy (Taxol) at the same dose in subcutaneous medulloblastoma (***P &lt; 0.0001) and orthotopic ovarian cancer xenograft models where a &gt;65-fold reduction in tumour bioluminescence was measured after treatment (*P = 0.012).	Paclitaxel	14-24	Fas cell surface death receptor	Homo sapiens	0-4
21824652-5	2011	CD95 modified paclitaxel-loaded PLGA microparticles are shown to be significantly more effective compared to conventional paclitaxel therapy (Taxol) at the same dose in subcutaneous medulloblastoma (***P &lt; 0.0001) and orthotopic ovarian cancer xenograft models where a &gt;65-fold reduction in tumour bioluminescence was measured after treatment (*P = 0.012).	Paclitaxel	122-132	Fas cell surface death receptor	Homo sapiens	0-4
11955676-4	2002	The results demonstrated that NAT activity, gene expression (NAT1 mRNA) and 2-AF-DNA adduct formation in human lung tumor cells were inhibited and decreased by paclitaxel in a dose-dependent manner.	Paclitaxel	160-170	N-acetyltransferase 1	Homo sapiens	61-65
12054644-2	2002	The cellular targets of PTX are microtubules, which are composed of alpha- and beta-tubulin.	Paclitaxel	24-27	tubulin alpha 1b	Homo sapiens	68-91
11953891-6	2002	Taxol only increased macrophage-colony stimulating factor release while reduced that of granulocyte-colony stimulating factor.	Paclitaxel	0-5	colony stimulating factor 3	Homo sapiens	88-125
12170770-0	2002	Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death.	Paclitaxel	0-10	Fas ligand	Homo sapiens	19-23
22000491-4	2011	The results showed that beta-catenin shRNA expression resulted in decreased beta-catenin mRNA and protein expression in the transfected A2780 cells, inhibition of cellular proliferation, decreased capability of clonogenicity in the plating and the soft agar, and increased sensitivities to chemotherapy drugs vincristine, paclitaxel and cisplatin compared to untransfected cells.	Paclitaxel	322-332	catenin beta 1	Homo sapiens	24-36
3481365-7	1987	A heat-stable MAP with a molecular weight of 180,000, termed here HeLa 180-kDa MAP, was purified by the taxol-dependent procedure (Vallee, R.B.	Paclitaxel	104-109	regulator of microtubule dynamics 1	Homo sapiens	14-17
21965726-7	2011	However, PA also increases surface expression of death receptors 4 and 5 (DR4 and DR5, respectively).	Paclitaxel	9-11	TNF receptor superfamily member 10b	Homo sapiens	82-85
22331716-3	2011	In this study, we aimed to determine the roles of sphingosine kinase-1 (SK-1) and glucosylceramide synthase (GCS) genes in paclitaxel, doxorubicin, tamoxifen, cyclophosphamide and docetaxel induced apoptosis in human MCF-7 breast cancer cells.	Paclitaxel	123-133	sphingosine kinase 1	Homo sapiens	50-76
22331716-3	2011	In this study, we aimed to determine the roles of sphingosine kinase-1 (SK-1) and glucosylceramide synthase (GCS) genes in paclitaxel, doxorubicin, tamoxifen, cyclophosphamide and docetaxel induced apoptosis in human MCF-7 breast cancer cells.	Paclitaxel	123-133	UDP-glucose ceramide glucosyltransferase	Homo sapiens	82-107
22331716-3	2011	In this study, we aimed to determine the roles of sphingosine kinase-1 (SK-1) and glucosylceramide synthase (GCS) genes in paclitaxel, doxorubicin, tamoxifen, cyclophosphamide and docetaxel induced apoptosis in human MCF-7 breast cancer cells.	Paclitaxel	123-133	UDP-glucose ceramide glucosyltransferase	Homo sapiens	109-112
11861387-0	2002	Inhibition of phosphatidylinositol 3"-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.	Paclitaxel	67-77	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	14-44
11843726-4	2002	The activity of paclitaxel was correlated with an elevation of cyclin B1/CDC2 activity, prolonged mitotic arrest, and Bcl-2 phosphorylation.	Paclitaxel	16-26	cyclin B1	Homo sapiens	63-72
11843726-4	2002	The activity of paclitaxel was correlated with an elevation of cyclin B1/CDC2 activity, prolonged mitotic arrest, and Bcl-2 phosphorylation.	Paclitaxel	16-26	cyclin dependent kinase 1	Homo sapiens	73-77
3481365-7	1987	A heat-stable MAP with a molecular weight of 180,000, termed here HeLa 180-kDa MAP, was purified by the taxol-dependent procedure (Vallee, R.B.	Paclitaxel	104-109	regulator of microtubule dynamics 1	Homo sapiens	79-82
11802207-0	2002	TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.	Paclitaxel	53-63	Fas ligand	Homo sapiens	7-11
11802207-0	2002	TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.	Paclitaxel	53-63	TNF receptor superfamily member 10b	Homo sapiens	32-35
3536962-7	1986	This tight temporal and topographical linkage between titin and myosin is also observed in postmitotic, mononucleated myoblasts and multinucleated myotubes when myofibrillogenesis is perturbed with Colcemid or taxol.	Paclitaxel	210-215	myosin heavy chain 14	Homo sapiens	64-70
11802207-10	2002	The combination treatments, FasL+PA, TRAIL+PA or PA+anti-DR5 antibody, greatly enhance PA-apoptotic effect in most cell lines.	Paclitaxel	49-52	TNF receptor superfamily member 10b	Homo sapiens	57-60
22331716-8	2011	Paclitaxel, doxorubicin, tamoxifen, cyclophosphamide and docetaxel application downregulated SK-1 expression while paclitaxel, tamoxifen, cyclophosphamide and docetaxel but not doxorubicin downregulated GCS comparing to untreated control cells.	Paclitaxel	0-10	sphingosine kinase 1	Homo sapiens	93-97
22331716-8	2011	Paclitaxel, doxorubicin, tamoxifen, cyclophosphamide and docetaxel application downregulated SK-1 expression while paclitaxel, tamoxifen, cyclophosphamide and docetaxel but not doxorubicin downregulated GCS comparing to untreated control cells.	Paclitaxel	0-10	UDP-glucose ceramide glucosyltransferase	Homo sapiens	203-206
6146626-10	1984	The codistribution of microtubules and Golgi elements can be reversed in taxol-treated cells by injection of a monoclonal (YL 1/2) antibody reacting specifically with the tyrosylated form of alpha-tubulin.	Paclitaxel	73-78	vacuolar protein sorting 72 homolog	Homo sapiens	123-129
22331726-1	2011	PURPOSE: The purpose of this study was to investigate whether the expression of excision repair cross complementing 1 (ERCC1) protein I in tumor tissue was associated with resistance to standard carboplatin and paclitaxel (PC) combination chemotherapy in patients newly diagnosed with advanced epithelial ovarian carcinoma (EOC).	Paclitaxel	211-221	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	80-117
22331726-1	2011	PURPOSE: The purpose of this study was to investigate whether the expression of excision repair cross complementing 1 (ERCC1) protein I in tumor tissue was associated with resistance to standard carboplatin and paclitaxel (PC) combination chemotherapy in patients newly diagnosed with advanced epithelial ovarian carcinoma (EOC).	Paclitaxel	211-221	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	119-124
22331726-3	2011	The protein expression levels of ERCC1 in tumor tissue were determined by Western blot analysis in 55 samples with advanced and metastatic EOC with different histologic subtypes; then these patients were treated with PC.	Paclitaxel	217-219	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	33-38
11821733-14	2002	Furthermore, paclitaxel reduced CTL activity and IL-2 production after alloantigen rechallenge.	Paclitaxel	13-23	interleukin 2	Rattus norvegicus	49-53
6136036-9	1983	The codistribution of Golgi-derived elements with taxol-induced microtubule bundles can be reversed by microinjection of a monoclonal (YL 1/2) antibody reacting specifically with the tyrosylated form of alpha-tubulin.	Paclitaxel	50-55	vacuolar protein sorting 72 homolog	Homo sapiens	135-141
11914641-0	2002	Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice.	Paclitaxel	74-84	interleukin 2	Mus musculus	12-25
11914641-8	2002	The Taxol + rIL-2 combination provoked the development of ascites, presumably due to the presence of Cremophor EL in the Taxol preparation.	Paclitaxel	121-126	interleukin 2	Rattus norvegicus	12-17
11914641-10	2002	Paclitaxel pharmacokinetics were strongly modified by rIL-2 pretreatment.	Paclitaxel	0-10	interleukin 2	Rattus norvegicus	54-59
21538355-6	2011	Other nonionizable P-gp substrates (digoxin, dexamethasone, paclitaxel, and etoposide) responded to acidic pH (4.5) in a manner similar to colchicine.	Paclitaxel	60-70	PGP	Canis lupus familiaris	19-23
21813412-13	2011	Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression.	Paclitaxel	133-143	cyclin dependent kinase inhibitor 1B	Homo sapiens	118-122
21813412-14	2011	CONCLUSION: Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.	Paclitaxel	94-104	cyclin dependent kinase inhibitor 1B	Homo sapiens	153-157
11914641-16	2002	We conclude that rIL-2 pretreatment is able to decrease P-gp activity and paclitaxel metabolism in vivo.	Paclitaxel	74-84	interleukin 2	Rattus norvegicus	17-22
6136036-9	1983	The codistribution of Golgi-derived elements with taxol-induced microtubule bundles can be reversed by microinjection of a monoclonal (YL 1/2) antibody reacting specifically with the tyrosylated form of alpha-tubulin.	Paclitaxel	50-55	tubulin alpha 1b	Homo sapiens	203-216
6982901-5	1982	Trifluoperazine, W-7, cytochalasin D, and taxol also block DNA synthesis in response to EGF as measured by autoradiography using [3H]thymidine.	Paclitaxel	42-47	epidermal growth factor	Homo sapiens	88-91
18475423-11	2002	The Cls for combinations of taxol with Pt1 or Pt2 revealed cytotoxic effects that were in most Cases synergistic (Pt1) or less than addtiive (Pt2).	Paclitaxel	28-33	zinc finger protein 77	Homo sapiens	114-117
11752211-4	2002	In this study, using a novel IkappaBalpha phosphorylation inhibitor, we demonstrated that the blockage of paclitaxel-induced IkappaBalpha degradation inhibited apoptotic cell death in human breast cancer BCap37 and ovarian cancer OV2008 cell lines.	Paclitaxel	106-116	prohibitin 2	Homo sapiens	204-210
21470206-5	2011	KEY RESULTS: Treatment with paclitaxel increased both mechanical and thermal hyperalgesia in mice (C57BL/6 and CD1 strains).	Paclitaxel	28-38	CD1 antigen complex	Mus musculus	111-114
21470206-7	2011	Treatment of CD1 mice with kinin receptor antagonists (DALBK for B1 or Hoe 140 for B2 receptors) significantly inhibited both mechanical and thermal hyperalgesia when tested at 7 and 14 days after the first paclitaxel injection.	Paclitaxel	207-217	CD1 antigen complex	Mus musculus	13-16
21482024-6	2011	Ki23057 decreased the ERCC1 expression level in OCUM-2M/SN38, OCUM-2M/PTX, and OCUM-2M/VP16.	Paclitaxel	70-73	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	22-27
21482024-8	2011	CONCLUSION: The FGFR2 inhibitor Ki23057 might be therapeutically promising for treating drug-resistant gastric cancer cells, especially when used in combination with SN38, PTX, or VP16.	Paclitaxel	172-175	fibroblast growth factor receptor 2	Homo sapiens	16-21
21821491-5	2011	TIP (paclitaxel, iposfamide, cisplatin) chemotherapy is still the standard salvage treatment for patients progressing after BEP chemotherapy.	Paclitaxel	5-15	TOR signaling pathway regulator	Homo sapiens	0-3
21220050-0	2011	Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer.	Paclitaxel	51-61	epidermal growth factor receptor	Mus musculus	70-74
21220050-1	2011	UNLABELLED: The aim of this study was to assess the biodistribution and pharmacokinetics of epidermal growth factor receptor (EGFR)-targeted polymer-blend nanoparticles loaded with the anticancer drugs lonidamine and paclitaxel.	Paclitaxel	217-227	epidermal growth factor receptor	Mus musculus	92-124
21220050-1	2011	UNLABELLED: The aim of this study was to assess the biodistribution and pharmacokinetics of epidermal growth factor receptor (EGFR)-targeted polymer-blend nanoparticles loaded with the anticancer drugs lonidamine and paclitaxel.	Paclitaxel	217-227	epidermal growth factor receptor	Mus musculus	126-130
21220050-7	2011	Lonidamine-paclitaxel combination therapy administered via EGFR-targeted polymer-blend nanocarriers may become a viable platform for the future treatment of multidrug-resistant cancer.	Paclitaxel	11-21	epidermal growth factor receptor	Mus musculus	59-63
21220050-8	2011	FROM THE CLINICAL EDITOR: In this study the biodistribution and pharmacokinetics of epidermal growth factor receptor (EGFR)-targeted polymer-blend nanoparticles loaded with lonidamine and paclitaxel were assessed.	Paclitaxel	188-198	epidermal growth factor receptor	Mus musculus	84-116
21220050-8	2011	FROM THE CLINICAL EDITOR: In this study the biodistribution and pharmacokinetics of epidermal growth factor receptor (EGFR)-targeted polymer-blend nanoparticles loaded with lonidamine and paclitaxel were assessed.	Paclitaxel	188-198	epidermal growth factor receptor	Mus musculus	118-122
21496891-1	2011	OBJECTIVE: This study evaluated common polymorphisms in excision repair cross-complementation group 1 (ERCC1) involved in repair of platinum-induced DNA damage in advanced-stage, epithelial ovarian/peritoneal/tubal cancer (EOC/PPC/FTC) patients treated with intravenous carboplatin- and paclitaxel-based chemotherapy.	Paclitaxel	287-297	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	103-108
21496891-8	2011	CONCLUSIONS: The polymorphism in codon 118 in the DNA repair gene ERCC1 was an independent predictor for better survival in EOC/PPC/FTC patients treated with intravenous carboplatin- and paclitaxel-based chemotherapy.	Paclitaxel	187-197	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	66-71
21622622-6	2011	To further determine the biological importance of this mechanism, we employed RNA oligonucleotides to redirect caspase 9 pre-mRNA splicing in favor of caspase 9b expression, which resulted in an increase in the IC(50) of non-small cell lung cancer (NSCLC) cells to daunorubicin, cisplatinum, and paclitaxel.	Paclitaxel	296-306	caspase 9	Homo sapiens	111-120
21622622-6	2011	To further determine the biological importance of this mechanism, we employed RNA oligonucleotides to redirect caspase 9 pre-mRNA splicing in favor of caspase 9b expression, which resulted in an increase in the IC(50) of non-small cell lung cancer (NSCLC) cells to daunorubicin, cisplatinum, and paclitaxel.	Paclitaxel	296-306	caspase 9	Homo sapiens	151-160
21584498-0	2011	Function of Aurora kinase A in Taxol-resistant breast cancer and its correlation with P-gp.	Paclitaxel	31-36	phosphoglycolate phosphatase	Homo sapiens	86-90
20816848-10	2011	Using offgel IEF/PAGE difference gel electrophoresis, we identified a number of proteins whose expression is reduced in the taxol-resistant stathmin-overexpressing cell lines, including proteins involved in the cytoskeleton and cell structure, the stress response, protein folding, glycolysis, and catalysis.	Paclitaxel	124-129	stathmin 1	Homo sapiens	140-148
21331814-6	2011	These findings suggested that the GM-CSF-surface-modified tumor-cell vaccine may have potential clinical benefit for patients with prostate cancer when it is combined with paclitaxel.	Paclitaxel	172-182	colony stimulating factor 2	Homo sapiens	34-40
21402713-5	2011	Inhibitory RNA (RNAi)-mediated knockdown and ectopic overexpression established a critical functional role for Plk2 in determining apoptotic sensitivity to paclitaxel and carboplatin.	Paclitaxel	156-166	polo like kinase 2	Homo sapiens	111-115
21402713-7	2011	RNAi-dependent knockdown of Plk2 abrogated G(2)-M cell-cycle blockade by paclitaxel, conferring resistance to both paclitaxel and platinum.	Paclitaxel	73-83	polo like kinase 2	Homo sapiens	28-32
21402713-7	2011	RNAi-dependent knockdown of Plk2 abrogated G(2)-M cell-cycle blockade by paclitaxel, conferring resistance to both paclitaxel and platinum.	Paclitaxel	115-125	polo like kinase 2	Homo sapiens	28-32
21402713-8	2011	Conversely, ectopic expression of Plk2 restored sensitivity to G(2)-M cell-cycle blockade and cytotoxicity triggered by paclitaxel.	Paclitaxel	120-130	polo like kinase 2	Homo sapiens	34-38
21402713-9	2011	In clinical cases, DNA methylation of the Plk2 CpG island in tumor tissue was associated with a higher risk of relapse in patients treated postoperatively with carboplatin and paclitaxel (P = 0.003).	Paclitaxel	176-186	polo like kinase 2	Homo sapiens	42-46
21349946-0	2011	Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF.	Paclitaxel	0-5	cellular communication network factor 1	Homo sapiens	130-135
21349946-5	2011	Short hairpin RNA-mediated knockdown of both Cyr61 and CTGF reversed TAZ-induced Taxol resistance in breast cancer cells.	Paclitaxel	81-86	cellular communication network factor 1	Homo sapiens	45-50
21349946-6	2011	Interaction of TAZ with the TEAD family of transcription factors was essential for TAZ to activate the Cyr61/CTGF promoters and to induce Taxol resistance.	Paclitaxel	138-143	cellular communication network factor 1	Homo sapiens	103-108
21349946-7	2011	Our findings define the TAZ-TEAD-Cyr61/CTGF signaling pathway as an important modifier of the Taxol response in breast cancer cells, as well as highlighting it as a novel therapeutic target to treat drug-resistant breast cancers that arise commonly at advanced stages of disease.	Paclitaxel	94-99	cellular communication network factor 1	Homo sapiens	33-38
21223350-0	2011	CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4.	Paclitaxel	43-53	forkhead box P3	Mus musculus	4-9
21223350-3	2011	Here, we demonstrated that PTX not only decreased the percentage of CD4+Foxp3+ regulatory T (Treg) cells both in vitro and in vivo but also impaired cell viability and cytokine production of Treg cells rather than CD4+Foxp3- effector T (Teff) cells.	Paclitaxel	27-30	forkhead box P3	Mus musculus	72-77
21223350-3	2011	Here, we demonstrated that PTX not only decreased the percentage of CD4+Foxp3+ regulatory T (Treg) cells both in vitro and in vivo but also impaired cell viability and cytokine production of Treg cells rather than CD4+Foxp3- effector T (Teff) cells.	Paclitaxel	27-30	forkhead box P3	Mus musculus	218-223
21240457-11	2011	Gene silencing of the microtubule regulatory gene STMN1 by RNAi suggested a distinct synergistic effect in the combined treatment with nab-paclitaxel.	Paclitaxel	139-149	stathmin 1	Homo sapiens	50-55
21464539-0	2011	Effect of CD147 monoclonal antibody on paclitaxel resistance in HCE1 multicellular spheroids.	Paclitaxel	39-49	basigin (Ok blood group)	Homo sapiens	10-15
21464539-1	2011	OBJECTIVE: To investigate the effect of CD147 monoclonal antibody (mAb) on the natural resistance to paclitaxel (TAX) in the human cervical cancer line (HCE1) multicellular spheroid (HCE1/MCS) model and if CD147 mAb can reverse the HCE1/MCS resistance to TAX.	Paclitaxel	101-111	basigin (Ok blood group)	Homo sapiens	40-45
21314952-10	2011	RESULTS: 43 SNPs were found significantly associated (FDR&lt;0.005) with paclitaxel response, with 10 belonging to protein-coding genes (CFTR, ROBO1, PTPRD, BTBD12, DCT, SNTG1, SGCD, LPHN2, GRIK1, ZNF607).	Paclitaxel	73-83	roundabout guidance receptor 1	Homo sapiens	143-148
21347438-7	2011	The CYP2C93 proteins heterologously expressed in Escherichia coli metabolized human CYP2C substrates, diclofenac, flurbiprofen, paclitaxel, S-mephenytoin, and tolbutamide.	Paclitaxel	128-138	cytochrome P450 family 2 subfamily C member 93	Macaca mulatta	4-11
20665703-7	2011	The combination of ZD6474 with paclitaxel versus either agent alone also more potently down-regulated the antiapoptotic bcl-2 protein, up-regulated pro-apoptotic signaling events involving expression of bax, activation of caspase-3 and caspase-7 proteins, and induced poly(ADP-ribose) polymerase resulting in apoptosis.	Paclitaxel	31-41	caspase 7	Homo sapiens	236-245
20975605-11	2011	In addition, small interfering RNA knockdown of c-Kit sensitized the cells to paclitaxel.	Paclitaxel	78-88	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	48-53
20975605-12	2011	These data show that combination of two tyrosine kinase inhibitors, imatinib and vatalanib, increases the effects of paclitaxel on B16/PDGF-BB tumors, thus suggesting a novel strategy for the treatment of melanomas expressing c-Kit.	Paclitaxel	117-127	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	226-231
22295202-2	2011	TIP is a regimen containing paclitaxel (Taxol), ifosfamide, and cisplatin that is known to have significant activity in patients with squamous cell cancers of the head and neck as well as in cervical cancer, both of which are malignancies strongly associated with oncogenic strains of human papilloma virus (HPV).	Paclitaxel	28-38	TOR signaling pathway regulator	Homo sapiens	0-3
22295202-2	2011	TIP is a regimen containing paclitaxel (Taxol), ifosfamide, and cisplatin that is known to have significant activity in patients with squamous cell cancers of the head and neck as well as in cervical cancer, both of which are malignancies strongly associated with oncogenic strains of human papilloma virus (HPV).	Paclitaxel	40-45	TOR signaling pathway regulator	Homo sapiens	0-3
21797112-15	2011	Furthermore, the use of paclitaxel and carboplatinum chemotherapy also appears a promising adjunct in patients with endometrioid histologies and nodal spread.	Paclitaxel	24-34	nodal growth differentiation factor	Homo sapiens	145-150
22187664-3	2011	RNAi-mediated knockdown of alpha-enolase in A549 and H460 lung, MCF7 breast and CaOV3 ovarian cancer cells caused a significant increase in the sensitivity of these cells to antitubulin chemotherapeutics (e.g., vincristine and taxol), but not to doxorubicin, etoposide or cisplatinum.	Paclitaxel	227-232	enolase 1	Homo sapiens	27-40
22070048-8	2011	Paclitaxel results in changes in cell shape and size similar to those of zinc but has different effects on cell cycle progression and cyclin expression.	Paclitaxel	0-10	proliferating cell nuclear antigen	Homo sapiens	134-140
21423464-0	2011	Paclitaxel induces thrombomodulin downregulation in human aortic endothelial cells.	Paclitaxel	0-10	thrombomodulin	Homo sapiens	19-33
21423464-2	2011	In this study, we set out to clarify whether paclitaxel can modulate thrombomodulin expression in human aortic endothelial cells.	Paclitaxel	45-55	thrombomodulin	Homo sapiens	69-83
21423464-6	2011	Paclitaxel (10(-5) to 10(-9) mol/L) treatment for 5 hours downregulated thrombomodulin expression dose-dependently, persisting even at 13 hours.	Paclitaxel	0-10	thrombomodulin	Homo sapiens	72-86
21423464-8	2011	Paclitaxel caused a 0.63-fold decrease in thrombomodulin messenger RNA expression, and thrombin cotreatment did not alter this decrease.	Paclitaxel	0-10	thrombomodulin	Homo sapiens	42-56
21423464-9	2011	In vivo studies confirmed that paclitaxel (10 mg/kg) caused endothelial thrombomodulin downregulation in mice.	Paclitaxel	31-41	thrombomodulin	Mus musculus	72-86
21423464-10	2011	In summary, paclitaxel downregulates thrombomodulin expression regardless of thrombin stimulation, which is an important factor for patients receiving paclitaxel-eluting stents.	Paclitaxel	12-22	thrombomodulin	Homo sapiens	37-51
21423464-10	2011	In summary, paclitaxel downregulates thrombomodulin expression regardless of thrombin stimulation, which is an important factor for patients receiving paclitaxel-eluting stents.	Paclitaxel	151-161	thrombomodulin	Homo sapiens	37-51
20933385-0	2010	Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.	Paclitaxel	34-44	kallikrein related peptidase 3	Homo sapiens	64-89
20933385-3	2010	In an attempt to improve both the water solubility and tumour-targeting properties of paclitaxel (Taxol ), we set out to develop a water soluble paclitaxel prodrug that is activated specifically by prostate-specific antigen (PSA) which is almost exclusively expressed in prostate tissue and prostate carcinoma making it an ideal molecular target for prodrug strategies.	Paclitaxel	86-96	kallikrein related peptidase 3	Homo sapiens	198-229
20933385-3	2010	In an attempt to improve both the water solubility and tumour-targeting properties of paclitaxel (Taxol ), we set out to develop a water soluble paclitaxel prodrug that is activated specifically by prostate-specific antigen (PSA) which is almost exclusively expressed in prostate tissue and prostate carcinoma making it an ideal molecular target for prodrug strategies.	Paclitaxel	98-103	kallikrein related peptidase 3	Homo sapiens	198-229
20933385-3	2010	In an attempt to improve both the water solubility and tumour-targeting properties of paclitaxel (Taxol ), we set out to develop a water soluble paclitaxel prodrug that is activated specifically by prostate-specific antigen (PSA) which is almost exclusively expressed in prostate tissue and prostate carcinoma making it an ideal molecular target for prodrug strategies.	Paclitaxel	145-155	kallikrein related peptidase 3	Homo sapiens	198-229
20933385-6	2010	Moreover, incubation studies with PSA demonstrated that the albumin-bound form of the prodrug was cleaved rapidly at the P1-P1" scissile bond releasing the paclitaxel-dipeptide H-Ser-Leu-PABC-paclitaxel.	Paclitaxel	156-166	kallikrein related peptidase 3	Homo sapiens	34-37
20933385-6	2010	Moreover, incubation studies with PSA demonstrated that the albumin-bound form of the prodrug was cleaved rapidly at the P1-P1" scissile bond releasing the paclitaxel-dipeptide H-Ser-Leu-PABC-paclitaxel.	Paclitaxel	192-202	kallikrein related peptidase 3	Homo sapiens	34-37
20933385-11	2010	The new paclitaxel prodrug (3 x 24 mg paclitaxel equivalents) showed comparable antitumour activity on the primary tumour to paclitaxel at its maximum-tolerated dose (3 x 12mg/kg), reduced circulating PSA levels and demonstrated a better antitumour effect on lung metastases but not on bone metastases.	Paclitaxel	8-18	kallikrein related peptidase 3	Homo sapiens	201-204
21139994-7	2010	Western blot analysis confirmed induction of EGR1 protein at 1 h and ATF3 at 24 h. Paclitaxel, as well as digitoxin, inhibited the in vitro activity of the purified Na(+)-K(+)-ATPase; digitoxin enhanced the growth inhibitory effects of paclitaxel on Her2 overexpressing breast cancer cells.	Paclitaxel	83-93	early growth response 1	Homo sapiens	45-49
21139994-7	2010	Western blot analysis confirmed induction of EGR1 protein at 1 h and ATF3 at 24 h. Paclitaxel, as well as digitoxin, inhibited the in vitro activity of the purified Na(+)-K(+)-ATPase; digitoxin enhanced the growth inhibitory effects of paclitaxel on Her2 overexpressing breast cancer cells.	Paclitaxel	83-93	activating transcription factor 3	Homo sapiens	69-73
20855974-9	2010	The SDI method revealed that CHFR gene methylation was significantly related to high sensitivity to paclitaxel (p.	Paclitaxel	100-110	checkpoint with forkhead and ring finger domains	Homo sapiens	29-33
20801127-0	2010	Paclitaxel accelerates spontaneous calcium oscillations in cardiomyocytes by interacting with NCS-1 and the InsP3R.	Paclitaxel	0-10	neuronal calcium sensor 1	Rattus norvegicus	94-99
20801127-3	2010	Recently, neuronal calcium sensor 1 (NCS-1), a calcium binding protein that modulates the inositol-1,4,5-trisphosphate receptor (InsP(3)R), was described as a binding partner of Taxol and as a substrate of calpain.	Paclitaxel	178-183	neuronal calcium sensor 1	Rattus norvegicus	10-35
20801127-3	2010	Recently, neuronal calcium sensor 1 (NCS-1), a calcium binding protein that modulates the inositol-1,4,5-trisphosphate receptor (InsP(3)R), was described as a binding partner of Taxol and as a substrate of calpain.	Paclitaxel	178-183	neuronal calcium sensor 1	Rattus norvegicus	37-42
20801127-8	2010	Taxol treated cells had increased expression of NCS-1, an effect also detectable after Taxol administration in vivo.	Paclitaxel	0-5	neuronal calcium sensor 1	Rattus norvegicus	48-53
20801127-8	2010	Taxol treated cells had increased expression of NCS-1, an effect also detectable after Taxol administration in vivo.	Paclitaxel	87-92	neuronal calcium sensor 1	Rattus norvegicus	48-53
20801127-9	2010	Short hairpin RNA mediated knockdown of NCS-1 decreased InsP(3)R dependent intracellular calcium release, whereas Taxol treatment, that increased NCS-1 levels, increased InsP(3)R dependent calcium release.	Paclitaxel	114-119	neuronal calcium sensor 1	Rattus norvegicus	146-151
20801127-13	2010	In short, our study shows that Taxol impacts calcium signaling and calcium oscillations in cardiomyocytes through NCS-1 and the InsP(3)R.	Paclitaxel	31-36	neuronal calcium sensor 1	Rattus norvegicus	114-119
20600879-3	2010	In contrast, macelignan (20muM) increased the cellular accumulation of paclitaxel by approximately 1.7-fold in NCI/ADR-RES cells overexpressing P-gp, while it did not alter the cellular accumulation of paclitaxel in OVCAR-8 cells lacking P-gp.	Paclitaxel	71-81	phosphoglycolate phosphatase	Homo sapiens	144-148
20700687-6	2010	RESULTS: Drug resistance of MCF-7/5-FU cells to 5-FU, MX, cDDP, ADM, TAXOL all increased significantly compared with MCF-7 cells and that maybe related to BCRP, but not MDR1 and MRP1.	Paclitaxel	69-74	BCR pseudogene 1	Homo sapiens	155-159
20811685-10	2010	PTX combined with radiation maintained high expressions of Chk1 and MAD2 proteins for 24 h post-radiation and, in particular, MAD2 protein was strongly induced by PTX with high-dose radiation.	Paclitaxel	0-3	mitotic arrest deficient 2 like 1	Homo sapiens	68-72
20811685-10	2010	PTX combined with radiation maintained high expressions of Chk1 and MAD2 proteins for 24 h post-radiation and, in particular, MAD2 protein was strongly induced by PTX with high-dose radiation.	Paclitaxel	0-3	mitotic arrest deficient 2 like 1	Homo sapiens	126-130
20811685-10	2010	PTX combined with radiation maintained high expressions of Chk1 and MAD2 proteins for 24 h post-radiation and, in particular, MAD2 protein was strongly induced by PTX with high-dose radiation.	Paclitaxel	163-166	mitotic arrest deficient 2 like 1	Homo sapiens	68-72
20811685-10	2010	PTX combined with radiation maintained high expressions of Chk1 and MAD2 proteins for 24 h post-radiation and, in particular, MAD2 protein was strongly induced by PTX with high-dose radiation.	Paclitaxel	163-166	mitotic arrest deficient 2 like 1	Homo sapiens	126-130
20438839-0	2010	Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells.	Paclitaxel	63-73	phosphoglycolate phosphatase	Homo sapiens	54-58
20438839-7	2010	P-gp inhibition obtained with verapamil or vinblastin improved Ptx transport up to 98%.	Paclitaxel	63-66	phosphoglycolate phosphatase	Homo sapiens	0-4
20438839-10	2010	These results demonstrated an effect of P-gp on the transport of Ptx when loaded in LNCs and support a direct effect of P-gp on their endocytosis in Caco-2 cells.	Paclitaxel	65-68	phosphoglycolate phosphatase	Homo sapiens	40-44
20438839-10	2010	These results demonstrated an effect of P-gp on the transport of Ptx when loaded in LNCs and support a direct effect of P-gp on their endocytosis in Caco-2 cells.	Paclitaxel	65-68	phosphoglycolate phosphatase	Homo sapiens	120-124
20420860-8	2010	Moreover, complementation experiments in Jurkat FADD-/- T cells indicated that: a) cells expressing FADD mutants in the CaM binding sites are protected from Taxol-induced G2/M cell cycle arrest; b) FADD/CaM interaction is not required for Fas receptor-mediated apoptosis although Fas and CaM might compete for binding to FADD.	Paclitaxel	157-162	Fas associated via death domain	Homo sapiens	100-104
20420860-8	2010	Moreover, complementation experiments in Jurkat FADD-/- T cells indicated that: a) cells expressing FADD mutants in the CaM binding sites are protected from Taxol-induced G2/M cell cycle arrest; b) FADD/CaM interaction is not required for Fas receptor-mediated apoptosis although Fas and CaM might compete for binding to FADD.	Paclitaxel	157-162	Fas associated via death domain	Homo sapiens	100-104
20420860-8	2010	Moreover, complementation experiments in Jurkat FADD-/- T cells indicated that: a) cells expressing FADD mutants in the CaM binding sites are protected from Taxol-induced G2/M cell cycle arrest; b) FADD/CaM interaction is not required for Fas receptor-mediated apoptosis although Fas and CaM might compete for binding to FADD.	Paclitaxel	157-162	Fas associated via death domain	Homo sapiens	100-104
20689763-0	2010	Artemin Reduces Sensitivity to Doxorubicin and Paclitaxel in Endometrial Carcinoma Cells through Specific Regulation of CD24.	Paclitaxel	47-57	artemin	Homo sapiens	0-7
20689763-3	2010	Forced expression of ARTN in endometrial carcinoma cells decreased sensitivity to doxorubicin and paclitaxel.	Paclitaxel	98-108	artemin	Homo sapiens	21-25
20689763-4	2010	Accordingly, depletion of ARTN by small interfering RNA or functional inhibition of ARTN with antibodies significantly increased sensitivity of endometrial carcinoma cells to doxorubicin and paclitaxel.	Paclitaxel	191-201	artemin	Homo sapiens	26-30
20689763-4	2010	Accordingly, depletion of ARTN by small interfering RNA or functional inhibition of ARTN with antibodies significantly increased sensitivity of endometrial carcinoma cells to doxorubicin and paclitaxel.	Paclitaxel	191-201	artemin	Homo sapiens	84-88
20689763-5	2010	Forced expression of ARTN in endometrial carcinoma cells abrogated doxorubicin-induced G(2)-M arrest and paclitaxel-induced apoptosis.	Paclitaxel	105-115	artemin	Homo sapiens	21-25
20689763-8	2010	Depletion of CD24 in endometrial carcinoma cells abrogated ARTN-stimulated resistance to doxorubicin and paclitaxel.	Paclitaxel	105-115	artemin	Homo sapiens	59-63
20689763-9	2010	ARTN-stimulated resistance to doxorubicin and paclitaxel in endometrial carcinoma cells is therefore mediated by the specific regulation of CD24.	Paclitaxel	46-56	artemin	Homo sapiens	0-4
20434553-11	2010	Considering its unique adjuvant effect demonstrated in this study and a safe record clinically used as an antineoplastic agent, paclitaxel could be an ideal adjuvant candidate when mixed Th1/Th2 immune responses are needed.	Paclitaxel	128-138	heart and neural crest derivatives expressed 2	Mus musculus	191-194
20404007-0	2010	Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.	Paclitaxel	50-55	insulin like growth factor 2	Homo sapiens	0-28
20404007-8	2010	RESULTS: Taxol-induced AKT phosphorylation required IGF1R tyrosine kinase activity and was associated with upregulation of IGF2.	Paclitaxel	9-14	insulin like growth factor 2	Homo sapiens	123-127
20404007-11	2010	CONCLUSIONS: IGF2 modulates Taxol resistance, and tumor IGF2 expression is a candidate prognostic biomarker in epithelial ovarian tumors.	Paclitaxel	28-33	insulin like growth factor 2	Homo sapiens	13-17
20404007-13	2010	Such novel findings suggest that IGF2 represents a therapeutic target in ovarian cancer, particularly in the setting of Taxol resistance.	Paclitaxel	120-125	insulin like growth factor 2	Homo sapiens	33-37
20822025-2	2010	METHOD: Paclitaxel, one of the substrate of P-gp, was selected as the model drug.	Paclitaxel	8-18	phosphoglycolate phosphatase	Homo sapiens	44-48
20332224-0	2010	Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma.	Paclitaxel	111-121	kallikrein related peptidase 7	Homo sapiens	0-30
20332224-9	2010	Additionally, both KLK7-253 and KLK7-181 clones were more resistant to paclitaxel treatment in vitro.	Paclitaxel	71-81	kallikrein related peptidase 7	Homo sapiens	19-23
20332224-9	2010	Additionally, both KLK7-253 and KLK7-181 clones were more resistant to paclitaxel treatment in vitro.	Paclitaxel	71-81	kallikrein related peptidase 7	Homo sapiens	32-36
20150272-7	2010	Coadministration of methotrexate, paclitaxel, or doxorubicin enhanced the cytotoxicity of (111)In-NLS-trastuzumab toward 231-H2N and TrR1 cells but not toward MDA-MB-231 or TrR2 cells.	Paclitaxel	34-44	tRNA-Arg (anticodon TCT) 2-1	Homo sapiens	133-137
20150272-7	2010	Coadministration of methotrexate, paclitaxel, or doxorubicin enhanced the cytotoxicity of (111)In-NLS-trastuzumab toward 231-H2N and TrR1 cells but not toward MDA-MB-231 or TrR2 cells.	Paclitaxel	34-44	tRNA-Arg (anticodon ACG) 1-2	Homo sapiens	173-177
20150272-8	2010	The radiation-enhancement ratios for methotrexate, paclitaxel, and doxorubicin for 231-H2N or TrR1 cells were 2.0-2.2, 1.6-1.8, and 2.7-2.8, respectively.	Paclitaxel	51-61	tRNA-Arg (anticodon TCT) 2-1	Homo sapiens	94-98
19543729-3	2010	This study demonstrates alterations in gene expression levels of several ECM components, matrix metalloproteinases (MMPs), adamalysins (ADAMs and ADAMTSs) and tissue inhibitors of metalloproteinases (TIMPs) in paclitaxel, docetaxel, vincristine and doxorubicin-resistant MCF-7 cells.	Paclitaxel	210-220	matrix metallopeptidase 1	Homo sapiens	116-120
20113523-0	2010	MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.	Paclitaxel	107-112	phosphatase and tensin homolog	Homo sapiens	64-68
20113523-0	2010	MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.	Paclitaxel	107-112	phosphatase and tensin homolog	Homo sapiens	88-92
20113523-3	2010	So far, the effect of downregulating miR-21 to enhance the chemotherapeutic effect to taxol has not been studied in human GBM.	Paclitaxel	86-91	microRNA 21	Homo sapiens	37-43
20113523-6	2010	The mechanism between the miR-21 inhibitor and the anticancer drug taxol was analyzed using the Zheng-Jun Jin method.	Paclitaxel	67-72	microRNA 21	Homo sapiens	26-32
20113523-9	2010	RESULTS: IC(50) values were dramatically decreased in cells treated with miR-21 inhibitor combine with taxol, to a greater extent than those treated with taxol alone.	Paclitaxel	103-108	microRNA 21	Homo sapiens	73-79
20113523-9	2010	RESULTS: IC(50) values were dramatically decreased in cells treated with miR-21 inhibitor combine with taxol, to a greater extent than those treated with taxol alone.	Paclitaxel	154-159	microRNA 21	Homo sapiens	73-79
20113523-11	2010	Interestingly, the above data suggested that in both the PTEN mutant and the wild-type GBM cells, miR-21 blockage increased the chemosensitivity to taxol.	Paclitaxel	148-153	phosphatase and tensin homolog	Homo sapiens	57-61
20113523-11	2010	Interestingly, the above data suggested that in both the PTEN mutant and the wild-type GBM cells, miR-21 blockage increased the chemosensitivity to taxol.	Paclitaxel	148-153	microRNA 21	Homo sapiens	98-104
20113523-12	2010	It is worth noting that the miR-21 inhibitor additively interacted with taxol on U251cells and synergistically on LN229 cells.	Paclitaxel	72-77	microRNA 21	Homo sapiens	28-34
20113523-16	2010	CONCLUSIONS: Taken together, the miR-21 inhibitor could enhance the chemo-sensitivity of human glioblastoma cells to taxol.	Paclitaxel	117-122	microRNA 21	Homo sapiens	33-39
19609944-0	2010	Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1.	Paclitaxel	80-90	cyclin B1	Homo sapiens	140-149
19609944-11	2010	The data showed that the TIMP-1-based decrease in PTX-induced apoptosis was reversed by cyclin B1.	Paclitaxel	50-53	cyclin B1	Homo sapiens	88-97
19609944-12	2010	Our data indicate that TIMP-1 can protect breast cancer cells from PTX-induced apoptosis by decreasing the stability of cyclin B1.	Paclitaxel	67-70	cyclin B1	Homo sapiens	120-129
11597122-10	2001	Moreover, it blocked Taxol-induced phosphorylation of p38 and Bcl-2, and prevented a Taxol-induced change in relative mobility of the apoptosis signal-regulating kinase 1 (Ask1).	Paclitaxel	85-90	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	134-170
11597122-10	2001	Moreover, it blocked Taxol-induced phosphorylation of p38 and Bcl-2, and prevented a Taxol-induced change in relative mobility of the apoptosis signal-regulating kinase 1 (Ask1).	Paclitaxel	85-90	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	172-176
11598801-8	2001	The anti-neoplastic agent, paclitaxel, activates ASK1 and JNK, and promotes the in vitro assembly of stable microtubules.	Paclitaxel	27-37	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	49-53
11598801-9	2001	Addition of 10 nM paclitaxel sensitised the NXS2 cell line to ASK1-induced cell death.	Paclitaxel	18-28	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	62-66
11598801-10	2001	Our results indicate that ASK1 induces apoptosis in neuroblastoma cells mainly via the p38 MAPK pathway, and resistant neuroblastoma cells can be sensitised to ASK1 by paclitaxel.	Paclitaxel	168-178	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	160-164
11593424-7	2001	Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells.	Paclitaxel	80-90	interferon alpha inducible protein 27	Homo sapiens	39-42
11593424-7	2001	Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells.	Paclitaxel	80-90	cyclin dependent kinase inhibitor 1B	Homo sapiens	43-47
11593424-7	2001	Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells.	Paclitaxel	80-90	choline kinase alpha	Homo sapiens	134-137
11593424-7	2001	Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells.	Paclitaxel	80-90	choline kinase alpha	Homo sapiens	175-178
11549769-8	2001	In immunofluorescence microscopy of intact tobacco BY-2 cells or lysed protoplasts, p90 colocalized with cortical microtubules, and taxol-induced microtubule bundling was accompanied by corresponding reorganization of p90.	Paclitaxel	132-137	F-box protein PP2-B11-like	Nicotiana tabacum	51-55
11489796-12	2001	The addition of 17-AAG to cells after exposure to Taxol significantly increased both the activation of caspases 9 and 3 and apoptosis.	Paclitaxel	50-55	caspase 9	Homo sapiens	103-119
11489808-0	2001	Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.	Paclitaxel	26-36	colony stimulating factor 3	Homo sapiens	42-79
11573250-4	2001	However, Taxol, a popular microtubule stabilizing agent that is frequently used in the study of these processes, severely disrupted the localization of Survivin.	Paclitaxel	9-14	Deterin	Drosophila melanogaster	152-160
11573250-5	2001	Taxol treatment of cells promoted extensive relocalization of Survivin with alpha-tubulin on microtubules during either interphase or mitosis.	Paclitaxel	0-5	Deterin	Drosophila melanogaster	62-70
11490342-6	2001	I kappa B-DN--transfection alone, or with TNF, doxorubicin, or paclitaxel treatments resulted in cell death of both APO- and APO+ cells as compared with vector-control; however, greater cytotoxicity was seen in the APO+ cells.	Paclitaxel	63-73	aminopeptidase O (putative)	Homo sapiens	116-119
11490342-6	2001	I kappa B-DN--transfection alone, or with TNF, doxorubicin, or paclitaxel treatments resulted in cell death of both APO- and APO+ cells as compared with vector-control; however, greater cytotoxicity was seen in the APO+ cells.	Paclitaxel	63-73	aminopeptidase O (putative)	Homo sapiens	125-128
11490342-6	2001	I kappa B-DN--transfection alone, or with TNF, doxorubicin, or paclitaxel treatments resulted in cell death of both APO- and APO+ cells as compared with vector-control; however, greater cytotoxicity was seen in the APO+ cells.	Paclitaxel	63-73	aminopeptidase O (putative)	Homo sapiens	125-128
11325840-0	2001	Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.	Paclitaxel	35-45	erb-b2 receptor tyrosine kinase 2	Mus musculus	169-178
11325840-6	2001	We found that cyclophosphamide, paclitaxel, and doxorubicin, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhanced the vaccine"s potential to delay tumor growth in neu transgenic mice.	Paclitaxel	32-42	erb-b2 receptor tyrosine kinase 2	Mus musculus	119-122
11325840-6	2001	We found that cyclophosphamide, paclitaxel, and doxorubicin, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhanced the vaccine"s potential to delay tumor growth in neu transgenic mice.	Paclitaxel	32-42	erb-b2 receptor tyrosine kinase 2	Mus musculus	212-215
11325840-8	2001	Furthermore, paclitaxel and cyclophosphamide appear to amplify the T helper 1 neu-specific T-cell response.	Paclitaxel	13-23	erb-b2 receptor tyrosine kinase 2	Mus musculus	78-81
11345135-6	2001	Taxol sensitized PANC1 and HPAC cells to CD95-mediated apoptosis without surface up-regulation of CD95R.	Paclitaxel	0-5	Fas cell surface death receptor	Homo sapiens	41-45
11181174-6	2001	These studies also showed that inhibition of stathmin expression results in increased susceptibility of K562 leukemic cells to the pharmacological agents, like taxol, which are known to stabilize the mitotic spindle.	Paclitaxel	160-165	stathmin 1	Homo sapiens	45-53
11179455-13	2001	All our data demonstrate that the caspase-mediated cleavage of beta-catenin, gamma-catenin, and APC protein might contribute to paclitaxel-induced apoptosis.	Paclitaxel	128-138	catenin beta 1	Homo sapiens	63-75
11181665-12	2001	CONCLUSION: The combination of paclitaxel, doxorubicin, and cisplatin at relevant single-agent doses is active and feasible with the addition of G-CSF.	Paclitaxel	31-41	colony stimulating factor 3	Homo sapiens	145-150
11170175-2	2001	We have previously shown that abnormal tau phosphorylation was induced in neuroblastoma SK-N-SH cells by the anticancer drug, paclitaxel, during apoptosis [Guise et al., 1999: Apoptosis 4:47-58].	Paclitaxel	126-136	microtubule associated protein tau	Homo sapiens	39-42
11170175-3	2001	In the present study, we first demonstrated a shift from fetal tau to hyperphosphorylated tau after incubation with paclitaxel, that showed some similarities with the hyperphosphorylated tau in AD, by using several tau antibodies, N-Term, Tau-1 and AT-8.	Paclitaxel	116-126	microtubule associated protein tau	Homo sapiens	63-66
11170175-3	2001	In the present study, we first demonstrated a shift from fetal tau to hyperphosphorylated tau after incubation with paclitaxel, that showed some similarities with the hyperphosphorylated tau in AD, by using several tau antibodies, N-Term, Tau-1 and AT-8.	Paclitaxel	116-126	microtubule associated protein tau	Homo sapiens	90-93
11170175-3	2001	In the present study, we first demonstrated a shift from fetal tau to hyperphosphorylated tau after incubation with paclitaxel, that showed some similarities with the hyperphosphorylated tau in AD, by using several tau antibodies, N-Term, Tau-1 and AT-8.	Paclitaxel	116-126	microtubule associated protein tau	Homo sapiens	90-93
11170175-3	2001	In the present study, we first demonstrated a shift from fetal tau to hyperphosphorylated tau after incubation with paclitaxel, that showed some similarities with the hyperphosphorylated tau in AD, by using several tau antibodies, N-Term, Tau-1 and AT-8.	Paclitaxel	116-126	microtubule associated protein tau	Homo sapiens	90-93
11170175-5	2001	We next showed that a sustained activation of ERK (extracellular signal-regulated kinase) induced both tau phosphorylation and apoptosis during paclitaxel treatment (1 microM).	Paclitaxel	144-154	microtubule associated protein tau	Homo sapiens	103-106
11165410-3	2001	After modification of the dosing schedule, the MTD of paclitaxel was found to be 115 mg/m(2) when combined with vinorelbine 20 mg/m(2) on day 1, followed by vinorelbine 20 mg/m(2) on day 5.	Paclitaxel	54-64	metallothionein 1E	Homo sapiens	47-50
11160861-3	2001	Overexpression of a dominant-negative mutant, mitogen-activated protein kinase kinase 1 (MEKK1-DN) or treatment with JNK-specific antisense oligonucleotide prevented paclitaxel-induced JNK activation, Bcl-2 phosphorylation and apoptosis.	Paclitaxel	166-176	mitogen-activated protein kinase kinase 1	Homo sapiens	46-87
11212279-9	2001	These findings indicate that up-regulation of DR4 and DR5 protein levels by treatment with paclitaxel enhances subsequent Apo-2L/TRAIL-induced apoptosis of human prostate cancer cells.	Paclitaxel	91-101	TNF receptor superfamily member 10b	Homo sapiens	54-57
11201384-6	2001	Even though the patient exhibited bone marrow suppression and G-CSF was administered twice for neutropenia, there were no adverse effects except mild alopecia, again suggesting the possibility that paclitaxel is effective chemotherapy for recurrent breast cancer.	Paclitaxel	198-208	colony stimulating factor 3	Homo sapiens	62-67
12065068-24	2001	In first-line treatment, vinorelbine, gemcitabine, and the lower-dose paclitaxel plus cisplatin combinations generally performed well against BSC under a range of different scenarios and especially when given as a maximum of 3 cycles.	Paclitaxel	70-80	solute carrier family 12 member 2	Homo sapiens	142-145
11581576-0	2001	Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by Taxol.	Paclitaxel	103-108	lymphocyte antigen 96	Mus musculus	20-24
11156413-11	2000	MidT2-1 tumor model p53 gene therapy enhanced the survival benefits of paclitaxel/cisplatin chemotherapy.	Paclitaxel	71-81	transformation related protein 53, pseudogene	Mus musculus	20-23
11077039-4	2000	By using both enzymatic assay and immunoblot detection of cleaved fragments, we showed that caspase-8, a central component of the CD95-induced apoptotic pathway, was significantly activated during paclitaxel exposure, contemporary to apoptosis occurrence.	Paclitaxel	197-207	Fas cell surface death receptor	Homo sapiens	130-134
10956385-0	2000	Up-regulation of cdc2 protein during paclitaxel-induced apoptosis.	Paclitaxel	37-47	cyclin dependent kinase 1	Homo sapiens	17-21
10956385-1	2000	Microtubule damages induced by paclitaxel inhibit proteasome-dependent degradation of cyclin B, resulting in a sustained activation of cyclin B/cdc2 kinase and a cell cycle arrest in mitosis.	Paclitaxel	31-41	cyclin dependent kinase 1	Homo sapiens	144-148
10956385-3	2000	We found here that paclitaxel increased cdc2 mRNA and protein levels and led to an accumulation of cdc2 in the active dephosphorylated form in NIH-OVCAR-3 cells.	Paclitaxel	19-29	cyclin dependent kinase 1	Homo sapiens	40-44
10956385-3	2000	We found here that paclitaxel increased cdc2 mRNA and protein levels and led to an accumulation of cdc2 in the active dephosphorylated form in NIH-OVCAR-3 cells.	Paclitaxel	19-29	cyclin dependent kinase 1	Homo sapiens	99-103
10956385-4	2000	The addition of cycloheximide inhibited the paclitaxel-induced increase in cdc2 protein level, further indicating that paclitaxel stimulates cdc2 synthesis.	Paclitaxel	44-54	cyclin dependent kinase 1	Homo sapiens	75-79
10956385-4	2000	The addition of cycloheximide inhibited the paclitaxel-induced increase in cdc2 protein level, further indicating that paclitaxel stimulates cdc2 synthesis.	Paclitaxel	44-54	cyclin dependent kinase 1	Homo sapiens	141-145
10956385-4	2000	The addition of cycloheximide inhibited the paclitaxel-induced increase in cdc2 protein level, further indicating that paclitaxel stimulates cdc2 synthesis.	Paclitaxel	119-129	cyclin dependent kinase 1	Homo sapiens	75-79
10956385-4	2000	The addition of cycloheximide inhibited the paclitaxel-induced increase in cdc2 protein level, further indicating that paclitaxel stimulates cdc2 synthesis.	Paclitaxel	119-129	cyclin dependent kinase 1	Homo sapiens	141-145
10956385-5	2000	This increase in cdc2 synthesis is a consequence of paclitaxel-induced arrest in mitosis.	Paclitaxel	52-62	cyclin dependent kinase 1	Homo sapiens	17-21
10956385-8	2000	In addition, when paclitaxel-induced apoptosis was inhibited by Bcl-2 over-expression, cdc2 up-regulation did not occur, leading to a lower level of activation of the cyclin B/cdc2 complex.	Paclitaxel	18-28	cyclin dependent kinase 1	Homo sapiens	87-91
10956385-8	2000	In addition, when paclitaxel-induced apoptosis was inhibited by Bcl-2 over-expression, cdc2 up-regulation did not occur, leading to a lower level of activation of the cyclin B/cdc2 complex.	Paclitaxel	18-28	cyclin dependent kinase 1	Homo sapiens	176-180
10956385-9	2000	Taken together, these results indicated that paclitaxel-induced cdc2 protein synthesis participates in a positive feedback loop designed to increase the activity of cyclin B/cdc2 kinase and thus may play a role in paclitaxel-induced apoptosis.	Paclitaxel	45-55	cyclin dependent kinase 1	Homo sapiens	64-68
10956385-9	2000	Taken together, these results indicated that paclitaxel-induced cdc2 protein synthesis participates in a positive feedback loop designed to increase the activity of cyclin B/cdc2 kinase and thus may play a role in paclitaxel-induced apoptosis.	Paclitaxel	45-55	cyclin dependent kinase 1	Homo sapiens	174-178
10956385-9	2000	Taken together, these results indicated that paclitaxel-induced cdc2 protein synthesis participates in a positive feedback loop designed to increase the activity of cyclin B/cdc2 kinase and thus may play a role in paclitaxel-induced apoptosis.	Paclitaxel	214-224	cyclin dependent kinase 1	Homo sapiens	64-68
10956385-9	2000	Taken together, these results indicated that paclitaxel-induced cdc2 protein synthesis participates in a positive feedback loop designed to increase the activity of cyclin B/cdc2 kinase and thus may play a role in paclitaxel-induced apoptosis.	Paclitaxel	214-224	cyclin dependent kinase 1	Homo sapiens	174-178
10996845-0	2000	Taxol reduces cytosolic E-cadherin and beta-catenin levels in nasopharyngeal carcinoma cell line TW-039: cross-talk between the microtubule- and actin-based cytoskeletons.	Paclitaxel	0-5	catenin beta 1	Homo sapiens	39-51
10996845-6	2000	These results suggest that modulation of microtubule dynamics by Taxol may have effects on the expression of actin and the cytosolic E-cadherin and beta-catenin in nasopharyngeal carcinoma cells through pathways not involving the phosphorylation of beta-catenin.	Paclitaxel	65-70	catenin beta 1	Homo sapiens	148-160
10996845-6	2000	These results suggest that modulation of microtubule dynamics by Taxol may have effects on the expression of actin and the cytosolic E-cadherin and beta-catenin in nasopharyngeal carcinoma cells through pathways not involving the phosphorylation of beta-catenin.	Paclitaxel	65-70	catenin beta 1	Homo sapiens	249-261
11079171-6	2000	Paclitaxel, 200 to 250 mg/m2, was given by 24-hour infusion on day 1, followed by cisplatin, 75 mg/m2, on day 2, with granulocyte colony stimulating factor support.	Paclitaxel	0-10	colony stimulating factor 3	Homo sapiens	118-155
11016746-0	2000	Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer.	Paclitaxel	21-31	colony stimulating factor 3	Homo sapiens	59-64
11225845-0	2000	Activation of MAD 2 checkprotein and persistence of cyclin B1/CDC 2 activity associate with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells.	Paclitaxel	92-102	mitotic arrest deficient 2 like 1	Homo sapiens	14-19
11225845-0	2000	Activation of MAD 2 checkprotein and persistence of cyclin B1/CDC 2 activity associate with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells.	Paclitaxel	92-102	cyclin B1	Homo sapiens	52-61
11225845-0	2000	Activation of MAD 2 checkprotein and persistence of cyclin B1/CDC 2 activity associate with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells.	Paclitaxel	92-102	cyclin dependent kinase 1	Homo sapiens	62-67
11225845-2	2000	In this study, we intended to explore the underlying molecular events and found that cellular cyclin B1/CDC 2 kinase activity was increased and persisted for &gt;6 h upon paclitaxel treatment both at high and low concentrations.	Paclitaxel	171-181	cyclin B1	Homo sapiens	94-103
11225845-2	2000	In this study, we intended to explore the underlying molecular events and found that cellular cyclin B1/CDC 2 kinase activity was increased and persisted for &gt;6 h upon paclitaxel treatment both at high and low concentrations.	Paclitaxel	171-181	cyclin dependent kinase 1	Homo sapiens	104-109
11225845-5	2000	The antibodies against cyclin B1 and MAD 2 indeed attenuated paclitaxel-induced cytotoxicity and DNA fragmentation.	Paclitaxel	61-71	cyclin B1	Homo sapiens	23-32
11225845-5	2000	The antibodies against cyclin B1 and MAD 2 indeed attenuated paclitaxel-induced cytotoxicity and DNA fragmentation.	Paclitaxel	61-71	mitotic arrest deficient 2 like 1	Homo sapiens	37-42
11225845-6	2000	Our study suggests that activation of cyclin B1/CDC 2 and MAD 2 were the M-phase events required for paclitaxel-induced apoptosis in NPC cells.	Paclitaxel	101-111	cyclin B1	Homo sapiens	38-47
11225845-6	2000	Our study suggests that activation of cyclin B1/CDC 2 and MAD 2 were the M-phase events required for paclitaxel-induced apoptosis in NPC cells.	Paclitaxel	101-111	cyclin dependent kinase 1	Homo sapiens	48-53
11225845-6	2000	Our study suggests that activation of cyclin B1/CDC 2 and MAD 2 were the M-phase events required for paclitaxel-induced apoptosis in NPC cells.	Paclitaxel	101-111	mitotic arrest deficient 2 like 1	Homo sapiens	58-63
10864197-0	2000	Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer.	Paclitaxel	26-36	colony stimulating factor 3	Homo sapiens	42-47
10644670-0	2000	Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol.	Paclitaxel	99-104	lymphocyte antigen 96	Mus musculus	27-31
10644670-5	2000	To determine whether TLR4.MD-2 complex mediates a Taxol-induced signal, we constructed transformants of the mouse pro-B cell line, Ba/F3, expressing mouse TLR4 alone, both mouse TLR4 and mouse MD-2, and both mouse MD-2 and mouse TLR4 lacking the cytoplasmic portion, and then examined whether Taxol induced NFkappaB activation in these transfectants.	Paclitaxel	50-55	lymphocyte antigen 96	Mus musculus	26-30
11021743-8	2000	paclitaxel, which produced a maximum 2.4 LCK.	Paclitaxel	0-10	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	41-44
10656451-4	2000	In the present work, the involvement of the Fas/FasL system in drug-induced apoptosis in lung cancer cells was investigated upon exposure to four cytotoxic drugs (cisplatin, gemcitabine, topotecan, and paclitaxel).	Paclitaxel	202-212	Fas ligand	Homo sapiens	48-52
10567879-4	1999	Characteristic features of Taxol- and doxorubicin-induced apoptosis were evidenced by the Annexin-V binding assay, TUNEL and DAPI staining.	Paclitaxel	27-32	annexin A5	Homo sapiens	90-99
10604265-4	1999	Of several agents recently shown to reduce prostate-specific antigen levels in phase II studies, 13-cis-retinoic acid and interferon-alpha can reduce the expression of bcl-2 and overcome bcl-2-mediated resistance to paclitaxel in resistant cell lines.	Paclitaxel	216-226	kallikrein related peptidase 3	Homo sapiens	43-68
10424768-7	1999	p53 and p21 protein content also increased markedly during paclitaxel exposure, accompanied by phosphorylation of Bcl-2.	Paclitaxel	59-69	H3 histone pseudogene 16	Homo sapiens	8-11
10432288-4	1999	Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis.	Paclitaxel	0-10	Fas ligand	Homo sapiens	81-91
10432288-4	1999	Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis.	Paclitaxel	0-10	Fas ligand	Homo sapiens	93-97
10432288-4	1999	Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis.	Paclitaxel	0-10	Fas ligand	Homo sapiens	129-133
10432288-4	1999	Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis.	Paclitaxel	143-153	Fas ligand	Homo sapiens	93-97
10432288-4	1999	Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis.	Paclitaxel	143-153	Fas ligand	Homo sapiens	129-133
10432288-5	1999	We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis.	Paclitaxel	81-91	Fas ligand	Homo sapiens	115-119
10432288-8	1999	Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill cells at least in part through the induction of FasL.	Paclitaxel	22-32	Fas ligand	Homo sapiens	136-140
10561276-12	1999	CONCLUSION: Multiple cycles of high-dose carboplatin (AUC 16) and paclitaxel (250 mg/m(2)) can be safely administered with GM-CSF and PBSC support.	Paclitaxel	66-76	colony stimulating factor 2	Homo sapiens	123-129
10321832-7	1999	However, ECM prevented p21 and Bcl-2 down-regulation induced by taxol or etoposide.	Paclitaxel	64-69	H3 histone pseudogene 16	Homo sapiens	23-26
10336499-3	1999	To evaluate the mechanism of EGF-induced apoptosis, MDA-MB-468 breast cancer cells were examined by microscopy, flow cytometry, immunoblotting, enzyme assays, and affinity labeling after treatment with EGF, paclitaxel, or 5-fluoro-2"-deoxyuridine (5FUdR).	Paclitaxel	207-217	epidermal growth factor	Homo sapiens	29-32
10336499-6	1999	Interestingly, caspase activation was consistently lower after EGF treatment than after paclitaxel or 5FUdR treatment.	Paclitaxel	88-98	caspase 6	Homo sapiens	15-22
10085260-8	1999	(3) A GST-P23 fusion protein interacts with alpha- and beta-tubulin, and recombinant P23 binds to taxol-stabilised microtubules in vitro.	Paclitaxel	98-103	tumor protein, translationally-controlled 1	Homo sapiens	85-88
10230460-18	1999	High intrinsic alpha components of the tumor cells as well as CEL/eth"s antagonizing actions could be likely to disturb and influence paclitaxel"s abilities leading to radiosensitization.	Paclitaxel	134-144	carboxyl ester lipase	Homo sapiens	62-65
10022911-7	1999	Analysis of Op18-mediated regulation of tubulin GTPase activity and taxol-promoted tubulin polymerization showed that while wild-type and Glu-substituted Op18 derivatives are active, the coiled-coil mutants are essentially inactive.	Paclitaxel	68-73	stathmin 1	Homo sapiens	154-158
10021296-8	1999	Only PKC-alpha and PKC-gamma expression increased with increasing indices of paclitaxel resistance.	Paclitaxel	77-87	protein kinase C gamma	Homo sapiens	19-28
10021296-9	1999	Interestingly, PMA induction of PKC activity reversed resistance to paclitaxel in all cell lines by 2- to 3-fold, and this reversal of drug resistance was associated with a time-dependent translocation of PKC-alpha and PKC-gamma to the plasma membrane compartment.	Paclitaxel	68-78	protein kinase C gamma	Homo sapiens	219-228
10021296-10	1999	CONCLUSIONS: Increased expression of only the PKC-alpha and PKC-gamma isoforms correlates with increasing levels of paclitaxel resistance in Mes-sa cells in this in vitro experimental model.	Paclitaxel	116-126	protein kinase C gamma	Homo sapiens	60-69
9844922-3	1998	Taxol-induced G2/M transition is mediated by p34(cdc-2) (CDK1) which, if prematurely activated, may also trigger apoptosis.	Paclitaxel	0-5	cyclin dependent kinase 1	Homo sapiens	49-54
9844922-3	1998	Taxol-induced G2/M transition is mediated by p34(cdc-2) (CDK1) which, if prematurely activated, may also trigger apoptosis.	Paclitaxel	0-5	cyclin dependent kinase 1	Homo sapiens	57-61
9844922-7	1998	Data presented here show that, while Taxol-induced peak CDK1 kinase activity occurs earlier in HL-60/neo cells, there are no significant differences in cyclin B1 accumulation, tyrosine dephosphorylation of CDK1, and mitotic arrest of Taxol-treated HL-60/neo vs HL-60/Bcl-xL cells.	Paclitaxel	37-42	cyclin dependent kinase 1	Homo sapiens	56-60
9844922-8	1998	Taxol-induced CDK1 activation and mitosis preceded the cytosolic accumulation (approximately six-fold) of cyt c.	Paclitaxel	0-5	cyclin dependent kinase 1	Homo sapiens	14-18
9813091-3	1998	Distinct from all other MAPs, the MAP1B light chain-induced formation of stable but apparently flexible microtubules resistant to the effects of nocodazole and taxol.	Paclitaxel	160-165	microtubule associated protein 1B	Homo sapiens	34-39
20654451-6	1998	We also demonstrate that isolated EAF hepatocytes do not respond to TGFalpha and that four different p53-inducing agents, namely DEN, taxol, doxorubicin and araC readily induce p53 in non-EAF, but not in EAF hepatocytes.	Paclitaxel	134-139	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	101-104
20654451-6	1998	We also demonstrate that isolated EAF hepatocytes do not respond to TGFalpha and that four different p53-inducing agents, namely DEN, taxol, doxorubicin and araC readily induce p53 in non-EAF, but not in EAF hepatocytes.	Paclitaxel	134-139	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	177-180
9858906-7	1998	In addition, growth inhibition by Paclitaxel was accompanied by an increase in the expression of proliferating cell nuclear antigen (PCNA) in hepatoma cells.	Paclitaxel	34-44	proliferating cell nuclear antigen	Homo sapiens	97-131
9858906-7	1998	In addition, growth inhibition by Paclitaxel was accompanied by an increase in the expression of proliferating cell nuclear antigen (PCNA) in hepatoma cells.	Paclitaxel	34-44	proliferating cell nuclear antigen	Homo sapiens	133-137
9873518-0	1998	Synthesis of a paclitaxel isomer: C-2-acetoxy-C-4-benzoate paclitaxel.	Paclitaxel	15-25	complement C2	Homo sapiens	34-37
9873518-0	1998	Synthesis of a paclitaxel isomer: C-2-acetoxy-C-4-benzoate paclitaxel.	Paclitaxel	15-25	complement C4A (Rodgers blood group)	Homo sapiens	46-49
9873518-0	1998	Synthesis of a paclitaxel isomer: C-2-acetoxy-C-4-benzoate paclitaxel.	Paclitaxel	59-69	complement C2	Homo sapiens	34-37
9873518-0	1998	Synthesis of a paclitaxel isomer: C-2-acetoxy-C-4-benzoate paclitaxel.	Paclitaxel	59-69	complement C4A (Rodgers blood group)	Homo sapiens	46-49
9873518-1	1998	A synthesis of the C-2-acetoxy-C-4-benzoate paclitaxel 2 is described.	Paclitaxel	44-54	complement C2	Homo sapiens	19-22
9873518-1	1998	A synthesis of the C-2-acetoxy-C-4-benzoate paclitaxel 2 is described.	Paclitaxel	44-54	complement C4A (Rodgers blood group)	Homo sapiens	31-34
9842986-7	1998	Paclitaxel (10 microM) was incubated with human liver microsomes (1 mg protein, -0.34 nmol CYP) in the presence of a NADPH generating system at 37 degrees C for 1 h, with and without the presence of interacting drug.	Paclitaxel	0-10	peptidylprolyl isomerase G	Homo sapiens	91-94
9626789-1	1998	The authors evaluated the novel chemotherapeutic regimen of paclitaxel (Taxol, Bristol-Myers Squibb, Princeton, NJ, U.S.A.) plus doxorubicin plus filgrastim--a granulocyte colony-stimulating factor (G-CSF)--in advanced or metastatic sarcoma.	Paclitaxel	60-70	colony stimulating factor 3	Homo sapiens	160-197
6120766-0	1981	Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor.	Paclitaxel	29-34	epidermal growth factor	Mus musculus	91-114
6120766-3	1981	Pretreatment of quiescent cultures of mouse embryo cells with 10 microgram/ml taxol inhibited up to 60% of the thrombin-stimulated and 47% of the EGF-stimulated DNA synthesis.	Paclitaxel	78-83	epidermal growth factor	Mus musculus	146-149
6120766-11	1981	These results confirm that taxol was not nonspecifically affecting transport or metabolism required for DNA synthesis and indicate that thrombin and EGF may initiate cell proliferation through a gradual microtubule depolymerization or rearrangement that is necessary to commit cells to a replicative cycle.	Paclitaxel	27-32	epidermal growth factor	Mus musculus	149-152
6116716-0	1981	Taxol induces postmitotic myoblasts to assemble interdigitating microtubule-myosin arrays that exclude actin filaments.	Paclitaxel	0-5	myosin heavy chain 14	Homo sapiens	76-82
34056794-10	2021	All these PTX-induced changes were prevented by the Nec-1 treatment.	Paclitaxel	10-13	proprotein convertase subtilisin/kexin type 1	Rattus norvegicus	52-57
34046939-0	2021	CircMYBL2 regulates the resistance of cervical cancer cells to paclitaxel via miR-665-dependent regulation of EGFR.	Paclitaxel	63-73	MYB proto-oncogene like 2	Homo sapiens	0-9
34046939-0	2021	CircMYBL2 regulates the resistance of cervical cancer cells to paclitaxel via miR-665-dependent regulation of EGFR.	Paclitaxel	63-73	microRNA 665	Homo sapiens	78-85
34046939-2	2021	This study aims to investigate the function and mechanism of circMYBL2 in paclitaxel (PTX) resistance of cervical cancer (CC).	Paclitaxel	74-84	MYB proto-oncogene like 2	Homo sapiens	61-70
34046939-2	2021	This study aims to investigate the function and mechanism of circMYBL2 in paclitaxel (PTX) resistance of cervical cancer (CC).	Paclitaxel	86-89	MYB proto-oncogene like 2	Homo sapiens	61-70
34046939-10	2021	Mechanistically, circMYBL2 could inhibit the PTX sensitivity and promote cell malignant behaviors in PTX-sensitive and PTX-resistant CC cells via upregulating EGFR mediated by miR-665.	Paclitaxel	45-48	MYB proto-oncogene like 2	Homo sapiens	17-26
34046939-10	2021	Mechanistically, circMYBL2 could inhibit the PTX sensitivity and promote cell malignant behaviors in PTX-sensitive and PTX-resistant CC cells via upregulating EGFR mediated by miR-665.	Paclitaxel	101-104	MYB proto-oncogene like 2	Homo sapiens	17-26
34046939-10	2021	Mechanistically, circMYBL2 could inhibit the PTX sensitivity and promote cell malignant behaviors in PTX-sensitive and PTX-resistant CC cells via upregulating EGFR mediated by miR-665.	Paclitaxel	101-104	MYB proto-oncogene like 2	Homo sapiens	17-26
33985619-5	2022	Paclitaxel-triggered necroptosis in lung adenocarcinoma cells was dependent on the phosphorylation or deficiency of Caspase-8, during which FADD interacted with RIPK1 to activateRIPK1/RIPK3/MLKL signaling axis.	Paclitaxel	0-10	Fas associated via death domain	Homo sapiens	140-144
33985619-5	2022	Paclitaxel-triggered necroptosis in lung adenocarcinoma cells was dependent on the phosphorylation or deficiency of Caspase-8, during which FADD interacted with RIPK1 to activateRIPK1/RIPK3/MLKL signaling axis.	Paclitaxel	0-10	receptor interacting serine/threonine kinase 1	Homo sapiens	161-166
33939252-12	2021	Thus, these findings highlight the antitumour impact of simultaneous suppression of c-Met and VEGFR2 signalling in GAC and its potential to enhance nanoparticle paclitaxel response.	Paclitaxel	161-171	met proto-oncogene	Mus musculus	84-89
33610731-7	2021	Additionally, chemo-sensitizing effects of paclitaxel were restored by exogenous WT p53 in lung cancer cells.	Paclitaxel	43-53	transformation related protein 53, pseudogene	Mus musculus	84-87
33893626-0	2021	Propofol enhanced the cell sensitivity to paclitaxel (PTX) in prostatic cancer (PC) through modulation of HOTAIR.	Paclitaxel	42-52	HOX transcript antisense RNA	Homo sapiens	106-112
33893626-0	2021	Propofol enhanced the cell sensitivity to paclitaxel (PTX) in prostatic cancer (PC) through modulation of HOTAIR.	Paclitaxel	54-57	HOX transcript antisense RNA	Homo sapiens	106-112
33893626-10	2021	Furthermore, E-cadherin protein concentration increased while N-cadherin and Vimentin decreased due to increasing PTX treatments.	Paclitaxel	114-117	vimentin	Homo sapiens	77-85
33893626-11	2021	HOTAIR expression dropped due to PTX treatment while overexpression of HOTAIR induced cell viability, EMT and deterred apoptosis.	Paclitaxel	33-36	HOX transcript antisense RNA	Homo sapiens	0-6
33896831-9	2021	CONCLUSIONS: Our results first revealed that TPM3, EFHD2, KRT19 and vimentin were novel autoantibodies in the ascites of relapsed PTX-resistant GC patients.	Paclitaxel	130-133	vimentin	Homo sapiens	68-76
33912169-6	2021	We found that systemically administered paclitaxel induces pain-like behaviors in both sexes, increases helper T-lymphocytes, downregulates cytotoxic T-lymphocytes, and increases mitochondrial dysfunction in dorsal root ganglia neurons; all of which is eIF4E-dependent in both sexes.	Paclitaxel	40-50	eukaryotic translation initiation factor 4E	Mus musculus	253-258
33912169-7	2021	We identified a robust paclitaxel-induced, eIF4E-dependent increase in spinal astrocyte immunoreactivity in males, but not females.	Paclitaxel	23-33	eukaryotic translation initiation factor 4E	Mus musculus	43-48
33611186-3	2021	More importantly, the valine was introduced in PTX-SS-Val molecule and made the molecule conform to the structural characteristics of intestinal oligopeptide transporter PEPT1 substrate.	Paclitaxel	47-50	solute carrier family 15 member 1	Rattus norvegicus	170-175
33797754-8	2021	Notably, treating with the beta-catenin/CBP inhibitor PRI-724 induced an enhancement of chemotherapeutic response of paclitaxel in BOP1-overexpressing TNBC cells.	Paclitaxel	117-127	catenin beta 1	Homo sapiens	27-39
33556340-6	2021	Furthermore, expression of AR and IL-6 is downregulated in TLR4-knockdown, taxol-resistant cells.	Paclitaxel	75-80	toll like receptor 4	Homo sapiens	59-63
33556340-8	2021	On the other hand, nuclear translocation of AR is induced by IL-6 treatment, whereas knockdown of endogenous IL-6 reduces AR and TLR4 expression in taxol-resistant ovarian cancer cells.	Paclitaxel	148-153	toll like receptor 4	Homo sapiens	129-133
33556340-12	2021	Overall, our findings indicate that the TLR4/IL-6/IRF1 signaling axis represents a potential therapeutic target to overcome AR-based taxol resistance in ovarian cancer.	Paclitaxel	133-138	toll like receptor 4	Homo sapiens	40-44
33931981-0	2021	Positive regulation of PFKFB3 by PIM2 promotes glycolysis and paclitaxel resistance in breast cancer.	Paclitaxel	62-72	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	23-29
33931981-0	2021	Positive regulation of PFKFB3 by PIM2 promotes glycolysis and paclitaxel resistance in breast cancer.	Paclitaxel	62-72	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	33-37
33931981-11	2021	Importantly, phosphorylation of PFKFB3 at Ser478 promoted glycolysis, BC cell growth, and paclitaxel resistance together with PIM2 in vitro and in vivo.	Paclitaxel	90-100	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	32-38
33931981-12	2021	CONCLUSION: Our study demonstrates that PIM2 mediates PFKFB3 phosphorylation thus regulates glycolysis and paclitaxel resistance to promote tumor progression in BC and provides preclinical evidence for targeting PFKFB3 as a new strategy in BC treatment to battle paclitaxel resistance.	Paclitaxel	107-117	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	40-44
33931981-12	2021	CONCLUSION: Our study demonstrates that PIM2 mediates PFKFB3 phosphorylation thus regulates glycolysis and paclitaxel resistance to promote tumor progression in BC and provides preclinical evidence for targeting PFKFB3 as a new strategy in BC treatment to battle paclitaxel resistance.	Paclitaxel	107-117	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	54-60
33931981-12	2021	CONCLUSION: Our study demonstrates that PIM2 mediates PFKFB3 phosphorylation thus regulates glycolysis and paclitaxel resistance to promote tumor progression in BC and provides preclinical evidence for targeting PFKFB3 as a new strategy in BC treatment to battle paclitaxel resistance.	Paclitaxel	263-273	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	40-44
33717236-3	2021	The aim of the present study was to investigate the role of IL-1beta in paclitaxel sensitivity of NSCLC cells and elucidate the underlying mechanism.	Paclitaxel	72-82	interleukin 1 alpha	Homo sapiens	60-68
33717236-5	2021	Subsequently, Cell Counting Kit-8 assay and flow cytometry revealed that IL-1beta weakened the sensitivity of A549 cells to paclitaxel.	Paclitaxel	124-134	interleukin 1 alpha	Homo sapiens	73-81
33717236-7	2021	Thus, the results revealed that IL-1beta reduced the sensitivity to paclitaxel in A549 cells by promoting autophagy and suggested that IL-1beta may be of value for improving the therapeutic efficacy of paclitaxel chemotherapy in NSCLC.	Paclitaxel	68-78	interleukin 1 alpha	Homo sapiens	32-40
33717236-7	2021	Thus, the results revealed that IL-1beta reduced the sensitivity to paclitaxel in A549 cells by promoting autophagy and suggested that IL-1beta may be of value for improving the therapeutic efficacy of paclitaxel chemotherapy in NSCLC.	Paclitaxel	68-78	interleukin 1 alpha	Homo sapiens	135-143
33717236-7	2021	Thus, the results revealed that IL-1beta reduced the sensitivity to paclitaxel in A549 cells by promoting autophagy and suggested that IL-1beta may be of value for improving the therapeutic efficacy of paclitaxel chemotherapy in NSCLC.	Paclitaxel	202-212	interleukin 1 alpha	Homo sapiens	32-40
33717236-7	2021	Thus, the results revealed that IL-1beta reduced the sensitivity to paclitaxel in A549 cells by promoting autophagy and suggested that IL-1beta may be of value for improving the therapeutic efficacy of paclitaxel chemotherapy in NSCLC.	Paclitaxel	202-212	interleukin 1 alpha	Homo sapiens	135-143
33867704-0	2021	Amelioration of Combination of Paclitaxel and Di Allyl Sulfide on the Alterations of Bcl2, P53 and Apoptosis Changes Against 7,12 Di Methyl Benz (A) Anthracene Induced Skin Cancer in Experimental Animals.	Paclitaxel	31-41	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	91-94
33758505-10	2021	Moreover, NE-PTX+BEZ235 treatment increased apoptosis, decreased Pgp and ABCC1 expression, and reduced tumor weights compared to the single drug treatment and the control group.	Paclitaxel	13-16	phosphoglycolate phosphatase	Homo sapiens	65-68
33690190-0	2021	Nanostructured lipid carrier co-delivering paclitaxel and doxorubicin restrains the proliferation and promotes apoptosis of glioma stem cells via regulating PI3K/Akt/mTOR signaling.	Paclitaxel	43-53	mechanistic target of rapamycin kinase	Mus musculus	166-170
33690190-11	2021	Mechanistic investigations evidenced that PTX-DOX-NLC inhibited tumor progression by suppressing the PI3K/AKT/mTOR signaling in vitro and in vivo.	Paclitaxel	42-45	mechanistic target of rapamycin kinase	Mus musculus	110-114
33461709-5	2021	Finally, this method was used to investigate the effects of n-oxalylglycine (NOG) and taxol on activity of TET1.	Paclitaxel	86-91	tet methylcytosine dioxygenase 1	Homo sapiens	107-111
33152392-2	2021	LH2 effectively delivered paclitaxel into triple-negative breast cancer cells, MDA-MB-231, via formation of non-covalent complexes (PTX-LH2(M)) or covalent conjugates (PTX-LH2(C)).	Paclitaxel	26-36	LIM homeobox protein 2	Mus musculus	0-3
33643546-6	2021	Systemic delivery of paclitaxel by EGFR-targeting EVs at a low dose significantly increases drug efficacy in a xenografted mouse model of EGFR-positive lung cancer.	Paclitaxel	21-31	epidermal growth factor receptor	Mus musculus	35-39
33643546-6	2021	Systemic delivery of paclitaxel by EGFR-targeting EVs at a low dose significantly increases drug efficacy in a xenografted mouse model of EGFR-positive lung cancer.	Paclitaxel	21-31	epidermal growth factor receptor	Mus musculus	138-142
33555529-10	2021	Moreover, miR-424-5p restoration in combination with Taxol treatment decreased the colony formation by regulating Oct-4 and led to G2 arrest via modulating Cdk-2 expression.	Paclitaxel	53-58	POU class 5 homeobox 1	Homo sapiens	114-119
33300063-12	2021	PTX was also shown to inhibit mTOR signaling, indicated by a decreased level of p-mTOR and increased expression of eukaryotic translation initiation factor 4E-binding protein 1.	Paclitaxel	0-3	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	115-176
33495450-6	2021	CRISPR/Cas9-mediated MALAT1 promoter deletion in BT-549 TNBC model enhanced sensitivity to paclitaxel and doxorubicin, suggesting a role for MALAT1 in conferring resistance.	Paclitaxel	91-101	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	21-27
33091531-8	2021	Our data indicated that PTX-loaded HSST could accurately "find" the tumors as well as metastasis cancer cells, and efficiently kill most of them.	Paclitaxel	24-27	N-deacetylase and N-sulfotransferase 1	Homo sapiens	35-39
33091531-9	2021	The joining of a durable PD-1 blockage significantly boosted the efficacy of PTX@HSST on multiple tumor models, including lung metastatic tumors and even multidrug-resistant tumors.	Paclitaxel	77-80	N-deacetylase and N-sulfotransferase 1	Homo sapiens	81-85
33475294-4	2021	Based on IMpassion130, the combination of atezolizumab and nab-paclitaxel is now considered a standard of care for the treatment of PD-L1-positive advanced TNBC.	Paclitaxel	63-73	CD274 molecule	Homo sapiens	132-137
33363381-15	2020	Furthermore, reversed regulation of Fos and P53 based on UBE2N reduction could reverse paclitaxel sensitivity, respectively.	Paclitaxel	87-97	ubiquitin conjugating enzyme E2 N	Homo sapiens	57-62
33363381-16	2020	Conclusion: Our study suggests that UBE2N could be used as a therapeutic agent for paclitaxel-resistant ovarian cancer through Fos/P53 pathway.	Paclitaxel	83-93	ubiquitin conjugating enzyme E2 N	Homo sapiens	36-41
32064933-0	2020	KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cells.	Paclitaxel	16-26	KN motif and ankyrin repeat domains 1	Homo sapiens	0-5
32064933-6	2020	Six genes (KANK1, ALDH3A1, GALNT14, PIK3R3, LRG1, WEE2), which may be related to paclitaxel resistance in lung adenocarcinoma, were identified.	Paclitaxel	81-91	KN motif and ankyrin repeat domains 1	Homo sapiens	11-16
32064933-9	2020	Transient transfection of SiKANK1 significantly reduced the expression of KANK1, reducing apoptosis, increasing cell migration, and enhancing the tolerance of A549 cells to paclitaxel.	Paclitaxel	173-183	KN motif and ankyrin repeat domains 1	Homo sapiens	28-33
32064933-10	2020	KANK1 acts as a tumour suppressor gene, mediating the resistance of lung adenocarcinoma A549 to paclitaxel.	Paclitaxel	96-106	KN motif and ankyrin repeat domains 1	Homo sapiens	0-5
32064933-11	2020	The reduction of KANK1 expression can increase the paclitaxel resistance of non-small cell lung cancer and increase the difficulty of clinical treatment.	Paclitaxel	51-61	KN motif and ankyrin repeat domains 1	Homo sapiens	17-22
33254426-2	2020	In this way, we prepared a PTX-loaded 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] polymeric micelles (PM/PTX) in an attempt to improve safety and effectiveness of conventional PTX formulation (CrEL/EtOH/PTX).	Paclitaxel	27-30	reticuloendotheliosis oncogene	Mus musculus	236-240
33254426-7	2020	In the acute toxicity evaluation in healthy mice, CrEL/EtOH/PTX (single dose of 20 mg/kg) induced peripheral neuropathy, which was not observed in PM/PTX group.	Paclitaxel	60-63	reticuloendotheliosis oncogene	Mus musculus	50-54
33254426-7	2020	In the acute toxicity evaluation in healthy mice, CrEL/EtOH/PTX (single dose of 20 mg/kg) induced peripheral neuropathy, which was not observed in PM/PTX group.	Paclitaxel	150-153	reticuloendotheliosis oncogene	Mus musculus	50-54
33254426-10	2020	Besides, PM/PTX exhibited a higher antitumor activity with an inhibition ratio approximately 1.5-fold higher than CrEL/EtOH/PTX group.	Paclitaxel	12-15	reticuloendotheliosis oncogene	Mus musculus	114-118
33121324-0	2020	Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells.	Paclitaxel	101-111	maternally expressed 3	Homo sapiens	19-23
33121324-3	2020	The current research focused on the function of MEG3 in paclitaxel (PTX)-resistance and human breast cancer growth.	Paclitaxel	56-66	maternally expressed 3	Homo sapiens	48-52
33121324-3	2020	The current research focused on the function of MEG3 in paclitaxel (PTX)-resistance and human breast cancer growth.	Paclitaxel	68-71	maternally expressed 3	Homo sapiens	48-52
33121324-10	2020	Overexpression of MEG3 could reinforce cell apoptosis, impede proliferation, migration, invasion, and the IC50 of PTX in breast cancer cells.	Paclitaxel	114-117	maternally expressed 3	Homo sapiens	18-22
33121324-11	2020	Moreover, the impact of miR-4513 inhibitor on cell progression and PTX-resistance was overturned by MEG3 deficiency.	Paclitaxel	67-70	maternally expressed 3	Homo sapiens	100-104
33121324-14	2020	MEG3/miR-4513/PBLD axis modulated PTX-resistance and the development of breast cancer cells, which might provide a promising therapeutic strategy for breast cancer.	Paclitaxel	34-37	maternally expressed 3	Homo sapiens	0-4
33256016-12	2020	SKOV-3 cells co-treated with sitagliptin and paclitaxel decreased concentrations of MMP-1, MMP-2, MMP-7, MMP-10, TIMP-1, TIMP-2.	Paclitaxel	45-55	matrix metallopeptidase 1	Homo sapiens	84-89
19781537-10	2010	We also found that the combination of ATO and PTX at low concentrations synergistically induced mitotic arrest followed by apoptosis in malignant lymphocytes, which increased phosphorylated cyclin-dependent kinase 1 (Cdk1) on Thr(161) and promoted the dysregulated activation of Cdk1.	Paclitaxel	46-49	cyclin dependent kinase 1	Homo sapiens	190-215
33256016-12	2020	SKOV-3 cells co-treated with sitagliptin and paclitaxel decreased concentrations of MMP-1, MMP-2, MMP-7, MMP-10, TIMP-1, TIMP-2.	Paclitaxel	45-55	matrix metallopeptidase 7	Homo sapiens	98-103
19781537-10	2010	We also found that the combination of ATO and PTX at low concentrations synergistically induced mitotic arrest followed by apoptosis in malignant lymphocytes, which increased phosphorylated cyclin-dependent kinase 1 (Cdk1) on Thr(161) and promoted the dysregulated activation of Cdk1.	Paclitaxel	46-49	cyclin dependent kinase 1	Homo sapiens	217-221
19781537-10	2010	We also found that the combination of ATO and PTX at low concentrations synergistically induced mitotic arrest followed by apoptosis in malignant lymphocytes, which increased phosphorylated cyclin-dependent kinase 1 (Cdk1) on Thr(161) and promoted the dysregulated activation of Cdk1.	Paclitaxel	46-49	cyclin dependent kinase 1	Homo sapiens	279-283
33137125-9	2020	We also found that LPCAT1 overexpression led to CRPC cell resistance to treatment with paclitaxel.	Paclitaxel	87-97	lysophosphatidylcholine acyltransferase 1	Mus musculus	19-25
19781537-11	2010	The ATO/PTX combination also significantly enhanced the activation of spindle checkpoint by inducing the formation of the inhibitory checkpoint complex BubR1/Cdc20.	Paclitaxel	8-11	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	152-157
19944065-0	2010	(-)-Epigallocatechin-3-gallate decreases thrombin/paclitaxel-induced endothelial tissue factor expression via the inhibition of c-Jun terminal NH2 kinase phosphorylation.	Paclitaxel	50-60	coagulation factor III, tissue factor	Homo sapiens	81-94
19944065-2	2010	This study investigates the effect of (-)-epigallocatechin-3-gallate (EGCG) on the expression of thrombin/paclitaxel-induced endothelial tissue factor (TF) expressions in human aortic endothelial cells (HAECs).	Paclitaxel	106-116	coagulation factor III, tissue factor	Homo sapiens	137-150
19944065-2	2010	This study investigates the effect of (-)-epigallocatechin-3-gallate (EGCG) on the expression of thrombin/paclitaxel-induced endothelial tissue factor (TF) expressions in human aortic endothelial cells (HAECs).	Paclitaxel	106-116	coagulation factor III, tissue factor	Homo sapiens	152-154
19944065-4	2010	At a concentration of 25 micromol/L, EGCG pretreatment potently inhibited both thrombin-stimulated and thrombin/paclitaxel-stimulated endothelial TF protein expression.	Paclitaxel	112-122	coagulation factor III, tissue factor	Homo sapiens	146-148
19944065-5	2010	Thrombin and thrombin/paclitaxel-induced 2.6-fold and 2.9-fold increases in TF activity compared with the control.	Paclitaxel	22-32	coagulation factor III, tissue factor	Homo sapiens	76-78
33138677-0	2020	LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.	Paclitaxel	46-56	FK506 binding protein 1a	Mus musculus	118-124
33138677-0	2020	LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.	Paclitaxel	92-102	FK506 binding protein 1a	Mus musculus	118-124
33300049-0	2020	MicroRNA-34b expression enhances chemosensitivity of endometrial cancer cells to paclitaxel.	Paclitaxel	81-91	microRNA 34b	Homo sapiens	0-12
33300049-7	2020	Sensitivity to paclitaxel was increased in cancer cells with miR-34b overexpression, compared with untreated cancer cells, but this difference was not identified for cisplatin or doxorubicin.	Paclitaxel	15-25	microRNA 34b	Homo sapiens	61-68
20806820-5	2010	During the first line palliative chemotherapy with combination regimen of carboplatin and paclitaxel, the disease progressed significantly and the patient"s condition deteriorated (performance status (PS) 3, severe dyspnoea at rest, malignant bronchorrhea).	Paclitaxel	90-100	taste 2 receptor member 6 pseudogene	Homo sapiens	181-206
20419056-3	2010	We have demonstrated recently that Taxol (paclitaxel and its semisynthetic analogue docetaxel) treatment of 22Rv1, a CRPC cell line that expresses the tumor suppressor gene PTEN, inhibits AR transcriptional activity.	Paclitaxel	35-40	phosphatase and tensin homolog	Homo sapiens	173-177
20419056-3	2010	We have demonstrated recently that Taxol (paclitaxel and its semisynthetic analogue docetaxel) treatment of 22Rv1, a CRPC cell line that expresses the tumor suppressor gene PTEN, inhibits AR transcriptional activity.	Paclitaxel	42-52	phosphatase and tensin homolog	Homo sapiens	173-177
20419056-6	2010	Further studies demonstrated that Taxol inhibition of the AR is mediated, at least in part, by Taxol-induced nuclear accumulation of FOXO1, a key downstream effector protein of PTEN and increased association of FOXO1 with the AR.	Paclitaxel	34-39	phosphatase and tensin homolog	Homo sapiens	177-181
33300049-8	2020	In vivo, combination treatment with miR-34b and paclitaxel markedly reduced tumor growth compared with treatment with negative control miRNA and paclitaxel.	Paclitaxel	145-155	microRNA 34b	Homo sapiens	36-43
33300049-9	2020	These data suggest that miR-34b enhances paclitaxel sensitivity in endometrial cancer cells, and that miR-34b and MET are key targets for treatment of endometrial cancer.	Paclitaxel	41-51	microRNA 34b	Homo sapiens	24-31
32745564-8	2020	This indicates that the combined effect of the SMEDDS formulation in addition to pretreatment with P-gp and CYP3A4 inhibitor, can improve the oral bioavailability of poorly soluble and poorly permeable drugs such as PTX in rabbits.	Paclitaxel	216-219	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	99-103
20419056-6	2010	Further studies demonstrated that Taxol inhibition of the AR is mediated, at least in part, by Taxol-induced nuclear accumulation of FOXO1, a key downstream effector protein of PTEN and increased association of FOXO1 with the AR.	Paclitaxel	95-100	phosphatase and tensin homolog	Homo sapiens	177-181
20419056-7	2010	These studies suggest that the status of the functional PTEN/FOXO pathway and the drug bioavailability may be the two key determinants for Taxol chemoresistance of CRPC in the clinic.	Paclitaxel	139-144	phosphatase and tensin homolog	Homo sapiens	56-60
19826413-8	2009	In MyD88(+) SCOV3 cells, LPS or PTX binding to TLR4 induced IRAK4 activation and cJun phosphorylation, activated the NF-kappaB pathway and promoted interleukin (IL)-8, IL-6, vascular endothelial growth factor and monocyte chemotactic protein-1 production and resistance to drug-induced apoptosis.	Paclitaxel	32-35	toll like receptor 4	Homo sapiens	47-51
19826413-9	2009	Silencing of TLR4 in SCOV3 cells with small interference RNA resulted in phosphorylated-cJun (p-cJun) downregulation and a loss of PTX resistance.	Paclitaxel	131-134	toll like receptor 4	Homo sapiens	13-17
19826413-10	2009	In PTX-sensitive, MyD88(neg) A2780 cells, TLR4 stimulation upregulated TRIF, and TLR4 silencing eliminated this effect.	Paclitaxel	3-6	toll like receptor 4	Homo sapiens	42-46
33000256-0	2020	Knockdown of SERPINE1 reverses resistance of triple-negative breast cancer to paclitaxel via suppression of VEGFA.	Paclitaxel	78-88	serpin family E member 1	Homo sapiens	13-21
19826413-10	2009	In PTX-sensitive, MyD88(neg) A2780 cells, TLR4 stimulation upregulated TRIF, and TLR4 silencing eliminated this effect.	Paclitaxel	3-6	toll like receptor 4	Homo sapiens	81-85
33000256-4	2020	In the present study, the role and mechanism of SERPINE1 in the development of paclitaxel (PTX) resistance in TNBC cells were investigated.	Paclitaxel	79-89	serpin family E member 1	Homo sapiens	48-56
33000256-4	2020	In the present study, the role and mechanism of SERPINE1 in the development of paclitaxel (PTX) resistance in TNBC cells were investigated.	Paclitaxel	91-94	serpin family E member 1	Homo sapiens	48-56
32505840-12	2020	The synergetic effect was played by Xiaoaiping injection inhibiting paclitaxel-induced PXR and CAR expression, which subsequently inhibited CYP450 enzymes CYP2C8 and CYP3A4, transporter P-gp and anti-apoptotic proteins Bcl-2 and Bcl-xl in SK-OV-3 cells.	Paclitaxel	68-78	CXADR pseudogene 1	Homo sapiens	95-98
19695246-7	2009	These effects of TNF-alpha were inhibited upon stabilization of microtubules by pre-treatment with paclitaxel or epothilone B.	Paclitaxel	99-109	tumor necrosis factor	Bos taurus	17-26
33021083-11	2021	At the MTD/RP2D of MP5/r 20-20/100-100, the maximum paclitaxel plasma concentration and area under the concentration-time curve until 24 hours were 34.6 ng/mL (coefficient of variation, 79%) and 255 ng   h/mL (coefficient of variation, 62%), respectively.	Paclitaxel	52-62	progesterone receptor membrane component 1	Homo sapiens	19-24
19039521-7	2009	Bortezomib alone or in combination with taxol induced a cell cycle arrest within the S phase, and downregulation of cdk1, a cyclin-dependent kinase that is necessary for the entry into the M phase.	Paclitaxel	40-45	cyclin dependent kinase 1	Homo sapiens	116-120
31993881-5	2020	In this study, we observed that Taxol treatment caused pyroptotic cell death, along with activation of Caspase-1 and maturation of IL-1beta, as well as cleavage of GSDMD, which is the canonical pyroptosis executor.	Paclitaxel	32-37	interleukin 1 alpha	Homo sapiens	131-139
20021611-0	2009	Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.	Paclitaxel	83-93	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-19
32447047-0	2020	Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling.	Paclitaxel	65-75	toll like receptor 4	Homo sapiens	92-96
19732770-5	2009	Although there was no additive effect of taxol and TNF-alpha on NF-kappaB activity suggesting a shared mechanism of activation, taxol strongly induced the NF-kappaB reporter in the presence of a TNF receptor (TNFR) blocking antibody while TNF-alpha did not.	Paclitaxel	128-133	TNF receptor superfamily member 1A	Homo sapiens	195-207
19732770-5	2009	Although there was no additive effect of taxol and TNF-alpha on NF-kappaB activity suggesting a shared mechanism of activation, taxol strongly induced the NF-kappaB reporter in the presence of a TNF receptor (TNFR) blocking antibody while TNF-alpha did not.	Paclitaxel	128-133	TNF receptor superfamily member 1A	Homo sapiens	209-213
32447047-8	2020	Intriguingly, paclitaxel stimulation activated the TLR4-NF-kappaB signaling, which was reversed after hyperoside administration.	Paclitaxel	14-24	toll like receptor 4	Homo sapiens	51-55
32447047-10	2020	Importantly, restoring the TLR4 pathway overturned hyperoside-evoked chemosensitivity to paclitaxel in MDA-MB-231 cells.	Paclitaxel	89-99	toll like receptor 4	Homo sapiens	27-31
32447047-11	2020	Thus, hyperoside may elevate breast cancer cell sensitivity to paclitaxel by blocking TLR4 activation-mediated pro-inflammatory and pro-survival approaches, thereby endorsing its usefulness as a promising therapeutic combination to overcome chemosensitivity in breast cancer.	Paclitaxel	63-73	toll like receptor 4	Homo sapiens	86-90
19861455-9	2009	Knockdown of TPX2 also sensitized pancreatic cancer cells to paclitaxel treatment.	Paclitaxel	61-71	TPX2, microtubule-associated	Mus musculus	13-17
32774496-0	2020	MicroRNA-212-3p inhibits paclitaxel resistance through regulating epithelial-mesenchymal transition, migration and invasion by targeting ZEB2 in human hepatocellular carcinoma.	Paclitaxel	25-35	zinc finger E-box binding homeobox 2	Homo sapiens	137-141
32774496-14	2020	The data from the present study suggest that miR-212-3p attenuates PTX resistance, by regulating EMT, migration and invasion via targeting ZEB2 in HCC cells, indicating a novel target for HCC chemotherapy.	Paclitaxel	67-70	zinc finger E-box binding homeobox 2	Homo sapiens	139-143
19841739-3	2009	One of these transporters, the multiple resistant protein 7 (MRP7, ABCC10), has recently been shown to produce resistance to antineoplastic drugs by increasing the efflux of paclitaxel.	Paclitaxel	174-184	ATP binding cassette subfamily C member 10	Homo sapiens	31-59
19841739-3	2009	One of these transporters, the multiple resistant protein 7 (MRP7, ABCC10), has recently been shown to produce resistance to antineoplastic drugs by increasing the efflux of paclitaxel.	Paclitaxel	174-184	ATP binding cassette subfamily C member 10	Homo sapiens	61-65
19841739-3	2009	One of these transporters, the multiple resistant protein 7 (MRP7, ABCC10), has recently been shown to produce resistance to antineoplastic drugs by increasing the efflux of paclitaxel.	Paclitaxel	174-184	ATP binding cassette subfamily C member 10	Homo sapiens	67-73
32875729-0	2020	Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.	Paclitaxel	52-62	monoamine oxidase A	Homo sapiens	10-29
19841739-7	2009	In addition, imatinib and nilotinib (1-5 microM) produced a significant concentration-dependent reversal of MRP7-mediated multidrug resistance by enhancing the sensitivity of HEK-MRP7-2 cells to paclitaxel and vincristine.	Paclitaxel	195-205	ATP binding cassette subfamily C member 10	Homo sapiens	108-112
19841739-7	2009	In addition, imatinib and nilotinib (1-5 microM) produced a significant concentration-dependent reversal of MRP7-mediated multidrug resistance by enhancing the sensitivity of HEK-MRP7-2 cells to paclitaxel and vincristine.	Paclitaxel	195-205	ATP binding cassette subfamily C member 10	Homo sapiens	179-183
19841739-9	2009	The incubation of the HEK-MRP7-2 cells with imatinib or nilotinib (5 microM) also significantly inhibited the efflux of paclitaxel.	Paclitaxel	120-130	ATP binding cassette subfamily C member 10	Homo sapiens	26-30
32875729-3	2020	Hence, the aim of this article was to evaluate a previously synthesized MAOA inhibitor (G11) on inhibiting paclitaxel-resistant NSCLC metastasis and growth.	Paclitaxel	107-117	monoamine oxidase A	Homo sapiens	72-76
19841739-10	2009	CONCLUSIONS: Imatinib and nilotinib reverse MRP7-mediated paclitaxel resistance, most likely due to their inhibition of the efflux of paclitaxel via MRP7.	Paclitaxel	58-68	ATP binding cassette subfamily C member 10	Homo sapiens	44-48
19841739-10	2009	CONCLUSIONS: Imatinib and nilotinib reverse MRP7-mediated paclitaxel resistance, most likely due to their inhibition of the efflux of paclitaxel via MRP7.	Paclitaxel	58-68	ATP binding cassette subfamily C member 10	Homo sapiens	149-153
32875729-10	2020	G11 dramatically reduced the expression of MAOA in A549/PTX and H460/PTX cells, which exhibited relatively high MAOA expression levels.	Paclitaxel	56-59	monoamine oxidase A	Homo sapiens	43-47
19841739-10	2009	CONCLUSIONS: Imatinib and nilotinib reverse MRP7-mediated paclitaxel resistance, most likely due to their inhibition of the efflux of paclitaxel via MRP7.	Paclitaxel	134-144	ATP binding cassette subfamily C member 10	Homo sapiens	44-48
19841739-10	2009	CONCLUSIONS: Imatinib and nilotinib reverse MRP7-mediated paclitaxel resistance, most likely due to their inhibition of the efflux of paclitaxel via MRP7.	Paclitaxel	134-144	ATP binding cassette subfamily C member 10	Homo sapiens	149-153
32875729-13	2020	CONCLUSIONS: These findings indicated G11 showed a moderate inhibitory effect on paclitaxel-resistant NSCLC metastasis and growth, and support further investigation on MAOA potentially as a promising therapeutic target for paclitaxel-resistant NSCLC treatment.	Paclitaxel	223-233	monoamine oxidase A	Homo sapiens	168-172
32875729-14	2020	KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Inhibition of MAOA might contribute to the suppression of metastasis and growth in PTX-resistant NSCLC cells.	Paclitaxel	130-133	monoamine oxidase A	Homo sapiens	61-65
32941465-0	2020	PINK1 alleviates thermal hypersensitivity in a paclitaxel-induced Drosophila model of peripheral neuropathy.	Paclitaxel	47-57	PTEN-induced putative kinase 1	Drosophila melanogaster	0-5
19533750-4	2009	In addition, expression and epigenetic regulation of ASS1 were analysed in human ovarian cancer cell lines, and ASS1 expression correlated with the ability of the lines to grow in media containing cisplatin, carboplatin or taxol or in arginine-depleted media.	Paclitaxel	223-228	argininosuccinate synthase 1	Homo sapiens	53-57
19533750-4	2009	In addition, expression and epigenetic regulation of ASS1 were analysed in human ovarian cancer cell lines, and ASS1 expression correlated with the ability of the lines to grow in media containing cisplatin, carboplatin or taxol or in arginine-depleted media.	Paclitaxel	223-228	argininosuccinate synthase 1	Homo sapiens	112-116
32782585-0	2020	xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma.	Paclitaxel	37-47	solute carrier family 7 member 11	Homo sapiens	0-3
32782585-11	2020	Taken together, the results of the present study suggest that xCT inhibition may be an effective treatment for patients with recurrent paclitaxel-resistant USC.	Paclitaxel	135-145	solute carrier family 7 member 11	Homo sapiens	62-65
19930842-0	2009	Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910).	Paclitaxel	104-114	heat shock protein family B (small) member 1	Homo sapiens	44-65
19930842-0	2009	Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910).	Paclitaxel	104-114	heat shock protein family B (small) member 1	Homo sapiens	67-72
33042263-0	2020	SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.	Paclitaxel	54-64	synaptotagmin like 4	Homo sapiens	0-5
19930842-6	2009	Reduction of HSP27 expression increased the in vitro chemosensitivity of HO8910 cells to paclitaxel and increased paclitaxel-induced apoptosis and ROS production, although the ROS scavenger, N-acetyl-L-cysteine, partly offset the effects of HSP27 siRNA.	Paclitaxel	89-99	heat shock protein family B (small) member 1	Homo sapiens	13-18
19930842-6	2009	Reduction of HSP27 expression increased the in vitro chemosensitivity of HO8910 cells to paclitaxel and increased paclitaxel-induced apoptosis and ROS production, although the ROS scavenger, N-acetyl-L-cysteine, partly offset the effects of HSP27 siRNA.	Paclitaxel	114-124	heat shock protein family B (small) member 1	Homo sapiens	13-18
19930842-7	2009	Thus, gene knock-down of HSP27 offsets the role of this protein in resisting oxidant stress, thereby indirectly increasing the sensitivity of cells to paclitaxel.	Paclitaxel	151-161	heat shock protein family B (small) member 1	Homo sapiens	25-30
19930842-8	2009	The siRNA-induced knock-down of HSP27 could be a novel and potent strategy to help overcome chemotherapeutic resistance to paclitaxel in epithelial ovarian cancer cells.	Paclitaxel	123-133	heat shock protein family B (small) member 1	Homo sapiens	32-37
19520687-5	2009	Paclitaxel was escalated if MTD was not reached.	Paclitaxel	0-10	metallothionein 1E	Homo sapiens	28-31
32628454-1	2020	The paclitaxel (PTX) resistance in most epithelial ovarian cancers (EOCs) with increasing membrane expression of mucin 16 (MUC16) is mediated by the Toll-like receptor-myeloid differentiation factor 2/myeloid differentiation factor 88 (TLR4-MD2/MyD88) signaling pathway.	Paclitaxel	4-14	toll like receptor 4	Homo sapiens	236-240
32360360-4	2020	While PG545 showed antitumor activity as monotherapy, a combination of PG545 with paclitaxel and cisplatin was highly effective in reducing the tumor burden and significantly prolonged survival of both Hec1B and ARK2 xenograft bearing mice.	Paclitaxel	82-92	aurora kinase B	Mus musculus	212-216
19218307-0	2009	Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.	Paclitaxel	41-51	colony stimulating factor 3	Homo sapiens	57-62
19574766-4	2009	The primary aim of the present study was to investigate if immunohistochemical expression of ERCC1 protein was associated with resistance to standard combination carboplatin and paclitaxel chemotherapy in newly diagnosed ovarian cancer patients.	Paclitaxel	178-188	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	93-98
19574789-1	2009	OBJECTIVES: To assess the effect of neoadjuvant chemotherapy with paclitaxel and cisplatin on long-term (5-year) survival of patients with stage IB2 to IIB cervical cancer.	Paclitaxel	66-76	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	145-148
19957654-7	2009	After the activity of caspase-9 was inhibited by Z-LETD-FMK, the inhibition effects of TRAIL, cisplatin and paclitaxel on Hep-2 cells decreased significantly (all P&lt;0.05).	Paclitaxel	108-118	caspase 9	Homo sapiens	22-31
19509181-0	2009	Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.	Paclitaxel	120-130	aldehyde dehydrogenase 1 family member A1	Homo sapiens	54-78
20641185-11	2004	Using HGS-ETR2 labeled with radioactive technetium ((99m)Tc) ((99m)Tc-EC-HGS-ETR2), the investigators determined that the activity of HGS-ETR2 was increased because the pretreatment with paclitaxel upregulated the expression of TRAIL-R2 in Colo205 cell xenograft tumors in nude mice.	Paclitaxel	187-197	TNF receptor superfamily member 10b	Homo sapiens	228-236
19360472-3	2009	The nuclear translocation of DHFR protein during apoptosis was independent of the cellular context, but it was more sensitive in cell death induction by DNA damaging agents such as doxorubicin, etoposide and ultraviolent radiation than endoplasmic reticulum stressors (brefeldin-A and tunicamycin) and anti-microtubule agents (paclitaxel and nocodozole).	Paclitaxel	327-337	dihydrofolate reductase	Homo sapiens	29-33
19150344-5	2009	Cepharanthine, at 2microM, completely reversed paclitaxel resistance in MRP7-transfected cells.	Paclitaxel	47-57	ATP binding cassette subfamily C member 10	Homo sapiens	72-76
19150344-7	2009	In addition, cepharanthine significantly increased the accumulation of paclitaxel in MRP7-transfected cells almost to the level of control cells in the absence of cepharanthine.	Paclitaxel	71-81	ATP binding cassette subfamily C member 10	Homo sapiens	85-89
19150344-8	2009	The efflux of paclitaxel from MRP7-transfected cells was also significantly inhibited by cepharanthine.	Paclitaxel	14-24	ATP binding cassette subfamily C member 10	Homo sapiens	30-34
19150344-11	2009	These findings indicate that cepharanthine reverses MRP7-mediated resistance to paclitaxel in a competitive manner.	Paclitaxel	80-90	ATP binding cassette subfamily C member 10	Homo sapiens	52-56
19048624-0	2009	Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.	Paclitaxel	33-43	heparin binding EGF like growth factor	Homo sapiens	73-79
19048624-3	2009	Paclitaxel induced transient ERK activation and sustained activation of JNK and p38 MAPK through the ectodomain shedding of HB-EGF in SKOV3 cells.	Paclitaxel	0-10	heparin binding EGF like growth factor	Homo sapiens	124-130
19048624-4	2009	In addition, the overexpression of HB-EGF in paclitaxel-treated SKOV3 cells resulted in modulation of paclitaxel-evoked MAPK signaling, including marked activation of ERK and Akt, and minimized activation of JNK and p38 MAPK, indicating that HB-EGF is involved in drug sensitivity through the balance of anti-apoptotic and pro-apoptotic signals induced by paclitaxel.	Paclitaxel	45-55	heparin binding EGF like growth factor	Homo sapiens	35-41
19048624-4	2009	In addition, the overexpression of HB-EGF in paclitaxel-treated SKOV3 cells resulted in modulation of paclitaxel-evoked MAPK signaling, including marked activation of ERK and Akt, and minimized activation of JNK and p38 MAPK, indicating that HB-EGF is involved in drug sensitivity through the balance of anti-apoptotic and pro-apoptotic signals induced by paclitaxel.	Paclitaxel	45-55	heparin binding EGF like growth factor	Homo sapiens	242-248
19046877-0	2009	Paclitaxel downregulates tissue factor in cancer and host tumour-associated cells.	Paclitaxel	0-10	coagulation factor III, tissue factor	Homo sapiens	25-38
19046877-3	2009	We investigated whether paclitaxel could modulate TF in human mononuclear (MN) cells, human umbilical vein endothelial cells (HUVEC) and the metastatic breast carcinoma cell line MDA-MB-231.	Paclitaxel	24-34	coagulation factor III, tissue factor	Homo sapiens	50-52
19046877-6	2009	Both the strong TF activity and antigen constitutively expressed by MDA-MB-231 and the TF induced by LPS, TNF-alpha and IL-1beta in MN cells and HUVEC were significantly reduced by paclitaxel.	Paclitaxel	181-191	coagulation factor III, tissue factor	Homo sapiens	16-18
19046877-7	2009	In the presence of paclitaxel, lower TF mRNA levels were also detected.	Paclitaxel	19-29	coagulation factor III, tissue factor	Homo sapiens	37-39
19200169-0	2009	Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells.	Paclitaxel	17-27	toll like receptor 4	Homo sapiens	8-12
19200169-1	2009	BACKGROUND: Paclitaxel has been reported to be a ligand to Toll like receptor 4 (TLR4).	Paclitaxel	12-22	toll like receptor 4	Homo sapiens	59-79
19200169-1	2009	BACKGROUND: Paclitaxel has been reported to be a ligand to Toll like receptor 4 (TLR4).	Paclitaxel	12-22	toll like receptor 4	Homo sapiens	81-85
19200169-6	2009	The aim of the present study is to investigate the role of TLR4 in paclitaxel resistance of ovarian cancer cells.	Paclitaxel	67-77	toll like receptor 4	Homo sapiens	59-63
19200169-12	2009	CONCLUSIONS: It suggests that TLR4 negatively regulates paclitaxel chemotherapy and MyD88 is an essential downstream factor to TLR4 signalling for this resistance.	Paclitaxel	56-66	toll like receptor 4	Homo sapiens	30-34
19200169-12	2009	CONCLUSIONS: It suggests that TLR4 negatively regulates paclitaxel chemotherapy and MyD88 is an essential downstream factor to TLR4 signalling for this resistance.	Paclitaxel	56-66	toll like receptor 4	Homo sapiens	127-131
19200169-13	2009	Knockdown of TLR4 induces paclitaxel chemosensitivity which might depress the Akt pathway.	Paclitaxel	26-36	toll like receptor 4	Homo sapiens	13-17
18758183-2	2009	P27 and P53 play important roles in the signal transduction leading to neointimal growth inhibition and induction of apoptosis of smooth muscle cells due to rapamycin and paclitaxel.	Paclitaxel	171-181	interferon alpha inducible protein 27	Homo sapiens	0-3
18996227-0	2009	Paclitaxel induces up-regulation of tissue factor in human aortic endothelial cells.	Paclitaxel	0-10	coagulation factor III, tissue factor	Homo sapiens	36-49
18996227-5	2009	In HAEC, while paclitaxel (10 (-5) mol/L to 10 (-9) mol/L) treatment for 5 h up-regulated the expression of TF in a dose-dependent manner, paclitaxel cotreatment with thrombin further enhanced it.	Paclitaxel	15-25	coagulation factor III, tissue factor	Homo sapiens	108-110
18996227-5	2009	In HAEC, while paclitaxel (10 (-5) mol/L to 10 (-9) mol/L) treatment for 5 h up-regulated the expression of TF in a dose-dependent manner, paclitaxel cotreatment with thrombin further enhanced it.	Paclitaxel	139-149	coagulation factor III, tissue factor	Homo sapiens	108-110
18996227-6	2009	While paclitaxel (10 (-5) mol/L) itself induced a 3.7-fold enhancement in TF activity, its cotreatment along with thrombin elicited a 7.6-fold increase in TF activity.	Paclitaxel	6-16	coagulation factor III, tissue factor	Homo sapiens	74-76
18996227-6	2009	While paclitaxel (10 (-5) mol/L) itself induced a 3.7-fold enhancement in TF activity, its cotreatment along with thrombin elicited a 7.6-fold increase in TF activity.	Paclitaxel	6-16	coagulation factor III, tissue factor	Homo sapiens	155-157
18996227-7	2009	Paclitaxel also caused an 8.1-fold increase in TF mRNA expression, and paclitaxel cotreatment with thrombin caused a 13.6-fold enhancement in TF mRNA expression.	Paclitaxel	0-10	coagulation factor III, tissue factor	Homo sapiens	47-49
18996227-7	2009	Paclitaxel also caused an 8.1-fold increase in TF mRNA expression, and paclitaxel cotreatment with thrombin caused a 13.6-fold enhancement in TF mRNA expression.	Paclitaxel	71-81	coagulation factor III, tissue factor	Homo sapiens	142-144
18996227-8	2009	In summary, paclitaxel alone can up-regulate endothelial TF expression.	Paclitaxel	12-22	coagulation factor III, tissue factor	Homo sapiens	57-59
19113992-0	2008	Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol.	Paclitaxel	81-86	cyclin B1	Homo sapiens	10-19
19113992-7	2008	After combining cyclin B1 siRNA with taxol, we observed an increased apoptotic rate accompanied by an enhanced antiproliferative effect in breast cancer cells.	Paclitaxel	37-42	cyclin B1	Homo sapiens	16-25
19113992-11	2008	Moreover, targeting cyclin B1 sensitizes breast cancer cells to taxol, suggesting that specific cyclin B1 targeting is an attractive strategy for the combination with conventionally used agents in gynecological cancer therapy.	Paclitaxel	64-69	cyclin B1	Homo sapiens	20-29
19113992-11	2008	Moreover, targeting cyclin B1 sensitizes breast cancer cells to taxol, suggesting that specific cyclin B1 targeting is an attractive strategy for the combination with conventionally used agents in gynecological cancer therapy.	Paclitaxel	64-69	cyclin B1	Homo sapiens	96-105
18798274-5	2008	Apoptotic cells were increased after transfection of NF-kappaB p65 siRNA compared with control siRNA in the treatment with paclitaxel.	Paclitaxel	123-133	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	63-66
18798274-8	2008	Finally, mice treated by intraperitoneal administration of NF-kappaB p65 siRNA and paclitaxel survived for a significantly longer time than mice treated by intraperitoneal administration of paclitaxel alone (p = 0.0002).	Paclitaxel	190-200	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	69-72
19080259-0	2008	Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat shock protein 27 overexpression.	Paclitaxel	0-10	heat shock protein family B (small) member 1	Homo sapiens	78-99
19080259-2	2008	Paclitaxel (Pacl) was reported to suppress HSP27 expression in ovarian and uterine cancer cells.	Paclitaxel	0-10	heat shock protein family B (small) member 1	Homo sapiens	43-48
19080259-2	2008	Paclitaxel (Pacl) was reported to suppress HSP27 expression in ovarian and uterine cancer cells.	Paclitaxel	0-4	heat shock protein family B (small) member 1	Homo sapiens	43-48
19080259-3	2008	The purposes of this study were to investigate whether Pacl inhibits the expression of HSP27 in breast cancer cells, whether Pacl can sensitize breast cancer cells with HSP27 overexpression to Dox, and to define a more effective schedule for the combination of Dox with Pacl.	Paclitaxel	55-59	heat shock protein family B (small) member 1	Homo sapiens	87-92
19080259-3	2008	The purposes of this study were to investigate whether Pacl inhibits the expression of HSP27 in breast cancer cells, whether Pacl can sensitize breast cancer cells with HSP27 overexpression to Dox, and to define a more effective schedule for the combination of Dox with Pacl.	Paclitaxel	125-129	heat shock protein family B (small) member 1	Homo sapiens	169-174
19080259-7	2008	RESULTS: Pacl (0.1 micromol/L) inhibited HSP27 expression by approximately 2-fold in MCF-7 and MDA-MB-435 cells, while up-regulating the level of topo IIalpha and beta.	Paclitaxel	9-13	heat shock protein family B (small) member 1	Homo sapiens	41-46
19080259-11	2008	CONCLUSIONS: Paclitaxel significantly decreases the level of HSP27 in breast cancer cells overexpressing HSP27.	Paclitaxel	13-23	heat shock protein family B (small) member 1	Homo sapiens	61-66
19080259-11	2008	CONCLUSIONS: Paclitaxel significantly decreases the level of HSP27 in breast cancer cells overexpressing HSP27.	Paclitaxel	13-23	heat shock protein family B (small) member 1	Homo sapiens	105-110
18688857-0	2008	Toll-like receptor-4 is expressed in meningiomas and mediates the antiproliferative action of paclitaxel.	Paclitaxel	94-104	toll like receptor 4	Homo sapiens	0-20
18688857-6	2008	Paclitaxel, a ligand of TLR4, exhibited a dose- and time-dependent growth suppression in both monolayer and spheroid meningioma cell cultures.	Paclitaxel	0-10	toll like receptor 4	Homo sapiens	24-28
18688857-7	2008	The knockdown of TLR4 with siRNA in meningioma cell cultures abrogated the inhibitory effect of paclitaxel.	Paclitaxel	96-106	toll like receptor 4	Homo sapiens	17-21
18688857-10	2008	In conclusion, our in vitro results suggest that paclitaxel alone or in combination with other inhibitors of cell growth (statins, MAPK inhibitors) could provide a potential tool for the treatment of TLR4 expressing meningiomas.	Paclitaxel	49-59	toll like receptor 4	Homo sapiens	200-204
18650420-0	2008	Paclitaxel binding to human and murine MD-2.	Paclitaxel	0-10	lymphocyte antigen 96	Mus musculus	39-43
18650420-2	2008	Recent evidence also implicates PTX in the induction of apoptosis of cancer cells via the TLR4 innate immune pathway.	Paclitaxel	32-35	toll like receptor 4	Homo sapiens	90-94
18650420-3	2008	The TLR4 accessory protein, MD-2, is an essential component for the species-specific proinflammatory activity of PTX on murine cells.	Paclitaxel	113-116	lymphocyte antigen 96	Mus musculus	28-32
18650420-7	2008	As measured by human tumor necrosis factor alpha production, human THP-1 monocytes expressing TLR4 and MD-2 were poorly responsive to the addition of PTX, but murine macrophages expressing TLR4 and MD-2 responded in a dose-dependent manner.	Paclitaxel	150-153	toll like receptor 4	Homo sapiens	94-98
18650420-9	2008	However, HEK293 cells transfected with murine MD-2 and human TLR4 or murine MD-2 and murine TLR4 were highly responsive to PTX (10 microm), indicating that the murine MD-2/PTX interaction is required for TLR4 activation.	Paclitaxel	123-126	toll like receptor 4	Homo sapiens	61-65
18690538-0	2008	Ran suppresses paclitaxel-induced apoptosis in human glioblastoma cells.	Paclitaxel	15-25	RAN, member RAS oncogene family	Homo sapiens	0-3
18690538-3	2008	In U373MG glioblastoma cells, stable overexpression of Ran significantly attenuated apoptotic cell death induced by the chemotherapeutic agent paclitaxel.	Paclitaxel	143-153	RAN, member RAS oncogene family	Homo sapiens	55-58
18690538-4	2008	FACS analysis demonstrated that Ran is involved in paclitaxel-induced cell cycle arrest.	Paclitaxel	51-61	RAN, member RAS oncogene family	Homo sapiens	32-35
18690538-5	2008	Stable overexpression of Ran also markedly inhibited the phosphorylation of Bcl-2 by paclitaxel, and inhibited the translocation of Bax, the release of cytochrome c and activation of caspase-3.	Paclitaxel	85-95	RAN, member RAS oncogene family	Homo sapiens	25-28
18690538-6	2008	Paclitaxel-induced phosphorylation of c-JUN N-terminal kinase (JNK), but not p38, extracellular signal-regulated kinase and Akt, was markedly suppressed in U373MG cells that stably expressed Ran.	Paclitaxel	0-10	RAN, member RAS oncogene family	Homo sapiens	191-194
18690538-7	2008	These results suggest that Ran suppresses paclitaxel-induced cell death through the downregulation of JNK-mediated signal pathways.	Paclitaxel	42-52	RAN, member RAS oncogene family	Homo sapiens	27-30
18672029-9	2008	RT-PCR and Western blot analysis revealed that exposure to taxol increased the expression of p47(phox) and gp91(phox) and induced translocation of the p47(phox) to the membrane in cortical cultures.	Paclitaxel	59-64	paired Ig-like receptor B	Mus musculus	107-111
18672029-12	2008	Moreover, treatment with NADPH oxidase inhibitors or suppression of gp91(phox) by siRNA significantly attenuated the taxol-induced neuronal death.	Paclitaxel	117-122	paired Ig-like receptor B	Mus musculus	68-72
18512732-7	2008	Surprisingly, low dose Eg5 ASO significantly antagonized cytotoxic effects of paclitaxel.	Paclitaxel	78-88	kinesin family member 11	Homo sapiens	23-26
18710614-8	2008	RESULTS: Results of Annexin V showed that PTX (1.5 nmol/L) plus TSA (25 nmol/L) induced a significantly higher apoptotic rate (45.2%) than PTX alone (14.1%) or TSA alone (11.2%) did in Ark2 cells after drug treatment for three days.	Paclitaxel	42-45	annexin A5	Homo sapiens	20-29
18710614-11	2008	Cleavages of PARP and caspase-9 were significantly apparent in PTX plus TSA group than in PTX group or TSA group (P&lt;0.05).	Paclitaxel	63-66	caspase 9	Homo sapiens	22-31
18710614-11	2008	Cleavages of PARP and caspase-9 were significantly apparent in PTX plus TSA group than in PTX group or TSA group (P&lt;0.05).	Paclitaxel	90-93	caspase 9	Homo sapiens	22-31
18640939-1	2008	PURPOSE: We hypothesized that common polymorphisms in excision repair cross-complementation group 1 (ERCC1), involved in nucleotide excision repair of platinum-induced damage, would be associated with progression-free survival (PFS) and overall survival (OS) in women with optimally resected, stage III epithelial ovarian cancer (EOC) treated with cisplatin and paclitaxel (C+P).	Paclitaxel	362-372	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	101-106
18751438-0	2008	Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG) study.	Paclitaxel	186-196	catenin beta 1	Homo sapiens	56-68
17764884-0	2008	Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers.	Paclitaxel	65-75	glutathione S-transferase pi 1	Homo sapiens	15-20
17764884-1	2008	AIMS: It has been reported that glutathione S-transferase P1 (GSTP1) expression is implicated in resistance to taxanes (docetaxel and paclitaxel) in human breast cancer cells in vitro.	Paclitaxel	134-144	glutathione S-transferase pi 1	Homo sapiens	32-60
17764884-1	2008	AIMS: It has been reported that glutathione S-transferase P1 (GSTP1) expression is implicated in resistance to taxanes (docetaxel and paclitaxel) in human breast cancer cells in vitro.	Paclitaxel	134-144	glutathione S-transferase pi 1	Homo sapiens	62-67
17764884-2	2008	In the study presented here, we examine whether GSTP1 expression is associated with resistance to docetaxel or paclitaxel in human breast cancers.	Paclitaxel	111-121	glutathione S-transferase pi 1	Homo sapiens	48-53
17764884-7	2008	The subset analysis showed that the mean reduction rate was significantly (p=0.005) higher in GSTP1 negative (0.59+/-0.06) than GSTP1 positive (0.11+/-0.13) tumors in the docetaxel group as well as in the paclitaxel group (p=0.006; GSTP1 negative tumors: 0.84+/-0.05; GSTP1 positive tumors: 0.56+/-0.08).	Paclitaxel	205-215	glutathione S-transferase pi 1	Homo sapiens	94-99
18575755-0	2008	Activation of the mitochondria-driven pathway of apoptosis in human PC-3 prostate cancer cells by a novel hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel.	Paclitaxel	118-128	chromobox 8	Homo sapiens	68-72
18575595-5	2008	APPROACH: Human p97 was covalently linked with the chemotherapeutic agents paclitaxel (PTAX) or adriamycin (ADR) and following intravenous injection, measured their penetration into brain tissue and other organs using radiolabeled and fluorescent derivatives of the drugs.	Paclitaxel	75-85	melanotransferrin	Homo sapiens	16-19
18575595-5	2008	APPROACH: Human p97 was covalently linked with the chemotherapeutic agents paclitaxel (PTAX) or adriamycin (ADR) and following intravenous injection, measured their penetration into brain tissue and other organs using radiolabeled and fluorescent derivatives of the drugs.	Paclitaxel	87-91	melanotransferrin	Homo sapiens	16-19
18420585-4	2008	Upon paclitaxel treatment, RACK1, DLC1, and CIS mediated the degradation of BimEL through the ElonginB/C-Cullin2-CIS ubiquitin-protein isopeptide ligase complex.	Paclitaxel	5-15	cytokine inducible SH2 containing protein	Homo sapiens	44-47
18420585-4	2008	Upon paclitaxel treatment, RACK1, DLC1, and CIS mediated the degradation of BimEL through the ElonginB/C-Cullin2-CIS ubiquitin-protein isopeptide ligase complex.	Paclitaxel	5-15	cytokine inducible SH2 containing protein	Homo sapiens	113-116
18324624-5	2008	Following transient expression of MDR-1 and MCJ, changes in the sensitivity of Sk-Ov-3 cells to paclitaxel were detected whereas expression of Src, Bcl-2 and Bcl-X(L) decreased the sensitivity of Sk-Ov-3 cells to carboplatin.	Paclitaxel	96-106	DnaJ heat shock protein family (Hsp40) member C15	Homo sapiens	44-47
18074150-0	2008	Paclitaxel (Taxol)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L).	Paclitaxel	0-10	Fas ligand	Homo sapiens	108-119
18074150-0	2008	Paclitaxel (Taxol)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L).	Paclitaxel	0-10	Fas ligand	Homo sapiens	121-125
18074150-0	2008	Paclitaxel (Taxol)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L).	Paclitaxel	12-17	Fas ligand	Homo sapiens	108-119
18074150-0	2008	Paclitaxel (Taxol)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L).	Paclitaxel	12-17	Fas ligand	Homo sapiens	121-125
18497956-5	2008	A combined Mcl-1 antisense oligonucleotide treatment with paclitaxel, cetuximab and gemcitabine led to a significant reduction in the viable cells.	Paclitaxel	58-68	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	11-16
9588740-0	1998	Inhibition of activator protein 1 activity by paclitaxel suppresses interleukin-1-induced collagenase and stromelysin expression by bovine chondrocytes.	Paclitaxel	46-56	Jun proto-oncogene, AP-1 transcription factor subunit	Bos taurus	14-33
9588740-2	1998	This study evaluates the effect of paclitaxel on AP-1 activation and examines its effect on the expression of 2 major matrix metalloproteinases, MMP-1 and MMP-3, and its effect on AP-1 activation.	Paclitaxel	35-45	Jun proto-oncogene, AP-1 transcription factor subunit	Bos taurus	49-53
9588740-2	1998	This study evaluates the effect of paclitaxel on AP-1 activation and examines its effect on the expression of 2 major matrix metalloproteinases, MMP-1 and MMP-3, and its effect on AP-1 activation.	Paclitaxel	35-45	interstitial collagenase	Bos taurus	145-150
9588740-4	1998	The effect of paclitaxel on AP-1 promoter activity was studied by chloramphenicol acetyltransferase assays in IL-1-stimulated chondrocytes.	Paclitaxel	14-24	Jun proto-oncogene, AP-1 transcription factor subunit	Bos taurus	28-32
9588740-5	1998	The same conditions were applied to studies of the effect of paclitaxel on binding at the AP-1 site by gel-shift mobility assays.	Paclitaxel	61-71	Jun proto-oncogene, AP-1 transcription factor subunit	Bos taurus	90-94
9588740-7	1998	RESULTS: IL-1-induced MMP-1 and MMP-3 mRNA levels were markedly reduced in paclitaxel-treated chondrocytes.	Paclitaxel	75-85	interstitial collagenase	Bos taurus	22-27
9588740-8	1998	Further, IL-1-induced AP-1 activation and AP-1 binding were inhibited by paclitaxel.	Paclitaxel	73-83	Jun proto-oncogene, AP-1 transcription factor subunit	Bos taurus	22-26
9588740-8	1998	Further, IL-1-induced AP-1 activation and AP-1 binding were inhibited by paclitaxel.	Paclitaxel	73-83	Jun proto-oncogene, AP-1 transcription factor subunit	Bos taurus	42-46
9588740-11	1998	CONCLUSION: These studies demonstrate that paclitaxel is a potent inhibitor of MMP-1 and MMP-3 synthesis through the AP-1 site.	Paclitaxel	43-53	interstitial collagenase	Bos taurus	79-84
9588740-11	1998	CONCLUSION: These studies demonstrate that paclitaxel is a potent inhibitor of MMP-1 and MMP-3 synthesis through the AP-1 site.	Paclitaxel	43-53	Jun proto-oncogene, AP-1 transcription factor subunit	Bos taurus	117-121
9588740-12	1998	However, inhibition of AP-1 activity by paclitaxel does not affect the viability of chondrocytes or the expression of matrix molecules.	Paclitaxel	40-50	Jun proto-oncogene, AP-1 transcription factor subunit	Bos taurus	23-27
9520464-12	1998	The functions of several induced genes (e.g., krox-24 and cyclooxygenase-2) are self-consistent with beneficial and adverse effects encountered during taxol administration.	Paclitaxel	151-156	early growth response 1	Homo sapiens	46-53
9502180-5	1998	The greatest changes in activity of enzymes at the taxol dose of 2.5 mg/kg bw were as follows: the activity of cathepsin D increased by 71%, that of alanine aminopeptidase increased by 103%, that of beta-glucuronidase decreased by 45% and that of beta-glucosidase decreased by 63%.	Paclitaxel	51-56	glucuronidase, beta	Mus musculus	199-217
9472635-0	1998	Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest.	Paclitaxel	0-5	Fas cell surface death receptor	Homo sapiens	31-35
9523735-6	1998	Some of the taxol analogs modified at positions C-1 and/or C-2 with increased hydrophobicity induced IL-8 expression more than threefold over that induced by taxol or taxotere and more than 20-fold over control cells.	Paclitaxel	12-17	complement C2	Homo sapiens	59-62
9523735-6	1998	Some of the taxol analogs modified at positions C-1 and/or C-2 with increased hydrophobicity induced IL-8 expression more than threefold over that induced by taxol or taxotere and more than 20-fold over control cells.	Paclitaxel	158-163	complement C2	Homo sapiens	59-62
9740541-1	1998	A phase I trial of a 24-hour infusion of paclitaxel was conducted to identify the maximum tolerated dose of paclitaxel with granulocyte colony-stimulating factor (G-CSF) in patients with unresectable malignancy previously untreated with chemotherapy.	Paclitaxel	41-51	colony stimulating factor 3	Homo sapiens	124-161
9740541-1	1998	A phase I trial of a 24-hour infusion of paclitaxel was conducted to identify the maximum tolerated dose of paclitaxel with granulocyte colony-stimulating factor (G-CSF) in patients with unresectable malignancy previously untreated with chemotherapy.	Paclitaxel	41-51	colony stimulating factor 3	Homo sapiens	163-168
9740541-1	1998	A phase I trial of a 24-hour infusion of paclitaxel was conducted to identify the maximum tolerated dose of paclitaxel with granulocyte colony-stimulating factor (G-CSF) in patients with unresectable malignancy previously untreated with chemotherapy.	Paclitaxel	108-118	colony stimulating factor 3	Homo sapiens	124-161
9740541-1	1998	A phase I trial of a 24-hour infusion of paclitaxel was conducted to identify the maximum tolerated dose of paclitaxel with granulocyte colony-stimulating factor (G-CSF) in patients with unresectable malignancy previously untreated with chemotherapy.	Paclitaxel	108-118	colony stimulating factor 3	Homo sapiens	163-168
9740541-5	1998	Paclitaxel can be safely administered as a 24-hour infusion at 300 mg/m2 with G-CSF.	Paclitaxel	0-10	colony stimulating factor 3	Homo sapiens	78-83
9419978-1	1997	It has been shown recently that expression of p21 is enhanced by paclitaxel.	Paclitaxel	65-75	H3 histone pseudogene 16	Homo sapiens	46-49
9419978-3	1997	In the present study, we showed that, in MCF-7 cells, paclitaxel induced accumulation of p21 in cells with a G2/M DNA content, corresponding to cells either in abnormal mitosis or in an interphase-like state (decondensed chromatin) with multiple nuclei.	Paclitaxel	54-64	H3 histone pseudogene 16	Homo sapiens	89-92
9419978-6	1997	High levels of p21 protein were also found to be associated with inactive p34cdc2/cyclin B protein complex after treatment with paclitaxel.	Paclitaxel	128-138	H3 histone pseudogene 16	Homo sapiens	15-18
9419978-6	1997	High levels of p21 protein were also found to be associated with inactive p34cdc2/cyclin B protein complex after treatment with paclitaxel.	Paclitaxel	128-138	cyclin dependent kinase 1	Homo sapiens	74-81
9419978-7	1997	Treatment with p21 antisense oligonucleotide partially blocked induction of p21 expression by paclitaxel and significantly reduced survival of MCF-7 cells exposed to this agent.	Paclitaxel	94-104	H3 histone pseudogene 16	Homo sapiens	15-18
9419978-7	1997	Treatment with p21 antisense oligonucleotide partially blocked induction of p21 expression by paclitaxel and significantly reduced survival of MCF-7 cells exposed to this agent.	Paclitaxel	94-104	H3 histone pseudogene 16	Homo sapiens	76-79
9419978-8	1997	In NIH-OVCAR-3 cells, which are deficient in basal and paclitaxel-induced p21 expression, paclitaxel led to a prolonged activation of p34cdc2 and a delayed mitotic exit associated with apoptotic cell death.	Paclitaxel	55-65	H3 histone pseudogene 16	Homo sapiens	74-77
9419978-8	1997	In NIH-OVCAR-3 cells, which are deficient in basal and paclitaxel-induced p21 expression, paclitaxel led to a prolonged activation of p34cdc2 and a delayed mitotic exit associated with apoptotic cell death.	Paclitaxel	55-65	cyclin dependent kinase 1	Homo sapiens	134-141
9419978-8	1997	In NIH-OVCAR-3 cells, which are deficient in basal and paclitaxel-induced p21 expression, paclitaxel led to a prolonged activation of p34cdc2 and a delayed mitotic exit associated with apoptotic cell death.	Paclitaxel	90-100	H3 histone pseudogene 16	Homo sapiens	74-77
9419978-8	1997	In NIH-OVCAR-3 cells, which are deficient in basal and paclitaxel-induced p21 expression, paclitaxel led to a prolonged activation of p34cdc2 and a delayed mitotic exit associated with apoptotic cell death.	Paclitaxel	90-100	cyclin dependent kinase 1	Homo sapiens	134-141
9815561-5	1997	Loss of either hMSH2 or hMLH1 function was associated with low level resistance to cisplatin, carboplatin, and etoposide, but there was no resistance to melphalan, perfosfamide, 5-fluorouracil, doxorubicin, or paclitaxel.	Paclitaxel	210-220	mutL homolog 1	Homo sapiens	24-29
9379451-0	1997	Conformational studies of paclitaxel analogs modified at the C-2" position in hydrophobic and hydrophilic solvent systems.	Paclitaxel	26-36	complement C2	Homo sapiens	61-64
9379451-1	1997	The conformations of two paclitaxel analogs modified at the C-2" position, 2"-deoxypaclitaxel and 2"-methoxypaclitaxel, were studied in hydrophobic and hydrophilic solvent systems by a combination of NMR spectroscopy, CD measurements, and molecular modeling.	Paclitaxel	25-35	complement C2	Homo sapiens	60-63
9275183-4	1997	Although paclitaxel is broadly effective against human tumor xenografts in mice, including some known to carry p53 mutations, we found that p53-containing mouse tumor cells were significantly more sensitive to direct treatment with this drug than were p53-deficient tumor cells.	Paclitaxel	9-19	transformation related protein 53, pseudogene	Mus musculus	140-143
9275183-6	1997	Conditioned medium from paclitaxel-treated macrophages was capable of inducing p53-independent apoptosis when applied to transformed mouse embryonic fibroblasts and was inhibitable by antibodies against TNF-alpha.	Paclitaxel	24-34	transformation related protein 53, pseudogene	Mus musculus	79-82
9285690-3	1997	Here we first demonstrated that paclitaxel sensitivity correlates with HER-2/neu expression level in a panel of mouse fibroblasts expressing different levels of HER-2/ neu, and that downregulation of HER-2/neu expression by E1A sensitizes the cells to paclitaxel.	Paclitaxel	32-42	erb-b2 receptor tyrosine kinase 2	Mus musculus	71-76
9285690-3	1997	Here we first demonstrated that paclitaxel sensitivity correlates with HER-2/neu expression level in a panel of mouse fibroblasts expressing different levels of HER-2/ neu, and that downregulation of HER-2/neu expression by E1A sensitizes the cells to paclitaxel.	Paclitaxel	32-42	erb-b2 receptor tyrosine kinase 2	Mus musculus	77-80
9285690-3	1997	Here we first demonstrated that paclitaxel sensitivity correlates with HER-2/neu expression level in a panel of mouse fibroblasts expressing different levels of HER-2/ neu, and that downregulation of HER-2/neu expression by E1A sensitizes the cells to paclitaxel.	Paclitaxel	32-42	erb-b2 receptor tyrosine kinase 2	Mus musculus	161-171
9285690-3	1997	Here we first demonstrated that paclitaxel sensitivity correlates with HER-2/neu expression level in a panel of mouse fibroblasts expressing different levels of HER-2/ neu, and that downregulation of HER-2/neu expression by E1A sensitizes the cells to paclitaxel.	Paclitaxel	32-42	erb-b2 receptor tyrosine kinase 2	Mus musculus	71-80
9311440-9	1997	IN CONCLUSION: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.	Paclitaxel	15-25	colony stimulating factor 3	Homo sapiens	137-142
9169462-1	1997	Role of protein kinase C. Paclitaxel can induce tumor necrosis factor (TNF) and interleukin-1 gene expression, similar to lipopolysaccharides.	Paclitaxel	26-36	interleukin 1 alpha	Homo sapiens	80-93
9180834-9	1997	These results clearly demonstrated that the biotransformation of paclitaxel and docetaxel by human liver microsomes was supported by 2 distinct CYP proteins and that drug interactions could modify the therapeutic efficiency of taxoids during chemotherapy.	Paclitaxel	65-75	peptidylprolyl isomerase G	Homo sapiens	144-147
9053494-5	1997	RESULTS: The medians of average daily CD34+ cell yields for patients who received paclitaxel plus CY, CE, and CEP with G-CSF were 12.9, 11.03, and 5.37 x 10(6)/kg, respectively, compared with 2.02 x 10(6)/kg in the reference group that received CY with G-CSF (P = &lt; .0001, .002, and .09, respectively).	Paclitaxel	82-92	colony stimulating factor 3	Homo sapiens	119-124
9053494-6	1997	On first-day collections, patients who received paclitaxel plus CY, CE, and CEP with G-CSF yielded medians of 11.07, 8.09, and 3.52 x 10(6) CD34+ cells/kg, respectively, compared with 0.90 x 10(6)/kg in the reference group that received CY with G-CSF (P = .0006, .02, and .09, respectively).	Paclitaxel	48-58	colony stimulating factor 3	Homo sapiens	85-90
9053494-6	1997	On first-day collections, patients who received paclitaxel plus CY, CE, and CEP with G-CSF yielded medians of 11.07, 8.09, and 3.52 x 10(6) CD34+ cells/kg, respectively, compared with 0.90 x 10(6)/kg in the reference group that received CY with G-CSF (P = .0006, .02, and .09, respectively).	Paclitaxel	48-58	colony stimulating factor 3	Homo sapiens	245-250
9053499-5	1997	With G-CSF support, one of three patients experienced both dose-limiting mucositis and fatal neutropenic sepsis at a dose of paclitaxel 180 mg/m2/96 hours and cisplatin 80 mg/m2.	Paclitaxel	125-135	colony stimulating factor 3	Homo sapiens	5-10
9053499-11	1997	CONCLUSION: The MTD without G-CSF is paclitaxel 120 mg/m2/96 hours and cisplatin 80 mg/m2, and the MTD with G-CSF is paclitaxel 160 mg/m2/96 hours and cisplatin 80 mg/m2.	Paclitaxel	117-127	colony stimulating factor 3	Homo sapiens	108-113
14646529-7	1997	Activation of cyclin B1-associated CDC 2 kinase seems to be an important G2/M event required for paclitaxel-induced apoptosis, and this activation of cyclin B1/CDC 2 kinase could be attributed to the increased activity of CDK 7 kinase.	Paclitaxel	97-107	cyclin B1	Homo sapiens	14-23
14646529-7	1997	Activation of cyclin B1-associated CDC 2 kinase seems to be an important G2/M event required for paclitaxel-induced apoptosis, and this activation of cyclin B1/CDC 2 kinase could be attributed to the increased activity of CDK 7 kinase.	Paclitaxel	97-107	cyclin dependent kinase 1	Homo sapiens	35-40
9815538-6	1997	In vitro, CsA significantly enhanced the efficacy of PCL against lung (Lu-CSF-1 and 3LL) and oropharyngeal (CSCC-20) cancer cell lines.	Paclitaxel	53-56	colony stimulating factor 1	Homo sapiens	74-87
8941411-13	1996	In measurable metastatic gastric carcinoma, only one PR occurred among 20 previously untreated patients given paclitaxel 250 mg/m2 over 24 hours with granulocyte colony-stimulating factor in a phase II Eastern Cooperative Oncology Group study.	Paclitaxel	110-120	colony stimulating factor 3	Homo sapiens	150-187
8811447-9	1996	Preliminary pharmacokinetic studies of CrEL in mice and patients receiving paclitaxel formulated in CrEL have demonstrated the applicability of the presented assay.	Paclitaxel	75-85	reticuloendotheliosis oncogene	Mus musculus	39-43
8629035-6	1996	Hematologic toxicities were dose limiting with the biweekly and low-dose 24-hour paclitaxel/cisplatin combinations; with granulocyte colony-stimulating factor, neurotoxicity became a prominent cumulative toxicity of the high-dose paclitaxel/cisplatin combination.	Paclitaxel	81-91	colony stimulating factor 3	Homo sapiens	121-158
8629035-6	1996	Hematologic toxicities were dose limiting with the biweekly and low-dose 24-hour paclitaxel/cisplatin combinations; with granulocyte colony-stimulating factor, neurotoxicity became a prominent cumulative toxicity of the high-dose paclitaxel/cisplatin combination.	Paclitaxel	230-240	colony stimulating factor 3	Homo sapiens	121-158
8558227-8	1996	Dose-limiting toxicity of grade 4 neutropenia for longer than 5 days and grade 4 thrombocytopenia occurred in three of five patients treated with paclitaxel 160 mg/m2 CIVI and cyclophosphamide 3,300 mg/m2 followed by G-CSF.	Paclitaxel	146-156	colony stimulating factor 3	Homo sapiens	217-222
8558227-15	1996	CONCLUSION: Paclitaxel by 72-hour CIVI with daily cyclophosphamide followed by G-CSF can be administered safely in the ambulatory setting, has acceptable toxicity, and is an active regimen in the treatment of metastatic breast cancer.	Paclitaxel	12-22	colony stimulating factor 3	Homo sapiens	79-84
7591286-0	1995	Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel.	Paclitaxel	122-132	cyclin dependent kinase 1	Homo sapiens	107-111
7591286-16	1995	Since it has been speculated that p34cdc2 kinase is also a kinase that phosphorylates MAP2, the effect of paclitaxel treatment on the p34cdc2-kinase activity of synchronized PC-14 and PC-9 cells was examined.	Paclitaxel	106-116	cyclin dependent kinase 1	Homo sapiens	134-141
7591286-17	1995	Paclitaxel inhibited p34cdc2-kinase activation at the G2/M phase.	Paclitaxel	0-10	cyclin dependent kinase 1	Homo sapiens	21-28
7591286-18	1995	These results suggest that paclitaxel inhibited MAP kinase and p34cdc2 kinase in vivo indirectly.	Paclitaxel	27-37	cyclin dependent kinase 1	Homo sapiens	63-70
7475274-2	1995	In the present studies, we have examined the effects of pIXY321, a genetically engineered fusion protein of GM-CSF and IL-3 (GM-CSF/IL-3), on high-dose Ara-C (HIDAC) and taxol-induced apoptosis and survival of a multilineage HPC, the CFU-GEMM.	Paclitaxel	170-175	interleukin 3	Homo sapiens	125-136
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	30-35	interferon gamma	Rattus norvegicus	175-185
7536686-1	1995	In our study we have used morphological and radio-immunological methods for the investigation of calcitonin gene-related peptide (CGRP) and substance P in cervical dorsal root ganglia (DRGs) in mice after administration of taxol or cisplatin and in spontaneously diabetic animals (db/db mice).	Paclitaxel	223-228	tachykinin 1	Mus musculus	140-151
7749130-15	1995	Paclitaxel is an excellent substrate for P-glycoprotein, the protein product of the multidrug resistance-1 (mdr-1) gene, and phase I trials are under way combining paclitaxel with several known blockers of Pgp function.	Paclitaxel	0-10	phosphoglycolate phosphatase	Homo sapiens	206-209
7556279-1	1995	This study was undertaken to determine if there was an association between the use of granulocyte colony-stimulating factor (G-CSF) and the clinical response to paclitaxel in patients with advanced ovarian cancer.	Paclitaxel	161-171	colony stimulating factor 3	Homo sapiens	86-123
7556279-1	1995	This study was undertaken to determine if there was an association between the use of granulocyte colony-stimulating factor (G-CSF) and the clinical response to paclitaxel in patients with advanced ovarian cancer.	Paclitaxel	161-171	colony stimulating factor 3	Homo sapiens	125-130
7524159-18	1994	The maximum tolerated dose of paclitaxel administered as a 3-hour infusion was 210 mg/m2 without G-CSF and 250 mg/m2 with G-CSF.	Paclitaxel	30-40	colony stimulating factor 3	Homo sapiens	97-102
7524159-18	1994	The maximum tolerated dose of paclitaxel administered as a 3-hour infusion was 210 mg/m2 without G-CSF and 250 mg/m2 with G-CSF.	Paclitaxel	30-40	colony stimulating factor 3	Homo sapiens	122-127
7939763-4	1994	In a recently completed phase II trial in patients with recurrent head and neck cancer, the complete and partial response rate to high-dose paclitaxel (250 mg/m2) given as a 24-hour infusion with granulocyte colony-stimulating factor support was 40% (12 of 30 patients).	Paclitaxel	140-150	colony stimulating factor 3	Homo sapiens	196-233
7906711-7	1994	In addition, keratanase treatment of a taxol microtubule fraction from chick or rat brain eliminated MAP1B, as detected by immunoblotting with the MAP5 monoclonal antibody.	Paclitaxel	39-44	microtubule-associated protein 1B	Rattus norvegicus	101-106
7901186-7	1993	Only TIS8 (also known as egr-1 or zif268) was significantly inducible by radiation, and this transient induction was decreased by at least four-fold by pretreatment for 24 hr with a dose of taxol that was previously shown to block 96.5% of the cells in G2/M and enhance radiosensitivity.	Paclitaxel	190-195	early growth response 1	Homo sapiens	5-9
7901186-7	1993	Only TIS8 (also known as egr-1 or zif268) was significantly inducible by radiation, and this transient induction was decreased by at least four-fold by pretreatment for 24 hr with a dose of taxol that was previously shown to block 96.5% of the cells in G2/M and enhance radiosensitivity.	Paclitaxel	190-195	early growth response 1	Homo sapiens	25-30
7901186-7	1993	Only TIS8 (also known as egr-1 or zif268) was significantly inducible by radiation, and this transient induction was decreased by at least four-fold by pretreatment for 24 hr with a dose of taxol that was previously shown to block 96.5% of the cells in G2/M and enhance radiosensitivity.	Paclitaxel	190-195	early growth response 1	Homo sapiens	34-40
7683933-8	1993	We conclude that taxol, when given with G-CSF support, can be safely administered in a dose-intense fashion for multiple cycles of therapy, without cumulative bone marrow toxicity.	Paclitaxel	17-22	colony stimulating factor 3	Homo sapiens	40-45
8096557-4	1993	The exposure to taxol moderately decreased c-myc expression, but did not induce c-jun expression--which has been previously noted for a variety of DNA interactive, antileukemic drugs.	Paclitaxel	16-21	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	43-48
8097434-5	1993	A comparison of taxol-stabilized microtubules prepared from MAP-free tubulin or tubulin coated with TAU or MAP2 showed that the microtubule-associated proteins diminished, or reduced to background levels, the formation of complexes with mitochondria.	Paclitaxel	16-21	microtubule-associated protein 2	Rattus norvegicus	107-111
8097434-6	1993	In contrast, the amount of MAP-free taxol microtubules that cosedimented with mitochondria increased two- and six-fold when mitochondria were coated with MAP2 or TAU.	Paclitaxel	36-41	microtubule-associated protein 2	Rattus norvegicus	154-158
1351422-7	1992	In TIG-1 cells, when taxol was added within 6 h, about halfway into the initiation of DNA synthesis after the addition of FBS or EGF, the inhibition of DNA synthesis still occurred.	Paclitaxel	21-26	epidermal growth factor	Homo sapiens	129-132
1672157-0	1991	Biologically active taxol analogues with deleted A-ring side chain substituents and variable C-2" configurations.	Paclitaxel	20-25	complement C2	Homo sapiens	93-96
1970787-4	1990	Furthermore, tubulin binding by neuraxin was found to be dependent on taxol.	Paclitaxel	70-75	microtubule-associated protein 1B	Rattus norvegicus	32-40
1970227-2	1990	This procedure is based upon the fact that poly(L-aspartic acid) (PLAA) can specifically remove MAP 1 from microtubules polymerized by taxol (Nakamura et al., 1989, J. Biochem.	Paclitaxel	135-140	Blood pressure QTL 196	Rattus norvegicus	96-101
1970227-6	1990	From microtubules devoid of MAP 1, MAP 2, consisting of MAPs 2A and 2B, could also be isolated by exposure to high ionic strength solutions in the presence of taxol without heat treatment.	Paclitaxel	159-164	microtubule-associated protein 2	Rattus norvegicus	35-40
33798550-13	2021	Overexpressed BCAT1 reversed xenograft tumor formation ability and attenuated the paclitaxel chemosensitivity induced by miR-98 downregulation.	Paclitaxel	82-92	branched chain amino acid transaminase 1	Homo sapiens	14-19
33824297-0	2021	Tubulin acetylation enhances lung cancer resistance to paclitaxel-induced cell death through Mcl-1 stabilization.	Paclitaxel	55-65	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	93-98
33824297-5	2021	Upregulation of tubulin acetylation by overexpression of alpha-tubulin acetyltransferase 1 wild-type (alphaTAT1wt), an enzyme required for acetylation, or by treatment with trichostatin A (TSA), a histone deacetylase 6 (HDAC6) inhibitor, significantly attenuated paclitaxel-induced apoptosis.	Paclitaxel	263-273	alpha tubulin acetyltransferase 1	Homo sapiens	57-90
33824297-7	2021	On the other hand, decreased tubulin acetylation by alphaTAT1 RNA interference downregulated Mcl-1 expression in patient-derived primary lung cancer and paclitaxel-resistant lung cancer cells.	Paclitaxel	153-163	alpha tubulin acetyltransferase 1	Homo sapiens	52-61
33824297-10	2021	These data indicate that tubulin acetylation enhances the resistance to paclitaxel-induced cell death by stabilizing Mcl-1 and protecting it from ubiquitin-proteasome-mediated degradation.	Paclitaxel	72-82	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	117-122
34920124-8	2022	When treated with metformin/LKB1, both SLCO1B3 expression and intracellular PTX concentration have increased.	Paclitaxel	76-79	serine/threonine kinase 11	Homo sapiens	28-32
34563619-6	2022	Furthermore, paclitaxel disrupted circulating corticosterone rhythms in DD by elevating its levels across a 24-hour cycle, which correlated with blunted amplitudes of Arntl, Nr1d1, Per1, and Star rhythms in the adrenal glands.	Paclitaxel	13-23	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	167-172
34563619-6	2022	Furthermore, paclitaxel disrupted circulating corticosterone rhythms in DD by elevating its levels across a 24-hour cycle, which correlated with blunted amplitudes of Arntl, Nr1d1, Per1, and Star rhythms in the adrenal glands.	Paclitaxel	13-23	steroidogenic acute regulatory protein	Mus musculus	191-195
34856211-7	2022	Annexin V/PI test, cell cycle analysis, activation of cleaved PARP1 confirm that VOA plus PTX induce apoptotic cell death.	Paclitaxel	90-93	annexin A5	Homo sapiens	0-9
34855343-4	2021	The released alphaPD-L1 sequentially synergizes with PTX released in the cytoplasm for boosted chemoimmunotherapy due to direct killing of PTX and intensified immune responses through immunogenic cell death (ICD) as well as suppression of immune escape by blocking the PD-1/PD-L1 axis.	Paclitaxel	53-56	CD274 molecule	Homo sapiens	274-279
34743946-4	2021	The data obtained show that PTX-induced MDA, NF-kappaB, IL-1beta, TNF-alpha, COX-2, nNOS, JAK2, STAT3, and GFAP levels decreased with HES administration.	Paclitaxel	28-31	signal transducer and activator of transcription 3	Rattus norvegicus	96-101
34743946-6	2021	It was determined that PTX caused apoptosis in the sciatic nerve by increasing Caspase-3 and Bax levels and suppressing Bcl-2 levels.	Paclitaxel	23-26	BCL2 associated X, apoptosis regulator	Rattus norvegicus	93-96
34743946-8	2021	Also, it was observed that PTX could cause endoplasmic reticulum stress (ERS) by increasing PERK, IRE1, ATF-6, GRP78 and CHOP mRNA transcript levels, while HES could alleviate ERS by suppressing them.	Paclitaxel	27-30	activating transcription factor 6	Rattus norvegicus	104-109
34743946-8	2021	Also, it was observed that PTX could cause endoplasmic reticulum stress (ERS) by increasing PERK, IRE1, ATF-6, GRP78 and CHOP mRNA transcript levels, while HES could alleviate ERS by suppressing them.	Paclitaxel	27-30	DNA-damage inducible transcript 3	Rattus norvegicus	121-125
34950596-0	2021	A Novel miR-98 Negatively Regulates the Resistance of Endometrial Cancer Cells to Paclitaxel by Suppressing ABCC10/MRP-7.	Paclitaxel	82-92	ATP binding cassette subfamily C member 10	Homo sapiens	108-114
34950596-0	2021	A Novel miR-98 Negatively Regulates the Resistance of Endometrial Cancer Cells to Paclitaxel by Suppressing ABCC10/MRP-7.	Paclitaxel	82-92	ATP binding cassette subfamily C member 10	Homo sapiens	115-120
34950596-4	2021	The purpose of this research is to determine whether MRP-7 has a role in mediating the sensitivity of EC cells to paclitaxel and whether the expression of MRP-7 is regulated by miR-98 and lncRNA NEAT1.	Paclitaxel	114-124	ATP binding cassette subfamily C member 10	Homo sapiens	53-58
34950596-6	2021	Downregulation of MRP-7 in EC cells sensitized these cells to paclitaxel and reduced cell invasion.	Paclitaxel	62-72	ATP binding cassette subfamily C member 10	Homo sapiens	18-23
34950596-7	2021	PLAUR serves as a downstream molecule of MRP-7 and facilitates paclitaxel resistance and EC cell invasiveness.	Paclitaxel	63-73	plasminogen activator, urokinase receptor	Homo sapiens	0-5
34950596-7	2021	PLAUR serves as a downstream molecule of MRP-7 and facilitates paclitaxel resistance and EC cell invasiveness.	Paclitaxel	63-73	ATP binding cassette subfamily C member 10	Homo sapiens	41-46
34950596-8	2021	Moreover, miR-98 serves as a tumor suppressor to inhibit MRP-7 expression, leading to the repression of paclitaxel resistance.	Paclitaxel	104-114	ATP binding cassette subfamily C member 10	Homo sapiens	57-62
34950596-10	2021	Taken together, these findings demonstrate that upregulation of MRP-7 and NEAT1, and downregulation of miR-98 have important roles in conferring paclitaxel resistance to EC cells.	Paclitaxel	145-155	ATP binding cassette subfamily C member 10	Homo sapiens	64-69
34873207-4	2021	Paclitaxel induced intrinsic apoptosis by activating caspase-3, caspase-9 and PARP.	Paclitaxel	0-10	caspase 9	Homo sapiens	64-73
34673421-0	2021	beta2-adrenoreceptor agonist ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of mitochondrial biogenesis.	Paclitaxel	65-75	adrenoceptor beta 2	Rattus norvegicus	0-20
34180747-10	2021	Ki-67, EGFR, and angiogenesis markers (Factor VIII, CD31, and CD34) expression were significantly lower in the PTX-NPs group compared with other groups (p < .05).	Paclitaxel	111-114	epidermal growth factor receptor	Mus musculus	7-11
34180747-10	2021	Ki-67, EGFR, and angiogenesis markers (Factor VIII, CD31, and CD34) expression were significantly lower in the PTX-NPs group compared with other groups (p < .05).	Paclitaxel	111-114	CD34 antigen	Mus musculus	62-66
34907739-9	2021	Furthermore, in Ehrlich solid tumor mice, rosmarinic acid, and/or Paclitaxel significantly suppressed tumor growth with an increase in apoptotic markers P53 and Caspase-3 levels, and suppressed the Bcl2/Bax ratio.	Paclitaxel	66-76	transformation related protein 53, pseudogene	Mus musculus	153-156
34849012-17	2021	Paclitaxel sensitivity and ABCC1 expression were higher in the wild CSMD1 group.	Paclitaxel	0-10	CUB and Sushi multiple domains 1	Homo sapiens	68-73
34849012-20	2021	Discussion: CSMD1 mutation could be used as an immune-related biomarker to predict prognosis and treatment effect of paclitaxel.	Paclitaxel	117-127	CUB and Sushi multiple domains 1	Homo sapiens	12-17
34694772-7	2021	On the other hand, treatment with apoptosis inducers, such as paclitaxel, silibinin, doxorubicin, actinomycin D, and camptothecin caused AIF translocation to the nucleus after 4 h incubation through AIF binding to CypA, reaching saturation after 6-7 h. It was also found that Hsp70 and CypA regulate AIF translocation in a mutually exclusive manner because they do not interact with AIF simultaneously in cells undergoing apoptosis.	Paclitaxel	62-72	peptidylprolyl isomerase A	Homo sapiens	214-218
34834551-0	2021	Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene.	Paclitaxel	60-70	catenin beta 1	Homo sapiens	144-150
34834551-7	2021	Accordingly, HCC cell lines harboring mutant TP53 or wild-type CTNNB1 genes are more sensitive to paclitaxel treatment.	Paclitaxel	98-108	catenin beta 1	Homo sapiens	63-69
34834551-8	2021	Therefore, our results imply that HCC patients with mutant TP53 or wild-type CTNNB1 genes may benefit from the paclitaxel therapy.	Paclitaxel	111-121	catenin beta 1	Homo sapiens	77-83
34761351-9	2021	Besides, miR-383-5p restoration and the combined therapy of miR-383-5p restoration with paclitaxel could remarkably increase apoptosis, decrease cell viability, arrest the cell cycle, inhibit clonogenicity, suppress tumor migration, suppress the PI3K/Akt signaling pathway, and down-regulate PD-L1 expression of BC cells.	Paclitaxel	88-98	CD274 molecule	Homo sapiens	292-297
34309886-9	2021	Paclitaxel significantly (p < .05) increased caspase-3 and p-53 and decreased Bcl-2 genes expression than control.	Paclitaxel	0-10	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	59-63
34600241-1	2021	Acquired paclitaxel (PTX) chemoresistance in triple-negative breast cancer (TNBC) can be inferred from the overexpression of toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MyD88) proteins and the activation of the TLR4/MyD88 cascading signalling pathway.	Paclitaxel	21-24	toll like receptor 4	Homo sapiens	244-248
34600241-4	2021	The trimethoxy-substituted compound significantly decreased MyD88 overexpression and improved PTX activity in MDA-MB-231TLR4+ cells but not in HCCTLR4- cells.	Paclitaxel	94-97	toll like receptor 4	Homo sapiens	120-124
32353410-0	2020	FNDC5 promotes paclitaxel sensitivity of non-small cell lung cancers via inhibiting MDR1.	Paclitaxel	15-25	fibronectin type III domain containing 5	Homo sapiens	0-5
34790572-3	2021	Among these 14 genes, SLC7A11 was significantly decreased in two paclitaxel-resistant OC cells (HeyA8-R and SKOV3-R) and in 90 drug-resistant tissues compared with their controls.	Paclitaxel	65-75	solute carrier family 7 member 11	Homo sapiens	22-29
34790572-4	2021	In vitro overexpression of SLC7A11 significantly increased the sensitivity of HeyA8-R cells to paclitaxel, inhibited colony formation, induced apoptosis, and arrested cell cycle.	Paclitaxel	95-105	solute carrier family 7 member 11	Homo sapiens	27-34
32353410-3	2020	However, the role and potential molecular basis for FNDC5 in paclitaxel sensitivity of NSCLCs remain unclear.	Paclitaxel	61-71	fibronectin type III domain containing 5	Homo sapiens	52-57
34717654-11	2021	CONCLUSION: Our results suggest that the combination of TB/PTX@RTK micelle-mediated chemo-PDT with anti-PD-L1 monoclonal antibodies can synergistically enhance systemic anti-tumor effects, and provide a novel insight into the development of new nanomedicine with precise controlled release and multimodal therapy to enhance the therapeutic efficacy of HCC.	Paclitaxel	59-62	CD274 molecule	Homo sapiens	104-109
32727972-8	2020	Among these candidate microRNAs, let-7c precursor treatment of paclitaxel-resistant USPC1-PTXR1 cells caused the greatest increase in paclitaxel-mediated cytotoxicity.	Paclitaxel	63-73	microRNA let-7c	Homo sapiens	33-39
34702806-0	2021	Correction: Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.	Paclitaxel	52-62	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	29-33
32727972-8	2020	Among these candidate microRNAs, let-7c precursor treatment of paclitaxel-resistant USPC1-PTXR1 cells caused the greatest increase in paclitaxel-mediated cytotoxicity.	Paclitaxel	134-144	microRNA let-7c	Homo sapiens	33-39
34729116-11	2021	The up-regulated expression of TTYH3 predicted worse survival in OC patients receiving platin, taxol, or platin + taxol chemotherapy regimen.	Paclitaxel	95-100	tweety family member 3	Homo sapiens	31-36
34729116-11	2021	The up-regulated expression of TTYH3 predicted worse survival in OC patients receiving platin, taxol, or platin + taxol chemotherapy regimen.	Paclitaxel	114-119	tweety family member 3	Homo sapiens	31-36
32727972-9	2020	Let-7c inhibition conversely decreased paclitaxel-induced apoptosis.	Paclitaxel	39-49	microRNA let-7c	Homo sapiens	0-6
34729116-13	2021	Conclusions: TTYH3 was a potential predictor for poor clinical outcome in OC patients, particularly in patients with serous, late-stage, poorly differentiated, TP53-mutation or the patients treated with chemotherapy regimens (platin, taxol, or platin + taxol).	Paclitaxel	234-239	tweety family member 3	Homo sapiens	13-18
34729116-13	2021	Conclusions: TTYH3 was a potential predictor for poor clinical outcome in OC patients, particularly in patients with serous, late-stage, poorly differentiated, TP53-mutation or the patients treated with chemotherapy regimens (platin, taxol, or platin + taxol).	Paclitaxel	253-258	tweety family member 3	Homo sapiens	13-18
32727972-14	2020	These results indicate that let-7c mediates paclitaxel resistance via inhibition of Aurora-B expression in ESC cells.	Paclitaxel	44-54	microRNA let-7c	Homo sapiens	28-34
32700738-0	2020	LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a.	Paclitaxel	26-31	HOX transcript antisense RNA	Homo sapiens	7-13
32700738-5	2020	HOTAIR knockdown suppresses proliferation, invasion and promotes apoptosis of in HepG2/Taxol and SMMC7721/Taxol cells through up-regulating miR-34a by MTT assay, transwell invasion assays and flow cytometry, while down-regulation of miR-34a had an opposite effect on reversing Taxol resistance.	Paclitaxel	87-92	HOX transcript antisense RNA	Homo sapiens	0-6
32700738-5	2020	HOTAIR knockdown suppresses proliferation, invasion and promotes apoptosis of in HepG2/Taxol and SMMC7721/Taxol cells through up-regulating miR-34a by MTT assay, transwell invasion assays and flow cytometry, while down-regulation of miR-34a had an opposite effect on reversing Taxol resistance.	Paclitaxel	106-111	HOX transcript antisense RNA	Homo sapiens	0-6
34786051-4	2021	The results showed that the Cul4A knockdown upregulated the p33ING1b expression in lung cancer cells and increased the lung cancer cell and mice tumor xenograft chemosensitivity to paclitaxel.	Paclitaxel	181-191	cullin 4A	Mus musculus	28-33
32700738-7	2020	Besides, HOTAIR knockdown impaired Taxol-resistance in HCC by accommodating Akt phosphorylation and Wnt/beta-catenin signaling via interacting with miR-34a.	Paclitaxel	35-40	HOX transcript antisense RNA	Homo sapiens	9-15
34786051-5	2021	The Cul4A knockdown also inhibited the growth and increased the apoptosis in the tumor xenografts treated with paclitaxel.	Paclitaxel	111-121	cullin 4A	Mus musculus	4-9
32700738-7	2020	Besides, HOTAIR knockdown impaired Taxol-resistance in HCC by accommodating Akt phosphorylation and Wnt/beta-catenin signaling via interacting with miR-34a.	Paclitaxel	35-40	catenin beta 1	Homo sapiens	104-116
34786051-8	2021	In conclusion, the present findings suggest that Cul4A mediates the chemosensitivity of lung cancer cells to paclitaxel by regulating p33ING1b.	Paclitaxel	109-119	cullin 4A	Mus musculus	49-54
32764924-13	2020	Conclusion: Our data provide evidence that Paclitaxel-loaded-FA-PPSu-PEG-NPs can be used for targeted delivery of the drug, FA-PPSu-PEG-NPs can be used as vehicles for other anticancer drugs and their cellular uptake is mediated through a combination of FOLR1 receptor-specific endocytosis, and macropinocytosis.	Paclitaxel	43-53	folate receptor alpha	Homo sapiens	254-259
34126457-11	2021	Through western blotting analysis, the beta-tubulin and cyclin B1 expression in the Tn-Lipo-PTX group were significantly higher compared with other groups and the CDK1 was down-regulated compared with PTX group, which indicated that targeting liposome delivery system could not only change periodic proteins expression, but also improve the killing effect of PTX on hepatocarcinoma cell.	Paclitaxel	359-362	cyclin dependent kinase 1	Homo sapiens	163-167
34796077-3	2021	Materials and Methods Chemotherapy-naive patients with metastatic NSCLC received carboplatin and paclitaxel (CP) on day one and repeated FDG-PET on day 18.	Paclitaxel	97-107	ceruloplasmin	Homo sapiens	109-111
32278794-0	2020	Role of the TLR4-androgen receptor axis and genistein in taxol-resistant ovarian cancer cells.	Paclitaxel	57-62	toll like receptor 4	Homo sapiens	12-16
34457060-1	2021	It has been reported that paclitaxel activates cell cycle arrest and increases caspase protein expression to induce apoptosis in head and neck squamous cell carcinoma (HNSCC) cell lines.	Paclitaxel	26-36	caspase 6	Homo sapiens	79-86
32278794-1	2020	Toll-like receptor 4 (TLR4) is often overexpressed in taxol-resistant cancer cells.	Paclitaxel	54-59	toll like receptor 4	Homo sapiens	0-20
32278794-1	2020	Toll-like receptor 4 (TLR4) is often overexpressed in taxol-resistant cancer cells.	Paclitaxel	54-59	toll like receptor 4	Homo sapiens	22-26
32278794-4	2020	Accordingly, AR expression was induced in taxol-resistant SKOV3 cells overexpressing TLR4, whereas depletion of TLR4 by shRNA repressed AR expression.	Paclitaxel	42-47	toll like receptor 4	Homo sapiens	85-89
34638252-0	2021	Pharmacological Inhibition of PP2A Overcomes Nab-Paclitaxel Resistance by Downregulating MCL1 in Esophageal Squamous Cell Carcinoma (ESCC).	Paclitaxel	49-59	protein phosphatase 2 phosphatase activator	Homo sapiens	30-34
32278794-6	2020	We found that expression of DCDC2, ANKRD18B, ALDH1A1, c14orf105, ITGBL1 and NEB was overexpressed in taxol-resistant cells, suggesting the involvement of these AR-related genes in taxol resistance.	Paclitaxel	101-106	doublecortin domain containing 2	Homo sapiens	28-33
32278794-6	2020	We found that expression of DCDC2, ANKRD18B, ALDH1A1, c14orf105, ITGBL1 and NEB was overexpressed in taxol-resistant cells, suggesting the involvement of these AR-related genes in taxol resistance.	Paclitaxel	101-106	aldehyde dehydrogenase 1 family member A1	Homo sapiens	45-52
34566640-4	2021	Based on the results, PTX inhibited the migration of RA-FLS in a dose-dependent manner and significantly reduced the spontaneous expression of IL-6, IL-8, and RANKL mRNA and TNF-alpha-induced transcription of the IL-1 beta, IL-8, MMP-8, and MMP-9 genes.	Paclitaxel	22-25	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	159-164
32278794-6	2020	We found that expression of DCDC2, ANKRD18B, ALDH1A1, c14orf105, ITGBL1 and NEB was overexpressed in taxol-resistant cells, suggesting the involvement of these AR-related genes in taxol resistance.	Paclitaxel	180-185	doublecortin domain containing 2	Homo sapiens	28-33
34566640-4	2021	Based on the results, PTX inhibited the migration of RA-FLS in a dose-dependent manner and significantly reduced the spontaneous expression of IL-6, IL-8, and RANKL mRNA and TNF-alpha-induced transcription of the IL-1 beta, IL-8, MMP-8, and MMP-9 genes.	Paclitaxel	22-25	interleukin 1 alpha	Mus musculus	213-222
34566640-6	2021	Mechanistic studies revealed that PTX significantly inhibited the TNF-alpha-induced phosphorylation of ERK1/2 and JNK in the mitogen-activated protein kinase (MAPK) pathway and suppressed the TNF-alpha-induced activation of AKT, p70S6K, 4EBP1, and HIF-1alpha in the AKT/mTOR pathway.	Paclitaxel	34-37	hypoxia inducible factor 1, alpha subunit	Mus musculus	248-258
34566640-6	2021	Mechanistic studies revealed that PTX significantly inhibited the TNF-alpha-induced phosphorylation of ERK1/2 and JNK in the mitogen-activated protein kinase (MAPK) pathway and suppressed the TNF-alpha-induced activation of AKT, p70S6K, 4EBP1, and HIF-1alpha in the AKT/mTOR pathway.	Paclitaxel	34-37	mechanistic target of rapamycin kinase	Mus musculus	270-274
34566640-8	2021	In conclusion, PTX inhibits the migration and inflammatory mediator production of RA-FLS by targeting the MAPK and AKT/mTOR signaling pathways, which provides an experimental basis for the potential application in the treatment of RA.	Paclitaxel	15-18	mechanistic target of rapamycin kinase	Mus musculus	119-123
34370483-3	2021	In this study, paclitaxel (PTX) molecules were encapsulated within an apoferritin nanocage-based drug delivery system with the modification of an extracellular-signal-regulated kinase (ERK) peptide inhibitor at the C-terminus of ferritin (HERK).	Paclitaxel	15-25	ferritin heavy chain 1	Homo sapiens	70-81
32278794-6	2020	We found that expression of DCDC2, ANKRD18B, ALDH1A1, c14orf105, ITGBL1 and NEB was overexpressed in taxol-resistant cells, suggesting the involvement of these AR-related genes in taxol resistance.	Paclitaxel	180-185	aldehyde dehydrogenase 1 family member A1	Homo sapiens	45-52
34370483-3	2021	In this study, paclitaxel (PTX) molecules were encapsulated within an apoferritin nanocage-based drug delivery system with the modification of an extracellular-signal-regulated kinase (ERK) peptide inhibitor at the C-terminus of ferritin (HERK).	Paclitaxel	27-30	ferritin heavy chain 1	Homo sapiens	70-81
32445273-14	2020	Moreover, miR-140-5p suppressed IC50 of PTX, cell viability, colony numbers, cell invasion and glycolysis by targeting E2F3.	Paclitaxel	40-43	microRNA 140	Homo sapiens	10-17
32581554-0	2020	Long Non-Coding RNA CRNDE Promotes Colorectal Carcinoma Cell Progression and Paclitaxel Resistance by Regulating miR-126-5p/ATAD2 Axis.	Paclitaxel	77-87	colorectal neoplasia differentially expressed	Homo sapiens	20-25
34327529-0	2021	lncRNA NEAT1 promotes the Taxol resistance of breast cancer via sponging the miR-23a-3p-FOXA1 axis.	Paclitaxel	26-31	forkhead box A1	Homo sapiens	88-93
34338752-0	2021	Correction: LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a.	Paclitaxel	38-43	HOX transcript antisense RNA	Homo sapiens	19-25
32581554-0	2020	Long Non-Coding RNA CRNDE Promotes Colorectal Carcinoma Cell Progression and Paclitaxel Resistance by Regulating miR-126-5p/ATAD2 Axis.	Paclitaxel	77-87	microRNA 126	Homo sapiens	113-120
32581554-11	2020	CRNDE depletion repressed PTX resistance and the growth of CRC cells.	Paclitaxel	26-29	colorectal neoplasia differentially expressed	Homo sapiens	0-5
32581554-14	2020	Conclusion: Our data suggested that CRNDE regulated CRC cell development and PTX resistance by modulating miR-126-5p/ATAD2 axis, providing the theoretical basis for the treatment of CRC patients.	Paclitaxel	77-80	colorectal neoplasia differentially expressed	Homo sapiens	36-41
34394349-5	2021	Methods: We conducted a retrospective cohort study on the total population of Croatian patients diagnosed with metastatic cervical cancer from 2016 to 2019 who were treated with bevacizumab in combination with cisplatin and paclitaxel (TCB) in the first line.	Paclitaxel	224-234	pyruvate kinase M1/2	Homo sapiens	236-239
32581554-14	2020	Conclusion: Our data suggested that CRNDE regulated CRC cell development and PTX resistance by modulating miR-126-5p/ATAD2 axis, providing the theoretical basis for the treatment of CRC patients.	Paclitaxel	77-80	microRNA 126	Homo sapiens	106-113
32240873-4	2020	Cells viability (assessed by MTT assay), apoptosis (assessed by flow cytometry) and the expression of PTX resistance gene (TRX1) and PTX metabolizing genes (CYP2C8 and CYP3A4) were investigated.	Paclitaxel	102-105	thioredoxin	Homo sapiens	123-127
32641986-10	2020	Knockdown of IFIT3 attenuates the chemotherapy resistance of PDAC cells to gemcitabine, paclitaxel, and FOLFIRINOX regimen treatments, independent of individual chemotherapy regimens.	Paclitaxel	88-98	interferon induced protein with tetratricopeptide repeats 3	Homo sapiens	13-18
34219000-10	2021	In the PD-L1-positive population, atezolizumab-paclitaxel was associated with more favourable unconfirmed best overall response rate (63% versus 55% with placebo-paclitaxel) and median duration of response (7.2 versus 5.5 months, respectively).	Paclitaxel	47-57	CD274 molecule	Homo sapiens	7-12
34359638-0	2021	Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer.	Paclitaxel	21-31	CD274 molecule	Homo sapiens	40-45
32897218-0	2020	[Long-chain non-coding RNA MALAT1 regulates paclitaxel resistance of breast cancer cells by targeting miR-485-3p].	Paclitaxel	44-54	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	27-33
34354859-9	2021	Furthermore, reduced SIKs, even triple knockdown of SIK1, SIK2 and SIK3 rendered the breast cancer cells to confer chemoresistance to paclitaxel and cisplatin.	Paclitaxel	134-144	salt inducible kinase 1	Homo sapiens	52-56
32897218-1	2020	OBJECTIVE: To investigate the role of long-chain non-coding RNA MALAT1 in modulating paclitaxel resistance in breast cancer cells.	Paclitaxel	85-95	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	64-70
32775453-0	2020	miR-520h Stimulates Drug Resistance to Paclitaxel by Targeting the OTUD3-PTEN Axis in Breast Cancer.	Paclitaxel	39-49	microRNA 520h	Homo sapiens	0-8
34174909-3	2021	We previously established paclitaxel-induced inositol trisphosphate receptor (InsP3R)-dependent calcium oscillations as a mechanism for peripheral neuropathy, which was prevented by lithium pretreatment.	Paclitaxel	26-36	inositol 1,4,5-trisphosphate receptor 1	Mus musculus	78-84
32775453-0	2020	miR-520h Stimulates Drug Resistance to Paclitaxel by Targeting the OTUD3-PTEN Axis in Breast Cancer.	Paclitaxel	39-49	OTU deubiquitinase 3	Homo sapiens	67-72
32775453-0	2020	miR-520h Stimulates Drug Resistance to Paclitaxel by Targeting the OTUD3-PTEN Axis in Breast Cancer.	Paclitaxel	39-49	phosphatase and tensin homolog	Homo sapiens	73-77
32775453-3	2020	The aim of this study was to investigate the molecular mechanisms of miR-520h in paclitaxel resistance in the MCF-7 breast cancer cell line.	Paclitaxel	81-91	microRNA 520h	Homo sapiens	69-77
34174909-14	2021	CONCLUSION: We establish the InsP3R calcium pathway and impaired neuronal morphology as mechanisms for paclitaxel-induced cognitive impairment.	Paclitaxel	103-113	inositol 1,4,5-trisphosphate receptor 1	Mus musculus	29-35
32775453-4	2020	Ectopic expression of miR-520h could promote the proliferation of breast cancer cells and inhibit paclitaxel-induced cell apoptosis.	Paclitaxel	98-108	microRNA 520h	Homo sapiens	22-30
32426048-8	2020	In all patients with unknown PD-L1 status, atezolizumab plus nab-paclitaxel treatment guiding by PD-L1 expression testing resulted in an ICER of $183,508 per QALY gained.	Paclitaxel	65-75	CD274 molecule	Homo sapiens	29-34
34205051-5	2021	While the concentrations of sEVs released from MTA-treated cells were not significantly altered, levels of CD63 and the CD63-associated cargos, ILK and beta-integrin, were reduced in sEVs isolated from eribulin-treated HCC1937 cells as compared to vehicle or paclitaxel-treated cells.	Paclitaxel	259-269	CD63 molecule	Homo sapiens	120-124
35533911-3	2022	In our previous studies, 11alpha-O-2-methylbutanoyl-12beta-O-tigloyl-tenacigenin B (MT2), the main steroid aglycone isolated from M. tenacissima, was found to significantly enhance the antitumor activity of paclitaxel (PTX) in vivo.	Paclitaxel	207-217	melatonin receptor 1B	Homo sapiens	84-87
35533911-3	2022	In our previous studies, 11alpha-O-2-methylbutanoyl-12beta-O-tigloyl-tenacigenin B (MT2), the main steroid aglycone isolated from M. tenacissima, was found to significantly enhance the antitumor activity of paclitaxel (PTX) in vivo.	Paclitaxel	219-222	melatonin receptor 1B	Homo sapiens	84-87
35533911-6	2022	MATERIALS AND METHODS: MDR cell line HeLa/Tax was established from the human cervical carcinoma cell line HeLa by long-term exposure to subtoxic concentrations of PTX and was used to evaluate the ability of MT2 to restore chemosensitivity of cells both in vitro and in a nude mouse model.	Paclitaxel	163-166	melatonin receptor 1B	Homo sapiens	207-210
32426048-8	2020	In all patients with unknown PD-L1 status, atezolizumab plus nab-paclitaxel treatment guiding by PD-L1 expression testing resulted in an ICER of $183,508 per QALY gained.	Paclitaxel	65-75	CD274 molecule	Homo sapiens	97-102
35533911-13	2022	Knockdown of P-gp with small interfering RNA partially reversed MT2-induced sensitivity to PTX in HeLa/Tax cells.	Paclitaxel	91-94	melatonin receptor 1B	Homo sapiens	64-67
32426048-9	2020	Atezolizumab plus nab-paclitaxel could maintain a trend of positive incremental net health benefits and >50% probabilities of cost-effectiveness at the threshold of $200,000/QALY in more than half of subgroups with PD-L1-positive.	Paclitaxel	22-32	CD274 molecule	Homo sapiens	215-220
35509138-4	2022	In response to paclitaxel, females had reduced mechanical hypersensitivity and a greater frequency of anti-inflammatory CD4+ T cells (FoxP3, IL-10, IL-4) in the DRG than male and ovariectomized female mice.	Paclitaxel	15-25	forkhead box P3	Mus musculus	134-139
35509138-4	2022	In response to paclitaxel, females had reduced mechanical hypersensitivity and a greater frequency of anti-inflammatory CD4+ T cells (FoxP3, IL-10, IL-4) in the DRG than male and ovariectomized female mice.	Paclitaxel	15-25	interleukin 4	Mus musculus	148-152
32426048-11	2020	Conclusion: The atezolizumab plus nab-paclitaxel treatment is likely to be a cost-effective option compared with chemotherapy based on nab-paclitaxel for the patients with PD-L1-positive advanced TNBC.	Paclitaxel	38-48	CD274 molecule	Homo sapiens	172-177
35614037-4	2022	By in vitro studies, we confirmed the specific and competitive nature of the C5aR1-paclitaxel binding and found that it triggers intracellularly the NFkB/P38 pathway and c-Fos.	Paclitaxel	83-93	FBJ osteosarcoma oncogene	Mus musculus	170-175
32089062-0	2020	Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.	Paclitaxel	50-60	colon cancer associated transcript 1	Homo sapiens	20-25
32089062-3	2020	However, the potential role of CCAT1 in the sensitivity of paclitaxel (PTX) in PCa and its mechanism remain largely unknown.	Paclitaxel	59-69	colon cancer associated transcript 1	Homo sapiens	31-36
32089062-3	2020	However, the potential role of CCAT1 in the sensitivity of paclitaxel (PTX) in PCa and its mechanism remain largely unknown.	Paclitaxel	71-74	colon cancer associated transcript 1	Homo sapiens	31-36
35623257-1	2022	Herein, novel laser-responsive multi-functional nanoparticles (NPs-Lip@PTX/CyA/Ce6) were fabricated with bovine serum albumins (BSA) based nanoparticles, which simultaneously carried chemotherapeutic drug paclitaxel (PTX) and P-gp inhibitor cyclosporin A (CyA), as core and photosensitizer agent Chlorin e6 (Ce6) loaded Tf-modified liposomal bilayer as shell.	Paclitaxel	205-215	phosphoglycolate phosphatase	Homo sapiens	226-230
32089062-4	2020	The PTX-resistant PCa cells were established in PC3 and DU145 cells by increasing concentrations of PTX.	Paclitaxel	4-7	proprotein convertase subtilisin/kexin type 1	Homo sapiens	48-51
35623257-1	2022	Herein, novel laser-responsive multi-functional nanoparticles (NPs-Lip@PTX/CyA/Ce6) were fabricated with bovine serum albumins (BSA) based nanoparticles, which simultaneously carried chemotherapeutic drug paclitaxel (PTX) and P-gp inhibitor cyclosporin A (CyA), as core and photosensitizer agent Chlorin e6 (Ce6) loaded Tf-modified liposomal bilayer as shell.	Paclitaxel	217-220	phosphoglycolate phosphatase	Homo sapiens	226-230
32089062-8	2020	Results showed that the expressions of CCAT1 were up-regulated and miR-24-3p was down-regulated in PCa and PTX-resistant PCa cells (PC3-TXR and DU145-TXR).	Paclitaxel	107-110	proprotein convertase subtilisin/kexin type 1	Homo sapiens	132-135
32089062-9	2020	Knockdown of CCAT1 or overexpression of miR-24-3p inhibited survival rate, half maximal inhibitory concentration (IC50) of PTX but increased apoptosis in PC3-TXR and DU145-TXR cells after treatment of PTX.	Paclitaxel	123-126	colon cancer associated transcript 1	Homo sapiens	13-18
35625886-7	2022	Inhibition of SERTAD1 promoted the sensitivity of breast cancer cells to Dox and paclitaxel, leading to a significant reduction in tumor volumes of xenograft mice.	Paclitaxel	81-91	SERTA domain containing 1	Mus musculus	14-21
32089062-9	2020	Knockdown of CCAT1 or overexpression of miR-24-3p inhibited survival rate, half maximal inhibitory concentration (IC50) of PTX but increased apoptosis in PC3-TXR and DU145-TXR cells after treatment of PTX.	Paclitaxel	201-204	colon cancer associated transcript 1	Homo sapiens	13-18
32089062-10	2020	miR-24-3p was bound to CCAT1 and its abrogation reversed knockdown of CCAT1-mediated increase of PTX sensitivity in PC3-TXR and DU145-TXR cells.	Paclitaxel	97-100	colon cancer associated transcript 1	Homo sapiens	23-28
32089062-10	2020	miR-24-3p was bound to CCAT1 and its abrogation reversed knockdown of CCAT1-mediated increase of PTX sensitivity in PC3-TXR and DU145-TXR cells.	Paclitaxel	97-100	colon cancer associated transcript 1	Homo sapiens	70-75
32089062-10	2020	miR-24-3p was bound to CCAT1 and its abrogation reversed knockdown of CCAT1-mediated increase of PTX sensitivity in PC3-TXR and DU145-TXR cells.	Paclitaxel	97-100	proprotein convertase subtilisin/kexin type 1	Homo sapiens	116-119
35584731-7	2022	Paclitaxel increased GDF9 expression in oocytes after 4 days of the culture (p <= 0.05).	Paclitaxel	0-10	growth differentiation factor 9	Mus musculus	21-25
32089062-13	2020	Our data suggested interference of CCAT1 contributed to PTX sensitivity in PCa by regulating miR-24-3p and FSCN1, indicating a novel avenue for treatment of PCa through regulating chemoresistance.	Paclitaxel	56-59	colon cancer associated transcript 1	Homo sapiens	35-40
35571619-0	2022	lncRNA-DANCR Promotes Taxol Resistance of Prostate Cancer Cells through Modulating the miR-33b-5p-LDHA Axis.	Paclitaxel	22-27	microRNA 33b	Homo sapiens	87-94
35571619-6	2022	Here, we report that the expressions of DANCR were significantly upregulated and miR-33b-5p were downregulated in prostate tumor specimens and cells as well as the Taxol-resistant prostate cancer cell line (PC3-TXR).	Paclitaxel	164-169	microRNA 33b	Homo sapiens	81-88
32114508-2	2020	This study aimed to elucidate in vivo inhibition potency of paclitaxel against OATP1B1 and OATP1B3 using endogenous OATP1B biomarkers.	Paclitaxel	60-70	solute carrier organic anion transporter family member 1B1	Homo sapiens	79-86
35571619-7	2022	Silencing DANCR or overexpressing miR-33b-5p effectively enhanced the Taxol sensitivity of PCa cells.	Paclitaxel	70-75	microRNA 33b	Homo sapiens	34-41
35571619-13	2022	Finally, the rescue of miR-33b-5p in DANCR-overexpressing PC3-TXR cells successfully overrode the DANCR-promoted Taxol resistance.	Paclitaxel	113-118	microRNA 33b	Homo sapiens	23-30
32114508-3	2020	Paclitaxel is an inhibitor of OATP1B1 and OATP1B3 with Ki of 0.579 +- 0.107 microM and 5.29 +- 3.87 microM, respectively.	Paclitaxel	0-10	solute carrier organic anion transporter family member 1B1	Homo sapiens	30-37
32114508-8	2020	Therapeutic doses of paclitaxel for the treatment of non-small cell lung cancer (200 mg/m2) will cause significant OATP1B1 inhibition during and at the end of the infusion.	Paclitaxel	21-31	solute carrier organic anion transporter family member 1B1	Homo sapiens	115-122
35633550-5	2022	The combined effect of the ethyl acetate fraction and paclitaxel were analyzed using combination index (CI) and immunoblotting on the pro-apoptotic protein Mcl-1S.	Paclitaxel	54-64	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	156-162
32114508-11	2020	In this study, we could elucidate a significant increment of the plasma concentrations of OATP1B endogenous biomarkers following a 3-h infusion (200 mg/m2) of paclitaxel, an inhibitor causing time-dependent inhibition of OATP1B1 and OATP1B3, in patients.	Paclitaxel	159-169	solute carrier organic anion transporter family member 1B1	Homo sapiens	221-228
35633550-14	2022	It has a synergistic cytotoxic effect with paclitaxel on MDA MB 231 cell death and upregulates Mcl-1S protein.	Paclitaxel	43-53	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	95-101
31818526-10	2020	CONCLUSION: This systematic review and meta-analysis suggests that NACT-IDS with carboplatin and paclitaxel does not negatively impact the survival of women with advanced ovarian cancer compared to PDS, while perioperative complications and mortality are significantly reduced by 70-80%.	Paclitaxel	97-107	solute carrier family 13 member 5	Homo sapiens	67-71
35184686-10	2022	STON2 overexpression reversed the effects of miR-144-5p overexpression.. MiR-144-5p overexpression enhanced the inhibiting effect of PTX on tumor volume, weight, and Ki67 level of xenotransplant tumor, and the effects of UTMD-mediated miR-144-5p overexpression were stronger than those mediated by liposome.	Paclitaxel	133-136	stonin 2	Mus musculus	0-5
35184686-11	2022	Collectively, UTMD-mediated miR-144-5p overexpression enhanced the anti-tumor effect of PTX on thyroid carcinoma by targeting STON2.	Paclitaxel	88-91	stonin 2	Mus musculus	126-131
35566044-7	2022	After 72 h of incubation, the mitochondrial activity showed that the combination of 5 nM Paclitaxel with 10 microM 6-Gingerol led to the same decrease in viability as the use of 20 nM Paclitaxel alone; 10 microM 6-Gingerol led to an enhancement of caspase 7 activity, with the highest activity observed after 24 h of incubation.	Paclitaxel	89-99	caspase 7	Homo sapiens	248-257
35440807-6	2022	Inhibition of the release of exosomes by GW4869 or inhibition of STAT3 phosphorylation by stattic could effectively reverse the resistance to paclitaxel mediated by exosomal PD-L1.	Paclitaxel	142-152	CD274 molecule	Homo sapiens	174-179
35440807-9	2022	Our results suggested that exosomal PD-L1 may contribute to drug resistance to paclitaxel by regulating the STAT3/miR-21/PTEN/Akt axis and promote tumorigenic phenotype.	Paclitaxel	79-89	CD274 molecule	Homo sapiens	36-41
18164931-2	2008	A chitosan-egg phosphatidylcholine (chitosan-ePC) implant system containing PLA-b-PEG/PLA nanoparticles has been developed for the delivery of paclitaxel to treat ovarian cancer.	Paclitaxel	143-153	transcription factor 21	Mus musculus	45-48
18164931-7	2008	Release of paclitaxel was found to be sustained over a four-week period following implantation of the chitosan-ePC system into the peritoneal cavity of healthy Balb/C mice.	Paclitaxel	11-21	transcription factor 21	Mus musculus	111-114
18006110-8	2008	G-CSF support allowed paclitaxel dose-escalation to 250 mg/m(2).	Paclitaxel	22-32	colony stimulating factor 3	Homo sapiens	0-5
35440807-9	2022	Our results suggested that exosomal PD-L1 may contribute to drug resistance to paclitaxel by regulating the STAT3/miR-21/PTEN/Akt axis and promote tumorigenic phenotype.	Paclitaxel	79-89	microRNA 21	Homo sapiens	114-120
32431514-0	2020	Tetrandrine Reverses Paclitaxel Resistance in Human Ovarian Cancer via Inducing Apoptosis, Cell Cycle Arrest Through beta-Catenin Pathway.	Paclitaxel	21-31	catenin beta 1	Homo sapiens	117-129
35440807-9	2022	Our results suggested that exosomal PD-L1 may contribute to drug resistance to paclitaxel by regulating the STAT3/miR-21/PTEN/Akt axis and promote tumorigenic phenotype.	Paclitaxel	79-89	phosphatase and tensin homolog	Homo sapiens	121-125
18445659-0	2008	MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer.	Paclitaxel	71-81	ATP binding cassette subfamily C member 10	Homo sapiens	0-4
32431514-9	2020	Moreover, combination of TET and PTX obviously induced cell cycle arrest in SKOV3/PTX cells via increasing the level of p21 and decreasing the levels of c-Myc and Cyclin D1.	Paclitaxel	33-36	H3 histone pseudogene 16	Homo sapiens	120-123
18445659-0	2008	MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer.	Paclitaxel	71-81	ATP binding cassette subfamily C member 10	Homo sapiens	5-11
35492735-5	2022	The purpose of this study is to clarify the role of Ca2+/calmodulin-dependent protein kinase II (CaMKII)-positive glutamatergic neurons in the amygdala in paclitaxel-induced pain and negative affective symptoms.	Paclitaxel	155-165	calcium/calmodulin-dependent protein kinase II gamma	Mus musculus	52-95
35492735-7	2022	Immunofluorescence staining revealed that c-fos-positive neurons were significantly more in the basolateral amygdala (BLA) and central amygdala (CeA) in paclitaxel-treated mice than untreated mice.	Paclitaxel	153-163	FBJ osteosarcoma oncogene	Mus musculus	42-47
32431514-9	2020	Moreover, combination of TET and PTX obviously induced cell cycle arrest in SKOV3/PTX cells via increasing the level of p21 and decreasing the levels of c-Myc and Cyclin D1.	Paclitaxel	33-36	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	153-158
35391656-0	2022	Downregulation of Circ-CEP128 Enhances the Paclitaxel Sensitivity of Cervical Cancer Through Regulating miR-432-5p/MCL1.	Paclitaxel	43-53	centrosomal protein 128	Mus musculus	23-29
32431514-10	2020	Meanwhile, combination of TET with PTX significantly decreased the expression of beta-catenin in SKOV3/PTX cells.	Paclitaxel	35-38	catenin beta 1	Homo sapiens	81-93
35391656-10	2022	Silencing of circ-CEP128 could enhance the paclitaxel sensitivity of CC cells by decreasing cell growth, migration, and invasion.	Paclitaxel	43-53	centrosomal protein 128	Mus musculus	18-24
32431514-10	2020	Meanwhile, combination of TET with PTX significantly decreased the expression of beta-catenin in SKOV3/PTX cells.	Paclitaxel	103-106	catenin beta 1	Homo sapiens	81-93
35391656-12	2022	MiR-432-5p was found to be sponged by circ-CEP128, and its inhibitor could reverse the promoting function of circ-CEP128 silencing on the paclitaxel sensitivity of CC cells.	Paclitaxel	138-148	centrosomal protein 128	Mus musculus	114-120
35391656-15	2022	In conclusion, the present study showed that circ-CEP128 silencing could increase the paclitaxel sensitivity of CC by regulating the miR-432-5p/MCL1 axis.	Paclitaxel	86-96	centrosomal protein 128	Mus musculus	50-56
32431514-12	2020	Conclusion: We found that TET could enhance the sensitivity of SKOV3/PTX cells to PTX via inhibiting the beta-catenin/c-Myc/Cyclin D1 signaling pathway.	Paclitaxel	69-72	catenin beta 1	Homo sapiens	105-117
35419287-8	2022	The ferroptosis-related p53-SLC7A11-GPX4 pathway was also altered under different treatment propofol, doxorubicin, or paclitaxel regimens.	Paclitaxel	118-128	solute carrier family 7 member 11	Homo sapiens	28-35
35419287-8	2022	The ferroptosis-related p53-SLC7A11-GPX4 pathway was also altered under different treatment propofol, doxorubicin, or paclitaxel regimens.	Paclitaxel	118-128	glutathione peroxidase 4	Homo sapiens	36-40
32431514-12	2020	Conclusion: We found that TET could enhance the sensitivity of SKOV3/PTX cells to PTX via inhibiting the beta-catenin/c-Myc/Cyclin D1 signaling pathway.	Paclitaxel	69-72	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	118-123
32431514-12	2020	Conclusion: We found that TET could enhance the sensitivity of SKOV3/PTX cells to PTX via inhibiting the beta-catenin/c-Myc/Cyclin D1 signaling pathway.	Paclitaxel	82-85	catenin beta 1	Homo sapiens	105-117
32431514-12	2020	Conclusion: We found that TET could enhance the sensitivity of SKOV3/PTX cells to PTX via inhibiting the beta-catenin/c-Myc/Cyclin D1 signaling pathway.	Paclitaxel	82-85	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	118-123
35038584-5	2022	In vitro characterization and cellular experiments indicated that NanoMn-GOx-PTX could catalyze the conversion of glucose into reactive oxygen species (ROS) through a cascade Fenton-like reaction as well as release free PTX.	Paclitaxel	77-80	hydroxyacid oxidase 1, liver	Mus musculus	73-76
32320668-6	2020	Overexpression of Wdr47 in wild-type neurons inhibits axon specification and neutralizes Taxol-induced neurite overgrowth and axon overproduction.	Paclitaxel	89-94	WD repeat domain 47	Mus musculus	18-23
35038584-5	2022	In vitro characterization and cellular experiments indicated that NanoMn-GOx-PTX could catalyze the conversion of glucose into reactive oxygen species (ROS) through a cascade Fenton-like reaction as well as release free PTX.	Paclitaxel	220-223	hydroxyacid oxidase 1, liver	Mus musculus	73-76
35038584-7	2022	Moreover, NanoMn-GOx-PTX effectively induced the production of large amounts of type I interferon and pro-inflammatory cytokines in vivo, activating the innate immune response.	Paclitaxel	21-24	hydroxyacid oxidase 1, liver	Mus musculus	17-20
35038584-8	2022	Through the synergistic functions of the above components, NanoMn-GOx-PTX exerted the strongest anti-tumor effect in 4T1 tumor-bearing models.	Paclitaxel	70-73	hydroxyacid oxidase 1, liver	Mus musculus	66-69
32129476-2	2020	Patients with metastatic or locally advanced TNBC with PD-L1 expression on immune cells occupying >=1% of tumor area demonstrated survival benefit with the addition of atezolizumab to nab-paclitaxel.	Paclitaxel	188-198	CD274 molecule	Homo sapiens	55-60
35328460-0	2022	Effect of ALDH1A1 Gene Knockout on Drug Resistance in Paclitaxel and Topotecan Resistant Human Ovarian Cancer Cell Lines in 2D and 3D Model.	Paclitaxel	54-64	aldehyde dehydrogenase 1 family member A1	Homo sapiens	10-17
35328460-3	2022	The goal of our study was to examine the role of aldehyde dehydrogenase 1A1 (ALDH1A1) expression in paclitaxel (PAC) and topotecan (TOP) resistant ovarian cancer cell lines.	Paclitaxel	100-110	aldehyde dehydrogenase 1 family member A1	Homo sapiens	49-75
35328460-3	2022	The goal of our study was to examine the role of aldehyde dehydrogenase 1A1 (ALDH1A1) expression in paclitaxel (PAC) and topotecan (TOP) resistant ovarian cancer cell lines.	Paclitaxel	100-110	aldehyde dehydrogenase 1 family member A1	Homo sapiens	77-84
35328460-3	2022	The goal of our study was to examine the role of aldehyde dehydrogenase 1A1 (ALDH1A1) expression in paclitaxel (PAC) and topotecan (TOP) resistant ovarian cancer cell lines.	Paclitaxel	112-115	aldehyde dehydrogenase 1 family member A1	Homo sapiens	49-75
35328460-3	2022	The goal of our study was to examine the role of aldehyde dehydrogenase 1A1 (ALDH1A1) expression in paclitaxel (PAC) and topotecan (TOP) resistant ovarian cancer cell lines.	Paclitaxel	112-115	aldehyde dehydrogenase 1 family member A1	Homo sapiens	77-84
35240000-11	2022	Western blot analysis indicated that zerumbone significantly upregulated BAX, caspase-7, and caspase-9 expression and decreased BCL-2 expression, thereby inducing proapoptotic protein-mediated cell death combined with PTX.	Paclitaxel	218-221	caspase 9	Homo sapiens	93-102
33014143-9	2020	Conclusions: Atezolizumab plus nab-paclitaxel represents a potential new first-line standard of care for patients with metastatic PD-L1-positive TNBC.	Paclitaxel	35-45	CD274 molecule	Homo sapiens	130-135
35042769-2	2022	Here we report a promising effect of duvelisib (Copiktra ), a novel FDA approved PI3Kdelta/gamma isoform-specific inhibitor, in preventing paclitaxel-induced pain-like behaviour and pronociceptive signalling in dorsal root ganglia (DRG) and spinal cord dorsal horn (SCDH) in rat and mouse model of PIPN.	Paclitaxel	139-149	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	81-90
32521934-0	2020	Paclitaxel inhibits transforming growth factor-beta-increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration.	Paclitaxel	0-10	plasminogen activator, urokinase	Mus musculus	62-98
35634603-0	2022	Effects of carboplatin combined with paclitaxel-based intraperitoneal hyperthermic perfusion chemotherapy on serum levels of HE4 and DJ-1 in patients with advanced recurrent ovarian cancer.	Paclitaxel	37-47	WAP four-disulfide core domain 2	Homo sapiens	125-128
35634603-0	2022	Effects of carboplatin combined with paclitaxel-based intraperitoneal hyperthermic perfusion chemotherapy on serum levels of HE4 and DJ-1 in patients with advanced recurrent ovarian cancer.	Paclitaxel	37-47	Parkinsonism associated deglycase	Homo sapiens	133-137
35634603-1	2022	Objective: To analyze the effects of carboplatin combined with paclitaxel-based intraperitoneal hyperthermic perfusion chemotherapy (IPCH) on serum levels of human epididymis protein 4 (HE4) and mitogen-dependent oncogene-1 (DJ-1) in patients with advanced recurrent ovarian cancer (OC).	Paclitaxel	63-73	WAP four-disulfide core domain 2	Homo sapiens	186-189
32521934-4	2020	In this study, we aimed to determine whether PTx regulates macrophage migration and urokinase-type plasminogen activator (uPA) expression induced by TGF-beta.	Paclitaxel	45-48	plasminogen activator, urokinase	Mus musculus	84-120
35634603-1	2022	Objective: To analyze the effects of carboplatin combined with paclitaxel-based intraperitoneal hyperthermic perfusion chemotherapy (IPCH) on serum levels of human epididymis protein 4 (HE4) and mitogen-dependent oncogene-1 (DJ-1) in patients with advanced recurrent ovarian cancer (OC).	Paclitaxel	63-73	Parkinsonism associated deglycase	Homo sapiens	225-229
35634603-8	2022	Conclusions: Carboplatin combined with paclitaxel IPCH had obvious inhibitory effects on HE4, DJ-1 and other serum tumor markers in patients with advanced recurrent OC, with a more prominent clinical effect, and could further significantly reduce the risk of adverse reactions and metastasis.	Paclitaxel	39-49	WAP four-disulfide core domain 2	Homo sapiens	89-92
32521934-4	2020	In this study, we aimed to determine whether PTx regulates macrophage migration and urokinase-type plasminogen activator (uPA) expression induced by TGF-beta.	Paclitaxel	45-48	plasminogen activator, urokinase	Mus musculus	122-125
35634603-8	2022	Conclusions: Carboplatin combined with paclitaxel IPCH had obvious inhibitory effects on HE4, DJ-1 and other serum tumor markers in patients with advanced recurrent OC, with a more prominent clinical effect, and could further significantly reduce the risk of adverse reactions and metastasis.	Paclitaxel	39-49	Parkinsonism associated deglycase	Homo sapiens	94-98
32521934-4	2020	In this study, we aimed to determine whether PTx regulates macrophage migration and urokinase-type plasminogen activator (uPA) expression induced by TGF-beta.	Paclitaxel	45-48	transforming growth factor alpha	Mus musculus	149-157
32521934-12	2020	Also, PTx inhibited TGF-beta-induced Smad3 activation.	Paclitaxel	6-9	transforming growth factor alpha	Mus musculus	20-28
35204562-9	2022	Moreover, KIF20A and KIF23 overexpression was associated with worse prognosis in OC patients treated with platinum/taxol chemotherapy, while OCs overexpressing mitotic KIFs (11, 15, 18B, and C1) were resistant to MAPK pathway inhibitors.	Paclitaxel	115-120	kinesin family member 20A	Homo sapiens	10-16
35200072-0	2022	Knockdown of nuclear receptor binding SET domain-containing protein 1 (NSD1) inhibits proliferation and facilitates apoptosis in paclitaxel-resistant breast cancer cells via inactivating the Wnt/beta-catenin signaling pathway.	Paclitaxel	129-139	catenin beta 1	Homo sapiens	195-207
35200072-10	2022	We conclude that NSD1 knockdown inhibits the viability and promotes the apoptosis of paclitaxel-resistant BC cells by inactivating the NSD1/H3K27me3/Wnt10b/beta-catenin signaling pathway.	Paclitaxel	85-95	catenin beta 1	Homo sapiens	156-168
32521934-13	2020	Furthermore, PTx decreased cell migration and uPA expression stimulated by TGF-beta.	Paclitaxel	13-16	plasminogen activator, urokinase	Mus musculus	46-49
34974521-0	2022	CD147 supports paclitaxel resistance via interacting with RanBP1.	Paclitaxel	15-25	basigin (Ok blood group)	Homo sapiens	0-5
34974521-0	2022	CD147 supports paclitaxel resistance via interacting with RanBP1.	Paclitaxel	15-25	RAN binding protein 1	Homo sapiens	58-64
32521934-13	2020	Furthermore, PTx decreased cell migration and uPA expression stimulated by TGF-beta.	Paclitaxel	13-16	transforming growth factor alpha	Mus musculus	75-83
34974521-2	2022	This study aims to verify the role and the underlying mechanisms of CD147 in paclitaxel resistance.	Paclitaxel	77-87	basigin (Ok blood group)	Homo sapiens	68-73
32521934-14	2020	Remarkably, p38 MAPK mediated PTx inhibition of uPA activity induced by TGF-beta but it was not implicated on cell migration inhibition.	Paclitaxel	30-33	plasminogen activator, urokinase	Mus musculus	48-51
34974521-9	2022	In vitro and in vivo assays showed that silencing CD147 sensitized the cancer cells to paclitaxel treatment.	Paclitaxel	87-97	basigin (Ok blood group)	Homo sapiens	50-55
34974521-10	2022	CD147 protected cancer cells from paclitaxel-induced caspase-3 mediated apoptosis regardless of p53 status.	Paclitaxel	34-44	basigin (Ok blood group)	Homo sapiens	0-5
32521934-14	2020	Remarkably, p38 MAPK mediated PTx inhibition of uPA activity induced by TGF-beta but it was not implicated on cell migration inhibition.	Paclitaxel	30-33	transforming growth factor alpha	Mus musculus	72-80
34974521-11	2022	Truncation analysis showed that the intracellular domain of CD147 (CD147ICD) was indispensable for CD147-regulated sensitivity to paclitaxel.	Paclitaxel	130-140	basigin (Ok blood group)	Homo sapiens	60-65
32521934-15	2020	CONCLUSIONS: PTx inhibits TGF-beta induction of mouse Mphi migration and uPA expression, suggesting that PTx, as TGF-beta targeting therapy, may enhance Mphi anticancer action within tumors.	Paclitaxel	13-16	transforming growth factor alpha	Mus musculus	26-34
34974521-11	2022	Truncation analysis showed that the intracellular domain of CD147 (CD147ICD) was indispensable for CD147-regulated sensitivity to paclitaxel.	Paclitaxel	130-140	basigin (Ok blood group)	Homo sapiens	67-75
34974521-11	2022	Truncation analysis showed that the intracellular domain of CD147 (CD147ICD) was indispensable for CD147-regulated sensitivity to paclitaxel.	Paclitaxel	130-140	basigin (Ok blood group)	Homo sapiens	99-104
32521934-15	2020	CONCLUSIONS: PTx inhibits TGF-beta induction of mouse Mphi migration and uPA expression, suggesting that PTx, as TGF-beta targeting therapy, may enhance Mphi anticancer action within tumors.	Paclitaxel	13-16	plasminogen activator, urokinase	Mus musculus	73-76
34974521-13	2022	Furthermore, we showed that RanBP1 mediated CD147-regulated microtubule stability and dynamics as well as response to paclitaxel treatment.	Paclitaxel	118-128	RAN binding protein 1	Homo sapiens	28-34
34974521-13	2022	Furthermore, we showed that RanBP1 mediated CD147-regulated microtubule stability and dynamics as well as response to paclitaxel treatment.	Paclitaxel	118-128	basigin (Ok blood group)	Homo sapiens	44-49
32521934-15	2020	CONCLUSIONS: PTx inhibits TGF-beta induction of mouse Mphi migration and uPA expression, suggesting that PTx, as TGF-beta targeting therapy, may enhance Mphi anticancer action within tumors.	Paclitaxel	105-108	transforming growth factor alpha	Mus musculus	26-34
34974521-14	2022	These results demonstrated that CD147 regulated paclitaxel response by interacting with the C-terminal tail of RanBP1 and targeting CD147 may be a promising strategy for preventing paclitaxel resistant.	Paclitaxel	48-58	basigin (Ok blood group)	Homo sapiens	32-37
34974521-14	2022	These results demonstrated that CD147 regulated paclitaxel response by interacting with the C-terminal tail of RanBP1 and targeting CD147 may be a promising strategy for preventing paclitaxel resistant.	Paclitaxel	48-58	RAN binding protein 1	Homo sapiens	111-117
32521934-15	2020	CONCLUSIONS: PTx inhibits TGF-beta induction of mouse Mphi migration and uPA expression, suggesting that PTx, as TGF-beta targeting therapy, may enhance Mphi anticancer action within tumors.	Paclitaxel	105-108	plasminogen activator, urokinase	Mus musculus	73-76
34974521-14	2022	These results demonstrated that CD147 regulated paclitaxel response by interacting with the C-terminal tail of RanBP1 and targeting CD147 may be a promising strategy for preventing paclitaxel resistant.	Paclitaxel	48-58	basigin (Ok blood group)	Homo sapiens	132-137
34974521-14	2022	These results demonstrated that CD147 regulated paclitaxel response by interacting with the C-terminal tail of RanBP1 and targeting CD147 may be a promising strategy for preventing paclitaxel resistant.	Paclitaxel	181-191	basigin (Ok blood group)	Homo sapiens	32-37
32521934-15	2020	CONCLUSIONS: PTx inhibits TGF-beta induction of mouse Mphi migration and uPA expression, suggesting that PTx, as TGF-beta targeting therapy, may enhance Mphi anticancer action within tumors.	Paclitaxel	105-108	transforming growth factor alpha	Mus musculus	113-121
34974521-14	2022	These results demonstrated that CD147 regulated paclitaxel response by interacting with the C-terminal tail of RanBP1 and targeting CD147 may be a promising strategy for preventing paclitaxel resistant.	Paclitaxel	181-191	RAN binding protein 1	Homo sapiens	111-117
34974521-14	2022	These results demonstrated that CD147 regulated paclitaxel response by interacting with the C-terminal tail of RanBP1 and targeting CD147 may be a promising strategy for preventing paclitaxel resistant.	Paclitaxel	181-191	basigin (Ok blood group)	Homo sapiens	132-137
32106859-9	2020	Importantly, cisplatin and paclitaxel promote miR-522 secretion from CAFs by activating USP7/hnRNPA1 axis, leading to ALOX15 suppression and decreased lipid-ROS accumulation in cancer cells, and ultimately result in decreased chemo-sensitivity.	Paclitaxel	27-37	microRNA 522	Homo sapiens	46-53
35105904-7	2022	Co-administration of carboplatin and paclitaxel resulted in a significant reduction of the ovarian reserve leading to a lower IVF performance, and an activation of the PI3K-Pten pathway, irrespective of the genetic background.	Paclitaxel	37-47	phosphatase and tensin homolog	Homo sapiens	173-177
31853539-4	2020	PTTG3P upregulation in LUAD cells shortens the metaphase to anaphase transition in mitosis, increases cell viability after cisplatin or paclitaxel treatment, facilitates tumor growth that leads to poor survival in orthotopic lung models, and is associated with a poor survival rate in LUAD patients in the TCGA cohort who received chemotherapy.	Paclitaxel	136-146	pituitary tumor-transforming 3, pseudogene	Homo sapiens	0-6
35127498-4	2021	This study aims to evaluate the clinical value of the new score system by combining SII and PNI (SII-PNI score) as a predictor of efficacy and prognosis after neoadjuvant intraperitoneal and systemic (NIPS) paclitaxel combined with Apatinib conversion therapy for GC-CY1 patients.	Paclitaxel	207-217	serpin family E member 2	Homo sapiens	101-104
35127498-14	2021	Conclusion: Pretreatment SII-PNI score is an important predictor for the efficacy of GC-CY1 patients after NIPS paclitaxel combined with Apatinib conversion therapy, which can help to identify high-risk groups and predict prognosis.	Paclitaxel	112-122	serpin family E member 2	Homo sapiens	29-32
31286496-8	2020	Using time-laps microscopy, we demonstrated that APC/C and MCL-1 inhibition under paclitaxel prevents mitotic slippage in ovarian cancer cell lines and restores death in mitosis.	Paclitaxel	82-92	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	59-64
31959066-0	2020	The microtubule targeting agents eribulin and paclitaxel activate similar signaling pathways and induce cell death predominantly in a caspase-independent manner.	Paclitaxel	46-56	caspase 2	Homo sapiens	134-141
34972717-7	2022	Maspin protein expression decreased after treatment with paclitaxel and NAC.	Paclitaxel	57-67	serpin family B member 5	Homo sapiens	0-6
35173526-10	2022	Collectively, our data revealed SOX8/EZH2/SPARC signaling induced primary chemo-resistance of albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.	Paclitaxel	108-118	secreted protein acidic and cysteine rich	Homo sapiens	42-47
31662220-14	2020	CONCLUSION: Weekly carboplatin-paclitaxel-based CRT seems to be well tolerated in elderly patients and in those with comorbidities, where cisplatin-fluoropyrimidine-based dCRT is contraindicated.	Paclitaxel	31-41	crt	Drosophila melanogaster	48-51
31512793-5	2020	Moreover, treatment with Taxol reduced cell survival with an increase in mRNA expression of metastasis-related genes caspase-3 and caspase-9, whereas miR-193a transfection alone didn"t significantly influence cell viability and apoptosis induction.	Paclitaxel	25-30	caspase 9	Homo sapiens	131-140
32095126-5	2020	The patient responded to gemcitabine plus nab-paclitaxel in terms of elimination of tumor cells from the CSF and concurrent clinical improvement for 3 months.	Paclitaxel	46-56	colony stimulating factor 2	Homo sapiens	105-108
32009887-8	2019	DBH expression was increased at the spinal dorsal horn of paclitaxel-injected animals.	Paclitaxel	58-68	dopamine beta-hydroxylase	Rattus norvegicus	0-3
31911655-6	2020	Deficiencies in RepID, CRL4 or RBBP7 delay mitotic exit, increase genomic instability and enhance sensitivity to paclitaxel, a microtubule stabilizer and anti-tumor drug.	Paclitaxel	113-123	RB binding protein 7, chromatin remodeling factor	Homo sapiens	31-36
31844921-12	2020	In vitro, significantly increased IDO protein, IDO mRNA expression and IDO enzyme activity in paclitaxel-resistant cells were demonstrated in comparing of sensitive cells.	Paclitaxel	94-104	indoleamine 2,3-dioxygenase 1	Homo sapiens	34-37
31844921-12	2020	In vitro, significantly increased IDO protein, IDO mRNA expression and IDO enzyme activity in paclitaxel-resistant cells were demonstrated in comparing of sensitive cells.	Paclitaxel	94-104	indoleamine 2,3-dioxygenase 1	Homo sapiens	47-50
31844921-12	2020	In vitro, significantly increased IDO protein, IDO mRNA expression and IDO enzyme activity in paclitaxel-resistant cells were demonstrated in comparing of sensitive cells.	Paclitaxel	94-104	indoleamine 2,3-dioxygenase 1	Homo sapiens	47-50
31844921-14	2020	IDO expression and activity were significantly increased in paclitaxel-resistant breast cancer cells.	Paclitaxel	60-70	indoleamine 2,3-dioxygenase 1	Homo sapiens	0-3
32407275-4	2020	Thus, our study aimed to evaluate whether Nav1.7 participates in the pathogenesis of paclitaxel-induced neuropathy.	Paclitaxel	85-95	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	42-48
32407275-6	2020	RESULTS: The results showed that DRG mRNA and protein expression levels of Nav1.7 were upregulated between days 7 and 21 after administration of paclitaxel.	Paclitaxel	145-155	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	75-81
32407275-9	2020	CONCLUSION: These results indicated that the sodium channel Nav1.7 in the DRG exerted an important function in paclitaxel-induced neuropathy, which was associated with ERK phosphorylation in neurons.	Paclitaxel	111-121	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	60-66
32248718-8	2020	Significantly, further study showed the overexpression of ATF3 in PTX-treated cell, while XAP counteracted the change of ATF3 induced by PTX.	Paclitaxel	66-69	activating transcription factor 3	Homo sapiens	58-62
32248718-8	2020	Significantly, further study showed the overexpression of ATF3 in PTX-treated cell, while XAP counteracted the change of ATF3 induced by PTX.	Paclitaxel	137-140	activating transcription factor 3	Homo sapiens	121-125
32248718-10	2020	Compared with PTX treatment, the downregulation of ATF3 indicated that ATF3 played a pivotal role in the combination of XAP with PTX to exert a synergistic effect.	Paclitaxel	129-132	activating transcription factor 3	Homo sapiens	51-55
32248718-10	2020	Compared with PTX treatment, the downregulation of ATF3 indicated that ATF3 played a pivotal role in the combination of XAP with PTX to exert a synergistic effect.	Paclitaxel	129-132	activating transcription factor 3	Homo sapiens	71-75
32248718-11	2020	Overall, it is expected that PTX combined with XAP may serve as an effective agent for antitumor treatment, and dampening ATF3 maybe a potential strategy to improve the efficacy of PTX.	Paclitaxel	181-184	activating transcription factor 3	Homo sapiens	122-126
31942189-4	2020	Furthermore, our results also revealed that bazedoxifene combining with paclitaxel had better efficacy to suppress glioblastoma progression by promoting apoptosis and reducing EMT.	Paclitaxel	72-82	IL2 inducible T cell kinase	Homo sapiens	176-179
32047545-16	2020	Conclusions: TCL6 effectively sensitizes RCC to PTX mainly through downregulation of miR-221.	Paclitaxel	48-51	microRNA 221	Homo sapiens	85-92
31662022-4	2020	During cytokinesis induced by treatment with taxol, the epithelial barrier was maintained and the tricellular tight junction molecules LSR and tricellulin were concentrated at the flank of the acetylated tubulin-positive midbody and in gamma-tubulin-positive centrosomes with the dynein adaptor Hook2, whereas the other molecules were localized there as well.	Paclitaxel	45-50	lipolysis stimulated lipoprotein receptor	Homo sapiens	135-138
31856090-0	2020	ATM-Mutated Pancreatic Cancer: Clinical and Molecular Response to Gemcitabine/Nab-Paclitaxel After Genome-Based Therapy Resistance.	Paclitaxel	82-92	ATM serine/threonine kinase	Homo sapiens	0-3
31906029-9	2019	A cross-activation of JNK and PERK by TAX and NOC leading to anti-CRC actions including apoptosis and G2/M arrest was first demonstrated herein.	Paclitaxel	38-41	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	30-34
32021239-11	2019	Besides, we showed in that knock-down of miR-26a-5p or overexpression of HOXA5 increased cell sensitivity to chemotherapeutic drug paclitaxel.	Paclitaxel	131-141	homeobox A5	Homo sapiens	73-78
32042799-0	2019	eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer.	Paclitaxel	69-79	eukaryotic translation elongation factor 2	Homo sapiens	0-4
31271703-10	2019	Knockdown of HOXB8 abolished the effects of miR-128 inhibitor on ovarian cancer cell proliferation and paclitaxel sensitivity.	Paclitaxel	103-113	homeobox B8	Homo sapiens	13-18
31488699-10	2019	These findings indicate that Transgelin 2 promotes paclitaxel resistance and the migration and invasion of breast cancer by directly interacting with PTEN and activating the PI3K/Akt/GSK-3beta pathway.	Paclitaxel	51-61	phosphatase and tensin homolog	Homo sapiens	150-154
31747607-6	2019	Selective knockdown of IL-17R in spinal somatostatin-expressing interneurons reduces paclitaxel-induced hypersensitivity.	Paclitaxel	85-95	interleukin 17 receptor A	Mus musculus	23-29
31747607-8	2019	In dorsal root ganglia, IL-17R expression in nociceptive sensory neurons is sufficient and required for inducing neuronal hyperexcitability after paclitaxel.	Paclitaxel	146-156	interleukin 17 receptor A	Mus musculus	24-30
31744174-8	2019	A reduction in monomeric alpha-tubulin levels by treatment with the chemotherapeutic paclitaxel resulted in a decline in the nuclear accumulation of c-Jun in melanoma cells in an experimental murine model and in patients" tissues.	Paclitaxel	85-95	tubulin alpha 1b	Homo sapiens	25-38
31815052-8	2019	It has been reported that the levels of MCL-1 play a role in regulating cell resistance to paclitaxel treatment.	Paclitaxel	91-101	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	40-45
31332047-8	2019	Results showed that clone 130A downregulated MFAP5-induced collagen production in CAFs, suppressed intratumoral microvessel leakiness, and enhanced paclitaxel bioavailability in both ovarian and pancreatic cancer mouse models.	Paclitaxel	148-158	microfibrillar associated protein 5	Mus musculus	45-50
31659154-6	2019	Furthermore, knockdown of miR-421 expression with an antisense morpholino oligonucleotide (AMO) increased ROS levels and treatment sensitivity to paclitaxel in vitro and in vivo, indicating that high miR-421 expression may at least partly account for paclitaxel tolerance in lung cancer patients.	Paclitaxel	146-156	microRNA 421	Homo sapiens	26-33
31659154-6	2019	Furthermore, knockdown of miR-421 expression with an antisense morpholino oligonucleotide (AMO) increased ROS levels and treatment sensitivity to paclitaxel in vitro and in vivo, indicating that high miR-421 expression may at least partly account for paclitaxel tolerance in lung cancer patients.	Paclitaxel	251-261	microRNA 421	Homo sapiens	26-33
31659154-10	2019	Taken together, our findings reveal the critical role of miR-421 in paclitaxel drug resistance and its upstream and downstream regulatory mechanisms.	Paclitaxel	68-78	microRNA 421	Homo sapiens	57-64
30684388-0	2019	DNMT3a-triggered downregulation of K2p 1.1 gene in primary sensory neurons contributes to paclitaxel-induced neuropathic pain.	Paclitaxel	90-100	DNA methyltransferase 3 alpha	Homo sapiens	0-6
30684388-0	2019	DNMT3a-triggered downregulation of K2p 1.1 gene in primary sensory neurons contributes to paclitaxel-induced neuropathic pain.	Paclitaxel	90-100	potassium two pore domain channel subfamily K member 1	Homo sapiens	35-42
30684388-3	2019	Here, we report that systemic injection of the chemotherapy agent paclitaxel time-dependently downregulates the expression of K 2p 1.1 mRNA and its coding K2p 1.1 protein in the DRG neurons.	Paclitaxel	66-76	potassium two pore domain channel subfamily K member 1	Homo sapiens	126-134
30684388-3	2019	Here, we report that systemic injection of the chemotherapy agent paclitaxel time-dependently downregulates the expression of K 2p 1.1 mRNA and its coding K2p 1.1 protein in the DRG neurons.	Paclitaxel	66-76	potassium two pore domain channel subfamily K member 1	Homo sapiens	155-162
30684388-6	2019	Mechanically, the downregulation of DRG K 2p 1.1 mRNA is attributed to paclitaxel-induced increase in DRG DNMT3a, as blocking this increase reverses the paclitaxel-induced the decrease of DRG K2p 1.1 and mimicking this increase reduces DRG K2p 1.1 expression.	Paclitaxel	71-81	potassium two pore domain channel subfamily K member 1	Homo sapiens	40-48
30684388-6	2019	Mechanically, the downregulation of DRG K 2p 1.1 mRNA is attributed to paclitaxel-induced increase in DRG DNMT3a, as blocking this increase reverses the paclitaxel-induced the decrease of DRG K2p 1.1 and mimicking this increase reduces DRG K2p 1.1 expression.	Paclitaxel	71-81	DNA methyltransferase 3 alpha	Homo sapiens	106-112
30684388-6	2019	Mechanically, the downregulation of DRG K 2p 1.1 mRNA is attributed to paclitaxel-induced increase in DRG DNMT3a, as blocking this increase reverses the paclitaxel-induced the decrease of DRG K2p 1.1 and mimicking this increase reduces DRG K2p 1.1 expression.	Paclitaxel	71-81	potassium two pore domain channel subfamily K member 1	Homo sapiens	192-199
30684388-6	2019	Mechanically, the downregulation of DRG K 2p 1.1 mRNA is attributed to paclitaxel-induced increase in DRG DNMT3a, as blocking this increase reverses the paclitaxel-induced the decrease of DRG K2p 1.1 and mimicking this increase reduces DRG K2p 1.1 expression.	Paclitaxel	71-81	potassium two pore domain channel subfamily K member 1	Homo sapiens	240-247
30684388-6	2019	Mechanically, the downregulation of DRG K 2p 1.1 mRNA is attributed to paclitaxel-induced increase in DRG DNMT3a, as blocking this increase reverses the paclitaxel-induced the decrease of DRG K2p 1.1 and mimicking this increase reduces DRG K2p 1.1 expression.	Paclitaxel	153-163	potassium two pore domain channel subfamily K member 1	Homo sapiens	40-48
30684388-6	2019	Mechanically, the downregulation of DRG K 2p 1.1 mRNA is attributed to paclitaxel-induced increase in DRG DNMT3a, as blocking this increase reverses the paclitaxel-induced the decrease of DRG K2p 1.1 and mimicking this increase reduces DRG K2p 1.1 expression.	Paclitaxel	153-163	DNA methyltransferase 3 alpha	Homo sapiens	106-112
30684388-6	2019	Mechanically, the downregulation of DRG K 2p 1.1 mRNA is attributed to paclitaxel-induced increase in DRG DNMT3a, as blocking this increase reverses the paclitaxel-induced the decrease of DRG K2p 1.1 and mimicking this increase reduces DRG K2p 1.1 expression.	Paclitaxel	153-163	potassium two pore domain channel subfamily K member 1	Homo sapiens	192-199
30684388-6	2019	Mechanically, the downregulation of DRG K 2p 1.1 mRNA is attributed to paclitaxel-induced increase in DRG DNMT3a, as blocking this increase reverses the paclitaxel-induced the decrease of DRG K2p 1.1 and mimicking this increase reduces DRG K2p 1.1 expression.	Paclitaxel	153-163	potassium two pore domain channel subfamily K member 1	Homo sapiens	240-247
30684388-7	2019	In addition, paclitaxel injection increases the binding of DNMT3a to the K 2p 1.1 gene promoter region and elevates the level of DNA methylation within this region in the DRG.	Paclitaxel	13-23	DNA methyltransferase 3 alpha	Homo sapiens	59-65
30684388-7	2019	In addition, paclitaxel injection increases the binding of DNMT3a to the K 2p 1.1 gene promoter region and elevates the level of DNA methylation within this region in the DRG.	Paclitaxel	13-23	potassium two pore domain channel subfamily K member 1	Homo sapiens	73-81
31326791-7	2019	In vitro studies have demonstrated contribution of MEG3 in defining response to chemotherapeutic agents such as paclitaxel, cisplatin and oxaliplatin.	Paclitaxel	112-122	maternally expressed 3	Homo sapiens	51-55
31490008-2	2019	Our previous study showed that cross-reacting material 197 (CRM197), a specific HB-EGF inhibitor, significantly reverses resistance against paclitaxel in paclitaxel-resistant ovarian cancer cells.	Paclitaxel	140-150	heparin binding EGF like growth factor	Homo sapiens	80-86
31490008-2	2019	Our previous study showed that cross-reacting material 197 (CRM197), a specific HB-EGF inhibitor, significantly reverses resistance against paclitaxel in paclitaxel-resistant ovarian cancer cells.	Paclitaxel	154-164	heparin binding EGF like growth factor	Homo sapiens	80-86
31632917-8	2019	Cell death and clonogenic assays of these isogenic clonal lines clearly showed that downregulation of CC2D1A resulted in increased sensitivity to cisplatin and paclitaxel in ovarian cancer cells.	Paclitaxel	160-170	coiled-coil and C2 domain containing 1A	Homo sapiens	102-108
31350703-1	2019	We previously reported that anti-paclitaxel-resistant ovarian carcinoma cells characteristically expressed the MDR1 (multidrug resistance 1) gene with enhanced synthesis of glycolipids, i.e., LacCer, Gb3Cer, Leb and GM3, and that anti-cisplatin-resistant cells lost GM3.	Paclitaxel	33-43	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	208-211
31416135-8	2019	Furthermore, the paclitaxel-combined XAV939 treatment reduced the expression of beta-catenin, a key molecule in the Wnt pathway, which led to suppression of the expression of epithelial-mesenchymal transition (EMT) markers and angiogenic proteins both at mRNA and protein levels.	Paclitaxel	17-27	catenin beta 1	Homo sapiens	80-92
31496800-0	2019	Integrative gene expression profiling reveals that dysregulated triple microRNAs confer paclitaxel resistance in non-small cell lung cancer via co-targeting MAPT.	Paclitaxel	88-98	microtubule associated protein tau	Homo sapiens	157-161
31496800-12	2019	Furthermore, integrative analysis of miRNAs and gene expression profiles revealed that dysregulated miR-362-3p, miR-766-3p, and miR-6507-3p might confer paclitaxel resistance in NSCLC via targeting MAPT simultaneously.	Paclitaxel	153-163	microtubule associated protein tau	Homo sapiens	198-202
31496800-13	2019	Conclusion: Our findings suggested that specific manipulation of MAPT-targeting miRNAs may be a novel strategy to overcome paclitaxel resistance in patients with NSCLC especially large-cell lung carcinoma.	Paclitaxel	123-133	microtubule associated protein tau	Homo sapiens	65-69
31337279-14	2019	Moreover, miR-4262 expression and PI3 K/Akt signalling pathway-related proteins were upregulated and PTEN was downregulated in A549/PTX and H1299/PTX.	Paclitaxel	132-135	phosphatase and tensin homolog	Homo sapiens	101-105
31337279-14	2019	Moreover, miR-4262 expression and PI3 K/Akt signalling pathway-related proteins were upregulated and PTEN was downregulated in A549/PTX and H1299/PTX.	Paclitaxel	146-149	phosphatase and tensin homolog	Homo sapiens	101-105
31337279-15	2019	Our results indicate that miR-4262 enhances PTX resistance in NSCLC cells through targeting PTEN and activating the PI3 K/Akt signalling pathway.	Paclitaxel	44-47	phosphatase and tensin homolog	Homo sapiens	92-96
31336860-5	2019	Pre-exposure of paclitaxel-resistant ovarian cancer cells to gliotoxin inhibited the expression of multidrug resistant-associated proteins (MDR1 and MRP1-3), disrupted the mitochondrial membrane potential, and induced caspase-dependent apoptosis through autophagy induction after subsequent treatment with paclitaxel.	Paclitaxel	16-26	MDM4 regulator of p53	Homo sapiens	149-155
32042863-6	2019	Biomarkers will allow clinicians to practice a precision medicine approach in ICBs (biomarker-based patient selection) such as treating triple-negative breast cancer patients that exhibit PD-L1 staining of tumor-infiltrating immune cells in >=1% of the tumor area with nanoparticle albumin-bound (nab)-paclitaxel plus anti-PD-L1 and treating patients of MSI-H or MMR deficient unresectable or metastatic solid tumors with pembrolizumab (anti-PD-1).	Paclitaxel	302-312	CD274 molecule	Homo sapiens	188-193
31289528-0	2019	Leptin contributes to the taxol chemoresistance in epithelial ovarian cancer.	Paclitaxel	26-31	leptin	Homo sapiens	0-6
31289528-4	2019	In the present study, survival database analysis demonstrated that leptin expression was associated with poor prognoses in patients treated with platinum and paclitaxel/docetaxel.	Paclitaxel	158-168	leptin	Homo sapiens	67-73
31289528-5	2019	A cell activity assay demonstrated that leptin reduced the chemosensitivity of ovarian cancer cells to paclitaxel/docetaxel.	Paclitaxel	103-113	leptin	Homo sapiens	40-46
31289528-6	2019	Furthermore, flow cytometry results revealed that treatment with exogenous leptin reduced the proportion of ovarian cancer cells in G2/M phase, which was significantly elevated following paclitaxel/docetaxel chemotherapy.	Paclitaxel	187-197	leptin	Homo sapiens	75-81
31289528-8	2019	Together, these results suggest that leptin serves an important role in chemoresistance and may serve as a novel therapeutic target for ovarian cancer in patients treated with platinum and paclitaxel chemotherapy.	Paclitaxel	189-199	leptin	Homo sapiens	37-43
31249607-4	2019	In the presence of nocodazole or taxol combined with M2I-1 cell death is triggered by the premature degradation of Cyclin B1, the perturbation of the microtubule network, and an increase in the level of the pro-apoptotic protein MCL-1s combined with a marginal increase in the level of NOXA.	Paclitaxel	33-38	cyclin B1	Homo sapiens	115-124
31249607-4	2019	In the presence of nocodazole or taxol combined with M2I-1 cell death is triggered by the premature degradation of Cyclin B1, the perturbation of the microtubule network, and an increase in the level of the pro-apoptotic protein MCL-1s combined with a marginal increase in the level of NOXA.	Paclitaxel	33-38	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	229-235
31217693-9	2019	There was a significant decrease in IL-11 levels in the other treatment group compared with the group receiving paclitaxel, docetaxel, gemcitabine, and vinorelbine in the first day following chemotherapy (P = .006).	Paclitaxel	112-122	interleukin 11	Homo sapiens	36-41
31181850-8	2019	Moreover, the amount of distant organ metastases observed at least in lung, liver, spleen, and kidney was reduced by 50% with MSC taxol exosomes, similar to the effects observed with taxol, although the concentration of taxol in exosomes was about 1000-fold reduced.	Paclitaxel	130-135	musculin	Homo sapiens	126-129
31285951-8	2019	We then found that overexpression of CDKN1A, ELAVL2 or TSPAN4 in ESCC cell lines significantly promoted the resistance to PTX by inhibiting cell apoptosis.	Paclitaxel	122-125	tetraspanin 4	Homo sapiens	55-61
30639741-2	2019	In this study, polygeline-bound paclitaxel nanoparticles (Npb-PTXS) were fabricated through a combination of low-pressure emulsification and high-pressure homogenization.	Paclitaxel	32-42	neuropeptide B	Homo sapiens	58-61
30639741-4	2019	The characteristics of Npb-PTXS, such as surface morphology, physical status of paclitaxel (PTX) in Npb-PTXS, redispersibility of Npb-PTXS in purified water and bioavailability in vivo were also investigated.	Paclitaxel	27-30	neuropeptide B	Homo sapiens	23-26
30639741-7	2019	PTX in Npb-PTX is amorphous, and its content is approximately 12.04%.	Paclitaxel	0-3	neuropeptide B	Homo sapiens	7-10
30639741-7	2019	PTX in Npb-PTX is amorphous, and its content is approximately 12.04%.	Paclitaxel	11-14	neuropeptide B	Homo sapiens	7-10
31118065-14	2019	Furthermore, progression-free survival (PFS) of mucosal melanoma patients upon temozolomide-based and paclitaxel-based chemotherapy was related to miR-let-7b and miR-let-7c expression.	Paclitaxel	102-112	microRNA let-7c	Homo sapiens	162-172
31118065-15	2019	Overexpression of miR-let-7b or miR-let-7c in patient-derived xenograft (PDX) models and certain mucosal melanoma cells had better growth inhibition after temozolomide and paclitaxel treatment.	Paclitaxel	172-182	microRNA let-7c	Homo sapiens	32-42
31118065-16	2019	MTDH reversed the sensitivity of miR-let-7b and miR-let-7c to paclitaxel in vitro.	Paclitaxel	62-72	microRNA let-7c	Homo sapiens	52-58
31156650-0	2019	Chemotherapeutic Agent Paclitaxel Mediates Priming of NLRP3 Inflammasome Activation.	Paclitaxel	23-33	NLR family, pyrin domain containing 3	Mus musculus	54-59
31156650-6	2019	However, paclitaxel could induce robust activation of caspase-1 in BMDMs in the presence of NLRP3 inflammasome-activating signal 2, such as ATP or nigericin.	Paclitaxel	9-19	NLR family, pyrin domain containing 3	Mus musculus	92-97
31156650-7	2019	This paclitaxel/ATP-mediated inflammasome activation was completely abrogated in Nlrp3-deficient macrophages.	Paclitaxel	5-15	NLR family, pyrin domain containing 3	Mus musculus	81-86
31156650-10	2019	These findings suggest that paclitaxel can drive the priming of signal-mediated events for NLRP3 activation but not a second signal-triggered phenomenon such as mitochondrial damage.	Paclitaxel	28-38	NLR family, pyrin domain containing 3	Mus musculus	91-96
31156650-12	2019	Collectively, our data strongly indicate that paclitaxel is able to facilitate the activation of NLRP3 inflammasome signaling in a certain physiological environment.	Paclitaxel	46-56	NLR family, pyrin domain containing 3	Mus musculus	97-102
30926680-10	2019	In addition, high SFN expression is associated with significantly worse overall survival in patients who received chemotherapy contains gemcitabine, taxol, taxol+platin, paclitaxel and avastin.	Paclitaxel	149-154	stratifin	Homo sapiens	18-21
30926680-10	2019	In addition, high SFN expression is associated with significantly worse overall survival in patients who received chemotherapy contains gemcitabine, taxol, taxol+platin, paclitaxel and avastin.	Paclitaxel	156-161	stratifin	Homo sapiens	18-21
30926680-10	2019	In addition, high SFN expression is associated with significantly worse overall survival in patients who received chemotherapy contains gemcitabine, taxol, taxol+platin, paclitaxel and avastin.	Paclitaxel	170-180	stratifin	Homo sapiens	18-21
30862505-8	2019	Genome-wide expression profiling identified aldo-keto reductases AKR1C1-3 as effectors of stemness and drug resistance, since their pharmacological inhibition with flufenamic acid restored both doxorubicin and paclitaxel sensitivity and diminished mammosphere formation.	Paclitaxel	210-220	aldo-keto reductase family 1 member C1	Homo sapiens	65-73
30813105-4	2019	The results showed that the addition of PEG into PLA fibers promoted the release of higher amounts of hydrophobic PTX over prolonged time periods compared to fibers without PEG.	Paclitaxel	114-117	progestagen associated endometrial protein	Homo sapiens	40-43
30813105-5	2019	An in vitro cell assay demonstrated the biocompatibility of PLA/PEG fibrous materials and showed significant cytotoxicity of PTX-loaded PLA/PEG fibers against a human fibrosarcoma HT1080 cell line.	Paclitaxel	125-128	progestagen associated endometrial protein	Homo sapiens	140-143
30813105-6	2019	The chick chorioallantoic membrane assay proved that PTX-loaded fibers exhibited antiangiogenic activity, with a pronounced effect in the case of the PEG-containing fibers.	Paclitaxel	53-56	progestagen associated endometrial protein	Homo sapiens	150-153
30813105-7	2019	In vivo evaluation of PTX-loaded PLA/PEG fibers in a human fibrosarcoma recurrence model showed statistically significant inhibition in tumor incidence and growth after primary tumor resection compared to other treatment groups.	Paclitaxel	22-25	progestagen associated endometrial protein	Homo sapiens	37-40
30942454-8	2019	In conclusion, the data suggested that elevated miR-302a levels, in part, mediate sensitivity to paclitaxel in prostate cancer through the aberrant regulation of its downstream targets, AOF2, BCRP and permeability glycoprotein 1.	Paclitaxel	97-107	microRNA 302a	Homo sapiens	48-56
31281722-9	2019	Myosin light chain (MLC) 2 phosphorylation and RhoA activity were upregulated by doxorubicin and downregulated by paclitaxel.	Paclitaxel	114-124	myosin light chain 2	Homo sapiens	0-26
32309609-3	2019	In March 2019, the US Food and Drug Administration granted accelerated approval for the first immunotherapy-based regimen comprising atezolizumab in combination with protein-bound paclitaxel for patients with advanced metastatic TNBC, expressing programmed cell death-ligand 1 (PD-L1) and without previous systemic treatment for metastatic disease.	Paclitaxel	180-190	CD274 molecule	Homo sapiens	246-276
32309609-3	2019	In March 2019, the US Food and Drug Administration granted accelerated approval for the first immunotherapy-based regimen comprising atezolizumab in combination with protein-bound paclitaxel for patients with advanced metastatic TNBC, expressing programmed cell death-ligand 1 (PD-L1) and without previous systemic treatment for metastatic disease.	Paclitaxel	180-190	CD274 molecule	Homo sapiens	278-283
30911326-13	2019	Furthermore, SKN/PTX-induced downregulation of PKM2 (a key enzyme in glycolysis) and the suppression of its activity were inhibited by a ROS scavenger N-acetyl cysteine (NAC), suggesting that the synergy of the SKN/PTX combination may be not rely on PKM2 suppression.	Paclitaxel	215-218	pyruvate kinase M1/2	Homo sapiens	47-51
30770442-3	2019	Here we show that macrophages acquire an immunosuppressive phenotype and increase the expression of programmed death ligand-1 (PD-L1) when treated with reactive oxygen species (ROS) inducers such as the glutathione synthesis inhibitor, buthionine sulphoximine (BSO), and paclitaxel.	Paclitaxel	271-281	CD274 molecule	Homo sapiens	100-125
30770442-3	2019	Here we show that macrophages acquire an immunosuppressive phenotype and increase the expression of programmed death ligand-1 (PD-L1) when treated with reactive oxygen species (ROS) inducers such as the glutathione synthesis inhibitor, buthionine sulphoximine (BSO), and paclitaxel.	Paclitaxel	271-281	CD274 molecule	Homo sapiens	127-132
30578561-3	2019	We recently reported that rodents receiving paclitaxel develop acute pain and activation of spinal microglial toll like receptor 4 (TLR4) by paclitaxel penetrating into the spinal cord is a critical event in the genesis of P-APS.	Paclitaxel	44-54	toll like receptor 4	Homo sapiens	132-136
30578561-3	2019	We recently reported that rodents receiving paclitaxel develop acute pain and activation of spinal microglial toll like receptor 4 (TLR4) by paclitaxel penetrating into the spinal cord is a critical event in the genesis of P-APS.	Paclitaxel	141-151	toll like receptor 4	Homo sapiens	132-136
30578561-7	2019	TLR4 activation in microglia by paclitaxel caused microglia to rapidly release interleukin-1beta (IL-1beta) but not tumor necrosis factor alpha, IL-6, or interferon-gamma.	Paclitaxel	32-42	toll like receptor 4	Homo sapiens	0-4
30853913-11	2019	Interestingly, SNHG7 levels were higher in taxol resistant patients than in taxol sensitive patients.	Paclitaxel	43-48	small nucleolar RNA host gene 7	Homo sapiens	15-20
30853913-11	2019	Interestingly, SNHG7 levels were higher in taxol resistant patients than in taxol sensitive patients.	Paclitaxel	76-81	small nucleolar RNA host gene 7	Homo sapiens	15-20
30853913-12	2019	Metformin sensitizes FaDu cells to taxol and irradiation through decreasing SNHG7.	Paclitaxel	35-40	small nucleolar RNA host gene 7	Homo sapiens	76-81
30462844-0	2019	Long non-coding RNA Linc00518 promotes paclitaxel resistance of the human prostate cancer by sequestering miR-216b-5p.	Paclitaxel	39-49	long intergenic non-protein coding RNA 518	Homo sapiens	20-29
30462844-6	2019	High level of Linc00518 transcripts associated with paclitaxel resistance.	Paclitaxel	52-62	long intergenic non-protein coding RNA 518	Homo sapiens	14-23
30462844-8	2019	Linc00518 deficiency compromised the paclitaxel resistance in the acquired resistance cell lines.	Paclitaxel	37-47	long intergenic non-protein coding RNA 518	Homo sapiens	0-9
30462844-9	2019	CONCLUSIONS AND SIGNIFICANCE: We demonstrated that overexpression of Linc00518 contributed to the paclitaxel resistance in prostate cancer via sequestering miR-216b-5p.	Paclitaxel	98-108	long intergenic non-protein coding RNA 518	Homo sapiens	69-78
30773131-0	2019	Elastin-Like Polypeptide Delivers a Notch Inhibitory Peptide to Inhibit Tumor Growth in Combination with Paclitaxel.	Paclitaxel	105-115	elastin	Mus musculus	0-7
30950353-0	2019	Inhibition of SOX15 Sensitizes Esophageal Squamous Carcinoma Cells to Paclitaxel.	Paclitaxel	70-80	SRY-box transcription factor 15	Homo sapiens	14-19
30950353-5	2019	RESULTS: Experimentally, inhibition of SOX15 through RNAi suppressed cell proliferation in ESCC cells and sensitized cancer cells to paclitaxel, but not to Cisplatin.	Paclitaxel	133-143	SRY-box transcription factor 15	Homo sapiens	39-44
18575321-5	2008	After siRNA transfection, OVCAR8/TR cells were sensitive to ADM and Taxol which are tansported by P-gp.	Paclitaxel	68-73	phosphoglycolate phosphatase	Homo sapiens	98-102
30950353-6	2019	Moreover, inhibition of SOX15 significantly repressed the expression of genes associated with WNT and NOTCH signaling pathways, which may contribute to the increased sensitivity to paclitaxel.	Paclitaxel	181-191	SRY-box transcription factor 15	Homo sapiens	24-29
30950353-7	2019	CONCLUSION: In conclusion, the current study revealed that inhibition of SOX15 in ESCC cells sensitizes the ESCC cells to paclitaxel, suggesting that the SOX15 expression level may predict the therapeutic outcomes for paclitaxel treatment for ESCC.	Paclitaxel	122-132	SRY-box transcription factor 15	Homo sapiens	73-78
30950353-7	2019	CONCLUSION: In conclusion, the current study revealed that inhibition of SOX15 in ESCC cells sensitizes the ESCC cells to paclitaxel, suggesting that the SOX15 expression level may predict the therapeutic outcomes for paclitaxel treatment for ESCC.	Paclitaxel	218-228	SRY-box transcription factor 15	Homo sapiens	73-78
30950353-7	2019	CONCLUSION: In conclusion, the current study revealed that inhibition of SOX15 in ESCC cells sensitizes the ESCC cells to paclitaxel, suggesting that the SOX15 expression level may predict the therapeutic outcomes for paclitaxel treatment for ESCC.	Paclitaxel	218-228	SRY-box transcription factor 15	Homo sapiens	154-159
30572856-1	2018	BACKGROUND: We wished to evaluate the efficacy and safety of liposomal paclitaxel and docetaxel for induction chemotherapy (IC) for nasopharyngeal carcinoma (NPC).	Paclitaxel	71-81	NPC intracellular cholesterol transporter 1	Homo sapiens	132-162
18257542-5	2008	Activities against P-gp-overexpressing and paclitaxel-resistant cell line H460 taxR and modeling using a previously validated P-gp substrate pharmacophore suggested that active compounds were not likely P-gp substrates.	Paclitaxel	43-53	phosphoglycolate phosphatase	Homo sapiens	126-130
18257542-5	2008	Activities against P-gp-overexpressing and paclitaxel-resistant cell line H460 taxR and modeling using a previously validated P-gp substrate pharmacophore suggested that active compounds were not likely P-gp substrates.	Paclitaxel	43-53	phosphoglycolate phosphatase	Homo sapiens	126-130
18279793-6	2008	The molecules of Taxol were mainly located in CDR of Fab regions and Fc regions of IgG.	Paclitaxel	17-22	FA complementation group B	Homo sapiens	53-56
30572856-9	2018	CONCLUSIONS: Compared with docetaxel, liposomal paclitaxel has identical anti-tumor efficacy, but causes fewer and milder adverse reactions in IC for NPC.	Paclitaxel	48-58	NPC intracellular cholesterol transporter 1	Homo sapiens	150-153
30308274-8	2018	In addition, these biotin-modified nanoparticles could also significantly reverse PTX resistance by suppressing the over-expression of P-gp, thus resulting in increased intracellular drug accumulation and reduced drug efflux in MCF-7/ADR cells, which showed a great anticancer effect.	Paclitaxel	82-85	phosphoglycolate phosphatase	Homo sapiens	135-139
17920123-6	2008	In the present studies, we examined the effects of chemopreventive agents, paclitaxel, etoposide and 5-fluorouracil, on the surface expression of programmed death-1-ligand 1 (PD-L1), a negative regulator of T cell anti-tumor immunity.	Paclitaxel	75-85	CD274 molecule	Homo sapiens	146-173
18281778-11	2008	In April, 2006, paclitaxel/S-1 therapy was performed, and the tumor markers were reduced remarkably (SCC 120--&gt; 10 ng/mL).	Paclitaxel	16-26	serpin family B member 3	Homo sapiens	101-104
30321641-1	2018	A dual-targeting drug delivery system for paclitaxel (PTX) was developed by functionalizing novel polyester-based nanoparticles (NPs) with peptides possessing special affinity for low-density lipoprotein receptor (LDLR), overcoming the limitations of the current chemotherapeutics, to transport drug from blood to brain, and then target glioma cells.	Paclitaxel	42-52	low density lipoprotein receptor	Homo sapiens	180-212
30321641-1	2018	A dual-targeting drug delivery system for paclitaxel (PTX) was developed by functionalizing novel polyester-based nanoparticles (NPs) with peptides possessing special affinity for low-density lipoprotein receptor (LDLR), overcoming the limitations of the current chemotherapeutics, to transport drug from blood to brain, and then target glioma cells.	Paclitaxel	42-52	low density lipoprotein receptor	Homo sapiens	214-218
30321641-1	2018	A dual-targeting drug delivery system for paclitaxel (PTX) was developed by functionalizing novel polyester-based nanoparticles (NPs) with peptides possessing special affinity for low-density lipoprotein receptor (LDLR), overcoming the limitations of the current chemotherapeutics, to transport drug from blood to brain, and then target glioma cells.	Paclitaxel	54-57	low density lipoprotein receptor	Homo sapiens	180-212
18199556-0	2008	Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.	Paclitaxel	130-140	heat shock protein 90 alpha family class A member 1	Homo sapiens	14-19
30321641-1	2018	A dual-targeting drug delivery system for paclitaxel (PTX) was developed by functionalizing novel polyester-based nanoparticles (NPs) with peptides possessing special affinity for low-density lipoprotein receptor (LDLR), overcoming the limitations of the current chemotherapeutics, to transport drug from blood to brain, and then target glioma cells.	Paclitaxel	54-57	low density lipoprotein receptor	Homo sapiens	214-218
30563080-2	2018	Mcl-1 is an anti-apoptotic protein that promotes resistance to paclitaxel in different tumors.	Paclitaxel	63-73	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	0-5
18083698-8	2007	Estrogen receptor negativity, low expression of microtubule-associated protein tau, and perhaps HER2 amplification may define a subset of patients with higher than average sensitivity to paclitaxel.	Paclitaxel	187-197	microtubule associated protein tau	Homo sapiens	48-82
17982636-5	2007	The shRNAs targeting SMAD4, LZTS2, ST14 and VHL all increased the cell"s sensitivity to paclitaxel.	Paclitaxel	88-98	ST14 transmembrane serine protease matriptase	Homo sapiens	35-39
30563080-7	2018	Our results confirmed that paclitaxel alone induced Mcl-1 downregulation and apoptosis in 5637, but not in HT1197 cells; however, combinations of obatoclax and paclitaxel sensitized HT1197 cells to the treatment.	Paclitaxel	27-37	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	52-57
17652622-0	2007	Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment.	Paclitaxel	119-129	caspase 9	Homo sapiens	11-20
30487062-9	2018	miR-1246 expression were significantly higher in paclitaxel-resistant OC exosomes than in their sensitive counterparts.	Paclitaxel	49-59	microRNA 1246	Homo sapiens	0-8
17652622-3	2007	Apoptosis by paclitaxel was reported to depend on the activation of the initiator caspase-10; however, we clearly demonstrate that paclitaxel kills murine embryonic fibroblasts (MEFs) devoid of caspase-10 as well as human tumor cell lines deficient in caspase-10, caspase-8, or Fas-associating protein with death domain.	Paclitaxel	13-23	caspase 10	Homo sapiens	82-92
17652622-3	2007	Apoptosis by paclitaxel was reported to depend on the activation of the initiator caspase-10; however, we clearly demonstrate that paclitaxel kills murine embryonic fibroblasts (MEFs) devoid of caspase-10 as well as human tumor cell lines deficient in caspase-10, caspase-8, or Fas-associating protein with death domain.	Paclitaxel	131-141	caspase 10	Homo sapiens	82-92
17652622-4	2007	In contrast, the lack of Apaf-1 or caspase-9, key regulators of the mitochondrial pathway, not only entirely protected against paclitaxel-induced apoptosis but could even confer clonogenic survival, depending on the cell type and drug concentration.	Paclitaxel	127-137	caspase 9	Homo sapiens	35-44
17652622-5	2007	Thus, paclitaxel triggers apoptosis not through caspase-10, but via caspase-9 activation at the apoptosome.	Paclitaxel	6-16	caspase 10	Homo sapiens	48-58
30487062-10	2018	Overexpression of Cav1 and anti-miR-1246 treatment significantly sensitized OC cells to paclitaxel.	Paclitaxel	88-98	microRNA 1246	Homo sapiens	32-40
30505814-6	2018	The combination of naringin and paclitaxel treatments synergistically increased the cytotoxic effects of paclitaxel in androgen-independent DU145 and PC3 cells, as well as in androgen-sensitive LNCaP cells.	Paclitaxel	32-42	proprotein convertase subtilisin/kexin type 1	Homo sapiens	150-153
18003990-10	2007	CONCLUSION: The promising response rates and tolerability of intraarterial chemotherapy with nanoparticle albumin-bound paclitaxel justify further investigation of this formulation, alone or in combination with other agents, in advanced SCC of the head and neck.	Paclitaxel	120-130	serpin family B member 3	Homo sapiens	237-240
17699588-4	2007	Replacing the chromosomal passenger protein INCENP with a mutant allele that lacks its coiled-coil domain results in an overt defect in a SAC-mediated mitotic arrest in response to taxol treatment, indicating that this domain is critical for CPC function in spindle checkpoint control.	Paclitaxel	181-186	inner centromere protein	Homo sapiens	44-50
30505814-6	2018	The combination of naringin and paclitaxel treatments synergistically increased the cytotoxic effects of paclitaxel in androgen-independent DU145 and PC3 cells, as well as in androgen-sensitive LNCaP cells.	Paclitaxel	105-115	proprotein convertase subtilisin/kexin type 1	Homo sapiens	150-153
30505814-9	2018	The flavonoid either alone or in combination with paclitaxel therapy resulted in an increase in tumor suppressor PTEN (phosphatase and tensin homolog deleted on chromosome 10) protein expression and decrease in nuclear factor-kappaB p50 protein level in DU145 cells.	Paclitaxel	50-60	phosphatase and tensin homolog	Homo sapiens	113-117
30345906-11	2018	CONCLUSIONS: Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the PD-L1-positive subgroup.	Paclitaxel	35-45	CD274 molecule	Homo sapiens	193-198
17952876-8	2007	Moreover, knockdown of the protein level of Hsp27 using small interfering RNA in Rac1N17 cells significantly increased the paclitaxel-elicited caspase-3 activation and apoptosis.	Paclitaxel	123-133	heat shock protein family B (small) member 1	Homo sapiens	44-49
17952876-10	2007	It appears that the dominant negative Rac1N17 reduces the apoptosis sensitivity toward paclitaxel in the melanoma cells through upregulation of Hsp27, which inhibits its down stream drug-elicited caspase-3 activation.	Paclitaxel	87-97	heat shock protein family B (small) member 1	Homo sapiens	144-149
30429459-2	2018	Here we uncovered that either sulforaphane-cysteine (SFN-Cys) or sulforaphane-N-acetyl-cysteine (SFN-NAC) induced apoptosis via phosphorylated ERK1/2-mediated upregulation of 26 S proteasome and Hsp70, and downregulation of betaIII-tubulin, XIAP, Tau, Stathmin1 and alpha-tubulin causing microtubule disruption in human PTX-resistant non-small cell lung cancer (NSCLC) cells.	Paclitaxel	320-323	RNA exonuclease 2	Homo sapiens	97-100
17565738-7	2007	In contrast, the manner by which Myc potentiates the apoptosis induced by PTX differs from that of CPT and remains to be explored.	Paclitaxel	74-77	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	33-36
30429459-2	2018	Here we uncovered that either sulforaphane-cysteine (SFN-Cys) or sulforaphane-N-acetyl-cysteine (SFN-NAC) induced apoptosis via phosphorylated ERK1/2-mediated upregulation of 26 S proteasome and Hsp70, and downregulation of betaIII-tubulin, XIAP, Tau, Stathmin1 and alpha-tubulin causing microtubule disruption in human PTX-resistant non-small cell lung cancer (NSCLC) cells.	Paclitaxel	320-323	synuclein alpha	Homo sapiens	101-104
30429459-7	2018	The combination of PTX with SFN metabolites decreased the resistance to PTX, and doses of both PTX and SFN metabolites, and enhanced apoptosis resulting from activated Caspase-3-caused microtubule degradation.	Paclitaxel	19-22	RNA exonuclease 2	Homo sapiens	103-106
30429459-7	2018	The combination of PTX with SFN metabolites decreased the resistance to PTX, and doses of both PTX and SFN metabolites, and enhanced apoptosis resulting from activated Caspase-3-caused microtubule degradation.	Paclitaxel	72-75	RNA exonuclease 2	Homo sapiens	28-31
30429459-7	2018	The combination of PTX with SFN metabolites decreased the resistance to PTX, and doses of both PTX and SFN metabolites, and enhanced apoptosis resulting from activated Caspase-3-caused microtubule degradation.	Paclitaxel	72-75	RNA exonuclease 2	Homo sapiens	28-31
17663418-5	2007	Loss of stathmin expression increased responsiveness of tumor cells to the treatment with cytostatic drugs targeting MT-stability (paclitaxel, vinblastine) and to DNA cross-linking agents (cisplatin).	Paclitaxel	131-141	stathmin 1	Homo sapiens	8-16
30429459-8	2018	Importantly, the effective dose of SFN metabolites combined with 20 nM PTX will be low to 4 muM.	Paclitaxel	71-74	RNA exonuclease 2	Homo sapiens	35-38
30207784-4	2018	Drugs commonly used in breast cancer patients (doxorubicin and paclitaxel) caused reductions in myosin expression, mitochondrial loss, and increased reactive oxygen species (ROS) production in C2C12 murine myotube cell cultures, supporting a role for chemotherapeutics in the atrophic and mitochondrial phenotypes.	Paclitaxel	63-73	myosin heavy chain 14	Homo sapiens	96-102
17708594-0	2007	Phosphorylation of human eukaryotic elongation factor 1Bgamma is regulated by paclitaxel.	Paclitaxel	78-88	eukaryotic translation elongation factor 1 gamma	Homo sapiens	25-61
17708594-2	2007	2-D PAGE and MALDI-TOF-MS analysis of HeLa cells extracts revealed that Ptx up-regulates a form of the eukaryotic elongation factor 1Bgamma (eEF1Bgamma) and down-regulates another one.	Paclitaxel	72-75	eukaryotic translation elongation factor 1 gamma	Homo sapiens	103-139
17708594-2	2007	2-D PAGE and MALDI-TOF-MS analysis of HeLa cells extracts revealed that Ptx up-regulates a form of the eukaryotic elongation factor 1Bgamma (eEF1Bgamma) and down-regulates another one.	Paclitaxel	72-75	eukaryotic translation elongation factor 1 gamma	Homo sapiens	141-151
28884602-13	2018	Expression analysis by real-time PCR showed the significant up-regulation of two tumour suppressor genes, P53 and P21 in response to combination of silibinin and paclitaxel.	Paclitaxel	162-172	H3 histone pseudogene 16	Homo sapiens	114-117
17611652-0	2007	Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer.	Paclitaxel	79-89	ankyrin repeat domain 36B	Homo sapiens	0-27
17611652-2	2007	Previous studies have revealed that the forced expression of MAGE genes induces a paclitaxel-resistant phenotype.	Paclitaxel	82-92	ankyrin repeat domain 36B	Homo sapiens	61-65
29299936-6	2018	Both in vitro and in vivo antitumor results demonstrated that the sustained-release PTX could induce the microtubules assembly and the over-expression of Bax and Cyclin B1 proteins, resulting in the microtubule dynamics disruption, G2/M phase arrest, and cell apoptosis accordingly.	Paclitaxel	84-87	cyclin B1	Homo sapiens	162-171
17174526-0	2007	Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats.	Paclitaxel	51-61	interleukin 10	Rattus norvegicus	12-26
17174526-10	2007	We propose that targeting the production of proinflammatory cytokines by intrathecal IL-10 gene therapy may be a promising therapeutic strategy for the relief of paclitaxel-induced neuropathic pain.	Paclitaxel	162-172	interleukin 10	Rattus norvegicus	85-90
17545614-5	2007	We showed that 17-beta estradiol significantly reduces the overall cytotoxicity of paclitaxel in BCap37-expressing ERalpha but has no influence on the ER- parental cells.	Paclitaxel	83-93	prohibitin 2	Homo sapiens	97-103
17545614-6	2007	Further analyses indicate that expression of ERalpha in BCap37 cells mainly interferes with paclitaxel-induced apoptotic cell death, without affecting paclitaxel-induced microtubule bundling and mitotic arrest.	Paclitaxel	92-102	prohibitin 2	Homo sapiens	56-62
17545614-7	2007	Moreover, we found that the addition of ICI 182,780 (Fulvestrant), a selective ER down-regulator, could completely reverse the resistance of ER+ BCap37 cells to paclitaxel.	Paclitaxel	161-171	prohibitin 2	Homo sapiens	145-151
30003972-4	2018	Here, we design a novel paclitaxel (PTX) nanocrystal stabilized with complexes of matrix metalloproteinase (MMP)-sensitive beta-casein/marimastat (MATT) for co-delivering MATT and PTX and combined therapy of metastatic breast cancer.	Paclitaxel	24-34	casein beta	Homo sapiens	123-134
30003972-4	2018	Here, we design a novel paclitaxel (PTX) nanocrystal stabilized with complexes of matrix metalloproteinase (MMP)-sensitive beta-casein/marimastat (MATT) for co-delivering MATT and PTX and combined therapy of metastatic breast cancer.	Paclitaxel	36-39	casein beta	Homo sapiens	123-134
30003972-4	2018	Here, we design a novel paclitaxel (PTX) nanocrystal stabilized with complexes of matrix metalloproteinase (MMP)-sensitive beta-casein/marimastat (MATT) for co-delivering MATT and PTX and combined therapy of metastatic breast cancer.	Paclitaxel	180-183	casein beta	Homo sapiens	123-134
30375371-0	2018	Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-beta1-induced EMT and confers paclitaxel resistance in ovarian cancer.	Paclitaxel	99-109	ST3 beta-galactoside alpha-2,3-sialyltransferase 1	Homo sapiens	18-25
17311258-6	2007	We also looked for correlations between the expression of IAPs and resistance to paclitaxel, doxorubicin, CDDP and 5-fluorouracil, and found that resistance to these drugs correlates most significantly with expression of cIAP-2.	Paclitaxel	81-91	baculoviral IAP repeat containing 3	Homo sapiens	221-227
17487377-6	2007	Cytokeratin-8, keratin-19, Hsp-27, 14-3-3 epsilon, annexin-A2 and phosphoglycerate kinase-1 showed altered expression in both adriamycin- and paclitaxel-resistant cells.	Paclitaxel	142-152	annexin A2	Homo sapiens	51-61
17487377-6	2007	Cytokeratin-8, keratin-19, Hsp-27, 14-3-3 epsilon, annexin-A2 and phosphoglycerate kinase-1 showed altered expression in both adriamycin- and paclitaxel-resistant cells.	Paclitaxel	142-152	phosphoglycerate kinase 1	Homo sapiens	66-91
17487387-1	2007	We previously reported that indoleamine-2,3-dioxygenase (IDO) is associated with paclitaxel resistance and that IDO serves as a marker of poor prognosis in ovarian serous adenocarcinomas (SA).	Paclitaxel	81-91	indoleamine 2,3-dioxygenase 1	Homo sapiens	28-55
30375371-8	2018	Furthermore, overexpression of ST3GAL1 increases resistance to paclitaxel while downregulation of ST3GAL1 decreases resistance to paclitaxel in vitro, and overexpression of ST3GAL1 increases tumorigenicity and resistance to paclitaxel in vivo.	Paclitaxel	63-73	ST3 beta-galactoside alpha-2,3-sialyltransferase 1	Homo sapiens	31-38
17487387-1	2007	We previously reported that indoleamine-2,3-dioxygenase (IDO) is associated with paclitaxel resistance and that IDO serves as a marker of poor prognosis in ovarian serous adenocarcinomas (SA).	Paclitaxel	81-91	indoleamine 2,3-dioxygenase 1	Homo sapiens	57-60
30375371-8	2018	Furthermore, overexpression of ST3GAL1 increases resistance to paclitaxel while downregulation of ST3GAL1 decreases resistance to paclitaxel in vitro, and overexpression of ST3GAL1 increases tumorigenicity and resistance to paclitaxel in vivo.	Paclitaxel	130-140	ST3 beta-galactoside alpha-2,3-sialyltransferase 1	Homo sapiens	98-105
30375371-8	2018	Furthermore, overexpression of ST3GAL1 increases resistance to paclitaxel while downregulation of ST3GAL1 decreases resistance to paclitaxel in vitro, and overexpression of ST3GAL1 increases tumorigenicity and resistance to paclitaxel in vivo.	Paclitaxel	130-140	ST3 beta-galactoside alpha-2,3-sialyltransferase 1	Homo sapiens	98-105
17593824-21	2007	mda-7/IL-24 infecting cell may have the capability of reversing the resistance of tumor cell against Taxol.	Paclitaxel	101-106	interleukin 24	Homo sapiens	0-5
30375371-8	2018	Furthermore, overexpression of ST3GAL1 increases resistance to paclitaxel while downregulation of ST3GAL1 decreases resistance to paclitaxel in vitro, and overexpression of ST3GAL1 increases tumorigenicity and resistance to paclitaxel in vivo.	Paclitaxel	130-140	ST3 beta-galactoside alpha-2,3-sialyltransferase 1	Homo sapiens	98-105
17593824-21	2007	mda-7/IL-24 infecting cell may have the capability of reversing the resistance of tumor cell against Taxol.	Paclitaxel	101-106	interleukin 24	Homo sapiens	6-11
30375371-8	2018	Furthermore, overexpression of ST3GAL1 increases resistance to paclitaxel while downregulation of ST3GAL1 decreases resistance to paclitaxel in vitro, and overexpression of ST3GAL1 increases tumorigenicity and resistance to paclitaxel in vivo.	Paclitaxel	130-140	ST3 beta-galactoside alpha-2,3-sialyltransferase 1	Homo sapiens	98-105
30375371-12	2018	ST3GAL1 may be a promising target for overcoming paclitaxel resistance in ovarian carcinoma.	Paclitaxel	49-59	ST3 beta-galactoside alpha-2,3-sialyltransferase 1	Homo sapiens	0-7
30243650-0	2018	Paclitaxel alleviates liver fibrosis induced by bile duct ligation in rats: Role of TGF-beta1, IL-10 and c-Myc.	Paclitaxel	0-10	interleukin 10	Rattus norvegicus	95-100
30243650-5	2018	Administration of PTX ameliorated BDL-induced elevation in biomarkers of hepatocellular damage (alanine transaminase; ALT and aspartate transaminase; AST) and obstructive cholestatic injury (total bilirubin and gamma glutamyl transferase; gamma-GT).	Paclitaxel	18-21	gamma-glutamyltransferase 1	Rattus norvegicus	211-237
17272681-0	2007	Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells.	Paclitaxel	44-54	stathmin 1	Homo sapiens	12-20
17272681-6	2007	We found that targeting stathmin or wee-1 expression with RNA interference can induce microtubule polymerization and promote G(2)/M progression, respectively, and sensitize stathmin-overexpressing breast cancer cells to paclitaxel and vinblastine.	Paclitaxel	220-230	stathmin 1	Homo sapiens	24-32
30243650-7	2018	Additionally, PTX treatment corrected the BDL-induced fibrosis of portal tracts, elevation of hydroxyproline content and increased alpha smooth muscle actin (alpha-SMA) mRNA and protein expression.	Paclitaxel	14-17	actin gamma 2, smooth muscle	Rattus norvegicus	131-156
17272681-6	2007	We found that targeting stathmin or wee-1 expression with RNA interference can induce microtubule polymerization and promote G(2)/M progression, respectively, and sensitize stathmin-overexpressing breast cancer cells to paclitaxel and vinblastine.	Paclitaxel	220-230	stathmin 1	Homo sapiens	173-181
30243650-7	2018	Additionally, PTX treatment corrected the BDL-induced fibrosis of portal tracts, elevation of hydroxyproline content and increased alpha smooth muscle actin (alpha-SMA) mRNA and protein expression.	Paclitaxel	14-17	actin gamma 2, smooth muscle	Rattus norvegicus	158-167
30243650-9	2018	Furthermore, PTX rectified the BDL-induced decrease in interleukin-10 (IL-10) mRNA and protein expression.	Paclitaxel	13-16	interleukin 10	Rattus norvegicus	55-69
30243650-9	2018	Furthermore, PTX rectified the BDL-induced decrease in interleukin-10 (IL-10) mRNA and protein expression.	Paclitaxel	13-16	interleukin 10	Rattus norvegicus	71-76
30243650-10	2018	In conclusion, this study suggests that PTX at low dose has the potential to treat BDL-induced liver fibrosis in rats possibly through suppression of TGF-beta1 and c-Myc and activation of IL-10 pathways.	Paclitaxel	40-43	interleukin 10	Rattus norvegicus	188-193
17303111-0	2007	Taxol normalizes the impaired agonist-induced beta2-adrenoceptor internalization in splenocytes from GRK2+/- mice.	Paclitaxel	0-5	adrenergic receptor, beta 2	Mus musculus	46-64
29935185-0	2018	Inhibition of microRNA-16 facilitates the paclitaxel resistance by targeting IKBKB via NF-kappaB signaling pathway in hepatocellular carcinoma.	Paclitaxel	42-52	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	77-82
17303111-0	2007	Taxol normalizes the impaired agonist-induced beta2-adrenoceptor internalization in splenocytes from GRK2+/- mice.	Paclitaxel	0-5	G protein-coupled receptor kinase 2	Mus musculus	101-105
17303111-8	2007	Importantly, increasing tubulin stability by taxol almost completely restores the defective agonist-induced beta2-adrenoceptor internalization in cells from GRK2+/- animals, without affecting WT cells.	Paclitaxel	45-50	adrenergic receptor, beta 2	Mus musculus	108-126
17303111-8	2007	Importantly, increasing tubulin stability by taxol almost completely restores the defective agonist-induced beta2-adrenoceptor internalization in cells from GRK2+/- animals, without affecting WT cells.	Paclitaxel	45-50	G protein-coupled receptor kinase 2	Mus musculus	157-161
2564894-6	1989	These observations suggested that esters at C-2" and/or C-7, which would tend to promote water solubility, might serve as useful prodrugs of taxol.	Paclitaxel	141-146	complement C7	Homo sapiens	56-59
29935185-6	2018	The results demonstrate that the inhibition of miR-16 renders resistance to paclitaxel in vitro and in vivo by targeting IKBKB via NF-kappaB signaling pathway, suggesting that miR-16 may be a meaningful therapeutic potential to overcome drug resistance in HCC.	Paclitaxel	76-86	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	121-126
30249901-0	2018	Four-and-a-half LIM protein 1 promotes paclitaxel resistance in hepatic carcinoma cells through the regulation of caspase-3 activation.	Paclitaxel	39-49	four and a half LIM domains 1	Homo sapiens	0-29
30249901-4	2018	Cell viability assay, colony formation and xenograft experiments assay were performed to detect effect of FHL1 on Paclitaxel or Oxaliplatin resistance in vitro and in vivo.	Paclitaxel	114-124	four and a half LIM domains 1	Homo sapiens	106-110
17332325-0	2007	Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel.	Paclitaxel	125-135	AKT serine/threonine kinase 2	Homo sapiens	37-41
30249901-5	2018	Caspase activity assay was performed to explore the activation of caspase-3 and caspase-9 in paclitaxel treated FHL1-knockdown HepG2 cells.	Paclitaxel	93-103	caspase 9	Homo sapiens	0-7
17332325-8	2007	Moreover, silencing AKT2 decreased Twist-promoted migration, invasion, and paclitaxel resistance.	Paclitaxel	75-85	AKT serine/threonine kinase 2	Homo sapiens	20-24
2887299-3	1987	Observations on cells that were treated with colcemid or taxol prior to induction of sIg redistribution have further shown that vimentin accumulation corresponds to a dynamic rearrangement of this filamentous system which is related to, but is not required for, the energy-dependent translocation of sIg.	Paclitaxel	57-62	vimentin	Mus musculus	128-136
30249901-5	2018	Caspase activity assay was performed to explore the activation of caspase-3 and caspase-9 in paclitaxel treated FHL1-knockdown HepG2 cells.	Paclitaxel	93-103	caspase 9	Homo sapiens	80-89
30249901-5	2018	Caspase activity assay was performed to explore the activation of caspase-3 and caspase-9 in paclitaxel treated FHL1-knockdown HepG2 cells.	Paclitaxel	93-103	four and a half LIM domains 1	Homo sapiens	112-116
30249901-7	2018	Knockdown of FHL1 significantly enhanced the sensitivity of paclitaxel, but had no effects on sensitivity of oxaliplatin.	Paclitaxel	60-70	four and a half LIM domains 1	Homo sapiens	13-17
17158870-3	2007	Relative to wild-type MEF cells, MKK4-null MEF cells were highly susceptible to apoptosis by LY294002, paclitaxel, or serum starvation.	Paclitaxel	103-113	mitogen-activated protein kinase kinase 4	Mus musculus	33-37
30111846-4	2018	We further show that the chemotherapeutic drug, paclitaxel, enhances IRE1 RNase activity and this contributes to paclitaxel-mediated expansion of tumor-initiating cells.	Paclitaxel	48-58	endoplasmic reticulum (ER) to nucleus signalling 2	Mus musculus	69-73
16778834-4	2007	Bim was involved in paclitaxel but not etoposide or cisplatin-induced cell death in NB cells.	Paclitaxel	20-30	BCL2 like 11	Homo sapiens	0-3
2885096-1	1987	The effects of colcemid (0.16-1.0 microM) and taxol (10 microM) on the primary cilia cycle in PtK1 cells were studied by antitubulin immunofluorescence microscopy and by high-voltage electron microscopy of serial 0.25-micron sections.	Paclitaxel	46-51	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	94-98
6146136-4	1984	The substituent at C-13 of taxol was required to prevent disassembly of brain microtubules with or without microtubule-associated proteins.	Paclitaxel	27-32	homeobox C13	Homo sapiens	19-23
30111846-4	2018	We further show that the chemotherapeutic drug, paclitaxel, enhances IRE1 RNase activity and this contributes to paclitaxel-mediated expansion of tumor-initiating cells.	Paclitaxel	113-123	endoplasmic reticulum (ER) to nucleus signalling 2	Mus musculus	69-73
16972069-2	2007	In this paper, we have investigated whether cell cycle transit and or Cdc2 (Cdk1) activity is required for the apoptosis induced by PTX.	Paclitaxel	132-135	cyclin dependent kinase 1	Homo sapiens	70-74
30111846-5	2018	In a xenograft mouse model of TNBC, inhibition of IRE1 RNase activity increases paclitaxel-mediated tumor suppression and delays tumor relapse post therapy.	Paclitaxel	80-90	endoplasmic reticulum (ER) to nucleus signalling 2	Mus musculus	50-54
16972069-2	2007	In this paper, we have investigated whether cell cycle transit and or Cdc2 (Cdk1) activity is required for the apoptosis induced by PTX.	Paclitaxel	132-135	cyclin dependent kinase 1	Homo sapiens	76-80
29715474-8	2018	Pretreatment of mice with the pharmacological TRPV4 inhibitor HC067047 prior to paclitaxel injections prevented electrophysiological and behavioral changes associated with paclitaxel-induced neuropathy.	Paclitaxel	80-90	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	46-51
17404030-0	2007	Effect of paclitaxel on intracellular localization of c-Myc and P-c-Myc in prostate carcinoma cell lines.	Paclitaxel	10-20	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	54-59
17404030-0	2007	Effect of paclitaxel on intracellular localization of c-Myc and P-c-Myc in prostate carcinoma cell lines.	Paclitaxel	10-20	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	66-71
6192993-5	1983	In the cells treated with colchicine or taxol, in which secretion was greatly inhibited, the fully processed alpha 1-protease inhibitor and albumin accumulated and were finally secreted into the medium.	Paclitaxel	40-45	serpin family A member 1	Rattus norvegicus	109-135
29715474-8	2018	Pretreatment of mice with the pharmacological TRPV4 inhibitor HC067047 prior to paclitaxel injections prevented electrophysiological and behavioral changes associated with paclitaxel-induced neuropathy.	Paclitaxel	172-182	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	46-51
17404030-3	2007	We speculated that subcellular localization of c-Myc protein and of its phosphorylated form (P-c-Myc) could have a role in the different response to paclitaxel (PTX) in two prostate carcinoma cell lines, PC3 and DU145, which undergo either multinucleation or c-myc-dependent apoptosis, respectively.	Paclitaxel	149-159	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	47-52
17404030-3	2007	We speculated that subcellular localization of c-Myc protein and of its phosphorylated form (P-c-Myc) could have a role in the different response to paclitaxel (PTX) in two prostate carcinoma cell lines, PC3 and DU145, which undergo either multinucleation or c-myc-dependent apoptosis, respectively.	Paclitaxel	149-159	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	95-100
30013648-6	2018	Patients with the ERCC1 C8092A genotype of A/A or A/C received paclitaxel and cisplatin, and those with the genotype of C/C received paclitaxel and fluorouracil.	Paclitaxel	63-73	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	18-23
17404030-3	2007	We speculated that subcellular localization of c-Myc protein and of its phosphorylated form (P-c-Myc) could have a role in the different response to paclitaxel (PTX) in two prostate carcinoma cell lines, PC3 and DU145, which undergo either multinucleation or c-myc-dependent apoptosis, respectively.	Paclitaxel	161-164	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	47-52
17404030-3	2007	We speculated that subcellular localization of c-Myc protein and of its phosphorylated form (P-c-Myc) could have a role in the different response to paclitaxel (PTX) in two prostate carcinoma cell lines, PC3 and DU145, which undergo either multinucleation or c-myc-dependent apoptosis, respectively.	Paclitaxel	161-164	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	95-100
17404030-4	2007	c-myc is amplified only in PC3, but a similar extent of c-Myc phosphorylation was observed in both cell lines after PTX treatment.	Paclitaxel	116-119	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	56-61
17404030-5	2007	We found that PTX-induced upregulation of c-myc in DU145 cells, not occurring in PC3 cells, cannot be ascribed to a different protein localization, and that a comparable c-Myc and P-c-Myc nuclear translocation occurs in both cell lines after drug treatment.	Paclitaxel	14-17	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	42-47
17404030-5	2007	We found that PTX-induced upregulation of c-myc in DU145 cells, not occurring in PC3 cells, cannot be ascribed to a different protein localization, and that a comparable c-Myc and P-c-Myc nuclear translocation occurs in both cell lines after drug treatment.	Paclitaxel	14-17	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	170-175
6139172-10	1983	Ultrastructural analyses show that taxol-treated fibroblasts contain parallel arrays of cross-bridged MT-IF as well as bundles of MT exclusive of IF.	Paclitaxel	35-40	metallothionein 1F	Homo sapiens	102-107
33894420-6	2021	Moreover, CCT at the non-toxic concentration exhibited obviously synergistic effects with taxol to induce apoptosis and cell cycle arrest in G2/M phase in vitro.	Paclitaxel	90-95	CCT	Homo sapiens	10-13
33894420-8	2021	Meanwhile, CCT combined with taxol caused significant ER stress through improving phosphorylated PERK, eukaryotic translation initiation factor 2alpha (eIF2alpha), C/EBP homologous protein (CHOP) and glucose-regulated protein 78 (GRP78).	Paclitaxel	29-34	eukaryotic translation initiation factor 2A	Homo sapiens	103-150
33894420-8	2021	Meanwhile, CCT combined with taxol caused significant ER stress through improving phosphorylated PERK, eukaryotic translation initiation factor 2alpha (eIF2alpha), C/EBP homologous protein (CHOP) and glucose-regulated protein 78 (GRP78).	Paclitaxel	29-34	eukaryotic translation initiation factor 2A	Homo sapiens	152-161
33894420-10	2021	Intriguingly, PERK knockdown markedly abolished the regulatory role of CCT and taxol cotreatments in cell proliferation suppression and apoptosis induction, indicating the importance of PERK for CCT to perform its anti-cancer bioactivity.	Paclitaxel	79-84	CCT	Homo sapiens	195-198
33894420-12	2021	Together, all these results suggested that promoting PERK activation by CCT may be an effective therapeutic strategy to improve CRC to taxol treatment.	Paclitaxel	135-140	CCT	Homo sapiens	72-75
34050450-8	2021	On the other hand, a synergistic effect on MMP9 gene expression was significantly seen in MDA-MB-231 cells treated with the combination (- 9.99 folds) in comparison with the cells treated with doxorubicin (- 3.62 folds) or paclitaxel (1.75 folds) alone.	Paclitaxel	223-233	matrix metallopeptidase 9	Homo sapiens	43-47
29697191-1	2018	BACKGROUND: Paclitaxel, ifosfamide, cisplatin (TIP) is commonly used as salvage for malignant germ cell tumors (MGCT) in adults; however, additional administration of cisplatin at a young age could cause significant short- and long-term toxicities in a group of patients with high expected salvage.	Paclitaxel	12-22	TOR signaling pathway regulator	Homo sapiens	47-50
33992713-6	2021	CrEL was also shown to enhance PTX-induced cell death in vitro by Annexin V/PI staining.	Paclitaxel	31-34	annexin A5	Mus musculus	66-75
17404030-5	2007	We found that PTX-induced upregulation of c-myc in DU145 cells, not occurring in PC3 cells, cannot be ascribed to a different protein localization, and that a comparable c-Myc and P-c-Myc nuclear translocation occurs in both cell lines after drug treatment.	Paclitaxel	14-17	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	182-187
33992713-7	2021	Treatment of C57BL/6 mice with PTX in a lower concentration of CrEL resulted in higher myelosuppression, decreased both Ki-67 expression and survival rate, suggesting that CrEL micelle formation above the CMC may lower the cytotoxic activity of PTX in vivo.	Paclitaxel	31-34	antigen identified by monoclonal antibody Ki 67	Mus musculus	120-125
17477027-9	2007	Paclitaxel 80 mg/m2 was administered weekly for 3 weeks per 4-week cycle.	Paclitaxel	0-10	PER3 pseudogene 1	Homo sapiens	56-61
29635137-0	2018	Improvements in the water dispersibility of paclitaxel by complexing with synthetic peptides derived from beta-casein.	Paclitaxel	44-54	casein beta	Homo sapiens	106-117
33151424-0	2021	Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells.	Paclitaxel	36-46	zinc finger E-box binding homeobox 1	Homo sapiens	19-23
33151424-6	2021	RESULTS: ZEB1-AS1 depletion using siRNA in chemosensitive A2780 cells significantly increased PTX and DDP resistance.	Paclitaxel	94-97	zinc finger E-box binding homeobox 1	Homo sapiens	9-13
29675791-5	2018	The decrease in PD-L1 expression, however, was significant only in patients who received cisplatin-gemcitabine combination (p = 0.020), while in the carboplatin-paclitaxel group, no similar tendency could be observed (p = 0.432).	Paclitaxel	161-171	CD274 molecule	Homo sapiens	16-21
33151424-7	2021	In contrast, ZEB1-AS1 overexpression in PTX- and DDP-resistant A2780/resistant (A2780/R) cells reversed the observed drug resistance.	Paclitaxel	40-43	zinc finger E-box binding homeobox 1	Homo sapiens	13-17
33151424-8	2021	Thus, ZEB1-AS1 plays an important role in PTX and DDP resistance in EOC cells.	Paclitaxel	42-45	zinc finger E-box binding homeobox 1	Homo sapiens	6-10
33151424-13	2021	CCK8 assay results suggested that MMP19 knockdown promoted ZEB1-AS1-induced chemoresistance to PTX and DDP in A2780 cells.	Paclitaxel	95-98	zinc finger E-box binding homeobox 1	Homo sapiens	59-63
33932086-0	2021	An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer.	Paclitaxel	81-91	B cell leukemia/lymphoma 6	Mus musculus	47-51
17218637-4	2007	Hsp27 overexpression increased UMUC-3 cell growth and resistance to paclitaxel.	Paclitaxel	68-78	heat shock protein family B (small) member 1	Homo sapiens	0-5
17218637-6	2007	OGX-427 or Hsp27 siRNA treatment induced apoptosis and enhanced sensitivity to paclitaxel in UMUC-3 cells.	Paclitaxel	79-89	heat shock protein family B (small) member 1	Homo sapiens	11-16
17143487-7	2007	Selective small interfering RNAs (siRNA) of P-gp with MDR1-targeted short hairpin RNAs (shRNA) expression vector sensitized the cells to Taxol.	Paclitaxel	137-142	phosphoglycolate phosphatase	Homo sapiens	44-48
17143487-8	2007	These results suggest that both p27 and P-gp can modulate Taxol sensitivity respectively, while p27 requires P-gp for its full function.	Paclitaxel	58-63	phosphoglycolate phosphatase	Homo sapiens	40-44
17143487-8	2007	These results suggest that both p27 and P-gp can modulate Taxol sensitivity respectively, while p27 requires P-gp for its full function.	Paclitaxel	58-63	phosphoglycolate phosphatase	Homo sapiens	109-113
17143487-9	2007	Increased P-gp protein expression through p27 mediation is one of the major mechanisms of Taxol resistance in ovarian cancer multicellular spheroids.	Paclitaxel	90-95	phosphoglycolate phosphatase	Homo sapiens	10-14
29716954-0	2018	Nmnat mitigates sensory dysfunction in a Drosophila model of paclitaxel-induced peripheral neuropathy.	Paclitaxel	61-71	Nicotinamide mononucleotide adenylyltransferase	Drosophila melanogaster	0-5
33968729-5	2021	The other patient exhibited a KRAS exon 3 mutation, so the paclitaxel (albumin-bound) plus nivolumab was administered.	Paclitaxel	59-69	KRAS proto-oncogene, GTPase	Homo sapiens	30-34
33896831-9	2021	CONCLUSIONS: Our results first revealed that TPM3, EFHD2, KRT19 and vimentin were novel autoantibodies in the ascites of relapsed PTX-resistant GC patients.	Paclitaxel	130-133	tropomyosin 3	Homo sapiens	45-49
33796975-10	2021	It has been shown that melittin and whole honey bee venom are effective in treating paclitaxel and oxaliplatin-induced peripheral neuropathy.	Paclitaxel	84-94	melittin	Apis mellifera	23-31
29866066-10	2018	In combination with either cisplatin or paclitaxel, 3PO (a novel PFKFB3 inhibitor) enhanced the cytotoxic effect in both platinum sensitive and platinum resistant ovarian cancer cells.	Paclitaxel	40-50	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	65-71
33742719-2	2021	In this work, we report that several microtubule-targeting agents (MTAs) such as vinblastine, taxol, and C12 (combretastatin-2-aminoimidazole analog) inhibit Wnt/beta-catenin signaling in oral squamous cell carcinoma (OSCC).	Paclitaxel	94-99	catenin (cadherin associated protein), beta 1	Mus musculus	162-174
18503359-15	2006	In tissue cultures Giemsa staining and immunohistochemical reactions for p53, Ki-67, CD-34, and SMA antigens revealed marked fibroblast hypertrophy in all of the paclitaxel-treated groups.	Paclitaxel	162-172	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	73-76
17148761-4	2006	Paclitaxel significantly increased in vivo expression of TRAIL-R1 and TRAIL-R2 in a time-dependent manner.	Paclitaxel	0-10	TNF receptor superfamily member 10b	Homo sapiens	70-78
17148761-5	2006	The imaging results were confirmed by immunoblots for steady-state protein levels (&gt;20-fold increase in TRAIL-R1 and TRAIL-R2 levels in tumor xenografts by 48 h after paclitaxel administration).	Paclitaxel	170-180	TNF receptor superfamily member 10b	Homo sapiens	120-128
29910679-5	2018	The PTX resistant cells showed stronger cell proliferation ability by exhibiting the upregulation of CENPF, CDC6, MCM3, CLSPN and SMC1A expression.	Paclitaxel	4-7	structural maintenance of chromosomes 1A	Homo sapiens	130-135
17013882-8	2006	CONCLUSION: Inhibiting VEGF-R and EGF-R activation on tumor-associated endothelial cells with AEE788 combined with paclitaxel can bypass CaP cell resistance and prevent lymph node metastasis.	Paclitaxel	115-125	epidermal growth factor receptor	Mus musculus	24-29
28509576-4	2018	In this study, we investigated the effect of paclitaxel treatment on the expression levels of two oncomirs (oncomiRs), miR-21 and miR-203, in breast cancer cell lines.	Paclitaxel	45-55	microRNA 21	Homo sapiens	119-125
33571907-6	2021	In-vitro transduction of a retrovirus encoding TLE3 to A549 lung cancer cells increased paclitaxel effectivity while TLE1 introduction to these cells decreased it.	Paclitaxel	88-98	TLE family member 3, transcriptional corepressor	Homo sapiens	47-51
29616103-1	2018	The effect of paclitaxel combined with lobaplatin on the sensitivity of lung cancer cell line NCI-H446 through influencing the phosphatidylinositol 3-kinase (PI3K)/Akt pathway was investigated.	Paclitaxel	14-24	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	127-156
16934227-4	2006	We have shown that the RTK inhibitor GW282974A (an analogue of GW2016; lapatinib) is effective in chemosensitisation of drug resistant EGFR over-expressing cells giving rise to a synergistic effect when used in combination with either cisplatin or paclitaxel in chemosensitivity assays.	Paclitaxel	248-258	ret proto-oncogene	Homo sapiens	23-26
29373839-0	2018	Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.	Paclitaxel	88-98	NUS1 dehydrodolichyl diphosphate synthase subunit	Homo sapiens	0-15
16934227-6	2006	A reduction in the downstream signalling effector phosphorylated ERK was seen in both resistant cell lines when GW282974A was used in combination with either cisplatin or paclitaxel.	Paclitaxel	171-181	EPH receptor B2	Homo sapiens	65-68
16721826-7	2006	Treatment with either paclitaxel or etoposide caused a transient phosphorylation/activation of p42 MAPK in ASMCs and DFs, but had no effect on phospho-p42/44 MAPK in VSMCs.	Paclitaxel	22-32	cyclin dependent kinase 20	Homo sapiens	95-98
33734317-13	2021	Overall, our results show that PTX treatment increases levels of functional endogenous NaV1.7 channels in DRG neurons and enhances trafficking and surface distribution of NaV1.7 in sensory axons, with outcomes that depend on the presence of an inflammatory milieu, providing a mechanistic explanation for increased excitability of primary afferents and pain in CIPN.	Paclitaxel	31-34	sodium voltage-gated channel alpha subunit 9	Homo sapiens	171-177
29373839-4	2018	Here, we demonstrate NgBR as a potential therapeutic target for ERalpha positive breast cancer patients to attenuate paclitaxel resistance.	Paclitaxel	117-127	NUS1 dehydrodolichyl diphosphate synthase subunit	Homo sapiens	21-25
33444116-2	2021	In this randomized, open-label, phase II study, we characterized the efficacy and safety of bevacizumab in combination with carboplatin plus paclitaxel (CPB) in patients with previously untreated advanced MM.	Paclitaxel	141-151	carboxypeptidase B1	Homo sapiens	153-156
29373839-5	2018	NgBR knockdown enhanced paclitaxel-induced cell apoptosis by modulating expression of p53 and survivin in ERalpha positive breast cancer cells via NgBR-mediated PI3K/Akt and MAPK/ERK signaling pathways.	Paclitaxel	24-34	NUS1 dehydrodolichyl diphosphate synthase subunit	Homo sapiens	0-4
33683482-5	2021	Arm 1 patients received nab-paclitaxel and cisplatin, then cisplatin with radiation.	Paclitaxel	28-38	kallikrein related peptidase 4	Homo sapiens	0-5
16920067-2	2006	Paxillin tyrosine phosphorylation is inhibited by cytochalasin D (CD), but slightly increased by colchicine and paclitaxol (taxol).	Paclitaxel	112-122	paxillin	Bos taurus	0-8
29373839-5	2018	NgBR knockdown enhanced paclitaxel-induced cell apoptosis by modulating expression of p53 and survivin in ERalpha positive breast cancer cells via NgBR-mediated PI3K/Akt and MAPK/ERK signaling pathways.	Paclitaxel	24-34	NUS1 dehydrodolichyl diphosphate synthase subunit	Homo sapiens	147-151
16920067-2	2006	Paxillin tyrosine phosphorylation is inhibited by cytochalasin D (CD), but slightly increased by colchicine and paclitaxol (taxol).	Paclitaxel	117-122	paxillin	Bos taurus	0-8
16920067-4	2006	Meanwhile, colchicine and taxol caused a disassembly of paxillin-FAs from cell periphery and lamellipodia, and their assembly in cell center.	Paclitaxel	26-31	paxillin	Bos taurus	56-64
33738251-0	2021	Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients.	Paclitaxel	48-58	long intergenic non-protein coding RNA 665	Homo sapiens	0-9
29373839-8	2018	In summary, our data suggest that NgBR expression is essential to promoting ERalpha positive breast cancer cell resistance to paclitaxel.	Paclitaxel	126-136	NUS1 dehydrodolichyl diphosphate synthase subunit	Homo sapiens	34-38
33402387-4	2021	Moreover, both paclitaxel-resistant NPC cells and relapsed/metastatic clinical samples exhibited increased IRAK1 phosphorylation and that pacritinib could abolish the IRAK1 phosphorylation to suppress S100A9 expression.	Paclitaxel	15-25	S100 calcium binding protein A9	Homo sapiens	201-207
29421551-4	2018	The micelle (HA-SS-TOS, HSST) can highly specifically bind with CD44 receptor over-expressed tumor, and response selectively to high GSH level in the cells, inducing disulfide bond breakage and the release of the payload (paclitaxel, PTX).	Paclitaxel	222-232	N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1	Mus musculus	24-28
33402387-6	2021	Together, these findings demonstrated an important role of the IRAK1-S100A9 axis in mediating resistance to paclitaxel.	Paclitaxel	108-118	S100 calcium binding protein A9	Homo sapiens	69-75
33387573-6	2021	measures of GFAP expression and counts of beta-III tubulin and tyrosine hydroxylase positive neurons reveals that a low dose of 3.5 nM of paclitaxel significantly reduced the density of GFAP + astrocytes in primary VM cultures, while maintaining the viability of neurons and dopamine neurons.	Paclitaxel	138-148	glial fibrillary acidic protein	Homo sapiens	12-16
33387573-6	2021	measures of GFAP expression and counts of beta-III tubulin and tyrosine hydroxylase positive neurons reveals that a low dose of 3.5 nM of paclitaxel significantly reduced the density of GFAP + astrocytes in primary VM cultures, while maintaining the viability of neurons and dopamine neurons.	Paclitaxel	138-148	glial fibrillary acidic protein	Homo sapiens	186-190
16846720-2	2006	Compounds were screened for Pgp interaction based on inhibition of Pgp mediated [3H]-taxol transport in Caco-2 cells.	Paclitaxel	85-90	phosphoglycolate phosphatase	Homo sapiens	28-31
16846720-2	2006	Compounds were screened for Pgp interaction based on inhibition of Pgp mediated [3H]-taxol transport in Caco-2 cells.	Paclitaxel	85-90	phosphoglycolate phosphatase	Homo sapiens	67-70
16846720-10	2006	In conclusion, we have demonstrated that a substantial number of antiparasitic and natural compounds, in a range of concentrations, are capable of inhibiting Pgp mediated [3H]-taxol efflux in Caco-2 cells, without being substrates and this may have implications for drug interactions with Pgp.	Paclitaxel	176-181	phosphoglycolate phosphatase	Homo sapiens	158-161
29540677-0	2018	SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cells.	Paclitaxel	37-47	forkhead box K2	Homo sapiens	22-27
16846720-10	2006	In conclusion, we have demonstrated that a substantial number of antiparasitic and natural compounds, in a range of concentrations, are capable of inhibiting Pgp mediated [3H]-taxol efflux in Caco-2 cells, without being substrates and this may have implications for drug interactions with Pgp.	Paclitaxel	176-181	phosphoglycolate phosphatase	Homo sapiens	289-292
16857764-5	2006	ET-1 also prevented Paclitaxel-induced up-regulation of pro-apoptotic Bax and cleaved (activated) caspase-3.	Paclitaxel	20-30	BCL2 associated X, apoptosis regulator	Rattus norvegicus	70-73
33558461-7	2021	Noninvasive imaging of autophagic flux using a novel autophagy sensor (mtFL-p62 fusion reporter) showed that combinatorial treatment of platinum-taxol along with Trametinib/chloroquine blocked autophagic flux in live cells and tumor xenografts.	Paclitaxel	145-150	nucleoporin 62	Mus musculus	76-79
29540677-11	2018	Collectively, our results suggest that SUMOylation positively regulates FOXK2 transcriptional activity and has a role in mediating the cytotoxic response to paclitaxel through the tumour suppressor FOXO3.	Paclitaxel	157-167	forkhead box K2	Homo sapiens	72-77
16598766-0	2006	p27kip1 overexpression promotes paclitaxel-induced apoptosis in pRb-defective SaOs-2 cells.	Paclitaxel	32-42	cyclin dependent kinase inhibitor 1B	Homo sapiens	0-7
29358095-5	2018	In this paper we found that the effect of paclitaxel can be significantly improved when used in combination with FEN1 inhibitor SC13, suggesting a synergistic mechanism between the two compounds.	Paclitaxel	42-52	flap structure-specific endonuclease 1	Homo sapiens	113-117
16598766-2	2006	We evaluated the role of p27kip1 in paclitaxel-induced apoptosis in the pRb-defective SaOs-2 cells.	Paclitaxel	36-46	cyclin dependent kinase inhibitor 1B	Homo sapiens	25-32
16598766-3	2006	Following 48 h of exposure of SaOs-2 cells to 100 nM paclitaxel, we observed an increase in p27kip1 expression caused by the decrease of the ubiquitin-proteasome activity.	Paclitaxel	53-63	cyclin dependent kinase inhibitor 1B	Homo sapiens	92-99
16598766-5	2006	Finally, we demonstrated that SaOs-2 cells transiently overexpressing the p27kip1 protein are more susceptible to paclitaxel-induced apoptosis than SaOs-2 cells transiently transfected with the empty vector.	Paclitaxel	114-124	cyclin dependent kinase inhibitor 1B	Homo sapiens	74-81
16598766-6	2006	Indeed, after 48 h of paclitaxel treatment, 41.8% of SaOs-2 cells transiently transfected with a pcDNA3-p27kip1 construct were Annexin V-positive compared to 30.6% of SaOs-2 cells transfected with the empty vector (P &lt; 0.05).	Paclitaxel	22-32	cyclin dependent kinase inhibitor 1B	Homo sapiens	104-111
16598766-6	2006	Indeed, after 48 h of paclitaxel treatment, 41.8% of SaOs-2 cells transiently transfected with a pcDNA3-p27kip1 construct were Annexin V-positive compared to 30.6% of SaOs-2 cells transfected with the empty vector (P &lt; 0.05).	Paclitaxel	22-32	annexin A5	Homo sapiens	127-136
16598766-7	2006	In conclusion, we demonstrated that transfection of the pRb-defective SaOs-2 cells with the p27kip1 gene via plasmid increases their susceptibility to paclitaxel-induced apoptosis.	Paclitaxel	151-161	cyclin dependent kinase inhibitor 1B	Homo sapiens	92-99
16895478-0	2006	Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS.	Paclitaxel	30-35	caspase 9	Homo sapiens	144-153
33506275-0	2021	Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells.	Paclitaxel	77-87	Kruppel like factor 4	Homo sapiens	45-49
33506275-7	2021	Considering stem cell markers, KLF4 expression elevated significantly, as soon as parental cells acquired resistance to the lowest dose of paclitaxel and its expression elevated stepwise.	Paclitaxel	139-149	Kruppel like factor 4	Homo sapiens	31-35
33506275-9	2021	Our findings suggest that higher expressions of ABCB1, ABCG2, and KLF4 might be considered as putative indicators for paclitaxel resistance in LSCC patients.	Paclitaxel	118-128	Kruppel like factor 4	Homo sapiens	66-70
33443463-17	2021	On the other hand, siRNAs were respectively implemented to inhibit the expression of endogenous Beclin1 and Atg5, two important autophagy-related genes, in BCa cells, which significantly increased 5637R cells death upon taxol exposing.	Paclitaxel	220-225	beclin 1	Homo sapiens	96-103
28771725-7	2018	Furthermore, taxol-induced NFkappaB signaling was reduced following TLR4 silencing in taxol-resistant SKOV3 cells.	Paclitaxel	86-91	toll like receptor 4	Homo sapiens	68-72
16849574-5	2006	In contrast, overexpression of E2F-1 resulted in a marked increase in sensitivity to vinblastine and paclitaxel, drugs that are known to be more effective against cells in M phase.	Paclitaxel	101-111	E2F transcription factor 1	Homo sapiens	31-36
33681397-9	2021	Paclitaxel and 17-AAG combination resulted in synergistic effect: paclitaxel in the combination with 17-AAG was half its original concentration and yielded similar cytotoxic effect.	Paclitaxel	66-76	N-methylpurine DNA glycosylase	Homo sapiens	18-21
16849574-8	2006	Overexpression of cyclin B1 also resulted in a specific increase in sensitivity to paclitaxel and an increase in the cellular growth rate.	Paclitaxel	83-93	cyclin B1	Homo sapiens	18-27
28771725-8	2018	Consistent with these results, ectopic expression of TLR4 in taxol-sensitive SKOV3 cells enhanced ABCB1 expression and conferred resistance to taxol.	Paclitaxel	61-66	toll like receptor 4	Homo sapiens	53-57
16849574-9	2006	Knockdown of cyclin B1 using an RNA interference oligo resulted in a slower cellular growth rate and an increase in resistance to paclitaxel.	Paclitaxel	130-140	cyclin B1	Homo sapiens	13-22
33681397-9	2021	Paclitaxel and 17-AAG combination resulted in synergistic effect: paclitaxel in the combination with 17-AAG was half its original concentration and yielded similar cytotoxic effect.	Paclitaxel	66-76	N-methylpurine DNA glycosylase	Homo sapiens	104-107
33319669-5	2021	PTX resistance pathways that involve major regulatory proteins/RNAs like RNF8/Twist/ROR1, TLR, ErbB3/ErbB2, BRCA1-IRIS, MENA, LIN9, MiRNA, FoxM1 and IRAK1 have expanded the complexity of resistance mechanisms, and brought newer insights for development of drug targets.	Paclitaxel	0-3	BRCA1 DNA repair associated	Homo sapiens	108-113
16432835-1	2006	We investigated the mechanisms responsible for paclitaxel resistance in HME-1 cells (human mammary epithelial cells immortalized with hTERT).	Paclitaxel	47-57	telomerase reverse transcriptase	Homo sapiens	134-139
28771725-8	2018	Consistent with these results, ectopic expression of TLR4 in taxol-sensitive SKOV3 cells enhanced ABCB1 expression and conferred resistance to taxol.	Paclitaxel	143-148	toll like receptor 4	Homo sapiens	53-57
28771725-9	2018	The protective effect of exogenous TLR4 expression against taxol was reduced by treatment with NFkappaB inhibitor in these cells.	Paclitaxel	59-64	toll like receptor 4	Homo sapiens	35-39
28771725-10	2018	These results demonstrate that taxol activates the TLR4-NFkappaB pathway which in turn induces ABCB1 gene expression.	Paclitaxel	31-36	toll like receptor 4	Homo sapiens	51-55
33096154-3	2020	Accordingly, several studies on combining glucose transporter (GLUT) inhibitors with chemotherapeutic agents, such as doxorubicin, paclitaxel, and cytarabine, showed synergistic or additive anticancer effects, reduced chemo-, radio-, and immuno-resistance, and reduced toxicity due to lowering the therapeutic doses required for desired chemotherapeutic effects, as compared with monotherapy.	Paclitaxel	131-141	solute carrier family 2 member 1	Homo sapiens	42-61
29482988-3	2018	Therefore, we assume that the inhibition of beta-catenin can enhanced the efficacy of taxol.	Paclitaxel	86-91	catenin beta 1	Homo sapiens	44-56
33096154-3	2020	Accordingly, several studies on combining glucose transporter (GLUT) inhibitors with chemotherapeutic agents, such as doxorubicin, paclitaxel, and cytarabine, showed synergistic or additive anticancer effects, reduced chemo-, radio-, and immuno-resistance, and reduced toxicity due to lowering the therapeutic doses required for desired chemotherapeutic effects, as compared with monotherapy.	Paclitaxel	131-141	solute carrier family 2 member 1	Homo sapiens	63-67
33058284-8	2020	Overexpression of LOX, LOXL3, and LOXL4 mRNA indicated worse OS and PFS among OC patients who received platinum, taxol, and taxol + platinum chemotherapy.	Paclitaxel	113-118	lysyl oxidase	Homo sapiens	18-21
33058284-8	2020	Overexpression of LOX, LOXL3, and LOXL4 mRNA indicated worse OS and PFS among OC patients who received platinum, taxol, and taxol + platinum chemotherapy.	Paclitaxel	124-129	lysyl oxidase	Homo sapiens	18-21
16767218-3	2006	Downregulation of HtrA1 attenuated cisplatin- and paclitaxel-induced cytotoxicity, while forced expression of HtrA1 enhanced cisplatin- and paclitaxel-induced cytotoxicity.	Paclitaxel	50-60	HtrA serine peptidase 1	Homo sapiens	18-23
29495431-7	2018	The combination of FIS and PTX significantly reduced cancer cell migration and invasion, at least partially, through a marked rearrangement of actin and vimentin cytoskeleton and the modulation of metastasis-related genes.	Paclitaxel	27-30	vimentin	Homo sapiens	153-161
16767218-3	2006	Downregulation of HtrA1 attenuated cisplatin- and paclitaxel-induced cytotoxicity, while forced expression of HtrA1 enhanced cisplatin- and paclitaxel-induced cytotoxicity.	Paclitaxel	140-150	HtrA serine peptidase 1	Homo sapiens	110-115
16767218-4	2006	HtrA1 expression was upregulated by both cisplatin and paclitaxel treatment.	Paclitaxel	55-65	HtrA serine peptidase 1	Homo sapiens	0-5
16767218-9	2006	These findings uncover what we believe to be a novel pathway by which serine protease HtrA1 mediates paclitaxel- and cisplatin-induced cytotoxicity and suggest that loss of HtrA1 in ovarian and gastric cancers may contribute to in vivo chemoresistance.	Paclitaxel	101-111	HtrA serine peptidase 1	Homo sapiens	86-91
16767218-9	2006	These findings uncover what we believe to be a novel pathway by which serine protease HtrA1 mediates paclitaxel- and cisplatin-induced cytotoxicity and suggest that loss of HtrA1 in ovarian and gastric cancers may contribute to in vivo chemoresistance.	Paclitaxel	101-111	HtrA serine peptidase 1	Homo sapiens	173-178
33207738-0	2020	Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance.	Paclitaxel	74-84	ubiquitin specific peptidase 7	Homo sapiens	29-33
33207738-0	2020	Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance.	Paclitaxel	74-84	polo like kinase 1	Homo sapiens	38-42
33207738-5	2020	When USP7 was blocked in the paclitaxel-resistant lung cancer NCI-H460TXR cells, which has resistance to mitotic catastrophe, NCI-H460TXR cells underwent apoptosis effectively.	Paclitaxel	29-39	ubiquitin specific peptidase 7	Homo sapiens	5-9
33207738-6	2020	Furthermore, combination treatment with the mitotic kinase PLK1 inhibitor volasertib and the USP7 inhibitor P22077 showed a strong synergism through down-regulation of MDR1/ABCB1 in paclitaxel-resistant lung cancer.	Paclitaxel	182-192	polo like kinase 1	Homo sapiens	59-63
33207738-6	2020	Furthermore, combination treatment with the mitotic kinase PLK1 inhibitor volasertib and the USP7 inhibitor P22077 showed a strong synergism through down-regulation of MDR1/ABCB1 in paclitaxel-resistant lung cancer.	Paclitaxel	182-192	ubiquitin specific peptidase 7	Homo sapiens	93-97
33207738-7	2020	Therefore, we suggest USP7 is a promising target for cancer therapy, and combination therapy with inhibitors of PLK1 and USP7 may be valuable for treating paclitaxel-resistant cancers, because of their strong synergism.	Paclitaxel	155-165	polo like kinase 1	Homo sapiens	112-116
33207738-7	2020	Therefore, we suggest USP7 is a promising target for cancer therapy, and combination therapy with inhibitors of PLK1 and USP7 may be valuable for treating paclitaxel-resistant cancers, because of their strong synergism.	Paclitaxel	155-165	ubiquitin specific peptidase 7	Homo sapiens	121-125
29253998-4	2018	Caco-2 cell experiments confirmed PTX or rhodamine-123-loaded SH-OGC demonstrated effective cellular accumulation via caveola-mediated endocytosis along with the inhibition of P-gp efflux.	Paclitaxel	34-37	phosphoglycolate phosphatase	Homo sapiens	176-180
33299648-2	2020	The aim of the present study was to develop an intravenous formulation of HM30181A (HM) to inhibit P-gp in the brain to effectively deliver paclitaxel (PTX) for the treatment of malignant glioma.	Paclitaxel	140-150	phosphoglycolate phosphatase	Mus musculus	99-103
33299648-2	2020	The aim of the present study was to develop an intravenous formulation of HM30181A (HM) to inhibit P-gp in the brain to effectively deliver paclitaxel (PTX) for the treatment of malignant glioma.	Paclitaxel	152-155	phosphoglycolate phosphatase	Mus musculus	99-103
16600800-9	2006	Treatment of LNCaP tumors by Rh2 plus paclitaxel produced a significant decrease in tumor growth and serum prostate specific antigen.	Paclitaxel	38-48	kallikrein related peptidase 3	Homo sapiens	107-132
29374144-4	2018	Data revealed that PTX-resistant GC cells were characterized by microtubular disorders, an EMT phenotype, reduced responses to antimitotic drugs, and resistance to apoptosis (marked by upregulated beta-tubulin III, vimentin, attenuated changes in G2/M molecules or pro-apoptotic factors in response to antimitotic drugs or apoptotic inducers, respectively).	Paclitaxel	19-22	vimentin	Homo sapiens	215-223
33269821-8	2020	In the PTX group, the apoptosis rate, the number of cells arrested in the G2/M phase and the expression levels of Cleaved caspase-3 and Bax were increased, but the number of invasive cells and the expression levels of Bcl-2, MMP-9, vascular endothelial growth factor (VEGF), p-AKT (Thr308), and p-AKT (Ser473) were decreased.	Paclitaxel	7-10	matrix metallopeptidase 9	Homo sapiens	225-230
16596196-0	2006	Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.	Paclitaxel	87-97	Rho GDP dissociation inhibitor alpha	Homo sapiens	53-59
16596196-4	2006	Among these genes, overexpression of the ATP-binding cassette subfamily (MDR-1), Rho guanine dinucleotide phosphate dissociation inhibitor beta (RhoGDI) and insulin-like growth factor binding protein 3 (IGFBP-3) was observed in both paclitaxel-resistant cell lines.	Paclitaxel	233-243	insulin like growth factor binding protein 3	Homo sapiens	157-201
29914005-0	2018	Targeted regulationof STAT3 by miR-29a in mediating Taxol resistance of nasopharyngeal carcinoma cell line CNE-1.	Paclitaxel	52-57	microRNA 29a	Homo sapiens	31-38
33313139-1	2020	Background: In recent research, high expression of kinesin family member 23 (KIF23), one of the kinesin motor proteins involved in the regulation of cytokinesis, has been shown to be related to poor prognosis in glioma and paclitaxel-resistant gastric cancer, as a results of the enhancement of proliferation, migration, and invasion.	Paclitaxel	223-233	kinesin family member 23	Homo sapiens	51-75
33313139-1	2020	Background: In recent research, high expression of kinesin family member 23 (KIF23), one of the kinesin motor proteins involved in the regulation of cytokinesis, has been shown to be related to poor prognosis in glioma and paclitaxel-resistant gastric cancer, as a results of the enhancement of proliferation, migration, and invasion.	Paclitaxel	223-233	kinesin family member 23	Homo sapiens	77-82
32963602-9	2020	In CD1133+ cells treated with PTX, a dose-dependent reduction in the expression levels of the key glycolytic enzymes GLUT1, PKM and LDHA was observed at both the mRNA and protein levels.	Paclitaxel	30-33	solute carrier family 2 member 1	Homo sapiens	117-122
29914005-7	2018	Flow cytometry was used to measure cell apoptosis and PCNA expression under Taxol treatment.	Paclitaxel	76-81	proliferating cell nuclear antigen	Homo sapiens	54-58
16596196-4	2006	Among these genes, overexpression of the ATP-binding cassette subfamily (MDR-1), Rho guanine dinucleotide phosphate dissociation inhibitor beta (RhoGDI) and insulin-like growth factor binding protein 3 (IGFBP-3) was observed in both paclitaxel-resistant cell lines.	Paclitaxel	233-243	insulin like growth factor binding protein 3	Homo sapiens	203-210
29914005-13	2018	MiR-29a down-regulation is correlated with drug resistance of nasopharyngeal carcinoma cell line CNE-1 and MiR-29a up-regulation decreases Taxol resistance of nasopharyngeal carcinoma CNE-1 cells possibly via inhibiting STAT3 and Bcl-2 expression.	Paclitaxel	139-144	microRNA 29a	Homo sapiens	0-7
16596196-6	2006	We therefore conclude that IGFBP-3, RhoGDI and MDR-1 were correlated with paclitaxel resistance.	Paclitaxel	74-84	insulin like growth factor binding protein 3	Homo sapiens	27-34
16596196-6	2006	We therefore conclude that IGFBP-3, RhoGDI and MDR-1 were correlated with paclitaxel resistance.	Paclitaxel	74-84	Rho GDP dissociation inhibitor alpha	Homo sapiens	36-42
16596196-7	2006	Moreover, immunohistochemical staining was analyzed in 22 serous ovarian cancer tissues from patients who received paclitaxel-based chemotherapy, and RhoGDI overexpression was observed more frequently in non-responsers than in responders (p=0.004).	Paclitaxel	115-125	Rho GDP dissociation inhibitor alpha	Homo sapiens	150-156
16596196-8	2006	RhoGDI expression proved to be a predictive marker of paclitaxel resistance not only in paclitaxel-resistant cell lines, but also in clinical samples.	Paclitaxel	54-64	Rho GDP dissociation inhibitor alpha	Homo sapiens	0-6
29914005-13	2018	MiR-29a down-regulation is correlated with drug resistance of nasopharyngeal carcinoma cell line CNE-1 and MiR-29a up-regulation decreases Taxol resistance of nasopharyngeal carcinoma CNE-1 cells possibly via inhibiting STAT3 and Bcl-2 expression.	Paclitaxel	139-144	microRNA 29a	Homo sapiens	107-114
16596196-8	2006	RhoGDI expression proved to be a predictive marker of paclitaxel resistance not only in paclitaxel-resistant cell lines, but also in clinical samples.	Paclitaxel	88-98	Rho GDP dissociation inhibitor alpha	Homo sapiens	0-6
33178002-9	2020	Furthermore, our findings using MEA reveal that Nav1.8 blocker A-803467 and delayed rectifier potassium enhancer L-alpha-phosphatidyl-D-myo-inositol 4,5-diphosphate, dioctanoyl (PIP2) can reduce paclitaxel-induced hyperexcitability of DRG neurons.	Paclitaxel	195-205	sodium voltage-gated channel alpha subunit 10	Homo sapiens	48-54
30001527-9	2018	Linc00518 knockdown enhanced chemosensitivity to ADR, VCR and PTX, and boosted ADR-, VCR- and PTX-induced apoptosis in MCF-7/ADR cells.	Paclitaxel	62-65	long intergenic non-protein coding RNA 518	Homo sapiens	0-9
33050539-8	2020	We also demonstrated that breast cancer patients treated with paclitaxel chemotherapy exhibited increased CD44-expressing TMPs.	Paclitaxel	62-72	CD44 molecule (Indian blood group)	Homo sapiens	106-110
16585214-0	2006	TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.	Paclitaxel	42-52	toll like receptor 4	Homo sapiens	0-5
30001527-9	2018	Linc00518 knockdown enhanced chemosensitivity to ADR, VCR and PTX, and boosted ADR-, VCR- and PTX-induced apoptosis in MCF-7/ADR cells.	Paclitaxel	94-97	long intergenic non-protein coding RNA 518	Homo sapiens	0-9
30282072-0	2018	MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.	Paclitaxel	24-34	jagged canonical Notch ligand 1	Homo sapiens	97-101
32996920-2	2020	In this paper, pH/redox dual responsive IC1-R peptide hydrogels were designed as drug delivery materials for the anti-tumor drug paclitaxel (PTX).	Paclitaxel	129-139	ICR1 differentially methylated region	Homo sapiens	40-43
30282072-17	2018	By regulating the JAG1/Notch1 axis, miR-34a or its target genes JAG1 or Notch1 might serve as potential predictive biomarkers of response to paclitaxel-based chemotherapy and/or therapeutic targets that will help to overcome chemoresistance at the mCRPC stage.	Paclitaxel	141-151	jagged canonical Notch ligand 1	Homo sapiens	18-22
32996920-2	2020	In this paper, pH/redox dual responsive IC1-R peptide hydrogels were designed as drug delivery materials for the anti-tumor drug paclitaxel (PTX).	Paclitaxel	141-144	ICR1 differentially methylated region	Homo sapiens	40-43
16648550-7	2006	Whereas most marker proteins showed similar alterations compared with treatment with paclitaxel, cdc25c was fully phosphorylated solely in paclitaxel-treated cells but only partially phosphorylated in Plk1-depleted cells, although both treatments caused a profound mitotic arrest.	Paclitaxel	139-149	cell division cycle 25C	Homo sapiens	97-103
32996920-5	2020	IC1-R was found to have high sensitivity to pH/redox conditions, and the encapsulation rate can reach more than 98% at different PTX dosages.	Paclitaxel	129-132	ICR1 differentially methylated region	Homo sapiens	0-3
30282072-17	2018	By regulating the JAG1/Notch1 axis, miR-34a or its target genes JAG1 or Notch1 might serve as potential predictive biomarkers of response to paclitaxel-based chemotherapy and/or therapeutic targets that will help to overcome chemoresistance at the mCRPC stage.	Paclitaxel	141-151	jagged canonical Notch ligand 1	Homo sapiens	64-68
32847971-3	2020	Paclitaxel (2 mg/kg, i.p., cumulative dose 8mg/kg) induced long-lasting mechanical allodynia (> 28days) with increased glutamate concentration and decreased EAAT2 expression with no changes in GABA/glycine or VGAT (vesicular GABA transporter) in rat spinal dorsal horn.	Paclitaxel	0-10	solute carrier family 6 member 12	Rattus norvegicus	215-241
29940750-1	2018	We aimed to investigate the role of FUT1 gene in Taxol resistance and to explore its mechanism in epithelial ovarian cancer.	Paclitaxel	49-54	fucosyltransferase 1 (H blood group)	Homo sapiens	36-40
32847971-5	2020	HDAC2 and transcription factor YY1 were also upregulated, and their interaction and co-localization were confirmed following paclitaxel treatment using co-immunoprecipitation (Co-IP).	Paclitaxel	125-135	YY1 transcription factor	Rattus norvegicus	31-34
32847971-6	2020	Inhibition or knockdown of HDAC2 expression by valproic acid (VPA), BRD6688 or HDAC2 siRNA (small interfering RNA) not only attenuated paclitaxel-induced mechanical allodynia but also suppressed HDAC2 upregulation, glutamate accumulation and the corresponding changes in EAAT2/VGLUT/synaptophysin expression and HDAC2/YY1 interaction.	Paclitaxel	135-145	synaptophysin	Rattus norvegicus	283-296
32847971-6	2020	Inhibition or knockdown of HDAC2 expression by valproic acid (VPA), BRD6688 or HDAC2 siRNA (small interfering RNA) not only attenuated paclitaxel-induced mechanical allodynia but also suppressed HDAC2 upregulation, glutamate accumulation and the corresponding changes in EAAT2/VGLUT/synaptophysin expression and HDAC2/YY1 interaction.	Paclitaxel	135-145	YY1 transcription factor	Rattus norvegicus	318-321
32847971-7	2020	These findings indicate that loss of the balance between glutamate release and reuptake due to dysregulation EAAT2/VGLUT2/synaptophysin cascade in the spinal dorsal horn plays an important role in the development of paclitaxel-induced neuropathic pain.	Paclitaxel	216-226	synaptophysin	Rattus norvegicus	122-135
33061434-0	2020	Circ_0006528 Contributes to Paclitaxel Resistance of Breast Cancer Cells by Regulating miR-1299/CDK8 Axis.	Paclitaxel	28-38	cyclin-dependent kinase 8	Mus musculus	96-100
33061434-16	2020	Circ_0006528 silencing impeded the growth of PTX-resistant tumors by regulating miR-1299/CDK8 axis in vivo.	Paclitaxel	45-48	cyclin-dependent kinase 8	Mus musculus	89-93
33061434-17	2020	Conclusion: Circ_0006528 partially contributed to PTX resistance of breast cancer cells through up-regulating CDK8 expression by sponging miR-1299.	Paclitaxel	50-53	cyclin-dependent kinase 8	Mus musculus	110-114
16278675-0	2006	Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo.	Paclitaxel	78-83	cyclin B1	Homo sapiens	25-34
16446153-5	2006	Pelleting experiments with paclitaxel-stabilized microtubules show that Bak is associated with the microtubule pellet, whereas Bid remains primarily with the unpolymerized fraction.	Paclitaxel	27-37	BCL2-antagonist/killer 1	Rattus norvegicus	72-75
29940750-12	2018	After the treatment with Taxol, the inhibition rate of Taxol was obviously decreased with the established cell model above, and the IC50 level was significantly increased in the FUT1 over-expression + Taxol group (p Keywords: FUT1, Lewis y, Taxol resistance, ovarian cancer, apoptosis.	Paclitaxel	25-30	fucosyltransferase 1 (H blood group)	Homo sapiens	178-182
29416675-0	2018	Phosphorylation of caspase-9 at Thr125 directs paclitaxel resistance in ovarian cancer.	Paclitaxel	47-57	caspase 9	Homo sapiens	19-28
16520664-0	2006	Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study.	Paclitaxel	7-17	colony stimulating factor 3	Homo sapiens	56-93
33455274-3	2020	The SMTDDC fabrication, with dual targeting cRGD and Cathepsin B (Cath B)-specific tripeptide (Glu-Lys-Phe), altered the microtubule network of glioblastoma cells by the orchestrated release of the cytotoxic paclitaxel (PTX).	Paclitaxel	208-218	cathepsin B	Homo sapiens	53-64
33455274-3	2020	The SMTDDC fabrication, with dual targeting cRGD and Cathepsin B (Cath B)-specific tripeptide (Glu-Lys-Phe), altered the microtubule network of glioblastoma cells by the orchestrated release of the cytotoxic paclitaxel (PTX).	Paclitaxel	208-218	cathepsin B	Homo sapiens	66-72
33455274-3	2020	The SMTDDC fabrication, with dual targeting cRGD and Cathepsin B (Cath B)-specific tripeptide (Glu-Lys-Phe), altered the microtubule network of glioblastoma cells by the orchestrated release of the cytotoxic paclitaxel (PTX).	Paclitaxel	220-223	cathepsin B	Homo sapiens	53-64
29416675-2	2018	A previous pharmacogenomic study revealed the importance of cyclin-dependent kinase 1 (CDK1) activity in a response on paclitaxel.	Paclitaxel	119-129	cyclin dependent kinase 1	Homo sapiens	60-85
33455274-3	2020	The SMTDDC fabrication, with dual targeting cRGD and Cathepsin B (Cath B)-specific tripeptide (Glu-Lys-Phe), altered the microtubule network of glioblastoma cells by the orchestrated release of the cytotoxic paclitaxel (PTX).	Paclitaxel	220-223	cathepsin B	Homo sapiens	66-72
33455274-4	2020	Cath B assisted PTX delivery was monitored by high-performance liquid chromatography and Surface-Enhanced Raman Scattering (SERS) modalities.	Paclitaxel	16-19	cathepsin B	Homo sapiens	0-6
29416675-2	2018	A previous pharmacogenomic study revealed the importance of cyclin-dependent kinase 1 (CDK1) activity in a response on paclitaxel.	Paclitaxel	119-129	cyclin dependent kinase 1	Homo sapiens	87-91
32943985-0	2020	XIST lost induces ovarian cancer stem cells to acquire taxol resistance via a KMT2C-dependent way.	Paclitaxel	55-60	inactive X specific transcripts	Mus musculus	0-4
29416675-6	2018	Its phosphorylation level was dependent on CDK1 activity and it directs paclitaxel resistance.	Paclitaxel	72-82	cyclin dependent kinase 1	Homo sapiens	43-47
32943985-1	2020	Background/aims: The expression levels of long non-coding RNA XIST are significantly associated with paclitaxel (Pac) sensitivity in ovarian cancer, but the mechanism of action remains unclear.	Paclitaxel	101-111	inactive X specific transcripts	Mus musculus	62-66
32943985-1	2020	Background/aims: The expression levels of long non-coding RNA XIST are significantly associated with paclitaxel (Pac) sensitivity in ovarian cancer, but the mechanism of action remains unclear.	Paclitaxel	113-116	inactive X specific transcripts	Mus musculus	62-66
16152620-1	2006	MEK1/2 inhibitors like U0126 can potentiate or antagonize the antitumor activity of cytotoxic agents such as cisplatin, paclitaxel or vinblastine, depending on the drug or the target cells.	Paclitaxel	120-130	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6
29416675-8	2018	Thus, the regulation of caspase-9 may be a novel therapeutic strategy to reverse paclitaxel-induced resistance in ovarian cancer cells.	Paclitaxel	81-91	caspase 9	Homo sapiens	24-33
32943985-2	2020	Therefore, this experimental design was based on lncRNA XIST analysis to regulate the effect of XIST on the tumor stem cell and paclitaxel sensitivity in ovarian cancer.	Paclitaxel	128-138	inactive X specific transcripts	Mus musculus	96-100
32943985-15	2020	Conclusion: XIST promoted the sensitivity of ovarian cancer stem cells to paclitaxel in a KMT2C-dependent manner.	Paclitaxel	74-84	inactive X specific transcripts	Mus musculus	12-16
29187479-9	2017	In the group of patients who received adjuvant chemotherapy based on platinum derivatives in combination with paclitaxel or gemcitabine, we found shorter DFI (p=0.0473) and OS (p=0.0053) in those with high expression of TS.	Paclitaxel	110-120	thymidylate synthetase	Homo sapiens	220-222
32420678-0	2020	Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells.	Paclitaxel	130-140	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Homo sapiens	110-115
32412771-10	2020	Overexpression of miR-145-5p or SOX2 knockdown repressed the proliferation, migration, invasion, and attenuated PTX resistance in PTX-resistant BC cells.	Paclitaxel	112-115	SRY-box transcription factor 2	Homo sapiens	32-36
32412771-10	2020	Overexpression of miR-145-5p or SOX2 knockdown repressed the proliferation, migration, invasion, and attenuated PTX resistance in PTX-resistant BC cells.	Paclitaxel	130-133	SRY-box transcription factor 2	Homo sapiens	32-36
32412771-12	2020	The inhibitory effects of miR-145-5p on the proliferation, migration, invasion, and PTX resistance were antagonized by SOX2 level restoration in PTX-resistant BC cells.	Paclitaxel	145-148	SRY-box transcription factor 2	Homo sapiens	119-123
32412771-14	2020	In conclusion, our study suggested that miR-145-5p reduced PTX resistance and repressed the progression at least partly by targeting SOX2 in PTX-resistant BC cells, highlighting miR-145-5p as a promising biomarker for BC treatment.	Paclitaxel	59-62	SRY-box transcription factor 2	Homo sapiens	133-137
32412771-14	2020	In conclusion, our study suggested that miR-145-5p reduced PTX resistance and repressed the progression at least partly by targeting SOX2 in PTX-resistant BC cells, highlighting miR-145-5p as a promising biomarker for BC treatment.	Paclitaxel	141-144	SRY-box transcription factor 2	Homo sapiens	133-137
16428938-0	2006	Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma.	Paclitaxel	73-83	interleukin 2	Mus musculus	12-25
16291872-9	2006	Furthermore, knockdown of either beta-cat or Tcf-4 substantially reduced cell proliferation and potentiated paclitaxel-induced apoptosis in DU145 cells, which largely were rescued by treatment with exogenous ET-1.	Paclitaxel	108-118	catenin beta 1	Homo sapiens	33-41
29290962-10	2017	After adjusting for multiple clinical covariates, SNPs on the LPHN2, ROBO1, SNTG1, and GRIK1 genes were significant independent predictors of poor tumor response (tumor growth) despite paclitaxel treatment.	Paclitaxel	185-195	roundabout guidance receptor 1	Homo sapiens	69-74
32492505-2	2020	Owing to associated poor bioavailability, oral administration of hydrophobic anticancer drugs like paclitaxel has been quite challenging, with the scenario being further complicated by Pgp efflux in drug-resistant tumours.	Paclitaxel	99-109	phosphoglycolate phosphatase	Mus musculus	185-188
32492505-9	2020	The enhanced efficacy of PTX-CPT speculated due to its internalization by active endocytosis, ability to escape Pgp efflux, and due to a combined effect of the pro-apoptotic and antiangiogenic role.	Paclitaxel	25-28	phosphoglycolate phosphatase	Mus musculus	112-115
16442593-9	2006	RESULTS: The prostate-specific antigen response to paclitaxel and carboplatin was significantly greater (40% [95% confidence interval 18.5% to 61.5%] versus 10% [95% confidence interval 1% to 32%], P = 0.031) and more durable (8.6 versus 2 months, P = 0.015) than the response to mitoxantrone.	Paclitaxel	51-61	kallikrein related peptidase 3	Homo sapiens	13-38
28756208-0	2017	Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species.	Paclitaxel	98-108	aldehyde dehydrogenase 1 family member A1	Homo sapiens	14-21
16442593-13	2006	CONCLUSIONS: The 3-week regimen of paclitaxel and carboplatin induced a greater and more durable prostate-specific antigen response than did mitoxantrone for HRPC treatment.	Paclitaxel	35-45	kallikrein related peptidase 3	Homo sapiens	97-122
32628454-3	2020	Herein, to improve the effectiveness of 6S, augment the sensibility of PTX, and enhance the targeting ability of PTX-resistant cancer therapies, we report a class of 6S-loaded phase transition nanobubbles conjugated with the MUC16 antibody (6S@NBs-MUC16A), which can enhance the sensibility of PTX to EOC cells through ultrasound-controlled targeted-delivery of 6S.	Paclitaxel	113-116	mucin 16, cell surface associated	Homo sapiens	225-230
32628454-3	2020	Herein, to improve the effectiveness of 6S, augment the sensibility of PTX, and enhance the targeting ability of PTX-resistant cancer therapies, we report a class of 6S-loaded phase transition nanobubbles conjugated with the MUC16 antibody (6S@NBs-MUC16A), which can enhance the sensibility of PTX to EOC cells through ultrasound-controlled targeted-delivery of 6S.	Paclitaxel	113-116	mucin 16, cell surface associated	Homo sapiens	225-230
28756208-8	2017	Silencing of ALDH1A1 restored the sensitivity of MDA-2J2 cells to paclitaxel, as indicated by a more pronounced decrease in proliferation, and greater increases in caspase activity and formation of ROS to levels comparable with control cells.	Paclitaxel	66-76	aldehyde dehydrogenase 1 family member A1	Homo sapiens	13-20
32354736-4	2020	Paclitaxel induced endoplasmic reticulum stress, which triggered protein kinase R-like ER kinase activation and eukaryotic translation initiation factor 2alpha phosphorylation independent of TLR4.	Paclitaxel	0-10	eukaryotic translation initiation factor 2A	Homo sapiens	112-159
32211849-0	2020	LncRNA SDHAP1 confers paclitaxel resistance of ovarian cancer by regulating EIF4G2 expression via miR-4465.	Paclitaxel	22-32	SDHA pseudogene 1	Homo sapiens	7-13
16299308-2	2005	Here we report that increases in caveolin-1 expression are manifested by different types of LPS, LPS-mimetic taxol, and heat-killed E. coli and to a much lesser extent by zymosan, polysaccharide-peptidoglycan, and heat-killed Staphylococcus aureus.	Paclitaxel	109-114	caveolin 1, caveolae protein	Mus musculus	33-43
32211849-0	2020	LncRNA SDHAP1 confers paclitaxel resistance of ovarian cancer by regulating EIF4G2 expression via miR-4465.	Paclitaxel	22-32	microRNA 4465	Homo sapiens	98-106
28756208-11	2017	ALDH1A1 modulates the production of ROS by anti-cancer agents such as paclitaxel and diminishes their efficacy.	Paclitaxel	70-80	aldehyde dehydrogenase 1 family member A1	Homo sapiens	0-7
29285257-5	2017	In this study, a chromene compound, J2 that exhibited better cross-linking activity of HSP27 than xanthone compound, SW15 which was previously identified, was yielding sensitization to NSCLC cells with high expression of HSP27 when combined with HSP90 inhibitor and standard anticancer modalities such as taxol and cisplatin.	Paclitaxel	305-310	heat shock protein family B (small) member 1	Homo sapiens	87-92
32779438-10	2020	Overexpression of GATA5 also promoted Paclitaxel to inhibit expression of reprogramming genes, such as Nanog, EpCAM, c-Myc and Sox2 in Bel7402 and PLC/PRF/5 cells.	Paclitaxel	38-48	Nanog homeobox	Homo sapiens	103-108
32779438-10	2020	Overexpression of GATA5 also promoted Paclitaxel to inhibit expression of reprogramming genes, such as Nanog, EpCAM, c-Myc and Sox2 in Bel7402 and PLC/PRF/5 cells.	Paclitaxel	38-48	SRY-box transcription factor 2	Homo sapiens	127-131
32779438-12	2020	Overexpression of GATA5 was not only alone but also synergized with Paclitaxel to inhibit expression of CD44 and CD133 in Bel7402 or PLC/PRF/5 cells.	Paclitaxel	68-78	CD44 molecule (Indian blood group)	Homo sapiens	104-108
16369748-7	2005	A computed tomography scan 1 month after the first course of paclitaxel showed remarkable regression of the liver metastases.	Paclitaxel	61-71	calcium activated nucleotidase 1	Homo sapiens	22-28
28631095-5	2017	And the effect of rAAV-DCN on the intratumoral uptake of paclitaxel was also studied in neuroblastoma-grafted nude mice.	Paclitaxel	57-67	decorin	Homo sapiens	23-26
16227576-7	2005	To confirm a direct link between caspase activity and BubR1 protein expression, we identified by site-directed mutagenesis the specific caspase cleavage sites cleaved after exposure to paclitaxel.	Paclitaxel	185-195	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	54-59
16227576-9	2005	BubR1 mutated at both locations (BubR1Delta579Delta610) was resistant to paclitaxel-induced degradation.	Paclitaxel	73-83	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	0-5
32487607-12	2020	CONCLUSION: The results imply that combining 1,25-D3 with paclitaxel and carboplatin may potentiate their growth inhibitory effect on ovarian cancer cells with high VDR expression.	Paclitaxel	58-68	vitamin D receptor	Homo sapiens	165-168
32142859-2	2020	We recently reported a pulsatile nature of IGF1R during acquirement of platinum-taxol resistance in Epithelial Ovarian Cancer (EOC) cells and a therapy induced upregulation in IGF1R expression in tumors of a small cohort of high grade serous EOC patients.	Paclitaxel	80-85	insulin like growth factor 1 receptor	Homo sapiens	43-48
32142859-3	2020	Here, we report Runt-related transcription factor 1 (RUNX1) as a novel transcriptional regulator which along with another known regulator Forkhead Box O3 (FOXO3a), drives the dynamic modulation of IGF1R expression during platinum-taxol resistance development in EOC cells.	Paclitaxel	230-235	insulin like growth factor 1 receptor	Homo sapiens	197-202
28631095-7	2017	Transfected neuroblastoma cells stably expressed DCN, with in vivo and in vitro studies demonstrating rAAV-DCN sensitized the anticancer effect of nab-paclitaxel.	Paclitaxel	151-161	decorin	Homo sapiens	49-52
30666557-4	2020	We also provided an overview of genes, including RSF1, CDK5, and SGOL1, whose disruption can synergize with the currently available drugs such as paclitaxel and sorafenib.	Paclitaxel	146-156	remodeling and spacing factor 1	Homo sapiens	49-53
28631095-7	2017	Transfected neuroblastoma cells stably expressed DCN, with in vivo and in vitro studies demonstrating rAAV-DCN sensitized the anticancer effect of nab-paclitaxel.	Paclitaxel	151-161	decorin	Homo sapiens	107-110
32775453-10	2020	Therefore, our findings showed that miR-520h targeted the OTUD3-PTEN axis to drive paclitaxel resistance, and this miR might be an important potential target for breast cancer treatment.	Paclitaxel	83-93	membrane associated ring-CH-type finger 8	Homo sapiens	36-39
28631095-8	2017	Systemic rAAV-DCN in neuroblastoma-grafted nude mice inhibited stabilin-1, up-regulated SPARC, and increased the intratumoral uptake of paclitaxel.	Paclitaxel	136-146	decorin	Homo sapiens	14-17
32154964-11	2020	In mice intraperitoneally inoculated with FRalpha-expressing or PCFT-expressing EOC cells, intraperitoneal administration of PTX/Fol-c1 -beta-CyD significantly suppressed the growth of both types of EOC cells relative to PTX alone, without inducing a significant change in the neutrophil/white blood cell ratio.	Paclitaxel	125-128	solute carrier family 46, member 1	Mus musculus	64-68
15864591-0	2005	Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.	Paclitaxel	133-143	clusterin	Mus musculus	62-71
28631095-10	2017	The systemic administration of rAAV-DCN up-regulates DCN in neuroblastoma and accelerates the intratumoral uptake of nab-paclitaxel by inhibiting stabilin-1 mediated SPARC degradation.	Paclitaxel	121-131	decorin	Homo sapiens	36-39
29034341-0	2017	Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells.	Paclitaxel	0-10	stathmin 1	Homo sapiens	19-29
16103753-0	2005	Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo.	Paclitaxel	62-72	regulator of microtubule dynamics 1	Homo sapiens	0-30
16103753-0	2005	Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo.	Paclitaxel	62-72	regulator of microtubule dynamics 1	Homo sapiens	32-35
32107001-10	2020	Cell cycle distribution was analyzed by propidium iodide (PI) staining, and paclitaxel (PTX)-induced apoptosis was detected by Annexin V-PI staining to evaluate the anti-apoptotic ability of the cells.	Paclitaxel	76-86	annexin A5	Mus musculus	127-136
32107001-10	2020	Cell cycle distribution was analyzed by propidium iodide (PI) staining, and paclitaxel (PTX)-induced apoptosis was detected by Annexin V-PI staining to evaluate the anti-apoptotic ability of the cells.	Paclitaxel	88-91	annexin A5	Mus musculus	127-136
32425595-11	2020	CDK12 was a downstream gene of miR-613 and miR-613 exerted the modulation of PTX resistance via targeting CDK12.	Paclitaxel	77-80	cyclin dependent kinase 12	Homo sapiens	0-5
32425595-11	2020	CDK12 was a downstream gene of miR-613 and miR-613 exerted the modulation of PTX resistance via targeting CDK12.	Paclitaxel	77-80	cyclin dependent kinase 12	Homo sapiens	106-111
32425595-13	2020	The regulatory role of UCA1 in PTX resistance of BC was achieved by miR-613/CDK12 axis in vivo.	Paclitaxel	31-34	cyclin dependent kinase 12	Homo sapiens	76-81
29034341-3	2017	In the present study, we expand our previous observations and aim to investigate Stathmin 1 expression and its impact on laboratory features and clinical outcomes in an independent cohort of ALL patients, and to verify the effects of paclitaxel treatment on Stathmin 1 phosphorylation and cell viability in ALL cell lines.	Paclitaxel	234-244	stathmin 1	Homo sapiens	258-268
32425595-14	2020	Conclusion: UCA1 mediated PTX resistance in BC through the miR-613/CDK12 axis, manifesting that UCA1 might improve the PTX treatment of BC as a significant therapeutic biomarker.	Paclitaxel	26-29	cyclin dependent kinase 12	Homo sapiens	67-72
29034341-5	2017	Functional assays revealed that paclitaxel induces Stathmin 1 phosphorylation at serine 16 (an inhibitory site), microtubule stability and apoptosis in Jurkat and Namalwa cell lines.	Paclitaxel	32-42	stathmin 1	Homo sapiens	51-61
32425595-14	2020	Conclusion: UCA1 mediated PTX resistance in BC through the miR-613/CDK12 axis, manifesting that UCA1 might improve the PTX treatment of BC as a significant therapeutic biomarker.	Paclitaxel	119-122	cyclin dependent kinase 12	Homo sapiens	67-72
16061179-5	2005	Inhibition of CKIalpha diminished FADD phosphorylation, prevented the ability of Taxol to arrest cells in mitosis, and blocked mitogen-induced proliferation of mouse splenocytes.	Paclitaxel	81-86	casein kinase 1, alpha 1	Mus musculus	14-22
29034341-7	2017	In conclusion, our data confirm increased levels of Stathmin 1 in ALL patients and that therapeutic doses of paclitaxel inhibits Stathmin 1 function and promote microtubule stability and apoptosis in ALL cells.	Paclitaxel	109-119	stathmin 1	Homo sapiens	129-139
28912415-0	2017	Targeting Overexpressed Activating Transcription Factor 1 (ATF1) Inhibits Proliferation and Migration and Enhances Sensitivity to Paclitaxel In Esophageal Cancer Cells.	Paclitaxel	130-140	activating transcription factor 1	Homo sapiens	59-63
15878526-3	2005	The observation of reduced nuclear beta-catenin levels in giant cells induced by taxol treatment prompted us to investigate the relationship between Wnt signaling and giant cell formation.	Paclitaxel	81-86	catenin beta 1	Homo sapiens	35-47
15897904-0	2005	Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism.	Paclitaxel	0-10	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	46-107
15897904-0	2005	Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism.	Paclitaxel	0-10	cyclin dependent kinase 1	Homo sapiens	118-122
32268876-0	2020	Shikonin suppresses NEAT1 and Akt signaling in treating paclitaxel-resistant non-small cell of lung cancer.	Paclitaxel	56-66	nuclear paraspeckle assembly transcript 1	Homo sapiens	20-25
32268876-6	2020	Shikonin induced apoptotic cell death of paclitaxel-resistant NSCLC cell lines and suppressed the level of NEAT1 and Akt signaling of paclitaxel-resistant NSCLC cell lines and xenograft tumors.	Paclitaxel	134-144	nuclear paraspeckle assembly transcript 1	Homo sapiens	107-112
31848297-6	2020	Mitotic kinase Aurora B activity is required for taxol-induced HIF-1a degradation.	Paclitaxel	49-54	aurora kinase B	Homo sapiens	15-23
15897904-2	2005	In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state.	Paclitaxel	33-43	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	200-206
15897904-2	2005	In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state.	Paclitaxel	45-48	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	200-206
15897904-3	2005	We found that PTX induced the hyperphosphorylation of 4E-BP1 in the breast cancer cell line, MDA MB 231, which reduced its association with eIF-4E, but did not alter the expression and phosphorylation of eIF-4E.	Paclitaxel	14-17	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	54-60
31894970-0	2020	Design, Synthesis, and Characterization of a Paclitaxel Formulation Activated by Extracellular MMP9.	Paclitaxel	45-55	matrix metallopeptidase 9	Homo sapiens	95-99
29069826-0	2017	miR-150 enhances apoptotic and anti-tumor effects of paclitaxel in paclitaxel-resistant ovarian cancer cells by targeting Notch3.	Paclitaxel	53-63	notch receptor 3	Homo sapiens	122-128
32129321-9	2020	RESULTS We observed fusion morphology of the mitochondrial network in A549/Taxol cells, with upregulation of fusion genes (Mfn1 and Mfn2) and downregulation of fission gene Fis1.	Paclitaxel	75-80	mitofusin 1	Homo sapiens	123-127
32129321-9	2020	RESULTS We observed fusion morphology of the mitochondrial network in A549/Taxol cells, with upregulation of fusion genes (Mfn1 and Mfn2) and downregulation of fission gene Fis1.	Paclitaxel	75-80	mitofusin 2	Homo sapiens	132-136
32129321-9	2020	RESULTS We observed fusion morphology of the mitochondrial network in A549/Taxol cells, with upregulation of fusion genes (Mfn1 and Mfn2) and downregulation of fission gene Fis1.	Paclitaxel	75-80	fission, mitochondrial 1	Homo sapiens	173-177
15897904-6	2005	The hyperphosphorylation of 4E-BP1 by PTX increased the association of eIF-4E with eIF-4G, whereas cotreatment with purvalanol A inhibited the association of eIF-4E with eIF-4G in PTX treated cells.	Paclitaxel	38-41	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	28-34
15897904-6	2005	The hyperphosphorylation of 4E-BP1 by PTX increased the association of eIF-4E with eIF-4G, whereas cotreatment with purvalanol A inhibited the association of eIF-4E with eIF-4G in PTX treated cells.	Paclitaxel	180-183	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	28-34
31884343-0	2020	SNHG5 enhances Paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a.	Paclitaxel	15-25	small nucleolar RNA host gene 5	Homo sapiens	0-5
15688426-10	2005	Chk1 inhibition facilitates paclitaxel-induced M-phase entry by activation of Cdc2 kinase and accumulation of cyclin B1, the required cofactor for Cdc2 kinase activity.	Paclitaxel	28-38	cyclin dependent kinase 1	Homo sapiens	78-82
29069826-0	2017	miR-150 enhances apoptotic and anti-tumor effects of paclitaxel in paclitaxel-resistant ovarian cancer cells by targeting Notch3.	Paclitaxel	67-77	notch receptor 3	Homo sapiens	122-128
15688426-10	2005	Chk1 inhibition facilitates paclitaxel-induced M-phase entry by activation of Cdc2 kinase and accumulation of cyclin B1, the required cofactor for Cdc2 kinase activity.	Paclitaxel	28-38	cyclin B1	Homo sapiens	110-119
15688426-10	2005	Chk1 inhibition facilitates paclitaxel-induced M-phase entry by activation of Cdc2 kinase and accumulation of cyclin B1, the required cofactor for Cdc2 kinase activity.	Paclitaxel	28-38	cyclin dependent kinase 1	Homo sapiens	147-151
31884343-0	2020	SNHG5 enhances Paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a.	Paclitaxel	15-25	microRNA 23a	Homo sapiens	79-86
31884343-4	2020	The effects of SNHG5 and miR-23a on the sensitivity of ovarian cancer cells to paclitaxel (PTX) were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay and flow cytometry.	Paclitaxel	79-89	small nucleolar RNA host gene 5	Homo sapiens	15-20
31884343-4	2020	The effects of SNHG5 and miR-23a on the sensitivity of ovarian cancer cells to paclitaxel (PTX) were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay and flow cytometry.	Paclitaxel	79-89	microRNA 23a	Homo sapiens	25-32
15688426-13	2005	We show that Chk1 elimination attenuates the paclitaxel-induced activation of the anti-apoptotic p42/p44 (ERK1/2) MAP kinase pathway, additionally contributing to the sensitization.	Paclitaxel	45-55	cyclin dependent kinase 20	Homo sapiens	97-100
31884343-4	2020	The effects of SNHG5 and miR-23a on the sensitivity of ovarian cancer cells to paclitaxel (PTX) were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay and flow cytometry.	Paclitaxel	91-94	small nucleolar RNA host gene 5	Homo sapiens	15-20
29137317-0	2017	Mcl-1 stabilization confers resistance to taxol in human gastric cancer.	Paclitaxel	42-47	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	0-5
31884343-11	2020	Overexpression of SNHG5 enhanced the sensitivity of SKOV3/PTX and HeyA-8/PTX cells to PTX in vitro and enhanced PTX sensitivity in tumors in vivo.	Paclitaxel	58-61	small nucleolar RNA host gene 5	Homo sapiens	18-23
31884343-11	2020	Overexpression of SNHG5 enhanced the sensitivity of SKOV3/PTX and HeyA-8/PTX cells to PTX in vitro and enhanced PTX sensitivity in tumors in vivo.	Paclitaxel	73-76	small nucleolar RNA host gene 5	Homo sapiens	18-23
31884343-11	2020	Overexpression of SNHG5 enhanced the sensitivity of SKOV3/PTX and HeyA-8/PTX cells to PTX in vitro and enhanced PTX sensitivity in tumors in vivo.	Paclitaxel	73-76	small nucleolar RNA host gene 5	Homo sapiens	18-23
31884343-13	2020	Silencing of miR-23a overcame the resistance of SKOV3/PTX and HeyA-8/PTX cells to PTX.	Paclitaxel	54-57	microRNA 23a	Homo sapiens	13-20
16020661-5	2005	Transfection of a dominant-negative (DN)-CDK2 evoked resistance to paclitaxel by preventing cellular progression to mitosis through loss of CDK1 activity.	Paclitaxel	67-77	cyclin dependent kinase 1	Homo sapiens	140-144
15657900-12	2005	We suggest that the alternate activation of both the pro-apoptotic p38 MAPK-p53 signaling and the cytoprotective MEK1/2 --&gt; ERK1/2 cascade, as well as the inactivation of the anti-apoptotic AKT activity may explain, at least in part, the sequence-dependent enhancement of Taxol-induced cytotoxicity and apoptosis that follows inhibition of FAS activity in breast cancer cells.	Paclitaxel	275-280	mitogen-activated protein kinase kinase 1	Homo sapiens	113-119
31884343-13	2020	Silencing of miR-23a overcame the resistance of SKOV3/PTX and HeyA-8/PTX cells to PTX.	Paclitaxel	69-72	microRNA 23a	Homo sapiens	13-20
29137317-4	2017	Here we report that upregulation of Mcl-1 (Myeloid cell leukemia-1) confers acquired resistance to Taxol in human gastric cancer.	Paclitaxel	99-104	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	36-41
31884343-14	2020	More importantly, miR-23a overexpression could reverse the inductive effect of SNHG5 overexpression on PTX sensitivity of ovarian cancer cells.	Paclitaxel	103-106	microRNA 23a	Homo sapiens	18-25
31884343-14	2020	More importantly, miR-23a overexpression could reverse the inductive effect of SNHG5 overexpression on PTX sensitivity of ovarian cancer cells.	Paclitaxel	103-106	small nucleolar RNA host gene 5	Homo sapiens	79-84
15766661-4	2005	Whereas paclitaxel induced BIM accumulation and BIM-dependent apoptosis in vitro and in tumors in vivo, the H-ras/MAPK pathway suppressed this BIM induction by phosphorylating BIM and targeting BIM for degradation in proteasomes.	Paclitaxel	8-18	BCL2 like 11	Homo sapiens	27-30
31884343-15	2020	CONCLUSION: SNHG5 enhanced the sensitivity of ovarian cancer cells to PTX through sponging miR-23a, providing a new mechanism of chemoresistance in ovarian cancer.	Paclitaxel	70-73	small nucleolar RNA host gene 5	Homo sapiens	12-17
31884343-15	2020	CONCLUSION: SNHG5 enhanced the sensitivity of ovarian cancer cells to PTX through sponging miR-23a, providing a new mechanism of chemoresistance in ovarian cancer.	Paclitaxel	70-73	microRNA 23a	Homo sapiens	91-98
15766661-4	2005	Whereas paclitaxel induced BIM accumulation and BIM-dependent apoptosis in vitro and in tumors in vivo, the H-ras/MAPK pathway suppressed this BIM induction by phosphorylating BIM and targeting BIM for degradation in proteasomes.	Paclitaxel	8-18	BCL2 like 11	Homo sapiens	48-51
15766661-4	2005	Whereas paclitaxel induced BIM accumulation and BIM-dependent apoptosis in vitro and in tumors in vivo, the H-ras/MAPK pathway suppressed this BIM induction by phosphorylating BIM and targeting BIM for degradation in proteasomes.	Paclitaxel	8-18	BCL2 like 11	Homo sapiens	48-51
29137317-4	2017	Here we report that upregulation of Mcl-1 (Myeloid cell leukemia-1) confers acquired resistance to Taxol in human gastric cancer.	Paclitaxel	99-104	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	43-66
32098204-9	2020	Further, combination therapy of anti-SMC2 micelles with paclitaxel (PTX) and 5-Fluorouracil (5-FU) was also explored.	Paclitaxel	56-66	structural maintenance of chromosomes 2	Homo sapiens	37-41
29137317-5	2017	Mcl-1 is shown to be stabilized in Taxol -resistant gastric cancer cells because of the hyper-activation of the PI3K/Akt signaling pathway.	Paclitaxel	35-40	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	0-5
32098204-10	2020	For this, PTX and 5-FU were respectively loaded into an anti-SMC2 decorated PM.	Paclitaxel	10-13	structural maintenance of chromosomes 2	Homo sapiens	61-65
29137317-6	2017	The increased Mcl-1 prevents of the permeabilization of the outer mitochondrial membrane, thereby blocking the Taxol-induced apoptosis.	Paclitaxel	111-116	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	14-19
31286496-0	2020	Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.	Paclitaxel	97-107	cyclin E1	Homo sapiens	74-79
15766661-4	2005	Whereas paclitaxel induced BIM accumulation and BIM-dependent apoptosis in vitro and in tumors in vivo, the H-ras/MAPK pathway suppressed this BIM induction by phosphorylating BIM and targeting BIM for degradation in proteasomes.	Paclitaxel	8-18	BCL2 like 11	Homo sapiens	48-51
15766661-4	2005	Whereas paclitaxel induced BIM accumulation and BIM-dependent apoptosis in vitro and in tumors in vivo, the H-ras/MAPK pathway suppressed this BIM induction by phosphorylating BIM and targeting BIM for degradation in proteasomes.	Paclitaxel	8-18	BCL2 like 11	Homo sapiens	48-51
28769027-4	2017	MATERIAL AND METHODS Here, we evaluated how Notch-3 inhibition by GSI can enhance the sensitivity of lung cancer cells to paclitaxel.	Paclitaxel	122-132	notch receptor 3	Homo sapiens	44-51
15766661-5	2005	The proteasome inhibitor Velcade (P-341, Bortezomib) restored BIM induction, abrogated H-ras-dependent paclitaxel resistance, and promoted BIM-dependent tumor regression, suggesting the potential benefits of combinatorial chemotherapy of Velcade and paclitaxel.	Paclitaxel	103-113	HRas proto-oncogene, GTPase	Homo sapiens	87-92
31388880-0	2020	Thiamine, riboflavin, and nicotinamide inhibit paclitaxel-induced allodynia by reducing TNF-alpha and CXCL-1 in dorsal root ganglia and thalamus and activating ATP-sensitive potassium channels.	Paclitaxel	47-57	C-X-C motif chemokine ligand 1	Homo sapiens	102-108
31884406-1	2020	BACKGROUND: Nobiletin (N), a polymethoxylated flavone from citrus fruits, enhanced anti-cancer effects of paclitaxel (PTX) in multi-drug resistance (MDR) cancer cells via inhibiting P-glycoprotein (P-gp) in our previous report.	Paclitaxel	106-116	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	182-196
15756024-0	2005	Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.	Paclitaxel	166-176	epidermal growth factor receptor	Mus musculus	32-64
31884406-1	2020	BACKGROUND: Nobiletin (N), a polymethoxylated flavone from citrus fruits, enhanced anti-cancer effects of paclitaxel (PTX) in multi-drug resistance (MDR) cancer cells via inhibiting P-glycoprotein (P-gp) in our previous report.	Paclitaxel	106-116	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	198-202
28769027-7	2017	Notch-3 was significantly overexpressed in both cell lines, and Notch-3 expression was elevated after paclitaxel treatment, indicating activation of the Notch signaling pathway.	Paclitaxel	102-112	notch receptor 3	Homo sapiens	64-71
31884406-1	2020	BACKGROUND: Nobiletin (N), a polymethoxylated flavone from citrus fruits, enhanced anti-cancer effects of paclitaxel (PTX) in multi-drug resistance (MDR) cancer cells via inhibiting P-glycoprotein (P-gp) in our previous report.	Paclitaxel	118-121	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	182-196
28769027-7	2017	Notch-3 was significantly overexpressed in both cell lines, and Notch-3 expression was elevated after paclitaxel treatment, indicating activation of the Notch signaling pathway.	Paclitaxel	102-112	notch receptor 3	Homo sapiens	0-5
31884406-1	2020	BACKGROUND: Nobiletin (N), a polymethoxylated flavone from citrus fruits, enhanced anti-cancer effects of paclitaxel (PTX) in multi-drug resistance (MDR) cancer cells via inhibiting P-glycoprotein (P-gp) in our previous report.	Paclitaxel	118-121	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	198-202
15590651-9	2005	Interestingly, tubulin polymerization and cyclin-dependent kinase Cdc2 activation induced by Taxol was not affected by curcumin.	Paclitaxel	93-98	cyclin dependent kinase 1	Homo sapiens	66-70
28769027-8	2017	Inhibition of the Notch signaling pathway by GSI and Notch-3 siRNA reduced cell proliferation and induced apoptosis in A549 and H1299 cells, thereby boosting sensitivity of the cell lines to paclitaxel.	Paclitaxel	191-201	notch receptor 3	Homo sapiens	18-23
15592521-6	2005	Moreover, CYR61 overexpression rendered MCF-7 cells significantly resistant (&gt;10-fold) to Taxol-induced cytotoxicity.	Paclitaxel	93-98	cellular communication network factor 1	Homo sapiens	10-15
15592521-7	2005	Remarkably, alphavbeta3 inhibition converted the CYR61-induced Taxol-resistant phenotype into a hypersensitive one.	Paclitaxel	63-68	cellular communication network factor 1	Homo sapiens	49-54
31918714-6	2020	Subsequently, TPH/PTX caused mitochondrial outer membrane permeabilization (MOMP) by inhibiting antiapoptotic Bcl-2, leading to cytochrome C release and activation of caspase-3 and caspase-9.	Paclitaxel	18-21	caspase 3	Mus musculus	167-176
28769027-10	2017	CONCLUSIONS These results indicate a synergistic effect of Notch-3-specific inhibition and paclitaxel through alteration of the intrinsic apoptosis pathway, which was involved in Notch-3-induced chemoresistance in NSCLC cells, and GSI inhibited Notch-3-induced chemoresistance in a concentration-dependent manner.	Paclitaxel	91-101	notch receptor 3	Homo sapiens	179-186
31041717-2	2020	Nab-paclitaxel is a solvent-free, albumin-bound, paclitaxel, which minimize the risk of HSR occurrence.	Paclitaxel	4-14	HSR	Homo sapiens	88-91
15592521-10	2005	Strikingly, CYR61 overexpression impaired the accumulation of wild-type p53 following Taxol exposure, while inhibition of alphavbeta3 or ERK1/ERK2 MAPK signalings completely restored Taxol-induced upregulation of p53.	Paclitaxel	86-91	cellular communication network factor 1	Homo sapiens	12-17
15592521-10	2005	Strikingly, CYR61 overexpression impaired the accumulation of wild-type p53 following Taxol exposure, while inhibition of alphavbeta3 or ERK1/ERK2 MAPK signalings completely restored Taxol-induced upregulation of p53.	Paclitaxel	183-188	cellular communication network factor 1	Homo sapiens	12-17
15662138-6	2005	Taken together, our data demonstrate that p33ING1b enhances taxol-induced apoptosis through p53-dependent pathway in human osteosarcoma cells.	Paclitaxel	60-65	inhibitor of growth family member 1	Homo sapiens	42-50
28769027-10	2017	CONCLUSIONS These results indicate a synergistic effect of Notch-3-specific inhibition and paclitaxel through alteration of the intrinsic apoptosis pathway, which was involved in Notch-3-induced chemoresistance in NSCLC cells, and GSI inhibited Notch-3-induced chemoresistance in a concentration-dependent manner.	Paclitaxel	91-101	notch receptor 3	Homo sapiens	179-186
28532857-4	2017	Therefore, we hypothesized that one possible mechanism underlying the beneficial effects of paclitaxel could be to counter the impact of stathmin.	Paclitaxel	92-102	stathmin 1	Homo sapiens	137-145
16020968-13	2005	CONCLUSIONS: Biweekly DTX/CPT-11 with G-CSF support is a well-tolerated and highly effective approach in anthracycline-/paclitaxel-pretreated patients.	Paclitaxel	120-130	colony stimulating factor 3	Homo sapiens	38-43
31908478-7	2019	Results: Higher miR-7 expression predicts better pathological complete response (pCR) of breast cancer patients receiving paclitaxel/carboplatin chemotherapy.	Paclitaxel	122-132	leukocyte immunoglobulin like receptor B1	Homo sapiens	16-21
31908478-8	2019	In vitro, miR-7 sensitizes breast cancer cell lines (MCF-7 and MDA-MB-231) to paclitaxel and carboplatin, alone and in combination.	Paclitaxel	78-88	leukocyte immunoglobulin like receptor B1	Homo sapiens	10-15
31908478-10	2019	Furthermore, miR-7-induced sensitization of breast cancer to paclitaxel/carboplatin is markedly reversed by restoration of MRP1 and BCL2.	Paclitaxel	61-71	leukocyte immunoglobulin like receptor B1	Homo sapiens	13-18
31867270-10	2019	In order to test this, we generated a paclitaxel-resistant TNBC cell line which demonstrated an elevated level of eIF4A along with increased levels of cancer stemness markers (ALDH activity and CD44), pluripotency transcription factors (SOX2, OCT4, and NANOG) and drug transporters (ABCB1, ABCG2, and ABCC1).	Paclitaxel	38-48	CD44 molecule (Indian blood group)	Homo sapiens	194-198
31867270-10	2019	In order to test this, we generated a paclitaxel-resistant TNBC cell line which demonstrated an elevated level of eIF4A along with increased levels of cancer stemness markers (ALDH activity and CD44), pluripotency transcription factors (SOX2, OCT4, and NANOG) and drug transporters (ABCB1, ABCG2, and ABCC1).	Paclitaxel	38-48	SRY-box transcription factor 2	Homo sapiens	237-241
31867270-10	2019	In order to test this, we generated a paclitaxel-resistant TNBC cell line which demonstrated an elevated level of eIF4A along with increased levels of cancer stemness markers (ALDH activity and CD44), pluripotency transcription factors (SOX2, OCT4, and NANOG) and drug transporters (ABCB1, ABCG2, and ABCC1).	Paclitaxel	38-48	Nanog homeobox	Homo sapiens	253-258
28532857-11	2017	Paclitaxel may help to negate the impact of stathmin overexpression when treating high risk endometrial cancer cases.	Paclitaxel	0-10	stathmin 1	Homo sapiens	44-52
15623645-9	2004	Treatment with PKI166 alone or in combination with paclitaxel diminished activation of EGFR on tumor cells, yet maximal therapeutic effect was observed in mice treated with paclitaxel alone.	Paclitaxel	51-61	epidermal growth factor receptor	Mus musculus	87-91
28296507-9	2017	Both PVT1 and miR-195 could inhibit paclitaxel (PTX) induced epithelial-to-mesenchymal transition (EMT) and also sensitize CaSki cells to PTX.	Paclitaxel	36-46	Pvt1 oncogene	Homo sapiens	5-9
15452117-10	2004	Therefore, these results demonstrate for the first time that taxol induces FADD-dependent apoptosis primarily through activation of caspase-10 but independently of death receptors.	Paclitaxel	61-66	Fas associated via death domain	Homo sapiens	75-79
31738019-2	2019	Herein, a biocompatible theranostic nanoplatform capable of simultaneous cancer imaging and therapy is attempted by loading of paclitaxel (PTX) and indocyanine green (ICG) molecules into the matrix of Gd2 O3 @human serum albumin (HSA) nanoparticles (PIGH NPs) via hydrophobic interaction.	Paclitaxel	127-137	phosphatidylinositol glycan anchor biosynthesis, class H	Mus musculus	250-254
31738019-2	2019	Herein, a biocompatible theranostic nanoplatform capable of simultaneous cancer imaging and therapy is attempted by loading of paclitaxel (PTX) and indocyanine green (ICG) molecules into the matrix of Gd2 O3 @human serum albumin (HSA) nanoparticles (PIGH NPs) via hydrophobic interaction.	Paclitaxel	139-142	phosphatidylinositol glycan anchor biosynthesis, class H	Mus musculus	250-254
31738019-4	2019	Moreover, the PIGH NPs achieve high cellular uptake, efficient cytoplasmic drug translocation based on singlet oxygen-triggered endolysosomal disruption and prominent cytotoxicity effect against 4T1 cells under 808 nm near-infrared (NIR) irradiation in contrast to PTX/ICG-loaded HSA nanoparticles (PIH NPs) and free PTX/ICG.	Paclitaxel	265-268	phosphatidylinositol glycan anchor biosynthesis, class H	Mus musculus	14-18
15452117-10	2004	Therefore, these results demonstrate for the first time that taxol induces FADD-dependent apoptosis primarily through activation of caspase-10 but independently of death receptors.	Paclitaxel	61-66	caspase 10	Homo sapiens	132-142
28296507-9	2017	Both PVT1 and miR-195 could inhibit paclitaxel (PTX) induced epithelial-to-mesenchymal transition (EMT) and also sensitize CaSki cells to PTX.	Paclitaxel	48-51	Pvt1 oncogene	Homo sapiens	5-9
31738019-4	2019	Moreover, the PIGH NPs achieve high cellular uptake, efficient cytoplasmic drug translocation based on singlet oxygen-triggered endolysosomal disruption and prominent cytotoxicity effect against 4T1 cells under 808 nm near-infrared (NIR) irradiation in contrast to PTX/ICG-loaded HSA nanoparticles (PIH NPs) and free PTX/ICG.	Paclitaxel	317-320	phosphatidylinositol glycan anchor biosynthesis, class H	Mus musculus	14-18
28296507-9	2017	Both PVT1 and miR-195 could inhibit paclitaxel (PTX) induced epithelial-to-mesenchymal transition (EMT) and also sensitize CaSki cells to PTX.	Paclitaxel	138-141	Pvt1 oncogene	Homo sapiens	5-9
28296507-11	2017	In addition, the PVT1/miR-195 axis can modulate responses of the cancer cells to PTX via regulating EMT.	Paclitaxel	81-84	Pvt1 oncogene	Homo sapiens	17-21
28681218-1	2017	The aim of this study is to evaluate the outcome and safety of the multidisciplinary strategy using cisplatin plus dose-dense paclitaxel (dose-dense TP) before and after radical hysterectomy (RH) for stage IB2, IIA2, or IIB patients with cervical cancer.	Paclitaxel	126-136	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	206-209
31779616-11	2019	Moreover, EHop-016, a small molecule inhibitor of RAC1, as an adjuvant could improve the Taxol monotherapy against lung cancer cells in vitro.	Paclitaxel	89-94	Rac family small GTPase 1	Homo sapiens	50-54
15501011-1	2004	The main objective of this study was to develop an optimal paclitaxel microemulsion prepared by self-microemulsifying drug delivery system (SMEDDS) which is a mixture of paclitaxel, tetraglycol, Cremophor ELP, and Labrafil 1944 and a paclitaxel microemulsion containing poly(D,L-lactide-co-glycolide) (PLGA) in order to offer controlled release of paclitaxel.	Paclitaxel	59-69	nuclear receptor subfamily 5 group A member 1	Homo sapiens	205-208
15480428-9	2004	Consistent with these data, RTKN-expressing cells showed increased chemoresistance to 5-fluorouracil and paclitaxol, and the resistance was greatly attenuated by NF-kappaB inhibitor.	Paclitaxel	105-115	rhotekin	Homo sapiens	28-32
29256224-0	2017	[Effects of lncRNA RP11-770J1.3 and TMEM25 expression on paclitaxel resistance in human breast cancer cells].	Paclitaxel	57-67	transmembrane protein 25	Homo sapiens	36-42
31625545-2	2019	siRNA mediated gene silencing of TAGLN2 is a promising strategy for paclitaxel resistance reversal in breast cancer.	Paclitaxel	68-78	transgelin 2	Homo sapiens	33-39
31625545-7	2019	Besides, paclitaxel showed higher cytotoxicity in cells incubated with PDCKM/TAGLN2 siRNA nanocomplexes.	Paclitaxel	9-19	transgelin 2	Homo sapiens	77-83
31772161-9	2019	Collectively, our work has demonstrated that the MUC1-EGFR-CREB/GRbeta axis stimulates IL-6 expression to induce CSCs enrichment and importantly, this effect can be abrogated by erlotinib, uncovering a novel strategy to treat paclitaxel-resistant cervical cancer.	Paclitaxel	226-236	cAMP responsive element binding protein 1	Homo sapiens	59-63
15449327-6	2004	Our results show that Taxol induces dose-dependent neuronal death accompanied by the loss of MAP2 and the presence of dystrophic neurites.	Paclitaxel	22-27	microtubule-associated protein 2	Rattus norvegicus	93-97
29256224-1	2017	OBJECTIVE: To investigate the effects of long non-coding RNA(lncRNA) RP11-770J1.3 and transmembrane protein 25 (TMEM25) on paclitaxel resistance in human breast cancer MCF-7/PR cell line.	Paclitaxel	123-133	transmembrane protein 25	Homo sapiens	86-110
31515668-0	2019	Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment.	Paclitaxel	121-131	serine and arginine rich splicing factor 3	Homo sapiens	18-23
31515668-6	2019	The function of SRSF3 in PTX treatment was analyzed by gain-of-function or loss-of-function assay in OSCC cell lines CAL 27 and SCC-9 and breast cancer cell line MCF-7.	Paclitaxel	25-28	serine and arginine rich splicing factor 3	Homo sapiens	16-21
29256224-1	2017	OBJECTIVE: To investigate the effects of long non-coding RNA(lncRNA) RP11-770J1.3 and transmembrane protein 25 (TMEM25) on paclitaxel resistance in human breast cancer MCF-7/PR cell line.	Paclitaxel	123-133	transmembrane protein 25	Homo sapiens	112-118
31515668-8	2019	SRSF3-specific antisense oligonucleotide (ASO) SR-3 was used to downregulate SRSF3 expression and enhance the effect of PTX treatment.	Paclitaxel	120-123	serine and arginine rich splicing factor 3	Homo sapiens	0-5
31515668-9	2019	RESULTS: PTX treatment decreased SRSF3 expression, and SRSF3 overexpression rescued the growth inhibition caused by PTX in both OSCC and breast cancer cells.	Paclitaxel	9-12	serine and arginine rich splicing factor 3	Homo sapiens	33-38
29256224-2	2017	METHODS: The expression of lncRNA RP11-770J1.3 and TMEM25 in human breast cancer MCF-7(paclitaxel sensitive) and MCF-7/PR(paclitaxel resistant) cells were detected by quantitative RT-PCR.	Paclitaxel	87-97	transmembrane protein 25	Homo sapiens	51-57
29256224-4	2017	Sulforhodamine B assay was used to detect the sensitivity of MCF-7/PR cells to paclitaxel after interference of lncRNA RP11-770J1.3 and TMEM25.	Paclitaxel	79-89	transmembrane protein 25	Homo sapiens	136-142
29256224-7	2017	Down-regulation of lncRNA RP11-770J1.3 and TMEM25 enhanced the sensitivity of MCF-7/PR cells to paclitaxel, and inhibited the expression of MRP, BCRP and MDR1/P-gp (all P&lt;0.05).	Paclitaxel	96-106	transmembrane protein 25	Homo sapiens	43-49
29256224-9	2017	CONCLUSIONS: lncRNA RP11-770J1.3 and TMEM25 are highly expressed in MCF-7/PR cells, and the down-regulation of lncRNA RP11-770J1.3 and TMEM25 can enhance paclitaxel sensitivity in MCF-7/PR cells.	Paclitaxel	154-164	transmembrane protein 25	Homo sapiens	37-43
15494938-8	2004	The proliferating histiocytes had ultrastructural findings of paclitaxel-induced cytotoxicity with disorganized stacks of intermediate filaments positive for vimentin by immunostains and fewer masses of tubulin.	Paclitaxel	62-72	vimentin	Homo sapiens	158-166
29256224-9	2017	CONCLUSIONS: lncRNA RP11-770J1.3 and TMEM25 are highly expressed in MCF-7/PR cells, and the down-regulation of lncRNA RP11-770J1.3 and TMEM25 can enhance paclitaxel sensitivity in MCF-7/PR cells.	Paclitaxel	154-164	transmembrane protein 25	Homo sapiens	135-141
31669221-8	2019	Induced degradation of Cdc20 by CP5V leads to significant inhibition of breast cancer cell proliferation and resensitization of Taxol-resistant cell lines.	Paclitaxel	128-133	cell division cycle 20	Homo sapiens	23-28
28187446-6	2017	Gene expression profiling of paclitaxel-residual, -resistant and naive MDA-MB-231 cells demonstrated that paclitaxel-residual, as opposed to -resistant cells, were characterized by an apoptotic signature, with downregulation of anti-apoptotic genes (BCL2, BIRC5), induction of apoptosis inducers (IL24, PDCD4), and enrichment of TNFalpha/NF-kappaB pathway, including upregulation of TNFSF15, coupled with cell-cycle arrest.	Paclitaxel	106-116	interleukin 24	Homo sapiens	297-301
31847939-8	2019	NAC, an ROS inhibitor, inhibited cell autophagy induced by free Ptx or Ptx-NPs.	Paclitaxel	64-67	X-linked Kx blood group	Homo sapiens	0-3
28498513-0	2017	Suberoylanilide hydroxamic acid sensitizes neuroblastoma to paclitaxel by inhibiting thioredoxin-related protein 14-mediated autophagy.	Paclitaxel	60-70	thioredoxin domain containing 17	Homo sapiens	85-115
31847939-8	2019	NAC, an ROS inhibitor, inhibited cell autophagy induced by free Ptx or Ptx-NPs.	Paclitaxel	71-74	X-linked Kx blood group	Homo sapiens	0-3
31664305-0	2019	Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells.	Paclitaxel	56-61	microRNA 1295a	Homo sapiens	16-26
31664305-4	2019	In this study, we aimed to explore the role of miR-129-5p in regulating the sensitivity of breast cancer cells to Taxol.	Paclitaxel	114-119	microRNA 1295a	Homo sapiens	47-56
31664305-8	2019	Furthermore, miR-129-5p overexpression increased the sensitivity of MCF-7 cells to Taxol.	Paclitaxel	83-88	microRNA 1295a	Homo sapiens	13-23
31664305-11	2019	Taken together, our findings suggested that miR-129-5p increased the chemosensitivity of MCF-7 cells to Taxol through suppressing autophagy and enhancing apoptosis by inhibiting HMGB1.	Paclitaxel	104-109	microRNA 1295a	Homo sapiens	44-54
31664305-12	2019	Using miR-129-5p/HMGB1/autophagy-based therapeutic strategies may be a potential treatment for overcoming Taxol resistance in breast cancer.	Paclitaxel	106-111	microRNA 1295a	Homo sapiens	6-16
15150548-3	2004	Treatment with docetaxel or paclitaxel, with or without estramustine, appears to convey higher rates of prostate-specific antigen response in phase II trials, but is more toxic.	Paclitaxel	28-38	kallikrein related peptidase 3	Homo sapiens	104-129
15294454-1	2004	Overexpression of human MDR1 P-glycoprotein [Pgp] is associated with cellular resistance to bulky amphipathic drugs, such as taxol, anthracyclines, vinca alkaloids, and epipodophyllotoxins by actively effluxing drugs from cells.	Paclitaxel	125-130	phosphoglycolate phosphatase	Homo sapiens	45-48
28498513-5	2017	Autophagy was induced and the autophagy-associated proteins LC3-I, LC3-II, Beclin 1, and thioredoxin-related protein 14 (TRP14), were found to be upregulated in neuroblastoma cells that were exposed to paclitaxel.	Paclitaxel	202-212	thioredoxin domain containing 17	Homo sapiens	89-119
31512803-3	2019	Paclitaxel and docetaxel induced massive mitotic defects and apoptosis in transit amplifying hair matrix keratinocytes and within epithelial stem/progenitor cell-rich outer root sheath compartments, including within Keratin 15+ cell populations, thus implicating direct damage to stem/progenitor cells as an explanation for the severity and permanence of taxane chemotherapy-induced alopecia.	Paclitaxel	0-10	keratin 15	Homo sapiens	216-226
28498513-5	2017	Autophagy was induced and the autophagy-associated proteins LC3-I, LC3-II, Beclin 1, and thioredoxin-related protein 14 (TRP14), were found to be upregulated in neuroblastoma cells that were exposed to paclitaxel.	Paclitaxel	202-212	thioredoxin domain containing 17	Homo sapiens	121-126
15155749-0	2004	Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis.	Paclitaxel	136-146	glutaminyl-tRNA amidotransferase subunit QRSL1	Homo sapiens	92-96
15001534-3	2004	Both were arrested at G2/M and FADD was found to be phosphorylated at Ser194 on treatment with paclitaxel.	Paclitaxel	95-105	Fas associated via death domain	Homo sapiens	31-35
31344499-6	2019	GTG loaded with paclitaxel (GPC) had potentiated anti-glioma efficacy.	Paclitaxel	16-26	gamma-glutamyltransferase 1	Homo sapiens	0-3
31344499-6	2019	GTG loaded with paclitaxel (GPC) had potentiated anti-glioma efficacy.	Paclitaxel	16-26	glycophorin C (Gerbich blood group)	Homo sapiens	28-31
28498513-6	2017	The inhibition of Beclin 1 or TRP14 by siRNA increased the sensitivity of the tumor cells to paclitaxel.	Paclitaxel	93-103	thioredoxin domain containing 17	Homo sapiens	30-35
28498513-8	2017	Furthermore, the TRP14 inhibitor suberoylanilide hydroxamic acid (SAHA) downregulated paclitaxel-induced autophagy and enhanced the anticancer effects of paclitaxel in normal control cancer cells but not in cells with upregulated Beclin 1 and TRP14 expression.	Paclitaxel	86-96	thioredoxin domain containing 17	Homo sapiens	17-22
28498513-8	2017	Furthermore, the TRP14 inhibitor suberoylanilide hydroxamic acid (SAHA) downregulated paclitaxel-induced autophagy and enhanced the anticancer effects of paclitaxel in normal control cancer cells but not in cells with upregulated Beclin 1 and TRP14 expression.	Paclitaxel	154-164	thioredoxin domain containing 17	Homo sapiens	17-22
31484396-9	2019	CONCLUSIONS: Stable paclitaxel-loaded nanoparticles with cathepsin B digestible peptide were formed and tested on the ovarian cancer cell line OVCAR-3.	Paclitaxel	20-30	cathepsin B	Homo sapiens	57-68
28498513-9	2017	Our findings showed that paclitaxel-induced autophagy in neuroblastoma cells was regulated by TRP14 and that SAHA could sensitize neuroblastoma cells to paclitaxel by specifically inhibiting TRP14.	Paclitaxel	25-35	thioredoxin domain containing 17	Homo sapiens	94-99
28498513-9	2017	Our findings showed that paclitaxel-induced autophagy in neuroblastoma cells was regulated by TRP14 and that SAHA could sensitize neuroblastoma cells to paclitaxel by specifically inhibiting TRP14.	Paclitaxel	25-35	thioredoxin domain containing 17	Homo sapiens	191-196
15001534-4	2004	Inhibition of paclitaxel-induced c-jun NH2-terminal kinase (JNK) activation by treatment with a specific inhibitor, SP600125, or overexpression of a dominant-negative mutant form of upstream kinases, MEK kinase 1 (MEKK1) and mitogen-activated protein kinase kinase (MKK) 7, significantly reduced the increase in phosphorylated FADD.	Paclitaxel	14-24	Fas associated via death domain	Homo sapiens	327-331
15001534-6	2004	Interestingly, MEKK1 up-regulation and the synergistic effects of paclitaxel on anticancer drug-induced apoptosis were abolished by overexpression of mutant FADD (Ser194--&gt;Ala).	Paclitaxel	66-76	Fas associated via death domain	Homo sapiens	157-161
31327462-9	2019	The combination of MNK kinase inhibitor with paclitaxel achieved greater efficacy in cervical cancer cells than paclitaxel alone.	Paclitaxel	112-122	ATPase copper transporting alpha	Homo sapiens	19-22
28541685-0	2017	Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo.	Paclitaxel	161-171	nucleotide binding oligomerization domain containing 1	Homo sapiens	68-124
31211507-0	2019	EIF2A promotes cell survival during paclitaxel treatment in vitro and in vivo.	Paclitaxel	36-46	eukaryotic translation initiation factor 2A	Homo sapiens	0-5
28541685-0	2017	Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo.	Paclitaxel	161-171	nucleotide binding oligomerization domain containing 1	Homo sapiens	126-130
31211507-2	2019	Here, we showed that paclitaxel, the major chemotherapy drug for breast cancer, induced ISR and phosphorylated ser51 residue of EIF2S1 by EIF2AK3 and EIF2AK4.	Paclitaxel	21-31	eukaryotic translation initiation factor 2 alpha kinase 4	Homo sapiens	150-157
31211507-3	2019	When exposed to paclitaxel, cancer cells activated the EIF2AK3/EIF2AK4-pEIF2S1-ATF4 axis and maintained redox homoeostasis by inducing expression of the major antioxidant enzymes HMOX1, SHMT2 and SLC7A11.	Paclitaxel	16-26	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	55-62
15201989-5	2004	Combination of hTERT/rev-caspase-6 gene therapy with PTX yielded a dose-dependent additive effect, while CDDP and BCNU had additive effect only when tumor cells were treated at IC75 of each agent.	Paclitaxel	53-56	caspase 6	Homo sapiens	25-34
28541685-0	2017	Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo.	Paclitaxel	173-176	nucleotide binding oligomerization domain containing 1	Homo sapiens	68-124
15196026-9	2004	Mutation of CYP2C8 at position 359 (S359I), a site of genetic polymorphism in CYP2C9, resulted in relatively minor changes in paclitaxel- and torsemide-hydroxylase activities.	Paclitaxel	126-136	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	78-84
31211507-3	2019	When exposed to paclitaxel, cancer cells activated the EIF2AK3/EIF2AK4-pEIF2S1-ATF4 axis and maintained redox homoeostasis by inducing expression of the major antioxidant enzymes HMOX1, SHMT2 and SLC7A11.	Paclitaxel	16-26	serine hydroxymethyltransferase 2 (mitochondrial)	Mus musculus	186-191
31211507-4	2019	Paclitaxel-mediated cell death was significantly increased following loss of ISR or ATF4 expression.	Paclitaxel	0-10	activating transcription factor 4	Homo sapiens	84-88
28541685-0	2017	Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo.	Paclitaxel	173-176	nucleotide binding oligomerization domain containing 1	Homo sapiens	126-130
31211507-6	2019	We demonstrated that the alternative initiation factor EIF2A was essential for cancer cell survival after paclitaxel-mediated ISR both in vitro and in vivo.	Paclitaxel	106-116	eukaryotic translation initiation factor 2A	Homo sapiens	55-60
31211507-8	2019	Collectively, our findings reveal a novel mechanism for paclitaxel resistance and suggest that targeting EIF2A combined with ISR agonist may be a potential treatment regimen to overcome drug resistance for breast cancer.	Paclitaxel	56-66	eukaryotic translation initiation factor 2A	Homo sapiens	105-110
28449309-1	2017	Herein we report the first example of an isoDGR-drug conjugate (2), designed to release paclitaxel selectively within cancer cells expressing integrin alphaV beta3 .	Paclitaxel	88-98	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	158-163
31077613-0	2019	Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer.	Paclitaxel	130-140	DIRAS family GTPase 3	Homo sapiens	46-50
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	102-112	DNA methyltransferase 1	Homo sapiens	198-203
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	102-112	DIRAS family GTPase 3	Homo sapiens	295-299
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	114-117	DNA methyltransferase 1	Homo sapiens	198-203
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	114-117	DIRAS family GTPase 3	Homo sapiens	295-299
15044484-4	2004	We showed that stable cell lines overexpressing Cyr61 had acquired a remarkable resistance to apoptosis induced by paclitaxel, adriamycin, and beta-lapachone.	Paclitaxel	115-125	cellular communication network factor 1	Homo sapiens	48-53
15130763-6	2004	Treatment with Doxorubicin, Paclitaxel or 5-Fluorouracil induced a breakdown of the mitochondrial membrane potential and apoptotic cell death in p56/Lck expressing Jurkat and the retransfected JCaM1.6/Lck cells within 48h of treatment.	Paclitaxel	28-38	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	149-152
15130763-6	2004	Treatment with Doxorubicin, Paclitaxel or 5-Fluorouracil induced a breakdown of the mitochondrial membrane potential and apoptotic cell death in p56/Lck expressing Jurkat and the retransfected JCaM1.6/Lck cells within 48h of treatment.	Paclitaxel	28-38	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	201-204
15130763-11	2004	In conclusion, the tyrosine kinase p56/Lck is essential for apoptosis induction by Doxorubicin, Paclitaxel and 5-Fluorouracil regulating early steps of the mitochondrial apoptosis signaling cascade, including alteration of mitochondrial functions and caspase-activation.	Paclitaxel	96-106	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	39-42
31270160-3	2019	In this study, we examined the role of TLR9 in CIPN induced by paclitaxel in WT and Tlr9 mutant mice of both sexes.	Paclitaxel	63-73	toll-like receptor 9	Mus musculus	39-43
25350466-0	2017	Phase I Dose-Escalation Study of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in Stages IB2 and IIA2 Cervical Cancer.	Paclitaxel	40-50	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	108-111
31270160-7	2019	Interestingly, the development of paclitaxel-evoked mechanical allodynia was attenuated by TLR9 antagonism or Tlr9 mutation only in male mice.	Paclitaxel	34-44	toll-like receptor 9	Mus musculus	91-95
31270160-7	2019	Interestingly, the development of paclitaxel-evoked mechanical allodynia was attenuated by TLR9 antagonism or Tlr9 mutation only in male mice.	Paclitaxel	34-44	toll-like receptor 9	Mus musculus	110-114
31270160-9	2019	Paclitaxel treatment also upregulated TNF and CXCL1 in macrophage cultures and DRG tissues in both sexes, but these changes were compromised by Tlr9 mutation in male animals.	Paclitaxel	0-10	toll-like receptor 9	Mus musculus	144-148
31270160-10	2019	Intraplantar adoptive transfer of paclitaxel-activated macrophages evoked mechanical allodynia in both sexes, which was compromised by Tlr9 mutation or by treatment with TLR9 inhibitor only in male animals.	Paclitaxel	34-44	toll-like receptor 9	Mus musculus	135-139
31270160-10	2019	Intraplantar adoptive transfer of paclitaxel-activated macrophages evoked mechanical allodynia in both sexes, which was compromised by Tlr9 mutation or by treatment with TLR9 inhibitor only in male animals.	Paclitaxel	34-44	toll-like receptor 9	Mus musculus	170-174
31270160-11	2019	Finally, TLR9 antagonism reduced paclitaxel-induced mechanical allodynia in female nude mice (T-cell and B-cell deficient).	Paclitaxel	33-43	toll-like receptor 9	Mus musculus	9-13
28670488-5	2017	RBX2 knockout attenuated proliferation, colony formation and enhanced sensitivity of colorectal cancer cells to paclitaxel treatment.	Paclitaxel	112-122	ring finger protein 7	Homo sapiens	0-4
31077084-0	2019	Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity.	Paclitaxel	137-147	solute carrier family 8 (sodium/calcium exchanger), member 1	Mus musculus	44-70
31077084-6	2019	The protective action of cannabidiol and KLS-13019 against paclitaxel-induced toxicity during a 5-h test period was significantly attenuated after a 4-day knockdown of mNCX-1 that was not attributable to toxicity.	Paclitaxel	59-69	solute carrier family 8 (sodium/calcium exchanger), member 1	Mus musculus	168-174
31077084-8	2019	Pharmacological blockade of mNCX-1 with CGP-37157 produced complete inhibition of cannabinoid-mediated protection from paclitaxel in DRG cultures, supporting the observed siRNA effects on mechanism.	Paclitaxel	119-129	solute carrier family 8 (sodium/calcium exchanger), member 1	Mus musculus	28-34
15128858-6	2004	Spinal administration of antisense oligodeoxynucleotides to TRPV4, which reduced the expression of TRPV4 in sensory nerve, abolished Taxol-induced mechanical hyperalgesia and attenuated hypotonic hyperalgesia by 42%.	Paclitaxel	133-138	transient receptor potential cation channel, subfamily V, member 4	Rattus norvegicus	60-65
15128858-6	2004	Spinal administration of antisense oligodeoxynucleotides to TRPV4, which reduced the expression of TRPV4 in sensory nerve, abolished Taxol-induced mechanical hyperalgesia and attenuated hypotonic hyperalgesia by 42%.	Paclitaxel	133-138	transient receptor potential cation channel, subfamily V, member 4	Rattus norvegicus	99-104
15128858-8	2004	Taxol-induced TRPV4-mediated hyperalgesia and the enhanced osmotransduction in cultured nociceptors were dependent on integrin/Src tyrosine kinase signaling.	Paclitaxel	0-5	transient receptor potential cation channel, subfamily V, member 4	Rattus norvegicus	14-19
15003732-6	2004	RESULTS: MCF-7 cells treated with taxol and etoposide were found positive for all hTERT splicing variants, while the expression of hTERT beta plus transcript did not differ significantly before and after exposure.	Paclitaxel	34-39	telomerase reverse transcriptase	Homo sapiens	82-87
28441715-4	2017	Our findings show that downregulation of Bcl-2, Bcl-XL and Mcl-1 can significantly promote EC109/PTX cell apoptosis and reduce the EC109/PTX cell resistance index (RI).	Paclitaxel	97-100	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	59-64
15003732-6	2004	RESULTS: MCF-7 cells treated with taxol and etoposide were found positive for all hTERT splicing variants, while the expression of hTERT beta plus transcript did not differ significantly before and after exposure.	Paclitaxel	34-39	telomerase reverse transcriptase	Homo sapiens	131-136
31559044-9	2019	The results indicated a beneficial effect of adjuvant paclitaxel-carboplatin in patients with high TMEM213 expression.	Paclitaxel	54-76	transmembrane protein 213	Homo sapiens	99-106
31559044-14	2019	Patients in the high TMEM213 group appear to benefit more from adjuvant paclitaxel-carboplatin, but this needs further validation.	Paclitaxel	72-94	transmembrane protein 213	Homo sapiens	21-28
28441715-4	2017	Our findings show that downregulation of Bcl-2, Bcl-XL and Mcl-1 can significantly promote EC109/PTX cell apoptosis and reduce the EC109/PTX cell resistance index (RI).	Paclitaxel	137-140	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	59-64
31337279-0	2019	Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer.	Paclitaxel	27-37	microRNA 4262	Homo sapiens	15-23
31337279-4	2019	This study aimed to investigate the role and underlying mechanism of miR-4262 in PTX-resistant NSCLC.	Paclitaxel	81-84	microRNA 4262	Homo sapiens	69-77
28441715-5	2017	Furthermore, TW37 in combination with a P-gp inhibitor can synergistically reverse the paclitaxel resistance in EC109/PTX cells.	Paclitaxel	87-97	phosphoglycolate phosphatase	Homo sapiens	40-44
28441715-5	2017	Furthermore, TW37 in combination with a P-gp inhibitor can synergistically reverse the paclitaxel resistance in EC109/PTX cells.	Paclitaxel	118-121	phosphoglycolate phosphatase	Homo sapiens	40-44
31103675-2	2019	Following confirmation of in vitro PTX efficacy in ID8-VEGF epithelial ovarian cancer cells, in vivo studies were performed upon surgical peritoneal implantation of nanotextile implants in orthotopic, syngeneic ID8-VEGF tumor-bearing C57BL/6 mice.	Paclitaxel	35-38	vascular endothelial growth factor A	Mus musculus	55-59
28441715-6	2017	These results suggest that targeting of the Bcl-2 family and P-gp is capable of reversing the resistance in EC109/PTX cells and the two-inhibitor combination may be a novel treatment strategy for resistant esophageal cancer.	Paclitaxel	114-117	phosphoglycolate phosphatase	Homo sapiens	61-65
31103675-5	2019	Additionally, VEGF levels measured in peritoneal lavage fluid were 300-fold lower compared to PTX-solution and 600-fold lower as compared to untreated tumor-bearing animals.	Paclitaxel	94-97	vascular endothelial growth factor A	Mus musculus	14-18
14762343-0	2004	Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.	Paclitaxel	16-26	protein tyrosine kinase 2 beta	Homo sapiens	137-153
27496854-0	2017	Crosstalk between E2f1 and c-Myc mediates hepato-protective effect of royal jelly on taxol-induced damages.	Paclitaxel	85-90	E2F transcription factor 1	Rattus norvegicus	18-22
14762343-10	2004	CONCLUSION: LY294002-mediated inhibition of the phosphoinositide 3-kinase/protein kinase B-dependent survival pathway with secondary suppression of nuclear factor-kappaB transcriptional activity was associated with enhancement of paclitaxel cytotoxicity in lung and esophageal cancer cells.	Paclitaxel	230-240	protein tyrosine kinase 2 beta	Homo sapiens	74-90
14762343-11	2004	Direct inhibition of nuclear factor-kappaB by BAY11-0782 also sensitized these cancer cells to paclitaxel, indicating that nuclear factor-kappaB may be the crucial intermediary step connecting phosphoinositide 3-kinase/protein kinase B (Akt) to the intrinsic susceptibility of cancer cells to chemotherapeutic agents.	Paclitaxel	95-105	protein tyrosine kinase 2 beta	Homo sapiens	219-235
27941877-3	2017	Here, we show that HuR cleavage associated with active caspase-3 in oral cancer cells treated with ionizing radiation and chemotherapeutic drug, paclitaxel.	Paclitaxel	145-155	ELAV like RNA binding protein 1	Homo sapiens	19-22
30980798-11	2019	Inhibition of miR-140-3p or miR-155-5p significantly reduced the malignancy of patient-derived chordoma cells and activation of PI3K-Akt-mTOR signaling, while significantly increasing the sensitivity to doxorubicin, paclitaxel or cisplatin treatment and PTEN protein level.	Paclitaxel	216-226	microRNA 155	Homo sapiens	28-35
31646806-0	2019	Comparisons of efficacy and safety between docetaxel + cisplatin and paclitaxel + cisplatin and their effects on serum HE4, CA125 and ROMA indicators in patients with ovarian carcinoma.	Paclitaxel	69-79	mucin 16, cell surface associated	Homo sapiens	124-129
27941877-4	2017	We determined that oral cancer cells overexpressing cyclooxygenase-2 (COX-2) limited the cleavage of caspase-3 and HuR, which reduced the rate of cell death in paclitaxel resistant oral cancer cells.	Paclitaxel	160-170	ELAV like RNA binding protein 1	Homo sapiens	115-118
31047896-0	2019	LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/CDK6 axis.	Paclitaxel	29-39	long intergenic non-protein coding RNA 511	Homo sapiens	0-9
14719078-0	2004	Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas.	Paclitaxel	82-92	H3 histone pseudogene 16	Homo sapiens	18-21
14719078-0	2004	Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas.	Paclitaxel	82-92	interferon alpha inducible protein 27	Homo sapiens	23-26
31047896-11	2019	LINC00511 knockdown enhanced paclitaxel cytotoxicity in breast cancer cells by upregulating miR-29c.	Paclitaxel	29-39	long intergenic non-protein coding RNA 511	Homo sapiens	0-9
27941877-5	2017	Specific inhibition of COX-2 by celecoxib, promoted apoptosis through activation of caspase-3 and cleavage of HuR in paclitaxel-resistant oral cancer cells, both in vitro and in vivo.	Paclitaxel	117-127	ELAV like RNA binding protein 1	Homo sapiens	110-113
31047896-15	2019	SIGNIFICANCE: LINC00511 knockdown enhanced paclitaxel cytotoxicity in breast cancer cells via regulating miR-29c/CDK6 axis.	Paclitaxel	43-53	long intergenic non-protein coding RNA 511	Homo sapiens	14-23
28653877-4	2017	Moreover, the expression of TUSC7 in endometrial carcinoma tissues and cell lines resistant to CDDP and Taxol was lower than that in sensitive endometrial carcinoma tissues and cell lines, which indicated that the TUSC7 expression level was positively correlated with the response of endometrial carcinoma patients to chemotherapy with CDDP and Taxol.	Paclitaxel	104-109	tumor suppressor candidate 7	Homo sapiens	28-33
31320873-0	2019	Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC.	Paclitaxel	297-307	BRCA2 DNA repair associated	Homo sapiens	8-13
15217493-0	2004	Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.	Paclitaxel	16-26	erb-b2 receptor tyrosine kinase 2	Mus musculus	87-92
15217493-0	2004	Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.	Paclitaxel	16-26	erb-b2 receptor tyrosine kinase 2	Mus musculus	93-96
15217493-9	2004	The results demonstrated that doxorubicin and paclitaxel, commonly used chemotherapeutic agents for the treatment of breast cancer, when used at immunomodulating doses augmented the antitumor efficacy of gene vaccines directed against HER2/neu.	Paclitaxel	46-56	erb-b2 receptor tyrosine kinase 2	Mus musculus	240-243
28653877-4	2017	Moreover, the expression of TUSC7 in endometrial carcinoma tissues and cell lines resistant to CDDP and Taxol was lower than that in sensitive endometrial carcinoma tissues and cell lines, which indicated that the TUSC7 expression level was positively correlated with the response of endometrial carcinoma patients to chemotherapy with CDDP and Taxol.	Paclitaxel	104-109	tumor suppressor candidate 7	Homo sapiens	214-219
15663292-0	2004	Enhanced oral bioavailability of paclitaxel by recombinant interleukin-2 in mice with murine Lewis lung carcinoma.	Paclitaxel	33-43	interleukin 2	Mus musculus	59-72
28653877-4	2017	Moreover, the expression of TUSC7 in endometrial carcinoma tissues and cell lines resistant to CDDP and Taxol was lower than that in sensitive endometrial carcinoma tissues and cell lines, which indicated that the TUSC7 expression level was positively correlated with the response of endometrial carcinoma patients to chemotherapy with CDDP and Taxol.	Paclitaxel	345-350	tumor suppressor candidate 7	Homo sapiens	28-33
15663292-1	2004	The effect of recombinant interleukin-2 (rIL-2) pretreatment on the pharmacokinetics of paclitaxel was investigated in the murine Lewis lung carcinoma model in C57B1/6 mice.	Paclitaxel	88-98	interleukin 2	Mus musculus	26-39
15663292-1	2004	The effect of recombinant interleukin-2 (rIL-2) pretreatment on the pharmacokinetics of paclitaxel was investigated in the murine Lewis lung carcinoma model in C57B1/6 mice.	Paclitaxel	88-98	interleukin 2	Rattus norvegicus	41-46
15663292-2	2004	Paclitaxel 15 mg/kg was administrated orally to mice, either alone or after 3 days pretreatment with twice daily dose of 16.5 microg rIL-2.	Paclitaxel	0-10	interleukin 2	Rattus norvegicus	133-138
31259152-11	2019	UA treatment significantly increased the expression of miR-149-5p, which was lower in 231/PTX cells than in 231 cells.	Paclitaxel	90-93	microRNA 149	Mus musculus	55-62
31259152-12	2019	Furthermore, the overexpression of miR-149-5p increased the sensitivity of 231/PTX cells to PTX treatment, whereas the knockdown of the miR-149-5p gene attenuated the effects of UA on the regulation of PTX sensitivity.	Paclitaxel	79-82	microRNA 149	Mus musculus	35-42
31259152-12	2019	Furthermore, the overexpression of miR-149-5p increased the sensitivity of 231/PTX cells to PTX treatment, whereas the knockdown of the miR-149-5p gene attenuated the effects of UA on the regulation of PTX sensitivity.	Paclitaxel	92-95	microRNA 149	Mus musculus	35-42
31259152-12	2019	Furthermore, the overexpression of miR-149-5p increased the sensitivity of 231/PTX cells to PTX treatment, whereas the knockdown of the miR-149-5p gene attenuated the effects of UA on the regulation of PTX sensitivity.	Paclitaxel	92-95	microRNA 149	Mus musculus	35-42
31259152-14	2019	Meanwhile, the downregulation of MyD88 through the overexpression of miR-149-5p or UA treatment inhibited the activation of the Akt signaling pathway in 231/PTX cells.	Paclitaxel	157-160	myeloid differentiation primary response gene 88	Mus musculus	33-38
31259152-14	2019	Meanwhile, the downregulation of MyD88 through the overexpression of miR-149-5p or UA treatment inhibited the activation of the Akt signaling pathway in 231/PTX cells.	Paclitaxel	157-160	microRNA 149	Mus musculus	69-76
31259152-15	2019	Thus, our data indicate that UA can reverse PTX resistance by targeting the miRNA-149-5p/MyD88 axis in breast cancer cells.	Paclitaxel	44-47	myeloid differentiation primary response gene 88	Mus musculus	89-94
28653877-4	2017	Moreover, the expression of TUSC7 in endometrial carcinoma tissues and cell lines resistant to CDDP and Taxol was lower than that in sensitive endometrial carcinoma tissues and cell lines, which indicated that the TUSC7 expression level was positively correlated with the response of endometrial carcinoma patients to chemotherapy with CDDP and Taxol.	Paclitaxel	345-350	tumor suppressor candidate 7	Homo sapiens	214-219
15663292-5	2004	Using Bailer"s method, a significant difference was observed in the AUCs of paclitaxel administrated alone and with rIL-2 pretreatment (928.2 +/- 136.8 vs 2549.6 +/- 131.3 ng.h.ml(-1), p &lt;0.0001).	Paclitaxel	76-86	interleukin 2	Rattus norvegicus	116-121
28653877-5	2017	TUSC7 upregulation inhibited proliferation, blocked cells at G1 phase, and advanced apoptosis and chemotherapy sensitivity to CDDP and Taxol in HEC1A/CR cell line.	Paclitaxel	135-140	tumor suppressor candidate 7	Homo sapiens	0-5
15663292-6	2004	Pretreatment with rIL-2 resulted in a 3-fold increase in the oral bioavailability of paclitaxel without altering its elimination half-life (0.798 vs 0.747 h).	Paclitaxel	85-95	interleukin 2	Rattus norvegicus	18-23
31169019-0	2019	MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4.	Paclitaxel	39-49	microRNA 215	Homo sapiens	0-9
27911869-0	2017	Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.	Paclitaxel	0-10	FEZ family zinc finger 2	Homo sapiens	37-40
31281464-6	2019	Loss-of-function studies showed that CDC25A promoted cisplatin-resistance and paclitaxel-resistance and inhibited the drug-induced apoptosis in ovarian cancer MCS.	Paclitaxel	78-88	cell division cycle 25A	Homo sapiens	37-43
15032274-5	2004	In patients with Stage III disease, the rates of nodal involvement in patients treated with initial surgery, interval debulking surgery (with paclitaxel-based regimen) and second-look surgery were respectively: 53% (15/28), 58% (15/26) and 48% (20/42).	Paclitaxel	142-152	nodal growth differentiation factor	Homo sapiens	49-54
28667027-7	2017	METHODS: The impact of exposure to paclitaxel on the surface expression of MDM-2 was assessed with the use of flow cytometry.	Paclitaxel	35-45	transformed mouse 3T3 cell double minute 2	Mus musculus	75-80
14751139-3	2004	Forty-three consecutive patients affected by International Federation of Gynecology and Obstetrics (FIGO) stage IB2 to IIB were treated with paclitaxel 60 mg/m(2) that was administered intravenously over a 3-h period, followed by cisplatin 60 mg/m(2), also administered intravenously.	Paclitaxel	141-151	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	112-115
14749477-7	2004	Paclitaxel down-regulated the expression of Bcl-x(L), Mcl-1, and cellular inhibitor of apoptosis protein-1 antiapoptotic proteins and up-regulated Bid and Apaf-1.	Paclitaxel	0-10	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	54-59
31016380-12	2019	Moreover, we demonstrated that TPP1-OB enhances the sensitivity of lung cancer cells to the chemotherapeutic drug paclitaxel.	Paclitaxel	114-124	tripeptidyl peptidase 1	Homo sapiens	31-35
30760861-7	2019	Reduction of FBP levels in cancer cells by the ectopic expression of ALDOB disrupted redox homeostasis, arrested cancer proliferation, and sensitized ccRCC cells to a chemotherapy agent (paclitaxel).	Paclitaxel	187-197	fructose-bisphosphatase 1	Homo sapiens	13-16
28667027-17	2017	ID8 cells surviving paclitaxel demonstrated increased expression of MDM-2 and increased susceptibility to PNC-27.	Paclitaxel	20-30	transformed mouse 3T3 cell double minute 2	Mus musculus	68-73
28235687-9	2017	In spleens, IM+PTX therapy elevated proportion of whole lymphocytes in the account of myelo-monocytic cells characteristic with low expression of CD11c+ and bearing Fc receptor (CD16/32) as well as T-lymphocytes, NK cells and dendritic cells.	Paclitaxel	15-18	Fc receptor	Mus musculus	165-176
30991054-0	2019	Spinal blockage of CXCL1 and its receptor CXCR2 inhibits paclitaxel-induced peripheral neuropathy in mice.	Paclitaxel	57-67	chemokine (C-X-C motif) receptor 2	Mus musculus	42-47
30991054-4	2019	Herein, we sought to evaluate the possible involvement of CXCL1 and CXCR2 in the pathogenesis of PTX-induced neuropathic pain in mice.	Paclitaxel	97-100	chemokine (C-X-C motif) receptor 2	Mus musculus	68-73
30991054-14	2019	Therefore, the spinal blockage of CXCL1/CXCR2 signalling might be a new innovative therapeutic approach to treat this clinical side effect of PTX.	Paclitaxel	142-145	chemokine (C-X-C motif) receptor 2	Mus musculus	40-45
14695171-6	2003	Cells not expressing CHFR showed impaired checkpoint function, which led to nuclear localization of cyclin B1 after treatment with docetaxel or paclitaxel, two microtubule inhibitors.	Paclitaxel	144-154	checkpoint with forkhead and ring finger domains	Homo sapiens	21-25
28358263-0	2017	LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis.	Paclitaxel	42-52	colon cancer associated transcript 1	Homo sapiens	7-12
14695171-6	2003	Cells not expressing CHFR showed impaired checkpoint function, which led to nuclear localization of cyclin B1 after treatment with docetaxel or paclitaxel, two microtubule inhibitors.	Paclitaxel	144-154	cyclin B1	Homo sapiens	100-109
28358263-2	2017	This study aimed to investigate whether long non-coding RNA CCAT1 was involved in Paclitaxel resistance in nasopharyngeal carcinoma (NPC).	Paclitaxel	82-92	colon cancer associated transcript 1	Homo sapiens	60-65
30720585-2	2019	Our previous findings show that CD8 T cells are necessary for the resolution of paclitaxel-induced mechanical allodynia in male mice.	Paclitaxel	80-90	CD8a molecule	Homo sapiens	32-35
30720585-8	2019	Moreover, adoptive transfer of cisplatin-educated CD8 T cells to Rag2 mice prevented CIPN development induced by either cisplatin or paclitaxel, indicating that the activity of the educated CD8 T is not cisplatin specific.	Paclitaxel	133-143	CD8a molecule	Homo sapiens	50-53
28358263-7	2017	Our findings revealed that the upregulated CCAT1 results in significantly enhancing paclitaxel resistance in nasopharyngeal cancer cells.	Paclitaxel	84-94	colon cancer associated transcript 1	Homo sapiens	43-48
30720585-8	2019	Moreover, adoptive transfer of cisplatin-educated CD8 T cells to Rag2 mice prevented CIPN development induced by either cisplatin or paclitaxel, indicating that the activity of the educated CD8 T is not cisplatin specific.	Paclitaxel	133-143	CD8a molecule	Homo sapiens	190-193
28358263-12	2017	Taken together, lncRNA CCAT1 regulates the sensitivity of paclitaxel in NPC cells via miR-181a/CPEB2 axis.	Paclitaxel	58-68	colon cancer associated transcript 1	Homo sapiens	23-28
28614779-10	2017	Doxorubicin, PTX and DTX induced OS, DNA damage and changes in expression of TNF-alpha, nNOS and PARP-1 in the rat brain.	Paclitaxel	13-16	poly (ADP-ribose) polymerase 1	Rattus norvegicus	97-103
31460017-5	2019	A GO-HA-Dox/Ptx system was significantly better than the GO-Dox/Ptx system at specifically killing CD44-expressing MDA-MB-231 cells but not BT-474 cells that do not express CD44.	Paclitaxel	12-15	CD44 molecule (Indian blood group)	Homo sapiens	99-103
31460017-5	2019	A GO-HA-Dox/Ptx system was significantly better than the GO-Dox/Ptx system at specifically killing CD44-expressing MDA-MB-231 cells but not BT-474 cells that do not express CD44.	Paclitaxel	12-15	CD44 molecule (Indian blood group)	Homo sapiens	173-177
31460017-5	2019	A GO-HA-Dox/Ptx system was significantly better than the GO-Dox/Ptx system at specifically killing CD44-expressing MDA-MB-231 cells but not BT-474 cells that do not express CD44.	Paclitaxel	64-67	CD44 molecule (Indian blood group)	Homo sapiens	99-103
31334335-0	2019	FoxM1 Induced Paclitaxel Resistance via Activation of the FoxM1/PHB1/RAF-MEK-ERK Pathway and Enhancement of the ABCA2 Transporter.	Paclitaxel	14-24	ATP binding cassette subfamily A member 2	Homo sapiens	112-117
31334335-1	2019	FoxM1 amplification in human pancreatic cancer predicts poor prognosis and resistance to paclitaxel.	Paclitaxel	89-99	forkhead box M1	Homo sapiens	0-5
31334335-2	2019	Here, a novel role between FoxM1 (FoxM1b and FoxM1c) and Prohibitin1 (PHB1) in paclitaxel resistance has been identified.	Paclitaxel	79-89	forkhead box M1	Homo sapiens	27-32
28407690-2	2017	After treated with cisplatin, MG132, paclitaxel and SAHA, BTG3 transfectants exhibited lower viability and higher apoptosis than the control in both time- and dose-dependent manners.	Paclitaxel	37-47	BTG anti-proliferation factor 3	Homo sapiens	58-62
31334335-2	2019	Here, a novel role between FoxM1 (FoxM1b and FoxM1c) and Prohibitin1 (PHB1) in paclitaxel resistance has been identified.	Paclitaxel	79-89	forkhead box M1	Homo sapiens	34-40
31334335-2	2019	Here, a novel role between FoxM1 (FoxM1b and FoxM1c) and Prohibitin1 (PHB1) in paclitaxel resistance has been identified.	Paclitaxel	79-89	forkhead box M1	Homo sapiens	45-51
31334335-5	2019	FoxM1 contributed to the PHB1/C-RAF interaction and phosphorylation of ERK1/2 kinases, thus promoting paclitaxel resistance.	Paclitaxel	102-112	forkhead box M1	Homo sapiens	0-5
31334335-6	2019	Notably, FoxM1 conferred tumor cell resistance to paclitaxel, but knocking down PHB1 could sensitize pancreatic cancer cells to it.	Paclitaxel	50-60	forkhead box M1	Homo sapiens	9-14
31334335-7	2019	Besides, we identified that ABCA2 promoted paclitaxel resistance under the regulation of FoxM1/PHB1/RAF-MEK-ERK.	Paclitaxel	43-53	ATP binding cassette subfamily A member 2	Homo sapiens	28-33
31334335-7	2019	Besides, we identified that ABCA2 promoted paclitaxel resistance under the regulation of FoxM1/PHB1/RAF-MEK-ERK.	Paclitaxel	43-53	forkhead box M1	Homo sapiens	89-94
28159518-4	2017	Here, we describe the design, synthesis, physico-chemical characterization and the biological evaluation of an NCAM-targeted conjugate of polyglutamic acid with paclitaxel that was developed and evaluated on neuroblastoma, a high NCAM-expressing tumor.	Paclitaxel	161-171	neural cell adhesion molecule 1	Homo sapiens	111-115
31334335-9	2019	It increased the influx of paclitaxel into the cell, and it attenuated FoxM1-mediated paclitaxel resistance in vitro and in vivo.	Paclitaxel	86-96	forkhead box M1	Homo sapiens	71-76
31334335-11	2019	It was regulated by FoxM1 to maintain phosphorylation of ERK1/2 in drug-resistant cells, and FoxM1 simultaneously enhanced the function of ABCA2, which collectively contributed to paclitaxel resistance.	Paclitaxel	180-190	forkhead box M1	Homo sapiens	20-25
31334335-11	2019	It was regulated by FoxM1 to maintain phosphorylation of ERK1/2 in drug-resistant cells, and FoxM1 simultaneously enhanced the function of ABCA2, which collectively contributed to paclitaxel resistance.	Paclitaxel	180-190	forkhead box M1	Homo sapiens	93-98
31334335-11	2019	It was regulated by FoxM1 to maintain phosphorylation of ERK1/2 in drug-resistant cells, and FoxM1 simultaneously enhanced the function of ABCA2, which collectively contributed to paclitaxel resistance.	Paclitaxel	180-190	ATP binding cassette subfamily A member 2	Homo sapiens	139-144
31334335-12	2019	Targeting FoxM1 and its downstream effector PHB1 increased the sensitivity of pancreatic cells to paclitaxel treatment, providing potential therapeutic strategies for patients with paclitaxel resistance.	Paclitaxel	98-108	forkhead box M1	Homo sapiens	10-15
31334335-12	2019	Targeting FoxM1 and its downstream effector PHB1 increased the sensitivity of pancreatic cells to paclitaxel treatment, providing potential therapeutic strategies for patients with paclitaxel resistance.	Paclitaxel	181-191	forkhead box M1	Homo sapiens	10-15
31156720-12	2019	Conclusions: We suggest that cotargeting Plk1 and AR would be effective in advanced chemoresistant prostate cancer cells to overcome the limitations associated with paclitaxel.	Paclitaxel	165-175	polo like kinase 1	Homo sapiens	41-45
30779921-0	2019	miR-29c regulates resistance to paclitaxel in nasopharyngeal cancer by targeting ITGB1.	Paclitaxel	32-42	integrin subunit beta 1	Homo sapiens	81-86
28159518-4	2017	Here, we describe the design, synthesis, physico-chemical characterization and the biological evaluation of an NCAM-targeted conjugate of polyglutamic acid with paclitaxel that was developed and evaluated on neuroblastoma, a high NCAM-expressing tumor.	Paclitaxel	161-171	neural cell adhesion molecule 1	Homo sapiens	230-234
30779921-5	2019	We established Taxol resistance in two human NPC cell lines, SUNE-1 and C666-1 (SUNE-1-Taxol and C666-1-Taxol) and found that miR-29c was downregulated and integrin beta-1 (ITGB1) was upregulated in Taxol-resistant NPC cells compared with parental NPC cells.	Paclitaxel	15-20	integrin subunit beta 1	Homo sapiens	156-171
28108630-5	2017	The macropinocytic uptake of nab-paclitaxel induced macrophage immunostimulatory (M1) cytokine expression and synergized with IFNgamma to promote inducible nitric oxide synthase expression in a TLR4-dependent manner.	Paclitaxel	33-43	toll like receptor 4	Homo sapiens	194-198
30779921-5	2019	We established Taxol resistance in two human NPC cell lines, SUNE-1 and C666-1 (SUNE-1-Taxol and C666-1-Taxol) and found that miR-29c was downregulated and integrin beta-1 (ITGB1) was upregulated in Taxol-resistant NPC cells compared with parental NPC cells.	Paclitaxel	15-20	integrin subunit beta 1	Homo sapiens	173-178
30779921-6	2019	Further investigations using a TUNEL assay and BAX/BCL-2 ratio, found that overexpression of miR-29c and knockdown of ITGB1 can resensitize drug-resistant NPC cells to Taxol and promote apoptosis.	Paclitaxel	168-173	integrin subunit beta 1	Homo sapiens	118-123
30779921-8	2019	Furthermore, silencing miR-29c markedly increased Taxol-resistant NPC tumor growth in a nude mouse xenograft model while knockdown of ITGB1 reversed this result.	Paclitaxel	50-55	microRNA 29c	Mus musculus	23-30
30779921-9	2019	Overall, these data demonstrate that miR-29c regulates resistance to Taxol in NPC by targeting ITGB1.	Paclitaxel	69-74	integrin subunit beta 1	Homo sapiens	95-100
31205528-7	2019	The association between P16 methylation and the sensitivity of paclitaxel in cell lines was determined by in vitro assay using a P16-specific DNA demethylase (P16-TET) and methyltransferase (P16-Dnmt).	Paclitaxel	63-73	DNA methyltransferase 1	Homo sapiens	195-199
31205528-10	2019	In contrast, P16-specific methylation by P16-Dnmt significantly increased paclitaxel resistance of lung cancer HCC827 cells and gastric cancer BGC823 cells (IC50 values increased from 18.2 to 24.0 ng/ml and 0.18 to 0.81 microg/ml, respectively; P=0.049 and &lt;0.001, respectively).	Paclitaxel	74-84	DNA methyltransferase 1	Homo sapiens	45-49
28112370-3	2017	In the present study, we evaluated the influence of anticancer agents 5-fluorouracil, gemcitabine and paclitaxel on PD-L1 expression in human pancreatic cancer cell lines MIA PaCa-2 and AsPC-1 and in murine pancreatic cancer cell line Pan02.	Paclitaxel	102-112	CD274 molecule	Homo sapiens	116-121
30421506-0	2019	Potentiation of paclitaxel effect by resveratrol in human breast cancer cells by counteracting the 17beta-estradiol/estrogen receptor alpha/neuroglobin pathway.	Paclitaxel	16-26	neuroglobin	Homo sapiens	140-151
30802327-4	2019	Taxol, a beta-tubulin binding and MT stabilizing drug, was found to abolish this CXCL1- and fMLP-stimulated MT polymerization.	Paclitaxel	0-5	C-X-C motif chemokine ligand 1	Homo sapiens	81-86
30802327-8	2019	Nevertheless, and consistent with its ability to suppress MT polymerization induced by soluble CXCL1 and fMLP, taxol treatment inhibited neutrophil chemotaxis toward both chemotactic peptides.	Paclitaxel	111-116	C-X-C motif chemokine ligand 1	Homo sapiens	95-100
30802327-9	2019	Taxol treatment also suppressed CXCL1- and fMLP-triggered elastase-dependent neutrophil invasion through collagen I barriers.	Paclitaxel	0-5	C-X-C motif chemokine ligand 1	Homo sapiens	32-37
28112370-5	2017	We observed that when AsPC-1, MIA PaCa-2 and Pan02 cells were stimulated by 5-fluorouracil, gemcitabine or paclitaxel, PD-L1 surface protein expression was enhanced.	Paclitaxel	107-117	CD274 molecule	Homo sapiens	119-124
28182729-11	2017	Ghrelin receptor antagonist reversed the RKT-induced attenuation of paclitaxel-induced mechanical hyperalgesia.	Paclitaxel	68-78	growth hormone secretagogue receptor	Mus musculus	0-16
30496702-5	2019	Consistent with this result, Hsp105 knockdown increased the number of anaphase cells with lagging chromosomes, through mitotic slippage, and decreased taxol sensitivity more than Mad2 knockdown.	Paclitaxel	151-156	heat shock protein family H (Hsp110) member 1	Homo sapiens	29-35
27887917-0	2017	MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.	Paclitaxel	86-96	notch receptor 3	Homo sapiens	154-160
30260001-6	2019	Melatonin and taxol markedly reduced DJ-1 and ID-1 and increased KLF17 messenger RNA and protein expression levels.	Paclitaxel	14-19	Kruppel like factor 17	Homo sapiens	65-70
30817750-8	2019	Multivariate analysis revealed four SNPs in VKORC1 (rs2884737), SLC22A14 (rs4679028), GSTA2 (rs6577), and DCK (rs4643786) were associated with paclitaxel toxicities.	Paclitaxel	143-153	solute carrier family 22 member 14	Homo sapiens	64-72
27887917-1	2017	To identify microRNAs (miRNAs) regulating Notch3 expression in association with paclitaxel resistance, candidate miRNAs targeting Notch3 were predicted using TargetScan.	Paclitaxel	80-90	notch receptor 3	Homo sapiens	42-48
27887917-1	2017	To identify microRNAs (miRNAs) regulating Notch3 expression in association with paclitaxel resistance, candidate miRNAs targeting Notch3 were predicted using TargetScan.	Paclitaxel	80-90	notch receptor 3	Homo sapiens	130-136
27887917-3	2017	Artificial miR-136 overexpression significantly reduced cell viability, proliferation, Cancer stem cell (CSC) spheroid formation, and angiogenesis, and increased apoptosis in paclitaxel-resistant SKpac cells compared with the effects of paclitaxel alone.	Paclitaxel	175-185	microRNA 136	Homo sapiens	11-18
30881589-13	2019	Furthermore, alpha-LA could reverse the mRNA and protein expressions of Nrf2 (nuclear factor erythroid 2-related factor 2) and three Nrf2-responsive genes (HO-1, gamma-GCLC, and NQO1) altered by nab-PTX in the dorsal root ganglion (DRG) of rats.	Paclitaxel	199-202	heme oxygenase 1	Rattus norvegicus	156-172
27887917-6	2017	miR-136 overexpression resensitized paclitaxel-resistant ovarian cancer cells and reduced CSC activities, suggesting a promising new target for the treatment of chemoresistant ovarian cancers.	Paclitaxel	36-46	microRNA 136	Homo sapiens	0-7
30778300-3	2019	When mouse MG6 cells were stimulated with the TLR4 ligands lipopolysaccharide (LPS) and paclitaxel, we found that interferon regulatory factor 1 (IRF1) protein expression and activation was upregulated, transcription of interferon-beta (IFN-beta) was accelerated, induction/activation of STAT1 and activation of STAT3 were promoted, and subsequently iNOS expression was upregulated.	Paclitaxel	88-98	interferon beta 1, fibroblast	Mus musculus	220-235
28077325-12	2017	This data indicates that 14-3-3sigma contributes to P-gp overexpression through interaction with PXR with rifampin and paclitaxel treatment.	Paclitaxel	119-129	stratifin	Homo sapiens	25-36
30778300-3	2019	When mouse MG6 cells were stimulated with the TLR4 ligands lipopolysaccharide (LPS) and paclitaxel, we found that interferon regulatory factor 1 (IRF1) protein expression and activation was upregulated, transcription of interferon-beta (IFN-beta) was accelerated, induction/activation of STAT1 and activation of STAT3 were promoted, and subsequently iNOS expression was upregulated.	Paclitaxel	88-98	interferon beta 1, fibroblast	Mus musculus	237-245
30778300-3	2019	When mouse MG6 cells were stimulated with the TLR4 ligands lipopolysaccharide (LPS) and paclitaxel, we found that interferon regulatory factor 1 (IRF1) protein expression and activation was upregulated, transcription of interferon-beta (IFN-beta) was accelerated, induction/activation of STAT1 and activation of STAT3 were promoted, and subsequently iNOS expression was upregulated.	Paclitaxel	88-98	signal transducer and activator of transcription 1	Mus musculus	288-293
25136768-0	2017	Insulin-like growth factor-1 attenuates apoptosis and protects neurochemical phenotypes of dorsal root ganglion neurons with paclitaxel-induced neurotoxicity in vitro.	Paclitaxel	125-135	insulin-like growth factor 1	Rattus norvegicus	0-28
25136768-4	2017	In this study, primary cultured rat DRG neurons were used to assess the effects of IGF-1 on DRG neurons with PT-induced neurotoxicity.	Paclitaxel	109-111	insulin-like growth factor 1	Rattus norvegicus	83-88
25136768-6	2017	PT exposure caused a decrease of cell viability and an increase in the ratio of apoptotic cells which could be reversed by IGF-1.	Paclitaxel	0-2	insulin-like growth factor 1	Rattus norvegicus	123-128
30670682-5	2019	We show that coupling septins (including SEPT9_i1) overexpression together with long-chain tubulin polyglutamylation induce significant paclitaxel resistance in several naive (taxane-sensitive) cell lines and accordingly stimulate the binding of CLIP-170 and MCAK to microtubules.	Paclitaxel	136-146	CAP-Gly domain containing linker protein 1	Homo sapiens	246-254
30670682-5	2019	We show that coupling septins (including SEPT9_i1) overexpression together with long-chain tubulin polyglutamylation induce significant paclitaxel resistance in several naive (taxane-sensitive) cell lines and accordingly stimulate the binding of CLIP-170 and MCAK to microtubules.	Paclitaxel	136-146	kinesin family member 2C	Homo sapiens	259-263
27821487-0	2017	Circadian Clock Gene Bmal1 Inhibits Tumorigenesis and Increases Paclitaxel Sensitivity in Tongue Squamous Cell Carcinoma.	Paclitaxel	64-74	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	21-26
30668583-2	2019	Syk inhibition was found to stabilize microtubules and potentiate paclitaxel activity in cellular models of taxane-resistant ovarian cancers.	Paclitaxel	66-76	spleen associated tyrosine kinase	Homo sapiens	0-3
27821487-3	2017	In this study, we investigated whether the circadian clock gene Bmal1 inhibited tumor development and increased paclitaxel sensitivity in tongue squamous cell carcinoma (TSCC).	Paclitaxel	112-122	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	64-69
30774764-0	2019	Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression.	Paclitaxel	37-47	MDM2 proto-oncogene	Homo sapiens	95-99
27821487-6	2017	After exposure to paclitaxel, Bmal1-overexpressing cells displayed a relative increase in apoptosis and were more susceptible to paclitaxel treatment in vivo Mechanistic investigations suggested a regulatory connection between Bmal1, TERT, and the oncogenic transcriptional repressor EZH2 (enhancer of zeste homolog 2), the recruitment of which to the TERT promoter increased paclitaxel-induced apoptosis and cell growth inhibition.	Paclitaxel	18-28	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	30-35
30774764-10	2019	MDM2 was upregulated in paclitaxel resistant cells compared with parental cells.	Paclitaxel	24-34	MDM2 proto-oncogene	Homo sapiens	0-4
27821487-6	2017	After exposure to paclitaxel, Bmal1-overexpressing cells displayed a relative increase in apoptosis and were more susceptible to paclitaxel treatment in vivo Mechanistic investigations suggested a regulatory connection between Bmal1, TERT, and the oncogenic transcriptional repressor EZH2 (enhancer of zeste homolog 2), the recruitment of which to the TERT promoter increased paclitaxel-induced apoptosis and cell growth inhibition.	Paclitaxel	18-28	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	227-232
30774764-11	2019	MDM2 inhibition also resensitized resistant cells to paclitaxel and forced MDM2 induced paclitaxel resistance in parental cells.	Paclitaxel	53-63	MDM2 proto-oncogene	Homo sapiens	0-4
30774764-11	2019	MDM2 inhibition also resensitized resistant cells to paclitaxel and forced MDM2 induced paclitaxel resistance in parental cells.	Paclitaxel	88-98	MDM2 proto-oncogene	Homo sapiens	0-4
27821487-6	2017	After exposure to paclitaxel, Bmal1-overexpressing cells displayed a relative increase in apoptosis and were more susceptible to paclitaxel treatment in vivo Mechanistic investigations suggested a regulatory connection between Bmal1, TERT, and the oncogenic transcriptional repressor EZH2 (enhancer of zeste homolog 2), the recruitment of which to the TERT promoter increased paclitaxel-induced apoptosis and cell growth inhibition.	Paclitaxel	18-28	telomerase reverse transcriptase	Mus musculus	234-238
30774764-11	2019	MDM2 inhibition also resensitized resistant cells to paclitaxel and forced MDM2 induced paclitaxel resistance in parental cells.	Paclitaxel	88-98	MDM2 proto-oncogene	Homo sapiens	75-79
27821487-6	2017	After exposure to paclitaxel, Bmal1-overexpressing cells displayed a relative increase in apoptosis and were more susceptible to paclitaxel treatment in vivo Mechanistic investigations suggested a regulatory connection between Bmal1, TERT, and the oncogenic transcriptional repressor EZH2 (enhancer of zeste homolog 2), the recruitment of which to the TERT promoter increased paclitaxel-induced apoptosis and cell growth inhibition.	Paclitaxel	129-139	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	30-35
30774764-13	2019	Furthermore, a public database showed that high MDM2 expression was associated with a shorter progression-free survival in EOC patients treated with paclitaxel.	Paclitaxel	149-159	MDM2 proto-oncogene	Homo sapiens	48-52
27821487-6	2017	After exposure to paclitaxel, Bmal1-overexpressing cells displayed a relative increase in apoptosis and were more susceptible to paclitaxel treatment in vivo Mechanistic investigations suggested a regulatory connection between Bmal1, TERT, and the oncogenic transcriptional repressor EZH2 (enhancer of zeste homolog 2), the recruitment of which to the TERT promoter increased paclitaxel-induced apoptosis and cell growth inhibition.	Paclitaxel	129-139	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	30-35
27821487-7	2017	Clinically, paclitaxel efficacy correlated positively with Bmal1 expression levels in TSCC.	Paclitaxel	12-22	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	59-64
27821487-8	2017	Overall, our results identified Bmal1 as a novel tumor suppressor gene that elevates the sensitivity of cancer cells to paclitaxel, with potential implications as a chronotherapy timing biomarker in TSCC.	Paclitaxel	120-130	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	32-37
27010394-2	2017	When progression occurs on Bmab monotherapy, one possible option is re-induction with the combination of Bmab and PTX (rBP therapy), because PTX was previously stopped due to toxicity rather than progression.	Paclitaxel	114-117	retinol binding protein 4	Rattus norvegicus	119-122
30719181-8	2019	GRP94-KD OS cells were more resistant to paclitaxel, gemcitabine, and epirubicin treatments than cells transfected with the scrambled control, and more cells transfected with the scrambled control underwent apoptosis after paclitaxel, gemcitabine, and epirubicin treatments than GRP94-KD cells.	Paclitaxel	41-51	heat shock protein 90 beta family member 1	Homo sapiens	0-5
30719181-8	2019	GRP94-KD OS cells were more resistant to paclitaxel, gemcitabine, and epirubicin treatments than cells transfected with the scrambled control, and more cells transfected with the scrambled control underwent apoptosis after paclitaxel, gemcitabine, and epirubicin treatments than GRP94-KD cells.	Paclitaxel	223-233	heat shock protein 90 beta family member 1	Homo sapiens	0-5
30719181-9	2019	Conclusions: Therefore, GRP94 silencing may increase the resistance of MG63 and 143B cells to paclitaxel, gemcitabine, and epirubicin treatments by inhibiting the induction of apoptosis.	Paclitaxel	94-104	heat shock protein 90 beta family member 1	Homo sapiens	24-29
27010394-2	2017	When progression occurs on Bmab monotherapy, one possible option is re-induction with the combination of Bmab and PTX (rBP therapy), because PTX was previously stopped due to toxicity rather than progression.	Paclitaxel	141-144	retinol binding protein 4	Rattus norvegicus	119-122
30183517-11	2019	In vivo, [valproate + palbociclib] and [neratinib + valproate + palbociclib] interacted to suppress the growth of a carboplatin/paclitaxel resistant PDX ovarian tumors that express a mutant N-RAS.	Paclitaxel	128-138	NRAS proto-oncogene, GTPase	Homo sapiens	190-195
27716527-8	2017	The PTX-M remarkably increased the upregulation of Bax, caspase-3, caspase-9, and PARP-1 expression and downregulated the Bcl-2 expression in K562 cancer cells.	Paclitaxel	4-7	caspase 9	Homo sapiens	67-76
30431082-11	2019	Notably, ERp57-siRNA and 100 nM paclitaxel co-treatment downregulated Bcl-2, Bcl-xl, MMP2, MMP9, TUBB3 and P-gp expression levels and upregulated the expression of Bax protein.	Paclitaxel	32-42	matrix metallopeptidase 9	Homo sapiens	91-95
28420840-0	2017	Successful Long-term Management with a Single Administration of Tri-weekly Nab-paclitaxel in a Patient with Advanced Gastric Cancer with Peritoneal Dissemination.	Paclitaxel	79-89	tRNA-Ile (anticodon AAT) 9-1	Homo sapiens	64-67
30112929-3	2018	Herein, we report a novel dual-functional paclitaxel (PTX) liposome system possessing both CD44-targeting and mitochondrial-targeting properties to enhance drug accumulation in mitochondria and trigger apoptosis of drug-resistant cancer cells.	Paclitaxel	42-52	CD44 molecule (Indian blood group)	Homo sapiens	91-95
30112929-3	2018	Herein, we report a novel dual-functional paclitaxel (PTX) liposome system possessing both CD44-targeting and mitochondrial-targeting properties to enhance drug accumulation in mitochondria and trigger apoptosis of drug-resistant cancer cells.	Paclitaxel	54-57	CD44 molecule (Indian blood group)	Homo sapiens	91-95
30038266-6	2018	Importantly, KLF4 inhibitor Kenpaullone sensitizes breast cancer cells and xenograft tumors to Paclitaxel and improves therapeutic effects.	Paclitaxel	95-105	Kruppel like factor 4	Homo sapiens	13-17
28679984-4	2017	The patient did not respond to FOLFIRINOX therapy (leucovorin, fluorouracil, irinotecan, and oxaliplatin), but nab-paclitaxel plus gemcitabine treatment was effective, resulting in tumor shrinkage and reduced G-CSF levels.	Paclitaxel	115-125	colony stimulating factor 3	Homo sapiens	209-214
30179299-0	2018	Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells.	Paclitaxel	47-57	CD44 molecule (Indian blood group)	Homo sapiens	88-92
30179299-7	2018	Furthermore, we established paclitaxel-resistant breast cancer cell lines and determined the function of ERalpha in the enhancement of paclitaxel resistance via the regulation of CD44 transcription.	Paclitaxel	28-38	CD44 molecule (Indian blood group)	Homo sapiens	179-183
30179299-7	2018	Furthermore, we established paclitaxel-resistant breast cancer cell lines and determined the function of ERalpha in the enhancement of paclitaxel resistance via the regulation of CD44 transcription.	Paclitaxel	135-145	CD44 molecule (Indian blood group)	Homo sapiens	179-183
30221728-6	2018	Autophagy was also activated by paclitaxel as observed by an elevated LC3-II level.	Paclitaxel	32-42	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	70-73
30221728-10	2018	Pristimerin and paclitaxel inhibited extracellular signal-regulated kinase (ERK)1/2/p90RSK signaling, consistent with autophagy indicators, namely p62 degradation and beclin 1 expression.	Paclitaxel	16-26	nucleoporin 62	Homo sapiens	147-150
30221728-10	2018	Pristimerin and paclitaxel inhibited extracellular signal-regulated kinase (ERK)1/2/p90RSK signaling, consistent with autophagy indicators, namely p62 degradation and beclin 1 expression.	Paclitaxel	16-26	beclin 1	Homo sapiens	167-175
28123557-6	2017	Notably, knockdown of the stress-response chaperone PPIA using small interfering RNA in MCF-7/PTX cells restored their sensitivity to paclitaxel.	Paclitaxel	134-144	peptidylprolyl isomerase A	Homo sapiens	52-56
30221728-11	2018	In addition, ERK activator ceramide C6 treatment suppressed the LC3-II levels induced by a combination of paclitaxel and pristimerin.	Paclitaxel	106-116	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	64-67
30099017-7	2018	Meanwhile, the antimetastasis mechanism studies confirmed that the combination of the chemotherapeutic PTX and the autophagy inhibitor HCQ further suppressed the degradation of paxillin, the expression of MMP9 and MMP2.	Paclitaxel	103-106	matrix metallopeptidase 2	Mus musculus	214-218
30516483-4	2018	PACT Admiral (Medtronic Inc. USA) with Free Pac coating containing urea and paclitaxel, the method of SAFARI (Subintimal Arterial Flossing with Antegrade-Retrograde Intervention).	Paclitaxel	76-86	RB binding protein 6, ubiquitin ligase	Homo sapiens	0-4
28123557-7	2017	These findings indicated that PPIA may have an important role in paclitaxel resistance in MCF-7/PTX cells.	Paclitaxel	65-75	peptidylprolyl isomerase A	Homo sapiens	30-34
27840408-0	2016	Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.	Paclitaxel	98-108	cathepsin L	Mus musculus	0-11
27840408-10	2016	RESULTS: Cisplatin or paclitaxel treatment (10-80 ng/mL) induced CTSL expression in A549 cells.	Paclitaxel	22-32	cathepsin L	Mus musculus	65-69
27863655-7	2016	In conclusion, mucoadhesive, drug solubilising GCPh nanoparticles enable the oral absorption of paclitaxel via the saturation of the P-gp pump (by high local drug concentrations) and by particle uptake and tight junction opening mechanisms.	Paclitaxel	96-106	phosphoglycolate phosphatase	Homo sapiens	133-137
30235479-4	2018	Paclitaxel-induced PS exposure in RBC was mediated by scramblase activation which was induced by calcium-independent protein kinase C (PKC)zeta activation.	Paclitaxel	0-10	protein kinase C zeta	Homo sapiens	135-143
29957956-0	2018	CD44-Targeted Polymer-Paclitaxel Conjugates to Control the Spread and Growth of Metastatic Tumors.	Paclitaxel	22-32	CD44 antigen	Mus musculus	0-4
14654788-0	2003	Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells.	Paclitaxel	45-55	stathmin 1	Homo sapiens	33-41
27723260-2	2016	Here, we have designed and developed targeted dual pH-sensitive lipid-siRNA self-assembly nanoparticles, RGD-PEG(HZ)-ECO/siRNA, which can efficiently silence the oncogene, eukaryotic translation initiation factor 4E (eIF4E), and consequently resensitize triple-negative breast tumors to paclitaxel.	Paclitaxel	287-297	eukaryotic translation initiation factor 4E	Mus musculus	172-215
12954630-4	2003	BJAB as well as MCF10A cells expressing moderate levels of C-FADD with a S194E mutation mimicking phosphorylated C-FADD were more susceptible to a Taxol-induced G2/M arrest than cells expressing C-FADD S194A suggesting that C-FADD S194E lowers the threshold for G2/M arrest.	Paclitaxel	147-152	Fas (TNFRSF6)-associated via death domain	Mus musculus	61-65
30015868-0	2018	NT21MP negatively regulates paclitaxel-resistant cells by targeting miR-155-3p and miR-155-5p via the CXCR4 pathway in breast cancer.	Paclitaxel	28-38	microRNA 155	Homo sapiens	68-75
30015868-0	2018	NT21MP negatively regulates paclitaxel-resistant cells by targeting miR-155-3p and miR-155-5p via the CXCR4 pathway in breast cancer.	Paclitaxel	28-38	microRNA 155	Homo sapiens	83-90
30015868-0	2018	NT21MP negatively regulates paclitaxel-resistant cells by targeting miR-155-3p and miR-155-5p via the CXCR4 pathway in breast cancer.	Paclitaxel	28-38	C-X-C motif chemokine receptor 4	Homo sapiens	102-107
30015868-3	2018	An miRNA microarray was used to show that miR-155-3p was downregulated whereas miR-155-5p was upregulated in paclitaxel-resistant (PR) cells compared with parental breast cancer cells.	Paclitaxel	109-119	microRNA 155	Homo sapiens	79-86
30015868-11	2018	Taken together, these findings suggested that miR-155-3p/5p and their target genes MYD88 and TP53INP1 may serve as novel biomarkers for NT21MP therapy through the CXCR4 pathway for improving sensitivity to paclitaxel in breast cancer.	Paclitaxel	206-216	microRNA 155	Homo sapiens	46-53
30015868-11	2018	Taken together, these findings suggested that miR-155-3p/5p and their target genes MYD88 and TP53INP1 may serve as novel biomarkers for NT21MP therapy through the CXCR4 pathway for improving sensitivity to paclitaxel in breast cancer.	Paclitaxel	206-216	C-X-C motif chemokine receptor 4	Homo sapiens	163-168
12954630-4	2003	BJAB as well as MCF10A cells expressing moderate levels of C-FADD with a S194E mutation mimicking phosphorylated C-FADD were more susceptible to a Taxol-induced G2/M arrest than cells expressing C-FADD S194A suggesting that C-FADD S194E lowers the threshold for G2/M arrest.	Paclitaxel	147-152	Fas (TNFRSF6)-associated via death domain	Mus musculus	115-119
12954630-4	2003	BJAB as well as MCF10A cells expressing moderate levels of C-FADD with a S194E mutation mimicking phosphorylated C-FADD were more susceptible to a Taxol-induced G2/M arrest than cells expressing C-FADD S194A suggesting that C-FADD S194E lowers the threshold for G2/M arrest.	Paclitaxel	147-152	Fas (TNFRSF6)-associated via death domain	Mus musculus	115-119
12954630-4	2003	BJAB as well as MCF10A cells expressing moderate levels of C-FADD with a S194E mutation mimicking phosphorylated C-FADD were more susceptible to a Taxol-induced G2/M arrest than cells expressing C-FADD S194A suggesting that C-FADD S194E lowers the threshold for G2/M arrest.	Paclitaxel	147-152	Fas (TNFRSF6)-associated via death domain	Mus musculus	115-119
27723260-2	2016	Here, we have designed and developed targeted dual pH-sensitive lipid-siRNA self-assembly nanoparticles, RGD-PEG(HZ)-ECO/siRNA, which can efficiently silence the oncogene, eukaryotic translation initiation factor 4E (eIF4E), and consequently resensitize triple-negative breast tumors to paclitaxel.	Paclitaxel	287-297	eukaryotic translation initiation factor 4E	Mus musculus	217-222
30004169-4	2018	Then, using MTT and soft agar assays of paclitaxel-treated Caov3 and SKOV3 cells transfected with miR-874-3p and miR-874-5p, we found that miR-874-3p and miR-874-5p enhance EOC cell chemosensitivity.	Paclitaxel	40-50	microRNA 874	Homo sapiens	98-105
30004169-4	2018	Then, using MTT and soft agar assays of paclitaxel-treated Caov3 and SKOV3 cells transfected with miR-874-3p and miR-874-5p, we found that miR-874-3p and miR-874-5p enhance EOC cell chemosensitivity.	Paclitaxel	40-50	microRNA 874	Homo sapiens	113-120
27723260-5	2016	In addition, treatment of athymic nude mice with RGD-PEG(HZ)-ECO/sieIF4E every 6 days for 6 weeks down-regulates the overexpression of eIF4E and resensitizes paclitaxel-resistant MDA-MB-231 tumors to paclitaxel, resulting in significant tumor regression at a low dose, with negligible side effects.	Paclitaxel	158-168	eukaryotic translation initiation factor 4E	Mus musculus	67-72
30004169-4	2018	Then, using MTT and soft agar assays of paclitaxel-treated Caov3 and SKOV3 cells transfected with miR-874-3p and miR-874-5p, we found that miR-874-3p and miR-874-5p enhance EOC cell chemosensitivity.	Paclitaxel	40-50	microRNA 874	Homo sapiens	113-120
30004169-4	2018	Then, using MTT and soft agar assays of paclitaxel-treated Caov3 and SKOV3 cells transfected with miR-874-3p and miR-874-5p, we found that miR-874-3p and miR-874-5p enhance EOC cell chemosensitivity.	Paclitaxel	40-50	microRNA 874	Homo sapiens	113-120
27723260-5	2016	In addition, treatment of athymic nude mice with RGD-PEG(HZ)-ECO/sieIF4E every 6 days for 6 weeks down-regulates the overexpression of eIF4E and resensitizes paclitaxel-resistant MDA-MB-231 tumors to paclitaxel, resulting in significant tumor regression at a low dose, with negligible side effects.	Paclitaxel	200-210	eukaryotic translation initiation factor 4E	Mus musculus	67-72
29660518-0	2018	HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.	Paclitaxel	49-59	homeobox B4	Homo sapiens	0-5
27669502-6	2016	RESULTS: Global RNA expression profiling and subsequent correlation studies of gene expression level and drug response has identified that elevated expression of cyclin A1 (CCNA1) was significantly associated with cellular resistance to paclitaxel, doxorubicin and 5-fluorouracil.	Paclitaxel	237-247	cyclin A1	Homo sapiens	162-171
29660518-2	2018	The aim of this study was to test whether knockdown of Homeobox B4 (HOXB4) enhanced the cytotoxic effect of paclitaxel and cisplatin in ovarian cancer cells.	Paclitaxel	108-118	homeobox B4	Homo sapiens	55-66
29660518-2	2018	The aim of this study was to test whether knockdown of Homeobox B4 (HOXB4) enhanced the cytotoxic effect of paclitaxel and cisplatin in ovarian cancer cells.	Paclitaxel	108-118	homeobox B4	Homo sapiens	68-73
29660518-3	2018	HOXB4 expressions at mRNA and protein levels were upregulated in Taxol-resistant A2780 (A2780/Taxol) and DDP-resistant SKOV-3 (SKOV-3/DDP) cells.	Paclitaxel	65-70	homeobox B4	Homo sapiens	0-5
14556633-11	2003	Heterozygous expression of Kalpha1- or betaI-tubulin mutants that introduced mass changes as small as 26 Da was readily detected in native tubulins isolated from Taxol- and epothilone-resistant cell lines.	Paclitaxel	162-167	tubulin alpha 1b	Homo sapiens	27-34
14583493-4	2003	We found that the combined treatment of paclitaxel and MEK inhibitor uniquely altered the proteins RS/DJ-1 (RNA-binding regulatory subunit/DJ-1 PARK7) and RhoGDIalpha (Rho GDP-dissociation inhibitor alpha).	Paclitaxel	40-50	Rho GDP dissociation inhibitor alpha	Homo sapiens	168-204
29660518-4	2018	HOXB4 knockdown enhanced the cytotoxic effects of Taxol and DDP in A2780/Taxol and SKOV-3/DDP cells, respectively.	Paclitaxel	50-55	homeobox B4	Homo sapiens	0-5
27895747-0	2016	Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9.	Paclitaxel	59-69	ATP binding cassette subfamily B member 9	Homo sapiens	130-135
29660518-7	2018	These findings revealed that HOXB4 knockdown enhanced the cytotoxic effects of Taxol and DDP by downregulating ABC transporters via inhibiting the PI3K/Akt pathway in ovarian cancer cells.	Paclitaxel	79-84	homeobox B4	Homo sapiens	29-34
14566475-12	2003	The MTD of paclitaxel was reached at the third dose level (30 mg/m(2) paclitaxel twice weekly).	Paclitaxel	11-21	metallothionein 1E	Homo sapiens	4-7
14566475-12	2003	The MTD of paclitaxel was reached at the third dose level (30 mg/m(2) paclitaxel twice weekly).	Paclitaxel	70-80	metallothionein 1E	Homo sapiens	4-7
27664577-9	2016	Employing mRNA expression profiling of all known human ABC transporters and subsequent Western blot analysis of the expression of selected transporters, we demonstrated that only the ABCB1/PgP and ABCC3/MRP3 proteins were up-regulated in both paclitaxel-resistant sublines.	Paclitaxel	243-253	phosphoglycolate phosphatase	Homo sapiens	189-192
30008617-9	2018	The monoclonal antibody of B7-H4 has the potential anti-proliferative effects on inhibiting the chemoresistant TNBC cell lines and increasing the sensitivity of TNBC cell lines to doxorubicin, paclitaxel or carboplatin.	Paclitaxel	193-203	V-set domain containing T cell activation inhibitor 1	Homo sapiens	27-32
27822069-0	2016	SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer.	Paclitaxel	56-66	secreted protein acidic and cysteine rich	Homo sapiens	0-5
29781242-3	2018	The self-assembling morphology of microtubules can be photo-tuned by the host-guest interaction of paclitaxel-modified beta-cyclodextrin (PTX-CD) and photochromic arylazopyrazole (PTX-AAP).	Paclitaxel	99-109	serpin family F member 2	Homo sapiens	184-187
12951060-8	2003	Inhibition of Src enhances the cell killing effects of both paclitaxel and cisplatinum.	Paclitaxel	60-70	Rous sarcoma oncogene	Mus musculus	14-17
12973835-5	2003	The underlying molecular mechanism is that ErbB2 inhibits p34(Cdc2) activation, which is required for taxol-induced apoptosis, by up-regulating p21(Cip1) and by hyperphosphorylating p34(Cdc2) on tyrosine-15.	Paclitaxel	102-107	cyclin dependent kinase 1	Homo sapiens	62-66
12973835-5	2003	The underlying molecular mechanism is that ErbB2 inhibits p34(Cdc2) activation, which is required for taxol-induced apoptosis, by up-regulating p21(Cip1) and by hyperphosphorylating p34(Cdc2) on tyrosine-15.	Paclitaxel	102-107	cyclin dependent kinase 1	Homo sapiens	186-190
28934847-0	2018	Participation of CCL1 in Snail-Positive Fibroblasts in Colorectal Cancer Contribute to 5-Fluorouracil/Paclitaxel Chemoresistance.	Paclitaxel	102-112	snail family zinc finger 1	Mus musculus	25-30
27822069-2	2016	Secreted protein acidic and rich in cysteine (SPARC) binds to albumin, suggesting that SPARC plays an important role in tumor uptake of nab-paclitaxel.	Paclitaxel	140-150	secreted protein acidic and cysteine rich	Homo sapiens	0-44
28934847-9	2018	CT26 co-cultured with 3T3-Snail resisted the impairment from 5-fluorouracil and paclitaxel in vitro.	Paclitaxel	80-90	snail family zinc finger 1	Mus musculus	26-31
28934847-12	2018	Conclusion: Taken together, Snail-expressing 3T3 fibroblasts display CAFs properties that support 5-fluorouracil and paclitaxel chemoresistance in CRC via participation of CCL1 and suggest that inhibition of the Snail-expression fibroblasts in tumor may be a useful strategy to limit chemoresistance.	Paclitaxel	117-127	snail family zinc finger 1	Mus musculus	28-33
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Paclitaxel	28-38	TNF receptor superfamily member 10b	Homo sapiens	179-182
27822069-2	2016	Secreted protein acidic and rich in cysteine (SPARC) binds to albumin, suggesting that SPARC plays an important role in tumor uptake of nab-paclitaxel.	Paclitaxel	140-150	secreted protein acidic and cysteine rich	Homo sapiens	46-51
27822069-2	2016	Secreted protein acidic and rich in cysteine (SPARC) binds to albumin, suggesting that SPARC plays an important role in tumor uptake of nab-paclitaxel.	Paclitaxel	140-150	secreted protein acidic and cysteine rich	Homo sapiens	87-92
29936454-5	2018	RESULTS: Paclitaxel was three-fold more cytotoxic towards human oral squamous cell carcinoma cell lines (Ca9-22, HSC-2, HSC-3.	Paclitaxel	9-19	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	120-125
27822069-9	2016	Furthermore, patients with high stromal SPARC reactivity in biopsy specimens such as transbronchial lung biopsy or surgical specimens tended to respond better to nab-paclitaxel.	Paclitaxel	166-176	secreted protein acidic and cysteine rich	Homo sapiens	40-45
27822069-11	2016	SPARC may be a useful predictive marker for selecting patients likely to respond favorably to nab-paclitaxel treatment.	Paclitaxel	98-108	secreted protein acidic and cysteine rich	Homo sapiens	0-5
27830010-0	2016	Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer.	Paclitaxel	78-88	glutaminase	Homo sapiens	0-11
29757876-10	2018	Of 8 patients who received carboplatin with paclitaxel, 3 (38%) had an HSR (20% of all patients who had an HSR [3/15]).	Paclitaxel	44-54	HSR	Homo sapiens	71-74
29897944-6	2018	Autophagic flux upon paclitaxel treatment in vitro was assessed by immunoblotting of LC3B-II and quantitative assessment of WIP1 mRNA.	Paclitaxel	21-31	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	124-128
29897944-11	2018	High p62 cytoplasmic expression on its own (p &lt;= 0.001), or in combination with low LC3B (p = 0.034), was associated with nonresponse to chemotherapy, regardless of whether or not the regiments contained paclitaxel, but there was no independent prognostic value of LC3B or p62 expression patterns for EAC after neoadjuvant treatment.	Paclitaxel	207-217	nucleoporin 62	Homo sapiens	5-8
12912971-0	2003	Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer.	Paclitaxel	76-86	epidermal growth factor receptor	Mus musculus	0-32
12912971-3	2003	The objective of this study was to determine the efficacy of paclitaxel and PKI166, a novel inhibitor of EGFR, against oral cavity cancer.	Paclitaxel	61-71	epidermal growth factor receptor	Mus musculus	105-109
27777872-0	2016	Sodium channel Nav1.7 expression is upregulated in the dorsal root ganglia in a rat model of paclitaxel-induced peripheral neuropathy.	Paclitaxel	93-103	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	15-21
12885812-7	2003	CONCLUSION: Arm 1, paclitaxel 100 mg/m2 weekly for 3 of 4 weeks with carboplatin (AUC = 6) administered on day 1, demonstrates the most favorable therapeutic index in patients with advanced NSCLC.	Paclitaxel	19-29	ADRM1 26S proteasome ubiquitin receptor	Homo sapiens	12-17
29620264-6	2018	The expression levels of caspase-3/9 were significantly upregulated within PL-PTX-treated ovarian cancer cells.	Paclitaxel	78-81	caspase 3	Mus musculus	25-34
29723165-0	2018	Interleukin-22 (IL-22) Regulates Apoptosis of Paclitaxel-Resistant Non-Small Cell Lung Cancer Cells Through C-Jun N-Terminal Kinase Signaling Pathway.	Paclitaxel	46-56	interleukin 22	Homo sapiens	0-14
29723165-0	2018	Interleukin-22 (IL-22) Regulates Apoptosis of Paclitaxel-Resistant Non-Small Cell Lung Cancer Cells Through C-Jun N-Terminal Kinase Signaling Pathway.	Paclitaxel	46-56	interleukin 22	Homo sapiens	16-21
29723165-2	2018	The purpose of this study was to investigate whether IL-22 was involved in lung cancer cell resistance to paclitaxel (PTX), and to explore the underlying molecular mechanism.	Paclitaxel	106-116	interleukin 22	Homo sapiens	53-58
29723165-2	2018	The purpose of this study was to investigate whether IL-22 was involved in lung cancer cell resistance to paclitaxel (PTX), and to explore the underlying molecular mechanism.	Paclitaxel	118-121	interleukin 22	Homo sapiens	53-58
12887092-7	2003	Plk1 was not found in the spindle region when colchicine was used to inhibit microtubule organization, while it accumulated as several dots in the cytoplasm after taxol treatment.	Paclitaxel	163-168	polo like kinase 1	Sus scrofa	0-4
29723165-6	2018	To elucidate the mechanism by which IL-22 is involved in PTX resistance, a stable IL-22-silenced A549/PTX cell line was generated by using IL-22-siRNA.	Paclitaxel	57-60	interleukin 22	Homo sapiens	36-41
27777872-2	2016	Since the sodium channel Nav1.7 has been implicated in pain perception, and is upregulated in pain disorders, we investigated the effect of paclitaxel on Nav1.7 expression in rat dorsal root ganglion (DRG) neurons.	Paclitaxel	140-150	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	154-160
29723165-6	2018	To elucidate the mechanism by which IL-22 is involved in PTX resistance, a stable IL-22-silenced A549/PTX cell line was generated by using IL-22-siRNA.	Paclitaxel	102-105	interleukin 22	Homo sapiens	82-87
29723165-6	2018	To elucidate the mechanism by which IL-22 is involved in PTX resistance, a stable IL-22-silenced A549/PTX cell line was generated by using IL-22-siRNA.	Paclitaxel	102-105	interleukin 22	Homo sapiens	82-87
27777872-8	2016	DRG Nav1.7 mRNA and protein levels were higher in animals administered paclitaxel than those administered vehicle on days 7, 14 and 21 (all P &lt; 0.05).	Paclitaxel	71-81	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	4-10
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	73-76	interleukin 22	Homo sapiens	22-27
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	22-27
12731085-10	2003	By administering paclitaxel, the proportions of P-glycoprotein- and gp91-positive cells were increased in all the four mice examined.	Paclitaxel	17-27	paired Ig-like receptor B	Mus musculus	68-72
12731085-11	2003	When mice transplanted with Ha-MDR-IRES-gp91-transduced cells were repeatedly administered paclitaxel, the ratios of P-glycoprotein- and gp91-positive cells were maintained for over 1 year.	Paclitaxel	91-101	paired Ig-like receptor B	Mus musculus	40-44
12731085-11	2003	When mice transplanted with Ha-MDR-IRES-gp91-transduced cells were repeatedly administered paclitaxel, the ratios of P-glycoprotein- and gp91-positive cells were maintained for over 1 year.	Paclitaxel	91-101	paired Ig-like receptor B	Mus musculus	137-141
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	107-112
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	107-112
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	22-27
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	107-112
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	107-112
27777872-9	2016	PWT decrease was significantly correlated with increased Nav1.7 protein levels on days 7 (r = -0.88, P = 0.04), 14 (r = -0.46, P = 0.03) and 21 (r = -0.27, P = 0.01) after first paclitaxel administration.	Paclitaxel	178-188	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	57-63
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	22-27
27777872-10	2016	In animals that received sham surgery, neutralized Nav1.7 antibody or Nav1.7 antibody, PWTs were significantly reduced 7 days after first paclitaxel administration (all P &lt; 0.05), but PWTs of animals that received Nav1.7 antibody were higher than those that received neutralized Nav1.7 antibody (P &lt; 0.05).	Paclitaxel	138-148	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	51-57
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	107-112
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	107-112
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	22-27
12644839-6	2003	Cyclosporin A combined with Taxol treatment augments caspase-9, -3 activation and loss of mitochondrial membrane potential in HepG2 cells.	Paclitaxel	28-33	caspase 9	Homo sapiens	53-62
27777872-10	2016	In animals that received sham surgery, neutralized Nav1.7 antibody or Nav1.7 antibody, PWTs were significantly reduced 7 days after first paclitaxel administration (all P &lt; 0.05), but PWTs of animals that received Nav1.7 antibody were higher than those that received neutralized Nav1.7 antibody (P &lt; 0.05).	Paclitaxel	138-148	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	70-76
12649178-8	2003	In the Taxol-resistant cells, the active nonphosphorylated form of stathmin was increased approximately 2-fold, whereas the inactive phosphorylated forms were barely detected.	Paclitaxel	7-12	stathmin 1	Homo sapiens	67-75
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	107-112
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	107-112
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	22-27
27777872-10	2016	In animals that received sham surgery, neutralized Nav1.7 antibody or Nav1.7 antibody, PWTs were significantly reduced 7 days after first paclitaxel administration (all P &lt; 0.05), but PWTs of animals that received Nav1.7 antibody were higher than those that received neutralized Nav1.7 antibody (P &lt; 0.05).	Paclitaxel	138-148	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	70-76
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	107-112
29723165-8	2018	RESULTS We found that IL-22 expression level was markedly higher in A549/PTX cells than in A549 cells, and IL-22 gene knockdown significantly enhanced the cell proliferation inhibition rate of PTX to A549/PTX cells and decreased the IC50 value of PTX to A549/PTX cells, indicating IL-22 was involved in cell PTX resistance.	Paclitaxel	193-196	interleukin 22	Homo sapiens	107-112
27777872-10	2016	In animals that received sham surgery, neutralized Nav1.7 antibody or Nav1.7 antibody, PWTs were significantly reduced 7 days after first paclitaxel administration (all P &lt; 0.05), but PWTs of animals that received Nav1.7 antibody were higher than those that received neutralized Nav1.7 antibody (P &lt; 0.05).	Paclitaxel	138-148	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	70-76
29723165-9	2018	Our findings also suggest that IL-22 knockdown notably increased PTX induced apoptosis in A549/PTX cells.	Paclitaxel	65-68	interleukin 22	Homo sapiens	31-36
29723165-9	2018	Our findings also suggest that IL-22 knockdown notably increased PTX induced apoptosis in A549/PTX cells.	Paclitaxel	95-98	interleukin 22	Homo sapiens	31-36
29706628-6	2018	In particular, paclitaxel modulates the splicing of ECT2, a key factor involved in the regulation of cytokinesis.	Paclitaxel	15-25	epithelial cell transforming 2	Homo sapiens	52-56
29706628-7	2018	Briefly, paclitaxel favors the production of ECT2-S, the short splicing isoforms of ECT2, thereby inhibiting cancer cell proliferation.	Paclitaxel	9-19	epithelial cell transforming 2	Homo sapiens	45-49
12820419-18	2003	The level of TS gene expression assessed by RT-PCR in KFr13 and KFr13/120 hours Taxol exposure cells was significantly lower than that in KF28 cells (p &lt; 0.001).	Paclitaxel	80-85	thymidylate synthetase	Homo sapiens	13-15
12820419-19	2003	Moreover, higher protein level expression of TS was noted in KF28 cells compared to KFr13 or KFr13/120 hours Taxol exposure cells.	Paclitaxel	109-114	thymidylate synthetase	Homo sapiens	45-47
29706628-7	2018	Briefly, paclitaxel favors the production of ECT2-S, the short splicing isoforms of ECT2, thereby inhibiting cancer cell proliferation.	Paclitaxel	9-19	epithelial cell transforming 2	Homo sapiens	84-88
27777872-11	2016	These results indicate that increased DRG Nav1.7 expression may be partially responsible for paclitaxel-induced peripheral neuropathy.	Paclitaxel	93-103	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	42-48
27284003-7	2016	Expression of truncated stathmin and use of MT-stabilizing taxol further showed that the C-terminal domain of stathmin is the main contributor to this binding and that the phosphorylation state of stathmin plays a role in its binding along the MT wall.	Paclitaxel	59-64	stathmin 1	Homo sapiens	110-118
12820487-3	2003	MATERIALS AND METHODS: To define the MTD of weekly paclitaxel (days 1-8-15-22, every 4 weeks with a starting dose of 75 mg/m2 and subsequent dose escalation: 90 mg/m2 and 105 mg/m2) in combination with a fixed dose of 5-fluorouracil in p.c.i.	Paclitaxel	51-61	metallothionein 1E	Homo sapiens	37-40
29863245-13	2018	Biological functions of SiHa cells showed that the expression of RP11-381N20.2 was negatively correlated with the treatment time and dose of paclitaxel.	Paclitaxel	141-151	pre-mRNA processing factor 31	Homo sapiens	65-69
27284003-7	2016	Expression of truncated stathmin and use of MT-stabilizing taxol further showed that the C-terminal domain of stathmin is the main contributor to this binding and that the phosphorylation state of stathmin plays a role in its binding along the MT wall.	Paclitaxel	59-64	stathmin 1	Homo sapiens	110-118
29863245-15	2018	Flow cytometry showed that paclitaxel induced apoptosis of cervical cancer cells, which was more promoted after combination with RP11-381N20.2.	Paclitaxel	27-37	pre-mRNA processing factor 31	Homo sapiens	129-133
27072400-0	2016	A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.	Paclitaxel	57-67	early growth response 1	Homo sapiens	8-13
29863245-18	2018	CONCLUSIONS: During the killing process of paclitaxel on cervical cancer SiHa cells, cell autophagy would affect the efficacy, after overexpression of RP11-381N20.2 in SiHa cells, autophagy induced by paclitaxel was inhibited, thereby enhancing the killing effect of paclitaxel on tumor cells.	Paclitaxel	43-53	pre-mRNA processing factor 31	Homo sapiens	151-155
29863245-18	2018	CONCLUSIONS: During the killing process of paclitaxel on cervical cancer SiHa cells, cell autophagy would affect the efficacy, after overexpression of RP11-381N20.2 in SiHa cells, autophagy induced by paclitaxel was inhibited, thereby enhancing the killing effect of paclitaxel on tumor cells.	Paclitaxel	201-211	pre-mRNA processing factor 31	Homo sapiens	151-155
29863245-18	2018	CONCLUSIONS: During the killing process of paclitaxel on cervical cancer SiHa cells, cell autophagy would affect the efficacy, after overexpression of RP11-381N20.2 in SiHa cells, autophagy induced by paclitaxel was inhibited, thereby enhancing the killing effect of paclitaxel on tumor cells.	Paclitaxel	201-211	pre-mRNA processing factor 31	Homo sapiens	151-155
27072400-10	2016	Reducing the levels of EGR1 caused TNBC cells to become more resistant to PTX.	Paclitaxel	74-77	early growth response 1	Homo sapiens	23-27
27072400-11	2016	Given that PTX targets cycling cells, we propose a model whereby high YB-1 levels in some TNBC cells can lead to reduced levels of EGR1, which in turn promotes slow cell cycling and resistance to PTX.	Paclitaxel	11-14	early growth response 1	Homo sapiens	131-135
27072400-11	2016	Given that PTX targets cycling cells, we propose a model whereby high YB-1 levels in some TNBC cells can lead to reduced levels of EGR1, which in turn promotes slow cell cycling and resistance to PTX.	Paclitaxel	196-199	early growth response 1	Homo sapiens	131-135
27072400-12	2016	Therefore YB-1 and EGR1 levels are biologically linked and may provide a biomarker for TNBC response to PTX.	Paclitaxel	104-107	early growth response 1	Homo sapiens	19-23
27059733-5	2016	With blood and cancer tissue samples obtained from 102 patients, we identified associations between serum galectin-3 level or TLR4 expression and paclitaxel resistance phenotype.	Paclitaxel	146-156	toll like receptor 4	Homo sapiens	126-130
30014630-0	2018	[Study on the Relationship Between XIAP Gene and Resistance of Taxol in Ovarian Cancer].	Paclitaxel	63-68	X-linked inhibitor of apoptosis	Homo sapiens	35-39
30014630-1	2018	OBJECTIVE: To research the expression of X-linked inhibitor of apoptosis protein gene (XIAP) on paclitaxel resistance in ovarian cancer.	Paclitaxel	96-106	X-linked inhibitor of apoptosis	Homo sapiens	41-85
27059733-10	2016	In summary, our study elucidated that exogenous galectin-3 might induce paclitaxel resistance through TLR4 signaling activation by inhibiting TLR4-Cav-1 interaction, revealing a novel insight into paclitaxel resistance induction.	Paclitaxel	72-82	toll like receptor 4	Homo sapiens	102-106
30014630-1	2018	OBJECTIVE: To research the expression of X-linked inhibitor of apoptosis protein gene (XIAP) on paclitaxel resistance in ovarian cancer.	Paclitaxel	96-106	X-linked inhibitor of apoptosis	Homo sapiens	87-91
30014630-3	2018	The expression of XIAP mRNA and protein among the A2780 and A2780/T cells treated respectively with paclitaxel at the concentration of 100 ng/mL was detected by reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) and Western blot.	Paclitaxel	100-110	X-linked inhibitor of apoptosis	Homo sapiens	18-22
27409838-12	2016	Also, FBXW7, MCL1 and PLK1 may be relevant predictive markers of tumor progression and response to paclitaxel treatment.	Paclitaxel	99-109	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	13-17
30014630-8	2018	After the treatment on these cells with paclitaxel at the concentration of 100 ng/mL,the expression of XIAP mRNA was lower than that non-treatment with paclitaxelin A2780 cells (P&lt;0.05),and the expression of XIAP mRNA in the A2780/T cells were no statistical significance between the treatment group and non-treatment group with paclitaxel (P&gt;0.05).	Paclitaxel	40-50	X-linked inhibitor of apoptosis	Homo sapiens	103-107
30014630-8	2018	After the treatment on these cells with paclitaxel at the concentration of 100 ng/mL,the expression of XIAP mRNA was lower than that non-treatment with paclitaxelin A2780 cells (P&lt;0.05),and the expression of XIAP mRNA in the A2780/T cells were no statistical significance between the treatment group and non-treatment group with paclitaxel (P&gt;0.05).	Paclitaxel	40-50	X-linked inhibitor of apoptosis	Homo sapiens	211-215
30014630-11	2018	The apoptotic rate of siRNA-XIAP group was higher than those of other groups treated with the paclitaxel at concentrations of 2 000 ng/mL and 2 500 ng/mL (P&lt;0.05).	Paclitaxel	94-104	X-linked inhibitor of apoptosis	Homo sapiens	28-32
30014630-12	2018	CONCLUSION: XIAP"s high expression on mRNA and protein was correlated with ovarian cancer paclitaxel-resistance,specific siRNA can promote cell apoptosis by reducing the expression of XIAP,and increase the sensitivity of drug-resistant cancer cells to paclitaxel.	Paclitaxel	90-100	X-linked inhibitor of apoptosis	Homo sapiens	12-16
30014630-12	2018	CONCLUSION: XIAP"s high expression on mRNA and protein was correlated with ovarian cancer paclitaxel-resistance,specific siRNA can promote cell apoptosis by reducing the expression of XIAP,and increase the sensitivity of drug-resistant cancer cells to paclitaxel.	Paclitaxel	90-100	X-linked inhibitor of apoptosis	Homo sapiens	184-188
30014630-12	2018	CONCLUSION: XIAP"s high expression on mRNA and protein was correlated with ovarian cancer paclitaxel-resistance,specific siRNA can promote cell apoptosis by reducing the expression of XIAP,and increase the sensitivity of drug-resistant cancer cells to paclitaxel.	Paclitaxel	252-262	X-linked inhibitor of apoptosis	Homo sapiens	12-16
30014630-12	2018	CONCLUSION: XIAP"s high expression on mRNA and protein was correlated with ovarian cancer paclitaxel-resistance,specific siRNA can promote cell apoptosis by reducing the expression of XIAP,and increase the sensitivity of drug-resistant cancer cells to paclitaxel.	Paclitaxel	252-262	X-linked inhibitor of apoptosis	Homo sapiens	184-188
27279103-0	2016	[Corrigendum] Downregulation of cytokeratin 18 is associated with paclitaxel-resistance and tumor aggressiveness in prostate cancer.	Paclitaxel	66-76	keratin 18	Homo sapiens	32-46
29701902-0	2018	Low doses of Paclitaxel repress breast cancer invasion through DJ-1/KLF17 signalling pathway.	Paclitaxel	13-23	Kruppel like factor 17	Homo sapiens	68-73
29701902-7	2018	Furthermore, paclitaxel-inhibiting breast cancer metastasis is associated with down-regulation of DJ-1 and ID-1 mRNA expression level with a concurrent increase in KLF17 expression.	Paclitaxel	13-23	Kruppel like factor 17	Homo sapiens	164-169
29701902-8	2018	Under the same experimental conditions, paclitaxel induces KLF17 and concurrently represses ID-1 protein levels.	Paclitaxel	40-50	Kruppel like factor 17	Homo sapiens	59-64
29701902-9	2018	Our results show for the first time that paclitaxel inhibits breast cancer metastasis through regulating DJ-1/KLF17/ID-1 signalling pathway; repressed DJ-1 and ID-1 and enhanced KLF17 expression.	Paclitaxel	41-51	Kruppel like factor 17	Homo sapiens	110-115
29701902-9	2018	Our results show for the first time that paclitaxel inhibits breast cancer metastasis through regulating DJ-1/KLF17/ID-1 signalling pathway; repressed DJ-1 and ID-1 and enhanced KLF17 expression.	Paclitaxel	41-51	Kruppel like factor 17	Homo sapiens	178-183
27312786-5	2016	The E2 pretreatment enhances the ERalpha activity and significantly impairs paclitaxel-induced apoptosis as evaluated by Annexin V assay and PARP-1 cleavage.	Paclitaxel	76-86	annexin A5	Homo sapiens	121-130
29569435-0	2018	Overcoming Multidrug Resistance through the GLUT1-Mediated and Enzyme-Triggered Mitochondrial Targeting Conjugate with Redox-Sensitive Paclitaxel Release.	Paclitaxel	135-145	solute carrier family 2 member 1	Homo sapiens	44-49
27446402-0	2016	Effect of STK17A on the sensitivity of ovarian cancer cells to paclitaxel and carboplatin.	Paclitaxel	63-73	serine/threonine kinase 17a	Homo sapiens	10-16
27446402-8	2016	In the cells that were transfected with siRNA resulting in reduced expression of STK17A, the 50% inhibitory concentration (IC50) of the chemotherapy drugs paclitaxel and carboplatin was increased compared with control cells (P&lt;0.05).	Paclitaxel	155-165	serine/threonine kinase 17a	Homo sapiens	81-87
29317344-4	2018	Moreover, paclitaxel-loaded HA-ss-TOS micelles (HA-ss-TOS-PTX) can be efficiently taken up by B16F10 cells overexpressing CD 44, thereafter exhibiting enhanced cytotoxicity.	Paclitaxel	10-20	CD44 antigen	Mus musculus	122-127
27446402-10	2016	There was a variable susceptibility to carboplatin and paclitaxel resulting from altering the levels of STK17A expression in ovarian cancer cell lines.	Paclitaxel	55-65	serine/threonine kinase 17a	Homo sapiens	104-110
27304668-6	2016	Further, the combined treatment of GLU-PTX had significant decrease in the expression levels of P-gp, MRPs, and BCRP in resistant KB cells at both mRNA and protein levels.	Paclitaxel	39-42	phosphoglycolate phosphatase	Homo sapiens	96-100
27304668-6	2016	Further, the combined treatment of GLU-PTX had significant decrease in the expression levels of P-gp, MRPs, and BCRP in resistant KB cells at both mRNA and protein levels.	Paclitaxel	39-42	BCR pseudogene 1	Homo sapiens	112-116
27304668-9	2016	Importantly, GLU and/or PTX triggered apoptosis through the activation of pro-apoptotic proteins such as p53, Bax, and caspase-9.	Paclitaxel	24-27	caspase 9	Homo sapiens	119-128
26979998-6	2016	Intrathecal injection of MCP-1 neutralizing antibodies reduced paclitaxel-induced macrophage recruitment into the DRG and also blocked the behavioral signs of CIPN.	Paclitaxel	63-73	C-C motif chemokine ligand 2	Rattus norvegicus	25-30
29343514-10	2018	Of note, by inhibiting cell proliferation and promoting apoptosis, the TRPM2 down-regulation enhanced the efficacy of paclitaxel and doxorubicin in gastric cancer cells.	Paclitaxel	118-128	transient receptor potential cation channel subfamily M member 2	Homo sapiens	71-76
29486738-10	2018	IL-6, IL-8 and XIAP showed increased expressions in PTX-treated cells and this over-production effect was inhibited in TLR4-transient knockdown cells.	Paclitaxel	52-55	X-linked inhibitor of apoptosis	Homo sapiens	15-19
26979998-9	2016	These results are the first to indicate a mechanistic link such that activation of TLR4 by paclitaxel leads to increased expression of MCP-1 by DRG neurons resulting in macrophage infiltration to the DRG that express inflammatory cytokines and the combination of these events results in IENF loss and the development of behavioral signs of CIPN.	Paclitaxel	91-101	C-C motif chemokine ligand 2	Rattus norvegicus	135-140
29486738-14	2018	CONCLUSIONS: The acquired TLR4-mediated PTX resistance in BCA and melanoma is explained partly by the paracrine effect of IL-6 and IL-8 released into the tumor microenvironment and over-production of anti-apoptotic protein, XIAP, in BCA cells and importantly CpdA could reduce this effect and sensitize PTX-induced apoptosis in a synergistic manner.	Paclitaxel	40-43	X-linked inhibitor of apoptosis	Homo sapiens	224-228
26207830-0	2016	Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.	Paclitaxel	67-77	notch receptor 3	Homo sapiens	0-6
29531835-11	2018	Moreover, inhibition of GLUT5 by specific small chemical inhibitor sensitizes LUAD cells to paclitaxel treatment.	Paclitaxel	92-102	solute carrier family 2 (facilitated glucose transporter), member 5	Mus musculus	24-29
29334216-4	2018	PTX-DODAB/pDNA-rHDL nanoparticles simultaneously improved the cellular uptake of PTX and pDNA via scavenger receptor B type I (SR-BI) mediated lysosome-independent internalization and promoted the transfection of pDNA in MCF-7 cells, which were revealed by flow cytometry and confocal laser scanning microscopy analyses.	Paclitaxel	0-3	scavenger receptor class B member 1	Homo sapiens	98-125
26207830-3	2016	The efficacy of Notch3-specific inhibition in paclitaxel-resistant ovarian cancers was assessed in this study, which has not yet been evaluated relative to GSI.	Paclitaxel	46-56	notch receptor 3	Homo sapiens	16-22
29334216-4	2018	PTX-DODAB/pDNA-rHDL nanoparticles simultaneously improved the cellular uptake of PTX and pDNA via scavenger receptor B type I (SR-BI) mediated lysosome-independent internalization and promoted the transfection of pDNA in MCF-7 cells, which were revealed by flow cytometry and confocal laser scanning microscopy analyses.	Paclitaxel	0-3	scavenger receptor class B member 1	Homo sapiens	127-132
29334216-6	2018	Moreover, PTX-DODAB/p53-rHDL nanoparticles showed superior cytotoxicity and significantly induced apoptosis in SR-BI overexpressed MCF-7 cells.	Paclitaxel	10-13	scavenger receptor class B member 1	Homo sapiens	111-116
29367423-4	2018	Here, we report that treatment of human or murine TNBC cells with carboplatin, doxorubicin, gemcitabine, or paclitaxel induces the coordinate transcriptional induction of CD47, CD73, and PDL1 mRNA and protein expression, leading to a marked increase in the percentage of CD47+CD73+PDL1+ breast cancer cells.	Paclitaxel	108-118	CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	Mus musculus	171-175
29367423-4	2018	Here, we report that treatment of human or murine TNBC cells with carboplatin, doxorubicin, gemcitabine, or paclitaxel induces the coordinate transcriptional induction of CD47, CD73, and PDL1 mRNA and protein expression, leading to a marked increase in the percentage of CD47+CD73+PDL1+ breast cancer cells.	Paclitaxel	108-118	CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	Mus musculus	271-275
29255002-2	2018	The voltage-gated sodium channel 1.7 (Nav1.7) plays an important role in multiple preclinical models of neuropathic pain and in inherited human pain phenotypes, and its gene expression is increased in dorsal root ganglia (DRGs) of paclitaxel-treated rats.	Paclitaxel	231-241	sodium voltage-gated channel alpha subunit 9	Homo sapiens	38-44
26207830-12	2016	These results indicate that Notch3-specific inhibition sensitizes paclitaxel-resistant cancer cells to paclitaxel treatment, with an efficacy comparable to that of GSI.	Paclitaxel	66-76	notch receptor 3	Homo sapiens	28-34
29255002-10	2018	This study suggests that Nav1.7 may provide a potential new target for the treatment of neuropathic pain, including chemotherapy (paclitaxel)-induced neuropathic pain.SIGNIFICANCE STATEMENT This work demonstrates that the expression and function of the voltage-gated sodium channel Nav1.7 are increased in a preclinical model of chemotherapy-induced peripheral neuropathy (CIPN), the most common treatment-limiting side effect of all the most common anticancer therapies.	Paclitaxel	130-140	sodium voltage-gated channel alpha subunit 9	Homo sapiens	25-31
29255002-10	2018	This study suggests that Nav1.7 may provide a potential new target for the treatment of neuropathic pain, including chemotherapy (paclitaxel)-induced neuropathic pain.SIGNIFICANCE STATEMENT This work demonstrates that the expression and function of the voltage-gated sodium channel Nav1.7 are increased in a preclinical model of chemotherapy-induced peripheral neuropathy (CIPN), the most common treatment-limiting side effect of all the most common anticancer therapies.	Paclitaxel	130-140	sodium voltage-gated channel alpha subunit 9	Homo sapiens	282-288
26207830-12	2016	These results indicate that Notch3-specific inhibition sensitizes paclitaxel-resistant cancer cells to paclitaxel treatment, with an efficacy comparable to that of GSI.	Paclitaxel	103-113	notch receptor 3	Homo sapiens	28-34
29367628-0	2018	The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.	Paclitaxel	97-107	DNA methyltransferase 1	Homo sapiens	55-60
27196755-0	2016	Loss of PKCdelta Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/beta-Catenin Pathway and Mcl-1 Accumulation.	Paclitaxel	55-65	catenin beta 1	Homo sapiens	92-104
29367628-5	2018	Our findings revealed a novel function for UBC13 in regulating paclitaxel sensitivity through a DNMT1-CHFR-Aurora A pathway in ovarian cancer cells.	Paclitaxel	63-73	DNA methyltransferase 1	Homo sapiens	96-101
29084921-0	2018	Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy.	Paclitaxel	63-73	DNA damage inducible transcript 4	Homo sapiens	14-19
27196755-4	2016	In this article, we demonstrate that PKCdelta silencing favors mitotic arrest after paclitaxel treatment in PC3 and LNCaP cells; however, this is associated with resistance to paclitaxel-induced apoptosis.	Paclitaxel	84-94	chromobox 8	Homo sapiens	108-111
28869599-5	2018	This distinct mitotic phenotype was interlinked with Paclitaxel-mediated radiosensitization via overexpression of mitotic Aurora kinase A (AURKA) and its cofactor TPX2 whose knockdown rescued the bipolar mode of cell division and largely attenuated the radiosensitizing effects of Paclitaxel.	Paclitaxel	53-63	TPX2 microtubule nucleation factor	Homo sapiens	163-167
28869599-5	2018	This distinct mitotic phenotype was interlinked with Paclitaxel-mediated radiosensitization via overexpression of mitotic Aurora kinase A (AURKA) and its cofactor TPX2 whose knockdown rescued the bipolar mode of cell division and largely attenuated the radiosensitizing effects of Paclitaxel.	Paclitaxel	281-291	TPX2 microtubule nucleation factor	Homo sapiens	163-167
27196755-7	2016	We also show that combined treatments with paclitaxel and Wnt/beta-catenin or Akt inhibitors improve the apoptotic response to paclitaxel, even in the absence of PKCdelta.	Paclitaxel	127-137	catenin beta 1	Homo sapiens	62-74
30043652-4	2018	Action mechanism studies manifested that DQA modified paclitaxel plus honokiol micelles could activate apoptotic enzymes caspase-3 and caspase-9 as well as down-regulate FAK, PI3K, MMP-2 and MMP-9.	Paclitaxel	54-64	caspase 3	Mus musculus	121-130
30043652-4	2018	Action mechanism studies manifested that DQA modified paclitaxel plus honokiol micelles could activate apoptotic enzymes caspase-3 and caspase-9 as well as down-regulate FAK, PI3K, MMP-2 and MMP-9.	Paclitaxel	54-64	matrix metallopeptidase 2	Mus musculus	181-186
26869361-12	2016	Moreover, a 2 nM dose of paclitaxel for 24 h significantly inhibited the TGF-beta1-stimulated activation of Smad2/3, JNK and ERK1/2 in IMCD cells.	Paclitaxel	25-35	mitogen-activated protein kinase 8	Rattus norvegicus	117-120
30064123-12	2018	Furthermore, CA increased the PTX-induced activation of Bax, Bid, and downstream cleaved PARP, and phosphorylation of extracellular signal regulated kinase1/2 and c-Jun NH2-terminal protein kinase1/2.	Paclitaxel	30-33	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	163-168
26976343-0	2016	STAT3-dependent TXNDC17 expression mediates Taxol resistance through inducing autophagy in human colorectal cancer cells.	Paclitaxel	44-49	thioredoxin domain containing 17	Homo sapiens	16-23
29027133-0	2017	Combination of a chemopreventive agent and paclitaxel in CD44-targeted hybrid nanoparticles for breast cancer treatment.	Paclitaxel	43-53	CD44 molecule (Indian blood group)	Homo sapiens	57-61
29027133-2	2017	We developed a hybrid nanocarrier for the CD44-targeted delivery of ibuprofen (IBU) and paclitaxel (PTX).	Paclitaxel	88-98	CD44 molecule (Indian blood group)	Homo sapiens	42-46
29027133-2	2017	We developed a hybrid nanocarrier for the CD44-targeted delivery of ibuprofen (IBU) and paclitaxel (PTX).	Paclitaxel	100-103	CD44 molecule (Indian blood group)	Homo sapiens	42-46
26976343-6	2016	In the present study, we observed that the high expression of TXNDC17 (thioredoxin domain containing 17) was associated with Taxol resistance in colorectal cancer cells.	Paclitaxel	125-130	thioredoxin domain containing 17	Homo sapiens	62-69
28978720-5	2017	On an extended panel of 31 NSCLC cell lines, 25 of which were adenocarcinoma, the synergy between BMS-906024 and paclitaxel was significantly greater in KRAS- and BRAF-wildtype than KRAS- or BRAF-mutant cells (mean CI, 0.43 vs. 0.90, respectively; P = 0.003).	Paclitaxel	113-123	KRAS proto-oncogene, GTPase	Homo sapiens	153-157
28978720-5	2017	On an extended panel of 31 NSCLC cell lines, 25 of which were adenocarcinoma, the synergy between BMS-906024 and paclitaxel was significantly greater in KRAS- and BRAF-wildtype than KRAS- or BRAF-mutant cells (mean CI, 0.43 vs. 0.90, respectively; P = 0.003).	Paclitaxel	113-123	KRAS proto-oncogene, GTPase	Homo sapiens	153-158
28978720-6	2017	Paclitaxel-induced Notch1 activation was associated with synergy between BMS-906024 and paclitaxel in the KRAS- or BRAF-mutant group.	Paclitaxel	0-10	KRAS proto-oncogene, GTPase	Homo sapiens	106-111
28978720-6	2017	Paclitaxel-induced Notch1 activation was associated with synergy between BMS-906024 and paclitaxel in the KRAS- or BRAF-mutant group.	Paclitaxel	88-98	KRAS proto-oncogene, GTPase	Homo sapiens	106-111
28978720-7	2017	Knockdown of mutant KRAS increased the synergy between BMS-906024 and paclitaxel in heterozygous KRAS-mutant cell lines.	Paclitaxel	70-80	KRAS proto-oncogene, GTPase	Homo sapiens	20-24
28978720-7	2017	Knockdown of mutant KRAS increased the synergy between BMS-906024 and paclitaxel in heterozygous KRAS-mutant cell lines.	Paclitaxel	70-80	KRAS proto-oncogene, GTPase	Homo sapiens	97-101
26976343-6	2016	In the present study, we observed that the high expression of TXNDC17 (thioredoxin domain containing 17) was associated with Taxol resistance in colorectal cancer cells.	Paclitaxel	125-130	thioredoxin domain containing 17	Homo sapiens	71-103
29179722-10	2017	The caspase-9 and caspase-3 cascade was activated by the AG-PEG-SS-PLA/PTX nanomicelles through upregulation of the pro-apoptotic proteins Bax and Bid and suppression of the anti-apoptotic protein Bcl-2, thereby increasing apoptosis.	Paclitaxel	71-74	caspase 3	Mus musculus	18-27
26976343-7	2016	And TXNDC17 mediated Taxol resistance was related with increased basal autophagy level.	Paclitaxel	21-26	thioredoxin domain containing 17	Homo sapiens	4-11
29179722-10	2017	The caspase-9 and caspase-3 cascade was activated by the AG-PEG-SS-PLA/PTX nanomicelles through upregulation of the pro-apoptotic proteins Bax and Bid and suppression of the anti-apoptotic protein Bcl-2, thereby increasing apoptosis.	Paclitaxel	71-74	BCL2-associated X protein	Mus musculus	139-142
29162853-5	2017	We found that miR-152 expression sensitized the breast cancer cells to paclitaxel treatment by inhibiting beta-catenin and PKM2 expression.	Paclitaxel	71-81	microRNA 152	Homo sapiens	14-21
26976343-8	2016	Taxol exposure induced high levels of phospho-STAT3 (Tyr 705) and TXNDC17; and increase of basal autophagy in colorectal cancer cells.	Paclitaxel	0-5	thioredoxin domain containing 17	Homo sapiens	66-73
26976343-9	2016	TXNDC17 overexpression cells obtained Taxol resistance and a high level of autophagy, and it is not surprising that stable downregulation of TXNDC17 accordingly reversed these phenomena.	Paclitaxel	38-43	thioredoxin domain containing 17	Homo sapiens	0-7
29340013-4	2017	Our previous work showed that the effectiveness of the spindle poison paclitaxel in inhibiting cancer cell growth was dependent on the expression of RANBP1, a regulatory target of the serine/threonine kinase SGK1.	Paclitaxel	70-80	serum/glucocorticoid regulated kinase 1	Homo sapiens	208-212
26976343-14	2016	These results suggest the possibility that TXNDC17 could play an important role in Taxol resistance via enhancing autophagy in human colorectal cancer cells.	Paclitaxel	83-88	thioredoxin domain containing 17	Homo sapiens	43-50
27478778-11	2016	CONCLUSION: These results propose that HMGI-C silencing and Paclitaxel treatment alone can inhibit the proliferation and migration significantly, furthermore, synergic effect of HMGI-C siRNA and Paclitaxel showed higher inhibition compared to mono treatment.	Paclitaxel	60-70	high mobility group AT-hook 2	Homo sapiens	178-184
27478778-11	2016	CONCLUSION: These results propose that HMGI-C silencing and Paclitaxel treatment alone can inhibit the proliferation and migration significantly, furthermore, synergic effect of HMGI-C siRNA and Paclitaxel showed higher inhibition compared to mono treatment.	Paclitaxel	195-205	high mobility group AT-hook 2	Homo sapiens	39-45
29125463-0	2017	Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy.	Paclitaxel	96-106	nicotinamide phosphoribosyltransferase	Rattus norvegicus	72-77
27262815-0	2016	PFKFB3 potentially contributes to paclitaxel resistance in breast cancer cells through TLR4 activation by stimulating lactate production.	Paclitaxel	34-44	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	0-6
29125463-3	2017	Here, we report that stimulation of nicotinamide phosphoribosyltransferase (NAMPT) produced robust neuroprotection in an aggressive CIPN model utilizing the frontline anticancer drug, paclitaxel (PTX).	Paclitaxel	184-194	nicotinamide phosphoribosyltransferase	Rattus norvegicus	76-81
29125463-3	2017	Here, we report that stimulation of nicotinamide phosphoribosyltransferase (NAMPT) produced robust neuroprotection in an aggressive CIPN model utilizing the frontline anticancer drug, paclitaxel (PTX).	Paclitaxel	196-199	nicotinamide phosphoribosyltransferase	Rattus norvegicus	76-81
29125463-4	2017	Daily treatment of rats with the first-in-class NAMPT stimulator, P7C3-A20, prevented behavioral and histologic indicators of peripheral neuropathy, stimulated tissue NAD recovery, improved general health, and abolished attrition produced by a near maximum-tolerated dose of PTX.	Paclitaxel	275-278	nicotinamide phosphoribosyltransferase	Rattus norvegicus	48-53
12576681-3	2003	The growth inhibitory curve of LLC-PK1 cells by paclitaxel was shifted to a higher concentration range by pretreatment with 1 micro M cisplatin for 48 h. The uptake and efflux of Rhodamine123 were significantly reduced and enhanced, respectively, by pretreatment with 1 micro M cisplatin for 48 h. This enhanced efflux was suppressed by the representative MDR1 substrate/inhibitor ciclosporin.	Paclitaxel	48-58	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	356-360
27262815-0	2016	PFKFB3 potentially contributes to paclitaxel resistance in breast cancer cells through TLR4 activation by stimulating lactate production.	Paclitaxel	34-44	toll like receptor 4	Homo sapiens	87-91
29180871-0	2017	LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194.	Paclitaxel	28-38	nuclear paraspeckle assembly transcript 1	Homo sapiens	7-12
27262815-3	2016	In this study, we sought to examine the role of 6-Phosphofructo-2-kinase (PFKFB3), a critical regulator of glycolysis, in paclitaxel resistance development.	Paclitaxel	122-132	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	74-80
29180871-0	2017	LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194.	Paclitaxel	28-38	zinc finger E-box binding homeobox 1	Homo sapiens	88-92
29180871-3	2017	This study is designed to investigate the function of NEAT1 in paclitaxel (PTX) resistance of ovarian cancer and its potential molecular mechanism.	Paclitaxel	63-73	nuclear paraspeckle assembly transcript 1	Homo sapiens	54-59
27262815-7	2016	Moreover, PFKFB3 modulated toll like receptor 4 (TLR4) and MyD88 expression as well as interleukin (IL)-6 and IL-8 release from breast cancer cells in response to paclitaxel exposure.	Paclitaxel	163-173	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	10-16
29180871-3	2017	This study is designed to investigate the function of NEAT1 in paclitaxel (PTX) resistance of ovarian cancer and its potential molecular mechanism.	Paclitaxel	75-78	nuclear paraspeckle assembly transcript 1	Homo sapiens	54-59
27262815-10	2016	In all, we characterized the novel role of PFKFB3 in induction of paclitaxel resistance by raising lactate production and activating TLR4 signaling.	Paclitaxel	66-76	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	43-49
29123088-4	2017	By connecting a tumor-targeting nucleolin aptamer (NucA) to the active hydroxyl group at 2" position of PTX via a cathepsin B sensitive dipeptide bond, NucA-PTX remains stable and inactive in the circulation.	Paclitaxel	104-107	cathepsin B	Homo sapiens	114-125
29123088-4	2017	By connecting a tumor-targeting nucleolin aptamer (NucA) to the active hydroxyl group at 2" position of PTX via a cathepsin B sensitive dipeptide bond, NucA-PTX remains stable and inactive in the circulation.	Paclitaxel	157-160	cathepsin B	Homo sapiens	114-125
29123088-6	2017	Once inside cells, the dipeptide bond linker of NucA-PTX is cleaved by cathepsin B and then the conjugated PTX is released for action.	Paclitaxel	53-56	cathepsin B	Homo sapiens	71-82
29123088-6	2017	Once inside cells, the dipeptide bond linker of NucA-PTX is cleaved by cathepsin B and then the conjugated PTX is released for action.	Paclitaxel	107-110	cathepsin B	Homo sapiens	71-82
27262815-10	2016	In all, we characterized the novel role of PFKFB3 in induction of paclitaxel resistance by raising lactate production and activating TLR4 signaling.	Paclitaxel	66-76	toll like receptor 4	Homo sapiens	133-137
27313461-1	2016	In this study, we report a novel kind of targeting with paclitaxel (PTX)-loaded silk fibroin nanoparticles conjugated with iRGD-EGFR nanobody recombinant protein (anti-EGFR-iRGD).	Paclitaxel	56-66	epidermal growth factor receptor	Mus musculus	128-132
28920531-9	2017	Knockdown of KLF4 expression in ATC cells decreased the resistance to doxorubicin and paclitaxel, and reduced ABC transporter expression.	Paclitaxel	86-96	Kruppel like factor 4	Homo sapiens	13-17
27313461-1	2016	In this study, we report a novel kind of targeting with paclitaxel (PTX)-loaded silk fibroin nanoparticles conjugated with iRGD-EGFR nanobody recombinant protein (anti-EGFR-iRGD).	Paclitaxel	56-66	epidermal growth factor receptor	Mus musculus	168-172
29066719-6	2017	We further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.	Paclitaxel	198-208	nectin cell adhesion molecule 4	Homo sapiens	102-109
27313461-1	2016	In this study, we report a novel kind of targeting with paclitaxel (PTX)-loaded silk fibroin nanoparticles conjugated with iRGD-EGFR nanobody recombinant protein (anti-EGFR-iRGD).	Paclitaxel	68-71	epidermal growth factor receptor	Mus musculus	128-132
27313461-1	2016	In this study, we report a novel kind of targeting with paclitaxel (PTX)-loaded silk fibroin nanoparticles conjugated with iRGD-EGFR nanobody recombinant protein (anti-EGFR-iRGD).	Paclitaxel	68-71	epidermal growth factor receptor	Mus musculus	168-172
27184254-0	2016	HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.	Paclitaxel	52-62	WAP four-disulfide core domain 2	Homo sapiens	0-3
27184254-3	2016	Here, we sought to confirm our previous results that HE4 contributes to collateral resistance to cisplatin and paclitaxel in vitro and uncover factors that may contribute to HE4-mediated chemoresistance.	Paclitaxel	111-121	WAP four-disulfide core domain 2	Homo sapiens	53-56
28778054-9	2017	PTX and PDC form micelles based on hydrophobic interactions, where PTX inserts into the hydrophobic PDEA-PCL core in a neutral environment.	Paclitaxel	0-3	phosphodiesterase 6A	Homo sapiens	100-104
28778054-9	2017	PTX and PDC form micelles based on hydrophobic interactions, where PTX inserts into the hydrophobic PDEA-PCL core in a neutral environment.	Paclitaxel	67-70	phosphodiesterase 6A	Homo sapiens	100-104
27181838-0	2016	PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.	Paclitaxel	112-122	CD274 molecule	Homo sapiens	0-5
28778054-10	2017	An acidic transition of the environment leads to rapid PTX release from the micelles due to the hydrophobic-hydrophilic transition of PDEA to PDEAH+, though some PTX molecules still remain in the PCL core.	Paclitaxel	55-58	phosphodiesterase 6A	Homo sapiens	134-138
29093604-9	2017	Secretion of the cytokines CCL5, CCL2 and IL-6 increased after paclitaxel treatment in several endometrial cancer cell lines, but no general effect on cytokine secretion was detected after heparin treatment.	Paclitaxel	63-73	C-C motif chemokine ligand 5	Homo sapiens	27-31
27181838-9	2016	PD-L1 rs2297136T &gt; C and rs4143815C &gt; G polymorphisms may be useful for the prediction of clinical outcome of 1(st) line paclitaxel-cisplatin chemotherapy in NSCLC.	Paclitaxel	127-137	CD274 molecule	Homo sapiens	0-5
29158820-8	2017	The down-regulated P-gp inhibits the efflux of PTX thereby increasing its intracellular concentration, improving the cytotoxicity, and inhibiting the migration and invasion of 4T1 cells.	Paclitaxel	47-50	phosphoglycolate phosphatase	Mus musculus	19-23
26608370-0	2016	MPT0B169, a novel tubulin inhibitor, induces apoptosis in taxol-resistant acute myeloid leukemia cells through mitochondrial dysfunction and Mcl-1 downregulation.	Paclitaxel	58-63	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	141-146
26832793-0	2016	SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.	Paclitaxel	34-44	secreted protein acidic and cysteine rich	Homo sapiens	0-5
28205290-10	2017	In addition, P-gp efflux studies on free and micellar paclitaxel showed the proficiency of PEG2000 -DSPE micelles in evading P-gp-mediated efflux, thus increasing paclitaxel uptake.	Paclitaxel	54-64	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	13-17
26832793-1	2016	The study goal was to examine the relationship between nab-paclitaxel delivery and SPARC (secreted protein acidic and rich in cysteine) expression in pancreatic tumor xenografts and to determine the antistromal effect of nab-paclitaxel, which may affect tumor vascular perfusion.	Paclitaxel	59-69	secreted protein acidic and cysteine rich	Homo sapiens	83-88
26832793-1	2016	The study goal was to examine the relationship between nab-paclitaxel delivery and SPARC (secreted protein acidic and rich in cysteine) expression in pancreatic tumor xenografts and to determine the antistromal effect of nab-paclitaxel, which may affect tumor vascular perfusion.	Paclitaxel	59-69	secreted protein acidic and cysteine rich	Homo sapiens	90-134
28523716-6	2017	We found that CD44+ Fbs promoted breast cancer cell survival and paclitaxel resistance and inhibited paclitaxel-induced apoptosis.	Paclitaxel	65-75	CD44 molecule (Indian blood group)	Homo sapiens	14-18
28523716-6	2017	We found that CD44+ Fbs promoted breast cancer cell survival and paclitaxel resistance and inhibited paclitaxel-induced apoptosis.	Paclitaxel	101-111	CD44 molecule (Indian blood group)	Homo sapiens	14-18
26893365-0	2016	A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.	Paclitaxel	92-102	ETS proto-oncogene 2, transcription factor	Homo sapiens	47-51
28748694-9	2017	Our results suggest that the VEGF plasmid-/PTX-loaded bilayered NPs exert a beneficial impact on atherosclerotic restenosis by sequentially releasing VEGF and PTX in vivo.	Paclitaxel	43-46	vascular endothelial growth factor A	Oryctolagus cuniculus	29-33
28748694-9	2017	Our results suggest that the VEGF plasmid-/PTX-loaded bilayered NPs exert a beneficial impact on atherosclerotic restenosis by sequentially releasing VEGF and PTX in vivo.	Paclitaxel	43-46	vascular endothelial growth factor A	Oryctolagus cuniculus	150-154
28748694-9	2017	Our results suggest that the VEGF plasmid-/PTX-loaded bilayered NPs exert a beneficial impact on atherosclerotic restenosis by sequentially releasing VEGF and PTX in vivo.	Paclitaxel	159-162	vascular endothelial growth factor A	Oryctolagus cuniculus	29-33
26893365-8	2016	These findings suggest that the four SNPs, especially ETS2 rs461155A&gt;G, could be used as biomarkers predicting the clinical outcomes of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy.	Paclitaxel	178-188	ETS proto-oncogene 2, transcription factor	Homo sapiens	54-58
26783937-7	2016	Over-expression of EPAS-1 increased the expression of PXR responsive genes, enhanced the proliferation of BGC-823 cells and boosted the resistance of BGC-823 cells against the cytotoxicity of chemotherapeutic drugs, e.g. Mitomycin C and Paclitaxel.	Paclitaxel	237-247	endothelial PAS domain protein 1	Homo sapiens	19-25
28947984-4	2017	In this study, PTX and Borneol (BNL), a natural compound with P-gp inhibition effect confirmed in intestinal absorption, were co-loaded in the fabricated PEG-PAMAM nanoparticle (NPs) by a one-step nano-precipitation method with high drug loading efficiency, narrow size distribution and low hemolysis rate.	Paclitaxel	15-18	phosphoglycolate phosphatase	Mus musculus	62-66
28947984-5	2017	Based on P-gp inhibition activity of BNL, confirmed by drug efflux test and molecular docking model, the combination of PTX and BNL could improve intracellular concentration of PTX in A2780/PTX cells.	Paclitaxel	120-123	phosphoglycolate phosphatase	Mus musculus	9-13
28587902-0	2017	Involvement of Charcot-Marie-Tooth disease gene mitofusin 2 expression in paclitaxel-induced mechanical allodynia in rats.	Paclitaxel	74-84	mitofusin 2	Rattus norvegicus	48-59
26838546-0	2016	Promotion of mitotic catastrophe via activation of PTEN by paclitaxel with supplement of mulberry water extract in bladder cancer cells.	Paclitaxel	59-69	phosphatase and tensin homolog	Homo sapiens	51-55
28587902-4	2017	It has recently been reported that allelic variability in the Charcot-Marie-Tooth disease (CMT) genes, mitofusin 2 (MFN2), Rho guanine nucleotide exchange factor 10 (ARHGEF10), and periaxin (PRX), affected paclitaxel-induced peripheral neuropathy in clinical cases.	Paclitaxel	206-216	mitofusin 2	Rattus norvegicus	103-114
28587902-5	2017	Therefore, we hypothesized that paclitaxel may induce peripheral neuropathy due to changes in Mfn2, Arhgef10, and Prx mRNA expression.	Paclitaxel	32-42	mitofusin 2	Rattus norvegicus	94-98
26769847-4	2016	Consistently, we show that blocking proteasome-mediated degradation inhibits taxol-induced mitotic apoptosis in a Mcl-1-dependent manner.	Paclitaxel	77-82	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	114-119
28587902-5	2017	Therefore, we hypothesized that paclitaxel may induce peripheral neuropathy due to changes in Mfn2, Arhgef10, and Prx mRNA expression.	Paclitaxel	32-42	periaxin	Rattus norvegicus	114-117
28587902-10	2017	In addition, paclitaxel reduced Mfn2 mRNA expression, but not Arhgef10 or Prx mRNA expression, on days 3 and 24.	Paclitaxel	13-23	mitofusin 2	Rattus norvegicus	32-36
28587902-12	2017	The results of the present study suggest that a reduction in Mfn2 mRNA expression contributes to paclitaxel-induced mechanical allodynia.	Paclitaxel	97-107	mitofusin 2	Rattus norvegicus	61-65
26769847-7	2016	We also show that Mcl-1 is continuously synthesized during mitosis and that blocking protein synthesis accelerates taxol induced death-in-mitosis.	Paclitaxel	115-120	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	18-23
27669706-0	2017	Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer.	Paclitaxel	52-62	ATPase H+/K+ transporting subunit alpha	Homo sapiens	0-11
26769847-8	2016	Modulating Mcl-1 levels also influences slippage; overexpressing Mcl-1 extends the time from mitotic entry to mitotic exit in the presence of taxol, while inhibiting Mcl-1 accelerates it.	Paclitaxel	142-147	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	11-16
28416606-12	2017	Collectively, our findings suggest that paclitaxel targets the TRA2A-RSRC2 splicing pathway, and deregulated TRA2A and RSRC2 expression may confer paclitaxel resistance.	Paclitaxel	147-157	arginine and serine rich coiled-coil 2	Homo sapiens	119-124
26769847-8	2016	Modulating Mcl-1 levels also influences slippage; overexpressing Mcl-1 extends the time from mitotic entry to mitotic exit in the presence of taxol, while inhibiting Mcl-1 accelerates it.	Paclitaxel	142-147	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	65-70
26769847-8	2016	Modulating Mcl-1 levels also influences slippage; overexpressing Mcl-1 extends the time from mitotic entry to mitotic exit in the presence of taxol, while inhibiting Mcl-1 accelerates it.	Paclitaxel	142-147	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	65-70
26573761-7	2016	Paclitaxel treatment in MTMECs led to an increase in early apoptotic cells (Annexin V-positive), activation of caspase-9 and increase in the proportion of cells at the G2/M phase of the cell cycle.	Paclitaxel	0-10	annexin A5	Homo sapiens	76-85
28412448-1	2017	In this report, a newly liposomal formulation of paclitaxel (PTX) based on dual paclitaxel succinate glycerophosphorylcholine (Di-PTX-GPC) prodrug was developed.	Paclitaxel	49-59	glycophorin C (Gerbich blood group)	Homo sapiens	134-137
28412448-1	2017	In this report, a newly liposomal formulation of paclitaxel (PTX) based on dual paclitaxel succinate glycerophosphorylcholine (Di-PTX-GPC) prodrug was developed.	Paclitaxel	61-64	glycophorin C (Gerbich blood group)	Homo sapiens	134-137
26573761-7	2016	Paclitaxel treatment in MTMECs led to an increase in early apoptotic cells (Annexin V-positive), activation of caspase-9 and increase in the proportion of cells at the G2/M phase of the cell cycle.	Paclitaxel	0-10	caspase 9	Homo sapiens	111-120
28412448-2	2017	The Di-PTX-GPC prodrug was synthesized by conjugating PTX with GPC through esterification under N,N"-carbonyldiimidazole (CDI) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) catalytic system.	Paclitaxel	7-10	glycophorin C (Gerbich blood group)	Homo sapiens	11-14
28412448-2	2017	The Di-PTX-GPC prodrug was synthesized by conjugating PTX with GPC through esterification under N,N"-carbonyldiimidazole (CDI) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) catalytic system.	Paclitaxel	7-10	glycophorin C (Gerbich blood group)	Homo sapiens	63-66
26807857-9	2016	Doxorubicin and paclitaxel both increased apoB protein levels and paclitaxel also decreased low density lipoprotein receptor (LDLR) protein levels.	Paclitaxel	66-76	low density lipoprotein receptor	Homo sapiens	92-124
28412448-3	2017	Di-PTX-GPC liposomes were prepared by thin film method and characterized by dynamic light scattering (DLS) and transmission electron microscope (TEM).	Paclitaxel	3-6	glycophorin C (Gerbich blood group)	Homo sapiens	7-10
28412448-5	2017	In vitro drug release studies confirmed that the Di-PTX-GPC liposomes have controlled release profile of PTX at a weakly acidic environment, which formulates them suitable for sustained drug delivery.	Paclitaxel	52-55	glycophorin C (Gerbich blood group)	Homo sapiens	56-59
28412448-8	2017	More importantly, Di-PTX-GPC liposomes demonstrated good in vivo anticancer activities compared to Taxol with reduced adverse effects.	Paclitaxel	21-24	glycophorin C (Gerbich blood group)	Homo sapiens	25-28
28412448-9	2017	Conclusively, these results suggest that Di-PTX-GPC liposomes could be an effective PTX delivery vehicles in clinical cancer chemotherapy.	Paclitaxel	44-47	glycophorin C (Gerbich blood group)	Homo sapiens	48-51
28415580-11	2017	Together, these results indicated that CXCR4 overexpression drives acquired paclitaxel resistance, partly by activating the PDGFA and PDGFB/PDGFRalpha autocrine signaling loops that activate AKT and ERK1/2.	Paclitaxel	76-86	C-X-C motif chemokine receptor 4	Homo sapiens	39-44
28415580-11	2017	Together, these results indicated that CXCR4 overexpression drives acquired paclitaxel resistance, partly by activating the PDGFA and PDGFB/PDGFRalpha autocrine signaling loops that activate AKT and ERK1/2.	Paclitaxel	76-86	platelet derived growth factor subunit A	Homo sapiens	124-129
26807857-9	2016	Doxorubicin and paclitaxel both increased apoB protein levels and paclitaxel also decreased low density lipoprotein receptor (LDLR) protein levels.	Paclitaxel	66-76	low density lipoprotein receptor	Homo sapiens	126-130
28242239-9	2017	Paclitaxel-mediated induction of genes involved in irinotecan metabolism such as Cyp3a11 and Ugt1a1 was TLR4-dependent, while induction of the transporter Mrp2 was TLR4-independent.	Paclitaxel	0-10	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	93-99
28423714-4	2017	Hepatoma cells transduced with MRP2pr-OATP1B1-V5 resulted in dexamethasone-sensitive inducible OATP1B1 expression and enhanced selective antitumor response to OATP1B1 substrates (paclitaxel, Bamet-R2 and Bamet-UD2).	Paclitaxel	179-189	ATP binding cassette subfamily C member 2	Homo sapiens	31-35
28522974-8	2017	Furthermore, expression of glutaminolysis-related genes GLS, SLC7A11 and SLC1A5 were significantly decreased in the colorectal carcinoma cells treated with low-dose PTX.	Paclitaxel	165-168	solute carrier family 1 member 5	Homo sapiens	73-79
26794658-5	2016	Furthermore, we observed that overexpression of HDAC1 was associated with the downregulation of p21, a known HDAC target, in advanced NSCLC patients with paclitaxel treatment, and predicted chemotherapy resistance and bad outcome.	Paclitaxel	154-164	H3 histone pseudogene 16	Homo sapiens	96-99
28195491-4	2017	Herein we report trichosanthin, a plant protein toxin, possesses synergistic effect with paclitaxel (PTX) in the PTX-resistance A549/T nonsmall cell lung cancer (NSCLC) cells, by reversing PTX-caused caspase 9 phosphorylation and inducing caspase 3-dependent apoptosis.	Paclitaxel	89-99	caspase 3	Mus musculus	239-248
28195491-4	2017	Herein we report trichosanthin, a plant protein toxin, possesses synergistic effect with paclitaxel (PTX) in the PTX-resistance A549/T nonsmall cell lung cancer (NSCLC) cells, by reversing PTX-caused caspase 9 phosphorylation and inducing caspase 3-dependent apoptosis.	Paclitaxel	101-104	caspase 3	Mus musculus	239-248
28195491-4	2017	Herein we report trichosanthin, a plant protein toxin, possesses synergistic effect with paclitaxel (PTX) in the PTX-resistance A549/T nonsmall cell lung cancer (NSCLC) cells, by reversing PTX-caused caspase 9 phosphorylation and inducing caspase 3-dependent apoptosis.	Paclitaxel	113-116	caspase 3	Mus musculus	239-248
28195491-4	2017	Herein we report trichosanthin, a plant protein toxin, possesses synergistic effect with paclitaxel (PTX) in the PTX-resistance A549/T nonsmall cell lung cancer (NSCLC) cells, by reversing PTX-caused caspase 9 phosphorylation and inducing caspase 3-dependent apoptosis.	Paclitaxel	113-116	caspase 3	Mus musculus	239-248
28206956-0	2017	NF-kappaB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.	Paclitaxel	87-97	REL proto-oncogene, NF-kB subunit	Homo sapiens	12-17
28206956-0	2017	NF-kappaB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.	Paclitaxel	87-97	ETS transcription factor ELK1	Homo sapiens	23-27
26779808-6	2016	Importantly, the levels of oncoproteins phosphoinositide-3 kinase/Akt, mucin 1 cytoplasmic domain (MUC1-C) and beta-catenin were also significantly elevated in A549/PTX.	Paclitaxel	165-168	catenin beta 1	Homo sapiens	111-123
28206956-3	2017	The results demonstrate that NF-kappaB1, c-Rel, and ELK1 are involved as transcription factors in repressing miR-134 expression in paclitaxel-resistant ovarian cancer cells.	Paclitaxel	131-141	REL proto-oncogene, NF-kB subunit	Homo sapiens	41-46
28206956-3	2017	The results demonstrate that NF-kappaB1, c-Rel, and ELK1 are involved as transcription factors in repressing miR-134 expression in paclitaxel-resistant ovarian cancer cells.	Paclitaxel	131-141	ETS transcription factor ELK1	Homo sapiens	52-56
26779808-7	2016	Furthermore, nuclear translocation of MUC1-C and beta-catenin increased in A549/PTX.	Paclitaxel	80-83	catenin beta 1	Homo sapiens	49-61
28145547-0	2017	Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-kappaB/Twist1 signaling pathways in a mouse 4T1 breast tumor model.	Paclitaxel	43-48	caspase 3	Mus musculus	76-85
26575017-6	2016	Importantly, we found that downregulating p-Akt by inhibiting SET-mediated protein phosphatase 2A (PP2A) inactivation determined the pro-apoptotic effects of EMQA and paclitaxel combination treatment.	Paclitaxel	167-177	protein phosphatase 2 phosphatase activator	Homo sapiens	83-97
28145547-0	2017	Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-kappaB/Twist1 signaling pathways in a mouse 4T1 breast tumor model.	Paclitaxel	43-48	twist basic helix-loop-helix transcription factor 1	Mus musculus	106-112
28145547-13	2017	The synergistic antitumor and anti-metastasis effects were enhanced primarily through the induction of Taxol-stimulated G2/M phase arrest and the inhibition of caspase-3/cytosolic Ca2+-independent phospholipase A2 (iPLA2) and nuclear factor-kappaB (NF-kappaB)/Twist-related protein 1 (Twist1) drive downstream events including tumor cell repopulation, survival, inflammation, angiogenesis, invasion, and EMT.	Paclitaxel	103-108	twist basic helix-loop-helix transcription factor 1	Mus musculus	260-283
28145547-13	2017	The synergistic antitumor and anti-metastasis effects were enhanced primarily through the induction of Taxol-stimulated G2/M phase arrest and the inhibition of caspase-3/cytosolic Ca2+-independent phospholipase A2 (iPLA2) and nuclear factor-kappaB (NF-kappaB)/Twist-related protein 1 (Twist1) drive downstream events including tumor cell repopulation, survival, inflammation, angiogenesis, invasion, and EMT.	Paclitaxel	103-108	twist basic helix-loop-helix transcription factor 1	Mus musculus	285-291
26575017-6	2016	Importantly, we found that downregulating p-Akt by inhibiting SET-mediated protein phosphatase 2A (PP2A) inactivation determined the pro-apoptotic effects of EMQA and paclitaxel combination treatment.	Paclitaxel	167-177	protein phosphatase 2 phosphatase activator	Homo sapiens	99-103
27635089-8	2017	In all three tumor xenograft models, changes in human serum mesothelin correlated with response to therapy and were undetectable in mice with complete tumor regression with RG7787 and nab-paclitaxel.Conclusions: RG7787 plus nab-paclitaxel is very active against primary human mesothelioma cells in vitro as well as in vivo, with serum mesothelin levels correlating with tumor response.	Paclitaxel	188-198	mesothelin	Mus musculus	60-70
27095936-3	2016	In this study, we aimed to investigate the effects of everolimus, gemcitabine, and paclitaxel in terms of cell viability and mRNA expression levels of GRP78, CCND1, CASP2, and BCL2 genes.	Paclitaxel	83-93	caspase 2	Homo sapiens	165-170
27635089-8	2017	In all three tumor xenograft models, changes in human serum mesothelin correlated with response to therapy and were undetectable in mice with complete tumor regression with RG7787 and nab-paclitaxel.Conclusions: RG7787 plus nab-paclitaxel is very active against primary human mesothelioma cells in vitro as well as in vivo, with serum mesothelin levels correlating with tumor response.	Paclitaxel	228-238	mesothelin	Mus musculus	60-70
29787015-0	2016	Clinical efficacy analysis of preoperative neoadjuvant chemotherapy with high-dose dense paclitaxel plus cisplatin in Stages IB2, IIA2, IIB cervical cancer in Iran.	Paclitaxel	89-99	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	125-128
28108288-4	2017	Enforced KLF4 expression by lentiviral transduction sensitized ovarian cancer cells to the effects of the chemotherapy drugs, paclitaxel and cisplatin.	Paclitaxel	126-136	Kruppel like factor 4	Homo sapiens	9-13
28277541-0	2017	The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells.	Paclitaxel	36-46	forkhead box M1	Homo sapiens	4-9
28277541-10	2017	The depletion of FOXM1 or ABCC5 with siRNA significantly blocked drug efflux and increased the intracellular concentrations of paclitaxel, thereby promoting paclitaxel-induced cell death.	Paclitaxel	127-137	forkhead box M1	Homo sapiens	17-22
28277541-10	2017	The depletion of FOXM1 or ABCC5 with siRNA significantly blocked drug efflux and increased the intracellular concentrations of paclitaxel, thereby promoting paclitaxel-induced cell death.	Paclitaxel	157-167	forkhead box M1	Homo sapiens	17-22
28277541-11	2017	Siomycin A, a FOXM1 inhibitor, significantly enhanced in vitro cell killing by paclitaxel in drug-resistant NPC cells.	Paclitaxel	79-89	forkhead box M1	Homo sapiens	14-19
28277541-12	2017	This study is the first to identify the roles of FOXM1 in drug efflux and paclitaxel resistance by regulating the gene transcription of abcc5, one of the ABC transporters.	Paclitaxel	74-84	forkhead box M1	Homo sapiens	49-54
12757643-0	2003	[Impact of cyclin-dependent kinase inhibitor p27 on resistance of ovarian cancer multicellular spheroids to taxol].	Paclitaxel	108-113	interferon alpha inducible protein 27	Homo sapiens	45-48
12757643-1	2003	OBJECTIVE: To examine the expression of the cyclin-dependent kinase inhibitor p27 in ovarian cancer multicellular spheroid (MCS) and explore the reversal effect of p27-antisense oligodeoxynucleotide (p27-ASON) on taxol resistance in ovarian cancer cell lines.	Paclitaxel	213-218	interferon alpha inducible protein 27	Homo sapiens	164-167
12757643-19	2003	P27-ASON reverses the resistance of ovarian cancer to taxol, thus increasing the chemotherapeutic sensitivity of ovarian cancer cells.	Paclitaxel	54-59	interferon alpha inducible protein 27	Homo sapiens	0-3
12538348-1	2003	Chfr, a mitotic stress checkpoint gene, regulates a prophase delay in cells exposed to agents that disrupt microtubules, such as nocodazole and taxol.	Paclitaxel	144-149	checkpoint with forkhead and ring finger domains	Homo sapiens	0-4
28277541-13	2017	Small molecular inhibitors of FOXM1 or ABCC5 have the potential to overcome paclitaxel chemoresistance in NPC patients.	Paclitaxel	76-86	forkhead box M1	Homo sapiens	30-35
29943935-0	2016	The expression and significance of WT1 in xenotransplanted ovarian carcinoma treated by paclitaxel.	Paclitaxel	88-98	WT1 transcription factor	Mus musculus	35-38
28534376-0	2017	VHL-TGFBI signaling is involved in the synergy between 5-aza-2"-deoxycytidine and paclitaxel against human renal cell carcinoma.	Paclitaxel	82-92	transforming growth factor beta induced	Homo sapiens	4-9
28534376-1	2017	PURPOSE: To analyse the role of von Hippel-Lindau (VHL) and transforming growth factor beta-induced (TGFBI) in synergistic mechanisms of 5-aza-2"-deoxycytidine (DAC) and paclitaxel (PTX) against renal cell carcinoma (RCC).	Paclitaxel	170-180	transforming growth factor beta induced	Homo sapiens	60-99
28534376-2	2017	METHODS: To elucidate the role in the synergy between DAC and PTX against RCC cells, TGFBI expression was regulated using siRNA technology and an expression vector containing the full-length cDNA for TGFBI was also transfected into RCC cells.	Paclitaxel	62-65	transforming growth factor beta induced	Homo sapiens	85-90
27301180-6	2016	However, although presenting an unfavorable pharmacokinetic profile, the biodistribution study showed that PTX/TPGS (1/40) micelles were more effective in promoting accumulation of PTX in drug resistant tumors than Taxol, due to the P-gp inhibition effect of TPGS.	Paclitaxel	107-110	phosphoglycolate phosphatase	Homo sapiens	233-237
28534376-4	2017	RESULTS: The results indicated that the expression of TGFBI was significantly decreased by DAC or PTX alone in vitro and in vivo.	Paclitaxel	98-101	transforming growth factor beta induced	Homo sapiens	54-59
28534376-5	2017	Moreover, the combination of DAC and PTX caused a synergistic decrease in the expression of TGFBI in RCC cells.	Paclitaxel	37-40	transforming growth factor beta induced	Homo sapiens	92-97
12708479-4	2003	Transport experiments using LLC-GA5-COL150 cell monolayers demonstrated that this effect of carvedilol was due to the inhibition of MDR1-mediated transport of vinblastine, paclitaxel, doxorubicin and daunorubicin.	Paclitaxel	172-182	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	132-136
26802653-10	2016	Our results revealed that inhibitors of microRNA-29a promote apoptosis through upregulation of HSP60 level and downregulation of HSP27, HSP40, HSP70, and HSP90 levels and could be contemplated as a compelling alternative for Taxol employment with similar effects and/or to sensitize cancer cells to chemotherapy with fewer side effects.	Paclitaxel	225-230	microRNA 29a	Homo sapiens	40-52
12480194-3	2002	In addition, overexpression of beta-tubulin III and stathmin can influence the sensitivity to microtubule interacting drugs, like vinorelbine and paclitaxel.	Paclitaxel	146-156	stathmin 1	Homo sapiens	52-60
26356996-8	2015	According to our data, cisplatin and paclitaxel strongly decreased T24 cells" viability, showing in parallel the ability to significantly down-regulate miR-143 levels, and up-regulate the expression levels of miR-145, miR-183, miR-96, and miR-182, which, in their total, demonstrated case-specific variations after recovery period.	Paclitaxel	37-47	microRNA 145	Homo sapiens	209-216
12435808-2	2002	In this study, we show that c-Myc expression is induced by many cellular insults, including cisplatin, doxorubicin, paclitaxel, 5-flourouracil, H(2)O(2), and radiation, and the enhanced expression of c-Myc protects against cell death caused by these cellular insults through ornithine decarboxylase (ODC) induction.	Paclitaxel	116-126	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	28-33
26460148-8	2015	Further histopathology, immunohistochemical and western blot analysis (bax, cas-9 and bcl-2) of apoptotic markers in breast tissues clearly showed the anti-carcinogenic property of fungal taxol.	Paclitaxel	188-193	BCL2 associated X, apoptosis regulator	Rattus norvegicus	71-74
12417528-12	2002	Arl3 behaved as a microtubule-associated protein: it co-localized with microtubules in HeLa cells and this was enhanced following microtubule stabilization with taxol.	Paclitaxel	161-166	regulator of microtubule dynamics 1	Homo sapiens	18-48
12150453-3	2002	Taxol treatment resulted in elevated expression of p53 and of p21, which was more pronounced and persistent in cyclin D1 overexpressing cells.	Paclitaxel	0-5	H3 histone pseudogene 16	Homo sapiens	62-65
12150453-4	2002	Overexpression of cyclin D1 altered sensitivity to taxol by modulating exit from mitosis, which is controlled by p21.	Paclitaxel	51-56	H3 histone pseudogene 16	Homo sapiens	113-116
26554377-0	2015	Down-Regulation of Nucleolar and Spindle-Associated Protein 1 (NUSAP1) Expression Suppresses Tumor and Cell Proliferation and Enhances Anti-Tumor Effect of Paclitaxel in Oral Squamous Cell Carcinoma.	Paclitaxel	156-166	nucleolar and spindle associated protein 1	Homo sapiens	19-61
12003772-3	2002	Incubation of PAEC with taxol (15 microM) for 2-4 h resulted in an increase in NO production, eNOS activity, and the amount of HSP90 binding to eNOS.	Paclitaxel	24-29	heat shock protein 90 alpha family class A member 1	Homo sapiens	127-132
12003772-6	2002	Geldanamycin, a HSP90 inhibitor, prevented the taxol-induced increase in eNOS activity.	Paclitaxel	47-52	heat shock protein 90 alpha family class A member 1	Homo sapiens	16-21
12032672-0	2002	Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent.	Paclitaxel	0-5	caspase 9	Homo sapiens	96-105
26554377-0	2015	Down-Regulation of Nucleolar and Spindle-Associated Protein 1 (NUSAP1) Expression Suppresses Tumor and Cell Proliferation and Enhances Anti-Tumor Effect of Paclitaxel in Oral Squamous Cell Carcinoma.	Paclitaxel	156-166	nucleolar and spindle associated protein 1	Homo sapiens	63-69
26554377-7	2015	In addition to the evaluation of cellular proliferation and cell cycle, we also investigated the potential role of NUSAP1 in paclitaxel (PTX)-induced cellular responses.	Paclitaxel	125-135	nucleolar and spindle associated protein 1	Homo sapiens	115-121
12032672-8	2002	We conclude that a unique caspase-3 and caspase-9 independent pathway is elicited by taxol to induce apoptosis in human ovarian and breast cancinoma cells.	Paclitaxel	85-90	caspase 9	Homo sapiens	40-49
11839682-2	2002	EXPERIMENTAL DESIGN: We have characterized paclitaxel-induced cell death with annexin V, propidium iodide staining, and poly(ADP-ribose) polymerase cleavage assays.	Paclitaxel	43-53	annexin A5	Homo sapiens	78-87
11839682-6	2002	RESULTS: Paclitaxel-treated cells displayed several features of apoptosis, including annexin V staining and poly(ADP-ribose) polymerase cleavage.	Paclitaxel	9-19	annexin A5	Homo sapiens	85-94
11677238-3	2002	In the present study, caspase activation and activity were examined in this cell line after treatment with the microtubule poison paclitaxel.	Paclitaxel	130-140	caspase 9	Homo sapiens	22-29
11677238-8	2002	Immunoblotting revealed that caspase-9, and -3, which were proteolytically cleaved in paclitaxel-treated MCF-7/caspase-3 cells, were sequestered in a salt-resistant sedimentable fraction rather than released to the cytosol.	Paclitaxel	86-96	caspase 9	Homo sapiens	29-46
11677238-8	2002	Immunoblotting revealed that caspase-9, and -3, which were proteolytically cleaved in paclitaxel-treated MCF-7/caspase-3 cells, were sequestered in a salt-resistant sedimentable fraction rather than released to the cytosol.	Paclitaxel	86-96	caspase 9	Homo sapiens	29-36
11751388-10	2001	These observations indicate that potent RAR alpha/beta selective agonists may be of therapeutic benefit in combination with Taxol therapy.	Paclitaxel	124-129	retinoic acid receptor alpha	Homo sapiens	40-49
11843253-1	2001	BACKGROUND: The combination of doxorubicin, paclitaxel, and cisplatin has activity in gynecologic malignancies but requires colony stimulating factor (G-CSF) support.	Paclitaxel	44-54	colony stimulating factor 3	Homo sapiens	151-156
11709565-5	2001	Paclitaxel 80 mg/m(2) was administered weekly for 4 weeks per 4-week cycle.	Paclitaxel	0-10	PER3 pseudogene 1	Homo sapiens	58-63
11724235-6	2001	In vitro release kinetics showed that the release was very slow, the release of paclitaxel from F68-SLN is linear, and the release of paclitaxel from Brij78-SLN followed the Weibull equation.	Paclitaxel	80-90	sarcolipin	Mus musculus	100-103
11724235-6	2001	In vitro release kinetics showed that the release was very slow, the release of paclitaxel from F68-SLN is linear, and the release of paclitaxel from Brij78-SLN followed the Weibull equation.	Paclitaxel	134-144	sarcolipin	Mus musculus	157-160
11759069-1	2001	The cytotoxic efficacy and kinetics involved in sensitization of Apo2L/TRAIL-resistant, androgen-independent prostate cancer cells to Apo2L/TRAIL or tumor necrosis factor-alpha or Fas ligand-mediated apoptosis were tested using subclinical concentrations of actinomycin D, paclitaxel, cisplatinum, gemcitabine, and radiation in CL-1, LNCaP, DU-145, and PC3 prostate cancer cell lines.	Paclitaxel	273-283	Fas ligand	Homo sapiens	180-190
11600533-0	2001	Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel.	Paclitaxel	172-182	caspase 9	Homo sapiens	50-59
11600533-3	2001	In ARO and KAT-4 cells, manumycin- plus paclitaxel-induced DNA fragmentation was blocked by the inhibitors of caspase-9, caspase-8, and caspase-3.	Paclitaxel	40-50	glutamic-oxaloacetic transaminase 2	Homo sapiens	11-16
11600533-3	2001	In ARO and KAT-4 cells, manumycin- plus paclitaxel-induced DNA fragmentation was blocked by the inhibitors of caspase-9, caspase-8, and caspase-3.	Paclitaxel	40-50	caspase 9	Homo sapiens	110-119
11605178-8	2001	Arm 1 has the best therapeutic index and will exceed the median survival seen in previous phase III trials with traditional schedules of paclitaxel and carboplatin.	Paclitaxel	137-147	ADRM1 26S proteasome ubiquitin receptor	Homo sapiens	0-5
11502446-10	2001	Species-specific clusterin ASOs also increased the cytotoxic effects of paclitaxel, reducing the 50% inhibitory concentration (IC(50)) of PC-3 and Shionogi cells by 75% to 90%.	Paclitaxel	72-82	clusterin	Mus musculus	17-26
11502446-11	2001	Although clusterin ASOs had no effect on the growth of established AI Shionogi or PC-3 tumors, clusterin ASOs synergistically enhanced paclitaxel-induced tumor regression in both Shionogi and PC-3 models.	Paclitaxel	135-145	clusterin	Mus musculus	95-104
11439344-0	2001	Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.	Paclitaxel	22-32	H3 histone pseudogene 16	Homo sapiens	65-68
11439344-3	2001	At these low concentrations that are insufficient to inhibit mitotic progression, PTX induced both p53 and p21 causing G1 and G2 arrest in A549.	Paclitaxel	82-85	H3 histone pseudogene 16	Homo sapiens	107-110
11877086-9	2001	Compared with the untransduced group, the expression of P-gp elevated by 10.98% after gene transduction and the CFU-GM yields were significantly increased at 48 nmol/L of MTX and 10 ng/ml or 12 ng/ml of taxol (P &lt; 0.05).	Paclitaxel	203-208	phosphoglycolate phosphatase	Homo sapiens	56-60
11350918-9	2001	Tumor regression was observed in all mice after treatment with ZD1839 plus paclitaxel, and it was accompanied by a significant potentiation in inhibition of TGF-alpha, VEGF, and bFGF expression with a few or no microvessels.	Paclitaxel	75-85	transforming growth factor alpha	Mus musculus	157-166
11676223-15	2001	Splenic cultures showed a linear dose-response to rh Epo at day 5 post-paclitaxel administration (p &lt; 0.05 with 125 mU/ml).	Paclitaxel	71-81	erythropoietin	Mus musculus	53-56
11676223-16	2001	Medullar and splenic total progenitor colony-forming units (CFU) scorings with and without rh Epo revealed a notable enhancement at 5 days post-paclitaxel treatment.	Paclitaxel	144-154	erythropoietin	Mus musculus	94-97
11676223-17	2001	Data from this study suggest that paclitaxel causes deep injury in the erythropoietic compartment, including temporary variations of Epo sensitivity in late bone marrow erythroid progenitors, early multilineage hematopoietic explosion and terminal erythroid precursors depletion as a result of a complex microenvironmental restitutive regulation.	Paclitaxel	34-44	erythropoietin	Mus musculus	133-136
11162660-1	2001	Cancer chemotherapy with taxol often fails due to acquired resistance of cancer cells, which is frequently associated with an overexpression of P-gp and alterations of beta-tubulin.	Paclitaxel	25-30	phosphoglycolate phosphatase	Homo sapiens	144-148
11179426-4	2001	We found that MT nucleation by centrosomes from Xenopus sperm or somatic cells and MT assembly promoted by dimethyl sulfoxide or paclitaxel induced stathmin/Op18 hyperphosphorylation in Xenopus egg extracts, leading to new stathmin/Op18 isoforms phosphorylated on Ser 16.	Paclitaxel	129-139	LOC108706401	Xenopus laevis	148-156
11405287-1	2001	PURPOSE: To develop a facile functional assay for quantitative determination of the apparent affinities of compounds that interact with the taxol binding site of P-glcoprotein (P-gp) in Caco-2 cell monolayers.	Paclitaxel	140-145	phosphoglycolate phosphatase	Homo sapiens	162-175
11405287-1	2001	PURPOSE: To develop a facile functional assay for quantitative determination of the apparent affinities of compounds that interact with the taxol binding site of P-glcoprotein (P-gp) in Caco-2 cell monolayers.	Paclitaxel	140-145	phosphoglycolate phosphatase	Homo sapiens	177-181
11405287-7	2001	This difference in [3H]-taxol flux could be totally abolished by inclusion of (+/-)-verapamil (0.2 mM), a known inhibitor of P-gp, in the incubation medium.	Paclitaxel	24-29	phosphoglycolate phosphatase	Homo sapiens	125-129
11405287-9	2001	These results suggest that P-gp, not MRP, was involved in taxol transport.	Paclitaxel	58-63	phosphoglycolate phosphatase	Homo sapiens	27-31
11405287-12	2001	CONCLUSIONS: This assay allows a facile quantitation of the apparent affinities of compounds to the taxol-binding site in P-gp, however, this assay does not permit the differentiation of substrates and inhibitors.	Paclitaxel	100-105	phosphoglycolate phosphatase	Homo sapiens	122-126
11405287-13	2001	The potential of drug-drug interactions involving the taxol binding site of P-gp can be conveniently estimated using the protocol described in this paper.	Paclitaxel	54-59	phosphoglycolate phosphatase	Homo sapiens	76-80
11581576-5	2001	Our results demonstrated that co-expression of mouse TLR4 and mouse MD-2 was required for Taxol responsiveness, and that the TLR4/MD-2 complex is the shared molecule in Taxol and LPS signal transduction in mice.	Paclitaxel	90-95	lymphocyte antigen 96	Mus musculus	68-72
11581576-5	2001	Our results demonstrated that co-expression of mouse TLR4 and mouse MD-2 was required for Taxol responsiveness, and that the TLR4/MD-2 complex is the shared molecule in Taxol and LPS signal transduction in mice.	Paclitaxel	169-174	lymphocyte antigen 96	Mus musculus	130-134
11581576-6	2001	We also found that mouse MD-2, but not human MD-2, is involved in Taxol signaling, suggesting that MD-2 is responsible for the species-specific responsiveness to Taxol.	Paclitaxel	66-71	lymphocyte antigen 96	Mus musculus	25-29
11581576-6	2001	We also found that mouse MD-2, but not human MD-2, is involved in Taxol signaling, suggesting that MD-2 is responsible for the species-specific responsiveness to Taxol.	Paclitaxel	162-167	lymphocyte antigen 96	Mus musculus	25-29
11106431-3	2000	Purified 250-kDa MAP was able to bind to taxol-stabilized microtubules, although it lacked the ability to polymerize purified tubulin into microtubules.	Paclitaxel	41-46	regulator of microtubule dynamics 1	Homo sapiens	17-20
11093360-1	2000	This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin).	Paclitaxel	221-231	cyclin dependent kinase 1	Homo sapiens	119-123
11195457-15	2000	p53-mutated or wild-type mice were equally susceptible to the therapeutic effects of Taxol or Adriamycin.	Paclitaxel	85-90	transformation related protein 53, pseudogene	Mus musculus	0-3
11762380-8	2000	Furthermore, roots treated with the microtubule-stabilizing drug taxol improved the quality of actin preservation as evidenced by the thicker bundles of cortical actin.	Paclitaxel	65-70	actin-7	Zea mays	95-100
11129289-12	2000	However, paclitaxel suppressed p21 expression induced by SCH58500 4-fold in DU-145 and SK-OV-3 tumors.	Paclitaxel	9-19	H3 histone pseudogene 16	Homo sapiens	31-34
11054675-0	2000	Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells.	Paclitaxel	67-77	insulin like growth factor binding protein 3	Homo sapiens	0-44
11054675-0	2000	Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells.	Paclitaxel	67-77	insulin like growth factor binding protein 3	Homo sapiens	46-53
11054675-3	2000	Pre-dosing cells with non-glycosylated insulin-like growth factor binding protein-3 (ngIGFBP-3) had no effect on the cells per se but accentuated paclitaxel-induced apoptosis.	Paclitaxel	146-156	insulin like growth factor binding protein 3	Homo sapiens	39-83
11054675-6	2000	Endogenous production of IGFBP-3 by the cells after incubation with paclitaxel was evaluated using Western ligand blotting, specific IGFBP-3 immunoblotting and radioimmunoassay.	Paclitaxel	68-78	insulin like growth factor binding protein 3	Homo sapiens	25-32
11054675-7	2000	Paclitaxel increased endogenous IGFBP-3, which was further increased if the cells had been pre-dosed with ngIGFBP-3.	Paclitaxel	0-10	insulin like growth factor binding protein 3	Homo sapiens	32-39
11054675-8	2000	These findings suggest that IGFBP-3 may be an important modulator of paclitaxel-induced apoptosis.	Paclitaxel	69-79	insulin like growth factor binding protein 3	Homo sapiens	28-35
11097380-5	2000	Cytotoxicity of DTX and PCT for P388D1 cells became apparent 24 h after a 2-h incubation period with the drugs, and their effects were enhanced by CYP2E1 microsomes, but markedly decreased by CYP3A-induced microsomes.	Paclitaxel	24-27	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	147-153
11025661-2	2000	Treatment with vincristine or paclitaxel before DNA-damage or before leptomycin B treatment reduces nuclear accumulation of p53 and expression of mdm2 and p21.	Paclitaxel	30-40	H3 histone pseudogene 16	Homo sapiens	155-158
11068817-6	2000	Paclitaxel was also seen to cause differential effects on alpha-tubulin levels in the two strains.	Paclitaxel	0-10	alpha tubulin	Leishmania donovani	58-71
10976921-7	2000	Taxol or UV activated caspase activity in a JNK-dependent fashion and caused the cleavage of procaspase-9 to caspase-9, each inhibited by E2.	Paclitaxel	0-5	caspase 9	Homo sapiens	22-29
10976921-7	2000	Taxol or UV activated caspase activity in a JNK-dependent fashion and caused the cleavage of procaspase-9 to caspase-9, each inhibited by E2.	Paclitaxel	0-5	caspase 9	Homo sapiens	96-105
10883672-6	2000	Short-term treatment of H460 cells with 10 nM paclitaxel for up to 4 days resulted in induction of annexin IV, but not annexin II expression.	Paclitaxel	46-56	annexin A2	Homo sapiens	119-129
10910066-4	2000	We demonstrate that antisense inhibition of stathmin expression chemosensitizes K562 leukemic cells to the antitumor effects of Taxol and results in a synergistic inhibition of their growth and clonogenic potential.	Paclitaxel	128-133	stathmin 1	Homo sapiens	44-52
10910066-5	2000	In the presence of stathmin inhibition, exposure to Taxol results in more severe mitotic abnormalities (hypodiploidy and multinucleation).	Paclitaxel	52-57	stathmin 1	Homo sapiens	19-27
10928049-9	2000	Addition of chemotherapeutic agents either Taxol or Doxorubicin with Selenium caused further inhibition of MCF-7, SKBR-3, RH2, HCF8, and HepG2 cells.	Paclitaxel	43-48	Rh associated glycoprotein	Homo sapiens	122-125
10885610-1	2000	We investigated the expression of c-myc in HT29-D4, HBL100 and Caco-2 cells treated with microtubule stabilising (paclitaxel) or depolymerising agents (vinblastine, nocodazole).	Paclitaxel	114-124	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	34-39
10885610-3	2000	In HBL100 and Caco-2, when microtubules were stabilised with paclitaxel, c-myc expression also decreased.	Paclitaxel	61-71	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	73-78
10810342-7	2000	Paclitaxel treatment gradually and significantly blocked cell-cycle progression at G2/M phase and increased the accumulation of cyclin B1 and cdc2 in H358 cells.	Paclitaxel	0-10	cyclin B1	Homo sapiens	128-137
10810342-7	2000	Paclitaxel treatment gradually and significantly blocked cell-cycle progression at G2/M phase and increased the accumulation of cyclin B1 and cdc2 in H358 cells.	Paclitaxel	0-10	cyclin dependent kinase 1	Homo sapiens	142-146
10688042-8	2000	On the other hand, using microtubule-active drugs, vinblastine and paclitaxel, we found that PC3M and PC3 cells were more resistant than either DU145 or LNCaP cells.	Paclitaxel	67-77	proprotein convertase subtilisin/kexin type 1	Homo sapiens	93-96
10706091-9	2000	was highly active against the two human ovarian carcinoma xenografts 1A9 and HOC18 (90-100% tumor regressions) and showed significant activity on the paclitaxel-resistant MNB-PTX1 xenograft (10% tumor regressions).	Paclitaxel	150-160	paired like homeodomain 1	Homo sapiens	175-179
10644670-6	2000	Noticeable NFkappaB activation by Taxol was detected in Ba/F3 expressing mouse TLR4 and mouse MD-2 but not in the other transfectants.	Paclitaxel	34-39	lymphocyte antigen 96	Mus musculus	94-98
10644670-8	2000	MD-2 complex is responsible for the species specificity with respect to Taxol responsiveness.	Paclitaxel	72-77	lymphocyte antigen 96	Mus musculus	0-4
10644670-9	2000	Furthermore, Taxol-induced NFkappaB activation via TLR4.MD-2 was blocked by an LPS antagonist that blocks LPS-induced NFkappaB activation via TLR4.MD-2.	Paclitaxel	13-18	lymphocyte antigen 96	Mus musculus	56-60
10644670-9	2000	Furthermore, Taxol-induced NFkappaB activation via TLR4.MD-2 was blocked by an LPS antagonist that blocks LPS-induced NFkappaB activation via TLR4.MD-2.	Paclitaxel	13-18	lymphocyte antigen 96	Mus musculus	147-151
10644670-10	2000	These results demonstrated that coexpression of mouse TLR4 and mouse MD-2 is required for Taxol responsiveness and that the TLR4.MD-2 complex is the shared molecule in Taxol and LPS signal transduction in mice.	Paclitaxel	90-95	lymphocyte antigen 96	Mus musculus	69-73
10644670-10	2000	These results demonstrated that coexpression of mouse TLR4 and mouse MD-2 is required for Taxol responsiveness and that the TLR4.MD-2 complex is the shared molecule in Taxol and LPS signal transduction in mice.	Paclitaxel	168-173	lymphocyte antigen 96	Mus musculus	129-133
10769641-5	2000	The induction of apoptosis by paclitaxel was accompanied by an elevated level of p34cdc2 kinase activity, which was inhibited in the presence of EGF during the post-paclitaxel culture period.	Paclitaxel	165-175	cyclin dependent kinase 1	Homo sapiens	81-88
10769641-5	2000	The induction of apoptosis by paclitaxel was accompanied by an elevated level of p34cdc2 kinase activity, which was inhibited in the presence of EGF during the post-paclitaxel culture period.	Paclitaxel	165-175	epidermal growth factor	Homo sapiens	145-148
10769641-7	2000	Incubation of paclitaxel-treated MDA-MB-468 cell extracts with EGF-treated MDA-MB-468 cell extract, which exhibited elevation of p34cdc2 activity, inhibited the kinase activity.	Paclitaxel	14-24	epidermal growth factor	Homo sapiens	63-66
10769641-7	2000	Incubation of paclitaxel-treated MDA-MB-468 cell extracts with EGF-treated MDA-MB-468 cell extract, which exhibited elevation of p34cdc2 activity, inhibited the kinase activity.	Paclitaxel	14-24	cyclin dependent kinase 1	Homo sapiens	129-136
10769641-9	2000	Transfection of the cells with p21Waf1 antisense oligonucleotide abolished the induction of p21Waf1 and also significantly reduced inhibition by EGF of paclitaxel-induced apoptosis.	Paclitaxel	152-162	epidermal growth factor	Homo sapiens	145-148
10769641-10	2000	These studies demonstrate that p21Waf1 plays a key role in the inhibition of paclitaxel-induced apoptosis by EGF in MDA-MB-468 cells.	Paclitaxel	77-87	epidermal growth factor	Homo sapiens	109-112
11240649-0	2000	Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel.	Paclitaxel	149-159	C-C motif chemokine ligand 2	Homo sapiens	38-43
11240649-0	2000	Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel.	Paclitaxel	149-159	colony stimulating factor 2	Homo sapiens	45-51
11240649-7	2000	In serum, IL-6, IL-8 and MCP-1 decreased with the administration of steroids prior to paclitaxel, and increased in the 24 h after paclitaxel.	Paclitaxel	86-96	C-C motif chemokine ligand 2	Homo sapiens	25-30
11240649-7	2000	In serum, IL-6, IL-8 and MCP-1 decreased with the administration of steroids prior to paclitaxel, and increased in the 24 h after paclitaxel.	Paclitaxel	130-140	C-C motif chemokine ligand 2	Homo sapiens	25-30
11240649-10	2000	Treatment with paclitaxel is associated with an increase in expression of a limited number of cytokines in patients with ovarian cancer, notably IL-6, IL-8 and MCP-1.	Paclitaxel	15-25	C-C motif chemokine ligand 2	Homo sapiens	160-165
10637471-8	2000	Serine/threonine phosphorylation is also involved in the regulation of the apoptosis-controlling Bcl-2 protein, as certain phosphorylation events induced by cytokines such as IL-3 are anti-apoptotic, whereas other phosphorylation events triggered by chemotherapeutic drugs such as Paclitaxel are associated with cell death.	Paclitaxel	281-291	interleukin 3	Homo sapiens	175-179
10567572-8	1999	Moreover, the combination of dominant negative ASK1, (dnASK1), dnMKK7, and dnJNK1 inhibited paclitaxel-induced BCL-2 phosphorylation.	Paclitaxel	92-102	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	47-51
10471519-3	1999	The effects of loss of p53 on paclitaxel cytotoxicity depend on cell type (normal murine fibroblasts vs. human cancer cells) and duration of exposure to paclitaxel; p53 status marginally affects paclitaxel sensitivity in human cancer.	Paclitaxel	30-40	transformation related protein 53, pseudogene	Mus musculus	23-26
10471519-3	1999	The effects of loss of p53 on paclitaxel cytotoxicity depend on cell type (normal murine fibroblasts vs. human cancer cells) and duration of exposure to paclitaxel; p53 status marginally affects paclitaxel sensitivity in human cancer.	Paclitaxel	153-163	transformation related protein 53, pseudogene	Mus musculus	23-26
10471519-3	1999	The effects of loss of p53 on paclitaxel cytotoxicity depend on cell type (normal murine fibroblasts vs. human cancer cells) and duration of exposure to paclitaxel; p53 status marginally affects paclitaxel sensitivity in human cancer.	Paclitaxel	153-163	transformation related protein 53, pseudogene	Mus musculus	23-26
10521070-20	1999	Key Words: Paclitaxel-G-CSF-Small-cell lung cancer-North Central Cancer Treatment Group.	Paclitaxel	11-21	colony stimulating factor 3	Homo sapiens	22-27
10510942-4	1999	Paclitaxel-induced G2/M cell cycle arrest correlated with cdc2 kinase activity and bcl-2 phosphorylation.	Paclitaxel	0-10	cyclin dependent kinase 1	Homo sapiens	58-62
10411906-1	1999	Apoptosis signal-regulating kinase 1 (ASK1) is a pivotal component of a signaling pathway induced by many death stimuli, including tumor necrosis factor alpha, Fas, and the anticancer drugs cisplatin and paclitaxel.	Paclitaxel	204-214	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	0-36
10411906-1	1999	Apoptosis signal-regulating kinase 1 (ASK1) is a pivotal component of a signaling pathway induced by many death stimuli, including tumor necrosis factor alpha, Fas, and the anticancer drugs cisplatin and paclitaxel.	Paclitaxel	204-214	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	38-42
10321832-6	1999	E2 prevented down-regulation of p21 and Bcl-2 induced by taxol but did not prevent the down-regulation of p21 induced by etoposide, consistent with the failure of E2 to inhibit etoposide-induced cell death.	Paclitaxel	57-62	H3 histone pseudogene 16	Homo sapiens	32-35
28534376-8	2017	CONCLUSIONS: Our study suggests that VHL-TGFBI signaling is involved in the synergy between DAC and PTX against RCC cells.	Paclitaxel	100-103	transforming growth factor beta induced	Homo sapiens	41-46
27999205-6	2017	Using siRNA, we showed that knockdown of MYH in PC cells 1) reduced PC cell proliferation and increased apoptosis; 2) further decreased PC cell growth in the presence of oxidative stress and chemotherapy agents (gemcitabine, paclitaxel and vincristine); 3) reduced PC cell metastatic potential; and 4) decreased PC tumor growth in a subcutaneous mouse model in vivo.	Paclitaxel	225-235	mutY DNA glycosylase	Mus musculus	41-44
27842858-2	2017	In addition, through modifying by tLyP-1, the anticancer scope of tLyP-1-HA-PTX conjugate was expanded from tumor cells expressing CD44 receptors to those of expressing NRP1 receptors.	Paclitaxel	76-79	CD44 molecule (Indian blood group)	Homo sapiens	131-135
27842858-5	2017	The tLyP-1-HA-PTX conjugate was especially endowed with efficient cell-penetrating and tumor NRP1 receptor targeting ability and compensate for the decreasing of uptake caused by suppression of CD44 receptor, which is more significant when NRP1 receptor is highly expressed.	Paclitaxel	14-17	CD44 molecule (Indian blood group)	Homo sapiens	194-198
28808193-2	2017	Paclitaxel, when incorporated into LDE, promotes atherosclerosis regression with reduced drug toxicity in rabbits through LDLR.	Paclitaxel	0-10	low-density lipoprotein receptor	Oryctolagus cuniculus	122-126
28138318-9	2016	Paclitaxel increased the levels of phosphorylated protein kinase C, phosphorylated nuclear factor kappaB, phosphodiesterase 4D (PDE4D), IL-1beta, and monocyte chemoattractant protein-1 in the lumbar dorsal root ganglia; however, tempol decreased these levels.	Paclitaxel	0-10	phosphodiesterase 4D	Rattus norvegicus	106-126
28138318-9	2016	Paclitaxel increased the levels of phosphorylated protein kinase C, phosphorylated nuclear factor kappaB, phosphodiesterase 4D (PDE4D), IL-1beta, and monocyte chemoattractant protein-1 in the lumbar dorsal root ganglia; however, tempol decreased these levels.	Paclitaxel	0-10	phosphodiesterase 4D	Rattus norvegicus	128-133
28714351-6	2017	Paclitaxel resulted in expression of NLRP3 and activated fragments of caspase-1 and interleukin-1beta in L4-6 dorsal root ganglia and sciatic nerve three weeks after injection, indicating activation of NLRP3 inflammasome.	Paclitaxel	0-10	caspase 1	Rattus norvegicus	70-79
27732968-12	2016	CONCLUSION: Rare variants in SBF2, a CMT gene, predict an increased risk of TIPN in AA patients receiving paclitaxel.	Paclitaxel	106-116	SET binding factor 2	Homo sapiens	29-33
28051262-8	2016	Knockdown of IGF1R significantly decreased IC50 of 5-FU, paclitaxel (PTX) and Doxorubicin (DOX) in Huh7 and HepG2 cells.	Paclitaxel	57-67	insulin like growth factor 1 receptor	Homo sapiens	13-18
28051262-8	2016	Knockdown of IGF1R significantly decreased IC50 of 5-FU, paclitaxel (PTX) and Doxorubicin (DOX) in Huh7 and HepG2 cells.	Paclitaxel	57-67	MIR7-3 host gene	Homo sapiens	99-103
28051262-8	2016	Knockdown of IGF1R significantly decreased IC50 of 5-FU, paclitaxel (PTX) and Doxorubicin (DOX) in Huh7 and HepG2 cells.	Paclitaxel	69-72	insulin like growth factor 1 receptor	Homo sapiens	13-18
28051262-8	2016	Knockdown of IGF1R significantly decreased IC50 of 5-FU, paclitaxel (PTX) and Doxorubicin (DOX) in Huh7 and HepG2 cells.	Paclitaxel	69-72	MIR7-3 host gene	Homo sapiens	99-103
28051262-10	2016	MiR-379 overexpression sensitized Huh7 and HepG2 cells to 5-FU, PTX and DOX and also enhanced DOX-induced cell apoptosis.	Paclitaxel	64-67	MIR7-3 host gene	Homo sapiens	34-38
27840924-0	2016	Basic helix-loop-helix transcription factor DEC2 functions as an anti-apoptotic factor during paclitaxel-induced apoptosis in human prostate cancer cells.	Paclitaxel	94-104	basic helix-loop-helix family member e41	Homo sapiens	44-48
27840924-5	2016	The expression of DEC1 and DEC2 was decreased in DU145 cells but was increased in PC-3 cells when treated with paclitaxel.	Paclitaxel	111-121	basic helix-loop-helix family member e41	Homo sapiens	27-31
27840924-7	2016	In addition, the amount of cleaved PARP was decreased by DEC1 siRNA, while it was increased by DEC2 siRNA in the presence of paclitaxel.	Paclitaxel	125-135	basic helix-loop-helix family member e41	Homo sapiens	95-99
27840924-9	2016	In conclusion, DEC1, at least partly, exerted a pro-apoptotic effect, whereas DEC2 exerted an anti-apoptotic effect in paclitaxel-induced apoptosis of human prostate cancer cells.	Paclitaxel	119-129	basic helix-loop-helix family member e41	Homo sapiens	78-82
27779704-5	2016	In addition, overexpression of miR-422a was able to inhibit cell proliferation and the ability of invasion, and enhance paclitaxel and cisplatin-mediated apoptosis in OS cells.	Paclitaxel	120-130	microRNA 422a	Homo sapiens	31-39
27845771-0	2016	The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non-small-cell Lung Cancer Through Altering STAT3 Expression.	Paclitaxel	61-71	membrane associated ring-CH-type finger 8	Homo sapiens	10-13
27845771-10	2016	Furthermore, we identified that miR-9600 augmented paclitaxel and cisplatin sensitivity by downregulating STAT3 and promoting chemotherapy-induced apoptosis.	Paclitaxel	51-61	membrane associated ring-CH-type finger 8	Homo sapiens	32-35
27754697-2	2016	This study is aimed to determine the impact of the MBP hematopoietic PBX-interaction protein (HPIP) on breast cancer cell sensitivity to paclitaxel.	Paclitaxel	137-147	PBX homeobox interacting protein 1	Homo sapiens	94-98
27754697-3	2016	RESULTS: In this study, we show that breast cancer cells (MCF-7 and MDA-MB-231) overexpressing HPIP were more sensitive to paclitaxel treatment as evaluated by MTT assay, exhibiting a significant reduction in IC50 of paclitaxel compared with the control.	Paclitaxel	123-133	PBX homeobox interacting protein 1	Homo sapiens	95-99
27754697-3	2016	RESULTS: In this study, we show that breast cancer cells (MCF-7 and MDA-MB-231) overexpressing HPIP were more sensitive to paclitaxel treatment as evaluated by MTT assay, exhibiting a significant reduction in IC50 of paclitaxel compared with the control.	Paclitaxel	217-227	PBX homeobox interacting protein 1	Homo sapiens	95-99
27754697-4	2016	In transwell assay, breast cancer cells overexpressing HPIP, but not the cells transfected with empty vector, showed significant migration inhibition in response to paclitaxel.	Paclitaxel	165-175	PBX homeobox interacting protein 1	Homo sapiens	55-59
27754697-7	2016	CONCLUSIONS: Collectively, HPIP sensitized breast cancer cells to paclitaxel through a microtubule-dependent mechanism.	Paclitaxel	66-76	PBX homeobox interacting protein 1	Homo sapiens	27-31
27754697-8	2016	Our finding hints at a clinical value of HPIP in breast cancer patient selection for paclitaxel-based regimens in the context of precision medicine.	Paclitaxel	85-95	PBX homeobox interacting protein 1	Homo sapiens	41-45
27600258-0	2016	Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.	Paclitaxel	34-44	musashi RNA binding protein 2	Homo sapiens	0-9
27600258-6	2016	We found that MSI2 was overexpressed in paclitaxel-resistant ovarian cancer SKOV3-TR cells but not in paclitaxel-sensitive cell lines.	Paclitaxel	40-50	musashi RNA binding protein 2	Homo sapiens	14-18
27600258-7	2016	The loss of MSI2 expression in lentivirus-mediated stable MSI2 knockdown SKOV3-TR cells impaired paclitaxel resistance as determined using cell viability and apoptosis assays.	Paclitaxel	97-107	musashi RNA binding protein 2	Homo sapiens	12-16
27600258-7	2016	The loss of MSI2 expression in lentivirus-mediated stable MSI2 knockdown SKOV3-TR cells impaired paclitaxel resistance as determined using cell viability and apoptosis assays.	Paclitaxel	97-107	musashi RNA binding protein 2	Homo sapiens	58-62
27600258-8	2016	In contrast, lentivirus-mediated MSI2 overexpression promoted the development of paclitaxel resistance in paclitaxel-sensitive ovarian cancer cells.	Paclitaxel	81-91	musashi RNA binding protein 2	Homo sapiens	33-37
27600258-8	2016	In contrast, lentivirus-mediated MSI2 overexpression promoted the development of paclitaxel resistance in paclitaxel-sensitive ovarian cancer cells.	Paclitaxel	106-116	musashi RNA binding protein 2	Homo sapiens	33-37
27664577-10	2016	We found up-regulation of ABCG2/BCRP and ABCC4 proteins only in paclitaxel-resistant SK-BR-3 cells.	Paclitaxel	64-74	ATP binding cassette subfamily C member 4	Homo sapiens	41-46
27664577-11	2016	In paclitaxel-resistant MCF-7 cells, ABCB4/MDR3 and ABCC2/MRP2 proteins were up-regulated.	Paclitaxel	3-13	ATP binding cassette subfamily B member 4	Homo sapiens	37-42
27664577-11	2016	In paclitaxel-resistant MCF-7 cells, ABCB4/MDR3 and ABCC2/MRP2 proteins were up-regulated.	Paclitaxel	3-13	ATP binding cassette subfamily B member 4	Homo sapiens	43-47
27664577-11	2016	In paclitaxel-resistant MCF-7 cells, ABCB4/MDR3 and ABCC2/MRP2 proteins were up-regulated.	Paclitaxel	3-13	ATP binding cassette subfamily C member 2	Homo sapiens	52-57
27664577-11	2016	In paclitaxel-resistant MCF-7 cells, ABCB4/MDR3 and ABCC2/MRP2 proteins were up-regulated.	Paclitaxel	3-13	ATP binding cassette subfamily C member 2	Homo sapiens	58-62
27798187-6	2016	Paclitaxel-induced mechanical allodynia was prolonged in T-cell-deficient (Rag1-/-) mice compared with wild-type (WT) mice.	Paclitaxel	0-10	recombination activating 1	Mus musculus	75-79
27798187-10	2016	Inhibition of endogenous IL-10 signaling by intrathecal injection of anti-IL-10 to WT mice or Rag1-/- mice reconstituted with CD8+ T cells delayed recovery from paclitaxel-induced mechanical allodynia.	Paclitaxel	161-171	recombination activating 1	Mus musculus	94-98
27563006-7	2016	The results showed that paclitaxel decreased the mechanical nociceptive thresholds and increased GFAP expression, leading to spinal astrocyte activation.	Paclitaxel	24-34	glial fibrillary acidic protein	Homo sapiens	97-101
27622658-1	2016	TGFBI has been shown to sensitize ovarian cancer cells to the cytotoxic effects of paclitaxel via an integrin receptor-mediated mechanism that modulates microtubule stability.	Paclitaxel	83-93	transforming growth factor beta induced	Homo sapiens	0-5
27698946-4	2016	We successfully design a paclitaxel (PTX) and alpha-galactosylceramide (alphaGC) co-loaded TH peptide (AGYLLGHINLHHLAHL(Aib)HHIL-Cys) -modified liposome (PTX/alphaGC-TH-Lip) and introduce a new concept of immuno-chemotherapy combination via accumulation of these liposomes at both spleen and tumor sites naturally and simultaneously.	Paclitaxel	25-35	ANIB1	Homo sapiens	120-123
27698946-4	2016	We successfully design a paclitaxel (PTX) and alpha-galactosylceramide (alphaGC) co-loaded TH peptide (AGYLLGHINLHHLAHL(Aib)HHIL-Cys) -modified liposome (PTX/alphaGC-TH-Lip) and introduce a new concept of immuno-chemotherapy combination via accumulation of these liposomes at both spleen and tumor sites naturally and simultaneously.	Paclitaxel	37-40	ANIB1	Homo sapiens	120-123
27422607-8	2016	Ectopic expression of MKK3, an upstream activator of p38 MAPK, significantly up-regulated the expression of p-glycoprotein and increased the consequent resistance against paclitaxel in HeyA8 cells.	Paclitaxel	171-181	mitogen-activated protein kinase kinase 3	Homo sapiens	22-26
27195913-6	2016	Subsequently, we identified a novel mechanism by which paclitaxel induced necroptosis in lung adenocarcinoma cells that was dependent upon p-Casp8, receptor-interacting protein kinase 1 (RIPK1), and RIPK3.	Paclitaxel	55-65	receptor interacting serine/threonine kinase 3	Homo sapiens	199-204
27233913-7	2016	We concluded that HCB-MSC can restore the ovarian function after paclitaxel injection through a direct triggering effect on the ovarian epithelium and/or indirect enrichment of ovarian niche through regulating tissue expression of CK 8/18, TGF-ss and PCNA.	Paclitaxel	65-75	keratin 8	Homo sapiens	231-235
27305935-8	2016	Notably, paclitaxel-loaded HA-PLGA NPs (PTX-HA-PLGA NPs) exhibited better antitumor effects in CD44-positive MCF-7 breast tumor cells than Taxol (a clinical paclitaxel formulation).	Paclitaxel	9-19	CD44 molecule (Indian blood group)	Homo sapiens	95-99
27060927-11	2016	CDX2 induced MDR1-dependent resistance to vincristine and paclitaxel, which was reversed by treatment with the MDR1-specific inhibitor verapamil.	Paclitaxel	58-68	caudal type homeobox 2	Homo sapiens	0-4
27177222-10	2016	Our findings also support that the combinatorial treatments of entinostat and paclitaxel will likely exhibit survival benefit in the NSCLC patients with overexpression of DNMT1 and/or Survivin.	Paclitaxel	78-88	DNA methyltransferase 1	Homo sapiens	171-176
27313746-12	2016	Beclin 1 inhibited proliferation and increased apoptosis of HeLa cells, and also increased the chemosensitivity of these cells to Taxol .	Paclitaxel	130-135	beclin 1	Homo sapiens	0-8
27455550-1	2016	Paclitaxel (PTX), a BCS class IV drug that is characterized by its poor solubility and is a substrate for P-glycoprotein, is one of the most widely used antineoplastic agents.	Paclitaxel	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	106-120
27455550-1	2016	Paclitaxel (PTX), a BCS class IV drug that is characterized by its poor solubility and is a substrate for P-glycoprotein, is one of the most widely used antineoplastic agents.	Paclitaxel	12-15	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	106-120
26666408-1	2016	To increase the anti-tumor activity of paclitaxel (PTX), novel temperature-sensitive liposomes loading paclitaxel (PTX-TSL) were developed.	Paclitaxel	39-49	TSL	Homo sapiens	119-122
26666408-1	2016	To increase the anti-tumor activity of paclitaxel (PTX), novel temperature-sensitive liposomes loading paclitaxel (PTX-TSL) were developed.	Paclitaxel	51-54	TSL	Homo sapiens	119-122
26666408-1	2016	To increase the anti-tumor activity of paclitaxel (PTX), novel temperature-sensitive liposomes loading paclitaxel (PTX-TSL) were developed.	Paclitaxel	103-113	TSL	Homo sapiens	119-122
26666408-2	2016	In vitro, characteristics of PTX-TSL were evaluated.	Paclitaxel	29-32	TSL	Homo sapiens	33-36
26666408-4	2016	The phase-transition temperature of PTX-TSL determined by differential scanning calorimetry was about 42  C. The result of in vitro drug release from PTX-TSL illustrated that release rate at 37  C was obviously lower than that at 42  C. Stability data indicated that the liposome was physically and chemically stable for at least 3 months at -20  C. In vivo study, after three injections with hyperthermia in the xenograft lung tumor model, PTX-TSL showed distinguished tumor growth suppression, compared with non-temperature-sensitive liposome and free drug.	Paclitaxel	36-39	TSL	Homo sapiens	40-43
26666408-4	2016	The phase-transition temperature of PTX-TSL determined by differential scanning calorimetry was about 42  C. The result of in vitro drug release from PTX-TSL illustrated that release rate at 37  C was obviously lower than that at 42  C. Stability data indicated that the liposome was physically and chemically stable for at least 3 months at -20  C. In vivo study, after three injections with hyperthermia in the xenograft lung tumor model, PTX-TSL showed distinguished tumor growth suppression, compared with non-temperature-sensitive liposome and free drug.	Paclitaxel	36-39	TSL	Homo sapiens	154-157
26666408-4	2016	The phase-transition temperature of PTX-TSL determined by differential scanning calorimetry was about 42  C. The result of in vitro drug release from PTX-TSL illustrated that release rate at 37  C was obviously lower than that at 42  C. Stability data indicated that the liposome was physically and chemically stable for at least 3 months at -20  C. In vivo study, after three injections with hyperthermia in the xenograft lung tumor model, PTX-TSL showed distinguished tumor growth suppression, compared with non-temperature-sensitive liposome and free drug.	Paclitaxel	36-39	TSL	Homo sapiens	154-157
26666408-4	2016	The phase-transition temperature of PTX-TSL determined by differential scanning calorimetry was about 42  C. The result of in vitro drug release from PTX-TSL illustrated that release rate at 37  C was obviously lower than that at 42  C. Stability data indicated that the liposome was physically and chemically stable for at least 3 months at -20  C. In vivo study, after three injections with hyperthermia in the xenograft lung tumor model, PTX-TSL showed distinguished tumor growth suppression, compared with non-temperature-sensitive liposome and free drug.	Paclitaxel	150-153	TSL	Homo sapiens	40-43
26666408-4	2016	The phase-transition temperature of PTX-TSL determined by differential scanning calorimetry was about 42  C. The result of in vitro drug release from PTX-TSL illustrated that release rate at 37  C was obviously lower than that at 42  C. Stability data indicated that the liposome was physically and chemically stable for at least 3 months at -20  C. In vivo study, after three injections with hyperthermia in the xenograft lung tumor model, PTX-TSL showed distinguished tumor growth suppression, compared with non-temperature-sensitive liposome and free drug.	Paclitaxel	150-153	TSL	Homo sapiens	154-157
26666408-4	2016	The phase-transition temperature of PTX-TSL determined by differential scanning calorimetry was about 42  C. The result of in vitro drug release from PTX-TSL illustrated that release rate at 37  C was obviously lower than that at 42  C. Stability data indicated that the liposome was physically and chemically stable for at least 3 months at -20  C. In vivo study, after three injections with hyperthermia in the xenograft lung tumor model, PTX-TSL showed distinguished tumor growth suppression, compared with non-temperature-sensitive liposome and free drug.	Paclitaxel	150-153	TSL	Homo sapiens	154-157
26666408-4	2016	The phase-transition temperature of PTX-TSL determined by differential scanning calorimetry was about 42  C. The result of in vitro drug release from PTX-TSL illustrated that release rate at 37  C was obviously lower than that at 42  C. Stability data indicated that the liposome was physically and chemically stable for at least 3 months at -20  C. In vivo study, after three injections with hyperthermia in the xenograft lung tumor model, PTX-TSL showed distinguished tumor growth suppression, compared with non-temperature-sensitive liposome and free drug.	Paclitaxel	150-153	TSL	Homo sapiens	40-43
26666408-4	2016	The phase-transition temperature of PTX-TSL determined by differential scanning calorimetry was about 42  C. The result of in vitro drug release from PTX-TSL illustrated that release rate at 37  C was obviously lower than that at 42  C. Stability data indicated that the liposome was physically and chemically stable for at least 3 months at -20  C. In vivo study, after three injections with hyperthermia in the xenograft lung tumor model, PTX-TSL showed distinguished tumor growth suppression, compared with non-temperature-sensitive liposome and free drug.	Paclitaxel	150-153	TSL	Homo sapiens	154-157
26666408-4	2016	The phase-transition temperature of PTX-TSL determined by differential scanning calorimetry was about 42  C. The result of in vitro drug release from PTX-TSL illustrated that release rate at 37  C was obviously lower than that at 42  C. Stability data indicated that the liposome was physically and chemically stable for at least 3 months at -20  C. In vivo study, after three injections with hyperthermia in the xenograft lung tumor model, PTX-TSL showed distinguished tumor growth suppression, compared with non-temperature-sensitive liposome and free drug.	Paclitaxel	150-153	TSL	Homo sapiens	154-157
26666408-5	2016	The results of intratumoral drug concentration indicated that PTX-TSL combined with hyperthermia delivered more paxlitaxel into the tumor location than the other two paxlitaxel formulations.	Paclitaxel	62-65	TSL	Homo sapiens	66-69
26666408-6	2016	In summary, PTX-TSL combined with hyperthermia significantly inhibited tumor growth, due to the increased targeting efficiency of PTX to tumor tissues.	Paclitaxel	12-15	TSL	Homo sapiens	16-19
26666408-6	2016	In summary, PTX-TSL combined with hyperthermia significantly inhibited tumor growth, due to the increased targeting efficiency of PTX to tumor tissues.	Paclitaxel	130-133	TSL	Homo sapiens	16-19
26921335-3	2016	p28 enhanced the cytotoxic activity of lower concentrations (IC20-50) of DNA-damaging drugs (doxorubicin, dacarbazine, temozolamide) or antimitotic drugs (paclitaxel and docetaxel) in a variety of cancer cells expressing wild-type or mutated p53.	Paclitaxel	155-165	golgi SNAP receptor complex member 1	Homo sapiens	0-3
26980709-4	2016	Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERalpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells.	Paclitaxel	43-53	DNA methyltransferase 1	Homo sapiens	93-98
26980709-4	2016	Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERalpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells.	Paclitaxel	43-53	DNA methyltransferase 1	Homo sapiens	132-137
26980709-4	2016	Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERalpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells.	Paclitaxel	55-58	DNA methyltransferase 1	Homo sapiens	93-98
26980709-4	2016	Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERalpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells.	Paclitaxel	55-58	DNA methyltransferase 1	Homo sapiens	132-137
26980709-4	2016	Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERalpha binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells.	Paclitaxel	170-173	DNA methyltransferase 1	Homo sapiens	93-98
27128470-0	2016	Up-regulation of KIF14 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in cervical cancer.	Paclitaxel	110-120	kinesin family member 14	Homo sapiens	17-22
27128470-3	2016	Real-time PCR was performed to assess the expression levels of KIF14 in 47 pairs of cervical cancer tissues and their matched normal tissues from patients who had not been exposed to chemotherapy as well as tissue samples from 57 cervical cancer patients who are sensitive to paclitaxel treatment and 53 patients who are resistant.	Paclitaxel	276-286	kinesin family member 14	Homo sapiens	63-68
27128470-8	2016	Kaplan-Meier analysis showed that high KIF14 expression levels predicted poor survival in patients with (P=0.0024) or without (P=0.0028) paclitaxel treatment.	Paclitaxel	137-147	kinesin family member 14	Homo sapiens	39-44
27128470-10	2016	Our study suggests that KIF14 may serve as a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in cervical cancer.	Paclitaxel	127-137	kinesin family member 14	Homo sapiens	24-29
26973433-14	2016	Suppressing Spry4 increased mammosphere formation, while decreasing the sensitivity of MDA-MB-231 cells to Paclitaxel treatment.	Paclitaxel	107-117	sprouty RTK signaling antagonist 4	Homo sapiens	12-17
26691219-12	2016	In vitro and in vivo experiments showed that ITM2A expression significantly reduced the paclitaxel and carboplatin IC50 and tumor mass after paclitaxel treatment.	Paclitaxel	88-98	integral membrane protein 2A	Homo sapiens	45-50
26691219-12	2016	In vitro and in vivo experiments showed that ITM2A expression significantly reduced the paclitaxel and carboplatin IC50 and tumor mass after paclitaxel treatment.	Paclitaxel	141-151	integral membrane protein 2A	Homo sapiens	45-50
26863629-4	2016	miR-217 and CAGE oppositely regulated the response to anti-cancer drugs such as taxol, gefitinib and trastuzumab, an inhibitor of HER2.	Paclitaxel	80-85	microRNA 217	Homo sapiens	0-7
10347252-6	1999	p21(waf1) induction also inhibited the increased cyclin B1-associated kinase activity induced by paclitaxel.	Paclitaxel	97-107	cyclin B1	Homo sapiens	49-58
10561191-0	1999	Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison.	Paclitaxel	182-192	colony stimulating factor 3	Homo sapiens	27-64
10053098-0	1999	A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer.	Paclitaxel	181-191	colony stimulating factor 3	Homo sapiens	133-170
10071279-8	1999	CONCLUSION: When combined with doxorubicin (60 mg/m2) and dexrazoxane (600 mg/m2), paclitaxel given as a 3-hour infusion had an MTD of 150 mg/m2, and G-CSF was required to prevent febrile neutropenia.	Paclitaxel	83-93	colony stimulating factor 3	Homo sapiens	150-155
9930748-12	1999	Consistent with these data, CSF cleaved tau bound taxol-polymerized microtubules, indicating a functionally intact microtubule binding domain.	Paclitaxel	50-55	microtubule associated protein tau	Homo sapiens	40-43
25961928-6	2016	Crucially, resembling paclitaxel treatment, silencing of FOXM1 and KIF20A similarly promotes abnormal mitotic spindle morphology and chromosome alignment, which have been shown to induce mitotic catastrophe-dependent senescence.	Paclitaxel	22-32	forkhead box M1	Homo sapiens	57-62
25961928-8	2016	Statistical analysis reveals that both FOXM1 and KIF20A protein and mRNA expression significantly associates with poor survival, consistent with a role of FOXM1 and KIF20A in paclitaxel action and resistance.	Paclitaxel	175-185	forkhead box M1	Homo sapiens	39-44
25961928-8	2016	Statistical analysis reveals that both FOXM1 and KIF20A protein and mRNA expression significantly associates with poor survival, consistent with a role of FOXM1 and KIF20A in paclitaxel action and resistance.	Paclitaxel	175-185	forkhead box M1	Homo sapiens	155-160
25961928-9	2016	Collectively, our findings suggest that paclitaxel targets the FOXM1-KIF20A axis to drive abnormal mitotic spindle formation and mitotic catastrophe and that deregulated FOXM1 and KIF20A expression may confer paclitaxel resistance.	Paclitaxel	40-50	forkhead box M1	Homo sapiens	63-68
25961928-9	2016	Collectively, our findings suggest that paclitaxel targets the FOXM1-KIF20A axis to drive abnormal mitotic spindle formation and mitotic catastrophe and that deregulated FOXM1 and KIF20A expression may confer paclitaxel resistance.	Paclitaxel	209-219	forkhead box M1	Homo sapiens	170-175
26554377-11	2015	Furthermore, apoptosis induced by PTX was enhanced in NUSAP1 knockdown OSCC cells.	Paclitaxel	34-37	nucleolar and spindle associated protein 1	Homo sapiens	54-60
26554377-13	2015	Moreover, down-regulated NUSAP1 expression suppresses tumor proliferation and also enhances anti-tumor effect of PTX by activating apoptotic pathways.	Paclitaxel	113-116	nucleolar and spindle associated protein 1	Homo sapiens	25-31
26913604-3	2016	To develop a new model to define this mechanism, we heterologously expressed a mouse Nmnat1 non-nuclear-localized gain-of-function mutant gene (m-nonN-Nmnat1) in the nematode Caenorhabditis elegans and show that it provides protection from both hypoxia-induced animal death and taxol-induced axonal pathology.	Paclitaxel	278-283	nicotinamide nucleotide adenylyltransferase 1	Mus musculus	85-91
26913604-8	2016	M-nonN-Nmnat1 was also protective against axonal degeneration in C. elegans induced by the chemotherapy drug taxol.	Paclitaxel	109-114	nicotinamide nucleotide adenylyltransferase 1	Mus musculus	7-13
26397839-0	2015	Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1alpha and FOXO3a by AMPK signaling.	Paclitaxel	0-10	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	89-97
26913604-9	2016	Taxol markedly reduced basal expression of a mitoUPR reporter; the expression was restored by m-nonN-Nmnat1.	Paclitaxel	0-5	nicotinamide nucleotide adenylyltransferase 1	Mus musculus	101-107
9927194-2	1999	In the present study, we demonstrated that microtubule-binding agents (MBAs) taxol and colchicine induced immediate early gene (c-jun and ATF3) expression, cell cycle arrest, and apoptosis in the human breast cancer cell line MCF-7.	Paclitaxel	77-82	activating transcription factor 3	Homo sapiens	138-142
26397839-4	2015	Paclitaxel increased the phosphorylation of AMPK and also downregulated the expression of EF1alpha in MCF7 cells.	Paclitaxel	0-10	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	90-98
26397839-9	2015	These results suggest that the antitumor effects of paclitaxel in breast cancer are mediated by activation of the AMPK/EF1alpha/FOXO3a signaling pathway.	Paclitaxel	52-62	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	119-127
10447584-1	1999	PURPOSE: To evaluate the pharmacokinetics of paclitaxel and cisplatin administered in combination with bleomycin and etoposide and Granulocyte Colony-Stimulating Factor (G-CSF) in patients with advanced solid tumours.	Paclitaxel	45-55	colony stimulating factor 3	Homo sapiens	170-175
10447584-2	1999	METHODS: Patients were recruited to a phase I trial where escalating doses of paclitaxel (125 to 200 mg/m(2)) were administered in combination with etoposide 100 or 120 mg/m(2), and fixed dose of cisplatin 20 mg/m(2) and bleomycin 30 mg, with the concomitant use of G-CSF.	Paclitaxel	78-88	colony stimulating factor 3	Homo sapiens	266-271
27172742-1	2016	PURPOSE OF INVESTIGATION: To correlate serum CA125 at relapse with survival in ovarian cancer patients who achieved a complete response after primary cytoreduction and paclitaxel- and platinum-based chemotherapy.	Paclitaxel	168-178	mucin 16, cell surface associated	Homo sapiens	45-50
26640594-4	2015	Either hTERT siRNA or BIBR1532 in combination with paclitaxel promoted a synergistic inhibitory effect on cell growth through induction of Annexin V expression and a remarkable reduction in cell invasion through reduction of protein expression of MMP9, MMP2, and MMP3.	Paclitaxel	51-61	annexin A5	Homo sapiens	139-148
26528412-4	2015	GFAP transcripts levels were elevated by more than fivefold and GFAP immunoreactivity increased in the ACC of paclitaxel-treated mice.	Paclitaxel	110-120	glial fibrillary acidic protein	Mus musculus	0-4
26712520-7	2016	Consistent with our previous studies identifying PRP4K as a taxane-response biomarker, reduced PRP4K expression in 4-OHT-treated cells correlated with reduced sensitivity to paclitaxel.	Paclitaxel	174-184	pre-mRNA processing factor 4B	Homo sapiens	95-100
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	Paclitaxel	107-117	CD44 molecule (Indian blood group)	Homo sapiens	236-240
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	Paclitaxel	107-117	Nanog homeobox	Homo sapiens	290-295
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	Paclitaxel	107-117	Kruppel like factor 4	Homo sapiens	297-301
9891452-4	1998	Tyrosinase activity was increased 2.2 fold after 16 hours of incubation with 10 microM paclitaxel.	Paclitaxel	87-97	tyrosinase	Mus musculus	0-10
9783732-6	1998	The mobility shift in Bcl-2 protein from cells exposed to taxol followed by bryostatin 1 was eliminated by treatment of lysates with the protein phosphatase 2A (PP2A); the latter effect was blocked by okadaic acid.	Paclitaxel	58-63	protein phosphatase 2 phosphatase activator	Homo sapiens	161-165
9668078-14	1998	Immune complex kinase assays in cell-free systems demonstrated that Bcl-2 protein can be a substrate of Cdc2/cyclin B1 kinase isolated from paclitaxel-treated cells arrested in M phase.	Paclitaxel	140-150	cyclin dependent kinase 1	Homo sapiens	104-108
9668078-14	1998	Immune complex kinase assays in cell-free systems demonstrated that Bcl-2 protein can be a substrate of Cdc2/cyclin B1 kinase isolated from paclitaxel-treated cells arrested in M phase.	Paclitaxel	140-150	cyclin B1	Homo sapiens	109-118
26462028-4	2015	Blocking TGF-beta signaling with the TGF-beta type I receptor kinase (ALK5) inhibitor, EW-7197, suppresses paclitaxel-induced EMT and CSC properties such as mammosphere-forming efficiency (MSFE), aldehyde dehydrogenase (ALDH) activity, CD44+/CD24- ratio, and pluripotency regulators (Oct4, Nanog, Klf4, Myc, and Sox2).	Paclitaxel	107-117	SRY-box transcription factor 2	Homo sapiens	312-316
26528412-4	2015	GFAP transcripts levels were elevated by more than fivefold and GFAP immunoreactivity increased in the ACC of paclitaxel-treated mice.	Paclitaxel	110-120	glial fibrillary acidic protein	Mus musculus	64-68
26143528-0	2015	Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance).	Paclitaxel	66-76	Rho guanine nucleotide exchange factor 10	Homo sapiens	52-60
26277716-4	2015	The water dispersibility test of Ptx-Pep prepared using different fractions of Pep demonstrated that a fraction (Pep-A), containing relatively hydrophobic peptides with high molecular weights, was effective in enhancing the water dispersibility of Ptx.	Paclitaxel	33-36	carnosine dipeptidase 2	Homo sapiens	113-118
26277716-4	2015	The water dispersibility test of Ptx-Pep prepared using different fractions of Pep demonstrated that a fraction (Pep-A), containing relatively hydrophobic peptides with high molecular weights, was effective in enhancing the water dispersibility of Ptx.	Paclitaxel	248-251	carnosine dipeptidase 2	Homo sapiens	113-118
26277716-6	2015	The water dispersibility of the complex between Ptx and Pep-A (Ptx-Pep-A) was independent of pH, even though it is positively or negatively charged under strongly acidic and neutral conditions.	Paclitaxel	48-51	carnosine dipeptidase 2	Homo sapiens	56-61
26277716-6	2015	The water dispersibility of the complex between Ptx and Pep-A (Ptx-Pep-A) was independent of pH, even though it is positively or negatively charged under strongly acidic and neutral conditions.	Paclitaxel	48-51	carnosine dipeptidase 2	Homo sapiens	63-72
26143528-2	2015	The previous study Alliance N08C1 found an association of the Charcot-Marie-Tooth disease (CMT) gene ARHGEF10 with paclitaxel chemotherapy induced peripheral neuropathy (CIPN) related to the three non-synonymous, recurrent single nucleotide variants (SNV), whereby rs9657362 had the strongest effect, and rs2294039 and rs17683288 contributed only weakly.	Paclitaxel	115-125	Rho guanine nucleotide exchange factor 10	Homo sapiens	101-109
26665000-8	2015	Neural differentiation markers NFL (for neurons), beta III-tubulin (for neurons), GFAP (for astrocytes), and CNPase (for oligodendrocytes) were detected in the taxol-treated C6 cells.	Paclitaxel	160-165	glial fibrillary acidic protein	Rattus norvegicus	82-86
9681085-6	1998	Paclitaxel doses of 175 mg/m2 and 150 mg/m2 produced dose-limiting myelosuppression, and the RPTD was determined to be paclitaxel 135 mg/m2 with ifosfamide 1.2 g/m2/day on days 1-3 and vinorelbine 20 mg/m2/ day on days 1-3 with G-CSF support.	Paclitaxel	0-10	colony stimulating factor 3	Homo sapiens	228-233
26356819-6	2015	To phenocopy the effect of Stathmin 1 inhibition, cells were treated with paclitaxel, a microtubule-stabilizing drug, in association or not with ruxolitinib; combined treatment significantly increased apoptosis, when compared to monotherapy.	Paclitaxel	74-84	stathmin 1	Homo sapiens	27-37
26316167-8	2015	Knockdown of CD147 increased the chemosensitivity of CSC-like cells to gemcitabine, cisplatin, docetaxel at 0.1, 1 and 10 microM respectively, however, there was no significant difference among the three groups to paclitaxel at 10 microM.	Paclitaxel	214-224	basigin (Ok blood group)	Homo sapiens	13-18
9606210-24	1998	In contrast, Mad2 only localized to an average of 2.6 out of the 22 kinetochores in taxol-treated PtK1 cells.	Paclitaxel	84-89	mitotic arrest deficient 2 like 1	Homo sapiens	13-17
9606210-26	1998	We also found that microinjecting antibodies against Mad2 caused cells arrested with taxol to exit mitosis after approximately 12 min, while uninjected cells remained in mitosis for at least 6 h, demonstrating that Mad2 is necessary for maintenance of the taxol-induced mitotic arrest.	Paclitaxel	85-90	mitotic arrest deficient 2 like 1	Homo sapiens	53-57
9606210-26	1998	We also found that microinjecting antibodies against Mad2 caused cells arrested with taxol to exit mitosis after approximately 12 min, while uninjected cells remained in mitosis for at least 6 h, demonstrating that Mad2 is necessary for maintenance of the taxol-induced mitotic arrest.	Paclitaxel	256-261	mitotic arrest deficient 2 like 1	Homo sapiens	53-57
9606210-26	1998	We also found that microinjecting antibodies against Mad2 caused cells arrested with taxol to exit mitosis after approximately 12 min, while uninjected cells remained in mitosis for at least 6 h, demonstrating that Mad2 is necessary for maintenance of the taxol-induced mitotic arrest.	Paclitaxel	256-261	mitotic arrest deficient 2 like 1	Homo sapiens	215-219
26300335-13	2015	Based on a series of in vitro and in vivo experiments, HA-ss-PTX performed well in drug loading, cellular internalization, tumor targeting by entering tumor cells via CD44-caveolae-mediated endocytosis and rapidly release drug at target in the presence of GSH.	Paclitaxel	61-64	CD44 molecule (Indian blood group)	Homo sapiens	167-171
26015512-7	2015	RESULTS: SNPs near AIPL1 were significantly associated with paclitaxel-induced cytotoxicity in Asian LCLs (P &lt; 10(-6)).	Paclitaxel	60-70	aryl hydrocarbon receptor interacting protein like 1	Homo sapiens	19-24
26015512-8	2015	Decreased expression of AIPL1 resulted in decreased sensitivity of neurons to paclitaxel by inducing neurite morphologic changes as measured by increased relative total outgrowth, number of processes and mean process length.	Paclitaxel	78-88	aryl hydrocarbon receptor interacting protein like 1	Homo sapiens	24-29
26015512-10	2015	Upon BCR knockdown, there was an increase in neuronal sensitivity to paclitaxel as measured by neurite morphologic characteristics.	Paclitaxel	69-79	BCR activator of RhoGEF and GTPase	Homo sapiens	5-8
26323677-8	2015	Paclitaxel- and cisplatin-resistant A549 cells acquired metastatic properties and EMT phenotype and had reduced PTEN expression as compared to sensitive cells.	Paclitaxel	0-10	phosphatase and tensin homolog	Homo sapiens	112-116
26015512-11	2015	CONCLUSIONS: We identified genetic variants associated with Asian paclitaxel-induced cytotoxicity and functionally validated the AIPL1 and BCR in a neuronal cell model.	Paclitaxel	66-76	aryl hydrocarbon receptor interacting protein like 1	Homo sapiens	129-134
26722421-9	2015	15 genes of 762 transcripts on this chromosome region were consistently up-regulated detected by cDNA microarray in three taxol resistant sub-lines, and functionally clustered into various groups, including genes related to vascular formation vascular formation (ANGPT1), apoptosis (MYC, TOP1MT), cell adhesion and cell cycle (PPP1R16A, SDC2, CA2, ANKRD46), gene regulation (HRSP12, ZNF696, SLC39A4, POP1), metabolism (PYCRL).	Paclitaxel	122-127	syndecan 2	Homo sapiens	337-341
26722421-9	2015	15 genes of 762 transcripts on this chromosome region were consistently up-regulated detected by cDNA microarray in three taxol resistant sub-lines, and functionally clustered into various groups, including genes related to vascular formation vascular formation (ANGPT1), apoptosis (MYC, TOP1MT), cell adhesion and cell cycle (PPP1R16A, SDC2, CA2, ANKRD46), gene regulation (HRSP12, ZNF696, SLC39A4, POP1), metabolism (PYCRL).	Paclitaxel	122-127	carbonic anhydrase 2	Homo sapiens	343-346
25988668-5	2015	Increased levels of CXCR2, CXCR4, S1P/S1PR1, PlGF and PDGF-BB were identified in the serum or primary tumour tissues of tumour-bearing mice treated by paclitaxel.	Paclitaxel	151-161	sphingosine-1-phosphate receptor 1	Mus musculus	34-37
26406239-0	2015	High Bak Expression Is Associated with a Favorable Prognosis in Breast Cancer and Sensitizes Breast Cancer Cells to Paclitaxel.	Paclitaxel	116-126	BCL2 antagonist/killer 1	Homo sapiens	5-8
9506539-0	1998	Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol.	Paclitaxel	159-164	cyclin B1	Homo sapiens	16-25
9506539-0	1998	Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol.	Paclitaxel	159-164	cyclin B1	Homo sapiens	41-50
9506539-2	1998	In this study, we investigated the relationship between taxol-induced M-phase arrest, disruption of the cyclin B1-regulation pathway and apoptosis in KB cells.	Paclitaxel	56-61	cyclin B1	Homo sapiens	104-113
9506539-6	1998	Taxol also caused an increase in cyclin B1 accumulation, as assessed by Western blot analysis, and stimulated cyclin B1-dependent kinase.	Paclitaxel	0-5	cyclin B1	Homo sapiens	33-42
25988668-5	2015	Increased levels of CXCR2, CXCR4, S1P/S1PR1, PlGF and PDGF-BB were identified in the serum or primary tumour tissues of tumour-bearing mice treated by paclitaxel.	Paclitaxel	151-161	sphingosine-1-phosphate receptor 1	Mus musculus	38-43
26335014-9	2015	Interestingly, it has been suggested that SPARC present in the tumor stroma could sequester albumin-bound paclitaxel, enhancing the delivery of paclitaxel into the tumor microenvironment.	Paclitaxel	106-116	secreted protein acidic and cysteine rich	Homo sapiens	42-47
9506539-6	1998	Taxol also caused an increase in cyclin B1 accumulation, as assessed by Western blot analysis, and stimulated cyclin B1-dependent kinase.	Paclitaxel	0-5	cyclin B1	Homo sapiens	110-119
9506539-11	1998	We conclude that taxol-induced stimulation of cyclin B1-dependent kinase activity parallels mitotic arrest, is more pronounced than mitotic arrest and precedes the induction of programmed cell death.	Paclitaxel	17-22	cyclin B1	Homo sapiens	46-55
9438385-5	1998	Olomoucine, a potent p34cdc2 inhibitor, effectively prevented Taxol-induced p34cdc2 kinase activation and subsequent apoptosis.	Paclitaxel	62-67	cyclin dependent kinase 1	Homo sapiens	21-28
9438385-5	1998	Olomoucine, a potent p34cdc2 inhibitor, effectively prevented Taxol-induced p34cdc2 kinase activation and subsequent apoptosis.	Paclitaxel	62-67	cyclin dependent kinase 1	Homo sapiens	76-83
9438385-6	1998	Furthermore, the treatment of cells with cyclin B1-specific antisense oligonucleotide also blocked Taxol-induced apoptosis, suggesting that cyclin B1-associated p34cdc2 kinase plays an important role in the induction of apoptosis by Taxol.	Paclitaxel	99-104	cyclin B1	Homo sapiens	41-50
9438385-6	1998	Furthermore, the treatment of cells with cyclin B1-specific antisense oligonucleotide also blocked Taxol-induced apoptosis, suggesting that cyclin B1-associated p34cdc2 kinase plays an important role in the induction of apoptosis by Taxol.	Paclitaxel	99-104	cyclin B1	Homo sapiens	140-149
9438385-6	1998	Furthermore, the treatment of cells with cyclin B1-specific antisense oligonucleotide also blocked Taxol-induced apoptosis, suggesting that cyclin B1-associated p34cdc2 kinase plays an important role in the induction of apoptosis by Taxol.	Paclitaxel	99-104	cyclin dependent kinase 1	Homo sapiens	161-168
9438385-6	1998	Furthermore, the treatment of cells with cyclin B1-specific antisense oligonucleotide also blocked Taxol-induced apoptosis, suggesting that cyclin B1-associated p34cdc2 kinase plays an important role in the induction of apoptosis by Taxol.	Paclitaxel	233-238	cyclin B1	Homo sapiens	41-50
9438385-6	1998	Furthermore, the treatment of cells with cyclin B1-specific antisense oligonucleotide also blocked Taxol-induced apoptosis, suggesting that cyclin B1-associated p34cdc2 kinase plays an important role in the induction of apoptosis by Taxol.	Paclitaxel	233-238	cyclin B1	Homo sapiens	140-149
9438385-6	1998	Furthermore, the treatment of cells with cyclin B1-specific antisense oligonucleotide also blocked Taxol-induced apoptosis, suggesting that cyclin B1-associated p34cdc2 kinase plays an important role in the induction of apoptosis by Taxol.	Paclitaxel	233-238	cyclin dependent kinase 1	Homo sapiens	161-168
9438385-8	1998	TPA inhibited Taxol-mediated activation of p34cdc2 kinase by preventing the dephosphorylation of the Tyr-15 residue on p34cdc2 without altering the levels of Cdc2 and cyclin B1.	Paclitaxel	14-19	cyclin dependent kinase 1	Homo sapiens	43-50
9438385-8	1998	TPA inhibited Taxol-mediated activation of p34cdc2 kinase by preventing the dephosphorylation of the Tyr-15 residue on p34cdc2 without altering the levels of Cdc2 and cyclin B1.	Paclitaxel	14-19	cyclin dependent kinase 1	Homo sapiens	119-126
9438385-10	1998	These findings suggest that modulation of protein kinase C signaling can protect against Taxol-induced cell death by inhibiting p34cdc2 kinase activation.	Paclitaxel	89-94	cyclin dependent kinase 1	Homo sapiens	128-135
9407097-4	1997	Heparin also promotes phosphorylation of tau by a number of protein kinases, prevents tau from binding to taxol-stabilized microtubules, and produces rapid disassembly of microtubules assembled from tau and tubulin.	Paclitaxel	106-111	microtubule associated protein tau	Homo sapiens	86-89
9407097-4	1997	Heparin also promotes phosphorylation of tau by a number of protein kinases, prevents tau from binding to taxol-stabilized microtubules, and produces rapid disassembly of microtubules assembled from tau and tubulin.	Paclitaxel	106-111	microtubule associated protein tau	Homo sapiens	86-89
9419978-0	1997	Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line.	Paclitaxel	41-51	H3 histone pseudogene 16	Homo sapiens	15-18
9374526-12	1997	Treatment of NIH-3T3 cells expressing GFP-Ki-Ras with Taxol (paclitaxel) resulted in accumulation of the expressed protein in intracellular locations, whereas in control cells the protein was correctly targeted to the plasma membrane.	Paclitaxel	54-59	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	42-48
9374526-12	1997	Treatment of NIH-3T3 cells expressing GFP-Ki-Ras with Taxol (paclitaxel) resulted in accumulation of the expressed protein in intracellular locations, whereas in control cells the protein was correctly targeted to the plasma membrane.	Paclitaxel	61-71	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	42-48
9374526-15	1997	Additionally, the finding that paclitaxel treatment of cells disrupts Ki-Ras trafficking suggests an additional mechanism for the anti-proliferative effects of this drug.	Paclitaxel	31-41	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	70-76
9346226-0	1997	Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.	Paclitaxel	17-27	colony stimulating factor 3	Homo sapiens	64-101
9275183-0	1997	p53-independent apoptosis induced by paclitaxel through an indirect mechanism.	Paclitaxel	37-47	transformation related protein 53, pseudogene	Mus musculus	0-3
9275183-3	1997	We tested the requirement for wild-type p53 in the response of tumor cells to treatment with paclitaxel (trade name Taxol), an antineoplastic agent that stabilizes cellular microtubules.	Paclitaxel	93-103	transformation related protein 53, pseudogene	Mus musculus	40-43
9275183-4	1997	Although paclitaxel is broadly effective against human tumor xenografts in mice, including some known to carry p53 mutations, we found that p53-containing mouse tumor cells were significantly more sensitive to direct treatment with this drug than were p53-deficient tumor cells.	Paclitaxel	9-19	transformation related protein 53, pseudogene	Mus musculus	111-114
9275183-4	1997	Although paclitaxel is broadly effective against human tumor xenografts in mice, including some known to carry p53 mutations, we found that p53-containing mouse tumor cells were significantly more sensitive to direct treatment with this drug than were p53-deficient tumor cells.	Paclitaxel	9-19	transformation related protein 53, pseudogene	Mus musculus	140-143
9278459-4	1997	Furthermore, the binding of MAP1B to taxol-stabilized microtubules was inhibited by the addition of phosphatidylserine or phosphatidylinositol.	Paclitaxel	37-42	microtubule-associated protein 1B	Rattus norvegicus	28-33
9315106-3	1997	In two resulting stable cell lines which expressed gml cDNA in the absence of wildtype p53, cell death occurred within 6 h after treatment with Taxol.	Paclitaxel	144-149	glycosylphosphatidylinositol anchored molecule like	Homo sapiens	51-54
9315106-5	1997	Morphological analysis confirmed that the increased chemosensitivity to Taxol conferred by gml was due to apoptosis.	Paclitaxel	72-77	glycosylphosphatidylinositol anchored molecule like	Homo sapiens	91-94
9231689-0	1997	Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction.	Paclitaxel	24-34	transformation related protein 53, pseudogene	Mus musculus	38-41
9231689-9	1997	Paclitaxel also induced an increase in both p53 and p21 expression in MCA-4 cells; however, the increase was delayed compared to that after irradiation.	Paclitaxel	0-10	transformation related protein 53, pseudogene	Mus musculus	44-47
9231689-10	1997	This upregulation occurred after the onset of apoptosis which would suggest that paclitaxel-induced apoptosis is p53 independent.	Paclitaxel	81-91	transformation related protein 53, pseudogene	Mus musculus	113-116
9231689-11	1997	Both radiation and paclitaxel caused p53 upregulation in the apoptosis-resistant SCC-VII tumors.	Paclitaxel	19-29	transformation related protein 53, pseudogene	Mus musculus	37-40
9231689-15	1997	Additional studies using these and other tumors are warranted to elucidate the role of p53 and its downstream effectors in the in vivo responsiveness of tumors to paclitaxel and radiation.	Paclitaxel	163-173	transformation related protein 53, pseudogene	Mus musculus	87-90
9144683-5	1997	Significant differences in response were observed between the cisplatin/etoposide and paclitaxel/cisplatin/G-CSF groups and the cisplatin/etoposide and paclitaxel/cisplatin groups; there was no significant difference between patients treated with paclitaxel/cisplatin vs paclitaxel/cisplatin/G-CSF.	Paclitaxel	86-96	colony stimulating factor 3	Homo sapiens	292-297
9137431-1	1997	In the current study, paclitaxel sensitivity of eight vulvar squamous cell carcinoma (SCC) cell lines was tested using a 96-well plate clonogenic assay.	Paclitaxel	22-32	serpin family B member 3	Homo sapiens	86-89
9137431-4	1997	The paclitaxel sensitivity of the eight vulvar SCC cell lines expressed as IC50 varied from 0.6 to 2.9 nM.	Paclitaxel	4-14	serpin family B member 3	Homo sapiens	47-50
9137431-6	1997	Paclitaxel sensitivity of vulvar SCC cell lines is of the same magnitude as the paclitaxel sensitivity of endometrial and ovarian carcinoma cell lines tested in our preliminary experiments with the same assay.	Paclitaxel	0-10	serpin family B member 3	Homo sapiens	33-36
9137431-9	1997	These results indicate that vulvar SCC is consistently sensitive to paclitaxel in vitro.	Paclitaxel	68-78	serpin family B member 3	Homo sapiens	35-38
10743071-2	1997	METHODS: Cell morphology, agarose gel electrophoresis, flow cytometry, video time-lapse monitor and Western blot were performed for taxol-induced apoptosis in human breast cancer cells (Bcap 37).	Paclitaxel	132-137	prohibitin 2	Homo sapiens	186-193
10743071-3	1997	RESULTS: BCap 37 cells treated with taxol (100 nm) underwent the arrests of cell mitosis at metaphase of mitosis and induction of apoptosis.	Paclitaxel	36-41	prohibitin 2	Homo sapiens	9-16
14646529-7	1997	Activation of cyclin B1-associated CDC 2 kinase seems to be an important G2/M event required for paclitaxel-induced apoptosis, and this activation of cyclin B1/CDC 2 kinase could be attributed to the increased activity of CDK 7 kinase.	Paclitaxel	97-107	cyclin dependent kinase 1	Homo sapiens	160-165
8978287-9	1997	Furthermore, the administration of SCF before drug administration allowed the dosages of taxol and vinblastine to be reduced by more than half, while retaining reductions in progenitor numbers that were unachievable using very high doses of the cytotoxic drug alone.	Paclitaxel	89-94	kit ligand	Mus musculus	35-38
9043028-0	1997	Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.	Paclitaxel	0-10	colony stimulating factor 3	Homo sapiens	42-79
8967975-0	1996	Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.	Paclitaxel	29-34	transformation related protein 53, pseudogene	Mus musculus	63-66
8967975-2	1996	However, these mutant p53-transfected cell lines retained sensitivity to taxol and camptothecin.	Paclitaxel	73-78	transformation related protein 53, pseudogene	Mus musculus	22-25
8892100-7	1996	Preincubation of taxol-stabilized MT with ACR produced a dose-dependent increase in MTD but no changes in rate.	Paclitaxel	17-22	metallothionein 1E	Homo sapiens	84-87
8635100-0	1996	Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support.	Paclitaxel	54-64	colony stimulating factor 2	Homo sapiens	70-118
21153290-0	1996	Effect of colchicine and taxol on thyrotropin-releasing hormone receptor coupling to G protein in GH(3) cells.	Paclitaxel	25-30	thyrotropin releasing hormone receptor	Homo sapiens	34-72
8630921-14	1996	In addition, the expression of PCNA was significantly increased in 0.1 and 1 microM paclitaxel-treated cells, suggesting that DNA repair was increased in these cells.	Paclitaxel	84-94	proliferating cell nuclear antigen	Homo sapiens	31-35
8986035-13	1996	The German Testicular Cancer Study Group uses a paclitaxel (Taxol, ifosfamide, cisplatin; TIP) combination regimen as salvage treatment.	Paclitaxel	48-58	TOR signaling pathway regulator	Homo sapiens	90-93
7553639-3	1995	Herein, we show that taxol induced dose- and time-dependent accumulation of the cyclin inhibitor p21WAF1 in both p53 wild-type and p53-null cells, although the degree of induction was greater in cells expressing wild-type p53.	Paclitaxel	21-26	proliferating cell nuclear antigen	Homo sapiens	80-86
8664192-4	1995	The pharmacokinetics of paclitaxel and its metabolites were investigated in anthracycline-resistant breast cancer patients treated with high-dose paclitaxel and granulocyte colony-stimulating factor (G-CSF) support.	Paclitaxel	24-34	colony stimulating factor 3	Homo sapiens	161-198
8714689-0	1995	Effects of taxol on the polymerization and posttranslational modification of class III beta-tubulin in P19 embryonal carcinoma cells.	Paclitaxel	11-16	interleukin 23 subunit alpha	Homo sapiens	103-106
8714689-2	1995	P19 cells were grown on cover slips and then treated with taxol at concentrations of 10(-6) to 10(-9) M for 24 h. The microtubule cytoskeleton was examined after double-immunofluorescence labelling with a monoclonal antibody to alpha-tubulin (YOL 1/34) and a monoclonal neuron-specific class III beta-tubulin antibody (TuJ1).	Paclitaxel	58-63	interleukin 23 subunit alpha	Homo sapiens	0-3
8714689-3	1995	Treatment of undifferentiated P19 cells with concentrations of taxol greater than 4 x 10(-8) M caused microtubule bundling and multiple aster formation and promoted polymerization of the low levels of class III beta-tubulin found in these cells.	Paclitaxel	63-68	interleukin 23 subunit alpha	Homo sapiens	30-33
7541450-1	1995	PURPOSE: Here we evaluate Taxol (paclitaxel; Bristol-Myers Squibb, Princeton, NJ) and cyclophosphamide (CY) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) for mobilization of peripheral-blood stem cells (PBSCs) for autologous stem-cell transplantation in patients with breast and ovarian cancer.	Paclitaxel	26-31	colony stimulating factor 3	Homo sapiens	131-168
7541450-1	1995	PURPOSE: Here we evaluate Taxol (paclitaxel; Bristol-Myers Squibb, Princeton, NJ) and cyclophosphamide (CY) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) for mobilization of peripheral-blood stem cells (PBSCs) for autologous stem-cell transplantation in patients with breast and ovarian cancer.	Paclitaxel	33-43	colony stimulating factor 3	Homo sapiens	131-168
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	interferon gamma	Rattus norvegicus	175-185
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	interferon gamma	Rattus norvegicus	175-185
7759887-8	1995	Synergy between IFN-gamma and taxol was mainly dependent on taxol-induced TNF-alpha secretion because not only the increase of inducible NO synthase (iNOS) gene expression by rIFN-gamma plus taxol was associated with the increased expression of TNF-alpha gene but also taxol-induced NO production was decreased by the treatment of anti-murine TNF-alpha neutralizing Abs.	Paclitaxel	60-65	interferon gamma	Rattus norvegicus	175-185
7759887-12	1995	In conclusion, the present results strongly suggest that the capacity of taxol to increase NO synthesis from rIFN-gamma-primed macrophages is the result of taxol-induced TNF-alpha secretion via the signal transduction pathway of PKC activation.	Paclitaxel	73-78	interferon gamma	Rattus norvegicus	109-119
7759887-12	1995	In conclusion, the present results strongly suggest that the capacity of taxol to increase NO synthesis from rIFN-gamma-primed macrophages is the result of taxol-induced TNF-alpha secretion via the signal transduction pathway of PKC activation.	Paclitaxel	156-161	interferon gamma	Rattus norvegicus	109-119
7541156-17	1995	Although dose limiting at a paclitaxel dose of 135 mg/m2, granulocytopenia can be reduced substantially with granulocyte colony-stimulating factor, allowing sequential dose escalation of paclitaxel to 175 mg/m2 and 215 mg/m2 in 70% of patients receiving three or more cycles.	Paclitaxel	187-197	colony stimulating factor 3	Homo sapiens	109-146
7696257-0	1995	Differential effects of paclitaxel (Taxol) analogs modified at positions C-2, C-7, and C-3" on tubulin polymerization and polymer stabilization: identification of a hyperactive paclitaxel derivative.	Paclitaxel	24-34	complement C2	Homo sapiens	73-76
7696257-0	1995	Differential effects of paclitaxel (Taxol) analogs modified at positions C-2, C-7, and C-3" on tubulin polymerization and polymer stabilization: identification of a hyperactive paclitaxel derivative.	Paclitaxel	36-41	complement C2	Homo sapiens	73-76
7696257-1	1995	Our finding that an analog of paclitaxel (Taxol) modified at position C-2 (2-debenzoyl-2-(m-azidobenzoyl)paclitaxel) was substantially more active than paclitaxel in promoting tubulin assembly [Chaudhary et al.	Paclitaxel	30-40	complement C2	Homo sapiens	70-73
7696257-1	1995	Our finding that an analog of paclitaxel (Taxol) modified at position C-2 (2-debenzoyl-2-(m-azidobenzoyl)paclitaxel) was substantially more active than paclitaxel in promoting tubulin assembly [Chaudhary et al.	Paclitaxel	42-47	complement C2	Homo sapiens	70-73
7696257-1	1995	Our finding that an analog of paclitaxel (Taxol) modified at position C-2 (2-debenzoyl-2-(m-azidobenzoyl)paclitaxel) was substantially more active than paclitaxel in promoting tubulin assembly [Chaudhary et al.	Paclitaxel	105-115	complement C2	Homo sapiens	70-73
7536686-6	1995	Application of 10 mg/kg NGF caused a significant elevation in peptide-immunoreactivity in control animals and in taxol-treated mice, i.e., statistically significant increase in peptide concentrations and in the number of substance P- and CGRP-immunoreactive DRG-neurons, suggesting a recruitment of additional peptide cells.	Paclitaxel	113-118	tachykinin 1	Mus musculus	221-232
7836356-2	1995	Recent equilibrium binding studies of high molecular weight MAP-2ab to taxol-stabilized MTs suggest that the interactions are highly cooperative, as indicated by sigmoidal binding curves, non-linear Scatchard plots, and an apparent all-or-none response in MAP binding in titration experiments (Wallis, K. T., Azhar, S., Rho, M. B., Lewis, S. A., Cowan, N. J., and Murphy, D. B.	Paclitaxel	71-76	microtubule associated protein 2	Bos taurus	60-65
7738109-8	1995	Because vimentin IF organization is at least partially dependent on microtubules, the effects of nocodazole and taxol on perinuclear vimentin foci were examined.	Paclitaxel	112-117	vimentin	Homo sapiens	133-141
7530677-1	1994	The purpose of this study was to review the clinical outcomes and cost of administration of a prophylactic antibiotic compared to G-CSF for the prevention of neutropenic morbidity associated with taxol.	Paclitaxel	196-201	colony stimulating factor 3	Homo sapiens	130-135
7848905-0	1994	Activation of p34cdc2 coincident with taxol-induced apoptosis.	Paclitaxel	38-43	cyclin dependent kinase 1	Homo sapiens	14-21
7876351-11	1994	An additional property of this MAP; namely, its unusually tight association with a calcium-insensitive population of MTs in the presence of taxol, was exploited in devising an efficient purification strategy.	Paclitaxel	140-145	regulator of microtubule dynamics 1	Homo sapiens	31-34
26081451-8	2015	The mRNA levels of c-fos in the spinal cord and ASIC3 in the DRG in the zoledronic acid group were reduced 14 and 21 days after inoculation, and this reduction was observed in the paclitaxel group 21 days after inoculation.	Paclitaxel	180-190	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	19-24
26366090-7	2015	Moreover, cordycepin plus cisplatin and/or paclitaxel significantly induced cleavage of caspase-8, caspase-9, caspase-3, and poly ADP-ribose polymerase, and phosphorylation of c-Jun NH2-terminal kinase, extracellular signal-regulated kinase, p38, and p53 proteins in MA-10 cells.	Paclitaxel	43-53	caspase 3	Mus musculus	110-119
26366090-7	2015	Moreover, cordycepin plus cisplatin and/or paclitaxel significantly induced cleavage of caspase-8, caspase-9, caspase-3, and poly ADP-ribose polymerase, and phosphorylation of c-Jun NH2-terminal kinase, extracellular signal-regulated kinase, p38, and p53 proteins in MA-10 cells.	Paclitaxel	43-53	poly (ADP-ribose) polymerase family, member 1	Mus musculus	125-151
26076081-5	2015	IF7-conjugated Anxa 1-targeting nanoparticles containing paclitaxel (IF7-PTX-NP) allowed controlled drug release and displayed favorable prolonged circulation in vivo.	Paclitaxel	57-67	annexin A1	Homo sapiens	15-21
26076081-6	2015	IF7-PTX-NP was significantly internalized by human umbilical vein endothelial cells (HUVEC) through the IF7-Anxa 1 interaction, and this facilitated uptake enhanced the expected antiangiogenic activity of inhibiting HUVEC proliferation, migration, and tube formation in a Matrigel plug relative to those of Taxol and PTX-NP.	Paclitaxel	307-312	annexin A1	Homo sapiens	108-114
26050197-3	2015	After treated with cisplatin, MG132, paclitaxel and SAHA, both BTG1 transfectants showed lower mRNA viability and higher apoptosis than the control in both time- and dose-dependent manners (p &lt; 0.05) with the hypoexpression of chemoresistance-related genes (slug, CD147, GRP78, GRP94, FBXW7 TOP1, TOP2 and GST-pi).	Paclitaxel	37-47	BTG anti-proliferation factor 1	Homo sapiens	63-67
25499884-0	2015	Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.	Paclitaxel	16-21	BRCA1 DNA repair associated	Homo sapiens	69-74
25499884-3	2015	We used a clinically relevant comparative selection strategy to develop novel chemoresistant cell lines which aim to investigate the mechanisms of resistance that arise from different exposures of carboplatin and taxol on cells having BRCA1 function (UPN251) or dysfunction (OVCAR8).	Paclitaxel	213-218	BRCA1 DNA repair associated	Homo sapiens	235-240
25499884-4	2015	Resistance to carboplatin and taxol developed quicker and more stably in UPN251 (BRCA1-wildtype) compared to OVCAR8 (BRCA1-methylated).	Paclitaxel	30-35	BRCA1 DNA repair associated	Homo sapiens	81-86
25499884-4	2015	Resistance to carboplatin and taxol developed quicker and more stably in UPN251 (BRCA1-wildtype) compared to OVCAR8 (BRCA1-methylated).	Paclitaxel	30-35	BRCA1 DNA repair associated	Homo sapiens	117-122
26096845-0	2015	Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.	Paclitaxel	49-59	TXK tyrosine kinase	Homo sapiens	21-36
26096845-2	2015	We report that recurrent ovarian carcinomas after paclitaxel/carboplatin treatment have higher levels of spleen tyrosine kinase (SYK) and phospho-SYK.	Paclitaxel	50-60	TXK tyrosine kinase	Homo sapiens	112-127
26096845-2	2015	We report that recurrent ovarian carcinomas after paclitaxel/carboplatin treatment have higher levels of spleen tyrosine kinase (SYK) and phospho-SYK.	Paclitaxel	50-60	spleen associated tyrosine kinase	Homo sapiens	129-132
26096845-2	2015	We report that recurrent ovarian carcinomas after paclitaxel/carboplatin treatment have higher levels of spleen tyrosine kinase (SYK) and phospho-SYK.	Paclitaxel	50-60	spleen associated tyrosine kinase	Homo sapiens	146-149
26096845-3	2015	In vitro, paclitaxel-resistant cells expressed higher SYK, and the ratio of phospho-SYK/SYK positively associated with paclitaxel resistance in ovarian cancer cells.	Paclitaxel	10-20	spleen associated tyrosine kinase	Homo sapiens	54-57
26096845-3	2015	In vitro, paclitaxel-resistant cells expressed higher SYK, and the ratio of phospho-SYK/SYK positively associated with paclitaxel resistance in ovarian cancer cells.	Paclitaxel	10-20	spleen associated tyrosine kinase	Homo sapiens	84-87
26096845-3	2015	In vitro, paclitaxel-resistant cells expressed higher SYK, and the ratio of phospho-SYK/SYK positively associated with paclitaxel resistance in ovarian cancer cells.	Paclitaxel	10-20	spleen associated tyrosine kinase	Homo sapiens	84-87
26096845-3	2015	In vitro, paclitaxel-resistant cells expressed higher SYK, and the ratio of phospho-SYK/SYK positively associated with paclitaxel resistance in ovarian cancer cells.	Paclitaxel	119-129	spleen associated tyrosine kinase	Homo sapiens	84-87
26096845-3	2015	In vitro, paclitaxel-resistant cells expressed higher SYK, and the ratio of phospho-SYK/SYK positively associated with paclitaxel resistance in ovarian cancer cells.	Paclitaxel	119-129	spleen associated tyrosine kinase	Homo sapiens	84-87
26096845-4	2015	Inactivation of SYK by inhibitors or gene knockdown sensitized paclitaxel cytotoxicity in vitro and in vivo.	Paclitaxel	63-73	spleen associated tyrosine kinase	Homo sapiens	16-19
26096845-5	2015	Analysis of the phosphotyrosine proteome in paclitaxel-resistant tumor cells revealed that SYK phosphorylates tubulins and microtubule-associated proteins.	Paclitaxel	44-54	spleen associated tyrosine kinase	Homo sapiens	91-94
26096845-6	2015	Inhibition of SYK enhanced microtubule stability in paclitaxel-resistant tumor cells that were otherwise insensitive.	Paclitaxel	52-62	spleen associated tyrosine kinase	Homo sapiens	14-17
26096845-7	2015	Thus, targeting SYK pathway is a promising strategy to enhance paclitaxel response.	Paclitaxel	63-73	spleen associated tyrosine kinase	Homo sapiens	16-19
26211582-13	2015	All data showed that the novel VEGF mAb-liposomes carried anticancer drugs, such as paclitaxel, to the interior of solid tumors and inhibited tumor growth effectively.	Paclitaxel	84-94	vascular endothelial growth factor A	Mus musculus	31-35
25981899-0	2015	Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).	Paclitaxel	47-57	myotubularin related protein 11	Homo sapiens	0-31
26117979-5	2015	Overexpression of CD44, observed in many ovarian cancer cells, is used in creating carriers for selective delivery of various drugs (paclitaxel, doxorubicin, camptothecin or cisplatin) to cancer cells.	Paclitaxel	133-143	CD44 molecule (Indian blood group)	Homo sapiens	18-22
25701310-4	2015	Human serum albumin nanoparticles loaded with melanin and paclitaxel (HMP-NPs) were developed using the desolvation technique.	Paclitaxel	58-68	inner membrane mitochondrial protein	Homo sapiens	70-73
25701310-7	2015	In in vitro experiments, HMP-NPs produced increased photoacoustic signal intensity because of the loaded melanin and decreased cellular viability because of the encapsulated paclitaxel, compared to the free human serum albumin nanoparticles (the control).	Paclitaxel	174-184	inner membrane mitochondrial protein	Homo sapiens	25-28
25897340-5	2015	Next we showed that administering PTX-loaded HA-SLNs led to efficient intracellular delivery of PTX and induced substantial apoptosis in CD44(+) cells in vitro.	Paclitaxel	34-37	CD44 antigen	Mus musculus	137-141
25897340-6	2015	In the B16F10-CD44(+) lung metastasis model, PTX-loaded HA-SLNs targeted the tumor-bearing lung tissues well and subsequently exhibited significant antitumor effects with a relative low dose of PTX, which provided significant survival benefit without evidence of adverse events.	Paclitaxel	45-48	CD44 antigen	Mus musculus	14-18
25096912-6	2015	When cells were treated with both 17-AAG and paclitaxel, all of the combination index values were higher than 1, indicating antagonism between 17-AAG and paclitaxel.	Paclitaxel	45-55	N-methylpurine DNA glycosylase	Homo sapiens	146-149
25096912-6	2015	When cells were treated with both 17-AAG and paclitaxel, all of the combination index values were higher than 1, indicating antagonism between 17-AAG and paclitaxel.	Paclitaxel	154-164	N-methylpurine DNA glycosylase	Homo sapiens	37-40
25096912-7	2015	In 17-AAG- and paclitaxel-treated cells, compared with paclitaxel alone-treated cells, the protein levels of hsp90, hsp70, and hsc70 increased.	Paclitaxel	15-25	heat shock protein family A (Hsp70) member 4	Homo sapiens	116-121
25096912-7	2015	In 17-AAG- and paclitaxel-treated cells, compared with paclitaxel alone-treated cells, the protein levels of hsp90, hsp70, and hsc70 increased.	Paclitaxel	15-25	heat shock protein family A (Hsp70) member 8	Homo sapiens	127-132
25096912-7	2015	In 17-AAG- and paclitaxel-treated cells, compared with paclitaxel alone-treated cells, the protein levels of hsp90, hsp70, and hsc70 increased.	Paclitaxel	55-65	N-methylpurine DNA glycosylase	Homo sapiens	6-9
25096912-7	2015	In 17-AAG- and paclitaxel-treated cells, compared with paclitaxel alone-treated cells, the protein levels of hsp90, hsp70, and hsc70 increased.	Paclitaxel	55-65	heat shock protein family A (Hsp70) member 4	Homo sapiens	116-121
25096912-7	2015	In 17-AAG- and paclitaxel-treated cells, compared with paclitaxel alone-treated cells, the protein levels of hsp90, hsp70, and hsc70 increased.	Paclitaxel	55-65	heat shock protein family A (Hsp70) member 8	Homo sapiens	127-132
25096912-9	2015	Moreover, these results demonstrate that 17-AAG antagonizes paclitaxel with concomitant alterations in hsp90 client proteins in ATC cells.	Paclitaxel	60-70	N-methylpurine DNA glycosylase	Homo sapiens	44-47
25633416-0	2015	3,3"-Diindolylmethane potentiates paclitaxel-induced antitumor effects on gastric cancer cells through the Akt/FOXM1 signaling cascade.	Paclitaxel	34-44	forkhead box M1	Homo sapiens	111-116
25633416-9	2015	FOXM1 effector genes such as CDK4, p53 and cyclin D1 were downregulated in gastric cancer cells by combination treatment with DIM and paclitaxel.	Paclitaxel	134-144	forkhead box M1	Homo sapiens	0-5
25874011-7	2015	Also, paclitaxel enhanced mitochondrial translocation of HSPB11 in wild type HeLa but not in NIH3T3 cells.	Paclitaxel	6-16	heat shock protein family B (small) member 11	Homo sapiens	57-63
25788678-0	2015	Nociceptor beta II, delta, and epsilon isoforms of PKC differentially mediate paclitaxel-induced spontaneous and evoked pain.	Paclitaxel	78-88	protein kinase C, delta	Mus musculus	51-54
25788678-4	2015	Employing multiple complementary approaches, we have identified a subset of PKC isoforms, namely betaII, delta, and epsilon, were activated by paclitaxel in the isolated primary afferent sensory neurons.	Paclitaxel	143-153	protein kinase C, delta	Mus musculus	76-79
25788678-5	2015	Persistent activation of PKCbetaII, PKCdelta, and PKCepsilon was also observed in the dorsal root ganglion neurons after chronic treatment with paclitaxel in a mouse model of PIPN.	Paclitaxel	144-154	protein kinase C, delta	Mus musculus	36-44
25776504-0	2015	MTDH/AEG-1-based DNA vaccine suppresses metastasis and enhances chemosensitivity to paclitaxel in pelvic lymph node metastasis.	Paclitaxel	84-94	metadherin	Mus musculus	0-4
25776504-0	2015	MTDH/AEG-1-based DNA vaccine suppresses metastasis and enhances chemosensitivity to paclitaxel in pelvic lymph node metastasis.	Paclitaxel	84-94	metadherin	Mus musculus	5-10
25776504-6	2015	In the therapy model, the MTDH/AEG-1 gene vaccine significantly enhanced chemosensitivity to paclitaxel, inhibited tumor growth, promoted tumor cell apoptosis, and prolonged the survival time of tumor-bearing mice without any apparent side effects.	Paclitaxel	93-103	metadherin	Mus musculus	26-30
25776504-6	2015	In the therapy model, the MTDH/AEG-1 gene vaccine significantly enhanced chemosensitivity to paclitaxel, inhibited tumor growth, promoted tumor cell apoptosis, and prolonged the survival time of tumor-bearing mice without any apparent side effects.	Paclitaxel	93-103	metadherin	Mus musculus	31-36
25435430-5	2015	Previously, utilizing miRNA arrays we reported that downregulation of miR-17 is at least partly involved in the development of paclitaxel resistance in lung cancer cells by modulating Beclin-1 expression [1].	Paclitaxel	127-137	beclin 1	Homo sapiens	184-192
25351620-7	2015	Inhibition of the PI3K/Akt signalling pathway restored sensitivity to paclitaxel in 5-8F cells over-expressing EphA2, which indicated that the PI3K/Akt pathway is involved in EphA2-mediated paclitaxel sensitivity.	Paclitaxel	190-200	EPH receptor A2	Homo sapiens	175-180
25351620-8	2015	The current study demonstrated that EphA2 mediates sensitivity to paclitaxel via the regulation of the PI3K/Akt signalling pathway in NPC.	Paclitaxel	66-76	EPH receptor A2	Homo sapiens	36-41
26225652-13	2015	Our findings suggest that arsenic trioxide increases paclitaxel-induced apoptosis by down regulation of PPM1D expression.	Paclitaxel	53-63	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	104-109
25607466-4	2015	Moreover, paclitaxel exposure induced upregulation of TXNDC17 and BECN1 expression, increase of autophagosome formation, and autophagic flux that conferred cytoprotection for ovarian cancer cells from paclitaxel.	Paclitaxel	10-20	beclin 1	Homo sapiens	66-71
25756509-0	2015	MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo.	Paclitaxel	54-64	membrane associated ring-CH-type finger 8	Homo sapiens	0-3
26390698-0	2015	Upregulation of microRNA-224 sensitizes human cervical cells SiHa to paclitaxel.	Paclitaxel	69-79	microRNA 224	Homo sapiens	16-28
26390698-2	2015	Materials and METHODS: The expression of miR-224 pre- and post-paclitaxel treatment was determined by using stem-loop real-time reverse transcription polymerase chain reaction (RT-PCR).	Paclitaxel	63-73	microRNA 224	Homo sapiens	41-48
26390698-3	2015	The authors exogenously upregulated miR-224 expression in SiHa cells using miRIDIAN miR-224 mimic transfection and observed its impact on paclitaxel sensitivity using Cytotoxicity assays.	Paclitaxel	138-148	microRNA 224	Homo sapiens	36-43
25481791-15	2015	INTERPRETATION: Olaparib plus paclitaxel and carboplatin followed by maintenance monotherapy significantly improved progression-free survival versus paclitaxel plus carboplatin alone, with the greatest clinical benefit in BRCA-mutated patients, and had an acceptable and manageable tolerability profile.	Paclitaxel	30-40	BRCA1 DNA repair associated	Homo sapiens	222-226
25135441-6	2014	PTX-NFM significantly inhibited the growth of CT-26 colon cancer in comparison with PTX injection.	Paclitaxel	0-3	neurofilament medium chain	Homo sapiens	4-7
25000945-1	2014	AIM: To develop a theranostic nanoemulsion (TNE) that can codeliver the conjugates of a hydrophobic drug paclitaxel (PTX) and a hydrophilic imaging probe sulforhodamine B (SRB).	Paclitaxel	117-120	chaperonin containing TCP1 subunit 4	Homo sapiens	154-170
25000945-1	2014	AIM: To develop a theranostic nanoemulsion (TNE) that can codeliver the conjugates of a hydrophobic drug paclitaxel (PTX) and a hydrophilic imaging probe sulforhodamine B (SRB).	Paclitaxel	117-120	chaperonin containing TCP1 subunit 4	Homo sapiens	172-175
25000945-3	2014	It has been examined for a correlation between the dynamic uptake of PTX and the intensity of SRB imaging signal in different organs.	Paclitaxel	69-72	chaperonin containing TCP1 subunit 4	Homo sapiens	94-97
25257554-8	2014	The expressions of lncRNA CDKN2B-AS1, HOTAIR and MALAT1 were dramatically reduced with the increasing concentration of cisplatin and paclitaxel and also lengthening of the treatment duration.	Paclitaxel	133-143	CDKN2B antisense RNA 1	Homo sapiens	26-36
24443309-0	2014	A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles.	Paclitaxel	90-100	transferrin	Mus musculus	56-67
24956463-0	2014	A novel approach to overcome multidrug resistance: utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors.	Paclitaxel	90-100	phosphoglycolate phosphatase	Mus musculus	66-70
24956463-1	2014	We tried to overcome the paclitaxel (PTX) resistance of cancer cells due to P-glycoprotein (P-gp) overexpression in the in vivo anti-tumor chemotherapy by utilizing polyethylene glycol-modified liposomal paclitaxel (PL-PTX).	Paclitaxel	25-35	phosphoglycolate phosphatase	Mus musculus	76-90
24956463-1	2014	We tried to overcome the paclitaxel (PTX) resistance of cancer cells due to P-glycoprotein (P-gp) overexpression in the in vivo anti-tumor chemotherapy by utilizing polyethylene glycol-modified liposomal paclitaxel (PL-PTX).	Paclitaxel	25-35	phosphoglycolate phosphatase	Mus musculus	92-96
24956463-1	2014	We tried to overcome the paclitaxel (PTX) resistance of cancer cells due to P-glycoprotein (P-gp) overexpression in the in vivo anti-tumor chemotherapy by utilizing polyethylene glycol-modified liposomal paclitaxel (PL-PTX).	Paclitaxel	37-40	phosphoglycolate phosphatase	Mus musculus	76-90
24956463-1	2014	We tried to overcome the paclitaxel (PTX) resistance of cancer cells due to P-glycoprotein (P-gp) overexpression in the in vivo anti-tumor chemotherapy by utilizing polyethylene glycol-modified liposomal paclitaxel (PL-PTX).	Paclitaxel	37-40	phosphoglycolate phosphatase	Mus musculus	92-96
24956463-1	2014	We tried to overcome the paclitaxel (PTX) resistance of cancer cells due to P-glycoprotein (P-gp) overexpression in the in vivo anti-tumor chemotherapy by utilizing polyethylene glycol-modified liposomal paclitaxel (PL-PTX).	Paclitaxel	204-214	phosphoglycolate phosphatase	Mus musculus	76-90
24956463-1	2014	We tried to overcome the paclitaxel (PTX) resistance of cancer cells due to P-glycoprotein (P-gp) overexpression in the in vivo anti-tumor chemotherapy by utilizing polyethylene glycol-modified liposomal paclitaxel (PL-PTX).	Paclitaxel	204-214	phosphoglycolate phosphatase	Mus musculus	92-96
24956463-2	2014	First of all, established were PTX-resistant Colon-26 cancer cells (C26/PTX) overexpressing P-gp, which provided IC50 value of PTX solution about 30 times larger than that obtained for control C26 (C26/control) in the in vitro MTT assay.	Paclitaxel	31-34	phosphoglycolate phosphatase	Mus musculus	92-96
24956463-2	2014	First of all, established were PTX-resistant Colon-26 cancer cells (C26/PTX) overexpressing P-gp, which provided IC50 value of PTX solution about 30 times larger than that obtained for control C26 (C26/control) in the in vitro MTT assay.	Paclitaxel	72-75	phosphoglycolate phosphatase	Mus musculus	92-96
24956463-2	2014	First of all, established were PTX-resistant Colon-26 cancer cells (C26/PTX) overexpressing P-gp, which provided IC50 value of PTX solution about 30 times larger than that obtained for control C26 (C26/control) in the in vitro MTT assay.	Paclitaxel	72-75	phosphoglycolate phosphatase	Mus musculus	92-96
24956463-3	2014	Western blot analysis confirmed P-gp expression in C26/PTX 10 times higher than that in C26/control, indicating that the resistance acquisition of C26/PTX to PTX would be ascribed to the enhanced efflux of PTX by P-gp overexpressed in C26/PTX.	Paclitaxel	55-58	phosphoglycolate phosphatase	Mus musculus	32-36
24956463-3	2014	Western blot analysis confirmed P-gp expression in C26/PTX 10 times higher than that in C26/control, indicating that the resistance acquisition of C26/PTX to PTX would be ascribed to the enhanced efflux of PTX by P-gp overexpressed in C26/PTX.	Paclitaxel	55-58	phosphoglycolate phosphatase	Mus musculus	213-217
24956463-3	2014	Western blot analysis confirmed P-gp expression in C26/PTX 10 times higher than that in C26/control, indicating that the resistance acquisition of C26/PTX to PTX would be ascribed to the enhanced efflux of PTX by P-gp overexpressed in C26/PTX.	Paclitaxel	151-154	phosphoglycolate phosphatase	Mus musculus	32-36
24956463-3	2014	Western blot analysis confirmed P-gp expression in C26/PTX 10 times higher than that in C26/control, indicating that the resistance acquisition of C26/PTX to PTX would be ascribed to the enhanced efflux of PTX by P-gp overexpressed in C26/PTX.	Paclitaxel	151-154	phosphoglycolate phosphatase	Mus musculus	213-217
24956463-3	2014	Western blot analysis confirmed P-gp expression in C26/PTX 10 times higher than that in C26/control, indicating that the resistance acquisition of C26/PTX to PTX would be ascribed to the enhanced efflux of PTX by P-gp overexpressed in C26/PTX.	Paclitaxel	151-154	phosphoglycolate phosphatase	Mus musculus	32-36
24956463-3	2014	Western blot analysis confirmed P-gp expression in C26/PTX 10 times higher than that in C26/control, indicating that the resistance acquisition of C26/PTX to PTX would be ascribed to the enhanced efflux of PTX by P-gp overexpressed in C26/PTX.	Paclitaxel	151-154	phosphoglycolate phosphatase	Mus musculus	213-217
24956463-3	2014	Western blot analysis confirmed P-gp expression in C26/PTX 10 times higher than that in C26/control, indicating that the resistance acquisition of C26/PTX to PTX would be ascribed to the enhanced efflux of PTX by P-gp overexpressed in C26/PTX.	Paclitaxel	151-154	phosphoglycolate phosphatase	Mus musculus	32-36
24956463-3	2014	Western blot analysis confirmed P-gp expression in C26/PTX 10 times higher than that in C26/control, indicating that the resistance acquisition of C26/PTX to PTX would be ascribed to the enhanced efflux of PTX by P-gp overexpressed in C26/PTX.	Paclitaxel	151-154	phosphoglycolate phosphatase	Mus musculus	213-217
24956463-3	2014	Western blot analysis confirmed P-gp expression in C26/PTX 10 times higher than that in C26/control, indicating that the resistance acquisition of C26/PTX to PTX would be ascribed to the enhanced efflux of PTX by P-gp overexpressed in C26/PTX.	Paclitaxel	151-154	phosphoglycolate phosphatase	Mus musculus	32-36
24956463-3	2014	Western blot analysis confirmed P-gp expression in C26/PTX 10 times higher than that in C26/control, indicating that the resistance acquisition of C26/PTX to PTX would be ascribed to the enhanced efflux of PTX by P-gp overexpressed in C26/PTX.	Paclitaxel	151-154	phosphoglycolate phosphatase	Mus musculus	213-217
24956463-6	2014	These results suggest that the in vivo anti-tumor effect of PL-PTX in C26/PTX-bearing mice would be ascribed to the cytotoxic action of PTX pumped out of tumor cells by overexpressed P-gp to vascular endothelial cells in tumor tissues.	Paclitaxel	63-66	phosphoglycolate phosphatase	Mus musculus	183-187
25160006-0	2014	Mechanical effects of EB1 on microtubules depend on GTP hydrolysis state and presence of paclitaxel.	Paclitaxel	89-99	microtubule associated protein RP/EB family member 1	Homo sapiens	22-25
25160006-3	2014	We find that the presence of EB1 can stiffen microtubules in a manner that depends on the hydrolysis state of the tubulin-bound nucleotide, as well as the presence of the small-molecule stabilizer paclitaxel.	Paclitaxel	197-207	microtubule associated protein RP/EB family member 1	Homo sapiens	29-32
25058922-4	2014	KEY FINDINGS: The combination of paclitaxel and CKD712 significantly decreased cell growth, invasion and MMP-9 expression/activity compared with paclitaxel alone.	Paclitaxel	33-43	matrix metallopeptidase 9	Homo sapiens	105-110
25089613-8	2014	Under hypoxia, downregulation of HIF-1alpha and upregulation of caspase-3, caspase-8, caspase-9, LC3 and Beclin-1 were observed when paclitaxel was combined with oxygen-CNT.	Paclitaxel	133-143	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	97-100
25089613-8	2014	Under hypoxia, downregulation of HIF-1alpha and upregulation of caspase-3, caspase-8, caspase-9, LC3 and Beclin-1 were observed when paclitaxel was combined with oxygen-CNT.	Paclitaxel	133-143	beclin 1	Homo sapiens	105-113
24786296-6	2014	This study systematically explored intrinsic link between ERalpha and the P-gp over-expression in paclitaxel-resistant ERalpha(+) breast cancer cell lines and mouse model in molecular details.	Paclitaxel	98-108	phosphoglycolate phosphatase	Mus musculus	74-78
24876379-6	2014	Noteworthy, systemic administration of the S1PR1 modulator FTY720 (Food and Drug Administration- approved for multiple sclerosis) attenuated the activation of these neuroinflammatory processes and abrogated neuropathic pain without altering anticancer properties of paclitaxel and with beneficial effects extended to oxaliplatin.	Paclitaxel	266-276	sphingosine-1-phosphate receptor 1	Homo sapiens	43-48
24869908-8	2014	PDZK1 overexpression was associated with resistance to paclitaxel/5-fluorouracil/etoposide only at low concentrations.	Paclitaxel	55-65	PDZ domain containing 1	Homo sapiens	0-5
24747086-5	2014	A very high loading efficiency of up to ~81% of doxorubicin hydrochloride (DOX) with an ~0.02 mg mg(-1) loading capacity and ~60% of paclitaxel (TXL) with an ~0.03 mg mg(-1) loading capacity are obtained with LMMNA.	Paclitaxel	133-143	thioredoxin like 1	Homo sapiens	145-148
24959746-6	2014	Interestingly, the mCAR agonist TCPOBOP enhanced the expression of two tumor suppressor genes, namely WT1 and MGMT, which were additively enhanced in cells treated with CAR agonist in combination with paclitaxel.	Paclitaxel	201-211	nuclear receptor subfamily 1 group I member 3	Homo sapiens	20-23
24959746-8	2014	Paclitaxel per se increases the expression of CAR in cancer cells.	Paclitaxel	0-10	nuclear receptor subfamily 1 group I member 3	Homo sapiens	46-49
24959746-14	2014	Most of NSCLC cases present CAR gene expression turning it possible to speculate the use of CAR modulation by ligands along with Paclitaxel in NSCLC therapy.	Paclitaxel	129-139	nuclear receptor subfamily 1 group I member 3	Homo sapiens	28-31
24680370-0	2014	Paeonol reverses paclitaxel resistance in human breast cancer cells by regulating the expression of transgelin 2.	Paclitaxel	17-27	transgelin 2	Homo sapiens	100-112
24680370-7	2014	It was found that transgelin 2 may mediate the resistance of MCF-7/PTX cells to paclitaxel by up-regulating the expressions of the adenosine-triphosphate binding cassette transporter proteins, including P-glycoprotein (P-gp), multidrug resistance associated protein 1 (MRP1), and breast cancer resistance protein (BCRP).	Paclitaxel	67-70	transgelin 2	Homo sapiens	18-30
24680370-7	2014	It was found that transgelin 2 may mediate the resistance of MCF-7/PTX cells to paclitaxel by up-regulating the expressions of the adenosine-triphosphate binding cassette transporter proteins, including P-glycoprotein (P-gp), multidrug resistance associated protein 1 (MRP1), and breast cancer resistance protein (BCRP).	Paclitaxel	80-90	transgelin 2	Homo sapiens	18-30
24680370-9	2014	In addition, this study found that paeonol down-regulated the transgelin 2-mediated paclitaxel resistance by reducing the expressions of P-gp, MRP1, and BCRP in MCF-7/PTX cells.	Paclitaxel	84-94	transgelin 2	Homo sapiens	62-74
24680370-9	2014	In addition, this study found that paeonol down-regulated the transgelin 2-mediated paclitaxel resistance by reducing the expressions of P-gp, MRP1, and BCRP in MCF-7/PTX cells.	Paclitaxel	167-170	transgelin 2	Homo sapiens	62-74
24680370-10	2014	These results not only provide insight into the potential application of paeonol to the reversal of paclitaxel resistance, thus facilitating the sensitivity of breast cancer chemotherapy, but also highlight a potential role of transgelin 2 in the development of paclitaxel resistance in breast cancer.	Paclitaxel	262-272	transgelin 2	Homo sapiens	227-239
24853425-0	2014	SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.	Paclitaxel	97-102	sperm associated antigen 5	Homo sapiens	0-5
24853425-6	2014	Under SPAG5 downregulation, the sensitivity of cervical cancer cells differed according to taxol dose, which correlated with mammalian target of rapamycin (mTOR) signaling pathway activity.	Paclitaxel	91-96	sperm associated antigen 5	Homo sapiens	6-11
24853425-7	2014	In general, SPAG5 upregulation relates to poor prognosis in cervical cancer patients, and SPAG5 is a regulator of mTOR activity during taxol treatment in cervical cancer.	Paclitaxel	135-140	sperm associated antigen 5	Homo sapiens	90-95
24831239-6	2014	Since paclitaxel sensitivity has been shown to correlate with E2F3 levels, we hypothesized that HLM006474 synergy with paclitaxel may be mediated by transient induction of E2F3.	Paclitaxel	6-16	E2F transcription factor 3 S homeolog	Xenopus laevis	62-66
24831239-6	2014	Since paclitaxel sensitivity has been shown to correlate with E2F3 levels, we hypothesized that HLM006474 synergy with paclitaxel may be mediated by transient induction of E2F3.	Paclitaxel	6-16	E2F transcription factor 3 S homeolog	Xenopus laevis	172-176
24831239-6	2014	Since paclitaxel sensitivity has been shown to correlate with E2F3 levels, we hypothesized that HLM006474 synergy with paclitaxel may be mediated by transient induction of E2F3.	Paclitaxel	119-129	E2F transcription factor 3 S homeolog	Xenopus laevis	172-176
24573741-0	2014	Paclitaxel-exposed ovarian cancer cells induce cancer-specific CD4+ T cells after doxorubicin exposure through regulation of MyD88 expression.	Paclitaxel	0-10	myeloid differentiation primary response gene 88	Mus musculus	125-130
24573741-6	2014	We also observed that in paclitaxel-exposed MOSECs treated with doxorubicin, but not cisplatin, the expression of MyD88 and related target proteins decreased compared to paclitaxel-exposed MOSECs only, while in BMDCs co-cultured with these MOSECs the expression of myeloid differentiation primary response gene 88 (MyD88) increased.	Paclitaxel	25-35	myeloid differentiation primary response gene 88	Mus musculus	114-119
24573741-6	2014	We also observed that in paclitaxel-exposed MOSECs treated with doxorubicin, but not cisplatin, the expression of MyD88 and related target proteins decreased compared to paclitaxel-exposed MOSECs only, while in BMDCs co-cultured with these MOSECs the expression of myeloid differentiation primary response gene 88 (MyD88) increased.	Paclitaxel	25-35	myeloid differentiation primary response gene 88	Mus musculus	315-320
24573741-6	2014	We also observed that in paclitaxel-exposed MOSECs treated with doxorubicin, but not cisplatin, the expression of MyD88 and related target proteins decreased compared to paclitaxel-exposed MOSECs only, while in BMDCs co-cultured with these MOSECs the expression of myeloid differentiation primary response gene 88 (MyD88) increased.	Paclitaxel	170-180	myeloid differentiation primary response gene 88	Mus musculus	114-119
24755562-0	2014	miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression.	Paclitaxel	40-50	beclin 1	Homo sapiens	100-107
24755562-8	2014	Overexpression of miR-17-5p into paclitaxel resistant lung cancer cells reduced beclin1 expression and a concordant decease in cellular autophagy.	Paclitaxel	33-43	beclin 1	Homo sapiens	80-87
24755562-10	2014	Our results indicated that paclitaxel resistance of lung cancer is associated with downregulation of miR-17-5p expression which might cause upregulation of BECN1 expression.	Paclitaxel	27-37	beclin 1	Homo sapiens	156-161
24742127-13	2014	mRNA expression levels of the astrocytic marker GFAP was marginally increased by paclitaxel treatment whereas expression of the microglial marker CD11b was unchanged.	Paclitaxel	81-91	glial fibrillary acidic protein	Homo sapiens	48-52
24566868-2	2014	In previous work, RSF1 was identified as an amplified gene that facilitated the development of paclitaxel-resistant ovarian cancer.	Paclitaxel	95-105	remodeling and spacing factor 1	Homo sapiens	18-22
24566868-3	2014	In the present study, we further demonstrated that RSF1 expression inversely correlated with paclitaxel response in patients with ovarian cancer and the mouse xenograft model.	Paclitaxel	93-103	remodeling and spacing factor 1	Homo sapiens	51-55
24566868-4	2014	In addition, RSF1-overexpressing paclitaxel-resistant ovarian cancer cell lines were found to express elevated levels of genes regulated by NF-kappaB, including some involved with the evasion of apoptosis (CFLAR, XIAP, BCL2, and BCL2L1) and inflammation (PTGS2).	Paclitaxel	33-43	remodeling and spacing factor 1	Homo sapiens	13-17
24566868-4	2014	In addition, RSF1-overexpressing paclitaxel-resistant ovarian cancer cell lines were found to express elevated levels of genes regulated by NF-kappaB, including some involved with the evasion of apoptosis (CFLAR, XIAP, BCL2, and BCL2L1) and inflammation (PTGS2).	Paclitaxel	33-43	X-linked inhibitor of apoptosis	Homo sapiens	213-217
24566868-7	2014	Moreover, pretreatment with NF-kappaB inhibitors or downregulation of NF-kappaB-regulated gene expression considerably enhanced paclitaxel sensitivity in RSF1-overexpressing OVCAR3 and/or RSF1-induced SKOV3 cells.	Paclitaxel	128-138	remodeling and spacing factor 1	Homo sapiens	154-158
24566868-7	2014	Moreover, pretreatment with NF-kappaB inhibitors or downregulation of NF-kappaB-regulated gene expression considerably enhanced paclitaxel sensitivity in RSF1-overexpressing OVCAR3 and/or RSF1-induced SKOV3 cells.	Paclitaxel	128-138	remodeling and spacing factor 1	Homo sapiens	188-192
24782986-4	2014	In the first approach, we demonstrate that a single intraperitoneal administration of paclitaxel in mice 7 days after subcutaneous transplantation of the HEY ovarian cancer cell line resulted in a significant increase in the expression of CA125, Oct4, and CD117 in mice xenografts compared to control mice xenografts which did not receive paclitaxel.	Paclitaxel	86-96	mucin 16, cell surface associated	Homo sapiens	239-244
24625050-2	2014	Through a combination of computational modeling, reagent screening, and oxidation sequence analysis, the first three of eight C-H oxidations (at the allylic sites corresponding to C-5, C-10, and C-13) required to reach Taxol from taxadiene were accomplished.	Paclitaxel	219-224	homeobox C13	Homo sapiens	195-199
7849649-2	1994	Taxol-stabilized tobacco and bovine brain microtubules had similar binding capacities for MAP2 (1 mol MAP2 per 8-9 mol tubulin).	Paclitaxel	0-5	microtubule associated protein 2	Bos taurus	90-94
7849649-2	1994	Taxol-stabilized tobacco and bovine brain microtubules had similar binding capacities for MAP2 (1 mol MAP2 per 8-9 mol tubulin).	Paclitaxel	0-5	microtubule associated protein 2	Bos taurus	102-106
7912076-6	1994	Taxol-induced aneuploidy increased the proportion of G0G1 phase cells, increased p53 positivity, and down-regulated mts1.	Paclitaxel	0-5	transformation related protein 53, pseudogene	Mus musculus	81-84
7509652-0	1994	Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy.	Paclitaxel	106-111	colony stimulating factor 3	Homo sapiens	9-46
7509652-2	1994	Granulocyte colony-stimulating factor (G-CSF) effectively protects the bone marrow from taxol-induced neutropenia and allows for higher taxol dose administration.	Paclitaxel	88-93	colony stimulating factor 3	Homo sapiens	0-37
7509652-2	1994	Granulocyte colony-stimulating factor (G-CSF) effectively protects the bone marrow from taxol-induced neutropenia and allows for higher taxol dose administration.	Paclitaxel	88-93	colony stimulating factor 3	Homo sapiens	39-44
7509652-2	1994	Granulocyte colony-stimulating factor (G-CSF) effectively protects the bone marrow from taxol-induced neutropenia and allows for higher taxol dose administration.	Paclitaxel	136-141	colony stimulating factor 3	Homo sapiens	0-37
7509652-2	1994	Granulocyte colony-stimulating factor (G-CSF) effectively protects the bone marrow from taxol-induced neutropenia and allows for higher taxol dose administration.	Paclitaxel	136-141	colony stimulating factor 3	Homo sapiens	39-44
7509652-3	1994	This report addresses the optimal use of G-CSF as a supportive agent for dose-intense taxol therapy.	Paclitaxel	86-91	colony stimulating factor 3	Homo sapiens	41-46
7509380-1	1994	PURPOSE: We conducted a phase I trial of a 3-hour infusion of Taxol (paclitaxel; Bristol-Myers Squibb Co, Princeton, NJ) to identify the maximum-tolerated dose of Taxol as a 3-hour infusion with and without granulocyte colony-stimulating factor (G-CSF) support.	Paclitaxel	163-168	colony stimulating factor 3	Homo sapiens	207-244
7509380-1	1994	PURPOSE: We conducted a phase I trial of a 3-hour infusion of Taxol (paclitaxel; Bristol-Myers Squibb Co, Princeton, NJ) to identify the maximum-tolerated dose of Taxol as a 3-hour infusion with and without granulocyte colony-stimulating factor (G-CSF) support.	Paclitaxel	163-168	colony stimulating factor 3	Homo sapiens	246-251
7509380-7	1994	The dose-limiting toxicity for Taxol with G-CSF was peripheral neuropathy at the 300-mg/m2 dose level.	Paclitaxel	31-36	colony stimulating factor 3	Homo sapiens	42-47
7509380-13	1994	CONCLUSION: The maximum dose of Taxol recommended for phase II and III studies, when administered as a 3-hour infusion alone and with G-CSF support, is 210 mg/m2 and 250 mg/m2, respectively.	Paclitaxel	32-37	colony stimulating factor 3	Homo sapiens	134-139
7909688-10	1994	Addition of granulocyte-colony stimulating factor (G-CSF), aimed at modulating myelosuppressive toxicity, showed in Phase I studies that the taxol dose could be increased to 250 mg/m2, with peripheral neuropathy as the dose limiting toxicity.	Paclitaxel	141-146	colony stimulating factor 3	Homo sapiens	12-49
7909688-10	1994	Addition of granulocyte-colony stimulating factor (G-CSF), aimed at modulating myelosuppressive toxicity, showed in Phase I studies that the taxol dose could be increased to 250 mg/m2, with peripheral neuropathy as the dose limiting toxicity.	Paclitaxel	141-146	colony stimulating factor 3	Homo sapiens	51-56
7912536-5	1993	We found that Taxol, like lipopolysaccharides (LPS), caused a marked increase in tyrosine phosphorylation of three proteins having M(r) of 40 (p40), 41 (p41), and 43 (p43) kd in RAW cells.	Paclitaxel	14-19	aminoacyl tRNA synthetase complex-interacting multifunctional protein 1	Mus musculus	167-170
1353517-7	1992	Induction of TNF mRNA by 10 microM taxol was detectable at 45 min of stimulation, maximal at 90 min, and evident for at least 8 h. The same low concentration of taxol also induced interleukin 1 (IL-1) alpha and beta mRNA expression.	Paclitaxel	35-40	interleukin 1 alpha	Mus musculus	195-206
1353517-7	1992	Induction of TNF mRNA by 10 microM taxol was detectable at 45 min of stimulation, maximal at 90 min, and evident for at least 8 h. The same low concentration of taxol also induced interleukin 1 (IL-1) alpha and beta mRNA expression.	Paclitaxel	161-166	interleukin 1 alpha	Mus musculus	195-206
24513320-7	2014	Pharmacodynamics outcomes revealed that the median survival time of glioma-bearing mice models treated with paclitaxel-loaded CNP (CNP-PTX) was significantly prolonged when compared with that of any other group.	Paclitaxel	108-118	2',3'-cyclic nucleotide 3' phosphodiesterase	Mus musculus	126-129
24513320-7	2014	Pharmacodynamics outcomes revealed that the median survival time of glioma-bearing mice models treated with paclitaxel-loaded CNP (CNP-PTX) was significantly prolonged when compared with that of any other group.	Paclitaxel	108-118	2',3'-cyclic nucleotide 3' phosphodiesterase	Mus musculus	131-138
26335014-9	2015	Interestingly, it has been suggested that SPARC present in the tumor stroma could sequester albumin-bound paclitaxel, enhancing the delivery of paclitaxel into the tumor microenvironment.	Paclitaxel	144-154	secreted protein acidic and cysteine rich	Homo sapiens	42-47
26087399-7	2015	In conclusion, the STMN1-E/P/C signature is a reliable prognostic indicator for luminal subtype breast cancer and may predict the therapeutic response to paclitaxel-based treatments, potentially facilitating individualized management.	Paclitaxel	154-164	stathmin 1	Homo sapiens	19-24
23848202-8	2014	The results revealed a distinct increase in the expression levels of RNase kappa mRNA (up to 9-fold) after treatment with the antineoplastic agent paclitaxel in both cell lines, while treatment with the remaining anticancer drugs did not alter drastically the mRNA levels of RNase kappa.	Paclitaxel	147-157	ribonuclease K	Homo sapiens	69-80
23848202-8	2014	The results revealed a distinct increase in the expression levels of RNase kappa mRNA (up to 9-fold) after treatment with the antineoplastic agent paclitaxel in both cell lines, while treatment with the remaining anticancer drugs did not alter drastically the mRNA levels of RNase kappa.	Paclitaxel	147-157	ribonuclease K	Homo sapiens	275-286
23848202-9	2014	Based on the fact that paclitaxel exerts its cytotoxic action by inducing apoptosis, the results could be indicative of a potential implication of RNase kappa in apoptosis-related pathways.	Paclitaxel	23-33	ribonuclease K	Homo sapiens	147-158
2026268-12	1991	Affinity chromatography of solubilized proteins on a column containing taxol-stabilized microtubules also revealed MAP2 as a protein of chromaffin granules interacting with the microtubules.	Paclitaxel	71-76	microtubule associated protein 2	Bos taurus	115-119
24375949-5	2014	In contrast, reduced glutathione/oxidized glutathione ratio and glucose-6-phosphate dehydrogenase activity were decreased upon PTX treatment.	Paclitaxel	127-130	glucose-6-phosphate dehydrogenase	Homo sapiens	64-97
26233798-2	2015	Among these derivatives, compound 12 with dimethoxy groups at rings A and B and tri-substitution at ring C with ortho-methoxyethylmorpholine, meta-bromo and para-benzyloxy groups displays the most potent P-gp modulating activity with EC50 of 423 nM to reverse paclitaxel resistance.	Paclitaxel	260-270	phosphoglycolate phosphatase	Homo sapiens	204-208
24378441-0	2014	Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation.	Paclitaxel	53-63	transferrin	Mus musculus	30-41
24378441-1	2014	The aim of the present study was to prepare and evaluate a paclitaxel nanocrystal-based formulation stabilized by serum protein transferrin in a non-covalent manner.	Paclitaxel	59-69	transferrin	Mus musculus	128-139
24378441-4	2014	Interestingly, the Taxol( ) formulation showed higher antitumor activity than the paclitaxel-transferrin formulation, achieving a 93.3% tumor inhibition rate 12days post initial dosing.	Paclitaxel	82-92	transferrin	Mus musculus	93-104
24378441-5	2014	However, the paclitaxel-transferrin formulation showed a lower level of toxicity, which is indicated by a steady increase in body weight of mice over the treatment period.	Paclitaxel	13-23	transferrin	Mus musculus	24-35
1705109-4	1991	Administration of taxol to mice resulted in a profound sensory neuropathy characterized by decreases in dorsal root ganglion content of the peptide neurotransmitter, substance P, elevated threshold to thermally induced pain, and diminished amplitude of the compound action potential in the caudal nerve.	Paclitaxel	18-23	tachykinin 1	Mus musculus	166-177
33765585-0	2021	ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells.	Paclitaxel	15-25	chloride voltage-gated channel 3	Homo sapiens	0-5
33765585-4	2021	Here, we demonstrated that the protein expression and channel function of ClC-3 was upregulated in PTX resistance A2780/PTX cells compared with its parental A2780 cells.	Paclitaxel	99-102	chloride voltage-gated channel 3	Homo sapiens	74-79
33765585-4	2021	Here, we demonstrated that the protein expression and channel function of ClC-3 was upregulated in PTX resistance A2780/PTX cells compared with its parental A2780 cells.	Paclitaxel	120-123	chloride voltage-gated channel 3	Homo sapiens	74-79
33765585-5	2021	The silence of ClC-3 expression by siRNA in A2780/PTX cells partly recovered the PTX sensitivity through restored the G2/M arrest and resumed the chloride channel blocked.	Paclitaxel	50-53	chloride voltage-gated channel 3	Homo sapiens	15-20
33765585-5	2021	The silence of ClC-3 expression by siRNA in A2780/PTX cells partly recovered the PTX sensitivity through restored the G2/M arrest and resumed the chloride channel blocked.	Paclitaxel	81-84	chloride voltage-gated channel 3	Homo sapiens	15-20
33765585-8	2021	Take together, the over-expression of ClC-3 protein in PTX-resistance ovarian cancer cells promotes the combination of ClC-3 and beta-tubulin, which in turn increase the ration of free form and decrease the quota of the polymeric form of beta-tubulin, and finally reduce the sensitivity to PTX.	Paclitaxel	55-58	chloride voltage-gated channel 3	Homo sapiens	38-43
33765585-8	2021	Take together, the over-expression of ClC-3 protein in PTX-resistance ovarian cancer cells promotes the combination of ClC-3 and beta-tubulin, which in turn increase the ration of free form and decrease the quota of the polymeric form of beta-tubulin, and finally reduce the sensitivity to PTX.	Paclitaxel	55-58	chloride voltage-gated channel 3	Homo sapiens	119-124
33765585-8	2021	Take together, the over-expression of ClC-3 protein in PTX-resistance ovarian cancer cells promotes the combination of ClC-3 and beta-tubulin, which in turn increase the ration of free form and decrease the quota of the polymeric form of beta-tubulin, and finally reduce the sensitivity to PTX.	Paclitaxel	290-293	chloride voltage-gated channel 3	Homo sapiens	38-43
33765585-8	2021	Take together, the over-expression of ClC-3 protein in PTX-resistance ovarian cancer cells promotes the combination of ClC-3 and beta-tubulin, which in turn increase the ration of free form and decrease the quota of the polymeric form of beta-tubulin, and finally reduce the sensitivity to PTX.	Paclitaxel	290-293	chloride voltage-gated channel 3	Homo sapiens	119-124
33765585-9	2021	Our findings elucidated a novel function of ClC-3 in regulating PTX resistance and ClC-3 could serve as a potential target to overcome the PTX resistance ovarian cancer.	Paclitaxel	64-67	chloride voltage-gated channel 3	Homo sapiens	44-49
33765585-9	2021	Our findings elucidated a novel function of ClC-3 in regulating PTX resistance and ClC-3 could serve as a potential target to overcome the PTX resistance ovarian cancer.	Paclitaxel	139-142	chloride voltage-gated channel 3	Homo sapiens	83-88
33972393-4	2021	However, recent evidence suggests that paclitaxel operates in cancer therapies via an as-yet-undefined mechanism rather than as a mitotic inhibitor.We found that paclitaxel caused a striking break up of nuclei (referred to as multimicronucleation) in malignant ovarian cancer cells but not in normal cells, and susceptibility to undergo nuclear fragmentation and cell death correlated with a reduction in nuclear lamina proteins, Lamin A/C.	Paclitaxel	39-49	lamin A	Mus musculus	430-439
33972393-4	2021	However, recent evidence suggests that paclitaxel operates in cancer therapies via an as-yet-undefined mechanism rather than as a mitotic inhibitor.We found that paclitaxel caused a striking break up of nuclei (referred to as multimicronucleation) in malignant ovarian cancer cells but not in normal cells, and susceptibility to undergo nuclear fragmentation and cell death correlated with a reduction in nuclear lamina proteins, Lamin A/C.	Paclitaxel	162-172	lamin A	Mus musculus	430-439
33972393-6	2021	Mouse ovarian epithelial cells isolated from Lamin A/C null mice were highly sensitive to paclitaxel and underwent nuclear breakage, compared to control wildtype cells.	Paclitaxel	90-100	lamin A	Mus musculus	45-54
33972393-7	2021	Forced over-expression of Lamin A/C led to resistance to paclitaxel-induced nuclear breakage in cancer cells.	Paclitaxel	57-67	lamin A	Mus musculus	26-35
33030957-8	2021	Knockout of PD-L1 was shown to attenuate the induction of DNA double-strand breaks (pH2AX) and caspase-3 cleavage by 5-fluorouracil (5-FU) and paclitaxel compared to parental CRC cells.	Paclitaxel	143-153	CD274 molecule	Homo sapiens	12-17
34979464-7	2022	All of the novel DFV-taxoids exhibited 2-4 orders of magnitude greater potency against extremely drug-resistant cancer cell lines, LCC6-MDR and DLD-1, as compared to paclitaxel, indicating that these new DFV-taxoids can overcome MDR caused by the overexpression of Pgp and other ABC cassette transporters.	Paclitaxel	166-176	phosphoglycolate phosphatase	Homo sapiens	265-268
34974029-0	2022	SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas.	Paclitaxel	42-52	secreted protein acidic and cysteine rich	Homo sapiens	0-5
34974029-2	2022	Because SPARC shows high binding affinity to albumin, we reasoned that pediatric sarcoma xenografts expressing SPARC would show enhanced uptake and accumulation of nanoparticle albumin-bound (nab)-paclitaxel, a potent anticancer drug formulation.	Paclitaxel	197-207	secreted protein acidic and cysteine rich	Homo sapiens	8-13
34974029-2	2022	Because SPARC shows high binding affinity to albumin, we reasoned that pediatric sarcoma xenografts expressing SPARC would show enhanced uptake and accumulation of nanoparticle albumin-bound (nab)-paclitaxel, a potent anticancer drug formulation.	Paclitaxel	197-207	secreted protein acidic and cysteine rich	Homo sapiens	111-116
34974029-5	2022	Then, we used SPARC-edited Ewing sarcoma cells (A673 line) to demonstrate that SPARC knocked down (KD) cells accumulated significantly less amount of nab-paclitaxel in vitro than SPARC wild type (WT) cells.	Paclitaxel	154-164	secreted protein acidic and cysteine rich	Homo sapiens	79-84
34974029-5	2022	Then, we used SPARC-edited Ewing sarcoma cells (A673 line) to demonstrate that SPARC knocked down (KD) cells accumulated significantly less amount of nab-paclitaxel in vitro than SPARC wild type (WT) cells.	Paclitaxel	154-164	secreted protein acidic and cysteine rich	Homo sapiens	179-184
34974029-9	2022	In addition, SPARC KD Ewing sarcoma xenografts responded better to soluble docetaxel and paclitaxel than to nab-paclitaxel, while SPARC WT ones showed similar response to soluble and albumin-carried drugs.	Paclitaxel	89-99	secreted protein acidic and cysteine rich	Homo sapiens	13-18
34974029-9	2022	In addition, SPARC KD Ewing sarcoma xenografts responded better to soluble docetaxel and paclitaxel than to nab-paclitaxel, while SPARC WT ones showed similar response to soluble and albumin-carried drugs.	Paclitaxel	112-122	secreted protein acidic and cysteine rich	Homo sapiens	13-18
34974029-10	2022	Overall, our results show that pediatric sarcomas expressing SPARC accumulate nab-paclitaxel for longer periods of time, which could have clinical implications for chemotherapy efficacy.	Paclitaxel	82-92	secreted protein acidic and cysteine rich	Homo sapiens	61-66
34915631-14	2021	The expression levels of ENO1, PI3K/Akt signaling pathway related proteins including p-PI3K and p-Akt and the expression levels of PCNA, MMP-9 and Bcl-2 in siRNA-ENO1 group and paclitaxel+ siRNA-NC group were lower than those in siRNA-NC group (P<0.05).	Paclitaxel	177-187	enolase 1	Homo sapiens	25-29
34653365-5	2021	Our data highlight the importance of CXCL13+ T cells in effective responses to anti-PD-L1 therapies and suggest that their reduction by paclitaxel regimen may compromise the clinical outcomes of accompanying atezolizumab for TNBC treatment.	Paclitaxel	136-146	CD274 molecule	Homo sapiens	84-89
34904193-9	2022	PECS-101 also decreased PTX-induced increase in Tnf, Il6, and Aif1 (Iba-1) gene expression in the DRGs and the loss of intra-epidermal nerve fibers.	Paclitaxel	24-27	induction of brown adipocytes 1	Mus musculus	68-73
34699215-0	2021	Bradykinin-Potentiating Peptide-Paclitaxel Conjugate Directed at Ectopically Expressed Angiotensin-Converting Enzyme in Triple-Negative Breast Cancer.	Paclitaxel	32-42	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	87-116
34709112-0	2021	Long non-coding RNA (LncRNA) SNHG7/ Eukaryotic translation initiation factor 4 gamma 2 (EIF4G2) involves in the malignant events of ovarian cancer cells with paclitaxel resistant.	Paclitaxel	158-168	small nucleolar RNA host gene 7	Homo sapiens	29-34
34709112-3	2021	In this study, we investigated whether lncRNA SNHG7 was involved in Paclitaxel sensitivity of ovarian cancer as well as the underlying mechanism regulating the behavior of ovarian cancer cells with Paclitaxel resistance.	Paclitaxel	68-78	small nucleolar RNA host gene 7	Homo sapiens	46-51
34709112-8	2021	Taken together, these results demonstrated that lncRNA SNHG7 could affect the degradation of EIF4G2 to regulate the sensitivity of ovarian cancer to Paclitaxel, inhibit cell viability, migration and invasion.	Paclitaxel	149-159	small nucleolar RNA host gene 7	Homo sapiens	55-60
34709112-9	2021	The interaction of lncRNA SNHG7 and EIF4G2 plays an important role in the migrative and invasive activity and Paclitaxel -resistance of ovarian cancer cells.	Paclitaxel	110-120	small nucleolar RNA host gene 7	Homo sapiens	26-31
33866918-2	2021	In this study, we show evidence that 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs), act as immunogenic cell death (ICD) inducers, stimulating an antitumor response which results in synergistic antitumor activity by combining anti-PD-L1 antibody (aPD-L1) in vivo.	Paclitaxel	70-80	CD274 molecule	Homo sapiens	257-262
34655925-2	2021	SNX-5422 is an oral HSP90 inhibitor with increased activity in vitro with the addition of carboplatin and paclitaxel.	Paclitaxel	106-116	heat shock protein 90 alpha family class A member 1	Homo sapiens	20-25
34583980-0	2021	Paclitaxel induces micronucleation and activates pro-inflammatory cGAS-STING signaling in triple-negative breast cancer.	Paclitaxel	0-10	cyclic GMP-AMP synthase	Homo sapiens	66-70
34742008-3	2021	We present the case of an elderly, frail and comorbid patient, with a high-PDL1 expressing and very locally-advanced unresectable oral cavity cancer, that was treated with the combination of pembrolizumab and weekly carboplatin and paclitaxel, achieving a major pathological response, that permitted to de-escalate adjuvant therapy after surgery and is free of locoregional relapse 7 months after surgery.	Paclitaxel	232-242	CD274 molecule	Homo sapiens	75-79
34942984-7	2021	Furthermore, in paclitaxel-resistant breast cancer cell lines, MCF-7R and MDA-MB-231R, a combination of JI017 and paclitaxel overcame paclitaxel resistance by blocking epithelial-mesenchymal transition (EMT) processes, such as the downregulation of E-cadherin expression and the upregulation of HIF-1alpha, vimentin, Snail, and Slug expression.	Paclitaxel	114-124	vimentin	Homo sapiens	307-315
34509058-0	2021	Corrigendum to "Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1" (Biochem.	Paclitaxel	40-50	glutathione S-transferase pi 1	Homo sapiens	95-100
34365218-5	2021	Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2.	Paclitaxel	102-107	ribosomal protein S6 kinase A1	Homo sapiens	192-201
34786051-0	2021	The effect of cullin 4A on lung cancer cell chemosensitivity to paclitaxel through p33ING1b regulation.	Paclitaxel	64-74	cullin 4A	Mus musculus	14-23
34692516-1	2021	This investigation was conducted to elucidate whether atractylenolide-I (ATL-1), which is the main component of Atractylodes macrocephala Koidz, can sensitize triple-negative breast cancer (TNBC) cells to paclitaxel and investigate the possible mechanism involved.	Paclitaxel	205-215	atlastin GTPase 1	Mus musculus	73-78
34692516-2	2021	We discovered that ATL-1 could inhibit tumor cell migration and increase the sensitivity of tumor cells to paclitaxel.	Paclitaxel	107-117	atlastin GTPase 1	Mus musculus	19-24
34692516-4	2021	Apart from inhibiting TNBC cell migration via CTGF, ATL-1 downregulated the expression of CTGF in fibroblasts and decreased the ability of breast cancer cells to transform fibroblasts into cancer-associated fibroblasts (CAFs), which in turn increased the sensitivity of TNBC cells to paclitaxel.	Paclitaxel	284-294	atlastin GTPase 1	Mus musculus	52-57
34692516-5	2021	In a mouse model, we found that ATL-1 treatments could enhance the chemotherapeutic effect of paclitaxel on tumors and reduce tumor metastasis to the lungs and liver.	Paclitaxel	94-104	atlastin GTPase 1	Mus musculus	32-37
34314939-0	2021	LINC00337 induces tumor development and chemoresistance to paclitaxel of breast cancer by recruiting M2 tumor-associated macrophages.	Paclitaxel	59-69	ICMT divergent transcript	Homo sapiens	0-9
34314939-12	2021	PAX significantly reduced the viability of BCa cells and down-regulated LINC00337.	Paclitaxel	0-3	ICMT divergent transcript	Homo sapiens	72-81
34314939-15	2021	CONCLUSION: LINC00337 accelerated the malignant phenotype of BCa cells and promoted chemoresistance to paclitaxel through M2-like macrophages.	Paclitaxel	103-113	ICMT divergent transcript	Homo sapiens	12-21
34457060-12	2021	Taken together, the results of the present study suggest that paclitaxel-activated JNK is required for caspase activation and loss of  Psim, which results in apoptosis of HNSCC cells.	Paclitaxel	62-72	caspase 6	Homo sapiens	103-110
34746885-7	2021	Furthermore, treatment with paclitaxel and DNMT1 inhibitor suppressed SPC25 expression.	Paclitaxel	28-38	SPC25 component of NDC80 kinetochore complex	Homo sapiens	70-75
34510641-9	2021	CONCLUSION: Our results suggest that orlistat enhances the chemosensitivity of SCC-9 LN-1 cells to cisplatin and paclitaxel by downregulating cyclin B1.	Paclitaxel	113-123	cyclin B1	Homo sapiens	142-151
34506610-0	2021	Correction: PINK1 alleviates thermal hypersensitivity in a paclitaxel-induced Drosophila model of peripheral neuropathy.	Paclitaxel	59-69	PTEN-induced putative kinase 1	Drosophila melanogaster	12-17
34476599-7	2022	As for chemosensitivity, upregulation of SIRT2 increased relative cell viability in cisplatin-treated and paclitaxel-treated Ishikawa cells.	Paclitaxel	106-116	sirtuin 2	Homo sapiens	41-46
34363313-4	2021	We show that diverse stress stimuli, including etoposide, brefeldin A and paclitaxel, as well as heat stress and gamma-irradiation, caused formation of a complex containing ATG5-ATG12, FADD and caspase-8 leading to activation of downstream caspases in caspase-9-deficient cells.	Paclitaxel	74-84	caspase 9	Homo sapiens	252-261
34465889-0	2022	Ubiquitination of NF-kappaB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance.	Paclitaxel	95-105	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	28-31
34465889-8	2022	FBXW2 overexpression abrogates the effects of p65 on paclitaxel resistance in vitro and in vivo.	Paclitaxel	53-63	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	46-49
34413359-5	2021	The best compounds showed a similar binding pattern and interactions to those of doxorubicin and tariquidar, as revealed by MD and hybrid QM/MM simulations performed with the recent experimental structure of P-gp co-crystallized with paclitaxel.	Paclitaxel	234-244	phosphoglycolate phosphatase	Homo sapiens	208-212
34161810-4	2021	Our tests demonstrated satisfactory preparation of paclitaxel-loaded, PD-L1-targeted albumin nanoparticles (PD-L1/PTX@HSA).	Paclitaxel	51-61	CD274 molecule	Homo sapiens	108-113
34294680-7	2021	Moreover, paclitaxel upregulates GBP2 expression, and paclitaxel-induced apoptotic activity was distinctively compromised by knockout of GBP2 in CML cells.	Paclitaxel	10-20	guanylate binding protein 2	Homo sapiens	33-37
34294680-7	2021	Moreover, paclitaxel upregulates GBP2 expression, and paclitaxel-induced apoptotic activity was distinctively compromised by knockout of GBP2 in CML cells.	Paclitaxel	10-20	guanylate binding protein 2	Homo sapiens	137-141
34294680-7	2021	Moreover, paclitaxel upregulates GBP2 expression, and paclitaxel-induced apoptotic activity was distinctively compromised by knockout of GBP2 in CML cells.	Paclitaxel	54-64	guanylate binding protein 2	Homo sapiens	137-141
34156070-4	2021	We show that yeast oxidative stress response mutants (sod1Delta, tsa1Delta and cta1Delta) and DNA damage response mutants (mre11 , sgs1  and sub1 ) are highly sensitive to Taxol.	Paclitaxel	172-177	chromatin-binding transcription coactivator SUB1	Saccharomyces cerevisiae S288C	141-145
34230132-0	2021	PTEN Is Activated by the Addition of Cetuximab to Paclitaxel in Oral Squamous Cell Carcinoma.	Paclitaxel	50-60	phosphatase and tensin homolog	Homo sapiens	0-4
34230132-5	2021	PTEN mRNA expression levels were also confirmed after administration of PTX + cMab in vivo.	Paclitaxel	72-75	phosphatase and tensin homolog	Homo sapiens	0-4
34230132-7	2021	RESULTS: PTEN mRNA and protein expression were significantly increased only in the cell lines with high sensitivity to PTX + cMab, and similar results were observed in vivo.	Paclitaxel	119-122	phosphatase and tensin homolog	Homo sapiens	9-13
34230132-8	2021	CONCLUSION: PTEN activation may enhance the antitumor effect of PTX + cMab.	Paclitaxel	64-67	phosphatase and tensin homolog	Homo sapiens	12-16
34086472-6	2021	Furthermore, we show that MRIA9 sensitizes ovarian cancer cells to treatment with the mitotic agent paclitaxel, confirming earlier data from genetic knockdown studies and suggesting a combination therapy with SIK inhibitors and paclitaxel for the treatment of paclitaxel-resistant ovarian cancer.	Paclitaxel	100-110	salt inducible kinase 1	Homo sapiens	209-212
34284854-10	2021	SSH-1 silencing mediated CFL-1 phosphorylation in paclitaxel-resistant SKOV3 cells.	Paclitaxel	50-60	slingshot protein phosphatase 1	Homo sapiens	0-5
34284854-12	2021	Conclusion: The SSH-1/p-CFL-1 signaling pathway mediates paclitaxel resistance by apoptosis inhibition in EOC and is expected to be a potential prognostic predictor.	Paclitaxel	57-67	slingshot protein phosphatase 1	Homo sapiens	16-21
34118960-14	2021	BQU57, a small molecule inhibitor of RALA and RALB, decreased TNBC cell line viability, sensitized cells to paclitaxel in vitro and decreased tumor growth and metastasis in TNBC cell line and PDX models in vivo.	Paclitaxel	108-118	RAS like proto-oncogene B	Homo sapiens	46-50
34189050-2	2021	A 48-year-old Japanese male with relapsed retroperitoneal lymph node metastases received four courses of paclitaxel, ifosfamide, and cisplatin (TIP).	Paclitaxel	105-115	TOR signaling pathway regulator	Homo sapiens	144-147
33735118-14	2021	MiR-149-5p overexpression suppressed paclitaxel resistance and cell progression in paclitaxel-resistant ovarian cancer cells by interacting with SIK2.	Paclitaxel	37-47	microRNA 149	Homo sapiens	0-7
33735118-14	2021	MiR-149-5p overexpression suppressed paclitaxel resistance and cell progression in paclitaxel-resistant ovarian cancer cells by interacting with SIK2.	Paclitaxel	83-93	microRNA 149	Homo sapiens	0-7
34031250-8	2021	Thus, we used the microtubule-stabilization drug paclitaxel to demonstrate that ZIKV repurposes RNase L to facilitate the cytoskeleton rearrangements required for proper generation of RFs.	Paclitaxel	49-59	ribonuclease L	Homo sapiens	96-103
34134965-1	2021	OBJECTIVE: To construct an ovarian cancer cell line stably overexpressing XAF1 gene and observe the effects of XAF1 gene overexpression on proliferation, apoptosis, cell cycle and sensitivity to paclitaxel of the cells.	Paclitaxel	195-205	XIAP associated factor 1	Homo sapiens	111-115
34134965-7	2021	The proliferative activity of A2780/XAF1 cells was significantly lower than that of A2780/NC cells after exposure to different paclitaxel concentrations (P < 0.001).	Paclitaxel	127-137	XIAP associated factor 1	Homo sapiens	36-40
34134965-8	2021	The half inhibitory concentration of paclitaxel was significantly lower in A2780/XAF1 than in A2780/NC cells.	Paclitaxel	37-47	XIAP associated factor 1	Homo sapiens	81-85
34134965-9	2021	OBJECTIVE: Overexpression of XAF1 significantly inhibits the proliferation, induces cell cycle arrest, promotes apoptosis, and increases paclitaxel sensitivity in ovarian cancer cells.	Paclitaxel	137-147	XIAP associated factor 1	Homo sapiens	29-33
35634239-8	2022	And HOXB9 expression regulated the resistance to chemotherapy (Gemcitabine and nab-Paclitaxel) and stem cell population.	Paclitaxel	83-93	homeobox B9	Homo sapiens	4-9
35304127-6	2022	KEY FINDINGS: DRG overexpression of TET1 mitigated the paclitaxel-induced mechanical allodynia, heat hyperalgesia and cold hyperalgesia on the ipsilateral side during the development and maintenance periods.	Paclitaxel	55-65	tet methylcytosine dioxygenase 1	Rattus norvegicus	36-40
35304127-8	2022	Mechanistically, DRG overexpression of TET1 rescued the expression of K2p1.1 by blocking the paclitaxel-induced increase in the level of 5-methylcytosine and correspondingly reversing the paclitaxel-induced decreases in the amount of 5-hydroxymethylcytosine within the K2p1.1 promoter region in the microinjected DRGs of male rats.	Paclitaxel	93-103	tet methylcytosine dioxygenase 1	Rattus norvegicus	39-43
35304127-8	2022	Mechanistically, DRG overexpression of TET1 rescued the expression of K2p1.1 by blocking the paclitaxel-induced increase in the level of 5-methylcytosine and correspondingly reversing the paclitaxel-induced decreases in the amount of 5-hydroxymethylcytosine within the K2p1.1 promoter region in the microinjected DRGs of male rats.	Paclitaxel	188-198	tet methylcytosine dioxygenase 1	Rattus norvegicus	39-43
35075596-8	2022	In addition, the PAX induced apoptosis and cell death via upregulation of caspases and downregulation of antioxidant glutathione peroxidase and glutathione in the cells.	Paclitaxel	17-20	caspase 9	Homo sapiens	74-82
35184686-0	2022	Ultrasound-targeted microbubble destruction-mediated miR-144-5p overexpression enhances the anti-tumor effect of paclitaxel on thyroid carcinoma by targeting STON2.	Paclitaxel	113-123	stonin 2	Mus musculus	158-163
35371298-0	2022	Radix ranunculus temate saponins sensitizes ovarian cancer to Taxol via upregulation of miR-let-7b.	Paclitaxel	62-67	myosin regulatory light chain interacting protein	Homo sapiens	88-91
35371298-10	2022	miR-let-7b overexpression suppressed cell growth and invasion and enhanced sensitivity to Taxol of ovarian cancer cells.	Paclitaxel	90-95	myosin regulatory light chain interacting protein	Homo sapiens	0-3
35371298-15	2022	In conclusion, the present results revealed synergistic cytotoxicity of RRTS and Taxol on against ovarian cancer cells via upregulating expression of miR-let-7b.	Paclitaxel	81-86	myosin regulatory light chain interacting protein	Homo sapiens	150-153
35473527-9	2022	Additionally, alpha-tubulin aggregation, DNA damage suggested the molecular mechanism behind cell death upon PTX-DHA-loaded nanoparticle treatment.	Paclitaxel	109-112	tubulin alpha 1b	Homo sapiens	14-27
35619841-5	2022	We report a case of a 74-year-old male with stage four (IV) BSCC of the lung who experienced a complete metabolic with partial anatomic response to combined chemotherapy and immunotherapy with carboplatin/nab-paclitaxel/pembrolizumab and has continued to be in partial remission on maintenance immunotherapy with pembrolizumab despite PD-L1-negative status.	Paclitaxel	209-219	CD274 molecule	Homo sapiens	335-340
24448468-0	2014	LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer.	Paclitaxel	29-39	leucine zipper tumor suppressor 1	Homo sapiens	0-5
24448468-4	2014	We investigate the role of Lzts1 in paclitaxel-resistance in breast cancer cells.	Paclitaxel	36-46	leucine zipper tumor suppressor 1	Homo sapiens	27-32
24448468-5	2014	Downregulation of Lzts1 expression significantly decreases sensitivity to paclitaxel in vitro.	Paclitaxel	74-84	leucine zipper tumor suppressor 1	Homo sapiens	18-23
24552184-0	2014	IN.PACT Amphirion paclitaxel eluting balloon versus standard percutaneous transluminal angioplasty for infrapopliteal revascularization of critical limb ischemia: rationale and protocol for an ongoing randomized controlled trial.	Paclitaxel	18-28	RB binding protein 6, ubiquitin ligase	Homo sapiens	3-7
24552184-3	2014	METHODS/DESIGN: IN.PACT DEEP is a 2:1 randomized controlled trial designed to assess the efficacy and safety of infrapopliteal arterial revascularization between the IN.PACT Amphirion  paclitaxel drug-eluting balloon (IA-DEB) and standard balloon angioplasty (PTA) in patients with Rutherford Class 4-5-6 CLI.	Paclitaxel	185-195	RB binding protein 6, ubiquitin ligase	Homo sapiens	19-23
24420921-0	2014	Tetraacylated lipid A and paclitaxel-selective activation of TLR4/MD-2 conferred through hydrophobic interactions.	Paclitaxel	26-36	lymphocyte antigen 96	Homo sapiens	66-70
24420921-2	2014	The hexaacylated lipid A is an agonist of mouse (mTLR4) and human TLR4/MD-2, whereas the tetraacylated lipid IVa and paclitaxel activate only mTLR4/MD-2 and antagonize activation of the human receptor complex.	Paclitaxel	117-127	lymphocyte antigen 96	Homo sapiens	148-152
24420921-4	2014	We show that each of the hydrophobic residues F438 and F461, which are located on the convex face of leucine-rich repeats 16 and 17 of the mTLR4 ectodomain, are essential for activation of with lipid IVa and paclitaxel, which, although not a structural analog of LPS, activates cells expressing mTLR4/MD-2.	Paclitaxel	208-218	lymphocyte antigen 96	Homo sapiens	301-305
24120346-2	2014	In OV-MZ-6 ovarian cancer cells, combined expression of KLK4-7 reduces cell adhesion and increases cell invasion and resistance to paclitaxel.	Paclitaxel	131-141	kallikrein related peptidase 4	Homo sapiens	56-60
24367683-11	2013	When 14-3-3z overexpressing neurons were treated with the microtubule stabilizing drug taxol, tau Ser(262) phosphorylation decreased and synaptophysin level was restored.	Paclitaxel	87-92	synaptophysin	Rattus norvegicus	137-150
24372428-9	2013	The number of administered cycles of carboplatin to develop G1-G4 resp. G1-G3 HSR was higher in comparison with number of cycles to develop HSR of the same grade to paclitaxel(p = 0.001, resp. p = 0.01).	Paclitaxel	165-175	HSR	Homo sapiens	140-143
23675978-6	2013	The experimental results were in agreement with the predicted values and the ethyl oxalyl derivative of GA-1 (GA-3) showed equal cytotoxic activity to that of standard anticancer drug paclitaxel.	Paclitaxel	184-194	succinyl-CoA:glutarate-CoA transferase	Homo sapiens	104-114
23792807-6	2013	Efficacy of targeting was shown on CD44 positive cells in the SUM159 breast cancer cell line by incubating the cells sequentially with a biotinylated anti-CD44 antibody, StA and the biotinylated nanospheres encapsulating PTX.	Paclitaxel	221-224	CD44 molecule (Indian blood group)	Homo sapiens	35-39
23871962-0	2013	CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer.	Paclitaxel	15-25	prominin 1	Mus musculus	0-5
23871962-9	2013	Tumor regrowth was significantly lower when paclitaxel was delivered through CD133NPs (tumor volume was 518.6+-228 vs. 1370.9+-295mm(3) for free paclitaxel at 63days; P&lt;0.05).	Paclitaxel	44-54	prominin 1	Mus musculus	77-82
23871962-9	2013	Tumor regrowth was significantly lower when paclitaxel was delivered through CD133NPs (tumor volume was 518.6+-228 vs. 1370.9+-295mm(3) for free paclitaxel at 63days; P&lt;0.05).	Paclitaxel	145-155	prominin 1	Mus musculus	77-82
23932498-0	2013	Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment.	Paclitaxel	86-96	transferrin	Mus musculus	0-11
23838193-0	2013	Paclitaxel nanosuspensions coated with P-gp inhibitory surfactants: I.	Paclitaxel	0-10	phosphoglycolate phosphatase	Mus musculus	39-43
23659854-4	2013	Furthermore, pre-treatment of PC3 cells with F3-targeted liposomes containing anti-PLK1 siRNA enabled a 3-fold reduction of paclitaxel IC50 and a 2.5-fold augment of the percentage of cancer cells in G2/mitosis arrest, which ultimately culminated in cell death.	Paclitaxel	124-134	polo like kinase 1	Homo sapiens	83-87
24254559-12	2013	The immunohistochemistry demonstrated that protein expression levels of Ki-67 and Bcl-xL were significantly increased, whereas cleaved caspase-3 decreased in the DEX+PTX group, compared to PTX group (p &lt; 0.0125).	Paclitaxel	166-169	caspase 3	Mus musculus	135-144
24155950-3	2013	Here we show that the combined regimens of bortezomib with mitotic inhibitors, such as the microtubule-stabilizing agent Paclitaxel and the PLK1 inhibitor BI2536, efficiently kill TKIs-resistant and -sensitive Bcr-Abl-positive leukemic cells.	Paclitaxel	121-131	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	210-217
24088129-2	2013	We determined the frequency of polymorphisms in the CYP2D6 gene associated with activation of tamoxifen, and those of the genes CYP2C8, CYP3A5 and DPYD associated with toxicity of paclitaxel and capecitabine.	Paclitaxel	180-190	dihydropyrimidine dehydrogenase	Homo sapiens	147-151
22341413-6	2013	RESULTS: The paclitaxel-hyaluronan bioconjugate bound to UC tumor cells entered intracellular compartments through a saturable and energy-dependent mechanism that involved CD44, as assessed by blocking with specific antibody.	Paclitaxel	13-23	CD44 molecule (Indian blood group)	Homo sapiens	172-176
23811008-7	2013	In vitro studies showed that FSH beta 81-95 peptide enabled the specific uptake of cytotoxic drugs and increased the intracellular paclitaxel concentration in FSH receptor-expressing cancer cells, resulting in enhanced cytotoxic effects.	Paclitaxel	131-141	follicle stimulating hormone receptor	Homo sapiens	159-171
24252213-0	2013	Excitotoxin-induced caspase-3 activation and microtubule disintegration in axons is inhibited by taxol.	Paclitaxel	97-102	caspase 3	Mus musculus	20-29
23583762-3	2013	Additionally, VEGF protects dorsal root ganglion (DRG) neurons against paclitaxel-induced neurotoxicity.	Paclitaxel	71-81	vascular endothelial growth factor A	Mus musculus	14-18
23583762-6	2013	In vivo, local VEGF application also protected against paclitaxel- and diabetes-induced neuropathies without causing side effects.	Paclitaxel	55-65	vascular endothelial growth factor A	Mus musculus	15-19
23583762-7	2013	A small synthetic VEGF mimicking pentadecapeptide (QK) exerted similar effects on DRG cultures: the peptide reduced ATF3 expression in vitro and ex vivo in paclitaxel- and hyperglycemia-induced models of neuropathy to a similar extent as the full-length recombinant VEGF protein.	Paclitaxel	156-166	vascular endothelial growth factor A	Mus musculus	18-22
23807165-9	2013	Modulation of these microRNAs resensitizes PTX-resistant cancer cells by targeting BCL10, caspase-7, and ZEB1.	Paclitaxel	43-46	zinc finger E-box binding homeobox 1	Homo sapiens	105-109
23792647-0	2013	A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.	Paclitaxel	44-54	KRAS proto-oncogene, GTPase	Homo sapiens	101-105
23792647-0	2013	A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.	Paclitaxel	44-54	KRAS proto-oncogene, GTPase	Homo sapiens	127-131
23792647-7	2013	CDK4 short interfering RNA (siRNA) significantly increased paclitaxel sensitivity in KRAS mutation-positive H23 cells.	Paclitaxel	59-69	KRAS proto-oncogene, GTPase	Homo sapiens	85-89
23792647-10	2013	Combined CINK4 and paclitaxel produced synergistic anti-proliferative activity and increased apoptosis through reduced cyclin D1 and Bcl-2 in KRAS mutation-positive cancer cells.	Paclitaxel	19-29	KRAS proto-oncogene, GTPase	Homo sapiens	142-146
23792647-11	2013	These data suggest CDK4 is a promising target for development of anti-cancer drugs and CINK4 combined with paclitaxel may be an effective therapeutic strategy for enhancing anti-tumor efficacy in KRAS mutation-positive lung adenocarcinoma.	Paclitaxel	107-117	KRAS proto-oncogene, GTPase	Homo sapiens	196-200
23852894-0	2013	Propofol inhibits invasion and enhances paclitaxel- induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug.	Paclitaxel	40-50	snail family transcriptional repressor 2	Homo sapiens	146-150
23852894-9	2013	Significant correlation was observed between basal Slug levels and paclitaxel sensitivity.	Paclitaxel	67-77	snail family transcriptional repressor 2	Homo sapiens	51-55
23852894-10	2013	Paclitaxel treatment increased Slug levels.	Paclitaxel	0-10	snail family transcriptional repressor 2	Homo sapiens	31-35
23296900-9	2013	Furthermore, miR-182 reduced the chemosensitivity of ovarian cancer cells to CDDP and Taxol, possibly by its anti-apoptosis activity.	Paclitaxel	86-91	microRNA 182	Homo sapiens	13-20
23562605-0	2013	Spinal CCL2 and microglial activation are involved in paclitaxel-evoked cold hyperalgesia.	Paclitaxel	54-64	chemokine (C-C motif) ligand 2	Mus musculus	7-11
23531193-2	2013	In addition, the effect of Plk-1 downregulation on the cancer cells chemosensitization to paclitaxel was further assessed.	Paclitaxel	90-100	polo like kinase 1	Homo sapiens	27-32
23531193-6	2013	In combination with paclitaxel, anti-PLK-1 siRNA chemosensitized non-small cell lung cancer (NSCLC) and prostate carcinoma cell lines, leading up to a 2-fold increase in the drug cytotoxic effect.	Paclitaxel	20-30	polo like kinase 1	Homo sapiens	37-42
23531193-7	2013	Moreover, the sequential incubation of anti-PLK-1 siRNA and paclitaxel led to a decrease in the IC50 of the latter up to 2.7- and 4.1-fold, in A-549 and PC-3 cells, respectively.	Paclitaxel	60-70	polo like kinase 1	Homo sapiens	44-49
23531193-8	2013	The combination of anti-PLK-1 siRNA with paclitaxel led to cell cycle arrest, increasing the number of cells at the G2/M and S phases to 1.5 and 1.3-fold in PC-3 cells, and to 1.6 and 1.4-fold in A-549 cells, respectively.	Paclitaxel	41-51	polo like kinase 1	Homo sapiens	24-29
23563171-7	2013	The augmentation of PCX-induced apoptosis by 3-MA was accompanied by increase in the cytochrome c release from the mitochondria, caspase-3 activity and XIAP downregulation, which suggests that inhibiting autophagy further stimulates the PCX-induced mitochondrion-related (intrinsic) apoptotic pathway by provoking caspase-3 activation.	Paclitaxel	20-23	X-linked inhibitor of apoptosis	Homo sapiens	152-156
23628996-9	2013	Microtubule-destabilizing treatments such as propyzamide or oryzalin and temperature stresses resulted in alpha-tubulin phosphorylation, whereas hyperosmotic stress-induced alpha-tubulin phosphorylation was partially inhibited by taxol, which stabilizes microtubules.	Paclitaxel	230-235	tubulin alpha-5	Arabidopsis thaliana	173-186
23580645-8	2013	Paclitaxel had no effect on TGF-beta-induced Smad activation and Smad-dependent gene transcription but inhibited actin polymerization, nuclear accumulation of megakaryoblastic leukemia-1 protein, and SRF activation.	Paclitaxel	0-10	serum response factor	Homo sapiens	200-203
23628417-0	2013	Tumor suppressor BLU promotes paclitaxel antitumor activity by inducing apoptosis through the down-regulation of Bcl-2 expression in tumorigenesis.	Paclitaxel	30-40	zinc finger MYND-type containing 10	Homo sapiens	17-20
23624503-8	2013	The sensitivity of CD44(+)CD24(+)p53wt cells to paclitaxel is associated with the downregulation of Bcl-2 expression, upregulation of Bax levels, and upregulation of caspase-3 activity.	Paclitaxel	48-58	CD44 molecule (Indian blood group)	Homo sapiens	19-23
23624503-9	2013	Silencing of Cdx1 expression and treatment with lysosomal inhibitor bafilomycin A increased paclitaxel-induced cytotoxicity in CD44(+)CD24(+)Cdx1(+) cells.	Paclitaxel	92-102	CD44 molecule (Indian blood group)	Homo sapiens	127-131
22877241-0	2013	GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients.	Paclitaxel	60-70	RWD domain containing 3	Homo sapiens	31-36
23348568-10	2013	In addition, we demonstrated that inhibition of Aurora-A attenuates USP7-mediated taxane resistance, suggesting that combinatorial drug regimens of Taxol and Aurora-A inhibitors may improve the outcome of chemotherapy response in cancer patients resistant to taxane treatment.	Paclitaxel	148-153	ubiquitin specific peptidase 7	Homo sapiens	68-72
23468530-7	2013	Knockdown of CXCR2 enhances paclitaxel and doxorubicin-mediated toxicity at suboptimal doses.	Paclitaxel	28-38	chemokine (C-X-C motif) receptor 2	Mus musculus	13-18
23468530-8	2013	Moreover, we observed an increase in the expression of CXCL1, a CXCR2 ligand in paclitaxel and doxorubicin-treated mammary tumor cells, which were inhibited following CXCR2 knockdown.	Paclitaxel	80-90	chemokine (C-X-C motif) receptor 2	Mus musculus	64-69
23468530-8	2013	Moreover, we observed an increase in the expression of CXCL1, a CXCR2 ligand in paclitaxel and doxorubicin-treated mammary tumor cells, which were inhibited following CXCR2 knockdown.	Paclitaxel	80-90	chemokine (C-X-C motif) receptor 2	Mus musculus	167-172
23468530-9	2013	Knockdown of CXCR2 enhanced antitumor activity of paclitaxel in an in vivo mammary tumor model.	Paclitaxel	50-60	chemokine (C-X-C motif) receptor 2	Mus musculus	13-18
23468530-10	2013	We observed significant inhibition of spontaneous lung metastases in animals bearing CXCR2 knockdown tumors and treated with paclitaxel as compared with the control group.	Paclitaxel	125-135	chemokine (C-X-C motif) receptor 2	Mus musculus	85-90
23462720-0	2013	BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.	Paclitaxel	109-119	BRCA1 DNA repair associated	Homo sapiens	0-5
23462720-16	2013	Although these results merit validation in future studies, the results suggest that decreased BRCA1 expression predicts for improved response to cisplatin-based IP chemotherapy with cisplatin and paclitaxel.	Paclitaxel	196-206	BRCA1 DNA repair associated	Homo sapiens	94-99
23371322-0	2013	Targeted inhibition of phosphatidyl inositol-3-kinase p110beta, but not p110alpha, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.	Paclitaxel	121-131	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	54-62
23371322-5	2013	We, first, evaluated the expression of PI3K p110 isoforms in chemosensitive and chemoresistant ovarian cancer cell lines and patient specimens, and found that p110beta-isoform was significantly overexpressed both in a panel of ovarian cancer samples, and in PTX-resistant sublines compared with their parent cell lines.	Paclitaxel	258-261	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	159-167
23371322-6	2013	RNA interference-mediated p110beta silencing augmented PTX-mediated apoptosis (31.15 +- 13.88 %) and reduced cell viability (67 %) in PTX-resistant cells, whereas targeting p110alpha did not show a significant change in cell viability and apoptosis.	Paclitaxel	55-58	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	26-34
23371322-6	2013	RNA interference-mediated p110beta silencing augmented PTX-mediated apoptosis (31.15 +- 13.88 %) and reduced cell viability (67 %) in PTX-resistant cells, whereas targeting p110alpha did not show a significant change in cell viability and apoptosis.	Paclitaxel	134-137	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	26-34
23371322-7	2013	In addition, p110beta silencing impaired cell proliferation (60 %) in PTX-resistant SKpac cells.	Paclitaxel	70-73	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	13-21
23371322-9	2013	Thus, the siRNA-mediated silencing of PI3K p110beta resensitizes PTX-resistant ovarian cancer cells, and may be a useful therapeutic strategy for PTX-resistant ovarian cancers.	Paclitaxel	65-68	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	43-51
23371322-9	2013	Thus, the siRNA-mediated silencing of PI3K p110beta resensitizes PTX-resistant ovarian cancer cells, and may be a useful therapeutic strategy for PTX-resistant ovarian cancers.	Paclitaxel	146-149	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	43-51
23354756-9	2013	We found that KD             of SLC25A43 resulted in a decreased cytotoxic effect of paclitaxel in the two             cancer cell lines (P&lt;0.05).	Paclitaxel	85-95	solute carrier family 25 member 43	Homo sapiens	32-40
23537295-6	2013	In addition, immunohistochemical studies on mouse tumors injected with cisplatin or paclitaxel treated residual cells displayed higher staining for the proliferative antigen Ki67, oncogeneic CA125, epithelial E-cadherin as well as cancer stem cell markers such as Oct4 and CD117, compared to mice injected with control untreated cells.	Paclitaxel	84-94	mucin 16	Mus musculus	191-196
23667401-10	2013	Results showed that circulating taxol (10nM) reduced PAEC polarity, NF-kappaB activation, gene expression of pro-inflammatory molecules (ICAM-1 and VCAM-1), and monocyte adhesion on the PAECs under high pulsatility flow.	Paclitaxel	32-37	intercellular adhesion molecule 1	Homo sapiens	137-143
22864818-6	2013	Subsequent in vitro study in SiHa and C-33A human cervical squamous carcinoma cell lines revealed that knocking down galectin-7 or S100A9 enhanced tumor cell invasion and tumor cell viability against paclitaxel-induced apoptotic stress, likely through increasing the matrix metalloproteinase-9 expression and activating the phosphatidylinositol 3-kinase/Akt signaling pathway, respectively.	Paclitaxel	200-210	S100 calcium binding protein A9	Homo sapiens	131-137
22864818-6	2013	Subsequent in vitro study in SiHa and C-33A human cervical squamous carcinoma cell lines revealed that knocking down galectin-7 or S100A9 enhanced tumor cell invasion and tumor cell viability against paclitaxel-induced apoptotic stress, likely through increasing the matrix metalloproteinase-9 expression and activating the phosphatidylinositol 3-kinase/Akt signaling pathway, respectively.	Paclitaxel	200-210	matrix metallopeptidase 9	Homo sapiens	267-293
23364970-0	2013	Blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in gastric cancer cells.	Paclitaxel	41-51	kinase insert domain receptor	Homo sapiens	24-31
23228696-4	2013	In this current study, paclitaxel was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.	Paclitaxel	23-33	mitogen-activated protein kinase kinase 3	Homo sapiens	127-134
23627059-7	2013	Cell growth inhibitory effects of the paclitaxel (PTX) chemotherapy combined with the HA component on SP cells of Huh-7 was determined using the trypan blue dye exclusion test.	Paclitaxel	38-48	MIR7-3 host gene	Homo sapiens	114-119
23627059-7	2013	Cell growth inhibitory effects of the paclitaxel (PTX) chemotherapy combined with the HA component on SP cells of Huh-7 was determined using the trypan blue dye exclusion test.	Paclitaxel	50-53	MIR7-3 host gene	Homo sapiens	114-119
23204130-7	2013	Decreased expression of this gene by siRNA resulted in increased sensitivity of Neuroscreen-1(NS-1; rat pheochromocytoma) cells to paclitaxel as measured by reduced neurite outgrowth and increased cytotoxicity, functionally validating the involvement of RFX2 in nerve cell response to paclitaxel.	Paclitaxel	131-141	regulatory factor X2	Rattus norvegicus	254-258
23099063-6	2013	ICAM-1-selective delivery of paclitaxel produced potent tumor suppression of not only ICAM-1-positive cervical cancer cells but also ICAM-1-negative tumors, presumably by causing cytotoxicity in tumor-associated endothelium (CD31(+)) and macrophages (CD68(+)) over-expressing ICAM-1.	Paclitaxel	29-39	intercellular adhesion molecule 1	Homo sapiens	0-6
23099063-6	2013	ICAM-1-selective delivery of paclitaxel produced potent tumor suppression of not only ICAM-1-positive cervical cancer cells but also ICAM-1-negative tumors, presumably by causing cytotoxicity in tumor-associated endothelium (CD31(+)) and macrophages (CD68(+)) over-expressing ICAM-1.	Paclitaxel	29-39	intercellular adhesion molecule 1	Homo sapiens	86-92
23099063-6	2013	ICAM-1-selective delivery of paclitaxel produced potent tumor suppression of not only ICAM-1-positive cervical cancer cells but also ICAM-1-negative tumors, presumably by causing cytotoxicity in tumor-associated endothelium (CD31(+)) and macrophages (CD68(+)) over-expressing ICAM-1.	Paclitaxel	29-39	intercellular adhesion molecule 1	Homo sapiens	86-92
23099063-6	2013	ICAM-1-selective delivery of paclitaxel produced potent tumor suppression of not only ICAM-1-positive cervical cancer cells but also ICAM-1-negative tumors, presumably by causing cytotoxicity in tumor-associated endothelium (CD31(+)) and macrophages (CD68(+)) over-expressing ICAM-1.	Paclitaxel	29-39	CD68 molecule	Homo sapiens	251-255
23099063-6	2013	ICAM-1-selective delivery of paclitaxel produced potent tumor suppression of not only ICAM-1-positive cervical cancer cells but also ICAM-1-negative tumors, presumably by causing cytotoxicity in tumor-associated endothelium (CD31(+)) and macrophages (CD68(+)) over-expressing ICAM-1.	Paclitaxel	29-39	intercellular adhesion molecule 1	Homo sapiens	86-92
23924470-0	2013	A preliminary study of imaging paclitaxel-induced tumor apoptosis with (99)Tc(m)-His10-Annexin V.	Paclitaxel	31-41	annexin A5	Mus musculus	87-96
23924470-3	2013	In this study, we evaluated the dynamics and feasibility of imaging non-small cell lung cancer (NSCLC) apoptosis induced by paclitaxel treatment using a (99)Tc(m)-labeled Annexin V recombinant with ten consecutive histidines (His10-Annexin V) in a mouse model.	Paclitaxel	124-134	annexin A5	Mus musculus	171-180
23577147-9	2013	Our data suggest that BAK is the mediator of paclitaxel-induced apoptosis and could be an alternative target for overcoming paclitaxel resistance.	Paclitaxel	45-55	BCL2 antagonist/killer 1	Homo sapiens	22-25
23577147-9	2013	Our data suggest that BAK is the mediator of paclitaxel-induced apoptosis and could be an alternative target for overcoming paclitaxel resistance.	Paclitaxel	124-134	BCL2 antagonist/killer 1	Homo sapiens	22-25
23326344-2	2013	Breast cancer susceptibility gene 1 (BRCA1) expression has been found to switch the response to cisplatin- or paclitaxel-based chemotherapy.	Paclitaxel	110-120	BRCA1 DNA repair associated	Homo sapiens	37-42
23023313-7	2012	The inhibitory effects of taxol on cell growth and apoptosis induced by taxol             were also associated with the downregulation of Wee1 kinase expression and a marked             induction in the activity of the cyclin-dependent kinase inhibitor, p21WAF/CIP1.	Paclitaxel	26-31	WEE1 G2 checkpoint kinase	Homo sapiens	138-142
23023313-7	2012	The inhibitory effects of taxol on cell growth and apoptosis induced by taxol             were also associated with the downregulation of Wee1 kinase expression and a marked             induction in the activity of the cyclin-dependent kinase inhibitor, p21WAF/CIP1.	Paclitaxel	72-77	WEE1 G2 checkpoint kinase	Homo sapiens	138-142
23072999-6	2012	In addition, nek4, nek5, and nek6/ibo1 mutants were hypersensitive to microtubule inhibitors such as propyzamide and taxol.	Paclitaxel	117-122	NIMA-related kinase 4	Arabidopsis thaliana	13-17
23072999-6	2012	In addition, nek4, nek5, and nek6/ibo1 mutants were hypersensitive to microtubule inhibitors such as propyzamide and taxol.	Paclitaxel	117-122	serine/threonine-protein kinase NEK5	Arabidopsis thaliana	29-38
22923389-9	2012	CIP2A depletion in ovarian cancer cell lines inhibited proliferation, blocked cell cycle progression, and increased paclitaxel-induced apoptosis.	Paclitaxel	116-126	cellular inhibitor of PP2A	Homo sapiens	0-5
22910221-2	2012	In this work, a new co-delivery system, P85-PEI/TPGS/PTX/shSur complex nanoparticles (PTPNs), to overcome paclitaxel (PTX) resistance in A549 human lung cancer was designed and developed.	Paclitaxel	106-116	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	40-43
22910221-2	2012	In this work, a new co-delivery system, P85-PEI/TPGS/PTX/shSur complex nanoparticles (PTPNs), to overcome paclitaxel (PTX) resistance in A549 human lung cancer was designed and developed.	Paclitaxel	118-121	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	40-43
22910221-7	2012	Moreover, the inhibition of GST activity by P85 was found to increase PTX accumulation in A549/T cells.	Paclitaxel	70-73	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	44-47
22936118-7	2012	Thus the pharmacokinetic changes of taxanes observed in the DMIS rats were attributed to changes in P-gp and Cyp3A, predominant factors that control the absorption of paclitaxel and docetaxel, respectively.	Paclitaxel	167-177	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	100-104
23095773-2	2012	METHODS: The expression of NANOG was evaluated in 6 ovarian carcinoma cell lines, paclitaxel-resistant SKOV3 cells, and SKOV3 spheroid cells with semiquantitative reverse transcription-polymerase chain reaction and Western blotting.	Paclitaxel	82-92	Nanog homeobox	Homo sapiens	27-32
23095773-6	2012	The mRNA level of NANOG was increased in the paclitaxel-resistant SKOV3 cells and SKOV3 spheroid cells compared with that in the SKOV3 cells.	Paclitaxel	45-55	Nanog homeobox	Homo sapiens	18-23
35453647-3	2022	Investigation of the role of Hsp27 in the resistance of various cancer cell types against doxorubicin, herceptin/trastuzumab, gemcitabine, 5-FU, temozolomide, and paclitaxel suggested that Hsp27 overexpression promotes cancer cell survival against the above-mentioned chemotherapeutic agents.	Paclitaxel	163-173	heat shock protein family B (small) member 1	Homo sapiens	29-34
35263095-3	2022	cRGD and cCLT1 peptides, which could target the integrin and fibronectin, respectively, overexpressed in pancreatic cancer cells and stroma, were decorated on PTX-loaded microbubbles, resulting in the formation of dual-targeting PTX-RCMBs.	Paclitaxel	159-162	fibronectin 1	Mus musculus	61-72
35263095-3	2022	cRGD and cCLT1 peptides, which could target the integrin and fibronectin, respectively, overexpressed in pancreatic cancer cells and stroma, were decorated on PTX-loaded microbubbles, resulting in the formation of dual-targeting PTX-RCMBs.	Paclitaxel	229-232	fibronectin 1	Mus musculus	61-72
35263095-5	2022	Then, the cCLT1 peptide modified on PTX-RCNPs selectively bound the fibronectin highly expressed in the stroma and later targeted the integrin (alpha5beta1) on the cell surface.	Paclitaxel	36-39	fibronectin 1	Mus musculus	68-79
35458619-3	2022	The results indicated that CD44 overexpressed on the surface of both MSCs and tumor cells not only improved PTX/HA-PLGA micelle loading in MSCs, but also promoted the drug transfer between MSCs and adjacent cancer cells.	Paclitaxel	108-111	CD44 molecule (Indian blood group)	Rattus norvegicus	27-31
35133982-4	2022	METHODS: NFL concentrations were measured in an in vitro model of CIPN, exposing induced pluripotent stem cell-derived sensory neurons (iPSC-DSN) to paclitaxel.	Paclitaxel	149-159	sprouty related EVH1 domain containing 1	Homo sapiens	9-12
35133982-8	2022	RESULTS: NFL is released from iPSC-DSN upon paclitaxel incubation in a dose- and time-dependent manner and inversely correlates with iPSC-DSN viability.	Paclitaxel	44-54	sprouty related EVH1 domain containing 1	Homo sapiens	9-12
35133982-9	2022	NFLs strongly increased in paclitaxel-treated patients with CIPN, but not in chemotherapy patients without CIPN or controls, resulting in an 86 % sensitivity and 87 % specificity.	Paclitaxel	27-37	sprouty related EVH1 domain containing 1	Homo sapiens	0-4
35051418-12	2022	The effect of KHDRBS3 overexpression on PTX resistance and glycolysis was rescued by MIR17HG overexpression.	Paclitaxel	40-43	miR-17-92a-1 cluster host gene	Homo sapiens	85-92
35051418-14	2022	MIR17HG overexpression suppressed the IC50 of PTX and glycolysis by targeting CLDN6.	Paclitaxel	46-49	miR-17-92a-1 cluster host gene	Homo sapiens	0-7
26617855-0	2015	Gene expression profiling of taxol-resistant nasopharyngeal carcinoma cells with siRNA-mediated FOLR1 downregulation.	Paclitaxel	29-34	folate receptor alpha	Homo sapiens	96-101
35371325-9	2022	In addition, BRDT was associated with better OS in all ovarian carcinoma patients, grade I and grade III, all clinical stage (I+II, III+IV) patients, as well as all patients cured with Taxol and concurrent Taxol+Platin chemotherapy.	Paclitaxel	185-190	bromodomain testis associated	Homo sapiens	13-17
35371325-9	2022	In addition, BRDT was associated with better OS in all ovarian carcinoma patients, grade I and grade III, all clinical stage (I+II, III+IV) patients, as well as all patients cured with Taxol and concurrent Taxol+Platin chemotherapy.	Paclitaxel	206-211	bromodomain testis associated	Homo sapiens	13-17
26617855-1	2015	OBJECTIVES: Our previous study has shown that downregulation of FOLR1 by siRNA partially reversed taxol-resistant phenotype in taxol-resistant nasopharyngeal carcinoma cell lines.	Paclitaxel	98-103	folate receptor alpha	Homo sapiens	64-69
26617855-1	2015	OBJECTIVES: Our previous study has shown that downregulation of FOLR1 by siRNA partially reversed taxol-resistant phenotype in taxol-resistant nasopharyngeal carcinoma cell lines.	Paclitaxel	127-132	folate receptor alpha	Homo sapiens	64-69
26135626-6	2015	We designed five combined radiation-PTX protocols of varying dose duration and treatment sequences against CL1-1 cells based on the gathered data.	Paclitaxel	36-39	adhesion G protein-coupled receptor L1	Homo sapiens	107-110
35279152-12	2022	MYC target genes and c-MYC protein were upregulated in the chemoresistant CDX model, while MYC/MAX dimerization blocking could overcome chemoresistance to carboplatin/paclitaxel.	Paclitaxel	167-177	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-3
35279152-12	2022	MYC target genes and c-MYC protein were upregulated in the chemoresistant CDX model, while MYC/MAX dimerization blocking could overcome chemoresistance to carboplatin/paclitaxel.	Paclitaxel	167-177	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	21-26
26135626-7	2015	Pretreatment of CL1-1 cells with PTX (100nM) for 24h before irradiation (2.5Gy) was the best combined protocol to achieve maximum radiosensitizing effects.	Paclitaxel	33-36	adhesion G protein-coupled receptor L1	Homo sapiens	16-19
25944168-2	2015	Several studies have shown that overexpression of STMN1 has been linked to chemoresistance of paclitaxel and vinblastine in tumor cells.	Paclitaxel	94-104	stathmin 1	Homo sapiens	50-55
35279152-12	2022	MYC target genes and c-MYC protein were upregulated in the chemoresistant CDX model, while MYC/MAX dimerization blocking could overcome chemoresistance to carboplatin/paclitaxel.	Paclitaxel	167-177	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	91-94
35263200-6	2022	Five hub genes (UBC, TSR1, WDR46, HSP90AA1, and NOP56) were obtained via network analysis from 971 differentially expressed genes (DEGs) based on the RNA-seq of Paclitaxel-intervened Pfeiffer/ADM.	Paclitaxel	161-171	heat shock protein 90 alpha family class A member 1	Homo sapiens	34-42
25944168-3	2015	This study aimed to investigate the effects of STMN1 silencing on chemosensitivities of paclitaxel or vinblastine in esophageal squamous cell carcinoma (ESCC).	Paclitaxel	88-98	stathmin 1	Homo sapiens	47-52
25944168-6	2015	The sensitivity of STMN1-silencing shRNA-transfected Eca109 and TE-1 cells increased 191.4- and 179.3-fold to paclitaxel, and 21.3- and 28.4-fold to vincristine, respectively.	Paclitaxel	110-120	stathmin 1	Homo sapiens	19-24
25944168-8	2015	After treatment with paclitaxel or vincristine, STMN1-silencing shRNA-transfected Eca109 and TE-1 cells were more likely to enter G2 but less likely to enter mitosis than control cells.	Paclitaxel	21-31	stathmin 1	Homo sapiens	48-53
35088239-9	2022	Collectively, this study provides experimental evidence for PRKCE/AURKB/RAB27B axis in regulating the resistance to paclitaxel (PTX) in breast cancer cells, offering a potential intervention target for reversing drug resistance.	Paclitaxel	116-126	protein kinase C epsilon	Homo sapiens	60-65
35088239-9	2022	Collectively, this study provides experimental evidence for PRKCE/AURKB/RAB27B axis in regulating the resistance to paclitaxel (PTX) in breast cancer cells, offering a potential intervention target for reversing drug resistance.	Paclitaxel	128-131	protein kinase C epsilon	Homo sapiens	60-65
25944168-9	2015	Therefore, these data suggests that silencing STMN1 gene could increase sensitivity of ESCC to paclitaxel and vincristine through G2/M phase block.	Paclitaxel	95-105	stathmin 1	Homo sapiens	46-51
35281908-12	2022	JG remarkably enhanced the anticancer effect of PTX by increasing the red blood cell and platelet counts; increasing hemoglobin, interleukin (IL)-2, and tumor necrosis factor-alpha levels; increasing CD4+T cells and the CD4+/CD8+ ratio; and decreasing IL-10 levels.	Paclitaxel	48-51	interleukin 2	Mus musculus	129-147
25904053-5	2015	After treated with cisplatin, MG132, paclitaxel and SAHA, both BTG3 transfectants showed lower viability and higher apoptosis than the control in both time- and dose-dependent manners (p &lt; 0.05).	Paclitaxel	37-47	BTG anti-proliferation factor 3	Homo sapiens	63-67
35194034-4	2022	Interestingly, DRAK1 protein level was markedly decreased in paclitaxel-resistant cervical cancer cells without affecting its mRNA expression, which resulted in an increase in tumor necrosis factor receptor-associated factor 6 (TRAF6) expression, as well as an activation of TRAF6-mediated nuclear factor-kappa B (NF-kappaB) signaling cascade, thereby promoting tumor progression.	Paclitaxel	61-71	TNF receptor associated factor 6	Homo sapiens	176-226
35194034-4	2022	Interestingly, DRAK1 protein level was markedly decreased in paclitaxel-resistant cervical cancer cells without affecting its mRNA expression, which resulted in an increase in tumor necrosis factor receptor-associated factor 6 (TRAF6) expression, as well as an activation of TRAF6-mediated nuclear factor-kappa B (NF-kappaB) signaling cascade, thereby promoting tumor progression.	Paclitaxel	61-71	TNF receptor associated factor 6	Homo sapiens	228-233
35194034-5	2022	DRAK1 depletion markedly increased the chemotherapeutic IC50 values of paclitaxel in cervical cancer cells.	Paclitaxel	71-81	serine/threonine kinase 17a	Homo sapiens	0-5
35194034-6	2022	Ectopic expression of DRAK1 inhibited growth of paclitaxel-resistant cervical cancer cells in vitro and in vivo.	Paclitaxel	48-58	serine/threonine kinase 17a	Homo sapiens	22-27
35194034-8	2022	We found that DRAK1 protein was destabilized through K48-linked polyubiquitination promoted by the Cullin scaffold protein 3 (CUL3) / speckle-type POZ (poxvirus and zinc finger protein) protein (SPOP) E3 ubiquitin ligase in paclitaxel-resistant cells.	Paclitaxel	224-234	serine/threonine kinase 17a	Homo sapiens	14-19
35194034-8	2022	We found that DRAK1 protein was destabilized through K48-linked polyubiquitination promoted by the Cullin scaffold protein 3 (CUL3) / speckle-type POZ (poxvirus and zinc finger protein) protein (SPOP) E3 ubiquitin ligase in paclitaxel-resistant cells.	Paclitaxel	224-234	mitochondrial E3 ubiquitin protein ligase 1	Homo sapiens	201-220
26071354-7	2015	CRC cells with SphK1-shRNA knockdown showed similar phenotypes as the miR-101-expressed CRC cells, presenting with elevated level of ceramide and high sensitivity to paclitaxel or doxorubicin.	Paclitaxel	166-176	sphingosine kinase 1	Homo sapiens	15-20
35194034-9	2022	Collectively, these findings suggest that DRAK1 may serve as a potential predictive biomarker for overcoming paclitaxel resistance in cervical cancer.	Paclitaxel	109-119	serine/threonine kinase 17a	Homo sapiens	42-47
35214172-10	2022	IMT/PTX resulted in significantly more necrotic tumor tissue and increased levels of IL-2, 4, and 12 compared to control.	Paclitaxel	4-7	interleukin 2	Mus musculus	85-89
25388329-0	2015	Activation of TLR-4 to produce tumour necrosis factor-alpha in neuropathic pain caused by paclitaxel.	Paclitaxel	90-100	toll like receptor 4	Homo sapiens	14-19
35168606-10	2022	The proteomics data indicated that the expressions of key enzymes glycerophosphocholine phosphodiesterase 1 (GPCPD1) and glycerophosphodiester phosphodiesterase 1 (GDE1) were significantly lower in the PTX-resistant tumors compared to the PTX-sensitive tumors (both P < 0.01).	Paclitaxel	202-205	glycerophosphocholine phosphodiesterase 1	Homo sapiens	66-107
25388329-8	2015	In vitro, paclitaxel enhanced the expression and release of TNF-alpha in enriched primary satellite glial cells, an effect that was blocked by an inhibitor of TLR-4.	Paclitaxel	10-20	toll like receptor 4	Homo sapiens	159-164
35168606-10	2022	The proteomics data indicated that the expressions of key enzymes glycerophosphocholine phosphodiesterase 1 (GPCPD1) and glycerophosphodiester phosphodiesterase 1 (GDE1) were significantly lower in the PTX-resistant tumors compared to the PTX-sensitive tumors (both P < 0.01).	Paclitaxel	202-205	glycerophosphocholine phosphodiesterase 1	Homo sapiens	109-115
35168606-10	2022	The proteomics data indicated that the expressions of key enzymes glycerophosphocholine phosphodiesterase 1 (GPCPD1) and glycerophosphodiester phosphodiesterase 1 (GDE1) were significantly lower in the PTX-resistant tumors compared to the PTX-sensitive tumors (both P < 0.01).	Paclitaxel	239-242	glycerophosphocholine phosphodiesterase 1	Homo sapiens	66-107
35168606-10	2022	The proteomics data indicated that the expressions of key enzymes glycerophosphocholine phosphodiesterase 1 (GPCPD1) and glycerophosphodiester phosphodiesterase 1 (GDE1) were significantly lower in the PTX-resistant tumors compared to the PTX-sensitive tumors (both P < 0.01).	Paclitaxel	239-242	glycerophosphocholine phosphodiesterase 1	Homo sapiens	109-115
35168606-11	2022	Decreased expressions of GPCPD1 and GDE1 in choline metabolism led to an increased GPC levels in the PTX-resistant EOCs, which was observed as an elevated total choline (tCho) on in vivo 1H-MRS.	Paclitaxel	101-104	glycerophosphocholine phosphodiesterase 1	Homo sapiens	25-31
25388329-11	2015	CONCLUSION: These results suggest that paclitaxel activation of TLR-4 to cause release of TNF-alpha from satellite glial cells increases the expression of TRPA1 and TRPV4 in DRG neurons to cause neuropathic pain.	Paclitaxel	39-49	toll like receptor 4	Homo sapiens	64-69
26049123-14	2015	CONCLUSION: Weekly paclitaxel/carboplatin with G-CSF is an effective treatment with acceptable toxicity in patients with platinum-resistant or platinum-refractory OC, advanced or recurrent EC and CC.	Paclitaxel	19-29	colony stimulating factor 3	Homo sapiens	47-52
25878333-10	2015	Significant antitumor effects were observed with XPO1 inhibitor monotherapy in orthotopic ovarian (P &lt; 0.001) and breast (P &lt; 0.001) cancer mouse models, with a further decrease in tumor burden observed in combination with topotecan or paclitaxel (P &lt; 0.05).	Paclitaxel	242-252	exportin 1	Mus musculus	49-53
35205672-12	2022	DKK3 was lost in paclitaxel-resistant cells, while beta-catenin and P-glycoprotein were upregulated.	Paclitaxel	17-27	catenin beta 1	Homo sapiens	51-63
35205672-13	2022	Exogenous secreted DKK3, incorporated by cells, enhanced anti-tumoral effect and paclitaxel susceptibility in paclitaxel-resistant cells, and reduced the levels of active beta-catenin and its downstream P-glycoprotein, suggesting that DKK3 can be used as a therapeutic for targeting paclitaxel-resistant cancer.	Paclitaxel	283-293	catenin beta 1	Homo sapiens	171-183
35119496-11	2022	Stabilizing microtubules via taxol prevented TAU-missorting, hinting towards a role for impaired microtubule dynamics in mitochondrial-dysfunction-induced TAU-missorting.	Paclitaxel	29-34	microtubule associated protein tau	Homo sapiens	45-48
23174570-9	2012	LMWH enhanced the down-regulation of MMP-9 and HPA induced by PTX.	Paclitaxel	62-65	matrix metallopeptidase 9	Homo sapiens	37-42
23174570-10	2012	CONCLUSION: LMWH can enhance the inhibitory effect of PTX on the migration and invasion of nasopharyngeal carcinoma cells, the mechanism of which may involve the down-regulation of MMP-9 and HPA expressions.	Paclitaxel	54-57	matrix metallopeptidase 9	Homo sapiens	181-186
26175417-2	2015	Following a genome-wide siRNA screen, we identified the oncogenic transcription factor Myc as a taxol sensitizer.	Paclitaxel	96-101	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	87-90
23060563-0	2012	Interference with ATF5 function enhances the sensitivity of human pancreatic cancer cells to paclitaxel-induced apoptosis.	Paclitaxel	93-103	activating transcription factor 5	Homo sapiens	18-22
23060563-7	2012	Interference with ATF5 function in SW1990 cells resulted in down-regulation of BCL-2 and up-regulation of BAX, resulting in enhanced sensitivity to apoptosis induced by paclitaxel treatment.	Paclitaxel	169-179	activating transcription factor 5	Homo sapiens	18-22
23060563-9	2012	Targeting ATF5 significantly enhances paclitaxel-induced apoptosis in human pancreatic cancer cells.	Paclitaxel	38-48	activating transcription factor 5	Homo sapiens	10-14
35137851-7	2022	Also, MLT had a protective effect against testicular apoptosis induced by TXL, as shown by the elevated expression of Bcl-2 and decreased expression of P53 and caspase-3.	Paclitaxel	74-77	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	152-155
35001532-5	2022	Decreased expressions of germ cell proliferation-associated protein PCNA and meiosis-related protein SYCP3 induced by PTX were determined by Western blot, while MLT ameliorated this effect and increased the expressions of PCNA, SYCP3, DMC1, STRA8 and fertility-related protein of HSPA2, resulting in significantly improved spermatogenesis and sperm quality levels.	Paclitaxel	118-121	synaptonemal complex protein 3	Mus musculus	101-106
35001532-5	2022	Decreased expressions of germ cell proliferation-associated protein PCNA and meiosis-related protein SYCP3 induced by PTX were determined by Western blot, while MLT ameliorated this effect and increased the expressions of PCNA, SYCP3, DMC1, STRA8 and fertility-related protein of HSPA2, resulting in significantly improved spermatogenesis and sperm quality levels.	Paclitaxel	118-121	synaptonemal complex protein 3	Mus musculus	228-233
35001532-5	2022	Decreased expressions of germ cell proliferation-associated protein PCNA and meiosis-related protein SYCP3 induced by PTX were determined by Western blot, while MLT ameliorated this effect and increased the expressions of PCNA, SYCP3, DMC1, STRA8 and fertility-related protein of HSPA2, resulting in significantly improved spermatogenesis and sperm quality levels.	Paclitaxel	118-121	stimulated by retinoic acid gene 8	Mus musculus	241-246
35001532-5	2022	Decreased expressions of germ cell proliferation-associated protein PCNA and meiosis-related protein SYCP3 induced by PTX were determined by Western blot, while MLT ameliorated this effect and increased the expressions of PCNA, SYCP3, DMC1, STRA8 and fertility-related protein of HSPA2, resulting in significantly improved spermatogenesis and sperm quality levels.	Paclitaxel	118-121	heat shock protein 2	Mus musculus	280-285
35163066-4	2022	In the present study, we demonstrated, by using both primary epidermal keratinocytes (NHEK) and a 3D epidermis model, that paclitaxel impairs different cellular processes: paclitaxel increased the release of IL-1alpha, IL-6, and IL-8 inflammatory cytokines, produced reactive oxygen species (ROS) release and apoptosis, and reduced the endothelial tube formation in the dermal microvascular endothelial cells (HDMEC).	Paclitaxel	123-133	interleukin 1 alpha	Homo sapiens	208-217
35163066-4	2022	In the present study, we demonstrated, by using both primary epidermal keratinocytes (NHEK) and a 3D epidermis model, that paclitaxel impairs different cellular processes: paclitaxel increased the release of IL-1alpha, IL-6, and IL-8 inflammatory cytokines, produced reactive oxygen species (ROS) release and apoptosis, and reduced the endothelial tube formation in the dermal microvascular endothelial cells (HDMEC).	Paclitaxel	172-182	interleukin 1 alpha	Homo sapiens	208-217
22693353-0	2012	Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.	Paclitaxel	53-63	CD44 antigen	Mus musculus	23-27
22581025-5	2012	CD44+/CD133+ EC-CICs were also             more resistant to growth inhibition induced by the chemotherapeutic drugs cisplatin             and paclitaxel.	Paclitaxel	143-153	CD44 molecule (Indian blood group)	Homo sapiens	0-4
26555418-12	2015	MTT results showed that miR-21 inhibitors induced sensitivity of MCF-7/PR and SKBR-3/PR cells to paclitaxel.	Paclitaxel	97-107	microRNA 21	Homo sapiens	24-30
26555418-15	2015	Down-regulated miR-21 expression in MCF-7/PR and SKBR-3/PR breast cancer cells can enhance cell sensitivity to paclitaxel.	Paclitaxel	111-121	microRNA 21	Homo sapiens	15-21
25998620-4	2015	In addition to endogenous ligands released by therapy-induced tumor destruction, TLR4 is directly activated by paclitaxel, one of the most commonly used chemotherapeutic drugs against various human cancers.	Paclitaxel	111-121	toll like receptor 4	Homo sapiens	81-85
22460125-5	2012	Overexpression of ING4 reverses DTX or paclitaxel resistance of DTX-resistant lung adenocarcinoma cells (SPC-A1/DTX or A549/Taxol) by inducing apoptosis enhancement and G2/M arrest, and small interfering RNA-mediated ING4 knockdown renders DTX-sensitive lung adenocarcinoma cells more resistant to DTX or paclitaxel.	Paclitaxel	39-49	inhibitor of growth family member 4	Homo sapiens	18-22
22460125-5	2012	Overexpression of ING4 reverses DTX or paclitaxel resistance of DTX-resistant lung adenocarcinoma cells (SPC-A1/DTX or A549/Taxol) by inducing apoptosis enhancement and G2/M arrest, and small interfering RNA-mediated ING4 knockdown renders DTX-sensitive lung adenocarcinoma cells more resistant to DTX or paclitaxel.	Paclitaxel	305-315	inhibitor of growth family member 4	Homo sapiens	18-22
22410114-10	2012	Importantly, the C(B)-sensitive conjugate indicated a similar in vivo efficacy with the Taxol control, but much lower in vivo toxicity at the same doses evidenced by body weight, animal status, liver toxicity and blood count.	Paclitaxel	88-93	cathepsin B	Homo sapiens	17-21
22410115-0	2012	Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo.	Paclitaxel	67-77	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	15-20
22410115-1	2012	Co-delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel (PTX) is an attractive strategy to enhance their anti-tumor efficacy.	Paclitaxel	95-98	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	15-70
35054875-9	2022	The analysis of our data obtained from the length of MCF7 microtubules polymerized under the interaction with Tau and Taxol in vitro suggests that the phenomenon known as drug resistance in microtubule-targeted drugs such as Taxol may not be directly linked to the different responses of microtubules to the drug.	Paclitaxel	225-230	microtubule associated protein tau	Homo sapiens	110-113
35019820-9	2022	In conclusion, combination therapy of Nab-paclitaxel and IL-15 fusion protein can effectively stimulate the antitumor activity of immune effector cells, thereby inhibiting immunosuppressive cells within the TME of colorectal cancer, and the overall therapeutic effect has a significant advantage over monotherapy.AbbreviationsInterleukin 15, IL-15; Human serum albumin, HSA; Myeloid-derived suppressor cells, MDSC; Albumin binding domain, ABD; Tumor drainage lymph node, TDLN; Natural killer (NK); Tumor-draining lymph node (TDLN); Tumor infiltrating lymphocyte, TIL; Immunogenic cell death, ICD; Enhanced permeability retention, EPR; Liposomal doxorubicin, Doxil; 5-fluorouracil, 5-FU.	Paclitaxel	42-52	toll-like receptor 1	Mus musculus	563-566
25827582-4	2015	We found that tonic GABA receptor activities in the spinal dorsal horn were reduced in rats with neuropathic pain induced by paclitaxel.	Paclitaxel	125-135	GABA type A receptor-associated protein	Homo sapiens	20-33
22434665-8	2012	In addition, RASSF1A methylation predicted longer DFS in patients treated with paclitaxel-carboplatin compared with gemcitabine-cisplatin (adjusted HR = 0.47, 95% CI: 0.23-0.97, P(interaction) = 0.042).	Paclitaxel	79-89	Ras association domain family member 1	Homo sapiens	13-20
26536707-7	2015	05), In con- trast, FTC and FTC+P-gp did not appear similar case; To the paclitaxel, when P-gp or FTC+P-gp used, the activity of Hep-2 was higher than that in the control and difference was significant(P&lt;0.	Paclitaxel	73-83	phosphoglycolate phosphatase	Homo sapiens	90-94
22434665-11	2012	Conversely, significantly longer DFS following paclitaxel-based neoadjuvant chemotherapy for patients whose tumors showed RASSF1A methylation suggested its predictive interest in stages I and II NSCLC.	Paclitaxel	47-57	Ras association domain family member 1	Homo sapiens	122-129
22306333-0	2012	Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation.	Paclitaxel	63-73	transferrin	Mus musculus	0-11
22306333-3	2012	In this study, Tf-modified paclitaxel-loaded polyphosphoester hybrid micells (TPM) was prepared and evaluated for its in vitro and in vivo brain-targeting efficiency.	Paclitaxel	27-37	transferrin	Mus musculus	15-17
34987021-4	2022	METHODS: T cell infiltration, effector function, and spatial localization in relation to XCR1+ cDC1s were evaluated in a murine orthotopic mammary carcinoma model during response to TIM-3 blockade and paclitaxel chemotherapy.	Paclitaxel	201-211	chemokine (C motif) receptor 1	Mus musculus	89-93
35531363-3	2022	Here we demonstrate a patient with recurrent uterine carcinosarcoma whose local recurrence and metastatic recurrence had a varied response to paclitaxel in combination with DKN-01, a monoclonal antibody against DKK1, a modulator of Wnt/beta-catenin and PI3K/AKT signaling pathways.	Paclitaxel	142-152	catenin beta 1	Homo sapiens	236-248
22339366-2	2012	METHODS: Tf modified DQAsomes (Tf-DQAsomes) were prepared by incubating preformed paclitaxel loaded DQAsomes with Tf in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride.	Paclitaxel	82-92	transferrin	Mus musculus	9-11
26536707-7	2015	05), In con- trast, FTC and FTC+P-gp did not appear similar case; To the paclitaxel, when P-gp or FTC+P-gp used, the activity of Hep-2 was higher than that in the control and difference was significant(P&lt;0.	Paclitaxel	73-83	phosphoglycolate phosphatase	Homo sapiens	90-94
22339366-2	2012	METHODS: Tf modified DQAsomes (Tf-DQAsomes) were prepared by incubating preformed paclitaxel loaded DQAsomes with Tf in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride.	Paclitaxel	82-92	transferrin	Mus musculus	31-33
22339366-2	2012	METHODS: Tf modified DQAsomes (Tf-DQAsomes) were prepared by incubating preformed paclitaxel loaded DQAsomes with Tf in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride.	Paclitaxel	82-92	transferrin	Mus musculus	31-33
25900406-3	2015	Finally, iminoboronates were used to assemble a folic acid/paclitaxel small-molecule/drug conjugate in situ with an IC50  value of 20.7 nM against NCI-H460 cancer cells and negligible cytotoxicity against the CRL-1502 noncancer cells.	Paclitaxel	59-69	interleukin 31 receptor A	Homo sapiens	209-212
22339366-8	2012	Tf-DQAsomes exhibited better antitumor activity in vitro as compared to plain DQAsomes and paclitaxel solution.	Paclitaxel	91-101	transferrin	Mus musculus	0-2
22339366-9	2012	In vivo biodistribution study revealed that paclitaxel concentration in the tumor was much higher in the case of Tf-DQAsomes as compared to plain DQAsomes and paclitaxel solution; however in other organs it was much lower than the latter two formulations.	Paclitaxel	44-54	transferrin	Mus musculus	113-115
27040946-5	2015	Moreover, over-expression of miR-21 significantly decreased antiproliferative effects and apoptosis induced by paclitaxel, while knockdown of miR-21 dramatically increased antiproliferative effects and apoptosis induction by paclitaxel.	Paclitaxel	225-235	microRNA 21	Homo sapiens	142-148
25724736-4	2015	The results showed that taxol rapidly induced UPR activation and that hypoxia modulated taxol-induced UPR activation differently according to the different UPR pathways (PERK, ATF6, and IRE1alpha).	Paclitaxel	88-93	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	170-174
21618519-6	2012	Introducing let-7g into ADR-RES cells expressing both IMP-1 and MDR1 reduced expression of both proteins rendering the cells more sensitive to treatment with either Taxol or vinblastine without affecting the sensitivity of the cells to carboplatin, a non-MDR1 substrate.	Paclitaxel	165-170	insulin like growth factor 2 mRNA binding protein 1	Homo sapiens	54-59
25724736-4	2015	The results showed that taxol rapidly induced UPR activation and that hypoxia modulated taxol-induced UPR activation differently according to the different UPR pathways (PERK, ATF6, and IRE1alpha).	Paclitaxel	88-93	activating transcription factor 6	Homo sapiens	176-180
25708932-9	2015	Different doses of paclitaxel were required in the two ACC cell line to induce a block in the G2 phase, characterized by increased cyclin B1 levels and to induce apoptosis by pro-caspase-3 activation.	Paclitaxel	19-29	cyclin B1	Homo sapiens	131-140
22475628-14	2012	Inactivation of PKCzeta expression enhanced cellular resistance to cisplatin and paclitaxel, and proliferation in HK-2 cells by specific PKCzeta siRNA and inhibitor.	Paclitaxel	81-91	protein kinase C zeta	Homo sapiens	16-23
25708932-10	2015	Interestingly, the silencing of C-MYC mRNA prevented paclitaxel induced apoptosis in SW13 cells, whereas in the H295R cells the overexpression of C-MYC rendered the cells more prone to growth inhibition after paclitaxel exposure.	Paclitaxel	53-63	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	32-37
21959683-4	2012	Our findings included an immediate plasmatic reduction in IL-1, IL-10, and TNF-alpha levels in doxorubicin-treated patients, as well as high levels of IL-10 in paclitaxel patients.	Paclitaxel	160-170	interleukin 10	Homo sapiens	151-156
25708932-10	2015	Interestingly, the silencing of C-MYC mRNA prevented paclitaxel induced apoptosis in SW13 cells, whereas in the H295R cells the overexpression of C-MYC rendered the cells more prone to growth inhibition after paclitaxel exposure.	Paclitaxel	209-219	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	32-37
25708932-10	2015	Interestingly, the silencing of C-MYC mRNA prevented paclitaxel induced apoptosis in SW13 cells, whereas in the H295R cells the overexpression of C-MYC rendered the cells more prone to growth inhibition after paclitaxel exposure.	Paclitaxel	209-219	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	146-151
25708932-11	2015	The present study directly demonstrates that C-MYC plays a central role in controlling proliferation in ACC cells after paclitaxel treatment and that c-Myc could be considered as a marker for predicting response to chemotherapeutic agents in ACC cell lines.	Paclitaxel	120-130	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	45-50
22262126-6	2012	Inhibition of STAT1 sensitized 786-O cells to radiotherapy and Taxol treatment.	Paclitaxel	63-68	signal transducer and activator of transcription 1	Homo sapiens	14-19
32262318-2	2015	Paclitaxel (PTX) was 95.5% encapsulated at a zein-CMC weight ratio of 1 : 3 and the NPs were spherical with an average particle size of approximately 159.4 nm, with the PTX concentration maintained at 80 mug mL-1.	Paclitaxel	0-10	L1 cell adhesion molecule	Mus musculus	208-212
22134971-2	2012	Exposure of cells to taxol induced time-dependent cytotoxicity and cytoplasmic vacuolization without the involvement of Bax, Bak, Mcl-1, Bcl-XL, and caspase-3.	Paclitaxel	21-26	BCL2-associated X protein	Mus musculus	120-123
22134971-2	2012	Exposure of cells to taxol induced time-dependent cytotoxicity and cytoplasmic vacuolization without the involvement of Bax, Bak, Mcl-1, Bcl-XL, and caspase-3.	Paclitaxel	21-26	caspase 3	Mus musculus	149-158
22258694-0	2012	TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism.	Paclitaxel	24-34	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	0-5
22258694-5	2012	Paclitaxel-evoked mechanical allodynia was reduced partially by the TRPA1 antagonist, HC-030031, and the TRPV4 antagonist, HC-067047, and was completely abated by the combination of the two antagonists.	Paclitaxel	0-10	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	68-73
22258694-6	2012	The reduced paclitaxel-evoked mechanical allodynia, observed in TRPA1-deficient mice, was completely abolished when mice were treated with HC-067047.	Paclitaxel	12-22	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	64-69
22258694-11	2012	Paclitaxel via oxygen radical formation targets TRPA1 and TRPV4, and both channels are key for the delayed development of mechanical allodynia.	Paclitaxel	0-10	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	48-53
25931810-0	2015	Paclitaxel attenuates renal interstitial fibroblast activation and interstitial fibrosis by inhibiting STAT3 signaling.	Paclitaxel	0-10	signal transducer and activator of transcription 3	Rattus norvegicus	103-108
25931810-5	2015	The results showed that paclitaxel treatment resulted in a dose- and time-dependent decrease in tyrosine-phosphorylated STAT3, and inhibited the expression of fibronectin, alpha-smooth muscle actin (alpha-SMA), and collagen I in cultured NRK-49F cells.	Paclitaxel	24-34	signal transducer and activator of transcription 3	Rattus norvegicus	120-125
25931810-5	2015	The results showed that paclitaxel treatment resulted in a dose- and time-dependent decrease in tyrosine-phosphorylated STAT3, and inhibited the expression of fibronectin, alpha-smooth muscle actin (alpha-SMA), and collagen I in cultured NRK-49F cells.	Paclitaxel	24-34	fibronectin 1	Rattus norvegicus	159-170
22226740-9	2012	Moreover, cells overexpressing KISS1 were found to enhance chemosensitivity to paclitaxel.	Paclitaxel	79-89	KiSS-1 metastasis suppressor	Homo sapiens	31-36
25931810-5	2015	The results showed that paclitaxel treatment resulted in a dose- and time-dependent decrease in tyrosine-phosphorylated STAT3, and inhibited the expression of fibronectin, alpha-smooth muscle actin (alpha-SMA), and collagen I in cultured NRK-49F cells.	Paclitaxel	24-34	actin gamma 2, smooth muscle	Rattus norvegicus	172-197
25931810-5	2015	The results showed that paclitaxel treatment resulted in a dose- and time-dependent decrease in tyrosine-phosphorylated STAT3, and inhibited the expression of fibronectin, alpha-smooth muscle actin (alpha-SMA), and collagen I in cultured NRK-49F cells.	Paclitaxel	24-34	actin gamma 2, smooth muscle	Rattus norvegicus	199-208
25931810-7	2015	Mechanistically, paclitaxel treatment blocked the STAT3 activity by disrupting the association of STAT3 with tubulin and inhibiting STAT3 nucleus translocation.	Paclitaxel	17-27	signal transducer and activator of transcription 3	Rattus norvegicus	50-55
25931810-7	2015	Mechanistically, paclitaxel treatment blocked the STAT3 activity by disrupting the association of STAT3 with tubulin and inhibiting STAT3 nucleus translocation.	Paclitaxel	17-27	signal transducer and activator of transcription 3	Rattus norvegicus	98-103
22248469-0	2012	TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer.	Paclitaxel	49-59	transforming growth factor beta induced	Homo sapiens	0-5
22248469-1	2012	The purpose of this study is to determine the methylation status of Transforming growth factor-beta-inducible gene-h3 (TGFBI) and its correlation with paclitaxel chemoresistance in ovarian cancer.	Paclitaxel	151-161	transforming growth factor beta induced	Homo sapiens	68-117
25931810-7	2015	Mechanistically, paclitaxel treatment blocked the STAT3 activity by disrupting the association of STAT3 with tubulin and inhibiting STAT3 nucleus translocation.	Paclitaxel	17-27	signal transducer and activator of transcription 3	Rattus norvegicus	98-103
22248469-1	2012	The purpose of this study is to determine the methylation status of Transforming growth factor-beta-inducible gene-h3 (TGFBI) and its correlation with paclitaxel chemoresistance in ovarian cancer.	Paclitaxel	151-161	transforming growth factor beta induced	Homo sapiens	119-124
25931810-8	2015	Furthermore, paclitaxel also ameliorated renal fibrosis by down-regulating the expression of fibronectin, alpha-SMA, and collagen I, and suppressed the infiltration of macrophages and production of TNF-alpha, IL-1beta, TGF-beta, and ICAM-1 (intercellular adhesion molecule 1) by inhibition of STAT3 activity in obstructive nephropathy.	Paclitaxel	13-23	fibronectin 1	Rattus norvegicus	93-104
22248469-8	2012	The methylation level of TGFBI was significantly higher in paclitaxel resistant cell lines (SKOV3/TR and 2780/TR) than that in the sensitive pairs (P &lt; 0.001).	Paclitaxel	59-69	transforming growth factor beta induced	Homo sapiens	25-30
25931810-8	2015	Furthermore, paclitaxel also ameliorated renal fibrosis by down-regulating the expression of fibronectin, alpha-SMA, and collagen I, and suppressed the infiltration of macrophages and production of TNF-alpha, IL-1beta, TGF-beta, and ICAM-1 (intercellular adhesion molecule 1) by inhibition of STAT3 activity in obstructive nephropathy.	Paclitaxel	13-23	actin gamma 2, smooth muscle	Rattus norvegicus	106-115
22248469-10	2012	However, no statistical differences of relative TGFBI mRNA expression and protein were found in other cells (all P &gt; 0.05), which showed that re-expression of TGFBI could reverse paclitaxel chemoresistance.	Paclitaxel	182-192	transforming growth factor beta induced	Homo sapiens	162-167
22248469-11	2012	Our results show that TGFBI is frequently methylated and associated with paclitaxel-resistance in ovarian cancer.	Paclitaxel	73-83	transforming growth factor beta induced	Homo sapiens	22-27
23037162-1	2012	Paclitaxel-resistant HuH-7 (HuH-7/PTX) cells were established by one-week exposure of HuH-7 cells to paclitaxel to analyze the effects of Kampo medicines on MDR-1-mediated multidrug resistance.	Paclitaxel	0-10	MIR7-3 host gene	Homo sapiens	21-26
25931810-8	2015	Furthermore, paclitaxel also ameliorated renal fibrosis by down-regulating the expression of fibronectin, alpha-SMA, and collagen I, and suppressed the infiltration of macrophages and production of TNF-alpha, IL-1beta, TGF-beta, and ICAM-1 (intercellular adhesion molecule 1) by inhibition of STAT3 activity in obstructive nephropathy.	Paclitaxel	13-23	signal transducer and activator of transcription 3	Rattus norvegicus	293-298
23037162-1	2012	Paclitaxel-resistant HuH-7 (HuH-7/PTX) cells were established by one-week exposure of HuH-7 cells to paclitaxel to analyze the effects of Kampo medicines on MDR-1-mediated multidrug resistance.	Paclitaxel	0-10	MIR7-3 host gene	Homo sapiens	28-33
23037162-1	2012	Paclitaxel-resistant HuH-7 (HuH-7/PTX) cells were established by one-week exposure of HuH-7 cells to paclitaxel to analyze the effects of Kampo medicines on MDR-1-mediated multidrug resistance.	Paclitaxel	0-10	MIR7-3 host gene	Homo sapiens	28-33
25931810-9	2015	These results suggest that paclitaxel may block the STAT3 activity by disrupting the association of STAT3 with tubulin and inhibiting STAT3 nucleus translocation, consequently leading to the suppression of renal interstitial fibroblast activation and the development of renal fibrosis, and inhibition of proinflammatory cytokine production.	Paclitaxel	27-37	signal transducer and activator of transcription 3	Rattus norvegicus	52-57
23037162-1	2012	Paclitaxel-resistant HuH-7 (HuH-7/PTX) cells were established by one-week exposure of HuH-7 cells to paclitaxel to analyze the effects of Kampo medicines on MDR-1-mediated multidrug resistance.	Paclitaxel	101-111	MIR7-3 host gene	Homo sapiens	21-26
23037162-1	2012	Paclitaxel-resistant HuH-7 (HuH-7/PTX) cells were established by one-week exposure of HuH-7 cells to paclitaxel to analyze the effects of Kampo medicines on MDR-1-mediated multidrug resistance.	Paclitaxel	101-111	MIR7-3 host gene	Homo sapiens	28-33
25931810-9	2015	These results suggest that paclitaxel may block the STAT3 activity by disrupting the association of STAT3 with tubulin and inhibiting STAT3 nucleus translocation, consequently leading to the suppression of renal interstitial fibroblast activation and the development of renal fibrosis, and inhibition of proinflammatory cytokine production.	Paclitaxel	27-37	signal transducer and activator of transcription 3	Rattus norvegicus	100-105
23037162-1	2012	Paclitaxel-resistant HuH-7 (HuH-7/PTX) cells were established by one-week exposure of HuH-7 cells to paclitaxel to analyze the effects of Kampo medicines on MDR-1-mediated multidrug resistance.	Paclitaxel	101-111	MIR7-3 host gene	Homo sapiens	28-33
25931810-9	2015	These results suggest that paclitaxel may block the STAT3 activity by disrupting the association of STAT3 with tubulin and inhibiting STAT3 nucleus translocation, consequently leading to the suppression of renal interstitial fibroblast activation and the development of renal fibrosis, and inhibition of proinflammatory cytokine production.	Paclitaxel	27-37	signal transducer and activator of transcription 3	Rattus norvegicus	100-105
25596561-0	2015	Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.	Paclitaxel	41-51	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	87-92
25596561-6	2015	By using Bcl-2 siRNA, Bcl-XL siRNA or Mcl-1 siRNA, we found although each of the three members exhibited activities to block paclitaxel-induced apoptosis, Mcl-1 was the determinant for the synergistic effect between paclitaxel and ABT-737 or S1.	Paclitaxel	125-135	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	38-43
25596561-6	2015	By using Bcl-2 siRNA, Bcl-XL siRNA or Mcl-1 siRNA, we found although each of the three members exhibited activities to block paclitaxel-induced apoptosis, Mcl-1 was the determinant for the synergistic effect between paclitaxel and ABT-737 or S1.	Paclitaxel	125-135	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	155-160
22413106-0	2012	Preparation and biological evaluation of paclitaxel loaded biodegradable PCL/PEG nanoparticles for the treatment of human neuroendocrine pancreatic tumor in mice.	Paclitaxel	41-51	PHD finger protein 1	Homo sapiens	73-76
25596561-7	2015	Furthermore, paclitaxel/ABT737 synergized to drastically upregulate Bim to displace Bak from Mcl-1, whereas S1 directly binds Mcl-1 to release both Bim and Bak.	Paclitaxel	13-23	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	93-98
25701027-3	2015	The experimental results showed that in the 4T1 tumor-bearing mice models, PEI-PDHA/PEG-PDHA/PTX/siSna/siTwi) complex nanoparticles (PPSTs) raised the accumulation and retention of both PTX and siRNA in tumor after administrated intravenously, resulted in the strong inhibition of the tumor growth and metastasis simultaneously.	Paclitaxel	93-96	pyruvate dehydrogenase E1 subunit alpha 1	Homo sapiens	79-83
22848173-6	2012	METHODS AND RESULTS: Intravenous administration of folate-targeted, paclitaxel-loaded micelles was demonstrated to be more efficient in inhibiting subcutaneous xenograft tumors and extending the survival rate of tumor-bearing nude mice than free paclitaxel and plain paclitaxel micelles at an equivalent paclitaxel dose of 20 mg/kg, which was further backed up by flow cytometry, TUNEL, and expression of apoptosis-related proteins, including Bax, Bcl2, and caspase 3 in this study.	Paclitaxel	68-78	BCL2-associated X protein	Mus musculus	443-446
22848173-6	2012	METHODS AND RESULTS: Intravenous administration of folate-targeted, paclitaxel-loaded micelles was demonstrated to be more efficient in inhibiting subcutaneous xenograft tumors and extending the survival rate of tumor-bearing nude mice than free paclitaxel and plain paclitaxel micelles at an equivalent paclitaxel dose of 20 mg/kg, which was further backed up by flow cytometry, TUNEL, and expression of apoptosis-related proteins, including Bax, Bcl2, and caspase 3 in this study.	Paclitaxel	68-78	caspase 3	Mus musculus	458-467
25701027-3	2015	The experimental results showed that in the 4T1 tumor-bearing mice models, PEI-PDHA/PEG-PDHA/PTX/siSna/siTwi) complex nanoparticles (PPSTs) raised the accumulation and retention of both PTX and siRNA in tumor after administrated intravenously, resulted in the strong inhibition of the tumor growth and metastasis simultaneously.	Paclitaxel	93-96	pyruvate dehydrogenase E1 subunit alpha 1	Homo sapiens	88-92
23094027-5	2012	Cytotoxic action by paclitaxel (0-100 nM) correlated well with SRB (Rho&gt;0.95) with similar IC(50) values.	Paclitaxel	20-30	chaperonin containing TCP1 subunit 4	Homo sapiens	63-66
25701027-3	2015	The experimental results showed that in the 4T1 tumor-bearing mice models, PEI-PDHA/PEG-PDHA/PTX/siSna/siTwi) complex nanoparticles (PPSTs) raised the accumulation and retention of both PTX and siRNA in tumor after administrated intravenously, resulted in the strong inhibition of the tumor growth and metastasis simultaneously.	Paclitaxel	186-189	pyruvate dehydrogenase E1 subunit alpha 1	Homo sapiens	79-83
25701027-3	2015	The experimental results showed that in the 4T1 tumor-bearing mice models, PEI-PDHA/PEG-PDHA/PTX/siSna/siTwi) complex nanoparticles (PPSTs) raised the accumulation and retention of both PTX and siRNA in tumor after administrated intravenously, resulted in the strong inhibition of the tumor growth and metastasis simultaneously.	Paclitaxel	186-189	pyruvate dehydrogenase E1 subunit alpha 1	Homo sapiens	88-92
22655084-6	2012	Results showed that integrin-alphavbeta3 expressing on the surface of U87MG cells was induced by 10 nM PTX pre-treatment for 12 hrs.	Paclitaxel	103-106	integrin subunit alpha V	Homo sapiens	20-40
25498514-9	2015	RESULTS: PAC-1 significantly reduced the inhibitory concentration 50% of paclitaxel from 35.3 to 0.33 nM in A-549 and 8.2 to 1.16 nM in H-322m cell lines.	Paclitaxel	73-83	ADCYAP receptor type I	Homo sapiens	9-14
22655084-9	2012	The increased expression of PTX-induced integrin-alphavbeta3 was correlated with the enhanced apoptosis in U87MG cells.	Paclitaxel	28-31	integrin subunit alpha V	Homo sapiens	40-60
25498514-13	2015	CONCLUSIONS: PAC-1 significantly enhances the antitumor activity of paclitaxel against NSCLC.	Paclitaxel	68-78	ADCYAP receptor type I	Homo sapiens	13-18
21945668-6	2011	Accordingly, LMP1-transformed BALB/c-3T3 cells were sensitized to cisplatin-induced apoptosis, whereas no sensitization effect was noted following treatment with the mitotic spindle-damaging drugs vincristine and taxol.	Paclitaxel	213-218	PDZ and LIM domain 7	Homo sapiens	13-17
25647149-10	2015	The downstream targets of this pathway, phospho-p70S6K and phospho-S6RP, were also inhibited by paclitaxel in 10A, 10AT and 10ATG3B cells, but minimally inhibited in 10CA1a cells, suggestive of chemoresistance in 10CA1a cells.	Paclitaxel	96-106	ribosomal protein S6 kinase B1	Homo sapiens	48-54
22036081-7	2011	A parameter space was selected to simulate an 18-fold P-gp effect, (K(p,brain) at distribution equilibrium in the absence [K(p,brain)=82] vs. presence [K(p,brain)=4.5] of P-gp-mediated flux), as observed for paclitaxel in P-gp-deficient vs. P-gp-competent mice.	Paclitaxel	208-218	phosphoglycolate phosphatase	Mus musculus	54-58
26462888-16	2015	As for resistance to paclitaxel, IC50 of MDA-MB-231 breast cancer stem cells with Oct4siRNA interference was significantly decreased [(4.48 +- 0.22) microg/ml] compared with that in the control [ (7.99 +- 0.59) microg/ml] and negative siRNA group [(8.10 +- 0.68) microg/ml] (P &lt; 0.05 for both).	Paclitaxel	21-31	POU class 5 homeobox 1	Homo sapiens	82-86
21909792-3	2011	About 60 ng/ml doses of paclitaxel cause a statistically significant increase in expression of all the 16 analysed genes coding transcriptional factors, ranging from 1.84-fold (for PO4F2) to 4.65-fold (for LMO4) (p &lt; 0.05) in comparison with the control cells, and enhanced the taxane mechanism of action.	Paclitaxel	24-34	LIM domain only 4	Homo sapiens	206-210
22060185-2	2011	Our data showed that paclitaxel can down-regulate the increased MLK3, JNK3, c-Jun, Bcl-2, and caspase-3 phosphorylation induced by ischemia injury.	Paclitaxel	21-31	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	64-68
25811469-6	2015	The results indicate that Bcl-xl has a protective role against paclitaxel-induced apoptosis in LNCaP and PC3 cells, and its overexpression causes the paclitaxel resistance seen in PC3 cells.	Paclitaxel	63-73	chromobox 8	Homo sapiens	105-108
22060185-2	2011	Our data showed that paclitaxel can down-regulate the increased MLK3, JNK3, c-Jun, Bcl-2, and caspase-3 phosphorylation induced by ischemia injury.	Paclitaxel	21-31	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	76-81
25811469-6	2015	The results indicate that Bcl-xl has a protective role against paclitaxel-induced apoptosis in LNCaP and PC3 cells, and its overexpression causes the paclitaxel resistance seen in PC3 cells.	Paclitaxel	150-160	chromobox 8	Homo sapiens	180-183
21775054-2	2011	We found that co-administration perifosine with paclitaxel in human ovarian cancer cells led to the inhibition of AKT/mTOR complex 1 (mTORC1), a marked increase in ceramide and reactive oxygen species (ROS) production, and a striking increase in the activation of pro-apoptosis pathways, including caspase 3, c-Jun N-terminal kinases (JNK) and AMP-activated protein kinase (AMPK).	Paclitaxel	48-58	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	309-314
25811469-7	2015	Interestingly, combined paclitaxel with ABT-263 to treat LNCaP and PC3 cells demonstrated synergistic apoptosis activation, indicating that ABT-263 could enhance paclitaxel-induced apoptosis in LNCaP cells and overcome Bcl-xl overexpression to trigger paclitaxel-induced apoptosis in PC3 cells.	Paclitaxel	24-34	chromobox 8	Homo sapiens	67-70
25811469-7	2015	Interestingly, combined paclitaxel with ABT-263 to treat LNCaP and PC3 cells demonstrated synergistic apoptosis activation, indicating that ABT-263 could enhance paclitaxel-induced apoptosis in LNCaP cells and overcome Bcl-xl overexpression to trigger paclitaxel-induced apoptosis in PC3 cells.	Paclitaxel	24-34	chromobox 8	Homo sapiens	284-287
25811469-7	2015	Interestingly, combined paclitaxel with ABT-263 to treat LNCaP and PC3 cells demonstrated synergistic apoptosis activation, indicating that ABT-263 could enhance paclitaxel-induced apoptosis in LNCaP cells and overcome Bcl-xl overexpression to trigger paclitaxel-induced apoptosis in PC3 cells.	Paclitaxel	162-172	chromobox 8	Homo sapiens	67-70
25811469-7	2015	Interestingly, combined paclitaxel with ABT-263 to treat LNCaP and PC3 cells demonstrated synergistic apoptosis activation, indicating that ABT-263 could enhance paclitaxel-induced apoptosis in LNCaP cells and overcome Bcl-xl overexpression to trigger paclitaxel-induced apoptosis in PC3 cells.	Paclitaxel	162-172	chromobox 8	Homo sapiens	284-287
21692650-1	2011	Paclitaxel is not effective for treatment of brain cancers because it cannot cross the blood-brain barrier (BBB) due to efflux by P-glycoprotein (P-gp).	Paclitaxel	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	130-144
21692650-1	2011	Paclitaxel is not effective for treatment of brain cancers because it cannot cross the blood-brain barrier (BBB) due to efflux by P-glycoprotein (P-gp).	Paclitaxel	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	146-150
25811469-7	2015	Interestingly, combined paclitaxel with ABT-263 to treat LNCaP and PC3 cells demonstrated synergistic apoptosis activation, indicating that ABT-263 could enhance paclitaxel-induced apoptosis in LNCaP cells and overcome Bcl-xl overexpression to trigger paclitaxel-induced apoptosis in PC3 cells.	Paclitaxel	162-172	chromobox 8	Homo sapiens	67-70
21984124-0	2011	Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192.	Paclitaxel	9-19	microRNA 192	Rattus norvegicus	88-95
25811469-7	2015	Interestingly, combined paclitaxel with ABT-263 to treat LNCaP and PC3 cells demonstrated synergistic apoptosis activation, indicating that ABT-263 could enhance paclitaxel-induced apoptosis in LNCaP cells and overcome Bcl-xl overexpression to trigger paclitaxel-induced apoptosis in PC3 cells.	Paclitaxel	162-172	chromobox 8	Homo sapiens	284-287
21984124-10	2011	Also, paclitaxel down-regulated the expression of miR-192, miR-217 and miR -377, while miR-15 was up-regulated in the remnant kidney.	Paclitaxel	6-16	microRNA 192	Rattus norvegicus	50-57
25811469-8	2015	We also observed that the activation of apoptosis in LNCaP cells was more efficient than in PC3 cells in response to paclitaxel plus ABT-263 or to ABT-263 alone, suggesting that the apoptosis pathway in PC3 cells might have further differences from that in LNCaP cells even after Bcl-xl overexpression is accounted for.	Paclitaxel	117-127	chromobox 8	Homo sapiens	92-95
21984124-12	2011	Furthermore, ChIP analyses indicated that Taxol suppressed Smad3-mediated miR-192 transcriptional activity.	Paclitaxel	42-47	microRNA 192	Rattus norvegicus	74-81
21984124-14	2011	These data suggest that low-dose paclitaxel ameliorates renal fibrosis via modulating miR-192 pathobiology and TGF-beta/Smad signalling.	Paclitaxel	33-43	microRNA 192	Rattus norvegicus	86-93
25811469-8	2015	We also observed that the activation of apoptosis in LNCaP cells was more efficient than in PC3 cells in response to paclitaxel plus ABT-263 or to ABT-263 alone, suggesting that the apoptosis pathway in PC3 cells might have further differences from that in LNCaP cells even after Bcl-xl overexpression is accounted for.	Paclitaxel	117-127	chromobox 8	Homo sapiens	203-206
25618019-6	2015	Substrate uptake experiments performed in the presence of antineoplastic compounds showed that vinblastine and paclitaxel strongly interacted with the OATP1B1 with Ki values of 10.2 muM and 0.84 muM, respectively.	Paclitaxel	111-121	solute carrier organic anion transporter family member 1B1	Homo sapiens	151-158
21820041-6	2011	Paclitaxel/17-AAG-loaded PEG-DSPE/TPGS mixed micelles were as effective in blocking the proliferation of human ovarian cancer SKOV-3 cells as the combined free drugs.	Paclitaxel	0-10	N-methylpurine DNA glycosylase	Homo sapiens	14-17
21820041-7	2011	PEG-DSPE/TPGS mixed micelles may provide a novel and advantageous delivery approach for paclitaxel/17-AAG combination therapy.	Paclitaxel	88-98	N-methylpurine DNA glycosylase	Homo sapiens	102-105
21763756-7	2011	These results revealed specific cellular signaling pathways leading to paclitaxel-induced neuropathy, including the activation of PAR2 and downstream enzymes PLC, PKCepsilon, and PKA and resultant sensitization of TRPV1, TRPV4, and TRPA1.	Paclitaxel	71-81	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	232-237
25962593-4	2015	RESULTS: Decreased resistance to cabazitaxel compared with paclitaxel was observed in KB-C2, LLC-MDR1-WT, and HEK293/ABCC10 cells.	Paclitaxel	59-69	ATP binding cassette subfamily C member 10	Homo sapiens	117-123
21870795-1	2011	Potential binding modes of (+)-discodermolide at the paclitaxel binding site of tubulin have been identified by computational studies based on earlier structural and SAR data.	Paclitaxel	53-63	sarcosine dehydrogenase	Homo sapiens	166-169
21642840-5	2011	A combined treatment with taxol and pristimerin induced cervical cancer cell death by increasing intracellular reactive oxygen species levels, upregulation of death receptor death receptor 5 (DR5), activation of Bax, and dissipation of mitochondrial membrane potential.	Paclitaxel	26-31	BCL2-associated X protein	Mus musculus	212-215
21775522-1	2011	The extracellular matrix protein TGFBI enhances the cytotoxic response of cancer cells to paclitaxel by affecting integrin signals that stabilize microtubules.	Paclitaxel	90-100	transforming growth factor beta induced	Homo sapiens	33-38
25544427-10	2015	Taken together, our data suggest that inhibition of IL-6/STAT3 signaling pathway and downregulation of Axl and Tyro3 RTKs expression might be a therapeutic strategy to overcome taxol resistance in ovarian cancer cells.	Paclitaxel	177-182	AXL receptor tyrosine kinase	Homo sapiens	103-106
25658796-0	2015	Three-dimensional collagen type I matrix up-regulates nuclear isoforms of the microtubule associated protein tau implicated in resistance to paclitaxel therapy in ovarian carcinoma.	Paclitaxel	141-151	microtubule associated protein tau	Homo sapiens	78-112
21190751-3	2011	Furthermore, the combination of paclitaxel and AVE1642 resulted in a sequence-dependent increase in the inhibition of cell proliferation, compared to each agent alone, which was associated with a dose-dependent increase in phosphorylated IGF-IR and Akt.	Paclitaxel	32-42	insulin like growth factor 1 receptor	Homo sapiens	238-244
25658796-3	2015	Expression of the microtubule associated protein tau has recently been proposed as a predictor of response to paclitaxel in ovarian carcinoma patients.	Paclitaxel	110-120	microtubule associated protein tau	Homo sapiens	18-52
25542804-6	2015	Here, a nano-DDS, GD16 peptide (H2N-GRCTNFHNFIYICFPD-CONH2, containing a disulfide bond between Cys3 and Cys13) conjugated nanoparticles loading paclitaxel (GD16-PTX-NP), which can specifically target the angiogenic marker Dll4, was fabricated for the investigation of antiangiogenic therapeutic efficacy in human head and neck cancer FaDu (Dll4-negative) xenograft in nude mice.	Paclitaxel	145-155	delta like canonical Notch ligand 4	Homo sapiens	223-227
21421899-0	2011	Differential effect of intraperitoneal albendazole and paclitaxel on ascites formation and expression of vascular endothelial growth factor in ovarian cancer cell-bearing athymic nude mice.	Paclitaxel	55-65	vascular endothelial growth factor A	Mus musculus	105-139
21421899-6	2011	CONCLUSION: We demonstrated a differential effect of albendazole and paclitaxel in a xenograft model of ovarian carcinoma; albendazole suppressed ascites formation by inhibiting VEGF secretion, and paclitaxel exerted its effects by direct cytotoxicity.	Paclitaxel	69-79	vascular endothelial growth factor A	Mus musculus	178-182
21111509-7	2011	A low expression level of TS or of DPD was associated with a better response and longer survival in patients treated with S-1-carboplatin but not in those treated with paclitaxel-carboplatin.	Paclitaxel	168-178	dihydropyrimidine dehydrogenase	Homo sapiens	35-38
25542804-6	2015	Here, a nano-DDS, GD16 peptide (H2N-GRCTNFHNFIYICFPD-CONH2, containing a disulfide bond between Cys3 and Cys13) conjugated nanoparticles loading paclitaxel (GD16-PTX-NP), which can specifically target the angiogenic marker Dll4, was fabricated for the investigation of antiangiogenic therapeutic efficacy in human head and neck cancer FaDu (Dll4-negative) xenograft in nude mice.	Paclitaxel	145-155	delta like canonical Notch ligand 4	Homo sapiens	341-345
25676404-0	2015	[Nimotuzumab significantly enhances chemosensitivity of : PC9 human lung adenocarcinoma cells to paclitaxel in vitro].	Paclitaxel	97-107	proprotein convertase subtilisin/kexin type 9	Homo sapiens	58-61
21471284-0	2011	Overexpression of mitotic centromere-associated Kinesin stimulates microtubule detachment and confers resistance to paclitaxel.	Paclitaxel	116-126	kinesin family member 2C	Homo sapiens	18-55
21471284-3	2011	Here, we examine mitotic centromere-associated kinesin (MCAK), a member of the kinesin family of microtubule motor proteins that has the ability to stimulate microtubule depolymerization, and show that overexpressing the protein confers resistance to paclitaxel and epothilone A, but increases sensitivity to colcemid.	Paclitaxel	251-261	kinesin family member 2C	Homo sapiens	17-54
21471284-3	2011	Here, we examine mitotic centromere-associated kinesin (MCAK), a member of the kinesin family of microtubule motor proteins that has the ability to stimulate microtubule depolymerization, and show that overexpressing the protein confers resistance to paclitaxel and epothilone A, but increases sensitivity to colcemid.	Paclitaxel	251-261	kinesin family member 2C	Homo sapiens	56-60
21471284-4	2011	Cells transfected with FLAG-tagged MCAK cDNA using a tet-off-regulated expression system had a disrupted microtubule cytoskeleton and were able to survive a toxic concentration of paclitaxel in the absence, but not in the presence of tetracycline, showing that drug resistance was caused by ectopic MCAK production.	Paclitaxel	180-190	kinesin family member 2C	Homo sapiens	35-39
21471284-5	2011	Moreover, a population that was heterogeneous with respect to FLAG-MCAK expression became enriched with cells that produced the ectopic protein when it was placed under paclitaxel selection.	Paclitaxel	169-179	kinesin family member 2C	Homo sapiens	67-71
21471284-6	2011	Similar to previously isolated mutants with altered tubulin, paclitaxel resistant cells resulting from MCAK overexpression were found to have decreased microtubule polymer and a seven-fold increase in the frequency of microtubule detachment from centrosomes.	Paclitaxel	61-71	kinesin family member 2C	Homo sapiens	103-107
21471284-7	2011	These data are consistent with a model for paclitaxel resistance that is based on stability of the attachment of microtubules to their nucleating centers, and they implicate MCAK in the mechanism of microtubule detachment.	Paclitaxel	43-53	kinesin family member 2C	Homo sapiens	174-178
21781528-1	2011	OBJECTIVE: To investigate the predictive value of breast cancer susceptibility gene 1 (BRCA1) and class IIIbeta-tubulin protein expression in tumor tissue for the efficacy of taxol and cisplatin combined chemotherapy (TP) in stage IIIB/IV non-small cell lung cancer (NSCLC) patients.	Paclitaxel	175-180	BRCA1 DNA repair associated	Homo sapiens	87-92
25676404-2	2015	The aim of this study is to investigate the effects of nimotuzumab on the chemosensitivities of PC9 human lung adenocarcinoma cells to common chemtherapeutic drugs including ciaplatin, gemcitabine, paclitaxel, pemetrexed and vinorelbine, and to elucidate possible mechanisms.	Paclitaxel	198-208	proprotein convertase subtilisin/kexin type 9	Homo sapiens	96-99
25676404-7	2015	RESULTS: Nimotuzumab significantly enhanced the chemosensitivity of PC9 cells to paclitaxel.	Paclitaxel	81-91	proprotein convertase subtilisin/kexin type 9	Homo sapiens	68-71
25676404-11	2015	CONCLUSIONS: Nimotuzumab enhanced the chemosensitivity of PC9 cell to paclitaxel by enhancing G2/M arrest and aggregation of tublin and microfilaments.	Paclitaxel	70-80	proprotein convertase subtilisin/kexin type 9	Homo sapiens	58-61
24911456-3	2015	The aim of this study was to determine the mechanism(s) by which lung cancer chemotherapy agents cisplatin, carboplatin, gemcitabine, and paclitaxel elicit increased tissue factor activity on endothelial cells, A549 cells, and monocytes.	Paclitaxel	138-148	coagulation factor III, tissue factor	Homo sapiens	166-179
21458148-3	2011	The LyP-1, a breast tumor homing peptide, was coated onto the surface of PTX-loaded MBs through biotin-avidin linkage.	Paclitaxel	73-76	protein tyrosine phosphatase non-receptor type 22	Homo sapiens	4-9
21458148-9	2011	In conclusion, the study indicated the LyP-1-coated PTX-loaded MBs significantly increased the antitumor efficacy and can be used as a potential chemotherapy approach for ultrasound-assisted breast cancer treatment.	Paclitaxel	52-55	protein tyrosine phosphatase non-receptor type 22	Homo sapiens	39-44
21556366-0	2011	Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.	Paclitaxel	139-149	MDM2 proto-oncogene	Homo sapiens	55-59
21556366-10	2011	Remarkably, TP53 mutations (p = 0.007) but also MDM2 309TG/GG genotype status (p = 0.012) were associated with a poor disease-specific survival among patients having paclitaxel but not patients having epirubicin first-line.	Paclitaxel	166-176	MDM2 proto-oncogene	Homo sapiens	48-52
21556366-13	2011	In contrast, TP53 mutations and MDM2 309G allele status conferred poor disease-specific survival among patients treated with primary paclitaxel but not epirubicin monotherapy.	Paclitaxel	133-143	MDM2 proto-oncogene	Homo sapiens	32-36
21296416-0	2011	BRCA1 suppresses the expression of survivin and promotes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in human breast cancer cells.	Paclitaxel	72-82	BRCA1 DNA repair associated	Homo sapiens	0-5
21296416-1	2011	Both BRCA1 and CaSR have been shown to suppress the expression of survivin and promote sensitivity to paclitaxel in human breast cancer cells.	Paclitaxel	102-112	BRCA1 DNA repair associated	Homo sapiens	5-10
21296416-3	2011	We found that mutant cells (harboring mutant BRCA1 with loss of BRCA1 expression) had a significant reduction in the expression of CaSR with a concurrent up-regulated expression of survivin and were resistant to paclitaxel by comparison to wild type cells (harboring wild type BRCA1 and expressing BRCA1).	Paclitaxel	212-222	BRCA1 DNA repair associated	Homo sapiens	45-50
26554242-3	2015	In the present study, we synthesized the second mitochondria-derived activator of caspase peptide (Smac-N7 for short) and explored its capacity in combination with taxol in vitro.	Paclitaxel	164-169	diablo IAP-binding mitochondrial protein	Homo sapiens	99-103
21296416-4	2011	Knocking down the expression of BRCA1 in wild type cells resulted in a reduction in CaSR expression with a concurrent up-regulated expression of survivin and reduction in sensitivity to paclitaxel.	Paclitaxel	186-196	BRCA1 DNA repair associated	Homo sapiens	32-37
21296416-5	2011	Re-expression of BRCA1 in BRCA1 knocked-down wild type cells restored CaSR expression with a concurrent down-regulated expression of survivin and restoration of sensitivity to paclitaxel.	Paclitaxel	176-186	BRCA1 DNA repair associated	Homo sapiens	17-22
21296416-5	2011	Re-expression of BRCA1 in BRCA1 knocked-down wild type cells restored CaSR expression with a concurrent down-regulated expression of survivin and restoration of sensitivity to paclitaxel.	Paclitaxel	176-186	BRCA1 DNA repair associated	Homo sapiens	26-31
21296416-6	2011	Corollary, ectopic expression of BRCA1 in mutant cells induced CaSR expression, suppressed the expression of survivin and restored sensitivity to paclitaxel.	Paclitaxel	146-156	BRCA1 DNA repair associated	Homo sapiens	33-38
21296416-12	2011	We conclude, and report for the first time, that BRCA1 regulates the expression of CaSR and that it functions through CaSR in suppressing the expression of survivin and promoting sensitivity to paclitaxel.	Paclitaxel	194-204	BRCA1 DNA repair associated	Homo sapiens	49-54
26554242-8	2015	The reversal folds were 2.52, 3.26, 3.67, and 5.4 in taxol + Smac-N7 (0.0390625, 0.078125, 0.15625, 0.3125 mug/mL, respectively), and concentrations of Smac-N7 and reversal folds appeared in an obvious positive correlation (r(s) = 1, p = 0.000).	Paclitaxel	53-58	diablo IAP-binding mitochondrial protein	Homo sapiens	61-65
21196304-3	2011	In the present study, we found that the CD44(+)/CD24(-/low) CSCs, isolated from both human breast cell line MCF-7 and MDA-MB-231, were more resistant to thiotepa, paclitaxel and anthracycline, when compared with the non-breast cancer stem cell subset from the same cell lines, whereas the chemosensitivities were remarkably reversed by higher concentration of thiotepa and paclitaxel except for adriamycin.	Paclitaxel	163-173	CD44 molecule (Indian blood group)	Homo sapiens	40-44
26554242-8	2015	The reversal folds were 2.52, 3.26, 3.67, and 5.4 in taxol + Smac-N7 (0.0390625, 0.078125, 0.15625, 0.3125 mug/mL, respectively), and concentrations of Smac-N7 and reversal folds appeared in an obvious positive correlation (r(s) = 1, p = 0.000).	Paclitaxel	53-58	diablo IAP-binding mitochondrial protein	Homo sapiens	152-156
21196304-3	2011	In the present study, we found that the CD44(+)/CD24(-/low) CSCs, isolated from both human breast cell line MCF-7 and MDA-MB-231, were more resistant to thiotepa, paclitaxel and anthracycline, when compared with the non-breast cancer stem cell subset from the same cell lines, whereas the chemosensitivities were remarkably reversed by higher concentration of thiotepa and paclitaxel except for adriamycin.	Paclitaxel	373-383	CD44 molecule (Indian blood group)	Homo sapiens	40-44
26554242-10	2015	Concentrations of Smac-N7 appeared to have negative correlations with PE and SF (r(s) = -1, p &lt; 0.05), which showed that the cells" cloning ability in 0.3125 mug/mL Smac-N7 + taxol group was worse than that of other groups.	Paclitaxel	178-183	diablo IAP-binding mitochondrial protein	Homo sapiens	18-22
26554242-11	2015	CONCLUSIONS: When combined with taxol, 0.3125 mug/mL Smac-N7 peptide may significantly increase taxol-induced apoptosis in chemoresistant A549/taxol lung cells at 48 hours, and is potentially useful as a reversal agent in lung cancer therapy.	Paclitaxel	96-101	diablo IAP-binding mitochondrial protein	Homo sapiens	53-57
22117968-2	2011	The effect of silencing the X-linked inhibitor of apoptosis gene (XIAP) on resistance to cisplatin, paclitaxel and gemcitabine was studied in the NSCLC cell lines A549  and H460.	Paclitaxel	100-110	X-linked inhibitor of apoptosis	Homo sapiens	28-64
22117968-2	2011	The effect of silencing the X-linked inhibitor of apoptosis gene (XIAP) on resistance to cisplatin, paclitaxel and gemcitabine was studied in the NSCLC cell lines A549  and H460.	Paclitaxel	100-110	X-linked inhibitor of apoptosis	Homo sapiens	66-70
22117968-3	2011	Transfection of these cells with small interfering RNA (siRNA) for XIAP blocked overexpression of the gene, suppressed cell proliferation, increased apoptosis and increased the cells" sensitivity to cisplatin and paclitaxel by preventing the binding of XIAP to caspase3 and  increasing the activity of this enzyme.	Paclitaxel	213-223	X-linked inhibitor of apoptosis	Homo sapiens	67-71
22117968-3	2011	Transfection of these cells with small interfering RNA (siRNA) for XIAP blocked overexpression of the gene, suppressed cell proliferation, increased apoptosis and increased the cells" sensitivity to cisplatin and paclitaxel by preventing the binding of XIAP to caspase3 and  increasing the activity of this enzyme.	Paclitaxel	213-223	X-linked inhibitor of apoptosis	Homo sapiens	253-257
25775012-9	2015	In conclusion, we have successfully prepared PTX tablets with solid dispersion granules (SDG) of amorphous PTX using fluid bed technology that could provide plasma PTX concentration in the range of 10-150 ng/mL for a period of 24 h following oral administration in dogs with a P-gp inhibitor.	Paclitaxel	45-48	PGP	Canis lupus familiaris	277-281
22140576-0	2011	Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion.	Paclitaxel	129-139	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	0-48
22140576-0	2011	Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion.	Paclitaxel	129-139	coagulation factor III, tissue factor	Rattus norvegicus	67-80
26775347-5	2015	RESULTS: Induction of p21 translocation into the cytoplasm via constitutively active Akt2 transfection in A2780 enhanced the resistance to PTX, while inhibition of p21 translocation into the cytoplasm via Akt2 shRNA trans- fection in A2780 cells significantly increased PTX treatment sensitivity.	Paclitaxel	139-142	AKT serine/threonine kinase 2	Homo sapiens	85-89
26775347-5	2015	RESULTS: Induction of p21 translocation into the cytoplasm via constitutively active Akt2 transfection in A2780 enhanced the resistance to PTX, while inhibition of p21 translocation into the cytoplasm via Akt2 shRNA trans- fection in A2780 cells significantly increased PTX treatment sensitivity.	Paclitaxel	270-273	AKT serine/threonine kinase 2	Homo sapiens	85-89
21050491-5	2010	RESULTS: Here, we investigate by immunohistochemistry the change of intraepidermal nerve fiber (IENF) in the hind paw glabrous skin, expression of macrophage and activating transcription factor 3 (ATF3) in DRG at different time points after moderate-dose paclitaxel treatment (cumulative dose 24 mg/kg; 3 x 8 mg/kg) in rats.	Paclitaxel	255-265	activating transcription factor 3	Rattus norvegicus	197-201
26775347-6	2015	Furthermore, knockdown of cytoplasmic p21 by direct p21 siRNA transfection in Akt2 overexpressed A2780 cells notably increased PTX-induced apoptosis.	Paclitaxel	127-130	AKT serine/threonine kinase 2	Homo sapiens	78-82
21050491-7	2010	The results showed that moderate-dose paclitaxel induced a persisted, gradual mechanical allodynia, which was accompanied by the loss of IENF in the hind paw glabrous skin and up-regulation of macrophages and ATF3 in DRG in rats.	Paclitaxel	38-48	activating transcription factor 3	Rattus norvegicus	209-213
26144859-0	2015	Novel dietary lipid-based self-nanoemulsifying drug delivery systems of paclitaxel with p-gp inhibitor: implications on cytotoxicity and biopharmaceutical performance.	Paclitaxel	72-82	phosphoglycolate phosphatase	Homo sapiens	88-92
21050491-10	2010	The evidence from immunohistochemistry showed that 30 mg/kg minocycline rescued the degeneration of IENF, attenuated infiltration of macrophages and up-regulation of ATF3 induced by paclitaxel treatment in rats.	Paclitaxel	182-192	activating transcription factor 3	Rattus norvegicus	166-170
21050491-11	2010	CONCLUSIONS: Minocycline prevents paclitaxel-evoked allodynia, likely due to its inhibition on loss of IENF, infiltration of macrophages and up-regulation of ATF3 in rats.	Paclitaxel	34-44	activating transcription factor 3	Rattus norvegicus	158-162
20726858-9	2010	However, gemcitabine, paclitaxel, or cisplatin treatment enhanced the Akt activation, heterodimer formation of EGFR with HER3, and secretion of amphiregulin, indicating that the presence of gemcitabine promoted the activity of targeted molecules including amphiregulin, Akt, and HER3 for pancreatic cancer therapy.	Paclitaxel	22-32	amphiregulin	Homo sapiens	144-156
20726858-9	2010	However, gemcitabine, paclitaxel, or cisplatin treatment enhanced the Akt activation, heterodimer formation of EGFR with HER3, and secretion of amphiregulin, indicating that the presence of gemcitabine promoted the activity of targeted molecules including amphiregulin, Akt, and HER3 for pancreatic cancer therapy.	Paclitaxel	22-32	amphiregulin	Homo sapiens	256-268
20726858-10	2010	Combined treatment with an inhibitor for amphiregulin and gemcitabine, paclitaxel, or cisplatin induced synergistic antitumor effects, accompanied by the suppression of Akt and ERK activation.	Paclitaxel	71-81	amphiregulin	Homo sapiens	41-53
25310526-0	2015	+TIP EB1 downregulates paclitaxel-induced proliferation inhibition and apoptosis in breast cancer cells through inhibition of paclitaxel binding on microtubules.	Paclitaxel	23-33	TOR signaling pathway regulator	Homo sapiens	1-4
20708296-7	2010	Furthermore, overexpression of TIP47 facilitated Bcl-2 expression and suppressed Bax expression in taxol-treated cells.	Paclitaxel	99-104	BCL2-associated X protein	Mus musculus	81-84
25310526-0	2015	+TIP EB1 downregulates paclitaxel-induced proliferation inhibition and apoptosis in breast cancer cells through inhibition of paclitaxel binding on microtubules.	Paclitaxel	126-136	TOR signaling pathway regulator	Homo sapiens	1-4
25164962-4	2015	Sequential treatment of Taxol or cisplatin, followed by MK-2206, induced a synergistic inhibition of cell proliferation and effectively promoted cell death, either by inhibiting the phosphorylation of Akt and its downstream effectors 4E-BP1 and p70S6K in SKOV3 cells or by restoring p53 levels, which were downregulated after Taxol or cisplatin treatment, in ES2 cells.	Paclitaxel	24-29	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	234-240
25164962-4	2015	Sequential treatment of Taxol or cisplatin, followed by MK-2206, induced a synergistic inhibition of cell proliferation and effectively promoted cell death, either by inhibiting the phosphorylation of Akt and its downstream effectors 4E-BP1 and p70S6K in SKOV3 cells or by restoring p53 levels, which were downregulated after Taxol or cisplatin treatment, in ES2 cells.	Paclitaxel	24-29	ribosomal protein S6 kinase B1	Homo sapiens	245-251
21089680-1	2010	This investigation was made with special reference to the effect of the combined use of nuclear factor-kappaB (NF-kappaB) inhibitor Pyrrolidine dithiocarbamate(PDTC) and Paclitaxel on the expression of Matrix metalloproteinases (MMP-9) and its inhibitor TIMP-1, and on the proliferation and invasion of human breast cancer cell line MCF-7.	Paclitaxel	170-180	matrix metallopeptidase 9	Homo sapiens	229-234
25419978-3	2014	Alstolucines B (2) and F (3) inhibited ABCC10 ATPase activity at 12.5 muM without affecting P-gp function; moreover, they resensitized ABCC10-transfected cell lines to paclitaxel at 10 muM.	Paclitaxel	168-178	ATP binding cassette subfamily C member 10	Homo sapiens	135-141
20944133-5	2010	RESULTS: Quantitative RT-PCR revealed significant up-regulation of DEPTOR in both paclitaxel-resistant cell lines.	Paclitaxel	82-92	DEP domain containing MTOR interacting protein	Homo sapiens	67-73
20460378-0	2010	MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.	Paclitaxel	63-73	BCL2 antagonist/killer 1	Homo sapiens	138-142
20460378-11	2010	Down-regulation of Bak1 suppressed Taxol-induced apoptosis and led to an increased resistance to Taxol.	Paclitaxel	35-40	BCL2 antagonist/killer 1	Homo sapiens	19-23
20460378-11	2010	Down-regulation of Bak1 suppressed Taxol-induced apoptosis and led to an increased resistance to Taxol.	Paclitaxel	97-102	BCL2 antagonist/killer 1	Homo sapiens	19-23
20460378-12	2010	Restoring Bak1 expression by either miR-125b inhibitor or re-expression of Bak1 in miR-125b-overexpressing cells recovered Taxol sensitivity, overcoming miR-125-mediated Taxol resistance.	Paclitaxel	123-128	BCL2 antagonist/killer 1	Homo sapiens	10-14
20460378-12	2010	Restoring Bak1 expression by either miR-125b inhibitor or re-expression of Bak1 in miR-125b-overexpressing cells recovered Taxol sensitivity, overcoming miR-125-mediated Taxol resistance.	Paclitaxel	123-128	BCL2 antagonist/killer 1	Homo sapiens	75-79
20460378-12	2010	Restoring Bak1 expression by either miR-125b inhibitor or re-expression of Bak1 in miR-125b-overexpressing cells recovered Taxol sensitivity, overcoming miR-125-mediated Taxol resistance.	Paclitaxel	170-175	BCL2 antagonist/killer 1	Homo sapiens	10-14
20460378-12	2010	Restoring Bak1 expression by either miR-125b inhibitor or re-expression of Bak1 in miR-125b-overexpressing cells recovered Taxol sensitivity, overcoming miR-125-mediated Taxol resistance.	Paclitaxel	170-175	BCL2 antagonist/killer 1	Homo sapiens	75-79
20460378-13	2010	Taken together, our data strongly support a central role for miR-125b in conferring Taxol resistance through the suppression of Bak1 expression.	Paclitaxel	84-89	BCL2 antagonist/killer 1	Homo sapiens	128-132
25625024-0	2015	PET imaging of apoptosis in tumor-bearing mice and rabbits after paclitaxel treatment with (18)F(-)Labeled recombinant human His10-annexin V.	Paclitaxel	65-75	annexin A5	Homo sapiens	131-140
20386470-7	2010	LPS stimulation of DCs induced IL-10, IL-12p70, TNFalpha and IL-1beta secretion, and taxol pretreatment modified this response by down-regulating IL-1beta secretion whereas colchicine induced a proinflammatory cytokine profile with reduced IL-10 and increased IL-12p70 and TNFalpha secretion.	Paclitaxel	85-90	interleukin 10	Homo sapiens	240-245
25411045-0	2014	Lysophosphatidic acid and its receptors LPA1 and LPA3 mediate paclitaxel-induced neuropathic pain in mice.	Paclitaxel	62-72	lysophosphatidic acid receptor 1	Mus musculus	40-44
25411045-6	2014	The paclitaxel-induced LPA production was completely abolished not only by intrathecal pretreatment with neurokinin 1 (NK1) or N-methyl-D-aspartate (NMDA) receptor antagonist, but also in LPA1 receptor-deficient (Lpar1-/-) and LPA3 receptor-deficient (Lpar3-/-) mice.	Paclitaxel	4-14	tachykinin 1	Mus musculus	105-117
20298756-0	2010	Farnesyl diphosphate synthase attenuates paclitaxel-induced apoptotic cell death in human glioblastoma U87MG cells.	Paclitaxel	41-51	farnesyl diphosphate synthase	Homo sapiens	0-29
20298756-1	2010	Increased expression of farnesyl diphosphate synthase (FPPS) by stable transfection appeared to attenuate paclitaxel-induced apoptotic cell death in human glioblastoma U87MG cells.	Paclitaxel	106-116	farnesyl diphosphate synthase	Homo sapiens	24-53
25411045-6	2014	The paclitaxel-induced LPA production was completely abolished not only by intrathecal pretreatment with neurokinin 1 (NK1) or N-methyl-D-aspartate (NMDA) receptor antagonist, but also in LPA1 receptor-deficient (Lpar1-/-) and LPA3 receptor-deficient (Lpar3-/-) mice.	Paclitaxel	4-14	tachykinin 1	Mus musculus	119-122
20298756-1	2010	Increased expression of farnesyl diphosphate synthase (FPPS) by stable transfection appeared to attenuate paclitaxel-induced apoptotic cell death in human glioblastoma U87MG cells.	Paclitaxel	106-116	farnesyl diphosphate synthase	Homo sapiens	55-59
20298756-3	2010	Farnesyl diphosphate, a catalytic product of FPPS, also attenuated mentioned paclitaxel-induced apoptotic cell death.	Paclitaxel	77-87	farnesyl diphosphate synthase	Homo sapiens	45-49
25411045-6	2014	The paclitaxel-induced LPA production was completely abolished not only by intrathecal pretreatment with neurokinin 1 (NK1) or N-methyl-D-aspartate (NMDA) receptor antagonist, but also in LPA1 receptor-deficient (Lpar1-/-) and LPA3 receptor-deficient (Lpar3-/-) mice.	Paclitaxel	4-14	lysophosphatidic acid receptor 1	Mus musculus	188-192
20298756-4	2010	As expected, the FPPS inhibitor, pamidronate, enhanced paclitaxel-induced apoptotic cell death.	Paclitaxel	55-65	farnesyl diphosphate synthase	Homo sapiens	17-21
25411045-6	2014	The paclitaxel-induced LPA production was completely abolished not only by intrathecal pretreatment with neurokinin 1 (NK1) or N-methyl-D-aspartate (NMDA) receptor antagonist, but also in LPA1 receptor-deficient (Lpar1-/-) and LPA3 receptor-deficient (Lpar3-/-) mice.	Paclitaxel	4-14	lysophosphatidic acid receptor 1	Mus musculus	213-218
20298756-5	2010	The present results suggest that FPPS plays an important role in apoptotic cell death of cancer cells by blocking the JNK signaling cascade and activating mevalonate metabolism in paclitaxel-treated glioblastoma cells.	Paclitaxel	180-190	farnesyl diphosphate synthase	Homo sapiens	33-37
25411045-7	2014	In addition, the pharmacological blockade of NK1 or NMDA receptor prevented a reduction in the paw withdrawal threshold against mechanical stimulation after paclitaxel treatments.	Paclitaxel	157-167	tachykinin 1	Mus musculus	45-48
25411045-8	2014	Importantly, the paclitaxel-induced mechanical allodynia was absent in Lpar1-/- and Lpar3-/- mice.	Paclitaxel	17-27	lysophosphatidic acid receptor 1	Mus musculus	71-76
25411045-9	2014	CONCLUSIONS: These results suggest that LPA1 and LPA3 receptors-mediated amplification of spinal LPA production is required for the development of paclitaxel-induced neuropathic pain.	Paclitaxel	147-157	lysophosphatidic acid receptor 1	Mus musculus	40-44
20043095-3	2010	The present study investigated the correlation between the antitumor effect of telomelysin and mRNA expression of hTERT and coxsackievirus and adenovirus receptor (CAR) in head and neck squamous cell carcinoma (HNSCC) in vitro and whether telomelysin enhances the antitumor effect of paclitaxel or cisplatin, in vivo using a HNSCC xenograft model.	Paclitaxel	284-294	CXADR Ig-like cell adhesion molecule	Homo sapiens	164-167
24700640-7	2014	EGF-displayed nanoparticles loaded with the anti-cancer drug paclitaxel were internalized into cells overexpressing the EGF receptor, and induced cell death.	Paclitaxel	61-71	epidermal growth factor	Homo sapiens	0-3
19826412-6	2010	The Tyr 1226/7 binds Shc, and the knockdown of Shc blocks the ability of ErbB2 to inhibit apoptosis and mediate paclitaxel resistance.	Paclitaxel	112-122	SHC adaptor protein 1	Homo sapiens	47-50
19944065-9	2010	The c-Jun terminal NH2 kinase (JNK) inhibitor SP600125 reduced thrombin/paclitaxel-induced TF expression.	Paclitaxel	72-82	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	4-9
24700640-7	2014	EGF-displayed nanoparticles loaded with the anti-cancer drug paclitaxel were internalized into cells overexpressing the EGF receptor, and induced cell death.	Paclitaxel	61-71	epidermal growth factor	Homo sapiens	120-123
24753077-5	2014	Primary Ewing sarcoma tumors expressed the transport protein SPARC, previously associated with nab-paclitaxel activity.	Paclitaxel	99-109	secreted protein acidic and cysteine rich	Homo sapiens	61-66
19800114-8	2010	Dual agent nanoparticles encapsulating the combination of paclitaxel and P-gp targeted siRNA showed significantly higher cytotoxicity in vitro than nanoparticles loaded with paclitaxel alone.	Paclitaxel	174-184	phosphoglycolate phosphatase	Mus musculus	73-77
19800114-10	2010	In vivo studies in a mouse model of drug-resistant tumor demonstrated significantly greater inhibition of tumor growth following treatment with biotin-functionalized nanoparticles encapsulating both paclitaxel and P-gp targeted siRNA at a paclitaxel dose that was ineffective in the absence of gene silencing.	Paclitaxel	239-249	phosphoglycolate phosphatase	Mus musculus	214-218
20001297-4	2010	Paclitaxel therapy downregulated expression of vascular endothelial growth factor receptor-2 (VEGFR2) and up-regulated expression of thrombospondin-1.	Paclitaxel	0-10	thrombospondin 1	Mus musculus	133-149
20346445-1	2010	Subclinical doses of Paclitaxel (PTX) given 1day prior to a HER-2/neu (neu)-targeted, granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting whole-cell vaccine enhances neu-specific T cell responses and slows neu(+) tumor growth in tolerized HER-2/neu (neu-N) mice.	Paclitaxel	21-31	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	86-134
25107571-5	2014	RESULTS: Patients with negative expression of APE1, ERCC1 or TUBB3 benefited from platinum plus paclitaxel regimen chemotherapy.	Paclitaxel	96-106	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	52-57
20346445-1	2010	Subclinical doses of Paclitaxel (PTX) given 1day prior to a HER-2/neu (neu)-targeted, granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting whole-cell vaccine enhances neu-specific T cell responses and slows neu(+) tumor growth in tolerized HER-2/neu (neu-N) mice.	Paclitaxel	21-31	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	136-142
20346445-1	2010	Subclinical doses of Paclitaxel (PTX) given 1day prior to a HER-2/neu (neu)-targeted, granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting whole-cell vaccine enhances neu-specific T cell responses and slows neu(+) tumor growth in tolerized HER-2/neu (neu-N) mice.	Paclitaxel	33-36	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	86-134
25107571-9	2014	Moreover, patients with both APE1- and ERCC1-negative or both APE1- and TUBB3-negative tumors had significantly higher response rate, longer median PFS and OS following treatment with platinum and paclitaxel (P &lt; 0.05).	Paclitaxel	197-207	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	39-44
24816187-3	2014	Elevated CCL2 expression was found in three non-MDR paclitaxel resistant ovarian cancer lines ES-2/TP, MES-OV/TP and OVCAR-3/TP, compared to parental cells.	Paclitaxel	52-62	C-C motif chemokine ligand 2	Homo sapiens	9-13
19924122-1	2010	Oral administration of the taxanes docetaxel and paclitaxel is hampered by their affinity for drug transporters, especially ABCB1 (P-glycoprotein, Pgp); extensive first-pass metabolism by cytochrome P450 3A (CYP3A); and poor drug solubility.	Paclitaxel	49-59	phosphoglycolate phosphatase	Mus musculus	147-150
19924122-1	2010	Oral administration of the taxanes docetaxel and paclitaxel is hampered by their affinity for drug transporters, especially ABCB1 (P-glycoprotein, Pgp); extensive first-pass metabolism by cytochrome P450 3A (CYP3A); and poor drug solubility.	Paclitaxel	49-59	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	188-206
19924122-1	2010	Oral administration of the taxanes docetaxel and paclitaxel is hampered by their affinity for drug transporters, especially ABCB1 (P-glycoprotein, Pgp); extensive first-pass metabolism by cytochrome P450 3A (CYP3A); and poor drug solubility.	Paclitaxel	49-59	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	208-213
25240613-5	2014	Expression of transient receptor potential vanilloid 4 (TRPV4) gene in PTX group significantly increased compared with that in control and PTX/GJG groups.	Paclitaxel	71-74	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	14-54
20645913-3	2010	PET/CT imaging with a radiolabeled form of paclitaxel, F-18 fluoropaclitaxel (FPAC), may be able to predict the uptake of paclitaxel in solid tumors, and as a substrate of P-glycoprotein, it may also predict which tumors exhibit multidrug resistance (MDR), a phenotype in which tumors fail to respond to a wide variety of chemically unrelated chemotherapeutic agents.	Paclitaxel	43-53	mastermind like domain containing 1	Homo sapiens	55-59
20645913-3	2010	PET/CT imaging with a radiolabeled form of paclitaxel, F-18 fluoropaclitaxel (FPAC), may be able to predict the uptake of paclitaxel in solid tumors, and as a substrate of P-glycoprotein, it may also predict which tumors exhibit multidrug resistance (MDR), a phenotype in which tumors fail to respond to a wide variety of chemically unrelated chemotherapeutic agents.	Paclitaxel	66-76	mastermind like domain containing 1	Homo sapiens	55-59
25240613-5	2014	Expression of transient receptor potential vanilloid 4 (TRPV4) gene in PTX group significantly increased compared with that in control and PTX/GJG groups.	Paclitaxel	71-74	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	56-61
25240613-5	2014	Expression of transient receptor potential vanilloid 4 (TRPV4) gene in PTX group significantly increased compared with that in control and PTX/GJG groups.	Paclitaxel	139-142	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	14-54
25240613-5	2014	Expression of transient receptor potential vanilloid 4 (TRPV4) gene in PTX group significantly increased compared with that in control and PTX/GJG groups.	Paclitaxel	139-142	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	56-61
25240613-7	2014	CONCLUSIONS: These results showed that PTX induced hyperalgesia by enhancing TRPV4 expression, and suggested that GJG might alleviate hyperalgesia by preventing degeneration of the ganglion cells and suppressing TRPV4 expression.	Paclitaxel	39-42	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	77-82
25240613-7	2014	CONCLUSIONS: These results showed that PTX induced hyperalgesia by enhancing TRPV4 expression, and suggested that GJG might alleviate hyperalgesia by preventing degeneration of the ganglion cells and suppressing TRPV4 expression.	Paclitaxel	39-42	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	212-217
19551867-5	2009	In BRCA1 knocked-down cells, the expression of survivin was significantly up regulated with a concurrent decrease in cellular sensitivity to paclitaxel.	Paclitaxel	141-151	BRCA1 DNA repair associated	Homo sapiens	3-8
24510775-7	2014	Intriguingly, demethylation with 5-aza-dC led to reactivation of miR-145 expression in drug-resistant ovarian cancer cell lines, which also resulted in increased sensitivity to paclitaxel.	Paclitaxel	177-187	microRNA 145	Homo sapiens	65-72
19551867-7	2009	Cells harboring mutated BRCA1 also expressed a high level of survivin and were relatively resistant to paclitaxel by comparison to wild-type cells.	Paclitaxel	103-113	BRCA1 DNA repair associated	Homo sapiens	24-29
19551867-8	2009	Increase resistance to paclitaxel was due to an increase in the expression of survivin in both the BRCA1 knocked-down and mutant BRCA1 cells because knocking down survivin expression by siRNA restored sensitivity to paclitaxel.	Paclitaxel	23-33	BRCA1 DNA repair associated	Homo sapiens	99-104
19551867-8	2009	Increase resistance to paclitaxel was due to an increase in the expression of survivin in both the BRCA1 knocked-down and mutant BRCA1 cells because knocking down survivin expression by siRNA restored sensitivity to paclitaxel.	Paclitaxel	23-33	BRCA1 DNA repair associated	Homo sapiens	129-134
19551867-10	2009	Moreover, loss of BRCA1 expression or function leads to an increase in survivin expression and a reduction in chemosensitivity to paclitaxel.	Paclitaxel	130-140	BRCA1 DNA repair associated	Homo sapiens	18-23
25016949-0	2014	Combination of microtubule associated protein-tau and beta-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer.	Paclitaxel	100-110	microtubule associated protein tau	Homo sapiens	15-49
19772851-6	2009	Furthermore, down-regulation of P-gp1 led to increased sensitivity of CH(R)C5 cells to paclitaxel and doxorubicin, but not to cis-platinum, due to inhibition of P-gp1 drug efflux pump.	Paclitaxel	87-97	CD44 molecule (Indian blood group)	Homo sapiens	32-37
25016949-1	2014	AIM: To investigate the role of microtubule associated protein-tau (MAP-tau) and beta-tubulin III (TUBB3) in predicting the chemosensitivity of paclitaxel in patients with advanced gastric cancer (GC).	Paclitaxel	144-154	microtubule associated protein tau	Homo sapiens	32-66
19772851-6	2009	Furthermore, down-regulation of P-gp1 led to increased sensitivity of CH(R)C5 cells to paclitaxel and doxorubicin, but not to cis-platinum, due to inhibition of P-gp1 drug efflux pump.	Paclitaxel	87-97	CD44 molecule (Indian blood group)	Homo sapiens	161-166
25016949-1	2014	AIM: To investigate the role of microtubule associated protein-tau (MAP-tau) and beta-tubulin III (TUBB3) in predicting the chemosensitivity of paclitaxel in patients with advanced gastric cancer (GC).	Paclitaxel	144-154	microtubule associated protein tau	Homo sapiens	68-75
19826044-3	2009	Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity.	Paclitaxel	78-88	NK3 homeobox 1	Homo sapiens	233-239
19823672-4	2009	Coincubating cells with a sublethal concentration of paclitaxel in combination with each of 2,000 small molecule compounds from the National Cancer Institute Diversity Set Library, we identified a previously uncharacterized molecule, NSC23925, that inhibits Pgp1 and reverses MDR1 (Pgp1) but does not inhibit MRP or BCRP-mediated MDR.	Paclitaxel	53-63	CD44 molecule (Indian blood group)	Homo sapiens	258-262
25016949-3	2014	The associations of MAP-tau and TUBB3 expressions with paclitaxel sensitivity were assessed using in vitro and in vivo xenograft analysis.	Paclitaxel	55-65	microtubule associated protein tau	Homo sapiens	20-27
19823672-4	2009	Coincubating cells with a sublethal concentration of paclitaxel in combination with each of 2,000 small molecule compounds from the National Cancer Institute Diversity Set Library, we identified a previously uncharacterized molecule, NSC23925, that inhibits Pgp1 and reverses MDR1 (Pgp1) but does not inhibit MRP or BCRP-mediated MDR.	Paclitaxel	53-63	CD44 molecule (Indian blood group)	Homo sapiens	282-286
19823672-7	2009	Additionally, NSC23925 increases the intracellular accumulation of Pgp1 substrates: calcein AM, Rhodamine-123, paclitaxel, mitoxantrone, and doxorubicin.	Paclitaxel	111-121	CD44 molecule (Indian blood group)	Homo sapiens	67-71
25016949-7	2014	In in vitro studies, the sensitivity of paclitaxel in human gastric cancer cells was inversely correlated with the expression levels of MAP-tau and TUBB3, as in in vivo animal xenografts.	Paclitaxel	40-50	microtubule associated protein tau	Homo sapiens	136-143
19476987-7	2009	The effect of SNCG knockdown in SPEC2 cells on cell proliferation and sensitivity to paclitaxel-induced apoptosis was measured using a cell viability assay, BrdU incorporation assay, as well as cleaved PARP analyses.	Paclitaxel	85-95	CDC42 small effector 2	Homo sapiens	32-37
25016949-8	2014	CONCLUSIONS: The combination of MAP-tau and TUBB3 was found to predict chemosensitivity to paclitaxel in gastric cancer in vitro and in vivo.	Paclitaxel	91-101	microtubule associated protein tau	Homo sapiens	32-39
19476987-11	2009	Knockdown of SNCG in SPEC2 cells caused a significant decrease in cell proliferation and increased sensitivity to paclitaxel-induced apoptosis.	Paclitaxel	114-124	CDC42 small effector 2	Homo sapiens	21-26
24947467-2	2014	For five P-gp substrates (indinavir, quinidine, loperamide, paclitaxel, and verapamil) and one nonsubstrate (diazepam), in vitro P-gp transport activities were determined by measuring transcellular transport across monolayers of cynomolgus monkey P-gp-transfected LLC-PK1 and parental cells.	Paclitaxel	60-70	phosphoglycolate phosphatase	Homo sapiens	129-133
19703346-1	2009	OBJECTIVES: The P-glycoprotein (P-gp) efflux pump plays an important role in paclitaxel detoxification.	Paclitaxel	77-87	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	16-30
19703346-1	2009	OBJECTIVES: The P-glycoprotein (P-gp) efflux pump plays an important role in paclitaxel detoxification.	Paclitaxel	77-87	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	32-36
24947467-2	2014	For five P-gp substrates (indinavir, quinidine, loperamide, paclitaxel, and verapamil) and one nonsubstrate (diazepam), in vitro P-gp transport activities were determined by measuring transcellular transport across monolayers of cynomolgus monkey P-gp-transfected LLC-PK1 and parental cells.	Paclitaxel	60-70	phosphoglycolate phosphatase	Homo sapiens	129-133
25177862-2	2014	In the present study, paclitaxel (PTX) and DNA were co-loaded in the hyaluronic acid (HA) and folate (FA)-modified liposomes (HA/FA/PPD), to obtain the dual targeting biomimetic nanovector.	Paclitaxel	22-32	cellular communication network factor 6	Homo sapiens	126-135
19034449-7	2009	XIAP knockdown sensitises cells to rhTRAIL by a factor of 3, to paclitaxel and docetaxel by a factor of &gt;2 and, to a lesser extent, radiotherapy (20% enhancement).	Paclitaxel	64-74	X-linked inhibitor of apoptosis	Homo sapiens	0-4
25177862-2	2014	In the present study, paclitaxel (PTX) and DNA were co-loaded in the hyaluronic acid (HA) and folate (FA)-modified liposomes (HA/FA/PPD), to obtain the dual targeting biomimetic nanovector.	Paclitaxel	34-37	cellular communication network factor 6	Homo sapiens	126-135
25177862-5	2014	In comparison with the FA-modified PTX/DNA co-loaded liposomes (FA/PPD), HA/FA/PPD showed significant superiority in protecting the nanoparticles from aggregation in the presence of plasma and degradation by DNase I.	Paclitaxel	35-38	cellular communication network factor 6	Homo sapiens	73-82
25177862-7	2014	Furthermore, fluorescence microscope and flow cytometry results showed that PTX and DNA could be effectively co-delivered into the same tumor cell via HA/FA/PPD, contributing to PTX/DNA combination cancer treatment.	Paclitaxel	76-79	cellular communication network factor 6	Homo sapiens	151-160
19376141-8	2009	Paclitaxel caused the membrane translocation of only PKCbeta within 10 min after stimulation, whereas vinorelbine induced the translocation of both PKCalpha and beta.	Paclitaxel	0-10	protein kinase C, beta	Rattus norvegicus	53-60
19376141-10	2009	These findings suggest that paclitaxel and vinorelbine evoke the sP release from cultured DRG cells by the extracellular Ca2+ influx through TRP channels activated by PKCbeta and VGCCs activated by both PKCalpha and beta, respectively.	Paclitaxel	28-38	protein kinase C, beta	Rattus norvegicus	167-174
19376141-10	2009	These findings suggest that paclitaxel and vinorelbine evoke the sP release from cultured DRG cells by the extracellular Ca2+ influx through TRP channels activated by PKCbeta and VGCCs activated by both PKCalpha and beta, respectively.	Paclitaxel	28-38	protein kinase C, alpha	Rattus norvegicus	203-220
25177862-7	2014	Furthermore, fluorescence microscope and flow cytometry results showed that PTX and DNA could be effectively co-delivered into the same tumor cell via HA/FA/PPD, contributing to PTX/DNA combination cancer treatment.	Paclitaxel	178-181	cellular communication network factor 6	Homo sapiens	151-160
19500405-2	2009	Therefore, we classified the drug-drug interaction and the effects of paclitaxel on deoxycytidine kinase (dCK) and cytidine deaminase (CDA) in three NSCLC cell lines.	Paclitaxel	70-80	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	106-109
19500405-10	2009	Paclitaxel significantly decreased dCK and CDA mRNA levels in H460 and H520 cells (40% to 60%, P &lt; 0.05) and lowered dCK protein (24% to 56%, P &lt; 0.05) without affecting CDA protein.	Paclitaxel	0-10	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	35-38
19500405-10	2009	Paclitaxel significantly decreased dCK and CDA mRNA levels in H460 and H520 cells (40% to 60%, P &lt; 0.05) and lowered dCK protein (24% to 56%, P &lt; 0.05) without affecting CDA protein.	Paclitaxel	0-10	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	120-123
19500405-11	2009	However, paclitaxel increased both dCK (10% to 50%) and CDA (75% to 153%) activity (P &lt; 0.05).	Paclitaxel	9-19	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	35-38
25177862-8	2014	In conclusion, the obtained HA/FA/PPD in the study could effectively target tumor cells, enhance transfection efficiency and subsequently achieve the co-delivery of PTX and DNA, displaying great potential for optimal combination therapy.	Paclitaxel	165-168	cellular communication network factor 6	Homo sapiens	28-37
19247716-0	2009	MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol.	Paclitaxel	108-113	DNL-type zinc finger	Homo sapiens	59-62
24866272-7	2014	The reversal of paclitaxel resistance could mainly ascribe to the significant inhibition of P-gp activity and enhancement of anti-cancer activity.	Paclitaxel	16-26	phosphoglycolate phosphatase	Homo sapiens	92-96
19247716-7	2009	RESULTS: The MDR cell line induced by Taxol (Hep-2T cell) was more invasive than its parent cell line (Hep-2 cell), which was at least in part mediated through the overexpressed MDR1/P-pg.	Paclitaxel	38-43	DNL-type zinc finger	Homo sapiens	45-48
25153728-0	2014	The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1alpha and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.	Paclitaxel	35-45	ribosomal protein S6 kinase B1	Homo sapiens	111-114
19442054-9	2009	We propose that BRCA1 should be the first of a panel of cellular markers to predict the inverse cisplatin/paclitaxel resistance phenotype.	Paclitaxel	106-116	BRCA1 DNA repair associated	Homo sapiens	16-21
25153728-6	2014	Treatment with sMEK1 and paclitaxel reduced phosphorylation of ribosomal S6 kinase (S6K) and 4E-binding protein (4E-BP), two critical downstream targets of the mTOR-signaling pathway.	Paclitaxel	25-35	ribosomal protein S6 kinase B1	Homo sapiens	84-87
25153728-7	2014	Furthermore, both sMEK1 and paclitaxel significantly inhibited the expression of signaling components downstream of S6K/4E-BP, such as hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF), both in vitro and in vivo.	Paclitaxel	28-38	ribosomal protein S6 kinase B1	Homo sapiens	116-119
24927684-0	2014	Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel.	Paclitaxel	108-118	phosphoglycolate phosphatase	Homo sapiens	60-64
19282672-5	2009	Furthermore, CDK5RAP2-knockdown cells have increased resistance to paclitaxel and doxorubicin, and this resistance is partially rescued upon restoration of CDK5RAP2 expression.	Paclitaxel	67-77	CDK5 regulatory subunit associated protein 2	Homo sapiens	13-21
25056500-2	2014	We studied the prognostic and predictive value of PIK3CA mutations and PTEN low in patients receiving paclitaxel alone or in combination with lapatinib.	Paclitaxel	102-112	phosphatase and tensin homolog	Homo sapiens	71-75
19718800-3	2009	With this in mind, we prepared PBR-targeted nanoparticulate drug delivery systems (PEG-PE micelles) loaded with the anticancer drug paclitaxel (PCL) to test possible synergistic anticancer effects.	Paclitaxel	144-147	translocator protein	Homo sapiens	31-34
19881253-1	2009	Paclitaxel-resistant HepG2 (PR-HepG2) cells were established by long-term exposure of HepG2 cells to paclitaxel and expression and function of efflux (P-glycoprotein, MRP2) and influx (OATP1B3) transporters for paclitaxel were examined to understand the mechanisms underlying the resistance.	Paclitaxel	0-10	ATP binding cassette subfamily C member 2	Homo sapiens	167-171
24805866-8	2014	Twist1 overexpression decreased the sensitivity of cells to taxol as revealed by a significant increase in MDR1/P-gp and IC50 (P&lt;0.05).	Paclitaxel	60-65	phosphoglycolate phosphatase	Homo sapiens	112-116
19648171-5	2009	It was hypothesized that ETR2 might affect the assembly of the microtubule cytoskeleton based on analysis of the cytoskeleton in developing trichomes, and exposures to paclitaxol and oryzalin, which respectively act either to stabilize or depolymerize the cytoskeleton.	Paclitaxel	168-178	Signal transduction histidine kinase, hybrid-type, ethylene sensor	Arabidopsis thaliana	25-29
25327734-0	2014	[Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].	Paclitaxel	94-104	heparin binding EGF like growth factor	Homo sapiens	32-90
18977229-3	2008	Paclitaxel binds to human MD-2.	Paclitaxel	0-10	lymphocyte antigen 96	Homo sapiens	26-30
18977229-5	2008	Circular dichroic spectra of human MD-2 indicated differences in the chemical environment in the presence of paclitaxel and docetaxel.	Paclitaxel	109-119	lymphocyte antigen 96	Homo sapiens	35-39
25327734-1	2014	OBJECTIVE: To examine the expression of heparin binding-epidermal growth factor-like growth factor (HB- EGF) in paclitaxel- resistant ovarian cancer and elucidate the relationship between HB-EGF and the resistance of ovarian cancer to paclitaxel.	Paclitaxel	112-122	heparin binding EGF like growth factor	Homo sapiens	40-98
25327734-1	2014	OBJECTIVE: To examine the expression of heparin binding-epidermal growth factor-like growth factor (HB- EGF) in paclitaxel- resistant ovarian cancer and elucidate the relationship between HB-EGF and the resistance of ovarian cancer to paclitaxel.	Paclitaxel	112-122	heparin binding EGF like growth factor	Homo sapiens	100-107
25327734-1	2014	OBJECTIVE: To examine the expression of heparin binding-epidermal growth factor-like growth factor (HB- EGF) in paclitaxel- resistant ovarian cancer and elucidate the relationship between HB-EGF and the resistance of ovarian cancer to paclitaxel.	Paclitaxel	235-245	heparin binding EGF like growth factor	Homo sapiens	100-107
25327734-3	2014	Western blot was used to dectect the expression of HB-EGF protein in A2780 and A2780/Taxol groups.	Paclitaxel	85-90	heparin binding EGF like growth factor	Homo sapiens	51-57
25327734-8	2014	Immunohistochemistry was used to determine the expression of HB-EGF protein in A2780 and A2780/Taxol group.	Paclitaxel	95-100	heparin binding EGF like growth factor	Homo sapiens	61-67
19005076-3	2008	Furthermore, stabilization and inhibition of MTs by low doses of taxol and nocodazole enhance and impair spine formation elicited by BDNF (brain-derived neurotrophic factor), respectively.	Paclitaxel	65-70	brain derived neurotrophic factor	Homo sapiens	133-137
25327734-9	2014	RESULTS: The expression level of HB-EGF protein in A2780/Taxol group (2.11 +- 0.41) was significantly higher than that of A2780 group (0.75 +- 0.20; P &lt; 0.01).	Paclitaxel	57-62	heparin binding EGF like growth factor	Homo sapiens	33-39
19005076-3	2008	Furthermore, stabilization and inhibition of MTs by low doses of taxol and nocodazole enhance and impair spine formation elicited by BDNF (brain-derived neurotrophic factor), respectively.	Paclitaxel	65-70	brain derived neurotrophic factor	Homo sapiens	139-172
25327734-14	2014	In experiments in vivo, the expression scores of HB- EGF protein in A2780/Taxol tumors (10.8 +- 3.3) were higher than that in A2780 tumors (5.0 +- 2.2; P &lt; 0.01).	Paclitaxel	74-79	heparin binding EGF like growth factor	Homo sapiens	49-56
25327734-17	2014	CONCLUSIONS: HB-EGF is over-expressed in paclitaxel-resistant ovarian cancer and may be contributes to drug resistance.	Paclitaxel	41-51	heparin binding EGF like growth factor	Homo sapiens	13-19
18923545-0	2008	Kinetics of human peptidylarginine deiminase 2 (hPAD2)--reduction of Ca2+ dependence by phospholipids and assessment of proposed inhibition by paclitaxel side chains.	Paclitaxel	143-153	peptidyl arginine deiminase 2	Homo sapiens	18-46
25327734-18	2014	Inhibition of HB- EGF expression potently enhances apoptosis and inhibit the growth of paclitaxel- resistant ovarian cancer, shedding light on the HB-EGF-targeted therapy options for chemoresistant ovarian cancer patients.	Paclitaxel	87-97	heparin binding EGF like growth factor	Homo sapiens	14-21
18923545-0	2008	Kinetics of human peptidylarginine deiminase 2 (hPAD2)--reduction of Ca2+ dependence by phospholipids and assessment of proposed inhibition by paclitaxel side chains.	Paclitaxel	143-153	peptidyl arginine deiminase 2	Homo sapiens	48-53
18923545-8	2008	Despite paclitaxel having previously been shown to inhibit hPAD2 in vitro, the side chain of paclitaxel alone did not inhibit this enzyme"s activity.	Paclitaxel	8-18	peptidyl arginine deiminase 2	Homo sapiens	59-64
24932685-0	2014	Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.	Paclitaxel	48-53	insulin like growth factor 2	Homo sapiens	0-28
18813780-7	2008	Consistently, PTX increased p21WAF1, bax and MDM2 levels, suggesting that p53 is transcriptionally active.	Paclitaxel	14-17	MDM2 proto-oncogene	Homo sapiens	45-49
18813783-4	2008	The paclitaxel resistance of the brain K1735 tumors was eliminated by combined treatment with a P-gp inhibitor, HM30181A, and paclitaxel.	Paclitaxel	4-14	phosphoglycolate phosphatase	Mus musculus	96-100
24932685-5	2014	In a genetically diverse panel of ovarian cancer cell lines, the IGF2 mRNA levels measured in cell lines resistant to various microtubule-stabilizing agents including Taxol were found to be significantly elevated compared to the drug sensitive cell lines.	Paclitaxel	167-172	insulin like growth factor 2	Homo sapiens	65-69
18441325-6	2008	Furthermore, we observed that HA-CD44 interaction induces ankyrin (a cytoskeletal protein) binding to MDR1 resulting in the efflux of chemotherapeutic drugs (e.g. doxorubicin and paclitaxel (Taxol)) and chemoresistance in these tumor cells.	Paclitaxel	179-189	CD44 molecule (Indian blood group)	Homo sapiens	33-37
18441325-6	2008	Furthermore, we observed that HA-CD44 interaction induces ankyrin (a cytoskeletal protein) binding to MDR1 resulting in the efflux of chemotherapeutic drugs (e.g. doxorubicin and paclitaxel (Taxol)) and chemoresistance in these tumor cells.	Paclitaxel	191-196	CD44 molecule (Indian blood group)	Homo sapiens	33-37
24932685-6	2014	The effect of IGF2 knockdown on Taxol resistance was investigated in vitro and in vivo.	Paclitaxel	32-37	insulin like growth factor 2	Homo sapiens	14-18
24932685-7	2014	Transient IGF2 knockdown significantly sensitized drug resistant cells to Taxol treatment.	Paclitaxel	74-79	insulin like growth factor 2	Homo sapiens	10-14
18583944-4	2008	Taxol-treated oocytes exhibited a number of cytoplasmic asters, in which both Plk1 and p-MEK1/2 were present, indicating that they might be complexed to participate in the acentrosomal spindle formation at the MTOCs during oocyte meiosis.	Paclitaxel	0-5	polo like kinase 1	Mus musculus	78-82
24932685-10	2014	However, stable IGF2 knockdown using short-hairpin RNA in HEY-T30 effectively restored Taxol sensitivity.	Paclitaxel	87-92	insulin like growth factor 2	Homo sapiens	16-20
26579384-3	2014	Recent studies revealed increased paclitaxel sensitivity in the Mrp7(-/-) mouse model compared to their wild-type counterparts.	Paclitaxel	34-44	ATP-binding cassette, sub-family C (CFTR/MRP), member 10	Mus musculus	64-68
18483263-10	2008	injection of HSV after caspase-8 activation or paclitaxel-TRAIL pretreatment retards tumor growth, whereas HSV administration before tumor cell death induction did not improve therapeutic efficacy.	Paclitaxel	47-57	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	58-63
17701176-9	2008	CONCLUSION: Anti-VEGFR2 conjugated PLLA microspheres containing PTX may offer an effective way of administering a controlled release formulation of the drug to target prostate tumors.	Paclitaxel	64-67	kinase insert domain receptor	Homo sapiens	17-23
24726739-4	2014	Furthermore, linsitinib significantly increased the intracellular accumulation and decreased the efflux of [(3)H]-MX in ABCG2-overexpressing cells and [(3)H]-paclitaxel in ABCC10-overexpressing cells.	Paclitaxel	158-168	ATP binding cassette subfamily C member 10	Homo sapiens	172-178
18297677-1	2008	Retinoid X receptor (RXR) agonists (rexinoids) are attracting much attention for their use in treatment of cancers, including tamoxifen-resistant breast cancer and taxol-resistant lung cancer, and metabolic disease.	Paclitaxel	164-169	retinoid X receptor alpha	Homo sapiens	0-19
18297677-1	2008	Retinoid X receptor (RXR) agonists (rexinoids) are attracting much attention for their use in treatment of cancers, including tamoxifen-resistant breast cancer and taxol-resistant lung cancer, and metabolic disease.	Paclitaxel	164-169	retinoid X receptor alpha	Homo sapiens	21-24
24566899-6	2014	ARID1A depletion by small interfering RNA (siRNA) in H460 and H1299 cell lines promoted proliferation, colony formation ability, and inhibited paclitaxel-induced apoptosis.	Paclitaxel	143-153	AT-rich interaction domain 1A	Homo sapiens	0-6
18329083-0	2008	Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.	Paclitaxel	75-85	mucin 16, cell surface associated	Homo sapiens	26-32
24681884-5	2014	The results showed that over-expressed Smac significantly inhibited A549 cell invasive and cloning ability and promoted apoptosis following Taxol treatment.	Paclitaxel	140-145	diablo IAP-binding mitochondrial protein	Homo sapiens	39-43
18329083-2	2008	METHODS: A multicentric study of CA 125 kinetics under paclitaxel/platinum-based chemotherapy was performed in 130 stage IIc-IV patients.	Paclitaxel	55-65	mucin 16, cell surface associated	Homo sapiens	33-39
18329083-11	2008	CONCLUSION: Characteristics of CA 125 kinetics during first line paclitaxel/platinum chemotherapy have a strong and independent prognostic value.	Paclitaxel	65-75	mucin 16, cell surface associated	Homo sapiens	31-37
24585004-4	2014	Therefore, the combination of ERCC1 and Tau may be a valuable predictor of sensitivity to platinum/paclitaxel treatment.	Paclitaxel	99-109	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	30-35
17960378-5	2008	In marked contrast, deletion of p21 promoted apoptosis induction by imatinib and taxol in BCR-ABL-transformed BM cells.	Paclitaxel	81-86	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	32-35
17987264-2	2008	Treatment of cells with 1 microM all-trans retinoic acid (ATRA) or 1 microM 13-cis retinoic acid (13-CRA) for 7 days induced astrocytic differentiation, overexpression of glial fibrillary acidic protein (GFAP), and also down regulated telomerase expression and activity, thereby increased sensitivity to TXL for apoptosis.	Paclitaxel	304-307	myotubularin related protein 11	Homo sapiens	101-104
17987264-2	2008	Treatment of cells with 1 microM all-trans retinoic acid (ATRA) or 1 microM 13-cis retinoic acid (13-CRA) for 7 days induced astrocytic differentiation, overexpression of glial fibrillary acidic protein (GFAP), and also down regulated telomerase expression and activity, thereby increased sensitivity to TXL for apoptosis.	Paclitaxel	304-307	glial fibrillary acidic protein	Homo sapiens	171-202
17987264-8	2008	Taken together, our results suggested that retinoid (ATRA or 13-CRA) induced astrocytic differentiation with down regulation of telomerase activity to increase sensitivity to TXL to enhance apoptosis in glioblastoma cells.	Paclitaxel	175-178	myotubularin related protein 11	Homo sapiens	64-67
18297461-1	2008	OBJECTIVES: The present study was designed to determine whether adjuvant chemotherapy with paclitaxel (TXL) and carboplatin (CBDCA) after surgical resection is feasible in Japanese patients with non-small cell lung cancer (NSCLC) in a multiinstitutional trial.	Paclitaxel	91-101	thioredoxin like 1	Homo sapiens	103-106
24774218-10	2014	And, in cervical SCC patients after treatment with Taxol chemotherapy, the expression level of miR-143 was higher and the positive expression of bcl-2 protein was lower.	Paclitaxel	51-56	serpin family B member 3	Homo sapiens	17-20
24699359-10	2014	Two genes were functionally validated for association with drug response using siRNA: SMC1A with cisplatin response and ZNF569 with paclitaxel response.	Paclitaxel	132-142	structural maintenance of chromosomes 1A	Homo sapiens	86-91
18274935-3	2008	Besides the low solubility, the main reason for the limited oral bioavailability of paclitaxel is that it is a substrate of the efflux pump P-glycoprotein (P-gp).	Paclitaxel	84-94	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	140-154
18274935-3	2008	Besides the low solubility, the main reason for the limited oral bioavailability of paclitaxel is that it is a substrate of the efflux pump P-glycoprotein (P-gp).	Paclitaxel	84-94	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	156-160
18274935-10	2008	According to the achieved results, thiolated polymers are believed to be interesting tools for the delivery of P-gp substrates such as paclitaxel.	Paclitaxel	135-145	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	111-115
24529623-2	2014	In this study, we reported a drug delivery system where nanoparticles were decorated with EGFP-EGF1 (ENP), a fusion protein derived from factor VII with special affinity for tissue factor (TF) over-expressed in glioma tissues, to facilitate anti-glioma delivery of paclitaxel (PTX) by targeting both neovascular and glioma cells.	Paclitaxel	265-275	G elongation factor mitochondrial 1	Homo sapiens	90-99
18068629-0	2007	The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel.	Paclitaxel	107-117	transforming growth factor beta induced	Homo sapiens	33-38
24529623-2	2014	In this study, we reported a drug delivery system where nanoparticles were decorated with EGFP-EGF1 (ENP), a fusion protein derived from factor VII with special affinity for tissue factor (TF) over-expressed in glioma tissues, to facilitate anti-glioma delivery of paclitaxel (PTX) by targeting both neovascular and glioma cells.	Paclitaxel	265-275	centromere protein H	Mus musculus	101-104
17940013-0	2007	Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.	Paclitaxel	16-21	mesothelin	Mus musculus	62-72
24529623-2	2014	In this study, we reported a drug delivery system where nanoparticles were decorated with EGFP-EGF1 (ENP), a fusion protein derived from factor VII with special affinity for tissue factor (TF) over-expressed in glioma tissues, to facilitate anti-glioma delivery of paclitaxel (PTX) by targeting both neovascular and glioma cells.	Paclitaxel	277-280	G elongation factor mitochondrial 1	Homo sapiens	90-99
24529623-2	2014	In this study, we reported a drug delivery system where nanoparticles were decorated with EGFP-EGF1 (ENP), a fusion protein derived from factor VII with special affinity for tissue factor (TF) over-expressed in glioma tissues, to facilitate anti-glioma delivery of paclitaxel (PTX) by targeting both neovascular and glioma cells.	Paclitaxel	277-280	centromere protein H	Mus musculus	101-104
17940013-3	2007	We recently reported that Taxol and other chemotherapeutic agents show striking synergistic antitumor activity in mice when immunotoxin SS1P, which targets the mesothelin antigen on solid tumors, is given with Taxol.	Paclitaxel	26-31	mesothelin	Mus musculus	160-170
24529623-7	2014	Pharmacodynamic results revealed that PTX-loaded ENP (ENP-PTX) significantly prolonged the median survival time of glioma-bearing mice compared with that of any other group.	Paclitaxel	38-41	centromere protein H	Mus musculus	49-52
17940013-3	2007	We recently reported that Taxol and other chemotherapeutic agents show striking synergistic antitumor activity in mice when immunotoxin SS1P, which targets the mesothelin antigen on solid tumors, is given with Taxol.	Paclitaxel	210-215	mesothelin	Mus musculus	160-170
17940013-6	2007	We also show that the KB tumors have high levels of shed mesothelin in their extracellular space; these levels increase with tumor size and, after Taxol treatment, dramatically fall in the drug-sensitive but not the drug-resistant tumors.	Paclitaxel	147-152	mesothelin	Mus musculus	57-67
24529623-7	2014	Pharmacodynamic results revealed that PTX-loaded ENP (ENP-PTX) significantly prolonged the median survival time of glioma-bearing mice compared with that of any other group.	Paclitaxel	38-41	centromere protein H	Mus musculus	54-61
17940013-7	2007	Because the mesothelin levels in the tumor exceed the levels of SS1P in the tumor, and because shed mesothelin is being continuously released into the circulation at a high rate, we propose that synergy is due to the Taxol-induced fall in shed antigen levels.	Paclitaxel	217-222	mesothelin	Mus musculus	12-22
17940013-7	2007	Because the mesothelin levels in the tumor exceed the levels of SS1P in the tumor, and because shed mesothelin is being continuously released into the circulation at a high rate, we propose that synergy is due to the Taxol-induced fall in shed antigen levels.	Paclitaxel	217-222	mesothelin	Mus musculus	100-110
24826054-3	2014	We investigated the effects of paclitaxel combined with olaparib on apoptosis in breast cancer Bcap37 cells.	Paclitaxel	31-41	prohibitin 2	Homo sapiens	95-101
17681754-9	2007	Paclitaxel, which induces microtubular stabilization and polymerization, exerted the opposite effects on thrombin- and TG-evoked SOCE and coupling between IP(3)RII and hTRPC1 compared with colchicine.	Paclitaxel	0-10	transient receptor potential cation channel subfamily C member 1	Homo sapiens	168-174
24826054-6	2014	RESULTS: Compared with paclitaxel alone, paclitaxel combined with 100 mg olaparib significantly reduced survival in Bcap37 cells at all tested treatment durations (P&lt;0.05); inhibition increased with increasing olaparib dose and treatment time (P&lt;0.01).	Paclitaxel	41-51	prohibitin 2	Homo sapiens	116-122
24826054-11	2014	CONCLUSIONS: Our findings suggest that paclitaxel and olaparib inhibit breast cancer Bcap37 cell proliferation and induce apoptosis.	Paclitaxel	39-49	prohibitin 2	Homo sapiens	85-91
24606760-1	2014	BACKGROUND: Translationally controlled tumor protein (TCTP), alternatively called fortilin, is believed to be involved in the development of the chemoresistance of tumor cells against anticancer drugs such as etoposide, taxol, and oxaliplatin, the underlying mechanisms of which still remain elusive.	Paclitaxel	220-225	tumor protein, translationally-controlled 1	Homo sapiens	12-52
17786362-2	2007	We previously reported that the FASN blockade can induce a synergistic chemosensitization of breast cancer cells to microtubule interfering agents (MIAs) such as docetaxel, paclitaxel and vinorelbine.	Paclitaxel	173-183	fatty acid synthase	Homo sapiens	32-36
24606760-1	2014	BACKGROUND: Translationally controlled tumor protein (TCTP), alternatively called fortilin, is believed to be involved in the development of the chemoresistance of tumor cells against anticancer drugs such as etoposide, taxol, and oxaliplatin, the underlying mechanisms of which still remain elusive.	Paclitaxel	220-225	tumor protein, translationally-controlled 1	Homo sapiens	54-58
17537765-6	2007	Intravenously delivered taxol significantly reduced inflammatory histological changes in lung parenchyma and parameters of LPS-induced inflammation: infiltration of proteins and inflammatory cells into bronchoalveolar lavage fluid, lung myeloperoxidase activity, and extravasation of Evans blue-labelled albumin into lung tissue.	Paclitaxel	24-29	myeloperoxidase	Mus musculus	237-252
17581879-3	2007	We also observed a Taxol-specific reduction in neuronal calcium sensor 1 (NCS-1) protein levels, a known modulator of InsP(3) receptor (InsP(3)R) activity.	Paclitaxel	19-24	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	118-134
17581879-3	2007	We also observed a Taxol-specific reduction in neuronal calcium sensor 1 (NCS-1) protein levels, a known modulator of InsP(3) receptor (InsP(3)R) activity.	Paclitaxel	19-24	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	136-144
24606760-1	2014	BACKGROUND: Translationally controlled tumor protein (TCTP), alternatively called fortilin, is believed to be involved in the development of the chemoresistance of tumor cells against anticancer drugs such as etoposide, taxol, and oxaliplatin, the underlying mechanisms of which still remain elusive.	Paclitaxel	220-225	tumor protein, translationally-controlled 1	Homo sapiens	82-90
24606760-6	2014	RESULTS: In the present study, we confirmed that adenoviral overexpression of TCTP protects HeLa cells from cell death induced by cytotoxic drugs such as taxol and etoposide.	Paclitaxel	154-159	tumor protein, translationally-controlled 1	Homo sapiens	78-82
24361916-0	2014	Spinal gene expression profiling and pathways analysis of a CB2 agonist (MDA7)-targeted prevention of paclitaxel-induced neuropathy.	Paclitaxel	102-112	cannabinoid receptor 2	Rattus norvegicus	60-63
17366594-2	2007	METHODS: The authors performed an in vitro chemosensitivity test, ATP-CRA, to evaluate the chemosensitivities of anticancer drugs such as cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine, and vinorelbine for chemonaive, unresectable NSCLC.	Paclitaxel	162-172	myotubularin related protein 11	Homo sapiens	70-73
24361916-2	2014	We found that a novel selective cannabinoid CB2 receptor agonist (MDA7) prevents paclitaxel-induced mechanical allodynia in rats and mice.	Paclitaxel	81-91	cannabinoid receptor 2	Rattus norvegicus	44-56
24591819-10	2014	Underexpressed miRNAs in Taxol-sensitive cells included miR-497, miR-187, miR-195, and miR-107.	Paclitaxel	25-30	microRNA 187	Homo sapiens	65-72
17400210-0	2007	Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes.	Paclitaxel	50-60	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	14-19
17400210-1	2007	Paclitaxel (Taxol) has been successfully combined with the monoclonal antibody trastuzumab (Herceptin) in the treatment of ErbB2 overexpressing cancers.	Paclitaxel	0-10	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	123-128
24495785-0	2014	Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells.	Paclitaxel	29-39	tubulin alpha 1b	Homo sapiens	79-92
17400210-1	2007	Paclitaxel (Taxol) has been successfully combined with the monoclonal antibody trastuzumab (Herceptin) in the treatment of ErbB2 overexpressing cancers.	Paclitaxel	12-17	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	123-128
17673047-9	2007	The viability rate of HO8910-DCC cells was significantly lower than other two groups after (0.1 - 5.0) peak plasma concentration (PPC) of cisplatin and paclitaxel were given (P &lt; 0.01).	Paclitaxel	152-162	DCC netrin 1 receptor	Homo sapiens	29-32
24495785-3	2014	By Western blotting analysis, treatment of MCF7 cells with both PEITC and taxol led to a 10.4-fold and 5.96-fold increase in specific acetylation of alpha-tubulin over single agent PEITC and taxol, respectively.	Paclitaxel	74-79	tubulin alpha 1b	Homo sapiens	149-162
17673047-10	2007	The viability rate of HO8910-DCC cells was lower than other two groups after 10.0 PPC concentration of cisplatin was given (P &lt; 0.05), but there was no difference between them after 10.0 PPC concentration of paclitaxel was given (P &gt; 0.05).	Paclitaxel	211-221	DCC netrin 1 receptor	Homo sapiens	29-32
24495785-5	2014	The combination of PEITC and taxol also reduced expressions of cell cycle regulator Cdk1, and anti-apoptotic protein bcl-2, enhanced expression of Bax and cleavage of PARP proteins.	Paclitaxel	29-34	cyclin dependent kinase 1	Homo sapiens	84-88
24080340-5	2014	In the CD133(-) subpopulation, the exposure to taxol induced the activation of apoptosis signal-regulating kinase1 (ASK1)/c-jun-N-terminal kinase (JNK), p38, extracellular signal regulated kinase (ERK) pathways and Bax expression, while in CD133(+) cells taxol was able only to enhance the activity of the ERK pathway.	Paclitaxel	47-52	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	79-114
17892130-0	2007	[Technetium-99m labeled synaptotagmin I C2A detection of paclitaxel-induced apoptosis in non-small cell lung cancer].	Paclitaxel	57-67	synaptotagmin I	Mus musculus	24-39
24080340-5	2014	In the CD133(-) subpopulation, the exposure to taxol induced the activation of apoptosis signal-regulating kinase1 (ASK1)/c-jun-N-terminal kinase (JNK), p38, extracellular signal regulated kinase (ERK) pathways and Bax expression, while in CD133(+) cells taxol was able only to enhance the activity of the ERK pathway.	Paclitaxel	47-52	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	116-120
24621501-4	2014	In taxol- and nocodazole-exposed cells, phospho-Bcl-xL(Ser62) also binds to Cdc20- Mad2-, BubR1-, and Bub3-bound complexes, while Bcl-xL(Ser62Ala) does not.	Paclitaxel	3-8	mitotic arrest deficient 2 like 1	Homo sapiens	83-87
25343293-8	2014	In addition, co-treatment with paclitaxel and clusterin siRNA significantly enhanced PP2AC levels.	Paclitaxel	31-41	protein phosphatase 2 catalytic subunit alpha	Homo sapiens	85-90
25343293-9	2014	Taken together, these results indicate that clusterin plays a crucial role in PC3 cell proliferation and that clusterin depletion may contribute to enhanced sensitivity of PC3 cells to anticancer agents such as paclitaxel.	Paclitaxel	211-221	proprotein convertase subtilisin/kexin type 1	Homo sapiens	172-175
17326770-5	2007	Down-regulation of caveolin-1 by siRNA reduced the interaction between p-gp and caveolin-1, followed by a decrease in [3H]-Taxol and [3H]-Vinblastine accumulation in RBE4 cells.	Paclitaxel	123-128	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	71-75
24173825-0	2014	Caffeine inhibits paclitaxel-induced apoptosis in colorectal cancer cells through the upregulation of Mcl-1 levels.	Paclitaxel	18-28	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	102-107
24305604-3	2013	In this report, we investigate the cellular and molecular mechanism of paclitaxel-induced autophagy and apoptosis in renal cancer cells with and without FLCN expression.	Paclitaxel	71-81	folliculin	Homo sapiens	153-157
17210569-6	2007	Whereas CAR-expressing U87 glioma cells had decreased migration in a chemotactic assay in Boyden chambers as compared with control cells, an effect that depended on the presence of the cytoplasmic domain of CAR, the difference was abrogated at low, non-cytotoxic doses of the taxane paclitaxel, a microtubule-stabilizing agent.	Paclitaxel	283-293	CXADR Ig-like cell adhesion molecule	Homo sapiens	8-11
17210569-6	2007	Whereas CAR-expressing U87 glioma cells had decreased migration in a chemotactic assay in Boyden chambers as compared with control cells, an effect that depended on the presence of the cytoplasmic domain of CAR, the difference was abrogated at low, non-cytotoxic doses of the taxane paclitaxel, a microtubule-stabilizing agent.	Paclitaxel	283-293	CXADR Ig-like cell adhesion molecule	Homo sapiens	207-210
24305604-8	2013	RESULTS: After paclitaxel treatment, a dose-dependent decrease in cell viability and increase in apoptosis were observed in FLCN-deficient UOK257 and ACHN-5968 cells compared to their FLCN-expressing counterparts, suggesting that renal cancer cells without FLCN were more sensitive to paclitaxel.	Paclitaxel	15-25	folliculin	Homo sapiens	124-128
19690636-3	2007	To address if BRCA1 expression plays a role in the chemotherapeutic response, we analyzed the effect of BRCA1 suppression on the sensitivity to cisplatin and paclitaxel in ovarian cancer cells.	Paclitaxel	158-168	BRCA1 DNA repair associated	Homo sapiens	104-109
24305604-8	2013	RESULTS: After paclitaxel treatment, a dose-dependent decrease in cell viability and increase in apoptosis were observed in FLCN-deficient UOK257 and ACHN-5968 cells compared to their FLCN-expressing counterparts, suggesting that renal cancer cells without FLCN were more sensitive to paclitaxel.	Paclitaxel	15-25	folliculin	Homo sapiens	184-188
24305604-8	2013	RESULTS: After paclitaxel treatment, a dose-dependent decrease in cell viability and increase in apoptosis were observed in FLCN-deficient UOK257 and ACHN-5968 cells compared to their FLCN-expressing counterparts, suggesting that renal cancer cells without FLCN were more sensitive to paclitaxel.	Paclitaxel	15-25	folliculin	Homo sapiens	184-188
17465210-4	2007	We hypothesized that pretreatment of ovarian cancer SKOV-3 cells at a non-cytotoxic to sublethal dose range of paclitaxel would result in increased sensitivity to LAK-mediated killing.	Paclitaxel	111-121	alpha kinase 1	Homo sapiens	163-166
24305604-8	2013	RESULTS: After paclitaxel treatment, a dose-dependent decrease in cell viability and increase in apoptosis were observed in FLCN-deficient UOK257 and ACHN-5968 cells compared to their FLCN-expressing counterparts, suggesting that renal cancer cells without FLCN were more sensitive to paclitaxel.	Paclitaxel	285-295	folliculin	Homo sapiens	124-128
17465210-9	2007	Pretreatment of SKOV-3 cells with paclitaxel at these doses for 72 h revealed significantly enhanced LAK-mediated killing against SKOV-3 cells with the highest sensitivity achieved with cells treated with 0.001 microM paclitaxel, as compared with the baseline killing of untreated cells using LAK cell alone (p &lt; 0.05).	Paclitaxel	34-44	alpha kinase 1	Homo sapiens	101-104
24305604-12	2013	Furthermore, after inhibition of autophagy with 3-Methyladenine (3-MA) or Beclin 1 siRNA, apoptosis induced by paclitaxel was significantly increased in FLCN-deficient UOK257 and ACHN-5968 cells.	Paclitaxel	111-121	folliculin	Homo sapiens	153-157
17465210-9	2007	Pretreatment of SKOV-3 cells with paclitaxel at these doses for 72 h revealed significantly enhanced LAK-mediated killing against SKOV-3 cells with the highest sensitivity achieved with cells treated with 0.001 microM paclitaxel, as compared with the baseline killing of untreated cells using LAK cell alone (p &lt; 0.05).	Paclitaxel	34-44	alpha kinase 1	Homo sapiens	293-296
17465210-9	2007	Pretreatment of SKOV-3 cells with paclitaxel at these doses for 72 h revealed significantly enhanced LAK-mediated killing against SKOV-3 cells with the highest sensitivity achieved with cells treated with 0.001 microM paclitaxel, as compared with the baseline killing of untreated cells using LAK cell alone (p &lt; 0.05).	Paclitaxel	218-228	alpha kinase 1	Homo sapiens	101-104
24097825-7	2013	Importantly, binding of endogenous Bcl-2 to Bim also increased during mitosis, when Bcl-2 is endogenously phosphorylated, and disruption of this mitotic Bcl-2/Bim binding with navitoclax or ABT-199, like Bcl-2 downregulation, enhanced the cytotoxicity of paclitaxel.	Paclitaxel	255-265	BCL2 like 11	Homo sapiens	44-47
17465210-9	2007	Pretreatment of SKOV-3 cells with paclitaxel at these doses for 72 h revealed significantly enhanced LAK-mediated killing against SKOV-3 cells with the highest sensitivity achieved with cells treated with 0.001 microM paclitaxel, as compared with the baseline killing of untreated cells using LAK cell alone (p &lt; 0.05).	Paclitaxel	218-228	alpha kinase 1	Homo sapiens	293-296
17465210-10	2007	The enhanced sensitivity of LAK-mediated killing appeared to be in part due to paclitaxel-induced expression of ICAM-1 on SKOV-3 cells.	Paclitaxel	79-89	alpha kinase 1	Homo sapiens	28-31
17465210-10	2007	The enhanced sensitivity of LAK-mediated killing appeared to be in part due to paclitaxel-induced expression of ICAM-1 on SKOV-3 cells.	Paclitaxel	79-89	intercellular adhesion molecule 1	Homo sapiens	112-118
24097825-7	2013	Importantly, binding of endogenous Bcl-2 to Bim also increased during mitosis, when Bcl-2 is endogenously phosphorylated, and disruption of this mitotic Bcl-2/Bim binding with navitoclax or ABT-199, like Bcl-2 downregulation, enhanced the cytotoxicity of paclitaxel.	Paclitaxel	255-265	BCL2 like 11	Homo sapiens	159-162
24026433-0	2013	Nanoparticulate paclitaxel demonstrates antitumor activity in PC3 and Ace-1 aggressive prostate cancer cell lines.	Paclitaxel	16-26	proprotein convertase subtilisin/kexin type 1	Homo sapiens	62-65
24263099-8	2013	In addition, Bortezomib antagonizes Taxol-mediated degradation of MCL-1 during mitotic arrest by preventing cells to enter mitosis and by inhibiting the proteasome.	Paclitaxel	36-41	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	66-71
17242698-7	2007	Moreover, ZOL acted synergistically in vitro when administered concurrently with paclitaxel (PAC) or gemcitabine (GEM), not only in wild-type osteosarcoma cells but also in P-glycoprotein (P-gp)-overexpressing osteosarcoma cells, which were much less sensitive against each anticancer agent.	Paclitaxel	81-91	phosphoglycolate phosphatase	Mus musculus	173-187
17242698-7	2007	Moreover, ZOL acted synergistically in vitro when administered concurrently with paclitaxel (PAC) or gemcitabine (GEM), not only in wild-type osteosarcoma cells but also in P-glycoprotein (P-gp)-overexpressing osteosarcoma cells, which were much less sensitive against each anticancer agent.	Paclitaxel	93-96	phosphoglycolate phosphatase	Mus musculus	173-187
17234772-10	2007	Overexpression of enhanced green fluorescent protein-tagged ANK reduces SNCG-mediated resistance to paclitaxel treatment by approximately 3.5-fold.	Paclitaxel	100-110	ankyrin 1	Homo sapiens	60-63
17159505-3	2007	Using the SNU-719 gastric cancer cell line, which is naturally infected with Epstein-Barr virus, we found that the chemotherapeutic agents, such as 5-fluorouracil, cis-platinum and taxol, induced the expressions of BMRF1, BZLF1 and BRLF1 proteins that are usually found in the lytic form of the virus.	Paclitaxel	181-186	BRLF1	Human gammaherpesvirus 4	232-237
24263099-9	2013	Downregulation of MCL-1 is critically required for Taxol-induced apoptosis, as overexpression of a phosphomutant MCL-1 variant, which is resistant to degradation, significantly diminishes Taxol-triggered apoptosis.	Paclitaxel	51-56	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	18-23
2906526-9	1988	The change in cellular morphology induced by colchicine, nocodozole and taxol was proportional to the extensiveness and the degree of change of the vimentin network.	Paclitaxel	72-77	vimentin	Macaca fascicularis	148-156
24263099-9	2013	Downregulation of MCL-1 is critically required for Taxol-induced apoptosis, as overexpression of a phosphomutant MCL-1 variant, which is resistant to degradation, significantly diminishes Taxol-triggered apoptosis.	Paclitaxel	51-56	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	113-118
24263099-9	2013	Downregulation of MCL-1 is critically required for Taxol-induced apoptosis, as overexpression of a phosphomutant MCL-1 variant, which is resistant to degradation, significantly diminishes Taxol-triggered apoptosis.	Paclitaxel	188-193	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	18-23
17291255-2	2007	We conducted an optimal-dose determination of combination chemotherapy consisting of paclitaxel (TXL), doxorubicin, and carboplatin (CBDCA) (TAC) in patients with endometrial cancer.	Paclitaxel	85-95	thioredoxin like 1	Homo sapiens	97-100
17009338-1	2006	It was reported that paclitaxel is an inhibitor of hepatic P-glycoprotein (P-gp) and hepatic microsomal cytochrome P450 (CYP) 3A1/2, and that naringin is an inhibitor of biliary P-gp and CYP3A1/2 in rats.	Paclitaxel	21-31	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	59-73
17009338-1	2006	It was reported that paclitaxel is an inhibitor of hepatic P-glycoprotein (P-gp) and hepatic microsomal cytochrome P450 (CYP) 3A1/2, and that naringin is an inhibitor of biliary P-gp and CYP3A1/2 in rats.	Paclitaxel	21-31	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	75-79
2879622-8	1987	Similar elevation of both nonexchangeable and exchangeable VP-16 by 10 microM vincristine and maytansine was observed; however, 50-100 microM podophyllotoxin or taxol was required for comparable elevation of exchangeable drug with no increase of nonexchangeable VP-16.	Paclitaxel	161-166	host cell factor C1	Homo sapiens	262-267
24263099-9	2013	Downregulation of MCL-1 is critically required for Taxol-induced apoptosis, as overexpression of a phosphomutant MCL-1 variant, which is resistant to degradation, significantly diminishes Taxol-triggered apoptosis.	Paclitaxel	188-193	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	113-118
24263099-10	2013	Vice versa, attenuation of Bortezomib-mediated accumulation of MCL-1 by knockdown of MCL-1 significantly enhances Taxol/Bortezomib-induced apoptosis.	Paclitaxel	114-119	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	63-68
24263099-10	2013	Vice versa, attenuation of Bortezomib-mediated accumulation of MCL-1 by knockdown of MCL-1 significantly enhances Taxol/Bortezomib-induced apoptosis.	Paclitaxel	114-119	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	85-90
16534613-2	2006	METHODS: Cisplatin- and paclitaxel-resistant HeLa sublines (HeLa/CDDP and HeLa/TXL, respectively) were established by continuous exposure and their cellular changes were examined based on growth inhibition assays, the transport activity of P-glycoprotein/MDR1, and a RT-PCR analysis of MDR-related factors.	Paclitaxel	24-34	thioredoxin like 1	Homo sapiens	79-82
24263099-11	2013	Thus, Bortezomib rescues Taxol-induced apoptosis by inhibiting G2/M transition and mitigating MCL-1 degradation.	Paclitaxel	25-30	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	94-99
24002547-16	2013	Bcl-2, Bax, Procaspase-3 and P-gp are involved in the resistance of cell lines to PTX, which are invaluable tools to study the resistance of anticancer drugs and to identify the methods to overcome resistance.	Paclitaxel	82-85	phosphoglycolate phosphatase	Homo sapiens	29-33
16995873-2	2006	In accordance with previous reports, taxol and cisplatin resistance was closely correlated with expression of the multidrug resistance 1 and bile acid export pump, and multidrug resistance-associated protein 2 genes, respectively.	Paclitaxel	37-42	ATP binding cassette subfamily C member 2	Homo sapiens	168-209
6114100-6	1981	Similarly, when incompetent tubulin was induced to polymerize by preincubation with purified microtubule-associated protein 2 (an assembly-promoting protein) or taxol, the initial rate of its detyrosinolation increased 3-5-fold, and this increase was blocked if podophyllotoxin was also added along with microtubule-associated protein 2 or taxol during the preincubation.	Paclitaxel	161-166	microtubule associated protein 2	Homo sapiens	304-336
24042845-0	2013	An oncolytic adenovirus expressing interleukin-24 enhances antitumor activities in combination with paclitaxel in breast cancer cells.	Paclitaxel	100-110	interleukin 24	Homo sapiens	35-49
33739449-1	2021	Through our involvement in KEYNOTE-059, we unexpectedly observed durable responses in two patients with metastatic gastroesophageal adenocarcinoma (mGEA) who received ramucirumab (anti-VEGFR-2)/paclitaxel after immune checkpoint inhibition (ICI).	Paclitaxel	194-204	MIA SH3 domain ER export factor 2	Mus musculus	148-152
16950615-0	2006	Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel.	Paclitaxel	120-130	TIMP metallopeptidase inhibitor 3	Homo sapiens	0-39
16950615-4	2006	In combination treatment, we found that adenovirus-mediated expression of TIMP-3 greatly sensitised prostate cancer cells to chemotherapeutic drug paclitaxel, indicating a superadditive or synergistic effect of TIMP-3 and cytostatic treatment on prostate cancer cell death.	Paclitaxel	147-157	TIMP metallopeptidase inhibitor 3	Homo sapiens	74-80
17077358-13	2006	CONCLUSIONS: EA5 in combination with paclitaxel decreased tumor growth in an orthotopic ovarian cancer mouse model through antiangiogenic mechanisms associated with reduced levels of VEGF and phosphorylated Src.	Paclitaxel	37-47	vascular endothelial growth factor A	Mus musculus	183-187
24042845-8	2013	Annexin V-fluorescein isothiocyanate/propidium iodide staining and the Hoechst 33258 assay indicated that ZD55-IL-24 induced an increase in the number of apoptotic cells when administered in combination with PTX.	Paclitaxel	208-211	interleukin 24	Homo sapiens	111-116
17062689-1	2006	PURPOSE: P-glycoprotein (P-gp; ABCB1) efficiently transports lipophilic amphipathic drugs, including the widely used anticancer drug paclitaxel (Taxol).	Paclitaxel	133-143	phosphoglycolate phosphatase	Mus musculus	9-23
34022910-0	2021	Circular RNA circ_0006168 enhances Taxol resistance in esophageal squamous cell carcinoma by regulating miR-194-5p/JMJD1C axis.	Paclitaxel	35-40	jumonji domain containing 1C	Mus musculus	115-121
34022910-12	2021	Functionally, knockdown of circ_0006168 or JMJD1C increased Taxol sensitivity of ESCC in vitro via inhibiting cell proliferation, migration and invasion, and promoting apoptosis.	Paclitaxel	60-65	jumonji domain containing 1C	Mus musculus	43-49
24042845-9	2013	It was demonstrated that ZD55-IL-24 conjugated with PTX was highly concomitant, and increased proapoptotic proteins levels, activated caspase-3, -7 and -9 and downregulated anti-apoptotic proteins.	Paclitaxel	52-55	interleukin 24	Homo sapiens	30-35
34022910-15	2021	Furthermore, JMJD1C overexpression reversed the promotive effect of circ_0006168 knockdown on Taxol sensitivity.	Paclitaxel	94-99	jumonji domain containing 1C	Mus musculus	13-19
34022910-17	2021	CONCLUSION: Circ_0006168 facilitated Taxol resistance in ESCC by regulating miR-194-5p/JMJD1C axis, providing a promising therapeutic target for ESCC chemotherapy.	Paclitaxel	37-42	jumonji domain containing 1C	Mus musculus	87-93
17062689-1	2006	PURPOSE: P-glycoprotein (P-gp; ABCB1) efficiently transports lipophilic amphipathic drugs, including the widely used anticancer drug paclitaxel (Taxol).	Paclitaxel	133-143	phosphoglycolate phosphatase	Mus musculus	25-29
24042845-10	2013	These results suggested that ZD55-IL-24 in combination with PTX exhibited a markedly increased cytotoxic and apoptosis-inducing effect in breast cancer cells.	Paclitaxel	60-63	interleukin 24	Homo sapiens	34-39
17062689-1	2006	PURPOSE: P-glycoprotein (P-gp; ABCB1) efficiently transports lipophilic amphipathic drugs, including the widely used anticancer drug paclitaxel (Taxol).	Paclitaxel	145-150	phosphoglycolate phosphatase	Mus musculus	9-23
23726937-0	2013	Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy.	Paclitaxel	120-130	C-C motif chemokine ligand 2	Homo sapiens	13-47
17062689-1	2006	PURPOSE: P-glycoprotein (P-gp; ABCB1) efficiently transports lipophilic amphipathic drugs, including the widely used anticancer drug paclitaxel (Taxol).	Paclitaxel	145-150	phosphoglycolate phosphatase	Mus musculus	25-29
17062689-2	2006	We found previously that human multidrug resistance protein 2 (MRP2; ABCC2) also transports paclitaxel in vitro, and although we expected that paclitaxel pharmacokinetics would be dominated by P-gp, the effect of Mrp2 was tested in vivo.	Paclitaxel	92-102	ATP binding cassette subfamily C member 2	Homo sapiens	31-61
17062689-2	2006	We found previously that human multidrug resistance protein 2 (MRP2; ABCC2) also transports paclitaxel in vitro, and although we expected that paclitaxel pharmacokinetics would be dominated by P-gp, the effect of Mrp2 was tested in vivo.	Paclitaxel	92-102	ATP binding cassette subfamily C member 2	Homo sapiens	63-67
17062689-2	2006	We found previously that human multidrug resistance protein 2 (MRP2; ABCC2) also transports paclitaxel in vitro, and although we expected that paclitaxel pharmacokinetics would be dominated by P-gp, the effect of Mrp2 was tested in vivo.	Paclitaxel	92-102	ATP binding cassette subfamily C member 2	Homo sapiens	69-74
17062689-2	2006	We found previously that human multidrug resistance protein 2 (MRP2; ABCC2) also transports paclitaxel in vitro, and although we expected that paclitaxel pharmacokinetics would be dominated by P-gp, the effect of Mrp2 was tested in vivo.	Paclitaxel	143-153	ATP binding cassette subfamily C member 2	Homo sapiens	31-61
17062689-2	2006	We found previously that human multidrug resistance protein 2 (MRP2; ABCC2) also transports paclitaxel in vitro, and although we expected that paclitaxel pharmacokinetics would be dominated by P-gp, the effect of Mrp2 was tested in vivo.	Paclitaxel	143-153	ATP binding cassette subfamily C member 2	Homo sapiens	63-67
17062689-2	2006	We found previously that human multidrug resistance protein 2 (MRP2; ABCC2) also transports paclitaxel in vitro, and although we expected that paclitaxel pharmacokinetics would be dominated by P-gp, the effect of Mrp2 was tested in vivo.	Paclitaxel	143-153	ATP binding cassette subfamily C member 2	Homo sapiens	69-74
17062689-8	2006	In spite of this similar effect, Mrp2 and P-gp had mostly complementary functions in paclitaxel elimination.	Paclitaxel	85-95	phosphoglycolate phosphatase	Mus musculus	42-46
34009327-0	2021	Uncomfortably numb: how Nav1.7 mediates paclitaxel-induced peripheral neuropathy.	Paclitaxel	40-50	NUMB endocytic adaptor protein	Homo sapiens	14-18
34009327-0	2021	Uncomfortably numb: how Nav1.7 mediates paclitaxel-induced peripheral neuropathy.	Paclitaxel	40-50	sodium voltage-gated channel alpha subunit 9	Homo sapiens	24-30
33966046-4	2021	In our pursuit to understand the impact of chemokine signaling in carcinogenesis, we reveal that instead of CXCR4-CXCL12 signaling, presence of CXCR4 intracellular protein augments paclitaxel resistance and pro-tumorigenic functions.	Paclitaxel	181-191	C-X-C motif chemokine receptor 4	Homo sapiens	144-149
23726937-0	2013	Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy.	Paclitaxel	120-130	C-C motif chemokine ligand 2	Homo sapiens	49-54
23726937-4	2013	Direct application of MCP-1 consistently induced intracellular calcium increases in dorsal root ganglia large and medium-sized neurons but not in small neurons mainly dissociated from paclitaxel-treated but not vehicle-treated animals.	Paclitaxel	184-194	C-C motif chemokine ligand 2	Homo sapiens	22-27
33966046-9	2021	Irrespective of CXCR4 surface expression, by utilizing stable gain and loss of function approaches, we observe that intracellular CXCR4 protein selectively resists and sensitizes colon cancer cells against paclitaxel therapy in vitro and in vivo.	Paclitaxel	206-216	C-X-C motif chemokine receptor 4	Homo sapiens	130-135
23726937-5	2013	Paclitaxel also induced increased expression of MCP-1 in spinal astrocytes, but no CCR2 signal was detected in the spinal cord.	Paclitaxel	0-10	C-C motif chemokine ligand 2	Homo sapiens	48-53
17018783-12	2006	Human neuroblastoma SH-EP cells transfected with gamma-actin siRNA displayed higher relative resistance to paclitaxel (P&lt;.001), vinblastine (P = .04), and epothilone B (P = .045) than mock-transfected cells.	Paclitaxel	107-117	actin, gamma, cytoplasmic 1	Mus musculus	49-60
24273886-6	2013	The results showed that paclitaxel detoxified in the single-transfected MDCK-MDR1 cell because of P-gp efflux.	Paclitaxel	24-34	PGP	Canis lupus familiaris	98-102
23108393-5	2013	We report that Sgk1-dependent regulation of RANBP1 has functional consequences on both mitotic microtubule activity and taxol sensitivity of cancer cells.	Paclitaxel	120-125	RAN binding protein 1	Homo sapiens	44-50
16876126-1	2006	The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and paclitaxel.	Paclitaxel	161-171	ATP binding cassette subfamily C member 2	Homo sapiens	62-67
33447878-6	2021	Paclitaxel prevented the delocalization of PLVAP by the inhibition of integrin alpha5beta1.	Paclitaxel	0-10	plasmalemma vesicle associated protein	Rattus norvegicus	43-48
16876126-1	2006	The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and paclitaxel.	Paclitaxel	161-171	ATP binding cassette subfamily C member 2	Homo sapiens	69-73
23966160-2	2013	Here we show that, in cells arrested in mitosis with the spindle toxins, nocodazole, or paclitaxel, the endogenous protein phosphatase 4 (Ppp4) complex Ppp4c-R2-R3A is phosphorylated on its regulatory (R) subunits, and its activity is inhibited.	Paclitaxel	88-98	protein phosphatase 4 catalytic subunit	Homo sapiens	115-136
16876126-1	2006	The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and paclitaxel.	Paclitaxel	161-171	ATP binding cassette subfamily C member 2	Homo sapiens	74-79
33996534-9	2021	Our case demonstrated a favorable clinical activity and survival advantage of the combined cisplatin and nanoparticle albumin-bound paclitaxel, which might serve as a therapeutic option for the patient with BRCA-mutant pancreatic SCC.	Paclitaxel	132-142	BRCA1 DNA repair associated	Homo sapiens	207-211
16854522-4	2006	Intravenous infusion of paclitaxel induced a significant increase of ATF3 in mainly but not exclusively large and medium sensory neurons in all sensory ganglia.	Paclitaxel	24-34	activating transcription factor 3	Rattus norvegicus	69-73
23966160-2	2013	Here we show that, in cells arrested in mitosis with the spindle toxins, nocodazole, or paclitaxel, the endogenous protein phosphatase 4 (Ppp4) complex Ppp4c-R2-R3A is phosphorylated on its regulatory (R) subunits, and its activity is inhibited.	Paclitaxel	88-98	protein phosphatase 4 catalytic subunit	Homo sapiens	138-142
16854522-5	2006	An increase in both GFAP immunofluorescence in satellite cells and the number of activated macrophages occurred in lumbar&gt;thoracic&gt;trigeminal ganglia of paclitaxel-treated rats.	Paclitaxel	159-169	glial fibrillary acidic protein	Rattus norvegicus	20-24
33876384-0	2021	Tenascin C Promotes Glioma Cell Malignant Behavior and Inhibits Chemosensitivity to Paclitaxel via Activation of the PI3K/AKT Signaling Pathway.	Paclitaxel	84-94	tenascin C	Homo sapiens	0-10
33876384-1	2021	The present study aimed to detect the effect of tenascin C (TNC) on cell function and chemosensitivity to paclitaxel and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signaling in glioma cells.Human glioma cells U87, LN-229, T98G and U251 and normal human astrocytes were obtained, in which TNC expression was detected.	Paclitaxel	106-116	tenascin C	Homo sapiens	48-58
23966160-2	2013	Here we show that, in cells arrested in mitosis with the spindle toxins, nocodazole, or paclitaxel, the endogenous protein phosphatase 4 (Ppp4) complex Ppp4c-R2-R3A is phosphorylated on its regulatory (R) subunits, and its activity is inhibited.	Paclitaxel	88-98	protein phosphatase 4 catalytic subunit	Homo sapiens	152-164
33876384-1	2021	The present study aimed to detect the effect of tenascin C (TNC) on cell function and chemosensitivity to paclitaxel and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signaling in glioma cells.Human glioma cells U87, LN-229, T98G and U251 and normal human astrocytes were obtained, in which TNC expression was detected.	Paclitaxel	106-116	tenascin C	Homo sapiens	60-63
33876384-3	2021	Rescue experiments were then performed to evaluate the effect of PI3K/AKT activator 740 Y-P on cell function and chemosensitivity to paclitaxel in TNC knockdown U251 cells.	Paclitaxel	133-143	tenascin C	Homo sapiens	147-150
33876384-7	2021	As for chemosensitivity, TNC increased relative viability in U251 cells treated with 400 ng/mL and 800 ng/mL paclitaxel.	Paclitaxel	109-119	tenascin C	Homo sapiens	25-28
33876384-9	2021	In rescue experiments, 740 Y-P reduced the effect of TNC on proliferation, apoptosis, chemosensitivity to paclitaxel, and stemness in U251 cells.	Paclitaxel	106-116	tenascin C	Homo sapiens	53-56
33876384-10	2021	TNC acts as an oncogenic factor by promoting cancer cell proliferation and stemness while inhibiting apoptosis and chemosensitivity to paclitaxel in glioma via modulation of PI3K/AKT signaling.	Paclitaxel	135-145	tenascin C	Homo sapiens	0-3
33846536-2	2021	Herein, we found that USP24 not only repressed DNA-damage repair (DDR) activity by decreasing Rad51 expression to cause the tumor genomic instability and cancer stemness, but also increased the levels of the ATP-binding cassette (ABC) transporters P-gp, ABCG2, and ezrin to enhance the pumping out of Taxol from cancer cells, thus resulted in drug resistance during cancer therapy.	Paclitaxel	301-306	RAD51 recombinase	Homo sapiens	94-99
33987391-0	2021	TGFBI is involved in the formation of polyploid cancer cells and the response to paclitaxel.	Paclitaxel	81-91	transforming growth factor beta induced	Homo sapiens	0-5
33987391-10	2021	Compared with the empty vector, under paclitaxel treatment, the over-expression of TGFBI in MDA-MB-231 and T-MDA-MB-231 both showed a higher growth inhibition rate.	Paclitaxel	38-48	transforming growth factor beta induced	Homo sapiens	83-88
33987391-13	2021	Conclusions: TGFBI can increase the sensitivity of paclitaxel in polyploid cancer cells and participate in the formation of polyploidy in MDA-MB-231 induced by nocodazole.	Paclitaxel	51-61	transforming growth factor beta induced	Homo sapiens	13-18
33756128-7	2021	The results of the present study revealed a strong positive association between miR-155-5p expression levels and the paclitaxel resistance, as the expression levels of miR-155-5p were upregulated in resistant cells.	Paclitaxel	117-127	microRNA 155	Homo sapiens	80-87
33756128-8	2021	MiR-155-5p was further validated to regulate paclitaxel resistance using gain- and loss-of-function experiments.	Paclitaxel	45-55	microRNA 155	Homo sapiens	0-7
33756128-10	2021	Also, miR-155-5p was suggested to be a key regulator of paclitaxel resistance in tumor cells, as it increased cell viability and motility, and promoted resistance to paclitaxel-induced apoptosis.	Paclitaxel	56-66	microRNA 155	Homo sapiens	6-13
33756128-10	2021	Also, miR-155-5p was suggested to be a key regulator of paclitaxel resistance in tumor cells, as it increased cell viability and motility, and promoted resistance to paclitaxel-induced apoptosis.	Paclitaxel	166-176	microRNA 155	Homo sapiens	6-13
33756128-11	2021	The transfection with miR-155-5p inhibitors re-sensitized the paclitaxel-resistant breast cancer cells, while the overexpression of miR-155-5p led to an increase in the resistance to paclitaxel.	Paclitaxel	62-72	microRNA 155	Homo sapiens	22-29
33756128-11	2021	The transfection with miR-155-5p inhibitors re-sensitized the paclitaxel-resistant breast cancer cells, while the overexpression of miR-155-5p led to an increase in the resistance to paclitaxel.	Paclitaxel	183-193	microRNA 155	Homo sapiens	22-29
33756128-11	2021	The transfection with miR-155-5p inhibitors re-sensitized the paclitaxel-resistant breast cancer cells, while the overexpression of miR-155-5p led to an increase in the resistance to paclitaxel.	Paclitaxel	183-193	microRNA 155	Homo sapiens	132-139
33756128-13	2021	The subsequent combination of the knockdown of miR-155-5p and the overexpression of TP53INP1 conferred paclitaxel sensitivity in resistant cells.	Paclitaxel	103-113	microRNA 155	Homo sapiens	47-54
33739080-3	2021	We revealed that beta-tubulin III, androgen receptor, and CXCR4 expressions were significantly increased in LNCaP/PTX cells and directly contributed to PTX resistance and EMT.	Paclitaxel	114-117	C-X-C motif chemokine receptor 4	Homo sapiens	58-63
33739080-3	2021	We revealed that beta-tubulin III, androgen receptor, and CXCR4 expressions were significantly increased in LNCaP/PTX cells and directly contributed to PTX resistance and EMT.	Paclitaxel	152-155	C-X-C motif chemokine receptor 4	Homo sapiens	58-63
33734317-0	2021	Paclitaxel increases axonal localization and vesicular trafficking of Nav1.7.	Paclitaxel	0-10	sodium voltage-gated channel alpha subunit 9	Homo sapiens	70-76
33734317-3	2021	However, the mechanisms underlying this increased NaV1.7 expression have not been explored, and the effects of PTX treatment on the dynamics of trafficking and localization of NaV1.7 channels in sensory axons have not been possible to investigate to date.	Paclitaxel	111-114	sodium voltage-gated channel alpha subunit 9	Homo sapiens	176-182
33734317-5	2021	We demonstrate concentration- and time-dependent effects of PTX on vesicular trafficking and membrane localization of NaV1.7 in real-time in sensory axons.	Paclitaxel	60-63	sodium voltage-gated channel alpha subunit 9	Homo sapiens	118-124
33734317-9	2021	Treatment with PTX increased levels of endogenous NaV1.7 mRNA and current density in DRG neurons.	Paclitaxel	15-18	sodium voltage-gated channel alpha subunit 9	Homo sapiens	50-56
33734317-11	2021	Taken together, this suggests that the increased trafficking and surface localization of Halo-NaV1.7 that we observed by live imaging in tranfected DRG neurons after treatment with PTX might be independent of an increased pool of NaV1.7 channels.	Paclitaxel	181-184	sodium voltage-gated channel alpha subunit 9	Homo sapiens	94-100
33734317-12	2021	After exposure to inflammatory mediators (IM) to mimic the inflammatory condition seen during chemotherapy, both NaV1.7 surface levels and vesicular transport are increased for both low and high concentrations of PTX.	Paclitaxel	213-216	sodium voltage-gated channel alpha subunit 9	Homo sapiens	113-119
33734317-13	2021	Overall, our results show that PTX treatment increases levels of functional endogenous NaV1.7 channels in DRG neurons and enhances trafficking and surface distribution of NaV1.7 in sensory axons, with outcomes that depend on the presence of an inflammatory milieu, providing a mechanistic explanation for increased excitability of primary afferents and pain in CIPN.	Paclitaxel	31-34	sodium voltage-gated channel alpha subunit 9	Homo sapiens	87-93
33859743-13	2021	DRD2 also promoted BrCa cells sensitivity to Paclitaxel.	Paclitaxel	45-55	BRCA1 DNA repair associated	Homo sapiens	19-23
33156701-0	2021	lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-kappaB Signaling Pathway.	Paclitaxel	20-30	remodeling and spacing factor 1	Homo sapiens	80-84
33402387-0	2021	Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma.	Paclitaxel	56-66	S100 calcium binding protein A9	Homo sapiens	20-26
33402387-3	2021	Transcriptome analysis of paclitaxel-sensitive and -resistant cell lines, as well as chemorefractory clinical samples identified S100A9 as the top candidate gene suppressed by pacritinib and whose overexpression was significantly associated with paclitaxel resistance and poor clinical outcome.	Paclitaxel	246-256	S100 calcium binding protein A9	Homo sapiens	129-135
33599261-0	2021	Nanog-mediated stem cell properties is critical for MBNL3 associated paclitaxel resistance of ovarian cancer.	Paclitaxel	69-79	Nanog homeobox	Homo sapiens	0-5
33599261-0	2021	Nanog-mediated stem cell properties is critical for MBNL3 associated paclitaxel resistance of ovarian cancer.	Paclitaxel	69-79	muscleblind like splicing regulator 3	Homo sapiens	52-57
33599261-5	2021	Cancer cell viability, apoptosis, spheroids formation, Nanog gene silencing were examined and conducted to dissect the underlying mechanism of MBNL3-mediated PTX-resistance.	Paclitaxel	158-161	muscleblind like splicing regulator 3	Homo sapiens	143-148
33599261-6	2021	High expression of MBNL3 was positively correlated with PTX-resistance and poor prognosis of ovarian cancer.	Paclitaxel	56-59	muscleblind like splicing regulator 3	Homo sapiens	19-24
33599261-8	2021	This study suggests the MBNL3-Nanog axis is a therapeutic target for the treatment of PTX-resistance in ovarian cancer management.	Paclitaxel	86-89	muscleblind like splicing regulator 3	Homo sapiens	24-29
33599261-8	2021	This study suggests the MBNL3-Nanog axis is a therapeutic target for the treatment of PTX-resistance in ovarian cancer management.	Paclitaxel	86-89	Nanog homeobox	Homo sapiens	30-35
33594306-5	2021	This study aimed to explore the regulatory effect of FMNT/miR-199a-3p/mTOR pathway on Taxol resistance and autophagy in breast cancer (BC).	Paclitaxel	86-91	microRNA 199a-2	Homo sapiens	58-69
33594306-6	2021	MiR-199a-3p, mTOR, LC3 and other autophagy related proteins were detected in Taxol sensitive and Taxol resistant TNBC cell lines, which were MDA-MB-231 and MDA-MB-231/Taxol, respectively.	Paclitaxel	77-82	microRNA 199a-2	Homo sapiens	0-11
33594306-6	2021	MiR-199a-3p, mTOR, LC3 and other autophagy related proteins were detected in Taxol sensitive and Taxol resistant TNBC cell lines, which were MDA-MB-231 and MDA-MB-231/Taxol, respectively.	Paclitaxel	77-82	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	19-22
33594306-6	2021	MiR-199a-3p, mTOR, LC3 and other autophagy related proteins were detected in Taxol sensitive and Taxol resistant TNBC cell lines, which were MDA-MB-231 and MDA-MB-231/Taxol, respectively.	Paclitaxel	97-102	microRNA 199a-2	Homo sapiens	0-11
33594306-6	2021	MiR-199a-3p, mTOR, LC3 and other autophagy related proteins were detected in Taxol sensitive and Taxol resistant TNBC cell lines, which were MDA-MB-231 and MDA-MB-231/Taxol, respectively.	Paclitaxel	97-102	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	19-22
33594306-6	2021	MiR-199a-3p, mTOR, LC3 and other autophagy related proteins were detected in Taxol sensitive and Taxol resistant TNBC cell lines, which were MDA-MB-231 and MDA-MB-231/Taxol, respectively.	Paclitaxel	97-102	microRNA 199a-2	Homo sapiens	0-11
33594306-6	2021	MiR-199a-3p, mTOR, LC3 and other autophagy related proteins were detected in Taxol sensitive and Taxol resistant TNBC cell lines, which were MDA-MB-231 and MDA-MB-231/Taxol, respectively.	Paclitaxel	97-102	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	19-22
33594306-14	2021	Moreover, oral administration of FMNT and Taxol suppressed autophagy and Taxol resistance by restoring mTOR protein level to that of the parent MDA-MB-231, suggesting that miR-199a-3p can severe as a new target to overcome Taxol resistance in TNBC.	Paclitaxel	42-47	microRNA 199a-2	Homo sapiens	172-183
33594306-14	2021	Moreover, oral administration of FMNT and Taxol suppressed autophagy and Taxol resistance by restoring mTOR protein level to that of the parent MDA-MB-231, suggesting that miR-199a-3p can severe as a new target to overcome Taxol resistance in TNBC.	Paclitaxel	73-78	microRNA 199a-2	Homo sapiens	172-183
33594306-14	2021	Moreover, oral administration of FMNT and Taxol suppressed autophagy and Taxol resistance by restoring mTOR protein level to that of the parent MDA-MB-231, suggesting that miR-199a-3p can severe as a new target to overcome Taxol resistance in TNBC.	Paclitaxel	73-78	microRNA 199a-2	Homo sapiens	172-183
32579788-0	2021	Targeting Wnt/beta-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer.	Paclitaxel	70-80	catenin (cadherin associated protein), beta 1	Mus musculus	14-26
32579788-8	2021	Stabilization of beta-catenin level by Wnt activator lithium chloride (LiCl) significantly abolishes the inhibitory effects of niclosamide in inhibiting proliferation and survival but not suppressing phosphorylation of STAT3 and 70S6K in paclitaxel-resistant esophageal cancer cells, suggesting that niclosamide sensitizes esophageal cancer cell to paclitaxel mainly through inhibiting Wnt/beta-catenin.	Paclitaxel	238-248	catenin (cadherin associated protein), beta 1	Mus musculus	17-29
32579788-8	2021	Stabilization of beta-catenin level by Wnt activator lithium chloride (LiCl) significantly abolishes the inhibitory effects of niclosamide in inhibiting proliferation and survival but not suppressing phosphorylation of STAT3 and 70S6K in paclitaxel-resistant esophageal cancer cells, suggesting that niclosamide sensitizes esophageal cancer cell to paclitaxel mainly through inhibiting Wnt/beta-catenin.	Paclitaxel	349-359	catenin (cadherin associated protein), beta 1	Mus musculus	17-29
33665229-0	2021	Molecular subtyping and functional validation of TTK, TPX2, UBE2C, and LRP8 in sensitivity of TNBC to paclitaxel.	Paclitaxel	102-112	TPX2 microtubule nucleation factor	Homo sapiens	54-58
33519462-8	2020	Mechanistically, CPEB4 binds with the taxol (paclitaxel)-resistance-associated gene-3 (TRAG-3/CSAG2) mRNAs and induces its expression at a translational level.	Paclitaxel	45-55	CSAG family member 2	Homo sapiens	87-93
33519462-8	2020	Mechanistically, CPEB4 binds with the taxol (paclitaxel)-resistance-associated gene-3 (TRAG-3/CSAG2) mRNAs and induces its expression at a translational level.	Paclitaxel	45-55	CSAG family member 2	Homo sapiens	94-99
33519462-9	2020	Moreover, CSAG2 expression is upregulated in paclitaxel-resistant ovarian carcinoma and cancer cell lines, and more importantly, siRNA-mediated CSAG2 knockdown overtly attenuates CPEB4-mediated paclitaxel resistance.	Paclitaxel	45-55	CSAG family member 2	Homo sapiens	10-15
33519462-9	2020	Moreover, CSAG2 expression is upregulated in paclitaxel-resistant ovarian carcinoma and cancer cell lines, and more importantly, siRNA-mediated CSAG2 knockdown overtly attenuates CPEB4-mediated paclitaxel resistance.	Paclitaxel	194-204	CSAG family member 2	Homo sapiens	144-149
33519462-10	2020	Conclusion: This study suggests that the drug-resistant protein CSAG2 is translationally induced by CPEB4, which underlies CPEB4-promoted paclitaxel resistance in ovarian cancer in vitro.	Paclitaxel	138-148	CSAG family member 2	Homo sapiens	64-69
33519462-11	2020	Thus, interfering CPEB4/CSAG2 axis might be of benefit to overcome paclitaxel-resistant ovarian cancer.	Paclitaxel	67-77	CSAG family member 2	Homo sapiens	24-29
33436648-8	2021	Subsequent cDNA array analysis confirmed multiple PI3K-AKT pathway members such as AKT2, PIK3R3, CDKN1A, CCND2 and FGF2 to be upregulated in PTX-resistant cells.	Paclitaxel	141-144	phosphoinositide-3-kinase regulatory subunit 3	Homo sapiens	89-95
33461170-8	2021	We also demonstrated that treatment with fluorouracil, carboplatin, paclitaxel, and doxorubicin resulted in decreased expression of CCDC167 and suppressed growth of MCF-7 cells.	Paclitaxel	68-78	coiled-coil domain containing 167	Homo sapiens	132-139
32988253-10	2021	TFs such as FOXA2, NFE2L2, as well as miRNAs like has-miR-508-3p and has-miR-584 also played role in the paclitaxel treatment.	Paclitaxel	105-115	microRNA 584	Homo sapiens	73-80
33051852-3	2021	Here, we showed that systemic administration of the chemotherapeutic drug paclitaxel significantly and time-dependently increased the levels of cyclic AMP response element-binding protein (CREB) in dorsal root ganglion (DRG) neurons.	Paclitaxel	74-84	cAMP responsive element binding protein 1	Homo sapiens	189-193
33051852-4	2021	Blocking this increase through DRG microinjection of Creb siRNA attenuated paclitaxel-induced mechanical, heat, and cold nociceptive hypersensitivities.	Paclitaxel	75-85	cAMP responsive element binding protein 1	Homo sapiens	53-57
33051852-5	2021	Mimicking this increase through DRG microinjection of the adeno-associated virus 5 expressing full-length Creb mRNA led to enhanced responses to basal mechanical, heat, and cold stimuli in mice in absence of paclitaxel treatment.	Paclitaxel	208-218	cAMP responsive element binding protein 1	Homo sapiens	106-110
33552853-0	2021	Improved Antiglioblastoma Activity and BBB Permeability by Conjugation of Paclitaxel to a Cell-Penetrative MMP-2-Cleavable Peptide.	Paclitaxel	74-84	matrix metallopeptidase 2	Mus musculus	107-112
33552853-2	2021	In this study, SynB3-PVGLIG-PTX is designed and screened out by matrix metalloproteinase-2 (MMP-2), to which it exhibits the best affinity.	Paclitaxel	28-31	matrix metallopeptidase 2	Mus musculus	64-90
33552853-2	2021	In this study, SynB3-PVGLIG-PTX is designed and screened out by matrix metalloproteinase-2 (MMP-2), to which it exhibits the best affinity.	Paclitaxel	28-31	matrix metallopeptidase 2	Mus musculus	92-97
33552853-4	2021	Moreover, as a drug-peptide nanocomplex, SynB3-PVGLIG-PTX exhibited a high potential to form an aggregation with good solubility that can release paclitaxel (PTX) through the cleavage of MMP-2.	Paclitaxel	54-57	matrix metallopeptidase 2	Mus musculus	187-192
33552853-4	2021	Moreover, as a drug-peptide nanocomplex, SynB3-PVGLIG-PTX exhibited a high potential to form an aggregation with good solubility that can release paclitaxel (PTX) through the cleavage of MMP-2.	Paclitaxel	146-156	matrix metallopeptidase 2	Mus musculus	187-192
33552853-4	2021	Moreover, as a drug-peptide nanocomplex, SynB3-PVGLIG-PTX exhibited a high potential to form an aggregation with good solubility that can release paclitaxel (PTX) through the cleavage of MMP-2.	Paclitaxel	158-161	matrix metallopeptidase 2	Mus musculus	187-192
33552853-5	2021	From a functional perspective, it is found that SynB3-PVGLIG-PTX can specifically inhibit the proliferation, migration, and invasion of GBM cells in vitro in the presence of MMP-2, in contrast to that observed in MMP-2 siRNA transfected cells.	Paclitaxel	61-64	matrix metallopeptidase 2	Mus musculus	174-179
33323915-10	2020	RESULTS Paclitaxel restored downregulated expression of nephrin and synaptopodin and upregulated VEGF expression after injury induced by palmitate.	Paclitaxel	8-18	nephrosis 1, nephrin	Mus musculus	56-63
33323915-10	2020	RESULTS Paclitaxel restored downregulated expression of nephrin and synaptopodin and upregulated VEGF expression after injury induced by palmitate.	Paclitaxel	8-18	vascular endothelial growth factor A	Mus musculus	97-101
33323915-17	2020	The paclitaxel effects were accompanied by inhibition of the inflammatory cytokines, MCP-1, TNF-alpha, TNF-R2, and TLR4, as well as attenuation of the apoptosis markers, Bax, Bcl-2, and Caspase-3.	Paclitaxel	4-14	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	103-109
33323915-17	2020	The paclitaxel effects were accompanied by inhibition of the inflammatory cytokines, MCP-1, TNF-alpha, TNF-R2, and TLR4, as well as attenuation of the apoptosis markers, Bax, Bcl-2, and Caspase-3.	Paclitaxel	4-14	BCL2-associated X protein	Mus musculus	170-173
33323915-17	2020	The paclitaxel effects were accompanied by inhibition of the inflammatory cytokines, MCP-1, TNF-alpha, TNF-R2, and TLR4, as well as attenuation of the apoptosis markers, Bax, Bcl-2, and Caspase-3.	Paclitaxel	4-14	caspase 3	Mus musculus	186-195
33363381-0	2020	UBE2N Regulates Paclitaxel Sensitivity of Ovarian Cancer via Fos/P53 Axis.	Paclitaxel	16-26	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	61-64
33363381-5	2020	The MTT assay was applied to observe the effect of UBE2N expression on paclitaxel sensitivity.	Paclitaxel	71-81	ubiquitin-conjugating enzyme E2N	Mus musculus	51-56
33363381-13	2020	Only Fos proto-oncogene, AP-1 transcription factor subunit (Fos), was overexpressed upon decreasing UBE2N levels, indicating a poor outcome for patients treated with paclitaxel.	Paclitaxel	166-176	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	5-8
33363381-13	2020	Only Fos proto-oncogene, AP-1 transcription factor subunit (Fos), was overexpressed upon decreasing UBE2N levels, indicating a poor outcome for patients treated with paclitaxel.	Paclitaxel	166-176	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	25-29
33363381-13	2020	Only Fos proto-oncogene, AP-1 transcription factor subunit (Fos), was overexpressed upon decreasing UBE2N levels, indicating a poor outcome for patients treated with paclitaxel.	Paclitaxel	166-176	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	60-63
33363381-15	2020	Furthermore, reversed regulation of Fos and P53 based on UBE2N reduction could reverse paclitaxel sensitivity, respectively.	Paclitaxel	87-97	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	36-39
33692661-7	2020	Due to vascular and stromal contributions, differences in the response of vascularized tumors to Taxol (shrinkage and CD44 expression) are apparent compared with simpler models.	Paclitaxel	97-102	CD44 molecule (Indian blood group)	Homo sapiens	118-122
33255409-0	2020	Increased FOXM1 Expression by Cisplatin Inhibits Paclitaxel-Related Apoptosis in Cisplatin-Resistant Human Oral Squamous Cell Carcinoma (OSCC) Cell Lines.	Paclitaxel	49-59	forkhead box M1	Homo sapiens	10-15
33255409-6	2020	Cisplatin-induced overexpression of FOXM1 showed the same trend only in cisplatin-resistant cell lines, indicating that it was associated with inhibition of paclitaxel-related apoptosis.	Paclitaxel	157-167	forkhead box M1	Homo sapiens	36-41
33023532-13	2020	Treatment with cisplatin or paclitaxel significantly elevated the expression of TIMP-2 in Cont cells but not in T2-KD cells, consistent with significantly elevated expression of chemoresistance and CSC markers and activation of STAT3.	Paclitaxel	28-38	TIMP metallopeptidase inhibitor 2	Homo sapiens	80-86
33043814-10	2020	Furthermore, the expression of STAT1, PD-1, and PD-L1 was lower in paclitaxel-resistant cells than sensitive cells.	Paclitaxel	67-77	signal transducer and activator of transcription 1	Homo sapiens	31-36
33043814-12	2020	These findings suggest that STAT1, PD-1, and PD-L1 are the tissue markers of EOC and imply the possibility that the high level of STAT1, PD-1, and PD-L1 may favor the checkpoint immunotherapy in patients with EOC, but may have a limit in paclitaxel-resistant patients because of the low expression of STAT1, PD-1, and PD-L1 in paclitaxel-resistant cells.	Paclitaxel	238-248	signal transducer and activator of transcription 1	Homo sapiens	130-135
33043814-12	2020	These findings suggest that STAT1, PD-1, and PD-L1 are the tissue markers of EOC and imply the possibility that the high level of STAT1, PD-1, and PD-L1 may favor the checkpoint immunotherapy in patients with EOC, but may have a limit in paclitaxel-resistant patients because of the low expression of STAT1, PD-1, and PD-L1 in paclitaxel-resistant cells.	Paclitaxel	238-248	signal transducer and activator of transcription 1	Homo sapiens	130-135
33043814-12	2020	These findings suggest that STAT1, PD-1, and PD-L1 are the tissue markers of EOC and imply the possibility that the high level of STAT1, PD-1, and PD-L1 may favor the checkpoint immunotherapy in patients with EOC, but may have a limit in paclitaxel-resistant patients because of the low expression of STAT1, PD-1, and PD-L1 in paclitaxel-resistant cells.	Paclitaxel	327-337	signal transducer and activator of transcription 1	Homo sapiens	130-135
33043814-12	2020	These findings suggest that STAT1, PD-1, and PD-L1 are the tissue markers of EOC and imply the possibility that the high level of STAT1, PD-1, and PD-L1 may favor the checkpoint immunotherapy in patients with EOC, but may have a limit in paclitaxel-resistant patients because of the low expression of STAT1, PD-1, and PD-L1 in paclitaxel-resistant cells.	Paclitaxel	327-337	signal transducer and activator of transcription 1	Homo sapiens	130-135
32861273-0	2020	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.	Paclitaxel	31-41	BRCA1 DNA repair associated	Homo sapiens	45-49
32847971-3	2020	Paclitaxel (2 mg/kg, i.p., cumulative dose 8mg/kg) induced long-lasting mechanical allodynia (> 28days) with increased glutamate concentration and decreased EAAT2 expression with no changes in GABA/glycine or VGAT (vesicular GABA transporter) in rat spinal dorsal horn.	Paclitaxel	0-10	solute carrier family 6 member 12	Rattus norvegicus	209-213
33061608-11	2020	Furthermore, circNRIP1 sponged miR-211-5p, and miR-211-5p inhibitor could reverse the inhibitory effect of circNRIP1 knockdown on the PTX resistance of OC cells.	Paclitaxel	134-137	microRNA 211	Homo sapiens	47-54
33061608-12	2020	In addition, miR-211-5p targeted HOXC8, and HOXC8 overexpression could reverse the suppression effect of miR-211-5p on the PTX resistance of OC cells.	Paclitaxel	123-126	microRNA 211	Homo sapiens	13-20
33061608-12	2020	In addition, miR-211-5p targeted HOXC8, and HOXC8 overexpression could reverse the suppression effect of miR-211-5p on the PTX resistance of OC cells.	Paclitaxel	123-126	microRNA 211	Homo sapiens	105-112
33061608-14	2020	Conclusion: CircNRIP1 silencing could inhibit the PTX resistance of OC via regulating the miR-211-5p/HOXC8 axis, showing that circNRIP1 might be a potential target for OC resistance treatment.	Paclitaxel	50-53	microRNA 211	Homo sapiens	90-97
33061425-0	2020	Paclitaxel Suppresses Hepatocellular Carcinoma Tumorigenesis Through Regulating Circ-BIRC6/miR-877-5p/YWHAZ Axis.	Paclitaxel	0-10	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Homo sapiens	102-107
33061425-12	2020	Paclitaxel treatment inhibited the expression of circ-BIRC6 and YWHAZ while promoted the expression of miR-877-5p.	Paclitaxel	0-10	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Homo sapiens	64-69
33061425-17	2020	Conclusion: Paclitaxel limited HCC tumorigenesis via modulating circ-BIRC6/miR-877-5p/YWHAZ axis, providing a novel therapeutic approach for the treatment of HCC.	Paclitaxel	12-22	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Homo sapiens	86-91
32615282-3	2020	Consistently, GCN2 knockdown severely impaired the clonal survival of parental and resistant MCF-7 cells and sensitised them to epirubicin and paclitaxel treatment.	Paclitaxel	143-153	eukaryotic translation initiation factor 2 alpha kinase 4	Homo sapiens	14-18
32943934-9	2020	Notably, moxibustion combined with paclitaxel inhibited the angiogenesis of tumors through the downregulation of CD34, HIF-1alpha, and VEGFA, and overcame the immunosuppressive microenvironment by inhibiting the PD-1/PD-L1 signaling pathway.	Paclitaxel	35-45	vascular endothelial growth factor A	Mus musculus	135-140
33042272-0	2020	Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.	Paclitaxel	85-95	histone deacetylase 9	Homo sapiens	10-15
33042272-6	2020	Results: MEF2-interacting transcriptional repressor (MITR), the truncated isoform of histone deacetylase 9 (HDAC9) lacking the deacetylation domain, was enriched in paclitaxel-resistant cells.	Paclitaxel	165-175	histone deacetylase 9	Homo sapiens	9-51
33042272-6	2020	Results: MEF2-interacting transcriptional repressor (MITR), the truncated isoform of histone deacetylase 9 (HDAC9) lacking the deacetylation domain, was enriched in paclitaxel-resistant cells.	Paclitaxel	165-175	histone deacetylase 9	Homo sapiens	53-57
33042272-6	2020	Results: MEF2-interacting transcriptional repressor (MITR), the truncated isoform of histone deacetylase 9 (HDAC9) lacking the deacetylation domain, was enriched in paclitaxel-resistant cells.	Paclitaxel	165-175	histone deacetylase 9	Homo sapiens	85-106
33042272-6	2020	Results: MEF2-interacting transcriptional repressor (MITR), the truncated isoform of histone deacetylase 9 (HDAC9) lacking the deacetylation domain, was enriched in paclitaxel-resistant cells.	Paclitaxel	165-175	histone deacetylase 9	Homo sapiens	108-113
33042272-8	2020	Mechanistically, MITR counteracted MEF2A-induced transcriptional suppression of IL11, ultimately causing paclitaxel resistance.	Paclitaxel	105-115	histone deacetylase 9	Homo sapiens	17-21
33042272-10	2020	Conclusion: Our in vitro and in vivo genetic and cellular analyses elucidated the pivotal role of MITR/MEF2A/IL11 axis in paclitaxel resistance and provided a novel therapeutic strategy for TNBC patients to overcome poor chemotherapy responses.	Paclitaxel	122-132	histone deacetylase 9	Homo sapiens	98-102
32529265-0	2020	Kappa opioid receptors mediate an initial aversive component of paclitaxel-induced neuropathy.	Paclitaxel	64-74	opioid receptor kappa 1	Homo sapiens	0-22
32529265-5	2020	The contributions of KOR signaling to paclitaxel-induced aversive-like state and CIPN in rodents remain to be explored.	Paclitaxel	38-48	opioid receptor kappa 1	Homo sapiens	21-24
32529265-6	2020	OBJECTIVES: We aimed to investigate whether dysregulation of the KOR/dynorphin system is associated with paclitaxel-mediated pain-like behavior and depression-like behavior.	Paclitaxel	105-115	opioid receptor kappa 1	Homo sapiens	65-68
32529265-11	2020	Paclitaxel treatment increased the levels of mRNA for prodynorphin, a precursor for endogenous KOR agonists, in the NAc.	Paclitaxel	0-10	opioid receptor kappa 1	Homo sapiens	95-98
32529265-12	2020	Paclitaxel also had time-dependent effects on KOR-mediated G protein activation in the NAc.	Paclitaxel	0-10	opioid receptor kappa 1	Homo sapiens	46-49
32529265-13	2020	CONCLUSIONS: These results suggest that KOR signaling mediates an initial aversive component of paclitaxel, but not necessarily paclitaxel-induced mechanical hypersensitivity.	Paclitaxel	96-106	opioid receptor kappa 1	Homo sapiens	40-43
32984343-3	2020	Previous, we uncovered that the Bruton"s tyrosine kinase (BTK) inhibitor ibrutinib is a potent reversal agent to overcomes paclitaxel resistance in ABCB1-overexpressing cells and tumors.	Paclitaxel	123-133	Bruton tyrosine kinase	Homo sapiens	32-56
32984343-3	2020	Previous, we uncovered that the Bruton"s tyrosine kinase (BTK) inhibitor ibrutinib is a potent reversal agent to overcomes paclitaxel resistance in ABCB1-overexpressing cells and tumors.	Paclitaxel	123-133	Bruton tyrosine kinase	Homo sapiens	58-61
32995483-7	2020	To augment CAR T cell activity against intraperitoneal tumors, combinations with paclitaxel or CAR activation-dependent interleukin (IL)-12 release were explored and found to significantly increase anti-tumor activity and survival benefit.	Paclitaxel	81-91	nuclear receptor subfamily 1 group I member 3	Homo sapiens	11-14
32913503-10	2020	Immunohistochemical staining demonstrated that SPR064 and paclitaxel significantly reduced the expression of Ki-67 and BCL-xL in the endometrial tumors of both obese and lean mice.	Paclitaxel	58-68	antigen identified by monoclonal antibody Ki 67	Mus musculus	109-114
32782439-0	2020	Long non-coding RNA SNHG6 regulates the sensitivity of prostate cancer cells to paclitaxel by sponging miR-186.	Paclitaxel	80-90	small nucleolar RNA host gene 6	Homo sapiens	20-25
32782439-3	2020	We aim to survey the role and underlying molecular mechanism of SNHG6 in PCa resistance to paclitaxel (PTX).	Paclitaxel	91-101	small nucleolar RNA host gene 6	Homo sapiens	64-69
32782439-3	2020	We aim to survey the role and underlying molecular mechanism of SNHG6 in PCa resistance to paclitaxel (PTX).	Paclitaxel	103-106	small nucleolar RNA host gene 6	Homo sapiens	64-69
32782439-10	2020	SNHG6 knockdown elevated PTX-resistant PCa cells sensitivity to PTX in vitro and in vivo, and repressed proliferation, migration, and invasion of PTX-resistant PCa cells in vitro.	Paclitaxel	25-28	small nucleolar RNA host gene 6	Homo sapiens	0-5
32782439-10	2020	SNHG6 knockdown elevated PTX-resistant PCa cells sensitivity to PTX in vitro and in vivo, and repressed proliferation, migration, and invasion of PTX-resistant PCa cells in vitro.	Paclitaxel	64-67	small nucleolar RNA host gene 6	Homo sapiens	0-5
32782439-10	2020	SNHG6 knockdown elevated PTX-resistant PCa cells sensitivity to PTX in vitro and in vivo, and repressed proliferation, migration, and invasion of PTX-resistant PCa cells in vitro.	Paclitaxel	64-67	small nucleolar RNA host gene 6	Homo sapiens	0-5
32782439-12	2020	Furthermore, miR-186 downregulation reversed SNHG6 silencing-mediated cell sensitivity to PTX, proliferation, migration, and invasion in PTX-resistant PCa cells.	Paclitaxel	90-93	small nucleolar RNA host gene 6	Homo sapiens	45-50
32782439-12	2020	Furthermore, miR-186 downregulation reversed SNHG6 silencing-mediated cell sensitivity to PTX, proliferation, migration, and invasion in PTX-resistant PCa cells.	Paclitaxel	137-140	small nucleolar RNA host gene 6	Homo sapiens	45-50
32782439-13	2020	Conclusions: SNHG6 knockdown elevated the sensitivity of PTX-resistant PCa cells to PTX by sponging miR-186, indicating that SNHG6 might be a therapeutic target for PCa.	Paclitaxel	57-60	small nucleolar RNA host gene 6	Homo sapiens	13-18
32782439-13	2020	Conclusions: SNHG6 knockdown elevated the sensitivity of PTX-resistant PCa cells to PTX by sponging miR-186, indicating that SNHG6 might be a therapeutic target for PCa.	Paclitaxel	57-60	small nucleolar RNA host gene 6	Homo sapiens	125-130
32782439-13	2020	Conclusions: SNHG6 knockdown elevated the sensitivity of PTX-resistant PCa cells to PTX by sponging miR-186, indicating that SNHG6 might be a therapeutic target for PCa.	Paclitaxel	84-87	small nucleolar RNA host gene 6	Homo sapiens	13-18
32782439-13	2020	Conclusions: SNHG6 knockdown elevated the sensitivity of PTX-resistant PCa cells to PTX by sponging miR-186, indicating that SNHG6 might be a therapeutic target for PCa.	Paclitaxel	84-87	small nucleolar RNA host gene 6	Homo sapiens	125-130
32848393-3	2020	We have reported that flavokawain A (FKA) inhibited P-gp protein expression in PTX-resistant A549 (A549/T) cells, indicating that FKA combined with PTX may reverse PTX resistance.	Paclitaxel	79-82	phosphoglycolate phosphatase	Mus musculus	52-56
32848393-3	2020	We have reported that flavokawain A (FKA) inhibited P-gp protein expression in PTX-resistant A549 (A549/T) cells, indicating that FKA combined with PTX may reverse PTX resistance.	Paclitaxel	148-151	phosphoglycolate phosphatase	Mus musculus	52-56
32848393-3	2020	We have reported that flavokawain A (FKA) inhibited P-gp protein expression in PTX-resistant A549 (A549/T) cells, indicating that FKA combined with PTX may reverse PTX resistance.	Paclitaxel	148-151	phosphoglycolate phosphatase	Mus musculus	52-56
32848393-8	2020	Synergistic effects and reversed PTX resistance were achieved by the combination of PTX-A NPs and FKA-A NPs by inhibiting P-gp expression in tumor cells.	Paclitaxel	33-36	phosphoglycolate phosphatase	Mus musculus	122-126
32535103-0	2020	0FF0DTargeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1.	Paclitaxel	29-39	glucose-6-phosphate dehydrogenase	Homo sapiens	15-19
32535103-4	2020	In this study, we demonstrated that the oxidative pentose phosphate pathway (PPP) enzyme glucose-6-phosphate dehydrogenase (G6PD) promotes paclitaxel resistance.	Paclitaxel	139-149	glucose-6-phosphate dehydrogenase	Homo sapiens	89-122
32535103-4	2020	In this study, we demonstrated that the oxidative pentose phosphate pathway (PPP) enzyme glucose-6-phosphate dehydrogenase (G6PD) promotes paclitaxel resistance.	Paclitaxel	139-149	glucose-6-phosphate dehydrogenase	Homo sapiens	124-128
32535103-5	2020	We showed that G6PD expression was higher in paclitaxel-resistant cancer cells than in their paclitaxel-sensitive counterparts.	Paclitaxel	45-55	glucose-6-phosphate dehydrogenase	Homo sapiens	15-19
32535103-5	2020	We showed that G6PD expression was higher in paclitaxel-resistant cancer cells than in their paclitaxel-sensitive counterparts.	Paclitaxel	93-103	glucose-6-phosphate dehydrogenase	Homo sapiens	15-19
32535103-6	2020	Furthermore, we demonstrated that suppressing G6PD using shRNA, or an inhibitor, either as single agents or in combination, sensitized paclitaxel-resistant cancer cells to paclitaxel treatment and thereby improving the therapeutic efficacy of paclitaxel.	Paclitaxel	135-145	glucose-6-phosphate dehydrogenase	Homo sapiens	46-50
32535103-6	2020	Furthermore, we demonstrated that suppressing G6PD using shRNA, or an inhibitor, either as single agents or in combination, sensitized paclitaxel-resistant cancer cells to paclitaxel treatment and thereby improving the therapeutic efficacy of paclitaxel.	Paclitaxel	172-182	glucose-6-phosphate dehydrogenase	Homo sapiens	46-50
32535103-6	2020	Furthermore, we demonstrated that suppressing G6PD using shRNA, or an inhibitor, either as single agents or in combination, sensitized paclitaxel-resistant cancer cells to paclitaxel treatment and thereby improving the therapeutic efficacy of paclitaxel.	Paclitaxel	172-182	glucose-6-phosphate dehydrogenase	Homo sapiens	46-50
32535103-7	2020	Interestingly, we found that the upregulation of G6PD in paclitaxel-resistant cells was due to the decreased expression of protein arginine methyltransferase 6 (PRMT6), which targets the promoter of G6PD.	Paclitaxel	57-67	glucose-6-phosphate dehydrogenase	Homo sapiens	49-53
32535103-7	2020	Interestingly, we found that the upregulation of G6PD in paclitaxel-resistant cells was due to the decreased expression of protein arginine methyltransferase 6 (PRMT6), which targets the promoter of G6PD.	Paclitaxel	57-67	glucose-6-phosphate dehydrogenase	Homo sapiens	199-203
32535103-8	2020	We further identified that G6PD promotes paclitaxel resistance by regulating the expression of glutathione S-transferase P1 (GSTP1), which confers resistance to chemotherapy by detoxifying several anticancer drugs.	Paclitaxel	41-51	glucose-6-phosphate dehydrogenase	Homo sapiens	27-31
32535103-9	2020	Taken together, our results suggest that G6PD serves as a novel potential target to overcome paclitaxel resistance.	Paclitaxel	93-103	glucose-6-phosphate dehydrogenase	Homo sapiens	41-45
32211849-3	2020	The aberrant upregulation of long non-coding RNA succinate dehydrogenase complex flavoprotein subunit A pseudogene1 (lncRNA SDHAP1) in the Paclitaxel (PTX)-resistant ovarian cancer cell lines has been reported.	Paclitaxel	139-149	SDHA pseudogene 1	Homo sapiens	49-115
32211849-3	2020	The aberrant upregulation of long non-coding RNA succinate dehydrogenase complex flavoprotein subunit A pseudogene1 (lncRNA SDHAP1) in the Paclitaxel (PTX)-resistant ovarian cancer cell lines has been reported.	Paclitaxel	139-149	SDHA pseudogene 1	Homo sapiens	124-130
32211849-3	2020	The aberrant upregulation of long non-coding RNA succinate dehydrogenase complex flavoprotein subunit A pseudogene1 (lncRNA SDHAP1) in the Paclitaxel (PTX)-resistant ovarian cancer cell lines has been reported.	Paclitaxel	151-154	SDHA pseudogene 1	Homo sapiens	49-115
32211849-3	2020	The aberrant upregulation of long non-coding RNA succinate dehydrogenase complex flavoprotein subunit A pseudogene1 (lncRNA SDHAP1) in the Paclitaxel (PTX)-resistant ovarian cancer cell lines has been reported.	Paclitaxel	151-154	SDHA pseudogene 1	Homo sapiens	124-130
32211849-5	2020	In this study, we demonstrated that SDHAP1 was upregulated in PTX-resistant SKOV3 and Hey-8 ovarian cancer cell lines while the level of miR-4465 was down-regulated.	Paclitaxel	62-65	SDHA pseudogene 1	Homo sapiens	36-42
32211849-6	2020	Knocking-down SDHAP1 induced re-acquirement of chemo-sensitivity to PTX in ovarian cancer cells in vitro.	Paclitaxel	68-71	SDHA pseudogene 1	Homo sapiens	14-20
32211849-7	2020	Mechanically, SDHAP1 upregulated the expression of EIF4G2 by sponging miR-4465 and thus facilitated the PTX-induced apoptosis in ovarian cancer cells.	Paclitaxel	104-107	SDHA pseudogene 1	Homo sapiens	14-20
32211849-8	2020	The regulation network involving SDHAP1, miR-4465 and EIF4G2 could be a potential therapy target for the PTX-resistant ovarian cancer.	Paclitaxel	105-108	SDHA pseudogene 1	Homo sapiens	33-39
32211849-8	2020	The regulation network involving SDHAP1, miR-4465 and EIF4G2 could be a potential therapy target for the PTX-resistant ovarian cancer.	Paclitaxel	105-108	microRNA 4465	Homo sapiens	41-49
32724113-5	2020	The organoid that harboured the BRCA1 pathogenic variant (p.L63*) showed a higher sensitivity to PARP inhibitor, olaparib, as well as to platinum drugs compared to the other organoids, whereas an organoid derived from clear cell ovarian cancer was resistant to conventional drugs for ovarian cancer, namely platinum drugs, paclitaxel, and olaparib.	Paclitaxel	323-333	BRCA1 DNA repair associated	Homo sapiens	32-37
32452013-0	2020	Interleukin-22 enhances chemoresistance of lung adenocarcinoma cells to paclitaxel.	Paclitaxel	72-82	interleukin 22	Homo sapiens	0-14
32452013-2	2020	Interleukin-22 (IL-22) plays an important role in the chemoresistance of multi-cancers; however, the roles of IL-22 in the paclitaxel resistance of lung adenocarcinoma cells remain to be investigated.	Paclitaxel	123-133	interleukin 22	Homo sapiens	110-115
32452013-3	2020	The present study aims to investigate the potential mechanisms of IL-22 enhancing the chemoresistance of lung adenocarcinoma cells to paclitaxel.	Paclitaxel	134-144	interleukin 22	Homo sapiens	66-71
32452013-11	2020	To sum up, IL-22 may mediate the chemosensitivity of lung adenocarcinoma cells to paclitaxel through inhibiting the AKT signaling pathways.	Paclitaxel	82-92	interleukin 22	Homo sapiens	11-16
32516753-0	2020	Highly expressed STAT1 contributes to the suppression of stemness properties in human paclitaxel-resistant ovarian cancer cells.	Paclitaxel	86-96	signal transducer and activator of transcription 1	Homo sapiens	17-22
32516753-8	2020	The PTX-resistant cells had a high expression of CSC-related markers and low expression of STAT1 that had a high methylation level of CpG in its promoter region.	Paclitaxel	4-7	signal transducer and activator of transcription 1	Mus musculus	91-96
32516753-10	2020	In summary, these data indicate a regulatory mechanism of STAT1 underlying drug resistance and provide a potential therapeutic application for EOC patients with PTX resistance.	Paclitaxel	161-164	signal transducer and activator of transcription 1	Homo sapiens	58-63
32522016-12	2020	Moreover, Met partly reversed SNHG7-mediated paclitaxel sensitivity and autophagy in ovarian cancer cells.	Paclitaxel	45-55	small nucleolar RNA host gene 7	Mus musculus	30-35
32522016-15	2020	Conclusion: The authors" findings indicated that Met expedited paclitaxel sensitivity by regulating SNHG7/miR-3127-5p-mediated autophagy in ovarian cancer cells.	Paclitaxel	63-73	small nucleolar RNA host gene 7	Mus musculus	100-105
31883148-8	2020	Furthermore, transport of cationic drugs, metformin and paclitaxel in HepG2 cells was blunted by OCT inhibitors, suggesting that hOCT1 and hOCT3 expressed in HepG2 cells exhibit notable impacts on cationic drug actions.	Paclitaxel	56-66	solute carrier family 22 member 3	Homo sapiens	139-144
32543136-0	2020	[In vivo Study of siRNA Silencing XIAP Gene to Reverse Taxol-resistance in Human Ovarian Cancer Cells].	Paclitaxel	55-60	X-linked inhibitor of apoptosis	Homo sapiens	34-38
32543136-1	2020	Objective: To study the relationship between down-regulated expression of X linked inhibitor of apoptosis protein (XIAP) gene and the reversal effect of taxol-resistance by using siRNA interference technology in the taxol-resistant ovarian cancer.	Paclitaxel	153-158	X-linked inhibitor of apoptosis	Homo sapiens	74-113
32543136-1	2020	Objective: To study the relationship between down-regulated expression of X linked inhibitor of apoptosis protein (XIAP) gene and the reversal effect of taxol-resistance by using siRNA interference technology in the taxol-resistant ovarian cancer.	Paclitaxel	153-158	X-linked inhibitor of apoptosis	Homo sapiens	115-119
32543136-1	2020	Objective: To study the relationship between down-regulated expression of X linked inhibitor of apoptosis protein (XIAP) gene and the reversal effect of taxol-resistance by using siRNA interference technology in the taxol-resistant ovarian cancer.	Paclitaxel	216-221	X-linked inhibitor of apoptosis	Homo sapiens	74-113
32543136-1	2020	Objective: To study the relationship between down-regulated expression of X linked inhibitor of apoptosis protein (XIAP) gene and the reversal effect of taxol-resistance by using siRNA interference technology in the taxol-resistant ovarian cancer.	Paclitaxel	216-221	X-linked inhibitor of apoptosis	Homo sapiens	115-119
32543136-9	2020	Conclusion: XIAP siRNA has synergy with taxol in taxol-resistant ovarian cancer cells.	Paclitaxel	40-45	X-linked inhibitor of apoptosis	Homo sapiens	12-16
32543136-9	2020	Conclusion: XIAP siRNA has synergy with taxol in taxol-resistant ovarian cancer cells.	Paclitaxel	49-54	X-linked inhibitor of apoptosis	Homo sapiens	12-16
32425595-0	2020	Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis.	Paclitaxel	35-45	cyclin dependent kinase 12	Homo sapiens	86-91
32124922-8	2020	RESULTS: In three chemotherapeutic models, oxaliplatin, paclitaxel or bortezomib accordantly up-regulated the expression of TRPC6 mRNA and protein without affecting the DNA methylation level of TRPC6 gene in DRG.	Paclitaxel	56-66	transient receptor potential cation channel, subfamily C, member 6	Rattus norvegicus	124-129
32124922-8	2020	RESULTS: In three chemotherapeutic models, oxaliplatin, paclitaxel or bortezomib accordantly up-regulated the expression of TRPC6 mRNA and protein without affecting the DNA methylation level of TRPC6 gene in DRG.	Paclitaxel	56-66	transient receptor potential cation channel, subfamily C, member 6	Rattus norvegicus	194-199
32313567-13	2020	Conclusions: These findings suggest that inhibiting the Wnt/beta-catenin pathway may have a potent immunomodulatory effect in the treatment of ovarian cancer, particularly when combined with paclitaxel.	Paclitaxel	191-201	catenin (cadherin associated protein), beta 1	Mus musculus	60-72
32351985-8	2020	TGF-beta2 was associated with poor OS and PFS from treatment with chemotherapy with platins, Taxol, or a platin+Taxol.	Paclitaxel	93-98	transforming growth factor beta 2	Homo sapiens	0-9
32351985-8	2020	TGF-beta2 was associated with poor OS and PFS from treatment with chemotherapy with platins, Taxol, or a platin+Taxol.	Paclitaxel	112-117	transforming growth factor beta 2	Homo sapiens	0-9
32351985-11	2020	Conclusion: Higher expression of TGF-beta2 functioned as a significant predictor of poor prognosis in women with ovarian cancer, especially those with TP53 mutations or who were undergoing chemotherapy with platins, Taxol, or a platin+Taxol.	Paclitaxel	216-221	transforming growth factor beta 2	Homo sapiens	33-42
32351985-11	2020	Conclusion: Higher expression of TGF-beta2 functioned as a significant predictor of poor prognosis in women with ovarian cancer, especially those with TP53 mutations or who were undergoing chemotherapy with platins, Taxol, or a platin+Taxol.	Paclitaxel	235-240	transforming growth factor beta 2	Homo sapiens	33-42
31913199-9	2020	Furthermore, there is evidence of an upregulation of Cyclin D1 expression in paclitaxel-treated tumors compared to control, suggesting that the neoplastic cells were highly proliferative and nonresponsive to the paclitaxel alone.	Paclitaxel	77-87	cyclin D1	Mus musculus	53-62
31691396-6	2020	The double-immunohistochemistry of pERK and tryptophan hydroxylase (TpH) showed higher expression of TpH and increased co-localization of TpH and pERK of paclitaxel-injected animals, indicating that CIN is associated with increased activation of serotoninergic RVM neurons.	Paclitaxel	154-164	tryptophan hydroxylase 1	Rattus norvegicus	44-66
31691396-6	2020	The double-immunohistochemistry of pERK and tryptophan hydroxylase (TpH) showed higher expression of TpH and increased co-localization of TpH and pERK of paclitaxel-injected animals, indicating that CIN is associated with increased activation of serotoninergic RVM neurons.	Paclitaxel	154-164	tryptophan hydroxylase 1	Rattus norvegicus	68-71
31691396-6	2020	The double-immunohistochemistry of pERK and tryptophan hydroxylase (TpH) showed higher expression of TpH and increased co-localization of TpH and pERK of paclitaxel-injected animals, indicating that CIN is associated with increased activation of serotoninergic RVM neurons.	Paclitaxel	154-164	tryptophan hydroxylase 1	Rattus norvegicus	101-104
31691396-6	2020	The double-immunohistochemistry of pERK and tryptophan hydroxylase (TpH) showed higher expression of TpH and increased co-localization of TpH and pERK of paclitaxel-injected animals, indicating that CIN is associated with increased activation of serotoninergic RVM neurons.	Paclitaxel	154-164	tryptophan hydroxylase 1	Rattus norvegicus	101-104
32226772-8	2020	The combination of DCST1-AS1 and ANXA1 also contributes to enhancement of the resistance of BT-549 cells to doxorubicin and paclitaxel.	Paclitaxel	124-134	DC-STAMP domain containing 1	Homo sapiens	19-24
32226772-8	2020	The combination of DCST1-AS1 and ANXA1 also contributes to enhancement of the resistance of BT-549 cells to doxorubicin and paclitaxel.	Paclitaxel	124-134	annexin A1	Homo sapiens	33-38
31884343-4	2020	The effects of SNHG5 and miR-23a on the sensitivity of ovarian cancer cells to paclitaxel (PTX) were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay and flow cytometry.	Paclitaxel	91-94	microRNA 23a	Homo sapiens	25-32
31692053-6	2020	RESULTS: In this study, the expression of lncRNA GAS5 was significantly downregulated in cells treated with paclitaxel (PTX) or cisplatin (CIS).	Paclitaxel	108-118	growth arrest specific 5	Homo sapiens	49-53
31692053-6	2020	RESULTS: In this study, the expression of lncRNA GAS5 was significantly downregulated in cells treated with paclitaxel (PTX) or cisplatin (CIS).	Paclitaxel	120-123	growth arrest specific 5	Homo sapiens	49-53
31692053-8	2020	More interestingly, the expression level of lncRNA GAS5 in TNBC patients was associated with tumor resistance to PTX and CIS.	Paclitaxel	113-116	growth arrest specific 5	Homo sapiens	51-55
31692053-11	2020	Finally, lncRNA GAS5 overexpressed MDA-231R could enhance the sensitivity of TNBC to PTX.	Paclitaxel	85-88	growth arrest specific 5	Homo sapiens	16-20
31883360-0	2020	SOX2 upregulates side population cells and enhances their chemoresistant ability by transactivating ABCC1 expression contributing to intrinsic resistance to paclitaxel in melanoma.	Paclitaxel	157-167	SRY-box transcription factor 2	Homo sapiens	0-4
31883360-2	2020	Here, we identified that high expression of SRY-box transcription factor 2 (SOX2) and high ratio of side population (SP) cells reduced the sensitivity to paclitaxel in melanoma cells.	Paclitaxel	154-164	SRY-box transcription factor 2	Homo sapiens	76-80
31883360-9	2020	Taken together, SOX2 upregulates SP cells and enhances their chemoresistant ability by increasing ABCC1 expression, which contributes to intrinsic resistance to paclitaxel in melanoma.	Paclitaxel	161-171	SRY-box transcription factor 2	Homo sapiens	16-20
32148492-14	2020	The only cost-effective strategy was paclitaxel monotherapy for all patients, with an ICER of $53,705/QALY.	Paclitaxel	37-47	cAMP responsive element modulator	Homo sapiens	86-90
32089626-0	2020	Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells.	Paclitaxel	76-86	microRNA 34c	Homo sapiens	16-23
32089626-2	2020	AIM: To investigate the effect of miR-34c and its upstream transcription factor E2F1 on paclitaxel combined with cisplatin resistance in GC cells.	Paclitaxel	88-98	microRNA 34c	Homo sapiens	34-41
32089626-9	2020	After inducing GC cells to be resistant to paclitaxel and cisplatin, E2F1 expression increased while miR-34c expression decreased.	Paclitaxel	43-53	microRNA 34c	Homo sapiens	101-108
32089626-10	2020	Both silencing E2F1 and over-expressing miR-34c could increase the sensitivity of drug-resistant GC cells to paclitaxel combined with cisplatin, promote cell apoptosis and inhibit cell proliferation.	Paclitaxel	109-119	microRNA 34c	Homo sapiens	40-47
32089626-12	2020	Rescue experiments demonstrated that inhibiting miR-34c could significantly weaken the sensitization of drug resistant cells, and Si E2F1 to paclitaxel combined with cisplatin.	Paclitaxel	141-151	microRNA 34c	Homo sapiens	48-55
32089626-13	2020	CONCLUSION: E2F1 inhibits miR-34c to promote the proliferation of GC cells and enhance the resistance to paclitaxel combined with cisplatin, and silencing E2F1 is conducive to improving the efficacy of paclitaxel combined with cisplatin in GC cells.	Paclitaxel	105-115	microRNA 34c	Homo sapiens	26-33
32194804-0	2020	Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets.	Paclitaxel	36-41	BRCA1 DNA repair associated	Homo sapiens	105-110
31793989-0	2019	Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through regulates ZEB1 expression by sponging miR-124-3p.	Paclitaxel	38-48	zinc finger E-box binding homeobox 1	Homo sapiens	102-106
31793989-5	2019	In the present study, the expression levels of circ-PVT1, miR-124-3p and ZEB1 in PTX-resistant GC tissues and cells were detected by quantitative real-time polymerase chain reaction (RT-qPCR).	Paclitaxel	81-84	zinc finger E-box binding homeobox 1	Homo sapiens	73-77
31793989-16	2019	Taken together, our studies disclosed that circ-PVT1 facilitated PTX resistance by upregulating ZEB1 mediated via miR-124-3p, suggesting an underlying therapeutic strategy for GC.	Paclitaxel	65-68	zinc finger E-box binding homeobox 1	Homo sapiens	96-100
31215650-0	2019	Long noncoding RNA AC073284.4 suppresses epithelial-mesenchymal transition by sponging miR-18b-5p in paclitaxel-resistant breast cancer cells.	Paclitaxel	101-111	microRNA 18b	Homo sapiens	87-94
31717555-2	2019	Here, we studied the effects of synthesized ferulic acid (FA) derivatives on P-gp function in vitro and examined PK alteration of paclitaxel (PTX), a well-known P-gp substrate drug by the derivative.	Paclitaxel	130-140	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	161-165
31717555-4	2019	These results suggest that FA derivative can increase PTX bioavailability by inhibiting P-gp existing in eliminating organs.	Paclitaxel	54-57	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	88-92
31616965-5	2019	A significant decrease in proliferating (Ki67+) CD3+CD8- T cells and FoxP3+(CD3+CD8-) regulatory T cells was observed in the tumor stroma after cisplatin and paclitaxel treatment, with increased rates of cytotoxic CD8+ T cells, including activated and CD8+Tbet+ T cells.	Paclitaxel	158-168	CD8a molecule	Homo sapiens	52-55
31616965-5	2019	A significant decrease in proliferating (Ki67+) CD3+CD8- T cells and FoxP3+(CD3+CD8-) regulatory T cells was observed in the tumor stroma after cisplatin and paclitaxel treatment, with increased rates of cytotoxic CD8+ T cells, including activated and CD8+Tbet+ T cells.	Paclitaxel	158-168	CD8a molecule	Homo sapiens	80-83
31616965-5	2019	A significant decrease in proliferating (Ki67+) CD3+CD8- T cells and FoxP3+(CD3+CD8-) regulatory T cells was observed in the tumor stroma after cisplatin and paclitaxel treatment, with increased rates of cytotoxic CD8+ T cells, including activated and CD8+Tbet+ T cells.	Paclitaxel	158-168	CD8a molecule	Homo sapiens	80-83
31616965-5	2019	A significant decrease in proliferating (Ki67+) CD3+CD8- T cells and FoxP3+(CD3+CD8-) regulatory T cells was observed in the tumor stroma after cisplatin and paclitaxel treatment, with increased rates of cytotoxic CD8+ T cells, including activated and CD8+Tbet+ T cells.	Paclitaxel	158-168	CD8a molecule	Homo sapiens	80-83
31467112-0	2019	Breast cancer risk-associated SNPs in the mTOR promoter form de novo KLF5 and ZEB1 binding sites that influence the cellular response to paclitaxel.	Paclitaxel	137-147	zinc finger E-box binding homeobox 1	Homo sapiens	78-82
31467112-5	2019	Mechanistically, the -141T allele of Ht2 creates a novel ZEB1 binding site; meanwhile, the -78C allele of Ht1 exists as an emerging KLF5 binding site, which synergistically induces promote/inhibit mTOR expression, cell proliferation and excretion of cytotoxic drugs through the ZEB1/KLF5-mTOR-CCND1/ABCB1 cascade, thereby affecting the response to PTX treatment in vivo and in vitro.	Paclitaxel	348-351	zinc finger E-box binding homeobox 1	Homo sapiens	57-61
31467112-5	2019	Mechanistically, the -141T allele of Ht2 creates a novel ZEB1 binding site; meanwhile, the -78C allele of Ht1 exists as an emerging KLF5 binding site, which synergistically induces promote/inhibit mTOR expression, cell proliferation and excretion of cytotoxic drugs through the ZEB1/KLF5-mTOR-CCND1/ABCB1 cascade, thereby affecting the response to PTX treatment in vivo and in vitro.	Paclitaxel	348-351	zinc finger E-box binding homeobox 1	Homo sapiens	278-282
31467112-6	2019	Our results suggest the existence of a ZEB1/KLF5-mTOR-CCND1/ABCB1 axis in human cells that could be involved in PTX response pathways and functionally regulate inter-individualized breast cancer susceptibility and prognosis.	Paclitaxel	112-115	zinc finger E-box binding homeobox 1	Homo sapiens	39-43
31467112-7	2019	Implications: The current study highlights the function of haplotypes of mTOR -78C/-141G and -78G/-141T, in affecting breast cancer susceptibility and PTX response regulated by ZEB1/KLF5-mTOR-CCND1/ABCB1 axis.	Paclitaxel	151-154	zinc finger E-box binding homeobox 1	Homo sapiens	177-181
31687397-5	2019	The expression levels of beta-catenin and C-myc were increased, thus indicating Wnt signaling was activated in SGNs after paclitaxel treatment.	Paclitaxel	122-132	catenin (cadherin associated protein), beta 1	Mus musculus	25-37
31352515-0	2019	Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.	Paclitaxel	34-44	cancer susceptibility 2	Homo sapiens	19-24
31352515-3	2019	We investigated the role of long noncoding RNA (lncRNA) cancer susceptibility candidate 2 (CASC2) in paclitaxel (PTX) resistance in breast cancer.	Paclitaxel	101-111	cancer susceptibility 2	Homo sapiens	91-96
31352515-3	2019	We investigated the role of long noncoding RNA (lncRNA) cancer susceptibility candidate 2 (CASC2) in paclitaxel (PTX) resistance in breast cancer.	Paclitaxel	113-116	cancer susceptibility 2	Homo sapiens	91-96
31352515-4	2019	CASC2 expression was increased in PTX-resistant clinical samples and cell lines.	Paclitaxel	34-37	cancer susceptibility 2	Homo sapiens	0-5
31352515-5	2019	PTX induced CASC2 expression in a concentration-dependent manner.	Paclitaxel	0-3	cancer susceptibility 2	Homo sapiens	12-17
31352515-6	2019	Downregulation of CASC2 increased PTX toxicity and decreased IC50 value, while upregulation of CASC2 decreased PTX toxicity and increased IC50 value in MCF-7/PTX and MDA-MB-231/PTX cells.	Paclitaxel	34-37	cancer susceptibility 2	Homo sapiens	18-23
31352515-6	2019	Downregulation of CASC2 increased PTX toxicity and decreased IC50 value, while upregulation of CASC2 decreased PTX toxicity and increased IC50 value in MCF-7/PTX and MDA-MB-231/PTX cells.	Paclitaxel	111-114	cancer susceptibility 2	Homo sapiens	95-100
31352515-6	2019	Downregulation of CASC2 increased PTX toxicity and decreased IC50 value, while upregulation of CASC2 decreased PTX toxicity and increased IC50 value in MCF-7/PTX and MDA-MB-231/PTX cells.	Paclitaxel	111-114	cancer susceptibility 2	Homo sapiens	95-100
31352515-6	2019	Downregulation of CASC2 increased PTX toxicity and decreased IC50 value, while upregulation of CASC2 decreased PTX toxicity and increased IC50 value in MCF-7/PTX and MDA-MB-231/PTX cells.	Paclitaxel	111-114	cancer susceptibility 2	Homo sapiens	95-100
31352515-7	2019	Moreover, downregulation of CASC2 decreased tumor growth in xenograft mice implanted with MCF-7/PTX cells.	Paclitaxel	96-99	cancer susceptibility 2	Homo sapiens	28-33
31352515-13	2019	In summary, we identified that CASC2 activated PTX resistance in breast cancer through regulation of miR-18a-5p/CDK19.	Paclitaxel	47-50	cancer susceptibility 2	Homo sapiens	31-36
30367323-7	2019	Results In the in vitro model, the expression of twelve drug-transporters genes was found to be significantly down-regulated after exposure to paclitaxel, including ABCC10, SLC28A3, SLC29A2, and ATP7B (involved in the transport of taxanes, antimetabolites, and cisplatin, respectively).	Paclitaxel	143-153	ATPase copper transporting beta	Homo sapiens	195-200
31576147-9	2019	In addition, downregulating BMP7 increased the sensitivity of the A2780 cells to paclitaxel.	Paclitaxel	81-91	bone morphogenetic protein 7	Homo sapiens	28-32
31391192-0	2019	6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.	Paclitaxel	79-89	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2	Homo sapiens	0-53
31391192-5	2019	RESULTS: Knockdown of PFKFB2 inhibited clonogenic growth and enhanced paclitaxel sensitivity in ovarian and breast cancer cell lines with wild-type TP53 (wtTP53).	Paclitaxel	70-80	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2	Homo sapiens	22-28
31391192-6	2019	Silencing PFKFB2 significantly inhibited tumor growth and enhanced paclitaxel sensitivity in four xenografts derived from two ovarian and two breast cancer cell lines, and prolonged survival in a triple-negative breast cancer PDX.	Paclitaxel	67-77	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2	Homo sapiens	10-16
31391192-9	2019	CONCLUSIONS: PFKFB2 is a novel target whose inhibition can enhance the effect of paclitaxel-based primary chemotherapy upon ovarian and breast cancers retaining wtTP53.	Paclitaxel	81-91	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2	Homo sapiens	13-19
31004874-10	2019	The HSD3B1 knockdown enhanced paclitaxel sensitivity, and IL-6 treatment partially reversed the augmented cytotoxicity.	Paclitaxel	30-40	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Homo sapiens	4-10
31163384-0	2019	In Preclinical Model of Ovarian Cancer, the SGK1 Inhibitor SI113 Counteracts the Development of Paclitaxel Resistance and Restores Drug Sensitivity.	Paclitaxel	96-106	serum/glucocorticoid regulated kinase 1	Homo sapiens	44-48
31163384-5	2019	Specifically, SGK1 affects paclitaxel sensitivity in RKO colon carcinoma cells by modulating the specificity protein 1 (SP1)-dependent expression of Ran-specific GTPase-activating protein (RANBP1), a member of the GTP-binding nuclear protein Ran (RAN) network that is required for the organization and function of the mitotic spindle.	Paclitaxel	27-37	serum/glucocorticoid regulated kinase 1	Homo sapiens	14-18
31163384-6	2019	SGK1 inhibition might thus be useful for counteracting the development of paclitaxel resistance.	Paclitaxel	74-84	serum/glucocorticoid regulated kinase 1	Homo sapiens	0-4
31163384-7	2019	Here, we present in vitro data obtained using ovarian carcinoma cell lines that indicate that the SGK1 inhibitor SI113 inhibits cancer cell proliferation, potentiates the effects of paclitaxel-based chemotherapy, counteracts the development of paclitaxel resistance, and restores paclitaxel sensitivity in paclitaxel-resistant A2780 ovarian cancer cells.	Paclitaxel	182-192	serum/glucocorticoid regulated kinase 1	Homo sapiens	98-102
31163384-7	2019	Here, we present in vitro data obtained using ovarian carcinoma cell lines that indicate that the SGK1 inhibitor SI113 inhibits cancer cell proliferation, potentiates the effects of paclitaxel-based chemotherapy, counteracts the development of paclitaxel resistance, and restores paclitaxel sensitivity in paclitaxel-resistant A2780 ovarian cancer cells.	Paclitaxel	244-254	serum/glucocorticoid regulated kinase 1	Homo sapiens	98-102
31163384-7	2019	Here, we present in vitro data obtained using ovarian carcinoma cell lines that indicate that the SGK1 inhibitor SI113 inhibits cancer cell proliferation, potentiates the effects of paclitaxel-based chemotherapy, counteracts the development of paclitaxel resistance, and restores paclitaxel sensitivity in paclitaxel-resistant A2780 ovarian cancer cells.	Paclitaxel	244-254	serum/glucocorticoid regulated kinase 1	Homo sapiens	98-102
31163384-7	2019	Here, we present in vitro data obtained using ovarian carcinoma cell lines that indicate that the SGK1 inhibitor SI113 inhibits cancer cell proliferation, potentiates the effects of paclitaxel-based chemotherapy, counteracts the development of paclitaxel resistance, and restores paclitaxel sensitivity in paclitaxel-resistant A2780 ovarian cancer cells.	Paclitaxel	244-254	serum/glucocorticoid regulated kinase 1	Homo sapiens	98-102
31163384-10	2019	Taken together, these data suggest that SGK1 inhibition should be investigated in clinical trials for the treatment of paclitaxel-resistant ovarian cancer.	Paclitaxel	119-129	serum/glucocorticoid regulated kinase 1	Homo sapiens	40-44
30701373-10	2019	The mitochondrial dysfunction evoked by paclitaxel was also remarkably improved in evodiamine-treated rats, evidenced by restoration of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), uncoupling protein 2 (UCP2), and superoxide dismutase 2 (SOD2) expression.	Paclitaxel	40-50	uncoupling protein 2	Rattus norvegicus	219-239
30701373-11	2019	In in vitro studies, we found that evodiamine prevented paclitaxel-induced the loss of mitochondrial membrane potential and PGC-1alpha, UCP2 and SOD2 expression in DRG cells.	Paclitaxel	56-66	uncoupling protein 2	Rattus norvegicus	136-140
30701373-11	2019	In in vitro studies, we found that evodiamine prevented paclitaxel-induced the loss of mitochondrial membrane potential and PGC-1alpha, UCP2 and SOD2 expression in DRG cells.	Paclitaxel	56-66	superoxide dismutase 2	Rattus norvegicus	145-149
33457057-10	2019	Hypersensitivity reactions to paclitaxel occurred in 1 of 13 (7.7%) BRCA-mutated patients and 26 of 49 (53.1%) BRCA wild-type patients (p = .0039).	Paclitaxel	30-40	BRCA1 DNA repair associated	Homo sapiens	68-72
33457057-10	2019	Hypersensitivity reactions to paclitaxel occurred in 1 of 13 (7.7%) BRCA-mutated patients and 26 of 49 (53.1%) BRCA wild-type patients (p = .0039).	Paclitaxel	30-40	BRCA1 DNA repair associated	Homo sapiens	111-115
33457057-15	2019	The presence of BRCA mutations was not statistically significantly associated with a higher incidence of HSRs to carboplatin, but was statistically significant with regards to paclitaxel.	Paclitaxel	176-186	BRCA1 DNA repair associated	Homo sapiens	16-20
31312656-8	2019	From TCGA and GEO data, SOC patients with ICAM1 mRNA overexpression treated with chemotherapeutic drugs that contained taxol or taxol and platin together had significantly reduced progression-free survival.	Paclitaxel	119-124	intercellular adhesion molecule 1	Homo sapiens	42-47
31312656-8	2019	From TCGA and GEO data, SOC patients with ICAM1 mRNA overexpression treated with chemotherapeutic drugs that contained taxol or taxol and platin together had significantly reduced progression-free survival.	Paclitaxel	128-133	intercellular adhesion molecule 1	Homo sapiens	42-47
31174562-18	2019	The tumors treated by Nek2B siRNA associated with paclitaxel were the smallest in nude mouse, and Nek2B can regulate the expression of beta-catenin and wnt downstream target genes in vivo.	Paclitaxel	50-60	catenin (cadherin associated protein), beta 1	Mus musculus	135-147
30878390-0	2019	MiR-155-3p acts as a tumor suppressor and reverses paclitaxel resistance via negative regulation of MYD88 in human breast cancer.	Paclitaxel	51-61	microRNA 155	Homo sapiens	0-7
30878390-4	2019	Moreover, miR-155-3p showed a negative effect on apoptosis, invasion and metastasis, reverses paclitaxel resistance by suppression of the corresponding target gene MYD88 in vitro and in vivo experiments.	Paclitaxel	94-104	microRNA 155	Homo sapiens	10-17
31169019-2	2019	Here, we explored the mechanism by which miR-21-5p regulated the progression and paclitaxel (PTX) resistance in drug-resistant breast cancer (BC) cell lines.	Paclitaxel	81-91	microRNA 215	Homo sapiens	41-49
31169019-2	2019	Here, we explored the mechanism by which miR-21-5p regulated the progression and paclitaxel (PTX) resistance in drug-resistant breast cancer (BC) cell lines.	Paclitaxel	93-96	microRNA 215	Homo sapiens	41-49
31169019-4	2019	Dual-luciferase reporter assay was used to observe the interaction between miR-21-5p and PDCD4 in PTX-resistant BC cell lines.	Paclitaxel	98-101	microRNA 215	Homo sapiens	75-84
31169019-7	2019	Then, we found that miR-21-5p was upregulated and PDCD4 was downregulated in BC tissues and PTX-resistant BC cell lines.	Paclitaxel	92-95	microRNA 215	Homo sapiens	20-29
31169019-8	2019	MiR-21-5p silencing or PDCD4 overexpression ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines.	Paclitaxel	56-59	microRNA 215	Homo sapiens	0-9
31169019-8	2019	MiR-21-5p silencing or PDCD4 overexpression ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines.	Paclitaxel	104-107	microRNA 215	Homo sapiens	0-9
31169019-10	2019	MiR-21-5p exerted its regulatory effect by PDCD4 in PTX-resistant BC cell lines.	Paclitaxel	52-55	microRNA 215	Homo sapiens	0-8
31169019-12	2019	Therefore, our study demonstrated that miR-21-5p silencing ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines at least partly by targeting PDCD4, providing miR-21-5p as an effective therapeutic target for PTX-resistant BC treatment.	Paclitaxel	71-74	microRNA 215	Homo sapiens	39-47
31169019-12	2019	Therefore, our study demonstrated that miR-21-5p silencing ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines at least partly by targeting PDCD4, providing miR-21-5p as an effective therapeutic target for PTX-resistant BC treatment.	Paclitaxel	71-74	microRNA 215	Homo sapiens	39-48
31169019-12	2019	Therefore, our study demonstrated that miR-21-5p silencing ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines at least partly by targeting PDCD4, providing miR-21-5p as an effective therapeutic target for PTX-resistant BC treatment.	Paclitaxel	119-122	microRNA 215	Homo sapiens	39-47
31169019-12	2019	Therefore, our study demonstrated that miR-21-5p silencing ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines at least partly by targeting PDCD4, providing miR-21-5p as an effective therapeutic target for PTX-resistant BC treatment.	Paclitaxel	119-122	microRNA 215	Homo sapiens	39-48
31169019-12	2019	Therefore, our study demonstrated that miR-21-5p silencing ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines at least partly by targeting PDCD4, providing miR-21-5p as an effective therapeutic target for PTX-resistant BC treatment.	Paclitaxel	119-122	microRNA 215	Homo sapiens	39-47
31169019-12	2019	Therefore, our study demonstrated that miR-21-5p silencing ameliorated PTX resistance and inhibited the progression in PTX-resistant BC cell lines at least partly by targeting PDCD4, providing miR-21-5p as an effective therapeutic target for PTX-resistant BC treatment.	Paclitaxel	119-122	microRNA 215	Homo sapiens	39-48
31180057-0	2019	LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel.	Paclitaxel	90-100	long intergenic non-protein coding RNA 511	Homo sapiens	0-9
31180057-3	2019	The present study aims to define the role of long non-coding RNA (lncRNA) LINC00511 in the progression of CC with the involvement of cell proliferation, apoptosis and resistance to PTX in Hela/PTX cells.	Paclitaxel	181-184	long intergenic non-protein coding RNA 511	Homo sapiens	74-83
31180057-3	2019	The present study aims to define the role of long non-coding RNA (lncRNA) LINC00511 in the progression of CC with the involvement of cell proliferation, apoptosis and resistance to PTX in Hela/PTX cells.	Paclitaxel	193-196	long intergenic non-protein coding RNA 511	Homo sapiens	74-83
31180057-9	2019	Furthermore, silencing of LINC00511 could suppress cell resistance to PTX, cell viability, cell proliferation, migration and invasion yet promoted cell apoptosis in PTX-resistant Hela/PTX cells.	Paclitaxel	70-73	long intergenic non-protein coding RNA 511	Homo sapiens	26-35
31180057-9	2019	Furthermore, silencing of LINC00511 could suppress cell resistance to PTX, cell viability, cell proliferation, migration and invasion yet promoted cell apoptosis in PTX-resistant Hela/PTX cells.	Paclitaxel	165-168	long intergenic non-protein coding RNA 511	Homo sapiens	26-35
31180057-9	2019	Furthermore, silencing of LINC00511 could suppress cell resistance to PTX, cell viability, cell proliferation, migration and invasion yet promoted cell apoptosis in PTX-resistant Hela/PTX cells.	Paclitaxel	165-168	long intergenic non-protein coding RNA 511	Homo sapiens	26-35
31180057-10	2019	Collectively, our findings demonstrate that silencing of LINC00511 could inhibit CC cell resistance to PTX, cell proliferation, migration and invasion, and promote cell apoptosis in CC.	Paclitaxel	103-106	long intergenic non-protein coding RNA 511	Homo sapiens	57-66
31101119-12	2019	Either inhibition of SIRT1 by EX527 or knockdown of SIRT1 by siRNA could reverse NNMT-mediated resistance to adriamycin and paclitaxel, which suggests that SIRT1 plays a critical role in NNMT-related chemoresistance in breast cancer.	Paclitaxel	124-134	sirtuin 1	Homo sapiens	52-57
31101119-12	2019	Either inhibition of SIRT1 by EX527 or knockdown of SIRT1 by siRNA could reverse NNMT-mediated resistance to adriamycin and paclitaxel, which suggests that SIRT1 plays a critical role in NNMT-related chemoresistance in breast cancer.	Paclitaxel	124-134	sirtuin 1	Homo sapiens	52-57
30414958-9	2019	Paclitaxel induced epigenetic upregulation of IRF8 and P2X purinoceptor 4 (P2X4) in microglia and subsequently increased the expression of alpha isoform of calcium/calmodulin-dependent protein kinase II (CaMKIIalpha), transcriptional factors p-CREB and DeltaFosB, leading to the overproduction of BDNF in microglia.	Paclitaxel	0-10	purinergic receptor P2X 4	Rattus norvegicus	55-73
30414958-9	2019	Paclitaxel induced epigenetic upregulation of IRF8 and P2X purinoceptor 4 (P2X4) in microglia and subsequently increased the expression of alpha isoform of calcium/calmodulin-dependent protein kinase II (CaMKIIalpha), transcriptional factors p-CREB and DeltaFosB, leading to the overproduction of BDNF in microglia.	Paclitaxel	0-10	FosB proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	253-262
30414958-9	2019	Paclitaxel induced epigenetic upregulation of IRF8 and P2X purinoceptor 4 (P2X4) in microglia and subsequently increased the expression of alpha isoform of calcium/calmodulin-dependent protein kinase II (CaMKIIalpha), transcriptional factors p-CREB and DeltaFosB, leading to the overproduction of BDNF in microglia.	Paclitaxel	0-10	brain-derived neurotrophic factor	Rattus norvegicus	297-301
30414958-10	2019	Paclitaxel also upregulated the expression of glutamate receptor subunits GluR1 and NR2B, decreased the expression of K+-Cl- cotransporter, and induced mechanical allodynia in rats.	Paclitaxel	0-10	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	84-88
30414958-13	2019	Perspective: This study provides evidence that paclitaxel induced microglia dysregulation and epigenetically upregulated the microglial expression of BDNF, which led to sensitization of dorsal horn neurons and mechanical allodynia in rats.	Paclitaxel	47-57	brain-derived neurotrophic factor	Rattus norvegicus	150-154
30471427-4	2019	Here, we report that paclitaxel-induced mechanical allodynia is associated with transcriptional increase in matrix metalloproteinase (MMP) 2 and 9 and decrease in metallopeptidase inhibitor 1 (TIMP1), a strong endogenous MMP9 inhibitor.	Paclitaxel	21-31	matrix metallopeptidase 2	Mus musculus	108-140
30928404-0	2019	KRT17 confers paclitaxel-induced resistance and migration to cervical cancer cells.	Paclitaxel	14-24	keratin 17	Homo sapiens	0-5
30117103-4	2019	To examine if Hsp27 could prevent the occurrence of CIPN, we first demonstrated that paclitaxel-induced allodynia was associated directly with axonal degeneration in sensory neurons in a mouse model of CIPN.	Paclitaxel	85-95	heat shock protein 1	Mus musculus	14-19
30623814-2	2019	In this study, a transferrin-conjugated pH-sensitive platform (Tf-PPP), comprising porous Pd nanoparticles (PdNPs) and paclitaxel (PTX), was successfully developed for combined chemo-phototherapy.	Paclitaxel	119-129	transferrin	Mus musculus	17-28
30623814-2	2019	In this study, a transferrin-conjugated pH-sensitive platform (Tf-PPP), comprising porous Pd nanoparticles (PdNPs) and paclitaxel (PTX), was successfully developed for combined chemo-phototherapy.	Paclitaxel	119-129	transferrin	Mus musculus	63-65
30623814-2	2019	In this study, a transferrin-conjugated pH-sensitive platform (Tf-PPP), comprising porous Pd nanoparticles (PdNPs) and paclitaxel (PTX), was successfully developed for combined chemo-phototherapy.	Paclitaxel	131-134	transferrin	Mus musculus	17-28
30623814-2	2019	In this study, a transferrin-conjugated pH-sensitive platform (Tf-PPP), comprising porous Pd nanoparticles (PdNPs) and paclitaxel (PTX), was successfully developed for combined chemo-phototherapy.	Paclitaxel	131-134	transferrin	Mus musculus	63-65
30841025-6	2019	The A549, H460, SPC-A-1 and SPC-A-1 displayed maximum resistances to cisplatin (IC50 = 15.70 mug/ml), adriamycin (IC50 = 5.58 mug/ml), gefitinib (96.82 mumol/L) and paclitaxel (141.97 nmol/L).	Paclitaxel	165-175	ATPase secretory pathway Ca2+ transporting 1	Homo sapiens	16-23
30841025-6	2019	The A549, H460, SPC-A-1 and SPC-A-1 displayed maximum resistances to cisplatin (IC50 = 15.70 mug/ml), adriamycin (IC50 = 5.58 mug/ml), gefitinib (96.82 mumol/L) and paclitaxel (141.97 nmol/L).	Paclitaxel	165-175	ATPase secretory pathway Ca2+ transporting 1	Homo sapiens	28-35
32254809-5	2019	The results of the role of autophagy in the sensitivity of chemotherapeutic PTX to glioma cells showed that the stemness-associating genes (SOX2, POU5F1 and NANOG) of live glioma cells increased in the presence of PTX, while they dropped sharply with the combination including CQ.	Paclitaxel	76-79	SRY-box transcription factor 2	Homo sapiens	140-144
32254809-5	2019	The results of the role of autophagy in the sensitivity of chemotherapeutic PTX to glioma cells showed that the stemness-associating genes (SOX2, POU5F1 and NANOG) of live glioma cells increased in the presence of PTX, while they dropped sharply with the combination including CQ.	Paclitaxel	76-79	Nanog homeobox	Homo sapiens	157-162
32254809-5	2019	The results of the role of autophagy in the sensitivity of chemotherapeutic PTX to glioma cells showed that the stemness-associating genes (SOX2, POU5F1 and NANOG) of live glioma cells increased in the presence of PTX, while they dropped sharply with the combination including CQ.	Paclitaxel	214-217	SRY-box transcription factor 2	Homo sapiens	140-144
30911062-9	2019	In addition, tumors from paclitaxel and PFL-treated mice showed reduced HER2 and beta-catenin expression, along with increased apoptosis.	Paclitaxel	25-35	catenin (cadherin associated protein), beta 1	Mus musculus	81-93
30865895-0	2019	FOXM1 Deubiquitination by USP21 Regulates Cell Cycle Progression and Paclitaxel Sensitivity in Basal-like Breast Cancer.	Paclitaxel	69-79	forkhead box M1	Homo sapiens	0-5
30865895-0	2019	FOXM1 Deubiquitination by USP21 Regulates Cell Cycle Progression and Paclitaxel Sensitivity in Basal-like Breast Cancer.	Paclitaxel	69-79	ubiquitin specific peptidase 21	Homo sapiens	26-31
30984336-0	2019	Resveratrol Enhances Apoptotic and Oxidant Effects of Paclitaxel through TRPM2 Channel Activation in DBTRG Glioblastoma Cells.	Paclitaxel	54-64	transient receptor potential cation channel subfamily M member 2	Homo sapiens	73-78
30984336-5	2019	The aim of this study was to evaluate the effect of combination therapy of RESV and PAX on activation of TRPM2 in DBTRG glioblastoma cells.	Paclitaxel	84-87	transient receptor potential cation channel subfamily M member 2	Homo sapiens	105-110
30984336-9	2019	The PAX and RESV-mediated increase in current density and Ca2+ florescence intensity was decreased with a TRPM2 blocker.	Paclitaxel	4-7	transient receptor potential cation channel subfamily M member 2	Homo sapiens	106-111
30658113-13	2019	In PMA-treated THP-1 cells, TRACP5a significantly increased after stimulation with gemcitabine and paclitaxel.	Paclitaxel	99-109	acid phosphatase 5, tartrate resistant	Homo sapiens	28-35
30592293-1	2019	Our previous study demonstrated that bromodomain-containing protein 7 (BRD7) inhibits cell proliferation and tumor growth, restoring the expression of B-cell lymphoma 2 antagonist/killer (Bak) sensitized breast cancer cells to paclitaxel.	Paclitaxel	227-237	BCL2 antagonist/killer 1	Homo sapiens	188-191
30592293-8	2019	Furthermore, ectopic expression of BRD7 inhibited cell proliferation, tumor growth and sensitized cancer cells to paclitaxel, while knockdown of Bak abolished BRD7-mediated inhibitory effects on cell proliferation and paclitaxel sensitization in breast cancer cells whether in vitro and in vivo.	Paclitaxel	218-228	BCL2 antagonist/killer 1	Homo sapiens	145-148
30592293-9	2019	The results demonstrated that BRD7 inhibits cell proliferation and sensitizes breast cancer cells to paclitaxel by activating Bak; they also provide promising targets for the diagnosis and treatment of breast cancer.	Paclitaxel	101-111	BCL2 antagonist/killer 1	Homo sapiens	126-129
30668434-9	2019	Our results also supported the involvement of p53-p21 axis in the anticancer effects of curcumin and PTX.	Paclitaxel	101-104	KRAS proto-oncogene, GTPase	Rattus norvegicus	50-53
30818864-0	2019	Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel.	Paclitaxel	99-109	CD44 molecule (Indian blood group)	Homo sapiens	46-50
30863062-3	2019	In our study, we investigated whether PTX-NPs regulated Period2 (Per2) during chronic chemotherapy to induce apoptosis in vivo and in vitro.	Paclitaxel	38-41	period circadian regulator 2	Homo sapiens	56-63
30863062-3	2019	In our study, we investigated whether PTX-NPs regulated Period2 (Per2) during chronic chemotherapy to induce apoptosis in vivo and in vitro.	Paclitaxel	38-41	period circadian regulator 2	Homo sapiens	65-69
30863062-11	2019	RT-PCR and Western blotting demonstrated that PTX-NPs upregulated Per2 mRNA and protein expression, and the highest Per2 expression was observed at 15 HALO in vivo and in vitro.	Paclitaxel	46-49	period circadian regulator 2	Homo sapiens	66-70
30863062-11	2019	RT-PCR and Western blotting demonstrated that PTX-NPs upregulated Per2 mRNA and protein expression, and the highest Per2 expression was observed at 15 HALO in vivo and in vitro.	Paclitaxel	46-49	period circadian regulator 2	Homo sapiens	116-120
30863062-14	2019	Conclusion: PTX-NPs exhibited the most effective antitumor activity and reduced liver damage at 15 HALO through upregulation of Per2 expression to induce apoptosis in vivo and in vitro.	Paclitaxel	12-15	period circadian regulator 2	Homo sapiens	128-132
30804792-13	2018	Taxol up-regulated the protein levels of P-H2A, PARP, Chk1, p53, and p21 and down-regulated Bcl-Xl and Mcl-1, and RAP reversed the expression of all these proteins.	Paclitaxel	0-5	poly (ADP-ribose) polymerase family, member 1	Mus musculus	48-52
30804792-13	2018	Taxol up-regulated the protein levels of P-H2A, PARP, Chk1, p53, and p21 and down-regulated Bcl-Xl and Mcl-1, and RAP reversed the expression of all these proteins.	Paclitaxel	0-5	checkpoint kinase 1	Mus musculus	54-58
30804792-13	2018	Taxol up-regulated the protein levels of P-H2A, PARP, Chk1, p53, and p21 and down-regulated Bcl-Xl and Mcl-1, and RAP reversed the expression of all these proteins.	Paclitaxel	0-5	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	69-72
30467925-6	2019	In an in vivo experiment, we found that verteporfin was able to shrink tumor weight and volume and decreased Ki67 expression in a taxol-resistant mouse model.	Paclitaxel	130-135	antigen identified by monoclonal antibody Ki 67	Mus musculus	109-113
30622051-5	2019	In LPS-stimulated or paclitaxel-resistant ovarian cancer cells, stimulation with recombinant human CD55 (rhCD55) of CD97 in ovarian cancer cells activated NF-kappaB-dependent miR-503-5p down-regulation and the JAK2/STAT3 pathway, consequently promoting the migratory and invasive capacity.	Paclitaxel	21-31	CD55 molecule (Cromer blood group)	Homo sapiens	99-103
30761140-3	2019	Here we showed that paclitaxel pre-treatment greatly enhanced ATP- or nigericin-induced NLRP3 inflammasome activation as indicated by increased release of cleaved caspase-1 and mature IL-1beta, enhanced formation of ASC speck, and increased gasdermin D cleavage and pyroptosis.	Paclitaxel	20-30	gasdermin D	Mus musculus	241-252
30761271-2	2019	In this study, we clarified the clinical significance of CDKN2B antisense RNA 1 (CDKN2B-AS) gene, and its effects on paclitaxel sensitivity in EC.	Paclitaxel	117-127	CDKN2B antisense RNA 1	Homo sapiens	57-79
30761271-2	2019	In this study, we clarified the clinical significance of CDKN2B antisense RNA 1 (CDKN2B-AS) gene, and its effects on paclitaxel sensitivity in EC.	Paclitaxel	117-127	CDKN2B antisense RNA 1	Homo sapiens	81-90
30687694-6	2018	The amphiphilic properties of CTS permit simultaneous entrapment of PTX and RB, while the encapsulation efficiency of RB was further improved by increasing the amount of short-chain bPEI.	Paclitaxel	68-71	transthyretin	Homo sapiens	30-33
30626065-1	2019	Paclitaxel (PTX) is an anticancer agent that is used to treat many cancers but it has a very low oral bioavailability due, at least in part, to the drug efflux transporter, P-glycoprotein (P-gp).	Paclitaxel	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	173-187
30626065-1	2019	Paclitaxel (PTX) is an anticancer agent that is used to treat many cancers but it has a very low oral bioavailability due, at least in part, to the drug efflux transporter, P-glycoprotein (P-gp).	Paclitaxel	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	189-193
30626065-1	2019	Paclitaxel (PTX) is an anticancer agent that is used to treat many cancers but it has a very low oral bioavailability due, at least in part, to the drug efflux transporter, P-glycoprotein (P-gp).	Paclitaxel	12-15	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	173-187
30626065-1	2019	Paclitaxel (PTX) is an anticancer agent that is used to treat many cancers but it has a very low oral bioavailability due, at least in part, to the drug efflux transporter, P-glycoprotein (P-gp).	Paclitaxel	12-15	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	189-193
30626065-4	2019	Compound 4 was selected as the most potent P-gp inhibitor from the in vitro results for examining the pharmacokinetic (PK) changes of PTX in rats.	Paclitaxel	134-137	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	43-47
30626065-9	2019	A piperazine derivative, compound 4, which was confirmed as a substantial P-gp inhibitor in vitro increased the BA of PTX up to 2-fold by a lingering absorption, in part due to inhibition of intestinal P-gp and a low oral clearance of PTX.	Paclitaxel	118-121	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	74-78
30626065-9	2019	A piperazine derivative, compound 4, which was confirmed as a substantial P-gp inhibitor in vitro increased the BA of PTX up to 2-fold by a lingering absorption, in part due to inhibition of intestinal P-gp and a low oral clearance of PTX.	Paclitaxel	235-238	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	74-78
30626065-10	2019	These results suggest that co-administering compound 4 may change the PK profile of PTX by inhibiting P-gp activity in the body.	Paclitaxel	84-87	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	102-106
30365045-0	2019	Paclitaxel-resistant gastric cancer MGC-803 cells promote epithelial-to-mesenchymal transition and chemoresistance in paclitaxel-sensitive cells via exosomal delivery of miR-155-5p.	Paclitaxel	0-10	microRNA 155	Homo sapiens	170-177
30365045-0	2019	Paclitaxel-resistant gastric cancer MGC-803 cells promote epithelial-to-mesenchymal transition and chemoresistance in paclitaxel-sensitive cells via exosomal delivery of miR-155-5p.	Paclitaxel	118-128	microRNA 155	Homo sapiens	170-177
30365045-3	2019	In the present study, a paclitaxel-resistant gastric cancer cell line (MGC-803R) was generated with a morphological phenotype of epithelial-to-mesenchymal transition (EMT) and increased expression levels of microRNA (miR)-155-5p.	Paclitaxel	24-34	microRNA 155	Homo sapiens	207-225
30365045-10	2019	These results demonstrated that exosomal delivery of miR-155-5p may induce EMT and chemoresistant phenotypes from paclitaxel-resistant gastric cancer cells to the sensitive cells, which may be mediated by GATA3 and TP53INP1 suppression.	Paclitaxel	114-124	microRNA 155	Homo sapiens	53-60
30365045-10	2019	These results demonstrated that exosomal delivery of miR-155-5p may induce EMT and chemoresistant phenotypes from paclitaxel-resistant gastric cancer cells to the sensitive cells, which may be mediated by GATA3 and TP53INP1 suppression.	Paclitaxel	114-124	GATA binding protein 3	Homo sapiens	205-210
30365045-11	2019	Targeting miR-155-5p may thus be a promising strategy to overcome paclitaxel resistance in gastric cancer.	Paclitaxel	66-76	microRNA 155	Homo sapiens	10-17
30325582-7	2019	Furthermore, the overexpression of miR-199b-5p inhibited cell proliferation, promoted apoptosis, and increased the chemo-sensitivity of thyroid carcinoma B-CPAP cells toward the chemotherapy drug paclitaxel.	Paclitaxel	196-206	centromere protein J	Homo sapiens	156-160
30161287-8	2019	Furthermore, the antiproliferative effects of ADM, cisplatin (DDP), and taxol (TAX) were significantly enhanced after suppressing Med19 expression.	Paclitaxel	72-77	mediator complex subunit 19	Homo sapiens	130-135
30431158-4	2019	Here we show that paclitaxel treatment in rats increases the alpha2delta-1 expression level in the dorsal root ganglion and spinal cord and the mRNA levels of GluN1, GluN2A, and GluN2B in the spinal cord.	Paclitaxel	18-28	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	178-184
30325723-7	2019	Paclitaxel also amplified the expression of p-mTOR, mTOR-mediated phosphorylation of p70 ribosomal S6 protein kinase 1 (p-S6K1), 4E-binding protein 1 (p-4E-BP1) in the DRG.	Paclitaxel	0-10	mechanistic target of rapamycin kinase	Rattus norvegicus	46-50
30325723-7	2019	Paclitaxel also amplified the expression of p-mTOR, mTOR-mediated phosphorylation of p70 ribosomal S6 protein kinase 1 (p-S6K1), 4E-binding protein 1 (p-4E-BP1) in the DRG.	Paclitaxel	0-10	mechanistic target of rapamycin kinase	Rattus norvegicus	52-56
30325723-8	2019	Blocking mTOR using rapamycin attenuated peripheral painful neuropathy observed in paclitaxel rats (P < 0.05 vs. without rapamycin).	Paclitaxel	83-93	mechanistic target of rapamycin kinase	Rattus norvegicus	9-13
30325723-11	2019	Conclusions: The data revealed specific signaling pathways leading to paclitaxel-induced peripheral neuropathic pain, including the activation of PI3K-mTOR, PIC signal, and substance P and CGRP.	Paclitaxel	70-80	mechanistic target of rapamycin kinase	Rattus norvegicus	151-155
30655858-0	2019	miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression.	Paclitaxel	80-85	leucine zipper tumor suppressor 1	Homo sapiens	119-124
16782806-5	2006	Overexpression of PDK1 or Akt1 conferred similar resistance to treatment with paclitaxel or doxorubicin compared with control cells.	Paclitaxel	78-88	3-phosphoinositide dependent protein kinase 1	Homo sapiens	18-22
16847284-4	2006	A synergistic interaction between trastuzumab in combination with CDDP (paclitaxel or vincristine) was obtained in MCF-7/HRG cells.	Paclitaxel	72-82	histidine rich glycoprotein	Homo sapiens	121-124
16847284-10	2006	CONCLUSION: We demonstrate that assessment of HRG expression and Her-2 activation define a particular breast cancer patient population for which trastuzumab plus CDDP or taxol are extremely efficient without Her-2 overexpression.	Paclitaxel	170-175	histidine rich glycoprotein	Homo sapiens	46-49
16794185-0	2006	Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation.	Paclitaxel	0-10	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	78-83
16794185-8	2006	Paclitaxel potently activated c-Jun terminal NH2 kinase (JNK) as compared with thrombin alone, whereas the thrombin-mediated phosphorylation of p38 and extracellular signal-regulated kinase remained unaffected.	Paclitaxel	0-10	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	30-35
16909595-6	2006	RESULTS: The combined low-dose therapy with cyclophosphamide and paclitaxel was most effective for antagonizing tumor-associated angiogensis; the mice of this group had the lowest MVD and VEGF expression, compared to mice of other groups (P &lt; 0.005).	Paclitaxel	65-75	vascular endothelial growth factor A	Mus musculus	188-192
16462766-0	2006	Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT.	Paclitaxel	72-77	MDS1 and EVI1 complex locus	Homo sapiens	0-4
16462766-8	2006	The ability of Evi1 to suppress apoptosis is not restricted to TGFbeta-mediated cell death, since Evi1 also protects intestinal epithelial cells from taxol-mediated apoptosis.	Paclitaxel	150-155	MDS1 and EVI1 complex locus	Homo sapiens	15-19
16462766-8	2006	The ability of Evi1 to suppress apoptosis is not restricted to TGFbeta-mediated cell death, since Evi1 also protects intestinal epithelial cells from taxol-mediated apoptosis.	Paclitaxel	150-155	MDS1 and EVI1 complex locus	Homo sapiens	98-102
16462766-10	2006	Knockdown of Evi1 by siRNA inhibited AKT phosphorylation in HT-29 human colon cancer cells and increased their sensitivity to taxol-mediated apoptosis.	Paclitaxel	126-131	MDS1 and EVI1 complex locus	Homo sapiens	13-17
16740723-5	2006	Whereas the dual treatment of breast cancer cells with Plk1-specific ASOs with carboplatin or Herceptin caused only a limited antiproliferative effect in breast cancer cells, we observed synergistic effects after combination of low doses of Plk1-specific ASOs with paclitaxel, which is used in a variety of clinical anticancer regimens.	Paclitaxel	265-275	polo like kinase 1	Homo sapiens	55-59
16740723-5	2006	Whereas the dual treatment of breast cancer cells with Plk1-specific ASOs with carboplatin or Herceptin caused only a limited antiproliferative effect in breast cancer cells, we observed synergistic effects after combination of low doses of Plk1-specific ASOs with paclitaxel, which is used in a variety of clinical anticancer regimens.	Paclitaxel	265-275	polo like kinase 1	Homo sapiens	241-245
16740723-6	2006	Plk1-specific ASOs also acted synergistically with paclitaxel in the arrest of the cell cycle at the G(2)-M phase and in the induction of apoptosis.	Paclitaxel	51-61	polo like kinase 1	Homo sapiens	0-4
16740723-8	2006	This study suggests that antisense inhibitors against Plk1 at well-tolerated doses may be considered as highly efficient promoters for the antineoplastic potential of taxanes, such as paclitaxel, causing synergistic effects in breast cancer cells.	Paclitaxel	184-194	polo like kinase 1	Homo sapiens	54-58
16740767-3	2006	We hypothesized that inhibiting the phosphorylation of EGFR and VEGFR by treatment with NVP-AEE788 (AEE788), a novel dual specific EGFR and VEGFR inhibitor, either alone or in combination with paclitaxel, would inhibit the growth of FTC xenografts in an orthotopic nude mouse model.	Paclitaxel	193-203	kinase insert domain receptor	Homo sapiens	64-69
16707463-6	2006	However, such resistance was readily reversed when Apo2L/TRAIL was used in combination with clinically relevant chemotherapeutic drugs, including taxol, etoposide, doxorubicin, cisplatin, or the histone deacetylase inhibitor suberoylanilide hydroxamic acid.	Paclitaxel	146-151	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	51-56
16546135-0	2006	Silencing of astrin induces the p53-dependent apoptosis by suppression of HPV18 E6 expression and sensitizes cells to paclitaxel treatment in HeLa cells.	Paclitaxel	118-128	sperm associated antigen 5	Homo sapiens	13-19
16546135-5	2006	Intriguingly, the expression of astrin decreased in paclitaxel-sensitive HeLa cells but remained steady in paclitaxel-resistant cells in response to paclitaxel treatment.	Paclitaxel	52-62	sperm associated antigen 5	Homo sapiens	32-38
16546135-5	2006	Intriguingly, the expression of astrin decreased in paclitaxel-sensitive HeLa cells but remained steady in paclitaxel-resistant cells in response to paclitaxel treatment.	Paclitaxel	107-117	sperm associated antigen 5	Homo sapiens	32-38
16546135-5	2006	Intriguingly, the expression of astrin decreased in paclitaxel-sensitive HeLa cells but remained steady in paclitaxel-resistant cells in response to paclitaxel treatment.	Paclitaxel	107-117	sperm associated antigen 5	Homo sapiens	32-38
16546135-6	2006	Furthermore, we identified that the depletion of astrin caused more cell death both in paclitaxel-sensitive and -resistant cells in combination with paclitaxel treatment.	Paclitaxel	87-97	sperm associated antigen 5	Homo sapiens	49-55
16546135-6	2006	Furthermore, we identified that the depletion of astrin caused more cell death both in paclitaxel-sensitive and -resistant cells in combination with paclitaxel treatment.	Paclitaxel	149-159	sperm associated antigen 5	Homo sapiens	49-55
16546135-7	2006	These findings suggest that the silencing of astrin induce a p53-dependent apoptosis and has an additive effect on paclitaxel treatment.	Paclitaxel	115-125	sperm associated antigen 5	Homo sapiens	45-51
16413505-11	2006	In conclusion, the combination of paclitaxel and PD168393 produced a profound synergistic growth inhibition of AIPC cells.	Paclitaxel	34-44	PDZ domain containing 2	Homo sapiens	111-115
16137660-0	2005	Preliminary assessment of the C13-side chain 2"-hydroxylase involved in taxol biosynthesis.	Paclitaxel	72-77	homeobox C13	Homo sapiens	30-33
16137660-1	2005	The biosynthesis of the anticancer drug Taxol in yew (Taxus) species is thought to involve the preliminary formation of the advanced taxane diterpenoid intermediate baccatin III upon which the functionally important N-benzoyl phenylisoserinoyl side chain is subsequently assembled at the C13-O-position.	Paclitaxel	40-45	homeobox C13	Homo sapiens	288-291
16137660-2	2005	In vivo feeding studies with Taxus tissues and characterization of the two transferases responsible for C13-side chain construction have suggested a sequential process in which an aminomutase converts alpha-phenylalanine to beta-phenylalanine which is then activated to the corresponding CoA ester and transferred to baccatin III to yield beta-phenylalanoyl baccatin III (i.e., N-debenzoyl-2"-deoxytaxol) that undergoes subsequent 2"-hydroxylation and N-benzoylation to afford Taxol.	Paclitaxel	477-482	homeobox C13	Homo sapiens	104-107
16272696-0	2005	YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors.	Paclitaxel	120-130	kinase insert domain receptor	Homo sapiens	52-97
15948138-9	2005	AEE788 treatment alone or in combination with paclitaxel inhibited the phosphorylation of EGF-R and VEGF-R on tumor cells and tumor-associated endothelial cells.	Paclitaxel	46-56	kinase insert domain receptor	Homo sapiens	100-106
16138009-0	2005	Low concentrations of taxol cause mitotic delay followed by premature dissociation of p55CDC from Mad2 and BubR1 and abrogation of the spindle checkpoint, leading to aneuploidy.	Paclitaxel	22-27	cell division cycle 20	Homo sapiens	86-92
16138009-6	2005	Low concentrations of Taxol dissociated p55CDC-Mad2 or p55CDC-BubR1 complexes after mitosis, whereas high concentrations of Taxol sustained the protein complex formation leading to mitotic block.	Paclitaxel	22-27	cell division cycle 20	Homo sapiens	40-51
16138009-6	2005	Low concentrations of Taxol dissociated p55CDC-Mad2 or p55CDC-BubR1 complexes after mitosis, whereas high concentrations of Taxol sustained the protein complex formation leading to mitotic block.	Paclitaxel	22-27	cell division cycle 20	Homo sapiens	40-46
15849751-0	2005	MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.	Paclitaxel	44-54	ATP binding cassette subfamily C member 2	Homo sapiens	0-4
15849751-0	2005	MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.	Paclitaxel	44-54	ATP binding cassette subfamily C member 2	Homo sapiens	6-11
15849751-4	2005	We here show that human MRP2 transduced into epithelial MDCKII cells efficiently transported the taxane anticancer drugs paclitaxel and docetaxel and that this transport could be substantially stimulated with the drug probenecid, a representative of a range of MRP2-stimulating drugs.	Paclitaxel	121-131	ATP binding cassette subfamily C member 2	Homo sapiens	24-28
15849751-6	2005	MRP2 further conferred substantial resistance against paclitaxel toxicity, and this resistance was 2.7-fold stimulated by probenecid.	Paclitaxel	54-64	ATP binding cassette subfamily C member 2	Homo sapiens	0-4
16144941-8	2005	To determine the mechanisms by which paclitaxel, discodermolide, and BMS-247550 activate hPXR, a mammalian two-hybrid assay was done using VP16SRC-1 (coactivator) and GAL4-SXR.	Paclitaxel	37-47	galectin 4	Homo sapiens	167-171
16061675-8	2005	When EphA2-targeting siRNA-DOPC was combined with paclitaxel, tumor growth was dramatically reduced compared with treatment with paclitaxel and a nonsilencing siRNA (SKOV3ip1: 0.04 versus 0.22 g; P &lt; 0.001; HeyA8: 0.21 versus 0.84 g; P = 0.0027).	Paclitaxel	129-139	EPH receptor A2	Homo sapiens	5-10
15986467-7	2005	Efflux inhibition ratio (EIR), the ratio of permeability due to P-gp-mediated efflux activity and passive permeability only, for these compounds was in the order of digoxin &gt; paclitaxel &gt; fexofenadine &gt; quinidine &gt; verapamil &gt; cyclosporine.	Paclitaxel	178-188	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	64-68
15994970-5	2005	3-Oxo-C12-(L)-HSL enhances the activity of 5-fluorodeoxyuridine, tomudex, and taxol but not the activity of 5-fluorouridine, methotrexate or Adriamycin.	Paclitaxel	78-83	lipase E, hormone sensitive type	Homo sapiens	14-17
15692086-10	2005	Angiopoietin-1 promoted survival of serum-starved C2C12, HSM, and NCM (MTT, trypan blue) and prevented taxol-induced apoptosis (caspase-3).	Paclitaxel	103-108	caspase 3	Mus musculus	128-137
15868904-6	2005	RESULTS: Paclitaxel treatment resulted in decreased conjugate formation, as well as decreased alpha4, alphaL, and beta7 integrin expression by YT cells and decreased ICAM-1 expression by K562 cells.	Paclitaxel	9-19	immunoglobulin binding protein 1	Homo sapiens	94-100
15868904-6	2005	RESULTS: Paclitaxel treatment resulted in decreased conjugate formation, as well as decreased alpha4, alphaL, and beta7 integrin expression by YT cells and decreased ICAM-1 expression by K562 cells.	Paclitaxel	9-19	intercellular adhesion molecule 1	Homo sapiens	166-172
15791823-1	2005	We report a patient with far-advanced gastric cancer treated by weekly administration of paclitaxel (TXL) over 2 years.	Paclitaxel	89-99	thioredoxin like 1	Homo sapiens	101-104
15548524-7	2005	In cells, the interaction between PLD2 and tubulin was increased by the microtubule disrupting agent nocodazole and reduced by the microtubule stabilizing agent Taxol.	Paclitaxel	161-166	phospholipase D2	Homo sapiens	34-38
15620876-13	2005	Thus, PEG-coated biodegradable polycyanoacrylate nanoparticles conjugated to transferrin could be an effective carrier for paclitaxel delivery.	Paclitaxel	123-133	transferrin	Mus musculus	77-88
15378273-1	2005	PURPOSE: Intrinsic P-glycoprotein (P-gp) expression in the gut limits paclitaxel uptake and, thus, its bioavailability when administered orally.	Paclitaxel	70-80	phosphoglycolate phosphatase	Mus musculus	19-33
15378273-1	2005	PURPOSE: Intrinsic P-glycoprotein (P-gp) expression in the gut limits paclitaxel uptake and, thus, its bioavailability when administered orally.	Paclitaxel	70-80	phosphoglycolate phosphatase	Mus musculus	35-39
15378273-16	2005	CONCLUSION: We found that a 3-day pretreatment with rIL2 had some in vivo inhibitory effects on P-gp activity for a short period after oral dosing of paclitaxel.	Paclitaxel	150-160	phosphoglycolate phosphatase	Mus musculus	96-100
15607317-4	2005	The method was applied to study the alteration of BRCA1 gene expression after exposure to taxol, doxorubicin, 5-fluorouracil, etoposide or gamma irradiation in human MCF-7 breast cancer cells.	Paclitaxel	90-95	BRCA1 DNA repair associated	Homo sapiens	50-55
15585644-2	2004	The purpose of this study is to investigate the possible role of pRb2/p130 in the sensitivity of ovarian cancer to camptothecin, doxorubicin, and taxol.	Paclitaxel	146-151	RB transcriptional corepressor like 2	Homo sapiens	70-74
15476281-8	2004	Drug sensitivity to doxorubicin, cisplatin, and paclitaxel (TXL) was increased 3-4-fold when used in combination with AS bcl-2, which was determined with 50% inhibitory concentration values, compared with the control group.	Paclitaxel	48-58	thioredoxin like 1	Homo sapiens	60-63
15549658-11	2004	Flow cytometric analysis of splenocytes in mice treated with paclitaxel showed a significant increase of CD11b+ cells.	Paclitaxel	61-71	integrin subunit alpha M	Homo sapiens	105-110
15358225-0	2004	Induction of heme oxygenase-1 is involved in anti-proliferative effects of paclitaxel on rat vascular smooth muscle cells.	Paclitaxel	75-85	heme oxygenase 1	Rattus norvegicus	13-29
15358225-1	2004	In this study, we evaluated the possibility that the anti-proliferative effects of paclitaxel on vascular smooth muscle cells (VSMCs) of the rat might be due to the induction of HO-1 gene expression.	Paclitaxel	83-93	heme oxygenase 1	Rattus norvegicus	178-182
15358225-2	2004	Treatment of the cells with paclitaxel resulted in marked time- and dose-dependent inductions of HO-1 mRNA, followed by corresponding increases in HO-1 protein expression and HO enzymatic activities.	Paclitaxel	28-38	heme oxygenase 1	Rattus norvegicus	97-101
15358225-2	2004	Treatment of the cells with paclitaxel resulted in marked time- and dose-dependent inductions of HO-1 mRNA, followed by corresponding increases in HO-1 protein expression and HO enzymatic activities.	Paclitaxel	28-38	heme oxygenase 1	Rattus norvegicus	147-151
15358225-4	2004	A specific inhibitor of JNK, SP600125, abolished paclitaxel-induced HO-1 mRNA expression, whereas PD98059, a specific inhibitor of ERK, and SB203580, a specific inhibitor of p38, had no significant effect.	Paclitaxel	49-59	heme oxygenase 1	Rattus norvegicus	68-72
15358225-6	2004	These results demonstrated that paclitaxel induces the expression of HO-1 via the JNK pathway in VSMC and that HO-1 expression might be responsible for the anti-proliferative effect of paclitaxel on VSMC.	Paclitaxel	32-42	heme oxygenase 1	Rattus norvegicus	69-73
15358225-6	2004	These results demonstrated that paclitaxel induces the expression of HO-1 via the JNK pathway in VSMC and that HO-1 expression might be responsible for the anti-proliferative effect of paclitaxel on VSMC.	Paclitaxel	185-195	heme oxygenase 1	Rattus norvegicus	69-73
15358225-6	2004	These results demonstrated that paclitaxel induces the expression of HO-1 via the JNK pathway in VSMC and that HO-1 expression might be responsible for the anti-proliferative effect of paclitaxel on VSMC.	Paclitaxel	185-195	heme oxygenase 1	Rattus norvegicus	111-115
15265561-9	2004	It might be considered that the significantly enhanced bioavailability of paclitaxel by the prodrug, which is water-soluble and easy to permeat through the intestinal mucosa, is due to the avoidance of being inhibited by p-glycoprotein efflux pump in the intestinal mucosa and reduction of metabolism by cytochrome-p-450 (CYP3A) in epitherial cells of small intestine.	Paclitaxel	74-84	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	221-235
15262123-0	2004	Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer.	Paclitaxel	32-42	kallikrein related peptidase 4	Homo sapiens	0-12
15262123-5	2004	The goal of this study was to investigate if KLK4 protein (hK4) is expressed in ovarian carcinoma lesions and if it is associated with paclitaxel resistance.	Paclitaxel	135-145	kallikrein related peptidase 4	Homo sapiens	45-49
15262123-5	2004	The goal of this study was to investigate if KLK4 protein (hK4) is expressed in ovarian carcinoma lesions and if it is associated with paclitaxel resistance.	Paclitaxel	135-145	keratin 4	Homo sapiens	59-62
15262123-9	2004	RESULTS: Immunohistochemistry indicated that 85% (79 of 93) of lesions from paclitaxel-resistant patients expressed hK4, while only 61% (20 of 33) of lesions were positive for hK4 from paclitaxel sensitive patients.	Paclitaxel	76-86	keratin 4	Homo sapiens	116-119
15262123-9	2004	RESULTS: Immunohistochemistry indicated that 85% (79 of 93) of lesions from paclitaxel-resistant patients expressed hK4, while only 61% (20 of 33) of lesions were positive for hK4 from paclitaxel sensitive patients.	Paclitaxel	185-195	keratin 4	Homo sapiens	176-179
15262123-10	2004	Statistical analysis showed that the intensity of hK4 staining was significantly associated with paclitaxel resistance (P = 0.005), whereas hK4 staining extent showed marginal significance (P = 0.05), but was significantly correlated with higher histological grade (P &lt; 0.001).	Paclitaxel	97-107	keratin 4	Homo sapiens	50-53
15262123-11	2004	CONCLUSION: These data show that hK4 is expressed in ovarian cancer and suggest that hK4 expression might be a predictive marker for paclitaxel resistance.	Paclitaxel	133-143	keratin 4	Homo sapiens	85-88
15252144-4	2004	In this study, we demonstrate that paclitaxel-resistant cell lines overexpress both ABCB1 and ABCB4 (MDR3).	Paclitaxel	35-45	ATP binding cassette subfamily B member 4	Homo sapiens	94-99
15252144-4	2004	In this study, we demonstrate that paclitaxel-resistant cell lines overexpress both ABCB1 and ABCB4 (MDR3).	Paclitaxel	35-45	ATP binding cassette subfamily B member 4	Homo sapiens	101-105
15120907-0	2004	Epigenetic regulation of the taxol resistance-associated gene TRAG-3 in human tumors.	Paclitaxel	29-34	CSAG family member 2	Homo sapiens	62-68
15120907-1	2004	TRAG-3, originally identified as a taxol resistance-associated gene from an ovarian carcinoma cell line, is upregulated in many human tumors.	Paclitaxel	35-40	CSAG family member 2	Homo sapiens	0-6
15063149-5	2004	To explore the mechanism of this effect, we employed flow cytometry to determine levels of p53, p21, bcl-2 and caspase proteins in the taxol-resistant cells, and found that the expression of the bcl-2 protein was markedly decreased and the expression of the caspase protein markedly increased after treatment with taxol in the presence of PMA.	Paclitaxel	135-140	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	96-99
15047226-1	2004	OBJECTIVES: Serum CA 125 kinetics during early chemotherapy has a strong predictive and prognostic relevance for patients with advanced ovarian carcinoma who received a first-line platinum-based regimen, whereas the ability of serum CA 125 assay to reflect the response to paclitaxel-based chemotherapy has not yet been defined.	Paclitaxel	273-283	mucin 16, cell surface associated	Homo sapiens	18-24
15047226-2	2004	The aim of the present paper is to calculate the serum CA 125 half-life during first-line paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma and to correlate this kinetic parameter with the response to treatment, progression-free survival and overall survival.	Paclitaxel	90-100	mucin 16, cell surface associated	Homo sapiens	55-61
15047226-8	2004	CONCLUSIONS: Serum CA 125 assay represents a reliable biochemical tool for the management of advanced ovarian carcinoma patients who receive a first-line paclitaxel/platinum-based chemotherapy.	Paclitaxel	154-164	mucin 16, cell surface associated	Homo sapiens	19-25
14670960-2	2004	We demonstrated previously that atypical PKCiota is required for Bcr-Abl-mediated resistance of human K562 chronic myelogenous leukemia (CML) cells to Taxol-induced apoptosis.	Paclitaxel	151-156	protein kinase C iota	Homo sapiens	41-48
14670960-2	2004	We demonstrated previously that atypical PKCiota is required for Bcr-Abl-mediated resistance of human K562 chronic myelogenous leukemia (CML) cells to Taxol-induced apoptosis.	Paclitaxel	151-156	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	65-72
15045960-1	2004	We treated a patient with recurrent ovarian cancer with cancerous peritonitis by weekly paclitaxel (w-TXL) therapy (65 mg/m2).	Paclitaxel	88-98	thioredoxin like 1	Homo sapiens	102-105
14605863-1	2004	We determined the effect of zosuquidar.3HCl, an inhibitor of P-gp, on the penetration of the anticancer drug paclitaxel into the brain.	Paclitaxel	109-119	phosphoglycolate phosphatase	Mus musculus	61-65
15032307-1	2004	PURPOSE: The objective of this study was to evaluate the pharmacokinetics of paclitaxel in a novel self-microemulsifying drug delivery system (SMEDDS) for improved oral administration with or without P-glycoprotein (P-gp) inhibitors.	Paclitaxel	77-87	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	216-220
15032307-10	2004	CONCLUSIONS: The results indicate that SMEDDS is a promising novel formulation to enhance the oral bioavailability of paclitaxel, especially when coadministered with a suitable P-gp inhibitor, such as CsA.	Paclitaxel	118-128	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	177-181
14974481-3	2004	In this case report, we describe the fatal outcome of an HSR in a patient receiving paclitaxel despite short-course premedication.	Paclitaxel	84-94	HSR	Homo sapiens	57-60
14579288-4	2003	NF-kappaB activation in Ba/F3 cells expressing murine Toll-like receptor (TLR) 4 and MD-2 was inhibited by Tm-Gp in a CD14/LPS-binding protein (LBP)-dependent manner when stimulated with LPS or its active center lipid A but not when stimulated with Taxol.	Paclitaxel	249-254	lipopolysaccharide binding protein	Mus musculus	144-147
14508823-12	2003	In vitro, the ErbB-2-overexpressing cells treated with combined trastuzumab plus paclitaxel secreted less VEGF than the cells treated with trastuzumab, paclitaxel, or control (185.9 pg/mL vs. 233.2 pg/mL, 261.3 pg/mL, and 286.4 pg/mL, respectively).	Paclitaxel	81-91	vascular endothelial growth factor A	Mus musculus	106-110
14508823-14	2003	Furthermore, Akt phosphorylation contributed to VEGF up-regulation and Akt phosphorylation was reduced more effectively by combined trastuzumab plus paclitaxel treatment compared with the other treatments.	Paclitaxel	149-159	vascular endothelial growth factor A	Mus musculus	48-52
14578588-8	2003	Taxol induced melanogenesis and apoptosis in the melanoma cells, inhibited angiogenesis in melanoma tissue lesions, and reduced the expression of VEGF.	Paclitaxel	0-5	vascular endothelial growth factor A	Mus musculus	146-150
14518418-0	2003	[A case of advanced type 4 gastric cancer with peritonitis dissemination, navel metastasis effectively treated with combined chemotherapy of biweekly paclitaxel (TXL) and TS-1].	Paclitaxel	150-160	thioredoxin like 1	Homo sapiens	162-165
12768320-1	2003	PURPOSE: Based on prior studies demonstrating the effect of 13- cis-retinoic acid and interferon alpha (CRA/IFN) in decreasing the expression of the antiapoptotic protein bcl-2, our prior clinical study of CRA/IFN with paclitaxel (TAX) administered every 3 weeks, and data demonstrating increased activity of weekly TAX against prostate cancer, we designed a phase I study of weekly TAX in combination with CRA/IFN in patients with prostate cancer and other advanced malignancies.	Paclitaxel	219-229	myotubularin related protein 11	Homo sapiens	86-111
12768320-1	2003	PURPOSE: Based on prior studies demonstrating the effect of 13- cis-retinoic acid and interferon alpha (CRA/IFN) in decreasing the expression of the antiapoptotic protein bcl-2, our prior clinical study of CRA/IFN with paclitaxel (TAX) administered every 3 weeks, and data demonstrating increased activity of weekly TAX against prostate cancer, we designed a phase I study of weekly TAX in combination with CRA/IFN in patients with prostate cancer and other advanced malignancies.	Paclitaxel	219-229	myotubularin related protein 11	Homo sapiens	104-107
12884273-3	2003	However, the ability of RACK1 from transformed cells to bind with beta-tubulin peptide specific for Taxol (PEPtaxol) is defective.	Paclitaxel	100-105	receptor for activated C kinase 1	Mus musculus	24-29
12855665-0	2003	Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.	Paclitaxel	25-35	phosphoglycolate phosphatase	Mus musculus	68-82
12855665-2	2003	We have determined the efficacy of several (putative) inhibitors of Pgp (cyclosporin A, PSC833, GF120918, and Cremophor EL) on the penetration of paclitaxel into the mouse brain.	Paclitaxel	146-156	phosphoglycolate phosphatase	Mus musculus	68-71
12738804-8	2003	Further, our data obtained from experiments involving in vitro taxol-polymerization of tubulin and confocal immunofluorescence suggest that PS1, via CLIP-170, may serve as an anchor to the microtubules for specific subcellular fractions containing amyloidogenic fragments.	Paclitaxel	63-68	CAP-Gly domain containing linker protein 1	Homo sapiens	149-157
12824894-7	2003	The results demonstrate the superior efficacy of orally administered DJ-927 over intravenously administered paclitaxel or docetaxel against P-gp-expressing tumors, probably due to higher intracellular accumulation.	Paclitaxel	108-118	phosphoglycolate phosphatase	Mus musculus	140-144
12707311-5	2003	Hesperadin also causes cells arrested by taxol or monastrol to enter anaphase within &lt;1 h, whereas cells in nocodazole stay arrested for 3-5 h. Together, our data suggest that Aurora B is required to generate unattached kinetochores on monooriented chromosomes, which in turn could promote bipolar attachment as well as maintain checkpoint signaling.	Paclitaxel	41-46	aurora kinase B	Homo sapiens	179-187
12624662-0	2003	The X-linked inhibitor of apoptosis protein inhibits taxol-induced apoptosis in LNCaP cells.	Paclitaxel	53-58	X-linked inhibitor of apoptosis	Homo sapiens	4-43
12624662-1	2003	To clarify the roles of the X-linked inhibitor of apoptosis protein (XIAP), we investigated the effects of XIAP overexpression on taxol-induced cell growth arrest and apoptosis in the prostate cancer cell line (LNCaP).	Paclitaxel	130-135	X-linked inhibitor of apoptosis	Homo sapiens	107-111
12624662-6	2003	Although the growth rates were reduced in a dose- and time-dependent manner by taxol, these effects were significantly decreased in XIAP stably overexpressing cell lines.	Paclitaxel	79-84	X-linked inhibitor of apoptosis	Homo sapiens	132-136
12624662-7	2003	In addition, we found that taxol treatment induced the cleavage of pro-caspase-3, followed by apoptosis, and that the overexpression of XIAP inhibited apoptosis by attenuating the cleavage of pro-caspase-3 and caspase-3 activity.	Paclitaxel	27-32	X-linked inhibitor of apoptosis	Homo sapiens	136-140
12624662-8	2003	Interestingly, XIAP bound to pro-caspase-3 in LNCaP cells transiently cotransfected with myc-XIAP and caspase-3-HA cDNAs, and this interaction was inhibited by taxol treatment.	Paclitaxel	160-165	X-linked inhibitor of apoptosis	Homo sapiens	15-19
12624662-8	2003	Interestingly, XIAP bound to pro-caspase-3 in LNCaP cells transiently cotransfected with myc-XIAP and caspase-3-HA cDNAs, and this interaction was inhibited by taxol treatment.	Paclitaxel	160-165	X-linked inhibitor of apoptosis	Homo sapiens	93-97
12624662-9	2003	These results suggest that the overexpression of XIAP inhibits taxol-induced apoptosis through the decrease of caspase-3 activity and inhibition of the processing of pro-caspase-3.	Paclitaxel	63-68	X-linked inhibitor of apoptosis	Homo sapiens	49-53
12610875-0	2003	[Effective transarterial neoadjuvant chemotherapy with paclitaxel (TXL) in a case of locally advanced breast cancer].	Paclitaxel	55-65	thioredoxin like 1	Homo sapiens	67-70
12465405-1	2002	We report a case of effective weekly paclitaxel (TXL) administration for metastatic gastric cancer.	Paclitaxel	37-47	thioredoxin like 1	Homo sapiens	49-52
12417570-2	2002	Since paclitaxel is excluded from some tumors by p-glycoprotein (p-gp), the same mechanism may prevent entry into the brain.	Paclitaxel	6-16	phosphoglycolate phosphatase	Mus musculus	49-63
12417570-2	2002	Since paclitaxel is excluded from some tumors by p-glycoprotein (p-gp), the same mechanism may prevent entry into the brain.	Paclitaxel	6-16	phosphoglycolate phosphatase	Mus musculus	65-69
12417570-8	2002	Luminal accumulation of NBDL-cyclosporin, a p-gp substrate, was inhibited by paclitaxel.	Paclitaxel	77-87	phosphoglycolate phosphatase	Mus musculus	44-48
12417570-13	2002	Thus, p-gp is an important obstacle preventing paclitaxel entry into the brain, and inhibition of this transporter allows the drug to reach sensitive tumors within the CNS.	Paclitaxel	47-57	phosphoglycolate phosphatase	Mus musculus	6-10
12370827-3	2002	Treatment of the transfected cells with cisplatin, staurosporine, paclitaxel and doxorubicine showed that BAG-1 p50, p46 and p33 isoforms enhanced the resistance to apoptosis.	Paclitaxel	66-76	activating signal cointegrator 1 complex subunit 1	Homo sapiens	112-115
12355953-1	2002	We report a case in which weekly paclitaxel (TXL) administration was effective for gastric cancer with malignant ascites.	Paclitaxel	33-43	thioredoxin like 1	Homo sapiens	45-48
12366658-3	2002	When we determine the CA125 regression rate to predict overall survival in ovarian cancer, we should take into account the kind of chemotherapy regimen, especially the use of paclitaxel.	Paclitaxel	175-185	mucin 16, cell surface associated	Homo sapiens	22-27
12167714-6	2002	Overexpression of a Plk phosphorylation site-deficient mutant of TCTP induced a dramatic increase in the number of multinucleate cells, rounded cells with condensed ball-like nuclei, and cells undergoing cell death, similar to both the reported anti-Plk antibody microinjection and the low-concentration taxol treatment phenotypes.	Paclitaxel	304-309	polo like kinase 1	Homo sapiens	20-23
12142397-0	2002	Predicting response of ovarian cancer to paclitaxel treatment based on trend analysis of serum CA125.	Paclitaxel	41-51	mucin 16, cell surface associated	Homo sapiens	95-100
12124833-0	2002	Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.	Paclitaxel	46-56	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	87-90
12119329-0	2002	Inhibition of vascular endothelial growth factor-mediated neointima progression with angiostatin or paclitaxel.	Paclitaxel	100-110	vascular endothelial growth factor A	Oryctolagus cuniculus	14-48
12063170-0	2002	Distinct mechanisms of taxol-induced serine phosphorylation of the 66-kDa Shc isoform in A549 and RAW 264.7 cells.	Paclitaxel	23-28	src homology 2 domain-containing transforming protein C1	Mus musculus	74-77
12063170-1	2002	Nanomolar concentrations of Taxol, and other antimitotic agents that interact with microtubules, mediate serine phosphorylation of the 66-kDa Shc isoform (p66shc) in A549 human lung carcinoma cells, 9-18 h after drug treatment.	Paclitaxel	28-33	src homology 2 domain-containing transforming protein C1	Mus musculus	142-145
12063170-1	2002	Nanomolar concentrations of Taxol, and other antimitotic agents that interact with microtubules, mediate serine phosphorylation of the 66-kDa Shc isoform (p66shc) in A549 human lung carcinoma cells, 9-18 h after drug treatment.	Paclitaxel	28-33	src homology 2 domain-containing transforming protein C1	Mus musculus	155-161
12063170-3	2002	Taxol-induced serine phosphorylation of p66shc results from a MEK-independent signaling pathway that is activated in A549 cells that have a prolonged or abnormal mitotic phase of the cell cycle [Cancer Res.	Paclitaxel	0-5	src homology 2 domain-containing transforming protein C1	Mus musculus	40-46
12063170-5	2002	In contrast, in murine macrophage RAW 264.7 cells, micromolar concentrations of Taxol but not other microtubule-interacting agents induced serine phosphorylation of p66shc that correlated with the phosphorylation of Raf-1 and extracellular signal-regulated kinase (ERK1/2), within 15-30 min after Taxol treatment.	Paclitaxel	80-85	src homology 2 domain-containing transforming protein C1	Mus musculus	165-171
12063170-5	2002	In contrast, in murine macrophage RAW 264.7 cells, micromolar concentrations of Taxol but not other microtubule-interacting agents induced serine phosphorylation of p66shc that correlated with the phosphorylation of Raf-1 and extracellular signal-regulated kinase (ERK1/2), within 15-30 min after Taxol treatment.	Paclitaxel	80-85	v-raf-leukemia viral oncogene 1	Mus musculus	216-221
12063170-5	2002	In contrast, in murine macrophage RAW 264.7 cells, micromolar concentrations of Taxol but not other microtubule-interacting agents induced serine phosphorylation of p66shc that correlated with the phosphorylation of Raf-1 and extracellular signal-regulated kinase (ERK1/2), within 15-30 min after Taxol treatment.	Paclitaxel	297-302	src homology 2 domain-containing transforming protein C1	Mus musculus	165-171
11955676-1	2002	In this study, paclitaxel was used to determine inhibition of arylamine N-acetyltransferase (NAT) activity, gene expression and 2-aminofluorene-DNA adduct formation in a human lung tumor cell line (A549).	Paclitaxel	15-25	bromodomain containing 2	Homo sapiens	93-96
11955676-4	2002	The results demonstrated that NAT activity, gene expression (NAT1 mRNA) and 2-AF-DNA adduct formation in human lung tumor cells were inhibited and decreased by paclitaxel in a dose-dependent manner.	Paclitaxel	160-170	bromodomain containing 2	Homo sapiens	30-33
11955676-5	2002	The effects of paclitaxel on the values of the apparent Km and Vmax of NAT from human lung tumor cells were also determined in both examined systems.	Paclitaxel	15-25	bromodomain containing 2	Homo sapiens	71-74
11955676-7	2002	Thus, paclitaxel is an uncompetitive inhibitor to NAT enzyme.	Paclitaxel	6-16	bromodomain containing 2	Homo sapiens	50-53
11955677-4	2002	In this study, paclitaxel was selected to determine the inhibition of arylamine N-acetyltransferase activity, gene expression (NAT mRNA) and DNA-2-aminofluorene adduct formation in human leukemia HL-60 cell line.	Paclitaxel	15-25	bromodomain containing 2	Homo sapiens	127-130
11955677-5	2002	Paclitaxel (0.01-l microM) did decrease the level of NAT mRNA in a dose-dependent manner.	Paclitaxel	0-10	bromodomain containing 2	Homo sapiens	53-56
11955677-6	2002	The results demonstrated that paclitaxel inhibited NAT activity and DNA-2-aminofluorene adduct formation in human leukemia HL-60 cells in a dose-dependent manner.	Paclitaxel	30-40	bromodomain containing 2	Homo sapiens	51-54
11955677-7	2002	Using standard steady-state kinetic analysis, it was demonstrated that paclitaxel was a possible uncompetitive inhibitor to NAT activity in cytosols based on the decrease in apparent values of K(m) and V(max).	Paclitaxel	71-81	bromodomain containing 2	Homo sapiens	124-127
11955677-8	2002	This report is the first demonstration that paclitaxel affected human leukemia HL-60 cells NAT activity and DNA-2-aminofluorene adduct formation.	Paclitaxel	44-54	bromodomain containing 2	Homo sapiens	91-94
12036452-1	2002	Combination chemotherapy with gemcitabine (Gem), doxorubicin (Dox), and paclitaxel (Pac) (GAT) has been considered attractive as first-line treatment in metastatic breast cancer.	Paclitaxel	72-82	glycine-N-acyltransferase	Homo sapiens	90-93
12036452-1	2002	Combination chemotherapy with gemcitabine (Gem), doxorubicin (Dox), and paclitaxel (Pac) (GAT) has been considered attractive as first-line treatment in metastatic breast cancer.	Paclitaxel	84-87	glycine-N-acyltransferase	Homo sapiens	90-93
11931848-0	2002	Overexpression of sorcin, a calcium-binding protein, induces a low level of paclitaxel resistance in human ovarian and breast cancer cells.	Paclitaxel	76-86	sorcin	Homo sapiens	18-24
11931848-7	2002	Transfection of the parental 2008 cells with full-length sorcin cDNA induced a low level (3-5-fold) of paclitaxel resistance.	Paclitaxel	103-113	sorcin	Homo sapiens	57-63
11931848-8	2002	In addition, transfection of human breast cancer cells with the full-length sorcin cDNA also led to the induction of a low level of paclitaxel resistance in the transfectants.	Paclitaxel	132-142	sorcin	Homo sapiens	76-82
11931848-9	2002	Although the overexpression of sorcin did not produce high levels of paclitaxel resistance, the results obtained present compelling evidence of the involvement of sorcin in developing low-level paclitaxel resistance in a variety of tumor cells.	Paclitaxel	194-204	sorcin	Homo sapiens	163-169
11931848-10	2002	The precise biochemical mechanism(s) by which sorcin overexpression induces low-level paclitaxel resistance is currently under investigation.	Paclitaxel	86-96	sorcin	Homo sapiens	46-52
11914641-2	2002	P-gp is considered an important factor in the control of Taxol efflux from tumor cells.	Paclitaxel	57-62	phosphoglycolate phosphatase	Mus musculus	0-4
11914641-3	2002	Based on the premise that Taxol pharmacokinetic parameters could be modified as a result of diminished P-gp expression induced by recombinant interleukin (rIL)-2 and that this might elicit an interaction between the two drugs, we evaluated the pharmacokinetics of a novel strategy combining i.p.	Paclitaxel	26-31	phosphoglycolate phosphatase	Mus musculus	103-107
11914641-3	2002	Based on the premise that Taxol pharmacokinetic parameters could be modified as a result of diminished P-gp expression induced by recombinant interleukin (rIL)-2 and that this might elicit an interaction between the two drugs, we evaluated the pharmacokinetics of a novel strategy combining i.p.	Paclitaxel	26-31	radiation-induced leukemia sensitivity 2	Mus musculus	130-161
11707402-2	2001	SH-EP1 and SH-SY5Y human neuroblastoma cells, derived from a single precursor cell line, differed in their sensitivity to taxol but showed the same sensitivity to cisplatin.	Paclitaxel	122-127	SH2 domain containing 3C	Homo sapiens	0-6
11587211-4	2001	Furthermore, GA sensitized Bcr-Abl-expressing cells to doxorubicin (DOX) and paclitaxel (PTX).	Paclitaxel	89-92	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	27-34
11593420-3	2001	Induction of BRCA1 in the presence of Taxol and Vincristine resulted in a dramatic increase in cell death; an effect that was preceded by an acute arrest at the G2/M phase of the cell cycle and which correlated with BRCA1 mediated induction of GADD45.	Paclitaxel	38-43	BRCA1 DNA repair associated	Homo sapiens	13-18
11593420-3	2001	Induction of BRCA1 in the presence of Taxol and Vincristine resulted in a dramatic increase in cell death; an effect that was preceded by an acute arrest at the G2/M phase of the cell cycle and which correlated with BRCA1 mediated induction of GADD45.	Paclitaxel	38-43	BRCA1 DNA repair associated	Homo sapiens	216-221
11511385-0	2001	Leukaemia inhibitory factor abrogates Paclitaxel-induced axonal atrophy in the Wistar rat.	Paclitaxel	38-48	LIF, interleukin 6 family cytokine	Rattus norvegicus	0-27
11511385-3	2001	We found that whereas animals administered Paclitaxel alone exhibited a significant decrease in the percentage of large myelinated axons, this reduction was prevented by the co-administration of LIF.	Paclitaxel	43-53	LIF, interleukin 6 family cytokine	Rattus norvegicus	195-198
11526484-3	2001	In the present study, we demonstrate that in the MDA-MB-231 and MDA-MB-435 breast cancer cells, ligation of beta1 integrins by their extracellular matrix ligands inhibits significantly apoptosis induced by paclitaxel and vincristine, two microtubule-directed chemotherapeutic agents that are widely used in the therapy of breast cancer.	Paclitaxel	206-216	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	108-113
11489796-10	2001	17-AAG sensitized tumor cells to Taxol and doxorubicin.	Paclitaxel	33-38	N-methylpurine DNA glycosylase	Homo sapiens	3-6
11489796-12	2001	The addition of 17-AAG to cells after exposure to Taxol significantly increased both the activation of caspases 9 and 3 and apoptosis.	Paclitaxel	50-55	N-methylpurine DNA glycosylase	Homo sapiens	19-22
11487703-6	2001	Arresting cells in mitosis through the stabilization of microtubules by taxol further enhanced the spindle-localized pool of Cdc2-GFP.	Paclitaxel	72-77	cell division control protein 2 homolog A	Nicotiana tabacum	125-129
11487703-10	2001	Furthermore, we demonstrate that both the endogenous CDK-A and Cdc2-GFP were cosedimented with taxol-stabilized plant microtubules from cell extracts and that Cdc2 activity was detected together with a fraction of polymerized tubulin.	Paclitaxel	95-100	cell division control protein 2 homolog A	Nicotiana tabacum	63-67
11334567-0	2001	Synthesis and NMR-driven conformational analysis of taxol analogues conformationally constrained on the C13 side chain.	Paclitaxel	52-57	homeobox C13	Homo sapiens	104-107
11325840-0	2001	Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.	Paclitaxel	35-45	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	87-135
11325840-6	2001	We found that cyclophosphamide, paclitaxel, and doxorubicin, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhanced the vaccine"s potential to delay tumor growth in neu transgenic mice.	Paclitaxel	32-42	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	101-107
11383212-1	2001	This study was performed to assess the feasibility of weekly paclitaxel (TXL) and cisplatin (CDDP) in patients with recurrent ovarian cancer.	Paclitaxel	61-71	thioredoxin like 1	Homo sapiens	73-76
11223949-9	2001	Albumin secretion and cytochrome P450 2B1/2 activities of hepatocytes were comparable in spheroids formed in the presence of taxol or nocodazole to those formed in control cultures.	Paclitaxel	125-130	albumin	Rattus norvegicus	0-7
11039505-7	2000	IL-10 serum levels significantly decreased in paclitaxel-treated patients (4.4+/-1.3 pg/ml at week 4 versus 7.8+/-2.1 pg/ml at baseline; p &lt; 0.05).	Paclitaxel	46-56	interleukin 10	Homo sapiens	0-5
10918072-6	2000	Here, we report an increased directional transport of several MDR1 P-glycoprotein substrates, such as digoxin, paclitaxel, and vinblastine, through polarized monolayers of MDR3-transfected cells.	Paclitaxel	111-121	ATP binding cassette subfamily B member 4	Homo sapiens	172-176
10963366-4	2000	In addition, there was a relative preservation of MAP2 labelling of dendrites surrounding the injury site in taxol-treated, as compared to vehicle-treated, animals at 1 day post-injury.	Paclitaxel	109-114	microtubule associated protein 2	Homo sapiens	50-54
10963366-6	2000	The degree of MAP2 labelling was also equally decreased in both vehicle- and taxol-treated animals as compared to normal cortex at this time point.	Paclitaxel	77-82	microtubule associated protein 2	Homo sapiens	14-18
10766876-7	2000	These results demonstrate that ch-TOGp is a major constituent of microtubule asters assembled in a mammalian mitotic extract and that it is required for robust microtubule polymerization in an ATP-dependent manner in this system even though taxol is present.	Paclitaxel	241-246	cytoskeleton associated protein 5	Homo sapiens	34-38
10738258-4	2000	Paclitaxel+AS101 synergistically activated c-raf-1 and MAPK ERK1 and ERK2.	Paclitaxel	0-10	v-raf-leukemia viral oncogene 1	Mus musculus	43-50
10554096-12	1999	Using a polarized epithelial cell transport assay, TPGS blocked P-gp mediated transport of R123 and paclitaxel in a dose responsive manner.	Paclitaxel	100-110	phosphoglycolate phosphatase	Mus musculus	64-68
10822530-4	1999	In addition, the model predicts the affinity of compounds not used in the training set and explains much of the SAR for the paclitaxel and epothilone families.	Paclitaxel	124-134	sarcosine dehydrogenase	Homo sapiens	112-115
10215936-5	1999	Cytochalasin B and colchicine decreased, and taxol or phalloidin increased INa and reduced its hypoxic inhibition.	Paclitaxel	45-50	internexin neuronal intermediate filament protein, alpha	Mus musculus	75-78
10095106-0	1999	TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line.	Paclitaxel	38-43	CSAG family member 2	Homo sapiens	0-6
10095106-4	1999	In comparison to the parental line, SKOV-3, TRAG-3 mRNA is overexpressed in the taxol-resistant cell line SKOV-3TR.	Paclitaxel	80-85	CSAG family member 2	Homo sapiens	44-50
10095106-8	1999	Northern analysis demonstrates that TRAG-3 is overexpressed in the taxol-resistant breast cancer cell line MDA 435TR as well as the doxorubicin-resistant multiple myeloma cell lines 8226/DOX40 and 8226/MDR10V.	Paclitaxel	67-72	CSAG family member 2	Homo sapiens	36-42
10850285-2	1999	In this study, we show that paclitaxel possesses an antiangiogenic property associated with a down-regulation of vascular endothelial growth factor (VEGF) in a highly-vascularized transgenic murine breast cancer (Met-1).	Paclitaxel	28-38	vascular endothelial growth factor A	Mus musculus	113-147
10850285-2	1999	In this study, we show that paclitaxel possesses an antiangiogenic property associated with a down-regulation of vascular endothelial growth factor (VEGF) in a highly-vascularized transgenic murine breast cancer (Met-1).	Paclitaxel	28-38	vascular endothelial growth factor A	Mus musculus	149-153
10850285-5	1999	Paclitaxel also suppressed expression of VEGF in the Met-1 cells transplanted in nude mice or maintained in cell culture.	Paclitaxel	0-10	vascular endothelial growth factor A	Mus musculus	41-45
10850285-6	1999	These results indicate that antiangiogenesis associated with a down-regulation of VEGF is an additional mode of action of paclitaxel.	Paclitaxel	122-132	vascular endothelial growth factor A	Mus musculus	82-86
10080591-1	1999	PURPOSE: To assess CA-125 as a measure of response in patients treated with paclitaxel.	Paclitaxel	76-86	mucin 16, cell surface associated	Homo sapiens	19-25
10080591-3	1999	The standard and CA-125 response rates to paclitaxel and platinum were compared.	Paclitaxel	42-52	mucin 16, cell surface associated	Homo sapiens	17-23
10080591-7	1999	Responders to paclitaxel had a significantly improved progression-free survival compared with non-responders by both standard criteria (median progression-free survival, 6.8 v 2.5 months; P&lt;.001) and CA-125 criteria (median progression-free survival, 6.8 v 3.4 months; P&lt;.001).	Paclitaxel	14-24	mucin 16, cell surface associated	Homo sapiens	203-209
9746563-0	1998	Induction of adrenomedullin mRNA and protein by lipopolysaccharide and paclitaxel (Taxol) in murine macrophages.	Paclitaxel	83-88	adrenomedullin	Mus musculus	13-27
9751629-0	1998	Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein.	Paclitaxel	0-5	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	79-93
9724749-6	1998	In vitro cosedimentation with taxol-stabilized microtubules demonstrated that a significant fraction of EB1 associated with microtubules.	Paclitaxel	30-35	microtubule associated protein RP/EB family member 1	Homo sapiens	104-107
9674995-8	1998	We show by Western analysis that the endogenous SPNR protein can be pelleted with murine testis microtubules in a taxol-dependent manner in vitro.	Paclitaxel	114-119	spermatid perinuclear RNA binding protein	Mus musculus	48-52
9842986-10	1998	Significant inhibition of paclitaxel conversion to 6alpha-hydroxypaclitaxel and 3"-p-hydroxypaclitaxel was observed in the presence of R-verapamil, tamoxifen and VP-16 (P 0.005).	Paclitaxel	26-36	host cell factor C1	Homo sapiens	162-167
9588740-2	1998	This study evaluates the effect of paclitaxel on AP-1 activation and examines its effect on the expression of 2 major matrix metalloproteinases, MMP-1 and MMP-3, and its effect on AP-1 activation.	Paclitaxel	35-45	stromelysin-1	Bos taurus	155-160
9588740-7	1998	RESULTS: IL-1-induced MMP-1 and MMP-3 mRNA levels were markedly reduced in paclitaxel-treated chondrocytes.	Paclitaxel	75-85	stromelysin-1	Bos taurus	32-37
9588740-11	1998	CONCLUSION: These studies demonstrate that paclitaxel is a potent inhibitor of MMP-1 and MMP-3 synthesis through the AP-1 site.	Paclitaxel	43-53	stromelysin-1	Bos taurus	89-94
9478937-3	1998	We have observed that paclitaxel (Taxol), docetaxel (Taxotere), vinblastine, vincristine, nocodazole, and colchicine activate the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) signaling pathway in a variety of human cells.	Paclitaxel	22-32	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	130-135
9478937-3	1998	We have observed that paclitaxel (Taxol), docetaxel (Taxotere), vinblastine, vincristine, nocodazole, and colchicine activate the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) signaling pathway in a variety of human cells.	Paclitaxel	34-39	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	130-135
9502180-5	1998	The greatest changes in activity of enzymes at the taxol dose of 2.5 mg/kg bw were as follows: the activity of cathepsin D increased by 71%, that of alanine aminopeptidase increased by 103%, that of beta-glucuronidase decreased by 45% and that of beta-glucosidase decreased by 63%.	Paclitaxel	51-56	cathepsin D	Mus musculus	111-122
9374539-4	1997	POH1 also confers P-glycoprotein-independent resistance to taxol (paclitaxel), doxorubicin, 7-hydroxystaurosporine, and ultraviolet light when transiently overexpressed in mammalian cells.	Paclitaxel	59-64	proteasome 26S subunit, non-ATPase 14	Homo sapiens	0-4
9374539-4	1997	POH1 also confers P-glycoprotein-independent resistance to taxol (paclitaxel), doxorubicin, 7-hydroxystaurosporine, and ultraviolet light when transiently overexpressed in mammalian cells.	Paclitaxel	66-76	proteasome 26S subunit, non-ATPase 14	Homo sapiens	0-4
9218008-0	1997	Effect of paclitaxel (Taxol) on CA 125 expression and release by ovarian cancer cell lines.	Paclitaxel	10-20	mucin 16, cell surface associated	Homo sapiens	32-38
9218008-0	1997	Effect of paclitaxel (Taxol) on CA 125 expression and release by ovarian cancer cell lines.	Paclitaxel	22-27	mucin 16, cell surface associated	Homo sapiens	32-38
9218008-4	1997	Immunohistochemical analysis demonstrated that both cell lines retained the CA 125 expression on the cell surface during exposure to paclitaxel.	Paclitaxel	133-143	mucin 16, cell surface associated	Homo sapiens	76-82
9218008-7	1997	It may be concluded from this study that CA 125 seems to be a reliable tumor marker in monitoring tumor response during paclitaxel treatment.	Paclitaxel	120-130	mucin 16, cell surface associated	Homo sapiens	41-47
9079744-3	1997	We investigated the resistance patterns of a hormone-sensitive and four hormone-independent Dunning rat carcinoma sublines against four drugs which are substrates of P-glycoprotein (vinblastine, taxol, doxorubicin, and etoposide) and two agents (methotrexate and cis-platinum) which are not transported by this efflux pump.	Paclitaxel	195-200	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	166-180
8756354-1	1996	The p-toluenesulfonamide derivate of the C-13 side-chain of taxol was prepared on a one third mole scale in a single step from methyl cinnamate.	Paclitaxel	60-65	homeobox C13	Homo sapiens	41-45
8646707-0	1996	CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?	Paclitaxel	66-76	mucin 16, cell surface associated	Homo sapiens	0-6
8646707-2	1996	Our study aimed to determine whether CA 125 changes relate to tumor response and overall survival during paclitaxel salvage treatment.	Paclitaxel	105-115	mucin 16, cell surface associated	Homo sapiens	37-43
8646707-7	1996	For both the stable disease group and the responders, the slopes of the exponential CA 125 regression curves during paclitaxel treatment were negative.	Paclitaxel	116-126	mucin 16, cell surface associated	Homo sapiens	84-90
8646707-9	1996	CONCLUSIONS: This study confirms that CA 125 changes in patients receiving paclitaxel treatment do not correlate with response allocations according to WHO criteria.	Paclitaxel	75-85	mucin 16, cell surface associated	Homo sapiens	38-44
8768096-3	1996	Depolymerization of microtubular system by colcemid and its disorganization by taxol lead to rapid and drastic changes in morphology of all cytoskeletal systems and in the organization of matrix network: fibronectin and tenascin filaments became disordered and, in particular, lost any orientation.	Paclitaxel	79-84	tenascin C	Homo sapiens	220-228
7591286-0	1995	Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel.	Paclitaxel	122-132	microtubule associated protein 2	Homo sapiens	41-73
7591286-8	1995	The samples were immunoprecipitated with anti-alpha- and anti-beta-tubulin antibodies and reblotted with an anti-MAP2 antibody, which showed that the amount of co-immuno-precipitated MAP2 in the synchronized cells, were increased by the brief paclitaxel treatment.	Paclitaxel	243-253	microtubule associated protein 2	Homo sapiens	183-187
7591286-9	1995	These results suggest that paclitaxel treatment enhances the interaction between alpha and beta tubulins and MAP2.	Paclitaxel	27-37	microtubule associated protein 2	Homo sapiens	109-113
7591286-19	1995	These actions of paclitaxel may be responsible for the increased affinity between MAP2 and tubulins that it induces.	Paclitaxel	17-27	microtubule associated protein 2	Homo sapiens	82-86
7553639-9	1995	These data suggest that induction of p21WAF1 by taxol requires c-raf-1 activity, but that it is not strictly dependent on wild-type p53.	Paclitaxel	48-53	TNF receptor associated factor 3	Homo sapiens	63-70
7553639-10	1995	Furthermore, the ability of taxol to both induce wild-type p53 in MCF7 cells and activate MAP kinase is also dependent on c-raf-1 expression.	Paclitaxel	28-33	TNF receptor associated factor 3	Homo sapiens	122-129
7581225-3	1995	Depolymerization of the microtubular system by colcemid and its disorganization by taxol led to rapid and drastic changes in the organization of matrix network: fibronectin and tenascin filaments became disordered and, in particular, lost any orientation.	Paclitaxel	83-88	tenascin C	Homo sapiens	177-185
7529746-17	1995	On the other hand, 3H-labeled taxol bound to both J774.1 cells and J7.DEF3 cells in similar time- and dose-dependent manners.	Paclitaxel	30-35	RNA binding motif protein 6	Mus musculus	70-74
7915328-0	1994	Structure-activity studies of antitumor taxanes: synthesis of novel C-13 side chain homologated taxol and taxotere analogs.	Paclitaxel	96-101	homeobox C13	Homo sapiens	68-72
7914372-0	1994	Coordinate depression of bradykinin receptor recycling and microtubule-dependent transport by taxol.	Paclitaxel	94-99	kininogen 1	Bos taurus	25-35
7914372-5	1994	Since the bradykinin receptor-agonist complex is internalized and recycled whereas the ATP agonist-receptor complex is not, we expected that a taxol inhibition of recycling would decrease bradykinin but not ATP receptor activity.	Paclitaxel	143-148	kininogen 1	Bos taurus	10-20
7914372-5	1994	Since the bradykinin receptor-agonist complex is internalized and recycled whereas the ATP agonist-receptor complex is not, we expected that a taxol inhibition of recycling would decrease bradykinin but not ATP receptor activity.	Paclitaxel	143-148	kininogen 1	Bos taurus	188-198
7914372-6	1994	We found that taxol depresses (i) the frequency (to 41% of control) and velocity (to 55% of control) of microtubule-dependent vesicle transport and (ii) bradykinin-evoked cytosolic Ca2+ transients (to 76% of control) in bovine aortic endothelial cells.	Paclitaxel	14-19	kininogen 1	Bos taurus	153-163
7914372-7	1994	In studying bradykinin receptor desensitization, which reflects receptor recycling, we demonstrate that taxol inhibits bradykinin-evoked Ca2+ transients by 50%.	Paclitaxel	104-109	kininogen 1	Bos taurus	12-22
7914372-7	1994	In studying bradykinin receptor desensitization, which reflects receptor recycling, we demonstrate that taxol inhibits bradykinin-evoked Ca2+ transients by 50%.	Paclitaxel	104-109	kininogen 1	Bos taurus	119-129
7914372-9	1994	We suggest that taxol"s reduction of bradykinin-evoked Ca2+ transients is due to altered microtubule-dependent membrane recycling.	Paclitaxel	16-21	kininogen 1	Bos taurus	37-47
7913412-0	1994	Taxol induces the hematopoietic growth factor granulocyte-macrophage colony-stimulating factor in murine B-cells by stabilization of granulocyte-macrophage colony-stimulating factor nuclear RNA.	Paclitaxel	0-5	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	46-94
7913412-0	1994	Taxol induces the hematopoietic growth factor granulocyte-macrophage colony-stimulating factor in murine B-cells by stabilization of granulocyte-macrophage colony-stimulating factor nuclear RNA.	Paclitaxel	0-5	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	133-181
7913412-4	1994	In light of the similarity of taxol and lipopolysaccharide in their effects on macrophages, we tested whether taxol could also induce the expression of GM-CSF in B-cell lines.	Paclitaxel	110-115	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	152-158
7913412-6	1994	In unstimulated cells, no GM-CSF mRNA was detected, whereas in taxol-stimulated stimulated cells at a concentration of 30 microM, GM-CSF mRNA was induced 4-8 h after stimulation.	Paclitaxel	63-68	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	130-136
7966458-7	1994	sera of these animals revealed a negative reaction in PCA using rats by challenge with paclitaxel or paclitaxel + RSA (rat serum albumin).	Paclitaxel	101-111	albumin	Rattus norvegicus	123-136
7911444-0	1994	Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol.	Paclitaxel	81-86	mucin 16, cell surface associated	Homo sapiens	26-32
7911444-9	1994	We conclude that changes in serum CA 125 levels follow an exponential regression curve in patients undergoing salvage chemotherapy with taxol for progressive or recurrent ovarian cancer.	Paclitaxel	136-141	mucin 16, cell surface associated	Homo sapiens	34-40
8074481-4	1994	HAC2/CPT showed no cross-resistance to other drugs tested (adriamycin, etoposide, cisplatin and Taxol), suggesting that HAC2/CPT acquired a phenotype specifically resistant to the Topo I inhibitor.	Paclitaxel	96-101	choline phosphotransferase 1	Homo sapiens	125-128
7514586-5	1994	Removal of the drug from the medium resulted in a 38% decrease in the growth rate of H69/Txl as compared with that in the presence of 30 nM taxol, suggesting that the growth of H69/Txl was partially dependent on taxol.	Paclitaxel	140-145	thioredoxin like 1	Homo sapiens	181-184
7514586-5	1994	Removal of the drug from the medium resulted in a 38% decrease in the growth rate of H69/Txl as compared with that in the presence of 30 nM taxol, suggesting that the growth of H69/Txl was partially dependent on taxol.	Paclitaxel	212-217	thioredoxin like 1	Homo sapiens	89-92
7514586-5	1994	Removal of the drug from the medium resulted in a 38% decrease in the growth rate of H69/Txl as compared with that in the presence of 30 nM taxol, suggesting that the growth of H69/Txl was partially dependent on taxol.	Paclitaxel	212-217	thioredoxin like 1	Homo sapiens	181-184
7514586-13	1994	The acetylation of alpha-tubulin may be responsible for the taxol resistance and/or taxol-dependent growth of H69/Txl.	Paclitaxel	84-89	thioredoxin like 1	Homo sapiens	114-117
7906984-0	1993	Analysis of spindle microtubule organization in untreated and taxol-treated PtK1 cells.	Paclitaxel	62-67	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	76-80
7906984-2	1993	PtK1 cells have been treated with 5 micrograms/ml taxol for brief periods to determine its effect on spindle architecture.	Paclitaxel	50-55	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	0-4
8104575-3	1993	MAP2 bound to the surface of preformed, taxol-stabilized maize microtubules, with binding saturation occurring with one MAP2 molecule per five to six tubulin dimers, as it does with mammalian microtubules.	Paclitaxel	40-45	microtubule associated protein 2	Homo sapiens	0-4
8104575-5	1993	MAP2 corrected in vitro folding errors in taxol-stabilized maize microtubules and reduced the critical concentration of maize tubulin polymerization eightfold, from 8.3 to 1.0 microM.	Paclitaxel	42-47	microtubule associated protein 2	Homo sapiens	0-4
1354220-0	1992	Ability to organize microtubules in taxol-treated mitotic PtK2 cells goes with the SPN antigen and not with the centrosome.	Paclitaxel	36-41	DEAF1 transcription factor	Homo sapiens	83-86
1354220-2	1992	Here we show, by examination of the relative locations of SPN antigen, the centrosomal 5051 antigen and tubulin in normal mitotic, and in taxol-treated mitotic cells, that the SPN antigen is involved in organizing the microtubules of the spindle.	Paclitaxel	138-143	DEAF1 transcription factor	Homo sapiens	176-179
1354220-4	1992	In taxol-treated mitotic cells, SPN staining shows a striking redistribution while 5051 antigen remains associated with centrosomes.	Paclitaxel	3-8	DEAF1 transcription factor	Homo sapiens	32-35
1354220-6	1992	SPN antigen is always at the center of the multiple microtubule asters (5 to 20 per cell) induced by taxol, whereas 5051 again remains associated with the centrosomal complex (1 to 2 foci per cell).	Paclitaxel	101-106	DEAF1 transcription factor	Homo sapiens	0-3
1354220-8	1992	Microinjection of SPN-3 antibody into taxol-treated mitotic PtK2 cells causes disruption of the asters as judged by tubulin staining of the same cells.	Paclitaxel	38-43	DEAF1 transcription factor	Homo sapiens	18-21
1354220-9	1992	Finally, SPN antigen extracted in soluble form from synchronized mitotic HeLa cells binds to, and sediments with, pig brain microtubules stabilized by taxol.	Paclitaxel	151-156	DEAF1 transcription factor	Homo sapiens	9-12
1725526-8	1991	Mitotic PtK1 cells treated with either nocodazole or taxol included microtubule-containing cytoplasmic foci and parallel bundles of short microtubules at the cell periphery.	Paclitaxel	53-58	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	8-12
1686118-0	1991	Interaction of C-9 aldehydes with microtubular protein in vitro and in cultured cells in the presence of taxol.	Paclitaxel	105-110	complement C9	Homo sapiens	15-18
1686118-2	1991	This paper examines the effects of taxol on the impairment of in vitro functionality of microtubular protein and of cytoplasmic microtubules by C-9 aliphatic aldehydes.	Paclitaxel	35-40	complement C9	Homo sapiens	144-147
33798550-11	2021	Using a xenograft model, we showed that miR-98 overexpression reversed paclitaxel resistance to CD44+ GCSCs.	Paclitaxel	71-81	CD44 molecule (Indian blood group)	Homo sapiens	96-100
33809707-12	2021	Conversely, the PTX-induced upregulation of the M2 marker gene, Il10 in CD11b+ myeloid cells from 4T1 tumor-bearing mice treated was dramatically reduced by the administration of the HO-1 inhibitor.	Paclitaxel	16-19	interleukin 10	Homo sapiens	64-68
33809707-12	2021	Conversely, the PTX-induced upregulation of the M2 marker gene, Il10 in CD11b+ myeloid cells from 4T1 tumor-bearing mice treated was dramatically reduced by the administration of the HO-1 inhibitor.	Paclitaxel	16-19	integrin subunit alpha M	Homo sapiens	72-77
34920124-0	2022	AMP-activated protein kinase re-sensitizes A549 to paclitaxel via up-regulating solute carrier organic anion transporter family member 1B3 expression.	Paclitaxel	51-61	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	0-28
34920124-3	2022	It has been widely reported that AMP-activated protein kinase (AMPK) could re-sensitize tumor cells to PTX.	Paclitaxel	103-106	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	33-61
34920124-3	2022	It has been widely reported that AMP-activated protein kinase (AMPK) could re-sensitize tumor cells to PTX.	Paclitaxel	103-106	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	63-67
34920124-5	2022	In this paper, we have tried to explain the relationships between PTX, SLCO1B3 and AMPK.	Paclitaxel	66-69	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	83-87
34920124-11	2022	To verify it, we have treated A549 cells with AMPK both activators and an inhibitor, and then found that AMPK activators could weaken the PTX effect in inhibiting SLCO1B3 while its inhibitor has opposite effect.	Paclitaxel	138-141	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	46-50
34920124-11	2022	To verify it, we have treated A549 cells with AMPK both activators and an inhibitor, and then found that AMPK activators could weaken the PTX effect in inhibiting SLCO1B3 while its inhibitor has opposite effect.	Paclitaxel	138-141	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	105-109
34920124-12	2022	With knockdown of SLCO1B3, the effect of AMPK in re-sensitizing A549 to paclitaxel has decreased.	Paclitaxel	72-82	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	41-45
34920124-13	2022	To sum up, activation of AMPK can up-regulate SLCO1B3 expression, enhance the sensitivity of A549 cells to PTX, providing a new way to re-sensitize PTX resistance.	Paclitaxel	107-110	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	25-29
34920124-13	2022	To sum up, activation of AMPK can up-regulate SLCO1B3 expression, enhance the sensitivity of A549 cells to PTX, providing a new way to re-sensitize PTX resistance.	Paclitaxel	148-151	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	25-29
34808333-0	2022	FOXM1-mediated activation of phospholipase D1 promotes lipid droplet accumulation and reduces ROS to support paclitaxel resistance in metastatic cancer cells.	Paclitaxel	109-119	forkhead box M1	Mus musculus	0-5
34808333-4	2022	FOXM1, an oncogenic transcriptional factor, was highly expressed in metastatic cancer cells, and overexpression of FOXM1 conferred parental cancer cells resistance to paclitaxel.	Paclitaxel	167-177	forkhead box M1	Mus musculus	0-5
34808333-4	2022	FOXM1, an oncogenic transcriptional factor, was highly expressed in metastatic cancer cells, and overexpression of FOXM1 conferred parental cancer cells resistance to paclitaxel.	Paclitaxel	167-177	forkhead box M1	Mus musculus	115-120
34563619-6	2022	Furthermore, paclitaxel disrupted circulating corticosterone rhythms in DD by elevating its levels across a 24-hour cycle, which correlated with blunted amplitudes of Arntl, Nr1d1, Per1, and Star rhythms in the adrenal glands.	Paclitaxel	13-23	nuclear receptor subfamily 1, group D, member 1	Mus musculus	174-179
34312098-2	2022	The aim of this study is to compare the efficacy and late-onset cardiac toxicity of neoadjuvant chemotherapy regimens, trastuzumab plus paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (PH-FECH) versus trastuzumab plus docetaxel and carboplatin (TCH), for human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC).	Paclitaxel	136-146	ferrochelatase	Homo sapiens	212-216
34752986-0	2022	CD44-targeted, indocyanine green-paclitaxel-loaded human serum albumin nanoparticles for potential image-guided drug delivery.	Paclitaxel	33-43	CD44 molecule (Indian blood group)	Homo sapiens	0-4
34752986-2	2022	In this study we evaluated the potential of an indocyanine green (ICG) and paclitaxel (PTX) loaded human serum albumin (HSA) nanoparticles that was conjugated with hyaluronic acid for use in image-guided drug delivery targeted to CD44-positive non-small cell lung cancer (NSCLC).	Paclitaxel	75-85	CD44 molecule (Indian blood group)	Homo sapiens	230-234
34752986-2	2022	In this study we evaluated the potential of an indocyanine green (ICG) and paclitaxel (PTX) loaded human serum albumin (HSA) nanoparticles that was conjugated with hyaluronic acid for use in image-guided drug delivery targeted to CD44-positive non-small cell lung cancer (NSCLC).	Paclitaxel	87-90	CD44 molecule (Indian blood group)	Homo sapiens	230-234
34743946-4	2021	The data obtained show that PTX-induced MDA, NF-kappaB, IL-1beta, TNF-alpha, COX-2, nNOS, JAK2, STAT3, and GFAP levels decreased with HES administration.	Paclitaxel	28-31	nitric oxide synthase 1	Rattus norvegicus	84-88
34743946-4	2021	The data obtained show that PTX-induced MDA, NF-kappaB, IL-1beta, TNF-alpha, COX-2, nNOS, JAK2, STAT3, and GFAP levels decreased with HES administration.	Paclitaxel	28-31	Janus kinase 2	Rattus norvegicus	90-94
34743946-4	2021	The data obtained show that PTX-induced MDA, NF-kappaB, IL-1beta, TNF-alpha, COX-2, nNOS, JAK2, STAT3, and GFAP levels decreased with HES administration.	Paclitaxel	28-31	glial fibrillary acidic protein	Rattus norvegicus	107-111
34743946-8	2021	Also, it was observed that PTX could cause endoplasmic reticulum stress (ERS) by increasing PERK, IRE1, ATF-6, GRP78 and CHOP mRNA transcript levels, while HES could alleviate ERS by suppressing them.	Paclitaxel	27-30	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	111-116
34893642-8	2021	Silencing MSMO1 could significantly enhance the sensitivity of MDA-MB-231 cells to paclitaxel and doxorubicin through modulating mTORC1 signaling pathway.	Paclitaxel	83-93	methylsterol monooxygenase 1	Homo sapiens	10-15
34950596-10	2021	Taken together, these findings demonstrate that upregulation of MRP-7 and NEAT1, and downregulation of miR-98 have important roles in conferring paclitaxel resistance to EC cells.	Paclitaxel	145-155	nuclear paraspeckle assembly transcript 1	Homo sapiens	74-79
34873207-5	2021	In addition, the significant increase in autophagy marker LC3B-II, together with Atg5, class III PI3K and Beclin-1, and the down-regulation of p62 following paclitaxel treatment verified that paclitaxel induced autophagy.	Paclitaxel	157-167	nucleoporin 62	Homo sapiens	143-146
34873207-5	2021	In addition, the significant increase in autophagy marker LC3B-II, together with Atg5, class III PI3K and Beclin-1, and the down-regulation of p62 following paclitaxel treatment verified that paclitaxel induced autophagy.	Paclitaxel	192-202	beclin 1	Homo sapiens	106-114
34873207-5	2021	In addition, the significant increase in autophagy marker LC3B-II, together with Atg5, class III PI3K and Beclin-1, and the down-regulation of p62 following paclitaxel treatment verified that paclitaxel induced autophagy.	Paclitaxel	192-202	nucleoporin 62	Homo sapiens	143-146
34882068-0	2021	Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models.	Paclitaxel	80-90	kinase insert domain receptor	Homo sapiens	14-19
34905470-0	2021	Nuclear receptor binding SET domain protein 1 promotes epithelial-mesenchymal transition in paclitaxel-resistant breast cancer cells via regulating nuclear factor kappa B and F-box and leucine-rich repeat protein 11.	Paclitaxel	92-102	lysine demethylase 2A	Homo sapiens	175-215
34509085-2	2021	This study aimed at understanding the binding mechanism and structural basis for the interaction of structurally and functionally unrelated chemotherapeutic agent, namely doxorubicin, etoposide, omacetaxine mepesuccinate and paclitaxel with Sorcin by utilizing docking and molecular dynamic simulation approaches.	Paclitaxel	225-235	sorcin	Homo sapiens	241-247
34509085-3	2021	The docking evaluation of etoposide, omacetaxine mepesuccinate and paclitaxel have shown a high affinity binding with Sorcin at the Ca2+-binding C-terminal domain (SCBD) in a comparable mode and affinity of binding to doxorubicin.	Paclitaxel	67-77	sorcin	Homo sapiens	118-124
34116927-0	2021	Acylglycerol kinase promotes paclitaxel resistance in nasopharyngeal carcinoma cells by regulating FOXM1 via the JAK2/STAT3 pathway.	Paclitaxel	29-39	forkhead box M1	Homo sapiens	99-104
34116927-12	2021	An in vivo tumour xenograft assay also verified that AGK knockdown inhibited tumour growth and mitigated paclitaxel resistance by regulating the JAK2/STAT3/FOXM1 axis.	Paclitaxel	105-115	forkhead box M1	Homo sapiens	156-161
34180747-10	2021	Ki-67, EGFR, and angiogenesis markers (Factor VIII, CD31, and CD34) expression were significantly lower in the PTX-NPs group compared with other groups (p < .05).	Paclitaxel	111-114	antigen identified by monoclonal antibody Ki 67	Mus musculus	0-5
34907739-9	2021	Furthermore, in Ehrlich solid tumor mice, rosmarinic acid, and/or Paclitaxel significantly suppressed tumor growth with an increase in apoptotic markers P53 and Caspase-3 levels, and suppressed the Bcl2/Bax ratio.	Paclitaxel	66-76	caspase 3	Mus musculus	161-170
34907739-9	2021	Furthermore, in Ehrlich solid tumor mice, rosmarinic acid, and/or Paclitaxel significantly suppressed tumor growth with an increase in apoptotic markers P53 and Caspase-3 levels, and suppressed the Bcl2/Bax ratio.	Paclitaxel	66-76	BCL2-associated X protein	Mus musculus	203-206
34837170-0	2022	AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.	Paclitaxel	51-61	SRY-box transcription factor 2	Homo sapiens	29-33
34837170-4	2022	In this study, we aimed at investigating the potential of using AZD4547, an orally bioavailable FGFR inhibitor, to overcome taxol-resistance by targeting the FGFR/Akt/SOX2 axis in HNSCC.	Paclitaxel	124-129	SRY-box transcription factor 2	Homo sapiens	167-171
34694772-7	2021	On the other hand, treatment with apoptosis inducers, such as paclitaxel, silibinin, doxorubicin, actinomycin D, and camptothecin caused AIF translocation to the nucleus after 4 h incubation through AIF binding to CypA, reaching saturation after 6-7 h. It was also found that Hsp70 and CypA regulate AIF translocation in a mutually exclusive manner because they do not interact with AIF simultaneously in cells undergoing apoptosis.	Paclitaxel	62-72	apoptosis inducing factor mitochondria associated 1	Homo sapiens	137-140
34694772-7	2021	On the other hand, treatment with apoptosis inducers, such as paclitaxel, silibinin, doxorubicin, actinomycin D, and camptothecin caused AIF translocation to the nucleus after 4 h incubation through AIF binding to CypA, reaching saturation after 6-7 h. It was also found that Hsp70 and CypA regulate AIF translocation in a mutually exclusive manner because they do not interact with AIF simultaneously in cells undergoing apoptosis.	Paclitaxel	62-72	apoptosis inducing factor mitochondria associated 1	Homo sapiens	199-202
34694772-7	2021	On the other hand, treatment with apoptosis inducers, such as paclitaxel, silibinin, doxorubicin, actinomycin D, and camptothecin caused AIF translocation to the nucleus after 4 h incubation through AIF binding to CypA, reaching saturation after 6-7 h. It was also found that Hsp70 and CypA regulate AIF translocation in a mutually exclusive manner because they do not interact with AIF simultaneously in cells undergoing apoptosis.	Paclitaxel	62-72	heat shock protein family A (Hsp70) member 4	Homo sapiens	276-281
34694772-7	2021	On the other hand, treatment with apoptosis inducers, such as paclitaxel, silibinin, doxorubicin, actinomycin D, and camptothecin caused AIF translocation to the nucleus after 4 h incubation through AIF binding to CypA, reaching saturation after 6-7 h. It was also found that Hsp70 and CypA regulate AIF translocation in a mutually exclusive manner because they do not interact with AIF simultaneously in cells undergoing apoptosis.	Paclitaxel	62-72	apoptosis inducing factor mitochondria associated 1	Homo sapiens	300-303
34761351-8	2021	The outcomes pointed out that the miR-383-5p might substantially enhance the chemosensitivity of MDA-MB-231 to taxol.	Paclitaxel	111-116	microRNA 383	Homo sapiens	34-41
34761351-9	2021	Besides, miR-383-5p restoration and the combined therapy of miR-383-5p restoration with paclitaxel could remarkably increase apoptosis, decrease cell viability, arrest the cell cycle, inhibit clonogenicity, suppress tumor migration, suppress the PI3K/Akt signaling pathway, and down-regulate PD-L1 expression of BC cells.	Paclitaxel	88-98	microRNA 383	Homo sapiens	9-16
34761351-9	2021	Besides, miR-383-5p restoration and the combined therapy of miR-383-5p restoration with paclitaxel could remarkably increase apoptosis, decrease cell viability, arrest the cell cycle, inhibit clonogenicity, suppress tumor migration, suppress the PI3K/Akt signaling pathway, and down-regulate PD-L1 expression of BC cells.	Paclitaxel	88-98	microRNA 383	Homo sapiens	60-67
34761351-10	2021	The restoration of miR-383-5p can enhance the chemosensitivity of MDA-MB-231 cells to taxol.	Paclitaxel	86-91	microRNA 383	Homo sapiens	19-26
34761351-11	2021	Despite the anti-tumoral effects of miR-383-5p restoration on MDA-MB-231 breast cancer development, the combined therapy of miR-383-5p restoration with paclitaxel can be more effective in repressing MDA-MB-231 breast cancer development.	Paclitaxel	152-162	microRNA 383	Homo sapiens	124-131
34749765-0	2021	PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells.	Paclitaxel	51-61	progesterone receptor membrane component 1	Mus musculus	0-6
34740994-9	2021	In general, our study found (1) miR-26a-5p was a protective factor of breast cancer, while OTUD6B-AS1 and MTDH were risk factors; (2) OTUD6B-AS1 was the up-stream regulator of miR-26a-5p verified by luciferase; (3) up-regulation of miR-26a-5p and down-regulation of MTDH promoted cellular cytotoxicity of paclitaxel (PTX) in vitro and in vivo.	Paclitaxel	317-320	OTUD6B antisense RNA 1 (head to head)	Homo sapiens	91-101
34740994-9	2021	In general, our study found (1) miR-26a-5p was a protective factor of breast cancer, while OTUD6B-AS1 and MTDH were risk factors; (2) OTUD6B-AS1 was the up-stream regulator of miR-26a-5p verified by luciferase; (3) up-regulation of miR-26a-5p and down-regulation of MTDH promoted cellular cytotoxicity of paclitaxel (PTX) in vitro and in vivo.	Paclitaxel	317-320	OTU deubiquitinase 6B	Homo sapiens	134-140
34748960-5	2022	Compared to free drugs and DOX/PTX@ANS, DOX/PTX/TET@ANS exhibited more effective anticancer effects on P-gp-overexpressing colorectal cancer cells and solid tumor mouse xenografts, without major toxicity.	Paclitaxel	31-34	phosphoglycolate phosphatase	Mus musculus	103-107
34748960-5	2022	Compared to free drugs and DOX/PTX@ANS, DOX/PTX/TET@ANS exhibited more effective anticancer effects on P-gp-overexpressing colorectal cancer cells and solid tumor mouse xenografts, without major toxicity.	Paclitaxel	44-47	phosphoglycolate phosphatase	Mus musculus	103-107
34790572-8	2021	Further, SLC7A11 induced the protein expression of other autophagy genes, such as LC3, Atg16L1, and Atg7, and the expression of the respective proteins was further increased when the cells were treated with paclitaxel.	Paclitaxel	207-217	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	82-85
34799910-0	2021	P1-39: Paclitaxel induces growth inhibition in gefitinib-resistant PC9-MET cells by downregulating MDM2 and activating p53.	Paclitaxel	7-17	MDM2 proto-oncogene	Homo sapiens	99-103
34702806-0	2021	Correction: Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.	Paclitaxel	52-62	BCL2 antagonist/killer 1	Homo sapiens	25-28
34729313-3	2021	Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction.	Paclitaxel	99-109	hydroxyacid oxidase 1	Homo sapiens	15-18
30655858-11	2019	In addition, there was a notable elevation in the expression of miR-1207-5p and a reduction in the expression of LZTS1 in the Taxol non-responsive TNBC tissues when compared with the Taxol-responsive TNBC tissues.	Paclitaxel	126-131	leucine zipper tumor suppressor 1	Homo sapiens	113-118
30583585-4	2018	The expression of LOX, COL1A2, COL3A1, and ALDH1A1 was performed in sensitive (A2780, W1) and resistant to paclitaxel (PAC) (A2780PR1 and W1PR2) and topotecan (TOP) (W1TR) cell lines at the mRNA (real-time PCR analysis) and protein level (Western blot and immunofluorescence analysis).	Paclitaxel	107-117	lysyl oxidase	Homo sapiens	18-21
30583585-12	2018	This represents the study where molecules related with CSCs (ALDH1A1) and ECM (LOX, collagens) models of drug resistance are described as occurring simultaneously in ovarian cancer cells treated with PAC and TOP.	Paclitaxel	200-203	lysyl oxidase	Homo sapiens	79-82
30550003-3	2018	OBJECTIVES: To check the association between BDNF Val66Met-SNP as a predisposition that enhances the development of chemotherapy-induced peripheral neuropathy in an Israeli cohort of patients with breast cancer who were treated with paclitaxel.	Paclitaxel	233-243	brain derived neurotrophic factor	Homo sapiens	45-49
30272330-0	2018	Downregulation of miR-200c-3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2.	Paclitaxel	86-96	SRY-box transcription factor 2	Homo sapiens	110-114
30272330-7	2018	Moreover, knockdown of SOX2 expression increased chemosensitivity to paclitaxel and upregulated miR-200c-3p expression in MCF-7/Tax cells.	Paclitaxel	69-79	SRY-box transcription factor 2	Homo sapiens	23-27
30272330-8	2018	Taken together, the results of the present study indicated that miR-200c-3p plays a key role in the development of paclitaxel resistance in breast cancer, possibly partially through regulating SOX2 expression, suggesting that the miR-200c-3p-SOX2 loop may serve as a potential target for the reversal of paclitaxel resistance in breast cancer.	Paclitaxel	115-125	SRY-box transcription factor 2	Homo sapiens	193-197
30272330-8	2018	Taken together, the results of the present study indicated that miR-200c-3p plays a key role in the development of paclitaxel resistance in breast cancer, possibly partially through regulating SOX2 expression, suggesting that the miR-200c-3p-SOX2 loop may serve as a potential target for the reversal of paclitaxel resistance in breast cancer.	Paclitaxel	115-125	SRY-box transcription factor 2	Homo sapiens	242-246
30272330-8	2018	Taken together, the results of the present study indicated that miR-200c-3p plays a key role in the development of paclitaxel resistance in breast cancer, possibly partially through regulating SOX2 expression, suggesting that the miR-200c-3p-SOX2 loop may serve as a potential target for the reversal of paclitaxel resistance in breast cancer.	Paclitaxel	304-314	SRY-box transcription factor 2	Homo sapiens	193-197
30272330-8	2018	Taken together, the results of the present study indicated that miR-200c-3p plays a key role in the development of paclitaxel resistance in breast cancer, possibly partially through regulating SOX2 expression, suggesting that the miR-200c-3p-SOX2 loop may serve as a potential target for the reversal of paclitaxel resistance in breast cancer.	Paclitaxel	304-314	SRY-box transcription factor 2	Homo sapiens	242-246
30477228-10	2018	Additionally, silencing both MAP1LC3B and SQSTM1 enhanced the cytotoxic effects of paclitaxel in the tumorspheres of BMSCC cells.	Paclitaxel	83-93	sequestosome 1	Homo sapiens	42-48
30115698-0	2018	CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.	Paclitaxel	48-58	CD44 molecule (Indian blood group)	Homo sapiens	0-4
30084832-0	2018	Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.	Paclitaxel	0-10	microtubule associated protein 4	Homo sapiens	105-109
30084832-7	2018	Dual knockdown of IKBKB/STK39 or EDN2/TBK1 enhanced paclitaxel sensitivity more than silencing single kinases.	Paclitaxel	52-62	endothelin 2	Homo sapiens	33-37
30084832-10	2018	Knockdown of IKBKB/STK39 or EDN2/TBK1 enhanced paclitaxel sensitivity in two ovarian xenograft models.Conclusions: Sequential knockdown of dual kinases increased microtubule stability by decreasing p38-mediated phosphorylation of MAP4 and enhanced response to paclitaxel in ovarian cancer cell lines and xenografts, suggesting a strategy to improve primary therapy.	Paclitaxel	47-57	endothelin 2	Homo sapiens	28-32
30084832-10	2018	Knockdown of IKBKB/STK39 or EDN2/TBK1 enhanced paclitaxel sensitivity in two ovarian xenograft models.Conclusions: Sequential knockdown of dual kinases increased microtubule stability by decreasing p38-mediated phosphorylation of MAP4 and enhanced response to paclitaxel in ovarian cancer cell lines and xenografts, suggesting a strategy to improve primary therapy.	Paclitaxel	47-57	microtubule associated protein 4	Homo sapiens	230-234
30293379-8	2018	The expression of HIF-1alpha in the cytoplasm and nucleus was very low in the control group, which was evidenced in both cytoplasm and nucleus in the hypoxic injury group.The expression was further increased in hypoxic preconditioning group, significant nuclear HIF-1 expression was found in the paclitaxel group, the expression was aggregated in the nucleus in the Paclitaxel+ hypoxia preconditioning group.	Paclitaxel	296-306	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	18-28
30293379-8	2018	The expression of HIF-1alpha in the cytoplasm and nucleus was very low in the control group, which was evidenced in both cytoplasm and nucleus in the hypoxic injury group.The expression was further increased in hypoxic preconditioning group, significant nuclear HIF-1 expression was found in the paclitaxel group, the expression was aggregated in the nucleus in the Paclitaxel+ hypoxia preconditioning group.	Paclitaxel	366-376	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	18-28
30293379-14	2018	Conclusion: Paclitaxel can enhance the myocardial protective effect of myocardial ischemia preconditioning through stabilizing microtubules of cardiomyocytes and promoting HIF-1alpha localization in the nucleus.	Paclitaxel	12-22	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	172-182
30072097-0	2018	Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.	Paclitaxel	74-84	interleukin 22	Homo sapiens	0-14
30072097-4	2018	Then we studied the role and mechanism of IL-22 in migration and paclitaxel resistance in TNBC cells MDA-MB 468 and MDA-MB 231.	Paclitaxel	65-75	interleukin 22	Homo sapiens	42-47
30072097-6	2018	In vitro, IL-22 promotes TNBC cells migration and induces paclitaxel resistance.	Paclitaxel	58-68	interleukin 22	Homo sapiens	10-15
30104402-9	2018	PRDX6 predicted a poorer OS in patients treated with Taxol and Taxol+Platin chemotherapy.Conclusion: These results suggest that there are distinct prognostic values of PRDX family members in patients with ovarian cancer, and that the expression of PRDX3, PRDX5, and PRDX6 mRNAs are a useful prognostic indicator in the effect of chemotherapy in ovarian cancer patients.	Paclitaxel	53-58	peroxiredoxin 3	Homo sapiens	248-253
30104402-9	2018	PRDX6 predicted a poorer OS in patients treated with Taxol and Taxol+Platin chemotherapy.Conclusion: These results suggest that there are distinct prognostic values of PRDX family members in patients with ovarian cancer, and that the expression of PRDX3, PRDX5, and PRDX6 mRNAs are a useful prognostic indicator in the effect of chemotherapy in ovarian cancer patients.	Paclitaxel	63-68	peroxiredoxin 3	Homo sapiens	248-253
29995353-0	2018	Rational Design of Redox-Responsive and P-gp-Inhibitory Lipid Nanoparticles with High Entrapment of Paclitaxel for Tumor Therapy.	Paclitaxel	100-110	phosphoglycolate phosphatase	Mus musculus	40-44
29995353-6	2018	Using an orthotopic 4T1 mouse mammary tumor model in BALB/c mice, PTX/Qu-SS-Gcc LNPs exhibit superior antitumor efficacy compared to Taxol, in addition better biosafety and inhibition of chemotherapy-triggered P-gp overexpression are achieved.	Paclitaxel	66-69	phosphoglycolate phosphatase	Mus musculus	210-214
29856087-0	2018	HOTAIR enhanced paclitaxel and doxorubicin resistance in gastric cancer cells partly through inhibiting miR-217 expression.	Paclitaxel	16-26	microRNA 217	Homo sapiens	104-111
29856087-9	2018	Furthermore, we demonstrated that overexpression of miR-217 suppressed paclitaxel and doxorubicin resistance in GC cells.	Paclitaxel	71-81	microRNA 217	Homo sapiens	52-59
29856087-11	2018	These data suggested that overexpression of HOTAIR enhanced paclitaxel and doxorubicin resistance in GC cells through inhibiting miR-217 expression.	Paclitaxel	60-70	microRNA 217	Homo sapiens	129-136
30147314-4	2018	MMP2/9-triggered-release micelles were constructed using PG and succinylated gelatin (SG) and loading paclitaxel (Ptx).	Paclitaxel	102-112	matrix metallopeptidase 2	Mus musculus	0-4
30147314-4	2018	MMP2/9-triggered-release micelles were constructed using PG and succinylated gelatin (SG) and loading paclitaxel (Ptx).	Paclitaxel	114-117	matrix metallopeptidase 2	Mus musculus	0-4
30147314-7	2018	Results: Ptx-release efficiency from PG-SG-Ptx micelles was MMP2/9-concentration-dependent.	Paclitaxel	9-12	matrix metallopeptidase 2	Mus musculus	60-66
30147314-7	2018	Results: Ptx-release efficiency from PG-SG-Ptx micelles was MMP2/9-concentration-dependent.	Paclitaxel	43-46	matrix metallopeptidase 2	Mus musculus	60-66
29902349-0	2018	Nab-paclitaxel interrupts cancer-stromal interaction through C-X-C motif chemokine 10-mediated interleukin-6 downregulation in vitro.	Paclitaxel	4-14	C-X-C motif chemokine ligand 10	Homo sapiens	61-85
30008912-7	2018	Results demonstrated that beta-elemene-paclitaxel decreased G-protein coupled receptor 124 (GPR124), vascular endothelial growth factor receptor, matrix metallopeptidase (MMP)-3, MMP-9 expression levels and increased endostatin, TIMP metallopeptidase inhibitor (TIMP)-1, TIMP-2 expression in U-2OS cells.	Paclitaxel	39-49	matrix metallopeptidase 9	Homo sapiens	179-184
30008912-7	2018	Results demonstrated that beta-elemene-paclitaxel decreased G-protein coupled receptor 124 (GPR124), vascular endothelial growth factor receptor, matrix metallopeptidase (MMP)-3, MMP-9 expression levels and increased endostatin, TIMP metallopeptidase inhibitor (TIMP)-1, TIMP-2 expression in U-2OS cells.	Paclitaxel	39-49	TIMP metallopeptidase inhibitor 2	Homo sapiens	271-277
30008912-9	2018	Immunostaining demonstrated that beta-elemene-paclitaxel treatment increased apoptotic bodies, GPR124 and increased endostatin, TIMP-1 and TIMP-2 expression in tumor tissues.	Paclitaxel	46-56	TIMP metallopeptidase inhibitor 2	Homo sapiens	139-145
29540562-5	2018	Complementary genetic and pharmacologic approaches revealed that the antiallodynic effects of each drug require both cannabinoid receptors, CB1 and CB2 MJN110 reduced paclitaxel-mediated increased expression of monocyte chemoattractant protein-1 (MCP-1, CCL2) and phospho-p38 MAPK in dorsal root ganglia as well as MCP-1 in spinal dorsal horn.	Paclitaxel	167-177	chemokine (C-C motif) ligand 2	Mus musculus	211-245
29540562-5	2018	Complementary genetic and pharmacologic approaches revealed that the antiallodynic effects of each drug require both cannabinoid receptors, CB1 and CB2 MJN110 reduced paclitaxel-mediated increased expression of monocyte chemoattractant protein-1 (MCP-1, CCL2) and phospho-p38 MAPK in dorsal root ganglia as well as MCP-1 in spinal dorsal horn.	Paclitaxel	167-177	chemokine (C-C motif) ligand 2	Mus musculus	247-252
29540562-5	2018	Complementary genetic and pharmacologic approaches revealed that the antiallodynic effects of each drug require both cannabinoid receptors, CB1 and CB2 MJN110 reduced paclitaxel-mediated increased expression of monocyte chemoattractant protein-1 (MCP-1, CCL2) and phospho-p38 MAPK in dorsal root ganglia as well as MCP-1 in spinal dorsal horn.	Paclitaxel	167-177	chemokine (C-C motif) ligand 2	Mus musculus	254-258
29540562-5	2018	Complementary genetic and pharmacologic approaches revealed that the antiallodynic effects of each drug require both cannabinoid receptors, CB1 and CB2 MJN110 reduced paclitaxel-mediated increased expression of monocyte chemoattractant protein-1 (MCP-1, CCL2) and phospho-p38 MAPK in dorsal root ganglia as well as MCP-1 in spinal dorsal horn.	Paclitaxel	167-177	chemokine (C-C motif) ligand 2	Mus musculus	315-320
29549161-7	2018	Istiratumab (MM-141), a novel bispecific antibody that blocks IGF-1R and ErbB3, restored the activity of paclitaxel and gemcitabine in the presence of IGF-1 and HRG in vitro Dual IGF-1R/ErbB3 blocking enhanced chemosensitivity through inhibition of AKT phosphorylation and promotion of IGF-1R and ErbB3 degradation.	Paclitaxel	105-115	insulin like growth factor 1 receptor	Homo sapiens	62-68
29549161-7	2018	Istiratumab (MM-141), a novel bispecific antibody that blocks IGF-1R and ErbB3, restored the activity of paclitaxel and gemcitabine in the presence of IGF-1 and HRG in vitro Dual IGF-1R/ErbB3 blocking enhanced chemosensitivity through inhibition of AKT phosphorylation and promotion of IGF-1R and ErbB3 degradation.	Paclitaxel	105-115	insulin like growth factor 1 receptor	Homo sapiens	179-185
29549161-7	2018	Istiratumab (MM-141), a novel bispecific antibody that blocks IGF-1R and ErbB3, restored the activity of paclitaxel and gemcitabine in the presence of IGF-1 and HRG in vitro Dual IGF-1R/ErbB3 blocking enhanced chemosensitivity through inhibition of AKT phosphorylation and promotion of IGF-1R and ErbB3 degradation.	Paclitaxel	105-115	insulin like growth factor 1 receptor	Homo sapiens	179-185
29531130-5	2018	Progression-free survival and overall survival were assessed to validate an association between TLE3 expression and response to taxane therapy that we previously observed in a smaller study.Results: Expression of TLE3 was associated with favorable outcome only in patients who had received paclitaxel as part of their treatment regimen for both 3-year progression-free survival (n = 160; HR, 0.56; P = 0.03) and 5-year overall survival (HR, 0.53; P = 0.04).	Paclitaxel	290-300	TLE family member 3, transcriptional corepressor	Homo sapiens	213-217
29658576-4	2018	In addition, paclitaxel upregulated the expression of Bax and cytochrome c, but reduced expression of apoptosis regulator Bcl-2, resulting in activation of caspase-3, chromatin condensation, karyopyknosis, intracellular vacuolization, increased production of ROS and MDA, and decreased activity of SOD.	Paclitaxel	13-23	BCL2 associated X, apoptosis regulator	Canis lupus familiaris	54-57
29658576-4	2018	In addition, paclitaxel upregulated the expression of Bax and cytochrome c, but reduced expression of apoptosis regulator Bcl-2, resulting in activation of caspase-3, chromatin condensation, karyopyknosis, intracellular vacuolization, increased production of ROS and MDA, and decreased activity of SOD.	Paclitaxel	13-23	cytochrome c, somatic	Canis lupus familiaris	62-74
29899826-3	2018	In this study, we conducted an siRNA-based kinome screen to identify modulators of mitotic progression in CCNE1-amplified HGSOC cells that may influence clinical paclitaxel response.	Paclitaxel	162-172	cyclin E1	Homo sapiens	106-111
29899826-5	2018	Here, we identified a novel synthetic lethal interaction of the clinical PLK1 inhibitor BI6727 and the microtubule-targeting drug paclitaxel in HGSOC cell lines with CCNE1-amplification and elucidated the underlying molecular mechanisms of this synergism.	Paclitaxel	130-140	polo like kinase 1	Homo sapiens	73-77
29899826-5	2018	Here, we identified a novel synthetic lethal interaction of the clinical PLK1 inhibitor BI6727 and the microtubule-targeting drug paclitaxel in HGSOC cell lines with CCNE1-amplification and elucidated the underlying molecular mechanisms of this synergism.	Paclitaxel	130-140	cyclin E1	Homo sapiens	166-171
29899826-7	2018	Moreover, the inhibition of PLK1 reduced the paclitaxel-induced neurotoxicity in a neurite outgrowth assay.	Paclitaxel	45-55	polo like kinase 1	Homo sapiens	28-32
29899826-9	2018	This conclusion is supported by data showing that BI6727/paclitaxel-co-treatment stabilizes FBW7, a component of SCF-type ubiquitin ligases that bind and regulate key modulators of cell division and growth including MCL-1 and Cyclin E. This identification of a novel synthetic lethality of PLK1 inhibitors and a microtubule-stabilizing drug has important implications for developing PLK1 inhibitor-based combination treatments in CCNE1-amplified HGSOC cells.	Paclitaxel	57-67	KIT ligand	Homo sapiens	113-116
29899826-9	2018	This conclusion is supported by data showing that BI6727/paclitaxel-co-treatment stabilizes FBW7, a component of SCF-type ubiquitin ligases that bind and regulate key modulators of cell division and growth including MCL-1 and Cyclin E. This identification of a novel synthetic lethality of PLK1 inhibitors and a microtubule-stabilizing drug has important implications for developing PLK1 inhibitor-based combination treatments in CCNE1-amplified HGSOC cells.	Paclitaxel	57-67	polo like kinase 1	Homo sapiens	290-294
29899826-9	2018	This conclusion is supported by data showing that BI6727/paclitaxel-co-treatment stabilizes FBW7, a component of SCF-type ubiquitin ligases that bind and regulate key modulators of cell division and growth including MCL-1 and Cyclin E. This identification of a novel synthetic lethality of PLK1 inhibitors and a microtubule-stabilizing drug has important implications for developing PLK1 inhibitor-based combination treatments in CCNE1-amplified HGSOC cells.	Paclitaxel	57-67	polo like kinase 1	Homo sapiens	383-387
29899826-9	2018	This conclusion is supported by data showing that BI6727/paclitaxel-co-treatment stabilizes FBW7, a component of SCF-type ubiquitin ligases that bind and regulate key modulators of cell division and growth including MCL-1 and Cyclin E. This identification of a novel synthetic lethality of PLK1 inhibitors and a microtubule-stabilizing drug has important implications for developing PLK1 inhibitor-based combination treatments in CCNE1-amplified HGSOC cells.	Paclitaxel	57-67	cyclin E1	Homo sapiens	430-435
29669928-3	2018	Here we show that a subset of circulating CD8+ T cells expressing the chemokine receptor CX3CR1 are able to withstand the toxicity of chemotherapy and are increased in patients with metastatic melanoma who responded to chemoimmunotherapy (paclitaxel and carboplatin plus PD-1 blockade).	Paclitaxel	239-249	C-X3-C motif chemokine receptor 1	Homo sapiens	89-95
29541211-6	2018	In addition, ASAP1 promoted cell proliferation, survival and inhibited chemotherapy drug paclitaxel-induced cell apoptosis.	Paclitaxel	89-99	ArfGAP with SH3 domain, ankyrin repeat and PH domain 1	Homo sapiens	13-18
29588586-6	2018	Furthermore, in vitro and in vivo antitumor activity of the PTX-loaded HSV nanoparticles was investigated in a CD44 over-expressed A549 tumor model.	Paclitaxel	60-63	CD44 antigen	Mus musculus	111-115
29588586-11	2018	The antitumor activity results showed that compared to redox-insensitive nanoparticles and Taxol , PTX-loaded redox-sensitive nanoparticles exhibited much greater in vitro cytotoxicity and apoptosis-inducing ability against CD44 over-expressed A549 tumor cells.	Paclitaxel	99-102	CD44 antigen	Mus musculus	224-228
29480799-7	2018	Downregulation of RSF-1 by siRNA silencing or RSF-D4 reduced cell growth and increased drug sensitivity toward paclitaxel treatment in HeLa cells.	Paclitaxel	111-121	remodeling and spacing factor 1	Homo sapiens	18-23
30359298-0	2018	The new 6q27 tumor suppressor DACT2, frequently silenced by CpG methylation, sensitizes nasopharyngeal cancer cells to paclitaxel and 5-FU toxicity via beta-catenin/Cdc25c signaling and G2/M arrest.	Paclitaxel	119-129	dishevelled binding antagonist of beta catenin 2	Homo sapiens	30-35
30359298-14	2018	DACT2 expression also induced G2/M arrest in NPC cells through directly suppressing beta-catenin/Cdc25c signaling, which sensitized NPC cells to paclitaxel and 5-FU, but not cisplatin.	Paclitaxel	145-155	dishevelled binding antagonist of beta catenin 2	Homo sapiens	0-5
29189915-12	2018	Finally, paclitaxel and docetaxel achieved additive cell-killing effects with CNDAC at concentration ranges of the taxanes similar for both BRCA1/2 deficient and proficient OC cells.	Paclitaxel	9-19	BRCA1 DNA repair associated	Homo sapiens	140-147
29084921-6	2018	In addition, the REDD1-mediated proliferation, apoptosis, and autophagy are found to be negatively regulated by miR-22 in vitro, which intensify the paclitaxel sensitivity via inhibition of the well-acknowledged REDD1-EEF2K-autophagy axis.	Paclitaxel	149-159	DNA damage inducible transcript 4	Homo sapiens	17-22
29084921-6	2018	In addition, the REDD1-mediated proliferation, apoptosis, and autophagy are found to be negatively regulated by miR-22 in vitro, which intensify the paclitaxel sensitivity via inhibition of the well-acknowledged REDD1-EEF2K-autophagy axis.	Paclitaxel	149-159	DNA damage inducible transcript 4	Homo sapiens	212-217
29084921-8	2018	Finally, the inhibited REDD1 expression by either RNAi or miR-22 sensitizes BUC tumor cells to paclitaxel in a subcutaneous transplant carcinoma model in vivoConclusions: REDD1 is confirmed as an oncogene in BUC, and antagonizing REDD1 could be a potential therapeutic strategy to sensitize BUC cells to paclitaxel.	Paclitaxel	95-105	DNA damage inducible transcript 4	Homo sapiens	23-28
29084921-8	2018	Finally, the inhibited REDD1 expression by either RNAi or miR-22 sensitizes BUC tumor cells to paclitaxel in a subcutaneous transplant carcinoma model in vivoConclusions: REDD1 is confirmed as an oncogene in BUC, and antagonizing REDD1 could be a potential therapeutic strategy to sensitize BUC cells to paclitaxel.	Paclitaxel	95-105	DNA damage inducible transcript 4	Homo sapiens	171-176
29084921-8	2018	Finally, the inhibited REDD1 expression by either RNAi or miR-22 sensitizes BUC tumor cells to paclitaxel in a subcutaneous transplant carcinoma model in vivoConclusions: REDD1 is confirmed as an oncogene in BUC, and antagonizing REDD1 could be a potential therapeutic strategy to sensitize BUC cells to paclitaxel.	Paclitaxel	95-105	DNA damage inducible transcript 4	Homo sapiens	171-176
29084921-8	2018	Finally, the inhibited REDD1 expression by either RNAi or miR-22 sensitizes BUC tumor cells to paclitaxel in a subcutaneous transplant carcinoma model in vivoConclusions: REDD1 is confirmed as an oncogene in BUC, and antagonizing REDD1 could be a potential therapeutic strategy to sensitize BUC cells to paclitaxel.	Paclitaxel	304-314	DNA damage inducible transcript 4	Homo sapiens	23-28
29084921-8	2018	Finally, the inhibited REDD1 expression by either RNAi or miR-22 sensitizes BUC tumor cells to paclitaxel in a subcutaneous transplant carcinoma model in vivoConclusions: REDD1 is confirmed as an oncogene in BUC, and antagonizing REDD1 could be a potential therapeutic strategy to sensitize BUC cells to paclitaxel.	Paclitaxel	304-314	DNA damage inducible transcript 4	Homo sapiens	171-176
29084921-8	2018	Finally, the inhibited REDD1 expression by either RNAi or miR-22 sensitizes BUC tumor cells to paclitaxel in a subcutaneous transplant carcinoma model in vivoConclusions: REDD1 is confirmed as an oncogene in BUC, and antagonizing REDD1 could be a potential therapeutic strategy to sensitize BUC cells to paclitaxel.	Paclitaxel	304-314	DNA damage inducible transcript 4	Homo sapiens	171-176
29233683-9	2018	This XRCC4-dependent, SRPK1/SRSF1-mediated regulatory mechanism was conserved in apoptosis in Jurkat human leukemia cells triggered by STS, and by two widely used anti-cancer agents, Paclitaxel and Vincristine.	Paclitaxel	183-193	serine and arginine rich splicing factor 1	Homo sapiens	28-33
30134224-6	2018	RESULTS: Our data reveals substantially increased YWHAZ expression in both cisplatin- and paclitaxel-resistant ovarian cancer cells.	Paclitaxel	90-100	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Homo sapiens	50-55
30134224-7	2018	Silencing YWHAZ restored the sensitivity of resistant ovarian cancer cells to cisplatin and paclitaxel.	Paclitaxel	92-102	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Homo sapiens	10-15
28986119-2	2018	Management strategies to guide care after a paclitaxel-induced HSR are needed.	Paclitaxel	44-54	HSR	Homo sapiens	63-66
28986119-13	2018	CONCLUSIONS: A management strategy using the initial HSR severity for risk stratification allowed patients to receive paclitaxel safely.	Paclitaxel	118-128	HSR	Homo sapiens	53-56
30384806-0	2018	MicroRNA-22 Suppresses Breast Cancer Cell Growth and Increases Paclitaxel Sensitivity by Targeting NRAS.	Paclitaxel	63-73	NRAS proto-oncogene, GTPase	Homo sapiens	99-103
30384806-8	2018	Moreover, microRNA-22 sensitized breast cancer cells to paclitaxel by regulation of NRAS.	Paclitaxel	56-66	NRAS proto-oncogene, GTPase	Homo sapiens	84-88
29371916-0	2017	The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.	Paclitaxel	59-69	interleukin 17B	Homo sapiens	4-10
28841776-7	2017	Paclitaxel is loaded in NP (NP/PTX) and CTB-NP (CTB-NP/PTX), and their antiglioma effects are assessed in nude mice bearing intracranial glioma.	Paclitaxel	0-10	phosphate cytidylyltransferase 1, choline, beta isoform	Mus musculus	40-43
28841776-7	2017	Paclitaxel is loaded in NP (NP/PTX) and CTB-NP (CTB-NP/PTX), and their antiglioma effects are assessed in nude mice bearing intracranial glioma.	Paclitaxel	0-10	phosphate cytidylyltransferase 1, choline, beta isoform	Mus musculus	48-51
28841776-8	2017	CTB-NP/PTX can efficiently induce apoptosis of intracranial glioma cells and ablate neovasulature in vivo, resulting in significant prolongation of survival of nude mice bearing intracranial glioma (34 d) in comparison to those treated with NP/PTX (29 d), Taxol (24 d), and saline (21 d).	Paclitaxel	256-261	phosphate cytidylyltransferase 1, choline, beta isoform	Mus musculus	0-3
29180320-7	2017	lncRNA-GAS5 expression was also significantly lowered in paclitaxel-resistant breast cancer cells and showed a positive correlation with P21 expression and a negative correlation with CDK6.	Paclitaxel	57-67	growth arrest specific 5	Homo sapiens	7-11
29180320-9	2017	In the tumor-bearing nude mouse models, lncRNA-GAS5 overexpression in the tumor cells obviously enhanced the inhibitory effect of paclitaxel on tumor growth and lung metastasis by reversing the EMT marker proteins.	Paclitaxel	130-140	growth arrest specific 5	Homo sapiens	47-51
29163177-5	2017	Methods: An extensive panel of five polymorphisms on four candidate genes (ABCB1, CYP2C8*3, CYP3A4*1B, XRCC3), previously validated as significant markers related to paclitaxel and Docetaxel toxicity, are analyzed and discussed.	Paclitaxel	166-176	X-ray repair cross complementing 3	Homo sapiens	103-108
29116098-6	2017	Whereas, normal human bronchial epithelial (NHBE) cells with poor integrin alphavbeta3 expression showed negligible toxicity to PTX-PLGA-CSNP-RGD, at equivalent drug concentrations used in cancer cells.	Paclitaxel	128-131	integrin subunit alpha V	Homo sapiens	66-86
31271140-11	2017	In addition, we revealed that free paclitaxel treatment resulted in higher levels of IL-6, IL-10, PDL-1, TGF-beta1, TNF-alpha and VEGF, while the expression levels of these inflammatory factors were much lower in the other two groups, especially in the Nano-PTX-GEL treated groups.	Paclitaxel	35-45	interleukin 10	Homo sapiens	91-96
29212257-9	2017	Inhibition of BIRC5 expression also sensitized cell responses to paclitaxel treatment.	Paclitaxel	65-75	baculoviral IAP repeat containing 5	Homo sapiens	14-19
28981108-0	2017	Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer.	Paclitaxel	40-50	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Homo sapiens	65-70
28817386-0	2017	CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth.	Paclitaxel	37-42	C-X-C motif chemokine receptor 4	Homo sapiens	0-5
29093604-10	2017	A significant decrease in CCL5 expression was only detected in KLE cells following treatment with heparin and paclitaxel, and an increase in the expression of CCL5 in RL 95-2 cells.	Paclitaxel	110-120	C-C motif chemokine ligand 5	Homo sapiens	26-30
29093604-11	2017	Conclusion: Further in-depth studies are needed to investigate the functions of cytokines CCL2, CCL5 and IL-6 in endometrial cancer cells treated with paclitaxel.	Paclitaxel	151-161	C-C motif chemokine ligand 5	Homo sapiens	96-100
28604461-1	2017	OBJECTIVE: Serous adenocarcinomas that arise in patients with inherited mutations in the tumor suppressor genes BRCA1 and BRCA2 are initially well treatable with platinum/paclitaxel.	Paclitaxel	171-181	BRCA1 DNA repair associated	Homo sapiens	112-117
28604461-1	2017	OBJECTIVE: Serous adenocarcinomas that arise in patients with inherited mutations in the tumor suppressor genes BRCA1 and BRCA2 are initially well treatable with platinum/paclitaxel.	Paclitaxel	171-181	BRCA2 DNA repair associated	Homo sapiens	122-127
28714030-4	2017	KDM5A was especially highly expressed in SKOV3/paclitaxel (PTX) cells, which are resistant to PTX.	Paclitaxel	47-57	lysine demethylase 5A	Homo sapiens	0-5
29137407-4	2017	Knockdown of SNHG12 reversed the resistance to cisplatin, paclitaxel and gefitinib in A549/DDP, A549/PTX and PC9/AB2 cells through inducing cell apoptosis.	Paclitaxel	58-68	small nucleolar RNA host gene 12	Homo sapiens	13-19
32264448-0	2017	Stent containing CD44-targeting polymeric prodrug nanoparticles that release paclitaxel and gemcitabine in a time interval-controlled manner for synergistic human biliary cancer therapy.	Paclitaxel	77-87	CD44 molecule (Indian blood group)	Homo sapiens	17-21
28661654-4	2017	P1 was further self-assembled into micellar nanoparticles (NPs) to load PTX, which show MMP-2-triggered dePEGylation due to cleavage of the peptide linkage.	Paclitaxel	72-75	matrix metallopeptidase 2	Mus musculus	88-93
28431939-0	2017	Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines.	Paclitaxel	80-90	BRCA2 DNA repair associated	Homo sapiens	34-39
28431939-3	2017	In the present study, we define a new resistance mechanism to paclitaxel based on BRCA2 variation.	Paclitaxel	62-72	BRCA2 DNA repair associated	Homo sapiens	82-87
28431939-5	2017	Restoration of paclitaxel sensitivity was induced indirectly with combined treatment of paclitaxel and HDAC inhibitor.	Paclitaxel	15-25	histone deacetylase 9	Homo sapiens	103-107
28431939-12	2017	After HDAC inhibitor treatment, HAT activity and paclitaxel sensitivity were restored in variant cells.	Paclitaxel	49-59	histone deacetylase 9	Homo sapiens	6-10
28431939-14	2017	Forced expression of the BRCA2 heterozygous variant induced paclitaxel resistance due to altered HAT activity (p&lt;0.001).	Paclitaxel	60-70	BRCA2 DNA repair associated	Homo sapiens	25-30
28431939-16	2017	Restoration of wild BRCA2 from variant type improved paclitaxel sensitivity (p&lt;0.001).	Paclitaxel	53-63	BRCA2 DNA repair associated	Homo sapiens	20-25
28431939-17	2017	Modulation of HAT activity by BRCA2 N372H variation is a new mechanism of paclitaxel resistance in breast cancer.	Paclitaxel	74-84	BRCA2 DNA repair associated	Homo sapiens	30-35
29245917-0	2017	Inhibition of ZEB1 leads to inversion of metastatic characteristics and restoration of paclitaxel sensitivity of chronic chemoresistant ovarian carcinoma cells.	Paclitaxel	87-97	zinc finger E-box binding homeobox 1	Homo sapiens	14-18
29245917-6	2017	Additionally, cell migration and invasion were significantly decreased by ZEB1 silencing in both PTX-sensitive and PTX- resistant cells.	Paclitaxel	97-100	zinc finger E-box binding homeobox 1	Homo sapiens	74-78
29245917-6	2017	Additionally, cell migration and invasion were significantly decreased by ZEB1 silencing in both PTX-sensitive and PTX- resistant cells.	Paclitaxel	115-118	zinc finger E-box binding homeobox 1	Homo sapiens	74-78
29245917-7	2017	Although PTX-sensitivity was not changed by silencing ZEB1 in parental EOC cells, the depletion of ZEB1 made the PTX-resistant EOC cells more sensitive to PTX treatment.	Paclitaxel	113-116	zinc finger E-box binding homeobox 1	Homo sapiens	99-103
28947984-5	2017	Based on P-gp inhibition activity of BNL, confirmed by drug efflux test and molecular docking model, the combination of PTX and BNL could improve intracellular concentration of PTX in A2780/PTX cells.	Paclitaxel	177-180	phosphoglycolate phosphatase	Mus musculus	9-13
28947984-5	2017	Based on P-gp inhibition activity of BNL, confirmed by drug efflux test and molecular docking model, the combination of PTX and BNL could improve intracellular concentration of PTX in A2780/PTX cells.	Paclitaxel	177-180	phosphoglycolate phosphatase	Mus musculus	9-13
28751630-13	2017	PKC zeta co-immunoprecipitated with beta-tubulin at different intervals upon insulin stimulus, and the activation of PKC zeta was affected by paclitaxel and nocodazole.	Paclitaxel	142-152	protein kinase C zeta	Homo sapiens	0-8
28751630-13	2017	PKC zeta co-immunoprecipitated with beta-tubulin at different intervals upon insulin stimulus, and the activation of PKC zeta was affected by paclitaxel and nocodazole.	Paclitaxel	142-152	protein kinase C zeta	Homo sapiens	117-125
28730839-0	2017	TRPV1 receptors contribute to paclitaxel-induced c-Fos expression in spinal cord dorsal horn neurons.	Paclitaxel	30-40	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	49-54
28730839-6	2017	PAC treatment induced significant upregulation of c-Fos nuclear expression in superficial dorsal horn neurons that was diminished by TRPV1 receptor antagonists pre-incubation.	Paclitaxel	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	50-55
28650490-7	2017	Moreover, in vivo studies (a HeLa tumor xenograft model using female BALB/c nude mice) demonstrate that the liposomes could not only increase the concentration of drugs in tumors over time but also successfully boosted the chemotherapeutic efficacy of PTX (synergistic therapy with GAPDH-siRNA).	Paclitaxel	252-255	glyceraldehyde-3-phosphate dehydrogenase	Mus musculus	282-287
28650490-8	2017	Tumor cells appeared to lose their resistance against PTX therapy, becoming more sensitive to PTX when GAPDH-siRNA was simultaneously administered in long-circulating liposomes.	Paclitaxel	94-97	glyceraldehyde-3-phosphate dehydrogenase	Mus musculus	103-108
28463810-0	2017	Rational design of hybrid nanomicelles integrating mucosal penetration and P-glycoprotein inhibition for efficient oral delivery of paclitaxel.	Paclitaxel	132-142	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	75-89
28391556-9	2017	Paclitaxel also increased expression levels of acetylated tubulin and end binding protein 1, markers of microtubule stability and growth, respectively.	Paclitaxel	0-10	microtubule associated protein RP/EB family member 1	Homo sapiens	70-91
28428276-10	2017	Systemic administration of micelles carrying paclitaxel and rubone inhibited orthotopic prostate tumor growth in nude mice, compared with monotherapy, by reversing the expression of miR-34a, SIRT1, cyclin D1, and E-cadherin.	Paclitaxel	45-55	cyclin D1	Mus musculus	198-207
28402932-0	2017	The long noncoding RNA ANRIL acts as an oncogene and contributes to paclitaxel resistance of lung adenocarcinoma A549 cells.	Paclitaxel	68-78	CDKN2B antisense RNA 1	Homo sapiens	23-28
28402932-2	2017	However, the potential function of lncRNA ANRIL contributed paclitaxel chemo-resistance in LAD is still unknown.	Paclitaxel	60-70	CDKN2B antisense RNA 1	Homo sapiens	42-47
28402932-3	2017	This study aimed to observe the expression of ANRIL in LAD, evaluate its biological role in the resistance of LAD cells to paclitaxel and explore the apoptosis role in the ANRIL associated mechanism.	Paclitaxel	123-133	CDKN2B antisense RNA 1	Homo sapiens	46-51
28402932-4	2017	Our results showed that ANRIL functioning as a potential oncogene was up-regulated in LAD, and promoted the acquisition of chemo-resistance in paclitaxel partly through the mitochondrial pathway by modulating the expression of apoptosis-related protein cleaved-PARP and Bcl-2.	Paclitaxel	143-153	CDKN2B antisense RNA 1	Homo sapiens	24-29
28402932-5	2017	These findings might improve LAD patients" paclitaxel treatment and made ANRIL to be a new target for paclitaxel-based chemotherapy in LAD.	Paclitaxel	102-112	CDKN2B antisense RNA 1	Homo sapiens	73-78
28415580-11	2017	Together, these results indicated that CXCR4 overexpression drives acquired paclitaxel resistance, partly by activating the PDGFA and PDGFB/PDGFRalpha autocrine signaling loops that activate AKT and ERK1/2.	Paclitaxel	76-86	platelet derived growth factor subunit B	Homo sapiens	134-139
28260803-4	2017	PTX-loaded PSST micelles (PTX/PSST-M) designed to display synergistic functions, including reversible inhibition of P-gp, intracellular redox-sensitive release and potent anticancer activities.	Paclitaxel	0-3	NADH:ubiquinone oxidoreductase core subunit S7	Homo sapiens	11-15
28260803-4	2017	PTX-loaded PSST micelles (PTX/PSST-M) designed to display synergistic functions, including reversible inhibition of P-gp, intracellular redox-sensitive release and potent anticancer activities.	Paclitaxel	0-3	NADH:ubiquinone oxidoreductase core subunit S7	Homo sapiens	30-34
28260803-5	2017	The average size of PTX/PSST-M was 68.1+-4.9 nm.	Paclitaxel	20-23	NADH:ubiquinone oxidoreductase core subunit S7	Homo sapiens	24-28
28260803-10	2017	Furthermore, PTX/PSST-M significantly increased cell apoptosis/necrosis and cell cycle arrest at the G2/M phase in A2780/PTX cells.	Paclitaxel	121-124	NADH:ubiquinone oxidoreductase core subunit S7	Homo sapiens	17-21
28260803-11	2017	These results demonstrate that the redox-responsive PSST micelles inhibit P-gp activity and have a good potential to effectively reverse PTX resistance in human ovarian carcinoma cells by activating intrinsic apoptotic pathways.	Paclitaxel	137-140	NADH:ubiquinone oxidoreductase core subunit S7	Homo sapiens	52-56
28498253-0	2017	Targeting Foxm1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.	Paclitaxel	41-51	forkhead box M1	Homo sapiens	10-15
28498253-3	2017	We aimed to determine if targeting the FOXM1 pathway with thiostrepton could improve the efficacy of paclitaxel and cisplatin in human ovarian cancer ascites cells ex vivo.	Paclitaxel	101-111	forkhead box M1	Homo sapiens	39-44
28242239-9	2017	Paclitaxel-mediated induction of genes involved in irinotecan metabolism such as Cyp3a11 and Ugt1a1 was TLR4-dependent, while induction of the transporter Mrp2 was TLR4-independent.	Paclitaxel	0-10	ATP binding cassette subfamily C member 2	Homo sapiens	155-159
29088738-0	2017	Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel.	Paclitaxel	86-96	WEE1 G2 checkpoint kinase	Homo sapiens	36-40
28915612-2	2017	It was found that ING5 overexpression suppressed proliferation, energy metabolism, migration, invasion, and induced G2/M arrest, apoptosis, dedifferentiation, senescence, mesenchymal- epithelial transition and chemoresistance to cisplatin, MG132, paclitaxel and SAHA in U87 cells.	Paclitaxel	247-257	inhibitor of growth family, member 5	Mus musculus	18-22
28469798-2	2017	We found that the taxol-resistant cells demonstrated higher basal levels of autophagy than parental cells, which could be inhibited by 3-MA and Beclin-1-siRNA.	Paclitaxel	18-23	beclin 1	Homo sapiens	144-152
28072604-8	2017	Finally, blockade of CXCR4 but not CXCR7 ameliorated the paclitaxel- or vincristine-induced mechanical allodynia.	Paclitaxel	57-67	chemokine (C-X-C motif) receptor 4	Mus musculus	21-26
34729313-3	2021	Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction.	Paclitaxel	99-109	hydroxyacid oxidase 1	Homo sapiens	50-65
34729313-3	2021	Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction.	Paclitaxel	99-109	hydroxyacid oxidase 1	Homo sapiens	67-70
34729313-3	2021	Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction.	Paclitaxel	99-109	hydroxyacid oxidase 1	Homo sapiens	144-147
34729313-3	2021	Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction.	Paclitaxel	111-114	hydroxyacid oxidase 1	Homo sapiens	15-18
34426249-9	2021	This study demonstrated that liposomal paclitaxel formulations are less toxic to normal tissues than free paclitaxel and are more effective in inhibiting tumor cell proliferation/migration and inducing ZEB1/TGF-beta2 gene expression.	Paclitaxel	39-49	zinc finger E-box binding homeobox 1	Homo sapiens	202-206
34426249-9	2021	This study demonstrated that liposomal paclitaxel formulations are less toxic to normal tissues than free paclitaxel and are more effective in inhibiting tumor cell proliferation/migration and inducing ZEB1/TGF-beta2 gene expression.	Paclitaxel	39-49	transforming growth factor beta 2	Homo sapiens	207-216
34426249-9	2021	This study demonstrated that liposomal paclitaxel formulations are less toxic to normal tissues than free paclitaxel and are more effective in inhibiting tumor cell proliferation/migration and inducing ZEB1/TGF-beta2 gene expression.	Paclitaxel	106-116	zinc finger E-box binding homeobox 1	Homo sapiens	202-206
34426249-9	2021	This study demonstrated that liposomal paclitaxel formulations are less toxic to normal tissues than free paclitaxel and are more effective in inhibiting tumor cell proliferation/migration and inducing ZEB1/TGF-beta2 gene expression.	Paclitaxel	106-116	transforming growth factor beta 2	Homo sapiens	207-216
34508957-2	2021	In this study, a polymeric nano-sized drug delivery system poly (OEGMA)-PTX@Ce6 (NPs@Ce6) composed of a photosensitizer chlorin e6 (Ce6) and a cathepsin B-sensitive polymer-paclitaxel (PTX) prodrug was constructed.	Paclitaxel	173-183	cathepsin B	Homo sapiens	143-154
34645770-0	2021	Elevated (Pro)renin Receptor Expression by Anti-Cancer Drugs, Carboplatin and Paclitaxel, in Cultured Cancer Cells: Possible Involvement of Apoptosis and Autophagy.	Paclitaxel	78-88	ATPase H+ transporting accessory protein 2	Homo sapiens	14-28
34645770-6	2021	Expression levels of (P)RR mRNA and soluble (P)RR protein were increased by carboplatin or paclitaxel in a dose-dependent manner.	Paclitaxel	91-101	ATPase H+ transporting accessory protein 2	Homo sapiens	21-26
34645770-6	2021	Expression levels of (P)RR mRNA and soluble (P)RR protein were increased by carboplatin or paclitaxel in a dose-dependent manner.	Paclitaxel	91-101	ATPase H+ transporting accessory protein 2	Homo sapiens	44-49
34645770-7	2021	Immunofluorescence staining of (P)RR was increased in both MCF-7 and A549 cells treated by carboplatin or paclitaxel.	Paclitaxel	106-116	ATPase H+ transporting accessory protein 2	Homo sapiens	31-36
34645770-10	2021	(P)RR knockdown by (P)RR-specific siRNA suppressed the cell viability in MCF-7 cells and A549 cells under the treatment of carboplatin or paclitaxel, suggesting that (P)RR deficiency inhibits the proliferation of cancer cells in a pathway different from carboplatin or paclitaxel.	Paclitaxel	138-148	ATPase H+ transporting accessory protein 2	Homo sapiens	0-5
34645770-10	2021	(P)RR knockdown by (P)RR-specific siRNA suppressed the cell viability in MCF-7 cells and A549 cells under the treatment of carboplatin or paclitaxel, suggesting that (P)RR deficiency inhibits the proliferation of cancer cells in a pathway different from carboplatin or paclitaxel.	Paclitaxel	138-148	ATPase H+ transporting accessory protein 2	Homo sapiens	19-24
34329591-2	2021	By investigating the molecular mechanism underlying this relocalization, we found that acute paclitaxel treatment triggers the release from stress fibers and subsequent proteasome-mediated degradation of binder of Rho GTPases 2 (BORG2)/Cdc42 effector protein 3 (Cdc42EP3) and to a lesser extent of BORG3/Cdc42EP5, two Cdc42 effectors that link septins to actin in interphase cells.	Paclitaxel	93-103	CDC42 effector protein 3	Homo sapiens	204-227
34329591-2	2021	By investigating the molecular mechanism underlying this relocalization, we found that acute paclitaxel treatment triggers the release from stress fibers and subsequent proteasome-mediated degradation of binder of Rho GTPases 2 (BORG2)/Cdc42 effector protein 3 (Cdc42EP3) and to a lesser extent of BORG3/Cdc42EP5, two Cdc42 effectors that link septins to actin in interphase cells.	Paclitaxel	93-103	CDC42 effector protein 3	Homo sapiens	229-234
34329591-2	2021	By investigating the molecular mechanism underlying this relocalization, we found that acute paclitaxel treatment triggers the release from stress fibers and subsequent proteasome-mediated degradation of binder of Rho GTPases 2 (BORG2)/Cdc42 effector protein 3 (Cdc42EP3) and to a lesser extent of BORG3/Cdc42EP5, two Cdc42 effectors that link septins to actin in interphase cells.	Paclitaxel	93-103	CDC42 effector protein 3	Homo sapiens	236-260
34329591-2	2021	By investigating the molecular mechanism underlying this relocalization, we found that acute paclitaxel treatment triggers the release from stress fibers and subsequent proteasome-mediated degradation of binder of Rho GTPases 2 (BORG2)/Cdc42 effector protein 3 (Cdc42EP3) and to a lesser extent of BORG3/Cdc42EP5, two Cdc42 effectors that link septins to actin in interphase cells.	Paclitaxel	93-103	CDC42 effector protein 3	Homo sapiens	262-270
34566640-4	2021	Based on the results, PTX inhibited the migration of RA-FLS in a dose-dependent manner and significantly reduced the spontaneous expression of IL-6, IL-8, and RANKL mRNA and TNF-alpha-induced transcription of the IL-1 beta, IL-8, MMP-8, and MMP-9 genes.	Paclitaxel	22-25	matrix metallopeptidase 8	Mus musculus	230-235
34566640-6	2021	Mechanistic studies revealed that PTX significantly inhibited the TNF-alpha-induced phosphorylation of ERK1/2 and JNK in the mitogen-activated protein kinase (MAPK) pathway and suppressed the TNF-alpha-induced activation of AKT, p70S6K, 4EBP1, and HIF-1alpha in the AKT/mTOR pathway.	Paclitaxel	34-37	mitogen-activated protein kinase 8	Mus musculus	114-117
34278466-0	2021	Chemokine CCL20 promotes the paclitaxel resistance of CD44+CD117+ cells via the Notch1 signaling pathway in ovarian cancer.	Paclitaxel	29-39	CD44 molecule (Indian blood group)	Homo sapiens	54-58
34278466-2	2021	The aim of the present study was to investigate the underlying mechanism of CCL20/CCR6/Notch1 signaling in paclitaxel (PTX) resistance of a CD44+CD117+ subgroup of cells in ovarian cancer.	Paclitaxel	107-117	C-C motif chemokine receptor 6	Homo sapiens	82-86
34278466-2	2021	The aim of the present study was to investigate the underlying mechanism of CCL20/CCR6/Notch1 signaling in paclitaxel (PTX) resistance of a CD44+CD117+ subgroup of cells in ovarian cancer.	Paclitaxel	107-117	CD44 molecule (Indian blood group)	Homo sapiens	140-144
34278466-2	2021	The aim of the present study was to investigate the underlying mechanism of CCL20/CCR6/Notch1 signaling in paclitaxel (PTX) resistance of a CD44+CD117+ subgroup of cells in ovarian cancer.	Paclitaxel	119-122	C-C motif chemokine receptor 6	Homo sapiens	82-86
34278466-2	2021	The aim of the present study was to investigate the underlying mechanism of CCL20/CCR6/Notch1 signaling in paclitaxel (PTX) resistance of a CD44+CD117+ subgroup of cells in ovarian cancer.	Paclitaxel	119-122	CD44 molecule (Indian blood group)	Homo sapiens	140-144
34327529-0	2021	lncRNA NEAT1 promotes the Taxol resistance of breast cancer via sponging the miR-23a-3p-FOXA1 axis.	Paclitaxel	26-31	nuclear paraspeckle assembly transcript 1	Homo sapiens	7-12
34327529-5	2021	However, the biological roles and molecular targets of lncRNA NEAT1 in Taxol-resistant breast cancer remain unclear.	Paclitaxel	71-76	nuclear paraspeckle assembly transcript 1	Homo sapiens	62-67
34327529-7	2021	In addition, silencing NEAT1 effectively sensitizes breast cancer cells to Taxol.	Paclitaxel	75-80	nuclear paraspeckle assembly transcript 1	Homo sapiens	23-28
34327529-10	2021	Furthermore, in the established Taxol-resistant MDA-MB-231 breast cancer cell line, we detected significantly increased NEAT1 expression and downregulated miR-23a-3p expression.	Paclitaxel	32-37	nuclear paraspeckle assembly transcript 1	Homo sapiens	120-125
34327529-12	2021	Rescue experiments demonstrated that the restoration of miR-23a-3p in NEAT1-overexpressing Taxol-resistant breast cancer cells successfully overcame the NEAT1-promoted Taxol resistance.	Paclitaxel	91-96	nuclear paraspeckle assembly transcript 1	Homo sapiens	70-75
34327529-12	2021	Rescue experiments demonstrated that the restoration of miR-23a-3p in NEAT1-overexpressing Taxol-resistant breast cancer cells successfully overcame the NEAT1-promoted Taxol resistance.	Paclitaxel	91-96	nuclear paraspeckle assembly transcript 1	Homo sapiens	153-158
34327529-12	2021	Rescue experiments demonstrated that the restoration of miR-23a-3p in NEAT1-overexpressing Taxol-resistant breast cancer cells successfully overcame the NEAT1-promoted Taxol resistance.	Paclitaxel	168-173	nuclear paraspeckle assembly transcript 1	Homo sapiens	70-75
34327529-12	2021	Rescue experiments demonstrated that the restoration of miR-23a-3p in NEAT1-overexpressing Taxol-resistant breast cancer cells successfully overcame the NEAT1-promoted Taxol resistance.	Paclitaxel	168-173	nuclear paraspeckle assembly transcript 1	Homo sapiens	153-158
34413645-3	2021	In this study, we used such smart NPs to co-deliver paclitaxel (PTX) and siRNA against vascular endothelial growth factor (VEGF) gene for breast cancer therapy in mice models.	Paclitaxel	52-62	vascular endothelial growth factor A	Mus musculus	87-121
34413645-3	2021	In this study, we used such smart NPs to co-deliver paclitaxel (PTX) and siRNA against vascular endothelial growth factor (VEGF) gene for breast cancer therapy in mice models.	Paclitaxel	52-62	vascular endothelial growth factor A	Mus musculus	123-127
34120223-2	2021	Here, we compare CRA rate with paclitaxel (T)-trastuzumab (H) to that with ado-trastuzumab emtansine (T-DM1).	Paclitaxel	31-41	myotubularin related protein 11	Homo sapiens	17-20
34452111-3	2021	To overcome these limitations, we suggest the development of PTX-loaded thermosponge nanoparticles (PTX@TNP), which result in improved anticancer effects, via a simple nanoprecipitation method, which allows the preparation of PTX@TNPs with hydrophobic interactions without any chemical conjugation.	Paclitaxel	61-64	C1GALT1 specific chaperone 1	Homo sapiens	230-234
34452111-3	2021	To overcome these limitations, we suggest the development of PTX-loaded thermosponge nanoparticles (PTX@TNP), which result in improved anticancer effects, via a simple nanoprecipitation method, which allows the preparation of PTX@TNPs with hydrophobic interactions without any chemical conjugation.	Paclitaxel	100-103	C1GALT1 specific chaperone 1	Homo sapiens	230-234
34452111-3	2021	To overcome these limitations, we suggest the development of PTX-loaded thermosponge nanoparticles (PTX@TNP), which result in improved anticancer effects, via a simple nanoprecipitation method, which allows the preparation of PTX@TNPs with hydrophobic interactions without any chemical conjugation.	Paclitaxel	226-229	C1GALT1 specific chaperone 1	Homo sapiens	230-234
34452111-5	2021	Thus, it was observed that the drug release rate increased as the drug capacity of PTX@TNPs increased.	Paclitaxel	83-86	C1GALT1 specific chaperone 1	Homo sapiens	87-91
34452111-7	2021	These results suggest that the solubilization of high drug amounts and the controlled release of poorly water-soluble PTX using TNPs could significantly improve its anticancer therapy, particularly in the treatment of MDR-p-glycoprotein-overexpressing cancers.	Paclitaxel	118-121	C1GALT1 specific chaperone 1	Homo sapiens	128-132
34270886-7	2021	In summary, these results suggest that KDM5A plays a key role in lung adenocarcinoma by promoting proliferation, EMT, and drug resistance to paclitaxel treatment.	Paclitaxel	141-151	lysine demethylase 5A	Homo sapiens	39-44
34264566-0	2021	The combination therapy of targeting both paclitaxel and Dendrophthoe pentandra leaves extract nanoparticles for improvement breast cancer treatment efficacy by reducing TUBB3 and MAP4 expressions.	Paclitaxel	42-52	microtubule associated protein 4	Homo sapiens	180-184
34264566-6	2021	The combination of paclitaxel-NPDP significantly decreases the expressions of TUBB3 (P<0.001) and MAP4 (P<0.001) in MCF-7 cells.	Paclitaxel	19-29	microtubule associated protein 4	Homo sapiens	98-102
34354859-9	2021	Furthermore, reduced SIKs, even triple knockdown of SIK1, SIK2 and SIK3 rendered the breast cancer cells to confer chemoresistance to paclitaxel and cisplatin.	Paclitaxel	134-144	SIK family kinase 3	Homo sapiens	67-71
34163033-0	2021	A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer.	Paclitaxel	42-52	sorcin	Homo sapiens	28-34
34163033-0	2021	A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer.	Paclitaxel	42-52	zinc finger E-box binding homeobox 1	Homo sapiens	100-104
34163033-4	2021	Here, we identified SRI as a key driver of paclitaxel (PTX)-resistance and explored its regulatory mechanism.	Paclitaxel	43-53	sorcin	Homo sapiens	20-23
34163033-4	2021	Here, we identified SRI as a key driver of paclitaxel (PTX)-resistance and explored its regulatory mechanism.	Paclitaxel	55-58	sorcin	Homo sapiens	20-23
34163033-5	2021	Using transcriptome profiles, qRT-PCR, proteomics, Western blot, immunohistochemistry, and bioinformatics analyses, we found that SRI was overexpressed in PTX-resistant OC cells and the overexpression of SRI was related to the poor prognosis of patients.	Paclitaxel	155-158	sorcin	Homo sapiens	130-133
34163033-6	2021	SRI was a key molecule required for growth, migration, and PTX-resistance in vitro and in vivo and was involved in epithelial-mesenchymal transition (EMT) and stemness.	Paclitaxel	59-62	sorcin	Homo sapiens	0-3
34163033-9	2021	Taken together, our findings unveil a novel homeostatic loop of SRI that drives the PTX-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human OC.	Paclitaxel	84-87	sorcin	Homo sapiens	64-67
34163033-10	2021	Targeting this SRI/Smad4/ZEB1/miR-142-5p loop may reverse the PTX-resistance.	Paclitaxel	62-65	sorcin	Homo sapiens	15-18
34163033-10	2021	Targeting this SRI/Smad4/ZEB1/miR-142-5p loop may reverse the PTX-resistance.	Paclitaxel	62-65	zinc finger E-box binding homeobox 1	Homo sapiens	25-29
34189759-0	2022	Overexpression of ARHI increases the sensitivity of cervical cancer cells to paclitaxel through inducing apoptosis and autophagy.	Paclitaxel	77-87	DIRAS family GTPase 3	Homo sapiens	18-22
34189759-8	2022	The results revealed that the levels of ARHI mRNA and protein were down-regulated in CC tissues, and were further reduced in paclitaxel-resistant tissues and Hela cell model.	Paclitaxel	125-135	DIRAS family GTPase 3	Homo sapiens	40-44
34189759-12	2022	In conclusion, overexpression of ARHI can increase the sensitivity of CC to paclitaxel through promoting apoptosis and autophagy in a AKT/mTOR inactivation dependent pathway.	Paclitaxel	76-86	DIRAS family GTPase 3	Homo sapiens	33-37
34150611-0	2021	3,3"-Diindolylmethane Enhances Paclitaxel Sensitivity by Suppressing DNMT1-Mediated KLF4 Methylation in Breast Cancer.	Paclitaxel	31-41	DNA methyltransferase 1	Homo sapiens	69-74
34150611-0	2021	3,3"-Diindolylmethane Enhances Paclitaxel Sensitivity by Suppressing DNMT1-Mediated KLF4 Methylation in Breast Cancer.	Paclitaxel	31-41	Kruppel like factor 4	Homo sapiens	84-88
34150611-5	2021	The lentivirus carrying KLF4 and DNMT1 gene or shRNA targeting DNMT1 were used to overexpress KLF4 or knockdown DNMT1 in MCF-7 and T47D breast cancer cells and the role of KLF4 and DNMT1 in regulation of PTX sensitivity was investigated.	Paclitaxel	204-207	Kruppel like factor 4	Homo sapiens	172-176
34150611-5	2021	The lentivirus carrying KLF4 and DNMT1 gene or shRNA targeting DNMT1 were used to overexpress KLF4 or knockdown DNMT1 in MCF-7 and T47D breast cancer cells and the role of KLF4 and DNMT1 in regulation of PTX sensitivity was investigated.	Paclitaxel	204-207	DNA methyltransferase 1	Homo sapiens	181-186
34150611-10	2021	Overexpression of KLF4 increased the sensitivity of MCF-7 and T47D cells to PTX.	Paclitaxel	76-79	Kruppel like factor 4	Homo sapiens	18-22
34150611-12	2021	Knockdown of DNMT1 increased the sensitivity of MCF-7 and T47D cells to PTX.	Paclitaxel	72-75	DNA methyltransferase 1	Homo sapiens	13-18
34150611-14	2021	Furthermore, overexpression of DNMT1 attenuated the effect of DIM on the regulation of PTX sensitivity.	Paclitaxel	87-90	DNA methyltransferase 1	Homo sapiens	31-36
34150611-16	2021	The level of KLF4 is correlated with the sensitivity of MCF-7 and T47D cells to PTX.	Paclitaxel	80-83	Kruppel like factor 4	Homo sapiens	13-17
34150611-17	2021	DIM could enhance the antitumor efficacy of PTX on MCF-7 and T47D cells by regulating DNMT1 and KLF4.	Paclitaxel	44-47	DNA methyltransferase 1	Homo sapiens	86-91
34150611-17	2021	DIM could enhance the antitumor efficacy of PTX on MCF-7 and T47D cells by regulating DNMT1 and KLF4.	Paclitaxel	44-47	Kruppel like factor 4	Homo sapiens	96-100
35533911-11	2022	RESULTS: Compared to parental cells, HeLa/Tax cells overexpress P-gp and MRP2 and are approximately 100-360 fold more resistant to the anticancer drugs PTX, docetaxel, and vinblastine.	Paclitaxel	152-155	ATP binding cassette subfamily C member 2	Homo sapiens	73-77
35533911-16	2022	In nude mice bearing HeLa/Tax xenografts, the combination treatment with MT2 and PTX exerted a synergistic inhibitory effect on the growth of tumors and the expression of P-gp and MRP2 without increasing toxicity.	Paclitaxel	81-84	phosphoglycolate phosphatase	Mus musculus	171-175
35150312-1	2022	BACKGROUND: Prophylaxis against infusion-related reactions (IRR) from paclitaxel with steroids and antihistamines is a standard of care due to high rates of IRR.	Paclitaxel	70-80	insulin receptor related receptor	Homo sapiens	60-63
35150312-1	2022	BACKGROUND: Prophylaxis against infusion-related reactions (IRR) from paclitaxel with steroids and antihistamines is a standard of care due to high rates of IRR.	Paclitaxel	70-80	insulin receptor related receptor	Homo sapiens	157-160
35150312-11	2022	De-escalation strategies after two previous successful paclitaxel infusions have an overall low incidence rate of severe IRR and warrant further prospective clinical trials.	Paclitaxel	55-65	insulin receptor related receptor	Homo sapiens	121-124
35509138-4	2022	In response to paclitaxel, females had reduced mechanical hypersensitivity and a greater frequency of anti-inflammatory CD4+ T cells (FoxP3, IL-10, IL-4) in the DRG than male and ovariectomized female mice.	Paclitaxel	15-25	CD4 antigen	Mus musculus	120-123
35500500-0	2022	Increased LZTS1 expression is associated with a good response to paclitaxel-based chemotherapy in breast cancer.	Paclitaxel	65-75	leucine zipper tumor suppressor 1	Homo sapiens	10-15
35500500-8	2022	In vitro cell proliferation assays revealed that LZTS1 expression was correlated with paclitaxel sensitivity in breast cancer cells.	Paclitaxel	86-96	leucine zipper tumor suppressor 1	Homo sapiens	49-54
35500500-9	2022	Cell cycle analysis and apoptosis experiments have demonstrated that LZTS1 could enhance the inhibitory effect of paclitaxel on the breast cancer cell cycle and the ability to induce apoptosis.	Paclitaxel	114-124	leucine zipper tumor suppressor 1	Homo sapiens	69-74
35500500-10	2022	Overexpression of LZTS1 could sensitize human breast carcinoma xenografts to paclitaxel.	Paclitaxel	77-87	leucine zipper tumor suppressor 1	Homo sapiens	18-23
35500500-11	2022	In addition, tumor with high LZTS1 expression was more sensitive to chemotherapy with paclitaxel in breast cancer.	Paclitaxel	86-96	leucine zipper tumor suppressor 1	Homo sapiens	29-34
35500500-13	2022	LZTS1 may play an important role in improving the sensitivity of paclitaxel-based breast cancer chemotherapy.	Paclitaxel	65-75	leucine zipper tumor suppressor 1	Homo sapiens	0-5
35597872-10	2022	CONCLUSIONS: EGFR signaling-mediated G6PD expression plays a pivotal role in paclitaxel resistance, highlighting the potential of targeting EGFR to overcome paclitaxel resistance in TNBC and NSCLC cells overexpressing G6PD.	Paclitaxel	157-167	glucose-6-phosphate dehydrogenase	Homo sapiens	37-41
35595817-5	2022	Low VSNL1 and CD44 expression predicted the benefit of sequential paclitaxel treatment for all three endpoints.	Paclitaxel	66-76	CD44 molecule (Indian blood group)	Homo sapiens	14-18
35595817-7	2022	This is the first study to identify VSNL1 and CD44 RNA expression levels as biomarkers for selecting GC patients that are likely to benefit from sequential paclitaxel treatment followed by fluorinated-pyrimidine-based adjuvant chemotherapy.	Paclitaxel	156-166	CD44 molecule (Indian blood group)	Homo sapiens	46-50
35552677-9	2022	Mechanistically, SSR3 confers susceptibility to PTX through regulation of phosphorylation of ER stress sensor IRE1alpha.	Paclitaxel	48-51	signal sequence receptor subunit 3	Homo sapiens	17-21
35552677-10	2022	CONCLUSION: Our hypothesis generating study showed SSR3 as a putative biomarker for susceptibility to PTX, warranting its prospective clinical validation.	Paclitaxel	102-105	signal sequence receptor subunit 3	Homo sapiens	51-55
35563845-8	2022	LINC00665 is closely associated with the effects of anticancer drugs, including gefitinib and cisplatin in non-small cell lung cancer, gemcitabine in cholangiocarcinoma, and cisplatin-paclitaxel in breast cancer.	Paclitaxel	184-194	long intergenic non-protein coding RNA 665	Homo sapiens	0-9
35184686-9	2022	MiR-144-5p overexpression and PTX further up-regulated E-cadherin level and down-regulated those of MMP-9 and N-cadherin in thyroid carcinoma cells.	Paclitaxel	30-33	cadherin 2	Mus musculus	110-120
35184686-10	2022	STON2 overexpression reversed the effects of miR-144-5p overexpression.. MiR-144-5p overexpression enhanced the inhibiting effect of PTX on tumor volume, weight, and Ki67 level of xenotransplant tumor, and the effects of UTMD-mediated miR-144-5p overexpression were stronger than those mediated by liposome.	Paclitaxel	133-136	antigen identified by monoclonal antibody Ki 67	Mus musculus	166-170
35184686-10	2022	STON2 overexpression reversed the effects of miR-144-5p overexpression.. MiR-144-5p overexpression enhanced the inhibiting effect of PTX on tumor volume, weight, and Ki67 level of xenotransplant tumor, and the effects of UTMD-mediated miR-144-5p overexpression were stronger than those mediated by liposome.	Paclitaxel	133-136	microRNA 144	Mus musculus	235-242
35477569-0	2022	An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer.	Paclitaxel	73-83	euchromatic histone lysine methyltransferase 2	Homo sapiens	3-8
35477569-0	2022	An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer.	Paclitaxel	73-83	nuclear transcription factor Y subunit alpha	Homo sapiens	9-13
35366771-2	2022	Methods- In this research, we developed the amphiphilic Heparin-Poloxamer P403 (HSP) nanogel that can load curcumin (CUR) and Paclitaxel (PTX) through the hydrophobic core of Poloxamer P403.	Paclitaxel	126-136	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	80-83
35366771-2	2022	Methods- In this research, we developed the amphiphilic Heparin-Poloxamer P403 (HSP) nanogel that can load curcumin (CUR) and Paclitaxel (PTX) through the hydrophobic core of Poloxamer P403.	Paclitaxel	138-141	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	80-83
35366771-6	2022	In vitro research confirms lower cytotoxicity of HSP@CUR@PTX compared with free PTX and higher inhibition effect with MCF-7 than HSP@PTX.	Paclitaxel	57-60	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	49-52
35366771-6	2022	In vitro research confirms lower cytotoxicity of HSP@CUR@PTX compared with free PTX and higher inhibition effect with MCF-7 than HSP@PTX.	Paclitaxel	80-83	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	49-52
35366771-6	2022	In vitro research confirms lower cytotoxicity of HSP@CUR@PTX compared with free PTX and higher inhibition effect with MCF-7 than HSP@PTX.	Paclitaxel	133-136	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	129-132
35366771-8	2022	Conclusion, HSP@CUR@PTX suggests a prominent strategy for achieving the synergistic effect of PTX and CUR to circumvent undesirable effects in breast cancer treatment.	Paclitaxel	20-23	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	12-15
35366771-8	2022	Conclusion, HSP@CUR@PTX suggests a prominent strategy for achieving the synergistic effect of PTX and CUR to circumvent undesirable effects in breast cancer treatment.	Paclitaxel	94-97	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	12-15
35190308-7	2022	We further found that bile acid mixture (BA mix) could inhibit hOAT2-mediated uptake of cGMP, 5-fluorouracil, irinotecan and paclitaxel.	Paclitaxel	125-135	solute carrier family 22 member 7	Homo sapiens	63-68
35190308-8	2022	BA mix could reduce the toxicity of paclitaxel to MDCK-hOAT2 cells.	Paclitaxel	36-46	solute carrier family 22 member 7	Homo sapiens	55-60
35196944-0	2022	Circ_0025033 deficiency suppresses paclitaxel resistance and malignant development of paclitaxel-resistant ovarian cancer cells by modulating the miR-532-3p/FOXM1 network.	Paclitaxel	35-45	forkhead box M1	Homo sapiens	157-162
35196944-10	2022	With respect to mechanism, circ_0025033 upregulated the expression of FOXM1 by targeting miR-532-3p, and circ_0025033 knockdown blocked the malignant activities of PTX-resistant OC cells by enriching miR-532-3p and suppressing FOXM1.	Paclitaxel	164-167	forkhead box M1	Homo sapiens	70-75
35196944-10	2022	With respect to mechanism, circ_0025033 upregulated the expression of FOXM1 by targeting miR-532-3p, and circ_0025033 knockdown blocked the malignant activities of PTX-resistant OC cells by enriching miR-532-3p and suppressing FOXM1.	Paclitaxel	164-167	forkhead box M1	Homo sapiens	227-232
35196944-12	2022	CONCLUSION: Circ_0025033 downregulation impaired PTX resistance and malignant activities of PTX-resistant OC cells by regulating the miR-532-3p/FOXM1 network.	Paclitaxel	49-52	forkhead box M1	Homo sapiens	144-149
35196944-12	2022	CONCLUSION: Circ_0025033 downregulation impaired PTX resistance and malignant activities of PTX-resistant OC cells by regulating the miR-532-3p/FOXM1 network.	Paclitaxel	92-95	forkhead box M1	Homo sapiens	144-149
35419295-5	2022	CASC9 knockdown significantly inhibited the cell proliferation, migration and invasion in vitro and enhanced the sensitivity of tumor cells to cisplatin and paclitaxel.	Paclitaxel	157-167	cancer susceptibility 9	Homo sapiens	0-5
35372004-13	2022	These results suggest that low-dose nab-paclitaxel plus tislelizumab is well tolerated and effective in elderly patients with advanced NSCLC, including those with EGFR/ALK variations.	Paclitaxel	40-50	ALK receptor tyrosine kinase	Homo sapiens	168-171
35168606-11	2022	Decreased expressions of GPCPD1 and GDE1 in choline metabolism led to an increased GPC levels in the PTX-resistant EOCs, which was observed as an elevated total choline (tCho) on in vivo 1H-MRS.	Paclitaxel	101-104	glycophorin C (Gerbich blood group)	Homo sapiens	83-86
35204562-9	2022	Moreover, KIF20A and KIF23 overexpression was associated with worse prognosis in OC patients treated with platinum/taxol chemotherapy, while OCs overexpressing mitotic KIFs (11, 15, 18B, and C1) were resistant to MAPK pathway inhibitors.	Paclitaxel	115-120	kinesin family member 23	Homo sapiens	21-26
35105904-3	2022	Recently, the combination of carboplatin and paclitaxel is being recommended to these BRCA-mutated patients as neoadjuvant therapy.	Paclitaxel	45-55	BRCA1 DNA repair associated	Homo sapiens	86-90
35088684-8	2022	It is arduous to totally regulate KRas-coordinated PDAC with traditional medicaments like "gemcitabine GEM" plus nab-paclitaxel/FOLFIRINOX.	Paclitaxel	117-127	KRAS proto-oncogene, GTPase	Homo sapiens	34-38
34996504-6	2022	RESULTS: ZFP64 overexpression was linked with aggressive phenotypes, nab-paclitaxel resistance and served as an independent prognostic factor in GC.	Paclitaxel	73-83	zinc finger protein 64	Mus musculus	9-14
34986146-5	2022	Knockdown of SBF2 exacerbated paclitaxel changes to cell viability and neurite outgrowth while attenuating paclitaxel-induced sodium current inhibition.	Paclitaxel	30-40	SET binding factor 2	Homo sapiens	13-17
34986146-5	2022	Knockdown of SBF2 exacerbated paclitaxel changes to cell viability and neurite outgrowth while attenuating paclitaxel-induced sodium current inhibition.	Paclitaxel	107-117	SET binding factor 2	Homo sapiens	13-17
34986146-6	2022	Our studies identified paclitaxel-induced expression changes specific to mature sensory neurons and revealed candidate genes involved in the exacerbation of paclitaxel-induced phenotypes accompanying SBF2 knockdown.	Paclitaxel	23-33	SET binding factor 2	Homo sapiens	200-204
34986146-6	2022	Our studies identified paclitaxel-induced expression changes specific to mature sensory neurons and revealed candidate genes involved in the exacerbation of paclitaxel-induced phenotypes accompanying SBF2 knockdown.	Paclitaxel	157-167	SET binding factor 2	Homo sapiens	200-204
28443468-0	2017	Curcumin increases the sensitivity of Paclitaxel-resistant NSCLC cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction.	Paclitaxel	38-48	metastasis associated 1	Homo sapiens	115-119
28443468-0	2017	Curcumin increases the sensitivity of Paclitaxel-resistant NSCLC cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction.	Paclitaxel	74-84	metastasis associated 1	Homo sapiens	115-119
28443468-6	2017	Mechanically, the study revealed that Curcumin could reduce the expression of metastasis-associated gene 1 (MTA1) gene through upregulation of microRNA-30c in Paclitaxel-resistant non-small-cell lung cancer cells.	Paclitaxel	159-169	metastasis associated 1	Homo sapiens	78-112
28443468-7	2017	During the course, MTA1 reduction sensitized Paclitaxel-resistant non-small-cell lung cancer cells and enhanced the effect of Paclitaxel.	Paclitaxel	45-55	metastasis associated 1	Homo sapiens	19-23
28443468-7	2017	During the course, MTA1 reduction sensitized Paclitaxel-resistant non-small-cell lung cancer cells and enhanced the effect of Paclitaxel.	Paclitaxel	126-136	metastasis associated 1	Homo sapiens	19-23
28443468-8	2017	Taken together, our studies indicate that Curcumin increases the sensitivity of Paclitaxel-resistant non-small-cell lung cancer cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction.	Paclitaxel	80-90	metastasis associated 1	Homo sapiens	178-182
28443468-8	2017	Taken together, our studies indicate that Curcumin increases the sensitivity of Paclitaxel-resistant non-small-cell lung cancer cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction.	Paclitaxel	137-147	metastasis associated 1	Homo sapiens	178-182
28298569-0	2017	Roles for CD8+ T Cells and IL-10 in the Resolution of Paclitaxel-Induced Neuropathic Pain.	Paclitaxel	54-64	CD8a molecule	Homo sapiens	10-13
28298569-0	2017	Roles for CD8+ T Cells and IL-10 in the Resolution of Paclitaxel-Induced Neuropathic Pain.	Paclitaxel	54-64	interleukin 10	Homo sapiens	27-32
23966160-3	2013	The phosphorylations are blocked by roscovitine, indicating that they may be mediated by Cdk1-cyclin B. Endogenous Ppp4c is enriched at the centrosomes in the absence and presence of paclitaxel, nocodazole, or roscovitine, and the activity of endogenous Ppp4c-R2-R3A is inhibited from G 1/S to the G 2/M phase of the cell cycle.	Paclitaxel	183-193	protein phosphatase 4 catalytic subunit	Homo sapiens	115-120
23966160-6	2013	The data indicate that Ppp4c-R2-R3A regulates microtubule organization at centrosomes during cell division in response to stress signals such as spindle toxins, paclitaxel, and nocodazole, and that inhibition of the Ppp4 complex may be advantageous for treatment of some cancers.	Paclitaxel	161-171	protein phosphatase 4 catalytic subunit	Homo sapiens	23-28
23966160-6	2013	The data indicate that Ppp4c-R2-R3A regulates microtubule organization at centrosomes during cell division in response to stress signals such as spindle toxins, paclitaxel, and nocodazole, and that inhibition of the Ppp4 complex may be advantageous for treatment of some cancers.	Paclitaxel	161-171	protein phosphatase 4 catalytic subunit	Homo sapiens	23-27
23807572-6	2013	Furthermore, we found that inhibition of phosphatidylinositol 3-kinase (PI3K) activity reduced the proliferation and migration and restored their sensitivity to paclitaxel.	Paclitaxel	161-171	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	41-70
24137413-0	2013	miR-21 modulates paclitaxel sensitivity and hypoxia-inducible factor-1alpha expression in human ovarian cancer cells.	Paclitaxel	17-27	microRNA 21	Homo sapiens	0-6
24137413-4	2013	The expression levels of miR-21 in the ovarian cancer A2780 and A2780/taxol cell lines were detected by stem-loop real-time PCR.	Paclitaxel	70-75	microRNA 21	Homo sapiens	25-31
24137413-8	2013	The expression levels of miR-21 and P-gp were upregulated to a greater extent in the paclitaxel-resistant ovarian cancer A2780/taxol cell line compared with the parental A2780 cell line.	Paclitaxel	85-95	microRNA 21	Homo sapiens	25-31
24137413-9	2013	Transfection of A2780/taxol cells with inhibitors of miR-21 decreased the expression levels of the P-gp and HIF-1alpha proteins, and increased the sensitivity of the A2780/taxol cells to paclitaxel.	Paclitaxel	187-197	microRNA 21	Homo sapiens	53-59
24137413-10	2013	The expression levels of P-gp were additionally increased; however, the sensitivity of the miR-21 mimic-treated A2780 cells to paclitaxel was decreased.	Paclitaxel	127-137	microRNA 21	Homo sapiens	91-97
23706689-3	2013	The K237 peptide-conjugated paclitaxel loaded nanoparticles (K237-PTX-NP), which can target KDR receptors highly expressed in the tumor vasculature, were fabricated for this investigation and the human colorectal adenocarcinoma HCT-15 with naturally expressed P-gp on the cell surface was adopted as the resistant tumor model.	Paclitaxel	28-38	phosphoglycolate phosphatase	Homo sapiens	260-264
23706689-7	2013	Low dose paclitaxel formulated in K237-PTX-NP (1 mg/kg) achieved significant anticancer efficacy of inhibiting the growth of HCT-15 tumors, but the same efficacy could be only obtained with 8 fold dose paclitaxel (8 mg/kg) in Taxol plus XR9576, a potent P-gp inhibitor.	Paclitaxel	9-19	phosphoglycolate phosphatase	Homo sapiens	254-258
23720768-0	2013	TLR4 is a novel determinant of the response to paclitaxel in breast cancer.	Paclitaxel	47-57	toll like receptor 4	Homo sapiens	0-4
23720768-3	2013	TLR4 is activated by lipopolysaccharide (LPS) and other ligands including the widely used drug paclitaxel.	Paclitaxel	95-105	toll like receptor 4	Homo sapiens	0-4
23720768-5	2013	We reasoned that paclitaxel-dependent activation of TLR4 is more relevant to breast cancer chemoresistance that could be mediated by activation of the NF-kappaB pathway leading to upregulation of prosurvival genes.	Paclitaxel	17-27	toll like receptor 4	Homo sapiens	52-56
23720768-6	2013	To test this hypothesis, we correlated TLR4 expression with resistance to paclitaxel in two modified breast cancer lines with either depleted or overexpressed TLR4 protein.	Paclitaxel	74-84	toll like receptor 4	Homo sapiens	39-43
23720768-7	2013	Depletion of TLR4 in naturally overexpressing MDA-MB-231 cells downregulated prosurvival genes concomitant with 2- to 3-fold reduced IC(50) to paclitaxel in vitro and a 6-fold decrease in recurrence rate in vivo.	Paclitaxel	143-153	toll like receptor 4	Homo sapiens	13-17
23720768-8	2013	Conversely, TLR4 overexpression in a negative cell line HCC1806 significantly increased expression of inflammatory and prosurvival genes along with a 3-fold increase of IC(50) to paclitaxel in vitro and enhanced tumor resistance to paclitaxel therapy in vivo.	Paclitaxel	179-189	toll like receptor 4	Homo sapiens	12-16
23720768-8	2013	Conversely, TLR4 overexpression in a negative cell line HCC1806 significantly increased expression of inflammatory and prosurvival genes along with a 3-fold increase of IC(50) to paclitaxel in vitro and enhanced tumor resistance to paclitaxel therapy in vivo.	Paclitaxel	232-242	toll like receptor 4	Homo sapiens	12-16
23720768-10	2013	Collectively, these results show that paclitaxel not only kills tumor cells but also enhances their survival by activating TLR4 pathway.	Paclitaxel	38-48	toll like receptor 4	Homo sapiens	123-127
23720768-11	2013	These findings suggest that blocking TLR4 could significantly improve response to paclitaxel therapy.	Paclitaxel	82-92	toll like receptor 4	Homo sapiens	37-41
23750239-6	2013	It was further explored that miR-26a increased sensitivity of breast cancer cells to paclitaxel in which MCL-1 was involved.	Paclitaxel	85-95	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	105-110
23782748-2	2013	Organic anion transporting polypeptide 1B3 (OATP1B3) and copper transporter 1 (CTR1) are critical for the uptake of paclitaxel and carboplatin, respectively.	Paclitaxel	116-126	solute carrier family 31 member 1	Homo sapiens	57-77
23782748-2	2013	Organic anion transporting polypeptide 1B3 (OATP1B3) and copper transporter 1 (CTR1) are critical for the uptake of paclitaxel and carboplatin, respectively.	Paclitaxel	116-126	solute carrier family 31 member 1	Homo sapiens	79-83
23423488-0	2013	Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel.	Paclitaxel	123-133	microtubule associated protein tau	Homo sapiens	14-48
23423488-0	2013	Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel.	Paclitaxel	123-133	microtubule associated protein tau	Homo sapiens	50-54
23423488-9	2013	Cells derived from gastric cancer tissues with low miR-34c-5p expression and high microtubule-associated protein tau (MAPT) protein expression tended to have increased chemoresistance to paclitaxel in vitro.	Paclitaxel	187-197	microtubule associated protein tau	Homo sapiens	82-116
23423488-9	2013	Cells derived from gastric cancer tissues with low miR-34c-5p expression and high microtubule-associated protein tau (MAPT) protein expression tended to have increased chemoresistance to paclitaxel in vitro.	Paclitaxel	187-197	microtubule associated protein tau	Homo sapiens	118-122
23434829-11	2013	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and rapamycin, which are also P-gp substrates.	Paclitaxel	83-93	secreted phosphoprotein 1	Homo sapiens	26-29
24649184-8	2013	More favorable therapeutic effects were observed in the high TS expression group compared with the low TS expression group, when carboplatin + paclitaxel combined chemotherapy (CbPac therapy) was used.	Paclitaxel	143-153	thymidylate synthetase	Homo sapiens	61-63
23631819-1	2013	BACKGROUND: The aim of the study was to evaluate predictive and prognostic significance of microtubule-associated protein Tau in epithelial ovarian cancer (EOC) patients treated with paclitaxel and platinum-based chemotherapy.	Paclitaxel	183-193	microtubule associated protein tau	Homo sapiens	91-125
23590835-13	2013	We identified a set of eight genes (EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32 and NNMT) showing significant gene-drug correlation with paclitaxel, docetaxel, erlotinib, everolimus and dasatinib.	Paclitaxel	136-146	myosin light chain kinase	Homo sapiens	49-53
23590835-13	2013	We identified a set of eight genes (EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32 and NNMT) showing significant gene-drug correlation with paclitaxel, docetaxel, erlotinib, everolimus and dasatinib.	Paclitaxel	136-146	interleukin 32	Homo sapiens	74-78
23373651-5	2013	This paper reviews over forty articles that examine cell lines, murine models, and human results for the response of taxol against squamous cell carcinoma (SCC) of the oral cavity and the tongue.	Paclitaxel	117-122	serpin family B member 3	Homo sapiens	156-159
24327986-10	2013	Light chain 3, a microtubule-associated protein, which reflect autophagy, was increased with 5 nM of paclitaxel after pretreatment with 10 nM of rapamycin.	Paclitaxel	101-111	regulator of microtubule dynamics 1	Homo sapiens	17-47
23364970-13	2013	Expressions of HIF-1alpha and TUBB3 were most decreased when AGS cells were treated with a combination of paclitaxel and anti-VEGFR-1.	Paclitaxel	106-116	jagged canonical Notch ligand 1	Homo sapiens	61-64
23364970-14	2013	AGS cell cytotoxicity was most increased in response to paclitaxel, anti-VEGFR-1, and anti-VEGFR-2.	Paclitaxel	56-66	jagged canonical Notch ligand 1	Homo sapiens	0-3
23228696-7	2013	Furthermore, metformin was able to not only decrease the paclitaxel-induced p38 MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.	Paclitaxel	57-67	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	94-99
23228696-8	2013	Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and paclitaxel as well as cell viability and DNA repair capacity.	Paclitaxel	153-163	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	115-120
23396109-0	2013	Downregulation of miR-17&amp;#126;92 Expression Increase Paclitaxel Sensitivity in Human Ovarian Carcinoma SKOV3-TR30 Cells via BIM Instead of PTEN.	Paclitaxel	57-67	phosphatase and tensin homolog	Homo sapiens	143-147
23396109-9	2013	Our results showed that miR-17~92 could be a causal factor of the downregulation of BIM in  SKOV3-TR30 cells and thus induce the paclitaxel resistance in SKOV3-TR30 cells.	Paclitaxel	129-139	miR-17-92a-1 cluster host gene	Homo sapiens	24-33
23151974-0	2013	Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.	Paclitaxel	35-45	diablo IAP-binding mitochondrial protein	Homo sapiens	0-4
23151974-2	2013	Our previous study showed that ectopic overexpression of Smac sensitizes drug-resistant tumor cells to TRAIL- or paclitaxel-induced apoptosis in vitro.	Paclitaxel	113-123	diablo IAP-binding mitochondrial protein	Homo sapiens	57-61
28454227-6	2017	In addition, the efficacy of Taxol was evaluated by comparing the survival of patients with high or low Cbx2 expression.	Paclitaxel	29-34	chromobox 2	Homo sapiens	104-108
23151974-4	2013	The results showed that the single-agent Smac N7 had a non-cytotoxic effect, but it effectively enhanced TRAIL- or paclitaxel-induced inhibition of cell proliferation in a dose-dependent manner, even in TRAIL-resistant A2780 cells.	Paclitaxel	115-125	diablo IAP-binding mitochondrial protein	Homo sapiens	41-45
28454227-11	2017	Among patients with high Cbx2 expression, the mean OS time of individuals treated with Taxol (71.01 months) was lower compared with patients that had not received Taxol treatment (78.43 months; log-rank test statistic, 13.03; P&lt;0.001).	Paclitaxel	87-92	chromobox 2	Homo sapiens	25-29
23229357-6	2013	The level of PTX-induced cell apoptosis was increased from 8.5+-1.2 to 16.4+-2.4% (p&lt;0.05) and from 15.2+-1.4 to 34.9+-2.8% (p&lt;0.05), at the end of the first and second hyperthermia cycles, respectively; both the activity and expression of caspase-7 were enhanced.	Paclitaxel	13-16	caspase 7	Homo sapiens	246-255
28454227-11	2017	Among patients with high Cbx2 expression, the mean OS time of individuals treated with Taxol (71.01 months) was lower compared with patients that had not received Taxol treatment (78.43 months; log-rank test statistic, 13.03; P&lt;0.001).	Paclitaxel	163-168	chromobox 2	Homo sapiens	25-29
28454227-14	2017	Cbx2 may also represent a potential target for treatment due to its important function in Taxol treatment responses.	Paclitaxel	90-95	chromobox 2	Homo sapiens	0-4
23066953-11	2013	Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation.	Paclitaxel	94-104	plasminogen activator, urokinase receptor	Homo sapiens	12-16
28196146-3	2017	We report a transient increase of a small distinctive CXCR4High/CD24Low cancer stem cell population (CXCR4High) in A2780 and SKOV-3 OVC cell lines in response to cisplatin, doxorubicin, and paclitaxel, treatments.	Paclitaxel	190-200	C-X-C motif chemokine receptor 4	Homo sapiens	54-59
23066953-11	2013	Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation.	Paclitaxel	94-104	plasminogen activator, urokinase receptor	Homo sapiens	29-33
23066953-11	2013	Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation.	Paclitaxel	94-104	plasminogen activator, urokinase receptor	Homo sapiens	29-33
23114644-2	2013	In this study, we found that elevated cyclin B1 expression attenuated the apoptosis induced by cisplatin or paclitaxel, while knockdown of cyclin B1 enhanced cisplatin or paclitaxel sensitivity in ESCC cells.	Paclitaxel	108-118	cyclin B1	Homo sapiens	38-47
28261335-0	2017	RSF1 regulates the proliferation and paclitaxel resistance via modulating NF-kappaB signaling pathway in nasopharyngeal carcinoma.	Paclitaxel	37-47	remodeling and spacing factor 1	Homo sapiens	0-4
28261335-5	2017	CCK8 assays and flow cytometry were applied to monitor the changes of proliferation and paclitaxel sensitivity caused by RSF1 modulation, inhibition of NF-kappaB pathway by inhibitor Bay 11-7082 and Survivin knockdown.	Paclitaxel	88-98	remodeling and spacing factor 1	Homo sapiens	121-125
28261335-8	2017	Functional analyses revealed that RSF1 inhibition or overexpression induced changes in cell cycle, apoptosis, and then led to altered proliferation and paclitaxel sensitivity in diverse NPC cells in vitro.	Paclitaxel	152-162	remodeling and spacing factor 1	Homo sapiens	34-38
28261335-10	2017	Importantly, inhibition of NF-kappaB pathway by Bay 11-7082 and knockdown its downstream Survivin reversed the paclitaxel resistance caused by RSF1 overexpression.	Paclitaxel	111-121	remodeling and spacing factor 1	Homo sapiens	143-147
23114644-2	2013	In this study, we found that elevated cyclin B1 expression attenuated the apoptosis induced by cisplatin or paclitaxel, while knockdown of cyclin B1 enhanced cisplatin or paclitaxel sensitivity in ESCC cells.	Paclitaxel	171-181	cyclin B1	Homo sapiens	139-148
28261335-11	2017	Conclusions: Taken together, our data indicate that RSF1 regulates the proliferation and paclitaxel resistance via activating NF-kappaB signaling pathway and NF-kappaB-dependent Survivin upregulation, suggesting that RSF1 may be used as a potential therapeutic target in NPC.	Paclitaxel	89-99	remodeling and spacing factor 1	Homo sapiens	52-56
28261335-11	2017	Conclusions: Taken together, our data indicate that RSF1 regulates the proliferation and paclitaxel resistance via activating NF-kappaB signaling pathway and NF-kappaB-dependent Survivin upregulation, suggesting that RSF1 may be used as a potential therapeutic target in NPC.	Paclitaxel	89-99	remodeling and spacing factor 1	Homo sapiens	217-221
24371445-6	2013	Taxol, not only a potent tumor-apoptosis-inducing, but also TLR4-activating chemotherapeutic compound, inhibited growth and viability of all cell lines, whereas the remaining TLR ligands had only marginal effects (R848 &gt; LPS &gt; Poly I:C).	Paclitaxel	0-5	toll like receptor 4	Homo sapiens	60-64
28223821-12	2017	AEP knockout decreased resistance to microtubule inhibitors, including paclitaxel, docetaxel, and T-DM1.	Paclitaxel	71-81	legumain	Homo sapiens	0-3
23610522-0	2013	Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice.	Paclitaxel	0-10	CD34 antigen	Mus musculus	58-62
23610522-3	2013	The purpose of this study was to investigate the inhibitory effect of paclitaxel-loaded Fe3O4 nanoparticles (PTX-NPs) on CD138(-) CD34(-) tumor stem cells in multiple myeloma-bearing mice.	Paclitaxel	70-80	CD34 antigen	Mus musculus	130-134
27887867-10	2017	RESULTS: PTX induced apoptosis, decreased the proliferation and cell migration rates of ASCs and inhibited ASCs multipotent differentiation in both in vitro human ASC populations and ex vivo rat ASC populations with PTX treatment.	Paclitaxel	9-12	PYD and CARD domain containing	Rattus norvegicus	107-110
23577147-6	2013	In human breast cancer cells, paclitaxel treatment resulted in MCL-1 degradation which was prevented by a proteasome inhibitor, MG132.	Paclitaxel	30-40	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	63-68
23600154-6	2013	The cumulative absorptions of Taxol and PTX-SLN were significantly promoted after the addition of P-glycoprotein inhibitor (verapamil) into the preparation (P &lt; 0.05), but absorption of SA-R8-PTX-SLN existed no significantly difference compared with the preparation without verapamil (P &gt; 0.05).	Paclitaxel	30-35	sarcolipin	Rattus norvegicus	199-202
27739325-0	2017	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.	Paclitaxel	117-127	BRCA1 DNA repair associated	Homo sapiens	131-136
28125674-9	2017	In the peripheral nervous system, PTX induced expression of the neuronal injury marker activating transcription factor-3 in IB4+ and NF200+ sensory neurons as well as an increase in the chemokines CCL2 and CCL3 in the lumbar dorsal root ganglion.	Paclitaxel	34-37	chemokine (C-C motif) ligand 2	Mus musculus	197-201
28125674-11	2017	We also found that PTX induced up-regulation of several inflammatory cytokines and chemokines (TNF-alpha, IFN-gamma, CCL11, CCL4, CCL3, IL-12p70 and GM-CSF) in the spinal cord.	Paclitaxel	19-22	chemokine (C-C motif) ligand 4	Mus musculus	124-128
28125674-11	2017	We also found that PTX induced up-regulation of several inflammatory cytokines and chemokines (TNF-alpha, IFN-gamma, CCL11, CCL4, CCL3, IL-12p70 and GM-CSF) in the spinal cord.	Paclitaxel	19-22	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	149-155
22226241-7	2012	An innovative approach to treatment therefore focuses on peritumoral fibroblasts and aims to induce a depletion of the stroma either by inhibition of the hedgehog pathway or by targeting SPARC (secreted protein acidic and rich in cysteine) via application of albumin-bound paclitaxel.	Paclitaxel	273-283	secreted protein acidic and cysteine rich	Homo sapiens	187-192
22226241-7	2012	An innovative approach to treatment therefore focuses on peritumoral fibroblasts and aims to induce a depletion of the stroma either by inhibition of the hedgehog pathway or by targeting SPARC (secreted protein acidic and rich in cysteine) via application of albumin-bound paclitaxel.	Paclitaxel	273-283	secreted protein acidic and cysteine rich	Homo sapiens	194-238
23063344-6	2012	Moreover, the acute administration of both sigma(1) receptor antagonists dose dependently reversed both types of paclitaxel-induced allodynia after they had fully developed.	Paclitaxel	113-123	sigma non-opioid intracellular receptor 1	Mus musculus	43-60
27435393-11	2017	CONCLUSIONS: Our results revealed the risk of CEBPD activation in CDDP-resistant UCUB cells and suggested a therapeutic strategy for patients with UCUB or UCUB resisted to CDDP and paclitaxel by combination with either gefitinib or S3I-201.	Paclitaxel	181-191	CCAAT enhancer binding protein delta	Homo sapiens	46-51
27365266-6	2017	TRIO: PTX/17-AAG/RAP at 15/15/7.5 mg kg-1 ) strongly inhibits A549 tumor growth.	Paclitaxel	6-9	N-methylpurine DNA glycosylase	Homo sapiens	13-16
23063344-8	2012	PERSPECTIVE: Antagonists of the sigma(1) receptor may have therapeutic value for the treatment and/or prevention of paclitaxel-induced neuropathic pain.	Paclitaxel	116-126	sigma non-opioid intracellular receptor 1	Mus musculus	32-49
23170249-8	2012	Tumor weights were significantly reduced in mice treated with HER-2 peptides alone, and even more in animals that received HER-2 peptide with low-dose paclitaxel, which alone had no significant effects on tumor growth in the transgenic model.	Paclitaxel	151-161	erb-b2 receptor tyrosine kinase 2	Mus musculus	123-128
27978745-1	2016	A highly functionalized intermediate in the synthesis of Taxol has been synthesized, which features the tricyclic core and the required oxygen substituents at C1, C2, C7, C10, and C13.	Paclitaxel	57-62	homeobox C13	Homo sapiens	180-183
27659528-7	2016	Mechanistic analysis revealed that administration of geridonin in combination with paclitaxel up-regulated the tumor suppressor PTEN and inhibited phosphorylation of Akt and MDM2.	Paclitaxel	83-93	MDM2 proto-oncogene	Homo sapiens	174-178
23170249-9	2012	Specifically engineered native peptide sequences from HER-2 and VEGF used in combination with metronomic paclitaxel demonstrate enhanced anticancer efficacy and an encouraging safety profile.	Paclitaxel	105-115	erb-b2 receptor tyrosine kinase 2	Mus musculus	54-59
22998838-0	2012	The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy.	Paclitaxel	34-44	cannabinoid receptor 2	Homo sapiens	112-115
22998838-15	2012	Our studies suggest that CB2 receptors represent a promising therapeutic target for the treatment of toxic neuropathies produced by cisplatin and paclitaxel chemotherapeutic agents.	Paclitaxel	146-156	cannabinoid receptor 2	Homo sapiens	25-28
27819360-4	2016	Previously we showed that upregulated IGF-1R expression is essential to initiate platinum-taxol resistance at early stage which declines with elevated levels of activated AKT at late resistant stage in ovarian cancer cells.	Paclitaxel	90-95	insulin like growth factor 1 receptor	Homo sapiens	38-44
22824824-10	2012	Six of them (DLC1, CHFR, ABCC5, PEG10, ERBB2, and GSTP1) were independently confirmed to contribute to taxol resistance by both methylation-specific PCR and quantitative real-time PCR.	Paclitaxel	103-108	checkpoint with forkhead and ring finger domains	Homo sapiens	19-23
22824824-10	2012	Six of them (DLC1, CHFR, ABCC5, PEG10, ERBB2, and GSTP1) were independently confirmed to contribute to taxol resistance by both methylation-specific PCR and quantitative real-time PCR.	Paclitaxel	103-108	glutathione S-transferase pi 1	Homo sapiens	50-55
22718863-10	2012	In addition, an inverse correlation between TUBB2A and paclitaxel-induced apoptosis (P = 0.001) in lymphoblastoid cell lines further supported that higher TUBB2A gene expression conferred lower paclitaxel sensitivity.	Paclitaxel	55-65	tubulin beta 2A class IIa	Homo sapiens	155-161
27713401-2	2016	The purpose of the present study was to investigate the inhibitory effect of RIZ1 gene therapy on the growth of SiHa cervical cancer cells and its synergism with paclitaxel.	Paclitaxel	162-172	PR/SET domain 2	Homo sapiens	77-81
27713401-6	2016	The expression level of RIZ1 in SiHa cells increased after treatment with paclitaxel, which indicated a synergism between them.	Paclitaxel	74-84	PR/SET domain 2	Homo sapiens	24-28
27713401-7	2016	RIZ1 gene therapy combined with paclitaxel showed stronger cell inhibition than paclitaxel alone, which indicated a synergism between them.	Paclitaxel	32-42	PR/SET domain 2	Homo sapiens	0-4
27713401-7	2016	RIZ1 gene therapy combined with paclitaxel showed stronger cell inhibition than paclitaxel alone, which indicated a synergism between them.	Paclitaxel	80-90	PR/SET domain 2	Homo sapiens	0-4
27600258-9	2016	The results of the present study are the first to demonstrate that MSI2 is a valuable marker of advanced, serous ovarian cancer and that MSI2 plays an important role in paclitaxel resistance.	Paclitaxel	169-179	musashi RNA binding protein 2	Homo sapiens	137-141
22718863-10	2012	In addition, an inverse correlation between TUBB2A and paclitaxel-induced apoptosis (P = 0.001) in lymphoblastoid cell lines further supported that higher TUBB2A gene expression conferred lower paclitaxel sensitivity.	Paclitaxel	194-204	tubulin beta 2A class IIa	Homo sapiens	155-161
22540333-11	2012	Cisplatin and paclitaxel markedly inhibited the proliferative ability of GloI-depleted endometrial cancer cells.	Paclitaxel	14-24	glyoxalase I	Homo sapiens	73-77
27708225-0	2016	NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.	Paclitaxel	74-84	growth differentiation factor 15	Homo sapiens	0-22
27708225-9	2016	NAG-1 and pro-inflammatory NF-kappaB were positively associated with resistance to paclitaxel in MyD88-positive type I EOC cells.	Paclitaxel	83-93	growth differentiation factor 15	Homo sapiens	0-5
27629142-4	2016	In this study, we generated a cell line of acquired resistance to paclitaxel therapy, A2780T, which is cross-resistant to other antimitotic drugs, such as PLK1 inhibitor or AURKA inhibitor.	Paclitaxel	66-76	polo like kinase 1	Mus musculus	155-159
27818790-5	2016	Here, we analyzed the levels and localization of the BUB1 and SURVIVIN proteins in cells that escaped from a paclitaxel-mediated prolonged mitosis.	Paclitaxel	109-119	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	53-57
22449053-4	2012	Using an IFNgamma ELISPOT assay, it was found that administration of 1 mg paclitaxel/kg in combination with the peptide vaccination strongly increased the frequencies of TRP-2 specific spleen T-cells as compared to levels due to the vaccination alone.	Paclitaxel	74-84	tRNA proline 2	Mus musculus	170-175
22469813-0	2012	RNA interference targeting CHFR enhances taxol chemosensitivity in endometrial             cancer cells.	Paclitaxel	41-46	checkpoint with forkhead and ring finger domains	Homo sapiens	27-31
27590858-9	2016	Additionally, drug sensitivity tests indicated that USP7-silenced A549 cells had enhanced sensitivity to paclitaxel and docetaxel, while there was no significant change in sensitivity toward carboplatin and cisplatin.	Paclitaxel	105-115	ubiquitin specific peptidase 7	Homo sapiens	52-56
27737687-13	2016	Molecular studies revealed that paclitaxel increased TNFalpha expression, thereby leading to the recruitment of various factors and the formation of the TRADD-TRAF2-RIP1-cIAP complex.	Paclitaxel	32-42	TNF receptor associated factor 2	Homo sapiens	159-164
27737687-16	2016	In nude mouse xenograft experiments, the combination of LCL161 and paclitaxel degraded cIAP1,2, activated caspase-3 and inhibited tumor growth with few toxic effects.	Paclitaxel	67-77	caspase 3	Mus musculus	106-115
22469813-4	2012	We found that inhibition of CHFR expression significantly enhanced             the cytotoxicity of taxol to both cell types, which was confirmed again by colony             formation assays.	Paclitaxel	99-104	checkpoint with forkhead and ring finger domains	Homo sapiens	28-32
22469813-5	2012	Moreover, suppression of CHFR induced a significant increase             of the mitotic index and much lower numbers of cells at the G2/M phase in both             cells treated with taxol, indicating mitotic checkpoint impairment.	Paclitaxel	183-188	checkpoint with forkhead and ring finger domains	Homo sapiens	25-29
22469813-6	2012	On the other             hand, the number of apoptotic cells significantly increased in Ishikawa and Hec-1a             cells transfected with CHFR siRNA after treatment with taxol, which was associated             with cyclin B1 nuclear localization.	Paclitaxel	175-180	checkpoint with forkhead and ring finger domains	Homo sapiens	143-147
22469813-6	2012	On the other             hand, the number of apoptotic cells significantly increased in Ishikawa and Hec-1a             cells transfected with CHFR siRNA after treatment with taxol, which was associated             with cyclin B1 nuclear localization.	Paclitaxel	175-180	cyclin B1	Homo sapiens	220-229
27422900-4	2016	Consistently with a potential involvement of TRAP1 in thyroid carcinogenesis, TRAP1 silencing resulted in increased sensitivity to paclitaxel-induced apoptosis, inhibition of cell cycle progression and attenuation of ERK signaling.	Paclitaxel	131-141	TNF receptor associated protein 1	Homo sapiens	45-50
27422900-4	2016	Consistently with a potential involvement of TRAP1 in thyroid carcinogenesis, TRAP1 silencing resulted in increased sensitivity to paclitaxel-induced apoptosis, inhibition of cell cycle progression and attenuation of ERK signaling.	Paclitaxel	131-141	TNF receptor associated protein 1	Homo sapiens	78-83
22469813-7	2012	Our data indicate that RNA interference targeting             CHFR can sensitize endometrial cancer cells to taxol and CHFR may be a promising             molecular target to enhance the therapeutic effect of taxol for endometrial cancer.	Paclitaxel	109-114	checkpoint with forkhead and ring finger domains	Homo sapiens	62-66
27409838-0	2016	Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.	Paclitaxel	56-66	polo like kinase 1	Homo sapiens	43-47
27409838-5	2016	We investigated the role of FBXW7 and their substrates MCL1 and PLK1 in regulating the apoptotic response to paclitaxel treatment in breast cancer cells and their expression in breast cancer tissues.	Paclitaxel	109-119	polo like kinase 1	Homo sapiens	64-68
22469813-7	2012	Our data indicate that RNA interference targeting             CHFR can sensitize endometrial cancer cells to taxol and CHFR may be a promising             molecular target to enhance the therapeutic effect of taxol for endometrial cancer.	Paclitaxel	209-214	checkpoint with forkhead and ring finger domains	Homo sapiens	62-66
27409838-7	2016	Forced expression of FBXW7 or downregulation of MCL1 or PLK1 restored sensitivity to paclitaxel in MDA-MB-468R cells.	Paclitaxel	85-95	polo like kinase 1	Homo sapiens	56-60
27409838-10	2016	In breast cancer tissues, loss of FBXW7 correlated with adverse prognosis markers and loss of FBXW7 and MCL1 or PLK1 accumulation were associated with diminished disease-free survival in paclitaxel-treated patients.	Paclitaxel	187-197	polo like kinase 1	Homo sapiens	112-116
22469813-7	2012	Our data indicate that RNA interference targeting             CHFR can sensitize endometrial cancer cells to taxol and CHFR may be a promising             molecular target to enhance the therapeutic effect of taxol for endometrial cancer.	Paclitaxel	209-214	checkpoint with forkhead and ring finger domains	Homo sapiens	119-123
27409838-11	2016	We conclude that FBXW7 regulates the response to paclitaxel by targeting MCL1 and PLK1 in breast cancer cells and thus targeting these substrates may be a valuable adjunct for paclitaxel treatment.	Paclitaxel	49-59	polo like kinase 1	Homo sapiens	82-86
22931803-0	2012	[Effects of paclitaxel on proliferation and transition of phenotype in platelet-derived growth factor-BB-induced pulmonary vascular smooth muscle cells].	Paclitaxel	12-22	myotrophin	Rattus norvegicus	88-101
27328733-0	2016	Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma.	Paclitaxel	9-19	S100 calcium binding protein A4	Homo sapiens	28-34
27328733-2	2016	In this study, we provide evidence that targeting S100A4 nuclear import by low-dose paclitaxel, a microtubule-stabilizing agent, inhibits cholangiocarcinoma invasiveness and metastatic spread.	Paclitaxel	84-94	S100 calcium binding protein A4	Homo sapiens	50-56
27328733-3	2016	Administration of low-dose paclitaxel to established (EGI-1) and primary (CCA-TV3) cholangiocarcinoma cell lines expressing nuclear S100A4 triggered a marked reduction in nuclear expression of S100A4 without modifying its cytoplasmic levels, an effect associated with a significant decrease in cell migration and invasiveness.	Paclitaxel	27-37	S100 calcium binding protein A4	Homo sapiens	132-138
27328733-3	2016	Administration of low-dose paclitaxel to established (EGI-1) and primary (CCA-TV3) cholangiocarcinoma cell lines expressing nuclear S100A4 triggered a marked reduction in nuclear expression of S100A4 without modifying its cytoplasmic levels, an effect associated with a significant decrease in cell migration and invasiveness.	Paclitaxel	27-37	S100 calcium binding protein A4	Homo sapiens	193-199
27328733-4	2016	While low-dose paclitaxel did not affect cellular proliferation, apoptosis, or cytoskeletal integrity, it significantly reduced SUMOylation of S100A4, a critical posttranslational modification that directs its trafficking to the nucleus.	Paclitaxel	15-25	S100 calcium binding protein A4	Homo sapiens	143-149
27328733-6	2016	Downregulation of nuclear S100A4 by low-dose paclitaxel was associated with a strong reduction in RhoA and Cdc42 GTPase activity, MT1-MMP expression, and MMP-9 secretion.	Paclitaxel	45-55	S100 calcium binding protein A4	Homo sapiens	26-32
27328733-6	2016	Downregulation of nuclear S100A4 by low-dose paclitaxel was associated with a strong reduction in RhoA and Cdc42 GTPase activity, MT1-MMP expression, and MMP-9 secretion.	Paclitaxel	45-55	matrix metallopeptidase 9	Homo sapiens	154-159
22931803-1	2012	OBJECTIVE: To investigate the effects of paclitaxel on the phenotypic modulation induced by platelet-derived growth factor (PDGF-BB) in rat pulmonary vascular smooth muscle cells (PVSMC).	Paclitaxel	41-51	myotrophin	Rattus norvegicus	109-122
22607637-3	2012	In a demonstration of the power of this directing effect, C-H oxidation is diverted away from an electronically favored C-1 H abstraction/rearrangement pathway in the paclitaxel framework to enable installation of C-2 oxidation in the naturally occurring oxidation state and stereoconfiguration.	Paclitaxel	167-177	complement C2	Homo sapiens	214-217
22634531-0	2012	Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study.	Paclitaxel	143-153	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	59-63
27106131-3	2016	Here we report the histone deacetylase inhibitor apicidin (APC) or ER stressor thapsigargin (TG) potentiate paclitaxel (TXL)-induced apoptosis in PCa cells and limit accumulation of cancer stem cells.	Paclitaxel	108-118	thioredoxin like 1	Homo sapiens	120-123
26852748-3	2016	In this study, we found that paclitaxel dose-dependently activated Beclin-1 in 2 NSCLC cell lines, A549 and Calu-3.	Paclitaxel	29-39	beclin 1	Homo sapiens	67-75
26852748-7	2016	Together, these data suggest that paclitaxel may decrease miR-216b levels in NSCLC cells, which subsequently upregulates Beclin-1 to increase NSCLC cell autophagy to antagonize paclitaxel-induced cell death.	Paclitaxel	34-44	beclin 1	Homo sapiens	121-129
26852748-7	2016	Together, these data suggest that paclitaxel may decrease miR-216b levels in NSCLC cells, which subsequently upregulates Beclin-1 to increase NSCLC cell autophagy to antagonize paclitaxel-induced cell death.	Paclitaxel	177-187	beclin 1	Homo sapiens	121-129
22488170-0	2012	GDF3 inhibits the growth of breast cancer cells and promotes the apoptosis induced by Taxol.	Paclitaxel	86-91	growth differentiation factor 3	Homo sapiens	0-4
26883251-7	2016	Under different concentrations of 5-FU and paclitaxel in MDA-MB231 cell, E-cadherin mRNA and protein expressions increased gradually with the increase of concentrations, and Vimentin and N-cadherin mRNA and protein expressions decreased gradually with the decrease of concentrations (all P &lt; 0.05).	Paclitaxel	43-53	cadherin 2	Homo sapiens	187-197
27474498-14	2016	Paclitaxel or vincristine treatment significantly decreased protein levels of HMGB1 in the dorsal root ganglia, but not sciatic nerves.	Paclitaxel	0-10	high mobility group box 1	Rattus norvegicus	78-83
22488170-10	2012	Furthermore, overexpression of GDF3 could promote the apoptosis induced by Taxol.	Paclitaxel	75-80	growth differentiation factor 3	Homo sapiens	31-35
27106527-0	2016	Effect of HM30181 mesylate salt-loaded microcapsules on the oral absorption of paclitaxel as a novel P-glycoprotein inhibitor.	Paclitaxel	79-89	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	101-115
27106527-1	2016	The purpose of this study was to develop HM30181 mesylate salt (HM30181M)-loaded microcapsules as a novel P-glycoprotein inhibitor for enhancing the oral absorption of paclitaxel.	Paclitaxel	168-178	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	106-120
22095282-7	2012	Moreover, PRMT1 depletion potentiated paclitaxel-induced ASK1 activation and apoptosis in human breast cancer cells.	Paclitaxel	38-48	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	57-61
27106527-10	2016	Thus, this novel microcapsule could be a potential candidate for effective P-glycoprotein inhibition during oral administration of paclitaxel.	Paclitaxel	131-141	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	75-89
22320227-1	2012	The purpose of the present study was to investigate the association of glutathione S-transferase P1 (GSTP1) expression with resistance to neoadjuvant paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (P-FEC) in human breast cancers.	Paclitaxel	150-160	glutathione S-transferase pi 1	Homo sapiens	71-99
27376029-12	2016	Several clinically available chemotherapeutic drugs (carboplatin, paclitaxel, and etoposide) and drugs at the developmental stage (Wee-1 and heat shock protein 90 inhibitors) show a sensitizing effect on tumor cells treated with carbon ions.	Paclitaxel	66-76	WEE1 G2 checkpoint kinase	Homo sapiens	131-136
27147573-6	2016	Among tested chemicals, rare ginsenoside, CSH1 (Rg6) shows obvious effect on inhibition of MTOC amplification, gamma-tubulin induction and Taxol resistance.	Paclitaxel	139-144	chorionic somatomammotropin hormone 1	Homo sapiens	42-46
27255186-5	2016	Bel 7402 cell resistance to paclitaxel was associated with the expression of the "stemness" markers CD44 and CD133.	Paclitaxel	28-38	CD44 molecule (Indian blood group)	Homo sapiens	100-104
27368038-2	2016	Recent introduction of a newer-generation drug-eluting stent (DES) has significantly reduced the occurrence of stent thrombosis.The aim of this study was to evaluate the impact of CYP2C19 LOF alleles on clinical outcome in patients treated with the newer-generation DES.The effects of CYP2C19 genotypes were evaluated on clinical outcome of clopidogrel therapy in 2062 patients treated with percutaneous coronary intervention using either first-generation DES (sirolimus- and paclitaxel-eluting stent, n = 1349) or newer-generation DES (everolimus- and zotarolimus-eluting stent, n = 713).	Paclitaxel	476-486	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	180-187
27313736-0	2016	Effect of taxol on the expression of FoxM1 ovarian cancer-associated gene.	Paclitaxel	10-15	forkhead box M1	Homo sapiens	37-42
27313736-2	2016	The aim of the present study was to examine the effects of taxol on the expression of ovarian cancer-associated gene forkhead box transcription factor M1 (FoxM1) and its therapeutic effects for ovarian cancer.	Paclitaxel	59-64	forkhead box M1	Homo sapiens	155-160
27313736-4	2016	RNA and protein levels of FoxM1 gene of ovarian cancer patients were detected at different time periods (1, 3, 6, 8, 12 and 24 months) after treatment with taxol.	Paclitaxel	156-161	forkhead box M1	Homo sapiens	26-31
27313736-6	2016	With time and progression of the disease, the expression of FoxM1 gene significantly increased in the patients not being administered taxol, whereas the expression of FoxM1 in the patients administered taxol was significantly lower comparatively (P&lt;0.05).	Paclitaxel	134-139	forkhead box M1	Homo sapiens	60-65
27313736-6	2016	With time and progression of the disease, the expression of FoxM1 gene significantly increased in the patients not being administered taxol, whereas the expression of FoxM1 in the patients administered taxol was significantly lower comparatively (P&lt;0.05).	Paclitaxel	202-207	forkhead box M1	Homo sapiens	167-172
27313746-1	2016	The present study aimed to evaluate the effect of the expression of the autophagic gene beclin 1 on the biological behavior and chemotherapy sensitivity towards Taxol  of cervical cancer HeLa cells.	Paclitaxel	161-166	beclin 1	Homo sapiens	88-96
26908046-5	2016	RESULTS: The findings that worth noting are: PTX-PU outperformed Taxol  in a Balb/C mouse model, furthermore, tumor growth was adequately curbed by folate and TRAIL-decorated nanomicelles rather than the unconjugated formulation.	Paclitaxel	65-70	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	159-164
27296552-5	2016	Further, purification of mitotic spindles from synchronized cells show that LOX fails to bind to microtubules in the presence of nocodazole, whereas paclitaxel treated samples showed enrichment in LOX expression, suggesting that LOX binds to stabilized microtubules.	Paclitaxel	149-159	lysyl oxidase	Homo sapiens	197-200
27296552-5	2016	Further, purification of mitotic spindles from synchronized cells show that LOX fails to bind to microtubules in the presence of nocodazole, whereas paclitaxel treated samples showed enrichment in LOX expression, suggesting that LOX binds to stabilized microtubules.	Paclitaxel	149-159	lysyl oxidase	Homo sapiens	197-200
27062670-3	2016	If the alkyne is at the C11 position (and thus flanked by a gem-dimethyl group), RCEDYM reaction only proceeds in the presence of a trisubstituted olefin at C13, which disfavors the competing diene ring-closing metathesis reaction, to give the tricyclic core of Taxol 44.	Paclitaxel	262-267	RNA polymerase III subunit K	Homo sapiens	24-27
27062670-3	2016	If the alkyne is at the C11 position (and thus flanked by a gem-dimethyl group), RCEDYM reaction only proceeds in the presence of a trisubstituted olefin at C13, which disfavors the competing diene ring-closing metathesis reaction, to give the tricyclic core of Taxol 44.	Paclitaxel	262-267	homeobox C13	Homo sapiens	157-160
27113739-0	2016	Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.	Paclitaxel	58-68	BRCA1 DNA repair associated	Homo sapiens	108-113
27113739-1	2016	The purpose of this study was to assess pathological complete response and whether it serves a surrogate for survival among patients receiving neo-adjuvant doxorubicin-cyclophosphamide followed by paclitaxel for triple-negative breast cancer with respect to BRCA1 mutation status.	Paclitaxel	197-207	BRCA1 DNA repair associated	Homo sapiens	258-263
26581910-5	2016	Our results showed that miR-143, but not let-7b, increased sensitization of KRAS mutant tumor cells to paclitaxel.	Paclitaxel	103-113	KRAS proto-oncogene, GTPase	Homo sapiens	76-80
26581910-7	2016	Combination of miR-143 mimic and paclitaxel induced the onset of apoptosis, and reverted in vitro metastatic properties (migration and invasion) in KRAS mutant tumor cells.	Paclitaxel	33-43	KRAS proto-oncogene, GTPase	Homo sapiens	148-152
26988911-1	2016	We previously reported that ATP7B is involved in cisplatin resistance and ATP7A confers multidrug resistance (MDR) in cancer cells.In this study, we show that ATP7B expressing cells also are resistant to doxorubicin, SN-38, etoposide, and paclitaxel as well as cisplatin.In ATP7B expressing cells, doxorubicin relocated from the nuclei to the late-endosome at 4 hours after doxorubicin exposure.	Paclitaxel	239-249	ATPase, Cu++ transporting, alpha polypeptide	Gallus gallus	74-79
26943585-0	2016	Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells" sensitivity to paclitaxel.	Paclitaxel	91-101	microRNA 493	Homo sapiens	21-28
26943585-7	2016	In human neoplasms, miR-493-3p and Mad2 expression alterations correlated with advanced ovarian cancer forms and high miR-493-3p levels were associated with reduced survival of ovarian and breast cancer patients with aggressive tumors, especially in the paclitaxel therapy arm.	Paclitaxel	254-264	microRNA 493	Homo sapiens	118-125
27022257-11	2016	In the Simva and LDE-PTX and Simva groups, expression of cyclin D1, a proliferation and survival promoter of tumor cells, was decreased.	Paclitaxel	21-24	cyclin D1	Mus musculus	57-66
26794530-0	2016	Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel.	Paclitaxel	146-156	polo like kinase 1	Homo sapiens	23-27
26886339-5	2016	Using this method, Tf-PTX-NPs (paclitaxel-loaded Tf nanoparticles) could be readily obtained.	Paclitaxel	31-41	transferrin	Mus musculus	19-21
25961928-0	2016	Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.	Paclitaxel	0-10	forkhead box M1	Homo sapiens	19-24
25961928-0	2016	Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.	Paclitaxel	85-95	forkhead box M1	Homo sapiens	19-24
25961928-2	2016	In here, we show that FOXM1 depletion can sensitize breast cancer cells and mouse embryonic fibroblasts into entering paclitaxel-induced senescence, with the loss of clonogenic ability, and the induction of senescence-associated beta-galactosidase activity and flat cell morphology.	Paclitaxel	118-128	forkhead box M1	Mus musculus	22-27
26900348-8	2016	RESULTS: We identified 22 TSGs involved in PTX resistance, including BRCA1, TP53, PTEN, APC, CDKN1A, CDKN2A, HIN-1, RASSF1, YAP, ING4, PLK2, FBW7, BLU, LZTS1, REST, FADD, PDCD4, TGFBI, ING1, Bax, PinX1 and hEx.	Paclitaxel	43-46	inhibitor of growth family member 4	Homo sapiens	129-133
26900348-8	2016	RESULTS: We identified 22 TSGs involved in PTX resistance, including BRCA1, TP53, PTEN, APC, CDKN1A, CDKN2A, HIN-1, RASSF1, YAP, ING4, PLK2, FBW7, BLU, LZTS1, REST, FADD, PDCD4, TGFBI, ING1, Bax, PinX1 and hEx.	Paclitaxel	43-46	zinc finger MYND-type containing 10	Homo sapiens	147-150
26900348-8	2016	RESULTS: We identified 22 TSGs involved in PTX resistance, including BRCA1, TP53, PTEN, APC, CDKN1A, CDKN2A, HIN-1, RASSF1, YAP, ING4, PLK2, FBW7, BLU, LZTS1, REST, FADD, PDCD4, TGFBI, ING1, Bax, PinX1 and hEx.	Paclitaxel	43-46	leucine zipper tumor suppressor 1	Homo sapiens	152-157
26900348-8	2016	RESULTS: We identified 22 TSGs involved in PTX resistance, including BRCA1, TP53, PTEN, APC, CDKN1A, CDKN2A, HIN-1, RASSF1, YAP, ING4, PLK2, FBW7, BLU, LZTS1, REST, FADD, PDCD4, TGFBI, ING1, Bax, PinX1 and hEx.	Paclitaxel	43-46	transforming growth factor beta induced	Homo sapiens	178-183
26799187-0	2016	p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.	Paclitaxel	42-52	MDM2 proto-oncogene	Homo sapiens	17-21
26404133-3	2016	MTT assay showed that knockdown of CIP2A expression increased the drug sensitivity of HeLa and Dox-resistant HeLa cells (HeLa-Dox) to doxorubicin, cisplatin, and paclitaxel significantly, while overexpression of CIP2A decreased the sensitivity of HeLa cells to chemo-drugs dramatically.	Paclitaxel	162-172	cellular inhibitor of PP2A	Homo sapiens	35-40
24786483-0	2016	Effects of lipid vehicle and P-glycoprotein inhibition on the mesenteric lymphatic transport of paclitaxel in unconscious, lymph duct-cannulated rats.	Paclitaxel	96-106	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	29-43
24786483-7	2016	P-gp inhibition can result in both increased intestinal lymphatic levels and absolute oral bioavailability of PTX.	Paclitaxel	110-113	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-4
26270131-0	2016	Taxol prevents myocardial ischemia-reperfusion injury by inducing JNK-mediated HO-1 expression.	Paclitaxel	0-5	heme oxygenase 1	Rattus norvegicus	79-83
26270131-3	2016	Induction of HO-1 is involved in cytoprotective effects of taxol.	Paclitaxel	59-64	heme oxygenase 1	Rattus norvegicus	13-17
26270131-4	2016	OBJECTIVE: We hypothesize that taxol protects cardiac myocytes possibly by preserving myocardial mitochondrial function and inducing HO-1 expression through the JNK pathway.	Paclitaxel	31-36	heme oxygenase 1	Rattus norvegicus	133-137
26270131-13	2016	Furthermore, the expression level of HO-1 increased with taxol treatments, which could be inhibited by the specific inhibitor of JNK, SP600125.	Paclitaxel	57-62	heme oxygenase 1	Rattus norvegicus	37-41
26270131-16	2016	Interestingly, taxol induced the expression of HO-1 via the JNK pathway in cardiac myocytes.	Paclitaxel	15-20	heme oxygenase 1	Rattus norvegicus	47-51
26474677-6	2015	The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells.	Paclitaxel	55-58	phosphoglycolate phosphatase	Mus musculus	105-109
26474677-6	2015	The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells.	Paclitaxel	55-58	phosphoglycolate phosphatase	Mus musculus	168-172
26474677-6	2015	The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells.	Paclitaxel	211-214	phosphoglycolate phosphatase	Mus musculus	105-109
26474677-6	2015	The most synergistic effect was found between LAPA and PTX on the cell line overexpressing both HER2 and P-gp, and the mechanisms related to LAPA-induced inhibition on P-gp expression, more G2/M phase arrest of PTX and more uptake of PTX in tumor cells.	Paclitaxel	211-214	phosphoglycolate phosphatase	Mus musculus	105-109
26367491-8	2015	SIRT1 overexpression significantly enhanced the resistance for cisplatin and paclitaxel in HHUA cells.	Paclitaxel	77-87	sirtuin 1	Homo sapiens	0-5
26722421-9	2015	15 genes of 762 transcripts on this chromosome region were consistently up-regulated detected by cDNA microarray in three taxol resistant sub-lines, and functionally clustered into various groups, including genes related to vascular formation vascular formation (ANGPT1), apoptosis (MYC, TOP1MT), cell adhesion and cell cycle (PPP1R16A, SDC2, CA2, ANKRD46), gene regulation (HRSP12, ZNF696, SLC39A4, POP1), metabolism (PYCRL).	Paclitaxel	122-127	reactive intermediate imine deaminase A homolog	Homo sapiens	375-381
26722421-9	2015	15 genes of 762 transcripts on this chromosome region were consistently up-regulated detected by cDNA microarray in three taxol resistant sub-lines, and functionally clustered into various groups, including genes related to vascular formation vascular formation (ANGPT1), apoptosis (MYC, TOP1MT), cell adhesion and cell cycle (PPP1R16A, SDC2, CA2, ANKRD46), gene regulation (HRSP12, ZNF696, SLC39A4, POP1), metabolism (PYCRL).	Paclitaxel	122-127	zinc finger protein 696	Homo sapiens	383-389
26722421-9	2015	15 genes of 762 transcripts on this chromosome region were consistently up-regulated detected by cDNA microarray in three taxol resistant sub-lines, and functionally clustered into various groups, including genes related to vascular formation vascular formation (ANGPT1), apoptosis (MYC, TOP1MT), cell adhesion and cell cycle (PPP1R16A, SDC2, CA2, ANKRD46), gene regulation (HRSP12, ZNF696, SLC39A4, POP1), metabolism (PYCRL).	Paclitaxel	122-127	solute carrier family 39 member 4	Homo sapiens	391-398
26496295-3	2015	We report successful treatment of a metastatic TNBC in a woman with a BRCA2 germline mutation using combined bevacizumab/paclitaxel/carboplatin (BPC) therapy.	Paclitaxel	121-131	BRCA2 DNA repair associated	Homo sapiens	70-75
26622855-12	2015	Furthermore, paclitaxel was observed to inhibit oral cancer cell proliferation through increased MMP-2 and MMP-9 protein levels.	Paclitaxel	13-23	matrix metallopeptidase 9	Homo sapiens	107-112
26337085-7	2015	In agreement with its suggested role in M phase, inhibition of MA-linc1 enhances apoptotic cell death induced by the antimitotic drug, Paclitaxel and this enhancement of apoptosis is rescued by Puralpha knockdown.	Paclitaxel	135-145	purine rich element binding protein A	Homo sapiens	194-202
26406239-5	2015	Pro-apoptotic Bcl-2 antagonist killer 1 (Bak) plays an important role in Taxol-induced apoptosis in breast cancer.	Paclitaxel	73-78	BCL2 antagonist/killer 1	Homo sapiens	41-44
26406239-9	2015	Importantly, higher Bak expression predicted a favorable clinical outcome in the cases treated with Taxol indicated by a higher overall survival than that of patients with lower Bak expression especially in Luminal and HER2 subtypes.	Paclitaxel	100-105	BCL2 antagonist/killer 1	Homo sapiens	20-23
26406239-9	2015	Importantly, higher Bak expression predicted a favorable clinical outcome in the cases treated with Taxol indicated by a higher overall survival than that of patients with lower Bak expression especially in Luminal and HER2 subtypes.	Paclitaxel	100-105	BCL2 antagonist/killer 1	Homo sapiens	178-181
26406239-10	2015	Furthermore, these results were confirmed in vitro since overexpression of Bak sensitized breast cancer cells to Taxol by inhibiting proliferation and promoting apoptosis; in contrast, downregulation of Bak through siRNA transfection inhibited Taxol induced-apoptosis.	Paclitaxel	113-118	BCL2 antagonist/killer 1	Homo sapiens	75-78
26406239-10	2015	Furthermore, these results were confirmed in vitro since overexpression of Bak sensitized breast cancer cells to Taxol by inhibiting proliferation and promoting apoptosis; in contrast, downregulation of Bak through siRNA transfection inhibited Taxol induced-apoptosis.	Paclitaxel	244-249	BCL2 antagonist/killer 1	Homo sapiens	75-78
26406239-10	2015	Furthermore, these results were confirmed in vitro since overexpression of Bak sensitized breast cancer cells to Taxol by inhibiting proliferation and promoting apoptosis; in contrast, downregulation of Bak through siRNA transfection inhibited Taxol induced-apoptosis.	Paclitaxel	244-249	BCL2 antagonist/killer 1	Homo sapiens	203-206
26406239-11	2015	Therefore, our results demonstrate that Bak acts as a sensitive biomarker and favorable prognostic factor for Taxol treatment in breast cancer.	Paclitaxel	110-115	BCL2 antagonist/killer 1	Homo sapiens	40-43
26406239-12	2015	The restoration of Bak expression would be therapeutically beneficial for Taxol resistant breast cancer patients.	Paclitaxel	74-79	BCL2 antagonist/killer 1	Homo sapiens	19-22
26317793-5	2015	We showed that EIF5A2 overexpression in ESCC cells resulted in increased chemoresistance to 5-fluorouracil (5-FU), docetaxel and taxol.	Paclitaxel	129-134	eukaryotic translation initiation factor 5A2	Mus musculus	15-21
26329920-7	2015	The levels of DR4 and caspase-3 were significantly increased (P&lt;0.01) in MCF-7 cells treated with the tested sample compared to untreated cells and possessed a similar activity of paclitaxel in DR4 induction but lower induction in caspase-3.	Paclitaxel	183-193	major histocompatibility complex, class II, DR beta 4	Homo sapiens	14-17
26329920-7	2015	The levels of DR4 and caspase-3 were significantly increased (P&lt;0.01) in MCF-7 cells treated with the tested sample compared to untreated cells and possessed a similar activity of paclitaxel in DR4 induction but lower induction in caspase-3.	Paclitaxel	183-193	major histocompatibility complex, class II, DR beta 4	Homo sapiens	197-200
26622726-8	2015	Individually PTX and HM were able to inhibit the migration and invasion of two human gastric cancer cells; however, the combination of PTX and HM exerted synergistic effects on migration and invasion inhibition, with downregulation of COX-2 and matrix metalloproteinase (MMP)-9.	Paclitaxel	13-16	matrix metallopeptidase 9	Homo sapiens	245-277
26622726-8	2015	Individually PTX and HM were able to inhibit the migration and invasion of two human gastric cancer cells; however, the combination of PTX and HM exerted synergistic effects on migration and invasion inhibition, with downregulation of COX-2 and matrix metalloproteinase (MMP)-9.	Paclitaxel	135-138	matrix metallopeptidase 9	Homo sapiens	245-277
25956854-5	2015	Thus, a multi-core, multi-targeting construct for tumor specific delivery of PTX was fabricated with (i) an inner-core prodrug targeting the cancer-overexpressed cathepsin B through a cathepsin B-cleavable tetrapeptide that conjugates PTX to a poly(amidoamine) dendrimer, and (ii) the encapsulation of this prodrug (PGD) in an outer core of a RES-evading, folate receptor (FR)-targeting liposome.	Paclitaxel	77-80	cathepsin B	Homo sapiens	162-173
25956854-5	2015	Thus, a multi-core, multi-targeting construct for tumor specific delivery of PTX was fabricated with (i) an inner-core prodrug targeting the cancer-overexpressed cathepsin B through a cathepsin B-cleavable tetrapeptide that conjugates PTX to a poly(amidoamine) dendrimer, and (ii) the encapsulation of this prodrug (PGD) in an outer core of a RES-evading, folate receptor (FR)-targeting liposome.	Paclitaxel	77-80	cathepsin B	Homo sapiens	184-195
25956854-5	2015	Thus, a multi-core, multi-targeting construct for tumor specific delivery of PTX was fabricated with (i) an inner-core prodrug targeting the cancer-overexpressed cathepsin B through a cathepsin B-cleavable tetrapeptide that conjugates PTX to a poly(amidoamine) dendrimer, and (ii) the encapsulation of this prodrug (PGD) in an outer core of a RES-evading, folate receptor (FR)-targeting liposome.	Paclitaxel	235-238	cathepsin B	Homo sapiens	184-195
25956854-6	2015	Compared to traditional FR-targeting PTX liposomes, this sequentially active-targeted dendrosome demonstrated better prodrug retention, an increased cytotoxicity to cancer cells (latter being true when FR and cathepsin B activities were both at moderate-to-high levels) and higher tumor reduction.	Paclitaxel	37-40	cathepsin B	Homo sapiens	209-220
26714597-13	2015	Estrogen and progesterone combined with paclitaxel show tumor suppressing or sensitizing effect through upregulated Drosha expression, and are associated with the estrogen receptor expression.	Paclitaxel	40-50	drosha ribonuclease III	Homo sapiens	116-122
25957661-6	2015	Docking simulation and confocal microscopy assay results further indicated that C13 could bind well to the tubulin at paclitaxel binding site, leading to tubulin polymerization and mitotic disruption.	Paclitaxel	118-128	homeobox C13	Homo sapiens	80-83
25946136-4	2015	We found that let-7b repletion selectively sensitized KRAS mutant tumor cells to the cytotoxicity of paclitaxel and gemcitabine.	Paclitaxel	101-111	microRNA let-7b	Homo sapiens	14-20
25946136-4	2015	We found that let-7b repletion selectively sensitized KRAS mutant tumor cells to the cytotoxicity of paclitaxel and gemcitabine.	Paclitaxel	101-111	KRAS proto-oncogene, GTPase	Homo sapiens	54-58
25946136-6	2015	Combination of let-7b mimic with paclitaxel or gemcitabine diminished MEK/ERK and PI3K/AKT signaling concurrently, triggered the onset of apoptosis, and reverted the epithelial-mesenchymal transition in KRAS mutant tumor cells.	Paclitaxel	33-43	KRAS proto-oncogene, GTPase	Homo sapiens	203-207
25946136-7	2015	In addition, let-7b repletion downregulated the expression of beta-tubulin III and ribonucleotide reductase subunit M2, two proteins known to mediate tumor resistance to paclitaxel and gemcitabine, respectively.	Paclitaxel	170-180	microRNA let-7b	Homo sapiens	13-19
26502701-3	2015	Paclitaxel-induced activation of nuclear factor kappa B (NF-kappaB) leads to an increase of some antiapoptotic proteins expression such as survivin, cIAP, XIAP.	Paclitaxel	0-10	X-linked inhibitor of apoptosis	Homo sapiens	155-159
25879875-13	2015	AF-6/afadin knockdown induced chemoresistance to doxorubicin, paclitaxel and cisplatin in Ishikawa cells, not in HEC1A.	Paclitaxel	62-72	afadin, adherens junction formation factor	Homo sapiens	0-4
25879875-13	2015	AF-6/afadin knockdown induced chemoresistance to doxorubicin, paclitaxel and cisplatin in Ishikawa cells, not in HEC1A.	Paclitaxel	62-72	afadin, adherens junction formation factor	Homo sapiens	5-11
25578058-7	2015	The expression of Beclin 1 and LC3 II were upregulated, but p62 was downregulated, which suggests that autophagy was promoted by paclitaxel.	Paclitaxel	129-139	beclin 1	Homo sapiens	18-26
25578058-7	2015	The expression of Beclin 1 and LC3 II were upregulated, but p62 was downregulated, which suggests that autophagy was promoted by paclitaxel.	Paclitaxel	129-139	nucleoporin 62	Homo sapiens	60-63
25578058-9	2015	The cell proliferation assay indicated that a knockdown of Beclin 1 sensitized HeLa cells to paclitaxel.	Paclitaxel	93-103	beclin 1	Homo sapiens	59-67
25578058-10	2015	Furthermore, paclitaxel-mediated apoptotic cell death was further potentiated by the pretreatment with autophagy inhibitor chloroquine or small interfering RNA against Beclin 1.	Paclitaxel	13-23	beclin 1	Homo sapiens	168-176
25502361-4	2015	The present study reported that expression of pyruvate dehydrogenase kinase 1 (PDK1) was induced by Taxol treatment at low toxic concentrations in oral cancer cells.	Paclitaxel	100-105	pyruvate dehydrogenase kinase 1	Homo sapiens	46-77
25502361-4	2015	The present study reported that expression of pyruvate dehydrogenase kinase 1 (PDK1) was induced by Taxol treatment at low toxic concentrations in oral cancer cells.	Paclitaxel	100-105	pyruvate dehydrogenase kinase 1	Homo sapiens	79-83
25502361-5	2015	In addition, Taxol-resistant cells exhibited upregulated PDK1 protein and mRNA expression.	Paclitaxel	13-18	pyruvate dehydrogenase kinase 1	Homo sapiens	57-61
25502361-6	2015	Elevated PDK1 levels contribute to Taxol resistance under hypoxic conditions.	Paclitaxel	35-40	pyruvate dehydrogenase kinase 1	Homo sapiens	9-13
25499080-3	2015	Silencing of p53 or KRAS in A549 or H358 cells either enhanced or attenuated the resistance of cells to cisplatin and taxol through promotion or suppression of the NF-kappaB p65 nuclear translocation.	Paclitaxel	118-123	KRAS proto-oncogene, GTPase	Homo sapiens	20-24
25767606-6	2015	RESULTS: Flow cytometry showed that Docetaxel, Paclitaxel, Gemzar and Cisplatin induced apoptosis more when they were added before somatostatin, whereas etoposide induced apoptosis more after somatostatin treatment.	Paclitaxel	47-57	somatostatin	Homo sapiens	131-143
25767606-6	2015	RESULTS: Flow cytometry showed that Docetaxel, Paclitaxel, Gemzar and Cisplatin induced apoptosis more when they were added before somatostatin, whereas etoposide induced apoptosis more after somatostatin treatment.	Paclitaxel	47-57	somatostatin	Homo sapiens	192-204
25667499-1	2015	AIM: To correlate CA125 levels after platinum- and paclitaxel-based chemotherapy with progression-free survival (PFS) and overall survival (OS) in advanced ovarian carcinoma following primary cytoreduction.	Paclitaxel	51-61	mucin 16, cell surface associated	Homo sapiens	18-23
25973036-0	2015	Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1.	Paclitaxel	36-46	forkhead box M1	Homo sapiens	117-122
25973036-13	2015	These results indicate that miR-877 could influence the sensitivity of paclitaxel treatment in hepatocellular carcinoma cell lines by targeting FOXM1.	Paclitaxel	71-81	forkhead box M1	Homo sapiens	144-149
25351620-0	2015	Ephrin type-A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3-kinase/Akt signalling pathway.	Paclitaxel	50-60	EPH receptor A2	Homo sapiens	0-24
25351620-3	2015	In the present study, upregulation of EphA2 expression enhanced the survival of NPC 5-8F cells, compared with control cells exposed to the same concentrations of paclitaxel.	Paclitaxel	162-172	EPH receptor A2	Homo sapiens	38-43
25351620-4	2015	Flow cytometry and western blot analysis demonstrated that over-expression of EphA2 decreased NPC cancer cell sensitivity to paclitaxel by regulating paclitaxel-mediated cell cycle progression but not apoptosis in vitro.	Paclitaxel	125-135	EPH receptor A2	Homo sapiens	78-83
25351620-4	2015	Flow cytometry and western blot analysis demonstrated that over-expression of EphA2 decreased NPC cancer cell sensitivity to paclitaxel by regulating paclitaxel-mediated cell cycle progression but not apoptosis in vitro.	Paclitaxel	150-160	EPH receptor A2	Homo sapiens	78-83
25351620-7	2015	Inhibition of the PI3K/Akt signalling pathway restored sensitivity to paclitaxel in 5-8F cells over-expressing EphA2, which indicated that the PI3K/Akt pathway is involved in EphA2-mediated paclitaxel sensitivity.	Paclitaxel	70-80	EPH receptor A2	Homo sapiens	111-116
25351620-7	2015	Inhibition of the PI3K/Akt signalling pathway restored sensitivity to paclitaxel in 5-8F cells over-expressing EphA2, which indicated that the PI3K/Akt pathway is involved in EphA2-mediated paclitaxel sensitivity.	Paclitaxel	70-80	EPH receptor A2	Homo sapiens	175-180
25351620-7	2015	Inhibition of the PI3K/Akt signalling pathway restored sensitivity to paclitaxel in 5-8F cells over-expressing EphA2, which indicated that the PI3K/Akt pathway is involved in EphA2-mediated paclitaxel sensitivity.	Paclitaxel	190-200	EPH receptor A2	Homo sapiens	111-116
25607466-6	2015	Additionally, the downregulation of BECN1 by siRNA attenuated the activation of autophagy and cytoprotection from paclitaxel induced by TXNDC17 overexpression in ovarian cancer cells.	Paclitaxel	114-124	beclin 1	Homo sapiens	36-41
25607466-7	2015	Thus, our findings suggest that TXNDC17, through participation of BECN1, induces autophagy and consequently results in paclitaxel resistance in ovarian cancer.	Paclitaxel	119-129	beclin 1	Homo sapiens	66-71
26370682-7	2015	Furthermore, overexpression of Clock and Bmal1 prevented the cells from entering into the G2/M phase induced by Paclitaxel, and made the cells more resistant to the agent.	Paclitaxel	112-122	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	41-46
26370682-9	2015	In addition, the present study raised the possibility that Clock and Bmal1 may in part play a role in preventing the cells from entering G1 to S phase of cell cycle via suppression of CyclinD1 expression, and thus acquiring resistance to Paclitaxel.	Paclitaxel	238-248	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	69-74
25825088-4	2015	In this study, we found that paclitaxel induced autophagy in paclitaxel-insensitive HEC-1A and JEC cells, exhibiting an increased microtubule associated protein 1 light chain 3 (LC3)-II/LC3-I ratio, a decrease in p62/SQSTM1 abundance, the upregulation of Beclin 1 expression and punctate dots of yellow fluorescent protein (YFP)-LC3 in the cytosol.	Paclitaxel	29-39	sequestosome 1	Homo sapiens	213-216
25825088-4	2015	In this study, we found that paclitaxel induced autophagy in paclitaxel-insensitive HEC-1A and JEC cells, exhibiting an increased microtubule associated protein 1 light chain 3 (LC3)-II/LC3-I ratio, a decrease in p62/SQSTM1 abundance, the upregulation of Beclin 1 expression and punctate dots of yellow fluorescent protein (YFP)-LC3 in the cytosol.	Paclitaxel	29-39	sequestosome 1	Homo sapiens	217-223
25825088-4	2015	In this study, we found that paclitaxel induced autophagy in paclitaxel-insensitive HEC-1A and JEC cells, exhibiting an increased microtubule associated protein 1 light chain 3 (LC3)-II/LC3-I ratio, a decrease in p62/SQSTM1 abundance, the upregulation of Beclin 1 expression and punctate dots of yellow fluorescent protein (YFP)-LC3 in the cytosol.	Paclitaxel	29-39	beclin 1	Homo sapiens	255-263
25825088-5	2015	Paclitaxel-mediated cell death was further potentiated by pretreatment with autophagy inhibitor chloroquine (CQ) or shRNA against the autophagic gene beclin 1.	Paclitaxel	0-10	beclin 1	Homo sapiens	150-158
25989666-0	2015	[The vitro research of effects of Beclin1 on paclitaxel-sensitivity in laryngeal carcinoma cell Hep-2].	Paclitaxel	45-55	beclin 1	Homo sapiens	34-41
25351906-4	2015	For this purpose, we examined cell proliferation and the SP cell ratio following treatment of Huh7 cells with the anticancer drugs 5-fluorouracil (5-FU) and paclitaxel.	Paclitaxel	157-167	MIR7-3 host gene	Homo sapiens	94-98
25481222-5	2015	Whereas NTCP did not show any strong interactions with the cytostatics tested, we observed a very strong inhibition of OAT2 mediated [(3)H] cGMP uptake in the presence of bendamustine, irinotecan and paclitaxel.	Paclitaxel	200-210	solute carrier family 22 member 7	Homo sapiens	119-123
25481222-6	2015	The Ki values of OAT2 for bendamustine, irinotecan and paclitaxel were determined to be 43.3+-4.33muM, 26.4+-2.34muM and 10.4+-0.45muM, respectively.	Paclitaxel	55-65	solute carrier family 22 member 7	Homo sapiens	17-21
26242340-8	2015	RESULTS: The Paclitaxel treatment group showed a significant relative reduction in nNOS expression at 2, 4, and 6 wk, and significantly improved mitochondrial function at 4 and 6 wk.	Paclitaxel	13-23	nitric oxide synthase 1	Rattus norvegicus	83-87
26242340-10	2015	CONCLUSION: Paclitaxel has a significant neuroprotective effect against spinal motoneuron degeneration following brachial plexus avulsion injury, which involves inhibition of nNOS expression and prevention of mitochondrial dysfunction.	Paclitaxel	12-22	nitric oxide synthase 1	Rattus norvegicus	175-179
25459427-0	2014	Immunotherapeutic vitamin E nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response.	Paclitaxel	85-95	negative elongation factor complex member C/D	Homo sapiens	134-137
25459427-8	2014	Cytokine estimation study in macrophages showed that both PTX loaded nanoemulsion and blank nanoemulsion enhanced secretion of IL-12 and downregulated secretion of IL-4 and IL-10.	Paclitaxel	58-61	interleukin 10	Homo sapiens	173-178
25520862-11	2014	Restoration of DACT2 expression sensitized gastric cancer cells to paclitaxel and 5-FU.	Paclitaxel	67-77	dishevelled binding antagonist of beta catenin 2	Homo sapiens	15-20
25228695-6	2014	In contrast, the reconstitution of 14-3-3beta expression in miR-152(high) cells increased the expression of the anti-apoptotic BCL2 gene, enhances the proliferative activity in the presence of the cytostatic drug paclitaxel, and causes resistance to apoptosis induced by this drug.	Paclitaxel	213-223	membrane associated ring-CH-type finger 8	Homo sapiens	60-63
25442283-0	2014	Salvianolic acid A reverses paclitaxel resistance in human breast cancer MCF-7 cells via targeting the expression of transgelin 2 and attenuating PI3 K/Akt pathway.	Paclitaxel	28-38	transgelin 2	Homo sapiens	117-129
25442283-2	2014	The purpose of this study was to investigate the role of transgelin 2 in human breast cancer paclitaxel resistance cell line (MCF-7/PTX) and the reversal mechanism of salvianolic acid A (SAA), a phenolic active compound extracted from Salvia miltiorrhiza.	Paclitaxel	93-103	transgelin 2	Homo sapiens	57-69
24614283-9	2014	HPMA copolymer-PTX/SQ-Cy5 systems enable site-specific release upon enzymatic degradation in cathepsin B-overexpressing breast cancer cells.	Paclitaxel	15-18	cathepsin B	Mus musculus	93-104
24928535-4	2014	PURPOSE: We examined whether the inhibition of CAR-mediated pathway could influence the cytotoxicity of three anticancer drugs, cisplatin, paclitaxel, and arsenic trioxide, in ovarian cancer cells.	Paclitaxel	139-149	nuclear receptor subfamily 1 group I member 3	Homo sapiens	47-50
25093335-4	2014	Treatment with NPB304 increased paclitaxel-induced apoptosis in a p53-dependent manner through PARP cleavage.	Paclitaxel	32-42	poly (ADP-ribose) polymerase family, member 1	Mus musculus	95-99
25093335-7	2014	Moreover, NPB304 increased paclitaxel accumulation by affecting P-gp function.	Paclitaxel	27-37	phosphoglycolate phosphatase	Mus musculus	64-68
24959746-0	2014	Constitutive androstane receptor ligands modulate the anti-tumor efficacy of paclitaxel in non-small cell lung cancer cells.	Paclitaxel	77-87	nuclear receptor subfamily 1 group I member 3	Homo sapiens	0-32
24959746-3	2014	Therefore, we wish to elucidate the effects of CAR ligands on the antineoplastic efficacy of paclitaxel in lung cancer cells.	Paclitaxel	93-103	nuclear receptor subfamily 1 group I member 3	Homo sapiens	47-50
24959746-5	2014	The CAR agonists increased the effect of Paclitaxel in 6 of 7 lung cancer cell lines, whereas the inverse-agonist had no effect on paclitaxel cytotoxicity.	Paclitaxel	41-51	nuclear receptor subfamily 1 group I member 3	Homo sapiens	4-7
24959746-6	2014	Interestingly, the mCAR agonist TCPOBOP enhanced the expression of two tumor suppressor genes, namely WT1 and MGMT, which were additively enhanced in cells treated with CAR agonist in combination with paclitaxel.	Paclitaxel	201-211	O-6-methylguanine-DNA methyltransferase	Homo sapiens	110-114
24847940-6	2014	Thus, PTX was conjugated to the hydrophilic poly(amdioamine) [PAMAM] dendrimer through the cathepsin B-cleavable tetrapeptide Gly-Phe-Leu-Gly.	Paclitaxel	6-9	cathepsin B	Homo sapiens	91-102
24755470-5	2014	Paclitaxel and docetaxel, but not cabazitaxel, were transported substrates of OATP1B1, OATP1B3, and OATP1B2, and these in vitro transport processes were strongly reduced in the presence of clinically relevant concentrations of PS80 and CrEL.	Paclitaxel	0-10	solute carrier organic anion transporter family, member 1b2	Mus musculus	100-107
24755470-6	2014	When paclitaxel was administered without any solubilizers, deficiency of OATP1B2 in mice was associated with a significantly decreased systemic clearance because of a liver distribution defect (P=0.000484).	Paclitaxel	5-15	solute carrier organic anion transporter family, member 1b2	Mus musculus	73-80
24755470-7	2014	However, this genotype dependence of paclitaxel clearance was masked in the presence of PS80 or CrEL because of significant inhibition of OATP1B2-mediated hepatocellular uptake of the drug (P&lt;0.05).	Paclitaxel	37-47	solute carrier organic anion transporter family, member 1b2	Mus musculus	138-145
24939301-6	2014	The percentage of cells in G0-G1 and G2-M phases was reduced, and that in S phase increased after treatment for 72 h. The expression of cyclin D1 and B1, p27 and PCNA in VSMCs of paclitaxel-treated group was up-regulated, but that of p21 down-regulated as compared with VECs.	Paclitaxel	179-189	proliferating cell nuclear antigen	Rattus norvegicus	162-166
24939301-6	2014	The percentage of cells in G0-G1 and G2-M phases was reduced, and that in S phase increased after treatment for 72 h. The expression of cyclin D1 and B1, p27 and PCNA in VSMCs of paclitaxel-treated group was up-regulated, but that of p21 down-regulated as compared with VECs.	Paclitaxel	179-189	KRAS proto-oncogene, GTPase	Rattus norvegicus	234-237
24748116-0	2014	End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability.	Paclitaxel	33-43	microtubule associated protein RP/EB family member 1	Homo sapiens	0-21
24748116-3	2014	Herein, we show that the expression of end-binding protein 1 (EB1), a regulator of microtubule dynamics involved in multiple cellular activities, in breast tumor tissues correlates with the pathological response of tumors to paclitaxel-based chemotherapy.	Paclitaxel	225-235	microtubule associated protein RP/EB family member 1	Homo sapiens	39-60
24748116-3	2014	Herein, we show that the expression of end-binding protein 1 (EB1), a regulator of microtubule dynamics involved in multiple cellular activities, in breast tumor tissues correlates with the pathological response of tumors to paclitaxel-based chemotherapy.	Paclitaxel	225-235	microtubule associated protein RP/EB family member 1	Homo sapiens	62-65
24748116-4	2014	In vitro cell proliferation assays reveal that EB1 stimulates paclitaxel sensitivity in breast cancer cell lines.	Paclitaxel	62-72	microtubule associated protein RP/EB family member 1	Homo sapiens	47-50
24748116-5	2014	Our data further demonstrate that EB1 increases the activity of paclitaxel to cause mitotic arrest and apoptosis in cancer cells.	Paclitaxel	64-74	microtubule associated protein RP/EB family member 1	Homo sapiens	34-37
24748116-6	2014	In addition, microtubule binding affinity analysis and polymerization/depolymerization assays show that EB1 enhances paclitaxel binding to microtubules and stimulates the ability of paclitaxel to promote microtubule assembly and stabilization.	Paclitaxel	117-127	microtubule associated protein RP/EB family member 1	Homo sapiens	104-107
24748116-6	2014	In addition, microtubule binding affinity analysis and polymerization/depolymerization assays show that EB1 enhances paclitaxel binding to microtubules and stimulates the ability of paclitaxel to promote microtubule assembly and stabilization.	Paclitaxel	182-192	microtubule associated protein RP/EB family member 1	Homo sapiens	104-107
24748116-7	2014	These findings thus reveal EB1 as a critical regulator of paclitaxel sensitivity and have important implications in breast cancer chemotherapy.	Paclitaxel	58-68	microtubule associated protein RP/EB family member 1	Homo sapiens	27-30
24886434-8	2014	In vitro analysis of tumor xenografts at protein and mRNA levels demonstrated a loss of CSC-like markers and CA125 expression in paclitaxel and CYT387-treated cell-derived xenografts, compared to paclitaxel only-treated cell-derived xenografts.	Paclitaxel	129-139	mucin 16, cell surface associated	Homo sapiens	109-114
24657894-2	2014	Myeloid progenitors express the fusion oncogene BCR-ABL, which has uncontrollable activity in malignant cells and prevents the cell apoptosis caused by some antineoplastic agents, such as paclitaxel.	Paclitaxel	188-198	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	48-55
24657894-7	2014	KEY FINDINGS: The effects of the tyrosine kinase inhibitor AG1024 were evaluated with regard to the regulation of BCR-ABL expression, inhibition of cell proliferation, and enhanced paclitaxel-induced apoptosis in BCR-ABL-expressing K562 cell lines.	Paclitaxel	181-191	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	213-220
24638863-8	2014	Paclitaxel is a substrate of P-glycoprotein (P-gp), so P-gp would affect the transport of paclitaxel to the fetus.	Paclitaxel	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	29-43
24638863-8	2014	Paclitaxel is a substrate of P-glycoprotein (P-gp), so P-gp would affect the transport of paclitaxel to the fetus.	Paclitaxel	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	45-49
24638863-8	2014	Paclitaxel is a substrate of P-glycoprotein (P-gp), so P-gp would affect the transport of paclitaxel to the fetus.	Paclitaxel	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	55-59
24638863-8	2014	Paclitaxel is a substrate of P-glycoprotein (P-gp), so P-gp would affect the transport of paclitaxel to the fetus.	Paclitaxel	90-100	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	29-43
24638863-8	2014	Paclitaxel is a substrate of P-glycoprotein (P-gp), so P-gp would affect the transport of paclitaxel to the fetus.	Paclitaxel	90-100	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	45-49
24638863-8	2014	Paclitaxel is a substrate of P-glycoprotein (P-gp), so P-gp would affect the transport of paclitaxel to the fetus.	Paclitaxel	90-100	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	55-59
24847251-12	2014	The author believes that this case is the first report of a robust response to nab-paclitaxel monotherapy in triple-negative BRCA1-positive breast cancer, and that it supports further studies of nab-paclitaxel in this aggressive indication.	Paclitaxel	83-93	BRCA1 DNA repair associated	Homo sapiens	125-130
24469707-3	2014	Results showed that treatment of Taxol could increase the inhibition rate of tumour growth, positive expression levels of Caspase-3, Bax and decrease positive expression levels of Bcl-2 and Bcl-2/Bax, expression levels of HGF, MACC1 and C-met proteins and MACC1 mRNA in tumour tissue of CC mice.	Paclitaxel	33-38	caspase 3	Mus musculus	122-131
24469707-3	2014	Results showed that treatment of Taxol could increase the inhibition rate of tumour growth, positive expression levels of Caspase-3, Bax and decrease positive expression levels of Bcl-2 and Bcl-2/Bax, expression levels of HGF, MACC1 and C-met proteins and MACC1 mRNA in tumour tissue of CC mice.	Paclitaxel	33-38	BCL2-associated X protein	Mus musculus	133-136
24469707-3	2014	Results showed that treatment of Taxol could increase the inhibition rate of tumour growth, positive expression levels of Caspase-3, Bax and decrease positive expression levels of Bcl-2 and Bcl-2/Bax, expression levels of HGF, MACC1 and C-met proteins and MACC1 mRNA in tumour tissue of CC mice.	Paclitaxel	33-38	BCL2-associated X protein	Mus musculus	196-199
24469707-3	2014	Results showed that treatment of Taxol could increase the inhibition rate of tumour growth, positive expression levels of Caspase-3, Bax and decrease positive expression levels of Bcl-2 and Bcl-2/Bax, expression levels of HGF, MACC1 and C-met proteins and MACC1 mRNA in tumour tissue of CC mice.	Paclitaxel	33-38	hepatocyte growth factor	Mus musculus	222-225
24469707-4	2014	It can be concluded that inhibitory activity of Taxol against tumour growth in CC mice is closely associated with its modulating positive expression of Bcl-2, Bax, Caspase-3, expression of HGF, MACC1, Caspase-3 and C-met proteins and MACC1 mRNA in tumour of CC mice.	Paclitaxel	48-53	BCL2-associated X protein	Mus musculus	159-162
24469707-4	2014	It can be concluded that inhibitory activity of Taxol against tumour growth in CC mice is closely associated with its modulating positive expression of Bcl-2, Bax, Caspase-3, expression of HGF, MACC1, Caspase-3 and C-met proteins and MACC1 mRNA in tumour of CC mice.	Paclitaxel	48-53	caspase 3	Mus musculus	164-173
24469707-4	2014	It can be concluded that inhibitory activity of Taxol against tumour growth in CC mice is closely associated with its modulating positive expression of Bcl-2, Bax, Caspase-3, expression of HGF, MACC1, Caspase-3 and C-met proteins and MACC1 mRNA in tumour of CC mice.	Paclitaxel	48-53	hepatocyte growth factor	Mus musculus	189-192
24469707-4	2014	It can be concluded that inhibitory activity of Taxol against tumour growth in CC mice is closely associated with its modulating positive expression of Bcl-2, Bax, Caspase-3, expression of HGF, MACC1, Caspase-3 and C-met proteins and MACC1 mRNA in tumour of CC mice.	Paclitaxel	48-53	caspase 3	Mus musculus	201-210
22320227-1	2012	The purpose of the present study was to investigate the association of glutathione S-transferase P1 (GSTP1) expression with resistance to neoadjuvant paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (P-FEC) in human breast cancers.	Paclitaxel	150-160	glutathione S-transferase pi 1	Homo sapiens	101-106
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	Paclitaxel	75-80	caspase 9	Homo sapiens	18-34
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	Paclitaxel	75-80	caspase 9	Homo sapiens	18-25
24140176-0	2014	Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines.	Paclitaxel	45-55	ATP binding cassette subfamily B member 4	Homo sapiens	23-27
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	Paclitaxel	75-80	caspase 9	Homo sapiens	263-271
24140176-12	2014	We also observed high correlations between MDR3 expression and resistance to doxorubicin and paclitaxel.	Paclitaxel	93-103	ATP binding cassette subfamily B member 4	Homo sapiens	43-47
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	Paclitaxel	159-164	caspase 9	Homo sapiens	18-34
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	Paclitaxel	159-164	caspase 9	Homo sapiens	18-25
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	Paclitaxel	159-164	caspase 9	Homo sapiens	263-271
22465666-0	2012	Identification of a novel protein kinase Cdelta-Smac complex that dissociates during paclitaxel-induced cell death.	Paclitaxel	85-95	diablo IAP-binding mitochondrial protein	Homo sapiens	48-52
24614510-9	2014	Paclitaxel reduced the expression of the mitochondrial fusion protein, mitofusin-2, and induced mitochondrial fragmentation.	Paclitaxel	0-10	mitofusin 2	Rattus norvegicus	71-82
22465666-4	2012	The interaction depends on the N-terminus of Smac and is disrupted upon treatment with paclitaxel.	Paclitaxel	87-97	diablo IAP-binding mitochondrial protein	Homo sapiens	45-49
24614510-11	2014	MT disorganization by paclitaxel could regulate mPTP through the outer mitochondrial membrane complex and the Ca(2+)-sensitive signaling pathway, which also interacts with the mitochondrial fusion protein, mitofusin-2.	Paclitaxel	22-32	mitofusin 2	Rattus norvegicus	206-217
22496551-7	2012	Taxol-induced axonal degeneration in Drosophila shares molecular execution mechanisms with vertebrates, including inhibition by both NMNAT (nicotinamide mononucleotide adenylyltransferase) expression and loss of wallenda/DLK (dual leucine zipper kinase).	Paclitaxel	0-5	Nicotinamide mononucleotide adenylyltransferase	Drosophila melanogaster	133-138
26609545-1	2014	Interfering with anaplerotic utilization of glutamine (Gln) was recently reported to sensitize KRAS-driven cancer cells to the cytotoxic effects of capecitabine and paclitaxel.	Paclitaxel	165-175	KRAS proto-oncogene, GTPase	Homo sapiens	95-99
22496551-7	2012	Taxol-induced axonal degeneration in Drosophila shares molecular execution mechanisms with vertebrates, including inhibition by both NMNAT (nicotinamide mononucleotide adenylyltransferase) expression and loss of wallenda/DLK (dual leucine zipper kinase).	Paclitaxel	0-5	Nicotinamide mononucleotide adenylyltransferase	Drosophila melanogaster	140-187
23959471-6	2014	Knockdown of WWTR1 by siRNA interference in A549 cells significantly inhibited cell proliferation and increased paclitaxel-induced apoptosis.	Paclitaxel	112-122	WW domain containing transcription regulator 1	Homo sapiens	13-18
22496551-8	2012	In a pilot RNAi-based screen we found that knockdown of retinophilin (rtp), which encodes a MORN (membrane occupation and recognition nexus) repeat-containing protein, protects axons from degeneration in the presence of taxol.	Paclitaxel	220-225	retinophilin	Drosophila melanogaster	56-68
24008043-2	2013	To obviate these limitations, dual-targeting paclitaxel-loaded nanoparticles were developed by decoration with peptide-22 (PNP-PTX), a peptide with special affinity for low-density lipoprotein receptor (LDLR), to transport the drug across the BBB, and then target brain tumour cells.	Paclitaxel	45-55	low density lipoprotein receptor	Mus musculus	169-201
22496551-8	2012	In a pilot RNAi-based screen we found that knockdown of retinophilin (rtp), which encodes a MORN (membrane occupation and recognition nexus) repeat-containing protein, protects axons from degeneration in the presence of taxol.	Paclitaxel	220-225	retinophilin	Drosophila melanogaster	70-73
24008043-2	2013	To obviate these limitations, dual-targeting paclitaxel-loaded nanoparticles were developed by decoration with peptide-22 (PNP-PTX), a peptide with special affinity for low-density lipoprotein receptor (LDLR), to transport the drug across the BBB, and then target brain tumour cells.	Paclitaxel	45-55	low density lipoprotein receptor	Mus musculus	203-207
22034016-0	2012	Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL-induced activation of NF-kappaB and ERK.	Paclitaxel	0-10	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	107-112
24372428-8	2013	To paclitaxel were reported 10 (34%) HSRs: 9 (31%) HSRs of G1-G3 and 1 (3%) HSR of G4.	Paclitaxel	3-13	HSR	Homo sapiens	37-40
24293316-3	2013	We show here that Doxorubicin, 5-Fluorouracil, Paclitaxel and Cisplatin treatments trigger, in various human cancer cell lines, an increase of netrin-1 expression which is accompanied by netrin-1 receptors increase.	Paclitaxel	47-57	netrin 1	Homo sapiens	143-151
22034016-4	2012	In the present study, we demonstrate that paclitaxel dose-dependently inhibits receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclastogenesis in both RAW264.7 cells and mouse bone marrow macrophage (BMM) systems.	Paclitaxel	42-52	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	79-130
22034016-4	2012	In the present study, we demonstrate that paclitaxel dose-dependently inhibits receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclastogenesis in both RAW264.7 cells and mouse bone marrow macrophage (BMM) systems.	Paclitaxel	42-52	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	132-137
22034016-7	2012	Furthermore, luciferase reporter gene assays and western blot analysis indicate that paclitaxel modulates key RANKL-induced activation pathways that are essential to osteoclast formation including NF-kappaB and ERK.	Paclitaxel	85-95	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	110-115
22264882-0	2012	Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1.	Paclitaxel	71-81	cyclin B1	Homo sapiens	90-99
24381502-5	2013	Through a membrane vesicular transport assay, we observed that the uptake of paclitaxel was significantly reduced in membrane vesicles expressing 2 ABCB4 mutations, F165I and S320F.	Paclitaxel	77-87	ATP binding cassette subfamily B member 4	Homo sapiens	148-153
24278179-11	2013	ALDH1A1, SOX2, CXCR4 and SDF-1 mRNA levels were higher in metastatic lesions than in primary tumors, and were significantly elevated in both locations by paclitaxel treatment.	Paclitaxel	154-164	SRY-box transcription factor 2	Homo sapiens	9-13
24278179-11	2013	ALDH1A1, SOX2, CXCR4 and SDF-1 mRNA levels were higher in metastatic lesions than in primary tumors, and were significantly elevated in both locations by paclitaxel treatment.	Paclitaxel	154-164	C-X-C motif chemokine receptor 4	Homo sapiens	15-20
22264882-7	2012	In addition, we also found hypoxia could suppress PTX-induced cell cycle protein-cyclin B1 expression in MCF-7 cells.	Paclitaxel	50-53	cyclin B1	Homo sapiens	81-90
22264882-9	2012	The data showed that the hypoxia-based decreasing chemosensitivity of breast cancer cells to PTX was reversed by cyclin B1.	Paclitaxel	93-96	cyclin B1	Homo sapiens	113-122
22264882-10	2012	We also found that overexpression of cyclin B1 could significantly increase the sensitivity of MCF-7 cells to PTX by stimulating soluble polymerized tubulin.	Paclitaxel	110-113	cyclin B1	Homo sapiens	37-46
23108794-6	2013	There were no significant differences in radiosensitivity or cisplatin sensitivity of stem or non-stem cells, but CD44-isolated stem cells were more resistant to paclitaxel.	Paclitaxel	162-172	CD44 molecule (Indian blood group)	Homo sapiens	114-118
22264882-11	2012	Overall, hypoxia decreases cyclin B1, which could in turn reverse hypoxia-induced decreasing chemosensitivity to PTX in breast cancer cell line MCF-7.	Paclitaxel	113-116	cyclin B1	Homo sapiens	27-36
24042258-9	2013	BEZ235 and nab-paclitaxel caused an increase in PARP-1 and caspase-3 cleavage.	Paclitaxel	15-25	poly (ADP-ribose) polymerase family, member 1	Mus musculus	48-54
22085654-1	2012	We studied a potential drug delivery system comprising the hydrophobic anticancer drug paclitaxel entrapped within beta-casein (beta-CN) nanoparticles and its cytotoxicity to human gastric carcinoma cells.	Paclitaxel	87-97	casein beta	Homo sapiens	115-126
24042258-9	2013	BEZ235 and nab-paclitaxel caused an increase in PARP-1 and caspase-3 cleavage.	Paclitaxel	15-25	caspase 3	Mus musculus	59-68
23943797-7	2013	Correspondingly, GRHL2 expression prevented tumor initiation in xenograft assays, sensitized breast cancer cells to paclitaxel, and suppressed the emergence of CD44(high)CD24(low) cells (defining the cancer stem cell phenotype in the cell type studied).	Paclitaxel	116-126	grainyhead like transcription factor 2	Homo sapiens	17-22
22085654-1	2012	We studied a potential drug delivery system comprising the hydrophobic anticancer drug paclitaxel entrapped within beta-casein (beta-CN) nanoparticles and its cytotoxicity to human gastric carcinoma cells.	Paclitaxel	87-97	casein beta	Homo sapiens	128-135
22085654-2	2012	Paclitaxel was entrapped by stirring its dimethyl sulfoxide (DMSO) solution into PBS containing beta-CN.	Paclitaxel	0-10	casein beta	Homo sapiens	96-103
22041223-5	2012	The correlation between FOLR1 expression and taxol sensitivity was statistically analyzed.	Paclitaxel	45-50	folate receptor alpha	Homo sapiens	24-29
23827191-6	2013	Upon paclitaxel administration, KLK4-7-expressing tumors declined in size by 91% (controls: 87%) and showed 90% less metastatic outgrowth (controls: 33%, P &lt; 0.001).	Paclitaxel	5-15	kallikrein related peptidase 4	Homo sapiens	32-36
23827191-7	2013	KLK4-7-expressing spheroids showed 53% survival upon paclitaxel treatment (controls: 51%), accompanied by enhanced chemoresistance-related factors, and their survival was further reduced by combination treatment of paclitaxel with KLK4/5/7 (22%, P = 0.007) or MAPK (6%, P = 0.006) inhibition.	Paclitaxel	53-63	kallikrein related peptidase 4	Homo sapiens	0-4
23827191-7	2013	KLK4-7-expressing spheroids showed 53% survival upon paclitaxel treatment (controls: 51%), accompanied by enhanced chemoresistance-related factors, and their survival was further reduced by combination treatment of paclitaxel with KLK4/5/7 (22%, P = 0.007) or MAPK (6%, P = 0.006) inhibition.	Paclitaxel	215-225	kallikrein related peptidase 4	Homo sapiens	0-4
22041223-8	2012	RESULTS: The levels of FOLR1 expression were positively and significantly correlated with a taxol resistance phenotype (P &lt; .05).	Paclitaxel	92-97	folate receptor alpha	Homo sapiens	23-28
23827191-9	2013	Combinatorial approaches of paclitaxel and KLK/MAPK inhibition may be more efficient for late-stage disease than chemotherapeutics alone as these inhibitory regimens reduced cancer spheroid growth to a greater extent than paclitaxel alone.	Paclitaxel	222-232	kallikrein related peptidase 4	Homo sapiens	43-46
22041223-9	2012	Inhibition of FOLR1 expression resulted in a significantly increased sensitivity of taxol to taxol-resistant NPC cells (P &lt; .05).	Paclitaxel	84-89	folate receptor alpha	Homo sapiens	14-19
23876369-1	2013	Four paclitaxel derivatives were afforded by preparative HPLC separation of two pairs of diastereoisomers, which were obtained by catalytic hydrogenation and epoxidation of the C-13 side-chain double bond of cephalomannine, a naturally occurring paclitaxel analog.	Paclitaxel	5-15	homeobox C13	Homo sapiens	177-181
22041223-9	2012	Inhibition of FOLR1 expression resulted in a significantly increased sensitivity of taxol to taxol-resistant NPC cells (P &lt; .05).	Paclitaxel	93-98	folate receptor alpha	Homo sapiens	14-19
22041223-10	2012	An increase of FOLR1 expression by gene transfection caused a taxol-resistant phenotype in parental NPC cells.	Paclitaxel	62-67	folate receptor alpha	Homo sapiens	15-20
23735188-6	2013	Furthermore, this TRAP1 function is relevant in favoring resistance to paclitaxel, a microtubule stabilizing/ER stress inducer agent widely used in BC therapy.	Paclitaxel	71-81	TNF receptor associated protein 1	Homo sapiens	18-23
23735188-7	2013	Indeed, the transfection of a TRAP1 deletion mutant, whose localization is restricted to the ER, in shTRAP1 cells enhances the expression of mitochondrial Sorcin and protects from apoptosis induced by ER stress agents and paclitaxel.	Paclitaxel	222-232	TNF receptor associated protein 1	Homo sapiens	30-35
23735188-8	2013	Furthermore, BC cells adapted to paclitaxel or ER stress inducers share common resistance mechanisms: both cell models exhibit cross-resistance to single agents and the inhibition of TRAP1 by siRNAs or gamitrinib, a mitochondria-directed HSP90 family inhibitor, in paclitaxel-resistant cells rescues the sensitivity to paclitaxel.	Paclitaxel	33-43	TNF receptor associated protein 1	Homo sapiens	183-188
23735188-8	2013	Furthermore, BC cells adapted to paclitaxel or ER stress inducers share common resistance mechanisms: both cell models exhibit cross-resistance to single agents and the inhibition of TRAP1 by siRNAs or gamitrinib, a mitochondria-directed HSP90 family inhibitor, in paclitaxel-resistant cells rescues the sensitivity to paclitaxel.	Paclitaxel	33-43	TNF receptor associated protein 1	Homo sapiens	238-243
22041223-12	2012	CONCLUSION: These results suggest that FOLR1 plays an important role in taxol resistance of NPC cells.	Paclitaxel	72-77	folate receptor alpha	Homo sapiens	39-44
22206665-0	2012	ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression.	Paclitaxel	46-56	ETS proto-oncogene 1, transcription factor	Homo sapiens	0-4
24252213-7	2013	Interestingly, taxol exposure to either the somatodendritic or axonal compartment resulted in reduced caspase-3 activation in axons, suggesting that caspase activation is a downstream event of microtubule destabilization and involves signalling from the cell soma.	Paclitaxel	15-20	caspase 3	Mus musculus	102-111
23869586-15	2013	Our work indicates that paclitaxel-induced reduction of ZEB1 and beta-tubulin isotypes are, in part, due to increased activity of miR-200c.	Paclitaxel	24-34	zinc finger E-box binding homeobox 1	Homo sapiens	56-60
22206665-0	2012	ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression.	Paclitaxel	46-56	proprotein convertase subtilisin/kexin type 1	Homo sapiens	87-90
22206665-2	2012	In the present study, we examined the functional roles of ETS1 in paclitaxel resistance and invasion using human prostate cancer PC3 cells and paclitaxel-resistant PC3PR cells established from PC3 cells.	Paclitaxel	66-76	ETS proto-oncogene 1, transcription factor	Homo sapiens	58-62
22206665-2	2012	In the present study, we examined the functional roles of ETS1 in paclitaxel resistance and invasion using human prostate cancer PC3 cells and paclitaxel-resistant PC3PR cells established from PC3 cells.	Paclitaxel	143-153	proprotein convertase subtilisin/kexin type 1	Homo sapiens	164-167
22206665-3	2012	Our results showed that ETS1mRNA and protein expression was markedly up-regulated in paclitaxel-resistant PC3PR cells compared with paclitaxel-sensitive PC3 cells.	Paclitaxel	85-95	ETS proto-oncogene 1, transcription factor	Homo sapiens	24-28
22776563-1	2013	The aim of our study was to develop hyaluronic acid-coated, paclitaxel-loaded, nanostructured lipid carriers (HA-NLCs) prepared via electrostatic attraction for delivering paclitaxel (PTX) to tumors overexpressing CD44.	Paclitaxel	60-70	CD44 antigen	Mus musculus	214-218
22776563-1	2013	The aim of our study was to develop hyaluronic acid-coated, paclitaxel-loaded, nanostructured lipid carriers (HA-NLCs) prepared via electrostatic attraction for delivering paclitaxel (PTX) to tumors overexpressing CD44.	Paclitaxel	172-182	CD44 antigen	Mus musculus	214-218
22206665-3	2012	Our results showed that ETS1mRNA and protein expression was markedly up-regulated in paclitaxel-resistant PC3PR cells compared with paclitaxel-sensitive PC3 cells.	Paclitaxel	85-95	proprotein convertase subtilisin/kexin type 1	Homo sapiens	106-109
22776563-11	2013	Therefore, HA-NLC prepared via electrostatic attraction was an effective carrier for delivering PTX to tumors overexpressing CD44.	Paclitaxel	96-99	CD44 antigen	Mus musculus	125-129
22206665-3	2012	Our results showed that ETS1mRNA and protein expression was markedly up-regulated in paclitaxel-resistant PC3PR cells compared with paclitaxel-sensitive PC3 cells.	Paclitaxel	132-142	ETS proto-oncogene 1, transcription factor	Homo sapiens	24-28
22206665-5	2012	In PC3PR cells, silencing of ETS1 expression by siRNAs inhibited the activity of the MDR1 promoter containing ETS binding sites, reduced the mRNA and protein levels of MDR1 and suppressed paclitaxel resistance.	Paclitaxel	188-198	ETS proto-oncogene 1, transcription factor	Homo sapiens	29-33
23852894-13	2013	CONCLUSIONS: These data suggest a new mechanism by which the propofol inhibits invasion and metastasis,enhances paclitaxel-induced ovarian cancer cell apoptosis through suppression of Slug.	Paclitaxel	112-122	snail family transcriptional repressor 2	Homo sapiens	184-188
22206665-7	2012	Our results suggest that ETS1 promotes paclitaxel resistance and invasion in part by up-regulating MDR1 and MMP9 expression.	Paclitaxel	39-49	ETS proto-oncogene 1, transcription factor	Homo sapiens	25-29
21391217-8	2012	In addition, treatment of nude mice with K8 combined with paclitaxel induced phospho-ERK1/2 and NAG-1 expression in vivo.	Paclitaxel	58-68	growth differentiation factor 15	Mus musculus	96-101
23763570-7	2013	In addition, SIRT1 inhibition reduced both the nuclear FoxO1 levels and MRP2 expression and enhanced cytotoxic effects of paclitaxel and doxorubicin in TAMR-MCF-7 cells.	Paclitaxel	122-132	sirtuin 1	Homo sapiens	13-18
22850598-7	2012	On the underling mechanisms, paclitaxel increased reactive oxygen species (ROS) production (dihydrorhodamine 123, DCF fluorescence intensity) and NADPH oxidase (p47(phox), gp91(phox) mRNA) in arteries and human coronary artery endothelial cells (HCAECs), while paclitaxel reduced nitric oxide (NO) release (DAF-2 fluorescence intensity), but not endothelial NO synthase (eNOS) phosphorylation in HCAECs.	Paclitaxel	29-39	pleckstrin	Homo sapiens	161-164
23826416-3	2013	In this work, Hep2, a laryngeal cancer cell line, untreated or treated with lower dose of paclitaxel for 24 h, was applied to DNA microarray chips for gene and miR expression profile analysis.	Paclitaxel	90-100	membrane associated ring-CH-type finger 8	Homo sapiens	160-163
22289679-2	2012	The methylation status of the PLK2 CpG island varies with sensitivity to paclitaxel and platinum in ovarian cancer cell lines.	Paclitaxel	73-83	polo like kinase 2	Homo sapiens	30-34
23785404-0	2013	miR-23a targets interferon regulatory factor 1 and modulates cellular proliferation and paclitaxel-induced apoptosis in gastric adenocarcinoma cells.	Paclitaxel	88-98	microRNA 23a	Homo sapiens	0-7
23785404-3	2013	In the current study, we demonstrate that miR-23a suppresses paclitaxel-induced apoptosis and promotes the cell proliferation and colony formation ability of gastric adenocarcinoma cells.	Paclitaxel	61-71	microRNA 23a	Homo sapiens	42-49
23785404-7	2013	The restoration of IRF1 expression counteracted the effects of miR-23a on the paclitaxel-induced apoptosis and cell proliferation of gastric adenocarcinoma cells.	Paclitaxel	78-88	microRNA 23a	Homo sapiens	63-70
23785404-9	2013	Altogether, these results indicate that miR-23a suppresses paclitaxel-induced apoptosis and promotes cell viability and the colony formation ability of gastric adenocarcinoma cells by targeting IRF1 at the post-transcriptional level.	Paclitaxel	59-69	microRNA 23a	Homo sapiens	40-47
23562605-3	2013	Paclitaxel-evoked cold hypernociception was assessed in mice by the unilateral cold plate test and the effects on cold hyperalgesia of the CCR2 antagonist RS 504393, the CCR1 antagonist J113863, the microglial inhibitor minocycline or an anti-CCL2 antibody were tested.	Paclitaxel	0-10	chemokine (C-C motif) ligand 2	Mus musculus	243-247
23562605-7	2013	CCL2 levels measured by ELISA in the lumbar spinal cord were augmented in mice treated with paclitaxel and the i.t.	Paclitaxel	92-102	chemokine (C-C motif) ligand 2	Mus musculus	0-4
23562605-8	2013	administration of an anti-CCL2 antibody completely suppressed paclitaxel-evoked cold hyperalgesia, strongly suggesting that CCL2 is involved in the hypernociception evoked by this taxane.	Paclitaxel	62-72	chemokine (C-C motif) ligand 2	Mus musculus	26-30
22289679-3	2012	Importantly, extrapolation of these in vitro data to the clinical setting confirms that the methylation status of the PLK2 CpG island predicts outcomes in patients treated with carboplatin and paclitaxel chemotherapy.	Paclitaxel	193-203	polo like kinase 2	Homo sapiens	118-122
22808086-0	2012	Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells.	Paclitaxel	15-25	H3 histone pseudogene 16	Homo sapiens	51-54
22074808-4	2012	2ME significantly increases the level of p38 and MLC phosphorylation in both endothelial monolayers and murine lungs; this increase is suppressed in the presence of taxol.	Paclitaxel	165-170	megalencephalic leukoencephalopathy with subcortical cysts 1 homolog (human)	Mus musculus	49-52
23562605-8	2013	administration of an anti-CCL2 antibody completely suppressed paclitaxel-evoked cold hyperalgesia, strongly suggesting that CCL2 is involved in the hypernociception evoked by this taxane.	Paclitaxel	62-72	chemokine (C-C motif) ligand 2	Mus musculus	124-128
23562605-13	2013	In conclusion, our results indicate that paclitaxel-evoked cold hypernociception depends on the activation of CCR2 due to the spinal release of CCL2 and the subsequent microglial activation.	Paclitaxel	41-51	chemokine (C-C motif) ligand 2	Mus musculus	144-148
22349379-6	2012	CYP1A1, one of P450 family members, was not expressed in CNE-1, but significantly increased expressions was found in CNE-1/taxol and these increased expressions were restored by cisplatin.	Paclitaxel	123-128	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	0-6
23090875-1	2013	Paclitaxel is avidly transported by P-glycoprotein (P-gp/MDR1/ABCB1).	Paclitaxel	0-10	phosphoglycolate phosphatase	Mus musculus	52-56
21584840-1	2011	BACKGROUND: TAP chemotherapy (paclitaxel, doxorubicin, and cisplatin) is effective for advanced and recurrent endometrial carcinoma, but has occasional severe toxicity.	Paclitaxel	30-40	filamin B	Homo sapiens	12-15
23305784-5	2013	The chimera protein was expressed on the plasma membrane and conferred resistance against vinblastine and paclitaxel, indicating that MDR3 NBDs can support drug transport.	Paclitaxel	106-116	ATP binding cassette subfamily B member 4	Homo sapiens	134-138
23358102-8	2011	CONCLUSION: TUBB3, TS and TP expressions could predict the response of advanced gastric cancer patients receiving capecitabine-based and paclitaxel-based chemotherapy.	Paclitaxel	137-147	thymidylate synthetase	Homo sapiens	19-21
21301917-7	2011	Paclitaxel-carboplatin administration may be an effective treatment for primary SCC of the ovary but further studies are required to investigate it true efficacy in the treatment of this disease.	Paclitaxel	0-10	serpin family B member 3	Homo sapiens	80-83
23634282-5	2013	Interestingly, stable Slug overexpression increased drug sensitivity to tubulin-binding agents including vinorelbine, vincristine, and paclitaxel (5.8- to 8.9-fold increase) in several lung cancer cell lines but did not increase sensitivity to agents other than tubulin-binding agents.	Paclitaxel	135-145	snail family transcriptional repressor 2	Homo sapiens	22-26
23265709-0	2013	Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.	Paclitaxel	62-72	BRCA1 DNA repair associated	Homo sapiens	16-21
23265709-0	2013	Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.	Paclitaxel	62-72	BRCA2 DNA repair associated	Homo sapiens	26-31
22071694-2	2011	Here we report that the pro-apoptotic BH3-only family member Bim undergoes phosphorylation in K562 cells following treatment with the microtubule targeting agents Taxol and Nocodazole.	Paclitaxel	163-168	BCL2 like 11	Homo sapiens	61-64
23413951-16	2013	CONCLUSIONS: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis.	Paclitaxel	124-134	teneurin transmembrane protein 1	Homo sapiens	249-252
23161364-9	2013	When acetylation was enhanced by anti-Sirt1 siRNA or an HDAC inhibitor, Taxol-induced apoptosis was enhanced, which was not observed in p53 null cells.	Paclitaxel	72-77	sirtuin 1	Homo sapiens	38-43
22071694-3	2011	The phosphorylation of two Bim isoforms, BimEL and BimL, at the mitochondria correlates with mitotic arrest and precedes cell death induced by Taxol.	Paclitaxel	143-148	BCL2 like 11	Homo sapiens	27-30
22071694-5	2011	In addition, siRNA silencing of Bim reduces sensitivity to Taxol-induced cell death.	Paclitaxel	59-64	BCL2 like 11	Homo sapiens	32-35
24460265-0	2013	Inhibition of nemo-like kinase increases taxol sensitivity in laryngeal cancer.	Paclitaxel	41-46	nemo like kinase	Homo sapiens	14-30
21413088-7	2011	The expressions of MMP-1 and MMP-2 did not change when a conventional tumoricidal agent paclitaxel was used.	Paclitaxel	88-98	matrix metallopeptidase 1	Homo sapiens	19-24
24460265-2	2013	The present research concerned effects and mechanisms of Taxol on NLK knockdown human laryngeal cancerHep-2 cell lines in vitro.	Paclitaxel	57-62	nemo like kinase	Homo sapiens	66-69
24460265-8	2013	Cell growth was also obviously suppressed in the Hep-2 cell line, knockdown of NLK making them more sensitive to Taxol treatment.	Paclitaxel	113-118	nemo like kinase	Homo sapiens	79-82
21903575-0	2011	Mitotic centromere-associated kinesin (MCAK) mediates paclitaxel resistance.	Paclitaxel	54-64	kinesin-like protein KIF2C	Cricetulus griseus	0-37
21903575-0	2011	Mitotic centromere-associated kinesin (MCAK) mediates paclitaxel resistance.	Paclitaxel	54-64	kinesin-like protein KIF2C	Cricetulus griseus	39-43
23451143-8	2013	Importantly, the KLK4-MCAs were paclitaxel resistant which was reversed by SFTI-FCQR and to a lesser degree by the general serine protease inhibitor, Aprotinin, suggesting that in addition to uPA, other as yet unidentified substrates of KLK4 must be involved.	Paclitaxel	32-42	kallikrein related peptidase 4	Homo sapiens	17-21
21903575-6	2011	In contrast, MCAK depletion rescued the proliferation of mutant paclitaxel-dependent cell lines that are unable to divide because of defective spindle function resulting from altered alpha-tubulin or class III beta-tubulin overexpression.	Paclitaxel	64-74	kinesin-like protein KIF2C	Cricetulus griseus	13-17
23451143-8	2013	Importantly, the KLK4-MCAs were paclitaxel resistant which was reversed by SFTI-FCQR and to a lesser degree by the general serine protease inhibitor, Aprotinin, suggesting that in addition to uPA, other as yet unidentified substrates of KLK4 must be involved.	Paclitaxel	32-42	kallikrein related peptidase 4	Homo sapiens	237-241
21903575-7	2011	In concert with the correction of mitotic defects, loss of MCAK reversed an aberrantly high frequency of microtubule detachment in the mutant cells and increased their sensitivity to paclitaxel.	Paclitaxel	183-193	kinesin-like protein KIF2C	Cricetulus griseus	59-63
22017876-6	2011	Biologically, DEPTOR accumulation upon betaTrCP knockdown inactivates mTORC1 and activates AKT in cancer cells to confer resistance to rapamycin and paclitaxel.	Paclitaxel	149-159	beta-transducin repeat containing E3 ubiquitin protein ligase	Homo sapiens	39-47
23320108-6	2013	We have identified additional pf15 and bld2 (epsilon-tubulin) alleles in screens for Taxol sensitivity.	Paclitaxel	85-90	uncharacterized protein	Chlamydomonas reinhardtii	30-34
23140358-0	2012	Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin alphaVbeta3.	Paclitaxel	117-127	integrin subunit alpha V	Homo sapiens	149-169
22005063-1	2011	In this study, we investigated the mechanisms by which the chemotherapeutic agent paclitaxel (PTX) induced the expression of B7-H1 immunosuppressive molecules in the human colorectal adenocarcinoma cell line SW480 and the hepatocellular carcinoma cell line HepG2.	Paclitaxel	82-92	CD274 molecule	Homo sapiens	125-130
22005063-1	2011	In this study, we investigated the mechanisms by which the chemotherapeutic agent paclitaxel (PTX) induced the expression of B7-H1 immunosuppressive molecules in the human colorectal adenocarcinoma cell line SW480 and the hepatocellular carcinoma cell line HepG2.	Paclitaxel	94-97	CD274 molecule	Homo sapiens	125-130
22005063-4	2011	PTX-increased B7-H1 mRNA expression was significantly blocked by MEK inhibitor U0126.	Paclitaxel	0-3	CD274 molecule	Homo sapiens	14-19
22005063-6	2011	Our results suggest that PTX upregulated B7-H1 expression in cultured SW480 and HepG2 cells via both transcriptional and post-transcriptional mechanisms.	Paclitaxel	25-28	CD274 molecule	Homo sapiens	41-46
21813412-0	2011	The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.	Paclitaxel	44-54	cyclin dependent kinase inhibitor 1B	Homo sapiens	16-20
23140358-2	2012	All the paclitaxel-RGD constructs 10-13 inhibited biotinylated vitronectin binding to the purified alphaVbeta3 integrin receptor at low nanomolar concentration and showed in vitro cytotoxic activity against a panel of human tumor cell lines similar to that of paclitaxel.	Paclitaxel	8-18	vitronectin	Homo sapiens	63-74
23140358-2	2012	All the paclitaxel-RGD constructs 10-13 inhibited biotinylated vitronectin binding to the purified alphaVbeta3 integrin receptor at low nanomolar concentration and showed in vitro cytotoxic activity against a panel of human tumor cell lines similar to that of paclitaxel.	Paclitaxel	260-270	vitronectin	Homo sapiens	63-74
21813412-8	2011	The siRNA knockdown of Src, Fyn, or Abl1 enhanced paclitaxel-mediated growth inhibition in ovarian cancer cells compared with a control siRNA.	Paclitaxel	50-60	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	28-31
21813412-12	2011	The siRNA knockdown of p27(Kip1) decreased dasatinib- and paclitaxel-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017).	Paclitaxel	58-68	cyclin dependent kinase inhibitor 1B	Homo sapiens	27-31
21687948-7	2011	Instead, polymorphisms in the XPD gene (Lys751Gln and Asp312Asn), a member of the nucleotide excision repair pathway, positively affects the response to therapy with carboplatin/paclitaxel.	Paclitaxel	178-188	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	30-33
23022332-1	2012	HM30181, a potent and selective inhibitor of the adenosine triphosphate-binding cassette transporter P-glycoprotein (Pgp), was shown to enhance oral bioavailability and improve antitumour efficacy of paclitaxel in mouse tumour models.	Paclitaxel	200-210	phosphoglycolate phosphatase	Mus musculus	101-115
23022332-1	2012	HM30181, a potent and selective inhibitor of the adenosine triphosphate-binding cassette transporter P-glycoprotein (Pgp), was shown to enhance oral bioavailability and improve antitumour efficacy of paclitaxel in mouse tumour models.	Paclitaxel	200-210	phosphoglycolate phosphatase	Mus musculus	117-120
22964375-0	2012	Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance.	Paclitaxel	106-116	kallikrein related peptidase 4	Homo sapiens	23-27
22964375-0	2012	Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance.	Paclitaxel	106-116	kallikrein related peptidase 6	Homo sapiens	35-39
21829205-6	2011	The SLK cells were also revealed to be cross-resistant to the structurally unrelated drug paclitaxel.	Paclitaxel	90-100	STE20 like kinase	Homo sapiens	4-7
22713763-1	2012	The purpose of this study was to target ovarian cancer cells by coupling paclitaxel (Tx)-loaded nanoparticles (NPs-Tx) to antibodies against KDEL sequence, able to recognize GRP94 and GRP78 that are located at cell surface in cancer cells whereas they are in the endoplasmic reticulum in healthy cells.	Paclitaxel	73-83	heat shock protein 90 beta family member 1	Homo sapiens	174-179
21792009-0	2011	CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel.	Paclitaxel	76-86	checkpoint with forkhead and ring finger domains	Homo sapiens	0-4
22910221-0	2012	Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer.	Paclitaxel	15-25	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	57-60
22910221-2	2012	In this work, a new co-delivery system, P85-PEI/TPGS/PTX/shSur complex nanoparticles (PTPNs), to overcome paclitaxel (PTX) resistance in A549 human lung cancer was designed and developed.	Paclitaxel	53-56	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	40-43
22936655-9	2012	Pretreatment of wild-type platelets with taxol caused microtubule stabilization and phenocopied the attenuated shape change in response to collagen, suggesting that RanBP10 inhibits premature microtubule polymerization of beta1-tubulin and plays a pivotal role in thrombus stabilization.	Paclitaxel	41-46	RAN binding protein 10	Mus musculus	165-172
21792009-2	2011	Here, we studied the correlations between the checkpoint with forkhead-associated and ring finger (CHFR) gene expression and responses to paclitaxel in endometrial cancer cells.	Paclitaxel	138-148	checkpoint with forkhead and ring finger domains	Homo sapiens	46-97
21792009-2	2011	Here, we studied the correlations between the checkpoint with forkhead-associated and ring finger (CHFR) gene expression and responses to paclitaxel in endometrial cancer cells.	Paclitaxel	138-148	checkpoint with forkhead and ring finger domains	Homo sapiens	99-103
23342271-6	2012	Consistent with clinical data, depletion of RFP by RNA interference (RNAi) in ovarian cancer cell lines, SKOV3 and HEY, significantly increased carboplatin- or paclitaxel-induced apoptosis and resulted in reduced anticancer drug resistance.	Paclitaxel	160-170	tripartite motif containing 27	Homo sapiens	44-47
21792009-7	2011	Moreover, CHFR was weakly expressed in these cells, whereas paclitaxel-resistant cells (ISH, HEC-1A, and KLE) had high CHFR expression.	Paclitaxel	60-70	checkpoint with forkhead and ring finger domains	Homo sapiens	119-123
22765290-3	2012	In this review, we focus on highlighting several representative plant natural compounds such as curcumin, resveratrol, paclitaxel, oridonin, quercetin and plant lectin - that may lead to cancer cell death - for regulation of some core autophagic pathways, involved in Ras-Raf signalling, Beclin-1 interactome, BCR-ABL, PI3KCI/Akt/mTOR, FOXO1 signalling and p53.	Paclitaxel	119-129	beclin 1	Homo sapiens	288-296
21792009-8	2011	Then we found that restored expression of CHFR by demethylation decreased the sensitivity to paclitaxel in AN3CA cells.	Paclitaxel	93-103	checkpoint with forkhead and ring finger domains	Homo sapiens	42-46
22765290-3	2012	In this review, we focus on highlighting several representative plant natural compounds such as curcumin, resveratrol, paclitaxel, oridonin, quercetin and plant lectin - that may lead to cancer cell death - for regulation of some core autophagic pathways, involved in Ras-Raf signalling, Beclin-1 interactome, BCR-ABL, PI3KCI/Akt/mTOR, FOXO1 signalling and p53.	Paclitaxel	119-129	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	310-317
24716145-3	2012	Both SB and PTX alone or SB+PTX treatment inhibited 4T1 cell migration and motility possibly through downregulation of the serpin protease nexin-1 (PN-1) and N-cadherin expression, inhibition of matrix metalloprotease (MMP)-9 activity, and upregulation of E-cadherin.	Paclitaxel	12-15	cadherin 2	Mus musculus	158-168
24716145-3	2012	Both SB and PTX alone or SB+PTX treatment inhibited 4T1 cell migration and motility possibly through downregulation of the serpin protease nexin-1 (PN-1) and N-cadherin expression, inhibition of matrix metalloprotease (MMP)-9 activity, and upregulation of E-cadherin.	Paclitaxel	28-31	cadherin 2	Mus musculus	158-168
21792009-9	2011	In addition, cells with CHFR demethylation resulted in G2/M phase arrest that induced to paclitaxel resistance.	Paclitaxel	89-99	checkpoint with forkhead and ring finger domains	Homo sapiens	24-28
21792009-12	2011	CONCLUSION: Our data suggest that CHFR suppression regulated by hypermethylation may sensitize endometrial cancer cells to paclitaxel, and CHFR may be a promising marker to predict the response of endometrial cancer to paclitaxel.	Paclitaxel	123-133	checkpoint with forkhead and ring finger domains	Homo sapiens	34-38
21792009-12	2011	CONCLUSION: Our data suggest that CHFR suppression regulated by hypermethylation may sensitize endometrial cancer cells to paclitaxel, and CHFR may be a promising marker to predict the response of endometrial cancer to paclitaxel.	Paclitaxel	219-229	checkpoint with forkhead and ring finger domains	Homo sapiens	34-38
21429662-0	2011	Dual blockade of phosphatidylinositol 3"-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer.	Paclitaxel	104-114	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	17-47
22711747-5	2012	In rats lacking P-gp, paclitaxel brain partitioning was significantly increased (4-fold).	Paclitaxel	22-32	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	16-20
21429662-2	2011	The present study was to examine whether and how phosphatidylinositol 3"-kinase (PI3K) signals affect the sensitivity of colorectal cancer to paclitaxel.	Paclitaxel	142-152	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	49-79
21920731-7	2012	RESULTS: Mib-1 expression was associated with sensitivity against Paclitaxel/Epirubicin (p = 0.014) and Docetaxel/Epirubicin (p = 0.014).	Paclitaxel	66-76	MIB E3 ubiquitin protein ligase 1	Homo sapiens	9-14
21406229-0	2011	Rescue of neurons from undergoing hallmark tau-induced Alzheimer"s disease cell pathologies by the antimitotic drug paclitaxel.	Paclitaxel	116-126	microtubule associated protein tau	Homo sapiens	43-46
22628199-5	2012	In vitro releases tests showed that release rate of PTX from P-d-rHDLs became faster when LCAT was added to P-d-rHDLs suspensions.	Paclitaxel	52-55	lecithin-cholesterol acyltransferase	Homo sapiens	90-94
21406229-1	2011	Through the use of live confocal imaging, electron microscopy, and the novel cell biological platform of cultured Aplysia neurons we show that unfolding of the hallmark cell pathologies induced by mutant-human-tau (mt-human-tau) expression is rescued by 10 nM paclitaxel.	Paclitaxel	260-270	microtubule associated protein tau	Homo sapiens	210-213
21406229-2	2011	At this concentration paclitaxel prevents mt-human-tau-induced swelling of axonal segments, translocation of tau and microtubules (MT) to submembrane domains, reduction in the number of MTs along the axon, reversal of the MT polar orientation, impaired organelle transport, accumulation of macro-autophagosomes and lysosomes, compromised neurite morphology and degeneration.	Paclitaxel	22-32	microtubule associated protein tau	Homo sapiens	51-54
21406229-2	2011	At this concentration paclitaxel prevents mt-human-tau-induced swelling of axonal segments, translocation of tau and microtubules (MT) to submembrane domains, reduction in the number of MTs along the axon, reversal of the MT polar orientation, impaired organelle transport, accumulation of macro-autophagosomes and lysosomes, compromised neurite morphology and degeneration.	Paclitaxel	22-32	microtubule associated protein tau	Homo sapiens	109-112
21711528-8	2011	The results showed that GSTP1 could contribute to paclitaxel resistance in EGF-stimulated CNE2 cells.	Paclitaxel	50-60	glutathione S-transferase pi 1	Homo sapiens	24-29
22276743-0	2012	Anti-miR-155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis.	Paclitaxel	71-76	microRNA 155	Homo sapiens	5-12
22276743-3	2012	Down-regulating miR-155 to enhance the effect of taxol has not been studied in human GBM.	Paclitaxel	49-54	microRNA 155	Homo sapiens	16-23
22511598-5	2012	The analysis demonstrated a significant association between enhanced stromal expression of TIMP-2 and better clinical response to cisplatin- and paclitaxel-based chemotherapy.	Paclitaxel	145-155	TIMP metallopeptidase inhibitor 2	Homo sapiens	91-97
22511598-8	2012	This study supports the concept of TIMP-2 expression in the stromal compartment of OC as a promising marker of prognosis and response to cisplatin- and paclitaxel-based chemotherapy in OC patients.	Paclitaxel	152-162	TIMP metallopeptidase inhibitor 2	Homo sapiens	35-41
22820595-7	2012	CG combined with Taxol increased the expression of Bax and reduced the expression of p53 and VEGF in the tumor xenografts.	Paclitaxel	17-22	BCL2-associated X protein	Mus musculus	51-54
21543517-6	2011	RESULTS: The results presented herein show that the addition of metformin to paclitaxel leads to quantitative potentialization of molecular signaling through AMPK and a subsequent potent inhibition of the mTOR signaling pathway.	Paclitaxel	77-87	mechanistic target of rapamycin kinase	Mus musculus	205-209
22820595-7	2012	CG combined with Taxol increased the expression of Bax and reduced the expression of p53 and VEGF in the tumor xenografts.	Paclitaxel	17-22	vascular endothelial growth factor A	Mus musculus	93-97
22640878-1	2012	BACKGROUND: The extracellular matrix (ECM) has a key role in facilitating the progression of ovarian cancer and we have shown recently that the secreted ECM protein TGFBI modulates the response of ovarian cancer to paclitaxel-induced cell death.	Paclitaxel	215-225	transforming growth factor beta induced	Homo sapiens	165-170
22640878-9	2012	CONCLUSIONS: Therefore, different ECM components use distinct signaling mechanisms in ovarian cancer cells and in particular, TGFBI preferentially interacts through a ss3 integrin receptor mediated mechanism to regulate the response of cells to paclitaxel-induced cell death.	Paclitaxel	245-255	transforming growth factor beta induced	Homo sapiens	126-131
21532503-2	2011	SPARC expression is thought to facilitate the intracellular accumulation of nanoparticle albumin-bound paclitaxel (nab-paclitaxel, abraxane [ABX]).	Paclitaxel	103-113	secreted protein acidic and cysteine rich	Homo sapiens	0-5
22350800-0	2012	Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma.	Paclitaxel	61-71	CD44 molecule (Indian blood group)	Homo sapiens	75-79
22350800-1	2012	PURPOSE: To evaluate the effect of the size of low molecular weight hyaluronan (LMW-HA) oligomers on the targeting ability of the HA-containing copolymers to the CD44-overexpressing cells for delivering Paclitaxel (PTX) to ovarian cancer.	Paclitaxel	203-213	CD44 molecule (Indian blood group)	Homo sapiens	162-166
21532503-11	2011	At equimolar doses in vitro, there was similar increased cytotoxicity on DEC pretreatment with either ABX or taxol in SPARC-negative cell lines.	Paclitaxel	109-114	secreted protein acidic and cysteine rich	Homo sapiens	118-123
21532503-14	2011	The greater antitumor effect of ABX compared with equitoxic dose of taxol observed in SPARC-expressing NSCLC tumors can also be seen in some SPARC-negative tumors.	Paclitaxel	68-73	secreted protein acidic and cysteine rich	Homo sapiens	86-91
21518725-0	2011	B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.	Paclitaxel	26-36	Janus kinase 2	Mus musculus	63-67
21518725-10	2011	Taken together, our data show that in breast cancer cells, B7-H3 induces paclitaxel resistance, at least partially by interfering with Jak2/Stat3 pathway.	Paclitaxel	73-83	Janus kinase 2	Mus musculus	135-139
21216588-6	2011	A tendency towards a better PFS was observed in patients with the highest level of ERCC1 and BRCA1 after platinum-based therapy than those given both platinum and taxol.	Paclitaxel	163-168	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	83-88
22310179-6	2012	The data corroborated that Integrinbeta1 played a significant role in CAM-DR. After the treatment of weakly-toxic concentrations of Oroxylin A, the apoptosis induced by Paclitaxel in the CAM-DR model increased dramatically.	Paclitaxel	169-179	integrin subunit beta 1	Homo sapiens	27-40
21248239-4	2011	However, primary DRG cultures lacking VEGF-B or FLT1 exhibited increased neuronal stress and were more susceptible to paclitaxel-induced cell death.	Paclitaxel	118-128	vascular endothelial growth factor B	Mus musculus	38-44
21999204-2	2012	MSLN (mesothelin), a secreted protein that is overexpressed in ovarian cancer tissues with a poor clinical outcome, has been previously identified to activate PI3K (phosphoinositide 3-kinase)/Akt signalling and inhibit paclitaxel-induced apoptosis.	Paclitaxel	219-229	mesothelin	Homo sapiens	0-4
21999204-2	2012	MSLN (mesothelin), a secreted protein that is overexpressed in ovarian cancer tissues with a poor clinical outcome, has been previously identified to activate PI3K (phosphoinositide 3-kinase)/Akt signalling and inhibit paclitaxel-induced apoptosis.	Paclitaxel	219-229	mesothelin	Homo sapiens	6-16
21479552-8	2012	Overexpression of KIFC3 and KIF5A in pre-chemotherapy samples similarly predicted resistance to paclitaxel in the MDACC cohorts (P = 0.01); no KIF predicted resistance to fluorouracil-epirubicin-cyclophosphamide or cisplatin in BLBC patient cohorts treated without taxanes.	Paclitaxel	96-106	kinesin family member 5A	Homo sapiens	28-33
21643015-5	2012	Rassf1/Daxx depletion or expression of Daxx-binding domain of Rassf1 elevates cyclin B stability and increases taxol resistance in cells and mouse xenograft models.	Paclitaxel	111-116	Fas death domain-associated protein	Mus musculus	7-11
21643015-7	2012	These data suggest that Daxx and Rassf1 define a mitotic stress checkpoint that enables cells to exit mitosis as micronucleated cells (and eventually die) when encountered with specific mitotic stress stimuli, including taxol.	Paclitaxel	220-225	Ras association domain family member 1	Homo sapiens	33-39
21576762-3	2011	Expression of beta3 in HeLa and MCF-7 did not alter the intrinsic rate of cell migration, but it prevented the inhibition of migration by low, nontoxic concentrations of paclitaxel.	Paclitaxel	170-180	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	14-19
22517709-8	2012	CONCLUSION: Our findings support that with carboplatin/ paclitaxel combination chemotherapy, important parameters of the immune system (IFN-gamma, CD4, CD4/CD8) can be used as prognostic factors for survival, while others (IL-3) as indicators of toxicity.	Paclitaxel	56-66	CD8a molecule	Homo sapiens	156-159
22548172-4	2012	We have observed a strong correlation between the loss of RASSF1A expression and the development of Taxol resistance in primary ovarian cancer samples.	Paclitaxel	100-105	Ras association domain family member 1	Homo sapiens	58-65
21576762-7	2011	These studies support a model in which paclitaxel inhibits cell migration by suppressing microtubule dynamics and beta3-tubulin counteracts paclitaxel action by maintaining microtubule dynamic activity.	Paclitaxel	140-150	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	114-119
22548172-6	2012	We found that knocking down RASSF1A expression in an ovarian cancer cell line inhibited Taxol-mediated apoptosis and promoted cell survival during Taxol treatment.	Paclitaxel	88-93	Ras association domain family member 1	Homo sapiens	28-35
22548172-6	2012	We found that knocking down RASSF1A expression in an ovarian cancer cell line inhibited Taxol-mediated apoptosis and promoted cell survival during Taxol treatment.	Paclitaxel	147-152	Ras association domain family member 1	Homo sapiens	28-35
21406114-0	2011	Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.	Paclitaxel	67-72	secreted phosphoprotein 1	Homo sapiens	15-26
22548172-8	2012	This identifies a role for RASSF1A in modulating the tumor response to Taxol and provides proof of principal for the use of epigenetic therapy to overcome Taxol resistance.	Paclitaxel	71-76	Ras association domain family member 1	Homo sapiens	27-34
21978935-0	2011	Cooperative phosphorylation of FADD by Aur-A and Plk1 in response to taxol triggers both apoptotic and necrotic cell death.	Paclitaxel	69-74	polo like kinase 1	Homo sapiens	49-53
21978935-8	2011	Collectively, our data show the existence of cooperative actions between Aur-A and Plk1 mitotic kinases in response to taxol, providing a molecular explanation for the action mechanism of taxol.	Paclitaxel	119-124	polo like kinase 1	Homo sapiens	83-87
21978935-8	2011	Collectively, our data show the existence of cooperative actions between Aur-A and Plk1 mitotic kinases in response to taxol, providing a molecular explanation for the action mechanism of taxol.	Paclitaxel	188-193	polo like kinase 1	Homo sapiens	83-87
21406114-8	2011	In addition, OPN is required for the protective effects of ATX-LPA against Taxol-induced apoptosis and ATX-LPA-induced migration of SGC7901 cells.	Paclitaxel	75-80	secreted phosphoprotein 1	Homo sapiens	13-16
21086124-4	2011	Here, we report that chA21 combined with Paclitaxel or Trastuzumab significantly enhances the tumor-inhibition effects on ErbB2-overexpressing breast and ovarian cancer in xenograft mice.	Paclitaxel	41-51	erb-b2 receptor tyrosine kinase 2	Mus musculus	122-127
22024163-5	2011	Overexpression of Aurora B(S331A), in which Ser331 is mutated to alanine, results in spontaneous chromosome missegregation, cell multinucleation, unstable binding of BubR1 to kinetochores, and impaired mitotic delay in the presence of taxol.	Paclitaxel	235-240	aurora kinase B	Homo sapiens	18-26
21965726-0	2011	Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.	Paclitaxel	0-10	apoptosis inducing factor mitochondria associated 1	Homo sapiens	146-149
21965726-0	2011	Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.	Paclitaxel	39-49	apoptosis inducing factor mitochondria associated 1	Homo sapiens	146-149
21209315-7	2011	We show association between this region of the C-terminus of Nup98 and both Taxol-stabilized microtubules and the microtubule-depolymerizing mitotic centromere-associated kinesin (MCAK).	Paclitaxel	76-81	nucleoporin 98 L homeolog	Xenopus laevis	61-66
21965726-7	2011	However, PA also increases surface expression of death receptors 4 and 5 (DR4 and DR5, respectively).	Paclitaxel	9-11	major histocompatibility complex, class II, DR beta 4	Homo sapiens	74-77
21965726-8	2011	The death receptors" ligand increased SCLC killing by PA through an apparent caspase-independent route involving activation/translocation of AIF.	Paclitaxel	54-56	apoptosis inducing factor mitochondria associated 1	Homo sapiens	141-144
21685373-4	2011	We compared the results obtained to mice treated with PTX and AMD3100, a small-molecule drug antagonist of CXCR4 which, like G-CSF, can be used to mobilize hematopoietic cells.	Paclitaxel	54-57	chemokine (C-X-C motif) receptor 4	Mus musculus	107-112
21549688-9	2011	Accordingly, downregulation of c-Rel using short-hairpin RNA was shown to reduce HURP protein level and enhance taxol-induced cell death.	Paclitaxel	112-117	REL proto-oncogene, NF-kB subunit	Homo sapiens	31-36
26596154-4	2011	In particular, the corresponding error in the MP2 correlation energy amounts to only 10(-7)Eh for the 113-atom taxol molecule in double-valence basis set (1099 basis functions).	Paclitaxel	111-116	tryptase pseudogene 1	Homo sapiens	46-49
21118710-10	2011	In addition, paclitaxel decreased expression of 3PGDH, a biosynthetic enzyme of l-serine, in the DRG.	Paclitaxel	13-23	phosphoglycerate dehydrogenase	Rattus norvegicus	48-53
21145827-13	2011	We show that LIP promotes survival in staurosporine- or taxol-induced Hep3B cell death.	Paclitaxel	56-61	SMG1 nonsense mediated mRNA decay associated PI3K related kinase	Homo sapiens	13-16
21091668-7	2011	The addition of paclitaxel, which competes with the MD-2 ligand, could inhibit the effects of anti-beta2GPI/beta2GPI on TLR-4, MD-2, MyD88 and TF expression.	Paclitaxel	16-26	apolipoprotein H	Homo sapiens	99-107
21331814-0	2011	Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.	Paclitaxel	9-19	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	56-62
21091668-7	2011	The addition of paclitaxel, which competes with the MD-2 ligand, could inhibit the effects of anti-beta2GPI/beta2GPI on TLR-4, MD-2, MyD88 and TF expression.	Paclitaxel	16-26	apolipoprotein H	Homo sapiens	108-116
21525288-7	2011	Defects in axon formation caused by perturbations of the DLK-JNK pathway were significantly improved by Taxol.	Paclitaxel	104-109	mitogen-activated protein kinase 8	Mus musculus	61-64
21091668-7	2011	The addition of paclitaxel, which competes with the MD-2 ligand, could inhibit the effects of anti-beta2GPI/beta2GPI on TLR-4, MD-2, MyD88 and TF expression.	Paclitaxel	16-26	toll like receptor 4	Homo sapiens	120-125
21525288-8	2011	However, defects in short-neurite formation caused by perturbations of the DLK-JNK pathway were enhanced by Taxol.	Paclitaxel	108-113	mitogen-activated protein kinase 8	Mus musculus	79-82
21091668-7	2011	The addition of paclitaxel, which competes with the MD-2 ligand, could inhibit the effects of anti-beta2GPI/beta2GPI on TLR-4, MD-2, MyD88 and TF expression.	Paclitaxel	16-26	coagulation factor III, tissue factor	Homo sapiens	143-145
21504091-0	2011	Beneft of anti-HER2-coated paclitaxel-loaded  immuno-nanoparticles in the treatment of  disseminated ovarian cancer: therapeutic effcacy and  biodistribution in mice.	Paclitaxel	27-37	erb-b2 receptor tyrosine kinase 2	Mus musculus	15-19
21472137-10	2011	The mechanism involves paclitaxel-induced NF-kappaB pathway that upregulates VEGF-A and other tumor prosurvival proteins.	Paclitaxel	23-33	vascular endothelial growth factor A	Mus musculus	77-83
21223350-0	2011	CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4.	Paclitaxel	43-53	CD4 antigen	Mus musculus	0-3
21223350-3	2011	Here, we demonstrated that PTX not only decreased the percentage of CD4+Foxp3+ regulatory T (Treg) cells both in vitro and in vivo but also impaired cell viability and cytokine production of Treg cells rather than CD4+Foxp3- effector T (Teff) cells.	Paclitaxel	27-30	CD4 antigen	Mus musculus	68-71
21044613-6	2011	Prior exposure to L-703606 prevented the formation of DVs by Sub P, implicating the neurokinin-1 receptor, a Gq type of G protein coupled receptor, in the formation of DVs by Sub P. Finally, stabilization of microtubules by prior exposure to taxol also prevented the formation of DVs, consistent with the idea that increases in intracellular Ca(2+) lead to the formation of DVs secondary to a disruption of the linear arrays of microtubules in dendrites.	Paclitaxel	242-247	tachykinin receptor 1	Rattus norvegicus	84-105
21170509-6	2011	This downregulation of MRP2 contributes to increase in paclitaxel-induced G2/M arrest and apoptosis, which might be due to intracellular accumulation of paclitaxel.	Paclitaxel	55-65	ATP binding cassette subfamily C member 2	Homo sapiens	23-27
21170509-6	2011	This downregulation of MRP2 contributes to increase in paclitaxel-induced G2/M arrest and apoptosis, which might be due to intracellular accumulation of paclitaxel.	Paclitaxel	153-163	ATP binding cassette subfamily C member 2	Homo sapiens	23-27
21144828-3	2011	Using telomerase-deficient cells derived from mTREC-/-p53-/- mice, here we show that, upon telomere erosion, paclitaxel propagates chromosomal instability by stimulating chromosomal end-to-end fusions and delaying the development of multinucleation.	Paclitaxel	109-119	transformation related protein 53, pseudogene	Mus musculus	54-57
21204585-6	2011	We further demonstrate that systemic administration of the micelleplex carrying polo-like kinase 1 (Plk1) specific siRNA and paclitaxel can induce a synergistic tumor suppression effect in the MDA-MB-435s xenograft murine model, requiring a thousand-fold less paclitaxel than needed for paclitaxel monotherapy delivered by the micelleplex and without activation of the innate immune response or generation of carrier-associated toxicity.	Paclitaxel	125-135	polo like kinase 1	Mus musculus	80-98
21204585-6	2011	We further demonstrate that systemic administration of the micelleplex carrying polo-like kinase 1 (Plk1) specific siRNA and paclitaxel can induce a synergistic tumor suppression effect in the MDA-MB-435s xenograft murine model, requiring a thousand-fold less paclitaxel than needed for paclitaxel monotherapy delivered by the micelleplex and without activation of the innate immune response or generation of carrier-associated toxicity.	Paclitaxel	260-270	polo like kinase 1	Mus musculus	80-98
21204585-6	2011	We further demonstrate that systemic administration of the micelleplex carrying polo-like kinase 1 (Plk1) specific siRNA and paclitaxel can induce a synergistic tumor suppression effect in the MDA-MB-435s xenograft murine model, requiring a thousand-fold less paclitaxel than needed for paclitaxel monotherapy delivered by the micelleplex and without activation of the innate immune response or generation of carrier-associated toxicity.	Paclitaxel	260-270	polo like kinase 1	Mus musculus	100-104
21204585-6	2011	We further demonstrate that systemic administration of the micelleplex carrying polo-like kinase 1 (Plk1) specific siRNA and paclitaxel can induce a synergistic tumor suppression effect in the MDA-MB-435s xenograft murine model, requiring a thousand-fold less paclitaxel than needed for paclitaxel monotherapy delivered by the micelleplex and without activation of the innate immune response or generation of carrier-associated toxicity.	Paclitaxel	260-270	polo like kinase 1	Mus musculus	80-98
22104080-6	2011	In contrast, taxol treatment triggered the rapid MT plus-end accumulation of Kif18A regardless of kinetochore association.	Paclitaxel	13-18	kinesin family member 18A	Homo sapiens	77-83
21204585-6	2011	We further demonstrate that systemic administration of the micelleplex carrying polo-like kinase 1 (Plk1) specific siRNA and paclitaxel can induce a synergistic tumor suppression effect in the MDA-MB-435s xenograft murine model, requiring a thousand-fold less paclitaxel than needed for paclitaxel monotherapy delivered by the micelleplex and without activation of the innate immune response or generation of carrier-associated toxicity.	Paclitaxel	260-270	polo like kinase 1	Mus musculus	100-104
21325537-4	2011	The current study demonstrates that Taxol markedly enhanced neurite extension of mature RGCs and PC12 cells by stabilization of microtubules and desensitized axons toward myelin and chondroitin sulfate proteoglycan (CSPG) inhibition in vitro without reducing RhoA activation.	Paclitaxel	36-41	ras homolog family member A	Rattus norvegicus	259-263
21314952-10	2011	RESULTS: 43 SNPs were found significantly associated (FDR&lt;0.005) with paclitaxel response, with 10 belonging to protein-coding genes (CFTR, ROBO1, PTPRD, BTBD12, DCT, SNTG1, SGCD, LPHN2, GRIK1, ZNF607).	Paclitaxel	73-83	SLX4 structure-specific endonuclease subunit	Homo sapiens	157-163
21314952-10	2011	RESULTS: 43 SNPs were found significantly associated (FDR&lt;0.005) with paclitaxel response, with 10 belonging to protein-coding genes (CFTR, ROBO1, PTPRD, BTBD12, DCT, SNTG1, SGCD, LPHN2, GRIK1, ZNF607).	Paclitaxel	73-83	dopachrome tautomerase	Homo sapiens	165-168
21314952-10	2011	RESULTS: 43 SNPs were found significantly associated (FDR&lt;0.005) with paclitaxel response, with 10 belonging to protein-coding genes (CFTR, ROBO1, PTPRD, BTBD12, DCT, SNTG1, SGCD, LPHN2, GRIK1, ZNF607).	Paclitaxel	73-83	syntrophin gamma 1	Homo sapiens	170-175
22104080-8	2011	In the absence of Kif18A, treatment with taxol but not Eg5 inhibitor causes highly elongated mitotic MTs, suggesting the importance of plus-end accumulation for the MT length-controlling activity of Kif18A.	Paclitaxel	41-46	kinesin family member 18A	Homo sapiens	199-205
21778718-7	2011	NAC reduced the paclitaxel-induced increase in activated caspase-10 levels, but potentiated that for caspase-3.	Paclitaxel	16-26	caspase 10	Homo sapiens	57-67
20665703-4	2011	In order to improve the antineoplastic activity of paclitaxel, we presently investigated the effects of ZD6474 in combination with paclitaxel in EGFR and VEGFR expressing human breast cancer cell lines MCF-7 and MDA-MB-231.	Paclitaxel	131-141	kinase insert domain receptor	Homo sapiens	154-159
21069434-1	2011	The previous studies by this author group has shown that paclitaxel, a mitotic inhibitor used in breast cancer chemotherapy, inhibits cell growth via induction of Raf-1-dependent apoptosis.	Paclitaxel	57-67	v-raf-leukemia viral oncogene 1	Mus musculus	163-168
21059829-6	2011	miR-21 knock-down in cell-line models has been associated with increased sensitivity to topotecan and taxol in vitro and the limitation of lung metastasis in vivo.	Paclitaxel	102-107	microRNA 21	Homo sapiens	0-6
21069434-7	2011	Conversely, Raf-1 shRNA expression protected against paclitaxel-induced cell death through the simultaneous inhibition of both autophagy and apoptosis.	Paclitaxel	53-63	v-raf-leukemia viral oncogene 1	Mus musculus	12-17
21372548-1	2011	BACKGROUND: We aimed to determine whether the inclusion of additional cycles of carboplatin-paclitaxel is beneficial to patients with high posttreatment serum CA-125 levels.	Paclitaxel	92-102	mucin 16, cell surface associated	Homo sapiens	159-165
20801127-0	2010	Paclitaxel accelerates spontaneous calcium oscillations in cardiomyocytes by interacting with NCS-1 and the InsP3R.	Paclitaxel	0-10	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	108-114
20801127-3	2010	Recently, neuronal calcium sensor 1 (NCS-1), a calcium binding protein that modulates the inositol-1,4,5-trisphosphate receptor (InsP(3)R), was described as a binding partner of Taxol and as a substrate of calpain.	Paclitaxel	178-183	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	129-137
20801127-9	2010	Short hairpin RNA mediated knockdown of NCS-1 decreased InsP(3)R dependent intracellular calcium release, whereas Taxol treatment, that increased NCS-1 levels, increased InsP(3)R dependent calcium release.	Paclitaxel	114-119	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	170-178
20801127-11	2010	At the single channel level Taxol and NCS-1 mediated an increase in InsP(3)R activity.	Paclitaxel	28-33	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	68-76
20801127-13	2010	In short, our study shows that Taxol impacts calcium signaling and calcium oscillations in cardiomyocytes through NCS-1 and the InsP(3)R.	Paclitaxel	31-36	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	128-136
22216199-11	2011	At the same time, data from caspase-2 over-expression and knocked-down experiments demonstrated that caspase-2 participated in apigenin and paclitaxel-induced HeLa cell apoptosis.	Paclitaxel	140-150	caspase 2	Homo sapiens	101-110
20845461-3	2010	PTX, a Pgp and CYP3A2 substrate, was administered orally at 20 mg/kg in solution or nanoemulsion either as single agent or upon pretreatment with CUR at 50 mg/kg in tumor-bearing mice.	Paclitaxel	0-3	phosphoglycolate phosphatase	Mus musculus	7-10
21078266-0	2010	[Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells].	Paclitaxel	56-66	C-X-C motif chemokine receptor 4	Homo sapiens	141-165
21078266-5	2010	The expressions of VEGF and CXCR4 mRNAs and proteins in the OI plus low-dose paclitaxel group were markedly lower than those in the low-dose paclitaxel group (P&lt;0.01).	Paclitaxel	77-87	C-X-C motif chemokine receptor 4	Homo sapiens	28-33
21078266-5	2010	The expressions of VEGF and CXCR4 mRNAs and proteins in the OI plus low-dose paclitaxel group were markedly lower than those in the low-dose paclitaxel group (P&lt;0.01).	Paclitaxel	141-151	C-X-C motif chemokine receptor 4	Homo sapiens	28-33
21078266-6	2010	CONCLUSION: OI combined with low-dose paclitaxel can inhibit VEGF and CXCR4 of gastric carcinoma SGC-7901 cells markedly, which may be one of its mechanisms of anti-angiogenic ability.	Paclitaxel	38-48	C-X-C motif chemokine receptor 4	Homo sapiens	70-75
20526888-0	2010	A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma.	Paclitaxel	47-57	solute carrier family 25 member 19	Homo sapiens	89-92
20699370-10	2010	Overexpression of CDX2 in HT-29 cells revealed increased resistance to the known substrate of MDR1, vincristine and paclitaxel, which was reversed by an MDR1 inhibitor, verapamil.	Paclitaxel	116-126	caudal type homeobox 2	Homo sapiens	18-22
22140576-7	2011	Intriguingly, two main drugs for drug-eluting stent, paclitaxel or rapamycin, significantly exaggerated thrombin-induced TF expression, which was also effectively blocked by the PPAR-gamma agonist in all cell types.	Paclitaxel	53-63	coagulation factor III, tissue factor	Homo sapiens	121-123
22140576-11	2011	Also, this PPAR-gamma agonist reversed the paclitaxel-induced aggravation of TF expression, which suggests a possibility that the benefits might outweigh its risks in a group of patients with paclitaxel-eluting stent implanted.	Paclitaxel	43-53	coagulation factor III, tissue factor	Homo sapiens	77-79
22140576-11	2011	Also, this PPAR-gamma agonist reversed the paclitaxel-induced aggravation of TF expression, which suggests a possibility that the benefits might outweigh its risks in a group of patients with paclitaxel-eluting stent implanted.	Paclitaxel	192-202	coagulation factor III, tissue factor	Homo sapiens	77-79
20717708-7	2010	We demonstrate that after taxol treatment, the c-Myc IRES activity is maintained meanwhile cap-dependent activity is inhibited.	Paclitaxel	26-31	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	47-52
20717708-8	2010	In addition, an increase in c-Myc mRNA was also observed after taxol treatment.	Paclitaxel	63-68	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	28-33
20717708-9	2010	We conclude that taxol-induced c-Myc expression is regulated at both transcriptional and translational levels, the last of them by a mechanism mediated by IRES.	Paclitaxel	17-22	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	31-36
20952655-6	2010	Also, doxorubicin, cisplatin, and paclitaxel increased this enriched population which, conversely, was significantly inhibited by Mullerian inhibiting substance (MIS) or the MIS mimetic SP600125.	Paclitaxel	34-44	anti-Mullerian hormone	Homo sapiens	130-160
20952655-6	2010	Also, doxorubicin, cisplatin, and paclitaxel increased this enriched population which, conversely, was significantly inhibited by Mullerian inhibiting substance (MIS) or the MIS mimetic SP600125.	Paclitaxel	34-44	anti-Mullerian hormone	Homo sapiens	162-165
20952655-6	2010	Also, doxorubicin, cisplatin, and paclitaxel increased this enriched population which, conversely, was significantly inhibited by Mullerian inhibiting substance (MIS) or the MIS mimetic SP600125.	Paclitaxel	34-44	anti-Mullerian hormone	Homo sapiens	174-177
20578985-5	2010	An examination of pathways common to Paclitaxel and parthenolide signaling revealed that this synergy was related to modulation of the NF-kappaB/ I-kappaB kinase (IKK) signal cascade through IKKbeta.	Paclitaxel	37-47	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	191-198
20823274-3	2010	Here, we performed a high-resolution phenotypic analysis to reveal the mechanistic underpinnings by which symplekin depletion collaborates with paclitaxel.	Paclitaxel	144-154	symplekin scaffold protein	Homo sapiens	106-115
21472350-4	2010	A549/CTP-11R cells were resistant to irinotecan, as well as paclitaxel, gemcitabine and carboplatin.	Paclitaxel	60-70	SPANX family member C	Homo sapiens	5-11
20600879-6	2010	In conclusion, macelignan appeared to be effective to improve the cellular accumulation as well as oral exposure of paclitaxel mainly via the inhibition of P-gp-mediated cellular efflux, suggesting that the concomitant use of macelignan may provide a therapeutic benefit in improving the anticancer efficacy of paclitaxel.	Paclitaxel	311-321	phosphoglycolate phosphatase	Homo sapiens	156-160
20947484-11	2010	ICER was mostly sensitive to hazard ratio (HR) (when varied from 1.46 to 1.09; $3,517/ QALY), discount over the ex-lab price of Taxol  (75%; $6,396/QALY) and granulocyte colony-stimulating factor (G-CSF) prophylactic treatment (when administered in 60% of cycles instead of 100%; cost saving).	Paclitaxel	128-133	colony stimulating factor 3	Homo sapiens	158-195
21092550-1	2010	OBJECTIVE: To explore the regulation of Bub1 mRNA expression in endometrial carcinoma cells by estrogen and paclitaxel.	Paclitaxel	108-118	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	40-44
21092550-11	2010	After being treated with serum-free culture, Ishikawa cells were exposed to 10 nmol/L paclitaxel for 8 and 24 hours, and the expression of Bub1 mRNA decreased (0.403 +- 0.008 vs. 0.775 +- 0.144, P = 0.251).	Paclitaxel	86-96	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	139-143
21092550-12	2010	Compared to the control cells, the mRNA expression levels of Bub1 in cells treated by paclitaxel for 8 hours was significantly decreased (P = 0.009), while there was not significantly decreased at 24 hours (P = 0.396).	Paclitaxel	86-96	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	61-65
20947484-11	2010	ICER was mostly sensitive to hazard ratio (HR) (when varied from 1.46 to 1.09; $3,517/ QALY), discount over the ex-lab price of Taxol  (75%; $6,396/QALY) and granulocyte colony-stimulating factor (G-CSF) prophylactic treatment (when administered in 60% of cycles instead of 100%; cost saving).	Paclitaxel	128-133	colony stimulating factor 3	Homo sapiens	197-202
21092550-13	2010	When exposed to 100 nmol/L paclitaxel for 8 and 24 hours, the expression of Bub1 mRNA was also decreased (0.697 +- 0.017 vs. 0.850 +- 0.004, P = 0.061).	Paclitaxel	27-37	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	76-80
21092550-16	2010	CONCLUSION: Bub1 expression could be regulated by estradiol and paclitaxel, in which deregulated Bub1 expression may contribute to chemotherapeutic efficacy of paclitaxel.	Paclitaxel	64-74	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	12-16
21063845-0	2010	Effect of Mad2 on paclitaxel-induced cell death in ovarian cancer cells.	Paclitaxel	18-28	mitotic arrest deficient 2 like 1	Homo sapiens	10-14
21092550-16	2010	CONCLUSION: Bub1 expression could be regulated by estradiol and paclitaxel, in which deregulated Bub1 expression may contribute to chemotherapeutic efficacy of paclitaxel.	Paclitaxel	160-170	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	12-16
21092550-16	2010	CONCLUSION: Bub1 expression could be regulated by estradiol and paclitaxel, in which deregulated Bub1 expression may contribute to chemotherapeutic efficacy of paclitaxel.	Paclitaxel	160-170	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	97-101
21063845-2	2010	Recombinant eukaryotic expression plasmid pEGFP-Mad2 was transfected into paclitaxel-resistant SKOV3 cells and Mad2 protein was knocked down by Mad2-specific siRNA in paclitaxel-sensitive A2780 cells.	Paclitaxel	74-84	mitotic arrest deficient 2 like 1	Homo sapiens	48-52
21063845-2	2010	Recombinant eukaryotic expression plasmid pEGFP-Mad2 was transfected into paclitaxel-resistant SKOV3 cells and Mad2 protein was knocked down by Mad2-specific siRNA in paclitaxel-sensitive A2780 cells.	Paclitaxel	167-177	mitotic arrest deficient 2 like 1	Homo sapiens	48-52
21063845-2	2010	Recombinant eukaryotic expression plasmid pEGFP-Mad2 was transfected into paclitaxel-resistant SKOV3 cells and Mad2 protein was knocked down by Mad2-specific siRNA in paclitaxel-sensitive A2780 cells.	Paclitaxel	167-177	mitotic arrest deficient 2 like 1	Homo sapiens	111-115
21063845-2	2010	Recombinant eukaryotic expression plasmid pEGFP-Mad2 was transfected into paclitaxel-resistant SKOV3 cells and Mad2 protein was knocked down by Mad2-specific siRNA in paclitaxel-sensitive A2780 cells.	Paclitaxel	167-177	mitotic arrest deficient 2 like 1	Homo sapiens	111-115
21063845-6	2010	These results suggest that weakened spindle checkpoint with reduced expression of Mad2 is associated with resistance to paclitaxel in ovarian cells and Bcl-2 may be involved in this process.	Paclitaxel	120-130	mitotic arrest deficient 2 like 1	Homo sapiens	82-86
20207475-3	2010	The MTT assay indicated that over-expression of Beclin1 sensitized CaSki cells to chemotherapeutic drugs (cisplatin, paclitaxel, 5-fluorouracil, and epirubicin) and induced greater degrees of cytotoxicity than vector-only controls.	Paclitaxel	117-127	beclin 1	Homo sapiens	48-55
20637781-14	2010	Paclitaxel-induced B16F10 mouse melanoma regression was physiologically inhibited in TB4-transgenic mice compared to wildtype mice.	Paclitaxel	0-10	thymosin, beta 4, X chromosome	Mus musculus	85-88
20596672-5	2010	In particular, we show that the occurrence of the interaction of nuclear ERp57 with beta-actin is associated with paclitaxel resistance and that specific actin conformations modulate this complex.	Paclitaxel	114-124	POTE ankyrin domain family member F	Homo sapiens	84-94
20012292-9	2010	Aminoflavone-induced CYP1A1 induction was observed in the presence of camptothecin or paclitaxel.	Paclitaxel	86-96	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	21-27
20547325-4	2010	These results suggest that HRAP enhances paclitaxel-induced apoptosis in a manner dependent on the PTEN/Akt signal transduction pathway.	Paclitaxel	41-51	phosphatase and tensin homolog	Homo sapiens	99-103
20530669-9	2010	Likewise, the ESC-derived SPEC-2 cell line had a higher level of Nrf2 expression and was more resistant to the toxic effects of cisplatin and paclitaxel than the Ishikawa cell line, which was generated from EEC.	Paclitaxel	142-152	CDC42 small effector 2	Homo sapiens	26-32
20676051-10	2010	This stems from our previous work where we demonstrated that MAD2 downregulation induces cellular senescence, a viable cellular fate, with resultant cellular resistance to paclitaxel.	Paclitaxel	172-182	mitotic arrest deficient 2 like 1	Homo sapiens	61-65
20353770-0	2010	Murine erythropoietic impairment induced by paclitaxel: interactions of GATA-1 and erythroid Kruppel-like transcription factors, apoptotic related proteins and erythropoietin receptor.	Paclitaxel	44-54	erythropoietin receptor	Mus musculus	160-183
20353770-3	2010	The aim of this study focuses on erythropoietin (EPO) receptor, GATA binding protein 1 (globin transcription factor 1) (GATA-1) and erythroid Kruppel-like factor (EKLF) expressions related to the apoptotic events triggered by paclitaxel in bone marrow and the subsequent in vivo erythropoietic recovery.	Paclitaxel	226-236	erythropoietin receptor	Mus musculus	33-62
20353770-7	2010	This study suggests that EPO receptor recovery is necessary for the subsequent bone marrow ability to accomplish the erythroid program through the modulation of apoptotic and survival events after a single paclitaxel insult.	Paclitaxel	206-216	erythropoietin	Mus musculus	25-28
20406806-0	2010	MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression.	Paclitaxel	20-30	microRNA 148a	Homo sapiens	0-8
20406806-5	2010	Transfection with miR-148a precursor inhibited cell growth, and cell migration and invasion, and increased the sensitivity to anti-cancer drug paclitaxel in PC3 cells.	Paclitaxel	143-153	microRNA 148a	Homo sapiens	18-26
20406806-10	2010	In PC3PR cells, a paclitaxel-resistant cell line established from PC3 cells, miR-148a inhibited cell growth, and cell migration and invasion, and also attenuated the resistance to paclitaxel.	Paclitaxel	18-28	microRNA 148a	Homo sapiens	77-85
20406806-10	2010	In PC3PR cells, a paclitaxel-resistant cell line established from PC3 cells, miR-148a inhibited cell growth, and cell migration and invasion, and also attenuated the resistance to paclitaxel.	Paclitaxel	180-190	microRNA 148a	Homo sapiens	77-85
20406806-12	2010	Furthermore, MSK1 knockdown reduced paclitaxel-resistance of PC3PR cells, indicating that miR-148a attenuates paclitaxel-resistance of hormone-refractory, drug-resistant PC3PR cells in part by regulating MSK1 expression.	Paclitaxel	36-46	microRNA 148a	Homo sapiens	90-98
20406806-12	2010	Furthermore, MSK1 knockdown reduced paclitaxel-resistance of PC3PR cells, indicating that miR-148a attenuates paclitaxel-resistance of hormone-refractory, drug-resistant PC3PR cells in part by regulating MSK1 expression.	Paclitaxel	110-120	microRNA 148a	Homo sapiens	90-98
20434553-0	2010	Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice.	Paclitaxel	0-10	heart and neural crest derivatives expressed 2	Mus musculus	55-58
20434553-7	2010	Results showed that coadministration of OVA with paclitaxel induced significantly higher IgG, IgG1, IgG2a, IgG2b, IgG3 and IgM responses than when OVA was used alone.	Paclitaxel	49-59	immunoglobulin heavy variable V1-9	Mus musculus	100-105
20434553-8	2010	In addition, up-regulated T-bet/GATA-3 together with significantly increased mRNA expression of IL-4, IL-10, IFN-gamma and IL-12 by splenocytes, as well as the proliferative responses of splenocytes to Con A, LPS and OVA were observed in paclitaxel-adjuvanted groups.	Paclitaxel	238-248	GATA binding protein 3	Mus musculus	32-38
20434553-8	2010	In addition, up-regulated T-bet/GATA-3 together with significantly increased mRNA expression of IL-4, IL-10, IFN-gamma and IL-12 by splenocytes, as well as the proliferative responses of splenocytes to Con A, LPS and OVA were observed in paclitaxel-adjuvanted groups.	Paclitaxel	238-248	interleukin 4	Mus musculus	96-100
20434553-9	2010	Incubation of a murine macrophage-like cell line with paclitaxel significantly increased TNF-alpha and -10 released from the cells and expression of microRNAs such as miR-155, miR-147, miR-146a and miR-132.	Paclitaxel	54-64	microRNA 146	Mus musculus	185-193
20434553-9	2010	Incubation of a murine macrophage-like cell line with paclitaxel significantly increased TNF-alpha and -10 released from the cells and expression of microRNAs such as miR-155, miR-147, miR-146a and miR-132.	Paclitaxel	54-64	microRNA 132	Mus musculus	198-205
20434553-10	2010	Therefore, paclitaxel activated both Th1 and Th2 responses.	Paclitaxel	11-21	heart and neural crest derivatives expressed 2	Mus musculus	45-48
20530690-5	2010	Mechanistic investigations revealed that the tubulin-destabilizing protein Stathmin, whose expression also confers resistance to paclitaxel, is a direct transcriptional target of FoxM1.	Paclitaxel	129-139	stathmin 1	Homo sapiens	75-83
20417177-6	2010	Furthermore, paclitaxel-induced apoptosis in IMC-3 tumors transplanted in nude mice was enhanced significantly by administration of ASOs for HDAC3, thereby suppressing tumor growth.	Paclitaxel	13-23	histone deacetylase 3	Mus musculus	141-146
20407875-0	2010	Effect of spindle checkpoint on Akt2-mediated paclitaxel-resistance in A2780 ovarian cancer cells.	Paclitaxel	46-56	AKT serine/threonine kinase 2	Homo sapiens	32-36
20407875-1	2010	Recent evidence has suggested that Akt2 plays an important role in the protection of cells from paclitaxel (PTX)-induced apoptosis and control of the cell cycle.	Paclitaxel	96-106	AKT serine/threonine kinase 2	Homo sapiens	35-39
20407875-1	2010	Recent evidence has suggested that Akt2 plays an important role in the protection of cells from paclitaxel (PTX)-induced apoptosis and control of the cell cycle.	Paclitaxel	108-111	AKT serine/threonine kinase 2	Homo sapiens	35-39
20407875-3	2010	In the present study, we investigated the role of the Akt2/Bub1 cross-talking in apoptosis and cell cycle after exposure of the A2780 ovarian cancer cells to paclitaxel (PTX).	Paclitaxel	158-168	AKT serine/threonine kinase 2	Homo sapiens	54-58
20407875-3	2010	In the present study, we investigated the role of the Akt2/Bub1 cross-talking in apoptosis and cell cycle after exposure of the A2780 ovarian cancer cells to paclitaxel (PTX).	Paclitaxel	170-173	AKT serine/threonine kinase 2	Homo sapiens	54-58
20407875-7	2010	Our study showed that up-regulation of Akt2 contributed to A2780 ovarian cancer cells overriding PTX-induced G(2)/M arrest, and inhibited Bub1 expression.	Paclitaxel	97-100	AKT serine/threonine kinase 2	Homo sapiens	39-43
19896927-4	2010	Homozygotes for the C1236T and C3435T variant allele (TT) were associated with 42% and 47% increase in placental P-gp transport activity, respectively (p=0.04 and p=0.02) of the prototypic substrate, [(3)H]-paclitaxel.	Paclitaxel	207-217	phosphoglycolate phosphatase	Homo sapiens	113-117
19861310-1	2010	AIMS: Treatment with the anticancer drug taxol (TXL), which polymerizes the cytoskeleton protein tubulin, may evoke cardiac arrhythmias based on reduced human cardiac sodium channel (Na(v)1.5) function.	Paclitaxel	41-46	immunoglobulin lambda variable 2-18	Homo sapiens	159-191
19861310-7	2010	Accordingly, HEK293 cells and NRCs stained with anti-Na(v)1.5 antibody revealed a reduced membrane-labelling intensity in the TXL-treated groups.	Paclitaxel	126-129	immunoglobulin lambda variable 2-18	Homo sapiens	53-61
19861310-9	2010	Finally, TXL reduced the fraction of channels that slow inactivated from 31% to 18%, and increased the time constant of slow inactivation by two-fold in Na(v)1.5.	Paclitaxel	9-12	immunoglobulin lambda variable 2-18	Homo sapiens	153-161
19460063-13	2010	CONCLUSION: In a poor prognostic cohort of patients paclitaxel and vinorelbine is a tolerable regimen, with a 20% PSA and objective response rate.	Paclitaxel	52-62	kallikrein related peptidase 3	Homo sapiens	114-117
20075745-6	2010	Cotreatment of paclitaxel with TNF-alpha markedly augmented the release of TF.	Paclitaxel	15-25	coagulation factor III, tissue factor	Homo sapiens	75-77
20075745-9	2010	Tissue factor pathway inhibitor expression was reduced by prolonged treatment with either paclitaxel or TNF-alpha.	Paclitaxel	90-100	coagulation factor III, tissue factor	Homo sapiens	0-13
20075745-14	2010	These findings indicate that paclitaxel enhances TNF-alpha-induced release of TF, and downregulated thrombomodulin, increased protein nitration, which may subsequently favor prothrombotic intimal surface.	Paclitaxel	29-39	coagulation factor III, tissue factor	Homo sapiens	78-80
20142807-8	2010	The paclitaxel treatment markedly suppressed Smad2 and Smad3 phosphorylation.	Paclitaxel	4-14	SMAD family member 2	Rattus norvegicus	45-50
19917055-0	2010	The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells.	Paclitaxel	103-113	dipeptidyl peptidase 4	Homo sapiens	18-41
19917055-0	2010	The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells.	Paclitaxel	103-113	dipeptidyl peptidase 4	Homo sapiens	43-48
19917055-0	2010	The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells.	Paclitaxel	103-113	dipeptidyl peptidase 4	Homo sapiens	49-53
19917055-3	2010	In the current study, we investigated the role of DPPIV in paclitaxel resistance in epithelial ovarian carcinoma (EOC) cells.	Paclitaxel	59-69	dipeptidyl peptidase 4	Homo sapiens	50-55
19917055-4	2010	We first examined the correlation between expression levels of DPPIV and sensitivity to paclitaxel in various EOC cell lines.	Paclitaxel	88-98	dipeptidyl peptidase 4	Homo sapiens	63-68
19917055-6	2010	We identified a positive correlation between DPPIV expression and paclitaxel sensitivity in various EOC cell lines.	Paclitaxel	66-76	dipeptidyl peptidase 4	Homo sapiens	45-50
19917055-7	2010	In addition, we observed a significant increase in the paclitaxel sensitivity of DPPIV-overexpressing EOC cells.	Paclitaxel	55-65	dipeptidyl peptidase 4	Homo sapiens	81-86
19917055-9	2010	In a subcutaneous murine model treated with paclitaxel, on Day 39, the tumor size of the DPPIV-transfected cell-inoculated group was as large as that of the vector-transfected cell-inoculated group.	Paclitaxel	44-54	dipeptidylpeptidase 4	Mus musculus	89-94
19917055-11	2010	The present findings show that DPPIV may be involved in the increased sensitivity to paclitaxel of EOC cells regardless of the involvement of DPPIV activity.	Paclitaxel	85-95	dipeptidyl peptidase 4	Homo sapiens	31-36
19621389-10	2010	In A549, combination of vorinostat with paclitaxel resulted in a synergistic increase in alpha-tubulin acetylation, which reversed upon drug washout.	Paclitaxel	40-50	tubulin alpha 1b	Homo sapiens	89-102
19910452-10	2010	MDA-7/IL-24 toxicity was enhanced in a weak additive fashion by paclitaxel; paclitaxel enhanced MDA-7/IL-24 + cisplatin lethality in a greater than additive fashion via BAX.	Paclitaxel	64-74	interleukin 24	Homo sapiens	0-5
19910452-10	2010	MDA-7/IL-24 toxicity was enhanced in a weak additive fashion by paclitaxel; paclitaxel enhanced MDA-7/IL-24 + cisplatin lethality in a greater than additive fashion via BAX.	Paclitaxel	64-74	interleukin 24	Homo sapiens	6-11
19910452-10	2010	MDA-7/IL-24 toxicity was enhanced in a weak additive fashion by paclitaxel; paclitaxel enhanced MDA-7/IL-24 + cisplatin lethality in a greater than additive fashion via BAX.	Paclitaxel	76-86	interleukin 24	Homo sapiens	96-101
19910452-10	2010	MDA-7/IL-24 toxicity was enhanced in a weak additive fashion by paclitaxel; paclitaxel enhanced MDA-7/IL-24 + cisplatin lethality in a greater than additive fashion via BAX.	Paclitaxel	76-86	interleukin 24	Homo sapiens	102-107
20357441-8	2010	Furthermore, paclitaxel and pirarubicin suppressed the expression of PCNA, cyclin D1, cyclin E and Bcl-2, and increased Bax expression.	Paclitaxel	13-23	proliferating cell nuclear antigen	Homo sapiens	69-84
19826413-0	2009	TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.	Paclitaxel	48-58	toll like receptor 4	Homo sapiens	0-4
19935801-0	2009	Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro.	Paclitaxel	63-73	mitotic arrest deficient 2 like 1	Homo sapiens	40-44
19935801-2	2009	MAD2 also has a function in cellular senescence and in a cell"s response to microtubule inhibitory (MI) chemotherapy exemplified by paclitaxel.	Paclitaxel	132-142	mitotic arrest deficient 2 like 1	Homo sapiens	0-4
19935801-3	2009	METHODS: Using an siRNA approach, the impact of MAD2 down-regulation on cellular senescence and paclitaxel responsiveness was investigated.	Paclitaxel	96-106	mitotic arrest deficient 2 like 1	Homo sapiens	48-52
19935801-10	2009	At 72 h after paclitaxel, MAD2 cells show a significant further induction of senescence compared with paclitaxel naive controls.	Paclitaxel	14-24	mitotic arrest deficient 2 like 1	Homo sapiens	26-30
19935801-10	2009	At 72 h after paclitaxel, MAD2 cells show a significant further induction of senescence compared with paclitaxel naive controls.	Paclitaxel	102-112	mitotic arrest deficient 2 like 1	Homo sapiens	26-30
19935801-11	2009	In addition, there are significantly more viable cells in the MAD2 MCF7 cell line after paclitaxel reflecting the observed increase in senescence.	Paclitaxel	88-98	mitotic arrest deficient 2 like 1	Homo sapiens	62-66
19935801-13	2009	In conclusion, compromised MAD2 levels induce a population of senescent cells resistant to paclitaxel.	Paclitaxel	91-101	mitotic arrest deficient 2 like 1	Homo sapiens	27-31
19717209-0	2009	Potentiation of paclitaxel-induced apoptosis by galectin-13 overexpression via activation of Ask-1-p38-MAP kinase and JNK/SAPK pathways and suppression of Akt and ERK1/2 activation in U-937 human macrophage cells.	Paclitaxel	16-26	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	93-98
19885629-9	2009	On the other hand, taxol-induced up-regulation of MCP-1 was reduced in cells treated with U73122, an inhibitor of phospholipase C (PLC), and ectopic expression of PLC-gamma1 increased the expression of MCP-1 in taxol-treated MCF-7 cells, indicating that PLC-gamma1 functions as a positive regulator in taxol-induced MCP-1 expression.	Paclitaxel	19-24	C-C motif chemokine ligand 2	Homo sapiens	202-207
19885629-9	2009	On the other hand, taxol-induced up-regulation of MCP-1 was reduced in cells treated with U73122, an inhibitor of phospholipase C (PLC), and ectopic expression of PLC-gamma1 increased the expression of MCP-1 in taxol-treated MCF-7 cells, indicating that PLC-gamma1 functions as a positive regulator in taxol-induced MCP-1 expression.	Paclitaxel	211-216	C-C motif chemokine ligand 2	Homo sapiens	202-207
19885629-9	2009	On the other hand, taxol-induced up-regulation of MCP-1 was reduced in cells treated with U73122, an inhibitor of phospholipase C (PLC), and ectopic expression of PLC-gamma1 increased the expression of MCP-1 in taxol-treated MCF-7 cells, indicating that PLC-gamma1 functions as a positive regulator in taxol-induced MCP-1 expression.	Paclitaxel	211-216	C-C motif chemokine ligand 2	Homo sapiens	202-207
19951914-5	2009	Intermediate kinase activity levels obtained with an INCENP mutant that binds aurora B but cannot fully activate it are sufficient for a robust response against taxol, but cannot trigger CPC transfer from the chromosomes to the anaphase spindle midzone.	Paclitaxel	161-166	inner centromere protein	Homo sapiens	53-59
20439112-7	2010	Treatment with increasing doses of paclitaxel or enzastaurin caused an increase of CA125 shedding in culture medium but also the membrane bound fraction of CA125 was increased.	Paclitaxel	35-45	mucin 16, cell surface associated	Homo sapiens	83-88
20439112-7	2010	Treatment with increasing doses of paclitaxel or enzastaurin caused an increase of CA125 shedding in culture medium but also the membrane bound fraction of CA125 was increased.	Paclitaxel	35-45	mucin 16, cell surface associated	Homo sapiens	156-161
19591810-8	2009	The vesicles were oriented approximately 75% inside-out, exhibited saturable ATP-dependent uptake of P-gp substrate [(3)H]-paclitaxel with an apparent K(t) of 66+/-38 nM and V(max) of 20+/-3 pmol mg protein (-1)min(-1).	Paclitaxel	123-133	phosphoglycolate phosphatase	Homo sapiens	101-105
20926015-4	2010	A number of paclitaxel binding proteins were present in MCF-7 cells but absent from MCF-7/Taxol cells, namely heat shock protein 90, actinin and dermcidin precursor.	Paclitaxel	12-22	dermcidin	Homo sapiens	145-154
20404007-8	2010	RESULTS: Taxol-induced AKT phosphorylation required IGF1R tyrosine kinase activity and was associated with upregulation of IGF2.	Paclitaxel	9-14	insulin like growth factor 1 receptor	Homo sapiens	52-57
19591810-10	2009	Our data indicate that a method has been established to determine the activity of the efflux transporter P-gp, expressed in placental brush border membranes, and the kinetics for the transfer of its prototypic substrate paclitaxel.	Paclitaxel	220-230	phosphoglycolate phosphatase	Homo sapiens	105-109
19591810-11	2009	Furthermore, the method was used to determine the effects of methadone, buprenorphine, and morphine on paclitaxel transfer by placental P-gp and revealed that they have higher affinity to the transporter than its classical inhibitor verapamil (K(i), 300 microM).	Paclitaxel	103-113	phosphoglycolate phosphatase	Homo sapiens	136-140
19619321-1	2009	BACKGROUND: We previously described a sub-population of epithelial ovarian cancer (EOC) cells with a functional TLR-4/MyD88/NF-kappaB pathway (Type I EOC cells), which confers the capacity to respond to Paclitaxel, a known TLR-4 ligand, by enhancing NF-kappaB activity and upregulating cytokine secretion - events that are known to promote tumor progression.	Paclitaxel	203-213	toll like receptor 4	Homo sapiens	112-117
19520256-5	2009	RESULTS: Treatment with paclitaxel, sirolimus, and everolimus significantly caused a senescent phenotype and PAI-1 up-regulation, associated with a decrease in endothelial nitric oxide synthase (eNOS) and Sirt1 expression.	Paclitaxel	24-34	serpin family E member 1	Homo sapiens	109-114
20515946-4	2010	OCIAD1 upregulated cells had significantly higher secondary colony-forming ability than had OCIAD1 downregulated cells following treatment with paclitaxel.	Paclitaxel	144-154	OCIA domain containing 1	Homo sapiens	0-6
20515946-4	2010	OCIAD1 upregulated cells had significantly higher secondary colony-forming ability than had OCIAD1 downregulated cells following treatment with paclitaxel.	Paclitaxel	144-154	OCIA domain containing 1	Homo sapiens	92-98
20515946-12	2010	Thus, OCIAD1 may play a role in cytoskeletal function which can alter sensitivity to paclitaxel.	Paclitaxel	85-95	OCIA domain containing 1	Homo sapiens	6-12
19953905-0	2009	[Effects of RNA interference silencing RhoC gene upon paclitaxel sensitivity in ovarian cancer cell lines].	Paclitaxel	54-64	ras homolog family member C	Homo sapiens	39-43
20428807-0	2010	Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells.	Paclitaxel	77-82	GLI family zinc finger 1	Homo sapiens	8-13
19953905-1	2009	OBJECTIVE: To explore the changes of paclitaxel sensitivity by RNA interference of RhoC gene in ovarian cancer cell lines.	Paclitaxel	37-47	ras homolog family member C	Homo sapiens	83-87
20428807-0	2010	Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells.	Paclitaxel	77-82	GLI family zinc finger 1	Homo sapiens	8-11
19953905-7	2009	The sensitivity of SKOV3 cell line to paclitaxel increased significantly after turning off the RhoC gene.	Paclitaxel	38-48	ras homolog family member C	Homo sapiens	95-99
20428807-0	2010	Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells.	Paclitaxel	77-82	CD44 molecule (Indian blood group)	Homo sapiens	54-58
19953905-8	2009	The proapoptotic gene Caspase-3 increased significantly and anti-apoptosis gene survivin dramatically decreased after the combination treatment of paclitaxel and RhoC-miRNA in comparison with paclitaxel alone treatment.	Paclitaxel	192-202	ras homolog family member C	Homo sapiens	162-166
20428807-3	2010	We investigated the effects of density of the Notch-activating ligand, Jag-1, and targeting Gli-1, in activation of division of paclitaxel/taxol-resistant, (PTX Res) ovarian cancer cells SKOV3 (SKOV3).	Paclitaxel	128-138	GLI family zinc finger 1	Homo sapiens	92-97
20428807-3	2010	We investigated the effects of density of the Notch-activating ligand, Jag-1, and targeting Gli-1, in activation of division of paclitaxel/taxol-resistant, (PTX Res) ovarian cancer cells SKOV3 (SKOV3).	Paclitaxel	139-144	GLI family zinc finger 1	Homo sapiens	92-97
19953905-9	2009	CONCLUSION: The sensitivity of ovarian cancer cell lines SKOV3 to paclitaxel can be enhanced by RNA interfering RhoC gene.	Paclitaxel	66-76	ras homolog family member C	Homo sapiens	112-116
20428807-16	2010	i.Gli-1 RNA should be more effective if used together with Taxol.	Paclitaxel	59-64	GLI family zinc finger 1	Homo sapiens	2-7
18751888-1	2009	PURPOSE: Granulocyte-colony stimulating factor (G-CSF) was used in CALGB 9741 to support dose-dense sequential chemotherapy with doxorubicin and cyclophosphamide (AC) followed by paclitaxel (P) (Citron et al.	Paclitaxel	179-189	colony stimulating factor 3	Homo sapiens	48-53
20622327-1	2010	OBJECTIVE: To observe the effect of autophagy on paclitaxel-induced CaSki cell death through the regulation of the expression of autophagy gene Beclin1, and to explore the interaction and relationship between autophagy and apoptosis.	Paclitaxel	49-59	beclin 1	Homo sapiens	144-151
19322891-8	2009	This association was independent of patient age, disease stage, tumor grade, histology, and residual tumor size and was observed in patients who received platinum plus paclitaxel, but not in patients who received platinum without paclitaxel, suggesting that stathmin expression in tumor tissue may interfere with paclitaxel treatment.	Paclitaxel	168-178	stathmin 1	Homo sapiens	258-266
20622327-9	2010	After being treated with paclitaxel, the percentages of apoptotic cells and autophagic cells were both increased in pcDNA3.1-Beclin1 group compared with that of the blank control group especially the increase of apoptosis was particularly evident.	Paclitaxel	25-35	beclin 1	Homo sapiens	125-132
20622327-11	2010	Overexpression of Beclin1 in CaSki cells may enhance the apoptosis induced by paclitaxel.	Paclitaxel	78-88	beclin 1	Homo sapiens	18-25
20332234-11	2010	Here, we show that paclitaxel induces P-YB-1(S102) expression, nuclear localization of activated YB-1, and CD44 expression.	Paclitaxel	19-29	CD44 molecule (Indian blood group)	Homo sapiens	107-111
20332234-13	2010	Importantly, targeting YB-1 sensitized the CD44(High)/CD24(Low) cells to paclitaxel.	Paclitaxel	73-83	CD44 molecule (Indian blood group)	Homo sapiens	43-47
19322891-8	2009	This association was independent of patient age, disease stage, tumor grade, histology, and residual tumor size and was observed in patients who received platinum plus paclitaxel, but not in patients who received platinum without paclitaxel, suggesting that stathmin expression in tumor tissue may interfere with paclitaxel treatment.	Paclitaxel	230-240	stathmin 1	Homo sapiens	258-266
19322891-8	2009	This association was independent of patient age, disease stage, tumor grade, histology, and residual tumor size and was observed in patients who received platinum plus paclitaxel, but not in patients who received platinum without paclitaxel, suggesting that stathmin expression in tumor tissue may interfere with paclitaxel treatment.	Paclitaxel	230-240	stathmin 1	Homo sapiens	258-266
19322891-12	2009	CONCLUSIONS: High stathmin expression predicted an unfavorable prognosis in patients with ovarian cancer who received paclitaxel and platinum chemotherapy.	Paclitaxel	118-128	stathmin 1	Homo sapiens	18-26
20234821-0	2010	The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.	Paclitaxel	93-103	thrombospondin 1	Mus musculus	4-20
19322891-13	2009	This finding supports the possibility that stathmin may interfere with paclitaxel treatment, leading to a poor prognosis for patients with ovarian cancer.	Paclitaxel	71-81	stathmin 1	Homo sapiens	43-51
19397590-6	2009	Western blot analysis showed that As(2)O(3) significantly blocked phosphorylation of BubR1, Cdc20, and Cdc27 in cells treated with paclitaxel, suggesting that arsenic compromised the activation of the spindle checkpoint.	Paclitaxel	131-141	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	85-90
19903471-0	2010	Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel.	Paclitaxel	107-117	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	24-28
19397590-6	2009	Western blot analysis showed that As(2)O(3) significantly blocked phosphorylation of BubR1, Cdc20, and Cdc27 in cells treated with paclitaxel, suggesting that arsenic compromised the activation of the spindle checkpoint.	Paclitaxel	131-141	cell division cycle 27	Homo sapiens	103-108
19491198-7	2009	Using a model system of paired breast cancer cell lines, we found that coactivation of STAT5 and STAT3 leads to decreased proliferation and increased sensitivity to the chemotherapeutic drugs paclitaxel and vinorelbine compared with cells that have only STAT3 activation.	Paclitaxel	192-202	signal transducer and activator of transcription 5A	Homo sapiens	87-92
19954024-5	2009	Drug sensitivity of si-Twist1 HNE1 to taxol was determined by Annexin V-fluorescein isothiocyanate( FITC)/propidium lodide (PI) double-labeled flow cytometry and detection of DNA ladder.	Paclitaxel	38-43	annexin A5	Homo sapiens	62-71
19954024-7	2009	RESULTS: Annexin V- FITC-PI assay showed that apoptosis ratio was 40.2% in si-Twist HNE1 after treated with 10 ng/ml taxol, significantly higher than that in the control siRNA group 24.3%.	Paclitaxel	117-122	annexin A5	Homo sapiens	9-18
20641892-11	2004	Using HGS-ETR2 labeled with radioactive indium ((111)In) ((111)In -EC-HGS-ETR2), the investigators determined that the activity of HGS-ETR2 was increased because the pretreatment with paclitaxel upregulated the expression of TRAIL-R2 in Colo205 cell xenograft tumors in nude mice.	Paclitaxel	184-194	TNF receptor superfamily member 10b	Homo sapiens	225-233
19412420-9	2009	If confirmed in larger studies, treatment with nab-paclitaxel may convert a poor prognosis SPARC-positive patient population into a group with better clinical outcomes.	Paclitaxel	51-61	secreted protein acidic and cysteine rich	Homo sapiens	91-96
19270727-0	2009	RanBP1 downregulation sensitizes cancer cells to taxol in a caspase-3-dependent manner.	Paclitaxel	49-54	RAN binding protein 1	Homo sapiens	0-6
19270727-4	2009	Several observations indicate that RanBP1 contributes to regulate the function of the mitotic apparatus: RanBP1 inactivation yields hyperstable MTs and induces apoptosis during mitosis, reminiscent of the effects of the MT-stabilizing drug taxol.	Paclitaxel	240-245	RAN binding protein 1	Homo sapiens	35-41
19270727-5	2009	Here we have investigated the influence of RanBP1 on spontaneous and taxol-induced apoptosis in transformed cells.	Paclitaxel	69-74	RAN binding protein 1	Homo sapiens	43-49
19270727-7	2009	Furthermore, RanBP1-interfered cells show an increased apoptotic response to taxol compared to their counterpart with normal or high RanBP1 levels, and this response is caspase-3 dependent.	Paclitaxel	77-82	RAN binding protein 1	Homo sapiens	13-19
19270727-7	2009	Furthermore, RanBP1-interfered cells show an increased apoptotic response to taxol compared to their counterpart with normal or high RanBP1 levels, and this response is caspase-3 dependent.	Paclitaxel	77-82	RAN binding protein 1	Homo sapiens	133-139
18802696-4	2009	Paclitaxel treatment decreased Treg numbers in a TLR4-independent fashion, and preferentially affected cycling Treg expressing high levels of FoxP3.	Paclitaxel	0-10	forkhead box P3	Mus musculus	142-147
18802696-5	2009	The paclitaxel-induced reduction in Treg FoxP3 expression was associated with reduced inhibitory function.	Paclitaxel	4-14	forkhead box P3	Mus musculus	41-46
19065664-10	2009	These results indicate that IL13-PE38 in combination with paclitaxel acting via different mechanisms may be a potential treatment option for IL-13Ralpha2 expressing OSCC or for the treatment of non-IL-13Ralpha2 expressing OSCC combined with gene transfer of IL-13Ralpha2.	Paclitaxel	58-68	interleukin 13 receptor, alpha 2	Mus musculus	141-153
19228748-4	2009	EXPERIMENTAL DESIGN: Drug sensitivity of paclitaxel or cisplatin was assessed in ovarian cancer cell lines treated with small interfering RNA of tubulin isoforms, MAP4, and stathmin.	Paclitaxel	41-51	stathmin 1	Homo sapiens	173-181
19099191-5	2009	Blocking P-gp activity or depletion of PrP(c) inhibited paclitaxel (P-gp substrate)- induced invasion.	Paclitaxel	56-66	phosphoglycolate phosphatase	Homo sapiens	9-13
19099191-5	2009	Blocking P-gp activity or depletion of PrP(c) inhibited paclitaxel (P-gp substrate)- induced invasion.	Paclitaxel	56-66	phosphoglycolate phosphatase	Homo sapiens	68-72
19099191-6	2009	Paclitaxel further facilitated the formation of P-gp/PrP(c) clusters residing in caveolar domains and promoted the association of P-gp with caveolin-1.	Paclitaxel	0-10	phosphoglycolate phosphatase	Homo sapiens	48-52
19099191-6	2009	Paclitaxel further facilitated the formation of P-gp/PrP(c) clusters residing in caveolar domains and promoted the association of P-gp with caveolin-1.	Paclitaxel	0-10	phosphoglycolate phosphatase	Homo sapiens	130-134
19239702-0	2009	Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells.	Paclitaxel	14-24	cyclin dependent kinase 1	Homo sapiens	40-44
19239702-4	2009	We hypothesized that cyclin-dependent kinase (CDK) 1 activity and CDK2 activity in cancer cells, which reflect the activation state of the spindle assembly checkpoint and the growth state, respectively, predict sensitivity to paclitaxel.	Paclitaxel	226-236	cyclin dependent kinase 1	Homo sapiens	21-52
19239702-9	2009	Among the breast cancer xenograft tumors, however, tumors with significantly increased CDK1 specific activity after paclitaxel treatment were sensitive to paclitaxel in vivo, whereas tumors without such an increase were resistant to paclitaxel in vivo.	Paclitaxel	116-126	cyclin dependent kinase 1	Homo sapiens	87-91
19239702-9	2009	Among the breast cancer xenograft tumors, however, tumors with significantly increased CDK1 specific activity after paclitaxel treatment were sensitive to paclitaxel in vivo, whereas tumors without such an increase were resistant to paclitaxel in vivo.	Paclitaxel	155-165	cyclin dependent kinase 1	Homo sapiens	87-91
19239702-9	2009	Among the breast cancer xenograft tumors, however, tumors with significantly increased CDK1 specific activity after paclitaxel treatment were sensitive to paclitaxel in vivo, whereas tumors without such an increase were resistant to paclitaxel in vivo.	Paclitaxel	155-165	cyclin dependent kinase 1	Homo sapiens	87-91
19239702-11	2009	CONCLUSIONS: The change in CDK1 specific activity of xenograft tumors after paclitaxel treatment and the CDK2 specific activity before paclitaxel treatment are both associated with the drug sensitivity in vivo.	Paclitaxel	76-86	cyclin dependent kinase 1	Homo sapiens	27-31
19239702-11	2009	CONCLUSIONS: The change in CDK1 specific activity of xenograft tumors after paclitaxel treatment and the CDK2 specific activity before paclitaxel treatment are both associated with the drug sensitivity in vivo.	Paclitaxel	135-145	cyclin dependent kinase 1	Homo sapiens	27-31
19421315-0	2009	MYC prevents apoptosis and enhances endoreduplication induced by paclitaxel.	Paclitaxel	65-75	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-3
19421315-6	2009	We used the microtubules damaging agent paclitaxel (PTX), to arrest the cells in the M phase, in a p53 mutated melanoma cell line with modulated Myc level and activity.	Paclitaxel	40-50	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	145-148
19421315-6	2009	We used the microtubules damaging agent paclitaxel (PTX), to arrest the cells in the M phase, in a p53 mutated melanoma cell line with modulated Myc level and activity.	Paclitaxel	52-55	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	145-148
19421315-8	2009	The PTX-induced endoreduplication is associated in Myc overexpressing cells with a reduced expression of MAD2, essential component of the molecular core of the spindle assembly checkpoint (SAC), indicating an impairment of this checkpoint.	Paclitaxel	4-7	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	51-54
19421315-8	2009	The PTX-induced endoreduplication is associated in Myc overexpressing cells with a reduced expression of MAD2, essential component of the molecular core of the spindle assembly checkpoint (SAC), indicating an impairment of this checkpoint.	Paclitaxel	4-7	mitotic arrest deficient 2 like 1	Homo sapiens	105-109
18762368-0	2008	S100P sensitizes ovarian cancer cells to carboplatin and paclitaxel in vitro.	Paclitaxel	57-67	S100 calcium binding protein P	Homo sapiens	0-5
18762368-6	2008	Alternatively, with down-regulation of S100P by siRNA, the IC50 to carboplatin and paclitaxel increased in each case (p&lt;0.05), which was significantly higher compared to untransfected cells.	Paclitaxel	83-93	S100 calcium binding protein P	Homo sapiens	39-44
18762368-7	2008	CONCLUSION: Changes in expression levels of S100P in SKOV3 and OVCAR3 cells results in variable susceptibility to carboplatin and paclitaxel.	Paclitaxel	130-140	S100 calcium binding protein P	Homo sapiens	44-49
18762368-8	2008	These data suggest that S100P contributes to chemosensitivity to carboplatin and paclitaxel in ovarian cancer cells.	Paclitaxel	81-91	S100 calcium binding protein P	Homo sapiens	24-29
18977229-2	2008	Murine but not human cells expressing MD-2/TLR4 are also activated by paclitaxel.	Paclitaxel	70-80	toll like receptor 4	Homo sapiens	43-47
19010841-10	2008	Finally, oral administration of the IDO inhibitor 1-methyl-D-tryptophan in combination with paclitaxel in AMEC-IDO-xenografted mice strongly potentiated the antitumor effect of paclitaxel, resulting in significantly prolonged survival.	Paclitaxel	92-102	indoleamine 2,3-dioxygenase 1	Mus musculus	111-114
19010841-10	2008	Finally, oral administration of the IDO inhibitor 1-methyl-D-tryptophan in combination with paclitaxel in AMEC-IDO-xenografted mice strongly potentiated the antitumor effect of paclitaxel, resulting in significantly prolonged survival.	Paclitaxel	177-187	indoleamine 2,3-dioxygenase 1	Mus musculus	36-39
20023432-0	2010	Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery.	Paclitaxel	25-35	matrix metallopeptidase 2	Mus musculus	70-74
19010841-10	2008	Finally, oral administration of the IDO inhibitor 1-methyl-D-tryptophan in combination with paclitaxel in AMEC-IDO-xenografted mice strongly potentiated the antitumor effect of paclitaxel, resulting in significantly prolonged survival.	Paclitaxel	177-187	indoleamine 2,3-dioxygenase 1	Mus musculus	111-114
20023432-4	2010	In the present study, we designed and synthesized two PTX prodrugs by conjugating PTX at different sites with an octapeptide (AcGPLGIAGQ) that can be cleaved by MMP2 at tumor sites.	Paclitaxel	54-57	matrix metallopeptidase 2	Mus musculus	161-165
18804099-10	2008	After treatment with Taxol, increases in p-Akt and VEGF could maintain survival and angiogenesis, respectively, in PTEN-negative glioblastoma.	Paclitaxel	21-26	phosphatase and tensin homolog	Homo sapiens	115-119
20023432-4	2010	In the present study, we designed and synthesized two PTX prodrugs by conjugating PTX at different sites with an octapeptide (AcGPLGIAGQ) that can be cleaved by MMP2 at tumor sites.	Paclitaxel	82-85	matrix metallopeptidase 2	Mus musculus	161-165
20023432-9	2010	Together, our results indicate the potential of the tumor-targeted delivery of PTX to exploit the specific recognition of MMP2, reduce toxicity, and selectively kill tumor cells.	Paclitaxel	79-82	matrix metallopeptidase 2	Mus musculus	122-126
18804099-11	2008	As a single chemotherapy, Taxol might be more efficacious in PTEN-positive glioblastoma than in PTEN-negative glioblastoma.	Paclitaxel	26-31	phosphatase and tensin homolog	Homo sapiens	61-65
19918798-5	2010	PTX/LPC combination acted by favoring p53 stabilization through a lowering in p-Akt levels and in ps166-MDM2, the phosphorylated-MDM2 form that enters the nucleus and induces p53 export and degradation.	Paclitaxel	0-3	MDM2 proto-oncogene	Homo sapiens	104-108
19918798-5	2010	PTX/LPC combination acted by favoring p53 stabilization through a lowering in p-Akt levels and in ps166-MDM2, the phosphorylated-MDM2 form that enters the nucleus and induces p53 export and degradation.	Paclitaxel	0-3	MDM2 proto-oncogene	Homo sapiens	129-133
18804099-12	2008	Thus, our study showed differential sensitivity of PTEN-positive and PTEN-negative glioblastoma cells to Taxol.	Paclitaxel	105-110	phosphatase and tensin homolog	Homo sapiens	51-55
19918798-8	2010	PTX/LPC treatment induced a weakness of Akt-MDM2-p53 complex and increased nuclear p53 levels.	Paclitaxel	0-3	MDM2 proto-oncogene	Homo sapiens	44-48
18804099-12	2008	Thus, our study showed differential sensitivity of PTEN-positive and PTEN-negative glioblastoma cells to Taxol.	Paclitaxel	105-110	phosphatase and tensin homolog	Homo sapiens	69-73
19781537-11	2010	The ATO/PTX combination also significantly enhanced the activation of spindle checkpoint by inducing the formation of the inhibitory checkpoint complex BubR1/Cdc20.	Paclitaxel	8-11	cell division cycle 20	Homo sapiens	158-163
18794097-1	2008	PURPOSE: To evaluate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of liposome-entrapped paclitaxel easy-to-use (LEP-ETU) and to characterize the relationship between LEP-ETU concentrations and the time course of neutropenia in cancer patients.	Paclitaxel	130-140	leptin	Homo sapiens	154-157
19944065-0	2010	(-)-Epigallocatechin-3-gallate decreases thrombin/paclitaxel-induced endothelial tissue factor expression via the inhibition of c-Jun terminal NH2 kinase phosphorylation.	Paclitaxel	50-60	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	128-133
20078855-16	2010	EGCG overcame paclitaxel-induced GRP78 expression and potentiated paclitaxel-induced JNK phosphorylation in 4T1 cells both in vitro and in vivo.	Paclitaxel	66-76	mitogen-activated protein kinase 8	Mus musculus	85-88
18794097-9	2008	The PK/PD model showed that LEP-ETU inhibition of neutrophil proliferation was 9.1% per 10 mug/mL of total paclitaxel concentration.	Paclitaxel	107-117	leptin	Homo sapiens	28-31
19637935-2	2010	The uptake of PTX was found to be facilitated by the scavenger receptor type B-1 (SR-B1) when drug-loaded rHDL particles were incubated with cells that express the SRB1 receptor.	Paclitaxel	14-17	scavenger receptor class B member 1	Homo sapiens	53-80
19637935-2	2010	The uptake of PTX was found to be facilitated by the scavenger receptor type B-1 (SR-B1) when drug-loaded rHDL particles were incubated with cells that express the SRB1 receptor.	Paclitaxel	14-17	scavenger receptor class B member 1	Homo sapiens	82-87
19637935-3	2010	Studies with double-labeled, PTX containing rHDL nanoparticles showed that prostate cancer (PC-3) cells incorporated PTX primarily via a selective (SR-B1 type) uptake mechanism.	Paclitaxel	117-120	scavenger receptor class B member 1	Homo sapiens	148-153
20113171-1	2010	Lipid nano-emulsions (LNEs) having a mean droplet size of approximately 50 nm were investigated as drug carriers for paclitaxel (TXL) to achieve its satisfactory loadings and to develop a pharmaceutically acceptable alternative to the current formulation, Taxol.	Paclitaxel	117-127	thioredoxin like 1	Homo sapiens	129-132
19725034-0	2010	CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer.	Paclitaxel	48-58	tensin 4	Homo sapiens	0-4
19725034-0	2010	CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer.	Paclitaxel	48-58	tensin 4	Homo sapiens	5-13
19725034-4	2010	We investigated the possibility that CTEN overexpression restores paclitaxel sensitivity.	Paclitaxel	66-76	tensin 4	Homo sapiens	37-41
19725034-5	2010	METHODS: We investigated how knockdown and overexpression of CTEN in androgen-independent cell lines affect paclitaxel sensitivity by colony formation assay and growth inhibition assay.	Paclitaxel	108-118	tensin 4	Homo sapiens	61-65
19725034-6	2010	To determine the mechanisms by which CTEN affects paclitaxel sensitivity, we investigated the relationships between CTEN and F-actin or epidermal growth factor receptor (EGFR) in PC-3 cells.	Paclitaxel	50-60	tensin 4	Homo sapiens	37-41
19725034-8	2010	RESULTS: Down-regulation of CTEN, which is located in the cytoskeleton, played an important role in paclitaxel resistance in PC-3-TxR cells.	Paclitaxel	100-110	tensin 4	Homo sapiens	28-32
19725034-9	2010	Knockdown of CTEN expression in PC-3 cells induced paclitaxel resistance.	Paclitaxel	51-61	tensin 4	Homo sapiens	13-17
19725034-10	2010	Overexpression of CTEN in PC-3-TxR and DU145-TxR cells restored paclitaxel sensitivity.	Paclitaxel	64-74	tensin 4	Homo sapiens	18-22
19725034-12	2010	Then knockdown of actin and EGFR in PC-3-TxR cells recovered paclitaxel sensitivity, indicating that CTEN down-regulation mediates paclitaxel resistance through elevation of EGFR and actin expression.	Paclitaxel	61-71	tensin 4	Homo sapiens	101-105
19725034-12	2010	Then knockdown of actin and EGFR in PC-3-TxR cells recovered paclitaxel sensitivity, indicating that CTEN down-regulation mediates paclitaxel resistance through elevation of EGFR and actin expression.	Paclitaxel	131-141	tensin 4	Homo sapiens	101-105
19725034-14	2010	CONCLUSIONS: These results strongly suggested that CTEN plays an important role in paclitaxel sensitivity and that CTEN expression level may be a prognostic predictive factor for PCa patients.	Paclitaxel	83-93	tensin 4	Homo sapiens	51-55
20173382-2	2010	We report 2 cases of advanced adenocarcinoma of the urinary tract producing carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125), which were completely resected after induction chemotherapy with paclitaxel and carboplatin.	Paclitaxel	246-256	mucin 16, cell surface associated	Homo sapiens	173-178
19747165-0	2009	Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway.	Paclitaxel	20-30	mesothelin	Homo sapiens	0-10
19747165-4	2009	Cancer tissues in paclitaxel-resistant ovarian cancer patients expressed higher levels of mesothelin as assessed using real-time PCR than paclitaxel-sensitive ovarian cancer patients (the mean crossing point value change of mesothelin was 26.9+/-0.4 in the resistant group and 34.3+/-0.7 for the sensitive group; P&lt;0.001).	Paclitaxel	18-28	mesothelin	Homo sapiens	90-100
19747165-4	2009	Cancer tissues in paclitaxel-resistant ovarian cancer patients expressed higher levels of mesothelin as assessed using real-time PCR than paclitaxel-sensitive ovarian cancer patients (the mean crossing point value change of mesothelin was 26.9+/-0.4 in the resistant group and 34.3+/-0.7 for the sensitive group; P&lt;0.001).	Paclitaxel	18-28	mesothelin	Homo sapiens	224-234
19747165-5	2009	Mesothelin also protected cells from paclitaxel-induced apoptosis.	Paclitaxel	37-47	mesothelin	Homo sapiens	0-10
19826413-8	2009	In MyD88(+) SCOV3 cells, LPS or PTX binding to TLR4 induced IRAK4 activation and cJun phosphorylation, activated the NF-kappaB pathway and promoted interleukin (IL)-8, IL-6, vascular endothelial growth factor and monocyte chemotactic protein-1 production and resistance to drug-induced apoptosis.	Paclitaxel	32-35	interleukin 1 receptor associated kinase 4	Homo sapiens	60-65
19826413-8	2009	In MyD88(+) SCOV3 cells, LPS or PTX binding to TLR4 induced IRAK4 activation and cJun phosphorylation, activated the NF-kappaB pathway and promoted interleukin (IL)-8, IL-6, vascular endothelial growth factor and monocyte chemotactic protein-1 production and resistance to drug-induced apoptosis.	Paclitaxel	32-35	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	81-85
20017221-1	2009	AIM: To explore the relationship between alteration in the expression of TWIST, highly conserved transcription factor from the basic helix-loop-helix family, and apoptosis of Hep-2 cells induced by chemotherapeutic agent paclitaxel.	Paclitaxel	221-231	DNL-type zinc finger	Homo sapiens	175-178
20017221-3	2009	Viability of Hep-2 cells treated with various concentrations of paclitaxel was examined by cell proliferation assay.	Paclitaxel	64-74	DNL-type zinc finger	Homo sapiens	13-16
20017221-9	2009	Both mRNA and protein expression of TWIST was markedly decreased at both mRNA levels and protein levels, at 24 hours, 48 hours, and 72 hours in the paclitaxel-induced apoptosis of Hep-2 cells (P&lt;0.001).	Paclitaxel	148-158	DNL-type zinc finger	Homo sapiens	180-183
19955925-0	2009	Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients?	Paclitaxel	5-15	BRCA1 DNA repair associated	Homo sapiens	85-89
19588231-0	2009	The enhancement of Raf-1 kinase activity by knockdown of Spry2 is associated with high sensitivity to paclitaxel in v-Ha-ras-transformed NIH 3T3 fibroblasts.	Paclitaxel	102-112	v-raf-leukemia viral oncogene 1	Mus musculus	19-24
19588231-0	2009	The enhancement of Raf-1 kinase activity by knockdown of Spry2 is associated with high sensitivity to paclitaxel in v-Ha-ras-transformed NIH 3T3 fibroblasts.	Paclitaxel	102-112	sprouty RTK signaling antagonist 2	Mus musculus	57-62
19588231-1	2009	We previously demonstrated that the downregulation of Raf-1 kinase may contribute to the development of acquired resistance in paclitaxel-resistant cells.	Paclitaxel	127-137	v-raf-leukemia viral oncogene 1	Mus musculus	54-59
19588231-2	2009	In this study, we determine whether the sensitivities of parental and its v-Ha-ras-transformed NIH 3T3 cells to paclitaxel were dependent on Raf-1 kinase activity.	Paclitaxel	112-122	v-raf-leukemia viral oncogene 1	Mus musculus	141-146
19588231-4	2009	Paclitaxel transiently increased Raf-1 kinase activity in v-Ha-ras-transformed cells while showing no effect on its parental cells, suggesting that the Raf-1-MAP kinase pathway is proapoptotic.	Paclitaxel	0-10	v-raf-leukemia viral oncogene 1	Mus musculus	33-38
19588231-4	2009	Paclitaxel transiently increased Raf-1 kinase activity in v-Ha-ras-transformed cells while showing no effect on its parental cells, suggesting that the Raf-1-MAP kinase pathway is proapoptotic.	Paclitaxel	0-10	v-raf-leukemia viral oncogene 1	Mus musculus	152-157
19588231-5	2009	Furthermore, using siRNA-mediated Raf-1 knockdown analysis, we showed that Raf-1 knockdown cells were more resistant than control cells to paclitaxel treatment.	Paclitaxel	139-149	v-raf-leukemia viral oncogene 1	Mus musculus	34-39
19588231-5	2009	Furthermore, using siRNA-mediated Raf-1 knockdown analysis, we showed that Raf-1 knockdown cells were more resistant than control cells to paclitaxel treatment.	Paclitaxel	139-149	v-raf-leukemia viral oncogene 1	Mus musculus	75-80
19588231-6	2009	In particular, the expression of the gene SPRY2, which has been known to act as an inhibitor on Ras/Raf/MAPK signaling, was downregulated after the treatment with paclitaxel.	Paclitaxel	163-173	sprouty RTK signaling antagonist 2	Mus musculus	42-47
19588231-8	2009	In addition, the Spry2 protein knockdown cells were more susceptible to paclitaxel treatment than control cells.	Paclitaxel	72-82	sprouty RTK signaling antagonist 2	Mus musculus	17-22
19588231-9	2009	Taken together, our results suggest that the enhancement of Raf-1 kinase activity by knockdown of Spry2 is associated with high sensitivity to paclitaxel.	Paclitaxel	143-153	v-raf-leukemia viral oncogene 1	Mus musculus	60-65
19588231-9	2009	Taken together, our results suggest that the enhancement of Raf-1 kinase activity by knockdown of Spry2 is associated with high sensitivity to paclitaxel.	Paclitaxel	143-153	sprouty RTK signaling antagonist 2	Mus musculus	98-103
19861998-7	2009	Intraepithelial CD8-positive T lymphocytes were correlated with improved OS in all optimally debulked patients (P=0.0201) and in those undergoing paclitaxel/carboplatin therapy (P=0.0092).	Paclitaxel	146-156	CD8a molecule	Homo sapiens	16-19
19806032-4	2009	Taxol treatment and immunoprecipitation show that Astrin may interact with the centrosomal proteins Aurora-A or Plk1 to regulate microtubule organization and spindle pole integrity.	Paclitaxel	0-5	polo like kinase 1	Mus musculus	112-116
20079104-0	2009	[Role of TWIST in the apoptosis of Hep-2 cells induced by paclitaxel].	Paclitaxel	58-68	DNL-type zinc finger	Homo sapiens	35-38
19755084-11	2009	Increased apoptosis has been observed in the MDR1 knockdown LSC-1/TAX cells when exposed to paclitaxel (TAX) treatment.	Paclitaxel	92-102	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	45-49
19482477-4	2009	The water-soluble polymer-drug conjugate was designed to release a triple payload of the hydrophobic drug paclitaxel as a result of cleavage by the endogenous enzyme cathepsin B.	Paclitaxel	106-116	cathepsin B	Mus musculus	166-177
19632946-11	2009	Encouraging increases in the NSCLC response rate have already been reported after the addition of an anti-IGF-1R antibody to first-line carboplatin and paclitaxel.	Paclitaxel	152-162	insulin like growth factor 1 receptor	Homo sapiens	106-112
19957654-1	2009	OBJECTIVE: To determine the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced apoptosis in Hep-2 cells by means of systematically evaluating the cytotoxicity of TRAIL alone and TRAIL in combination with chemotherapeutic agents (cisplatin, paclitaxel) or radiation in Hep-2 cells in vitro, and whether the synergistic killing effects correlated with the expression level of TRAIL receptors and the activity of caspase-8 or caspase-9.	Paclitaxel	276-286	DNL-type zinc finger	Homo sapiens	128-131
19957654-6	2009	Cisplatin, paclitaxel and radiation had synergistic inhibitory effects with TRAIL on the growth of Hep-2 cell line.	Paclitaxel	11-21	DNL-type zinc finger	Homo sapiens	99-102
19957654-7	2009	After the activity of caspase-9 was inhibited by Z-LETD-FMK, the inhibition effects of TRAIL, cisplatin and paclitaxel on Hep-2 cells decreased significantly (all P&lt;0.05).	Paclitaxel	108-118	DNL-type zinc finger	Homo sapiens	122-125
19531357-3	2009	In Tetrahymena, deletion of TTLL3 shortened axonemes and increased their resistance to paclitaxel-mediated microtubule stabilization.	Paclitaxel	87-97	tubulin tyrosine ligase-like family, member 3	Danio rerio	28-33
18828019-3	2009	METHODS: We evaluate the association between expression of Pgp1, MRP1, and BCRP proteins and ET-743 or PM00104 resistance in a large panel of multi-drug resistant cell lines derived from histologically unrelated human tumors that were selected with paclitaxel, doxorubicin, cisplatin, mitoxantrane, or gemcitibine.	Paclitaxel	249-259	CD44 molecule (Indian blood group)	Homo sapiens	59-63
19282672-6	2009	Cancer cells cultured in the presence of paclitaxel or doxorubicin exhibit dramatically decreased CDK5RAP2 levels.	Paclitaxel	41-51	CDK5 regulatory subunit associated protein 2	Homo sapiens	98-106
19282672-7	2009	These results suggest that CDK5RAP2 is required for spindle checkpoint function and is a common target in paclitaxel and doxorubicin resistance.	Paclitaxel	106-116	CDK5 regulatory subunit associated protein 2	Homo sapiens	27-35
19276157-13	2009	Our data suggest that EGFR expression and KRAS mutation status is predictive for clinical response to matuzumab +/- paclitaxel in patients with advanced NSCLC.	Paclitaxel	116-126	KRAS proto-oncogene, GTPase	Homo sapiens	42-46
18992308-0	2009	In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3.	Paclitaxel	37-47	integrin subunit alpha V	Homo sapiens	111-134
19190325-0	2009	Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer.	Paclitaxel	87-97	remodeling and spacing factor 1	Homo sapiens	51-56
19190325-0	2009	Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer.	Paclitaxel	87-97	remodeling and spacing factor 1	Homo sapiens	58-63
19190325-4	2009	Rsf-1 (also known as HBXAP) was found to be the only gene in which gene knockdown sensitized tumor cells to paclitaxel.	Paclitaxel	108-118	remodeling and spacing factor 1	Homo sapiens	0-5
19190325-4	2009	Rsf-1 (also known as HBXAP) was found to be the only gene in which gene knockdown sensitized tumor cells to paclitaxel.	Paclitaxel	108-118	remodeling and spacing factor 1	Homo sapiens	21-26
19190325-6	2009	We found that Rsf-1 was up-regulated in paclitaxel-resistant ovarian cancer cell lines, and Rsf-1 immunoreactivity in primary ovarian carcinoma tissues correlated with in vitro paclitaxel resistance.	Paclitaxel	40-50	remodeling and spacing factor 1	Homo sapiens	14-19
19190325-6	2009	We found that Rsf-1 was up-regulated in paclitaxel-resistant ovarian cancer cell lines, and Rsf-1 immunoreactivity in primary ovarian carcinoma tissues correlated with in vitro paclitaxel resistance.	Paclitaxel	177-187	remodeling and spacing factor 1	Homo sapiens	14-19
19190325-6	2009	We found that Rsf-1 was up-regulated in paclitaxel-resistant ovarian cancer cell lines, and Rsf-1 immunoreactivity in primary ovarian carcinoma tissues correlated with in vitro paclitaxel resistance.	Paclitaxel	177-187	remodeling and spacing factor 1	Homo sapiens	92-97
19190325-7	2009	Ectopic expression of Rsf-1 significantly enhanced paclitaxel resistance in ovarian cancer cells.	Paclitaxel	51-61	remodeling and spacing factor 1	Homo sapiens	22-27
19190325-8	2009	Down-regulation of hSNF2H or disruption of hSNF2H and Rsf-1 interaction enhanced paclitaxel sensitivity in tumor cells with Rsf-1 up-regulation.	Paclitaxel	81-91	remodeling and spacing factor 1	Homo sapiens	54-59
19190325-8	2009	Down-regulation of hSNF2H or disruption of hSNF2H and Rsf-1 interaction enhanced paclitaxel sensitivity in tumor cells with Rsf-1 up-regulation.	Paclitaxel	81-91	remodeling and spacing factor 1	Homo sapiens	124-129
19190325-10	2009	In conclusion, our results suggest that Rsf-1 is the major gene within the 11q13.5 amplicon that contributes to paclitaxel resistance, and the formation of the Rsf-1/hSNF2H complex is required for inducing this phenotype.	Paclitaxel	112-122	remodeling and spacing factor 1	Homo sapiens	40-45
19190325-10	2009	In conclusion, our results suggest that Rsf-1 is the major gene within the 11q13.5 amplicon that contributes to paclitaxel resistance, and the formation of the Rsf-1/hSNF2H complex is required for inducing this phenotype.	Paclitaxel	112-122	remodeling and spacing factor 1	Homo sapiens	160-165
19095448-1	2009	Retinoid X receptor (RXR) ligands are attractive candidates for clinical application because of their activity against tamoxifen-resistant breast cancer, taxol-resistant lung cancer, metabolic syndrome, and allergy.	Paclitaxel	154-159	retinoid X receptor alpha	Homo sapiens	0-19
19095448-1	2009	Retinoid X receptor (RXR) ligands are attractive candidates for clinical application because of their activity against tamoxifen-resistant breast cancer, taxol-resistant lung cancer, metabolic syndrome, and allergy.	Paclitaxel	154-159	retinoid X receptor alpha	Homo sapiens	21-24
19396000-9	2009	Despite the limited sample size and nonrandomized nature of this study, these results are provocative and suggest that advanced ovarian cancer patients who achieve an excellent response to primary platinum-based chemotherapy with a CA-125 serum level less than 10 U/mL may be more amenable to the benefits of paclitaxel maintenance therapy.	Paclitaxel	309-319	mucin 16, cell surface associated	Homo sapiens	232-238
19101511-0	2009	Bim is reversibly phosphorylated but plays a limited role in paclitaxel cytotoxicity of breast cancer cell lines.	Paclitaxel	61-71	BCL2-like 11 (apoptosis facilitator)	Mus musculus	0-3
19101511-3	2009	We decided to investigate the regulatory mechanism of the pro-apoptotic BH3-only protein Bim, which is known to play a role in paclitaxel cytotoxicity.	Paclitaxel	127-137	BCL2-like 11 (apoptosis facilitator)	Mus musculus	89-92
19101511-4	2009	We discovered that paclitaxel induces reversible phosphorylation of Bim.	Paclitaxel	19-29	BCL2-like 11 (apoptosis facilitator)	Mus musculus	68-71
19101511-5	2009	Bim initially displays enhanced phosphorylation during paclitaxel-induced mitotic arrest, and then undergoes de-phosphorylation as cells become apoptotic.	Paclitaxel	55-65	BCL2-like 11 (apoptosis facilitator)	Mus musculus	0-3
19101511-9	2009	Clearly it is imperative to define the contribution of Bim in paclitaxel-induced apoptosis of clinically relevant targets in order to rationally develop enhanced treatment strategies.	Paclitaxel	62-72	BCL2-like 11 (apoptosis facilitator)	Mus musculus	55-58
19087722-10	2008	Lysis of caspase-9 and PARP in the Ark2 and KLE cells increased greatly 24 hours after the TSA and PTX treatment.	Paclitaxel	99-102	caspase 9	Homo sapiens	9-18
18555006-4	2008	Furthermore, endogenous expression of p19(ras) and p73beta is significantly increased by Taxol treatment, and Taxol-enhanced endogenous p73beta transcriptional activities are further amplified by p19(ras), which markedly increased cellular apoptosis in p53-null SAOS2 cancer cell line.	Paclitaxel	89-94	interleukin 23 subunit alpha	Homo sapiens	38-41
19697632-0	2009	Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy.	Paclitaxel	87-97	BRCA1 DNA repair associated	Homo sapiens	61-66
18555006-4	2008	Furthermore, endogenous expression of p19(ras) and p73beta is significantly increased by Taxol treatment, and Taxol-enhanced endogenous p73beta transcriptional activities are further amplified by p19(ras), which markedly increased cellular apoptosis in p53-null SAOS2 cancer cell line.	Paclitaxel	110-115	interleukin 23 subunit alpha	Homo sapiens	38-41
18555006-4	2008	Furthermore, endogenous expression of p19(ras) and p73beta is significantly increased by Taxol treatment, and Taxol-enhanced endogenous p73beta transcriptional activities are further amplified by p19(ras), which markedly increased cellular apoptosis in p53-null SAOS2 cancer cell line.	Paclitaxel	110-115	interleukin 23 subunit alpha	Homo sapiens	196-199
18400375-8	2008	EGF plus EGFR inhibitor-primed ovarian cancer cells display increased sensitivity to taxol-induced cell death, resistant to EGF-induced cell migration and cell proliferation as well as ERK and PI3K/AKT activation.	Paclitaxel	85-90	epidermal growth factor	Homo sapiens	0-3
18938075-1	2008	Several novel gadolinium chelates conjugated with paclitaxel, colchicine and thyroxine have been prepared as MRI contrast agents targeted to tubulin and thyroxine-binding globulin, respectively.	Paclitaxel	50-60	serpin family A member 7	Homo sapiens	153-179
18977229-2	2008	Murine but not human cells expressing MD-2/TLR4 are also activated by paclitaxel.	Paclitaxel	70-80	lymphocyte antigen 96	Homo sapiens	38-42
18400375-8	2008	EGF plus EGFR inhibitor-primed ovarian cancer cells display increased sensitivity to taxol-induced cell death, resistant to EGF-induced cell migration and cell proliferation as well as ERK and PI3K/AKT activation.	Paclitaxel	85-90	epidermal growth factor	Homo sapiens	9-12
17960385-8	2008	1 muM PTX was found to increase cyclin B1 production in MKN28 cells, but not in MKN 45 cells.	Paclitaxel	6-9	cyclin B1	Homo sapiens	32-41
18803635-4	2008	Three substrates, paclitaxel, tolbutamide and omeprazole, were chosen, as they are metabolized by three different CYP2C isoenzymes in human beings.	Paclitaxel	18-28	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	114-119
17960385-11	2008	CONCLUSION: Both p53 status and cyclin-B1 expression might be useful for predicting the therapeutic response of stomach cancer to PTX.	Paclitaxel	130-133	cyclin B1	Homo sapiens	32-41
18508881-6	2008	After oral administration of PLX, areas under the curve (AUC) in plasma, lung, and s.c. tumors were significantly higher (2.98, 2.66, and 3.41-fold, respectively) in the rIL-2 + PLX group as compared with the PLX group.	Paclitaxel	29-32	interleukin 2	Rattus norvegicus	170-175
17764884-9	2008	CONCLUSION: Our present study has suggested that GSTP1 protein expression, but not GSTP1 methylation status, might be associated with response to docetaxel and paclitaxel.	Paclitaxel	160-170	glutathione S-transferase pi 1	Homo sapiens	49-54
18771959-6	2008	Importantly, the inhibitory function of Treg was significantly impaired, while the production of Th1 cytokines IFN-gamma and IL-2 and the expression of the activation marker CD44 among CD4(+) and CD8(+) T cells were augmented after paclitaxel treatment.	Paclitaxel	232-242	CD44 molecule (Indian blood group)	Homo sapiens	174-178
17764884-10	2008	This suggests that GSTP1 immunohistochemical expression might be a potentially clinically useful predictive factor for response to docetaxel and paclitaxel.	Paclitaxel	145-155	glutathione S-transferase pi 1	Homo sapiens	19-24
18644986-0	2008	Role of activating transcription factor 3 on TAp73 stability and apoptosis in paclitaxel-treated cervical cancer cells.	Paclitaxel	78-88	activating transcription factor 3	Homo sapiens	8-41
18577449-4	2008	In this paper, we propose and test novel models for drug (notably paclitaxel) release from films made of neat poly (epsilon-caprolactone) PCL, neat poly (dl-lactide-co-glycolide) PLGA and their blends.	Paclitaxel	66-76	PHD finger protein 1	Homo sapiens	138-141
18650420-4	2008	However, whether PTX binds to human MD-2 and how MD-2 and TLR4 interact with PTX are not well defined.	Paclitaxel	17-20	lymphocyte antigen 96	Homo sapiens	36-40
18644986-4	2008	In wild-type activating transcription factor 3 (ATF3)-overexpressed cells, paclitaxel enhanced apoptosis through increased alpha and beta isoform expression of TAp73; however, these events were attenuated in cells containing inactive COOH-terminal-deleted ATF3 [ATF3(DeltaC)] or ATF3 siRNA.	Paclitaxel	75-85	activating transcription factor 3	Homo sapiens	13-46
18650420-4	2008	However, whether PTX binds to human MD-2 and how MD-2 and TLR4 interact with PTX are not well defined.	Paclitaxel	77-80	lymphocyte antigen 96	Homo sapiens	49-53
18650420-5	2008	Recombinant human MD-2 (rhMD-2) was produced in a Pichia pastoris expression system, and the interaction between rhMD-2 and PTX was assessed by an enzyme-linked immunosorbent assay to show that PTX binds rhMD-2.	Paclitaxel	124-127	lymphocyte antigen 96	Homo sapiens	18-22
18644986-4	2008	In wild-type activating transcription factor 3 (ATF3)-overexpressed cells, paclitaxel enhanced apoptosis through increased alpha and beta isoform expression of TAp73; however, these events were attenuated in cells containing inactive COOH-terminal-deleted ATF3 [ATF3(DeltaC)] or ATF3 siRNA.	Paclitaxel	75-85	activating transcription factor 3	Homo sapiens	48-52
18650420-5	2008	Recombinant human MD-2 (rhMD-2) was produced in a Pichia pastoris expression system, and the interaction between rhMD-2 and PTX was assessed by an enzyme-linked immunosorbent assay to show that PTX binds rhMD-2.	Paclitaxel	194-197	lymphocyte antigen 96	Homo sapiens	18-22
18650420-7	2008	As measured by human tumor necrosis factor alpha production, human THP-1 monocytes expressing TLR4 and MD-2 were poorly responsive to the addition of PTX, but murine macrophages expressing TLR4 and MD-2 responded in a dose-dependent manner.	Paclitaxel	150-153	lymphocyte antigen 96	Homo sapiens	103-107
18644986-4	2008	In wild-type activating transcription factor 3 (ATF3)-overexpressed cells, paclitaxel enhanced apoptosis through increased alpha and beta isoform expression of TAp73; however, these events were attenuated in cells containing inactive COOH-terminal-deleted ATF3 [ATF3(DeltaC)] or ATF3 siRNA.	Paclitaxel	75-85	activating transcription factor 3	Homo sapiens	256-260
18650420-9	2008	However, HEK293 cells transfected with murine MD-2 and human TLR4 or murine MD-2 and murine TLR4 were highly responsive to PTX (10 microm), indicating that the murine MD-2/PTX interaction is required for TLR4 activation.	Paclitaxel	123-126	lymphocyte antigen 96	Homo sapiens	46-50
18650420-9	2008	However, HEK293 cells transfected with murine MD-2 and human TLR4 or murine MD-2 and murine TLR4 were highly responsive to PTX (10 microm), indicating that the murine MD-2/PTX interaction is required for TLR4 activation.	Paclitaxel	123-126	lymphocyte antigen 96	Homo sapiens	76-80
18650420-9	2008	However, HEK293 cells transfected with murine MD-2 and human TLR4 or murine MD-2 and murine TLR4 were highly responsive to PTX (10 microm), indicating that the murine MD-2/PTX interaction is required for TLR4 activation.	Paclitaxel	123-126	lymphocyte antigen 96	Homo sapiens	76-80
18644986-4	2008	In wild-type activating transcription factor 3 (ATF3)-overexpressed cells, paclitaxel enhanced apoptosis through increased alpha and beta isoform expression of TAp73; however, these events were attenuated in cells containing inactive COOH-terminal-deleted ATF3 [ATF3(DeltaC)] or ATF3 siRNA.	Paclitaxel	75-85	activating transcription factor 3	Homo sapiens	52-53
18644986-4	2008	In wild-type activating transcription factor 3 (ATF3)-overexpressed cells, paclitaxel enhanced apoptosis through increased alpha and beta isoform expression of TAp73; however, these events were attenuated in cells containing inactive COOH-terminal-deleted ATF3 [ATF3(DeltaC)] or ATF3 siRNA.	Paclitaxel	75-85	activating transcription factor 3	Homo sapiens	256-260
18644986-5	2008	In contrast, paclitaxel-induced ATF3 expression did not change in TAp73beta-overexpressed or TAp73beta siRNA-cotransfected cells.	Paclitaxel	13-23	activating transcription factor 3	Homo sapiens	32-36
18644986-6	2008	Furthermore, paclitaxel-induced ATF3 translocated into the nucleus where TAp73beta is expressed, but not in ATF3(DeltaC) or TAp73beta siRNA-transfected cells.	Paclitaxel	13-23	activating transcription factor 3	Homo sapiens	32-36
19087722-7	2008	RESULTS: The growth of the Ark2, KLE, and AN3 cells of the TSA, PTX, and TSA + PTX group, especially in the latter group, was inhibited.	Paclitaxel	64-67	aurora kinase B	Homo sapiens	27-31
18644986-9	2008	Additionally, ATF3 induced by paclitaxel potentiated the stability of TAp73beta, not its transcriptional level.	Paclitaxel	30-40	activating transcription factor 3	Homo sapiens	14-18
19087722-7	2008	RESULTS: The growth of the Ark2, KLE, and AN3 cells of the TSA, PTX, and TSA + PTX group, especially in the latter group, was inhibited.	Paclitaxel	79-82	aurora kinase B	Homo sapiens	27-31
18644986-11	2008	Collectively, these results reveal that overexpression of ATF3 potentiates paclitaxel-induced apoptosis of HeLa cells, at least in part, by enhancing TAp73beta"s stability and its transcriptional activity.	Paclitaxel	75-85	activating transcription factor 3	Homo sapiens	58-62
19087722-8	2008	The Ark2 cell apoptotic rates 4 days later of the TSA, PTX, TSA + PTX, and control group were 4.25% +/- 0.25%, 12.12% +/- 0.62%, 16.56% +/- 0.74%, and 46.78% +/- 2.68% respectively by annexin V staining, and 3.39% +/- 0.12%, 6.00% +/- 0.25%, 10.05% +/- 0.53%, and 22.30% +/- 1.25% respectively by Hoechst staining.	Paclitaxel	55-58	aurora kinase B	Homo sapiens	4-8
19080518-1	2008	OBJECTIVE: To study the expression of COP9, JAK2, HSP and NADH genes in ovarian carcinoma tissues after taxol-chemotherapy and their significance.	Paclitaxel	104-109	COP9 signalosome subunit 8	Homo sapiens	38-42
18710614-0	2008	[Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells].	Paclitaxel	31-41	aurora kinase B	Homo sapiens	123-127
18710614-5	2008	This study was to investigate the effect and mechanism of trichostatin A (TSA), a histone deacetylase inhibitor, combined with paclitaxel (PTX) on the apoptosis of human endometrial carcinoma cell line Ark2.	Paclitaxel	127-137	aurora kinase B	Homo sapiens	202-206
18710614-5	2008	This study was to investigate the effect and mechanism of trichostatin A (TSA), a histone deacetylase inhibitor, combined with paclitaxel (PTX) on the apoptosis of human endometrial carcinoma cell line Ark2.	Paclitaxel	139-142	aurora kinase B	Homo sapiens	202-206
19080518-2	2008	METHODS: The up-regulated genes of JAK2, HSP, NADH and the down-regulated gene of COP9, which were revealed by micro-array from our previous study were examined by RT-PCR and real-time-PCR in 33 cases of ovarian cancer who previously received taxol-based chemotherapy (group 1), and 21 cases of ovarian cancer who never received chemotherapy before operation (group 2).	Paclitaxel	243-248	COP9 signalosome subunit 8	Homo sapiens	82-86
18710614-8	2008	RESULTS: Results of Annexin V showed that PTX (1.5 nmol/L) plus TSA (25 nmol/L) induced a significantly higher apoptotic rate (45.2%) than PTX alone (14.1%) or TSA alone (11.2%) did in Ark2 cells after drug treatment for three days.	Paclitaxel	42-45	aurora kinase B	Homo sapiens	185-189
18710614-16	2008	CONCLUSION: TSA and PTX could induce apoptosis of Ark2 cells, which may be through the loss of mitochondrial membrane potential and acetylation of non-histone proteins induced by histone deacetylase inhibitors.	Paclitaxel	20-23	aurora kinase B	Homo sapiens	50-54
18074150-8	2008	Both paclitaxel and 5-FU are able to trigger apoptosis, and furthermore, to upregulate CD95, whereas only paclitaxel increases CD95 ligand expression.	Paclitaxel	5-15	Fas cell surface death receptor	Homo sapiens	87-91
18074150-8	2008	Both paclitaxel and 5-FU are able to trigger apoptosis, and furthermore, to upregulate CD95, whereas only paclitaxel increases CD95 ligand expression.	Paclitaxel	106-116	Fas cell surface death receptor	Homo sapiens	127-131
18074150-9	2008	Neutralizing antibodies directed against CD95 ligand effectively inhibited paclitaxel-induced cell death, thereby providing evidence for a direct involvement of the CD95 system in paclitaxel-induced apoptosis.	Paclitaxel	75-85	Fas cell surface death receptor	Homo sapiens	41-45
18754875-0	2008	Up-regulation of matrix metalloproteinase-3 in the dorsal root ganglion of rats with paclitaxel-induced neuropathy.	Paclitaxel	85-95	matrix metallopeptidase 3	Rattus norvegicus	17-43
18074150-9	2008	Neutralizing antibodies directed against CD95 ligand effectively inhibited paclitaxel-induced cell death, thereby providing evidence for a direct involvement of the CD95 system in paclitaxel-induced apoptosis.	Paclitaxel	75-85	Fas cell surface death receptor	Homo sapiens	165-169
18754875-6	2008	By reverse transcription-polymerase chain reaction, the expression levels of MMP-3 and CD163 were markedly up-regulated in paclitaxel-treated dorsal root ganglion.	Paclitaxel	123-133	matrix metallopeptidase 3	Rattus norvegicus	77-82
18074150-9	2008	Neutralizing antibodies directed against CD95 ligand effectively inhibited paclitaxel-induced cell death, thereby providing evidence for a direct involvement of the CD95 system in paclitaxel-induced apoptosis.	Paclitaxel	180-190	Fas cell surface death receptor	Homo sapiens	41-45
18754875-10	2008	Taken together, the up-regulation of MMP-3 and following macrophage activation caused in the dorsal root ganglion might be a significant event to trigger a series of reactions developing paclitaxel-induced peripheral neuropathic pain.	Paclitaxel	187-197	matrix metallopeptidase 3	Rattus norvegicus	37-42
18074150-9	2008	Neutralizing antibodies directed against CD95 ligand effectively inhibited paclitaxel-induced cell death, thereby providing evidence for a direct involvement of the CD95 system in paclitaxel-induced apoptosis.	Paclitaxel	180-190	Fas cell surface death receptor	Homo sapiens	165-169
18575757-7	2008	The use of paclitaxel in A-549 lung cancer cells transfected with gef gene enhanced the chemotherapeutic effect of this drug.	Paclitaxel	11-21	Rho/Rac guanine nucleotide exchange factor 2	Homo sapiens	66-69
18575757-10	2008	In conclusion, gef gene has a cytotoxic effect in lung cancer cells and enhances cell growth inhibition when used with paclitaxel.	Paclitaxel	119-129	Rho/Rac guanine nucleotide exchange factor 2	Homo sapiens	15-18
18074150-11	2008	As evident from the differential response of our clonal ES subpopulations to paclitaxel and 5-FU, effective activation of the CD95 system depends on intrinsic properties of both the chemotherapeutic agent and target cell population.	Paclitaxel	77-87	Fas cell surface death receptor	Homo sapiens	126-130
18451172-6	2008	The addition of TRAIL to either nocodazole or paclitaxel (Taxol) reduced levels of the mitotic checkpoint proteins BubR1 and Bub1.	Paclitaxel	46-56	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	115-120
18452161-7	2008	Paclitaxel-induced Bax/Bak translocation to the ER and Bax dimerization on the ER membrane occurred within 3 h, which led to a Ca(2+) efflux into cytosol.	Paclitaxel	0-10	BCL2 antagonist/killer 1	Homo sapiens	23-26
18451172-6	2008	The addition of TRAIL to either nocodazole or paclitaxel (Taxol) reduced levels of the mitotic checkpoint proteins BubR1 and Bub1.	Paclitaxel	58-63	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	115-120
18377724-0	2008	CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs.	Paclitaxel	54-59	chromosome segregation 1 like	Homo sapiens	0-5
18411046-6	2008	Fibroblast-derived three-dimensional matrix increased beta1-integrin-dependent survival of a subset of human cancer cell lines during taxol treatment, while it sensitized or minimally influenced survival of other cells.	Paclitaxel	134-139	integrin subunit beta 1	Homo sapiens	54-68
18411046-7	2008	beta1-integrin-dependent changes in cell resistance to taxol did not correlate with the degree of modulation of FAK and Akt, implying that additional signaling factors are involved.	Paclitaxel	55-60	integrin subunit beta 1	Homo sapiens	0-14
18420585-4	2008	Upon paclitaxel treatment, RACK1, DLC1, and CIS mediated the degradation of BimEL through the ElonginB/C-Cullin2-CIS ubiquitin-protein isopeptide ligase complex.	Paclitaxel	5-15	receptor for activated C kinase 1	Homo sapiens	27-32
18420585-5	2008	We further showed that RACK1 conferred paclitaxel resistance to breast cancer cells in vitro and in vivo.	Paclitaxel	39-49	receptor for activated C kinase 1	Homo sapiens	23-28
18377724-0	2008	CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs.	Paclitaxel	54-59	chromosome segregation 1 like	Homo sapiens	6-9
18377724-0	2008	CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs.	Paclitaxel	54-59	regulator of microtubule dynamics 1	Homo sapiens	13-43
18377724-0	2008	CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs.	Paclitaxel	61-71	chromosome segregation 1 like	Homo sapiens	0-5
18377724-0	2008	CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs.	Paclitaxel	61-71	chromosome segregation 1 like	Homo sapiens	6-9
18519777-1	2008	BACKGROUND: 17-Allylamino-17-demethoxygeldanamycin (17-AAG) inhibits heat shock protein 90, promotes degradation of oncoproteins, and exhibits synergy with paclitaxel in vitro.	Paclitaxel	156-166	N-methylpurine DNA glycosylase	Homo sapiens	55-58
18377724-0	2008	CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs.	Paclitaxel	61-71	regulator of microtubule dynamics 1	Homo sapiens	13-43
18519777-12	2008	The ratio of paclitaxel area under the concentration to time curve when given alone versus in combination with 17-AAG was 0.97 +/- 0.20.	Paclitaxel	13-23	N-methylpurine DNA glycosylase	Homo sapiens	114-117
18377724-4	2008	Our results showed that CAS overexpression enhanced apoptosis induced by doxorubicin, 5-fluorouracil, cisplatin, and tamoxifen, but inhibited paclitaxel-induced apoptosis of cancer cells.	Paclitaxel	142-152	chromosome segregation 1 like	Homo sapiens	24-27
18377724-8	2008	Paclitaxel can induce G2/M phase cell cycle arrest and microtubule aster formation during apoptosis induction, but CAS overexpression reduced paclitaxel-induced G2/M phase cell cycle arrest and microtubule aster formation.	Paclitaxel	142-152	chromosome segregation 1 like	Homo sapiens	115-118
18256541-7	2008	Prolonged treatment with two commonly-used chemotoxic compounds, doxorubicin and paclitaxel, caused increased activation of ERK in PTEN-positive DU145 cells, but not PTEN-negative PC3 cells.	Paclitaxel	81-91	phosphatase and tensin homolog	Homo sapiens	131-135
18547972-1	2008	AIM: The aim of this study was to evaluate the prognostic value of the serum CA-125 level for complete responders after 6 cycles of primary adjuvant paclitaxel/carboplatin chemotherapy in advanced epithelial ovarian cancer.	Paclitaxel	149-159	mucin 16, cell surface associated	Homo sapiens	77-83
18547972-7	2008	CONCLUSION: The serum CA-125 level after 6 cycles of primary adjuvant paclitaxel/carboplatin chemotherapy may be a good prognostic factor for survival in complete responders after 6 cycles of chemotherapy in advanced epithelial ovarian cancer.	Paclitaxel	70-80	mucin 16, cell surface associated	Homo sapiens	22-28
18256541-7	2008	Prolonged treatment with two commonly-used chemotoxic compounds, doxorubicin and paclitaxel, caused increased activation of ERK in PTEN-positive DU145 cells, but not PTEN-negative PC3 cells.	Paclitaxel	81-91	phosphatase and tensin homolog	Homo sapiens	166-170
18068334-5	2008	Taxol resulted in the activation of apoptosis signal regulated kinase (ASK)1, c-jun NH(2)-terminal kinase (JNK), p38(MAPK) and extracellular-regulated kinase (ERK) together with the downregulation of uncoupling protein 2 (UCP2).	Paclitaxel	0-5	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	71-76
18630511-5	2008	In addition, the knockdown of CDC20 caused enhancement of the cytotoxicity of paclitaxel and increased the effect of gamma-irradiation against pancreatic carcinoma cells.	Paclitaxel	78-88	cell division cycle 20	Homo sapiens	30-35
18281778-0	2008	[Remarkably reduced tumor marker SCC levels by combined chemotherapy of paclitaxel and S-1 in two cases of advanced cervical cancer].	Paclitaxel	72-82	serpin family B member 3	Homo sapiens	33-36
18281778-6	2008	In September, paclitaxel/S-1 therapy was performed, and the tumor markers were again reduced remarkably (SCC 9.8--&gt; 1.3 ng/mL).	Paclitaxel	14-24	serpin family B member 3	Homo sapiens	105-108
17900261-0	2007	Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3"-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.	Paclitaxel	139-149	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	75-105
17900261-1	2007	Paclitaxel (PTX), one of the key drugs used to treat ovarian cancer, activates the Raf-mitogen-activated protein kinase kinase (MEK) and phosphatidylinositol 3"-kinase (PI3K) pathways, both considered to be proliferation and cell-survival pathways.	Paclitaxel	0-10	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	137-167
17932689-2	2008	Valspodar significantly increased the brain levels of paclitaxel by inhibition of p-gp expressed at the blood brain barrier.	Paclitaxel	54-64	phosphoglycolate phosphatase	Mus musculus	82-86
17932689-4	2008	However, the paclitaxel dose had to be reduced because of toxic side effects resulting from increased drug levels due to p-gp modulation in peripheral tissues.	Paclitaxel	13-23	phosphoglycolate phosphatase	Mus musculus	121-125
17932689-5	2008	Therefore, in the present study we examined the co-application of paclitaxel with the third generation ABCB1 modulators elacridar and tariquidar, which were supposed to preferentially modulate p-gp in brain capillaries.	Paclitaxel	66-76	phosphoglycolate phosphatase	Mus musculus	193-197
17900261-1	2007	Paclitaxel (PTX), one of the key drugs used to treat ovarian cancer, activates the Raf-mitogen-activated protein kinase kinase (MEK) and phosphatidylinositol 3"-kinase (PI3K) pathways, both considered to be proliferation and cell-survival pathways.	Paclitaxel	12-15	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	137-167
18056463-8	2007	We also show that CRx-026 synergizes in vitro and in vivo with the microtubule-binding agents paclitaxel and vinorelbine.	Paclitaxel	94-104	cone-rod homeobox	Homo sapiens	18-21
18029193-0	2007	Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro.	Paclitaxel	78-88	diablo IAP-binding mitochondrial protein	Homo sapiens	16-20
18275843-2	2008	In this study, we show that the histone deacetylase (HDAC) inhibitor apicidin leads to resistance of HeLa cells to paclitaxel through the induction of P-gp expression.	Paclitaxel	115-125	histone deacetylase 9	Homo sapiens	32-51
18275843-2	2008	In this study, we show that the histone deacetylase (HDAC) inhibitor apicidin leads to resistance of HeLa cells to paclitaxel through the induction of P-gp expression.	Paclitaxel	115-125	histone deacetylase 9	Homo sapiens	53-57
18029193-0	2007	Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro.	Paclitaxel	78-88	diablo IAP-binding mitochondrial protein	Homo sapiens	21-27
18241828-2	2008	paclitaxel administration in reducing vascular endothelial growth factor (VEGF) concentration in peritoneal fluid and preventing intraoperative cancer scattering during laparoscopy.	Paclitaxel	0-10	vascular endothelial growth factor A	Mus musculus	38-72
18029193-4	2007	Smac/DIABLO expression showed no correlation with TRAIL sensitivity, while lower Smac/DIABLO expression and decreased release of Smac/DIABLO from mitochondria upon apoptosis stimuli were observed in paclitaxel-resistant A2780/pac cells as compared to the sensitive controls.	Paclitaxel	199-209	diablo IAP-binding mitochondrial protein	Homo sapiens	81-85
18241828-2	2008	paclitaxel administration in reducing vascular endothelial growth factor (VEGF) concentration in peritoneal fluid and preventing intraoperative cancer scattering during laparoscopy.	Paclitaxel	0-10	vascular endothelial growth factor A	Mus musculus	74-78
18241828-8	2008	CONCLUSION: Early treatment with IP paclitaxel significantly decreased the VEGF concentration in peritoneal fluid, which was associated with reduced implantation and growth of disseminated cancer cells after laparoscopy.	Paclitaxel	36-46	vascular endothelial growth factor A	Mus musculus	75-79
18029193-4	2007	Smac/DIABLO expression showed no correlation with TRAIL sensitivity, while lower Smac/DIABLO expression and decreased release of Smac/DIABLO from mitochondria upon apoptosis stimuli were observed in paclitaxel-resistant A2780/pac cells as compared to the sensitive controls.	Paclitaxel	199-209	diablo IAP-binding mitochondrial protein	Homo sapiens	86-92
18341588-7	2008	These results suggest that although JNK activation plays an important role in cell death induced by both agents, vinblastine and Taxol differ markedly with respect to signaling downstream of JNK, with AP-1-dependent and -independent mechanisms, respectively.	Paclitaxel	129-134	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	201-205
18029193-4	2007	Smac/DIABLO expression showed no correlation with TRAIL sensitivity, while lower Smac/DIABLO expression and decreased release of Smac/DIABLO from mitochondria upon apoptosis stimuli were observed in paclitaxel-resistant A2780/pac cells as compared to the sensitive controls.	Paclitaxel	199-209	diablo IAP-binding mitochondrial protein	Homo sapiens	81-85
18199556-9	2008	17-AAG could be safely coadministered with paclitaxel, and the combination was significantly more effective than either drug alone.	Paclitaxel	43-53	N-methylpurine DNA glycosylase	Homo sapiens	3-6
18029193-4	2007	Smac/DIABLO expression showed no correlation with TRAIL sensitivity, while lower Smac/DIABLO expression and decreased release of Smac/DIABLO from mitochondria upon apoptosis stimuli were observed in paclitaxel-resistant A2780/pac cells as compared to the sensitive controls.	Paclitaxel	199-209	diablo IAP-binding mitochondrial protein	Homo sapiens	86-92
18029193-5	2007	Ectopic Smac/DIABLO alone inhibited cell growth, arrested cells in G0/G1 phase, and sensitized drug-resistant EOC cells to TRAIL or paclitaxel-induced apoptosis.	Paclitaxel	132-142	diablo IAP-binding mitochondrial protein	Homo sapiens	8-12
18029193-5	2007	Ectopic Smac/DIABLO alone inhibited cell growth, arrested cells in G0/G1 phase, and sensitized drug-resistant EOC cells to TRAIL or paclitaxel-induced apoptosis.	Paclitaxel	132-142	diablo IAP-binding mitochondrial protein	Homo sapiens	13-19
18024864-0	2007	ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.	Paclitaxel	99-109	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
18195548-5	2008	Postoperatively, the sole treatment was comprised of combination chemotherapy of paclitaxel and carboplatin following which the tumor marker(CA125)levels normalized.	Paclitaxel	81-91	mucin 16, cell surface associated	Homo sapiens	141-146
17982636-5	2007	The shRNAs targeting SMAD4, LZTS2, ST14 and VHL all increased the cell"s sensitivity to paclitaxel.	Paclitaxel	88-98	leucine zipper tumor suppressor 2	Homo sapiens	28-33
17952876-0	2007	Dominant negative Rac1 attenuates paclitaxel-induced apoptosis in human melanoma cells through upregulation of heat shock protein 27: a functional proteomic analysis.	Paclitaxel	34-44	Rac family small GTPase 1	Homo sapiens	18-22
17952876-4	2007	Compared to the Rac1pIRES and Rac1V12 cells, Rac1N17 cells were more resistant to paclitaxel-triggered caspase-3 activation and apoptosis.	Paclitaxel	82-92	Rac family small GTPase 1	Homo sapiens	16-20
18024864-1	2007	PURPOSE: To investigate the effect of excision repair cross-complementation group 1 (ERCC1) on treatment response and survival of patients treated with platinum chemotherapy with or without paclitaxel.	Paclitaxel	190-200	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	38-83
18024864-1	2007	PURPOSE: To investigate the effect of excision repair cross-complementation group 1 (ERCC1) on treatment response and survival of patients treated with platinum chemotherapy with or without paclitaxel.	Paclitaxel	190-200	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	85-90
18024864-7	2007	However, for the 75 patients treated with platinum plus paclitaxel, the C/C genotype and high ERCC1 expression were not associated with poor prognosis, suggesting that paclitaxel may help to alleviate ERCC1-related platinum resistance.	Paclitaxel	168-178	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	201-206
17804754-9	2007	On a total protein basis, Taxol induced ISMMC, expanded more CD8(+) cells, activated more CD56(+) NKG2D(+) cells to produce IFN-gamma, and were more potent inducers of high T-cell receptor density Perforin(+) cells than native ISMMC and peptide E75.	Paclitaxel	26-31	CD8a molecule	Homo sapiens	61-64
18024864-8	2007	CONCLUSION: Ovarian cancer patients with high ERCC1 expression or the C/C genotype at codon 118 may benefit from the combination of platinum and paclitaxel, while those with low ERCC1 expression or the C/T or T/T genotype may respond well to platinum without paclitaxel.	Paclitaxel	145-155	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	46-51
17652622-5	2007	Thus, paclitaxel triggers apoptosis not through caspase-10, but via caspase-9 activation at the apoptosome.	Paclitaxel	6-16	caspase 9	Homo sapiens	68-77
17652622-7	2007	Interestingly, also the single knockout of Bim or Bax, but not that of Bak or Bid, conferred partial resistance, suggesting a particular role of these mediators in the cell-death pathway activated by paclitaxel.	Paclitaxel	200-210	BCL2 like 11	Homo sapiens	43-46
17879382-0	2007	Design and synthesis of paclitaxel conjugated with an ErbB2-recognizing peptide, EC-1.	Paclitaxel	24-34	Susceptibility to lysis by alloreactive natural killer cells	Homo sapiens	81-85
17879382-2	2007	In this study, we report the design and synthesis of paclitaxel (PTX) conjugated with an erbB2-recognizing peptide (EC-1).	Paclitaxel	53-63	Susceptibility to lysis by alloreactive natural killer cells	Homo sapiens	116-120
17449502-10	2007	Moreover, transcriptional analysis by real-time RT-PCR showed an increased level of pro-apoptotic mRNA transcripts (FAS, BAX, caspase 3) in paclitaxel-treated arteries.	Paclitaxel	140-150	BCL2-associated X protein	Mus musculus	121-124
17449502-10	2007	Moreover, transcriptional analysis by real-time RT-PCR showed an increased level of pro-apoptotic mRNA transcripts (FAS, BAX, caspase 3) in paclitaxel-treated arteries.	Paclitaxel	140-150	caspase 3	Mus musculus	126-135
17879382-2	2007	In this study, we report the design and synthesis of paclitaxel (PTX) conjugated with an erbB2-recognizing peptide (EC-1).	Paclitaxel	65-68	Susceptibility to lysis by alloreactive natural killer cells	Homo sapiens	116-120
17701006-12	2007	The modified premedication protocol was found to be feasible for preventing paclitaxel-related HSR, but case accumulation is needed.	Paclitaxel	76-86	HSR	Homo sapiens	95-98
18057697-3	2007	Retrospective observation of breast cancer tissues obtained by core needle biopsy before surgery from stages II and III patients demonstrates that Fra-1 expression is high in estrogen receptor-negative human breast cancers, and negatively correlated to paclitaxel sensitivity.	Paclitaxel	253-263	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	147-152
17611652-3	2007	In the present study, we examined whether the expression of MAGE-A1 could predict the response of advanced and recurrent gastric cancers (GCs) to taxan (doce-taxel or paclitaxel)-based chemotherapy.	Paclitaxel	167-177	MAGE family member A1	Homo sapiens	60-67
17611652-9	2007	The forced MAGE-A1 expression in the TMK-1 GC cell line increased the sensitivity to paclitaxel and docetaxel.	Paclitaxel	85-95	MAGE family member A1	Homo sapiens	11-18
17174526-7	2007	Intrathecal IL-1ra reversed paclitaxel-induced allodynia and intrathecal IL-10 gene therapy both prevented, and progressively reversed, this allodynic state.	Paclitaxel	28-38	interleukin 1 receptor antagonist	Rattus norvegicus	12-18
17487377-6	2007	Cytokeratin-8, keratin-19, Hsp-27, 14-3-3 epsilon, annexin-A2 and phosphoglycerate kinase-1 showed altered expression in both adriamycin- and paclitaxel-resistant cells.	Paclitaxel	142-152	keratin 8	Homo sapiens	0-13
17706465-1	2007	Epothilone D (Epo-D) is a paclitaxel-like microtubule-stabilizing agent that was isolated from the myxobacterium Sorangium cellulosum.	Paclitaxel	26-36	erythropoietin	Rattus norvegicus	0-3
17697605-0	2007	[Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel].	Paclitaxel	87-97	ATP binding cassette subfamily B member 4	Homo sapiens	29-33
17697605-1	2007	OBJECTIVE: To investigate the reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel.	Paclitaxel	116-126	ATP binding cassette subfamily B member 4	Homo sapiens	58-62
17697605-13	2007	CONCLUSION: MDR1 and MDR3 gene silencing could recover sensitivity of A2780/taxol cells to paclitaxel and induce cell apoptosis, thus reversing cell resistance to paclitaxel.	Paclitaxel	91-101	ATP binding cassette subfamily B member 4	Homo sapiens	21-25
17697605-13	2007	CONCLUSION: MDR1 and MDR3 gene silencing could recover sensitivity of A2780/taxol cells to paclitaxel and induce cell apoptosis, thus reversing cell resistance to paclitaxel.	Paclitaxel	163-173	ATP binding cassette subfamily B member 4	Homo sapiens	21-25
17230521-5	2007	By comparison of the parental HNE1 and its derivative HNE1-T3 cell lines, we found that the resistance to taxol in HNE1-T3 cells was associated with suppression of taxol-induced apoptosis evidenced by decreased expression of Bak and Bax and increased Bcl-2, as well as inhibition of PARP and caspase cleavage and DNA ladder formation.	Paclitaxel	106-111	BCL2 antagonist/killer 1	Homo sapiens	225-228
17230521-5	2007	By comparison of the parental HNE1 and its derivative HNE1-T3 cell lines, we found that the resistance to taxol in HNE1-T3 cells was associated with suppression of taxol-induced apoptosis evidenced by decreased expression of Bak and Bax and increased Bcl-2, as well as inhibition of PARP and caspase cleavage and DNA ladder formation.	Paclitaxel	164-169	BCL2 antagonist/killer 1	Homo sapiens	225-228
17804754-9	2007	On a total protein basis, Taxol induced ISMMC, expanded more CD8(+) cells, activated more CD56(+) NKG2D(+) cells to produce IFN-gamma, and were more potent inducers of high T-cell receptor density Perforin(+) cells than native ISMMC and peptide E75.	Paclitaxel	26-31	neural cell adhesion molecule 1	Homo sapiens	90-94
17272681-6	2007	We found that targeting stathmin or wee-1 expression with RNA interference can induce microtubule polymerization and promote G(2)/M progression, respectively, and sensitize stathmin-overexpressing breast cancer cells to paclitaxel and vinblastine.	Paclitaxel	220-230	WEE1 G2 checkpoint kinase	Homo sapiens	36-41
17708594-5	2007	Moreover, this Ptx up-regulated form of eEF1Bgamma disappears upon treatment with protein phosphatase.	Paclitaxel	15-18	eukaryotic translation elongation factor 1 gamma	Homo sapiens	40-50
17708594-6	2007	Thus, we demonstrate that human eEF1Bgamma phosphorylation is regulated by Ptx.	Paclitaxel	75-78	eukaryotic translation elongation factor 1 gamma	Homo sapiens	32-42
17367746-7	2007	Interestingly, pre-treatment of cells with a ten-fold excess of paclitaxel abolishes vincristine-induced phosphorylation of HSP27.	Paclitaxel	64-74	heat shock protein family B (small) member 1	Homo sapiens	124-129
17204494-7	2007	Treatment of hST vesicles with either the microtubular disrupter colchicine (15 microM) or the microtubular stabilizer paclitaxel (taxol, 15 microM) resulted in distinct patterns of microtubular re-organization and PC2 redistribution.	Paclitaxel	119-129	sulfotransferase family 2A member 1	Homo sapiens	13-16
17204494-7	2007	Treatment of hST vesicles with either the microtubular disrupter colchicine (15 microM) or the microtubular stabilizer paclitaxel (taxol, 15 microM) resulted in distinct patterns of microtubular re-organization and PC2 redistribution.	Paclitaxel	131-136	sulfotransferase family 2A member 1	Homo sapiens	13-16
17204494-10	2007	Addition of either tubulin and GTP, or taxol, however, stimulated PC2 channel activity in control hST membranes.	Paclitaxel	39-44	sulfotransferase family 2A member 1	Homo sapiens	98-101
17257668-9	2007	These results collectively suggest that our optimized SLN formulation may have a potential as alternative delivery system for parenteral administration of paclitaxel.	Paclitaxel	155-165	sarcolipin	Homo sapiens	54-57
17190787-1	2007	By comparing ovarian carcinoma-derived KF28 cells with the corresponding anticancer drug-resistant cells, the taxol- and cisplatin-resistant properties were found to be closely related with MDR1 and BSEP, and MRP2 transporters, respectively.	Paclitaxel	110-115	ATP binding cassette subfamily B member 11	Homo sapiens	199-203
17190787-1	2007	By comparing ovarian carcinoma-derived KF28 cells with the corresponding anticancer drug-resistant cells, the taxol- and cisplatin-resistant properties were found to be closely related with MDR1 and BSEP, and MRP2 transporters, respectively.	Paclitaxel	110-115	ATP binding cassette subfamily C member 2	Homo sapiens	209-213
17145055-3	2007	In this study we demonstrate that taxol induces caspase-3-independent apoptosis in NIH3T3 cells by a calpain-mediated mechanism.	Paclitaxel	34-39	caspase 3	Mus musculus	48-57
17145055-5	2007	Interestingly, we show that calpain produced proteolysis of caspase-3 and demonstrate that, accordingly, calpain inhibition increased taxol-induced apoptosis.	Paclitaxel	134-139	caspase 3	Mus musculus	60-69
17264671-6	2007	In the STA mice group, three cycles of paclitaxel induced a 2.4-fold increase in MNE frequencies compared to the control group (p &lt; 0.01).	Paclitaxel	39-49	autosomal striping	Mus musculus	7-10
17245652-1	2007	PURPOSE: The aim of the study was to investigate whether 2"-ethylcarbonate-linked paclitaxel (TAX-2"-Et) circumvents P-glycoprotein (P-gp)-mediated cellular efflux and cytotoxicity enhanced by TAX-2"-Et activation within human culture cells transfected with a rabbit liver carboxylesterase (Ra-CES) cDNA.	Paclitaxel	82-92	liver carboxylesterase 1	Oryctolagus cuniculus	267-289
17145055-6	2007	In addition, we reveal that poly (ADP-ribose) polymerase (PARP) was processed by calpain in taxol-treated cells and by caspase-3 after calpain inhibition.	Paclitaxel	92-97	poly (ADP-ribose) polymerase family, member 1	Mus musculus	28-56
17145055-6	2007	In addition, we reveal that poly (ADP-ribose) polymerase (PARP) was processed by calpain in taxol-treated cells and by caspase-3 after calpain inhibition.	Paclitaxel	92-97	poly (ADP-ribose) polymerase family, member 1	Mus musculus	58-62
17263521-0	2007	Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3" bridged paclitaxel analogues.	Paclitaxel	32-42	complement C4A (Rodgers blood group)	Homo sapiens	96-99
16891397-7	2006	Pretreatment of the matrix with either sirolimus (2.5 nM) or paclitaxel (10 nM) abolishes the increases in both TGF-beta2 and second harmonic generation in response to epithelial injury.	Paclitaxel	61-71	transforming growth factor beta 2	Homo sapiens	112-121
18503359-15	2006	In tissue cultures Giemsa staining and immunohistochemical reactions for p53, Ki-67, CD-34, and SMA antigens revealed marked fibroblast hypertrophy in all of the paclitaxel-treated groups.	Paclitaxel	162-172	CD34 molecule	Rattus norvegicus	85-90
17263521-0	2007	Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3" bridged paclitaxel analogues.	Paclitaxel	116-126	complement C4A (Rodgers blood group)	Homo sapiens	96-99
16888034-1	2006	The taxol resistance gene TRAG-3 was initially isolated from cancer cell lines that became resistant to taxol in vitro.	Paclitaxel	4-9	CSAG family member 2	Homo sapiens	26-32
17645840-1	2007	OBJECTIVE: To explore the effect of hypoxia and hypoxia-inducible factor-1alpha (HIF-1alpha) on the expression of multidrug resistance gene-1 (mdr-1) and its coded p-glyeoprotein (P-gp) as well as the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism.	Paclitaxel	263-273	phosphoglycolate phosphatase	Homo sapiens	164-178
17645840-12	2007	CONCLUSION: Hypoxia can decrease the chemotherapeutic sensitivity of human ovarian cancer A2780 cells to paclitaxel through HIF-1alpha regulating the expression of mdr-1 and p-gp.	Paclitaxel	105-115	phosphoglycolate phosphatase	Homo sapiens	174-178
17696592-13	2007	The present studies support the use of ALC in cancer patients with persisting neurotoxicity induced by paclitaxel or cisplatin treatment.	Paclitaxel	103-113	allantoicase	Homo sapiens	39-42
16496381-7	2006	Further analyses with histological examination and TdT-mediated dUTP nick end labeling assay indicate that pretreatment with dexamethasone clearly interferes with the cytotoxic effects of paclitaxel on both morphological alterations and induction of cell death.	Paclitaxel	188-198	DNA nucleotidylexotransferase	Homo sapiens	51-54
16432835-3	2006	PSP demonstrated high levels of resistance to paclitaxel cytotoxicity as compared with HME-1 cells.	Paclitaxel	46-56	microseminoprotein beta	Homo sapiens	0-3
17917084-7	2007	When tested against PC-3 cells and combined with LD50 Cytoxan, MR2, MR4, MR24, MR42 significantly inhibited 47.3, 45.7, 68.3, and 64.9%; with LD50 Taxol MR2, MR4, MR24, MR42 significantly inhibited 49.8, 45.8, 64.1, and 59.2%; and with LD50 DES MR2, MR4, MR24, MR42 significantly inhibited 66.6, 67.6, 64.3, and 67.2% respectively.	Paclitaxel	147-152	proprotein convertase subtilisin/kexin type 1	Homo sapiens	20-24
17088539-6	2006	Additivity, synergy, or competition was observed with MIS and rapamycin, AzadC, doxorubicin, cisplatin, and paclitaxel, suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone.	Paclitaxel	108-118	anti-Mullerian hormone	Homo sapiens	136-139
16914101-0	2006	The interferon-induced GTPase, mGBP-2, confers resistance to paclitaxel-induced cytotoxicity without inhibiting multinucleation.	Paclitaxel	61-71	guanylate binding protein 2	Mus musculus	31-37
16914101-4	2006	In this study we show that a murine GBP, mGBP-2, confers resistance to a microtubule-stabilizing drug used in cancer therapy, paclitaxel.	Paclitaxel	126-136	guanylate binding protein 2	Mus musculus	41-47
16914101-5	2006	Paclitaxel-treated, mGBP-2-expressing NIH 3T3 cells showed less rounding and substrate detachment than treated control cells.	Paclitaxel	0-10	guanylate binding protein 2	Mus musculus	20-26
16914101-6	2006	mGBP-2 also conferred resistance to paclitaxel-induced cytotoxicity at paclitaxel concentrations from 0.005 to 15 microM.	Paclitaxel	36-46	guanylate binding protein 2	Mus musculus	0-6
16914101-6	2006	mGBP-2 also conferred resistance to paclitaxel-induced cytotoxicity at paclitaxel concentrations from 0.005 to 15 microM.	Paclitaxel	71-81	guanylate binding protein 2	Mus musculus	0-6
16914101-7	2006	mGBP-2-mediated paclitaxel resistance did not protect against the generation of multinucleate cells but fewer of these cells progressed to apoptosis.	Paclitaxel	16-26	guanylate binding protein 2	Mus musculus	0-6
17121923-6	2006	Using cell cycle analysis, nuclear staining, and Western blot analysis for poly(ADP-ribose) polymerase and caspase-9 degradation products, TSA/paclitaxel showed the most dramatic activation of the apoptotic cascade.	Paclitaxel	143-153	caspase 9	Homo sapiens	107-116
16596227-4	2006	In this study, RAD51 protein levels were quantified by immunohistochemistry in tumor samples from twelve head and neck cancer patients who received identical treatment with induction chemotherapy (paclitaxel and carboplatinum) followed by radiation therapy given concurrently with additional chemotherapy (paclitaxel, fluorouracil, hydroxyurea).	Paclitaxel	197-207	RAD51 recombinase	Homo sapiens	15-20
16596227-4	2006	In this study, RAD51 protein levels were quantified by immunohistochemistry in tumor samples from twelve head and neck cancer patients who received identical treatment with induction chemotherapy (paclitaxel and carboplatinum) followed by radiation therapy given concurrently with additional chemotherapy (paclitaxel, fluorouracil, hydroxyurea).	Paclitaxel	306-316	RAD51 recombinase	Homo sapiens	15-20
16957420-3	2006	Studies by a number of laboratories have also linked suppression of MEK1/2 signaling to enhanced Taxol toxicity in vitro and in vivo.	Paclitaxel	97-102	mitogen-activated protein kinase kinase 1	Homo sapiens	68-74
16678050-0	2006	HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer.	Paclitaxel	18-28	tubulin polymerization promoting protein family member 3	Homo sapiens	7-10
16678050-1	2006	OBJECTIVE: To report the development of a new water-soluble paclitaxel-hyaluronic acid bioconjugate, HYTAD1-p20, for intravesical treatment of superficial bladder cancer.	Paclitaxel	60-70	tubulin polymerization promoting protein family member 3	Homo sapiens	108-111
16678050-2	2006	MATERIALS AND METHODS: HYTAD1-p20 was synthesized by carboxyl esterification of hyaluronic acid with paclitaxel, and its physicochemical and biologic properties were characterized.	Paclitaxel	101-111	tubulin polymerization promoting protein family member 3	Homo sapiens	30-33
16678050-8	2006	CONCLUSIONS: These data suggest that HYTAD1-p20 significantly improved results obtained with conventional paclitaxel in terms of hydrosolubility, in vitro activity against human bladder cancer cells, and in vivo biocompatibility.	Paclitaxel	106-116	tubulin polymerization promoting protein family member 3	Homo sapiens	44-47
17041103-10	2006	Checkpoint-deficient cells treated with paclitaxel, on the other hand, yielded a higher frequency of cells with &gt;4N DNA content and a decreased incidence of apoptotic events, particularly in Mad2-depleted cells.	Paclitaxel	40-50	mitotic arrest deficient 2 like 1	Homo sapiens	194-198
16516478-4	2006	Aurones CB-284, CB-285, CB-287, and ML-50 most effectively inhibited P-gp related transport in the resistant line in comparison with chalcones, flavones, flavonols, chromones, and isoflavone derivatives and accordingly increased the accumulation of [(14)C]paclitaxel and decreased its efflux.	Paclitaxel	256-266	phosphoglycolate phosphatase	Homo sapiens	69-73
16638536-0	2006	Profiling a Taxol pathway 10beta-acetyltransferase: assessment of the specificity and the production of baccatin III by in vivo acetylation in E. coli.	Paclitaxel	12-17	acetyltransferase	Escherichia coli	33-50
16516478-5	2006	Those agents efficiently modulated paclitaxel transport in P-gp highly expressing resistant human breast cancer cells and they could increase the efficiency of chemotherapy in paclitaxel-resistant tumors.	Paclitaxel	35-45	phosphoglycolate phosphatase	Homo sapiens	59-63
16516478-8	2006	Opposite effects of flavonoid derivatives on the P-gp highly expressing and MDA-MB-435 non-expressing cell lines indicate that paclitaxel is not only transported by P-gp and let us assume that Mrp2 or ABCC5 seem to be good transport-candidates in these cells.	Paclitaxel	127-137	phosphoglycolate phosphatase	Homo sapiens	49-53
16516478-8	2006	Opposite effects of flavonoid derivatives on the P-gp highly expressing and MDA-MB-435 non-expressing cell lines indicate that paclitaxel is not only transported by P-gp and let us assume that Mrp2 or ABCC5 seem to be good transport-candidates in these cells.	Paclitaxel	127-137	phosphoglycolate phosphatase	Homo sapiens	165-169
16516478-9	2006	The inhibition of paclitaxel accumulation and stimulation of its efflux are potentially unfavorable for drug therapy and since they could be due to modulation of drug transporters other than P-gp, their expression in tumors is of great significance for efficient chemotherapy.	Paclitaxel	18-28	phosphoglycolate phosphatase	Homo sapiens	191-195
16729912-19	2006	CONCLUSION: The combined dosing of paclitaxel (100 mg/m(2) weekly), doxorubicin (20 mg/m(2) weekly), and thalidomide (300 mg daily) is tolerated by men with AIPC and merits continued phase II study.	Paclitaxel	35-45	PDZ domain containing 2	Homo sapiens	157-161
16639080-5	2006	We next demonstrate that downregulation of BRCA1 reduces the mitotic index and triggers premature cyclin B1 degradation and decrease in Cdk1 activity following paclitaxel treatment, suggesting that BRCA1 downregulation results in precocious inactivation of the spindle checkpoint.	Paclitaxel	160-170	cyclin dependent kinase 1	Homo sapiens	136-140
16639080-7	2006	Furthermore, we show that BRCA1 up-regulates the expression of the protein kinase BubR1, essential component of the functional spindle checkpoint, whose downregulation is known to result in paclitaxel resistance in MCF-7 cells.	Paclitaxel	190-200	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	82-87
16545208-25	2006	Incorporating the results of the additional trial data resulted in less favourable estimates for the ICER for PLDH versus paclitaxel compared with the base-case results.	Paclitaxel	122-132	cAMP responsive element modulator	Homo sapiens	101-105
16545208-34	2006	The ICER for paclitaxel-platinum combination therapy compared with CAP was pound 20,950 per QALY.	Paclitaxel	13-23	cAMP responsive element modulator	Homo sapiens	4-8
16545208-50	2006	Incorporating the results of additional trial data gave less favourable estimates for the ICER for PLDH versus paclitaxel monotherapy, compared with the base-case results.	Paclitaxel	111-121	cAMP responsive element modulator	Homo sapiens	90-94
16606364-6	2006	Paclitaxel (taxol), a compound to stabilize microtubules, suppressed the apoA-I-mediated intracellular translocation and release from the cells of the de novo synthesized cholesterol and phospholipid.	Paclitaxel	0-10	apolipoprotein A1	Rattus norvegicus	73-79
16412331-9	2005	RNA interference targeted against specific sequences of survivin in SKOV3/ADM cell could significantly reduce the level of survivin mRNA transcripts and protein, effectively induce the cells apoptosis and restore the sensitivity of cell to conventional chemotherapeutic agents Taxol.	Paclitaxel	277-282	adrenomedullin	Homo sapiens	74-77
15897904-6	2005	The hyperphosphorylation of 4E-BP1 by PTX increased the association of eIF-4E with eIF-4G, whereas cotreatment with purvalanol A inhibited the association of eIF-4E with eIF-4G in PTX treated cells.	Paclitaxel	38-41	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	83-89
16606364-6	2006	Paclitaxel (taxol), a compound to stabilize microtubules, suppressed the apoA-I-mediated intracellular translocation and release from the cells of the de novo synthesized cholesterol and phospholipid.	Paclitaxel	12-17	apolipoprotein A1	Rattus norvegicus	73-79
16616141-0	2006	Evidence that low doses of Taxol enhance the functional transactivatory properties of p53 on p21 waf promoter in MCF-7 breast cancer cells.	Paclitaxel	27-32	H3 histone pseudogene 16	Homo sapiens	93-96
15890503-4	2005	Presence of P-glycoprotein (P-gp) inhibitor, verapamil (200 microM), diminished asymmetric transport of paclitaxel suggesting the role of P-gp-mediated efflux.	Paclitaxel	104-114	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	12-26
16616141-1	2006	In the present study, we evidence how in breast cancer cells low doses of Taxol for 18 h determined the upregulation of p53 and p21 waf expression concomitantly with a decrease of the anti-apoptotic Bcl-2.	Paclitaxel	74-79	H3 histone pseudogene 16	Homo sapiens	128-131
15890503-4	2005	Presence of P-glycoprotein (P-gp) inhibitor, verapamil (200 microM), diminished asymmetric transport of paclitaxel suggesting the role of P-gp-mediated efflux.	Paclitaxel	104-114	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	28-32
15890503-4	2005	Presence of P-glycoprotein (P-gp) inhibitor, verapamil (200 microM), diminished asymmetric transport of paclitaxel suggesting the role of P-gp-mediated efflux.	Paclitaxel	104-114	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	138-142
16616141-3	2006	Indeed, the most important finding of this study consists with the evidence that Taxol at lower concentrations is able to produce the activation of p21 promoter via p53.	Paclitaxel	81-86	H3 histone pseudogene 16	Homo sapiens	148-151
15890503-7	2005	Thus, the maximum paclitaxel permeability attained with 0.1 mg/ml TPGS was attributed to the interplay between TPGS concentration dependent P-gp inhibition activity and miceller formation.	Paclitaxel	18-28	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	140-144
16616141-4	2006	Prolonged exposure of MCF-7 cells to Taxol (48 h) resulted in an increased co-association between p21 and PCNA compared to control and this well fits with the simultaneous block of cell cycle into the G2/M phase.	Paclitaxel	37-42	H3 histone pseudogene 16	Homo sapiens	98-101
15645438-4	2005	A significant positive correlation was observed for sensitivity to paclitaxel and MRP2 expression only (r = 0.8; p = 0.013).	Paclitaxel	67-77	ATP binding cassette subfamily C member 2	Homo sapiens	82-86
16616141-4	2006	Prolonged exposure of MCF-7 cells to Taxol (48 h) resulted in an increased co-association between p21 and PCNA compared to control and this well fits with the simultaneous block of cell cycle into the G2/M phase.	Paclitaxel	37-42	proliferating cell nuclear antigen	Homo sapiens	106-110
16364249-0	2006	TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.	Paclitaxel	52-62	H3 histone pseudogene 16	Homo sapiens	9-12
16110492-5	2006	The taxol-dependent cytoplasmic accumulation of RUNX2 is inhibited by leptomycin B, which blocks CRM-1 dependent nuclear export, and is not affected by the protein synthesis inhibitor cycloheximide.	Paclitaxel	4-9	exportin 1	Homo sapiens	97-102
15657900-0	2005	Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.	Paclitaxel	160-165	fatty acid synthase	Homo sapiens	91-110
15657900-0	2005	Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.	Paclitaxel	167-177	fatty acid synthase	Homo sapiens	91-110
15657900-7	2005	As single agents, FAS blocker C75 and Taxol induced a significant stimulation of the proliferation and cell survival mitogen-activated protein kinase extracellular signal-regulated kinase (ERK1/ERK2 MAPK) activity, whereas, in combination, they interfered with ERK1/ERK2 activation.	Paclitaxel	38-43	fatty acid synthase	Homo sapiens	18-21
16356831-5	2006	Cyclin-dependent kinase inhibitors prevented 2-ME and paclitaxel-mediated increase in cyclin B1-dependent kinase activity and blocked induction of apoptosis.	Paclitaxel	54-64	cyclin B1	Homo sapiens	86-95
15657900-10	2005	Importantly, SK-Br3 and multi-drug resistant MCF-7/AdrR cells transiently transfected with sequence-specific double-stranded RNA oligonucleotides targeting FAS gene demonstrated hypersensitivity to Taxol-induced apoptotic cell death.	Paclitaxel	198-203	fatty acid synthase	Homo sapiens	156-159
16356831-8	2006	We suggest that 2-ME and paclitaxel-mediated induction of apoptosis in prostate cancer cells requires activation of cyclin B1-dependent kinase that arrests cells in G2/M and subsequently leads to the induction of apoptotic cell death.	Paclitaxel	25-35	cyclin B1	Homo sapiens	116-125
15918564-2	2005	This study was designed to evaluate the effectiveness and safety of weekly paclitaxel (TXL) therapy in patients who suffered a cervical cancer relapse after heavy treatment.	Paclitaxel	75-85	thioredoxin like 1	Homo sapiens	87-90
15918568-0	2005	[A case of advanced gastric cancer with peritoneal dissemination effectively treated by combined chemotherapy of paclitaxel (TXL) and TS-1].	Paclitaxel	113-123	thioredoxin like 1	Homo sapiens	125-128
16475678-8	2006	Among 12 patients treated with paclitaxel alone, only 1 (20.0%) of the 5 patients with CHFR methylation had a partial response (PR) to paclitaxel, whereas 3 (42.9%) of the 7 patients without CHFR methylation had a PR to paclitaxel (p = 0.836).	Paclitaxel	135-145	checkpoint with forkhead and ring finger domains	Homo sapiens	87-91
15901346-6	2005	Moreover, we observed that hOat2 mediates the transport of bumetanide, ES, glutarate, dehydroepiandrosterone sulfate, allopurinol, prostaglandin E2, 5-fluorouracil, paclitaxel and L-ascorbic acid.	Paclitaxel	165-175	solute carrier family 22 member 7	Homo sapiens	27-32
16475678-8	2006	Among 12 patients treated with paclitaxel alone, only 1 (20.0%) of the 5 patients with CHFR methylation had a partial response (PR) to paclitaxel, whereas 3 (42.9%) of the 7 patients without CHFR methylation had a PR to paclitaxel (p = 0.836).	Paclitaxel	135-145	checkpoint with forkhead and ring finger domains	Homo sapiens	87-91
15829295-7	2005	Using splenic macrophages harvested from IRAK-1 knockout and control mice, we further demonstrated that the presence of IRAK-1 is required for taxol-induced PARP cleavage.	Paclitaxel	143-148	poly (ADP-ribose) polymerase family, member 1	Mus musculus	157-161
16051289-6	2006	As compared to the treatment with Taxol only, a co-administration with esculetin and Taxol could result in a further enhancement of apoptosis as revealed by DNA fragmentation assay and Annexin-V-based assay.	Paclitaxel	85-90	annexin A5	Homo sapiens	185-194
16051289-7	2006	Meanwhile, immunoblotting analysis also showed that the co-administration of esculetin and Taxol could increase the expression of Bax and the cytosolic release of cytochrome C and enhance the expression of Fas and Fas ligand while the activation of caspase-8 and caspase-3 was also increased.	Paclitaxel	91-96	Fas ligand	Homo sapiens	214-224
15580499-1	2005	Expression of the cancer-testis antigen Taxol resistance-associated gene-3 (TRAG-3) protein is associated with acquired paclitaxel (Taxol) resistance, and is expressed in various cancer types; e.g., breast cancer, leukemia, and melanoma.	Paclitaxel	120-130	CSAG family member 2	Homo sapiens	40-74
16289419-5	2005	Furthermore, paclitaxel-incorporated chitosan hydrogel markedly reduced the number of CD34-positive vessels in subcutaneous 3LL tumors, indicating a strong inhibition of angiogenesis.	Paclitaxel	13-23	CD34 antigen	Mus musculus	86-90
15580499-1	2005	Expression of the cancer-testis antigen Taxol resistance-associated gene-3 (TRAG-3) protein is associated with acquired paclitaxel (Taxol) resistance, and is expressed in various cancer types; e.g., breast cancer, leukemia, and melanoma.	Paclitaxel	120-130	CSAG family member 2	Homo sapiens	76-82
15580499-1	2005	Expression of the cancer-testis antigen Taxol resistance-associated gene-3 (TRAG-3) protein is associated with acquired paclitaxel (Taxol) resistance, and is expressed in various cancer types; e.g., breast cancer, leukemia, and melanoma.	Paclitaxel	40-45	CSAG family member 2	Homo sapiens	76-82
16353081-10	2005	In all of the HebG2 cells treated with paclitaxel (1.0-1000 nM) mRNA specific for EGFR, MMP-2 and MMP-9 were undetectable.	Paclitaxel	39-49	matrix metallopeptidase 9	Homo sapiens	98-103
16289420-2	2005	The commercially available DES drugs rapamycin and paclitaxel bind specifically to their respective therapeutic targets, FKBP12 and polymerized microtubules, while also associating in a more general manner with other tissue elements.	Paclitaxel	51-61	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	121-127
15689167-0	2005	Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ.	Paclitaxel	25-35	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	52-66
15689167-0	2005	Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ.	Paclitaxel	37-42	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	52-66
15689167-1	2005	The purpose of this work was to introduce a chemical modification into the paclitaxel (Taxol) structure to reduce interactions with the product of the multidrug resistant type 1 (MDR1) gene, P-glycoprotein (Pgp), resulting in improved blood-brain barrier (BBB) permeability.	Paclitaxel	75-85	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	151-177
16373699-6	2005	The effect of OGX-011 or siRNA clusterin treatment on chemosensitivity to paclitaxel was done in both cell lines in vitro, whereas the ability of OGX-011 to chemosensitize in vivo was evaluated in athymic mice bearing MCF-7 tumors.	Paclitaxel	74-84	clusterin	Mus musculus	31-40
15689167-1	2005	The purpose of this work was to introduce a chemical modification into the paclitaxel (Taxol) structure to reduce interactions with the product of the multidrug resistant type 1 (MDR1) gene, P-glycoprotein (Pgp), resulting in improved blood-brain barrier (BBB) permeability.	Paclitaxel	75-85	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	179-183
15689167-1	2005	The purpose of this work was to introduce a chemical modification into the paclitaxel (Taxol) structure to reduce interactions with the product of the multidrug resistant type 1 (MDR1) gene, P-glycoprotein (Pgp), resulting in improved blood-brain barrier (BBB) permeability.	Paclitaxel	75-85	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	191-205
15689167-1	2005	The purpose of this work was to introduce a chemical modification into the paclitaxel (Taxol) structure to reduce interactions with the product of the multidrug resistant type 1 (MDR1) gene, P-glycoprotein (Pgp), resulting in improved blood-brain barrier (BBB) permeability.	Paclitaxel	75-85	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	207-210
15689167-1	2005	The purpose of this work was to introduce a chemical modification into the paclitaxel (Taxol) structure to reduce interactions with the product of the multidrug resistant type 1 (MDR1) gene, P-glycoprotein (Pgp), resulting in improved blood-brain barrier (BBB) permeability.	Paclitaxel	87-92	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	151-177
16243823-5	2005	Curcumin also suppressed the paclitaxel-induced expression of antiapoptotic (XIAP, IAP-1, IAP-2, Bcl-2, and Bcl-xL), proliferative (cyclooxygenase 2, c-Myc, and cyclin D1), and metastatic proteins (vascular endothelial growth factor, matrix metalloproteinase-9, and intercellular adhesion molecule-1).	Paclitaxel	29-39	baculoviral IAP repeat containing 3	Homo sapiens	83-88
16243823-5	2005	Curcumin also suppressed the paclitaxel-induced expression of antiapoptotic (XIAP, IAP-1, IAP-2, Bcl-2, and Bcl-xL), proliferative (cyclooxygenase 2, c-Myc, and cyclin D1), and metastatic proteins (vascular endothelial growth factor, matrix metalloproteinase-9, and intercellular adhesion molecule-1).	Paclitaxel	29-39	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	150-155
16183861-8	2005	Ran"s concentration around the spindle disappeared when microtubule assembly was inhibited by colchicine, while it was concentrated around the chromosomes after microtubule stabilization with taxol treatment.	Paclitaxel	192-197	RAN, member RAS oncogene family	Mus musculus	0-3
15642166-5	2005	METHODS: We evaluated the cytotoxicity of AZ-1 and the anti-breast cancer drugs tamoxifen and paclitaxel to BC-M1 cells and MCF-7 cells by the MTT assay and measured the apoptosis phenomena by Hoechst 33258 staining for apoptotic bodies.	Paclitaxel	94-104	CD48 molecule	Homo sapiens	108-113
16155344-4	2005	Moreover, we observed similarly reduced taxol/GTP-stimulated tubulin polymerization from gray matter obtained from patients with AD caused by PSEN2 N141I mutation or frontotemporal dementia with parkinsonism linked to chromosome-17 caused (FTDP-17) by TAU V337M or P301L mutation.	Paclitaxel	40-45	microtubule associated protein tau	Homo sapiens	240-247
15626582-8	2005	Based on these results, it might be considered that the pharmacokinetic parameters of paclitaxel was significantly affected by verapamil which is an inhibitor of the metabolizing enzyme (CYP3A4) in the intestinal mucosa and liver, and the p-glycoprotein efflux pump in the intestinal mucosa.	Paclitaxel	86-96	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	239-253
16155344-4	2005	Moreover, we observed similarly reduced taxol/GTP-stimulated tubulin polymerization from gray matter obtained from patients with AD caused by PSEN2 N141I mutation or frontotemporal dementia with parkinsonism linked to chromosome-17 caused (FTDP-17) by TAU V337M or P301L mutation.	Paclitaxel	40-45	microtubule associated protein tau	Homo sapiens	252-255
16170024-6	2005	Similarly, the extent of caspase-9 and caspase-3 activation in paclitaxel-NU6140-treated cells was approximately 4-fold higher than after the paclitaxel-purvalanol A combination.	Paclitaxel	63-73	caspase 9	Homo sapiens	25-34
15604254-8	2004	Although cell proliferation is not altered, paclitaxel treatment impairs secretion of MMP-2/MMP-9 and significantly reduces invasive activity in our new cell invasion assay.	Paclitaxel	44-54	matrix metallopeptidase 9	Homo sapiens	92-97
16170024-8	2005	A synergistic effect of the paclitaxel-NU6140 combination, as a consequence of survivin inhibition and increased activation of caspase-9 and caspase-3, was also observed in OAW42/e ovarian cancer line but not in the derived OAW42/Surv subline ectopically expressing survivin.	Paclitaxel	28-38	caspase 9	Homo sapiens	127-136
15623650-0	2004	A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.	Paclitaxel	95-105	retinoid X receptor alpha	Homo sapiens	12-31
15907802-1	2005	C19ORF5 is a homologue of microtubule-associated protein MAP1B that interacts with natural paclitaxel-like microtubule stabilizer and candidate tumor suppressor RASSF1A.	Paclitaxel	91-101	microtubule associated protein 1B	Homo sapiens	57-62
15623650-0	2004	A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.	Paclitaxel	107-112	retinoid X receptor alpha	Homo sapiens	12-31
15778245-6	2005	MT stabilization by taxol (5 microM, 1 h) attenuated nocodazole-induced ERK1/2 and p38 MAPK activation and phosphorylation of p38 MAPK substrate 27-kDa heat shock protein and regulatory myosin light chains, the proteins involved in actin polymerization and actomyosin contraction.	Paclitaxel	20-25	myosin heavy chain 14	Homo sapiens	186-192
15628758-1	2004	This pilot study was performed to evaluate the safety and efficacy of weekly paclitaxel (TXL) administration by 1-hour infusion.	Paclitaxel	77-87	thioredoxin like 1	Homo sapiens	89-92
15987939-4	2005	Focal in vivo inhibition of initiator caspase activation or microtubule-dependent transport (with Taxol) at the lesioned axon terminus results in a significant reduction in retrograde axonal caspase-8 and caspase-3 activation and inhibition of retrograde ORN death.	Paclitaxel	98-103	caspase 8	Mus musculus	191-200
15337769-5	2004	Knockdown of c-Kit or Slug expression with their respective small interfering RNA sensitized MM DX cells to the induction of apoptosis by different chemotherapeutic agents, including doxorubicin, paclitaxel, and vincristine.	Paclitaxel	196-206	snail family transcriptional repressor 2	Homo sapiens	22-26
15514563-2	2004	We also show by the in situ brain perfusion in P-glycoprotein (P-gp)-deficient and wild-type mice that vectorized paclitaxel bypasses the P-gp present at the luminal side of the blood-brain barrier.	Paclitaxel	114-124	phosphoglycolate phosphatase	Mus musculus	63-67
15467449-0	2004	The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells.	Paclitaxel	60-70	cyclin dependent kinase inhibitor 3	Homo sapiens	4-37
15467449-1	2004	The functional significance of the cyclin-dependent kinase inhibitor (CDKI) p21(Cip1/WAF1) in paclitaxel-mediated lethality was examined in p53-null human leukemia cells (U937 and Jurkat).	Paclitaxel	94-104	cyclin dependent kinase inhibitor 3	Homo sapiens	35-68
15914550-0	2005	Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.	Paclitaxel	48-58	microtubule associated protein tau	Homo sapiens	0-34
15467449-1	2004	The functional significance of the cyclin-dependent kinase inhibitor (CDKI) p21(Cip1/WAF1) in paclitaxel-mediated lethality was examined in p53-null human leukemia cells (U937 and Jurkat).	Paclitaxel	94-104	cyclin dependent kinase inhibitor 3	Homo sapiens	70-74
15155749-0	2004	Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis.	Paclitaxel	136-146	heat shock protein family A (Hsp70) member 4	Homo sapiens	58-79
15155749-10	2004	Short interfering RNA mediated "knockdown" of Hsp70 expression in K562 cells induced marked sensitivity to paclitaxel-induced apoptosis.	Paclitaxel	107-117	heat shock protein family A (Hsp70) member 4	Homo sapiens	46-51
15867385-2	2005	We previously showed that transfection of doxorubicin-resistant MCF-7-AdrR cells with GCS antisense restored cell sensitivity to doxorubicin and greatly enhanced sensitivity to vinblastine and paclitaxel.	Paclitaxel	193-203	UDP-glucose ceramide glucosyltransferase	Homo sapiens	86-89
15867385-4	2005	Although GCS antisense cells showed enhanced ceramide formation compared with MCF-7-AdrR when challenged with paclitaxel, GCS antisense cells also showed a 10-fold increase in levels of intracellular drug (paclitaxel and vinblastine).	Paclitaxel	206-216	UDP-glucose ceramide glucosyltransferase	Homo sapiens	122-125
14615911-1	2004	We report on a 21-year-old man with a mediastinal germ cell tumor (MGCT) who developed a myelodysplastic syndrome (MDS) (refractory anemia with ringed sideroblasts, RARS) 10 months after the start of successful treatment with cisplatin, etoposide, ifosfamide, and paclitaxel.	Paclitaxel	264-274	MGCT	Homo sapiens	67-71
15829295-1	2005	Numerous microbial as well as other stimulants including lipopolysaccharide and taxol can activate TLR4, and elicit diverse downstream signaling events including cytokine gene expression and cell growth regulation.	Paclitaxel	80-85	toll like receptor 4	Homo sapiens	99-103
15138593-2	2004	This study was carried out in order to determine the role of extracellular signal-regulated kinases (ERK) and retinoblastoma protein (pRB) in the governing mechanism resistance to paclitaxel using two lung adenocarcinoma cell lines with differing sensitivities.	Paclitaxel	180-190	RB transcriptional corepressor 1	Mus musculus	134-137
15138593-3	2004	In paclitaxel-sensitive Ma-10 cells, treatment with paclitaxel induced pRB phosphorylation at Ser795 and ERK activation.	Paclitaxel	3-13	RB transcriptional corepressor 1	Mus musculus	71-74
15828763-4	2005	As a model system, a competitive phase-separation immunoassay based on the ELP-SpA format was established for paclitaxel (taxol) with IC(50) (20.18 nM) and the lower detection limit (2.94 nM) very similar to those reported for the ELISA format.	Paclitaxel	110-120	nuclear receptor subfamily 5 group A member 1	Homo sapiens	75-78
15138593-3	2004	In paclitaxel-sensitive Ma-10 cells, treatment with paclitaxel induced pRB phosphorylation at Ser795 and ERK activation.	Paclitaxel	52-62	RB transcriptional corepressor 1	Mus musculus	71-74
15828763-4	2005	As a model system, a competitive phase-separation immunoassay based on the ELP-SpA format was established for paclitaxel (taxol) with IC(50) (20.18 nM) and the lower detection limit (2.94 nM) very similar to those reported for the ELISA format.	Paclitaxel	122-127	nuclear receptor subfamily 5 group A member 1	Homo sapiens	75-78
15047226-0	2004	The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.	Paclitaxel	69-79	mucin 16, cell surface associated	Homo sapiens	45-51
15790463-2	2005	CASE: A 56-year-old Japanese woman diagnosed as having pT2c pN1 M0 pure-type ovarian squamous cell carcinoma was treated with combination chemotherapy consisting of paclitaxel and carboplatin every 3 weeks.	Paclitaxel	165-175	serpin family E member 2	Homo sapiens	60-63
15653676-10	2005	Taken together, our results show that Eg5 inhibitors have promising anticancer activity and can be potentially used to overcome Taxol resistance in the clinical setting.	Paclitaxel	128-133	kinesin family member 11	Homo sapiens	38-41
14662759-7	2004	Consistent with this increased expression of cell survival genes, MEKK3 stable cells showed reduced activation of caspases 3 and 8 and poly(ADP-ribose) polymerase cleavage and dramatically increased resistance to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand, doxorubicin, daunorubicin, camptothecin, and paclitaxel.	Paclitaxel	336-346	mitogen-activated protein kinase kinase kinase 3	Homo sapiens	66-71
15766661-2	2005	Here we demonstrate that the proapoptotic BH3-only protein BIM is a tumor suppressor in epithelial solid tumors and also is a determinant in paclitaxel sensitivity in vivo.	Paclitaxel	141-151	BCL2 like 11	Homo sapiens	59-62
14698135-10	2004	In the every 3-week paclitaxel group, IL-6 and IL-8 increased whereas in the weekly paclitaxel group IL-10 increased significantly compared to baseline.	Paclitaxel	84-94	interleukin 10	Homo sapiens	101-106
14698135-12	2004	In the weekly paclitaxel group, increase in IL-10 level correlated positively with joint pain (p=0.003).	Paclitaxel	14-24	interleukin 10	Homo sapiens	44-49
15766661-3	2005	Furthermore, the H-ras/mitogen-activated protein kinase (MAPK) pathway conferred resistance to paclitaxel that was dependent on functional inactivation of BIM.	Paclitaxel	95-105	HRas proto-oncogene, GTPase	Homo sapiens	17-22
14698135-15	2004	CONCLUSIONS: Weekly paclitaxel induces transient increase in IL-10 levels whereas every 3-week higher dose treatments induce IL-8 and IL-6 in the plasma.	Paclitaxel	20-30	interleukin 10	Homo sapiens	61-66
15766661-3	2005	Furthermore, the H-ras/mitogen-activated protein kinase (MAPK) pathway conferred resistance to paclitaxel that was dependent on functional inactivation of BIM.	Paclitaxel	95-105	BCL2 like 11	Homo sapiens	155-158
15680171-3	2005	The Annexin V and PI analysis revealed that, after paclitaxel treatment, the cells in G1 and S stages died predominantly through apoptosis, whereas G2/M-stage cells died through both apoptosis and necrosis.	Paclitaxel	51-61	annexin A5	Homo sapiens	4-13
14711415-6	2004	Rod flux from kinetochores appears to require biorientation but not tension because it continues in the presence of taxol.	Paclitaxel	116-121	rough deal	Drosophila melanogaster	0-3
15663292-7	2004	This could be due to the inhibition of P-glycoprotein (P-gp) mediated transport, thus enhancing paclitaxel intestinal absorption.	Paclitaxel	96-106	phosphoglycolate phosphatase	Mus musculus	39-53
15663292-7	2004	This could be due to the inhibition of P-glycoprotein (P-gp) mediated transport, thus enhancing paclitaxel intestinal absorption.	Paclitaxel	96-106	phosphoglycolate phosphatase	Mus musculus	55-59
15713893-0	2005	Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3.	Paclitaxel	24-34	caspase 9	Homo sapiens	75-84
14734682-14	2004	Increase in tumor uptake of the nonspecific PEGylated protein (111)In-DTPA-PEG-ovalbumin was also observed after poly(L-glutamic acid)-paclitaxel treatment (55.6%), although this increase was less than that observed for (111)In-DTPA-PEG-annexin V (96.7%).	Paclitaxel	135-145	annexin A5	Mus musculus	237-246
15713893-4	2005	Inhibition of Src, either pharmacologically or through expression of a Src dominant-negative fusion construct, enhanced the cytotoxicity of two different classes of chemotherapeutics: paclitaxel and cisplatinum, in both mouse and human ovarian cancer cells.	Paclitaxel	184-194	Rous sarcoma oncogene	Mus musculus	14-17
15713893-4	2005	Inhibition of Src, either pharmacologically or through expression of a Src dominant-negative fusion construct, enhanced the cytotoxicity of two different classes of chemotherapeutics: paclitaxel and cisplatinum, in both mouse and human ovarian cancer cells.	Paclitaxel	184-194	Rous sarcoma oncogene	Mus musculus	71-74
15370668-4	2004	The flow cytometric analysis showed that the NS1-transfected cells were arrested at G1 phase by paclitaxel treatment and there was increased apoptosis.	Paclitaxel	96-106	influenza virus NS1A binding protein	Homo sapiens	45-48
15875079-0	2005	Estimation of taxol influence on changes in tubulin and vimentin systems in K-562 and HL-60 cell lines by immunofluorescence microscopy.	Paclitaxel	14-19	vimentin	Homo sapiens	56-64
15875079-2	2005	The study describes alterations in the distribution of vimentin and tubulin in taxol treated K-562 and HL-60 cells in relation to apoptotic changes.	Paclitaxel	79-84	vimentin	Homo sapiens	55-63
14567990-6	2003	The microtubule agents nocodazole and taxol dramatically alter Rab11a"s localization in the cell, while effects on Rab11b"s distribution were less apparent.	Paclitaxel	38-43	ras-related protein Rab-11A	Oryctolagus cuniculus	63-69
15452117-0	2004	Taxol induces caspase-10-dependent apoptosis.	Paclitaxel	0-5	caspase 10	Homo sapiens	14-24
15452117-3	2004	In this study we investigated death receptors, FAS-associated death domain protein (FADD), the activation of caspases-10 and -8 as well as the downstream caspases, and reactive oxygen species (ROS) in taxol-induced apoptosis in the CCRF-HSB-2 human lymphoblastic leukemia cell line.	Paclitaxel	201-206	Fas associated via death domain	Homo sapiens	47-82
15452117-3	2004	In this study we investigated death receptors, FAS-associated death domain protein (FADD), the activation of caspases-10 and -8 as well as the downstream caspases, and reactive oxygen species (ROS) in taxol-induced apoptosis in the CCRF-HSB-2 human lymphoblastic leukemia cell line.	Paclitaxel	201-206	Fas associated via death domain	Homo sapiens	84-88
14650960-1	2003	We conducted combination chemotherapy with gemcitabine (GEM) and paclitaxel (TXL) for stage III non-small cell lung cancer.	Paclitaxel	65-75	thioredoxin like 1	Homo sapiens	77-80
15452117-3	2004	In this study we investigated death receptors, FAS-associated death domain protein (FADD), the activation of caspases-10 and -8 as well as the downstream caspases, and reactive oxygen species (ROS) in taxol-induced apoptosis in the CCRF-HSB-2 human lymphoblastic leukemia cell line.	Paclitaxel	201-206	caspase 6	Homo sapiens	109-117
15899616-5	2004	Conversely, two randomized trials have demonstrated that dose-dense scheduled chemotherapy with G-CSF support, containing an anthracycline, cyclophosphamide and paclitaxel, improves clinical outcomes compared with the same regimen administered every 3 weeks.	Paclitaxel	161-171	colony stimulating factor 3	Homo sapiens	96-101
12941840-6	2003	The MGSA/Gro1 gene, important in melanoma growth, was induced by paclitaxel and reduced by MEK inhibition.	Paclitaxel	65-75	C-X-C motif chemokine ligand 1	Homo sapiens	4-8
15631682-1	2004	Chfr, a mitotic stress checkpoint gene, regulates a prophase delay in cells exposed to agents that disrupt microtubules, such as nocodazole and taxol.	Paclitaxel	144-149	checkpoint with forkhead and ring finger domains	Homo sapiens	0-4
12941840-6	2003	The MGSA/Gro1 gene, important in melanoma growth, was induced by paclitaxel and reduced by MEK inhibition.	Paclitaxel	65-75	C-X-C motif chemokine ligand 1	Homo sapiens	9-13
12941842-0	2003	The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice.	Paclitaxel	32-42	phosphoglycolate phosphatase	Mus musculus	14-28
12941842-3	2003	To address this question, we studied the normal brain and brain tumor distribution of paclitaxel (PAC), a known Pgp substrate, using steady-state PAC dosing regimens in wild-type and Pgp knockout (mdr1a -/- and mdr1b -/-) mice bearing an intracerebral B-16 melanoma.	Paclitaxel	86-96	phosphoglycolate phosphatase	Mus musculus	112-115
15548710-4	2004	PTEN-negative PC3 cells were observed to have increased resistance to both doxorubicin and paclitaxel when compared with PTEN-positive DU145 cells.	Paclitaxel	91-101	phosphatase and tensin homolog	Homo sapiens	0-4
12902902-6	2003	The chemoresistance of LoVo-R and C13 cells was confirmed by cytotoxicity tests consisting of 24-hour paclitaxel and 1-hour cisplatin incubation, respectively.	Paclitaxel	102-112	homeobox C13	Homo sapiens	34-37
15546192-4	2004	In this new method, a metabolite of PTX, 3"-(4-hydroxyphenyl)paclitaxel (3"-OH-PTX, 2, Figure 1) was used as a tyrosine mimic for the synthesis of the drug site-labeled conjugate (DSL, [(125)I]-3"-OH-PTXSXC225).	Paclitaxel	36-39	paired like homeodomain 1	Homo sapiens	61-72
12938275-1	2003	We report a case of long-term effectiveness of weekly paclitaxel (TXL) administration for metastatic gastric cancer.	Paclitaxel	54-64	thioredoxin like 1	Homo sapiens	66-69
15197489-0	2004	Involvement of oxidative stress and caspase activation in paclitaxel-induced apoptosis of primary effusion lymphoma cells.	Paclitaxel	58-68	caspase 2	Homo sapiens	36-43
15197489-6	2004	Upon paclitaxel treatment, caspase-2, caspase-3, and caspase-8 were activated in BCBL-1 cells.	Paclitaxel	5-15	caspase 2	Homo sapiens	27-36
12851839-3	2003	METHODS: In the present study we analyzed GSTM1 and GSTT1 polymorphisms in the genomic DNA isolated from peripheral blood of patients with ovarian cancer treated with chemotherapy (paclitaxel and cisplatinum) after cytoreductive surgery and assessed its correlation with the clinical outcome of these patients.	Paclitaxel	181-191	glutathione S-transferase theta 1	Homo sapiens	52-57
15197489-10	2004	These results suggest that oxidative stress is only partially involved in the cytotoxicity of paclitaxel in BCBL-1 cells, and that paclitaxel-induced apoptosis of BCBL-1 cells is primarily mediated by the caspase activation pathway.	Paclitaxel	131-141	caspase 2	Homo sapiens	205-212
15294455-0	2004	Role of c-myc protein in hormone refractory prostate carcinoma: cellular response to paclitaxel.	Paclitaxel	85-95	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	8-13
15294455-2	2004	In an attempt to investigate the role of c-myc in the cellular response to paclitaxel (PTX), we used two HRPC cell lines, DU145 and PC3, characterised by different levels of the protein and by different behaviour in response to taxane.	Paclitaxel	75-85	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	41-46
12727831-5	2003	The combination of 17-AAG and Taxol is synergistic, and 17-AAG sensitizes tumor cells to Taxol-induced apoptosis in a schedule-dependent manner.	Paclitaxel	89-94	N-methylpurine DNA glycosylase	Homo sapiens	59-62
15294455-2	2004	In an attempt to investigate the role of c-myc in the cellular response to paclitaxel (PTX), we used two HRPC cell lines, DU145 and PC3, characterised by different levels of the protein and by different behaviour in response to taxane.	Paclitaxel	87-90	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	41-46
12727831-8	2003	Doses of 17-AAG that induce HER2 degradation and cause Akt inactivation but have no single agent activity were effective in sensitizing tumors to Taxol.	Paclitaxel	146-151	N-methylpurine DNA glycosylase	Homo sapiens	12-15
15294455-4	2004	In DU145 cells, PTX induced an early apoptotic response associated with upregulation of c-myc restricted to the G2/M cell population.	Paclitaxel	16-19	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	88-93
15294455-8	2004	In both cell lines, PTX-induced c-myc phosphorylation was concomitant with the mitotic arrest and not related to the modulation of the activation state of AKT and MAPK kinases.	Paclitaxel	20-23	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	32-37
15294455-9	2004	Our data indicate that the cellular response to PTX of HRPC cells can involve c-myc and suggest that its pro-apoptotic role is affected by the genetic background, thus supporting a complex and differentiated HRPC cell response to taxanes.	Paclitaxel	48-51	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	78-83
12694868-2	2003	The present study shows that ML formation occurs at two different stages of apoptosis induced in human erythroleukemia K562 cells by a brief (3 hr) exposure to paclitaxel (Taxol), an antitumour drug with a stabilising effect on microtubules, or to paclitaxel plus tyrphostin AG957, a selective inhibitor of the p210(BCR-ABL) tyrosine kinase activity.	Paclitaxel	160-170	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	316-323
12694868-2	2003	The present study shows that ML formation occurs at two different stages of apoptosis induced in human erythroleukemia K562 cells by a brief (3 hr) exposure to paclitaxel (Taxol), an antitumour drug with a stabilising effect on microtubules, or to paclitaxel plus tyrphostin AG957, a selective inhibitor of the p210(BCR-ABL) tyrosine kinase activity.	Paclitaxel	172-177	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	316-323
15479494-8	2004	The rate of PSA decline for paclitaxel/estramustine was almost 2 times that of paclitaxel (47% vs. 27%), with acceptable toxicity.	Paclitaxel	28-38	kallikrein related peptidase 3	Homo sapiens	12-15
15248754-1	2004	Cmd 4 is a colcemid resistant beta-tubulin mutant of Chinese hamster ovary cells that exhibits hypersensitivity to paclitaxel and temperature sensitivity for growth.	Paclitaxel	115-125	beta tubulin	Cricetulus griseus	30-42
12615969-6	2003	The change in IP(3)R1 localization induced by arginine-vasopressin could be blocked by the simultaneous addition of nocodazole or taxol and depended on Ca(2+) release from intracellular stores since Ca(2+)-mobilizing agents such as thapsigargin and cyclopiazonic acid could induce the redistribution.	Paclitaxel	130-135	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	14-21
15256465-8	2004	Consistent with the operation of an ATP-dependent efflux pump, MRP7-transfected cells exhibited reduced accumulation of radiolabeled paclitaxel compared with HEK293 cells transfected with parental plasmid.	Paclitaxel	133-143	ATP binding cassette subfamily C member 10	Homo sapiens	63-67
12557722-2	2003	A total of 7 patients with recurrent ovarian cancer were treated with weekly paclitaxel (TXL).	Paclitaxel	77-87	thioredoxin like 1	Homo sapiens	89-92
15241487-0	2004	MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol.	Paclitaxel	149-154	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	0-4
12724856-0	2003	Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker.	Paclitaxel	86-96	CINN	Homo sapiens	111-115
12724856-3	2003	A-Z-CINN Linker links to a potent chemotherapeutic agent, paclitaxel, via an energy-reversible ester bond and also binds a targeting agent, the monoclonal antibody trastuzumab (Herceptin).	Paclitaxel	58-68	CINN	Homo sapiens	4-8
12724856-4	2003	This study demonstrates the effectiveness of a single-treatment use of A-Z-CINN 310 in decreasing tumor volume and tumor cell density of human HER-2-positive BT-474 mammary tumor cells implanted in scid mice, compared to treatment with simultaneously administered trastuzumab and paclitaxel and with saline control.	Paclitaxel	280-290	CINN	Homo sapiens	75-79
12724856-7	2003	Animals treated with A-Z-CINN 310, then light, showed dose-dependent decreases in tumor volume and tumor cell density which were more rapid and extensive than those seen with A-Z-CINN 310 without light or a 10-fold higher concentration of co-administered trastuzumab plus paclitaxel.	Paclitaxel	272-282	CINN	Homo sapiens	25-29
12724856-8	2003	This suggests that targeted delivery of paclitaxel using A-Z-CINN 310 kills tumor cells by localized release of paclitaxel at the tumor site, which can be accelerated by light treatment.	Paclitaxel	40-50	CINN	Homo sapiens	61-65
12724856-8	2003	This suggests that targeted delivery of paclitaxel using A-Z-CINN 310 kills tumor cells by localized release of paclitaxel at the tumor site, which can be accelerated by light treatment.	Paclitaxel	112-122	CINN	Homo sapiens	61-65
15241487-4	2004	A multiple pathway model is now presented, which demonstrates that MCL1 can undergo distinct phosphorylation events - mediated through separate signaling processes and involving different target sites - in cells that remain viable in the presence of TPA versus cells destined to die upon exposure to taxol or okadaic acid.	Paclitaxel	300-305	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	67-71
12724856-9	2003	These results indicate that a targeted prodrug therapy containing trastuzumab as the targeting agent and A-Z-CINN-paclitaxel as the prodrug results in a conjugate that is more effective in killing tumor cells than equivalent concentrations of co-administered trastuzumab and paclitaxel.	Paclitaxel	114-124	CINN	Homo sapiens	109-113
15304155-0	2004	Paclitaxel inhibits expression of heat shock protein 27 in ovarian and uterine cancer cells.	Paclitaxel	0-10	heat shock protein family B (small) member 1	Homo sapiens	34-55
12622926-6	2002	The extent of paclitaxel-induced apoptosis was determined by flow cytometry and immunohistochemical detection (TdT-mediated dUTP nick end labeling technique, TUNEL).	Paclitaxel	14-24	DNA nucleotidylexotransferase	Homo sapiens	111-114
15304155-1	2004	The purpose of the study was to determine whether paclitaxel inhibits the expression of heat shock protein 27 (HSP27) in two gynecologic cancer cell lines compared with other antineoplastic agents having different cytotoxic mechanisms.	Paclitaxel	50-60	heat shock protein family B (small) member 1	Homo sapiens	88-109
15304155-1	2004	The purpose of the study was to determine whether paclitaxel inhibits the expression of heat shock protein 27 (HSP27) in two gynecologic cancer cell lines compared with other antineoplastic agents having different cytotoxic mechanisms.	Paclitaxel	50-60	heat shock protein family B (small) member 1	Homo sapiens	111-116
15304155-8	2004	Paclitaxel completely inhibited the expression of HSP27.	Paclitaxel	0-10	heat shock protein family B (small) member 1	Homo sapiens	50-55
15304155-9	2004	The results of this study indicated that paclitaxel may possess unique mechanisms able to overcome drug resistance by inhibiting HSP27 expression.	Paclitaxel	41-51	heat shock protein family B (small) member 1	Homo sapiens	129-134
12218061-3	2002	Here we demonstrate that the first 4-8 N-terminal amino acids of Smac/DIABLO fused to the Drosophila antennapaedia penetratin sequence, a carrier peptide, enhance the induction of apoptosis and long term antiproliferative effects of diverse antineoplastic agents including paclitaxel, etoposide, 7-ethyl-10-hydroxycamptothecin (SN-38), and doxorubicin in MCF-7 breast cancer cells.	Paclitaxel	273-283	diablo	Drosophila melanogaster	65-69
14742319-6	2004	Using four stable Id-1 transfectant clones, we found that exogenous Id-1 expression led to phosphorylation of Raf-1 and MEK1/2 kinases, which was associated with resistance to taxol.	Paclitaxel	176-181	mitogen-activated protein kinase kinase 1	Homo sapiens	120-126
12218061-3	2002	Here we demonstrate that the first 4-8 N-terminal amino acids of Smac/DIABLO fused to the Drosophila antennapaedia penetratin sequence, a carrier peptide, enhance the induction of apoptosis and long term antiproliferative effects of diverse antineoplastic agents including paclitaxel, etoposide, 7-ethyl-10-hydroxycamptothecin (SN-38), and doxorubicin in MCF-7 breast cancer cells.	Paclitaxel	273-283	diablo	Drosophila melanogaster	70-76
15054472-7	2004	Compared to the parental cells, INT.ACP/PTX cells exhibited a high level of Pgp expression, resulting in a reduced in vitro sensitivity to both PTX and IDN 5390.	Paclitaxel	40-43	phosphoglycolate phosphatase	Homo sapiens	76-79
12530536-1	2002	Here we report on the study of the effects of different antineoplastic agents, including cytarabine, 4-hydroperoxyifosfamide, the activated form of ifosfamide, vincristine, and paclitaxel, with regard to their capacity to modulate the amount of cytoplasmic and membrane-bound heat shock protein 70 (Hsp70).	Paclitaxel	177-187	heat shock protein family A (Hsp70) member 4	Homo sapiens	276-297
12530536-1	2002	Here we report on the study of the effects of different antineoplastic agents, including cytarabine, 4-hydroperoxyifosfamide, the activated form of ifosfamide, vincristine, and paclitaxel, with regard to their capacity to modulate the amount of cytoplasmic and membrane-bound heat shock protein 70 (Hsp70).	Paclitaxel	177-187	heat shock protein family A (Hsp70) member 4	Homo sapiens	299-304
12530536-3	2002	Our results show that tubulin-interacting agents, including vincristine and paclitaxel, but not DNA-interacting agents, including cytarabine and ifosfamide, selectively increase the amount of cytoplasmic Hsp70 in tumor and normal cells, as measured by semi-quantitative Western blot analysis.	Paclitaxel	76-86	heat shock protein family A (Hsp70) member 4	Homo sapiens	204-209
12530536-4	2002	Mechanistically, a vincristine- and paclitaxel-induced tubulin assembly, as demonstrated by immunofluorescence microscopy, might be responsible for the elevated cytoplasmic Hsp70 levels.	Paclitaxel	36-46	heat shock protein family A (Hsp70) member 4	Homo sapiens	173-178
12530536-5	2002	Interestingly, an increased membrane expression of Hsp70 following treatment with vincristine or paclitaxel was selectively observed on tumor cells, but not on normal cells.	Paclitaxel	97-107	heat shock protein family A (Hsp70) member 4	Homo sapiens	51-56
15054472-7	2004	Compared to the parental cells, INT.ACP/PTX cells exhibited a high level of Pgp expression, resulting in a reduced in vitro sensitivity to both PTX and IDN 5390.	Paclitaxel	144-147	phosphoglycolate phosphatase	Homo sapiens	76-79
14760103-5	2004	SKRC-49 tumor xenografts in athymic nude mice were treated with ZD1839 and/or paclitaxel, and tumor volume was determined RESULTS: EGFR protein was expressed and phosphorylated in eight RCC lines and EGFR expression was markedly increased in RCC specimens compared with adjacent normal renal tissues.	Paclitaxel	78-88	epidermal growth factor receptor	Mus musculus	131-135
15015580-5	2004	The results demonstrated that NAT activity percent of NAT in examined cells, gene expression (NAT1 mRNA) and AF-DNA adduct formation in human osteogenic sarcoma cells were inhibited and decreased by paclitaxel in a dose-dependent manner.	Paclitaxel	199-209	N-acetyltransferase 1	Homo sapiens	94-98
12226754-8	2002	This is due to the Taxol-mediated reactivation of RelA through phosphorylation and degradation of IkappaBbeta and the re-expression of NF-kappaB regulated bcl-xl gene in these cancer cells as ectopic expression of the bcl-xl gene confers resistance to Taxol-induced apoptosis in PS-341 sensitized cells.	Paclitaxel	19-24	NFKB inhibitor beta	Homo sapiens	98-109
15565814-8	2004	Disease-free and overall survival with dose-dense sequential or concurrent doxorubicin, cyclophosphamide, and paclitaxel with filgrastim (rhG-CSF; NEUPOGEN) support are significantly greater than with conventional schedules (q21d).	Paclitaxel	110-120	colony stimulating factor 2	Homo sapiens	142-145
14500571-8	2004	The inhibitory effect of E2 on the paclitaxel-induced reduction of cell viability and apoptosis was diminished in cells transfected with ASK1S83A.	Paclitaxel	35-45	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	137-141
12135894-9	2002	Plk1 disappeared at the spindle region when microtubule formation was inhibited by colchicine or staurosporine, while it was concentrated as several dots in the cytoplasm after taxol treatment.	Paclitaxel	177-182	polo like kinase 1	Mus musculus	0-4
14500571-9	2004	These results indicate that E2 inhibits paclitaxel-induced cell damage by inhibiting JNK activity via phosphorylation of Akt-ASK1.	Paclitaxel	40-50	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	125-129
12063170-10	2002	The time course of Taxol-induced TNF-alpha expression coincides with that of Taxol-induced p66shc phosphorylation, and U0126 inhibits significantly Taxol-induced TNF-alpha expression in RAW 264.7 cells.	Paclitaxel	77-82	src homology 2 domain-containing transforming protein C1	Mus musculus	91-97
14703065-0	2003	Dose-dense vinorelbine and paclitaxel with granulocyte colony-stimulating factor in metastatic breast cancer patients: anti-tumor activity and peripheral blood progenitor cell mobilization capability.	Paclitaxel	27-37	colony stimulating factor 3	Homo sapiens	43-80
12063170-10	2002	The time course of Taxol-induced TNF-alpha expression coincides with that of Taxol-induced p66shc phosphorylation, and U0126 inhibits significantly Taxol-induced TNF-alpha expression in RAW 264.7 cells.	Paclitaxel	77-82	src homology 2 domain-containing transforming protein C1	Mus musculus	91-97
12063170-11	2002	Our data indicate that the Taxol-induced serine phosphorylation of p66shc in RAW 264.7 cells is microtubule-independent and may be related to increased TNF-alpha expression after Taxol and LPS treatment.	Paclitaxel	27-32	src homology 2 domain-containing transforming protein C1	Mus musculus	67-73
12063170-11	2002	Our data indicate that the Taxol-induced serine phosphorylation of p66shc in RAW 264.7 cells is microtubule-independent and may be related to increased TNF-alpha expression after Taxol and LPS treatment.	Paclitaxel	179-184	src homology 2 domain-containing transforming protein C1	Mus musculus	67-73
12063170-12	2002	It is concluded that the mechanisms involved in Taxol-induced p66shc phosphorylation are distinct in A549 and RAW 264.7 cells.	Paclitaxel	48-53	src homology 2 domain-containing transforming protein C1	Mus musculus	62-68
14516787-0	2003	Multiple effects of paclitaxel are modulated by a high c-myc amplification level.	Paclitaxel	20-30	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	55-60
11901098-2	2002	In spite of their close chemical structure, the two drugs are oxidized by two different enzymes; CYP2C8 catalyzes the 6-hydroxylation on the taxane ring of paclitaxel, whereas CYP3A4 oxidizes docetaxel on the tert-butyl group of the lateral chain in C13.	Paclitaxel	156-166	homeobox C13	Homo sapiens	250-253
11860338-2	2002	Most of the C10 analogues were slightly less active than paclitaxel in the tubulin assembly assay and had reduced potency in the B16 melanoma and MCF-7 cell line cytotoxicity assays.	Paclitaxel	57-67	gene rich cluster, C10 gene	Mus musculus	12-15
11751388-8	2001	Examination of pathways common to Taxol and retinoid signaling revealed that this synergy was related in part to effects on Bcl-2 expression/phosphorylation as well as the activity of the c-Jun NH(2)-terminal kinase and activator protein-1.	Paclitaxel	34-39	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	220-239
14516787-2	2003	Because both cell proliferation and apoptosis could be somehow regulated by the protooncogene c-myc, in this work we have investigated whether the c-myc amplification level could modulate the multiple effects of paclitaxel.	Paclitaxel	212-222	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	147-152
14516787-3	2003	To this aim, paclitaxel was administered to SW613-12A1 and -B3 human colon carcinoma cell lines (which are characterized by a high and low c-myc endogenous amplification level, respectively), and to the B3mycC5 cell line, with an enforced exogenous expression of c-myc copies.	Paclitaxel	13-23	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	263-268
11707575-4	2001	A dramatic stimulation of P-gp activity against Adr and Rho-123 by the identified compounds was accompanied by suppression of P-gp-mediated efflux of other substrates, such as Taxol (paclitaxel) or Hoechst 33342, indicating that they act as modulators of substrate specificity of P-gp.	Paclitaxel	176-181	phosphoglycolate phosphatase	Mus musculus	26-30
14516787-5	2003	Accordingly, the present results indicate that a high c-myc amplification level potentiates paclitaxel cytotoxicity, confers a multinucleated phenotype, and promotes apoptosis to a great extent, thus suggesting that c-myc expression level is relevant in modulating the cellular responses to paclitaxel.	Paclitaxel	92-102	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	54-59
11707575-4	2001	A dramatic stimulation of P-gp activity against Adr and Rho-123 by the identified compounds was accompanied by suppression of P-gp-mediated efflux of other substrates, such as Taxol (paclitaxel) or Hoechst 33342, indicating that they act as modulators of substrate specificity of P-gp.	Paclitaxel	176-181	phosphoglycolate phosphatase	Mus musculus	126-130
11707575-4	2001	A dramatic stimulation of P-gp activity against Adr and Rho-123 by the identified compounds was accompanied by suppression of P-gp-mediated efflux of other substrates, such as Taxol (paclitaxel) or Hoechst 33342, indicating that they act as modulators of substrate specificity of P-gp.	Paclitaxel	176-181	phosphoglycolate phosphatase	Mus musculus	126-130
11707575-4	2001	A dramatic stimulation of P-gp activity against Adr and Rho-123 by the identified compounds was accompanied by suppression of P-gp-mediated efflux of other substrates, such as Taxol (paclitaxel) or Hoechst 33342, indicating that they act as modulators of substrate specificity of P-gp.	Paclitaxel	183-193	phosphoglycolate phosphatase	Mus musculus	26-30
14516787-5	2003	Accordingly, the present results indicate that a high c-myc amplification level potentiates paclitaxel cytotoxicity, confers a multinucleated phenotype, and promotes apoptosis to a great extent, thus suggesting that c-myc expression level is relevant in modulating the cellular responses to paclitaxel.	Paclitaxel	92-102	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	216-221
14516787-5	2003	Accordingly, the present results indicate that a high c-myc amplification level potentiates paclitaxel cytotoxicity, confers a multinucleated phenotype, and promotes apoptosis to a great extent, thus suggesting that c-myc expression level is relevant in modulating the cellular responses to paclitaxel.	Paclitaxel	291-301	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	54-59
14516787-5	2003	Accordingly, the present results indicate that a high c-myc amplification level potentiates paclitaxel cytotoxicity, confers a multinucleated phenotype, and promotes apoptosis to a great extent, thus suggesting that c-myc expression level is relevant in modulating the cellular responses to paclitaxel.	Paclitaxel	291-301	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	216-221
14516787-6	2003	We have recently shown in HeLa cells that the phosphorylated form of c-Myc accumulates in the nucleus, as distinct nucleolar and extranucleolar spots; here, we demonstrated that, after the treatment with paclitaxel, phosphorylated c-Myc undergoes redistribution, becoming diffused in the nucleoplasm.	Paclitaxel	204-214	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	69-74
14516787-6	2003	We have recently shown in HeLa cells that the phosphorylated form of c-Myc accumulates in the nucleus, as distinct nucleolar and extranucleolar spots; here, we demonstrated that, after the treatment with paclitaxel, phosphorylated c-Myc undergoes redistribution, becoming diffused in the nucleoplasm.	Paclitaxel	204-214	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	231-236
11707575-4	2001	A dramatic stimulation of P-gp activity against Adr and Rho-123 by the identified compounds was accompanied by suppression of P-gp-mediated efflux of other substrates, such as Taxol (paclitaxel) or Hoechst 33342, indicating that they act as modulators of substrate specificity of P-gp.	Paclitaxel	183-193	phosphoglycolate phosphatase	Mus musculus	126-130
13130078-8	2003	The anti-MDM2 oligonucleotide showed antitumor activity and increased therapeutic effectiveness of paclitaxel in both LNCaP and PC3 xenografts, causing changes in gene expression similar to those seen in vitro.	Paclitaxel	99-109	proprotein convertase subtilisin/kexin type 1	Homo sapiens	128-131
11707575-4	2001	A dramatic stimulation of P-gp activity against Adr and Rho-123 by the identified compounds was accompanied by suppression of P-gp-mediated efflux of other substrates, such as Taxol (paclitaxel) or Hoechst 33342, indicating that they act as modulators of substrate specificity of P-gp.	Paclitaxel	183-193	phosphoglycolate phosphatase	Mus musculus	126-130
11707575-5	2001	Consistently, P-gp modulators dramatically altered the pattern of cross-resistance of P-gp-expressing cells to different P-gp substrates: an increase in resistance to Adr, daunorubicin, and etoposide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect on cell sensitivity to colchicine, actinomycin D, puromycin, and colcemid, as well as to several non-P-gp substrates.	Paclitaxel	276-281	phosphoglycolate phosphatase	Mus musculus	14-18
12783201-6	2003	The median MTD in those receiving carboplatin alone (AUC 6.9) was significantly lower than in those treated with carboplatin and paclitaxel (AUC 7.6) ( P=0.01).	Paclitaxel	129-139	metallothionein 1E	Homo sapiens	11-14
11562742-4	2001	The enhanced loss of BRCA1 protein by taxol, okadaic acid or nocodazole treatment was prevented by the proteasome inhibitors, while inhibition of other proteases was ineffective.	Paclitaxel	38-43	BRCA1 DNA repair associated	Homo sapiens	21-26
11521190-9	2001	Using a chimeric GAL4-RelA transactivator, we find that taxol potently activates GAL4-RelA-dependent transcription.	Paclitaxel	56-61	galectin 4	Homo sapiens	17-21
11521190-9	2001	Using a chimeric GAL4-RelA transactivator, we find that taxol potently activates GAL4-RelA-dependent transcription.	Paclitaxel	56-61	galectin 4	Homo sapiens	81-85
11521190-11	2001	Our results indicate that RelA transactivation is an important downstream target of the PKC iota-mediated Bcr-Abl signaling pathway and is required for resistance to taxol-induced apoptosis.	Paclitaxel	166-171	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	106-113
12783201-8	2003	CONCLUSIONS: The median MTD documented here using intrapatient dose escalation for carboplatin combined with paclitaxel is remarkably similar to that derived from conventional phase I studies.	Paclitaxel	109-119	metallothionein 1E	Homo sapiens	24-27
11554785-3	2001	A subset of the genes examined (e.g., G-CSF, MIP-2, iNOS, and IL-1 beta, and GM-CSF) was upregulated &gt;3-20-fold by both LPS and paclitaxel in the DA-3 cell line, while IP-10 mRNA was induced by paclitaxel, but not by LPS.	Paclitaxel	131-141	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	77-83
12897130-0	2003	Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells.	Paclitaxel	80-90	polo like kinase 2	Homo sapiens	39-42
11554785-4	2001	In the human MDA-MB-231 breast cancer cell line, LPS also increased mRNA levels for both GM-CSF and IP-10 significantly, while, paclitaxel increased IP-10 mRNA levels with delayed kinetics and failed to induce GM-CSF mRNA.	Paclitaxel	128-138	C-X-C motif chemokine ligand 10	Homo sapiens	149-154
11500829-0	2001	The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol.	Paclitaxel	58-63	myeloid differentiation primary response gene 88	Mus musculus	12-17
11500829-5	2001	Taxol-induced NF-kappa B-driven luciferase activity was reduced after transfection of RAW 264.7 macrophages with a dominant negative version of mouse MyD88.	Paclitaxel	0-5	myeloid differentiation primary response gene 88	Mus musculus	150-155
11500829-6	2001	Taxol-induced microtubule-associated protein kinase (MAPK) activation and NF-kappa B nuclear translocation were absent from TLR4-null macrophages, but were preserved in MyD88 knockout macrophages with a slight delay in kinetics.	Paclitaxel	0-5	myeloid differentiation primary response gene 88	Mus musculus	169-174
11500829-8	2001	These results suggest that Taxol and LPS not only share a TLR4/MyD88-dependent pathway in generating inflammatory mediators, but also share a TLR4-dependent/MyD88-independent pathway leading to activation of MAPK and NF-kappa B.	Paclitaxel	27-32	myeloid differentiation primary response gene 88	Mus musculus	63-68
11500829-8	2001	These results suggest that Taxol and LPS not only share a TLR4/MyD88-dependent pathway in generating inflammatory mediators, but also share a TLR4-dependent/MyD88-independent pathway leading to activation of MAPK and NF-kappa B.	Paclitaxel	27-32	myeloid differentiation primary response gene 88	Mus musculus	157-162
11425893-9	2001	However, taxol activated a subpool of JNK in the nucleus and stimulated c-Jun phosphorylation.	Paclitaxel	9-14	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	72-77
11425893-10	2001	JNK inhibition or expression of a dominant-negative c-Jun abrogated taxol-induced apoptosis in cortical neurons, suggesting a role for JNK and JNK-mediated transcription in taxol-stimulated apoptosis.	Paclitaxel	68-73	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	52-57
12897130-0	2003	Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells.	Paclitaxel	80-90	polo like kinase 2	Homo sapiens	43-47
12897130-0	2003	Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells.	Paclitaxel	92-97	polo like kinase 2	Homo sapiens	39-42
12897130-0	2003	Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells.	Paclitaxel	92-97	polo like kinase 2	Homo sapiens	43-47
12897130-4	2003	Small interfering RNA (siRNA)-mediated Snk/Plk2 silencing in the presence of the mitotic poisons paclitaxel (Taxol) or nocodazole significantly increased apoptosis, similar to p53 mutations, which confer paclitaxel sensitivity.	Paclitaxel	97-107	polo like kinase 2	Homo sapiens	39-42
11425893-10	2001	JNK inhibition or expression of a dominant-negative c-Jun abrogated taxol-induced apoptosis in cortical neurons, suggesting a role for JNK and JNK-mediated transcription in taxol-stimulated apoptosis.	Paclitaxel	173-178	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	52-57
12897130-4	2003	Small interfering RNA (siRNA)-mediated Snk/Plk2 silencing in the presence of the mitotic poisons paclitaxel (Taxol) or nocodazole significantly increased apoptosis, similar to p53 mutations, which confer paclitaxel sensitivity.	Paclitaxel	97-107	polo like kinase 2	Homo sapiens	43-47
12897130-4	2003	Small interfering RNA (siRNA)-mediated Snk/Plk2 silencing in the presence of the mitotic poisons paclitaxel (Taxol) or nocodazole significantly increased apoptosis, similar to p53 mutations, which confer paclitaxel sensitivity.	Paclitaxel	109-114	polo like kinase 2	Homo sapiens	39-42
12897130-4	2003	Small interfering RNA (siRNA)-mediated Snk/Plk2 silencing in the presence of the mitotic poisons paclitaxel (Taxol) or nocodazole significantly increased apoptosis, similar to p53 mutations, which confer paclitaxel sensitivity.	Paclitaxel	109-114	polo like kinase 2	Homo sapiens	43-47
12897130-4	2003	Small interfering RNA (siRNA)-mediated Snk/Plk2 silencing in the presence of the mitotic poisons paclitaxel (Taxol) or nocodazole significantly increased apoptosis, similar to p53 mutations, which confer paclitaxel sensitivity.	Paclitaxel	204-214	polo like kinase 2	Homo sapiens	39-42
12897130-4	2003	Small interfering RNA (siRNA)-mediated Snk/Plk2 silencing in the presence of the mitotic poisons paclitaxel (Taxol) or nocodazole significantly increased apoptosis, similar to p53 mutations, which confer paclitaxel sensitivity.	Paclitaxel	204-214	polo like kinase 2	Homo sapiens	43-47
11408590-5	2001	As with Rab11a in MDCK cells, the myosin Vb immunoreactivity was dispersed with nocodazole treatment and relocated to the apical corners of cells with taxol treatment.	Paclitaxel	151-156	myosin VB	Canis lupus familiaris	34-43
12897130-6	2003	Since siRNA directed against Snk/Plk2 promoted death of paclitaxel-treated cells in mitosis, we envision a mitotic checkpoint wherein p53-dependent activation of Snk/Plk2 prevents mitotic catastrophe following spindle damage.	Paclitaxel	56-66	polo like kinase 2	Homo sapiens	29-32
11350918-9	2001	Tumor regression was observed in all mice after treatment with ZD1839 plus paclitaxel, and it was accompanied by a significant potentiation in inhibition of TGF-alpha, VEGF, and bFGF expression with a few or no microvessels.	Paclitaxel	75-85	vascular endothelial growth factor A	Mus musculus	168-172
12897130-6	2003	Since siRNA directed against Snk/Plk2 promoted death of paclitaxel-treated cells in mitosis, we envision a mitotic checkpoint wherein p53-dependent activation of Snk/Plk2 prevents mitotic catastrophe following spindle damage.	Paclitaxel	56-66	polo like kinase 2	Homo sapiens	33-37
12897130-6	2003	Since siRNA directed against Snk/Plk2 promoted death of paclitaxel-treated cells in mitosis, we envision a mitotic checkpoint wherein p53-dependent activation of Snk/Plk2 prevents mitotic catastrophe following spindle damage.	Paclitaxel	56-66	polo like kinase 2	Homo sapiens	162-165
12897130-6	2003	Since siRNA directed against Snk/Plk2 promoted death of paclitaxel-treated cells in mitosis, we envision a mitotic checkpoint wherein p53-dependent activation of Snk/Plk2 prevents mitotic catastrophe following spindle damage.	Paclitaxel	56-66	polo like kinase 2	Homo sapiens	166-170
12897130-7	2003	Finally, these studies suggest that disruption of Snk/Plk2 may be of therapeutic value in sensitizing paclitaxel-resistant tumors.	Paclitaxel	102-112	polo like kinase 2	Homo sapiens	50-53
11295099-0	2001	Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines.	Paclitaxel	79-84	BRCA1 DNA repair associated	Homo sapiens	14-19
11295099-0	2001	Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines.	Paclitaxel	79-84	BRCA2 DNA repair associated	Homo sapiens	24-29
12897130-7	2003	Finally, these studies suggest that disruption of Snk/Plk2 may be of therapeutic value in sensitizing paclitaxel-resistant tumors.	Paclitaxel	102-112	polo like kinase 2	Homo sapiens	54-58
12848775-7	2003	A standard dose of 175 mg x m(-2) of paclitaxel could be safely combined with doses of zosuquidar 3HCl resulting in plasma concentrations known, from previous studies, to result in maximal P-gp inhibition.	Paclitaxel	37-47	phosphoglycolate phosphatase	Homo sapiens	189-193
12848775-8	2003	CONCLUSIONS: This analysis provides a model which accurately characterized the increase in paclitaxel exposure, which is most likely to be due to P-gp inhibition in the bile canaliculi, in the presence of zosuquidar 3HCl (Cmax &gt; 350 microg x l(-1)) and is predictive of paclitaxel pharmacokinetics following a 3 h infusion.	Paclitaxel	91-101	phosphoglycolate phosphatase	Homo sapiens	146-150
11329783-1	2001	We conducted a dose-finding study for combination therapy of paclitaxel (Taxol; TXL) and carboplatin (Paraplatin; CBDCA).	Paclitaxel	61-71	thioredoxin like 1	Homo sapiens	80-83
12765196-7	2003	The results demonstrated that both taxol and CPT could inhibit the migration of B16F10 cells, and inhibit the adhesion of B16F10 to fibronectin and laminin.	Paclitaxel	35-40	fibronectin 1	Mus musculus	132-143
11329783-1	2001	We conducted a dose-finding study for combination therapy of paclitaxel (Taxol; TXL) and carboplatin (Paraplatin; CBDCA).	Paclitaxel	73-78	thioredoxin like 1	Homo sapiens	80-83
11237678-3	2001	Macrophages killed the mM-CSF-expressing tumors in the presence of noncytotoxic doses of either taxol or taxol plus cisplatin.	Paclitaxel	96-101	colony stimulating factor 1 (macrophage)	Mus musculus	23-29
11237678-3	2001	Macrophages killed the mM-CSF-expressing tumors in the presence of noncytotoxic doses of either taxol or taxol plus cisplatin.	Paclitaxel	105-110	colony stimulating factor 1 (macrophage)	Mus musculus	23-29
11123339-6	2001	In contrast, for optimal induction of COX-2, IL-12 p35, and IL-12 p40 genes by low concentrations of LPS or by all concentrations of Taxol, CD11b/CD18 was also required.	Paclitaxel	133-138	interleukin 12b	Mus musculus	66-69
12787261-0	2003	Paclitaxel (taxol) inhibits the arylamine N-acetyltransferase activity and gene expression (mRNA NAT1) and 2-aminofluorene-DNA adduct formation in human bladder carcinoma cells (T24 and TSGH 8301).	Paclitaxel	0-10	N-acetyltransferase 1	Homo sapiens	97-101
11123339-7	2001	Mitigated induction of COX-2, IL-12 p35, and IL-12 p40 gene expression by CD11b/CD18-deficient macrophages correlated with a marked inhibition of NF-kappa B nuclear translocation and mitogen-activated protein kinase (MAPK) activation in response to Taxol and of NF-kappa B nuclear translocation in response to LPS.	Paclitaxel	249-254	interleukin 12b	Mus musculus	45-54
11200057-0	2001	Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation.	Paclitaxel	50-60	interleukin 10	Homo sapiens	32-37
12787261-0	2003	Paclitaxel (taxol) inhibits the arylamine N-acetyltransferase activity and gene expression (mRNA NAT1) and 2-aminofluorene-DNA adduct formation in human bladder carcinoma cells (T24 and TSGH 8301).	Paclitaxel	12-17	N-acetyltransferase 1	Homo sapiens	97-101
11200057-6	2001	Depletion studies revealed that IL-10 and transforming growth factor-beta1 (TGF-beta1), but not prostaglandin E2 (PGE2), impaired paclitaxel-mediated activation, suggesting that abrogation of these factors in situ might restore paclitaxel"s activating capacity and enhance anti-tumor efficacy.	Paclitaxel	130-140	interleukin 10	Homo sapiens	32-37
11200057-6	2001	Depletion studies revealed that IL-10 and transforming growth factor-beta1 (TGF-beta1), but not prostaglandin E2 (PGE2), impaired paclitaxel-mediated activation, suggesting that abrogation of these factors in situ might restore paclitaxel"s activating capacity and enhance anti-tumor efficacy.	Paclitaxel	228-238	interleukin 10	Homo sapiens	32-37
12787261-7	2003	The results demonstrated that the N-acetyltransferase activity, gene expression (NAT1 mRNA) and 2-aminofluorene-DNA adduct formation in intact human bladder carcinoma cells were inhibited and decreased by paclitaxel in a dose-dependent manner.	Paclitaxel	205-215	N-acetyltransferase 1	Homo sapiens	81-85
11097380-5	2000	Cytotoxicity of DTX and PCT for P388D1 cells became apparent 24 h after a 2-h incubation period with the drugs, and their effects were enhanced by CYP2E1 microsomes, but markedly decreased by CYP3A-induced microsomes.	Paclitaxel	24-27	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	192-197
12761496-0	2003	Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells.	Paclitaxel	0-10	H3 histone pseudogene 16	Homo sapiens	21-24
11025661-2	2000	Treatment with vincristine or paclitaxel before DNA-damage or before leptomycin B treatment reduces nuclear accumulation of p53 and expression of mdm2 and p21.	Paclitaxel	30-40	MDM2 proto-oncogene	Homo sapiens	146-150
12761496-1	2003	CKI p21 is a regulator of cellular responses to microtubule damage induced by drugs such as paclitaxel (PTX).	Paclitaxel	92-102	H3 histone pseudogene 16	Homo sapiens	4-7
12761496-1	2003	CKI p21 is a regulator of cellular responses to microtubule damage induced by drugs such as paclitaxel (PTX).	Paclitaxel	104-107	H3 histone pseudogene 16	Homo sapiens	4-7
12761496-3	2003	We demonstrated here that low doses of PTX that are unable to activate the spindle assembly checkpoint, upregulate p21 by a p53-dependent pathway and induce its translocation to the cytoplasm.	Paclitaxel	39-42	H3 histone pseudogene 16	Homo sapiens	115-118
11016645-0	2000	Taxol mediates serine phosphorylation of the 66-kDa Shc isoform.	Paclitaxel	0-5	SHC adaptor protein 1	Homo sapiens	52-55
12761496-5	2003	Furthermore, the cytoplasmic p21 accumulation observed in PTX-treated cells was inhibited by LY 294002, a specific PI-3 kinase inhibitor or by the expression of a dominant-negative AKT mutant.	Paclitaxel	58-61	H3 histone pseudogene 16	Homo sapiens	29-32
11016645-1	2000	In the human lung carcinoma cell line A549, Taxol (20 nM) causes a decreased electrophoretic mobility of the 66-kDa Shc isoform (p66shc), beginning 4 h after drug exposure, and reaching a maximum at 9-18 h. No shift was observed for the 52- and 46-kDa isoforms of Shc.	Paclitaxel	44-49	SHC adaptor protein 1	Homo sapiens	116-119
11016645-1	2000	In the human lung carcinoma cell line A549, Taxol (20 nM) causes a decreased electrophoretic mobility of the 66-kDa Shc isoform (p66shc), beginning 4 h after drug exposure, and reaching a maximum at 9-18 h. No shift was observed for the 52- and 46-kDa isoforms of Shc.	Paclitaxel	44-49	SHC adaptor protein 1	Homo sapiens	264-267
12761496-6	2003	However, the kinase activity of AKT was unchanged in PTX-treated cells, suggesting that low doses of PTX could regulate p21 phosphorylation via inhibition of its dephosphorylation.	Paclitaxel	101-104	H3 histone pseudogene 16	Homo sapiens	120-123
10988356-6	2000	Our results indicate that taxol treatment inhibits Raf-1 kinase activation while having no effect on ERK activation suggesting that ERK activation is distinct from upstream Raf-1 kinase in taxol-induced immunomodulation.	Paclitaxel	26-31	v-raf-leukemia viral oncogene 1	Mus musculus	51-56
10988356-7	2000	Furthermore, paclitaxel pretreatment caused down-regulation of stress-activated MAPKs, JNK and p38 MAPK in lipopolysaccharide (LPS)-stimulated mouse splenic lymphocytes, demonstrating that spleen cells are induced to a state hyporesponsive to LPS stimulation by pre-exposing them to paclitaxel.	Paclitaxel	13-23	mitogen-activated protein kinase 8	Mus musculus	87-90
26680929-10	2003	The Taxol-induced apoptosis in p53 defected-osteogenic sarcoma cells was associated with the PARP cleavage as a result of the increased activity of caspase 3, and the high expressions of cyclin B1 and PLK.	Paclitaxel	4-9	cyclin B1	Homo sapiens	187-196
10988356-8	2000	Taken together, these results suggest that down-regulation of JNK/p38 MAP kinase may contribute to paclitaxel-induced immunosuppression in mouse splenic lymphocytes.	Paclitaxel	99-109	mitogen-activated protein kinase 8	Mus musculus	62-65
12649748-0	2003	Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody.	Paclitaxel	12-22	integrin alpha L	Mus musculus	53-58
12649748-5	2003	Flow cytometric analysis of paclitaxel- or vinblastine-treated P815 cells revealed reduced cell-surface expression of the adhesion molecules LFA-1 (CD11a /CD18) and ICAM-1 (CD54).	Paclitaxel	28-38	integrin alpha L	Mus musculus	141-146
12649748-5	2003	Flow cytometric analysis of paclitaxel- or vinblastine-treated P815 cells revealed reduced cell-surface expression of the adhesion molecules LFA-1 (CD11a /CD18) and ICAM-1 (CD54).	Paclitaxel	28-38	integrin alpha L	Mus musculus	148-153
12649748-7	2003	RT-PCR analysis revealed reduced levels of mRNAs coding for CD11a and CD54 in paclitaxel- or vinblastine-pretreated P815 cells.	Paclitaxel	78-88	integrin alpha L	Mus musculus	60-65
12649748-8	2003	Collectively, these data lead us to conclude that paclitaxel and vinblastine render P815 mastocytoma cells resistant to T cell-mediated cytotoxicity by interfering with CD11a and CD54 expression by the tumor cells.	Paclitaxel	50-60	integrin alpha L	Mus musculus	169-174
12672789-1	2003	BACKGROUND: Paclitaxel, ifosfamide and cisplatin (TIP) has been tested with successful results on metastatic testicular cancer in Western countries.	Paclitaxel	12-22	TOR signaling pathway regulator	Homo sapiens	50-53
12672789-6	2003	TIP consisted of paclitaxel 175 mg/m(2) by 24 h infusion on day 1, followed by ifosfamide 1.2 g/m(2) infusions over 2 h and cisplatin 20 mg/m(2 )given over 2 h on days 2-6.	Paclitaxel	17-27	TOR signaling pathway regulator	Homo sapiens	0-3
12574211-4	2003	We hypothesized that p21 had a proapoptotic effect in cells treated with manumycin, or paclitaxel, or both agents.	Paclitaxel	87-97	H3 histone pseudogene 16	Homo sapiens	21-24
12574211-5	2003	By measuring viability and caspase-3 activity, we found that stably transfected KAT-4 cells with p21 cDNA under the control of a metallothionein promoter were more sensitive to manumycin alone, paclitaxel alone, and manumycin plus paclitaxel when p21was induced.	Paclitaxel	194-204	H3 histone pseudogene 16	Homo sapiens	97-100
12574211-5	2003	By measuring viability and caspase-3 activity, we found that stably transfected KAT-4 cells with p21 cDNA under the control of a metallothionein promoter were more sensitive to manumycin alone, paclitaxel alone, and manumycin plus paclitaxel when p21was induced.	Paclitaxel	231-241	H3 histone pseudogene 16	Homo sapiens	97-100
12574211-7	2003	We also found that cells with both p21 alleles deleted were less sensitive to manumycin plus paclitaxel than its wild-type parent cells.	Paclitaxel	93-103	H3 histone pseudogene 16	Homo sapiens	35-38
12574211-8	2003	Expression of p21 per se did not induce apoptosis but enhanced the cytotoxic effects of manumycin and paclitaxel.	Paclitaxel	102-112	H3 histone pseudogene 16	Homo sapiens	14-17
12574211-9	2003	These findings suggested that p21 might be required to maintain cell sensitivity to the cytotoxic effects of manumycin and paclitaxel.	Paclitaxel	123-133	H3 histone pseudogene 16	Homo sapiens	30-33
12555062-3	2003	Here, we report that paclitaxel, a microtubule-damaging agent, induces phosphorylation of p70S6K at threonine 421 and serine 424 (T421/S424) in a concentration- and time-dependent manner in multiple breast and ovarian cancer cell lines demonstrated by a T421/S424 phospho-p70S6K antibody.	Paclitaxel	21-31	ribosomal protein S6 kinase B1	Homo sapiens	90-96
12555062-3	2003	Here, we report that paclitaxel, a microtubule-damaging agent, induces phosphorylation of p70S6K at threonine 421 and serine 424 (T421/S424) in a concentration- and time-dependent manner in multiple breast and ovarian cancer cell lines demonstrated by a T421/S424 phospho-p70S6K antibody.	Paclitaxel	21-31	ribosomal protein S6 kinase B1	Homo sapiens	272-278
12555062-4	2003	Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorylated in p70S6K following treatment with paclitaxel.	Paclitaxel	205-215	ribosomal protein S6 kinase B1	Homo sapiens	173-179
12555062-5	2003	Paclitaxel-induced p70S6K(T421/S424) phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca(++), PI3K, and mammalian target of rapamycin (mTOR).	Paclitaxel	0-10	ribosomal protein S6 kinase B1	Homo sapiens	19-25
12555062-8	2003	Inhibition of PKC and JNK prevents paclitaxel-induced p70S6K inactivation.	Paclitaxel	35-45	ribosomal protein S6 kinase B1	Homo sapiens	54-60
12555062-9	2003	Moreover, the paclitaxel-induced phosphorylation and low activity of p70S6K mainly occurs during mitosis.	Paclitaxel	14-24	ribosomal protein S6 kinase B1	Homo sapiens	69-75
12555062-10	2003	In summary, paclitaxel is able to induce p70S6K(T421/S424) phosphorylation and decrease its activity in mitotic cells via multiple signaling pathways.	Paclitaxel	12-22	ribosomal protein S6 kinase B1	Homo sapiens	41-47
12555062-11	2003	Our data suggest that paclitaxel-induced p70S6K(T421/S424) phosphorylation and kinase inactivation are differentially regulated.	Paclitaxel	22-32	ribosomal protein S6 kinase B1	Homo sapiens	41-47
12555062-12	2003	Our data also indicate that paclitaxel may exert its antitumor effect, at least in part, via inhibition of p70S6K.	Paclitaxel	28-38	ribosomal protein S6 kinase B1	Homo sapiens	107-113
12496426-6	2003	These results suggest that the ability of MD-2 to form the cell surface mouse TLR4-mouse MD-2 complex recognized by MTS510 is essential for conferring LPS and Taxol responsiveness on TLR4, but not sufficient.	Paclitaxel	159-164	lymphocyte antigen 96	Mus musculus	42-46
12496426-6	2003	These results suggest that the ability of MD-2 to form the cell surface mouse TLR4-mouse MD-2 complex recognized by MTS510 is essential for conferring LPS and Taxol responsiveness on TLR4, but not sufficient.	Paclitaxel	159-164	lymphocyte antigen 96	Mus musculus	89-93
12460900-6	2002	Overexpression of stathmin decreased polymerization of microtubules, markedly decreased binding of paclitaxel, and increased binding of vinblastine.	Paclitaxel	99-109	stathmin 1	Homo sapiens	18-26
12460900-7	2002	Stathmin overexpression decreased sensitivity to paclitaxel and, to a lesser extent, to vinblastine.	Paclitaxel	49-59	stathmin 1	Homo sapiens	0-8
12384528-5	2002	Herceptin plus Taxol treatment led to higher levels of p34(Cdc2) kinase activity and apoptosis in ErbB2-overexpressing breast cancer cells, which is likely attributable to inhibition of Cdc2-Tyr-15 phosphorylation and p21(Cip1) expression.	Paclitaxel	15-20	cyclin dependent kinase 1	Homo sapiens	186-190
12384528-5	2002	Herceptin plus Taxol treatment led to higher levels of p34(Cdc2) kinase activity and apoptosis in ErbB2-overexpressing breast cancer cells, which is likely attributable to inhibition of Cdc2-Tyr-15 phosphorylation and p21(Cip1) expression.	Paclitaxel	15-20	H3 histone pseudogene 16	Homo sapiens	218-221
12384528-8	2002	Thus, Herceptin treatment of ErbB2-overexpressing cells can inhibit ErbB2-mediated Cdc2-Tyr-15 phosphorylation and p21(Cip1) up-regulation, which allows effective p34(Cdc2) activation and induction of apoptosis upon Taxol treatment.	Paclitaxel	216-221	cyclin dependent kinase 1	Homo sapiens	83-87
12384528-8	2002	Thus, Herceptin treatment of ErbB2-overexpressing cells can inhibit ErbB2-mediated Cdc2-Tyr-15 phosphorylation and p21(Cip1) up-regulation, which allows effective p34(Cdc2) activation and induction of apoptosis upon Taxol treatment.	Paclitaxel	216-221	H3 histone pseudogene 16	Homo sapiens	115-118
12415202-9	2002	Recently, it became apparent that coumarin antibiotics, cisplatin and paclitaxel also bind to Hsp90.	Paclitaxel	70-80	heat shock protein 90 alpha family class A member 1	Homo sapiens	94-99
12236791-5	2002	In the absence of plasma, only the 2"-(N-methylpyridinium acetate) derivative of paclitaxel (2"-MPA-paclitaxel) revealed a complete abrogation of paclitaxel specific microtubule assembly disassembly dynamics and a 3 log reduction in cellular binding, indicating that reversible blockage of the C-2" position by methylpyridinium acetate yields a true paclitaxel prodrug.	Paclitaxel	81-91	complement C2	Homo sapiens	294-297
12236791-5	2002	In the absence of plasma, only the 2"-(N-methylpyridinium acetate) derivative of paclitaxel (2"-MPA-paclitaxel) revealed a complete abrogation of paclitaxel specific microtubule assembly disassembly dynamics and a 3 log reduction in cellular binding, indicating that reversible blockage of the C-2" position by methylpyridinium acetate yields a true paclitaxel prodrug.	Paclitaxel	100-110	complement C2	Homo sapiens	294-297
12236791-5	2002	In the absence of plasma, only the 2"-(N-methylpyridinium acetate) derivative of paclitaxel (2"-MPA-paclitaxel) revealed a complete abrogation of paclitaxel specific microtubule assembly disassembly dynamics and a 3 log reduction in cellular binding, indicating that reversible blockage of the C-2" position by methylpyridinium acetate yields a true paclitaxel prodrug.	Paclitaxel	100-110	complement C2	Homo sapiens	294-297
12519017-1	2002	We have established a reliable, reproducible and objective growth assay to measure whether leukemia inhibitory factor (LIF) was able to protect tumour-derived cell lines from toxic effects of the chemotherapy agents, cisplatin and paclitaxel.	Paclitaxel	231-241	LIF interleukin 6 family cytokine	Homo sapiens	91-117
12519017-1	2002	We have established a reliable, reproducible and objective growth assay to measure whether leukemia inhibitory factor (LIF) was able to protect tumour-derived cell lines from toxic effects of the chemotherapy agents, cisplatin and paclitaxel.	Paclitaxel	231-241	LIF interleukin 6 family cytokine	Homo sapiens	119-122
12139759-7	2002	In accordance with the previous reports, Taxol induced the expression of TNF-alpha and apoptosis in a TLR4-independent manner.	Paclitaxel	41-46	toll like receptor 4	Homo sapiens	102-106
12174867-6	2002	Retransfection of the PGK1 insert into U-20S confers a multidrug resistant phenotype, characterized by a 30-fold increase in paclitaxel resistance, and cross-resistance to vincristine; adriamycin and mitoxantrone, but not methotrexate or cisplatin.	Paclitaxel	125-135	phosphoglycerate kinase 1	Homo sapiens	22-26
12085250-13	2002	The present study indicates that patients responded to treatment of advanced breast cancer with single-agent paclitaxel or docetaxel leads to an increase in serum IFN-gamma, IL-2, IL-6, GM-CSF cytokine levels and enhancement of PBMC NK and LAK cell activity, while they both lead to a decrease of acute phase serum cytokine levels of IL-1 and TNF-alpha.	Paclitaxel	109-119	colony stimulating factor 2	Homo sapiens	186-192
12222966-1	2002	We evaluated in vitro the effect of paclitaxel and docetaxel on PC-3 and DU-145 prostate cancer cell lines to understand better the downstream events in drug-induced tumor cell death.	Paclitaxel	36-46	chromobox 8	Homo sapiens	64-68
12049736-0	2002	Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis.	Paclitaxel	116-121	cyclin dependent kinase 1	Homo sapiens	38-42
12049736-1	2002	ErbB2 overexpression confers resistance to taxol-induced apoptosis by inhibiting p34(Cdc2) activation.	Paclitaxel	43-48	cyclin dependent kinase 1	Homo sapiens	85-89
12049736-7	2002	Expressing a nonphosphorylatable mutant of Cdc2 renders cells more sensitive to taxol-induced apoptosis.	Paclitaxel	80-85	cyclin dependent kinase 1	Homo sapiens	43-47
12049736-8	2002	Thus, ErbB2 membrane RTK can confer resistance to taxol-induced apoptosis by directly phosphorylating Cdc2.	Paclitaxel	50-55	cyclin dependent kinase 1	Homo sapiens	102-106
11988841-7	2002	Interestingly, proteasomal degradation of Pin1 facilitates dephosphorylation of phospho Bcl2 due to longer exposure of Taxol.	Paclitaxel	119-124	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	42-46
11912157-6	2002	Our studies with DLD1 cells stably expressing wild-type Chfr and Chfr lacking the RING domain indicated that the RING-finger deletion mutant was defective in inhibiting chromosome condensation after Taxol treatment.	Paclitaxel	199-204	checkpoint with forkhead and ring finger domains	Homo sapiens	65-69
11912157-7	2002	In addition, Chfr expression increases the survival rate after Taxol treatment, an activity requiring the RING domain.	Paclitaxel	63-68	checkpoint with forkhead and ring finger domains	Homo sapiens	13-17
12168940-0	2002	Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatin.	Paclitaxel	123-133	H3 histone pseudogene 16	Homo sapiens	45-48
11798816-13	2000	The enhanced expression of tPA indicated the increased ability of metastasis after the acquisition of resistance to taxol.	Paclitaxel	116-121	chromosome 20 open reading frame 181	Homo sapiens	27-30
12168940-1	2002	BACKGROUND: The purpose of the present study was to correlate the nuclear expression of p53 and p21 with response to paclitaxel and carboplatin, progression-free survival (PFS) as well as overall survival (OS), in patients with urothelial metastatic transitional-cell carcinoma (TCC).	Paclitaxel	117-127	H3 histone pseudogene 16	Homo sapiens	96-99
11911840-8	2002	In addition, after treatment with topoisomerase I inhibitors, the up-regulation of Fas/CD95 resulted in an increased susceptibility of GBM cells to antibody-stimulated Fas/CD95-mediated apoptosis, while no synergistic effects were detected after treatment with cisplatin or taxol.	Paclitaxel	274-279	Fas cell surface death receptor	Homo sapiens	87-91
11854432-4	2002	Our results demonstrated that the addition of ET-1 markedly inhibited serum withdrawal and paclitaxel-induced apoptosis in a concentration-dependent manner, as demonstrated by Annexin-V assay, sub-G(1) peak in DNA content histograms, internucleosomal DNA fragmentation, and terminal deoxynucleotidyl transferase-mediated dUTP biotin nick-end labeling method.	Paclitaxel	91-101	annexin A5	Homo sapiens	176-185
10747785-7	2000	The observation that the C-13 side chain is not an absolute requirement for biological activity in a taxane molecule has enabled the development of a new common pharmacophore model between Taxol and the epothilones.	Paclitaxel	189-194	homeobox C13	Homo sapiens	25-29
12475416-0	2002	[Paclitaxel-induced apoptosis in ACC-2 cells is associated with the arrest of G(2)/M].	Paclitaxel	1-11	acetyl-CoA carboxylase beta	Homo sapiens	33-38
10888038-4	2000	The C-5 cinnamoyl side chain in taxuspine D is found to mimic the C-13 side chain of paclitaxel.	Paclitaxel	85-95	homeobox C13	Homo sapiens	66-70
12475416-1	2002	OBJECTIVE: To investigate whether paclitaxel (Taxel) can efficiently induce apoptosis of ACC-2 or not, and to study the relation of apoptosis and arrest of cell mitosis.	Paclitaxel	34-44	acetyl-CoA carboxylase beta	Homo sapiens	89-94
12475416-2	2002	METHODS: Paclitaxel-induced arrest of cell mitosis and apoptosis of ACC-2 cells in various concentration and different treat time were determined using transmission electron microscope (TEM), fluorescence microscope, flow-cytometry and DNA agarose gel electrophoresis technique.	Paclitaxel	9-19	acetyl-CoA carboxylase beta	Homo sapiens	68-73
10773541-1	2000	This study investigated P-glycoprotein (Pgp) expression by murine tumors with and without resistance to paclitaxel and the role of (99m)Tc-2-methoxyisobutylisonitrile (MIBI)/(201)Tl imaging in predicting the effect of paclitaxel.	Paclitaxel	104-114	phosphoglycolate phosphatase	Mus musculus	40-43
12475416-5	2002	"DNA Ladder" was absent in agarose gel electrophoresis of DNA extracted from culture of ACC-2 cells and paclitaxel-induced ACC-2 cells.	Paclitaxel	104-114	acetyl-CoA carboxylase beta	Homo sapiens	123-128
12475416-6	2002	"Sub-G(1)" phase peak of ACC-2 cells induced by 50 nmol/L paclitaxel in 48 h and 72 h was 17.13% and 16.26%, respectively.	Paclitaxel	58-68	acetyl-CoA carboxylase beta	Homo sapiens	25-30
15216888-5	1999	In cell lysates both GFP-EMTB and endogenous ensconsin were dissociated from microtubules by identical salt extraction conditions, and both molecules remained bound to a calcium-stable subset of Taxol-stabilized microtubules.	Paclitaxel	195-200	microtubule associated protein 7	Homo sapiens	45-54
12475416-9	2002	CONCLUSIONS: Paclitaxel could induce apoptosis of ACC-2 cells.	Paclitaxel	13-23	acetyl-CoA carboxylase beta	Homo sapiens	50-55
12236102-6	2002	In K-mitotic cells, after a 3-6 h treatment with nocodazole or taxol, considerable dissociation of XCAP-E and pEg7 from chromosomes was observed without significant changes in overall level of chromosome compactization.	Paclitaxel	63-68	structural maintenance of chromosomes 2 L homeolog	Xenopus laevis	99-105
12579901-8	2002	The nanoparticles release paclitaxel slowly and linearly, within 24 h, Brij78-SLN and F68-SLN release 8% and 20% of total drug, respectively.	Paclitaxel	26-36	sarcolipin	Mus musculus	90-93
10446979-6	1999	Increased expression of MAP4, which occurs when p53 is transcriptionally inactive, increases microtubule polymerization, paclitaxel binding, and sensitivity to paclitaxel, a drug that stabilizes polymerized microtubules.	Paclitaxel	121-131	microtubule associated protein 4	Homo sapiens	24-28
10446979-6	1999	Increased expression of MAP4, which occurs when p53 is transcriptionally inactive, increases microtubule polymerization, paclitaxel binding, and sensitivity to paclitaxel, a drug that stabilizes polymerized microtubules.	Paclitaxel	160-170	microtubule associated protein 4	Homo sapiens	24-28
20654527-5	1999	The functionality of each expressed CYP2C was assessed by determining specific catalytic activities in these cells, that is, taxol-6-hydroxylation for CYP2C8; diclofenac-4"-hydroxylation for CYP2C9; S-mephenytoin-4"-hydroxylation for CYP2C18; S-mephenytoin-4"-hydroxylation for CYP2C19.	Paclitaxel	125-130	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	36-41
10411903-9	1999	Intriguingly, the number of lagging chromosomes with high Bub3 staining increases dramatically in cells treated with low (and pharmacologically relevant) concentrations of the chemotherapeutic taxol and the microtubule poison nocodazole.	Paclitaxel	193-198	Bub3p	Saccharomyces cerevisiae S288C	58-62
11728383-4	2001	Furthermore, Mcl-1 protein turned over more rapidly following exposure to tubulin-modifying agents, the stability of Mcl-1 protein paralleling the drug sensitivity profile of the paclitaxel or epothilone-A resistant cell lines.	Paclitaxel	179-189	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	13-18
10358184-8	1999	In addition, Taxol-induced IL-12 p40 mRNA was markedly reduced in Mac-1 knockout macrophages and anti-Mac-1 Ab blocked secretion of IL-12 p70 in Taxol- and LPS-stimulated macrophages.	Paclitaxel	13-18	interleukin 12b	Mus musculus	27-36
11800022-14	2001	CONCLUSIONS: These results suggest that LIF may be safely used in human trials as a neuroprotectant for patients receiving cisplatin, paclitaxel and carboplatin without concern for impairment of antitumour effect.	Paclitaxel	134-144	LIF interleukin 6 family cytokine	Homo sapiens	40-43
9933579-8	1999	In contrast, Bcr-Abl-negative HL60 myeloid leukemia cells, which are sensitive to taxol-induced apoptosis, do not exhibit sustained PKCiota activation in response to taxol.	Paclitaxel	82-87	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	13-20
9933579-9	1999	Treatment of K562 cells with tyrphostin AG957, a selective Bcr-Abl inhibitor, blocks taxol-induced PKCiota activation and sensitizes these cells to taxol-induced apoptosis, indicating that PKCiota is a relevant downstream target of Bcr-Abl-mediated resistance.	Paclitaxel	85-90	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	59-66
11781568-8	2001	Anti-LGN antibodies and the LGN-binding domain of NuMA both trigger microtubule aster formation in mitotic Xenopus egg extracts, and the NuMA-binding domain of LGN blocks aster assembly in egg extracts treated with taxol.	Paclitaxel	215-220	nuclear mitotic apparatus protein 1 L homeolog	Xenopus laevis	137-141
9933579-9	1999	Treatment of K562 cells with tyrphostin AG957, a selective Bcr-Abl inhibitor, blocks taxol-induced PKCiota activation and sensitizes these cells to taxol-induced apoptosis, indicating that PKCiota is a relevant downstream target of Bcr-Abl-mediated resistance.	Paclitaxel	85-90	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	232-239
9927194-2	1999	In the present study, we demonstrated that microtubule-binding agents (MBAs) taxol and colchicine induced immediate early gene (c-jun and ATF3) expression, cell cycle arrest, and apoptosis in the human breast cancer cell line MCF-7.	Paclitaxel	77-82	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	128-133
11705873-9	2001	Moreover, CPT-11, cisplatin, oxaliplatin, and Taxol remain highly cytotoxic in cells that overexpress TS.	Paclitaxel	46-51	thymidylate synthetase	Homo sapiens	102-104
10030671-7	1998	Interestingly, treatment with taxol abolished the EB1 association with microtubules.	Paclitaxel	30-35	microtubule associated protein RP/EB family member 1	Homo sapiens	50-53
10030671-9	1998	In taxol wash-out experiments EB1 rapidly re-associated with the microtubule cytoskeleton, resembling untreated control cells within 10 min.	Paclitaxel	3-8	microtubule associated protein RP/EB family member 1	Homo sapiens	30-33
11602686-3	2001	Steady-state CYP1A1 mRNA contents were reduced (45-90%) in TCDD-treated cultures arrested in G2/M as a consequence of exposure to microtubule disrupters (Colcemid, estramustine, vinblastine) or the microtubule stabilizer Taxol, relative to TCDD-treated asynchronous 1c1c7 cultures.	Paclitaxel	221-226	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	13-19
9873732-3	1998	Substrates containing doxorubicin (DOX), paclitaxel (taxol), and mitomycin C (MMC) attached to the cathepsin B-sensitive dipeptide Phe-Lys via a self-immolative spacer were prepared as model compounds for internalizing anticancer immunoconjugates.	Paclitaxel	41-51	cathepsin B	Homo sapiens	99-110
9873732-3	1998	Substrates containing doxorubicin (DOX), paclitaxel (taxol), and mitomycin C (MMC) attached to the cathepsin B-sensitive dipeptide Phe-Lys via a self-immolative spacer were prepared as model compounds for internalizing anticancer immunoconjugates.	Paclitaxel	53-58	cathepsin B	Homo sapiens	99-110
9746563-0	1998	Induction of adrenomedullin mRNA and protein by lipopolysaccharide and paclitaxel (Taxol) in murine macrophages.	Paclitaxel	71-81	adrenomedullin	Mus musculus	13-27
11600533-8	2001	We concluded that the cytochrome c release was upstream of the activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells treated with manumycin plus paclitaxel, and that the interaction between manumycin and paclitaxel occurred at or upstream of cytochrome c in the apoptosis regulatory pathway in anaplastic thyroid cancer cells.	Paclitaxel	202-212	caspase 9	Homo sapiens	77-86
11716366-4	2001	We have found that microtubule-damaging drugs (e.g. Paclitaxel) induce apoptosis in a Fas/FasL-dependent manner.	Paclitaxel	52-62	Fas ligand	Homo sapiens	90-94
9729279-8	1998	Taxol suppressed polymerization between neurofilament light and heavy (NF-L and NF-H), and MB2 cell extract rescued it.	Paclitaxel	0-5	neurofilament heavy chain	Rattus norvegicus	80-84
11716366-5	2001	Inhibition of Fas/FasL pathway by anti-FasL antibody, mutant Fas or a dominant negative FADD blocks paclitaxel-induced apoptosis.	Paclitaxel	100-110	Fas ligand	Homo sapiens	18-22
9783325-5	1998	In GLUT1-transfected cells paclitaxel stimulated 2-deoxy-D-glucose uptake by about 35%.	Paclitaxel	27-37	solute carrier family 2 member 1	Homo sapiens	3-8
11716366-5	2001	Inhibition of Fas/FasL pathway by anti-FasL antibody, mutant Fas or a dominant negative FADD blocks paclitaxel-induced apoptosis.	Paclitaxel	100-110	Fas ligand	Homo sapiens	39-43
11716366-5	2001	Inhibition of Fas/FasL pathway by anti-FasL antibody, mutant Fas or a dominant negative FADD blocks paclitaxel-induced apoptosis.	Paclitaxel	100-110	Fas associated via death domain	Homo sapiens	88-92
11716366-7	2001	Overexpression of Bcl-XL leads to inhibition of paclitaxel-induced FasL expression and apoptosis.	Paclitaxel	48-58	Fas ligand	Homo sapiens	67-71
11716366-12	2001	Thus, paclitaxel and other drugs that disturb microtubule function kill cells, at least in part, through the induction of FasL, and Bcl-XL-mediated resistance to these agents is related to failure to induce FasL expression.	Paclitaxel	6-16	Fas ligand	Homo sapiens	122-126
9681997-7	1998	HL-60/hsp70 cells also showed more resistance than parental cells against apoptotic agents such as sodium nitroprusside, a NO-generating agent, or Taxol, a microtubule stabilizing agent.	Paclitaxel	147-152	heat shock protein family A (Hsp70) member 4	Homo sapiens	6-11
11668581-0	2001	Abundant expression of the microtubule-associated protein, ensconsin (E-MAP-115), alters the cellular response to Taxol.	Paclitaxel	114-119	regulator of microtubule dynamics 1	Homo sapiens	27-57
9606210-24	1998	In contrast, Mad2 only localized to an average of 2.6 out of the 22 kinetochores in taxol-treated PtK1 cells.	Paclitaxel	84-89	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	98-102
9584207-0	1998	Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.	Paclitaxel	15-25	BCL2 antagonist/killer 1	Homo sapiens	108-111
9402312-0	1997	Effects of cisplatin and taxol on inducible nitric oxide synthase, gastrin and somatostatin in gastrointestinal toxicity.	Paclitaxel	25-30	gastrin	Rattus norvegicus	67-74
9402312-1	1997	Cisplatin (9 mg/kg) or taxol (20 mg/kg) treatment of Wistar rats produced a sharp decrease in inducible nitric oxide synthase (iNOS) and gastrin in the pyloric region of the stomach, and an increase in iNOS and somatostatin in the pancreatic islets.	Paclitaxel	23-28	gastrin	Rattus norvegicus	137-144
11668581-1	2001	Correlation between expression level of a microtubule-associated protein called ensconsin (E-MAP-115) and degree of Taxol sensitivity in several cultured cell lines prompted us to investigate potential cause-and-effect relationships between ensconsin level and Taxol action.	Paclitaxel	116-121	regulator of microtubule dynamics 1	Homo sapiens	42-72
11668581-5	2001	However, heightening the Taxol sensitivity of GFP-EMTB-TC-7 cells by pre-incubating cells with the p-glycoprotein inhibitor, verapamil, did result in selective killing of cells highly expressing GFP-EMTB.	Paclitaxel	25-30	ribosomal protein S14	Homo sapiens	50-54
11668581-5	2001	However, heightening the Taxol sensitivity of GFP-EMTB-TC-7 cells by pre-incubating cells with the p-glycoprotein inhibitor, verapamil, did result in selective killing of cells highly expressing GFP-EMTB.	Paclitaxel	25-30	ribosomal protein S14	Homo sapiens	199-203
11408609-4	2001	Subsequent exposure of paclitaxel-treated cells to PD98059 did not enhance dephosphorylation/activation of p34(cdc2) but diminished expression of the antiapoptotic protein Mcl-1.	Paclitaxel	23-33	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	172-177
9402312-3	1997	It is proposed that a decline of the iNOS and gastrin after cisplatin or taxol treatments is related to distention of the stomach, and possibly nausea and vomiting.	Paclitaxel	73-78	gastrin	Rattus norvegicus	46-53
11439344-5	2001	Furthermore, we observed that the levels of p53 and p21 induced by adriamycin and by low concentrations of PTX in A549 cells were comparable.	Paclitaxel	107-110	H3 histone pseudogene 16	Homo sapiens	52-55
9317152-1	1997	Activation of macrophages by LPS and taxol results in production of IL-1, IL-6, TNF-alpha, and granulocyte-macrophage CSF (GM-CSF), which are involved in regulating hemopoiesis, inflammation, and immune responses.	Paclitaxel	37-42	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	95-121
11439344-6	2001	This observation led us to conclude that low concentrations of PTX can induce p53 and p21 sufficiently to cause G1 and G2.	Paclitaxel	63-66	H3 histone pseudogene 16	Homo sapiens	86-89
11358853-10	2001	MCJ expression was associated with enhanced sensitivity to paclitaxel, topotecan, and cisplatin, suggesting that MCJ loss may play a role in de novo chemoresistance in ovarian carcinoma.	Paclitaxel	59-69	DnaJ heat shock protein family (Hsp40) member C15	Homo sapiens	0-3
9288793-0	1997	Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells.	Paclitaxel	0-10	mucin 16, cell surface associated	Homo sapiens	50-56
9288793-2	1997	However, CA-125 has been suggested to be an unreliable marker for monitoring response to paclitaxel therapy.	Paclitaxel	89-99	mucin 16, cell surface associated	Homo sapiens	9-15
9288793-6	1997	In addition to in vitro antiproliferative activity, paclitaxel and docetaxel augmented the expression of the tumor marker CA-125 in the three ovarian carcinoma cell lines, OVCAR-3, HOC-7, and SKOV-6, constitutively expressing this tumor marker.	Paclitaxel	52-62	mucin 16, cell surface associated	Homo sapiens	122-128
9231689-9	1997	Paclitaxel also induced an increase in both p53 and p21 expression in MCA-4 cells; however, the increase was delayed compared to that after irradiation.	Paclitaxel	0-10	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	52-55
11336465-1	2001	The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC).	Paclitaxel	81-91	colony stimulating factor 3	Homo sapiens	135-140
9062409-19	1997	Taxol and taxotere were highly correlated (cross-resistant) to VP-16 (0.76 and 0.81 respectively) and inversely correlated to cisplatin (both -0.58).	Paclitaxel	0-5	host cell factor C1	Homo sapiens	63-68
11278107-4	2001	However, trans-resveratrol is able to inhibit the activation of caspase 7 and degradation of poly-(ADP-ribose)-polymerase which occur in SH-SY5Y exposed to paclitaxel.	Paclitaxel	156-166	caspase 7	Homo sapiens	64-73
8922193-2	1996	Since both paclitaxel and cremophor are substrates of Pgp, it was hypothesized that they could modify the pharmacokinetics of anthracyclines in a similar fashion.	Paclitaxel	11-21	phosphoglycolate phosphatase	Mus musculus	54-57
8646707-12	1996	The CA 125 ratio, as determined after 4 courses of paclitaxel treatment, may be a better indicator of response than WHO defined response status.	Paclitaxel	51-61	mucin 16, cell surface associated	Homo sapiens	4-10
11357875-4	2001	TLR2 discriminates peptidoglycan (PGN), lipoprotein, lipoarabinomannan (LAM) and zymosan, whereas TLR4 recognizes lipopolysaccharide (LPS), lipoteichoic acid (LTA) and Taxol.	Paclitaxel	168-173	toll like receptor 4	Homo sapiens	98-102
9816240-5	1996	Rapid induction of the early-response gene c-jun but not c-myc was associated with paclitaxel treatment.	Paclitaxel	83-93	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	43-48
9816180-8	1996	In athymic nude mice, PAK-104P significantly potentiated the therapeutic efficacy of doxorubicin and paclitaxel against resistant HT1080/DR4 xenografts.	Paclitaxel	101-111	major histocompatibility complex, class II, DR beta 4	Homo sapiens	137-140
11179455-6	2001	Western blot analysis revealed that paclitaxel caused a time- and concentration-dependent cleavage of beta-catenin, gamma-catenin, and APC protein, but not alpha-catenin or E-cadherin.	Paclitaxel	36-46	catenin beta 1	Homo sapiens	102-114
11179455-9	2001	Furthermore, paclitaxel-induced apoptosis and cleavage of beta-catenin and gamma-catenin were inhibited by the pan-caspase inhibitor Z-VAD-FMK and partially inhibited by the caspase-3 inhibitor Z-DEVD-FMK but were not affected by the caspase-1 inhibitor AC-YVAD-CMK.	Paclitaxel	13-23	catenin beta 1	Homo sapiens	58-70
8718623-5	1995	Confirmation of endwise annealing rather than of dynamic instability as the mechanism for microtubule growth was made using mammalian MAP2, which also promoted the redistribution of length, increase in mean length, and decrease in number concentration of taxol-stabilized maize microtubules.	Paclitaxel	255-260	microtubule associated protein 2	Homo sapiens	134-138
11179455-12	2001	Interestingly, the paclitaxel-induced beta-catenin fragment lost its ability to bind to E-cadherin, alpha-catenin, or APC protein and to serve as a substrate for tyrosine kinase.	Paclitaxel	19-29	catenin beta 1	Homo sapiens	38-50
7553639-0	1995	Taxol induction of p21WAF1 and p53 requires c-raf-1.	Paclitaxel	0-5	TNF receptor associated factor 3	Homo sapiens	44-51
11179426-4	2001	We found that MT nucleation by centrosomes from Xenopus sperm or somatic cells and MT assembly promoted by dimethyl sulfoxide or paclitaxel induced stathmin/Op18 hyperphosphorylation in Xenopus egg extracts, leading to new stathmin/Op18 isoforms phosphorylated on Ser 16.	Paclitaxel	129-139	LOC108706401	Xenopus laevis	223-231
7553639-7	1995	Coincident with these biochemical effects, taxol altered the electrophoretic mobility of c-raf-1 and stimulated mitogen activated protein kinase.	Paclitaxel	43-48	TNF receptor associated factor 3	Homo sapiens	89-96
7553639-8	1995	Previous depletion of c-raf-1 inhibited both the p21WAF1- and p53-inducing properties of taxol, as well as the activation of MAP kinase.	Paclitaxel	89-94	TNF receptor associated factor 3	Homo sapiens	22-29
7696257-0	1995	Differential effects of paclitaxel (Taxol) analogs modified at positions C-2, C-7, and C-3" on tubulin polymerization and polymer stabilization: identification of a hyperactive paclitaxel derivative.	Paclitaxel	36-41	complement C7	Homo sapiens	78-81
11160860-6	2001	Interestingly, the activity of IkappaB kinase (IKK-beta), which plays an essential role in NF-kappaB activation through IkappaB phosphorylation, was largely enhanced in paclitaxel-treated cells, detected as IkappaBalpha phosphorylation.	Paclitaxel	169-179	inhibitor of kappaB kinase beta	Mus musculus	47-55
11160860-10	2001	Therefore, these data suggest that paclitaxel may activate IKK-beta via conventional PKC isotypes, resulting in NF-kappaB activation and, finally, desensitization of LPS-inducible signaling pathway in 70Z/3 pre-B cells.	Paclitaxel	35-45	inhibitor of kappaB kinase beta	Mus musculus	59-67
11160861-0	2001	Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells.	Paclitaxel	187-197	mitogen-activated protein kinase kinase 1	Homo sapiens	58-99
11212279-5	2001	Treatment with paclitaxel or taxotere increased DR4 and/or DR5 protein levels (up to 8-fold) without affecting the protein levels of DcR1 and DcR2, Apo-2L/TRAIL, Fas, or Fas ligand.	Paclitaxel	15-25	TNF receptor superfamily member 10b	Homo sapiens	59-62
11212279-5	2001	Treatment with paclitaxel or taxotere increased DR4 and/or DR5 protein levels (up to 8-fold) without affecting the protein levels of DcR1 and DcR2, Apo-2L/TRAIL, Fas, or Fas ligand.	Paclitaxel	15-25	Fas ligand	Homo sapiens	170-180
11123270-0	2001	Cutting edge: Gln22 of mouse MD-2 is essential for species-specific lipopolysaccharide mimetic action of taxol.	Paclitaxel	105-110	lymphocyte antigen 96	Mus musculus	29-33
7961787-4	1994	Because the microtubule-binding region (MTBR) retains virtually all of the binding affinity of intact MAP-2 for microtubules, we focused on understanding the effect of protein kinase C phosphorylation on MTBR binding to taxol-stabilized microtubules.	Paclitaxel	220-225	microtubule associated protein 2	Homo sapiens	102-107
11123270-2	2001	Taxol, which mimics the action of LPS on murine macrophages, induces signals via mouse TLR4-MD-2, but not via human TLR4-MD-2.	Paclitaxel	0-5	lymphocyte antigen 96	Mus musculus	92-96
11123270-4	2001	Expression of mouse MD-2 conferred both LPS and Taxol responsiveness on human embryonic kidney 293 cells expressing mouse TLR4, whereas expression of human MD-2 conferred LPS responsiveness alone, suggesting that MD-2 is responsible for the species-specificity as to Taxol responsiveness.	Paclitaxel	48-53	lymphocyte antigen 96	Mus musculus	20-24
7913831-7	1994	The taxol C13 side chain was found to be fluorescent, and it displays an environment-sensitive shift in emission spectrum; taxol fluorescence was used to confirm the insertion of the drug into the bilayer.	Paclitaxel	4-9	homeobox C13	Homo sapiens	10-13
7913831-7	1994	The taxol C13 side chain was found to be fluorescent, and it displays an environment-sensitive shift in emission spectrum; taxol fluorescence was used to confirm the insertion of the drug into the bilayer.	Paclitaxel	123-128	homeobox C13	Homo sapiens	10-13
11123270-4	2001	Expression of mouse MD-2 conferred both LPS and Taxol responsiveness on human embryonic kidney 293 cells expressing mouse TLR4, whereas expression of human MD-2 conferred LPS responsiveness alone, suggesting that MD-2 is responsible for the species-specificity as to Taxol responsiveness.	Paclitaxel	267-272	lymphocyte antigen 96	Mus musculus	20-24
11123270-5	2001	Furthermore, mouse MD-2 mutants, in which Gln(22) was changed to other amino acids, showed dramatically reduced ability to confer Taxol responsiveness, although their ability to confer LPS responsiveness was not affected.	Paclitaxel	130-135	lymphocyte antigen 96	Mus musculus	19-23
11123270-6	2001	These results indicated that Gln(22) of mouse MD-2 is essential for Taxol signaling but not for LPS signaling.	Paclitaxel	68-73	lymphocyte antigen 96	Mus musculus	46-50
7908792-11	1994	In S 180 tumor bearing mice pretreated with CCl4, the paclitaxel level was found to be lower in the liver and higher in the other tissues including tumor, plasma, urine and bile than in non-treated mice.	Paclitaxel	54-64	chemokine (C-C motif) ligand 4	Mus musculus	44-48
11197970-1	2001	UNLABELLED: The purpose of this study was to retrospectively predict the chemotherapeutic response to paclitaxel for non-small cell lung cancer (NSCLC) using 99mTc-tetrofosmin (TF) uptake and to detect the expression of 170-kDa multidrug resistance-mediated P-glycoprotein (MDR-Pgp).	Paclitaxel	102-112	phosphoglycolate phosphatase	Homo sapiens	278-281
7908793-3	1994	Thus, a study was carried out to determine the modifying activity of Cremophor EL on the antitumor activity of paclitaxel against P388 leukemia, adriamycin-resistant subline (P388/ADM) and vincristine-resistant subline (P388/VCR) in vivo.	Paclitaxel	111-121	adrenomedullin	Homo sapiens	175-183
7514586-3	1994	We have established a taxol-resistant human small-cell lung cancer cell line (H69/Txl) by exposing H69 cells to stepwise increases in taxol concentration.	Paclitaxel	22-27	thioredoxin like 1	Homo sapiens	82-85
7514586-3	1994	We have established a taxol-resistant human small-cell lung cancer cell line (H69/Txl) by exposing H69 cells to stepwise increases in taxol concentration.	Paclitaxel	134-139	thioredoxin like 1	Homo sapiens	82-85
7514586-4	1994	The resistance of H69/Txl cells to taxol was 4.7-fold that of the original H69 cells: the IC50 values for H69 and H69/Txl were 113.7 +/- 56.54 nM and 538.7 +/- 214.7 nM by the tetrazolium dye assay, respectively.	Paclitaxel	35-40	thioredoxin like 1	Homo sapiens	22-25
7514586-4	1994	The resistance of H69/Txl cells to taxol was 4.7-fold that of the original H69 cells: the IC50 values for H69 and H69/Txl were 113.7 +/- 56.54 nM and 538.7 +/- 214.7 nM by the tetrazolium dye assay, respectively.	Paclitaxel	35-40	thioredoxin like 1	Homo sapiens	118-121
11738263-0	2001	Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat.	Paclitaxel	67-77	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	36-52
8096507-0	1993	Taxol-induced flexibility of microtubules and its reversal by MAP-2 and Tau.	Paclitaxel	0-5	microtubule associated protein 2	Homo sapiens	62-67
7912536-5	1993	We found that Taxol, like lipopolysaccharides (LPS), caused a marked increase in tyrosine phosphorylation of three proteins having M(r) of 40 (p40), 41 (p41), and 43 (p43) kd in RAW cells.	Paclitaxel	14-19	interleukin 12b	Mus musculus	143-146
11738263-8	2001	Hyperalgesia, produced by both acute and chronic Taxol, was attenuated by intradermal injection of selective second messenger antagonists for protein kinase Cepsilon and protein kinase A.	Paclitaxel	49-54	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	170-186
11735678-14	2001	In two large head-to-head comparative clinical trials, paclitaxel plus cisplatin was associated with significantly greater response rates than cisplatin in combination with either teniposide or etoposide, and a survival advantage was shown for paclitaxel plus cisplatin (with or without G-CSF) over etoposide plus cisplatin.	Paclitaxel	55-65	colony stimulating factor 3	Homo sapiens	287-292
1338311-8	1992	By comparing these patterns to those produced by two chemical agents that stabilise microtubules, taxol and dimethyl sulphoxide, we conclude that effects of MAP2c arise from two sources.	Paclitaxel	98-103	microtubule associated protein 2	Homo sapiens	157-162
11156247-0	2000	Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.	Paclitaxel	0-10	epidermal growth factor receptor	Mus musculus	44-76
11156248-11	2000	Although the taxanes, paclitaxel or docetaxel, as single agents markedly inhibited the growth of A431, LX-1, SK-LC-16, TSU-PR1, and PC-3, when combined with ZD1839, partial or complete regression was usually seen.	Paclitaxel	22-32	proprotein convertase subtilisin/kexin type 1	Homo sapiens	132-136
11102737-9	2000	Our previous work, also using P-gp knockout (KO) mice, already showed that P-gp has a major effect on the oral bioavailability of several drugs and that blockers of P-gp can drastically improve oral bioavailability of paclitaxel and other drugs in mice and humans (Schinkel et al., Cell 77 (1994) 491; Sparreboom et al., Proc.	Paclitaxel	218-228	phosphoglycolate phosphatase	Homo sapiens	30-34
1679010-2	1991	Early mitotic PtK1 cells treated with 10 micrograms/ml taxol contained short bundles of parallel microtubules around the nuclei and cell periphery.	Paclitaxel	55-60	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	14-18
1705109-2	1991	Taxol is also cytotoxic to dorsal root ganglion neurons in vitro, but this effect is prevented by cotreatment with the trophic protein, nerve growth factor.	Paclitaxel	0-5	nerve growth factor	Mus musculus	136-155
11102737-15	2000	The taxanes paclitaxel and docetaxel are considered excellent substrate drugs to test the concept that by inhibition of P-gp in the gut wall and CYP activity in gut wall and/or liver low oral bioavailability can be increased substantially.	Paclitaxel	12-22	phosphoglycolate phosphatase	Homo sapiens	120-124
11762380-8	2000	Furthermore, roots treated with the microtubule-stabilizing drug taxol improved the quality of actin preservation as evidenced by the thicker bundles of cortical actin.	Paclitaxel	65-70	actin-7	Zea mays	162-167
11762380-9	2000	This suggested that taxol was also capable of stabilizing the cortical actin networks.	Paclitaxel	20-25	actin-7	Zea mays	71-76
2199459-11	1990	The CHO1 antigen in HeLa cell extracts copurifies with taxol-stabilized microtubules.	Paclitaxel	55-60	kinesin family member 23	Homo sapiens	4-8
11142692-11	2000	TPT also enhanced the cytotoxic activity of PTX in A-431 and Ca Ski.	Paclitaxel	44-47	SKI proto-oncogene	Homo sapiens	64-67
33539984-7	2021	High metHb generation, revealing intense OS, was also mostly expressed in paclitaxel "TXL" and etoposide "VP16".	Paclitaxel	74-84	hemoglobin subunit gamma 2	Homo sapiens	5-10
28766096-4	2018	RESULTS: Increased phosphorylation levels of ERK, Mnk1, and eIF4E were observed in ovarian cancer cell exposed to chemotherapeutic agents, and paclitaxel-resistant SK-OV-3-r cells, and is a common response of ovarian cancer patients undergoing chemotherapy.	Paclitaxel	143-153	MAPK interacting serine/threonine kinase 1	Homo sapiens	50-54
11205313-3	2000	RESULTS: The techniques used herein determined accumulation of paclitaxel/PSC 833 induced apoptotic cells with sub-G0 (hypodiploid) DNA content and blocked in the G2/M phase of the cell cycle, internucleosomal DNA fragmentation, poly (ADP-ribose) polymerase cleavage, Bcl-2 modulation and Bax up-regulation, without any significant alterations in the levels of Bcl-xL, CD95/Fas or Fas-L proteins.	Paclitaxel	63-73	Fas cell surface death receptor	Homo sapiens	369-373
34808333-9	2022	Moreover, inhibition of PLD1 reversed FOXM1-conferred paclitaxel resistance in vitro and in vivo.	Paclitaxel	54-64	forkhead box M1	Mus musculus	38-43
11205313-3	2000	RESULTS: The techniques used herein determined accumulation of paclitaxel/PSC 833 induced apoptotic cells with sub-G0 (hypodiploid) DNA content and blocked in the G2/M phase of the cell cycle, internucleosomal DNA fragmentation, poly (ADP-ribose) polymerase cleavage, Bcl-2 modulation and Bax up-regulation, without any significant alterations in the levels of Bcl-xL, CD95/Fas or Fas-L proteins.	Paclitaxel	63-73	Fas ligand	Homo sapiens	381-386
34808333-10	2022	This study, for the first time, reveals the role of FOXM1-mediated PLD1 in LD accumulation and paclitaxel resistance.	Paclitaxel	95-105	forkhead box M1	Mus musculus	52-57
11034077-0	2000	The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.	Paclitaxel	152-162	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	4-33
34808333-12	2022	Generally, our results identified FOXM1 as a driver of paclitaxel resistance via activation of PLD1 to promote of LD accumulation, which contributes to the maintenace of ER homeostasis when metastatic cancer cells are confronted with ROS induced by paclitaxel.	Paclitaxel	55-65	forkhead box M1	Mus musculus	34-39
34808333-12	2022	Generally, our results identified FOXM1 as a driver of paclitaxel resistance via activation of PLD1 to promote of LD accumulation, which contributes to the maintenace of ER homeostasis when metastatic cancer cells are confronted with ROS induced by paclitaxel.	Paclitaxel	249-259	forkhead box M1	Mus musculus	34-39
11034077-0	2000	The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.	Paclitaxel	152-162	AKT serine/threonine kinase 2	Homo sapiens	34-37
11034077-3	2000	Here, we demonstrate that phosphatidylinositol 3-kinase (PI3K) and its downstream targets serine/threonine kinases AKT1 and AKT2 (AKT), are required for the full induction of p21 in A2780 cells treated with cisplatin or paclitaxel.	Paclitaxel	220-230	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	26-55
11034077-4	2000	Inactivation of the PI3K/AKT signal transduction pathway either by its specific inhibitor LY294002 or by expression of dominant negative AKT inhibited p21 expression but had no inhibitory effect on the expression of the proapoptotic protein BAX by cisplatin and paclitaxel treatment.	Paclitaxel	262-272	AKT serine/threonine kinase 2	Homo sapiens	25-28
11006039-0	2000	Cisplatin-paclitaxel-cyclophosphamide with G-CSF in primary advanced epithelial ovarian cancer.	Paclitaxel	10-20	colony stimulating factor 3	Homo sapiens	43-48
34883139-3	2022	Here, employing clinically validated ATN peptide as a ligand and reduction-sensitive biodegradable micelles as a vehicle we constructed alpha5beta1 integrin-targeted micellar paclitaxel (ATN-MPTX) to elicit strong and selective ICD and chemo-immunotherapy of TNBC.	Paclitaxel	175-185	mucosal pentraxin 1	Mus musculus	191-195
34915631-14	2021	The expression levels of ENO1, PI3K/Akt signaling pathway related proteins including p-PI3K and p-Akt and the expression levels of PCNA, MMP-9 and Bcl-2 in siRNA-ENO1 group and paclitaxel+ siRNA-NC group were lower than those in siRNA-NC group (P<0.05).	Paclitaxel	177-187	matrix metallopeptidase 9	Homo sapiens	137-142
34653365-4	2021	In responsive patients, lymphoid tissue inducer (LTi) cells, follicular B (Bfoc) cells, CXCL13+ T cells, and conventional type 1 dendritic cells (cDC1) concertedly increase following the combination therapy, but instead decrease after paclitaxel monotherapy.	Paclitaxel	235-245	C-X-C motif chemokine ligand 13	Homo sapiens	88-94
34653365-5	2021	Our data highlight the importance of CXCL13+ T cells in effective responses to anti-PD-L1 therapies and suggest that their reduction by paclitaxel regimen may compromise the clinical outcomes of accompanying atezolizumab for TNBC treatment.	Paclitaxel	136-146	C-X-C motif chemokine ligand 13	Homo sapiens	37-43
34904193-9	2022	PECS-101 also decreased PTX-induced increase in Tnf, Il6, and Aif1 (Iba-1) gene expression in the DRGs and the loss of intra-epidermal nerve fibers.	Paclitaxel	24-27	allograft inflammatory factor 1	Mus musculus	62-66
34882068-11	2021	These results demonstrate that the FGFR/VEGFR/PDGFR inhibitor, dovitinib, has the potential to augment the antitumor effects of nab-paclitaxel, with implications for use in the advancement of clinical GAC therapy.	Paclitaxel	132-142	kinase insert domain receptor	Homo sapiens	40-45
34942984-7	2021	Furthermore, in paclitaxel-resistant breast cancer cell lines, MCF-7R and MDA-MB-231R, a combination of JI017 and paclitaxel overcame paclitaxel resistance by blocking epithelial-mesenchymal transition (EMT) processes, such as the downregulation of E-cadherin expression and the upregulation of HIF-1alpha, vimentin, Snail, and Slug expression.	Paclitaxel	114-124	snail family transcriptional repressor 2	Homo sapiens	328-332
34869449-12	2021	Intriguingly, the SRI expression was negatively correlated with drug sensitivity of fluorouracil, paclitaxel, docetaxel, and isotretinoin.	Paclitaxel	98-108	sorcin	Homo sapiens	18-21
34736480-14	2021	The PTX score was significantly better than TRIM22, PI3, SPP1, IDO1 and CXCL13 in predicting paclitaxel sensitivity, so was CBP score in predicting carboplatin sensitivity.	Paclitaxel	93-103	C-X-C motif chemokine ligand 13	Homo sapiens	72-78
34509058-0	2021	Corrigendum to "Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1" (Biochem.	Paclitaxel	40-50	glucose-6-phosphate dehydrogenase	Homo sapiens	26-30
34462267-8	2021	Methionine deprivation or CTH silencing induced a resistant MCF-7R and lowered paclitaxel activity, yet methionine supplementation or CTH overexpression reversed the above effects, induced a sensitive phenotype of MCF-7S and significantly increased the cytotoxicity of paclitaxel both in vitro and in vivo.	Paclitaxel	79-89	cystathionine gamma-lyase	Homo sapiens	26-29
34462267-8	2021	Methionine deprivation or CTH silencing induced a resistant MCF-7R and lowered paclitaxel activity, yet methionine supplementation or CTH overexpression reversed the above effects, induced a sensitive phenotype of MCF-7S and significantly increased the cytotoxicity of paclitaxel both in vitro and in vivo.	Paclitaxel	269-279	cystathionine gamma-lyase	Homo sapiens	26-29
34462267-8	2021	Methionine deprivation or CTH silencing induced a resistant MCF-7R and lowered paclitaxel activity, yet methionine supplementation or CTH overexpression reversed the above effects, induced a sensitive phenotype of MCF-7S and significantly increased the cytotoxicity of paclitaxel both in vitro and in vivo.	Paclitaxel	269-279	cystathionine gamma-lyase	Homo sapiens	134-137
34272796-0	2021	Norcantharidin combined with paclitaxel induces endoplasmic reticulum stress mediated apoptotic effect in prostate cancer cells by targeting SIRT7 expression.	Paclitaxel	29-39	sirtuin 7	Homo sapiens	141-146
34272796-9	2021	Furthermore, NCTD-PTX combination treatment was significantly decreasing the protein and mRNA expression of SIRT7 in PCa cells.	Paclitaxel	18-21	sirtuin 7	Homo sapiens	108-113
34272796-11	2021	These results indicate that NCTD combined with PTX induces ER stress-mediated apoptosis of PCa cells by regulating the SIRT7 expression axis.	Paclitaxel	47-50	sirtuin 7	Homo sapiens	119-124
34768915-0	2021	Ursolic Acid Accelerates Paclitaxel-Induced Cell Death in Esophageal Cancer Cells by Suppressing Akt/FOXM1 Signaling Cascade.	Paclitaxel	25-35	forkhead box M1	Homo sapiens	101-106
34676207-0	2021	Breast Cancer Stem Cell-Derived ANXA6-Containing Exosomes Sustain Paclitaxel Resistance and Cancer Aggressiveness in Breast Cancer.	Paclitaxel	66-76	annexin A6	Homo sapiens	32-37
34676207-1	2021	Continuous chemotherapy pressure-elicited annexin-A6 (ANXA6)-containing exosome (ANXA6-exo) secretion contributes to paclitaxel (PTX) resistance in breast cancer (BC), but the molecular mechanisms are not fully elucidated.	Paclitaxel	117-127	annexin A6	Homo sapiens	42-52
34676207-1	2021	Continuous chemotherapy pressure-elicited annexin-A6 (ANXA6)-containing exosome (ANXA6-exo) secretion contributes to paclitaxel (PTX) resistance in breast cancer (BC), but the molecular mechanisms are not fully elucidated.	Paclitaxel	117-127	annexin A6	Homo sapiens	54-59
34676207-1	2021	Continuous chemotherapy pressure-elicited annexin-A6 (ANXA6)-containing exosome (ANXA6-exo) secretion contributes to paclitaxel (PTX) resistance in breast cancer (BC), but the molecular mechanisms are not fully elucidated.	Paclitaxel	117-127	annexin A6	Homo sapiens	81-86
34676207-1	2021	Continuous chemotherapy pressure-elicited annexin-A6 (ANXA6)-containing exosome (ANXA6-exo) secretion contributes to paclitaxel (PTX) resistance in breast cancer (BC), but the molecular mechanisms are not fully elucidated.	Paclitaxel	129-132	annexin A6	Homo sapiens	42-52
34676207-1	2021	Continuous chemotherapy pressure-elicited annexin-A6 (ANXA6)-containing exosome (ANXA6-exo) secretion contributes to paclitaxel (PTX) resistance in breast cancer (BC), but the molecular mechanisms are not fully elucidated.	Paclitaxel	129-132	annexin A6	Homo sapiens	54-59
34676207-1	2021	Continuous chemotherapy pressure-elicited annexin-A6 (ANXA6)-containing exosome (ANXA6-exo) secretion contributes to paclitaxel (PTX) resistance in breast cancer (BC), but the molecular mechanisms are not fully elucidated.	Paclitaxel	129-132	annexin A6	Homo sapiens	81-86
34676207-2	2021	The present study managed to investigate this issue and found that ANXA6-exo promoted PTX resistance and cancer progression in BC cells in a Yes-associated protein 1 (YAP1)-dependent manner.	Paclitaxel	86-89	annexin A6	Homo sapiens	67-72
34676207-5	2021	Interestingly, ANXA6-exo increased PTX resistance in PS-BC cells via inducing autophagy, and the effects of ANXA6-exo on PTX resistance in PS-BC cells were abrogated by co-treating cells with the autophagy inhibitor 3-methyladenine.	Paclitaxel	35-38	annexin A6	Homo sapiens	15-20
34676207-5	2021	Interestingly, ANXA6-exo increased PTX resistance in PS-BC cells via inducing autophagy, and the effects of ANXA6-exo on PTX resistance in PS-BC cells were abrogated by co-treating cells with the autophagy inhibitor 3-methyladenine.	Paclitaxel	35-38	annexin A6	Homo sapiens	108-113
34676207-5	2021	Interestingly, ANXA6-exo increased PTX resistance in PS-BC cells via inducing autophagy, and the effects of ANXA6-exo on PTX resistance in PS-BC cells were abrogated by co-treating cells with the autophagy inhibitor 3-methyladenine.	Paclitaxel	121-124	annexin A6	Homo sapiens	15-20
34676207-5	2021	Interestingly, ANXA6-exo increased PTX resistance in PS-BC cells via inducing autophagy, and the effects of ANXA6-exo on PTX resistance in PS-BC cells were abrogated by co-treating cells with the autophagy inhibitor 3-methyladenine.	Paclitaxel	121-124	annexin A6	Homo sapiens	108-113
34676207-6	2021	Moreover, the underlying mechanisms were uncovered, and we evidenced that ANXA6-exo up-regulated YAP1 to promote Hippo pathway dysregulation, and the promoting effects of ANXA6-exo on PTX resistance and cancer aggressiveness in BC cells were abrogated by silencing YAP1.	Paclitaxel	184-187	annexin A6	Homo sapiens	74-79
34676207-6	2021	Moreover, the underlying mechanisms were uncovered, and we evidenced that ANXA6-exo up-regulated YAP1 to promote Hippo pathway dysregulation, and the promoting effects of ANXA6-exo on PTX resistance and cancer aggressiveness in BC cells were abrogated by silencing YAP1.	Paclitaxel	184-187	annexin A6	Homo sapiens	171-176
34676207-7	2021	Taken together, this study firstly elucidated the underlying mechanisms by which BCSC-derived ANXA6-exo facilitated BC progression and PTX resistance, which might help to develop novel treatment strategies for BC in clinic.	Paclitaxel	135-138	annexin A6	Homo sapiens	94-99
34685613-7	2021	Interestingly, a 7-Epitaxol-mediated induction of LC3-I/II expression and suppression of p62 expression were observed in OSCC cells lines.	Paclitaxel	17-27	nucleoporin 62	Homo sapiens	89-92
34541682-9	2022	To summarize, circATL2 promoted the resistance of OC to PTX by sponging miR-506-3p to upregulate NFIB expression, providing a new sight in chemoresistance of OC.	Paclitaxel	56-59	nuclear factor I B	Homo sapiens	97-101
34595177-10	2021	Experiments in vitro verified that HIF1alpha/IL-17 pathway influences paclitaxel sensitivity to BC cells.	Paclitaxel	70-80	interleukin 17A	Homo sapiens	45-50
34080040-7	2021	All patients with CCNE1 amplification (n = 7), TP53 R175H substitution (n = 6), and RB1 mutation (n = 4) had poor response to paclitaxel plus carboplatin.	Paclitaxel	126-136	cyclin E1	Homo sapiens	18-23
34382768-5	2021	Outer membrane vesicles (OMVs) derived from Gram-negative bacteria were applied to coload paclitaxel (PTX) and regulated in development and DNA damage response 1 (Redd1)-siRNA and regulate tumor metabolism microenvironment and suppress tumor growth.	Paclitaxel	90-100	DNA damage inducible transcript 4	Homo sapiens	111-161
34382768-5	2021	Outer membrane vesicles (OMVs) derived from Gram-negative bacteria were applied to coload paclitaxel (PTX) and regulated in development and DNA damage response 1 (Redd1)-siRNA and regulate tumor metabolism microenvironment and suppress tumor growth.	Paclitaxel	90-100	DNA damage inducible transcript 4	Homo sapiens	163-168
34270886-0	2021	Histone demethylase KDM5A enhances cell proliferation, induces EMT in lung adenocarcinoma cells, and have a strong causal association with paclitaxel resistance.	Paclitaxel	139-149	lysine demethylase 5A	Homo sapiens	20-25
34270886-2	2021	Here, we explore the role of KDM5A in cell proliferation, epithelial-mesenchymal transition (EMT)and its causal association with paclitaxel resistance in lung adenocarcinoma.	Paclitaxel	129-139	lysine demethylase 5A	Homo sapiens	29-34
34270886-4	2021	We found that expression of KDM5A and P-glycoprotein (P-gp), which plays a critical role in the development of paclitaxel resistance, were significantly higher in PTX-Calu-3 cells compared to SK-LI-1, Calu-3, and A549 cells.. We observed a significant increase in the expression of mesenchymal markers N-cadherin and vimentin, and a concomitant decrease in expression of E-cadherin and alpha-catenin in PTX-Calu-3 compared to SK-LI-1, Calu-3, and A549 lung cancer cell lines.	Paclitaxel	111-121	lysine demethylase 5A	Homo sapiens	28-33
34118960-14	2021	BQU57, a small molecule inhibitor of RALA and RALB, decreased TNBC cell line viability, sensitized cells to paclitaxel in vitro and decreased tumor growth and metastasis in TNBC cell line and PDX models in vivo.	Paclitaxel	108-118	RAS like proto-oncogene A	Homo sapiens	37-41
34093828-8	2021	Furthermore, knockdown of p22phox significantly increased the chemosensitivity of A2780 cells to cisplatin or paclitaxel.	Paclitaxel	110-120	cytochrome b-245, alpha polypeptide	Mus musculus	26-33
35533911-1	2022	Wight et Arn reversed paclitaxel-induced MDR in vitro and in vivo by inhibiting both P-gp and MRP2.	Paclitaxel	22-32	ATP binding cassette subfamily C member 2	Homo sapiens	94-98
35134139-6	2022	A combination with paclitaxel dramatically enhanced the anti-cancer efficacy of CD47-targeted therapy toward late-stage NHL.	Paclitaxel	19-29	CD47 molecule	Homo sapiens	80-84
35134139-9	2022	In addition, we identified a role of paclitaxel in modifying the TME by preventing the accumulation of a TAM subpopulation that is only present in late-stage lymphoma resistant to CD47-targeted therapy.	Paclitaxel	37-47	CD47 molecule	Homo sapiens	180-184
35597872-0	2022	Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.	Paclitaxel	46-56	glucose-6-phosphate dehydrogenase	Homo sapiens	119-152
35597872-5	2022	RESULTS: Glucose-6-phosphate dehydrogenase (G6PD) expression along with an increase in 3-phosphoglycerates and ribulose-5-phosphate production was upregulated in paclitaxel-resistant cells.	Paclitaxel	162-172	glucose-6-phosphate dehydrogenase	Homo sapiens	9-42
35597872-5	2022	RESULTS: Glucose-6-phosphate dehydrogenase (G6PD) expression along with an increase in 3-phosphoglycerates and ribulose-5-phosphate production was upregulated in paclitaxel-resistant cells.	Paclitaxel	162-172	glucose-6-phosphate dehydrogenase	Homo sapiens	44-48
35597872-6	2022	Blockade of G6PD decreased viability of paclitaxel-resistant cells in vitro and the growth of paclitaxel-resistant MDA/R xenograft tumours in vivo.	Paclitaxel	40-50	glucose-6-phosphate dehydrogenase	Homo sapiens	12-16
35597872-10	2022	CONCLUSIONS: EGFR signaling-mediated G6PD expression plays a pivotal role in paclitaxel resistance, highlighting the potential of targeting EGFR to overcome paclitaxel resistance in TNBC and NSCLC cells overexpressing G6PD.	Paclitaxel	77-87	glucose-6-phosphate dehydrogenase	Homo sapiens	37-41
35597872-10	2022	CONCLUSIONS: EGFR signaling-mediated G6PD expression plays a pivotal role in paclitaxel resistance, highlighting the potential of targeting EGFR to overcome paclitaxel resistance in TNBC and NSCLC cells overexpressing G6PD.	Paclitaxel	77-87	glucose-6-phosphate dehydrogenase	Homo sapiens	218-222
35452214-3	2022	To augment therapeutic efficacy and tumor selectivity, folic acid (FA)-functionalized carbon dots (CDs) embedded with GOx and paclitaxel (PTX) (FA-CD-(PTX-GOx)) was developed that showed the efficient killing of TNBC, MDA-MB-468 cells over noncancerous HEK 293 cells through synergistic effects of cancer starvation-induced oxidative stress and chemotherapy.	Paclitaxel	126-136	FA complementation group D2	Homo sapiens	144-149
35452214-3	2022	To augment therapeutic efficacy and tumor selectivity, folic acid (FA)-functionalized carbon dots (CDs) embedded with GOx and paclitaxel (PTX) (FA-CD-(PTX-GOx)) was developed that showed the efficient killing of TNBC, MDA-MB-468 cells over noncancerous HEK 293 cells through synergistic effects of cancer starvation-induced oxidative stress and chemotherapy.	Paclitaxel	126-136	hydroxyacid oxidase 1	Homo sapiens	155-158
35452214-3	2022	To augment therapeutic efficacy and tumor selectivity, folic acid (FA)-functionalized carbon dots (CDs) embedded with GOx and paclitaxel (PTX) (FA-CD-(PTX-GOx)) was developed that showed the efficient killing of TNBC, MDA-MB-468 cells over noncancerous HEK 293 cells through synergistic effects of cancer starvation-induced oxidative stress and chemotherapy.	Paclitaxel	138-141	FA complementation group D2	Homo sapiens	144-149
35452214-3	2022	To augment therapeutic efficacy and tumor selectivity, folic acid (FA)-functionalized carbon dots (CDs) embedded with GOx and paclitaxel (PTX) (FA-CD-(PTX-GOx)) was developed that showed the efficient killing of TNBC, MDA-MB-468 cells over noncancerous HEK 293 cells through synergistic effects of cancer starvation-induced oxidative stress and chemotherapy.	Paclitaxel	138-141	hydroxyacid oxidase 1	Homo sapiens	155-158
35452214-3	2022	To augment therapeutic efficacy and tumor selectivity, folic acid (FA)-functionalized carbon dots (CDs) embedded with GOx and paclitaxel (PTX) (FA-CD-(PTX-GOx)) was developed that showed the efficient killing of TNBC, MDA-MB-468 cells over noncancerous HEK 293 cells through synergistic effects of cancer starvation-induced oxidative stress and chemotherapy.	Paclitaxel	151-154	hydroxyacid oxidase 1	Homo sapiens	118-121
35452214-3	2022	To augment therapeutic efficacy and tumor selectivity, folic acid (FA)-functionalized carbon dots (CDs) embedded with GOx and paclitaxel (PTX) (FA-CD-(PTX-GOx)) was developed that showed the efficient killing of TNBC, MDA-MB-468 cells over noncancerous HEK 293 cells through synergistic effects of cancer starvation-induced oxidative stress and chemotherapy.	Paclitaxel	151-154	FA complementation group D2	Homo sapiens	144-149
35452214-3	2022	To augment therapeutic efficacy and tumor selectivity, folic acid (FA)-functionalized carbon dots (CDs) embedded with GOx and paclitaxel (PTX) (FA-CD-(PTX-GOx)) was developed that showed the efficient killing of TNBC, MDA-MB-468 cells over noncancerous HEK 293 cells through synergistic effects of cancer starvation-induced oxidative stress and chemotherapy.	Paclitaxel	151-154	hydroxyacid oxidase 1	Homo sapiens	155-158
35452214-5	2022	This improved cancer cell killing efficacy of the FA-CD-(PTX-GOx) complex could be endorsed by folate receptor (FR)-mediated target-specific cellular internalization of the FA-CD complex.	Paclitaxel	57-60	FA complementation group D2	Homo sapiens	50-55
35452214-5	2022	This improved cancer cell killing efficacy of the FA-CD-(PTX-GOx) complex could be endorsed by folate receptor (FR)-mediated target-specific cellular internalization of the FA-CD complex.	Paclitaxel	57-60	hydroxyacid oxidase 1	Homo sapiens	61-64
35452214-5	2022	This improved cancer cell killing efficacy of the FA-CD-(PTX-GOx) complex could be endorsed by folate receptor (FR)-mediated target-specific cellular internalization of the FA-CD complex.	Paclitaxel	57-60	FA complementation group D2	Homo sapiens	173-178
35452214-6	2022	The antitumorigenic efficacy of the FA-CD-(PTX-GOx) complex was further validated in a three-dimensional (3D) breast tumor spheroid model.	Paclitaxel	43-46	FA complementation group D2	Homo sapiens	36-41
35452214-6	2022	The antitumorigenic efficacy of the FA-CD-(PTX-GOx) complex was further validated in a three-dimensional (3D) breast tumor spheroid model.	Paclitaxel	43-46	hydroxyacid oxidase 1	Homo sapiens	47-50
35452214-7	2022	A significant 4.5-fold reduction in spheroid dimension along with antiproliferation was observed with time up to 72 h following exposure to the FA-CD-(PTX-GOx) complex.	Paclitaxel	151-154	FA complementation group D2	Homo sapiens	144-149
35452214-7	2022	A significant 4.5-fold reduction in spheroid dimension along with antiproliferation was observed with time up to 72 h following exposure to the FA-CD-(PTX-GOx) complex.	Paclitaxel	151-154	hydroxyacid oxidase 1	Homo sapiens	155-158
35452214-8	2022	This antitumorigenic potential of FA-CD-(PTX-GOx) could be attributed to the enhanced intratumoral reactive oxygen species generation following glucose depletion by GOx that has been facilitated by the chemotherapeutic efficacy of PTX resulting in the efficient killing of cancer cells.	Paclitaxel	41-44	FA complementation group D2	Homo sapiens	34-39
35452214-8	2022	This antitumorigenic potential of FA-CD-(PTX-GOx) could be attributed to the enhanced intratumoral reactive oxygen species generation following glucose depletion by GOx that has been facilitated by the chemotherapeutic efficacy of PTX resulting in the efficient killing of cancer cells.	Paclitaxel	41-44	hydroxyacid oxidase 1	Homo sapiens	45-48
35452214-8	2022	This antitumorigenic potential of FA-CD-(PTX-GOx) could be attributed to the enhanced intratumoral reactive oxygen species generation following glucose depletion by GOx that has been facilitated by the chemotherapeutic efficacy of PTX resulting in the efficient killing of cancer cells.	Paclitaxel	41-44	hydroxyacid oxidase 1	Homo sapiens	165-168
35452214-8	2022	This antitumorigenic potential of FA-CD-(PTX-GOx) could be attributed to the enhanced intratumoral reactive oxygen species generation following glucose depletion by GOx that has been facilitated by the chemotherapeutic efficacy of PTX resulting in the efficient killing of cancer cells.	Paclitaxel	231-234	FA complementation group D2	Homo sapiens	34-39
35452214-8	2022	This antitumorigenic potential of FA-CD-(PTX-GOx) could be attributed to the enhanced intratumoral reactive oxygen species generation following glucose depletion by GOx that has been facilitated by the chemotherapeutic efficacy of PTX resulting in the efficient killing of cancer cells.	Paclitaxel	231-234	hydroxyacid oxidase 1	Homo sapiens	45-48
35452214-8	2022	This antitumorigenic potential of FA-CD-(PTX-GOx) could be attributed to the enhanced intratumoral reactive oxygen species generation following glucose depletion by GOx that has been facilitated by the chemotherapeutic efficacy of PTX resulting in the efficient killing of cancer cells.	Paclitaxel	231-234	hydroxyacid oxidase 1	Homo sapiens	165-168
35506169-6	2022	The depletion and pharmacological inhibition of USP9X by WP1130, an inhibitor of USP9X, downregulate endogenous Snail1 protein, inhibit cell migration, invasion, metastasis, and increase cellular sensitivity to cisplatin and paclitaxel both in vitro and in vivo, whereas the reconstitution of Snail1 in cells with USP9X depletion at least partially reverses these phenotypes.	Paclitaxel	225-235	ubiquitin specific peptidase 9 X-linked	Homo sapiens	48-53
35506169-6	2022	The depletion and pharmacological inhibition of USP9X by WP1130, an inhibitor of USP9X, downregulate endogenous Snail1 protein, inhibit cell migration, invasion, metastasis, and increase cellular sensitivity to cisplatin and paclitaxel both in vitro and in vivo, whereas the reconstitution of Snail1 in cells with USP9X depletion at least partially reverses these phenotypes.	Paclitaxel	225-235	ubiquitin specific peptidase 9 X-linked	Homo sapiens	81-86
35075596-3	2022	The stimulation of TRPM2 may increase the anticancer action of PAX after the treatment of MLT.	Paclitaxel	63-66	transient receptor potential cation channel subfamily M member 2	Homo sapiens	19-24
35075596-7	2022	The stimulation of TRPM2 induced the increase of TRPM2 current densities, lipid peroxidation, cytosolic ROS, miROS, cytosolic Ca2+, and Zn2+ values in the Hep2 cells after the treatment of PAX, although their values were decreased by the treatment of MLT and TRPM2 antagonists (ACA and 2APB).	Paclitaxel	189-192	transient receptor potential cation channel subfamily M member 2	Homo sapiens	19-24
35075596-11	2022	In conclusion, PAX induced the increase of Hep2 cell death via upregulations of TRPM2 and Zn2+, although its downregulation via the treatment of MLT did not change the antitumor action of PAX.	Paclitaxel	15-18	transient receptor potential cation channel subfamily M member 2	Homo sapiens	80-85
35184686-6	2022	After a subcutaneous-xenotransplant tumor model was established using BALB/c nude mice and further treated with PTX and UTMD-mediated miR-144-5p, the volume, weight, and Ki67 level of tumor were recorded or evaluated by immunohistochemical assays.	Paclitaxel	112-115	microRNA 144	Mus musculus	134-141
35184686-6	2022	After a subcutaneous-xenotransplant tumor model was established using BALB/c nude mice and further treated with PTX and UTMD-mediated miR-144-5p, the volume, weight, and Ki67 level of tumor were recorded or evaluated by immunohistochemical assays.	Paclitaxel	112-115	antigen identified by monoclonal antibody Ki 67	Mus musculus	170-174
35371298-0	2022	Radix ranunculus temate saponins sensitizes ovarian cancer to Taxol via upregulation of miR-let-7b.	Paclitaxel	62-67	microRNA let-7b	Homo sapiens	92-98
35371298-10	2022	miR-let-7b overexpression suppressed cell growth and invasion and enhanced sensitivity to Taxol of ovarian cancer cells.	Paclitaxel	90-95	microRNA let-7b	Homo sapiens	4-10
35371298-15	2022	In conclusion, the present results revealed synergistic cytotoxicity of RRTS and Taxol on against ovarian cancer cells via upregulating expression of miR-let-7b.	Paclitaxel	81-86	microRNA let-7b	Homo sapiens	154-160
35396749-14	2022	Moreover, miR-486-3p directly targeted CRABP2, and miR-486-3p inhibited Taxol resistance by targeting CRABP2.	Paclitaxel	72-77	cellular retinoic acid binding protein 2	Homo sapiens	102-108
35396749-17	2022	CONCLUSION: Circ_0011298 elevated Taxol resistance of NSCLC by sponging miR-486-3p and upregulating CRABP2, providing a possible circRNA-targeted therapy for NSCLC.	Paclitaxel	34-39	cellular retinoic acid binding protein 2	Homo sapiens	100-106
35477569-11	2022	NSCLC/PTX cells re-acquired sensitivity to PTX in vivo and in vitro when ALDH2 was inhibited by pharmacological agents, including the ALDH2 inhibitors Daidzin (DZN)/Disulfiram (DSF) and JIB04, which reverses the effect of EHMT2.	Paclitaxel	43-46	euchromatic histone lysine methyltransferase 2	Homo sapiens	222-227
35180471-0	2022	USP18 reduces paclitaxol sensitivity of triple-negative breast cancer via autophagy.	Paclitaxel	14-24	ubiquitin specific peptidase 18	Homo sapiens	0-5
35180471-4	2022	Among these DEGs, USP18 mRNA expression was significantly increased in taxol-R TNBC cells.	Paclitaxel	71-76	ubiquitin specific peptidase 18	Homo sapiens	18-23
35180471-5	2022	USP18 overexpression reduced paclitaxol sensitivity by decreasing paclitaxol-induced apoptosis and cell cycle arrest in TNBC cells.	Paclitaxel	29-39	ubiquitin specific peptidase 18	Homo sapiens	0-5
35180471-5	2022	USP18 overexpression reduced paclitaxol sensitivity by decreasing paclitaxol-induced apoptosis and cell cycle arrest in TNBC cells.	Paclitaxel	66-76	ubiquitin specific peptidase 18	Homo sapiens	0-5
35180471-6	2022	In contrast, USP18 knockdown increased paclitaxol mediated anticancer activity in taxol-R TNBC cells in vitro and in vivo.	Paclitaxel	39-49	ubiquitin specific peptidase 18	Homo sapiens	13-18
35180471-8	2022	The autophagy inhibitor leupeptin could effectively reverse the effect of USP18 on paclitaxol resistance phenotype.	Paclitaxel	83-93	ubiquitin specific peptidase 18	Homo sapiens	74-79
35180471-9	2022	These findings suggested that USP18 may be a promising target for overcoming paclitaxol resistance in TNBC.	Paclitaxel	77-87	ubiquitin specific peptidase 18	Homo sapiens	30-35
35453613-8	2022	In addition, niclosamide suppressed paclitaxel-induced mitochondrial dysfunction in human SH-SY5Y cells in a PINK1-dependent manner.	Paclitaxel	36-46	PTEN induced kinase 1	Homo sapiens	109-114
35448163-7	2022	Furthermore, a few lncRNAs, such as AFAP1-AS1 and LINC01014, block the efficiency of chemotherapeutic drugs, including cisplatin, 5-fluorouracil, paclitaxel, and gefitinib, used for ESCC treatment.	Paclitaxel	146-156	actin filament associated protein 1	Homo sapiens	36-41
35371325-8	2022	As for BRD3, we found that BRD3 expression was related to better OS in endometrioid ovarian carcinoma and stage III+IV ovarian carcinoma patients, as well as all patients managed with Taxol and concurrent Taxol+Platin based chemotherapy.	Paclitaxel	184-189	bromodomain containing 3	Homo sapiens	27-31
35371325-8	2022	As for BRD3, we found that BRD3 expression was related to better OS in endometrioid ovarian carcinoma and stage III+IV ovarian carcinoma patients, as well as all patients managed with Taxol and concurrent Taxol+Platin based chemotherapy.	Paclitaxel	205-210	bromodomain containing 3	Homo sapiens	27-31
35051615-3	2022	Herein, we showed that the immunotherapeutic HCW9218, comprising TGF-beta receptor II and IL-15/IL-15 receptor alpha domains, enhanced metabolic and cytotoxic activities of immune cells and reduced TIS tumor cells in vivo to improve the efficacy of docetaxel and gemcitabine plus nab-paclitaxel against B16F10 melanoma and SW1990 pancreatic tumors, respectively.	Paclitaxel	284-294	interleukin 15	Mus musculus	90-95
35263200-5	2022	A CCK-8 assay showed that the inhibitory effect of Paclitaxel on Pfeiffer and Pfeiffer/ADM (Adriamycin-resistant DLBCL cell lines) is significantly higher than that of Adriamycin (P < 0.05).	Paclitaxel	51-61	adrenomedullin	Homo sapiens	87-90
35263200-6	2022	Five hub genes (UBC, TSR1, WDR46, HSP90AA1, and NOP56) were obtained via network analysis from 971 differentially expressed genes (DEGs) based on the RNA-seq of Paclitaxel-intervened Pfeiffer/ADM.	Paclitaxel	161-171	adrenomedullin	Homo sapiens	192-195
35263200-7	2022	The results of the network function module analysis showed that the inhibition of Pfeiffer/ADM by Paclitaxel was closely related to ribosome biosynthesis in eukaryotes.	Paclitaxel	98-108	adrenomedullin	Homo sapiens	91-94
35263200-8	2022	The results of RT-qPCR showed that the mRNA levels of the five hub genes in the Pfeiffer/ADM group were significantly lower than those in the Pfeiffer group and the Pfeiffer/ADM Paclitaxel-treated group (P < 0.05).	Paclitaxel	178-188	adrenomedullin	Homo sapiens	174-177
35088239-0	2022	Role of aurora kinase B in regulating resistance to paclitaxel in breast cancer cells.	Paclitaxel	52-62	aurora kinase B	Homo sapiens	8-23
35088239-9	2022	Collectively, this study provides experimental evidence for PRKCE/AURKB/RAB27B axis in regulating the resistance to paclitaxel (PTX) in breast cancer cells, offering a potential intervention target for reversing drug resistance.	Paclitaxel	116-126	aurora kinase B	Homo sapiens	66-71
35088239-9	2022	Collectively, this study provides experimental evidence for PRKCE/AURKB/RAB27B axis in regulating the resistance to paclitaxel (PTX) in breast cancer cells, offering a potential intervention target for reversing drug resistance.	Paclitaxel	116-126	RAB27B, member RAS oncogene family	Homo sapiens	72-78
35088239-9	2022	Collectively, this study provides experimental evidence for PRKCE/AURKB/RAB27B axis in regulating the resistance to paclitaxel (PTX) in breast cancer cells, offering a potential intervention target for reversing drug resistance.	Paclitaxel	128-131	aurora kinase B	Homo sapiens	66-71
35088239-9	2022	Collectively, this study provides experimental evidence for PRKCE/AURKB/RAB27B axis in regulating the resistance to paclitaxel (PTX) in breast cancer cells, offering a potential intervention target for reversing drug resistance.	Paclitaxel	128-131	RAB27B, member RAS oncogene family	Homo sapiens	72-78
35281908-10	2022	The anticancer mechanism of the PTX-JG combination in A549/PTX cells was elucidated based on cell proliferation, annexin V-FITC apoptosis assay, and western blotting.	Paclitaxel	32-35	annexin A5	Mus musculus	113-122
35281908-12	2022	JG remarkably enhanced the anticancer effect of PTX by increasing the red blood cell and platelet counts; increasing hemoglobin, interleukin (IL)-2, and tumor necrosis factor-alpha levels; increasing CD4+T cells and the CD4+/CD8+ ratio; and decreasing IL-10 levels.	Paclitaxel	48-51	CD4 antigen	Mus musculus	200-203
35281908-12	2022	JG remarkably enhanced the anticancer effect of PTX by increasing the red blood cell and platelet counts; increasing hemoglobin, interleukin (IL)-2, and tumor necrosis factor-alpha levels; increasing CD4+T cells and the CD4+/CD8+ ratio; and decreasing IL-10 levels.	Paclitaxel	48-51	CD4 antigen	Mus musculus	220-223
35194034-8	2022	We found that DRAK1 protein was destabilized through K48-linked polyubiquitination promoted by the Cullin scaffold protein 3 (CUL3) / speckle-type POZ (poxvirus and zinc finger protein) protein (SPOP) E3 ubiquitin ligase in paclitaxel-resistant cells.	Paclitaxel	224-234	speckle type BTB/POZ protein	Homo sapiens	195-199
35172762-13	2022	The addition of chemotherapy was associated with reduced number of myeloid and lymphoid cell types, except for CD4 + cells whose levels were largely unaltered only in tumors treated with gemcitabine/nab-paclitaxel.	Paclitaxel	203-213	CD4 antigen	Mus musculus	111-114
35168606-6	2022	RESULTS: On in vivo 1H-MRS, the ratio of (glycerophosphocholine + phosphocholine) to (creatine + phosphocreatine) ((GPC + PC) to (Cr + PCr))(i.e. Cho/Cr) in the PTX-resistant tumors (1.64 (0.69, 4.18)) was significantly higher than that in the PTX-sensitive tumors (0.33 (0.10, 1.13)) (P = 0.04).	Paclitaxel	161-164	glycophorin C (Gerbich blood group)	Homo sapiens	116-119
35168606-6	2022	RESULTS: On in vivo 1H-MRS, the ratio of (glycerophosphocholine + phosphocholine) to (creatine + phosphocreatine) ((GPC + PC) to (Cr + PCr))(i.e. Cho/Cr) in the PTX-resistant tumors (1.64 (0.69, 4.18)) was significantly higher than that in the PTX-sensitive tumors (0.33 (0.10, 1.13)) (P = 0.04).	Paclitaxel	244-247	glycophorin C (Gerbich blood group)	Homo sapiens	116-119
35001532-5	2022	Decreased expressions of germ cell proliferation-associated protein PCNA and meiosis-related protein SYCP3 induced by PTX were determined by Western blot, while MLT ameliorated this effect and increased the expressions of PCNA, SYCP3, DMC1, STRA8 and fertility-related protein of HSPA2, resulting in significantly improved spermatogenesis and sperm quality levels.	Paclitaxel	118-121	proliferating cell nuclear antigen	Mus musculus	68-72
35001532-5	2022	Decreased expressions of germ cell proliferation-associated protein PCNA and meiosis-related protein SYCP3 induced by PTX were determined by Western blot, while MLT ameliorated this effect and increased the expressions of PCNA, SYCP3, DMC1, STRA8 and fertility-related protein of HSPA2, resulting in significantly improved spermatogenesis and sperm quality levels.	Paclitaxel	118-121	proliferating cell nuclear antigen	Mus musculus	222-226
35141332-1	2022	Objective: The aim of the present study was to investigate the effect of forkhead box M1 (FOXM1) to paclitaxel resistance in cervical cancer cells, to determine the underlying mechanism, and to identify novel targets for the treatment of paclitaxel-resistant cervical cancer.	Paclitaxel	100-110	forkhead box M1	Homo sapiens	73-88
35280672-4	2022	Further study demonstrated that PTX upregulated the expression of C-C chemokine receptor type 7 (CCR7) in B16F10 cells, enhancing their migration through the activation of JNK and p38 signalling pathways.	Paclitaxel	32-35	mitogen-activated protein kinase 8	Mus musculus	172-175
35173861-10	2022	Overexpression of VEGFR2 can offset the rescue effect of Apa on PTX-induced drug resistance of MGC803 cells.	Paclitaxel	64-67	kinase insert domain receptor	Homo sapiens	18-24
35173861-11	2022	Taken together, Apa may inhibit PTX resistance of MGC803 cells via the VEGFR2 signaling pathway.	Paclitaxel	32-35	kinase insert domain receptor	Homo sapiens	71-77
35011550-5	2022	Additionally, compounds 4-8, 10 and 12-13 circumvented Pgp and betaIII-tubulin mediated drug resistance, mechanisms that diminish the clinical efficacy of paclitaxel (PTX).	Paclitaxel	155-165	phosphoglycolate phosphatase	Mus musculus	55-58
35011550-5	2022	Additionally, compounds 4-8, 10 and 12-13 circumvented Pgp and betaIII-tubulin mediated drug resistance, mechanisms that diminish the clinical efficacy of paclitaxel (PTX).	Paclitaxel	155-165	tubulin, beta 3 class III	Mus musculus	63-78
35011550-5	2022	Additionally, compounds 4-8, 10 and 12-13 circumvented Pgp and betaIII-tubulin mediated drug resistance, mechanisms that diminish the clinical efficacy of paclitaxel (PTX).	Paclitaxel	167-170	phosphoglycolate phosphatase	Mus musculus	55-58
35011550-5	2022	Additionally, compounds 4-8, 10 and 12-13 circumvented Pgp and betaIII-tubulin mediated drug resistance, mechanisms that diminish the clinical efficacy of paclitaxel (PTX).	Paclitaxel	167-170	tubulin, beta 3 class III	Mus musculus	63-78
35019820-2	2022	In vitro binding test of IL15 fusion protein to HSA and Nab-paclitaxel, as well as CTLL-2 cell stimulation assay were performed.	Paclitaxel	60-70	interleukin 15	Mus musculus	25-29
35019820-9	2022	In conclusion, combination therapy of Nab-paclitaxel and IL-15 fusion protein can effectively stimulate the antitumor activity of immune effector cells, thereby inhibiting immunosuppressive cells within the TME of colorectal cancer, and the overall therapeutic effect has a significant advantage over monotherapy.AbbreviationsInterleukin 15, IL-15; Human serum albumin, HSA; Myeloid-derived suppressor cells, MDSC; Albumin binding domain, ABD; Tumor drainage lymph node, TDLN; Natural killer (NK); Tumor-draining lymph node (TDLN); Tumor infiltrating lymphocyte, TIL; Immunogenic cell death, ICD; Enhanced permeability retention, EPR; Liposomal doxorubicin, Doxil; 5-fluorouracil, 5-FU.	Paclitaxel	42-52	interleukin 15	Mus musculus	342-347
10964468-7	2000	In contrast, the microtubule stabilizer taxol induced the loss of Mad2 from the majority of the first-division-metaphase kinetochores in which it was normally present in untreated cells.	Paclitaxel	40-45	mitotic arrest deficient 2 like 1	Homo sapiens	66-70
10899939-8	2000	The cellular distribution is altered by treatment with taxol, nocodazole, and cytochalasin D. The tubulin binding domain was located at the N terminus of GABARAP by using synthetic peptides and deletion constructs and is marked by a specific arrangement of basic amino acids.	Paclitaxel	55-60	GABA type A receptor-associated protein	Homo sapiens	154-161
10900343-7	2000	A similar dose of PTX, given on days 6 and 8 to animals developing active EAE after immunization with GP MBP peptide 68-88 in complete Freund"s adjuvant, greatly reduced the severity of paralysis and delayed the onset of disease by 8-9 days.	Paclitaxel	18-21	myelin basic protein	Cavia porcellus	105-108
10873410-9	2000	CONCLUSION: The combination of paclitaxel with cisplatin with G-CSF support appears active in patients with metastatic or recurrent carcinoma of the endometrium.	Paclitaxel	31-41	colony stimulating factor 3	Homo sapiens	62-67
10828884-0	2000	Differential modulation of paclitaxel-mediated apoptosis by p21Waf1 and p27Kip1.	Paclitaxel	27-37	cyclin dependent kinase inhibitor 1B	Homo sapiens	72-79
10828884-1	2000	The impact of the cyclin dependent kinase (CDK) inhibitors p21Waf1 and p27Kip1 on paclitaxel-mediated cytotoxicity was investigated in RKO human colon adenocarcinoma cells with the ecdysone-inducible expression of p21Waf1 or p27Kip1.	Paclitaxel	82-92	cyclin dependent kinase inhibitor 1B	Homo sapiens	71-78
10811138-3	2000	Here, we demonstrated that overexpression of TRPM-2 in human androgen-dependent LNCaP prostate cancer cells by stable transfection rendered them highly resistant to paclitaxel treatment than control LNCaP cells, with a 20-fold higher IC50 through the inhibition of apoptotic cell death.	Paclitaxel	165-175	clusterin	Mus musculus	45-51
10811138-4	2000	In mice bearing TRPM-2-overexpressing LNCaP tumors, tumor volume and serum prostate-specific antigen increased two to three times faster after castration and paclitaxel treatment compared with mice bearing control tumors.	Paclitaxel	158-168	clusterin	Mus musculus	16-22
10811138-6	2000	Antisense TRPM-2 ODN treatment significantly enhanced paclitaxel chemosensitivity of Shionogi tumor cells in a dose-dependent manner, reducing the IC50 by 75%.	Paclitaxel	54-64	clusterin	Mus musculus	10-16
10811138-8	2000	Adjuvant administration of antisense TRPM-2 ODN and polymeric micellar paclitaxel after castration resulted in reduced TRPM-2 levels in vivo and a significant delay of emergence of androgen-independent recurrent Shionogi tumors compared with administration of either agent alone.	Paclitaxel	71-81	clusterin	Mus musculus	119-125
10777697-4	2000	Further, sucrose-cushioned ultra centrifugation revealed that HSP27 is co-sedimented with taxol-stabilized microtubules.	Paclitaxel	90-95	heat shock protein family B (small) member 1	Homo sapiens	62-67
10706103-0	2000	A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin.	Paclitaxel	181-186	transformation related protein 53, pseudogene	Mus musculus	12-15
10706103-10	2000	Similarly, when mice bearing established lung adenomas were treated with Taxol or Adriamycin, a decrease in tumor volume of approximately 70% was observed independent of p53 mutation status.	Paclitaxel	73-78	transformation related protein 53, pseudogene	Mus musculus	170-173
10769641-0	2000	Involvement of p21Waf1 in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells.	Paclitaxel	50-60	epidermal growth factor	Homo sapiens	82-105
10769641-2	2000	In this study, we investigated how epidermal growth factor (EGF) modulated paclitaxel-induced apoptosis in MDA-MB-468 human breast adenocarcinoma cells.	Paclitaxel	75-85	epidermal growth factor	Homo sapiens	35-58
10769641-2	2000	In this study, we investigated how epidermal growth factor (EGF) modulated paclitaxel-induced apoptosis in MDA-MB-468 human breast adenocarcinoma cells.	Paclitaxel	75-85	epidermal growth factor	Homo sapiens	60-63
10769641-4	2000	When EGF was present during the post-paclitaxel culture period, this paclitaxel-induced apoptosis was inhibited in an EGF dose-dependent manner.	Paclitaxel	37-47	epidermal growth factor	Homo sapiens	5-8
10769641-4	2000	When EGF was present during the post-paclitaxel culture period, this paclitaxel-induced apoptosis was inhibited in an EGF dose-dependent manner.	Paclitaxel	37-47	epidermal growth factor	Homo sapiens	118-121
10769641-4	2000	When EGF was present during the post-paclitaxel culture period, this paclitaxel-induced apoptosis was inhibited in an EGF dose-dependent manner.	Paclitaxel	69-79	epidermal growth factor	Homo sapiens	5-8
10769641-4	2000	When EGF was present during the post-paclitaxel culture period, this paclitaxel-induced apoptosis was inhibited in an EGF dose-dependent manner.	Paclitaxel	69-79	epidermal growth factor	Homo sapiens	118-121
10769641-5	2000	The induction of apoptosis by paclitaxel was accompanied by an elevated level of p34cdc2 kinase activity, which was inhibited in the presence of EGF during the post-paclitaxel culture period.	Paclitaxel	30-40	cyclin dependent kinase 1	Homo sapiens	81-88
10769641-5	2000	The induction of apoptosis by paclitaxel was accompanied by an elevated level of p34cdc2 kinase activity, which was inhibited in the presence of EGF during the post-paclitaxel culture period.	Paclitaxel	30-40	epidermal growth factor	Homo sapiens	145-148
10769688-3	2000	We showed that ovarian cancer cells either overexpressing constitutively active Akt/AKT1 or containing AKT2 gene amplification were highly resistant to paclitaxel than cancer cells express low AKT levels.	Paclitaxel	152-162	AKT serine/threonine kinase 2	Homo sapiens	103-107
10583383-11	1999	In vitro, enovin stimulates neurite outgrowth and counteracts taxol-induced neurotoxicity in staurosporine-differentiated SH-SY5Y human neuroblastoma cells.	Paclitaxel	62-67	artemin	Homo sapiens	10-16
10565827-9	1999	A microtubule stabilizer (paclitaxel,Taxol) mimicked, in part, the effects of EGF and TGF-alpha, whereas a microtubule disruptive drug (colchicine) prevented the protective effects of these growth factors.	Paclitaxel	26-36	epidermal growth factor	Homo sapiens	78-81
10565827-9	1999	A microtubule stabilizer (paclitaxel,Taxol) mimicked, in part, the effects of EGF and TGF-alpha, whereas a microtubule disruptive drug (colchicine) prevented the protective effects of these growth factors.	Paclitaxel	37-42	epidermal growth factor	Homo sapiens	78-81
10589757-0	1999	Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.	Paclitaxel	191-201	C-C motif chemokine ligand 2	Homo sapiens	153-183
10534572-9	1999	Furthermore, down-regulation of cyclin B and cdk1 was observed in Taxol and Caffeine treated HPAC cells.	Paclitaxel	66-71	cyclin dependent kinase 1	Homo sapiens	45-49
10534572-13	1999	The up-regulation of p21WAF1 and down-regulation of cyclin B and cdk1 suggest their possible roles in G2/M cell cycle arrest caused by both Taxol and Caffeine as reported earlier.	Paclitaxel	140-145	cyclin dependent kinase 1	Homo sapiens	65-69
10471534-0	1999	Modulation of urokinase-type plasminogen activator and metalloproteinase activities in cultured mouse mammary-carcinoma cells: enhancement by paclitaxel and inhibition by nocodazole.	Paclitaxel	142-152	plasminogen activator, urokinase	Mus musculus	14-50
10471534-4	1999	In the present study, the effects of paclitaxel and nocodazole, 2 drugs known to affect microtubules with opposite mechanisms of action, have been tested for their effect on the secretion of uPA and MMPs in cultures of F3II mouse mammary-tumor cells.	Paclitaxel	37-47	plasminogen activator, urokinase	Mus musculus	191-194
10471534-5	1999	Tumor-derived uPA activity significantly increased after pre-treatment of tumor cells for 24 hr with micromolar concentrations of paclitaxel (4 microM), while decreasing after pre-treatment with nocodazole (1 microM).	Paclitaxel	130-140	plasminogen activator, urokinase	Mus musculus	14-17
10502406-0	1999	Paclitaxel induces apoptosis in Saos-2 cells with CD95L upregulation and Bcl-2 phosphorylation.	Paclitaxel	0-10	Fas ligand	Homo sapiens	50-55
10516758-4	1999	Potentiation of paclitaxel-induced apoptosis by bryostatin 1 in U937/Bcl-xL cells occurred primarily in the G2M cell population, and was associated with alterations in Bcl-xL gel mobility and a reduction in paclitaxel-mediated stimulation of CDK1 activity.	Paclitaxel	16-26	cyclin dependent kinase 1	Homo sapiens	242-246
10430075-11	1999	Granulocyte colony-stimulating factor (G-CSF; 5 microg/kg/day) was administered s.c. from day 6, routinely after 250 mg/m2 dose of paclitaxel or after a lower dose of paclitaxel if ANC &lt;500/microl or febrile neutropenia was observed.	Paclitaxel	131-141	colony stimulating factor 3	Homo sapiens	0-37
10430075-14	1999	In previously untreated patients, the maximally tolerated dose of paclitaxel in the drug regimen was determined to be 170 mg/m2 without and 250 mg/m2 with G-CSF support.	Paclitaxel	66-76	colony stimulating factor 3	Homo sapiens	155-160
10362110-2	1999	The major cellular target of Taxol is the microtubule that is comprised of alpha- and beta-tubulin heterodimers.	Paclitaxel	29-34	tubulin alpha 1b	Homo sapiens	75-98
10355583-0	1999	Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.	Paclitaxel	20-30	colony stimulating factor 3	Homo sapiens	58-63
10037184-5	1999	Furthermore, the combination of emodin and paclitaxel synergistically inhibited the anchorage-dependent and -independent growth of HER-2/neu-overexpressing breast cancer cells in vitro and synergistically inhibited tumor growth and prolonged survival in athymic mice bearing s.c. xenografts of human tumor cells expressing high levels of p185neu.	Paclitaxel	43-53	erb-b2 receptor tyrosine kinase 2	Mus musculus	131-136
10037184-5	1999	Furthermore, the combination of emodin and paclitaxel synergistically inhibited the anchorage-dependent and -independent growth of HER-2/neu-overexpressing breast cancer cells in vitro and synergistically inhibited tumor growth and prolonged survival in athymic mice bearing s.c. xenografts of human tumor cells expressing high levels of p185neu.	Paclitaxel	43-53	erb-b2 receptor tyrosine kinase 2	Mus musculus	137-140
10037184-7	1999	Taken together, our results suggest that the tyrosine kinase activity of HER-2/neu is required for tumor growth and chemoresistance and that tyrosine kinase inhibitors such as emodin can inhibit the growth of HER-2/neu-overexpressing tumors in mice and also sensitize these tumors to paclitaxel.	Paclitaxel	284-294	erb-b2 receptor tyrosine kinase 2	Mus musculus	73-82
10037184-7	1999	Taken together, our results suggest that the tyrosine kinase activity of HER-2/neu is required for tumor growth and chemoresistance and that tyrosine kinase inhibitors such as emodin can inhibit the growth of HER-2/neu-overexpressing tumors in mice and also sensitize these tumors to paclitaxel.	Paclitaxel	284-294	erb-b2 receptor tyrosine kinase 2	Mus musculus	73-78
10037184-7	1999	Taken together, our results suggest that the tyrosine kinase activity of HER-2/neu is required for tumor growth and chemoresistance and that tyrosine kinase inhibitors such as emodin can inhibit the growth of HER-2/neu-overexpressing tumors in mice and also sensitize these tumors to paclitaxel.	Paclitaxel	284-294	erb-b2 receptor tyrosine kinase 2	Mus musculus	79-82
10742982-6	1999	Numerous investigations with drugs such as digoxin, etoposide, cyclosporine, vinblastine, Taxol, loperamide, dom-peridone, and ondansteron demonstrate that P-gp has an important role in determining the pharmacokinetics of substrate drugs.	Paclitaxel	90-95	phosphoglycolate phosphatase	Homo sapiens	156-160
9886182-3	1998	A 36-year-old woman had received neoadjuvant chemotherapy (cyclophosphamide, epirubicin and 5-fluorouracil), modified radical mastectomy and adjuvant chemotherapy with paclitaxel and mitoxantrone followed by GM-CSF administration for the treatment of locally advanced breast cancer.	Paclitaxel	168-178	colony stimulating factor 2	Homo sapiens	208-214
9844922-0	1998	Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome C and caspase-3 activity during Taxol-induced apoptosis of human AML HL-60 cells.	Paclitaxel	132-137	cyclin dependent kinase 1	Homo sapiens	25-29
12016856-3	1998	These included taxol derivatives modified at C-2 position with benzoate, m-Cl benzoate, valerate and phenylacetate.	Paclitaxel	15-20	complement C2	Homo sapiens	45-48
9844631-0	1998	Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase.	Paclitaxel	31-36	cyclin dependent kinase 1	Homo sapiens	98-105
9844631-3	1998	Taxol activates p34Cdc2 kinase in MDA-MB-435 breast cancer cells, leading to cell cycle arrest at the G2/M phase and, subsequently, apoptosis.	Paclitaxel	0-5	cyclin dependent kinase 1	Homo sapiens	16-23
9844631-4	1998	A chemical inhibitor of p34Cdc2 and a dominant-negative mutant of p34Cdc2 blocked Taxol-induced apoptosis in these cells.	Paclitaxel	82-87	cyclin dependent kinase 1	Homo sapiens	24-31
9844631-4	1998	A chemical inhibitor of p34Cdc2 and a dominant-negative mutant of p34Cdc2 blocked Taxol-induced apoptosis in these cells.	Paclitaxel	82-87	cyclin dependent kinase 1	Homo sapiens	66-73
9844631-5	1998	Overexpression of p185ErbB2 in MDA-MB-435 cells by transfection transcriptionally upregulates p21Cip1, which associates with p34Cdc2, inhibits Taxol-mediated p34Cdc2 activation, delays cell entrance to G2/M phase, and thereby inhibits Taxol-induced apoptosis.	Paclitaxel	143-148	cyclin dependent kinase 1	Homo sapiens	158-165
9858906-11	1998	The expression of PCNA and the development of polyploidization appear to be good markers for measuring Paclitaxel response.	Paclitaxel	103-113	proliferating cell nuclear antigen	Homo sapiens	18-22
9784008-1	1998	The regulation of parathyroid hormone-related protein expression by colchicine, vinblastine, nocodazole, taxol, transforming growth factor-beta1 (TGFbeta1), and epidermal growth factor (EGF) was investigated in a canine squamous carcinoma cell line (SCC 2/88 cells).	Paclitaxel	105-110	parathyroid hormone like hormone	Canis lupus familiaris	18-53
9721872-4	1998	The first cellular effect observed with continuous exposure to 50 ng/ml paclitaxel (ID50) was mitotic arrest with an increase in the accumulation of cyclin B1 and stimulation of cdc2/cyclin B1 kinase in a time-dependent manner during a 36-h incubation.	Paclitaxel	72-82	cyclin B1	Homo sapiens	149-158
9721872-4	1998	The first cellular effect observed with continuous exposure to 50 ng/ml paclitaxel (ID50) was mitotic arrest with an increase in the accumulation of cyclin B1 and stimulation of cdc2/cyclin B1 kinase in a time-dependent manner during a 36-h incubation.	Paclitaxel	72-82	cyclin dependent kinase 1	Homo sapiens	178-182
9721872-4	1998	The first cellular effect observed with continuous exposure to 50 ng/ml paclitaxel (ID50) was mitotic arrest with an increase in the accumulation of cyclin B1 and stimulation of cdc2/cyclin B1 kinase in a time-dependent manner during a 36-h incubation.	Paclitaxel	72-82	cyclin B1	Homo sapiens	183-192
9668078-4	1998	The number of mitotic cells was highest at 24 h (82%), then declined as arrested cells progressed into apoptosis, and barely no mitotic cells were present at 48-60 h. The time curves of paclitaxel-induced cyclin B1 accumulation and stimulation of Cdc2/cyclin B1 kinase activity were identical and superimposable to that of M phase arrest.	Paclitaxel	186-196	cyclin B1	Homo sapiens	205-214
9668078-4	1998	The number of mitotic cells was highest at 24 h (82%), then declined as arrested cells progressed into apoptosis, and barely no mitotic cells were present at 48-60 h. The time curves of paclitaxel-induced cyclin B1 accumulation and stimulation of Cdc2/cyclin B1 kinase activity were identical and superimposable to that of M phase arrest.	Paclitaxel	186-196	cyclin dependent kinase 1	Homo sapiens	247-251
9668078-4	1998	The number of mitotic cells was highest at 24 h (82%), then declined as arrested cells progressed into apoptosis, and barely no mitotic cells were present at 48-60 h. The time curves of paclitaxel-induced cyclin B1 accumulation and stimulation of Cdc2/cyclin B1 kinase activity were identical and superimposable to that of M phase arrest.	Paclitaxel	186-196	cyclin B1	Homo sapiens	252-261
9673415-16	1998	Comparable to Taxol the diluent CEL/eth had a significant but less pronounced cytotoxic effect.	Paclitaxel	14-19	carboxyl ester lipase	Homo sapiens	32-35
9694607-0	1998	Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer.	Paclitaxel	7-17	colony stimulating factor 3	Homo sapiens	48-53
9569030-3	1998	In studying the underlying mechanism(s), we found that increased MAP4 expression, which occurs with transcriptionally silent p53, is associated with increased sensitivity to paclitaxel and decreased sensitivity to vinca alkaloids.	Paclitaxel	174-184	transformation related protein 53, pseudogene	Mus musculus	125-128
9472635-3	1998	At clinically relevant taxol concentrations of 5-100 nM, taxol and CD95 ligand showed significant synergistic cytotoxicity and growth inhibition.	Paclitaxel	23-28	Fas cell surface death receptor	Homo sapiens	67-71
9472635-10	1998	Considering (1) that phosphorylation of bcl-2 interferes with its heterodimerization with bax and (2) the inhibition of CD95-mediated apoptosis by bcl-2, we propose that taxol sensitizes malignant glioma cells to CD95 ligand by increasing the functional bax/bcl-2 rheostat in favour of bax and thus cell death.	Paclitaxel	170-175	Fas cell surface death receptor	Homo sapiens	120-124
9472635-10	1998	Considering (1) that phosphorylation of bcl-2 interferes with its heterodimerization with bax and (2) the inhibition of CD95-mediated apoptosis by bcl-2, we propose that taxol sensitizes malignant glioma cells to CD95 ligand by increasing the functional bax/bcl-2 rheostat in favour of bax and thus cell death.	Paclitaxel	170-175	Fas cell surface death receptor	Homo sapiens	213-217
9438385-0	1998	Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells.	Paclitaxel	0-5	cyclin dependent kinase 1	Homo sapiens	14-21
9438385-3	1998	Here, we show that Taxol induced p34cdc2 kinase activity with a peak at 6 h in human breast carcinoma MCF-7 cells.	Paclitaxel	19-24	cyclin dependent kinase 1	Homo sapiens	33-40
9476146-1	1998	P-gp (Pgp) is a cell surface ATPase which confers resistance to many of the most active chemotherapy drugs, including taxol, doxorubicin, and vinca alkaloids.	Paclitaxel	118-123	phosphoglycolate phosphatase	Homo sapiens	0-4
9476146-1	1998	P-gp (Pgp) is a cell surface ATPase which confers resistance to many of the most active chemotherapy drugs, including taxol, doxorubicin, and vinca alkaloids.	Paclitaxel	118-123	phosphoglycolate phosphatase	Homo sapiens	6-9
9371520-3	1997	We found that the signal generated by the DNA damage checkpoint in G2 was dominant over that from the spindle microtubule-assembly checkpoint, because the high Cdc2 activity present in nocodazole or Taxol-arrested cells was reduced by DNA damage.	Paclitaxel	199-204	cyclin dependent kinase 1	Homo sapiens	160-164
9230211-2	1997	Abnormal activation of cyclin B-associated CDC 2 kinase has been implicated in apoptosis induced by cancer chemotherapeutic agents such as paclitaxel (Taxol) and etoposide (VP-16).	Paclitaxel	139-149	cyclin dependent kinase 1	Homo sapiens	43-48
9230211-2	1997	Abnormal activation of cyclin B-associated CDC 2 kinase has been implicated in apoptosis induced by cancer chemotherapeutic agents such as paclitaxel (Taxol) and etoposide (VP-16).	Paclitaxel	151-156	cyclin dependent kinase 1	Homo sapiens	43-48
9250789-4	1997	Pretreatment of K562 cells with taxol (6 and 30 ng/ml) resulted in an increase in K562 cell lysis by NK cells (or NK cells stimulated with 100 units/ml of rIL-2) in 7 out of 9 donors.	Paclitaxel	32-37	interleukin 2	Rattus norvegicus	155-160
9250789-5	1997	The amplification of NK cell-mediated lysis of tumor targets due to taxol pretreatment may provide a combination therapeutic approach which includes taxol treatment followed by rIL-2 stimulation of the immune killer cell function.	Paclitaxel	68-73	interleukin 2	Rattus norvegicus	177-182
10453491-1	1997	The method of mRNA differential display was employed to isolate expressing genes involved in taxol-induced apoptosis of human breast cancer cells (BCap 37).	Paclitaxel	93-98	prohibitin 2	Homo sapiens	147-154
9233524-16	1997	CONCLUSIONS: The combination of paclitaxel and carboplatin appears to be well tolerated but only moderately active in patients with advanced non-NPC of the head and neck region.	Paclitaxel	32-42	NPC intracellular cholesterol transporter 1	Homo sapiens	145-148
9164208-1	1997	PURPOSE: To determine the maximum-tolerable dose (MTD) of paclitaxel in a phase I dose-escalation study when combined with cisplatin in patients with advanced ovarian cancer receiving filgrastim for prophylaxis of myelosuppression.	Paclitaxel	58-68	metallothionein 1E	Homo sapiens	50-53
9164208-12	1997	CONCLUSION: The MTD of paclitaxel was determined to be 225 mg/m2 when administered as a 3-hour infusion and combined with cisplatin (75 mg/m2).	Paclitaxel	23-33	metallothionein 1E	Homo sapiens	16-19
9193331-0	1997	Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.	Paclitaxel	92-102	colony stimulating factor 3	Homo sapiens	43-80
9070886-2	1997	We then studied the effect of antimitotic agents, nocodazole and the taxoids [paclitaxel (taxol) and docetaxel (taxotere)] on c-myc oncogene expression.	Paclitaxel	78-88	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	126-131
9070886-2	1997	We then studied the effect of antimitotic agents, nocodazole and the taxoids [paclitaxel (taxol) and docetaxel (taxotere)] on c-myc oncogene expression.	Paclitaxel	90-95	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	126-131
9070886-4	1997	Taxol (1 microM), taxotere (1 microM) and nocodazole (3 microM) inhibited by 30-50% the c-myc induction produced by growth factors in culture medium.	Paclitaxel	0-5	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	88-93
9045339-1	1997	This phase I/II study sought to determine the response rate and toxicity profile of escalating doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) when administered with fixed doses of cisplatin with granulocyte colony-stimulating factor support in 28 patients with head or neck cancer.	Paclitaxel	104-114	colony stimulating factor 3	Homo sapiens	221-258
9220287-4	1997	Following 96-h drug exposure in a 5-day sulphohodamine B (SRB) in vitro assay, taxol demonstrated potent cytotoxicity in cell lines which were cisplatin sensitive (577 LM, H32, H12.1; mean IC50s 1.5-3.0 nM) or those with acquired or intrinsic cisplatin resistance (H12DDP, H23.1; mean IC50s 2.5 nM).	Paclitaxel	79-84	H1.2 linker histone, cluster member	Homo sapiens	177-180
9220287-5	1997	Compared to the drug-sensitive cell line, H12.1, the IC50 values of taxol were increased in cell line 1777NRp Cl-A with intermediate level resistance to cisplatin and ifosfamide (4.7 nM; p &gt; 0.05) and significantly elevated in cell line 1411HP, with a high level of cisplatin resistance (6.9 nM; p &lt; 0.01).	Paclitaxel	68-73	H1.2 linker histone, cluster member	Homo sapiens	42-45
8824189-4	1996	Finally, T47D, a human breast tumor cell line that is sensitive to taxol and nocodazole, had reduced MAD2 expression and failed to arrest in mitosis after nocodazole treatment.	Paclitaxel	67-72	mitotic arrest deficient 2 like 1	Homo sapiens	101-105
8808711-5	1996	The increased Taxol resistance was independent from oncogenic transformation since it was observed only in c-erbB-2/neu-transformed cells and not ras-transformed cells when oncogene-transformed NIH3T3 cells were examined.	Paclitaxel	14-19	erb-b2 receptor tyrosine kinase 2	Mus musculus	107-115
8808711-5	1996	The increased Taxol resistance was independent from oncogenic transformation since it was observed only in c-erbB-2/neu-transformed cells and not ras-transformed cells when oncogene-transformed NIH3T3 cells were examined.	Paclitaxel	14-19	erb-b2 receptor tyrosine kinase 2	Mus musculus	116-119
9816298-19	1996	Paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated at this dose schedule with G-CSF support.	Paclitaxel	0-10	colony stimulating factor 3	Homo sapiens	122-127
8610099-8	1996	CAS is removed from microtubules by mild detergent treatment (cytoskeleton preparations) and in vincristine- or taxol-treated cells.	Paclitaxel	112-117	chromosome segregation 1 like	Homo sapiens	0-3
9186547-0	1996	Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice.	Paclitaxel	27-32	chromobox 8	Homo sapiens	36-40
9186547-1	1996	The combined influence of alendronate, a bisphosphonate compound, and taxol on the establishment and growth of human PC-3 ML subclones injected intravenously via the tail vein in SCID mice was investigated.	Paclitaxel	70-75	chromobox 8	Homo sapiens	117-121
8601573-1	1996	Paclitaxel (Taxol) is a potent chemotherapeutic drug for squamous-cell carcinoma (SCC) of the head and neck in vitro with microtubule-stabilizing activity that arrests cells in G2-M. To study the mechanism of its cytotoxic effect on SCC in vitro, we exposed five laryngeal SCC cell lines to 10 nM paclitaxel.	Paclitaxel	0-10	serpin family B member 3	Homo sapiens	82-85
8601573-1	1996	Paclitaxel (Taxol) is a potent chemotherapeutic drug for squamous-cell carcinoma (SCC) of the head and neck in vitro with microtubule-stabilizing activity that arrests cells in G2-M. To study the mechanism of its cytotoxic effect on SCC in vitro, we exposed five laryngeal SCC cell lines to 10 nM paclitaxel.	Paclitaxel	0-10	serpin family B member 3	Homo sapiens	233-236
8601573-1	1996	Paclitaxel (Taxol) is a potent chemotherapeutic drug for squamous-cell carcinoma (SCC) of the head and neck in vitro with microtubule-stabilizing activity that arrests cells in G2-M. To study the mechanism of its cytotoxic effect on SCC in vitro, we exposed five laryngeal SCC cell lines to 10 nM paclitaxel.	Paclitaxel	0-10	serpin family B member 3	Homo sapiens	233-236
8601573-1	1996	Paclitaxel (Taxol) is a potent chemotherapeutic drug for squamous-cell carcinoma (SCC) of the head and neck in vitro with microtubule-stabilizing activity that arrests cells in G2-M. To study the mechanism of its cytotoxic effect on SCC in vitro, we exposed five laryngeal SCC cell lines to 10 nM paclitaxel.	Paclitaxel	12-17	serpin family B member 3	Homo sapiens	82-85
8601573-1	1996	Paclitaxel (Taxol) is a potent chemotherapeutic drug for squamous-cell carcinoma (SCC) of the head and neck in vitro with microtubule-stabilizing activity that arrests cells in G2-M. To study the mechanism of its cytotoxic effect on SCC in vitro, we exposed five laryngeal SCC cell lines to 10 nM paclitaxel.	Paclitaxel	12-17	serpin family B member 3	Homo sapiens	233-236
8601573-1	1996	Paclitaxel (Taxol) is a potent chemotherapeutic drug for squamous-cell carcinoma (SCC) of the head and neck in vitro with microtubule-stabilizing activity that arrests cells in G2-M. To study the mechanism of its cytotoxic effect on SCC in vitro, we exposed five laryngeal SCC cell lines to 10 nM paclitaxel.	Paclitaxel	12-17	serpin family B member 3	Homo sapiens	233-236
8558203-1	1996	PURPOSE: Cyclosporin A has been shown to reverse paclitaxel resistance in vitro by inhibiting P-gp function.	Paclitaxel	49-59	phosphoglycolate phosphatase	Homo sapiens	94-98
7543699-0	1995	High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.	Paclitaxel	10-20	colony stimulating factor 3	Homo sapiens	26-63
8529117-0	1995	Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway.	Paclitaxel	0-5	transformation related protein 53, pseudogene	Mus musculus	54-57
7783160-0	1995	Synthesis and biological evaluation of novel C-4 aziridine-bearing paclitaxel (taxol) analogs.	Paclitaxel	67-77	complement C4A (Rodgers blood group)	Homo sapiens	45-48
7783160-0	1995	Synthesis and biological evaluation of novel C-4 aziridine-bearing paclitaxel (taxol) analogs.	Paclitaxel	79-84	complement C4A (Rodgers blood group)	Homo sapiens	45-48
7783160-1	1995	Three novel C-4 aziridine-bearing paclitaxel analogs, 3-5, have been synthesized during the course of our continuing effort at C-4 modification.	Paclitaxel	34-44	complement C4A (Rodgers blood group)	Homo sapiens	12-15
7783160-1	1995	Three novel C-4 aziridine-bearing paclitaxel analogs, 3-5, have been synthesized during the course of our continuing effort at C-4 modification.	Paclitaxel	34-44	complement C4A (Rodgers blood group)	Homo sapiens	127-130
7737146-2	1995	We show here that the chemosensitizers, reserpine and verapamil, display a dramatic potentiation of taxol, anthracycline and Vinca alkaloids cytotoxicity in P-glycoprotein-(P-gp)-deficient hamster and human nasopharyngeal carcinoma cells.	Paclitaxel	100-105	phosphoglycolate phosphatase	Homo sapiens	173-177
8695545-5	1995	Taxol produces response rates of about 25% in previously untreated patients and is currently undergoing trials at higher doses in combination with cisplatin and granulocyte colony-stimulating factor.	Paclitaxel	0-5	colony stimulating factor 3	Homo sapiens	161-198
8765198-1	1995	The correlative effects of taxol on the reduction of circulating PC-3 ML human prostatic tumor cells and bone metastasis have been examined in SCID mice.	Paclitaxel	27-32	chromobox 8	Homo sapiens	65-69
7907208-9	1994	Peripheral neuropathy is likely to become the major dose-limiting toxicity of taxol-cisplatin combination chemotherapy when higher doses of these agents are administered with granulocyte-colony stimulating factor.	Paclitaxel	78-83	colony stimulating factor 3	Homo sapiens	175-212
7509652-11	1994	With flexible G-CSF dosing, taxol dose intensity could be maintained at the target level in 34 of 42 patients (81% of the cohort).	Paclitaxel	28-33	colony stimulating factor 3	Homo sapiens	14-19
7509652-14	1994	These data suggest that flexible G-CSF dosing may have merit and may allow the administration of more dose-intense taxol.	Paclitaxel	115-120	colony stimulating factor 3	Homo sapiens	33-38
7505830-6	1994	If a patient showed fever and neutropenia, G-CSF dosage was increased to 20 micrograms/kg per day so that paclitaxel dose intensity could be maintained.	Paclitaxel	106-116	colony stimulating factor 3	Homo sapiens	43-48
7692001-11	1993	CONCLUSION: Taxol and cisplatin doses of 250 mg/m2 and 75 mg/m2, respectively, can be administered repetitively with G-CSF to untreated and minimally pretreated patients.	Paclitaxel	12-17	colony stimulating factor 3	Homo sapiens	117-122
7517152-7	1993	Taxol dose escalation with granulocyte-colony stimulating factor support, and Taxol in combination with cisplatin, have been tested and shown to be feasible.	Paclitaxel	0-5	colony stimulating factor 3	Homo sapiens	27-64
1376773-4	1992	G-CSF was given as a daily subcutaneous injection that started 24 hours after the completion of the taxol infusion.	Paclitaxel	100-105	colony stimulating factor 3	Homo sapiens	0-5
1376773-11	1992	CONCLUSION: Taxol can be safely administered in doses up to 250 mg/m2 with G-CSF support, which may make it possible to study taxol dose intensification.	Paclitaxel	12-17	colony stimulating factor 3	Homo sapiens	75-80
1376773-11	1992	CONCLUSION: Taxol can be safely administered in doses up to 250 mg/m2 with G-CSF support, which may make it possible to study taxol dose intensification.	Paclitaxel	126-131	colony stimulating factor 3	Homo sapiens	75-80
1351422-3	1992	Taxol inhibited the induction of DNA synthesis after stimulation with FBS or EGF in TIG-1, but did not in 3Y1.	Paclitaxel	0-5	epidermal growth factor	Homo sapiens	77-80
1350792-5	1992	But Taxol seemed to be a weak inducer of the two interleukins IL-1 and IL-2, since their detection occurred late in the cell culture supernatants.	Paclitaxel	4-9	interleukin 2	Mus musculus	71-75
1687728-1	1991	In a patient with a debulked mullerian adenocarcinoma involving the ovary, an elevated serum concentration of macrophage-colony stimulating factor (M-CSF) (5.3 ng/ml) was lowered into the range of the age- and gender-matched controls by a 24-hour infusion of 135 mg/m2 of taxol, as was a Ca125 of 1480 U/ml by three such taxol courses given at 3-week intervals (to 14 U/ml).	Paclitaxel	272-277	colony stimulating factor 1	Homo sapiens	110-146
1687728-1	1991	In a patient with a debulked mullerian adenocarcinoma involving the ovary, an elevated serum concentration of macrophage-colony stimulating factor (M-CSF) (5.3 ng/ml) was lowered into the range of the age- and gender-matched controls by a 24-hour infusion of 135 mg/m2 of taxol, as was a Ca125 of 1480 U/ml by three such taxol courses given at 3-week intervals (to 14 U/ml).	Paclitaxel	272-277	colony stimulating factor 1	Homo sapiens	148-153
1687728-1	1991	In a patient with a debulked mullerian adenocarcinoma involving the ovary, an elevated serum concentration of macrophage-colony stimulating factor (M-CSF) (5.3 ng/ml) was lowered into the range of the age- and gender-matched controls by a 24-hour infusion of 135 mg/m2 of taxol, as was a Ca125 of 1480 U/ml by three such taxol courses given at 3-week intervals (to 14 U/ml).	Paclitaxel	321-326	colony stimulating factor 1	Homo sapiens	110-146
1687728-1	1991	In a patient with a debulked mullerian adenocarcinoma involving the ovary, an elevated serum concentration of macrophage-colony stimulating factor (M-CSF) (5.3 ng/ml) was lowered into the range of the age- and gender-matched controls by a 24-hour infusion of 135 mg/m2 of taxol, as was a Ca125 of 1480 U/ml by three such taxol courses given at 3-week intervals (to 14 U/ml).	Paclitaxel	321-326	colony stimulating factor 1	Homo sapiens	148-153
1686473-0	1991	Developmental changes in phosphorylation of MAP-2 and synapsin I in cytosol and taxol polymerised microtubules from chicken brain.	Paclitaxel	80-85	microtubule associated protein 2	Gallus gallus	44-49
33798735-9	2021	Tau binds to the same site on the inner side of the microtubules that is also occupied by paclitaxel or docetaxel, and several studies have demonstrated that low/no tau expression significantly correlated with better response to the taxane treatment, suggesting that levels of tau expression could have a predictive value in pre-selecting patient cohorts that are likely to benefit from the treatment.	Paclitaxel	90-100	microtubule associated protein tau	Homo sapiens	0-3
33771522-4	2021	The study aimed to investigate the aberrant expression of miR-221-3p in NSCLC and to elucidate its molecular mechanisms in relation to PTX resistance.	Paclitaxel	135-138	microRNA 221	Homo sapiens	58-65
33804018-4	2021	GF120918, LY335979, and XR9576 significantly decreased the basal-to-apical transport of paclitaxel, a P-gp substrate, across Caco-2 cell monolayers.	Paclitaxel	88-98	phosphoglycolate phosphatase	Homo sapiens	102-106
32164732-9	2020	RESULTS: Our results showed that ERK5-IN-1 significantly increased the sensitivity of vincristine, paclitaxel and doxorubicin in KBv200, MCF7/adr and HEK293/ABCB1 cells, respectively.	Paclitaxel	99-109	mitogen-activated protein kinase 7	Homo sapiens	33-37
32164732-11	2020	Moreover, in vivo combination studies showed that ERK5-IN-1 effectively enhanced the antitumor activity of paclitaxel in KBv200 xenografts without causing addition toxicity.	Paclitaxel	107-117	mitogen-activated protein kinase 7	Homo sapiens	50-54
25747310-6	2015	In general, PF127-CS/PF127-cysteine/NaC micelles were proven to be a potential oral drug delivery system for paclitaxel.	Paclitaxel	109-119	synuclein alpha	Homo sapiens	36-39
34953979-5	2022	The innovative liposomal nanosystem was rationally designed by a remote loading of BMS-202 (a small molecule PD-1/PD-L1 inhibitor) and PSN into the liposomes for a ROS-sensitive paclitaxel release and sustained BMS-202 release.	Paclitaxel	178-188	CD274 molecule	Homo sapiens	114-119
34953979-8	2022	The antitumor immunity was activated by paclitaxel-mediated immunogenic cell death, while BMS-202 continuously blocked PD-L1 which could be up-regulated by paclitaxel in tumors to increase the response to ICB and further recover the host immune surveillance.	Paclitaxel	156-166	CD274 molecule	Homo sapiens	119-124
34953982-5	2022	Meanwhile, CQ-HF/PTX nanogels play two roles in anti-metastasis: i) For reducing the "attractive force", it could block the CXCR4/SDF-1 pathway, preventing tumor cells metastasis to the lung; ii) For reinforcing "adhesion force", it could inhibit the excessive autophagy for hindering the degradation of paxillin and enhancing the cell adhesion.	Paclitaxel	17-20	paxillin	Homo sapiens	304-312
34915631-15	2021	The expression levels of ENO1, p-PI3K, p-Akt, PCNA, MMP-9 and Bcl-2 in paclitaxel+ siRNA-ENO1 group were lower than those in siRNA-ENO1 group or paclitaxel+ siRNA-NC group (P<0.05).	Paclitaxel	71-81	enolase 1	Homo sapiens	25-29
34915631-15	2021	The expression levels of ENO1, p-PI3K, p-Akt, PCNA, MMP-9 and Bcl-2 in paclitaxel+ siRNA-ENO1 group were lower than those in siRNA-ENO1 group or paclitaxel+ siRNA-NC group (P<0.05).	Paclitaxel	71-81	proliferating cell nuclear antigen	Homo sapiens	46-50
34915631-15	2021	The expression levels of ENO1, p-PI3K, p-Akt, PCNA, MMP-9 and Bcl-2 in paclitaxel+ siRNA-ENO1 group were lower than those in siRNA-ENO1 group or paclitaxel+ siRNA-NC group (P<0.05).	Paclitaxel	145-155	enolase 1	Homo sapiens	25-29
34915631-16	2021	Conclusion: siRNA targeting inhibition of ENO1 expression can enhance the inhibitory effect of paclitaxel on proliferation, invasion and apoptosis of SK-HEP-1 cells, and its mechanism may be related to the inhibition of PI3K/AKT signaling pathway.	Paclitaxel	95-105	enolase 1	Homo sapiens	42-46
34419608-4	2021	In our previous study, 11alpha-O-2-methybutyryl-12beta-O-tigloyl-tenacigenin B (MT2), a main steroid aglycone isolated from the total aglycones of M. tenacissima, significantly enhanced the in vivo antitumor effect of paclitaxel in mice bearing human tumor xenografts, showing its potential as a chemosensitizer.	Paclitaxel	218-228	melatonin receptor 1B	Homo sapiens	80-83
34610216-7	2021	RESULTS: The expression levels of C-MYC and NANOG were significantly higher in paclitaxel-resistant PC-3 cells compared to the parental PC-3 cells.	Paclitaxel	79-89	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	34-39
34281459-4	2021	Previous studies have found that long non-coding RNA (lncRNA) DDX11-AS1 expression enhances the paclitaxel resistance of ESCA cells.	Paclitaxel	96-106	DDX11 antisense RNA 1	Homo sapiens	62-71
34415232-0	2021	MicroRNA-624-mediated ARRDC3/YAP/HIF1alpha axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel.	Paclitaxel	125-135	microRNA 624	Homo sapiens	0-12
34415232-3	2021	Here, we aimed to investigate the role of miR-624 in ESCC and its molecular mechanism in mediating the resistance of ESCC cells to two common chemotherapeutic drugs, cisplatin (CIS) and paclitaxel (PT).	Paclitaxel	186-196	microRNA 624	Homo sapiens	42-49
34415232-3	2021	Here, we aimed to investigate the role of miR-624 in ESCC and its molecular mechanism in mediating the resistance of ESCC cells to two common chemotherapeutic drugs, cisplatin (CIS) and paclitaxel (PT).	Paclitaxel	198-200	microRNA 624	Homo sapiens	42-49
34415232-10	2021	miR-624 downregulated ARRDC3 to increase YAP and HIF1alpha expression so as to enhance ESCC cell resistance to CIS and PT in vitro and in vivo.	Paclitaxel	119-121	microRNA 624	Homo sapiens	0-7
34799660-0	2021	Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer.	Paclitaxel	73-83	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	0-28
34799660-6	2021	Furthermore, inactivation of PKR confers resistance to paclitaxel in ovarian and breast cancer cells in vitro and in vivo.	Paclitaxel	55-65	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	29-32
34799660-8	2021	Mechanistically, our findings suggest that PKR controls paclitaxel chemosensitivity through repressing Bcl2 expression.	Paclitaxel	56-66	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	43-46
34799660-10	2021	Our results suggest that PKR is a critical determinant of paclitaxel cytotoxicity and that PKR-Bcl2 axis as a potential therapeutic target for the treatment of recurrent drug-resistant ovarian tumors.	Paclitaxel	58-68	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	25-28
34885153-2	2021	The deubiquitinase UBC13, which regulates CHFR levels, has been associated with better overall survival in paclitaxel-treated ovarian cancer.	Paclitaxel	107-117	ubiquitin conjugating enzyme E2 N	Homo sapiens	19-24
34885153-2	2021	The deubiquitinase UBC13, which regulates CHFR levels, has been associated with better overall survival in paclitaxel-treated ovarian cancer.	Paclitaxel	107-117	checkpoint with forkhead and ring finger domains	Homo sapiens	42-46
34730359-6	2021	Tau peptides strengthen the longitudinal protein-protein contacts within the MT lattice and exert a cooperative MT-stabilizing effect in MT complexes simultaneously bonded to taxol or peloruside A.	Paclitaxel	175-180	microtubule associated protein tau	Homo sapiens	0-3
34600241-1	2021	Acquired paclitaxel (PTX) chemoresistance in triple-negative breast cancer (TNBC) can be inferred from the overexpression of toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MyD88) proteins and the activation of the TLR4/MyD88 cascading signalling pathway.	Paclitaxel	9-19	toll like receptor 4	Homo sapiens	125-145
34600241-1	2021	Acquired paclitaxel (PTX) chemoresistance in triple-negative breast cancer (TNBC) can be inferred from the overexpression of toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MyD88) proteins and the activation of the TLR4/MyD88 cascading signalling pathway.	Paclitaxel	9-19	toll like receptor 4	Homo sapiens	147-151
34600241-1	2021	Acquired paclitaxel (PTX) chemoresistance in triple-negative breast cancer (TNBC) can be inferred from the overexpression of toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MyD88) proteins and the activation of the TLR4/MyD88 cascading signalling pathway.	Paclitaxel	9-19	toll like receptor 4	Homo sapiens	244-248
34600241-1	2021	Acquired paclitaxel (PTX) chemoresistance in triple-negative breast cancer (TNBC) can be inferred from the overexpression of toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MyD88) proteins and the activation of the TLR4/MyD88 cascading signalling pathway.	Paclitaxel	21-24	toll like receptor 4	Homo sapiens	125-145
34600241-1	2021	Acquired paclitaxel (PTX) chemoresistance in triple-negative breast cancer (TNBC) can be inferred from the overexpression of toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MyD88) proteins and the activation of the TLR4/MyD88 cascading signalling pathway.	Paclitaxel	21-24	toll like receptor 4	Homo sapiens	147-151
34778188-9	2021	Results: In the base-case analysis, the ICER of atezolizumab plus nab-paclitaxel vs. nab-paclitaxel is respectively, $176,056/QALY, $118,146/QALY, and $323,077/QALY in the ITT, PD-L1(+) and PD-L1(-) group.	Paclitaxel	70-80	CD274 molecule	Homo sapiens	177-182
34778188-9	2021	Results: In the base-case analysis, the ICER of atezolizumab plus nab-paclitaxel vs. nab-paclitaxel is respectively, $176,056/QALY, $118,146/QALY, and $323,077/QALY in the ITT, PD-L1(+) and PD-L1(-) group.	Paclitaxel	89-99	CD274 molecule	Homo sapiens	177-182
34768915-4	2021	Combination treatment with UA and PTX inhibited cell proliferation and cell growth more effectively than either treatment alone by inducing more significant apoptosis, as indicated by increased sub-G1 phase distribution and protein levels of cleaved-PARP and cleaved caspase-9.	Paclitaxel	34-37	caspase 9	Homo sapiens	267-276
34687372-5	2021	In the present study, the effects of common chemotherapy drugs including doxorubicin, paclitaxel, and docetaxel on the expression of the PD-L1 gene were investigated by qRT-PCR before and after the treatment with these drugs in MD231, MD468, SKBR3 breast cancer cell lines.	Paclitaxel	86-96	CD274 molecule	Homo sapiens	137-142
34803458-2	2021	Here, it is aimed to investigate the differences in the expression levels of let-7a, miR-10b, miR-21, miR-125b, miR-145, miR-155, miR-200c, miR-221, miR-222 and miR-335, which associated with gene and proteins in MCF-7 (parental) and MCF-7s (Mammosphere/stem cell-enriched population/CD44+/CD24-cells) cells treated with paclitaxel.	Paclitaxel	321-331	microRNA 21	Homo sapiens	94-100
34803458-2	2021	Here, it is aimed to investigate the differences in the expression levels of let-7a, miR-10b, miR-21, miR-125b, miR-145, miR-155, miR-200c, miR-221, miR-222 and miR-335, which associated with gene and proteins in MCF-7 (parental) and MCF-7s (Mammosphere/stem cell-enriched population/CD44+/CD24-cells) cells treated with paclitaxel.	Paclitaxel	321-331	microRNA 145	Homo sapiens	112-119
34803458-2	2021	Here, it is aimed to investigate the differences in the expression levels of let-7a, miR-10b, miR-21, miR-125b, miR-145, miR-155, miR-200c, miR-221, miR-222 and miR-335, which associated with gene and proteins in MCF-7 (parental) and MCF-7s (Mammosphere/stem cell-enriched population/CD44+/CD24-cells) cells treated with paclitaxel.	Paclitaxel	321-331	microRNA 221	Homo sapiens	140-147
34803458-2	2021	Here, it is aimed to investigate the differences in the expression levels of let-7a, miR-10b, miR-21, miR-125b, miR-145, miR-155, miR-200c, miR-221, miR-222 and miR-335, which associated with gene and proteins in MCF-7 (parental) and MCF-7s (Mammosphere/stem cell-enriched population/CD44+/CD24-cells) cells treated with paclitaxel.	Paclitaxel	321-331	microRNA 222	Homo sapiens	149-156
34126457-11	2021	Through western blotting analysis, the beta-tubulin and cyclin B1 expression in the Tn-Lipo-PTX group were significantly higher compared with other groups and the CDK1 was down-regulated compared with PTX group, which indicated that targeting liposome delivery system could not only change periodic proteins expression, but also improve the killing effect of PTX on hepatocarcinoma cell.	Paclitaxel	92-95	cyclin B1	Homo sapiens	56-65
34126457-11	2021	Through western blotting analysis, the beta-tubulin and cyclin B1 expression in the Tn-Lipo-PTX group were significantly higher compared with other groups and the CDK1 was down-regulated compared with PTX group, which indicated that targeting liposome delivery system could not only change periodic proteins expression, but also improve the killing effect of PTX on hepatocarcinoma cell.	Paclitaxel	201-204	cyclin B1	Homo sapiens	56-65
34126457-11	2021	Through western blotting analysis, the beta-tubulin and cyclin B1 expression in the Tn-Lipo-PTX group were significantly higher compared with other groups and the CDK1 was down-regulated compared with PTX group, which indicated that targeting liposome delivery system could not only change periodic proteins expression, but also improve the killing effect of PTX on hepatocarcinoma cell.	Paclitaxel	359-362	cyclin B1	Homo sapiens	56-65
34722508-8	2021	Finally, sensitivity analysis found that patients with high MAVS expression were predicted to be significantly less responsive to cisplatin and paclitaxel.	Paclitaxel	144-154	mitochondrial antiviral signaling protein	Homo sapiens	60-64
34649611-0	2021	Circ_0061140 knockdown inhibits tumorigenesis and improves PTX sensitivity by regulating miR-136/CBX2 axis in ovarian cancer.	Paclitaxel	59-62	microRNA 136	Homo sapiens	89-96
34649611-12	2021	RESULTS: Circ_0061140 and CBX2 expressions were upregulated, while miR-136 expression was downregulated in PTX-resistant tissues and cells compared with control groups.	Paclitaxel	107-110	microRNA 136	Homo sapiens	67-74
34649611-16	2021	CONCLUSIONS: Circ_0061140 silencing repressed the progression and PTX resistance of ovarian cancer by downregulating CBX2 expression via sponging miR-136, which provided novel insight into studying the therapy of ovarian cancer with PTX.	Paclitaxel	66-69	microRNA 136	Homo sapiens	146-153
34649611-16	2021	CONCLUSIONS: Circ_0061140 silencing repressed the progression and PTX resistance of ovarian cancer by downregulating CBX2 expression via sponging miR-136, which provided novel insight into studying the therapy of ovarian cancer with PTX.	Paclitaxel	233-236	microRNA 136	Homo sapiens	146-153
34692516-7	2021	Collectively, our data indicate that ATL-1 can sensitize TNBC cells to paclitaxel by blocking CTGF expression and fibroblast activation and could be helpful in future research to determine the value of ATL-1 in the clinical setting.	Paclitaxel	71-81	atlastin GTPase 1	Mus musculus	37-42
34729317-4	2021	HD10 NPs significantly enhanced the cytotoxicity of low-dose paclitaxel because of active and mitochondrial targeting by HA and TPGS, respectively.	Paclitaxel	61-71	histone deacetylase 10	Mus musculus	0-4
34348966-8	2021	Targeting PCK1 synergized with paclitaxel to reduce the growth of triple-negative breast cancer (TNBC).	Paclitaxel	31-41	phosphoenolpyruvate carboxykinase 1	Homo sapiens	10-14
34435645-0	2021	Proteasome inhibitors decrease paclitaxel-induced cell death in nasopharyngeal carcinoma with the accumulation of CDK1/cyclin B1.	Paclitaxel	31-41	cyclin dependent kinase 1	Homo sapiens	114-118
34435645-0	2021	Proteasome inhibitors decrease paclitaxel-induced cell death in nasopharyngeal carcinoma with the accumulation of CDK1/cyclin B1.	Paclitaxel	31-41	cyclin B1	Homo sapiens	119-128
34435645-7	2021	In addition, proteasome inhibitors combined with paclitaxel led to decreased MCL1 apoptosis regulator, BCL2 family member/Caspase-9/poly (ADP-ribose) polymerase apoptosis signaling triggered by CDK1/cyclin B1.	Paclitaxel	49-59	caspase 9	Homo sapiens	122-131
34435645-7	2021	In addition, proteasome inhibitors combined with paclitaxel led to decreased MCL1 apoptosis regulator, BCL2 family member/Caspase-9/poly (ADP-ribose) polymerase apoptosis signaling triggered by CDK1/cyclin B1.	Paclitaxel	49-59	cyclin dependent kinase 1	Homo sapiens	194-198
34435645-7	2021	In addition, proteasome inhibitors combined with paclitaxel led to decreased MCL1 apoptosis regulator, BCL2 family member/Caspase-9/poly (ADP-ribose) polymerase apoptosis signaling triggered by CDK1/cyclin B1.	Paclitaxel	49-59	cyclin B1	Homo sapiens	199-208
34435645-8	2021	Therefore, dysfunction of CDK1/cyclin B1 could be defining the loss of paclitaxel lethality against cancer cells, a phenomenon affirmed by the CDK1 inhibitor Ro3306.	Paclitaxel	71-81	cyclin dependent kinase 1	Homo sapiens	26-30
34435645-8	2021	Therefore, dysfunction of CDK1/cyclin B1 could be defining the loss of paclitaxel lethality against cancer cells, a phenomenon affirmed by the CDK1 inhibitor Ro3306.	Paclitaxel	71-81	cyclin B1	Homo sapiens	31-40
34435645-8	2021	Therefore, dysfunction of CDK1/cyclin B1 could be defining the loss of paclitaxel lethality against cancer cells, a phenomenon affirmed by the CDK1 inhibitor Ro3306.	Paclitaxel	71-81	cyclin dependent kinase 1	Homo sapiens	143-147
34435645-9	2021	Overall, the present results demonstrated that a combination of paclitaxel with proteasome inhibitors or CDK1 inhibitors is antagonistic to effective clinical management of NPC.	Paclitaxel	64-74	cyclin dependent kinase 1	Homo sapiens	105-109
34510641-0	2021	FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1.	Paclitaxel	66-76	cyclin B1	Homo sapiens	95-104
34510641-7	2021	RESULTS: Inhibition of FASN with orlistat sensitized SCC-9 LN-1 cells to the cytotoxic effects of paclitaxel and cisplatin, but not 5-fluorouracil, which was accompanied by a significant reduction in cyclin B1.	Paclitaxel	98-108	cyclin B1	Homo sapiens	200-209
34507591-4	2021	The antitumor activity of paclitaxel (PTX) in HA synthase 3-overexpressing and wild-type SKOV3 ovarian cancer model and in the BxPC3 pancreas xenograft tumour model, was evaluated by monitoring tumour growth with or without PEGPH20 pre-treatment.	Paclitaxel	26-36	hyaluronan synthase 3	Homo sapiens	46-59
34507591-7	2021	RESULTS: Pre-treatment with PEGPH20 modified tumour tissue architecture and improved the antitumor activity of paclitaxel in the SKOV3/HAS3 tumour model, favouring its accumulation and more homogeneous intra-tumour distribution, as assessed by quantitative and qualitative analysis.	Paclitaxel	111-121	hyaluronan synthase 3	Homo sapiens	135-139
34479917-7	2021	Furthermore, paclitaxel induced ROS-mediated DNA damage that triggered the activation of the extrinsic pathway of apoptosis via the up-regulation of death receptor (DR5) and caspase-8 activation.	Paclitaxel	13-23	TNF receptor superfamily member 10b	Homo sapiens	165-168
34479918-8	2021	The apoptotic effects of paclitaxel were observed by increased levels of cleaved caspase-3 (Asp 175), cleaved caspase-9 (Asp 330) and cleaved PARP (Asp 214).	Paclitaxel	25-35	caspase 9	Homo sapiens	110-119
34278466-10	2021	After treatment with PTX, apoptosis and ROS levels were decreased in the CD44+CD117+ groups compared with the CD44-CD117- groups.	Paclitaxel	21-24	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	78-83
34278466-10	2021	After treatment with PTX, apoptosis and ROS levels were decreased in the CD44+CD117+ groups compared with the CD44-CD117- groups.	Paclitaxel	21-24	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	115-120
34278466-11	2021	Collectively, the present results demonstrated that, via the Notch1 pathway, CCL20/CCR6 may promote the stemness and PTX resistance of CD44+CD117+ cells in ovarian cancer.	Paclitaxel	117-120	notch 1	Mus musculus	61-67
34278466-11	2021	Collectively, the present results demonstrated that, via the Notch1 pathway, CCL20/CCR6 may promote the stemness and PTX resistance of CD44+CD117+ cells in ovarian cancer.	Paclitaxel	117-120	chemokine (C-C motif) ligand 20	Mus musculus	77-82
34278466-11	2021	Collectively, the present results demonstrated that, via the Notch1 pathway, CCL20/CCR6 may promote the stemness and PTX resistance of CD44+CD117+ cells in ovarian cancer.	Paclitaxel	117-120	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	140-145
34408017-8	2021	This paclitaxel sensitivity depended on the presence of stathmin 2 (STMN2), a microtubule regulator that is specifically expressed in the resistant state.	Paclitaxel	5-15	stathmin 2	Homo sapiens	56-66
34408017-8	2021	This paclitaxel sensitivity depended on the presence of stathmin 2 (STMN2), a microtubule regulator that is specifically expressed in the resistant state.	Paclitaxel	5-15	stathmin 2	Homo sapiens	68-73
34387205-1	2021	OBJECTIVE: To compare the efficacy and safety of induction FOLFOX followed by PET-directed neoadjuvant chemoradiation therapy (nCRT), induction carboplatin plus paclitaxel (CP) followed by PET-directed nCRT, and nCRT with CP alone in patients with esophageal adenocarcinoma (EAC).	Paclitaxel	161-171	ceruloplasmin	Homo sapiens	173-175
34385422-0	2021	Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.	Paclitaxel	40-50	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	17-21
34385422-4	2021	Cells bearing BAK/MCL1 complexes were more sensitive to paclitaxel and the MCL1 antagonist S63845.	Paclitaxel	56-66	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	18-22
34385422-5	2021	Likewise, PDX models with BAK/MCL1 complexes were more likely to respond to paclitaxel.	Paclitaxel	76-86	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	30-34
34385422-6	2021	Mechanistically, BIM induced by low paclitaxel concentrations interacted preferentially with MCL1 and displaced MCL1-bound BAK.	Paclitaxel	36-46	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	93-97
34385422-6	2021	Mechanistically, BIM induced by low paclitaxel concentrations interacted preferentially with MCL1 and displaced MCL1-bound BAK.	Paclitaxel	36-46	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	112-116
34385422-7	2021	Further studies indicated that cells with preformed BAK/MCL1 complexes were sensitive to the paclitaxel/S63845 combination, while cells without BAK/MCL1 complexes were not.	Paclitaxel	93-103	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	56-60
34385422-8	2021	Our study suggested that the assessment of BAK/MCL1 complexes might be useful for predicting response to paclitaxel alone or in combination with BH3 mimetics.	Paclitaxel	105-115	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	47-51
34305410-10	2021	TUSC7 overexpression significantly promoted the sensitivity of MDA-MB-468 cells to paclitaxel and carboplatin.	Paclitaxel	83-93	tumor suppressor candidate 7	Homo sapiens	0-5
34156070-4	2021	We show that yeast oxidative stress response mutants (sod1Delta, tsa1Delta and cta1Delta) and DNA damage response mutants (mre11 , sgs1  and sub1 ) are highly sensitive to Taxol.	Paclitaxel	172-177	MRX complex nuclease subunit	Saccharomyces cerevisiae S288C	123-128
34088893-7	2021	We investigated the in vitro effect of Smac-mimetic added to carboplatin and paclitaxel treatment of ovarian cancer cells expressing wild type and low Caspase 8 levels, which resulted in a 2-4-fold enhancement of cell death.	Paclitaxel	77-87	diablo IAP-binding mitochondrial protein	Homo sapiens	39-43
34088893-8	2021	Mice bearing subcutaneous or intraperitoneal ovarian xenografts showed greater aggressiveness of Caspase 8-deficient versus wild-type tumors; combined in vivo treatment with chemotherapy and Smac-mimetic resulted in >50% decrease in low Caspase 8 xenograft growth, as well as significantly enhanced overall survival, especially when given simultaneously with paclitaxel.	Paclitaxel	359-369	caspase 8	Mus musculus	237-246
34205051-4	2021	Eribulin and paclitaxel caused an intracellular accumulation of CD63, a tetraspanin component of sEVs, in late/multivesicular endosomes of triple-negative breast cancer cells, consistent with the disruption of endosomal sorting and exosome cargo loading in these cells.	Paclitaxel	13-23	CD63 molecule	Homo sapiens	64-68
34205051-5	2021	While the concentrations of sEVs released from MTA-treated cells were not significantly altered, levels of CD63 and the CD63-associated cargos, ILK and beta-integrin, were reduced in sEVs isolated from eribulin-treated HCC1937 cells as compared to vehicle or paclitaxel-treated cells.	Paclitaxel	259-269	CD63 molecule	Homo sapiens	107-111
34277801-0	2021	Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer.	Paclitaxel	43-53	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	67-70
34277801-2	2021	This study aimed to investigate the synergistic effects of apatinib and paclitaxel (PTX) on triple-negative breast cancer (TNBC) in vivo and in vitro, and to explore the molecular mechanism of the PI3K/p65/Bcl-xl pathway.	Paclitaxel	72-82	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	202-205
34277801-2	2021	This study aimed to investigate the synergistic effects of apatinib and paclitaxel (PTX) on triple-negative breast cancer (TNBC) in vivo and in vitro, and to explore the molecular mechanism of the PI3K/p65/Bcl-xl pathway.	Paclitaxel	84-87	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	202-205
34277801-4	2021	Western blot (WB) was conducted to detect protein expression levels of PI3K, p65, and Bcl-xl after the application of apatinib and PTX.	Paclitaxel	131-134	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	77-80
34277801-10	2021	Conclusions: Apatinib could enhance the anti-tumor effect of PTX on TNBC cells through the PI3K/p65/Bcl-xl molecular pathway, and apatinib combined with PTX might be a promising option for TNBC treatment.	Paclitaxel	61-64	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	96-99
34072728-11	2021	Interestingly, NSC777201 demonstrated anti-proliferative and cytotoxic activities (GI50 = 1.6 microM~1.82 microM and TGI50 = 3.5 microM~3.63 microM) against the NCI panels of ovarian cancer cell lines and exhibited a robust interaction with stronger affinities for TTK, NEK2, and CDK1, than do the standard drug, paclitaxel.	Paclitaxel	313-323	cyclin dependent kinase 1	Homo sapiens	280-284
34071530-5	2021	Compared to control, catechin nanoemulsion at 20 mug/mL and paclitaxel at 10 mug/mL were the most effective in reducing tumor volume by 41.3% and 52.5% and tumor weight by 77.5% and 90.6% in mice, respectively, through a decrease in EGF and VEGF levels in serum.	Paclitaxel	60-70	epidermal growth factor	Mus musculus	233-236
35625898-3	2022	This study showed that OGT expression levels in two human UCB cell models with acquired resistance to gemcitabine and paclitaxel were significantly upregulated compared with those in parental cells.	Paclitaxel	118-128	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	23-26
35304127-0	2022	TET1 overexpression attenuates paclitaxel-induced neuropathic pain through rescuing K2p1.1 expression in primary sensory neurons of male rats.	Paclitaxel	31-41	tet methylcytosine dioxygenase 1	Rattus norvegicus	0-4
35586672-0	2022	Timosaponin AIII Suppresses RAP1 Signaling Pathway to Enhance the Inhibitory Effect of Paclitaxel on Nasopharyngeal Carcinoma.	Paclitaxel	87-97	RAB guanine nucleotide exchange factor 1	Homo sapiens	28-32
35504904-0	2022	HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel.	Paclitaxel	144-154	high mobility group AT-hook 1	Homo sapiens	0-5
35504904-10	2022	Finally, we show in an in vivo xenograft model that depletion of HMGA1 chemo-sensitizes tumour cells to paclitaxel, a drug that is commonly used in TNBC treatments.	Paclitaxel	104-114	high mobility group AT-hook 1	Homo sapiens	65-70
35504904-12	2022	Moreover, our data suggest that taxol-based treatments may be more effective in reducing the tumour burden when tumour cells express low levels of HMGA1.	Paclitaxel	32-37	high mobility group AT-hook 1	Homo sapiens	147-152
35477477-9	2022	CONCLUSIONS: Our studies suggested that high expression of RIPK2 is related to Taxol resistance in serous ovarian cancer, and that RIPK2 induces Taxol resistance through NOD1/RIPK2/NF-kappaB inflammatory pathway activation and tumor microenvironment changes.	Paclitaxel	145-150	nucleotide binding oligomerization domain containing 1	Homo sapiens	170-174
35397087-13	2022	The IC50 value of miR-211-3p overexpression (OE) group was significantly higher than negative control (NC) group treated with paclitaxel, suggesting miR-211-3p enhanced IC insensitivity in HSCC.	Paclitaxel	126-136	microRNA 2113	Homo sapiens	18-28
35453613-3	2022	We have previously shown that the expression of PINK1, a key mediator of mitochondrial quality control, ameliorated the paclitaxel-induced thermal hyperalgesia phenotype and restored mitochondrial homeostasis in Drosophila larvae.	Paclitaxel	120-130	PTEN-induced putative kinase 1	Drosophila melanogaster	48-53
35453613-5	2022	Specifically, niclosamide cotreatment significantly ameliorated the paclitaxel-induced thermal hyperalgesia phenotype in Drosophila larvae in a PINK1-dependent manner.	Paclitaxel	68-78	PTEN-induced putative kinase 1	Drosophila melanogaster	144-149
35406775-0	2022	Assessment of Pharmacological Interactions between SIRT2 Inhibitor AGK2 and Paclitaxel in Different Molecular Subtypes of Breast Cancer Cells.	Paclitaxel	76-86	sirtuin 2	Homo sapiens	51-56
35399640-0	2022	Paclitaxel Resistance Modulated by the Interaction between TRPS1 and AF178030.2 in Triple-Negative Breast Cancer.	Paclitaxel	0-10	transcriptional repressor GATA binding 1	Homo sapiens	59-64
35399640-7	2022	Furthermore, bioinformatic analysis and RNA binding protein immunoprecipitation assay reveal that AF178030.2 can directly bind with trichorhinophalangeal syndrome-1 (TRPS1), an oncogene in breast cancer, and downregulate its expression in paclitaxel-resistant TNBC cells.	Paclitaxel	239-249	transcriptional repressor GATA binding 1	Homo sapiens	132-164
35399640-7	2022	Furthermore, bioinformatic analysis and RNA binding protein immunoprecipitation assay reveal that AF178030.2 can directly bind with trichorhinophalangeal syndrome-1 (TRPS1), an oncogene in breast cancer, and downregulate its expression in paclitaxel-resistant TNBC cells.	Paclitaxel	239-249	transcriptional repressor GATA binding 1	Homo sapiens	166-171
35399640-8	2022	TRPS1 overexpression effectively increased the sensitivity of paclitaxel-resistant TNBC cells to paclitaxel.	Paclitaxel	62-72	transcriptional repressor GATA binding 1	Homo sapiens	0-5
35399640-8	2022	TRPS1 overexpression effectively increased the sensitivity of paclitaxel-resistant TNBC cells to paclitaxel.	Paclitaxel	97-107	transcriptional repressor GATA binding 1	Homo sapiens	0-5
35399640-9	2022	Taking together, high AF178030.2 expression contributed to paclitaxel resistance in TNBC through TRPS1 and poor clinical outcomes, which may provide a new treatment strategy for paclitaxel-resistant TNBC patients.	Paclitaxel	59-69	transcriptional repressor GATA binding 1	Homo sapiens	97-102
35368966-7	2022	The CMB-PTX-CRISPR/Cas9 increased the GSK-3, P21, P27, and Bad expression levels, while reduced the C-erbB-2 and mTOR expressions.	Paclitaxel	8-11	dynactin 6	Mus musculus	50-53
35368966-7	2022	The CMB-PTX-CRISPR/Cas9 increased the GSK-3, P21, P27, and Bad expression levels, while reduced the C-erbB-2 and mTOR expressions.	Paclitaxel	8-11	erb-b2 receptor tyrosine kinase 2	Mus musculus	100-108
35368966-7	2022	The CMB-PTX-CRISPR/Cas9 increased the GSK-3, P21, P27, and Bad expression levels, while reduced the C-erbB-2 and mTOR expressions.	Paclitaxel	8-11	mechanistic target of rapamycin kinase	Mus musculus	113-117
35368966-9	2022	CMB-PTX-CRISPR/Cas9 may regulate the tumor cell viability, invasion, and metastasis of endometrial cancer naked mouse model by upregulating expressions of GSK-3, P21, P27, and Bad.	Paclitaxel	4-7	dynactin 6	Mus musculus	167-170
35327403-5	2022	Indeed, when MDR-overexpressing cancer cells were treated with a combination of BGJ 398 and PTX (or Dox), we observed a significant increase of apoptosis which was evidenced by an increased expression of cleaved forms of PARP, caspase-3, and increased numbers of Annexin V-positive cells, as well.	Paclitaxel	92-95	annexin A5	Homo sapiens	263-272
35263200-9	2022	Consistent with studies, Paclitaxel exhibited a significant inhibitory effect on Adriamycin-resistant DLBCL, which may have played a role in the five hub genes (UBC, TSR1, WDR46, HSP90AA1 and NOP56) and ribosome biosynthesis in eukaryotes pathway, but the specific regulation needs further experimental verification.	Paclitaxel	25-35	heat shock protein 90 alpha family class A member 1	Homo sapiens	179-187
35149839-8	2022	Targeting CBLC inhibited tumor growth of LAD cells and enhanced their sensitivity to paclitaxel in xenograft models.	Paclitaxel	85-95	Cbl proto-oncogene C	Homo sapiens	10-14
35194034-0	2022	Degradation of DRAK1 by CUL3/SPOP E3 Ubiquitin ligase promotes tumor growth of paclitaxel-resistant cervical cancer cells.	Paclitaxel	79-89	serine/threonine kinase 17a	Homo sapiens	15-20
35194034-3	2022	Here, we report a unique role of death-associated protein kinase-related apoptosis-inducing kinase 1 (DRAK1) associated with paclitaxel resistance in cervical cancer cells.	Paclitaxel	125-135	serine/threonine kinase 17a	Homo sapiens	33-100
35194034-3	2022	Here, we report a unique role of death-associated protein kinase-related apoptosis-inducing kinase 1 (DRAK1) associated with paclitaxel resistance in cervical cancer cells.	Paclitaxel	125-135	serine/threonine kinase 17a	Homo sapiens	102-107
35194034-4	2022	Interestingly, DRAK1 protein level was markedly decreased in paclitaxel-resistant cervical cancer cells without affecting its mRNA expression, which resulted in an increase in tumor necrosis factor receptor-associated factor 6 (TRAF6) expression, as well as an activation of TRAF6-mediated nuclear factor-kappa B (NF-kappaB) signaling cascade, thereby promoting tumor progression.	Paclitaxel	61-71	serine/threonine kinase 17a	Homo sapiens	15-20
35058503-6	2022	Knockdown of p53, RBL2, or the DREAM component LIN37 increased AURKA/B pathway gene expression and reduced paclitaxel and radiation toxicity in NSCLC cells.	Paclitaxel	107-117	lin-37 DREAM MuvB core complex component	Homo sapiens	47-52
35173861-9	2022	After Apa intervention, PTX-resistant MGC803 cells showed decreased cell migration, invasion and proliferation, reduced MDR1, P-gp and VEGFR2 levels, and increased Bax protein level.	Paclitaxel	24-27	phosphoglycolate phosphatase	Homo sapiens	126-130
35059287-0	2022	A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab.	Paclitaxel	118-128	CD274 molecule	Homo sapiens	10-15
35282117-11	2022	Four genes showed significant association with the estimated half-maximal inhibitory concentration (IC50) of paclitaxel: bone morphogenetic protein 1 (BMP1), dumbbell former 4 protein (DBF4), angiogenin (ANG), and MAP7 domain containing 2 (MAP7D2).	Paclitaxel	109-119	bone morphogenetic protein 1	Homo sapiens	121-149
35282117-11	2022	Four genes showed significant association with the estimated half-maximal inhibitory concentration (IC50) of paclitaxel: bone morphogenetic protein 1 (BMP1), dumbbell former 4 protein (DBF4), angiogenin (ANG), and MAP7 domain containing 2 (MAP7D2).	Paclitaxel	109-119	bone morphogenetic protein 1	Homo sapiens	151-155
35282117-11	2022	Four genes showed significant association with the estimated half-maximal inhibitory concentration (IC50) of paclitaxel: bone morphogenetic protein 1 (BMP1), dumbbell former 4 protein (DBF4), angiogenin (ANG), and MAP7 domain containing 2 (MAP7D2).	Paclitaxel	109-119	MAP7 domain containing 2	Homo sapiens	214-238
35282117-11	2022	Four genes showed significant association with the estimated half-maximal inhibitory concentration (IC50) of paclitaxel: bone morphogenetic protein 1 (BMP1), dumbbell former 4 protein (DBF4), angiogenin (ANG), and MAP7 domain containing 2 (MAP7D2).	Paclitaxel	109-119	MAP7 domain containing 2	Homo sapiens	240-246
35173526-0	2022	SOX8 Affects Tumoral SPARC Expression by Regulating EZH2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC.	Paclitaxel	101-111	secreted protein acidic and cysteine rich	Homo sapiens	21-26
35173526-8	2022	SOX8 transcriptionally regulated EZH2, which reduced expression of SPARC by promoting the methylation of SPARC, thereby reducing the transport of albumin-bound paclitaxel in pancreatic cancer cells.	Paclitaxel	160-170	secreted protein acidic and cysteine rich	Homo sapiens	67-72
35173526-8	2022	SOX8 transcriptionally regulated EZH2, which reduced expression of SPARC by promoting the methylation of SPARC, thereby reducing the transport of albumin-bound paclitaxel in pancreatic cancer cells.	Paclitaxel	160-170	secreted protein acidic and cysteine rich	Homo sapiens	105-110
2901104-6	1988	In the presence of MAP-2 and taxol, the antibodies decreased the MAP-2 content of taxol-promoted microtubules.	Paclitaxel	29-34	microtubule associated protein 2	Homo sapiens	65-70
2901104-6	1988	In the presence of MAP-2 and taxol, the antibodies decreased the MAP-2 content of taxol-promoted microtubules.	Paclitaxel	82-87	microtubule associated protein 2	Homo sapiens	19-24
2901104-6	1988	In the presence of MAP-2 and taxol, the antibodies decreased the MAP-2 content of taxol-promoted microtubules.	Paclitaxel	82-87	microtubule associated protein 2	Homo sapiens	65-70
2897863-3	1988	When alpha-tubulin mRNA is translated in rabbit reticulocyte lysates, the isolated alpha subunit is fully functional as assayed by coassembly with bovine brain tubulin using temperature-dependent or taxol/salt assembly procedures.	Paclitaxel	199-204	tubulin alpha-1B chain	Oryctolagus cuniculus	5-18
2890724-11	1987	In contrast, microtubules formed in the presence of taxol were almost completely devoid of chartin MAPs and MAP-2 compared to controls.	Paclitaxel	52-57	microtubule associated protein 2	Homo sapiens	108-113
3319197-6	1987	Using several agents, such as colchicine, colcemid, nocodazole, and taxol, which affect microtubule assembly, we have observed that the vimentin system, although closely related spatially to the microtubule complex in lymphocytes, can still reorganize independently as these cells progress through the cell cycle.	Paclitaxel	68-73	vimentin	Mus musculus	136-144
2868546-2	1986	After 4 hr of incubation, taxol (50 microM) inhibited albumin secretion by only 10% on gestation Day 19, by 16% 4 days after birth, but by 40% in the adult.	Paclitaxel	26-31	albumin	Rattus norvegicus	54-61
2417124-4	1986	Synapsin I binds saturably to microtubules stabilized by taxol, with an estimated dissociation constant (Kd) of 4.5 microM and a stoichiometry of 1.2 mol of synapsin binding sites per mol tubulin dimer.	Paclitaxel	57-62	synapsin I	Homo sapiens	0-10
3460414-10	1986	MAP-1- and MAP-2-related polypeptides, together with other high Mr proteins, such as plectin, were associated with microtubules polymerized by taxol from extracts of a nonneuronal cultured cell line.	Paclitaxel	143-148	modulator of apoptosis 1	Homo sapiens	0-6
3460414-10	1986	MAP-1- and MAP-2-related polypeptides, together with other high Mr proteins, such as plectin, were associated with microtubules polymerized by taxol from extracts of a nonneuronal cultured cell line.	Paclitaxel	143-148	microtubule associated protein 2	Homo sapiens	11-16
6146522-1	1984	Pre-phosphorylation of the microtubule-associated protein MAP2 with the co-purifying cAMP-independent protein kinase (a) decrease the affinity of MAP2 for taxol-stabilised microtubules, (b) increases the dissociation rate constant for microtubule polymerisation, each of which is dependent upon the level of phosphorylation, but (c) has no effect on the association rate constant.	Paclitaxel	155-160	microtubule associated protein 2	Homo sapiens	58-62
6146522-1	1984	Pre-phosphorylation of the microtubule-associated protein MAP2 with the co-purifying cAMP-independent protein kinase (a) decrease the affinity of MAP2 for taxol-stabilised microtubules, (b) increases the dissociation rate constant for microtubule polymerisation, each of which is dependent upon the level of phosphorylation, but (c) has no effect on the association rate constant.	Paclitaxel	155-160	microtubule associated protein 2	Homo sapiens	146-150
6140163-4	1983	Phosphorylation also reduced the binding of MAP-2 to taxol-stabilized microtubules.	Paclitaxel	53-58	microtubule associated protein 2	Homo sapiens	44-49
6124041-0	1982	Nerve growth factor attenuates neurotoxic effects of taxol on spinal cord-ganglion explants from fetal mice.	Paclitaxel	53-58	nerve growth factor	Mus musculus	0-19
34056794-0	2021	RIP3/MLKL pathway-regulated necroptosis: A new mechanism of paclitaxel-induced peripheral neuropathy.	Paclitaxel	60-70	receptor-interacting serine-threonine kinase 3	Rattus norvegicus	0-4
34056794-8	2021	PTX application also increased RIP3 and MLKL protein levels in DRG, which were primarily in neurons.	Paclitaxel	0-3	receptor-interacting serine-threonine kinase 3	Rattus norvegicus	31-35
34046939-8	2021	CircMYBL2 was upregulated in CC tissues and cells, especially in PTX-resistant CC tissues and cells, and it was a stable circRNA mainly distributed in the cytoplasm.	Paclitaxel	65-68	myeloblastosis oncogene-like 2	Mus musculus	0-9
34046939-9	2021	CircMYBL2 could enhance the PTX resistance of CC cells in vitro and promote CC tumor growth in vivo.	Paclitaxel	28-31	myeloblastosis oncogene-like 2	Mus musculus	0-9
34051575-0	2021	GDI2 is a target of paclitaxel that affects tumorigenesis of prostate cancer via the p75NTR signaling pathway.	Paclitaxel	20-30	guanosine diphosphate (GDP) dissociation inhibitor 2	Mus musculus	0-4
34051575-12	2021	CONCLUSION: Taken together, these results indicate that GDI2 is a therapeutic target of paclitaxel.	Paclitaxel	88-98	guanosine diphosphate (GDP) dissociation inhibitor 2	Mus musculus	56-60
34051575-14	2021	Notably, paclitaxel inhibits GDI2 expression, implying that GDI2 may be a promising therapeutic target in prostate cancer.	Paclitaxel	9-19	guanosine diphosphate (GDP) dissociation inhibitor 2	Mus musculus	29-33
34051575-14	2021	Notably, paclitaxel inhibits GDI2 expression, implying that GDI2 may be a promising therapeutic target in prostate cancer.	Paclitaxel	9-19	guanosine diphosphate (GDP) dissociation inhibitor 2	Mus musculus	60-64
34023418-6	2021	Silencing GABRP induced down-regulation of EGFR signaling, which hindered cell stemness and enhanced sensitivity to chemotherapies, including paclitaxel, doxorubicin, and cisplatin.	Paclitaxel	142-152	gamma-aminobutyric acid type A receptor subunit pi	Homo sapiens	10-15
34004196-5	2021	Functionalized with the outer CS shell, TLA/PTX@CS entered MDR breast cancer (MCF-7/MDR) cells via CD44 receptor-mediated endocytosis.	Paclitaxel	44-47	CD44 molecule (Indian blood group)	Homo sapiens	99-103
34000456-5	2021	In paclitaxel (PTX) resistant MCF7 cells, 19 differentially expressed N-glycan-related proteins were identified, of which MGAT4A was the most significantly down-regulated, consistent with decrease in MGAT4A expression at mRNA level in PTX treated BC cells.	Paclitaxel	3-13	alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A	Homo sapiens	122-128
34000456-5	2021	In paclitaxel (PTX) resistant MCF7 cells, 19 differentially expressed N-glycan-related proteins were identified, of which MGAT4A was the most significantly down-regulated, consistent with decrease in MGAT4A expression at mRNA level in PTX treated BC cells.	Paclitaxel	3-13	alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A	Homo sapiens	200-206
34000456-5	2021	In paclitaxel (PTX) resistant MCF7 cells, 19 differentially expressed N-glycan-related proteins were identified, of which MGAT4A was the most significantly down-regulated, consistent with decrease in MGAT4A expression at mRNA level in PTX treated BC cells.	Paclitaxel	15-18	alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A	Homo sapiens	122-128
34000456-5	2021	In paclitaxel (PTX) resistant MCF7 cells, 19 differentially expressed N-glycan-related proteins were identified, of which MGAT4A was the most significantly down-regulated, consistent with decrease in MGAT4A expression at mRNA level in PTX treated BC cells.	Paclitaxel	15-18	alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A	Homo sapiens	200-206
34000456-5	2021	In paclitaxel (PTX) resistant MCF7 cells, 19 differentially expressed N-glycan-related proteins were identified, of which MGAT4A was the most significantly down-regulated, consistent with decrease in MGAT4A expression at mRNA level in PTX treated BC cells.	Paclitaxel	235-238	alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A	Homo sapiens	122-128
34000456-5	2021	In paclitaxel (PTX) resistant MCF7 cells, 19 differentially expressed N-glycan-related proteins were identified, of which MGAT4A was the most significantly down-regulated, consistent with decrease in MGAT4A expression at mRNA level in PTX treated BC cells.	Paclitaxel	235-238	alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A	Homo sapiens	200-206
33985619-5	2022	Paclitaxel-triggered necroptosis in lung adenocarcinoma cells was dependent on the phosphorylation or deficiency of Caspase-8, during which FADD interacted with RIPK1 to activateRIPK1/RIPK3/MLKL signaling axis.	Paclitaxel	0-10	receptor interacting serine/threonine kinase 3	Homo sapiens	184-189
33749060-11	2021	Moreover, PTX prevented TAA-induced elevation of transforming growth factor-beta1 (TGF-beta1), platelet-derived growth factor-BB (PDGF-BB), and tissue inhibitor of metalloproteinase 1 (TIMP-1) levels in liver tissues.	Paclitaxel	10-13	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	144-183
33749060-12	2021	These findings suggest that the low dose of PTX prevented TAA-induced liver fibrosis in rats, possibly by inhibiting the expression of TGF-beta1 and PDGF-BB and subsequently suppressing the apoptosis and the expression of TIMP-1.	Paclitaxel	44-47	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	222-228
33932086-6	2021	Knockdown of BCL6 resulted in increased tumor regression in mice treated with paclitaxel.	Paclitaxel	78-88	B cell leukemia/lymphoma 6	Mus musculus	13-17
33932086-7	2021	Similarly, inhibiting BCL6 using a small molecule inhibitor enhanced paclitaxel treatment efficacy both in vitro and in vivo in breast cancer models.	Paclitaxel	69-79	B cell leukemia/lymphoma 6	Mus musculus	22-26
33932086-8	2021	Mechanism studies revealed that reduced BCL6 enhances the efficacy of paclitaxel by inducing sustained G1/S arrest, concurrent with increased apoptosis and expression of target gene cyclin dependent kinase inhibitor 1A (CDKN1A).	Paclitaxel	70-80	B cell leukemia/lymphoma 6	Mus musculus	40-44
33932086-9	2021	In summary, the genome-wide shRNA knockdown screen has identified BCL6 as a potential targetable resistance biomarker of paclitaxel response in breast cancer.	Paclitaxel	121-131	B cell leukemia/lymphoma 6	Mus musculus	66-70
33550530-0	2021	DNMT3b SUMOylation Mediated MMP-2 Upregulation Contribute to Paclitaxel Induced Neuropathic Pain.	Paclitaxel	61-71	DNA methyltransferase 3 beta	Rattus norvegicus	0-6
33550530-8	2021	Further investigation suggested that DNMT3b binding activity to the promoter region of the MMP-2 gene is significantly decreased in paclitaxel treated rats, and the administration of GA can reverse these effects, which is also accompanied by changes in the promoter methylation status of the MMP-2 gene.	Paclitaxel	132-142	DNA methyltransferase 3 beta	Rattus norvegicus	37-43
33550530-9	2021	Our study demonstrates that MMP-2 up-regulation mediated by DNMT3b SUMOylation is essential for paclitaxel induced NP development, which brings us new therapeutic options for CIPN.	Paclitaxel	96-106	DNA methyltransferase 3 beta	Rattus norvegicus	60-66
33996534-0	2021	The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report.	Paclitaxel	66-76	BRCA2 DNA repair associated	Homo sapiens	149-154
33893626-10	2021	Furthermore, E-cadherin protein concentration increased while N-cadherin and Vimentin decreased due to increasing PTX treatments.	Paclitaxel	114-117	cadherin 2	Homo sapiens	62-72
33764366-0	2021	CCL26 is upregulated by nab-paclitaxel in pancreatic cancer-associated fibroblasts and promotes PDAC invasiveness through activation of the PI3K/AKT/mTOR pathway.	Paclitaxel	28-38	C-C motif chemokine ligand 26	Homo sapiens	0-5
33764366-5	2021	In the present study, we aimed to determine the expression of CCL26 in the pancreatic cancer-associated fibroblasts (CAFs) after nab-paclitaxel treatment and to explore the role of CCL26 in the pancreatic adenocarcinoma (PDAC) invasion.	Paclitaxel	133-143	C-C motif chemokine ligand 26	Homo sapiens	62-67
33764366-6	2021	Our results showed that nab-paclitaxel increased CCL26 mRNA and protein expression levels in a dose- and time-dependent manner.	Paclitaxel	28-38	C-C motif chemokine ligand 26	Homo sapiens	49-54
33764366-11	2021	In summary, our results showed that nab-paclitaxel increased the expression of CCL26 in CAFs, and CCL26 enhanced the invasive potential of pancreatic cancer cells by activating the PI3K/AKT/mTOR axis.	Paclitaxel	40-50	C-C motif chemokine ligand 26	Homo sapiens	79-84
33717235-5	2021	The anticancer drug paclitaxel (PTX) was packed into nanoparticles that were composed of amphiphilic poly (gamma-glutamic-acid-maleimide-co-L-lactide)-1,2-dipalmitoylsn-glycero-3-phosphoethanolaminecopolymer conjugated with targeting moiety transferrin (Tf).	Paclitaxel	20-30	transferrin	Mus musculus	241-252
33717235-5	2021	The anticancer drug paclitaxel (PTX) was packed into nanoparticles that were composed of amphiphilic poly (gamma-glutamic-acid-maleimide-co-L-lactide)-1,2-dipalmitoylsn-glycero-3-phosphoethanolaminecopolymer conjugated with targeting moiety transferrin (Tf).	Paclitaxel	32-35	transferrin	Mus musculus	241-252
33377156-4	2021	We describe the discovery and treatment of occult cancer at the edge of the left fimbria in a BRCA1 mutation carrier who had, just a short time previously, undergone neoadjuvant paclitaxel plus carboplatin (TC) chemotherapy for triple-negative breast cancer.	Paclitaxel	178-188	BRCA1 DNA repair associated	Homo sapiens	94-99
33340428-8	2021	Moreover, patient-derived breast CSCs were found to be dependent on MCM10 for their maintenance, even after enrichment for CSCs that were resistant to paclitaxel, the standard chemotherapeutic agent.	Paclitaxel	151-161	minichromosome maintenance 10 replication initiation factor	Homo sapiens	68-73
32936421-13	2021	Cellular protein light chain 3 (LC3) may play an important role in paclitaxel/honokiol induced cytoplasmic vacuolation and NSCLC cell death.	Paclitaxel	67-77	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	32-35
33300063-10	2021	The upregulated expression levels of the autophagy-related protein 12-5 complex, Beclin-1 and LC3, as well as the downregulation of P62, were also detected following PTX treatment, suggesting that PTX induced autophagic flux in both types of EOC cells.	Paclitaxel	166-169	beclin 1	Homo sapiens	81-89
33300063-10	2021	The upregulated expression levels of the autophagy-related protein 12-5 complex, Beclin-1 and LC3, as well as the downregulation of P62, were also detected following PTX treatment, suggesting that PTX induced autophagic flux in both types of EOC cells.	Paclitaxel	166-169	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	94-97
33300063-10	2021	The upregulated expression levels of the autophagy-related protein 12-5 complex, Beclin-1 and LC3, as well as the downregulation of P62, were also detected following PTX treatment, suggesting that PTX induced autophagic flux in both types of EOC cells.	Paclitaxel	166-169	nucleoporin 62	Homo sapiens	132-135
33300063-10	2021	The upregulated expression levels of the autophagy-related protein 12-5 complex, Beclin-1 and LC3, as well as the downregulation of P62, were also detected following PTX treatment, suggesting that PTX induced autophagic flux in both types of EOC cells.	Paclitaxel	197-200	beclin 1	Homo sapiens	81-89
33300063-10	2021	The upregulated expression levels of the autophagy-related protein 12-5 complex, Beclin-1 and LC3, as well as the downregulation of P62, were also detected following PTX treatment, suggesting that PTX induced autophagic flux in both types of EOC cells.	Paclitaxel	197-200	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	94-97
33300063-10	2021	The upregulated expression levels of the autophagy-related protein 12-5 complex, Beclin-1 and LC3, as well as the downregulation of P62, were also detected following PTX treatment, suggesting that PTX induced autophagic flux in both types of EOC cells.	Paclitaxel	197-200	nucleoporin 62	Homo sapiens	132-135
33519462-0	2020	CPEB4-Promoted Paclitaxel Resistance in Ovarian Cancer In Vitro Relies on Translational Regulation of CSAG2.	Paclitaxel	15-25	CSAG family member 2	Homo sapiens	102-107
33519462-8	2020	Mechanistically, CPEB4 binds with the taxol (paclitaxel)-resistance-associated gene-3 (TRAG-3/CSAG2) mRNAs and induces its expression at a translational level.	Paclitaxel	38-43	CSAG family member 2	Homo sapiens	87-93
33519462-8	2020	Mechanistically, CPEB4 binds with the taxol (paclitaxel)-resistance-associated gene-3 (TRAG-3/CSAG2) mRNAs and induces its expression at a translational level.	Paclitaxel	38-43	CSAG family member 2	Homo sapiens	94-99
33207243-0	2021	FSC231 can alleviate paclitaxel-induced neuralgia by inhibiting PICK1 and affecting related factors.	Paclitaxel	21-31	protein interacting with C kinase 1	Mus musculus	64-69
33207243-1	2021	AIM: To explore the inhibitory effect of FSC231, a PDZ domain inhibitor of protein interacting with C kinase 1 (PICK1), on paclitaxel induced neuralgia and its possible pathways.	Paclitaxel	123-133	protein interacting with C kinase 1	Mus musculus	75-110
33207243-1	2021	AIM: To explore the inhibitory effect of FSC231, a PDZ domain inhibitor of protein interacting with C kinase 1 (PICK1), on paclitaxel induced neuralgia and its possible pathways.	Paclitaxel	123-133	protein interacting with C kinase 1	Mus musculus	112-117
33207243-7	2021	CONCLUSION: FSC231 could alleviate paclitaxel-induced neuralgia by inhibiting PICK1 and affecting the secretion of inflammatory factors and substance P.	Paclitaxel	35-45	protein interacting with C kinase 1	Mus musculus	78-83
33162028-2	2021	In this study, angiopep-2 modified lipid-coated mesoporous silica nanoparticle loading paclitaxel (ANG-LP-MSN-PTX) was developed to transport paclitaxel (PTX) across BBB mediated by low-density lipoprotein receptor-related protein 1 (LRP1), which is over-expressed on both BBB and glioma cells.	Paclitaxel	87-97	angiogenin	Rattus norvegicus	99-102
33162028-2	2021	In this study, angiopep-2 modified lipid-coated mesoporous silica nanoparticle loading paclitaxel (ANG-LP-MSN-PTX) was developed to transport paclitaxel (PTX) across BBB mediated by low-density lipoprotein receptor-related protein 1 (LRP1), which is over-expressed on both BBB and glioma cells.	Paclitaxel	142-152	angiogenin	Rattus norvegicus	99-102
33162028-2	2021	In this study, angiopep-2 modified lipid-coated mesoporous silica nanoparticle loading paclitaxel (ANG-LP-MSN-PTX) was developed to transport paclitaxel (PTX) across BBB mediated by low-density lipoprotein receptor-related protein 1 (LRP1), which is over-expressed on both BBB and glioma cells.	Paclitaxel	110-113	angiogenin	Rattus norvegicus	99-102
33162028-4	2021	In vitro experiments demonstrated that the targeting efficiency of PTX was enhanced by ANG-LP-MSN-PTX with higher penetration ability (10.74%) and causing more C6 cell apoptosis.	Paclitaxel	67-70	angiogenin	Rattus norvegicus	87-90
33162028-4	2021	In vitro experiments demonstrated that the targeting efficiency of PTX was enhanced by ANG-LP-MSN-PTX with higher penetration ability (10.74%) and causing more C6 cell apoptosis.	Paclitaxel	97-101	angiogenin	Rattus norvegicus	87-90
33162028-5	2021	ANG-LP-MSN-PTX (20.6%) revealed higher targeting efficiency compared with LP-MSN-PTX (10.6%) via blood and intracerebral microdialysis method in the pharmacokinetic study.	Paclitaxel	10-14	angiogenin	Rattus norvegicus	0-3
33162028-7	2021	Taken together, ANG-LP-MSN-PTX might hold great promise as a targeting delivery system for glioma treatment.	Paclitaxel	27-30	angiogenin	Rattus norvegicus	16-19
33790078-2	2021	Here, we intended to discover the role and mechanism of miR-509-5p in the paclitaxel chemoresistance of CC cells.	Paclitaxel	74-84	microRNA 5095	Homo sapiens	56-66
33790078-9	2021	On the other hand, miR-509-3p was distinctly downregulated in paclitaxel-resistant HCC94 and C-33A cells (vs. normal cells).	Paclitaxel	62-72	microRNA 5093	Homo sapiens	19-29
33790078-10	2021	The transfection of miR-509-3p mimics notably increased their sensitivity to paclitaxel.	Paclitaxel	77-87	microRNA 5093	Homo sapiens	20-30
33790078-12	2021	Moreover, the RAC1/p21 (RAC1) activated kinase 1 (PAK1)/LIM kinase 1 (LIMK1)/Cofilin pathway was significantly activated in paclitaxel-resistant HCC94 and C-33A cells, while miR-509-3p overexpression significantly inactivated this pathway.	Paclitaxel	124-134	microRNA 5093	Homo sapiens	174-184
33790078-13	2021	Additionally, downregulation of RAC1 also partly reversed the paclitaxel-resistance of CC cells and inhibited PAK1/LIMK1/Cofilin.	Paclitaxel	62-72	Rac family small GTPase 1	Homo sapiens	32-36
33319669-5	2021	PTX resistance pathways that involve major regulatory proteins/RNAs like RNF8/Twist/ROR1, TLR, ErbB3/ErbB2, BRCA1-IRIS, MENA, LIN9, MiRNA, FoxM1 and IRAK1 have expanded the complexity of resistance mechanisms, and brought newer insights for development of drug targets.	Paclitaxel	0-3	forkhead box M1	Homo sapiens	139-144
33363381-16	2020	Conclusion: Our study suggests that UBE2N could be used as a therapeutic agent for paclitaxel-resistant ovarian cancer through Fos/P53 pathway.	Paclitaxel	83-93	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	127-130
33302997-7	2020	The knockdown of SNHG1 and the overexpression of miR-216b-5p stimulated paclitaxel sensitivity in A2780/Taxol cells through inhibiting cell growth and migration and promoting apoptosis.	Paclitaxel	72-82	small nucleolar RNA host gene 1	Homo sapiens	17-22
33302997-8	2020	The inhibition of miR-216b-5p could rescue the effect of lnc-SNHG1 inhibition on the sensitivity of A2780/Taxol cells to paclitaxel.	Paclitaxel	106-111	small nucleolar RNA host gene 1	Homo sapiens	61-66
33302997-8	2020	The inhibition of miR-216b-5p could rescue the effect of lnc-SNHG1 inhibition on the sensitivity of A2780/Taxol cells to paclitaxel.	Paclitaxel	121-131	small nucleolar RNA host gene 1	Homo sapiens	61-66
33302997-11	2020	Lnc-SNHG1 functioned as a ceRNA with miR-216b-5p, which was critical in modulating the paclitaxel sensitivity of ovarian cancer cells.	Paclitaxel	87-97	small nucleolar RNA host gene 1	Homo sapiens	4-9
32064933-6	2020	Six genes (KANK1, ALDH3A1, GALNT14, PIK3R3, LRG1, WEE2), which may be related to paclitaxel resistance in lung adenocarcinoma, were identified.	Paclitaxel	81-91	polypeptide N-acetylgalactosaminyltransferase 14	Homo sapiens	27-34
32064933-6	2020	Six genes (KANK1, ALDH3A1, GALNT14, PIK3R3, LRG1, WEE2), which may be related to paclitaxel resistance in lung adenocarcinoma, were identified.	Paclitaxel	81-91	phosphoinositide-3-kinase regulatory subunit 3	Homo sapiens	36-42
33256016-12	2020	SKOV-3 cells co-treated with sitagliptin and paclitaxel decreased concentrations of MMP-1, MMP-2, MMP-7, MMP-10, TIMP-1, TIMP-2.	Paclitaxel	45-55	matrix metallopeptidase 10	Homo sapiens	105-111
33256016-12	2020	SKOV-3 cells co-treated with sitagliptin and paclitaxel decreased concentrations of MMP-1, MMP-2, MMP-7, MMP-10, TIMP-1, TIMP-2.	Paclitaxel	45-55	TIMP metallopeptidase inhibitor 2	Homo sapiens	121-127
33138677-0	2020	LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.	Paclitaxel	46-56	microRNA 195a	Mus musculus	107-114
33138677-0	2020	LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.	Paclitaxel	92-102	microRNA 195a	Mus musculus	107-114
33155839-7	2020	Overexpression of Tip60 increased cancer cell line sensitivity to paclitaxel regardless of changes in localization.	Paclitaxel	66-76	lysine acetyltransferase 5	Homo sapiens	18-23
33223752-0	2020	Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-kappaB/STAT3 signalling pathway in breast cancer cells.	Paclitaxel	39-49	hepatitis A virus cellular receptor 2	Homo sapiens	0-5
33223752-7	2020	Tim-3 also enhanced cellular resistance to paclitaxel.	Paclitaxel	43-53	hepatitis A virus cellular receptor 2	Homo sapiens	0-5
32986398-0	2020	Internal Oligoguanidinium Transporter: Mercury Free Scalable Synthesis, Improvement of Cellular Localization, Endosomal Escape, Mitochondrial Localization and Conjugation with Antisense Morpholino for NANOG Inhibition to Induce Chemosensitisation of Taxol in MCF-7 Cells.	Paclitaxel	250-255	Nanog homeobox	Homo sapiens	201-206
32986398-8	2020	To the best of our knowledge, this is the first report to illustrate that the IGT-PMO-mediated NANOG inhibition increases the therapeutic potential of taxol and induces G0-G1 arrest in cancer cells to prevent the cancer progression.	Paclitaxel	151-156	Nanog homeobox	Homo sapiens	95-100
33049964-8	2020	Moreover, neutrophils showed increased secretion of MMP9 when cultured with the supernatant of chemotherapy-resistant Cl66-Doxorubicin (Cl66-Dox) and Cl66-Paclitaxel (Cl66-Pac) cells in comparison with the supernatant of Cl66-parent cells.	Paclitaxel	155-165	matrix metallopeptidase 9	Homo sapiens	52-56
31993881-8	2020	By transfecting an siRNA targeting Beclin-1 into NPC Taxol-resistant cells, we discovered that autophagy could negatively regulate pyroptosis by inhibiting Caspase-1/GSDMD activation.	Paclitaxel	53-58	beclin 1	Homo sapiens	35-43
32774496-11	2020	Furthermore, EMT, migration and invasion were induced in Huh7/PTX cells and the addition of miR-212-3p inhibited EMT, migration and invasion.	Paclitaxel	62-65	MIR7-3 host gene	Homo sapiens	57-61
32774496-14	2020	The data from the present study suggest that miR-212-3p attenuates PTX resistance, by regulating EMT, migration and invasion via targeting ZEB2 in HCC cells, indicating a novel target for HCC chemotherapy.	Paclitaxel	67-70	microRNA 212	Homo sapiens	45-52
33005101-17	2020	Ectopic expression of SOX4 increased the susceptibility of cells to paclitaxel.	Paclitaxel	68-78	SRY-box transcription factor 4	Homo sapiens	22-26
33005101-20	2020	Paclitaxel may be a good therapeutic option if the expression level of SOX4 is high.	Paclitaxel	0-10	SRY-box transcription factor 4	Homo sapiens	71-75
33014430-10	2020	Blockade of EDIL3-integrin alphaVbeta3 interaction by cilengitide restores sensitivity to paclitaxel and reverts EMT in paclitaxel-resistant cancer cells.	Paclitaxel	90-100	integrin subunit alpha V	Homo sapiens	18-38
33014430-10	2020	Blockade of EDIL3-integrin alphaVbeta3 interaction by cilengitide restores sensitivity to paclitaxel and reverts EMT in paclitaxel-resistant cancer cells.	Paclitaxel	120-130	integrin subunit alpha V	Homo sapiens	18-38
32934031-0	2020	Correction: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.	Paclitaxel	12-22	microtubule associated protein 4	Homo sapiens	117-121
32535388-0	2020	PPARgamma activation mitigates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of Nrf2/HO-1 signaling pathway.	Paclitaxel	55-65	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	0-9
32535388-0	2020	PPARgamma activation mitigates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of Nrf2/HO-1 signaling pathway.	Paclitaxel	55-65	heme oxygenase 1	Rattus norvegicus	113-117
32562552-8	2020	Inhibition of S1PR1 function in iPSC-derived human sensory neurons shows partial protection against paclitaxel-induced neurite damage.	Paclitaxel	100-110	sphingosine-1-phosphate receptor 1	Homo sapiens	14-19
32628454-1	2020	The paclitaxel (PTX) resistance in most epithelial ovarian cancers (EOCs) with increasing membrane expression of mucin 16 (MUC16) is mediated by the Toll-like receptor-myeloid differentiation factor 2/myeloid differentiation factor 88 (TLR4-MD2/MyD88) signaling pathway.	Paclitaxel	4-14	mucin 16, cell surface associated	Homo sapiens	113-121
32628454-1	2020	The paclitaxel (PTX) resistance in most epithelial ovarian cancers (EOCs) with increasing membrane expression of mucin 16 (MUC16) is mediated by the Toll-like receptor-myeloid differentiation factor 2/myeloid differentiation factor 88 (TLR4-MD2/MyD88) signaling pathway.	Paclitaxel	4-14	mucin 16, cell surface associated	Homo sapiens	123-128
32628454-1	2020	The paclitaxel (PTX) resistance in most epithelial ovarian cancers (EOCs) with increasing membrane expression of mucin 16 (MUC16) is mediated by the Toll-like receptor-myeloid differentiation factor 2/myeloid differentiation factor 88 (TLR4-MD2/MyD88) signaling pathway.	Paclitaxel	16-19	mucin 16, cell surface associated	Homo sapiens	113-121
32628454-1	2020	The paclitaxel (PTX) resistance in most epithelial ovarian cancers (EOCs) with increasing membrane expression of mucin 16 (MUC16) is mediated by the Toll-like receptor-myeloid differentiation factor 2/myeloid differentiation factor 88 (TLR4-MD2/MyD88) signaling pathway.	Paclitaxel	16-19	mucin 16, cell surface associated	Homo sapiens	123-128
32848392-13	2020	We also confirmed that AMD-NP-PTX worked through targeting CXCL12/CXCR4 axis, thereby disturbing its downstream signaling pathways including epithelial-mesenchymal transition (EMT) processes and nuclear factor kappaB (NF-kappaB) pathway.	Paclitaxel	30-33	C-X-C motif chemokine receptor 4	Homo sapiens	66-71
32727972-0	2020	MicroRNA Let-7c Contributes to Paclitaxel Resistance via Aurora-B in Endometrial Serous Carcinoma.	Paclitaxel	31-41	aurora kinase B	Homo sapiens	57-65
32727972-14	2020	These results indicate that let-7c mediates paclitaxel resistance via inhibition of Aurora-B expression in ESC cells.	Paclitaxel	44-54	aurora kinase B	Homo sapiens	84-92
32026660-6	2020	Knockdown of SURF4 reduced the expression of the related stem markers (SOX2 and c-MYC), inhibited self-renewal ability, and improved the sensitivity to chemotherapeutic drugs (paclitaxel and cisplatin) in OCSCs.	Paclitaxel	176-186	surfeit gene 4	Mus musculus	13-18
32445273-6	2020	A murine xenograft model was established to investigate the role of circ-RNF111 in PTX resistance of BC in vivo.	Paclitaxel	83-86	ring finger 111	Mus musculus	73-79
32445273-9	2020	RESULTS: Circ-RNF111 was upregulated in PTX-resistant BC tissues and cells.	Paclitaxel	40-43	ring finger 111	Mus musculus	14-20
32445273-10	2020	Circ-RNF111 knockdown restrained IC50 of PTX, cell viability, colony numbers, cell invasion and glycolysis in PTX-resistant BC cells in vitro and enhanced PTX sensitivity in vivo.	Paclitaxel	41-44	ring finger 111	Mus musculus	5-11
32445273-10	2020	Circ-RNF111 knockdown restrained IC50 of PTX, cell viability, colony numbers, cell invasion and glycolysis in PTX-resistant BC cells in vitro and enhanced PTX sensitivity in vivo.	Paclitaxel	110-113	ring finger 111	Mus musculus	5-11
32445273-10	2020	Circ-RNF111 knockdown restrained IC50 of PTX, cell viability, colony numbers, cell invasion and glycolysis in PTX-resistant BC cells in vitro and enhanced PTX sensitivity in vivo.	Paclitaxel	110-113	ring finger 111	Mus musculus	5-11
32445273-12	2020	The effect of circ-RNF111 knockdown on PTX resistance was rescued by miR-140-5p deletion.	Paclitaxel	39-42	ring finger 111	Mus musculus	19-25
32237255-0	2020	Distinct roles of srGAP3-Rac1 in the initiation and maintenance phases of neuropathic pain induced by paclitaxel.	Paclitaxel	102-112	SLIT-ROBO Rho GTPase activating protein 3	Homo sapiens	18-24
32470092-0	2020	Retraction: miR-23a Targets Interferon Regulatory Factor 1 and Modulates Cellular Proliferation and Paclitaxel-Induced Apoptosis in Gastric Adenocarcinoma Cells.	Paclitaxel	100-110	microRNA 23a	Homo sapiens	12-19
31883395-7	2020	Adriyamicin/cyclophosphamide and Paclitaxel resistant MDA-MB-231 cells activated NRP-1/TNC/Integrin beta3/FAK/NF-kappaBp65 axis and displayed a decrease in breast cancer resistant protein (BCRP/ABCB2).	Paclitaxel	33-43	tenascin C	Homo sapiens	87-90
31818526-10	2020	CONCLUSION: This systematic review and meta-analysis suggests that NACT-IDS with carboplatin and paclitaxel does not negatively impact the survival of women with advanced ovarian cancer compared to PDS, while perioperative complications and mortality are significantly reduced by 70-80%.	Paclitaxel	97-107	iduronate 2-sulfatase	Homo sapiens	72-75
32281270-7	2020	Scribble (SCRIB), a cell polarity protein, was notably down-regulated in tamoxifen- and paclitaxel-resistant breast cancer cells relative to sensitive cells.	Paclitaxel	88-98	scribble planar cell polarity protein	Homo sapiens	0-8
32281270-7	2020	Scribble (SCRIB), a cell polarity protein, was notably down-regulated in tamoxifen- and paclitaxel-resistant breast cancer cells relative to sensitive cells.	Paclitaxel	88-98	scribble planar cell polarity protein	Homo sapiens	10-15
32273769-9	2020	Results: Circ-ABCB10 depletion promoted the PTX sensitivity and apoptosis while suppressed the invasion and autophagy of PTX-resistant BC cells.	Paclitaxel	44-47	ATP-binding cassette, sub-family B (MDR/TAP), member 10	Mus musculus	14-20
32273769-9	2020	Results: Circ-ABCB10 depletion promoted the PTX sensitivity and apoptosis while suppressed the invasion and autophagy of PTX-resistant BC cells.	Paclitaxel	121-124	ATP-binding cassette, sub-family B (MDR/TAP), member 10	Mus musculus	14-20
32273769-10	2020	Circ-ABCB10 could bind to let-7a-5p in BC cells, and circ-ABCB10 contributed to PTX resistance of BC cells via let-7a-5p.	Paclitaxel	80-83	ATP-binding cassette, sub-family B (MDR/TAP), member 10	Mus musculus	58-64
32273769-13	2020	Conclusion: Circ-ABCB10 mediated PTX resistance, apoptosis, invasion and autophagy of BC cells via let-7a-5p/DUSP7 axis.	Paclitaxel	33-36	ATP-binding cassette, sub-family B (MDR/TAP), member 10	Mus musculus	17-23
32090232-3	2020	Next, HNPs obtained using 49 kDa HA have been used to encapsulate paclitaxel (PTX-HNPs), which demonstrated selective lung accumulation due to both size effect and CD44-mediated targetability.	Paclitaxel	66-76	CD44 antigen	Mus musculus	164-168
31713924-2	2020	Therefore, this study was aimed to study the effect of applying linoleic acid (LA) and docosahexaenoic acid (DHA) fatty acids alone or combined with Taxol on the expression of the matrix metalloproteinase (MMP)-9, MMP-2, vimentin, and talin2 genes, tumor-suppressor miR-194 and, onco-miR-106b in triple-negative breast cancer cell line, known as MDA-MB-231.	Paclitaxel	149-154	matrix metallopeptidase 9	Homo sapiens	180-212
32016470-5	2020	Moreover, ST6Gal-I overexpression cells had strong resistance to paclitaxel, as demonstrated by low growth inhibition rate and cell apoptosis level.	Paclitaxel	65-75	ST6 beta-galactoside alpha-2,6-sialyltransferase 1	Homo sapiens	10-18
31420851-0	2020	LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.	Paclitaxel	13-23	centriole, cilia and spindle associated protein	Homo sapiens	90-95
32106859-9	2020	Importantly, cisplatin and paclitaxel promote miR-522 secretion from CAFs by activating USP7/hnRNPA1 axis, leading to ALOX15 suppression and decreased lipid-ROS accumulation in cancer cells, and ultimately result in decreased chemo-sensitivity.	Paclitaxel	27-37	ubiquitin specific peptidase 7	Homo sapiens	88-92
31286496-11	2020	Thus, our study provides not only elements to understand the causes of taxane resistance in CCNE1-amplified ovarian cancers but also suggests a new combinatorial strategy that may improve paclitaxel-based efficacy in this highly lethal gynecological disease.	Paclitaxel	188-198	cyclin E1	Homo sapiens	92-97
32005098-5	2020	Tumors from mice treated with stampidine or stampidine plus paclitaxel displayed unique changes of a signature protein cassette comprised of BRCA1, p21, Bax, and Bcl-2.Conclusion: Stampidine has potent chemopreventive activity and is as effective as the standard chemotherapy drug paclitaxel in the chemical carcinogenesis model of DMBA-induced murine breast cancer.	Paclitaxel	60-70	breast cancer 1, early onset	Mus musculus	141-146
32005098-5	2020	Tumors from mice treated with stampidine or stampidine plus paclitaxel displayed unique changes of a signature protein cassette comprised of BRCA1, p21, Bax, and Bcl-2.Conclusion: Stampidine has potent chemopreventive activity and is as effective as the standard chemotherapy drug paclitaxel in the chemical carcinogenesis model of DMBA-induced murine breast cancer.	Paclitaxel	60-70	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	148-151
32005098-5	2020	Tumors from mice treated with stampidine or stampidine plus paclitaxel displayed unique changes of a signature protein cassette comprised of BRCA1, p21, Bax, and Bcl-2.Conclusion: Stampidine has potent chemopreventive activity and is as effective as the standard chemotherapy drug paclitaxel in the chemical carcinogenesis model of DMBA-induced murine breast cancer.	Paclitaxel	60-70	BCL2-associated X protein	Mus musculus	153-156
31830613-2	2020	LOX-traceable nanoparticles (LOXab-NPs) consisting of LOX antibodies (LOXab) and paclitaxel, can accumulate at high concentrations at radiation-treated target sites, as a tumor-targeting drug carrier for chemotherapy.	Paclitaxel	81-91	lysyl oxidase	Homo sapiens	0-3
31830613-2	2020	LOX-traceable nanoparticles (LOXab-NPs) consisting of LOX antibodies (LOXab) and paclitaxel, can accumulate at high concentrations at radiation-treated target sites, as a tumor-targeting drug carrier for chemotherapy.	Paclitaxel	81-91	lysyl oxidase	Homo sapiens	29-32
31690669-6	2020	paclitaxel-treated macrophages enhanced the growth of Lewis lung carcinoma tumors that was attenuated by a CXCR2 inhibitor.	Paclitaxel	0-10	chemokine (C-X-C motif) receptor 2	Mus musculus	107-112
31662022-4	2020	During cytokinesis induced by treatment with taxol, the epithelial barrier was maintained and the tricellular tight junction molecules LSR and tricellulin were concentrated at the flank of the acetylated tubulin-positive midbody and in gamma-tubulin-positive centrosomes with the dynein adaptor Hook2, whereas the other molecules were localized there as well.	Paclitaxel	45-50	hook microtubule tethering protein 2	Homo sapiens	295-300
31375828-3	2019	This study aimed to explore interactions of conventional paclitaxel and experimental taxane SB-T-1216 with the KRAS signalling pathway expression in in vivo and in vitro PDAC models in order to decipher potential predictive biomarkers or targets for future individualised therapy.	Paclitaxel	57-67	KRAS proto-oncogene, GTPase	Homo sapiens	111-115
31844042-0	2019	Hsa_circ_0002483 inhibited the progression and enhanced the Taxol sensitivity of non-small cell lung cancer by targeting miR-182-5p.	Paclitaxel	60-65	microRNA 182	Homo sapiens	121-128
31664795-2	2019	In this study, a pulmonary microspheres system that codelivers afatinib and paclitaxel (PTX) is developed for treatment of EGFR TKIs resistant NSCLC.	Paclitaxel	76-86	epidermal growth factor receptor	Rattus norvegicus	123-127
31664795-2	2019	In this study, a pulmonary microspheres system that codelivers afatinib and paclitaxel (PTX) is developed for treatment of EGFR TKIs resistant NSCLC.	Paclitaxel	88-91	epidermal growth factor receptor	Rattus norvegicus	123-127
30782035-0	2019	NEAT1 mediates paclitaxel-resistance of non-small cell of lung cancer through activation of Akt/mTOR signalling pathway.	Paclitaxel	15-25	nuclear paraspeckle assembly transcript 1	Homo sapiens	0-5
30782035-3	2019	In this study, we investigated the mechanism by which NEAT1 contributed to paclitaxel-resistance in NSCLC.	Paclitaxel	75-85	nuclear paraspeckle assembly transcript 1	Homo sapiens	54-59
30782035-4	2019	NEAT1 was upregulated significantly in paclitaxel-resistant NSCLC cell line, compared with other NSCLC cell lines and normal bronchial epithelial (BE) cell line.	Paclitaxel	39-49	nuclear paraspeckle assembly transcript 1	Homo sapiens	0-5
30782035-5	2019	Knockdown of NEAT1 could reverse the paclitaxel-resistance through induction of apoptosis by increasing cleaved PARP and cleaved caspase-3 expression.	Paclitaxel	37-47	nuclear paraspeckle assembly transcript 1	Homo sapiens	13-18
30782035-7	2019	In conclusion, these results demonstrated that NEAT1 underlay paclitaxel-resistance in NSCLC.	Paclitaxel	62-72	nuclear paraspeckle assembly transcript 1	Homo sapiens	47-52
31546458-0	2019	177Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer.	Paclitaxel	21-31	gastrin releasing peptide	Homo sapiens	6-14
31488699-0	2019	Transgelin 2 Promotes Paclitaxel Resistance, Migration, and Invasion of Breast Cancer by Directly Interacting with PTEN and Activating PI3K/Akt/GSK-3beta Pathway.	Paclitaxel	22-32	transgelin 2	Homo sapiens	0-12
31488699-3	2019	The aim of this study was to determine the biological functions of Transgelin 2 and the mechanism underlying how Transgelin 2 induces paclitaxel (PTX) resistance and the migration and invasion of breast cancer.	Paclitaxel	134-144	transgelin 2	Homo sapiens	67-79
31488699-3	2019	The aim of this study was to determine the biological functions of Transgelin 2 and the mechanism underlying how Transgelin 2 induces paclitaxel (PTX) resistance and the migration and invasion of breast cancer.	Paclitaxel	134-144	transgelin 2	Homo sapiens	113-125
31488699-3	2019	The aim of this study was to determine the biological functions of Transgelin 2 and the mechanism underlying how Transgelin 2 induces paclitaxel (PTX) resistance and the migration and invasion of breast cancer.	Paclitaxel	146-149	transgelin 2	Homo sapiens	67-79
31488699-3	2019	The aim of this study was to determine the biological functions of Transgelin 2 and the mechanism underlying how Transgelin 2 induces paclitaxel (PTX) resistance and the migration and invasion of breast cancer.	Paclitaxel	146-149	transgelin 2	Homo sapiens	113-125
31488699-6	2019	Overexpression of Transgelin 2 enhanced the migration and invasion of human breast cancer cells and decreased the sensitivity of breast cancer cells to paclitaxel.	Paclitaxel	152-162	transgelin 2	Homo sapiens	18-30
31488699-10	2019	These findings indicate that Transgelin 2 promotes paclitaxel resistance and the migration and invasion of breast cancer by directly interacting with PTEN and activating the PI3K/Akt/GSK-3beta pathway.	Paclitaxel	51-61	transgelin 2	Homo sapiens	29-41
31766357-1	2019	RASSF1 gene methylation predicts longer disease-free survival (DFS) and overall survival (OS) in patients with early-stage non-small-cell lung cancer treated using paclitaxel-based neo-adjuvant chemotherapy compared to patients receiving a gemcitabine-based regimen, according to the randomized Phase 3 IFCT (Intergroupe Francophone de Cancerologie Thoracique)-0002 trial.	Paclitaxel	164-174	Ras association domain family member 1	Homo sapiens	0-6
31766357-6	2019	Conversely, paclitaxel does not increase the IAP-2 expression but limits the invasiveness of RASSF1A-depleted cells, presumably by rescuing microtubule stabilization.	Paclitaxel	12-22	Ras association domain family member 1	Homo sapiens	93-100
31766357-7	2019	Overall, these data provide a functional insight that supports the prognostic value of RASSF1 gene methylation on survival of early-stage lung cancer patients receiving perioperative paclitaxel-based treatment compared to gemcitabine-based treatment, identifying IAP-2 as a novel biomarker indicative of YAP-1-mediated modulation of chemo-sensitivity in lung cancer.	Paclitaxel	183-193	Ras association domain family member 1	Homo sapiens	87-93
31668068-6	2019	After the anticancer drug paclitaxel was loaded, two AIE-active polymers, P1 and P2, could be engineered into polymer dots (Pdots) and applied in self-illuminating cancer therapy.	Paclitaxel	26-36	crystallin gamma F, pseudogene	Homo sapiens	74-83
31499197-8	2019	In this study, we designed integrin alphavbeta3 targeting, acid environmental sensitive liposomal platforms to co-loaded paclitaxel and the autophagy inhibitor hydroxychloroquine.	Paclitaxel	121-131	integrin subunit alpha V	Homo sapiens	27-47
31437461-0	2019	Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats.	Paclitaxel	100-110	solute carrier organic anion transporter family, member 1b2	Mus musculus	0-39
31437461-5	2019	In Oatp1b2-overexpressed cells, sorafenib inhibited the uptake of paclitaxel in a concentration-dependent manner.	Paclitaxel	66-76	solute carrier organic anion transporter family, member 1b2	Mus musculus	3-10
31437461-10	2019	In general, the combination of paclitaxel and sorafenib caused Oatp1b2-mediated DDI in vitro and in vivo, because sorafenib inhibited Oatp1b2 activity and affected the pharmacokinetic properties of paclitaxel.	Paclitaxel	31-41	solute carrier organic anion transporter family, member 1b2	Mus musculus	63-70
31437461-10	2019	In general, the combination of paclitaxel and sorafenib caused Oatp1b2-mediated DDI in vitro and in vivo, because sorafenib inhibited Oatp1b2 activity and affected the pharmacokinetic properties of paclitaxel.	Paclitaxel	31-41	solute carrier organic anion transporter family, member 1b2	Mus musculus	134-141
31515668-9	2019	RESULTS: PTX treatment decreased SRSF3 expression, and SRSF3 overexpression rescued the growth inhibition caused by PTX in both OSCC and breast cancer cells.	Paclitaxel	116-119	serine and arginine rich splicing factor 3	Homo sapiens	55-60
31515668-10	2019	Moreover, we found that PTX treatment could repress SRSF3 exon 4 (containing an in-frame stop codon) exclusion and then decrease the SRSF3 protein expression.	Paclitaxel	24-27	serine and arginine rich splicing factor 3	Homo sapiens	52-57
31515668-10	2019	Moreover, we found that PTX treatment could repress SRSF3 exon 4 (containing an in-frame stop codon) exclusion and then decrease the SRSF3 protein expression.	Paclitaxel	24-27	serine and arginine rich splicing factor 3	Homo sapiens	133-138
31515668-13	2019	CONCLUSIONS: SRSF3 downregulation by ASO sensitizes cancer cells to PTX treatment.	Paclitaxel	68-71	serine and arginine rich splicing factor 3	Homo sapiens	13-18
31762812-9	2019	Ovarian cancer cells with SIK3 knockdown display increased chemoresistance to Taxol plus cisplatin treatment, which is associated with the upregulation of the ABCG2 transporter.	Paclitaxel	78-83	SIK family kinase 3	Homo sapiens	26-30
31749880-7	2019	Oocyte-specific genes such as growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) were more suppressed in the paclitaxel group than in the cisplatin group.	Paclitaxel	139-149	growth differentiation factor 9	Homo sapiens	30-61
31749880-7	2019	Oocyte-specific genes such as growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) were more suppressed in the paclitaxel group than in the cisplatin group.	Paclitaxel	139-149	growth differentiation factor 9	Homo sapiens	63-67
31288064-5	2019	These HA-PEI-miR-125b nanoparticles in combination with intraperitoneal paclitaxel can enhance the anti-tumor efficacy of paclitaxel during the later stages of disease progression as seen by the significant reduction in the ascitic fluid and peritoneal VEGF levels.	Paclitaxel	72-82	vascular endothelial growth factor A	Mus musculus	253-257
31288064-5	2019	These HA-PEI-miR-125b nanoparticles in combination with intraperitoneal paclitaxel can enhance the anti-tumor efficacy of paclitaxel during the later stages of disease progression as seen by the significant reduction in the ascitic fluid and peritoneal VEGF levels.	Paclitaxel	122-132	vascular endothelial growth factor A	Mus musculus	253-257
31172606-9	2019	Also, the decrease in the expression levels of matrix metalloproteinase-9 confirmed the antimetastatic efficacy of COR + PTX.	Paclitaxel	121-124	matrix metallopeptidase 9	Homo sapiens	47-73
31359594-0	2019	Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.	Paclitaxel	44-54	forkhead box M1	Homo sapiens	27-32
31359594-7	2019	We observe that paclitaxel-resistant TNBC cells exhibit high expression of Aurora-A and FOXM1.	Paclitaxel	16-26	forkhead box M1	Homo sapiens	88-93
31359594-11	2019	In conclusion, our study reveals additional mechanism through which Aurora-A regulates FOXM1 and provides a new therapeutic strategy to treat paclitaxel-resistant triple-negative breast cancer.	Paclitaxel	142-152	forkhead box M1	Homo sapiens	87-92
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	353-356	DNA methyltransferase 1	Homo sapiens	198-203
31077613-3	2019	Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.	Paclitaxel	353-356	DIRAS family GTPase 3	Homo sapiens	295-299
31528755-10	2019	In the same animals evaluated for nociceptive responding, paclitaxel also reduced cellular proliferation but not cellular survival in the dentate gyrus of the hippocampus, as measured by immunohistochemistry for Ki67 and BrdU expression, respectively.	Paclitaxel	58-68	antigen identified by monoclonal antibody Ki 67	Mus musculus	212-216
30739312-6	2019	NR1I3 was correlated to paclitaxel-TrPN and UGT2B7 to docetaxel-TrPN.	Paclitaxel	24-34	nuclear receptor subfamily 1 group I member 3	Homo sapiens	0-5
31423204-5	2019	Upregulation of PDCD4 significantly enhanced the sensitivity of CRC cells to Taxol, by partially contributing to pro-apoptosis and anti-invasion pathways, both through upregulation of the apoptosis-associated protein Bax, and downregulation of the anti-apoptosis protein Bcl-2 and invasion-associated proteins MMP-9.	Paclitaxel	77-82	matrix metallopeptidase 9	Homo sapiens	310-315
31337279-13	2019	In addition, miR-4262 induced PTX chemoresistance by promoting survival and migration in A549/PTX and H1299/PTX cells.	Paclitaxel	30-33	microRNA 4262	Homo sapiens	13-21
31337279-13	2019	In addition, miR-4262 induced PTX chemoresistance by promoting survival and migration in A549/PTX and H1299/PTX cells.	Paclitaxel	94-97	microRNA 4262	Homo sapiens	13-21
31337279-13	2019	In addition, miR-4262 induced PTX chemoresistance by promoting survival and migration in A549/PTX and H1299/PTX cells.	Paclitaxel	94-97	microRNA 4262	Homo sapiens	13-21
31337279-14	2019	Moreover, miR-4262 expression and PI3 K/Akt signalling pathway-related proteins were upregulated and PTEN was downregulated in A549/PTX and H1299/PTX.	Paclitaxel	132-135	microRNA 4262	Homo sapiens	10-18
31337279-14	2019	Moreover, miR-4262 expression and PI3 K/Akt signalling pathway-related proteins were upregulated and PTEN was downregulated in A549/PTX and H1299/PTX.	Paclitaxel	146-149	microRNA 4262	Homo sapiens	10-18
31337279-15	2019	Our results indicate that miR-4262 enhances PTX resistance in NSCLC cells through targeting PTEN and activating the PI3 K/Akt signalling pathway.	Paclitaxel	44-47	microRNA 4262	Homo sapiens	26-34
31337279-16	2019	The inhibition of miR-4262 expression might be an improved treatment to overcome PTX resistance in NSCLC.	Paclitaxel	81-84	microRNA 4262	Homo sapiens	18-26
31155297-7	2019	In particular, the relative uptake efficiency (RE) and concentration efficiency (CE) of (Bio2-Chol)Lip were respectively enhanced by 5.61- and 5.06-fold compared to that of naked paclitaxel.	Paclitaxel	179-189	SMG1 nonsense mediated mRNA decay associated PI3K related kinase	Homo sapiens	99-102
31333464-11	2019	Notably, PTX-induced mechanical allodynia was fully developed in Trpv1 or Trpa1 knockout mice, showing no sex differences.	Paclitaxel	9-12	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	74-79
31259152-0	2019	Ursolic Acid Reverses the Chemoresistance of Breast Cancer Cells to Paclitaxel by Targeting MiRNA-149-5p/MyD88.	Paclitaxel	68-78	myeloid differentiation primary response gene 88	Mus musculus	105-110
31259152-4	2019	The role of miRNA-149-5p/MyD88 in the regulation of PTX resistance was investigated by the transfection of breast cancer cells with MDA-MB-231 (231) and MDA-MB-231/PTX-resistance (231/PTX) with lentiviruses carrying the MyD88 gene, shRNA specific for MyD88, the miR-149-5p gene, and shRNA specific for miR-149-5p.	Paclitaxel	52-55	myeloid differentiation primary response gene 88	Mus musculus	25-30
31160603-0	2019	EPHB6 mutation induces cell adhesion-mediated paclitaxel resistance via EPHA2 and CDH11 expression.	Paclitaxel	46-56	EPH receptor A2	Homo sapiens	72-77
31160603-5	2019	EPHB6 mutation-induced paclitaxel resistance was mediated by an interaction with EPHA2, which promotes c-Jun N-terminal kinase (JNK)-mediated cadherin 11 (CDH11) expression.	Paclitaxel	23-33	EPH receptor A2	Homo sapiens	81-86
31160603-7	2019	Targeted inhibition of EPHA2 or CDH11 reversed the acquired paclitaxel resistance, suggesting its potential clinical utility.	Paclitaxel	60-70	EPH receptor A2	Homo sapiens	23-28
31160603-8	2019	The present results suggest that the EPHB6 mutation and its downstream EPHA2/JNK/CDH11/RhoA/FAK signaling axis are novel diagnostic and therapeutic targets for overcoming paclitaxel resistance in cancer patients.	Paclitaxel	171-181	EPH receptor A2	Homo sapiens	71-76
31285951-0	2019	Genome-scale CRISPR activation screening identifies a role of ELAVL2-CDKN1A axis in paclitaxel resistance in esophageal squamous cell carcinoma.	Paclitaxel	84-94	ELAV like RNA binding protein 2	Homo sapiens	62-68
31285951-8	2019	We then found that overexpression of CDKN1A, ELAVL2 or TSPAN4 in ESCC cell lines significantly promoted the resistance to PTX by inhibiting cell apoptosis.	Paclitaxel	122-125	ELAV like RNA binding protein 2	Homo sapiens	45-51
30701575-0	2019	SMAD3 inducing the transcription of  STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.	Paclitaxel	126-136	serine/threonine/tyrosine kinase 1	Rattus norvegicus	37-42
30701575-1	2019	OBJECTIVE: To figure out the relationship between SMAD3 and serine-threonine tyrosine kinase (STYK1) in ovarian carcinoma cell"s paclitaxel resistance.	Paclitaxel	129-139	serine/threonine/tyrosine kinase 1	Rattus norvegicus	94-99
30701575-9	2019	Upregulating STYK1 improved the paclitaxel resistance of ovarian carcinoma cells.	Paclitaxel	32-42	serine/threonine/tyrosine kinase 1	Rattus norvegicus	13-18
30701575-11	2019	The animal assay showed that downregulating STYK1 inhibited the EMT process and the paclitaxel resistance, further promoting the treatment of cervical cancer.	Paclitaxel	84-94	serine/threonine/tyrosine kinase 1	Rattus norvegicus	44-49
30701575-12	2019	CONCLUSION: SMAD3 combined with the promoter region of STYK1 to promote the transcription process of STYK1, thereby promoting the EMT process and paclitaxel resistance of ovarian cancer cells.	Paclitaxel	146-156	serine/threonine/tyrosine kinase 1	Rattus norvegicus	55-60
30701575-12	2019	CONCLUSION: SMAD3 combined with the promoter region of STYK1 to promote the transcription process of STYK1, thereby promoting the EMT process and paclitaxel resistance of ovarian cancer cells.	Paclitaxel	146-156	serine/threonine/tyrosine kinase 1	Rattus norvegicus	101-106
31015308-10	2019	Pretreatment with MT4 also sensitized ovarian cancer cells to paclitaxel.	Paclitaxel	62-72	metallothionein 4	Homo sapiens	18-21
31118065-14	2019	Furthermore, progression-free survival (PFS) of mucosal melanoma patients upon temozolomide-based and paclitaxel-based chemotherapy was related to miR-let-7b and miR-let-7c expression.	Paclitaxel	102-112	microRNA let-7b	Homo sapiens	147-157
31118065-15	2019	Overexpression of miR-let-7b or miR-let-7c in patient-derived xenograft (PDX) models and certain mucosal melanoma cells had better growth inhibition after temozolomide and paclitaxel treatment.	Paclitaxel	172-182	microRNA let-7b	Homo sapiens	18-28
31118065-16	2019	MTDH reversed the sensitivity of miR-let-7b and miR-let-7c to paclitaxel in vitro.	Paclitaxel	62-72	membrane associated ring-CH-type finger 8	Homo sapiens	33-36
31118065-16	2019	MTDH reversed the sensitivity of miR-let-7b and miR-let-7c to paclitaxel in vitro.	Paclitaxel	62-72	membrane associated ring-CH-type finger 8	Homo sapiens	48-51
31334335-0	2019	FoxM1 Induced Paclitaxel Resistance via Activation of the FoxM1/PHB1/RAF-MEK-ERK Pathway and Enhancement of the ABCA2 Transporter.	Paclitaxel	14-24	forkhead box M1	Homo sapiens	0-5
31334335-0	2019	FoxM1 Induced Paclitaxel Resistance via Activation of the FoxM1/PHB1/RAF-MEK-ERK Pathway and Enhancement of the ABCA2 Transporter.	Paclitaxel	14-24	forkhead box M1	Homo sapiens	58-63
31156650-8	2019	Mechanistically, paclitaxel treatment induced robust activation of the TLR4 signaling cascade, including phosphorylation of IkappaB and JNK and upregulation of proinflammatory cytokine mRNA levels in a TLR4-dependent manner.	Paclitaxel	17-27	mitogen-activated protein kinase 8	Mus musculus	136-139
31156720-0	2019	Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer.	Paclitaxel	79-89	polo like kinase 1	Homo sapiens	12-16
31156720-3	2019	Because paclitaxel-resistant cancer shows high levels of Plk1, a promising target in chemotherapy, the effectiveness of Plk1 inhibitors in paclitaxel-resistant cancer cells has been investigated.	Paclitaxel	8-18	polo like kinase 1	Homo sapiens	57-61
31156720-8	2019	Results: Treatment with Plk1 inhibitors markedly reduced the expression of MDR1, MRP1, and Plk1 in the paclitaxel-resistant cancer.	Paclitaxel	103-113	polo like kinase 1	Homo sapiens	24-28
31156720-8	2019	Results: Treatment with Plk1 inhibitors markedly reduced the expression of MDR1, MRP1, and Plk1 in the paclitaxel-resistant cancer.	Paclitaxel	103-113	polo like kinase 1	Homo sapiens	91-95
30471427-7	2019	These findings suggest that MMP signaling plays a key role in paclitaxel-induced peripheral neuropathy, and MMP9 mAb may offer new therapeutic approaches for the treatment of CIPN.	Paclitaxel	62-72	matrix metallopeptidase 2	Mus musculus	28-31
30928404-13	2019	SIGNIFICANCE: KRT17 played pivotal oncogenic roles in cell survival, migration and paclitaxel-induced resistance of cervical cancer cells.	Paclitaxel	83-93	keratin 17	Homo sapiens	14-19
30928404-14	2019	Thus, KRT17 would serve as a promising target for compromising paclitaxel-induced resistance and metastasis.	Paclitaxel	63-73	keratin 17	Homo sapiens	6-11
30942454-8	2019	In conclusion, the data suggested that elevated miR-302a levels, in part, mediate sensitivity to paclitaxel in prostate cancer through the aberrant regulation of its downstream targets, AOF2, BCRP and permeability glycoprotein 1.	Paclitaxel	97-107	lysine demethylase 1A	Homo sapiens	186-190
30642911-0	2019	Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.	Paclitaxel	76-86	CD8a molecule	Homo sapiens	33-36
30642911-10	2019	CONCLUSIONS: Paclitaxel/carboplatin/bevacizumab induces proliferation of CD8 T cells, consisting of effector cells expressing coinhibitory checkpoint molecules.	Paclitaxel	13-23	CD8a molecule	Homo sapiens	73-76
30623814-0	2019	Transferrin-conjugated pH-sensitive platform for effective delivery of porous palladium nanoparticles and paclitaxel in cancer treatment.	Paclitaxel	106-116	transferrin	Mus musculus	0-11
30720049-0	2019	Beclin1 inhibition enhances paclitaxel-mediated cytotoxicity in breast cancer in vitro and in vivo.	Paclitaxel	28-38	beclin 1	Homo sapiens	0-7
30720049-3	2019	However, the function and mechanism of Beclin1 in paclitaxel-mediated cytotoxicity in breast cancer are not well defined.	Paclitaxel	50-60	beclin 1	Homo sapiens	39-46
30720049-4	2019	The present study demonstrated that paclitaxel suppressed cell viability and Beclin1 expression levels in BT-474 breast cancer cells in a dose- and time-dependent fashion.	Paclitaxel	36-46	beclin 1	Homo sapiens	77-84
30720049-5	2019	Compared with the control, the knockdown of Beclin1 significantly enhanced breast cancer cell death via the induction of caspase-dependent apoptosis following paclitaxel treatment in vitro (P&lt;0.05).	Paclitaxel	159-169	beclin 1	Homo sapiens	44-51
30720049-6	2019	In a BT-474 xenograft model, paclitaxel achieved substantial inhibition of tumor growth in the Beclin1 knockdown group compared with the control group.	Paclitaxel	29-39	beclin 1	Homo sapiens	95-102
30720049-7	2019	Furthermore, analysis of the publicly available Gene Expression Omnibus datasets revealed a clinical correlation between Beclin1 levels and the response to paclitaxel therapy in patients with breast cancer.	Paclitaxel	156-166	beclin 1	Homo sapiens	121-128
30720049-9	2019	Thus, the inhibition of Beclin1 may be a novel way to improve the effect of paclitaxel.	Paclitaxel	76-86	beclin 1	Homo sapiens	24-31
30720049-10	2019	Additionally, Beclin1 may function as a favorable prognostic biomarker for paclitaxel treatment in patients with breast cancer.	Paclitaxel	75-85	beclin 1	Homo sapiens	14-21
30608899-7	2019	Based on the survival analyses, the advanced-stage patients with high SOX30 expression can receive the platin and/or taxol based chemotherapy, whereas should not receive chemotherapy containing gemcitabine or topotecan.	Paclitaxel	117-122	SRY-box transcription factor 30	Homo sapiens	70-75
29671386-1	2019	This study aimed to develop novel temperature-sensitive liposomes loading paclitaxel (PTX-TSL) and evaluate them in vitro to improve the delivery efficiency and targeting of PTX.	Paclitaxel	74-84	TSL	Homo sapiens	90-93
30529691-9	2019	In nude mice, 0.5 or 1 mg.kg-1 PP-13 intraperitoneally administered three-times a week reduced the sizes of paclitaxel-refractory orthotopic breast tumors, delayed the progression of metastasis, and decreased the global metastatic load compared to 0.5 mg.kg-1 paclitaxel or vehicle alone.	Paclitaxel	108-118	galectin 13	Homo sapiens	31-36
30529691-9	2019	In nude mice, 0.5 or 1 mg.kg-1 PP-13 intraperitoneally administered three-times a week reduced the sizes of paclitaxel-refractory orthotopic breast tumors, delayed the progression of metastasis, and decreased the global metastatic load compared to 0.5 mg.kg-1 paclitaxel or vehicle alone.	Paclitaxel	260-270	galectin 13	Homo sapiens	31-36
30761271-4	2019	The high-expression of CDKN2B-AS gene was associated with high pathological grade and low paclitaxel sensitivity of EC tissues.	Paclitaxel	90-100	CDKN2B antisense RNA 1	Homo sapiens	23-32
30761271-5	2019	Knockdown of CDKN2B-AS gene sensitized Ishikawa/PA and HEC1A/PA cells to paclitaxel, and promoted paclitaxel-induced cytotoxicity.	Paclitaxel	73-83	CDKN2B antisense RNA 1	Homo sapiens	13-22
30761271-5	2019	Knockdown of CDKN2B-AS gene sensitized Ishikawa/PA and HEC1A/PA cells to paclitaxel, and promoted paclitaxel-induced cytotoxicity.	Paclitaxel	98-108	CDKN2B antisense RNA 1	Homo sapiens	13-22
30761271-7	2019	MiR-125a-5p also mediated the suppressive effects of knockdown of CDKN2B-AS on paclitaxel resistance in EC cells.	Paclitaxel	79-89	CDKN2B antisense RNA 1	Homo sapiens	66-75
30761271-8	2019	Thirdly, B-cell lymphoma-2 (Bcl2) and Multidrug Resistance-Associated Protein 4 (MRP4) genes were target genes of miR-125a-5p, which modulated paclitaxel resistance of Ishikawa/PA and HEC1A/PA cells through targeted silencing Bcl2 and MRP4.	Paclitaxel	143-153	ATP binding cassette subfamily C member 4	Homo sapiens	38-79
30761271-8	2019	Thirdly, B-cell lymphoma-2 (Bcl2) and Multidrug Resistance-Associated Protein 4 (MRP4) genes were target genes of miR-125a-5p, which modulated paclitaxel resistance of Ishikawa/PA and HEC1A/PA cells through targeted silencing Bcl2 and MRP4.	Paclitaxel	143-153	ATP binding cassette subfamily C member 4	Homo sapiens	81-85
30761271-8	2019	Thirdly, B-cell lymphoma-2 (Bcl2) and Multidrug Resistance-Associated Protein 4 (MRP4) genes were target genes of miR-125a-5p, which modulated paclitaxel resistance of Ishikawa/PA and HEC1A/PA cells through targeted silencing Bcl2 and MRP4.	Paclitaxel	143-153	ATP binding cassette subfamily C member 4	Homo sapiens	235-239
30761271-9	2019	In conclusion, high-expression of CDKN2B-AS is associated with a poor response to paclitaxel of EC patients, and knockdown of CDKN2B-AS inhibits paclitaxel resistance through miR-125a-5p-Bcl2/MRP4 pathway in EC patients.	Paclitaxel	82-92	CDKN2B antisense RNA 1	Homo sapiens	34-43
30761271-9	2019	In conclusion, high-expression of CDKN2B-AS is associated with a poor response to paclitaxel of EC patients, and knockdown of CDKN2B-AS inhibits paclitaxel resistance through miR-125a-5p-Bcl2/MRP4 pathway in EC patients.	Paclitaxel	145-155	CDKN2B antisense RNA 1	Homo sapiens	126-135
30761271-9	2019	In conclusion, high-expression of CDKN2B-AS is associated with a poor response to paclitaxel of EC patients, and knockdown of CDKN2B-AS inhibits paclitaxel resistance through miR-125a-5p-Bcl2/MRP4 pathway in EC patients.	Paclitaxel	145-155	ATP binding cassette subfamily C member 4	Homo sapiens	192-196
30399596-8	2019	In addition, up-regulation of miR-383-5p decreased the IC50 value of ovarian cancer cells to paclitaxel and increased cell apoptosis rate under the treatment of paclitaxel, indicating that overexpressed miR-383-5p enhanced chemosensitivity in ovarian cancer cells.	Paclitaxel	93-103	microRNA 383	Homo sapiens	30-37
30399596-8	2019	In addition, up-regulation of miR-383-5p decreased the IC50 value of ovarian cancer cells to paclitaxel and increased cell apoptosis rate under the treatment of paclitaxel, indicating that overexpressed miR-383-5p enhanced chemosensitivity in ovarian cancer cells.	Paclitaxel	93-103	microRNA 383	Homo sapiens	203-210
30399596-8	2019	In addition, up-regulation of miR-383-5p decreased the IC50 value of ovarian cancer cells to paclitaxel and increased cell apoptosis rate under the treatment of paclitaxel, indicating that overexpressed miR-383-5p enhanced chemosensitivity in ovarian cancer cells.	Paclitaxel	161-171	microRNA 383	Homo sapiens	30-37
30399596-8	2019	In addition, up-regulation of miR-383-5p decreased the IC50 value of ovarian cancer cells to paclitaxel and increased cell apoptosis rate under the treatment of paclitaxel, indicating that overexpressed miR-383-5p enhanced chemosensitivity in ovarian cancer cells.	Paclitaxel	161-171	microRNA 383	Homo sapiens	203-210
30809285-7	2019	Results: PTX was able to restore pancreatic cancer sensitivity to MSC-delivered TRAIL by reverting its pro-survival gene expression profile.	Paclitaxel	9-12	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	80-85
30114390-3	2018	We had earlier shown that the microRNA-143 (miR-143) replenishment not only chemosensitizers CRC cell line with mutant KRAS instead of wild-type KRAS gene, to paclitaxel-mediated cytotoxicity, but also inhibits cell migration and invasion ability.	Paclitaxel	159-169	KRAS proto-oncogene, GTPase	Homo sapiens	119-123
30114390-3	2018	We had earlier shown that the microRNA-143 (miR-143) replenishment not only chemosensitizers CRC cell line with mutant KRAS instead of wild-type KRAS gene, to paclitaxel-mediated cytotoxicity, but also inhibits cell migration and invasion ability.	Paclitaxel	159-169	KRAS proto-oncogene, GTPase	Homo sapiens	145-149
30563080-8	2018	In obatoclax-treated 5637 and obatoclax + paclitaxel-treated HT1197 cells, the blockade of the autophagic flux correlated with apoptosis and was associated with caspase-dependent cleavage of beclin-1.	Paclitaxel	42-52	beclin 1	Homo sapiens	191-199
29627786-4	2018	There is little evidence of DEB employment in intracranial stenosis, especially of paclitaxel-eluted balloons (pDEB).	Paclitaxel	83-93	phosphodiesterase 6B	Homo sapiens	111-115
30444026-0	2018	Overexpression of the lncRNA FER1L4 inhibits paclitaxel tolerance of ovarian cancer cells via the regulation of the MAPK signaling pathway.	Paclitaxel	45-55	fer-1 like family member 4 (pseudogene)	Homo sapiens	29-35
30444026-11	2018	The upregulation of FER1L4 could promote the PTX sensitivity of ovarian cancer cells.	Paclitaxel	45-48	fer-1 like family member 4 (pseudogene)	Homo sapiens	20-26
30444026-12	2018	The increased level of FER1L4 could suppress the PTX resistance of ovarian cancer cells through the inhibition of the MAPK signaling pathway.	Paclitaxel	49-52	fer-1 like family member 4 (pseudogene)	Homo sapiens	23-29
30008286-6	2018	In cattle, manipulation of the microtubules of the spindle by nocodazole, taxol or cryopreservation revealed a close association with PAFAH1B3.	Paclitaxel	74-79	platelet activating factor acetylhydrolase 1b catalytic subunit 3	Bos taurus	134-142
29936386-0	2018	Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.	Paclitaxel	0-10	CD44 antigen	Mus musculus	24-28
29936386-4	2018	Compared with Taxol solution and HA-DOCA micelles, the cytotoxicity of PTX loaded in HA-DOCA-His micelles against drug-resistant tumor cells was improved significantly and possessed superior MDR-overcoming performance; this phenomenon is due to the increased intracellular PTX delivery by CD44 receptor-mediated endocytosis pathway and endosome-pH sensitivity-mediated PTX triggering release.	Paclitaxel	71-74	CD44 antigen	Mus musculus	289-293
30179591-4	2018	Paclitaxel caused upregulation of RAGE and CXCR4 in the dorsal root ganglia and macrophage accumulation in the sciatic nerve.	Paclitaxel	0-10	chemokine (C-X-C motif) receptor 4	Mus musculus	43-48
30126852-0	2018	LINC00473 promotes the Taxol resistance via miR-15a in colorectal cancer.	Paclitaxel	23-28	long intergenic non-protein coding RNA 473	Homo sapiens	0-9
30126852-8	2018	Moreover, in the Taxol-resistant HCT116, the LINC00473 level was further increased than that in HCT116.	Paclitaxel	17-22	long intergenic non-protein coding RNA 473	Homo sapiens	45-54
30126852-9	2018	Knockdown of LINC00473 restored the Taxol-induced cytotoxicity, inhibited the cell vitality, colony formation and induced apoptosis, impaired the ability of migration or invasion, but these effects could be abrogated by the inhibition of miR-15a.	Paclitaxel	36-41	long intergenic non-protein coding RNA 473	Homo sapiens	13-22
30126852-11	2018	Furthermore, inhibition of LINC00473 in vivo could overcome the Taxol resistance of CRC cells, could recover the expression of tumor suppressor miR-15a and chemotherapy-induced tumor regression, indicating that LINC00473 functioned as oncogene in CRC via miR-15a.	Paclitaxel	64-69	long intergenic non-protein coding RNA 473	Homo sapiens	27-36
29719197-0	2018	Metabolic cofactors NAD(P)H and FAD as potential indicators of cancer cell response to chemotherapy with paclitaxel.	Paclitaxel	105-115	BRCA2 DNA repair associated	Homo sapiens	32-35
29719197-3	2018	In this study we considered the auto-fluorescent metabolic cofactors NAD(P)H and FAD as possible indicators of cancer cell response to therapy with paclitaxel.	Paclitaxel	148-158	BRCA2 DNA repair associated	Homo sapiens	81-84
30087895-7	2018	Taxol eliminates microtubule dynamics, alters spindle microtubule arrangements, and inhibits dynein motor activity in vivo.	Paclitaxel	0-5	Dynein heavy chain 64C	Drosophila melanogaster	93-99
30087895-8	2018	If the dynein interpretation is correct, taxol should interfere with chromosome movements after kinetochore microtubules are severed because it alters the arrangements of spindle microtubules and because it blocks dynein activity.	Paclitaxel	41-46	Dynein heavy chain 64C	Drosophila melanogaster	7-13
30087895-8	2018	If the dynein interpretation is correct, taxol should interfere with chromosome movements after kinetochore microtubules are severed because it alters the arrangements of spindle microtubules and because it blocks dynein activity.	Paclitaxel	41-46	Dynein heavy chain 64C	Drosophila melanogaster	214-220
29641982-2	2018	However, the effectiveness of PTX is limited by resistance mechanisms mediated in part by upregulation of the anti-apoptotic BCL-2 and P-glycoprotein (P-gp).	Paclitaxel	30-33	phosphoglycolate phosphatase	Mus musculus	135-149
29641982-2	2018	However, the effectiveness of PTX is limited by resistance mechanisms mediated in part by upregulation of the anti-apoptotic BCL-2 and P-glycoprotein (P-gp).	Paclitaxel	30-33	phosphoglycolate phosphatase	Mus musculus	151-155
29808798-0	2018	Knockdown of SIRT1 inhibits proliferation and promotes apoptosis of paclitaxel-resistant human cervical cancer cells.	Paclitaxel	68-78	sirtuin 1	Homo sapiens	13-18
29808798-2	2018	This study investigates the role of Sirtuin 1 (SIRT1) in paclitaxel (PTX)-resistant CC lines.	Paclitaxel	57-67	sirtuin 1	Homo sapiens	36-45
29808798-2	2018	This study investigates the role of Sirtuin 1 (SIRT1) in paclitaxel (PTX)-resistant CC lines.	Paclitaxel	57-67	sirtuin 1	Homo sapiens	47-52
29808798-2	2018	This study investigates the role of Sirtuin 1 (SIRT1) in paclitaxel (PTX)-resistant CC lines.	Paclitaxel	69-72	sirtuin 1	Homo sapiens	36-45
29808798-2	2018	This study investigates the role of Sirtuin 1 (SIRT1) in paclitaxel (PTX)-resistant CC lines.	Paclitaxel	69-72	sirtuin 1	Homo sapiens	47-52
29808798-4	2018	We compared the expression levels of SIRT1 between sensitive CC cell lines and PTX-resistant cell lines.	Paclitaxel	79-82	sirtuin 1	Homo sapiens	37-42
29808798-5	2018	Subsequently, we used SIRT1 siRNA to knockdown the expression of SIRT1, and then measured cell proliferation, cell apoptosis rate, cell cycle distribution, and expression levels of Bcl-2 and Bax in PTX-sensitive Hela cell line, PTX-resistant Hela and Sila-resistant cell lines.	Paclitaxel	198-201	sirtuin 1	Homo sapiens	22-27
29808798-5	2018	Subsequently, we used SIRT1 siRNA to knockdown the expression of SIRT1, and then measured cell proliferation, cell apoptosis rate, cell cycle distribution, and expression levels of Bcl-2 and Bax in PTX-sensitive Hela cell line, PTX-resistant Hela and Sila-resistant cell lines.	Paclitaxel	198-201	sirtuin 1	Homo sapiens	65-70
29808798-7	2018	We found that SIRT1 expression was higher in PTX-sensitive CC tissues than in normal tissues, and significantly higher in PTX-resistant CC tissues than in PTX-sensitive CC tissues.	Paclitaxel	45-48	sirtuin 1	Homo sapiens	14-19
29808798-7	2018	We found that SIRT1 expression was higher in PTX-sensitive CC tissues than in normal tissues, and significantly higher in PTX-resistant CC tissues than in PTX-sensitive CC tissues.	Paclitaxel	122-125	sirtuin 1	Homo sapiens	14-19
29808798-7	2018	We found that SIRT1 expression was higher in PTX-sensitive CC tissues than in normal tissues, and significantly higher in PTX-resistant CC tissues than in PTX-sensitive CC tissues.	Paclitaxel	122-125	sirtuin 1	Homo sapiens	14-19
29808798-8	2018	We further demonstrated that knockdown of SIRT1 in PTX-resistant CC cell lines and PTX-sensitive CC cell line inhibited cell proliferation and promoted cell apoptosis.	Paclitaxel	51-54	sirtuin 1	Homo sapiens	42-47
29808798-9	2018	In addition, we observed that blocking SIRT1 expression in PTX-resistant CC cell lines significantly decreased MRP expression.	Paclitaxel	59-62	sirtuin 1	Homo sapiens	39-44
29808798-10	2018	SIRT1 exhibited high expression levels in both PTX-resistant cell lines and patients.	Paclitaxel	47-50	sirtuin 1	Homo sapiens	0-5
29808798-11	2018	Our results suggest that SIRT1 serves as a potential therapeutic target in PTX-resistant CC.	Paclitaxel	75-78	sirtuin 1	Homo sapiens	25-30
29723165-10	2018	Moreover, the results showed that p-JNK and Caspase 3 expression were significantly increased in IL-22 knockdown A549/PTX cells, while Bcl-2 expression was significantly decreased.	Paclitaxel	118-121	interleukin 22	Homo sapiens	97-102
29723165-11	2018	CONCLUSIONS IL-22 is involved in A549 cell resistance to PTX through regulating cell apoptosis via the JNK signaling pathway.	Paclitaxel	57-60	interleukin 22	Homo sapiens	12-17
29707994-6	2018	Aurora-B overexpression was also observed in NSCLC cells developing impaired response to both CDDP and paclitaxel.	Paclitaxel	103-113	aurora kinase B	Homo sapiens	0-8
29771087-6	2018	NPC had different chemosensitivity with 8 anticancer drugs(P&lt;0.001).There was a significant difference in chemosensitivity of paclitaxel between the high expression of C-fos group and the low expression of C-fos group(P=0.036).	Paclitaxel	129-139	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	171-176
29771087-6	2018	NPC had different chemosensitivity with 8 anticancer drugs(P&lt;0.001).There was a significant difference in chemosensitivity of paclitaxel between the high expression of C-fos group and the low expression of C-fos group(P=0.036).	Paclitaxel	129-139	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	209-214
29771087-8	2018	Conclusion:C-fos is highly expressed in NPC tissues, and the high expression of C-fos in NPC tissues may be related to tumor progression and resistance to paclitaxel.	Paclitaxel	155-165	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	80-85
29424266-3	2018	The silencing of ZFAS1 inhibited the growth, proliferation, cell cycle progress, migration, invasion and epithelial-mesenchymal transition (EMT), and enhanced the sensitivity to cis-platinum or paclitaxel in SGC7901 cells, as evidenced by the expression changes of proliferating cell nuclear antigen, Cyclin D1, Cyclin E, Cyclin B1, E-cadherin, N-cadherin, vimentin, matrix metalloproteinase (MMP)-2 and MMP-14.	Paclitaxel	194-204	ZNFX1 antisense RNA 1	Homo sapiens	17-22
29577187-0	2018	Combined Action of PGRPs-Hsp70 Cytotoxic Complex with Paclitaxel Improves Outcomes of Melanoma Treatment in Mice.	Paclitaxel	54-64	peptidoglycan recognition protein 1	Mus musculus	19-24
29350904-5	2018	Triggered by mild hyperthermia, HA-PTX/MATT-LTSLs HNPs rapidly release their payloads into the extracellular environment, and the released HA-PTX quickly enters 4T1 cells through a CD44-HA affinity.	Paclitaxel	35-38	CD44 antigen	Mus musculus	181-185
29421659-4	2018	We also demonstrate that RIP2 confers TNBC cell resistance against paclitaxel and ceramide-induced apoptosis.	Paclitaxel	67-77	receptor interacting serine/threonine kinase 2	Homo sapiens	25-29
29337310-0	2018	OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.	Paclitaxel	36-46	solute carrier organic anion transporter family, member 1b2	Mus musculus	0-7
29337310-2	2018	Here, we identified the murine solute carrier organic anion-transporting polypeptide B2 (OATP1B2) as a mediator of paclitaxel-induced neurotoxicity.	Paclitaxel	115-125	solute carrier organic anion transporter family, member 1b2	Mus musculus	89-96
29337310-3	2018	Additionally, using established tests to assess acute and chronic paclitaxel-induced neurotoxicity, we found that genetic or pharmacologic knockout of OATP1B2 protected mice from mechanically induced allodynia, thermal hyperalgesia, and changes in digital maximal action potential amplitudes.	Paclitaxel	66-76	solute carrier organic anion transporter family, member 1b2	Mus musculus	151-158
29238994-6	2018	Paclitaxel (PTX), a P-gp substrate anticancer drug, was orally administered to rats with/without compound 1 (8,10-bis(thiiran-2-ylmethoxy)-7H-benzo[c]xanthen-7-one).	Paclitaxel	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	20-24
29238994-6	2018	Paclitaxel (PTX), a P-gp substrate anticancer drug, was orally administered to rats with/without compound 1 (8,10-bis(thiiran-2-ylmethoxy)-7H-benzo[c]xanthen-7-one).	Paclitaxel	12-15	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	20-24
28424991-5	2018	To mimic Nav regulation in chronic pain, we treated hDRG neurons in primary cultures with paclitaxel (0.1-1 mumol/L) for 24 h. Paclitaxel increased the Nav1.7 but not Nav1.8 expression and also increased the transient Na+ currents and action potential firing frequency in small-diameter (&lt;50 mum) hDRG neurons.	Paclitaxel	90-100	sodium voltage-gated channel alpha subunit 9	Homo sapiens	152-158
28424991-5	2018	To mimic Nav regulation in chronic pain, we treated hDRG neurons in primary cultures with paclitaxel (0.1-1 mumol/L) for 24 h. Paclitaxel increased the Nav1.7 but not Nav1.8 expression and also increased the transient Na+ currents and action potential firing frequency in small-diameter (&lt;50 mum) hDRG neurons.	Paclitaxel	127-137	sodium voltage-gated channel alpha subunit 9	Homo sapiens	152-158
29079319-4	2018	MATERIALS AND METHODS: PINCH-1 expression was studied in two estrogen positive(T47D and MCF-7) and one estrogen negative cell lines before and after treatment with six drugs (Cyclophosphamide, Celecoxib, Doxorubicin, Paclitaxel, Etoposide and Tamoxifen).	Paclitaxel	217-227	LIM zinc finger domain containing 1	Homo sapiens	23-30
29079319-7	2018	Knocking down of PINCH-1 led to a significant (p-value&lt;0.05) enhancement in apoptosis in T47D cells in response to 4/6 (cyclophosphamide, celecoxib, paclitaxel, doxorubicin) drugs.	Paclitaxel	152-162	LIM zinc finger domain containing 1	Homo sapiens	17-24
29156532-7	2018	Subsequent microarray and qRT-PCR analysis further showed that miR-27a was significantly decreased in mice with sepsis, which was recovered by paclitaxel pretreatment.	Paclitaxel	143-153	microRNA 27a	Mus musculus	63-70
29156532-8	2018	Antagomir-miR-27a suppressed the therapeutic effects of paclitaxel in mice liver injury model via promoting inflammatory response.	Paclitaxel	56-66	microRNA 27a	Mus musculus	10-17
29156532-12	2018	Notably, the inhibitory effects of paclitaxel on NF-kappaB signaling pathway were reversed by antagomir-miR-27a.	Paclitaxel	35-45	microRNA 27a	Mus musculus	104-111
29156532-13	2018	Our data indicated that paclitaxel significantly attenuated septic induced liver injury through reducing inflammatory response via miR-27a/TAB3/NF-kappaB signaling pathway.	Paclitaxel	24-34	microRNA 27a	Mus musculus	131-138
29414807-16	2018	TPM2 knockdown significantly reduced cell sensitivity to paclitaxel.	Paclitaxel	57-67	tropomyosin 2	Homo sapiens	0-4
29414807-18	2018	TPM2 is associated with poor survival and chemoresistance to paclitaxel in breast cancer, and TPM2 may represent a promising therapeutic gene target for breast cancer patients with chemoresistance.	Paclitaxel	61-71	tropomyosin 2	Homo sapiens	0-4
28623645-6	2018	Moreover, we also found that PSMB5 knockdown induced TNBC apoptosis and significantly enhanced cancer cell sensitivity to the chemotherapeutic agents bortezomib and paclitaxel.	Paclitaxel	165-175	proteasome 20S subunit beta 5	Homo sapiens	29-34
29483955-10	2018	Moreover, the properties of more precise target and delayed release of PTX were proved by NIRF imaging.	Paclitaxel	71-74	interleukin 17B	Homo sapiens	90-94
29416635-9	2018	In silico analysis suggested that OTUD7B regulation, probably owing to miR-1180 downregulation, may negatively regulate the NF-kappaB-Lin28 axis which in turn triggers Let-7 microRNA-mediated caspase-3 downregulation, thereby conferring paclitaxel resistance in TNBCs.	Paclitaxel	237-247	microRNA 1180	Homo sapiens	71-79
29371916-5	2017	In vivo, IL-17B induced resistance to paclitaxel and treatment with an anti-IL-17RB neutralizing antibody completely restored breast tumor chemosensitivity, leading to tumor shrinkage.	Paclitaxel	38-48	interleukin 17B	Homo sapiens	9-15
29169729-4	2017	Ectopic expression of miR-193b-3p and PAK3 knockdown repressed cell proliferation, promoted paclitaxel-induced cytotoxicity, and reinforced paclitaxel-mediated caspase-3 activity increase in OC cells.	Paclitaxel	92-102	p21 (RAC1) activated kinase 3	Homo sapiens	38-42
29169729-4	2017	Ectopic expression of miR-193b-3p and PAK3 knockdown repressed cell proliferation, promoted paclitaxel-induced cytotoxicity, and reinforced paclitaxel-mediated caspase-3 activity increase in OC cells.	Paclitaxel	140-150	p21 (RAC1) activated kinase 3	Homo sapiens	38-42
29169729-6	2017	Moreover, enforced expression of PAK3 partially overturned the effects of miR-193b-3p on OC cell proliferation and paclitaxel sensitivity.	Paclitaxel	115-125	p21 (RAC1) activated kinase 3	Homo sapiens	33-37
29299167-6	2017	When miR-128 was stably expressed in PTX-resistant lung cancer stem cells, the cells showed decreased proliferation, metastasis, self-renewal, migration, invasive ability, clonogenicity, and tumorigenicity in vitro and in vivo and increased apoptosis compared with miR-NC (negative control) CSCs.	Paclitaxel	37-40	membrane associated ring-CH-type finger 8	Homo sapiens	5-8
29299167-6	2017	When miR-128 was stably expressed in PTX-resistant lung cancer stem cells, the cells showed decreased proliferation, metastasis, self-renewal, migration, invasive ability, clonogenicity, and tumorigenicity in vitro and in vivo and increased apoptosis compared with miR-NC (negative control) CSCs.	Paclitaxel	37-40	membrane associated ring-CH-type finger 8	Homo sapiens	265-268
29299167-9	2017	These results suggested miR-128 as an attractive therapeutic strategy for PTX-resistant lung cancer via inhibition of BMI-1 and MUC1-C.	Paclitaxel	74-77	membrane associated ring-CH-type finger 8	Homo sapiens	24-27
32264281-0	2017	Correction: Stent containing CD44-targeting polymeric prodrug nanoparticles that release paclitaxel and gemcitabine in a time interval-controlled manner for synergistic human biliary cancer therapy.	Paclitaxel	89-99	CD44 molecule (Indian blood group)	Homo sapiens	29-33
32264281-1	2017	Correction for "Stent containing CD44-targeting polymeric prodrug nanoparticles that release paclitaxel and gemcitabine in a time interval-controlled manner for synergistic human biliary cancer therapy" by Dayeon Yun et al., J.	Paclitaxel	93-103	CD44 molecule (Indian blood group)	Homo sapiens	33-37
29180871-5	2017	MTT, flow cytometry, and Western blot assays were used to assess the effect of NEAT1 on PTX resistance in PTX-resistant ovarian cancer cells.	Paclitaxel	88-91	nuclear paraspeckle assembly transcript 1	Homo sapiens	79-84
29180871-5	2017	MTT, flow cytometry, and Western blot assays were used to assess the effect of NEAT1 on PTX resistance in PTX-resistant ovarian cancer cells.	Paclitaxel	106-109	nuclear paraspeckle assembly transcript 1	Homo sapiens	79-84
29180871-7	2017	Xenograft tumor model was established to confirm the biological role of NEAT1 in PTX resistance of ovarian cancer in vivo.	Paclitaxel	81-84	nuclear paraspeckle assembly transcript 1	Homo sapiens	72-77
29180871-8	2017	Results: NEAT1 was upregulated, and miR-194 was downregulated in PTX-resistant ovarian cancer tissues and cells.	Paclitaxel	65-68	nuclear paraspeckle assembly transcript 1	Homo sapiens	9-14
29180871-9	2017	Functionally, NEAT1 knockdown enhanced cell sensitivity to PTX via promoting PTX-induced apoptosis in vitro.	Paclitaxel	59-62	nuclear paraspeckle assembly transcript 1	Homo sapiens	14-19
29180871-9	2017	Functionally, NEAT1 knockdown enhanced cell sensitivity to PTX via promoting PTX-induced apoptosis in vitro.	Paclitaxel	77-80	nuclear paraspeckle assembly transcript 1	Homo sapiens	14-19
29180871-11	2017	Mechanistically, NEAT1-knockdown-induced PTX sensitivity was mediated by miR-194/ZEB1 axis.	Paclitaxel	41-44	nuclear paraspeckle assembly transcript 1	Homo sapiens	17-22
29180871-11	2017	Mechanistically, NEAT1-knockdown-induced PTX sensitivity was mediated by miR-194/ZEB1 axis.	Paclitaxel	41-44	zinc finger E-box binding homeobox 1	Homo sapiens	81-85
29180871-12	2017	Moreover, NEAT1 knockdown improved PTX sensitivity of ovarian cancer in vivo.	Paclitaxel	35-38	nuclear paraspeckle assembly transcript 1	Homo sapiens	10-15
29180871-13	2017	Conclusion: NEAT1 contributed to PTX resistance of ovarian cancer cells at least partly through upregulating ZEB1 expression by sponging miR-194, elucidating a novel regulatory pathway of chemoresistance in PTX-resistant ovarian cancer cells and providing a possible long noncoding RNA (lncRNA)-targeted therapy for ovarian cancer.	Paclitaxel	33-36	nuclear paraspeckle assembly transcript 1	Homo sapiens	12-17
29180871-13	2017	Conclusion: NEAT1 contributed to PTX resistance of ovarian cancer cells at least partly through upregulating ZEB1 expression by sponging miR-194, elucidating a novel regulatory pathway of chemoresistance in PTX-resistant ovarian cancer cells and providing a possible long noncoding RNA (lncRNA)-targeted therapy for ovarian cancer.	Paclitaxel	33-36	zinc finger E-box binding homeobox 1	Homo sapiens	109-113
29180871-13	2017	Conclusion: NEAT1 contributed to PTX resistance of ovarian cancer cells at least partly through upregulating ZEB1 expression by sponging miR-194, elucidating a novel regulatory pathway of chemoresistance in PTX-resistant ovarian cancer cells and providing a possible long noncoding RNA (lncRNA)-targeted therapy for ovarian cancer.	Paclitaxel	207-210	nuclear paraspeckle assembly transcript 1	Homo sapiens	12-17
29180871-13	2017	Conclusion: NEAT1 contributed to PTX resistance of ovarian cancer cells at least partly through upregulating ZEB1 expression by sponging miR-194, elucidating a novel regulatory pathway of chemoresistance in PTX-resistant ovarian cancer cells and providing a possible long noncoding RNA (lncRNA)-targeted therapy for ovarian cancer.	Paclitaxel	207-210	zinc finger E-box binding homeobox 1	Homo sapiens	109-113
28950656-8	2017	Mechanistically, the combination treatment was more efficient than paclitaxel monotherapy in reducing ATP, MDA, TNF-alpha and Il-17 contents in SEC.	Paclitaxel	67-77	interleukin 17A	Mus musculus	126-131
28856937-6	2017	In vivo, AP/PTX-SLNs were revealed to be much more effective in suppressing tumor growth in B16F10-bearing mice and in eliminating cancer cells in the lungs than single drug (AP or PTX)-loaded SLNs via a synergistic effect through reducing the Bcl-2/Bax ratio.	Paclitaxel	12-15	BCL2-associated X protein	Mus musculus	250-253
28816404-0	2017	Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin alphaV beta3.	Paclitaxel	66-76	integrin subunit alpha V	Homo sapiens	91-112
28816404-2	2017	These constructs were assembled by conjugation of the integrin alphaV beta3 ligand cyclo[DKP-RGD]-CH2 NH2 with paclitaxel via a 2"-carbamate with a self-immolative spacer, the lysosomally cleavable Val-Ala dipeptide linker, a multimeric scaffold, a triazole linkage, and finally a PEG spacer.	Paclitaxel	111-121	integrin subunit alpha V	Homo sapiens	54-75
28779263-11	2017	Both annexin V-FITC/propidium iodide assay and TUNEL assay indicated that the combination of tunicamycin with paclitaxel resulted in significant increased cell apoptosis as compared with individual treatment in vitro and in vivo.	Paclitaxel	110-120	annexin A5	Mus musculus	5-14
28692634-0	2017	Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.	Paclitaxel	41-51	forkhead box M1	Homo sapiens	10-15
28692634-3	2017	We aimed to determine if targeting the FOXM1 pathway with thiostrepton could improve the efficacy of paclitaxel and cisplatin in human ovarian cancer ascites cells ex vivo.	Paclitaxel	101-111	forkhead box M1	Homo sapiens	39-44
28704328-13	2017	CONCLUSIONS: Adding HCT to routine DXM prophylaxis significantly decreased paclitaxel HSR frequency.	Paclitaxel	75-85	HSR	Homo sapiens	86-89
28631095-10	2017	The systemic administration of rAAV-DCN up-regulates DCN in neuroblastoma and accelerates the intratumoral uptake of nab-paclitaxel by inhibiting stabilin-1 mediated SPARC degradation.	Paclitaxel	121-131	stabilin 1	Mus musculus	146-156
29113360-6	2017	Cell viability and Annexin V/PI staining showed that miR-488 downregulated cell survival and increased apoptosis rate when treated with cisplatin and paclitaxel.	Paclitaxel	150-160	microRNA 488	Homo sapiens	53-60
28849826-0	2017	Multifunctional nanoparticles for co-delivery of paclitaxel and carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis.	Paclitaxel	49-59	lysine demethylase 6B	Homo sapiens	119-124
28205290-10	2017	In addition, P-gp efflux studies on free and micellar paclitaxel showed the proficiency of PEG2000 -DSPE micelles in evading P-gp-mediated efflux, thus increasing paclitaxel uptake.	Paclitaxel	163-173	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	13-17
28205290-10	2017	In addition, P-gp efflux studies on free and micellar paclitaxel showed the proficiency of PEG2000 -DSPE micelles in evading P-gp-mediated efflux, thus increasing paclitaxel uptake.	Paclitaxel	163-173	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	125-129
28835684-0	2017	Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.	Paclitaxel	58-68	SRY-box transcription factor 2	Homo sapiens	14-18
28835684-11	2017	This study eventually established that SOX2 silencing of CSCs along with paclitaxel treatment reduced SOX2-ABCG2-TWIST1 expression, disrupted sphere forming capacity and also reduced invasiveness by retaining epithelial-like properties of the cells, thereby suggesting a more comprehensive therapy for TNBC patients in future.	Paclitaxel	73-83	SRY-box transcription factor 2	Homo sapiens	102-106
29069826-0	2017	miR-150 enhances apoptotic and anti-tumor effects of paclitaxel in paclitaxel-resistant ovarian cancer cells by targeting Notch3.	Paclitaxel	53-63	microRNA 150	Homo sapiens	0-7
29069826-0	2017	miR-150 enhances apoptotic and anti-tumor effects of paclitaxel in paclitaxel-resistant ovarian cancer cells by targeting Notch3.	Paclitaxel	67-77	microRNA 150	Homo sapiens	0-7
29069826-6	2017	Treatment with pre-miR-150 significantly inhibited cancer cell proliferation, and induced apoptosis in PTX (paclitaxel) -resistant SKpac cells, which was not seen by PTX only treatment.	Paclitaxel	103-106	microRNA 150	Homo sapiens	19-26
29069826-6	2017	Treatment with pre-miR-150 significantly inhibited cancer cell proliferation, and induced apoptosis in PTX (paclitaxel) -resistant SKpac cells, which was not seen by PTX only treatment.	Paclitaxel	108-118	microRNA 150	Homo sapiens	19-26
29069826-6	2017	Treatment with pre-miR-150 significantly inhibited cancer cell proliferation, and induced apoptosis in PTX (paclitaxel) -resistant SKpac cells, which was not seen by PTX only treatment.	Paclitaxel	166-169	microRNA 150	Homo sapiens	19-26
29069826-7	2017	On spheroid forming assay, an additional pre-miR-150 treatment with PTX decreased cancer stem cell activation in PTX-resistant SKpac cells.	Paclitaxel	68-71	microRNA 150	Homo sapiens	45-52
29069826-10	2017	Taken together, miR-150 is related with PTX-resistance in ovarian cancer, and treatment with pre-miR-150 resensitizes cancer cells to PTX.	Paclitaxel	40-43	microRNA 150	Homo sapiens	16-23
29069826-10	2017	Taken together, miR-150 is related with PTX-resistance in ovarian cancer, and treatment with pre-miR-150 resensitizes cancer cells to PTX.	Paclitaxel	40-43	microRNA 150	Homo sapiens	97-104
29069826-10	2017	Taken together, miR-150 is related with PTX-resistance in ovarian cancer, and treatment with pre-miR-150 resensitizes cancer cells to PTX.	Paclitaxel	134-137	microRNA 150	Homo sapiens	97-104
29245917-7	2017	Although PTX-sensitivity was not changed by silencing ZEB1 in parental EOC cells, the depletion of ZEB1 made the PTX-resistant EOC cells more sensitive to PTX treatment.	Paclitaxel	113-116	zinc finger E-box binding homeobox 1	Homo sapiens	99-103
29245917-10	2017	The current data indicate the possible involvement of ZEB1 in the metastasis and paclitaxel resistance of EOC, and suggest that targeting this molecule may reverse the malignant potential and improve the oncologic outcome for EOC patients.	Paclitaxel	81-91	zinc finger E-box binding homeobox 1	Homo sapiens	54-58
27727202-0	2017	Paclitaxel-coated versus plain old balloon angioplasty for the treatment of infrainguinal arterial disease in diabetic patients: the Belgian diabetic IN.PACT Trial.	Paclitaxel	0-10	RB binding protein 6, ubiquitin ligase	Homo sapiens	153-157
29256224-0	2017	[Effects of lncRNA RP11-770J1.3 and TMEM25 expression on paclitaxel resistance in human breast cancer cells].	Paclitaxel	57-67	pre-mRNA processing factor 31	Homo sapiens	19-23
29256224-1	2017	OBJECTIVE: To investigate the effects of long non-coding RNA(lncRNA) RP11-770J1.3 and transmembrane protein 25 (TMEM25) on paclitaxel resistance in human breast cancer MCF-7/PR cell line.	Paclitaxel	123-133	pre-mRNA processing factor 31	Homo sapiens	69-73
29256224-2	2017	METHODS: The expression of lncRNA RP11-770J1.3 and TMEM25 in human breast cancer MCF-7(paclitaxel sensitive) and MCF-7/PR(paclitaxel resistant) cells were detected by quantitative RT-PCR.	Paclitaxel	87-97	pre-mRNA processing factor 31	Homo sapiens	34-38
29256224-2	2017	METHODS: The expression of lncRNA RP11-770J1.3 and TMEM25 in human breast cancer MCF-7(paclitaxel sensitive) and MCF-7/PR(paclitaxel resistant) cells were detected by quantitative RT-PCR.	Paclitaxel	122-132	pre-mRNA processing factor 31	Homo sapiens	34-38
29256224-4	2017	Sulforhodamine B assay was used to detect the sensitivity of MCF-7/PR cells to paclitaxel after interference of lncRNA RP11-770J1.3 and TMEM25.	Paclitaxel	79-89	pre-mRNA processing factor 31	Homo sapiens	119-123
29256224-7	2017	Down-regulation of lncRNA RP11-770J1.3 and TMEM25 enhanced the sensitivity of MCF-7/PR cells to paclitaxel, and inhibited the expression of MRP, BCRP and MDR1/P-gp (all P&lt;0.05).	Paclitaxel	96-106	pre-mRNA processing factor 31	Homo sapiens	26-30
29256224-9	2017	CONCLUSIONS: lncRNA RP11-770J1.3 and TMEM25 are highly expressed in MCF-7/PR cells, and the down-regulation of lncRNA RP11-770J1.3 and TMEM25 can enhance paclitaxel sensitivity in MCF-7/PR cells.	Paclitaxel	154-164	pre-mRNA processing factor 31	Homo sapiens	20-24
29256224-9	2017	CONCLUSIONS: lncRNA RP11-770J1.3 and TMEM25 are highly expressed in MCF-7/PR cells, and the down-regulation of lncRNA RP11-770J1.3 and TMEM25 can enhance paclitaxel sensitivity in MCF-7/PR cells.	Paclitaxel	154-164	pre-mRNA processing factor 31	Homo sapiens	118-122
28726784-2	2017	In this study, we show that Sorcin is able to bind doxorubicin, vincristine, paclitaxel and cisplatin directly and with high affinity.	Paclitaxel	77-87	sorcin	Homo sapiens	28-34
28729624-3	2017	Exposure of primary cultured rat Schwann cells to paclitaxel (0.01 muM), cisplatin (1 muM), or oxaliplatin (3 muM) for 48 h induced cytotoxicity and reduced myelin basic protein expression at concentrations lower than those required to induce neurotoxicity in cultured rat dorsal root ganglion (DRG) neurons.	Paclitaxel	50-60	myelin basic protein	Rattus norvegicus	157-177
28599307-0	2017	Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis.	Paclitaxel	57-67	microRNA 155	Homo sapiens	76-83
28599307-12	2017	In conclusion, morin might be a potential adjuvant of paclitaxel in treating prostate cancer through regulating miR-155/GATA3 axis.	Paclitaxel	54-64	microRNA 155	Homo sapiens	112-119
28187446-6	2017	Gene expression profiling of paclitaxel-residual, -resistant and naive MDA-MB-231 cells demonstrated that paclitaxel-residual, as opposed to -resistant cells, were characterized by an apoptotic signature, with downregulation of anti-apoptotic genes (BCL2, BIRC5), induction of apoptosis inducers (IL24, PDCD4), and enrichment of TNFalpha/NF-kappaB pathway, including upregulation of TNFSF15, coupled with cell-cycle arrest.	Paclitaxel	106-116	baculoviral IAP repeat containing 5	Homo sapiens	256-261
28498513-6	2017	The inhibition of Beclin 1 or TRP14 by siRNA increased the sensitivity of the tumor cells to paclitaxel.	Paclitaxel	93-103	beclin 1	Homo sapiens	18-26
28158929-11	2017	Substitution with a tetrahydropyran group at C-2 produced potent analgesic and anti-inflammatory effects, including a reduction in paclitaxel-induced neuropathic pain.	Paclitaxel	131-141	complement component 2 (within H-2S)	Mus musculus	45-48
28604448-11	2017	Furthermore, either MAP2K6-FP alone or in combination with paclitaxel increased the ratio of expressions of Beclin-1/Bcl-2, another autophagy-related markers, compared with paclitaxel alone.	Paclitaxel	59-69	beclin 1	Homo sapiens	108-116
28952225-0	2017	VHL-TGFBI signaling is involved in the synergy between 5-aza-2"-deoxycytidine and paclitaxel against human renal cell carcinoma.	Paclitaxel	82-92	transforming growth factor beta induced	Homo sapiens	4-9
28952225-1	2017	PURPOSE: To analyse the role of von Hippel-Lindau (VHL) and transforming growth factor beta-induced (TGFBI) in synergistic mechanisms of 5-aza-2"-deoxycytidine (DAC) and paclitaxel (PTX) against renal cell carcinoma (RCC).	Paclitaxel	170-180	transforming growth factor beta induced	Homo sapiens	60-99
28952225-2	2017	METHODS: To elucidate the role in the synergy between DAC and PTX against RCC cells, TGFBI expression was regulated using siRNA technology and an expression vector containing the full-length cDNA for TGFBI was also transfected into RCC cells.	Paclitaxel	62-65	transforming growth factor beta induced	Homo sapiens	85-90
28952225-4	2017	RESULTS: The results indicated that the expression of TGFBI was significantly decreased by DAC or PTX alone in vitro and in vivo.	Paclitaxel	98-101	transforming growth factor beta induced	Homo sapiens	54-59
28952225-5	2017	Moreover, the combination of DAC and PTX caused a synergistic decrease in the expression of TGFBI in RCC cells.	Paclitaxel	37-40	transforming growth factor beta induced	Homo sapiens	92-97
28952225-8	2017	CONCLUSION: Our study suggests that VHL-TGFBI signaling is involved in the synergy between DAC and PTX against RCC cells.	Paclitaxel	99-102	transforming growth factor beta induced	Homo sapiens	40-45
28541630-1	2017	OBJECTIVE: To report on the incidence of nab-paclitaxel hypersensitivity reactions (HSRs) in patients with prior taxane HSR.	Paclitaxel	45-55	HSR	Homo sapiens	84-87
28541630-4	2017	RESULTS: We identified 37 patients with gynecologic malignancies with a history of paclitaxel HSR who received nab-paclitaxel.	Paclitaxel	83-93	HSR	Homo sapiens	94-97
28541630-5	2017	Six patients (16.2%) had a prior HSR to both paclitaxel and docetaxel while the other 31 patients had not received docetaxel.	Paclitaxel	45-55	HSR	Homo sapiens	33-36
28416606-9	2017	The isoform shift of RSRC2 from RSRC2s to RSRC2l leads to a decreased RSRC2 protein expression, which could contribute to TNBC paclitaxel resistance.	Paclitaxel	127-137	arginine and serine rich coiled-coil 2	Homo sapiens	21-26
28416606-9	2017	The isoform shift of RSRC2 from RSRC2s to RSRC2l leads to a decreased RSRC2 protein expression, which could contribute to TNBC paclitaxel resistance.	Paclitaxel	127-137	arginine and serine rich coiled-coil 2	Homo sapiens	32-37
28416606-9	2017	The isoform shift of RSRC2 from RSRC2s to RSRC2l leads to a decreased RSRC2 protein expression, which could contribute to TNBC paclitaxel resistance.	Paclitaxel	127-137	arginine and serine rich coiled-coil 2	Homo sapiens	32-37
28416606-9	2017	The isoform shift of RSRC2 from RSRC2s to RSRC2l leads to a decreased RSRC2 protein expression, which could contribute to TNBC paclitaxel resistance.	Paclitaxel	127-137	arginine and serine rich coiled-coil 2	Homo sapiens	32-37
28416606-12	2017	Collectively, our findings suggest that paclitaxel targets the TRA2A-RSRC2 splicing pathway, and deregulated TRA2A and RSRC2 expression may confer paclitaxel resistance.	Paclitaxel	40-50	arginine and serine rich coiled-coil 2	Homo sapiens	69-74
28702476-5	2017	Intermittent expression of either NT-3 or IL-10 3 days before and 1 day after paclitaxel administration protected animals against paclitaxel-induced peripheral neuropathy over the course of 5 weeks.	Paclitaxel	78-88	interleukin 10	Homo sapiens	42-47
28702476-5	2017	Intermittent expression of either NT-3 or IL-10 3 days before and 1 day after paclitaxel administration protected animals against paclitaxel-induced peripheral neuropathy over the course of 5 weeks.	Paclitaxel	130-140	interleukin 10	Homo sapiens	42-47
28615627-6	2017	Partial silencing of S100A4 suppressed migratory capabilities of TMD cells, while Paclitaxel decreased the S100A4 level and reduced TMD"s cellular motility.	Paclitaxel	82-92	S100 calcium binding protein A4	Homo sapiens	107-113
28326458-0	2017	Vitamin E-rich Nanoemulsion Enhances the Antitumor Efficacy of Low-Dose Paclitaxel by Driving Th1 Immune Response.	Paclitaxel	72-82	negative elongation factor complex member C/D	Homo sapiens	94-97
28326458-8	2017	CONCLUSIONS: Vitamin E-rich nanoemulsion has great potential for the treatment of breast cancers with a low dose of paclitaxel via driving Th1 immune response.	Paclitaxel	116-126	negative elongation factor complex member C/D	Homo sapiens	139-142
28285942-12	2017	Co-immunoprecipitation experiments revealed the presence of the PSD95-nNOS complex in lumbar spinal cord of paclitaxel-treated rats, although ZL006 did not reliably disrupt the complex in all subjects.	Paclitaxel	108-118	nitric oxide synthase 1	Rattus norvegicus	70-74
28614779-10	2017	Doxorubicin, PTX and DTX induced OS, DNA damage and changes in expression of TNF-alpha, nNOS and PARP-1 in the rat brain.	Paclitaxel	13-16	nitric oxide synthase 1	Rattus norvegicus	88-92
28095398-0	2017	Aurora B expression modulates paclitaxel response in non-small cell lung cancer.	Paclitaxel	30-40	aurora kinase B	Homo sapiens	0-8
28095398-8	2017	Aurora B expression in cell lines strongly correlated with sensitivity to both docetaxel (P=0.004) and paclitaxel (P=0.007).	Paclitaxel	103-113	aurora kinase B	Homo sapiens	0-8
28095398-9	2017	Aurora B knockdown derivatives consistently showed a dose-dependent association between low-AURKB expression and resistance to paclitaxel.	Paclitaxel	127-137	aurora kinase B	Homo sapiens	0-8
28095398-9	2017	Aurora B knockdown derivatives consistently showed a dose-dependent association between low-AURKB expression and resistance to paclitaxel.	Paclitaxel	127-137	aurora kinase B	Homo sapiens	92-97
28095398-10	2017	Specific chemical inhibition of Aurora B activity also demonstrated a strong dose-dependent efficiency in triggering paclitaxel resistance.	Paclitaxel	117-127	aurora kinase B	Homo sapiens	32-40
28146436-5	2017	Moreover, the expression of CASC9 was even higher in BGC823/DR and SGC7901/DR cells that are resistant to paclitaxel or adriamycin.	Paclitaxel	106-116	cancer susceptibility 9	Homo sapiens	28-33
28146436-8	2017	In addition, CASC9 knockdown in BGC823/DR and SGC7901/DR cells restored chemosensitivity to paclitaxel and adriamycin.	Paclitaxel	92-102	cancer susceptibility 9	Homo sapiens	13-18
27435393-0	2017	Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.	Paclitaxel	81-91	CCAAT enhancer binding protein delta	Homo sapiens	29-34
29258089-0	2017	Rsf-1 Influences the Sensitivity of Non-Small Cell Lung Cancer to Paclitaxel by Regulating NF-kappaB Pathway and Its Downstream Proteins.	Paclitaxel	66-76	remodeling and spacing factor 1	Homo sapiens	0-5
29258089-2	2017	Rsf-1 enhanced paclitaxel resistance via nuclear factor-kappaB (NF-kappaB) in ovarian cancer cells and nasopharyngeal carcinoma.	Paclitaxel	15-25	remodeling and spacing factor 1	Homo sapiens	0-5
29258089-3	2017	This study assessed the function of Rsf-1 in the modulation of the sensitivity of NSCLC to paclitaxel via the NF-kappaB pathway.	Paclitaxel	91-101	remodeling and spacing factor 1	Homo sapiens	36-41
29258089-11	2017	Rsf-1 knockout increased the inhibition of cell proliferation, the reduction in cell migration and the augment in cell apoptosis in paclitaxel treated H460 and H1299 cells.	Paclitaxel	132-142	remodeling and spacing factor 1	Homo sapiens	0-5
29258089-12	2017	Rsf-1 knockout further enhanced the paclitaxel-mediated decrease in the volume and weight of the tumors in H460 cell xenograft mice.	Paclitaxel	36-46	remodeling and spacing factor 1	Homo sapiens	0-5
29258089-14	2017	CONCLUSION: These results demonstrate that Rsf-1 influences the sensitivity of NSCLC to paclitaxel via regulation of the NF-kappaB pathway and its downstream genes.	Paclitaxel	88-98	remodeling and spacing factor 1	Homo sapiens	43-48
27864640-4	2017	Treatment with the microtubule-stabilizing drug paclitaxel resulted in less growth inhibition and decreased rightward slant of roots, longitudinal alignment of microtubules, and enhanced length of hypocotyl epidermal cells in the pldalpha1 mutant, the phenotype of which was rescued by exogenous application of PA.	Paclitaxel	48-58	phospholipase D alpha 1	Arabidopsis thaliana	230-239
27992556-2	2016	A recent study in mice showed that VEGF receptor inhibitors can interfere with the neuroprotective effects of endogenous VEGF, potentially triggering the exacerbation of PTX-induced neuropathy.	Paclitaxel	170-173	vascular endothelial growth factor A	Mus musculus	35-39
27992556-2	2016	A recent study in mice showed that VEGF receptor inhibitors can interfere with the neuroprotective effects of endogenous VEGF, potentially triggering the exacerbation of PTX-induced neuropathy.	Paclitaxel	170-173	vascular endothelial growth factor A	Mus musculus	121-125
27796093-1	2016	A novel CD44 receptor targeting and endosome pH-sensitive dual functional hyaluronic acid-deoxycholic acid-histidine (HA-DOCA-His) micellar system was designed for intracellular paclitaxel (PTX) delivery.	Paclitaxel	178-188	CD44 molecule (Indian blood group)	Homo sapiens	8-12
27796093-1	2016	A novel CD44 receptor targeting and endosome pH-sensitive dual functional hyaluronic acid-deoxycholic acid-histidine (HA-DOCA-His) micellar system was designed for intracellular paclitaxel (PTX) delivery.	Paclitaxel	190-193	CD44 molecule (Indian blood group)	Homo sapiens	8-12
28105187-2	2016	In our preliminary experiments, it was observed that the expression of the ATF2 protein was induced following treatment with adriamycin (ADR) and paclitaxel (PTX), which may be regulated by internal ribosome entry segment (IRES)-mediated translation.	Paclitaxel	146-156	activating transcription factor 2	Homo sapiens	75-79
28105187-2	2016	In our preliminary experiments, it was observed that the expression of the ATF2 protein was induced following treatment with adriamycin (ADR) and paclitaxel (PTX), which may be regulated by internal ribosome entry segment (IRES)-mediated translation.	Paclitaxel	158-161	activating transcription factor 2	Homo sapiens	75-79
28105187-5	2016	In addition, it was observed that ADR and PTX also induced ATF2 IRES activity in Bel7402 cells.	Paclitaxel	42-45	activating transcription factor 2	Homo sapiens	59-63
28105187-6	2016	The present study has demonstrated that ATF2 translation is initiated via IRES, which is upregulated by ADR and PTX, thus suggesting that the regulation of the IRES-dependent translation of ATF2 may be involved in effecting the cancer cell response to chemotherapeutic drugs-mediated cellular stress.	Paclitaxel	112-115	activating transcription factor 2	Homo sapiens	40-44
28105187-6	2016	The present study has demonstrated that ATF2 translation is initiated via IRES, which is upregulated by ADR and PTX, thus suggesting that the regulation of the IRES-dependent translation of ATF2 may be involved in effecting the cancer cell response to chemotherapeutic drugs-mediated cellular stress.	Paclitaxel	112-115	activating transcription factor 2	Homo sapiens	190-194
27716814-0	2016	Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy.	Paclitaxel	61-71	N-myc downstream regulated 1	Homo sapiens	14-19
27716814-2	2016	We investigated the relationship between the Charcot-Marie-Tooth protein NDRG1 and paclitaxel-induced neuropathy.	Paclitaxel	83-93	N-myc downstream regulated 1	Homo sapiens	73-78
27716814-5	2016	NDRG1 scores were correlated with paclitaxel induced neuropathy.	Paclitaxel	34-44	N-myc downstream regulated 1	Homo sapiens	0-5
27716814-11	2016	CONCLUSION: Low NDRG1 expression in nerve tissue present within samples of surgical resection may identify subjects at risk for severe paclitaxel-induced neuropathy.	Paclitaxel	135-145	N-myc downstream regulated 1	Homo sapiens	16-21
27343697-7	2016	Mechanism studies demonstrated that these improvements could be correlated with increased cellular uptake of PTX mediated by scavenger receptor class B type I (SR-BI) as well as prolonged intracellular retention of PTX due to the HZ08 mediated drug-efflux inhibition.	Paclitaxel	109-112	scavenger receptor class B member 1	Homo sapiens	125-158
27343697-7	2016	Mechanism studies demonstrated that these improvements could be correlated with increased cellular uptake of PTX mediated by scavenger receptor class B type I (SR-BI) as well as prolonged intracellular retention of PTX due to the HZ08 mediated drug-efflux inhibition.	Paclitaxel	109-112	scavenger receptor class B member 1	Homo sapiens	160-165
27422809-6	2016	The addition of paclitaxel further increased cell kill and significantly reduced tumor growth in an HN5 xenograft model.	Paclitaxel	16-26	MT-RNR2 like 5 (pseudogene)	Homo sapiens	100-103
27409838-12	2016	Also, FBXW7, MCL1 and PLK1 may be relevant predictive markers of tumor progression and response to paclitaxel treatment.	Paclitaxel	99-109	polo like kinase 1	Homo sapiens	22-26
27312786-0	2016	Neuroglobin overexpression induced by the 17beta-Estradiol-Estrogen receptor-alpha Pathway reduces the sensitivity of MCF-7 Breast cancer cell to paclitaxel.	Paclitaxel	146-156	neuroglobin	Homo sapiens	0-11
27312786-4	2016	Here, the effect of the E2/ERalpha-dependent upregulation of neuroglobin (NGB), an antiapoptotic globin, on the reduced sensitivity of breast cancer cells to paclitaxel-induced apoptosis has been evaluated in ERalpha-containing MCF-7 cells.	Paclitaxel	158-168	cystatin 12, pseudogene	Homo sapiens	24-34
27312786-4	2016	Here, the effect of the E2/ERalpha-dependent upregulation of neuroglobin (NGB), an antiapoptotic globin, on the reduced sensitivity of breast cancer cells to paclitaxel-induced apoptosis has been evaluated in ERalpha-containing MCF-7 cells.	Paclitaxel	158-168	neuroglobin	Homo sapiens	61-72
27312786-4	2016	Here, the effect of the E2/ERalpha-dependent upregulation of neuroglobin (NGB), an antiapoptotic globin, on the reduced sensitivity of breast cancer cells to paclitaxel-induced apoptosis has been evaluated in ERalpha-containing MCF-7 cells.	Paclitaxel	158-168	neuroglobin	Homo sapiens	74-77
27312786-6	2016	NGB displays a pivotal role in the E2/ERalpha-induced antiapoptotic pathway to abrogate paclitaxel-induced cell death in stable NGB-silenced MCF-7 cell clones.	Paclitaxel	88-98	neuroglobin	Homo sapiens	0-3
27312786-6	2016	NGB displays a pivotal role in the E2/ERalpha-induced antiapoptotic pathway to abrogate paclitaxel-induced cell death in stable NGB-silenced MCF-7 cell clones.	Paclitaxel	88-98	cystatin 12, pseudogene	Homo sapiens	35-45
27312786-6	2016	NGB displays a pivotal role in the E2/ERalpha-induced antiapoptotic pathway to abrogate paclitaxel-induced cell death in stable NGB-silenced MCF-7 cell clones.	Paclitaxel	88-98	neuroglobin	Homo sapiens	128-131
27312786-7	2016	Moreover, in the absence of the active ERalpha, paclitaxel significantly reduces the NGB cell content.	Paclitaxel	48-58	neuroglobin	Homo sapiens	85-88
26850595-3	2016	MTT cell viability assays revealed that the sensitivities of ovarian cancer lines to cisplatin and paclitaxel increased following transfection with miR-873 (P &lt; 0.05).	Paclitaxel	99-109	microRNA 873a	Mus musculus	148-155
26850595-7	2016	ABCB1 overexpression reduced sensitivities of ovarian cancer lines OVCAR3 and A2780 to cisplatin and paclitaxel, which can be reversed by miR-873 mimic transfection (P &lt; 0.05).	Paclitaxel	101-111	microRNA 873a	Mus musculus	138-145
26850595-8	2016	In summary, we demonstrated that overexpression of miR-873 increased the sensitivity of ovarian cancer cells to cisplatin and paclitaxel by targeting MDR1 expression.	Paclitaxel	126-136	microRNA 873a	Mus musculus	51-58
27248820-5	2016	Pellino-1 overexpression in these cells also conferred resistance to cisplatin- or paclitaxel-induced apoptosis.	Paclitaxel	83-93	pellino E3 ubiquitin protein ligase 1	Homo sapiens	0-9
27248820-6	2016	In contrast, depletion of Pellino-1 decreased the survival of A549 and H1299 cells and sensitized these cells to cisplatin- and paclitaxel-induced apoptosis.	Paclitaxel	128-138	pellino E3 ubiquitin protein ligase 1	Homo sapiens	26-35
27045981-0	2016	CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel.	Paclitaxel	140-150	CD44 molecule (Indian blood group)	Homo sapiens	0-4
27045981-13	2016	Combination of HA coated SLM nanoparticles and PTX nanoparticles showed the highest cytotoxicity against CD44(+) cells.	Paclitaxel	47-50	CD44 molecule (Indian blood group)	Homo sapiens	105-109
26979998-2	2016	Recent reports showed that paclitaxel treatment results in the activation of Toll-like receptor 4 (TLR4) signaling and increased expression of monocyte chemoattractant protein 1 (MCP-1) in dorsal root ganglion cells.	Paclitaxel	27-37	chemokine (C-C motif) ligand 2	Mus musculus	143-177
26979998-2	2016	Recent reports showed that paclitaxel treatment results in the activation of Toll-like receptor 4 (TLR4) signaling and increased expression of monocyte chemoattractant protein 1 (MCP-1) in dorsal root ganglion cells.	Paclitaxel	27-37	chemokine (C-C motif) ligand 2	Mus musculus	179-184
27462592-10	2016	And growth inhibition of OVCAR3 CD44(+)CD117(+) cells by paclitaxel combined with salinomycin was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay.	Paclitaxel	57-67	CD44 molecule (Indian blood group)	Homo sapiens	32-36
27462592-12	2016	Treatment with a combination of paclitaxel and salinomycin demonstrated growth inhibition of OVCAR3 CD44(+)CD117(+) cells.	Paclitaxel	32-42	CD44 molecule (Indian blood group)	Homo sapiens	100-104
26810068-4	2016	Here, we showed that suppression of GRIM-19 by shRNA enhanced cell-type-dependent autophagy by activating extracellular regulated protein kinase (ERK) and hypoxia inducible factor-1a (HIF-1a) in a reactive oxygen species (ROS)-mediated manner, and thereby conferred resistance to paclitaxel.	Paclitaxel	280-290	NADH:ubiquinone oxidoreductase subunit A13	Homo sapiens	36-43
27277808-7	2016	The present study illustrates for the first time a mir-500-mediated mechanism underlying spinal GABAergic dysfunction and sensitized pain behavior in neuropathic pain induced by the chemotherapeutic drug paclitaxel or L5 ventral root transection, which sheds light on the development of novel therapeutic options for neuropathic pain.	Paclitaxel	204-214	microRNA 500	Rattus norvegicus	51-58
26961886-0	2016	CX3CR1-Mediated Akt1 Activation Contributes to the Paclitaxel-Induced Painful Peripheral Neuropathy in Rats.	Paclitaxel	51-61	C-X3-C motif chemokine receptor 1	Rattus norvegicus	0-6
26961886-3	2016	Here, we found that paclitaxel treatment (3 x 8 mg/kg, cumulative dose 24 mg/kg) upregulated the expression of CX3CR1 and phosphorylated Akt1 in DRG and spinal dorsal horn.	Paclitaxel	20-30	C-X3-C motif chemokine receptor 1	Rattus norvegicus	111-117
26961886-5	2016	Furthermore, inhibition of CX3CR1 by using neutralizing antibody not only prevented Akt1 activation in DRG and spinal dorsal horn but also alleviated pain-related behavior induced by paclitaxel treatment.	Paclitaxel	183-193	C-X3-C motif chemokine receptor 1	Rattus norvegicus	27-33
26961886-6	2016	This study suggested that CX3CR1/Akt1 signaling pathway may be a potential target for prevention and reversion of the painful peripheral neuropathy induced by paclitaxel.	Paclitaxel	159-169	C-X3-C motif chemokine receptor 1	Rattus norvegicus	26-32
27148873-5	2016	RESULTS: Paclitaxel induced the upregulation of pS6 (S240/S244) and pS6 (S235/S236) in HeyA8 and SKOV3 cells, and pPRAS40 (T246) in HeyA8 cells.	Paclitaxel	9-19	taste 2 receptor member 63 pseudogene	Homo sapiens	48-51
27148873-5	2016	RESULTS: Paclitaxel induced the upregulation of pS6 (S240/S244) and pS6 (S235/S236) in HeyA8 and SKOV3 cells, and pPRAS40 (T246) in HeyA8 cells.	Paclitaxel	9-19	taste 2 receptor member 63 pseudogene	Homo sapiens	68-71
27148873-10	2016	CONCLUSION: Addition of BX795 or CCT128930 to inhibit pS6 (S240/S244) or pS6 (S235/S236) restricted the compensatory adaptive response to paclitaxel in HeyA8 and SKOV3 cells.	Paclitaxel	138-148	taste 2 receptor member 63 pseudogene	Homo sapiens	54-57
27148873-10	2016	CONCLUSION: Addition of BX795 or CCT128930 to inhibit pS6 (S240/S244) or pS6 (S235/S236) restricted the compensatory adaptive response to paclitaxel in HeyA8 and SKOV3 cells.	Paclitaxel	138-148	taste 2 receptor member 63 pseudogene	Homo sapiens	73-76
26851390-0	2016	Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.	Paclitaxel	41-51	CD44 molecule (Indian blood group)	Homo sapiens	98-102
26498640-7	2016	Additionally, knock-down of KDM3A not only could enhance cellular apoptosis induced by Cisplatin and Paclitaxel, but also induced some pro-apoptotic genes expression.	Paclitaxel	101-111	lysine demethylase 3A	Homo sapiens	28-33
26586551-5	2016	Importantly, incorporation of PTX into exosomes increased cytotoxicity more than 50 times in drug resistant MDCKMDR1 (Pgp+) cells.	Paclitaxel	30-33	phosphoglycolate phosphatase	Mus musculus	118-121
26827662-2	2016	Here, we propose to evaluate the potential therapeutic efficacy of combining Paclitaxel and Salinomycin drugs actively targeted to both breast cancer and CSCs in xenograft murine model after conjugation with biocompatible CD44 antibody conjugated SWCNTs via hydrazone linker allowing pH-responsive release mechanism near the acidic tumor microenvironment.	Paclitaxel	77-87	CD44 antigen	Mus musculus	222-226
26840567-8	2016	KIT+CD11b+ cells decreased in response to paclitaxel with bevacizumab, but not paclitaxel alone.	Paclitaxel	42-52	integrin subunit alpha M	Homo sapiens	4-9
26840567-8	2016	KIT+CD11b+ cells decreased in response to paclitaxel with bevacizumab, but not paclitaxel alone.	Paclitaxel	79-89	integrin subunit alpha M	Homo sapiens	4-9
26840567-11	2016	Chemotherapy with paclitaxel and bevacizumab, but not with paclitaxel alone, significantly decreased IL-10 mRNA in CD11b+ cells and IL-10 protein in plasma.	Paclitaxel	18-28	interleukin 10	Homo sapiens	101-106
26840567-11	2016	Chemotherapy with paclitaxel and bevacizumab, but not with paclitaxel alone, significantly decreased IL-10 mRNA in CD11b+ cells and IL-10 protein in plasma.	Paclitaxel	18-28	integrin subunit alpha M	Homo sapiens	115-120
26840567-11	2016	Chemotherapy with paclitaxel and bevacizumab, but not with paclitaxel alone, significantly decreased IL-10 mRNA in CD11b+ cells and IL-10 protein in plasma.	Paclitaxel	18-28	interleukin 10	Homo sapiens	132-137
26697987-4	2016	Combination of weekly paclitaxel and ramucirumab, a novel anti-angiogenic VEGFR2 antibody, pushes the overall survival up to over 9.5 months, whereas apatinib, a novel oral VEGFR2 tyrosine kinase inhibitor, seems to be promising in heavily pretreated patients.	Paclitaxel	22-32	kinase insert domain receptor	Homo sapiens	74-80
26838546-5	2016	Differences in the expression and activation of Aurora A and Plk1 between cells treated with paclitaxel/MWE and paclitaxel alone suggested that the combined treatment caused a defect in the early steps of cytokinesis.	Paclitaxel	93-103	polo like kinase 1	Homo sapiens	61-65
26356996-8	2015	According to our data, cisplatin and paclitaxel strongly decreased T24 cells" viability, showing in parallel the ability to significantly down-regulate miR-143 levels, and up-regulate the expression levels of miR-145, miR-183, miR-96, and miR-182, which, in their total, demonstrated case-specific variations after recovery period.	Paclitaxel	37-47	microRNA 182	Homo sapiens	239-246
26159849-0	2015	Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.	Paclitaxel	38-48	SRY-box transcription factor 2	Homo sapiens	18-22
26159849-5	2015	In the present study, the expression of SOX2 was examined by immunohistochemistry (IHC) and real-time PCR in 40 clinical samples and in SKOV3 cells and SKOV3/TAX cells (paclitaxel-resistant human ovarian adenocarcinoma cell line).	Paclitaxel	169-179	SRY-box transcription factor 2	Homo sapiens	40-44
26159849-9	2015	Western blot analysis showed that the SOX2 protein was overexpressed in paclitaxel-resistant cells and weakly detectable in paclitaxel-sensitive cells.	Paclitaxel	72-82	SRY-box transcription factor 2	Homo sapiens	38-42
26159849-9	2015	Western blot analysis showed that the SOX2 protein was overexpressed in paclitaxel-resistant cells and weakly detectable in paclitaxel-sensitive cells.	Paclitaxel	124-134	SRY-box transcription factor 2	Homo sapiens	38-42
26159849-10	2015	SOX2 silencing significantly potentiated apoptosis induced by paclitaxel in SKOV3-TR with SOX2 knockdown compared to SKOV3-TR transfected with control small interfering RNA (siRNA).	Paclitaxel	62-72	SRY-box transcription factor 2	Homo sapiens	0-4
26159849-10	2015	SOX2 silencing significantly potentiated apoptosis induced by paclitaxel in SKOV3-TR with SOX2 knockdown compared to SKOV3-TR transfected with control small interfering RNA (siRNA).	Paclitaxel	62-72	SRY-box transcription factor 2	Homo sapiens	90-94
26640594-4	2015	Either hTERT siRNA or BIBR1532 in combination with paclitaxel promoted a synergistic inhibitory effect on cell growth through induction of Annexin V expression and a remarkable reduction in cell invasion through reduction of protein expression of MMP9, MMP2, and MMP3.	Paclitaxel	51-61	matrix metallopeptidase 9	Homo sapiens	247-251
25904021-0	2015	Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.	Paclitaxel	37-47	phosphoglycolate phosphatase	Mus musculus	93-107
25904021-3	2015	We first developed a paclitaxel-resistant ovarian cancer cell line, and demonstrated that NSC23925 could prevent the introduction of paclitaxel resistance by specifically inhibiting the overexpression of P-glycoprotein (Pgp) in vitro.	Paclitaxel	21-31	phosphoglycolate phosphatase	Mus musculus	204-218
25904021-3	2015	We first developed a paclitaxel-resistant ovarian cancer cell line, and demonstrated that NSC23925 could prevent the introduction of paclitaxel resistance by specifically inhibiting the overexpression of P-glycoprotein (Pgp) in vitro.	Paclitaxel	21-31	phosphoglycolate phosphatase	Mus musculus	220-223
25904021-3	2015	We first developed a paclitaxel-resistant ovarian cancer cell line, and demonstrated that NSC23925 could prevent the introduction of paclitaxel resistance by specifically inhibiting the overexpression of P-glycoprotein (Pgp) in vitro.	Paclitaxel	133-143	phosphoglycolate phosphatase	Mus musculus	204-218
25904021-3	2015	We first developed a paclitaxel-resistant ovarian cancer cell line, and demonstrated that NSC23925 could prevent the introduction of paclitaxel resistance by specifically inhibiting the overexpression of P-glycoprotein (Pgp) in vitro.	Paclitaxel	133-143	phosphoglycolate phosphatase	Mus musculus	220-223
25904021-5	2015	The majority of mice continuously treated with paclitaxel alone eventually developed paclitaxel resistance with overexpression of Pgp and antiapoptotic proteins, whereas mice remained sensitivity to paclitaxel and displayed lower expression levels of Pgp and antiapoptotic proteins after administered continuously with combination of paclitaxel-NSC23925.	Paclitaxel	47-57	phosphoglycolate phosphatase	Mus musculus	130-133
25904021-5	2015	The majority of mice continuously treated with paclitaxel alone eventually developed paclitaxel resistance with overexpression of Pgp and antiapoptotic proteins, whereas mice remained sensitivity to paclitaxel and displayed lower expression levels of Pgp and antiapoptotic proteins after administered continuously with combination of paclitaxel-NSC23925.	Paclitaxel	47-57	phosphoglycolate phosphatase	Mus musculus	251-254
26272744-0	2015	Association between Met-BDNF allele and vulnerability to paclitaxel-induced peripheral neuropathy.	Paclitaxel	57-67	brain derived neurotrophic factor	Homo sapiens	24-28
25988668-5	2015	Increased levels of CXCR2, CXCR4, S1P/S1PR1, PlGF and PDGF-BB were identified in the serum or primary tumour tissues of tumour-bearing mice treated by paclitaxel.	Paclitaxel	151-161	chemokine (C-X-C motif) receptor 2	Mus musculus	20-25
25988668-5	2015	Increased levels of CXCR2, CXCR4, S1P/S1PR1, PlGF and PDGF-BB were identified in the serum or primary tumour tissues of tumour-bearing mice treated by paclitaxel.	Paclitaxel	151-161	chemokine (C-X-C motif) receptor 4	Mus musculus	27-32
25833695-0	2015	MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK.	Paclitaxel	16-21	microRNA 197	Homo sapiens	0-7
25833695-0	2015	MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK.	Paclitaxel	16-21	nemo like kinase	Homo sapiens	77-80
25833695-4	2015	We used Taqman probe stem loop real-time PCR to accurately measure the levels of miR-197 in normal ovarian cells, ovarian cancer cells, and Taxol-resistant ovarian cancer cells and found that miR-197 was significantly increased in Taxol-resistant ovarian cancer cells.	Paclitaxel	140-145	microRNA 197	Homo sapiens	192-199
25833695-4	2015	We used Taqman probe stem loop real-time PCR to accurately measure the levels of miR-197 in normal ovarian cells, ovarian cancer cells, and Taxol-resistant ovarian cancer cells and found that miR-197 was significantly increased in Taxol-resistant ovarian cancer cells.	Paclitaxel	231-236	microRNA 197	Homo sapiens	81-88
25833695-4	2015	We used Taqman probe stem loop real-time PCR to accurately measure the levels of miR-197 in normal ovarian cells, ovarian cancer cells, and Taxol-resistant ovarian cancer cells and found that miR-197 was significantly increased in Taxol-resistant ovarian cancer cells.	Paclitaxel	231-236	microRNA 197	Homo sapiens	192-199
25833695-5	2015	Enforced expression of miR-197 can promote Taxol resistance, cell proliferation, and invasion of ovarian cancer cells.	Paclitaxel	43-48	microRNA 197	Homo sapiens	23-30
25833695-6	2015	Meanwhile, repression of miR-197 in ovarian cancer cells can sensitize its response to Taxol and also induced attenuated cell proliferation and invasion ability.	Paclitaxel	87-92	microRNA 197	Homo sapiens	25-32
25833695-8	2015	Taken together, our work first demonstrated that miR-197 can confer drug resistance to Taxol, by regulating tumor suppressor, NLK expression in ovarian cancer cells.	Paclitaxel	87-92	microRNA 197	Homo sapiens	49-56
25833695-8	2015	Taken together, our work first demonstrated that miR-197 can confer drug resistance to Taxol, by regulating tumor suppressor, NLK expression in ovarian cancer cells.	Paclitaxel	87-92	nemo like kinase	Homo sapiens	126-129
26351908-9	2015	More importantly, overexpression of miR-125b or depletion of Sema4C sensitized PR cells to paclitaxel.	Paclitaxel	91-101	sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4C	Mus musculus	61-67
26349973-0	2015	BI2536--A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells.	Paclitaxel	33-43	polo like kinase 1	Homo sapiens	10-13
26033570-11	2015	Mimitin and 14-3-3 protein zeta/delta are potential markers of paclitaxel resistance and prognostic factors in ovarian cancer.	Paclitaxel	63-73	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Homo sapiens	12-37
26261926-8	2015	The anti-VEGFR2 antibody Ramucirumab improves survival in second line treatment both as a monotherapy and in combination with paclitaxel and represents a novel treatment option.	Paclitaxel	126-136	kinase insert domain receptor	Homo sapiens	9-15
25676595-6	2015	RESULTS: The prepared dual-ligand-modified micelles with about 30 nm in diameter and rapid intracellular drug release behavior at endo/lysosomal pH were very effective in enhancing the cytotoxicity of paclitaxel against 22Rv1 cells by increasing the cellular uptake, which was verified the correlation with the expression of integrin alphavbeta3 and prostate specific membrane antigen in tumor cells by flow cytometric analysis and confocal microscopy, compared with single ligand-modified micelles.	Paclitaxel	201-211	integrin subunit alpha V	Homo sapiens	325-345
26175410-2	2015	In this issue of Cancer Cell, Yu and colleagues describe the critical role of spleen tyrosine kinase (SYK) in paclitaxel resistance by modulating the stability of microtubules.	Paclitaxel	110-120	spleen associated tyrosine kinase	Homo sapiens	102-105
26068792-0	2015	SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.	Paclitaxel	97-102	sperm associated antigen 5	Homo sapiens	0-5
25900794-11	2015	Ectopic expression of miR-218 resensitized both drug-resistant cell lines to doxorubicin and taxol due to an increase in apoptosis.	Paclitaxel	93-98	membrane associated ring-CH-type finger 8	Homo sapiens	22-25
25827582-7	2015	In rats with paclitaxel-induced neuropathic pain, the protein expression of GAT-1 was increased while GAT-3 was decreased.	Paclitaxel	13-23	solute carrier family 6 member 12	Rattus norvegicus	76-81
25827582-7	2015	In rats with paclitaxel-induced neuropathic pain, the protein expression of GAT-1 was increased while GAT-3 was decreased.	Paclitaxel	13-23	solute carrier family 6 member 11	Rattus norvegicus	102-107
25724736-0	2015	Taxol-induced unfolded protein response activation in breast cancer cells exposed to hypoxia: ATF4 activation regulates autophagy and inhibits apoptosis.	Paclitaxel	0-5	activating transcription factor 4	Homo sapiens	94-98
25724736-6	2015	However, while no link between the activation of these three ER stress sensors and autophagy or apoptosis regulation could be evidenced, results showed that ATF4 activation, which occurs independently of UPR activation, was involved in taxol-induced autophagy completion.	Paclitaxel	236-241	activating transcription factor 4	Homo sapiens	157-161
25724736-7	2015	In addition, an ATF4-dependent mechanism leading to cancer cell adaptation and resistance against taxol-induced cell death was evidenced.	Paclitaxel	98-103	activating transcription factor 4	Homo sapiens	16-20
25960665-4	2015	One HDAC inhibitor, valproic acid (VPA), also inhibits tumor growth by inducing apoptosis, and enhances the efficacy of paclitaxel in a mouse xenograft model of gastric cancer.	Paclitaxel	120-130	histone deacetylase 9	Homo sapiens	4-8
25931810-8	2015	Furthermore, paclitaxel also ameliorated renal fibrosis by down-regulating the expression of fibronectin, alpha-SMA, and collagen I, and suppressed the infiltration of macrophages and production of TNF-alpha, IL-1beta, TGF-beta, and ICAM-1 (intercellular adhesion molecule 1) by inhibition of STAT3 activity in obstructive nephropathy.	Paclitaxel	13-23	intercellular adhesion molecule 1	Rattus norvegicus	233-239
25931810-8	2015	Furthermore, paclitaxel also ameliorated renal fibrosis by down-regulating the expression of fibronectin, alpha-SMA, and collagen I, and suppressed the infiltration of macrophages and production of TNF-alpha, IL-1beta, TGF-beta, and ICAM-1 (intercellular adhesion molecule 1) by inhibition of STAT3 activity in obstructive nephropathy.	Paclitaxel	13-23	intercellular adhesion molecule 1	Rattus norvegicus	241-274
25596561-7	2015	Furthermore, paclitaxel/ABT737 synergized to drastically upregulate Bim to displace Bak from Mcl-1, whereas S1 directly binds Mcl-1 to release both Bim and Bak.	Paclitaxel	13-23	BCL2 antagonist/killer 1	Homo sapiens	84-87
25748058-0	2015	Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.	Paclitaxel	19-29	A-kinase anchoring protein 12	Homo sapiens	9-15
25748058-5	2015	Among the 81 differentially abundant proteins identified (q &lt; 0.05) from paclitaxel-sensitive vs -resistant HGSOC cell secretomes, AKAP12 was verified to be elevated in all models of paclitaxel-resistant HGSOC.	Paclitaxel	76-86	A-kinase anchoring protein 12	Homo sapiens	134-140
25748058-5	2015	Among the 81 differentially abundant proteins identified (q &lt; 0.05) from paclitaxel-sensitive vs -resistant HGSOC cell secretomes, AKAP12 was verified to be elevated in all models of paclitaxel-resistant HGSOC.	Paclitaxel	186-196	A-kinase anchoring protein 12	Homo sapiens	134-140
25748058-8	2015	We further provide evidence to support that differential gene methylation status is associated with elevated expression of AKAP12 in taxol-resistant ovarian cancer cells and ovarian cancer patient subsets.	Paclitaxel	133-138	A-kinase anchoring protein 12	Homo sapiens	123-129
25748058-9	2015	Elevated expression and shedding/secretion of AKAP12 is characteristic of paclitaxel-resistant HGSOC cells, and elevated AKAP12 transcript expression is a poor prognostic and predictive marker for progression-free and overall survival in SOC patients.	Paclitaxel	74-84	A-kinase anchoring protein 12	Homo sapiens	46-52
25630979-1	2015	A novel nanostructured lipid carrier (NLC) modified with photon-sensitive cell penetrating peptides (psCPP) and Asn-Gly-Arg (NGR) was designed to enhance paclitaxel (PTX)-targeted delivery and antitumor effect.	Paclitaxel	154-164	reticulon 4 receptor	Homo sapiens	125-128
25630979-1	2015	A novel nanostructured lipid carrier (NLC) modified with photon-sensitive cell penetrating peptides (psCPP) and Asn-Gly-Arg (NGR) was designed to enhance paclitaxel (PTX)-targeted delivery and antitumor effect.	Paclitaxel	166-169	reticulon 4 receptor	Homo sapiens	125-128
25630979-8	2015	Pharmacokinetic study showed that the prepared psCPP/NGR-NLC possessed the long-circulation characteristic with the t1/2 of 6.112 +- 0.304 h. Pharmacodynamics results confirmed that, with the aid of NIR illumination and NGR, the tumor inhibition ratio of psCPP/NGR-NLC group was significantly higher than the other PTX groups.	Paclitaxel	315-318	reticulon 4 receptor	Homo sapiens	53-56
25560085-0	2015	Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.	Paclitaxel	0-10	CXADR Ig-like cell adhesion molecule	Homo sapiens	78-81
25560085-8	2015	There was increased CAR expression in intraperitoneal tumours with de novo paclitaxel resistance and in tumours from patients with clinical resistance to paclitaxel.	Paclitaxel	75-85	CXADR Ig-like cell adhesion molecule	Homo sapiens	20-23
25560085-8	2015	There was increased CAR expression in intraperitoneal tumours with de novo paclitaxel resistance and in tumours from patients with clinical resistance to paclitaxel.	Paclitaxel	154-164	CXADR Ig-like cell adhesion molecule	Homo sapiens	20-23
25633416-11	2015	Therefore, our results indicate that DIM effectively potentiates the efficacy of chemotherapeutic agents such as paclitaxel by downregulation of the Akt/FOXM1 signaling cascade in gastric cancer cells.	Paclitaxel	113-123	forkhead box M1	Homo sapiens	153-158
25788267-7	2015	Most importantly, when administered intraperitoneally, combination of BSN and paclitaxel significantly decreased the tumor development in a xenograft lung cancer mouse model associated with down-modulation of phospho-STAT3, Ki-67 and CD31.	Paclitaxel	78-88	antigen identified by monoclonal antibody Ki 67	Mus musculus	224-229
25788678-6	2015	Isoform-selective inhibitors of PKCbetaII, PKCdelta, and PKCepsilon given intrathecally dose-dependently attenuated paclitaxel-induced mechanical allodynia and heat hyperalgesia.	Paclitaxel	116-126	protein kinase C, delta	Mus musculus	43-51
25788678-7	2015	Surprisingly, spinal inhibition of PKCbetaII and PKCdelta, but not PKCepsilon, blocked the spontaneous pain induced by paclitaxel.	Paclitaxel	119-129	protein kinase C, delta	Mus musculus	49-57
25759021-3	2015	Paclitaxel-induced ER stress to breast cancer (BCa) cells promotes RNF5 association, ubiquitination, and degradation of SLC1A5/38A2.	Paclitaxel	0-10	ring finger protein 5	Homo sapiens	67-71
25759021-3	2015	Paclitaxel-induced ER stress to breast cancer (BCa) cells promotes RNF5 association, ubiquitination, and degradation of SLC1A5/38A2.	Paclitaxel	0-10	solute carrier family 1 member 5	Homo sapiens	120-126
25759021-6	2015	Whereas RNF5 depletion in MDA-MB-231 cells promoted tumorigenesis and abolished paclitaxel responsiveness, SLC1A5/38A2 knockdown elicited opposing effects.	Paclitaxel	80-90	ring finger protein 5	Homo sapiens	8-12
24853387-11	2015	Finally, both acute and chronic administration of AM1710 decreased messenger RNA levels of tumor necrosis factor-alpha and monocyte chemoattractant protein 1 in lumbar spinal cord of paclitaxel-treated WT mice.	Paclitaxel	183-193	chemokine (C-C motif) ligand 2	Mus musculus	123-157
26045800-0	2015	ING4 enhances paclitaxel"s effect on colorectal cancer growth in vitro and in vivo.	Paclitaxel	14-24	inhibitor of growth family member 4	Homo sapiens	0-4
25837919-7	2015	Furthermore, mechanical allodynia in paclitaxel-induced peripheral neuropathy and streptozotocin-induced painful diabetic neuropathy models were significantly attenuated in TRPM2-knockout mice.	Paclitaxel	37-47	transient receptor potential cation channel, subfamily M, member 2	Mus musculus	173-178
25687880-7	2015	Administration of HA-PEI/HA-PEG/MDR1 siRNA nanoparticles followed by paclitaxel treatment induced a significant inhibitory effect on the tumor growth, decreased Pgp expression and increased apoptosis in MDR ovarian cancer mice model.	Paclitaxel	69-79	phosphoglycolate phosphatase	Mus musculus	161-164
25583261-0	2015	BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.	Paclitaxel	34-44	BRCA1 DNA repair associated	Homo sapiens	0-5
25583261-3	2015	Here we investigate the role of BRCA1-IRIS as a novel treatment target for TNBCs and their paclitaxel-resistant recurrences.	Paclitaxel	91-101	BRCA1 DNA repair associated	Homo sapiens	32-37
25583261-4	2015	METHODS: We analyzed the response of BRCA1-IRIS overexpressing normal mammary cells or established TNBC cells silenced from BRCA1-IRIS to paclitaxel in vitro and in vivo.	Paclitaxel	138-148	BRCA1 DNA repair associated	Homo sapiens	37-42
25583261-5	2015	We analyzed BRCA1-IRIS downstream signaling pathways in relation to paclitaxel treatment.	Paclitaxel	68-78	BRCA1 DNA repair associated	Homo sapiens	12-17
25583261-8	2015	RESULTS: We show that low concentrations of paclitaxel triggers BRCA1-IRIS expression in vitro and in vivo, and that BRCA1-IRIS activates two autocrine signaling loops (epidermal growth factor (EGF)/EGF receptor 1 (EGFR)-EGF receptor 2 (ErbB2) and neurogulin 1 (NRG1)/ErbB2-EGF receptor 3 (ErbB3), which enhances protein kinase B (AKT) and thus survivin expression/activation through promoting FOXO3a degradation.	Paclitaxel	44-54	BRCA1 DNA repair associated	Homo sapiens	64-69
25583261-10	2015	These events trigger the intrinsic and acquired paclitaxel resistance phenotype known for BRCA1-IRIS-overexpressing TNBCs.	Paclitaxel	48-58	BRCA1 DNA repair associated	Homo sapiens	90-95
25583261-11	2015	Inactivating BRCA1-IRIS signaling using a novel inhibitory mimetic peptide inactivates these autocrine loops, AKT and survivin activity/expression, in part by restoring FOXO3a expression, and sensitizes TNBC cells to low paclitaxel concentrations in vitro and in vivo.	Paclitaxel	221-231	BRCA1 DNA repair associated	Homo sapiens	13-18
25583261-13	2015	CONCLUSIONS: In addition to driving TNBC tumor formation, BRCA1-IRIS overexpression drives their intrinsic and acquired paclitaxel resistance, partly by activating autocrine signaling loops EGF/EGFR-ErbB2 and NRG1/ErbB2-ErbB3.	Paclitaxel	120-130	BRCA1 DNA repair associated	Homo sapiens	58-63
25890771-0	2015	Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer.	Paclitaxel	15-25	CD44 molecule (Indian blood group)	Homo sapiens	46-50
26176734-2	2015	This study investigated the potential of transgelin 2 and salvianolic acid A to modulate the resistance and the migration and invasion abilities of paclitaxel-resistant human breast cancer cells (MCF-7/PTX).	Paclitaxel	148-158	transgelin 2	Homo sapiens	41-53
26176734-4	2015	Small interfering RNA-mediated knockdown of TAGLN2 sensitized the MCF-7/PTX cells to paclitaxel, and inhibited their migration and invasion abilities.	Paclitaxel	85-95	transgelin 2	Homo sapiens	44-50
26176734-5	2015	In addition, we also observed that combined salvianolic acid A and paclitaxel treatment could reverse paclitaxel resistance, markedly inhibit tumor migration and invasion, and suppress the expression of transgelin 2 in MCF-7/PTX cells.	Paclitaxel	67-77	transgelin 2	Homo sapiens	203-215
26390698-4	2015	RESULTS: MiR-224 was significantly downregulated with fold values at 2.130435 and 4.26087 under five and ten nM paclitaxel treatments, respectively.	Paclitaxel	112-122	microRNA 224	Homo sapiens	9-16
26390698-6	2015	Exogenous miR-224 facilitates paclitaxel sensitivity in cervical cancer cells.	Paclitaxel	30-40	microRNA 224	Homo sapiens	10-17
26390698-8	2015	CONCLUSION: The results suggests that miR-224 might serve as a predictor for paclitaxel response or a therapeutic target in cervical cancer therapy.	Paclitaxel	77-87	microRNA 224	Homo sapiens	38-45
26162837-6	2015	In rats with neuropathy induced by L5 spinal nerve cutting or by repeated administration of paclitaxel, an anticancer drug, the neuropathic hyperalgesia is reversed by inhibitors of CSE or T-channels and by silencing of Cav3.2.	Paclitaxel	92-102	calcium channel, voltage-dependent, T type, alpha 1H subunit	Mus musculus	220-226
25224289-1	2015	The main aim of this work was to evaluate a nanoconjugate system of paclitaxel loaded self-assembling, biodegradable micelles for targeting CD44 overexpression in cancer cells.	Paclitaxel	68-78	CD44 antigen	Mus musculus	140-144
25224289-7	2015	In conclusion, paclitaxel-loaded HA nanoparticulate micelles might be found to be a specific and efficient chemotherapeutic treatment for CD44 overexpressing cancer cells.	Paclitaxel	15-25	CD44 antigen	Mus musculus	138-142
25310526-0	2015	+TIP EB1 downregulates paclitaxel-induced proliferation inhibition and apoptosis in breast cancer cells through inhibition of paclitaxel binding on microtubules.	Paclitaxel	23-33	microtubule associated protein RP/EB family member 1	Homo sapiens	5-8
25310526-0	2015	+TIP EB1 downregulates paclitaxel-induced proliferation inhibition and apoptosis in breast cancer cells through inhibition of paclitaxel binding on microtubules.	Paclitaxel	126-136	microtubule associated protein RP/EB family member 1	Homo sapiens	5-8
25310526-3	2015	By using cellular and biochemical assays, we demonstrate that EB1 plays a critical role in regulating the sensitivity of breast cancer cells to anti-microtubule drug, paclitaxel (PTX).	Paclitaxel	167-177	microtubule associated protein RP/EB family member 1	Homo sapiens	62-65
25310526-3	2015	By using cellular and biochemical assays, we demonstrate that EB1 plays a critical role in regulating the sensitivity of breast cancer cells to anti-microtubule drug, paclitaxel (PTX).	Paclitaxel	179-182	microtubule associated protein RP/EB family member 1	Homo sapiens	62-65
25310526-4	2015	Cell viability assays revealed that EB1 expression in the breast cancer cell lines correlated with the reduction of their sensitivity to PTX.	Paclitaxel	137-140	microtubule associated protein RP/EB family member 1	Homo sapiens	36-39
25310526-5	2015	Knockdown of EB1 by enzymatically-prepared siRNA pools (esiRNAs) increased PTX-induced cytotoxicity and sensitized cells to PTX-induced apoptosis in three breast cancer cell lines, MCF-7, MDA MB-231 and T47D.	Paclitaxel	75-78	microtubule associated protein RP/EB family member 1	Homo sapiens	13-16
25310526-5	2015	Knockdown of EB1 by enzymatically-prepared siRNA pools (esiRNAs) increased PTX-induced cytotoxicity and sensitized cells to PTX-induced apoptosis in three breast cancer cell lines, MCF-7, MDA MB-231 and T47D.	Paclitaxel	124-127	microtubule associated protein RP/EB family member 1	Homo sapiens	13-16
25310526-7	2015	p53 and Bax were upregulated and Bcl2 was downregulated in the EB1-depleted PTX-treated MCF-7 cells, indicating that the apoptosis occurs via a p53-dependent pathway.	Paclitaxel	76-79	microtubule associated protein RP/EB family member 1	Homo sapiens	63-66
25310526-9	2015	EB1 depletion increased PTX-induced microtubule bundling in the interphase cells and induced formation of multiple spindle foci with abnormally elongated spindles in the mitotic MCF-7 cells, indicating that loss of EB1 promotes PTX-induced stabilization of microtubules.	Paclitaxel	24-27	microtubule associated protein RP/EB family member 1	Homo sapiens	0-3
25310526-9	2015	EB1 depletion increased PTX-induced microtubule bundling in the interphase cells and induced formation of multiple spindle foci with abnormally elongated spindles in the mitotic MCF-7 cells, indicating that loss of EB1 promotes PTX-induced stabilization of microtubules.	Paclitaxel	228-231	microtubule associated protein RP/EB family member 1	Homo sapiens	0-3
25310526-9	2015	EB1 depletion increased PTX-induced microtubule bundling in the interphase cells and induced formation of multiple spindle foci with abnormally elongated spindles in the mitotic MCF-7 cells, indicating that loss of EB1 promotes PTX-induced stabilization of microtubules.	Paclitaxel	228-231	microtubule associated protein RP/EB family member 1	Homo sapiens	215-218
25310526-10	2015	EB1 inhibited PTX-induced microtubule polymerization and diminished PTX binding to microtubules in vitro, suggesting that it modulates the binding sites of PTX at the growing microtubule ends.	Paclitaxel	14-17	microtubule associated protein RP/EB family member 1	Homo sapiens	0-3
25310526-10	2015	EB1 inhibited PTX-induced microtubule polymerization and diminished PTX binding to microtubules in vitro, suggesting that it modulates the binding sites of PTX at the growing microtubule ends.	Paclitaxel	68-71	microtubule associated protein RP/EB family member 1	Homo sapiens	0-3
25310526-10	2015	EB1 inhibited PTX-induced microtubule polymerization and diminished PTX binding to microtubules in vitro, suggesting that it modulates the binding sites of PTX at the growing microtubule ends.	Paclitaxel	68-71	microtubule associated protein RP/EB family member 1	Homo sapiens	0-3
25310526-11	2015	Results demonstrate that EB1 downregulates inhibition of PTX-induced proliferation and apoptosis in breast cancer cells through a mechanism in which it impairs PTX-mediated stabilization of microtubule polymerization and inhibits PTX binding on microtubules.	Paclitaxel	57-60	microtubule associated protein RP/EB family member 1	Homo sapiens	25-28
25310526-11	2015	Results demonstrate that EB1 downregulates inhibition of PTX-induced proliferation and apoptosis in breast cancer cells through a mechanism in which it impairs PTX-mediated stabilization of microtubule polymerization and inhibits PTX binding on microtubules.	Paclitaxel	160-163	microtubule associated protein RP/EB family member 1	Homo sapiens	25-28
25310526-11	2015	Results demonstrate that EB1 downregulates inhibition of PTX-induced proliferation and apoptosis in breast cancer cells through a mechanism in which it impairs PTX-mediated stabilization of microtubule polymerization and inhibits PTX binding on microtubules.	Paclitaxel	160-163	microtubule associated protein RP/EB family member 1	Homo sapiens	25-28
25535473-5	2015	Moreover, SG significantly increased the mitochondrial accumulation of both Bax and Bak triggered by epirubicin or paclitaxel as well as the subsequent release of cytochrome c in the targeted cells.	Paclitaxel	115-125	BCL2 antagonist/killer 1	Homo sapiens	84-87
25625024-9	2015	High focal uptake of (18)F-rh-His10-annexin V was visualized in A549 (SUVmax: 0.35+-0.13) and VX2 (0.41+-0.23) tumor models after paclitaxel treatment, whereas lower uptake was found in the corresponding tumors before treatment (A549 SUVmax: 0.04+-0.02; VX2: 0.009+-0.002).	Paclitaxel	130-140	annexin A5	Mus musculus	36-45
25230791-2	2014	Treatment of OSCC (HSC2, HSC3 and HSC4) cells with PTX (0.02 microg/ml) and cetuximab (1 microg/ml) combination resulted in a significant inhibition of cell growth in vitro compared to either agent alone.	Paclitaxel	51-54	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	25-29
25103625-8	2014	At level 1B (200 mg dovitinib 5-days-on/2-days-off plus 60 mg/m 2-week of paclitaxel) more than 50% FGF23 upregulation was observed and no dose-limiting-toxicities (DLTs) occurred.	Paclitaxel	74-84	fibroblast growth factor 23	Homo sapiens	100-105
25310235-0	2014	Sox2 is involved in paclitaxel resistance of the prostate cancer cell line PC-3 via the PI3K/Akt pathway.	Paclitaxel	20-30	SRY-box transcription factor 2	Homo sapiens	0-4
25310235-4	2014	In the present study, using MTT, clone formation, cell cycle and apoptosis assays, over-expression of Sox2 was demonstrated to enhance the paclitaxel (Pac) resistance of the PC-3 prostate cancer cell line, promoting cell proliferation and exhibiting an anti-apoptotic effect.	Paclitaxel	139-149	SRY-box transcription factor 2	Homo sapiens	102-106
25310235-4	2014	In the present study, using MTT, clone formation, cell cycle and apoptosis assays, over-expression of Sox2 was demonstrated to enhance the paclitaxel (Pac) resistance of the PC-3 prostate cancer cell line, promoting cell proliferation and exhibiting an anti-apoptotic effect.	Paclitaxel	151-154	SRY-box transcription factor 2	Homo sapiens	102-106
25521357-0	2014	Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.	Paclitaxel	119-129	kinase insert domain receptor	Homo sapiens	40-47
25344919-5	2014	In the nude mice xenograft model, the tumor growth was reduced to a large degree in the Id1-overexpressing group upon treatment with paclitaxel and cisplatin.	Paclitaxel	133-143	inhibitor of DNA binding 1, HLH protein	Mus musculus	88-91
25157649-1	2014	The kinetics and effect of hyper activated IGF-1R signaling is not well investigated during acquirement of platinum and taxol resistance in ovarian cancer cells.	Paclitaxel	120-125	insulin like growth factor 1 receptor	Homo sapiens	43-49
25157649-2	2014	Herein we reported an upregulated IGF-1R expression in early stages of cisplatin paclitaxel and cisplatin-taxol resistance.	Paclitaxel	106-111	insulin like growth factor 1 receptor	Homo sapiens	34-40
25411964-0	2014	Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.	Paclitaxel	125-135	forkhead box M1	Homo sapiens	18-41
25411964-0	2014	Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.	Paclitaxel	125-135	forkhead box M1	Homo sapiens	43-48
25411964-8	2014	FOXM1 knockdown significantly inhibited migration and invasion of ovarian cancer cells and enhanced paclitaxel-mediated cell death and mitotic catastrophe in a p53-independent manner.	Paclitaxel	100-110	forkhead box M1	Homo sapiens	0-5
25411964-10	2014	One of the potential targets, KIF2C, exhibited similar expression pattern to FOXM1 in chemosensitive and chemoresistant cells in response to paclitaxel treatment.	Paclitaxel	141-151	kinesin family member 2C	Homo sapiens	30-35
25411964-10	2014	One of the potential targets, KIF2C, exhibited similar expression pattern to FOXM1 in chemosensitive and chemoresistant cells in response to paclitaxel treatment.	Paclitaxel	141-151	forkhead box M1	Homo sapiens	77-82
25411964-12	2014	CONCLUSION: Our findings suggest that FOXM1 is associated with poor patient outcome and contributes to paclitaxel resistance by blocking mitotic catastrophe.	Paclitaxel	103-113	forkhead box M1	Homo sapiens	38-43
25411045-0	2014	Lysophosphatidic acid and its receptors LPA1 and LPA3 mediate paclitaxel-induced neuropathic pain in mice.	Paclitaxel	62-72	lysophosphatidic acid receptor 3	Mus musculus	49-53
25411045-6	2014	The paclitaxel-induced LPA production was completely abolished not only by intrathecal pretreatment with neurokinin 1 (NK1) or N-methyl-D-aspartate (NMDA) receptor antagonist, but also in LPA1 receptor-deficient (Lpar1-/-) and LPA3 receptor-deficient (Lpar3-/-) mice.	Paclitaxel	4-14	lysophosphatidic acid receptor 3	Mus musculus	227-231
25411045-6	2014	The paclitaxel-induced LPA production was completely abolished not only by intrathecal pretreatment with neurokinin 1 (NK1) or N-methyl-D-aspartate (NMDA) receptor antagonist, but also in LPA1 receptor-deficient (Lpar1-/-) and LPA3 receptor-deficient (Lpar3-/-) mice.	Paclitaxel	4-14	lysophosphatidic acid receptor 3	Mus musculus	252-257
25411045-8	2014	Importantly, the paclitaxel-induced mechanical allodynia was absent in Lpar1-/- and Lpar3-/- mice.	Paclitaxel	17-27	lysophosphatidic acid receptor 3	Mus musculus	84-89
25411045-9	2014	CONCLUSIONS: These results suggest that LPA1 and LPA3 receptors-mediated amplification of spinal LPA production is required for the development of paclitaxel-induced neuropathic pain.	Paclitaxel	147-157	lysophosphatidic acid receptor 3	Mus musculus	49-53
25446896-6	2014	In human breast cancer, expression of IL12A and cytotoxic effector molecules were predictive of pathological complete response rates to paclitaxel.	Paclitaxel	136-146	interleukin 12A	Homo sapiens	38-43
25086622-8	2014	p90/CIP2A depletion in breast cancer cells inhibited proliferation and increased paclitaxel-induced apoptosis.	Paclitaxel	81-91	cellular inhibitor of PP2A	Homo sapiens	0-3
25086622-8	2014	p90/CIP2A depletion in breast cancer cells inhibited proliferation and increased paclitaxel-induced apoptosis.	Paclitaxel	81-91	cellular inhibitor of PP2A	Homo sapiens	4-9
25181333-7	2014	In addition, caspase-6, caspase-8 and caspase-9 labeling was present in SGN treated with 30 muM paclitaxel for 48 h. These results suggest that caspase-dependent apoptotic pathways are involved in paclitaxel-induced damage of SGN, but not hair cells in cochlea.	Paclitaxel	96-106	caspase 8	Rattus norvegicus	24-33
25181333-7	2014	In addition, caspase-6, caspase-8 and caspase-9 labeling was present in SGN treated with 30 muM paclitaxel for 48 h. These results suggest that caspase-dependent apoptotic pathways are involved in paclitaxel-induced damage of SGN, but not hair cells in cochlea.	Paclitaxel	197-207	caspase 8	Rattus norvegicus	24-33
25442283-3	2014	Western blotting and real-time quantitative polymerase chain reaction (qRT-PCR) indicated that transgelin 2 may mediate paclitaxel resistance by activating the phosphatidylinositol 3-kinase (PI3 K)/Akt signaling pathway to suppress MCF-7/PTX cells apoptosis.	Paclitaxel	120-130	transgelin 2	Homo sapiens	95-107
25442283-4	2014	The reversal ability of SAA was confirmed by MTT assay and flow cytometry, with a superior 9.1-fold reversal index and enhancement of the apoptotic cytotoxicity induced by paclitaxel.	Paclitaxel	172-182	serum amyloid A1 cluster	Homo sapiens	24-27
25442283-6	2014	Taken together, SAA can reverse paclitaxel resistance through suppressing transgelin 2 expression by mechanisms involving attenuation of PI3 K/Akt pathway activation and ABC transporter up-regulation.	Paclitaxel	32-42	serum amyloid A1 cluster	Homo sapiens	16-19
25442283-6	2014	Taken together, SAA can reverse paclitaxel resistance through suppressing transgelin 2 expression by mechanisms involving attenuation of PI3 K/Akt pathway activation and ABC transporter up-regulation.	Paclitaxel	32-42	transgelin 2	Homo sapiens	74-86
25442283-7	2014	These results not only provide insight into the potential application of SAA in reversing paclitaxel resistance, thus facilitating the sensitivity of breast cancer chemotherapy, but also highlight a potential role of transgelin 2 in the development of paclitaxel resistance in breast cancer.	Paclitaxel	90-100	serum amyloid A1 cluster	Homo sapiens	73-76
25442283-7	2014	These results not only provide insight into the potential application of SAA in reversing paclitaxel resistance, thus facilitating the sensitivity of breast cancer chemotherapy, but also highlight a potential role of transgelin 2 in the development of paclitaxel resistance in breast cancer.	Paclitaxel	252-262	serum amyloid A1 cluster	Homo sapiens	73-76
25442283-7	2014	These results not only provide insight into the potential application of SAA in reversing paclitaxel resistance, thus facilitating the sensitivity of breast cancer chemotherapy, but also highlight a potential role of transgelin 2 in the development of paclitaxel resistance in breast cancer.	Paclitaxel	252-262	transgelin 2	Homo sapiens	217-229
24816187-2	2014	We tested the hypothesis that CCL2 inhibition can enhance chemotherapy with carboplatin and paclitaxel.	Paclitaxel	92-102	chemokine (C-C motif) ligand 2	Mus musculus	30-34
24816187-5	2014	Our results show an additive effect of CCL2 blockade on the efficacy of paclitaxel and carboplatin.	Paclitaxel	72-82	chemokine (C-C motif) ligand 2	Mus musculus	39-43
24816187-7	2014	We show that inhibition of CCL2 can enhance paclitaxel and carboplatin therapy of ovarian cancer.	Paclitaxel	44-54	chemokine (C-C motif) ligand 2	Mus musculus	27-31
24954663-0	2014	Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity.	Paclitaxel	17-27	phosphoglycolate phosphatase	Mus musculus	58-61
24954663-2	2014	The main objective of the present investigation was to develop a paclitaxel (PTX) formulation which can circumvent the hurdles of its extremely poor solubility and permeability, Pgp efflux and high pre-systemic metabolism.	Paclitaxel	65-75	phosphoglycolate phosphatase	Mus musculus	178-181
24954663-2	2014	The main objective of the present investigation was to develop a paclitaxel (PTX) formulation which can circumvent the hurdles of its extremely poor solubility and permeability, Pgp efflux and high pre-systemic metabolism.	Paclitaxel	77-80	phosphoglycolate phosphatase	Mus musculus	178-181
23681900-8	2014	However, when the MCF7/Adr cells transfected with CD44 siRNA were incubated with 10 times the peak plasma concentration (PPC) of taxol, their invasive ability was again enhanced.	Paclitaxel	129-134	CD44 molecule (Indian blood group)	Homo sapiens	50-54
32261660-5	2014	When two anticancer drugs, i.e., paclitaxel (TXL) and doxorubicin (DOX), were loaded separately into the core and the shell domains of the microspheres, the experimental results showed that the MSP-TXL@P(MAA-Cy)-DOX nanodrug exhibited better inhibitive efficacy than the free drugs under the same dosing level, demonstrating the great potential of this stimuli-sensitive drug delivery system for programmed and stimuli-responsive drug release characteristics.	Paclitaxel	33-43	thioredoxin like 1	Homo sapiens	45-48
32261660-5	2014	When two anticancer drugs, i.e., paclitaxel (TXL) and doxorubicin (DOX), were loaded separately into the core and the shell domains of the microspheres, the experimental results showed that the MSP-TXL@P(MAA-Cy)-DOX nanodrug exhibited better inhibitive efficacy than the free drugs under the same dosing level, demonstrating the great potential of this stimuli-sensitive drug delivery system for programmed and stimuli-responsive drug release characteristics.	Paclitaxel	33-43	thioredoxin like 1	Homo sapiens	198-201
24858391-6	2014	The in vivo imaging study revealed that DIR or DID (near infrared fluorescent substances) loaded PEG-PTX nanoparticles distributed more in tumors in MCF-7 tumor bearing mice than DIR or DID loaded PEG-PLA micelles and solvent system of Taxol( ).	Paclitaxel	236-241	arginine vasopressin receptor 2	Mus musculus	40-43
24952376-4	2014	Subsequently, their reversing activity for Taxol resistance has been evaluated in P-gp-mediated multidrug resistance breast cancer cell line MDA435/LCC6MDR.	Paclitaxel	43-48	phosphoglycolate phosphatase	Mus musculus	82-86
25202946-0	2014	[Expression of Annexin A1 in paclitaxel-resistant ovarian carcinoma and its clinical significance].	Paclitaxel	29-39	annexin A1	Homo sapiens	15-25
25202946-1	2014	OBJECTIVE: To investigate the correlation of Annexin A1 (ANXA1) expression with paclitaxel response and clinicopathological features of ovarian carcinoma.	Paclitaxel	80-90	annexin A1	Homo sapiens	45-55
25202946-1	2014	OBJECTIVE: To investigate the correlation of Annexin A1 (ANXA1) expression with paclitaxel response and clinicopathological features of ovarian carcinoma.	Paclitaxel	80-90	annexin A1	Homo sapiens	57-62
25202946-4	2014	The correlation of ANXA1 expression with paclitaxel response and clinicopathological features of ovarian carcinoma was analyzed.	Paclitaxel	41-51	annexin A1	Homo sapiens	19-24
25202946-6	2014	The positive specimens of ANXA1 expression in paclitaxel-resistant tissues (14/20) were significantly lower than those in the sensitive ones (21/22, P&lt;0.05), and there was also a significant difference between the mild and the strong positive specimens (P&lt;0.01).	Paclitaxel	46-56	annexin A1	Homo sapiens	26-31
25202946-8	2014	CONCLUSION: ANXA1 expression is downregulated in paclitaxel-resistant ovarian carcinoma, which might be a valuable predictor for paclitaxel susceptibility of ovarian carcinoma.	Paclitaxel	49-59	annexin A1	Homo sapiens	12-17
25202946-8	2014	CONCLUSION: ANXA1 expression is downregulated in paclitaxel-resistant ovarian carcinoma, which might be a valuable predictor for paclitaxel susceptibility of ovarian carcinoma.	Paclitaxel	129-139	annexin A1	Homo sapiens	12-17
24812278-1	2014	AIMS: The anticancer drug paclitaxel (TXL) that polymerizes microtubules is associated with arrhythmias and sinus node dysfunction.	Paclitaxel	26-36	thioredoxin like 1	Homo sapiens	38-41
25233640-7	2014	The quantitative analysis of apoptosis induced by different PTX-loaded liposomes was performed by Annexin V-FITC/PI double staining.	Paclitaxel	60-63	annexin A5	Mus musculus	98-107
24534904-8	2014	Meanwhile, real-time polymerase chain reaction array revealed an alteration in expression of some neuronal ion channel genes including up-regulation of hyperpolarization-activated cyclic nucleotide-gated channel 1 (fold change 1.76 +- 0.06) and Nav1.7 (1.26 +- 0.02) and down-regulation of Kir channels (Kir1.1, 0.73 +- 0.05, Kir3.4, 0.66 +- 0.06) in paclitaxel-treated animals.	Paclitaxel	351-361	sodium voltage-gated channel alpha subunit 9	Homo sapiens	245-251
24534904-8	2014	Meanwhile, real-time polymerase chain reaction array revealed an alteration in expression of some neuronal ion channel genes including up-regulation of hyperpolarization-activated cyclic nucleotide-gated channel 1 (fold change 1.76 +- 0.06) and Nav1.7 (1.26 +- 0.02) and down-regulation of Kir channels (Kir1.1, 0.73 +- 0.05, Kir3.4, 0.66 +- 0.06) in paclitaxel-treated animals.	Paclitaxel	351-361	potassium inwardly rectifying channel subfamily J member 5	Homo sapiens	326-332
24781280-1	2014	BACKGROUND: The intestinal uptake of the taxanes paclitaxel and docetaxel is seriously hampered by drug efflux through P-glycoprotein (P-gp) and drug metabolism via cytochrome P450 (CYP) 3A.	Paclitaxel	49-59	phosphoglycolate phosphatase	Mus musculus	119-133
24781280-1	2014	BACKGROUND: The intestinal uptake of the taxanes paclitaxel and docetaxel is seriously hampered by drug efflux through P-glycoprotein (P-gp) and drug metabolism via cytochrome P450 (CYP) 3A.	Paclitaxel	49-59	phosphoglycolate phosphatase	Mus musculus	135-139
24781280-1	2014	BACKGROUND: The intestinal uptake of the taxanes paclitaxel and docetaxel is seriously hampered by drug efflux through P-glycoprotein (P-gp) and drug metabolism via cytochrome P450 (CYP) 3A.	Paclitaxel	49-59	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	165-189
24619562-0	2014	Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution.	Paclitaxel	71-81	CD44 antigen	Mus musculus	11-15
24448417-9	2014	However, P-glycoprotein (Pgp) protein expression was increased by paclitaxel (P&lt;0.01).	Paclitaxel	66-76	phosphoglycolate phosphatase	Mus musculus	9-23
24448417-9	2014	However, P-glycoprotein (Pgp) protein expression was increased by paclitaxel (P&lt;0.01).	Paclitaxel	66-76	phosphoglycolate phosphatase	Mus musculus	25-28
24448417-12	2014	Paclitaxel enhanced Pgp expression at the protein level, but not at the mRNA level suggesting transcriptional induction to be of minor relevance.	Paclitaxel	0-10	phosphoglycolate phosphatase	Mus musculus	20-23
24338942-6	2014	Others and we have shown that with a variety of tumours in both mice and rats, the inhibition of the SDF-1/CXCR4 pathway delays or prevents the recurrence of implanted or autochthonous tumours following irradiation or following treatment with vascular disrupting agents or some chemotherapeutic drugs such as paclitaxel.	Paclitaxel	309-319	C-X-C motif chemokine receptor 4	Rattus norvegicus	107-112
24271006-5	2014	In contrast, the microtubule-stabilizing drug paclitaxel arrested ABA-induced microtubule depolymerization and inhibited ABA-induced stomatal closure in both WT and pldalpha1.	Paclitaxel	46-56	phospholipase D alpha 1	Arabidopsis thaliana	165-174
24480438-5	2014	administration of paclitaxel induced significant mechanical hypersensitivity and cold allodynia in rats, significantly increased the expression of NGF and its receptor tyrosine kinase receptor A (trkA) in the DRG, and increased NGF expression in the DH.	Paclitaxel	18-28	neurotrophic receptor tyrosine kinase 1	Rattus norvegicus	196-200
24480438-7	2014	Moreover, expression of NEDD4-2, a negative regulator of trkA, was significantly increased in the DRG of paclitaxel-treated rats.	Paclitaxel	105-115	neurotrophic receptor tyrosine kinase 1	Rattus norvegicus	57-61
24480438-10	2014	Our results suggest that NGF-trkA signaling is involved in mechanical allodynia in paclitaxel-induced neuropathy.	Paclitaxel	83-93	neurotrophic receptor tyrosine kinase 1	Rattus norvegicus	29-33
24292090-7	2014	Accordingly, knockdown of TAGLN2 by siRNA sensitized MCF-7/P cells to paclitaxel and reduced the multidrug resistance (MDR).	Paclitaxel	70-80	transgelin 2	Homo sapiens	26-32
24292090-8	2014	Our identification of differential proteins, particularly transgelin-2, provides new insights into the mechanism of MDR to paclitaxel and novel biological targets for breast cancer treatment.	Paclitaxel	123-133	transgelin 2	Homo sapiens	58-70
24589594-0	2014	[2-Deoxy-D-glucose combined with Taxol inhibits VEGF expression and induces apoptosis in orthotopically transplanted breast cancer in C3H mice].	Paclitaxel	33-38	vascular endothelial growth factor A	Mus musculus	48-52
24589594-7	2014	CONCLUSION: 2-DG can enhance the inhibitory effect of Taxol on orthotopically transplanted breast cancer xenograft in C3H mice probably by inducing tumor cell apoptosis and lowering VEGF expressions.	Paclitaxel	54-59	vascular endothelial growth factor A	Mus musculus	182-186
24180344-11	2014	The CD4(+) lymphocyte numbers in the IE spaces were significantly lower in both PTX groups than in the control group.	Paclitaxel	80-83	CD4 antigen	Mus musculus	4-7
24512789-5	2014	Besides, near infra-red agent DiR was used to prepare PTX/DiR hybrid NCs and PTX/DiR hybrid NCs-Gel as well.	Paclitaxel	54-57	arginine vasopressin receptor 2	Mus musculus	30-33
24512789-5	2014	Besides, near infra-red agent DiR was used to prepare PTX/DiR hybrid NCs and PTX/DiR hybrid NCs-Gel as well.	Paclitaxel	54-57	arginine vasopressin receptor 2	Mus musculus	58-61
24512789-5	2014	Besides, near infra-red agent DiR was used to prepare PTX/DiR hybrid NCs and PTX/DiR hybrid NCs-Gel as well.	Paclitaxel	54-57	arginine vasopressin receptor 2	Mus musculus	58-61
24512789-5	2014	Besides, near infra-red agent DiR was used to prepare PTX/DiR hybrid NCs and PTX/DiR hybrid NCs-Gel as well.	Paclitaxel	77-80	arginine vasopressin receptor 2	Mus musculus	30-33
24512789-8	2014	Obviously, PTX/DiR hybrid NCs-Gel presented better localized retention capacity and a much longer retention time in murine 4T1 tumor than PTX/DiR hybrid NCs and Cremophor/ethanol solubilized DiR in vivo.	Paclitaxel	11-14	arginine vasopressin receptor 2	Mus musculus	142-145
24512789-8	2014	Obviously, PTX/DiR hybrid NCs-Gel presented better localized retention capacity and a much longer retention time in murine 4T1 tumor than PTX/DiR hybrid NCs and Cremophor/ethanol solubilized DiR in vivo.	Paclitaxel	11-14	arginine vasopressin receptor 2	Mus musculus	142-145
25490359-1	2014	The authors analysed the results of balloon angioplasty using paclitaxel-coated balloons (IN.PACT Admiral, Medtronic Inc., USA) in patients with occlusive and stenotic lesions of arteries of the femoropopliteal segment.	Paclitaxel	62-72	RB binding protein 6, ubiquitin ligase	Homo sapiens	93-97
24621501-4	2014	In taxol- and nocodazole-exposed cells, phospho-Bcl-xL(Ser62) also binds to Cdc20- Mad2-, BubR1-, and Bub3-bound complexes, while Bcl-xL(Ser62Ala) does not.	Paclitaxel	3-8	cell division cycle 20	Homo sapiens	76-81
24060929-0	2014	Paclitaxel-loaded PCL-TPGS nanoparticles: in vitro and in vivo performance compared with Abraxane .	Paclitaxel	0-10	PHD finger protein 1	Homo sapiens	18-21
24060929-3	2014	PTX-loaded poly(epsilon-caprolactone)-alpha tocopheryl polyethylene glycol 1000 succinate (PCL-TPGS) NPs were prepared using three different techniques: (i) by nanoprecipitation (NPr-method), (ii) by emulsion-solvent evaporation homogenized with an Ultra-Turrax( ) (UT-method) and (iii) by emulsion-solvent evaporation homogenized with an ultrasonicator (US-method).	Paclitaxel	0-3	PHD finger protein 1	Homo sapiens	91-94
24060929-7	2014	Cytotoxicity studies with both cell lines showed that PTX-loaded PCL-TPGS NPs exhibited better anti-cancer activity compared to PTX solution and the commercial formulation Abraxane( ) at different concentrations.	Paclitaxel	54-57	PHD finger protein 1	Homo sapiens	65-68
24060929-8	2014	Importantly, in the case of triple negative MDA-MB-231 breast cancer cells, the IC50 value for PTX-loaded PCL-TPGS NPs was 7.8 times lower than Abraxane( ).	Paclitaxel	95-98	PHD finger protein 1	Homo sapiens	106-109
24060929-9	2014	Finally, in vivo studies demonstrated that PTX-loaded PCL-TPGS NPs exhibited longer systemic circulation time and slower plasma elimination rate than Taxol( ) and Abraxane( ).	Paclitaxel	43-46	PHD finger protein 1	Homo sapiens	54-57
25022573-6	2014	MDM2 ASONs downregulated MDM2 expression in a dose-dependent manner and increased the rate of paclitaxel-induced cell growth inhibition.	Paclitaxel	94-104	MDM2 proto-oncogene	Homo sapiens	0-4
24305604-12	2013	Furthermore, after inhibition of autophagy with 3-Methyladenine (3-MA) or Beclin 1 siRNA, apoptosis induced by paclitaxel was significantly increased in FLCN-deficient UOK257 and ACHN-5968 cells.	Paclitaxel	111-121	beclin 1	Homo sapiens	74-82
24263099-7	2013	Consequently, Bortezomib counteracts Taxol-induced mitotic arrest and polyploidy, as shown by reduced expression of PLK1 and phosphorylated histone H3.	Paclitaxel	37-42	polo like kinase 1	Homo sapiens	116-120
24036854-3	2013	We hypothesize that a developed cancer-targeted delivery system that combines CD44 siRNA with paclitaxel would successfully deliver its payload inside cancer cells, effectively induce cell death, and prevent metastases.	Paclitaxel	94-104	CD44 molecule (Indian blood group)	Homo sapiens	78-82
24260253-4	2013	Docetaxel (Doc) and paclitaxel (Pac) agents showed different effects on LNCaP and LNb4 evidenced by alteration in the protein and mRNA levels of c-jun, AR and PSA.	Paclitaxel	20-30	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	145-150
24002934-3	2013	Therefore to improve efficacy, we have developed an ultra-small hyaluronic acid (HA) paclitaxel nanoconjugate (~5 kDa) that can passively diffuse across the leaky blood-tumor barrier and then be taken up into cancer cells (MDA-MB-231Br) via CD44 receptor-mediated endocytocis.	Paclitaxel	85-95	CD44 molecule (Indian blood group)	Homo sapiens	241-245
23803690-8	2013	Tumor stromal density was decreased by nab-paclitaxel and to a lesser extent by docetaxel as measured through reduction in alpha-smooth muscle actin, S100A4 and collagen 1 expression.	Paclitaxel	43-53	S100 calcium binding protein A4	Homo sapiens	150-156
23108393-0	2013	Sgk1 enhances RANBP1 transcript levels and decreases taxol sensitivity in RKO colon carcinoma cells.	Paclitaxel	53-58	serum/glucocorticoid regulated kinase 1	Homo sapiens	0-4
23108393-5	2013	We report that Sgk1-dependent regulation of RANBP1 has functional consequences on both mitotic microtubule activity and taxol sensitivity of cancer cells.	Paclitaxel	120-125	serum/glucocorticoid regulated kinase 1	Homo sapiens	15-19
23907557-12	2013	Post-HSR paclitaxel on a desensitization protocol is a cost-effective alternative to discontinuing paclitaxel altogether.	Paclitaxel	9-19	HSR	Homo sapiens	5-8
23776197-10	2013	CONCLUSIONS: This study provides independent support of EPHA5-rs7349683 and XKR4-rs4737264 as the first markers of risk of paclitaxel induced neuropathy.	Paclitaxel	123-133	XK related 4	Homo sapiens	76-80
23661607-8	2013	RESULTS: We show that Plk1 phosphorylation of CLIP-170 and p150(Glued) affects cellular responses to paclitaxel.	Paclitaxel	101-111	polo like kinase 1	Homo sapiens	22-26
23661607-8	2013	RESULTS: We show that Plk1 phosphorylation of CLIP-170 and p150(Glued) affects cellular responses to paclitaxel.	Paclitaxel	101-111	CAP-Gly domain containing linker protein 1	Homo sapiens	46-54
23661607-9	2013	Expression of Plk1-unphosphorylatable mutants of CLIP-170 and p150(Glued) results in increased paclitaxel-induced apoptosis, increased protein degradation of the AR, and decreased nuclear accumulation of the AR in response to androgen in prostate cancer cells.	Paclitaxel	95-105	polo like kinase 1	Homo sapiens	14-18
23661607-9	2013	Expression of Plk1-unphosphorylatable mutants of CLIP-170 and p150(Glued) results in increased paclitaxel-induced apoptosis, increased protein degradation of the AR, and decreased nuclear accumulation of the AR in response to androgen in prostate cancer cells.	Paclitaxel	95-105	CAP-Gly domain containing linker protein 1	Homo sapiens	49-57
23978876-6	2013	Further, resistance to paclitaxel-induced cell death was associated with high gremlin-1 and slug expression.	Paclitaxel	23-33	snail family transcriptional repressor 2	Homo sapiens	92-96
23964347-0	2013	Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study.	Paclitaxel	137-147	BRCA1 DNA repair associated	Homo sapiens	61-66
23964347-0	2013	Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study.	Paclitaxel	137-147	BRCA2 DNA repair associated	Homo sapiens	71-76
23706689-3	2013	The K237 peptide-conjugated paclitaxel loaded nanoparticles (K237-PTX-NP), which can target KDR receptors highly expressed in the tumor vasculature, were fabricated for this investigation and the human colorectal adenocarcinoma HCT-15 with naturally expressed P-gp on the cell surface was adopted as the resistant tumor model.	Paclitaxel	28-38	kinase insert domain receptor	Homo sapiens	92-95
24074794-8	2013	However, using a VEGF pathway targeting antibody drug instead of a TKI, with (paclitaxel) chemotherapy, resulted in anti-tumor activity in the metastatic setting, partially reflecting prior clinical results of the E2100 phase III trial of weekly paclitaxel plus bevacizumab.	Paclitaxel	246-256	vascular endothelial growth factor A	Mus musculus	17-21
23868188-0	2013	A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.	Paclitaxel	91-101	kinase insert domain receptor	Homo sapiens	39-44
23500524-5	2013	In this study, we confirmed that paclitaxel enriched breast CSCs (CD44+/CD24-) in a dose-dependent manner in MCF-7 human breast cancer cell line.	Paclitaxel	33-43	CD44 molecule (Indian blood group)	Homo sapiens	66-70
23500524-9	2013	Paclitaxel decreased CD44+/CD24- cell population in MCF-7 cells and reduced the size and number of primary mammospheres after down-regulating the Notch1.	Paclitaxel	0-10	CD44 molecule (Indian blood group)	Homo sapiens	21-25
23624503-3	2013	METHODS: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCT116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells).	Paclitaxel	60-70	CD44 molecule (Indian blood group)	Homo sapiens	74-78
23624503-3	2013	METHODS: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCT116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells).	Paclitaxel	60-70	CD44 molecule (Indian blood group)	Homo sapiens	132-136
23624503-3	2013	METHODS: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCT116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells).	Paclitaxel	60-70	CD44 molecule (Indian blood group)	Homo sapiens	132-136
23624503-3	2013	METHODS: In this study, we investigated the cytotoxicity of paclitaxel in CD44(+)CD24(+) SW1222 colon cancer cells expressing Cdx1 (CD44(+)CD24(+)Cdx1(+) stem cells) and CD44(+)CD24(+) HCT116 colon cancer cells expressing wild-type p53 (CD44(+)CD24(+)p53wt stem cells).	Paclitaxel	60-70	CD44 molecule (Indian blood group)	Homo sapiens	132-136
23624503-6	2013	The isolated CD44(+)CD24(+)Cdx1(+) cells showed higher resistance to paclitaxel-induced cytotoxicity than CD44(+)CD24(+)p53wt cells.	Paclitaxel	69-79	CD44 molecule (Indian blood group)	Homo sapiens	13-17
23624503-7	2013	The resistance of CD44(+)CD24(+)Cdx1(+) cells to paclitaxel is associated with upregulation of Cdx1 and Bcl-2 expression, caspase-3 activity, and the ratio of LC3-II/LC3-I.	Paclitaxel	49-59	CD44 molecule (Indian blood group)	Homo sapiens	18-22
23090875-10	2013	However, in the absence of P-gp, Cyp3a decreased paclitaxel plasma concentrations twofold (p &lt; 0.001).	Paclitaxel	49-59	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	33-38
23453062-6	2013	On the basis of confirming the antitumor activity of HNP:siRNA, we continued to encapsulate a hydrophobic chemotherapeutic drug-paclitaxel (PTX) into HNP to form a "two-in-one" nano-complex (HNP:siRNA/PTX).	Paclitaxel	128-138	kallikrein related peptidase 8	Homo sapiens	53-56
23423488-0	2013	Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel.	Paclitaxel	123-133	microRNA 34c	Homo sapiens	59-66
23423488-8	2013	RESULTS: Quantitative real-time polymerase chain reaction demonstrated that expression of miR-34c-5p was downregulated in paclitaxel-resistant gastric cancer samples (p &lt; 0.01).	Paclitaxel	122-132	microRNA 34c	Homo sapiens	90-97
23423488-11	2013	Overexpression of miR-34c-5p significantly downregulated MAPT protein expression and increased the chemosensitivity of paclitaxel-resistant gastric cancer cells.	Paclitaxel	119-129	microRNA 34c	Homo sapiens	18-25
23423488-13	2013	CONCLUSIONS: DNA methylation, dysregulation of miR-34c-5p, and MAPT expression are critical factors in the chemoresistance of gastric cancer to paclitaxel.	Paclitaxel	144-154	microRNA 34c	Homo sapiens	47-54
23515224-4	2013	XCLASP1 depletion reduced MT advance rates in neuronal growth cones, very much like treatment with Taxol, demonstrating a potential link between MT dynamics in the growth cone and axon extension.	Paclitaxel	99-104	cytoplasmic linker associated protein 1 L homeolog	Xenopus laevis	0-7
23590835-13	2013	We identified a set of eight genes (EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32 and NNMT) showing significant gene-drug correlation with paclitaxel, docetaxel, erlotinib, everolimus and dasatinib.	Paclitaxel	136-146	integrin subunit alpha 3	Homo sapiens	42-47
23590835-13	2013	We identified a set of eight genes (EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32 and NNMT) showing significant gene-drug correlation with paclitaxel, docetaxel, erlotinib, everolimus and dasatinib.	Paclitaxel	136-146	AHNAK nucleoprotein	Homo sapiens	62-67
23329649-8	2013	In vitro studies have shown that BLU could upregulate the expression of BAX and enhance the effect of paclitaxel-induced apoptosis in ovarian cancer cells.	Paclitaxel	102-112	zinc finger MYND-type containing 10	Homo sapiens	33-36
23522120-4	2013	METHODS: We performed exome sequencing on the blood, primary tumor, omental metastasis and recurrence following therapy with carboplatin and paclitaxel, from a patient carrying a BRCA1 S1841R mutation.	Paclitaxel	141-151	BRCA1 DNA repair associated	Homo sapiens	179-184
23364970-15	2013	CONCLUSION: We suggest that blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in TUBB3-expressing gastric cancer cells.	Paclitaxel	69-79	kinase insert domain receptor	Homo sapiens	52-59
23255607-6	2013	Restoring the expression of Bak1 or depleting miR-125b re-sensitizes Snail-expressing cancer cells to Taxol, indicating that miR-125b is critical in Snail-induced chemoresistance.	Paclitaxel	102-107	BCL2 antagonist/killer 1	Homo sapiens	28-32
22721387-7	2013	Finally, mesothelin expression promotes resistance to certain chemotherapy drugs such as TNF-alpha, paclitaxel, and a combination of platinum and cyclophosphamide.	Paclitaxel	100-110	mesothelin	Homo sapiens	9-19
23368632-5	2013	Effect of paclitaxel on the CD44+CD117+cell viability indicated that fewer cells underwent apoptosis in 3D culture than that in 2D one.	Paclitaxel	10-20	CD44 molecule (Indian blood group)	Homo sapiens	28-32
22370637-0	2013	miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis.	Paclitaxel	43-53	microRNA 34c	Homo sapiens	0-7
22370637-8	2013	Among them, miR-34c-5p markedly increased resistance to paclitaxel-induced apoptosis.	Paclitaxel	56-66	microRNA 34c	Homo sapiens	12-19
22370637-9	2013	We demonstrate that Bmf (Bcl-2-modifying factor) is a target of miR-34c-5p, and that its silencing, together with that of c-myc, a known target of miR-34c-5p, contributes to resistance to apoptosis induced by paclitaxel through p53 downregulation.	Paclitaxel	209-219	microRNA 34c	Homo sapiens	64-71
23127332-0	2013	Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel.	Paclitaxel	93-103	reticulon 4 receptor	Homo sapiens	59-62
23127332-1	2013	In the present study, we prepared NGR-modified sterically stabilized liposomes containing paclitaxel (NGR-SSL-PTX) in order to evaluate their potential targeting to aminopeptidase N receptors expressed on tumor endothelial cells and the tumor cell surface and its anti-angiogenic activity following metronomic administration.	Paclitaxel	90-100	reticulon 4 receptor	Homo sapiens	34-37
23577147-0	2013	Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor.	Paclitaxel	0-10	BCL2 antagonist/killer 1	Homo sapiens	32-35
23577147-2	2013	Previous studies indicate that a BH3-only protein BIM (BCL-2 Interacting Mediator of cell death) plays a role in paclitaxel-induced apoptosis.	Paclitaxel	113-123	BCL2-like 11 (apoptosis facilitator)	Mus musculus	50-53
23577147-4	2013	In contrast, both bak (-/-) MEFs and human breast cancer cells in which BAK was down-regulated by shRNA were more resistant to paclitaxel.	Paclitaxel	127-137	BCL2 antagonist/killer 1	Homo sapiens	18-21
23577147-4	2013	In contrast, both bak (-/-) MEFs and human breast cancer cells in which BAK was down-regulated by shRNA were more resistant to paclitaxel.	Paclitaxel	127-137	BCL2 antagonist/killer 1	Homo sapiens	72-75
23577147-5	2013	However, paclitaxel sensitivity was not affected in bax(-/-) MEFs or in human breast cancer cells in which BAX was down-regulated, suggesting that paclitaxel-induced apoptosis is BAK-dependent, but BAX-independent.	Paclitaxel	147-157	BCL2 antagonist/killer 1	Homo sapiens	179-182
23534290-5	2013	Thus, in ATC cells the ionizing radiation and Ptx exhibited competitive effects upon phosphorylation of cell cycle controllers: p53, pRb, CHK2, cAbl and expression of Bax.	Paclitaxel	46-49	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	144-148
22962307-0	2012	Disruption of the interaction between PMCA2 and calcineurin triggers apoptosis and enhances paclitaxel-induced cytotoxicity in breast cancer cells.	Paclitaxel	92-102	ATPase plasma membrane Ca2+ transporting 2	Homo sapiens	38-43
22962307-8	2012	Impairment of the PMCA2/calcineurin interaction enhances paclitaxel-mediated cytotoxicity of breast tumoral cells.	Paclitaxel	57-67	ATPase plasma membrane Ca2+ transporting 2	Homo sapiens	18-23
23146280-8	2012	High VEGF-C mRNA expression was predictive for benefit from adjuvant treatment with paclitaxel (E-T-CMF arm) for OS (test for interaction, Wald"s P = 0.038), while in multivariate analysis the interaction of VEGF-C with taxane treatment was significant for both OS (Wald"s P = 0.019) and DFS (P = 0.041) and continuous VEGF-B mRNA expression values for OS (P = 0.019).	Paclitaxel	84-94	vascular endothelial growth factor B	Homo sapiens	319-325
22506717-8	2012	Finally, human recombinant RANTES and thrombospondin-1 improved survival of Caco-2 cells challenged with paclitaxel.	Paclitaxel	105-115	C-C motif chemokine ligand 5	Homo sapiens	27-33
22619090-0	2012	Sustained delivery of paclitaxel using thermogelling poly(PEG/PPG/PCL urethane)s for enhanced toxicity against cancer cells.	Paclitaxel	22-32	PHD finger protein 1	Homo sapiens	66-69
22998838-0	2012	The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy.	Paclitaxel	34-44	C-X-C motif chemokine receptor 4	Homo sapiens	155-160
23741245-0	2012	EphA2 silencing in nasopharyngeal carcinoma leads to decreased proliferation, invasion and increased sensitization to paclitaxel.	Paclitaxel	118-128	EPH receptor A2	Homo sapiens	0-5
23741245-6	2012	Moreover, human NPC 5-8F cells were infected with lentiviral vector-mediated EphA2-specific shRNA, which resulted in the significant inhibition of cell growth, invasion of 5-8F cells and markedly enhanced the sensitivity of 5-8F cells to the chemotherapeutic agent paclitaxel in vitro.	Paclitaxel	265-275	EPH receptor A2	Homo sapiens	77-82
28920305-11	2012	On days three and six, endostatin-treated mice had greater paclitaxel delivery.	Paclitaxel	59-69	collagen, type XVIII, alpha 1	Mus musculus	23-33
22276743-5	2012	IC50 values were dramatically decreased in cells treated with miR-155 inhibitor combined with taxol, to a greater extent than those treated with taxol alone.	Paclitaxel	94-99	microRNA 155	Homo sapiens	62-69
22276743-5	2012	IC50 values were dramatically decreased in cells treated with miR-155 inhibitor combined with taxol, to a greater extent than those treated with taxol alone.	Paclitaxel	145-150	microRNA 155	Homo sapiens	62-69
22276743-7	2012	The data suggest that miR-155 blockage increased the chemosensitivity to taxol in GBM cells, making combined treatment an effective therapeutic strategy for controlling the growth by inhibiting EAG1 expression.	Paclitaxel	73-78	microRNA 155	Homo sapiens	22-29
22931803-7	2012	Meanwhile, the paclitaxel promoted the expression level of SM-alpha-actin and SM22alpha.	Paclitaxel	15-25	transgelin	Rattus norvegicus	78-87
22410114-0	2012	Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity.	Paclitaxel	28-38	cathepsin B	Homo sapiens	6-17
22497485-0	2012	Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy.	Paclitaxel	30-40	transferrin	Mus musculus	0-11
22497485-2	2012	In this study, Transferrin (Tf) modified cyclo-[Arg-Gly-Asp-d-Phe-Lys] (c[RGDfK])-paclitaxel conjugate (RP) loaded micelle (TRPM) was prepared and evaluated for its targeting efficiency, antiglioma activity, and toxicity in vitro and in vivo.	Paclitaxel	82-92	transferrin	Mus musculus	15-26
22497485-2	2012	In this study, Transferrin (Tf) modified cyclo-[Arg-Gly-Asp-d-Phe-Lys] (c[RGDfK])-paclitaxel conjugate (RP) loaded micelle (TRPM) was prepared and evaluated for its targeting efficiency, antiglioma activity, and toxicity in vitro and in vivo.	Paclitaxel	82-92	transferrin	Mus musculus	28-30
22497485-3	2012	Tf modification significantly enhanced the cellular uptake of TRPM by primary brain microvascular endothelial cells (BMEC) to 2.4-fold of RP loaded micelle (RPM) through Tf receptor mediated endocytosis, resulting in a high drug accumulation in the brain after intravenous injection.The c[RGDfK] modified paclitaxel (PTX) was released from micelle subsequently and targeted to integrin overexpressed glioma cells in vitro, and showed significantly prolonged retention in glioma tumor and peritumoral tissue.	Paclitaxel	305-315	transferrin	Mus musculus	0-2
22497485-3	2012	Tf modification significantly enhanced the cellular uptake of TRPM by primary brain microvascular endothelial cells (BMEC) to 2.4-fold of RP loaded micelle (RPM) through Tf receptor mediated endocytosis, resulting in a high drug accumulation in the brain after intravenous injection.The c[RGDfK] modified paclitaxel (PTX) was released from micelle subsequently and targeted to integrin overexpressed glioma cells in vitro, and showed significantly prolonged retention in glioma tumor and peritumoral tissue.	Paclitaxel	317-320	transferrin	Mus musculus	0-2
22497485-4	2012	Most importantly, TRPM exhibited the strongest antiglioma activity, as the mean survival time of mice bearing intracranial U-87 MG glioma treated with TRPM (42.8 days) was significantly longer than those treated with Tf modified PTX loaded micelle (TPM) (39.5 days), PTX loaded micelle (PM) (34.8 days), Taxol (33.6 days), and saline (34.5 days).	Paclitaxel	229-232	transferrin	Mus musculus	217-219
22076480-0	2012	Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction.	Paclitaxel	0-10	BCL2 antagonist/killer 1	Homo sapiens	105-108
22194218-8	2012	This cell death was mainly caused through phosphorylated caspase 3 (11% increase in paclitaxel + DM-1 compared to the paclitaxel group), as confirmed by reduced malignancy criteria in the ascitic fluid.	Paclitaxel	84-94	caspase 3	Mus musculus	57-66
22194218-8	2012	This cell death was mainly caused through phosphorylated caspase 3 (11% increase in paclitaxel + DM-1 compared to the paclitaxel group), as confirmed by reduced malignancy criteria in the ascitic fluid.	Paclitaxel	118-128	caspase 3	Mus musculus	57-66
22095282-7	2012	Moreover, PRMT1 depletion potentiated paclitaxel-induced ASK1 activation and apoptosis in human breast cancer cells.	Paclitaxel	38-48	protein arginine methyltransferase 1	Homo sapiens	10-15
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	Paclitaxel	75-80	X-linked Kx blood group	Homo sapiens	119-122
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	Paclitaxel	159-164	X-linked Kx blood group	Homo sapiens	119-122
22270553-3	2012	In the current study, amide hydrogen/deuterium exchange coupled with mass spectrometry (HDX-MS) was used to examine the structural and dynamic properties of the MT complex with the microtubule binding domain of MAP4 (MTB-MAP4) in the presence and absence of Taxol.	Paclitaxel	258-263	microtubule associated protein 4	Homo sapiens	211-215
22270553-6	2012	Paradoxically, despite Taxol"s negative effects on MAP4 interactions with the MTs, its binding to the MTB-MAP4-MT complex further reduces the overall deuterium incorporation, suggesting that a more stable complex is formed in the presence of the drug.	Paclitaxel	23-28	microtubule associated protein 4	Homo sapiens	51-55
22270553-6	2012	Paradoxically, despite Taxol"s negative effects on MAP4 interactions with the MTs, its binding to the MTB-MAP4-MT complex further reduces the overall deuterium incorporation, suggesting that a more stable complex is formed in the presence of the drug.	Paclitaxel	23-28	microtubule associated protein 4	Homo sapiens	102-110
22496551-7	2012	Taxol-induced axonal degeneration in Drosophila shares molecular execution mechanisms with vertebrates, including inhibition by both NMNAT (nicotinamide mononucleotide adenylyltransferase) expression and loss of wallenda/DLK (dual leucine zipper kinase).	Paclitaxel	0-5	wallenda	Drosophila melanogaster	221-224
22350800-7	2012	The HA-modified HPMA-copolymer PTX conjugate (P-(HA)(34)-PTX) exhibited 50-times higher cytotoxicity towards CD44-overexpressing cells relative to the control, non-targeted, HPMA-copolymer PTX conjugate (P-PTX).	Paclitaxel	31-34	CD44 molecule (Indian blood group)	Homo sapiens	109-113
22350800-7	2012	The HA-modified HPMA-copolymer PTX conjugate (P-(HA)(34)-PTX) exhibited 50-times higher cytotoxicity towards CD44-overexpressing cells relative to the control, non-targeted, HPMA-copolymer PTX conjugate (P-PTX).	Paclitaxel	57-60	CD44 molecule (Indian blood group)	Homo sapiens	109-113
22350800-7	2012	The HA-modified HPMA-copolymer PTX conjugate (P-(HA)(34)-PTX) exhibited 50-times higher cytotoxicity towards CD44-overexpressing cells relative to the control, non-targeted, HPMA-copolymer PTX conjugate (P-PTX).	Paclitaxel	57-60	CD44 molecule (Indian blood group)	Homo sapiens	109-113
22350800-8	2012	CONCLUSIONS: P-(HA)(34)-PTX was significantly more toxic than the non-targeted P-PTX in cells expressing high levels of CD44.	Paclitaxel	24-27	CD44 molecule (Indian blood group)	Homo sapiens	120-124
22329578-3	2012	Hence, we report on the synthesis and characterizations of a novel EphA2-targeting agent conjugated with the chemotherapeutic drug paclitaxel.	Paclitaxel	131-141	EPH receptor A2	Homo sapiens	67-72
22309939-15	2012	Finally, whereas paclitaxel, doxorubicin, and 5-fluorouracil enriched the CD44high/CD24-/low population compared with control in SUM149, subsequent treatment with BI 2536 killed the emergent population, suggesting that it could potentially be used to prevent relapse.	Paclitaxel	17-27	CD44 molecule (Indian blood group)	Homo sapiens	74-78
21953249-4	2012	Live cell microscopy analysis revealed that CERT depletion induces LAMP2-dependent death of polyploid cells following exit from mitosis in the presence of paclitaxel.	Paclitaxel	155-165	ceramide transporter 1	Homo sapiens	44-48
21953249-4	2012	Live cell microscopy analysis revealed that CERT depletion induces LAMP2-dependent death of polyploid cells following exit from mitosis in the presence of paclitaxel.	Paclitaxel	155-165	lysosomal associated membrane protein 2	Homo sapiens	67-72
21953249-6	2012	These data suggest that the induction of LAMP2-dependent autophagic flux through CERT targeting may provide a rational approach to enhance multidrug sensitization and potentiate the death of polyploid cells following paclitaxel exposure to limit the acquisition of CIN and intra-tumour heterogeneity.	Paclitaxel	217-227	lysosomal associated membrane protein 2	Homo sapiens	41-46
21953249-6	2012	These data suggest that the induction of LAMP2-dependent autophagic flux through CERT targeting may provide a rational approach to enhance multidrug sensitization and potentiate the death of polyploid cells following paclitaxel exposure to limit the acquisition of CIN and intra-tumour heterogeneity.	Paclitaxel	217-227	ceramide transporter 1	Homo sapiens	81-85
22206665-0	2012	ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression.	Paclitaxel	46-56	matrix metallopeptidase 9	Homo sapiens	139-143
22206665-7	2012	Our results suggest that ETS1 promotes paclitaxel resistance and invasion in part by up-regulating MDR1 and MMP9 expression.	Paclitaxel	39-49	matrix metallopeptidase 9	Homo sapiens	108-112
23037162-2	2012	HuH-7/PTX cells expressed high levels of MDR-1 and efficiently exported calcein-acetoxymethylester (calcein-AM), which is a substrate of MDR-1, suggesting that HuH-7/PTX cells resist paclitaxel by overexpressing MDR-1.	Paclitaxel	183-193	MIR7-3 host gene	Homo sapiens	0-5
23037162-2	2012	HuH-7/PTX cells expressed high levels of MDR-1 and efficiently exported calcein-acetoxymethylester (calcein-AM), which is a substrate of MDR-1, suggesting that HuH-7/PTX cells resist paclitaxel by overexpressing MDR-1.	Paclitaxel	183-193	MIR7-3 host gene	Homo sapiens	160-165
23037162-4	2012	Additionally, the sensitivity of HuH-7/PTX cells to paclitaxel was increased in combination with these Kampo medicines, indicating that takushato and goreisan overcame paclitaxel resistance in the cells by suppressing drug export by MDR-1.	Paclitaxel	52-62	MIR7-3 host gene	Homo sapiens	33-38
23037162-4	2012	Additionally, the sensitivity of HuH-7/PTX cells to paclitaxel was increased in combination with these Kampo medicines, indicating that takushato and goreisan overcame paclitaxel resistance in the cells by suppressing drug export by MDR-1.	Paclitaxel	168-178	MIR7-3 host gene	Homo sapiens	33-38
23037162-6	2012	Moreover, the principal components of Alismatis Rhizoma, Alisol A, Alisol B, and Alisol B acetate, were found to increase the sensitivity to paclitaxel in HuH-7/PTX by inhibiting drug export by MDR-1 without affecting the expression levels of MDR-1.	Paclitaxel	141-151	MIR7-3 host gene	Homo sapiens	155-160
22313785-2	2012	The structure of paclitaxel is composed of two key elements, a taxane ring and an N-benzoylphenylisoserine side chain at C-13.	Paclitaxel	17-27	homeobox C13	Homo sapiens	121-125
21391217-5	2012	Furthermore, the activity of ERK1/2 was enhanced by the combination of K8 and paclitaxel, and an ERK1/2 inhibitor dramatically inhibited NAG-1 expression in human lung cancer cells.	Paclitaxel	78-88	growth differentiation factor 15	Homo sapiens	137-142
21391217-7	2012	Moreover, over-expression of NAG-1 enhanced K8/paclitaxel-induced apoptosis in human lung cancer cells.	Paclitaxel	47-57	growth differentiation factor 15	Homo sapiens	29-34
21391217-10	2012	Our results reveal that activation of NAG-1 by K8 enhanced the therapeutic efficacy of paclitaxel in human lung cancer cells via the ERK1/2 signaling pathway.	Paclitaxel	87-97	growth differentiation factor 15	Homo sapiens	38-43
23193911-5	2012	In the SC-560/celecoxib/taxol group, the index of cell proliferation and apoptosis and quantification of cyclin D1-postive cells were 6.93%, 69.62%, and 19.14%, respectively, which are statistically significant compared with those of the control group (29.85%, p &lt; 0.001; 32.81% and 36.99%, both p &lt; 0.05).	Paclitaxel	24-29	cyclin D1	Mus musculus	105-114
23152892-4	2012	In taxol-treated oocytes, ASPM colocalized with Ac-tubulin on the excessively polymerized microtubule fibers of enlarged spindles and the numerous asters in the cytoplasm.	Paclitaxel	3-8	abnormal spindle microtubule assembly	Mus musculus	26-30
22080896-3	2011	RESULTS: Serum deprivation treatment resulted in significant increase in paclitaxel sensitivity by factors of mean +- SD, 148.6 +- 28.1 and 10.1 +- 1.0 (n = 3; P &lt; 0.001) fold in platinum-resistant C13 and CP70 cells, respectively.	Paclitaxel	73-83	homeobox C13	Homo sapiens	201-204
22080896-7	2011	More than 7-fold increase of apoptotic cells were observed in C13 or CP70 cells when they were treated by serum deprivation followed by paclitaxel compared with the treatment of either serum deprivation or paclitaxel alone.	Paclitaxel	136-146	homeobox C13	Homo sapiens	62-65
22080896-7	2011	More than 7-fold increase of apoptotic cells were observed in C13 or CP70 cells when they were treated by serum deprivation followed by paclitaxel compared with the treatment of either serum deprivation or paclitaxel alone.	Paclitaxel	206-216	homeobox C13	Homo sapiens	62-65
21903450-6	2011	HA-paclitaxel concentration-dependent growth inhibition of human SCCHN cell lines OSC-19 and HN5 in vitro, very similarly to free paclitaxel treatment.	Paclitaxel	3-13	MT-RNR2 like 5 (pseudogene)	Homo sapiens	93-96
21903450-8	2011	HA-paclitaxel administered intravenously once per week for three weeks at 120 mg/kg paclitaxel equivalents, far above the paclitaxel maximum tolerated dose, exerted superior tumor growth control to that of paclitaxel in both orthotopic OSC-19-luciferase and HN5 xenograft models in vivo.	Paclitaxel	3-13	MT-RNR2 like 5 (pseudogene)	Homo sapiens	258-261
22017876-6	2011	Biologically, DEPTOR accumulation upon betaTrCP knockdown inactivates mTORC1 and activates AKT in cancer cells to confer resistance to rapamycin and paclitaxel.	Paclitaxel	149-159	DEP domain containing MTOR interacting protein	Homo sapiens	14-20
22701761-10	2011	MDM2-mediated increase in p100/NF-kappaB2 expression reduced cell death mediated by paclitaxel.	Paclitaxel	84-94	MDM2 proto-oncogene	Homo sapiens	0-4
22701761-10	2011	MDM2-mediated increase in p100/NF-kappaB2 expression reduced cell death mediated by paclitaxel.	Paclitaxel	84-94	nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100	Mus musculus	31-41
21761557-4	2011	Interestingly, four septins (SEPT2, 8, 9 and 11), which are GTPases involved in cytokinesis and in MT/actin cytoskeleton organization, were overexpressed and enriched in the MT environment of Taxol-resistant cells compared to their sensitive counterpart.	Paclitaxel	192-197	septin 2	Homo sapiens	29-47
21813412-8	2011	The siRNA knockdown of Src, Fyn, or Abl1 enhanced paclitaxel-mediated growth inhibition in ovarian cancer cells compared with a control siRNA.	Paclitaxel	50-60	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	36-40
21511395-3	2011	Paclitaxel treatment could lead to the formation of acidic vesicular organelles (AVOs), the induction of Atg5, Beclin 1 and microtubule-associated protein 1 light chain 3 (LC3) expressions, and the increase of punctate fluorescent signals in A549 cells pre-transfected with green fluorescent protein (GFP)-tagged LC3.	Paclitaxel	0-10	beclin 1	Homo sapiens	111-119
21511395-3	2011	Paclitaxel treatment could lead to the formation of acidic vesicular organelles (AVOs), the induction of Atg5, Beclin 1 and microtubule-associated protein 1 light chain 3 (LC3) expressions, and the increase of punctate fluorescent signals in A549 cells pre-transfected with green fluorescent protein (GFP)-tagged LC3.	Paclitaxel	0-10	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	172-175
21511395-3	2011	Paclitaxel treatment could lead to the formation of acidic vesicular organelles (AVOs), the induction of Atg5, Beclin 1 and microtubule-associated protein 1 light chain 3 (LC3) expressions, and the increase of punctate fluorescent signals in A549 cells pre-transfected with green fluorescent protein (GFP)-tagged LC3.	Paclitaxel	0-10	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	313-316
21511395-4	2011	Interestingly, paclitaxel-mediated apoptotic cell death was further potentiated by pretreatment with autophagy inhibitor 3-methyladenine (3-MA) or small interfering RNA against the autophagic gene beclin1.	Paclitaxel	15-25	beclin 1	Homo sapiens	197-204
21775090-2	2011	We explored the MDR induced by PTX in human colon cancer DLD1 and glioblastoma U87 cell lines.	Paclitaxel	31-34	small nucleolar RNA, C/D box 87	Homo sapiens	79-82
21792009-11	2011	Furthermore, in nude mice model, restored expression of CHFR by demethylation inhibited tumor growth and decreased sensitivity to paclitaxel.	Paclitaxel	130-140	checkpoint with forkhead and ring finger domains	Mus musculus	56-60
21482433-2	2011	We recently developed particle clusters coated with hyaluronan (termed gagomers; GAG), and showed that they can deliver the insoluble drug paclitaxel directly into CD44-over-expressing tumors in a mouse tumor model.	Paclitaxel	139-149	CD44 antigen	Mus musculus	164-168
21518725-0	2011	B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.	Paclitaxel	26-36	CD276 antigen	Mus musculus	0-5
21518725-5	2011	Next, we investigated the mechanisms behind B7-H3-mediated paclitaxel resistance and found that the level of Stat3 Tyr705 phosphorylation was decreased in B7-H3 knockdown cells along with the expression of its direct downstream targets Mcl-1 and survivin.	Paclitaxel	59-69	CD276 antigen	Mus musculus	44-49
21518725-5	2011	Next, we investigated the mechanisms behind B7-H3-mediated paclitaxel resistance and found that the level of Stat3 Tyr705 phosphorylation was decreased in B7-H3 knockdown cells along with the expression of its direct downstream targets Mcl-1 and survivin.	Paclitaxel	59-69	CD276 antigen	Mus musculus	155-160
21518725-10	2011	Taken together, our data show that in breast cancer cells, B7-H3 induces paclitaxel resistance, at least partially by interfering with Jak2/Stat3 pathway.	Paclitaxel	73-83	CD276 antigen	Mus musculus	59-64
21248239-4	2011	However, primary DRG cultures lacking VEGF-B or FLT1 exhibited increased neuronal stress and were more susceptible to paclitaxel-induced cell death.	Paclitaxel	118-128	FMS-like tyrosine kinase 1	Mus musculus	48-52
21327324-0	2011	Basic helix-loop-helix transcription factors DEC1 and DEC2 regulate the paclitaxel-induced apoptotic pathway of MCF-7 human breast cancer cells.	Paclitaxel	72-82	basic helix-loop-helix family member e41	Homo sapiens	54-58
21327324-3	2011	In this study, we sought to examine the roles of DEC1 and DEC2 in MCF-7 human breast cancer cells that had been treated with paclitaxel.	Paclitaxel	125-135	basic helix-loop-helix family member e41	Homo sapiens	58-62
21327324-4	2011	The expression of DEC1 and DEC2 was up-regulated in paclitaxel-treated MCF-7 cells.	Paclitaxel	52-62	basic helix-loop-helix family member e41	Homo sapiens	27-31
21327324-6	2011	Immunofluorescent staining revealed that paclitaxel treatment increased the amount of DEC1 in the nucleus, and increased the amount of DEC2 in both the nucleus and cytoplasm.	Paclitaxel	41-51	basic helix-loop-helix family member e41	Homo sapiens	135-139
21327324-7	2011	These results indicate that DEC1 has pro-apoptotic effects, whereas DEC2 has anti-apoptotic effects on the paclitaxel-induced apoptosis in human breast cancer MCF-7 cells.	Paclitaxel	107-117	basic helix-loop-helix family member e41	Homo sapiens	68-72
21547672-7	2011	Furthermore, the activity of MMP-2, a key enzyme in tumor cell invasion, was significantly decreased in cells treated with the combination of paclitaxel and ATRA while other combinations and single agents did not significantly affect its activity.	Paclitaxel	142-152	matrix metallopeptidase 2	Mus musculus	29-34
21057857-6	2011	In 24-h incubation, the encapsulated PTX could induce caspase 3/7-dependent apoptosis at 50 nM, whereas the CA4-loaded NPs could disrupt tubulin structure at 2.5 muM.	Paclitaxel	37-40	caspase 3	Mus musculus	54-63
20844568-1	2011	Endostatin potentiates the antimitotic effects of paclitaxel (taxol) on endothelial cells (ECs).	Paclitaxel	50-60	collagen, type XVIII, alpha 1	Mus musculus	0-10
20844568-1	2011	Endostatin potentiates the antimitotic effects of paclitaxel (taxol) on endothelial cells (ECs).	Paclitaxel	62-67	collagen, type XVIII, alpha 1	Mus musculus	0-10
21485835-1	2011	This study was aimed to develop chitosan coupled lipid nanoparticle (Ch-Ptx-Lip), where immunomodulatory activity of chitosan and chemotherapeutic effect of paclitaxel can synergistically enhance efficacy of this novel drug delivery system.	Paclitaxel	157-167	SMG1 nonsense mediated mRNA decay associated PI3K related kinase	Homo sapiens	76-79
20890306-4	2011	Plk1 phosphorylates FADD at Ser-194 in response to treatment with taxol.	Paclitaxel	66-71	polo like kinase 1	Homo sapiens	0-4
20890306-12	2011	Collectively, our data demonstrate that in response to taxol, Plk1 endows death-promoting and tumor-suppressor functions to its substrate, FADD.	Paclitaxel	55-60	polo like kinase 1	Homo sapiens	62-66
20926128-9	2011	Thus, according to the achieved results it is suggested that PAA-cysteine in combination with GSH would be a potentially valuable tool for improving the oral bioavailability of P-gp and CYP450 substrates such as paclitaxel.	Paclitaxel	212-222	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	177-181
22216199-4	2011	METHODOLOGY/PRINCIPAL FINDINGS: Our results from cell viability assay, western-blots and TdT-mediated dUTP-biotin nick end labeling (TUNEL) assay demonstrated the synergistic pro-apoptotic effects of a low dose of apigenin and paclitaxel in human cancer cell lines.	Paclitaxel	227-237	DNA nucleotidylexotransferase	Homo sapiens	89-92
22140576-9	2011	In rat balloon injury model (Sprague-Dawley rats, n = 10/group) with continuous paclitaxel infusion, the PPAR-gamma agonist attenuated TF expression by 70+-5% (n = 4; P&lt;0.0001) in injured vasculature.	Paclitaxel	80-90	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	105-115
22110595-2	2011	In the present study, we have investigated the efficacy of microtubule stabilizing paclitaxel loaded magnetic nanoparticles (pac-MNPs) to ascertain its cytotoxic effect on Bcr-Abl positive K562 cells.	Paclitaxel	83-93	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	172-179
21935404-11	2011	Our results thus reveal that 1) not all DTCs are necessarily CSCs; 2) conventional chemotherapeutic drugs such as taxol and etoposide may directly target CD44(+) tumor-initiating cells; and 3) DTCs generated via chronic drug selection involve epigenetic mechanisms.	Paclitaxel	114-119	CD44 molecule (Indian blood group)	Homo sapiens	154-158
21059223-0	2010	ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.	Paclitaxel	58-68	zinc finger protein 217	Homo sapiens	0-6
21059223-3	2010	RESULTS: We provide evidence that stable overexpression of ZNF217 in MDA-MB-231 breast cancer cells conferred resistance to paclitaxel, stimulated cell proliferation in vitro associated with aberrant expression of several cyclins, and increased tumor growth in mouse xenograft models.	Paclitaxel	124-134	zinc finger protein 217	Homo sapiens	59-65
21059223-4	2010	Conversely, siRNA-mediated silencing of ZNF217 expression in MCF7 breast cancer cells, which possess high endogenous levels of ZNF217, led to decreased cell proliferation and increased sensitivity to paclitaxel.	Paclitaxel	200-210	zinc finger protein 217	Homo sapiens	40-46
21059223-4	2010	Conversely, siRNA-mediated silencing of ZNF217 expression in MCF7 breast cancer cells, which possess high endogenous levels of ZNF217, led to decreased cell proliferation and increased sensitivity to paclitaxel.	Paclitaxel	200-210	zinc finger protein 217	Homo sapiens	127-133
21059223-5	2010	The paclitaxel resistance developed by ZNF217-overexpressing MDA-MB-231 cells was not mediated by the ABCB1/PgP transporter.	Paclitaxel	4-14	zinc finger protein 217	Homo sapiens	39-45
21059223-6	2010	However, ZNF217 was able to counteract the apoptotic signals mediated by paclitaxel as a consequence of alterations in the intrinsic apoptotic pathway through constitutive deregulation of the balance of Bcl-2 family proteins.	Paclitaxel	73-83	zinc finger protein 217	Homo sapiens	9-15
21059223-8	2010	We showed that a potent Aurora-A kinase inhibitor was able to reverse paclitaxel resistance in the ZNF217-overexpressing cells.	Paclitaxel	70-80	zinc finger protein 217	Homo sapiens	99-105
20858016-9	2010	Our results suggest that hnRNP A2 and GDI 2 may represent potential biomarkers of the paclitaxel-resistant ovarian cancers for tailored cancer therapy.	Paclitaxel	86-96	GDP dissociation inhibitor 2	Homo sapiens	38-43
20549538-6	2010	In vitro experiments verified that CD44(+)CD24- cells were markedly resistant to carboplatin and paclitaxol.	Paclitaxel	97-107	CD44 molecule (Indian blood group)	Homo sapiens	35-39
20687223-6	2010	RESULTS: MiR-34a over-expression and SIRT1 knockdown attenuated paclitaxel resistance of PC3PR cells.	Paclitaxel	64-74	sirtuin 1	Homo sapiens	37-42
20687223-12	2010	Thus, in PC3PR cells, reduced expression of miR-34a confers paclitaxel resistance via up-regulating SIRT1 and Bcl2 expression.	Paclitaxel	60-70	sirtuin 1	Homo sapiens	100-105
20687223-13	2010	CONCLUSIONS: MiR-34a and its downstream targets SIRT1 and Bcl2 play important roles in the development of paclitaxel resistance, all of which can be useful biomarkers and promising therapeutic targets for the drug resistance in hormone-refractory prostate cancer.	Paclitaxel	106-116	sirtuin 1	Homo sapiens	48-53
20683396-8	2010	RESULTS: Macrophage chemoattractant protein-1 transcript levels were up-regulated in MA-148 after treatment with paclitaxel and carboplatin individually and in combination.	Paclitaxel	113-123	chemokine (C-C motif) ligand 2	Mus musculus	9-45
20656224-9	2010	Paclitaxel was measurable in only the plasma immediately after stent placement, with a linear dose relationship and a timely regression: measurements in high-dose stents were 0.0454-0.656 ng/mL at 1 minute and 0.0329-0.0879 ng/mL at 5 minutes.	Paclitaxel	0-10	solute carrier family 7 (cationic amino acid transporter, y+ system), member 5	Mus musculus	191-198
20353770-4	2010	Results showed a massive impairment of erythropoiesis early post paclitaxel administration (1-2 days), which involved induction of high Bax/Bcl-x(L) ratio, caspase-3 activation, disruptions of the medullar niche and cell death by both apoptosis and necrosis.	Paclitaxel	65-75	BCL2-associated X protein	Mus musculus	136-139
20353770-4	2010	Results showed a massive impairment of erythropoiesis early post paclitaxel administration (1-2 days), which involved induction of high Bax/Bcl-x(L) ratio, caspase-3 activation, disruptions of the medullar niche and cell death by both apoptosis and necrosis.	Paclitaxel	65-75	caspase 3	Mus musculus	156-165
20434553-7	2010	Results showed that coadministration of OVA with paclitaxel induced significantly higher IgG, IgG1, IgG2a, IgG2b, IgG3 and IgM responses than when OVA was used alone.	Paclitaxel	49-59	LOC105243590	Mus musculus	94-98
20434553-7	2010	Results showed that coadministration of OVA with paclitaxel induced significantly higher IgG, IgG1, IgG2a, IgG2b, IgG3 and IgM responses than when OVA was used alone.	Paclitaxel	49-59	immunoglobulin heavy constant gamma 2B	Mus musculus	107-112
20434553-8	2010	In addition, up-regulated T-bet/GATA-3 together with significantly increased mRNA expression of IL-4, IL-10, IFN-gamma and IL-12 by splenocytes, as well as the proliferative responses of splenocytes to Con A, LPS and OVA were observed in paclitaxel-adjuvanted groups.	Paclitaxel	238-248	T-box 21	Mus musculus	26-31
20530690-0	2010	FoxM1 mediates resistance to herceptin and paclitaxel.	Paclitaxel	43-53	forkhead box M1	Homo sapiens	0-5
20530690-3	2010	In this study, we report that FoxM1 overexpression confers resistance to the human epidermal growth factor receptor 2 monoclonal antibody Herceptin and microtubule-stabilizing drug paclitaxel, both as single agents and in combination.	Paclitaxel	181-191	forkhead box M1	Homo sapiens	30-35
20530690-4	2010	FoxM1 altered microtubule dynamics to protect tumor cells from paclitaxel-induced apoptosis.	Paclitaxel	63-73	forkhead box M1	Homo sapiens	0-5
20530690-5	2010	Mechanistic investigations revealed that the tubulin-destabilizing protein Stathmin, whose expression also confers resistance to paclitaxel, is a direct transcriptional target of FoxM1.	Paclitaxel	129-139	forkhead box M1	Homo sapiens	179-184
20515770-6	2010	Taxol and nocodazole treatment showed that the localization of Borealin was dependent on microtubule dynamics, whereas survivin was independent of this.	Paclitaxel	0-5	cell division cycle associated 8	Mus musculus	63-71
20515799-4	2010	Taxol treatment resulted in localization of PAK1 on spindle and aster microtubules, while nocodazole treatment induced the dispersion of PAK1 protein into the cytoplasm.	Paclitaxel	0-5	p21 (RAC1) activated kinase 1	Mus musculus	44-48
20509890-9	2010	Cells over-expressing TGFBI displayed increased sensitivity to etoposide, paclitaxel, cisplatin and gemcitabine.	Paclitaxel	74-84	transforming growth factor beta induced	Homo sapiens	22-27
19771430-8	2010	RESULTS: Our results demonstrate that combined therapy gef gene/drugs (paclitaxel, docetaxel or doxurubicin) caused a decrease in cell viability.	Paclitaxel	71-81	Rho/Rac guanine nucleotide exchange factor 2	Homo sapiens	55-58
20436702-7	2010	ATP-CRA could predict clinical response to paclitaxel and cisplatin chemotherapy with high accuracy in advanced gastric cancer patients.	Paclitaxel	43-53	myotubularin related protein 11	Homo sapiens	4-7
20407875-3	2010	In the present study, we investigated the role of the Akt2/Bub1 cross-talking in apoptosis and cell cycle after exposure of the A2780 ovarian cancer cells to paclitaxel (PTX).	Paclitaxel	158-168	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	59-63
20407875-3	2010	In the present study, we investigated the role of the Akt2/Bub1 cross-talking in apoptosis and cell cycle after exposure of the A2780 ovarian cancer cells to paclitaxel (PTX).	Paclitaxel	170-173	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	59-63
19460063-3	2010	The aim of the Pacl-Vin study was to determine the efficacy and safety of paclitaxel in combination with vinorelbine in patients with HRPC, following from a phase I trial.	Paclitaxel	74-84	long intergenic non-protein coding RNA 1191	Homo sapiens	20-23
19604626-9	2010	Previous reports have also shown that a combination of HF10 and paclitaxel (TAX) was more efficacious than either regimen alone for some types of malignant tumors [S. Shimoyama, F. Goshima, O. Teshigahara, H. Kasuya, Y. Kodera, A. Nakao, et al., Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models, Hepatogastroenterology 54 (2007) 1038-1042].	Paclitaxel	64-74	zinc finger protein 35	Homo sapiens	295-299
19604626-9	2010	Previous reports have also shown that a combination of HF10 and paclitaxel (TAX) was more efficacious than either regimen alone for some types of malignant tumors [S. Shimoyama, F. Goshima, O. Teshigahara, H. Kasuya, Y. Kodera, A. Nakao, et al., Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models, Hepatogastroenterology 54 (2007) 1038-1042].	Paclitaxel	314-324	zinc finger protein 35	Homo sapiens	55-59
19876721-3	2010	The structure of HA-amino acid-paclitaxel conjugates was characterized by (1)H NMR and GPC.	Paclitaxel	31-41	glycophorin C (Gerbich blood group)	Homo sapiens	87-90
20068102-7	2010	Elevation of MAP2 in breast cancer cell lines led to increased paclitaxel sensitivity.	Paclitaxel	63-73	microtubule associated protein 2	Homo sapiens	13-17
19924122-2	2010	Preclinical studies in Pgp-deficient and wild-type mice demonstrated that modulation of either Pgp or CYP3A resulted in high systemic exposure to docetaxel or paclitaxel.	Paclitaxel	159-169	phosphoglycolate phosphatase	Mus musculus	95-98
19924122-2	2010	Preclinical studies in Pgp-deficient and wild-type mice demonstrated that modulation of either Pgp or CYP3A resulted in high systemic exposure to docetaxel or paclitaxel.	Paclitaxel	159-169	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	102-107
20015077-2	2010	In this study we show that enforced expression of Evi1 in Rat1 fibroblasts protects from paclitaxel-induced apoptosis, consistent with previously published studies.	Paclitaxel	89-99	MDS1 and EVI1 complex locus	Rattus norvegicus	50-54
20523105-11	2010	Accordingly, the enhanced oral bioavailability in the presence of silibinin could mainly be due to the increased intestinal absorption of paclitaxel via P-gp inhibition.	Paclitaxel	138-148	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	153-157
19747165-9	2009	Thus mesothelin can inhibit paclitaxel-induced cell death mainly by involving PI3K signalling in the regulation of Bcl-2 family expression.	Paclitaxel	28-38	mesothelin	Homo sapiens	5-15
19952419-0	2009	Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.	Paclitaxel	99-104	ATP binding cassette subfamily C member 2	Homo sapiens	49-79
19952419-11	2009	Our findings implicate that montelukast, a relatively safe anti-asthmatic agent, may be used as an adjunct therapy to suppress the efflux of taxol and saquinavir from MRP2 overexpressing cells.	Paclitaxel	141-146	ATP binding cassette subfamily C member 2	Homo sapiens	167-171
20017221-10	2009	CONCLUSION: TWIST, which has a significantly decreased expression in response to paclitaxel in Hep-2 cells, may play a pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.	Paclitaxel	81-91	DNL-type zinc finger	Homo sapiens	95-98
20017221-10	2009	CONCLUSION: TWIST, which has a significantly decreased expression in response to paclitaxel in Hep-2 cells, may play a pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.	Paclitaxel	81-91	DNL-type zinc finger	Homo sapiens	167-170
20017221-10	2009	CONCLUSION: TWIST, which has a significantly decreased expression in response to paclitaxel in Hep-2 cells, may play a pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.	Paclitaxel	135-145	DNL-type zinc finger	Homo sapiens	95-98
20017221-10	2009	CONCLUSION: TWIST, which has a significantly decreased expression in response to paclitaxel in Hep-2 cells, may play a pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.	Paclitaxel	135-145	DNL-type zinc finger	Homo sapiens	167-170
19717209-0	2009	Potentiation of paclitaxel-induced apoptosis by galectin-13 overexpression via activation of Ask-1-p38-MAP kinase and JNK/SAPK pathways and suppression of Akt and ERK1/2 activation in U-937 human macrophage cells.	Paclitaxel	16-26	galectin 13	Homo sapiens	48-59
19717209-4	2009	Galectin-13 overexpression facilitated paclitaxel-induced cell death and nuclear translocation of apoptosis-inducing factor (AIF) and endonuclease-G without inducing mitochondrial cytochrome-c release or caspase-3 activation.	Paclitaxel	39-49	galectin 13	Homo sapiens	0-11
19885629-0	2009	Effects of protein kinase Cdelta and phospholipase C-gamma1 on monocyte chemoattractant protein-1 expression in taxol-induced breast cancer cell death.	Paclitaxel	112-117	protein kinase C, delta	Mus musculus	11-32
19885629-0	2009	Effects of protein kinase Cdelta and phospholipase C-gamma1 on monocyte chemoattractant protein-1 expression in taxol-induced breast cancer cell death.	Paclitaxel	112-117	chemokine (C-C motif) ligand 2	Mus musculus	63-97
19885629-4	2009	We investigated the involvement of MCP-1 in taxol-induced breast cancer cell death.	Paclitaxel	44-49	chemokine (C-C motif) ligand 2	Mus musculus	35-40
19885629-6	2009	Treatment with taxol increased the mRNA expression level of MCP-1 in a dose- and time-dependent manner.	Paclitaxel	15-20	chemokine (C-C motif) ligand 2	Mus musculus	60-65
19885629-7	2009	Up-regulation of MCP-1 by taxol was augmented in cells treated with rottlerin, a specific inhibitor of protein kinase Cdelta (PKCdelta).	Paclitaxel	26-31	chemokine (C-C motif) ligand 2	Mus musculus	17-22
19885629-7	2009	Up-regulation of MCP-1 by taxol was augmented in cells treated with rottlerin, a specific inhibitor of protein kinase Cdelta (PKCdelta).	Paclitaxel	26-31	protein kinase C, delta	Mus musculus	103-124
19885629-7	2009	Up-regulation of MCP-1 by taxol was augmented in cells treated with rottlerin, a specific inhibitor of protein kinase Cdelta (PKCdelta).	Paclitaxel	26-31	protein kinase C, delta	Mus musculus	126-134
19885629-8	2009	In addition, taxol-induced MCP-1 expression was reduced by the ectopic expression of PKCdelta in a dose-dependent manner, indicating that PKCdelta plays a negative role in taxol-induced MCP-1 expression in MCF-7 cells.	Paclitaxel	13-18	chemokine (C-C motif) ligand 2	Mus musculus	27-32
19885629-8	2009	In addition, taxol-induced MCP-1 expression was reduced by the ectopic expression of PKCdelta in a dose-dependent manner, indicating that PKCdelta plays a negative role in taxol-induced MCP-1 expression in MCF-7 cells.	Paclitaxel	13-18	protein kinase C, delta	Mus musculus	85-93
19885629-8	2009	In addition, taxol-induced MCP-1 expression was reduced by the ectopic expression of PKCdelta in a dose-dependent manner, indicating that PKCdelta plays a negative role in taxol-induced MCP-1 expression in MCF-7 cells.	Paclitaxel	13-18	protein kinase C, delta	Mus musculus	138-146
19885629-8	2009	In addition, taxol-induced MCP-1 expression was reduced by the ectopic expression of PKCdelta in a dose-dependent manner, indicating that PKCdelta plays a negative role in taxol-induced MCP-1 expression in MCF-7 cells.	Paclitaxel	13-18	chemokine (C-C motif) ligand 2	Mus musculus	186-191
19885629-8	2009	In addition, taxol-induced MCP-1 expression was reduced by the ectopic expression of PKCdelta in a dose-dependent manner, indicating that PKCdelta plays a negative role in taxol-induced MCP-1 expression in MCF-7 cells.	Paclitaxel	172-177	chemokine (C-C motif) ligand 2	Mus musculus	27-32
19885629-8	2009	In addition, taxol-induced MCP-1 expression was reduced by the ectopic expression of PKCdelta in a dose-dependent manner, indicating that PKCdelta plays a negative role in taxol-induced MCP-1 expression in MCF-7 cells.	Paclitaxel	172-177	protein kinase C, delta	Mus musculus	85-93
19885629-8	2009	In addition, taxol-induced MCP-1 expression was reduced by the ectopic expression of PKCdelta in a dose-dependent manner, indicating that PKCdelta plays a negative role in taxol-induced MCP-1 expression in MCF-7 cells.	Paclitaxel	172-177	protein kinase C, delta	Mus musculus	138-146
19885629-8	2009	In addition, taxol-induced MCP-1 expression was reduced by the ectopic expression of PKCdelta in a dose-dependent manner, indicating that PKCdelta plays a negative role in taxol-induced MCP-1 expression in MCF-7 cells.	Paclitaxel	172-177	chemokine (C-C motif) ligand 2	Mus musculus	186-191
19885629-9	2009	On the other hand, taxol-induced up-regulation of MCP-1 was reduced in cells treated with U73122, an inhibitor of phospholipase C (PLC), and ectopic expression of PLC-gamma1 increased the expression of MCP-1 in taxol-treated MCF-7 cells, indicating that PLC-gamma1 functions as a positive regulator in taxol-induced MCP-1 expression.	Paclitaxel	19-24	chemokine (C-C motif) ligand 2	Mus musculus	50-55
19885629-9	2009	On the other hand, taxol-induced up-regulation of MCP-1 was reduced in cells treated with U73122, an inhibitor of phospholipase C (PLC), and ectopic expression of PLC-gamma1 increased the expression of MCP-1 in taxol-treated MCF-7 cells, indicating that PLC-gamma1 functions as a positive regulator in taxol-induced MCP-1 expression.	Paclitaxel	19-24	phospholipase C, gamma 1	Mus musculus	163-173
19885629-9	2009	On the other hand, taxol-induced up-regulation of MCP-1 was reduced in cells treated with U73122, an inhibitor of phospholipase C (PLC), and ectopic expression of PLC-gamma1 increased the expression of MCP-1 in taxol-treated MCF-7 cells, indicating that PLC-gamma1 functions as a positive regulator in taxol-induced MCP-1 expression.	Paclitaxel	19-24	chemokine (C-C motif) ligand 2	Mus musculus	202-207
19885629-9	2009	On the other hand, taxol-induced up-regulation of MCP-1 was reduced in cells treated with U73122, an inhibitor of phospholipase C (PLC), and ectopic expression of PLC-gamma1 increased the expression of MCP-1 in taxol-treated MCF-7 cells, indicating that PLC-gamma1 functions as a positive regulator in taxol-induced MCP-1 expression.	Paclitaxel	211-216	chemokine (C-C motif) ligand 2	Mus musculus	50-55
19885629-9	2009	On the other hand, taxol-induced up-regulation of MCP-1 was reduced in cells treated with U73122, an inhibitor of phospholipase C (PLC), and ectopic expression of PLC-gamma1 increased the expression of MCP-1 in taxol-treated MCF-7 cells, indicating that PLC-gamma1 functions as a positive regulator in taxol-induced MCP-1 expression.	Paclitaxel	211-216	phospholipase C, gamma 1	Mus musculus	163-173
19885629-9	2009	On the other hand, taxol-induced up-regulation of MCP-1 was reduced in cells treated with U73122, an inhibitor of phospholipase C (PLC), and ectopic expression of PLC-gamma1 increased the expression of MCP-1 in taxol-treated MCF-7 cells, indicating that PLC-gamma1 functions as a positive regulator in taxol-induced MCP-1 expression.	Paclitaxel	211-216	chemokine (C-C motif) ligand 2	Mus musculus	202-207
19885629-9	2009	On the other hand, taxol-induced up-regulation of MCP-1 was reduced in cells treated with U73122, an inhibitor of phospholipase C (PLC), and ectopic expression of PLC-gamma1 increased the expression of MCP-1 in taxol-treated MCF-7 cells, indicating that PLC-gamma1 functions as a positive regulator in taxol-induced MCP-1 expression.	Paclitaxel	211-216	chemokine (C-C motif) ligand 2	Mus musculus	50-55
19885629-9	2009	On the other hand, taxol-induced up-regulation of MCP-1 was reduced in cells treated with U73122, an inhibitor of phospholipase C (PLC), and ectopic expression of PLC-gamma1 increased the expression of MCP-1 in taxol-treated MCF-7 cells, indicating that PLC-gamma1 functions as a positive regulator in taxol-induced MCP-1 expression.	Paclitaxel	211-216	phospholipase C, gamma 1	Mus musculus	163-173
19885629-9	2009	On the other hand, taxol-induced up-regulation of MCP-1 was reduced in cells treated with U73122, an inhibitor of phospholipase C (PLC), and ectopic expression of PLC-gamma1 increased the expression of MCP-1 in taxol-treated MCF-7 cells, indicating that PLC-gamma1 functions as a positive regulator in taxol-induced MCP-1 expression.	Paclitaxel	211-216	chemokine (C-C motif) ligand 2	Mus musculus	202-207
19885629-10	2009	These results indicate that MCP-1 is involved in taxol-induced breast cancer cell death and we propose that taxol induces up-regulation of MCP-1 by affecting both positive and negative regulatory signaling pathways.	Paclitaxel	49-54	chemokine (C-C motif) ligand 2	Mus musculus	28-33
19885629-10	2009	These results indicate that MCP-1 is involved in taxol-induced breast cancer cell death and we propose that taxol induces up-regulation of MCP-1 by affecting both positive and negative regulatory signaling pathways.	Paclitaxel	108-113	chemokine (C-C motif) ligand 2	Mus musculus	139-144
19949674-2	2009	Adenosine triphosphate-based chemotherapy response assay (ATP-CRA) was employed to retrieve chemoresponse to 5-fluorouracil (5-FU), doxetaxel, doxorubicin, epirubicin, and paclitaxel in 49 patients.	Paclitaxel	172-182	myotubularin related protein 11	Homo sapiens	62-65
19996278-7	2009	These studies together provide the first in vivo confirmation that combined TRAIL plus paclitaxel results in better tumor control compared with either TRAIL or paclitaxel alone, and with no discernable increased normal tissue toxicity in the mouse.	Paclitaxel	160-170	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	76-81
19951914-5	2009	Intermediate kinase activity levels obtained with an INCENP mutant that binds aurora B but cannot fully activate it are sufficient for a robust response against taxol, but cannot trigger CPC transfer from the chromosomes to the anaphase spindle midzone.	Paclitaxel	161-166	aurora kinase B	Homo sapiens	78-86
19821097-8	2009	These results suggested that transfection of pEGFP-H1/mdr1 could efficiently down-regulate the expression of mdr1 mRNA and P-gp in A2780/Taxol cells, and effectively restore the sensitivity of A2780/Taxol cells to Taxol both in vitro and in vivo.	Paclitaxel	137-142	phosphoglycolate phosphatase	Mus musculus	123-127
19517469-11	2009	Knockdown of MEKK3 with small interfering RNA significantly increased cancer cell sensitivity to paclitaxel.	Paclitaxel	97-107	mitogen-activated protein kinase kinase kinase 3	Homo sapiens	13-18
19345211-8	2009	Pre-treatment with paclitaxel to stabilize microtubules opposed the thrombin effects.	Paclitaxel	19-29	coagulation factor II, thrombin	Bos taurus	68-76
20079104-1	2009	OBJECTIVE: To explore the relationship between the expression of transcription factor TWIST and apoptosis of Hep-2 cells induced by paclitaxel.	Paclitaxel	132-142	DNL-type zinc finger	Homo sapiens	109-112
20079104-3	2009	Viability of Hep-2 cells treated with various concentrations of paclitaxel was detected by MTT assay.	Paclitaxel	64-74	DNL-type zinc finger	Homo sapiens	13-16
20079104-10	2009	The expression of TWIST at both mRNA and protein levels for 24 h, 48 h or 72 h in the paclitaxel-induced apoptosis of Hep-2 cells were decreased by 16.7%, 46.8%, 76.9% (F = 10.407, P &lt; 0.05) and 16.4%, 33.6%, 69.6% (F = 18.013, P &lt; 0.05) respectively.	Paclitaxel	86-96	DNL-type zinc finger	Homo sapiens	118-121
20079104-11	2009	CONCLUSIONS: TWIST, which is significantly decreased in expression in response to paclitaxel in Hep-2 cells, may play a pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.	Paclitaxel	82-92	DNL-type zinc finger	Homo sapiens	96-99
20079104-11	2009	CONCLUSIONS: TWIST, which is significantly decreased in expression in response to paclitaxel in Hep-2 cells, may play a pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.	Paclitaxel	82-92	DNL-type zinc finger	Homo sapiens	168-171
20079104-11	2009	CONCLUSIONS: TWIST, which is significantly decreased in expression in response to paclitaxel in Hep-2 cells, may play a pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.	Paclitaxel	136-146	DNL-type zinc finger	Homo sapiens	96-99
20079104-11	2009	CONCLUSIONS: TWIST, which is significantly decreased in expression in response to paclitaxel in Hep-2 cells, may play a pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.	Paclitaxel	136-146	DNL-type zinc finger	Homo sapiens	168-171
19520256-5	2009	RESULTS: Treatment with paclitaxel, sirolimus, and everolimus significantly caused a senescent phenotype and PAI-1 up-regulation, associated with a decrease in endothelial nitric oxide synthase (eNOS) and Sirt1 expression.	Paclitaxel	24-34	sirtuin 1	Homo sapiens	205-210
19520256-11	2009	In contrast, the development of endothelial senescence by paclitaxel involves a Sirt1-independent pathway.	Paclitaxel	58-68	sirtuin 1	Homo sapiens	80-85
19500405-13	2009	The ratio of dCK to CDA mRNA levels corresponded to the combination index (CI) estimated for sequential paclitaxel-gemcitabine.	Paclitaxel	104-114	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	13-16
19500405-14	2009	CONCLUSION: In summary, paclitaxel altered the mRNA levels and specific activity of dCK and CDA and these effects could be dependent on histological subtype.	Paclitaxel	24-34	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	84-87
19397590-6	2009	Western blot analysis showed that As(2)O(3) significantly blocked phosphorylation of BubR1, Cdc20, and Cdc27 in cells treated with paclitaxel, suggesting that arsenic compromised the activation of the spindle checkpoint.	Paclitaxel	131-141	cell division cycle 20	Homo sapiens	92-97
19424643-8	2009	It enhanced the sensitivity of A2780/taxol cells to paclitaxel with down-regulation of P-glycoprotein, XIAP and survivin.	Paclitaxel	52-62	X-linked inhibitor of apoptosis	Homo sapiens	103-107
19285047-8	2009	Collectively, the combination of 4-HPR and PTX diminished the survival factors (e.g., rTERT, PCNA, and Bcl-2) to make glioblastoma cells highly prone to apoptosis with activation of cysteine proteases (e.g., calpain, cathepsins, caspase-8, caspase-3).	Paclitaxel	43-46	proliferating cell nuclear antigen	Rattus norvegicus	93-97
19285047-8	2009	Collectively, the combination of 4-HPR and PTX diminished the survival factors (e.g., rTERT, PCNA, and Bcl-2) to make glioblastoma cells highly prone to apoptosis with activation of cysteine proteases (e.g., calpain, cathepsins, caspase-8, caspase-3).	Paclitaxel	43-46	caspase 8	Rattus norvegicus	229-238
18767070-4	2009	Inhibition of GLUT2 by Ph potentiated the anticancer effects of PTX, resensitizing human liver cancer cells to drugs.	Paclitaxel	64-67	solute carrier family 2 member 2	Homo sapiens	14-19
18802696-0	2009	Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse.	Paclitaxel	0-10	toll-like receptor 9	Mus musculus	112-116
18802696-3	2009	We now report that, similar to the depletion of regulatory T cells (Treg) using anti-CD25, paclitaxel increased the anti-tumor effect of the TLR9 agonist PF-3512676 in a CD8(+) T cell-dependent fashion.	Paclitaxel	91-101	toll-like receptor 9	Mus musculus	141-145
19697632-1	2009	We present here a case of a BRCA1 mutation carrier with repeat responsiveness of recurrent EOC to paclitaxel/platinum.	Paclitaxel	98-108	BRCA1 DNA repair associated	Homo sapiens	28-33
19697632-5	2009	In conclusion, recurrent EOC in BRCA1 mutation carriers may retain sensitivity to paclitaxel/platinum combination chemotherapy, and this combination could be therapy of first choice in this patient population.	Paclitaxel	82-92	BRCA1 DNA repair associated	Homo sapiens	32-37
18650420-10	2008	To further define the structural differences for MD-2/TLR4 activation, crystal structures of both murine and human MD-2 were subjected to PTX docking by computational methods.	Paclitaxel	138-141	lymphocyte antigen 96	Homo sapiens	115-119
18650420-11	2008	These models indicate that PTX binds in the pocket of both human and mouse MD-2 structures.	Paclitaxel	27-30	lymphocyte antigen 96	Homo sapiens	75-79
18650420-12	2008	The species-specific difference between human and murine MD-2 activation of TLR4 by PTX can be explained by alterations of surface charge distribution (i.e. electrostatic potential), binding pocket size, and the locus of PTX binding within the MD-2 pocket, which results in reorganization of the 123-130 amino acid loop.	Paclitaxel	84-87	lymphocyte antigen 96	Homo sapiens	57-61
18650420-12	2008	The species-specific difference between human and murine MD-2 activation of TLR4 by PTX can be explained by alterations of surface charge distribution (i.e. electrostatic potential), binding pocket size, and the locus of PTX binding within the MD-2 pocket, which results in reorganization of the 123-130 amino acid loop.	Paclitaxel	84-87	lymphocyte antigen 96	Homo sapiens	244-248
18650420-12	2008	The species-specific difference between human and murine MD-2 activation of TLR4 by PTX can be explained by alterations of surface charge distribution (i.e. electrostatic potential), binding pocket size, and the locus of PTX binding within the MD-2 pocket, which results in reorganization of the 123-130 amino acid loop.	Paclitaxel	221-224	lymphocyte antigen 96	Homo sapiens	57-61
18794086-10	2008	Systematic administration of GLI2 ASO in athymic mice significantly delayed PC-3 tumor progression and enhanced paclitaxel chemosensitivity.	Paclitaxel	112-122	GLI-Kruppel family member GLI2	Mus musculus	29-33
19087722-8	2008	The Ark2 cell apoptotic rates 4 days later of the TSA, PTX, TSA + PTX, and control group were 4.25% +/- 0.25%, 12.12% +/- 0.62%, 16.56% +/- 0.74%, and 46.78% +/- 2.68% respectively by annexin V staining, and 3.39% +/- 0.12%, 6.00% +/- 0.25%, 10.05% +/- 0.53%, and 22.30% +/- 1.25% respectively by Hoechst staining.	Paclitaxel	66-69	aurora kinase B	Homo sapiens	4-8
19087722-10	2008	Lysis of caspase-9 and PARP in the Ark2 and KLE cells increased greatly 24 hours after the TSA and PTX treatment.	Paclitaxel	99-102	aurora kinase B	Homo sapiens	35-39
19087722-11	2008	The disappearance rate of MMP in the Ark2 and AN3 cells of the TSA + PTX groups were 16.80% +/- 0.92% and 11.28% +/- 0.78% respectively, significantly higher than that of the PTX group (5.34% +/- 0.45% and 5.61% +/- 0.56% respectively) and TSA group (4.96% +/- 0.47% and 6.46% +/- 0.62% respectively, all P &lt; 0.05).	Paclitaxel	69-72	aurora kinase B	Homo sapiens	37-41
19087722-12	2008	The expression of acetylated microtubulin was increased in the Ark2 and KLE cells of the TSA + PTX groups.	Paclitaxel	95-98	aurora kinase B	Homo sapiens	63-67
18690848-10	2008	Importantly, we also report that NUPR1 conferred resistance to two chemotherapeutic drugs, Taxol and doxorubicin.	Paclitaxel	91-96	nuclear protein 1, transcriptional regulator	Homo sapiens	33-38
18508881-1	2008	The aim of the present study was to investigate the effects of recombinant interleukin (rIL)-2 treatment on paclitaxel (PLX) pharmacokinetics in the plasma and tissue of Lewis lung carcinoma-bearing mice (lung tissues and s.c. tumors).	Paclitaxel	108-118	radiation-induced leukemia sensitivity 2	Mus musculus	63-94
18508881-1	2008	The aim of the present study was to investigate the effects of recombinant interleukin (rIL)-2 treatment on paclitaxel (PLX) pharmacokinetics in the plasma and tissue of Lewis lung carcinoma-bearing mice (lung tissues and s.c. tumors).	Paclitaxel	120-123	radiation-induced leukemia sensitivity 2	Mus musculus	63-94
18547621-10	2008	BRCA mutation analysis identified germline BRCA1 mutation for further testing and this xenograft showed a significant response to carboplatin/paclitaxel chemotherapy, including a decrease in tumor volume and proliferation but did not demonstrate a response to the poly (ADP-ribose) polymerase-1 inhibitor PJ34.	Paclitaxel	142-152	BRCA1 DNA repair associated	Homo sapiens	0-4
19080518-1	2008	OBJECTIVE: To study the expression of COP9, JAK2, HSP and NADH genes in ovarian carcinoma tissues after taxol-chemotherapy and their significance.	Paclitaxel	104-109	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	50-53
20731930-7	2008	From 1*10(-14) M to 1*10(-6) M, both paclitaxel and gefitinib inhibited the cell proliferation of SPC-A1 cells in a dose-dependent and time-dependent manner in vitro .	Paclitaxel	37-47	ATPase secretory pathway Ca2+ transporting 1	Homo sapiens	98-104
20731930-10	2008	However, sequential administration of gefitinib following paclitaxel can remarkably enhanced the effect of paclitaxel on the cell proliferation of SPC-A1 cells.	Paclitaxel	58-68	ATPase secretory pathway Ca2+ transporting 1	Homo sapiens	147-153
20731930-10	2008	However, sequential administration of gefitinib following paclitaxel can remarkably enhanced the effect of paclitaxel on the cell proliferation of SPC-A1 cells.	Paclitaxel	107-117	ATPase secretory pathway Ca2+ transporting 1	Homo sapiens	147-153
20731930-14	2008	CONCLUSIONS: Both paclitaxel and gefitinib inhibits the cell proliferation of SPC-A1 cells.	Paclitaxel	18-28	ATPase secretory pathway Ca2+ transporting 1	Homo sapiens	78-84
17701176-0	2008	The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors.	Paclitaxel	64-74	kinase insert domain receptor	Homo sapiens	45-51
17701176-1	2008	PURPOSE: The objective of this study was to manufacture paclitaxel (PTX) loaded polymeric microspheres, that were surface conjugated with antibodies to vascular endothelial growth factor receptor 2 (anti-VEGFR2), for systemic targeting to angiogenic sites in prostate tumors.	Paclitaxel	56-66	kinase insert domain receptor	Homo sapiens	152-197
17701176-1	2008	PURPOSE: The objective of this study was to manufacture paclitaxel (PTX) loaded polymeric microspheres, that were surface conjugated with antibodies to vascular endothelial growth factor receptor 2 (anti-VEGFR2), for systemic targeting to angiogenic sites in prostate tumors.	Paclitaxel	56-66	kinase insert domain receptor	Homo sapiens	204-210
17701176-1	2008	PURPOSE: The objective of this study was to manufacture paclitaxel (PTX) loaded polymeric microspheres, that were surface conjugated with antibodies to vascular endothelial growth factor receptor 2 (anti-VEGFR2), for systemic targeting to angiogenic sites in prostate tumors.	Paclitaxel	68-71	kinase insert domain receptor	Homo sapiens	152-197
17701176-1	2008	PURPOSE: The objective of this study was to manufacture paclitaxel (PTX) loaded polymeric microspheres, that were surface conjugated with antibodies to vascular endothelial growth factor receptor 2 (anti-VEGFR2), for systemic targeting to angiogenic sites in prostate tumors.	Paclitaxel	68-71	kinase insert domain receptor	Homo sapiens	204-210
18451172-6	2008	The addition of TRAIL to either nocodazole or paclitaxel (Taxol) reduced levels of the mitotic checkpoint proteins BubR1 and Bub1.	Paclitaxel	46-56	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	125-129
18451172-6	2008	The addition of TRAIL to either nocodazole or paclitaxel (Taxol) reduced levels of the mitotic checkpoint proteins BubR1 and Bub1.	Paclitaxel	58-63	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	125-129
20731895-7	2008	RESULTS: The tumor-inhibiting rate of paclitaxel plus LY294002 (92.47%) was significantly higher than the paclitaxel alone (65.59%)(P &lt;0.05).The protein expression of bcl-2 in paclitaxel plus LY294002 group were significantly higher, while bax was significantly lower than that in the other two groups (P &lt;0.05).	Paclitaxel	38-48	BCL2-associated X protein	Mus musculus	243-246
18341588-0	2008	Distinct signaling pathways of microtubule inhibitors--vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively.	Paclitaxel	71-76	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	121-125
18341588-0	2008	Distinct signaling pathways of microtubule inhibitors--vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively.	Paclitaxel	71-76	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	140-144
18355692-0	2008	Imaging paclitaxel (chemotherapy)-induced tumor apoptosis with 99mTc C2A, a domain of synaptotagmin I: a preliminary study.	Paclitaxel	8-18	synaptotagmin I	Mus musculus	86-101
18355692-1	2008	PURPOSE: To evaluate the dynamics and feasibility of imaging non-small cell lung cancer (NSCLC) apoptosis induced by paclitaxel treatment using 99mTc-labeled C2A domain of synaptotagmin I in a mouse model.	Paclitaxel	117-127	synaptotagmin I	Mus musculus	172-187
18157857-1	2008	Retinoid X receptor agonists (RXR agonists, rexinoids) are interesting candidates for the treatment of cancers such as tamoxifen-resistant breast cancer and taxol-resistant lung cancer.	Paclitaxel	157-162	retinoid X receptor alpha	Homo sapiens	30-33
18316577-11	2008	paclitaxel injections in athymic nude mice bearing KAT4 flank tumors showed significantly reduced mean tumor volume (74 +/- 38 mm(3)) compared with G207 alone (388 +/- 109 mm(3)), paclitaxel alone (439 +/- 137 mm(3)), and control (520 +/- 160 mm(3)) groups at 16 days.	Paclitaxel	0-10	TATA-box binding protein associated factor 1	Mus musculus	51-55
18071906-0	2008	Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol.	Paclitaxel	98-103	X-linked inhibitor of apoptosis	Homo sapiens	8-12
19075668-14	2008	ATP7A-overexpressing cells are resistant to many anticancer drugs including SN-38, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11), vincristine, paclitaxel, etoposide, doxorubicin (Dox), and mitoxantron.	Paclitaxel	173-183	ATPase copper transporting alpha	Homo sapiens	0-5
17881279-10	2008	Half of Abl resolved with Triton X-100 was demonstrated to have catalytic activity as shown with positive phosphotyrosine staining on the Western blot and competitive elution with a specific phosphate, such as sodium beta-glycerophosphate, from HiTrap-PEP(Taxol), but this was not associated with RACK1.	Paclitaxel	256-261	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	8-11
17705027-0	2008	Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice.	Paclitaxel	49-59	collagen, type XVIII, alpha 1	Mus musculus	0-10
17705027-2	2008	The aim of this study was to investigate whether endostatin, a potent anti-angiogenic agent, could enhance the efficacy of paclitaxel to combat breast cancer.	Paclitaxel	123-133	collagen, type XVIII, alpha 1	Mus musculus	49-59
17705027-7	2008	Endostatin gene therapy synergized with paclitaxel in suppressing the growth of 4T1 tumors and their metastasis to the lung and liver.	Paclitaxel	40-50	collagen, type XVIII, alpha 1	Mus musculus	0-10
18187809-4	2008	Using this approach, we discovered that semaphorin 6A (SEMA6A) is down-regulated not only in IDN5390-resistant cells but also in cells made resistant to cisplatin, topotecan, and doxorubicin, whereas no changes were noticed in paclitaxel- and gemcitabine-resistant cells.	Paclitaxel	227-237	semaphorin 6A	Homo sapiens	40-53
18187809-4	2008	Using this approach, we discovered that semaphorin 6A (SEMA6A) is down-regulated not only in IDN5390-resistant cells but also in cells made resistant to cisplatin, topotecan, and doxorubicin, whereas no changes were noticed in paclitaxel- and gemcitabine-resistant cells.	Paclitaxel	227-237	semaphorin 6A	Homo sapiens	55-61
19238186-0	2008	Differential activity of caspase-3 regulates susceptibility of lung and breast tumor cell lines to Paclitaxel.	Paclitaxel	99-109	caspase 3	Mus musculus	25-34
19238186-4	2008	In this study, we investigated the role of caspase-3 in breast and lung tumor cell line sensitivity to paclitaxel.	Paclitaxel	103-113	caspase 3	Mus musculus	43-52
19238186-5	2008	Clonogenic survival and live/dead viability-assays, together with enzymatic activity and cell proliferation assays, reveal that the levels of paclitaxel-induced caspase-3 enzymatic activity in tumor cells correlate directly with tumor sensitivity to the drug.We observed a 2-fold increase in caspase-3 activity in 4T1-Luc breast tumor cells, but a 3-fold and 4-fold decrease in A549 and A427 lung tumor cell lines, respectively.	Paclitaxel	142-152	caspase 3	Mus musculus	161-170
19238186-5	2008	Clonogenic survival and live/dead viability-assays, together with enzymatic activity and cell proliferation assays, reveal that the levels of paclitaxel-induced caspase-3 enzymatic activity in tumor cells correlate directly with tumor sensitivity to the drug.We observed a 2-fold increase in caspase-3 activity in 4T1-Luc breast tumor cells, but a 3-fold and 4-fold decrease in A549 and A427 lung tumor cell lines, respectively.	Paclitaxel	142-152	caspase 3	Mus musculus	292-301
19002265-2	2008	BRCA1 overexpression increases sensitivity to paclitaxel and docetaxel.	Paclitaxel	46-56	BRCA1 DNA repair associated	Homo sapiens	0-5
18068629-2	2007	Here, we show that loss of the ECM protein TGFBI (transforming growth factor beta induced) is sufficient to induce specific resistance to paclitaxel and mitotic spindle abnormalities in ovarian cancer cells.	Paclitaxel	138-148	transforming growth factor beta induced	Homo sapiens	43-48
18068629-2	2007	Here, we show that loss of the ECM protein TGFBI (transforming growth factor beta induced) is sufficient to induce specific resistance to paclitaxel and mitotic spindle abnormalities in ovarian cancer cells.	Paclitaxel	138-148	transforming growth factor beta induced	Homo sapiens	50-89
18068629-3	2007	Paclitaxel-resistant cells treated with recombinant TGFBI protein show integrin-dependent restoration of paclitaxel sensitivity via FAK- and Rho-dependent stabilization of microtubules.	Paclitaxel	0-10	transforming growth factor beta induced	Homo sapiens	52-57
18068629-3	2007	Paclitaxel-resistant cells treated with recombinant TGFBI protein show integrin-dependent restoration of paclitaxel sensitivity via FAK- and Rho-dependent stabilization of microtubules.	Paclitaxel	105-115	transforming growth factor beta induced	Homo sapiens	52-57
18068629-4	2007	Immunohistochemical staining for TGFBI in paclitaxel-treated ovarian cancers from a prospective clinical trial showed that morphological changes of paclitaxel-induced cytotoxicity were restricted to areas of strong expression of TGFBI.	Paclitaxel	42-52	transforming growth factor beta induced	Homo sapiens	33-38
18068629-4	2007	Immunohistochemical staining for TGFBI in paclitaxel-treated ovarian cancers from a prospective clinical trial showed that morphological changes of paclitaxel-induced cytotoxicity were restricted to areas of strong expression of TGFBI.	Paclitaxel	148-158	transforming growth factor beta induced	Homo sapiens	33-38
18068629-4	2007	Immunohistochemical staining for TGFBI in paclitaxel-treated ovarian cancers from a prospective clinical trial showed that morphological changes of paclitaxel-induced cytotoxicity were restricted to areas of strong expression of TGFBI.	Paclitaxel	148-158	transforming growth factor beta induced	Homo sapiens	229-234
17652622-6	2007	This conclusion is supported by the fact that Bcl-2-overexpressing cells and Bax/Bak doubly-deficient MEFs were entirely resistant to paclitaxel-induced apoptosis.	Paclitaxel	134-144	BCL2 antagonist/killer 1	Homo sapiens	81-84
17686523-7	2007	Paclitaxel treatment increased immunohistochemical staining for activating transcription factor-3 (ATF-3), c-Jun and neuropeptide Y (NPY) but only in a small percentage of neuronal cell bodies and mainly in those with large cell bodies.	Paclitaxel	0-10	activating transcription factor 3	Rattus norvegicus	64-97
17686523-7	2007	Paclitaxel treatment increased immunohistochemical staining for activating transcription factor-3 (ATF-3), c-Jun and neuropeptide Y (NPY) but only in a small percentage of neuronal cell bodies and mainly in those with large cell bodies.	Paclitaxel	0-10	activating transcription factor 3	Rattus norvegicus	99-104
17957256-8	2007	Consistently, the MT-stabilizing drug taxol could partially rescue the wavy root hair phenotype of mrh2-3, and the MT-depolymerizing drug Oryzalin slightly enhanced the root hair tip growth defect in CA1-1.	Paclitaxel	38-43	Armadillo/beta-catenin repeat family protein / kinesin motor family protein	Arabidopsis thaliana	99-105
17875775-6	2007	Significant inhibition of tumor growth in mice treated with low-dose paclitaxel plus intratumoral dendritic cell vaccine, associated with increased tumor infiltration by CD4(+) and CD8(+) T cells and elevated tumor-specific IFN-gamma production by draining lymph node cells, was revealed.	Paclitaxel	69-79	CD4 antigen	Mus musculus	170-173
17804730-4	2007	Elevated expression of RNF5 was seen in breast cancer cell lines that became more sensitive to cytochalasin D- and paclitaxel-induced apoptosis following its knockdown with specific short interfering RNA.	Paclitaxel	115-125	ring finger protein 5	Homo sapiens	23-27
17369857-6	2007	Interestingly, the caspase pathway was activated after treatment with Plk1-specific siRNAs and paclitaxel or Herceptin.	Paclitaxel	95-105	polo like kinase 1	Homo sapiens	70-74
17369857-7	2007	Treatment of breast cancer cells with siRNAs targeting Plk1 improved the sensitivity toward paclitaxel and Herceptin in a synergistic manner.	Paclitaxel	92-102	polo like kinase 1	Homo sapiens	55-59
17568772-8	2007	Moreover, such SGK1 depletion prevented the dexamethasone-induced increase in SGK1 expression, as well as the inhibitory effects of dexamethasone on paclitaxel-induced SEK1-JNK signaling and apoptosis in MDA-MB-231 breast cancer cells.	Paclitaxel	149-159	serum/glucocorticoid regulated kinase 1	Homo sapiens	15-19
17560332-6	2007	COL4A3BP expression is increased in drug-resistant cell lines and in residual tumor following paclitaxel treatment of ovarian cancer, suggesting that it could be a target for chemotherapy-resistant cancers.	Paclitaxel	94-104	ceramide transporter 1	Homo sapiens	0-8
17611394-5	2007	Treatment with XIAP siRNA in combination with Paclitaxel, Cisplatin, Fluorouracil and Etoposide enhanced chemosensitivity.	Paclitaxel	46-56	X-linked inhibitor of apoptosis	Homo sapiens	15-19
17629094-4	2007	Combination therapy with TS-1/Paclitaxel (TXL)/CDDP was effective, as confirmed by marked reduction in tumor size on chest computed tomography.	Paclitaxel	30-40	thioredoxin like 1	Homo sapiens	42-45
17603630-2	2007	To develop tumor-targeted drugs, we have initially evaluated whether the CD44 ligand hyaluronic acid (HA) could serve as a backbone for paclitaxel (TXL) prodrugs.	Paclitaxel	136-146	CD44 molecule (Indian blood group)	Homo sapiens	73-77
17438109-6	2007	Furthermore, in contrast to that observed in PXR (+/+) mice, genetic loss of PXR results in increased (preserved) blood levels of paclitaxel.	Paclitaxel	130-140	nuclear receptor subfamily 1, group I, member 2	Mus musculus	77-80
17195090-7	2007	Our data show that Taxol treatment of MCF-7 cells induced a transient increase in Na(+)-dependent transport of the neutral amino acid transporter B0 at both gene and protein level.	Paclitaxel	19-24	solute carrier family 7 member 9	Homo sapiens	146-151
17195090-16	2007	In summary, our study showed that Taxol induced apoptosis in several breast cancer cells results in activation of amino acid transporter System B0 at both gene and protein level.	Paclitaxel	34-39	solute carrier family 7 member 9	Homo sapiens	144-149
17221932-1	2007	A simple and sensitive HPLC-UV method was developed for the determination of paclitaxel (TXL) in human and rat blood samples.	Paclitaxel	77-87	thioredoxin like 1	Homo sapiens	89-92
16924498-9	2007	CONCLUSIONS: The cathepsin B-mediated release of paclitaxel may have therapeutic implications as cathepsin B is upregulated in malignant cells, particularly during tumor progression.	Paclitaxel	49-59	cathepsin B	Mus musculus	17-28
16924498-9	2007	CONCLUSIONS: The cathepsin B-mediated release of paclitaxel may have therapeutic implications as cathepsin B is upregulated in malignant cells, particularly during tumor progression.	Paclitaxel	49-59	cathepsin B	Mus musculus	97-108
17471022-1	2007	OBJECTIVE: To evaluate the specific killing effects of the adenoviral vector in which the CD::UPP genes were directed by the MDR1 promoter on Taxol-resistance ovarian cancer cells in vitro and in vivo.	Paclitaxel	142-147	uracil phosphoribosyltransferase homolog	Homo sapiens	94-97
17471022-8	2007	CONCLUSION: AdMDR1-CD::UPP in combination with 5-FC is an effective approach to suppress the growth of Taxol-resistant ovarian cancer.	Paclitaxel	103-108	uracil phosphoribosyltransferase homolog	Homo sapiens	23-26
17263521-0	2007	Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3" bridged paclitaxel analogues.	Paclitaxel	32-42	complement C3	Homo sapiens	103-106
17263521-0	2007	Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3" bridged paclitaxel analogues.	Paclitaxel	116-126	complement C3	Homo sapiens	103-106
17216190-2	2007	Taxol (paclitaxel)-resistance-associated gene-3 (TRAG-3/CSAG2) was found to be overexpressed in a paclitaxel-resistant ovarian carcinoma cell line.	Paclitaxel	0-5	CSAG family member 2	Homo sapiens	49-55
17216190-2	2007	Taxol (paclitaxel)-resistance-associated gene-3 (TRAG-3/CSAG2) was found to be overexpressed in a paclitaxel-resistant ovarian carcinoma cell line.	Paclitaxel	0-5	CSAG family member 2	Homo sapiens	56-61
17216190-2	2007	Taxol (paclitaxel)-resistance-associated gene-3 (TRAG-3/CSAG2) was found to be overexpressed in a paclitaxel-resistant ovarian carcinoma cell line.	Paclitaxel	7-17	CSAG family member 2	Homo sapiens	49-55
17216190-2	2007	Taxol (paclitaxel)-resistance-associated gene-3 (TRAG-3/CSAG2) was found to be overexpressed in a paclitaxel-resistant ovarian carcinoma cell line.	Paclitaxel	7-17	CSAG family member 2	Homo sapiens	56-61
17216190-2	2007	Taxol (paclitaxel)-resistance-associated gene-3 (TRAG-3/CSAG2) was found to be overexpressed in a paclitaxel-resistant ovarian carcinoma cell line.	Paclitaxel	98-108	CSAG family member 2	Homo sapiens	49-55
17216190-2	2007	Taxol (paclitaxel)-resistance-associated gene-3 (TRAG-3/CSAG2) was found to be overexpressed in a paclitaxel-resistant ovarian carcinoma cell line.	Paclitaxel	98-108	CSAG family member 2	Homo sapiens	56-61
17216190-8	2007	In summary, TRAG-3 was found to be a prognostic factor for the prediction of clinical outcome after the application of paclitaxel-based chemotherapy.	Paclitaxel	119-129	CSAG family member 2	Homo sapiens	12-18
17010942-3	2006	The P450 M-2C enzyme expressed in yeast cells catalyzed p-methylhydroxylation of only tolbutamide among four substrates tested, paclitaxel as a CYP2C8 substrate, diclofenac and tolbutamide as CYP2C9 substrates and S-mephenytoin as a CYP2C19 substrate.	Paclitaxel	128-138	cytochrome P450 2C8	Callithrix jacchus	144-150
17009338-1	2006	It was reported that paclitaxel is an inhibitor of hepatic P-glycoprotein (P-gp) and hepatic microsomal cytochrome P450 (CYP) 3A1/2, and that naringin is an inhibitor of biliary P-gp and CYP3A1/2 in rats.	Paclitaxel	21-31	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	178-182
17009338-6	2006	The inhibition of hepatic P-gp by oral naringin could also contribute to the significantly greater AUC of intravenous paclitaxel by oral naringin.	Paclitaxel	118-128	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	26-30
16982696-5	2006	In vitro MT depolymerization experiments revealed that SGK1, especially N-truncated SGK1, directly disassembled self-polymerized MTs and taxol-stabilized MTs in a dose-dependent and ATP-independent manner.	Paclitaxel	137-142	serum/glucocorticoid regulated kinase 1	Homo sapiens	55-59
16982696-5	2006	In vitro MT depolymerization experiments revealed that SGK1, especially N-truncated SGK1, directly disassembled self-polymerized MTs and taxol-stabilized MTs in a dose-dependent and ATP-independent manner.	Paclitaxel	137-142	serum/glucocorticoid regulated kinase 1	Homo sapiens	84-88
17121923-3	2006	Significant reductions in growth were observed in Ark2 and KLE endometrial cancer cells following treatment with paclitaxel, doxorubicin, carboplatin, or the HDAC inhibitor trichostatin A (TSA).	Paclitaxel	113-123	aurora kinase B	Homo sapiens	50-54
16982732-7	2006	Consistent with the reported platinum chemosensitivity in patients with Brca1-associated ovarian cancer, the Brca1-deficient OSE cells have increased sensitivity to the DNA-damaging agent cisplatin, whereas sensitivity to the microtubule poison paclitaxel is similar between Brca1 wild-type and Brca1-deficient cells.	Paclitaxel	245-255	BRCA1 DNA repair associated	Homo sapiens	109-114
16982732-7	2006	Consistent with the reported platinum chemosensitivity in patients with Brca1-associated ovarian cancer, the Brca1-deficient OSE cells have increased sensitivity to the DNA-damaging agent cisplatin, whereas sensitivity to the microtubule poison paclitaxel is similar between Brca1 wild-type and Brca1-deficient cells.	Paclitaxel	245-255	BRCA1 DNA repair associated	Homo sapiens	109-114
16982732-7	2006	Consistent with the reported platinum chemosensitivity in patients with Brca1-associated ovarian cancer, the Brca1-deficient OSE cells have increased sensitivity to the DNA-damaging agent cisplatin, whereas sensitivity to the microtubule poison paclitaxel is similar between Brca1 wild-type and Brca1-deficient cells.	Paclitaxel	245-255	BRCA1 DNA repair associated	Homo sapiens	109-114
16893427-7	2006	Paclitaxel (a microtubule aggregating agent that interacts with beta-tubulin) reduced NAP tubulin binding.	Paclitaxel	0-10	catenin beta like 1	Homo sapiens	86-89
17037023-3	2006	METHOD: Nonradioactive cell counting Kit-8 (Dojindo, Kumamoto, Japan) was used to asses growth inhibition of cancer cells by 5-FU, Carboplatin and paclitaxel (TXL) against each concentration and exposure time.	Paclitaxel	147-157	thioredoxin like 1	Homo sapiens	159-162
16516478-8	2006	Opposite effects of flavonoid derivatives on the P-gp highly expressing and MDA-MB-435 non-expressing cell lines indicate that paclitaxel is not only transported by P-gp and let us assume that Mrp2 or ABCC5 seem to be good transport-candidates in these cells.	Paclitaxel	127-137	ATP binding cassette subfamily C member 2	Homo sapiens	193-197
16639080-0	2006	BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.	Paclitaxel	87-97	BRCA1 DNA repair associated	Homo sapiens	0-5
16639080-3	2006	In this report, we studied BRCA1 contribution to paclitaxel response in MCF-7 breast cancer cells.	Paclitaxel	49-59	BRCA1 DNA repair associated	Homo sapiens	27-32
16639080-4	2006	We show that MCF-7 cells transfected with BRCA1 siRNA display a significant increase in resistance to paclitaxel compared with the control cells.	Paclitaxel	102-112	BRCA1 DNA repair associated	Homo sapiens	42-47
16639080-5	2006	We next demonstrate that downregulation of BRCA1 reduces the mitotic index and triggers premature cyclin B1 degradation and decrease in Cdk1 activity following paclitaxel treatment, suggesting that BRCA1 downregulation results in precocious inactivation of the spindle checkpoint.	Paclitaxel	160-170	BRCA1 DNA repair associated	Homo sapiens	43-48
16639080-5	2006	We next demonstrate that downregulation of BRCA1 reduces the mitotic index and triggers premature cyclin B1 degradation and decrease in Cdk1 activity following paclitaxel treatment, suggesting that BRCA1 downregulation results in precocious inactivation of the spindle checkpoint.	Paclitaxel	160-170	BRCA1 DNA repair associated	Homo sapiens	198-203
16639080-7	2006	Furthermore, we show that BRCA1 up-regulates the expression of the protein kinase BubR1, essential component of the functional spindle checkpoint, whose downregulation is known to result in paclitaxel resistance in MCF-7 cells.	Paclitaxel	190-200	BRCA1 DNA repair associated	Homo sapiens	26-31
16639080-8	2006	Altogether, our findings support the notion that downregulation of BRCA1 expression mediates paclitaxel resistance through premature inactivation of spindle checkpoint in MCF-7 breast cancer cells.	Paclitaxel	93-103	BRCA1 DNA repair associated	Homo sapiens	67-72
16638536-1	2006	The 10beta-acetyltransferase on the biosynthetic pathway of the antineoplastic drug Taxol catalyzes the regiospecific transfer of the acetyl group of acetyl-coenzyme A (CoA) to 10-deacetylbaccatin III.	Paclitaxel	84-89	acetyltransferase	Escherichia coli	11-28
16465425-4	2006	MVP protein levels were enhanced in SW-620 cells after a 72 h treatment with doxorubicin (Adr), etoposide (VP-16), cis-platinum (II) diammine dichloride (CDDP) or SN-38, but not vincristine (VCR) or paclitaxel (Taxol) at their IC50 concentration.	Paclitaxel	199-209	host cell factor C1	Homo sapiens	107-112
16465425-4	2006	MVP protein levels were enhanced in SW-620 cells after a 72 h treatment with doxorubicin (Adr), etoposide (VP-16), cis-platinum (II) diammine dichloride (CDDP) or SN-38, but not vincristine (VCR) or paclitaxel (Taxol) at their IC50 concentration.	Paclitaxel	211-216	host cell factor C1	Homo sapiens	107-112
16356831-6	2006	Reduction of X-linked inhibitor of apoptosis (XIAP) protein by 2-ME and paclitaxel correlated with increased apoptosis.	Paclitaxel	72-82	X-linked inhibitor of apoptosis	Homo sapiens	13-44
16356831-6	2006	Reduction of X-linked inhibitor of apoptosis (XIAP) protein by 2-ME and paclitaxel correlated with increased apoptosis.	Paclitaxel	72-82	X-linked inhibitor of apoptosis	Homo sapiens	46-50
16454695-6	2006	The intracellular accumulation of TPT and paclitaxel (a PgP substrate) by V/HepG2 and MRP4/HepG2 cells was determined by incubation of TPT with the cells and the amounts of the drug in cells were determined by validated HPLC methods.	Paclitaxel	42-52	ATP binding cassette subfamily C member 4	Homo sapiens	86-90
17722272-4	2006	The release of paclitaxel from the polymeric backbone is, at least in part, dependent on the metabolism of PPX by the lysosomal protease cathepsin B, which is upregulated in many tumor types.	Paclitaxel	15-25	cathepsin B	Homo sapiens	137-148
16273228-0	2005	Contribution of reactive oxygen species and caspase-3 to apoptosis and attenuated ICAM-1 expression by paclitaxel-treated MDA-MB-435 breast carcinoma cells.	Paclitaxel	103-113	intercellular adhesion molecule 1	Homo sapiens	82-88
16273228-3	2005	In the present study we show that MDA-MB-435 human breast carcinoma cells that survived culture for 72 h in the presence of submaximal cytotoxic concentrations of paclitaxel (0.02 and 0.01 microg/ml) showed decreased expression of the adhesion molecule ICAM-1.	Paclitaxel	163-173	intercellular adhesion molecule 1	Homo sapiens	253-259
16273228-6	2005	In addition, a selective inhibitor of caspase-3 (Z-DEVD-FMK), as well as a pan-caspase inhibitor (Z-VAD-FMK), partially prevented the decrease in ICAM-1 expression observed following paclitaxel treatment, but did not protect against paclitaxel-induced cytotoxicity.	Paclitaxel	183-193	intercellular adhesion molecule 1	Homo sapiens	146-152
16273228-6	2005	In addition, a selective inhibitor of caspase-3 (Z-DEVD-FMK), as well as a pan-caspase inhibitor (Z-VAD-FMK), partially prevented the decrease in ICAM-1 expression observed following paclitaxel treatment, but did not protect against paclitaxel-induced cytotoxicity.	Paclitaxel	233-243	intercellular adhesion molecule 1	Homo sapiens	146-152
16273228-7	2005	We conclude that the paclitaxel-induced reduction in ICAM-1 expression by MDA-MB-435 breast carcinoma cells is both ROS- and caspase-dependent, whereas paclitaxel-induced cytotoxicity is ROS-dependent and does not involve caspases.	Paclitaxel	21-31	intercellular adhesion molecule 1	Homo sapiens	53-59
16273228-8	2005	Decreased ICAM-1 expression by breast carcinoma cells that survive paclitaxel treatment may negatively impact on cytotoxic lymphocyte-mediated destruction of paclitaxel-resistant breast cancer cells in the context of chemo-immunotherapy or chemo-adoptive immunotherapy.	Paclitaxel	67-77	intercellular adhesion molecule 1	Homo sapiens	10-16
16273228-8	2005	Decreased ICAM-1 expression by breast carcinoma cells that survive paclitaxel treatment may negatively impact on cytotoxic lymphocyte-mediated destruction of paclitaxel-resistant breast cancer cells in the context of chemo-immunotherapy or chemo-adoptive immunotherapy.	Paclitaxel	158-168	intercellular adhesion molecule 1	Homo sapiens	10-16
16243823-5	2005	Curcumin also suppressed the paclitaxel-induced expression of antiapoptotic (XIAP, IAP-1, IAP-2, Bcl-2, and Bcl-xL), proliferative (cyclooxygenase 2, c-Myc, and cyclin D1), and metastatic proteins (vascular endothelial growth factor, matrix metalloproteinase-9, and intercellular adhesion molecule-1).	Paclitaxel	29-39	X-linked inhibitor of apoptosis	Homo sapiens	77-81
16243823-5	2005	Curcumin also suppressed the paclitaxel-induced expression of antiapoptotic (XIAP, IAP-1, IAP-2, Bcl-2, and Bcl-xL), proliferative (cyclooxygenase 2, c-Myc, and cyclin D1), and metastatic proteins (vascular endothelial growth factor, matrix metalloproteinase-9, and intercellular adhesion molecule-1).	Paclitaxel	29-39	matrix metallopeptidase 9	Homo sapiens	234-260
16243823-5	2005	Curcumin also suppressed the paclitaxel-induced expression of antiapoptotic (XIAP, IAP-1, IAP-2, Bcl-2, and Bcl-xL), proliferative (cyclooxygenase 2, c-Myc, and cyclin D1), and metastatic proteins (vascular endothelial growth factor, matrix metalloproteinase-9, and intercellular adhesion molecule-1).	Paclitaxel	29-39	intercellular adhesion molecule 1	Homo sapiens	266-300
15961125-6	2005	Intracellular accumulation of the well-characterized Pgp-substrate Taxol was markedly increased by the non-selective transporter inhibitor verapamil and the Pgp-selective antagonist PGP-4008, demonstrating that Pgp is active in these endothelial cells.	Paclitaxel	67-72	phosphoglycolate phosphatase	Bos taurus	53-56
15961125-6	2005	Intracellular accumulation of the well-characterized Pgp-substrate Taxol was markedly increased by the non-selective transporter inhibitor verapamil and the Pgp-selective antagonist PGP-4008, demonstrating that Pgp is active in these endothelial cells.	Paclitaxel	67-72	phosphoglycolate phosphatase	Bos taurus	157-160
15961125-6	2005	Intracellular accumulation of the well-characterized Pgp-substrate Taxol was markedly increased by the non-selective transporter inhibitor verapamil and the Pgp-selective antagonist PGP-4008, demonstrating that Pgp is active in these endothelial cells.	Paclitaxel	67-72	phosphoglycolate phosphatase	Bos taurus	182-185
15961125-6	2005	Intracellular accumulation of the well-characterized Pgp-substrate Taxol was markedly increased by the non-selective transporter inhibitor verapamil and the Pgp-selective antagonist PGP-4008, demonstrating that Pgp is active in these endothelial cells.	Paclitaxel	67-72	phosphoglycolate phosphatase	Bos taurus	157-160
16210916-0	2005	Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel.	Paclitaxel	75-85	solute carrier organic anion transporter family member 1B3 S homeolog	Xenopus laevis	18-25
16210916-4	2005	Taxane transport by OATP1B1 expressing oocytes was not significantly different from that by water-injected controls, whereas uptake by OATP1B3 was 2.2-fold higher for docetaxel (p = 0.0007) and 3.3-fold higher for paclitaxel (p &lt; 0.0001).	Paclitaxel	214-224	solute carrier organic anion transporter family member 1B3 S homeolog	Xenopus laevis	135-142
16210916-5	2005	OATP1B3-mediated paclitaxel transport was saturable (Michaelis-Menten constant, 6.79 microM), time-dependent, and highly sensitive to chemical inhibition.	Paclitaxel	17-27	solute carrier organic anion transporter family member 1B3 S homeolog	Xenopus laevis	0-7
15987939-4	2005	Focal in vivo inhibition of initiator caspase activation or microtubule-dependent transport (with Taxol) at the lesioned axon terminus results in a significant reduction in retrograde axonal caspase-8 and caspase-3 activation and inhibition of retrograde ORN death.	Paclitaxel	98-103	caspase 3	Mus musculus	205-214
15930290-3	2005	We hypothesized that inhibiting the phosphorylation of the EGFR and vascular endothelial growth factor receptor (VEGFR) by AEE788, a dual tyrosine kinase inhibitor of EGFR and VEGFR, in combination with paclitaxel would inhibit experimental FTC bone lesions and preserve bone structure.	Paclitaxel	203-213	kinase insert domain receptor	Homo sapiens	68-111
15930290-3	2005	We hypothesized that inhibiting the phosphorylation of the EGFR and vascular endothelial growth factor receptor (VEGFR) by AEE788, a dual tyrosine kinase inhibitor of EGFR and VEGFR, in combination with paclitaxel would inhibit experimental FTC bone lesions and preserve bone structure.	Paclitaxel	203-213	kinase insert domain receptor	Homo sapiens	113-118
15689167-1	2005	The purpose of this work was to introduce a chemical modification into the paclitaxel (Taxol) structure to reduce interactions with the product of the multidrug resistant type 1 (MDR1) gene, P-glycoprotein (Pgp), resulting in improved blood-brain barrier (BBB) permeability.	Paclitaxel	87-92	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	179-183
15689167-1	2005	The purpose of this work was to introduce a chemical modification into the paclitaxel (Taxol) structure to reduce interactions with the product of the multidrug resistant type 1 (MDR1) gene, P-glycoprotein (Pgp), resulting in improved blood-brain barrier (BBB) permeability.	Paclitaxel	87-92	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	191-205
15689167-1	2005	The purpose of this work was to introduce a chemical modification into the paclitaxel (Taxol) structure to reduce interactions with the product of the multidrug resistant type 1 (MDR1) gene, P-glycoprotein (Pgp), resulting in improved blood-brain barrier (BBB) permeability.	Paclitaxel	87-92	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	207-210
15689167-4	2005	By contrast, Taxol exposure substantially enhanced rhodamine 123 uptake by BMECs through inhibition of Pgp.	Paclitaxel	13-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	103-106
15689167-8	2005	These results demonstrate that the Taxol analogue Tx-67 had a reduced interaction with Pgp and, as a consequence, enhanced permeation across the blood-brain barrier in vitro and in situ.	Paclitaxel	35-40	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	87-90
15389801-10	2005	Chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, doxorubicin, and camptothecin) significantly augmented TRAIL-induced apoptosis in cancer cells through up-regulation of DR4, DR5, Bax, and Bak, and induction of caspase activation.	Paclitaxel	24-34	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	128-133
15389801-10	2005	Chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, doxorubicin, and camptothecin) significantly augmented TRAIL-induced apoptosis in cancer cells through up-regulation of DR4, DR5, Bax, and Bak, and induction of caspase activation.	Paclitaxel	24-34	BCL2-associated X protein	Mus musculus	203-206
15991527-0	2005	Comparative evaluation of standard criteria and CA-125 in ovarian cancers treated with platinum or paclitaxel.	Paclitaxel	99-109	mucin 16, cell surface associated	Homo sapiens	48-54
15991527-1	2005	PURPOSE: To assess CA-125 in defining tumor response in patients treated with paclitaxel.	Paclitaxel	78-88	mucin 16, cell surface associated	Homo sapiens	19-25
15389810-7	2005	Overexpression of WIF-1 resulted in sensitizing PC-3 cells for paclitaxel to induce apoptosis.	Paclitaxel	63-73	WNT inhibitory factor 1	Homo sapiens	18-23
15611650-8	2004	However, Bin1 loss increased sensitivity to paclitaxel, a drug that can affect endocytotic trafficking by disrupting microtubule dynamics.	Paclitaxel	44-54	bridging integrator 1	Mus musculus	9-13
15352049-0	2004	Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer.	Paclitaxel	35-45	transferrin	Mus musculus	12-23
15519653-0	2004	Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1.	Paclitaxel	154-164	translocator protein	Homo sapiens	0-34
15369823-2	2004	Taxol bears an acetate at C10 and another at C4 thought to originate by intramolecular migration of a C5 acetate function in the process of oxetane ring formation, but many other naturally occurring taxoids bear acetate groups at C1, C2, C7, C9, and C13, in addition to C5 and C10.	Paclitaxel	0-5	homeobox C13	Homo sapiens	250-253
15374973-7	2004	Hsp27 ASO and small interference RNA also enhanced paclitaxel chemosensitivity in vitro, whereas in vivo, systemic administration of Hsp27 ASO in athymic mice decreased PC-3 tumor progression and also significantly enhanced paclitaxel chemosensitivity.	Paclitaxel	51-61	heat shock protein 1	Mus musculus	0-5
15374973-7	2004	Hsp27 ASO and small interference RNA also enhanced paclitaxel chemosensitivity in vitro, whereas in vivo, systemic administration of Hsp27 ASO in athymic mice decreased PC-3 tumor progression and also significantly enhanced paclitaxel chemosensitivity.	Paclitaxel	224-234	heat shock protein 1	Mus musculus	133-138
15446569-1	2004	We report a patient with unresectable stage IV stomach cancer with metastasis to the paraaortic lymph nodes who achieved an effective response to neoajuvant chemotherapy, which allowed curability-B resection, and in whom weekly paclitaxel (TXL) therapy for postoperative recurrence was very effective in improving QOL.	Paclitaxel	228-238	thioredoxin like 1	Homo sapiens	240-243
15322237-7	2004	NH125 increased accumulation of P-gp substrates such as paclitaxel and doxorubicin but had no effect on the accumulation of non-P-gp substrates.	Paclitaxel	56-66	phosphoglycolate phosphatase	Mus musculus	32-36
15322256-0	2004	A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.	Paclitaxel	134-144	kinase insert domain receptor	Homo sapiens	2-47
15548364-3	2004	Using a p73-specific antibody, we confirmed that c-Abl is required for cisplatin-induced p73 upregulation, and further demonstrate that the p73 protein is upregulated by UV irradiation and other stress stimuli including sorbitol, hydrogen peroxide, nocodazol, and taxol.	Paclitaxel	264-269	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	49-54
15252144-5	2004	To evaluate the role of these transporters in paclitaxel-resistant ovarian cancer cells, small interference RNAs (siRNAs) were used to target ABCB1 and ABCB4 RNA in the paclitaxel-resistant SKOV-3TR and OVCAR8TR ovarian cancer cell lines.	Paclitaxel	169-179	ATP binding cassette subfamily B member 4	Homo sapiens	152-157
15252144-8	2004	ABCB4 siRNA-treated cell lines showed minor reduction in paclitaxel resistance.	Paclitaxel	57-67	ATP binding cassette subfamily B member 4	Homo sapiens	0-5
15047868-2	2004	Here, we report that CPAP carries a novel microtubule-destabilizing motif that not only inhibits microtubule nucleation from the centrosome but also depolymerizes taxol-stabilized microtubules.	Paclitaxel	163-168	centromere protein J	Homo sapiens	21-25
15274316-0	2004	N-acetyltransferase activity is involved in paclitaxel-induced N-acetylation of 2-aminofluorene in human bladder cancer cells (T24).	Paclitaxel	44-54	bromodomain containing 2	Homo sapiens	0-19
15274316-2	2004	Our previous studies have demonstrated that paclitaxel decreases NAT activity in human bladder, blood, colon and lung cancer cells.	Paclitaxel	44-54	bromodomain containing 2	Homo sapiens	65-68
15274316-3	2004	In this study, paclitaxel was selected to test the inhibition of NAT activity (N-acetylation of AF) and NAT gene expression in a human bladder cancer cell line (T24).	Paclitaxel	15-25	bromodomain containing 2	Homo sapiens	65-68
15274316-3	2004	In this study, paclitaxel was selected to test the inhibition of NAT activity (N-acetylation of AF) and NAT gene expression in a human bladder cancer cell line (T24).	Paclitaxel	15-25	bromodomain containing 2	Homo sapiens	104-107
15274316-7	2004	The tests indicated that paclitaxel decreased the levels of NAT in T24 cells.	Paclitaxel	25-35	bromodomain containing 2	Homo sapiens	60-63
15274316-8	2004	The expression of the NAT gene (mRNAT NAT) was determined by polymerase chain reaction (PCR) and cDNA microarray and it was found that paclitaxel induced the down-regulation of mRNA NAT expression in T24 cells.	Paclitaxel	135-145	bromodomain containing 2	Homo sapiens	22-25
15274316-8	2004	The expression of the NAT gene (mRNAT NAT) was determined by polymerase chain reaction (PCR) and cDNA microarray and it was found that paclitaxel induced the down-regulation of mRNA NAT expression in T24 cells.	Paclitaxel	135-145	bromodomain containing 2	Homo sapiens	34-37
15274316-8	2004	The expression of the NAT gene (mRNAT NAT) was determined by polymerase chain reaction (PCR) and cDNA microarray and it was found that paclitaxel induced the down-regulation of mRNA NAT expression in T24 cells.	Paclitaxel	135-145	bromodomain containing 2	Homo sapiens	34-37
15010891-4	2004	Flow cytometric analysis of paclitaxel-treated Jurkat T cells revealed reduced surface expression of alphaL, alpha4, alpha5, and beta7 integrins, but normal beta1 integrin expression.	Paclitaxel	28-38	immunoglobulin binding protein 1	Homo sapiens	109-115
15152941-4	2004	Other changes in glucose metabolism that may affect 2-DG as an antimetabolite were observed, including increases in glucose-6-phosphate dehydrogenase of 10-fold and 100-fold for taxol- and melphalan-resistant variants, respectively, suggesting higher pentose phosphate activity; increased glutamine utilisation and greater sensitivity to iodoacetic acid-induced depletion of ATP levels in the parent relative to the resistant variants.	Paclitaxel	178-183	glucose-6-phosphate dehydrogenase	Homo sapiens	116-149
14610615-10	2004	SK-OV-3 cells were sensitive and HAC-2 cells were resistant to both PTX and DTX.	Paclitaxel	68-71	hyperpolarization activated cyclic nucleotide gated potassium channel 1	Homo sapiens	33-38
14996748-11	2004	Sensitization of GBM tumors to paclitaxel (Taxol) in vivo was obtained by either AS101 or by implantation of antisense IL-10-transfected cells.	Paclitaxel	31-41	interleukin 10	Homo sapiens	119-124
14996748-11	2004	Sensitization of GBM tumors to paclitaxel (Taxol) in vivo was obtained by either AS101 or by implantation of antisense IL-10-transfected cells.	Paclitaxel	43-48	interleukin 10	Homo sapiens	119-124
14991204-8	2004	By contrast, tyrosine phosphorylation, as one of the major events following beta(1)-integrin clustering, showed a 3.7-fold, FN-related enhancement, and treatment of cells with the IC(50) of radiation, cisplatin, paclitaxel, or mitomycin showed a substratum-dependent induction.	Paclitaxel	212-222	integrin subunit beta 1	Homo sapiens	76-92
14770430-1	2004	BACKGROUND: The current study determined the efficacy and toxicity of weekly paclitaxel in combination with estramustine phosphate (EMP) in patients with androgen-independent prostate carcinoma (AIPC).	Paclitaxel	77-87	PDZ domain containing 2	Homo sapiens	195-199
14770430-2	2004	METHODS: Patients with progressive AIPC received 90 mg/m2 paclitaxel by 1-hour intravenous infusion weekly for 3 weeks, followed by a 1-week treatment rest.	Paclitaxel	58-68	PDZ domain containing 2	Homo sapiens	35-39
14770430-12	2004	CONCLUSIONS: This regimen of EMP plus weekly paclitaxel was an active and well tolerated treatment for patients with AIPC.	Paclitaxel	45-55	PDZ domain containing 2	Homo sapiens	117-121
14757126-4	2004	In addition, ADC and paclitaxel prevented the IFN-gamma-triggered activation of p44/p42 mitogen-activated protein (MAP) kinase in L929 fibroblasts, suggesting a possible mechanism for the observed inhibition of iNOS expression.	Paclitaxel	21-31	interferon-induced protein 44	Mus musculus	80-83
15015580-0	2004	PCR and flow cytometric analysis of paclitaxel-inhibited arylamine N-acetyltransferase activity and gene expression in human osteogenic sarcoma cells (U-2 OS).	Paclitaxel	36-46	bromodomain containing 2	Homo sapiens	67-86
15015580-2	2004	In this study, paclitaxel was selected to examine the inhibition of arylamine NAT activity, gene expression and 2-aminofluorene-DNA adduct formation in a human osteogenic sarcoma cell line (U-2 OS).	Paclitaxel	15-25	bromodomain containing 2	Homo sapiens	78-81
15015580-5	2004	The results demonstrated that NAT activity percent of NAT in examined cells, gene expression (NAT1 mRNA) and AF-DNA adduct formation in human osteogenic sarcoma cells were inhibited and decreased by paclitaxel in a dose-dependent manner.	Paclitaxel	199-209	bromodomain containing 2	Homo sapiens	30-33
15015580-5	2004	The results demonstrated that NAT activity percent of NAT in examined cells, gene expression (NAT1 mRNA) and AF-DNA adduct formation in human osteogenic sarcoma cells were inhibited and decreased by paclitaxel in a dose-dependent manner.	Paclitaxel	199-209	bromodomain containing 2	Homo sapiens	54-57
15015580-7	2004	Thus, paclitaxel is an uncompetitive inhibitor of the NAT enzyme.	Paclitaxel	6-16	bromodomain containing 2	Homo sapiens	54-57
15031599-13	2004	Suppression of those pathways and upregulation of bag-1 and hsp-70 played an important role in acquiring resistance to PTX.	Paclitaxel	119-122	heat shock protein family A (Hsp70) member 4	Homo sapiens	60-66
17564303-0	2004	Paclitaxel inhibits N-acetyltransferase activity and gene expression in human stomach tumor cells (SC-M1).	Paclitaxel	0-10	bromodomain containing 2	Homo sapiens	20-39
17564303-4	2004	The aim of the present study is to demonstrate whether paclitaxel (taxol) can inhibit the NAT activity, NAT gene expression and DNA-AF adduct formation in human stomach tumor cell line (SC-M1).	Paclitaxel	55-65	bromodomain containing 2	Homo sapiens	90-93
17564303-4	2004	The aim of the present study is to demonstrate whether paclitaxel (taxol) can inhibit the NAT activity, NAT gene expression and DNA-AF adduct formation in human stomach tumor cell line (SC-M1).	Paclitaxel	55-65	bromodomain containing 2	Homo sapiens	104-107
17564303-4	2004	The aim of the present study is to demonstrate whether paclitaxel (taxol) can inhibit the NAT activity, NAT gene expression and DNA-AF adduct formation in human stomach tumor cell line (SC-M1).	Paclitaxel	67-72	bromodomain containing 2	Homo sapiens	90-93
17564303-4	2004	The aim of the present study is to demonstrate whether paclitaxel (taxol) can inhibit the NAT activity, NAT gene expression and DNA-AF adduct formation in human stomach tumor cell line (SC-M1).	Paclitaxel	67-72	bromodomain containing 2	Homo sapiens	104-107
17564303-7	2004	As compared with the control group, the paclitaxel- treated group showed decreased NAT activity and DNA-AF adduct formation in SC-M1 cells and the decrease was dose-dependent.	Paclitaxel	40-50	bromodomain containing 2	Homo sapiens	83-86
14559807-6	2003	In contrast, BRCA1 induces a &gt;1000-fold increase in sensitivity to the spindle poisons, paclitaxel and vinorelbine.	Paclitaxel	91-101	BRCA1 DNA repair associated	Homo sapiens	13-18
14584281-2	2003	They were given 3 and 4 courses of paclitaxel (TXL) weekly therapy (80 mg/m2, day 1, 8, 15, repeated every 4 weeks).	Paclitaxel	35-45	thioredoxin like 1	Homo sapiens	47-50
13130078-7	2003	In all three cell lines, MDM2 inhibition reduced cell proliferation, induced apoptosis, and potentiated the effects of the chemotherapeutic agents 10-hydroxycamptothecin and paclitaxel.	Paclitaxel	174-184	MDM2 proto-oncogene	Homo sapiens	25-29
13130078-8	2003	The anti-MDM2 oligonucleotide showed antitumor activity and increased therapeutic effectiveness of paclitaxel in both LNCaP and PC3 xenografts, causing changes in gene expression similar to those seen in vitro.	Paclitaxel	99-109	MDM2 proto-oncogene	Homo sapiens	9-13
12855658-1	2003	Previous studies directed at identifying paclitaxel resistance genes in a paclitaxel-resistant subclone of the human ovarian cancer cell line SKOV-3 identified a novel cancer testis antigen, Taxol resistance-associated gene 3 (TRAG-3).	Paclitaxel	41-51	CSAG family member 2	Homo sapiens	191-225
12855658-1	2003	Previous studies directed at identifying paclitaxel resistance genes in a paclitaxel-resistant subclone of the human ovarian cancer cell line SKOV-3 identified a novel cancer testis antigen, Taxol resistance-associated gene 3 (TRAG-3).	Paclitaxel	41-51	CSAG family member 2	Homo sapiens	227-233
12855658-1	2003	Previous studies directed at identifying paclitaxel resistance genes in a paclitaxel-resistant subclone of the human ovarian cancer cell line SKOV-3 identified a novel cancer testis antigen, Taxol resistance-associated gene 3 (TRAG-3).	Paclitaxel	74-84	CSAG family member 2	Homo sapiens	191-225
12855658-1	2003	Previous studies directed at identifying paclitaxel resistance genes in a paclitaxel-resistant subclone of the human ovarian cancer cell line SKOV-3 identified a novel cancer testis antigen, Taxol resistance-associated gene 3 (TRAG-3).	Paclitaxel	74-84	CSAG family member 2	Homo sapiens	227-233
12883037-3	2003	We demonstrated that Dox and Taxol induced apoptosis through down-regulation of XIAP and phosphorylation of Bcl-2 in a concentration-dependent manner without changing expression of Bcl-xL in H460 cells.	Paclitaxel	29-34	X-linked inhibitor of apoptosis	Homo sapiens	80-84
12709826-1	2003	PURPOSE: Paclitaxel (Taxol, TXL) is an antimicrotubule agent that stabilizes microtubules, arrests the cell cycle at the G(2)/M phase and induces apoptosis.	Paclitaxel	9-19	thioredoxin like 1	Homo sapiens	28-31
12695359-3	2003	We investigated the role of PXR activation, in vitro and in vivo, in mediating Cyp3a induction by paclitaxel.	Paclitaxel	98-108	nuclear receptor subfamily 1, group I, member 2	Mus musculus	28-31
12695359-3	2003	We investigated the role of PXR activation, in vitro and in vivo, in mediating Cyp3a induction by paclitaxel.	Paclitaxel	98-108	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	79-84
12695359-6	2003	Employing PXR wild-type and transgenic mice lacking functional PXR (-/-), we evaluated the expression and activity of CYP3A following treatment with paclitaxel and PCN.	Paclitaxel	149-159	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	118-123
12695359-7	2003	Paclitaxel significantly induced CYP3A11 mRNA and immunoreactive CYP3A protein in PXR wild-type mice.	Paclitaxel	0-10	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	33-40
12695359-7	2003	Paclitaxel significantly induced CYP3A11 mRNA and immunoreactive CYP3A protein in PXR wild-type mice.	Paclitaxel	0-10	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	33-38
12695359-7	2003	Paclitaxel significantly induced CYP3A11 mRNA and immunoreactive CYP3A protein in PXR wild-type mice.	Paclitaxel	0-10	nuclear receptor subfamily 1, group I, member 2	Mus musculus	82-85
12695359-8	2003	Consistent with kinetics of CYP3A induction, the V(max) of testosterone 6 beta-hydroxylation in microsomal fraction increased 15- and 30-fold in paclitaxel- and PCN-treated mice, respectively.	Paclitaxel	145-155	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	28-33
12695359-9	2003	The Cyp3a induction response was completely abolished in paclitaxel- and PCN-treated PXR-null mice.	Paclitaxel	57-67	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	4-9
12695359-9	2003	The Cyp3a induction response was completely abolished in paclitaxel- and PCN-treated PXR-null mice.	Paclitaxel	57-67	nuclear receptor subfamily 1, group I, member 2	Mus musculus	85-88
12695359-10	2003	This suggests that paclitaxel-mediated CYP3A induction in vivo requires an intact PXR-signaling mechanism.	Paclitaxel	19-29	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	39-44
12695359-10	2003	This suggests that paclitaxel-mediated CYP3A induction in vivo requires an intact PXR-signaling mechanism.	Paclitaxel	19-29	nuclear receptor subfamily 1, group I, member 2	Mus musculus	82-85
12717416-0	2003	Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1.	Paclitaxel	40-50	BRCA1 DNA repair associated	Homo sapiens	8-13
12717416-7	2003	The BRCA1 mutation in SNU-251 cells inhibited BRCA1 subnuclear assembly for DNA-damage repair and increased cellular sensitivity to ionizing radiation and paclitaxel.	Paclitaxel	155-165	BRCA1 DNA repair associated	Homo sapiens	4-9
12717416-7	2003	The BRCA1 mutation in SNU-251 cells inhibited BRCA1 subnuclear assembly for DNA-damage repair and increased cellular sensitivity to ionizing radiation and paclitaxel.	Paclitaxel	155-165	BRCA1 DNA repair associated	Homo sapiens	46-51
12717416-10	2003	BRCA1 helps to mediate the resistance to both radiation and paclitaxel.	Paclitaxel	60-70	BRCA1 DNA repair associated	Homo sapiens	0-5
12628678-4	2003	In addition, the presence of one sugar moiety on C-7 doubled the water solubility versus that of paclitaxel.	Paclitaxel	97-107	complement C7	Homo sapiens	49-52
26680929-10	2003	The Taxol-induced apoptosis in p53 defected-osteogenic sarcoma cells was associated with the PARP cleavage as a result of the increased activity of caspase 3, and the high expressions of cyclin B1 and PLK.	Paclitaxel	4-9	polo like kinase 1	Homo sapiens	201-204
12669402-1	2003	We report a 65-year-old man with advanced gastric cancer that showed a remarkable response to treatment with a new combination of paclitaxel (TXL) and low-dose 5-fluorouracil and cisplatin (FP) as neoadjuvant chemotherapy (NAC).	Paclitaxel	130-140	thioredoxin like 1	Homo sapiens	142-145
12401814-5	2003	Transfected JNK3 significantly enhanced cell death after UV irradiation (0.5-6 J/cm(2)) and paclitaxel/taxol treatment (1-10 microm).	Paclitaxel	92-102	mitogen activated protein kinase 10	Rattus norvegicus	12-16
12401814-5	2003	Transfected JNK3 significantly enhanced cell death after UV irradiation (0.5-6 J/cm(2)) and paclitaxel/taxol treatment (1-10 microm).	Paclitaxel	103-108	mitogen activated protein kinase 10	Rattus norvegicus	12-16
12558997-0	2003	Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons.	Paclitaxel	66-76	cyclin-dependent kinase 5	Mus musculus	21-46
12558997-3	2003	MT stabilizing agents have been proposed as potential therapeutics that may minimize Abeta toxicity and here we report that paclitaxel (taxol) prevents cell death induced by Abeta peptides, inhibits Abeta-induced activation of cyclin-dependent kinase 5 (cdk5) and decreases tau hyperphosphorylation.	Paclitaxel	124-134	cyclin-dependent kinase 5	Mus musculus	227-252
12558997-3	2003	MT stabilizing agents have been proposed as potential therapeutics that may minimize Abeta toxicity and here we report that paclitaxel (taxol) prevents cell death induced by Abeta peptides, inhibits Abeta-induced activation of cyclin-dependent kinase 5 (cdk5) and decreases tau hyperphosphorylation.	Paclitaxel	124-134	cyclin-dependent kinase 5	Mus musculus	254-258
12558997-3	2003	MT stabilizing agents have been proposed as potential therapeutics that may minimize Abeta toxicity and here we report that paclitaxel (taxol) prevents cell death induced by Abeta peptides, inhibits Abeta-induced activation of cyclin-dependent kinase 5 (cdk5) and decreases tau hyperphosphorylation.	Paclitaxel	136-141	cyclin-dependent kinase 5	Mus musculus	227-252
12558997-3	2003	MT stabilizing agents have been proposed as potential therapeutics that may minimize Abeta toxicity and here we report that paclitaxel (taxol) prevents cell death induced by Abeta peptides, inhibits Abeta-induced activation of cyclin-dependent kinase 5 (cdk5) and decreases tau hyperphosphorylation.	Paclitaxel	136-141	cyclin-dependent kinase 5	Mus musculus	254-258
12558997-4	2003	Taxol did not inhibit cdk5 directly but significantly blocked Abeta-induced calpain activation and decreased formation of the cdk5 activator, p25, from p35.	Paclitaxel	0-5	cyclin-dependent kinase 5	Mus musculus	126-130
12558997-5	2003	Taxol specifically inhibited the Abeta-induced activation of the cytosolic cdk5-p25 complex, but not the membrane-associated cdk5-p35 complex.	Paclitaxel	0-5	cyclin-dependent kinase 5	Mus musculus	75-79
12466878-6	2002	The elicitor-induced activities of catalase (CAT) and phenylalanine ammonia-lyase (PAL) also depended mainly on inoculum age; higher PAL activity and lower CAT activity were obtained with an older inoculum, corresponding to a higher taxol yield.	Paclitaxel	233-238	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	83-86
12438532-3	2002	The present study uses this approach to investigate the impact of PGP on intestinal permeability of paclitaxel and digoxin in different regions of the mouse intestine (jejunum, ileum, and proximal and distal colon).	Paclitaxel	100-110	phosphoglycolate phosphatase	Mus musculus	66-69
12467445-0	2002	Alterations in Taxol production in plant cell culture via manipulation of the phenylalanine ammonia lyase pathway.	Paclitaxel	15-20	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	78-105
12359756-4	2002	Inhibitory PDGF aptamers and the PDGF receptor tyrosine kinase inhibitor STI571 enhanced the antitumor effect of Taxol on s.c. KAT-4 tumors in SCID mice.	Paclitaxel	113-118	TATA-box binding protein associated factor 1	Mus musculus	127-132
12402440-1	2002	We report a case of postoperative liver metastasis from gastric cancer showing a remarkable response to weekly administration of paclitaxel (TXL).	Paclitaxel	129-139	thioredoxin like 1	Homo sapiens	141-144
12366658-0	2002	The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer.	Paclitaxel	69-79	mucin 16, cell surface associated	Homo sapiens	4-9
12366658-1	2002	In this study, we compare the time to normalization of CA125 after cytoreductive surgery between a paclitaxel-containing regimen and a non-paclitaxel regimen.	Paclitaxel	99-109	mucin 16, cell surface associated	Homo sapiens	55-60
12366658-2	2002	This study demonstrates that CA125 regression in a paclitaxel-containing regimen was slower than that in a non-paclitaxel regimen.	Paclitaxel	51-61	mucin 16, cell surface associated	Homo sapiens	29-34
12085250-13	2002	The present study indicates that patients responded to treatment of advanced breast cancer with single-agent paclitaxel or docetaxel leads to an increase in serum IFN-gamma, IL-2, IL-6, GM-CSF cytokine levels and enhancement of PBMC NK and LAK cell activity, while they both lead to a decrease of acute phase serum cytokine levels of IL-1 and TNF-alpha.	Paclitaxel	109-119	alpha kinase 1	Homo sapiens	240-243
11996815-0	2002	Efficacy of BCNU and paclitaxel loaded subcutaneous implants in the interstitial chemotherapy of U-87 MG human glioblastoma xenografts.	Paclitaxel	21-31	small nucleolar RNA, C/D box 87	Homo sapiens	97-101
12437026-4	2002	IL-1beta production in response to other microbial stimulators, such as Pansorbin, Sansorbin, insoluble peptidoglycan, and Taxol, was also potentiated by rCTB.	Paclitaxel	123-128	phosphate cytidylyltransferase 1B, choline	Rattus norvegicus	154-158
11741476-0	2001	Synthesis and antitumor activity of novel C-7 paclitaxel ethers: discovery of BMS-184476.	Paclitaxel	46-56	complement C7	Homo sapiens	42-45
11741476-1	2001	The preparation of C-7 paclitaxel ethers is described.	Paclitaxel	23-33	complement C7	Homo sapiens	19-22
11753988-7	2001	RESULTS: The analog was as potent as paclitaxel in inhibiting the proliferation of three human glioma cell lines (U-87 MG, SW1783, and GBM) and was as effective as paclitaxel in inhibiting the heterotopic (subcutaneous) tumor growth in nude mice of U-87 MG cells (tumor weight inhibition, approximately 60%).	Paclitaxel	37-47	small nucleolar RNA, C/D box 87	Homo sapiens	114-118
11792804-9	2001	Furthermore, Bub1 levels increase at metaphase kinetochores following loss of tension caused by taxol treatment.	Paclitaxel	96-101	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	13-17
11792804-11	2001	Consistent with this, we also show that Bub1 is rapidly phosphorylated following brief treatments with nocodazole or taxol.	Paclitaxel	117-122	BUB1 mitotic checkpoint serine/threonine kinase	Homo sapiens	40-44
11781568-8	2001	Anti-LGN antibodies and the LGN-binding domain of NuMA both trigger microtubule aster formation in mitotic Xenopus egg extracts, and the NuMA-binding domain of LGN blocks aster assembly in egg extracts treated with taxol.	Paclitaxel	215-220	G-protein signaling modulator 2 S homeolog	Xenopus laevis	5-8
11707575-5	2001	Consistently, P-gp modulators dramatically altered the pattern of cross-resistance of P-gp-expressing cells to different P-gp substrates: an increase in resistance to Adr, daunorubicin, and etoposide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect on cell sensitivity to colchicine, actinomycin D, puromycin, and colcemid, as well as to several non-P-gp substrates.	Paclitaxel	276-281	phosphoglycolate phosphatase	Mus musculus	86-90
11707575-5	2001	Consistently, P-gp modulators dramatically altered the pattern of cross-resistance of P-gp-expressing cells to different P-gp substrates: an increase in resistance to Adr, daunorubicin, and etoposide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect on cell sensitivity to colchicine, actinomycin D, puromycin, and colcemid, as well as to several non-P-gp substrates.	Paclitaxel	276-281	phosphoglycolate phosphatase	Mus musculus	86-90
11707575-5	2001	Consistently, P-gp modulators dramatically altered the pattern of cross-resistance of P-gp-expressing cells to different P-gp substrates: an increase in resistance to Adr, daunorubicin, and etoposide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect on cell sensitivity to colchicine, actinomycin D, puromycin, and colcemid, as well as to several non-P-gp substrates.	Paclitaxel	276-281	phosphoglycolate phosphatase	Mus musculus	86-90
11641785-4	2001	Decreased expression of BRCA1 led to sensitivity to the DNA damaging agents cisplatin and etoposide, resistance to the microtubule-interfering agents (MIA) taxol and vincristine.	Paclitaxel	156-161	BRCA1 DNA repair associated	Homo sapiens	24-29
11587211-4	2001	Furthermore, GA sensitized Bcr-Abl-expressing cells to doxorubicin (DOX) and paclitaxel (PTX).	Paclitaxel	77-87	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	27-34
11521190-2	2001	We showed previously that human erythroleukemia K562 cells are resistant to antineoplastic drug (taxol)-induced apoptosis through the atypical protein kinase C iota isozyme (PKC iota), a kinase downstream of Bcr-Abl.	Paclitaxel	97-102	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	208-215
11461121-4	2001	We have shown previously that Taxol activates ERK 1/2 MAP-kinases and results in the formation of GRB2/SHC complexes in murine macrophage-like RAW 267.4 cells.	Paclitaxel	30-35	growth factor receptor bound protein 2	Mus musculus	98-102
11461121-4	2001	We have shown previously that Taxol activates ERK 1/2 MAP-kinases and results in the formation of GRB2/SHC complexes in murine macrophage-like RAW 267.4 cells.	Paclitaxel	30-35	src homology 2 domain-containing transforming protein C1	Mus musculus	103-106
11668581-0	2001	Abundant expression of the microtubule-associated protein, ensconsin (E-MAP-115), alters the cellular response to Taxol.	Paclitaxel	114-119	microtubule associated protein 7	Homo sapiens	59-68
11668581-0	2001	Abundant expression of the microtubule-associated protein, ensconsin (E-MAP-115), alters the cellular response to Taxol.	Paclitaxel	114-119	microtubule associated protein 7	Homo sapiens	70-79
11668581-1	2001	Correlation between expression level of a microtubule-associated protein called ensconsin (E-MAP-115) and degree of Taxol sensitivity in several cultured cell lines prompted us to investigate potential cause-and-effect relationships between ensconsin level and Taxol action.	Paclitaxel	116-121	microtubule associated protein 7	Homo sapiens	80-89
11668581-1	2001	Correlation between expression level of a microtubule-associated protein called ensconsin (E-MAP-115) and degree of Taxol sensitivity in several cultured cell lines prompted us to investigate potential cause-and-effect relationships between ensconsin level and Taxol action.	Paclitaxel	116-121	microtubule associated protein 7	Homo sapiens	91-100
11668581-6	2001	Taken together, results obtained in MCF-7, HeLa, and TC-7 cells suggest that elevated ensconsin level bestowed a selective disadvantage upon Taxol-sensitive cells.	Paclitaxel	141-146	microtubule associated protein 7	Homo sapiens	86-95
11668581-7	2001	To probe potential mechanisms by which ensconsin could alter the Taxol response, we isolated microtubules from HeLa cells that were or were not pretreated with Taxol.	Paclitaxel	65-70	microtubule associated protein 7	Homo sapiens	39-48
11668581-8	2001	In vivo Taxol treatment significantly tightened microtubule-binding of ensconsin, suggesting that Taxol alters ensconsin"s microtubule-binding properties and may, in turn, alter the Taxol response of the microtubules.	Paclitaxel	8-13	microtubule associated protein 7	Homo sapiens	71-80
11668581-8	2001	In vivo Taxol treatment significantly tightened microtubule-binding of ensconsin, suggesting that Taxol alters ensconsin"s microtubule-binding properties and may, in turn, alter the Taxol response of the microtubules.	Paclitaxel	8-13	microtubule associated protein 7	Homo sapiens	111-120
11668581-8	2001	In vivo Taxol treatment significantly tightened microtubule-binding of ensconsin, suggesting that Taxol alters ensconsin"s microtubule-binding properties and may, in turn, alter the Taxol response of the microtubules.	Paclitaxel	98-103	microtubule associated protein 7	Homo sapiens	71-80
11668581-8	2001	In vivo Taxol treatment significantly tightened microtubule-binding of ensconsin, suggesting that Taxol alters ensconsin"s microtubule-binding properties and may, in turn, alter the Taxol response of the microtubules.	Paclitaxel	98-103	microtubule associated protein 7	Homo sapiens	111-120
11668581-8	2001	In vivo Taxol treatment significantly tightened microtubule-binding of ensconsin, suggesting that Taxol alters ensconsin"s microtubule-binding properties and may, in turn, alter the Taxol response of the microtubules.	Paclitaxel	98-103	microtubule associated protein 7	Homo sapiens	71-80
11668581-8	2001	In vivo Taxol treatment significantly tightened microtubule-binding of ensconsin, suggesting that Taxol alters ensconsin"s microtubule-binding properties and may, in turn, alter the Taxol response of the microtubules.	Paclitaxel	98-103	microtubule associated protein 7	Homo sapiens	111-120
11478132-2	2001	A CT scan of the abdomen showed enlargement of abdominal para-aortic lymph nodes (PAN) after the primary operation and 8 cycles of the combination chemotherapy with paclitaxel (TXL) and carboplatinum (CBDCA).	Paclitaxel	165-175	thioredoxin like 1	Homo sapiens	177-180
11405668-1	2001	Paclitaxel analogues with a sulfur group at the 7beta position were required for SAR studies.	Paclitaxel	0-10	sarcosine dehydrogenase	Homo sapiens	81-84
11279118-6	2001	Sorbitol, and to a lesser extent, sodium chloride, Taxol, and nocodazole increased TAO2 activity toward itself and kinase-dead MEKs 3 and 6.	Paclitaxel	51-56	TAO kinase 2	Homo sapiens	83-87
11179455-9	2001	Furthermore, paclitaxel-induced apoptosis and cleavage of beta-catenin and gamma-catenin were inhibited by the pan-caspase inhibitor Z-VAD-FMK and partially inhibited by the caspase-3 inhibitor Z-DEVD-FMK but were not affected by the caspase-1 inhibitor AC-YVAD-CMK.	Paclitaxel	13-23	cytidine/uridine monophosphate kinase 1	Homo sapiens	262-265
11172691-7	2001	Coadministration of LY335979 with paclitaxel compared to paclitaxel alone significantly reduced the tumor mass of the Pgp-expressing UCLA-P3.003VLB lung carcinoma in a xenograph model and delayed the development of tumors in mice implanted with the parental drug-sensitive UCLA-P3 tumor.	Paclitaxel	34-44	phosphoglycolate phosphatase	Mus musculus	118-121
11007785-6	2000	Studies in intact cells confirmed the importance of the K-Ras polylysine region for microtubule binding, as deletion or replacement of this region resulted in loss of paclitaxel-induced mislocalization of a fluorescent K-Ras fusion protein.	Paclitaxel	167-177	KRAS proto-oncogene, GTPase	Homo sapiens	56-61
11007785-6	2000	Studies in intact cells confirmed the importance of the K-Ras polylysine region for microtubule binding, as deletion or replacement of this region resulted in loss of paclitaxel-induced mislocalization of a fluorescent K-Ras fusion protein.	Paclitaxel	167-177	KRAS proto-oncogene, GTPase	Homo sapiens	219-224
11007785-10	2000	Consistent with these results, localization of the fluorescent K-Ras fusion protein remained paclitaxel-sensitive in cells lacking Rce1, whereas no paclitaxel effect was observed in cells lacking the methyltransferase.	Paclitaxel	93-103	KRAS proto-oncogene, GTPase	Homo sapiens	63-68
11102737-9	2000	Our previous work, also using P-gp knockout (KO) mice, already showed that P-gp has a major effect on the oral bioavailability of several drugs and that blockers of P-gp can drastically improve oral bioavailability of paclitaxel and other drugs in mice and humans (Schinkel et al., Cell 77 (1994) 491; Sparreboom et al., Proc.	Paclitaxel	218-228	phosphoglycolate phosphatase	Mus musculus	75-79
11102737-9	2000	Our previous work, also using P-gp knockout (KO) mice, already showed that P-gp has a major effect on the oral bioavailability of several drugs and that blockers of P-gp can drastically improve oral bioavailability of paclitaxel and other drugs in mice and humans (Schinkel et al., Cell 77 (1994) 491; Sparreboom et al., Proc.	Paclitaxel	218-228	phosphoglycolate phosphatase	Mus musculus	75-79
11142692-8	2000	On the other hand, the cytotoxic activity of TPT was weaker than PTX in C-33, CAL-39 and A-431.	Paclitaxel	65-68	CD82 molecule	Homo sapiens	72-76
11044362-0	2000	Effect of c-Abl tyrosine kinase on the cellular response to paclitaxel-induced microtubule damage.	Paclitaxel	60-70	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	10-15
11044362-2	2000	We now report that, in addition to DNA damage, microtubule damage induced by paclitaxel results in activation of c-Abl kinase.	Paclitaxel	77-87	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	113-118
11044362-3	2000	In 3T3 cells, the presence of c-Abl kinase increased paclitaxel-induced cell death.	Paclitaxel	53-63	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	30-35
11044362-4	2000	In Abl-proficient cells, paclitaxel produced a marked and prolonged G2/M arrest which peaked at 24 h and a rapid and marked induction of p21(WAF1)which also peaked at 24 h. In Abl-deficient cells, the G2/M arrest induced by paclitaxel was less prominent and shorter in duration and the effect of paclitaxel on p21(WAF1)expression was reduced and delayed.	Paclitaxel	25-35	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	137-140
11044362-4	2000	In Abl-proficient cells, paclitaxel produced a marked and prolonged G2/M arrest which peaked at 24 h and a rapid and marked induction of p21(WAF1)which also peaked at 24 h. In Abl-deficient cells, the G2/M arrest induced by paclitaxel was less prominent and shorter in duration and the effect of paclitaxel on p21(WAF1)expression was reduced and delayed.	Paclitaxel	25-35	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	141-145
11044362-4	2000	In Abl-proficient cells, paclitaxel produced a marked and prolonged G2/M arrest which peaked at 24 h and a rapid and marked induction of p21(WAF1)which also peaked at 24 h. In Abl-deficient cells, the G2/M arrest induced by paclitaxel was less prominent and shorter in duration and the effect of paclitaxel on p21(WAF1)expression was reduced and delayed.	Paclitaxel	25-35	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	310-313
11044362-4	2000	In Abl-proficient cells, paclitaxel produced a marked and prolonged G2/M arrest which peaked at 24 h and a rapid and marked induction of p21(WAF1)which also peaked at 24 h. In Abl-deficient cells, the G2/M arrest induced by paclitaxel was less prominent and shorter in duration and the effect of paclitaxel on p21(WAF1)expression was reduced and delayed.	Paclitaxel	25-35	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	314-318
11044362-6	2000	These findings indicate that, in 3T3 cells, c-Abl kinase facilitates cell death and regulates G2/M arrest in response to paclitaxel-induced microtubule damage in a pathway that is dependent on p21(WAF1)and independent of MAPK activity.	Paclitaxel	121-131	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	44-49
11044362-6	2000	These findings indicate that, in 3T3 cells, c-Abl kinase facilitates cell death and regulates G2/M arrest in response to paclitaxel-induced microtubule damage in a pathway that is dependent on p21(WAF1)and independent of MAPK activity.	Paclitaxel	121-131	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	193-196
11044362-6	2000	These findings indicate that, in 3T3 cells, c-Abl kinase facilitates cell death and regulates G2/M arrest in response to paclitaxel-induced microtubule damage in a pathway that is dependent on p21(WAF1)and independent of MAPK activity.	Paclitaxel	121-131	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	197-201
11059771-5	2000	Lines lacking functional P-gp were, on average, markedly more sensitive to paclitaxel (16-fold), anthracyclines (4-fold) and Vinca alkaloids (3-fold).	Paclitaxel	75-85	phosphoglycolate phosphatase	Mus musculus	25-29
11227215-3	2000	This report documents that, similar to proliferating cells, taxol induces apoptosis in NGF-differentiated PC12 cells, as assessed by exogenous FITC-annexin-V binding and nuclear fragmentation.	Paclitaxel	60-65	annexin A5	Rattus norvegicus	148-157
10842201-9	2000	Apoptotic DNA laddering and cleavage of poly(ADP-ribose) polymerase were more substantial after treatment with combined antisense Bcl-2 and Bcl-xL ODNs plus taxol than that with either 2 agents.	Paclitaxel	157-162	poly (ADP-ribose) polymerase family, member 1	Mus musculus	40-67
10747785-0	2000	A common pharmacophore for Taxol and the epothilones based on the biological activity of a taxane molecule lacking a C-13 side chain.	Paclitaxel	27-32	homeobox C13	Homo sapiens	117-121
10747785-1	2000	Extensive structure-activity studies done with Taxol have identified the side chain at C-13 as one of the requirements for biological activity.	Paclitaxel	47-52	homeobox C13	Homo sapiens	87-91
10803320-0	2000	Phase I study of CBT-1 and Taxol in patients with Taxol resistant cancers.	Paclitaxel	50-55	succinate dehydrogenase complex subunit D	Homo sapiens	17-22
10803320-1	2000	CBT-1, a natural product, was studied as an MDR modulator with Taxol (135 mg/m2) in an escalating dose Phase I clinical trial.	Paclitaxel	63-68	succinate dehydrogenase complex subunit D	Homo sapiens	0-5
20937210-6	2000	RESULTS: The MDR cell line expressing P-gp was established , which exhibited a typical drug resistance to vincristine (VCR) , vindesin (VDS) , etoposide (VP-16) , mitomycin (MMC) , taxol and navelbine (NOR) .	Paclitaxel	181-186	phosphoglycolate phosphatase	Mus musculus	38-42
10620631-10	2000	Adjuvant in vivo administration of antisense Bcl-2 oligodeoxynucleotides and micellar paclitaxel following castration resulted in a statistically significant delay of androgen-independent, recurrent tumors compared with administration of either agent alone (P&lt;.001, Mantel-Cox log-rank test).	Paclitaxel	86-96	cytochrome c oxidase subunit 4I1	Mus musculus	276-279
10641981-4	2000	In addition, paclitaxel is a hydrophobic agent that requires a vehicle, cremophor (CrEL), for solubility.	Paclitaxel	13-23	REL proto-oncogene, NF-kB subunit	Homo sapiens	83-87
18521433-7	2000	Paclitaxel induced cell cycle arrest with an accumulation of cells in sub-G1.This was accompanied in vitro by various events typical of apoptosis: phosphorylation of two anti-apoptotic proteins Bcl-2 and Bcl-(xL) , release of cytochrome c into the cytoplasm, cleavage and activation of caspase-3.	Paclitaxel	0-10	caspase 3	Mus musculus	286-295
10579854-3	1999	A 7-amino acid synthetic peptide, BBN[7-13], which binds to the cell surface bombesin/gastrin-releasing peptide (BBN/GRP) receptor, was conjugated to the paclitaxel-2"-hydroxy function by a heterobifunctional poly(ethylene glycol) linker.	Paclitaxel	154-164	gastrin releasing peptide	Homo sapiens	77-85
10579854-3	1999	A 7-amino acid synthetic peptide, BBN[7-13], which binds to the cell surface bombesin/gastrin-releasing peptide (BBN/GRP) receptor, was conjugated to the paclitaxel-2"-hydroxy function by a heterobifunctional poly(ethylene glycol) linker.	Paclitaxel	154-164	gastrin releasing peptide	Homo sapiens	86-111
10562306-4	1999	Intravenous administration of the P-gp substrate drugs [(3)H]digoxin, [(14)C]saquinavir, or paclitaxel to pregnant dams revealed that 2.4-, 7-, or 16-fold more drug, respectively, entered the Mdr1a(-/-)/1b(-/-) fetuses than entered wild-type fetuses.	Paclitaxel	92-102	phosphoglycolate phosphatase	Mus musculus	34-38
10534697-2	1999	The aim of this study was to investigate whether depletion of the erbB-2 gene product (p185) by 17-allylamino 17-demethoxygeldanamycin would sensitize lung cancer cells to paclitaxel (Taxol) in vitro.	Paclitaxel	172-182	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	87-91
10534697-2	1999	The aim of this study was to investigate whether depletion of the erbB-2 gene product (p185) by 17-allylamino 17-demethoxygeldanamycin would sensitize lung cancer cells to paclitaxel (Taxol) in vitro.	Paclitaxel	184-189	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	87-91
10534697-3	1999	METHODS: Paclitaxel cytotoxicity was evaluated in a panel of non-small cell lung cancer cell lines that expressed varying levels of p185 by means in vitro proliferation assays and 2 drug combination schedules.	Paclitaxel	9-19	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	132-136
10534697-6	1999	Concurrent exposure of these cells to paclitaxel and 17-allylamino 17-demethoxygeldanamycin significantly enhanced paclitaxel-mediated cytotoxicity, particularly in cells which overexpressed p185.	Paclitaxel	38-48	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	191-195
10534697-6	1999	Concurrent exposure of these cells to paclitaxel and 17-allylamino 17-demethoxygeldanamycin significantly enhanced paclitaxel-mediated cytotoxicity, particularly in cells which overexpressed p185.	Paclitaxel	115-125	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	191-195
10534697-11	1999	CONCLUSION: The compound 17-allylamino 17-demethoxygeldanamycin sensitizes non-small cell lung cancer cells expressing high levels of p185 to paclitaxel-mediated growth arrest and apoptosis.	Paclitaxel	142-152	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	134-138
10534697-12	1999	These preclinical data support the evaluation of the combination of paclitaxel and 17-allylamino 17-demethoxygeldanamycin in the treatment of patients with lung cancer whose tumors exhibit p185 overexpression.	Paclitaxel	68-78	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	189-193
10571172-1	1999	Analysis of the 1H NMR data of paclitaxel in comparison with its oxetane ring-opened analogue D-secopaclitaxel suggests that the oxetane moiety (D-ring) of paclitaxel serves as a conformational lock for the diterpene moiety and the C13 side chain.	Paclitaxel	31-41	homeobox C13	Homo sapiens	232-235
10571172-1	1999	Analysis of the 1H NMR data of paclitaxel in comparison with its oxetane ring-opened analogue D-secopaclitaxel suggests that the oxetane moiety (D-ring) of paclitaxel serves as a conformational lock for the diterpene moiety and the C13 side chain.	Paclitaxel	100-110	homeobox C13	Homo sapiens	232-235
10499507-9	1999	By comparison, transforming growth factor alpha, a factor previously found to attenuate apoptosis and apoptosis-inducing agents (e.g. paclitaxel, C8-ceramide, daunorubicin, UV irradiation) failed to phosphorylate Bcl-X(LONG).	Paclitaxel	134-144	transforming growth factor alpha	Gallus gallus	15-47
10496651-4	1999	RESULTS: Exposure of the cells to P85 significantly enhanced AP to BL permeability coefficients of Flu, Tax, Dox and AZT in both cell models.	Paclitaxel	104-107	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	34-37
10376521-2	1999	Taxol-induced apoptosis was associated with phosphorylation of both c-Raf-1 and Bcl-2 and activation of ERK and JNK MAP kinases.	Paclitaxel	0-5	TNF receptor associated factor 3	Homo sapiens	68-75
10376521-4	1999	TPCK treatment also prevented phosphorylation of c-Raf-1 and Bcl-2 in response to Taxol treatment.	Paclitaxel	82-87	TNF receptor associated factor 3	Homo sapiens	49-56
10376521-8	1999	Thus, while the Taxol-induced phosphorylations of c-Raf-1 and Bcl-2 proteins appear to be coupled, these events can be disassociated from ERK1/2 activation.	Paclitaxel	16-21	TNF receptor associated factor 3	Homo sapiens	50-57
10376521-9	1999	In summary, these findings suggest that phosphorylation of c-Raf-1 and Bcl-2, but not ERK1/2, are important signaling events in Taxol-induced apoptosis of MCF-7 breast cancer cells and that a TPCK inhibitable protease(s) is required for these processes.	Paclitaxel	128-133	TNF receptor associated factor 3	Homo sapiens	59-66
10423272-7	1999	XMAP215 binding to taxol microtubules was also not changed by phosphorylation.	Paclitaxel	19-24	cytoskeleton associated protein 5 L homeolog	Xenopus laevis	0-7
12016929-2	1998	The structure-activity relationship study on taxol and its analogs has indicated the importance of the C13 side chain and the C4-C5-C20 epoxypropane group.	Paclitaxel	45-50	homeobox C13	Homo sapiens	103-106
9721872-0	1998	Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells.	Paclitaxel	0-10	MOS proto-oncogene, serine/threonine kinase	Homo sapiens	77-82
9721872-3	1998	We studied whether paclitaxel-induced M-phase arrest and apoptosis are associated with c-Mos gene expression and activation in SKOV3 ovarian carcinoma cells.	Paclitaxel	19-29	MOS proto-oncogene, serine/threonine kinase	Homo sapiens	87-92
9721872-9	1998	Paclitaxel-induced c-Mos gene expression was completely abrogated by cycloheximide and actinomycin D.	Paclitaxel	0-10	MOS proto-oncogene, serine/threonine kinase	Homo sapiens	19-24
9596701-6	1998	Two LPS-mimetic molecules-taxol from yew bark and lipoteichoic acid (LTA) from gram-positive bacterial cell walls-also induced SLPI.	Paclitaxel	26-31	secretory leukocyte peptidase inhibitor	Mus musculus	127-131
9570755-7	1998	TOGp co-sedimented with taxol-stabilized microtubules in vitro.	Paclitaxel	24-29	cytoskeleton associated protein 5	Homo sapiens	0-4
9584207-7	1998	Paclitaxel, but not cisplatin, increased Bak and 21-kDa Bax levels in A2780/cp70 cells.	Paclitaxel	0-10	BCL2 antagonist/killer 1	Homo sapiens	41-44
9365275-6	1997	MAP4 preferentially inhibited receptor-dependent uptake and degradation of LDL, and repositioning of Golgi elements after disruption by the drug, brefeldin A. L-MOCK cells treated with Taxol to stabilize the MTs to an extent equivalent to MAP4 overexpression did not show similar inhibition of vesicle motility or organellar trafficking, suggesting that deficits in organelle movements in vivo represent a direct effect of the presence of MAP4 or MTB, rather than an indirect effect of the stabilization of MTs by overexpressed MAP constructs.	Paclitaxel	185-190	microtubule associated protein 4	Homo sapiens	0-4
9365275-6	1997	MAP4 preferentially inhibited receptor-dependent uptake and degradation of LDL, and repositioning of Golgi elements after disruption by the drug, brefeldin A. L-MOCK cells treated with Taxol to stabilize the MTs to an extent equivalent to MAP4 overexpression did not show similar inhibition of vesicle motility or organellar trafficking, suggesting that deficits in organelle movements in vivo represent a direct effect of the presence of MAP4 or MTB, rather than an indirect effect of the stabilization of MTs by overexpressed MAP constructs.	Paclitaxel	185-190	microtubule associated protein 4	Homo sapiens	239-243
9365275-6	1997	MAP4 preferentially inhibited receptor-dependent uptake and degradation of LDL, and repositioning of Golgi elements after disruption by the drug, brefeldin A. L-MOCK cells treated with Taxol to stabilize the MTs to an extent equivalent to MAP4 overexpression did not show similar inhibition of vesicle motility or organellar trafficking, suggesting that deficits in organelle movements in vivo represent a direct effect of the presence of MAP4 or MTB, rather than an indirect effect of the stabilization of MTs by overexpressed MAP constructs.	Paclitaxel	185-190	microtubule associated protein 4	Homo sapiens	239-243
9337349-2	1997	MDA-MB-435 human breast cancer cells that have been transfected with oncogene c-erbB2 complementary DNA (435.eb cells) express high levels of the transmembrane glycoprotein p185(c-erbB2) and exhibit increased resistance to the chemotherapeutic agent paclitaxel via p170(mdr-1)-independent mechanisms.	Paclitaxel	250-260	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	173-177
9317152-1	1997	Activation of macrophages by LPS and taxol results in production of IL-1, IL-6, TNF-alpha, and granulocyte-macrophage CSF (GM-CSF), which are involved in regulating hemopoiesis, inflammation, and immune responses.	Paclitaxel	37-42	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	123-129
9174131-7	1997	Interestingly, paclitaxel increased the appearance of TIMP-2 protein in culture medium (P = 0.002) but did not change the expression of mRNA for TIMP-2 in Ovcar-3 cells.	Paclitaxel	15-25	TIMP metallopeptidase inhibitor 2	Homo sapiens	54-60
9009167-0	1997	Taxol induces tyrosine phosphorylation of Shc and its association with Grb2 in murine RAW 264.7 cells.	Paclitaxel	0-5	src homology 2 domain-containing transforming protein C1	Mus musculus	42-45
9009167-0	1997	Taxol induces tyrosine phosphorylation of Shc and its association with Grb2 in murine RAW 264.7 cells.	Paclitaxel	0-5	growth factor receptor bound protein 2	Mus musculus	71-75
9009167-3	1997	We investigated a possible effect of taxol on tyrosine phosphorylation of Shc and on formation of the Shc/Grb-2 complex in the murine macrophage-like cell line RAW 264.7.	Paclitaxel	37-42	src homology 2 domain-containing transforming protein C1	Mus musculus	74-77
9009167-4	1997	Shc, an SH2 domain containing adaptor protein, was immunoprecipitated from lysates of taxol-treated cells with anti-phosphotyrosine antibody and its identity determined by Western blotting with anti-Shc antibody.	Paclitaxel	86-91	src homology 2 domain-containing transforming protein C1	Mus musculus	0-3
9009167-4	1997	Shc, an SH2 domain containing adaptor protein, was immunoprecipitated from lysates of taxol-treated cells with anti-phosphotyrosine antibody and its identity determined by Western blotting with anti-Shc antibody.	Paclitaxel	86-91	src homology 2 domain-containing transforming protein C1	Mus musculus	199-202
9009167-6	1997	Taxol also activated Raf-1 kinase and ERK1/ERK2 MAP kinases in these cells.	Paclitaxel	0-5	v-raf-leukemia viral oncogene 1	Mus musculus	21-26
9009167-7	1997	These results demonstrate that taxol affects tyrosine phosphorylation of Shc and this may result in the activation of the Raf-1/MAPK cascade.	Paclitaxel	31-36	src homology 2 domain-containing transforming protein C1	Mus musculus	73-76
9009167-7	1997	These results demonstrate that taxol affects tyrosine phosphorylation of Shc and this may result in the activation of the Raf-1/MAPK cascade.	Paclitaxel	31-36	v-raf-leukemia viral oncogene 1	Mus musculus	122-127
8988045-7	1997	Taxol (6 mg/kg i.p., n = 17) inhibited bFGF and VEGF-induced neovascularization by 45% and 37%, respectively.	Paclitaxel	0-5	vascular endothelial growth factor A	Mus musculus	48-52
9307847-9	1997	A Western blot analysis revealed that hsp70 was coprecipitated with taxol-polymerized tubulin.	Paclitaxel	68-73	heat shock protein family A (Hsp70) member 4	Homo sapiens	38-43
8986791-8	1996	When growing in the presence of Taxol, growth cones at tenascin borders were not able to turn and grow along the laminin-tenascin border, and consequently stopped at the border.	Paclitaxel	32-37	tenascin C	Homo sapiens	55-63
8808711-2	1996	To investigate whether overexpression of the c-erbB-2/neu-encoded p185 can indeed lead to increased chemoresistance in breast cancers, we introduced the human c-erbB-2/neu gene into the very low p185-expressing MDA-MB435 human breast cancer cells and examined Taxol sensitivities among the parental MDA-MB-435 cells and stable transfectants which express increased levels of p185.	Paclitaxel	260-265	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	66-70
8808711-3	1996	The p185-overexpressing MDA-MB-435 transfectants were more resistant to Taxol than the parental cells.	Paclitaxel	72-77	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	4-8
8808711-6	1996	To study whether p185 induced Taxol resistance through the mdr-1 pathway, we examined the mdr-l-encoded p170 levels in these transfectants.	Paclitaxel	30-35	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	17-21
8938991-0	1996	Taxol reduces the rate of cytokinesis in PtK1 cells.	Paclitaxel	0-5	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	41-45
8938991-3	1996	Incubation of PtK1 cells during mid-anaphase with 5 micrograms/ml taxol slows the rate of cytokinesis by an average of 43%.	Paclitaxel	66-71	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	14-18
8818330-10	1996	Associated with its effect on microtubule assembly, taxol prevented the inhibitory effects of nocodazole and colchicine on cyclic GMP accumulation and iNOS mRNA levels.	Paclitaxel	52-57	5'-nucleotidase, cytosolic II	Homo sapiens	130-133
7585598-12	1995	These results thus indicate that the drug specificity of MRP is quite similar to that of MDR1, but also suggest potential differences in Taxol specificity and the level of verapamil sensitivity.	Paclitaxel	137-142	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	57-60
7914541-3	1994	The C-2 cyclohexanecarboxylate analog of paclitaxel (15) is also synthesized for comparison.	Paclitaxel	41-51	complement component 2 (within H-2S)	Mus musculus	4-7
7913412-9	1994	Polymerase chain reaction analysis of nuclear RNA, utilizing probes specific for sequences in the first intron of GM-CSF, indicated that taxol enhances accumulation of nuclear precursor RNA and that interleukin 4 decreases this accumulation.	Paclitaxel	137-142	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	114-120
7913412-10	1994	The present study shows a novel activity of taxol in inducing the release of the hematopoietic growth factor GM-CSF from B-cells.	Paclitaxel	44-49	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	109-115
7913412-11	1994	Since GM-CSF is known to recruit macrophages and enhance their cytotoxicity against tumor cells, our observations suggest that part of the known antitumor activity of taxol may be due to synergistic effects of GM-CSF activity together with direct cytotoxic actions through microtubule stabilization.	Paclitaxel	167-172	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	6-12
7913412-11	1994	Since GM-CSF is known to recruit macrophages and enhance their cytotoxicity against tumor cells, our observations suggest that part of the known antitumor activity of taxol may be due to synergistic effects of GM-CSF activity together with direct cytotoxic actions through microtubule stabilization.	Paclitaxel	167-172	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	210-216
7932091-8	1994	We have developed a simple and rapid purification procedure for MAP1 using poly (L-aspartic acid) and taxol, and observed MAP1-F-actin interaction as well as MAP1-microtubules interaction.	Paclitaxel	102-107	modulator of apoptosis 1	Homo sapiens	64-68
7841542-11	1994	Quantitative ELISAs confirmed the blotting data and showed that taxol blocked MMP-2 but not TIMP-1 production in these advanced tumors.	Paclitaxel	64-69	matrix metallopeptidase 2	Mus musculus	78-83
8112825-5	1993	Since podophyllotoxin, colcemid, and nocodazole are all microtubule-disrupting agents, and since taxol is a microtubule-stabilizing agent, these results suggest that microtubules are involved in the response of the microvessels to PAF.	Paclitaxel	97-102	PCNA clamp associated factor	Rattus norvegicus	231-234
1674704-0	1991	Prothrombinase expression of taxol treated platelets.	Paclitaxel	29-34	coagulation factor X	Homo sapiens	0-14
33771522-0	2021	MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.	Paclitaxel	56-66	MDM2 proto-oncogene	Homo sapiens	38-42
33771522-5	2021	PTX increased miR-221-3p expression and regulated MDM2/P53 expression in the PTX-sensitive NSCLC strain (A549).	Paclitaxel	0-3	MDM2 proto-oncogene	Homo sapiens	50-54
33771522-5	2021	PTX increased miR-221-3p expression and regulated MDM2/P53 expression in the PTX-sensitive NSCLC strain (A549).	Paclitaxel	77-80	MDM2 proto-oncogene	Homo sapiens	50-54
33771522-13	2021	In conclusion, miR-221-3p overexpression could regulate MDM2/p53 signaling pathway to reverse the PTX resistance of NSCLC and induce apoptosis in vitro and vivo.	Paclitaxel	98-101	MDM2 proto-oncogene	Homo sapiens	56-60
32796817-5	2020	Knockdown of E2F1 and CCND1 reduced cell proliferation and PTX-sensitivity, whereas overexpression of them had the opposite effect.	Paclitaxel	59-62	cyclin D1 S homeolog	Xenopus laevis	22-27
25445425-0	2015	Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report.	Paclitaxel	108-118	BRCA1 DNA repair associated	Homo sapiens	33-38
34839191-0	2022	Effects and mechanisms of FBXO31 on Taxol chemoresistance in esophageal squamous cell carcinoma.	Paclitaxel	36-41	F-box protein 31	Homo sapiens	26-32
34839191-3	2022	Here we showed FBXO31, which was reported to be highly expressed in ESCC and significantly associated with poor prognosis, could regulate ESCC chemosensitivity to Taxol.	Paclitaxel	163-168	F-box protein 31	Homo sapiens	15-21
34839191-4	2022	Silencing of FBXO31 in ESCC cells sensitized cells to Taxol treatment, evidenced by FACS analysis and TUNEL assay, showing as an increased apoptotic population in FBXO31-knockdown cells compared to the control cells.	Paclitaxel	54-59	F-box protein 31	Homo sapiens	13-19
34839191-4	2022	Silencing of FBXO31 in ESCC cells sensitized cells to Taxol treatment, evidenced by FACS analysis and TUNEL assay, showing as an increased apoptotic population in FBXO31-knockdown cells compared to the control cells.	Paclitaxel	54-59	F-box protein 31	Homo sapiens	163-169
34839191-6	2022	Cofilin-1 knockdown in FBXO31-overexpression cells reversed FBXO31-induced suppression of cell apoptosis, suggesting FBXO31-mediated Taxol chemoresistance is associated with cofilin-1.	Paclitaxel	133-138	F-box protein 31	Homo sapiens	23-29
34839191-6	2022	Cofilin-1 knockdown in FBXO31-overexpression cells reversed FBXO31-induced suppression of cell apoptosis, suggesting FBXO31-mediated Taxol chemoresistance is associated with cofilin-1.	Paclitaxel	133-138	F-box protein 31	Homo sapiens	60-66
34839191-6	2022	Cofilin-1 knockdown in FBXO31-overexpression cells reversed FBXO31-induced suppression of cell apoptosis, suggesting FBXO31-mediated Taxol chemoresistance is associated with cofilin-1.	Paclitaxel	133-138	F-box protein 31	Homo sapiens	117-123
34839191-7	2022	Furthermore, in vivo experiments confirmed that knockdown of FBXO31 sensitized ESCC to Taxol treatment.	Paclitaxel	87-92	F-box protein 31	Homo sapiens	61-67
34953982-5	2022	Meanwhile, CQ-HF/PTX nanogels play two roles in anti-metastasis: i) For reducing the "attractive force", it could block the CXCR4/SDF-1 pathway, preventing tumor cells metastasis to the lung; ii) For reinforcing "adhesion force", it could inhibit the excessive autophagy for hindering the degradation of paxillin and enhancing the cell adhesion.	Paclitaxel	17-20	C-X-C motif chemokine receptor 4	Homo sapiens	124-129
34915631-15	2021	The expression levels of ENO1, p-PI3K, p-Akt, PCNA, MMP-9 and Bcl-2 in paclitaxel+ siRNA-ENO1 group were lower than those in siRNA-ENO1 group or paclitaxel+ siRNA-NC group (P<0.05).	Paclitaxel	71-81	matrix metallopeptidase 9	Homo sapiens	52-57
34610216-7	2021	RESULTS: The expression levels of C-MYC and NANOG were significantly higher in paclitaxel-resistant PC-3 cells compared to the parental PC-3 cells.	Paclitaxel	79-89	Nanog homeobox	Homo sapiens	44-49
34415232-0	2021	MicroRNA-624-mediated ARRDC3/YAP/HIF1alpha axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel.	Paclitaxel	125-135	arrestin domain containing 3	Homo sapiens	22-28
34415232-10	2021	miR-624 downregulated ARRDC3 to increase YAP and HIF1alpha expression so as to enhance ESCC cell resistance to CIS and PT in vitro and in vivo.	Paclitaxel	119-121	arrestin domain containing 3	Homo sapiens	22-28
34617313-2	2021	Recently, we reported that Hsp105 knockdown increases sensitivity to the DNA-damaging agent Adriamycin but decreases sensitivity to the microtubule-targeting agent paclitaxel.	Paclitaxel	164-174	heat shock protein family H (Hsp110) member 1	Homo sapiens	27-33
34617313-8	2021	The cell synchronization experiment suggests that Apg-1 functions in mitotic progression at a different mitotic subphase from Hsp105, which cause difference in paclitaxel sensitivity.	Paclitaxel	160-170	heat shock protein family A (Hsp70) member 4 like	Homo sapiens	50-55
34617313-8	2021	The cell synchronization experiment suggests that Apg-1 functions in mitotic progression at a different mitotic subphase from Hsp105, which cause difference in paclitaxel sensitivity.	Paclitaxel	160-170	heat shock protein family H (Hsp110) member 1	Homo sapiens	126-132
34893524-16	2021	Five out of six patients with matched pre-treatment and post-treatment biopsies treated with intravenous enadenotucirev plus paclitaxel had increased (mean 3.1-fold) infiltration of CD8 +T cells in post-treatment biopsies.	Paclitaxel	125-135	CD8a molecule	Homo sapiens	182-185
34942984-7	2021	Furthermore, in paclitaxel-resistant breast cancer cell lines, MCF-7R and MDA-MB-231R, a combination of JI017 and paclitaxel overcame paclitaxel resistance by blocking epithelial-mesenchymal transition (EMT) processes, such as the downregulation of E-cadherin expression and the upregulation of HIF-1alpha, vimentin, Snail, and Slug expression.	Paclitaxel	134-144	snail family transcriptional repressor 2	Homo sapiens	328-332
34867360-9	2021	Results: Multifunctional CD44-targeted nanoparticles HA-BNPs@Ptx were successfully prepared and validated in vitro.	Paclitaxel	61-64	CD44 antigen	Mus musculus	25-29
34740994-0	2021	LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability.	Paclitaxel	27-37	OTUD6B antisense RNA 1 (head to head)	Homo sapiens	7-17
34740994-9	2021	In general, our study found (1) miR-26a-5p was a protective factor of breast cancer, while OTUD6B-AS1 and MTDH were risk factors; (2) OTUD6B-AS1 was the up-stream regulator of miR-26a-5p verified by luciferase; (3) up-regulation of miR-26a-5p and down-regulation of MTDH promoted cellular cytotoxicity of paclitaxel (PTX) in vitro and in vivo.	Paclitaxel	305-315	OTUD6B antisense RNA 1 (head to head)	Homo sapiens	91-101
34740994-9	2021	In general, our study found (1) miR-26a-5p was a protective factor of breast cancer, while OTUD6B-AS1 and MTDH were risk factors; (2) OTUD6B-AS1 was the up-stream regulator of miR-26a-5p verified by luciferase; (3) up-regulation of miR-26a-5p and down-regulation of MTDH promoted cellular cytotoxicity of paclitaxel (PTX) in vitro and in vivo.	Paclitaxel	305-315	OTU deubiquitinase 6B	Homo sapiens	134-140
34787847-0	2021	Author Correction: Propofol inhibits invasion and enhances paclitaxel-induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug.	Paclitaxel	59-69	snail family transcriptional repressor 2	Homo sapiens	164-168
34994611-0	2021	Metastatic CDK12-Mutated Neuroendocrine Tumor of Lung Showed an Exceptional Response to Olaparib and Paclitaxel.	Paclitaxel	101-111	cyclin dependent kinase 12	Homo sapiens	11-16
34768915-5	2021	Similar to the cell growth suppressive effect, the combination of UA and PTX significantly inhibited cell migration by targeting uPA, MMP-9, and E-cadherin in ESCC cells.	Paclitaxel	73-76	matrix metallopeptidase 9	Homo sapiens	134-139
34768915-6	2021	In addition, combination treatment with UA and PTX significantly activated p-GSK-3beta and suppressed the activation of Akt and FOXM1 in ESCC cells.	Paclitaxel	47-50	forkhead box M1	Homo sapiens	128-133
34768915-9	2021	Thus, UA effectively potentiates the anti-tumor efficacy of PTX by targeting the Akt/FOXM1 cascade since combination treatment shows significantly more anti-tumor potential than PTX alone both in vitro and in vivo.	Paclitaxel	60-63	forkhead box M1	Homo sapiens	85-90
34803458-2	2021	Here, it is aimed to investigate the differences in the expression levels of let-7a, miR-10b, miR-21, miR-125b, miR-145, miR-155, miR-200c, miR-221, miR-222 and miR-335, which associated with gene and proteins in MCF-7 (parental) and MCF-7s (Mammosphere/stem cell-enriched population/CD44+/CD24-cells) cells treated with paclitaxel.	Paclitaxel	321-331	microRNA 10b	Homo sapiens	85-92
34803458-2	2021	Here, it is aimed to investigate the differences in the expression levels of let-7a, miR-10b, miR-21, miR-125b, miR-145, miR-155, miR-200c, miR-221, miR-222 and miR-335, which associated with gene and proteins in MCF-7 (parental) and MCF-7s (Mammosphere/stem cell-enriched population/CD44+/CD24-cells) cells treated with paclitaxel.	Paclitaxel	321-331	microRNA 155	Homo sapiens	121-128
34803458-2	2021	Here, it is aimed to investigate the differences in the expression levels of let-7a, miR-10b, miR-21, miR-125b, miR-145, miR-155, miR-200c, miR-221, miR-222 and miR-335, which associated with gene and proteins in MCF-7 (parental) and MCF-7s (Mammosphere/stem cell-enriched population/CD44+/CD24-cells) cells treated with paclitaxel.	Paclitaxel	321-331	CD44 molecule (Indian blood group)	Homo sapiens	284-288
34649611-0	2021	Circ_0061140 knockdown inhibits tumorigenesis and improves PTX sensitivity by regulating miR-136/CBX2 axis in ovarian cancer.	Paclitaxel	59-62	chromobox 2	Homo sapiens	97-101
34649611-12	2021	RESULTS: Circ_0061140 and CBX2 expressions were upregulated, while miR-136 expression was downregulated in PTX-resistant tissues and cells compared with control groups.	Paclitaxel	107-110	chromobox 2	Homo sapiens	26-30
34649611-16	2021	CONCLUSIONS: Circ_0061140 silencing repressed the progression and PTX resistance of ovarian cancer by downregulating CBX2 expression via sponging miR-136, which provided novel insight into studying the therapy of ovarian cancer with PTX.	Paclitaxel	66-69	chromobox 2	Homo sapiens	117-121
34649611-16	2021	CONCLUSIONS: Circ_0061140 silencing repressed the progression and PTX resistance of ovarian cancer by downregulating CBX2 expression via sponging miR-136, which provided novel insight into studying the therapy of ovarian cancer with PTX.	Paclitaxel	233-236	chromobox 2	Homo sapiens	117-121
34729313-3	2021	Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction.	Paclitaxel	111-114	hydroxyacid oxidase 1	Homo sapiens	50-65
34729313-3	2021	Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction.	Paclitaxel	111-114	hydroxyacid oxidase 1	Homo sapiens	67-70
34729313-3	2021	Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction.	Paclitaxel	111-114	hydroxyacid oxidase 1	Homo sapiens	144-147
34729313-3	2021	Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction.	Paclitaxel	148-151	hydroxyacid oxidase 1	Homo sapiens	15-18
34729313-3	2021	Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction.	Paclitaxel	148-151	hydroxyacid oxidase 1	Homo sapiens	50-65
34729313-3	2021	Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction.	Paclitaxel	148-151	hydroxyacid oxidase 1	Homo sapiens	67-70
34729313-3	2021	Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction.	Paclitaxel	148-151	hydroxyacid oxidase 1	Homo sapiens	144-147
34638704-7	2021	Moreover, the down-regulation of TRPV1 in DRG of Nogo-A KO rats after injection of CFA was reversed by intrathecal injection of paclitaxel, a microtubule stabilizer.	Paclitaxel	128-138	reticulon 4	Rattus norvegicus	49-55
34681199-8	2021	Paclitaxel-induced neuropathic pain was associated with nitration of proteins in the spinal cord including MnSOD, glutamine synthetase, and glutamate transporter GLT-1.	Paclitaxel	0-10	superoxide dismutase 2	Rattus norvegicus	107-112
34681199-8	2021	Paclitaxel-induced neuropathic pain was associated with nitration of proteins in the spinal cord including MnSOD, glutamine synthetase, and glutamate transporter GLT-1.	Paclitaxel	0-10	glutamate-ammonia ligase	Rattus norvegicus	114-134
34535163-0	2021	Up-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin.	Paclitaxel	78-83	glutathione S-transferase theta 1	Homo sapiens	17-22
34535163-6	2021	Meanwhile, GSTT1 expression was also significantly upregulated in the SOC patient tissues after taxol treatment, indicating this upregulation was physiologically relevant to chemotherapy.	Paclitaxel	96-101	glutathione S-transferase theta 1	Homo sapiens	11-16
34510641-0	2021	FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1.	Paclitaxel	66-76	fatty acid synthase	Homo sapiens	0-4
34510641-1	2021	OBJECTIVES: To investigate the potential effect of fatty acid synthase (FASN) inhibitor orlistat to enhance the effectiveness of chemotherapy drugs widely used to treat oral squamous cell carcinomas (OSCC), such as 5-fluorouracil, cisplatin, and paclitaxel.	Paclitaxel	246-256	fatty acid synthase	Homo sapiens	51-70
34510641-1	2021	OBJECTIVES: To investigate the potential effect of fatty acid synthase (FASN) inhibitor orlistat to enhance the effectiveness of chemotherapy drugs widely used to treat oral squamous cell carcinomas (OSCC), such as 5-fluorouracil, cisplatin, and paclitaxel.	Paclitaxel	246-256	fatty acid synthase	Homo sapiens	72-76
34510641-7	2021	RESULTS: Inhibition of FASN with orlistat sensitized SCC-9 LN-1 cells to the cytotoxic effects of paclitaxel and cisplatin, but not 5-fluorouracil, which was accompanied by a significant reduction in cyclin B1.	Paclitaxel	98-108	fatty acid synthase	Homo sapiens	23-27
34175815-6	2021	Upstream mediators of EMT such as ZEB1/2, TGF-beta, microRNAs, and so on are involved in regulating response of cancer cells to PTX and DTX.	Paclitaxel	128-131	zinc finger E-box binding homeobox 1	Homo sapiens	34-40
34181803-9	2021	Furthermore, a treatment with a potent and selective KCa 1.1 inhibitor overcame the chemoresistance of the MG-63 and human chondrosarcoma SW-1353 spheroid models to paclitaxel, doxorubicin, and cisplatin.	Paclitaxel	165-175	potassium calcium-activated channel subfamily M alpha 1	Homo sapiens	53-60
34479917-9	2021	Paclitaxel induced cell cycle arrest at the G1 phase in response to DNA damage, in association with the suppression of CDC25A, Cdk2 and Cyclin E1 protein expression.	Paclitaxel	0-10	cell division cycle 25A	Homo sapiens	119-125
34479917-9	2021	Paclitaxel induced cell cycle arrest at the G1 phase in response to DNA damage, in association with the suppression of CDC25A, Cdk2 and Cyclin E1 protein expression.	Paclitaxel	0-10	cyclin E1	Homo sapiens	136-145
34278466-10	2021	After treatment with PTX, apoptosis and ROS levels were decreased in the CD44+CD117+ groups compared with the CD44-CD117- groups.	Paclitaxel	21-24	CD44 antigen	Mus musculus	73-77
34278466-10	2021	After treatment with PTX, apoptosis and ROS levels were decreased in the CD44+CD117+ groups compared with the CD44-CD117- groups.	Paclitaxel	21-24	CD44 antigen	Mus musculus	110-114
34278466-11	2021	Collectively, the present results demonstrated that, via the Notch1 pathway, CCL20/CCR6 may promote the stemness and PTX resistance of CD44+CD117+ cells in ovarian cancer.	Paclitaxel	117-120	chemokine (C-C motif) receptor 6	Mus musculus	83-87
34278466-11	2021	Collectively, the present results demonstrated that, via the Notch1 pathway, CCL20/CCR6 may promote the stemness and PTX resistance of CD44+CD117+ cells in ovarian cancer.	Paclitaxel	117-120	CD44 antigen	Mus musculus	135-139
34512368-3	2021	In this review, we focus on summarizing some representative natural active compounds, mainly including curcumin, resveratrol, paclitaxel, Bufalin, and Ursolic acid that may ultimately trigger cancer cell death through the regulation of some key autophagic signaling pathways, such as RAS-RAF-MEK-ERK, PI3K-AKT-mTOR, AMPK, ULK1, Beclin-1, Atg5 and p53.	Paclitaxel	126-136	beclin 1	Homo sapiens	328-336
34405338-8	2022	Altogether, the results demonstrate that this intelligent drug co-delivery system is capable of effectively transferring PTX and TMZ to U-87 stem cells and without any toxic effect on Apt-NPs alone to U-87 stem cells.	Paclitaxel	121-124	small nucleolar RNA, C/D box 87	Homo sapiens	136-140
34385422-0	2021	Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.	Paclitaxel	40-50	BCL2 antagonist/killer 1	Homo sapiens	13-16
34385422-4	2021	Cells bearing BAK/MCL1 complexes were more sensitive to paclitaxel and the MCL1 antagonist S63845.	Paclitaxel	56-66	BCL2 antagonist/killer 1	Homo sapiens	14-17
34385422-5	2021	Likewise, PDX models with BAK/MCL1 complexes were more likely to respond to paclitaxel.	Paclitaxel	76-86	BCL2 antagonist/killer 1	Homo sapiens	26-29
34385422-6	2021	Mechanistically, BIM induced by low paclitaxel concentrations interacted preferentially with MCL1 and displaced MCL1-bound BAK.	Paclitaxel	36-46	BCL2 antagonist/killer 1	Homo sapiens	123-126
34385422-7	2021	Further studies indicated that cells with preformed BAK/MCL1 complexes were sensitive to the paclitaxel/S63845 combination, while cells without BAK/MCL1 complexes were not.	Paclitaxel	93-103	BCL2 antagonist/killer 1	Homo sapiens	52-55
34385422-8	2021	Our study suggested that the assessment of BAK/MCL1 complexes might be useful for predicting response to paclitaxel alone or in combination with BH3 mimetics.	Paclitaxel	105-115	BCL2 antagonist/killer 1	Homo sapiens	43-46
34421585-3	2021	Further investigation showed that the combination of paclitaxel and HY could increase the level of mitochondrial damage and the concentration of cytochrome c, causing the expression of caspase-3 and the cleavage of PARP..	Paclitaxel	53-63	caspase 3	Mus musculus	185-194
34421585-3	2021	Further investigation showed that the combination of paclitaxel and HY could increase the level of mitochondrial damage and the concentration of cytochrome c, causing the expression of caspase-3 and the cleavage of PARP..	Paclitaxel	53-63	poly (ADP-ribose) polymerase family, member 1	Mus musculus	215-219
34318540-0	2021	Ketogenic Diet Prevents Paclitaxel-Induced Neuropathic Nociception through Activation of PPARgamma Signaling Pathway and Inhibition of Neuroinflammation in Rat Dorsal Root Ganglion.	Paclitaxel	24-34	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	89-98
34318540-10	2021	It was found that PPARgamma agonist rosiglitazone significantly protected DRG neurons against cell apoptosis and reactive oxygen species generation induced by paclitaxel administration.	Paclitaxel	159-169	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	18-27
34149413-6	2021	Furthermore, autophagy in ADQ-treated breast CSCs was blocked by taxol via regulation of beta-catenin/ABCG2 signaling.	Paclitaxel	65-70	catenin (cadherin associated protein), beta 1	Mus musculus	89-101
34071530-5	2021	Compared to control, catechin nanoemulsion at 20 mug/mL and paclitaxel at 10 mug/mL were the most effective in reducing tumor volume by 41.3% and 52.5% and tumor weight by 77.5% and 90.6% in mice, respectively, through a decrease in EGF and VEGF levels in serum.	Paclitaxel	60-70	vascular endothelial growth factor A	Mus musculus	241-245
35489285-3	2022	METHODS: Here we performed a detailed IFI16 expression analysis in ovarian cancer cell lines sensitive (A2780) and resistant to doxorubicin (DOX) (A2780DR1 and A2780DR2) and paclitaxel (PAC) (A2780PR1).	Paclitaxel	174-184	interferon gamma inducible protein 16	Homo sapiens	38-43
35489285-3	2022	METHODS: Here we performed a detailed IFI16 expression analysis in ovarian cancer cell lines sensitive (A2780) and resistant to doxorubicin (DOX) (A2780DR1 and A2780DR2) and paclitaxel (PAC) (A2780PR1).	Paclitaxel	186-189	interferon gamma inducible protein 16	Homo sapiens	38-43
35552677-0	2022	Translocon-associated protein subunit SSR3 determines and predicts susceptibility to paclitaxel in breast cancer and glioblastoma.	Paclitaxel	85-95	signal sequence receptor subunit 3	Homo sapiens	38-42
35552677-6	2022	RESULTS: Combination of CRISPR screen results with outcomes from taxane-treated breast cancer patients led to the discovery of endoplasmic reticulum (ER) protein SSR3 as a putative predictive biomarker for PTX.	Paclitaxel	206-209	signal sequence receptor subunit 3	Homo sapiens	162-166
35552677-7	2022	SSR3 protein levels showed positive correlation with susceptibility to PTX in breast cancer cells, glioma cells and in multiple intracranial glioma xenografts models.	Paclitaxel	71-74	signal sequence receptor subunit 3	Homo sapiens	0-4
35552677-8	2022	Knockout of SSR3 turned the cells resistant to PTX while its overexpression sensitized the cells to PTX.	Paclitaxel	47-50	signal sequence receptor subunit 3	Homo sapiens	12-16
35552677-8	2022	Knockout of SSR3 turned the cells resistant to PTX while its overexpression sensitized the cells to PTX.	Paclitaxel	100-103	signal sequence receptor subunit 3	Homo sapiens	12-16
35504951-6	2022	Additionally, ASPP2-rAd injection promotes paclitaxel-suppressed tumor growth by suppressing cell proliferation in the BALB/c nude mice model.	Paclitaxel	43-53	transformation related protein 53 binding protein 2	Mus musculus	14-19
35434866-5	2022	RESULTS: A total of 152 patients were included, with 34/23 (CAI/CWPI) receiving paclitaxel/bevacizumab (PB), 24/11 paclitaxel (P), 27/12 gemcitabine (G) and 6/15 pemetrexed (PE).	Paclitaxel	80-90	carbonic anhydrase 1	Homo sapiens	60-63
35477477-0	2022	High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer.	Paclitaxel	44-49	receptor interacting serine/threonine kinase 2	Homo sapiens	19-24
35477477-6	2022	RESULTS: RIPK2 was highly expressed in Taxol resistant ovarian cancer cell lines, and its high expression was also linked with shorter OS and PFI in serous ovarian cancer patients.	Paclitaxel	39-44	receptor interacting serine/threonine kinase 2	Homo sapiens	9-14
35477477-8	2022	RIPK2 expression was related to tumor microenvironment alterations, which might participate in the formation of Taxol resistance.	Paclitaxel	112-117	receptor interacting serine/threonine kinase 2	Homo sapiens	0-5
35477477-9	2022	CONCLUSIONS: Our studies suggested that high expression of RIPK2 is related to Taxol resistance in serous ovarian cancer, and that RIPK2 induces Taxol resistance through NOD1/RIPK2/NF-kappaB inflammatory pathway activation and tumor microenvironment changes.	Paclitaxel	79-84	receptor interacting serine/threonine kinase 2	Homo sapiens	59-64
35477477-9	2022	CONCLUSIONS: Our studies suggested that high expression of RIPK2 is related to Taxol resistance in serous ovarian cancer, and that RIPK2 induces Taxol resistance through NOD1/RIPK2/NF-kappaB inflammatory pathway activation and tumor microenvironment changes.	Paclitaxel	145-150	receptor interacting serine/threonine kinase 2	Homo sapiens	59-64
35477477-9	2022	CONCLUSIONS: Our studies suggested that high expression of RIPK2 is related to Taxol resistance in serous ovarian cancer, and that RIPK2 induces Taxol resistance through NOD1/RIPK2/NF-kappaB inflammatory pathway activation and tumor microenvironment changes.	Paclitaxel	145-150	receptor interacting serine/threonine kinase 2	Homo sapiens	131-136
35477477-9	2022	CONCLUSIONS: Our studies suggested that high expression of RIPK2 is related to Taxol resistance in serous ovarian cancer, and that RIPK2 induces Taxol resistance through NOD1/RIPK2/NF-kappaB inflammatory pathway activation and tumor microenvironment changes.	Paclitaxel	145-150	receptor interacting serine/threonine kinase 2	Homo sapiens	175-180
35566403-11	2022	Neoadjuvant chemotherapy (NACT) containing both paclitaxel and cisplatin induced a reduction in stromal FoxP3 Treg numbers and an increase in stromal and intratumoral CD8 T cells.	Paclitaxel	48-58	CD8a molecule	Homo sapiens	167-170
35397087-13	2022	The IC50 value of miR-211-3p overexpression (OE) group was significantly higher than negative control (NC) group treated with paclitaxel, suggesting miR-211-3p enhanced IC insensitivity in HSCC.	Paclitaxel	126-136	microRNA 211	Homo sapiens	149-156
34997314-1	2022	PURPOSE: Cetirizine is a less sedative alternative to diphenhydramine for the prevention of infusion-related reactions (IRR) to paclitaxel.	Paclitaxel	128-138	insulin receptor related receptor	Homo sapiens	120-123
34997314-3	2022	In this study, we assessed feasibility for a future definitive non-inferiority trial comparing cetirizine to diphenhydramine as premedication to prevent paclitaxel-related IRR.	Paclitaxel	153-163	insulin receptor related receptor	Homo sapiens	172-175
35368966-7	2022	The CMB-PTX-CRISPR/Cas9 increased the GSK-3, P21, P27, and Bad expression levels, while reduced the C-erbB-2 and mTOR expressions.	Paclitaxel	8-11	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	45-48
35368966-9	2022	CMB-PTX-CRISPR/Cas9 may regulate the tumor cell viability, invasion, and metastasis of endometrial cancer naked mouse model by upregulating expressions of GSK-3, P21, P27, and Bad.	Paclitaxel	4-7	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	162-165
35314692-6	2022	In the bevacizumab plus paclitaxel group, the MDR software provided two pharmacogenetic interaction profiles consisting of the combination between specific VEGF-A rs833061 and VEGFR-2 rs1870377 genotypes.	Paclitaxel	24-34	kinase insert domain receptor	Homo sapiens	176-183
35238054-0	2022	TRPM2-AS promotes paclitaxel resistance in prostate cancer by regulating FOXK1 via sponging miR-497-5p.	Paclitaxel	18-28	TRPM2 antisense RNA	Homo sapiens	0-8
35238054-3	2022	We aimed to explore the function of transient receptor potential cation channel subfamily M member 2 (TRPM2) antisense RNA (TRPM2-AS) in paclitaxel (PTX) resistance in PCa.	Paclitaxel	137-147	transient receptor potential cation channel subfamily M member 2	Homo sapiens	36-100
35238054-3	2022	We aimed to explore the function of transient receptor potential cation channel subfamily M member 2 (TRPM2) antisense RNA (TRPM2-AS) in paclitaxel (PTX) resistance in PCa.	Paclitaxel	137-147	transient receptor potential cation channel subfamily M member 2	Homo sapiens	102-107
35238054-3	2022	We aimed to explore the function of transient receptor potential cation channel subfamily M member 2 (TRPM2) antisense RNA (TRPM2-AS) in paclitaxel (PTX) resistance in PCa.	Paclitaxel	137-147	TRPM2 antisense RNA	Homo sapiens	124-132
35238054-3	2022	We aimed to explore the function of transient receptor potential cation channel subfamily M member 2 (TRPM2) antisense RNA (TRPM2-AS) in paclitaxel (PTX) resistance in PCa.	Paclitaxel	149-152	transient receptor potential cation channel subfamily M member 2	Homo sapiens	36-100
35238054-3	2022	We aimed to explore the function of transient receptor potential cation channel subfamily M member 2 (TRPM2) antisense RNA (TRPM2-AS) in paclitaxel (PTX) resistance in PCa.	Paclitaxel	149-152	transient receptor potential cation channel subfamily M member 2	Homo sapiens	102-107
35238054-3	2022	We aimed to explore the function of transient receptor potential cation channel subfamily M member 2 (TRPM2) antisense RNA (TRPM2-AS) in paclitaxel (PTX) resistance in PCa.	Paclitaxel	149-152	TRPM2 antisense RNA	Homo sapiens	124-132
35238054-4	2022	Our results showed that TRPM2-AS was increased in PTX-resistant PCa cells.	Paclitaxel	50-53	transient receptor potential cation channel subfamily M member 2	Homo sapiens	24-29
35238054-5	2022	TRPM2-AS knockdown accelerated cell apoptosis and inhibited cell proliferation, migration, invasion, and PTX resistance in PTX-resistant PCa cells.	Paclitaxel	105-108	TRPM2 antisense RNA	Homo sapiens	0-8
35238054-5	2022	TRPM2-AS knockdown accelerated cell apoptosis and inhibited cell proliferation, migration, invasion, and PTX resistance in PTX-resistant PCa cells.	Paclitaxel	123-126	TRPM2 antisense RNA	Homo sapiens	0-8
35238054-6	2022	MiR-497-5p was bound to TRPM2-AS and its inhibition reversed the effects of TRPM2-AS knockdown on cell progression and PTX resistance in PTX-resistant PCa cells.	Paclitaxel	119-122	transient receptor potential cation channel subfamily M member 2	Homo sapiens	24-29
35238054-8	2022	In conclusion, TRPM2-AS knockdown suppressed cell progression and PTX resistance in PTX-resistant PCa cells by miR-497-5p/FOXK1 axis.	Paclitaxel	66-69	TRPM2 antisense RNA	Homo sapiens	15-23
35194034-0	2022	Degradation of DRAK1 by CUL3/SPOP E3 Ubiquitin ligase promotes tumor growth of paclitaxel-resistant cervical cancer cells.	Paclitaxel	79-89	speckle type BTB/POZ protein	Homo sapiens	29-33
35214154-5	2022	The PTX diffused into microtubules to induce tumor cell apoptosis, while QU promoted PTX retention by down-regulating P-gp expression.	Paclitaxel	85-88	phosphoglycolate phosphatase	Mus musculus	118-122
35139880-7	2022	Drug response was coupled to elevated expression of EGFR, Mdm2, Ptch1 and Tsc1 (Erlotinib), or Nras and Ptch1 (Paclitaxel) and reduced expression of Egfr, Erbb2 and Foxa (Paclitaxel).	Paclitaxel	111-121	NRAS proto-oncogene, GTPase	Homo sapiens	95-99
35139880-7	2022	Drug response was coupled to elevated expression of EGFR, Mdm2, Ptch1 and Tsc1 (Erlotinib), or Nras and Ptch1 (Paclitaxel) and reduced expression of Egfr, Erbb2 and Foxa (Paclitaxel).	Paclitaxel	171-181	NRAS proto-oncogene, GTPase	Homo sapiens	95-99
35178446-7	2022	Ectopically expressed Ajuba in MCF-7 cells stimulated in vitro and in vivo cell growth, invasion, cell cycle progression, and decreased paclitaxel-induced apoptosis.	Paclitaxel	136-146	ajuba LIM protein	Homo sapiens	22-27
35014689-5	2022	Furthermore, it was found that forkhead box transcription factor O1 (FOXO1) enhanced PTX-induced autophagy through a transcriptional activation pattern in MDA-MB-231 cells, which was associated with the downstream target genes autophagy related 5, class III phosphoinositide 3-kinase vacuolar protein sorting 34, autophagy related 4B cysteine peptidase, beclin 1 and microtubule associated protein 1 light chain 3beta.	Paclitaxel	85-88	beclin 1	Homo sapiens	354-362
35141332-1	2022	Objective: The aim of the present study was to investigate the effect of forkhead box M1 (FOXM1) to paclitaxel resistance in cervical cancer cells, to determine the underlying mechanism, and to identify novel targets for the treatment of paclitaxel-resistant cervical cancer.	Paclitaxel	100-110	forkhead box M1	Homo sapiens	90-95
35141332-1	2022	Objective: The aim of the present study was to investigate the effect of forkhead box M1 (FOXM1) to paclitaxel resistance in cervical cancer cells, to determine the underlying mechanism, and to identify novel targets for the treatment of paclitaxel-resistant cervical cancer.	Paclitaxel	238-248	forkhead box M1	Homo sapiens	73-88
35141332-1	2022	Objective: The aim of the present study was to investigate the effect of forkhead box M1 (FOXM1) to paclitaxel resistance in cervical cancer cells, to determine the underlying mechanism, and to identify novel targets for the treatment of paclitaxel-resistant cervical cancer.	Paclitaxel	238-248	forkhead box M1	Homo sapiens	90-95
35141332-6	2022	Both the protein and mRNA expression levels of FOXM1 and ABCC5 transporters were significantly higher in the paclitaxel-resistant Caski/Taxol cells compared with Caski cells (P < 0.05).	Paclitaxel	109-119	forkhead box M1	Homo sapiens	47-52
35141332-8	2022	Intracellular paclitaxel concentrations were significantly higher amongst the Caski/Taxol cells following the knockdown of FOXM1 by shRNA or Siomycin A (P < 0.05).	Paclitaxel	14-24	forkhead box M1	Homo sapiens	123-128
35141332-10	2022	The knockdown of FOXM1 with shRNA or Siomycin A promotes paclitaxel-induced cell death by regulating ABCC5 gene transcription.	Paclitaxel	57-67	forkhead box M1	Homo sapiens	17-22
35058503-6	2022	Knockdown of p53, RBL2, or the DREAM component LIN37 increased AURKA/B pathway gene expression and reduced paclitaxel and radiation toxicity in NSCLC cells.	Paclitaxel	107-117	RB transcriptional corepressor like 2	Homo sapiens	18-22
35173861-0	2022	Apatinib inhibits paclitaxel resistance of gastric carcinoma cells through VEGFR2 pathway.	Paclitaxel	18-28	kinase insert domain receptor	Homo sapiens	75-81
35173861-9	2022	After Apa intervention, PTX-resistant MGC803 cells showed decreased cell migration, invasion and proliferation, reduced MDR1, P-gp and VEGFR2 levels, and increased Bax protein level.	Paclitaxel	24-27	kinase insert domain receptor	Homo sapiens	135-141
34996504-0	2022	Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer.	Paclitaxel	62-72	zinc finger protein 64	Mus musculus	10-15